{
"meta": {
    "total_records": 49789,
    "timestamp": "2026-06-29T06:08:21Z"
},
"data": [
    {"id":"2399","name":"Agenda - Innovation Forum - Programme","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-09-29T02:09:21Z","last_updated_date":"2008-09-29T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-innovation-forum-programme_en.pdf"},
    {"id":"2465","name":"Agenda - Workshop on pharmacogenomics: from science to clinical care","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-09-19T11:40:00Z","last_updated_date":"2012-09-19T11:40:00Z","reference_number":"EMA/324423/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-pharmacogenomics-science-clinical-care_en.pdf"},
    {"id":"2491","name":"Agenda – European Medicines Agency paediatric osteoporosis expert meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T00:00:00Z","last_updated_date":"2014-05-16T00:00:00Z","reference_number":"EMA/247130/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-paediatric-osteoporosis-expert-meeting_en.pdf"},
    {"id":"2503","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (London, UK)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-22T15:00:00Z","last_updated_date":"2015-01-29T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-london-uk_en.pdf"},
    {"id":"2550","name":"Agenda - Ethical considerations for paediatric trials","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2011-09-20T16:23:00Z","last_updated_date":"2011-11-28T19:38:00Z","reference_number":"EMA/740227/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ethical-considerations-paediatric-trials_en.pdf"},
    {"id":"2583","name":"Agenda - CVMP agenda of the 16-18 February 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-02-16T13:15:00Z","last_updated_date":"2016-02-16T13:15:00Z","reference_number":"EMA/CVMP/128074/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-16-18-february-2016-meeting_en.pdf"},
    {"id":"2670","name":"Agenda - Joint European Medicines Agency/Parenteral Drug Association quality-by-design workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T01:00:00Z","last_updated_date":"2014-02-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-european-medicines-agencyparenteral-drug-association-quality-design-workshop_en.pdf"},
    {"id":"2677","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (Vienna, Austria)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-22T15:00:00Z","last_updated_date":"2015-01-29T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-vienna-austria_en.pdf"},
    {"id":"2696","name":"Agenda - COMP agenda of the 10-12 June 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-03T15:30:00Z","last_updated_date":"2014-06-03T15:30:00Z","reference_number":"EMA/COMP/321121/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-10-12-june-2014-meeting_en.pdf"},
    {"id":"2713","name":"Agenda - CHMP agenda of the 10-13 October 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-10-10T14:00:00Z","last_updated_date":"2016-10-10T14:00:00Z","reference_number":"EMA/CHMP/611664/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-10-13-october-2016-meeting_en.pdf"},
    {"id":"2791","name":"Agenda - Joint European Medicines Agency / European Directorate for the Quality of Medicines and Healthcare workshop on characterisation of new clotting factor concentrates (factor VIII and factor IX) with respect to pot...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-09-10T02:00:00Z","last_updated_date":"2013-09-10T02:00:00Z","reference_number":"EMA/439957/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-european-medicines-agency-european-directorate-quality-medicines-and-healthcare-workshop-characterisation-new-clotting-factor-concentrates-factor-viii-and-factor-ix-respect-pot_en.pdf"},
    {"id":"2819","name":"Agenda - PRAC draft agenda of meeting 30 August – 2 September 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-08-30T19:45:00Z","last_updated_date":"2016-10-04T19:20:00Z","reference_number":"EMA/PRAC/495379/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-30-august-2-september-2016_en.pdf"},
    {"id":"2854","name":"Agenda and list of participants - European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) stakeholders meeting 2015","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T13:00:00Z","last_updated_date":"2015-04-20T13:00:00Z","reference_number":"EMA/147754/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-list-participants-european-surveillance-veterinary-antimicrobial-consumption-esvac-stakeholders-meeting-2015_en.pdf"},
    {"id":"2856","name":"Agenda - 2017 Pharmacovigilance Inspectors Working Group training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T02:00:00Z","last_updated_date":"2017-10-12T02:00:00Z","reference_number":"EMA/INS/PhV/174813/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2017-pharmacovigilance-inspectors-working-group-training-course_en.pdf"},
    {"id":"2872","name":"Programme - Targeted consultation on development of new medicinal products for the treatment of rheumatoid arthritis","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-05-12T13:00:00Z","last_updated_date":"2016-05-12T13:00:00Z","reference_number":"EMA/251741/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-targeted-consultation-development-new-medicinal-products-treatment-rheumatoid-arthritis_en.pdf"},
    {"id":"2959","name":"Agenda for the 83rd meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2014-03-14T16:20:00Z","last_updated_date":"2014-03-25T13:30:00Z","reference_number":"EMA/MB/2712/2014 Version 4","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-83rd-meeting-management-board_en.pdf"},
    {"id":"3001","name":"Agenda - Medicines Agency workshop on extrapolation across age groups","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-07-14T14:00:00Z","last_updated_date":"2015-12-09T18:40:00Z","reference_number":"EMA/462579/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicines-agency-workshop-extrapolation-across-age-groups_en.pdf"},
    {"id":"3059","name":"Agenda and registration form - The new EudraVigilance System and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course (Athens)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T12:57:00Z","last_updated_date":"2017-06-15T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-athens_en.pdf"},
    {"id":"3073","name":"Agenda and registration form - EudraVigilance training on electronic reporting of ICSRs in the European Economic Area","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T13:00:00Z","last_updated_date":"2016-11-18T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-icsrs-european-economic-area_en.pdf"},
    {"id":"3098","name":"Agenda - COMP agenda of the 8-10 July 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-07-03T19:30:00Z","last_updated_date":"2014-07-03T19:30:00Z","reference_number":"EMA/COMP/373247/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-8-10-july-2014-meeting_en.pdf"},
    {"id":"3100","name":"Agenda - EudraVigilance Training in 2006, A joint initiative of the EMEA with DIA acting as the conference organiser","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-04-07T02:09:21Z","last_updated_date":"2006-04-07T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eudravigilance-training-2006-joint-initiative-emea-dia-acting-conference-organiser_en.pdf"},
    {"id":"3109","name":"Agenda for the 77th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/MB/397583/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-77th-meeting-management-board_en.pdf"},
    {"id":"3173","name":"Agenda - Eighth stakeholders forum on the implementation of the pharmacovigilance legislation: Building on two years of operation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-10T16:00:00Z","last_updated_date":"2014-09-10T16:00:00Z","reference_number":"EMA/449800/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eighth-stakeholders-forum-implementation-pharmacovigilance-legislation-building-two-years-operation_en.pdf"},
    {"id":"3177","name":"Agenda of the seventh annual meeting of Enpr-EMA members","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"EMA/153757/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-seventh-annual-meeting-enpr-ema-members_en.pdf"},
    {"id":"3191","name":"Agenda - Patients’ and Consumers’ Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint meeting - June 2013","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"EMA/228739/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-meeting-june-2013_en.pdf"},
    {"id":"3200","name":"Agenda – Update on the implementation of EMA policy on publication of clinical data (Policy 0070) – industry associations webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-07-05T02:00:00Z","last_updated_date":"2017-07-05T02:00:00Z","reference_number":"EMA/337506/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-update-implementation-ema-policy-publication-clinical-data-policy-0070-industry-associations-webinar_en.pdf"},
    {"id":"3218","name":"Agenda - PDCO agenda of the  12-15 September 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-09-18T12:26:00Z","last_updated_date":"2017-09-18T12:26:00Z","reference_number":"EMA/PDCO/550371/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-15-september-2017-meeting_en.pdf"},
    {"id":"3225","name":"Agenda - PRAC draft agenda of meeting 24-27 October 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-10-24T19:50:00Z","last_updated_date":"2016-10-24T19:50:00Z","reference_number":"EMA/PRAC/637685/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-24-27-october-2016_en.pdf"},
    {"id":"3284","name":"Agenda - PRAC draft agenda of meeting 5-8 February 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-02-05T17:34:00Z","last_updated_date":"2018-02-05T17:34:00Z","reference_number":"EMA/PRAC/73812/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-5-8-february-2018_en.pdf"},
    {"id":"3326","name":"Agenda - PRAC draft agenda of meeting 14-17 March 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-03-14T20:00:00Z","last_updated_date":"2016-03-14T20:00:00Z","reference_number":"EMA/PRAC/199507/2016 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-14-17-march-2016_en.pdf"},
    {"id":"3341","name":"Agenda - CAT agenda of the 15-16 February 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-02-19T10:00:00Z","last_updated_date":"2018-02-19T10:00:00Z","reference_number":"EMA/CAT/103975/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-15-16-february-2018-meeting_en.pdf"},
    {"id":"3374","name":"Agenda - PRAC draft agenda of meeting 9-12 April 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-04-09T17:44:00Z","last_updated_date":"2018-04-09T17:44:00Z","reference_number":"EMA/223357/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-9-12-april-2018_en.pdf"},
    {"id":"3410","name":"Agenda - PRAC draft agenda of meeting 5-8 March 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-03-05T14:30:00Z","last_updated_date":"2018-03-05T14:30:00Z","reference_number":"EMA/PRAC/140547/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-5-8-march-2018_en.pdf"},
    {"id":"3415","name":"Agenda - Workshop on first-line acute promyelocytic leukaemia treatment: European Union cooperative groups and the pharmaceutical industry","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-07-03T14:00:00Z","last_updated_date":"2015-07-03T14:00:00Z","reference_number":"EMA/330325/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-first-line-acute-promyelocytic-leukaemia-treatment-european-union-cooperative-groups-and-pharmaceutical-industry_en.pdf"},
    {"id":"3480","name":"Agenda - EMA workshop on the collaboration with general practitioners / family physicians","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-04-18T12:00:00Z","last_updated_date":"2016-04-28T12:00:00Z","reference_number":"EMA/40570/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-workshop-collaboration-general-practitioners-family-physicians_en.pdf"},
    {"id":"3510","name":"Agenda - Heads of Medicines Agencies (HMA) / European Medicines Agency (EMA) Joint Big Data Task Force meeting: identifying solutions for big data challenges","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-04-27T13:10:00Z","last_updated_date":"2018-05-02T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-heads-medicines-agencies-hma-european-medicines-agency-ema-joint-big-data-task-force-meeting-identifying-solutions-big-data-challenges_en.pdf"},
    {"id":"3511","name":"Agenda - Programme and registration form for: Global animal health conference: Global availability of veterinary medicines - providing a climate for science and innovation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-11-17T01:00:00Z","last_updated_date":"2011-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-and-registration-form-global-animal-health-conference-global-availability-veterinary-medicines-providing-climate-science-and-innovation_en.pdf"},
    {"id":"3540","name":"Agenda - Data anonymisation workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T11:00:00Z","last_updated_date":"2018-12-04T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-data-anonymisation-workshop_en.pdf"},
    {"id":"3551","name":"Agenda - European network of paediatric research-European Medicines Agency meeting: workshop on gastrointestinal (GI) outcome measures to evaluate CFTR modulators for the treatment of cystic fibrosis (CF) (afternoon sess...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-11-19T11:00:00Z","last_updated_date":"2015-11-19T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-meeting-workshop-gastrointestinal-gi-outcome-measures-evaluate-cftr-modulators-treatment-cystic-fibrosis-cf-afternoon-sess_en.pdf"},
    {"id":"3634","name":"Agenda - Conference on environmental risk assessment For human and veterinary medicinal products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2005-10-27T02:09:21Z","last_updated_date":"2005-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-conference-environmental-risk-assessment-human-and-veterinary-medicinal-products_en.pdf"},
    {"id":"3769","name":"Agenda - Second 2017 meeting of the coordinating group of the European network of paediatric research at the European Medicines Agency (Enpr-EMA)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-05-02T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-2017-meeting-coordinating-group-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"3795","name":"Agenda - PDCO agenda of the 18-20 June 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-18T16:50:00Z","last_updated_date":"2014-06-18T16:50:00Z","reference_number":"EMA/PDCO/324947/2014 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-18-20-june-2014-meeting_en.pdf"},
    {"id":"3796","name":"Agenda - CAT agenda of the 6-8 December 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-12-08T17:21:00Z","last_updated_date":"2017-12-08T17:21:00Z","reference_number":"EMA/CAT/815841/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-6-8-december-2017-meeting_en.pdf"},
    {"id":"3844","name":"Agenda - European network of paediatric research-European Medicines Agency meeting: rare gastrointestinal and liver diseases initiative (morning session)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-11-19T11:00:00Z","last_updated_date":"2015-11-19T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-meeting-rare-gastrointestinal-and-liver-diseases-initiative-morning-session_en.pdf"},
    {"id":"3853","name":"Agenda - European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-09-17T14:00:00Z","last_updated_date":"2018-11-08T17:00:00Z","reference_number":"EMA/610994/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp_en.pdf"},
    {"id":"3967","name":"Agenda - PRAC draft agenda of meeting 3-6 November 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-11-03T18:50:00Z","last_updated_date":"2015-11-03T18:50:00Z","reference_number":"EMA/PRAC/727372/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-3-6-november-2015_en.pdf"},
    {"id":"4002","name":"Agenda - Workshop on draft reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"EMA/44715/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-draft-reflection-paper-statistical-methodology-comparative-assessment-quality-attributes-drug-development_en.pdf"},
    {"id":"4021","name":"Agenda – Sixth stakeholder forum on the implementation of the new pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-11-06T17:00:00Z","last_updated_date":"2012-12-07T17:00:00Z","reference_number":"EMA/652724/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixth-stakeholder-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"4057","name":"Agenda and registration form - The new EudraVigilance System and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course (Madrid)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T12:57:00Z","last_updated_date":"2017-06-15T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-madrid_en.pdf"},
    {"id":"4094","name":"Agenda - COMP agenda of the 10-12 December  2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-11-29T12:45:00Z","last_updated_date":"2013-11-29T12:45:00Z","reference_number":"EMA/COMP/738467/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-10-12-december-2013-meeting_en.pdf"},
    {"id":"4156","name":"Agenda - PDCO agenda of the 15-18 August 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-08-16T16:04:00Z","last_updated_date":"2017-08-16T16:04:00Z","reference_number":"EMA/PDCO/472811/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-15-18-august-2017-meeting_en.pdf"},
    {"id":"4211","name":"CHMP ORGAM agenda for the meeting on 5 December 2016","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T15:45:00Z","last_updated_date":"2016-12-16T15:45:00Z","reference_number":"EMA/CHMP/814177/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-5-december-2016_en.pdf"},
    {"id":"4273","name":"Agenda - CHMP Blood Products Working Party (BPWP) Stakeholder Meeting on IVIg guidance","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2009-10-14T02:09:21Z","last_updated_date":"2009-10-14T02:09:21Z","reference_number":"EMEA/CHMP/BPWP/657503/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-blood-products-working-party-bpwp-stakeholder-meeting-ivig-guidance_en.pdf"},
    {"id":"4302","name":"Programme - Science, Medicines, Health: Patients at the heart of future innovation conference","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-26T17:30:00Z","last_updated_date":"2015-03-16T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-science-medicines-health-patients-heart-future-innovation-conference_en.pdf"},
    {"id":"4336","name":"Agenda - CVMP agenda of the 17-19 April 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-04-16T16:00:00Z","last_updated_date":"2018-04-16T16:00:00Z","reference_number":"EMA/CVMP/207411/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-17-19-april-2018-meeting_en.pdf"},
    {"id":"4354","name":"Agenda - PDCO agenda of the 16-19 May 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-05-19T16:15:00Z","last_updated_date":"2017-05-19T16:15:00Z","reference_number":"EMA/PDCO/265689/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-16-19-may-2017-meeting_en.pdf"},
    {"id":"4360","name":"Agenda - CHMP agenda of the 23-26 July 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-07-23T15:28:00Z","last_updated_date":"2018-07-31T15:28:00Z","reference_number":"EMA/CHMP/446483/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-23-26-july-2018-meeting_en.pdf"},
    {"id":"4406","name":"Agenda - Orphan medicines development in Europe and Japan","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-10-17T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"EMA/551226/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-orphan-medicines-development-europe-and-japan_en.pdf"},
    {"id":"4439","name":"Agenda and registration form - EudraVigilance information day: 21 June 2016","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T12:40:00Z","last_updated_date":"2016-06-07T11:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-information-day-21-june-2016_en.pdf"},
    {"id":"4516","name":"Agenda - PRAC draft agenda of meeting 30 November-3 December 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-12-01T17:00:00Z","last_updated_date":"2015-12-01T17:00:00Z","reference_number":"EMA/PRAC/808595/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-30-november-3-december-2015_en.pdf"},
    {"id":"4528","name":"Agenda - Launch of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2011-03-09T00:31:00Z","last_updated_date":"2011-03-09T00:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-launch-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"4577","name":"CVMP interested parties’ meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-04-20T17:50:00Z","last_updated_date":"2016-04-20T17:50:00Z","reference_number":"EMA/CVMP/47072/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/cvmp-interested-parties-meeting_en.pdf"},
    {"id":"4603","name":"Agenda and registration form - EudraVigilance training on electronic reporting of ICSRs in the European Economic Area","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T18:30:00Z","last_updated_date":"2017-01-04T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-icsrs-european-economic-area_en.pdf-0"},
    {"id":"4634","name":"Agenda - 10th anniversary of European Medicines Agency’s Patients' and Consumers' Working Party (PCWP)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-06-10T16:00:00Z","last_updated_date":"2016-06-28T16:00:00Z","reference_number":"EMA/392315/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-10th-anniversary-european-medicines-agencys-patients-and-consumers-working-party-pcwp_en.pdf"},
    {"id":"4664","name":"Agenda - CAT agenda of the 11–12 December 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-09T18:00:00Z","last_updated_date":"2015-01-09T18:00:00Z","reference_number":"EMA/CAT/652186/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-11-12-december-2014-meeting_en.pdf"},
    {"id":"4676","name":"Programme - EMA/EC multi-stakeholder workshop to further improve the implementation of the paediatric regulation","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-01-31T14:46:00Z","last_updated_date":"2018-04-19T17:50:00Z","reference_number":"EMA/49414/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-emaec-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation_en.pdf"},
    {"id":"4685","name":"Agenda - CAT agenda of the 12-13 May 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-05-20T19:15:00Z","last_updated_date":"2015-05-20T19:15:00Z","reference_number":"EMA/CAT/282059/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-12-13-may-2015-meeting_en.pdf"},
    {"id":"4698","name":"Agenda - Second periodic safety update report information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-04-10T11:45:00Z","last_updated_date":"2014-04-10T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-periodic-safety-update-report-information-day_en.pdf"},
    {"id":"4727","name":"Agenda - Patients’ and Consumers’ Working Party and Healthcare Professionals Working Party joint meeting - September 2013","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-09-24T18:45:00Z","last_updated_date":"2013-12-11T17:45:00Z","reference_number":"EMA/448547/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patients-and-consumers-working-party-and-healthcare-professionals-working-party-joint-meeting-september-2013_en.pdf"},
    {"id":"4750","name":"Agenda - CAT agenda of the 13-14 February 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-02-18T11:30:00Z","last_updated_date":"2014-02-18T11:30:00Z","reference_number":"EMA/CAT/89478/2014 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-13-14-february-2014-meeting_en.pdf"},
    {"id":"4771","name":"Agenda - CHMP agenda of the 22-25 January 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-01-22T14:21:00Z","last_updated_date":"2018-01-23T14:05:00Z","reference_number":"EMA/37929/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-22-25-january-2018-meeting_en.pdf"},
    {"id":"4772","name":"Agenda - PDCO agenda of the 4-6 July 2012 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-07-18T20:14:40Z","last_updated_date":"2012-07-18T20:14:40Z","reference_number":"EMA/PDCO/488196/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-4-6-july-2012-meeting_en.pdf"},
    {"id":"4785","name":"Agenda - 2009 EMEA MUMS Info Day: Procedural advice for classification and incentives for veterinary medicinal products indicated for Minor Use Minor Species Limited Markets","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-08-28T02:09:21Z","last_updated_date":"2009-08-28T02:09:21Z","reference_number":"EMEA/487062/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2009-emea-mums-info-day-procedural-advice-classification-and-incentives-veterinary-medicinal-products-indicated-minor-use-minor-species-limited-markets_en.pdf"},
    {"id":"4849","name":"Agenda - COMP agenda of the 16-18 June 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-05T14:00:00Z","last_updated_date":"2015-06-05T14:00:00Z","reference_number":"EMA/COMP/327079/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-16-18-june-2015-meeting_en.pdf"},
    {"id":"5008","name":"Agenda - Global Animal Health Conference","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-global-animal-health-conference_en.pdf"},
    {"id":"5020","name":"Agenda - EudraVigilance training on electronic reporting of Individual Case Safety Reports (ICSRs) in the European Economic Area (EEA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T11:45:00Z","last_updated_date":"2016-01-19T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eudravigilance-training-electronic-reporting-individual-case-safety-reports-icsrs-european-economic-area-eea_en.pdf"},
    {"id":"5067","name":"Agenda - Enpr-EMA Coordinating group members meeting 6 October 2016","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T13:45:00Z","last_updated_date":"2016-10-28T13:45:00Z","reference_number":"EMA/456581/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-members-meeting-6-october-2016_en.pdf"},
    {"id":"5138","name":"Programme - European Medicines Agency roundtable with stakeholders on the 10-year anniversary of the SME office","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-11-26T17:00:00Z","last_updated_date":"2015-11-26T17:00:00Z","reference_number":"EMA/719296/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-european-medicines-agency-roundtable-stakeholders-10-year-anniversary-sme-office_en.pdf"},
    {"id":"5146","name":"Agenda - COMP agenda of the 14-15 March 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-03-13T17:20:00Z","last_updated_date":"2017-03-13T17:20:00Z","reference_number":"EMA/COMP/121331/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-14-15-march-2017-meeting_en.pdf"},
    {"id":"5205","name":"Agenda - ENCePP information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-09-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-encepp-information-day_en.pdf"},
    {"id":"5251","name":"Agenda for the 69th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/MB/660138/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-69th-meeting-management-board_en.pdf"},
    {"id":"5307","name":"Agenda - Sixth annual face to face meeting of European network of paediatric research at the European Medicines Agency Coordinating Group members - 27 June 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-18T19:00:00Z","last_updated_date":"2014-06-18T19:00:00Z","reference_number":"EMA/245783/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixth-annual-face-face-meeting-european-network-paediatric-research-european-medicines-agency-coordinating-group-members-27-june-2014_en.pdf"},
    {"id":"5359","name":"Agenda - PRAC draft agenda of meeting 11-14 January 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-01-11T17:30:00Z","last_updated_date":"2016-01-11T17:30:00Z","reference_number":"EMA/PRAC/22240/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-11-14-january-2016_en.pdf"},
    {"id":"5360","name":"Agenda - First EMEA Workshop for Micro, Small and Medium-Sized Enterprises (SMEs) 'Navigating the Regulatory Maze'","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"EMEA/273211/2006","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-emea-workshop-micro-small-and-medium-sized-enterprises-smes-navigating-regulatory-maze_en.pdf"},
    {"id":"5428","name":"Agenda - CVMP agenda of the 6-8 October 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-10-06T12:30:00Z","last_updated_date":"2015-10-06T12:30:00Z","reference_number":"EMA/CVMP/654741/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-6-8-october-2015-meeting_en.pdf"},
    {"id":"5434","name":"Agenda - EMA / European Biopharmaceutical Enterprises (EBE) fifth annual regulatory conference on optimising the development of advanced therapies to meet patient needs","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T13:30:00Z","last_updated_date":"2016-12-19T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-european-biopharmaceutical-enterprises-ebe-fifth-annual-regulatory-conference-optimising-development-advanced-therapies-meet-patient-needs_en.pdf"},
    {"id":"5436","name":"Agenda - PRAC draft agenda of meeting 3-6 March 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-03-05T17:00:00Z","last_updated_date":"2014-03-05T17:00:00Z","reference_number":"EMA/PRAC/127750/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-3-6-march-2014_en.pdf"},
    {"id":"5468","name":"Agenda - PRAC draft agenda of meeting 11-14 April 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-04-11T19:30:00Z","last_updated_date":"2016-04-11T19:30:00Z","reference_number":"EMA/PRAC/262317/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-11-14-april-2016_en.pdf"},
    {"id":"5539","name":"Agenda - CAT agenda of the 18-20 July 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-07-20T15:45:00Z","last_updated_date":"2018-07-20T15:45:00Z","reference_number":"EMA/CAT/501027/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-18-20-july-2018-meeting_en.pdf"},
    {"id":"5543","name":"Agenda - PRAC draft agenda of meeting 8-11 September 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-09-08T19:00:00Z","last_updated_date":"2014-09-08T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-september-2014_en.pdf"},
    {"id":"5583","name":"Draft agenda - Second stakeholder meeting on the implementation of EMA policy 0070 (on the publication of clinical data)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"EMA/552187/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-second-stakeholder-meeting-implementation-ema-policy-0070-publication-clinical-data_en.pdf"},
    {"id":"5633","name":"Programme and registration form - European Medicines Agency information day on risk management planning: implementation of GVP V and RMP template rev. 2 guidance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-07T12:15:00Z","last_updated_date":"2017-11-22T13:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-european-medicines-agency-information-day-risk-management-planning-implementation-gvp-v-and-rmp-template-rev-2-guidance_en.pdf"},
    {"id":"5634","name":"Agenda - Veterinary Focus group Meeting - PK/PD modelling","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-09-24T02:09:21Z","last_updated_date":"2008-09-24T02:09:21Z","reference_number":"EMEA/CVMP/EWP/148075/2008","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-veterinary-focus-group-meeting-pkpd-modelling_en.pdf"},
    {"id":"5672","name":"Agenda - Workshop for Micro, Small and Medium-Sized Enterprises: statistical perspectives in regulatory clinical development programmes","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-12-11T17:40:00Z","last_updated_date":"2015-12-11T17:40:00Z","reference_number":"EMA/350683/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-micro-small-and-medium-sized-enterprises-statistical-perspectives-regulatory-clinical-development-programmes_en.pdf"},
    {"id":"5684","name":"Agenda - Workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-10-24T11:40:00Z","last_updated_date":"2011-10-24T11:40:00Z","reference_number":"EMA/838645/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-biosimilar-monoclonal-antibodies-and-immunogenicity-monoclonal-antibodies_en.pdf"},
    {"id":"5704","name":"Agenda - Joint HMA/EMEA meeting on promoting prudent and responsible use of antimicrobials in veterinary medicine","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:09:21Z","last_updated_date":"2009-05-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-hmaemea-meeting-promoting-prudent-and-responsible-use-antimicrobials-veterinary-medicine_en.pdf"},
    {"id":"5751","name":"Agenda - PRAC draft agenda of meeting 28 November - 1 December 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-11-28T18:18:00Z","last_updated_date":"2016-11-28T18:18:00Z","reference_number":"EMA/PRAC/724425/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-28-november-1-december-2016_en.pdf"},
    {"id":"5787","name":"Agenda - PRAC draft agenda of meeting 7-10 October 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-10-08T18:55:00Z","last_updated_date":"2013-10-14T14:30:00Z","reference_number":"EMA/PRAC/610367/2013 Corr","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-7-10-october-2013_en.pdf"},
    {"id":"5803","name":"Agenda and registration form  - eXtended EudraVigilance medicinal product dictionary face-to-face training course, London","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T13:00:00Z","last_updated_date":"2017-11-23T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-london_en.pdf"},
    {"id":"5804","name":"Agenda - European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) - 2nd annual network meeting 2012 - Agenda and summary","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2012-02-20T12:17:00Z","last_updated_date":"2012-03-29T12:27:00Z","reference_number":"EMA/965820/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-surveillance-veterinary-antimicrobial-consumption-esvac-2nd-annual-network-meeting-2012-agenda-and-summary_en.pdf"}    {"id":"5846","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMA/545915/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations_en.pdf"},
    {"id":"6023","name":"Agenda - Annual workshop of the European network of paediatric research at the European Medicines Agency","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-04-08T17:00:00Z","last_updated_date":"2015-06-18T16:00:00Z","reference_number":"EMA/150699/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-annual-workshop-european-network-paediatric-research-european-medicines-agency_en.pdf"},
    {"id":"6033","name":"Agenda - PDCO agenda of the 9-11 December 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-12-11T16:55:00Z","last_updated_date":"2015-12-11T16:55:00Z","reference_number":"EMA/PDCO/795522/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-9-11-december-2015-meeting_en.pdf"},
    {"id":"6116","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting on 4 June 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-05-27T13:00:00Z","last_updated_date":"2015-09-01T13:00:00Z","reference_number":"EMA/167496/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-4-june-2015_en.pdf"},
    {"id":"6177","name":"Agenda - CVMP agenda of the 8-10 September 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-09-07T20:00:00Z","last_updated_date":"2015-09-07T20:00:00Z","reference_number":"EMA/CVMP/593362/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-8-10-september-2015-meeting_en.pdf"},
    {"id":"6196","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Madrid","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2018-02-12T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-madrid_en.pdf-0"},
    {"id":"6199","name":"Programme - Workshop on measuring the impact of pharmacovigilance activities","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-08-04T15:50:00Z","last_updated_date":"2016-11-25T16:00:00Z","reference_number":"EMA/512056/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-workshop-measuring-impact-pharmacovigilance-activities_en.pdf"},
    {"id":"6208","name":"Agenda - CVMP agenda of the 19-21 June 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-06-19T14:19:00Z","last_updated_date":"2018-06-19T14:19:00Z","reference_number":"EMA/CVMP/365941/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-19-21-june-2018-meeting_en.pdf"},
    {"id":"6285","name":"Agenda - CAT agenda of the 15-16 April 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-04-16T18:30:00Z","last_updated_date":"2014-04-16T18:30:00Z","reference_number":"EMA/CAT/231892/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-15-16-april-2014-meeting_en.pdf"},
    {"id":"6321","name":"Agenda - CVMP agenda of the 10-12 December 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T13:00:00Z","last_updated_date":"2013-12-17T13:00:00Z","reference_number":"EMA/CVMP/776275/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-10-12-december-2013-meeting_en.pdf"},
    {"id":"6367","name":"Programme and registration form - European Medicines Agency (EMA) / Drug Information Association (DIA) signal management information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-02-23T17:00:00Z","last_updated_date":"2017-09-25T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-european-medicines-agency-ema-drug-information-association-dia-signal-management-information-day_en.pdf"},
    {"id":"6387","name":"Agenda - COMP agenda of the 8-9 January 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-12-19T16:01:00Z","last_updated_date":"2012-12-19T16:01:00Z","reference_number":"EMA/COMP/792332/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-8-9-january-2013-meeting_en.pdf"},
    {"id":"6570","name":"Agenda - Meeting of the Paediatric Diabetes Mellitus Experts Group","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-05-06T02:00:00Z","last_updated_date":"2010-05-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-paediatric-diabetes-mellitus-experts-group_en.pdf"},
    {"id":"6605","name":"Programme - Introduction to the European Union regulatory system and European Medicines Agency for international regulators and non-governmental organisations","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-06-09T02:00:00Z","last_updated_date":"2017-07-10T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-introduction-european-union-regulatory-system-and-european-medicines-agency-international-regulators-and-non-governmental-organisations_en.pdf"},
    {"id":"6614","name":"Agenda - CVMP agenda of the 17-19 May 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-05-19T12:10:00Z","last_updated_date":"2016-05-19T12:10:00Z","reference_number":"EMA/CVMP/337144/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-17-19-may-2016-meeting_en.pdf"},
    {"id":"6649","name":"Agenda - European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) stakeholders annual meeting 2017","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-04-03T02:00:00Z","last_updated_date":"2017-04-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-surveillance-veterinary-antimicrobial-consumption-esvac-stakeholders-annual-meeting-2017_en.pdf"},
    {"id":"6666","name":"Agenda - CHMP agenda of the 23-26 May 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-05-23T14:35:00Z","last_updated_date":"2016-05-23T14:35:00Z","reference_number":"EMA/CHMP/349943/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-23-26-may-2016-meeting_en.pdf"},
    {"id":"6667","name":"Agenda - COMP agenda of the 17-19 April 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-04-16T17:00:00Z","last_updated_date":"2018-04-16T17:00:00Z","reference_number":"EMA/COMP/171165/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-17-19-april-2018-meeting_en.pdf"},
    {"id":"6689","name":"Agenda - Third industry stakeholder platform on the operation of European Union pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"EMA/56551/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-industry-stakeholder-platform-operation-european-union-pharmacovigilance-legislation_en.pdf"},
    {"id":"6708","name":"Agenda - CVMP agenda of the 15-17 March 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-03-14T16:30:00Z","last_updated_date":"2016-03-14T16:30:00Z","reference_number":"EMA/CVMP/192750/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-15-17-march-2016-meeting_en.pdf"},
    {"id":"6750","name":"Agenda - PDA/EMA 2011 Conference - Regulation, Cooperation, Innovation: An Effective Partnership among Authorities and Industry in Europe","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-03-17T01:00:00Z","last_updated_date":"2011-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdaema-2011-conference-regulation-cooperation-innovation-effective-partnership-among-authorities-and-industry-europe_en.pdf"},
    {"id":"6754","name":"Agenda - Veterinary Focus Group Meeting - CVMP Bioequivalence Guideline (Revision)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-05-06T02:09:21Z","last_updated_date":"2009-05-06T02:09:21Z","reference_number":"EMEA/CVMP/98792/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-veterinary-focus-group-meeting-cvmp-bioequivalence-guideline-revision_en.pdf"},
    {"id":"6801","name":"Agenda - PDCO agenda of the 9-11 January 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T16:04:00Z","last_updated_date":"2013-01-11T16:04:00Z","reference_number":"EMA/PDCO/820062/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-9-11-january-2013-meeting_en.pdf"},
    {"id":"6815","name":"Agenda - CHMP agenda of the 20-23 October 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-10-20T17:52:00Z","last_updated_date":"2014-10-20T17:52:00Z","reference_number":"EMA/CHMP/601124/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-20-23-october-2014-meeting_en.pdf"},
    {"id":"6836","name":"Agenda – follow up information session on the TransCelerate initiative","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-06-16T02:00:00Z","last_updated_date":"2016-06-16T02:00:00Z","reference_number":"EMA/419751/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-follow-information-session-transcelerate-initiative_en.pdf"},
    {"id":"6938","name":"Agenda - CVMP agenda of the 5-7 May 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-05-05T18:00:00Z","last_updated_date":"2015-05-05T18:00:00Z","reference_number":"EMA/CVMP/287758/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-5-7-may-2015-meeting_en.pdf"},
    {"id":"7040","name":"Agenda - Workshop on identifying opportunities for 'big data' in medicines development and regulatory science","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-11-08T10:30:00Z","last_updated_date":"2016-11-08T10:30:00Z","reference_number":"EMA/707605/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-identifying-opportunities-big-data-medicines-development-and-regulatory-science_en.pdf"},
    {"id":"7045","name":"Agenda - COMP agenda of the 14-16 February 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-02-14T12:30:00Z","last_updated_date":"2017-02-14T12:30:00Z","reference_number":"EMA/COMP/50377/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-14-16-february-2017-meeting_en.pdf"},
    {"id":"7114","name":"Agenda: 2016 annual meeting of Enpr-EMA members","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2016-annual-meeting-enpr-ema-members_en.pdf"},
    {"id":"7117","name":"Agenda - PRAC draft agenda of meeting 3-6 April 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-04-04T17:18:00Z","last_updated_date":"2017-04-04T17:18:00Z","reference_number":"EMA/PRAC/227083/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-3-6-april-2017_en.pdf"},
    {"id":"7158","name":"Agenda – 6th industry stakeholder platform - operation of EU pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"EMA/727477/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-6th-industry-stakeholder-platform-operation-eu-pharmacovigilance-legislation_en.pdf"},
    {"id":"7284","name":"Agenda - European Medicines Agency / health-technology-assessment-body workshop on parallel scientific advice in drug development","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-10-10T12:20:00Z","last_updated_date":"2013-11-22T18:05:00Z","reference_number":"EMA/620552/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-health-technology-assessment-body-workshop-parallel-scientific-advice-drug-development_en.pdf"},
    {"id":"7286","name":"Agenda – Industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T18:21:00Z","last_updated_date":"2017-05-12T18:21:00Z","reference_number":"EMA/88749/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"7371","name":"Agenda - 2016 annual workshop of the European network of paediatric research at the EMA (Enpr-EMA)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-04-14T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"EMA/795122/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2016-annual-workshop-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"7415","name":"Agenda - CHMP agenda of the 6-9 November 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-11-06T14:00:00Z","last_updated_date":"2017-11-06T14:00:00Z","reference_number":"EMA/CHMP/721012/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-6-9-november-2017-meeting_en.pdf"},
    {"id":"7423","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting Session on communicatio...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-03-08T11:15:00Z","last_updated_date":"2016-07-05T12:15:00Z","reference_number":"EMA/856049/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-session_en.pdf"},
    {"id":"7469","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary training course 20-21 November 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-24T14:00:00Z","last_updated_date":"2014-09-24T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-training-course-20-21-november-2014_en.pdf"},
    {"id":"7513","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-06-10T16:00:00Z","last_updated_date":"2016-06-28T16:00:00Z","reference_number":"EMA/274681/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting_en.pdf"},
    {"id":"7572","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Paris","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-paris_en.pdf"},
    {"id":"7575","name":"Agenda - COMP agenda of the 17-19 March 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-03-09T16:30:00Z","last_updated_date":"2015-03-09T16:30:00Z","reference_number":"EMA/COMP/125148/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-17-19-march-2015-meeting_en.pdf"},
    {"id":"7578","name":"Agenda - ISPE/PDA Joint Workshop on Challenges of Implementing ICH Q8 and ICH Q9","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-12-06T00:09:21Z","last_updated_date":"2006-12-06T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ispepda-joint-workshop-challenges-implementing-ich-q8-and-ich-q9_en.pdf"},
    {"id":"7603","name":"Agenda - CAT agenda of the 3-4 November 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T16:55:00Z","last_updated_date":"2016-11-07T16:55:00Z","reference_number":"EMA/CAT/707323/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-3-4-november-2016-meeting_en.pdf"},
    {"id":"7638","name":"Agenda for the 78th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/MB/659251/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-78th-meeting-management-board_en.pdf"},
    {"id":"7641","name":"Agenda - European Union International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) task force meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T16:00:00Z","last_updated_date":"2015-10-29T16:00:00Z","reference_number":"EMA/528507/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-international-organization-standardization-iso-identification-medicinal-products-idmp-task-force-meeting_en.pdf"},
    {"id":"7681","name":"Agenda: Outcomes of the evaluation of the European medicines agency – the Future sustainability of the system","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-12-13T01:00:00Z","last_updated_date":"2010-12-13T01:00:00Z","reference_number":"EMA/251818/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-outcomes-evaluation-european-medicines-agency-future-sustainability-system_en.pdf"},
    {"id":"7711","name":"Agenda - CVMP agenda of the 8-10 April 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-04-07T19:00:00Z","last_updated_date":"2014-04-07T19:00:00Z","reference_number":"EMA/CVMP/177854/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-8-10-april-2014-meeting_en.pdf"},
    {"id":"7738","name":"Agenda - European network of paediatric research at the European Medicines Agency Coordinating Group meeting with Chairs of the working groups","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T17:00:00Z","last_updated_date":"2016-03-14T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-coordinating-group-meeting-chairs-working-groups_en.pdf"},
    {"id":"7811","name":"Agenda - EudraVigilance Training in 2006, A joint initiative of the EMEA with DIA acting as the conference organiser","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-04-10T02:09:21Z","last_updated_date":"2006-04-10T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eudravigilance-training-2006-joint-initiative-emea-dia-acting-conference-organiser_en.pdf-0"},
    {"id":"7933","name":"Agenda - PRAC draft agenda of meeting 3-6 September 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-09-03T18:44:00Z","last_updated_date":"2018-09-03T18:44:00Z","reference_number":"EMA/PRAC/596678/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-3-6-september-2018_en.pdf"},
    {"id":"7997","name":"Agenda: Workshop on paediatric formulations for assessors in national regulatory agencies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"EMA/53312/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-paediatric-formulations-assessors-national-regulatory-agencies_en.pdf"},
    {"id":"8002","name":"Agenda - Homeopathic Workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-11-26T00:09:21Z","last_updated_date":"2006-11-26T00:09:21Z","reference_number":"EMEA/314681/2006","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-homeopathic-workshop_en.pdf"},
    {"id":"8029","name":"Agenda - 2015 Forum on bioequivalence inspections","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-10-12T13:00:00Z","last_updated_date":"2015-10-12T13:00:00Z","reference_number":"EMA/670206/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2015-forum-bioequivalence-inspections_en.pdf"},
    {"id":"8068","name":"Agenda and registration form - EudraVigilance training on electronic reporting of Individual Case Safety Reports in the European Economic Area (San Marino)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-29T13:30:00Z","reference_number":"Course #15520","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-safety-reports-european-economic-area-san-marino_en.pdf"},
    {"id":"8077","name":"Agenda - CHMP agenda of the 19-22 March 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-03-19T14:27:00Z","last_updated_date":"2018-03-27T18:37:00Z","reference_number":"EMA/170926/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-march-2018-meeting_en.pdf"},
    {"id":"8189","name":"Agenda - PRAC draft agenda of meeting 2-5 September 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-09-02T14:50:00Z","last_updated_date":"2013-09-02T14:50:00Z","reference_number":"EMA/PRAC/534993/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-2-5-september-2013_en.pdf"},
    {"id":"8206","name":"Agenda - Regulatory workshop on clinical trials designs in neuromyelitis optica and spectrum disorders","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T16:00:00Z","last_updated_date":"2014-10-07T11:35:00Z","reference_number":"EMA/149595/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-regulatory-workshop-clinical-trials-designs-neuromyelitis-optica-and-spectrum-disorders_en.pdf"},
    {"id":"8282","name":"Agenda - Schmallenberg workshop at the European Medicines Agency","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2012-03-22T12:30:00Z","last_updated_date":"2012-03-22T12:30:00Z","reference_number":"EMA/CVMP/IWP/180422/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-schmallenberg-workshop-european-medicines-agency_en.pdf"},
    {"id":"8289","name":"Agenda - CVMP agenda of the 7-9 November 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-11-09T12:24:00Z","last_updated_date":"2017-11-09T12:24:00Z","reference_number":"EMA/CVMP/727215/2017 draft 2","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-7-9-november-2017-meeting_en.pdf"},
    {"id":"8328","name":"Agenda - Extraordinary Management Board meeting for the building approval process of European Medicines Agency premises in Amsterdam (in-camera): 28 February 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-02-28T11:00:00Z","last_updated_date":"2018-02-28T11:00:00Z","reference_number":"EMA/MB/102050/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-extraordinary-management-board-meeting-building-approval-process-european-medicines-agency-premises-amsterdam-camera-28-february-2018_en.pdf"},
    {"id":"8352","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Vienna, October 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-06-14T17:00:00Z","last_updated_date":"2018-06-14T17:00:00Z","reference_number":"Course # 18517","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-vienna-october-2018_en.pdf"},
    {"id":"8376","name":"Agenda - PRAC draft agenda of meeting 14-17 May 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-05-14T17:30:00Z","last_updated_date":"2018-05-14T17:30:00Z","reference_number":"EMA/292387/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-14-17-may-2018_en.pdf"},
    {"id":"8390","name":"Agenda - Joint EMA-FDA-MHLW-PMDA orphan medicinal product workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-12-19T13:00:00Z","last_updated_date":"2013-12-19T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-ema-fda-mhlw-pmda-orphan-medicinal-product-workshop_en.pdf"},
    {"id":"8412","name":"Agenda - CVMP agenda of the 11-13 July 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-07-10T16:40:00Z","last_updated_date":"2017-07-10T16:40:00Z","reference_number":"EMA/CVMP/435607/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-11-13-july-2017-meeting_en.pdf"},
    {"id":"8456","name":"Agenda - PDCO agenda of the 14-16 January 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-14T15:00:00Z","last_updated_date":"2015-01-14T15:00:00Z","reference_number":"EMA/PDCO/779162/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-14-16-january-2015-meeting_en.pdf"},
    {"id":"8486","name":"Agenda - CVMP agenda of the 11-13 February 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-02-10T17:30:00Z","last_updated_date":"2014-02-11T10:25:00Z","reference_number":"EMA/CVMP/78423/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-11-13-february-2014-meeting_en.pdf"},
    {"id":"8511","name":"Agenda - GMP training program for Turkish inspectors","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-11-25T00:09:21Z","last_updated_date":"2009-11-25T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-gmp-training-program-turkish-inspectors_en.pdf"},
    {"id":"8530","name":"Agenda - European Medicines Agency-European Federation of Pharmaceutical Industries and Associations modelling and simulation workshop - Break-out session 2","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-11-29T17:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"EMA/926027/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-european-federation-pharmaceutical-industries-and-associations-modelling-and-simulation-workshop-break-out-session-2_en.pdf"},
    {"id":"8546","name":"Agenda of the 80th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2013-06-18T19:00:00Z","last_updated_date":"2013-06-18T19:00:00Z","reference_number":"EMA/MB/197800/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-80th-meeting-management-board_en.pdf"},
    {"id":"8685","name":"Agenda - PRAC draft agenda of meeting 6-9 June 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-06-06T20:00:00Z","last_updated_date":"2016-06-06T20:00:00Z","reference_number":"EMA/PRAC/231459/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-6-9-june-2016_en.pdf"},
    {"id":"8775","name":"Agenda and registration form  - eXtended EudraVigilance medicinal product dictionary face-to-face training course, Madrid","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T13:00:00Z","last_updated_date":"2017-11-23T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-madrid_en.pdf"},
    {"id":"8788","name":"Agenda - COMP agenda of the 30-31 October 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-10-26T17:47:00Z","last_updated_date":"2017-10-26T17:47:00Z","reference_number":"EMA/COMP/663531/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-30-31-october-2017-meeting_en.pdf"},
    {"id":"8798","name":"Agenda - PDCO agenda of the 13-15 August 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-08-11T13:45:00Z","last_updated_date":"2014-08-13T17:06:00Z","reference_number":"EMA/449773/2014 Rev 2 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-13-15-august-2014-meeting_en.pdf"},
    {"id":"8807","name":"Agenda - Second stakeholders forum on the implementation of the new pharmacovigilance legislation","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2011-06-10T03:00:00Z","last_updated_date":"2011-06-24T03:00:00Z","reference_number":"EMA/366836/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-stakeholders-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"8827","name":"Agenda - Seventh industry stakeholder platform: operation of European Union pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T19:30:00Z","last_updated_date":"2016-04-01T19:30:00Z","reference_number":"EMA/179833/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-seventh-industry-stakeholder-platform-operation-european-union-pharmacovigilance-legislation_en.pdf"},
    {"id":"8873","name":"Agenda and registration form - Introduction to pharmacovigilance and rules for expedited reporting of individual case safety reports (ICSRs) in Europe","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-22T11:00:00Z","last_updated_date":"2015-01-29T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-introduction-pharmacovigilance-and-rules-expedited-reporting-individual-case-safety-reports-icsrs-europe_en.pdf"},
    {"id":"8964","name":"Agenda and registration form - 14th EudraVigilance information day, 23 May 2013","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-04-17T18:50:00Z","last_updated_date":"2013-04-22T13:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-14th-eudravigilance-information-day-23-may-2013_en.pdf"},
    {"id":"8968","name":"Agenda - CVMP agenda of the 3-5 October 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-10-03T16:30:00Z","last_updated_date":"2017-10-03T16:30:00Z","reference_number":"EMA/CVMP/647713/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-3-5-october-2017-meeting_en.pdf"},
    {"id":"8979","name":"Agenda - HMPC agenda of the 26-27 March 2018 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-03-26T18:26:00Z","last_updated_date":"2018-03-26T18:26:00Z","reference_number":"EMA/HMPC/188141/2018 - ver.3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-26-27-march-2018-meeting_en.pdf"},
    {"id":"9001","name":"Agenda - CVMP agenda of the 4-6 October 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-10-04T12:00:00Z","last_updated_date":"2016-10-04T12:00:00Z","reference_number":"EMA/CVMP/649396/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-4-6-october-2016-meeting_en.pdf"},
    {"id":"9090","name":"Agenda - Training session for patients and consumers involved in European Medicines Agency activities","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-11-13T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"EMA/632556/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-patients-and-consumers-involved-european-medicines-agency-activities_en.pdf"},
    {"id":"9150","name":"Agenda - CVMP agenda of the 10-12 March 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-03-10T11:00:00Z","last_updated_date":"2015-03-10T11:00:00Z","reference_number":"EMA/CVMP/159020/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-10-12-march-2015-meeting_en.pdf"},
    {"id":"9259","name":"Agenda - Meeting with Alliance for Regenerative Medicine","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T16:30:00Z","last_updated_date":"2017-12-19T16:30:00Z","reference_number":"EMA/821009/201","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-alliance-regenerative-medicine_en.pdf"},
    {"id":"9278","name":"Agenda - PRAC draft agenda of meeting 9-12 January 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-01-09T14:55:00Z","last_updated_date":"2017-01-09T14:55:00Z","reference_number":"EMA/PRAC/816784/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-9-12-january-2017_en.pdf"},
    {"id":"9400","name":"Agenda - COMP agenda of the 5-6 February 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T09:54:00Z","last_updated_date":"2013-01-29T09:54:00Z","reference_number":"EMA/COMP/20458/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-5-6-february-2013-meeting_en.pdf"},
    {"id":"9443","name":"Agenda - EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting (27 June 2017)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-06-06T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"EMA/213892/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-27-june-2017_en.pdf"},
    {"id":"9475","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-09-08T02:00:00Z","last_updated_date":"2011-09-08T02:00:00Z","reference_number":"EMA/544716/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting_en.pdf-0"},
    {"id":"9476","name":"Agenda - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-03-07T10:13:00Z","last_updated_date":"2017-05-17T12:30:00Z","reference_number":"EMA/762357/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-medicines_en.pdf"},
    {"id":"9550","name":"Programme - European Medicines Agency/International Federation for Animal Health-Europe info day 2015","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-22T17:00:00Z","last_updated_date":"2015-03-10T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-european-medicines-agencyinternational-federation-animal-health-europe-info-day-2015_en.pdf"},
    {"id":"9561","name":"Agenda - PRAC draft agenda of meeting 2-5 December 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-12-02T18:20:00Z","last_updated_date":"2013-12-02T18:20:00Z","reference_number":"EMA/PRAC/748572/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-2-5-december-2013_en.pdf"},
    {"id":"9592","name":"Agenda - CHMP agenda of the 15-18 May 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-05-15T18:44:00Z","last_updated_date":"2017-05-15T18:44:00Z","reference_number":"EMA/CHMP/262210/2017 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-15-18-may-2017-meeting_en.pdf"},
    {"id":"9609","name":"Agenda and registration form - The new EudraVigilance System and the electronic reporting of individual case safety report (ICSRs) in the ISO/ICH E2B(R3) format: hands-on training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-03-20T15:57:00Z","last_updated_date":"2017-06-15T16:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-individual-case-safety-report-icsrs-isoich-e2br3-format-hands-training-course_en.pdf"},
    {"id":"9626","name":"Agenda - PDCO agenda of the 9-11 October 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-10-03T18:45:00Z","last_updated_date":"2013-10-03T18:45:00Z","reference_number":"EMA/PDCO/592362/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-9-11-october-2013-meeting_en.pdf"},
    {"id":"9638","name":"Agenda - Workshop on biosimilars","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-11-12T13:00:00Z","reference_number":"EMA/473908/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-biosimilars_en.pdf"},
    {"id":"9741","name":"Agenda - CHMP agenda of the 22-25 February 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-02-22T12:30:00Z","last_updated_date":"2016-02-22T12:30:00Z","reference_number":"EMA/CHMP/139839/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-22-25-february-2016-meeting_en.pdf"},
    {"id":"9814","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting: info session on antimi...","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-09-05T14:30:00Z","last_updated_date":"2017-10-09T13:30:00Z","reference_number":"EMA/765134/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-info-session_en.pdf"},
    {"id":"9879","name":"Agenda - PDCO agenda of the 10-12 April 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T17:00:00Z","last_updated_date":"2013-04-08T17:00:00Z","reference_number":"EMA/PDCO/208985/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-10-12-april-2013-meeting_en.pdf"},
    {"id":"9904","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting: workshop on risk minim...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-08-04T15:05:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"EMA/292901/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-workshop-risk_en.pdf"},
    {"id":"9941","name":"CHMP ORGAM agenda for the meeting on 3 October 2016","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-10-04T18:00:00Z","last_updated_date":"2016-10-04T18:00:00Z","reference_number":"EMA/CHMP/620067/2016 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-3-october-2016_en.pdf"},
    {"id":"9954","name":"Agenda - CHMP agenda of the 18-21 July 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-07-19T12:00:00Z","last_updated_date":"2016-07-19T12:00:00Z","reference_number":"EMA/CHMP/490374/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-18-21-july-2016-meeting_en.pdf"},
    {"id":"9976","name":"Agenda - Eighth industry stakeholder platform: operation of EU pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T16:15:00Z","last_updated_date":"2016-08-15T16:15:00Z","reference_number":"EMA/375852/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eighth-industry-stakeholder-platform-operation-eu-pharmacovigilance-legislation_en.pdf"}    {"id":"9984","name":"Agenda - PDCO agenda of the 24-27 April 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-04-24T17:30:00Z","last_updated_date":"2018-04-24T17:30:00Z","reference_number":"EMA/257299/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-24-27-april-2018-meeting_en.pdf"},
    {"id":"9996","name":"Agenda - Adaptive pathways workshop","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-09-07T02:00:00Z","last_updated_date":"2016-12-07T15:00:00Z","reference_number":"EMA/594912/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-adaptive-pathways-workshop_en.pdf"},
    {"id":"10057","name":"Programme - SME workshop: Focus on quality for medicines containing chemical entities","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-sme-workshop-focus-quality-medicines-containing-chemical-entities_en.pdf"},
    {"id":"10074","name":"Agenda - 72nd meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/MB/234822/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-72nd-meeting-management-board_en.pdf"},
    {"id":"10075","name":"Agenda - PDCO agenda of the 14-16 September 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-09-14T18:40:00Z","last_updated_date":"2016-09-14T18:40:00Z","reference_number":"EMA/PDCO/534561/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-14-16-september-2016-meeting_en.pdf"},
    {"id":"10084","name":"Agenda - CHMP agenda of the 20-23 August 2018 written procedure","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-09-04T17:30:00Z","last_updated_date":"2018-09-04T17:30:00Z","reference_number":"EMA/CHMP/565731/2018 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-20-23-august-2018-written-procedure_en.pdf"},
    {"id":"10091","name":"Agenda - CHMP agenda of the 22-25 September 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T15:30:00Z","last_updated_date":"2014-09-22T15:30:00Z","reference_number":"EMA/CHMP/465006/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-22-25-september-2014-meeting_en.pdf"},
    {"id":"10123","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-10-27T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"EMA/654451/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations_en.pdf-0"},
    {"id":"10138","name":"Agenda - PRAC draft agenda of meeting 10-13 June 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-06-10T20:00:00Z","last_updated_date":"2013-06-10T20:00:00Z","reference_number":"EMA/PRAC/352733/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-10-13-june-2013_en.pdf"},
    {"id":"10150","name":"Agenda - HMPC agenda of the 30-31 January 2017 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T14:30:00Z","last_updated_date":"2017-01-30T14:30:00Z","reference_number":"EMA/HMPC/59024/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-30-31-january-2017-meeting_en.pdf"},
    {"id":"10170","name":"Agenda - CAT agenda of the 6-8 September 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-09-07T20:00:00Z","last_updated_date":"2017-09-07T20:00:00Z","reference_number":"EMA/CAT/599328/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-6-8-september-2017-meeting_en.pdf"},
    {"id":"10207","name":"Agenda - European Medicines Agency/International Federation for Animal Health Europe info day 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-02-06T18:10:00Z","last_updated_date":"2014-02-06T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agencyinternational-federation-animal-health-europe-info-day-2014_en.pdf"},
    {"id":"10245","name":"Agenda - Second EMEA - EGA Info Day; Generic and Biosimilar Medicines in the Centralised Procedure - For EGA Members Only","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-10-03T02:09:21Z","last_updated_date":"2008-10-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-emea-ega-info-day-generic-and-biosimilar-medicines-centralised-procedure-ega-members-only_en.pdf"},
    {"id":"10281","name":"Agenda - CAT agenda of the 18-19 February 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-02-22T15:20:00Z","last_updated_date":"2016-02-22T15:20:00Z","reference_number":"EMA/CAT/82731/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-18-19-february-2016-meeting_en.pdf"},
    {"id":"10290","name":"Agenda - CVMP agenda of the 14-16 March 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-03-14T13:42:00Z","last_updated_date":"2017-03-14T13:42:00Z","reference_number":"EMA/CVMP/171139/2017 draft","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-14-16-march-2017-meeting_en.pdf"},
    {"id":"10295","name":"Agenda - Public hearing: Valproate","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-09-22T14:30:00Z","last_updated_date":"2017-09-25T19:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-public-hearing-valproate_en.pdf"},
    {"id":"10298","name":"Agenda - CAT agenda of the 22-23 March 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-03-23T16:40:00Z","last_updated_date":"2016-03-23T16:40:00Z","reference_number":"EMA/CAT/164275/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-22-23-march-2016-meeting_en.pdf"},
    {"id":"10407","name":"Agenda - HMPC agenda of the 16-17 September 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-09-16T17:25:00Z","last_updated_date":"2013-09-16T17:25:00Z","reference_number":"EMA/HMPC/566094/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-16-17-september-2013-meeting_en.pdf"},
    {"id":"10430","name":"Agenda and registration form - EudraVigilance Information Day(London, November 2016)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-09-26T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-information-daylondon-november-2016_en.pdf"},
    {"id":"10452","name":"Agenda and registration form - eXtended EudraVigilance medicinal product dictionary face-to-face training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-08-04T14:10:01Z","last_updated_date":"2015-09-16T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course_en.pdf"},
    {"id":"10458","name":"Agenda and registration form - EudraVigilance training on electronic reporting of Individual Case Study Reports (ICSRs) in the European Economic Area (Vienna, Nov 2016)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-08-19T02:00:00Z","last_updated_date":"2016-08-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-study-reports-icsrs-european-economic-area-vienna-nov-2016_en.pdf"},
    {"id":"10472","name":"Agenda - PRAC draft agenda of the inaugural plenary meeting 19-20 July 2012","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2012-07-18T20:14:41Z","last_updated_date":"2012-07-18T20:14:41Z","reference_number":"EMA/PRAC/239375/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-inaugural-plenary-meeting-19-20-july-2012_en.pdf"},
    {"id":"10486","name":"Agenda - 2017 annual members meeting of the European network of paediatric research at the European Medicines Agency (Enpr-EMA)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-05-02T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2017-annual-members-meeting-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"10536","name":"Agenda - European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-04-04T16:35:00Z","last_updated_date":"2018-06-27T17:30:00Z","reference_number":"EMA/775204/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf"},
    {"id":"10554","name":"Agenda - PRAC draft agenda of meeting 29 August-1 September 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-08-29T19:00:00Z","last_updated_date":"2017-08-29T19:00:00Z","reference_number":"EMA/PRAC/568796/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-29-august-1-september-2017_en.pdf"},
    {"id":"10573","name":"Agenda: Veterinary pharmacovigilance question time: better regulation for electronic reporting and periodic safety update reports (PSURs)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2010-11-11T01:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"EMA/433980/2010-Draft","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-veterinary-pharmacovigilance-question-time-better-regulation-electronic-reporting-and-periodic-safety-update-reports-psurs_en.pdf"},
    {"id":"10579","name":"Agenda - CAT agenda of the 16-17 June 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T11:50:00Z","last_updated_date":"2016-06-17T11:50:00Z","reference_number":"EMA/CAT/423125/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-16-17-june-2016-meeting_en.pdf"},
    {"id":"10720","name":"Agenda - CHMP agenda of the 28-31 May 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-05-28T12:00:00Z","last_updated_date":"2018-05-28T12:00:00Z","reference_number":"EMA/CHMP/352527/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-28-31-may-2018-meeting_en.pdf"},
    {"id":"10742","name":"Agenda - CAT agenda of the 13-14 November 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T14:30:00Z","last_updated_date":"2014-11-24T14:30:00Z","reference_number":"EMA/CAT/706533/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-13-14-november-2014-meeting_en.pdf"},
    {"id":"10759","name":"Agenda and registration form - EudraVigilance training on electronic reporting of individual case safety reports in the European Economic Area (Austria, Dec 2015)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-09-21T02:00:00Z","last_updated_date":"2015-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-safety-reports-european-economic-area-austria-dec-2015_en.pdf"},
    {"id":"10784","name":"Agenda - PRAC draft agenda of meeting 29-31 October 2012","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2012-10-29T09:28:00Z","last_updated_date":"2012-10-29T09:28:00Z","reference_number":"EMA/PRAC/519417/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-29-31-october-2012_en.pdf"},
    {"id":"10802","name":"Draft agenda - Visit of the Danish Association of the Pharmaceutical Industry","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/336081/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-visit-danish-association-pharmaceutical-industry_en.pdf"},
    {"id":"10897","name":"Agenda - CAT agenda of the 18-20 April 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-04-19T17:26:00Z","last_updated_date":"2018-04-19T17:26:00Z","reference_number":"EMA/CAT/247071/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-18-20-april-2018-meeting_en.pdf"},
    {"id":"10908","name":"CHMP ORGAM agenda for the meeting on 15 January 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-01-22T14:27:00Z","last_updated_date":"2018-01-22T14:27:00Z","reference_number":"EMA/26255/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-15-january-2018_en.pdf"},
    {"id":"11012","name":"Agenda - HMPC agenda of the 28-29 September 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-09-28T11:10:00Z","last_updated_date":"2015-09-28T11:10:00Z","reference_number":"EMA/HMPC/635496/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-28-29-september-2015-meeting_en.pdf"},
    {"id":"11022","name":"Agenda - Second international awareness session for international regulators, academia and non-governmental organisations","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-12-18T18:15:00Z","last_updated_date":"2018-02-13T18:00:00Z","reference_number":"EMA/829042/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-international-awareness-session-international-regulators-academia-and-non-governmental-organisations_en.pdf"},
    {"id":"11040","name":"Agenda - Workshop on development of antibacterial medicinal products for paediatric patients","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-05-24T02:00:00Z","last_updated_date":"2018-10-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-development-antibacterial-medicinal-products-paediatric-patients_en.pdf"},
    {"id":"11091","name":"Agenda - PDCO agenda of the 19-21 March 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-14T16:30:00Z","last_updated_date":"2014-03-14T16:30:00Z","reference_number":"EMA/PDCO/134041/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-19-21-march-2014-meeting_en.pdf"},
    {"id":"11102","name":"Agenda - HMPC agenda of the 4-5 June 2018 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-06-11T17:30:00Z","last_updated_date":"2018-06-11T17:30:00Z","reference_number":"EMA/HMPC/370139/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-4-5-june-2018-meeting_en.pdf"},
    {"id":"11113","name":"Agenda - CVMP agenda of the 2-4 June 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-06-02T17:35:00Z","last_updated_date":"2015-06-02T17:35:00Z","reference_number":"EMA/CVMP/362586/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-2-4-june-2015-meeting_en.pdf"},
    {"id":"11128","name":"Agenda - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-07-30T12:25:00Z","last_updated_date":"2018-11-20T16:58:00Z","reference_number":"EMA/493240/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies_en.pdf"},
    {"id":"11218","name":"Agenda - Info day for micro, small and medium-sized enterprises: regulatory toolbox for medicines and combined devices developers","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-05-14T17:00:00Z","last_updated_date":"2018-10-25T15:00:00Z","reference_number":"EMA/150123/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-info-day-micro-small-and-medium-sized-enterprises-regulatory-toolbox-medicines-and-combined-devices-developers_en.pdf"},
    {"id":"11242","name":"Agenda - CAT agenda of the 13-14 March 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-20T14:45:00Z","last_updated_date":"2014-03-20T14:45:00Z","reference_number":"EMA/CAT/150740/2014 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-13-14-march-2014-meeting_en.pdf"},
    {"id":"11258","name":"Agenda - HMPC agenda of the 27-28 January 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-01-30T13:15:00Z","last_updated_date":"2014-01-30T13:15:00Z","reference_number":"EMA/HMPC/50290/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-27-28-january-2014-meeting_en.pdf"},
    {"id":"11292","name":"Agenda - CAT agenda of the 16-17 April 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-04-22T13:50:00Z","last_updated_date":"2015-04-22T13:50:00Z","reference_number":"EMA/CAT/258888/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-16-17-april-2015-meeting_en.pdf"},
    {"id":"11293","name":"Agenda – Industry stakeholder meeting on Brexit and operation of the centralised procedure for human medicinal products","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-03-02T11:00:00Z","last_updated_date":"2018-03-02T11:00:00Z","reference_number":"EMA/132201/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-stakeholder-meeting-brexit-and-operation-centralised-procedure-human-medicinal-products_en.pdf"},
    {"id":"11294","name":"Agenda - Training session on the review of product information","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-11-22T01:00:00Z","last_updated_date":"2010-11-22T01:00:00Z","reference_number":"EMA/564815/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-review-product-information_en.pdf"},
    {"id":"11303","name":"Agenda - HMPC agenda of the 5-6 May 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-05-05T19:15:00Z","last_updated_date":"2014-05-07T11:30:00Z","reference_number":"EMA/HMPC/273396/2014 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-5-6-may-2014-meeting_en.pdf"},
    {"id":"11369","name":"Agenda and registration form - EudraVigilance training on electronic reporting of Individual Case Study Reports (ICSRs) in the European Economic Area (Madrid, Sept 2016)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-08-19T02:00:00Z","last_updated_date":"2016-08-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-study-reports-icsrs-european-economic-area-madrid-sept-2016_en.pdf"},
    {"id":"11419","name":"Agenda - COMP agenda of the 8-9 April 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T12:50:00Z","last_updated_date":"2014-03-28T12:50:00Z","reference_number":"EMA/COMP/179739/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-8-9-april-2014-meeting_en.pdf"},
    {"id":"11421","name":"CHMP ORGAM agenda for the meeting on 30 October 2017","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-11-28T13:00:00Z","last_updated_date":"2017-11-28T13:00:00Z","reference_number":"EMA/720087/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-30-october-2017_en.pdf"},
    {"id":"11483","name":"Agenda - Risk management plan information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-09-12T19:00:00Z","last_updated_date":"2018-10-18T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-risk-management-plan-information-day_en.pdf"},
    {"id":"11591","name":"Agenda - Industry stakeholder meeting on Brexit and operation of the centralised procedure for human medicinal products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-10-02T14:00:00Z","last_updated_date":"2017-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-stakeholder-meeting-brexit-and-operation-centralised-procedure-human-medicinal-products_en.pdf-0"},
    {"id":"11598","name":"Agenda and registration form - Training on electronic reporting of individual case safety reports (ICSRs) to EudraVigilance in the European Economic Area (Paris)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-09-21T02:00:00Z","last_updated_date":"2016-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-training-electronic-reporting-individual-case-safety-reports-icsrs-eudravigilance-european-economic-area-paris_en.pdf"},
    {"id":"11659","name":"Agenda - Ninth industry stakeholder platform on the operation of EU pharmacovigilance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-09-20T17:52:00Z","last_updated_date":"2016-09-20T17:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ninth-industry-stakeholder-platform-operation-eu-pharmacovigilance_en.pdf"},
    {"id":"11661","name":"Agenda - EMEA-EFPIA Info day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emea-efpia-info-day_en.pdf"},
    {"id":"11681","name":"Agenda - Workshop on product shortages due to manufacturing and quality problems: Developing a proactive approach to prevention","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-10-09T14:00:00Z","last_updated_date":"2013-10-10T18:00:00Z","reference_number":"EMA/INS/GMP/461767/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-product-shortages-due-manufacturing-and-quality-problems-developing-proactive-approach-prevention_en.pdf"},
    {"id":"11760","name":"Agenda - CVMP agenda of the 9-11 September 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-08T18:00:00Z","last_updated_date":"2014-09-08T18:00:00Z","reference_number":"EMA/CVMP/543110/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-9-11-september-2014-meeting_en.pdf"},
    {"id":"11814","name":"Agenda and registration form - Joint Drug Information Association/European Medicines Agency information day on post-authorisation studies (PAS)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2015-06-02T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-joint-drug-information-associationeuropean-medicines-agency-information-day-post-authorisation-studies-pas_en.pdf"},
    {"id":"11817","name":"Agenda - Workshop on regulatory and scientific issues related to the Investigation of medicinal products intended for neonatal use - Neonates Workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-08-31T02:09:21Z","last_updated_date":"2006-08-31T02:09:21Z","reference_number":"EMEA/359419/2006","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-regulatory-and-scientific-issues-related-investigation-medicinal-products-intended-neonatal-use-neonates-workshop_en.pdf"},
    {"id":"11821","name":"Agenda - CAT scientific workshop: Reducing the number of laboratory animals used in tissue-engineering research","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-11-12T18:15:00Z","last_updated_date":"2012-11-12T18:15:00Z","reference_number":"EMA/CAT/653272/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-scientific-workshop-reducing-number-laboratory-animals-used-tissue-engineering-research_en.pdf"},
    {"id":"11847","name":"Agenda - Twelfth joint EMA/EUnetHTA dialogue meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T13:00:00Z","last_updated_date":"2016-12-05T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-twelfth-joint-emaeunethta-dialogue-meeting_en.pdf"},
    {"id":"11869","name":"Agenda - PRAC draft agenda of meeting 3-6 November 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-11-03T17:05:00Z","last_updated_date":"2014-11-03T17:05:00Z","reference_number":"EMA/PRAC/677871/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-3-6-november-2014_en.pdf"},
    {"id":"11997","name":"Agenda - PDCO agenda of the 24-27 July 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-07-24T18:30:00Z","last_updated_date":"2018-07-24T18:30:00Z","reference_number":"EMA/PDCO/463361/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-24-27-july-2018-meeting_en.pdf"},
    {"id":"12003","name":"Agenda - CAT agenda of the 15-16 May 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T13:25:00Z","last_updated_date":"2014-05-16T13:25:00Z","reference_number":"EMA/CAT/295498/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-15-16-may-2014-meeting_en.pdf"},
    {"id":"12022","name":"Agenda - COMP agenda of the 3-4 September 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-08-22T13:18:00Z","last_updated_date":"2013-08-22T13:18:00Z","reference_number":"EMA/COMP/418589/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-3-4-september-2013-meeting_en.pdf"},
    {"id":"12070","name":"Agenda - 2017 annual workshop of the European network of paediatric research at the European Medicines Agency (Enpr-EMA)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-02-09T15:00:00Z","last_updated_date":"2017-05-22T16:00:00Z","reference_number":"EMA/452047/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2017-annual-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"12110","name":"Agenda - CHMP agenda of the 25-28 April 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-04-25T15:05:00Z","last_updated_date":"2016-04-25T15:05:00Z","reference_number":"EMA/CHMP/287724/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-25-28-april-2016-meeting_en.pdf"},
    {"id":"12122","name":"Agenda - CVMP agenda of the 7-9 July 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-07-07T15:00:00Z","last_updated_date":"2015-07-07T15:00:00Z","reference_number":"EMA/CVMP/452291/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-7-9-july-2015-meeting_en.pdf"},
    {"id":"12195","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting on 17 September 2015","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-08-04T15:00:00Z","last_updated_date":"2015-12-11T14:00:00Z","reference_number":"EMA/347054/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-17-september-2015_en.pdf"},
    {"id":"12212","name":"Agenda and registration form - The new EudraVigilance System and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course (Vienna)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T12:57:00Z","last_updated_date":"2017-06-15T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-vienna_en.pdf"},
    {"id":"12297","name":"Agenda - EMEA/ICH Workshop on Viral/Vector Shedding","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emeaich-workshop-viralvector-shedding_en.pdf"},
    {"id":"12334","name":"Agenda - CHMP agenda of the 17-20 March 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-17T11:40:00Z","last_updated_date":"2014-03-17T11:40:00Z","reference_number":"EMA/CHMP/105714/2014 Version 4","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-17-20-march-2014-meeting_en.pdf"},
    {"id":"12344","name":"Agenda - CHMP agenda of the 14-17 August 2017 written procedure","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-08-14T17:12:00Z","last_updated_date":"2017-08-14T17:12:00Z","reference_number":"EMA/CHMP/516741/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-14-17-august-2017-written-procedure_en.pdf"},
    {"id":"12357","name":"Agenda - 6th ICH E2B (R3) Individual Case Safety Report (ICSR) information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-25T01:00:00Z","last_updated_date":"2014-03-25T01:00:00Z","reference_number":"Course #14502","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-6th-ich-e2b-r3-individual-case-safety-report-icsr-information-day_en.pdf"},
    {"id":"12372","name":"Agenda - CVMP agenda of the 8-10 November 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-11-07T18:20:00Z","last_updated_date":"2016-11-07T18:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-8-10-november-2016-meeting_en.pdf"},
    {"id":"12389","name":"Agenda - Workshop on access to clinical-trial data and transparency","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T17:13:02Z","last_updated_date":"2012-11-22T11:57:00Z","reference_number":"EMA/406355/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-access-clinical-trial-data-and-transparency_en.pdf"},
    {"id":"12424","name":"Agenda - CHMP agenda of the 23-26 February 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-02-24T10:20:00Z","last_updated_date":"2015-02-24T10:20:00Z","reference_number":"EMA/CHMP/48163/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-23-26-february-2015-meeting_en.pdf"},
    {"id":"12426","name":"Agenda - CVMP agenda of the 4-6 November 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-11-03T17:30:00Z","last_updated_date":"2015-11-03T17:30:00Z","reference_number":"EMA/CVMP/723983/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-4-6-november-2015-meeting_en.pdf"},
    {"id":"12466","name":"Agenda - COMP agenda of the 9-11 December 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T16:30:00Z","last_updated_date":"2014-12-01T16:30:00Z","reference_number":"EMA/COMP/719717/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-9-11-december-2014-meeting_en.pdf"},
    {"id":"12474","name":"Agenda - PRAC draft agenda of meeting 5-8 October 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-10-05T18:40:00Z","last_updated_date":"2015-10-05T18:40:00Z","reference_number":"EMA/PRAC/656971/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-5-8-october-2015_en.pdf"},
    {"id":"12589","name":"Agenda - Industry stakeholder platform on the operation of the centralised procedure","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T12:00:00Z","last_updated_date":"2015-04-29T12:00:00Z","reference_number":"EMA/207894/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-stakeholder-platform-operation-centralised-procedure_en.pdf"},
    {"id":"12604","name":"Agenda – Update on the implementation of EMA policy on publication of clinical data (Policy 0070) – industry associations webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-03-31T13:11:00Z","last_updated_date":"2017-03-31T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-update-implementation-ema-policy-publication-clinical-data-policy-0070-industry-associations-webinar_en.pdf-0"},
    {"id":"12636","name":"Programme and registration form - Joint European Medicines Agency/Drug Information Association information day on International Organization for Standardization identification of medicinal products standards: achieving c...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-05T17:00:00Z","last_updated_date":"2015-06-17T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-joint-european-medicines-agencydrug-information-association-information-day-international-organization-standardization-identification-medicinal-products-standards_en.pdf"},
    {"id":"12695","name":"Agenda - Focus group on promotion of pharmacovigilance for food producing animals","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"EMA/634595/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-focus-group-promotion-pharmacovigilance-food-producing-animals_en.pdf"},
    {"id":"12818","name":"Agenda and registration form - EudraVigilance information day on 19 September 2017","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T16:30:00Z","last_updated_date":"2017-08-18T17:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-information-day-19-september-2017_en.pdf"},
    {"id":"12875","name":"Agenda and registration form - eXtended EudraVigilance medicinal product dictionary face-to-face training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-09-21T02:00:00Z","last_updated_date":"2015-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course_en.pdf-0"},
    {"id":"12928","name":"Agenda and registration form - Individual Case Safety Report (ICSR) information day: 26 April 2016","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T13:30:00Z","last_updated_date":"2016-03-11T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-individual-case-safety-report-icsr-information-day-26-april-2016_en.pdf"},
    {"id":"12964","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Berlin, September 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-06-14T17:00:00Z","last_updated_date":"2018-06-14T17:00:00Z","reference_number":"Course # 18515","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-berlin-september-2018_en.pdf"},
    {"id":"12974","name":"Agenda - Expert meeting on the clinical investigation of medicines for the treatment of paediatric hepatitis C","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-12-02T17:30:00Z","last_updated_date":"2014-12-02T17:30:00Z","reference_number":"EMA/728001/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-expert-meeting-clinical-investigation-medicines-treatment-paediatric-hepatitis-c_en.pdf"},
    {"id":"12979","name":"Agenda for the 74th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T11:30:00Z","last_updated_date":"2011-12-20T11:30:00Z","reference_number":"EMA/MB/826035/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-74th-meeting-management-board_en.pdf"},
    {"id":"13014","name":"Agenda - PDCO agenda of the 10-12 September 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-09T11:25:00Z","last_updated_date":"2014-09-09T11:25:00Z","reference_number":"EMA/PDCO/509779/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-10-12-september-2014-meeting_en.pdf"},
    {"id":"13072","name":"Agenda - HMPC agenda of the 30-31 May 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T18:00:00Z","last_updated_date":"2016-05-27T18:00:00Z","reference_number":"EMA/HMPC/373146/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-30-31-may-2016-meeting_en.pdf"},
    {"id":"13111","name":"Agenda and registration form - Joint European Medicines Agency/Drug Information Association information day on risk management planning - 30 June 2015","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-09T18:30:00Z","last_updated_date":"2015-06-16T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-joint-european-medicines-agencydrug-information-association-information-day-risk-management-planning-30-june-2015_en.pdf"},
    {"id":"13134","name":"Agenda - BMWP/BWP Workshop on Immunogenicity Assessment of Therapeutic Proteins","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2007-08-24T02:09:21Z","last_updated_date":"2007-08-24T02:09:21Z","reference_number":"EMEA/CHMP/BMWP/580944/2007","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-bmwpbwp-workshop-immunogenicity-assessment-therapeutic-proteins_en.pdf"},
    {"id":"13136","name":"Agenda - PDCO agenda of the 12-15 December 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-12-11T16:23:00Z","last_updated_date":"2017-12-11T16:23:00Z","reference_number":"EMA/PDCO/766329/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-15-december-2017-meeting_en.pdf"},
    {"id":"13155","name":"Agenda - Patients/Consumers Working Party (PCWP) and Healthcare Professionals Working Group (HCP WG) joint meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2012-02-27T01:00:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"EMA/995452/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patientsconsumers-working-party-pcwp-and-healthcare-professionals-working-group-hcp-wg-joint-meeting_en.pdf"},
    {"id":"13179","name":"Agenda for the 76th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2012-06-14T16:30:00Z","last_updated_date":"2012-06-14T16:30:00Z","reference_number":"EMA/MB/92770/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-76th-meeting-management-board_en.pdf"},
    {"id":"13192","name":"Agenda - Third EMA-EGA Info Day - Generic and biosimilar medicines in the centralised procedure","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-11-09T01:00:00Z","last_updated_date":"2010-11-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-ema-ega-info-day-generic-and-biosimilar-medicines-centralised-procedure_en.pdf"},
    {"id":"13201","name":"Agenda - CVMP agenda of the 14-16 January 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-01-13T15:20:00Z","last_updated_date":"2014-01-13T15:20:00Z","reference_number":"EMA/CVMP/17499/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-14-16-january-2014-meeting_en.pdf"}    {"id":"13208","name":"Agenda - PDCO agenda of the 7-9 October 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-10-07T17:20:00Z","last_updated_date":"2015-10-07T17:20:00Z","reference_number":"EMA/PDCO/614334/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-7-9-october-2015-meeting_en.pdf"},
    {"id":"13239","name":"Agenda - First European Medicines Agency and the European Generic and Biosimilar Medicines Association (EGA) annual bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"EMA/866175/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-european-medicines-agency-and-european-generic-and-biosimilar-medicines-association-ega-annual-bilateral-meeting_en.pdf"},
    {"id":"13241","name":"Agenda: First anniversary of PRIME: experience so far","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-03-22T15:00:00Z","last_updated_date":"2017-05-12T18:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-anniversary-prime-experience-so-far_en.pdf"},
    {"id":"13245","name":"Agenda - PDCO agenda of the 12-14 August 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-08-13T11:20:00Z","last_updated_date":"2015-08-13T11:20:00Z","reference_number":"EMA/PDCO/490676/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-14-august-2015-meeting_en.pdf"},
    {"id":"13268","name":"Agenda - Fourth stakeholder forum on the implementation of the new 2010 pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-02-23T19:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"EMA/53186/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-stakeholder-forum-implementation-new-2010-pharmacovigilance-legislation_en.pdf"},
    {"id":"13278","name":"Agenda - PRAC draft agenda of meeting 6-9 March 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-03-06T06:30:00Z","last_updated_date":"2017-03-06T06:30:00Z","reference_number":"EMA/PRAC/159496/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-6-9-march-2017_en.pdf"},
    {"id":"13283","name":"Agenda - Innovative medicines initiative WEB-RADR workshop: mobile technologies and social media as new tools in pharmacovigilance","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-12-08T16:00:00Z","last_updated_date":"2014-12-08T16:00:00Z","reference_number":"EMA/657669/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-innovative-medicines-initiative-web-radr-workshop-mobile-technologies-and-social-media-new-tools-pharmacovigilance_en.pdf"},
    {"id":"13291","name":"Agenda - CVMP agenda of the 17-19 January 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-01-16T15:29:00Z","last_updated_date":"2017-01-16T15:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-17-19-january-2017-meeting_en.pdf"},
    {"id":"13322","name":"Agenda - COMP agenda of the 11-13 June 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T15:10:00Z","last_updated_date":"2013-06-04T11:15:00Z","reference_number":"EMA/COMP/310701/2013, Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-11-13-june-2013-meeting_en.pdf"},
    {"id":"13359","name":"Agenda - “Progress in the area of Antimicrobial Resistance – Veterinary Medicines” organised by the EMA and the HMA (veterinary)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-progress-area-antimicrobial-resistance-veterinary-medicines-organised-ema-and-hma-veterinary_en.pdf"},
    {"id":"13409","name":"Agenda - PDCO agenda of the 26-29 June 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-06-26T17:42:00Z","last_updated_date":"2018-07-06T15:56:00Z","reference_number":"EMA/376005/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-26-29-june-2018-meeting_en.pdf"},
    {"id":"13433","name":"Agenda - CHMP agenda of the 18-21 April 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-04-18T16:42:00Z","last_updated_date":"2017-04-18T16:42:00Z","reference_number":"EMA/244895/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-18-21-april-2017-meeting_en.pdf"},
    {"id":"13482","name":"Agenda - COMP agenda of the 5-6 December 2012 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-11-23T13:30:00Z","last_updated_date":"2012-11-23T13:30:00Z","reference_number":"EMA/COMP/751952/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-5-6-december-2012-meeting_en.pdf"},
    {"id":"13575","name":"Agenda - Meeting on plasma master file epidemiology - 18-19 November 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-08-01T12:45:00Z","last_updated_date":"2014-08-01T12:45:00Z","reference_number":"EMA/412937/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-plasma-master-file-epidemiology-18-19-november-2014_en.pdf"},
    {"id":"13593","name":"Agenda - Consultation meeting with stakeholders - Request from the European Commission for advice on the impact on public and animal health of the use of antibiotics in animals","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T16:15:00Z","last_updated_date":"2013-12-17T16:15:00Z","reference_number":"EMA/695339/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-consultation-meeting-stakeholders-request-european-commission-advice-impact-public-and-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"13594","name":"Agenda - CAT agenda of the 15-17 March 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-03-17T10:10:00Z","last_updated_date":"2017-03-17T10:10:00Z","reference_number":"EMA/CAT/185409/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-15-17-march-2017-meeting_en.pdf"},
    {"id":"13630","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Paris, November 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-06-14T17:00:00Z","last_updated_date":"2018-06-14T17:00:00Z","reference_number":"Course # 18521","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-paris-november-2018_en.pdf"},
    {"id":"13651","name":"Agenda - COMP agenda of the 4-6 October 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-10-05T02:00:00Z","last_updated_date":"2016-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-4-6-october-2016-meeting_en.pdf"},
    {"id":"13663","name":"Agenda - European Medicines Agency veterinary medicines info day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T12:00:00Z","last_updated_date":"2017-03-27T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-veterinary-medicines-info-day_en.pdf"},
    {"id":"13674","name":"Agenda and registration form - The new EudraVigilance System and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T17:52:00Z","last_updated_date":"2017-06-15T17:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course_en.pdf"},
    {"id":"13677","name":"Agenda - EMEA/DIA Joint Workshop on: EMEA new Guidelines for development and approval of Biosimilars","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2005-12-02T00:09:21Z","last_updated_date":"2005-12-02T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emeadia-joint-workshop-emea-new-guidelines-development-and-approval-biosimilars_en.pdf"},
    {"id":"13754","name":"Agenda - Best expertise vs conflicts of interests: Striking the right balance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T17:20:00Z","last_updated_date":"2013-09-04T14:15:00Z","reference_number":"EMA/189739/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-best-expertise-vs-conflicts-interests-striking-right-balance_en.pdf"},
    {"id":"13798","name":"Agenda – Tenth Stakeholder forum on the Pharmacovigilance legislation","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-09-14T17:00:00Z","last_updated_date":"2016-09-14T17:00:00Z","reference_number":"EMA/348709/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-tenth-stakeholder-forum-pharmacovigilance-legislation_en.pdf"},
    {"id":"13820","name":"Agenda - EMEA Workshop on the Guideline for first-in-man clinical trials for potential high-risk medicinal products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2007-06-08T02:09:21Z","last_updated_date":"2007-06-08T02:09:21Z","reference_number":"EMEA/177203/2007","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emea-workshop-guideline-first-man-clinical-trials-potential-high-risk-medicinal-products_en.pdf"},
    {"id":"13882","name":"Agenda - DIA/EMEA/CMD(h) Joint Conference on Variations - Programme","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-10-26T02:09:21Z","last_updated_date":"2006-10-26T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-diaemeacmdh-joint-conference-variations-programme_en.pdf"},
    {"id":"14028","name":"Agenda - PRAC draft agenda of meeting 6-9 January 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-01-06T20:00:00Z","last_updated_date":"2015-01-06T20:00:00Z","reference_number":"EMA/PRAC/9223/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-6-9-january-2015_en.pdf"},
    {"id":"14043","name":"Agenda - Fourth industry stakeholder platform - operation of European Union pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T16:00:00Z","last_updated_date":"2015-06-25T16:00:00Z","reference_number":"EMA/402820/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-industry-stakeholder-platform-operation-european-union-pharmacovigilance-legislation_en.pdf"},
    {"id":"14051","name":"Agenda and registration form - The new EudraVigilance System and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course (Amsterdam)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T12:57:00Z","last_updated_date":"2017-06-15T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-amsterdam_en.pdf"},
    {"id":"14057","name":"Agenda – Registries Initiative – Cystic Fibrosis Workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"EMA/648897/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-registries-initiative-cystic-fibrosis-workshop_en.pdf"},
    {"id":"14066","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - 3 June 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T02:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"EMA/136044/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-3-june-2014_en.pdf"},
    {"id":"14071","name":"Agenda - PDCO agenda of the 15-17 May 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-05-15T14:30:00Z","last_updated_date":"2013-05-15T14:30:00Z","reference_number":"EMA/PDCO/285727/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-15-17-may-2013-meeting_en.pdf"},
    {"id":"14088","name":"Agenda for the 95th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-03-15T11:50:00Z","last_updated_date":"2017-03-17T17:00:00Z","reference_number":"EMA/MB/1181/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-95th-meeting-management-board_en.pdf"},
    {"id":"14095","name":"Agenda - CHMP agenda of the 19-22 October 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-10-19T15:10:00Z","last_updated_date":"2015-10-19T15:10:00Z","reference_number":"EMA/CHMP/684198/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-october-2015-meeting_en.pdf"},
    {"id":"14113","name":"Agenda - COMP agenda of the 10-12 November 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-11-05T16:27:00Z","last_updated_date":"2015-11-05T16:27:00Z","reference_number":"EMA/COMP/674065/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-10-12-november-2015-meeting_en.pdf"},
    {"id":"14123","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH 2B(R3) format: hands-on training course (Bucharest)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-12-12T12:14:00Z","last_updated_date":"2017-12-12T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-2br3-format-hands-training-course-bucharest_en.pdf"},
    {"id":"14167","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-02-23T01:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"EMA/10452/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf"},
    {"id":"14338","name":"Agenda and registration form - The new EudraVigilance System and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course (London)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T12:57:00Z","last_updated_date":"2017-06-15T12:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-london_en.pdf"},
    {"id":"14468","name":"Agenda - Programme  - European Medicines Agency workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T17:15:00Z","last_updated_date":"2013-10-07T17:15:00Z","reference_number":"EMA/263897/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-european-medicines-agency-workshop-clinical-investigation-new-medicines-treatment-multiple-sclerosis_en.pdf"},
    {"id":"14505","name":"Agenda and registration form - EudraVigilance information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-27T12:00:00Z","last_updated_date":"2017-12-06T17:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-information-day_en.pdf"},
    {"id":"14507","name":"Agenda - Committee for Advanced Therapies (CAT) meeting with interested parties","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-05-18T11:00:00Z","last_updated_date":"2015-05-18T11:00:00Z","reference_number":"EMA/CAT/750592/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-committee-advanced-therapies-cat-meeting-interested-parties_en.pdf"},
    {"id":"14574","name":"Agenda - follow up information session on the TransCelerate initiative","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-01T17:13:00Z","last_updated_date":"2017-09-01T17:13:00Z","reference_number":"EMA/530505/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-follow-information-session-transcelerate-initiative_en.pdf-0"},
    {"id":"14577","name":"Agenda - PDCO agenda of the 24-26 February 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-02-24T16:30:00Z","last_updated_date":"2016-02-24T16:30:00Z","reference_number":"EMA/PDCO/100838/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-24-26-february-2016-meeting_en.pdf"},
    {"id":"14580","name":"Agenda - COMP agenda of the 10-12 May 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-05-11T17:47:00Z","last_updated_date":"2017-05-11T17:47:00Z","reference_number":"EMA/COMP/246330/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-10-12-may-2017-meeting_en.pdf"},
    {"id":"14586","name":"Agenda - Annual Patients/Consumers Working Party (PCWP) and Healthcare Professionals Working Group (HCP WG) joint meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-06-16T17:32:08Z","last_updated_date":"2011-08-22T17:32:08Z","reference_number":"EMA/816573/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-annual-patientsconsumers-working-party-pcwp-and-healthcare-professionals-working-group-hcp-wg-joint-meeting_en.pdf"},
    {"id":"14661","name":"Agenda - CAT agenda of the 23-25 May 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-05-25T14:00:00Z","last_updated_date":"2018-05-25T14:00:00Z","reference_number":"EMA/CAT/352923/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-23-25-may-2018-meeting_en.pdf"},
    {"id":"14722","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH 2B(R3) format: hands-on training course (Zagreb)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-12-12T12:14:00Z","last_updated_date":"2017-12-12T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-2br3-format-hands-training-course-zagreb_en.pdf"},
    {"id":"14725","name":"Agenda - Workshop on single-arm trials (SAT) in oncology","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-06-23T17:20:00Z","reference_number":"EMA/328790/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-single-arm-trials-sat-oncology_en.pdf"},
    {"id":"14747","name":"Agenda - Preliminary agenda of the pharmacovigilance in the paediatric population workshop","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-04-23T02:00:00Z","last_updated_date":"2014-04-23T02:00:00Z","reference_number":"EMA/785588/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-preliminary-agenda-pharmacovigilance-paediatric-population-workshop_en.pdf"},
    {"id":"14771","name":"Agenda - HMPC agenda of the 23-24 July 2018 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T19:11:00Z","last_updated_date":"2018-07-23T19:11:00Z","reference_number":"EMA/HMPC/496646/2018 – ver.3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-23-24-july-2018-meeting_en.pdf"},
    {"id":"14776","name":"Agenda - CHMP agenda of the 19-22 January 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-01-19T11:20:00Z","last_updated_date":"2015-01-19T11:20:00Z","reference_number":"EMA/CHMP/776474/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-january-2015-meeting_en.pdf"},
    {"id":"14883","name":"Agenda - HMPC agenda of the 6-7 July 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-07-03T16:12:00Z","last_updated_date":"2015-07-03T16:12:00Z","reference_number":"EMA/HMPC/449990/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-6-7-july-2015-meeting_en.pdf"},
    {"id":"14896","name":"Draft agenda - Focus group meeting on the guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food-producing animals","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-09-11T18:00:00Z","last_updated_date":"2018-09-11T18:00:00Z","reference_number":"EMA/459760/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-focus-group-meeting-guideline-assessment-risk-public-health-antimicrobial-resistance-due-use-antimicrobial-veterinary-medicinal-product-food-producing-animals_en.pdf"},
    {"id":"14899","name":"Agenda - 2009 EMEA/IFAH-Europe Info Day - 'The latest developments' in scientific review, legislation and marketing authorisation procedures - Programme","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-03-20T00:09:21Z","last_updated_date":"2009-03-20T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2009-emeaifah-europe-info-day-latest-developments-scientific-review-legislation-and-marketing-authorisation-procedures-programme_en.pdf"},
    {"id":"14996","name":"Agenda - CHMP agenda of the 7-10 November 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-11-07T12:45:00Z","last_updated_date":"2016-11-07T12:45:00Z","reference_number":"EMA/CHMP/682760/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-7-10-november-2016-meeting_en.pdf"},
    {"id":"15017","name":"Agenda and registration form - Information day on new services and systems in pharmacovigilance: preparing for business change","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-03-23T15:00:01Z","last_updated_date":"2015-03-23T15:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-information-day-new-services-and-systems-pharmacovigilance-preparing-business-change_en.pdf"},
    {"id":"15077","name":"Draft agenda - Focus group meeting  on dose optimisation of established veterinary antibiotics in the context of summary of product characteristics harmonisation","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-09-11T12:42:00Z","last_updated_date":"2018-09-11T12:42:00Z","reference_number":"EMA/517715/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-focus-group-meeting-dose-optimisation-established-veterinary-antibiotics-context-summary-product-characteristics-harmonisation_en.pdf"},
    {"id":"15081","name":"Agenda - COMP agenda of the 11-13 July 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-07-07T12:00:00Z","last_updated_date":"2016-07-07T12:00:00Z","reference_number":"EMA/COMP/428333/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-11-13-july-2016-meeting_en.pdf"},
    {"id":"15099","name":"Agenda for the 89th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-09-29T16:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"EMA/MB/169330/2015 V.3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-89th-meeting-management-board_en.pdf"},
    {"id":"15122","name":"Agenda - Fifth training workshop SMEs","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2010-03-04T01:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"EMA/770537/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fifth-training-workshop-smes_en.pdf"},
    {"id":"15174","name":"Agenda - Training session for patients, consumers and healthcare professionals interested in European Medicines Agency activities","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-17T18:09:00Z","last_updated_date":"2017-12-13T12:15:00Z","reference_number":"EMA/662990/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-patients-consumers-and-healthcare-professionals-interested-european-medicines-agency-activities_en.pdf"},
    {"id":"15215","name":"Agenda - PRAC draft agenda of meeting 6-9 January 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-01-06T18:15:00Z","last_updated_date":"2014-01-06T18:15:00Z","reference_number":"EMA/PRAC/4877/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-6-9-january-2014_en.pdf"},
    {"id":"15235","name":"Agenda - Innovative Medicines Initiative WEB-RADR project: mobile technologies and social media as new tools in pharmacovigilance workshop programme","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-08-03T02:00:00Z","last_updated_date":"2016-10-17T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-innovative-medicines-initiative-web-radr-project-mobile-technologies-and-social-media-new-tools-pharmacovigilance-workshop-programme_en.pdf"},
    {"id":"15251","name":"Agenda - COMP agenda of the 11-12 March 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-02-26T11:40:00Z","last_updated_date":"2014-02-26T11:40:00Z","reference_number":"EMA/COMP/95442/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-11-12-march-2014-meeting_en.pdf"},
    {"id":"15339","name":"Agenda and registration form - eXtended EudraVigilance Medicinal\n\nProduct Dictionary training course 9-10 October 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T02:00:00Z","last_updated_date":"2014-09-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-training-course-9-10-october-2014_en.pdf"},
    {"id":"15360","name":"Agenda and registration form - First information day on periodic safety update reports – International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use E2C(R2) perio...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-04-17T19:00:00Z","last_updated_date":"2013-06-05T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-first-information-day-periodic-safety-update-reports-international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-e2cr2-perio_en.pdf"},
    {"id":"15455","name":"Agenda - CAT agenda of the 18-19 September 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-30T18:50:00Z","last_updated_date":"2014-09-30T18:50:00Z","reference_number":"EMA/CAT/541592/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-18-19-september-2014-meeting_en.pdf"},
    {"id":"15504","name":"Agenda - Programme and registration form - European Medicines Agency excellence in pharmacovigilance: Clinical trials and post-marketing training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-02-11T11:00:00Z","last_updated_date":"2013-02-11T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-and-registration-form-european-medicines-agency-excellence-pharmacovigilance-clinical-trials-and-post-marketing-training-course_en.pdf"},
    {"id":"15593","name":"Agenda - CVMP agenda of the 6-8 September 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-09-05T17:45:00Z","last_updated_date":"2016-09-05T17:45:00Z","reference_number":"EMA/CVMP/566936/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-6-8-september-2016-meeting_en.pdf"},
    {"id":"15616","name":"Agenda - Workshop on the EMEA transparency policy","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"EMEA/665540/2008","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-emea-transparency-policy_en.pdf"},
    {"id":"15687","name":"Agenda - Vaccines Working Party closed workshop on correlates for the protection and serological assays for influenza vaccines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-06-05T11:15:00Z","last_updated_date":"2013-06-05T11:15:00Z","reference_number":"EMA/CHMP/VWP/263668/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-vaccines-working-party-closed-workshop-correlates-protection-and-serological-assays-influenza-vaccines_en.pdf"},
    {"id":"15717","name":"Agenda - PRAC draft agenda of meeting 6-9 October 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-10-06T19:30:00Z","last_updated_date":"2014-10-06T19:30:00Z","reference_number":"EMA/PRAC/463490/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-6-9-october-2014_en.pdf"},
    {"id":"15802","name":"Agenda - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Group (HCPWG) joint meeting - February 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-02-25T12:00:00Z","last_updated_date":"2013-05-24T18:00:00Z","reference_number":"EMA/810501/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-group-hcpwg-joint-meeting-february-2013_en.pdf"},
    {"id":"15856","name":"Agenda - HMPC agenda of the 24-25 March 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-24T17:00:00Z","last_updated_date":"2014-03-24T17:00:00Z","reference_number":"EMA/HMPC/174259/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-24-25-march-2014-meeting_en.pdf"},
    {"id":"15942","name":"Agenda - EU Regulatory Network - Challenges and Opportunities for Croatia","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eu-regulatory-network-challenges-and-opportunities-croatia_en.pdf"},
    {"id":"15949","name":"Agenda - CHMP agenda of the 12-15 December 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-12-12T18:42:00Z","last_updated_date":"2016-12-21T18:45:00Z","reference_number":"EMA/847927/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-12-15-december-2016-meeting_en.pdf"},
    {"id":"15971","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, London","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-25T18:00:00Z","last_updated_date":"2017-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-london_en.pdf-0"},
    {"id":"16026","name":"Agenda - PDCO agenda of the 7-10 November 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-11-08T16:00:00Z","last_updated_date":"2017-11-16T16:00:00Z","reference_number":"EMA/PDCO/730337/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-7-10-november-2017-meeting_en.pdf"},
    {"id":"16030","name":"Agenda - CHMP agenda of the 23-26 March 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-03-24T15:10:00Z","last_updated_date":"2015-03-24T15:10:00Z","reference_number":"EMA/CHMP/148199/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-23-26-march-2015-meeting_en.pdf"},
    {"id":"16150","name":"Agenda - Workshop agenda: Launch of the European Network of Paediatric\n\nResearch at the European Medicines Agency (Enpr-EMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-02-22T00:31:00Z","last_updated_date":"2011-05-28T01:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-agenda-launch-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"16261","name":"Agenda - EMA - Spinal muscular atrophy workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T10:50:00Z","last_updated_date":"2016-11-07T10:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-spinal-muscular-atrophy-workshop_en.pdf"},
    {"id":"16262","name":"Agenda - Second industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-14T17:57:00Z","last_updated_date":"2017-11-14T17:57:00Z","reference_number":"EMA/630645/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"16279","name":"Agenda - Meeting with stakeholders on monitoring sales of veterinary antimicrobial agents in Europe","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-12-22T13:01:27Z","last_updated_date":"2010-12-22T13:01:27Z","reference_number":"EMA/271500/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-stakeholders-monitoring-sales-veterinary-antimicrobial-agents-europe_en.pdf"},
    {"id":"16353","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting: Information session on...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T01:00:00Z","last_updated_date":"2015-06-04T13:00:00Z","reference_number":"EMA/59760/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-information_en.pdf"},
    {"id":"16393","name":"Agenda - CAT agenda of the 13-15 July 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-07-14T18:15:00Z","last_updated_date":"2016-07-14T18:15:00Z","reference_number":"EMA/CAT/489613/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-13-15-july-2016-meeting_en.pdf"},
    {"id":"16472","name":"Agenda - CAT agenda of the 19–20 June 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-24T18:00:00Z","last_updated_date":"2014-06-24T18:00:00Z","reference_number":"EMA/CAT/368856/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-19-20-june-2014-meeting_en.pdf"},
    {"id":"16476","name":"Agenda - CHMP agenda of the 18-21 May 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-05-19T13:30:00Z","last_updated_date":"2015-05-19T13:30:00Z","reference_number":"EMA/CHMP/322484/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-18-21-may-2015-meeting_en.pdf"},
    {"id":"16525","name":"Agenda - PDCO agenda of the 13-16 December 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-12-19T12:05:00Z","last_updated_date":"2016-12-19T12:05:00Z","reference_number":"EMA/PDCO/801853/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-13-16-december-2016-meeting_en.pdf"},
    {"id":"16553","name":"Agenda - PDCO agenda of the 20-22 July 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-07-20T13:00:00Z","last_updated_date":"2016-07-20T13:00:00Z","reference_number":"EMA/PDCO/452922/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-20-22-july-2016-meeting_en.pdf"},
    {"id":"16567","name":"Agenda - PRAC draft agenda of meeting 9-12 March 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-03-10T18:30:00Z","last_updated_date":"2015-03-10T18:30:00Z","reference_number":"EMA/PRAC/644853/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-9-12-march-2015_en.pdf"},
    {"id":"16707","name":"Agenda - PRAC draft agenda of meeting 3-6 February 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-02-05T17:30:00Z","last_updated_date":"2014-02-05T17:30:00Z","reference_number":"EMA/PRAC/66008/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-3-6-february-2014_en.pdf"},
    {"id":"16721","name":"Agenda - PRAC draft agenda of meeting 11-14 June 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-06-11T17:00:00Z","last_updated_date":"2018-06-11T17:00:00Z","reference_number":"EMA/PRAC/395628/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-11-14-june-2018_en.pdf"},
    {"id":"16833","name":"Agenda and registration form - EMA EudraVigilance and signal management information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-02-16T12:04:00Z","last_updated_date":"2018-02-16T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-ema-eudravigilance-and-signal-management-information-day_en.pdf"},
    {"id":"16894","name":"Agenda – Thalidomide - Follow-up meeting with patients’ and victims’ organisations","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-09-02T17:56:56Z","last_updated_date":"2011-10-18T17:31:00Z","reference_number":"EMA/540386/2011 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-thalidomide-follow-meeting-patients-and-victims-organisations_en.pdf"},
    {"id":"17003","name":"Agenda - Evaluation of Drugs in rare diseases, Eudipharm & EMEA seminar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-02-15T00:09:21Z","last_updated_date":"2006-02-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-evaluation-drugs-rare-diseases-eudipharm-emea-seminar_en.pdf"},
    {"id":"17015","name":"Agenda - Twelfth industry stakeholder platform on the operation of pharmacovigilance in the European Union","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T15:08:00Z","last_updated_date":"2018-01-04T15:08:00Z","reference_number":"EMA/666321/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-twelfth-industry-stakeholder-platform-operation-pharmacovigilance-european-union_en.pdf"},
    {"id":"17055","name":"Agenda - CHMP agenda of the 20-23 March 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-03-20T15:30:00Z","last_updated_date":"2017-03-20T15:30:00Z","reference_number":"EMA/CHMP/184758/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-20-23-march-2017-meeting_en.pdf"},
    {"id":"17085","name":"Agenda and registration form - The new EudraVigilance System and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course (Prague)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T12:57:00Z","last_updated_date":"2017-06-15T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-prague_en.pdf"},
    {"id":"17116","name":"Agenda - Workshop on endpoints for cystic fibrosis","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-07-02T14:00:00Z","last_updated_date":"2012-12-11T17:05:00Z","reference_number":"EMA/895687/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-endpoints-cystic-fibrosis_en.pdf"},
    {"id":"17123","name":"Agenda and registration form - EudraVigilance training on electronic reporting of Individual Case Safety Reports in the European Economic Area (Vienna, Austria)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-29T13:30:00Z","reference_number":"Course #15519","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-safety-reports-european-economic-area-vienna-austria_en.pdf"},
    {"id":"17365","name":"Agenda - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Group (HCP WG) joint meeting: September 2012","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-09-24T02:00:00Z","last_updated_date":"2012-11-26T17:00:00Z","reference_number":"EMA/43750/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-group-hcp-wg-joint-meeting-september-2012_en.pdf"}    {"id":"17412","name":"Agenda: International Neonatal Consortiu: Programme and agenda","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-international-neonatal-consortiu-programme-and-agenda_en.pdf"},
    {"id":"17447","name":"Agenda – Ninth stakeholder forum on the Pharmacovigilance legislation:\n\nObservations on 3-years of operation and opportunities for the future","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-09-15T02:00:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"EMA/499552/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ninth-stakeholder-forum-pharmacovigilance-legislation-observations-3-years-operation-and-opportunities-future_en.pdf"},
    {"id":"17454","name":"Agenda - PDCO agenda of the 08-10 October 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-10-09T18:00:00Z","last_updated_date":"2014-10-20T13:22:00Z","reference_number":"EMA/PDCO/563581/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-08-10-october-2014-meeting_en.pdf"},
    {"id":"17470","name":"Agenda - European Medicines Agency-industry stakeholders platform meeting on paediatric medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-05-11T17:10:00Z","last_updated_date":"2015-05-22T17:00:00Z","reference_number":"EMA/265165/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-industry-stakeholders-platform-meeting-paediatric-medicines_en.pdf"},
    {"id":"17530","name":"Agenda - CAT agenda of the 21-22 January 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-01-21T16:00:00Z","last_updated_date":"2016-01-21T16:00:00Z","reference_number":"EMA/CAT/49183/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-21-22-january-2016-meeting_en.pdf"},
    {"id":"17535","name":"Agenda - EMA expert meeting on genome editing technologies used in medicinal product development","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T02:00:00Z","last_updated_date":"2018-07-19T02:00:00Z","reference_number":"EMA/359806/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-expert-meeting-genome-editing-technologies-used-medicinal-product-development_en.pdf"},
    {"id":"17572","name":"Agenda - PDCO agenda of the 23-25 April 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-04-16T17:00:00Z","last_updated_date":"2014-05-05T11:40:00Z","reference_number":"EMA/PDCO/209977/2014 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-23-25-april-2014-meeting_en.pdf"},
    {"id":"17597","name":"Agenda - PRAC draft agenda of meeting 10-13 June 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-06-10T20:00:00Z","last_updated_date":"2014-06-10T20:00:00Z","reference_number":"EMA/PRAC/345401/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-10-13-june-2014_en.pdf"},
    {"id":"17623","name":"Agenda - PDCO agenda of the 24-27 January 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-01-26T17:30:00Z","last_updated_date":"2017-01-26T17:30:00Z","reference_number":"EMA/PDCO/20221/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-24-27-january-2017-meeting_en.pdf"},
    {"id":"17624","name":"Agenda - PRAC draft agenda of meeting 8-11 February 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-02-08T18:00:00Z","last_updated_date":"2016-02-08T18:00:00Z","reference_number":"EMA/PRAC/94187/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-february-2016_en.pdf"},
    {"id":"17629","name":"Agenda - Paediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-04-19T19:00:00Z","last_updated_date":"2018-08-30T19:00:00Z","reference_number":"EMA/242738/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-paediatric-strategy-forum-medicinal-product-development-checkpoint-inhibitors-use-combination-therapy-paediatric-patients_en.pdf"},
    {"id":"17648","name":"Agenda - PRAC draft agenda of meeting 23-26 October 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-10-23T19:50:00Z","last_updated_date":"2017-10-23T19:50:00Z","reference_number":"EMA/PRAC/707172/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-23-26-october-2017_en.pdf"},
    {"id":"17678","name":"Agenda - PRAC draft agenda of meeting 9-12 July 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-07-09T18:56:00Z","last_updated_date":"2018-07-09T18:56:00Z","reference_number":"EMA/PRAC/470871/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-9-12-july-2018_en.pdf"},
    {"id":"17711","name":"Agenda - European Medicines Agency Human Scientific Committee’s Working Party with Healthcare Professionals’ Organisations (HCPWP) meeting on 4 June 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-05-27T13:00:00Z","last_updated_date":"2015-09-01T13:00:00Z","reference_number":"EMA/272606/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-meeting-4-june-2015_en.pdf"},
    {"id":"17739","name":"Agenda - HMPC agenda of the 9-10 March 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-03-09T16:40:00Z","last_updated_date":"2015-03-09T16:40:00Z","reference_number":"EMA/HMPC/108187/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-9-10-march-2015-meeting_en.pdf"},
    {"id":"17761","name":"Agenda for the 68th meeting of the Management Board","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/398075/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-68th-meeting-management-board_en.pdf"},
    {"id":"17805","name":"Agenda for the 96th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-06-13T17:37:00Z","last_updated_date":"2017-06-14T18:53:00Z","reference_number":"EMA/MB/1884/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-96th-meeting-management-board_en.pdf"},
    {"id":"17810","name":"Agenda - CHMP agenda of the 17-20 July 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-07-17T14:00:00Z","last_updated_date":"2017-07-17T14:00:00Z","reference_number":"EMA/CHMP/451869/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-17-20-july-2017-meeting_en.pdf"},
    {"id":"17840","name":"Agenda - CVMP agenda of the 8-10 July 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T13:50:00Z","last_updated_date":"2014-07-08T13:50:00Z","reference_number":"EMA/CVMP/410683/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-8-10-july-2014-meeting_en.pdf"},
    {"id":"17857","name":"Agenda - COMP agenda of the 8-10 October 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-09-30T12:00:00Z","last_updated_date":"2013-09-30T12:00:00Z","reference_number":"EMA/COMP/590870/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-8-10-october-2013-meeting_en.pdf"},
    {"id":"17861","name":"Agenda - COMP agenda of the 10-11 April 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-04-10T10:53:00Z","last_updated_date":"2017-04-10T10:53:00Z","reference_number":"EMA/COMP/188982/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-10-11-april-2017-meeting_en.pdf"},
    {"id":"17867","name":"CHMP ORGAM agenda for the meeting on 4 September 2017","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-09-12T19:07:00Z","last_updated_date":"2017-09-12T19:07:00Z","reference_number":"EMA/CHMP/581740/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-4-september-2017_en.pdf"},
    {"id":"17879","name":"Agenda - Second EMA-EFPIA annual bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-07-07T17:45:00Z","last_updated_date":"2017-07-07T17:45:00Z","reference_number":"EMA/426082/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-ema-efpia-annual-bilateral-meeting_en.pdf"},
    {"id":"17886","name":"Agenda - COMP agenda of the 17-19 January 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-01-17T13:45:00Z","last_updated_date":"2017-01-17T13:45:00Z","reference_number":"EMA/30888/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-17-19-january-2017-meeting_en.pdf"},
    {"id":"18112","name":"Agenda - PRAC draft agenda of meeting 4-7 February 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-02-05T18:00:00Z","last_updated_date":"2013-02-05T18:00:00Z","reference_number":"EMA/PRAC/729256/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-4-7-february-2013_en.pdf"},
    {"id":"18115","name":"Agenda - CVMP agenda of the 3-5 June 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-03T13:00:00Z","last_updated_date":"2014-06-03T13:00:00Z","reference_number":"EMA/CVMP/327616/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-3-5-june-2014-meeting_en.pdf"},
    {"id":"18118","name":"Agenda - PDCO agenda of the 6-8 February 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-02-04T11:00:00Z","last_updated_date":"2013-02-04T11:00:00Z","reference_number":"EMA/PDCO/60785/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-6-8-february-2013-meeting_en.pdf"},
    {"id":"18121","name":"Agenda - Workshop on methods for efficacy studies in everyday medical practice - 24-25 October 2013","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-10-24T11:10:00Z","last_updated_date":"2013-11-27T11:20:00Z","reference_number":"EMA/607212/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-methods-efficacy-studies-everyday-medical-practice-24-25-october-2013_en.pdf"},
    {"id":"18132","name":"CHMP ORGAM agenda for the meeting on 10 April 2017","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-04-10T11:55:00Z","last_updated_date":"2017-04-10T11:55:00Z","reference_number":"EMA/CHMP/206179/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-10-april-2017_en.pdf"},
    {"id":"18171","name":"Agenda - PRAC draft agenda of meeting 8-11 April 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-04-11T14:00:00Z","last_updated_date":"2013-04-11T14:00:00Z","reference_number":"EMA/218110/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-april-2013_en.pdf"},
    {"id":"18198","name":"Agenda - First webinar on regulatory and procedural aspects of type I variations","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T14:10:00Z","last_updated_date":"2016-11-14T13:10:00Z","reference_number":"EMA/478438/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-webinar-regulatory-and-procedural-aspects-type-i-variations_en.pdf"},
    {"id":"18202","name":"Agenda - Brexit regulatory preparedness for veterinary medicinal products in the centralised procedure","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-02-19T13:00:00Z","last_updated_date":"2018-04-18T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-brexit-regulatory-preparedness-veterinary-medicinal-products-centralised-procedure_en.pdf"},
    {"id":"18246","name":"Agenda - CVMP agenda of the 11-13 March 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-10T18:15:00Z","last_updated_date":"2014-03-10T18:15:00Z","reference_number":"EMA/CVMP/140404/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-11-13-march-2014-meeting_en.pdf"},
    {"id":"18308","name":"Agenda - Training session for patients and consumers involved in European Medicines Agency activities","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-12-05T17:31:00Z","last_updated_date":"2014-02-03T16:00:00Z","reference_number":"EMA/508479/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-patients-and-consumers-involved-european-medicines-agency-activities_en.pdf-0"},
    {"id":"18311","name":"CHMP ORGAM agenda for the meeting on 28 October 2016","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-11-04T15:25:00Z","last_updated_date":"2016-11-04T15:25:00Z","reference_number":"EMA/CHMP/679213/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-28-october-2016_en.pdf"},
    {"id":"18428","name":"Agenda - HMPC agenda of the 18-19 September 2017 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-19T12:30:00Z","last_updated_date":"2017-09-19T12:30:00Z","reference_number":"EMA/HMPC/610004/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-18-19-september-2017-meeting_en.pdf"},
    {"id":"18454","name":"Agenda - Reinforcing communication with patients and healthcare professionals","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-06-10T02:00:00Z","last_updated_date":"2014-06-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-reinforcing-communication-patients-and-healthcare-professionals_en.pdf"},
    {"id":"18486","name":"Agenda - PDCO agenda of the 3-5 October 2012 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-10-02T11:36:00Z","last_updated_date":"2012-10-02T11:36:00Z","reference_number":"EMA/PDCO/622209/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-3-5-october-2012-meeting_en.pdf"},
    {"id":"18560","name":"Agenda and registration form - EudraVigilance training on the electronic reporting of Individual Case Safety Reports (ICSRs) in the European Economic Area","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T15:00:00Z","last_updated_date":"2014-06-13T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-safety-reports-icsrs-european-economic-area_en.pdf"},
    {"id":"18575","name":"Programme of the Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-08-16T19:00:00Z","last_updated_date":"2016-11-15T17:10:00Z","reference_number":"EMA/481413/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-committee-advanced-therapies-cat-workshop-scientific-and-regulatory-challenges-genetically-modified-cell-based-cancer-immunotherapy-products_en.pdf"},
    {"id":"18576","name":"Agenda - Harmonising the approach to VeDDRA coding workshop - 27 November 2013","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2013-11-27T01:00:00Z","last_updated_date":"2014-02-11T01:00:00Z","reference_number":"EMA/500544/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-harmonising-approach-veddra-coding-workshop-27-november-2013_en.pdf"},
    {"id":"18621","name":"Draft agenda - European Union International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) and Substance, Product, Organisation and Referential data (SPOR) task force meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-02-28T01:00:00Z","last_updated_date":"2017-02-28T01:00:00Z","reference_number":"EMA/86223/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-european-union-international-organization-standardization-iso-identification-medicinal-products-idmp-and-substance-product-organisation-and-referential-data-spor-task-force-meeting_en.pdf"},
    {"id":"18688","name":"Agenda – European Medicines Agency-European Federation of Pharmaceutical Industries and Associations modelling and simulation workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"EMA/455573/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-european-federation-pharmaceutical-industries-and-associations-modelling-and-simulation-workshop_en.pdf"},
    {"id":"18866","name":"Agenda - EMEA workshop on biosimilar monoclonal antibodies - Programme","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-07-01T02:09:21Z","last_updated_date":"2009-07-01T02:09:21Z","reference_number":"EMEA/CHMP/BMWP/494490/2008","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emea-workshop-biosimilar-monoclonal-antibodies-programme_en.pdf"},
    {"id":"18879","name":"Agenda - EMA Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals Working Party (HCPWP) joint meeting: Workshop on regulatory and methodological stand...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-02-06T01:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"EMA/796225/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-meeting-workshop-regulatory-and-methodological_en.pdf"},
    {"id":"18888","name":"Agenda - Evaluation of Medicinal Products in Children, Forth European Course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2005-09-19T02:09:21Z","last_updated_date":"2005-09-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-evaluation-medicinal-products-children-forth-european-course_en.pdf"},
    {"id":"18890","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-06-14T13:41:00Z","last_updated_date":"2018-06-14T13:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course_en.pdf-0"},
    {"id":"18891","name":"Programme of European Medicines Agency workshop on the clinical investigation of medicines for the treatment of Alzheimer’s disease","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-11-19T17:00:00Z","last_updated_date":"2014-11-19T17:00:00Z","reference_number":"EMA/180375/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-european-medicines-agency-workshop-clinical-investigation-medicines-treatment-alzheimers-disease_en.pdf"},
    {"id":"18899","name":"Agenda - Information meeting on participation of Croatia and Turkey in EMEA activities in 2006 and 2007","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-09-29T02:09:21Z","last_updated_date":"2006-09-29T02:09:21Z","reference_number":"EMEA/380958/2006","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-information-meeting-participation-croatia-and-turkey-emea-activities-2006-and-2007_en.pdf"},
    {"id":"18914","name":"Agenda - A common data model for Europe? – Why? Which? How?","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-10-31T15:10:00Z","last_updated_date":"2017-12-12T13:00:00Z","reference_number":"EMA/550682/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-common-data-model-europe-why-which-how_en.pdf"},
    {"id":"18922","name":"Agenda - Eighth stakeholders forum on the implementation of the new pharmacovigilance legislation: Building on two years of operation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"EMA/449800/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eighth-stakeholders-forum-implementation-new-pharmacovigilance-legislation-building-two-years-operation_en.pdf"},
    {"id":"18951","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-03-02T01:00:00Z","last_updated_date":"2016-06-23T15:30:00Z","reference_number":"EMA/855288/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf-0"},
    {"id":"18954","name":"Agenda - CVMP agenda of the 9-11 December 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-12-09T18:00:00Z","last_updated_date":"2014-12-09T18:00:00Z","reference_number":"EMA/CVMP/763244/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-9-11-december-2014-meeting_en.pdf"},
    {"id":"18979","name":"Agenda - Fourth industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-06-30T18:10:00Z","last_updated_date":"2017-06-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"18997","name":"Agenda - PDCO agenda of the 20-23 March 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-03-20T13:36:00Z","last_updated_date":"2018-03-20T13:36:00Z","reference_number":"EMA/PDCO/140668/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-20-23-march-2018-meeting_en.pdf"},
    {"id":"19064","name":"Agenda – Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-09-26T18:00:00Z","last_updated_date":"2013-11-06T11:00:00Z","reference_number":"EMA/291054/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-best-use-medicines-legislation-bring-new-antibiotics-patients-and-combat-resistance-problem_en.pdf"},
    {"id":"19079","name":"Agenda for the 91st meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-03-16T16:10:00Z","last_updated_date":"2016-03-18T16:25:00Z","reference_number":"EMA/MB/266/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-91st-meeting-management-board_en.pdf"},
    {"id":"19103","name":"Agenda - EMA – Payer Community meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-payer-community-meeting_en.pdf"},
    {"id":"19194","name":"Agenda for the 73rd meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/MB/650168/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-73rd-meeting-management-board_en.pdf"},
    {"id":"19197","name":"Agenda – Update on the implementation of EMA policy on publication of clinical data (Policy 0070) and revisions to the guidance to industry – industry associations webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-12-09T10:30:00Z","last_updated_date":"2016-12-09T10:30:00Z","reference_number":"EMA/805050/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-update-implementation-ema-policy-publication-clinical-data-policy-0070-and-revisions-guidance-industry-industry-associations-webinar_en.pdf"},
    {"id":"19199","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course (Zagreb)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-20T19:00:00Z","last_updated_date":"2017-09-20T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-zagreb_en.pdf"},
    {"id":"19263","name":"Agenda and registration form - European Medicines Agency excellence in pharmacovigilance: Clinical trials and post-marketing training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-09-06T02:00:00Z","last_updated_date":"2012-09-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-european-medicines-agency-excellence-pharmacovigilance-clinical-trials-and-post-marketing-training-course_en.pdf"},
    {"id":"19268","name":"Agenda - COMP agenda of the 1-3 September 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-08-27T12:49:00Z","last_updated_date":"2015-08-27T12:49:00Z","reference_number":"EMA/COMP/572401/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-1-3-september-2015-meeting_en.pdf"},
    {"id":"19298","name":"Agenda - Healthcare Professionals Working Group meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2011-10-25T02:00:00Z","last_updated_date":"2011-12-19T10:57:00Z","reference_number":"EMA/83568/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-healthcare-professionals-working-group-meeting_en.pdf"},
    {"id":"19383","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting Workshop on benefit-ris...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-12T16:00:00Z","last_updated_date":"2014-12-08T15:45:00Z","reference_number":"EMA/254724/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-workshop-benefit_en.pdf"},
    {"id":"19546","name":"Agenda - European Medicines Agency workshop for micro, small and medium-sized enterprises (SMEs) - Focus on pharmacovigilance","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T11:00:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"EMA/49479/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-workshop-micro-small-and-medium-sized-enterprises-smes-focus-pharmacovigilance_en.pdf"},
    {"id":"19628","name":"Agenda - PDCO agenda of the 6-8 November 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-11-05T10:07:00Z","last_updated_date":"2013-11-05T10:07:00Z","reference_number":"EMA/PDCO/673586/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-6-8-november-2013-meeting_en.pdf"},
    {"id":"19726","name":"Agenda - Sixty second meeting of the Management Board, 4 March 2009","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2009-03-04T00:09:21Z","last_updated_date":"2009-03-04T00:09:21Z","reference_number":"EMEA/MB/663707/2008Adopted","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixty-second-meeting-management-board-4-march-2009_en.pdf"},
    {"id":"19765","name":"Agenda - HMPC assessors training on quality for herbal medicinal products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-10-07T17:10:00Z","last_updated_date":"2011-10-07T17:10:00Z","reference_number":"EMA/HMPC/269947/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-assessors-training-quality-herbal-medicinal-products_en.pdf"},
    {"id":"19774","name":"Agenda - Sixty-forth meeting of the Management Board, 1 October 2009","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/MB/358420/2009Adopted","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixty-forth-meeting-management-board-1-october-2009_en.pdf"},
    {"id":"19847","name":"Agenda - Workshop on haemophilia registries","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-04-30T15:00:02Z","last_updated_date":"2015-06-25T11:30:00Z","reference_number":"EMA/CHMP/BPWP/190322/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-haemophilia-registries_en.pdf"},
    {"id":"19849","name":"Agenda - PDCO agenda of the 12-14 November 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-11-18T10:35:00Z","last_updated_date":"2014-11-18T10:35:00Z","reference_number":"EMA/PDCO/633895/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-14-november-2014-meeting_en.pdf"},
    {"id":"19887","name":"Agenda - COMP agenda of the 3-5 October 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-09-29T18:55:00Z","last_updated_date":"2017-09-29T18:55:00Z","reference_number":"EMA/COMP/606831/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-3-5-october-2017-meeting_en.pdf"},
    {"id":"19888","name":"Agenda - European Medicines Agency - EuropaBio information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T02:00:00Z","last_updated_date":"2015-10-06T02:00:00Z","reference_number":"EMA/656844/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-europabio-information-day_en.pdf"},
    {"id":"19959","name":"Agenda - CHMP agenda of the 14-17 December 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-12-14T17:10:00Z","last_updated_date":"2015-12-14T17:10:00Z","reference_number":"EMA/CHMP/838619/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-14-17-december-2015-meeting_en.pdf"},
    {"id":"19964","name":"Agenda - European Union International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) / substance, product, organisation and referential data (SPOR) task force meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T17:00:00Z","last_updated_date":"2017-12-20T17:00:00Z","reference_number":"EMA/647593/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-international-organization-standardization-iso-identification-medicinal-products-idmp-substance-product-organisation-and-referential-data-spor-task-force-meeting_en.pdf"},
    {"id":"20078","name":"Agenda - European Union (EU) International Organisation for Standardisation (ISO) identification of medical products (IDMP) task force meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-11-30T13:50:00Z","last_updated_date":"2016-11-30T13:50:00Z","reference_number":"EMA/746283/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-eu-international-organisation-standardisation-iso-identification-medical-products-idmp-task-force-meeting_en.pdf"},
    {"id":"20096","name":"Agenda - CAT agenda of the 18-20 January 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-01-19T16:00:00Z","last_updated_date":"2017-01-19T16:00:00Z","reference_number":"EMA/CAT/39859/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-18-20-january-2017-meeting_en.pdf"},
    {"id":"20114","name":"Agenda - 2017 Forum on bioequivalence inspections","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-25T18:30:00Z","last_updated_date":"2017-09-25T18:30:00Z","reference_number":"EMA/620344/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2017-forum-bioequivalence-inspections_en.pdf"},
    {"id":"20118","name":"Agenda - Sixty-fifth meeting of the Management Board, 10 December 2009","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/MB/672992/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixty-fifth-meeting-management-board-10-december-2009_en.pdf"},
    {"id":"20141","name":"Agenda second workshop on European Paediatric Network (EnprEMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"EMA/337008/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-workshop-european-paediatric-network-enprema_en.pdf"},
    {"id":"20150","name":"Agenda - Workshop on health-related quality of life in oncology","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T10:44:00Z","last_updated_date":"2012-04-30T10:44:00Z","reference_number":"EMA/2044/16/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-health-related-quality-life-oncology_en.pdf"},
    {"id":"20160","name":"Agenda - CVMP interested parties’ meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-09-05T12:30:00Z","last_updated_date":"2017-09-05T12:30:00Z","reference_number":"EMA/CVMP/99927/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-interested-parties-meeting_en.pdf"},
    {"id":"20172","name":"Agenda - PDCO agenda of the 18-21 July 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-07-18T19:25:00Z","last_updated_date":"2017-07-19T18:30:00Z","reference_number":"EMA/406917/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-18-21-july-2017-meeting_en.pdf"},
    {"id":"20266","name":"Agenda and registration form  - eXtended EudraVigilance medicinal product dictionary face-to-face training course, Prague","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T13:00:00Z","last_updated_date":"2017-11-23T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-prague_en.pdf"},
    {"id":"20318","name":"CHMP ORGAM agenda for the meeting on 8 May 2017","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-06-13T02:00:00Z","last_updated_date":"2017-06-13T02:00:00Z","reference_number":"EMA/CHMP/293225/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-8-may-2017_en.pdf"},
    {"id":"20340","name":"Agenda - PDCO agenda of the 12-14 June 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-06-10T17:42:00Z","last_updated_date":"2013-06-10T17:42:00Z","reference_number":"EMA/PDCO/349551/2013  ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-14-june-2013-meeting_en.pdf"},
    {"id":"20391","name":"Agenda - 2016 EU GCP Inspectors Working Group Workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-10-17T02:00:00Z","last_updated_date":"2016-10-17T02:00:00Z","reference_number":"EMA/858631/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2016-eu-gcp-inspectors-working-group-workshop_en.pdf"},
    {"id":"20443","name":"Agenda and registration form - The new EudraVigilance system and electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Paris","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T14:30:00Z","last_updated_date":"2017-09-26T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-paris_en.pdf-0"},
    {"id":"20516","name":"Agenda for the 87th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-03-18T10:20:00Z","last_updated_date":"2015-03-26T14:10:00Z","reference_number":"EMA/MB/551/2015 V.5","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-87th-meeting-management-board_en.pdf"},
    {"id":"20522","name":"Agenda of the sixth annual meeting of European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) members","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-18T19:00:00Z","last_updated_date":"2014-06-18T19:00:00Z","reference_number":"EMA/245782/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixth-annual-meeting-european-network-paediatric-research-european-medicines-agency-enpr-ema-members_en.pdf"},
    {"id":"20546","name":"Agenda - Public ICH Regional Meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-public-ich-regional-meeting_en.pdf"},
    {"id":"20553","name":"Agenda - 2015 Pharmacovigilance Inspectors Working Group training course (veterinary session)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-11-05T01:00:00Z","last_updated_date":"2015-11-05T01:00:00Z","reference_number":"EMA/INS/PhV/724709/2015 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2015-pharmacovigilance-inspectors-working-group-training-course-veterinary-session_en.pdf"},
    {"id":"20590","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, San Marino","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-25T18:00:00Z","last_updated_date":"2017-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-san-marino_en.pdf"},
    {"id":"20658","name":"Agenda - HMPC agenda of the 19-20 September 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-09-19T13:45:00Z","last_updated_date":"2016-09-19T13:45:00Z","reference_number":"EMA/HMPC/616784/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-19-20-september-2016-meeting_en.pdf"},
    {"id":"20668","name":"Agenda - CVMP agenda of the 14-16 February 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-02-14T12:10:00Z","last_updated_date":"2017-02-14T12:10:00Z","reference_number":"EMA/CVMP/102247/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-14-16-february-2017-meeting_en.pdf"},
    {"id":"20675","name":"Agenda - COMP agenda of the 14-16 June 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-06-10T12:20:00Z","last_updated_date":"2016-06-10T12:20:00Z","reference_number":"EMA/COMP/356295/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-14-16-june-2016-meeting_en.pdf"},
    {"id":"20709","name":"Agenda - CAT agenda of the 6-7 October 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T18:00:00Z","last_updated_date":"2016-10-07T18:00:00Z","reference_number":"EMA/CAT/662943/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-6-7-october-2016-meeting_en.pdf"},
    {"id":"20754","name":"Agenda - Multi-stakeholder paediatric oncology strategy workshop (cancers with anaplastic lymphoma kinase aberrations)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/764474/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-paediatric-oncology-strategy-workshop-cancers-anaplastic-lymphoma-kinase-aberrations_en.pdf"},
    {"id":"20765","name":"Agenda - PDCO agenda of the 20-23 June 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-06-20T16:33:00Z","last_updated_date":"2017-06-20T16:33:00Z","reference_number":"EMA/331620/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-20-23-june-2017-meeting_en.pdf"}    {"id":"20860","name":"Agenda - CVMP agenda of the 8-10 April 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-04-08T17:10:00Z","last_updated_date":"2015-04-08T17:10:00Z","reference_number":"EMA/CVMP/220258/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-8-10-april-2015-meeting_en.pdf"},
    {"id":"20883","name":"Agenda and registration form - EMA/DIA statistics forum: The role of observational data in assessing the benefits and risks of drugs","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-20T02:00:00Z","last_updated_date":"2017-09-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-emadia-statistics-forum-role-observational-data-assessing-benefits-and-risks-drugs_en.pdf"},
    {"id":"20970","name":"Agenda - First EudraVigilance Information Day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-03-23T00:09:21Z","last_updated_date":"2006-03-23T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-eudravigilance-information-day_en.pdf"},
    {"id":"21014","name":"Agenda and registration form - EudraVigilance Information Day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-03-24T01:00:00Z","last_updated_date":"2011-03-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-information-day_en.pdf-0"},
    {"id":"21030","name":"Agenda - Third industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-05-18T15:40:00Z","last_updated_date":"2018-05-18T15:40:00Z","reference_number":"EMA/195267/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"21056","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (Sept 2016)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-08-19T02:00:00Z","last_updated_date":"2016-08-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-sept-2016_en.pdf"},
    {"id":"21099","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (2016)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T13:45:00Z","last_updated_date":"2016-03-11T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-2016_en.pdf"},
    {"id":"21273","name":"Agenda - PRAC draft agenda of meeting 3-6 July 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-07-03T18:30:00Z","last_updated_date":"2017-07-03T18:30:00Z","reference_number":"EMA/PRAC/423016/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-3-6-july-2017_en.pdf"},
    {"id":"21517","name":"Agenda - European Medicines Agency-European Federation of Pharmaceutical Industries and Associations modelling and simulation workshop - Break-out session 3","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-11-29T17:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"EMA/926028/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-european-federation-pharmaceutical-industries-and-associations-modelling-and-simulation-workshop-break-out-session-3_en.pdf"},
    {"id":"21567","name":"Agenda - CVMP agenda of the 8-10 December 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-12-08T14:40:00Z","last_updated_date":"2015-12-08T14:40:00Z","reference_number":"EMA/CVMP/823166/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-8-10-december-2015-meeting_en.pdf"},
    {"id":"21576","name":"Workshop programme - Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) workshop on advanced-therapy medicinal products: How to bring cell-based medicinal ...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-26T02:00:00Z","last_updated_date":"2014-06-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/workshop-programme-committee-advanced-therapies-cat-and-german-society-transfusion-medicine-and-immunohaematology-dgti-workshop-advanced-therapy-medicinal-products-how-bring-cell-based-medicinal_en.pdf"},
    {"id":"21581","name":"Agenda - PDCO agenda of the 5-7 September 2012 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-08-31T14:00:00Z","last_updated_date":"2012-08-31T14:00:00Z","reference_number":"EMA/PDCO/563185/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-5-7-september-2012-meeting_en.pdf"},
    {"id":"21596","name":"Agenda - PDCO agenda of the 11-13 November 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-11-10T16:04:00Z","last_updated_date":"2015-11-10T16:04:00Z","reference_number":"EMA/PDCO/677901/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-11-13-november-2015-meeting_en.pdf"},
    {"id":"21639","name":"Agenda - Focus Group Meeting of CVMP Experts and Interested Parties - Reflection paper on the use of fluoroquinolones in food producing animals","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"EMEA/228442/2006","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-focus-group-meeting-cvmp-experts-and-interested-parties-reflection-paper-use-fluoroquinolones-food-producing-animals_en.pdf"},
    {"id":"21647","name":"Agenda - Workshop on good clinical practice (GCP) compliance in bioequivalence trials/generics","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-10-12T02:00:00Z","last_updated_date":"2015-10-12T02:00:00Z","reference_number":"EMA/499514/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-good-clinical-practice-gcp-compliance-bioequivalence-trials-generics_en.pdf"},
    {"id":"21726","name":"Agenda - CVMP agenda of the 4-6 November 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-11-04T16:30:00Z","last_updated_date":"2014-11-04T16:30:00Z","reference_number":"EMA/CVMP/675239/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-4-6-november-2014-meeting_en.pdf"},
    {"id":"21745","name":"Agenda - European network of paediatric research at the European Medicines Agency coordinating group meeting by teleconference - 24 October 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-02-02T15:00:00Z","last_updated_date":"2015-02-02T15:00:00Z","reference_number":"EMA/511563/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-coordinating-group-meeting-teleconference-24-october-2014_en.pdf"},
    {"id":"21748","name":"Agenda - Thirteenth industry stakeholder platform - operation of EU pharmacovigilance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-03-14T14:06:00Z","last_updated_date":"2018-03-14T14:06:00Z","reference_number":"EMA/117206/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-thirteenth-industry-stakeholder-platform-operation-eu-pharmacovigilance_en.pdf"},
    {"id":"21753","name":"Agenda - CAT agenda of the 30-31 October 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-10-31T17:25:00Z","last_updated_date":"2017-10-31T17:25:00Z","reference_number":"EMA/CAT/726328/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-30-31-october-2017-meeting_en.pdf"},
    {"id":"21788","name":"Agenda - CHMP agenda of the 22-25 April 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-04-22T14:00:00Z","last_updated_date":"2014-04-22T14:00:00Z","reference_number":"EMA/CHMP/169875/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-22-25-april-2014-meeting_en.pdf"},
    {"id":"21838","name":"Agenda - Joint BWP/QWP/GMDP IWG – Industry European workshop on lifecycle management","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-10-12T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/468878/2015 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-bwpqwpgmdp-iwg-industry-european-workshop-lifecycle-management_en.pdf"},
    {"id":"21842","name":"Agenda - Third EMEA Workshop for Micro, Small and Medium-Sized Enterprises (SMEs) 'Focus on non-clinical aspects'","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T01:00:00Z","last_updated_date":"2009-02-02T01:00:00Z","reference_number":"EMEA/547748/2008","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-emea-workshop-micro-small-and-medium-sized-enterprises-smes-focus-non-clinical-aspects_en.pdf"},
    {"id":"21873","name":"Agenda - Regulatory science conference","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"EMA/445280/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-regulatory-science-conference_en.pdf"},
    {"id":"21905","name":"Agenda - PDCO agenda of the 15-17 January 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-01-10T14:54:00Z","last_updated_date":"2014-01-10T14:54:00Z","reference_number":"EMA/PDCO/801136/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-15-17-january-2014-meeting_en.pdf"},
    {"id":"21907","name":"Agenda - COMP agenda of the 5-7 December 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-12-05T10:40:00Z","last_updated_date":"2017-12-05T10:40:00Z","reference_number":"EMA/COMP/730551/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-5-7-december-2017-meeting_en.pdf"},
    {"id":"21939","name":"Agenda - CAT agenda of the 10-11 December 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T17:20:00Z","last_updated_date":"2015-12-14T17:20:00Z","reference_number":"EMA/CAT/841770/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-10-11-december-2015-meeting_en.pdf"},
    {"id":"21945","name":"Agenda and registration form - EMA Information Day: 2nd Information Day on the New Individual Case Safety Report (ICSR) International Standard and ICH E2B/M2","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-03-24T01:00:00Z","last_updated_date":"2011-03-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-ema-information-day-2nd-information-day-new-individual-case-safety-report-icsr-international-standard-and-ich-e2bm2_en.pdf"},
    {"id":"22149","name":"Agenda - COMP agenda of the 13-14 May 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-05-02T18:40:00Z","last_updated_date":"2014-05-02T18:40:00Z","reference_number":"EMA/COMP/257297/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-13-14-may-2014-meeting_en.pdf"},
    {"id":"22268","name":"Agenda and registration form - Introduction to pharmacovigilance and rules for expedited reporting of individual case safety reports in Europe","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-08-04T14:15:01Z","last_updated_date":"2015-09-16T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-introduction-pharmacovigilance-and-rules-expedited-reporting-individual-case-safety-reports-europe_en.pdf"},
    {"id":"22329","name":"Agenda – Implementation of EMA policy on publication of clinical data – Current status – Stakeholder webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-08T20:30:00Z","last_updated_date":"2015-06-23T19:00:00Z","reference_number":"EMA/380643/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-implementation-ema-policy-publication-clinical-data-current-status-stakeholder-webinar_en.pdf"},
    {"id":"22335","name":"Agenda - Second annual scientific workshop at EMA: Applying regulatory science to neonates","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-09-07T13:30:00Z","last_updated_date":"2016-09-07T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-annual-scientific-workshop-ema-applying-regulatory-science-neonates_en.pdf"},
    {"id":"22429","name":"Agenda - PDCO agenda of the 12-14 October 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-10-11T16:57:00Z","last_updated_date":"2016-10-11T16:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-14-october-2016-meeting_en.pdf"},
    {"id":"22516","name":"Agenda and registration form - Medicines and Healthcare Products Regulatory Agency information day: Medical Dictionary for Regulatory Activities in the pharmacovigilance regulatory process","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-10-15T18:35:00Z","last_updated_date":"2014-10-15T18:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-medicines-and-healthcare-products-regulatory-agency-information-day-medical-dictionary-regulatory-activities-pharmacovigilance-regulatory-process_en.pdf"},
    {"id":"22646","name":"Agenda of the 82nd meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2013-12-17T11:30:00Z","last_updated_date":"2014-01-16T12:40:00Z","reference_number":"EMA/MB/531192/2013 Version.5 Adopted Corr","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-82nd-meeting-management-board_en.pdf"},
    {"id":"22742","name":"Agenda - Programme - EU 28: science, medicines, health","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-02-06T12:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-eu-28-science-medicines-health_en.pdf"},
    {"id":"22756","name":"CHMP ORGAM agenda for the meeting on 12 June 2017","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-06-16T19:30:00Z","last_updated_date":"2017-06-16T19:30:00Z","reference_number":"EMA/CHMP/371261/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-12-june-2017_en.pdf"},
    {"id":"22794","name":"Agenda - European Medicines Agency-EuropaBio information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-11-04T01:00:00Z","last_updated_date":"2016-11-25T16:35:00Z","reference_number":"EMA/723535/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-europabio-information-day_en.pdf-0"},
    {"id":"22798","name":"Agenda - Meeting on monitoring of sales of veterinary antimicrobial agents in Europe","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-11-12T01:00:00Z","last_updated_date":"2009-11-12T01:00:00Z","reference_number":"EMEA/419053/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-monitoring-sales-veterinary-antimicrobial-agents-europe_en.pdf"},
    {"id":"22806","name":"Agenda - CAT agenda of the 15-17 February 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-02-21T17:50:00Z","last_updated_date":"2017-02-21T17:50:00Z","reference_number":"EMA/CAT/126633/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-15-17-february-2017-meeting_en.pdf"},
    {"id":"22832","name":"Agenda - First European Medicines Agency-EuropaBio annual bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-30T13:00:00Z","last_updated_date":"2017-05-30T13:00:00Z","reference_number":"EMA/326145/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-european-medicines-agency-europabio-annual-bilateral-meeting_en.pdf"},
    {"id":"22864","name":"Agenda and registration form - EudraVigilance training on electronic reporting of individual case safety reports in the European Economic Area (Spain, Dec 2015)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-09-21T02:00:00Z","last_updated_date":"2015-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-safety-reports-european-economic-area-spain-dec-2015_en.pdf"},
    {"id":"22936","name":"Agenda and webinar login instructions - Enpr-EMA awareness webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-11-16T16:30:00Z","last_updated_date":"2016-11-16T16:30:00Z","reference_number":"EMA/740943/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-webinar-login-instructions-enpr-ema-awareness-webinar_en.pdf"},
    {"id":"22949","name":"Agenda - Fourth EMEA workshop for Micro, Small and Medium-Sized Enterprises (SMEs) 'Paediatric Medicines'","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-08-05T02:00:00Z","last_updated_date":"2009-10-30T00:00:00Z","reference_number":"EMEA/345935/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-emea-workshop-micro-small-and-medium-sized-enterprises-smes-paediatric-medicines_en.pdf"},
    {"id":"23048","name":"CHMP ORGAM agenda for the meeting on 4 December 2017","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-12-18T12:30:00Z","last_updated_date":"2017-12-18T12:30:00Z","reference_number":"EMA/800758/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-4-december-2017_en.pdf"},
    {"id":"23053","name":"Agenda - Workshop on viral safety of plasma-derived medicinal products with respect to hepatitis E virus","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2014-07-28T13:40:00Z","last_updated_date":"2015-06-26T13:40:00Z","reference_number":"EMA/CHMP/BWP/196177/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-viral-safety-plasma-derived-medicinal-products-respect-hepatitis-e-virus_en.pdf"},
    {"id":"23056","name":"Agenda and registration form - Signal detection and management information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-11-21T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-signal-detection-and-management-information-day_en.pdf"},
    {"id":"23083","name":"Agenda - COMP agenda of the 7-9 January 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-01-07T09:58:00Z","last_updated_date":"2014-01-07T09:58:00Z","reference_number":"EMA/COMP/741437/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-7-9-january-2014-meeting_en.pdf"},
    {"id":"23222","name":"Agenda – Expert meeting on paediatric asthma","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-11-23T17:01:00Z","last_updated_date":"2012-11-23T17:01:00Z","reference_number":"EMA/620746/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-expert-meeting-paediatric-asthma_en.pdf"},
    {"id":"23311","name":"Agenda - Patient registries workshop","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-08-01T14:00:00Z","last_updated_date":"2016-10-20T14:00:00Z","reference_number":"EMA/439861/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patient-registries-workshop_en.pdf"},
    {"id":"23369","name":"Agenda - PRAC draft agenda of meeting 4-8 July 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-07-04T19:26:00Z","last_updated_date":"2016-07-04T19:26:00Z","reference_number":"EMA/PRAC/463028/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-4-8-july-2016_en.pdf"},
    {"id":"23371","name":"Agenda - Healthcare Professionals Working Group meeting: February 2013","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2013-02-25T12:00:00Z","last_updated_date":"2013-05-31T13:00:00Z","reference_number":"EMA/810498/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-healthcare-professionals-working-group-meeting-february-2013_en.pdf"},
    {"id":"23408","name":"Agenda - PRAC draft agenda of meeting 6-9 July 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-07-07T14:45:00Z","last_updated_date":"2015-07-07T14:45:00Z","reference_number":"EMA/PRAC/455682/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-6-9-july-2015_en.pdf"},
    {"id":"23436","name":"Agenda - Workshop on the 'Guideline on pharmaceutical development of medicines for paediatric use'","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-11-19T01:00:00Z","last_updated_date":"2014-11-19T01:00:00Z","reference_number":"EMA/545429/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf"},
    {"id":"23526","name":"Agenda - Slowing the progression of neurodegenerative diseases:  Medicinal products (MP) clinical development","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-09-28T02:09:21Z","last_updated_date":"2006-09-28T02:09:21Z","reference_number":"EMEA/EWP/44912/2006 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-slowing-progression-neurodegenerative-diseases-medicinal-products-mp-clinical-development_en.pdf"},
    {"id":"23597","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-09-05T14:30:00Z","last_updated_date":"2017-10-26T14:30:00Z","reference_number":"EMA/370525/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf-1"},
    {"id":"23778","name":"Agenda – Paediatric Rheumatology Expert Group Meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"EMA/719882/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-paediatric-rheumatology-expert-group-meeting_en.pdf"},
    {"id":"23915","name":"Agenda - CHMP agenda of the 21-24 July 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-07-22T11:35:00Z","last_updated_date":"2014-07-23T17:30:00Z","reference_number":"EMA/CHMP/387601/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-21-24-july-2014-meeting_en.pdf"},
    {"id":"23951","name":"CHMP ORGAM agenda for the meeting on 10 July 2017","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2017-08-01T18:00:00Z","reference_number":"EMA/CHMP/439826/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-10-july-2017_en.pdf"},
    {"id":"23953","name":"Agenda - European Medicines Agency-Industry Stakeholders Platform second meeting on paediatric medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T16:45:00Z","last_updated_date":"2016-05-27T17:35:00Z","reference_number":"EMA/43044/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-industry-stakeholders-platform-second-meeting-paediatric-medicines_en.pdf"},
    {"id":"23984","name":"Agenda - HMPC agenda of the 30 June - 1 July 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-07-01T13:20:00Z","last_updated_date":"2014-07-01T13:20:00Z","reference_number":"EMA/HMPC/355484/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-30-june-1-july-2014-meeting_en.pdf"},
    {"id":"24015","name":"Agenda - PDCO agenda of the 29 May-01 June 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-05-28T19:00:00Z","last_updated_date":"2018-05-28T19:00:00Z","reference_number":"EMA/357098/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-29-may-01-june-2018-meeting_en.pdf"},
    {"id":"24049","name":"Agenda for the 86th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2014-12-16T19:00:00Z","last_updated_date":"2014-12-22T15:00:00Z","reference_number":"EMA/MB/572168/2014 V.5","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-86th-meeting-management-board_en.pdf"},
    {"id":"24089","name":"Agenda - CAT agenda of the 20-21 April 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-04-22T12:15:00Z","last_updated_date":"2016-04-22T12:15:00Z","reference_number":"EMA/CAT/286924/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-20-21-april-2016-meeting_en.pdf"},
    {"id":"24112","name":"Agenda for the 88th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-06-09T18:35:00Z","last_updated_date":"2015-06-16T12:00:00Z","reference_number":"EMA/MB/170636/2015 v.3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-88th-meeting-management-board_en.pdf"},
    {"id":"24162","name":"Agenda - Final programme - Expert workshop on process validation for the manufacture of biotechnology-derived active substances","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T17:00:00Z","last_updated_date":"2013-04-03T18:00:00Z","reference_number":"EMA/34741/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-final-programme-expert-workshop-process-validation-manufacture-biotechnology-derived-active-substances_en.pdf"},
    {"id":"24186","name":"Agenda - CVMP agenda of the 5-7 December 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-12-07T12:34:00Z","last_updated_date":"2017-12-07T12:34:00Z","reference_number":"EMA/CVMP/799382/2017 draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-5-7-december-2017-meeting_en.pdf"},
    {"id":"24190","name":"Agenda – Workshop on development of new antibacterial medicines","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2012-10-23T16:00:00Z","last_updated_date":"2012-10-24T16:00:00Z","reference_number":"EMA/225314/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-development-new-antibacterial-medicines_en.pdf"},
    {"id":"24198","name":"Agenda for the 100th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-06-05T17:47:00Z","last_updated_date":"2018-06-06T18:33:00Z","reference_number":"EMA/MB/802/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-100th-meeting-management-board_en.pdf"},
    {"id":"24219","name":"Agenda and registration form - European Medicines Agency information day on services and systems in Pharmacovigilance: preparing for business change","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-10-27T15:00:00Z","last_updated_date":"2015-11-20T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-european-medicines-agency-information-day-services-and-systems-pharmacovigilance-preparing-business-change_en.pdf"},
    {"id":"24228","name":"Agenda - CAT agenda of the 15-16 June 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-06-19T19:10:00Z","last_updated_date":"2017-06-19T19:10:00Z","reference_number":"EMA/CAT/344401/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-15-16-june-2017-meeting_en.pdf"},
    {"id":"24231","name":"Agenda - HMPC agenda of the 21-22 November 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T16:20:00Z","last_updated_date":"2016-11-18T16:20:00Z","reference_number":"EMA/HMPC/758101/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-21-22-november-2016-meeting_en.pdf"},
    {"id":"24248","name":"Agenda - CVMP agenda of the 6-8 December 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-12-06T16:36:00Z","last_updated_date":"2016-12-06T16:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-6-8-december-2016-meeting_en.pdf"},
    {"id":"24325","name":"Agenda - FP7 Small-population research methods projects and regulatory application workshop","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-02-06T16:40:00Z","last_updated_date":"2017-03-28T17:33:00Z","reference_number":"EMA/849195/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fp7-small-population-research-methods-projects-and-regulatory-application-workshop_en.pdf"},
    {"id":"24333","name":"Agenda - First Workshop on Advanced Therapy Medicinal Products (ATMPs)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-03-09T00:09:21Z","last_updated_date":"2009-03-09T00:09:21Z","reference_number":"EMEA/119832/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-workshop-advanced-therapy-medicinal-products-atmps_en.pdf"},
    {"id":"24348","name":"Agenda – Consultation meeting with industry stakeholders on new scheme to support development of innovative medicines for unmet medical needs","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-09-28T02:00:00Z","last_updated_date":"2015-09-28T02:00:00Z","reference_number":"EMA/607002/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-consultation-meeting-industry-stakeholders-new-scheme-support-development-innovative-medicines-unmet-medical-needs_en.pdf"},
    {"id":"24349","name":"Agenda - PRAC draft agenda of meeting 4 -7 March 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-03-06T18:00:00Z","last_updated_date":"2013-03-06T18:00:00Z","reference_number":"EMA/PRAC/141813/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-4-7-march-2013_en.pdf"},
    {"id":"24370","name":"Agenda - CHMP agenda of the 15-18 December 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-12-15T10:16:00Z","last_updated_date":"2014-12-15T10:16:00Z","reference_number":"EMA/CHMP/722409/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-15-18-december-2014-meeting_en.pdf"},
    {"id":"24388","name":"Agenda - CVMP agenda of the 13-15 January 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-01-14T10:25:00Z","last_updated_date":"2015-01-14T10:25:00Z","reference_number":"EMA/CVMP/21488/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-13-15-january-2015-meeting_en.pdf"},
    {"id":"24399","name":"Agenda - COMP agenda of the 14-16 April 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-04-08T17:00:00Z","last_updated_date":"2015-04-09T12:00:00Z","reference_number":"EMA/COMP/211194/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-14-16-april-2015-meeting_en.pdf"},
    {"id":"24462","name":"Agenda - Agenda and list of questions for the workshop on paediatric investigation plans in type-2 diabetes mellitus","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-01-29T01:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"EMA/36057/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-agenda-and-list-questions-workshop-paediatric-investigation-plans-type-2-diabetes-mellitus_en.pdf"},
    {"id":"24463","name":"Agenda for the 84th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2014-06-19T14:30:00Z","last_updated_date":"2014-06-19T14:30:00Z","reference_number":"EMA/MB/22128/2014 Version 4","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-84th-meeting-management-board_en.pdf"},
    {"id":"24568","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Vienna","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-vienna_en.pdf-0"},
    {"id":"24574","name":"Agenda – Eleventh stakeholder forum on the pharmacovigilance legislation","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-08-25T14:00:00Z","last_updated_date":"2017-09-28T17:00:00Z","reference_number":"EMA/303132/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eleventh-stakeholder-forum-pharmacovigilance-legislation_en.pdf"},
    {"id":"24595","name":"Agenda for the 79th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/MB/685719/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-79th-meeting-management-board_en.pdf"},
    {"id":"24630","name":"Agenda - CHMP agenda of the 20-23 July 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-07-20T18:00:00Z","last_updated_date":"2015-08-06T12:25:00Z","reference_number":"EMA/CHMP/483193/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-20-23-july-2015-meeting_en.pdf"},
    {"id":"24655","name":"Agenda - CVMP agenda of the 7-9 October 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-10-07T14:00:00Z","last_updated_date":"2014-10-07T14:00:00Z","reference_number":"EMA/CVMP/610787/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-7-9-october-2014-meeting_en.pdf"},
    {"id":"24657","name":"Agenda - Patients and Consumers Working Party (PCWP) meeting with all EMA eligible patient/consumer organisations","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-17T16:55:00Z","last_updated_date":"2017-12-11T16:55:00Z","reference_number":"EMA/663268/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patients-and-consumers-working-party-pcwp-meeting-all-ema-eligible-patientconsumer-organisations_en.pdf"},
    {"id":"24672","name":"Agenda and registration form - Information day on risk management planning and post-authorisation studies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-06-02T16:00:00Z","last_updated_date":"2016-06-02T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-information-day-risk-management-planning-and-post-authorisation-studies_en.pdf"},
    {"id":"24727","name":"Agenda - PRAC draft agenda of meeting 7-10 September 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-09-07T20:00:00Z","last_updated_date":"2015-09-07T20:00:00Z","reference_number":"EMA/PRAC/596669/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-7-10-september-2015_en.pdf"},
    {"id":"24788","name":"Agenda - Third stakeholders forum on the implementation of the new pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"EMA/779345/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-stakeholders-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"24797","name":"Agenda - First EMA-EFPIA annual bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-07-27T02:00:00Z","last_updated_date":"2016-07-27T02:00:00Z","reference_number":"EMA/409204/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-ema-efpia-annual-bilateral-meeting_en.pdf"},
    {"id":"24824","name":"Agenda - DIA/EFGCP/EMA conference on how to optimise children's access to innovative medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-10-06T02:00:00Z","last_updated_date":"2017-10-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-diaefgcpema-conference-how-optimise-childrens-access-innovative-medicines_en.pdf"},
    {"id":"24842","name":"Agenda - PDCO agenda of the 10-12 December 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-12-09T16:30:00Z","last_updated_date":"2014-12-09T16:30:00Z","reference_number":"EMA/PDCO/713847/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-10-12-december-2014-meeting_en.pdf"},
    {"id":"24870","name":"Agenda for the 67th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/MB/210895/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-67th-meeting-management-board_en.pdf"},
    {"id":"24899","name":"Agenda - COMP agenda of the 11-13 November 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-10-28T17:45:00Z","last_updated_date":"2014-10-28T17:45:00Z","reference_number":"EMA/COMP/638404/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-11-13-november-2014-meeting_en.pdf"},
    {"id":"24978","name":"Agenda – Stakeholder focus group meeting on availability of lumpy skin disease (LSD) vaccines authorised to European Union (EU) standards","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-01-03T11:00:00Z","last_updated_date":"2017-01-27T11:00:00Z","reference_number":"EMA/CVMP/IWP/661057/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-stakeholder-focus-group-meeting-availability-lumpy-skin-disease-lsd-vaccines-authorised-european-union-eu-standards_en.pdf"},
    {"id":"24989","name":"Agenda - PRAC draft agenda of meeting 27-30 November 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-11-27T18:00:00Z","last_updated_date":"2017-11-27T18:00:00Z","reference_number":"EMA/PRAC/785853/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-27-30-november-2017_en.pdf"},
    {"id":"24997","name":"Agenda - HMPC agenda of the 4-5 May 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T17:07:00Z","last_updated_date":"2015-05-04T17:07:00Z","reference_number":"EMA/HMPC/290448/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-4-5-may-2015-meeting_en.pdf"},
    {"id":"25003","name":"Agenda - Workshop on immunogenicity assessment of biotechnology-derived therapeutic proteins","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T16:30:00Z","last_updated_date":"2016-03-09T11:00:00Z","reference_number":"EMA/48362/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins_en.pdf"},
    {"id":"25055","name":"Agenda - PDCO agenda of the 7-9 November 2012 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-11-07T13:10:00Z","last_updated_date":"2012-11-07T13:10:00Z","reference_number":"EMA/PDCO/701166/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-7-9-november-2012-meeting_en.pdf"}    {"id":"25115","name":"Agenda - 2010 European Medicines Agency/IFAH-Europe Info Day - Programme","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-01-28T01:00:00Z","last_updated_date":"2010-03-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2010-european-medicines-agencyifah-europe-info-day-programme_en.pdf"},
    {"id":"25208","name":"Agenda - Medical literature monitoring workshop","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-08-22T13:46:00Z","last_updated_date":"2016-08-25T02:00:00Z","reference_number":"EMA/559778/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medical-literature-monitoring-workshop_en.pdf"},
    {"id":"25214","name":"Agenda for the 92nd meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-06-14T20:00:00Z","last_updated_date":"2016-06-21T20:00:00Z","reference_number":"EMA/MB/3373/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-92nd-meeting-management-board_en.pdf"},
    {"id":"25254","name":"Agenda - Programme - 2013 European Medicines Agency / International Federation for Animal Health Europe info day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T16:00:02Z","last_updated_date":"2013-01-24T16:00:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-2013-european-medicines-agency-international-federation-animal-health-europe-info-day_en.pdf"},
    {"id":"25340","name":"Agenda - CAT agenda of the 4-6 October 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-10-06T13:00:00Z","last_updated_date":"2017-10-06T13:00:00Z","reference_number":"EMA/CAT/623276/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-4-6-october-2017-meeting_en.pdf"},
    {"id":"25344","name":"Agenda - HMPC agenda of the 24 November meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-11-25T15:25:00Z","last_updated_date":"2014-11-25T15:25:00Z","reference_number":"EMA/HMPC/638812/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-24-november-meeting_en.pdf"},
    {"id":"25412","name":"Agenda - Reinforcing patient safety in Europe - Conference programme","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2011-04-27T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"EMA/172829/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-reinforcing-patient-safety-europe-conference-programme_en.pdf"},
    {"id":"25436","name":"Agenda – SME info day: supporting innovative medicines’ development and early access","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-06-13T02:00:00Z","last_updated_date":"2017-11-14T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sme-info-day-supporting-innovative-medicines-development-and-early-access_en.pdf"},
    {"id":"25460","name":"Agenda - Workshop on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-10-28T01:00:00Z","last_updated_date":"2015-11-10T17:00:00Z","reference_number":"EMA/400205/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-use-pharmacokinetics-and-pharmacodynamics-development-antibacterial-medicinal-products_en.pdf"},
    {"id":"25507","name":"Agenda - PDCO agenda of the 27-29 April 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-04-26T11:29:00Z","last_updated_date":"2016-04-26T11:29:00Z","reference_number":"EMA/PDCO/244355/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-27-29-april-2016-meeting_en.pdf"},
    {"id":"25508","name":"Agenda - PRAC draft agenda of meeting 7-10 April 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-04-08T18:00:00Z","last_updated_date":"2015-04-08T18:00:00Z","reference_number":"EMA/PRAC/59170/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-7-10-april-2015_en.pdf"},
    {"id":"25522","name":"Agenda - PDCO agenda of the 15-17 August 2012 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-08-10T14:15:00Z","last_updated_date":"2012-08-10T14:15:00Z","reference_number":"EMA/PDCO/521483/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-15-17-august-2012-meeting_en.pdf"},
    {"id":"25569","name":"Agenda - Joint EMEA(NRG)/Interested Parties Meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-09-06T02:09:21Z","last_updated_date":"2006-09-06T02:09:21Z","reference_number":"EMEA/136217/2006","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-emeanrginterested-parties-meeting_en.pdf"},
    {"id":"25592","name":"Agenda - Industry associations webinar: update on the implementation of the European Medicines Agency policy on publication of clinical data - Policy 0070","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T17:15:00Z","last_updated_date":"2018-02-07T17:15:00Z","reference_number":"EMA/38307/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-associations-webinar-update-implementation-european-medicines-agency-policy-publication-clinical-data-policy-0070_en.pdf"},
    {"id":"25626","name":"Agenda - Healthcare Professionals Organisations Working Party (HCPWP) workshop with academia","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-06-10T16:20:00Z","last_updated_date":"2016-08-01T15:50:00Z","reference_number":"EMA/262750/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-healthcare-professionals-organisations-working-party-hcpwp-workshop-academia_en.pdf"},
    {"id":"25627","name":"Programme - 2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-04-25T16:00:00Z","last_updated_date":"2018-06-18T17:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-2018-annual-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"25751","name":"Agenda - CVMP agenda of the 12-14 July 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-07-12T14:35:00Z","last_updated_date":"2016-07-12T14:35:00Z","reference_number":"EMA/CVMP/477115/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-12-14-july-2016-meeting_en.pdf"},
    {"id":"25793","name":"Agenda - EMEA's provision of information to the EMEA's stakeholders - Brainstorming meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2007-09-18T02:09:21Z","last_updated_date":"2007-09-18T02:09:21Z","reference_number":"EMEA/295775/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emeas-provision-information-emeas-stakeholders-brainstorming-meeting_en.pdf"},
    {"id":"25881","name":"Agenda - European Network of Paediatric Research at the European Medicines Agency Coordinating Group meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-06-26T19:00:00Z","last_updated_date":"2013-06-26T19:00:00Z","reference_number":"EMA/150389/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-coordinating-group-meeting_en.pdf"},
    {"id":"25921","name":"CHMP ORGAM agenda for the meeting on 22 May 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-06-06T13:59:00Z","last_updated_date":"2018-06-06T13:59:00Z","reference_number":"EMA/CHMP/324079/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-22-may-2018_en.pdf"},
    {"id":"25933","name":"Agenda - CHMP agenda of the 29 March-1 April 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-03-29T15:30:00Z","last_updated_date":"2016-03-29T15:30:00Z","reference_number":"EMA/CHMP/221503/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-29-march-1-april-2016-meeting_en.pdf"},
    {"id":"25943","name":"Agenda and registration form for: 2nd DIA/EMA Innovation Forum: Is the EU regulatory framework ready?","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-10-26T02:00:00Z","last_updated_date":"2010-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-2nd-diaema-innovation-forum-eu-regulatory-framework-ready_en.pdf"},
    {"id":"25944","name":"Agenda - PDCO agenda of the 21-24 February 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-02-20T14:30:00Z","last_updated_date":"2017-02-20T14:30:00Z","reference_number":"EMA/PDCO/72697/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-21-24-february-2017-meeting_en.pdf"},
    {"id":"26050","name":"Agenda - European Union workshop on ICH Q3D from a quality perspective","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T16:15:00Z","last_updated_date":"2016-04-25T16:40:00Z","reference_number":"EMA/INS/189297/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-workshop-ich-q3d-quality-perspective_en.pdf"},
    {"id":"26102","name":"Agenda and registration form - EudraVigilance training on electronic reporting of individual case safety reports in the European Economic Area (France, Dec 2015)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-09-21T02:00:00Z","last_updated_date":"2015-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-safety-reports-european-economic-area-france-dec-2015_en.pdf"},
    {"id":"26148","name":"Agenda - EMEA Workshop on Pharmacovigilance Systems and Inspections for Veterinary Medicinal Products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2007-10-29T00:09:21Z","last_updated_date":"2007-10-29T00:09:21Z","reference_number":"EMEA/CVMP/PhVWP/521086/2006","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emea-workshop-pharmacovigilance-systems-and-inspections-veterinary-medicinal-products_en.pdf"},
    {"id":"26151","name":"Agenda - CHMP agenda of the 19-22 February 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-02-19T12:00:00Z","last_updated_date":"2018-02-19T12:00:00Z","reference_number":"EMA/CHMP/56177/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-february-2018-meeting_en.pdf"},
    {"id":"26155","name":"Agenda - HMPC agenda of the 29-30 September meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-29T12:00:00Z","last_updated_date":"2014-09-29T12:00:00Z","reference_number":"EMA/HMPC/481453/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-29-30-september-meeting_en.pdf"},
    {"id":"26219","name":"Agenda - European Medicines Agency information day: The new individual-case-safety-report international standard and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-01-08T01:00:00Z","last_updated_date":"2013-01-16T11:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-information-day-new-individual-case-safety-report-international-standard-and-international-conference-harmonisation-technical-requirements-registration-pharmaceuticals_en.pdf"},
    {"id":"26280","name":"Agenda - PRAC draft agenda of meeting 1-3 October 2012","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2012-10-01T13:30:00Z","last_updated_date":"2012-10-01T13:30:00Z","reference_number":"EMA/PRAC/519416/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-1-3-october-2012_en.pdf"},
    {"id":"26327","name":"Agenda - European Union (EU) International Organization for Standardization (ISO) identification of medicinal products task force meeting - 12 June 2015","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-05T17:10:00Z","last_updated_date":"2015-06-05T17:10:00Z","reference_number":"EMA/333264/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-eu-international-organization-standardization-iso-identification-medicinal-products-task-force-meeting-12-june-2015_en.pdf"},
    {"id":"26421","name":"Agenda - COMP agenda of the 10-12 February 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-02-02T01:00:00Z","last_updated_date":"2015-02-02T01:00:00Z","reference_number":"EMA/COMP/45848/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-10-12-february-2015-meeting_en.pdf"},
    {"id":"26431","name":"Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, 25 October 2017","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-12-18T13:40:00Z","last_updated_date":"2017-12-18T13:40:00Z","reference_number":"EMA/642660/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting-25-october-2017_en.pdf"},
    {"id":"26453","name":"Agenda - Programme - European Medicines Agency workshop: Ensuring safe and effective medicines for an ageing population","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-02-07T17:45:00Z","last_updated_date":"2012-03-21T13:32:00Z","reference_number":"EMA/966612/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-european-medicines-agency-workshop-ensuring-safe-and-effective-medicines-ageing-population_en.pdf"},
    {"id":"26465","name":"Agenda - PDCO agenda of the 22-24 June 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2010-06-24T11:13:00Z","last_updated_date":"2010-06-24T11:13:00Z","reference_number":"EMA/PDCO/316468/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-22-24-june-2016-meeting_en.pdf"},
    {"id":"26571","name":"Agenda for the 75th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"EMA/MB/47692/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-75th-meeting-management-board_en.pdf"},
    {"id":"26602","name":"Agenda - CVMP agenda of the 6-8 May 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-05-06T18:25:00Z","last_updated_date":"2014-05-06T18:25:00Z","reference_number":"EMA/CVMP/268458/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-6-8-may-2014-meeting_en.pdf"},
    {"id":"26664","name":"Agenda - Preliminary Programme: CLINAM 2011","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-03-07T11:51:14Z","last_updated_date":"2011-05-06T12:51:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-preliminary-programme-clinam-2011_en.pdf"},
    {"id":"26808","name":"Agenda - Programme - Expert workshop on subgroup analysis","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2011-10-06T16:03:00Z","last_updated_date":"2011-11-15T10:09:00Z","reference_number":"EMA/795686/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-expert-workshop-subgroup-analysis_en.pdf"},
    {"id":"26818","name":"Agenda - Collaboration on neonatal issues between researchers and the European Medicines Agency","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-03-10T11:28:00Z","last_updated_date":"2015-03-10T11:28:00Z","reference_number":"EMA/66870/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-collaboration-neonatal-issues-between-researchers-and-european-medicines-agency_en.pdf"},
    {"id":"26858","name":"Agenda and registration form - EudraVigilance training on electronic reporting of individual case safety reports in the European Economic Area","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-08-04T14:00:01Z","last_updated_date":"2015-09-16T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-safety-reports-european-economic-area_en.pdf"},
    {"id":"26908","name":"Agenda - COMP agenda of the 13-15 June 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-06-13T10:26:00Z","last_updated_date":"2017-06-13T10:26:00Z","reference_number":"EMA/COMP/311421/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-13-15-june-2017-meeting_en.pdf"},
    {"id":"26935","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Amsterdam, December 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-06-14T17:00:00Z","last_updated_date":"2018-06-14T17:00:00Z","reference_number":"Course # 18599","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-amsterdam-december-2018_en.pdf"},
    {"id":"26947","name":"Agenda - PDCO agenda of the 18-21 April 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-04-19T13:03:00Z","last_updated_date":"2017-04-19T13:03:00Z","reference_number":"EMA/PDCO/213348/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-18-21-april-2017-meeting_en.pdf"},
    {"id":"27021","name":"Agenda - EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting (20 September 2016)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-09-01T15:31:00Z","last_updated_date":"2017-01-03T14:31:00Z","reference_number":"EMA/428004/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-20-september-2016_en.pdf"},
    {"id":"27077","name":"Agenda - 2011 European Medicines Agency/IFAH-Europe Info Day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-02-17T01:00:00Z","last_updated_date":"2011-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2011-european-medicines-agencyifah-europe-info-day_en.pdf"},
    {"id":"27080","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Prague","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-prague_en.pdf-0"},
    {"id":"27158","name":"Agenda - CVMP agenda of the 19-21 April 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-04-19T16:00:00Z","last_updated_date":"2016-04-19T16:00:00Z","reference_number":"EMA/CVMP/273497/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-19-21-april-2016-meeting_en.pdf"},
    {"id":"27290","name":"Agenda – Registries initiative – Multiple sclerosis workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"EMA/648996/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-registries-initiative-multiple-sclerosis-workshop_en.pdf"},
    {"id":"27340","name":"Agenda and registration form - EudraVigilance training on electronic reporting of ICSRs in the EEA (Berlin, Germany)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-01-26T16:30:00Z","last_updated_date":"2017-01-26T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-icsrs-eea-berlin-germany_en.pdf"},
    {"id":"27376","name":"Agenda - COMP agenda of the 14-15 May 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-05-07T11:18:00Z","last_updated_date":"2013-05-07T11:18:00Z","reference_number":"EMA/COMP/274020/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-14-15-may-2013-meeting_en.pdf"},
    {"id":"27459","name":"Agenda - COMP agenda of the 5-6 November 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T16:00:00Z","last_updated_date":"2013-10-29T16:00:00Z","reference_number":"EMA/COMP/632148/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-5-6-november-2013-meeting_en.pdf"},
    {"id":"27466","name":"Agenda - COMP agenda of the 16-18 January 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-01-15T15:10:00Z","last_updated_date":"2018-01-15T15:10:00Z","reference_number":"EMA/COMP/818236/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-16-18-january-2018-meeting_en.pdf"},
    {"id":"27468","name":"Programme - European Medicines Agency/International Federation for Animal Health Europe info day 2016","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-12-21T01:00:00Z","last_updated_date":"2016-03-16T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-european-medicines-agencyinternational-federation-animal-health-europe-info-day-2016_en.pdf"},
    {"id":"27494","name":"Agenda for the 98th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-12-13T10:12:00Z","last_updated_date":"2017-12-13T15:20:00Z","reference_number":"EMA/MB/611419/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-98th-meeting-management-board_en.pdf"},
    {"id":"27530","name":"Agenda - COMP agenda of the 9-11 July 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T18:50:00Z","last_updated_date":"2013-06-28T18:50:00Z","reference_number":"EMA/COMP/379025/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-9-11-july-2013-meeting_en.pdf"},
    {"id":"27538","name":"Agenda and registration form - EudraVigilance training on electronic reporting of ICSRs in the EEA (Paris, France)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-01-26T16:30:00Z","last_updated_date":"2017-01-26T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-icsrs-eea-paris-france_en.pdf"},
    {"id":"27594","name":"Agenda - European network of paediatric research at the European Medicines Agency coordinating group and working group meeting - 21 January 2015","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-02-16T16:30:00Z","last_updated_date":"2015-02-16T16:30:00Z","reference_number":"EMA/706157/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-coordinating-group-and-working-group-meeting-21-january-2015_en.pdf"},
    {"id":"27654","name":"Agenda - Expert meeting on paediatric development of fix-dose combinations for treatment of HIV","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-09-29T02:00:00Z","last_updated_date":"2015-09-29T02:00:00Z","reference_number":"EMA/589180/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-expert-meeting-paediatric-development-fix-dose-combinations-treatment-hiv_en.pdf"},
    {"id":"27822","name":"Programme of the European Medicines Agency (EMA)/European Generic medicines Association joint workshop on the impact of the revised EMA guideline on the pharmacokinetic and clinical evaluation of modified-release dosage ...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-03-16T14:30:00Z","last_updated_date":"2015-04-30T10:40:00Z","reference_number":"EMA/157739/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-european-medicines-agency-emaeuropean-generic-medicines-association-joint-workshop-impact-revised-ema-guideline-pharmacokinetic-and-clinical-evaluation-modified-release-dosage_en.pdf"},
    {"id":"27917","name":"Agenda – Expert Group Meeting on Paediatric Heart Failure","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-04-19T02:00:00Z","last_updated_date":"2011-04-19T02:00:00Z","reference_number":"EMA/572868/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-expert-group-meeting-paediatric-heart-failure_en.pdf"},
    {"id":"27969","name":"Agenda – Experts meeting on gastroenterology and rheumatology","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-03-22T01:00:00Z","last_updated_date":"2011-03-22T01:00:00Z","reference_number":"EMA/404170/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-experts-meeting-gastroenterology-and-rheumatology_en.pdf"},
    {"id":"28017","name":"Agenda - European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) stakeholders annual meeting 2016","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T17:00:00Z","last_updated_date":"2016-03-30T17:00:00Z","reference_number":"EMA/852361/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-surveillance-veterinary-antimicrobial-consumption-esvac-stakeholders-annual-meeting-2016_en.pdf"},
    {"id":"28024","name":"Agenda - CHMP agenda of the 25-28 June 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-06-25T16:00:00Z","last_updated_date":"2018-06-25T16:00:00Z","reference_number":"EMA/CHMP/424087/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-25-28-june-2018-meeting_en.pdf"},
    {"id":"28069","name":"Agenda - COMP agenda of the 7-9 January 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-12-22T12:40:00Z","last_updated_date":"2014-12-22T12:40:00Z","reference_number":"EMA/COMP/782108/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-7-9-january-2015-meeting_en.pdf"},
    {"id":"28092","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Athens","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-athens_en.pdf-0"},
    {"id":"28166","name":"Appendix 2: Agenda and Participants - CAR-T cell therapy registries workshop","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-01-25T17:40:00Z","last_updated_date":"2018-05-22T18:40:00Z","reference_number":"EMA/794031/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/appendix-2-agenda-and-participants-car-t-cell-therapy-registries-workshop_en.pdf"},
    {"id":"28172","name":"Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-12-18T13:00:00Z","last_updated_date":"2017-12-18T13:00:00Z","reference_number":"EMA/697940/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting_en.pdf"},
    {"id":"28197","name":"Agenda - CHMP agenda of the 11-14 September 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-09-11T17:00:00Z","last_updated_date":"2017-09-12T19:50:00Z","reference_number":"EMA/CHMP/479458/2017 Corr1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-11-14-september-2017-meeting_en.pdf"},
    {"id":"28237","name":"Agenda - Training session for patients and consumers interested in European Medicines Agency activities","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T16:00:00Z","last_updated_date":"2016-02-01T15:00:00Z","reference_number":"EMA/654468/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-patients-and-consumers-interested-european-medicines-agency-activities_en.pdf"},
    {"id":"28246","name":"Agenda - HMPC agenda of the 20-21 November 2017 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T17:30:00Z","last_updated_date":"2017-11-20T17:30:00Z","reference_number":"EMA/HMPC/757234/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-20-21-november-2017-meeting_en.pdf"},
    {"id":"28323","name":"Agenda - EMA Human Scientific Committees’ Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting with all eligible organisations","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"EMA/668397/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations_en.pdf"},
    {"id":"28346","name":"Agenda - COMP agenda of the 6-8 December 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-11-05T01:00:00Z","last_updated_date":"2016-11-05T01:00:00Z","reference_number":"EMA/COMP/734740/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-6-8-december-2016-meeting_en.pdf"},
    {"id":"28373","name":"Agenda - COMP agenda of the 7-9 October 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-30T18:40:00Z","last_updated_date":"2014-09-30T18:40:00Z","reference_number":"EMA/COMP/575394/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-7-9-october-2014-meeting_en.pdf"},
    {"id":"28409","name":"CHMP ORGAM agenda for the meeting on 12 February 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-03-09T16:30:00Z","last_updated_date":"2018-03-09T16:30:00Z","reference_number":"EMA/CHMP/91430/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-12-february-2018_en.pdf"},
    {"id":"28422","name":"Agenda - Programme - European Medicines Agency workshop on multiplicity issues in clinical trials","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-10-18T10:52:00Z","last_updated_date":"2012-10-18T10:52:00Z","reference_number":"EMA/519224/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-european-medicines-agency-workshop-multiplicity-issues-clinical-trials_en.pdf"},
    {"id":"28441","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations - November 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-11-13T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"EMA/632557/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations-november-2014_en.pdf"},
    {"id":"28450","name":"Agenda - European Union regulatory workshop in ophthalmology","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2011-07-04T02:00:00Z","last_updated_date":"2011-07-04T02:00:00Z","reference_number":"EMA/375555/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-regulatory-workshop-ophthalmology_en.pdf"},
    {"id":"28521","name":"Agenda and registration form - 13th EudraVigilance information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-09-13T02:00:00Z","last_updated_date":"2012-09-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-13th-eudravigilance-information-day_en.pdf"},
    {"id":"28532","name":"Agenda - Training session on the new pharmaceutical legislation, 29 November 2012","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-11-23T17:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"EMA/483816/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-new-pharmaceutical-legislation-29-november-2012_en.pdf"},
    {"id":"28590","name":"Agenda – Annual workshop on the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-03-12T10:05:00Z","last_updated_date":"2012-03-12T10:05:00Z","reference_number":"EMA/39173/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-annual-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"28624","name":"Agenda - PDCO agenda of the 5-7 December 2012 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T11:00:00Z","last_updated_date":"2012-11-30T11:00:00Z","reference_number":"EMA/PDCO/764750/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-5-7-december-2012-meeting_en.pdf"},
    {"id":"28689","name":"Agenda - Workshop on patient-support programmes and market-research programmes – Understanding the diversity of such programmes and the management of safety information","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"EMA/254698/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-patient-support-programmes-and-market-research-programmes-understanding-diversity-such-programmes-and-management-safety-information_en.pdf"},
    {"id":"28867","name":"Agenda - Joint Biologics Working Party / Quality Working Party workshop with stakeholders in relation to prior knowledge and its use in regulatory applications","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-07-28T18:30:00Z","last_updated_date":"2017-11-22T16:37:00Z","reference_number":"EMA/CHMP/BWP/149179/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-biologics-working-party-quality-working-party-workshop-stakeholders-relation-prior-knowledge-and-its-use-regulatory-applications_en.pdf"},
    {"id":"28910","name":"Agenda - European Medicines Agency-European Federation of Pharmaceutical Industries and Associations modelling and simulation workshop - Break-out session 4","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-11-29T17:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"EMA/926029/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-european-federation-pharmaceutical-industries-and-associations-modelling-and-simulation-workshop-break-out-session-4_en.pdf"},
    {"id":"28918","name":"Agenda: 2016 annual face to face meeting of the Enpr-EMA Coordinating Group members","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"EMA/204746/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2016-annual-face-face-meeting-enpr-ema-coordinating-group-members_en.pdf"},
    {"id":"28946","name":"Agenda - CVMP agenda of the 13-15 June 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-06-13T10:26:00Z","last_updated_date":"2017-06-13T10:26:00Z","reference_number":"EMA/CVMP/368384/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-13-15-june-2017-meeting_en.pdf"},
    {"id":"28965","name":"Agenda and registration form - Information day on the new identification of medicinal products (IDMP) international standards and International Conference on Harmonisation (ICH) M5/M2, and implementation of electronic su...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-07-01T17:22:22Z","last_updated_date":"2011-07-01T17:22:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-information-day-new-identification-medicinal-products-idmp-international-standards-and-international-conference-harmonisation-ich-m5m2-and-implementation-electronic-su_en.pdf"},
    {"id":"28990","name":"Agenda - Workshop programme - Pre- and post-authorisation regulatory support for micro, small and medium-sized enterprises","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-05-06T02:00:00Z","reference_number":"EMA/214813/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-programme-pre-and-post-authorisation-regulatory-support-micro-small-and-medium-sized-enterprises_en.pdf"},
    {"id":"29203","name":"Agenda - CVMP agenda of the 13-15 February 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-02-13T12:30:00Z","last_updated_date":"2018-02-13T12:30:00Z","reference_number":"EMA/CVMP/88236/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-13-15-february-2018-meeting_en.pdf"},
    {"id":"29243","name":"Agenda - COMP agenda of the 11-13 July 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-07-11T18:23:00Z","last_updated_date":"2017-07-11T18:23:00Z","reference_number":"EMA/COMP/391757/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-11-13-july-2017-meeting_en.pdf"},
    {"id":"29259","name":"Agenda - Programme - Expert workshop on setting specifications for biotechnological products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-09-22T02:00:00Z","last_updated_date":"2011-09-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-expert-workshop-setting-specifications-biotechnological-products_en.pdf"},
    {"id":"29322","name":"Agenda - PDCO agenda of the 8-11 November 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-11-10T16:35:00Z","last_updated_date":"2016-11-10T16:35:00Z","reference_number":"EMA/PDCO/701773/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-8-11-november-2016-meeting_en.pdf"},
    {"id":"29333","name":"Agenda – 5th industry stakeholder platform - Operation of EU pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"EMA/549299/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-5th-industry-stakeholder-platform-operation-eu-pharmacovigilance-legislation_en.pdf"},
    {"id":"29433","name":"Agenda - CAT agenda of the 10-12 April 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-04-11T18:16:00Z","last_updated_date":"2017-04-11T18:16:00Z","reference_number":"EMA/CAT/242785/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-10-12-april-2017-meeting_en.pdf"},
    {"id":"29441","name":"Agenda - Annual workshop on the European Network of Paediatric Research at the European Medicines Agency","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-04-08T19:00:00Z","last_updated_date":"2013-06-26T19:00:00Z","reference_number":"EMA/215015/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-annual-workshop-european-network-paediatric-research-european-medicines-agency_en.pdf-0"},
    {"id":"29442","name":"Agenda - European Union International Organisation for Standardization (ISO) identification of medicinal products (IDMP) task force meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-03-15T15:00:00Z","last_updated_date":"2016-03-15T15:00:00Z","reference_number":"EMA/47181/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-international-organisation-standardization-iso-identification-medicinal-products-idmp-task-force-meeting_en.pdf"},
    {"id":"29466","name":"Agenda - COMP agenda of the 4-6 February 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T17:35:00Z","last_updated_date":"2014-01-31T17:35:00Z","reference_number":"EMA/COMP/46712/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-4-6-february-2014-meeting_en.pdf"},
    {"id":"29516","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2012-07-06T14:00:00Z","last_updated_date":"2012-07-06T14:00:00Z","reference_number":"EMA/234702/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting_en.pdf-1"},
    {"id":"29616","name":"Agenda - PDCO agenda of the 13-15 March 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T16:20:00Z","last_updated_date":"2013-03-08T16:20:00Z","reference_number":"EMA/PDCO/110302/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-13-15-march-2013-meeting_en.pdf"}    {"id":"29659","name":"Agenda - CAT agenda of the 19–20 February 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T13:00:00Z","last_updated_date":"2015-03-02T13:00:00Z","reference_number":"EMA/CAT/81435/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-19-20-february-2015-meeting_en.pdf"},
    {"id":"29666","name":"Agenda - PRAC draft agenda of meeting 13-16 May 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-05-14T18:15:00Z","last_updated_date":"2013-05-14T18:15:00Z","reference_number":"EMA/PRAC/291178/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-13-16-may-2013_en.pdf"},
    {"id":"29695","name":"Agenda - CVMP agenda of the 13-15 March 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-03-13T14:49:00Z","last_updated_date":"2018-03-13T14:49:00Z","reference_number":"EMA/CVMP/125055/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-13-15-march-2018-meeting_en.pdf"},
    {"id":"29784","name":"Agenda - PCWP and HCPWP joint meeting - Workshop on social media","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-09-01T15:45:00Z","last_updated_date":"2016-11-17T14:45:00Z","reference_number":"EMA/825257/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwp-and-hcpwp-joint-meeting-workshop-social-media_en.pdf"},
    {"id":"29851","name":"Agenda - COMP agenda of the 19-21 April 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-04-20T17:30:00Z","last_updated_date":"2016-04-20T17:30:00Z","reference_number":"EMA/COMP/225244/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-19-21-april-2016-meeting_en.pdf"},
    {"id":"29908","name":"Agenda - PDCO agenda of the 17-19 August 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-08-17T17:10:00Z","last_updated_date":"2016-08-17T17:10:00Z","reference_number":"EMA/PDCO/517532/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-17-19-august-2016-meeting_en.pdf"},
    {"id":"29921","name":"Agenda - Workshop for micro, small and medium-sized enterprises (SMEs) organised by the SME office \"Focus on Scientific and Regulatory Advice\"","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-03-24T01:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"EMA/204912/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-micro-small-and-medium-sized-enterprises-smes-organised-sme-office-focus-scientific-and-regulatory-advice_en.pdf"},
    {"id":"29959","name":"Agenda - Tenth industry stakeholder platform on the operation of EU pharmacovigilance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T17:00:00Z","last_updated_date":"2017-02-02T17:00:00Z","reference_number":"EMA/42931/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-tenth-industry-stakeholder-platform-operation-eu-pharmacovigilance_en.pdf"},
    {"id":"30018","name":"Agenda - PRAC draft agenda of meeting 7-10 January 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-01-09T20:00:00Z","last_updated_date":"2013-01-09T20:00:00Z","reference_number":"EMA/PRAC/731552/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-7-10-january-2013_en.pdf"},
    {"id":"30163","name":"Agenda - Committee for Advanced Therapies stakeholders workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T18:15:02Z","last_updated_date":"2011-11-30T18:15:02Z","reference_number":"EMA/CAT/929342/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-committee-advanced-therapies-stakeholders-workshop_en.pdf"},
    {"id":"30196","name":"Agenda - Expert meeting on clinical investigation of new drugs for the treatment of chronic hepatitis C in the paediatric population","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T03:00:00Z","last_updated_date":"2011-07-12T03:00:00Z","reference_number":"EMA/97974/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-expert-meeting-clinical-investigation-new-drugs-treatment-chronic-hepatitis-c-paediatric-population_en.pdf"},
    {"id":"30210","name":"Agenda - Joint DIA - EMEA - CMD(h) workshop on user testing - Programme and registration form","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-09-24T02:09:21Z","last_updated_date":"2008-09-24T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-dia-emea-cmdh-workshop-user-testing-programme-and-registration-form_en.pdf"},
    {"id":"30217","name":"Agenda and registration form - 15th EudraVigilance information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-04T11:00:00Z","last_updated_date":"2014-03-04T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-15th-eudravigilance-information-day_en.pdf"},
    {"id":"30221","name":"Agenda and registration form - EudraVigilance training on electronic reporting of ICSRs in the EEA (San Marino)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-01-26T16:30:00Z","last_updated_date":"2017-01-26T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-icsrs-eea-san-marino_en.pdf"},
    {"id":"30439","name":"EU IDMP/SPOR Task Force meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/47181/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/eu-idmpspor-task-force-meeting_en.pdf"},
    {"id":"30489","name":"Agenda - PDCO agenda of the 7-9 August 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-08-07T18:40:00Z","last_updated_date":"2013-08-07T18:40:00Z","reference_number":"EMA/PDCO/472742/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-7-9-august-2013-meeting_en.pdf"},
    {"id":"30491","name":"CHMP ORGAM agenda for the meeting on 18 June 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-07-31T16:10:00Z","last_updated_date":"2018-07-31T16:10:00Z","reference_number":"EMA/CHMP/412142/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-18-june-2018_en.pdf"},
    {"id":"30539","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Amsterdam","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-amsterdam_en.pdf-0"},
    {"id":"30578","name":"Agenda and registration form - EudraVigilance training on electronic reporting of Individual Case Safety Reports in the European Economic Area (Madrid, Spain)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-29T13:30:00Z","reference_number":"Course #15507","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-safety-reports-european-economic-area-madrid-spain_en.pdf"},
    {"id":"30598","name":"Agenda - FP7 and off patent medicines developed for children","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:09:21Z","last_updated_date":"2007-06-06T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fp7-and-patent-medicines-developed-children_en.pdf"},
    {"id":"30620","name":"Agenda - HMPC agenda of the 29-30 May 2017 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-29T15:00:00Z","last_updated_date":"2017-05-29T15:00:00Z","reference_number":"EMA/HMPC/333718/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-29-30-may-2017-meeting_en.pdf"},
    {"id":"30718","name":"Agenda - Visit of GIRP - European Association of Pharmaceutical Full-line Wholesalers","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-10-06T02:00:00Z","reference_number":"EMA/338607/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-visit-girp-european-association-pharmaceutical-full-line-wholesalers_en.pdf"},
    {"id":"30721","name":"Agenda and registration form - First information day on the use of the Medical Dictionary for Regulatory Activities (MedDRA) including medication errors","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-08-21T02:00:00Z","last_updated_date":"2013-09-19T12:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-first-information-day-use-medical-dictionary-regulatory-activities-meddra-including-medication-errors_en.pdf"},
    {"id":"30737","name":"Agenda - Training session for patients and consumers interested in EMA activities","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-12-20T16:30:00Z","reference_number":"EMA/636824/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-patients-and-consumers-interested-ema-activities_en.pdf"},
    {"id":"30763","name":"Agenda - Paediatric anticoagulation therapy expert meeting 6 November 2012","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-07-08T19:00:00Z","last_updated_date":"2013-07-08T19:00:00Z","reference_number":"EMA/673870/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-paediatric-anticoagulation-therapy-expert-meeting-6-november-2012_en.pdf"},
    {"id":"30766","name":"Programme - European Medicines Agency workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn’s disease","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/292143/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-european-medicines-agency-workshop-development-new-medicinal-products-treatment-ulcerative-colitis-and-crohns-disease_en.pdf"},
    {"id":"30782","name":"Agenda - Workshop on antibacterials","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-02-04T00:31:00Z","last_updated_date":"2011-02-04T00:31:00Z","reference_number":"EMA/90390/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-antibacterials_en.pdf"},
    {"id":"30822","name":"Agenda - CAT agenda of the 12-13 November 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-11-16T10:20:00Z","last_updated_date":"2015-11-16T10:20:00Z","reference_number":"EMA/CAT/716666/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-12-13-november-2015-meeting_en.pdf"},
    {"id":"30886","name":"Agenda - Workshop on the patient’s voice in the evaluation of medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-09-24T18:30:00Z","last_updated_date":"2013-10-29T16:30:00Z","reference_number":"EMA/437597/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-patients-voice-evaluation-medicines_en.pdf"},
    {"id":"30935","name":"Agenda for the 94th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-12-12T16:17:00Z","last_updated_date":"2016-12-19T17:30:00Z","reference_number":"EMA/MB/488455/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-94th-meeting-management-board_en.pdf"},
    {"id":"30947","name":"Agenda - PRAC draft agenda of meeting 4-7 May 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-05-05T17:45:00Z","last_updated_date":"2015-05-05T17:45:00Z","reference_number":"EMA/PRAC/59170/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-4-7-may-2015_en.pdf"},
    {"id":"31054","name":"Agenda - HMPC agenda of the 27-28 March 2017 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T13:36:00Z","last_updated_date":"2017-03-27T13:36:00Z","reference_number":"EMA/HMPC/201087/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-27-28-march-2017-meeting_en.pdf"},
    {"id":"31069","name":"Agenda - Veterinary E-Submission Workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-04-29T02:09:21Z","last_updated_date":"2009-04-29T02:09:21Z","reference_number":"EMEA/220682/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-veterinary-e-submission-workshop_en.pdf"},
    {"id":"31093","name":"Agenda - First EMEA Workshop on European Paediatric Network","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T00:09:21Z","last_updated_date":"2009-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-emea-workshop-european-paediatric-network_en.pdf"},
    {"id":"31101","name":"Agenda - PRAC draft agenda of meeting 2-5 May 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-05-02T19:28:00Z","last_updated_date":"2017-05-02T19:28:00Z","reference_number":"EMA/PRAC/280563/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-2-5-may-2017_en.pdf"},
    {"id":"31102","name":"Agenda - CAT agenda of the 16-17 October 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T12:15:00Z","last_updated_date":"2014-10-21T12:15:00Z","reference_number":"EMA/CAT/541592/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-16-17-october-2014-meeting_en.pdf"},
    {"id":"31124","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Lisbon, October 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-08-24T15:25:00Z","last_updated_date":"2018-08-24T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-lisbon-october-2018_en.pdf"},
    {"id":"31181","name":"Agenda and registration form for: 2nd joint DIA/EMA/CMDh Conference on Variations","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-11-12T01:00:00Z","last_updated_date":"2010-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-2nd-joint-diaemacmdh-conference-variations_en.pdf"},
    {"id":"31193","name":"Agenda - Expert meeting on neonatal and paediatric sepsis","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/234804/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-expert-meeting-neonatal-and-paediatric-sepsis_en.pdf"},
    {"id":"31198","name":"Agenda - CHMP agenda of the 20-23 February 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-02-20T13:23:00Z","last_updated_date":"2017-02-20T13:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-20-23-february-2017-meeting_en.pdf"},
    {"id":"31214","name":"Agenda - CAT agenda of the 15–16 January 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-20T10:55:00Z","last_updated_date":"2015-01-20T10:55:00Z","reference_number":"EMA/CAT/781788/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-15-16-january-2015-meeting_en.pdf"},
    {"id":"31220","name":"Agenda - Follow up information session on the TransCelerate initiative, 17 July 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T11:00:00Z","last_updated_date":"2018-07-17T11:00:00Z","reference_number":"EMA/422878/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-follow-information-session-transcelerate-initiative-17-july-2018_en.pdf"},
    {"id":"31278","name":"Agenda - European Medicines Agency Human Scientific Committee’s Working Party with Healthcare Professionals’ Organisations (HCPWP) meeting on 5 June 2013","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T18:00:00Z","last_updated_date":"2013-07-12T17:00:00Z","reference_number":"EMA/228646/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-meeting-5-june-2013_en.pdf"},
    {"id":"31316","name":"Agenda - CHMP agenda of the 23-26 April 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-04-23T17:40:00Z","last_updated_date":"2018-04-23T17:40:00Z","reference_number":"EMA/CHMP/181307/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-23-26-april-2018-meeting_en.pdf"},
    {"id":"31441","name":"Agenda - PRAC draft agenda of meeting 7-10 July 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-07-07T19:30:00Z","last_updated_date":"2014-07-07T19:30:00Z","reference_number":"EMA/PRAC/412722/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-7-10-july-2014_en.pdf"},
    {"id":"31509","name":"Agenda - CAT agenda of the 16-17 July 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-07-21T17:40:00Z","last_updated_date":"2015-07-21T17:40:00Z","reference_number":"EMA/CAT/481509/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-16-17-july-2015-meeting_en.pdf"},
    {"id":"31540","name":"Agenda - COMP agenda of the 17-19 July 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-07-17T16:15:00Z","last_updated_date":"2018-07-17T16:15:00Z","reference_number":"EMA/COMP/425925/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-17-19-july-2018-meeting_en.pdf"},
    {"id":"31559","name":"Agenda - COMP agenda of the 13-15 March 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-03-12T15:25:00Z","last_updated_date":"2018-03-12T15:25:00Z","reference_number":"EMA/COMP/103052/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-13-15-march-2018-meeting_en.pdf"},
    {"id":"31582","name":"Agenda - PDCO agenda of the 6-8 June 2012 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-07-18T20:14:41Z","last_updated_date":"2012-07-18T20:14:41Z","reference_number":"EMA/PDCO/483938/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-6-8-june-2012-meeting_en.pdf"},
    {"id":"31588","name":"Agenda - CAT agenda of the 18-20 May 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-05-19T18:20:00Z","last_updated_date":"2016-05-19T18:20:00Z","reference_number":"EMA/CAT/315321/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-18-20-may-2016-meeting_en.pdf"},
    {"id":"31615","name":"Agenda - PRAC draft agenda of meeting 26-29 November 2012","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2012-11-26T11:00:00Z","last_updated_date":"2012-11-26T11:00:00Z","reference_number":"EMA/PRAC/519419/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-26-29-november-2012_en.pdf"},
    {"id":"31624","name":"Agenda - HMPC agenda of the 29-30 January 2018 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-01-29T17:46:00Z","last_updated_date":"2018-01-29T17:46:00Z","reference_number":"EMA/HMPC/18658/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-29-30-january-2018-meeting_en.pdf"},
    {"id":"31664","name":"Agenda - CHMP agenda of the 16-19 November 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-11-16T14:25:00Z","last_updated_date":"2015-11-16T14:25:00Z","reference_number":"EMA/CHMP/754777/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-16-19-november-2015-meeting_en.pdf"},
    {"id":"31695","name":"Agenda - Patient Registries workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-09-19T12:29:00Z","last_updated_date":"2016-09-19T12:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patient-registries-workshop_en.pdf-0"},
    {"id":"31715","name":"Agenda - 10 years of the Orphan Regulation in Europe conference","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2010-02-04T01:00:00Z","last_updated_date":"2010-04-28T02:00:00Z","reference_number":"EMA/63930/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-10-years-orphan-regulation-europe-conference_en.pdf"},
    {"id":"31728","name":"Agenda - CVMP agenda of the 11-13 September 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-09-12T12:00:00Z","last_updated_date":"2018-09-12T12:00:00Z","reference_number":"EMA/CVMP/435798/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-11-13-september-2018_en.pdf"},
    {"id":"31755","name":"Announcement - Sixth Enpr-EMA workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/announcement-sixth-enpr-ema-workshop_en.pdf"},
    {"id":"31780","name":"Agenda - Veterinary Scientific Advice Workshop - Introduction","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2008-05-08T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-veterinary-scientific-advice-workshop-introduction_en.pdf"},
    {"id":"31827","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-09T01:00:00Z","last_updated_date":"2017-11-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course_en.pdf-1"},
    {"id":"31859","name":"Agenda - 2012 European Union Good Clinical Practice Inspectors Working Group workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-11-12T13:00:00Z","last_updated_date":"2012-11-12T13:00:00Z","reference_number":"EMA/INS/GCP/720678/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2012-european-union-good-clinical-practice-inspectors-working-group-workshop_en.pdf"},
    {"id":"31966","name":"Agenda - Second EMEA workshop for Micro, Small and Medium-Sized Enterprises (SMEs) 'Focus on Quality'","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"EMEA/331656/2007","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-emea-workshop-micro-small-and-medium-sized-enterprises-smes-focus-quality_en.pdf"},
    {"id":"32033","name":"Agenda - HMPC agenda of the 27-28 January 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-28T16:33:00Z","last_updated_date":"2015-01-28T16:33:00Z","reference_number":"EMA/HMPC/21023/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-27-28-january-2015-meeting_en.pdf"},
    {"id":"32069","name":"Agenda - Seventh stakeholders' forum on the implementation of the new pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"EMA/422496/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-seventh-stakeholders-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"32147","name":"Agenda - CHMP agenda of the 22-25 June 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-06-22T11:24:00Z","last_updated_date":"2015-06-22T11:24:00Z","reference_number":"EMA/CHMP/412522/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-22-25-june-2015-meeting_en.pdf"},
    {"id":"32156","name":"Agenda - EMEA - EFPIA info - day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emea-efpia-info-day_en.pdf-0"},
    {"id":"32164","name":"Agenda - HMPC agenda of the 1-2 February 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T15:20:00Z","last_updated_date":"2016-01-29T15:20:00Z","reference_number":"EMA/HMPC/17360/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-1-2-february-2016-meeting_en.pdf"},
    {"id":"32179","name":"Agenda - PDCO agenda of the 20-23 February 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-02-20T16:10:00Z","last_updated_date":"2018-02-20T16:10:00Z","reference_number":"EMA/PDCO/66082/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-20-23-february-2018-meeting_en.pdf"},
    {"id":"32212","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-09T13:27:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"EMA/323287/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf-2"},
    {"id":"32367","name":"Agenda for the 85th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T13:30:00Z","last_updated_date":"2014-10-02T13:30:00Z","reference_number":"EMA/MB/354958/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-85th-meeting-management-board_en.pdf"},
    {"id":"32410","name":"Agenda - Congress Programme ESDP 2006, 10th Biannual Congress","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2005-12-22T00:09:21Z","last_updated_date":"2005-12-22T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-congress-programme-esdp-2006-10th-biannual-congress_en.pdf"},
    {"id":"32430","name":"Agenda - PRAC draft agenda of meeting 4-7 November 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-11-05T19:30:00Z","last_updated_date":"2013-11-06T12:35:00Z","reference_number":"EMA/PRAC/676915/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-4-7-november-2013_en.pdf"},
    {"id":"32462","name":"Agenda - COMP agenda of the 6-7 November 2012 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-10-25T14:05:00Z","last_updated_date":"2012-10-25T14:05:00Z","reference_number":"EMA/COMP/658591/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-6-7-november-2012-meeting_en.pdf"},
    {"id":"32465","name":"Agenda - First EMA workshop on non-animal approaches in support of medicinal product development – challenges and opportunities for use of micro-physiological systems","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-25T02:00:00Z","last_updated_date":"2017-09-25T02:00:00Z","reference_number":"EMA/CHMP/SWP/522061/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-ema-workshop-non-animal-approaches-support-medicinal-product-development-challenges-and-opportunities-use-micro-physiological-systems_en.pdf"},
    {"id":"32530","name":"Agenda - RD-ACTION, European Medicines Agency, and European Commission-DG SANTE workshop: how European Reference Networks can add value to clinical research","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-05-22T17:36:00Z","last_updated_date":"2018-06-19T18:45:00Z","reference_number":"EMA/270801/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-rd-action-european-medicines-agency-and-european-commission-dg-sante-workshop-how-european-reference-networks-can-add-value-clinical-research_en.pdf"},
    {"id":"32569","name":"Agenda - COMP agenda of the 6-8 October 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-09-30T16:05:00Z","last_updated_date":"2015-10-01T13:05:00Z","reference_number":"EMA/COMP/640510/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-6-8-october-2015-meeting_en.pdf"},
    {"id":"32690","name":"Agenda - Workshop on site and histology - Independent indications in oncology","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-30T16:00:00Z","last_updated_date":"2017-12-14T12:00:00Z","reference_number":"EMA/CHMP/673240/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-site-and-histology-independent-indications-oncology_en.pdf"},
    {"id":"32790","name":"Agenda - Second EMEA Workshop on Neurodegenerative Diseases, 'Focus on Dementia'","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T00:09:21Z","last_updated_date":"2008-02-08T00:09:21Z","reference_number":"EMEA/48200/2008 Rev. 1.5","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-emea-workshop-neurodegenerative-diseases-focus-dementia_en.pdf"},
    {"id":"32794","name":"Agenda - COMP agenda of the 21-23 March 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-03-16T17:20:00Z","last_updated_date":"2016-03-16T17:20:00Z","reference_number":"EMA/COMP/145890/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-21-23-march-2016-meeting_en.pdf"},
    {"id":"32821","name":"Agenda - 2006 EMEA/EFPIA Workshop on Biomarkers","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"EMEA/262936/2006","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2006-emeaefpia-workshop-biomarkers_en.pdf"},
    {"id":"32822","name":"Agenda - CHMP agenda of the 12-15 September 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-09-12T18:40:00Z","last_updated_date":"2016-09-12T18:40:00Z","reference_number":"EMA/CHMP/603605/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-12-15-september-2016-meeting_en.pdf"},
    {"id":"32823","name":"Agenda and registration form - European Medicines Agency Excellence in Pharmacovigilance: Clinical trials and post-marketing training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T02:00:00Z","last_updated_date":"2014-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-european-medicines-agency-excellence-pharmacovigilance-clinical-trials-and-post-marketing-training-course_en.pdf-0"},
    {"id":"32829","name":"Agenda - Focus group meeting - Revision of the CVMP guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-11-27T01:00:00Z","last_updated_date":"2013-11-27T01:00:00Z","reference_number":"EMA/408480/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-focus-group-meeting-revision-cvmp-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances_en.pdf"},
    {"id":"32846","name":"Agenda - PDCO agenda of the 15-17 April 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T17:20:00Z","last_updated_date":"2015-04-16T17:20:00Z","reference_number":"EMA/PDCO/200198/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-15-17-april-2015-meeting_en.pdf"},
    {"id":"32853","name":"Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-05-29T18:00:00Z","last_updated_date":"2018-05-29T18:00:00Z","reference_number":"EMA/213044/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting_en.pdf-0"},
    {"id":"32926","name":"Agenda - GCC Biosimilar Medicinal Products Workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-gcc-biosimilar-medicinal-products-workshop_en.pdf"},
    {"id":"32960","name":"CHMP ORGAM agenda for the meeting on 13 March 2017","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-03-28T17:16:00Z","last_updated_date":"2017-03-28T17:16:00Z","reference_number":"EMA/CHMP/174281/2017 Rev.0","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-13-march-2017_en.pdf"},
    {"id":"32975","name":"Agenda - EudraVigilance Training in 2006, A joint initiative of the EMEA with DIA acting as the conference organiser","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-04-11T02:09:21Z","last_updated_date":"2006-04-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eudravigilance-training-2006-joint-initiative-emea-dia-acting-conference-organiser_en.pdf-1"},
    {"id":"32985","name":"Agenda - PDCO agenda of the 25-27 May 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-05-24T19:45:00Z","last_updated_date":"2016-05-24T19:45:00Z","reference_number":"EMA/PDCO/316468/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-25-27-may-2016-meeting_en.pdf"},
    {"id":"32998","name":"Programme – Focus group with invited stakeholders on field efficacy trials in the context of an EU authorisation for veterinary vaccines","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-06-06T02:00:00Z","last_updated_date":"2017-11-16T13:30:00Z","reference_number":"EMA/159266/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-focus-group-invited-stakeholders-field-efficacy-trials-context-eu-authorisation-veterinary-vaccines_en.pdf"},
    {"id":"33003","name":"Agenda - PRAC draft agenda of meeting 6-9 June 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-06-06T14:30:00Z","last_updated_date":"2017-06-06T14:30:00Z","reference_number":"EMA/PRAC/355498/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-6-9-june-2017_en.pdf"},
    {"id":"33019","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations and Healthcare Professionals Working Party joint meeting - February 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-02-05T16:45:00Z","last_updated_date":"2014-04-28T17:45:00Z","reference_number":"EMA/13760/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-and-healthcare-professionals-working-party-joint-meeting-february-2014_en.pdf"},
    {"id":"33045","name":"Agenda – Fifth stakeholders forum on the implementation of the new pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-05-24T17:22:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"EMA/284201/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fifth-stakeholders-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"33073","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting on 6 June 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-07-02T02:00:00Z","reference_number":"EMA/248075/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-6-june-2013_en.pdf"},
    {"id":"33190","name":"Agenda - CAT agenda for the written procedure - 7-11 August 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-08-11T19:17:00Z","last_updated_date":"2017-08-11T19:17:00Z","reference_number":"EMA/CAT/518173/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-written-procedure-7-11-august-2017_en.pdf"},
    {"id":"33217","name":"Agenda - EMEA - EGA Info Day on Generic and Biosimilar Medicinal Products and the Centralised Procedure - For EGA members only","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2006-11-24T00:09:21Z","last_updated_date":"2006-11-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emea-ega-info-day-generic-and-biosimilar-medicinal-products-and-centralised-procedure-ega-members-only_en.pdf"},
    {"id":"33238","name":"Agenda - European Union (EU) International Organization for Standardization (ISO) identification of medicinal products task force meeting - 31 March 2015","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-05T17:00:00Z","last_updated_date":"2015-06-05T17:00:00Z","reference_number":"EMA/164209/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-eu-international-organization-standardization-iso-identification-medicinal-products-task-force-meeting-31-march-2015_en.pdf"},
    {"id":"33440","name":"Agenda - Quality Assessors Training","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-11-09T00:09:21Z","last_updated_date":"2009-11-09T00:09:21Z","reference_number":"CHMP/CVMP/QWP/696999/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quality-assessors-training_en.pdf"},
    {"id":"33554","name":"Agenda - Seventh annual  face to face meeting of European network of paediatric research at the European Medicines Agency Coordinating Group members - 29 May 2015","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"EMA/240560/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-seventh-annual-face-face-meeting-european-network-paediatric-research-european-medicines-agency-coordinating-group-members-29-may-2015_en.pdf"},
    {"id":"33585","name":"Agenda - PRAC draft agenda of meeting 5-8 May 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-05-06T15:50:00Z","last_updated_date":"2014-05-06T15:50:00Z","reference_number":"EMA/PRAC/274254/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-5-8-may-2014_en.pdf"},
    {"id":"33627","name":"Agenda - PDCO agenda of the 21-23 May 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-05-22T15:50:00Z","last_updated_date":"2014-05-22T15:50:00Z","reference_number":"EMA/PDCO/276223/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-21-23-may-2014-meeting_en.pdf"}    {"id":"33632","name":"Schedule - EU 28: science, medicines, health","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"EMA/74857/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/schedule-eu-28-science-medicines-health_en.pdf"},
    {"id":"33644","name":"Agenda - International workshop: Agenda - Draft reflection paper on ethical and good-clinical practice aspects of clinical trials of medicinal products for human use conducted in third countries and submitted in marketin...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-09-03T02:00:00Z","last_updated_date":"2011-05-17T02:00:00Z","reference_number":"International workshop","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-international-workshop-agenda-draft-reflection-paper-ethical-and-good-clinical-practice-aspects-clinical-trials-medicinal-products-human-use-conducted-third-countries-and-submitted-marketin_en.pdf"},
    {"id":"33680","name":"Agenda - CHMP agenda of the 17-20 November 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-11-18T11:00:00Z","last_updated_date":"2014-11-18T11:00:00Z","reference_number":"EMA/CHMP/659045/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-17-20-november-2014-meeting_en.pdf"},
    {"id":"33687","name":"Agenda and registration form - Eudra Vigilance training on electronic reporting of ICSRs in the European Economic Area","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-09-29T02:00:00Z","last_updated_date":"2016-09-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudra-vigilance-training-electronic-reporting-icsrs-european-economic-area_en.pdf"},
    {"id":"33733","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting on 3 June 2015","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-05-27T13:00:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"EMA/167755/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-3-june-2015_en.pdf"},
    {"id":"33759","name":"Agenda - HMPC agenda of the 17-18 July 2017 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-07-18T17:50:00Z","last_updated_date":"2017-07-18T17:50:00Z","reference_number":"EMA/HMPC/452670/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-17-18-july-2017-meeting_en.pdf"},
    {"id":"33780","name":"Agenda - Workshop on nanomedicines: 2-3 September 2010","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-03-15T01:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"EMA/273690/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-nanomedicines-2-3-september-2010_en.pdf"},
    {"id":"33812","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Lisbon","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-lisbon_en.pdf"},
    {"id":"33813","name":"Agenda for the Extraordinary meeting of the Management Board on 1 October 2015","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-09-29T16:00:00Z","last_updated_date":"2015-10-01T16:00:00Z","reference_number":"EMA/MB/392855/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-extraordinary-meeting-management-board-1-october-2015_en.pdf"},
    {"id":"33861","name":"Agenda - COMP agenda of the 8-10 December 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-12-01T10:35:00Z","last_updated_date":"2015-12-01T10:35:00Z","reference_number":"EMA/COMP/760301/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-8-10-december-2015-meeting_en.pdf"},
    {"id":"33909","name":"Agenda - CAT agenda of the 8-9 September 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-09-09T19:00:00Z","last_updated_date":"2016-09-09T19:00:00Z","reference_number":"EMA/CAT/605735/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-8-9-september-2016-meeting_en.pdf"},
    {"id":"34001","name":"Agenda - European Medicines Agency/European Federation of Pharmaceutical Industries and Associations (EFPIA) workshop on the importance of dose finding and dose selection for the successful development, licensing and lif...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-23T02:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"EMA/341714/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agencyeuropean-federation-pharmaceutical-industries-and-associations-efpia-workshop-importance-dose-finding-and-dose-selection-successful-development-licensing-and-lif_en.pdf"},
    {"id":"34018","name":"Agenda - European Medicines Agency-European Federation of Pharmaceutical Industries and Associations workshop on adaptive designs in confirmatory clinical trials","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-european-federation-pharmaceutical-industries-and-associations-workshop-adaptive-designs-confirmatory-clinical-trials_en.pdf"},
    {"id":"34071","name":"Agenda and registration form - The new EudraVigilance System and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course (Lisbon)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T12:57:00Z","last_updated_date":"2017-06-15T16:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-lisbon_en.pdf-0"},
    {"id":"34077","name":"Agenda for the 66th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/MB/3790/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-66th-meeting-management-board_en.pdf"},
    {"id":"34123","name":"CHMP ORGAM agenda for the meeting on 13 February 2017","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-02-15T13:35:00Z","last_updated_date":"2017-02-15T13:35:00Z","reference_number":"EMA/CHMP/105294/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-13-february-2017_en.pdf"},
    {"id":"34320","name":"Agenda - Workshop: In vitro Cytokine release assays; To predict Cytokine release syndrome: The current state-of-the-science","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-08-12T02:09:21Z","last_updated_date":"2009-11-18T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-vitro-cytokine-release-assays-predict-cytokine-release-syndrome-current-state-science_en.pdf"},
    {"id":"34367","name":"Agenda - PRAC draft agenda of meeting 10-13 May 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-05-10T18:30:00Z","last_updated_date":"2016-05-10T18:30:00Z","reference_number":"EMA/PRAC/325452/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-10-13-may-2016_en.pdf"},
    {"id":"34393","name":"Agenda - 2012 European Medicines Agency/International Federation for Animal Health Europe info day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-02-21T16:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2012-european-medicines-agencyinternational-federation-animal-health-europe-info-day_en.pdf"},
    {"id":"34435","name":"Agenda - CAT agenda of the 16-17 January 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-01-20T18:25:00Z","last_updated_date":"2014-01-20T18:25:00Z","reference_number":"EMA/CAT/27142/2014 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-16-17-january-2014-meeting_en.pdf"},
    {"id":"34462","name":"Agenda - CHMP agenda of the 20-23 June 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-06-20T16:00:00Z","last_updated_date":"2016-06-20T16:00:00Z","reference_number":"EMA/CHMP/424610/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-20-23-june-2016-meeting_en.pdf"},
    {"id":"34472","name":"Agenda - Committee for Advanced Therapies (CAT) and the International Society for Cellular Therapy (ISCT) workshop: challenges and opportunities for a successful development and approval of advanced therapy medicinal pro...","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-30T17:00:00Z","last_updated_date":"2015-06-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-committee-advanced-therapies-cat-and-international-society-cellular-therapy-isct-workshop-challenges-and-opportunities-successful-development-and-approval-advanced-therapy-medicinal-pro_en.pdf"},
    {"id":"34567","name":"Agenda - COMP agenda of the 19-21 January 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-01-13T17:10:00Z","last_updated_date":"2016-01-13T17:10:00Z","reference_number":"EMA/COMP/844188/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-19-21-january-2016-meeting_en.pdf"},
    {"id":"34581","name":"Agenda - PDCO agenda of the 20-22 May 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-05-20T16:30:00Z","last_updated_date":"2015-05-20T16:30:00Z","reference_number":"EMA/PRAC/332948/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-20-22-may-2015-meeting_en.pdf"},
    {"id":"34909","name":"Agenda - HMPC agenda of the 4-5 April 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T11:10:00Z","last_updated_date":"2016-04-01T11:10:00Z","reference_number":"EMA/HMPC/69315/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-4-5-april-2016-meeting_en.pdf"},
    {"id":"34969","name":"Agenda: Expert meeting in familial neurodegenerative disorders","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-11-05T01:00:00Z","last_updated_date":"2010-11-05T01:00:00Z","reference_number":"EMA/696330/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-expert-meeting-familial-neurodegenerative-disorders_en.pdf"},
    {"id":"34978","name":"Agenda - CHMP agenda of the 23-26 June 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-06-23T14:00:00Z","last_updated_date":"2014-06-23T14:00:00Z","reference_number":"EMA/CHMP/312497/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-23-26-june-2014-meeting_en.pdf"},
    {"id":"35025","name":"Agenda for the 97th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-10-03T10:45:00Z","last_updated_date":"2017-10-05T13:00:00Z","reference_number":"EMA/MB/158073/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-97th-meeting-management-board_en.pdf"},
    {"id":"35164","name":"Agenda - EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations - December 2013","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-12-05T17:30:00Z","last_updated_date":"2014-02-07T13:30:00Z","reference_number":"EMA/644851/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations-december-2013_en.pdf"},
    {"id":"35242","name":"Agenda - CHMP agenda of the 23-26 January 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-01-23T13:20:00Z","last_updated_date":"2017-01-23T13:20:00Z","reference_number":"EMA/41689/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-23-26-january-2017-meeting_en.pdf"},
    {"id":"35248","name":"Agenda - PRAC draft agenda of meeting 6-9 February 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-02-06T19:15:00Z","last_updated_date":"2017-02-06T19:15:00Z","reference_number":"EMA/PRAC/35833/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-6-9-february-2017_en.pdf"},
    {"id":"35302","name":"Agenda - HMPC agenda of the 23-24 November 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-11-23T17:58:00Z","last_updated_date":"2015-11-23T17:58:00Z","reference_number":"EMA/HMPC/776470/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-23-24-november-2015-meeting_en.pdf"},
    {"id":"35367","name":"Programme of the joint European Forum for Good Clinical Practice / Drug Information Association / European Medicines Agency conference: Better medicines for children","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-04T13:30:00Z","last_updated_date":"2014-09-24T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-joint-european-forum-good-clinical-practice-drug-information-association-european-medicines-agency-conference-better-medicines-children_en.pdf"},
    {"id":"35374","name":"Agenda - Veterinary focus group meeting with stakeholders: revision of the reflection paper on anthelmintic resistance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T12:30:00Z","last_updated_date":"2016-05-31T12:30:00Z","reference_number":"EMA/CVMP/EWP/29236/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-veterinary-focus-group-meeting-stakeholders-revision-reflection-paper-anthelmintic-resistance_en.pdf"},
    {"id":"35379","name":"Agenda - TREAT-NMD Workshop on the development of Antisense Oligonucleotide Therapies for Duchenne Muscular Dystrophy","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:09:21Z","last_updated_date":"2009-09-25T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-treat-nmd-workshop-development-antisense-oligonucleotide-therapies-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"35508","name":"Agenda - Medication-errors workshop - Final programme","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2013-02-27T11:35:00Z","reference_number":"EMA/35980/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medication-errors-workshop-final-programme_en.pdf"},
    {"id":"35614","name":"Agenda - Industry stakeholder teleconference on Brexit and operation of the centralised procedure for veterinary medicinal products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-10-17T16:27:00Z","last_updated_date":"2017-10-17T16:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-stakeholder-teleconference-brexit-and-operation-centralised-procedure-veterinary-medicinal-products_en.pdf"},
    {"id":"35650","name":"Agenda - Workshop on the therapeutic use of bacteriophages","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-05-21T14:45:00Z","last_updated_date":"2015-06-05T14:45:00Z","reference_number":"EMA/265715/2015 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-therapeutic-use-bacteriophages_en.pdf"},
    {"id":"35666","name":"Agenda for the 90th meeting of the Management Board on 16-17 December 2015","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-12-17T10:05:00Z","last_updated_date":"2015-12-17T10:05:00Z","reference_number":"EMA/MB/169416/2015 Version 4 Adopted","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-90th-meeting-management-board-16-17-december-2015_en.pdf"},
    {"id":"35671","name":"Agenda - Conference programme: Human and Veterinary Pharmaceuticals’ Regulation - Towards EU Accession: Serbia’s Regulatory Challenges, Expectations and Opportunities","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-12-15T01:00:00Z","reference_number":"EMA/663451/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-conference-programme-human-and-veterinary-pharmaceuticals-regulation-towards-eu-accession-serbias-regulatory-challenges-expectations-and-opportunities_en.pdf"},
    {"id":"35859","name":"Agenda - PRAC draft agenda of meeting 3-5 September 2012","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2012-09-03T14:00:00Z","last_updated_date":"2012-09-03T14:00:00Z","reference_number":"EMA/PRAC/432046/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-3-5-september-2012_en.pdf"},
    {"id":"35879","name":"Agenda and registration form - EudraVigilance training on electronic reporting of ICSRs in the European Economic Area (Bucharest, Romania)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-01-26T16:30:00Z","last_updated_date":"2017-01-26T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-icsrs-european-economic-area-bucharest-romania_en.pdf"},
    {"id":"35941","name":"Agenda and registration form - individual case safety report information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-03-23T15:00:01Z","last_updated_date":"2015-03-24T14:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-individual-case-safety-report-information-day_en.pdf"},
    {"id":"36016","name":"Agenda - Workshops for micro, small and medium-sized enterprises: focus on non-clinical aspects","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-05-19T17:10:00Z","last_updated_date":"2016-09-09T11:50:00Z","reference_number":"EMA/26126/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshops-micro-small-and-medium-sized-enterprises-focus-non-clinical-aspects_en.pdf"},
    {"id":"36025","name":"Agenda - Workshop on development of antimycobacterial medicinal products (to treat Mycobacterium tuberculosis)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/427839/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-development-antimycobacterial-medicinal-products-treat-mycobacterium-tuberculosis_en.pdf"},
    {"id":"36046","name":"Programme of the EMA-FDA-Health Canada workshop on paediatric pulmonary arterial hypertension (PAH)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-06-06T12:49:00Z","last_updated_date":"2017-06-20T12:49:00Z","reference_number":"EMA/848554/2016 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-ema-fda-health-canada-workshop-paediatric-pulmonary-arterial-hypertension-pah_en.pdf"},
    {"id":"36067","name":"Agenda - COMP agenda of the 17-19 May 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-05-19T12:00:00Z","last_updated_date":"2016-05-19T12:00:00Z","reference_number":"EMA/COMP/292880/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-17-19-may-2016-meeting_en.pdf"},
    {"id":"36080","name":"Agenda - CVMP agenda of the 5-7 September 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-09-05T16:47:00Z","last_updated_date":"2017-09-05T16:47:00Z","reference_number":"EMA/CVMP/580683/2017 draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-5-7-september-2017-meeting_en.pdf"},
    {"id":"36147","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-01-12T17:00:00Z","last_updated_date":"2017-01-12T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course_en.pdf-1"},
    {"id":"36173","name":"Agenda - Second industry stakeholder platform on the operation of the centralised procedure for human medicinal products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-11-12T14:00:01Z","last_updated_date":"2015-11-12T14:00:01Z","reference_number":"EMA/633298/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-industry-stakeholder-platform-operation-centralised-procedure-human-medicinal-products_en.pdf"},
    {"id":"36222","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations meeting with all eligible organisations","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T17:00:00Z","last_updated_date":"2013-02-12T17:00:00Z","reference_number":"EMA/658954/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-meeting-all-eligible-organisations_en.pdf"},
    {"id":"36310","name":"Agenda - Emerging medicinal products: from laboratory to patient use","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-10-08T02:00:00Z","last_updated_date":"2015-12-10T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emerging-medicinal-products-laboratory-patient-use_en.pdf"},
    {"id":"36313","name":"Programme - Joint European Medicines Agency / Heads of Medicines Agencies  workshop on requirements for the authorisation of veterinary vaccines in the European Union","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-03-18T17:20:00Z","last_updated_date":"2015-04-01T18:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-joint-european-medicines-agency-heads-medicines-agencies-workshop-requirements-authorisation-veterinary-vaccines-european-union_en.pdf"},
    {"id":"36334","name":"Agenda - COMP agenda of the 6-8 September 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-09-06T18:30:00Z","last_updated_date":"2016-09-06T18:30:00Z","reference_number":"EMA/COMP/502043/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-6-8-september-2016-meeting_en.pdf"},
    {"id":"36372","name":"Agenda - CVMP agenda of the 17-19 July 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-07-18T18:30:00Z","last_updated_date":"2018-07-18T18:30:00Z","reference_number":"EMA/CVMP/435798/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-17-19-july-2018-meeting_en.pdf"},
    {"id":"36478","name":"Agenda - CVMP agenda of the 10-11 May 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-05-08T19:12:00Z","last_updated_date":"2017-05-08T19:12:00Z","reference_number":"EMA/CVMP/287794/2017 draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-10-11-may-2017-meeting_en.pdf"},
    {"id":"36489","name":"Agenda - Programme of the 2015 European Union Good-clinical-practice Inspectors Working Group workshop on 12-14 October","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-10-09T14:30:00Z","last_updated_date":"2015-10-09T14:30:00Z","reference_number":"EMA/104761/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-2015-european-union-good-clinical-practice-inspectors-working-group-workshop-12-14-october_en.pdf"},
    {"id":"36490","name":"Agenda - European Medicines Agency and Medicines for Europe annual bilateral meeting 2017","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-01-13T01:00:00Z","last_updated_date":"2017-01-13T01:00:00Z","reference_number":"EMA/2341/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-and-medicines-europe-annual-bilateral-meeting-2017_en.pdf"},
    {"id":"36537","name":"Agenda - CHMP agenda of the 11-14 December 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-12-12T11:00:00Z","last_updated_date":"2017-12-12T11:00:00Z","reference_number":"EMA/CHMP/741899/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-11-14-december-2017-meeting_en.pdf"},
    {"id":"36555","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Madrid, October 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-06-14T17:00:00Z","last_updated_date":"2018-08-24T12:20:00Z","reference_number":"Course # 18518","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-madrid-october-2018_en.pdf"},
    {"id":"36575","name":"Agenda - CHMP agenda of the 16-19 December 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T13:00:01Z","last_updated_date":"2013-12-17T13:00:01Z","reference_number":"EMA/CHMP/723655/2013 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-16-19-december-2013-meeting_en.pdf"},
    {"id":"36587","name":"Agenda of the 81st meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T14:20:00Z","last_updated_date":"2013-10-08T14:20:00Z","reference_number":"EMA/MB/197800/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-81st-meeting-management-board_en.pdf"},
    {"id":"36615","name":"Agenda - Workshop on generation and use of Health Based Exposure Limits (HBEL)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-06-19T18:00:00Z","last_updated_date":"2017-07-10T18:00:00Z","reference_number":"EMA/274950/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-generation-and-use-health-based-exposure-limits-hbel_en.pdf"},
    {"id":"36618","name":"Agenda - Fifth annual meeting of European Network of Paediatric Research at the European Medicines members","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-06-26T19:00:00Z","last_updated_date":"2013-06-26T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fifth-annual-meeting-european-network-paediatric-research-european-medicines-members_en.pdf"},
    {"id":"36741","name":"Agenda - Eleventh industry stakeholder platform on the operation of EU pharmacovigilance","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-06-06T02:00:00Z","last_updated_date":"2017-06-06T02:00:00Z","reference_number":"EMA/286244/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eleventh-industry-stakeholder-platform-operation-eu-pharmacovigilance_en.pdf"},
    {"id":"36744","name":"Agenda - European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) stakeholders meeting 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-surveillance-veterinary-antimicrobial-consumption-esvac-stakeholders-meeting-2014_en.pdf"},
    {"id":"36755","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, San Marino, November 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-06-14T17:00:00Z","last_updated_date":"2018-06-14T17:00:00Z","reference_number":"Course # 18520","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-san-marino-november-2018_en.pdf"},
    {"id":"36762","name":"Agenda - CAT agenda of the 17-18 July 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T11:40:00Z","last_updated_date":"2014-07-30T11:40:00Z","reference_number":"EMA/CAT/397249/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-17-18-july-2014-meeting_en.pdf"},
    {"id":"36777","name":"Agenda - CAT agenda of the 12-13 December 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T13:00:00Z","last_updated_date":"2013-12-17T13:00:00Z","reference_number":"EMA/CAT/793081/2013 rev. 2","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-12-13-december-2013-meeting_en.pdf"},
    {"id":"36778","name":"Agenda - European Medicines Agency Human Scientific Committee’s Working Party with Healthcare Professionals’ Organisations (HCPWP) meeting on 15 June 2016","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-06-10T12:30:00Z","last_updated_date":"2016-08-22T12:30:00Z","reference_number":"EMA/285607/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-meeting-15-june-2016_en.pdf"},
    {"id":"36781","name":"Agenda for the 70th meeting of the Management Board, 16–17 March 2011","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2011-03-29T02:00:00Z","reference_number":"EMA/MB/19969/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-70th-meeting-management-board-16-17-march-2011_en.pdf"},
    {"id":"36803","name":"Agenda - Draft workshop programme - Joint European Medicines Agency/European Directorate for the Quality of Medicines and Healthcare workshop on improved potency assays for inactivated influenza vaccines","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2011-12-07T01:00:00Z","last_updated_date":"2011-12-07T01:00:00Z","reference_number":"EMA/902224/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-draft-workshop-programme-joint-european-medicines-agencyeuropean-directorate-quality-medicines-and-healthcare-workshop-improved-potency-assays-inactivated-influenza-vaccines_en.pdf"},
    {"id":"36947","name":"Agenda - CVMP agenda of the 19-21 January 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-01-18T16:10:00Z","last_updated_date":"2016-01-18T16:10:00Z","reference_number":"EMA/CVMP/36589/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-19-21-january-2016-meeting_en.pdf"},
    {"id":"36981","name":"Agenda - CHMP agenda of the 09-12 October 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-10-09T12:44:00Z","last_updated_date":"2017-10-09T12:44:00Z","reference_number":"EMA/CHMP/662799/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-09-12-october-2017-meeting_en.pdf"},
    {"id":"37006","name":"Agenda - Brain Diseases in the Elderly; Joint workshop - European School for Scientific and Regulatory Assessment of New Medicines and European Medicines Agency (EMEA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-05-16T02:09:21Z","last_updated_date":"2008-05-16T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-brain-diseases-elderly-joint-workshop-european-school-scientific-and-regulatory-assessment-new-medicines-and-european-medicines-agency-emea_en.pdf"},
    {"id":"37019","name":"Agenda - European Union Committee of Experts on Rare Diseases/European Medicines Agency workshop : Towards a public-private partnership for registries in the field of rare diseases","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-09-29T11:50:20Z","last_updated_date":"2011-09-29T11:50:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-committee-experts-rare-diseaseseuropean-medicines-agency-workshop-towards-public-private-partnership-registries-field-rare-diseases_en.pdf"},
    {"id":"37157","name":"Agenda - CAT agenda of the 14-16 March 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-03-15T15:00:00Z","last_updated_date":"2018-03-15T15:00:00Z","reference_number":"EMA/CAT/168481/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-14-16-march-2018-meeting_en.pdf"},
    {"id":"37161","name":"Agenda - Workshop on medicines for bees","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2009-11-27T00:09:21Z","last_updated_date":"2010-02-23T00:09:21Z","reference_number":"EMEA/627614/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-medicines-bees_en.pdf"},
    {"id":"37170","name":"Agenda - European Medicines Agency roundtable on the small and medium-sized enterprise initiative","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-10-03T12:30:00Z","last_updated_date":"2011-10-03T12:30:00Z","reference_number":"EMA/507914/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-roundtable-small-and-medium-sized-enterprise-initiative_en.pdf"},
    {"id":"37223","name":"CVMP interested parties’ meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-05-05T18:20:00Z","last_updated_date":"2015-05-05T18:20:00Z","reference_number":"EMA/CVMP/161959/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/cvmp-interested-parties-meeting_en.pdf-0"},
    {"id":"37273","name":"CHMP ORGAM agenda for the meeting on 16 April 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T13:00:00Z","last_updated_date":"2018-05-03T13:00:00Z","reference_number":"EMA/CHMP/237329/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-16-april-2018_en.pdf"},
    {"id":"37280","name":"Agenda - Training session on the review of product information 29/11/11","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2011-11-23T01:00:00Z","reference_number":"EMA/818489/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-review-product-information-291111_en.pdf"},
    {"id":"37407","name":"Agenda - PDCO agenda of the 11-13 February 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-02-18T12:10:00Z","last_updated_date":"2015-02-18T12:10:00Z","reference_number":"EMA/PDCO/41469/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-11-13-february-2015-meeting_en.pdf"},
    {"id":"37582","name":"Agenda - PRAC draft agenda of meeting 7-10 April 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-04-07T19:10:00Z","last_updated_date":"2014-04-07T19:10:00Z","reference_number":"EMA/PRAC/210339/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-7-10-april-2014_en.pdf"},
    {"id":"37619","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (Madrid, Spain)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-22T15:00:00Z","last_updated_date":"2015-01-29T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-madrid-spain_en.pdf"},
    {"id":"37634","name":"Agenda - COMP agenda of the 12-13 May 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T03:46:00Z","last_updated_date":"2015-05-04T03:46:00Z","reference_number":"EMA/COMP/281296/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-12-13-may-2015-meeting_en.pdf"},
    {"id":"37759","name":"Agenda - PRAC draft agenda of meeting 8-11 January 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-01-08T18:10:00Z","last_updated_date":"2018-01-08T18:10:00Z","reference_number":"EMA/PRAC/9221/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-january-2018_en.pdf"},
    {"id":"37776","name":"Agenda - COMP agenda of the 2-4 September 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-08-21T17:00:00Z","last_updated_date":"2014-09-03T11:36:00Z","reference_number":"EMA/COMP/442034/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-2-4-september-2014-meeting_en.pdf"},
    {"id":"37799","name":"Agenda - European Medicines Agency-European Federation of Pharmaceutical Industries and Associations modelling and simulation workshop - Break-out session 1","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-11-29T17:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"EMA/926026/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-european-federation-pharmaceutical-industries-and-associations-modelling-and-simulation-workshop-break-out-session-1_en.pdf"},
    {"id":"37804","name":"Agenda - PRAC draft agenda of meeting 8-11 June 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-06-09T19:35:00Z","last_updated_date":"2015-06-09T19:35:00Z","reference_number":"EMA/PRAC/386470/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-june-2015_en.pdf"},
    {"id":"37856","name":"Agenda - CAT agenda of the 17-19 January 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-01-18T15:04:00Z","last_updated_date":"2018-01-18T15:04:00Z","reference_number":"EMA/CAT/34202/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-17-19-january-2018-meeting_en.pdf"},
    {"id":"37861","name":"Agenda - COMP agenda of the 16-17 April 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T11:30:00Z","last_updated_date":"2013-04-02T11:30:00Z","reference_number":"EMA/COMP/188612/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-16-17-april-2013-meeting_en.pdf"},
    {"id":"37921","name":"Agenda - COMP agenda of the 3-4 November 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-10-03T15:50:00Z","last_updated_date":"2016-10-03T15:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-3-4-november-2016-meeting_en.pdf"},
    {"id":"38003","name":"Agenda - European Medicines Agency veterinary medicines innovation day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-02-21T11:40:00Z","last_updated_date":"2018-04-18T17:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-veterinary-medicines-innovation-day_en.pdf"},
    {"id":"38018","name":"Agenda - EMA/EFPIA info day - 23 May 2011","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-03-30T01:31:00Z","last_updated_date":"2011-05-28T01:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emaefpia-info-day-23-may-2011_en.pdf"},
    {"id":"38042","name":"Agenda - CVMP interested parties' meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2013-06-04T02:00:00Z","last_updated_date":"2013-06-04T02:00:00Z","reference_number":"EMA/CVMP/192734/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-interested-parties-meeting_en.pdf-0"},
    {"id":"38055","name":"Agenda - Sixth annual workshop of the European network of paediatric research at the EMA (Enpr-EMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-06-18T19:00:00Z","reference_number":"EMA/110531/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixth-annual-workshop-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"38082","name":"Agenda - Workshop on Clinical Outcome Measures and endpoints for efficacy assessment in spinal muscular atrophy","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-09-11T02:09:21Z","last_updated_date":"2008-09-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-clinical-outcome-measures-and-endpoints-efficacy-assessment-spinal-muscular-atrophy_en.pdf"},
    {"id":"38091","name":"Agenda - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations meeting - February 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-02-05T16:00:00Z","last_updated_date":"2014-04-28T13:40:00Z","reference_number":"EMA/19425/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-meeting-february-2014_en.pdf"},
    {"id":"38122","name":"Agenda - PDCO agenda of the 16-18 July 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-07-17T13:00:00Z","last_updated_date":"2014-07-17T13:00:00Z","reference_number":"EMA/PDCO/381665/2014 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-16-18-july-2014-meeting_en.pdf"}    {"id":"38160","name":"Agenda - First Stakeholders forum on the implementation of the new Pharmacovigilance legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-04-19T02:00:00Z","last_updated_date":"2011-04-19T02:00:00Z","reference_number":"EMA/280084/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-stakeholders-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"38161","name":"Programme - Challenges for the approval of anti-cancer immunotherapeutic drugs","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-02-02T12:00:00Z","last_updated_date":"2016-02-03T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-challenges-approval-anti-cancer-immunotherapeutic-drugs_en.pdf"},
    {"id":"38198","name":"Agenda - 2017 European Union Good Clinical Practice Inspectors Working Group workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-25T19:00:00Z","last_updated_date":"2017-09-25T19:00:00Z","reference_number":"EMA/195334/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2017-european-union-good-clinical-practice-inspectors-working-group-workshop_en.pdf"},
    {"id":"38275","name":"Agenda - Sixty-third meeting of the Management Board, 11 June 2009","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2009-06-11T02:09:21Z","last_updated_date":"2009-06-11T02:09:21Z","reference_number":"EMEA/MB/45799/2009Adopted","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixty-third-meeting-management-board-11-june-2009_en.pdf"},
    {"id":"38322","name":"Agenda and registration form - The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2B(R3) format: hands-on training course, Berlin","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-new-eudravigilance-system-and-electronic-reporting-icsrs-isoich-e2br3-format-hands-training-course-berlin_en.pdf"},
    {"id":"38336","name":"Agenda - CHMP agenda of the 25-28 January 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-01-25T12:55:00Z","last_updated_date":"2016-01-25T12:55:00Z","reference_number":"EMA/CHMP/50700/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-25-28-january-2016-meeting_en.pdf"},
    {"id":"38362","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T13:30:00Z","last_updated_date":"2017-04-20T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course_en.pdf-2"},
    {"id":"38396","name":"Agenda - CAT agenda of the 18-19 June 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"EMA/CAT/358344/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-18-19-june-2015-meeting_en.pdf"},
    {"id":"38409","name":"Agenda - Demonstrating significant benefit of orphan medicines: concepts, methodology, and impact on access","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-09-04T02:00:00Z","last_updated_date":"2015-12-04T17:32:00Z","reference_number":"EMA/588712/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-demonstrating-significant-benefit-orphan-medicines-concepts-methodology-and-impact-access_en.pdf"},
    {"id":"38437","name":"Agenda - COMP agenda of the 19-21 June 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-06-18T17:40:00Z","last_updated_date":"2018-06-18T17:40:00Z","reference_number":"EMA/COMP/355979/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-19-21-june-2018-meeting_en.pdf"},
    {"id":"38490","name":"Agenda - CVMP agenda of the 16-18 January 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-01-16T13:30:00Z","last_updated_date":"2018-01-16T13:30:00Z","reference_number":"EMA/CVMP/1779/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-16-18-january-2018-meeting_en.pdf"},
    {"id":"38531","name":"Agenda - Programme - Workshop on veterinary regulatory support for micro, small and medium-sized enterprises (SMEs)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-10-09T13:00:00Z","last_updated_date":"2013-11-12T12:00:00Z","reference_number":"EMA/339258/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-programme-workshop-veterinary-regulatory-support-micro-small-and-medium-sized-enterprises-smes_en.pdf"},
    {"id":"38536","name":"Agenda - PDCO agenda of the 4-6 December 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-11-29T12:30:00Z","last_updated_date":"2013-11-29T12:30:00Z","reference_number":"EMA/PDCO/714542/20133","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-4-6-december-2013-meeting_en.pdf"},
    {"id":"38553","name":"Agenda and registration form - EudraVigilance training on electronic reporting of Individual Case Safety Reports in the European Economic Area (London, UK)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-29T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-training-electronic-reporting-individual-case-safety-reports-european-economic-area-london-uk_en.pdf"},
    {"id":"38655","name":"Agenda - COMP agenda of the 5-7 September 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-09-05T12:00:00Z","last_updated_date":"2017-09-05T12:00:00Z","reference_number":"EMA/COMP/456162/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-5-7-september-2017-meeting_en.pdf"},
    {"id":"38673","name":"Agenda - CAT agenda of the 20-22 June 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-06-22T18:00:00Z","last_updated_date":"2018-06-22T18:00:00Z","reference_number":"EMA/CAT/426129/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-20-22-june-2018-meeting_en.pdf"},
    {"id":"38698","name":"Agenda - CHMP agenda of the 19-22 June 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-06-19T15:30:00Z","last_updated_date":"2017-06-19T15:30:00Z","reference_number":"EMA/CHMP/309580/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-june-2017-meeting_en.pdf"},
    {"id":"38718","name":"Agenda - EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2011-02-22T01:00:00Z","last_updated_date":"2011-02-22T01:00:00Z","reference_number":"EMA/45985/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting_en.pdf"},
    {"id":"38737","name":"Agenda – Industry and assessors’ joint training on the explanatory note to GVP Module VII and the Q&A for assessors","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-04T19:06:00Z","last_updated_date":"2017-09-21T19:30:00Z","reference_number":"EMA/406983/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-and-assessors-joint-training-explanatory-note-gvp-module-vii-and-qa-assessors_en.pdf"},
    {"id":"38807","name":"Agenda for the 93rd meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2016-10-05T18:30:00Z","last_updated_date":"2016-10-07T17:30:00Z","reference_number":"EMA/MB/440637/2016 v.4","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-93rd-meeting-management-board_en.pdf"},
    {"id":"38817","name":"Agenda - 72nd meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/MB/234822/2011","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-72nd-meeting-management-board_en.pdf-0"},
    {"id":"38822","name":"Agenda - European Medicines Agency workshop on modelling in paediatric medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"EMEA/533246/2007, Final","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-workshop-modelling-paediatric-medicines_en.pdf"},
    {"id":"38838","name":"Programme - Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-10-16T13:18:00Z","last_updated_date":"2015-11-17T16:10:00Z","reference_number":"EMA/681537/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-workshop-role-pharmacokinetic-and-pharmacodynamic-measurements-use-direct-oral-anticoagulants_en.pdf"},
    {"id":"38873","name":"Agenda - Global Animal Health Conference","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2007-10-29T00:09:21Z","last_updated_date":"2007-10-29T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-global-animal-health-conference_en.pdf-0"},
    {"id":"38893","name":"Programme - European Medicines Agency workshop on the investigation of subgroups in confirmatory clinical trials","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-11-07T01:00:00Z","last_updated_date":"2014-11-07T01:00:00Z","reference_number":"EMA/257665/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-european-medicines-agency-workshop-investigation-subgroups-confirmatory-clinical-trials_en.pdf"},
    {"id":"38902","name":"Agenda - European network of paediatric research at the European Medicines Agency Coordinating Group members meeting - 21 October 2015","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-10-20T18:40:00Z","last_updated_date":"2015-10-20T18:40:00Z","reference_number":"EMA/554410/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-coordinating-group-members-meeting-21-october-2015_en.pdf"},
    {"id":"38969","name":"Agenda - CHMP agenda of the 17-20 February 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T14:40:00Z","last_updated_date":"2014-02-17T14:40:00Z","reference_number":"EMA/CHMP/723655/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-17-20-february-2014-meeting_en.pdf"},
    {"id":"39028","name":"Agenda - PDCO agenda of the 15-17 July 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-07-15T13:05:00Z","last_updated_date":"2015-07-15T13:05:00Z","reference_number":"EMA/PDCO/69021/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-15-17-july-2015-meeting_en.pdf"},
    {"id":"39074","name":"Agenda - CAT agenda of the 12-14 July 2017 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-07-14T15:25:00Z","last_updated_date":"2017-07-14T15:25:00Z","reference_number":"EMA/CAT/451773/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-12-14-july-2017-meeting_en.pdf"},
    {"id":"39097","name":"Agenda - Second industry stakeholder platform on the operation of European Union pharmacovigilance legislation","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMA/654663/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-industry-stakeholder-platform-operation-european-union-pharmacovigilance-legislation_en.pdf"},
    {"id":"39184","name":"Agenda - PDCO agenda of the 10-13 October 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-10-10T16:00:00Z","last_updated_date":"2017-10-10T16:00:00Z","reference_number":"EMA/PDCO/622369/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-10-13-october-2017-meeting_en.pdf"},
    {"id":"39238","name":"Programme and registration form - European Medicines Agency information day on measuring the impact of pharmacovigilance activities, 14 November 2017","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-10-18T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-european-medicines-agency-information-day-measuring-impact-pharmacovigilance-activities-14-november-2017_en.pdf"},
    {"id":"39274","name":"Agenda and registration form - ICH-GCG ASEAN Training Workshop, ICH Q5C : Stability Testing for Biotechnological/Biological Products, 30-31 May 2011, Kuala Lumpur, Malaysia","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2011-05-30T02:00:00Z","last_updated_date":"2011-05-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-ich-gcg-asean-training-workshop-ich-q5c-stability-testing-biotechnologicalbiological-products-30-31-may-2011-kuala-lumpur-malaysia_en.pdf"},
    {"id":"39289","name":"Agenda - PDCO agenda of the 17-19 July 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T12:20:00Z","last_updated_date":"2013-07-19T12:20:00Z","reference_number":"EMA/PDCO/425226/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-17-19-july-2013-meeting_en.pdf"},
    {"id":"39301","name":"Agenda - CHMP agenda of the 19-22 May 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-05-19T14:20:00Z","last_updated_date":"2014-06-06T11:40:00Z","reference_number":"EMA/CHMP/252366/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-may-2014-meeting_en.pdf"},
    {"id":"39358","name":"Agenda - SME info day on the new clinical trial regulation","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-01-20T10:00:00Z","last_updated_date":"2017-03-16T12:46:00Z","reference_number":"EMA/816344/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sme-info-day-new-clinical-trial-regulation_en.pdf"},
    {"id":"39409","name":"Agenda - European Medicines Agency/European Federation of Pharmaceutical Industries and Associations second workshop on adaptive design in confirmatory trials","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-04-02T02:09:21Z","last_updated_date":"2009-04-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agencyeuropean-federation-pharmaceutical-industries-and-associations-second-workshop-adaptive-design-confirmatory-trials_en.pdf"},
    {"id":"39546","name":"Agenda - CVMP agenda of the 23-25 May 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-05-23T13:00:00Z","last_updated_date":"2018-05-23T13:00:00Z","reference_number":"EMA/CVMP/287208/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-23-25-may-2018-meeting_en.pdf"},
    {"id":"39548","name":"Agenda - SME workshop: Focus on chemistry, manufacturing and controls (CMC) regulatory compliance for biopharmaceuticals and advanced therapies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-03-03T01:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMA/49639/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sme-workshop-focus-chemistry-manufacturing-controls-cmc-regulatory-compliance-biopharmaceuticals-advanced-therapies_en.pdf"},
    {"id":"39569","name":"Agenda - Healthcare Professionals' Working Group meeting 8 May 2012","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-08-14T14:00:00Z","last_updated_date":"2012-08-14T14:00:00Z","reference_number":"EMA/61182/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-healthcare-professionals-working-group-meeting-8-may-2012_en.pdf"},
    {"id":"39590","name":"Agenda - Human & Veterinary Medicinal Products' Regulation - Turkey's Road to EU Membership","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2007-10-22T02:09:21Z","last_updated_date":"2007-10-22T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-human-veterinary-medicinal-products-regulation-turkeys-road-eu-membership_en.pdf"},
    {"id":"39617","name":"Agenda - CAT agenda of the 19–20 March 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-04-01T14:10:00Z","last_updated_date":"2015-04-01T14:10:00Z","reference_number":"EMA/CAT/187818/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-19-20-march-2015-meeting_en.pdf"},
    {"id":"39649","name":"Agenda - Fate of veterinary medicinal products in manure Focus Group Meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2009-06-23T02:09:21Z","last_updated_date":"2009-06-23T02:09:21Z","reference_number":"EMEA/CVMP/ERA/233378/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fate-veterinary-medicinal-products-manure-focus-group-meeting_en.pdf"},
    {"id":"39710","name":"Agenda - PROTECT symposium","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-02-16T16:25:00Z","last_updated_date":"2015-02-16T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-protect-symposium_en.pdf"},
    {"id":"39761","name":"Agenda - Meeting on redacting commercially confidential information (CCI) in clinical reports and anonymising clinical reports for the purpose of publication","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-07-01T15:20:00Z","last_updated_date":"2015-07-01T15:20:00Z","reference_number":"EMA/431518/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-redacting-commercially-confidential-information-cci-clinical-reports-and-anonymising-clinical-reports-purpose-publication_en.pdf"},
    {"id":"39796","name":"Agenda - Periodic safety update report information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-06-14T15:50:00Z","last_updated_date":"2016-10-04T13:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-periodic-safety-update-report-information-day_en.pdf"},
    {"id":"39802","name":"Agenda - Stakeholder meeting on Product Shortages due to manufacturing and quality problems: developing a proactive approach to prevention","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2015-10-08T02:00:00Z","last_updated_date":"2015-10-08T02:00:00Z","reference_number":"EMA/INS/GMP/665392/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-stakeholder-meeting-product-shortages-due-manufacturing-and-quality-problems-developing-proactive-approach-prevention_en.pdf"},
    {"id":"39865","name":"Agenda - PDCO agenda of the 23-26 January 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-01-24T13:30:00Z","last_updated_date":"2018-01-24T13:30:00Z","reference_number":"EMA/PDCO/8432/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-23-26-january-2018-meeting_en.pdf"},
    {"id":"39882","name":"Agenda - Risk-based quality management in clinical trials workshop","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-11-27T01:00:00Z","last_updated_date":"2013-11-27T01:00:00Z","reference_number":"EMA/314826/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-risk-based-quality-management-clinical-trials-workshop_en.pdf"},
    {"id":"39935","name":"Agenda - PDCO agenda of the 17-19 June 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T15:45:00Z","last_updated_date":"2015-06-18T15:45:00Z","reference_number":"EMA/PDCO/351567/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-17-19-june-2015-meeting_en.pdf"},
    {"id":"39983","name":"Agenda - PDCO agenda of the 27-29 January 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-01-28T12:55:00Z","last_updated_date":"2016-01-28T12:55:00Z","reference_number":"EMA/PDCO/12664/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-27-29-january-2016-meeting_en.pdf"},
    {"id":"40028","name":"Agenda and registration form - EudraVigilance Information Day (London, 7 June 2017)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T13:30:00Z","last_updated_date":"2017-05-24T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-eudravigilance-information-day-london-7-june-2017_en.pdf"},
    {"id":"40142","name":"Agenda - European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) stakeholders meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T13:00:00Z","last_updated_date":"2013-04-15T13:00:00Z","reference_number":"EMA/172893/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-surveillance-veterinary-antimicrobial-consumption-esvac-stakeholders-meeting_en.pdf"},
    {"id":"40205","name":"Agenda - HMPC agenda of the 11-12 July 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:35:00Z","last_updated_date":"2016-07-08T17:35:00Z","reference_number":"EMA/HMPC/474350/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-11-12-july-2016-meeting_en.pdf"},
    {"id":"40267","name":"Agenda - COMP agenda of the 16-18 February 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-02-15T16:55:00Z","last_updated_date":"2016-02-15T16:55:00Z","reference_number":"EMA/COMP/130661/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-16-18-february-2016-meeting_en.pdf"},
    {"id":"40347","name":"Agenda - PRAC draft agenda of meeting 9-12 February 2015","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-02-10T13:00:00Z","last_updated_date":"2015-02-10T13:00:00Z","reference_number":"EMA/PRAC/92670/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-9-12-february-2015_en.pdf"},
    {"id":"40389","name":"Agenda - Agenda and list of questions for the workshop on paediatric investigation plans in type-2 diabetes mellitus","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-agenda-and-list-questions-workshop-paediatric-investigation-plans-type-2-diabetes-mellitus_en.pdf-0"},
    {"id":"40415","name":"Agenda and list of speakers - Public Hearing: quinolone and fluoroquinolone medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T12:00:00Z","last_updated_date":"2018-06-11T18:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-list-speakers-public-hearing-quinolone-and-fluoroquinolone-medicines_en.pdf"},
    {"id":"40424","name":"Agenda - PRAC draft agenda of meeting 1-4 December 2014","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2014-12-01T18:15:00Z","last_updated_date":"2014-12-01T18:15:00Z","reference_number":"EMA/PRAC/745328/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-1-4-december-2014_en.pdf"},
    {"id":"40477","name":"Agenda - CAT agenda of the 8-9 December 2016 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-12-08T18:00:00Z","last_updated_date":"2016-12-08T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-8-9-december-2016-meeting_en.pdf"},
    {"id":"40522","name":"Agenda for the 71st extraordinary meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2011-06-16T02:00:00Z","last_updated_date":"2011-06-16T02:00:00Z","reference_number":"EMA/MB/296221/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-71st-extraordinary-meeting-management-board_en.pdf"},
    {"id":"40613","name":"Agenda - 2008 EMEA/IFAH-Europe Info Day, 'Balancing the benefits and risks of veterinary medicinal products' - Programme and Registration","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-03-13T00:09:21Z","last_updated_date":"2008-03-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2008-emeaifah-europe-info-day-balancing-benefits-and-risks-veterinary-medicinal-products-programme-and-registration_en.pdf"},
    {"id":"40633","name":"Agenda - IPA introductory meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ipa-introductory-meeting_en.pdf"},
    {"id":"40642","name":"Agenda - PRAC draft agenda of meeting 26-29 September 2016","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-09-26T18:30:00Z","last_updated_date":"2016-09-26T18:30:00Z","reference_number":"EMA/PRAC/635914/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-26-29-september-2016_en.pdf"},
    {"id":"40677","name":"Agenda - Workshop on stem cell-based therapies","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2010-04-23T02:00:00Z","reference_number":"EMA/CAT/80413/2010","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-stem-cell-based-therapies_en.pdf"},
    {"id":"40750","name":"Agenda - PDCO agenda of the 9-11 September 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-09-09T12:10:00Z","last_updated_date":"2015-09-09T12:10:00Z","reference_number":"EMA/PDCO/556070/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-9-11-september-2015-meeting_en.pdf"},
    {"id":"40768","name":"Agenda – Third industry stakeholder platform on the operation of the centralised procedure for human medicinal products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T10:40:00Z","last_updated_date":"2016-04-28T10:40:00Z","reference_number":"EMA/186832/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-industry-stakeholder-platform-operation-centralised-procedure-human-medicinal-products_en.pdf"},
    {"id":"40779","name":"Agenda - CAT agenda of the 15-16 October 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-10-21T12:00:00Z","last_updated_date":"2015-10-21T12:00:00Z","reference_number":"EMA/CAT/691987/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-15-16-october-2015-meeting_en.pdf"},
    {"id":"40786","name":"Agenda - PDCO agenda of the 30 March-1 April 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-03-30T16:15:00Z","last_updated_date":"2016-03-30T16:15:00Z","reference_number":"EMA/PDCO/171815/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-30-march-1-april-2016-meeting_en.pdf"},
    {"id":"40798","name":"Agenda - CAT agenda of the 17-18 September 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-09-25T15:45:00Z","last_updated_date":"2015-09-25T15:45:00Z","reference_number":"EMA/CAT/629516/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-17-18-september-2015-meeting_en.pdf"},
    {"id":"40859","name":"Agenda - European Medicines Agency/European Federation of Pharmaceutical Industries and Associations workshop: Integrating pharmacogenomics early into drug development: Pharmacokinetics as a working example","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agencyeuropean-federation-pharmaceutical-industries-and-associations-workshop-integrating-pharmacogenomics-early-drug-development-pharmacokinetics-working-example_en.pdf"},
    {"id":"40897","name":"Agenda - Symposium: Raw materials for production of cell-based and gene-therapy products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T15:00:00Z","last_updated_date":"2013-01-28T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-symposium-raw-materials-production-cell-based-and-gene-therapy-products_en.pdf"},
    {"id":"40919","name":"Agenda - HMPC agenda of the 11-12 November 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-11-15T10:35:00Z","last_updated_date":"2013-11-15T10:35:00Z","reference_number":"EMA/HMPC/704114/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-11-12-november-2013-meeting_en.pdf"},
    {"id":"40938","name":"Agenda - COMP agenda of the 11-13 September 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-09-11T11:00:00Z","last_updated_date":"2018-09-11T11:00:00Z","reference_number":"EMA/COMP/506115/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-11-13-september-2018-meeting_en.pdf"},
    {"id":"40966","name":"Agenda - PDCO agenda of the 18-20 March 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-03-23T11:30:00Z","last_updated_date":"2015-03-23T11:30:00Z","reference_number":"EMA/PDCO/115468/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-18-20-march-2015-meeting_en.pdf"},
    {"id":"40993","name":"Programme and registration form - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) face-to-face training course","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-01-26T01:00:00Z","last_updated_date":"2017-01-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-xevmpd-face-face-training-course_en.pdf"},
    {"id":"41001","name":"Agenda - Workshop on extrapolation of efficacy and safety in medicine development across age groups","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-01-14T17:50:00Z","last_updated_date":"2016-05-13T13:40:00Z","reference_number":"EMA/12429/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-extrapolation-efficacy-and-safety-medicine-development-across-age-groups_en.pdf"},
    {"id":"41024","name":"Agenda - CVMP agenda of the 14-16 June 2016 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2016-06-13T18:20:00Z","last_updated_date":"2016-06-13T18:20:00Z","reference_number":"EMA/CVMP/406999/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-14-16-june-2016-meeting_en.pdf"},
    {"id":"41056","name":"Agenda - Workshop on Medicines for the Treatment of Pain in children","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2004-10-27T02:09:21Z","last_updated_date":"2004-10-27T02:09:21Z","reference_number":"EMEA/8957/04","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-medicines-treatment-pain-children_en.pdf"},
    {"id":"41171","name":"Agenda - COMP agenda of the 13-15 February 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-02-12T12:30:00Z","last_updated_date":"2018-02-12T12:30:00Z","reference_number":"EMA/COMP/40855/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-13-15-february-2018-meeting_en.pdf"},
    {"id":"41252","name":"Programme - European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T17:52:00Z","last_updated_date":"2018-10-30T17:52:00Z","reference_number":"EMA/269375/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-european-medicines-agency-stakeholder-interaction-development-medicinal-products-chronic-non-infectious-liver-diseases-pbc-psc-nash_en.pdf"},
    {"id":"41283","name":"Agenda - PDCO agenda of the 21-24 August 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-08-28T17:10:00Z","last_updated_date":"2018-08-28T17:10:00Z","reference_number":"EMA/527101/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-21-24-august-2018-meeting_en.pdf"},
    {"id":"41294","name":"Agenda - COMP agenda of the 3-5 October 2012 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2012-10-04T10:52:00Z","last_updated_date":"2012-10-18T14:10:00Z","reference_number":"EMA/COMP/600813/2012","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-3-5-october-2012-meeting_en.pdf"},
    {"id":"41346","name":"Agenda - PDCO agenda of the 12-14 February 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-02-10T16:05:00Z","last_updated_date":"2014-02-10T16:05:00Z","reference_number":"EMA/PDCO/56818/2014","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-14-february-2014-meeting_en.pdf"},
    {"id":"41353","name":"Agenda - COMP agenda of the 12-13 March 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-03-05T10:10:00Z","last_updated_date":"2013-03-05T10:10:00Z","reference_number":"EMA/COMP/129296/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-12-13-march-2013-meeting_en.pdf"},
    {"id":"41370","name":"Agenda - EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting (15 March 2017)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/69326/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-15-march-2017_en.pdf"},
    {"id":"41380","name":"Agenda - CHMP agenda of the 20-23 April 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-04-20T14:00:00Z","last_updated_date":"2015-04-20T14:00:00Z","reference_number":"EMA/CHMP/206325/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-20-23-april-2015-meeting_en.pdf"},
    {"id":"41397","name":"Agenda - CVMP agenda of the 10-12 April 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-04-10T19:10:00Z","last_updated_date":"2017-04-10T19:10:00Z","reference_number":"EMA/CVMP/235742/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-10-12-april-2017-meeting_en.pdf"},
    {"id":"41411","name":"Agenda - PDCO agenda of the 21-24 March 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-03-23T13:30:00Z","last_updated_date":"2017-03-23T13:30:00Z","reference_number":"EMA/PDCO/146574/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-21-24-march-2017-meeting_en.pdf"},
    {"id":"41445","name":"Agenda - EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2010-11-22T01:00:00Z","last_updated_date":"2010-11-22T01:00:00Z","reference_number":"EMA/579304/2010 rev. 2","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations_en.pdf-0"},
    {"id":"41457","name":"Agenda - Extraordinary Management Board meeting for the building approval process of European Medicines Agency premises in Amsterdam: 6 February 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-02-06T12:30:00Z","last_updated_date":"2018-02-06T12:30:00Z","reference_number":"EMA/MB/59964/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-extraordinary-management-board-meeting-building-approval-process-european-medicines-agency-premises-amsterdam-6-february-2018_en.pdf"},
    {"id":"41586","name":"Agenda - 2015 Pharmacovigilance Inspectors Working Group training course (human session)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-11-05T01:00:00Z","last_updated_date":"2015-11-05T01:00:00Z","reference_number":"EMA/INS/PhV/724709/2015 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2015-pharmacovigilance-inspectors-working-group-training-course-human-session_en.pdf"},
    {"id":"41600","name":"Agenda - CVMP agenda of the 10-12 February 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-02-10T17:00:00Z","last_updated_date":"2015-02-10T17:00:00Z","reference_number":"EMA/CVMP/89183/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-10-12-february-2015-meeting_en.pdf"},
    {"id":"41604","name":"Agenda - Paediatric rheumatology expert group meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/809438/2009","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-paediatric-rheumatology-expert-group-meeting_en.pdf-0"},
    {"id":"41636","name":"Agenda - CHMP agenda of the 20-23 January 2014 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-01-21T10:50:00Z","last_updated_date":"2014-01-21T10:50:00Z","reference_number":"EMA/CHMP/805419/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-20-23-january-2014-meeting_en.pdf"},
    {"id":"41657","name":"Agenda - COMP agenda of the 22-24 May 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-05-22T12:08:00Z","last_updated_date":"2018-05-22T12:08:00Z","reference_number":"EMA/COMP/251740/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-22-24-may-2018-meeting_en.pdf"},
    {"id":"41673","name":"Agenda - EudraVigilance training on electronic reporting of ICSRs in the European Economic Area, Paris","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-09-25T18:00:00Z","last_updated_date":"2017-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eudravigilance-training-electronic-reporting-icsrs-european-economic-area-paris_en.pdf"},
    {"id":"41705","name":"Agenda and registration form - Information Day on Medication Errors","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-02-18T01:00:00Z","last_updated_date":"2016-10-18T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-information-day-medication-errors_en.pdf"},
    {"id":"41767","name":"Agenda - PRAC draft agenda of meeting 8-11 July 2013","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2013-07-09T11:10:00Z","last_updated_date":"2013-07-09T11:10:00Z","reference_number":"EMA/PRAC/417172/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-july-2013_en.pdf"},
    {"id":"41774","name":"Agenda - CAT agenda of the 10-12 May 2017 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-05-12T16:00:00Z","last_updated_date":"2017-05-12T16:00:00Z","reference_number":"EMA/CAT/303936/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-10-12-may-2017-meeting_en.pdf"}    {"id":"41780","name":"Agenda for the 99th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-03-14T15:23:00Z","last_updated_date":"2018-03-15T18:30:00Z","reference_number":"EMA/MB/790/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-99th-meeting-management-board_en.pdf"},
    {"id":"41846","name":"Agenda - European Medicines Agency and Association of the European Self-Medication Industry (AESGP) annual bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T18:20:00Z","last_updated_date":"2017-01-03T18:20:00Z","reference_number":"EMA/624263/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-and-association-european-self-medication-industry-aesgp-annual-bilateral-meeting_en.pdf"},
    {"id":"41859","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary training course 25-26 September 2014","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2014-09-24T14:00:00Z","last_updated_date":"2014-09-24T14:00:00Z","reference_number":"Course #14527","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-training-course-25-26-september-2014_en.pdf"},
    {"id":"41903","name":"CHMP ORGAM agenda for the meeting on 16 July 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-07-31T17:30:00Z","last_updated_date":"2018-07-31T17:30:00Z","reference_number":"EMA/CHMP/492328/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-16-july-2018_en.pdf"},
    {"id":"41904","name":"Agenda - COMP agenda of the 14-16 July 2015 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T15:00:00Z","last_updated_date":"2015-07-07T15:00:00Z","reference_number":"EMA/COMP/453252/2015","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-14-16-july-2015-meeting_en.pdf"},
    {"id":"41919","name":"Agenda - PDCO agenda of the 11-13 September 2013 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2013-09-09T16:20:00Z","last_updated_date":"2013-09-09T16:20:00Z","reference_number":"EMA/PDCO/512982/2013","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-11-13-september-2013-meeting_en.pdf"},
    {"id":"41973","name":"Agenda - CHMP agenda of the 21-24 September 2015 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2015-09-21T15:20:00Z","last_updated_date":"2015-09-25T17:00:00Z","reference_number":"EMA/CHMP/620116/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-21-24-september-2015-meeting_en.pdf"},
    {"id":"42012","name":"Agenda - PRAC draft agenda of meeting 25-29 September 2017","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2017-09-25T19:05:00Z","last_updated_date":"2017-09-25T19:05:00Z","reference_number":"EMA/PRAC/634126/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-25-29-september-2017_en.pdf"},
    {"id":"42026","name":"Agenda - Multi-stakeholders Advanced Therapy Medicinal Products (ATMPs) Expert Meeting: exploring solutions to foster ATMPs’ development and access to patients in Europe","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2016-05-13T02:00:00Z","last_updated_date":"2016-05-13T02:00:00Z","reference_number":"EMA/323946/2016","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholders-advanced-therapy-medicinal-products-atmps-expert-meeting-exploring-solutions-foster-atmps-development-and-access-patients-europe_en.pdf"},
    {"id":"42057","name":"Agenda - PDCO agenda of the 18-21 September 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-09-18T14:00:00Z","last_updated_date":"2018-10-01T12:46:00Z","reference_number":"EMA/581674/2018 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-18-21-september-2018-meeting_en.pdf"},
    {"id":"42083","name":"Agenda - European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals' Organisations (HCPWP)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-09-17T16:00:00Z","last_updated_date":"2018-11-09T18:00:00Z","reference_number":"EMA/610994/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp_en.pdf"},
    {"id":"42085","name":"Agenda - European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) and with Healthcare Professionals' Organisations (HCPWP)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-09-17T16:00:00Z","last_updated_date":"2018-11-09T18:00:00Z","reference_number":"EMA/610994/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp_en.pdf"},
    {"id":"42112","name":"Agenda – 12th Pharmacovigilance stakeholder forum","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-09-19T12:30:00Z","last_updated_date":"2018-10-02T15:30:00Z","reference_number":"EMA/274125/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-12th-pharmacovigilance-stakeholder-forum_en.pdf"},
    {"id":"42117","name":"Agenda - CHMP agenda of the 17-20 September 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-09-17T14:26:00Z","last_updated_date":"2018-09-17T14:26:00Z","reference_number":"EMA/628683/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-17-20-september-2018-meeting_en.pdf"},
    {"id":"42126","name":"Agenda - CAT agenda of the 12-14 September 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-09-14T11:47:00Z","last_updated_date":"2018-09-14T11:47:00Z","reference_number":"EMA/CAT/628659/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-12-14-september-2018-meeting_en.pdf"},
    {"id":"42167","name":"Agenda - PRAC draft agenda of meeting 1-4 October 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-01T19:13:00Z","last_updated_date":"2018-10-01T19:13:00Z","reference_number":"EMA/PRAC/678706/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-1-4-october-2018_en.pdf"},
    {"id":"42170","name":"Programme – 2018 European Union Good Clinical Practice Inspectors Working Group workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-10-02T15:34:00Z","last_updated_date":"2018-10-02T15:34:00Z","reference_number":"EMA/INS/GCP/658233/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-2018-european-union-good-clinical-practice-inspectors-working-group-workshop_en.pdf"},
    {"id":"42174","name":"Agenda – Industry stakeholder meeting on Brexit and operation of centralised procedure for human and veterinary medicinal products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-10-02T16:27:00Z","last_updated_date":"2018-10-02T16:27:00Z","reference_number":"EMA/642642/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-stakeholder-meeting-brexit-and-operation-centralised-procedure-human-and-veterinary-medicinal-products_en.pdf"},
    {"id":"42177","name":"Agenda for the 101st meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-10-03T10:21:00Z","last_updated_date":"2018-10-04T14:02:00Z","reference_number":"EMA/MB/297556/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-101st-meeting-management-board_en.pdf"},
    {"id":"42178","name":"Agenda - HMPC agenda of the 24-25 September 2018 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-10-03T11:38:00Z","last_updated_date":"2018-10-03T11:38:00Z","reference_number":"EMA/HMPC/650626/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-24-25-september-2018-meeting_en.pdf"},
    {"id":"42191","name":"Agenda – 14th Industry stakeholder platform – operation of European Union (EU) Pharmacovigilance","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-04T12:36:00Z","last_updated_date":"2018-10-04T12:36:00Z","reference_number":"EMA/496794/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-14th-industry-stakeholder-platform-operation-european-union-eu-pharmacovigilance_en.pdf"},
    {"id":"42192","name":"Agenda and List of Participants - Haemophilia Registries Workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-10-04T14:06:00Z","last_updated_date":"2018-10-04T14:06:00Z","reference_number":"EMA/654423/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-list-participants-haemophilia-registries-workshop_en.pdf"},
    {"id":"42195","name":"Agenda – 14th Industry Stakeholder Platform – Operation of EU Pharmacovigilance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-10-02T10:25:00Z","last_updated_date":"2018-10-02T10:25:00Z","reference_number":"EMA/496794/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-14th-industry-stakeholder-platform-operation-eu-pharmacovigilance_en.pdf"},
    {"id":"42239","name":"Agenda - COMP agenda of the 9-11 October 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-09T14:39:00Z","last_updated_date":"2018-10-09T14:39:00Z","reference_number":"EMA/COMP/634073/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-9-11-october-2018-meeting_en.pdf"},
    {"id":"42251","name":"Agenda - Multistakeholder workshop to launch consultation on European Medicines Agency (EMA) human regulatory science to 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-09T18:14:00Z","last_updated_date":"2018-10-23T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multistakeholder-workshop-launch-consultation-european-medicines-agency-ema-human-regulatory-science-2025_en.pdf"},
    {"id":"42270","name":"Agenda - CVMP agenda of the 9-11 October 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-10T15:55:00Z","last_updated_date":"2018-10-10T15:55:00Z","reference_number":"EMA/CVMP/662126/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-9-11-october-2018_en.pdf"},
    {"id":"42341","name":"Agenda - CHMP agenda of the 15-18 October 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-15T13:23:00Z","last_updated_date":"2018-11-06T15:02:00Z","reference_number":"EMA/CHMP/714806/2018 Corr.2 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-15-18-october-2018-meeting_en.pdf"},
    {"id":"42347","name":"Agenda - PDCO agenda of the 16-19 October 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-16T15:04:00Z","last_updated_date":"2018-10-16T15:04:00Z","reference_number":"EMA/PDCO/667076/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-16-19-october-2018-meeting_en.pdf"},
    {"id":"42361","name":"Agenda - CAT agenda of the 10-12 October 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-18T10:00:00Z","last_updated_date":"2018-10-18T10:00:00Z","reference_number":"EMA/CAT/709578/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-10-12-october-2018-meeting_en.pdf"},
    {"id":"42362","name":"Agenda - CAT agenda of the 10-12 October 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-18T10:00:00Z","last_updated_date":"2018-10-18T10:00:00Z","reference_number":"EMA/CAT/709578/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-10-12-october-2018-meeting_en.pdf-0"},
    {"id":"42382","name":"Agenda – European Union (EU) International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) / Substance, Product, Organisation and Referential data (SPOR) task force meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T15:10:00Z","last_updated_date":"2018-10-19T15:10:00Z","reference_number":"EMA/23322/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-eu-international-organization-standardization-iso-identification-medicinal-products-idmp-substance-product-organisation-and-referential-data-spor-task-force-meeting_en.pdf"},
    {"id":"42396","name":"Agenda - European Union International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) / Substance, Product, Organisation and Referential data (SPOR) task force meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:30:00Z","last_updated_date":"2018-10-19T16:30:00Z","reference_number":"EMA/289228/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-union-international-organization-standardization-iso-identification-medicinal-products-idmp-substance-product-organisation-and-referential-data-spor-task-force-meeting_en.pdf-0"},
    {"id":"42412","name":"Agenda - Heads of Medicines Agencies / European Medicines Agency technical meeting on availability of authorised human medicines","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-22T17:18:00Z","last_updated_date":"2018-10-22T17:18:00Z","reference_number":"EMA/516015/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-heads-medicines-agencies-european-medicines-agency-technical-meeting-availability-authorised-human-medicines_en.pdf"},
    {"id":"42432","name":"Agenda - Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-10-25T15:30:00Z","last_updated_date":"2018-11-26T11:30:00Z","reference_number":"EMA/201498/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-workshop-hmaema-task-force-availability-authorised-medicines_en.pdf"},
    {"id":"42454","name":"Presentation - Challenges in conducting trials involving children: Sponsor’s view (G. Noel; S.Cammarata)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T11:48:00Z","last_updated_date":"2018-10-29T11:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/presentation-challenges-conducting-trials-involving-children-sponsors-view-g-noel-scammarata_en.pdf"},
    {"id":"42469","name":"Agenda - PRAC draft agenda of meeting 29-31 October 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-29T13:15:00Z","last_updated_date":"2018-10-29T13:15:00Z","reference_number":"EMA/PRAC/765002/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-29-31-october-2018_en.pdf"},
    {"id":"42482","name":"Agenda - Technical Anonymisation Group (TAG): First meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T13:05:00Z","last_updated_date":"2018-10-30T13:05:00Z","reference_number":"EMA/579507/2017","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-technical-anonymisation-group-tag-first-meeting_en.pdf"},
    {"id":"42510","name":"Agenda - COMP agenda of the 6-8 November 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-10-30T17:22:00Z","last_updated_date":"2018-10-30T17:22:00Z","reference_number":"EMA/COMP/712920/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-6-8-november-2018-meeting_en.pdf"},
    {"id":"42519","name":"CHMP ORGAM agenda for the meeting on 10 September 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-10-31T17:08:00Z","last_updated_date":"2018-10-31T17:08:00Z","reference_number":"EMA/611026/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-10-september-2018_en.pdf"},
    {"id":"42538","name":"Agenda -  European Medicines Agency (EMA) / Heads of Medicines Agencies (HMA) / European Commission (EC) workshop on electronic product information (ePI)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-11-05T17:17:00Z","last_updated_date":"2018-12-20T10:00:00Z","reference_number":"EMA/669345/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-heads-medicines-agencies-hma-european-commission-ec-workshop-electronic-product-information-epi_en.pdf"},
    {"id":"42539","name":"Agenda - CVMP agenda of the 6-8 November 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-11-06T10:49:00Z","last_updated_date":"2018-11-06T10:49:00Z","reference_number":"EMA/CVMP/770637/2018 - draft 2","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-6-8-november-2018_en.pdf"},
    {"id":"42650","name":"Agenda - CHMP agenda of the 12-15 November 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-11-12T13:30:00Z","last_updated_date":"2018-11-12T13:30:00Z","reference_number":"EMA/790869/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-12-15-november-2018-meeting_en.pdf"},
    {"id":"42655","name":"CHMP ORGAM agenda for the meeting on 8 October 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-11-12T18:05:00Z","last_updated_date":"2018-11-12T18:05:00Z","reference_number":"EMA/CHMP/693788/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-8-october-2018_en.pdf"},
    {"id":"42657","name":"Agenda - CAT agenda of the 7-8 November 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-11-13T10:28:00Z","last_updated_date":"2018-11-13T10:28:00Z","reference_number":"EMA/CAT/791519/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-7-8-november-2018-meeting_en.pdf"},
    {"id":"42664","name":"Agenda - PDCO agenda of the 13-16 November 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-11-13T15:55:00Z","last_updated_date":"2018-11-13T15:55:00Z","reference_number":"EMA/754134/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-13-16-november-2018-meeting_en.pdf"},
    {"id":"42680","name":"Agenda - EU-Innovation network workshop with academia","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-11-14T16:48:00Z","last_updated_date":"2018-11-14T16:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eu-innovation-network-workshop-academia_en.pdf"},
    {"id":"42732","name":"Agenda - HMPC agenda of the 19-20 November 2018 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-11-21T16:04:00Z","last_updated_date":"2018-11-21T16:04:00Z","reference_number":"EMA/HMPC/801864/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-19-20-november-2018-meeting_en.pdf"},
    {"id":"42751","name":"Agenda – Industry stakeholder platform on research and development support","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T13:56:00Z","last_updated_date":"2018-11-22T13:56:00Z","reference_number":"EMA/769203/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-stakeholder-platform-research-and-development-support_en.pdf-0"},
    {"id":"42800","name":"Agenda - PRAC draft agenda of meeting 26-29 November 2018","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-11-26T17:44:00Z","last_updated_date":"2018-11-26T17:44:00Z","reference_number":"EMA/PRAC/829194/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-26-29-november-2018_en.pdf"},
    {"id":"42871","name":"Agenda and registration form - European Medicines Agency EudraVigilance and signal management information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-11-28T15:30:00Z","last_updated_date":"2018-11-28T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-european-medicines-agency-eudravigilance-and-signal-management-information-day_en.pdf"},
    {"id":"42886","name":"Agenda - Regulatory science to 2025: launch of veterinary stakeholder consultation","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-11-29T14:39:00Z","last_updated_date":"2018-12-03T15:00:00Z","reference_number":"EMA/780555/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-regulatory-science-2025-launch-veterinary-stakeholder-consultation_en.pdf"},
    {"id":"42899","name":"Agenda - COMP agenda of the 4-6 December 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-11-30T17:44:00Z","last_updated_date":"2018-11-30T17:44:00Z","reference_number":"EMA/COMP/792954/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-4-6-december-2018-meeting_en.pdf"},
    {"id":"42914","name":"Agenda - CVMP agenda of the 4-6 December 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-12-04T12:59:00Z","last_updated_date":"2018-12-04T12:59:00Z","reference_number":"EMA/CVMP/812471/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-4-6-december-2018-meeting_en.pdf"},
    {"id":"42928","name":"Agenda - Enpr-EMA Coordinating Group and networks meeting on 22 October 2018","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2018-12-04T17:45:00Z","last_updated_date":"2018-12-04T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-and-networks-meeting-22-october-2018_en.pdf"},
    {"id":"42952","name":"Agenda - CAT agenda of the 5-7 December 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-12-07T10:16:00Z","last_updated_date":"2018-12-07T10:16:00Z","reference_number":"EMA/CAT/857624/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-5-7-december-2018-meeting_en.pdf"},
    {"id":"42971","name":"Agenda - CHMP agenda of the 10-13 December 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-12-10T13:38:00Z","last_updated_date":"2018-12-10T13:38:00Z","reference_number":"EMA/CHMP/862876/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-10-13-december-2018-meeting_en.pdf"},
    {"id":"42987","name":"Agenda for the 102nd meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-12-12T17:28:00Z","last_updated_date":"2018-12-14T15:19:00Z","reference_number":"EMA/MB/297576/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-102nd-meeting-management-board_en.pdf"},
    {"id":"42989","name":"Agenda - PDCO agenda of the 11-14 December 2018 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2018-12-11T17:45:00Z","last_updated_date":"2018-12-11T17:45:00Z","reference_number":"EMA/827973/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-11-14-december-2018-meeting_en.pdf"},
    {"id":"42990","name":"Agenda and registration - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System - Berlin","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T17:39:00Z","last_updated_date":"2019-07-03T17:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-berlin_en.pdf"},
    {"id":"42991","name":"Agenda and registration - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System - London","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T17:59:00Z","last_updated_date":"2019-07-03T17:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-london_en.pdf"},
    {"id":"42994","name":"Agenda and registration - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on Training Course using the EudraVigilance System - Vienna","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T18:08:00Z","last_updated_date":"2019-07-03T18:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-vienna_en.pdf"},
    {"id":"42995","name":"Agenda and registration - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System - Madrid","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T15:23:00Z","last_updated_date":"2019-07-03T15:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-madrid_en.pdf"},
    {"id":"42996","name":"Agenda and registration - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System - San Marino","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T18:33:00Z","last_updated_date":"2019-07-03T18:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-san-marino_en.pdf"},
    {"id":"42997","name":"Agenda and registration - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System - Lisbon","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T18:41:00Z","last_updated_date":"2019-07-03T18:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-lisbon_en.pdf"},
    {"id":"42998","name":"Agenda and registration - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System - Basel","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T19:08:00Z","last_updated_date":"2019-07-03T19:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-basel_en.pdf"},
    {"id":"43114","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (Amsterdam)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T11:02:00Z","last_updated_date":"2019-07-03T11:02:00Z","reference_number":"Course # 19582","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-amsterdam_en.pdf"},
    {"id":"43115","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (Lisbon)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T10:15:00Z","last_updated_date":"2019-07-03T10:15:00Z","reference_number":"Course # 19584","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-lisbon_en.pdf"},
    {"id":"43121","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (London)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T10:20:00Z","last_updated_date":"2019-07-03T10:20:00Z","reference_number":"Course # 19583","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-london_en.pdf-0"},
    {"id":"43217","name":"CHMP ORGAM agenda for the meeting on 4 December 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T08:35:00Z","last_updated_date":"2019-01-07T08:35:00Z","reference_number":"EMA/848375/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-4-december-2018_en.pdf"},
    {"id":"43227","name":"CHMP ORGAM agenda for the meeting on 5 November 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T12:03:00Z","last_updated_date":"2019-01-07T12:03:00Z","reference_number":"EMA/CHMP/777011/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-5-november-2018_en.pdf"},
    {"id":"43361","name":"Agenda - PRAC draft agenda of meeting 14-17 January 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-01-14T17:55:00Z","last_updated_date":"2019-01-14T17:55:00Z","reference_number":"EMA/PRAC/10734/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-14-17-january-2019_en.pdf"},
    {"id":"43427","name":"Agenda - COMP agenda of the 22-24 January 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-01-22T11:22:00Z","last_updated_date":"2019-01-22T11:22:00Z","reference_number":"EMA/COMP/862725/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-22-24-january-2019-meeting_en.pdf"},
    {"id":"43430","name":"Agenda - HMPC agenda of the 14-16 January 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T11:39:00Z","last_updated_date":"2019-01-22T11:39:00Z","reference_number":"EMA/HMPC/5189/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-14-16-january-2019-meeting_en.pdf"},
    {"id":"43466","name":"Agenda - CVMP agenda of the 22-24 January 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-01-23T16:58:00Z","last_updated_date":"2019-01-23T16:58:00Z","reference_number":"EMA/CVMP/25963/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-22-24-january-2019-meeting_en.pdf"},
    {"id":"43474","name":"Agenda - CAT agenda of the 23-25 January 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-01-24T15:56:00Z","last_updated_date":"2019-01-24T15:56:00Z","reference_number":"EMA/CAT/38789/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-23-25-january-2019-meeting_en.pdf"},
    {"id":"43483","name":"Agenda - Industry stakeholder meeting on Brexit and operation of the centralised procedure for human and veterinary medicine products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-01-25T14:49:00Z","last_updated_date":"2019-01-25T14:49:00Z","reference_number":"EMA/36715/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-stakeholder-meeting-brexit-and-operation-centralised-procedure-human-and-veterinary-medicine-products_en.pdf"},
    {"id":"43518","name":"Agenda - CHMP agenda of the 28-31 January 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-01-28T14:49:00Z","last_updated_date":"2019-02-01T12:30:00Z","reference_number":"EMA/CHMP/44613/2019 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-28-31-january-2019-meeting_en.pdf"},
    {"id":"43545","name":"Agenda - PDCO agenda of the 29 January - 1 February 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-01-29T16:26:00Z","last_updated_date":"2019-01-29T16:26:00Z","reference_number":"EMA/912078/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-29-january-1-february-2019-meeting_en.pdf"},
    {"id":"43692","name":"Agenda - PRAC draft agenda of meeting 11-14 February 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-02-11T17:45:00Z","last_updated_date":"2019-02-11T17:45:00Z","reference_number":"EMA/PRAC/111893/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-11-14-february-2019_en.pdf"},
    {"id":"43780","name":"Agenda - COMP agenda of the 19-21 February 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-02-18T16:30:00Z","last_updated_date":"2019-02-18T16:30:00Z","reference_number":"EMA/COMP/47580/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-19-21-february-2019-meeting_en.pdf"},
    {"id":"43860","name":"Agenda - CVMP agenda of the 19-21 February 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-02-20T17:40:00Z","last_updated_date":"2019-02-20T17:40:00Z","reference_number":"EMA/CVMP/97249/2019 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-19-21-february-2019-meeting_en.pdf"},
    {"id":"43898","name":"Agenda - CHMP agenda of the 25-28 February 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-02-25T16:22:00Z","last_updated_date":"2019-02-25T16:22:00Z","reference_number":"EMA/CHMP/134786/2019 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-25-28-february-2019-meeting_en.pdf"},
    {"id":"43914","name":"Agenda - PDCO agenda of the 26 February - 1 March  2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-02-26T15:42:00Z","last_updated_date":"2019-02-26T15:42:00Z","reference_number":"EMA/PDCO/69021/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-26-february-1-march-2019-meeting_en.pdf"},
    {"id":"43962","name":"CHMP ORGAM agenda for the meeting on 21 January 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T15:46:00Z","last_updated_date":"2019-03-01T15:46:00Z","reference_number":"EMA/CHMP/140798/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-21-january-2019_en.pdf"},
    {"id":"44014","name":"Agenda - CAT agenda of the 20-22 February 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-03-12T16:30:00Z","last_updated_date":"2019-03-12T16:30:00Z","reference_number":"EMA/CAT/92832/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-20-22-february-2019-meeting_en.pdf"},
    {"id":"44015","name":"Agenda - PRAC draft agenda of meeting 12-15 March 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-03-12T17:40:00Z","last_updated_date":"2019-03-12T17:40:00Z","reference_number":"EMA/PRAC/170203/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-12-15-march-2019_en.pdf"},
    {"id":"44071","name":"Agenda - COMP agenda of the 19-21 March 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-03-20T11:55:00Z","last_updated_date":"2019-03-20T11:55:00Z","reference_number":"EMA/COMP/141502/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-19-21-march-2019-meeting_en.pdf"},
    {"id":"44074","name":"Agenda - CVMP agenda of the 19-21 March 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-03-20T14:19:00Z","last_updated_date":"2019-03-20T14:19:00Z","reference_number":"EMA/CVMP/159614/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-19-21-march-2019-meeting_en.pdf"},
    {"id":"44077","name":"Agenda for the 103rd meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-03-22T15:14:00Z","last_updated_date":"2019-03-22T15:14:00Z","reference_number":"EMA/MB/916015/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-103rd-meeting-management-board_en.pdf"},
    {"id":"44100","name":"Agenda - CAT agenda of the 20-22 March 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-03-25T09:57:00Z","last_updated_date":"2019-03-25T09:57:00Z","reference_number":"EMA/CAT/191544/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-20-22-march-2019-meeting_en.pdf"},
    {"id":"44101","name":"Agenda - CHMP agenda of the 25-28 March 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-03-25T13:03:00Z","last_updated_date":"2019-03-25T13:03:00Z","reference_number":"EMA/CHMP/190227/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-25-28-march-2019-meeting_en.pdf"},
    {"id":"44110","name":"Agenda - PDCO agenda of the 26-29 March 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-03-26T14:29:00Z","last_updated_date":"2019-03-29T13:18:00Z","reference_number":"EMA/PDCO/161218/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-26-29-march-2019-meeting_en.pdf"},
    {"id":"44160","name":"CHMP ORGAM agenda for the meeting on 18 February 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-04-01T15:32:00Z","last_updated_date":"2019-04-01T15:32:00Z","reference_number":"EMA/CHMP/203261/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-18-february-2019_en.pdf"},
    {"id":"44187","name":"Agenda - PRAC draft agenda of meeting 8-11 April 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-04-08T17:30:00Z","last_updated_date":"2019-04-08T17:30:00Z","reference_number":"EMA/PRAC/219089/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-april-2019_en.pdf"},
    {"id":"44259","name":"Agenda - COMP agenda of the 15-17  April 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-04-12T16:30:00Z","last_updated_date":"2019-04-12T16:30:00Z","reference_number":"EMA/COMP/193772/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-15-17-april-2019-meeting_en.pdf"},
    {"id":"44262","name":"Agenda - CVMP agenda of the 15-17 April 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-04-15T12:00:00Z","last_updated_date":"2019-04-15T12:00:00Z","reference_number":"EMA/CVMP/226983/2019 draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-15-17-april-2019-meeting_en.pdf"},
    {"id":"44286","name":"Agenda - CAT agenda of the 16-17 April 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-04-17T11:08:00Z","last_updated_date":"2019-04-17T11:08:00Z","reference_number":"EMA/CAT/231591/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-16-17-april-2019-meeting_en.pdf"},
    {"id":"44322","name":"Agenda - CHMP agenda of the 23-26 April 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-04-23T15:56:00Z","last_updated_date":"2019-04-23T15:56:00Z","reference_number":"EMA/CHMP/232099/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-23-26-april-2019-meeting_en.pdf"},
    {"id":"44323","name":"Agenda - PDCO agenda of the 23-26 April 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-04-23T16:23:00Z","last_updated_date":"2019-04-23T16:23:00Z","reference_number":"EMA/PDCO/209562/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-23-26-april-2019-meeting_en.pdf"},
    {"id":"44429","name":"Agenda - Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (Dec 2018)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-05-06T10:43:00Z","last_updated_date":"2019-05-06T10:43:00Z","reference_number":"EMA/790603/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-substance-product-organisation-and-referential-data-spor-task-force-meeting-dec-2018_en.pdf"}    {"id":"44486","name":"Agenda - PRAC draft agenda of meeting 13-16 May 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-05-13T18:35:00Z","last_updated_date":"2019-05-13T18:35:00Z","reference_number":"EMA/PRAC/267564/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-13-16-may-2019_en.pdf"},
    {"id":"44541","name":"Agenda - COMP agenda of the 21-23 May 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-05-20T13:52:00Z","last_updated_date":"2019-05-20T13:52:00Z","reference_number":"EMA/COMP/240339/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-21-23-may-2019-meeting_en.pdf"},
    {"id":"44551","name":"Agenda - CVMP agenda of the 21-22 May 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-05-21T12:11:00Z","last_updated_date":"2019-05-21T12:11:00Z","reference_number":"EMA/CVMP/277755/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-21-22-may-2019-meeting_en.pdf"},
    {"id":"44585","name":"Agenda - CAT agenda of the 22-24 May 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-05-24T09:48:00Z","last_updated_date":"2019-05-24T09:48:00Z","reference_number":"EMA/CAT/287669/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-22-24-may-2019-meeting_en.pdf"},
    {"id":"44596","name":"Agenda - CHMP agenda of the 27-29 May 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-05-27T15:52:00Z","last_updated_date":"2019-05-27T15:52:00Z","reference_number":"EMA/CHMP/289313/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-27-29-may-2019-meeting_en.pdf"},
    {"id":"44606","name":"Agenda - PDCO agenda of the 27-29 May 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-05-29T10:28:00Z","last_updated_date":"2019-05-29T10:28:00Z","reference_number":"EMA/PDCO/250257/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-27-29-may-2019-meeting_en.pdf"},
    {"id":"44685","name":"Agenda - PRAC draft agenda of meeting 11-14 June 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-06-11T15:14:00Z","last_updated_date":"2019-06-11T15:14:00Z","reference_number":"EMA/PRAC/325596/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-11-14-june-2019_en.pdf"},
    {"id":"44686","name":"Agenda for the 104th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-06-11T15:23:00Z","last_updated_date":"2019-06-14T10:00:00Z","reference_number":"EMA/MB/157340/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-104th-meeting-management-board_en.pdf"},
    {"id":"44730","name":"Agenda - COMP agenda of the 18-20 June 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-06-18T08:56:00Z","last_updated_date":"2019-06-18T08:56:00Z","reference_number":"EMA/COMP/290416/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-18-20-june-2019-meeting_en.pdf"},
    {"id":"44755","name":"Agenda - CVMP agenda of the 18-20 June 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-06-19T13:18:00Z","last_updated_date":"2019-06-19T13:18:00Z","reference_number":"EMA/CVMP/339821/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-18-20-june-2019-meeting_en.pdf"},
    {"id":"44775","name":"CHMP ORGAM agenda for the meeting on 18 March 2019","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-06-20T16:39:00Z","last_updated_date":"2019-06-20T16:39:00Z","reference_number":"EMA/CHMP/349980/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-18-march-2019_en.pdf"},
    {"id":"44777","name":"Agenda - CAT agenda of the 19-21 June 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-06-20T16:50:00Z","last_updated_date":"2019-06-20T16:50:00Z","reference_number":"EMA/CAT/ 350204/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-19-21-june-2019-meeting_en.pdf"},
    {"id":"44822","name":"Agenda - CHMP agenda of the 24-27 June 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-06-24T14:15:00Z","last_updated_date":"2019-06-24T14:15:00Z","reference_number":"EMA/CHMP/354403/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-24-27-june-2019-meeting_en.pdf"},
    {"id":"44893","name":"Agenda - PDCO agenda of the 25-28 June 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-06-26T14:37:00Z","last_updated_date":"2019-06-26T14:37:00Z","reference_number":"EMA /PDCO /309721/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-25-28-june-2019-meeting_en.pdf"},
    {"id":"44912","name":"Agenda - Enpr-EMA Coordinating Group and networks meeting on 19 February 2019","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-06-27T15:30:00Z","last_updated_date":"2019-06-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-and-networks-meeting-19-february-2019_en.pdf"},
    {"id":"44984","name":"Agenda and registration - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System - Amsterdam","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T15:42:00Z","last_updated_date":"2019-07-03T15:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-amsterdam_en.pdf"},
    {"id":"45020","name":"Agenda - PRAC draft agenda of meeting 8-11 July 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-07-08T17:27:00Z","last_updated_date":"2019-07-08T17:27:00Z","reference_number":"EMA/PRAC/ 392749/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-july-2019_en.pdf"},
    {"id":"45022","name":"Agenda - HMPC agenda of the 8-10 July 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-09T15:11:00Z","last_updated_date":"2019-07-09T15:11:00Z","reference_number":"EMA/HMPC/381730/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-8-10-july-2019-meeting_en.pdf"},
    {"id":"45065","name":"Agenda - COMP agenda of the 16-18 July 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-07-16T08:55:00Z","last_updated_date":"2019-07-16T08:55:00Z","reference_number":"EMA/COMP/361001/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-16-18-july-2019-meeting_en.pdf"},
    {"id":"45072","name":"Agenda - CVMP agenda of the 16-18 July 2019 meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-07-16T15:41:00Z","last_updated_date":"2019-07-16T15:41:00Z","reference_number":"EMA/CVMP/399992/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-16-18-july-2019-meeting_en.pdf"},
    {"id":"45088","name":"Agenda - CAT agenda of the 17-19 July 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-07-18T15:51:00Z","last_updated_date":"2019-07-18T15:51:00Z","reference_number":"EMA/CAT/408363/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-17-19-july-2019-meeting_en.pdf"},
    {"id":"45093","name":"Agenda - European Medicines Agency and European Union payer community meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-07-19T11:11:00Z","last_updated_date":"2019-07-19T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-and-european-union-payer-community-meeting_en.pdf"},
    {"id":"45112","name":"Agenda - CHMP agenda of the 22-25 July 2019 meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-07-22T13:21:00Z","last_updated_date":"2019-07-22T13:21:00Z","reference_number":"EMA/CHMP/410783/2019 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-22-25-july-2019-meeting_en.pdf"},
    {"id":"45119","name":"Agenda - PDCO agenda of the 23-26 July 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-07-24T16:39:00Z","last_updated_date":"2019-07-24T16:39:00Z","reference_number":"EMA/PDCO/380845/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-23-26-july-2019-meeting_en.pdf"},
    {"id":"45183","name":"Agenda - Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (May 2019)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-08-01T10:50:00Z","last_updated_date":"2019-08-01T10:50:00Z","reference_number":"EMA/204768/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-substance-product-organisation-and-referential-data-spor-task-force-meeting-may-2019_en.pdf"},
    {"id":"45212","name":"Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-08-08T11:41:00Z","last_updated_date":"2019-08-08T11:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting_en.pdf-1"},
    {"id":"45214","name":"CHMP ORGAM agenda for the meeting on 20 May 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-08-08T12:01:00Z","last_updated_date":"2019-08-08T12:01:00Z","reference_number":"EMA/CHMP/246396/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-20-may-2019_en.pdf"},
    {"id":"45215","name":"CHMP ORGAM agenda for the meeting on 17 June 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-08-08T12:40:00Z","last_updated_date":"2019-08-08T12:40:00Z","reference_number":"EMA/CHMP/447861/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-17-june-2019_en.pdf"},
    {"id":"45216","name":"CHMP ORGAM agenda for the meeting on 15 July 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-08-08T12:46:00Z","last_updated_date":"2019-08-08T12:46:00Z","reference_number":"EMA/CHMP/371338/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-15-july-2019_en.pdf"},
    {"id":"45231","name":"CHMP ORGAM agenda for the meeting on 15 April 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-08-12T09:17:00Z","last_updated_date":"2019-08-12T09:17:00Z","reference_number":"EMA/CHMP/447251/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-15-april-2019_en.pdf"},
    {"id":"45294","name":"Agenda - PDCO agenda of the 20-23 August 2019 written procedure","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-08-20T17:16:00Z","last_updated_date":"2019-08-20T17:16:00Z","reference_number":"EMA/PDCO/4352091/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-20-23-august-2019-written-procedure_en.pdf"},
    {"id":"45297","name":"Agenda - CHMP agenda of the 19-22 August 2019 written procedure","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-08-21T16:25:00Z","last_updated_date":"2019-08-21T16:25:00Z","reference_number":"EMA/CHMP/463206/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-august-2019-written-procedure_en.pdf"},
    {"id":"45369","name":"Agenda - PRAC draft agenda of meeting 2-5 September 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-09-02T17:23:00Z","last_updated_date":"2019-09-02T17:23:00Z","reference_number":"EMA/PRAC/483724/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-2-5-september-2019_en.pdf"},
    {"id":"45402","name":"Agenda - COMP agenda of the 10-12 September 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-09-10T10:19:00Z","last_updated_date":"2019-09-10T10:19:00Z","reference_number":"EMA/COMP/416435/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-10-12-september-2019-meeting_en.pdf"},
    {"id":"45403","name":"Agenda - CVMP agenda of the 10-12 September 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-09-10T10:45:00Z","last_updated_date":"2019-09-10T10:45:00Z","reference_number":"EMA/493877/2019 draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-10-12-september-2019-meeting_en.pdf"},
    {"id":"45434","name":"Agenda - CAT agenda of the 11-13 September 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-09-12T16:50:00Z","last_updated_date":"2019-09-12T16:50:00Z","reference_number":"EMA/CAT/501754/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-11-13-september-2019-meeting_en.pdf"},
    {"id":"45454","name":"Agenda - CHMP agenda of the 16-19 September 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-09-16T10:08:00Z","last_updated_date":"2019-09-16T10:08:00Z","reference_number":"EMA/CHMP/502557/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-16-19-september-2019-meeting_en.pdf"},
    {"id":"45461","name":"Agenda - PDCO agenda of the 17-20 September 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-09-17T17:38:00Z","last_updated_date":"2019-09-17T17:38:00Z","reference_number":"EMA/PDCO/477081/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-17-20-september-2019-meeting_en.pdf"},
    {"id":"45495","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' Working Party meeting (PCWP) - September 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T10:47:00Z","last_updated_date":"2019-10-09T11:19:00Z","reference_number":"EMA/309134/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-and-consumers-working-party-meeting-pcwp-september-2019_en.pdf"},
    {"id":"45496","name":"Agenda - European Medicines Agency (EMA) Healthcare Professionals' Working Party (HCPWP) meeting - September 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T10:50:00Z","last_updated_date":"2019-10-09T11:28:00Z","reference_number":"EMA/309140/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-healthcare-professionals-working-party-hcpwp-meeting-september-2019_en.pdf"},
    {"id":"45497","name":"Agenda - European Medicines Agency (EMA) Joint Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) meeting - September 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T10:52:00Z","last_updated_date":"2019-10-09T11:38:00Z","reference_number":"EMA/309127/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-joint-patients-and-consumers-pcwp-and-healthcare-professionals-hcpwp-meeting-september-2019_en.pdf"},
    {"id":"45541","name":"Agenda - PRAC draft agenda of meeting 30 September-3 October 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-09-30T15:21:00Z","last_updated_date":"2019-09-30T15:21:00Z","reference_number":"EMA/PRAC/485716/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-30-september-3-october-2019_en.pdf"},
    {"id":"45580","name":"Agenda for the 105th meeting of the Management Board: 3 October 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-10-02T16:36:00Z","last_updated_date":"2019-10-07T17:37:00Z","reference_number":"EMA/MB/414950/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-105th-meeting-management-board-3-october-2019_en.pdf"},
    {"id":"45589","name":"Agenda - COMP agenda of the 8-10 October 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-10-08T14:02:00Z","last_updated_date":"2019-10-08T14:02:00Z","reference_number":"EMA/COMP/548395/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-8-10-october-2019-meeting_en.pdf"},
    {"id":"45591","name":"Agenda - CVMP agenda of the 8-10 October 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-10-08T14:16:00Z","last_updated_date":"2019-10-08T14:16:00Z","reference_number":"EMA/545556/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-8-10-october-2019-meeting_en.pdf"},
    {"id":"45592","name":"Agenda - HMPC agenda of the 23-25 September 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-10-08T14:35:00Z","last_updated_date":"2019-10-08T14:35:00Z","reference_number":"EMA/HMPC/517402/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-23-25-september-2019-meeting_en.pdf"},
    {"id":"45628","name":"Agenda - Workshop on the role of registries in the monitoring of cancer therapies based on genetic and molecular features","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-10-04T15:35:00Z","last_updated_date":"2019-11-04T15:50:00Z","reference_number":"EMA/499786/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-role-registries-monitoring-cancer-therapies-based-genetic-and-molecular-features_en.pdf"},
    {"id":"45655","name":"Agenda - CAT agenda of the 9-11 October 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-10-11T08:56:00Z","last_updated_date":"2019-10-11T08:56:00Z","reference_number":"EMA/CAT/556528/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-9-11-october-2019-meeting_en.pdf"},
    {"id":"45675","name":"Agenda - CHMP agenda of the 14-17 October 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-10-14T15:20:00Z","last_updated_date":"2019-10-29T17:18:00Z","reference_number":"EMA/CHMP/556731/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-14-17-october-2019-meeting_en.pdf"},
    {"id":"45721","name":"Agenda - PDCO agenda of the 15-18 October 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-10-16T09:29:00Z","last_updated_date":"2019-10-16T09:29:00Z","reference_number":"EMA/PDCO/523933/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-15-18-october-2019-meeting_en.pdf"},
    {"id":"45815","name":"Agenda - PRAC draft agenda of meeting 28-31 October 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-10-28T17:21:00Z","last_updated_date":"2019-10-28T17:21:00Z","reference_number":"EMA/PRAC/585930/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-28-31-october-2019_en.pdf"},
    {"id":"45868","name":"Agenda - COMP agenda of the 05-07 November 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-10-31T16:04:00Z","last_updated_date":"2019-11-04T16:00:00Z","reference_number":"EMA/COMP/564928/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-05-07-november-2019-meeting_en.pdf"},
    {"id":"45881","name":"Agenda and registration - ISO/ICH E2B(R3) Individual case safety reporting in the EU: Hands-on training course using the EudraVigilance system - Lyon","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-11-04T12:36:00Z","last_updated_date":"2019-11-04T12:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-lyon_en.pdf"},
    {"id":"45882","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (Lyon)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-11-04T13:41:00Z","last_updated_date":"2019-11-04T13:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-lyon_en.pdf"},
    {"id":"45887","name":"Agenda - CVMP agenda of the 5-7 November 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-11-05T16:57:00Z","last_updated_date":"2019-11-05T16:57:00Z","reference_number":"EMA/CVMP/592201/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-5-7-november-2019-meeting_en.pdf"},
    {"id":"45918","name":"Agenda - CAT agenda of the 6-8 November 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-11-07T17:24:00Z","last_updated_date":"2019-11-07T17:24:00Z","reference_number":"EMA/CAT/602883/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-6-8-november-2019-meeting_en.pdf"},
    {"id":"45951","name":"Agenda - Annual Patients and Consumers Working Party (PCWP) and Healthcare Professionals Working Party (HCPWP) meeting with all eligible organisations","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-11-11T14:20:00Z","last_updated_date":"2019-11-26T10:00:00Z","reference_number":"EMA/557028/2019 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-annual-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-meeting-all-eligible-organisations_en.pdf"},
    {"id":"45954","name":"Agenda - CHMP agenda of the 11-14 November 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-11-11T12:00:00Z","last_updated_date":"2019-11-11T12:00:00Z","reference_number":"EMA/CHMP/606044/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-11-14-november-2019-meeting_en.pdf"},
    {"id":"45955","name":"CHMP ORGAM agenda for the meeting on 7 October 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-11-11T13:11:00Z","last_updated_date":"2019-11-11T13:11:00Z","reference_number":"EMA/CHMP/518388/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-7-october-2019_en.pdf"},
    {"id":"45956","name":"Agenda - Multi-stakeholder workshop on draft 'Regulatory Science to 2025' strategy (stakeholders for human medicines)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-11-11T14:20:00Z","last_updated_date":"2019-11-14T14:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-workshop-draft-regulatory-science-2025-strategy-stakeholders-human-medicines_en.pdf"},
    {"id":"45961","name":"Agenda - PDCO agenda of the 12-15 November 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-11-12T11:50:00Z","last_updated_date":"2019-11-12T11:50:00Z","reference_number":"EMA/578675/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-15-november-2019-meeting_en.pdf"},
    {"id":"46049","name":"CHMP ORGAM agenda for the meeting on 9 September 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-09-24T17:34:00Z","last_updated_date":"2019-09-24T17:34:00Z","reference_number":"EMA/CHMP/500900/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-9-september-2019_en.pdf"},
    {"id":"46055","name":"Agenda - HMPC agenda of the 18-20 November 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-11-19T10:25:00Z","last_updated_date":"2019-11-19T10:25:00Z","reference_number":"EMA/HMPC/621895/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-18-20-november-2019-meeting_en.pdf"},
    {"id":"46131","name":"Agenda - PRAC draft agenda of meeting 25-28 November 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-11-25T16:19:00Z","last_updated_date":"2019-11-25T16:19:00Z","reference_number":"EMA/PRAC/640603/2019 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-25-28-november-2019_en.pdf"},
    {"id":"46193","name":"Agenda - Multi-stakeholder workshop on draft 'Regulatory Science to 2025' strategy (stakeholders for veterinary medicines)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-11-28T14:00:00Z","last_updated_date":"2019-11-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-workshop-draft-regulatory-science-2025-strategy-stakeholders-veterinary-medicines_en.pdf"},
    {"id":"46219","name":"Agenda - EMA 3rd International Awareness Session on science and regulation for animal health and welfare, public health and the environment","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2019-12-03T14:57:00Z","last_updated_date":"2020-03-06T09:58:00Z","reference_number":"EMA/644204/2019 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-3rd-international-awareness-session-science-and-regulation-animal-health-and-welfare-public-health-and-environment_en.pdf"},
    {"id":"46222","name":"Agenda - COMP agenda of the 03-05 December 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-12-03T15:34:00Z","last_updated_date":"2019-12-03T15:34:00Z","reference_number":"EMA/COMP/615654/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-03-05-december-2019-meeting_en.pdf"},
    {"id":"46232","name":"Agenda - CVMP agenda of the 3-5 December 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-12-04T12:03:00Z","last_updated_date":"2019-12-04T12:03:00Z","reference_number":"EMA/653381/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-3-5-december-2019-meeting_en.pdf"},
    {"id":"46248","name":"Agenda - CAT agenda of the 4-6 December 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-12-05T16:48:00Z","last_updated_date":"2019-12-05T16:48:00Z","reference_number":"EMA/CAT/664648/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-4-6-december-2019-meeting_en.pdf"},
    {"id":"46260","name":"Agenda - CHMP agenda of the 9-12 December 2019 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T14:27:00Z","last_updated_date":"2019-12-09T14:27:00Z","reference_number":"EMA/CHMP/666136/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-9-12-december-2019-meeting_en.pdf"},
    {"id":"46272","name":"Agenda - PDCO agenda of the 9-11 December 2019 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-12-10T10:00:00Z","last_updated_date":"2019-12-10T10:00:00Z","reference_number":"EMA/PDCO/630621/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-9-11-december-2019-meeting_en.pdf"},
    {"id":"46335","name":"Agenda for the 106th meeting of the Management Board: 18-19 December 2019","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2019-12-18T16:14:00Z","last_updated_date":"2019-12-20T16:02:00Z","reference_number":"EMA/MB/547838/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-106th-meeting-management-board-18-19-december-2019_en.pdf"},
    {"id":"46414","name":"Agenda - PRAC draft agenda of meeting 13-16 January 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-01-13T15:58:00Z","last_updated_date":"2020-01-13T15:58:00Z","reference_number":"EMA/PRAC/645087/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-13-16-january-2020_en.pdf"},
    {"id":"46432","name":"Agenda - HMPC agenda of the 13-15 January 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-01-15T15:31:00Z","last_updated_date":"2020-01-15T15:31:00Z","reference_number":"EMA/HMPC/13533/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-13-15-january-2020-meeting_en.pdf"},
    {"id":"46471","name":"Agenda - CVMP agenda of the 21-23 January 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-01-21T11:42:00Z","last_updated_date":"2020-01-21T11:42:00Z","reference_number":"EMA/28170/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-21-23-january-2020-meeting_en.pdf"},
    {"id":"46491","name":"Agenda - COMP agenda of the 20-22 January 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-01-22T18:05:00Z","last_updated_date":"2020-01-22T18:05:00Z","reference_number":"EMA/COMP/676409/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-20-22-january-2020-meeting_en.pdf"},
    {"id":"46614","name":"Agenda - EMA EORTC workshop on novel PRO and QoL approaches in cancer clinical research","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-01-29T16:38:00Z","last_updated_date":"2020-03-03T14:10:00Z","reference_number":"EMA/668786/2019 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-eortc-workshop-novel-pro-and-qol-approaches-cancer-clinical-research_en.pdf"},
    {"id":"46618","name":"Agenda - PDCO agenda of the 28-31 January 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-01-30T10:27:00Z","last_updated_date":"2020-01-30T10:27:00Z","reference_number":"EMA/PDCO/3481/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-28-31-january-2020-meeting_en.pdf"},
    {"id":"46624","name":"Agenda - CHMP agenda of the 27-30 January 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-01-27T12:56:00Z","last_updated_date":"2020-01-30T09:08:00Z","reference_number":"EMA/CHMP/43518/2020 Corr. 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-27-30-january-2020-meeting_en.pdf"},
    {"id":"46696","name":"Agenda - PRAC draft agenda of meeting 10-13 February 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-02-10T15:28:00Z","last_updated_date":"2020-02-10T15:28:00Z","reference_number":"EMA/PRAC/20444/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-10-13-february-2020_en.pdf"},
    {"id":"46772","name":"Agenda - COMP agenda of the 18-20 February 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-02-17T16:07:00Z","last_updated_date":"2020-02-17T16:07:00Z","reference_number":"EMA/COMP/51841/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-18-20-february-2020-meeting_en.pdf"},
    {"id":"46788","name":"Agenda - CVMP agenda of the 18-20 February 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-02-18T13:47:00Z","last_updated_date":"2020-02-18T13:47:00Z","reference_number":"EMA/82677/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-18-20-february-2020-meeting_en.pdf"},
    {"id":"46807","name":"Agenda - CAT agenda of the 19-21 February 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-02-19T16:34:00Z","last_updated_date":"2020-02-19T16:34:00Z","reference_number":"EMA/CAT/89346/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-19-21-february-2020-meeting_en.pdf"},
    {"id":"46866","name":"Agenda - Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (Oct 2019)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T10:43:00Z","last_updated_date":"2020-02-25T10:43:00Z","reference_number":"EMA/481333/2019 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-substance-product-organisation-and-referential-data-spor-task-force-meeting-oct-2019_en.pdf"},
    {"id":"46868","name":"Agenda - CHMP agenda of the 24-27 February 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:36:00Z","last_updated_date":"2020-02-25T09:36:00Z","reference_number":"EMA/CHMP/92703/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-24-27-february-2020-meeting_en.pdf"},
    {"id":"46875","name":"Agenda - PDCO agenda of the 25-28 February 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-02-25T16:06:00Z","last_updated_date":"2020-02-25T16:06:00Z","reference_number":"EMA/PDCO/68068/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-25-28-february-2020-meeting_en.pdf"},
    {"id":"46885","name":"Agenda - PCWP/HCPWP joint meeting on 3-4 March 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-02-27T13:45:00Z","last_updated_date":"2020-03-06T12:10:00Z","reference_number":"EMA/633892/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwphcpwp-joint-meeting-3-4-march-2020_en.pdf"},
    {"id":"46926","name":"Agenda - HMPC agenda of the 2-4 March 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-03-02T14:48:00Z","last_updated_date":"2020-03-02T14:48:00Z","reference_number":"EMA/HMPC/81088/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-2-4-march-2020-meeting_en.pdf"},
    {"id":"46927","name":"Agenda - Multi-stakeholder workshop to support implementation of Article 117 of the MDR 2017/745 on drug-device combinations","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-03-02T15:29:00Z","last_updated_date":"2020-03-02T15:29:00Z","reference_number":"EMA/464742/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-workshop-support-implementation-article-117-mdr-2017745-drug-device-combinations_en.pdf"},
    {"id":"46990","name":"Agenda - Third European Medicines Agency-Medicines for Europe bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-03-10T12:00:00Z","last_updated_date":"2020-03-20T15:10:00Z","reference_number":"EXT/147165/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-european-medicines-agency-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"46999","name":"Agenda - PRAC draft agenda of meeting 9-12 March 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-03-11T14:07:00Z","last_updated_date":"2020-03-11T14:07:00Z","reference_number":"EMA/PRAC/78004/2020 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-9-12-march-2020_en.pdf"},
    {"id":"47035","name":"Agenda - CVMP agenda of the 17-18 March 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-03-17T14:05:00Z","last_updated_date":"2020-03-17T14:05:00Z","reference_number":"EMA/136373/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-17-18-march-2020-meeting_en.pdf"},
    {"id":"47048","name":"Agenda - CAT agenda of the 18-20 March 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-03-19T09:35:00Z","last_updated_date":"2020-03-19T09:35:00Z","reference_number":"EMA/CAT/143367/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-18-20-march-2020-meeting_en.pdf"},
    {"id":"47049","name":"Agenda for the 107th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-03-19T10:10:00Z","last_updated_date":"2020-03-19T10:10:00Z","reference_number":"EMA/MB/1404/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-107th-meeting-management-board_en.pdf"},
    {"id":"47060","name":"EMA Management Board – highlights of March 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-03-20T09:16:00Z","last_updated_date":"2020-03-20T09:16:00Z","reference_number":"EMA/126753/2020 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/ema-management-board-highlights-march-2020-meeting_en.pdf"},
    {"id":"47091","name":"Agenda - COMP agenda of the 17-19 March 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-03-20T16:45:00Z","last_updated_date":"2020-03-20T16:45:00Z","reference_number":"EMA/COMP/94360/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-17-19-march-2020-meeting_en.pdf"},
    {"id":"47095","name":"Agenda - CHMP agenda of the 23-26 March 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-03-23T14:02:00Z","last_updated_date":"2020-03-23T14:02:00Z","reference_number":"EMA/CHMP/147656/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-23-26-march-2020-meeting_en.pdf"},
    {"id":"47121","name":"Agenda - PDCO agenda of the 24-27 March 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-03-25T15:33:00Z","last_updated_date":"2020-03-25T15:33:00Z","reference_number":"EMA/PDCO/116804/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-24-27-march-2020-meeting_en.pdf"},
    {"id":"47220","name":"CHMP ORGAM agenda for the meeting on 2 December 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T14:58:00Z","last_updated_date":"2020-03-30T14:58:00Z","reference_number":"EMA/CHMP/614413/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-2-december-2019_en.pdf"},
    {"id":"47401","name":"Agenda - PRAC draft agenda of meeting 14-17 April 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-04-14T13:55:00Z","last_updated_date":"2020-04-14T13:55:00Z","reference_number":"EMA/PRAC/132684/2020 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-14-17-april-2020_en.pdf"}    {"id":"47441","name":"Agenda - CVMP agenda of the 21-23 April 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-04-21T12:39:00Z","last_updated_date":"2020-04-24T13:49:00Z","reference_number":"EMA/CVMP/211697/2020 draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-21-23-april-2020-meeting_en.pdf"},
    {"id":"47444","name":"Agenda - COMP agenda of the 21-23 April 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-04-21T16:53:00Z","last_updated_date":"2020-04-21T16:53:00Z","reference_number":"EMA/COMP/159945/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-21-23-april-2020-meeting_en.pdf"},
    {"id":"47454","name":"Agenda - CAT agenda of the 22-24 April 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-04-22T12:05:00Z","last_updated_date":"2020-04-22T12:05:00Z","reference_number":"EMA/CAT/220061/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-22-24-april-2020-meeting_en.pdf"},
    {"id":"47506","name":"Agenda - CHMP agenda of the 28-30 April 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-04-29T11:30:00Z","last_updated_date":"2020-04-29T11:30:00Z","reference_number":"EMA/CHMP/228836/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-28-30-april-2020-meeting_en.pdf"},
    {"id":"47577","name":"Agenda - HMPC agenda of the 4-6 May 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-05-06T11:12:00Z","last_updated_date":"2020-05-06T11:12:00Z","reference_number":"EMA/HMPC/239419/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-4-6-may-2020-meeting_en.pdf"},
    {"id":"47588","name":"CHMP ORGAM agenda for the meeting on 17 February 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-05-07T12:40:00Z","last_updated_date":"2020-05-07T12:40:00Z","reference_number":"EMA/244307/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-17-february-2020_en.pdf"},
    {"id":"47637","name":"Agenda - PRAC draft agenda of meeting 11-14 May 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-05-11T14:07:00Z","last_updated_date":"2020-05-11T14:07:00Z","reference_number":"EMA/PRAC/257460/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-11-14-may-2020_en.pdf"},
    {"id":"47654","name":"Agenda - Enpr-EMA Coordinating Group & networks meeting on 21 February 2020","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-13T11:30:00Z","last_updated_date":"2020-05-13T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-networks-meeting-21-february-2020_en.pdf"},
    {"id":"47683","name":"Agenda - COMP agenda of the 18-20 May 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-05-18T09:00:00Z","last_updated_date":"2020-05-18T09:00:00Z","reference_number":"EMA/COMP/235630/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-18-20-may-2020-meeting_en.pdf"},
    {"id":"47684","name":"Agenda - CAT agenda of the 18-20 May 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T09:05:00Z","last_updated_date":"2020-05-18T09:05:00Z","reference_number":"EMA/CAT/268957/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-18-20-may-2020-meeting_en.pdf"},
    {"id":"47689","name":"Agenda - PDCO agenda of the 28-30 April 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T14:45:00Z","last_updated_date":"2020-05-18T14:45:00Z","reference_number":"EMA/PDCO/173462/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-28-30-april-2020-meeting_en.pdf"},
    {"id":"47690","name":"Agenda - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Virtual live hands-on training course using the EudraVigilance System on 25-29 May 2020","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T15:00:00Z","last_updated_date":"2020-05-18T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-isoich-e2br3-individual-case-safety-reporting-eu-virtual-live-hands-training-course-using-eudravigilance-system-25-29-may-2020_en.pdf"},
    {"id":"47691","name":"Agenda - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Virtual live hands-on training course using the EudraVigilance System on 8-12 June 2020","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T14:15:00Z","last_updated_date":"2020-05-18T14:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-isoich-e2br3-individual-case-safety-reporting-eu-virtual-live-hands-training-course-using-eudravigilance-system-8-12-june-2020_en.pdf"},
    {"id":"47692","name":"Agenda - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Virtual live hands-on training course using the EudraVigilance System on 22-26 June 2020","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T15:03:00Z","last_updated_date":"2020-05-18T15:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-isoich-e2br3-individual-case-safety-reporting-eu-virtual-live-hands-training-course-using-eudravigilance-system-22-26-june-2020_en.pdf"},
    {"id":"47693","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (22-24 June 2020)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T10:20:00Z","last_updated_date":"2020-05-18T10:20:00Z","reference_number":"Course #20581","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-22-24-june-2020_en.pdf"},
    {"id":"47694","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (8-10 July 2020)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T10:20:00Z","last_updated_date":"2020-05-18T10:20:00Z","reference_number":"Course #20580","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-face-face-training-course-8-10-july-2020_en.pdf"},
    {"id":"47695","name":"Agenda - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Virtual live hands-on training course using the EudraVigilance System on 6-10 July 2020","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T15:07:00Z","last_updated_date":"2020-05-18T15:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-isoich-e2br3-individual-case-safety-reporting-eu-virtual-live-hands-training-course-using-eudravigilance-system-6-10-july-2020_en.pdf"},
    {"id":"47696","name":"Agenda - CVMP agenda of the 18-20 May 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-05-18T15:17:00Z","last_updated_date":"2020-05-18T15:17:00Z","reference_number":"EMA/269170/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-18-20-may-2020-meeting_en.pdf"},
    {"id":"47716","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties Joint - Virtual meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T16:27:00Z","last_updated_date":"2020-06-05T08:55:00Z","reference_number":"EMA/147856/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-and-consumers-pcwp-and-healthcare-professionals-hcpwp-working-parties-joint-virtual-meeting_en.pdf"},
    {"id":"47717","name":"Agenda - ICH E6(R3) Good Clinical Practice workshop with PCWP and HCPWP on 3 June 2020","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T16:32:00Z","last_updated_date":"2020-06-04T15:06:00Z","reference_number":"EMA/126621/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ich-e6r3-good-clinical-practice-workshop-pcwp-and-hcpwp-3-june-2020_en.pdf"},
    {"id":"47719","name":"Agenda - 2019 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA (Enpr-EMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T16:53:00Z","last_updated_date":"2020-05-19T16:53:00Z","reference_number":"EMA/409422/2019","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2019-annual-meeting-members-and-coordinating-group-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"47737","name":"Agenda - European Medicines Agency and EuropaBio annual bilateral meeting 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-05-20T12:21:00Z","last_updated_date":"2020-05-20T12:21:00Z","reference_number":"EMA/273601/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-and-europabio-annual-bilateral-meeting-2020_en.pdf"},
    {"id":"47763","name":"Agenda - CHMP agenda of the 25-28 May 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-05-27T09:41:00Z","last_updated_date":"2020-05-27T09:41:00Z","reference_number":"EMA/CHMP/276755/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-25-28-may-2020-meeting_en.pdf"},
    {"id":"47885","name":"Agenda - PDCO agenda of the 26-29 May 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-06-05T16:23:00Z","last_updated_date":"2020-06-05T16:23:00Z","reference_number":"EMA/PDCO/247681/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-26-29-may-2020-meeting_en.pdf"},
    {"id":"47895","name":"Agenda - PRAC draft agenda of meeting 8-11 June 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-06-08T16:38:00Z","last_updated_date":"2020-06-08T16:38:00Z","reference_number":"EMA/PRAC/309588/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-june-2020_en.pdf"},
    {"id":"47938","name":"Agenda of the 108th meeting of the Management Board: 11 June 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:45:00Z","last_updated_date":"2020-06-11T11:15:00Z","reference_number":"EMA/MB/155342/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-108th-meeting-management-board-11-june-2020_en.pdf"},
    {"id":"48005","name":"Agenda - COMP agenda of the 16-18 June 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-06-15T10:15:00Z","last_updated_date":"2020-06-15T10:15:00Z","reference_number":"EMA/COMP/285717/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-16-18-june-2020-meeting_en.pdf"},
    {"id":"48014","name":"Agenda - CVMP agenda of the 16-18 June 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-06-16T09:32:00Z","last_updated_date":"2020-06-16T09:32:00Z","reference_number":"EMA/321774/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-16-18-june-2020-meeting_en.pdf"},
    {"id":"48017","name":"Agenda - PCWP/HCPWP joint meeting on 24 June 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-06-16T10:41:00Z","last_updated_date":"2020-07-02T17:00:00Z","reference_number":"EMA/275209/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwphcpwp-joint-meeting-24-june-2020_en.pdf"},
    {"id":"48038","name":"Agenda - CAT agenda of the 17-19 June 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-06-17T13:37:00Z","last_updated_date":"2020-06-17T13:37:00Z","reference_number":"EMA/CAT/326151/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-17-19-june-2020-meeting_en.pdf"},
    {"id":"48063","name":"Agenda - CHMP agenda of the 22-25 June 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-06-22T15:10:00Z","last_updated_date":"2020-06-22T15:10:00Z","reference_number":"EMA/CHMP/333600/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-22-25-june-2020-meeting_en.pdf"},
    {"id":"48115","name":"Agenda - PDCO agenda of the 23-26 June 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-06-24T17:15:00Z","last_updated_date":"2020-06-24T17:15:00Z","reference_number":"EMA/PDCO/302368/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-23-26-june-2020-meeting_en.pdf"},
    {"id":"48117","name":"Agenda and registration form - eXtended EudraVigilance Medicinal Product Dictionary training course (September, October, November, December 2020)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-06-25T10:20:00Z","last_updated_date":"2020-09-03T09:38:00Z","reference_number":"Course #20582, #20583, #20579, #20584","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-training-course-september-october-november-december-2020_en.pdf"},
    {"id":"48118","name":"Agenda - Extraordinary Management Board meeting to nominate a new EMA Executive Director: 25 June 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-06-25T10:38:00Z","last_updated_date":"2020-06-25T11:23:00Z","reference_number":"EMA/MB/238692/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-extraordinary-management-board-meeting-nominate-new-ema-executive-director-25-june-2020_en.pdf"},
    {"id":"48162","name":"Agenda - ISO/ICH E2B(R3) Individual case safety report (ICSR) in the EU: Virtual live hands-on training course using the EudraVigilance system","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-07-02T10:30:00Z","last_updated_date":"2020-08-25T11:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-isoich-e2br3-individual-case-safety-report-icsr-eu-virtual-live-hands-training-course-using-eudravigilance-system_en.pdf"},
    {"id":"48184","name":"Agenda - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System (Lisbon)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-06-30T10:30:00Z","last_updated_date":"2020-06-30T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-lisbon_en.pdf"},
    {"id":"48185","name":"Agenda - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System (Vienna)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-06-30T10:46:00Z","last_updated_date":"2020-06-30T10:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-vienna_en.pdf"},
    {"id":"48186","name":"Agenda - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System (Munich)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-06-30T10:49:00Z","last_updated_date":"2020-06-30T10:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-munich_en.pdf"},
    {"id":"48187","name":"Agenda - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System (Madrid)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-06-30T10:52:00Z","last_updated_date":"2020-06-30T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-madrid_en.pdf"},
    {"id":"48188","name":"Agenda - ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System (Paris)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-06-30T10:55:00Z","last_updated_date":"2020-06-30T10:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-paris_en.pdf"},
    {"id":"48232","name":"Agenda - PRAC draft agenda of meeting 6-9 July 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-07-06T12:55:00Z","last_updated_date":"2020-07-06T12:55:00Z","reference_number":"EMA/PRAC/366695/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-6-9-july-2020_en.pdf"},
    {"id":"48254","name":"Agenda - HMPC agenda of the 6-8 July 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-07-08T08:56:00Z","last_updated_date":"2020-07-08T08:56:00Z","reference_number":"EMA/HMPC/302450/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-6-8-july-2020-meeting_en.pdf"},
    {"id":"48261","name":"Agenda - Workshop on benefit-risk of medicines used during pregnancy and breastfeeding","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-07-08T14:30:00Z","last_updated_date":"2020-09-17T17:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-benefit-risk-medicines-used-during-pregnancy-and-breastfeeding_en.pdf"},
    {"id":"48291","name":"Agenda - Workshop on the application of the General Data  Protection Regulation (GDPR) in the area of health and  Secondary Use of Data for Medicines and Public Health Purposes","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-07-13T11:45:00Z","last_updated_date":"2020-12-04T17:30:00Z","reference_number":"EMA /307527/2020 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-application-general-data-protection-regulation-gdpr-area-health-and-secondary-use-data-medicines-and-public-health-purposes_en.pdf"},
    {"id":"48293","name":"Agenda - COMP agenda of the 14-16 July 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-07-13T14:17:00Z","last_updated_date":"2020-07-13T14:17:00Z","reference_number":"EMA/COMP/343863/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-14-16-july-2020-meeting_en.pdf"},
    {"id":"48298","name":"Agenda - CVMP agenda of the 14-16 July 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-07-14T10:31:00Z","last_updated_date":"2020-07-14T10:31:00Z","reference_number":"EMA/377609/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-14-16-july-2020-meeting_en.pdf"},
    {"id":"48300","name":"Agenda - CAT agenda of the 15-17 July 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-07-14T11:36:00Z","last_updated_date":"2020-07-14T11:36:00Z","reference_number":"EMA/CAT/381201/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-15-17-july-2020-meeting_en.pdf"},
    {"id":"48304","name":"Agenda - Workshop on the General Data Protection Regulation (GDPR) and secondary use of data for medicines and public health purposes","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-07-14T15:45:00Z","last_updated_date":"2020-09-29T10:00:00Z","reference_number":"EMA/350890/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-general-data-protection-regulation-gdpr-and-secondary-use-data-medicines-and-public-health-purposes_en.pdf"},
    {"id":"48330","name":"Agenda - CHMP agenda of the 20-23 July 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-07-20T09:37:00Z","last_updated_date":"2020-07-27T11:32:00Z","reference_number":"EMA/CHMP/389029/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-20-23-july-2020-meeting_en.pdf"},
    {"id":"48463","name":"Agenda - PDCO agenda of the 21-24 July 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-07-28T16:36:00Z","last_updated_date":"2020-07-28T16:36:00Z","reference_number":"EMA/PDCO/369320/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-21-24-july-2020-meeting_en.pdf"},
    {"id":"48600","name":"Agenda - EMA Clinical Trial Information System (CTIS) webinar: Dynamic demo of sponsor workspace","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-08-13T11:39:00Z","last_updated_date":"2020-09-10T12:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-clinical-trial-information-system-ctis-webinar-dynamic-demo-sponsor-workspace_en.pdf"},
    {"id":"48630","name":"Agenda - CHMP agenda of the 17-20 August 2020 written procedure","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-08-18T12:10:00Z","last_updated_date":"2020-08-25T12:06:00Z","reference_number":"EMA/CHMP/430123/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-17-20-august-2020-written-procedure_en.pdf"},
    {"id":"48728","name":"Agenda - PRAC draft agenda of meeting 31 August - 3 September 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-08-31T17:00:00Z","last_updated_date":"2020-08-31T17:00:00Z","reference_number":"EMA/PRAC/459031/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-31-august-3-september-2020_en.pdf"},
    {"id":"48743","name":"Agenda - PDCO agenda of the 1-4 September 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-09-03T10:53:00Z","last_updated_date":"2020-09-03T10:53:00Z","reference_number":"EMA/PDCO/439902/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-1-4-september-2020-meeting_en.pdf"},
    {"id":"48763","name":"Agenda - Workshop on the draft guideline on registry-based studies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-09-07T15:25:00Z","last_updated_date":"2020-10-15T16:14:00Z","reference_number":"EMA/428155/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-draft-guideline-registry-based-studies_en.pdf"},
    {"id":"48766","name":"Agenda - COMP agenda of the 8-10 September 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-09-08T12:07:00Z","last_updated_date":"2020-09-08T12:07:00Z","reference_number":"EMA/COMP/393282/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-8-10-september-2020-meeting_en.pdf"},
    {"id":"48767","name":"Agenda - CVMP agenda of the 8-10 September 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-09-08T12:13:00Z","last_updated_date":"2020-09-08T12:13:00Z","reference_number":"EMA/469339/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-8-10-september-2020-meeting_en.pdf"},
    {"id":"48777","name":"Agenda - CAT agenda of the 9-11 September 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-09-10T10:37:00Z","last_updated_date":"2020-09-10T10:37:00Z","reference_number":"EMA/CAT/476108/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-9-11-september-2020-meeting_en.pdf"},
    {"id":"48804","name":"Agenda - CHMP agenda of the 14-17 September 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-09-14T09:48:00Z","last_updated_date":"2020-09-14T09:48:00Z","reference_number":"EMA/CHMP/481238/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-14-17-september-2020-meeting_en.pdf"},
    {"id":"48822","name":"Agenda and registration form - EMA EudraVigilance information day on 2 December 2020","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-09-16T12:12:00Z","last_updated_date":"2020-11-25T10:52:00Z","reference_number":"Event #20525","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-ema-eudravigilance-information-day-2-december-2020_en.pdf"},
    {"id":"48827","name":"Agenda - EMA 25th anniversary symposium: New approaches in patient-focused cancer drug development","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-09-16T16:31:00Z","last_updated_date":"2020-10-28T16:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-25th-anniversary-symposium-new-approaches-patient-focused-cancer-drug-development_en.pdf"},
    {"id":"48865","name":"Agenda - HMPC agenda of the 21-23 September 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-09-21T15:25:00Z","last_updated_date":"2020-09-21T15:25:00Z","reference_number":"EMA/HMPC/459014/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-21-23-september-2020-meeting_en.pdf"},
    {"id":"48906","name":"Agenda - PRAC draft agenda of meeting 28 September - 1 October 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-09-29T09:33:00Z","last_updated_date":"2020-09-29T09:33:00Z","reference_number":"EMA/PRAC/512067/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-28-september-1-october-2020_en.pdf"},
    {"id":"48919","name":"Agenda - Workshop on support for orphan medicines development","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-09-30T14:25:00Z","last_updated_date":"2020-10-12T17:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-support-orphan-medicines-development_en.pdf"},
    {"id":"48923","name":"Agenda of the 109th meeting of the Management Board: 1 October 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-09-30T17:03:00Z","last_updated_date":"2020-10-05T13:00:00Z","reference_number":"EMA/MB/388242/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-109th-meeting-management-board-1-october-2020_en.pdf"},
    {"id":"48949","name":"Agenda - 25 Years of EMA: building, learning and adapting to new challenges","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-10-05T17:51:00Z","last_updated_date":"2020-10-21T11:38:00Z","reference_number":"EMA/449946/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-25-years-ema-building-learning-and-adapting-new-challenges_en.pdf"},
    {"id":"48953","name":"Agenda - CVMP agenda of the 6-7 October 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-10-06T11:30:00Z","last_updated_date":"2020-10-06T11:30:00Z","reference_number":"EMA/523278/2020 draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-6-7-october-2020-meeting_en.pdf"},
    {"id":"48955","name":"Agenda - Training session for patients, consumers and healthcare professionals interested in EMA activities","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-10-06T14:39:00Z","last_updated_date":"2020-10-06T14:39:00Z","reference_number":"EMA/134548/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-patients-consumers-and-healthcare-professionals-interested-ema-activities_en.pdf"},
    {"id":"48966","name":"Agenda - COMP agenda of the 6-8 October 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-10-08T11:43:00Z","last_updated_date":"2020-10-08T11:43:00Z","reference_number":"EMA/COMP/491947/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-6-8-october-2020-meeting_en.pdf"},
    {"id":"48992","name":"Agenda - CAT agenda of the 7-9 October 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-10-12T11:16:00Z","last_updated_date":"2020-10-12T11:16:00Z","reference_number":"EMA/CAT/531222/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-7-9-october-2020-meeting_en.pdf"},
    {"id":"48998","name":"Agenda - CHMP agenda of the 12-15 October 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-10-12T15:16:00Z","last_updated_date":"2020-10-12T15:16:00Z","reference_number":"EMA/CHMP/537222/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-12-15-october-2020-meeting_en.pdf"},
    {"id":"49004","name":"Agenda - PDCO agenda of the 13-16 October 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-10-14T08:42:00Z","last_updated_date":"2020-10-14T08:42:00Z","reference_number":"EMA/PDCO/490611/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-13-16-october-2020-meeting_en.pdf"},
    {"id":"49120","name":"CHMP ORGAM agenda for the meeting on 5 October 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-10-23T15:27:00Z","last_updated_date":"2020-10-23T15:27:00Z","reference_number":"EMA/534390/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-5-october-2020_en.pdf"},
    {"id":"49121","name":"Agenda - European networkof paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T15:58:00Z","last_updated_date":"2020-10-23T15:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-networkof-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting_en.pdf"},
    {"id":"49130","name":"Agenda - PRAC draft agenda of meeting 26-29 October 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-10-26T16:13:00Z","last_updated_date":"2020-10-26T16:13:00Z","reference_number":"EMA/PRAC/570668/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-26-29-october-2020_en.pdf"},
    {"id":"49142","name":"Agenda - PCWP/HCPWP meeting with all eligible organisations: COVID-19 pandemic update","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-10-28T13:30:00Z","last_updated_date":"2020-11-16T09:30:00Z","reference_number":"EMA/537890/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwphcpwp-meeting-all-eligible-organisations-covid-19-pandemic-update_en.pdf"},
    {"id":"49171","name":"Agenda - CVMP agenda of the 3-5 November 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-11-03T17:04:00Z","last_updated_date":"2020-11-03T17:04:00Z","reference_number":"EMA/583050/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-3-5-november-2020-meeting_en.pdf"},
    {"id":"49179","name":"Agenda - CAT agenda of the 4-6 November 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-11-04T17:18:00Z","last_updated_date":"2020-11-04T17:18:00Z","reference_number":"EMA/CAT/588925/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-4-6-november-2020-meeting_en.pdf"},
    {"id":"49185","name":"Agenda - COMP agenda of the 3-5 November 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-11-06T10:16:00Z","last_updated_date":"2020-11-06T10:16:00Z","reference_number":"EMA/COMP/545698/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-3-5-november-2020-meeting_en.pdf"},
    {"id":"49198","name":"Agenda - CHMP agenda of the 9-12 November 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-11-09T11:06:00Z","last_updated_date":"2020-11-09T11:06:00Z","reference_number":"EMA/CHMP/592608/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-9-12-november-2020-meeting_en.pdf"},
    {"id":"49199","name":"Agenda - EMA roundtable with stakeholders 15 years supporting SMEs","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-11-09T16:23:00Z","last_updated_date":"2020-12-15T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-roundtable-stakeholders-15-years-supporting-smes_en.pdf"},
    {"id":"49259","name":"Agenda - PDCO agenda of the 10-13 November 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-11-16T09:39:00Z","last_updated_date":"2020-11-16T09:39:00Z","reference_number":"EMA/PDCO/557670/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-10-13-november-2020-meeting_en.pdf"},
    {"id":"49260","name":"Agenda - HMPC agenda of the 16-18 November 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-11-16T09:50:00Z","last_updated_date":"2020-11-16T09:50:00Z","reference_number":"EMA/HMPC/559321/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-16-18-november-2020-meeting_en.pdf"},
    {"id":"49262","name":"Agenda - EMA public stakeholder meeting on COVID-19","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-12-10T11:00:00Z","last_updated_date":"2020-12-10T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-public-stakeholder-meeting-covid-19_en.pdf"},
    {"id":"49263","name":"Agenda - 15th industry stakeholder platform - Operation of European Union (EU) pharmacovigilance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-11-17T17:26:00Z","last_updated_date":"2020-11-17T17:26:00Z","reference_number":"EMA/342512/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-15th-industry-stakeholder-platform-operation-european-union-eu-pharmacovigilance_en.pdf"},
    {"id":"49316","name":"Agenda - PRAC draft agenda of meeting 23-26 November 2020","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-11-23T15:15:00Z","last_updated_date":"2020-11-23T15:15:00Z","reference_number":"EMA/PRAC/630501/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-23-26-november-2020_en.pdf"},
    {"id":"49319","name":"Agenda - Multi-stakeholder webinar to support implementation of Article 117 of the MDR 2017/745 on drug-device combinations","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-11-23T16:00:00Z","last_updated_date":"2020-11-27T10:30:00Z","reference_number":"EMA/128303/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-webinar-support-implementation-article-117-mdr-2017745-drug-device-combinations_en.pdf"},
    {"id":"49416","name":"Agenda - COMP agenda of the 1-3 December 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-12-01T15:31:00Z","last_updated_date":"2020-12-01T15:31:00Z","reference_number":"EMA/COMP/598981/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-1-3-december-2020-meeting_en.pdf"},
    {"id":"49431","name":"Agenda - EU big data stakeholder virtual forum","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-12-03T11:35:00Z","last_updated_date":"2020-12-14T16:05:00Z","reference_number":"EMA/109720/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eu-big-data-stakeholder-virtual-forum_en.pdf"},
    {"id":"49456","name":"Agenda - Industry stakeholders webinar on the UK withdrawal from the European Union - End of transition period","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T13:25:00Z","last_updated_date":"2020-12-04T13:25:00Z","reference_number":"EMA/587179/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-stakeholders-webinar-uk-withdrawal-european-union-end-transition-period_en.pdf"},
    {"id":"49468","name":"Agenda - CHMP agenda of the 7-10 December 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-12-07T11:47:00Z","last_updated_date":"2020-12-07T11:47:00Z","reference_number":"EMA/CHMP/659998/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-7-10-december-2020-meeting_en.pdf"},
    {"id":"49480","name":"Agenda - CVMP agenda of the 8-10 December 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-12-08T12:09:00Z","last_updated_date":"2020-12-08T12:09:00Z","reference_number":"EMA/661799/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-8-10-december-2020-meeting_en.pdf"},
    {"id":"49489","name":"Agenda - CAT agenda of the 2-4 December 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-12-09T14:37:00Z","last_updated_date":"2020-12-09T14:37:00Z","reference_number":"EMA/CAT/662327/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-2-4-december-2020-meeting_en.pdf"},
    {"id":"49511","name":"Agenda - PDCO agenda of the 8-11 December 2020 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-12-10T12:17:00Z","last_updated_date":"2020-12-10T12:17:00Z","reference_number":"EMA/PDCO/622400/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-8-11-december-2020-meeting_en.pdf"},
    {"id":"49572","name":"Agenda - 2020 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA (Enpr-EMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-12-16T10:53:00Z","last_updated_date":"2020-12-16T10:53:00Z","reference_number":"EMA/440708/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2020-annual-meeting-members-and-coordinating-group-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"49589","name":"Agenda for the 110th meeting of the Management Board: 16-17 December 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2020-12-15T17:45:00Z","last_updated_date":"2020-12-21T09:43:00Z","reference_number":"EMA/MB/547010/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-110th-meeting-management-board-16-17-december-2020_en.pdf"},
    {"id":"49596","name":"Programme and registration form - eXtended EudraVigilance Medicinal Product Dictionary training course (2021)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T09:19:00Z","last_updated_date":"2021-04-14T17:29:00Z","reference_number":"Course #21580, Course #21581, Course #21582","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-training-course-2021_en.pdf"},
    {"id":"49597","name":"Programme and registration form - Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on Training Course using the EudraVigilance System (Feb-Jul 2021)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T09:38:00Z","last_updated_date":"2021-04-14T11:10:00Z","reference_number":"Course #21500, Course #21501, Course #21502, Course #21503, Course #21504, Course #21505","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-mandatory-use-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-feb-jul-2021_en.pdf"},
    {"id":"49661","name":"Programme - European Medicines Agency / AnimalhealthEurope veterinary medicines info day 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-12-21T10:37:00Z","last_updated_date":"2021-03-17T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-european-medicines-agency-animalhealtheurope-veterinary-medicines-info-day-2021_en.pdf"},
    {"id":"49686","name":"Draft agenda - EMA public stakeholder meeting on the approval and roll-out of COVID-19 vaccines in the EU","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2020-12-22T16:14:00Z","last_updated_date":"2020-12-22T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-ema-public-stakeholder-meeting-approval-and-roll-out-covid-19-vaccines-eu_en.pdf"}    {"id":"49776","name":"Agenda - PRAC draft agenda of meeting 11-14 January 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-01-11T16:00:00Z","last_updated_date":"2021-01-11T16:00:00Z","reference_number":"EMA/PRAC/17329/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-11-14-january-2021_en.pdf"},
    {"id":"49783","name":"Agenda - Fifth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-01-12T11:46:00Z","last_updated_date":"2021-01-12T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fifth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"49794","name":"Agenda - European Medicines Agency and European Healthcare Distribution Association (GIRP) bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-01-13T11:00:00Z","last_updated_date":"2021-01-13T11:00:00Z","reference_number":"EMA/703015/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-and-european-healthcare-distribution-association-girp-bilateral-meeting_en.pdf"},
    {"id":"49810","name":"Agenda - HMPC agenda of the 11-13 January 2021 meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-01-15T12:01:00Z","last_updated_date":"2021-01-15T12:01:00Z","reference_number":"EMA/HMPC/668124/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-11-13-january-2021-meeting_en.pdf"},
    {"id":"49827","name":"Agenda - COMP agenda of the 19-21 January 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-01-18T15:11:00Z","last_updated_date":"2021-01-18T15:11:00Z","reference_number":"EMA/COMP/665917/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-19-21-january-2021-meeting_en.pdf"},
    {"id":"49836","name":"Agenda - CVMP agenda of the 19-21 January 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-01-19T14:06:00Z","last_updated_date":"2021-01-19T14:06:00Z","reference_number":"EMA/32304/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-19-21-january-2021-meeting_en.pdf"},
    {"id":"49837","name":"Agenda - CAT agenda of the 20-22 January 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-01-19T14:14:00Z","last_updated_date":"2021-01-19T14:14:00Z","reference_number":"EMA/CAT/34179/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-20-22-january-2021-meeting_en.pdf"},
    {"id":"49839","name":"Agenda - SME and Academia Clinical Trials Information System (CTIS) two-part training webinar","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-01-19T14:43:00Z","last_updated_date":"2021-02-19T09:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sme-and-academia-clinical-trials-information-system-ctis-two-part-training-webinar_en.pdf"},
    {"id":"49840","name":"Draft agenda - SME and Academia Clinical Trials Information System (CTIS) two-part training webinar - Day 2","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-01-19T14:43:00Z","last_updated_date":"2021-01-19T14:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-sme-and-academia-clinical-trials-information-system-ctis-two-part-training-webinar-day-2_en.pdf"},
    {"id":"49877","name":"Agenda - Fourth EMA-Medicines for Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T14:13:00Z","last_updated_date":"2021-01-21T14:13:00Z","reference_number":"EMA/694974/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-ema-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"49923","name":"Agenda - Real World research on medicinal products: key contribution of the European Network of Centres in Pharmacoepidemiology and Pharmacovigilance (ENCePP)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-01-25T10:13:00Z","last_updated_date":"2021-01-25T10:13:00Z","reference_number":"EMA/676969/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-real-world-research-medicinal-products-key-contribution-european-network-centres-pharmacoepidemiology-and-pharmacovigilance-encepp_en.pdf"},
    {"id":"49925","name":"Agenda - CHMP agenda of the 25-29 January 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-01-25T10:23:00Z","last_updated_date":"2021-01-26T16:08:00Z","reference_number":"EMA/CHMP/47240/2021 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-25-29-january-2021-meeting_en.pdf"},
    {"id":"49947","name":"CHMP ORGAM agenda for the meeting on 20 April 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-01-27T11:09:00Z","last_updated_date":"2021-01-27T11:09:00Z","reference_number":"EMA/CHMP/54236/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-20-april-2020_en.pdf"},
    {"id":"49948","name":"CHMP ORGAM agenda for the meeting on 18 May 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-01-27T11:12:00Z","last_updated_date":"2021-01-27T11:12:00Z","reference_number":"EMA/CHMP/54387/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-18-may-2020_en.pdf"},
    {"id":"49949","name":"Agenda - PDCO agenda of the 26-29 January 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-01-27T11:47:00Z","last_updated_date":"2021-01-27T11:47:00Z","reference_number":"EMA/PDCO/1681/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-26-29-january-2021-meeting_en.pdf"},
    {"id":"49956","name":"CHMP ORGAM agenda for the meeting on 15 June 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-01-28T09:53:00Z","last_updated_date":"2021-01-28T09:53:00Z","reference_number":"EMA/CHMP/56212/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-15-june-2020_en.pdf"},
    {"id":"49972","name":"CHMP ORGAM agenda for the meeting on 4 November 2019","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-01-29T09:05:00Z","last_updated_date":"2021-01-29T09:05:00Z","reference_number":"EMA/CHMP/421761/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-4-november-2019_en.pdf"},
    {"id":"49973","name":"CHMP ORGAM agenda for the meeting on 20 January 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-01-29T09:13:00Z","last_updated_date":"2021-01-29T09:13:00Z","reference_number":"EMA/CHMP/53952/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-20-january-2020_en.pdf"},
    {"id":"49974","name":"CHMP ORGAM agenda for the meeting on 16 March 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-01-29T09:19:00Z","last_updated_date":"2021-01-29T09:19:00Z","reference_number":"EMA/CHMP/54201/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-16-march-2020_en.pdf"},
    {"id":"49982","name":"CHMP ORGAM minutes for the meeting on 15 June 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-01-29T10:30:00Z","last_updated_date":"2021-01-29T10:30:00Z","reference_number":"EMA/CHMP/56387/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-minutes-meeting-15-june-2020_en.pdf"},
    {"id":"50104","name":"Agenda - PRAC draft agenda of meeting 8-11 February 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-02-08T17:10:00Z","last_updated_date":"2021-02-08T17:10:00Z","reference_number":"EMA/PRAC/80497/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-february-2021_en.pdf"},
    {"id":"50117","name":"Agenda - Third EMA-EFPIA annual bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-02-10T13:24:00Z","last_updated_date":"2021-02-10T13:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-ema-efpia-annual-bilateral-meeting_en.pdf"},
    {"id":"50178","name":"Agenda - CVMP agenda of the 16-18 February 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-02-16T09:26:00Z","last_updated_date":"2021-02-16T09:26:00Z","reference_number":"EMA/CVMP/68573/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-16-18-february-2021-meeting_en.pdf"},
    {"id":"50180","name":"Agenda - PCWP/HCPWP joint meeting on 2-3 March 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-02-16T09:36:00Z","last_updated_date":"2021-02-22T14:19:00Z","reference_number":"EMA/62114/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwphcpwp-joint-meeting-2-3-march-2021_en.pdf"},
    {"id":"50185","name":"Agenda - COMP agenda of the 16-18 February 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-02-16T12:47:00Z","last_updated_date":"2021-02-16T12:47:00Z","reference_number":"EMA/COMP/52622/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-16-18-february-2021-meeting_en.pdf"},
    {"id":"50203","name":"Agenda - CAT agenda of the 17-19 February 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-02-17T14:29:00Z","last_updated_date":"2021-02-17T14:29:00Z","reference_number":"EMA/CAT/98742/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-17-19-february-2021-meeting_en.pdf"},
    {"id":"50252","name":"Agenda - CHMP agenda of the 22-25 February 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-02-22T13:16:00Z","last_updated_date":"2021-02-22T13:16:00Z","reference_number":"EMA/CHMP/107904/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-22-25-february-2021-meeting_en.pdf"},
    {"id":"50253","name":"Agenda - Public stakeholder meeting: approval, safety monitoring and impact of COVID-19 vaccines in the EU","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-02-22T14:09:00Z","last_updated_date":"2021-03-24T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-public-stakeholder-meeting-approval-safety-monitoring-and-impact-covid-19-vaccines-eu_en.pdf"},
    {"id":"50259","name":"Agenda - PDCO agenda of the 23-26 February 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-02-23T11:35:00Z","last_updated_date":"2021-02-23T11:35:00Z","reference_number":"EMA/PDCO/67461/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-23-26-february-2021-meeting_en.pdf"},
    {"id":"50365","name":"Programme - Veterinary Big Data Stakeholder Forum","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-03-02T15:10:00Z","last_updated_date":"2021-06-01T09:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-veterinary-big-data-stakeholder-forum_en.pdf"},
    {"id":"50377","name":"Agenda - HMPC agenda of the 1-3 March 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-03-03T11:36:00Z","last_updated_date":"2021-03-03T11:36:00Z","reference_number":"EMA/HMPC/84827/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-1-3-march-2021-meeting_en.pdf"},
    {"id":"50476","name":"CHMP ORGAM agenda for the meeting on 13 July 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T14:12:00Z","last_updated_date":"2021-03-08T14:12:00Z","reference_number":"EMA/346251/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-13-july-2020_en.pdf"},
    {"id":"50507","name":"CHMP ORGAM agenda for the meeting on 7 September 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-03-10T11:40:00Z","last_updated_date":"2021-03-10T11:40:00Z","reference_number":"EMA/CHMP/404263/2020 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-7-september-2020_en.pdf"},
    {"id":"50519","name":"Agenda for the 111th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-03-11T15:30:00Z","last_updated_date":"2021-03-12T15:35:00Z","reference_number":"EMA/MB/34198/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-111th-meeting-management-board_en.pdf"},
    {"id":"50561","name":"Agenda - CVMP agenda of the 16-18 March 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-03-15T16:16:00Z","last_updated_date":"2021-03-15T16:16:00Z","reference_number":"EMA/CVMP/133239/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-16-18-march-2021-meeting_en.pdf"},
    {"id":"50562","name":"Agenda - COMP agenda of the 16-18 March 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-03-15T17:01:00Z","last_updated_date":"2021-03-15T17:01:00Z","reference_number":"EMA/COMP/108776/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-16-18-march-2021-meeting_en.pdf"},
    {"id":"50612","name":"Agenda - CAT agenda of the 17-18 March 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:36:00Z","last_updated_date":"2021-03-17T14:36:00Z","reference_number":"EMA/CAT/165783/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-17-18-march-2021-meeting_en.pdf"},
    {"id":"50628","name":"CHMP ORGAM agenda for the meeting on 30 November 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T15:58:00Z","last_updated_date":"2021-03-17T15:58:00Z","reference_number":"EMA/CHMP/615039/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-30-november-2020_en.pdf"},
    {"id":"50662","name":"Agenda - CHMP agenda of the 22-25 March 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-03-22T11:33:00Z","last_updated_date":"2021-03-22T11:33:00Z","reference_number":"EMA/CHMP/171652/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-22-25-march-2021-meeting_en.pdf"},
    {"id":"50667","name":"Agenda - Technical workshop on real-world metadata for regulatory purposes","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-03-22T17:26:00Z","last_updated_date":"2021-04-14T11:06:00Z","reference_number":"EMA/139729/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-technical-workshop-real-world-metadata-regulatory-purposes_en.pdf"},
    {"id":"50668","name":"Agenda - PDCO agenda of the 23-26 March 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-03-22T17:28:00Z","last_updated_date":"2021-03-22T17:28:00Z","reference_number":"EMA/PDCO/129227/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-23-26-march-2021-meeting_en.pdf"},
    {"id":"50684","name":"Agenda - Joint HMA/EMA workshop on artificial intelligence in medicines regulation","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-03-24T09:20:00Z","last_updated_date":"2021-04-19T09:39:00Z","reference_number":"EMA/176509/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-hmaema-workshop-artificial-intelligence-medicines-regulation_en.pdf"},
    {"id":"50702","name":"Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting (March 2021)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-03-25T15:58:00Z","last_updated_date":"2021-03-25T15:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting-march-2021_en.pdf"},
    {"id":"50709","name":"Agenda - Webinar on reporting suspected side effects following administration of veterinary medicines","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-03-25T16:05:00Z","last_updated_date":"2021-03-25T16:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-webinar-reporting-suspected-side-effects-following-administration-veterinary-medicines_en.pdf"},
    {"id":"50763","name":"Agenda - PRAC draft agenda of meeting 6-9 April 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-04-06T17:26:00Z","last_updated_date":"2021-04-06T17:26:00Z","reference_number":"EMA/PRAC/197861/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-6-9-april-2021_en.pdf"},
    {"id":"50785","name":"Programme and registration form - Risk management information day 2021","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-04-09T15:00:00Z","last_updated_date":"2021-06-14T12:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-risk-management-information-day-2021_en.pdf"},
    {"id":"50791","name":"Agenda - Nitrosamine Implementation Oversight Group (NIOG) - meeting with pharmaceutical industry","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-04-12T15:29:00Z","last_updated_date":"2021-04-12T15:29:00Z","reference_number":"EMA/167020/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-nitrosamine-implementation-oversight-group-niog-meeting-pharmaceutical-industry_en.pdf"},
    {"id":"50800","name":"Agenda - CVMP agenda of the 13-15 April 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-04-13T12:14:00Z","last_updated_date":"2021-04-13T12:14:00Z","reference_number":"EMA/CVMP/191262/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-13-15-april-2021-meeting_en.pdf"},
    {"id":"50801","name":"Agenda - COMP agenda of the 13-15 April 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-04-13T12:19:00Z","last_updated_date":"2021-04-13T12:19:00Z","reference_number":"EMA/COMP/173664/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-13-15-april-2021-meeting_en.pdf"},
    {"id":"50818","name":"Agenda - CAT agenda of the 14-16 April 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T11:19:00Z","last_updated_date":"2021-04-14T11:19:00Z","reference_number":"EMA/CAT/212367/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-14-16-april-2021-meeting_en.pdf"},
    {"id":"50898","name":"Agenda - CHMP agenda of the 19-22 April 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-04-19T09:44:00Z","last_updated_date":"2021-04-19T09:44:00Z","reference_number":"EMA/CHMP/220334/2021 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-april-2021-meeting_en.pdf"},
    {"id":"50915","name":"Draft agenda for the Extraordinary Management Board meeting on CTIS audit","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-04-20T14:49:00Z","last_updated_date":"2021-04-20T14:49:00Z","reference_number":"EMA/MB/221593/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-extraordinary-management-board-meeting-ctis-audit_en.pdf"},
    {"id":"50916","name":"Agenda - Veterinary Big Data Stakeholder Forum","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-04-20T15:08:00Z","last_updated_date":"2021-06-01T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-veterinary-big-data-stakeholder-forum_en.pdf"},
    {"id":"50991","name":"Agenda - PDCO agenda of the 20-23 April 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-04-26T15:52:00Z","last_updated_date":"2021-04-26T15:52:00Z","reference_number":"EMA/PDCO/188066/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-20-23-april-2021-meeting_en.pdf"},
    {"id":"51026","name":"Agenda - Third EMA-EuropaBio bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T15:12:00Z","last_updated_date":"2021-04-30T15:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-ema-europabio-bilateral-meeting_en.pdf"},
    {"id":"51044","name":"Agenda - HMPC agenda of the 3-5 May 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-05-03T16:21:00Z","last_updated_date":"2021-05-03T16:21:00Z","reference_number":"EMA/HMPC/188939/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-3-5-may-2021-meeting_en.pdf"},
    {"id":"51046","name":"Agenda - PRAC draft agenda of meeting 3-6 May 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-05-03T16:42:00Z","last_updated_date":"2021-05-03T16:42:00Z","reference_number":"EMA/PRAC/252450/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-3-6-may-2021_en.pdf"},
    {"id":"51090","name":"Agenda - Data Standardisation Strategy stakeholder workshop","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-05-05T17:03:00Z","last_updated_date":"2021-05-17T11:58:00Z","reference_number":"EMA/346477/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-data-standardisation-strategy-stakeholder-workshop_en.pdf"},
    {"id":"51126","name":"Agenda - CVMP agenda of the 10-12 May 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-05-10T16:18:00Z","last_updated_date":"2021-05-10T16:18:00Z","reference_number":"EMA/CVMP/242543/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-10-12-may-2021-meeting_en.pdf"},
    {"id":"51127","name":"Agenda - COMP agenda of the 10-12 May 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-05-10T17:07:00Z","last_updated_date":"2021-05-10T17:07:00Z","reference_number":"EMA/COMP/221232/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-10-12-may-2021-meeting_en.pdf"},
    {"id":"51138","name":"Agenda - CAT agenda of the 10-12 May 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-05-11T15:48:00Z","last_updated_date":"2021-05-11T15:48:00Z","reference_number":"EMA/CAT/268790/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-10-12-may-2021-meeting_en.pdf"},
    {"id":"51140","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint virtual meeting - June 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-05-12T09:53:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"EMA/231316/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-and-consumers-pcwp-and-healthcare-professionals-hcpwp-working-parties-joint-virtual-meeting-june-2021_en.pdf"},
    {"id":"51157","name":"Agenda - CHMP agenda of the 17-20 May 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-05-17T12:01:00Z","last_updated_date":"2021-05-17T12:01:00Z","reference_number":"EMA/CHMP/276743/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-17-20-may-2021-meeting_en.pdf"},
    {"id":"51203","name":"Agenda - PDCO agenda of the 18-21 May 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-05-20T12:40:00Z","last_updated_date":"2021-05-20T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-18-21-may-2021-meeting_en.pdf"},
    {"id":"51330","name":"Programme - Webinar on EMA’s categorisation of antibiotics used in animals","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-06-01T16:06:00Z","last_updated_date":"2021-06-01T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-webinar-emas-categorisation-antibiotics-used-animals_en.pdf"},
    {"id":"51368","name":"Agenda - ePI information workshop 5 July 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-06-07T16:00:00Z","last_updated_date":"2021-06-28T11:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-epi-information-workshop-5-july-2021_en.pdf"},
    {"id":"51369","name":"Agenda - ePI exploratory workshop on 6, 7 and 8 July","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-06-07T16:00:00Z","last_updated_date":"2021-06-30T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-epi-exploratory-workshop-6-7-and-8-july_en.pdf"},
    {"id":"51370","name":"Agenda - PRAC draft agenda of meeting 7-10 June 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-06-07T14:46:00Z","last_updated_date":"2021-06-07T14:46:00Z","reference_number":"EMA/PRAC/319890/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-7-10-june-2021_en.pdf"},
    {"id":"51406","name":"Agenda - COMP agenda of the 15-17 June 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-06-11T09:33:00Z","last_updated_date":"2021-06-11T09:33:00Z","reference_number":"EMA/COMP/276731/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-15-17-june-2021-meeting_en.pdf"},
    {"id":"51435","name":"Agenda - CVMP agenda of the 15-17 June 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-06-15T11:03:00Z","last_updated_date":"2021-06-15T11:03:00Z","reference_number":"EMA/308464/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-15-17-june-2021-meeting_en.pdf"},
    {"id":"51451","name":"Agenda - CAT agenda of the 16-18 June 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-06-16T12:18:00Z","last_updated_date":"2021-06-16T12:18:00Z","reference_number":"EMA/342564/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-16-18-june-2021-meeting_en.pdf"},
    {"id":"51460","name":"Agenda for the 112th meeting of the Management Board: 17 June 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T17:09:00Z","last_updated_date":"2021-06-18T14:00:00Z","reference_number":"EMA/MB/196797/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-112th-meeting-management-board-17-june-2021_en.pdf"},
    {"id":"51515","name":"Agenda - CHMP agenda of the 21-24 June 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-06-21T14:47:00Z","last_updated_date":"2021-06-21T14:47:00Z","reference_number":"EMA/CHMP/347670/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-21-24-june-2021-meeting_en.pdf"},
    {"id":"51556","name":"Agenda - Sixth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-06-23T15:00:00Z","last_updated_date":"2021-06-23T15:00:00Z","reference_number":"EMA/234664/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"51558","name":"Agenda - PDCO agenda of the 22-25 June 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-06-23T15:04:00Z","last_updated_date":"2021-10-08T16:15:00Z","reference_number":"EMA/PDCO/350437/2021 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-22-25-june-2021-meeting_en.pdf"},
    {"id":"51621","name":"Agenda - Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (Dec 2020)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-06-25T16:06:00Z","last_updated_date":"2021-06-25T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-substance-product-organisation-and-referential-data-spor-task-force-meeting-dec-2020_en.pdf"},
    {"id":"51623","name":"Agenda - Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (Sept 2020)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-06-25T16:17:00Z","last_updated_date":"2021-06-25T16:17:00Z","reference_number":"EMA/362837/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-substance-product-organisation-and-referential-data-spor-task-force-meeting-sept-2020_en.pdf"},
    {"id":"51626","name":"Agenda - Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (Jul 2020)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-06-25T16:23:00Z","last_updated_date":"2021-06-25T16:23:00Z","reference_number":"EMA/362837/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-substance-product-organisation-and-referential-data-spor-task-force-meeting-jul-2020_en.pdf"},
    {"id":"51628","name":"Agenda - Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (Apr 2020)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-06-25T16:31:00Z","last_updated_date":"2021-06-25T16:31:00Z","reference_number":"EMA/134497/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-substance-product-organisation-and-referential-data-spor-task-force-meeting-apr-2020_en.pdf"},
    {"id":"51647","name":"Agenda - European Medicines Agency (EMA) and MedTech Europe bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-06-28T13:53:00Z","last_updated_date":"2021-06-28T13:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-and-medtech-europe-bilateral-meeting_en.pdf"},
    {"id":"51706","name":"Agenda - Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-07-01T08:50:00Z","last_updated_date":"2021-07-06T11:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-cttifda-patient-engagement-collaborative-pec-and-ema-patients-and-consumers-working-party-pcwp_en.pdf"},
    {"id":"51770","name":"Agenda - HMPC agenda of the 5-7 July 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-07-05T10:25:00Z","last_updated_date":"2021-07-05T10:25:00Z","reference_number":"EMA/HMPC/297871/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-5-7-july-2021-meeting_en.pdf"},
    {"id":"51802","name":"Agenda - PRAC draft agenda of meeting 05-08 July 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-07-05T17:03:00Z","last_updated_date":"2021-07-05T17:03:00Z","reference_number":"EMA/PRAC/379709/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-05-08-july-2021_en.pdf"},
    {"id":"51825","name":"Programme and registration form - Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on Training Course using the EudraVigilance System (Sept-Dec 2021)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T09:38:00Z","last_updated_date":"2021-07-06T09:38:00Z","reference_number":"Course #21506, Course #21508, Course #21509, Course #21510, Course #21511, Course #21512","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-mandatory-use-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-sept-dec-2021_en.pdf"},
    {"id":"51860","name":"Agenda - Clinical Trials Information System (CTIS) webinar: How sponsor organisations can prepare for CTIS","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T15:33:00Z","last_updated_date":"2021-07-27T17:40:00Z","reference_number":"EMA/363108/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-trials-information-system-ctis-webinar-how-sponsor-organisations-can-prepare-ctis_en.pdf"},
    {"id":"51870","name":"Agenda - First European Medicines Agency and Affordable Medicines Europe bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-07-08T09:24:00Z","last_updated_date":"2021-07-08T09:24:00Z","reference_number":"EMA/234069/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-european-medicines-agency-and-affordable-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"51911","name":"Agenda - CVMP agenda of the 13-15 July 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-07-12T16:03:00Z","last_updated_date":"2021-07-12T16:03:00Z","reference_number":"EMA/393347/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-13-15-july-2021-meeting_en.pdf"},
    {"id":"51912","name":"Agenda - COMP agenda of the 13-15 July 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-07-12T16:08:00Z","last_updated_date":"2021-07-12T16:08:00Z","reference_number":"EMA/COMP/348863/2021 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-13-15-july-2021-meeting_en.pdf"},
    {"id":"51938","name":"Agenda - CAT agenda of the 14-16 July 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-07-15T15:30:00Z","last_updated_date":"2021-07-15T15:30:00Z","reference_number":"EMA/CAT/396514/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-14-16-july-2021-meeting_en.pdf"},
    {"id":"51940","name":"Agenda - Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (April 2021)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-07-15T10:43:00Z","last_updated_date":"2021-07-15T10:43:00Z","reference_number":"EMA/84485/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-substance-product-organisation-and-referential-data-spor-task-force-meeting-april-2021_en.pdf"},
    {"id":"51957","name":"Agenda - CHMP agenda of the 19-22 July 2021 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-07-19T10:53:00Z","last_updated_date":"2021-07-19T10:53:00Z","reference_number":"EMA/CHMP/404698/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-july-2021-meeting_en.pdf"},
    {"id":"52105","name":"Agenda - PDCO agenda of the 20-23 July 2021 meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-07-27T17:12:00Z","last_updated_date":"2021-07-27T17:12:00Z","reference_number":"EMA/PDCO/364641/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-20-23-july-2021-meeting_en.pdf"},
    {"id":"52172","name":"Agenda - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting on 29 June 2021","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-08-02T17:31:00Z","last_updated_date":"2021-08-02T17:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting-29-june-2021_en.pdf"},
    {"id":"52203","name":"Agenda - PRAC draft agenda of meeting 5 August 2021","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-08-05T16:42:00Z","last_updated_date":"2021-08-05T16:42:00Z","reference_number":"EMA/PRAC/444131/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-5-august-2021_en.pdf"},
    {"id":"52219","name":"Agenda - CHMP agenda of the 16-19 August 2021 meeting: written procedure","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-08-16T09:56:00Z","last_updated_date":"2021-08-16T09:56:00Z","reference_number":"EMA/CHMP/455051/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-16-19-august-2021-meeting-written-procedure_en.pdf"},
    {"id":"52226","name":"CHMP ORGAM agenda for the meeting on 3 November 2020","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-08-16T16:48:00Z","last_updated_date":"2021-08-16T16:48:00Z","reference_number":"EMA/CHMP/555821/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-3-november-2020_en.pdf"},
    {"id":"52233","name":"CHMP ORGAM agenda for the meeting on 18 January 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-08-17T15:45:00Z","last_updated_date":"2021-08-17T15:45:00Z","reference_number":"EMA/CHMP/689695/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-orgam-agenda-meeting-18-january-2021_en.pdf"},
    {"id":"52295","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting on 21-22 September 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-08-30T12:11:00Z","last_updated_date":"2021-09-27T09:53:00Z","reference_number":"EMA/364259/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-and-consumers-pcwp-and-healthcare-professionals-hcpwp-working-parties-joint-meeting-21-22-september-2021_en.pdf"},
    {"id":"52300","name":"Agenda - PRAC draft agenda of meeting 30 August - 2 September 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-08-30T16:38:00Z","last_updated_date":"2021-08-30T16:38:00Z","reference_number":"EMA/PRAC/425079/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-30-august-2-september-2021_en.pdf"},
    {"id":"52353","name":"Agenda - COMP agenda of the 7-9 September 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-09-07T11:14:00Z","last_updated_date":"2021-09-07T11:14:00Z","reference_number":"EMA/COMP/490692/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-7-9-september-2021-meeting_en.pdf"}    {"id":"52357","name":"Agenda - CVMP agenda of the 7-9 September 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-09-07T13:37:00Z","last_updated_date":"2021-09-07T13:37:00Z","reference_number":"EMA/497915/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-7-9-september-2021-meeting_en.pdf"},
    {"id":"52358","name":"Agenda - CAT agenda of the 8-10 September 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-09-07T15:20:00Z","last_updated_date":"2021-09-07T15:20:00Z","reference_number":"EMA/CAT/468912/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-8-10-september-2021-meeting_en.pdf"},
    {"id":"52387","name":"Excel document that is now a zip file","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-09-09T10:31:00Z","last_updated_date":"2021-09-09T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/excel-document-now-zip-file_en.zip"},
    {"id":"52408","name":"Agenda - Union Product Database (UPD): webinar for marketing authorisation holders","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-09-09T16:42:00Z","last_updated_date":"2021-09-09T16:42:00Z","reference_number":"EMA/502482/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-union-product-database-upd-webinar-marketing-authorisation-holders_en.pdf"},
    {"id":"52410","name":"Agenda - PDCO agenda of the 7-10 September 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-09-09T17:09:00Z","last_updated_date":"2021-09-09T17:09:00Z","reference_number":"EMA/PDCO/494499/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-7-10-september-2021-meeting_en.pdf"},
    {"id":"52412","name":"Agenda - Webinar for SMEs and Academia on the Clinical Trial Regulation (Regulation (EU) No 536/2014) and the Clinical Trials Information System (CTIS)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-09-10T17:39:00Z","last_updated_date":"2021-11-25T12:30:00Z","reference_number":"EMA/323074/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-webinar-smes-and-academia-clinical-trial-regulation-regulation-eu-no-5362014-and-clinical-trials-information-system-ctis_en.pdf"},
    {"id":"52425","name":"Agenda - CHMP agenda of the 13-16 September 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-09-13T11:32:00Z","last_updated_date":"2021-09-13T11:32:00Z","reference_number":"EMA/CHMP/510466/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-13-16-september-2021-meeting_en.pdf"},
    {"id":"52459","name":"Agenda - DARWIN EU Advisory Board meeting: 28 June 2021","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T11:26:00Z","last_updated_date":"2021-09-17T11:26:00Z","reference_number":"EMA/350063/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-meeting-28-june-2021_en.pdf"},
    {"id":"52514","name":"Agenda - HMPC agenda of the 20-22 September 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-09-20T14:55:00Z","last_updated_date":"2021-09-20T14:55:00Z","reference_number":"EMA/HMPC/519371/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-20-22-september-2021-meeting_en.pdf"},
    {"id":"52551","name":"Agenda - Info day for micro, small and medium-sized enterprises (SMEs): EMA support for SMEs under the new Veterinary Medicinal Products Regulation","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T13:48:00Z","last_updated_date":"2021-10-14T10:23:00Z","reference_number":"EMA/529177/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-info-day-micro-small-and-medium-sized-enterprises-smes-ema-support-smes-under-new-veterinary-medicinal-products-regulation_en.pdf"},
    {"id":"52571","name":"Agenda - European Medicines Agency-Nuclear Medicines Europe meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-09-23T09:54:00Z","last_updated_date":"2021-09-23T09:54:00Z","reference_number":"EMA/531426/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-nuclear-medicines-europe-meeting_en.pdf"},
    {"id":"52640","name":"Agenda - PRAC draft agenda of meeting 27-30 September 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-09-27T15:22:00Z","last_updated_date":"2021-09-27T15:22:00Z","reference_number":"EMA/PRAC/483204/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-27-30-september-2021_en.pdf"},
    {"id":"52699","name":"Agenda - COMP agenda of the 5-7 October 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-01T15:17:00Z","last_updated_date":"2021-10-01T15:17:00Z","reference_number":"EMA/COMP/513657/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-5-7-october-2021-meeting_en.pdf"},
    {"id":"52720","name":"Agenda - CVMP agenda of the 5-7 October 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-04T16:12:00Z","last_updated_date":"2021-10-04T16:12:00Z","reference_number":"EMA/556577/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-5-7-october-2021-meeting_en.pdf"},
    {"id":"52757","name":"Agenda and registration form - European Medicines Agency EudraVigilance and signal management information day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-10-13T16:17:00Z","last_updated_date":"2021-10-13T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-european-medicines-agency-eudravigilance-and-signal-management-information-day_en.pdf-0"},
    {"id":"52769","name":"Agenda for the 113th meeting of the Management Board: 7 October 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-10-07T10:24:00Z","last_updated_date":"2021-10-07T10:24:00Z","reference_number":"EMA/MB/218267/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-113th-meeting-management-board-7-october-2021_en.pdf"},
    {"id":"52794","name":"Agenda - CAT agenda of the 6-8 October 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-08T15:34:00Z","last_updated_date":"2021-11-29T11:10:00Z","reference_number":"EMA/CAT/526882/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-6-8-october-2021-meeting_en.pdf"},
    {"id":"52803","name":"Agenda - CHMP agenda of the 11-14 October 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-11T16:21:00Z","last_updated_date":"2021-10-11T16:21:00Z","reference_number":"EMA/CHMP/573222/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-11-14-october-2021-meeting_en.pdf"},
    {"id":"52812","name":"Agenda - PDCO agenda of the 12-15 October 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-12T14:33:00Z","last_updated_date":"2021-10-12T14:33:00Z","reference_number":"EMA/PDCO/520091/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-15-october-2021-meeting_en.pdf"},
    {"id":"52819","name":"Agenda - Clinical Trials Information System (CTIS) Virtual Information Day: The Future User Perspective","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-10-13T09:10:00Z","last_updated_date":"2021-10-13T09:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-trials-information-system-ctis-virtual-information-day-future-user-perspective_en.pdf"},
    {"id":"52891","name":"Agenda - Training session for patients, consumers and healthcare professionals interested in EMA activities","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-21T14:39:00Z","last_updated_date":"2021-11-10T11:06:00Z","reference_number":"EMA/589101/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-patients-consumers-and-healthcare-professionals-interested-ema-activities_en.pdf-0"},
    {"id":"52896","name":"Agenda - PRAC draft agenda of meeting 25-28 October 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-25T17:03:00Z","last_updated_date":"2021-10-25T17:03:00Z","reference_number":"EMA/PRAC/544246/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-25-28-october-2021_en.pdf"},
    {"id":"52907","name":"Agenda - Public stakeholder meeting on COVID-19 vaccines and therapeutics in the EU","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-10-26T15:30:00Z","last_updated_date":"2021-11-22T08:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-public-stakeholder-meeting-covid-19-vaccines-and-therapeutics-eu_en.pdf"},
    {"id":"52912","name":"Agenda - Annual PCWP/HCPWP meeting with all eligible organisations","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-26T17:16:00Z","last_updated_date":"2021-12-01T17:52:00Z","reference_number":"EMA/516784/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-annual-pcwphcpwp-meeting-all-eligible-organisations_en.pdf"},
    {"id":"52937","name":"Draft agenda - Learnings initiative webinar for optimal use of big data for regulatory purpose","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-28T17:47:00Z","last_updated_date":"2021-11-23T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-learnings-initiative-webinar-optimal-use-big-data-regulatory-purpose_en.pdf"},
    {"id":"52964","name":"Agenda - COMP agenda of the 3 - 5 November 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-29T16:13:00Z","last_updated_date":"2021-10-29T16:13:00Z","reference_number":"EMA/COMP/576903/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-3-5-november-2021-meeting_en.pdf"},
    {"id":"52967","name":"Agenda - Union Pharmacovigilance Database: webinar on adverse event collection and recording","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-10-29T17:44:00Z","last_updated_date":"2021-11-05T15:33:00Z","reference_number":"EMA/597574/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-union-pharmacovigilance-database-webinar-adverse-event-collection-and-recording_en.pdf"},
    {"id":"52977","name":"Agenda - CAT agenda of the 3-5 November 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-11-03T11:24:00Z","last_updated_date":"2021-11-03T11:24:00Z","reference_number":"EMA/CAT/618998/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-3-5-november-2021-meeting_en.pdf"},
    {"id":"52978","name":"Agenda - CVMP agenda of the 3-5 November 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-11-03T11:34:00Z","last_updated_date":"2021-11-03T11:34:00Z","reference_number":"EMA/619106/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-3-5-november-2021-meeting_en.pdf"},
    {"id":"53008","name":"Agenda - CHMP agenda of the 8-11 November 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-11-08T10:21:00Z","last_updated_date":"2021-11-08T10:21:00Z","reference_number":"EMA/CHMP/625918/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-8-11-november-2021-meeting_en.pdf"},
    {"id":"53013","name":"Agenda - First EMA-COCIR bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-11-09T14:59:00Z","last_updated_date":"2021-11-09T14:59:00Z","reference_number":"EMA/398757/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-ema-cocir-bilateral-meeting_en.pdf"},
    {"id":"53015","name":"Agenda - 2021 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA (Enpr-EMA)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T16:31:00Z","last_updated_date":"2021-11-09T16:31:00Z","reference_number":"EMA/439238/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2021-annual-meeting-members-and-coordinating-group-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"53022","name":"Agenda - European Medicines Agency veterinary medicines info day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-11-08T16:49:00Z","last_updated_date":"2021-11-25T15:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-veterinary-medicines-info-day_en.pdf-0"},
    {"id":"53042","name":"Agenda - PDCO agenda of the 9-12 November 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-11-09T17:02:00Z","last_updated_date":"2021-11-09T17:02:00Z","reference_number":"EMA/PDCO/598143/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-9-12-november-2021-meeting_en.pdf"},
    {"id":"53104","name":"Draft agenda - Union Pharmacovigilance Database - webinar on signal detection and analysis","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-11-12T10:35:00Z","last_updated_date":"2021-11-12T10:35:00Z","reference_number":"EMA/609109/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-union-pharmacovigilance-database-webinar-signal-detection-and-analysis_en.pdf"},
    {"id":"53108","name":"Programme and registration form - Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on Training Course using the EudraVigilance System (Feb-Jul 2022)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:38:00Z","last_updated_date":"2022-03-09T11:12:00Z","reference_number":"Course #22500, Course #22501, Course #22502, Course #22504, Course #22505, Course #22505","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-mandatory-use-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-feb-jul-2022_en.pdf"},
    {"id":"53110","name":"Programme and registration form - Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on Training Course using the EudraVigilance System (May 2022)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:38:00Z","last_updated_date":"2022-05-02T11:52:00Z","reference_number":"Course #22503","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-mandatory-use-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-may-2022_en.pdf"},
    {"id":"53140","name":"Agenda - Webinar on veterinary pharmacovigilance (PhV) inspections and systems, their quality management systems and PhV system master files: Introduction and principles","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-11-17T09:18:00Z","last_updated_date":"2021-11-22T14:49:00Z","reference_number":"EMA/618317/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-webinar-veterinary-pharmacovigilance-phv-inspections-and-systems-their-quality-management-systems-and-phv-system-master-files-introduction-and-principles_en.pdf"},
    {"id":"53148","name":"Agenda - European Medicines Agency (EMA) and Federation of Veterinarians of Europe (FVE) webinar on data collection on sales and use of antimicrobials","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-11-18T11:20:00Z","last_updated_date":"2021-11-23T16:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-and-federation-veterinarians-europe-fve-webinar-data-collection-sales-and-use-antimicrobials_en.pdf"},
    {"id":"53188","name":"Agenda - EU Big Data Stakeholder Forum 2021","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T16:40:00Z","last_updated_date":"2021-12-06T14:20:00Z","reference_number":"EMA/109720/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eu-big-data-stakeholder-forum-2021_en.pdf"},
    {"id":"53193","name":"Agenda - HMPC agenda of the 22-24 November 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-11-22T09:12:00Z","last_updated_date":"2021-11-22T09:12:00Z","reference_number":"EMA/HMPC/570052/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-agenda-22-24-november-2021-meeting_en.pdf"},
    {"id":"53325","name":"Agenda - PRAC draft agenda of meeting 29 November-02 December 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-11-29T15:43:00Z","last_updated_date":"2021-11-29T15:43:00Z","reference_number":"EMA/PRAC/611142/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-29-november-02-december-2021_en.pdf"},
    {"id":"53329","name":"Agenda - Seventh meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicine","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T16:55:00Z","last_updated_date":"2021-11-29T16:55:00Z","reference_number":"EMA/701495/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-seventh-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicine_en.pdf"},
    {"id":"53352","name":"Agenda - 16th industry stakeholder platform - operation of European Union (EU) pharmacovigilance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2021-12-02T15:52:00Z","last_updated_date":"2021-12-02T15:52:00Z","reference_number":"EMA/526063/2021 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-16th-industry-stakeholder-platform-operation-european-union-eu-pharmacovigilance_en.pdf"},
    {"id":"53366","name":"Agenda - COMP agenda of the 7-9 December 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-12-06T12:10:00Z","last_updated_date":"2021-12-06T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-agenda-7-9-december-2021-meeting_en.pdf"},
    {"id":"53383","name":"Agenda - CVMP agenda of the 7-9 December 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-12-07T12:05:00Z","last_updated_date":"2021-12-07T12:05:00Z","reference_number":"EMA/722972/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-agenda-7-9-december-2021-meeting_en.pdf"},
    {"id":"53384","name":"CHMP PROM agenda for the meeting on 15 February 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T12:02:00Z","last_updated_date":"2021-12-07T12:02:00Z","reference_number":"EMA/CHMP/62546/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-15-february-2021_en.pdf"},
    {"id":"53386","name":"CHMP PROM agenda for the meeting on 15 March 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T12:30:00Z","last_updated_date":"2021-12-07T12:30:00Z","reference_number":"EMA/CHMP/128280/2021 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-15-march-2021_en.pdf"},
    {"id":"53392","name":"CHMP PROM agenda for the meeting on 12 April 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-12-07T13:58:00Z","last_updated_date":"2021-12-07T13:58:00Z","reference_number":"EMA/CHMP/188718/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-12-april-2021_en.pdf"},
    {"id":"53393","name":"CHMP PROM agenda for the meeting on  10 May 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-12-07T14:18:00Z","last_updated_date":"2021-12-07T14:18:00Z","reference_number":"EMA/CHMP/250952/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-10-may-2021_en.pdf"},
    {"id":"53396","name":"CHMP PROM agenda for the meeting on 14 June 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T14:39:00Z","last_updated_date":"2021-12-07T14:39:00Z","reference_number":"EMA/CHMP/287712/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-14-june-2021_en.pdf"},
    {"id":"53402","name":"Agenda - DADI webinar - Introducing DADI: The digital application dataset integration network project to replace electronic application forms","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-12-08T17:24:00Z","last_updated_date":"2021-12-20T11:19:00Z","reference_number":"EMA/729279/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-dadi-webinar-introducing-dadi-digital-application-dataset-integration-network-project-replace-electronic-application-forms_en.pdf"},
    {"id":"53403","name":"Agenda - DADI webinar - Common factors in the fast healthcare interoperability resources (FHIR) data standard for Art.57(2) and eAF","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-12-08T09:42:00Z","last_updated_date":"2022-01-25T14:52:00Z","reference_number":"EMA/729278/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-dadi-webinar-common-factors-fast-healthcare-interoperability-resources-fhir-data-standard-art572-and-eaf_en.pdf"},
    {"id":"53404","name":"Agenda - CAT agenda of the 8-10 December 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-12-08T10:31:00Z","last_updated_date":"2021-12-08T10:31:00Z","reference_number":"EMA/CAT/685109/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-8-10-december-2021-meeting_en.pdf"},
    {"id":"53446","name":"Agenda - CHMP agenda of the 13-16 December 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-12-13T10:08:00Z","last_updated_date":"2021-12-13T10:08:00Z","reference_number":"EMA/CHMP/745698/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-13-16-december-2021-meeting_en.pdf"},
    {"id":"53456","name":"Agenda - Regulatory science research needs (RSRN) launch event","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-12-15T17:00:00Z","last_updated_date":"2022-01-17T14:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-regulatory-science-research-needs-rsrn-launch-event_en.pdf"},
    {"id":"53504","name":"Agenda - PDCO agenda of the 14-17 December 2021 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-12-14T16:25:00Z","last_updated_date":"2021-12-14T16:25:00Z","reference_number":"EMA/PDCO/695889/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-14-17-december-2021-meeting_en.pdf"},
    {"id":"53527","name":"Agenda for the 114th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-12-15T15:13:00Z","last_updated_date":"2021-12-20T10:45:00Z","reference_number":"EMA/MB/521726/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-114th-meeting-management-board_en.pdf"},
    {"id":"53588","name":"Agenda - Nitrosamine Implementation Oversight Group (NIOG) - second meeting with pharmaceutical industry","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T14:18:00Z","last_updated_date":"2021-12-17T14:18:00Z","reference_number":"EMA/535229/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-nitrosamine-implementation-oversight-group-niog-second-meeting-pharmaceutical-industry_en.pdf"},
    {"id":"53652","name":"Agenda - Union Pharmacovigilance Database: follow up webinar on collection and recording of suspected adverse events (AEs) for veterinary medicinal products","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-01-07T14:21:00Z","last_updated_date":"2022-01-07T14:21:00Z","reference_number":"EMA/752268/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-union-pharmacovigilance-database-follow-webinar-collection-and-recording-suspected-adverse-events-aes-veterinary-medicinal-products_en.pdf"},
    {"id":"53674","name":"Agenda of the PRAC meeting 10 - 13 January 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-01-10T17:26:00Z","last_updated_date":"2022-01-10T17:26:00Z","reference_number":"EMA/PRAC/13739/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-10-13-january-2022_en.pdf"},
    {"id":"53676","name":"Agenda - DARWIN EU Advisory Board meeting: 20 September 2021","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-01-11T09:26:00Z","last_updated_date":"2022-01-11T09:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-meeting-20-september-2021_en.pdf"},
    {"id":"53678","name":"Agenda  - DARWIN EU Advisory Board meeting (12 November 2021)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-01-11T09:34:00Z","last_updated_date":"2022-01-11T09:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-meeting-12-november-2021_en.pdf"},
    {"id":"53731","name":"Agenda - Union Pharmacovigilance Database: follow up webinar on signal detection, evaluation and yearly reporting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T15:28:00Z","last_updated_date":"2022-01-14T15:28:00Z","reference_number":"EMA/6754/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-union-pharmacovigilance-database-follow-webinar-signal-detection-evaluation-and-yearly-reporting_en.pdf"},
    {"id":"53736","name":"Programme - Clinical Trials Information System (CTIS) sponsor end user training programme - January 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T16:33:00Z","last_updated_date":"2022-01-14T16:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-clinical-trials-information-system-ctis-sponsor-end-user-training-programme-january-2022_en.pdf"},
    {"id":"53770","name":"Agenda of the COMP meeting 18-20 January 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-01-17T17:14:00Z","last_updated_date":"2022-01-17T17:14:00Z","reference_number":"EMA/COMP/749019/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-18-20-january-2022_en.pdf"},
    {"id":"53776","name":"Agenda of the CVMP meeting 18-20 January 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-01-18T08:36:00Z","last_updated_date":"2022-01-18T08:36:00Z","reference_number":"EMA/27915/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-18-20-january-2022_en.pdf"},
    {"id":"53824","name":"Agenda of the PDCO meeting 18-21 January 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-01-18T17:35:00Z","last_updated_date":"2022-01-18T17:35:00Z","reference_number":"EMA/PDCO/5821/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-18-21-january-2022_en.pdf"},
    {"id":"53826","name":"CHMP PROM agenda for the meeting on 12 July 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-01-19T09:07:00Z","last_updated_date":"2022-01-19T09:07:00Z","reference_number":"EMA/CHMP/363904/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-12-july-2021_en.pdf"},
    {"id":"53829","name":"CHMP PROM agenda for the meeting on 6 September 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-01-19T09:19:00Z","last_updated_date":"2022-01-19T09:19:00Z","reference_number":"EMA/CHMP/429582/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-6-september-2021_en.pdf"},
    {"id":"53853","name":"Agenda of the CAT meeting 19-21 January 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-01-20T12:20:00Z","last_updated_date":"2022-01-20T12:20:00Z","reference_number":"EMA/CAT/778538/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-19-21-january-2022_en.pdf"},
    {"id":"53854","name":"CHMP PROM agenda for the meeting on 4 October 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-01-20T12:25:00Z","last_updated_date":"2022-01-20T12:25:00Z","reference_number":"EMA/CHMP/529450/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-4-october-2021_en.pdf"},
    {"id":"53855","name":"Agenda – Union Product Database: follow up webinar for marketing authorisation holders","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-01-20T12:32:00Z","last_updated_date":"2022-01-20T12:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-union-product-database-follow-webinar-marketing-authorisation-holders_en.pdf"},
    {"id":"53856","name":"CHMP PROM agenda for the meeting on 3 November 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-01-20T12:40:00Z","last_updated_date":"2022-01-20T12:40:00Z","reference_number":"EMA/CHMP/591197/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-3-november-2021_en.pdf"},
    {"id":"53891","name":"Agenda of the CHMP meeting 24-27 January 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-01-24T12:53:00Z","last_updated_date":"2022-01-24T12:53:00Z","reference_number":"EMA/CHMP/778542/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-24-27-january-2022_en.pdf"},
    {"id":"53897","name":"Agenda of the HMPC meeting 24-26 January 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-01-24T15:56:00Z","last_updated_date":"2022-01-24T15:56:00Z","reference_number":"EMA/HMPC/32469/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-24-26-january-2022_en.pdf"},
    {"id":"54059","name":"Programme - Clinical Trials Information System (CTIS) sponsor end user training programme - 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T13:39:00Z","last_updated_date":"2022-02-03T13:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-clinical-trials-information-system-ctis-sponsor-end-user-training-programme-2022_en.pdf"},
    {"id":"54096","name":"Agenda of the PRAC meeting 7-10 February 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-02-08T08:52:00Z","last_updated_date":"2022-02-08T08:52:00Z","reference_number":"EMA/PRAC/76191/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-7-10-february-2022_en.pdf"},
    {"id":"54103","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting on 2-3 March 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T16:14:00Z","last_updated_date":"2022-03-08T12:58:00Z","reference_number":"EMA/15726/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-and-consumers-pcwp-and-healthcare-professionals-hcpwp-working-parties-joint-meeting-2-3-march-2022_en.pdf"},
    {"id":"54108","name":"Agenda - Committee for Advanced Therapies (CAT) meeting with interested parties - October 2021","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T17:33:00Z","last_updated_date":"2022-02-08T17:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-committee-advanced-therapies-cat-meeting-interested-parties-october-2021_en.pdf"},
    {"id":"54124","name":"Agenda - Demonstration for CTIS stakeholders on the functionalities of the Clinical Trials Information System","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-02-10T14:25:00Z","last_updated_date":"2022-02-10T14:25:00Z","reference_number":"EMA/28670/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-demonstration-ctis-stakeholders-functionalities-clinical-trials-information-system_en.pdf"},
    {"id":"54126","name":"CHMP PROM agenda for the meeting on 6 December 2021","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-02-10T14:42:00Z","last_updated_date":"2022-02-10T14:42:00Z","reference_number":"EMA/CHMP/678431/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-6-december-2021_en.pdf"},
    {"id":"54165","name":"Agenda of the CVMP meeting 15-17 February 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-02-15T11:06:00Z","last_updated_date":"2022-02-15T11:06:00Z","reference_number":"EMA/96832/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-15-17-february-2022_en.pdf"},
    {"id":"54199","name":"Agenda of the CAT meeting 16-17 February 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-02-16T17:01:00Z","last_updated_date":"2022-02-16T17:01:00Z","reference_number":"EMA/CAT/58286/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-16-17-february-2022_en.pdf"},
    {"id":"54228","name":"Agenda of the COMP meeting 15-17 February 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-02-21T10:38:00Z","last_updated_date":"2022-02-21T10:38:00Z","reference_number":"EMA/COMP/98856/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-15-17-february-2022_en.pdf"},
    {"id":"54238","name":"Agenda of the CHMP meeting 21-24 February 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-02-21T14:19:00Z","last_updated_date":"2022-02-21T14:19:00Z","reference_number":"EMA/CHMP/60787/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-21-24-february-2022_en.pdf"},
    {"id":"54256","name":"Agenda - Third European Medicines Agency and Association of the European Self-Medication Industry (AESGP) annual bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T14:10:00Z","last_updated_date":"2022-02-23T14:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-european-medicines-agency-and-association-european-self-medication-industry-aesgp-annual-bilateral-meeting_en.pdf"},
    {"id":"54257","name":"Agenda - DARWIN EU: multi-stakeholder information webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T09:34:00Z","last_updated_date":"2022-02-23T09:34:00Z","reference_number":"EMA/77537/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-multi-stakeholder-information-webinar_en.pdf"},
    {"id":"54260","name":"CHMP PROM agenda for the meeting on 17 January 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-02-23T09:57:00Z","last_updated_date":"2022-02-23T09:57:00Z","reference_number":"EMA/CHMP/6647/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-17-january-2022_en.pdf"},
    {"id":"54301","name":"Agenda of the PDCO meeting 22-25 February 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-02-25T11:29:00Z","last_updated_date":"2022-02-25T11:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-22-25-february-2022_en.pdf"},
    {"id":"54333","name":"Agenda - DARWIN EU Advisory Board meeting: 16 February 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-03-02T17:09:00Z","last_updated_date":"2022-03-02T17:09:00Z","reference_number":"EMA/51604/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-meeting-16-february-2022_en.pdf"},
    {"id":"54361","name":"Agenda - Multistakeholder workshop on EMA’s extended mandate","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-03-07T11:31:00Z","last_updated_date":"2022-04-05T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multistakeholder-workshop-emas-extended-mandate_en.pdf"},
    {"id":"54364","name":"Agenda of the PRAC meeting 7-10 March 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-03-07T14:04:00Z","last_updated_date":"2022-03-07T14:04:00Z","reference_number":"EMA/PRAC/76497/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-7-10-march-2022_en.pdf"},
    {"id":"54466","name":"Agenda of the CVMP meeting 15-17 March 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-03-15T11:09:00Z","last_updated_date":"2022-03-15T11:09:00Z","reference_number":"EMA/154330/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-15-17-march-2022_en.pdf"},
    {"id":"54489","name":"Agenda of the CAT meeting 16-18 March 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-03-16T16:40:00Z","last_updated_date":"2022-03-16T16:40:00Z","reference_number":"EMA/CAT/135722/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-16-18-march-2022_en.pdf"},
    {"id":"54490","name":"Agenda for the 115th meeting of the Management Board: 16-17 March 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-03-16T15:46:00Z","last_updated_date":"2022-03-18T16:34:00Z","reference_number":"EMA/MB/30014/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-115th-meeting-management-board-16-17-march-2022_en.pdf"},
    {"id":"54491","name":"Agenda of the COMP meeting 15-17 March 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-03-16T17:08:00Z","last_updated_date":"2022-03-16T17:08:00Z","reference_number":"EMA/COMP/149289/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-15-17-march-2022_en.pdf"},
    {"id":"54523","name":"Agenda of the CHMP meeting 21-24 March 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-03-21T09:48:00Z","last_updated_date":"2022-03-21T09:48:00Z","reference_number":"EMA/CHMP/125434/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-21-24-march-2022_en.pdf"},
    {"id":"54524","name":"Agenda - Fourth European Medicines Agency and European Federation of Pharmaceutical Industries and Associations annual bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-03-21T10:03:00Z","last_updated_date":"2022-03-21T10:03:00Z","reference_number":"EMA/166473/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-european-medicines-agency-and-european-federation-pharmaceutical-industries-and-associations-annual-bilateral-meeting_en.pdf"},
    {"id":"54543","name":"Agenda of the PDCO meeting 22-25 March 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-03-22T14:50:00Z","last_updated_date":"2022-03-22T14:50:00Z","reference_number":"EMA/PDCO/128811/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-22-25-march-2022_en.pdf"}    {"id":"54545","name":"Agenda - Data quality framework for medicines regulation","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-03-22T15:07:00Z","last_updated_date":"2022-04-06T15:03:00Z","reference_number":"EMA/172989/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-data-quality-framework-medicines-regulation_en.pdf"},
    {"id":"54606","name":"Agenda of the HMPC meeting 28-30 March 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-03-29T10:07:00Z","last_updated_date":"2022-03-29T10:07:00Z","reference_number":"EMA/HMPC/116513/2022 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-28-30-march-2022_en.pdf"},
    {"id":"54669","name":"Agenda of the PRAC meeting 4-7 April 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-04-04T17:05:00Z","last_updated_date":"2022-04-04T17:05:00Z","reference_number":"EMA/PRAC/142420/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-4-7-april-2022_en.pdf"},
    {"id":"54718","name":"Agenda of the CVMP meeting 11-13 April 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-04-11T12:26:00Z","last_updated_date":"2022-04-11T12:26:00Z","reference_number":"EMA/213330/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-11-13-april-2022_en.pdf"},
    {"id":"54719","name":"Agenda of the CAT meeting 11-13 April 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-04-11T12:35:00Z","last_updated_date":"2022-04-11T12:35:00Z","reference_number":"EMA/CAT/184995/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-11-13-april-2022_en.pdf"},
    {"id":"54721","name":"Agenda of the COMP meeting 11-13 April 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-04-11T15:00:00Z","last_updated_date":"2022-04-11T15:00:00Z","reference_number":"EMA/COMP/209670/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-11-13-april-2022_en.pdf"},
    {"id":"54722","name":"Agenda - Enpr-EMA Coordinating Group and networks meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T16:12:00Z","last_updated_date":"2022-04-11T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-and-networks-meeting_en.pdf"},
    {"id":"54758","name":"Agenda of the CHMP meeting 19-22 April 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-04-19T10:24:00Z","last_updated_date":"2022-04-21T12:23:00Z","reference_number":"EMA/CHMP/184332/2022 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-19-22-april-2022_en.pdf"},
    {"id":"54780","name":"Agenda of the PDCO meeting 19-22 April 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-04-21T13:48:00Z","last_updated_date":"2022-09-19T09:39:00Z","reference_number":"EMA/PDCO/188592/2022 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-19-22-april-2022_en.pdf"},
    {"id":"54872","name":"Agenda of the PRAC meeting 2-5 May 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-05-02T14:50:00Z","last_updated_date":"2022-05-02T14:50:00Z","reference_number":"EMA/PRAC/198890/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-2-5-may-2022_en.pdf"},
    {"id":"54874","name":"Agenda - Digital application dataset integration (DADI) and Product Management Service (PMS) webinar - Variations form for human medicinal products - What will happen at go-live","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-05-02T15:34:00Z","last_updated_date":"2022-05-11T16:24:00Z","reference_number":"EMA/226955/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-digital-application-dataset-integration-dadi-and-product-management-service-pms-webinar-variations-form-human-medicinal-products-what-will-happen-go-live_en.pdf"},
    {"id":"54880","name":"Agenda - European Medicines Agency veterinary medicines info day 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-05-03T13:56:00Z","last_updated_date":"2022-05-11T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-veterinary-medicines-info-day-2022_en.pdf"},
    {"id":"54926","name":"Agenda of the CVMP meeting 10-12 May 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-05-10T12:06:00Z","last_updated_date":"2022-05-10T12:06:00Z","reference_number":"EMA/258586/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-10-12-may-2022_en.pdf"},
    {"id":"54932","name":"Agenda of the COMP meeting 10-12 May 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-05-11T10:41:00Z","last_updated_date":"2022-05-11T10:41:00Z","reference_number":"EMA/COMP/262112/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-10-12-may-2022_en.pdf"},
    {"id":"54944","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-05-11T15:37:00Z","last_updated_date":"2022-05-11T15:37:00Z","reference_number":"EMA/127956/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg_en.pdf-1"},
    {"id":"54950","name":"Agenda of the CAT meeting 11-13 May 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-05-11T16:27:00Z","last_updated_date":"2022-05-11T16:27:00Z","reference_number":"EMA/CAT/231456/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-11-13-may-2022_en.pdf"},
    {"id":"54962","name":"Agenda of the CHMP meeting 16-19 May 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-05-16T10:53:00Z","last_updated_date":"2022-06-29T11:42:00Z","reference_number":"EMA/CHMP/234723/2022 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-16-19-may-2022_en.pdf"},
    {"id":"54963","name":"Agenda of the HMPC meeting 16-18 May 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-05-16T13:17:00Z","last_updated_date":"2022-05-16T13:17:00Z","reference_number":"EMA/HMPC/225479/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-16-18-may-2022_en.pdf"},
    {"id":"54981","name":"Agenda of the PDCO meeting 17-20 May 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-05-18T10:47:00Z","last_updated_date":"2022-05-18T10:47:00Z","reference_number":"EMA/PDCO/233334/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-17-20-may-2022_en.pdf"},
    {"id":"55006","name":"Draft agenda - PCWP/HCPWP joint meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-05-19T11:13:00Z","last_updated_date":"2022-05-19T11:13:00Z","reference_number":"EMA/72089/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-pcwphcpwp-joint-meeting_en.pdf"},
    {"id":"55088","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-05-24T15:37:00Z","last_updated_date":"2022-06-03T13:36:00Z","reference_number":"EMA/277567/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg_en.pdf-0"},
    {"id":"55095","name":"Agenda - Nitrosamine Implementation Oversight Group (NIOG) - third meeting with pharmaceutical industry","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-05-25T14:18:00Z","last_updated_date":"2022-05-25T14:18:00Z","reference_number":"EMA/171422/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-nitrosamine-implementation-oversight-group-niog-third-meeting-pharmaceutical-industry_en.pdf"},
    {"id":"55132","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-06-07T15:37:00Z","last_updated_date":"2022-06-07T15:37:00Z","reference_number":"EMA/278388/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg_en.pdf"},
    {"id":"55133","name":"Agenda - European Medicines Agency and EuropaBio annual bilateral meeting 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-06-07T12:21:00Z","last_updated_date":"2022-06-07T12:21:00Z","reference_number":"EMA/159475/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-and-europabio-annual-bilateral-meeting-2022_en.pdf"},
    {"id":"55169","name":"Agenda of the COMP meeting 14-16 June 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-06-09T12:53:00Z","last_updated_date":"2022-06-09T12:53:00Z","reference_number":"EMA/COMP/577731/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-14-16-june-2022_en.pdf"},
    {"id":"55231","name":"Agenda - Big Data Steering Group and industry stakeholders meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-06-14T11:47:00Z","last_updated_date":"2022-06-14T11:47:00Z","reference_number":"EMA/259766/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-big-data-steering-group-and-industry-stakeholders-meeting_en.pdf"},
    {"id":"55233","name":"Agenda of the CVMP meeting 14-15 June 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-06-14T11:53:00Z","last_updated_date":"2022-06-14T11:53:00Z","reference_number":"EMA/583174/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-14-15-june-2022_en.pdf"},
    {"id":"55246","name":"Agenda and registration form - Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: Hands-on training course on using the EudraVigilance system","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-06-15T11:00:00Z","last_updated_date":"2022-06-15T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-mandatory-use-isoich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system_en.pdf"},
    {"id":"55248","name":"Agenda of the CAT meeting 15-17 June 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-06-15T14:35:00Z","last_updated_date":"2022-06-15T14:35:00Z","reference_number":"EMA/CAT/376180/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-15-17-june-2022_en.pdf"},
    {"id":"55249","name":"Agenda and registration form - Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-06-15T15:49:00Z","last_updated_date":"2022-06-15T15:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system_en.pdf"},
    {"id":"55256","name":"Agenda for the 116th meeting of the Management Board","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-06-16T11:49:00Z","last_updated_date":"2022-06-17T18:27:00Z","reference_number":"EMA/MB/94596/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-116th-meeting-management-board_en.pdf"},
    {"id":"55289","name":"Agenda - Eighth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicine","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-06-20T16:55:00Z","last_updated_date":"2022-06-20T16:55:00Z","reference_number":"EMA/590258/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eighth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicine_en.pdf"},
    {"id":"55291","name":"Agenda of the CHMP meeting 20-23 June 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-06-20T10:04:00Z","last_updated_date":"2022-06-20T10:04:00Z","reference_number":"EMA/CHMP/298604/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-20-23-june-2022_en.pdf"},
    {"id":"55314","name":"Agenda of the PDCO meeting 21-24 June 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-06-21T16:04:00Z","last_updated_date":"2022-06-21T16:04:00Z","reference_number":"EMA/PDCO/557550/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-21-24-june-2022_en.pdf"},
    {"id":"55372","name":"Agenda - First industry standing group (ISG) meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:17:00Z","last_updated_date":"2022-06-24T15:17:00Z","reference_number":"EMA/601355/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"55393","name":"Programme and registration form - eXtended EudraVigilance Medicinal Product Dictionary training courses - September, October, November 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-06-28T10:58:00Z","last_updated_date":"2022-06-28T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-training-courses-september-october-november-2022_en.pdf"},
    {"id":"55394","name":"Programme and registration form - eXtended EudraVigilance Medicinal Product Dictionary live virtual training course for sponsors - September, October, November 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-06-28T11:22:00Z","last_updated_date":"2022-06-28T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-live-virtual-training-course-sponsors-september-october-november-2022_en.pdf"},
    {"id":"55406","name":"Agenda - European Medicines Agency (EMA) and Federation of Veterinarians of Europe (FVE) webinar on the Union Product Database website","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-06-29T13:22:00Z","last_updated_date":"2022-06-29T13:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-and-federation-veterinarians-europe-fve-webinar-union-product-database-website_en.pdf"},
    {"id":"55423","name":"Agenda - Clinical Trials Information System (CTIS) webinar: Six months of CTIS and looking forward","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-06-30T14:53:00Z","last_updated_date":"2022-06-30T14:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-trials-information-system-ctis-webinar-six-months-ctis-and-looking-forward_en.pdf"},
    {"id":"55450","name":"Agenda of the PRAC meeting 4-7 July 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-04T14:14:00Z","last_updated_date":"2022-07-04T14:14:00Z","reference_number":"EMA/PRAC/573334/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-4-7-july-2022_en.pdf"},
    {"id":"55451","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (7 July 2022)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-04T14:31:00Z","last_updated_date":"2022-07-04T14:31:00Z","reference_number":"EMA/568151/2022EMA/568151/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-7-july-2022_en.pdf"},
    {"id":"55468","name":"Agenda - DADI webinar - Variations form for human medicinal products","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-07-06T09:23:00Z","last_updated_date":"2022-07-06T09:23:00Z","reference_number":"EMA/627535/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-dadi-webinar-variations-form-human-medicinal-products_en.pdf"},
    {"id":"55472","name":"Agenda - Understanding the pathophysiology of thrombosis with thrombocytopenia syndrome (TTS) and discussing next steps in research","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-06T14:34:00Z","last_updated_date":"2022-07-06T14:34:00Z","reference_number":"EMA/210541/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-understanding-pathophysiology-thrombosis-thrombocytopenia-syndrome-tts-and-discussing-next-steps-research_en.pdf"},
    {"id":"55499","name":"Draft agenda - PCWP and HCPWP meeting - 22 September 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-08T10:50:00Z","last_updated_date":"2022-09-20T11:00:00Z","reference_number":"EMA/271431/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-pcwp-and-hcpwp-meeting-22-september-2022_en.pdf"},
    {"id":"55513","name":"Agenda of the CVMP meeting 12-14 July 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-12T09:40:00Z","last_updated_date":"2022-07-12T09:40:00Z","reference_number":"EMA/636044/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-12-14-july-2022_en.pdf"},
    {"id":"55515","name":"Agenda - DARWIN EU Advisory Board meeting: 20 April 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-07-12T11:39:00Z","last_updated_date":"2022-07-12T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-meeting-20-april-2022_en.pdf"},
    {"id":"55523","name":"Agenda of the COMP meeting 12-14 July 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-12T15:18:00Z","last_updated_date":"2022-07-12T15:18:00Z","reference_number":"EMA/COMP/602828/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-12-14-july-2022_en.pdf"},
    {"id":"55524","name":"Agenda of the CAT meeting 13-15 July 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-12T15:45:00Z","last_updated_date":"2022-07-12T15:45:00Z","reference_number":"EMA/CAT/613798/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-13-15-july-2022_en.pdf"},
    {"id":"55529","name":"Agenda - DARWIN EU Advisory Board meeting: 6 July 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-07-13T11:30:00Z","last_updated_date":"2022-07-13T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-meeting-6-july-2022_en.pdf"},
    {"id":"55530","name":"Agenda of the HMPC meeting 18-20 July 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-13T11:47:00Z","last_updated_date":"2022-07-13T11:47:00Z","reference_number":"EMA/HMPC/637772/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-18-20-july-2022_en.pdf"},
    {"id":"55555","name":"Agenda - Eight industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:56:00Z","last_updated_date":"2022-07-14T16:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eight-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"55560","name":"Agenda and registration form - DADI PDF electronic application forms (eAF) training webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-07-15T14:36:00Z","last_updated_date":"2022-07-15T14:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-dadi-pdf-electronic-application-forms-eaf-training-webinar_en.pdf"},
    {"id":"55561","name":"Agenda and registration form - DADI PDF electronic application forms (eAF) training webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-07-15T14:48:00Z","last_updated_date":"2022-07-15T14:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-dadi-pdf-electronic-application-forms-eaf-training-webinar_en.pdf-0"},
    {"id":"55563","name":"Agenda of the CHMP meeting 18-21 July 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-18T09:31:00Z","last_updated_date":"2022-07-18T09:31:00Z","reference_number":"EMA/CHMP/608233/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-18-21-july-2022_en.pdf"},
    {"id":"55584","name":"Agenda of the PDCO meeting 19-22 July 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-19T10:37:00Z","last_updated_date":"2022-07-19T10:37:00Z","reference_number":"EMA/PDCO/639568/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-19-22-july-2022_en.pdf"},
    {"id":"55671","name":"Agenda - Multi-stakeholder workshop: Patient experience data in medicines development and regulatory decision-making","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T17:15:00Z","last_updated_date":"2022-09-20T11:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-workshop-patient-experience-data-medicines-development-and-regulatory-decision-making_en.pdf"},
    {"id":"55732","name":"Agenda - EMA IRIS industry training for GVP Inspections","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-07-29T11:36:00Z","last_updated_date":"2022-08-09T16:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-iris-industry-training-gvp-inspections_en.pdf"},
    {"id":"55815","name":"CHMP PROM agenda for the meeting on 14 March 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-08-12T09:23:00Z","last_updated_date":"2022-08-12T09:23:00Z","reference_number":"EMA/CHMP/121881/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-14-march-2022_en.pdf"},
    {"id":"55817","name":"CHMP PROM agenda for the meeting on  11 April 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-08-12T09:58:00Z","last_updated_date":"2022-08-12T09:58:00Z","reference_number":"EMA/CHMP/183772/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-11-april-2022_en.pdf"},
    {"id":"55822","name":"CHMP PROM agenda for the meeting on 13 June 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-08-12T16:35:00Z","last_updated_date":"2022-08-12T16:35:00Z","reference_number":"EMA/CHMP/288113/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-13-june-2022_en.pdf"},
    {"id":"55824","name":"Agenda of the CHMP written procedure 16-19 August 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-08-16T09:16:00Z","last_updated_date":"2022-08-16T09:16:00Z","reference_number":"EMA/691785/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-written-procedure-16-19-august-2022_en.pdf"},
    {"id":"55881","name":"Agenda of the PRAC meeting 29 August - 1 September 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-08-29T17:58:00Z","last_updated_date":"2022-08-29T17:58:00Z","reference_number":"EMA/PRAC/626661/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-29-august-1-september-2022_en.pdf"},
    {"id":"55927","name":"Agenda of the COMP meeting 6-8 September 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-01T13:21:00Z","last_updated_date":"2022-09-01T13:21:00Z","reference_number":"EMA/COMP/653513/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-6-8-september-2022_en.pdf"},
    {"id":"55949","name":"Agenda - Enpr-EMA Coordinating Group meeting (June 2022)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T16:12:00Z","last_updated_date":"2022-09-02T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-meeting-june-2022_en.pdf"},
    {"id":"55969","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (2 September 2022)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-02T16:52:00Z","last_updated_date":"2022-09-02T16:52:00Z","reference_number":"EMA/713188/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-2-september-2022_en.pdf"},
    {"id":"55981","name":"Agenda - Union Product Database: webinar on variations not requiring assessment (VNRAs) for marketing authorisation holders","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T15:24:00Z","last_updated_date":"2022-09-05T15:24:00Z","reference_number":"EMA/704900/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-union-product-database-webinar-variations-not-requiring-assessment-vnras-marketing-authorisation-holders_en.pdf"},
    {"id":"55993","name":"Agenda of the CVMP meeting 6-8 September 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-06T09:37:00Z","last_updated_date":"2022-09-06T09:37:00Z","reference_number":"EMA/723776/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-6-8-september-2022_en.pdf"},
    {"id":"56010","name":"Agenda of the CAT meeting 7-9 September 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-07T12:25:00Z","last_updated_date":"2022-09-07T12:25:00Z","reference_number":"EMA/CAT/712285/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-7-9-september-2022_en.pdf"},
    {"id":"56028","name":"Agenda of the PDCO meeting 6-9 September 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-08T12:03:00Z","last_updated_date":"2022-09-08T12:03:00Z","reference_number":"EMA/PDCO/696132/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-6-9-september-2022_en.pdf"},
    {"id":"56059","name":"Agenda of the CHMP meeting 12-15 September 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-12T10:33:00Z","last_updated_date":"2022-09-12T10:33:00Z","reference_number":"EMA/CHMP/700565/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-12-15-september-2022_en.pdf"},
    {"id":"56073","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (14 September 2022)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-12T16:52:00Z","last_updated_date":"2022-09-12T16:52:00Z","reference_number":"EMA/637884/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-14-september-2022_en.pdf"},
    {"id":"56093","name":"Agenda - Fifth EMA-Medicines for Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-09-13T14:03:00Z","last_updated_date":"2022-09-13T14:03:00Z","reference_number":"EMA/661919/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fifth-ema-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"56119","name":"Agenda - Clinical Trials Information System (CTIS) Webinar - 9 months on and going forward","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-09-16T09:26:00Z","last_updated_date":"2022-10-28T14:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-trials-information-system-ctis-webinar-9-months-and-going-forward_en.pdf"},
    {"id":"56134","name":"Agenda of the HMPC meeting 19-21 September 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-19T10:13:00Z","last_updated_date":"2022-09-19T10:13:00Z","reference_number":"EMA/HMPC/767056/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-19-21-september-2022_en.pdf"},
    {"id":"56174","name":"Agenda - Second Veterinary Big Data Stakeholder Forum","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-23T15:08:00Z","last_updated_date":"2022-11-22T09:14:00Z","reference_number":"EMA/777506/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-veterinary-big-data-stakeholder-forum_en.pdf"},
    {"id":"56184","name":"Agenda of the PRAC meeting 26-29 September 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-26T14:11:00Z","last_updated_date":"2022-09-26T14:11:00Z","reference_number":"EMA/PRAC/712762/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-26-29-september-2022_en.pdf"},
    {"id":"56198","name":"Draft agenda - Training sessions for patients, consumers and healthcare professionals involved in medicine regulatory activities","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-09-27T11:04:00Z","last_updated_date":"2022-09-27T11:04:00Z","reference_number":"EMA/630927/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-training-sessions-patients-consumers-and-healthcare-professionals-involved-medicine-regulatory-activities_en.pdf"},
    {"id":"56226","name":"Agenda - ACT EU multi-stakeholder meeting on decentralised clinical trials","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:58:00Z","last_updated_date":"2025-12-17T15:50:00Z","reference_number":"EMA/789028/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-multi-stakeholder-meeting-decentralised-clinical-trials_en.pdf"},
    {"id":"56250","name":"Agenda - Joint Meeting of the CTTI-FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T10:16:00Z","last_updated_date":"2022-09-29T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-meeting-ctti-fda-patient-engagement-collaborative-pec-and-ema-patients-and-consumers-working-party-pcwp_en.pdf"},
    {"id":"56279","name":"Agenda of the COMP meeting 4-6 October 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-10-03T11:31:00Z","last_updated_date":"2022-10-03T11:31:00Z","reference_number":"EMA/COMP/762286/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-4-6-october-2022_en.pdf"},
    {"id":"56298","name":"Agenda – Industry Standing Group (ISG) meeting on EMA’s extended mandate","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T09:58:00Z","last_updated_date":"2022-10-04T09:58:00Z","reference_number":"EMA/601355/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-standing-group-isg-meeting-emas-extended-mandate_en.pdf"},
    {"id":"56311","name":"Agenda of the CVMP meeting 4-6 October 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-10-04T13:12:00Z","last_updated_date":"2022-10-04T13:12:00Z","reference_number":"EMA/795167/2022 - draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-4-6-october-2022_en.pdf"},
    {"id":"56314","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (5 October 2022)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T14:28:00Z","last_updated_date":"2022-10-04T14:28:00Z","reference_number":"EMA/768375/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-5-october-2022_en.pdf"},
    {"id":"56322","name":"Agenda of the CAT meeting 5-7 October 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-10-05T11:13:00Z","last_updated_date":"2022-10-05T11:13:00Z","reference_number":"EMA/CAT/772339/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-5-7-october-2022_en.pdf"},
    {"id":"56326","name":"Agenda for the 117th meeting of the Management Board : 6 October 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-10-05T15:28:00Z","last_updated_date":"2022-10-10T09:53:00Z","reference_number":"EMA/MB/598368/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-117th-meeting-management-board-6-october-2022_en.pdf"},
    {"id":"56328","name":"Agenda - First European Medicines Agency - European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-10-05T17:01:00Z","last_updated_date":"2022-10-05T17:01:00Z","reference_number":"EMA/264853/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-european-medicines-agency-european-confederation-pharmaceutical-entrepreneurs-eucope-bilateral-meeting_en.pdf"},
    {"id":"56330","name":"Agenda - PCWP/HCPWP annual meeting with all eligible organisations - 15 November 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-10-06T10:47:00Z","last_updated_date":"2022-11-10T11:08:00Z","reference_number":"EMA/605514/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwphcpwp-annual-meeting-all-eligible-organisations-15-november-2022_en.pdf"},
    {"id":"56334","name":"Agenda - DARWIN EU Advisory Board meeting: 8 September 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-10-06T13:10:00Z","last_updated_date":"2022-10-06T13:10:00Z","reference_number":"EMA/656750/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-meeting-8-september-2022_en.pdf"},
    {"id":"56356","name":"Agenda of the CHMP meeting 10-13 October 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-10-10T12:14:00Z","last_updated_date":"2022-10-10T12:14:00Z","reference_number":"EMA/CHMP/770559/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-10-13-october-2022_en.pdf"},
    {"id":"56363","name":"Agenda of the PDCO meeting 11-14 October 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-10-12T12:03:00Z","last_updated_date":"2022-10-12T12:03:00Z","reference_number":"EMA/PDCO/764496/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-11-14-october-2022_en.pdf"},
    {"id":"56378","name":"Agenda - Data Quality Framework for EU medicines regulation (1st draft): webinar to support public consultation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-10-13T10:01:00Z","last_updated_date":"2022-10-13T10:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-data-quality-framework-eu-medicines-regulation-1st-draft-webinar-support-public-consultation_en.pdf"},
    {"id":"56379","name":"Agenda - Data Quality Framework for EU medicines regulation (1st draft): webinar to support public consultation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-10-13T10:03:00Z","last_updated_date":"2022-10-13T10:03:00Z","reference_number":"EMA/822839/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-data-quality-framework-eu-medicines-regulation-1st-draft-webinar-support-public-consultation_en.pdf-0"},
    {"id":"56390","name":"Agenda - EMA – Parenteral Drug Association bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-11-28T11:47:00Z","last_updated_date":"2022-11-28T11:47:00Z","reference_number":"EMA/795101/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-parenteral-drug-association-bilateral-meeting_en.pdf"},
    {"id":"56463","name":"Agenda of the PRAC meeting 24-27 October 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-10-24T16:02:00Z","last_updated_date":"2022-10-24T16:02:00Z","reference_number":"EMA/785930/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-24-27-october-2022_en.pdf"},
    {"id":"56503","name":"Agenda - EU Big Data Stakeholder Forum","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T15:19:00Z","last_updated_date":"2022-11-30T14:36:00Z","reference_number":"EMA/724391/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eu-big-data-stakeholder-forum_en.pdf"},
    {"id":"56505","name":"Agenda - Second European Medicines Agency-Nuclear Medicines Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T16:22:00Z","last_updated_date":"2022-10-28T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-european-medicines-agency-nuclear-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"56508","name":"Agenda of the CAT meeting 3-4 November 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-10-31T08:51:00Z","last_updated_date":"2022-10-31T08:51:00Z","reference_number":"EMA/CAT/836651/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-3-4-november-2022_en.pdf"},
    {"id":"56536","name":"Agenda of the CHMP meeting 7-10 November 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-11-07T10:44:00Z","last_updated_date":"2023-01-10T10:58:00Z","reference_number":"EMA/CHMP/816076/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-7-10-november-2022_en.pdf"},
    {"id":"56537","name":"Agenda of the COMP meeting 8-10 November 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-11-07T10:53:00Z","last_updated_date":"2022-11-08T16:08:00Z","reference_number":"EMA/COMP/808207/2022 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-8-10-november-2022_en.pdf"},
    {"id":"56541","name":"Agenda of the CVMP meeting 8-10 November 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-11-07T16:58:00Z","last_updated_date":"2022-11-07T16:58:00Z","reference_number":"EMA/866843/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-8-10-november-2022_en.pdf"}    {"id":"56542","name":"Agenda and registration form - Human variations eAF Form (DADI) training session","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-11-07T17:15:00Z","last_updated_date":"2022-11-07T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-human-variations-eaf-form-dadi-training-session_en.pdf"},
    {"id":"56551","name":"Agenda of the PDCO meeting 8-11 November 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-11-08T16:15:00Z","last_updated_date":"2022-11-08T16:15:00Z","reference_number":"EMA/PDCO/838355/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-8-11-november-2022_en.pdf"},
    {"id":"56592","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (11 November 2022)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-11-11T10:24:00Z","last_updated_date":"2022-11-11T10:24:00Z","reference_number":"EMA/803437/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-11-november-2022_en.pdf"},
    {"id":"56615","name":"Agenda - Third Industry Standing Group (ISG) meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-11-14T14:48:00Z","last_updated_date":"2022-11-17T09:05:00Z","reference_number":"EMA/876870/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"56621","name":"Agenda - Second European Medicines Agency and Affordable Medicines Europe bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-11-16T09:24:00Z","last_updated_date":"2022-11-16T09:24:00Z","reference_number":"EMA/845891/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-european-medicines-agency-and-affordable-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"56639","name":"Agenda - Quarterly system demo - Q4 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-11-16T10:37:00Z","last_updated_date":"2022-12-16T09:48:00Z","reference_number":"EMA/884121/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quarterly-system-demo-q4-2022_en.pdf"},
    {"id":"56701","name":"CHMP PROM agenda for the meeting on 11 July 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-11-17T17:29:00Z","last_updated_date":"2022-11-17T17:29:00Z","reference_number":"EMA/CHMP/617339/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-11-july-2022_en.pdf"},
    {"id":"56712","name":"Agenda - Ninth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T13:28:00Z","last_updated_date":"2022-11-18T13:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ninth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"56732","name":"Agenda of the HMPC meeting 21-23 November 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-11-22T09:30:00Z","last_updated_date":"2022-11-22T09:30:00Z","reference_number":"EMA/HMPC/889321/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-21-23-november-2022_en.pdf"},
    {"id":"56811","name":"Agenda - Second bi-annual Big Data Steering Group and industry stakeholders meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-11-28T10:56:00Z","last_updated_date":"2022-11-28T10:56:00Z","reference_number":"EMA/860813/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-bi-annual-big-data-steering-group-and-industry-stakeholders-meeting_en.pdf"},
    {"id":"56812","name":"Report - Second bi-annual Big Data Steering Group and industry stakeholders meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T10:56:00Z","last_updated_date":"2022-11-28T10:56:00Z","reference_number":"EMA/880433/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/report-second-bi-annual-big-data-steering-group-and-industry-stakeholders-meeting_en.pdf"},
    {"id":"56817","name":"Agenda - First European Medicines Agency - Vaccines Europe meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T13:58:00Z","last_updated_date":"2022-11-28T13:58:00Z","reference_number":"EMA/758903/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-european-medicines-agency-vaccines-europe-meeting_en.pdf"},
    {"id":"56822","name":"Agenda of the PRAC meeting 28 November - 1 December 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-11-29T08:32:00Z","last_updated_date":"2022-12-09T15:03:00Z","reference_number":"EMA/PRAC/853738/2022 Corr.2","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-28-november-1-december-2022_en.pdf"},
    {"id":"56833","name":"Agenda - 17th industry stakeholder platform - operation of European Union (EU) pharmacovigilance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-11-30T15:52:00Z","last_updated_date":"2022-11-30T15:52:00Z","reference_number":"EMA/855037/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-17th-industry-stakeholder-platform-operation-european-union-eu-pharmacovigilance_en.pdf"},
    {"id":"56868","name":"Agenda of the COMP meeting 6-8 December 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-12-02T15:12:00Z","last_updated_date":"2022-12-02T15:12:00Z","reference_number":"EMA/COMP/886990/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-6-8-december-2022_en.pdf"},
    {"id":"56883","name":"Agenda of the CVMP meeting 6-8 December 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-12-06T09:44:00Z","last_updated_date":"2022-12-06T09:44:00Z","reference_number":"EMA/918919/2022 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-6-8-december-2022_en.pdf"},
    {"id":"56889","name":"Agenda - Human variations electronic application forms Q&A clinics – session 4","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-06T15:24:00Z","last_updated_date":"2022-12-06T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-human-variations-electronic-application-forms-qa-clinics-session-4_en.pdf"},
    {"id":"56892","name":"Agenda of the CAT meeting 7-9 December 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-12-07T15:28:00Z","last_updated_date":"2022-12-07T15:28:00Z","reference_number":"EMA/CAT/881712/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-7-9-december-2022_en.pdf"},
    {"id":"56904","name":"Agenda - 2022 annual meeting of the members and Coordinating Group of Enpr-EMA","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:30:00Z","last_updated_date":"2022-12-07T17:30:00Z","reference_number":"EMA/564166/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2022-annual-meeting-members-and-coordinating-group-enpr-ema_en.pdf"},
    {"id":"56910","name":"Agenda - Human variations electronic application forms Q&A clinics – session 5","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-08T13:32:00Z","last_updated_date":"2022-12-08T13:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-human-variations-electronic-application-forms-qa-clinics-session-5_en.pdf"},
    {"id":"56934","name":"Agenda - Regulatory and scientific virtual conference on RNA-based medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-09T16:15:00Z","last_updated_date":"2023-02-09T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-regulatory-and-scientific-virtual-conference-rna-based-medicines_en.pdf"},
    {"id":"56935","name":"Agenda of the CHMP meeting 12-15 December 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-12-12T11:05:00Z","last_updated_date":"2022-12-12T11:05:00Z","reference_number":"EMA/CHMP/869948/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-12-15-december-2022_en.pdf"},
    {"id":"56977","name":"Agenda of the PDCO meeting 13-16 December 2022","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-12-13T14:08:00Z","last_updated_date":"2022-12-13T14:08:00Z","reference_number":"EMA/PDCO/898908/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-13-16-december-2022_en.pdf"},
    {"id":"56984","name":"Programme - Clinical Trials Information System (CTIS) sponsor end user training programme (Feb, May, June 2023)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T16:15:00Z","last_updated_date":"2022-12-13T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-clinical-trials-information-system-ctis-sponsor-end-user-training-programme-feb-may-june-2023_en.pdf"},
    {"id":"56985","name":"Agenda and registration form - Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Virtual hands-on training course using the EudraVigilance system","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T16:16:00Z","last_updated_date":"2022-12-13T16:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-and-registration-form-mandatory-use-isoich-e2br3-individual-case-safety-reporting-eu-virtual-hands-training-course-using-eudravigilance-system_en.pdf"},
    {"id":"57009","name":"Agenda - Joint EMA-FDA workshop: Efficacy of monoclonal antibodies in the context of rapidly evolving SARS-CoV-2 variants","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T14:20:00Z","last_updated_date":"2022-12-14T14:20:00Z","reference_number":"EMA/601355/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-ema-fda-workshop-efficacy-monoclonal-antibodies-context-rapidly-evolving-sars-cov-2-variants_en.pdf"},
    {"id":"57011","name":"Agenda for the 118th meeting of the Management Board: 14-15 December 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-12-14T14:50:00Z","last_updated_date":"2022-12-15T10:14:00Z","reference_number":"EMA/MB/817029/20222","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-118th-meeting-management-board-14-15-december-2022_en.pdf"},
    {"id":"57012","name":"Agenda - Human Variations eAF Form training session","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T15:25:00Z","last_updated_date":"2022-12-14T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-human-variations-eaf-form-training-session_en.pdf"},
    {"id":"57045","name":"Agenda - Ninth industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T15:51:00Z","last_updated_date":"2022-12-15T15:51:00Z","reference_number":"EMA/832164/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ninth-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"57127","name":"Agenda - Human variations electronic application form (eAF) Q&A clinics – session 7","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T10:05:00Z","last_updated_date":"2022-12-22T10:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-human-variations-electronic-application-form-eaf-qa-clinics-session-7_en.pdf"},
    {"id":"57128","name":"Agenda - Human variations electronic application form (eAF) Q&A clinics – session 6","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T10:00:00Z","last_updated_date":"2022-12-22T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-human-variations-electronic-application-form-eaf-qa-clinics-session-6_en.pdf"},
    {"id":"57170","name":"Agenda - Clinical Trials Information System (CTIS): Readiness for mandatory use of the Clinical Trials Regulation from 31 January 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-01-06T09:26:00Z","last_updated_date":"2023-01-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-trials-information-system-ctis-readiness-mandatory-use-clinical-trials-regulation-31-january-2023_en.pdf"},
    {"id":"57195","name":"CHMP PROM agenda for the meeting on 31 October 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T11:30:00Z","last_updated_date":"2023-01-10T11:30:00Z","reference_number":"EMA/CHMP/832725/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-31-october-2022_en.pdf"},
    {"id":"57208","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (11 January 2022)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-01-11T08:32:00Z","last_updated_date":"2023-01-11T08:32:00Z","reference_number":"EMA/899499/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-11-january-2022_en.pdf"},
    {"id":"57266","name":"Agenda of the COMP meeting 17-19 January 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-01-12T14:51:00Z","last_updated_date":"2023-01-12T14:51:00Z","reference_number":"EMA/COMP/943145/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-17-19-january-2023_en.pdf"},
    {"id":"57267","name":"CHMP PROM agenda for the meeting on 3 October 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T15:18:00Z","last_updated_date":"2023-01-12T15:18:00Z","reference_number":"EMA/CHMP/770426/2022 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-3-october-2022_en.pdf"},
    {"id":"57296","name":"Agenda - Information session on the pilot for expert panels’ scientific advice to manufacturers of high-risk medical devices","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-01-16T14:44:00Z","last_updated_date":"2023-01-24T17:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-information-session-pilot-expert-panels-scientific-advice-manufacturers-high-risk-medical-devices_en.pdf"},
    {"id":"57300","name":"Agenda of the CVMP meeting 17-19 January 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-01-16T17:29:00Z","last_updated_date":"2023-01-16T17:29:00Z","reference_number":"EMA/22156/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-17-19-january-2023_en.pdf"},
    {"id":"57301","name":"Agenda of the CAT meeting 18-19 January 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-01-16T17:48:00Z","last_updated_date":"2023-01-16T17:48:00Z","reference_number":"EMA/CAT/943290/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-18-19-january-2023_en.pdf"},
    {"id":"57317","name":"Agenda of the PDCO meeting 17-20 January 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-01-17T17:59:00Z","last_updated_date":"2023-01-17T17:59:00Z","reference_number":"EMA/PDCO/2399/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-17-20-january-2023_en.pdf"},
    {"id":"57344","name":"Agenda of the HMPC meeting 23-25 January 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-01-20T14:52:00Z","last_updated_date":"2023-02-01T11:40:00Z","reference_number":"EMA/HMPC/938569/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-23-25-january-2023_en.pdf"},
    {"id":"57355","name":"Agenda of the CHMP meeting 23-26 January 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-01-23T10:16:00Z","last_updated_date":"2023-01-23T10:16:00Z","reference_number":"EMA/CHMP/953395/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-23-26-january-2023_en.pdf"},
    {"id":"57376","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-01-24T15:25:00Z","last_updated_date":"2023-03-01T10:15:00Z","reference_number":"EMA/836371/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-and-consumers-pcwp-and-healthcare-professionals-hcpwp-working-parties-joint-meeting_en.pdf"},
    {"id":"57388","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (23 February 2023)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-02-23T09:30:00Z","last_updated_date":"2023-02-23T09:30:00Z","reference_number":"EMA/37382/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-23-february-2023_en.pdf"},
    {"id":"57407","name":"Agenda - European Medicines Agency veterinary medicines info day 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-01-26T15:09:00Z","last_updated_date":"2023-03-03T11:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-veterinary-medicines-info-day-2023_en.pdf"},
    {"id":"57446","name":"CHMP PROM agenda for the meeting on 5 December 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-01-30T12:16:00Z","last_updated_date":"2023-01-30T12:16:00Z","reference_number":"EMA/CHMP/878170/2022 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-5-december-2022_en.pdf"},
    {"id":"57468","name":"Agenda - EMA virtual workshop on myocarditis post COVID-19 vaccination","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T14:00:00Z","last_updated_date":"2023-01-31T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-virtual-workshop-myocarditis-post-covid-19-vaccination_en.pdf"},
    {"id":"57536","name":"Agenda of the PRAC meeting 6-9 February 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-02-06T16:43:00Z","last_updated_date":"2023-02-06T16:43:00Z","reference_number":"EMA/PRAC/12766/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-6-9-february-2023_en.pdf"},
    {"id":"57538","name":"Agenda - HMA/EMA multi-stakeholder workshop on shortages","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-02-06T17:33:00Z","last_updated_date":"2023-03-07T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmaema-multi-stakeholder-workshop-shortages_en.pdf"},
    {"id":"57544","name":"Agenda - Fourth meeting of the Nitrosamine Implementation Oversight Group - Industry Associations","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-02-07T15:59:00Z","last_updated_date":"2023-02-07T15:59:00Z","reference_number":"EMA/735648/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-meeting-nitrosamine-implementation-oversight-group-industry-associations_en.pdf"},
    {"id":"57555","name":"Agenda - Fifth EMA-EFPIA annual bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T10:40:00Z","last_updated_date":"2023-02-08T10:40:00Z","reference_number":"EMA/47787/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fifth-ema-efpia-annual-bilateral-meeting_en.pdf"},
    {"id":"57572","name":"Agenda of the COMP meeting 14-16 February 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-02-08T15:34:00Z","last_updated_date":"2023-02-08T15:34:00Z","reference_number":"EMA/COMP/41150/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-14-16-february-2023_en.pdf"},
    {"id":"57579","name":"Agenda - DARWIN EU Advisory Board meeting: 6 February 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-02-08T15:48:00Z","last_updated_date":"2023-02-08T15:48:00Z","reference_number":"EMA/831618/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-meeting-6-february-2023_en.pdf"},
    {"id":"57657","name":"Agenda of the CVMP meeting 14-16 February 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-02-13T16:46:00Z","last_updated_date":"2023-02-13T16:46:00Z","reference_number":"EMA/68188/2023 – draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-14-16-february-2023_en.pdf"},
    {"id":"57670","name":"Agenda of the CAT meeting 15-17 February 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-02-15T09:00:00Z","last_updated_date":"2023-02-15T09:00:00Z","reference_number":"EMA/CAT/43624/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-15-17-february-2023_en.pdf"},
    {"id":"57686","name":"Agenda - Product Management Service (PMS) Webinar on  Data Migration","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-02-15T17:39:00Z","last_updated_date":"2023-02-15T17:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-management-service-pms-webinar-data-migration_en.pdf"},
    {"id":"57736","name":"Agenda of the CHMP meeting 20-23 February 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-02-20T13:00:00Z","last_updated_date":"2023-02-23T15:47:00Z","reference_number":"EMA/CHMP/44874/2023 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-20-23-february-2023_en.pdf"},
    {"id":"57762","name":"Agenda of the PDCO meeting 21-24 February 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-02-21T15:31:00Z","last_updated_date":"2023-02-22T08:27:00Z","reference_number":"EMA/PDCO/49245/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-21-24-february-2023_en.pdf"},
    {"id":"57763","name":"Agenda - Quarterly system demo - Q1 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-02-21T10:37:00Z","last_updated_date":"2023-03-17T12:48:00Z","reference_number":"EMA/48429/2023 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quarterly-system-demo-q1-2023_en.pdf"},
    {"id":"57815","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (26 January 2023)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-01-25T10:59:00Z","last_updated_date":"2023-01-25T10:59:00Z","reference_number":"EMA/899499/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-26-january-2023_en.pdf"},
    {"id":"57999","name":"Agenda - EMA multi-stakeholder workshop on qualification of novel methodologies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-03-13T10:31:00Z","last_updated_date":"2023-04-14T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-multi-stakeholder-workshop-qualification-novel-methodologies_en.pdf"},
    {"id":"58000","name":"Agenda of the HMPC meeting 13-15 March 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-03-13T11:30:00Z","last_updated_date":"2023-03-13T11:30:00Z","reference_number":"EMA/HMPC/68747/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-13-15-march-2023_en.pdf"},
    {"id":"58013","name":"Agenda of the PRAC meeting 13-16 March 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-03-13T17:27:00Z","last_updated_date":"2023-03-13T17:27:00Z","reference_number":"EMA/PRAC/60842/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-13-16-march-2023_en.pdf"},
    {"id":"58027","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (15 March 2023)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-03-14T17:14:00Z","last_updated_date":"2023-03-14T17:14:00Z","reference_number":"EMA/84223/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-15-march-2023_en.pdf"},
    {"id":"58029","name":"Agenda for the 119th meeting of the Management Board: 16 March 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-03-16T14:05:00Z","last_updated_date":"2023-03-20T12:55:00Z","reference_number":"EMA/MB/948302/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-119th-meeting-management-board-16-march-2023_en.pdf"},
    {"id":"58060","name":"Agenda of the COMP meeting 21-23 March 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-03-17T12:36:00Z","last_updated_date":"2023-03-17T12:36:00Z","reference_number":"EMA/COMP/83634/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-21-23-march-2023_en.pdf"},
    {"id":"58080","name":"Agenda of the CVMP meeting 21-23 March 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-03-20T16:33:00Z","last_updated_date":"2023-03-20T16:33:00Z","reference_number":"EMA/CVMP/128829/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-21-23-march-2023_en.pdf"},
    {"id":"58096","name":"Agenda - Fourth Industry Standing Group (ISG) meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-03-21T15:22:00Z","last_updated_date":"2023-03-21T15:22:00Z","reference_number":"EMA/909712/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"58107","name":"Agenda - Enpr-EMA Coordinating Group meeting (February 2023)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-03-22T16:12:00Z","last_updated_date":"2023-03-22T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-meeting-february-2023_en.pdf"},
    {"id":"58130","name":"Agenda of the CAT meeting 22-23 March 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-03-23T10:36:00Z","last_updated_date":"2023-03-23T10:36:00Z","reference_number":"EMA/CAT/86647/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-22-23-march-2023_en.pdf"},
    {"id":"58163","name":"Agenda of the CHMP meeting 27-30 March 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-03-27T12:19:00Z","last_updated_date":"2023-03-27T12:19:00Z","reference_number":"EMA/CHMP/47815/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-27-30-march-2023_en.pdf"},
    {"id":"58208","name":"Agenda of the PDCO meeting 28-31 March 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-03-29T17:24:00Z","last_updated_date":"2023-03-29T17:24:00Z","reference_number":"EMA/PDCO/95095/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-28-31-march-2023_en.pdf"},
    {"id":"58219","name":"Agenda of the Medicine Shortages (SPOC) Working Party meeting 13 December 2022","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T12:34:00Z","last_updated_date":"2023-03-30T12:34:00Z","reference_number":"EMA/93474/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-13-december-2022_en.pdf"},
    {"id":"58221","name":"Agenda of the Medicine Shortages (SPOC) Working Party 18 January 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T12:42:00Z","last_updated_date":"2023-03-30T12:42:00Z","reference_number":"EMA/93494/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-18-january-2023_en.pdf"},
    {"id":"58223","name":"Agenda of the Medicine Shortages (SPOC) Working Party 15 February 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T12:47:00Z","last_updated_date":"2023-03-30T12:47:00Z","reference_number":"EMA/93334/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-15-february-2023_en.pdf"},
    {"id":"58258","name":"Agenda - Union Product Database – Volume of sales webinar for UPD industry users","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T16:11:00Z","last_updated_date":"2023-03-31T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-union-product-database-volume-sales-webinar-upd-industry-users_en.pdf"},
    {"id":"58311","name":"Agenda of the PRAC meeting 11-14 April 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-04-11T15:41:00Z","last_updated_date":"2023-04-11T15:41:00Z","reference_number":"EMA/PRAC/120400/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-11-14-april-2023_en.pdf"},
    {"id":"58319","name":"Agenda - Second European Medicines Agency-MedTech Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-04-12T12:11:00Z","last_updated_date":"2023-04-12T12:11:00Z","reference_number":"EMA/40818/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-european-medicines-agency-medtech-europe-bilateral-meeting_en.pdf"},
    {"id":"58337","name":"Agenda of the COMP meeting 18-20 April 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-04-13T14:05:00Z","last_updated_date":"2023-04-13T14:05:00Z","reference_number":"EMA/COMP/145882/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-18-20-april-2023_en.pdf"},
    {"id":"58405","name":"Agenda of the CVMP meeting 18-20 April 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-04-18T13:22:00Z","last_updated_date":"2023-04-18T13:22:00Z","reference_number":"EMA/171689/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-18-20-april-2023_en.pdf"},
    {"id":"58406","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (20 April 2023)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-04-18T13:52:00Z","last_updated_date":"2023-04-18T13:52:00Z","reference_number":"EMA/118628/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-20-april-2023_en.pdf"},
    {"id":"58429","name":"Agenda of the CAT meeting 19-21 April 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-04-19T12:45:00Z","last_updated_date":"2023-04-19T12:45:00Z","reference_number":"EMA/CAT/151444/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-19-21-april-2023_en.pdf"},
    {"id":"58432","name":"Agenda of the Medicine Shortages (SPOC) Working Party 18 April 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-04-19T12:47:00Z","last_updated_date":"2023-04-19T12:47:00Z","reference_number":"EMA/148452/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-18-april-2023_en.pdf"},
    {"id":"58497","name":"Agenda of the CHMP meeting 24-26 April 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-04-24T10:21:00Z","last_updated_date":"2023-04-24T10:21:00Z","reference_number":"EMA/CHMP/57011/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-24-26-april-2023_en.pdf"},
    {"id":"58498","name":"Agenda of the PDCO meeting 24-26 April 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-04-24T11:22:00Z","last_updated_date":"2023-04-24T11:22:00Z","reference_number":"EMA/PDCO/153477/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-24-26-april-2023_en.pdf"},
    {"id":"58545","name":"Focus Group Meeting on Bacteriophages - Programme (11 May 2023)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-04-28T10:01:00Z","last_updated_date":"2023-05-10T08:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/focus-group-meeting-bacteriophages-programme-11-may-2023_en.pdf"},
    {"id":"58576","name":"Agenda - ACT EU multi-stakeholder platform kick off workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-05-03T17:00:00Z","last_updated_date":"2023-07-03T12:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-multi-stakeholder-platform-kick-workshop_en.pdf"},
    {"id":"58579","name":"Agenda of the Medicine Shortages (SPOC) Working Party meeting 21 March 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-03-20T08:50:00Z","last_updated_date":"2023-03-20T08:50:00Z","reference_number":"EMA/180631/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-21-march-2023_en.pdf"},
    {"id":"58600","name":"Agenda of the HMPC meeting 10-12 May 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-10T08:38:00Z","last_updated_date":"2023-05-10T08:38:00Z","reference_number":"EMA/HMPC/174041/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-10-12-may-2023_en.pdf"},
    {"id":"58604","name":"Agenda - Patients and Consumers Working Party (PCWP) meeting - 27 June 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-10T11:12:00Z","last_updated_date":"2023-06-22T16:37:00Z","reference_number":"EMA/180779/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patients-and-consumers-working-party-pcwp-meeting-27-june-2023_en.pdf"},
    {"id":"58605","name":"Agenda - Healthcare Professionals' Working Party (HCPWP) meeting - 27 June 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-10T11:22:00Z","last_updated_date":"2023-06-22T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-healthcare-professionals-working-party-hcpwp-meeting-27-june-2023_en.pdf"},
    {"id":"58606","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting - 28 June 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-10T11:29:00Z","last_updated_date":"2023-06-22T16:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-and-consumers-pcwp-and-healthcare-professionals-hcpwp-working-parties-joint-meeting-28-june-2023_en.pdf"},
    {"id":"58608","name":"Agenda: Product Lifecycle Management (PLM) Portal Access Management Training Session","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-05-10T12:10:00Z","last_updated_date":"2023-05-10T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-lifecycle-management-plm-portal-access-management-training-session_en.pdf"},
    {"id":"58610","name":"Agenda of the PRAC meeting 10-12 May 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-10T14:14:00Z","last_updated_date":"2023-05-10T14:14:00Z","reference_number":"EMA/PRAC/213551/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-10-12-may-2023_en.pdf"},
    {"id":"58625","name":"Agenda of the COMP meeting 15-17 May 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-11T11:49:00Z","last_updated_date":"2023-05-11T11:49:00Z","reference_number":"EMA/COMP/192353/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-15-17-may-2023_en.pdf"},
    {"id":"58673","name":"Agenda - Clinical Data Publication (Policy 0070) re-launch - EMA webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:31:00Z","last_updated_date":"2023-05-22T17:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-data-publication-policy-0070-re-launch-ema-webinar_en.pdf"},
    {"id":"58676","name":"Agenda - Webinar on Nationally Authorised Products (NAPs) release on Product Lifecycle Management (PLM) Portal electronic Application Forms (eAFs)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:53:00Z","last_updated_date":"2023-05-12T16:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-webinar-nationally-authorised-products-naps-release-product-lifecycle-management-plm-portal-electronic-application-forms-eafs_en.pdf"},
    {"id":"58692","name":"Agenda of the CVMP meeting 15-17 May 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-15T16:26:00Z","last_updated_date":"2023-05-15T16:26:00Z","reference_number":"EMA/219677/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-15-17-may-2023_en.pdf"},
    {"id":"58693","name":"Agenda of the CAT meeting 15-17 May 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-15T16:31:00Z","last_updated_date":"2023-05-15T16:31:00Z","reference_number":"EMA/CAT/198093/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-15-17-may-2023_en.pdf"},
    {"id":"58722","name":"Agenda - Product Management Service (PMS) Progress Webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-05-17T15:35:00Z","last_updated_date":"2023-05-17T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-management-service-pms-progress-webinar_en.pdf"}    {"id":"58724","name":"Agenda of the CHMP meeting 22-25 May 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-22T10:46:00Z","last_updated_date":"2023-05-22T10:46:00Z","reference_number":"EMA/CHMP/122959/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-may-2023_en.pdf"},
    {"id":"58731","name":"Draft agenda – CVMP Interested Parties’ meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-22T11:38:00Z","last_updated_date":"2023-05-22T11:38:00Z","reference_number":"EMA/CVMP/184304/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-cvmp-interested-parties-meeting_en.pdf"},
    {"id":"58743","name":"Agenda of the PDCO meeting 23-26 May 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-23T17:19:00Z","last_updated_date":"2023-05-23T17:19:00Z","reference_number":"EMA/PDCO/227981/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-23-26-may-2023_en.pdf"},
    {"id":"58773","name":"Report - HMA/EMA multi-stakeholder workshop on shortages","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-05-25T09:30:00Z","last_updated_date":"2023-05-25T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/report-hmaema-multi-stakeholder-workshop-shortages_en.pdf"},
    {"id":"58776","name":"Programme - Clinical Trials Information System (CTIS) sponsor end user training programme (Sept, Nov, Dec 2023)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T16:15:00Z","last_updated_date":"2022-12-13T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-clinical-trials-information-system-ctis-sponsor-end-user-training-programme-sept-nov-dec-2023_en.pdf"},
    {"id":"58798","name":"Agenda - Multi-stakeholder workshop on Real World Data (RWD) quality and Real World Evidence (RWE) use","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T12:15:00Z","last_updated_date":"2023-06-26T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-workshop-real-world-data-rwd-quality-and-real-world-evidence-rwe-use_en.pdf"},
    {"id":"58800","name":"Agenda - Quarterly system demo - Q2 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-05-26T10:37:00Z","last_updated_date":"2023-06-09T15:05:00Z","reference_number":"EMA/201080/2023 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quarterly-system-demo-q2-2023_en.pdf"},
    {"id":"58801","name":"Agenda - ACT EU PA04 - Multi-stakeholder Workshop on ICH E6 R3","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-05-26T15:37:00Z","last_updated_date":"2023-07-07T09:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-pa04-multi-stakeholder-workshop-ich-e6-r3_en.pdf"},
    {"id":"58814","name":"Programme - Clinical Trials Information System (CTIS) sponsor end user training programme (Sep, Nov, Dec 2023)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-05-30T16:15:00Z","last_updated_date":"2023-07-03T17:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-clinical-trials-information-system-ctis-sponsor-end-user-training-programme-sep-nov-dec-2023_en.pdf"},
    {"id":"58825","name":"CHMP PROM agenda for the meeting on 16 January 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-05-31T12:35:00Z","last_updated_date":"2023-05-31T12:35:00Z","reference_number":"EMA/CHMP/953415/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-16-january-2023_en.pdf"},
    {"id":"58838","name":"CHMP PROM agenda for the meeting on 13 February 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-05-31T15:05:00Z","last_updated_date":"2023-05-31T15:05:00Z","reference_number":"EMA/CHMP/42378/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-13-february-2023_en.pdf"},
    {"id":"58842","name":"Agenda - Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-01T09:42:00Z","last_updated_date":"2023-07-11T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system_en.pdf"},
    {"id":"58876","name":"Agenda of the PRAC meeting 5-8 June 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-06-05T17:58:00Z","last_updated_date":"2023-06-07T14:11:00Z","reference_number":"EMA/PRAC/215930/2023 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-5-8-june-2023_en.pdf"},
    {"id":"58881","name":"Agenda for the 120th meeting of the Management Board: 7-8 June 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-06-07T14:13:00Z","last_updated_date":"2023-06-09T12:50:00Z","reference_number":"EMA/MB/129985/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-120th-meeting-management-board-7-8-june-2023_en.pdf"},
    {"id":"58904","name":"Agenda of the COMP meeting 13-15 June 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-06-09T11:37:00Z","last_updated_date":"2023-06-09T11:37:00Z","reference_number":"EMA/COMP/234403/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-13-15-june-2023_en.pdf"},
    {"id":"58908","name":"Agenda - Tenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-06-09T13:47:00Z","last_updated_date":"2023-06-14T15:07:00Z","reference_number":"EMA/266811/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-tenth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"58929","name":"Agenda of the CVMP meeting 13-15 June 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-06-13T10:42:00Z","last_updated_date":"2023-06-13T10:42:00Z","reference_number":"EMA/267672/2023 – draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-13-15-june-2023_en.pdf"},
    {"id":"58941","name":"Agenda - Clinical Trials Information System Webinar: Second Year of Transition","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-14T14:57:00Z","last_updated_date":"2023-06-14T14:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-trials-information-system-webinar-second-year-transition_en.pdf"},
    {"id":"58947","name":"Agenda of the CAT meeting 15 June 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-06-15T09:00:00Z","last_updated_date":"2023-06-15T09:00:00Z","reference_number":"EMA/CAT/240971/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-15-june-2023_en.pdf"},
    {"id":"58965","name":"Agenda - Executive Steering Group on Shortages of Medical Devices (MDSSG) (19 June 2023)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-06-15T13:52:00Z","last_updated_date":"2023-06-15T13:52:00Z","reference_number":"EMA/124924/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-medical-devices-mdssg-19-june-2023_en.pdf"},
    {"id":"58984","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-06-19T09:25:00Z","last_updated_date":"2023-06-19T09:25:00Z","reference_number":"EMA/182888/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg_en.pdf-2"},
    {"id":"58986","name":"Agenda of the CHMP meeting 19-22 June 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-06-19T11:25:00Z","last_updated_date":"2023-06-19T11:25:00Z","reference_number":"EMA/CHMP/243980/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-19-22-june-2023_en.pdf"},
    {"id":"58994","name":"Agenda of the Medicine Shortages (SPOC) Working Party 24 May 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T17:09:00Z","last_updated_date":"2023-07-12T12:21:00Z","reference_number":"EMA/200648/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-24-may-2023_en.pdf"},
    {"id":"58995","name":"Agenda of the Medicine Shortages (SPOC) Working Party meeting 16 June 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T17:17:00Z","last_updated_date":"2023-07-12T12:22:00Z","reference_number":"EMA/251595/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-16-june-2023_en.pdf"},
    {"id":"59002","name":"Agenda - Fifth Industry Standing Group (ISG) meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-20T11:59:00Z","last_updated_date":"2023-06-20T11:59:00Z","reference_number":"EMA/283080/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fifth-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"59004","name":"Agenda of the PDCO meeting 20-23 June 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-06-20T12:12:00Z","last_updated_date":"2023-06-20T12:12:00Z","reference_number":"EMA/PDCO/242901/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-meeting-20-23-june-2023_en.pdf"},
    {"id":"59008","name":"Agenda - Third European Medicines Agency and Nuclear Medicines Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T09:27:00Z","last_updated_date":"2023-06-21T09:27:00Z","reference_number":"EMA/108752/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-european-medicines-agency-and-nuclear-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"59112","name":"Agenda – biannual Big Data Steering Group and industry  stakeholders meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-27T12:04:00Z","last_updated_date":"2023-06-27T12:04:00Z","reference_number":"EMA/200171/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-biannual-big-data-steering-group-and-industry-stakeholders-meeting_en.pdf"},
    {"id":"59193","name":"Agenda - Shaping a European innovation ecosystem: EU-Innovation network multi-stakeholder meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T16:11:00Z","last_updated_date":"2023-09-20T17:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-shaping-european-innovation-ecosystem-eu-innovation-network-multi-stakeholder-meeting_en.pdf"},
    {"id":"59214","name":"Agenda of the PRAC meeting 3-6 July 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-07-03T17:31:00Z","last_updated_date":"2023-07-03T17:31:00Z","reference_number":"EMA/PRAC/258271/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-3-6-july-2023_en.pdf"},
    {"id":"59270","name":"Agenda - EMA Veterinary Awareness Day","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-07-05T17:17:00Z","last_updated_date":"2023-09-11T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-veterinary-awareness-day_en.pdf"},
    {"id":"59273","name":"Agenda of the COMP meeting 11-13 July 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-07-06T11:33:00Z","last_updated_date":"2023-07-06T11:33:00Z","reference_number":"EMA/COMP/285310/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-11-13-july-2023_en.pdf"},
    {"id":"59281","name":"Agenda - EMA/EuropaBio Bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-07-06T14:31:00Z","last_updated_date":"2023-07-06T14:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emaeuropabio-bilateral-meeting_en.pdf"},
    {"id":"59291","name":"CHMP PROM agenda for the meeting on 15 May 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-07-07T10:46:00Z","last_updated_date":"2023-07-07T10:46:00Z","reference_number":"EMA/CHMP/194942/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-15-may-2023_en.pdf"},
    {"id":"59323","name":"Agenda of the CVMP meeting 11-13 July 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-07-11T15:08:00Z","last_updated_date":"2023-07-11T15:08:00Z","reference_number":"EMA/317476/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-11-13-july-2023_en.pdf"},
    {"id":"59326","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (14 July 2023)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-07-12T08:54:00Z","last_updated_date":"2023-07-12T08:54:00Z","reference_number":"EMA/287647/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-14-july-2023_en.pdf"},
    {"id":"59339","name":"Agenda of the Medicine Shortages (SPOC) Working Party 6 July 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T12:29:00Z","last_updated_date":"2023-07-12T12:29:00Z","reference_number":"EMA/293652/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-6-july-2023_en.pdf"},
    {"id":"59351","name":"Agenda - Clinical Trials Information System (CTIS): Information day (17/10/2023)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-07-13T16:17:00Z","last_updated_date":"2023-10-13T11:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-trials-information-system-ctis-information-day-17-10-2023_en.pdf"},
    {"id":"59353","name":"Agenda - Fourth EMA-AESGP bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-07-13T17:41:00Z","last_updated_date":"2023-07-13T17:41:00Z","reference_number":"EMA/157813/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-ema-aesgp-bilateral-meeting_en.pdf"},
    {"id":"59357","name":"Agenda of the CHMP meeting 17-20 July 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-07-17T09:17:00Z","last_updated_date":"2023-07-17T09:17:00Z","reference_number":"EMA/CHMP/289654/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-17-20-july-2023_en.pdf"},
    {"id":"59361","name":"Agenda of the CAT meeting 12-14 July 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-07-17T09:57:00Z","last_updated_date":"2023-07-17T09:57:00Z","reference_number":"EMA/CAT/329617/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-12-14-july-2023_en.pdf"},
    {"id":"59412","name":"Agenda - PDCO agenda of the 18-21 July 2023 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-07-19T17:26:00Z","last_updated_date":"2023-07-19T17:26:00Z","reference_number":"EMA/PDCO/321529/2023 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-18-21-july-2023-meeting_en.pdf"},
    {"id":"59414","name":"Agenda of the HMPC meeting 17-19 July 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-07-20T08:00:00Z","last_updated_date":"2023-07-20T08:00:00Z","reference_number":"EMA/HMPC/284286/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-17-19-july-2023_en.pdf"},
    {"id":"59418","name":"Agenda - Tenth industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-07-20T11:20:00Z","last_updated_date":"2023-07-20T11:20:00Z","reference_number":"EMA/168978/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-tenth-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"59470","name":"Agenda - Enpr-EMA Coordinating Group and networks meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-07-24T14:05:00Z","last_updated_date":"2023-07-24T14:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-and-networks-meeting_en.pdf-0"},
    {"id":"59498","name":"Agenda - Lessons-learned workshop on Clinical Trials in Public Health Emergencies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:52:00Z","last_updated_date":"2023-07-25T13:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-lessons-learned-workshop-clinical-trials-public-health-emergencies_en.pdf"},
    {"id":"59505","name":"Agenda - Union Product Database - Product grouping and third country product names Webinar for Industry users","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-07-26T10:58:00Z","last_updated_date":"2023-07-26T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-union-product-database-product-grouping-and-third-country-product-names-webinar-industry-users_en.pdf"},
    {"id":"59555","name":"Agenda - Strengthening life-sciences innovation across Europe: EU-Innovation Network conference","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-08-04T16:00:00Z","last_updated_date":"2023-11-21T10:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-strengthening-life-sciences-innovation-across-europe-eu-innovation-network-conference_en.pdf"},
    {"id":"59564","name":"Programme of the 2023 annual workshop of the European network of paediatric research at the EMA (Enpr-EMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-08-07T14:53:00Z","last_updated_date":"2023-10-05T12:03:00Z","reference_number":"EMA/345059/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-2023-annual-workshop-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"59575","name":"Agenda - System Demo Q3 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-08-09T10:36:00Z","last_updated_date":"2023-09-07T11:32:00Z","reference_number":"EMA/348486/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-system-demo-q3-2023_en.pdf"},
    {"id":"59601","name":"Agenda of the CHMP written procedure 14-17 August 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-08-14T16:21:00Z","last_updated_date":"2023-08-14T16:21:00Z","reference_number":"EMA/CHMP/362824/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-written-procedure-14-17-august-2023_en.pdf"},
    {"id":"59653","name":"Agenda of the PRAC meeting 28-31 August 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-08-28T08:57:00Z","last_updated_date":"2023-08-28T08:57:00Z","reference_number":"EMA/PRAC/307705/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-28-31-august-2023_en.pdf"},
    {"id":"59878","name":"Agenda of the COMP meeting 5-7 September 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-09-01T10:37:00Z","last_updated_date":"2023-09-01T10:37:00Z","reference_number":"EMA/COMP/336655/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-5-7-september-2023_en.pdf"},
    {"id":"59893","name":"Agenda of the CVMP meeting 5-7 September 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-09-05T09:59:00Z","last_updated_date":"2023-09-05T09:59:00Z","reference_number":"EMA/397508/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-5-7-september-2023_en.pdf"},
    {"id":"59910","name":"Agenda of the CAT meeting 6-8 September 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-09-07T10:14:00Z","last_updated_date":"2023-09-07T10:14:00Z","reference_number":"EMA/CAT/369627/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-6-8-september-2023_en.pdf"},
    {"id":"59926","name":"Agenda of the CHMP meeting 11-14 September 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-09-11T10:35:00Z","last_updated_date":"2023-09-14T12:36:00Z","reference_number":"EMA/CHMP/355400/2023 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-11-14-september-2023_en.pdf"},
    {"id":"59967","name":"Agenda - Informative Webinar on Regulatory Procedure Management for Product Lifecycle Management 1st roll-out on IRIS","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-09-14T11:42:00Z","last_updated_date":"2023-09-14T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-informative-webinar-regulatory-procedure-management-product-lifecycle-management-1st-roll-out-iris_en.pdf"},
    {"id":"60030","name":"Agenda - PCWP/HCPWP joint meeting (19-20 September 2023)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-09-15T13:37:00Z","last_updated_date":"2023-09-25T16:05:00Z","reference_number":"EMA/901780/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwp-hcpwp-joint-meeting-19-20-september-2023_en.pdf"},
    {"id":"60044","name":"Agenda - EU Network Training Centre: Oncology pilot educational program for external experts","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T14:19:00Z","last_updated_date":"2023-09-18T14:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eu-network-training-centre-oncology-pilot-educational-program-external-experts_en.pdf"},
    {"id":"60053","name":"Draft agenda – 6th Industry Standing Group (ISG) meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T16:22:00Z","last_updated_date":"2023-09-18T16:22:00Z","reference_number":"EMA/269763/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-6th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"60068","name":"Agenda of the Medicine Shortages (SPOC) Working Party meeting 12 September 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-09-20T08:25:00Z","last_updated_date":"2023-09-20T08:25:00Z","reference_number":"EMA/346780/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-12-september-2023_en.pdf"},
    {"id":"60083","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (22 September 2023)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-09-21T10:56:00Z","last_updated_date":"2023-09-21T10:56:00Z","reference_number":"EMA/314491/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-22-september-2023_en.pdf"},
    {"id":"60105","name":"Agenda of the HMPC meeting 18-20 September 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-09-21T17:24:00Z","last_updated_date":"2023-09-21T17:24:00Z","reference_number":"EMA/HMPC/358554/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-18-20-september-2023_en.pdf"},
    {"id":"60138","name":"Agenda of the PRAC meeting 25-28 September 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-09-25T15:40:00Z","last_updated_date":"2023-09-25T15:40:00Z","reference_number":"EMA/PRAC/355801/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-25-28-september-2023_en.pdf"},
    {"id":"60156","name":"Academia Info Day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-09-26T14:46:00Z","last_updated_date":"2023-09-26T14:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/academia-info-day_en.pdf"},
    {"id":"60158","name":"Agenda - EMA Academia Info Day Agenda","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-09-26T17:11:00Z","last_updated_date":"2023-11-10T09:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-academia-info-day-agenda_en.pdf"},
    {"id":"60169","name":"Joint Meeting of CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients’ and Consumers’ Working Party (PCWP)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T14:23:00Z","last_updated_date":"2023-09-27T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/joint-meeting-ctti-fda-patient-engagement-collaborative-pec-and-ema-patients-and-consumers-working-party-pcwp_en.pdf"},
    {"id":"60213","name":"Agenda of the COMP meeting 3-5 October 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-09-29T13:18:00Z","last_updated_date":"2023-09-29T13:18:00Z","reference_number":"EMA/COMP/412052/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-3-5-october-2023_en.pdf"},
    {"id":"60231","name":"Agenda of the CVMP meeting 3-5 October 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-10-03T09:19:00Z","last_updated_date":"2023-10-03T09:19:00Z","reference_number":"EMA/440934/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-3-5-october-2023_en.pdf"},
    {"id":"60267","name":"Agenda for the 121st meeting of the Management Board: 5 October 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-10-05T14:21:00Z","last_updated_date":"2023-10-05T14:21:00Z","reference_number":"EMA/MB/308874/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-121st-meeting-management-board-5-october-2023_en.pdf"},
    {"id":"60295","name":"Agenda - HMA/EMA Big Data Stakeholder Forum 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-10-09T13:49:00Z","last_updated_date":"2023-12-01T10:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hma-ema-big-data-stakeholder-forum-2023_en.pdf"},
    {"id":"60361","name":"Agenda - Second listen-and-learn focus group meeting of the Quality Innovation Group","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-10-11T10:23:00Z","last_updated_date":"2024-03-12T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-listen-learn-focus-group-meeting-quality-innovation-group_en.pdf"},
    {"id":"60454","name":"Agenda - PCWP/HCPWP and all eligible organisations meeting (Nov 2023)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-10-19T11:33:00Z","last_updated_date":"2024-01-19T11:32:00Z","reference_number":"EMA/236061/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwp-hcpwp-and-all-eligible-organisations-meeting-nov-2023_en.pdf"},
    {"id":"60456","name":"Agenda - Third Veterinary Big Data Stakeholder Forum","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-10-19T17:34:00Z","last_updated_date":"2023-11-22T16:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-veterinary-big-data-stakeholder-forum_en.pdf"},
    {"id":"60460","name":"Agenda - Focus group meeting for veterinarians or other healthcare professionals on facilitating pharmacovigilance reporting of medicinal products used in aquaculture","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-10-20T12:46:00Z","last_updated_date":"2024-04-11T13:57:00Z","reference_number":"EMA/473375/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-focus-group-meeting-veterinarians-or-other-healthcare-professionals-facilitating-pharmacovigilance-reporting-medicinal-products-used-aquaculture_en.pdf"},
    {"id":"60464","name":"Agenda : Joint Heads of Medicines Agencies (HMA) / European Medicines Agency (EMA) AI workshop – Smart regulation in a rapidly evolving world","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-10-23T11:36:00Z","last_updated_date":"2023-11-10T10:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-heads-medicines-agencies-hma-european-medicines-agency-ema-ai-workshop-smart-regulation-rapidly-evolving-world_en.pdf"},
    {"id":"60465","name":"Agenda of the PRAC meeting 23-26 October 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-10-23T13:02:00Z","last_updated_date":"2023-10-26T11:32:00Z","reference_number":"EMA/PRAC/434138/2023 Corr1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-23-26-october-2023_en.pdf"},
    {"id":"60491","name":"Agenda - Awareness session for SMEs on the reform of the EU pharmaceutical legislation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-10-25T17:40:00Z","last_updated_date":"2023-11-23T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-awareness-session-smes-reform-eu-pharmaceutical-legislation_en.pdf"},
    {"id":"60511","name":"Agenda of the CAT meeting 30-31 October 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-10-30T17:20:00Z","last_updated_date":"2023-10-30T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-30-31-october-2023_en.pdf"},
    {"id":"60585","name":"Agenda - CAT agenda for the written procedure of 15-17 August 2018","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2018-10-03T17:10:00Z","last_updated_date":"2018-10-03T17:10:00Z","reference_number":"EMA/CAT/553521/2018","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-written-procedure-15-17-august-2018_en.pdf"},
    {"id":"60606","name":"Agenda - CAT agenda of the 22-24 January 2020 meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2020-01-27T11:37:00Z","last_updated_date":"2020-01-27T11:37:00Z","reference_number":"EMA/CAT/41678/2020","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-22-24-january-2020-meeting_en.pdf"},
    {"id":"60627","name":"Agenda - PRAC draft agenda of meeting 8-11 March 2021","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2021-03-08T19:00:00Z","last_updated_date":"2021-03-08T19:00:00Z","reference_number":"EMA/PRAC/145863/2021","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-march-2021_en.pdf"},
    {"id":"60671","name":"CHMP PROM agenda for the meeting on 14 February 2022","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2022-03-24T16:47:00Z","last_updated_date":"2022-03-24T16:47:00Z","reference_number":"EMA/CHMP/57793/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-14-february-2022_en.pdf"},
    {"id":"60681","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (25 July 2022)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2022-07-29T14:31:00Z","last_updated_date":"2022-07-29T14:31:00Z","reference_number":"EMA/660758/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-25-july-2022_en.pdf"},
    {"id":"60703","name":"CHMP PROM agenda for the meeting on 20 March 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-06-06T12:40:00Z","last_updated_date":"2023-06-06T12:40:00Z","reference_number":"EMA/CHMP/85734/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-20-march-2023_en.pdf"},
    {"id":"60704","name":"CTIS Bitesize Talk: IMPD-Q-only submission","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-07T11:17:00Z","last_updated_date":"2023-06-07T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/ctis-bitesize-talk-impd-q-only-submission_en.pdf"},
    {"id":"60705","name":"CTIS Bitesize Talk - IMPD-Q-only Submission - presentation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-07T11:48:00Z","last_updated_date":"2023-06-07T11:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/ctis-bitesize-talk-impd-q-only-submission-presentation_en.pdf"},
    {"id":"60706","name":"CTIS Bitesize Talk - IMPD-Q-only Submission - presentation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-07T11:57:00Z","last_updated_date":"2023-06-07T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/ctis-bitesize-talk-impd-q-only-submission-presentation_en.pdf-0"},
    {"id":"60707","name":"CTIS Bitesize Talk - IMPD-Q-only Submission - presentation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-06-07T12:02:00Z","last_updated_date":"2023-06-07T12:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/ctis-bitesize-talk-impd-q-only-submission-presentation_en.pdf-1"},
    {"id":"60711","name":"CHMP PROM agenda for the meeting on 17 April 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-06-08T19:02:00Z","last_updated_date":"2023-06-08T19:02:00Z","reference_number":"EMA/CHMP/153279/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-prom-agenda-meeting-17-april-2023_en.pdf"},
    {"id":"60735","name":"Agenda ACT EU Multi-stakeholder workshop on methodology guidance","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-08-10T16:59:00Z","last_updated_date":"2023-11-07T14:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-multi-stakeholder-workshop-methodology-guidance_en.pdf"},
    {"id":"60740","name":"Agenda – Nitrosamine Implementation Oversight Group (NIOG) – fifth meeting with  pharmaceutical industry","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-09-05T11:59:00Z","last_updated_date":"2023-09-05T11:59:00Z","reference_number":"EMA/INS/GMP/208026/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-nitrosamine-implementation-oversight-group-niog-fifth-meeting-pharmaceutical-industry_en.pdf"},
    {"id":"60751","name":"Agenda - PDCO agenda of the 5-8 September 2023 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-09-27T16:45:00Z","last_updated_date":"2023-09-27T16:45:00Z","reference_number":"EMA/PDCO/372376/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-5-8-september-2023-meeting_en.pdf"},
    {"id":"60758","name":"Agenda of the CAT meeting 4-6 October 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-10-03T17:19:00Z","last_updated_date":"2023-10-03T17:19:00Z","reference_number":"EMA/CAT/419753/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-4-6-october-2023_en.pdf"},
    {"id":"60759","name":"Draft agenda - Focus group meeting for veterinarians or  other healthcare professionals on facilitating  pharmacovigilance reporting of medicinal products used  in poultry","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-10-04T15:35:00Z","last_updated_date":"2023-10-04T15:35:00Z","reference_number":"EMA/619465/2022 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-focus-group-meeting-veterinarians-or-other-healthcare-professionals-facilitating-pharmacovigilance-reporting-medicinal-products-used-poultry_en.pdf"},
    {"id":"60761","name":"Agenda of the CHMP meeting 09-12 October 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-10-09T14:36:00Z","last_updated_date":"2023-10-09T14:36:00Z","reference_number":"EMA/CHMP/421839/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-09-12-october-2023_en.pdf"},
    {"id":"60764","name":"Agenda - PDCO agenda of the 10-13 October 2023 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-10-10T14:07:00Z","last_updated_date":"2023-10-10T14:07:00Z","reference_number":"EMA/PDCO/413254/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-10-13-october-2023-meeting_en.pdf"},
    {"id":"60770","name":"Agenda – EMA - Thalassaemia International Federation (TIF) bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-10-23T14:23:00Z","last_updated_date":"2023-10-23T14:23:00Z","reference_number":"EMA/382643/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-thalassaemia-international-federation-tif-bilateral-meeting_en.pdf"},
    {"id":"60777","name":"Agenda of the CHMP meeting 6-9 November 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-11-06T12:11:00Z","last_updated_date":"2023-11-06T12:11:00Z","reference_number":"EMA/CHMP/460963/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-6-9-november-2023_en.pdf"},
    {"id":"60784","name":"Agenda of the COMP meeting 7-9 November 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-11-07T12:25:00Z","last_updated_date":"2023-11-07T12:25:00Z","reference_number":"EMA/COMP/458095/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-7-9-november-2023_en.pdf"}    {"id":"60785","name":"Agenda of the CVMP meeting 7-9 November 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-11-07T12:42:00Z","last_updated_date":"2023-11-07T12:42:00Z","reference_number":"EMA/494916/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-7-9-november-2023_en.pdf"},
    {"id":"60801","name":"Agenda - PDCO agenda of the 7-10 November 2023 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-11-08T10:08:00Z","last_updated_date":"2023-11-08T10:08:00Z","reference_number":"EMA/PDCO/469060/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-7-10-november-2023-meeting_en.pdf"},
    {"id":"60807","name":"Agenda - Eleventh meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T10:45:00Z","last_updated_date":"2023-11-22T12:00:00Z","reference_number":"EMA/501563/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eleventh-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"60865","name":"Agenda - Update on human variations web-based electronic application form implementation on product lifecycle management portal","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T13:56:00Z","last_updated_date":"2023-11-10T13:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-update-human-variations-web-based-electronic-application-form-implementation-product-lifecycle-management-portal_en.pdf"},
    {"id":"60867","name":"Agenda - Product Lifecycle Management (PLM) Value Stream Deep-Dive Webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T14:10:00Z","last_updated_date":"2023-12-01T17:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-lifecycle-management-plm-value-stream-deep-dive-webinar_en.pdf"},
    {"id":"60920","name":"Agenda – System Demo Q4 2023 - 19 December 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-11-20T13:14:52Z","last_updated_date":"2023-12-11T15:00:00Z","reference_number":"EMA/448909/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-system-demo-q4-2023-19-december-2023_en.pdf"},
    {"id":"60929","name":"Agenda – 19th industry stakeholder platform – operation of EU pharmacovigilance ","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-11-05T11:29:40Z","last_updated_date":"2024-11-05T11:29:40Z","reference_number":"EMA/499299/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-19th-industry-stakeholder-platform-operation-eu-pharmacovigilance_en.pdf"},
    {"id":"60959","name":"Draft Agenda – Executive Steering Group on Shortages  and Safety of Medicinal Products (MSSG)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-11-22T16:34:41Z","last_updated_date":"2023-11-22T16:34:41Z","reference_number":"EMA/439541/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-executive-steering-group-shortages-safety-medicinal-products-mssg_en.pdf"},
    {"id":"60991","name":"Agenda - ACT EU Multi-stakeholder workshop on methodology guidance","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-11-27T14:05:51Z","last_updated_date":"2023-11-27T14:05:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-multi-stakeholder-workshop-methodology-guidance_en.pdf-0"},
    {"id":"61003","name":"Agenda of the PRAC meeting 27-30 November 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-11-27T11:26:33Z","last_updated_date":"2023-11-27T11:26:33Z","reference_number":"EMA/PRAC/477373/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-27-30-november-2023_en.pdf"},
    {"id":"61056","name":"Agenda of the HMPC meeting 20-22 November 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-11-22T19:08:05Z","last_updated_date":"2023-12-14T16:38:00Z","reference_number":"EMA/HMPC/468028/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-20-22-november-2023_en.pdf"},
    {"id":"61064","name":"Agenda - seventh ISG meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-11-23T11:27:37Z","last_updated_date":"2023-11-23T11:27:37Z","reference_number":"EMA/511974/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-seventh-isg-meeting_en.pdf"},
    {"id":"61108","name":"Agenda - second bilateral EMA-EUCOPE meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T11:11:35Z","last_updated_date":"2023-12-01T11:11:35Z","reference_number":" EMA/540309/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-bilateral-ema-eucope-meeting_en.pdf"},
    {"id":"61232","name":"Agenda of the COMP meeting 5-7 December 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-12-05T09:05:00Z","last_updated_date":"2023-12-05T09:05:00Z","reference_number":"EMA/COMP/511996/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-5-7-december-2023_en.pdf"},
    {"id":"61241","name":"Agenda of the CVMP meeting 5-7 December 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-12-05T14:01:03Z","last_updated_date":"2023-12-05T14:01:03Z","reference_number":"EMA/550532/2023 – draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-5-7-december-2023_en.pdf"},
    {"id":"61255","name":"Agenda of the CAT meeting 6-8 December 2023","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-12-05T15:40:49Z","last_updated_date":"2023-12-05T15:40:49Z","reference_number":"EMA/CAT/503867/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-6-8-december-2023_en.pdf"},
    {"id":"61257","name":"Agenda of the Medicine Shortages (SPOC) Working Party 20 November 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T16:15:34Z","last_updated_date":"2023-12-05T16:15:34Z","reference_number":"EMA/549634/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-20-november-2023_en.pdf"},
    {"id":"61260","name":"Draft agenda - Second bilateral meeting between European Medicines Agency and Vaccines Europe","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T16:59:33Z","last_updated_date":"2023-12-05T16:59:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-second-bilateral-meeting-between-european-medicines-agency-and-vaccines-europe_en.pdf"},
    {"id":"61268","name":"Agenda of the Medicine Shortages (SPOC) Working Party 26-27 October 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T13:32:24Z","last_updated_date":"2023-12-06T13:32:24Z","reference_number":"EMA/499095/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-26-27-october-2023_en.pdf"},
    {"id":"61287","name":"Agenda - EMA EORTC workshop on soft tissue and sarcoma ","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T17:12:13Z","last_updated_date":"2024-01-09T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-eortc-workshop-soft-tissue-and-sarcoma_en.pdf"},
    {"id":"61348","name":"Agenda of the CHMP meeting 11-14 December 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-11T14:08:46Z","last_updated_date":"2023-12-11T14:08:46Z","reference_number":"EMA/CHMP/501322/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-11-14-december-2023_en.pdf"},
    {"id":"61357","name":"Agenda - PDCO agenda of the 12-15 December 2023 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-12-11T16:04:09Z","last_updated_date":"2023-12-11T16:04:09Z","reference_number":"EMA/PDCO/528422/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-15-december-2023-meeting_en.pdf"},
    {"id":"61382","name":"Agenda - DARWIN EU Advisory Board - 24 May 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T12:36:07Z","last_updated_date":"2023-12-12T12:36:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-24-may-2023_en.pdf"},
    {"id":"61385","name":"Agenda - Eleventh industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T15:38:17Z","last_updated_date":"2023-12-12T15:38:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eleventh-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"61393","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (13 December 2023)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2023-12-12T17:02:46Z","last_updated_date":"2023-12-12T17:02:46Z","reference_number":"EMA/537405/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-13-december-2023_en.pdf"},
    {"id":"61396","name":"Agenda of the 122nd meeting of the Management Board, 13-14 December 2023","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2023-12-13T11:48:36Z","last_updated_date":"2023-12-15T09:22:00Z","reference_number":"EMA/MB/490304/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-122nd-meeting-management-board-13-14-december-2023_en.pdf"},
    {"id":"61483","name":"Agenda - EMA multi-stakeholder workshop on psychedelics – Towards an EU regulatory framework","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-18T14:12:47Z","last_updated_date":"2024-04-19T14:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-multi-stakeholder-workshop-psychedelics-towards-eu-regulatory-framework_en.pdf"},
    {"id":"61484","name":"Agenda - ACT EU Clinical Trials Analytics Workshop - January 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-18T14:31:24Z","last_updated_date":"2024-02-02T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-clinical-trials-analytics-workshop-january-2024_en.pdf"},
    {"id":"61561","name":"Agenda - Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T11:50:46Z","last_updated_date":"2023-12-21T11:50:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system_en.pdf-0"},
    {"id":"61562","name":"Agenda of the Medicine Shortages (SPOC) Working Party 14 December 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T12:35:23Z","last_updated_date":"2023-12-21T12:35:23Z","reference_number":"EMA/547123/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-14-december-2023_en.pdf"},
    {"id":"61568","name":"Agenda – biannual Big Data Steering Group and industry stakeholders meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T13:40:15Z","last_updated_date":"2023-12-21T13:40:15Z","reference_number":"EMA/488460/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-biannual-big-data-steering-group-and-industry-stakeholders-meeting_en.pdf-0"},
    {"id":"61573","name":"Agenda -  Virtual live hands-on training for clinical trials sponsors using EudraVigilance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-05T12:00:10Z","last_updated_date":"2024-06-05T12:00:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-virtual-live-hands-training-clinical-trials-sponsors-using-eudravigilance_en.pdf"},
    {"id":"61642","name":"eXtended EudraVigilance Medicinal Product Dictionary training course - February, April and June 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T14:37:58Z","last_updated_date":"2024-01-05T14:37:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/extended-eudravigilance-medicinal-product-dictionary-training-course-february-april-and-june-2024_en.pdf"},
    {"id":"61655","name":"eXtended EudraVigilance medicinal product dictionary (XEVMPD) live virtual training course for sponsors","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-01-08T10:46:46Z","last_updated_date":"2024-01-08T10:46:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/extended-eudravigilance-medicinal-product-dictionary-xevmpd-live-virtual-training-course-sponsors_en.pdf"},
    {"id":"61663","name":"Agenda of the PRAC meeting 8-11 January 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-01-08T14:42:21Z","last_updated_date":"2024-01-08T14:42:21Z","reference_number":"EMA/PRAC/545005/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-8-11-january-2024_en.pdf"},
    {"id":"61765","name":"Agenda of the CAT meeting 17-19 January 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-01-15T14:25:39Z","last_updated_date":"2024-01-15T14:25:39Z","reference_number":"EMA/CAT/20622/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-17-19-january-2024_en.pdf"},
    {"id":"61769","name":"Agenda - Network users training for Regulatory Procedure Management 1st roll-out on IRIS","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-01-15T15:47:35Z","last_updated_date":"2024-01-15T15:47:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-network-users-training-regulatory-procedure-management-1st-roll-out-iris_en.pdf"},
    {"id":"61774","name":"Agenda - PDCO agenda of the 16-19 January 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-01-16T11:31:21Z","last_updated_date":"2024-01-16T11:31:21Z","reference_number":"EMA/PDCO/550/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-16-19-january-2024-meeting_en.pdf"},
    {"id":"61775","name":"Agenda - Orphan medicines development : ask the European regulator","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-01-16T11:45:34Z","last_updated_date":"2024-02-13T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-orphan-medicines-development-ask-european-regulator_en.pdf"},
    {"id":"61788","name":"Agenda of the COMP meeting 16-18 January 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-01-17T10:12:08Z","last_updated_date":"2024-01-17T10:12:08Z","reference_number":"EMA/COMP/568809/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-16-18-january-2024_en.pdf"},
    {"id":"61790","name":"Agenda of the CVMP meeting 16-18 January 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-01-17T11:16:08Z","last_updated_date":"2024-01-17T11:16:08Z","reference_number":"EMA/19707/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-16-18-january-2024_en.pdf"},
    {"id":"61791","name":"Agenda - Joint HMA/EMA multi-stakeholder  workshop on Patient Registries","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-01-17T11:36:41Z","last_updated_date":"2024-02-12T10:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-hma-ema-multi-stakeholder-workshop-patient-registries_en.pdf"},
    {"id":"61793","name":"Agenda - How can Patient Reported Outcomes (PROs) and Health Related Quality of Life (HRQoL) data inform regulatory decisions for cancer treatments?","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-01-17T13:04:04Z","last_updated_date":"2024-02-27T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-how-can-patient-reported-outcomes-pros-health-related-quality-life-hrqol-data-inform-regulatory-decisions-cancer-treatments_en.pdf"},
    {"id":"61818","name":"Agenda of the CHMP meeting 22-25 January 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-01-22T10:47:45Z","last_updated_date":"2024-01-22T10:47:45Z","reference_number":"EMA/CHMP/572349/2023 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-january-2024_en.pdf"},
    {"id":"61820","name":"Agenda - EMA multi-stakeholder workshop on the guideline on clinical investigation of medicinal products in the treatment of epileptic disorders","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T12:00:58Z","last_updated_date":"2024-01-22T18:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-multi-stakeholder-workshop-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders_en.pdf"},
    {"id":"61848","name":"Agenda - Medicine Shortages (SPOC) Working Party (22 January 2024)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-01-23T16:23:26Z","last_updated_date":"2024-01-23T16:23:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-22-january-2024_en.pdf"},
    {"id":"61878","name":"Agenda - ACT EU Training for non-commercial sponsors: Transitioning trials to the CTR (CTIS)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-01-25T10:24:02Z","last_updated_date":"2024-02-01T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-training-non-commercial-sponsors-transitioning-trials-ctr-ctis_en.pdf"},
    {"id":"61895","name":"Agenda - Enpr-EMA Coordinating Group and networks meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-01-25T16:15:40Z","last_updated_date":"2024-01-25T16:15:40Z","reference_number":"EMA/219219/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-and-networks-meeting_en.pdf-1"},
    {"id":"61916","name":"Agenda of the HMPC meeting 29-31 January 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-01-26T14:45:13Z","last_updated_date":"2024-01-26T14:45:13Z","reference_number":"EMA/HMPC/572004/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-29-31-january-2024_en.pdf"},
    {"id":"61923","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (29 January 2024)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T16:07:06Z","last_updated_date":"2024-01-26T16:07:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-29-january-2024_en.pdf"},
    {"id":"61924","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T16:15:48Z","last_updated_date":"2024-03-15T15:47:00Z","reference_number":"EMA/567941/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting_en.pdf"},
    {"id":"61937","name":"Agenda - 6th meeting of the Nitrosamine Implementation Oversight Group - Industry Association","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-01-29T14:22:37Z","last_updated_date":"2024-01-29T14:22:37Z","reference_number":"EMA/469661/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-6th-meeting-nitrosamine-implementation-oversight-group-industry-association_en.pdf"},
    {"id":"61978","name":"Agenda - Sixth European Medicines Agency (EMA) EFPIA bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-02-01T15:51:17Z","last_updated_date":"2024-02-01T15:51:17Z","reference_number":"EMA/519226/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixth-european-medicines-agency-ema-efpia-bilateral-meeting_en.pdf"},
    {"id":"62005","name":"Agenda of the PRAC meeting 5-8 February 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-02-05T16:30:16Z","last_updated_date":"2024-02-06T17:12:00Z","reference_number":"EMA/PRAC/11237/2024 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-5-8-february-2024_en.pdf"},
    {"id":"62007","name":"Test media access","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-02-06T11:55:54Z","last_updated_date":"2024-02-06T11:55:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/test-media-access_en.pdf"},
    {"id":"62085","name":"Agenda - European Medicines Agency veterinary medicines info day 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-02-12T16:21:40Z","last_updated_date":"2024-03-06T10:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-veterinary-medicines-info-day-2024_en.pdf"},
    {"id":"62102","name":"Agenda - Multi-stakeholder workshop on Data Quality Framework for Adverse Drug Reaction reporting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-02-13T12:00:00Z","last_updated_date":"2024-03-01T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-workshop-data-quality-framework-adverse-drug-reaction-reporting_en.pdf"},
    {"id":"62103","name":"Agenda of the CVMP meeting 13-15 February 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-02-13T13:45:00Z","last_updated_date":"2024-02-13T13:45:00Z","reference_number":"EMA/63473/2024 – draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-13-15-february-2024_en.pdf"},
    {"id":"62113","name":"Agenda of the COMP meeting 13-15 February 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-02-13T15:16:06Z","last_updated_date":"2024-02-13T15:16:06Z","reference_number":"EMA/COMP/37898/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-13-15-february-2024_en.pdf"},
    {"id":"62115","name":"Agenda - Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-02-13T15:28:52Z","last_updated_date":"2024-02-13T15:28:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-update-webinar-regulatory-procedure-management-product-lifecycle-management-iris_en.pdf"},
    {"id":"62131","name":"Agenda of the CAT meeting 14-16 February 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-02-14T08:51:07Z","last_updated_date":"2024-02-14T08:51:07Z","reference_number":"EMA/CAT/39852/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-14-16-february-2024_en.pdf"},
    {"id":"62171","name":"Agenda - Medicine Shortages (SPOC) Working Party 14 February 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-02-15T11:15:00Z","last_updated_date":"2024-02-15T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-14-february-2024_en.pdf"},
    {"id":"62207","name":"Agenda of the CHMP meeting 19-22 February 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-02-19T11:46:54Z","last_updated_date":"2024-02-19T11:46:54Z","reference_number":"EMA/CHMP/39398/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-19-22-february-2024_en.pdf"},
    {"id":"62218","name":"Agenda - PDCO agenda of the 20-23 February 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-02-20T13:53:15Z","last_updated_date":"2024-02-20T13:53:15Z","reference_number":"EMA/PDCO/35476/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-20-23-february-2024-meeting_en.pdf"},
    {"id":"62220","name":"Agenda - Cancer Medicines Forum - a way forward for treatment optimisation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-02-20T15:20:29Z","last_updated_date":"2024-04-04T14:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cancer-medicines-forum-way-forward-treatment-optimisation_en.pdf"},
    {"id":"62314","name":"Agenda - Multi-stakeholder webinar on the HMA-EMA Catalogues of real-world data sources and studies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-02-27T17:31:15Z","last_updated_date":"2024-02-27T17:31:15Z","reference_number":"EMA/85128/2024 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-webinar-hma-ema-catalogues-real-world-data-sources-studies_en.pdf"},
    {"id":"62391","name":"Agenda - Quarterly System Demo Q1 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T11:12:19Z","last_updated_date":"2024-03-13T13:51:00Z","reference_number":"EMA/16426/2024 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quarterly-system-demo-q1-2024_en.pdf"},
    {"id":"62428","name":"Agenda of the PRAC meeting 4-7 March 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-03-04T15:01:30Z","last_updated_date":"2024-03-04T15:01:30Z","reference_number":"EMA/PRAC/57049/2024 Corr1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-4-7-march-2024_en.pdf"},
    {"id":"62531","name":"Agenda of the COMP meeting 12-14 March 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-03-11T11:53:30Z","last_updated_date":"2024-03-11T11:53:30Z","reference_number":"EMA/COMP/79894/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-12-14-march-2024_en.pdf"},
    {"id":"62545","name":"Agenda of the CVMP meeting 12-14 March 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-03-11T16:33:02Z","last_updated_date":"2024-03-11T16:33:02Z","reference_number":"EMA/107153/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-12-14-march-2024_en.pdf"},
    {"id":"62555","name":"Agenda - DARWIN EU Advisory Board - 11 December 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T14:38:04Z","last_updated_date":"2024-03-12T14:38:04Z","reference_number":"EMA/423117/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-11-december-2023_en.pdf"},
    {"id":"62582","name":"Agenda of the CAT meeting 13-15 March 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-03-13T09:04:27Z","last_updated_date":"2024-03-13T09:04:27Z","reference_number":"EMA/CAT/81614/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-13-15-march-2024_en.pdf"},
    {"id":"62620","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (19 March 2024)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-03-15T15:56:05Z","last_updated_date":"2024-03-15T15:56:05Z","reference_number":"EMA/43949/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-19-march-2024_en.pdf"},
    {"id":"62626","name":"Agenda of the CHMP meeting 18-21 March 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-03-18T10:58:43Z","last_updated_date":"2024-03-18T10:58:43Z","reference_number":"EMA/CHMP/82603/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-18-21-march-2024_en.pdf"},
    {"id":"62638","name":"Agenda - CTIS Webinar: Last Year of Transition","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-03-18T15:27:50Z","last_updated_date":"2024-03-18T15:27:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ctis-webinar-last-year-transition_en.pdf"},
    {"id":"62641","name":"Agenda of the HMPC meeting 18-20 March 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-03-18T15:54:29Z","last_updated_date":"2024-03-18T15:54:29Z","reference_number":"EMA/HMPC/86409/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-18-20-march-2024_en.pdf"},
    {"id":"62653","name":"Agenda - PDCO agenda of the 19-22 March 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-03-20T13:44:22Z","last_updated_date":"2024-03-20T13:44:22Z","reference_number":"EMA/PDCO/87226/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-19-22-march-2024-meeting_en.pdf"},
    {"id":"62654","name":"Agenda - Electronic Common Technical Document (eCTD) vendor workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-03-20T13:54:51Z","last_updated_date":"2024-03-20T13:54:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-electronic-common-technical-document-ectd-vendor-workshop_en.pdf"},
    {"id":"62664","name":"Agenda – 8th Industry Standing Group (ISG) meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-03-21T08:38:52Z","last_updated_date":"2024-03-22T13:40:00Z","reference_number":"EMA/125572/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-8th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"62676","name":"Agenda of the 123rd meeting of the Management Board : 21 March 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-03-21T14:09:20Z","last_updated_date":"2024-03-21T14:09:20Z","reference_number":"EMA/MB/52682/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-123rd-meeting-management-board-21-march-2024_en.pdf"},
    {"id":"62788","name":"Agenda - Product Management Service (PMS) Info-Day","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-04-03T12:38:46Z","last_updated_date":"2024-04-11T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-management-service-pms-info-day_en.pdf"},
    {"id":"62868","name":"Agenda of the PRAC meeting 8-11 April 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-04-08T16:33:20Z","last_updated_date":"2024-04-08T16:33:20Z","reference_number":"EMA/PRAC/97608/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-8-11-april-2024_en.pdf"},
    {"id":"62875","name":"Agenda - Focus group meeting for veterinarians or other healthcare professionals on facilitating pharmacovigilance reporting of medicinal products used in poultry","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-09T15:15:12Z","last_updated_date":"2024-04-09T15:15:12Z","reference_number":"EMA/619465/2022","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-focus-group-meeting-veterinarians-or-other-healthcare-professionals-facilitating-pharmacovigilance-reporting-medicinal-products-used-poultry_en.pdf"},
    {"id":"62913","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (12 April 2024)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-04-11T13:47:56Z","last_updated_date":"2024-04-11T13:47:56Z","reference_number":"EMA/120760/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-12-april-2024_en.pdf"},
    {"id":"62940","name":"Agenda - Committee for Advanced Therapies (CAT) meeting with interested parties - May 2023","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T16:02:44Z","last_updated_date":"2024-04-12T16:02:44Z","reference_number":"EMA/193793/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-committee-advanced-therapies-cat-meeting-interested-parties-may-2023_en.pdf"},
    {"id":"62964","name":"Agenda - Simultaneous National Scientific Advice (SNSA) information and training webinar for Applicants","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-04-16T09:50:12Z","last_updated_date":"2024-04-16T09:50:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-simultaneous-national-scientific-advice-snsa-information-training-webinar-applicants_en.pdf"},
    {"id":"62965","name":"Agenda of the COMP meeting 16-18 April 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T09:55:01Z","last_updated_date":"2024-04-16T09:55:01Z","reference_number":"EMA/COMP/122528/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-16-18-april-2024_en.pdf"},
    {"id":"62966","name":"Agenda - Medicine Shortages Single Point of Contact (SPOC) Working Party - 15-16 April 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T11:49:14Z","last_updated_date":"2024-04-16T11:49:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-single-point-contact-spoc-working-party-15-16-april-2024_en.pdf"},
    {"id":"62978","name":"Agenda of the CAT meeting 17-19 April 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-04-16T14:21:22Z","last_updated_date":"2024-04-16T14:21:22Z","reference_number":"EMA/CAT/162597/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-17-19-april-2024_en.pdf"},
    {"id":"62980","name":"Agenda of the CVMP meeting 16-18 April 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-04-16T16:04:20Z","last_updated_date":"2024-04-16T16:04:20Z","reference_number":"EMA/158463/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-16-18-april-2024_en.pdf"},
    {"id":"62987","name":"Agenda - EMA/FVE info session on restrictions for the use of certain antimicrobials in animals","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-17T15:01:44Z","last_updated_date":"2024-05-14T09:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-fve-info-session-restrictions-use-certain-antimicrobials-animals_en.pdf"},
    {"id":"63033","name":"Agenda of the CHMP meeting 22-25 April 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-04-22T12:09:22Z","last_updated_date":"2024-04-23T09:37:00Z","reference_number":"EMA/CHMP/127161/2024 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-april-2024_en.pdf"},
    {"id":"63034","name":"Agenda - Ad-hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - April 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-22T12:15:33Z","last_updated_date":"2024-04-22T12:15:33Z","reference_number":"EMA/128602/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ad-hoc-executive-steering-group-shortages-safety-medicinal-products-mssg-april-2024_en.pdf"},
    {"id":"63037","name":"Agenda - Joint HMA/EMA Big Data Steering Group workshop on real-world evidence (RWE) methods","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-22T15:43:21Z","last_updated_date":"2024-06-13T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-hma-ema-big-data-steering-group-workshop-real-world-evidence-rwe-methods_en.pdf"},
    {"id":"63044","name":"Agenda - PDCO agenda of the 23-26 April 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-04-23T11:55:44Z","last_updated_date":"2024-04-23T11:55:44Z","reference_number":"EMA/PDCO/141537/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-23-26-april-2024-meeting_en.pdf"},
    {"id":"63095","name":"Programme - EU NTC ten year anniversary event","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-05-02T16:00:00Z","last_updated_date":"2024-05-29T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-eu-ntc-ten-year-anniversary-event_en.pdf"},
    {"id":"63097","name":"Agenda - Enpr-EMA Coordinating Group meeting (March 2024)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-29T09:07:38Z","last_updated_date":"2024-04-29T09:07:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-meeting-march-2024_en.pdf"},
    {"id":"63098","name":"Agenda - Information and Q&A session on updated CAPs in web-based eAF","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-29T09:49:56Z","last_updated_date":"2024-04-29T09:49:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-information-qa-session-updated-caps-web-based-eaf_en.pdf"},
    {"id":"63105","name":"Agenda - Twelfth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-29T17:00:00Z","last_updated_date":"2024-05-03T14:30:00Z","reference_number":"EMA/180473/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-twelfth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"63157","name":"Agenda - Third European Medicines Agency and Affordable Medicines Europe bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-05-03T10:00:00Z","last_updated_date":"2024-05-03T10:00:00Z","reference_number":"EMA/135336/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-european-medicines-agency-affordable-medicines-europe-bilateral-meeting_en.pdf"}    {"id":"63206","name":"Agenda of the PRAC meeting 13-16 May 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-05-13T16:45:00Z","last_updated_date":"2024-05-14T18:00:00Z","reference_number":"EMA/PRAC/151850/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-13-16-may-2024_en.pdf"},
    {"id":"63216","name":"Agenda - Quarterly System Demo Q2 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-05-16T10:46:00Z","last_updated_date":"2024-06-12T13:26:00Z","reference_number":"EMA/152799/2024 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quarterly-system-demo-q2-2024_en.pdf"},
    {"id":"63233","name":"Agenda - Medicine Shortages (SPOC) Working Party 14 March 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-05-16T12:24:00Z","last_updated_date":"2024-05-16T12:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-14-march-2024_en.pdf"},
    {"id":"63245","name":"Agenda - Follow up EMA and EORTC multi-stakeholder workshop on soft tissue and bone sarcoma","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T16:23:00Z","last_updated_date":"2024-05-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-follow-ema-eortc-multi-stakeholder-workshop-soft-tissue-bone-sarcoma_en.pdf"},
    {"id":"63272","name":"Agenda of the COMP meeting 21-23 May 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-05-21T09:41:13Z","last_updated_date":"2024-05-21T09:41:13Z","reference_number":"EMA/COMP/176815/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-21-23-may-2024_en.pdf"},
    {"id":"63273","name":"Agenda of the CVMP meeting 21-23 May 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-05-21T10:05:16Z","last_updated_date":"2024-05-21T10:05:16Z","reference_number":"EMA/237161/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-21-23-may-2024_en.pdf"},
    {"id":"63288","name":"Agenda - Product Management Service (PMS) Product UI training (access & navigation)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-05-21T15:49:26Z","last_updated_date":"2024-05-31T15:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-management-service-pms-product-ui-training-access-navigation_en.pdf"},
    {"id":"63293","name":"Agenda of the CAT meeting 22-24 May 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-05-22T10:14:55Z","last_updated_date":"2024-05-22T10:14:55Z","reference_number":"EMA/CAT/180860/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-22-24-may-2024_en.pdf"},
    {"id":"63302","name":"Agenda - Medicine Shortages (SPOC) Working Party meeting on 22 May 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-05-22T15:12:25Z","last_updated_date":"2024-05-22T15:12:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-22-may-2024_en.pdf"},
    {"id":"63311","name":"Agenda - European Shortages Monitoring Platform Essentials and Industry Reporting Requirements","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-05-23T17:55:17Z","last_updated_date":"2024-06-11T13:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-shortages-monitoring-platform-essentials-industry-reporting-requirements_en.pdf"},
    {"id":"63316","name":"Agenda - Seventh  European Medicines Agency - Medicines for Europe annual bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-05-24T09:42:47Z","last_updated_date":"2024-05-24T09:42:47Z","reference_number":"EMA/164965/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-seventh-european-medicines-agency-medicines-europe-annual-bilateral-meeting_en.pdf"},
    {"id":"63325","name":"Agenda of the HMPC meeting 27-29 May 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-05-24T15:58:34Z","last_updated_date":"2024-05-24T15:58:34Z","reference_number":"EMA/HMPC/149272/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-27-29-may-2024_en.pdf"},
    {"id":"63328","name":"Agenda of the CHMP meeting 27-30 May 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-05-27T15:16:00Z","last_updated_date":"2024-05-27T15:16:00Z","reference_number":"EMA/CHMP/182386/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-27-30-may-2024_en.pdf"},
    {"id":"63339","name":"Agenda - DARWIN EU Advisory Board - 03 May 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T14:23:27Z","last_updated_date":"2024-05-28T14:23:27Z","reference_number":"EMA/149470/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-03-may-2024_en.pdf"},
    {"id":"63340","name":"Agenda - PDCO agenda of the 28-31 May 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-05-28T14:34:16Z","last_updated_date":"2024-05-28T14:34:16Z","reference_number":"EMA/PDCO/189594/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-28-31-may-2024-meeting_en.pdf"},
    {"id":"63445","name":"Agenda - Multistakeholder workshop on shortages of Glucagon-Like Peptide-1 (GLP-1) receptor agonists","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-05-31T11:11:11Z","last_updated_date":"2024-07-01T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multistakeholder-workshop-shortages-glucagon-peptide-1-glp-1-receptor-agonists_en.pdf"},
    {"id":"63487","name":"Agenda - Mandatory use of ISO ICH E2B(R3) Individual Case Safety Reporting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-11-12T13:47:00Z","last_updated_date":"2024-11-12T13:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-mandatory-use-iso-ich-e2br3-individual-case-safety-reporting_en.pdf"},
    {"id":"63536","name":"Agenda - New Fee Regulation: webinar for veterinary Marketing Authorisation Holders","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-07T12:28:46Z","last_updated_date":"2024-06-07T12:28:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-new-fee-regulation-webinar-veterinary-marketing-authorisation-holders_en.pdf"},
    {"id":"63551","name":"Agenda of the PRAC meeting 10-13 June  2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-06-10T15:30:00Z","last_updated_date":"2024-06-10T15:30:00Z","reference_number":"EMA/PRAC/230613/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-10-13-june-2024_en.pdf"},
    {"id":"63558","name":"Document to be published in 2 minutes at 12:24","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-11T12:22:20Z","last_updated_date":"2024-06-11T12:22:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/document-be-published-2-minutes-1224_en.pdf"},
    {"id":"63565","name":"Agenda - Industry Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-11T13:36:52Z","last_updated_date":"2024-06-11T13:36:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-industry-update-webinar-regulatory-procedure-management-product-lifecycle-management-iris_en.pdf"},
    {"id":"63570","name":"Agenda - Quality Innovation Group (QIG) Listen and Learn Focus Group (LLFG) meeting on Process Models","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-11T14:00:19Z","last_updated_date":"2024-06-11T14:00:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quality-innovation-group-qig-listen-learn-focus-group-llfg-meeting-process-models_en.pdf"},
    {"id":"63588","name":"Agenda - Workshop on the challenges in drug development, regulation and clinical practice in haemoglobinopathies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-12T14:51:43Z","last_updated_date":"2024-06-12T14:51:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-challenges-drug-development-regulation-clinical-practice-haemoglobinopathies_en.pdf"},
    {"id":"63590","name":"Agenda - Biannual Big Data Steering Group and industry stakeholders meeting 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-12T16:20:00Z","last_updated_date":"2024-06-12T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-biannual-big-data-steering-group-industry-stakeholders-meeting-2024_en.pdf"},
    {"id":"63593","name":"Agenda of the 124th meeting of the Management Board : 12-13 June 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-06-13T11:26:45Z","last_updated_date":"2024-06-13T11:26:45Z","reference_number":"EMA/MB/145463/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-124th-meeting-management-board-12-13-june-2024_en.pdf"},
    {"id":"63639","name":"Agenda: Healthcare Professionals' (HCPWP) working party meeting, 2 July 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-06-14T17:22:00Z","last_updated_date":"2024-06-14T17:22:00Z","reference_number":"EMA/187783/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-healthcare-professionals-hcpwp-working-party-meeting-2-july-2024_en.pdf"},
    {"id":"63644","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) Working Party meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-06-17T09:49:56Z","last_updated_date":"2024-06-17T09:49:56Z","reference_number":"EMA/187783/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-consumers-pcwp-working-party-meeting_en.pdf"},
    {"id":"63657","name":"Agenda of the CVMP meeting 18-20 June 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-17T16:31:08Z","last_updated_date":"2024-06-17T16:31:08Z","reference_number":"EMA/281901/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-18-20-june-2024_en.pdf"},
    {"id":"63660","name":"Agenda of the COMP meeting 18-20 June 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-06-18T11:21:58Z","last_updated_date":"2024-06-18T11:21:58Z","reference_number":"EMA/COMP/252180/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-18-20-june-2024_en.pdf"},
    {"id":"63662","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-06-18T11:55:26Z","last_updated_date":"2024-06-18T11:55:26Z","reference_number":"EMA/187783/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting_en.pdf-0"},
    {"id":"63666","name":"Agenda of the CAT meeting 19-21 June 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-06-18T13:49:26Z","last_updated_date":"2024-06-18T13:49:26Z","reference_number":"EMA/CAT/283543/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-19-21-june-2024_en.pdf"},
    {"id":"63708","name":"Agenda - Medicine Shortages (SPOC) Working Party, 20 June 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-06-20T14:45:00Z","last_updated_date":"2024-06-20T14:45:00Z","reference_number":"EMA/222205/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-20-june-2024_en.pdf"},
    {"id":"63709","name":"Agenda - Joint EC/HMA/EMA multi-stakeholder workshop on pharmacogenomics (24 September 2024)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-06-20T17:13:00Z","last_updated_date":"2024-09-17T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-ec-hma-ema-multi-stakeholder-workshop-pharmacogenomics-24-september-2024_en.pdf"},
    {"id":"63720","name":"Agenda - Enpr-EMA Coordinating Group and networks meeting - June 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-12T14:49:02Z","last_updated_date":"2024-06-12T14:49:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-networks-meeting-june-2024_en.pdf"},
    {"id":"63723","name":"Agenda of the CHMP meeting 24-27 June 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-06-24T12:02:00Z","last_updated_date":"2024-06-27T17:30:00Z","reference_number":"EMA/CHMP/259829/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-24-27-june-2024_en.pdf"},
    {"id":"63725","name":"Agenda - First EMA-Animal Health Europe annual bilateral meeting July 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-06-24T13:35:00Z","last_updated_date":"2024-06-24T13:35:00Z","reference_number":"EMA/159753/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-ema-animal-health-europe-annual-bilateral-meeting-july-2024_en.pdf"},
    {"id":"63735","name":"Agenda - Ninth Industry Standing Group (ISG) meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-24T15:20:24Z","last_updated_date":"2024-06-24T15:20:24Z","reference_number":"EMA/135119/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ninth-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"63737","name":"Agenda Methodology Working Party (MWP) Interested Parties Meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-07T10:43:06Z","last_updated_date":"2024-06-07T10:43:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-methodology-working-party-mwp-interested-parties-meeting_en.pdf"},
    {"id":"63741","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), 26 June 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-06-25T11:30:00Z","last_updated_date":"2024-06-25T11:30:00Z","reference_number":"EMA/ 242137 /2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-26-june-2024_en.pdf"},
    {"id":"63747","name":"Agenda - PDCO agenda of the 25-28 June 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-06-25T16:45:19Z","last_updated_date":"2024-07-25T16:01:00Z","reference_number":"EMA/PDCO/267948/2024 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-25-28-june-2024-meeting_en.pdf"},
    {"id":"63770","name":"Agenda - Ad-hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), 1 July 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-06-27T14:56:38Z","last_updated_date":"2024-06-27T14:56:38Z","reference_number":"EMA/236079/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ad-hoc-executive-steering-group-shortages-safety-medicinal-products-mssg-1-july-2024_en.pdf"},
    {"id":"63775","name":"Programme - Extended EudraVigilance medicinal product dictionary (XEVMPD) training course for sponsors 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-27T16:11:00Z","last_updated_date":"2024-09-04T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-sponsors-2024_en.pdf"},
    {"id":"63776","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-27T16:13:00Z","last_updated_date":"2024-09-04T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-2024_en.pdf"},
    {"id":"63818","name":"Agenda - Product Management Service (PMS) Application Programming Interface (API) training session","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T16:00:00Z","last_updated_date":"2024-07-04T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-management-service-pms-application-programming-interface-api-training-session_en.pdf"},
    {"id":"63819","name":"Agenda - Public webinar on pack size submissions: from XEVMPD to product management service (PMS)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T16:15:00Z","last_updated_date":"2024-07-10T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-public-webinar-pack-size-submissions-xevmpd-product-management-service-pms_en.pdf"},
    {"id":"63894","name":"Agenda: SPOR and XEVMPD status update webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T12:30:00Z","last_updated_date":"2024-07-05T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-spor-xevmpd-status-update-webinar_en.pdf"},
    {"id":"63949","name":"Agenda of the PRAC meeting 8-11 July 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-07-08T17:45:04Z","last_updated_date":"2024-07-08T17:45:04Z","reference_number":"EMA/PRAC/276333/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-8-11-july-2024_en.pdf"},
    {"id":"63956","name":"Agenda - Twelfth meeting of the industry stakeholder platform on research and development support","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-07-09T09:13:42Z","last_updated_date":"2024-07-09T09:13:42Z","reference_number":"EMA/174789/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-twelfth-meeting-industry-stakeholder-platform-research-development-support_en.pdf"},
    {"id":"63958","name":"Agenda - Fifth EMA-AESGP annual bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-04-26T09:29:26Z","last_updated_date":"2024-07-09T09:30:00Z","reference_number":"EMA/137738/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fifth-ema-aesgp-annual-bilateral-meeting_en.pdf"},
    {"id":"63983","name":"Agenda - Info session on web-based electronic Application Form (eAF) add package","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T17:47:19Z","last_updated_date":"2024-07-09T17:47:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-info-session-web-based-electronic-application-form-eaf-add-package_en.pdf"},
    {"id":"64154","name":"Agenda - Joint HMA/EMA multi-stakeholder workshop on submission predictability","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T11:47:20Z","last_updated_date":"2024-09-20T15:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-joint-hma-ema-multi-stakeholder-workshop-submission-predictability_en.pdf"},
    {"id":"64156","name":"Agenda of the CVMP meeting 16-18 July 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-07-15T15:29:28Z","last_updated_date":"2024-07-15T15:29:28Z","reference_number":"EMA/329607/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-16-18-july-2024_en.pdf"},
    {"id":"64185","name":"Agenda of the CAT meeting 17-19 July 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-07-17T16:04:09Z","last_updated_date":"2024-07-17T16:04:09Z","reference_number":"EMA/CAT/328264/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-17-19-july-2024_en.pdf"},
    {"id":"64191","name":"Agenda of the Medicine Shortages SPOC Working Party meeting - 17 July 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-07-18T10:39:00Z","last_updated_date":"2024-07-23T15:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-17-july-2024_en.pdf"},
    {"id":"64224","name":"Agenda – Annual training session for patients, consumers and healthcare professionals involved in medicines regulatory activities - December 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-07-19T12:46:00Z","last_updated_date":"2024-07-19T12:46:00Z","reference_number":"EMA/325178/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-annual-training-session-patients-consumers-healthcare-professionals-involved-medicines-regulatory-activities-december-2024_en.pdf"},
    {"id":"64252","name":"Agenda of the HMPC meeting 22-24 July 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-07-22T09:44:00Z","last_updated_date":"2024-07-22T09:44:00Z","reference_number":"EMA/HMPC/308012/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-22-24-july-2024_en.pdf"},
    {"id":"64270","name":"Agenda of the CHMP meeting 22-25 July 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-07-22T14:04:00Z","last_updated_date":"2024-07-22T14:04:00Z","reference_number":"EMA/CHMP/304093/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-july-2024_en.pdf"},
    {"id":"64285","name":"Agenda - PDCO agenda of the 23-26 July 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-07-24T09:28:09Z","last_updated_date":"2024-07-24T09:28:09Z","reference_number":"EMA/PDCO/321578/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-23-26-july-2024-meeting_en.pdf"},
    {"id":"64370","name":"Agenda of the extraordinary CHMP meeting 29 July 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-07-29T15:52:14Z","last_updated_date":"2024-07-29T15:52:14Z","reference_number":"EMA/CHMP/350070/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-extraordinary-chmp-meeting-29-july-2024_en.pdf"},
    {"id":"64448","name":"Agenda of the COMP meeting 16-18 July 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-07-31T16:32:22Z","last_updated_date":"2024-07-31T16:32:22Z","reference_number":"EMA/COMP/298873/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-16-18-july-2024_en.pdf"},
    {"id":"64571","name":"Agenda - Quarterly System Demo Q3 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-08-14T14:57:35Z","last_updated_date":"2024-09-04T14:52:00Z","reference_number":"EMA/360486/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quarterly-system-demo-q3-2024_en.pdf"},
    {"id":"64592","name":"Agenda of the CHMP written procedure 19-22 August 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-08-19T14:39:41Z","last_updated_date":"2024-08-19T14:39:41Z","reference_number":"EMA/378229/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-written-procedure-19-22-august-2024_en.pdf"},
    {"id":"64647","name":"Agenda - Third EMA and MedTech Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-08-28T14:14:50Z","last_updated_date":"2024-08-28T14:14:50Z","reference_number":"EMA/67014/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-ema-medtech-europe-bilateral-meeting_en.pdf"},
    {"id":"64649","name":"Agenda - Fourth EMA and Nuclear Medicines Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-08-28T14:19:46Z","last_updated_date":"2024-08-28T14:19:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-ema-nuclear-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"64681","name":"Agenda of the PRAC meeting 2-5 September 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-02T16:27:00Z","last_updated_date":"2024-09-02T16:27:00Z","reference_number":"EMA/PRAC/323875/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-2-5-september-2024_en.pdf"},
    {"id":"64683","name":"Agenda - PDCO agenda of the 3-6 September 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-02T16:42:52Z","last_updated_date":"2024-09-02T16:42:52Z","reference_number":"EMA/PDCO/401502/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-3-6-september-2024-meeting_en.xlsx"},
    {"id":"64701","name":"Agenda - Fourth veterinary big data stakeholder forum","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-04T15:46:58Z","last_updated_date":"2024-10-07T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-veterinary-big-data-stakeholder-forum_en.pdf"},
    {"id":"64711","name":"Agenda - Clinical Trials Regulation (CTR) Collaborate Stakeholder meeting, supported by ACT EU","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-05T10:47:27Z","last_updated_date":"2024-09-05T10:47:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-trials-regulation-ctr-collaborate-stakeholder-meeting-supported-act-eu_en.pdf"},
    {"id":"64754","name":"Agenda - Scientific Symposium on Advanced Therapy Medicinal Products - ‘Contribution, evolution, revolution’","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T15:49:55Z","last_updated_date":"2024-10-09T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-scientific-symposium-advanced-therapy-medicinal-products-contribution-evolution-revolution_en.pdf"},
    {"id":"64758","name":"Agenda of the CAT meeting 11-12 September 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T10:53:31Z","last_updated_date":"2024-09-09T10:53:31Z","reference_number":"EMA/CAT/400955/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-11-12-september-2024_en.pdf"},
    {"id":"64765","name":"Agenda of the CVMP meeting 10-12 September 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-09T15:10:22Z","last_updated_date":"2024-09-09T15:10:22Z","reference_number":"EMA/420270/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-10-12-september-2024_en.pdf"},
    {"id":"64769","name":"Agenda of the COMP meeting 10-12 September 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-10T11:06:10Z","last_updated_date":"2024-09-10T11:06:10Z","reference_number":"EMA/COMP/347157/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-10-12-september-2024_en.pdf"},
    {"id":"64794","name":"Agenda - Union Product Database webinar for veterinary marketing authorisation holders on an industry-dedicated read API","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-11T14:11:17Z","last_updated_date":"2024-09-11T14:11:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-union-product-database-webinar-veterinary-marketing-authorisation-holders-industry-dedicated-read-api_en.pdf"},
    {"id":"64796","name":"Agenda - Information session on the pilot for expert panels' advice for orphan medical devices","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-11T14:48:00Z","last_updated_date":"2024-09-23T13:30:00Z","reference_number":"EMA/415588/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-information-session-pilot-expert-panels-advice-orphan-medical-devices_en.pdf"},
    {"id":"64802","name":"Agenda of the Medicine Shortages SPOC Working Party meeting - 11 September 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-12T08:34:22Z","last_updated_date":"2024-09-12T08:34:22Z","reference_number":"EMA/354153/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-11-september-2024_en.pdf"},
    {"id":"64854","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (18 September 2024)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-13T15:52:13Z","last_updated_date":"2024-09-17T14:03:00Z","reference_number":"EMA/322804/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-18-september-2024_en.pdf"},
    {"id":"64870","name":"Agenda of the CHMP meeting 16-19 September 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-16T15:18:00Z","last_updated_date":"2024-09-20T14:00:00Z","reference_number":"EMA/CHMP/392298/2024 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-16-19-september-2024_en.pdf"},
    {"id":"64871","name":"Agenda : Translating innovation to access for ATMPs: 3rd EU-Innovation network multi-stakeholder meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T15:51:00Z","last_updated_date":"2024-11-11T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-translating-innovation-access-atmps-3rd-eu-innovation-network-multi-stakeholder-meeting_en.pdf"},
    {"id":"64911","name":"Agenda - Third European Medicines Agency (EMA) and European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-18T15:40:50Z","last_updated_date":"2024-09-18T15:40:50Z","reference_number":"EMA/335143/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-european-medicines-agency-ema-european-confederation-pharmaceutical-entrepreneurs-eucope-bilateral-meeting_en.pdf"},
    {"id":"64912","name":"Agenda – sixth EMA/EuropaBio bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-18T16:07:37Z","last_updated_date":"2024-09-18T16:07:37Z","reference_number":"EMA/26827/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixth-ema-europabio-bilateral-meeting_en.pdf"},
    {"id":"64914","name":"Agenda - Second EMA/COCIR bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-18T16:41:36Z","last_updated_date":"2024-09-18T16:41:36Z","reference_number":"EMA/313158/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-ema-cocir-bilateral-meeting_en.pdf"},
    {"id":"64939","name":"Agenda - Tenth Industry Standing Group (ISG) meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-19T14:41:22Z","last_updated_date":"2024-09-19T14:41:22Z","reference_number":"EMA/313262/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-tenth-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"65003","name":"Agenda of the HMPC meeting 23-25 September 2024 ","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-23T16:30:00Z","last_updated_date":"2024-09-23T16:30:00Z","reference_number":"EMA/HMPC/374094/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-23-25-september-2024_en.pdf"},
    {"id":"65042","name":"Agenda of the Extraordinary CHMP meeting 26 September 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-26T10:00:00Z","last_updated_date":"2024-09-26T10:00:00Z","reference_number":"EMA/CHMP/447920/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-extraordinary-chmp-meeting-26-september-2024_en.pdf"},
    {"id":"65043","name":"Agenda - ACT EU multi-stakeholder platform annual meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-26T11:17:00Z","last_updated_date":"2024-10-21T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-multi-stakeholder-platform-annual-meeting_en.pdf"},
    {"id":"65047","name":"Agenda - New Fee Regulation: webinar on Regulation (EU) 2024/568 and changes foreseen for industry stakeholders (V)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-26T16:10:00Z","last_updated_date":"2024-09-26T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-new-fee-regulation-webinar-regulation-eu-2024-568-changes-foreseen-industry-stakeholders-v_en.pdf"},
    {"id":"65051","name":"Agenda - New Fee Regulation: webinar on Regulation (EU) 2024/568 and changes foreseen for industry stakeholders (H)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-09-30T11:28:24Z","last_updated_date":"2024-09-30T11:28:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-new-fee-regulation-webinar-regulation-eu-2024-568-changes-foreseen-industry-stakeholders-h_en.pdf"},
    {"id":"65067","name":"Agenda of the PRAC meeting 30 September - 03 October 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-09-30T16:10:00Z","last_updated_date":"2024-09-30T16:10:00Z","reference_number":"EMA/PRAC/410474/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-30-september-03-october-2024_en.pdf"},
    {"id":"65117","name":"Agenda for the 125th meeting of the EMA Management Board: 3 October 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-10-02T14:35:29Z","last_updated_date":"2024-10-03T15:21:00Z","reference_number":"EMA/MB/377084/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-125th-meeting-ema-management-board-3-october-2024_en.pdf"},
    {"id":"65124","name":"Agenda - HMA-EMA Big Data Stakeholder Forum 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-10-03T12:20:00Z","last_updated_date":"2024-11-27T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hma-ema-big-data-stakeholder-forum-2024_en.pdf"},
    {"id":"65226","name":"Agenda of the COMP meeting 08-10 October 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-10-07T17:37:08Z","last_updated_date":"2024-10-07T17:37:08Z","reference_number":"EMA/COMP/438930/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-08-10-october-2024_en.pdf"},
    {"id":"65227","name":"Agenda of the CVMP meeting 8-10 October 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-10-08T10:01:00Z","last_updated_date":"2024-10-08T10:01:00Z","reference_number":"EMA/CVMP/425782/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-8-10-october-2024_en.pdf"},
    {"id":"65229","name":"Agenda - Medicine Shortages (SPOC) Working Party 7-8 October 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-10-08T11:19:59Z","last_updated_date":"2024-10-08T11:19:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-7-8-october-2024_en.pdf"},
    {"id":"65270","name":"Agenda of the CAT meeting 9-11 October 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-10-10T13:32:00Z","last_updated_date":"2024-10-10T13:32:00Z","reference_number":"EMA/CAT/471065/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-9-11-october-2024_en.pdf"},
    {"id":"65274","name":"Agenda - Thirteenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-10-10T16:53:53Z","last_updated_date":"2024-11-15T15:30:00Z","reference_number":"EMA/468836/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-thirteenth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"65283","name":"Agenda - HMA/EMA Multi–stakeholder workshop on Artificial Intelligence (AI) - enabling the  safe and responsible use of AI","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-10-11T16:02:24Z","last_updated_date":"2024-11-04T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hma-ema-multi-stakeholder-workshop-artificial-intelligence-ai-enabling-safe-responsible-use-ai_en.pdf"},
    {"id":"65287","name":"Agenda of the CHMP meeting 14-17 October 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-10-14T14:07:00Z","last_updated_date":"2024-10-14T14:07:00Z","reference_number":"EMA/CHMP/441223/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-14-17-october-2024_en.pdf"},
    {"id":"65289","name":"Agenda - Product Management Service (PMS) Product UI training (access and navigation)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-10-14T14:48:00Z","last_updated_date":"2024-10-14T14:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-management-service-pms-product-ui-training-access-navigation_en.pdf-0"},
    {"id":"65302","name":"Agenda - PDCO agenda of the 15-18 October 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-10-15T16:31:51Z","last_updated_date":"2024-10-15T16:31:51Z","reference_number":"EMA/PDCO/436703/2024\t","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-15-18-october-2024-meeting_en.xlsx"},
    {"id":"65368","name":"Agenda - ESMP training session on routine shortage reporting for marketing authorisation holders of CAPs","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-10-23T09:22:00Z","last_updated_date":"2024-10-23T09:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-esmp-training-session-routine-shortage-reporting-marketing-authorisation-holders-caps_en.pdf"}    {"id":"65414","name":"Draft agenda – PCWP/HCPWP and all eligible organisations meeting 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-10-24T10:42:00Z","last_updated_date":"2024-11-14T14:46:00Z","reference_number":"EMA/318271/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-pcwp-hcpwp-all-eligible-organisations-meeting-2024_en.pdf"},
    {"id":"65439","name":"Agenda - SME info day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T11:22:18Z","last_updated_date":"2024-10-25T11:22:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sme-info-day_en.pdf"},
    {"id":"65448","name":"Agenda: Informative webinar on PMS product user interface usage and key actions for marketing authorisation holders (with demo)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T12:30:00Z","last_updated_date":"2024-10-25T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-informative-webinar-pms-product-user-interface-usage-key-actions-marketing-authorisation-holders-demo_en.pdf"},
    {"id":"65459","name":"Agenda of the PRAC meeting 28-31 October 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-10-28T17:21:56Z","last_updated_date":"2024-10-28T17:21:56Z","reference_number":"EMA/PRAC/457736/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-28-31-october-2024_en.pdf"},
    {"id":"65494","name":"Agenda: Advancing regulatory science research agenda","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-10-30T15:10:00Z","last_updated_date":"2024-11-13T16:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-advancing-regulatory-science-research-agenda_en.pdf"},
    {"id":"65497","name":"Agenda - Clinical Data Publication (Policy 0070) Step 2 - EMA webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-10-30T14:46:46Z","last_updated_date":"2024-10-30T14:46:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-data-publication-policy-0070-step-2-ema-webinar_en.pdf"},
    {"id":"65535","name":"Agenda of the CVMP meeting 5-7 November 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-04T16:50:00Z","last_updated_date":"2024-11-04T16:50:00Z","reference_number":"EMA/CVMP/493417/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-5-7-november-2024_en.pdf"},
    {"id":"65550","name":"Agenda - Fourth listen-and-learn focus group meeting of the Quality Innovation Group","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-11-05T16:31:34Z","last_updated_date":"2024-11-14T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-listen-learn-focus-group-meeting-quality-innovation-group_en.pdf"},
    {"id":"65553","name":"Agenda of the COMP meeting 5-7 November 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-05T17:45:11Z","last_updated_date":"2024-11-05T17:45:11Z","reference_number":"EMA/COMP/487032/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-5-7-november-2024_en.pdf"},
    {"id":"65554","name":"Agenda of the CAT meeting 6-8 November 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-06T08:28:38Z","last_updated_date":"2024-11-06T08:28:38Z","reference_number":"EMA/CAT/514663/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-6-8-november-2024_en.pdf"},
    {"id":"65580","name":"Agenda - Medicine Shortages (SPOC) Working Party 6 November 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-11-08T16:51:12Z","last_updated_date":"2024-11-08T16:51:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-6-november-2024_en.pdf"},
    {"id":"65587","name":"Agenda - Training webinar on post-authorisation procedure management in IRIS for Marketing Authorisation Holders","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-11-11T13:43:27Z","last_updated_date":"2024-11-11T13:43:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-webinar-post-authorisation-procedure-management-iris-marketing-authorisation-holders_en.pdf"},
    {"id":"65588","name":"Agenda of the CHMP meeting 11-14 November 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-11T13:54:34Z","last_updated_date":"2024-11-11T13:54:34Z","reference_number":"EMA/CHMP/491490/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-11-14-november-2024_en.pdf"},
    {"id":"65590","name":"Agenda - Quarterly System Demo Q4 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-11-11T16:03:30Z","last_updated_date":"2024-12-03T14:07:00Z","reference_number":"EMA/517039/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quarterly-system-demo-q4-2024_en.pdf"},
    {"id":"65593","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-12T11:35:41Z","last_updated_date":"2024-11-22T11:54:00Z","reference_number":"EMA/443576/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-november-2024_en.pdf"},
    {"id":"65595","name":"Agenda - PDCO agenda of the 12-15 November 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-12T14:52:04Z","last_updated_date":"2024-11-12T14:52:04Z","reference_number":"EMA/PDCO/506665/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-12-15-november-2024-meeting_en.xlsx"},
    {"id":"65599","name":"Agenda - Second European Medicines Agency (EMA) and IPFA - PPTA global bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-11-12T15:29:36Z","last_updated_date":"2024-11-12T15:29:36Z","reference_number":"EMA/417397/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-european-medicines-agency-ema-ipfa-ppta-global-bilateral-meeting_en.pdf"},
    {"id":"65601","name":"Agenda - Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system (February, May)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-11-12T16:37:00Z","last_updated_date":"2024-11-12T16:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system-february-may_en.pdf"},
    {"id":"65608","name":"Agenda - Third EMA and Vaccines Europe bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-13T13:25:17Z","last_updated_date":"2024-11-13T13:25:17Z","reference_number":"EMA/531143/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-third-ema-vaccines-europe-bilateral-meeting_en.pdf"},
    {"id":"65618","name":"Agenda - Biannual Big Data Steering Group and industry stakeholders meeting - Oct 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-13T16:25:35Z","last_updated_date":"2024-11-13T16:25:35Z","reference_number":"EMA/466753/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-biannual-big-data-steering-group-industry-stakeholders-meeting-oct-2024_en.pdf"},
    {"id":"65680","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-23T16:10:17Z","last_updated_date":"2025-06-23T16:10:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-2025_en.pdf"},
    {"id":"65681","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course for sponsors 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-11-18T16:10:58Z","last_updated_date":"2024-11-18T16:10:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-sponsors-2025_en.pdf"},
    {"id":"65688","name":"Agenda - Eleventh Industry Standing Group (ISG) meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-15T17:01:17Z","last_updated_date":"2024-11-15T17:01:17Z","reference_number":"EMA/427165/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eleventh-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"65721","name":"Agenda of the HMPC meeting 18-20 November 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-20T11:14:27Z","last_updated_date":"2024-11-20T11:14:27Z","reference_number":"EMA/HMPC/498666/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-18-20-november-2024_en.pdf"},
    {"id":"65722","name":"Agenda - Submission of Manufacturers, Manufacturing Business Operations (MBOs) and structured pack size data to Product Management Service (PMS)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-11-20T11:39:46Z","last_updated_date":"2024-11-20T11:39:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-submission-manufacturers-manufacturing-business-operations-mbos-structured-pack-size-data-product-management-service-pms_en.pdf"},
    {"id":"65807","name":"Agenda of the PRAC meeting 25-28 November 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-11-25T15:41:37Z","last_updated_date":"2024-11-25T15:41:37Z","reference_number":"EMA/PRAC/520862/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-25-28-november-2024_en.pdf"},
    {"id":"65882","name":"Agenda – 18th industry stakeholder platform – operation of EU pharmacovigilance","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-11-29T11:23:42Z","last_updated_date":"2024-11-29T11:23:42Z","reference_number":"EMA/296352/2023","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-18th-industry-stakeholder-platform-operation-eu-pharmacovigilance_en.pdf"},
    {"id":"65892","name":"Agenda of the CAT meeting 4-6 December 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-12-02T13:33:08Z","last_updated_date":"2024-12-02T13:33:08Z","reference_number":"EMA/CAT/556207/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-4-6-december-2024_en.pdf"},
    {"id":"65914","name":"Agenda of the CVMP meeting 3-5 December 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-12-03T11:33:23Z","last_updated_date":"2024-12-03T11:33:23Z","reference_number":"EMA/558441/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-3-5-december-2024_en.pdf"},
    {"id":"65921","name":"Agenda of the COMP meeting 3-5 December 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-12-03T13:02:16Z","last_updated_date":"2025-02-21T12:12:29Z","reference_number":"EMA/COMP/529687/2024 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-3-5-december-2024_en.pdf"},
    {"id":"65940","name":"Agenda - Medicine Shortages (SPOC) Working Party 5 December 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-12-04T11:51:10Z","last_updated_date":"2024-12-04T11:51:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-5-december-2024_en.pdf"},
    {"id":"65950","name":"Agenda - Seventh European Medicines Agency (EMA) EFPIA bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-12-04T15:22:47Z","last_updated_date":"2024-12-04T15:22:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-seventh-european-medicines-agency-ema-efpia-bilateral-meeting_en.pdf"},
    {"id":"66016","name":"Agenda - European Commission/EMA meeting with stakeholders on Translarna (ataluren)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-12-09T13:18:23Z","last_updated_date":"2024-12-09T13:18:23Z","reference_number":"EMA/563348/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-commission-ema-meeting-stakeholders-translarna-ataluren_en.pdf"},
    {"id":"66017","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-12-09T13:40:48Z","last_updated_date":"2024-12-09T13:40:48Z","reference_number":"EMA/510938/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg_en.pdf-3"},
    {"id":"66018","name":"Agenda of the CHMP meeting 9-12 December 2024","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-12-09T13:38:54Z","last_updated_date":"2024-12-09T13:38:54Z","reference_number":"EMA/CHMP/539348/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-9-12-december-2024_en.pdf"},
    {"id":"66025","name":"Agenda – 13th Industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T15:43:43Z","last_updated_date":"2024-12-09T15:43:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-13th-industry-stakeholder-platform-research-development-support_en.pdf"},
    {"id":"66040","name":"Agenda - Enpr-EMA Coordinating Group and networks meeting (October 2024)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T11:39:52Z","last_updated_date":"2024-12-10T11:39:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-networks-meeting-october-2024_en.pdf"},
    {"id":"66052","name":"Agenda - PDCO agenda of the 10-13 December 2024 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2024-12-10T14:03:05Z","last_updated_date":"2024-12-10T14:03:05Z","reference_number":"EMA/PDCO/550692/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-10-13-december-2024-meeting_en.xlsx"},
    {"id":"66093","name":"Agenda - Management Board meeting: 11 - 12 December 2024","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2024-12-12T15:07:52Z","last_updated_date":"2024-12-12T15:07:52Z","reference_number":"EMA/MB/501393/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-management-board-meeting-11-12-december-2024_en.pdf"},
    {"id":"66115","name":"Programme of the 2024 annual workshop of the European network of paediatric research at EMA (Enpr-EMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-07-29T13:44:39Z","last_updated_date":"2024-07-29T13:44:39Z","reference_number":"EMA/223162/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-2024-annual-workshop-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"66299","name":"Agenda of the CVMP meeting 14-15 January 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-01-13T16:55:08Z","last_updated_date":"2025-01-13T16:55:08Z","reference_number":"EMA/11086/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-14-15-january-2025_en.pdf"},
    {"id":"66300","name":"Agenda of the PRAC meeting 13-16 January 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-01-13T17:15:25Z","last_updated_date":"2025-01-13T17:15:25Z","reference_number":"EMA/PRAC/549682/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-13-16-january-2025_en.pdf"},
    {"id":"66316","name":"Agenda - Instrument for Pre-accession Assistance (IPA) advanced EMA training on Quality and Inspections","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-01-15T13:57:04Z","last_updated_date":"2025-01-15T13:57:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-instrument-pre-accession-assistance-ipa-advanced-ema-training-quality-inspections_en.pdf"},
    {"id":"66317","name":"Agenda - Instrument for Pre-accession Assistance (IPA) advanced EMA training on Clinical Trials, Pharmacovigilance and Shortages","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-01-15T14:40:14Z","last_updated_date":"2025-01-15T14:40:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-instrument-pre-accession-assistance-ipa-advanced-ema-training-clinical-trials-pharmacovigilance-shortages_en.pdf"},
    {"id":"66318","name":"Agenda - Instrument for Pre-accession Assistance (IPA) EMA training on veterinary aspects of AMR and the One Health approach","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-01-15T14:44:46Z","last_updated_date":"2025-01-15T14:44:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-instrument-pre-accession-assistance-ipa-ema-training-veterinary-aspects-amr-one-health-approach_en.pdf"},
    {"id":"66371","name":"Agenda - SPOR & XEVMPD status update webinar - 22 January 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-01-20T12:52:36Z","last_updated_date":"2025-01-20T12:52:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-spor-xevmpd-status-update-webinar-22-january-2025_en.pdf"},
    {"id":"66384","name":"Agenda of the HMPC meeting 20-22 January 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-01-21T08:57:41Z","last_updated_date":"2025-01-21T08:57:41Z","reference_number":"EMA/HMPC/577676/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-20-22-january-2025_en.pdf"},
    {"id":"66403","name":"Agenda - Medicine Shortages (SPOC) Working Party 21 January 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-01-21T16:34:09Z","last_updated_date":"2025-01-21T16:34:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-21-january-2025_en.pdf"},
    {"id":"66404","name":"Agenda of the COMP meeting 21-23 January 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-01-21T16:43:05Z","last_updated_date":"2025-02-21T11:55:29Z","reference_number":"EMA/COMP/60685/2025 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-21-23-january-2025_en.pdf"},
    {"id":"66407","name":"Agenda of the CAT meeting 22-24 January 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-01-21T17:08:41Z","last_updated_date":"2025-01-21T17:08:41Z","reference_number":"EMA/CAT/25914/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-22-24-january-2025_en.pdf"},
    {"id":"66445","name":"Agenda - European medicines agencies network strategy (EMANS) to 2028 - webinar","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-01-24T12:20:44Z","last_updated_date":"2025-02-12T09:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agencies-network-strategy-emans-2028-webinar_en.pdf"},
    {"id":"66464","name":"Agenda - European Shortages Monitoring Platform (ESMP) training on crisis and MSSG-led preparedness reporting for marketing authorisation holders (MAHs)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-01-27T10:41:56Z","last_updated_date":"2025-02-13T13:59:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-shortages-monitoring-platform-esmp-training-crisis-mssg-led-preparedness-reporting-marketing-authorisation-holders-mahs_en.pdf"},
    {"id":"66472","name":"Agenda of the CHMP meeting 27-30 January 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-01-27T15:06:45Z","last_updated_date":"2025-01-27T15:06:45Z","reference_number":"EMA/CHMP/585836/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-27-30-january-2025_en.pdf"},
    {"id":"66473","name":"Annex to 27-30 January 2025 CHMP Agenda","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-01-27T14:58:39Z","last_updated_date":"2025-01-27T14:58:39Z","reference_number":"EMA/CHMP/584291/2024","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-27-30-january-2025-chmp-agenda_en.xlsx"},
    {"id":"66485","name":"Agenda - PDCO agenda of the 28-31 January 2025 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-01-28T14:43:07Z","last_updated_date":"2025-01-28T14:43:07Z","reference_number":"EMA/PDCO/1869/2025\t","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-28-31-january-2025-meeting_en.xlsx"},
    {"id":"66487","name":"Agenda - Twelfth Industry Standing group (ISG)  meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-01-28T16:00:00Z","last_updated_date":"2025-01-28T16:00:00Z","reference_number":"EMA/14552/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-twelfth-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"66553","name":"Agenda - ACT EU workshop on ICH E6 (R3)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T11:19:05Z","last_updated_date":"2025-02-18T09:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-workshop-ich-e6-r3_en.pdf"},
    {"id":"66556","name":"Agenda: Product Management Service (PMS) Info-Day","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T14:00:51Z","last_updated_date":"2025-05-12T16:12:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-management-service-pms-info-day_en.pdf-0"},
    {"id":"66658","name":"Agenda of the PRAC meeting 10-13 February 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-02-10T16:47:36Z","last_updated_date":"2025-02-10T16:47:36Z","reference_number":"EMA/PRAC/15940/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-10-13-february-2025_en.pdf"},
    {"id":"66676","name":"Agenda of the CVMP meeting 11-13 February 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-02-11T13:01:13Z","last_updated_date":"2025-02-11T13:01:13Z","reference_number":"EMA/52364/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-11-13-february-2025_en.pdf"},
    {"id":"66738","name":"Agenda - EMA Veterinary Innovation Day - March 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T14:02:38Z","last_updated_date":"2025-03-06T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-veterinary-innovation-day-march-2025_en.pdf"},
    {"id":"66743","name":"Agenda - Quarterly System Demo Q1 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T14:17:05Z","last_updated_date":"2025-03-12T08:42:00Z","reference_number":"EMA/30265/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quarterly-system-demo-q1-2025_en.pdf"},
    {"id":"66832","name":"Agenda of the COMP meeting 18-19 February 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-02-17T16:48:49Z","last_updated_date":"2025-02-17T16:48:49Z","reference_number":"EMA/COMP/42497/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-18-19-february-2025_en.pdf"},
    {"id":"66838","name":"Programme - EMA's Open Door Day ","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-02-18T09:28:57Z","last_updated_date":"2025-02-18T09:28:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-emas-open-door-day_en.pdf"},
    {"id":"66845","name":"Agenda of the CAT meeting 19-21 February 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-02-18T13:42:03Z","last_updated_date":"2025-02-18T13:42:03Z","reference_number":"EMA/CAT/62701/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-19-21-february-2025_en.pdf"},
    {"id":"66875","name":"Agenda - EMA workshop on the challenges in drug development, regulation and clinical practice for immunoglobulins","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-02-19T14:13:08Z","last_updated_date":"2025-03-04T09:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-workshop-challenges-drug-development-regulation-clinical-practice-immunoglobulins_en.pdf"},
    {"id":"66910","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) 26 February 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-02-21T11:27:00Z","last_updated_date":"2025-02-21T11:27:00Z","reference_number":"EMA/24213/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-26-february-2025_en.pdf"},
    {"id":"66926","name":"Agenda of the CHMP meeting 24-27 February 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-02-24T14:47:43Z","last_updated_date":"2025-02-24T14:47:43Z","reference_number":"EMA/CHMP/41869/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-24-27-february-2025_en.pdf"},
    {"id":"66927","name":"Annex to 24-27 February 2025 CHMP Agenda","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-02-24T14:50:03Z","last_updated_date":"2025-03-05T14:03:22Z","reference_number":"EMA/CHMP/584291/2025 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-24-27-february-2025-chmp-agenda_en.xlsx"},
    {"id":"66981","name":"Agenda - PDCO agenda of the 25-28 February 2025 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-02-26T10:08:36Z","last_updated_date":"2025-02-26T10:08:36Z","reference_number":"EMA/PDCO/52829/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-25-28-february-2025-meeting_en.xlsx"},
    {"id":"67002","name":"Agenda - Medicine Shortages (SPOC) Working Party 18 February 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-02-27T09:51:45Z","last_updated_date":"2025-02-27T09:51:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-18-february-2025_en.pdf"},
    {"id":"67087","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting on 1-2 April 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-03-03T16:26:49Z","last_updated_date":"2025-03-03T16:26:49Z","reference_number":"EMA/31466/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting-1-2-april-2025_en.pdf"},
    {"id":"67164","name":"Agenda of the CVMP meeting 11-13 March 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-03-10T12:00:57Z","last_updated_date":"2025-03-10T12:00:57Z","reference_number":"EMA/87728/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-11-13-march-2025_en.pdf"},
    {"id":"67168","name":"Agenda of the PRAC meeting 10-13 March 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-03-10T14:03:27Z","last_updated_date":"2025-03-10T14:03:27Z","reference_number":"EMA/PRAC/54646/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-10-13-march-2025_en.pdf"},
    {"id":"67227","name":"Agenda - Management Board meeting: 13 March 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-03-12T11:16:42Z","last_updated_date":"2025-03-14T15:10:29Z","reference_number":"EMA/MB/45410/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-management-board-meeting-13-march-2025_en.pdf"},
    {"id":"67241","name":"Agenda of the HMPC meeting 17-19 March 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-03-13T10:10:30Z","last_updated_date":"2025-03-13T10:10:30Z","reference_number":"EMA/HMPC/71602/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-17-19-march-2025_en.pdf"},
    {"id":"67255","name":"Agenda - HMA/EMA multi-stakeholder workshop on reporting and qualification of mechanistic models for regulatory assessment October 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-03-25T15:15:29Z","last_updated_date":"2025-10-21T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hma-ema-multi-stakeholder-workshop-reporting-qualification-mechanistic-models-regulatory-assessment-october-2025_en.pdf"},
    {"id":"67318","name":"Agenda of the COMP meeting 18-20 March 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-03-18T09:23:46Z","last_updated_date":"2025-03-18T09:23:46Z","reference_number":"EMA/COMP/77031/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-18-20-march-2025_en.pdf"},
    {"id":"67331","name":"Agenda of the CAT meeting 19-21 March 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-03-18T14:04:24Z","last_updated_date":"2025-03-18T14:04:24Z","reference_number":"EMA/CAT/97209/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-19-21-march-2025_en.pdf"},
    {"id":"67412","name":"Agenda of the CHMP meeting 24-27 March 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-03-24T11:36:00Z","last_updated_date":"2025-03-24T11:36:00Z","reference_number":"EMA/CHMP/64819/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-24-27-march-2025_en.pdf"},
    {"id":"67413","name":"Annex to 24-27 March 2025 CHMP Agenda","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-03-24T11:39:08Z","last_updated_date":"2025-03-24T11:39:08Z","reference_number":"EMA/CHMP/76695/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-24-27-march-2025-chmp-agenda_en.xlsx"},
    {"id":"67434","name":"Agenda - PDCO agenda of the 25-28 March 2025 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-03-25T11:56:55Z","last_updated_date":"2025-03-25T11:56:55Z","reference_number":"EMA/PDCO/88999/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-25-28-march-2025-meeting_en.xlsx"},
    {"id":"67444","name":"Agenda - Second EMA / Alliance for Regenerative Medicine bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-03-25T16:26:59Z","last_updated_date":"2025-03-25T16:26:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-ema-alliance-regenerative-medicine-bilateral-meeting_en.pdf"},
    {"id":"67528","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (April 2025)","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-03-28T11:34:27Z","last_updated_date":"2025-03-28T11:34:27Z","reference_number":"EMA/73788/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-april-2025_en.pdf"},
    {"id":"67543","name":"Agenda - EMA’s 30th anniversary scientific conference","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T14:19:50Z","last_updated_date":"2025-06-19T10:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-emas-30th-anniversary-scientific-conference_en.pdf"},
    {"id":"67558","name":"Agenda - ICMRA Summit 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-04-01T09:59:31Z","last_updated_date":"2025-04-01T09:59:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-icmra-summit-2025_en.pdf"},
    {"id":"67603","name":"Agenda - Medicine Shortages (SPOC) Working Party 18 March 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-04-02T15:10:00Z","last_updated_date":"2025-04-02T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-18-march-2025_en.pdf"},
    {"id":"67649","name":"Agenda - SPOR status update webinar 9 April 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T15:40:10Z","last_updated_date":"2025-04-04T15:40:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-spor-status-update-webinar-9-april-2025_en.pdf"},
    {"id":"67672","name":"Agenda of the PRAC meeting 7-10 April 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-04-07T16:14:57Z","last_updated_date":"2025-04-07T16:14:57Z","reference_number":"EMA/PRAC/89624/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-7-10-april-2025_en.pdf"},
    {"id":"67677","name":"Agenda - Quality Innovation Group (QIG) Listen and Learn Focus Group (LLFG) meeting on personalised medicines Event Human","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-04-08T11:03:39Z","last_updated_date":"2025-04-08T11:03:39Z","reference_number":"EMA/107455/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quality-innovation-group-qig-listen-learn-focus-group-llfg-meeting-personalised-medicines-event-human_en.pdf"},
    {"id":"67693","name":"Agenda of the CVMP meeting 8-10 April 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-04-08T12:19:15Z","last_updated_date":"2025-04-08T12:19:15Z","reference_number":"EMA/122052/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-8-10-april-2025_en.pdf"},
    {"id":"67737","name":"Agenda - Medicine Shortages (SPOC) Working Party 10-11 April 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-04-10T15:26:24Z","last_updated_date":"2025-04-10T15:26:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-10-11-april-2025_en.pdf"},
    {"id":"67767","name":"Agenda of the COMP meeting 14-15 April 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-04-11T16:05:00Z","last_updated_date":"2025-04-14T09:30:00Z","reference_number":"EMA/COMP/111392/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-14-15-april-2025_en.xlsx"},
    {"id":"67834","name":"Agenda of the CAT meeting 14-16 April 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-04-14T17:17:14Z","last_updated_date":"2025-04-14T17:17:14Z","reference_number":"EMA/CAT/131283/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-14-16-april-2025_en.pdf"},
    {"id":"67892","name":"Agenda - PDCO agenda of the 22-25 April 2025 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-04-22T11:09:20Z","last_updated_date":"2025-04-22T11:09:20Z","reference_number":"EMA/PDCO/122754/2025\t","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-22-25-april-2025-meeting_en.xlsx"},
    {"id":"67898","name":"Agenda of the CHMP meeting 22-25 April 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-04-22T14:58:16Z","last_updated_date":"2025-04-22T14:58:16Z","reference_number":"EMA/CHMP/112185/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-april-2025_en.pdf"},
    {"id":"67922","name":"Annex to 22-25 April 2025 CHMP Agenda","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-04-23T09:52:25Z","last_updated_date":"2025-04-23T09:52:25Z","reference_number":"EMA/CHMP/115393/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-22-25-april-2025-chmp-agenda_en.xlsx"},
    {"id":"68005","name":"Agenda - Extraordinary Management Board meeting: 28 April 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-04-28T12:40:53Z","last_updated_date":"2025-04-28T12:40:53Z","reference_number":"EMA/MB/125620/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-extraordinary-management-board-meeting-28-april-2025_en.pdf"},
    {"id":"68066","name":"Agenda of the HMPC meeting 5-7 May 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-05-02T14:04:34Z","last_updated_date":"2025-05-02T14:04:34Z","reference_number":"EMA/HMPC/122977/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-5-7-may-2025_en.pdf"},
    {"id":"68108","name":"Agenda of the PRAC meeting 5-8 May 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-05-06T11:26:43Z","last_updated_date":"2025-05-06T11:26:43Z","reference_number":"EMA/PRAC/125561/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-5-8-may-2025_en.pdf"}    {"id":"68149","name":"Agenda - Enpr-EMA Coordinating Group – newly appointed members and observers (April 2025)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-05-07T16:12:12Z","last_updated_date":"2025-05-07T16:12:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-newly-appointed-members-observers-april-2025_en.pdf"},
    {"id":"68150","name":"Agenda - Enpr-EMA Coordinating Group (March 2025)","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-05-07T16:11:16Z","last_updated_date":"2025-05-07T16:11:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-march-2025_en.pdf"},
    {"id":"68241","name":"Agenda - EMA workshop on primary efficacy endpoints  for antivirals and monoclonal antibodies intended to treat COVID-19 and Influenza","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-05-12T16:47:21Z","last_updated_date":"2025-07-28T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-workshop-primary-efficacy-endpoints-antivirals-monoclonal-antibodies-intended-treat-covid-19-influenza_en.pdf"},
    {"id":"68245","name":"Agenda of the CVMP meeting 13-15 May 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-05-13T09:39:38Z","last_updated_date":"2025-05-13T09:39:38Z","reference_number":"EMA/158781/2025 – draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-13-15-may-2025_en.pdf"},
    {"id":"68258","name":"Agenda - System Demo Q2 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-05-13T15:15:14Z","last_updated_date":"2025-06-19T16:05:18Z","reference_number":"EMA/142981/2025 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-system-demo-q2-2025_en.pdf"},
    {"id":"68275","name":"Agenda of the COMP meeting 13-15 May 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-05-14T09:20:47Z","last_updated_date":"2025-05-14T09:20:47Z","reference_number":"EMA/COMP/142753/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-13-15-may-2025_en.xlsx"},
    {"id":"68276","name":"Agenda of the CAT meeting 14-16 May 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-05-14T10:59:19Z","last_updated_date":"2025-05-14T10:59:19Z","reference_number":"EMA/CAT/163785/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-14-16-may-2025_en.pdf"},
    {"id":"68286","name":"Agenda of the Medicine Shortages SPOC Working Party meeting on 13 May 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-05-14T16:37:57Z","last_updated_date":"2025-05-14T16:37:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-13-may-2025_en.pdf"},
    {"id":"68293","name":"Agenda - ADRA project information session for veterinary pharmaceutical industry","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-05-15T10:36:55Z","last_updated_date":"2025-05-15T10:36:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-adra-project-information-session-veterinary-pharmaceutical-industry_en.pdf"},
    {"id":"68294","name":"Agenda - Fourteenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-05-15T10:49:00Z","last_updated_date":"2025-05-28T10:04:59Z","reference_number":"EMA/163710/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourteenth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"68300","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 21 May 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-05-15T12:23:21Z","last_updated_date":"2025-05-15T12:23:21Z","reference_number":"EMA/111558/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-21-may-2025_en.pdf"},
    {"id":"68346","name":"Agenda of the CHMP meeting 19-22 May 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-05-19T15:18:25Z","last_updated_date":"2025-05-19T15:18:25Z","reference_number":"EMA/CHMP/143218/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-19-22-may-2025_en.pdf"},
    {"id":"68347","name":"Annex to 19-22 May 2025 CHMP Agenda","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-05-19T15:21:31Z","last_updated_date":"2025-05-19T15:21:31Z","reference_number":"EMA/CHMP/143868/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-19-22-may-2025-chmp-agenda_en.xlsx"},
    {"id":"68352","name":"Agenda - Clinical Trials Information System (CTIS): Information day (22/05/2025)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-05-19T15:56:11Z","last_updated_date":"2025-05-19T15:56:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-trials-information-system-ctis-information-day-22-05-2025_en.pdf"},
    {"id":"68362","name":"Agenda - PDCO agenda of the 20-23 May 2025 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-05-20T11:28:22Z","last_updated_date":"2025-05-20T11:28:22Z","reference_number":"EMA/PDCO/152848/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-20-23-may-2025-meeting_en.xlsx"},
    {"id":"68390","name":"Agenda - Training session for patients, consumers and healthcare professionals involved in medicine regulatory activities July 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-05-22T16:44:11Z","last_updated_date":"2025-05-22T16:44:11Z","reference_number":"EMA/49128/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-training-session-patients-consumers-healthcare-professionals-involved-medicine-regulatory-activities-july-2025_en.pdf"},
    {"id":"68531","name":"Agenda - EMA roundtable with stakeholders on the 20th anniversary of the SME regulation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-02T15:22:46Z","last_updated_date":"2025-10-29T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-roundtable-stakeholders-20th-anniversary-sme-regulation_en.pdf"},
    {"id":"68534","name":"Agenda - Workshop on the use of Bayesian statistics in clinical development","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-02T17:16:19Z","last_updated_date":"2025-06-16T16:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-use-bayesian-statistics-clinical-development_en.pdf"},
    {"id":"68537","name":"Agenda of the PRAC meeting 2-5 June 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-06-02T17:18:24Z","last_updated_date":"2025-06-02T17:18:24Z","reference_number":"EMA/PRAC/168514/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-2-5-june-2025_en.pdf"},
    {"id":"68560","name":"Agenda - 13th Industry Standing Group (ISG) meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-06-03T15:24:56Z","last_updated_date":"2025-06-03T15:24:56Z","reference_number":"EMA/66610/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-13th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"68567","name":"Agenda - Public webinar on shortages: putting patients first","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-04T10:59:17Z","last_updated_date":"2025-10-31T16:20:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-public-webinar-shortages-putting-patients-first_en.pdf"},
    {"id":"68584","name":"Agenda: EU Medicines Assessment - Opportunities for expert involvement - 9 July 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-06-05T14:04:50Z","last_updated_date":"2025-06-05T14:04:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eu-medicines-assessment-opportunities-expert-involvement-9-july-2025_en.pdf"},
    {"id":"68628","name":"Agenda of the CVMP meeting 10-12 June 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-06-10T10:13:29Z","last_updated_date":"2025-06-10T10:13:29Z","reference_number":"EMA/196317/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-10-12-june-2025_en.pdf"},
    {"id":"68629","name":"Agenda of the COMP meeting 10-12 June 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-06-10T10:26:36Z","last_updated_date":"2025-06-10T10:26:36Z","reference_number":"EMA/COMP/174226/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-10-12-june-2025_en.xlsx"},
    {"id":"68630","name":"Agenda - Management Board meeting: 11-12 June 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T11:00:10Z","last_updated_date":"2025-06-12T13:49:00Z","reference_number":"EMA/MB/116543/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-management-board-meeting-11-12-june-2025_en.pdf"},
    {"id":"68685","name":"Agenda of the CAT meeting 11-13 June 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-06-11T10:37:55Z","last_updated_date":"2025-06-11T10:37:55Z","reference_number":"EMA/CAT/197609/2025 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-11-13-june-2025_en.pdf"},
    {"id":"68686","name":"Agenda – 14th Industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-11T11:06:49Z","last_updated_date":"2025-07-09T13:29:04Z","reference_number":"EMA/119654/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-14th-industry-stakeholder-platform-research-development-support_en.pdf"},
    {"id":"68710","name":"Agenda - Mandatory use of ISO ICH E2B(R3) Individual Case Safety Reporting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-12T10:53:49Z","last_updated_date":"2025-06-12T10:53:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-mandatory-use-iso-ich-e2br3-individual-case-safety-reporting_en.pdf-0"},
    {"id":"68718","name":"Agenda - Eighth EMA-EFPIA bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-12T14:13:37Z","last_updated_date":"2025-07-04T11:45:26Z","reference_number":"EMA/169565/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eighth-ema-efpia-bilateral-meeting_en.pdf"},
    {"id":"68775","name":"Agenda of the CHMP meeting 16-19 June 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-06-16T15:30:00Z","last_updated_date":"2025-06-16T15:30:00Z","reference_number":"EMA/CHMP/177216/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-16-19-june-2025_en.pdf"},
    {"id":"68776","name":"Annex to 16-19 June 2025 CHMP Agenda","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-16T15:31:00Z","last_updated_date":"2025-06-16T15:31:00Z","reference_number":"EMA/CHMP/178616/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-16-19-june-2025-chmp-agenda_en.xlsx"},
    {"id":"68785","name":"Agenda - PDCO agenda of the 17-20 June 2025 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-06-17T11:34:33Z","last_updated_date":"2025-06-17T11:34:33Z","reference_number":"EMA/PDCO/182724/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-17-20-june-2025-meeting_en.xlsx"},
    {"id":"68842","name":"Agenda - Fourth European Medicines Agency (EMA)-Vaccines Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-19T16:33:10Z","last_updated_date":"2025-06-19T16:33:10Z","reference_number":"EMA/149368/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-european-medicines-agency-ema-vaccines-europe-bilateral-meeting_en.pdf"},
    {"id":"68847","name":"Agenda of the Medicine Shortages SPOC Working Party meeting on 17 June 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T08:35:46Z","last_updated_date":"2025-06-20T08:35:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-17-june-2025_en.pdf"},
    {"id":"68868","name":"Agenda - Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system (October, December 2025)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-20T13:46:31Z","last_updated_date":"2025-06-20T13:46:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system-october-december-2025_en.pdf"},
    {"id":"68888","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2024-11-18T15:44:59Z","last_updated_date":"2024-11-18T15:44:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-2025_en.pdf-0"},
    {"id":"69015","name":"Agenda - Second EMA and European Society of Cardiology (ESC) bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-27T14:49:32Z","last_updated_date":"2025-11-11T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-second-ema-european-society-cardiology-esc-bilateral-meeting_en.pdf"},
    {"id":"69045","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course for sponsors 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T13:02:40Z","last_updated_date":"2025-06-30T13:02:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-sponsors-2025_en.pdf-0"},
    {"id":"69096","name":"Agenda - First EMA-ACRO bilateral meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-07-03T16:10:40Z","last_updated_date":"2025-07-03T16:10:40Z","reference_number":"EMA/199274/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-ema-acro-bilateral-meeting_en.pdf"},
    {"id":"69098","name":"Agenda of the HMPC meeting 7-9 July 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-07-04T10:20:59Z","last_updated_date":"2025-07-04T10:20:59Z","reference_number":"EMA/HMPC/200229/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-7-9-july-2025_en.pdf"},
    {"id":"69156","name":"Agenda of the PRAC meeting 7-10 July 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-07-07T16:40:15Z","last_updated_date":"2025-07-07T16:40:15Z","reference_number":"EMA/PRAC/202278/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-7-10-july-2025_en.pdf"},
    {"id":"69272","name":"Agenda - EMA Information Day on submission predictability of initial marketing authorisation December 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-07-14T17:15:10Z","last_updated_date":"2025-07-14T17:15:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-information-day-submission-predictability-initial-marketing-authorisation-december-2025_en.pdf"},
    {"id":"69275","name":"Agenda of the CVMP meeting 15-17 July 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-07-15T09:30:37Z","last_updated_date":"2025-07-15T09:30:37Z","reference_number":"EMA/231168/2025 – draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-15-17-july-2025_en.pdf"},
    {"id":"69278","name":"Agenda of the COMP meeting 15-17 July 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-07-15T09:50:31Z","last_updated_date":"2025-07-15T09:50:31Z","reference_number":"EMA/COMP/211695/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-15-17-july-2025_en.xlsx"},
    {"id":"69294","name":"Agenda - European Platform for Regulatory Science Research meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T14:50:36Z","last_updated_date":"2025-07-15T14:50:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-platform-regulatory-science-research-meeting_en.pdf"},
    {"id":"69302","name":"Agenda of the CAT meeting 16-18 July 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-07-15T15:30:00Z","last_updated_date":"2025-07-15T15:30:00Z","reference_number":"EMA/CAT/232974/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-16-18-july-2025_en.pdf"},
    {"id":"69305","name":"Agenda - Medicine Shortages (SPOC) Working Party meeting on 14 July 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-07-16T09:57:05Z","last_updated_date":"2025-07-16T09:57:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-14-july-2025_en.pdf"},
    {"id":"69395","name":"Agenda of the CHMP meeting 21-24 July 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-07-21T15:21:39Z","last_updated_date":"2025-07-21T15:21:39Z","reference_number":"EMA/CHMP/211682/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-21-24-july-2025_en.pdf"},
    {"id":"69396","name":"Annex to 21-24 July 2025 CHMP Agenda","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-07-21T15:23:40Z","last_updated_date":"2025-07-21T15:23:40Z","reference_number":"EMA/CHMP/218440/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-21-24-july-2025-chmp-agenda_en.xlsx"},
    {"id":"69405","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 23 July 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-07-22T15:57:05Z","last_updated_date":"2025-07-22T15:57:05Z","reference_number":"EMA/189032/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-23-july-2025_en.pdf"},
    {"id":"69406","name":"Agenda - PDCO agenda of the 22-25 July 2025 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-07-22T16:01:10Z","last_updated_date":"2025-07-22T16:01:10Z","reference_number":"EMA/PDCO/226916/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-22-25-july-2025-meeting_en.xlsx"},
    {"id":"69681","name":"Agenda - Multi-stakeholder workshop on tailored clinical approach for biosimilars ","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-08-07T11:08:19Z","last_updated_date":"2025-08-07T11:08:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-multi-stakeholder-workshop-tailored-clinical-approach-biosimilars_en.pdf"},
    {"id":"69743","name":"Agenda - System Demo Q3 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-08-14T15:14:20Z","last_updated_date":"2025-09-02T16:40:00Z","reference_number":"EMA/260297/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-system-demo-q3-2025_en.pdf"},
    {"id":"69755","name":"Programme of the 2025 annual open meeting of the European network of paediatric research at EMA (Enpr-EMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-08-18T14:43:38Z","last_updated_date":"2025-12-10T11:43:35Z","reference_number":"EMA/156670/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-2025-annual-open-meeting-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"69756","name":"Agenda of the CHMP written procedure 18-21 August 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-08-18T15:00:27Z","last_updated_date":"2025-08-18T15:00:27Z","reference_number":"EMA/CHMP/251704/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-written-procedure-18-21-august-2025_en.pdf"},
    {"id":"69847","name":"Agenda of the Extraordinary CHMP meeting 25 August 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-08-25T12:39:44Z","last_updated_date":"2025-08-25T12:39:44Z","reference_number":"EMA/CHMP/252119/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-extraordinary-chmp-meeting-25-august-2025_en.pdf"},
    {"id":"69899","name":"Agenda - Annual Network Data Steering Group and industry stakeholders meeting 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-08-28T16:28:30Z","last_updated_date":"2025-08-28T16:28:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-annual-network-data-steering-group-industry-stakeholders-meeting-2025_en.pdf"},
    {"id":"69914","name":"Agenda - 14th Industry Standing Group (ISG) meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-09-01T12:04:49Z","last_updated_date":"2025-09-01T12:04:49Z","reference_number":"EMA/141039/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-14th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"69917","name":"Agenda of the PRAC meeting 1-4 September 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-01T16:45:28Z","last_updated_date":"2025-09-01T16:45:28Z","reference_number":"EMA/PRAC/234907/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-1-4-september-2025_en.pdf"},
    {"id":"69996","name":"Agenda of the CVMP meeting 9-11 September 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-08T15:15:45Z","last_updated_date":"2025-09-08T15:15:45Z","reference_number":"EMA/290141/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-9-11-september-2025_en.pdf"},
    {"id":"70008","name":"Agenda - Committee for Advanced Therapies (CAT) workshop on gene editing","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-09-09T09:46:25Z","last_updated_date":"2025-09-15T17:07:00Z","reference_number":"EMA/CAT/287112/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-committee-advanced-therapies-cat-workshop-gene-editing_en.pdf"},
    {"id":"70011","name":"Agenda - Healthcare Professionals' Working Party (HCPWP) meeting - 23 September 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-09T09:55:06Z","last_updated_date":"2025-09-09T09:55:06Z","reference_number":"EMA/240573/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-healthcare-professionals-working-party-hcpwp-meeting-23-september-2025_en.pdf"},
    {"id":"70014","name":"Agenda - Patients and Consumers Working Party (PCWP) meeting - 23 September 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-09T11:00:35Z","last_updated_date":"2025-09-09T11:00:35Z","reference_number":"EMA/240573/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patients-consumers-working-party-pcwp-meeting-23-september-2025_en.pdf"},
    {"id":"70015","name":"Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting on 24 September 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-09-09T11:03:29Z","last_updated_date":"2025-09-30T11:04:00Z","reference_number":"EMA/240573/2025 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting-24-september-2025_en.pdf"},
    {"id":"70019","name":"Agenda of the COMP meeting 9-11 September 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-09T14:38:04Z","last_updated_date":"2025-09-09T14:38:04Z","reference_number":"EMA/COMP/239938/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-9-11-september-2025_en.xlsx"},
    {"id":"70021","name":"Programme - Joint HMA/EMA multi-stakeholder workshop on Patient Registries December 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-09T14:54:27Z","last_updated_date":"2025-12-08T16:22:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-joint-hma-ema-multi-stakeholder-workshop-patient-registries-december-2025_en.pdf"},
    {"id":"70022","name":"Agenda - PDCO agenda of the 9-12 September 2025 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-09T15:18:33Z","last_updated_date":"2025-09-09T15:18:33Z","reference_number":"EMA/PDCO/272811/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-9-12-september-2025-meeting_en.xlsx"},
    {"id":"70024","name":"Agenda of the CAT meeting 10-12 September 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-09T15:38:10Z","last_updated_date":"2025-09-09T15:38:10Z","reference_number":"EMA/CAT/291880/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-10-12-september-2025_en.pdf"},
    {"id":"70032","name":"Agenda - Medicine Shortages (SPOC) Working Party meeting on 10 September 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-09-10T08:46:49Z","last_updated_date":"2025-09-10T16:49:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-10-september-2025_en.pdf"},
    {"id":"70075","name":"Agenda - European Medicine Agency (EMA) and European Association for the Study of Diabetes (EASD) bilateral meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-09-12T14:39:27Z","last_updated_date":"2025-11-11T10:38:00Z","reference_number":"EMA/103325/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicine-agency-ema-european-association-study-diabetes-easd-bilateral-meeting_en.pdf"},
    {"id":"70084","name":"Agenda of the CHMP meeting 15-18 September 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-15T16:12:26Z","last_updated_date":"2025-09-15T16:12:26Z","reference_number":"EMA/CHMP/276284/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-15-18-september-2025_en.pdf"},
    {"id":"70085","name":"Annex to agenda of the CHMP meeting 15-18 September 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-15T16:16:26Z","last_updated_date":"2025-09-15T16:16:26Z","reference_number":"EMA/CHMP/276540/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-agenda-chmp-meeting-15-18-september-2025_en.xlsx"},
    {"id":"70184","name":"Agenda - EMA Cancer Medicines Forum (CMF) meeting with industry stakeholders on cancer treatment optimisation","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T10:18:24Z","last_updated_date":"2025-11-12T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-cancer-medicines-forum-cmf-meeting-industry-stakeholders-cancer-treatment-optimisation_en.pdf"},
    {"id":"70196","name":"Agenda - First EMA-HMA multi-stakeholder forum on EudraVigilance and signal detection","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T17:11:05Z","last_updated_date":"2025-10-29T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-first-ema-hma-multi-stakeholder-forum-eudravigilance-signal-detection_en.pdf"},
    {"id":"70204","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 24 September 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-09-22T11:50:32Z","last_updated_date":"2025-09-22T11:50:32Z","reference_number":"EMA/277970/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-24-september-2025_en.pdf"},
    {"id":"70211","name":"Agenda of the HMPC meeting 22-24 September 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-22T13:39:34Z","last_updated_date":"2025-09-22T13:39:34Z","reference_number":"EMA/HMPC/285954/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-22-24-september-2025_en.pdf"},
    {"id":"70253","name":"Agenda -  Refresher training webinar on post-authorisation  procedure management in IRIS for MAHs","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-09-24T14:43:51Z","last_updated_date":"2025-09-24T14:43:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-refresher-training-webinar-post-authorisation-procedure-management-iris-mahs_en.pdf"},
    {"id":"70285","name":"Agenda - European Platform for Regulatory Science Research meeting September 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T16:46:59Z","last_updated_date":"2025-09-26T09:33:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-platform-regulatory-science-research-meeting-september-2025_en.pdf"},
    {"id":"70303","name":"Agenda - Enpr-EMA Coordinating Group and networks meeting - June 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-09-26T16:17:32Z","last_updated_date":"2025-09-26T16:17:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enpr-ema-coordinating-group-networks-meeting-june-2025_en.pdf"},
    {"id":"70329","name":"Agenda of the PRAC meeting 29 September - 2 October 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-09-29T16:11:36Z","last_updated_date":"2025-09-29T16:11:36Z","reference_number":"EMA/PRAC/291018/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-29-september-2-october-2025_en.pdf"},
    {"id":"70390","name":"Agenda - Management Board meeting: 2 October 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-10-02T10:42:37Z","last_updated_date":"2025-10-02T15:30:00Z","reference_number":"EMA/MB/261306/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-management-board-meeting-2-october-2025_en.pdf"},
    {"id":"70455","name":"Agenda of the COMP meeting 7-8 October 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-10-06T14:33:12Z","last_updated_date":"2025-10-06T14:33:12Z","reference_number":"EMA/COMP/304640/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-7-8-october-2025_en.xlsx"},
    {"id":"70463","name":"Agenda of the CVMP meeting 7-9 October 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-10-07T10:14:17Z","last_updated_date":"2025-10-07T10:14:17Z","reference_number":"EMA/322060/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-7-9-october-2025_en.pdf"},
    {"id":"70474","name":"Agenda - Instrument for Pre-accession Assistance (IPA) training on assessing medicinal products in the EU: A practical introduction","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-10-07T15:55:47Z","last_updated_date":"2025-10-07T15:55:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-instrument-pre-accession-assistance-ipa-training-assessing-medicinal-products-eu-practical-introduction_en.pdf"},
    {"id":"70479","name":"Agenda of the CAT meeting 8-9 October 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-10-07T16:33:51Z","last_updated_date":"2025-10-08T15:50:00Z","reference_number":"EMA/CAT/324071/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-8-9-october-2025_en.pdf"},
    {"id":"70495","name":"Agenda: Non-clinical data for regulatory decision-making on the efficacy of medical countermeasures","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-10-08T15:24:31Z","last_updated_date":"2025-11-18T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-non-clinical-data-regulatory-decision-making-efficacy-medical-countermeasures_en.pdf"},
    {"id":"70534","name":"Agenda of the CHMP meeting 13-16 October 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-10-13T13:21:57Z","last_updated_date":"2025-10-13T13:21:57Z","reference_number":"EMA/CHMP/307616/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-13-16-october-2025_en.pdf"},
    {"id":"70535","name":"Annex to agenda of the CHMP meeting 13-16 October 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-10-13T13:24:10Z","last_updated_date":"2025-10-13T13:24:10Z","reference_number":"EMA/CHMP/309305/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-agenda-chmp-meeting-13-16-october-2025_en.xlsx"},
    {"id":"70536","name":"Agenda - PDCO agenda of the 14-17 October 2025 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-10-14T10:04:37Z","last_updated_date":"2025-10-14T10:04:37Z","reference_number":"EMA/PDCO/309627/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-14-17-october-2025-meeting_en.xlsx"},
    {"id":"70537","name":" Agenda - Medicine Shortages (SPOC) Working Party meeting on 14-15 October 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-10-14T10:11:58Z","last_updated_date":"2025-10-14T10:11:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-14-15-october-2025_en.pdf"},
    {"id":"70542","name":"Agenda - HMA/EMA Annual Data Forum 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-10-14T11:32:10Z","last_updated_date":"2025-12-08T15:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hma-ema-annual-data-forum-2025_en.pdf"},
    {"id":"70579","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 20 October 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-10-15T16:53:36Z","last_updated_date":"2025-10-15T16:53:36Z","reference_number":"EMA/310945/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-20-october-2025_en.pdf"},
    {"id":"70580","name":"Agenda - ACT EU multi-stakeholder platform annual meeting - October 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-10-15T16:58:18Z","last_updated_date":"2025-10-28T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-multi-stakeholder-platform-annual-meeting-october-2025_en.pdf"},
    {"id":"70637","name":"Agenda - Fifth veterinary big data stakeholder forum","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-10-17T14:26:53Z","last_updated_date":"2025-11-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fifth-veterinary-big-data-stakeholder-forum_en.pdf"},
    {"id":"70660","name":"Agenda - 15th meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-10-20T10:13:47Z","last_updated_date":"2025-10-20T10:13:47Z","reference_number":"EMA/335419/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-15th-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"70663","name":"Agenda - HMA/EMA Multi-stakeholder workshop on Artificial Intelligence (AI)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-10-20T12:05:42Z","last_updated_date":"2025-11-19T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hma-ema-multi-stakeholder-workshop-artificial-intelligence-ai_en.pdf"},
    {"id":"70762","name":"Agenda - 20th industry stakeholder platform - operation of European Union (EU) pharmacovigilance","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-10-22T15:36:00Z","last_updated_date":"2025-11-11T11:25:00Z","reference_number":"EMA/147010/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-20th-industry-stakeholder-platform-operation-european-union-eu-pharmacovigilance_en.pdf"},
    {"id":"70789","name":"Agenda - Workshop on the use of external controls for evidence generation in regulatory decision-making","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-10-23T16:18:38Z","last_updated_date":"2025-11-18T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-use-external-controls-evidence-generation-regulatory-decision-making_en.pdf"},
    {"id":"70854","name":"Agenda of the PRAC meeting 27 - 30 October 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-10-27T17:27:56Z","last_updated_date":"2025-10-27T17:27:56Z","reference_number":"EMA/PRAC/316561/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-27-30-october-2025_en.pdf"},
    {"id":"70943","name":"Agenda - European Medicines Agency (EMA) and European Association of Urology (EAU) bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-10-30T15:19:11Z","last_updated_date":"2025-11-17T11:20:04Z","reference_number":"EMA/293576/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-european-association-urology-eau-bilateral-meeting_en.pdf"}    {"id":"70976","name":"Agenda - Combination products operational group, MD stream, 7 November 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-03T14:20:09Z","last_updated_date":"2025-11-03T14:20:09Z","reference_number":"EMA/324489/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-combination-products-operational-group-md-stream-7-november-2025_en.pdf"},
    {"id":"70977","name":"Agenda - Combination products operational group, IVD stream, 4 November 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-03T14:22:12Z","last_updated_date":"2025-11-03T14:22:12Z","reference_number":"EMA/324488/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-combination-products-operational-group-ivd-stream-4-november-2025_en.pdf"},
    {"id":"70979","name":"Agenda of the COMP meeting 4-6 November 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-11-03T16:14:00Z","last_updated_date":"2025-11-03T16:14:00Z","reference_number":"EMA/COMP/332122/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-4-6-november-2025_en.xlsx"},
    {"id":"70983","name":"Agenda of the CVMP meeting 4-6 November 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-11-03T17:17:29Z","last_updated_date":"2025-11-03T17:17:29Z","reference_number":"EMA/348754/2025 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-4-6-november-2025_en.pdf"},
    {"id":"70994","name":"Agenda - 1st EMA and European Respiratory Society (ERS) bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-04T11:31:41Z","last_updated_date":"2025-11-04T11:31:41Z","reference_number":"EMA/348591/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-1st-ema-european-respiratory-society-ers-bilateral-meeting_en.pdf"},
    {"id":"70999","name":"Agenda of the CAT meeting 5-7 November 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-11-04T16:12:45Z","last_updated_date":"2025-11-04T16:12:45Z","reference_number":"EMA/CAT/352855/2025  ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-5-7-november-2025_en.pdf"},
    {"id":"71000","name":"Agenda - 15th Industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-04T17:18:07Z","last_updated_date":"2025-12-09T11:11:11Z","reference_number":"EMA/293578/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-15th-industry-stakeholder-platform-research-development-support_en.pdf"},
    {"id":"71071","name":"Agenda of the CHMP meeting 10-13 November 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-11-10T14:40:43Z","last_updated_date":"2025-11-10T14:40:43Z","reference_number":"EMA/CHMP/331479/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-10-13-november-2025_en.pdf"},
    {"id":"71072","name":"Annex to agenda of the CHMP meeting 10-13 November 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-11-10T14:42:38Z","last_updated_date":"2025-11-10T14:42:38Z","reference_number":"EMA/CHMP/335242/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-agenda-chmp-meeting-10-13-november-2025_en.xlsx"},
    {"id":"71073","name":"Agenda - Quarterly System Demo Q4 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T16:00:42Z","last_updated_date":"2025-12-08T15:03:03Z","reference_number":"EMA/356849/2025 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quarterly-system-demo-q4-2025_en.pdf"},
    {"id":"71078","name":"Agenda - PCWP/HCPWP and all eligible organisations meeting 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-11-10T16:36:47Z","last_updated_date":"2025-11-11T15:52:47Z","reference_number":"EMA/271255/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwp-hcpwp-all-eligible-organisations-meeting-2025_en.pdf"},
    {"id":"71082","name":"Agenda - PDCO agenda of the 11-14 November 2025 meeting","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-11-11T10:31:49Z","last_updated_date":"2025-11-11T10:31:49Z","reference_number":"EMA/PDCO/338749/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-11-14-november-2025-meeting_en.xlsx"},
    {"id":"71101","name":"Agenda - Fourth European Medicines Agency - MedTech Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-12T10:54:19Z","last_updated_date":"2025-11-12T10:54:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-european-medicines-agency-medtech-europe-bilateral-meeting_en.pdf"},
    {"id":"71102","name":"Agenda - Fourth European Medicines Agency (EMA) and European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-12T11:04:12Z","last_updated_date":"2025-11-12T11:04:12Z","reference_number":"EMA/190715/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fourth-european-medicines-agency-ema-european-confederation-pharmaceutical-entrepreneurs-eucope-bilateral-meeting_en.pdf"},
    {"id":"71107","name":"Agenda - Medicine Shortages (SPOC) Working Party 11 November 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-12T15:41:15Z","last_updated_date":"2025-11-13T13:39:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-11-november-2025_en.pdf"},
    {"id":"71203","name":"Agenda of the HMPC meeting 17-19 November 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-11-17T16:23:38Z","last_updated_date":"2025-11-17T16:23:38Z","reference_number":"EMA/HMPC/336818/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-17-19-november-2025_en.pdf"},
    {"id":"71204","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 20 November 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-17T16:27:40Z","last_updated_date":"2025-11-17T16:27:40Z","reference_number":"EMA/337901/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-20-november-2025_en.pdf"},
    {"id":"71315","name":"Agenda of the PRAC meeting 24 - 27 November 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-11-24T16:01:58Z","last_updated_date":"2025-11-24T16:01:58Z","reference_number":"EMA/PRAC/354765/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-24-27-november-2025_en.pdf"},
    {"id":"71339","name":"Agenda - DARWIN EU Advisory Board - 25 November 2024","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T10:19:32Z","last_updated_date":"2025-11-26T10:19:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-25-november-2024_en.pdf"},
    {"id":"71341","name":"Agenda - DARWIN EU Advisory Board - 20 January 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T10:23:21Z","last_updated_date":"2025-11-26T10:23:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-darwin-eu-advisory-board-20-january-2025_en.pdf"},
    {"id":"71343","name":"Agenda - 15th Industry Standing Group (ISG) meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T11:05:39Z","last_updated_date":"2025-12-05T15:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-15th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"71386","name":"Agenda - HMA-EMA group focused on AI with industry stakeholders kick-off meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T11:24:28Z","last_updated_date":"2025-11-28T11:24:28Z","reference_number":"EMA/366162/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hma-ema-group-focused-ai-industry-stakeholders-kick-meeting_en.pdf"},
    {"id":"71443","name":"Draft agenda – Workshop between notified bodies and expert panels","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-12-01T16:55:35Z","last_updated_date":"2025-12-01T16:55:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/draft-agenda-workshop-between-notified-bodies-expert-panels_en.pdf"},
    {"id":"71445","name":"Agenda of the COMP meeting 2-3 December 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-12-02T09:47:53Z","last_updated_date":"2025-12-02T09:47:53Z","reference_number":"EMA/COMP/360557/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-2-3-december-2025_en.xlsx"},
    {"id":"71449","name":"Agenda of the CVMP meeting 2-4 December 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-12-02T11:31:29Z","last_updated_date":"2025-12-02T11:31:29Z","reference_number":"EMA/CVMP/366230/2025 – draft 3","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-2-4-december-2025_en.pdf"},
    {"id":"71463","name":"Agenda of the CAT meeting 3-5 December 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-12-03T09:00:00Z","last_updated_date":"2025-12-03T09:00:00Z","reference_number":"EMA/CAT/380010/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-3-5-december-2025_en.pdf"},
    {"id":"71590","name":"Agenda of the CHMP meeting 8-11 December 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-12-08T15:01:38Z","last_updated_date":"2025-12-08T15:01:38Z","reference_number":"EMA/CHMP/347361/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-8-11-december-2025_en.pdf"},
    {"id":"71591","name":"Annex to agenda of the CHMP meeting 8-11 December 2025","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-12-08T15:03:38Z","last_updated_date":"2025-12-08T15:03:38Z","reference_number":"EMA/CHMP/362409/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-agenda-chmp-meeting-8-11-december-2025_en.xlsx"},
    {"id":"71598","name":"Agenda - PDCO agenda of the 9-12 December 2025 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2025-12-08T18:16:23Z","last_updated_date":"2025-12-08T18:16:23Z","reference_number":"EMA/PDCO/372844/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-9-12-december-2025-meeting_en.xlsx"},
    {"id":"71614","name":"Agenda - Medicine Shortages SPOC Working Party meeting 9 December 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T12:05:31Z","last_updated_date":"2025-12-09T12:05:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-9-december-2025_en.pdf"},
    {"id":"71662","name":"Agenda - 2025 annual internal meeting of the European network of paediatric research at the EMA (Enpr-EMA)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:00:16Z","last_updated_date":"2025-12-10T15:00:16Z","reference_number":"EMA/156669/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-2025-annual-internal-meeting-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"71680","name":"Agenda - Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting inthe EU: Hands-on Training Course using the EudraVigilance System - 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-12-11T08:40:54Z","last_updated_date":"2026-02-02T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-mandatory-use-iso-ich-e2br3-individual-case-safety-reporting-inthe-eu-hands-training-course-using-eudravigilance-system-2026_en.pdf"},
    {"id":"71686","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 17 December 2025","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-12-11T12:35:00Z","last_updated_date":"2025-12-11T12:35:00Z","reference_number":"EMA/367190/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-17-december-2025_en.pdf"},
    {"id":"71698","name":"Agenda - Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system (February, May 2026)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-12-11T16:09:06Z","last_updated_date":"2025-12-11T16:09:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system-february-may-2026_en.pdf"},
    {"id":"71796","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-12-17T10:08:23Z","last_updated_date":"2026-03-09T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-2026_en.pdf"},
    {"id":"71797","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course for sponsors 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-12-17T10:19:52Z","last_updated_date":"2025-12-17T10:19:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-sponsors-2026_en.pdf"},
    {"id":"71805","name":"Agenda - Management Board meeting: 17-18 December 2025","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T13:40:00Z","last_updated_date":"2025-12-18T12:20:29Z","reference_number":"EMA/MB/331769/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-management-board-meeting-17-18-december-2025_en.pdf"},
    {"id":"71853","name":"Agenda - EMA/BEUC Bilateral","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2025-12-18T15:18:11Z","last_updated_date":"2025-12-18T15:18:11Z","reference_number":"EMA/230706/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-beuc-bilateral_en.pdf"},
    {"id":"71996","name":"Agenda - Seventh EMA-EuropaBio bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-08T16:01:26Z","last_updated_date":"2026-01-08T16:01:26Z","reference_number":"EMA/262307/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-seventh-ema-europabio-bilateral-meeting_en.pdf"},
    {"id":"71997","name":"Agenda - 6th EMA-AESGP bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-08T16:05:46Z","last_updated_date":"2026-01-08T16:05:46Z","reference_number":"EMA/312438/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-6th-ema-aesgp-bilateral-meeting_en.pdf"},
    {"id":"72014","name":"Agenda - New variations guidelines: webinar for marketing authorisation holders (human)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-12T14:53:35Z","last_updated_date":"2026-01-12T14:53:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-new-variations-guidelines-webinar-marketing-authorisation-holders-human_en.pdf"},
    {"id":"72018","name":"Agenda of the PRAC meeting 12 - 15 January 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-01-12T16:12:46Z","last_updated_date":"2026-01-12T16:12:46Z","reference_number":"EMA/PRAC/388300/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-12-15-january-2026_en.pdf"},
    {"id":"72020","name":"Agenda of the CVMP meeting 13-15 January 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-01-12T16:34:43Z","last_updated_date":"2026-01-12T16:34:43Z","reference_number":"EMA/CVMP/5317/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-13-15-january-2026_en.pdf"},
    {"id":"72051","name":"Agenda - Webinar for stakeholder engagement on the new draft guideline on general considerations for patient preference studies (ICH E22)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-14T17:21:53Z","last_updated_date":"2026-01-14T17:21:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-webinar-stakeholder-engagement-new-draft-guideline-general-considerations-patient-preference-studies-ich-e22_en.pdf"},
    {"id":"72076","name":"Agenda of the HMPC meeting 19-21 January 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-01-19T08:31:16Z","last_updated_date":"2026-01-19T08:31:16Z","reference_number":"EMA/HMPC/388321/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-19-21-january-2026_en.pdf"},
    {"id":"72078","name":"Agenda - Webinar on the use of platform approaches in the non-clinical and clinical domains","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T17:09:34Z","last_updated_date":"2026-02-24T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-webinar-use-platform-approaches-non-clinical-clinical-domains_en.pdf"},
    {"id":"72080","name":"Agenda - Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP) (2023)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:15:06Z","last_updated_date":"2026-01-16T09:15:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-ctti-fda-patient-engagement-collaborative-pec-ema-patients-consumers-working-party-pcwp-2023_en.pdf"},
    {"id":"72084","name":"Agenda - Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP) (2024)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:21:03Z","last_updated_date":"2026-01-16T09:21:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-ctti-fda-patient-engagement-collaborative-pec-ema-patients-consumers-working-party-pcwp-2024_en.pdf"},
    {"id":"72091","name":"Agenda - Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP) (2025)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:28:30Z","last_updated_date":"2026-01-16T09:28:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-ctti-fda-patient-engagement-collaborative-pec-ema-patients-consumers-working-party-pcwp-2025_en.pdf"},
    {"id":"72150","name":"Agenda of the COMP meeting 20-22 January 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-01-20T10:40:30Z","last_updated_date":"2026-01-20T10:40:30Z","reference_number":"EMA/COMP/389133/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-20-22-january-2026_en.xlsx"},
    {"id":"72173","name":"Agenda of the CAT meeting 21-23 January 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-01-20T16:31:34Z","last_updated_date":"2026-01-20T16:31:34Z","reference_number":"EMA/CAT/13322/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-21-23-january-2026_en.pdf"},
    {"id":"72200","name":"Agenda - Medicine Shortages SPOC Working Party meeting 20 January 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T16:54:03Z","last_updated_date":"2026-01-21T16:54:03Z","reference_number":"EMA/368242/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-20-january-2026_en.pdf"},
    {"id":"72261","name":"Agenda of the CHMP meeting 26-29 January 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-01-26T16:37:38Z","last_updated_date":"2026-01-26T16:37:38Z","reference_number":"EMA/CHMP/390303/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-26-29-january-2026_en.pdf"},
    {"id":"72262","name":"Annex to agenda of the CHMP meeting 26-29 January 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-01-26T16:38:48Z","last_updated_date":"2026-01-26T16:38:48Z","reference_number":"EMA/CHMP/390905/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-agenda-chmp-meeting-26-29-january-2026_en.xlsx"},
    {"id":"72263","name":"Agenda - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 30 January 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-26T16:44:56Z","last_updated_date":"2026-01-26T16:44:56Z","reference_number":"EMA/384778/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-30-january-2026_en.pdf"},
    {"id":"72278","name":"Agenda  - SPOR & XEVMPD status update webinar - 28 January 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T10:30:00Z","last_updated_date":"2026-02-12T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-spor-xevmpd-status-update-webinar-28-january-2026_en.pdf"},
    {"id":"72301","name":"Agenda - PDCO agenda of the 27-30 January 2026 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-01-27T16:40:31Z","last_updated_date":"2026-01-27T16:40:31Z","reference_number":"EMA/PDCO/7195/2026 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-27-30-january-2026-meeting_en.xlsx"},
    {"id":"72337","name":"Agenda - Healthcare Professionals' Working Party (HCPWP) plenary meeting - 3 February 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-01-28T16:42:28Z","last_updated_date":"2026-01-28T16:42:28Z","reference_number":"EMA/384211/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-healthcare-professionals-working-party-hcpwp-plenary-meeting-3-february-2026_en.pdf"},
    {"id":"72381","name":"Agenda - Meeting on the impact of chemical and environmental policies on the healthcare sector and availability of medicines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T12:07:12Z","last_updated_date":"2026-01-30T12:07:12Z","reference_number":"EMA/366126/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-impact-chemical-environmental-policies-healthcare-sector-availability-medicines_en.pdf"},
    {"id":"72388","name":"Agenda - PCWP and HCPWP joint meeting February 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-01-30T14:42:49Z","last_updated_date":"2026-01-30T14:42:49Z","reference_number":"EMA/384211/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwp-hcpwp-joint-meeting-february-2026_en.pdf"},
    {"id":"72401","name":"Agenda - EMA Veterinary Medicines Info Day 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-02T16:26:23Z","last_updated_date":"2026-03-13T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-veterinary-medicines-info-day-2026_en.pdf"},
    {"id":"72445","name":"Agenda - Combination products operational group, Medical devices (MD) stream, 12 February 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-06T14:13:49Z","last_updated_date":"2026-02-06T14:13:49Z","reference_number":"EMA/382365/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-combination-products-operational-group-medical-devices-md-stream-12-february-2026_en.pdf"},
    {"id":"72446","name":"Agenda - Combination products operational group, In vitro diagnostics (IVD) stream, 9 February 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-06T14:15:34Z","last_updated_date":"2026-02-06T14:15:34Z","reference_number":"EMA/386654/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-combination-products-operational-group-vitro-diagnostics-ivd-stream-9-february-2026_en.pdf"},
    {"id":"72456","name":"Agenda - 3rd EMA-IPFA-PPTA bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-09T14:35:37Z","last_updated_date":"2026-02-09T14:35:37Z","reference_number":"EMA/239739/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-3rd-ema-ipfa-ppta-bilateral-meeting_en.pdf"},
    {"id":"72462","name":"Agenda of the PRAC meeting 9-12 February 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-02-09T17:41:07Z","last_updated_date":"2026-02-09T17:41:07Z","reference_number":"EMA/PRAC/15618/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-9-12-february-2026_en.pdf"},
    {"id":"72490","name":"Agenda of the CVMP meeting 10-12 February 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-02-10T14:50:00Z","last_updated_date":"2026-02-10T14:50:00Z","reference_number":"EMA/31907/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-10-12-february-2026_en.pdf"},
    {"id":"72542","name":"Agenda - Public System Demo Q1 2026","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2026-02-12T16:35:47Z","last_updated_date":"2026-03-16T15:25:00Z","reference_number":"EMA/12532/2026 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-public-system-demo-q1-2026_en.pdf"},
    {"id":"72571","name":"Agenda of the COMP meeting 17-19 February 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-02-16T15:24:45Z","last_updated_date":"2026-02-16T15:24:45Z","reference_number":"EMA/COMP/21379/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-17-19-february-2026_en.xlsx"},
    {"id":"72578","name":"Agenda - Medicine Shortages SPOC Working Party meeting 17 February 2026","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2026-02-17T10:11:55Z","last_updated_date":"2026-02-17T10:11:55Z","reference_number":"EMA/13780/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-17-february-2026_en.pdf"},
    {"id":"72589","name":"Agenda - European Medicines Regulatory Network workshop on Geographic Atrophy endpoints","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-02-18T15:01:31Z","last_updated_date":"2026-04-28T12:00:00Z","reference_number":"Revision 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-regulatory-network-workshop-geographic-atrophy-endpoints_en.pdf"},
    {"id":"72590","name":"Agenda of the CAT meeting 18-20 February 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-18T15:05:20Z","last_updated_date":"2026-02-18T15:05:20Z","reference_number":"EMA/CAT/40771/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-18-20-february-2026_en.pdf"},
    {"id":"72650","name":"Agenda - Eighth European Medicines Agency (EMA) and Medicines for Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-23T16:27:42Z","last_updated_date":"2026-02-23T16:27:42Z","reference_number":"EMA/189807/20","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-eighth-european-medicines-agency-ema-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"72651","name":"Agenda of the CHMP meeting 23-26 February 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-02-23T16:45:00Z","last_updated_date":"2026-02-23T16:45:00Z","reference_number":"EMA/CHMP/41571/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-23-26-february-2026_en.pdf"},
    {"id":"72652","name":"Annex to agenda of the CHMP meeting 23-26 February 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-23T16:38:08Z","last_updated_date":"2026-02-23T16:38:08Z","reference_number":"EMA/CHMP/20183/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-agenda-chmp-meeting-23-26-february-2026_en.xlsx"},
    {"id":"72656","name":"Agenda - PDCO agenda of the 24-27 February 2026 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-02-24T09:20:02Z","last_updated_date":"2026-02-24T09:20:02Z","reference_number":"EMA/PDCO/33429/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-24-27-february-2026-meeting_en.xlsx"},
    {"id":"72657","name":"Agenda - Product Management Service (PMS) information day 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-24T09:29:18Z","last_updated_date":"2026-05-04T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-management-service-pms-information-day-2026_en.pdf"},
    {"id":"72744","name":"Agenda - EMA multi-stakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-02-27T12:25:32Z","last_updated_date":"2026-06-12T09:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-multi-stakeholder-workshop-supporting-innovation-cardiovascular-medicines-medical-devices-eu_en.pdf"},
    {"id":"72749","name":"Agenda of the HMPC meeting 2-4 March 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-02-27T12:45:00Z","last_updated_date":"2026-02-27T12:45:00Z","reference_number":"EMA/HMPC/30298/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-2-4-march-2026_en.pdf"},
    {"id":"72756","name":"Agenda - Quality Innovation Group (QIG): Listen and learn focus group meeting on sustainability","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-27T15:21:35Z","last_updated_date":"2026-02-27T15:21:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quality-innovation-group-qig-listen-learn-focus-group-meeting-sustainability_en.pdf"},
    {"id":"72757","name":"Agenda - Meeting of the HMA-EMA group focused on AI with industry stakeholders - February 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-02-27T15:43:43Z","last_updated_date":"2026-02-27T15:43:43Z","reference_number":"EMA/19650/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-hma-ema-group-focused-ai-industry-stakeholders-february-2026_en.pdf"},
    {"id":"72777","name":"Agenda - European Medicines Agency (EMA) - European Alliance of Associations for Rheumatology (EULAR) bilateral meeting - March 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-02T16:10:04Z","last_updated_date":"2026-03-02T16:10:04Z","reference_number":"EMA/13450/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-european-alliance-associations-rheumatology-eular-bilateral-meeting-march-2026_en.pdf"},
    {"id":"72840","name":"Agenda - Ad hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 5 March 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-03-05T09:28:53Z","last_updated_date":"2026-03-05T09:28:53Z","reference_number":"EMA/40834/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ad-hoc-executive-steering-group-shortages-safety-medicinal-products-mssg-5-march-2026_en.pdf"},
    {"id":"72872","name":"Agenda - 16th Industry Standing Group meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-03-06T11:58:17Z","last_updated_date":"2026-03-06T11:58:17Z","reference_number":"EMA/1657/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-16th-industry-standing-group-meeting_en.pdf"},
    {"id":"72904","name":"Agenda of the PRAC meeting 9-12 March 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-09T14:50:00Z","last_updated_date":"2026-03-09T14:50:00Z","reference_number":"EMA/PRAC/42166/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-9-12-march-2026_en.pdf"},
    {"id":"72909","name":"Agenda of the CVMP meeting 10-12 March 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-10T10:16:10Z","last_updated_date":"2026-03-11T16:08:00Z","reference_number":"EMA/56515/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-10-12-march-2026_en.pdf"},
    {"id":"72948","name":"Agenda - Management Board meeting: 12 March 2026","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T15:04:40Z","last_updated_date":"2026-03-17T09:45:00Z","reference_number":"EMA/MB/29027/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-management-board-meeting-12-march-2026_en.pdf"},
    {"id":"73018","name":"Agenda - ACT EU webinar on contractual agreements","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-16T09:15:28Z","last_updated_date":"2026-04-10T14:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-act-eu-webinar-contractual-agreements_en.pdf"},
    {"id":"73021","name":"Agenda - EMA - Alzheimer Europe (AE) bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-03-16T09:52:07Z","last_updated_date":"2026-03-16T09:52:07Z","reference_number":"EMA/389775/2025","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-alzheimer-europe-ae-bilateral-meeting_en.pdf"},
    {"id":"73023","name":"Agenda - Workshop on Vulnerability Assessment","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-03-16T10:03:29Z","last_updated_date":"2026-03-16T10:03:29Z","reference_number":"EMA/62055/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-workshop-vulnerability-assessment_en.pdf"},
    {"id":"73045","name":"Agenda - Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 16 March 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-03-16T14:21:00Z","last_updated_date":"2026-03-16T14:21:00Z","reference_number":"EMA/CHMP/46712/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-extraordinary-meeting-committee-medicinal-products-human-use-chmp-16-march-2026_en.pdf"},
    {"id":"73047","name":"Agenda of the COMP meeting 17-18 March 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-17T09:11:46Z","last_updated_date":"2026-03-17T09:11:46Z","reference_number":"EMA/COMP/45745/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-17-18-march-2026_en.xlsx"},
    {"id":"73052","name":"Agenda - Medicine Shortages SPOC Working Party meeting 16-17 March 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T10:50:00Z","last_updated_date":"2026-03-17T10:50:00Z","reference_number":"EMA/58544/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-16-17-march-2026_en.pdf"},
    {"id":"73077","name":"Agenda of the CAT meeting 18-20 March 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-17T16:42:28Z","last_updated_date":"2026-03-17T16:42:28Z","reference_number":"EMA/CAT/64755/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-18-20-march-2026_en.pdf"},
    {"id":"73128","name":"Agenda - Executive steering group on shortages and safety of medicinal products (MSSG) - 23 March 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-03-20T10:23:28Z","last_updated_date":"2026-03-20T10:23:28Z","reference_number":"EMA/34686/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-23-march-2026_en.pdf"},
    {"id":"73129","name":"Agenda - European shortages monitoring platform (ESMP) training on readable IDs and general updates for industry","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-03-20T10:55:17Z","last_updated_date":"2026-03-20T10:55:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-shortages-monitoring-platform-esmp-training-readable-ids-general-updates-industry_en.pdf"},
    {"id":"73145","name":"Agenda - Executive Steering Group on Shortages of Medical Devices (MDSSG) (23 March 2026)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-03-23T14:19:22Z","last_updated_date":"2026-03-24T16:33:00Z","reference_number":"EMA/26580/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-medical-devices-mdssg-23-march-2026_en.pdf"},
    {"id":"73146","name":"Agenda of the CHMP meeting 23-26 March 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-23T14:34:39Z","last_updated_date":"2026-03-23T14:34:39Z","reference_number":"EMA/CHMP/67141/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-23-26-march-2026_en.pdf"},
    {"id":"73147","name":"Annex to agenda of the CHMP meeting 23-26 March 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-23T14:20:00Z","last_updated_date":"2026-03-23T14:20:00Z","reference_number":"EMA/CHMP/49808/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-agenda-chmp-meeting-23-26-march-2026_en.xlsx"},
    {"id":"73157","name":"Agenda - PDCO agenda of the 24-27 March 2026 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-24T11:17:47Z","last_updated_date":"2026-03-24T11:17:47Z","reference_number":"EMA/PDCO/58973/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-24-27-march-2026-meeting_en.xlsx"},
    {"id":"73201","name":"Agenda - Patients' and Consumers' Working Party (PCWP) meeting - June 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-25T11:12:44Z","last_updated_date":"2026-06-11T15:30:00Z","reference_number":"EMA/4253/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-patients-consumers-working-party-pcwp-meeting-june-2026_en.pdf"}    {"id":"73203","name":"Agenda - Webinar on draft guidance on the conduct of clinical trials during public health emergencies","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T15:00:00Z","last_updated_date":"2026-04-01T16:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-webinar-draft-guidance-conduct-clinical-trials-during-public-health-emergencies_en.pdf"},
    {"id":"73252","name":"Agenda - PCWP/HCPWP joint meeting 30 June 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-27T16:47:46Z","last_updated_date":"2026-03-27T16:47:46Z","reference_number":"EMA/73375/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwp-hcpwp-joint-meeting-30-june-2026_en.pdf"},
    {"id":"73253","name":"Agenda - PCWP/HCPWP joint meeting 1 July 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-27T16:48:52Z","last_updated_date":"2026-03-27T16:48:52Z","reference_number":"EMA/4253/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pcwp-hcpwp-joint-meeting-1-july-2026_en.pdf"},
    {"id":"73254","name":"Agenda - EnprEMA & ACT EU workshop on paediatric clinical trials","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-03-27T16:55:55Z","last_updated_date":"2026-05-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-enprema-act-eu-workshop-paediatric-clinical-trials_en.pdf"},
    {"id":"73322","name":"Agenda - SPOR and XEVMPD status update webinar - Q2 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T13:34:18Z","last_updated_date":"2026-04-07T13:34:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-spor-xevmpd-status-update-webinar-q2-2026_en.pdf"},
    {"id":"73335","name":"Agenda of the PRAC meeting 7-10 April 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-04-07T14:41:20Z","last_updated_date":"2026-04-07T14:41:20Z","reference_number":"EMA/PRAC/68437/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-7-10-april-2026_en.pdf"},
    {"id":"73338","name":"Agenda - EMA and European Association of Nuclear Medicine (EANM)  bilateral meeting  ","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-04-07T15:58:48Z","last_updated_date":"2026-04-07T15:58:48Z","reference_number":"EMA/78026/2026 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ema-european-association-nuclear-medicine-eanm-bilateral-meeting_en.pdf"},
    {"id":"73353","name":"Agenda - Breakthrough medical devices: information session","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-04-08T14:16:54Z","last_updated_date":"2026-04-08T14:16:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-breakthrough-medical-devices-information-session_en.pdf"},
    {"id":"73430","name":"Agenda of the CVMP meeting 14-16 April 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-04-14T09:09:25Z","last_updated_date":"2026-04-14T09:09:25Z","reference_number":"EMA/CVMP/65896/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-14-16-april-2026_en.pdf"},
    {"id":"73431","name":"Agenda of the COMP Meeting 14-16 April 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-04-14T09:24:30Z","last_updated_date":"2026-05-04T16:49:00Z","reference_number":"EMA/COMP/71305/2026 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-14-16-april-2026_en.xlsx"},
    {"id":"73438","name":"Agenda of the CAT meeting 15-17 April 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-04-14T15:22:36Z","last_updated_date":"2026-04-14T15:22:36Z","reference_number":"EMA/CAT/86491/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-15-17-april-2026_en.pdf"},
    {"id":"73440","name":"Agenda - Medicine shortages SPOC working party meeting 15 April 2026","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2026-04-15T10:00:00Z","last_updated_date":"2026-04-15T10:00:00Z","reference_number":"EMA/70065/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-15-april-2026_en.pdf"},
    {"id":"73498","name":"Agenda of the CHMP meeting 20-23 April 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-04-20T17:22:54Z","last_updated_date":"2026-04-20T17:22:54Z","reference_number":"EMA/CHMP/74711/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-20-23-april-2026_en.pdf"},
    {"id":"73499","name":"Annex to agenda of the CHMP meeting 20-23 April 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-04-20T17:24:44Z","last_updated_date":"2026-04-20T17:24:44Z","reference_number":"EMA/CHMP/74740/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-agenda-chmp-meeting-20-23-april-2026_en.xlsx"},
    {"id":"73506","name":"Agenda - PDCO agenda of the 21-24 April 2026 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-04-21T16:04:39Z","last_updated_date":"2026-04-21T16:04:39Z","reference_number":"EMA/PDCO/80692/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-21-24-april-2026-meeting_en.xlsx"},
    {"id":"73552","name":"Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) 24 April 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-04-24T09:01:38Z","last_updated_date":"2026-04-24T09:01:38Z","reference_number":"EMA/57794/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-executive-steering-group-shortages-safety-medicinal-products-mssg-24-april-2026_en.pdf"},
    {"id":"73565","name":"Agenda - European Platform for Regulatory Science Research meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-04-24T10:58:49Z","last_updated_date":"2026-04-28T16:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-platform-regulatory-science-research-meeting_en.pdf-0"},
    {"id":"73601","name":"Agenda of the HMPC meeting 4-6 May 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-05-04T08:48:12Z","last_updated_date":"2026-05-04T08:48:12Z","reference_number":"EMA/HMPC/86201/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-hmpc-meeting-4-6-may-2026_en.pdf"},
    {"id":"73606","name":"Agenda - Product Management Service (PMS) information day 2026 (p.m.)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-04T16:43:20Z","last_updated_date":"2026-05-28T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-product-management-service-pms-information-day-2026-pm_en.pdf"},
    {"id":"73607","name":"Agenda of the PRAC meeting 4-7 May 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-05-04T16:50:21Z","last_updated_date":"2026-05-05T16:43:00Z","reference_number":"EMA/PRAC/89531/2026 Corr.","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-4-7-may-2026_en.pdf"},
    {"id":"73687","name":"Agenda of the COMP Meeting 11-12 May 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-05-11T08:35:00Z","last_updated_date":"2026-05-11T08:35:00Z","reference_number":"EMA/COMP/93011/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-11-12-may-2026_en.xlsx"},
    {"id":"73705","name":"Agenda of the CAT meeting 11-13 May 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-05-11T14:25:12Z","last_updated_date":"2026-05-11T14:25:12Z","reference_number":"EMA/CAT/111528/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-11-13-may-2026_en.pdf"},
    {"id":"73716","name":"Agenda - Medicine Shortages SPOC Working Party meeting 12 May 2026","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2026-05-12T10:13:54Z","last_updated_date":"2026-05-12T10:13:54Z","reference_number":"EMA/77926/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-12-may-2026_en.pdf"},
    {"id":"73729","name":"Agenda – Quarterly System Demo - Q2 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-12T13:29:44Z","last_updated_date":"2026-06-10T10:21:30Z","reference_number":"EMA/87593/2026 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-quarterly-system-demo-q2-2026_en.pdf"},
    {"id":"73742","name":"Agenda of the CHMP meeting 18-21 May 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-05-18T12:06:21Z","last_updated_date":"2026-05-18T12:06:21Z","reference_number":"EMA/CHMP/93949/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-18-21-may-2026_en.pdf"},
    {"id":"73743","name":"Annex to agenda of the CHMP meeting 18-21 May 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-05-18T12:08:38Z","last_updated_date":"2026-05-18T12:08:38Z","reference_number":"EMA/CHMP/94809/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-agenda-chmp-meeting-18-21-may-2026_en.xlsx"},
    {"id":"73759","name":"Agenda - PDCO agenda of the 19-22 May 2026 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-05-19T13:59:30Z","last_updated_date":"2026-05-19T13:59:30Z","reference_number":"EMA/PDCO/110090/2026 ","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-19-22-may-2026-meeting_en.xlsx"},
    {"id":"73760","name":"Agenda of the CVMP meeting 19-21 May 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-05-19T14:23:35Z","last_updated_date":"2026-05-19T14:23:35Z","reference_number":"EMA/113692/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-19-21-may-2026_en.pdf"},
    {"id":"73761","name":"Agenda - 16th meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-05-19T14:38:24Z","last_updated_date":"2026-05-29T10:30:00Z","reference_number":"EMA/116340/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-16th-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"73765","name":"Agenda - Challenges in drug development, regulation and clinical practice in immune thrombocytopenia","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-19T14:59:23Z","last_updated_date":"2026-06-19T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-challenges-drug-development-regulation-clinical-practice-immune-thrombocytopenia_en.pdf"},
    {"id":"73784","name":"Agenda - Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - May 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-20T15:52:25Z","last_updated_date":"2026-05-20T15:52:25Z","reference_number":"EMA/87794/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-meeting-executive-steering-group-shortages-safety-medicinal-products-mssg-may-2026_en.pdf"},
    {"id":"73785","name":"Agenda - Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-20T16:56:57Z","last_updated_date":"2026-05-20T16:56:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-mandatory-use-iso-ich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system_en.pdf"},
    {"id":"73786","name":"Agenda - Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system (October / November 2026)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-21T10:17:05Z","last_updated_date":"2026-05-21T10:17:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system-october-november-2026_en.pdf"},
    {"id":"73853","name":"Agenda - Clinical trials information system information day webinar","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-26T14:09:49Z","last_updated_date":"2026-06-23T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-clinical-trials-information-system-information-day-webinar_en.pdf"},
    {"id":"73867","name":"Agenda - European Medicines Agency (EMA) / European Chemicals Agency (ECHA) joint meeting with industry stakeholders","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-27T16:16:47Z","last_updated_date":"2026-05-27T16:16:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-european-medicines-agency-ema-european-chemicals-agency-echa-joint-meeting-industry-stakeholders_en.pdf"},
    {"id":"73890","name":"Programme - eXtended EudraVigilance medicinal product dictionary (XEVMPD) training course 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-29T09:05:15Z","last_updated_date":"2026-05-29T09:05:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-2026_en.pdf-0"},
    {"id":"73891","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course for sponsors 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-29T09:58:06Z","last_updated_date":"2026-05-29T09:58:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-course-sponsors-2026_en.pdf-0"},
    {"id":"73894","name":"Programme  - Multistakeholder workshop on real world data collection in Duchenne muscular dystrophy","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-05-29T11:51:04Z","last_updated_date":"2026-06-23T17:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/programme-multistakeholder-workshop-real-world-data-collection-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"73913","name":"Agenda - Combination products operational group, IVD stream, 12 June 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-06-01T10:07:05Z","last_updated_date":"2026-06-01T10:07:05Z","reference_number":"EMA/32336/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-combination-products-operational-group-ivd-stream-12-june-2026_en.pdf"},
    {"id":"74005","name":"Agenda of the PRAC meeting 8-11 June 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-06-08T17:20:51Z","last_updated_date":"2026-06-08T17:20:51Z","reference_number":"EMA/PRAC/115322/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-8-11-june-2026_en.pdf"},
    {"id":"74006","name":"EMA/HMA European platform for regulatory science research platform meeting – draft agenda","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-06-09T09:19:57Z","last_updated_date":"2026-06-10T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/ema-hma-european-platform-regulatory-science-research-platform-meeting-draft-agenda_en.pdf"},
    {"id":"74012","name":"Agenda - Sixteenth industry stakeholder platform on research and development support","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T14:06:12Z","last_updated_date":"2026-06-09T14:06:12Z","reference_number":"EMA/107723/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-sixteenth-industry-stakeholder-platform-research-development-support_en.pdf"},
    {"id":"74021","name":"Agenda - Management Board meeting: 10-11 June 2026","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2026-06-09T16:13:35Z","last_updated_date":"2026-06-12T09:00:00Z","reference_number":"EMA/MB/87650/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-management-board-meeting-10-11-june-2026_en.pdf"},
    {"id":"74042","name":"Agenda – Ad hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 12 June 2026","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-06-12T10:00:00Z","last_updated_date":"2026-06-12T10:00:00Z","reference_number":"EMA/122296/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-ad-hoc-executive-steering-group-shortages-safety-medicinal-products-mssg-12-june-2026_en.pdf"},
    {"id":"74051","name":"Agenda - Updates to industry contact management for authorisation products (IRIS)","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-06-10T14:56:09Z","last_updated_date":"2026-06-10T14:56:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-updates-industry-contact-management-authorisation-products-iris_en.pdf"},
    {"id":"74086","name":"Regulatory Perspectives on Herbal Medicinal  Botanical Drug Product Development - Joint FDA-EMA Workshop: Event agenda","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-06-12T15:01:50Z","last_updated_date":"2026-06-12T15:01:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/regulatory-perspectives-herbal-medicinal-botanical-drug-product-development-joint-fda-ema-workshop-event-agenda_en.pdf"},
    {"id":"74100","name":"Agenda of the COMP Meeting 16-18 June 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-06-15T16:40:44Z","last_updated_date":"2026-06-15T16:40:44Z","reference_number":"EMA/COMP/117970/2026\t","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-16-18-june-2026_en.xlsx"},
    {"id":"74113","name":"Agenda of the CVMP meeting 16-18 June 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-06-16T09:41:31Z","last_updated_date":"2026-06-16T09:41:31Z","reference_number":"EMA/137917/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cvmp-meeting-16-18-june-2026_en.pdf"},
    {"id":"74123","name":"Agenda - Medicine Shortages SPOC Working Party meeting 16-17 June 2026","type":"agenda","status":"Adopted","consultation_date":"","first_published_date":"2026-06-16T16:28:29Z","last_updated_date":"2026-06-18T15:00:00Z","reference_number":"EMA/135300/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-medicine-shortages-spoc-working-party-meeting-16-17-june-2026_en.pdf"},
    {"id":"74125","name":"Agenda of the CAT meeting 17-19 June 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-06-16T16:52:18Z","last_updated_date":"2026-06-16T16:52:18Z","reference_number":"EMA/CAT/139022/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-17-19-june-2026_en.pdf"},
    {"id":"74175","name":"Agenda - Shortage prevention plan (SPP) workshop","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-06-22T14:23:37Z","last_updated_date":"2026-06-22T14:23:37Z","reference_number":"EMA/142147/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-shortage-prevention-plan-spp-workshop_en.pdf"},
    {"id":"74177","name":"Agenda - PDCO agenda of the 23-26 June 2026 meeting","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-06-22T15:34:03Z","last_updated_date":"2026-06-23T17:00:00Z","reference_number":"EMA/PDCO/134940/2026 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-23-26-june-2026-meeting_en.xlsx"},
    {"id":"74181","name":"Agenda of the CHMP meeting 22-25 June 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-06-22T16:24:39Z","last_updated_date":"2026-06-22T16:24:39Z","reference_number":"EMA/CHMP/114951/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-june-2026_en.pdf"},
    {"id":"74182","name":"Annex to agenda of the CHMP meeting 22-25 June 2026","type":"agenda","status":"Draft","consultation_date":"","first_published_date":"2026-06-22T16:26:22Z","last_updated_date":"2026-06-22T16:26:22Z","reference_number":"EMA/CHMP/120608/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-agenda-chmp-meeting-22-25-june-2026_en.xlsx"},
    {"id":"74183","name":"Agenda - Fifth EMA and Nuclear Medicines Europe bilateral meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-06-22T16:45:40Z","last_updated_date":"2026-06-22T16:45:40Z","reference_number":"EMA/45392/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-fifth-ema-nuclear-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"74184","name":"Agenda for ETF-stakeholders meeting on biodistribution of mRNA vaccines","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-06-22T16:51:11Z","last_updated_date":"2026-06-22T16:51:11Z","reference_number":"EMA/141831/2026","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-etf-stakeholders-meeting-biodistribution-mrna-vaccines_en.pdf"},
    {"id":"74219","name":"Annex 22 expert workshop draft agenda: Day 1 - session with interested parties","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T10:52:22Z","last_updated_date":"2026-06-23T10:52:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/annex-22-expert-workshop-draft-agenda-day-1-session-interested-parties_en.pdf"},
    {"id":"74304","name":"Agenda – 17th Industry Standing Group (ISG) meeting","type":"agenda","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T16:25:16Z","last_updated_date":"2026-06-25T16:25:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-17th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"3066","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2008","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/INS/PhV/114151/2009","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2008_en.pdf"},
    {"id":"3491","name":"Annual report of the Good Clinical Practice Inspections Working Group 2014","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2015-07-03T16:35:00Z","last_updated_date":"2015-07-03T16:35:00Z","reference_number":"EMA/INS/GCP/434373/2014","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-clinical-practice-inspections-working-group-2014_en.pdf"},
    {"id":"4419","name":"Annual report of the European Agency for the Evaluation of Medicinal Products 2002","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2002-12-19T00:09:21Z","last_updated_date":"2002-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_es.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_de.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2002_sv.pdf"}},
    {"id":"4729","name":"2017 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T16:00:00Z","last_updated_date":"2018-06-06T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2017-annual-report-european-medicines-agency_en.pdf"},
    {"id":"5106","name":"Annual report of the European Agency for Evaluation of Medicinal Products 2003","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2004-03-11T00:09:21Z","last_updated_date":"2004-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_es.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_de.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2003_sv.pdf"}},
    {"id":"5723","name":"Annual report of the good clinical practice inspections working group 2009","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2010-03-22T01:00:00Z","last_updated_date":"2010-03-22T01:00:00Z","reference_number":"EMA/INS/GCP/782679/2009","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-clinical-practice-inspections-working-group-2009_en.pdf"},
    {"id":"5838","name":"Annual report of the European Medicines Agency 2005","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2006-03-09T00:09:21Z","last_updated_date":"2006-03-09T00:09:21Z","reference_number":"EMEA/MB/63019/2006","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2005_en.pdf"},
    {"id":"6305","name":"Annual report of the European Medicines Agency 2008","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2009-07-03T02:00:00Z","last_updated_date":"2009-07-03T02:00:00Z","reference_number":"EMEA/330566/2009","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2008_en.pdf"},
    {"id":"7295","name":"Small and medium-sized enterprise (SME) Office annual report 2013","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2014-01-30T15:45:00Z","last_updated_date":"2014-01-30T15:45:00Z","reference_number":"EMA/716205/2013","document_url":"https://www.ema.europa.eu/en/documents/annual-report/small-and-medium-sized-enterprise-sme-office-annual-report-2013_en.pdf"},
    {"id":"7432","name":"Annual report of the Good Clinical Practice Inspectors Working Group 2012","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2013-06-14T13:23:00Z","last_updated_date":"2013-06-14T13:23:00Z","reference_number":"EMA/627138/2012","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-clinical-practice-inspectors-working-group-2012_en.pdf"},
    {"id":"7666","name":"Annual report of the European Agency for Evaluation of Medicinal Products 1999","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"1999-12-01T00:09:21Z","last_updated_date":"1999-12-01T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_es.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_de.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1999_sv.pdf"}},
    {"id":"8171","name":"Summary of the European Medicines Agency’s annual report for 2008","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2009-07-03T02:00:00Z","last_updated_date":"2009-07-03T02:00:00Z","reference_number":"EMEA/362115/2009","document_url":"https://www.ema.europa.eu/en/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_bg.pdf","es":"https://www.ema.europa.eu/es/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_cs.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_de.pdf","et":"https://www.ema.europa.eu/et/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_et.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/summary-european-medicines-agencys-annual-report-2008_sv.pdf"}},
    {"id":"8656","name":"Annual report of the European Agency for Evaluation of Medicinal Products 1996","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"1996-12-04T00:09:21Z","last_updated_date":"1996-12-04T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1996_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1996_es.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1996_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1996_fr.pdf"}},
    {"id":"8729","name":"Annex 10 – 2016 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2017-05-10T12:00:00Z","last_updated_date":"2017-05-10T12:00:00Z","reference_number":"EMA/4995/2017","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2016-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-and-extensions-therapeutic-indication_en.xlsx"},
    {"id":"9034","name":"Annexes - 2017 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T16:00:00Z","last_updated_date":"2018-05-02T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2017-annual-report-european-medicines-agency_en.pdf"},
    {"id":"9502","name":"Consolidated final report on the activities of patients’ and consumers’ working party and healthcare professionals’ working party  topic groups (2015)","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2017-05-30T11:56:00Z","last_updated_date":"2017-05-30T11:56:00Z","reference_number":"EMA/225307/2017","document_url":"https://www.ema.europa.eu/en/documents/annual-report/consolidated-final-report-activities-patients-and-consumers-working-party-and-healthcare-professionals-working-party-topic-groups-2015_en.pdf"},
    {"id":"9819","name":"Annex 10 - 2015 annual report of the European Medicines Agency - Positive and negative opinions; Withdrawn applications","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2016-05-17T18:00:00Z","last_updated_date":"2016-05-17T18:00:00Z","reference_number":"EMA/156961/2016","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2015-annual-report-european-medicines-agency-positive-and-negative-opinions-withdrawn-applications_en.xlsx"},
    {"id":"10323","name":"Annexes to the annual report of the European Medicines Agency 2012","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2013-04-16T17:59:00Z","last_updated_date":"2013-04-16T17:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-annual-report-european-medicines-agency-2012_en.pdf"},
    {"id":"10382","name":"Annual report of the European Medicines Agency 2014","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2015-04-30T12:00:01Z","last_updated_date":"2015-04-30T12:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2014_en.pdf"},
    {"id":"10634","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2011","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2012-07-13T02:00:00Z","last_updated_date":"2012-07-13T02:00:00Z","reference_number":"EMA/INS/PhV/193153/2012","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2011_en.pdf"},
    {"id":"10848","name":"Annual report of the Good Clinical Practice Inspections Working Group 2010","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2012-07-17T12:20:00Z","last_updated_date":"2012-07-17T12:20:00Z","reference_number":"EMA/INS/GCP/711391/2010","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-clinical-practice-inspections-working-group-2010_en.pdf"},
    {"id":"11917","name":"Annual report of the European Agency for Evaluation of Medicinal Products 1998","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"1998-12-02T00:09:21Z","last_updated_date":"1998-12-02T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_es.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_de.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1998_sv.pdf"}},
    {"id":"14064","name":"Annual report of the European Medicines Agency 2011","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-06T18:11:02Z","last_updated_date":"2012-06-06T18:11:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2011_en.pdf"},
    {"id":"14169","name":"Annual report of the European Agency for Evaluation of Medicinal Products 2000","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2000-12-20T00:09:21Z","last_updated_date":"2000-12-20T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_es.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_de.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2000_sv.pdf"}},
    {"id":"14217","name":"Annual report of the European Medicines Agency 2007","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2008-05-13T02:00:00Z","last_updated_date":"2008-05-13T02:00:00Z","reference_number":"EMEA/MB/17464/2008","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2007_en.pdf"},
    {"id":"14304","name":"Summary of the European Medicines Agency’s annual report for 2007","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2008-06-17T02:00:00Z","last_updated_date":"2008-06-17T02:00:00Z","reference_number":"EMEA/197729/2008/EN/FINAL","document_url":"https://www.ema.europa.eu/en/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_bg.pdf","es":"https://www.ema.europa.eu/es/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_cs.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_de.pdf","et":"https://www.ema.europa.eu/et/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_et.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/summary-european-medicines-agencys-annual-report-2007_sv.pdf"}},
    {"id":"15049","name":"Results of the sampling and testing programme for the year 2008","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2010-03-01T01:00:00Z","last_updated_date":"2010-03-01T01:00:00Z","reference_number":"EMA/INS/S&T/34689/2010","document_url":"https://www.ema.europa.eu/en/documents/annual-report/results-sampling-and-testing-programme-year-2008_en.pdf"},
    {"id":"15200","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2014","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-12T13:17:00Z","last_updated_date":"2015-08-12T13:17:00Z","reference_number":"EMA/INS/PhV/380702/2015","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2014_en.pdf"},
    {"id":"15609","name":"Annual report from the SME office 2012","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2013-02-20T13:26:00Z","last_updated_date":"2013-02-20T13:26:00Z","reference_number":"EMA/801597/2012","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-sme-office-2012_en.pdf"},
    {"id":"16497","name":"Annual report of the Good Clinical Practice Inspections Working Group 2015","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2016-08-01T16:15:00Z","last_updated_date":"2016-08-01T16:15:00Z","reference_number":"EMA/INS/GCP/137204/2016","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-clinical-practice-inspections-working-group-2015_en.pdf"},
    {"id":"16926","name":"Annual report of the European Medicines Agency 2013","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2014-04-30T16:00:00Z","last_updated_date":"2014-05-08T15:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2013_en.pdf"},
    {"id":"17005","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2009","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2010-04-22T02:00:00Z","reference_number":"EMA/INS/PhV/788454/2009","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2009_en.pdf"},
    {"id":"17586","name":"Annual report of the European Medicines Agency 2006","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2007-05-01T02:00:00Z","last_updated_date":"2007-05-01T02:00:00Z","reference_number":"EMEA/MB/24167/2007/EN/FINAL","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2006_en.pdf"},
    {"id":"17786","name":"Annual report of the European Agency for Evaluation of Medicinal Products 2001","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2001-12-18T00:09:21Z","last_updated_date":"2001-12-18T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_es.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_de.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-2001_sv.pdf"}},
    {"id":"18456","name":"Summary of the annual report of the European Medicines Agency 2009","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2010-10-04T02:00:00Z","last_updated_date":"2010-10-04T02:00:00Z","reference_number":"EMA/499025/2010","document_url":"https://www.ema.europa.eu/en/documents/annual-report/summary-annual-report-european-medicines-agency-2009_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/annual-report/summary-annual-report-european-medicines-agency-2009_bg.pdf","es":"https://www.ema.europa.eu/es/documents/annual-report/summary-annual-report-european-medicines-agency-2009_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/annual-report/summary-annual-report-european-medicines-agency-2009_cs.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/summary-annual-report-european-medicines-agency-2009_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/summary-annual-report-european-medicines-agency-2009_de.pdf","et":"https://www.ema.europa.eu/et/documents/annual-report/summary-annual-report-european-medicines-agency-2009_et.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/summary-annual-report-european-medicines-agency-2009_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/summary-annual-report-european-medicines-agency-2009_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/summary-annual-report-european-medicines-agency-2009_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/annual-report/summary-annual-report-european-medicines-agency-2009_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/annual-report/summary-annual-report-european-medicines-agency-2009_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/annual-report/summary-annual-report-european-medicines-agency-2009_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/annual-report/summary-annual-report-european-medicines-agency-2009_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/summary-annual-report-european-medicines-agency-2009_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/annual-report/summary-annual-report-european-medicines-agency-2009_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/summary-annual-report-european-medicines-agency-2009_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/annual-report/summary-annual-report-european-medicines-agency-2009_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/annual-report/summary-annual-report-european-medicines-agency-2009_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/annual-report/summary-annual-report-european-medicines-agency-2009_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/summary-annual-report-european-medicines-agency-2009_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/summary-annual-report-european-medicines-agency-2009_sv.pdf"}},
    {"id":"20070","name":"Annual report of the European Medicines Agency 2010","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2011-06-29T02:00:00Z","last_updated_date":"2011-06-29T02:00:00Z","reference_number":"EMA/306870/2011","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2010_en.pdf"},
    {"id":"21304","name":"Annexes - 2015 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2016-05-17T18:00:00Z","last_updated_date":"2016-05-27T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2015-annual-report-european-medicines-agency_en.pdf"},
    {"id":"21506","name":"Annual report of the European Medicines Agency 2009","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2010-05-19T03:00:00Z","last_updated_date":"2010-05-19T03:00:00Z","reference_number":"EMA/MB/69923/2010","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2009_en.pdf"},
    {"id":"22799","name":"Annual reports for the period from 2012 to 2015 on staff engaging in an occupational activity within two years of leaving the service (article 16 of the staff regulations)","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2014-05-07T02:00:00Z","last_updated_date":"2016-08-22T13:05:00Z","reference_number":"EMA/302717/2015","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-reports-period-2012-2015-staff-engaging-occupational-activity-within-two-years-leaving-service-article-16-staff-regulations_en.pdf"},
    {"id":"24010","name":"Annual report of the European Agency for Evaluation of Medicinal Products 1995","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2006-01-15T00:09:21Z","last_updated_date":"2006-01-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1995_en.pdf"},
    {"id":"24552","name":"Annual report of the European Agency for Evaluation of Medicinal Products 1997","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"1997-12-03T00:09:21Z","last_updated_date":"1997-12-03T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1997_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1997_es.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1997_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/annual-report-european-agency-evaluation-medicinal-products-1997_fr.pdf"}},
    {"id":"25290","name":"2015 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2016-05-17T18:00:00Z","last_updated_date":"2016-07-18T14:10:00Z","reference_number":"Corr","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2015-annual-report-european-medicines-agency_en.pdf"}    {"id":"26110","name":"Annexes - 2016 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2017-05-10T12:00:00Z","last_updated_date":"2017-05-10T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2016-annual-report-european-medicines-agency_en.pdf"},
    {"id":"26567","name":"Annexes to the annual report of the European Medicines Agency 2013","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2014-04-30T16:00:01Z","last_updated_date":"2014-04-30T16:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-annual-report-european-medicines-agency-2013_en.pdf"},
    {"id":"26750","name":"Annual report of the European Medicines Agency 2012","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2013-04-16T17:59:00Z","last_updated_date":"2013-04-16T17:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2012_en.pdf"},
    {"id":"27846","name":"Annual report of the Good Clinical Practice Inspections Working Group 2011","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2012-07-17T12:20:00Z","last_updated_date":"2012-07-17T12:20:00Z","reference_number":"EMA/INS/GCP/972336/2011","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-clinical-practice-inspections-working-group-2011_en.pdf"},
    {"id":"28051","name":"Annual report 2011 (Annexes)","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-06T18:11:03Z","last_updated_date":"2012-06-06T18:11:03Z","reference_number":"EMA/363033/2012","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-2011-annexes_en.pdf"},
    {"id":"28348","name":"Summary of the annual report of the European Medicines Agency 2010","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2012-09-13T13:25:00Z","last_updated_date":"2012-09-13T13:25:00Z","reference_number":"EMA/697914/2011","document_url":"https://www.ema.europa.eu/en/documents/annual-report/summary-annual-report-european-medicines-agency-2010_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/annual-report/summary-annual-report-european-medicines-agency-2010_bg.pdf","es":"https://www.ema.europa.eu/es/documents/annual-report/summary-annual-report-european-medicines-agency-2010_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/annual-report/summary-annual-report-european-medicines-agency-2010_cs.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/summary-annual-report-european-medicines-agency-2010_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/summary-annual-report-european-medicines-agency-2010_de.pdf","et":"https://www.ema.europa.eu/et/documents/annual-report/summary-annual-report-european-medicines-agency-2010_et.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/summary-annual-report-european-medicines-agency-2010_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/summary-annual-report-european-medicines-agency-2010_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/summary-annual-report-european-medicines-agency-2010_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/annual-report/summary-annual-report-european-medicines-agency-2010_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/annual-report/summary-annual-report-european-medicines-agency-2010_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/annual-report/summary-annual-report-european-medicines-agency-2010_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/annual-report/summary-annual-report-european-medicines-agency-2010_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/summary-annual-report-european-medicines-agency-2010_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/annual-report/summary-annual-report-european-medicines-agency-2010_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/summary-annual-report-european-medicines-agency-2010_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/annual-report/summary-annual-report-european-medicines-agency-2010_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/annual-report/summary-annual-report-european-medicines-agency-2010_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/annual-report/summary-annual-report-european-medicines-agency-2010_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/summary-annual-report-european-medicines-agency-2010_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/summary-annual-report-european-medicines-agency-2010_sv.pdf"}},
    {"id":"29217","name":"Annual report 2009 (Annexes)","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2010-05-19T03:00:00Z","last_updated_date":"2010-05-19T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-2009-annexes_en.pdf"},
    {"id":"29899","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2010","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2011-09-02T02:00:00Z","last_updated_date":"2011-09-02T02:00:00Z","reference_number":"EMA/INS/PhV/788454/2009","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2010_en.pdf"},
    {"id":"30506","name":"Summary of the European Medicines Agency’s annual report for 2006","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2007-03-08T01:00:00Z","last_updated_date":"2007-03-08T01:00:00Z","reference_number":"EMEA/88802/2007/EN/FINAL","document_url":"https://www.ema.europa.eu/en/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_bg.pdf","es":"https://www.ema.europa.eu/es/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_cs.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_de.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_mt.pdf","pl":"https://www.ema.europa.eu/pl/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_pl.pdf","ro":"https://www.ema.europa.eu/ro/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_ro.pdf","sl":"https://www.ema.europa.eu/sl/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/summary-european-medicines-agencys-annual-report-2006_sv.pdf"}},
    {"id":"30611","name":"European Medicines Agency’s interaction with patients, consumers, healthcare professionals and their organisations - Annual report 2015","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2016-06-21T18:00:00Z","last_updated_date":"2016-06-21T18:00:00Z","reference_number":"EMA/727872/2015","document_url":"https://www.ema.europa.eu/en/documents/annual-report/european-medicines-agencys-interaction-patients-consumers-healthcare-professionals-and-their-organisations-annual-report-2015_en.pdf"},
    {"id":"30917","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2015","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2016-07-29T12:10:00Z","last_updated_date":"2016-07-29T12:10:00Z","reference_number":"EMA/INS/PhV/646141/2015","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2015_en.pdf"},
    {"id":"31009","name":"Annual report of the good clinical practice inspectors working group 2008","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/INS/GCP/594196/2008","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-clinical-practice-inspectors-working-group-2008_en.pdf"},
    {"id":"32816","name":"Summary of the annual report of the European Medicines Agency 2005","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2006-03-09T00:09:21Z","last_updated_date":"2006-03-09T00:09:21Z","reference_number":"EMEA/81246/2006","document_url":"https://www.ema.europa.eu/en/documents/annual-report/summary-annual-report-european-medicines-agency-2005_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/annual-report/summary-annual-report-european-medicines-agency-2005_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/annual-report/summary-annual-report-european-medicines-agency-2005_cs.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/summary-annual-report-european-medicines-agency-2005_da.pdf","de":"https://www.ema.europa.eu/de/documents/annual-report/summary-annual-report-european-medicines-agency-2005_de.pdf","et":"https://www.ema.europa.eu/et/documents/annual-report/summary-annual-report-european-medicines-agency-2005_et.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/summary-annual-report-european-medicines-agency-2005_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/summary-annual-report-european-medicines-agency-2005_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/summary-annual-report-european-medicines-agency-2005_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/annual-report/summary-annual-report-european-medicines-agency-2005_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/annual-report/summary-annual-report-european-medicines-agency-2005_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/annual-report/summary-annual-report-european-medicines-agency-2005_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/annual-report/summary-annual-report-european-medicines-agency-2005_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/summary-annual-report-european-medicines-agency-2005_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/annual-report/summary-annual-report-european-medicines-agency-2005_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/summary-annual-report-european-medicines-agency-2005_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/annual-report/summary-annual-report-european-medicines-agency-2005_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/annual-report/summary-annual-report-european-medicines-agency-2005_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/summary-annual-report-european-medicines-agency-2005_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/summary-annual-report-european-medicines-agency-2005_sv.pdf"}},
    {"id":"33999","name":"Annual report 2016 on staff engaging in an occupational activity within two years of leaving the service (article 16 of the staff regulations)","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2017-06-27T10:50:00Z","last_updated_date":"2017-06-27T10:50:00Z","reference_number":"EMA/184994/2017","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-2016-staff-engaging-occupational-activity-within-two-years-leaving-service-article-16-staff-regulations_en.pdf"},
    {"id":"34727","name":"2016 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2017-05-10T12:00:00Z","last_updated_date":"2017-05-29T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2016-annual-report-european-medicines-agency_en.pdf"},
    {"id":"37330","name":"Annual report 2010 (Annexes)","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2011-06-29T02:00:00Z","last_updated_date":"2011-06-29T02:00:00Z","reference_number":"EMA/457721/2011","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-2010-annexes_en.pdf"},
    {"id":"37860","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2013","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2014-08-06T16:40:00Z","last_updated_date":"2014-08-06T16:40:00Z","reference_number":"EMA/INS/PhV/732929/2013","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2013_en.pdf"},
    {"id":"38392","name":"2010 EudraVigilance Human annual report","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-13T13:05:00Z","last_updated_date":"2012-06-13T13:05:00Z","reference_number":"EMA/MB/399156/2011","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2010-eudravigilance-human-annual-report_en.pdf"},
    {"id":"38662","name":"Annual report of the European Medicines Agency 2004","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2005-03-10T00:09:21Z","last_updated_date":"2005-03-10T00:09:21Z","reference_number":"EMEA/61492/2005/EN/Final","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2004_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/annual-report/annual-report-european-medicines-agency-2004_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/annual-report/annual-report-european-medicines-agency-2004_cs.pdf","da":"https://www.ema.europa.eu/da/documents/annual-report/annual-report-european-medicines-agency-2004_da.pdf","et":"https://www.ema.europa.eu/et/documents/annual-report/annual-report-european-medicines-agency-2004_et.pdf","el":"https://www.ema.europa.eu/el/documents/annual-report/annual-report-european-medicines-agency-2004_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/annual-report/annual-report-european-medicines-agency-2004_fr.pdf","it":"https://www.ema.europa.eu/it/documents/annual-report/annual-report-european-medicines-agency-2004_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/annual-report/annual-report-european-medicines-agency-2004_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/annual-report/annual-report-european-medicines-agency-2004_lt.pdf","mt":"https://www.ema.europa.eu/mt/documents/annual-report/annual-report-european-medicines-agency-2004_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/annual-report/annual-report-european-medicines-agency-2004_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/annual-report/annual-report-european-medicines-agency-2004_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/annual-report/annual-report-european-medicines-agency-2004_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/annual-report/annual-report-european-medicines-agency-2004_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/annual-report/annual-report-european-medicines-agency-2004_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/annual-report/annual-report-european-medicines-agency-2004_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/annual-report/annual-report-european-medicines-agency-2004_sv.pdf"}},
    {"id":"38890","name":"Annexes to the annual report of the European Medicines Agency 2014","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2015-04-30T12:00:00Z","last_updated_date":"2015-04-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-annual-report-european-medicines-agency-2014_en.pdf"},
    {"id":"39245","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2012","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2013-07-25T12:00:00Z","last_updated_date":"2013-07-25T12:00:00Z","reference_number":"EMA/INS/PhV/697756/2012","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2012_en.pdf"},
    {"id":"40239","name":"Minor use or minor species (MUMS)/limited market scheme for veterinary medicinal products - 4th annual report (2013)","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2014-03-25T13:30:00Z","last_updated_date":"2014-03-25T13:30:00Z","reference_number":"EMA/14945/2014","document_url":"https://www.ema.europa.eu/en/documents/annual-report/minor-use-or-minor-species-mumslimited-market-scheme-veterinary-medicinal-products-4th-annual-report-2013_en.pdf"},
    {"id":"41209","name":"Annex 10 – 2017 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T16:00:00Z","last_updated_date":"2018-05-02T16:00:00Z","reference_number":"EMA/780996/2017","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2017-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-and-extensions-therapeutic-indication_en.xlsx"},
    {"id":"41719","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2016","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2017-08-08T16:20:00Z","last_updated_date":"2017-08-08T16:20:00Z","reference_number":"EMA/INS/PhV/614022/2016","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2016_en.pdf"},
    {"id":"44425","name":"Annex 10 – 2018 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2019-05-03T15:24:00Z","last_updated_date":"2019-09-19T09:39:00Z","reference_number":"EMA/848994/2019 Corr.2","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2018-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-and-extensions-therapeutic-indication_en.xlsx"},
    {"id":"44426","name":"2018 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2019-05-03T16:54:00Z","last_updated_date":"2019-05-20T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2018-annual-report-european-medicines-agency_en.pdf"},
    {"id":"44427","name":"Annexes - 2018 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2019-05-03T16:11:00Z","last_updated_date":"2019-05-03T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2018-annual-report-european-medicines-agency_en.pdf"},
    {"id":"47513","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2017","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2020-04-29T15:08:00Z","last_updated_date":"2020-04-29T15:08:00Z","reference_number":"EMA/INS/PhV/742931/2017","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2017_en.pdf"},
    {"id":"47661","name":"Annual report of the Good Clinical Practice Inspectors' Working Group 2018","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2020-05-14T10:30:00Z","last_updated_date":"2020-05-14T10:30:00Z","reference_number":"EMA/INS/GCP/819744/2018","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-clinical-practice-inspectors-working-group-2018_en.pdf"},
    {"id":"47940","name":"Annexes - 2019 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2020-06-15T13:34:00Z","last_updated_date":"2020-06-15T13:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2019-annual-report-european-medicines-agency_en.pdf"},
    {"id":"47941","name":"Annex 10 – 2019 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2020-06-15T13:34:00Z","last_updated_date":"2020-06-15T13:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2019-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-and-extensions-therapeutic-indication_en.xlsx"},
    {"id":"47942","name":"2019 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2020-06-15T13:35:00Z","last_updated_date":"2020-06-15T13:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2019-annual-report-european-medicines-agency_en.pdf"},
    {"id":"48201","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2018","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2020-07-02T15:09:00Z","last_updated_date":"2020-07-02T15:09:00Z","reference_number":"EMA/INS/PhV/569203/2019","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2018_en.pdf"},
    {"id":"51357","name":"2020 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2021-06-14T15:54:00Z","last_updated_date":"2021-06-14T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2020-annual-report-european-medicines-agency_en.pdf"},
    {"id":"51428","name":"Annexes - 2020 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2021-06-14T15:55:00Z","last_updated_date":"2021-06-14T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2020-annual-report-european-medicines-agency_en.pdf"},
    {"id":"51429","name":"Annex 10 - 2020 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2021-06-14T15:53:00Z","last_updated_date":"2021-06-14T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2020-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-and-extensions-therapeutic-indication_en.xlsx"},
    {"id":"53290","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2019-2020","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2021-11-26T10:56:00Z","last_updated_date":"2021-11-26T10:56:00Z","reference_number":"EMA/INS/PhV/130475/2021","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2019-2020_en.pdf"},
    {"id":"55176","name":"2021 annual report of the European Medicines Agency","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2022-06-10T12:00:00Z","last_updated_date":"2022-06-10T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2021-annual-report-european-medicines-agency_en.pdf"},
    {"id":"55178","name":"Annexes - 2021 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2022-06-10T12:00:00Z","last_updated_date":"2022-06-10T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2021-annual-report-european-medicines-agency_en.pdf"},
    {"id":"55180","name":"Annex 10 - 2021 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2022-06-10T12:00:00Z","last_updated_date":"2022-06-10T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2021-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-and-extensions-therapeutic-indication_en.xlsx"},
    {"id":"58681","name":"Annex 10 - 2022 annual report of the European Medicines Agency - CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2023-05-15T14:17:00Z","last_updated_date":"2023-05-15T14:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2022-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-and-extensions-therapeutic-indication_en.xlsx"},
    {"id":"58682","name":"2022 annual report of the European Medicines Agency","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2023-05-15T16:10:00Z","last_updated_date":"2023-05-15T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2022-annual-report-european-medicines-agency_en.pdf"},
    {"id":"58683","name":"Annexes - 2022 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2023-05-15T16:10:00Z","last_updated_date":"2023-05-15T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2022-annual-report-european-medicines-agency_en.pdf"},
    {"id":"58684","name":"Annex 10 - 2022 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2023-05-15T16:10:00Z","last_updated_date":"2023-05-15T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2022-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-extensions-therapeutic-indication_en.xlsx"},
    {"id":"61711","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2021-2022","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2024-01-10T17:14:15Z","last_updated_date":"2024-01-10T17:14:15Z","reference_number":"EMA/420038/2023","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-pharmacovigilance-inspectors-working-group-2021-2022_en.pdf"},
    {"id":"61739","name":"Annual report of the Good Clinical Practice Inspectors Working Group 2022","type":"annual-report","status":"Adopted","consultation_date":"","first_published_date":"2024-01-11T15:16:27Z","last_updated_date":"2024-01-11T15:16:27Z","reference_number":"EMA/INS/GCP/126568/2023","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-clinical-practice-inspectors-working-group-2022_en.pdf"},
    {"id":"62997","name":"Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2023","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2024-04-18T10:46:52Z","last_updated_date":"2024-04-18T10:46:52Z","reference_number":"EMA/INS/GMP/51175/2024","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-manufacturing-distribution-practice-inspectors-working-group-2023_en.pdf"},
    {"id":"63380","name":"Annexes - 2023 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T11:50:00Z","last_updated_date":"2024-05-30T11:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2023-annual-report-european-medicines-agency_en.pdf"},
    {"id":"63381","name":"Annex 10 - 2023 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T11:49:00Z","last_updated_date":"2024-05-30T11:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2023-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-extensions-therapeutic-indication_en.xlsx"},
    {"id":"63382","name":"2023 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T11:48:00Z","last_updated_date":"2024-07-05T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2023-annual-report-european-medicines-agency_en.pdf"},
    {"id":"67488","name":"Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2024","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2025-03-27T13:14:03Z","last_updated_date":"2025-03-27T13:14:03Z","reference_number":"EMA/INS/GMP/50638/2025","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annual-report-good-manufacturing-distribution-practice-inspectors-working-group-2024_en.pdf"},
    {"id":"68640","name":"2024 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2025-06-10T14:38:00Z","last_updated_date":"2026-06-10T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2024-annual-report-european-medicines-agency_en.pdf"},
    {"id":"68641","name":"Annexes - 2024 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2025-06-10T14:41:00Z","last_updated_date":"2025-06-10T14:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2024-annual-report-european-medicines-agency_en.pdf"},
    {"id":"68642","name":"Annex 10 - 2024 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2025-06-10T14:40:00Z","last_updated_date":"2025-06-10T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2024-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-extensions-therapeutic-indication_en.xlsx"},
    {"id":"74008","name":"2025 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2026-06-11T13:00:00Z","last_updated_date":"2026-06-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/2025-annual-report-european-medicines-agency_en.pdf"},
    {"id":"74009","name":"Annexes - 2025 annual report of the European Medicines Agency","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2026-06-11T13:00:00Z","last_updated_date":"2026-06-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annexes-2025-annual-report-european-medicines-agency_en.pdf"},
    {"id":"74010","name":"Annex 10 - 2025 annual report of the European Medicines Agency – CHMP opinions on initial evaluations and extensions of therapeutic indication","type":"annual-report","status":"unknown","consultation_date":"","first_published_date":"2026-06-11T12:00:00Z","last_updated_date":"2026-06-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/annual-report/annex-10-2025-annual-report-european-medicines-agency-chmp-opinions-initial-evaluations-extensions-therapeutic-indication_en.xlsx"},
    {"id":"2562","name":"Overview of (invented) names reviewed in July 2015 by the Name Review Group (NRG) adopted at the CHMP meeting of 19-22 October 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T14:00:00Z","last_updated_date":"2015-10-23T14:00:00Z","reference_number":"EMA/695525/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-july-2015-name-review-group-nrg-adopted-chmp-meeting-19-22-october-2015_en.pdf"},
    {"id":"2798","name":"Guidelines and concept papers adopted during the CHMP meeting 23-26 February 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-03-09T18:00:00Z","last_updated_date":"2015-03-09T18:00:00Z","reference_number":"EMA/27943/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-23-26-february-2015_en.pdf"},
    {"id":"2816","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 23-26 April 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-05-03T12:10:00Z","last_updated_date":"2018-05-03T12:10:00Z","reference_number":"EMA/116717/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-april-2018_en.pdf"},
    {"id":"2875","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 23-26 March 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T18:00:00Z","last_updated_date":"2015-04-09T18:00:00Z","reference_number":"EMA/27958/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-23-26-march-2015_en.pdf"},
    {"id":"2889","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 16-19 September 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T14:00:00Z","last_updated_date":"2013-09-20T14:00:00Z","reference_number":"EMA/CHMP/SAWP/573231/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-16-19-september-2013_en.pdf"},
    {"id":"2962","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 16-19 January 2012","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/CHMP/SAWP/50093/2012","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-16-19-january-2012_en.pdf"},
    {"id":"2989","name":"Guidelines and concept papers adopted during the CHMP meeting 25-28 January 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T10:45:00Z","last_updated_date":"2016-02-03T10:45:00Z","reference_number":"EMA/67199/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-25-28-january-2016_en.pdf"},
    {"id":"3003","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 19-22 January 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-02-02T16:30:00Z","last_updated_date":"2015-02-02T16:30:00Z","reference_number":"EMA/38511/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-19-22-january-2015_en.pdf"},
    {"id":"3307","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 19-22 February 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-02-28T15:30:00Z","last_updated_date":"2018-02-28T15:30:00Z","reference_number":"EMA/777146/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-19-22-february-2018_en.pdf"},
    {"id":"3798","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 18-21 May 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-05-26T16:00:00Z","last_updated_date":"2015-05-26T16:00:00Z","reference_number":"EMA/28012/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-18-21-may-2015_en.pdf"},
    {"id":"3880","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 22-25 June 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-07-02T12:15:00Z","last_updated_date":"2015-07-02T12:15:00Z","reference_number":"EMA/28020/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-22-25-june-2015_en.pdf"},
    {"id":"3885","name":"Overview of invented names reviewed in May 2012 by the Name Review Group - Adopted at the CHMP meeting of 18–21 June 2012","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T13:59:00Z","last_updated_date":"2012-06-22T13:59:00Z","reference_number":"EMA/92686/2012","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-may-2012-name-review-group-adopted-chmp-meeting-18-21-june-2012_en.pdf"},
    {"id":"4175","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 11 – 14 September 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/CHMP/SAWP/615470/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-11-14-september-2017_en.pdf"},
    {"id":"4182","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 25-28 June 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-07-04T14:00:00Z","last_updated_date":"2018-07-17T12:51:00Z","reference_number":"EMA/284962/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-25-28-june-2018_en.pdf"},
    {"id":"4256","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 18 – 21 May 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T14:00:00Z","last_updated_date":"2015-05-22T14:00:00Z","reference_number":"EMA/CHMP/SAWP/344744/20155","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-18-21-may-2015_en.pdf"},
    {"id":"4639","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 14-17 December 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-01-05T13:30:00Z","last_updated_date":"2016-01-05T13:30:00Z","reference_number":"EMA/38807/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-14-17-december-2015_en.pdf"},
    {"id":"4650","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 14-17 December 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T13:00:00Z","last_updated_date":"2015-12-18T13:00:00Z","reference_number":"EMA/CHMP/SAWP/857429/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-14-17-december-2015_en.pdf"},
    {"id":"4686","name":"Overview of invented names reviewed in November 2013 by the Name Review Group (NRG) adopted at the CHMP meeting of 16 – 19 December 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/774164/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2013-name-review-group-nrg-adopted-chmp-meeting-16-19-december-2013_en.pdf"},
    {"id":"4781","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 22-25 June 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-07-02T12:15:00Z","last_updated_date":"2015-07-02T12:15:00Z","reference_number":"EMA/28022/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-22-25-june-2015_en.pdf"},
    {"id":"5058","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 14-17 January 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-01-18T14:54:00Z","last_updated_date":"2013-01-18T14:54:00Z","reference_number":"EMA/CHMP/SAWP/29382/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-14-17-january-2013_en.pdf"},
    {"id":"5154","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 12-15 December 2011","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T13:00:00Z","last_updated_date":"2011-12-16T13:00:00Z","reference_number":"EMA/CHMP/SAWP/974493/2011","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-12-15-december-2011_en.pdf"},
    {"id":"5261","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 23–26 May 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-06-13T12:25:00Z","last_updated_date":"2016-06-13T12:25:00Z","reference_number":"EMA/76604/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-23-26-may-2016_en.pdf"},
    {"id":"5466","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 July 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/CHMP/SAWP/445836/2013 ","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-22-25-july-2013_en.pdf"},
    {"id":"5603","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 22-25 January 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-02-01T11:00:00Z","last_updated_date":"2018-02-01T11:00:00Z","reference_number":"EMA/777015/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-january-2018_en.pdf"},
    {"id":"5685","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 12-15 September 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-09-21T14:00:00Z","last_updated_date":"2016-09-21T14:00:00Z","reference_number":"EMA/605563/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-12-15-september-2016_en.pdf"},
    {"id":"5784","name":"Overview of invented names reviewed in September 2016 by the Name Review Group adopted at the CHMP meeting of 10-13 October 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2016-10-14T14:00:00Z","reference_number":"EMA/672772/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2016-name-review-group-adopted-chmp-meeting-10-13-october-2016_en.pdf"},
    {"id":"5858","name":"Guidelines and concept papers adopted during the CHMP meeting 23-26 March 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T18:00:00Z","last_updated_date":"2015-04-09T18:00:00Z","reference_number":"EMA/CHMP/27955/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-23-26-march-2015_en.pdf"},
    {"id":"6287","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 16-19 November 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-11-27T12:30:00Z","last_updated_date":"2015-11-27T12:30:00Z","reference_number":"EMA/38688/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-during-chmp-meeting-16-19-november-2015_en.pdf"},
    {"id":"6421","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 20-23 April 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-04-29T17:10:00Z","last_updated_date":"2015-04-29T17:10:00Z","reference_number":"EMA/28002/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-20-23-april-2015_en.pdf"},
    {"id":"6545","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 October 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-10-19T19:00:00Z","last_updated_date":"2016-10-19T19:00:00Z","reference_number":"EMA/571987/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-10-13-october-2016_en.pdf"},
    {"id":"6791","name":"Guidelines and concept papers adopted during the CHMP meeting 22-25 September 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-10-13T16:00:00Z","last_updated_date":"2014-10-13T16:00:00Z","reference_number":"EMA/CHMP/129673/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-22-25-september-2014_en.pdf"},
    {"id":"7290","name":"Overview of invented names reviewed in January 2012 by the Name Review Group (NRG) adopted at the CHMP meeting of 13-16 February 2012","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T13:00:00Z","last_updated_date":"2012-02-17T13:00:00Z","reference_number":"EMA/92686/2012","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-january-2012-name-review-group-nrg-adopted-chmp-meeting-13-16-february-2012_en.pdf"},
    {"id":"7321","name":"Start of community reviews - December 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T10:20:00Z","last_updated_date":"2016-12-16T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-december-2016_en.pdf"},
    {"id":"7332","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 20-23 February 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-03-01T15:30:00Z","last_updated_date":"2017-03-01T15:30:00Z","reference_number":"EMA/668803/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-20-23-february-2017_en.pdf"},
    {"id":"7353","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22–25 April 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T17:02:00Z","last_updated_date":"2014-04-25T17:02:00Z","reference_number":"EMA/247936/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-22-25-april-2014_en.pdf"},
    {"id":"7401","name":"Start of community reviews - CHMP meeting of 20-23 October 2014","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/388940/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-20-23-october-2014_en.pdf"},
    {"id":"7683","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 19-22 March 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-03-28T13:00:00Z","last_updated_date":"2018-03-28T13:00:00Z","reference_number":"EMA/50576/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-19-22-march-2018_en.pdf"},
    {"id":"8279","name":"Start of community reviews - CHMP meeting of 29 March - 1 April 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/227635/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-29-march-1-april-2016_en.pdf"},
    {"id":"8537","name":"Guidelines and concept papers adopted during the CHMP meeting 20-23 June 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-06-30T18:00:00Z","last_updated_date":"2016-06-30T18:00:00Z","reference_number":"EMA/76607/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-20-23-june-2016_en.pdf"},
    {"id":"8574","name":"Start of community reviews - CHMP meeting of 21-24 September 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/609858/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-21-24-september-2015_en.pdf"},
    {"id":"8586","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19–22 June 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T14:00:00Z","last_updated_date":"2017-06-23T14:00:00Z","reference_number":"EMA/CHMP/SAWP/395099/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-19-22-june-2017_en.pdf"},
    {"id":"8613","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 23–26 March 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T13:00:00Z","last_updated_date":"2015-03-27T13:00:00Z","reference_number":"EMA/CHMP/SAWP/210613/20155","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-23-26-march-2015_en.pdf"},
    {"id":"9026","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 14-17 November 2011","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T13:02:00Z","last_updated_date":"2011-11-18T13:02:00Z","reference_number":"EMA/905217/2011","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-14-17-november-2011_en.pdf"}    {"id":"9393","name":"Overview of (invented) names reviewed in November 2017 by the Name Review Group (NRG) adopted at the CHMP meeting of 11-14 December 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/820554/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2017-name-review-group-nrg-adopted-chmp-meeting-11-14-december-2017_en.pdf"},
    {"id":"9406","name":"Overview of (invented) names reviewed in February 2016 by the Name Review Group (NRG) adopted at the CHMP meeting of 22-25 February 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T13:00:00Z","last_updated_date":"2016-02-26T13:00:00Z","reference_number":"EMA/844352/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-february-2016-name-review-group-nrg-adopted-chmp-meeting-22-25-february-2016_en.pdf"},
    {"id":"9432","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 14-17 December 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-01-05T13:30:00Z","last_updated_date":"2016-01-05T13:30:00Z","reference_number":"EMA/38808/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-14-17-december-2015_en.pdf"},
    {"id":"9454","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 23-26 April 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-04-26T14:00:00Z","last_updated_date":"2018-04-26T14:00:00Z","reference_number":"EMA/CHMP/SAWP/262775/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-23-26-april-2018_en.pdf"},
    {"id":"9725","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 20 – 23 October 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/CHMP/SAWP/659072/2014 ","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-20-23-october-2014_en.pdf"},
    {"id":"10014","name":"Guidelines and concept papers adopted during the CHMP meeting 19-22 October 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-10-30T15:45:00Z","last_updated_date":"2015-10-30T15:45:00Z","reference_number":"EMA/38687/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-19-22-october-2015_en.pdf"},
    {"id":"10073","name":"Organisational matters - CHMP meeting 15-18 December 2014","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-01-08T16:15:00Z","last_updated_date":"2015-01-08T16:15:00Z","reference_number":"EMA/129903/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-15-18-december-2014_en.pdf"},
    {"id":"10380","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 9 – 12 October 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-10-13T14:00:00Z","last_updated_date":"2017-10-13T14:00:00Z","reference_number":"EMA/CHMP/SAWP/674284/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-9-12-october-2017_en.pdf"},
    {"id":"10439","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 25- 28 June 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-07-03T17:45:00Z","last_updated_date":"2018-07-03T17:45:00Z","reference_number":"EMA/CHMP/SAWP/447681/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-25-28-june-2018_en.pdf"},
    {"id":"10663","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 19-22 October 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-10-30T15:45:00Z","last_updated_date":"2015-10-30T15:45:00Z","reference_number":"EMA/38689/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-19-22-october-2015_en.pdf"},
    {"id":"10665","name":"Opinions on safety variations / periodic safety update reports adopted at the CHMP meeting of 17-20 November 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-11-27T10:35:00Z","last_updated_date":"2014-11-27T10:35:00Z","reference_number":"EMA/129815/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-17-20-november-2014_en.pdf"},
    {"id":"11067","name":"Overview of invented names reviewed in April 2013 by the Name Review Group (NRG) adopted at the CHMP meeting of 22–25 April 2013","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/255009/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-april-2013-name-review-group-nrg-adopted-chmp-meeting-22-25-april-2013_en.pdf"},
    {"id":"11964","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 23-26 January 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-02-01T17:00:00Z","last_updated_date":"2017-02-01T17:00:00Z","reference_number":"EMA/668882/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-january-2017_en.pdf"},
    {"id":"11969","name":"Overview of invented names reviewed in January 2014 by the Name Review Group (NRG) adopted at the CHMP meeting of 20 February 2014 ","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T13:00:00Z","last_updated_date":"2014-02-21T13:00:00Z","reference_number":"EMA/102172/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-january-2014-name-review-group-nrg-adopted-chmp-meeting-20-february-2014_en.pdf"},
    {"id":"12050","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 21 – 24 October 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T15:00:00Z","last_updated_date":"2013-10-25T15:00:00Z","reference_number":"EMA/CHMP/SAWP/657916/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-21-24-october-2013_en.pdf"},
    {"id":"12248","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 21 – 24 September 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/SAWP/635474/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-21-24-september-2015_en.pdf"},
    {"id":"12278","name":"Overview of (invented) names reviewed in November 2016 by the Name Review Group (NRG)","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T10:28:00Z","last_updated_date":"2016-12-16T10:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2016-name-review-group-nrg_en.pdf"},
    {"id":"13061","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 20-23 July 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-07-29T12:00:00Z","last_updated_date":"2015-08-06T12:25:00Z","reference_number":"EMA/38582/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-during-chmp-meeting-20-23-july-2015_en.pdf"},
    {"id":"13141","name":"Overview of (invented) names reviewed in May 2015 by the Name Review Group\n\n(NRG) adopted at the CHMP meeting of 22-25 June 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/428084/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-may-2015-name-review-group-nrg-adopted-chmp-meeting-22-25-june-2015_en.pdf"},
    {"id":"13502","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 20– 23 July 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-07-23T14:00:00Z","last_updated_date":"2015-07-23T14:00:00Z","reference_number":"EMA/CHMP/SAWP/502864/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-20-23-july-2015_en.pdf"},
    {"id":"13880","name":"Start of community reviews - CHMP meeting of 25-28 April 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T14:00:00Z","last_updated_date":"2016-04-29T14:00:00Z","reference_number":"EMA/301361/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-25-28-april-2016_en.pdf"},
    {"id":"14383","name":"Overview of (invented) names reviewed in March 2017 by the Name Review Group (NRG)","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T20:00:00Z","last_updated_date":"2017-04-21T20:00:00Z","reference_number":"EMA/247177/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-march-2017-name-review-group-nrg_en.pdf"},
    {"id":"14588","name":"Overview of invented names reviewed in July 2014 by the Name Review Group (NRG) adopted at the CHMP meeting of 21-24 July 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T14:00:00Z","last_updated_date":"2014-07-25T14:00:00Z","reference_number":"EMA/440911/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-july-2014-name-review-group-nrg-adopted-chmp-meeting-21-24-july-2014_en.pdf"},
    {"id":"14719","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 29 March - 1 April 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T14:00:00Z","last_updated_date":"2016-04-01T14:00:00Z","reference_number":"EMA/CHMP/SAWP/236499/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-29-march-1-april-2016_en.pdf"},
    {"id":"14775","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 23–26 May 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-06-13T12:25:00Z","last_updated_date":"2016-06-13T12:25:00Z","reference_number":"EMA/76603/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-23-26-may-2016_en.pdf"},
    {"id":"14789","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 22-25 September 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-10-13T16:00:00Z","last_updated_date":"2014-10-13T16:00:00Z","reference_number":"EMA/CHMP/129674/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-during-chmp-meeting-22-25-september-2014_en.pdf"},
    {"id":"14806","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 11-14 September 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-09-20T19:00:00Z","last_updated_date":"2017-09-20T19:00:00Z","reference_number":"EMA/668862/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-11-14-september-2017_en.pdf"},
    {"id":"15020","name":"Guidelines and concept papers adopted during the CHMP meeting 18-21 May 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-05-26T16:00:00Z","last_updated_date":"2015-05-26T16:00:00Z","reference_number":"EMA/28009/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-18-21-may-2015_en.pdf"},
    {"id":"15043","name":"Start of community reviews - CHMP meeting of 25-28 January 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T13:00:00Z","last_updated_date":"2016-01-29T13:00:00Z","reference_number":"EMA/50029/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-25-28-january-2016_en.pdf"},
    {"id":"15148","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 17 – 20 March 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/CHMP/SAWP/166871/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-17-20-march-2014_en.pdf"},
    {"id":"15187","name":"Organisational matters - CHMP meeting 22-25 February 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-03-04T15:00:00Z","last_updated_date":"2016-03-04T15:00:00Z","reference_number":"EMA/67076/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-22-25-february-2016_en.pdf"},
    {"id":"15302","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 20-23 March 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-03-29T18:30:00Z","last_updated_date":"2017-03-29T18:30:00Z","reference_number":"EMA/668812/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-20-23-march-2017_en.pdf"},
    {"id":"15372","name":"Overview of (invented) names reviewed in November 2015 by the Name Review\n\nGroup (NRG) adopted at the CHMP meeting of 14-17 December 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/844352/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2015-name-review-group-nrg-adopted-chmp-meeting-14-17-december-2015_en.pdf"},
    {"id":"15377","name":"Overview of invented names reviewed in March 2012 by the Name Review Group (NRG) adopted at the CHMP meeting of 16–19 April 2012","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2012-04-20T14:01:00Z","last_updated_date":"2012-04-20T14:01:00Z","reference_number":"EMA/92686/2012","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-march-2012-name-review-group-nrg-adopted-chmp-meeting-16-19-april-2012_en.pdf"},
    {"id":"15642","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 20-23 April 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-04-29T17:10:00Z","last_updated_date":"2015-04-29T17:10:00Z","reference_number":"EMA/28004/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-20-23-april-2015_en.pdf"},
    {"id":"15707","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 24 – 27 June 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/SAWP/389179/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-24-27-june-2013_en.pdf"},
    {"id":"15958","name":"Opinions on safety variations / periodic safety update reports adopted during the CHMP meeting 22-25 September 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-10-13T16:00:00Z","last_updated_date":"2014-10-13T16:00:00Z","reference_number":"EMA/129677/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variations-periodic-safety-update-reports-adopted-during-chmp-meeting-22-25-september-2014_en.pdf"},
    {"id":"16152","name":"Organisational matters - CHMP meeting 18-21 May 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-05-26T16:00:00Z","last_updated_date":"2015-05-26T16:00:00Z","reference_number":"EMA/28011/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-18-21-may-2015_en.pdf"},
    {"id":"16175","name":"Start of community reviews - CHMP meeting of 23-26 April 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T14:00:00Z","last_updated_date":"2018-04-27T14:00:00Z","reference_number":"EMA/219594/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-23-26-april-2018_en.pdf"},
    {"id":"16273","name":"Overview of invented names reviewed in September 2016 by the Name Review Group adopted at the CHMP meeting of 19-22 June 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T14:00:00Z","last_updated_date":"2017-06-23T14:00:00Z","reference_number":"EMA/393062/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2016-name-review-group-adopted-chmp-meeting-19-22-june-2017_en.pdf"},
    {"id":"16684","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22 – 25 June 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T14:00:00Z","last_updated_date":"2015-06-26T14:00:00Z","reference_number":"EMA/CHMP/SAWP/428252/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-22-25-june-2015_en.pdf"},
    {"id":"16756","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 7 – 11 November 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2016-11-11T13:00:00Z","reference_number":"EMA/CHMP/SAWP/743808/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-7-11-november-2016_en.pdf"},
    {"id":"17050","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 20-23 April 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/CHMP/SAWP/210613/20155","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-20-23-april-2015_en.pdf"},
    {"id":"17084","name":"Organisational matters - CHMP meeting 14-17 December 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-01-05T13:30:00Z","last_updated_date":"2016-01-05T13:30:00Z","reference_number":"EMA/38810/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-14-17-december-2015_en.pdf"},
    {"id":"17383","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 15-18 December 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-01-08T16:15:00Z","last_updated_date":"2015-01-08T16:15:00Z","reference_number":"EMA/129898/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-15-18-december-2014_en.pdf"},
    {"id":"17436","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 23-26 February 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-03-09T18:00:00Z","last_updated_date":"2015-03-09T18:00:00Z","reference_number":"EMA/27945/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-23-26-february-2015_en.pdf"},
    {"id":"17439","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 20 – 23 February 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T13:00:00Z","last_updated_date":"2017-02-24T13:00:00Z","reference_number":"EMA/121408/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-20-23-february-2017_en.pdf"},
    {"id":"17605","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 23-26 July 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-08-01T14:00:00Z","last_updated_date":"2018-08-01T14:00:00Z","reference_number":"EMA/387634/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-july-2018_en.pdf"},
    {"id":"17728","name":"Start of community reviews - CHMP meeting of 22-25 June 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/418074/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-22-25-june-2015_en.pdf"},
    {"id":"17784","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 12 –15 September 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/CHMP/SAWP/604222/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-12-15-september-2016_en.pdf"},
    {"id":"17800","name":"Overview of (invented) names reviewed in February 2017 by the Name Review Group (NRG) adopted at the CHMP meeting of 20-23 February 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T13:00:00Z","last_updated_date":"2017-02-24T13:00:00Z","reference_number":"EMA/121408/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-february-2017-name-review-group-nrg-adopted-chmp-meeting-20-23-february-2017_en.pdf"},
    {"id":"17955","name":"Overview of invented names reviewed in June 2013 by the Name Review Group (NRG) adopted at the CHMP meeting of 24 – 27 June 2013","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/383378/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-june-2013-name-review-group-nrg-adopted-chmp-meeting-24-27-june-2013_en.pdf"},
    {"id":"17978","name":"Opinions on safety variations/Periodic Safety Update Reports (PSURs) adopted at the CHMP meeting of 25-28 April 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-05-11T17:10:00Z","last_updated_date":"2016-05-11T17:10:00Z","reference_number":"EMA/76599/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-psurs-adopted-chmp-meeting-25-28-april-2016_en.pdf"},
    {"id":"18122","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 25-28 January 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T10:45:00Z","last_updated_date":"2016-02-03T10:45:00Z","reference_number":"EMA/67219/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-25-28-january-2016_en.pdf"},
    {"id":"18191","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 17-20 July 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-07-27T12:09:00Z","last_updated_date":"2017-07-27T12:09:00Z","reference_number":"EMA/668852/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-17-20-july-2017_en.pdf"},
    {"id":"18283","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 12 – 15 December 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T10:20:00Z","last_updated_date":"2016-12-16T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-12-15-december-2016_en.pdf"},
    {"id":"18754","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 28 – 31 May 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/CHMP/SAWP/366547/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-28-31-may-2018_en.pdf"},
    {"id":"19161","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 17-20 November 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-11-27T10:35:00Z","last_updated_date":"2014-11-27T10:35:00Z","reference_number":"EMA/129814/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-17-20-november-2014_en.pdf"},
    {"id":"19779","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 February 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/CHMP/SAWP/158000/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-22-25-february-2016_en.pdf"},
    {"id":"19965","name":"Organisational matters - CHMP meeting 25-28 April 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-05-11T17:10:00Z","last_updated_date":"2016-05-11T17:10:00Z","reference_number":"EMA/67136/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-25-28-april-2016_en.pdf"},
    {"id":"20004","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19 – 22 May 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/CHMP/SAWP/312025/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-19-22-may-2014_en.pdf"},
    {"id":"20032","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 25-28 January 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-01-29T13:00:00Z","last_updated_date":"2016-01-29T13:00:00Z","reference_number":"EMA/CHMP/SAWP/57185/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-25-28-january-2016_en.pdf"},
    {"id":"20062","name":"Opinions on safety variations / periodic safety update reports adopted during the CHMP meeting 16-19 November 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-11-27T12:30:00Z","last_updated_date":"2015-11-27T12:30:00Z","reference_number":"EMA/38747/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variations-periodic-safety-update-reports-adopted-during-chmp-meeting-16-19-november-2015_en.pdf"},
    {"id":"20087","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 18 – 21 November 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T13:01:00Z","last_updated_date":"2013-11-22T13:01:00Z","reference_number":"EMA/CHMP/SAWP/718027/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-18-21-november-2013_en.pdf"},
    {"id":"20099","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 21–24 July 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T14:00:00Z","last_updated_date":"2014-07-25T14:00:00Z","reference_number":"EMA/CHMP/SAWP/430613/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-21-24-july-2014_en.pdf"},
    {"id":"20204","name":"Organisational matters: CHMP meeting 20-23 June 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-06-30T18:00:00Z","last_updated_date":"2016-06-30T18:00:00Z","reference_number":"EMA/67161/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-20-23-june-2016_en.pdf"},
    {"id":"20262","name":"Scientific advice and protocol assistance adopted during the CHMP meeting of 27-30 May 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/CHMP/SAWP/332193/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-27-30-may-2013_en.pdf"},
    {"id":"20509","name":"Overview of invented names reviewed in November 2012 by the Name Review Group (NRG) adopted at the CHMP meeting of 10 - 13 December 2012","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T13:00:00Z","last_updated_date":"2012-12-14T13:00:00Z","reference_number":"EMA/678442/2012","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2012-name-review-group-nrg-adopted-chmp-meeting-10-13-december-2012_en.pdf"},
    {"id":"20518","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 6 – 9 November 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/CHMP/SAWP/743845/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-6-9-november-2017_en.pdf"},
    {"id":"20571","name":"Opinions on safety variations/periodic safety update reports adopted during the CHMP meeting 20-23 July 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-07-29T12:00:00Z","last_updated_date":"2015-07-29T12:00:00Z","reference_number":"EMA/38584/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-during-chmp-meeting-20-23-july-2015_en.pdf"},
    {"id":"20844","name":"Overview of invented names reviewed in October 2012 by the Name Review Group (NRG) - Adopted at the CHMP meeting of 15–18 October 2012","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T14:29:00Z","last_updated_date":"2012-10-19T14:29:00Z","reference_number":"EMA/678442/2012","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-october-2012-name-review-group-nrg-adopted-chmp-meeting-15-18-october-2012_en.pdf"},
    {"id":"21463","name":"Organisational matters - CHMP meeting 22-25 June 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-07-02T12:15:00Z","last_updated_date":"2015-07-02T12:15:00Z","reference_number":"EMA/28021/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-22-25-june-2015_en.pdf"},
    {"id":"21516","name":"Organisational matters - CHMP meeting 20-23 October 2014","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2014-10-29T12:20:00Z","last_updated_date":"2014-10-29T12:20:00Z","reference_number":"EMA/129702/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-20-23-october-2014_en.pdf"},
    {"id":"21662","name":"Start of community reviews - CHMP meeting of 20-23 February 2017","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T13:00:00Z","last_updated_date":"2017-02-24T13:00:00Z","reference_number":"EMA/125576/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-20-23-february-2017_en.pdf"},
    {"id":"21780","name":"Start of community reviews - CHMP meeting of 20-23 July 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T14:00:00Z","last_updated_date":"2015-07-24T14:00:00Z","reference_number":"EMA/495872/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-20-23-july-2015_en.pdf"},
    {"id":"21899","name":"Guidelines and concept papers adopted during the CHMP meeting 12-15 September 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-09-23T18:35:00Z","last_updated_date":"2016-09-23T18:35:00Z","reference_number":"EMA/76622/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-12-15-september-2016_en.pdf"},
    {"id":"22298","name":"Overview of (invented) names reviewed in September 2017 by the Name Review Group (NRG)","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T14:00:00Z","last_updated_date":"2017-10-13T14:00:00Z","reference_number":"EMA/663528/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2017-name-review-group-nrg_en.pdf"},
    {"id":"22395","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 15-18 May 2017","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2017-05-24T17:32:00Z","last_updated_date":"2017-05-24T17:32:00Z","reference_number":"EMA/668833/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-15-18-may-2017_en.pdf"},
    {"id":"22520","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 9-12 October 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-10-19T12:15:00Z","last_updated_date":"2017-10-19T12:15:00Z","reference_number":"EMA/668873/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-9-12-october-2017_en.pdf"},
    {"id":"22522","name":"Guidelines and concept papers adopted during the CHMP meeting 15-18 December 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-01-08T16:15:00Z","last_updated_date":"2015-01-08T16:15:00Z","reference_number":"EMA/129896/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-15-18-december-2014_en.pdf"},
    {"id":"22582","name":"Overview of invented names reviewed in September 2011 by the Name Review Group (NRG) adopted at the CHMP meeting of 17-20 October 2011","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2011-10-21T14:01:00Z","last_updated_date":"2011-10-21T14:01:00Z","reference_number":"EMA/802336/2011","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2011-name-review-group-nrg-adopted-chmp-meeting-17-20-october-2011_en.pdf"},
    {"id":"23068","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 21-24 September 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-09-30T17:10:00Z","last_updated_date":"2015-09-30T17:10:00Z","reference_number":"EMA/38595/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-during-chmp-meeting-21-24-september-2015_en.pdf"},
    {"id":"23132","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22–25 April 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T13:59:00Z","last_updated_date":"2013-04-26T13:59:00Z","reference_number":"EMA/CHMP/SAWP/239007/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-22-25-april-2013_en.pdf"},
    {"id":"23703","name":"Start of community reviews - CHMP meeting of 23-26 July 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/484306/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-23-26-july-2018_en.pdf"},
    {"id":"23742","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 23-26 March 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T18:00:00Z","last_updated_date":"2015-04-09T18:00:00Z","reference_number":"EMA/27956/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-23-26-march-2015_en.pdf"},
    {"id":"23966","name":"Overview of invented names reviewed in Noveber 2014 by the Name Review Group (NRG) adopted at the CHMP meeting of 15-18 December 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T13:00:00Z","last_updated_date":"2014-12-19T13:00:00Z","reference_number":"EMA/790636/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-noveber-2014-name-review-group-nrg-adopted-chmp-meeting-15-18-december-2014_en.pdf"},
    {"id":"24354","name":"Start of community reviews  - CHMP meeting of 16-19 November 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-11-20T13:00:00Z","last_updated_date":"2015-11-20T13:00:00Z","reference_number":"EMA/756442/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-16-19-november-2015_en.pdf"},
    {"id":"24410","name":"Overview of invented names reviewed in October 2014 by the Name Review Group (NRG) adopted at the CHMP meeting of 20 - 23 October 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/648915/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-october-2014-name-review-group-nrg-adopted-chmp-meeting-20-23-october-2014_en.pdf"},
    {"id":"24567","name":"Guidelines and concept papers adopted during the CHMP meeting 16-19 November 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-11-27T12:30:00Z","last_updated_date":"2015-11-27T12:30:00Z","reference_number":"EMA/38745/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-16-19-november-2015_en.pdf"},
    {"id":"24570","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 21-24 May 2012","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T13:59:00Z","last_updated_date":"2012-05-25T13:59:00Z","reference_number":"EMA/CHMP/SAWP/335823/2012","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-21-24-may-2012_en.pdf"},
    {"id":"24607","name":"Organisational matters - CHMP meeting 16-19 November 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-11-27T12:30:00Z","last_updated_date":"2015-11-27T12:30:00Z","reference_number":"EMA/38748/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-16-19-november-2015_en.pdf"},
    {"id":"24897","name":"Organisational matters - CHMP meeting of 29 March - 1 April 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T12:20:00Z","last_updated_date":"2016-04-08T12:20:00Z","reference_number":"EMA/67121/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-29-march-1-april-2016_en.pdf"},
    {"id":"24921","name":"Overview of (invented) names reviewed in April 2016 by the Name Review Group (NRG) adopted at the CHMP meeting of 25-28 April 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T14:00:00Z","last_updated_date":"2016-04-29T14:00:00Z","reference_number":"EMA/297095/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-april-2016-name-review-group-nrg-adopted-chmp-meeting-25-28-april-2016_en.pdf"},
    {"id":"25047","name":"Organisational matters: CHMP meeting 18-21 July 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T16:00:00Z","last_updated_date":"2016-07-27T16:00:00Z","reference_number":"EMA/76544/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-18-21-july-2016_en.pdf"},
    {"id":"25125","name":"Organisational matters - CHMP meeting of 12-15 September 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-09-23T18:35:00Z","last_updated_date":"2016-09-23T18:35:00Z","reference_number":"EMA/76550/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-12-15-september-2016_en.pdf"},
    {"id":"25224","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 10–13 December 2012","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2012-12-14T13:00:00Z","last_updated_date":"2012-12-14T13:00:00Z","reference_number":"EMA/CHMP/SAWP/800282/2012","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-10-13-december-2012_en.pdf"},
    {"id":"25775","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 23 – 26 June 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/SAWP/382409/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-23-26-june-2014_en.pdf"},
    {"id":"25864","name":"Organisational matters - CHMP meeting 19-22 January 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-02-02T16:30:00Z","last_updated_date":"2015-02-02T16:30:00Z","reference_number":"EMA/27893/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-19-22-january-2015_en.pdf"},
    {"id":"26026","name":"Start of community reviews: CHMP meeting of 20-23 June 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T14:00:00Z","last_updated_date":"2016-06-24T14:00:00Z","reference_number":"EMA/427430/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-20-23-june-2016_en.pdf"},
    {"id":"26169","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 25-28 January 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T10:45:00Z","last_updated_date":"2016-02-03T10:45:00Z","reference_number":"EMA/61594/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-25-28-january-2016_en.pdf"}    {"id":"26270","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 11 – 14 December 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/CHMP/SAWP/833040/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-11-14-december-2017_en.pdf"},
    {"id":"26615","name":"Opinions on safety variations/Periodic Safety Update Reports (PSURs) adopted at the CHMP meeting of 29 March - 1 April 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-04-08T12:20:00Z","last_updated_date":"2016-04-08T12:20:00Z","reference_number":"EMA/76590/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-psurs-adopted-chmp-meeting-29-march-1-april-2016_en.pdf"},
    {"id":"26648","name":"Start of community reviews - CHMP meeting of 23-26 January 2017","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T13:00:00Z","last_updated_date":"2017-01-27T13:00:00Z","reference_number":"EMA/46681/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-23-26-january-2017_en.pdf"},
    {"id":"26763","name":"Guidelines and concept papers adopted during the CHMP meeting 25-28 April 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-05-20T19:14:00Z","last_updated_date":"2016-05-20T19:14:00Z","reference_number":"EMA/76597/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-25-28-april-2016_en.pdf"},
    {"id":"26820","name":"Overview of (invented) names reviewed in February 2018 by the Name Review Group (NRG)","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T13:00:00Z","last_updated_date":"2018-03-23T13:00:00Z","reference_number":"EMA/156933/20188","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-february-2018-name-review-group-nrg_en.pdf"},
    {"id":"26870","name":"Guidelines and concept papers adopted during the CHMP meeting 20-23 April 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-04-29T17:10:00Z","last_updated_date":"2015-04-29T17:10:00Z","reference_number":"EMA/28001/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-20-23-april-2015_en.pdf"},
    {"id":"26962","name":"Organisational matters - CHMP meeting 25-28 January 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T10:45:00Z","last_updated_date":"2016-02-03T10:45:00Z","reference_number":"EMA/67044/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-25-28-january-2016_en.pdf"},
    {"id":"27092","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 18 – 21 April 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T20:00:00Z","last_updated_date":"2017-04-21T20:00:00Z","reference_number":"EMA/CHMP/SAWP/253962/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-18-21-april-2017_en.pdf"},
    {"id":"27272","name":"Opinions on safety variations / periodic safety update reports adopted at the CHMP meeting of 20-23 October 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-10-29T12:20:00Z","last_updated_date":"2014-10-29T12:20:00Z","reference_number":"EMA/129701/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-20-23-october-2014_en.pdf"},
    {"id":"27324","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 18-21 May 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-05-26T16:00:00Z","last_updated_date":"2015-05-26T16:00:00Z","reference_number":"EMA/28010/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-18-21-may-2015_en.pdf"},
    {"id":"27502","name":"Organisational matters - CHMP meeting 20-23 July 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-07-29T12:00:00Z","last_updated_date":"2015-07-29T12:00:00Z","reference_number":"EMA/38583/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-20-23-july-2015_en.pdf"},
    {"id":"27633","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 23-26 May 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-06-01T16:00:00Z","last_updated_date":"2016-06-01T16:00:00Z","reference_number":"EMA/345382/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-may-2016_en.pdf"},
    {"id":"27661","name":"Overview of (invented) names reviewed in March 2015 by the Name Review Group (NRG) adopted at the CHMP meeting of 20-23 April 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/264729/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-march-2015-name-review-group-nrg-adopted-chmp-meeting-20-23-april-2015_en.pdf"},
    {"id":"27802","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 18-21 April 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-04-26T18:30:00Z","last_updated_date":"2017-04-26T18:30:00Z","reference_number":"EMA/668824/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-18-21-april-2017_en.pdf"},
    {"id":"27909","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 15-18 December 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/CHMP/SAWP/794686/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-15-18-december-2014_en.pdf"},
    {"id":"28109","name":"Organisational matters - CHMP meeting 20-23 April 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T17:10:00Z","last_updated_date":"2015-04-29T17:10:00Z","reference_number":"EMA/28003/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-20-23-april-2015_en.pdf"},
    {"id":"28294","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19 – 22 March 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-03-26T18:07:00Z","last_updated_date":"2018-03-26T18:07:00Z","reference_number":"EMA/CHMP/SAWP/195437/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-19-22-march-2018_en.pdf"},
    {"id":"28382","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 13-16 February 2012","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T13:00:00Z","last_updated_date":"2012-02-17T13:00:00Z","reference_number":"EMA/CHMP/SAWP/114282/2012","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-13-16-february-2012_en.pdf"},
    {"id":"28603","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 20-23 June 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-06-30T18:00:00Z","last_updated_date":"2016-06-30T18:00:00Z","reference_number":"EMA/76608/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-20-23-june-2016_en.pdf"},
    {"id":"28779","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 6-9 November 2017","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T11:10:00Z","last_updated_date":"2017-11-16T11:10:00Z","reference_number":"EMA/668793/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-6-9-november-2017_en.pdf"},
    {"id":"28836","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of  22-25 February 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-03-04T15:00:00Z","last_updated_date":"2016-03-04T15:00:00Z","reference_number":"EMA/76583/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-22-25-february-2016_en.pdf"},
    {"id":"28896","name":"Organisational matters: CHMP meeting 23-26 May 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-06-13T12:25:00Z","last_updated_date":"2016-06-13T12:25:00Z","reference_number":"EMA/67145/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-23-26-may-2016_en.pdf"},
    {"id":"29156","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19-22 September 2011","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/SAWP/768314/2011 ","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-19-22-september-2011_en.pdf"},
    {"id":"29191","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 15-18 December 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-01-08T16:15:00Z","last_updated_date":"2015-01-08T16:15:00Z","reference_number":"EMA/129897/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-15-18-december-2014_en.pdf"},
    {"id":"29517","name":"Start of community reviews - CHMP meeting of 18-31 May 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/353695/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-18-31-may-2018_en.pdf"},
    {"id":"29538","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 20-23 October 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-10-29T12:20:00Z","last_updated_date":"2014-10-29T12:20:00Z","reference_number":"EMA/129699/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-20-23-october-2014_en.pdf"},
    {"id":"29549","name":"Organisational matters - CHMP meeting 22-25 September 2014","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2014-10-13T16:00:00Z","last_updated_date":"2014-10-13T16:00:00Z","reference_number":"EMA/CHMP/129678/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-22-25-september-2014_en.pdf"},
    {"id":"29693","name":"Scientific advice and protocol assistance adopted during the CHMP meeting of 18-21 March 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T01:00:00Z","last_updated_date":"2013-03-22T01:00:00Z","reference_number":"EMA/174552/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-18-21-march-2013_en.pdf"},
    {"id":"29775","name":"Scientific advice and protocol assistance adopted during the Committee for Medicinal Products for Human Use meeting 17-20 October 2011","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T14:01:00Z","last_updated_date":"2011-10-21T14:01:00Z","reference_number":"EMA/CHMP/SAWP/840907/2011","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-committee-medicinal-products-human-use-meeting-17-20-october-2011_en.pdf"},
    {"id":"29809","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 16–19 November 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/SAWP/776856/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-16-19-november-2015_en.pdf"},
    {"id":"29821","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 7-10 November 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-11-16T17:30:00Z","last_updated_date":"2016-11-16T17:30:00Z","reference_number":"EMA/615021/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-7-10-november-2016_en.pdf"},
    {"id":"29999","name":"Overview of (invented) names reviewed in May 2018 by the Name Review Group (NRG)","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/414496/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-may-2018-name-review-group-nrg_en.pdf"},
    {"id":"30125","name":"Start of community reviews - CHMP meeting of 07-10 November 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2016-11-11T13:00:00Z","reference_number":"EMA/702479/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-07-10-november-2016_en.pdf"},
    {"id":"30211","name":"Overview of invented names reviewed in October 2013 by the Name Review Group (NRG) adopted at the CHMP meeting of 21 – 24 October 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T15:00:00Z","last_updated_date":"2013-10-25T15:00:00Z","reference_number":"EMA/645195/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-october-2013-name-review-group-nrg-adopted-chmp-meeting-21-24-october-2013_en.pdf"},
    {"id":"30463","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 25 – 28 April 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/SAWP/304744/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-25-28-april-2016_en.pdf"},
    {"id":"31159","name":"Start of community reviews - CHMP meeting of 19-22 October 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T14:00:00Z","last_updated_date":"2015-10-23T14:00:00Z","reference_number":"EMA/677252/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-19-22-october-2015_en.pdf"},
    {"id":"31296","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 23–26 February 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T14:00:00Z","last_updated_date":"2015-02-27T14:00:00Z","reference_number":"EMA/CHMP/SAWP/139113/20155 ","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-23-26-february-2015_en.pdf"},
    {"id":"31408","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures\n\nAdopted at the CHMP meeting of 12-15 September 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-09-23T18:35:00Z","last_updated_date":"2016-09-23T18:35:00Z","reference_number":"EMA/76623/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-12-15-september-2016_en.pdf"},
    {"id":"31467","name":"Overview of invented names reviewed in May 2014 by the Name Review Group (NRG) adopted at the CHMP meeting of 23 - 26 June 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/345397/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-may-2014-name-review-group-nrg-adopted-chmp-meeting-23-26-june-2014_en.pdf"},
    {"id":"31472","name":"Overview of invented names reviewed in November 2011 by the Name Review Group (NRG) adopted at the CHMP meeting of 12-15 December 2011","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2011-12-16T13:00:00Z","last_updated_date":"2011-12-16T13:00:00Z","reference_number":"EMA/802336/2011","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2011-name-review-group-nrg-adopted-chmp-meeting-12-15-december-2011_en.pdf"},
    {"id":"31802","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 19-22 January 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-02-02T16:30:00Z","last_updated_date":"2015-02-02T16:30:00Z","reference_number":"EMA/27848/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-19-22-january-2015_en.pdf"},
    {"id":"31934","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19-22 January 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T13:00:00Z","last_updated_date":"2015-01-23T13:00:00Z","reference_number":"EMA/CHMP/SAWP/54035/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-19-22-january-2015_en.pdf"},
    {"id":"32306","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 18-21 July 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/CHMP/SAWP/508519/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-18-21-july-2016_en.pdf"},
    {"id":"32805","name":"Organisational matters - CHMP meeting 21-24 September 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-09-30T17:10:00Z","last_updated_date":"2015-09-30T17:10:00Z","reference_number":"EMA/38597/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-21-24-september-2015_en.pdf"},
    {"id":"32922","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 20-23 June 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-06-29T16:00:00Z","last_updated_date":"2016-06-29T16:00:00Z","reference_number":"EMA/424592/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-20-23-june-2016_en.pdf"},
    {"id":"33021","name":"Start of community reviews - CHMP meeting of 22-25 February 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/147069/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-22-25-february-2016_en.pdf"},
    {"id":"33464","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 17-20 November 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T13:30:00Z","last_updated_date":"2014-11-21T13:30:00Z","reference_number":"EMA/CHMP/SAWP/722708/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-17-20-november-2014_en.pdf"},
    {"id":"33469","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 18-21 July 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T15:30:00Z","last_updated_date":"2016-07-27T15:30:00Z","reference_number":"EMA/424593/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-18-21-july-2016_en.pdf"},
    {"id":"33965","name":"Overview of invented names reviewed in January 2013 by the Name Review Group (NRG) - CHMP meeting 18-21 February 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/109616/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-january-2013-name-review-group-nrg-chmp-meeting-18-21-february-2013_en.pdf"},
    {"id":"34202","name":"Start of community reviews - CHMP meeting of 23-26 March 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T13:00:00Z","last_updated_date":"2015-03-27T13:00:00Z","reference_number":"EMA/185300/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-23-26-march-2015_en.pdf"},
    {"id":"34281","name":"Start of community reviews - CHMP meeting of 14-17 December 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/817359/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-14-17-december-2015_en.pdf"},
    {"id":"34317","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 25-28 April 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-05-11T17:10:00Z","last_updated_date":"2016-05-11T17:10:00Z","reference_number":"EMA/76598/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-25-28-april-2016_en.pdf"},
    {"id":"34455","name":"Overview of (invented) names reviewed in July 2015 by the Name Review Group (NRG) adopted at the CHMP meeting of 20-23 July 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/494389/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-july-2015-name-review-group-nrg-adopted-chmp-meeting-20-23-july-2015_en.pdf"},
    {"id":"34587","name":"Overview of (invented) names reviewed in November 2016 by the Name Review Group (NRG) adopted at the CHMP meeting of 12-15 December 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"EMA/830002/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2016-name-review-group-nrg-adopted-chmp-meeting-12-15-december-2016_en.pdf"},
    {"id":"34781","name":"Organisational matters - CHMP meeting 23-26 February 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-03-09T18:00:00Z","last_updated_date":"2015-03-09T18:00:00Z","reference_number":"EMA/27948/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-23-26-february-2015_en.pdf"},
    {"id":"34921","name":"Guidelines and concept papers adopted during the CHMP meeting 18-21 July 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T16:00:00Z","last_updated_date":"2016-07-27T16:00:00Z","reference_number":"EMA/76611/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-18-21-july-2016_en.pdf"},
    {"id":"35497","name":"Organisational matters - CHMP meeting 23-26 March 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-04-09T18:00:00Z","last_updated_date":"2015-04-09T18:00:00Z","reference_number":"EMA/27957/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-23-26-march-2015_en.pdf"},
    {"id":"35514","name":"Guidelines and concept papers adopted during the CHMP meeting 19-22 January 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-02-02T16:30:00Z","last_updated_date":"2015-02-02T16:30:00Z","reference_number":"EMA/27896/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-19-22-january-2015_en.pdf"},
    {"id":"35667","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 15 – 18 May 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-05-19T02:00:00Z","reference_number":"EMA/CHMP/SAWP/321832/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-15-18-may-2017_en.pdf"},
    {"id":"35679","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 10 – 13 October 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"EMA/CHMP/SAWP/681417/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-10-13-october-2016_en.pdf"},
    {"id":"35721","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 29 March - 1 April 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-04-08T12:20:00Z","last_updated_date":"2016-04-08T12:20:00Z","reference_number":"EMA/76589/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-29-march-1-april-2016_en.pdf"},
    {"id":"35948","name":"Opinions on safety variations September 2016 adopted at the CHMP meeting of 12-15 September 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-09-23T18:35:00Z","last_updated_date":"2016-09-23T18:35:00Z","reference_number":"EMA/76624/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variations-september-2016-adopted-chmp-meeting-12-15-september-2016_en.pdf"},
    {"id":"36031","name":"Guidelines and concept papers adopted during the CHMP meeting 22-25 June 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-07-02T12:15:00Z","last_updated_date":"2015-07-02T12:15:00Z","reference_number":"EMA/28019/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-22-25-june-2015_en.pdf"},
    {"id":"36040","name":"Start of community reviews - CHMP meeting of 19-22 January 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-01-23T13:00:00Z","last_updated_date":"2015-01-23T13:00:00Z","reference_number":"EMA/388940/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-19-22-january-2015_en.pdf"},
    {"id":"36119","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 17 – 20 February 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/CHMP/SAWP/105255/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-17-20-february-2014_en.pdf"},
    {"id":"36143","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 19-22 October 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-10-30T15:45:00Z","last_updated_date":"2015-10-30T15:45:00Z","reference_number":"EMA/38688/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-19-22-october-2015_en.pdf"},
    {"id":"36212","name":"Guidelines and concept papers adopted during the CHMP meeting 17-20 November 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-11-27T10:35:00Z","last_updated_date":"2014-11-27T10:35:00Z","reference_number":"EMA/129813/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-17-20-november-2014_en.pdf"},
    {"id":"36260","name":"Guidelines and concept papers adopted during the CHMP meeting 20-23 October 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-10-29T12:20:00Z","last_updated_date":"2014-10-29T12:20:00Z","reference_number":"EMA/129697/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-20-23-october-2014_en.pdf"},
    {"id":"36456","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 12-15 March 2012","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T13:01:00Z","last_updated_date":"2012-03-16T13:01:00Z","reference_number":"EMA/CHMP/SAWP/184762/2012","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-12-15-march-2012_en.pdf"},
    {"id":"36501","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19 - 22 October 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T14:00:00Z","last_updated_date":"2015-10-23T14:00:00Z","reference_number":"EMA/CHMP/SAWP/701884/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-19-22-october-2015_en.pdf"},
    {"id":"36861","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 18-21 July 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T16:00:00Z","last_updated_date":"2016-07-27T16:00:00Z","reference_number":"EMA/76612/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-18-21-july-2016_en.pdf"},
    {"id":"36883","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 16-19 December 2013","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2013-12-20T13:00:00Z","reference_number":"EMA/CHMP/SAWP/807436/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-16-19-december-2013_en.pdf"},
    {"id":"37035","name":"Organisational matters - CHMP meeting 17-20 November 2014","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2014-11-27T10:35:00Z","last_updated_date":"2014-11-27T10:35:00Z","reference_number":"EMA/129820/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-17-20-november-2014_en.pdf"},
    {"id":"37112","name":"Overview of (invented) names reviewed in June 2016 by the Name Review Group (NRG) adopted at the CHMP meeting of 20-23 June 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T14:00:00Z","last_updated_date":"2016-06-24T14:00:00Z","reference_number":"EMA/435524/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-june-2016-name-review-group-nrg-adopted-chmp-meeting-20-23-june-2016_en.pdf"},
    {"id":"37181","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 18-21 July 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T16:00:00Z","last_updated_date":"2016-07-27T16:00:00Z","reference_number":"EMA/76613/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-18-21-july-2016_en.pdf"},
    {"id":"37340","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 12-15 December 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-12-21T11:00:00Z","last_updated_date":"2016-12-21T11:00:00Z","reference_number":"EMA/668748/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-12-15-december-2016_en.pdf"},
    {"id":"37521","name":"Guidelines and concept papers adopted during the CHMP meeting 21-24 September 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-09-30T17:10:00Z","last_updated_date":"2015-09-30T17:10:00Z","reference_number":"EMA/38594/2015 Corr.","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-21-24-september-2015_en.pdf"},
    {"id":"37745","name":"Overview of invented names reviewed in July 2016 by the Name Review Group (NRG) adopted at the CHMP meeting of 18-21 July 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/487528/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-july-2016-name-review-group-nrg-adopted-chmp-meeting-18-21-july-2016_en.pdf"},
    {"id":"38149","name":"Guidelines and concept papers adopted during the CHMP meeting 20-23 July 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-07-29T12:00:00Z","last_updated_date":"2015-07-29T12:00:00Z","reference_number":"EMA/38572/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-20-23-july-2015_en.pdf"},
    {"id":"38173","name":"Organisational matters - CHMP meeting 19-22 October 2015","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2015-10-30T15:45:00Z","last_updated_date":"2015-10-30T15:45:00Z","reference_number":"EMA/38690/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/organisational-matters-chmp-meeting-19-22-october-2015_en.pdf"},
    {"id":"38422","name":"Overview of invented names reviewed in March 2014 by the Name Review Group (NRG) adopted at the CHMP meeting of 22-25 April 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T17:00:00Z","last_updated_date":"2014-04-25T17:00:00Z","reference_number":"EMA/218433/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-march-2014-name-review-group-nrg-adopted-chmp-meeting-22-25-april-2014_en.pdf"},
    {"id":"38579","name":"Opinions on safety variations/periodic safety update reports adopted during the CHMP meeting 21-24 September 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-09-30T17:10:00Z","last_updated_date":"2015-09-30T17:10:00Z","reference_number":"EMA/38596/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-during-chmp-meeting-21-24-september-2015_en.pdf"},
    {"id":"38591","name":"Guidelines and concept papers adopted during the CHMP meeting 14-17 December 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-01-05T13:30:00Z","last_updated_date":"2016-01-05T13:30:00Z","reference_number":"EMA/38806/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-14-17-december-2015_en.pdf"},
    {"id":"38844","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 22-25 February 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-03-04T15:00:00Z","last_updated_date":"2016-03-04T15:00:00Z","reference_number":"EMA/76584/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-22-25-february-2016_en.pdf"},
    {"id":"38981","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 20-23 March 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-03-24T16:20:00Z","last_updated_date":"2017-03-24T16:20:00Z","reference_number":"EMA/CHMP/SAWP/206041/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-20-23-march-2017_en.pdf"},
    {"id":"39015","name":"Start of community reviews - CHMP meeting of 11-14 September 2017","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/611275/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-11-14-september-2017_en.pdf"},
    {"id":"39126","name":"Overview of invented names reviewed in July 2013 by the Name Review Group (NRG) adopted at the CHMP meeting of 22 – 25 July 2013","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/447707/2013","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-july-2013-name-review-group-nrg-adopted-chmp-meeting-22-25-july-2013_en.pdf"},
    {"id":"39634","name":"Guidelines and concept papers adopted during the CHMP meeting 23-26 May 2016","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2016-06-13T12:25:00Z","last_updated_date":"2016-06-13T12:25:00Z","reference_number":"EMA/76602/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-23-26-may-2016_en.pdf"},
    {"id":"39764","name":"Overview of (invented) names reviewed in January 2015 by the Name Review Group (NRG) adopted at the CHMP meeting of 23-26 February 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T13:00:00Z","last_updated_date":"2015-02-27T13:00:00Z","reference_number":"EMA/134020/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-january-2015-name-review-group-nrg-adopted-chmp-meeting-23-26-february-2015_en.pdf"},
    {"id":"39821","name":"Guidelines and concept papers adopted during the CHMP meeting 22-25 February 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-03-04T15:00:00Z","last_updated_date":"2016-03-04T15:00:00Z","reference_number":"EMA/76582/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-22-25-february-2016_en.pdf"},
    {"id":"39842","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 19-22 June 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-06-28T19:30:00Z","last_updated_date":"2017-06-28T19:30:00Z","reference_number":"EMA/668842/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-19-22-june-2017_en.pdf"},
    {"id":"40320","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 17 – 20 July 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/CHMP/SAWP/466217/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-17-20-july-2017_en.pdf"},
    {"id":"40434","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting of 23-26 February 2015","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2015-03-09T18:00:00Z","last_updated_date":"2015-03-09T18:00:00Z","reference_number":"EMA/27949/2015","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-23-26-february-2015_en.pdf"},
    {"id":"40520","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22 – 25 January 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/SAWP/53915/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-22-25-january-2018_en.pdf"},
    {"id":"40599","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19 – 22 February 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T17:22:00Z","last_updated_date":"2018-02-23T17:22:00Z","reference_number":"EMA/CHMP/SAWP/119553/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-19-22-february-2018_en.pdf"},
    {"id":"40843","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 28-31 May 2018","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T13:00:00Z","last_updated_date":"2018-06-06T13:00:00Z","reference_number":"EMA/116728/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-28-31-may-2018_en.pdf"},
    {"id":"41040","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 23 – 26 January 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T13:00:00Z","last_updated_date":"2017-01-27T13:00:00Z","reference_number":"EMA/CHMP/SAWP/59168/2017","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-23-26-january-2017_en.pdf"},
    {"id":"41215","name":"Start of community reviews - CHMP meeting of 25-28 June 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/421929/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-25-28-june-2018_en.pdf"},
    {"id":"41571","name":"Guidelines and concept papers adopted during the CHMP meeting 29 March - 1 April 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-04-08T12:20:00Z","last_updated_date":"2016-04-08T12:20:00Z","reference_number":"EMA/76588/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/guidelines-and-concept-papers-adopted-during-chmp-meeting-29-march-1-april-2016_en.pdf"},
    {"id":"41698","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 20-23 June 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T14:00:00Z","last_updated_date":"2016-06-24T14:00:00Z","reference_number":"EMA/CHMP/SAWP/436366/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-20-23-june-2016_en.pdf"}    {"id":"41772","name":"Opinions on safety variations/periodic safety update reports adopted at the  CHMP meeting of 20-23 June 2016","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2016-06-30T18:00:00Z","last_updated_date":"2016-06-30T18:00:00Z","reference_number":"EMA/76609/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-20-23-june-2016_en.pdf"},
    {"id":"41800","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 20–23 January 2014","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T13:00:00Z","last_updated_date":"2014-01-24T13:00:00Z","reference_number":"EMA/CHMP/SAWP/44167/2014","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-20-23-january-2014_en.pdf"},
    {"id":"42124","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 17 – 20 September 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T14:00:00Z","last_updated_date":"2018-09-21T14:00:00Z","reference_number":"EMA/CHMP/SAWP/644162/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-17-20-september-2018_en.pdf"},
    {"id":"42371","name":"Overview of (invented) names reviewed in September 2018 by the Name Review Group (NRG)","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T12:00:00Z","last_updated_date":"2018-10-19T12:00:00Z","reference_number":"EMA/727739/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2018-name-review-group-nrg_en.pdf"},
    {"id":"42376","name":"Start of community reviews - CHMP meeting of 15-18 October 2018","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T12:00:00Z","last_updated_date":"2018-10-19T12:00:00Z","reference_number":"EMA/712987/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-15-18-october-2018_en.pdf"},
    {"id":"42422","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 15-18 October 2018","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2018-10-24T16:00:00Z","last_updated_date":"2018-10-24T16:00:00Z","reference_number":"EMA/583429/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-15-18-october-2018_en.pdf"},
    {"id":"42675","name":"Start of community reviews - CHMP meeting of 12-15 November 2018","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T15:16:00Z","last_updated_date":"2018-11-16T15:16:00Z","reference_number":"EMA/712987/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-12-15-november-2018_en.pdf"},
    {"id":"42703","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 12-15 November 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T13:00:00Z","last_updated_date":"2018-11-16T13:00:00Z","reference_number":"EMA/CHMP/SAWP/800757/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-12-15-november-2018_en.pdf"},
    {"id":"43041","name":"Start of community reviews - CHMP meeting of 10-13 December 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/855943/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-10-13-december-2018_en.pdf"},
    {"id":"43075","name":"Overview of (invented) names reviewed in November 2018 by the Name Review Group (NRG)","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T15:00:00Z","last_updated_date":"2018-12-14T15:00:00Z","reference_number":"EMA/863497/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2018-name-review-group-nrg_en.pdf"},
    {"id":"43589","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 28 – 31 January 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T17:31:00Z","last_updated_date":"2019-02-01T17:31:00Z","reference_number":"EMA/CHMP/SAWP/49364/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-28-31-january-2019_en.pdf"},
    {"id":"43604","name":"Start of Union reviews adopted during the CHMP meeting of 28 - 31 January 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T11:32:00Z","last_updated_date":"2019-02-01T11:32:00Z","reference_number":"EMA/65306/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-28-31-january-2019_en.pdf"},
    {"id":"43654","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 25-28 February 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-03-06T15:01:00Z","last_updated_date":"2019-03-06T15:01:00Z","reference_number":"EMA/814059/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-25-28-february-2019_en.pdf"},
    {"id":"43936","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 25-28 February 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T12:42:00Z","last_updated_date":"2019-03-01T12:42:00Z","reference_number":"EMA/CHMP/SAWP/147640/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-25-28-february-2019_en.pdf"},
    {"id":"43981","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 28-31 January 2019","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T16:55:00Z","last_updated_date":"2019-02-01T16:55:00Z","reference_number":"EMA/814052/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-28-31-january-2019_en.pdf"},
    {"id":"44111","name":"Scientific advice and protocol assistance adopted at the CHMP meeting of 10–13 December 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-03-26T16:41:00Z","last_updated_date":"2019-03-26T16:41:00Z","reference_number":"EMA/CHMP/SAWP/876120/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-chmp-meeting-10-13-december-2018_en.pdf"},
    {"id":"44112","name":"Scientific advice and protocol assistance adopted at the CHMP meeting of 15-18 October 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-03-26T16:46:00Z","last_updated_date":"2019-03-26T16:46:00Z","reference_number":"EMA/CHMP/SAWP/742101/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-chmp-meeting-15-18-october-2018_en.pdf"},
    {"id":"44113","name":"Scientific advice and protocol assistance adopted at the CHMP meeting of 23 – 26 July 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-03-26T16:51:00Z","last_updated_date":"2019-03-26T16:51:00Z","reference_number":"EMA/CHMP/SAWP/517642/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-chmp-meeting-23-26-july-2018_en.pdf"},
    {"id":"44144","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 25 - 28 March 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-03-29T10:01:00Z","last_updated_date":"2019-03-29T10:01:00Z","reference_number":"EMA/CHMP/SAWP/196240/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-25-28-march-2019_en.pdf"},
    {"id":"44145","name":"Overview of (invented) names reviewed in February 2019 by the Name Review Group (NRG) adopted at the CHMP meeting of 25-28 March 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-03-29T10:10:00Z","last_updated_date":"2019-03-29T10:10:00Z","reference_number":"EMA/195285/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-february-2019-name-review-group-nrg-adopted-chmp-meeting-25-28-march-2019_en.pdf"},
    {"id":"44172","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 25-28 March 2019","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2019-04-04T10:56:00Z","last_updated_date":"2019-04-04T10:56:00Z","reference_number":"EMA/101446/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-25-28-march-2019_en.pdf"},
    {"id":"44381","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22 - 26 April 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T16:05:00Z","last_updated_date":"2019-04-26T16:05:00Z","reference_number":"EMA/CHMP/SAWP/243272/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-22-26-april-2019_en.pdf"},
    {"id":"44400","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 23-26 April 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-04-30T12:05:00Z","last_updated_date":"2019-04-30T12:05:00Z","reference_number":"EMA/164406/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-april-2019_en.pdf"},
    {"id":"44622","name":"Start of Union reviews adopted during the CHMP meeting of 27-29 May 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-05-29T15:55:00Z","last_updated_date":"2019-05-29T15:55:00Z","reference_number":"EMA/287458/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-27-29-may-2019_en.pdf"},
    {"id":"44666","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 27-29 May 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-06-06T11:45:00Z","last_updated_date":"2019-06-06T11:45:00Z","reference_number":"EMA/212618/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-27-29-may-2019_en.pdf"},
    {"id":"44687","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 27 – 29 May 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-06-11T16:40:00Z","last_updated_date":"2019-06-11T16:40:00Z","reference_number":"EMA/CHMP/SAWP/296612/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-27-29-may-2019_en.pdf"},
    {"id":"44888","name":"Overview of (invented) names reviewed in May 2019 by the Name Review Group (NRG) adopted at the CHMP meeting of 24-27 June 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T12:00:00Z","last_updated_date":"2019-06-28T12:00:00Z","reference_number":"EMA/359989/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-may-2019-name-review-group-nrg-adopted-chmp-meeting-24-27-june-2019_en.pdf"},
    {"id":"44928","name":"Start of Union reviews adopted during the CHMP meeting of 24 - 27 June 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T12:13:00Z","last_updated_date":"2019-06-28T12:13:00Z","reference_number":"EMA/365000/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-24-27-june-2019_en.pdf"},
    {"id":"44946","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 24 – 27 June 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T12:20:00Z","last_updated_date":"2019-06-28T12:20:00Z","reference_number":"EMA/CHMP/SAWP/367140/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-24-27-june-2019_en.pdf"},
    {"id":"44985","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 24-27 June 2019","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T16:08:00Z","last_updated_date":"2019-07-03T16:08:00Z","reference_number":"EMA/212625/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-24-27-june-2019_en.pdf"},
    {"id":"45135","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 July 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/SAWP/420885/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-22-25-july-2019_en.pdf"},
    {"id":"45166","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 22-25 July 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-07-31T14:36:00Z","last_updated_date":"2019-07-31T14:36:00Z","reference_number":"EMA/317956/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-july-2019_en.pdf"},
    {"id":"45494","name":"Start of Community reviews - CHMP meeting of 16-19 September 2019","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2019-09-20T12:00:00Z","last_updated_date":"2019-09-20T12:00:00Z","reference_number":"EMA/508074/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-community-reviews-chmp-meeting-16-19-september-2019_en.pdf"},
    {"id":"45498","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 16 – 19 September 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:00:00Z","last_updated_date":"2019-09-20T12:00:00Z","reference_number":"EMA/CHMP/SAWP/516059/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-16-19-september-2019_en.pdf"},
    {"id":"45520","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 16-19 September 2019","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2019-09-25T09:51:00Z","last_updated_date":"2019-09-27T16:16:00Z","reference_number":"EMA/385338/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-16-19-september-2019_en.pdf"},
    {"id":"45723","name":"Start of Union reviews adopted during the CHMP meeting of 14-17 October 2019","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"EMA/565608/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-14-17-october-2019_en.pdf"},
    {"id":"45737","name":"Overview of (invented) names reviewed in September 2019 by the Name Review Group (NRG) adopted at the CHMP meeting of 14-17 October 2019","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"EMA/567443/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2019-name-review-group-nrg-adopted-chmp-meeting-14-17-october-2019_en.pdf"},
    {"id":"45766","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 14 - 17 October 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-10-22T10:27:00Z","last_updated_date":"2019-10-22T10:27:00Z","reference_number":"EMA/CHMP/SAWP/571393/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-14-17-october-2019_en.pdf"},
    {"id":"45777","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 14-17 October 2019","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2019-10-23T15:57:00Z","last_updated_date":"2019-10-23T15:57:00Z","reference_number":"EMA/385345/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-14-17-october-2019_en.pdf"},
    {"id":"46092","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 11-14 November 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-11-21T14:01:00Z","last_updated_date":"2019-11-21T14:01:00Z","reference_number":"EMA/506363/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-11-14-november-2019_en.pdf"},
    {"id":"46182","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 11-14 November 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-11-27T11:27:00Z","last_updated_date":"2019-11-27T11:27:00Z","reference_number":"EMA/CHMP/SAWP/643843/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-11-14-november-2019_en.pdf"},
    {"id":"46281","name":"Overview of (invented) names reviewed in November 2019 by the Name Review Group (NRG) adopted at the CHMP meeting of 09-12 December 2019","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T12:00:00Z","last_updated_date":"2019-12-13T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2019-name-review-group-nrg-adopted-chmp-meeting-09-12-december-2019_en.pdf"},
    {"id":"46341","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 9-12 December 2019","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2019-12-19T12:30:00Z","last_updated_date":"2019-12-19T12:30:00Z","reference_number":"EMA/506373/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-9-12-december-2019_en.pdf"},
    {"id":"46641","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 27-30 January 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T12:00:00Z","last_updated_date":"2020-01-31T12:00:00Z","reference_number":"EMA/CHMP/SAWP/47592/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-27-30-january-2020_en.pdf"},
    {"id":"46702","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 27-30 January 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-02-11T13:51:00Z","last_updated_date":"2020-02-11T13:51:00Z","reference_number":"EMA/634510/2019 ","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-27-30-january-2020_en.pdf"},
    {"id":"46890","name":"Start of Union reviews adopted during the CHMP meeting of 24-27 February 2020","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-02-28T12:00:00Z","reference_number":"EMA/103570/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-24-27-february-2020_en.pdf"},
    {"id":"46900","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 24-27 February 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-02-28T12:00:00Z","reference_number":"EMA/CHMP/SAWP/98532/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-24-27-february-2020_en.pdf"},
    {"id":"46945","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 24-27 February 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-03-05T14:19:00Z","last_updated_date":"2020-03-05T14:19:00Z","reference_number":"EMA/634519/2019","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-24-27-february-2020_en.pdf"},
    {"id":"47159","name":"Overview of invented names reviewed in February 2020 by the Name Review Group adopted at the CHMP meeting of 23-26 March 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T09:08:00Z","last_updated_date":"2020-03-27T09:08:00Z","reference_number":"EMA/158954/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-february-2020-name-review-group-adopted-chmp-meeting-23-26-march-2020_en.pdf"},
    {"id":"47174","name":"Start of Union reviews adopted during the CHMP meeting of 23-26 March 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T18:19:00Z","last_updated_date":"2020-03-27T18:19:00Z","reference_number":"EMA/153417/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-23-26-march-2020_en.pdf"},
    {"id":"47191","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 9-12 March 2020","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/159887/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-9-12-march-2020_en.pdf"},
    {"id":"47260","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 23-26 March 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T12:25:00Z","last_updated_date":"2020-04-01T12:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-march-2020_en.pdf"},
    {"id":"47520","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 28-30 April 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-04-29T17:28:00Z","last_updated_date":"2020-04-29T17:28:00Z","reference_number":"EMA/CHMP/SAWP/232798/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-28-30-april-2020_en.pdf"},
    {"id":"47630","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 28-30 April 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-05-08T09:18:00Z","last_updated_date":"2020-05-08T09:18:00Z","reference_number":"EMA/65740/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-28-30-april-2020_en.pdf"},
    {"id":"47815","name":"Overview of invented names reviewed in April 2020 by the Name Review Group (NRG) adopted at the CHMP meeting of 23 April 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/280671/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-april-2020-name-review-group-nrg-adopted-chmp-meeting-23-april-2020_en.pdf"},
    {"id":"47816","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 25 – 28 May 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/CHMP/SAWP//2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-25-28-may-2020_en.pdf"},
    {"id":"47843","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 25-28 May 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-06-04T09:27:00Z","last_updated_date":"2020-06-04T09:27:00Z","reference_number":"EMA/194047/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-25-28-may-2020_en.pdf"},
    {"id":"48141","name":"Start of Union reviews adopted during the CHMP meeting of 22-25 June 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/341356/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-22-25-june-2020_en.pdf"},
    {"id":"48146","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 June 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/CHMP/SAWP/347887/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-22-25-june-2020_en.pdf"},
    {"id":"48196","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 22-25 June 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-07-01T12:46:00Z","last_updated_date":"2020-07-01T12:46:00Z","reference_number":"EMA/254662/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-june-2020_en.pdf"},
    {"id":"48399","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 20-23 July 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2020-07-24T12:00:00Z","reference_number":"EMA/CHMP/SAWP/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-20-23-july-2020_en.pdf"},
    {"id":"48404","name":"Overview of invented names reviewed in June 2020 by the Name Review Group (NRG) adopted at the CHMP meeting of 2-3 June 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-07-27T13:47:00Z","last_updated_date":"2020-07-27T13:47:00Z","reference_number":"EMA/355918/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-june-2020-name-review-group-nrg-adopted-chmp-meeting-2-3-june-2020_en.pdf"},
    {"id":"48405","name":"Overview of invented names reviewed in June/July 2020 by the Name Review Group (NRG) adopted at the CHMP meeting of 20-23 July 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T11:59:00Z","last_updated_date":"2020-07-24T11:59:00Z","reference_number":"EMA/356004/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-june-july-2020-name-review-group-nrg-adopted-chmp-meeting-20-23-july-2020_en.pdf"},
    {"id":"48462","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 20-23 July 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T16:07:00Z","last_updated_date":"2020-07-28T16:07:00Z","reference_number":"EMA/254669/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-20-23-july-2020_en.pdf"},
    {"id":"48851","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 14-17 September 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T12:00:00Z","last_updated_date":"2020-09-18T12:00:00Z","reference_number":"EMA/CHMP/SAWP/483496/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-14-17-september-2020_en.pdf"},
    {"id":"48918","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 17 September 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-09-30T10:47:00Z","last_updated_date":"2020-09-30T10:47:00Z","reference_number":"EMA/362882/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-17-september-2020_en.pdf"},
    {"id":"49033","name":"Overview of (invented) names reviewed in September 2020 by the Name Review Group (NRG) adopted at the CHMP meeting of 12-15 October 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/548655/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2020-name-review-group-nrg-adopted-chmp-meeting-12-15-october-2020_en.pdf"},
    {"id":"49034","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 12-15 October 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/SAWP/483496/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-12-15-october-2020_en.pdf"},
    {"id":"49106","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 15 October 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-10-22T14:25:00Z","last_updated_date":"2020-10-22T14:25:00Z","reference_number":"EMA/363072/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-15-october-2020_en.pdf"},
    {"id":"49248","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 9-12 November 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T11:59:00Z","last_updated_date":"2020-11-13T11:59:00Z","reference_number":"EMA/CHMP/SAWP/600410/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-9-12-november-2020_en.pdf"},
    {"id":"49298","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 9-12 November 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-11-20T12:01:00Z","last_updated_date":"2020-11-20T12:01:00Z","reference_number":"EMA/505373/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-9-12-november-2020_en.pdf"},
    {"id":"49537","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 7-10 December 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/SAWP/667391/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-7-10-december-2020_en.pdf"},
    {"id":"49623","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 7-10 December 2020","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2020-12-18T12:02:00Z","last_updated_date":"2020-12-18T12:02:00Z","reference_number":"EMA/565217/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-7-10-december-2020_en.pdf"},
    {"id":"50011","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 25-29 January 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T11:40:00Z","last_updated_date":"2021-02-01T11:40:00Z","reference_number":"EMA/CHMP/SAWP/57756/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-25-29-january-2021_en.pdf"},
    {"id":"50014","name":"Overview of (invented) names reviewed in November 2020 by the Name Review Group (NRG) adopted at the CHMP meeting of 25-29 January 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T11:30:00Z","last_updated_date":"2021-02-01T11:30:00Z","reference_number":"EMA/56099/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2020-name-review-group-nrg-adopted-chmp-meeting-25-29-january-2021_en.pdf"},
    {"id":"50069","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 25-29 January 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-02-04T17:23:00Z","last_updated_date":"2021-02-04T17:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-25-29-january-2021_en.pdf"},
    {"id":"50289","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 February 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T12:00:00Z","last_updated_date":"2021-02-26T12:00:00Z","reference_number":"EMA/CHMP/SAWP/123436/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-22-25-february-2021_en.pdf"},
    {"id":"50398","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 22-25 February 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T13:20:00Z","last_updated_date":"2021-03-04T13:20:00Z","reference_number":"EMA/617298/2020","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-february-2021_en.pdf"},
    {"id":"50723","name":"Start of Union reviews adopted during the CHMP meeting of 22-25 March 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T11:59:00Z","last_updated_date":"2021-03-26T11:59:00Z","reference_number":"EMA/150528/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-22-25-march-2021_en.pdf"},
    {"id":"50727","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 March 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T11:59:00Z","last_updated_date":"2021-03-26T11:59:00Z","reference_number":"EMA/CHMP/SAWP/179045/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-22-25-march-2021_en.pdf"},
    {"id":"50728","name":"Overview of (invented) names reviewed in February 2021 by the Name Review Group (NRG) adopted at the CHMP meeting of 22-25 March 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T11:59:00Z","last_updated_date":"2021-03-26T11:59:00Z","reference_number":"EMA/176449/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-february-2021-name-review-group-nrg-adopted-chmp-meeting-22-25-march-2021_en.pdf"},
    {"id":"50754","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 22-25 March 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-03-31T15:13:00Z","last_updated_date":"2021-03-31T15:13:00Z","reference_number":"EMA/25115/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-march-2021_en.pdf"},
    {"id":"50961","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19-22 April 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/SAWP/232152/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-19-22-april-2021_en.pdf"},
    {"id":"50969","name":"Annex to Vaxzevria Art.5.3 - Visual risk contextualisation","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2021-04-23T15:50:00Z","last_updated_date":"2021-04-26T12:01:00Z","reference_number":"EMA/234525/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/annex-vaxzevria-art53-visual-risk-contextualisation_en.pdf"},
    {"id":"51005","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 19-22 April 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-04-29T16:18:00Z","last_updated_date":"2021-04-29T16:18:00Z","reference_number":"EMA/25119/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-19-22-april-2021_en.pdf"},
    {"id":"51224","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 17-20 May 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T12:01:00Z","last_updated_date":"2021-05-21T12:01:00Z","reference_number":"EMA/CHMP/SAWP/284236/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-17-20-may-2021_en.pdf"},
    {"id":"51289","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 17-20 May 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-05-27T16:59:00Z","last_updated_date":"2021-05-27T16:59:00Z","reference_number":"EMA/25123/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-17-20-may-2021_en.pdf"},
    {"id":"51570","name":"Start of Union reviews - CHMP meeting of 21-24 June 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T12:00:00Z","last_updated_date":"2021-06-25T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-chmp-meeting-21-24-june-2021_en.pdf"},
    {"id":"51571","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 21-24 June 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T12:00:00Z","last_updated_date":"2021-06-25T12:00:00Z","reference_number":"EMA/CHMP/SAWP/355768/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-21-24-june-2021_en.pdf"},
    {"id":"51572","name":"Overview of invented names reviewed in February 2020 by the Name Review Group adopted at the CHMP meeting of 21-24 June 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T12:00:00Z","last_updated_date":"2021-06-25T12:00:00Z","reference_number":"EMA/354021/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-february-2020-name-review-group-adopted-chmp-meeting-21-24-june-2021_en.pdf"},
    {"id":"51725","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 21-24 June 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T15:09:00Z","last_updated_date":"2021-07-01T15:09:00Z","reference_number":"EMA/235088/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-21-24-june-2021_en.pdf"},
    {"id":"52038","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19-22 July 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T19:26:00Z","last_updated_date":"2021-07-23T19:26:00Z","reference_number":"EMA/CHMP/SAWP/412101/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-19-22-july-2021_en.pdf"},
    {"id":"52041","name":"Overview of (invented) names reviewed in June 2021 by the Name Review Group (NRG): Adopted at the CHMP meeting of 19-22 July 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:00:00Z","last_updated_date":"2021-07-23T12:00:00Z","reference_number":"EMA/412895/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-june-2021-name-review-group-nrg-adopted-chmp-meeting-19-22-july-2021_en.pdf"},
    {"id":"52113","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 19-22 July 2021","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2021-07-28T10:25:00Z","last_updated_date":"2021-07-28T10:25:00Z","reference_number":"EMA/235092/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-19-22-july-2021_en.pdf"},
    {"id":"52485","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 13-16 September 2021","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/SAWP/519377/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-13-16-september-2021_en.pdf"},
    {"id":"52544","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 13-16 September 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T11:05:00Z","last_updated_date":"2021-09-22T11:05:00Z","reference_number":"EMA/324180/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-13-16-september-2021_en.pdf"},
    {"id":"52858","name":"Start of Union reviews adopted during the CHMP meeting of 11-14 October 2021","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/581049/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-11-14-october-2021_en.pdf"},
    {"id":"52863","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 11-14 October 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/CHMP/SAWP/586853/202","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-11-14-october-2021_en.pdf"},
    {"id":"52864","name":"Overview of (invented) names reviewed in September 2021 by the Name Review Group (NRG) adopted at the CHMP meeting of 11-14 October 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/586201/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2021-name-review-group-nrg-adopted-chmp-meeting-11-14-october-2021_en.pdf"},
    {"id":"52892","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 11-14 October 2021","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2021-10-21T16:21:00Z","last_updated_date":"2021-10-21T16:21:00Z","reference_number":"EMA/324213/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-11-14-october-2021_en.pdf"}    {"id":"53049","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 8-11 November 2021","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/CHMP/SAWP/586853/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-8-11-november-2021_en.pdf"},
    {"id":"53143","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 8-11 November 2021","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2021-11-17T16:15:00Z","last_updated_date":"2021-11-17T16:15:00Z","reference_number":"EMA/498393/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-8-11-november-2021_en.pdf"},
    {"id":"53577","name":"Overview of (invented) names reviewed in November 2021 by the Name Review  Group (NRG) - Adopted at the CHMP meeting of 13-16 December 2021","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T12:00:00Z","last_updated_date":"2021-12-17T12:00:00Z","reference_number":"EMA/751669/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2021-name-review-group-nrg-adopted-chmp-meeting-13-16-december-2021_en.pdf"},
    {"id":"53611","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 13-16 December 2021","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2021-12-21T11:50:00Z","last_updated_date":"2021-12-21T11:50:00Z","reference_number":"EMA/498400/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-13-16-december-2021_en.pdf"},
    {"id":"53902","name":"Start of Union reviews adopted during the CHMP meeting of 24-27 January 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T11:59:00Z","last_updated_date":"2022-01-28T11:59:00Z","reference_number":"EMA/33473/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-24-27-january-2022_en.pdf"},
    {"id":"53972","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 24 – 27 January 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T12:00:00Z","last_updated_date":"2022-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-24-27-january-2022_en.pdf"},
    {"id":"54048","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 24-27 January 2022","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2022-02-02T16:18:00Z","last_updated_date":"2022-02-02T16:18:00Z","reference_number":"EMA/519982/2021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-24-27-january-2022_en.pdf"},
    {"id":"54293","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 21-24 February 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2022-02-25T12:00:00Z","reference_number":"EMA/CHMP/SAWP/12021","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-21-24-february-2022_en.pdf"},
    {"id":"54336","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 21-24 February 2022","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2022-03-02T17:14:00Z","last_updated_date":"2022-03-02T17:14:00Z","reference_number":"EMA/67989/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-21-24-february-2022_en.pdf"},
    {"id":"54546","name":"Overview of (invented) names reviewed in February 2022 by the Name Review Group (NRG) adopted at the CHMP meeting of 21-24 March 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:00:00Z","last_updated_date":"2022-03-25T12:00:00Z","reference_number":"EMA/172225/20222","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-february-2022-name-review-group-nrg-adopted-chmp-meeting-21-24-march-2022_en.pdf"},
    {"id":"54587","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 21– 24 March 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:00:00Z","last_updated_date":"2022-03-25T12:00:00Z","reference_number":"EMA/CHMP/SAWP/181972/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-21-24-march-2022_en.pdf"},
    {"id":"54623","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 21-24 March 2022","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2022-03-30T13:06:00Z","last_updated_date":"2022-03-30T13:06:00Z","reference_number":"EMA/67990/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-21-24-march-2022_en.pdf"},
    {"id":"54806","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19–22 April 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/SAWP/181972/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-19-22-april-2022_en.pdf"},
    {"id":"54817","name":"Start of Union reviews adopted during the CHMP meeting of 19-22 April 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T17:11:00Z","last_updated_date":"2022-04-22T17:11:00Z","reference_number":"EMA/226804/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-19-22-april-2022_en.pdf"},
    {"id":"54844","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 19-22 April 2022","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2022-04-28T10:45:00Z","last_updated_date":"2022-04-28T10:45:00Z","reference_number":"EMA/67991/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-19-22-april-2022_en.pdf"},
    {"id":"55021","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 16-19 May 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/CHMP/SAWP/284919/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-16-19-may-2022_en.pdf"},
    {"id":"55039","name":"Overview of (invented) names reviewed in April 2022 by the Name Review Group (NRG) adopted at the CHMP meeting of 16-19 May 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/275684/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-april-2022-name-review-group-nrg-adopted-chmp-meeting-16-19-may-2022_en.pdf"},
    {"id":"55093","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 16-19 May 2022","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2022-05-25T08:38:00Z","last_updated_date":"2022-05-25T08:38:00Z","reference_number":"EMA/67993/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-16-19-may-2022_en.pdf"},
    {"id":"55322","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 20-23 June 2022","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:07:00Z","last_updated_date":"2022-06-24T15:07:00Z","reference_number":"EMA/CHMP/SAWP/603443/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-20-23-june-2022_en.pdf"},
    {"id":"55352","name":"Start of union reviews adopted during the CHMP meeting of 20-23 June 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T09:43:00Z","last_updated_date":"2022-06-24T09:43:00Z","reference_number":"EMA/598738/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-20-23-june-2022_en.pdf"},
    {"id":"55401","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 18-21 July 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-07-27T09:13:00Z","last_updated_date":"2022-07-27T09:13:00Z","reference_number":"EMA/67996/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-18-21-july-2022_en.pdf"},
    {"id":"55651","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 18-21 July 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T12:00:00Z","last_updated_date":"2022-07-22T12:00:00Z","reference_number":"EMA/CHMP/SAWP/655078/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-18-21-july-2022_en.pdf"},
    {"id":"55652","name":"Overview of (invented) names reviewed in April 2022 by the Name Review Group (NRG) adopted at the CHMP meeting of 18-21 July 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T12:00:00Z","last_updated_date":"2022-07-22T12:00:00Z","reference_number":"EMA/649536/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-april-2022-name-review-group-nrg-adopted-chmp-meeting-18-21-july-2022_en.pdf"},
    {"id":"55691","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 20-23 June 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-06-29T10:42:00Z","last_updated_date":"2022-06-29T10:42:00Z","reference_number":"EMA/67994/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-20-23-june-2022_en.pdf"},
    {"id":"56120","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 12-15 September 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T12:00:00Z","last_updated_date":"2022-09-16T12:00:00Z","reference_number":"EMA/CHMP/SAWP/769857/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-12-15-september-2022_en.pdf"},
    {"id":"56147","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 12-15 September 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-09-21T10:23:00Z","last_updated_date":"2022-09-21T10:23:00Z","reference_number":"EMA/68000/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-12-15-september-2022_en.pdf"},
    {"id":"56396","name":"Overview of (invented) names reviewed in September 2022 by the Name Review Group (NRG) adopted at the CHMP meeting of 10-13 October 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/825713/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2022-name-review-group-nrg-adopted-chmp-meeting-10-13-october-2022_en.pdf"},
    {"id":"56410","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 10-13 October 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/CHMP/SAWP/827118/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-10-13-october-2022_en.pdf"},
    {"id":"56432","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 October 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-10-19T10:25:00Z","last_updated_date":"2022-10-19T10:25:00Z","reference_number":"EMA/68003/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-10-13-october-2022_en.pdf"},
    {"id":"56569","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 7-10 November 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-11-11T17:55:00Z","last_updated_date":"2022-11-11T17:55:00Z","reference_number":"EMA/CHMP/SAWP/872304/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-7-10-november-2022_en.pdf"},
    {"id":"56580","name":"Start of Union reviews adopted during the CHMP meeting of 7-10 November 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-11-11T12:00:00Z","last_updated_date":"2022-11-11T12:00:00Z","reference_number":"EMA/846051/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-7-10-november-2022_en.pdf"},
    {"id":"56637","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 7-10 November 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-11-16T08:57:00Z","last_updated_date":"2022-11-16T08:57:00Z","reference_number":"EMA/68004/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-7-10-november-2022_en.pdf"},
    {"id":"56893","name":"Agenda and registration form - Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T16:40:00Z","last_updated_date":"2022-12-07T16:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/agenda-and-registration-form-virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system_en.pdf"},
    {"id":"57034","name":"Overview of (invented) names reviewed in November 2022 by the Name Review Group (NRG) Adopted at the CHMP meeting of 12-15 December 2022","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T13:24:00Z","last_updated_date":"2022-12-16T13:24:00Z","reference_number":"EMA/934083/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2022-name-review-group-nrg-adopted-chmp-meeting-12-15-december-2022_en.pdf"},
    {"id":"57066","name":"Scientific advice and protocol assistance Adopted during the CHMP meeting 12-15 December 2022","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T09:52:00Z","last_updated_date":"2022-12-16T09:52:00Z","reference_number":"EMA/CHMP/SAWP/939122/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-12-15-december-2022_en.pdf"},
    {"id":"57105","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 12-15 December 2022","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2022-12-21T10:47:00Z","last_updated_date":"2022-12-21T10:47:00Z","reference_number":"EMA/68007/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-12-15-december-2022_en.pdf"},
    {"id":"57427","name":"Scientific advice and protocol assistance Adopted during the CHMP meeting 23-26 January 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T11:09:00Z","last_updated_date":"2023-01-27T11:09:00Z","reference_number":"EMA/CHMP/SAWP/41275/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-23-26-january-2023_en.pdf"},
    {"id":"57434","name":"Start of Union reviews adopted during the CHMP meeting of 23-26 January 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T11:48:00Z","last_updated_date":"2023-01-27T11:48:00Z","reference_number":"EMA/29414/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-23-26-january-2023_en.pdf"},
    {"id":"57495","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 23-26 January 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-02-01T17:05:00Z","last_updated_date":"2023-02-01T17:05:00Z","reference_number":"EMA/898113/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-january-2023_en.pdf"},
    {"id":"57805","name":"Scientific advice and protocol assistance Adopted during the CHMP meeting 20-23 February 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T12:00:00Z","last_updated_date":"2023-02-24T12:00:00Z","reference_number":"EMA/CHMP/SAWP/84536/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-20-23-february-2023_en.pdf"},
    {"id":"57850","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 20-23 February 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-03-01T16:41:00Z","last_updated_date":"2023-03-01T16:41:00Z","reference_number":"EMA/898158/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-20-23-february-2023_en.pdf"},
    {"id":"58188","name":"Overview of invented names reviewed in February 2023 by the Name Review Group adopted at the CHMP meeting of 27-30 March 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/124155/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-february-2023-name-review-group-adopted-chmp-meeting-27-30-march-2023_en.pdf"},
    {"id":"58214","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 27-30 March 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-03-30T11:45:00Z","last_updated_date":"2023-03-30T11:45:00Z","reference_number":"EMA/CHMP/SAWP/149934/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-27-30-march-2023_en.pdf"},
    {"id":"58293","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 27-30 March 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-04-05T14:56:00Z","last_updated_date":"2023-04-05T14:56:00Z","reference_number":"EMA/898162/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-27-30-march-2023_en.pdf"},
    {"id":"58535","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 24-26 April 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T11:45:00Z","last_updated_date":"2023-04-26T11:45:00Z","reference_number":"EMA/CHMP/SAWP/188869/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-24-26-april-2023_en.pdf"},
    {"id":"58587","name":"Recommendations on eligibility to PRIME scheme Adopted at the CHMP meeting of 24-26 April 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-05-04T17:16:00Z","last_updated_date":"2023-05-04T17:16:00Z","reference_number":"EMA/898166/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-24-26-april-2023_en.pdf"},
    {"id":"58784","name":"Overview of invented names reviewed in April 2023 by the Name Review Group adopted at the CHMP meeting of 22-25 May 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-05-26T12:00:00Z","last_updated_date":"2023-05-26T12:00:00Z","reference_number":"EMA/215732/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-april-2023-name-review-group-adopted-chmp-meeting-22-25-may-2023_en.pdf"},
    {"id":"58794","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 May 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-05-26T13:46:00Z","last_updated_date":"2023-05-26T13:46:00Z","reference_number":"EMA/CHMP/SAWP/234267/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-22-25-may-2023_en.pdf"},
    {"id":"58877","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 22-25 May 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-06-06T08:28:00Z","last_updated_date":"2023-06-06T08:28:00Z","reference_number":"EMA/898122/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-may-2023_en.pdf"},
    {"id":"59071","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19-22 June 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T11:17:00Z","last_updated_date":"2023-06-23T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-19-22-june-2023_en.pdf"},
    {"id":"59120","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 17-20 July 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-07-27T16:49:00Z","last_updated_date":"2023-07-27T16:49:00Z","reference_number":"EMA/898130/20223","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-17-20-july-2023_en.pdf"},
    {"id":"59408","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 17-20 July 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T16:24:00Z","last_updated_date":"2023-07-21T16:24:00Z","reference_number":"EMA/CHMP/SAWP/333461/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-17-20-july-2023_en.pdf"},
    {"id":"59443","name":"Overview of (invented) names reviewed in June 2023 by the Name Review Group (NRG) adopted at the CHMP meeting of 17-20 July 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-21T12:00:00Z","reference_number":"EMA/310145/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-june-2023-name-review-group-nrg-adopted-chmp-meeting-17-20-july-2023_en.pdf"},
    {"id":"59457","name":"Start of Union reviews adopted during the CHMP meeting of 17-20 July 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T16:05:00Z","last_updated_date":"2023-07-21T16:05:00Z","reference_number":"EMA/232911/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-17-20-july-2023_en.pdf"},
    {"id":"59991","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 11-14 September 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T12:01:00Z","last_updated_date":"2023-09-15T12:01:00Z","reference_number":"EMA/CHMP/SAWP/416080/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-11-14-september-2023_en.pdf"},
    {"id":"59995","name":"Start of Union reviews adopted during the CHMP meeting of 11-14 September 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T12:00:00Z","last_updated_date":"2023-09-15T12:00:00Z","reference_number":"EMA/351480/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-11-14-september-2023_en.pdf"},
    {"id":"60106","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 9-12 October 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-10-20T17:08:00Z","last_updated_date":"2023-10-20T17:08:00Z","reference_number":"EMA/898134/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-9-12-october-2023_en.pdf"},
    {"id":"60422","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 9-12 October 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T13:03:00Z","last_updated_date":"2023-10-13T13:03:00Z","reference_number":"EMA/CHMP/SAWP/458078/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-9-12-october-2023_en.pdf"},
    {"id":"60423","name":"Start of Union reviews adopted during the CHMP meeting of 9-12 October 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T13:05:00Z","last_updated_date":"2023-10-13T13:05:00Z","reference_number":"EMA/461358/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-9-12-october-2023_en.pdf"},
    {"id":"60446","name":"Overview of (invented) names reviewed in September 2023 by the Name Review Group (NRG) adopted at the CHMP meeting of 18-19 September 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-10-17T16:32:00Z","last_updated_date":"2023-10-17T16:32:00Z","reference_number":"EMA/457023/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2023-name-review-group-nrg-adopted-chmp-meeting-18-19-september-2023_en.pdf"},
    {"id":"60871","name":"Scientific advice and protocol assistance adopted during the CHMP meeting of 6-9 November 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T16:58:00Z","last_updated_date":"2023-11-10T16:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-6-9-november-2023_en.pdf"},
    {"id":"61002","name":"Recommendations on eligibility to PRIME scheme Adopted at the CHMP meeting of 6-9 November 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-11-23T11:03:52Z","last_updated_date":"2023-11-23T11:03:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-6-9-november-2023_en.pdf"},
    {"id":"61473","name":"Start of Union reviews adopted during the CHMP meeting of 11-14 December 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T16:48:38Z","last_updated_date":"2023-12-15T16:48:38Z","reference_number":"EMA/562040/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-11-14-december-2023_en.pdf"},
    {"id":"61495","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 11-14 December 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T11:13:58Z","last_updated_date":"2023-12-19T11:13:58Z","reference_number":"EMA/CHMP/SAWP/554627/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-11-14-december-2023_en.pdf"},
    {"id":"61540","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 11-14 September 2017","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2017-09-20T10:40:17Z","last_updated_date":"2017-09-20T10:40:17Z","reference_number":"EMA/668862/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-11-14-september-2017_en.pdf-0"},
    {"id":"61574","name":"Overview of (invented) names reviewed in November 2023 by the Name Review  Group (NRG) adopted at the CHMP meeting of 11-14 December 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-12-21T15:25:00Z","last_updated_date":"2023-12-21T15:25:00Z","reference_number":"EMA/547475/2023","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2023-name-review-group-nrg-adopted-chmp-meeting-11-14-december-2023_en.pdf"},
    {"id":"61610","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 11-14 December 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-12-22T16:36:29Z","last_updated_date":"2023-12-22T16:36:29Z","reference_number":"EMA/898147/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-11-14-december-2023_en.pdf"},
    {"id":"61921","name":"Start of Union reviews adopted during the CHMP meeting of 22-25 January 2024","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T15:37:21Z","last_updated_date":"2024-01-26T15:37:21Z","reference_number":"EMA/22205/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-22-25-january-2024_en.pdf"},
    {"id":"61922","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 January 2023","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T15:38:26Z","last_updated_date":"2024-01-26T15:38:26Z","reference_number":"EMA/CHMP/SAWP/35437/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-22-25-january-2023_en.pdf"},
    {"id":"62001","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 22-25 January 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-02-05T15:37:16Z","last_updated_date":"2024-02-05T15:37:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-january-2024_en.pdf"},
    {"id":"62278","name":"Start of Union reviews adopted during the CHMP meeting of 19-22 February 2024","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/65773/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-19-22-february-2024_en.pdf"},
    {"id":"62330","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19-22 February 2024","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T10:09:28Z","last_updated_date":"2024-02-28T10:09:28Z","reference_number":"EMA/CHMP/SAWP/85681/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-19-22-february-2024_en.pdf"},
    {"id":"62387","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 19-22 February 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-03-01T08:53:32Z","last_updated_date":"2024-03-01T08:53:32Z","reference_number":"EMA/71120/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-19-22-february-2024_en.pdf"},
    {"id":"62697","name":"Overview of (invented) names reviewed in February 2024 by the Name Review Group (NRG) adopted at the CHMP meeting of 18-21 March 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T10:12:23Z","last_updated_date":"2024-03-22T10:12:23Z","reference_number":"EMA/49114/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-february-2024-name-review-group-nrg-adopted-chmp-meeting-18-21-march-2024_en.pdf"},
    {"id":"62796","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 18-21 March 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-04-03T15:34:48Z","last_updated_date":"2024-04-03T15:34:48Z","reference_number":"EMA/97338/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-18-21-march-2024_en.pdf"},
    {"id":"62871","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 18-21 March 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-04-09T12:02:07Z","last_updated_date":"2024-04-09T12:02:07Z","reference_number":"EMA/CHMP/SAWP/123600/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-18-21-march-2024_en.pdf"},
    {"id":"63086","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 April 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/CHMP/SAWP/179086/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-22-25-april-2024_en.pdf"},
    {"id":"63186","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 22-25 April 2024","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2024-05-07T13:18:47Z","last_updated_date":"2024-05-07T13:18:47Z","reference_number":"EMA/156631/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-april-2024_en.pdf"},
    {"id":"63262","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 11-14 September 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-05-17T14:46:08Z","last_updated_date":"2024-05-17T14:46:08Z","reference_number":"EMA/898134/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-11-14-september-2023_en.pdf"},
    {"id":"63266","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 17-20 September 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-09-26T15:15:57Z","last_updated_date":"2018-09-26T15:15:57Z","reference_number":"EMA/463653/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-17-20-september-2018_en.pdf"},
    {"id":"63479","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 27-30 May 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-06-05T09:43:11Z","last_updated_date":"2024-06-05T09:43:11Z","reference_number":"EMA/220680/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-27-30-may-2024_en.pdf"},
    {"id":"63499","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 27-30 May 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-06-05T16:40:00Z","last_updated_date":"2024-06-05T16:40:00Z","reference_number":"EMA/CHMP/SAWP/252273/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-27-30-may-2024_en.pdf"},
    {"id":"63589","name":"Overview of (invented) names reviewed in April 2024 by the Name Review Group (NRG) adopted at the CHMP meeting of 27-30 May 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-06-12T15:40:00Z","last_updated_date":"2024-06-12T15:40:00Z","reference_number":"EMA/217318/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-april-2024-name-review-group-nrg-adopted-chmp-meeting-27-30-may-2024_en.pdf"},
    {"id":"63961","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 24-27 June 2024","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T14:00:02Z","last_updated_date":"2024-07-09T14:00:02Z","reference_number":"EMA/270047/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-24-27-june-2024_en.pdf"},
    {"id":"64158","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 24-27 June","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-07-16T11:35:36Z","last_updated_date":"2024-07-16T11:35:36Z","reference_number":"EMA/CHMP/SAWP/332435/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-24-27-june_en.pdf"},
    {"id":"64358","name":"Start of Union reviews adopted during the extraordinary CHMP meeting of 29 July 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-07-30T14:00:00Z","last_updated_date":"2024-07-30T14:00:00Z","reference_number":"EMA/348616/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-extraordinary-chmp-meeting-29-july-2024_en.pdf"},
    {"id":"64403","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 12-15 November 2018","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2018-11-21T14:47:43Z","last_updated_date":"2018-11-21T14:47:43Z","reference_number":"EMA/664833/2018","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-12-15-november-2018_en.pdf"},
    {"id":"64404","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 19-22 June 2023","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2023-06-28T14:54:39Z","last_updated_date":"2023-06-28T14:54:39Z","reference_number":"EMA/898126/2022","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-19-22-june-2023_en.pdf"},
    {"id":"64482","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 22-25 July 2024","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T17:39:57Z","last_updated_date":"2024-08-01T17:39:57Z","reference_number":"EMA/332388/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-july-2024_en.pdf"},
    {"id":"64519","name":"Overview of (invented) names reviewed in June 2024 by the Name Review Group (NRG) Adopted at the CHMP meeting of 22-25 July 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-08-06T14:07:38Z","last_updated_date":"2024-08-06T14:07:38Z","reference_number":"EMA/302580/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-june-2024-name-review-group-nrg-adopted-chmp-meeting-22-25-july-2024_en.pdf"},
    {"id":"64570","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 July 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-08-14T14:36:21Z","last_updated_date":"2024-08-14T14:36:21Z","reference_number":"EMA/CHMP/SAWP/373208/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-22-25-july-2024_en.pdf"},
    {"id":"65062","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 16-19 September 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-09-30T15:54:09Z","last_updated_date":"2024-09-30T15:54:09Z","reference_number":"EMA/421953/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-16-19-september-2024_en.pdf"},
    {"id":"65234","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 16-19 September 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-10-08T11:33:53Z","last_updated_date":"2024-10-08T11:33:53Z","reference_number":"EMA/CHMP/SAWP/463927/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-16-19-september-2024_en.pdf"},
    {"id":"65341","name":"Overview of (invented) names reviewed in September 2024 by the Name Review Group (NRG) Adopted at the CHMP meeting of 14-17 October 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/459051/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2024-name-review-group-nrg-adopted-chmp-meeting-14-17-october-2024_en.pdf"},
    {"id":"65381","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 14-17 October 2024","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2024-10-23T16:20:20Z","last_updated_date":"2024-10-23T16:20:20Z","reference_number":"EMA/457029/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-14-17-october-2024_en.pdf"},
    {"id":"65666","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 14-17 October 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/SAWP/531144/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-14-17-october-2024_en.pdf"},
    {"id":"65817","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 11-14 November 2024","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2024-11-26T12:22:59Z","last_updated_date":"2024-11-26T12:22:59Z","reference_number":"EMA/517347/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-11-14-november-2024_en.pdf"},
    {"id":"66111","name":"Overview of (invented) names reviewed in November 2024 by the Name Review Group (NRG) - Adopted at the CHMP meeting of 19 November 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T11:25:16Z","last_updated_date":"2024-12-13T11:25:16Z","reference_number":"EMA/566389/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2024-name-review-group-nrg-adopted-chmp-meeting-19-november-2024_en.pdf"},
    {"id":"66229","name":"\tRecommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 9-12 December 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-01-06T09:41:19Z","last_updated_date":"2025-01-06T09:41:19Z","reference_number":"EMA/557312/2024","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-9-12-december-2024_en.pdf"},
    {"id":"66291","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 11-14 November 2024","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-01-10T16:04:21Z","last_updated_date":"2025-01-10T16:04:21Z","reference_number":"EMA/CHMP/SAWP/7733/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-11-14-november-2024_en.pdf"}    {"id":"66635","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 27-30 January 2025","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2025-02-07T11:59:20Z","last_updated_date":"2025-02-07T11:59:20Z","reference_number":"EMA/4248/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-27-30-january-2025_en.pdf"},
    {"id":"66912","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 27-30 January 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-02-21T11:36:12Z","last_updated_date":"2025-02-21T11:36:12Z","reference_number":"EMA/CHMP/SAWP/64358/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-27-30-january-2025_en.pdf"},
    {"id":"67185","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting 24-27 February 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-03-11T13:59:08Z","last_updated_date":"2025-03-11T13:59:08Z","reference_number":"EMA/63235/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-24-27-february-2025_en.pdf"},
    {"id":"67289","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 24-27 February 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T15:37:09Z","last_updated_date":"2025-03-14T15:37:09Z","reference_number":"EMA/CHMP/SAWP/95093/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-24-27-february-2025_en.pdf"},
    {"id":"67560","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 24-27 March 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-04-01T11:44:47Z","last_updated_date":"2025-04-01T11:44:47Z","reference_number":"EMA/CHMP/SAWP/114446/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-24-27-march-2025_en.pdf"},
    {"id":"67719","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 24-27 March 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-04-09T14:54:45Z","last_updated_date":"2025-04-09T14:54:45Z","reference_number":"EMA/96923/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-24-27-march-2025_en.pdf"},
    {"id":"68132","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 22-25 April 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-05-06T16:49:47Z","last_updated_date":"2025-05-06T16:49:47Z","reference_number":"EMA/135852/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-april-2025_en.pdf"},
    {"id":"68274","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 April 2025","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2025-05-14T09:15:04Z","last_updated_date":"2025-05-14T09:15:04Z","reference_number":"EMA/CHMP/SAWP/162581/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-22-25-april-2025_en.pdf"},
    {"id":"68411","name":"Start of Union reviews adopted during the CHMP meeting of 19-22 May 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T11:59:03Z","last_updated_date":"2025-05-23T11:59:03Z","reference_number":"EMA/170235/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-19-22-may-2025_en.pdf"},
    {"id":"68473","name":"Overview of (invented) names reviewed in April 2025 by the Name Review Group (NRG) adopted at the CHMP meeting of 22 May 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-05-27T15:17:40Z","last_updated_date":"2025-05-27T15:17:40Z","reference_number":"EMA/148455/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-april-2025-name-review-group-nrg-adopted-chmp-meeting-22-may-2025_en.pdf"},
    {"id":"68526","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 19-22 May 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-06-02T14:58:13Z","last_updated_date":"2025-06-02T14:58:13Z","reference_number":"EMA/175872/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-19-22-may-2025_en.pdf"},
    {"id":"68866","name":"Start of Union reviews adopted during the CHMP meeting of 16-19 June 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T13:32:56Z","last_updated_date":"2025-06-20T13:32:56Z","reference_number":"EMA/202194/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-16-19-june-2025_en.pdf"},
    {"id":"68975","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 16-19 June 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-06-25T17:48:04Z","last_updated_date":"2025-06-25T17:48:04Z","reference_number":"EMA/CHMP/SAWP/162581/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-16-19-june-2025_en.pdf"},
    {"id":"68990","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 19-22 May 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T13:49:34Z","last_updated_date":"2025-06-26T13:49:34Z","reference_number":"EMA/212403/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-19-22-may-2025_en.pdf"},
    {"id":"69014","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 16-19 June 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-06-27T13:05:07Z","last_updated_date":"2025-06-27T13:05:07Z","reference_number":"EMA/200552/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-16-19-june-2025_en.pdf"},
    {"id":"69440","name":"Start of Union reviews adopted during the CHMP meeting of 21-24 July 2025","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T10:00:00Z","last_updated_date":"2025-07-25T10:00:00Z","reference_number":"EMA/202194/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-21-24-july-2025_en.pdf"},
    {"id":"69490","name":"Overview of (invented) names reviewed in June 2025 by the Name Review Group (NRG) adopted at the CHMP meeting of 24 July 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T12:00:00Z","last_updated_date":"2025-07-25T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-june-2025-name-review-group-nrg-adopted-chmp-meeting-24-july-2025_en.pdf"},
    {"id":"69635","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 21- 24 July 2025","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2025-08-04T10:09:15Z","last_updated_date":"2025-08-04T10:09:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-21-24-july-2025_en.pdf"},
    {"id":"69651","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 21-24 July 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-08-05T08:55:07Z","last_updated_date":"2025-08-05T08:55:07Z","reference_number":"EMA/223988/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-21-24-july-2025_en.pdf"},
    {"id":"70290","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 15-18 September 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-09-26T09:06:07Z","last_updated_date":"2025-09-26T09:06:07Z","reference_number":"EMA/290349/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-15-18-september-2025_en.pdf"},
    {"id":"70618","name":"Start of Union reviews adopted during the CHMP meeting of 13-16 October 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T12:10:00Z","last_updated_date":"2025-10-17T12:10:00Z","reference_number":"EMA/332104/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-13-16-october-2025_en.pdf"},
    {"id":"70785","name":"Overview of (invented) names reviewed in September 2025 by the Name Review Group (NRG) adopted at the CHMP meeting of 16 October 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-10-23T13:55:31Z","last_updated_date":"2025-10-23T13:55:31Z","reference_number":"EMA/148455/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-september-2025-name-review-group-nrg-adopted-chmp-meeting-16-october-2025_en.pdf"},
    {"id":"70954","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 13-16 October 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-10-31T08:00:37Z","last_updated_date":"2025-10-31T08:00:37Z","reference_number":"EMA/317115/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-13-16-october-2025_en.pdf"},
    {"id":"71223","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 15-18 September 2025","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2025-11-18T14:28:35Z","last_updated_date":"2025-11-18T14:28:35Z","reference_number":"EMA/289375/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-15-18-september-2025_en.pdf"},
    {"id":"71224","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 13-16 October 2025","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2025-11-18T14:33:58Z","last_updated_date":"2025-11-18T14:33:58Z","reference_number":"EMA/341128/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-13-16-october-2025_en.pdf"},
    {"id":"71225","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 10-13 November 2025","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2025-11-18T14:36:20Z","last_updated_date":"2025-11-18T14:36:20Z","reference_number":"EMA/364024/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-10-13-november-2025_en.pdf"},
    {"id":"71292","name":"Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 10-13 November 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-11-21T15:25:21Z","last_updated_date":"2025-11-21T15:25:21Z","reference_number":"EMA/346799/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-10-13-november-2025_en.pdf"},
    {"id":"71821","name":"Overview of (invented) names reviewed in November 2025 by the Name Review Group (NRG) adopted at the CHMP meeting of 11 December 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T15:58:28Z","last_updated_date":"2026-02-06T14:01:31Z","reference_number":"EMA/394227/2025 Corr 1","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-november-2025-name-review-group-nrg-adopted-chmp-meeting-11-december-2025_en.pdf"},
    {"id":"71851","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 26-29 January 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-02-05T12:00:00Z","last_updated_date":"2025-02-05T12:00:00Z","reference_number":"EMA/18748/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-26-29-january-2026_en.pdf"},
    {"id":"72209","name":" Scientific advice and protocol assistance adopted during the CHMP meeting 8-11 December 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-01-23T09:01:15Z","last_updated_date":"2026-01-23T09:01:15Z","reference_number":"EMA/16761/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-8-11-december-2025_en.pdf"},
    {"id":"72375","name":"Start of Union reviews adopted during the CHMP meeting of 26-29 January 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T12:00:00Z","last_updated_date":"2026-01-30T12:00:00Z","reference_number":"EMA/18830/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-26-29-january-2026_en.pdf"},
    {"id":"72583","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 26-29 January 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-02-17T13:37:23Z","last_updated_date":"2026-02-17T13:37:23Z","reference_number":"EMA/39865/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-26-29-january-2026_en.pdf"},
    {"id":"72809","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 23-26 February 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-03-03T17:03:57Z","last_updated_date":"2026-03-03T17:03:57Z","reference_number":"EMA/52141/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-23-26-february-2026_en.pdf"},
    {"id":"72984","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of of 23-26 February 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T15:41:32Z","last_updated_date":"2026-03-12T15:41:32Z","reference_number":"EMA/521657/2016","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-february-2026_en.pdf"},
    {"id":"72985","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 8-11 December 2025","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T12:00:00Z","last_updated_date":"2025-12-05T12:00:00Z","reference_number":"EMA/371701/2025","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-8-11-december-2025_en.pdf"},
    {"id":"73301","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 23-26 March 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-04-01T16:16:49Z","last_updated_date":"2026-04-01T16:16:49Z","reference_number":"EMA/78459/2026 ","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-23-26-march-2026_en.pdf"},
    {"id":"73371","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 23-26 March 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-04-09T10:15:05Z","last_updated_date":"2026-04-09T10:15:05Z","reference_number":"EMA/68264/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-march-2026_en.pdf"},
    {"id":"73558","name":"Questions and answers on the outcome of assessment on use of Opdualag in the treatment of advanced melanoma","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-04-24T12:00:00Z","reference_number":"EMA/89906/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/questions-answers-outcome-assessment-use-opdualag-treatment-advanced-melanoma_en.pdf"},
    {"id":"73682","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 20-23 April 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-05-08T16:16:57Z","last_updated_date":"2026-05-08T16:16:57Z","reference_number":"EMA/93274/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-20-23-april-2026_en.pdf"},
    {"id":"73804","name":"Overview of (invented) names reviewed in April 2026 by the Name Review Group (NRG) adopted at the CHMP meeting of 21 May 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:00:00Z","last_updated_date":"2026-05-22T12:00:00Z","reference_number":"EMA/97170/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/overview-invented-names-reviewed-april-2026-name-review-group-nrg-adopted-chmp-meeting-21-may-2026_en.pdf"},
    {"id":"73805","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 20-23 April 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-05-21T15:14:33Z","last_updated_date":"2026-05-21T15:14:33Z","reference_number":"EMA/118426/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-20-23-april-2026_en.pdf"},
    {"id":"74002","name":"Scientific advice and protocol assistance adopted during the CHMP meeting 18-21 May 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-06-08T14:42:59Z","last_updated_date":"2026-06-08T14:42:59Z","reference_number":"EMA/132508/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/scientific-advice-protocol-assistance-adopted-during-chmp-meeting-18-21-may-2026_en.pdf"},
    {"id":"74032","name":"Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 18-21 May 2026","type":"chmp-annex","status":"Adopted","consultation_date":"","first_published_date":"2026-06-09T17:18:20Z","last_updated_date":"2026-06-09T17:18:20Z","reference_number":"EMA/117263/2026","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-18-21-may-2026_en.pdf"},
    {"id":"74320","name":"Start of Union reviews adopted during the CHMP meeting of 22-25 June 2026","type":"chmp-annex","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T12:10:14Z","last_updated_date":"2026-06-26T12:10:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/chmp-annex/start-union-reviews-adopted-during-chmp-meeting-22-25-june-2026_en.pdf"},
    {"id":"2525","name":"Withdrawal assessment report for Somavert","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-09-19T02:00:00Z","last_updated_date":"2014-09-19T02:00:00Z","reference_number":"EMA/271972/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-somavert_en.pdf"},
    {"id":"2538","name":"Withdrawal assessment report for Multaq","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2006-10-18T02:00:00Z","last_updated_date":"2006-10-18T02:00:00Z","reference_number":"EMEA/CHMP/370798/2006","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-multaq_en.pdf"},
    {"id":"2753","name":"Withdrawal assessment report for Efgratin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-06-27T02:00:00Z","last_updated_date":"2017-06-27T02:00:00Z","reference_number":"EMA/18691/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-efgratin_en.pdf"},
    {"id":"3194","name":"Withdrawal assessment report for Repaglinide Sun","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-06-15T02:00:00Z","last_updated_date":"2010-06-15T02:00:00Z","reference_number":"EMA/316506/2010","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-repaglinide-sun_en.pdf"},
    {"id":"3728","name":"Withdrawal assessment report for Movectro","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-03-30T02:00:00Z","last_updated_date":"2011-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-movectro_en.pdf"},
    {"id":"3935","name":"Withdrawal assessment report for Fanaptum","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-05-17T02:00:00Z","last_updated_date":"2013-05-17T17:00:00Z","reference_number":"EMA/177796/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-fanaptum_en.pdf"},
    {"id":"3950","name":"Withdrawal assessment report for: Balimek (binimetinib)","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2018-03-27T17:11:00Z","last_updated_date":"2018-03-27T17:11:00Z","reference_number":"EMA/CHMP/86716/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-balimek-binimetinib_en.pdf"},
    {"id":"3961","name":"Withdrawal assessment report for Prohippur","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"EMA/358079/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-prohippur_en.pdf"},
    {"id":"4104","name":"Withdrawal assessment report for Pristiqs","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-06-27T02:00:00Z","last_updated_date":"2008-06-27T02:00:00Z","reference_number":"EMEA/207284/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-pristiqs_en.pdf"},
    {"id":"4180","name":"Withdrawal assessment report for DuoPlavin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-07-31T02:00:00Z","last_updated_date":"2010-03-31T02:00:00Z","reference_number":"EMEA/CHMP/272324/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-duoplavin_en.pdf"},
    {"id":"4369","name":"Withdrawal public assessment report of the marketing authorisation application for Scintimun","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2006-06-28T02:00:00Z","last_updated_date":"2010-03-15T01:00:00Z","reference_number":"EMEA/CHMP/239422/2006/Adopted","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-public-assessment-report-marketing-authorisation-application-scintimun_en.pdf"},
    {"id":"4794","name":"Withdrawal assessment report for Solithromycin Triskel EU Services","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-06-02T02:00:00Z","last_updated_date":"2017-06-02T02:00:00Z","reference_number":"EMA/CHMP/226929/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-solithromycin-triskel-eu-services_en.pdf"},
    {"id":"4893","name":"Withdrawal assessment report for Ixempra","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-06-04T02:00:00Z","last_updated_date":"2009-06-04T02:00:00Z","reference_number":"EMEA/594033/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ixempra_en.pdf"},
    {"id":"4905","name":"Withdrawal assessment report for Orathecin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-12-19T01:00:00Z","last_updated_date":"2007-12-19T01:00:00Z","reference_number":"EMEA/CHMP/90172/2006","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-orathecin_en.pdf"},
    {"id":"5412","name":"Withdrawal assessment report for Graspa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-04-25T02:00:00Z","last_updated_date":"2017-04-25T02:00:00Z","reference_number":"EMA/CHMP/238678/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-graspa_en.pdf"},
    {"id":"5758","name":"Withdrawal assessment report for Oncept Melanoma","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-24T11:00:00Z","last_updated_date":"2015-02-24T11:00:00Z","reference_number":"EMA/CVMP/311730/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-oncept-melanoma_en.pdf"},
    {"id":"5759","name":"Withdrawal assessment report for Zunrisa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/615816/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zunrisa_en.pdf"},
    {"id":"5875","name":"Withdrawal assessment report for Gastromotal","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-03-10T01:00:00Z","last_updated_date":"2008-03-10T01:00:00Z","reference_number":"EMEA/111865/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-gastromotal_en.pdf"},
    {"id":"6257","name":"Withdrawal assessment report for Vekacia","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-02-26T01:00:00Z","last_updated_date":"2009-02-26T01:00:00Z","reference_number":"EMEA/CHMP/51709/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-vekacia_en.pdf"},
    {"id":"6284","name":"Withdrawal assessment report for Taxotere","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"EMEA/632212/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-taxotere_en.pdf"},
    {"id":"6439","name":"Withdrawal assessment report for Xgeva","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/CHMP/52035/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-xgeva_en.pdf"},
    {"id":"6590","name":"Withdrawal assessment report for Aripiprazole Mylan","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-07-20T02:00:00Z","last_updated_date":"2015-07-20T02:00:00Z","reference_number":"EMA/CHMP/705827/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aripiprazole-mylan_en.pdf"},
    {"id":"6770","name":"Withdrawal assessment report for Biferonex","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-08-06T02:00:00Z","last_updated_date":"2009-08-06T02:00:00Z","reference_number":"EMEA/334517/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-biferonex_en.pdf"},
    {"id":"6802","name":"Withdrawal assessment report for Corluxin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-06-12T17:00:00Z","last_updated_date":"2015-06-12T17:00:00Z","reference_number":"EMA/235012/2015","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-corluxin_en.pdf"},
    {"id":"6867","name":"Withdrawal assessment report for Zubrin – oral suspension","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-02-24T01:00:00Z","last_updated_date":"2009-02-24T01:00:00Z","reference_number":"EMEA/46907/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zubrin-oral-suspension_en.pdf"},
    {"id":"6958","name":"Withdrawal assessment report for Folcepri","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-08-14T02:00:00Z","last_updated_date":"2014-08-14T02:00:00Z","reference_number":"EMA/CHMP/219148/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-folcepri_en.pdf"},
    {"id":"6983","name":"Withdrawal assessment report for Erbitux","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-11-22T15:36:00Z","last_updated_date":"2012-11-22T15:36:00Z","reference_number":"EMA/CHMP/628005/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-erbitux_en.pdf"},
    {"id":"7049","name":"Withdrawal assessment report for Opaxio","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-12-04T01:00:00Z","last_updated_date":"2009-12-04T01:00:00Z","reference_number":"EMA/CHMP/731026/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-opaxio_en.pdf"},
    {"id":"7336","name":"Withdrawal assessment report for Recothrom","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-03-25T01:00:00Z","last_updated_date":"2010-03-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-recothrom_en.pdf"},
    {"id":"7568","name":"Withdrawal assessment report for Macugen","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-09-29T13:00:00Z","last_updated_date":"2011-09-29T13:00:00Z","reference_number":"EMA/737688/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-macugen_en.pdf"},
    {"id":"7643","name":"Withdrawal assessment report for Ruvise","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-04-10T02:00:00Z","last_updated_date":"2013-04-10T02:00:00Z","reference_number":"EMA/CHMP/795704/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ruvise_en.pdf"},
    {"id":"7657","name":"Withdrawal assessment report for Opatanol","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2006-05-19T02:00:00Z","last_updated_date":"2006-05-19T02:00:00Z","reference_number":"EMEA/H/C/000407/X/0004","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-opatanol_en.pdf"},
    {"id":"7722","name":"Withdrawal assessment report for IXinity","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-09-18T02:00:00Z","last_updated_date":"2013-09-18T02:00:00Z","reference_number":"EMA/CHMP/598935/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ixinity_en.pdf"},
    {"id":"8248","name":"Withdrawal assessment report for Aivlosin: Extension (new target species)","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2014-07-21T18:00:00Z","last_updated_date":"2014-07-21T18:00:00Z","reference_number":"EMA/CVMP/12822/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aivlosin-extension-new-target-species_en.pdf"},
    {"id":"8602","name":"Withdrawal assessment report for Retaane","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2006-03-30T02:00:00Z","last_updated_date":"2006-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retaane_en.pdf"},
    {"id":"8726","name":"Withdrawal assessment report for Pioglitazone Ratiopharm GmbH","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2012-07-12T13:55:00Z","last_updated_date":"2012-07-12T13:55:00Z","reference_number":"EMA/394132/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-pioglitazone-ratiopharm-gmbh_en.pdf"},
    {"id":"8768","name":"Withdrawal assessment report for Zafiride","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-02-08T01:00:00Z","last_updated_date":"2018-02-08T01:00:00Z","reference_number":"EMA/353057/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zafiride_en.pdf"},
    {"id":"8899","name":"Withdrawal assessment report for Docetaxel SUN","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-09-29T02:00:00Z","last_updated_date":"2016-09-29T02:00:00Z","reference_number":"EMA/434463/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-docetaxel-sun_en.pdf"},
    {"id":"9043","name":"Withdrawal assessment report for Memantine FGK","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-04-10T02:00:00Z","last_updated_date":"2013-04-10T02:00:00Z","reference_number":"EMA/17269/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-memantine-fgk_en.pdf"},
    {"id":"9160","name":"Withdrawal assessment report for Begedina","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2017-01-17T10:19:00Z","last_updated_date":"2017-01-17T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-begedina_en.pdf"},
    {"id":"9327","name":"Withdrawal assessment report for Garenoxacin mesylate","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/CHMP/363573/2007","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-garenoxacin-mesylate_en.pdf"},
    {"id":"9364","name":"Withdrawal assessment report for Plivensia","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2018-02-05T17:03:00Z","last_updated_date":"2018-02-05T17:03:00Z","reference_number":"EMA/CHMP/576037/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-plivensia_en.pdf"},
    {"id":"9613","name":"Withdrawal assessment report for Exulett","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-01-05T01:00:00Z","last_updated_date":"2009-01-05T01:00:00Z","reference_number":"EMEA/CHMP/655741/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-exulett_en.pdf"},
    {"id":"9621","name":"Withdrawal assessment report for Sutent","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-08-17T11:20:00Z","last_updated_date":"2018-08-17T11:20:00Z","reference_number":"EMA/CHMP/481973/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sutent_en.pdf"},
    {"id":"9699","name":"Withdrawal assessment report for Xegafri","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2016-06-22T02:00:00Z","last_updated_date":"2016-06-22T02:00:00Z","reference_number":"EMA/CHMP/390341/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-xegafri_en.pdf"},
    {"id":"10925","name":"Withdrawal assessment report for Jenzyl","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-02-18T15:20:00Z","last_updated_date":"2013-02-18T15:20:00Z","reference_number":"EMA/774827/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-jenzyl_en.pdf"},
    {"id":"10938","name":"Withdrawal assessment report for Diractin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-11-28T01:00:00Z","last_updated_date":"2008-11-28T01:00:00Z","reference_number":"EMEA/CHMP/435233/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-diractin_en.pdf"},
    {"id":"10980","name":"Withdrawal assessment report for Voraxaze","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T02:00:00Z","last_updated_date":"2008-06-02T02:00:00Z","reference_number":"EMEA/CHMP/171907/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-voraxaze_en.pdf"},
    {"id":"11001","name":"Withdrawal assessment report for Neocepri","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-08-14T02:00:00Z","last_updated_date":"2014-08-14T02:00:00Z","reference_number":"EMA/CHMP/691219/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-neocepri_en.pdf"},
    {"id":"11109","name":"Withdrawal assessment report for Cheristin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-09-29T02:00:00Z","last_updated_date":"2017-09-29T02:00:00Z","reference_number":"EMA/221301/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-cheristin_en.pdf"},
    {"id":"11282","name":"Withdrawal assessment report for Vynfinit","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-08-14T02:00:00Z","last_updated_date":"2014-08-14T02:00:00Z","reference_number":"EMA/CHMP/797690/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-vynfinit_en.pdf"},
    {"id":"11826","name":"Withdrawal assessment report for Omontys","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-09-10T02:00:00Z","last_updated_date":"2013-09-10T02:00:00Z","reference_number":"EMA/419554/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-omontys_en.pdf"},
    {"id":"11840","name":"Withdrawal assessment report for Cerepro","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-04-14T02:00:00Z","last_updated_date":"2009-04-14T02:00:00Z","reference_number":"EMEA/203243/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-cerepro_en.pdf"},
    {"id":"12102","name":"Withdrawal assessment report for Viagra","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-06-26T02:00:00Z","last_updated_date":"2008-06-26T02:00:00Z","reference_number":"EMEA/130321/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-viagra_en.pdf"},
    {"id":"12288","name":"Withdrawal assessment report for Tysabri","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-08-20T02:00:00Z","last_updated_date":"2013-08-20T02:00:00Z","reference_number":"EMA/492191/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tysabri_en.pdf"},
    {"id":"12674","name":"Withdrawal assessment report for Isomarv medium","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T15:45:00Z","last_updated_date":"2013-02-15T15:45:00Z","reference_number":"EMA/CHMP/780915/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-isomarv-medium_en.pdf"}    {"id":"12753","name":"Withdrawal assessment report for Lacosamide Pain UCB Pharma","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-01-20T01:00:00Z","last_updated_date":"2009-01-20T01:00:00Z","reference_number":"EMEA/CHMP/658067/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lacosamide-pain-ucb-pharma_en.pdf"},
    {"id":"13335","name":"Withdrawal assessment report for Infinia","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/398059/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-infinia_en.pdf"},
    {"id":"13540","name":"Withdrawal assessment report for Ramvocid","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-12-22T01:00:00Z","last_updated_date":"2009-12-22T01:00:00Z","reference_number":"EMA/571673/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ramvocid_en.pdf"},
    {"id":"13628","name":"Withdrawal assessment report for Ibuprofen/Diphenhydramine Hydrochloride Wyeth","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-04-20T02:00:00Z","last_updated_date":"2010-04-20T02:00:00Z","reference_number":"EMA/CHMP/239978/2010","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ibuprofendiphenhydramine-hydrochloride-wyeth_en.pdf"},
    {"id":"13705","name":"Withdrawal assessment report for Sliwens","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-06-01T02:00:00Z","last_updated_date":"2010-06-01T02:00:00Z","reference_number":"EMA/CHMP/90435/2010","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sliwens_en.pdf"},
    {"id":"14249","name":"Withdrawal assessment report for Tyverb","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T01:00:00Z","last_updated_date":"2012-03-16T01:00:00Z","reference_number":"EMA/CHMP/145195/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tyverb_en.pdf"},
    {"id":"14376","name":"Withdrawal assessment report for Aripiprazole Mylan","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/49072/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aripiprazole-mylan_en.pdf-0"},
    {"id":"14427","name":"Withdrawal assessment report for Mersarex","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-01-04T01:00:00Z","last_updated_date":"2010-01-04T01:00:00Z","reference_number":"EMA/CHMP/697798/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-mersarex_en.pdf"},
    {"id":"14822","name":"Withdrawal assessment report for Theraloc","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-05-07T02:00:00Z","last_updated_date":"2009-05-07T02:00:00Z","reference_number":"EMEA/67305/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-theraloc_en.pdf"},
    {"id":"14851","name":"Withdrawal assessment report for Insulin Human Long Marvel","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-03-19T01:00:00Z","last_updated_date":"2008-03-19T01:00:00Z","reference_number":"EMEA/CHMP/70349/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-insulin-human-long-marvel_en.pdf"},
    {"id":"15059","name":"Withdrawal Assessment report for Zioxtenzo","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-04-25T02:00:00Z","last_updated_date":"2017-04-25T02:00:00Z","reference_number":"EMA/172440 /2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zioxtenzo_en.pdf"},
    {"id":"15316","name":"Withdrawal assessment report for Kiacta","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-06-16T02:00:00Z","last_updated_date":"2008-06-16T02:00:00Z","reference_number":"EMEA/CHMP/562687/2007","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-kiacta_en.pdf"},
    {"id":"15357","name":"Withdrawal assessment report for Intrinsa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-10-26T02:00:00Z","last_updated_date":"2010-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-intrinsa_en.pdf"},
    {"id":"15396","name":"Withdrawal assessment report for Hyalograft C autograft","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-05-14T02:00:00Z","last_updated_date":"2013-05-14T02:00:00Z","reference_number":"EMA/167433/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-hyalograft-c-autograft_en.pdf"},
    {"id":"15450","name":"Withdrawal assessment report for Tekinex","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-03-17T01:00:00Z","last_updated_date":"2011-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tekinex_en.pdf"},
    {"id":"15495","name":"Withdrawal assessment report for Globorix","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2007-12-18T01:00:00Z","last_updated_date":"2007-12-18T01:00:00Z","reference_number":"EMEA/CHMP/300656/2007","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-globorix_en.pdf"},
    {"id":"15527","name":"Withdrawal assessment report for Fulphila","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2018-05-29T17:16:00Z","last_updated_date":"2018-05-29T17:16:00Z","reference_number":"EMA/523054/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-fulphila_en.pdf"},
    {"id":"15552","name":"Withdrawal assessment report for Raxone","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-08-06T11:50:00Z","last_updated_date":"2013-08-06T11:50:00Z","reference_number":"EMA/191284/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-raxone_en.pdf"},
    {"id":"15610","name":"Withdrawal assessment report for Evoltra","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-04-09T02:00:00Z","last_updated_date":"2008-04-09T02:00:00Z","reference_number":"EMEA/184556/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-evoltra_en.pdf"},
    {"id":"15799","name":"Withdrawal assessment report for Sinerem","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-04-17T02:00:00Z","last_updated_date":"2008-04-17T02:00:00Z","reference_number":"EMEA/CHMP/11527/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sinerem_en.pdf"},
    {"id":"16000","name":"Withdrawal assessment report for Kyndrisa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/439369/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-kyndrisa_en.pdf"},
    {"id":"16264","name":"Withdrawal assessment report for Surfaxin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2006-07-26T02:00:00Z","last_updated_date":"2006-07-26T02:00:00Z","reference_number":"EMEA/CHMP/255780/2006","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-surfaxin_en.pdf"},
    {"id":"16334","name":"Withdrawal assessment report for Qutenza","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T14:25:00Z","last_updated_date":"2012-04-20T14:25:00Z","reference_number":"EMA/252892/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-qutenza_en.pdf"},
    {"id":"16600","name":"Withdrawal assessment report for Arikayce","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T11:15:00Z","last_updated_date":"2016-10-14T11:15:00Z","reference_number":"EMA/493973/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-arikayce_en.pdf"},
    {"id":"16842","name":"Withdrawal assessment report for Nenad","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-03-16T01:00:00Z","last_updated_date":"2010-03-16T01:00:00Z","reference_number":"EMA/816879/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-nenad_en.pdf"},
    {"id":"17168","name":"Withdrawal assessment report for Fluad Paediatric","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-04-24T02:00:00Z","last_updated_date":"2012-04-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-fluad-paediatric_en.pdf"},
    {"id":"17687","name":"Withdrawal assessment report for Ketoconazole AID-SCFM","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-05-20T13:50:00Z","last_updated_date":"2015-05-20T13:50:00Z","reference_number":"EMA/214194/2015","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ketoconazole-aid-scfm_en.pdf"},
    {"id":"17748","name":"Withdrawal assessment report for Doxorubicin SUN","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-09-26T02:00:00Z","last_updated_date":"2011-09-26T02:00:00Z","reference_number":"EMA/588790/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-doxorubicin-sun_en.pdf"},
    {"id":"17958","name":"Withdrawal assessment report for Aflunov","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-12-19T01:00:00Z","last_updated_date":"2008-12-19T01:00:00Z","reference_number":"EMEA/540171/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aflunov_en.pdf"},
    {"id":"17989","name":"Withdrawal assessment report for Ibandronic Acid Hexal","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T18:07:00Z","last_updated_date":"2011-10-21T18:07:00Z","reference_number":"EMA/CHMP/90168/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ibandronic-acid-hexal_en.pdf"},
    {"id":"18022","name":"Withdrawal assessment report for Retisert","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/CHMP/412692/2007","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf"},
    {"id":"18101","name":"Withdrawal assessment report for NovoNorm","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2006-12-14T01:00:00Z","last_updated_date":"2006-12-14T01:00:00Z","reference_number":"EMEA/CHMP/511689/2006","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-novonorm_en.pdf"},
    {"id":"18294","name":"Withdrawal assessment report for Abilify","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-02-24T01:09:21Z","last_updated_date":"2010-02-24T01:09:21Z","reference_number":"EMA/CHMP/820673/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-abilify_en.pdf"},
    {"id":"18310","name":"Withdrawal assessment report for Prandin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2006-12-14T01:00:00Z","last_updated_date":"2006-12-14T01:00:00Z","reference_number":"EMEA/CHMP/511690/2006","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-prandin_en.pdf"},
    {"id":"18609","name":"Withdrawal assessment report for Contusugene ladenovec gendux","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T01:00:00Z","last_updated_date":"2009-12-07T01:00:00Z","reference_number":"EMEA/CHMP/453445/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-contusugene-ladenovec-gendux_en.pdf"},
    {"id":"18736","name":"Withdrawal assessment report for Imagify","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-04T10:10:00Z","last_updated_date":"2015-02-04T10:10:00Z","reference_number":"EMA/CHMP/312452/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-imagify_en.pdf"},
    {"id":"19242","name":"Withdrawal assessment report for NutropinAq","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-01-28T01:00:00Z","last_updated_date":"2008-01-28T01:00:00Z","reference_number":"EMEA/H/C/315/II/24","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-nutropinaq_en.pdf"},
    {"id":"19515","name":"Withdrawal assessment report for Docetaxel Winthrop","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"EMEA/633183/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-docetaxel-winthrop_en.pdf"},
    {"id":"19540","name":"Withdrawal assessment report for: Rotigotine Mylan (rotigotine)","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2018-07-11T13:37:00Z","last_updated_date":"2018-07-11T13:37:00Z","reference_number":"EMA/29245/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-rotigotine-mylan-rotigotine_en.pdf"},
    {"id":"19552","name":"Withdrawal assessment report for Kalbitor","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-02-09T15:40:00Z","last_updated_date":"2012-02-09T15:40:00Z","reference_number":"EMA/CHMP/476618/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-kalbitor_en.pdf"},
    {"id":"19606","name":"Withdrawal assessment report for Duloxetine Sandoz","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2015-06-23T02:00:00Z","last_updated_date":"2015-06-23T02:00:00Z","reference_number":"EMA/368328/2015","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-duloxetine-sandoz_en.pdf"},
    {"id":"19913","name":"Withdrawal assessment report for Tyvaso","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-05-17T02:00:00Z","last_updated_date":"2010-05-17T02:00:00Z","reference_number":"EMEA/CHMP/739698/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tyvaso_en.pdf"},
    {"id":"19982","name":"Withdrawal assessment report for Velcade","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-08-30T02:00:00Z","last_updated_date":"2012-08-30T02:00:00Z","reference_number":"EMA/460796/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-velcade_en.pdf"},
    {"id":"20351","name":"Withdrawal assessment report for Protelos","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T02:00:00Z","last_updated_date":"2014-07-01T02:00:00Z","reference_number":"EMA/232003/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-protelos_en.pdf"},
    {"id":"20434","name":"Withdrawal assessment report for Ibandronic acid Hexal","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T14:15:00Z","last_updated_date":"2011-10-21T14:15:00Z","reference_number":"EMEA/H/C/000859","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ibandronic-acid-hexal_en.pdf-0"},
    {"id":"20639","name":"Withdrawal assessment report for Ellefore","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-05-13T02:00:00Z","last_updated_date":"2009-05-13T02:00:00Z","reference_number":"EMEA/45054/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ellefore_en.pdf"},
    {"id":"21271","name":"Withdrawal assessment report for Arxxant","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-09-18T02:00:00Z","last_updated_date":"2007-09-18T02:00:00Z","reference_number":"EMEA/150964/2007","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-arxxant_en.pdf"},
    {"id":"21371","name":"Withdrawal assessment report for Lenalidomide Celgene Europe","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-08-01T02:00:00Z","last_updated_date":"2008-08-01T02:00:00Z","reference_number":"EMEA/CHMP/249329/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lenalidomide-celgene-europe_en.pdf"},
    {"id":"21922","name":"Withdrawal assessment report for Oxapex","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CVMP/926850/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-oxapex_en.pdf"},
    {"id":"21957","name":"Withdrawal assessment report for Exelon and Prometax","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-05-21T02:00:00Z","last_updated_date":"2012-05-21T02:00:00Z","reference_number":"EMA/270221/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-exelon-and-prometax_en.pdf"},
    {"id":"22007","name":"Withdrawal assessment report for orBec","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-07-07T02:00:00Z","last_updated_date":"2008-07-07T02:00:00Z","reference_number":"EMEA/CHMP/277406/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-orbec_en.pdf"},
    {"id":"22719","name":"Withdrawal assessment report for Vorinostat MSD","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/CHMP/559066/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-vorinostat-msd_en.pdf"},
    {"id":"23248","name":"Withdrawal assessment report for Belviq","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-08-20T02:00:00Z","last_updated_date":"2013-08-20T02:00:00Z","reference_number":"EMA/CHMP/151372013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-belviq_en.pdf"},
    {"id":"23310","name":"Withdrawal assessment report for Gallimune Flu H5N9(i)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-11-16T01:00:00Z","last_updated_date":"2010-11-16T01:00:00Z","reference_number":"EMA/675117/2010","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-gallimune-flu-h5n9i_en.pdf"},
    {"id":"23384","name":"Withdrawal assessment report for Naxcel: Extension (new target species)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMA/CVMP/115706/2010","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-naxcel-extension-new-target-species_en.pdf"},
    {"id":"23781","name":"Withdrawal assessment report for Aquilda","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-07-25T02:00:00Z","last_updated_date":"2008-07-25T02:00:00Z","reference_number":"EMEA/CHMP/316130/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aquilda_en.pdf"},
    {"id":"23830","name":"Withdrawal assessment report for Ditelos","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/CHMP/710301/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ditelos_en.pdf"},
    {"id":"24115","name":"Withdrawal assessment report for Zolvix: Extension (new target species)","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2013-01-25T11:00:00Z","last_updated_date":"2013-01-25T11:00:00Z","reference_number":"EMA/794474/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zolvix-extension-new-target-species_en.pdf"},
    {"id":"24226","name":"Withdrawal assessment report for Issarlos","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/CHMP/710310/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-issarlos_en.pdf"},
    {"id":"24352","name":"Withdrawal assessment report for Spanidin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-09-05T02:00:00Z","last_updated_date":"2008-09-05T02:00:00Z","reference_number":"EMEA/CHMP/342291/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-spanidin_en.pdf"},
    {"id":"24395","name":"Withdrawal assessment report for Clopidogrel Teva Pharma","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-06-24T02:00:00Z","last_updated_date":"2009-06-24T02:00:00Z","reference_number":"EMEA/CHMP/363700/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-clopidogrel-teva-pharma_en.pdf"},
    {"id":"24543","name":"Withdrawal assessment report for Opsiria","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-09-30T02:00:00Z","last_updated_date":"2016-09-30T02:00:00Z","reference_number":"EMA/433651/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-opsiria_en.pdf"},
    {"id":"24720","name":"Withdrawal assessment report for Draxxin: Extension of indication for Bordetella bronchiseptica","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-07-04T02:00:00Z","last_updated_date":"2012-07-04T02:00:00Z","reference_number":"EMA/323019/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-draxxin-extension-indication-bordetella-bronchiseptica_en.pdf"},
    {"id":"24851","name":"Withdrawal assessment report for Rasival","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-rasival_en.pdf"},
    {"id":"24949","name":"Withdrawal assessment report for Iplex","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-06-26T02:00:00Z","last_updated_date":"2007-06-26T02:00:00Z","reference_number":"EMEA/CHMP/162304/2007","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-iplex_en.pdf"},
    {"id":"25010","name":"Withdrawal assessment report for Neofordex","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-11-20T01:00:00Z","last_updated_date":"2014-11-20T01:00:00Z","reference_number":"EMA/CHMP/673863/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-neofordex_en.pdf"},
    {"id":"25127","name":"Withdrawal assessment report for Cylatron","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-05-20T02:00:00Z","last_updated_date":"2009-05-20T02:00:00Z","reference_number":"EMEA/CHMP/495722/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-cylatron_en.pdf"},
    {"id":"25282","name":"Withdrawal assessment report for Desloratadine Krka","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-01-26T13:55:00Z","last_updated_date":"2012-01-26T13:55:00Z","reference_number":"EMA/32973/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-desloratadine-krka_en.pdf"},
    {"id":"25294","name":"Withdrawal assessment report for: Blectifor","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"EMA/CHMP/41570/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-blectifor_en.pdf"},
    {"id":"25745","name":"Withdrawal assessment report for Joicela","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T01:00:00Z","last_updated_date":"2011-11-30T01:00:00Z","reference_number":"EMA/CHMP/444155/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-joicela_en.pdf"},
    {"id":"26045","name":"Withdrawal assessment report for Emerflu","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-emerflu_en.pdf"},
    {"id":"26176","name":"Withdrawal assessment report for Ethyl eicosapent soft gelatin capsules","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:09:21Z","last_updated_date":"2010-03-03T01:09:21Z","reference_number":"EMA/103030/2010","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ethyl-eicosapent-soft-gelatin-capsules_en.pdf"},
    {"id":"26260","name":"Withdrawal assessment report for Zenhale","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"EMA/25158/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zenhale_en.pdf"},
    {"id":"26481","name":"Withdrawal assessment report for Aranesp","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-04-24T02:00:00Z","last_updated_date":"2018-04-24T02:00:00Z","reference_number":"EMA/CHMP/453348/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aranesp_en.pdf"},
    {"id":"26596","name":"Withdrawal assessment report for Pemetrexed ditromethamine Hospira","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-12-21T01:00:00Z","last_updated_date":"2016-12-21T01:00:00Z","reference_number":"EMA/CHMP/485042/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-pemetrexed-ditromethamine-hospira_en.pdf"},
    {"id":"26639","name":"Withdrawal assessment report for Pioglitazone Ratio","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2012-07-12T13:55:00Z","last_updated_date":"2012-07-12T13:55:00Z","reference_number":"EMA/391408/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-pioglitazone-ratio_en.pdf"},
    {"id":"26653","name":"Withdrawal assessment report for Ramelteon","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-12-16T01:00:00Z","last_updated_date":"2008-12-16T01:00:00Z","reference_number":"EMEA/CHMP/551287/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ramelteon_en.pdf"},
    {"id":"26842","name":"Withdrawal assessment report for Tygacil","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/382036/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tygacil_en.pdf"},
    {"id":"28275","name":"Withdrawal assessment report for Advexin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-09-10T02:00:00Z","last_updated_date":"2009-09-10T02:00:00Z","reference_number":"EMEA/692328/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-advexin_en.pdf"},
    {"id":"28739","name":"Withdrawal assessment report for Insulin Human 30/70 Mix Marvel","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-03-19T01:00:00Z","last_updated_date":"2008-03-19T01:00:00Z","reference_number":"EMEA/CHMP/70179/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-insulin-human-3070-mix-marvel_en.pdf"},
    {"id":"29298","name":"Withdrawal assessment report for Simponi","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/416184/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-simponi_en.pdf"},
    {"id":"29623","name":"Withdrawal assessment report for Restaysis","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-08-06T02:00:00Z","last_updated_date":"2018-08-06T02:00:00Z","reference_number":"EMA/293638/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-restaysis_en.pdf"},
    {"id":"29888","name":"Withdrawal assessment report for Keytruda","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-11-28T01:00:00Z","last_updated_date":"2017-11-28T01:00:00Z","reference_number":"EMA/687095/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-keytruda_en.pdf"},
    {"id":"29898","name":"Withdrawal assessment report for Veraseal","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-12-10T01:00:00Z","last_updated_date":"2015-12-10T01:00:00Z","reference_number":"EMA/674875/2015","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-veraseal_en.pdf"},
    {"id":"30467","name":"Withdrawal assessment report for Factive","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-11-20T01:00:00Z","last_updated_date":"2009-11-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-factive_en.pdf"},
    {"id":"30908","name":"Withdrawal assessment report for Oncophage","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-03-12T01:00:00Z","last_updated_date":"2010-03-12T01:00:00Z","reference_number":"EMA/CHMP/775076/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-oncophage_en.pdf"},
    {"id":"31119","name":"Withdrawal assessment report for Orplatna","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-11-10T01:00:00Z","last_updated_date":"2008-11-10T01:00:00Z","reference_number":"EMEA/579702/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-orplatna_en.pdf"},
    {"id":"31325","name":"Withdrawal assessment report for Heplisav","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-05-26T02:00:00Z","last_updated_date":"2014-05-26T02:00:00Z","reference_number":"EMA/186212/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-heplisav_en.pdf"},
    {"id":"31970","name":"Withdrawal assessment report for Opdivo  (II-30)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-02-13T01:00:00Z","last_updated_date":"2018-02-13T01:00:00Z","reference_number":"EMA/12767/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-opdivo-ii-30_en.pdf"},
    {"id":"32017","name":"Withdrawal assessment report for Zometa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2011-03-08T01:00:00Z","reference_number":"EMA/CHMP/10929/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zometa_en.pdf"},
    {"id":"32484","name":"Withdrawal assessment report for Egrifta","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-10-23T02:00:00Z","last_updated_date":"2012-10-23T02:00:00Z","reference_number":"EMA/588044/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-egrifta_en.pdf"},
    {"id":"32586","name":"Withdrawal assessment report for Qizenday","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2018-02-06T14:41:00Z","last_updated_date":"2018-02-06T14:41:00Z","reference_number":"EMA/828231/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-qizenday_en.pdf"},
    {"id":"33439","name":"Withdrawal assessment report for Cavoley","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-06-27T02:00:00Z","last_updated_date":"2017-06-27T02:00:00Z","reference_number":"EMA/18691/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-cavoley_en.pdf"},
    {"id":"34466","name":"Withdrawal assessment report for Faldaprevir Boehringer Ingelheim","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-09-16T02:00:00Z","last_updated_date":"2014-09-16T02:00:00Z","reference_number":"EMA/519229/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-faldaprevir-boehringer-ingelheim_en.pdf"},
    {"id":"34673","name":"Withdrawal assessment report for Beprana","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-10-06T18:24:00Z","last_updated_date":"2011-10-06T18:24:00Z","reference_number":"EMA/657046/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-beprana_en.pdf"},
    {"id":"35359","name":"Withdrawal assessment report for Solumarv","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T15:45:00Z","last_updated_date":"2013-02-15T15:45:00Z","reference_number":"EMA/CHMP/780927/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-solumarv_en.pdf"},
    {"id":"35555","name":"Withdrawal assessment report for Pioglitazone Ratiopharm","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2012-07-12T13:55:00Z","last_updated_date":"2012-07-12T13:55:00Z","reference_number":"EMA/394137/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-pioglitazone-ratiopharm_en.pdf"},
    {"id":"36099","name":"Withdrawal assessment report for SecreFlo","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"EMA/482305/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-secreflo_en.pdf"},
    {"id":"36132","name":"Withdrawal assessment report for Insulin Human Rapid Marvel","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-03-19T01:00:00Z","last_updated_date":"2008-03-19T01:00:00Z","reference_number":"EMEA/CHMP/317778/2007","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-insulin-human-rapid-marvel_en.pdf"},
    {"id":"36196","name":"Withdrawal assessment report for Zemfirza","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-12-21T01:00:00Z","last_updated_date":"2016-12-21T01:00:00Z","reference_number":"EMA/CHMP/616303/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zemfirza_en.pdf"}    {"id":"36666","name":"Withdrawal assessment report for Paccal Vet","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2012-04-25T02:00:00Z","last_updated_date":"2012-04-25T02:00:00Z","reference_number":"EMA/CVMP/170960/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-paccal-vet_en.pdf"},
    {"id":"36793","name":"Withdrawal assessment report for Megestrol Alkermes (megestrol)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-07T11:40:00Z","last_updated_date":"2012-06-07T11:40:00Z","reference_number":"EMA/253013/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-megestrol-alkermes-megestrol_en.pdf"},
    {"id":"36905","name":"Withdrawal assessment report for Docetaxel Mylan","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/383877/2010","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-docetaxel-mylan_en.pdf"},
    {"id":"37117","name":"Withdrawal assessment report for Vitragan","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-08-23T02:00:00Z","last_updated_date":"2007-08-23T02:00:00Z","reference_number":"EMEA/CHMP/226682/2007","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-vitragan_en.pdf"},
    {"id":"37439","name":"Withdrawal assessment report for Qinprezo","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-08-15T02:00:00Z","last_updated_date":"2017-08-15T02:00:00Z","reference_number":"EMA/462376/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-qinprezo_en.pdf"},
    {"id":"37476","name":"Withdrawal assessment report for Opdivo","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-12-06T16:30:00Z","last_updated_date":"2017-12-06T16:30:00Z","reference_number":"EMA/772719/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-opdivo_en.pdf"},
    {"id":"37657","name":"Withdrawal assessment report for Oxapex","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-07-29T14:00:00Z","last_updated_date":"2015-07-29T14:00:00Z","reference_number":"EMA/787914/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-oxapex_en.pdf-0"},
    {"id":"37761","name":"Withdrawal assessment report for Zavesca","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/254026/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zavesca_en.pdf"},
    {"id":"38103","name":"Withdrawal assessment report for Elmisol","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-07-18T02:00:00Z","last_updated_date":"2017-07-18T02:00:00Z","reference_number":"EMA/CHMP/824474/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-elmisol_en.pdf"},
    {"id":"38138","name":"Withdrawal assessment report for Kexxtone","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-03-04T01:00:00Z","last_updated_date":"2009-03-04T01:00:00Z","reference_number":"EMEA/12430/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-kexxtone_en.pdf"},
    {"id":"38416","name":"Withdrawal assessment report for OraNera","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-07-30T13:30:00Z","last_updated_date":"2013-07-30T13:30:00Z","reference_number":"EMA/250338/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-oranera_en.pdf"},
    {"id":"38706","name":"Withdrawal assessment report for Luveniq","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-02-03T11:52:00Z","last_updated_date":"2012-02-03T11:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-luveniq_en.pdf"},
    {"id":"38801","name":"Withdrawal assessment report for DuoCover","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-07-31T02:00:00Z","last_updated_date":"2010-03-31T02:00:00Z","reference_number":"EMEA/CHMP/272319/2008","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-duocover_en.pdf"},
    {"id":"39279","name":"Withdrawal assessment report for Combimarv","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T15:45:00Z","last_updated_date":"2013-02-15T15:45:00Z","reference_number":"EMA/CHMP/780907/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-combimarv_en.pdf"},
    {"id":"39338","name":"Withdrawal assessment report for Effentora","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-08-29T02:00:00Z","last_updated_date":"2013-08-29T02:00:00Z","reference_number":"EMA/CHMP/297003/2013","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-effentora_en.pdf"},
    {"id":"39400","name":"Withdrawal assessment report for Lunivia","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-06-24T02:00:00Z","last_updated_date":"2009-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf"},
    {"id":"39544","name":"Withdrawal assessment report for Cerepro","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-02-01T01:00:00Z","last_updated_date":"2011-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-cerepro_en.pdf-0"},
    {"id":"39871","name":"Withdrawal assessment report for Ogivri","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-11-28T01:00:00Z","last_updated_date":"2017-11-28T01:00:00Z","reference_number":"EMA/305022/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ogivri_en.pdf"},
    {"id":"39947","name":"Withdrawal assessment report for Cokiera","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-10-24T19:40:00Z","last_updated_date":"2016-10-24T19:40:00Z","reference_number":"EMA/606748/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-cokiera_en.pdf"},
    {"id":"40069","name":"Withdrawal assessment report for Exelon and Prometax","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-18T01:00:00Z","last_updated_date":"2014-02-18T01:00:00Z","reference_number":"EMA/81748/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-exelon-and-prometax_en.pdf-0"},
    {"id":"40087","name":"Withdrawal assessment report for Osseor","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T02:00:00Z","last_updated_date":"2014-07-01T02:00:00Z","reference_number":"EMA/232003/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-osseor_en.pdf"},
    {"id":"40499","name":"Withdrawal assessment report for Enthryv","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-11-06T01:00:00Z","last_updated_date":"2014-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-enthryv_en.pdf"},
    {"id":"41006","name":"Withdrawal assessment report for Ertapenem Hospira","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-12-06T01:00:00Z","last_updated_date":"2016-12-06T01:00:00Z","reference_number":"EMA/620892/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ertapenem-hospira_en.pdf"},
    {"id":"41075","name":"Withdrawal assessment report for Tigecycline Accord","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-10-10T02:00:00Z","last_updated_date":"2017-10-10T02:00:00Z","reference_number":"EMA/CHMP/663395/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tigecycline-accord_en.pdf"},
    {"id":"41126","name":"Withdrawal assessment report for Egranli","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-16T01:00:00Z","last_updated_date":"2015-02-16T01:00:00Z","reference_number":"EMA/CHMP/453321/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-egranli_en.pdf"},
    {"id":"41218","name":"Withdrawal assessment report for Pioglitazone Teva Generics","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-07-03T02:00:00Z","last_updated_date":"2012-07-03T02:00:00Z","reference_number":"EMA/252892/2012","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-pioglitazone-teva-generics_en.pdf"},
    {"id":"41249","name":"Withdrawal assessment report for Enpaxiq","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-06-09T02:00:00Z","last_updated_date":"2017-06-09T02:00:00Z","reference_number":"EMA/178779/2017","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-enpaxiq_en.pdf"},
    {"id":"41312","name":"Withdrawal assessment report for Bosatria","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/454803/2009","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-bosatria_en.pdf"},
    {"id":"41338","name":"Withdrawal assessment report for Somnena","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-09-14T02:00:00Z","last_updated_date":"2017-09-14T02:00:00Z","reference_number":"EMA/CVMP/636012/2016","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-somnena_en.pdf"},
    {"id":"41544","name":"Withdrawal assessment report for Winfuran","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-03-11T01:00:00Z","last_updated_date":"2014-03-11T01:00:00Z","reference_number":"EMA/CHMP/138212/2014","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf"},
    {"id":"42797","name":"Withdrawal assessment report for HopGuard Gold","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-11-26T16:14:00Z","last_updated_date":"2018-11-26T16:14:00Z","reference_number":"EMA/CVMP/234584/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-hopguard-gold_en.pdf"},
    {"id":"42913","name":"Withdrawal assessment report for Zydax","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-12-03T18:10:00Z","last_updated_date":"2018-12-03T18:10:00Z","reference_number":"EMA/85877/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zydax_en.pdf"},
    {"id":"42986","name":"Withdrawal assessment report for Opdivo","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2018-12-11T12:46:00Z","last_updated_date":"2018-12-11T12:46:00Z","reference_number":"EMA/CHMP/634022/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-opdivo_en.pdf-0"},
    {"id":"43017","name":"Withdrawal assessment report for Entolimod TMC","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-12-12T16:18:00Z","last_updated_date":"2018-12-12T16:18:00Z","reference_number":"EMA/CHMP/781541/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-entolimod-tmc_en.pdf"},
    {"id":"43459","name":"Withdrawal Assessment Report for Graspa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-01-23T11:33:00Z","last_updated_date":"2019-01-23T11:33:00Z","reference_number":"EMA/CHMP/438029/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-graspa_en.pdf-0"},
    {"id":"44164","name":"Withdrawal assessment report for Equitend","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-04-01T18:44:00Z","last_updated_date":"2019-04-01T18:44:00Z","reference_number":"EMA/783110/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-equitend_en.pdf"},
    {"id":"44177","name":"Withdrawal assessment report for Efgratin and Cavoley","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-04-05T09:50:00Z","last_updated_date":"2019-04-05T09:50:00Z","reference_number":"EMA/CHMP/425550/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-efgratin-and-cavoley_en.pdf"},
    {"id":"44448","name":"Withdrawal assessment report for Canakinumab Novartis","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-05-07T11:15:00Z","last_updated_date":"2019-05-07T11:15:00Z","reference_number":"EMA/241276/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-canakinumab-novartis_en.pdf"},
    {"id":"45257","name":"Withdrawal assessment report for Radicava","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-08-14T17:07:00Z","last_updated_date":"2019-08-14T17:07:00Z","reference_number":"EMA/CHMP/290284/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-radicava_en.pdf"},
    {"id":"45464","name":"Withdrawal assessment report for Coliprotec F4/F18: Extension (new target species)","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2019-09-18T11:19:00Z","last_updated_date":"2019-09-18T11:19:00Z","reference_number":"EMA/309676/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-coliprotec-f4f18-extension-new-target-species_en.pdf"},
    {"id":"46520","name":"Withdrawal assessment report for Linhaliq","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-01-24T10:06:00Z","last_updated_date":"2020-01-24T10:06:00Z","reference_number":"EMA/595944/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-linhaliq_en.pdf"},
    {"id":"46677","name":"Withdrawal assessment report for Nuzyra","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-02-05T10:06:00Z","last_updated_date":"2020-02-05T10:06:00Z","reference_number":"EMA/595311/2019 ","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-nuzyra_en.pdf"},
    {"id":"46685","name":"Withdrawal assessment report for Idhifa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-02-07T12:24:00Z","last_updated_date":"2020-02-07T12:24:00Z","reference_number":"EMA/CHMP/13746/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-idhifa_en.pdf"},
    {"id":"46701","name":"Withdrawal assessment report for Xyndari","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2020-02-11T14:41:00Z","last_updated_date":"2020-02-11T14:41:00Z","reference_number":"EMA/CHMP/257513/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-xyndari_en.pdf"},
    {"id":"46770","name":"Withdrawal assessment report for Opsumit","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-02-17T15:11:00Z","last_updated_date":"2020-02-17T15:11:00Z","reference_number":"EMA/620481/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-opsumit_en.pdf"},
    {"id":"46771","name":"Withdrawal assessment report for Luxceptar","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-02-17T16:06:00Z","last_updated_date":"2020-02-17T16:06:00Z","reference_number":"EMA/CHMP/CAT/343753/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-luxceptar_en.pdf"},
    {"id":"46973","name":"Withdrawal assessment report for Ekesivy","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-03-06T13:45:00Z","last_updated_date":"2020-03-06T13:45:00Z","reference_number":"EMA/603042/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ekesivy_en.pdf"},
    {"id":"47059","name":"Withdrawal assessment report for Keytruda (II-72)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-03-19T17:17:00Z","last_updated_date":"2020-03-19T17:17:00Z","reference_number":"EMA/CHMP/128687/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-keytruda-ii-72_en.pdf"},
    {"id":"47118","name":"Withdrawal assessment report for Axumin (II-11)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T14:27:00Z","last_updated_date":"2020-03-25T14:27:00Z","reference_number":"EMA/CHMP/140420/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-axumin-ii-11_en.pdf"},
    {"id":"47458","name":"Withdrawal assessment report for Opdivo and Yervoy (WS/1372)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-04-23T01:09:00Z","last_updated_date":"2020-04-23T01:09:00Z","reference_number":"EMA/CHMP/193977/2020 ","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-opdivo-and-yervoy-ws1372_en.pdf"},
    {"id":"47682","name":"Withdrawal assessment report for Vynpenta","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2020-05-15T16:49:00Z","last_updated_date":"2020-05-15T16:49:00Z","reference_number":"EMA/CHMP/570808/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-vynpenta_en.pdf"},
    {"id":"48042","name":"Withdrawal assessment report for Fingolimod Mylan","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-06-17T16:40:00Z","last_updated_date":"2020-06-17T16:40:00Z","reference_number":"EMA/CHMP/267761/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-fingolimod-mylan_en.pdf"},
    {"id":"48113","name":"Withdrawal assessment report for Rituximab Mabion","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-06-24T16:44:00Z","last_updated_date":"2020-06-24T16:44:00Z","reference_number":"EMA/CHMP/141953/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-rituximab-mabion_en.pdf"},
    {"id":"48429","name":"Withdrawal assessment report for Doxorubicin Hydrochloride Tillomed","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-07-27T15:44:00Z","last_updated_date":"2020-07-27T15:44:00Z","reference_number":"EMA/666721/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-doxorubicin-hydrochloride-tillomed_en.pdf"},
    {"id":"48552","name":"Withdrawal assessment report for Tulatrixx","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2020-08-04T17:13:00Z","last_updated_date":"2020-08-04T17:13:00Z","reference_number":"EMA/CVMP/174639/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tulatrixx_en.pdf"},
    {"id":"48634","name":"Withdrawal assessment report for Xiidra","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T17:13:00Z","last_updated_date":"2020-08-19T17:13:00Z","reference_number":"EMA/334174/2020 ","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-xiidra_en.pdf"},
    {"id":"48901","name":"Withdrawal assessment report for Sondelbay","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-09-28T15:49:00Z","last_updated_date":"2020-09-28T15:49:00Z","reference_number":"EMA/379279/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sondelbay_en.pdf"},
    {"id":"49064","name":"Withdrawal assessment report for Rayoqta","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-10-21T11:55:00Z","last_updated_date":"2020-10-21T11:55:00Z","reference_number":"EMA/CHMP/279665/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-rayoqta_en.pdf"},
    {"id":"49104","name":"Withdrawal assessment report for Abilify MyCite","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-10-22T11:55:00Z","last_updated_date":"2020-10-22T11:55:00Z","reference_number":"EMA/CHMP/431264/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-abilify-mycite_en.pdf"},
    {"id":"49150","name":"Withdrawal assessment report for Upkanz","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-10-28T11:55:00Z","last_updated_date":"2020-10-28T11:55:00Z","reference_number":"EMA/CHMP/532991/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-upkanz_en.pdf"},
    {"id":"49826","name":"Withdrawal assessment report for Puldysa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-01-18T15:03:00Z","last_updated_date":"2021-01-18T15:03:00Z","reference_number":"EMA/CHMP/629264/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-puldysa_en.pdf"},
    {"id":"50659","name":"Withdrawal assessment report for Dexamethasone Taw","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-03-19T17:47:00Z","last_updated_date":"2021-03-19T17:47:00Z","reference_number":"EMA/78138/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-dexamethasone-taw_en.pdf"},
    {"id":"50887","name":"Withdrawal assessment report for Tibsovo","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-04-16T15:06:00Z","last_updated_date":"2021-04-16T15:06:00Z","reference_number":"EMA/CHMP/602725/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tibsovo_en.pdf"},
    {"id":"51267","name":"Withdrawal assessment report for Brilique","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-05-25T17:21:00Z","last_updated_date":"2021-05-25T17:21:00Z","reference_number":"EMA/459475/2019","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-brilique_en.pdf"},
    {"id":"51592","name":"Withdrawal assessment report for Esbriet (II-69)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T16:31:00Z","last_updated_date":"2021-06-25T16:31:00Z","reference_number":"EMA/286537/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-esbriet-ii-69_en.pdf"},
    {"id":"52722","name":"Withdrawal assessment report for Sildenafil FGK (sildenafil)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-10-05T10:12:00Z","last_updated_date":"2021-10-05T10:12:00Z","reference_number":"EMA/409352/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sildenafil-fgk-sildenafil_en.pdf"},
    {"id":"52884","name":"Withdrawal assessment report for Oportuzumab monatox DLRC Pharma Services","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-10-20T11:17:00Z","last_updated_date":"2021-10-20T11:17:00Z","reference_number":"EMA/CHMP/576523/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-oportuzumab-monatox-dlrc-pharma-services_en.pdf"},
    {"id":"53301","name":"Withdrawal Assessment Report for Zynyz","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-11-29T11:10:00Z","last_updated_date":"2021-11-29T11:10:00Z","reference_number":"EMA/CHMP/621679/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zynyz_en.pdf"},
    {"id":"53382","name":"Withdrawal Assessment Report for Flynpovi","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T11:19:00Z","last_updated_date":"2021-12-07T11:19:00Z","reference_number":"EMA/CHMP/244212/2021 ","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-flynpovi_en.pdf"},
    {"id":"53388","name":"Withdrawal assessment report for Aivlosin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T11:19:00Z","last_updated_date":"2021-12-07T11:19:00Z","reference_number":"EMA/174508/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aivlosin_en.pdf"},
    {"id":"53584","name":"Withdrawal assessment report for Livmarli","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T11:19:00Z","last_updated_date":"2021-12-17T11:19:00Z","reference_number":"EMA/574349/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-livmarli_en.pdf"},
    {"id":"53673","name":"Withdrawal assessment report for Cervarix","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-01-10T11:19:00Z","last_updated_date":"2022-01-10T11:19:00Z","reference_number":"EMA/612496/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-cervarix_en.pdf"},
    {"id":"54547","name":"Withdrawal assessment report for Zektayos - Hepjuvo","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-03-23T15:03:00Z","last_updated_date":"2022-03-23T15:03:00Z","reference_number":"EMA/CHMP/751783/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zektayos-hepjuvo_en.pdf"},
    {"id":"54610","name":"Withdrawal assessement report for Bravecto","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-29T15:07:00Z","last_updated_date":"2022-03-29T15:07:00Z","reference_number":"EMA/472488/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessement-report-bravecto_en.pdf"},
    {"id":"54645","name":"Withdrawal assessment report for Brilique (II-49)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-04-01T09:02:00Z","last_updated_date":"2022-04-01T09:02:00Z","reference_number":"EMA/CHMP/125700/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-brilique-ii-49_en.pdf"},
    {"id":"55054","name":"Withdrawal assessment report for Neffy","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T16:38:00Z","last_updated_date":"2022-05-20T16:38:00Z","reference_number":"EMA/204348/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-neffy_en.pdf"},
    {"id":"55281","name":"Withdrawal assessement report for Sitoiganap","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-06-17T13:06:00Z","last_updated_date":"2022-06-17T13:06:00Z","reference_number":"EMA/352570/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessement-report-sitoiganap_en.pdf"},
    {"id":"55283","name":"Withdrawal assessment report for Sitoiganap","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-06-17T13:39:00Z","last_updated_date":"2022-06-17T13:39:00Z","reference_number":"EMA/352570/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sitoiganap_en.pdf"},
    {"id":"55743","name":"Withdrawal assessment report for Aduhelm","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-08-01T16:38:00Z","last_updated_date":"2022-08-01T16:38:00Z","reference_number":"EMA/CHMP/557556/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aduhelm_en.pdf"},
    {"id":"56192","name":"Withdrawal assessment report for HemAryo","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-09-27T09:30:00Z","last_updated_date":"2022-09-27T09:30:00Z","reference_number":"EMA/CHMP/631976/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-hemaryo_en.pdf"},
    {"id":"56223","name":"Withdrawal assessment report for Imcivree","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-09-28T10:39:00Z","last_updated_date":"2022-09-28T10:39:00Z","reference_number":"EMA/677095/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-imcivree_en.pdf"},
    {"id":"56516","name":"Withdrawal assessment report for Dimherity","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-11-03T10:04:00Z","last_updated_date":"2022-11-03T10:04:00Z","reference_number":"EMEA/H/C/5955/0000","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-dimherity_en.pdf"},
    {"id":"56548","name":"Withdrawal assessment report for Parsaclisib Incyte Biosciences Distribution B.V.","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-11-08T14:42:00Z","last_updated_date":"2022-11-08T14:42:00Z","reference_number":"EMA/616224/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-parsaclisib-incyte-biosciences-distribution-bv_en.pdf"},
    {"id":"56640","name":"Withdrawal assessment report for Sevsury","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-11-16T11:20:00Z","last_updated_date":"2022-11-16T11:20:00Z","reference_number":"EMA/CHMP/697928/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sevsury_en.pdf"},
    {"id":"56751","name":"Withdrawal assessment report for Abylqis","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-11-23T09:38:00Z","last_updated_date":"2022-11-23T09:38:00Z","reference_number":"EMA/772201/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-abylqis_en.pdf"},
    {"id":"56775","name":"Withdrawal assessment report for Exkivity","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-11-24T12:14:00Z","last_updated_date":"2022-11-24T12:14:00Z","reference_number":"EMA/787858/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-exkivity_en.pdf"},
    {"id":"56982","name":"Withdrawal assessment report for Tuznue","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-12-13T15:29:00Z","last_updated_date":"2022-12-13T15:29:00Z","reference_number":"EMA/CHMP/902445/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tuznue_en.pdf"},
    {"id":"56983","name":"Withdrawal assessment report for Hervelous","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-12-13T15:37:00Z","last_updated_date":"2022-12-13T15:37:00Z","reference_number":"EMA/CHMP/915668/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-hervelous_en.pdf"},
    {"id":"57386","name":"Withdrawal assessment report for Versiguard SARS CoV2","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-01-25T15:13:00Z","last_updated_date":"2023-01-25T15:13:00Z","reference_number":"EMA/CVMP/772508/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-versiguard-sars-cov2_en.pdf"},
    {"id":"57442","name":"Withdrawal assessment report for Febseltiq","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-01-30T10:15:00Z","last_updated_date":"2023-01-30T10:15:00Z","reference_number":"EMA/939316/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-febseltiq_en.pdf"},
    {"id":"57507","name":"Withdrawal assessment report for Olumiant (II-0028)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-02-02T13:10:00Z","last_updated_date":"2023-02-02T13:10:00Z","reference_number":"EMA/926734/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-olumiant-ii-0028_en.pdf"},
    {"id":"57511","name":"Withdrawal assessment report for Gavreto (pralsetinib) (II-0002-G)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-02-02T16:06:00Z","last_updated_date":"2023-02-02T16:06:00Z","reference_number":"EMA/45270/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-gavreto-pralsetinib-ii-0002-g_en.pdf"},
    {"id":"57541","name":"Withdrawal assessment report for Imbarkyd","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-02-07T12:34:00Z","last_updated_date":"2023-02-07T12:34:00Z","reference_number":"EMA/913943/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-imbarkyd_en.pdf"},
    {"id":"57554","name":"Withdrawal assessment report for Miplyffa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-02-07T12:34:00Z","last_updated_date":"2023-02-07T12:34:00Z","reference_number":"EMA/177363/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-miplyffa_en.pdf"},
    {"id":"57605","name":"Withdrawal assessment report for Aliqopa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-02-10T13:42:00Z","last_updated_date":"2023-02-10T13:42:00Z","reference_number":"EMA/948113/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aliqopa_en.pdf"},
    {"id":"57795","name":"Withdrawal assessment report for Ilaris","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-02-23T10:43:00Z","last_updated_date":"2023-02-23T10:43:00Z","reference_number":"EMA/881775/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ilaris_en.pdf"},
    {"id":"57844","name":"Withdrawal assessment report for Garsun (artesunate)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-03-01T11:59:00Z","last_updated_date":"2023-03-01T11:59:00Z","reference_number":"EMA/48303/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-garsun-artesunate_en.pdf"},
    {"id":"58283","name":"Withdrawal assessment report for Raltegravir Viatris","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-04-05T10:41:00Z","last_updated_date":"2023-04-05T10:41:00Z","reference_number":"EMA/CHMP/116101/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-raltegravir-viatris_en.pdf"},
    {"id":"58812","name":"Withdrawal assessment report for Tidhesco","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-05-30T13:58:00Z","last_updated_date":"2023-05-30T13:58:00Z","reference_number":"EMA/173663/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tidhesco_en.pdf"},
    {"id":"58939","name":"Withdrawal assessment report for Buvidal (II-17)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-06-14T12:39:00Z","last_updated_date":"2023-06-14T12:39:00Z","reference_number":"EMA/88938/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-buvidal-ii-17_en.pdf"}    {"id":"59306","name":"Withdrawal assessment report for Asimtufii","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-07-07T16:24:00Z","last_updated_date":"2023-07-07T16:24:00Z","reference_number":"EMA/CHMP/231170/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-asimtufii_en.pdf"},
    {"id":"59322","name":"Withdrawal assessment report for Feraheme","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-07-11T13:55:00Z","last_updated_date":"2023-07-11T13:55:00Z","reference_number":"EMA/142149/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-feraheme_en.pdf"},
    {"id":"59392","name":"Withdrawal assessment report for Susvimo","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-07-18T13:55:00Z","last_updated_date":"2023-07-18T13:55:00Z","reference_number":"EMA/206018/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-susvimo_en.pdf"},
    {"id":"59567","name":"Withdrawal assessment report for Lumevoq","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-08-08T11:41:00Z","last_updated_date":"2023-08-08T11:41:00Z","reference_number":"EMA/CHMP/248970/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lumevoq_en.pdf-0"},
    {"id":"59576","name":"Withdrawal assessment report for Lagevrio","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-08-09T10:47:00Z","last_updated_date":"2023-08-09T10:47:00Z","reference_number":"EMA/116128/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lagevrio_en.pdf"},
    {"id":"59678","name":"Withdrawal assessment report for Zefylti","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-08-30T15:14:00Z","last_updated_date":"2023-08-30T15:14:00Z","reference_number":"EMA/CHMP/596395/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zefylti_en.pdf"},
    {"id":"60254","name":"Withdrawal assessment report for Gazyvaro","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2023-10-04T16:44:00Z","last_updated_date":"2023-10-04T16:44:00Z","reference_number":"EMA/CHMP/371337/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-gazyvaro_en.pdf"},
    {"id":"60468","name":"Withdrawal assessment report for Vivjoa","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-10-23T16:05:00Z","last_updated_date":"2023-10-23T16:05:00Z","reference_number":"EMA/428048/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-vivjoa_en.pdf"},
    {"id":"60788","name":"Withdrawal assessment report for Lutholaz","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-11-07T15:00:00Z","last_updated_date":"2023-11-07T15:00:00Z","reference_number":"EMA/CHMP/343552/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lutholaz_en.pdf"},
    {"id":"60796","name":"Withdrawal assessment report for RoActemra","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2023-11-07T17:44:00Z","last_updated_date":"2023-11-07T17:44:00Z","reference_number":"EMA/495669/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-roactemra_en.pdf"},
    {"id":"60805","name":"Withdrawal assessment report for Gefzuris","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-11-08T15:21:00Z","last_updated_date":"2023-11-08T15:21:00Z","reference_number":"EMA/357359/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-gefzuris_en.pdf"},
    {"id":"60962","name":"Withdrawal assessment report for Jivadco","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2023-11-23T12:09:50Z","last_updated_date":"2023-11-23T12:09:50Z","reference_number":"EMA/391838/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-jivadco_en.pdf-0"},
    {"id":"61025","name":"Withdrawal assessment report for Bylvay (II-11)","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2023-11-23T17:22:38Z","last_updated_date":"2023-11-23T17:22:38Z","reference_number":"EMA/371338/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-bylvay-ii-11_en.pdf"},
    {"id":"61102","name":"Withdrawal assessment report for Iclusig (II-64)","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2023-11-30T18:36:26Z","last_updated_date":"2023-11-30T18:36:26Z","reference_number":"EMA/CHMP/874113/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-iclusig-ii-64_en.pdf"},
    {"id":"61394","name":"Withdrawal Assessment report for Jesduvroq","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-12-13T09:24:32Z","last_updated_date":"2023-12-13T09:24:32Z","reference_number":"EMA/319166/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-jesduvroq_en.pdf"},
    {"id":"61418","name":"Withdrawal assessment report for Dyrupeg","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-12-14T13:09:58Z","last_updated_date":"2023-12-14T13:09:58Z","reference_number":"EMA/298992/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-dyrupeg_en.pdf"},
    {"id":"62033","name":"Withdrawal assessment report for Sugammadex Lorien","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-02-08T10:51:56Z","last_updated_date":"2024-02-08T10:51:56Z","reference_number":"EMA/CHMP/230066/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sugammadex-lorien_en.pdf"},
    {"id":"62613","name":"Withdrawal assessment report for Vijoice","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-03-14T10:48:00Z","last_updated_date":"2024-03-14T10:48:00Z","reference_number":"EMA/506300/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-vijoice_en.pdf"},
    {"id":"63110","name":"Withdrawal assessment report for Orencia (II-152)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-04-30T11:40:00Z","last_updated_date":"2024-04-30T11:40:00Z","reference_number":"EMA/74789/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-orencia-ii-152_en.pdf"},
    {"id":"64203","name":"Withdrawal assessment report for Adcetris (II-109)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-07-18T12:18:00Z","last_updated_date":"2024-07-18T12:18:00Z","reference_number":"EMA/336551/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-adcetris-ii-109_en.pdf"},
    {"id":"64399","name":"Withdrawal assessment report for Upstelda","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-07-30T12:42:20Z","last_updated_date":"2024-07-30T12:42:20Z","reference_number":"EMA/250302/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-upstelda_en.pdf"},
    {"id":"64897","name":"Withdrawal assessment report for Ongentys (WS2552-60)","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2024-09-18T12:45:00Z","last_updated_date":"2024-09-18T12:45:00Z","reference_number":"EMA/CHMP/289566/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ongentys-ws2552-60_en.pdf"},
    {"id":"64898","name":"Withdrawal assessment report for Ontilyv (WS-2552)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-09-18T13:00:00Z","last_updated_date":"2024-09-18T13:00:00Z","reference_number":"EMA/CHMP/289566/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-ontilyv-ws-2552_en.pdf"},
    {"id":"65056","name":"Withdrawal assessment report for Kinharto (omecamtiv mecarbil)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-09-30T10:57:00Z","last_updated_date":"2024-09-30T10:57:00Z","reference_number":"EMA/400270/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-kinharto-omecamtiv-mecarbil_en.pdf"},
    {"id":"66237","name":"Withdrawal assessment report for Apremilast Viatris","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-01-06T13:04:42Z","last_updated_date":"2025-01-06T13:04:42Z","reference_number":"EMA/471783/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-apremilast-viatris_en.pdf"},
    {"id":"66584","name":"Withdrawal assessment report for Izelvay","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2025-02-04T11:52:35Z","last_updated_date":"2025-02-04T11:52:35Z","reference_number":"EMA/503729/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-izelvay_en.pdf"},
    {"id":"66988","name":"Withdrawal assessment report for GeGant (germanium (68Ge) chloride / gallium (68Ga) chloride)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-02-26T13:45:03Z","last_updated_date":"2025-02-26T13:45:03Z","reference_number":"EMA/247635/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-gegant-germanium-68ge-chloride-gallium-68ga-chloride_en.pdf"},
    {"id":"67776","name":"Withdrawal assessment report for Skojoy","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-04-14T11:48:24Z","last_updated_date":"2025-04-14T11:48:24Z","reference_number":"EMA/60973/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-skojoy_en.pdf"},
    {"id":"68446","name":"Withdrawal assessment report for Cinainu","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-05-26T09:14:44Z","last_updated_date":"2025-05-26T09:14:44Z","reference_number":"EMA/101957/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-cinainu_en.pdf"},
    {"id":"68486","name":"Withdrawal assessment report for Amyvid (II-46)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-05-28T11:15:18Z","last_updated_date":"2025-05-28T11:15:18Z","reference_number":"EMA/89198/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-amyvid-ii-46_en.pdf"},
    {"id":"68579","name":"Withdrawal assessment report for Pelgraz Paediatric","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-06-04T17:18:14Z","last_updated_date":"2025-06-04T17:18:14Z","reference_number":"EMA/CHMP/79535/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-pelgraz-paediatric_en.pdf"},
    {"id":"68781","name":"Withdrawal assessment report for Inaqovi (II-0002)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-06-17T09:35:27Z","last_updated_date":"2025-06-17T09:35:27Z","reference_number":"EMA/573983/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-inaqovi-ii-0002_en.pdf"},
    {"id":"69017","name":"Withdrawal assessment report for Lutathera (II-52)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-06-27T15:08:03Z","last_updated_date":"2025-06-27T15:08:03Z","reference_number":"EMA/CHMP/165811/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lutathera-ii-52_en.pdf"},
    {"id":"69112","name":"Withdrawal assessment report for Rilonacept FGK Representative Service GmbH","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-07-04T15:59:12Z","last_updated_date":"2025-07-04T15:59:12Z","reference_number":"EMA/63022/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-rilonacept-fgk-representative-service-gmbh_en.pdf"},
    {"id":"70275","name":"Withdrawal assessment report for Equilis EHV 1+4","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-09-25T14:28:40Z","last_updated_date":"2025-09-25T14:28:40Z","reference_number":"EMA/362560/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-equilis-ehv-14_en.pdf"},
    {"id":"70384","name":"Withdrawal assessment report for Nidlegy","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-10-01T14:18:50Z","last_updated_date":"2025-10-01T14:18:50Z","reference_number":"EMA/CHMP/169210/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-nidlegy_en.pdf"},
    {"id":"70441","name":"Withdrawal assessment report for Sileo (II-22)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-10-03T14:29:45Z","last_updated_date":"2025-10-03T14:29:45Z","reference_number":"EMA/767835/2022","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sileo-ii-22_en.pdf"},
    {"id":"70456","name":"Withdrawal assessment report for Aplidin","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2025-10-06T16:25:20Z","last_updated_date":"2025-10-06T16:25:20Z","reference_number":"EMA/249101/2018","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aplidin_en.pdf"},
    {"id":"70760","name":"Withdrawal assessment report for Insulin Human Rechon","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T15:04:14Z","last_updated_date":"2025-10-22T15:04:14Z","reference_number":"EMA/CHMP/340099/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-insulin-human-rechon_en.pdf"},
    {"id":"70784","name":"Withdrawal assessment report for Amtagvi","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T13:48:11Z","last_updated_date":"2025-10-23T13:48:11Z","reference_number":"EMA/263892/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-amtagvi_en.pdf"},
    {"id":"70849","name":"Withdrawal assessment report for Fanskya","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2025-10-27T15:17:52Z","last_updated_date":"2025-10-27T15:17:52Z","reference_number":"EMA/CAT/271921/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-fanskya_en.pdf"},
    {"id":"71048","name":"Withdrawal assessment report for Dupixant (II-0083)","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2025-11-07T11:39:15Z","last_updated_date":"2025-11-07T11:39:15Z","reference_number":"EMA/67383/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-dupixant-ii-0083_en.pdf"},
    {"id":"71097","name":"Withdrawal assessment report for Datopotamab deruxtecan Daiichi Sankyo","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-11-11T13:13:15Z","last_updated_date":"2025-11-11T13:13:15Z","reference_number":"EMA/67925/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-datopotamab-deruxtecan-daiichi-sankyo_en.pdf"},
    {"id":"71334","name":"Withdrawal assessment report for Hydrocortisone Aguettant","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T14:49:35Z","last_updated_date":"2025-11-25T14:49:35Z","reference_number":"EMA/CHMP/570616/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-hydrocortisone-aguettant_en.pdf"},
    {"id":"71335","name":"Withdrawal assessment report for Vectra 3D (VRA/0026/G)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-11-25T15:16:28Z","last_updated_date":"2025-11-25T15:16:28Z","reference_number":"EMA/563432/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-vectra-3d-vra-0026-g_en.pdf"},
    {"id":"71493","name":"Withdrawal assessment report for Tuzodi","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-12-04T09:25:28Z","last_updated_date":"2025-12-04T09:25:28Z","reference_number":"EMADOC-1829012207-24310","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-tuzodi_en.pdf"},
    {"id":"71648","name":"Withdrawal assessment report for Sirolimus TriviumVet","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-12-10T14:51:53Z","last_updated_date":"2025-12-10T14:51:53Z","reference_number":"EMA/108424/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-sirolimus-triviumvet_en.pdf"},
    {"id":"71776","name":"Withdrawal assessment report for Omforro","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T12:37:32Z","last_updated_date":"2025-12-16T12:37:32Z","reference_number":"EMADOC-1829012207-24322","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-omforro_en.pdf"},
    {"id":"72002","name":"Withdrawal assessment report for Nurzigma","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2026-01-09T11:18:01Z","last_updated_date":"2026-01-09T11:18:01Z","reference_number":"EMA/CHM/231085/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-nurzigma_en.pdf"},
    {"id":"72863","name":"Withdrawal assessment report for Scenesse","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2026-03-05T15:34:35Z","last_updated_date":"2026-03-05T15:34:35Z","reference_number":"EMA/333545/2024","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-scenesse_en.pdf"},
    {"id":"73139","name":"Withdrawal assessment report for Cunitraxx","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2026-03-20T16:27:08Z","last_updated_date":"2026-03-20T16:27:08Z","reference_number":"EMA/171245/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-cunitraxx_en.pdf"},
    {"id":"73419","name":"Withdrawal assessment report for Equidormin","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2026-04-10T13:48:53Z","last_updated_date":"2026-04-10T13:48:53Z","reference_number":"EMA/301662/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-equidormin_en.pdf"},
    {"id":"73466","name":"Withdrawal assessment report for Jelrix","type":"withdrawal-report","status":"unknown","consultation_date":"","first_published_date":"2026-04-15T16:11:08Z","last_updated_date":"2026-04-15T16:11:08Z","reference_number":"EMA/CAT/216988/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-jelrix_en.pdf"},
    {"id":"73975","name":"Withdrawal assessment report for Nugalviq","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T13:19:52Z","last_updated_date":"2026-06-04T13:19:52Z","reference_number":"EMA/76889/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-nugalviq_en.pdf"},
    {"id":"74057","name":"Withdrawal assessment report for Pluvicto (VR-0000288073)","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2026-06-11T11:04:45Z","last_updated_date":"2026-06-11T11:04:45Z","reference_number":"EMADOC-1700519818-2327249","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-pluvicto-vr-0000288073_en.pdf"},
    {"id":"74251","name":"Withdrawal assessment report for Dazluma","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2026-06-24T16:24:01Z","last_updated_date":"2026-06-24T16:24:01Z","reference_number":"EMA/280465/2025","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-dazluma_en.pdf"},
    {"id":"74271","name":"Withdrawal assessment report for Blarcamesine Anavex","type":"withdrawal-report","status":"Adopted","consultation_date":"","first_published_date":"2026-06-25T12:00:21Z","last_updated_date":"2026-06-25T12:00:21Z","reference_number":"EMA/CHMP/130428/2026","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-blarcamesine-anavex_en.pdf"},
    {"id":"2479","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - February 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-02-29T01:00:00Z","last_updated_date":"2008-02-29T01:00:00Z","reference_number":"EMEA/106646/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-february-2008_en.pdf"},
    {"id":"2487","name":"Committee for Medicinal Products for Human Use (CHMP) - June 2011 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-07-04T20:38:08Z","last_updated_date":"2011-07-04T20:38:08Z","reference_number":"EMA/CHMP/426905/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-june-2011-plenary-meeting-monthly-report_en.pdf"},
    {"id":"2544","name":"Committee for Medicinal Products for Human Use (CHMP) - November 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-12-01T01:00:00Z","last_updated_date":"2005-12-01T01:00:00Z","reference_number":"General-EMEA/CHMP/364660/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-november-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"2584","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: November 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T15:41:00Z","last_updated_date":"2012-11-16T15:41:00Z","reference_number":"EMA/CAT/724123/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-november-2012-meeting_en.pdf"},
    {"id":"2689","name":"Committee for Advanced Therapies (CAT): November 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-12-01T01:00:00Z","last_updated_date":"2010-12-01T01:00:00Z","reference_number":"EMA/CAT/731404/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-november-2010-meeting-monthly-report_en.pdf"},
    {"id":"2750","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities: 5-7 September 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-09-13T11:17:00Z","last_updated_date":"2012-09-13T11:17:00Z","reference_number":"EMA/528504/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-5-7-september-2012_en.pdf"},
    {"id":"2886","name":"Committee for Medicinal Products for Human Use (CHMP) - April 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-04-29T02:00:00Z","last_updated_date":"2009-04-29T02:00:00Z","reference_number":"EMEA/CHMP/271292/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-april-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"2904","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the July 2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-07-11T02:09:21Z","last_updated_date":"2008-07-11T02:09:21Z","reference_number":"EMEA/COMP/363132/08","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-july-2008-meeting_en.pdf"},
    {"id":"3020","name":"Committee for Medicinal Products for Human Use (CHMP) - November 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-12-03T01:00:00Z","last_updated_date":"2003-12-03T01:00:00Z","reference_number":"EMEA/CPMP/5728/03/Rev 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-november-2003-plenary-meeting-monthly-report_en.pdf"},
    {"id":"3162","name":"Committee for Medicinal Products for Human Use (CHMP) - December 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-12-23T01:00:00Z","last_updated_date":"2003-12-23T01:00:00Z","reference_number":"EMEA/CPMP/6016/03","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-december-2003-plenary-meeting-monthly-report_en.pdf"},
    {"id":"3166","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 17-19 June 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-07-01T12:50:00Z","last_updated_date":"2015-07-01T12:50:00Z","reference_number":"EMA/411248/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-17-19-june-2015_en.pdf"},
    {"id":"3167","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 16-17 September 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-10-10T16:40:00Z","last_updated_date":"2013-10-10T16:40:00Z","reference_number":"EMA/HMPC/587804/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-16-17-september-2013_en.pdf"},
    {"id":"3180","name":"Committee for Medicinal Products for Human Use (CHMP) - November 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-11-27T00:00:00Z","last_updated_date":"2008-11-27T00:00:00Z","reference_number":"EMEA/612074/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-november-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"3212","name":"COMP meeting report on the review of applications for orphan designation: July 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-07-31T16:11:00Z","last_updated_date":"2018-07-31T16:11:00Z","reference_number":"EMA/COMP/462312/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-july-2018_en.pdf"},
    {"id":"3281","name":"Committee for Medicinal Products for Human Use (CHMP) - February 2011 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-02-25T01:00:00Z","last_updated_date":"2011-02-25T01:00:00Z","reference_number":"EMA/CHMP/14522/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-february-2011-plenary-meeting-monthly-report_en.pdf"},
    {"id":"3290","name":"Committee for Medicinal Products for Human Use (CHMP) - January 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-01-30T01:00:00Z","last_updated_date":"2003-01-30T01:00:00Z","reference_number":"EMEA/CPMP/209/03","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-january-2003-plenary-meeting-monthly-report_en.pdf"},
    {"id":"3381","name":"PDCO meeting report 7-9 September 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-09-16T11:21:00Z","last_updated_date":"2011-09-16T11:21:00Z","reference_number":"EMA/PDCO/725936/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-7-9-september-2011_en.pdf"},
    {"id":"3385","name":"Committee for proprietary medicinal products December 2001 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2001-12-19T01:00:00Z","last_updated_date":"2001-12-19T01:00:00Z","reference_number":"CPMP/3926/01","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-december-2001-plenary-meeting-monthly-report_en.pdf"},
    {"id":"3398","name":"COMP meeting report on the review of applications for orphan designation: July 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-07-27T11:33:00Z","last_updated_date":"2017-07-27T11:33:00Z","reference_number":"EMA/COMP/406092/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-july-2017_en.pdf"},
    {"id":"3434","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: April 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-05-31T12:30:00Z","last_updated_date":"2018-05-31T12:30:00Z","reference_number":"EMA/278339/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-april-2018_en.pdf"},
    {"id":"3577","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - July 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-08-03T02:00:00Z","last_updated_date":"2010-08-03T02:00:00Z","reference_number":"EMA/CVMP/450079/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-july-2010_en.pdf"},
    {"id":"3586","name":"COMP meeting report on the review of applications for orphan designation: December 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-01-13T15:15:00Z","last_updated_date":"2014-01-13T15:15:00Z","reference_number":"EMA/COMP/699713/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2013_en.pdf"},
    {"id":"3620","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - October 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-11-08T12:18:00Z","last_updated_date":"2011-11-08T12:18:00Z","reference_number":"EMA/CVMP/832227/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-october-2011_en.pdf"},
    {"id":"3658","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 12-14 February 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T16:50:00Z","last_updated_date":"2014-02-21T16:50:00Z","reference_number":"EMA/PDCO/60726/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-12-14-february-2014_en.pdf"},
    {"id":"3737","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: July 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-07-31T17:45:00Z","last_updated_date":"2013-07-31T17:45:00Z","reference_number":"EMA/CAT/453488/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-july-2013-meeting_en.pdf"},
    {"id":"3937","name":"Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation - March 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-03-19T12:00:00Z","last_updated_date":"2012-03-19T12:00:00Z","reference_number":"EMA/COMP/130447/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-meeting-report-review-applications-orphan-designation-march-2012_en.pdf"},
    {"id":"4072","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - September 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-09-30T02:00:00Z","last_updated_date":"2005-09-30T02:00:00Z","reference_number":"EMEA/324405/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-september-2005_en.pdf"},
    {"id":"4078","name":"Committee for Medicinal Products for Human Use (CHMP) - June 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-07-03T02:00:00Z","last_updated_date":"2009-07-03T02:00:00Z","reference_number":"EMEA/CHMP/389326/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-june-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"4131","name":"COMP meeting report on the review of applications for orphan designation: November 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-11-14T15:35:00Z","last_updated_date":"2016-11-14T15:35:00Z","reference_number":"EMA/COMP/676785/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-november-2016_en.pdf"},
    {"id":"4300","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 14-15 July 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-08-05T02:00:00Z","last_updated_date":"2010-08-05T02:00:00Z","reference_number":"EMA/HMPC/468796/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-14-15-july-2010_en.pdf"},
    {"id":"4436","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - October 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-10-31T01:00:00Z","last_updated_date":"2008-10-31T01:00:00Z","reference_number":"EMEA/625759/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-october-2008_en.pdf"},
    {"id":"4488","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 29-30 January 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-02-19T14:40:00Z","last_updated_date":"2018-03-02T15:32:00Z","reference_number":"EMA/HMPC/74171/2018 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-29-30-january-2018_en.pdf"},
    {"id":"4621","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: February 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-03-26T12:53:00Z","last_updated_date":"2018-03-26T12:53:00Z","reference_number":"EMA/51903/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-february-2018_en.pdf"},
    {"id":"4640","name":"Committee on herbal medicinal products (HMPC): Meeting report, 7-8 March 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-04-02T02:00:00Z","last_updated_date":"2007-04-02T02:00:00Z","reference_number":"EMEA/HMPC/138217/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-7-8-march-2007_en.pdf"},
    {"id":"4656","name":"COMP meeting report on the review of applications for orphan designation: June 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T14:00:00Z","last_updated_date":"2013-06-20T14:00:00Z","reference_number":"EMA/COMP/318718/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-june-2013_en.pdf"},
    {"id":"4749","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - June 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-06-30T02:00:00Z","last_updated_date":"2008-06-30T02:00:00Z","reference_number":"EMEA/346149/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-june-2008_en.pdf"},
    {"id":"4751","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 22-24 June 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-07-04T16:05:00Z","last_updated_date":"2016-07-04T16:05:00Z","reference_number":"EMA/PDCO/448103/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-22-24-june-2016_en.pdf"},
    {"id":"4928","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 7-10 November 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-11-30T13:20:00Z","last_updated_date":"2017-11-30T13:20:00Z","reference_number":"EMEA/PDCO/754430/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-7-10-november-2017_en.pdf"},
    {"id":"4930","name":"Committee for Medicinal Products for Human Use (CHMP) - April 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-05-12T02:00:00Z","last_updated_date":"2006-05-12T02:00:00Z","reference_number":"EMEA/CHMP/111495/2006, Rev 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-april-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"4940","name":"Committee for Medicinal Products for Human Use (CHMP) - January 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-01-28T00:09:21Z","last_updated_date":"2010-01-28T00:09:21Z","reference_number":"EMA/CHMP/35712/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-january-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"4947","name":"PDCO meeting highlights 9-11 June 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/PDCO/360361/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-9-11-june-2010_en.pdf"},
    {"id":"5014","name":"Committee for proprietary medicinal products May 2001 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2001-06-07T02:00:00Z","last_updated_date":"2001-06-07T02:00:00Z","reference_number":"CPMP/1577/01 corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-may-2001-plenary-meeting-monthly-report_en.pdf"},
    {"id":"5029","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - May 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/CVMP/37837/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-may-2011_en.pdf"}    {"id":"5074","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: June 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-07-13T13:56:00Z","last_updated_date":"2017-07-13T13:56:00Z","reference_number":"EMA/CAT/394234/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-june-2017_en.pdf"},
    {"id":"5181","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the June 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-06-15T02:00:00Z","last_updated_date":"2011-06-15T02:00:00Z","reference_number":"EMA/COMP/399950/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-june-2011-meeting_en.pdf"},
    {"id":"5342","name":"PDCO meeting highlights 27-29 August 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/PDCO/458218/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-27-29-august-2008_en.pdf"},
    {"id":"5372","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: April 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T17:20:00Z","last_updated_date":"2017-05-18T17:20:00Z","reference_number":"EMA/251577/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-april-2017_en.pdf"},
    {"id":"5544","name":"COMP meeting report on the review of applications for orphan designation: January 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T16:45:00Z","last_updated_date":"2013-01-11T16:45:00Z","reference_number":"EMA/COMP/797126/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2013_en.pdf"},
    {"id":"5556","name":"Committee for Medicinal Products for Human Use (CHMP) - January 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-02-05T01:00:00Z","last_updated_date":"2008-02-05T01:00:00Z","reference_number":"EMEA/37124/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-january-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"5586","name":"COMP meeting report on the review of applications for orphan designation: December 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-12-12T19:00:00Z","last_updated_date":"2017-12-12T19:00:00Z","reference_number":"EMA/COMP/790607/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2017_en.pdf"},
    {"id":"5775","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 17-19 July 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-07-29T16:00:00Z","last_updated_date":"2013-07-29T16:00:00Z","reference_number":"EMA/435730/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-17-19-july-2013_en.pdf"},
    {"id":"5940","name":"PDCO meeting highlights 15-17 October 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-10-24T02:00:00Z","last_updated_date":"2008-10-24T02:00:00Z","reference_number":"EMEA/PDCO/552811/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-15-17-october-2008_en.pdf"},
    {"id":"5958","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the June 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-06-08T02:00:00Z","last_updated_date":"2010-06-24T02:00:00Z","reference_number":"EMA/COMP/342322/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-june-2010-meeting_en.pdf"},
    {"id":"5963","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - January 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-01-31T01:00:00Z","last_updated_date":"2008-01-31T01:00:00Z","reference_number":"EMEA/59971/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-january-2008_en.pdf"},
    {"id":"5992","name":"Committee for Medicinal Products for Human Use (CHMP) - December 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-12-21T00:00:00Z","last_updated_date":"2007-12-21T00:00:00Z","reference_number":"EMEA/CHMP/585637/07","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-december-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"6269","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - February 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-02-28T00:00:00Z","last_updated_date":"2005-02-28T00:00:00Z","reference_number":"EMEA/CVMP/53816/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-february-2005_en.pdf"},
    {"id":"6385","name":"COMP meeting report on the review of applications for orphan designation: November 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T15:50:00Z","last_updated_date":"2014-11-21T15:50:00Z","reference_number":"EMA/COMP/641491/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-november-2014_en.pdf"},
    {"id":"6400","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: January 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T11:26:00Z","last_updated_date":"2017-02-10T11:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-january-2017_en.pdf"},
    {"id":"6430","name":"Committee for Medicinal Products for Human Use (CHMP) - July 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-08-04T02:00:00Z","last_updated_date":"2006-08-04T02:00:00Z","reference_number":"EMEA/296185/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-july-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"6557","name":"Committee on herbal medicinal products (HMPC): Meeting report, 27-28 January 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-03-18T00:00:00Z","last_updated_date":"2005-03-18T00:00:00Z","reference_number":"EMEA/HMPC/83845/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-27-28-january-2005_en.pdf"},
    {"id":"6592","name":"PDCO meeting highlights 28-30 April 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-05-05T02:00:00Z","last_updated_date":"2009-05-05T02:00:00Z","reference_number":"EMEA/PDCO/259461/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-28-30-april-2009_en.pdf"},
    {"id":"6595","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: June 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-07-10T13:10:00Z","last_updated_date":"2014-07-10T13:10:00Z","reference_number":"EMA/346545/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-june-2014_en.pdf"},
    {"id":"6625","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 20-23 June 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-07-13T13:40:00Z","last_updated_date":"2017-07-13T13:40:00Z","reference_number":"EMA/PDCO/400324/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-20-23-june-2017_en.pdf"},
    {"id":"6718","name":"Committee for proprietary medicinal products September 2001 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2001-09-25T02:00:00Z","last_updated_date":"2001-09-25T02:00:00Z","reference_number":"CPMP/2936/01","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-september-2001-plenary-meeting-monthly-report_en.pdf"},
    {"id":"6898","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: May 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T15:00:00Z","last_updated_date":"2013-05-31T15:00:00Z","reference_number":"EMA/CAT/323934/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-may-2013-meeting_en.pdf"},
    {"id":"6912","name":"Committee for proprietary medicinal products November 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2002-11-28T01:00:00Z","last_updated_date":"2002-11-28T01:00:00Z","reference_number":"EMEA/CPMP/5857/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-november-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"6962","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the September 2009 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-09-11T02:09:21Z","last_updated_date":"2009-09-11T02:09:21Z","reference_number":"EMEA/COMP/506723/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-september-2009-meeting_en.pdf"},
    {"id":"7038","name":"Committee on herbal medicinal products (HMPC): Meeting report, 14-15 January 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-02-05T00:00:00Z","last_updated_date":"2009-02-05T00:00:00Z","reference_number":"EMEA/HMPC/44177/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-14-15-january-2009_en.pdf"},
    {"id":"7047","name":"PDCO monthly report of opinions on paediatric investigation plans: 7-9 March 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-03-15T16:38:00Z","last_updated_date":"2012-03-15T16:38:00Z","reference_number":"EMA/PDCO/162635/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-7-9-march-2012_en.pdf"},
    {"id":"7053","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - November 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-12-06T14:25:00Z","last_updated_date":"2011-12-06T14:25:00Z","reference_number":"EMA/CVMP/899128/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-november-2011_en.pdf"},
    {"id":"7189","name":"COMP meeting report on the review of applications for orphan designation: February 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-02-13T11:00:00Z","last_updated_date":"2013-02-13T11:00:00Z","reference_number":"EMA/COMP/63660/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-february-2013_en.pdf"},
    {"id":"7240","name":"Committee for Medicinal Products for Human Use (CHMP) - March 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-04-01T02:00:00Z","last_updated_date":"2005-04-01T02:00:00Z","reference_number":"EMEA/CHMP/82984/2005 corr 2","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-march-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"7255","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 21-22 November 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-12-09T15:55:00Z","last_updated_date":"2011-12-09T15:55:00Z","reference_number":"EMA/HMPC/932075/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-21-22-november-2011_en.pdf"},
    {"id":"7264","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 13-16 December 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-01-19T10:30:00Z","last_updated_date":"2017-01-19T10:30:00Z","reference_number":"EMA/PDCO/853813/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-13-16-december-2016_en.pdf"},
    {"id":"7265","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: June 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-07-04T12:05:00Z","last_updated_date":"2013-07-04T12:05:00Z","reference_number":"EMA/CAT/323934/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-june-2013-meeting_en.pdf"},
    {"id":"7294","name":"COMP meeting report on the review of applications for orphan designation: December 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T17:30:00Z","last_updated_date":"2015-12-14T17:30:00Z","reference_number":"EMA/COMP/782305/2015 corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2015_en.pdf"},
    {"id":"7311","name":"PDCO meeting highlights 13-15 February 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-03-27T00:00:00Z","last_updated_date":"2008-03-27T00:00:00Z","reference_number":"EMEA/PDCO/83264/2008-corr.2","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-13-15-february-2008_en.pdf"},
    {"id":"7333","name":"Committee for proprietary medicinal products October 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2002-10-24T02:00:00Z","last_updated_date":"2002-10-24T02:00:00Z","reference_number":"EMEA/CPMP/4979/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-october-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"7345","name":"Committee for Medicinal Products for Human Use (CHMP) - 1-3 June 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-06-11T02:00:00Z","last_updated_date":"2004-06-11T02:00:00Z","reference_number":"EMEA/CHMP/409/04","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-1-3-june-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"7414","name":"PDCO meeting highlights 16-18 January 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-01-25T00:00:00Z","last_updated_date":"2008-01-25T00:00:00Z","reference_number":"EMEA/PDCO/33961/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-16-18-january-2008_en.pdf"},
    {"id":"7450","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: May 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-06-02T16:15:00Z","last_updated_date":"2014-06-02T16:15:00Z","reference_number":"EMA/CAT/312972/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-may-2014-meeting_en.pdf"},
    {"id":"7483","name":"Committee on herbal medicinal products (HMPC): Meeting report, 11 January 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-02-06T00:00:00Z","last_updated_date":"2007-02-06T00:00:00Z","reference_number":"EMEA/HMPC/45867/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-11-january-2007_en.pdf"},
    {"id":"7510","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-03-08T11:45:00Z","last_updated_date":"2018-03-08T11:45:00Z","reference_number":"EMA/113149/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-february-2018_en.pdf"},
    {"id":"7557","name":"COMP meeting report on the review of applications for orphan designation: November 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T10:45:00Z","last_updated_date":"2013-11-18T10:10:00Z","reference_number":"EMA/COMP/609737/2013 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-november-2013_en.pdf"},
    {"id":"7629","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the May 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-05-17T02:00:00Z","last_updated_date":"2010-06-11T02:00:00Z","reference_number":"EMA/COMP/270496/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-may-2010-meeting_en.pdf"},
    {"id":"7664","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 19-21 March 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T11:30:00Z","last_updated_date":"2014-03-26T11:30:00Z","reference_number":"EMA/PDCO/130096/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-19-21-march-2014_en.pdf"},
    {"id":"7676","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-03-09T17:25:00Z","last_updated_date":"2015-03-09T17:25:00Z","reference_number":"EMA/CAT/136408/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-february-2015-meeting_en.pdf"},
    {"id":"7832","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - March 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-03-19T16:30:00Z","last_updated_date":"2012-03-19T16:30:00Z","reference_number":"EMA/185313/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-march-2012_en.pdf"},
    {"id":"7839","name":"Committee on herbal medicinal products (HMPC): Meeting report, 25-26 October 2006","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-11-15T01:00:00Z","last_updated_date":"2006-11-15T01:00:00Z","reference_number":"EMEA/HMPC/450200/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-25-26-october-2006_en.pdf"},
    {"id":"7876","name":"Committee for Medicinal Products for Human Use (CHMP) - January 2011 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-01-31T01:00:00Z","last_updated_date":"2011-01-31T01:00:00Z","reference_number":"EMA/CHMP/55372/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-january-2011-plenary-meeting-monthly-report_en.pdf"},
    {"id":"7988","name":"Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation: May 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-05-22T19:01:03Z","last_updated_date":"2012-05-22T19:01:03Z","reference_number":"EMA/COMP/278126/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-meeting-report-review-applications-orphan-designation-may-2012_en.pdf"},
    {"id":"8014","name":"Committee for Medicinal Products for Human Use (CHMP) - September 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-09-28T02:00:00Z","last_updated_date":"2004-09-28T02:00:00Z","reference_number":"EMEA/CHMP/269/2004","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-september-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"8016","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 26-27 March 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-04-10T17:40:00Z","last_updated_date":"2018-04-10T17:40:00Z","reference_number":"EMA/HMPC/213739/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-26-27-march-2018_en.pdf"},
    {"id":"8054","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 14-15 January 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-02-07T11:06:00Z","last_updated_date":"2013-02-07T11:06:00Z","reference_number":"EMA/HMPC/44844/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-14-15-january-2013_en.pdf"},
    {"id":"8084","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 9-11 December 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-12-21T11:15:00Z","last_updated_date":"2015-12-21T11:15:00Z","reference_number":"EMA/PDCO/789214/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-9-11-december-2015_en.pdf"},
    {"id":"8154","name":"Committee for Medicinal Products for Human Use (CHMP) - February 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-03-02T01:00:00Z","last_updated_date":"2007-03-02T01:00:00Z","reference_number":"EMEA/85096/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-february-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"8166","name":"COMP meeting report on the review of applications for orphan designation: January 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T01:00:00Z","last_updated_date":"2017-02-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2017_en.pdf"},
    {"id":"8177","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: February 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-03-20T15:00:00Z","last_updated_date":"2015-03-20T15:00:00Z","reference_number":"EMA/128095/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-february-2015_en.pdf"},
    {"id":"8299","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: December 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T18:00:00Z","last_updated_date":"2012-12-14T18:00:00Z","reference_number":"EMA/CAT/798213/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-december-2012-meeting_en.pdf"},
    {"id":"8300","name":"COMP meeting report on the review of applications for orphan designation: January 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-02-05T15:50:00Z","last_updated_date":"2018-02-05T15:50:00Z","reference_number":"EMA/COMP/831897/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2018_en.pdf"},
    {"id":"8329","name":"Committee for Medicinal Products for Human Use (CHMP) -  September 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-09-29T02:00:00Z","last_updated_date":"2006-09-29T02:00:00Z","reference_number":"EMEA/325128/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-september-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"8425","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: July 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-08-17T11:40:00Z","last_updated_date":"2018-08-17T11:40:00Z","reference_number":"EMA/497556/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-july-2018_en.pdf"},
    {"id":"8499","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - April 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-04-30T02:00:00Z","last_updated_date":"2008-04-30T02:00:00Z","reference_number":"EMEA/241937/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-april-2008_en.pdf"},
    {"id":"8512","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 7-9 November 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-11-15T12:03:00Z","last_updated_date":"2012-11-15T12:03:00Z","reference_number":"EMA/PDCO/664206/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-7-9-november-2012_en.pdf"},
    {"id":"8542","name":"PDCO meeting highlights 1-2 August 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-08-06T02:00:00Z","last_updated_date":"2007-08-06T02:00:00Z","reference_number":"EMEA/354317/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-1-2-august-2007_en.pdf"},
    {"id":"8566","name":"Committee on herbal medicinal products (HMPC): Meeting report, 5-6 March 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-03-27T00:00:00Z","last_updated_date":"2008-03-27T00:00:00Z","reference_number":"EMEA/HMPC/144374/200","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-5-6-march-2008_en.pdf"},
    {"id":"8648","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: June 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-07-17T11:00:00Z","last_updated_date":"2014-07-17T11:00:00Z","reference_number":"EMA/CAT/375230/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-june-2014-meeting_en.pdf"},
    {"id":"8731","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 12-14 October 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T11:55:00Z","last_updated_date":"2016-11-07T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-12-14-october-2016_en.pdf"},
    {"id":"8752","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: September 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-10-13T19:00:00Z","last_updated_date":"2014-10-13T19:00:00Z","reference_number":"EMA/484743/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-september-2014_en.pdf"},
    {"id":"8857","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 8-11 November 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-11-21T17:50:00Z","last_updated_date":"2016-11-21T17:50:00Z","reference_number":"EMA/PDCO/102084/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-8-11-november-2016_en.pdf"},
    {"id":"8935","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 5-6 May 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/HMPC/291747/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-5-6-may-2010_en.pdf"},
    {"id":"9028","name":"Committee for proprietary medicinal products February 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2002-03-01T01:00:00Z","last_updated_date":"2002-03-01T01:00:00Z","reference_number":"CPMP/590/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-february-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"9136","name":"Committee for Medicinal Products for Human Use (CHMP) - October 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-10-25T02:00:00Z","last_updated_date":"2007-10-25T02:00:00Z","reference_number":"EMEA/473066/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-october-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"9217","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the July 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-07-20T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/COMP/399953/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-july-2011-meeting_en.pdf"},
    {"id":"9263","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: May 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-06-09T17:47:00Z","last_updated_date":"2015-06-09T17:47:00Z","reference_number":"EMA/308423/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-may-2015_en.pdf"},
    {"id":"9301","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the May 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-05-06T02:00:00Z","last_updated_date":"2011-05-06T02:00:00Z","reference_number":"EMA/COMP/135191/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-may-2011-meeting_en.pdf"},
    {"id":"9305","name":"Committee for proprietary medicinal products December 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-01-06T01:00:00Z","last_updated_date":"2003-01-06T01:00:00Z","reference_number":"EMEA/CPMP/6248/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-december-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"9367","name":"PDCO meeting highlights 24-26 June 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2009-07-01T02:00:00Z","reference_number":"EMEA/PDCO/386750/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-24-26-june-2009_en.pdf"},
    {"id":"9691","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - November 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-12-01T01:00:00Z","last_updated_date":"2010-12-01T01:00:00Z","reference_number":"EMA/CVMP/649372/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-november-2010_en.pdf"},
    {"id":"9695","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 15–18 August 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-09-05T13:30:00Z","last_updated_date":"2017-09-05T13:30:00Z","reference_number":"EMEA/PDCO/549875/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-15-18-august-2017_en.pdf"},
    {"id":"9752","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: September 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-09-24T17:54:00Z","last_updated_date":"2012-09-24T17:54:00Z","reference_number":"EMA/CAT/608504/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-september-2012-meeting_en.pdf"},
    {"id":"9762","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - May 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-05-31T02:00:00Z","last_updated_date":"2009-05-31T02:00:00Z","reference_number":"EMEA/CVMP/335565/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-may-2009_en.pdf"},
    {"id":"9876","name":"Committee for Advanced Therapies (CAT): September 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-10-04T02:00:00Z","last_updated_date":"2010-10-04T02:00:00Z","reference_number":"EMA/CAT/601590/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-september-2010-meeting-monthly-report_en.pdf"},
    {"id":"9965","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 27-28 March 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-04-10T12:06:17Z","last_updated_date":"2017-04-10T12:06:17Z","reference_number":"EMA/HMPC/224698/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-27-28-march-2017_en.pdf"},
    {"id":"10054","name":"Committee for Medicinal Products for Human Use (CHMP) - December 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T01:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"EMA/CHMP/814037/2010 corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-december-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"10117","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 28-29 September 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-10-12T18:40:00Z","last_updated_date":"2015-10-12T18:40:00Z","reference_number":"EMA/HMPC/657448/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-28-29-september-2015_en.pdf"},
    {"id":"10164","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 20-21 November 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-12-18T13:08:00Z","last_updated_date":"2017-12-18T13:08:00Z","reference_number":"EMA/HMPC/784341/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-20-21-november-2017_en.pdf"},
    {"id":"10426","name":"Committee for Advanced Therapies (CAT): December 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T09:51:00Z","last_updated_date":"2011-12-19T09:51:00Z","reference_number":"EMA/CAT/972719/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-december-2011-meeting-monthly-report_en.pdf"},
    {"id":"10485","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 6-8 November 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T10:02:00Z","last_updated_date":"2013-11-18T10:02:00Z","reference_number":"EMA/PDCO/687508/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-6-8-november-2013_en.pdf"},
    {"id":"10511","name":"Committee on herbal medicinal products (HMPC): Meeting report, 23-24 September 2004","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-10-01T02:00:00Z","last_updated_date":"2004-10-01T02:00:00Z","reference_number":"EMEA/HMPC/86934/2004","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-23-24-september-2004_en.pdf"},
    {"id":"10551","name":"Committee for Medicinal Products for Human Use (CHMP) - May 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-06-07T02:00:00Z","last_updated_date":"2005-06-07T02:00:00Z","reference_number":"EMEA/CHMP/160895/2005, corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-may-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"10692","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 14-16 September 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-10-04T17:20:00Z","last_updated_date":"2016-10-04T17:20:00Z","reference_number":"EMA/PDCO/616910/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-14-16-september-2016_en.pdf"},
    {"id":"10732","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 15-16 September 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/HMPC/592652/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-15-16-september-2010_en.pdf"},
    {"id":"10761","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - April 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T18:05:00Z","last_updated_date":"2012-04-30T18:05:00Z","reference_number":"EMA/262759/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-april-2012_en.pdf"},
    {"id":"10836","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 24 September 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-11-05T15:15:00Z","last_updated_date":"2012-11-05T15:15:00Z","reference_number":"EMA/HMPC/639244/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-24-september-2012_en.pdf"},
    {"id":"10844","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: June 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-07-30T12:36:00Z","last_updated_date":"2018-07-30T12:36:00Z","reference_number":"EMA/443042/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-june-2018_en.pdf"},
    {"id":"10916","name":"COMP meeting report on the review of applications for orphan designation: February 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-02-24T16:30:00Z","last_updated_date":"2016-02-25T17:30:00Z","reference_number":"EMA/COMP/65529/2016 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-february-2016_en.pdf"},
    {"id":"11024","name":"COMP meeting report on the review of applications for orphan designation: October 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-10-13T17:57:00Z","last_updated_date":"2016-10-13T17:57:00Z","reference_number":"EMA/COMP/616664/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-october-2016_en.pdf"},
    {"id":"11028","name":"COMP meeting report on the review of applications for orphan designation: December 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T14:55:00Z","last_updated_date":"2016-12-19T14:55:00Z","reference_number":"EMA/COMP/747832/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2016_en.pdf"},
    {"id":"11100","name":"Committee for Medicinal Products for Human Use (CHMP) - November 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-11-26T01:00:00Z","last_updated_date":"2010-11-26T01:00:00Z","reference_number":"EMA/CHMP/739938/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-november-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"11170","name":"Committee for Medicinal Products for Human Use (CHMP) - May 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-06-05T02:00:00Z","last_updated_date":"2009-06-05T02:00:00Z","reference_number":"EMEA/CHMP/330510/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-may-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"11211","name":"Committee on herbal medicinal products (HMPC): Meeting report, 11-12 March 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-03-31T02:00:00Z","last_updated_date":"2009-03-31T02:00:00Z","reference_number":"EMEA/HMPC/192861/2009 Corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-11-12-march-2009_en.pdf"},
    {"id":"11224","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: July 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-08-10T11:37:00Z","last_updated_date":"2017-08-10T11:37:00Z","reference_number":"EMA/436821/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-july-2017_en.pdf"}    {"id":"11244","name":"Committee for Medicinal Products for Human Use (CHMP) - February 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-03-03T01:00:00Z","last_updated_date":"2008-03-03T01:00:00Z","reference_number":"EMEA/95268/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-february-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"11296","name":"COMP meeting report on the review of applications for orphan designation: February 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-02-20T17:05:00Z","last_updated_date":"2014-02-20T17:05:00Z","reference_number":"EMA/COMP/35549/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-february-2014_en.pdf"},
    {"id":"11331","name":"Committee for medicinal products for human use June 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-07-08T02:00:00Z","last_updated_date":"2005-07-08T02:00:00Z","reference_number":"EMEA/CHMP/207020/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-june-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"11382","name":"Committee for Advanced Therapies (CAT): October 2009 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-11-03T00:09:21Z","last_updated_date":"2009-11-03T00:09:21Z","reference_number":"EMEA/CAT/667758/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-october-2009-meeting-monthly-report_en.pdf"},
    {"id":"11394","name":"PDCO meeting highlights 22-24 July 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-07-31T02:00:00Z","last_updated_date":"2009-07-31T02:00:00Z","reference_number":"EMEA/PDCO/449592/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-22-24-july-2009_en.pdf"},
    {"id":"11447","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 11-12 July 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-07-25T18:20:00Z","last_updated_date":"2016-07-25T18:20:00Z","reference_number":"EMA/HMPC/489336/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-11-12-july-2016_en.pdf"},
    {"id":"11528","name":"PDCO meeting report 10-12 August 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-08-19T02:00:00Z","last_updated_date":"2011-08-19T02:00:00Z","reference_number":"EMA/PDCO/626428/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-10-12-august-2011_en.pdf"},
    {"id":"11583","name":"PDCO meeting highlights 24-26 October 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-10-29T00:00:00Z","last_updated_date":"2007-10-29T00:00:00Z","reference_number":"EMEA/492629/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-24-26-october-2007_en.pdf"},
    {"id":"11588","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 20-22 July 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-08-04T12:35:00Z","last_updated_date":"2016-08-04T12:35:00Z","reference_number":"EMA/PDCO/510975/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-20-22-july-2016_en.pdf"},
    {"id":"11652","name":"COMP meeting report on the review of applications for orphan designation: July 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T12:20:00Z","last_updated_date":"2013-07-19T12:20:00Z","reference_number":"EMA/COMP/378822/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-july-2013_en.pdf"},
    {"id":"11693","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 4-5 May 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T11:51:00Z","last_updated_date":"2015-05-22T16:00:00Z","reference_number":"EMA/HMPC/315739/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-4-5-may-2015_en.pdf"},
    {"id":"11767","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: July 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-08-17T17:10:00Z","last_updated_date":"2016-08-17T17:10:00Z","reference_number":"EMA/499630/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-july-2016_en.pdf"},
    {"id":"11809","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 30-31 March 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-05-04T02:00:00Z","last_updated_date":"2011-05-04T02:00:00Z","reference_number":"EMA/HMPC/288516/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-30-31-march-2011_en.pdf"},
    {"id":"11871","name":"Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation: June 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-06-18T19:29:43Z","last_updated_date":"2012-06-18T19:29:43Z","reference_number":"EMA/COMP/343137/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-meeting-report-review-applications-orphan-designation-june-2012_en.pdf"},
    {"id":"11890","name":"PDCO meeting highlights 7-9 January 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-01-16T00:00:00Z","last_updated_date":"2009-01-16T00:00:00Z","reference_number":"EMEA/20576/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-7-9-january-2009_en.pdf"},
    {"id":"11922","name":"COMP meeting report on the review of applications for orphan designation: December 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"EMA/COMP/731762/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2012_en.pdf"},
    {"id":"12010","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 18-21 April 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-05-04T18:24:00Z","last_updated_date":"2017-05-04T18:24:00Z","reference_number":"EMA/PDCO/261272/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-18-21-april-2017_en.pdf"},
    {"id":"12059","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: May 2016 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T18:00:00Z","last_updated_date":"2016-05-27T18:00:00Z","reference_number":"EMA/CAT/358066/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-may-2016-meeting_en.pdf"},
    {"id":"12080","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: July 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-08-07T18:20:00Z","last_updated_date":"2014-08-08T11:30:00Z","reference_number":"EMA/418545/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-july-2014_en.pdf"},
    {"id":"12118","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 24-27 July 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-08-10T19:30:00Z","last_updated_date":"2018-08-10T19:30:00Z","reference_number":"EMA/PDCO/530202/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-24-27-july-2018_en.pdf"},
    {"id":"12139","name":"Committee for Advanced Therapies (CAT) monthly report of application procedures, guidelines and related documents on advanced therapies: March 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-03-19T16:40:00Z","last_updated_date":"2012-03-19T16:40:00Z","reference_number":"EMA/CAT/180791/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-march-2012-meeting_en.pdf"},
    {"id":"12142","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the April 2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-04-11T02:09:21Z","last_updated_date":"2008-04-11T02:09:21Z","reference_number":"EMEA/COMP/184029/08","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-april-2008-meeting_en.pdf"},
    {"id":"12201","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - January 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-01-31T00:00:00Z","last_updated_date":"2009-01-31T00:00:00Z","reference_number":"EMEA/85080/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-january-2009_en.pdf"},
    {"id":"12269","name":"Committee on herbal medicinal products (HMPC): Meeting report, 31 May-1 June 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-07-15T02:00:00Z","last_updated_date":"2005-07-15T02:00:00Z","reference_number":"EMEA/HMPC/228713/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-31-may-1-june-2005_en.pdf"},
    {"id":"12280","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 12-13 September 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-09-28T12:00:00Z","last_updated_date":"2011-09-28T12:00:00Z","reference_number":"EMA/HMPC/767990/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-12-13-september-2011_en.pdf"},
    {"id":"12281","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the December 2009 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-12-17T00:09:21Z","last_updated_date":"2009-12-17T00:09:21Z","reference_number":"EMA/COMP/718385/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-december-2009-meeting_en.pdf"},
    {"id":"12286","name":"Committee on herbal medicinal products (HMPC): Meeting report, 11-12 May 2006","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-06-13T02:00:00Z","last_updated_date":"2006-06-13T02:00:00Z","reference_number":"EMEA/HMPC/183469/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-11-12-may-2006_en.pdf"},
    {"id":"12343","name":"Committee for Advanced Therapies (CAT): July 2009 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-07-22T02:00:00Z","last_updated_date":"2009-07-22T02:00:00Z","reference_number":"EMEA/CAT/442707/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-july-2009-meeting-monthly-report_en.pdf"},
    {"id":"12364","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the October 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-10-12T02:00:00Z","last_updated_date":"2010-10-12T02:00:00Z","reference_number":"EMA/COMP/586816/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-october-2010-meeting_en.pdf"},
    {"id":"12368","name":"PDCO meeting highlights 26-28 September 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-10-01T02:00:00Z","last_updated_date":"2007-10-01T02:00:00Z","reference_number":"EMEA/440694/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-26-28-september-2007_en.pdf"},
    {"id":"12394","name":"Committee for Medicinal Products for Human Use (CHMP) - July 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-10-18T02:00:00Z","last_updated_date":"2004-10-18T02:00:00Z","reference_number":"EMEA/CHMP/1214/04","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-july-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"12495","name":"Committee for Medicinal Products for Human Use (CHMP) -  December 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-12-20T01:00:00Z","last_updated_date":"2006-12-20T01:00:00Z","reference_number":"EMEA/488156/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-december-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"12530","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the September 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-09-20T11:41:22Z","last_updated_date":"2010-09-20T11:41:22Z","reference_number":"EMA/COMP/383921/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-september-2010-meeting_en.pdf"},
    {"id":"12557","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: October 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-11-12T16:50:00Z","last_updated_date":"2015-11-12T16:50:00Z","reference_number":"EMA/666595/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-october-2015_en.pdf"},
    {"id":"12573","name":"COMP meeting report on the review of applications for orphan designation: December 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-12-17T15:30:00Z","last_updated_date":"2014-12-17T15:30:00Z","reference_number":"EMA/COMP/737192/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2014_en.pdf"},
    {"id":"12627","name":"Committee for Advanced Therapies (CAT): December 2009 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-12-18T01:00:00Z","last_updated_date":"2009-12-18T01:00:00Z","reference_number":"EMA/CAT'/803850/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-december-2009-meeting-monthly-report_en.pdf"},
    {"id":"12649","name":"COMP meeting report on the review of applications for orphan designation: July 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T18:00:00Z","last_updated_date":"2016-07-22T18:00:00Z","reference_number":"EMA/COMP/451206/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-july-2016_en.pdf"},
    {"id":"12713","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 16-19 May 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-06-08T16:15:00Z","last_updated_date":"2017-06-08T16:15:00Z","reference_number":"EMA/PDCO/308316/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-16-19-may-2017_en.pdf"},
    {"id":"12807","name":"CVMP monthly report of application procedures, guidelines and related documents: July 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-08-08T14:45:00Z","last_updated_date":"2013-08-08T14:45:00Z","reference_number":"EMA/433049/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-july-2013_en.pdf"},
    {"id":"12835","name":"Committee for Advanced Therapies (CAT): May 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"EMA/CAT/322959/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-may-2010-meeting-monthly-report_en.pdf"},
    {"id":"12864","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 9-11 September 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-09-23T11:10:00Z","last_updated_date":"2015-09-23T11:10:00Z","reference_number":"EMA/PDCO/595590/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-9-11-september-2015_en.pdf"},
    {"id":"12877","name":"Committee for Medicinal Products for Human Use (CHMP) - April 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-04-30T02:00:00Z","last_updated_date":"2010-05-06T02:00:00Z","reference_number":"EMA/CHMP/256110/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-april-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"12886","name":"COMP meeting report on the review of applications for orphan designation: June 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T18:00:00Z","last_updated_date":"2018-07-05T18:00:00Z","reference_number":"EMA/COMP/396617/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-june-2018_en.pdf"},
    {"id":"12895","name":"CVMP monthly report of application procedures, guidelines and related documents: September 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T15:07:00Z","last_updated_date":"2013-10-17T15:07:00Z","reference_number":"EMA/587321/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-september-2013_en.pdf"},
    {"id":"12907","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 24-25 March 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-04-08T16:00:00Z","last_updated_date":"2014-04-08T16:00:00Z","reference_number":"EMA/HMPC/171245/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-24-25-march-2014_en.pdf"},
    {"id":"12959","name":"Committee for Medicinal Products for Human Use (CHMP) - February 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-03-04T01:00:00Z","last_updated_date":"2004-03-04T01:00:00Z","reference_number":"EMEA/CPMP/537/04","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-february-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"13030","name":"PDCO meeting highlights 11-13 November 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-11-20T00:09:21Z","last_updated_date":"2009-11-25T00:00:00Z","reference_number":"EMEA/PDCO/716413/2009 Corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-11-13-november-2009_en.pdf"},
    {"id":"13033","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: March 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-03-24T14:55:00Z","last_updated_date":"2014-03-24T14:55:00Z","reference_number":"EMA/CAT/161687/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-march-2014-meeting_en.pdf"},
    {"id":"13114","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 26-27 March 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-04-27T12:00:01Z","last_updated_date":"2012-04-27T12:00:01Z","reference_number":"EMA/HMPC/236765/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-26-27-march-2012_en.pdf"},
    {"id":"13272","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: June 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-07-12T16:00:00Z","last_updated_date":"2017-07-12T16:00:00Z","reference_number":"EMA/412075/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-june-2017_en.pdf"},
    {"id":"13325","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the January 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-01-11T01:00:00Z","last_updated_date":"2010-01-11T01:00:00Z","reference_number":"EMA/COMP/1358/12010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-january-2010-meeting_en.pdf"},
    {"id":"13343","name":"Committee for Medicinal Products for Human Use (CHMP) - January 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-01-29T01:00:00Z","last_updated_date":"2004-01-29T01:00:00Z","reference_number":"EMEA/CPMP/269/04","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-january-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"13441","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 10 May 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-06-07T02:00:00Z","last_updated_date":"2011-06-07T02:00:00Z","reference_number":"EMA/HMPC/288516/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-10-may-2011_en.pdf"},
    {"id":"13505","name":"Committee for Advanced Therapies (CAT): June 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-07-06T02:00:00Z","last_updated_date":"2011-07-06T02:00:00Z","reference_number":"EMA/CAT/499702/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-june-2011-meeting-monthly-report_en.pdf"},
    {"id":"13564","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - December 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-12-23T00:31:00Z","last_updated_date":"2010-12-23T00:31:00Z","reference_number":"EMA/CVMP/649372/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-december-2010_en.pdf"},
    {"id":"13614","name":"Committee for Medicinal Products for Human Use (CHMP) - January 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"EMEA/521168/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-january-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"13625","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - April 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-04-30T02:00:00Z","last_updated_date":"2009-04-30T02:00:00Z","reference_number":"EMEA/284966/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-april-2009_en.pdf"},
    {"id":"13680","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2016 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-03-02T13:00:00Z","last_updated_date":"2016-03-02T13:00:00Z","reference_number":"EMA/158306/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-february-2016-meeting_en.pdf"},
    {"id":"13829","name":"COMP meeting report on the review of applications for orphan designation: February 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-03-04T13:50:00Z","last_updated_date":"2015-03-04T13:50:00Z","reference_number":"EMA/COMP/38966/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-february-2015_en.pdf"},
    {"id":"13847","name":"COMP meeting report on the review of applications for orphan designation: September 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-09-13T13:55:00Z","last_updated_date":"2012-09-13T13:55:00Z","reference_number":"EMA/COMP/548701/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2012_en.pdf"},
    {"id":"13894","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 24-27 January 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-02-08T12:30:00Z","last_updated_date":"2017-02-08T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-24-27-january-2017_en.pdf"},
    {"id":"14014","name":"COMP meeting report on the review of applications for orphan designation: September 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-09-25T13:45:00Z","last_updated_date":"2017-09-25T13:45:00Z","reference_number":"EMA/COMP/462552/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2017_en.pdf"},
    {"id":"14114","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 21-23 May 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-06-03T15:50:00Z","last_updated_date":"2014-06-03T15:50:00Z","reference_number":"EMA/PDCO/311173/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-21-23-may-2014_en.pdf"},
    {"id":"14165","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: December 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-01-05T10:00:00Z","last_updated_date":"2017-01-05T10:00:00Z","reference_number":"EMA/CAT/863030/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-december-2016_en.pdf"},
    {"id":"14193","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - June 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-06-30T02:00:00Z","last_updated_date":"2007-06-30T02:00:00Z","reference_number":"EMEA/292674/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-june-2007_en.pdf"},
    {"id":"14244","name":"Committee for Advanced Therapies (CAT): November 2009 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-11-24T00:09:21Z","last_updated_date":"2009-11-24T00:09:21Z","reference_number":"EMEA/CAT/756774/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-november-2009-meeting-monthly-report_en.pdf"},
    {"id":"14322","name":"Committee for Medicinal Products for Human Use (CHMP) - April 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-05-03T02:00:00Z","last_updated_date":"2005-05-03T02:00:00Z","reference_number":"EMEA/CHMP/121307/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-april-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"14535","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: September 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T19:15:00Z","last_updated_date":"2017-10-23T19:15:00Z","reference_number":"EMA/516191/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-september-2017_en.pdf"},
    {"id":"14548","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: June 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T16:32:00Z","last_updated_date":"2015-06-26T16:32:00Z","reference_number":"EMA/CAT/428422/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-june-2015-meeting_en.pdf"},
    {"id":"14592","name":"Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation: July 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-07-17T12:05:00Z","last_updated_date":"2012-07-17T12:05:00Z","reference_number":"EMA/COMP/428415/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-meeting-report-review-applications-orphan-designation-july-2012_en.pdf"},
    {"id":"14613","name":"Committee for Advanced Therapies (CAT): June 2009 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-06-26T02:00:00Z","last_updated_date":"2009-06-26T02:00:00Z","reference_number":"EMEA/CAT/394179/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-june-2009-meeting-monthly-report_en.pdf"},
    {"id":"14620","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - February 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-02-28T00:00:00Z","last_updated_date":"2009-02-28T00:00:00Z","reference_number":"EMEA/131690/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-february-2009_en.pdf"},
    {"id":"14622","name":"Committee for Medicinal Products for Human Use (CHMP) - December 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-01-07T01:00:00Z","last_updated_date":"2010-01-13T00:00:00Z","reference_number":"EMA/CHMP/834035/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-december-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"14637","name":"Committee for Medicinal Products for Human Use (CHMP) - March 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-03-27T01:00:00Z","last_updated_date":"2009-03-27T01:00:00Z","reference_number":"EMEA/174243/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-march-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"14649","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - December 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-12-22T12:55:00Z","last_updated_date":"2011-12-22T12:55:00Z","reference_number":"EMA/973338/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-december-2011_en.pdf"},
    {"id":"14787","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the November 2007 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-11-08T00:09:21Z","last_updated_date":"2007-11-08T00:09:21Z","reference_number":"EMEA/COMP/521471/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-november-2007-meeting_en.pdf"},
    {"id":"14792","name":"Committee for Medicinal Products for Human Use (CHMP) - November 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-11-30T01:00:00Z","last_updated_date":"2004-11-30T01:00:00Z","reference_number":"EMEA/CHMP/160431/2004","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-november-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"14825","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - March 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-03-31T02:00:00Z","last_updated_date":"2005-03-31T02:00:00Z","reference_number":"EMEA/CVMP/103137/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-march-2005_en.pdf"},
    {"id":"14846","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the December 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-12-09T11:56:00Z","last_updated_date":"2011-12-09T11:56:00Z","reference_number":"EMA/COMP/811367/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-december-2011-meeting_en.pdf"},
    {"id":"14853","name":"COMP meeting report on the review of applications for orphan designation: February 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T16:30:00Z","last_updated_date":"2018-03-09T16:30:00Z","reference_number":"EMA/COMP/76718/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-february-2018_en.pdf"},
    {"id":"14855","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - May 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-05-31T02:00:00Z","last_updated_date":"2007-05-31T02:00:00Z","reference_number":"EMEA/238705/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-may-2007_en.pdf"},
    {"id":"14894","name":"Committee for proprietary medicinal products July 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2002-07-31T02:00:00Z","last_updated_date":"2002-07-31T02:00:00Z","reference_number":"EMEA/CPMP/3473/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-july-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"14936","name":"Committee for Medicinal Products for Human Use (CHMP) - March 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-03-29T02:00:00Z","last_updated_date":"2007-03-29T02:00:00Z","reference_number":"EMEA/144134/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-march-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"15146","name":"PDCO meeting highlights 4-6 March 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-03-13T00:00:00Z","last_updated_date":"2009-03-13T00:00:00Z","reference_number":"EMEA/PDCO/118305/2009 - corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-4-6-march-2009_en.pdf"},
    {"id":"15153","name":"COMP meeting report on the review of applications for orphan designation: January 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-01-28T12:30:00Z","last_updated_date":"2016-02-02T12:30:00Z","reference_number":"EMA/COMP/843956/2015 Corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2016_en.pdf"},
    {"id":"15156","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: December 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-02-05T16:02:00Z","last_updated_date":"2018-02-05T16:02:00Z","reference_number":"EMA/827608/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-december-2017_en.pdf"},
    {"id":"15163","name":"Committee for Medicinal Products for Human Use (CHMP) -  October 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:00:00Z","last_updated_date":"2006-10-27T02:00:00Z","reference_number":"EMEA/410526/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-october-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"15217","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: March 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-04-17T12:10:00Z","last_updated_date":"2015-04-17T12:10:00Z","reference_number":"EMA/189863/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-march-2015_en.pdf"},
    {"id":"15255","name":"PDCO meeting highlights 29-31 July 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/PDCO/412084/2008-Corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-29-31-july-2008_en.pdf"},
    {"id":"15309","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: December 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-12-19T15:00:00Z","last_updated_date":"2013-12-19T15:00:00Z","reference_number":"EMA/CAT/785931/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-december-2013-meeting_en.pdf"},
    {"id":"15376","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: June 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T12:08:00Z","last_updated_date":"2018-07-17T12:08:00Z","reference_number":"EMA/CAT/435550/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-june-2018_en.pdf"},
    {"id":"15391","name":"COMP meeting report on the review of applications for orphan designation: June 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-06-24T11:20:00Z","last_updated_date":"2015-06-24T11:20:00Z","reference_number":"EMA/COMP/334381/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-june-2015_en.pdf"},
    {"id":"15479","name":"Committee for Medicinal Products for Human Use (CHMP) - April 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-05-02T02:00:00Z","last_updated_date":"2003-05-02T02:00:00Z","reference_number":"EMEA/CPMP/2347/03","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-april-2003-plenary-meeting-monthly-report_en.pdf"},
    {"id":"15487","name":"Committee for Advanced Therapies (CAT) monthly report of application procedures, guidelines and related documents on advanced therapies: February 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-02-20T01:00:00Z","last_updated_date":"2012-02-20T01:00:00Z","reference_number":"EMA/CAT/47894/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-february-2012-meeting_en.pdf"},
    {"id":"15510","name":"COMP meeting report on the review of applications for orphan designation: October 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-10-15T16:55:00Z","last_updated_date":"2015-11-16T12:50:00Z","reference_number":"EMA/COMP/624217/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-october-2015_en.pdf"},
    {"id":"15529","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: July 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T11:40:00Z","last_updated_date":"2014-07-30T11:40:00Z","reference_number":"EMA/CAT/434851/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-july-2014-meeting_en.pdf"},
    {"id":"15646","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: April 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T13:40:00Z","last_updated_date":"2015-05-04T13:40:00Z","reference_number":"EMA/CAT/268414/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-april-2015-meeting_en.pdf"},
    {"id":"15796","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - July 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-07-31T02:00:00Z","last_updated_date":"2008-07-31T02:00:00Z","reference_number":"EMEA/444404/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-july-2008_en.pdf"},
    {"id":"15826","name":"Committee for Advanced Therapies (CAT): January 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2011-01-28T01:00:00Z","reference_number":"EMA/CAT/63733/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-january-2011-meeting-monthly-report_en.pdf"},
    {"id":"15827","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: May 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-06-13T18:00:00Z","last_updated_date":"2016-06-13T18:00:00Z","reference_number":"EMA/396131/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-may-2016_en.pdf"}    {"id":"15834","name":"Committee for Medicinal Products for Human Use (CHMP) - September 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-09-28T02:00:00Z","last_updated_date":"2007-09-28T02:00:00Z","reference_number":"EMEA/427480/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-september-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"15965","name":"Committee for proprietary medicinal products June 2001 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2001-06-26T02:00:00Z","last_updated_date":"2001-06-26T02:00:00Z","reference_number":"CPMP/2020/01 corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-june-2001-plenary-meeting-monthly-report_en.pdf"},
    {"id":"16066","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 18-20 June 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-06-26T17:40:00Z","last_updated_date":"2014-06-26T17:40:00Z","reference_number":"EMA/376871/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-18-20-june-2014_en.pdf"},
    {"id":"16113","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 21-24 February 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T10:40:00Z","last_updated_date":"2017-03-09T10:40:00Z","reference_number":"EMA/PDCO/140294/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-21-24-february-2017_en.pdf"},
    {"id":"16146","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: October 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T16:10:00Z","last_updated_date":"2016-11-17T16:10:00Z","reference_number":"EMA/664125/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-october-2016_en.pdf"},
    {"id":"16225","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 27-29 April 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-05-10T17:35:00Z","last_updated_date":"2016-05-10T17:35:00Z","reference_number":"EMA/PDCO/289960/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-27-29-april-2016_en.pdf"},
    {"id":"16291","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the March 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-03-05T01:00:00Z","last_updated_date":"2010-03-05T01:00:00Z","reference_number":"EMA/COMP/89960/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-march-2010-meeting_en.pdf"},
    {"id":"16312","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the December 2007 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-12-06T00:09:21Z","last_updated_date":"2007-12-06T00:09:21Z","reference_number":"EMEA/COMP/554248/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-december-2007-meeting_en.pdf"},
    {"id":"16348","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: November 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-11-28T11:40:00Z","last_updated_date":"2014-11-28T11:40:00Z","reference_number":"EMA/CAT/718445/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-november-2014-meeting_en.pdf"},
    {"id":"16361","name":"Committee for Advanced Therapies (CAT): June 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-07-06T02:00:00Z","last_updated_date":"2010-07-06T02:00:00Z","reference_number":"EMA/CAT/407854/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-june-2010-meeting-monthly-report_en.pdf"},
    {"id":"16513","name":"COMP meeting report on the review of applications for orphan designation: May 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-05-24T17:21:00Z","last_updated_date":"2017-05-24T17:21:00Z","reference_number":"EMA/COMP/265114/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-may-2017_en.pdf"},
    {"id":"16535","name":"Committee for Medicinal Products for Veterinary Use Monthly report of application procedures, guidelines and related documents - February 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-02-24T01:00:00Z","last_updated_date":"2010-02-24T01:00:00Z","reference_number":"EMA/CVMP/79908/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-monthly-report-application-procedures-guidelines-and-related-documents-february-2010_en.pdf"},
    {"id":"16607","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: September 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T17:50:00Z","last_updated_date":"2013-09-25T17:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-september-2013-meeting_en.pdf"},
    {"id":"16651","name":"PDCO monthly report of opinions on paediatric investigation plans: 6-8 June 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-06-20T16:35:00Z","last_updated_date":"2012-06-20T16:35:00Z","reference_number":"EMA/PDCO/347974/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-6-8-june-2012_en.pdf"},
    {"id":"16681","name":"COMP meeting report on the review of applications for orphan designation: January 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-01-16T16:50:00Z","last_updated_date":"2014-01-16T16:50:00Z","reference_number":"EMA/COMP/741655/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2014_en.pdf"},
    {"id":"16688","name":"Committee for proprietary medicinal products April 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2002-04-28T02:00:00Z","last_updated_date":"2002-04-28T02:00:00Z","reference_number":"EMEA/CPMP/8204/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-april-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"16763","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 23-26 January 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-02-08T18:00:00Z","last_updated_date":"2018-02-08T18:00:00Z","reference_number":"EMA/PDCO/59775/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-23-26-january-2018_en.pdf"},
    {"id":"16915","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 4-6 December 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T15:00:00Z","last_updated_date":"2014-01-08T13:45:00Z","reference_number":"EMA/PDCO/751770/2013 Corr1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-4-6-december-2013_en.pdf"},
    {"id":"16917","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - December 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-12-31T00:00:00Z","last_updated_date":"2008-12-31T00:00:00Z","reference_number":"EMEA/30275/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-december-2008_en.pdf"},
    {"id":"16931","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 24-27 April 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-05-08T11:33:00Z","last_updated_date":"2018-05-08T11:33:00Z","reference_number":"EMA/PDCO/274173/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-24-27-april-2018_en.pdf"},
    {"id":"16932","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 10–12 September 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-09-19T16:20:00Z","last_updated_date":"2014-09-19T16:20:00Z","reference_number":"EMA/PDCO/551023/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-10-12-september-2014_en.pdf"},
    {"id":"16990","name":"PDCO meeting report 13-15 July 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-07-25T02:00:00Z","last_updated_date":"2011-08-19T02:00:00Z","reference_number":"EMA/PDCO/513837/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-13-15-july-2011_en.pdf"},
    {"id":"17038","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-02-28T17:55:00Z","last_updated_date":"2017-02-28T17:55:00Z","reference_number":"EMA/CAT/126788/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-february-2017_en.pdf"},
    {"id":"17058","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 11-12 July 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/HMPC/555872/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-11-12-july-2011_en.pdf"},
    {"id":"17145","name":"Committee on herbal medicinal products (HMPC): Meeting report, 11-12 November 2004","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-12-01T01:00:00Z","last_updated_date":"2004-12-01T01:00:00Z","reference_number":"EMEA/HMPC/153046/2004","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-11-12-november-2004_en.pdf"},
    {"id":"17147","name":"Committee for Medicinal Products for Human Use (CHMP) - September 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-10-08T02:00:00Z","last_updated_date":"2008-10-08T02:00:00Z","reference_number":"EMEA/CHMP/505537/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-september-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"17159","name":"PDCO meeting highlights 2-4 June 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/PDCO/296494/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-2-4-june-2008_en.pdf"},
    {"id":"17169","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 13-15 August 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-08-21T17:00:00Z","last_updated_date":"2014-08-21T17:00:00Z","reference_number":"EMA/PDCO/500618/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-13-15-august-2014_en.pdf"},
    {"id":"17346","name":"Committee for Medicinal Products for Human Use (CHMP) - July 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/CHMP/476111/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-july-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"17360","name":"CVMP monthly report of application procedures, guidelines and related documents: October 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-11-28T11:27:00Z","last_updated_date":"2013-11-28T11:27:00Z","reference_number":"EMA/673417/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-october-2013_en.pdf"},
    {"id":"17445","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: May 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T17:25:00Z","last_updated_date":"2018-06-19T17:25:00Z","reference_number":"EMA/CAT/372833/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-may-2018_en.pdf"},
    {"id":"17787","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: March 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-04-09T19:30:00Z","last_updated_date":"2014-04-09T19:30:00Z","reference_number":"EMA/156949/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-march-2014_en.pdf"},
    {"id":"17897","name":"COMP meeting report on the review of applications for orphan designation: May 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-06-14T12:00:00Z","last_updated_date":"2018-06-14T12:00:00Z","reference_number":"EMA/COMP/270019/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-may-2018_en.pdf"},
    {"id":"17929","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: December 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-01-12T18:00:01Z","last_updated_date":"2018-01-12T18:00:01Z","reference_number":"EMA/CAT/830803/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-december-2017_en.pdf"},
    {"id":"17946","name":"Committee for Medicinal Products for Human Use (CHMP) - May 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-06-14T02:00:00Z","last_updated_date":"2006-06-14T02:00:00Z","reference_number":"EMEA/209537/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-may-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"17953","name":"PDCO meeting highlights 17-19 September 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-09-24T02:00:00Z","last_updated_date":"2008-09-24T02:00:00Z","reference_number":"EMEA/PDCO/493761/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-17-19-september-2008_en.pdf"},
    {"id":"17976","name":"Committee for Medicinal Products for Human Use (CHMP) - February 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-03-17T01:00:00Z","last_updated_date":"2006-03-17T01:00:00Z","reference_number":"CHMP/70961/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-february-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"17998","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 11-12 November 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-11-29T12:45:00Z","last_updated_date":"2013-11-29T12:45:00Z","reference_number":"EMA/HMPC/702025/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-11-12-november-2013_en.pdf"},
    {"id":"18007","name":"CVMP monthly report of application procedures, guidelines and related documents: October 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-12-13T09:38:00Z","last_updated_date":"2012-12-13T09:38:00Z","reference_number":"EMA/736049/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-october-2012_en.pdf"},
    {"id":"18033","name":"Committee for proprietary medicinal products January 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2002-01-24T01:00:00Z","last_updated_date":"2002-01-24T01:00:00Z","reference_number":"CPMP/197/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-january-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"18035","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - May 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-06-03T02:00:00Z","last_updated_date":"2010-06-03T02:00:00Z","reference_number":"EMA/CVMP/334379/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-may-2010_en.pdf"},
    {"id":"18082","name":"Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation - January 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T16:51:02Z","last_updated_date":"2012-01-16T16:51:02Z","reference_number":"EMA/COMP/969544/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-meeting-report-review-applications-orphan-designation-january-2012_en.pdf"},
    {"id":"18120","name":"COMP meeting report on the review of applications for orphan designation: April 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-04-25T18:30:00Z","last_updated_date":"2017-04-25T18:30:00Z","reference_number":"MA/COMP/188861/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-april-2017_en.pdf"},
    {"id":"18128","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 7-9 October 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-10-20T18:00:00Z","last_updated_date":"2015-10-20T18:00:00Z","reference_number":"EMA/PDCO/672645/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-7-9-october-2015_en.pdf"},
    {"id":"18165","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - September 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T16:30:00Z","last_updated_date":"2011-10-11T16:30:00Z","reference_number":"EMA/CVMP/777739/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-september-2011_en.pdf"},
    {"id":"18330","name":"CVMP monthly report of application procedures, guidelines and related documents: March 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T12:00:00Z","last_updated_date":"2013-03-25T12:00:00Z","reference_number":"EMA/155509/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-march-2013_en.pdf"},
    {"id":"18382","name":"PDCO meeting report 16-18 February 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-03-02T01:00:00Z","last_updated_date":"2011-03-02T01:00:00Z","reference_number":"EMA/PDCO/126704/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-16-18-february-2011_en.pdf"},
    {"id":"18530","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - September 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-09-30T02:00:00Z","last_updated_date":"2009-09-30T02:00:00Z","reference_number":"EMEA/CVMP/645745/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-september-2009_en.pdf"},
    {"id":"18541","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 13-14 May 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T13:00:00Z","last_updated_date":"2013-06-07T13:00:00Z","reference_number":"EMA/HMPC/301544/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-13-14-may-2013_en.pdf"},
    {"id":"18580","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the April 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-04-16T02:00:00Z","last_updated_date":"2010-04-16T02:00:00Z","reference_number":"EMA/COMP/159501/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-april-2010-meeting_en.pdf"},
    {"id":"18611","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: June 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-07-01T19:00:00Z","last_updated_date":"2016-07-01T19:00:00Z","reference_number":"EMA/CAT/358066/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-june-2016_en.pdf"},
    {"id":"18612","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 26-29 June 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-07-18T18:20:00Z","last_updated_date":"2018-07-18T18:20:00Z","reference_number":"EMA/PDCO/462978/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-26-29-june-2018_en.pdf"},
    {"id":"18665","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - April 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-04-20T02:00:00Z","last_updated_date":"2011-04-20T02:00:00Z","reference_number":"EMA/CVMP/37837/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-april-2011_en.pdf"},
    {"id":"18718","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the June 2009  meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-06-09T02:09:21Z","last_updated_date":"2009-06-09T02:09:21Z","reference_number":"EMEA/COMP/344079/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-june-2009-meeting_en.pdf"},
    {"id":"18761","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the April 2009 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-04-08T02:09:21Z","last_updated_date":"2009-04-08T02:09:21Z","reference_number":"EMEA/COMP/159165/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-april-2009-meeting_en.pdf"},
    {"id":"18769","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 30 March-1 April 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T17:10:00Z","last_updated_date":"2016-04-08T17:10:00Z","reference_number":"EMA/PDCO/253224/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-30-march-1-april-2016_en.pdf"},
    {"id":"18859","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - December 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-12-31T00:00:00Z","last_updated_date":"2007-12-31T00:00:00Z","reference_number":"EMEA/CVMP/605093/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-december-2007_en.pdf"},
    {"id":"18872","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the July 2009 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-07-14T02:09:21Z","last_updated_date":"2009-07-14T02:09:21Z","reference_number":"EMEA/COMP/367198/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-july-2009-meeting_en.pdf"},
    {"id":"18993","name":"Committee for Medicinal Products for Human Use (CHMP) - June 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-07-12T02:00:00Z","last_updated_date":"2006-07-12T02:00:00Z","reference_number":"EMEA/222629/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-june-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"19041","name":"Committee for Medicinal Products for Human Use (CHMP) - December 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-01-13T00:00:00Z","last_updated_date":"2009-01-13T00:00:00Z","reference_number":"EMEA/CHMP/679401/2008 – corr*","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-december-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"19089","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 5-7 December 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-12-18T18:00:01Z","last_updated_date":"2013-01-17T15:30:00Z","reference_number":"EMA/PDCO/764589/2012 Corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-5-7-december-2012_en.pdf"},
    {"id":"19389","name":"COMP meeting report on the review of applications for orphan designation: May 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T11:09:00Z","last_updated_date":"2013-05-24T11:09:00Z","reference_number":"EMA/COMP/274523/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-may-2013_en.pdf"},
    {"id":"19390","name":"PDCO meeting highlights 13-15 January 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-01-28T01:00:00Z","last_updated_date":"2010-01-28T01:00:00Z","reference_number":"EMA/PDCO/10156/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-13-15-january-2010_en.pdf"},
    {"id":"19471","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - October 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-11-19T00:09:21Z","last_updated_date":"2009-11-19T00:09:21Z","reference_number":"EMEA/CVMP/737551/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-october-2009_en.pdf"},
    {"id":"19479","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T11:35:00Z","last_updated_date":"2017-10-23T11:35:00Z","reference_number":"EMA/CAT/674185/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-october-2017_en.pdf"},
    {"id":"19535","name":"Committee for Advanced Therapies (CAT) monthly report of application procedures, guidelines and related documents on advanced therapies: May 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T14:25:00Z","last_updated_date":"2012-05-30T14:25:00Z","reference_number":"EMA/CAT/337185/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-may-2012-meeting_en.pdf"},
    {"id":"19594","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: September 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T12:00:00Z","last_updated_date":"2016-10-20T12:00:00Z","reference_number":"EMA/536722/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-september-2016_en.pdf"},
    {"id":"19655","name":"Committee for Medicinal Products for Human Use (CHMP) - July 2011 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"EMA/CHMP/571474/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-july-2011-plenary-meeting-monthly-report_en.pdf"},
    {"id":"19745","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: November 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T16:45:00Z","last_updated_date":"2013-11-26T16:45:00Z","reference_number":"EMA/CAT/574533/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-november-2013-meeting_en.pdf"},
    {"id":"19949","name":"PDCO meeting highlights 12-14 November 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-11-26T00:00:00Z","last_updated_date":"2008-11-26T00:00:00Z","reference_number":"EMEA/610751/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-12-14-november-2008_en.pdf"},
    {"id":"19990","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - June 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-06-30T02:00:00Z","last_updated_date":"2009-06-30T02:00:00Z","reference_number":"EMEA/CVMP/433818/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-june-2009_en.pdf"},
    {"id":"20008","name":"Committee on herbal medicinal products (HMPC): Meeting report, 3-4 September 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-09-16T02:00:00Z","last_updated_date":"2008-09-16T02:00:00Z","reference_number":"EMEA/HMPC/472450/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-3-4-september-2008_en.pdf"},
    {"id":"20042","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - October 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-11-09T01:00:00Z","last_updated_date":"2010-11-09T01:00:00Z","reference_number":"EMA/CVMP/649372/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-october-2010_en.pdf"},
    {"id":"20068","name":"COMP meeting report on the review of applications for orphan designation: 30-31 October 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T14:45:00Z","last_updated_date":"2017-12-01T14:45:00Z","reference_number":"EMA/COMP/685336/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-30-31-october-2017_en.pdf"},
    {"id":"20110","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the October 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-10-13T11:19:00Z","last_updated_date":"2011-10-13T11:19:00Z","reference_number":"EMA/COMP/811210/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-october-2011-meeting_en.pdf"},
    {"id":"20207","name":"PDCO meeting highlights 6-8 May 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-05-15T02:00:00Z","last_updated_date":"2008-05-15T02:00:00Z","reference_number":"EMEA/PDCO/246860/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-6-8-may-2008_en.pdf"},
    {"id":"20255","name":"Committee for Medicinal Products for Human Use (CHMP) - Janaury 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-02-05T00:00:00Z","last_updated_date":"2008-02-05T00:00:00Z","reference_number":"EMEA/37124/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-janaury-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"20289","name":"CVMP monthly report of application procedures, guidelines and related documents: February 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T12:00:00Z","last_updated_date":"2013-03-25T12:00:00Z","reference_number":"EMA/153999/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-february-2013_en.pdf"},
    {"id":"20352","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the February 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-02-10T00:09:21Z","last_updated_date":"2010-02-24T01:00:00Z","reference_number":"EMA/COMP/42611/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-february-2010-meeting_en.pdf"},
    {"id":"20448","name":"PDCO meeting highlights 9-11 April 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-04-15T02:00:00Z","last_updated_date":"2008-04-15T02:00:00Z","reference_number":"EMEA/PDCO/190452/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-9-11-april-2008_en.pdf"},
    {"id":"20460","name":"Committee for Medicinal Products for Human Use (CHMP) - February 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-02-25T01:00:00Z","last_updated_date":"2005-02-25T01:00:00Z","reference_number":"CHMP/45462/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-february-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"20495","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the May 2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-05-19T02:09:21Z","last_updated_date":"2008-05-19T02:09:21Z","reference_number":"EMEA/COMP/260441/08","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-may-2008-meeting_en.pdf"},
    {"id":"20497","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 23-24 January 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-02-14T11:00:00Z","last_updated_date":"2012-02-14T11:00:00Z","reference_number":"EMA/HMPC/78352/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-23-24-january-2012_en.pdf"},
    {"id":"20526","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-02-25T17:05:00Z","last_updated_date":"2013-02-25T17:05:00Z","reference_number":"EMA/CAT/108604/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-february-2013-meeting_en.pdf"},
    {"id":"20535","name":"COMP meeting report on the review of applications for orphan designation: April 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-04-22T12:00:00Z","last_updated_date":"2015-04-22T16:30:00Z","reference_number":"EMA/COMP/205240/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-april-2015_en.pdf"},
    {"id":"20572","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 29-30 May 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-07-04T19:00:00Z","last_updated_date":"2017-07-04T19:00:00Z","reference_number":"EMA/HMPC/356423/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-29-30-may-2017_en.pdf"},
    {"id":"20605","name":"Committee for Medicinal Products for Human Use (CHMP) - January 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-02-01T01:00:00Z","last_updated_date":"2005-02-01T01:00:00Z","reference_number":"EMEA/22735/2005 corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-january-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"20628","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - June 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-06-30T02:00:00Z","last_updated_date":"2005-06-30T02:00:00Z","reference_number":"EMEA/212345/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-june-2005_en.pdf"},
    {"id":"20741","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 21-24 March 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-04-11T18:04:00Z","last_updated_date":"2017-04-11T18:04:00Z","reference_number":"EMA/PDCO/209961/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-21-24-march-2017_en.pdf"},
    {"id":"20802","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 9-11 January 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-01-17T15:33:00Z","last_updated_date":"2013-01-17T15:33:00Z","reference_number":"EMA/PDCO/24099/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-9-11-january-2013_en.pdf"},
    {"id":"20814","name":"COMP meeting report on the review of applications for orphan designation: September 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-09-09T12:10:00Z","last_updated_date":"2015-09-29T13:40:00Z","reference_number":"EMA/COMP/497878/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2015_en.pdf"},
    {"id":"20941","name":"Committee on herbal medicinal products (HMPC): Meeting report, 22-23 March 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-05-11T02:00:00Z","last_updated_date":"2005-05-11T02:00:00Z","reference_number":"EMEA/HMPC/119829/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-22-23-march-2005_en.pdf"},
    {"id":"20993","name":"Committee for Medicinal Products for Human Use (CHMP) - May 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-06-05T02:00:00Z","last_updated_date":"2003-06-05T02:00:00Z","reference_number":"EMEA/CPMP/2568/03/Rev 01","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-may-2003-plenary-meeting-monthly-report_en.pdf"},
    {"id":"21195","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: February 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T16:29:00Z","last_updated_date":"2016-03-14T16:29:00Z","reference_number":"EMA/112087/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-february-2016_en.pdf"},
    {"id":"21196","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 27-28 January 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-02-11T11:20:00Z","last_updated_date":"2015-02-11T11:20:00Z","reference_number":"EMA/HMPC/82378/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-27-28-january-2015_en.pdf"},
    {"id":"21209","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - March 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-03-31T02:00:00Z","last_updated_date":"2009-03-31T02:00:00Z","reference_number":"EMEA/202723/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-march-2009_en.pdf"},
    {"id":"21246","name":"Committee on herbal medicinal products (HMPC): Meeting report, 4-5 July 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/HMPC/314187/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-4-5-july-2007_en.pdf"},
    {"id":"21286","name":"COMP meeting report on the review of applications for orphan designation: September 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-09-09T15:30:00Z","last_updated_date":"2014-11-18T16:20:00Z","reference_number":"EMA/COMP/449891/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2014_en.pdf"},
    {"id":"21331","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 15-17 January 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-01-24T14:40:00Z","last_updated_date":"2014-01-24T14:40:00Z","reference_number":"EMA/PDCO/799206/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-15-17-january-2014_en.pdf"},
    {"id":"21334","name":"Committee for Medicinal Products for Human Use (CHMP) - February 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-03-03T01:00:00Z","last_updated_date":"2003-03-03T01:00:00Z","reference_number":"EMEA/CPMP/3794/03/corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-february-2003-plenary-meeting-monthly-report_en.pdf"}    {"id":"21357","name":"Committee on herbal medicinal products (HMPC): Meeting report, 15-16 July 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-07-21T02:00:00Z","last_updated_date":"2009-07-21T02:00:00Z","reference_number":"EMEA/HMPC/466806/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-15-16-july-2009_en.pdf"},
    {"id":"21376","name":"Committee for Medicinal Products for Human Use (CHMP) - June 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-07-04T02:00:00Z","last_updated_date":"2003-07-04T02:00:00Z","reference_number":"EMEA/CPMP/3297/03","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-june-2003-plenary-meeting-monthly-report_en.pdf"},
    {"id":"21470","name":"Committee on herbal medicinal products (HMPC): Meeting report, 13-14 May 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-06-05T02:00:00Z","last_updated_date":"2009-06-05T02:00:00Z","reference_number":"EMEA/HMPC/332964/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-13-14-may-2009_en.pdf"},
    {"id":"21522","name":"PDCO monthly report of opinions on paediatric investigation plans: 7-9 December 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-12-16T15:00:00Z","last_updated_date":"2011-12-16T15:00:00Z","reference_number":"EMA/PDCO/925174/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-7-9-december-2011_en.pdf"},
    {"id":"21772","name":"PDCO meeting highlights 1-3 April 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/PDCO/201824/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-1-3-april-2009_en.pdf"},
    {"id":"21914","name":"Committee for Medicinal Products for Human Use (CHMP) - March 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-03-28T01:00:00Z","last_updated_date":"2003-03-28T01:00:00Z","reference_number":"EMEA/CPMP/13508/03","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-march-2003-plenary-meeting-monthly-report_en.pdf"},
    {"id":"21931","name":"PDCO meeting highlights 12-14 March 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-04-25T02:00:00Z","last_updated_date":"2008-04-25T02:00:00Z","reference_number":"EMEA/PDCO/133735/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-12-14-march-2008_en.pdf"},
    {"id":"21936","name":"PDCO meeting highlights 19-21 May 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/PDCO/323686/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-19-21-may-2010_en.pdf"},
    {"id":"21977","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the March 2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-03-17T00:09:21Z","last_updated_date":"2009-03-17T00:09:21Z","reference_number":"EMEA/COMP/100434/08","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-march-2008-meeting_en.pdf"},
    {"id":"22020","name":"Committee on herbal medicinal products (HMPC): Meeting report, 12-13 July 2006","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-08-02T02:00:00Z","last_updated_date":"2006-08-02T02:00:00Z","reference_number":"EMEA/HMPC/285470/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-12-13-july-2006_en.pdf"},
    {"id":"22082","name":"Committee for Medicinal Products for Human Use (CHMP) - March 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-03-27T00:00:00Z","last_updated_date":"2008-03-27T00:00:00Z","reference_number":"EMEA/137943/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-march-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"22156","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - July 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-07-31T02:00:00Z","last_updated_date":"2009-07-31T02:00:00Z","reference_number":"EMEA/543763/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-july-2009_en.pdf"},
    {"id":"22190","name":"Committee for Medicinal Products for Human Use (CHMP) - January 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-01-30T01:00:00Z","last_updated_date":"2009-01-30T01:00:00Z","reference_number":"EMEA/39660/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-january-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"22254","name":"Committee for Advanced Therapies (CAT): April 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-04-30T02:00:00Z","last_updated_date":"2010-04-30T02:00:00Z","reference_number":"EMA/CAT/255298/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-april-2010-meeting-monthly-report_en.pdf"},
    {"id":"22282","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the November  2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"EMEA/COMP/540306/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-november-2008-meeting_en.pdf"},
    {"id":"22304","name":"Committee for Medicinal Products for Human Use (CHMP) - May 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-06-05T02:00:00Z","last_updated_date":"2007-06-05T02:00:00Z","reference_number":"EMEA/222371/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-may-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"22528","name":"Committee for proprietary medicinal products March 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2002-03-25T01:00:00Z","last_updated_date":"2002-03-25T01:00:00Z","reference_number":"CPMP/1110/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-march-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"22689","name":"Committee for proprietary medicinal products July 2001 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2001-07-31T02:00:00Z","last_updated_date":"2001-07-31T02:00:00Z","reference_number":"CPMP/2358/01","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-july-2001-plenary-meeting-monthly-report_en.pdf"},
    {"id":"22795","name":"Committee for Advanced Therapies (CAT): July 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-07-21T02:00:00Z","last_updated_date":"2011-07-21T02:00:00Z","reference_number":"EMA/CAT/576474/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-july-2011-meeting-monthly-report_en.pdf"},
    {"id":"22891","name":"COMP meeting report on the review of applications for orphan designation: November 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-11-12T12:00:00Z","last_updated_date":"2012-11-12T12:00:00Z","reference_number":"EMA/COMP/663960/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-november-2012_en.pdf"},
    {"id":"22910","name":"Committee on herbal medicinal products (HMPC): Meeting report, 11-12 November 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-12-16T01:00:00Z","last_updated_date":"2009-12-16T01:00:00Z","reference_number":"EMA/HMPC/764249/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-11-12-november-2009_en.pdf"},
    {"id":"22931","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 20-22 May 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-06-05T17:10:00Z","last_updated_date":"2015-06-05T17:10:00Z","reference_number":"EMA/PDCO/348974/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-20-22-may-2015_en.pdf"},
    {"id":"23096","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - February 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-03-02T01:00:00Z","last_updated_date":"2011-03-02T01:00:00Z","reference_number":"EMA/CVMP/37837/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-february-2011_en.pdf"},
    {"id":"23146","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: December 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T14:46:00Z","last_updated_date":"2016-01-19T14:46:00Z","reference_number":"EMA/844081/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-december-2015_en.pdf"},
    {"id":"23150","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 17-18 July 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-07-31T16:30:00Z","last_updated_date":"2017-07-31T16:30:00Z","reference_number":"EMA/HMPC/469476/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-17-18-july-2017_en.pdf"},
    {"id":"23226","name":"COMP meeting report on the review of applications for orphan designation: March 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T13:30:00Z","last_updated_date":"2015-03-30T13:30:00Z","reference_number":"EMA/COMP/138154/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-march-2015_en.pdf"},
    {"id":"23374","name":"COMP meeting report on the review of applications for orphan designation: October 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-10-16T12:20:00Z","last_updated_date":"2014-11-18T16:20:00Z","reference_number":"EMA/COMP/559651/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-october-2014_en.pdf"},
    {"id":"23444","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the January 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-01-17T01:00:00Z","last_updated_date":"2011-01-17T01:00:00Z","reference_number":"EMA/781001/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-january-2011-meeting_en.pdf"},
    {"id":"23644","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: March 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T12:00:00Z","last_updated_date":"2018-04-27T12:00:00Z","reference_number":"EMA/189006/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-march-2018_en.pdf"},
    {"id":"23687","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: September 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-10-02T14:30:00Z","last_updated_date":"2015-10-02T14:30:00Z","reference_number":"EMA/CAT/632147/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-september-2015-meeting_en.pdf"},
    {"id":"23739","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 15-17 July 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T13:40:00Z","last_updated_date":"2015-07-24T13:40:00Z","reference_number":"EMA/PDCO/464458/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-15-17-july-2015_en.pdf"},
    {"id":"23784","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: December 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-01-19T11:37:00Z","last_updated_date":"2015-01-19T11:37:00Z","reference_number":"EMA/784039/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-december-2014_en.pdf"},
    {"id":"23878","name":"COMP meeting report on the review of applications for orphan designation: March 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-03-20T17:00:00Z","last_updated_date":"2018-03-20T17:00:00Z","reference_number":"EMA/COMP/145093/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-march-2018_en.pdf"},
    {"id":"23947","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: June 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T18:45:00Z","last_updated_date":"2015-07-07T18:45:00Z","reference_number":"EMA/391547/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-june-2015_en.pdf"},
    {"id":"24005","name":"Committee for Medicinal Products for Human Use (CHMP) - April 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-04-30T02:00:00Z","last_updated_date":"2004-04-30T02:00:00Z","reference_number":"EMEA/CPMP/11951/04","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-april-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"24016","name":"Committee for Medicinal Products for Human Use (CHMP) - September 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-11-05T01:00:00Z","last_updated_date":"2003-11-05T01:00:00Z","reference_number":"EMEA/CPMP/4482/03/Rev 2","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-september-2003-plenary-meeting-monthly-report_en.pdf"},
    {"id":"24026","name":"Committee for Medicinal Products for Human Use (CHMP) - January 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-02-17T01:00:00Z","last_updated_date":"2006-02-17T01:00:00Z","reference_number":"EMEA/CHMP/35006/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-january-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"24048","name":"COMP meeting report on the review of applications for orphan designation: November 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-11-18T18:00:00Z","last_updated_date":"2015-11-18T18:00:00Z","reference_number":"EMA/COMP/719285/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-november-2015_en.pdf"},
    {"id":"24069","name":"Committee for Medicinal Products for Human Use (CHMP) - April 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-05-06T02:00:00Z","last_updated_date":"2008-05-06T02:00:00Z","reference_number":"EMEA/CHMP/213268/2008 - corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-april-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"24259","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the March 2009 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-03-06T00:09:21Z","last_updated_date":"2009-03-06T00:09:21Z","reference_number":"EMEA/COMP/27104/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-march-2009-meeting_en.pdf"},
    {"id":"24263","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T17:35:00Z","last_updated_date":"2014-02-21T17:35:00Z","reference_number":"EMA/CAT/97293/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-february-2014-meeting_en.pdf"},
    {"id":"24417","name":"Committee for proprietary medicinal products September 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2002-10-01T02:00:00Z","last_updated_date":"2002-10-01T02:00:00Z","reference_number":"EMEA/CPMP/4634/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-september-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"24426","name":"Committee for Medicinal Products for Human Use (CHMP) - May 2011 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/CHMP/403396/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-may-2011-plenary-meeting-monthly-report_en.pdf"},
    {"id":"24434","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the September 2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-09-11T02:09:21Z","last_updated_date":"2008-09-11T02:09:21Z","reference_number":"EMEA/COMP/479052/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-september-2008-meeting_en.pdf"},
    {"id":"24456","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 26-27 January 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-02-22T01:00:00Z","last_updated_date":"2011-02-22T01:00:00Z","reference_number":"EMA/HMPC/93315/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-26-27-january-2011_en.pdf"},
    {"id":"24551","name":"Committee for Medicinal Products for Human Use (CHMP) - March 2011 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-03-25T01:00:00Z","last_updated_date":"2011-03-25T01:00:00Z","reference_number":"EMA/CHMP/224689/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-march-2011-plenary-meeting-monthly-report_en.pdf"},
    {"id":"24569","name":"Committee on herbal medicinal products (HMPC): Meeting report, 21-22 July 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-07-29T02:00:00Z","last_updated_date":"2005-07-29T02:00:00Z","reference_number":"EMEA/HMPC/243465/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-21-22-july-2005_en.pdf"},
    {"id":"24597","name":"COMP meeting report on the review of applications for orphan designation: April 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-04-26T13:00:00Z","last_updated_date":"2018-04-26T13:00:00Z","reference_number":"EMA/COMP/145093/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-april-2018_en.pdf"},
    {"id":"24604","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: May 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T15:13:00Z","last_updated_date":"2018-07-05T15:13:00Z","reference_number":"EMA/374249/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-may-2018_en.pdf"},
    {"id":"24658","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - May 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-05-31T02:00:00Z","last_updated_date":"2008-05-31T02:00:00Z","reference_number":"EMEA/281942/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-may-2008_en.pdf"},
    {"id":"24758","name":"Committee for Medicinal Products for Human Use (CHMP) - October 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-10-28T00:00:00Z","last_updated_date":"2008-10-28T00:00:00Z","reference_number":"EMEA/CHMP/539474/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-october-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"24827","name":"COMP meeting report on the review of applications for orphan designation: March 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-04-05T16:05:00Z","last_updated_date":"2016-04-05T16:05:00Z","reference_number":"EMA/COMP/150969/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-march-2016_en.pdf"},
    {"id":"24843","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: March 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T12:25:00Z","last_updated_date":"2017-03-24T12:25:00Z","reference_number":"EMA/CAT/195978/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-march-2017_en.pdf"},
    {"id":"25030","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: May 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-06-13T16:40:00Z","last_updated_date":"2017-06-13T16:40:00Z","reference_number":"EMA/305737/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-may-2017_en.pdf"},
    {"id":"25170","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: July 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-07-30T16:00:00Z","last_updated_date":"2012-07-30T16:00:00Z","reference_number":"EMA/CAT/497804/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-july-2012-meeting_en.pdf"},
    {"id":"25198","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - January 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-01-26T16:45:00Z","last_updated_date":"2012-01-26T16:45:00Z","reference_number":"EMA/47559/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-january-2012_en.pdf"},
    {"id":"25249","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 29-30 September 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-10-16T11:40:00Z","last_updated_date":"2014-10-16T11:40:00Z","reference_number":"EMA/HMPC/620221/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-29-30-september-2014_en.pdf"},
    {"id":"25269","name":"Committee for medicinal products for human use October 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-10-24T02:00:00Z","last_updated_date":"2003-10-24T02:00:00Z","reference_number":"EMEA/CPMP/5020/03/Rev0","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-october-2003-plenary-meeting-monthly-report_en.pdf"},
    {"id":"25332","name":"PDCO meeting highlights 14-16 October 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/PDCO/645737/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-14-16-october-2009_en.pdf"},
    {"id":"25383","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-11-06T10:46:00Z","last_updated_date":"2015-11-06T10:46:00Z","reference_number":"EMA/CAT/701141/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-october-2015-meeting_en.pdf"},
    {"id":"25419","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - June 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-07-04T02:00:00Z","last_updated_date":"2011-07-04T02:00:00Z","reference_number":"EMA/CVMP/37837/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-june-2011_en.pdf"},
    {"id":"25458","name":"Committee on herbal medicinal products (HMPC): Meeting report, 7 September 2006","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-09-29T02:00:00Z","last_updated_date":"2006-09-29T02:00:00Z","reference_number":"EMEA/HMPC/359284/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-7-september-2006_en.pdf"},
    {"id":"25472","name":"Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation - April 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-04-23T18:30:00Z","last_updated_date":"2012-05-03T18:30:00Z","reference_number":"EMA/COMP/175202/2012 Rev.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-meeting-report-review-applications-orphan-designation-april-2012_en.pdf"},
    {"id":"25650","name":"COMP meeting report on the review of applications for orphan designation: July 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-07-27T13:45:00Z","last_updated_date":"2015-07-27T13:45:00Z","reference_number":"EMA/COMP/426505/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-july-2015_en.pdf"},
    {"id":"25654","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the March 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-03-10T01:00:00Z","last_updated_date":"2011-03-10T01:00:00Z","reference_number":"EMA/COMP/134956/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-march-2011-meeting_en.pdf"},
    {"id":"25692","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: July 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-08-11T19:00:00Z","last_updated_date":"2017-08-11T19:00:00Z","reference_number":"EMA/CAT/462094/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-july-2017_en.pdf"},
    {"id":"25879","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the December 2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-12-12T00:09:21Z","last_updated_date":"2008-12-23T00:09:21Z","reference_number":"EMEA/666785/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-december-2008-meeting_en.pdf"},
    {"id":"25889","name":"CVMP monthly report of application procedures, guidelines and related documents: November 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-12-12T10:23:00Z","last_updated_date":"2012-12-12T10:23:00Z","reference_number":"EMA/792274/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-november-2012_en.pdf"},
    {"id":"26068","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 15-17 April 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-04-28T13:25:00Z","last_updated_date":"2015-04-28T13:25:00Z","reference_number":"EMA/PDCO/249612/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-15-17-april-2015_en.pdf"},
    {"id":"26076","name":"Committee for proprietary medicinal products November 2001 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2001-11-21T01:00:00Z","last_updated_date":"2001-11-21T01:00:00Z","reference_number":"CPMP/3536/01","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-november-2001-plenary-meeting-monthly-report_en.pdf"},
    {"id":"26111","name":"Committee for Medicinal Products for Human Use (CHMP) - March 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-03-30T02:00:00Z","last_updated_date":"2010-03-30T02:00:00Z","reference_number":"EMA/CHMP/190774/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-march-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"26136","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the February 2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-02-11T00:09:21Z","last_updated_date":"2008-02-11T00:09:21Z","reference_number":"EMEA/COMP/44555/08","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-february-2008-meeting_en.pdf"},
    {"id":"26193","name":"COMP meeting report on the review of applications for orphan designation: June 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T19:35:00Z","last_updated_date":"2014-06-16T19:35:00Z","reference_number":"EMA/COMP/309595/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-june-2014_en.pdf"},
    {"id":"26293","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 21-22 May  2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-06-14T11:45:00Z","last_updated_date":"2012-06-14T11:45:00Z","reference_number":"EMA/HMPC/349877/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-21-22-may-2012_en.pdf"},
    {"id":"26451","name":"Committee for Medicinal Products for Human Use (CHMP) - June 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-06-29T02:00:00Z","last_updated_date":"2007-06-29T02:00:00Z","reference_number":"EMEA/267656/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-june-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"26519","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 8-10 October 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-10-17T18:20:00Z","last_updated_date":"2014-10-17T18:20:00Z","reference_number":"EMA/PDCO/623408/2014 ","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-8-10-october-2014_en.pdf"},
    {"id":"26654","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: November 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-11-21T10:00:00Z","last_updated_date":"2017-11-21T10:00:00Z","reference_number":"EMA/CAT/740936/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-november-2017_en.pdf"},
    {"id":"26696","name":"Committee for Advanced Therapies (CAT): September 2009 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2009-09-17T02:00:00Z","reference_number":"EMEA/CAT/586842/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-september-2009-meeting-monthly-report_en.pdf"},
    {"id":"26813","name":"Committee for Advanced Therapies (CAT): July 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/CAT/407854/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-july-2010-meeting-monthly-report_en.pdf"},
    {"id":"26999","name":"CVMP monthly report of application procedures, guidelines and related documents: April 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T12:40:00Z","last_updated_date":"2013-05-17T12:40:00Z","reference_number":"EMA/249895/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-april-2013_en.pdf"},
    {"id":"27047","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 7-9 August 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-08-16T11:30:00Z","last_updated_date":"2013-08-22T12:50:00Z","reference_number":"EMA/499786/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-7-9-august-2013_en.pdf"},
    {"id":"27187","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: November 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T12:32:00Z","last_updated_date":"2016-12-13T12:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-november-2016_en.pdf"},
    {"id":"27198","name":"PDCO meeting report 9-11 November 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-11-17T13:02:00Z","last_updated_date":"2011-11-23T12:00:00Z","reference_number":"EMA/PDCO/859946/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-9-11-november-2011_en.pdf"},
    {"id":"27259","name":"Committee for Medicinal Products for Human Use (CHMP) - July 2003 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2003-08-01T02:00:00Z","last_updated_date":"2003-08-01T02:00:00Z","reference_number":"EMEA/CPMP/3754/03","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-july-2003-plenary-meeting-monthly-report_en.pdf"},
    {"id":"27294","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-10-27T11:35:00Z","last_updated_date":"2014-10-27T11:35:00Z","reference_number":"EMA/CAT/654520/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-october-2014-meeting_en.pdf"},
    {"id":"27316","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 19-20 November 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-12-12T11:45:00Z","last_updated_date":"2012-12-12T11:45:00Z","reference_number":"EMA/HMPC/768189/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-19-20-november-2012_en.pdf"},
    {"id":"27422","name":"Committee for Medicinal Products for Human Use (CHMP) - June 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/CHMP/327265/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-june-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"27475","name":"PDCO meeting report 6-8 October 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-10-15T02:00:00Z","last_updated_date":"2010-10-15T02:00:00Z","reference_number":"EMA/PDCO/620211/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-6-8-october-2010_en.pdf"},
    {"id":"27586","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: July 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-08-04T12:35:00Z","last_updated_date":"2016-08-04T12:35:00Z","reference_number":"EMA/CAT/531607/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-july-2016_en.pdf"},
    {"id":"27627","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: May 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-05-29T13:00:00Z","last_updated_date":"2015-05-29T13:00:00Z","reference_number":"EMA/CAT/335502/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-may-2015-meeting_en.pdf"},
    {"id":"27632","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - January 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/CVMP/37837/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-january-2011_en.pdf"},
    {"id":"27777","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: March 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-04-19T19:00:00Z","last_updated_date":"2017-04-19T19:00:00Z","reference_number":"EMA/177535/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-march-2017_en.pdf"},
    {"id":"27795","name":"Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation - February 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-02-21T14:42:00Z","last_updated_date":"2012-02-21T14:42:00Z","reference_number":"EMA/COMP/81554/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-meeting-report-review-applications-orphan-designation-february-2012_en.pdf"},
    {"id":"27810","name":"Committee for Advanced Therapies (CAT): May 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-05-23T02:00:00Z","last_updated_date":"2011-05-23T02:00:00Z","reference_number":"EMA/CAT/393591/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-may-2011-meeting-monthly-report_en.pdf"},
    {"id":"27867","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 10-13 October 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-10-20T19:10:00Z","last_updated_date":"2017-10-20T19:10:00Z","reference_number":"EMA/PDCO/692078/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-10-13-october-2017_en.pdf"},
    {"id":"27873","name":"Committee for Medicinal Products for Human Use (CHMP) - July 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-07-31T02:00:00Z","last_updated_date":"2008-07-31T02:00:00Z","reference_number":"EMEA/CHMP/390768/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-july-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"27985","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - September 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/CVMP/450079/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-september-2010_en.pdf"},
    {"id":"27992","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the November 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-11-12T01:00:00Z","last_updated_date":"2010-11-12T01:00:00Z","reference_number":"EMA/645806/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-november-2010-meeting_en.pdf"},
    {"id":"28016","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: February 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-03-18T14:50:00Z","last_updated_date":"2014-03-18T14:50:00Z","reference_number":"EMA/125456/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-february-2014_en.pdf"},
    {"id":"28029","name":"COMP meeting report on the review of applications for orphan designation: May 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T17:40:00Z","last_updated_date":"2015-05-19T17:40:00Z","reference_number":"EMA/COMP/287101/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-may-2015_en.pdf"}    {"id":"28080","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 20-23 March 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-04-09T15:41:00Z","last_updated_date":"2018-04-09T15:41:00Z","reference_number":"EMA/PDCO/203743/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-20-23-march-2018_en.pdf"},
    {"id":"28099","name":"Committee for Medicinal Products for Human Use (CHMP) - July 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-07-30T02:00:00Z","last_updated_date":"2009-07-30T02:00:00Z","reference_number":"EMEA/CHMP/473955/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-july-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"28114","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the December 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-12-15T01:00:00Z","last_updated_date":"2011-11-22T16:48:00Z","reference_number":"EMA/773028/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-december-2010-meeting_en.pdf"},
    {"id":"28134","name":"Committee for Medicinal Products for Human Use (CHMP) - March 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-04-06T02:00:00Z","last_updated_date":"2006-04-06T02:00:00Z","reference_number":"CHMP/102937/2006, Rev 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-march-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"28186","name":"PDCO meeting highlights 21-23 November 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-11-27T00:00:00Z","last_updated_date":"2007-11-27T00:00:00Z","reference_number":"Ref. EMEA/553291/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-21-23-november-2007_en.pdf"},
    {"id":"28480","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the September 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-09-20T17:13:00Z","last_updated_date":"2011-09-20T17:13:00Z","reference_number":"EMA/COMP/399956/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-september-2011-meeting_en.pdf"},
    {"id":"28587","name":"Committee for Medicinal Products for Human Use (CHMP) - November 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-11-30T00:09:21Z","last_updated_date":"2009-11-30T00:09:21Z","reference_number":"EMEA/CHMP/745639/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-november-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"28637","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 24 November 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T11:30:00Z","last_updated_date":"2014-12-12T11:30:00Z","reference_number":"EMA/HMPC/744424/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-24-november-2014_en.pdf"},
    {"id":"28684","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: June 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-07-21T17:25:00Z","last_updated_date":"2016-07-21T17:25:00Z","reference_number":"EMA/842254/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-june-2016_en.pdf"},
    {"id":"28694","name":"CVMP monthly report of application procedures, guidelines and related documents: January 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T11:00:00Z","last_updated_date":"2013-03-08T11:00:00Z","reference_number":"EMA/98737/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-january-2013_en.pdf"},
    {"id":"28705","name":"Committee for Medicinal Products for Human Use (CHMP) - September 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-10-02T02:09:21Z","last_updated_date":"2009-10-02T02:09:21Z","reference_number":"EMEA/CHMP/599418/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-september-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"28879","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: April 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-04-30T17:28:00Z","last_updated_date":"2018-04-30T17:28:00Z","reference_number":"EMA/CAT/262029/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-april-2018_en.pdf"},
    {"id":"28921","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 12-15 December 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T14:50:00Z","last_updated_date":"2018-01-18T14:50:00Z","reference_number":"EMA/PDCO/844387/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-12-15-december-2017_en.pdf"},
    {"id":"28947","name":"Committee on herbal medicinal products (HMPC): Meeting report, 2-3 July 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-07-15T02:00:00Z","last_updated_date":"2009-07-15T02:00:00Z","reference_number":"EMEA/HMPC/369359/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-2-3-july-2008_en.pdf"},
    {"id":"29054","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - March 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-03-28T02:00:00Z","last_updated_date":"2011-03-28T02:00:00Z","reference_number":"EMA/CVMP/37837/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-march-2011_en.pdf"},
    {"id":"29162","name":"Committee for Advanced Therapies (CAT) monthly report of application procedures, guidelines and related documents on advanced therapies: June 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-07-13T17:23:00Z","last_updated_date":"2012-07-13T17:23:00Z","reference_number":"EMA/CAT/415586/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-june-2012-meeting_en.pdf"},
    {"id":"29198","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 12-14 June 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-06-27T12:00:00Z","last_updated_date":"2013-06-27T12:00:00Z","reference_number":"EMA/356485/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-12-14-june-2013_en.pdf"},
    {"id":"29271","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 3-5 October 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-10-11T13:35:00Z","last_updated_date":"2012-10-11T13:35:00Z","reference_number":"EMA/PDCO/626247/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-3-5-october-2012_en.pdf"},
    {"id":"29287","name":"Committee for proprietary medicinal products May 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2002-06-06T02:00:00Z","last_updated_date":"2002-06-06T02:00:00Z","reference_number":"EMEA/CPMP/2222/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-may-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"29293","name":"PDCO meeting highlights 2-4 July 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/PDCO/355329/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-2-4-july-2008_en.pdf"},
    {"id":"29376","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the February 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-02-14T01:00:00Z","last_updated_date":"2011-02-18T01:00:00Z","reference_number":"EMA/COMP/107542/2011 corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-february-2011-meeting_en.pdf"},
    {"id":"29469","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: December 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T15:30:00Z","last_updated_date":"2017-01-23T15:30:00Z","reference_number":"EMA/872789/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-december-2016_en.pdf"},
    {"id":"29477","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: November 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T10:30:00Z","last_updated_date":"2015-12-14T10:30:00Z","reference_number":"EMA/748539/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-november-2015_en.pdf"},
    {"id":"29634","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: July 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T13:30:00Z","last_updated_date":"2015-08-11T13:30:00Z","reference_number":"EMA/454226/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-july-2015_en.pdf"},
    {"id":"29650","name":"Committee on herbal medicinal products (HMPC): Meeting report, 19-20 September 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-10-24T02:00:00Z","last_updated_date":"2005-10-24T02:00:00Z","reference_number":"EMEA/HMPC/322553/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-19-20-september-2005_en.pdf"},
    {"id":"29731","name":"COMP meeting report on the review of applications for orphan designation: October 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-10-11T11:55:00Z","last_updated_date":"2012-10-11T11:55:00Z","reference_number":"EMA/COMP/621766/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-october-2012_en.pdf"},
    {"id":"29747","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 9-10 March 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-04-01T17:05:00Z","last_updated_date":"2015-04-01T17:05:00Z","reference_number":"EMA/HMPC/180661/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-9-10-march-2015_en.pdf"},
    {"id":"29896","name":"PDCO meeting highlights 8-10 September 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-09-22T02:00:00Z","last_updated_date":"2010-09-27T02:00:00Z","reference_number":"EMA/PDCO/534094/2010 Correction 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-8-10-september-2010_en.pdf"},
    {"id":"29939","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: April 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-05-13T14:11:00Z","last_updated_date":"2016-05-13T14:11:00Z","reference_number":"EMA/246326/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-april-2016_en.pdf"},
    {"id":"29991","name":"Committee for Medicinal Products for Human Use (CHMP) - October 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-10-28T02:00:00Z","last_updated_date":"2010-10-28T02:00:00Z","reference_number":"EMA/CHMP/656448/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-october-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"30025","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 18-19 September 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T13:48:00Z","last_updated_date":"2017-10-12T13:48:00Z","reference_number":"EMA/HMPC/637548/2017 FINAL","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-18-19-september-2017_en.pdf"},
    {"id":"30084","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: January 2016 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-02-03T10:45:00Z","last_updated_date":"2016-02-03T10:45:00Z","reference_number":"EMA/68141/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-january-2016-meeting_en.pdf"},
    {"id":"30108","name":"Committee for Medicinal Products for Human Use (CHMP) - February 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-04-29T02:00:00Z","last_updated_date":"2009-04-29T02:00:00Z","reference_number":"EMEA/97795/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-february-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"30149","name":"COMP meeting report on the review of applications for orphan designation: March 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T14:13:00Z","last_updated_date":"2017-03-30T14:13:00Z","reference_number":"EMA/COMP/140585/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-march-2017_en.pdf"},
    {"id":"30192","name":"CVMP monthly report of application procedures, guidelines and related documents: July 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-08-21T13:40:00Z","last_updated_date":"2012-08-21T13:40:00Z","reference_number":"EMA/483316/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-july-2012_en.pdf"},
    {"id":"30401","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - March 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-03-31T02:00:00Z","last_updated_date":"2008-03-31T02:00:00Z","reference_number":"EMEA/174962/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-march-2008_en.pdf"},
    {"id":"30455","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - January 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-02-10T01:00:00Z","last_updated_date":"2010-02-10T01:00:00Z","reference_number":"EMA/CVMP/64865/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-january-2010_en.pdf"},
    {"id":"30574","name":"PDCO meeting highlights held by written procedure 19-21 August 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-08-25T02:00:00Z","last_updated_date":"2009-08-25T02:00:00Z","reference_number":"EMEA/PDCO/518054/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-held-written-procedure-19-21-august-2009_en.pdf"},
    {"id":"30686","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 12–15 September 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-10-16T11:16:00Z","last_updated_date":"2017-10-16T11:16:00Z","reference_number":"EMEA/PDCO/644202/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-12-15-september-2017_en.pdf"},
    {"id":"30768","name":"CVMP monthly report of application procedures, guidelines and related documents: June 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-07-09T11:50:00Z","last_updated_date":"2013-07-09T11:50:00Z","reference_number":"EMA/249895/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-june-2013_en.pdf"},
    {"id":"30799","name":"Committee for Medicinal Products for Veterinary Use (CVMP) monthly report of application procedures, guidelines and related documents: May 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T14:30:00Z","last_updated_date":"2012-05-30T14:30:00Z","reference_number":"EMA/343346/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-may-2012_en.pdf"},
    {"id":"30820","name":"PDCO meeting highlights 27-29 May 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-06-03T02:00:00Z","last_updated_date":"2009-06-03T02:00:00Z","reference_number":"EMEA/PDCO/298970/2009- Rev1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-27-29-may-2009_en.pdf"},
    {"id":"30869","name":"PDCO meeting report 15-17 June 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-07-25T02:00:00Z","reference_number":"EMA/PDCO/469116/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-15-17-june-2011_en.pdf"},
    {"id":"30879","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 23-24 July 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-08-15T13:35:00Z","last_updated_date":"2018-08-15T13:35:00Z","reference_number":"EMA/HMPC/510266/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-23-24-july-2018_en.pdf"},
    {"id":"30905","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the October 2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-10-10T02:09:21Z","last_updated_date":"2008-10-10T02:09:21Z","reference_number":"EMEA/COPM/497503/08","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-october-2008-meeting_en.pdf"},
    {"id":"30915","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 18-20 March 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T13:25:00Z","last_updated_date":"2015-06-02T18:22:00Z","reference_number":"EMA/PDCO/189408/2015 Corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-18-20-march-2015_en.pdf"},
    {"id":"30938","name":"COMP meeting report on the review of applications for orphan designation: May 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T13:30:00Z","last_updated_date":"2014-06-05T17:25:00Z","reference_number":"EMA/231784/2014 Corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-may-2014_en.pdf"},
    {"id":"31035","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - July 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-07-31T02:00:00Z","last_updated_date":"2007-07-31T02:00:00Z","reference_number":"EMEA/358967/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-july-2007_en.pdf"},
    {"id":"31051","name":"Committee for Advanced Therapies (CAT): April 2009 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-04-22T02:00:00Z","last_updated_date":"2009-04-22T02:00:00Z","reference_number":"EMEA/CAT/248054/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-april-2009-meeting-monthly-report_en.pdf"},
    {"id":"31212","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - July 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2011-08-05T02:00:00Z","reference_number":"EMA/CVMP/37837/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-july-2011_en.pdf"},
    {"id":"31280","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: January 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T16:00:01Z","last_updated_date":"2013-01-18T16:00:01Z","reference_number":"EMA/CAT/25123/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-january-2013-meeting_en.pdf"},
    {"id":"31355","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 11-12 March 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-03-26T16:30:00Z","last_updated_date":"2013-03-26T16:30:00Z","reference_number":"EMA/HMPC/172743/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-11-12-march-2013_en.pdf"},
    {"id":"31382","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 20-23 February 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T18:10:00Z","last_updated_date":"2018-03-07T18:10:00Z","reference_number":"EMA/PDCO/124776/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-20-23-february-2018_en.pdf"},
    {"id":"31393","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - March 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"EMA/CVMP/168891/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-march-2010_en.pdf"},
    {"id":"31500","name":"PDCO meeting highlights 10-12 December 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-12-17T00:00:00Z","last_updated_date":"2008-12-17T00:00:00Z","reference_number":"EMEA/PDCO/675823/2008 - corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-10-12-december-2008_en.pdf"},
    {"id":"31510","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: July 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-08-02T19:00:00Z","last_updated_date":"2018-08-02T19:00:00Z","reference_number":"EMA/CAT/514869/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-july-2018_en.pdf"},
    {"id":"31533","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 30-31 May 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-06-15T11:42:00Z","last_updated_date":"2016-06-15T11:42:00Z","reference_number":"EMA/HMPC/398247/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-30-31-may-2016_en.pdf"},
    {"id":"31785","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 29 May-01 June 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-06-20T16:00:00Z","last_updated_date":"2018-06-20T16:00:00Z","reference_number":"EMA/PDCO/387556/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-29-may-01-june-2018_en.pdf"},
    {"id":"31797","name":"COMP meeting report on the review of applications for orphan designation: February 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-02-27T17:05:00Z","last_updated_date":"2017-02-27T17:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-february-2017_en.pdf"},
    {"id":"31862","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: April 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-05-13T16:20:00Z","last_updated_date":"2014-05-13T16:20:00Z","reference_number":"EMA/242696/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-april-2014_en.pdf"},
    {"id":"31935","name":"PDCO meeting highlights 4-6 February 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-02-13T00:00:00Z","last_updated_date":"2009-02-13T00:00:00Z","reference_number":"EMEA/85197/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-4-6-february-2009_en.pdf"},
    {"id":"31955","name":"Committee for Medicinal Products for Human Use (CHMP) - September 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-10-01T02:00:00Z","last_updated_date":"2010-10-01T02:00:00Z","reference_number":"EMA/CHMP/601293/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-september-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"31971","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - January 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-01-31T00:00:00Z","last_updated_date":"2005-01-31T00:00:00Z","reference_number":"EMEA/14403/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-january-2005_en.pdf"},
    {"id":"32012","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 19 - 20 September 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-10-05T02:00:00Z","last_updated_date":"2016-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-19-20-september-2016_en.pdf"},
    {"id":"32020","name":"PDCO meeting highlights 4-6 August 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-08-16T02:00:00Z","last_updated_date":"2010-08-16T02:00:00Z","reference_number":"EMA/PDCO/495373/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-4-6-august-2010_en.pdf"},
    {"id":"32035","name":"PDCO meeting report 12-14 January 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/PDCO/9884/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-12-14-january-2011_en.pdf"},
    {"id":"32099","name":"COMP meeting report on the review of applications for orphan designation: January 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-01-15T13:15:00Z","last_updated_date":"2015-01-15T13:15:00Z","reference_number":"EMA/COMP/804888/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2015_en.pdf"},
    {"id":"32124","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 30-31 January 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-02-21T16:30:00Z","last_updated_date":"2017-02-21T16:30:00Z","reference_number":"EMA/HMPC/85712/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-30-31-january-2017_en.pdf"},
    {"id":"32139","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the October 2009 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-10-13T02:09:21Z","last_updated_date":"2009-10-13T02:09:21Z","reference_number":"EMEA/COMP/617218/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-october-2009-meeting_en.pdf"},
    {"id":"32308","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 11-13 September 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T16:00:00Z","last_updated_date":"2013-11-18T14:00:00Z","reference_number":"EMA/PDCO/556834/2013 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-11-13-september-2013_en.pdf"},
    {"id":"32317","name":"PDCO meeting highlights 18-20 December 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-01-10T00:00:00Z","last_updated_date":"2008-01-10T00:00:00Z","reference_number":"EMEA/PDCO/606122/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-18-20-december-2007_en.pdf"},
    {"id":"32344","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: February 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-03-23T18:00:00Z","last_updated_date":"2017-03-23T18:00:00Z","reference_number":"EMA/118109/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-february-2017_en.pdf"},
    {"id":"32478","name":"PDCO monthly report of opinions on paediatric investigation plans: 11-13 April 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-04-20T17:33:00Z","last_updated_date":"2012-05-22T16:12:00Z","reference_number":"EMA/PDCO/243834/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-11-13-april-2012_en.pdf"},
    {"id":"32574","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the January 2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-01-11T00:09:21Z","last_updated_date":"2008-01-11T00:09:21Z","reference_number":"EMEA/COMP/609618/07","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-january-2008-meeting_en.pdf"},
    {"id":"32595","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: January 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T16:45:00Z","last_updated_date":"2015-01-27T16:45:00Z","reference_number":"EMA/CAT/45673/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-january-2015-meeting_en.pdf"},
    {"id":"32698","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the June 2008 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-06-13T02:09:21Z","last_updated_date":"2008-06-13T02:09:21Z","reference_number":"EMEA/COMP/308994/08","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-june-2008-meeting_en.pdf"},
    {"id":"32746","name":"Committee on herbal medicinal products (HMPC): Meeting report, 5-6 November 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T00:00:00Z","last_updated_date":"2008-11-20T00:00:00Z","reference_number":"EMEA/HMPC/610485/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-5-6-november-2008_en.pdf"},
    {"id":"32775","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - April 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-04-29T02:00:00Z","last_updated_date":"2005-04-29T02:00:00Z","reference_number":"EMEA/CVMP/142316/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-april-2005_en.pdf"},
    {"id":"32777","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: September 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-10-09T02:00:00Z","last_updated_date":"2015-10-09T02:00:00Z","reference_number":"EMA/540868/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-september-2015_en.pdf"},
    {"id":"32807","name":"COMP meeting report on the review of applications for orphan designation: March 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-03-21T10:30:00Z","last_updated_date":"2013-03-21T10:30:00Z","reference_number":"EMA/COMP/93974/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-march-2013_en.pdf"},
    {"id":"32875","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: October 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T17:10:00Z","last_updated_date":"2014-11-14T17:10:00Z","reference_number":"EMA/629261/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-october-2014_en.pdf"},
    {"id":"32951","name":"PDCO meeting report 10-12 November 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2010-12-06T01:00:00Z","reference_number":"EMA/PDCO/690063/2010 Corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-10-12-november-2010_en.pdf"},
    {"id":"32987","name":"Committee on herbal medicinal products (HMPC): Meeting report, 7-8 May 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-05-21T02:00:00Z","last_updated_date":"2008-05-21T02:00:00Z","reference_number":"EMEA/HMPC/248007/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-7-8-may-2008_en.pdf"},
    {"id":"33031","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 8-9 July 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-07-30T15:45:00Z","last_updated_date":"2013-07-30T15:45:00Z","reference_number":"EMA/HMPC/301544/213","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-8-9-july-2013_en.pdf"},
    {"id":"33057","name":"COMP meeting report on the review of applications for orphan designation: April 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-04-14T18:50:00Z","last_updated_date":"2014-04-14T18:50:00Z","reference_number":"EMA/COMP/189040/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-april-2014_en.pdf"},
    {"id":"33167","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: March 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T14:00:00Z","last_updated_date":"2016-04-06T14:00:00Z","reference_number":"EMA/191606/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-march-2016_en.pdf"},
    {"id":"33219","name":"Committee for Advanced Therapies (CAT): April 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-05-06T02:00:00Z","last_updated_date":"2011-07-07T02:00:00Z","reference_number":"EMA/CAT/328232/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-april-2011-meeting-monthly-report_en.pdf"},
    {"id":"33274","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: May 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-06-11T17:00:00Z","last_updated_date":"2014-06-11T17:00:00Z","reference_number":"EMA/286257/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-may-2014_en.pdf"},
    {"id":"33382","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 30 June - 1 July 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-07-14T13:05:00Z","last_updated_date":"2014-07-14T13:05:00Z","reference_number":"EMA/HMPC/415092/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-30-june-1-july-2014_en.pdf"},
    {"id":"33422","name":"CAT monthly report of application procedures, guidelines\n\nand related documents on advanced therapies: April 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-04-30T16:30:00Z","last_updated_date":"2014-04-30T16:30:00Z","reference_number":"EMA/CAT/244887/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-april-2014-meeting_en.pdf"},
    {"id":"33424","name":"Committee for Advanced Therapies (CAT): May 2009 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"EMEA/CAT/312239/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-may-2009-meeting-monthly-report_en.pdf"},
    {"id":"33544","name":"PDCO meeting report 8-10 December 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/PDCO/790151/2010 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-8-10-december-2010_en.pdf"},
    {"id":"33704","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - September 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-09-30T02:00:00Z","last_updated_date":"2007-09-30T02:00:00Z","reference_number":"EMEA/504391/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-september-2007_en.pdf"},
    {"id":"33709","name":"COMP meeting report on the review of applications for orphan designation: May 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-06-01T12:45:00Z","last_updated_date":"2016-06-01T12:45:00Z","reference_number":"EMA/COMP/331689/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-may-2016_en.pdf"},
    {"id":"33784","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the October 2007 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-10-11T02:09:21Z","last_updated_date":"2007-10-11T02:09:21Z","reference_number":"EMEA/COMP/458438/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-october-2007-meeting_en.pdf"},
    {"id":"33831","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: September 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-09-30T11:30:00Z","last_updated_date":"2014-09-30T11:30:00Z","reference_number":"EMA/CAT/581538/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-september-2014-meeting_en.pdf"},
    {"id":"33930","name":"PDCO monthly report of opinions on paediatric investigation plans: 8-10 February 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T15:00:00Z","last_updated_date":"2012-02-16T15:00:00Z","reference_number":"EMA/PDCO/95918/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-8-10-february-2012_en.pdf"},
    {"id":"33983","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: January 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-01-27T15:30:00Z","last_updated_date":"2014-01-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-january-2014-meeting_en.pdf"},
    {"id":"34004","name":"Committee for Medicinal Products for Human Use (CHMP) - April 2011 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-04-20T02:00:00Z","last_updated_date":"2011-05-04T02:00:00Z","reference_number":"EMA/CHMP/306549/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-april-2011-plenary-meeting-monthly-report_en.pdf"},
    {"id":"34037","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: July 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-07-27T15:54:00Z","last_updated_date":"2015-07-27T15:54:00Z","reference_number":"EMA/CAT/499506/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-july-2015-meeting_en.pdf"}    {"id":"34151","name":"Committee on herbal medicinal products (HMPC): Meeting report, 11-12 January 2006","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-02-02T01:00:00Z","last_updated_date":"2006-02-02T01:00:00Z","reference_number":"EMEA/HMPC/21014/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-11-12-january-2006_en.pdf"},
    {"id":"34196","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-10-24T17:40:00Z","last_updated_date":"2013-10-24T17:40:00Z","reference_number":"EMA/CAT/574533/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-october-2013-meeting_en.pdf"},
    {"id":"34273","name":"COMP November 2009 plenary meeting: Monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-11-11T00:09:21Z","last_updated_date":"2009-11-18T00:00:00Z","reference_number":"EMEA/COMP/679278/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-november-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"34360","name":"PDCO meeting highlights 17-19 March 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-03-30T02:00:00Z","last_updated_date":"2010-03-30T02:00:00Z","reference_number":"EMA/PDCO/151391/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-17-19-march-2010_en.pdf"},
    {"id":"34453","name":"Committee on herbal medicinal products (HMPC): Meeting report, 9-10 January 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-01-23T00:00:00Z","last_updated_date":"2008-01-23T00:00:00Z","reference_number":"EMEA/HMPC/29102/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-9-10-january-2008_en.pdf"},
    {"id":"34598","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 27-28 January 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-02-13T11:20:00Z","last_updated_date":"2014-02-13T11:20:00Z","reference_number":"EMA/HMPC/67144/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-27-28-january-2014_en.pdf"},
    {"id":"34631","name":"Committee for Medicinal Products for Human Use (CHMP) - December 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-01-16T01:00:00Z","last_updated_date":"2006-01-16T01:00:00Z","reference_number":"EMEA/CHMP/420100/2005, rev 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-december-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"34688","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - November 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-11-30T01:00:00Z","last_updated_date":"2008-11-30T01:00:00Z","reference_number":"EMEA/666257/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-november-2008_en.pdf"},
    {"id":"34722","name":"Committee on herbal medicinal products (HMPC): Meeting report, 8 May 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-05-21T02:00:00Z","last_updated_date":"2007-05-21T02:00:00Z","reference_number":"EMEA/HMPC/216295/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-8-may-2007_en.pdf"},
    {"id":"34813","name":"PDCO monthly report of opinions on paediatric investigation plans: 11-13 January 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-01-24T13:10:00Z","last_updated_date":"2012-01-24T13:10:00Z","reference_number":"EMA/PDCO/993731/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-11-13-january-2012_en.pdf"},
    {"id":"34860","name":"CVMP monthly report of application procedures, guidelines and related documents: September 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-10-01T12:10:00Z","last_updated_date":"2012-10-01T12:10:00Z","reference_number":"EMA/615951/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-september-2012_en.pdf"},
    {"id":"34895","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - September 2008","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-09-30T02:00:00Z","last_updated_date":"2008-09-30T02:00:00Z","reference_number":"EMEA/543525/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-september-2008_en.pdf"},
    {"id":"34930","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: September 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-09-19T18:23:00Z","last_updated_date":"2016-09-19T18:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-september-2016_en.pdf"},
    {"id":"34942","name":"CVMP monthly report of application procedures, guidelines and related documents: November 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-12-10T15:51:00Z","last_updated_date":"2013-12-10T15:51:00Z","reference_number":"EMA/736920/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-november-2013_en.pdf"},
    {"id":"34973","name":"COMP meeting report on the review of applications for orphan designation: 3-5 October 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-10-16T13:55:00Z","last_updated_date":"2017-10-16T13:55:00Z","reference_number":"EMA/COMP/634206/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-3-5-october-2017_en.pdf"},
    {"id":"34992","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the January 2009 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-01-08T00:09:21Z","last_updated_date":"2009-01-08T00:09:21Z","reference_number":"EMEA/COMP/694107/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-january-2009-meeting_en.pdf"},
    {"id":"35038","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: April 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T12:59:00Z","last_updated_date":"2017-05-08T12:59:00Z","reference_number":"EMA/CAT/251488/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-april-2017_en.pdf"},
    {"id":"35086","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: November2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-12-21T11:00:00Z","last_updated_date":"2017-12-21T11:00:00Z","reference_number":"EMA/779051/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-november2017_en.pdf"},
    {"id":"35170","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 5-6 May 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-05-26T17:30:00Z","last_updated_date":"2014-05-26T17:30:00Z","reference_number":"EMA/HMPC/292352/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-5-6-may-2014_en.pdf"},
    {"id":"35195","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: April 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T18:10:00Z","last_updated_date":"2013-04-30T18:10:00Z","reference_number":"EMA/CAT/256262/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-april-2013-meeting_en.pdf"},
    {"id":"35290","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 4-5 April 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-04-21T12:50:00Z","last_updated_date":"2016-04-21T12:50:00Z","reference_number":"EMA/HMPC/271408/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-4-5-april-2016_en.pdf"},
    {"id":"35383","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 14-16 January 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-01-28T01:00:00Z","last_updated_date":"2015-01-28T01:00:00Z","reference_number":"EMA/PDCO/34456/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-14-16-january-2015_en.pdf"},
    {"id":"35404","name":"Committee for Medicinal Products for Human Use (CHMP) - October 2009 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-10-30T00:09:21Z","last_updated_date":"2009-10-30T00:09:21Z","reference_number":"EMEA/CHMP/674356/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-october-2009-plenary-meeting-monthly-report_en.pdf"},
    {"id":"35417","name":"Committee for Advanced Therapies (CAT): February 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-03-21T01:00:00Z","last_updated_date":"2011-03-21T01:00:00Z","reference_number":"EMA/CAT/136236/201","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-february-2011-meeting-monthly-report_en.pdf"},
    {"id":"35441","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 23-24 November 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-12-04T17:27:00Z","last_updated_date":"2015-12-04T17:27:00Z","reference_number":"EMA/HMPC/803211/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-23-24-november-2015_en.pdf"},
    {"id":"35478","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - October 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-10-31T00:00:00Z","last_updated_date":"2007-10-31T00:00:00Z","reference_number":"EMEA/538783/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-october-2007_en.pdf"},
    {"id":"35615","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - December 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-02-10T01:00:00Z","last_updated_date":"2010-02-10T01:00:00Z","reference_number":"EMA/CVMP/69430/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-december-2009_en.pdf"},
    {"id":"35652","name":"Committee for Medicinal Products for Human Use (CHMP) - June 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-07-02T02:00:00Z","last_updated_date":"2010-07-02T02:00:00Z","reference_number":"EMA/CHMP/410431/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-june-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"35675","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the November 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-11-16T17:10:00Z","last_updated_date":"2011-11-18T12:00:00Z","reference_number":"EMA/COMP/883783/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-november-2011-meeting_en.pdf"},
    {"id":"35740","name":"COMP meeting report on the review of applications for orphan designation: October 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T11:13:00Z","last_updated_date":"2013-10-17T11:13:00Z","reference_number":"EMA/COMP/557300/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-october-2013_en.pdf"},
    {"id":"35758","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 23-25 April 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-05-02T14:10:00Z","last_updated_date":"2014-05-02T14:10:00Z","reference_number":"EMA/PDCO/239140/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-23-25-april-2014_en.pdf"},
    {"id":"35784","name":"Committee for Advanced Therapies (CAT): November 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-12-01T15:10:00Z","last_updated_date":"2011-12-01T15:10:00Z","reference_number":"EMA/CAT/923034/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-november-2011-meeting-monthly-report_en.pdf"},
    {"id":"35805","name":"Committee on herbal medicinal products (HMPC): Meeting report, 7 September 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-09-27T02:00:00Z","last_updated_date":"2007-09-27T02:00:00Z","reference_number":"EMEA/HMPC/422946/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-7-september-2007_en.pdf"},
    {"id":"35896","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - April 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-04-30T02:00:00Z","last_updated_date":"2010-04-30T02:00:00Z","reference_number":"EMA/CVMP/257821/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-april-2010_en.pdf"},
    {"id":"35905","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: December 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T17:30:00Z","last_updated_date":"2015-12-18T17:30:00Z","reference_number":"EMA/853093/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-december-2015-meeting_en.pdf"},
    {"id":"35927","name":"Committee for Medicinal Products for Human Use (CHMP) - October 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-10-29T02:00:00Z","last_updated_date":"2004-10-29T02:00:00Z","reference_number":"EMEA/CHMP/119155/2004","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-october-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"35935","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: March 2016 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-04-05T16:25:00Z","last_updated_date":"2016-04-05T16:25:00Z","reference_number":"EMA/CAT/237075/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-march-2016-meeting_en.pdf"},
    {"id":"36001","name":"Committee for Advanced Therapies (CAT): January 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-01-27T00:09:21Z","last_updated_date":"2010-01-27T00:09:21Z","reference_number":"EMA/CAT/38910/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-january-2010-meeting-monthly-report_en.pdf"},
    {"id":"36050","name":"Committee for Advanced Therapies (CAT): October 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-10-28T02:00:00Z","last_updated_date":"2010-10-28T02:00:00Z","reference_number":"EMA/CAT/657770/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-october-2010-meeting-monthly-report_en.pdf"},
    {"id":"36054","name":"Committee for Advanced Therapies (CAT): October 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-10-25T17:18:00Z","last_updated_date":"2011-10-25T17:30:00Z","reference_number":"EMA/CAT/850481/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-october-2011-meeting-monthly-report_en.pdf"},
    {"id":"36092","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - May 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-05-27T02:00:00Z","last_updated_date":"2005-05-27T02:00:00Z","reference_number":"EMEA/172550/2005, corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-may-2005_en.pdf"},
    {"id":"36116","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 17-19 August 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-09-01T12:00:00Z","last_updated_date":"2016-09-01T12:00:00Z","reference_number":"EMA/PDCO/567509/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-17-19-august-2016_en.pdf"},
    {"id":"36302","name":"Committee for Medicinal Products for Human Use (CHMP) - May 2008 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2008-06-06T02:00:00Z","last_updated_date":"2008-06-06T02:00:00Z","reference_number":"EMEA/CHMP/279235/2008","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-may-2008-plenary-meeting-monthly-report_en.pdf"},
    {"id":"36391","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 27-29 January 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-02-16T15:20:00Z","last_updated_date":"2016-02-16T15:20:00Z","reference_number":"EMA/PDCO/20678/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-27-29-january-2016_en.pdf"},
    {"id":"36518","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - November 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-11-30T00:00:00Z","last_updated_date":"2007-11-30T00:00:00Z","reference_number":"EMEA/571778/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-november-2007_en.pdf"},
    {"id":"36524","name":"Committee on herbal medicinal products (HMPC): Meeting report, 31 October 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-11-13T00:00:00Z","last_updated_date":"2007-11-13T00:00:00Z","reference_number":"EMEA/HMPC/521358/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-31-october-2007_en.pdf"},
    {"id":"36586","name":"PDCO meeting highlights 16-18 September 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/PDCO/570808/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-16-18-september-2009_en.pdf"},
    {"id":"36693","name":"COMP meeting report on the review of applications for orphan designation: September 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-09-09T16:02:13Z","last_updated_date":"2013-09-09T16:02:13Z","reference_number":"EMA/COMP/378836/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2013_en.pdf"},
    {"id":"36815","name":"Committee for Advanced Therapies (CAT): September 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-10-04T02:00:00Z","last_updated_date":"2011-10-04T02:00:00Z","reference_number":"EMA/CAT/770104/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-september-2011-meeting-monthly-report_en.pdf"},
    {"id":"36829","name":"CVMP monthly report of application procedures, guidelines and related documents: May 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-06-12T13:40:00Z","last_updated_date":"2013-06-12T13:40:00Z","reference_number":"EMA/249895/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-may-2013_en.pdf"},
    {"id":"36840","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 18-21 July 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:20:00Z","last_updated_date":"2017-08-01T18:20:00Z","reference_number":"EMA/PDCO/473581/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-18-21-july-2017_en.pdf"},
    {"id":"36908","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 10-12 December 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-12-22T10:15:00Z","last_updated_date":"2014-12-22T10:15:00Z","reference_number":"EMA/PDCO/780247/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-10-12-december-2014_en.pdf"},
    {"id":"36982","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 16-18 July 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-07-29T13:00:00Z","last_updated_date":"2014-07-29T13:00:00Z","reference_number":"EMA/443651/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-16-18-july-2014_en.pdf"},
    {"id":"36985","name":"COMP meeting report on the review of applications for orphan designation: September 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-09-19T13:00:00Z","last_updated_date":"2016-09-19T13:00:00Z","reference_number":"EMA/COMP/498821/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2016_en.pdf"},
    {"id":"36989","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 10-11 March 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-03-31T02:00:00Z","last_updated_date":"2010-03-31T02:00:00Z","reference_number":"EMA/HMPC/190124/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-10-11-march-2010_en.pdf"},
    {"id":"37017","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 4-5 June 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-06-22T13:00:00Z","last_updated_date":"2018-06-22T13:00:00Z","reference_number":"EMA/HMPC/388189/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-4-5-june-2018_en.pdf"},
    {"id":"37064","name":"Committee for Advanced Therapies (CAT): March 2009 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-03-27T01:00:00Z","last_updated_date":"2009-03-27T01:00:00Z","reference_number":"EMEA/CAT/169206/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-march-2009-meeting-monthly-report_en.pdf"},
    {"id":"37077","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 12-14 November 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T13:00:00Z","last_updated_date":"2014-11-24T13:00:00Z","reference_number":"EMA/PDCO/704339/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-12-14-november-2014_en.pdf"},
    {"id":"37169","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 11-13 February 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-03-23T11:30:00Z","last_updated_date":"2015-03-23T11:30:00Z","reference_number":"EMA/PDCO/102906/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-11-13-february-2015_en.pdf"},
    {"id":"37230","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-10-18T13:30:00Z","last_updated_date":"2012-10-18T13:30:00Z","reference_number":"EMA/CAT/608504/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-october-2012-meeting_en.pdf"},
    {"id":"37271","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - July 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-07-31T02:00:00Z","last_updated_date":"2005-07-31T02:00:00Z","reference_number":"EMEA/252976/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-july-2005_en.pdf"},
    {"id":"37312","name":"PDCO monthly report of opinions on paediatric investigation plans: 4-6 July 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-07-13T11:37:00Z","last_updated_date":"2012-07-13T11:37:00Z","reference_number":"EMA/PDCO/425203/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-4-6-july-2012_en.pdf"},
    {"id":"37344","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 21-22 November 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-12-15T10:00:00Z","last_updated_date":"2016-12-15T10:00:00Z","reference_number":"EMA/HMPC/798592/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-21-22-november-2016_en.pdf"},
    {"id":"37346","name":"Committee for Medicinal Products for Veterinary Use (CVMP) monthly report of application procedures, guidelines and related documents: June  2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-07-25T13:00:00Z","last_updated_date":"2012-07-25T13:00:00Z","reference_number":"EMA/343346/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-june-2012_en.pdf"},
    {"id":"37459","name":"Committee for Medicinal Products for Human Use (CHMP) - April 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-05-04T02:00:00Z","last_updated_date":"2007-05-04T02:00:00Z","reference_number":"EMEA/181739/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-april-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"37464","name":"PDCO meeting report 18-20 April 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-05-02T02:00:00Z","last_updated_date":"2011-05-02T02:00:00Z","reference_number":"EMA/PDCO/300057/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-18-20-april-2011_en.pdf"},
    {"id":"37484","name":"Committee for Medicinal Products for Human Use (CHMP) - December 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-01-06T01:00:00Z","last_updated_date":"2005-01-06T01:00:00Z","reference_number":"CHMP/203834/2004","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-december-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"37531","name":"Committee on herbal medicinal products (HMPC): Meeting report, 8-9 March 2006","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-04-03T02:00:00Z","last_updated_date":"2006-04-03T02:00:00Z","reference_number":"EMEA/HMPC/92198/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-8-9-march-2006_en.pdf"},
    {"id":"37535","name":"COMP meeting report on the review of applications for orphan designation: June 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-06-29T13:36:00Z","last_updated_date":"2017-06-29T13:36:00Z","reference_number":"EMA/COMP/336592/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-june-2017_en.pdf"},
    {"id":"37590","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: January 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-02-27T14:50:00Z","last_updated_date":"2018-02-27T14:50:00Z","reference_number":"EMA/51903/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-january-2018_en.pdf"},
    {"id":"37614","name":"PDCO meeting report 18-20 May 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/PDCO/372487/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-18-20-may-2011_en.pdf"},
    {"id":"37618","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: January 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T12:15:00Z","last_updated_date":"2018-02-07T12:15:00Z","reference_number":"EMA/CAT/65887/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-january-2018_en.pdf"},
    {"id":"37664","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 1-2 February 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T16:35:00Z","last_updated_date":"2016-02-15T16:35:00Z","reference_number":"EMA/HMPC/99558/2016 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-1-2-february-2016_en.pdf"},
    {"id":"37788","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 9-11 October 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-10-18T12:00:00Z","last_updated_date":"2013-10-18T12:00:00Z","reference_number":"EMA/PDCO/618657/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-9-11-october-2013_en.pdf"},
    {"id":"37835","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: April 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-05-12T17:00:00Z","last_updated_date":"2015-05-12T17:00:00Z","reference_number":"EMA/246014/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-april-2015_en.pdf"},
    {"id":"37937","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - February 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-02-21T15:43:00Z","last_updated_date":"2012-02-21T15:43:00Z","reference_number":"EMA/112844/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-february-2012_en.pdf"},
    {"id":"37969","name":"PDCO meeting report 12-14 October 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-10-20T16:16:00Z","last_updated_date":"2011-10-20T16:16:00Z","reference_number":"EMA/PDCO/813133/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-12-14-october-2011_en.pdf"},
    {"id":"37987","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 6-8 February 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-02-15T12:50:00Z","last_updated_date":"2013-02-15T12:50:00Z","reference_number":"EMA/PDCO/92072/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-6-8-february-2013_en.pdf"},
    {"id":"38028","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the May 2009  meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-05-08T02:09:21Z","last_updated_date":"2009-05-08T02:09:21Z","reference_number":"EMEA/281967/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-may-2009-meeting_en.pdf"},
    {"id":"38107","name":"Committee for Advanced Therapies (CAT): March 2011 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-03-25T01:00:00Z","last_updated_date":"2011-07-07T02:00:00Z","reference_number":"EMA/CAT/229545/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-march-2011-meeting-monthly-report_en.pdf"},
    {"id":"38200","name":"Committee for proprietary medicinal products June 2002 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2002-07-10T02:00:00Z","last_updated_date":"2002-07-10T02:00:00Z","reference_number":"EMEA/CPMP/2749/02","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-proprietary-medicinal-products-june-2002-plenary-meeting-monthly-report_en.pdf"},
    {"id":"38293","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: January 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-02-18T18:35:00Z","last_updated_date":"2015-02-18T18:35:00Z","reference_number":"EMA/786165/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-january-2015_en.pdf"},
    {"id":"38342","name":"Committee for Advanced Therapies (CAT): February 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"EMA/CAT/109681/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-february-2010-meeting-monthly-report_en.pdf"},
    {"id":"38343","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 24-26 February 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-03-04T15:00:00Z","last_updated_date":"2016-03-04T15:00:00Z","reference_number":"EMA/PDCO/142970/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-24-26-february-2016_en.pdf"},
    {"id":"38371","name":"Committee for Orphan Medicinal Products (COMP) - Monthly report from the July 2010 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/COMP/364048/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-july-2010-meeting_en.pdf"},
    {"id":"38374","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: March 2013 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T11:40:00Z","last_updated_date":"2013-03-25T11:40:00Z","reference_number":"EMA/CAT/182530//2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-march-2013-meeting_en.pdf"},
    {"id":"38448","name":"PDCO meeting highlights 14-16 April 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2010-04-22T02:00:00Z","reference_number":"EMA/PDCO/226811/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-14-16-april-2010_en.pdf"},
    {"id":"38481","name":"COMP meeting report on the review of applications for orphan designation: July 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-07-22T16:05:00Z","last_updated_date":"2014-09-09T15:30:00Z","reference_number":"EMA/COMP/396320/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-july-2014_en.pdf"},
    {"id":"38485","name":"Committee for Advanced Therapies (CAT): March 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/CAT/178413/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-march-2010-meeting-monthly-report_en.pdf"},
    {"id":"38562","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 14 January 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-02-02T01:00:00Z","last_updated_date":"2010-02-02T01:00:00Z","reference_number":"EMA/HMPC/2974/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-14-january-2010_en.pdf"},
    {"id":"38567","name":"Committee on Herbal Medicinal Products (HMPC): Meeting report, 24-25 November 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/HMPC/775051/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-24-25-november-2010_en.pdf"},
    {"id":"38713","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 10-12 April 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T12:20:00Z","last_updated_date":"2013-04-22T12:20:00Z","reference_number":"EMA/232769/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-10-12-april-2013_en.pdf"},
    {"id":"38772","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: March 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-04-01T12:55:00Z","last_updated_date":"2015-04-01T12:55:00Z","reference_number":"EMA/CAT/210624/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-march-2015-meeting_en.pdf"},
    {"id":"38881","name":"COMP meeting report on the review of applications for orphan designation: March 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-03-14T16:40:00Z","last_updated_date":"2014-03-14T16:40:00Z","reference_number":"EMA/COMP/105712/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-march-2014_en.pdf"},
    {"id":"38994","name":"COMP meeting report on the review of applications for orphan designation: April 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-04-25T02:00:00Z","last_updated_date":"2013-04-25T02:00:00Z","reference_number":"EMA/COMP/192536/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-april-2013_en.pdf"},
    {"id":"39047","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - November 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-11-30T00:00:00Z","last_updated_date":"2005-11-30T00:00:00Z","reference_number":"EMEA/396235/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-november-2005_en.pdf"},
    {"id":"39215","name":"CVMP monthly report of application procedures, guidelines and related documents: December 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-01-16T12:55:00Z","last_updated_date":"2014-01-16T12:55:00Z","reference_number":"EMA/778335/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-december-2013_en.pdf"},
    {"id":"39282","name":"PDCO meeting highlights 14-16 July 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/PDCO/451774/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-14-16-july-2010_en.pdf"},
    {"id":"39315","name":"HMPC meeting report on Community herbal monographs, guidelines and other activities - 6-7 July 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-07-22T17:18:00Z","last_updated_date":"2015-07-22T17:18:00Z","reference_number":"EMA/HMPC/473270/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-community-herbal-monographs-guidelines-and-other-activities-6-7-july-2015_en.pdf"},
    {"id":"39319","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: November 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-12-17T16:15:15Z","last_updated_date":"2014-12-17T16:15:15Z","reference_number":"EMA/699369/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-november-2014_en.pdf"}    {"id":"39347","name":"PDCO meeting report 16-18 March 2011","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-03-25T01:00:00Z","last_updated_date":"2011-03-25T01:00:00Z","reference_number":"EMA/PDCO/213115/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-16-18-march-2011_en.pdf"},
    {"id":"39376","name":"PDCO meeting highlights 29-31 August 2007","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-09-05T02:00:00Z","last_updated_date":"2007-09-05T02:00:00Z","reference_number":"EMEA/294650/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-29-31-august-2007_en.pdf"},
    {"id":"39422","name":"Committee for Medicinal Products for Human Use (CHMP) - February 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/CHMP/108850/201","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-february-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"39452","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - October 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-10-31T00:00:00Z","last_updated_date":"2005-10-31T00:00:00Z","reference_number":"EMEA/351115/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-october-2005_en.pdf"},
    {"id":"39457","name":"CVMP monthly report of application procedures, guidelines and related documents: December 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T16:00:00Z","last_updated_date":"2013-01-18T16:00:00Z","reference_number":"EMA/807890/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-december-2012_en.pdf"},
    {"id":"39549","name":"Committee for Medicinal Products for Human Use (CHMP) - March 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-04-01T02:00:00Z","last_updated_date":"2004-04-01T02:00:00Z","reference_number":"EMEA/CPMP/1238/04","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-march-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"39591","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: November 2015 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-11-24T13:10:00Z","last_updated_date":"2015-11-24T13:10:00Z","reference_number":"EMA/CAT/774566/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-november-2015-meeting_en.pdf"},
    {"id":"39597","name":"Committee for Orphan Medicinal Products (COMP): Monthly report from the April 2011 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2011-04-11T02:00:00Z","last_updated_date":"2011-04-11T02:00:00Z","reference_number":"EMA/COMP/135188/2011","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-orphan-medicinal-products-comp-monthly-report-april-2011-meeting_en.pdf"},
    {"id":"39616","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 25-27 May 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-06-02T16:35:00Z","last_updated_date":"2016-06-02T16:35:00Z","reference_number":"EMA/PDCO/376295/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-25-27-may-2016_en.pdf"},
    {"id":"39719","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 12-14 August 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T13:25:00Z","last_updated_date":"2015-08-20T13:25:00Z","reference_number":"EMA/PDCO/492280/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-12-14-august-2015_en.pdf"},
    {"id":"39779","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T12:00:00Z","last_updated_date":"2016-10-20T12:00:00Z","reference_number":"EMA/CAT/675972/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-october-2016_en.pdf"},
    {"id":"39806","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: March 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-04-03T12:31:00Z","last_updated_date":"2018-04-03T12:31:00Z","reference_number":"EMA/CAT/189031/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-march-2018_en.pdf"},
    {"id":"39860","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - June 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-07-06T02:00:00Z","last_updated_date":"2010-07-06T02:00:00Z","reference_number":"EMA/CVMP/404291/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-june-2010_en.pdf"},
    {"id":"39990","name":"PDCO monthly report of opinions on paediatric investigation plans: 14-16 May 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-05-25T16:30:00Z","last_updated_date":"2012-05-25T16:30:00Z","reference_number":"EMA/PDCO/307494/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-14-16-may-2012_en.pdf"},
    {"id":"40079","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 11-13 November 2015","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-11-25T14:35:00Z","last_updated_date":"2015-11-25T14:35:00Z","reference_number":"EMA/PDCO/723182/2015","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-11-13-november-2015_en.pdf"},
    {"id":"40117","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - December 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-02-06T00:00:00Z","last_updated_date":"2006-02-06T00:00:00Z","reference_number":"EMEA/CVMP/413531/05-corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-december-2005_en.pdf"},
    {"id":"40128","name":"COMP meeting report on the review of applications for orphan designation: June 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T13:50:00Z","last_updated_date":"2016-06-23T13:50:00Z","reference_number":"EMA/COMP/365915/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-june-2016_en.pdf"},
    {"id":"40285","name":"Committee on herbal medicinal products (HMPC): Meeting report, 22-23 November 2005","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-12-15T00:00:00Z","last_updated_date":"2005-12-15T00:00:00Z","reference_number":"EMEA/HMPC/399168/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-herbal-medicinal-products-hmpc-meeting-report-22-23-november-2005_en.pdf"},
    {"id":"40298","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: May 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-05-31T12:10:00Z","last_updated_date":"2017-05-31T12:10:00Z","reference_number":"EMA/CAT/313682/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-may-2017_en.pdf"},
    {"id":"40301","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 15-17 May 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-05-29T18:40:00Z","last_updated_date":"2013-05-29T18:40:00Z","reference_number":"EMA/PDCO/310894/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-15-17-may-2013_en.pdf"},
    {"id":"40362","name":"Committee for Medicinal Products for Human Use (CHMP) - 22nd-23rd June 2004 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2004-07-04T02:00:00Z","last_updated_date":"2004-07-04T02:00:00Z","reference_number":"EMEA/CHMP/651/04","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-22nd-23rd-june-2004-plenary-meeting-monthly-report_en.pdf"},
    {"id":"40368","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: January 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-02-17T16:00:00Z","last_updated_date":"2016-02-17T16:00:00Z","reference_number":"EMA/77646/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-january-2016_en.pdf"},
    {"id":"40486","name":"Committee for Medicinal Products for Human Use (CHMP) - November 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:00:00Z","last_updated_date":"2009-10-27T00:00:00Z","reference_number":"EMEA/522109/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-november-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"40490","name":"Committee for Advanced Therapies (CAT) monthly report of application procedures, guidelines and related documents on advanced therapies:  April 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-04-27T12:30:00Z","last_updated_date":"2012-04-27T12:30:00Z","reference_number":"EMA/CAT/263109/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-april-2012-meeting_en.pdf"},
    {"id":"40519","name":"CVMP monthly report of application procedures, guidelines and related documents: January 2014","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2014-02-20T16:55:00Z","last_updated_date":"2014-02-20T16:55:00Z","reference_number":"EMA/68959/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cvmp-monthly-report-application-procedures-guidelines-and-related-documents-january-2014_en.pdf"},
    {"id":"40574","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: September 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T12:23:00Z","last_updated_date":"2017-09-26T12:23:00Z","reference_number":"EMA/CAT/613091/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-september-2017_en.pdf"},
    {"id":"40594","name":"PDCO monthly report of opinions on paediatric investigation plans: 15-17 August 2012","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-08-23T17:45:00Z","last_updated_date":"2012-08-23T17:45:00Z","reference_number":"EMA/PDCO/530890/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-15-17-august-2012_en.pdf"},
    {"id":"40751","name":"Committee for Medicinal Products for Human Use (CHMP) - July 2007 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2007-07-25T02:00:00Z","last_updated_date":"2007-07-25T02:00:00Z","reference_number":"EMEA/318931/2007","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-july-2007-plenary-meeting-monthly-report_en.pdf"},
    {"id":"40787","name":"Committee for Medicinal Products for Human Use (CHMP) - May 2010 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/CHMP/330906/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-may-2010-plenary-meeting-monthly-report_en.pdf"},
    {"id":"40797","name":"Committee for Advanced Therapies (CAT) monthly report of application procedures, guidelines and related documents on advanced therapies: January 2012 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2012-01-24T12:41:00Z","last_updated_date":"2012-01-24T12:41:00Z","reference_number":"EMA/CAT/47894/2012","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-january-2012-meeting_en.pdf"},
    {"id":"40845","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 13-15 March 2013","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T12:30:00Z","last_updated_date":"2013-03-25T12:30:00Z","reference_number":"EMA/PDCO/16009/2013","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-13-15-march-2013_en.pdf"},
    {"id":"40984","name":"Committee for Medicinal Products for Human Use (CHMP) - October 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"EMEA/CHMP/362348/2005, rev.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-october-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"41013","name":"Committee for Medicinal Products for Human Use (CHMP) - September 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-09-28T02:00:00Z","last_updated_date":"2005-09-28T02:00:00Z","reference_number":"EMEA/CHMP/295298/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-september-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"41160","name":"Committee for Medicinal Products for Human Use (CHMP) - July 2005 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2005-08-04T02:00:00Z","last_updated_date":"2005-08-04T02:00:00Z","reference_number":"EMEA/CHMP/229460/2005","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-july-2005-plenary-meeting-monthly-report_en.pdf"},
    {"id":"41200","name":"PDCO meeting highlights 9-11 December 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/PDCO/788549/2009","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-9-11-december-2009_en.pdf"},
    {"id":"41227","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: October 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-12-06T11:00:00Z","last_updated_date":"2017-12-06T11:00:00Z","reference_number":"EMA/680821/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-october-2017_en.pdf"},
    {"id":"41322","name":"Committee for Medicinal Products for Human Use (CHMP) -  November 2006 plenary meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2006-11-29T01:00:00Z","last_updated_date":"2006-11-29T01:00:00Z","reference_number":"EMEA/484273/2006","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-human-use-chmp-november-2006-plenary-meeting-monthly-report_en.pdf"},
    {"id":"41327","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: November 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T16:05:00Z","last_updated_date":"2016-11-18T16:05:00Z","reference_number":"EMA/CAT/675972/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-november-2016_en.pdf"},
    {"id":"41339","name":"COMP meeting report on the review of applications for orphan designation: April 2016","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-04-27T19:30:00Z","last_updated_date":"2016-04-27T19:30:00Z","reference_number":"EMA/COMP/225346/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-april-2016_en.pdf"},
    {"id":"41384","name":"Committee for Advanced Therapies (CAT): December 2010 meeting monthly report","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/CAT/731404/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-advanced-therapies-cat-december-2010-meeting-monthly-report_en.pdf"},
    {"id":"41465","name":"PDCO meeting highlights 17-19 February 2010","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-02-24T00:09:21Z","last_updated_date":"2010-02-24T01:00:00Z","reference_number":"EMA/PDCO/97062/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-highlights-17-19-february-2010_en.pdf"},
    {"id":"41575","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: January 2017","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2017-02-20T11:50:00Z","last_updated_date":"2017-02-20T11:50:00Z","reference_number":"EMA/43619/2017","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-january-2017_en.pdf"},
    {"id":"41610","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: April 2016 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2016-05-13T16:05:00Z","last_updated_date":"2016-05-13T16:05:00Z","reference_number":"EMA/CAT/318967/2016","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-april-2016-meeting_en.pdf"},
    {"id":"41620","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: December 2014 meeting","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2015-01-06T17:11:00Z","last_updated_date":"2015-01-06T17:11:00Z","reference_number":"EMA/CAT/789277/2014","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-december-2014-meeting_en.pdf"},
    {"id":"41692","name":"Committee for Medicinal Products for Veterinary Use (CVMP) - Monthly report of application procedures, guidelines and related documents - November 2009","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2010-02-10T01:00:00Z","last_updated_date":"2010-02-10T01:00:00Z","reference_number":"EMA/CVMP/44332/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/committee-medicinal-products-veterinary-use-cvmp-monthly-report-application-procedures-guidelines-and-related-documents-november-2009_en.pdf"},
    {"id":"42054","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 21-24 August 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-09-17T16:26:00Z","last_updated_date":"2018-09-17T16:26:00Z","reference_number":"EMEA/585656/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-21-24-august-2018_en.pdf"},
    {"id":"42152","name":"COMP meeting report on the review of applications for orphan designation: September 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-10-01T11:18:00Z","last_updated_date":"2018-10-01T11:18:00Z","reference_number":"EMA/COMP/547914/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2018_en.pdf"},
    {"id":"42156","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: September 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-10-01T15:26:00Z","last_updated_date":"2018-10-01T15:26:00Z","reference_number":"EMA/CAT/643189/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-september-2018_en.pdf"},
    {"id":"42240","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 18-21 September 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-10-09T15:00:00Z","last_updated_date":"2018-10-09T15:00:00Z","reference_number":"EMEA/PDCO/668248/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-18-21-september-2018_en.pdf"},
    {"id":"42423","name":"COMP meeting report on the review of applications for orphan designation: October 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-10-24T16:44:00Z","last_updated_date":"2018-10-24T16:44:00Z","reference_number":"EMA/COMP/679187/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-october-2018_en.pdf"},
    {"id":"42508","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T17:06:00Z","last_updated_date":"2018-10-30T17:06:00Z","reference_number":"EMA/CAT/737190/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-october-2018_en.pdf"},
    {"id":"42509","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: August-September 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T17:11:00Z","last_updated_date":"2018-10-30T17:11:00Z","reference_number":"EMA/581906/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-august-september-2018_en.pdf"},
    {"id":"42541","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 24-25 September 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T11:59:00Z","last_updated_date":"2018-11-06T11:59:00Z","reference_number":"EMA/HMPC/677632/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-24-25-september-2018_en.pdf"},
    {"id":"42741","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 16-19 October 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-11-22T11:20:00Z","last_updated_date":"2018-11-22T11:20:00Z","reference_number":"EMEA/PDCO/758018/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-16-19-october-2018_en.pdf"},
    {"id":"42796","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: November 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-11-26T16:36:00Z","last_updated_date":"2018-11-26T16:36:00Z","reference_number":"EMA/CAT/803430/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-november-2018_en.pdf"},
    {"id":"42799","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: October 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-11-26T17:02:00Z","last_updated_date":"2018-11-26T17:02:00Z","reference_number":"EMA/747295/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-october-2018_en.pdf"},
    {"id":"42888","name":"COMP meeting report on the review of applications for orphan designation: November 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-11-29T18:37:00Z","last_updated_date":"2018-11-29T18:37:00Z","reference_number":"EMA/COMP/762677/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-november-2018_en.pdf"},
    {"id":"42940","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 13-16 November 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-12-05T18:01:00Z","last_updated_date":"2018-12-05T18:01:00Z","reference_number":"EMEA/PDCO/820568/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-13-16-november-2018_en.pdf"},
    {"id":"43068","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: November 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T11:10:00Z","last_updated_date":"2018-12-14T11:10:00Z","reference_number":"EMA/818520/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-november-2018_en.pdf"},
    {"id":"43108","name":"COMP meeting report on the review of applications for orphan designation: December 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2018-12-17T17:27:00Z","last_updated_date":"2019-02-14T10:41:00Z","reference_number":"EMA/COMP/762677/2018 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2018_en.pdf"},
    {"id":"43219","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 19-20 November 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T10:30:00Z","last_updated_date":"2019-01-07T10:30:00Z","reference_number":"EMA/HMPC/204861/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-19-20-november-2018_en.pdf"},
    {"id":"43465","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 11-14 December 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T15:31:00Z","last_updated_date":"2019-01-23T15:31:00Z","reference_number":"EMEA/PDCO/902740/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-11-14-december-2018_en.pdf"},
    {"id":"43548","name":"COMP meeting report on the review of applications for orphan designation: January 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-01-29T17:01:00Z","last_updated_date":"2019-01-29T17:01:00Z","reference_number":"EMA/COMP/762677/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2019_en.pdf"},
    {"id":"43613","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 14-16 January 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T17:16:00Z","last_updated_date":"2019-02-01T17:16:00Z","reference_number":"EMA/HMPC/26549/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-14-16-january-2019_en.pdf"},
    {"id":"43652","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: December 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-02-06T13:45:00Z","last_updated_date":"2019-02-06T13:45:00Z","reference_number":"EMA/CAT/884288/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-december-2018_en.pdf"},
    {"id":"43653","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: December 2018","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-02-06T13:45:00Z","last_updated_date":"2019-02-06T13:45:00Z","reference_number":"EMA/895561/2018","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-december-2018_en.pdf"},
    {"id":"43869","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: January 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-02-21T14:44:00Z","last_updated_date":"2019-02-21T14:44:00Z","reference_number":"EMA/CAT/97278/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-january-2019_en.pdf"},
    {"id":"43983","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-03-06T16:50:00Z","last_updated_date":"2019-03-06T16:50:00Z","reference_number":"EMA/CAT/146798/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-february-2019_en.pdf"},
    {"id":"44151","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: January 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-03-29T14:05:00Z","last_updated_date":"2019-03-29T14:05:00Z","reference_number":"EMA/101877/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-january-2019_en.pdf"},
    {"id":"44170","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 26 February-01 March 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-04-03T16:48:00Z","last_updated_date":"2019-04-03T16:48:00Z","reference_number":"EMA/PDCO/168688/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-26-february-01-march-2019_en.pdf"},
    {"id":"44190","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 29 January - 1 February 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-04-09T09:31:00Z","last_updated_date":"2019-04-09T09:31:00Z","reference_number":"EMA/PDCO/114746/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-29-january-1-february-2019_en.pdf"},
    {"id":"44289","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: March 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-04-17T11:30:00Z","last_updated_date":"2019-04-17T11:30:00Z","reference_number":"EMA/CAT/198680/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-march-2019_en.pdf"},
    {"id":"44300","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 26-29 March 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-04-17T16:00:00Z","last_updated_date":"2019-04-17T16:00:00Z","reference_number":"EMA/PDC O/213525/2019 ","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-26-29-march-2019_en.pdf"},
    {"id":"44608","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 23-26 April 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T10:34:00Z","last_updated_date":"2019-05-29T10:34:00Z","reference_number":"EMEA/PDCO/251835/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-23-26-april-2019_en.pdf"},
    {"id":"44610","name":"COMP meeting report on the review of applications for orphan designation: May 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T10:58:00Z","last_updated_date":"2019-05-29T10:58:00Z","reference_number":"EMA/COMP/202458/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-may-2019_en.pdf"},
    {"id":"44778","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: March 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-06-20T16:56:00Z","last_updated_date":"2019-06-20T16:56:00Z","reference_number":"EMA/289298/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-march-2019_en.pdf"},
    {"id":"44855","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 27-29 May 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-06-24T17:41:00Z","last_updated_date":"2019-06-24T17:41:00Z","reference_number":"EMA/PDCO/309429/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-27-29-may-2019_en.pdf"},
    {"id":"44907","name":"COMP meeting report on the review of applications for orphan designation: June 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-06-27T11:40:00Z","last_updated_date":"2019-07-02T17:18:00Z","reference_number":"EMA/COMP/342217/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-june-2019_en.pdf"},
    {"id":"44963","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: April 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-07-01T09:56:00Z","last_updated_date":"2019-07-01T09:56:00Z","reference_number":"EMA/CAT/238992/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-april-2019_en.pdf"},
    {"id":"44964","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: May 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-07-01T09:57:00Z","last_updated_date":"2019-07-01T09:57:00Z","reference_number":"EMA/CAT/298710/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-may-2019_en.pdf"},
    {"id":"44993","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: April 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-07-05T09:24:00Z","last_updated_date":"2019-07-05T09:24:00Z","reference_number":"EMA/307808/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-april-2019_en.pdf"},
    {"id":"45054","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: June 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-07-15T09:05:00Z","last_updated_date":"2019-07-15T09:05:00Z","reference_number":"EMA/CAT/367316/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-june-2019_en.pdf"},
    {"id":"45078","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 25-28 June 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-07-17T11:33:00Z","last_updated_date":"2019-07-17T11:33:00Z","reference_number":"EMEA/PDCO/380229/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-25-28-june-2019_en.pdf"},
    {"id":"45153","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: May 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-07-30T10:47:00Z","last_updated_date":"2019-07-30T10:47:00Z","reference_number":"EMA/368487/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-may-2019_en.pdf"},
    {"id":"45160","name":"COMP meeting report on the review of applications for orphan designation: July 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-07-31T12:13:00Z","last_updated_date":"2019-07-31T12:13:00Z","reference_number":"EMA/COMP/386594/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-july-2019_en.pdf"},
    {"id":"45255","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: June 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-08-14T14:32:00Z","last_updated_date":"2019-08-14T14:32:00Z","reference_number":"EMA/412788/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-june-2019_en.pdf"},
    {"id":"45270","name":"COMP meeting report on the review of applications for orphan designation: April 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-08-19T13:56:00Z","last_updated_date":"2019-08-19T13:56:00Z","reference_number":"EMA/COMP/202458/2019 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-april-2019_en.pdf"},
    {"id":"45271","name":"COMP meeting report on the review of applications for orphan designation: February 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-08-19T13:55:00Z","last_updated_date":"2019-08-19T13:55:00Z","reference_number":"EMA/COMP/89125/2019 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-february-2019_en.pdf"},
    {"id":"45272","name":"COMP meeting report on the review of applications for orphan designation: March 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-08-19T13:56:00Z","last_updated_date":"2019-08-19T13:56:00Z","reference_number":"EMA/COMP/89125/2019 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-march-2019_en.pdf"},
    {"id":"45316","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: July 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-08-23T13:45:00Z","last_updated_date":"2019-08-23T13:45:00Z","reference_number":"EMA/CAT/417650/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-july-2019_en.pdf"},
    {"id":"45382","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 23-26 July 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-09-04T15:11:00Z","last_updated_date":"2019-09-04T15:11:00Z","reference_number":"EMA/PDCO/417613/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-23-26-july-2019_en.pdf"},
    {"id":"45457","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: July 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-09-16T15:45:00Z","last_updated_date":"2019-09-16T15:45:00Z","reference_number":"EMA/438093/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-july-2019_en.pdf"},
    {"id":"45516","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 20-23 August 2019 written procedure","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-09-24T15:24:00Z","last_updated_date":"2019-09-24T15:24:00Z","reference_number":"EMEA/PDCO/481535/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-20-23-august-2019-written-procedure_en.pdf"},
    {"id":"45517","name":"COMP meeting report on the review of applications for orphan designation: September 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-09-24T15:33:00Z","last_updated_date":"2019-09-24T15:33:00Z","reference_number":"EMA/COMP/437105/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2019_en.pdf"},
    {"id":"45518","name":"COMP meeting report on the review of applications for orphan designation: Septmeber 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-09-24T15:33:00Z","last_updated_date":"2019-09-24T15:33:00Z","reference_number":"EMA/COMP/437105/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-septmeber-2019_en.pdf"},
    {"id":"45572","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: September 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-10-04T15:40:00Z","last_updated_date":"2019-10-04T15:40:00Z","reference_number":"EMA/CAT/517590/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-september-2019_en.pdf"},
    {"id":"45668","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 23-25 September 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-10-14T14:59:00Z","last_updated_date":"2019-10-14T14:59:00Z","reference_number":"EMA/HMPC/532472/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-23-25-september-2019_en.pdf"},
    {"id":"45679","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 17-20 September 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-10-14T15:45:00Z","last_updated_date":"2019-10-14T15:45:00Z","reference_number":"EMEA/PDCO/523637/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-17-20-september-2019_en.pdf"},
    {"id":"45698","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 13-15 May 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-10-15T09:19:00Z","last_updated_date":"2019-10-15T09:19:00Z","reference_number":"EMA/HMPC/278395/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-13-15-may-2019_en.pdf"},
    {"id":"45699","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 8-10 July 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-10-15T09:20:00Z","last_updated_date":"2019-10-15T09:20:00Z","reference_number":"EMA/HMPC/400010/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-8-10-july-2019_en.pdf"}    {"id":"45706","name":"COMP meeting report on the review of applications for orphan designation: October 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-10-15T14:06:00Z","last_updated_date":"2019-10-15T14:06:00Z","reference_number":"EMA/COMP/527035/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-october-2019_en.pdf"},
    {"id":"45884","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: August-September 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-11-04T15:42:00Z","last_updated_date":"2019-11-04T15:42:00Z","reference_number":"EMA/483974/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-august-september-2019_en.pdf"},
    {"id":"45917","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-11-07T14:13:00Z","last_updated_date":"2019-11-07T14:13:00Z","reference_number":"EMA/CAT/568302/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-october-2019_en.pdf"},
    {"id":"45957","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 15-18 October 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-11-11T14:08:00Z","last_updated_date":"2019-11-11T14:08:00Z","reference_number":"EMEA/582190/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-15-18-october-2019_en.pdf"},
    {"id":"46054","name":"COMP meeting report on the review of applications for orphan designation: November 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-11-18T16:40:00Z","last_updated_date":"2019-11-18T16:40:00Z","reference_number":"EMA/COMP/557148/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-november-2019_en.pdf"},
    {"id":"46199","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: November 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-11-29T09:31:00Z","last_updated_date":"2019-11-29T09:31:00Z","reference_number":"EMA/CAT/622113/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-november-2019_en.pdf"},
    {"id":"46261","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: October 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T15:24:00Z","last_updated_date":"2019-12-09T15:24:00Z","reference_number":"EMA/596031/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-october-2019_en.pdf"},
    {"id":"46320","name":"COMP meeting report on the review of applications for orphan designation: December 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-12-13T12:26:00Z","last_updated_date":"2019-12-13T12:26:00Z","reference_number":"EMA/COMP/666924/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2019_en.pdf"},
    {"id":"46349","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 18-20 November 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2019-12-19T16:10:00Z","last_updated_date":"2019-12-19T16:10:00Z","reference_number":"EMA/HMPC/639497/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-18-20-november-2019_en.pdf"},
    {"id":"46433","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 12-15 November 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-01-15T15:37:00Z","last_updated_date":"2020-01-15T15:37:00Z","reference_number":"EMEA/630633/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-12-15-november-2019_en.pdf"},
    {"id":"46597","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: November 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-01-28T11:36:00Z","last_updated_date":"2020-01-28T11:36:00Z","reference_number":"EMA/682307/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-november-2019_en.pdf"},
    {"id":"46605","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: December 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-01-29T08:37:00Z","last_updated_date":"2020-01-29T08:37:00Z","reference_number":"EMA/CAT/677731/2019","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-december-2019_en.pdf"},
    {"id":"46610","name":"COMP meeting report on the review of applications for orphan designation: January 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-01-29T14:29:00Z","last_updated_date":"2020-01-29T14:29:00Z","reference_number":"EMA/COMP/426032/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2020_en.pdf"},
    {"id":"46697","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: December 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-02-10T15:37:00Z","last_updated_date":"2020-02-10T15:37:00Z","reference_number":"EMA/13708/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-december-2019_en.pdf"},
    {"id":"46719","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: January 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-02-12T10:00:00Z","last_updated_date":"2020-02-12T10:00:00Z","reference_number":"EMA/CAT/54845/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-january-2020_en.pdf"},
    {"id":"46869","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 28-31 January 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:42:00Z","last_updated_date":"2020-02-25T09:42:00Z","reference_number":"EMEA/PDCO/68072/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-28-31-january-2020_en.pdf"},
    {"id":"46984","name":"COMP meeting report on the review of applications for orphan designation: February 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-03-09T17:12:00Z","last_updated_date":"2020-03-09T17:12:00Z","reference_number":"EMA/COMP/87794/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-february-2020_en.pdf"},
    {"id":"46985","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: January 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-03-09T17:27:00Z","last_updated_date":"2020-03-09T17:27:00Z","reference_number":"EMA/46356/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-january-2020_en.pdf"},
    {"id":"47010","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T10:29:00Z","last_updated_date":"2020-03-13T10:29:00Z","reference_number":"EMA/CAT/107194/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-february-2020_en.pdf"},
    {"id":"47198","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 2-4 March 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T13:23:00Z","last_updated_date":"2020-03-27T13:23:00Z","reference_number":"EMA/HMPC/121831/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-2-4-march-2020_en.pdf"},
    {"id":"47212","name":"COMP meeting report on the review of applications for orphan designation: March 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-03-30T13:49:00Z","last_updated_date":"2020-03-30T13:49:00Z","reference_number":"EMA/COMP/152850/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-march-2020_en.pdf"},
    {"id":"47439","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: February 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-04-20T15:45:00Z","last_updated_date":"2020-04-20T15:45:00Z","reference_number":"EMA/144648/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-february-2020_en.pdf"},
    {"id":"47503","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 24-27 March 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-04-28T15:08:00Z","last_updated_date":"2020-04-28T15:08:00Z","reference_number":"EMA/175935/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-24-27-march-2020_en.pdf"},
    {"id":"47656","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: April 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-05-13T11:31:00Z","last_updated_date":"2020-05-13T11:31:00Z","reference_number":"EMA/CAT/247536/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-april-2020_en.pdf"},
    {"id":"47668","name":"COMP meeting report on the review of applications for orphan designation: April 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-05-14T15:41:00Z","last_updated_date":"2020-05-14T15:41:00Z","reference_number":"EMA/COMP/230411/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-april-2020_en.pdf"},
    {"id":"47715","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: March 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T16:23:00Z","last_updated_date":"2020-05-19T16:23:00Z","reference_number":"EMA/191989/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-march-2020_en.pdf"},
    {"id":"47841","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 4-6 May 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-06-03T11:11:00Z","last_updated_date":"2020-06-03T11:11:00Z","reference_number":"EMA/HMPC/257185/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-4-6-may-2020_en.pdf"},
    {"id":"47851","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: April 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T14:50:00Z","last_updated_date":"2020-06-04T14:50:00Z","reference_number":"EMA/249657/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-april-2020_en.pdf"},
    {"id":"47882","name":"COMP meeting report on the review of applications for orphan designation: May 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T11:10:00Z","last_updated_date":"2020-06-05T11:10:00Z","reference_number":"EMA/COMP/284050/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-may-2020_en.pdf"},
    {"id":"47884","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: May 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T11:41:00Z","last_updated_date":"2020-06-05T11:41:00Z","reference_number":"EMA/CAT/287339/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-may-2020_en.pdf"},
    {"id":"48088","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: May 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T13:17:00Z","last_updated_date":"2020-06-23T13:17:00Z","reference_number":"EMA/298881/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-may-2020_en.pdf"},
    {"id":"48120","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: March 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-06-25T11:34:00Z","last_updated_date":"2020-06-25T11:34:00Z","reference_number":"EMA/CAT/159950/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-march-2020_en.pdf"},
    {"id":"48183","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: June 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-06-30T10:09:00Z","last_updated_date":"2020-06-30T10:09:00Z","reference_number":"EMA/CAT/345769/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-june-2020_en.pdf"},
    {"id":"48222","name":"COMP meeting report on the review of applications for orphan designation: July 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-07-23T15:18:00Z","last_updated_date":"2020-07-23T15:18:00Z","reference_number":"EMA/COMP/382197/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-july-2020_en.pdf"},
    {"id":"48223","name":"COMP meeting report on the review of applications for orphan designation: June 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-07-03T15:18:00Z","last_updated_date":"2020-07-03T15:18:00Z","reference_number":"EMA/COMP/341461/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-june-2020_en.pdf"},
    {"id":"48371","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 6-8 July 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-07-23T12:04:00Z","last_updated_date":"2020-07-23T12:04:00Z","reference_number":"EMA/HMPC/381575/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-6-8-july-2020_en.pdf"},
    {"id":"48426","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: July 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-07-27T11:33:00Z","last_updated_date":"2020-07-27T11:33:00Z","reference_number":"EMA/CAT/399507/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-july-2020_en.pdf"},
    {"id":"48427","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: June 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-07-27T11:39:00Z","last_updated_date":"2020-07-27T11:39:00Z","reference_number":"EMA/355313/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-june-2020_en.pdf"},
    {"id":"48715","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 28-30 April 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-08-28T12:08:00Z","last_updated_date":"2020-08-28T12:08:00Z","reference_number":"EMEA/260317/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-28-30-april-2020_en.pdf"},
    {"id":"48721","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 25-28 February 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-08-28T14:02:00Z","last_updated_date":"2020-09-15T16:22:00Z","reference_number":"EMEA/120052/2020 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-25-28-february-2020_en.pdf"},
    {"id":"48723","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 26-29 May 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-08-28T17:40:00Z","last_updated_date":"2020-08-28T17:40:00Z","reference_number":"EMEA/PDCO/306738/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-26-29-may-2020_en.pdf"},
    {"id":"48730","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 23-26 June 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-09-01T08:59:00Z","last_updated_date":"2020-09-01T08:59:00Z","reference_number":"EMEA/PDCO/365145/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-23-26-june-2020_en.pdf"},
    {"id":"48868","name":"COMP meeting report on the review of applications for orphan designation: September 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-09-21T15:38:00Z","last_updated_date":"2021-01-15T14:00:00Z","reference_number":"EMA/COMP/479534/2020 Corr.","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2020_en.pdf"},
    {"id":"48879","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: September 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-09-22T15:58:00Z","last_updated_date":"2020-09-22T15:58:00Z","reference_number":"EMA/CAT/493027/2010","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-september-2020_en.pdf"},
    {"id":"48903","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: July 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-09-29T09:18:00Z","last_updated_date":"2020-09-29T09:18:00Z","reference_number":"EMA/402999/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-july-2020_en.pdf"},
    {"id":"48978","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 21-23 September 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-10-09T12:07:00Z","last_updated_date":"2020-10-09T12:07:00Z","reference_number":"EMA/HMPC/512587/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-21-23-september-2020_en.pdf"},
    {"id":"49021","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 21-24 July 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-10-15T14:35:00Z","last_updated_date":"2020-10-15T14:35:00Z","reference_number":"EMEA/PDCO/419819/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-21-24-july-2020_en.pdf"},
    {"id":"49037","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 1-4 September 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-10-16T11:58:00Z","last_updated_date":"2020-10-16T11:58:00Z","reference_number":"EMA/PDCO/486336/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-1-4-september-2020_en.pdf"},
    {"id":"49123","name":"COMP meeting report on the review of applications for orphan designation: October 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T16:47:00Z","last_updated_date":"2020-10-23T16:47:00Z","reference_number":"EMA/COMP/546547/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-october-2020_en.pdf"},
    {"id":"49180","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: August-September 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-11-04T17:25:00Z","last_updated_date":"2020-11-04T17:25:00Z","reference_number":"EMA/477659/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-august-september-2020_en.pdf"},
    {"id":"49208","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 13-16 October 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-11-11T14:00:00Z","last_updated_date":"2020-11-11T14:00:00Z","reference_number":"EMA/578758/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-13-16-october-2020_en.pdf"},
    {"id":"49221","name":"COMP meeting report on the review of applications for orphan designation: November 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T09:11:00Z","last_updated_date":"2020-11-12T09:11:00Z","reference_number":"EMA/COMP/593730/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-november-2020_en.pdf"},
    {"id":"49482","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 16-18 November 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-12-08T13:42:00Z","last_updated_date":"2020-12-08T13:42:00Z","reference_number":"EMA/HMPC/632627/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-16-18-november-2020_en.pdf"},
    {"id":"49563","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 10-13 November 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-12-14T17:57:00Z","last_updated_date":"2020-12-14T17:57:00Z","reference_number":"EMA/PDCO/629288/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-10-13-november-2020_en.pdf"},
    {"id":"49643","name":"COMP meeting report on the review of applications for orphan designation: December 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T13:39:00Z","last_updated_date":"2020-12-18T13:39:00Z","reference_number":"EMA/COMP/664821/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2020_en.pdf"},
    {"id":"49654","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: December 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T09:33:00Z","last_updated_date":"2020-12-21T09:33:00Z","reference_number":"EMA/CAT/676681/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-december-2020_en.pdf"},
    {"id":"49822","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: November 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T14:47:00Z","last_updated_date":"2021-01-18T14:47:00Z","reference_number":"EMA/664502/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-november-2020_en.pdf"},
    {"id":"49908","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 8-11 December 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T16:20:00Z","last_updated_date":"2021-01-22T16:20:00Z","reference_number":"EMEA/PDCO/1735/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-8-11-december-2020_en.pdf"},
    {"id":"50021","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: December 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-02-01T15:46:00Z","last_updated_date":"2021-02-01T15:46:00Z","reference_number":"EMA/705858/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-december-2020_en.pdf"},
    {"id":"50022","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 11-13 January 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-02-01T15:53:00Z","last_updated_date":"2021-02-01T15:53:00Z","reference_number":"EMA/HMPC/35098/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-11-13-january-2021_en.pdf"},
    {"id":"50037","name":"COMP meeting report on the review of applications for orphan designation: January 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-02-03T09:00:00Z","last_updated_date":"2021-02-03T09:00:00Z","reference_number":"EMA/COMP/48017/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2021_en.pdf"},
    {"id":"50074","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: January 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-02-05T17:27:00Z","last_updated_date":"2021-02-05T17:27:00Z","reference_number":"EMA/CAT/57543/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-january-2021_en.pdf"},
    {"id":"50325","name":"COMP meeting report on the review of applications for orphan designation: February 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-03-01T13:52:00Z","last_updated_date":"2021-03-01T13:52:00Z","reference_number":"EMA/COMP/109507/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-february-2021_en.pdf"},
    {"id":"50393","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T10:28:00Z","last_updated_date":"2021-03-04T10:28:00Z","reference_number":"EMA/CAT/136600/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-february-2021_en.pdf"},
    {"id":"50520","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: January 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-03-11T09:27:00Z","last_updated_date":"2021-03-11T09:27:00Z","reference_number":"EMA/78054/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-january-2021_en.pdf"},
    {"id":"50528","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 26-29 January 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-03-11T16:20:00Z","last_updated_date":"2021-03-11T16:20:00Z","reference_number":"EMA/PDCO/78413/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-26-29-january-2021_en.pdf"},
    {"id":"50657","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 1-3 March 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-03-19T16:46:00Z","last_updated_date":"2021-03-19T16:46:00Z","reference_number":"EMA/HMPC/139454/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-1-3-march-2021_en.pdf"},
    {"id":"50685","name":"COMP meeting report on the review of applications for orphan designation: March 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-03-24T09:29:00Z","last_updated_date":"2021-03-24T09:29:00Z","reference_number":"EMA/COMP/170529/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-march-2021_en.pdf"},
    {"id":"50827","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: February 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T12:32:00Z","last_updated_date":"2021-04-14T12:32:00Z","reference_number":"EMA/78054/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-february-2021_en.pdf"},
    {"id":"50923","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 23-26 February 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-04-20T17:35:00Z","last_updated_date":"2021-04-20T17:35:00Z","reference_number":"EMA/PDCO/144922/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-23-26-february-2021_en.pdf"},
    {"id":"50943","name":"COMP meeting report on the review of applications for orphan designation: April 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-04-22T14:49:00Z","last_updated_date":"2021-04-22T14:49:00Z","reference_number":"EMA/COMP/223759/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-april-2021_en.pdf"},
    {"id":"51087","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: April 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T16:49:00Z","last_updated_date":"2021-05-05T16:49:00Z","reference_number":"EMA/CAT/234540/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-april-2021_en.pdf"},
    {"id":"51088","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: March 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T16:50:00Z","last_updated_date":"2021-05-05T16:50:00Z","reference_number":"EMA/CAT/184358/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-march-2021_en.pdf"},
    {"id":"51128","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 23-26 March 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T17:24:00Z","last_updated_date":"2021-05-10T17:24:00Z","reference_number":"EMA/PDCO/210599/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-23-26-march-2021_en.pdf"},
    {"id":"51191","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 3-5 May 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-05-19T15:04:00Z","last_updated_date":"2021-05-19T15:04:00Z","reference_number":"EMA/HMPC/262813/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-3-5-may-2021_en.pdf"},
    {"id":"51233","name":"COMP meeting report on the review of applications for orphan designation: May 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T16:25:00Z","last_updated_date":"2021-05-21T16:25:00Z","reference_number":"EMA/COMP/279124/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-may-2021_en.pdf"},
    {"id":"51510","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 20-23 April 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-06-18T16:59:00Z","last_updated_date":"2021-06-18T16:59:00Z","reference_number":"EMA/PDCO/249515/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-20-23-april-2021_en.pdf"},
    {"id":"51577","name":"COMP meeting report on the review of applications for orphan designation: June 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-06-24T11:49:00Z","last_updated_date":"2021-06-24T11:49:00Z","reference_number":"EMA/COMP/352245/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-june-2021_en.pdf"},
    {"id":"51850","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: May 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T13:19:00Z","last_updated_date":"2021-07-06T13:19:00Z","reference_number":"EMA/CAT/303497/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-may-2021_en.pdf"},
    {"id":"51901","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 18-21 May 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T16:00:00Z","last_updated_date":"2021-07-09T16:00:00Z","reference_number":"EMA/PDCO/300340/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-18-21-may-2021_en.pdf"},
    {"id":"51970","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 5-7 July 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-07-20T15:42:00Z","last_updated_date":"2021-07-20T15:42:00Z","reference_number":"EMA/HMPC/386494/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-5-7-july-2021_en.pdf"},
    {"id":"52090","name":"COMP meeting report on the review of applications for orphan designation: July 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-07-27T10:50:00Z","last_updated_date":"2021-07-27T10:50:00Z","reference_number":"EMA/COMP/409325/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-july-2021_en.pdf"},
    {"id":"52106","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: May 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-07-27T17:27:00Z","last_updated_date":"2021-07-27T17:27:00Z","reference_number":"EMA/311250/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-may-2021_en.pdf"},
    {"id":"52143","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: July 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-07-29T11:58:00Z","last_updated_date":"2021-07-29T11:58:00Z","reference_number":"EMA/CAT/358059/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-july-2021_en.pdf"},
    {"id":"52232","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: June 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-08-17T15:26:00Z","last_updated_date":"2021-08-17T15:26:00Z","reference_number":"EMA/CAT/358059/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-june-2021_en.pdf"},
    {"id":"52464","name":"COMP meeting report on the review of applications for orphan designation: September 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-09-16T14:59:00Z","last_updated_date":"2021-09-16T14:59:00Z","reference_number":"EMA/COMP/518139/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2021_en.pdf"},
    {"id":"52593","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: September 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-09-23T15:59:00Z","last_updated_date":"2021-09-23T15:59:00Z","reference_number":"EMA/CAT/524986/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-september-2021_en.pdf"},
    {"id":"52841","name":"COMP meeting report on the review of applications for orphan designation: October 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-10-14T12:09:00Z","last_updated_date":"2021-10-14T12:09:00Z","reference_number":"EMA/COMP/576496/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-october-2021_en.pdf"},
    {"id":"52893","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: July 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-10-22T13:06:00Z","last_updated_date":"2021-10-22T13:06:00Z","reference_number":"EMA/436030/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-july-2021_en.pdf"},
    {"id":"52987","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: August-September 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-11-04T10:16:00Z","last_updated_date":"2021-11-04T10:16:00Z","reference_number":"EMA/555220/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-august-september-2021_en.pdf"},
    {"id":"53050","name":"COMP meeting report on the review of applications for orphan designation: November 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-11-10T11:00:00Z","last_updated_date":"2021-11-10T11:00:00Z","reference_number":"EMA/COMP/639056/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-november-2021_en.pdf"},
    {"id":"53131","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 20-22 September 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-11-15T17:45:00Z","last_updated_date":"2021-11-15T17:45:00Z","reference_number":"EMA/HMPC/537632/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-20-22-september-2021_en.pdf"},
    {"id":"53133","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 22-25 June 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-11-16T09:34:00Z","last_updated_date":"2021-11-16T09:34:00Z","reference_number":"EMA/PDCO/378631/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-22-25-june-2021_en.pdf"},
    {"id":"53307","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T13:18:00Z","last_updated_date":"2021-11-29T13:18:00Z","reference_number":"EMA/CAT/586930/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-october-2021_en.pdf"},
    {"id":"53308","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: November 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T13:21:00Z","last_updated_date":"2021-11-29T13:21:00Z","reference_number":"EMA/CAT/586930/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-november-2021_en.pdf"},
    {"id":"53399","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 22-24 November 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-12-07T16:25:00Z","last_updated_date":"2021-12-07T16:25:00Z","reference_number":"EMA/HMPC/708689/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-22-24-november-2021_en.pdf"},
    {"id":"53400","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: October 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-12-07T16:37:00Z","last_updated_date":"2021-12-07T16:37:00Z","reference_number":"EMA/622578/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-october-2021_en.pdf"},
    {"id":"53524","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 20-23 July 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-12-15T10:59:00Z","last_updated_date":"2021-12-15T10:59:00Z","reference_number":"EMA/PDCO/433151/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-20-23-july-2021_en.pdf"},
    {"id":"53614","name":"COMP meeting report on the review of applications for orphan designation: December 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2021-12-21T16:00:00Z","last_updated_date":"2022-01-21T08:53:00Z","reference_number":"EMA/COMP/751974/2021 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2021_en.pdf"},
    {"id":"53863","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: November 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T08:55:00Z","last_updated_date":"2022-01-21T08:55:00Z","reference_number":"EMA/732242/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-november-2021_en.pdf"}    {"id":"53949","name":"COMP meeting report on the review of applications for orphan designation: January 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-01-27T12:56:00Z","last_updated_date":"2022-01-27T12:56:00Z","reference_number":"EMA/COMP/46465/2022 Corr","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2022_en.pdf"},
    {"id":"54047","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 7-10 September 2021","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-02-02T16:10:00Z","last_updated_date":"2022-02-08T17:12:00Z","reference_number":"EMA/PDCO/526054/2021 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-7-10-september-2021_en.pdf"},
    {"id":"54122","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 24-26 January 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-02-09T16:43:00Z","last_updated_date":"2022-02-09T16:43:00Z","reference_number":"EMA/HMPC/55879/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-24-26-january-2022_en.pdf"},
    {"id":"54223","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 12-15 October 2021","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2022-02-18T14:03:00Z","last_updated_date":"2022-02-18T14:03:00Z","reference_number":"EMA/PDCO/604992/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-12-15-october-2021_en.pdf"},
    {"id":"54395","name":"COMP meeting report on the review of applications for orphan designation: February 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T13:53:00Z","last_updated_date":"2022-03-08T13:53:00Z","reference_number":"EMA/COMP/46465/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-february-2022_en.pdf"},
    {"id":"54605","name":"COMP meeting report on the review of applications for orphan designation: March 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-29T09:54:00Z","last_updated_date":"2022-03-29T09:54:00Z","reference_number":"EMA/COMP/166690/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-march-2022_en.pdf"},
    {"id":"54654","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 9-12 November 2021","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2022-04-04T09:58:00Z","last_updated_date":"2022-04-04T09:58:00Z","reference_number":"EMA/PDCO/688390/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-9-12-november-2021_en.pdf"},
    {"id":"54655","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 14-17 December 2021","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2022-04-04T10:00:00Z","last_updated_date":"2022-04-04T10:00:00Z","reference_number":"EMA/PDCO/780344/2021","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-14-17-december-2021_en.pdf"},
    {"id":"54732","name":"PDCO meeting report of opinions on paediatric investigation plans and other activities 22-25 February 2022","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2022-04-12T14:17:00Z","last_updated_date":"2022-04-12T14:17:00Z","reference_number":"EMA/PDCO/137600/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-opinions-paediatric-investigation-plans-and-other-activities-22-25-february-2022_en.pdf"},
    {"id":"54755","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 28-30 March 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-04-13T17:02:00Z","last_updated_date":"2022-04-13T17:02:00Z","reference_number":"EMA/HMPC/197395/20222","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-28-30-march-2022_en.pdf"},
    {"id":"54881","name":"COMP meeting report on the review of applications for orphan designation: April 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-05-03T14:03:00Z","last_updated_date":"2022-05-03T14:03:00Z","reference_number":"EMA/COMP/222806/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-april-2022_en.pdf"},
    {"id":"54899","name":"PDCO meeting report of opinions on paediatric investigation plans and other activities 22-25 March 2022","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2022-05-05T09:59:00Z","last_updated_date":"2022-05-05T09:59:00Z","reference_number":"EMA/PDCO/203798/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-meeting-report-opinions-paediatric-investigation-plans-and-other-activities-22-25-march-2022_en.pdf"},
    {"id":"55008","name":"COMP meeting report on the review of applications for orphan designation: May 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-05-19T13:37:00Z","last_updated_date":"2022-05-19T13:37:00Z","reference_number":"EMA/COMP/272969/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-may-2022_en.pdf"},
    {"id":"55131","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 16-18 May 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-06-03T16:19:00Z","last_updated_date":"2022-06-03T16:19:00Z","reference_number":"EMA/HMPC/328770/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-16-18-may-2022_en.pdf"},
    {"id":"55391","name":"COMP meeting report on the review of applications for orphan designation: June 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-06-28T10:27:00Z","last_updated_date":"2022-06-28T10:27:00Z","reference_number":"EMA/COMP/601960/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-june-2022_en.pdf"},
    {"id":"55610","name":"COMP meeting report on the review of applications for orphan designation: July 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-07-21T11:33:00Z","last_updated_date":"2022-07-21T11:33:00Z","reference_number":"EMA/COMP/646272/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-july-2022_en.pdf"},
    {"id":"55619","name":"CAT quarterly highlights and approved ATMPs - April 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-07-21T15:14:00Z","last_updated_date":"2022-07-21T15:14:00Z","reference_number":"EMA/CAT/253709/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-april-2022_en.pdf"},
    {"id":"55731","name":"CAT quarterly highlights and approved ATMPs - July 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-07-29T11:30:00Z","last_updated_date":"2022-07-29T11:30:00Z","reference_number":"EMA/CAT/654429/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-july-2022_en.pdf"},
    {"id":"56292","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 19-21 September 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-10-03T16:32:00Z","last_updated_date":"2022-10-03T16:32:00Z","reference_number":"EMA/HMPC/782037/20222","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-19-21-september-2022_en.pdf"},
    {"id":"56499","name":"CAT quarterly highlights and approved ATMPs - October 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T09:40:00Z","last_updated_date":"2022-10-28T09:40:00Z","reference_number":"EMA/CAT/841175/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-october-2022_en.pdf"},
    {"id":"56911","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 21-23 November 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-12-08T13:49:00Z","last_updated_date":"2022-12-08T13:49:00Z","reference_number":"EMA/HMPC/907971/2022","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-21-23-november-2022_en.pdf"},
    {"id":"57494","name":"CAT quarterly highlights and approved ATMPs - January 2023","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2023-02-01T15:58:00Z","last_updated_date":"2023-02-01T15:58:00Z","reference_number":"EMA/CAT/50775/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-january-2023_en.pdf"},
    {"id":"57569","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 23-25 January 2023","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T14:22:00Z","last_updated_date":"2023-02-08T14:22:00Z","reference_number":"EMA/HMPC/43482/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-23-25-january-2023_en.pdf"},
    {"id":"58209","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 13-15 March 2023","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2023-03-29T17:34:00Z","last_updated_date":"2023-03-29T17:34:00Z","reference_number":"EMA/HMPC/125070/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-13-15-march-2023_en.pdf"},
    {"id":"58778","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 10-12 May 2023","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2023-05-25T12:15:00Z","last_updated_date":"2023-05-25T12:15:00Z","reference_number":"EMA/HMPC/220353/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-10-12-may-2023_en.pdf"},
    {"id":"58824","name":"CAT quarterly highlights and approved ATMPs - May 2023","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2023-05-31T12:28:00Z","last_updated_date":"2023-05-31T12:28:00Z","reference_number":"EMA/CAT/247792/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-may-2023_en.pdf"},
    {"id":"59467","name":"CAT quarterly highlights and approved ATMPs - July 2023","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2023-07-24T13:51:00Z","last_updated_date":"2023-07-24T13:51:00Z","reference_number":"EMA/CAT/247792/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-july-2023_en.pdf"},
    {"id":"59538","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 17-19 July 2023","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2023-08-02T15:18:00Z","last_updated_date":"2023-08-02T15:18:00Z","reference_number":"EMA/HMPC/338621/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-17-19-july-2023_en.pdf"},
    {"id":"60461","name":"PRAC recommendations on signals adopted at the 25-28 September 2023 PRAC","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2023-10-23T09:06:00Z","last_updated_date":"2023-10-23T09:06:00Z","reference_number":"EMA/PRAC/416575/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/prac-recommendations-signals-adopted-25-28-september-2023-prac_en.pdf"},
    {"id":"60607","name":"PDCO monthly report of opinions on paediatric investigation plans and other activities 9-11 December 2019","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-01-27T13:32:00Z","last_updated_date":"2020-01-27T13:32:00Z","reference_number":"EMEA/13268/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/pdco-monthly-report-opinions-paediatric-investigation-plans-and-other-activities-9-11-december-2019_en.pdf"},
    {"id":"60609","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 13-15 January 2020","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2020-01-27T14:09:00Z","last_updated_date":"2020-01-27T14:09:00Z","reference_number":"EMA/HMPC/28633/2020","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-13-15-january-2020_en.pdf"},
    {"id":"60683","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 18-20 July 2022","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2022-08-10T14:04:00Z","last_updated_date":"2022-08-10T14:04:00Z","reference_number":"EMA/HMPC/658338/20222","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-18-20-july-2022_en.pdf"},
    {"id":"60756","name":"HMPC meeting report on European Union herbal monographs 18-20 September 2023","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2023-10-03T12:16:00Z","last_updated_date":"2023-10-03T12:16:00Z","reference_number":"EMA/HMPC/430913/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-18-20-september-2023_en.pdf"},
    {"id":"60868","name":"CAT quarterly highlights and approved ATMPs - October 2023","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T14:17:00Z","last_updated_date":"2023-11-10T14:17:00Z","reference_number":"EMA/CAT/247792/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-october-2023_en.pdf"},
    {"id":"61296","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 20-22 November 2023","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T13:06:52Z","last_updated_date":"2023-12-07T13:06:52Z","reference_number":"EMA/HMPC/535681/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-and-other-activities-20-22-november-2023_en.pdf"},
    {"id":"62100","name":"HMPC meeting report on European Union herbal  monographs, guidelines and other activities - 29-31 January 2024","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2024-02-13T13:30:00Z","last_updated_date":"2024-02-13T13:30:00Z","reference_number":"EMA/HMPC/54241/2024","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-29-31-january-2024_en.pdf"},
    {"id":"62282","name":"CAT quarterly highlights and approved ATMPs - January 2024","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T14:47:17Z","last_updated_date":"2024-02-23T14:47:17Z","reference_number":"EMA/CAT/456472/2023","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-january-2024_en.pdf"},
    {"id":"62887","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 18-20 March 2024","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2024-04-10T12:02:24Z","last_updated_date":"2024-04-10T12:02:24Z","reference_number":"EMA/HMPC/129763/2024","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-18-20-march-2024_en.pdf"},
    {"id":"63147","name":"CAT quarterly highlights and approved ATMPs - April 2024","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2024-05-02T11:11:01Z","last_updated_date":"2024-05-02T11:11:01Z","reference_number":"EMA/CAT/177024/2024","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-april-2024_en.pdf"},
    {"id":"63784","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 27-29 May 2024","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T10:36:00Z","last_updated_date":"2024-08-14T17:39:00Z","reference_number":"EMA/HMPC/259200/2024","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-27-29-may-2024_en.pdf"},
    {"id":"64574","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 22-24 July 2024","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2024-08-14T16:06:46Z","last_updated_date":"2024-08-14T16:06:46Z","reference_number":"EMA/HMPC/349181/2024","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-22-24-july-2024_en.pdf"},
    {"id":"64781","name":"CAT quarterly highlights and approved ATMPs - August 2024","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2024-09-10T16:28:31Z","last_updated_date":"2024-09-10T16:28:31Z","reference_number":"EMA/CAT/177024/2024","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-august-2024_en.pdf"},
    {"id":"65303","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 23-25 September 2024","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2024-10-16T10:33:00Z","last_updated_date":"2024-10-16T10:33:00Z","reference_number":"EMA/HMPC/455545/2024","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-23-25-september-2024_en.pdf"},
    {"id":"65626","name":"CAT quarterly highlights and approved ATMPs - November 2024","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2024-11-14T11:37:54Z","last_updated_date":"2024-11-14T11:37:54Z","reference_number":"EMA/CAT/511673/2024","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-november-2024_en.pdf"},
    {"id":"66222","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 18-20 November 2024","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2024-12-19T11:25:24Z","last_updated_date":"2024-12-19T11:25:24Z","reference_number":"EMA/549783/2024","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-18-20-november-2024_en.pdf"},
    {"id":"66695","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 20-22 January 2025","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2025-02-12T10:52:58Z","last_updated_date":"2025-02-12T10:52:58Z","reference_number":"EMA/HMPC/33304/2025","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-20-22-january-2025_en.pdf"},
    {"id":"66871","name":"CAT quarterly highlights and approved ATMPs - February 2025","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2025-02-19T11:28:15Z","last_updated_date":"2025-02-19T11:28:15Z","reference_number":"EMA/CAT/52354/2025","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-february-2025_en.pdf"},
    {"id":"67732","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 17-19 March 2025","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2025-04-10T14:27:09Z","last_updated_date":"2025-04-10T14:27:09Z","reference_number":"EMA/HMPC/106227/20255","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-17-19-march-2025_en.pdf"},
    {"id":"68383","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 05-07 May 2025","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2025-05-22T13:39:56Z","last_updated_date":"2025-05-22T13:39:56Z","reference_number":"EMA/HMPC/160594/2025","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-05-07-may-2025_en.pdf"},
    {"id":"68533","name":"CAT quarterly highlights and approved ATMPs - May 2025","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2025-06-02T17:10:34Z","last_updated_date":"2025-06-02T17:10:34Z","reference_number":"EMA/CAT/174611/2025","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-may-2025_en.pdf"},
    {"id":"69500","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 07-09 July 2025","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T14:35:38Z","last_updated_date":"2025-07-25T14:35:38Z","reference_number":"EMA/HMPC/227855/2025","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-07-09-july-2025_en.pdf"},
    {"id":"70526","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 22-24 September 2025","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2025-10-10T14:29:23Z","last_updated_date":"2025-10-10T14:29:23Z","reference_number":"EMA/HMPC/313955/2025","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-22-24-september-2025_en.pdf"},
    {"id":"71460","name":"CAT quarterly highlights and approved ATMPs - December 2025","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2025-12-02T16:39:46Z","last_updated_date":"2025-12-02T16:39:46Z","reference_number":"EMA/CAT/380337/2025","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-december-2025_en.pdf"},
    {"id":"71713","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 17-19 November 2025","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T12:02:00Z","last_updated_date":"2025-12-12T12:02:00Z","reference_number":"EMA/HMPC/371247/2025","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-17-19-november-2025_en.pdf"},
    {"id":"72422","name":"HMPC meeting report on European Union herbal  monographs, guidelines and other activities - 19-21 January 2026","type":"committee-report","status":"unknown","consultation_date":"","first_published_date":"2026-02-05T10:42:26Z","last_updated_date":"2026-02-05T10:42:26Z","reference_number":"EMA/HMPC/19618/2026","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-19-21-january-2026_en.pdf"},
    {"id":"72968","name":"CAT quarterly highlights and approved ATMPs - March 2026","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T10:29:16Z","last_updated_date":"2026-03-12T10:29:16Z","reference_number":"EMA/53733/2026","document_url":"https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-march-2026_en.pdf"},
    {"id":"73208","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 2-4 March 2026","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2026-03-25T15:58:24Z","last_updated_date":"2026-03-25T15:58:24Z","reference_number":"EMA/HMPC/57558/2026","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-2-4-march-2026_en.pdf"},
    {"id":"73783","name":"HMPC meeting report on European Union herbal monographs, guidelines and other activities - 4-6 May 2026","type":"committee-report","status":"Adopted","consultation_date":"","first_published_date":"2026-05-20T14:04:05Z","last_updated_date":"2026-05-20T14:04:05Z","reference_number":"EMA/HMPC/112091/2026","document_url":"https://www.ema.europa.eu/en/documents/committee-report/hmpc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-4-6-may-2026_en.pdf"},
    {"id":"2431","name":"Call for submission of scientific data relating to the assessment of agrimoniae herba agrimonia eupatoria L., herba - First version","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-06-16T02:00:00Z","last_updated_date":"2008-06-16T02:00:00Z","reference_number":"EMEA/HMPC/245044/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-agrimoniae-herba-agrimonia-eupatoria-l-herba-first-version_en.pdf"},
    {"id":"2549","name":"Call for submission of scientific data relating to the assessment of Rosmarini folium Rosmarinus officinalis L., folium","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-06-16T02:00:00Z","last_updated_date":"2008-06-16T02:00:00Z","reference_number":"EMEA/HMPC/324419/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-rosmarini-folium-rosmarinus-officinalis-l-folium_en.pdf"},
    {"id":"2638","name":"Call for scientific data for use in HMPC assessment work on Adhatoda vasica Nees, folium - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558963/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-adhatoda-vasica-nees-folium-first-version_en.pdf"},
    {"id":"3195","name":"Call for scientific data for the review of the HMPC assessment on Centella asiatica L. Urban, herba - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-04-30 - 2018-07-31","first_published_date":"2018-04-30T18:45:00Z","last_updated_date":"2018-04-30T18:45:00Z","reference_number":"EMA/HMPC/248637/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-review-hmpc-assessment-centella-asiatica-l-urban-herba-first-version_en.pdf"},
    {"id":"3288","name":"Call for scientific data for the systematic review of the monograph on Sambucus nigra L., flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-04-15 - 2016-07-15","first_published_date":"2016-04-15T20:00:00Z","last_updated_date":"2016-04-15T20:00:00Z","reference_number":"EMA/269955/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-sambucus-nigra-l-flos_en.pdf"},
    {"id":"3462","name":"Call for scientific data for the systematic review of the monograph on Tanacetum parthenium (L.) Schulz Bip., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-06-15 - 2016-09-15","first_published_date":"2016-06-15T13:00:00Z","last_updated_date":"2016-06-15T13:00:00Z","reference_number":"EMA/HMPC/403695/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-tanacetum-parthenium-l-schulz-bip-herba_en.pdf"},
    {"id":"3550","name":"Call for scientific data for the systematic review of the monograph on Althaea officinalis L., radix.","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-12-12 - 2015-03-15","first_published_date":"2014-12-15T13:40:00Z","last_updated_date":"2014-12-15T13:40:00Z","reference_number":"EMA/HMPC/776605/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-althaea-officinalis-l-radix_en.pdf"},
    {"id":"3782","name":"Call for scientific data for the systematic review of the monograph on Thymus vulgaris L., Thymus zygis Loefl. ex. L., aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-04-15 - 2016-07-15","first_published_date":"2016-04-15T20:00:00Z","last_updated_date":"2016-04-15T20:00:00Z","reference_number":"EMA/269949/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-thymus-vulgaris-l-thymus-zygis-loefl-ex-l-aetheroleum_en.pdf"},
    {"id":"4155","name":"Call for scientific data for the systematic review of the monograph on Verbascum thapsus L., V. densiflorum Bertol., V. phlomoides L., flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-06-15 - 2016-09-15","first_published_date":"2016-06-15T13:00:00Z","last_updated_date":"2016-06-15T13:00:00Z","reference_number":"EMA/HMPC/403696/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-verbascum-thapsus-l-v-densiflorum-bertol-v-phlomoides-l-flos_en.pdf"},
    {"id":"4356","name":"Call for scientific data for use in HMPC assessment work on Phaseolus vulgaris L., fructus (sine semine)","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-17T19:43:00Z","last_updated_date":"2011-10-17T19:43:00Z","reference_number":"EMA/HMPC/558951/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-phaseolus-vulgaris-l-fructus-sine-semine_en.pdf"},
    {"id":"4913","name":"Call for scientific data for use in HMPC assessment work on Centaurium erythraea Rafn, herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-07-23 - 2014-10-31","first_published_date":"2014-07-24T18:30:00Z","last_updated_date":"2014-07-24T18:30:00Z","reference_number":"EMA/HMPC/447913/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-centaurium-erythraea-rafn-herba_en.pdf"},
    {"id":"4921","name":"Call for scientific data for the systematic review of the monograph on Betula pendula Roth; Betula pubescens Ehrh., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2013-02-15 - 2013-05-15","first_published_date":"2013-02-14T18:00:00Z","last_updated_date":"2013-02-14T18:00:00Z","reference_number":"EMA/HMPC/91037/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-betula-pendula-roth-betula-pubescens-ehrh-folium_en.pdf"},
    {"id":"4922","name":"Call for scientific data for the systematic review of the monograph on Peumus boldus Molina, folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-02-15 - 2016-05-15","first_published_date":"2016-02-15T18:45:00Z","last_updated_date":"2016-02-15T18:45:00Z","reference_number":"EMA/HMPC/129846/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-peumus-boldus-molina-folium_en.pdf"},
    {"id":"5256","name":"Call for scientific data for use in HMPC assessment work on Fucus vesiculosus L.","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-17T19:40:00Z","last_updated_date":"2011-10-17T19:40:00Z","reference_number":"EMA/HMPC/558965/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-fucus-vesiculosus-l_en.pdf"},
    {"id":"5523","name":"Call for scientific data for the systematic review of the monograph on Arctostaphylos uva-ursi (L.) Spreng., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:00:00Z","last_updated_date":"2015-10-14T14:00:00Z","reference_number":"EMA/HMPC/669365/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-arctostaphylos-uva-ursi-l-spreng-folium_en.pdf"},
    {"id":"5801","name":"Call for scientific data for the systematic review of the monograph on Vitis vinifera L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:00:00Z","last_updated_date":"2015-10-14T14:00:00Z","reference_number":"EMA/HMPC/669367/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-vitis-vinifera-l-folium_en.pdf"},
    {"id":"6149","name":"Call for scientific data for use in HMPC assessment work on Aloysia citriodora Palà¡u (syn. Aloysia triphylla (L’Hà©r.) Kuntze; Verbena triphylla L’Hà©r.; Lippia citriodora Kunth.), folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-31 - 2018-06-30","first_published_date":"2018-03-28T19:00:00Z","last_updated_date":"2018-03-28T19:00:00Z","reference_number":"EMA/HMPC/188875/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-aloysia-citriodora-palau-syn-aloysia-triphylla-lhacr-kuntze-verbena-triphylla-lhacr-lippia-citriodora-kunth-folium_en.pdf"},
    {"id":"6286","name":"Call for scientific data for use in HMPC assessment work on Capsicum annuum L. var. minimum (Miller) Heiser and Capsicum frutescens L., fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-04-15 - 2011-07-15","first_published_date":"2011-04-14T04:00:00Z","last_updated_date":"2011-04-14T04:00:00Z","reference_number":"EMA/HMPC/129733/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-capsicum-annuum-l-var-minimum-miller-heiser-and-capsicum-frutescens-l-fructus_en.pdf"},
    {"id":"6419","name":"Call for scientific data for use in HMPC assessment work on Glycine max and/or lecithin derived from Glycine max (soy bean lecithin)","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-06-15","first_published_date":"2014-02-17T11:35:00Z","last_updated_date":"2014-04-15T15:10:00Z","reference_number":"EMA/HMPC/87618/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-glycine-max-and-or-lecithin-derived-glycine-max-soy-bean-lecithin_en.pdf"},
    {"id":"6527","name":"Call for scientific data for use in HMPC assessment work on Sideritis herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-17T11:00:00Z","last_updated_date":"2014-02-17T11:00:00Z","reference_number":"EMA/HMPC/87641/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-sideritis-herba_en.pdf"},
    {"id":"6793","name":"Call for submission of scientific data relating to the assessment of Hederae helices folium Hedera helix l., folium (ivy leaf)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-11-15T01:00:00Z","last_updated_date":"2008-11-15T01:00:00Z","reference_number":"EMEA/HMPC/617260/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-hederae-helices-folium-hedera-helix-l-folium-ivy-leaf_en.pdf"},
    {"id":"7104","name":"Call for scientific data for the review of the HMPC assessment on Angelica sinensis (Oliv.) Diels, radix - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-04-30 - 2018-07-31","first_published_date":"2018-04-30T18:45:00Z","last_updated_date":"2018-04-30T18:45:00Z","reference_number":"EMA/HMPC/248608/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-review-hmpc-assessment-angelica-sinensis-oliv-diels-radix-first-version_en.pdf"},
    {"id":"7251","name":"Call for scientific data for use in HMPC assessment work on Malva sylvestris L., folium and flos - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:00:00Z","last_updated_date":"2015-10-14T14:00:00Z","reference_number":"EMA/HMPC/669364/2015 Corr","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-malva-sylvestris-l-folium-and-flos-first-version_en.pdf"},
    {"id":"7723","name":"Call for submission of scientific data relating to the assessment of  Melaleucae alternifoliae aetheroleum; Melaleuca alternifolia (Maiden and Betche) Cheel, aetheroleum (tea tree oil)  - First version","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2009-08-15T02:00:00Z","last_updated_date":"2009-08-15T02:00:00Z","reference_number":"EMEA/HMPC/468683/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-melaleucae-alternifoliae-aetheroleum-melaleuca-alternifolia-maiden-and-betche-cheel-aetheroleum-tea-tree-oil-first-version_en.pdf"},
    {"id":"7808","name":"Call for scientific data for use in HMPC assessment work on Cetraria islandica (L.) Acharius s.l. - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-02-15","first_published_date":"2012-10-15T14:30:00Z","last_updated_date":"2012-10-15T14:30:00Z","reference_number":"EMA/HMPC/648703/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-cetraria-islandica-l-acharius-sl-first-version_en.pdf"},
    {"id":"7838","name":"Call for scientific data for the systematic review of the monograph on Echinacea purpurea (L.) Moench, herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2013-02-15 - 2013-05-15","first_published_date":"2013-02-14T18:00:00Z","last_updated_date":"2013-02-14T18:00:00Z","reference_number":"EMA/HMPC/91101/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-echinacea-purpurea-l-moench-herba_en.pdf"},
    {"id":"8308","name":"Call for scientific data for use in HMPC assessment work on Piper methysticum G. Forst., rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-05-28 - 2015-08-31","first_published_date":"2015-05-28T13:20:00Z","last_updated_date":"2015-05-28T13:20:00Z","reference_number":"EMA/HMPC/343245/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-piper-methysticum-g-forst-rhizoma_en.pdf"},
    {"id":"8333","name":"Call for submission of scientific data relating to the assessment of Mate folium Ilex paraguariensis St. Hil., folium - First version","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-07-16T02:00:00Z","last_updated_date":"2008-07-16T02:00:00Z","reference_number":"EMEA/HMPC/377815/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-mate-folium-ilex-paraguariensis-st-hil-folium-first-version_en.pdf"},
    {"id":"8906","name":"Call for scientific data for use in HMPC assessment work on Paullinia cupana Kunth, semen - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-04-15 - 2011-07-15","first_published_date":"2011-04-14T04:00:00Z","last_updated_date":"2011-04-14T04:00:00Z","reference_number":"EMA/HMPC/278492/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-paullinia-cupana-kunth-semen-first-version_en.pdf"},
    {"id":"9092","name":"Call for scientific data for the systematic review of the monograph on Cassia senna L.; Cassia angustifolia Vahl, folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-02-15","first_published_date":"2012-10-15T14:30:00Z","last_updated_date":"2012-10-15T14:30:00Z","reference_number":"EMA/HMPC/648291/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-cassia-senna-l-cassia-angustifolia-vahl-folium_en.pdf"},
    {"id":"9330","name":"Call for submission of scientific data relating to the assessment of Agni casti fructus Vitex agnus-castus L., fructus (agnus castus fruit) - First version","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-11-15T01:00:00Z","last_updated_date":"2008-11-15T01:00:00Z","reference_number":"EMEA/HMPC/617265/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-agni-casti-fructus-vitex-agnus-castus-l-fructus-agnus-castus-fruit-first-version_en.pdf"},
    {"id":"9387","name":"Call for scientific data for use in HMPC assessment work on Ononis spinosa L. and Ononis arvensis L., radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-02-15 - 2012-05-15","first_published_date":"2012-02-15T18:00:00Z","last_updated_date":"2012-02-15T18:00:00Z","reference_number":"EMA/HMPC/66224/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-ononis-spinosa-l-and-ononis-arvensis-l-radix_en.pdf"},
    {"id":"9851","name":"Call for scientific data for the systematic review of the monograph on Cassia senna L.; Cassia angustifolia Vahl, fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-02-15","first_published_date":"2012-10-15T14:30:00Z","last_updated_date":"2012-10-15T14:30:00Z","reference_number":"EMA/HMPC/648271/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-cassia-senna-l-cassia-angustifolia-vahl-fructus_en.pdf"},
    {"id":"9920","name":"Call for scientific data for the review of the HMPC assessment on Andrographis paniculata Nees, folium - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-04-30 - 2018-07-31","first_published_date":"2018-04-30T18:45:00Z","last_updated_date":"2018-04-30T18:45:00Z","reference_number":"EMA/HMPC/248556/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-review-hmpc-assessment-andrographis-paniculata-nees-folium-first-version_en.pdf"},
    {"id":"10478","name":"Call for scientific data for the systematic review of the monograph on Linum usitatissimum L., semen","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558977/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-linum-usitatissimum-l-semen_en.pdf"},
    {"id":"10899","name":"Call for scientific data for use in HMPC assessment work on Saccharomyces cerevisiae/Saccharomyces boulardii","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-14T18:50:00Z","last_updated_date":"2014-02-14T18:50:00Z","reference_number":"EMA/HMPC/87634/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-saccharomyces-cerevisiae-saccharomyces-boulardii_en.pdf"},
    {"id":"11332","name":"Call for scientific data for use in HMPC assessment work on Origani majoranae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-17T12:00:00Z","last_updated_date":"2014-02-17T12:00:00Z","reference_number":"EMA/HMPC/87625/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-origani-majoranae-herba_en.pdf"},
    {"id":"11688","name":"Call for scientific data for the systematic review of the monograph on Aesculus hippocastanum L., semen","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:00:00Z","last_updated_date":"2015-10-14T14:00:00Z","reference_number":"EMA/HMPC/669362/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-aesculus-hippocastanum-l-semen_en.pdf"},
    {"id":"11727","name":"Call for scientific data for use in HMPC assessment work on Allium sativum L., bulbus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-06-01 - 2011-09-15","first_published_date":"2011-06-07T04:00:00Z","last_updated_date":"2011-06-07T04:00:00Z","reference_number":"EMA/HMPC/261528/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-allium-sativum-l-bulbus_en.pdf"},
    {"id":"12146","name":"Call for scientific data for the systematic review of the monograph on Commiphora molmol Engler, gummi-resina","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-07-15 - 2016-10-15","first_published_date":"2016-07-15T13:00:00Z","last_updated_date":"2016-07-15T13:00:00Z","reference_number":"EMA/HMPC/403788/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-commiphora-molmol-engler-gummi-resina_en.pdf"},
    {"id":"12500","name":"Call for scientific data for the systematic review of the monograph on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2013-02-15 - 2013-05-15","first_published_date":"2013-02-14T18:00:00Z","last_updated_date":"2013-02-14T18:00:00Z","reference_number":"EMA/HMPC/91102/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf"},
    {"id":"12729","name":"Call for scientific data for the systematic review of the monograph on Oenothera biennis L.; Oenothera lamarckiana L., oleum - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-07-15 - 2016-10-15","first_published_date":"2016-07-15T13:00:00Z","last_updated_date":"2016-07-15T13:00:00Z","reference_number":"EMA/HMPC/403789/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-oenothera-biennis-l-oenothera-lamarckiana-l-oleum-first-version_en.pdf"}    {"id":"12922","name":"Call for scientific data for the systematic review of the monograph on Salix (various species including S. purpurea L., S. daphnoides Vill., S. fragilis L.), whole or fragmented dried bark","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-05-28 - 2015-08-31","first_published_date":"2015-05-28T13:20:00Z","last_updated_date":"2015-05-28T13:20:00Z","reference_number":"EMA/HMPC/343246/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-whole-or-fragmented-dried-bark_en.pdf"},
    {"id":"13023","name":"Call for scientific data for the periodic review of the monograph on Capsella bursa-pastoris (L.) Medikus, herba - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-04-30 - 2018-07-31","first_published_date":"2018-04-30T18:45:00Z","last_updated_date":"2018-04-30T18:45:00Z","reference_number":"EMA/HMPC/248382/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-capsella-bursa-pastoris-l-medikus-herba-first-version_en.pdf"},
    {"id":"13093","name":"Call for scientific data for the systematic review of the monograph on Humulus lupulus L., flos - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2013-02-15 - 2013-05-15","first_published_date":"2013-02-14T18:00:00Z","last_updated_date":"2013-02-14T18:00:00Z","reference_number":"EMA/HMPC/91099/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"13214","name":"Call for scientific data for use in HMPC assessment work on Malva sylvestris L., folium and flos - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:00:00Z","last_updated_date":"2015-10-14T14:00:00Z","reference_number":"EMA/HMPC/669364/2015 Corr","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-malva-sylvestris-l-folium-and-flos-first-version_en.pdf-0"},
    {"id":"13763","name":"Call for submission of scientific data on Serenoa repens (Bartram) Small (Sabal serrulata (Michaux) Nichols), fructus","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2010-03-22T01:00:00Z","last_updated_date":"2010-03-22T01:00:00Z","reference_number":"EMA/HMPC/152363/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-serenoa-repens-bartram-small-sabal-serrulata-michaux-nichols-fructus_en.pdf"},
    {"id":"14191","name":"Call for scientific data for use in HMPC assessment work on Herniariae glabra L.; Herniariae hirsuta L.; Herniariae incana LAM., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-31 - 2018-06-30","first_published_date":"2018-03-28T19:00:00Z","last_updated_date":"2018-03-28T19:00:00Z","reference_number":"EMA/HMPC/1887935/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-herniariae-glabra-l-herniariae-hirsuta-l-herniariae-incana-lam-herba_en.pdf"},
    {"id":"14684","name":"Call for scientific data for the systematic review of the monograph on Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung., fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2013-02-15 - 2013-05-15","first_published_date":"2013-02-14T18:00:00Z","last_updated_date":"2013-02-14T18:00:00Z","reference_number":"EMA/HMPC/91105/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus_en.pdf"},
    {"id":"15036","name":"Call for scientific data for the systematic review of the monograph on Plantago ovata Forssk., semen","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558983/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-plantago-ovata-forssk-semen_en.pdf"},
    {"id":"15223","name":"Call for scientific data for the systematic review of the monograph on Echinacea purpurea (L.) Moench, radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:00:00Z","last_updated_date":"2015-10-14T14:00:00Z","reference_number":"EMA/HMPC/669361/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-echinacea-purpurea-l-moench-radix_en.pdf"},
    {"id":"15414","name":"Call for scientific data for use in HMPC assessment work on Polygoni avicularis herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-03-15 - 2014-06-15","first_published_date":"2014-03-14T18:15:00Z","last_updated_date":"2014-03-14T18:15:00Z","reference_number":"EMA/HMPC/143245/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-polygoni-avicularis-herba_en.pdf"},
    {"id":"15443","name":"Call for scientific data for use in HMPC assessment work on Panax ginseng C.A. Meyer, radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-04-15 - 2011-07-15","first_published_date":"2011-04-14T04:00:00Z","last_updated_date":"2011-04-14T04:00:00Z","reference_number":"EMA/HMPC/278493/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-panax-ginseng-ca-meyer-radix_en.pdf"},
    {"id":"15618","name":"Call for scientific data for the review of the HMPC assessment on Withania somnifera (L.) Dunal, radix - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-04-30 - 2018-07-31","first_published_date":"2018-04-30T18:45:00Z","last_updated_date":"2018-04-30T18:45:00Z","reference_number":"EMA/HMPC/250486/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-review-hmpc-assessment-withania-somnifera-l-dunal-radix-first-version_en.pdf"},
    {"id":"16105","name":"Call for scientific data for use in HMPC assessment work on Eucalyptus globulus Labill., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-06-07 - 2011-09-15","first_published_date":"2011-06-07T04:00:00Z","last_updated_date":"2011-06-07T04:00:00Z","reference_number":"EMA/HMPC/417632/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-eucalyptus-globulus-labill-folium_en.pdf"},
    {"id":"16252","name":"Call for scientific data for the periodic review of the monograph on Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria L.), herba - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-04-30 - 2018-07-31","first_published_date":"2018-04-30T18:45:00Z","last_updated_date":"2018-04-30T18:45:00Z","reference_number":"EMA/HMPC/252429/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-filipendula-ulmaria-l-maxim-spiraea-ulmaria-l-herba-first-version_en.pdf"},
    {"id":"16631","name":"Call for submission of scientific data relating to the assessment of Oleae folium Olea europaea L., folium","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-06-16T02:09:21Z","last_updated_date":"2008-06-16T02:09:21Z","reference_number":"EMEA/HMPC/245033/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-oleae-folium-olea-europaea-l-folium_en.pdf"},
    {"id":"16736","name":"Call for scientific data for the systematic review of the monograph on Salvia officinalis L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-12-12 - 2015-03-15","first_published_date":"2014-12-15T13:40:00Z","last_updated_date":"2014-12-15T13:40:00Z","reference_number":"EMA/HMPC/776602/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-salvia-officinalis-l-folium_en.pdf"},
    {"id":"16909","name":"Call for submission of scientific data on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne, flos (lime flower) - First version","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2010-03-22T01:00:00Z","last_updated_date":"2010-03-22T01:00:00Z","reference_number":"EMA/HMPC/160868/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-flos-lime-flower-first-version_en.pdf"},
    {"id":"18416","name":"Call for scientific data for the systematic review of the monograph on Foeniculum vulgare Miller subsp. vulgare var. vulgare, aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2013-02-15 - 2013-05-15","first_published_date":"2013-02-14T18:00:00Z","last_updated_date":"2013-02-14T18:00:00Z","reference_number":"EMA/HMPC/91104/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-aetheroleum_en.pdf"},
    {"id":"18802","name":"Call for scientific data for use in HMPC assessment work on Erysimum officinale L., flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-02-15 - 2011-05-15","first_published_date":"2011-02-17T02:00:00Z","last_updated_date":"2011-02-17T02:00:00Z","reference_number":"EMA/HMPC/129740/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-erysimum-officinale-l-flos_en.pdf"},
    {"id":"19176","name":"Call for submission of scientific data relating to the assessment of Pelargonii radix Pelargonium sidoides DC and / or Pelargonium reniforme Curt., radix (pelargonium root)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/HMPC/604877/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-pelargonii-radix-pelargonium-sidoides-dc-and-or-pelargonium-reniforme-curt-radix-pelargonium-root_en.pdf"},
    {"id":"19329","name":"Call for scientific data for use in HMPC assessment work on Epilobii herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-17T11:25:00Z","last_updated_date":"2014-02-17T11:25:00Z","reference_number":"EMA/HMPC/87611/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-epilobii-herba_en.pdf"},
    {"id":"19392","name":"Call for scientific data for use in HMPC assessment work on Hieracium pilosella L., herba cum flore","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-12-15 - 2012-04-15","first_published_date":"2012-01-03T12:03:00Z","last_updated_date":"2012-01-03T12:03:00Z","reference_number":"EMA/HMPC/890471/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-hieracium-pilosella-l-herba-cum-flore_en.pdf"},
    {"id":"19416","name":"Call for scientific data for use in HMPC assessment work on Hamamelis virginiana L., cortex – First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-01 - 2018-05-31","first_published_date":"2018-03-01T19:00:00Z","last_updated_date":"2018-03-01T19:00:00Z","reference_number":"EMA/HMPC/125353/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-hamamelis-virginiana-l-cortex-first-version_en.pdf"},
    {"id":"19648","name":"Call for scientific data for the systematic review of the monograph on Thymus vulgaris L.; Thymus zygis Loefl. ex L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-02-15","first_published_date":"2012-10-15T14:30:00Z","last_updated_date":"2012-10-15T14:30:00Z","reference_number":"EMA/HMPC/648276/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-thymus-vulgaris-l-thymus-zygis-loefl-ex-l-herba_en.pdf"},
    {"id":"19700","name":"Call for scientific data for use in HMPC assessment work on Ginkgo biloba L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-27T14:27:00Z","last_updated_date":"2011-10-27T14:27:00Z","reference_number":"EMA/HMPC/853775/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-ginkgo-biloba-l-folium_en.pdf"},
    {"id":"19760","name":"Call for submission of scientific data relating to the assessment of  Matricariae aetheroleum; Matricaria recutita L. (Chamomilla recutita L. Rauschert), aetheroleum (Matricaria oil) - First version","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2009-08-15T02:00:00Z","last_updated_date":"2009-08-15T02:00:00Z","reference_number":"EMEA/HMPC/468687/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-matricariae-aetheroleum-matricaria-recutita-l-chamomilla-recutita-l-rauschert-aetheroleum-matricaria-oil-first-version_en.pdf"},
    {"id":"19773","name":"Call for scientific data for the systematic review of the monograph on Vitex agnus-castus L., fructus - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:00:00Z","last_updated_date":"2015-10-14T14:00:00Z","reference_number":"EMA/HMPC/669359/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-vitex-agnus-castus-l-fructus-first-version_en.pdf"},
    {"id":"19909","name":"Call for scientific data for the systematic review of the monograph on Rheum palmatum L.; Rheum officinale Baillon, radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-02-15","first_published_date":"2012-10-15T14:30:00Z","last_updated_date":"2012-10-15T14:30:00Z","reference_number":"EMA/HMPC/648289/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-rheum-palmatum-l-rheum-officinale-baillon-radix_en.pdf"},
    {"id":"20161","name":"Call for scientific data for use in HMPC assessment work on Withania somnifera (L.) Dunal, radix - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558961/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-withania-somnifera-l-dunal-radix-first-version_en.pdf"},
    {"id":"20328","name":"Call for submission of scientific data relating to the assessment of  plantaginis lanceolatae folium Plantago lanceolata L., folium (ribwort plantain)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-11-15T01:00:00Z","last_updated_date":"2008-11-15T01:00:00Z","reference_number":"EMEA/HMPC/617256/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-plantaginis-lanceolatae-folium-plantago-lanceolata-l-folium-ribwort-plantain_en.pdf"},
    {"id":"20633","name":"Call for scientific data for the systematic review of the monograph on Olea europaea L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-03-15","first_published_date":"2015-12-15T11:00:00Z","last_updated_date":"2015-12-15T11:00:00Z","reference_number":"EMA/HMPC/845010/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-olea-europaea-l-folium_en.pdf"},
    {"id":"20796","name":"Call for scientific data for use in HMPC assessment work on Hyoscyamus niger L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-12-15 - 2012-04-15","first_published_date":"2012-01-03T11:50:00Z","last_updated_date":"2012-01-03T11:50:00Z","reference_number":"EMA/HMPC/890472/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-hyoscyamus-niger-l-herba_en.pdf"},
    {"id":"20803","name":"Call for scientific data for the systematic review of the monograph on Cynara scolymus L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-03-15","first_published_date":"2015-12-15T11:00:00Z","last_updated_date":"2015-12-15T11:00:00Z","reference_number":"EMA/HMPC/844975/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-cynara-scolymus-l-folium_en.pdf"},
    {"id":"20966","name":"Call for scientific data for use in HMPC assessment work on Echinaceae angustifolia DC., radix – First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-01 - 2018-05-31","first_published_date":"2018-03-01T19:00:00Z","last_updated_date":"2018-03-01T19:00:00Z","reference_number":"EMA/HMPC/125289/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-echinaceae-angustifolia-dc-radix-first-version_en.pdf"},
    {"id":"21486","name":"Call for scientific data for use in HMPC assessment work on Carum carvi L., aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-06-15 - 2012-10-15","first_published_date":"2012-06-15T15:30:00Z","last_updated_date":"2012-06-15T15:30:00Z","reference_number":"EMA/HMPC/356252/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"21507","name":"Call for submission of scientific data relating to the assessment of Vitis viniferae folium Vitis vinifera L., folium","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-06-16T02:09:21Z","last_updated_date":"2008-06-16T02:09:21Z","reference_number":"EMEA/HMPC/245028/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-vitis-viniferae-folium-vitis-vinifera-l-folium_en.pdf"},
    {"id":"21713","name":"Call for scientific data for use in HMPC assessment work on Phaseolus vulgaris L., fructus – Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-01 - 2018-05-31","first_published_date":"2018-03-01T19:00:00Z","last_updated_date":"2018-03-01T19:00:00Z","reference_number":"EMA/HMPC/131795/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-phaseolus-vulgaris-l-fructus-revision-1_en.pdf"},
    {"id":"21750","name":"Call for scientific data for the systematic review of the monograph on Cimicifuga racemosa (L.) Nutt., rhizome - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:00:00Z","last_updated_date":"2015-10-14T14:00:00Z","reference_number":"EMA/HMPC/669360/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-cimicifuga-racemosa-l-nutt-rhizome-first-version_en.pdf"},
    {"id":"21784","name":"Call for submission of scientific data relating to the assessment of Colae semen Cola nitida (Vent.) Schott et Endl. (c. Vera K. Schum.) and Cola acuminata (P. Beauv.) Schott et Endl. (Sterculia acuminata P. Beauv.), sem...","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2009-10-15T02:09:21Z","last_updated_date":"2009-10-15T02:09:21Z","reference_number":"EMEA/HMPC/604684/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-colae-semen-cola-nitida-vent-schott-et-endl-c-vera-k-schum-and-cola-acuminata-p-beauv-schott-et-endl-sterculia-acuminata-p-beauv-sem_en.pdf"},
    {"id":"21841","name":"Call for scientific data for use in HMPC assessment work on Origanum dictamnus L., herba - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558967/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-origanum-dictamnus-l-herba-first-version_en.pdf"},
    {"id":"22324","name":"Call for scientific data for the periodic review of the monograph on Quercus robur L.; Quercus petraea (Matt.) Liebl.; Quercus pubescens Willd., cortex","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-31 - 2018-06-30","first_published_date":"2018-03-28T19:00:00Z","last_updated_date":"2018-03-28T19:00:00Z","reference_number":"EMA/HMPC/188889/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-quercus-robur-l-quercus-petraea-matt-liebl-quercus-pubescens-willd-cortex_en.pdf"},
    {"id":"22391","name":"Call for submission of scientific data relating to the assessment of Fraxini folium Fraxinus excelsior L. or Fraxinus oxyphylla M. Bieb., folium (ash leaf)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/HMPC/604802/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-fraxini-folium-fraxinus-excelsior-l-or-fraxinus-oxyphylla-m-bieb-folium-ash-leaf_en.pdf"},
    {"id":"23019","name":"Call for scientific data for use in HMPC assessment work on Ricini oleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-14T18:45:00Z","last_updated_date":"2014-02-14T18:45:00Z","reference_number":"EMA/HMPC/87631/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-ricini-oleum_en.pdf"},
    {"id":"23298","name":"Call for scientific data for use in HMPC assessment work on Rubus idaeus L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-17T19:44:00Z","last_updated_date":"2011-10-17T19:44:00Z","reference_number":"EMA/HMPC/778980/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-rubus-idaeus-l-folium_en.pdf"},
    {"id":"23312","name":"Call for submission of scientific data relating to the assessment of Gentianae radix - First version","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-03-19T00:09:21Z","last_updated_date":"2008-03-19T00:09:21Z","reference_number":"EMEA/HMPC/145174/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-gentianae-radix-first-version_en.pdf"},
    {"id":"24150","name":"Call for scientific data for the systematic review of the monograph on Pimpinella anisum L., aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558972/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-pimpinella-anisum-l-aetheroleum_en.pdf"},
    {"id":"24615","name":"Call for scientific data for the periodic review of the monograph on Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria L.), flos - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-04-30 - 2018-07-31","first_published_date":"2018-04-30T18:45:00Z","last_updated_date":"2018-04-30T18:45:00Z","reference_number":"EMA/HMPC/248310/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-filipendula-ulmaria-l-maxim-spiraea-ulmaria-l-flos-first-version_en.pdf"},
    {"id":"24649","name":"Call for scientific data for use in HMPC assessment work on Artemisia absinthium L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-07-23 - 2014-10-31","first_published_date":"2014-07-24T18:30:00Z","last_updated_date":"2014-07-24T18:30:00Z","reference_number":"EMA/HMPC/447912/2014 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-artemisia-absinthium-l-herba_en.pdf"},
    {"id":"24956","name":"Call for scientific data for the systematic review of the monograph on Achillea millefolium L., flos and Achillea millefolium L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-03-15","first_published_date":"2015-12-15T11:00:00Z","last_updated_date":"2015-12-15T11:00:00Z","reference_number":"EMA/HMPC/844909/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-achillea-millefolium-l-flos-and-achillea-millefolium-l-herba_en.pdf"},
    {"id":"25054","name":"Call for scientific data for the systematic review of the monograph on Centaurium erythraea Rafn., herba.","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-12-12 - 2015-03-15","first_published_date":"2014-12-15T13:40:00Z","last_updated_date":"2014-12-15T13:40:00Z","reference_number":"EMA/HMPC/776606/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-centaurium-erythraea-rafn-herba_en.pdf"},
    {"id":"25119","name":"Call for scientific data for the systematic review of the monograph on Avena sativa L., herba and Avena sativa L., fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-06-15 - 2016-09-15","first_published_date":"2016-06-15T13:00:00Z","last_updated_date":"2016-06-15T13:00:00Z","reference_number":"EMA/HMPC/403693/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-avena-sativa-l-herba-and-avena-sativa-l-fructus_en.pdf"},
    {"id":"25358","name":"Call for scientific data for the systematic review of the monograph on Trigonella foenum-graecum L., semen","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-07-15 - 2016-10-15","first_published_date":"2016-07-15T13:00:00Z","last_updated_date":"2016-07-15T13:00:00Z","reference_number":"EMA/HMPC/403792/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-trigonella-foenum-graecum-l-semen_en.pdf"},
    {"id":"26055","name":"Call for scientific data for use in HMPC assessment work on Potenilla erecta (L.) Raeusch., rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-31 - 2018-06-30","first_published_date":"2018-03-28T19:00:00Z","last_updated_date":"2018-03-28T19:00:00Z","reference_number":"EMA/HMPC/188907/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-potenilla-erecta-l-raeusch-rhizoma_en.pdf"},
    {"id":"26189","name":"Call for scientific data for use in HMPC assessment work on herbal tea combinations traditionally used in the therapeutic area ‘nervous tensions and to aid sleep’","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2017-02-28 - 2017-05-31","first_published_date":"2017-03-06T16:00:00Z","last_updated_date":"2017-03-06T16:00:00Z","reference_number":"EMA/HMPC/133347/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-herbal-tea-combinations-traditionally-used-therapeutic-area-nervous-tensions-and-aid-sleep_en.pdf"},
    {"id":"26328","name":"Call for submission of scientific data on Fumaria officinalis L., herba\n\nFumariae herba (fumitory)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2010-03-22T01:00:00Z","last_updated_date":"2010-03-22T01:00:00Z","reference_number":"EMA/HMPC/160864/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-fumaria-officinalis-l-herba-fumariae-herba-fumitory_en.pdf"},
    {"id":"26550","name":"Call for scientific data for use in HMPC assessment work on Vaccinium macrocarpon Aiton, fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:00:00Z","last_updated_date":"2015-10-14T14:00:00Z","reference_number":"EMA/HMPC/669366/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-vaccinium-macrocarpon-aiton-fructus_en.pdf"},
    {"id":"26741","name":"Call for submission of scientific data relating to the assessment of Centellae asiaticae herba Centella asiatica (L.) Urban, herba  - First version","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-09-15T02:09:21Z","last_updated_date":"2008-09-15T02:09:21Z","reference_number":"EMEA/HMPC/464551/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-centellae-asiaticae-herba-centella-asiatica-l-urban-herba-first-version_en.pdf"},
    {"id":"27078","name":"Call for scientific data for use in HMPC assessment work on Calendulae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-14T02:00:00Z","last_updated_date":"2014-02-14T02:00:00Z","reference_number":"EMA/HMPC/84830/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-calendulae-herba_en.pdf"},
    {"id":"27168","name":"Call for scientific data for use in HMPC assessment work on Leonurus cardiaca L., herba – Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-01 - 2018-05-31","first_published_date":"2018-03-01T19:00:00Z","last_updated_date":"2018-03-01T19:00:00Z","reference_number":"EMA/HMPC/131485/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-leonurus-cardiaca-l-herba-revision-1_en.pdf"},
    {"id":"27215","name":"Call for submission of scientific data relating to the assessment of Symphyti radix Symphytum officinale L., radix (comfrey root)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-09-15T02:00:00Z","last_updated_date":"2008-09-15T02:00:00Z","reference_number":"EMEA/HMPC/510354/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-symphyti-radix-symphytum-officinale-l-radix-comfrey-root_en.pdf"},
    {"id":"28355","name":"Call for submission of scientific data relating to the assessment of Liquiritiae radix Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix (liquorice root) - First version","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-11-15T01:00:00Z","last_updated_date":"2008-11-15T01:00:00Z","reference_number":"EMEA/HMPC/592063/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-liquiritiae-radix-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-liquorice-root-first-version_en.pdf"},
    {"id":"28377","name":"Call for scientific data for use in HMPC assessment work on Crataegus spp., folium cum flore","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-27T14:25:00Z","last_updated_date":"2011-10-27T14:25:00Z","reference_number":"EMA/HMPC/853777/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-crataegus-spp-folium-cum-flore_en.pdf"},
    {"id":"28907","name":"Call for scientific data for the systematic review of the monograph on Hedera helix L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:00:00Z","last_updated_date":"2015-10-14T14:00:00Z","reference_number":"EMA/HMPC/669362/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-hedera-helix-l-folium_en.pdf"},
    {"id":"28961","name":"Call for submission of scientific data relating to the assessment of  Matricariae flos; Matricaria recutita L. (Chamomilla recutita (L.) Rauschert), flos (Matricaria flower)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2009-08-15T02:00:00Z","last_updated_date":"2009-08-15T02:00:00Z","reference_number":"EMEA/HMPC/468689/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-matricariae-flos-matricaria-recutita-l-chamomilla-recutita-l-rauschert-flos-matricaria-flower_en.pdf"},
    {"id":"29435","name":"Call for scientific data for use in HMPC assessment work on Sambucus nigra L., fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-17T19:44:00Z","last_updated_date":"2011-10-17T19:44:00Z","reference_number":"EMA/HMPC/778979/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-sambucus-nigra-l-fructus_en.pdf"},
    {"id":"29464","name":"Call for scientific data for the systematic review of the monograph on Melissa officinalis L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558979/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-melissa-officinalis-l-folium_en.pdf"},
    {"id":"29484","name":"Call for scientific data for the systematic review of the monograph on Hypericum perforatum L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-02-09 - 2015-05-15","first_published_date":"2015-02-09T12:45:00Z","last_updated_date":"2015-02-09T12:45:00Z","reference_number":"EMA/HMPC/79040/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-hypericum-perforatum-l-herba_en.pdf"},
    {"id":"29654","name":"Call for scientific data for use in HMPC assessment work on Cisti cretici folium/resinum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-14T18:40:00Z","last_updated_date":"2014-02-14T18:40:00Z","reference_number":"EMA/HMPC/87605/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-cisti-cretici-folium-resinum_en.pdf"},
    {"id":"29879","name":"Call for submission of scientific data on Allium cepa L., bulbus Allii cepae bulbus (onion)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2010-03-22T01:00:00Z","last_updated_date":"2010-03-22T01:00:00Z","reference_number":"EMA/HMPC/148780/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-allium-cepa-l-bulbus-allii-cepae-bulbus-onion_en.pdf"},
    {"id":"29974","name":"Grindelia robusta Nutt., G. squarrosa Dunal, G. humilis Hook. et Arn., G. camporum Greene, herba","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2010-03-22T01:00:00Z","last_updated_date":"2010-03-22T01:00:00Z","reference_number":"EMA/HMPC/160866/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/grindelia-robusta-nutt-g-squarrosa-dunal-g-humilis-hook-et-arn-g-camporum-greene-herba_en.pdf"},
    {"id":"30004","name":"Call for submission of scientific data on Tilia tomentosa Moench, flos (silver lime)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2010-03-22T01:00:00Z","last_updated_date":"2010-03-22T01:00:00Z","reference_number":"EMA/HMPC/160869/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-tilia-tomentosa-moench-flos-silver-lime_en.pdf"},
    {"id":"30346","name":"Call for submission of scientific data on Uncaria tomentosa (Willd.) DC., cortex (Cat's Claw)","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2010-10-01 - 2010-12-15","first_published_date":"2010-10-07T04:00:00Z","last_updated_date":"2010-10-07T04:00:00Z","reference_number":"EMA/HMPC/615722/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-uncaria-tomentosa-willd-dc-cortex-cats-claw_en.pdf"},
    {"id":"30349","name":"Call for scientific data for use in HMPC assessment work on Paeoniae radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-17T12:05:00Z","last_updated_date":"2014-02-17T12:05:00Z","reference_number":"EMA/HMPC/87628/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-paeoniae-radix_en.pdf"},
    {"id":"30651","name":"Call for submission of scientific data relating to the assessment of Chamomillae romanae flos chamaemelum nobile (l.) all. (anthemis nobilis l.), flos (chamomile flower, roman)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2009-10-15T02:09:21Z","last_updated_date":"2009-10-15T02:09:21Z","reference_number":"EMEA/HMPC/604441/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-chamomillae-romanae-flos-chamaemelum-nobile-l-all-anthemis-nobilis-l-flos-chamomile-flower-roman_en.pdf"},
    {"id":"30759","name":"Call for submission of scientific data relating to the assessment of Cichorii intybi planta tota; Cichorium intybus l., planta tota (chicory whole plant) Cichorii intybi folium; Cichorium intybus l., folium (chicory leaf...","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2009-02-15T00:09:21Z","last_updated_date":"2009-02-15T00:09:21Z","reference_number":"EMEA/HMPC/74358/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-cichorii-intybi-planta-tota-cichorium-intybus-l-planta-tota-chicory-whole-plant-cichorii-intybi-folium-cichorium-intybus-l-folium-chicory-leaf_en.pdf"},
    {"id":"30858","name":"Call for scientific data for use in HMPC assessment work on herbal tea combinations traditionally used in the therapeutic area ‘urinary tract disorders’","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-03-15","first_published_date":"2015-12-15T11:00:00Z","last_updated_date":"2015-12-15T11:00:00Z","reference_number":"EMA/HMPC/816399/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-herbal-tea-combinations-traditionally-used-therapeutic-area-urinary-tract-disorders_en.pdf"},
    {"id":"30980","name":"Call for submission of scientific data relating to the assessment of Marrubii herba; Marrubium vulgare L., herba (white horehound) - First version","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2009-08-15T02:00:00Z","last_updated_date":"2009-08-15T02:00:00Z","reference_number":"EMEA/HMPC/468681/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-marrubii-herba-marrubium-vulgare-l-herba-white-horehound-first-version_en.pdf"},
    {"id":"31231","name":"Call for submission of scientific data relating to the assessment of Uvae ursi folium Arctostaphylos uva-ursi (L.) Spreng., folium","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-06-16T02:09:21Z","last_updated_date":"2008-06-16T02:09:21Z","reference_number":"EMEA/HMPC/304807/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-uvae-ursi-folium-arctostaphylos-uva-ursi-l-spreng-folium_en.pdf"},
    {"id":"31287","name":"Call for scientific data for the systematic review of the monograph on Mentha x piperita L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-02-15","first_published_date":"2012-10-15T14:30:00Z","last_updated_date":"2012-10-15T14:30:00Z","reference_number":"EMA/HMPC/648284/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-mentha-x-piperita-l-folium_en.pdf"},
    {"id":"31525","name":"Call for scientific data for use in HMPC assessment work on Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-04-15 - 2011-07-15","first_published_date":"2011-04-14T04:00:00Z","last_updated_date":"2011-04-14T04:00:00Z","reference_number":"EMA/HMPC/278488/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"31618","name":"Call for scientific data for the review of the HMPC assessment on Adhatoda vasica Nees, folium - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-04-30 - 2018-07-31","first_published_date":"2018-04-30T18:45:00Z","last_updated_date":"2018-04-30T18:45:00Z","reference_number":"EMA/HMPC/248464/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-review-hmpc-assessment-adhatoda-vasica-nees-folium-revision-1_en.pdf"},
    {"id":"31632","name":"Call for scientific data for the systematic review of the monograph on Passiflora incarnata L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558981/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-passiflora-incarnata-l-herba_en.pdf"},
    {"id":"31854","name":"Call for scientific data for the systematic review of the monograph on Echinacea pallida (Nutt.) Nutt., radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-03-15","first_published_date":"2015-12-15T11:00:00Z","last_updated_date":"2015-12-15T11:00:00Z","reference_number":"EMA/HMPC/845008/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-echinacea-pallida-nutt-nutt-radix_en.pdf"},
    {"id":"32168","name":"Call for scientific data for use in HMPC assessment work on Rosa centifolia L.; Rosa gallica L.; Rosa damascena Mill., aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558956/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-rosa-centifolia-l-rosa-gallica-l-rosa-damascena-mill-aetheroleum_en.pdf"},
    {"id":"32277","name":"Call for scientific data for the systematic review of the monograph on Mentha x piperita L., aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-02-15","first_published_date":"2012-10-15T14:30:00Z","last_updated_date":"2012-10-15T14:30:00Z","reference_number":"EMA/HMPC/648282/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-mentha-x-piperita-l-aetheroleum_en.pdf"},
    {"id":"32422","name":"Call for submission of scientific data relating to the assessment of  Solani dulcamarae stipites Solanum dulcamara L., stalk (bittersweet stalk)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2008-09-15T02:00:00Z","last_updated_date":"2008-09-15T02:00:00Z","reference_number":"EMEA/HMPC/462025/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-solani-dulcamarae-stipites-solanum-dulcamara-l-stalk-bittersweet-stalk_en.pdf"},
    {"id":"32561","name":"Call for scientific data for use in HMPC assessment work on Curcuma longa L., rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-07-23 - 2014-10-31","first_published_date":"2014-07-24T18:30:00Z","last_updated_date":"2014-07-24T18:30:00Z","reference_number":"EMA/HMPC/447914/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-curcuma-longa-l-rhizoma_en.pdf"},
    {"id":"32910","name":"Call for scientific data for use in HMPC assessment work on Andrographis paniculata Nees, folium - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-02-15 - 2011-05-15","first_published_date":"2011-02-17T02:00:00Z","last_updated_date":"2011-02-17T02:00:00Z","reference_number":"EMA/HMPC/129735/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-andrographis-paniculata-nees-folium-first-version_en.pdf"},
    {"id":"33127","name":"Call for scientific data for the systematic review of the monograph on Valeriana officinalis L., radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558991/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-valeriana-officinalis-l-radix_en.pdf"},
    {"id":"33693","name":"Call for scientific data for the systematic review of the monograph on Achillea millefolium L., flos and Achillea millefolium L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-03-15","first_published_date":"2015-12-15T11:00:00Z","last_updated_date":"2015-12-15T11:00:00Z","reference_number":"EMA/HMPC/844895/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-achillea-millefolium-l-flos-and-achillea-millefolium-l-herba_en.pdf-0"},
    {"id":"33745","name":"Call for scientific data for use in HMPC assessment work on Salviae trilobae folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-17T11:10:00Z","last_updated_date":"2014-02-17T11:10:00Z","reference_number":"EMA/HMPC/87640/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-salviae-trilobae-folium_en.pdf"},
    {"id":"33788","name":"Call for scientific data for use in HMPC assessment work on Prunus africana (Hook f.) Kalkm., cortex","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558955/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-prunus-africana-hook-f-kalkm-cortex_en.pdf"},
    {"id":"33891","name":"Call for scientific data for the systematic review of the monograph on Ruscus aculeatus L., rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-04-15 - 2016-07-15","first_published_date":"2016-04-15T20:00:00Z","last_updated_date":"2016-04-15T20:00:00Z","reference_number":"EMA/269960/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-ruscus-aculeatus-l-rhizoma_en.pdf"},
    {"id":"34128","name":"Call for scientific data for the systematic review of the monograph on Fragaria vesca L., folium - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-12-12 - 2015-03-15","first_published_date":"2014-12-15T13:40:00Z","last_updated_date":"2014-12-15T13:40:00Z","reference_number":"EMA/HMPC/776619/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-fragaria-vesca-l-folium-first-version_en.pdf"},
    {"id":"34458","name":"Call for scientific data for use in HMPC assessment work on herbal tea combinations traditionally used in the therapeutic area ‘digestive disorders’","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2017-02-28 - 2017-05-31","first_published_date":"2017-03-06T16:00:00Z","last_updated_date":"2017-03-06T16:00:00Z","reference_number":"EMA/HMPC/133337/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-herbal-tea-combinations-traditionally-used-therapeutic-area-digestive-disorders_en.pdf"},
    {"id":"34469","name":"Call for scientific data for the systematic review of the monograph on Pimpinella anisum L., fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558974/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-pimpinella-anisum-l-fructus_en.pdf"},
    {"id":"34531","name":"Call for scientific data for use in HMPC assessment work on Helichrysi flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-17T11:45:00Z","last_updated_date":"2014-02-17T11:45:00Z","reference_number":"EMA/HMPC/87622/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-helichrysi-flos_en.pdf"},
    {"id":"34683","name":"Call for scientific data for use in HMPC assessment work on Ilex paraguariensis St. Hilaire, folium – First round","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-01 - 2018-05-31","first_published_date":"2018-03-01T19:00:00Z","last_updated_date":"2018-03-01T19:00:00Z","reference_number":"EMA/HMPC/131776/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-ilex-paraguariensis-st-hilaire-folium-first-round_en.pdf"},
    {"id":"34742","name":"Call for scientific data for the systematic review of the monograph on Meliloti herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-03-15 - 2014-06-15","first_published_date":"2014-03-14T18:15:00Z","last_updated_date":"2014-03-14T18:15:00Z","reference_number":"EMA/HMPC/143302/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-meliloti-herba_en.pdf"},
    {"id":"35037","name":"Call for scientific data for use in HMPC assessment work on Pistacia lentiscus, resinum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-05-15","first_published_date":"2014-02-14T18:30:00Z","last_updated_date":"2014-02-14T18:30:00Z","reference_number":"EMA/HMPC/87630/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-pistacia-lentiscus-resinum_en.pdf"}    {"id":"35445","name":"Call for scientific data for the systematic review of the monograph on Valeriana officinalis L., radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558991/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-valeriana-officinalis-l-radix_en.pdf-0"},
    {"id":"36087","name":"Call for scientific data for the systematic review of the monograph on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2013-02-15 - 2013-05-15","first_published_date":"2013-02-14T18:00:00Z","last_updated_date":"2013-02-14T18:00:00Z","reference_number":"EMA/HMPC/91103/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf"},
    {"id":"36400","name":"Call for scientific data for use in HMPC assessment work on Equisetum arvense L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-07-23 - 2014-10-31","first_published_date":"2014-07-24T18:30:00Z","last_updated_date":"2014-07-24T18:30:00Z","reference_number":"EMA/HMPC/447917/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-equisetum-arvense-l-herba_en.pdf"},
    {"id":"36433","name":"Call for scientific data for the systematic review of the monograph on Primula veris L.; Primula elatior (L.) Hill, radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558987/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-primula-veris-l-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"36515","name":"Call for scientific data for use in HMPC assessment work on Hamamelis virginiana L., folium et cortex aut ramunculus destillatum – First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-01 - 2018-05-31","first_published_date":"2018-03-01T19:00:00Z","last_updated_date":"2018-03-01T19:00:00Z","reference_number":"EMA/HMPC/133818/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-hamamelis-virginiana-l-folium-et-cortex-aut-ramunculus-destillatum-first-version_en.pdf"},
    {"id":"36784","name":"Call for scientific data for the systematic review of the monograph on Harpagophytum procumbens DC.; Harpagophytum zeyheri Decne, radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-02-09 - 2015-05-15","first_published_date":"2015-02-09T12:45:00Z","last_updated_date":"2015-02-09T12:45:00Z","reference_number":"EMA/HMPC/79054/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-harpagophytum-procumbens-dc-harpagophytum-zeyheri-decne-radix_en.pdf"},
    {"id":"37118","name":"Call for scientific data for use in HMPC assessment work on Gentiana lutea L., radix - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-07-23 - 2014-10-31","first_published_date":"2014-07-24T18:30:00Z","last_updated_date":"2014-07-24T18:30:00Z","reference_number":"EMA/HMPC/447918/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-gentiana-lutea-l-radix-revision-1_en.pdf"},
    {"id":"37486","name":"Call for scientific data for use in HMPC assessment work on Myroxylon balsamum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2014-07-15 - 2014-10-15","first_published_date":"2014-07-15T13:00:00Z","last_updated_date":"2014-07-15T13:00:00Z","reference_number":"EMA/HMPC/87595/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-myroxylon-balsamum_en.pdf"},
    {"id":"37497","name":"Call for scientific data for use in HMPC assessment work on Menyanthes trifoliata L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-31 - 2018-06-30","first_published_date":"2018-03-28T19:00:00Z","last_updated_date":"2018-03-28T19:00:00Z","reference_number":"EMA/HMPC/187996/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-menyanthes-trifoliata-l-folium_en.pdf"},
    {"id":"37785","name":"Call for submission of scientific data on Silybum marianum (L.) Gaertner, fructus: Silybi mariani fructus (milkthistle fruit)","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2010-03-22 - 2010-05-22","first_published_date":"2010-03-22T02:00:00Z","last_updated_date":"2010-03-22T02:00:00Z","reference_number":"EMA/HMPC/152362/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-silybum-marianum-l-gaertner-fructus-silybi-mariani-fructus-milkthistle-fruit_en.pdf"},
    {"id":"37787","name":"Call for scientific data for use in HMPC assessment work on Rosa centifolia L.; Rosa gallica L.; Rosa damascena Mill., flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558959/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-rosa-centifolia-l-rosa-gallica-l-rosa-damascena-mill-flos_en.pdf"},
    {"id":"38279","name":"Call for scientific data for use in HMPC assessment work on Eschscholtzia californica Cham., herba cum flore","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-12-15 - 2012-04-15","first_published_date":"2012-01-03T11:55:00Z","last_updated_date":"2012-01-03T11:55:00Z","reference_number":"EMA/HMPC/890470/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-eschscholtzia-californica-cham-herba-cum-flore_en.pdf"},
    {"id":"38907","name":"Call for scientific data for the periodic review of the monograph on Solidago virgaurea L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-31 - 2018-06-30","first_published_date":"2018-03-28T19:00:00Z","last_updated_date":"2018-03-28T19:00:00Z","reference_number":"EMA/HMPC/188895/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-solidago-virgaurea-l-herba_en.pdf"},
    {"id":"39133","name":"Call for scientific data for use in HMPC assessment work on herbal tea combinations traditionally used in the therapeutic area ‘loss of appetite’","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2017-02-28 - 2017-05-31","first_published_date":"2017-03-06T16:00:00Z","last_updated_date":"2017-03-06T16:00:00Z","reference_number":"EMA/HMPC/133334/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-herbal-tea-combinations-traditionally-used-therapeutic-area-loss-appetite_en.pdf"},
    {"id":"39222","name":"Call for scientific data for the systematic review of the monograph on Aloe barbadensis Miller; Aloe ferox Miller","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-02-15","first_published_date":"2012-10-15T14:30:00Z","last_updated_date":"2012-10-15T14:30:00Z","reference_number":"EMA/HMPC/648278/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-aloe-barbadensis-miller-aloe-ferox-miller_en.pdf"},
    {"id":"39260","name":"Call for submission of scientific data relating to the assessment of  Leonuri cardiacae herba Leonurus cardiaca l., herba (Motherwort herb)","type":"herbal-call-data","status":"unknown","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/HMPC/657306/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-submission-scientific-data-relating-assessment-leonuri-cardiacae-herba-leonurus-cardiaca-l-herba-motherwort-herb_en.pdf"},
    {"id":"39725","name":"Call for scientific data for the systematic review of the monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-03-15","first_published_date":"2015-12-15T11:00:00Z","last_updated_date":"2015-12-15T11:00:00Z","reference_number":"EMA/HMPC/845014/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos_en.pdf"},
    {"id":"40013","name":"Call for scientific data for the systematic review of the monograph on Rhamnus frangula L., cortex","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-02-15","first_published_date":"2012-10-15T14:30:00Z","last_updated_date":"2012-10-15T14:30:00Z","reference_number":"EMA/HMPC/648280/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-rhamnus-frangula-l-cortex_en.pdf"},
    {"id":"40073","name":"Call for scientific data for use in HMPC assessment work on Angelica sinensis (Oliv.) Diels, radix - First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-12-15 - 2012-04-15","first_published_date":"2012-01-03T12:07:00Z","last_updated_date":"2012-01-03T12:07:00Z","reference_number":"EMA/HMPC/890469/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-angelica-sinensis-oliv-diels-radix-first-version_en.pdf"},
    {"id":"40175","name":"Call for scientific data for use in HMPC assessment work on Eucalyptus globulus Labill., E. polybractea R.T. Baker and E. smithii R.T. Baker., aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-06-01 - 2011-09-15","first_published_date":"2011-06-07T04:00:00Z","last_updated_date":"2011-06-07T04:00:00Z","reference_number":"EMA/HMPC/422012/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-eucalyptus-globulus-labill-e-polybractea-rt-baker-and-e-smithii-rt-baker-aetheroleum_en.pdf"},
    {"id":"40349","name":"Call for scientific data for use in HMPC assessment work on Hamamelis virginiana L., folium – First version","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-01 - 2018-05-31","first_published_date":"2018-03-01T19:00:00Z","last_updated_date":"2018-03-01T19:00:00Z","reference_number":"EMA/HMPC/129591/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-hamamelis-virginiana-l-folium-first-version_en.pdf"},
    {"id":"40402","name":"Call for scientific data for use in HMPC assessment work on Carum carvi L., fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-06-15 - 2012-10-15","first_published_date":"2012-06-15T15:30:00Z","last_updated_date":"2012-06-15T15:30:00Z","reference_number":"EMA/HMPC/332752/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-carum-carvi-l-fructus_en.pdf"},
    {"id":"40419","name":"Call for scientific data for the systematic review of the monograph on Ribes nigrum L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-04-15 - 2016-07-15","first_published_date":"2016-04-15T20:00:00Z","last_updated_date":"2016-04-15T20:00:00Z","reference_number":"EMA/269967/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-ribes-nigrum-l-folium_en.pdf"},
    {"id":"40622","name":"Call for scientific data for the systematic review of the monograph on Primula veris L.; Primula elatior (L.) Hill, flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558987/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-primula-veris-l-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"40774","name":"Call for scientific data for the systematic review of the monograph on Rhamni purshianus D.C., cortex","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-02-15","first_published_date":"2012-10-15T14:30:00Z","last_updated_date":"2012-10-15T14:30:00Z","reference_number":"EMA/HMPC/648287/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-rhamni-purshianus-dc-cortex_en.pdf"},
    {"id":"40884","name":"Call for scientific data for use in HMPC assessment work on Salvia miltiorrhiza Bunge, radix et rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2018-03-31 - 2018-06-30","first_published_date":"2018-03-28T19:00:00Z","last_updated_date":"2018-03-28T19:00:00Z","reference_number":"EMA/HMPC/188011/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-salvia-miltiorrhiza-bunge-radix-et-rhizoma_en.pdf"},
    {"id":"41205","name":"Call for scientific data for use in HMPC assessment work on Picrorhiza kurroa Royle ex. Benth., rhizoma et radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2011-07-15 - 2011-11-15","first_published_date":"2011-07-18T04:00:00Z","last_updated_date":"2011-07-18T04:00:00Z","reference_number":"EMA/HMPC/558953/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-picrorhiza-kurroa-royle-ex-benth-rhizoma-et-radix_en.pdf"},
    {"id":"41555","name":"Call for scientific data for the systematic review of the monograph on Calendula officinalis L., flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-06-15 - 2016-09-15","first_published_date":"2016-06-15T13:00:00Z","last_updated_date":"2016-06-15T13:00:00Z","reference_number":"EMA/HMPC/403694/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-calendula-officinalis-l-flos_en.pdf"},
    {"id":"41720","name":"Call for scientific data for the systematic review of the monograph on Avena sativa L., herba and Avena sativa L., fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-06-15 - 2016-09-15","first_published_date":"2016-06-15T13:00:00Z","last_updated_date":"2016-06-15T13:00:00Z","reference_number":"EMA/HMPC/403693/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-avena-sativa-l-herba-and-avena-sativa-l-fructus_en.pdf-0"},
    {"id":"41959","name":"Call for scientific data for the systematic review of the monograph on Polypodium vulgare L., rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2016-07-15 - 2016-10-15","first_published_date":"2016-07-15T13:00:00Z","last_updated_date":"2016-07-15T13:00:00Z","reference_number":"EMA/HMPC/403790/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-systematic-review-monograph-polypodium-vulgare-l-rhizoma_en.pdf"},
    {"id":"43739","name":"Call for scientific data for the periodic review of the monograph on Arctium lappa L., radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2019-02-15 - 2019-05-15","first_published_date":"2019-02-15T09:33:00Z","last_updated_date":"2019-02-15T09:33:00Z","reference_number":"EMA/HMPC/38300/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-arctium-lappa-l-radix_en.pdf"},
    {"id":"43740","name":"Call for scientific data for the periodic review of the monograph on Juniperus communis L., aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2019-02-15 - 2019-05-15","first_published_date":"2019-02-15T09:35:00Z","last_updated_date":"2019-02-15T09:35:00Z","reference_number":"EMA/HMPC/38797/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-juniperus-communis-l-aetheroleum_en.pdf"},
    {"id":"43741","name":"Call for scientific data for the periodic review of the monograph on Juniperus communis L., pseudo-fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2019-02-15 - 2019-05-15","first_published_date":"2019-02-15T09:40:00Z","last_updated_date":"2019-02-15T09:40:00Z","reference_number":"EMA/HMPC/38812/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-juniperus-communis-l-pseudo-fructus_en.pdf"},
    {"id":"43742","name":"Call for scientific data for the periodic review of the monograph on Orthosiphon stamineus Benth., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2019-02-15 - 2019-05-15","first_published_date":"2019-02-15T09:42:00Z","last_updated_date":"2019-02-15T09:42:00Z","reference_number":"EMA/HMPC/38821/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-orthosiphon-stamineus-benth-folium_en.pdf"},
    {"id":"43743","name":"Call for scientific data for the periodic review of the monograph on Rosmarinus officinalis L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2019-02-15 - 2019-05-15","first_published_date":"2019-02-15T09:44:00Z","last_updated_date":"2019-02-15T09:44:00Z","reference_number":"EMA/HMPC/38836/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-rosmarinus-officinalis-l-folium_en.pdf"},
    {"id":"43744","name":"Call for scientific data for the periodic review of the monograph on Rosmarinus officinalis L., aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2019-02-15 - 2019-05-15","first_published_date":"2019-02-15T09:46:00Z","last_updated_date":"2019-02-15T09:46:00Z","reference_number":"EMA/HMPC/38833/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-rosmarinus-officinalis-l-aetheroleum_en.pdf"},
    {"id":"43745","name":"Call for scientific data for the periodic review of the monograph on Taraxacum officinale Weber ex Wigg., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2019-02-15 - 2019-05-15","first_published_date":"2019-02-15T09:48:00Z","last_updated_date":"2019-02-15T09:48:00Z","reference_number":"EMA/HMPC/38842/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-taraxacum-officinale-weber-ex-wigg-folium_en.pdf"},
    {"id":"43746","name":"Call for scientific data for the periodic review of the monograph on Taraxacum officinale Weber ex Wigg., radix cum herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2019-02-15 - 2019-05-15","first_published_date":"2019-02-15T09:50:00Z","last_updated_date":"2019-02-15T09:50:00Z","reference_number":"EMA/HMPC/38849/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf"},
    {"id":"43929","name":"Call for scientific data for use in HMPC assessment work on ‘Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) - First version’","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2019-02-28 - 2019-08-31","first_published_date":"2019-02-28T11:26:00Z","last_updated_date":"2019-02-28T11:26:00Z","reference_number":"EMA/HMPC/39600/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-first-version_en.pdf"},
    {"id":"43930","name":"Call for scientific data for use in HMPC assessment work on ‘Public statement on contamination of herbal medicinal products/traditional herbal medicinal products with pyrrolizidine alkaloids (EMA/HMPC/328782/2016)’","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2019-02-28 - 2019-08-31","first_published_date":"2019-02-28T11:33:00Z","last_updated_date":"2019-02-28T11:33:00Z","reference_number":"EMA/HMPC/37920/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-public-statement-contamination-herbal-medicinal-products-traditional-herbal-medicinal-products-pyrrolizidine-alkaloids-ema-hmpc-328782-2016_en.pdf"},
    {"id":"46654","name":"Call for scientific data for the revision of the monograph on Pelargonium sidoides DC; Pelargonium reniforme Curt., radix - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-02-01 - 2020-04-30","first_published_date":"2020-01-31T17:59:00Z","last_updated_date":"2020-01-31T17:59:00Z","reference_number":"EMA/HMPC/47573/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-revision-monograph-pelargonium-sidoides-dc-pelargonium-reniforme-curt-radix-revision-1_en.pdf"},
    {"id":"46655","name":"Call for scientific data for the periodic review of the monograph on Cola nitida (Vent.) Schott et Endl. (C. vera K. Schum.); Cola acuminata (P. Beauv.) Schott et Endl. (Sterculia acuminata P. Beauv.), semen - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-02-01 - 2020-04-30","first_published_date":"2020-01-31T18:08:00Z","last_updated_date":"2020-01-31T18:08:00Z","reference_number":"EMA/HMPC/50864/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-cola-nitida-vent-schott-et-endl-c-vera-k-schum-cola-acuminata-p-beauv-schott-et-endl-sterculia-acuminata-p-beauv-semen-revision-1_en.pdf"},
    {"id":"46656","name":"Call for scientific data for the periodic review of the monograph on Chamaemelum nobile (L.) All. (Anthemis nobilis L.), flos - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-02-01 - 2020-04-30","first_published_date":"2020-01-31T18:21:00Z","last_updated_date":"2020-01-31T18:21:00Z","reference_number":"EMA/HMPC/50752/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-chamaemelum-nobile-l-all-anthemis-nobilis-l-flos-revision-1_en.pdf"},
    {"id":"46657","name":"Call for scientific data for the periodic review of the monograph on Zingiber officinale Roscoe, rhizoma - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-02-01 - 2020-04-30","first_published_date":"2020-01-31T18:28:00Z","last_updated_date":"2020-01-31T18:28:00Z","reference_number":"EMA/HMPC/47493/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-zingiber-officinale-roscoe-rhizoma-revision-1_en.pdf"},
    {"id":"46658","name":"Call for scientific data for the periodic review of the monograph on Carum carvi L., fructus - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-02-01 - 2020-04-30","first_published_date":"2020-01-31T18:53:00Z","last_updated_date":"2020-01-31T18:53:00Z","reference_number":"EMA/HMPC/47469/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-carum-carvi-l-fructus-revision-1_en.pdf"},
    {"id":"46659","name":"Call for scientific data for the periodic review of the monograph on Carum carvi L., aetheroleum - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-02-01 - 2020-04-30","first_published_date":"2020-01-31T18:59:00Z","last_updated_date":"2020-01-31T18:59:00Z","reference_number":"EMA/HMPC/47463/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-carum-carvi-l-aetheroleum-revision-1_en.pdf"},
    {"id":"46660","name":"Call for scientific data for the periodic review of the monograph on Syzygium aromaticum (L.) Merill et L. M. Perry (Eugenia caryophyllus (C. Spreng.) Bull. et Harr.), aetheroleum - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-02-01 - 2020-04-30","first_published_date":"2020-01-31T19:07:00Z","last_updated_date":"2020-01-31T19:07:00Z","reference_number":"EMA/HMPC/47048/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-syzygium-aromaticum-l-merill-et-l-m-perry-eugenia-caryophyllus-c-spreng-bull-et-harr-aetheroleum-revision-1_en.pdf"},
    {"id":"46661","name":"Call for scientific data for the periodic review of the monograph on Agropyron repens (L.) P. Beauv., rhizoma - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-02-01 - 2020-04-30","first_published_date":"2020-01-31T19:12:00Z","last_updated_date":"2020-01-31T19:12:00Z","reference_number":"EMA/HMPC/47033/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-agropyron-repens-l-p-beauv-rhizoma-revision-1_en.pdf"},
    {"id":"46915","name":"Call for scientific data for the periodic review of the monograph on Cinnamomum verum J.S. Presl, cortex","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-03-01 - 2020-05-31","first_published_date":"2020-03-02T11:15:00Z","last_updated_date":"2020-03-02T11:15:00Z","reference_number":"EMA/HMPC/103543/2020 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-cinnamomum-verum-js-presl-cortex_en.pdf"},
    {"id":"46916","name":"Call for scientific data for the periodic review of the monograph on Cinnamomum verum J.S. Presl, corticis aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-03-01 - 2020-05-31","first_published_date":"2020-03-02T11:15:00Z","last_updated_date":"2020-03-02T11:15:00Z","reference_number":"EMA/HMPC/103542/2020 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-cinnamomum-verum-js-presl-corticis-aetheroleum_en.pdf"},
    {"id":"46917","name":"Call for scientific data for the periodic review of the monograph on Fucus vesiculosus L., thallus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-03-01 - 2020-05-31","first_published_date":"2020-03-02T11:15:00Z","last_updated_date":"2020-03-02T11:15:00Z","reference_number":"EMA/HMPC/103567/2020 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-fucus-vesiculosus-l-thallus_en.pdf"},
    {"id":"46918","name":"Call for scientific data for the periodic review of the monograph on Fumaria officinalis L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-03-01 - 2020-05-31","first_published_date":"2020-03-02T11:15:00Z","last_updated_date":"2020-03-02T11:15:00Z","reference_number":"EMA/HMPC/103631/2020 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-fumaria-officinalis-l-herba_en.pdf"},
    {"id":"46919","name":"Call for scientific data for the periodic review of the monograph on Lavandula angustifolia Miller, aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-03-01 - 2020-05-31","first_published_date":"2020-03-02T11:15:00Z","last_updated_date":"2020-03-02T11:15:00Z","reference_number":"EMA/HMPC/103634/2020 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-lavandula-angustifolia-miller-aetheroleum_en.pdf"},
    {"id":"46920","name":"Call for scientific data for the periodic review of the monograph on Lavandula angustifolia Miller, flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-03-01 - 2020-05-31","first_published_date":"2020-03-02T11:15:00Z","last_updated_date":"2020-03-02T11:15:00Z","reference_number":"EMA/HMPC/103640/2020 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-lavandula-angustifolia-miller-flos_en.pdf"},
    {"id":"46921","name":"Call for scientific data for use in HMPC assessment work on Taraxacum officinale F.H. Wigg., radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-03-01 - 2020-05-31","first_published_date":"2020-03-02T11:15:00Z","last_updated_date":"2020-03-02T11:15:00Z","reference_number":"EMA/HMPC/47428/2020 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-taraxacum-officinale-fh-wigg-radix_en.pdf"},
    {"id":"47238","name":"Call for scientific data for the periodic review of the monograph on Ilex paraguariensis St. Hilaire, folium - Second round","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-04-01 - 2020-06-30","first_published_date":"2020-04-01T11:00:00Z","last_updated_date":"2020-04-01T11:00:00Z","reference_number":"EMA/HMPC/149070/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-ilex-paraguariensis-st-hilaire-folium-second-round_en.pdf"},
    {"id":"47239","name":"Call for scientific data for the periodic review of the monograph on Plantago lanceolata L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-04-01 - 2020-06-30","first_published_date":"2020-04-01T11:00:00Z","last_updated_date":"2020-04-01T11:00:00Z","reference_number":"EMA/HMPC/149054/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-plantago-lanceolata-l-folium_en.pdf"},
    {"id":"47240","name":"Call for scientific data for the periodic review of the monograph on Solanum dulcamara L., stipites","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-04-01 - 2020-06-30","first_published_date":"2020-04-01T11:00:00Z","last_updated_date":"2020-04-01T11:00:00Z","reference_number":"EMA/HMPC/149095/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-solanum-dulcamara-l-stipites_en.pdf"},
    {"id":"47241","name":"Call for scientific data for the periodic review of the monograph on Urtica dioica L.; Urtica urens L., folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-04-01 - 2020-06-30","first_published_date":"2020-04-01T11:00:00Z","last_updated_date":"2020-04-01T11:00:00Z","reference_number":"EMA/HMPC/149137/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-urtica-dioica-l-urtica-urens-l-folium_en.pdf"},
    {"id":"47242","name":"Call for scientific data for the periodic review of the monograph on Urtica dioica L. and Urtica urens L., herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-04-01 - 2020-06-30","first_published_date":"2020-04-01T11:00:00Z","last_updated_date":"2020-04-01T11:00:00Z","reference_number":"EMA/HMPC/149163/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-urtica-dioica-l-and-urtica-urens-l-herba_en.pdf"},
    {"id":"47243","name":"Call for scientific data for the periodic review of the monograph on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny), herba cum flore","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-04-01 - 2020-06-30","first_published_date":"2020-04-01T11:00:00Z","last_updated_date":"2020-04-01T11:00:00Z","reference_number":"EMA/HMPC/149175/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-viola-tricolor-l-and-or-subspecies-viola-arvensis-murray-gaud-and-viola-vulgaris-koch-oborny-herba-cum-flore_en.pdf"},
    {"id":"48513","name":"Call for scientific data for the periodic review of the monograph on Serenoa repens (Bartram) Small (Sabal serrulata (Michaux) Nichols)","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2020-08-01 - 2020-10-31","first_published_date":"2020-07-31T12:32:00Z","last_updated_date":"2020-07-31T12:32:00Z","reference_number":"EMA/HMPC/283960/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-serenoa-repens-bartram-small-sabal-serrulata-michaux-nichols_en.pdf"},
    {"id":"50030","name":"Call for scientific data for the periodic review of the monograph on Arnica montana L., flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-02-01 - 2021-04-30","first_published_date":"2021-02-02T15:45:00Z","last_updated_date":"2021-02-02T15:45:00Z","reference_number":"EMA/HMPC/58504/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-arnica-montana-l-flos_en.pdf"},
    {"id":"50031","name":"Call for scientific data for the periodic review of the monograph on Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-02-01 - 2021-04-30","first_published_date":"2021-02-02T15:45:00Z","last_updated_date":"2021-02-02T15:45:00Z","reference_number":"EMA/HMPC/58633/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"50032","name":"Call for scientific data for the periodic review of the monograph on Cichorium intybus L., radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-02-01 - 2021-04-30","first_published_date":"2021-02-02T15:45:00Z","last_updated_date":"2021-02-02T15:45:00Z","reference_number":"EMA/HMPC/58690/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-cichorium-intybus-l-radix_en.pdf"},
    {"id":"50033","name":"Call for scientific data for the periodic review of the monograph on Cucurbita pepo L., semen","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-02-01 - 2021-04-30","first_published_date":"2021-02-02T15:45:00Z","last_updated_date":"2021-02-02T15:45:00Z","reference_number":"EMA/HMPC/58701/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-cucurbita-pepo-l-semen_en.pdf"},
    {"id":"50034","name":"Call for scientific data for the periodic review of the monograph on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich), rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-02-01 - 2021-04-30","first_published_date":"2021-02-02T15:45:00Z","last_updated_date":"2021-02-02T15:45:00Z","reference_number":"EMA/HMPC/58738/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-curcuma-xanthorrhiza-roxb-c-xanthorrhiza-d-dietrich-rhizoma_en.pdf"},
    {"id":"50357","name":"Call for scientific data for the periodic review of the monograph on Eucalypti aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-03-01 - 2021-05-31","first_published_date":"2021-03-02T14:26:00Z","last_updated_date":"2021-03-02T14:26:00Z","reference_number":"EMA/HMPC/121765/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-eucalypti-aetheroleum_en.pdf"},
    {"id":"50358","name":"Call for scientific data for the periodic review of the monograph on Eucalypti folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-03-01 - 2021-05-31","first_published_date":"2021-03-02T14:26:00Z","last_updated_date":"2021-03-02T14:26:00Z","reference_number":"EMA/HMPC/121805/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-eucalypti-folium_en.pdf"},
    {"id":"50359","name":"Call for scientific data for the periodic review of the monograph on Fraxini folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-03-01 - 2021-05-31","first_published_date":"2021-03-02T14:26:00Z","last_updated_date":"2021-03-02T14:26:00Z","reference_number":"EMA/HMPC/121840/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-fraxini-folium_en.pdf"},
    {"id":"50360","name":"Call for scientific data for the periodic review of the monograph on Ginseng radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-03-01 - 2021-05-31","first_published_date":"2021-03-02T14:26:00Z","last_updated_date":"2021-03-02T14:26:00Z","reference_number":"EMA/HMPC/121842/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-ginseng-radix_en.pdf"},
    {"id":"50361","name":"Call for scientific data for the periodic review of the monograph on Grindeliae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-03-01 - 2021-05-31","first_published_date":"2021-03-02T14:26:00Z","last_updated_date":"2021-03-02T14:26:00Z","reference_number":"EMA/HMPC/121845/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-grindeliae-herba_en.pdf"},
    {"id":"50362","name":"Call for scientific data for the periodic review of the monograph on Hippocastani cortex","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-03-01 - 2021-05-31","first_published_date":"2021-03-02T14:26:00Z","last_updated_date":"2021-03-02T14:26:00Z","reference_number":"EMA/HMPC/121848/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-hippocastani-cortex_en.pdf"},
    {"id":"50363","name":"Call for scientific data for the periodic review of the monograph on Juglandis folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-03-01 - 2021-05-31","first_published_date":"2021-03-02T14:26:00Z","last_updated_date":"2021-03-02T14:26:00Z","reference_number":"EMA/HMPC/121859/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-juglandis-folium_en.pdf"},
    {"id":"50364","name":"Call for scientific data for the periodic review of the monograph on Levistici radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-03-01 - 2021-05-31","first_published_date":"2021-03-02T14:26:00Z","last_updated_date":"2021-03-02T14:26:00Z","reference_number":"EMA/HMPC/121865/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-levistici-radix_en.pdf"},
    {"id":"50554","name":"Call for scientific data for use in HMPC assessment work on Combination: Hyperici herba and Cimicifugae rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-03-15 - 2021-06-14","first_published_date":"2021-03-15T13:10:00Z","last_updated_date":"2021-03-15T13:10:00Z","reference_number":"EMA/HMPC/58287/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-combination-hyperici-herba-and-cimicifugae-rhizoma_en.pdf"},
    {"id":"50555","name":"Call for scientific data for use in HMPC assessment work on on Cnici benedicti herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-03-15 - 2021-06-14","first_published_date":"2021-03-15T13:15:00Z","last_updated_date":"2021-03-15T13:15:00Z","reference_number":"EMA/HMPC/58236/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-cnici-benedicti-herba_en.pdf"},
    {"id":"50735","name":"Call for scientific data for use in HMPC assessment work on Cetraria islandica (L.) Acharius s.l. - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-04-01 - 2021-06-30","first_published_date":"2021-03-31T11:50:00Z","last_updated_date":"2021-03-31T11:50:00Z","reference_number":"EMA/HMPC/145228/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-cetraria-islandica-l-acharius-sl-revision-1_en.pdf"},
    {"id":"50736","name":"Call for scientific data for the periodic review of the monograph on Liquiritiae radix - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-04-01 - 2021-06-30","first_published_date":"2021-03-31T11:50:00Z","last_updated_date":"2021-03-31T11:50:00Z","reference_number":"EMA/HMPC/145322/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-liquiritiae-radix-revision-1_en.pdf"},
    {"id":"50743","name":"Call for scientific data for the periodic review of the monograph on Marrubii herba - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-04-01 - 2021-06-30","first_published_date":"2021-03-31T18:23:00Z","last_updated_date":"2021-03-31T18:23:00Z","reference_number":"EMA/HMPC/145543/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-marrubii-herba-revision-1_en.pdf"},
    {"id":"50744","name":"Call for scientific data for the periodic review of the monograph on Origani dictamni herba - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-04-01 - 2021-06-30","first_published_date":"2021-03-31T11:46:00Z","last_updated_date":"2021-03-31T11:46:00Z","reference_number":"EMA/HMPC/147922/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-origani-dictamni-herba-revision-1_en.pdf"},
    {"id":"50745","name":"Call for scientific data for the periodic review of the monograph on Paulliniae semen - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-04-01 - 2021-06-30","first_published_date":"2021-03-31T11:44:00Z","last_updated_date":"2021-03-31T11:44:00Z","reference_number":"EMA/HMPC/145594/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-paulliniae-semen-revision-1_en.pdf"},
    {"id":"50746","name":"Call for scientific data for the periodic review of the monograph on Rhodiolae roseae rhizoma et radix - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-04-01 - 2021-06-30","first_published_date":"2021-03-31T11:41:00Z","last_updated_date":"2021-03-31T11:41:00Z","reference_number":"EMA/HMPC/145602/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-rhodiolae-roseae-rhizoma-et-radix-revision-1_en.pdf"},
    {"id":"50747","name":"Call for scientific data for the periodic review of the monograph on Urticae radix - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-04-01 - 2021-06-30","first_published_date":"2021-03-31T12:04:00Z","last_updated_date":"2021-03-31T12:04:00Z","reference_number":"EMA/HMPC/146382/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-urticae-radix-revision-1_en.pdf"},
    {"id":"50748","name":"Call for scientific data for the periodic review of the monograph on Tiliae flos - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-04-01 - 2021-06-30","first_published_date":"2021-03-31T11:33:00Z","last_updated_date":"2021-03-31T11:33:00Z","reference_number":"EMA/HMPC/146356/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-tiliae-flos-revision-1_en.pdf"},
    {"id":"51434","name":"Call for scientific data for use in HMPC assessment work on Tribuli terrestris herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2021-06-15 - 2021-09-15","first_published_date":"2021-06-15T12:12:00Z","last_updated_date":"2021-06-15T12:12:00Z","reference_number":"EMA/HMPC/291056/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-tribuli-terrestris-herba_en.pdf"},
    {"id":"54157","name":"Call for scientific data for the periodic review of the monograph on Agrimoniae herba - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-02-15 - 2022-05-14","first_published_date":"2022-02-15T10:17:00Z","last_updated_date":"2022-02-15T10:17:00Z","reference_number":"EMA/HMPC/72155/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-agrimoniae-herba-revision-1_en.pdf"},
    {"id":"54158","name":"Call for scientific data for the periodic review of the monograph on Capsici fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-02-15 - 2022-05-14","first_published_date":"2022-02-15T10:24:00Z","last_updated_date":"2022-02-15T10:24:00Z","reference_number":"EMA/HMPC/72196/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-capsici-fructus_en.pdf"},
    {"id":"54159","name":"Call for scientific data for the periodic review of the monograph on Crataegi folium cum flore - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-02-15 - 2022-05-14","first_published_date":"2022-02-15T10:28:00Z","last_updated_date":"2022-02-15T10:28:00Z","reference_number":"EMA/HMPC/72203/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-crataegi-folium-cum-flore-revision-1_en.pdf"},
    {"id":"54160","name":"Call for scientific data for the periodic review of the  monograph on Epilobii herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-02-15 - 2022-05-14","first_published_date":"2022-02-15T10:31:00Z","last_updated_date":"2022-02-15T10:31:00Z","reference_number":"EMA/HMPC/72238/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-epilobii-herba_en.pdf"},
    {"id":"54179","name":"Call for scientific data for the periodic review of the monograph on Eschscholziae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-02-15 - 2022-05-14","first_published_date":"2022-02-15T15:56:00Z","last_updated_date":"2022-02-15T15:56:00Z","reference_number":"EMA/HMPC/72283/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-eschscholziae-herba_en.pdf"},
    {"id":"54182","name":"Call for scientific data for the periodic review of the monograph on Ginkgo folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-02-15 - 2022-05-14","first_published_date":"2022-02-15T16:09:00Z","last_updated_date":"2022-02-15T16:09:00Z","reference_number":"EMA/HMPC/72288/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-ginkgo-folium_en.pdf"},
    {"id":"54183","name":"Call for scientific data for the periodic review of the monograph on Helichrysi flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-02-15 - 2022-05-14","first_published_date":"2022-02-15T16:20:00Z","last_updated_date":"2022-02-15T16:20:00Z","reference_number":"EMA/HMPC/72296/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-helichrysi-flos_en.pdf"},
    {"id":"54184","name":"Call for scientific data for the periodic review of the monograph on Matricariae flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-02-15 - 2022-05-14","first_published_date":"2022-02-15T16:25:00Z","last_updated_date":"2022-02-15T16:25:00Z","reference_number":"EMA/HMPC/72301/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-matricariae-flos_en.pdf"},
    {"id":"54430","name":"Call for scientific data for the periodic review of the monograph on Ononidis radix - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-03-15 - 2022-06-14","first_published_date":"2022-03-15T11:10:00Z","last_updated_date":"2022-03-15T11:10:00Z","reference_number":"EMA/HMPC/120241/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-ononidis-radix-revision-1_en.pdf"},
    {"id":"54432","name":"Call for scientific data for the periodic review of the monograph on Myrtilli fructus siccus - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-03-15 - 2022-06-14","first_published_date":"2022-03-15T11:00:00Z","last_updated_date":"2022-03-15T11:00:00Z","reference_number":"EMA/HMPC/120062/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-myrtilli-fructus-siccus-revision-1_en.pdf"},
    {"id":"54433","name":"Call for scientific data for the periodic review of the monograph on Melaleucae aetheroleum - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-03-15 - 2022-06-14","first_published_date":"2022-03-15T11:00:00Z","last_updated_date":"2022-03-15T11:00:00Z","reference_number":"EMA/HMPC/120033/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-melaleucae-aetheroleum-revision-1_en.pdf"},
    {"id":"54448","name":"Call for scientific data for the periodic review of the monograph on Polygoni avicularis herba - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-03-15 - 2022-06-14","first_published_date":"2022-03-15T18:05:00Z","last_updated_date":"2022-03-15T18:05:00Z","reference_number":"EMA/HMPC/121979/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-polygoni-avicularis-herba-revision-1_en.pdf"},
    {"id":"54449","name":"Call for scientific data for the periodic review of the monograph on Pruni africanae cortex - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-03-15 - 2022-06-14","first_published_date":"2022-03-15T18:11:00Z","last_updated_date":"2022-03-15T18:11:00Z","reference_number":"EMA/HMPC/122008/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-pruni-africanae-cortex-revision-1_en.pdf"},
    {"id":"54453","name":"Call for scientific data for the periodic review of the  monograph on Pilosellae herba cum radice - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-03-15 - 2022-06-14","first_published_date":"2022-03-15T18:29:00Z","last_updated_date":"2022-03-15T18:29:00Z","reference_number":"EMA/HMPC/121970/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-pilosellae-herba-cum-radice-revision-1_en.pdf"}    {"id":"54455","name":"Call for scientific data for the periodic review of the  monograph on Origani majoranae herba - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-03-15 - 2022-06-14","first_published_date":"2022-03-15T18:34:00Z","last_updated_date":"2022-03-15T18:34:00Z","reference_number":"EMA/HMPC/121934/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-origani-majoranae-herba-revision-1_en.pdf"},
    {"id":"54456","name":"Call for scientific data for the periodic review of the  monograph on Myrtilli fructus recens - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-03-15 - 2022-06-14","first_published_date":"2022-03-15T18:38:00Z","last_updated_date":"2022-03-15T18:38:00Z","reference_number":"EMA/HMPC/120142/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-myrtilli-fructus-recens-revision-1_en.pdf"},
    {"id":"54742","name":"Call for scientific data for the periodic review of the monograph on Ricini oleum - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-04-15 - 2022-07-14","first_published_date":"2022-04-13T13:30:00Z","last_updated_date":"2022-04-13T13:30:00Z","reference_number":"EMA/HMPC/201470/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-ricini-oleum-revision-1_en.pdf"},
    {"id":"54743","name":"Call for scientific data for the periodic review of the monograph on Rosae flos - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-04-15 - 2022-07-14","first_published_date":"2022-04-13T13:30:00Z","last_updated_date":"2022-04-13T13:30:00Z","reference_number":"EMA/HMPC/201700/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-rosae-flos-revision-1_en.pdf"},
    {"id":"54744","name":"Call for scientific data for the periodic review of the monograph on Rubi idaei folium - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-04-15 - 2022-07-14","first_published_date":"2022-04-13T13:30:00Z","last_updated_date":"2022-04-13T13:30:00Z","reference_number":"EMA/HMPC/201707/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-rubi-idaei-folium-revision-1_en.pdf"},
    {"id":"54746","name":"Call for scientific data for the periodic review of the  monograph on Sideritis herba - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-04-15 - 2022-07-14","first_published_date":"2022-04-13T11:12:00Z","last_updated_date":"2022-04-13T11:12:00Z","reference_number":"EMA/HMPC/201708/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-sideritis-herba-revision-1_en.pdf"},
    {"id":"54747","name":"Call for scientific data for the periodic review of the  monograph on Sisymbrii officinalis herba - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-04-15 - 2022-07-14","first_published_date":"2022-04-13T11:17:00Z","last_updated_date":"2022-04-13T11:17:00Z","reference_number":"EMA/HMPC/201713/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-sisymbrii-officinalis-herba-revision-1_en.pdf"},
    {"id":"54748","name":"Call for scientific data for the periodic review of the  monograph on Symphyti radix - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2022-04-15 - 2022-07-14","first_published_date":"2022-04-13T11:21:00Z","last_updated_date":"2022-04-13T11:21:00Z","reference_number":"EMA/HMPC/201716/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-symphyti-radix-revision-1_en.pdf"},
    {"id":"57672","name":"Call for scientific data for use in HMPC assessment work on Cannabis sativa L., flos (Cannabis sativa flowering tops)","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-02-15 - 2023-05-14","first_published_date":"2023-02-15T11:02:00Z","last_updated_date":"2023-02-15T11:02:00Z","reference_number":"EMA/HMPC/697513/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-cannabis-sativa-l-flos-cannabis-sativa-flowering-tops_en.pdf"},
    {"id":"57681","name":"Call for scientific data for use in HMPC assessment work on herbal tea combinations traditionally used in the therapeutic area ‘cough and cold’","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-02-15 - 2023-05-14","first_published_date":"2023-02-15T16:35:00Z","last_updated_date":"2023-02-15T16:35:00Z","reference_number":"EMA/HMPC/68490/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-herbal-tea-combinations-traditionally-used-therapeutic-area-cough-and-cold_en.pdf"},
    {"id":"57682","name":"Call for scientific data for the use in HMPC assessment work on Pruni cerasi stipites","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-02-15 - 2023-05-14","first_published_date":"2023-02-15T16:35:00Z","last_updated_date":"2023-02-15T16:35:00Z","reference_number":"EMA/HMPC/68488/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-pruni-cerasi-stipites_en.pdf"},
    {"id":"58240","name":"Call for scientific data for the periodic review of the monograph on Lecithinum ex soya - Revision 1","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-03-31 - 2023-06-30","first_published_date":"2023-03-31T10:49:00Z","last_updated_date":"2023-03-31T10:49:00Z","reference_number":"EMA/HMPC/141083/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-lecithinum-ex-soya-revision-1_en.pdf"},
    {"id":"58243","name":"Call for scientific data for the periodic review of the monograph on Matricariae aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-03-31 - 2023-06-30","first_published_date":"2023-03-31T12:41:00Z","last_updated_date":"2023-03-31T12:41:00Z","reference_number":"EMA/HMPC/141099/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-matricariae-aetheroleum_en.pdf"},
    {"id":"58244","name":"Call for scientific data for the periodic review of the monograph on Soiae oleum raffinatum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-03-31 - 2023-06-30","first_published_date":"2023-03-31T12:51:00Z","last_updated_date":"2023-03-31T12:51:00Z","reference_number":"EMA/HMPC/141196/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-soiae-oleum-raffinatum_en.pdf"},
    {"id":"58245","name":"Call for scientific data for the periodic review of the monograph on Malvae sylvestris flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-03-31 - 2023-06-30","first_published_date":"2023-03-31T12:55:00Z","last_updated_date":"2023-03-31T12:55:00Z","reference_number":"EMA/HMPC/141161/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-malvae-sylvestris-flos_en.pdf"},
    {"id":"58249","name":"Call for scientific data for the periodic review of the monograph on Malvae folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-03-31 - 2023-06-30","first_published_date":"2023-03-31T15:29:00Z","last_updated_date":"2023-03-31T15:29:00Z","reference_number":"EMA/HMPC/141175/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-malvae-folium_en.pdf"},
    {"id":"58556","name":"Call for scientific data for the periodic review of the monograph on Allii sativi bulbus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-04-30 - 2023-07-31","first_published_date":"2023-05-02T13:29:00Z","last_updated_date":"2023-05-02T13:29:00Z","reference_number":"EMA/HMPC/187357/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-allii-sativi-bulbus_en.pdf"},
    {"id":"58557","name":"Call for scientific data for the periodic review of the monograph on Mastic (Pistaciae lentisci resina)","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-04-30 - 2023-07-31","first_published_date":"2023-05-02T14:24:00Z","last_updated_date":"2023-05-02T14:24:00Z","reference_number":"EMA/HMPC/187451/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-mastic-pistaciae-lentisci-resina_en.pdf"},
    {"id":"58558","name":"Call for scientific data for the periodic review of the monograph on Silybi mariani fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-04-30 - 2023-07-31","first_published_date":"2023-05-02T14:30:00Z","last_updated_date":"2023-05-02T14:30:00Z","reference_number":"EMA/HMPC/187481/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-silybi-mariani-fructus_en.pdf"},
    {"id":"58559","name":"Call for scientific data for the periodic review of the monograph on Combination: Species diureticae","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-04-30 - 2023-07-31","first_published_date":"2023-05-02T14:38:00Z","last_updated_date":"2023-05-02T14:38:00Z","reference_number":"EMA/HMPC/187490/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-combination-species-diureticae_en.pdf"},
    {"id":"58953","name":"Call for scientific data for the use in HMPC assessment work on Maydis stigma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2023-06-15 - 2023-09-15","first_published_date":"2023-06-15T13:18:00Z","last_updated_date":"2023-06-15T13:18:00Z","reference_number":"EMA/HMPC/267698/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-maydis-stigma_en.pdf"},
    {"id":"62157","name":"Call for scientific data for the periodic review of the monograph on Oleae folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T08:12:40Z","last_updated_date":"2024-02-15T08:12:40Z","reference_number":"EMA/HMPC/62365/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-oleae-folium_en.pdf"},
    {"id":"62158","name":"Call for scientific data for the periodic review of the monograph on Plantaginis ovatae semen","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T08:25:44Z","last_updated_date":"2024-02-15T08:25:44Z","reference_number":"EMA/HMPC/62679/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-plantaginis-ovatae-semen_en.pdf"},
    {"id":"62159","name":"Call for scientific data for the periodic review of the monograph on Plantaginis ovatae seminis tegumentum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T08:30:43Z","last_updated_date":"2024-02-15T08:30:43Z","reference_number":"EMA/HMPC/62844/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-plantaginis-ovatae-seminis-tegumentum_en.pdf"},
    {"id":"62160","name":"Call for scientific data for the periodic review of the monograph on Polypodii rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T08:36:06Z","last_updated_date":"2024-02-15T08:36:06Z","reference_number":"EMA/HMPC/63089/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-polypodii-rhizoma_en.pdf"},
    {"id":"62161","name":"Call for scientific data for the periodic review of the monograph on Agni casti fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T08:40:30Z","last_updated_date":"2024-02-15T08:40:30Z","reference_number":"EMA/HMPC/61306/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-agni-casti-fructus_en.pdf"},
    {"id":"62162","name":"Call for scientific data for the periodic review of the monograph on Echinaceae angustifoliae radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T08:44:23Z","last_updated_date":"2024-02-15T08:44:23Z","reference_number":"EMA/HMPC/62660/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-echinaceae-angustifoliae-radix_en.pdf"},
    {"id":"62163","name":"Call for scientific data for the periodic review of the monograph on Echinaceae pallidae radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T08:47:40Z","last_updated_date":"2024-02-15T08:47:40Z","reference_number":"EMA/HMPC/62728/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-echinaceae-pallidae-radix_en.pdf"},
    {"id":"62164","name":"Call for scientific data for the periodic review of the monograph on Echinaceae purpureae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T08:50:54Z","last_updated_date":"2024-02-15T08:50:54Z","reference_number":"EMA/HMPC/62776/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-echinaceae-purpureae-herba_en.pdf"},
    {"id":"62166","name":"Call for scientific data for the periodic review of the monograph on Echinaceae purpureae radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T08:58:01Z","last_updated_date":"2024-02-15T08:58:01Z","reference_number":"EMA/HMPC/62831/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-echinaceae-purpureae-radix_en.pdf"},
    {"id":"62167","name":"Call for scientific data for the periodic review of the monograph on Ribis nigri folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T09:01:13Z","last_updated_date":"2024-02-15T09:01:13Z","reference_number":"EMA/HMPC/63202/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-ribis-nigri-folium_en.pdf"},
    {"id":"62168","name":"Call for scientific data for the periodic review of the monograph on Cimicifugae rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-05-15","first_published_date":"2024-02-15T09:03:41Z","last_updated_date":"2024-02-15T09:03:41Z","reference_number":"EMA/HMPC/64820/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-cimicifugae-rhizoma_en.pdf"},
    {"id":"62412","name":"Call for scientific data for the periodic review of the monograph on Thymi herba and Primulae radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-03-01 - 2024-05-31","first_published_date":"2024-03-01T16:43:29Z","last_updated_date":"2024-03-01T16:43:29Z","reference_number":"EMA/HMPC/95155/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-thymi-herba-primulae-radix_en.pdf"},
    {"id":"62413","name":"Call for scientific data for the periodic review of the monograph on Sambuci flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-03-01 - 2024-05-31","first_published_date":"2024-03-01T16:46:46Z","last_updated_date":"2024-03-01T16:46:46Z","reference_number":"EMA/HMPC/95128/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-sambuci-flos_en.pdf"},
    {"id":"62414","name":"Call for scientific data for the periodic review of the monograph on Rusci rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-03-01 - 2024-05-31","first_published_date":"2024-03-01T16:49:18Z","last_updated_date":"2024-03-01T16:49:18Z","reference_number":"EMA/HMPC/95110/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-rusci-rhizoma_en.pdf"},
    {"id":"62415","name":"Call for scientific data for the periodic review of the monograph on Lupuli flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-03-01 - 2024-05-31","first_published_date":"2024-03-01T16:52:29Z","last_updated_date":"2024-03-01T16:52:29Z","reference_number":"EMA/HMPC/95045/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-lupuli-flos_en.pdf"},
    {"id":"62416","name":"Call for scientific data for the periodic review of the monograph on Lini semen","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-03-01 - 2024-05-31","first_published_date":"2024-03-01T16:54:56Z","last_updated_date":"2024-03-01T16:54:56Z","reference_number":"EMA/HMPC/95020/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-lini-semen_en.pdf"},
    {"id":"62417","name":"Call for scientific data for the periodic review of the monograph on Avenae fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-03-01 - 2024-05-31","first_published_date":"2024-03-04T08:45:53Z","last_updated_date":"2024-03-04T08:45:53Z","reference_number":"EMA/91133/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-avenae-fructus_en.pdf"},
    {"id":"62418","name":"Call for scientific data for the periodic review of the monograph on Avenae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-03-01 - 2024-05-31","first_published_date":"2024-03-04T08:51:19Z","last_updated_date":"2024-03-04T08:51:19Z","reference_number":"EMA/91151/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-avenae-herba_en.pdf"},
    {"id":"62419","name":"Call for scientific data for the periodic review of the monograph on Boldi folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-03-01 - 2024-05-31","first_published_date":"2024-03-04T08:54:13Z","last_updated_date":"2024-03-04T08:54:13Z","reference_number":"EMA/91043/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-boldi-folium_en.pdf"},
    {"id":"62420","name":"Call for scientific data for the periodic review of the monograph on Calendulae flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-03-01 - 2024-05-31","first_published_date":"2024-03-04T08:56:55Z","last_updated_date":"2024-03-04T08:56:55Z","reference_number":"EMA/91096/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-calendulae-flos_en.pdf"},
    {"id":"62421","name":"Call for scientific data for the periodic review of the monograph on Gentianae radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2024-03-01 - 2024-05-31","first_published_date":"2024-03-04T08:59:24Z","last_updated_date":"2024-03-04T08:59:24Z","reference_number":"EMA/91109/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-gentianae-radix_en.pdf"},
    {"id":"62767","name":"Call for scientific data for the periodic review of the monograph on Curcumae longae rhizoma","type":"herbal-call-data","status":"unknown","consultation_date":"2024-04-01 - 2024-06-30","first_published_date":"2024-04-02T11:03:08Z","last_updated_date":"2024-04-02T11:03:08Z","reference_number":"EMA/HMPC/130775/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-curcumae-longae-rhizoma_en.pdf"},
    {"id":"62768","name":"Call for scientific data for the periodic review of the monograph on Cynarae folium","type":"herbal-call-data","status":"unknown","consultation_date":"2024-04-01 - 2024-06-30","first_published_date":"2024-04-02T11:06:25Z","last_updated_date":"2024-04-02T11:06:25Z","reference_number":"EMA/HMPC/130842/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-cynarae-folium_en.pdf"},
    {"id":"62769","name":"Call for scientific data for the periodic review of the monograph on Meliloti herba","type":"herbal-call-data","status":"unknown","consultation_date":"2024-04-01 - 2024-06-30","first_published_date":"2024-04-02T11:09:46Z","last_updated_date":"2024-04-02T11:09:46Z","reference_number":"EMA/HMPC/130907/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-meliloti-herba_en.pdf"},
    {"id":"62770","name":"Call for scientific data for the periodic review of the monograph on Melissae folium","type":"herbal-call-data","status":"unknown","consultation_date":"2024-04-01 - 2024-06-30","first_published_date":"2024-04-02T11:12:14Z","last_updated_date":"2024-04-02T11:12:14Z","reference_number":"EMA/HMPC/130926/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-melissae-folium_en.pdf"},
    {"id":"62772","name":"Call for scientific data for the periodic review of the monograph on Myrrha","type":"herbal-call-data","status":"unknown","consultation_date":"2024-04-01 - 2024-06-30","first_published_date":"2024-04-02T11:15:02Z","last_updated_date":"2024-04-02T11:15:02Z","reference_number":"EMA/HMPC/130940/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-myrrha_en.pdf"},
    {"id":"62774","name":"Call for scientific data for the periodic review of the monograph on Oenotherae oleum","type":"herbal-call-data","status":"unknown","consultation_date":"2024-04-01 - 2024-06-30","first_published_date":"2024-04-02T11:19:33Z","last_updated_date":"2024-04-02T11:19:33Z","reference_number":"EMA/HMPC/131224/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-oenotherae-oleum_en.pdf"},
    {"id":"62776","name":"Call for scientific data for the periodic review of the monograph on Uvae ursi folium","type":"herbal-call-data","status":"unknown","consultation_date":"2024-04-01 - 2024-06-30","first_published_date":"2024-04-02T11:25:20Z","last_updated_date":"2024-04-02T11:25:20Z","reference_number":"EMA/HMPC/132081/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-uvae-ursi-folium_en.pdf"},
    {"id":"62777","name":"Call for scientific data for the periodic review of the monograph on Verbasci flos","type":"herbal-call-data","status":"unknown","consultation_date":"2024-04-01 - 2024-06-30","first_published_date":"2024-04-02T11:27:33Z","last_updated_date":"2024-04-02T11:27:33Z","reference_number":"EMA/HMPC/131808/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-verbasci-flos_en.pdf"},
    {"id":"62778","name":"Call for scientific data for the periodic review of the monograph on Vitis viniferae folium","type":"herbal-call-data","status":"unknown","consultation_date":"2024-04-01 - 2024-06-30","first_published_date":"2024-04-02T11:29:39Z","last_updated_date":"2024-04-02T11:29:39Z","reference_number":"EMA/HMPC/132264/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-vitis-viniferae-folium_en.pdf"},
    {"id":"66769","name":"Call for scientific data for the periodic review of the monograph on Anisi aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-02-15 - 2025-05-15","first_published_date":"2025-02-14T12:56:55Z","last_updated_date":"2025-02-14T12:56:55Z","reference_number":"EMA/HMPC/41176/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-anisi-aetheroleum_en.pdf"},
    {"id":"66771","name":"Call for scientific data for the periodic review of the monograph on Anisi fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-02-15 - 2025-05-15","first_published_date":"2025-02-14T13:00:19Z","last_updated_date":"2025-02-14T13:00:19Z","reference_number":"EMA/HMPC/41594/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-anisi-fructus_en.pdf"},
    {"id":"66772","name":"Call for scientific data for the periodic review of the monograph on Centaurii herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-02-15 - 2025-05-15","first_published_date":"2025-02-14T13:03:07Z","last_updated_date":"2025-02-14T13:03:07Z","reference_number":"EMA/HMPC/41748/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-centaurii-herba_en.pdf"},
    {"id":"66774","name":"Call for scientific data for the periodic review of the monograph on Salviae officinalis folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-02-15 - 2025-05-15","first_published_date":"2025-02-14T13:06:51Z","last_updated_date":"2025-02-14T13:06:51Z","reference_number":"EMA/HMPC/42211/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-salviae-officinalis-folium_en.pdf"},
    {"id":"66775","name":"Call for scientific data for the periodic review of the monograph on Valerianae aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-02-15 - 2025-05-15","first_published_date":"2025-02-14T13:09:25Z","last_updated_date":"2025-02-14T13:09:25Z","reference_number":"EMA/HMPC/42266/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-valerianae-aetheroleum_en.pdf"},
    {"id":"66776","name":"Call for scientific data for the periodic review of the monograph on Valerianae radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-02-15 - 2025-05-15","first_published_date":"2025-02-14T13:15:24Z","last_updated_date":"2025-02-14T13:15:24Z","reference_number":"EMA/HMPC/42303/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-valerianae-radix_en.pdf"},
    {"id":"67053","name":"Call for scientific data for the periodic review of the monograph on Primulae flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-03-01 - 2025-05-31","first_published_date":"2025-02-28T14:34:37Z","last_updated_date":"2025-02-28T14:34:37Z","reference_number":"EMA/HMPC/64619/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-primulae-flos_en.pdf"},
    {"id":"67054","name":"Call for scientific data for the periodic review of the monograph on Primulae radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-03-01 - 2025-05-31","first_published_date":"2025-02-28T14:43:59Z","last_updated_date":"2025-02-28T14:43:59Z","reference_number":"EMA/HMPC/64684/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-primulae-radix_en.pdf"},
    {"id":"67055","name":"Call for scientific data for the periodic review of the monograph on Betulae folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-03-01 - 2025-05-31","first_published_date":"2025-02-28T14:58:46Z","last_updated_date":"2025-02-28T14:58:46Z","reference_number":"EMA/HMPC/64356/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-betulae-folium_en.pdf"},
    {"id":"67056","name":"Call for scientific data for the periodic review of the monograph on Eleutherococci radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-03-01 - 2025-05-31","first_published_date":"2025-02-28T15:03:41Z","last_updated_date":"2025-02-28T15:03:41Z","reference_number":"EMA/HMPC/64400/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-eleutherococci-radix_en.pdf"},
    {"id":"67057","name":"Call for scientific data for the periodic review of the monograph on Hederae helicis folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-03-01 - 2025-05-31","first_published_date":"2025-02-28T15:12:01Z","last_updated_date":"2025-02-28T15:12:01Z","reference_number":"EMA/HMPC/64513/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-hederae-helicis-folium_en.pdf"},
    {"id":"67058","name":"Call for scientific data for the periodic review of the monograph on Passiflorae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-03-01 - 2025-05-31","first_published_date":"2025-02-28T15:15:41Z","last_updated_date":"2025-02-28T15:15:41Z","reference_number":"EMA/HMPC/64557/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-passiflorae-herba_en.pdf"},
    {"id":"67530","name":"Call for scientific data for the periodic review of the monograph on Althaeae radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:00Z","last_updated_date":"2025-04-01T09:00:00Z","reference_number":"EMA/HMPC/92238/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-althaeae-radix_en.pdf"},
    {"id":"67531","name":"Call for scientific data for the periodic review of the monograph on Carvi aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:01Z","last_updated_date":"2025-04-01T09:00:01Z","reference_number":"EMA/HMPC/110735/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-carvi-aetheroleum_en.pdf"},
    {"id":"67532","name":"Call for scientific data for the periodic review of the monograph on Carvi fructus","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:02Z","last_updated_date":"2025-04-01T09:00:02Z","reference_number":"EMA/HMPC/110965/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-carvi-fructus_en.pdf"},
    {"id":"67533","name":"Call for scientific data for the periodic review of the monograph on Equiseti herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:04Z","last_updated_date":"2025-04-01T09:00:04Z","reference_number":"EMA/HMPC/93113/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-equiseti-herba_en.pdf"},
    {"id":"67534","name":"Call for scientific data for the periodic review of the monograph on Hamamelidis cortex","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:05Z","last_updated_date":"2025-04-01T09:00:05Z","reference_number":"EMA/HMPC/110242/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-hamamelidis-cortex_en.pdf"},
    {"id":"67535","name":"Call for scientific data for the periodic review of the monograph on Hamamelidis folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:06Z","last_updated_date":"2025-04-01T09:00:06Z","reference_number":"EMA/HMPC/110502/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-hamamelidis-folium_en.pdf"},
    {"id":"67536","name":"Call for scientific data for the periodic review of the monograph on Hamamelidis folium et cortex aut ramunculus destillatum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:07Z","last_updated_date":"2025-04-01T09:00:07Z","reference_number":"EMA/HMPC/110527/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-hamamelidis-folium-et-cortex-aut-ramunculus-destillatum_en.pdf"},
    {"id":"67537","name":"Call for scientific data for the periodic review of the monograph on Harpagophyti radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:08Z","last_updated_date":"2025-04-01T09:00:08Z","reference_number":"EMA/HMPC/95238/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-harpagophyti-radix_en.pdf"},
    {"id":"67538","name":"Call for scientific data for the periodic review of the monograph on Psyllii semen","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:09Z","last_updated_date":"2025-04-01T09:00:09Z","reference_number":"EMA/HMPC/95545/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-psyllii-semen_en.pdf"},
    {"id":"67539","name":"Call for scientific data for the periodic review of the monograph on Salicis cortex","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:10Z","last_updated_date":"2025-04-01T09:00:10Z","reference_number":"EMA/HMPC/95838/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-salicis-cortex_en.pdf"},
    {"id":"67540","name":"Call for scientific data for the periodic review of the monograph on Valerianae radix and Lupuli flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-06-30","first_published_date":"2025-04-01T09:00:11Z","last_updated_date":"2025-04-01T09:00:11Z","reference_number":"EMA/HMPC/110690/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-valerianae-radix-lupuli-flos_en.pdf"},
    {"id":"67837","name":"Call for scientific data for the use in HMPC assessment work on Valerianae radix and Passiflorae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2025-04-15 - 2025-07-15","first_published_date":"2025-04-15T13:12:00Z","last_updated_date":"2025-04-15T13:12:00Z","reference_number":"EMA/HMPC/125437/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-use-hmpc-assessment-work-valerianae-radix-passiflorae-herba_en.pdf"},
    {"id":"73025","name":"Call for scientific data for the periodic review of the monograph on Tormentillae rhizoma","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T10:11:12Z","last_updated_date":"2026-03-16T10:11:12Z","reference_number":"EMA/HMPC/57656/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-tormentillae-rhizoma_en.pdf"},
    {"id":"73026","name":"Call for scientific data for the periodic review of the monograph on Arctii radix","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T10:18:10Z","last_updated_date":"2026-03-16T10:18:10Z","reference_number":"EMA/HMPC/37510/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-arctii-radix_en.pdf"},
    {"id":"73028","name":"Call for scientific data for the periodic review of the monograph on Chamomillae romanae flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T10:23:27Z","last_updated_date":"2026-03-16T10:23:27Z","reference_number":"EMA/HMPC/37916/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-chamomillae-romanae-flos_en.pdf"},
    {"id":"73029","name":"Call for scientific data for the periodic review of the monograph on Filipendulae ulmariae flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T10:29:05Z","last_updated_date":"2026-03-16T10:29:05Z","reference_number":"EMA/HMPC/37952/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-filipendulae-ulmariae-flos_en.pdf"},
    {"id":"73030","name":"Call for scientific data for the periodic review of the monograph on Filipendulae ulmariae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T10:32:48Z","last_updated_date":"2026-03-16T10:32:48Z","reference_number":"EMA/HMPC/39822/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-filipendulae-ulmariae-herba_en.pdf"},
    {"id":"73031","name":"Call for scientific data for the periodic review of the monograph on Herniariae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T10:39:14Z","last_updated_date":"2026-03-16T10:39:14Z","reference_number":"EMA/HMPC/57022/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-herniariae-herba_en.pdf"},
    {"id":"73032","name":"Call for scientific data for the periodic review of the monograph on Menthae piperitae aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T10:44:37Z","last_updated_date":"2026-03-16T10:44:37Z","reference_number":"EMA/HMPC/57283/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-menthae-piperitae-aetheroleum_en.pdf"},
    {"id":"73033","name":"Call for scientific data for the periodic review of the monograph on Menthae piperitae folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T10:48:04Z","last_updated_date":"2026-03-16T10:48:04Z","reference_number":"EMA/HMPC/57660/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-menthae-piperitae-folium_en.pdf"},
    {"id":"73034","name":"Call for scientific data for the periodic review of the monograph on Tanaceti parthenii herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T10:51:17Z","last_updated_date":"2026-03-16T10:51:17Z","reference_number":"EMA/HMPC/57716/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-tanaceti-parthenii-herba_en.pdf"},
    {"id":"73035","name":"Call for scientific data for the periodic review of the monograph on Thymi aetheroleum","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T10:55:57Z","last_updated_date":"2026-03-16T10:55:57Z","reference_number":"EMA/HMPC/57737/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-thymi-aetheroleum_en.pdf"},
    {"id":"73037","name":"Call for scientific data for the periodic review of the monograph on Leonuri cardiacae herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T11:42:28Z","last_updated_date":"2026-03-16T11:42:28Z","reference_number":"EMA/HMPC/56725/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-leonuri-cardiacae-herba_en.pdf"},
    {"id":"73038","name":"Call for scientific data for the periodic review of the monograph on Millefolii flos","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T11:53:22Z","last_updated_date":"2026-03-16T11:53:22Z","reference_number":"EMA/HMPC/57003/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-millefolii-flos_en.pdf"},
    {"id":"73039","name":"Call for scientific data for the periodic review of the monograph on Millefolii herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T11:57:08Z","last_updated_date":"2026-03-16T11:57:08Z","reference_number":"EMA/HMPC/57270/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-millefolii-herba_en.pdf"},
    {"id":"73040","name":"Call for scientific data for the periodic review of the monograph on Phaseoli fructus (sine semine)","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T12:00:42Z","last_updated_date":"2026-03-16T12:00:42Z","reference_number":"EMA/HMPC/57285/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-phaseoli-fructus-sine-semine_en.pdf"},
    {"id":"73041","name":"Call for scientific data for the periodic review of the monograph on Quercus cortex","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T12:03:39Z","last_updated_date":"2026-03-16T12:03:39Z","reference_number":"EMA/HMPC/57401/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-quercus-cortex_en.pdf"},
    {"id":"73042","name":"Call for scientific data for the periodic review of the monograph on Taraxaci folium","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T12:08:11Z","last_updated_date":"2026-03-16T12:08:11Z","reference_number":"EMA/HMPC/57637/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-taraxaci-folium_en.pdf"},
    {"id":"73043","name":"Call for scientific data for the periodic review of the monograph on Taraxaci radix cum herba","type":"herbal-call-data","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T12:10:28Z","last_updated_date":"2026-03-16T12:10:28Z","reference_number":"EMA/HMPC/57646/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-call-data/call-scientific-data-periodic-review-monograph-taraxaci-radix-cum-herba_en.pdf"},
    {"id":"2394","name":"Final community herbal monograph on Polypodium vulgare L., rhizome","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/600668/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-polypodium-vulgare-l-rhizome_en.pdf"},
    {"id":"3223","name":"Draft community herbal monograph on Vitex agnus-castus L., fructus - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-09-17T02:09:00Z","last_updated_date":"2009-09-17T02:09:00Z","reference_number":"EMEA/HMPC/144006/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-vitex-agnus-castus-l-fructus-first-version_en.pdf"},
    {"id":"3306","name":"Draft community herbal monograph on Polypodium vulgare L., rhizoma","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-05-08T02:00:00Z","last_updated_date":"2008-05-08T02:00:00Z","reference_number":"EMEA/HMPC/600668/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-polypodium-vulgare-l-rhizoma_en.pdf"},
    {"id":"3761","name":"Draft community herbal monograph on Melilotus officinalis (L.) Lam., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/HMPC/354177/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"3973","name":"Superseded Community herbal monograph on Plantago ovate Forssk., seminis tegumentum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMEA/HMPC/340857/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-plantago-ovate-forssk-seminis-tegumentum_en.pdf"},
    {"id":"4222","name":"Superseded Community herbal monograph on Zingiber officinale Roscoe, rhizoma","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2012-06-04T02:00:00Z","last_updated_date":"2025-06-19T02:00:00Z","reference_number":"EMA/HMPC/749154/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-zingiber-officinale-roscoe-rhizoma_en.pdf"},
    {"id":"4550","name":"Final Community herbal monograph on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-10-06T02:00:00Z","last_updated_date":"2014-10-06T02:00:00Z","reference_number":"EMA/HMPC/680618/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf"},
    {"id":"4790","name":"Draft Community herbal monograph on Symphytum officinale L., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-08-15 - 2011-11-15","first_published_date":"2011-08-19T04:00:00Z","last_updated_date":"2011-08-19T04:00:00Z","reference_number":"EMA/HMPC/572846/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-symphytum-officinale-l-radix_en.pdf"}    {"id":"4873","name":"Final Community herbal monograph on Solanum dulcamara L., stipites","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T01:00:00Z","last_updated_date":"2013-02-15T01:00:00Z","reference_number":"EMA/HMPC/734361/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-solanum-dulcamara-l-stipites_en.pdf"},
    {"id":"4876","name":"Draft community herbal monograph on Capsella bursa-pastoris (L.) Medikus, herba - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-01-15 - 2011-04-15","first_published_date":"2011-01-18T02:00:00Z","last_updated_date":"2011-01-18T02:00:00Z","reference_number":"EMA/HMPC/262766/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-capsella-bursa-pastoris-l-medikus-herba-first-version_en.pdf"},
    {"id":"5028","name":"Final Community herbal monograph on Rosa gallica L., Rosa centifolia L., Rosa damascena Mill., flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-09-10T02:00:00Z","last_updated_date":"2014-09-10T02:00:00Z","reference_number":"EMA/HMPC/137299/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-rosa-gallica-l-rosa-centifolia-l-rosa-damascena-mill-flos_en.pdf"},
    {"id":"5203","name":"Draft Community herbal monograph on Urtica dioica L., Urtica urens L., their hybrids or their mixtures, radix - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-19T19:00:00Z","last_updated_date":"2011-10-19T19:00:00Z","reference_number":"EMA/HMPC/461160/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-their-hybrids-or-their-mixtures-radix-first-version_en.pdf"},
    {"id":"5275","name":"Draft community herbal monograph on Gentiana lutea L., radix - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-03-12T00:09:21Z","last_updated_date":"2009-03-12T00:09:21Z","reference_number":"EMEA/HMPC/578324/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-gentiana-lutea-l-radix-first-version_en.pdf"},
    {"id":"5293","name":"Draft community herbal monograph on Viola tricolor L.","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-05-15 - 2010-08-15","first_published_date":"2010-05-28T04:00:00Z","last_updated_date":"2010-05-28T04:00:00Z","reference_number":"EMA/HMPC/131734/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-viola-tricolor-l_en.pdf"},
    {"id":"5463","name":"Superseded community herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2010-09-02T02:00:00Z","last_updated_date":"2011-06-07T02:00:00Z","reference_number":"EMA/HMPC/585558/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos_en.pdf"},
    {"id":"5612","name":"Draft Community herbal monograph on Eucalyptus globulus Labill., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2012-04-15 - 2012-10-15","first_published_date":"2012-06-21T18:01:00Z","last_updated_date":"2012-06-21T18:01:00Z","reference_number":"EMA/HMPC/892618/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-eucalyptus-globulus-labill-folium_en.pdf"},
    {"id":"5617","name":"Final community herbal monograph on Plantago lanceolata L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T01:00:00Z","last_updated_date":"2014-02-10T17:00:00Z","reference_number":"EMA/HMPC/437858/2010 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-lanceolata-l-folium_en.pdf"},
    {"id":"5646","name":"Final community herbal monograph on Potentilla erecta (L.) Raeusch., rhizoma","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"EMA/HMPC/5513/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-potentilla-erecta-l-raeusch-rhizoma_en.pdf"},
    {"id":"5798","name":"Draft European Union herbal monograph on Vaccinium myrtillus L., fructus siccus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-02-09 - 2015-05-15","first_published_date":"2015-02-09T12:30:00Z","last_updated_date":"2015-02-09T12:30:00Z","reference_number":"EMA/HMPC/678995/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-vaccinium-myrtillus-l-fructus-siccus_en.pdf"},
    {"id":"5847","name":"Final Community herbal monograph on Origanum dictamnus L., herba - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-08-05T02:00:00Z","last_updated_date":"2014-02-10T16:50:00Z","reference_number":"EMA/HMPC/200429/2012 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-origanum-dictamnus-l-herba-first-version_en.pdf"},
    {"id":"5898","name":"Final European Union herbal monograph on Ginkgo biloba L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2015-04-08T02:00:00Z","reference_number":"EMA/HMPC/321097/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-ginkgo-biloba-l-folium_en.pdf"},
    {"id":"5918","name":"Draft Community herbal monograph on Juglans regia L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-01-15 - 2013-04-15","first_published_date":"2013-01-25T02:00:00Z","last_updated_date":"2013-01-25T02:00:00Z","reference_number":"EMA/HMPC/346737/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-juglans-regia-l-folium_en.pdf"},
    {"id":"6176","name":"Final community herbal monograph on Filipendula ulmaria (L.) Maxim., herba - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-09-29T02:00:00Z","last_updated_date":"2011-09-29T02:00:00Z","reference_number":"EMA/HMPC/434881/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-filipendula-ulmaria-l-maxim-herba-first-version_en.pdf"},
    {"id":"6191","name":"Draft European Union herbal monograph on Serenoa repens (W. Bartram) Small, fructus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-12-22 - 2015-03-15","first_published_date":"2014-12-22T18:40:00Z","last_updated_date":"2014-12-22T18:40:00Z","reference_number":"EMA/HMPC/280079/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-serenoa-repens-w-bartram-small-fructus_en.pdf"},
    {"id":"6315","name":"Final European Union herbal monograph on Echinacea purpurea (L.) Moench., herba recens","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-04-13T02:00:00Z","last_updated_date":"2015-12-11T14:30:00Z","reference_number":"EMA/HMPC/48704/2014 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-echinacea-purpurea-l-moench-herba-recens_en.pdf"},
    {"id":"6438","name":"Superseded final community herbal monograph on Plantago ovata Forssk., seminis tegumentum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2006-10-26T02:00:00Z","last_updated_date":"2013-07-23T02:00:00Z","reference_number":"EMEA/HMPC/340857/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-plantago-ovata-forssk-seminis-tegumentum_en.pdf"},
    {"id":"6499","name":"Superseded community herbal monograph on Pimpinella anisum L., aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2014-06-18T02:09:21Z","reference_number":"EMEA/HMPC/263273/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-pimpinella-anisum-l-aetheroleum_en.pdf"},
    {"id":"6588","name":"Draft European Union herbal monograph on Hedera helix L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-02-12 - 2015-05-15","first_published_date":"2010-03-08T02:00:00Z","last_updated_date":"2015-02-12T15:30:00Z","reference_number":"EMA/HMPC/586888/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-hedera-helix-l-folium_en.pdf"},
    {"id":"6906","name":"Draft community herbal monograph on Taraxacum officinale Weber ex Wigg., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-01-14T00:09:21Z","last_updated_date":"2009-01-14T00:09:21Z","reference_number":"EMEA/HMPC/579636/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-folium_en.pdf"},
    {"id":"7161","name":"Draft community herbal monograph on Potentilla erecta (L.) Raeusch., rhizoma","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-05-15 - 2010-08-15","first_published_date":"2010-05-28T04:00:00Z","last_updated_date":"2010-05-28T04:00:00Z","reference_number":"EMA/HMPC/5513/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-potentilla-erecta-l-raeusch-rhizoma_en.pdf"},
    {"id":"7173","name":"Superseded final Community herbal monograph on Mentha x piperita L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/193909/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-mentha-x-piperita-l-folium_en.pdf"},
    {"id":"7261","name":"Draft community herbal monograph on Hamamelis virginiana L., folium et cortex destillatum and Hamamelis virginiana L., ramunculus destillatium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/114584/2008 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-hamamelis-virginiana-l-folium-et-cortex-destillatum-and-hamamelis-virginiana-l-ramunculus-destillatium_en.pdf"},
    {"id":"7305","name":"Draft Community herbal monograph on Arnica montana L., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-08-22 - 2013-12-15","first_published_date":"2013-08-22T04:00:00Z","last_updated_date":"2013-08-22T04:00:00Z","reference_number":"EMA/HMPC/198793/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-arnica-montana-l-flos_en.pdf"},
    {"id":"7342","name":"Draft Community herbal monograph on Aesculus hippocastanum L., cortex","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-26T14:30:01Z","last_updated_date":"2011-10-26T14:30:01Z","reference_number":"EMA/HMPC/354156/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-aesculus-hippocastanum-l-cortex_en.pdf"},
    {"id":"7503","name":"Draft Community herbal monograph on Matricaria recutita L., aetheroleum - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-07-24 - 2014-10-31","first_published_date":"2014-07-24T19:50:00Z","last_updated_date":"2014-07-24T19:50:00Z","reference_number":"EMA/HMPC/278814/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-matricaria-recutita-l-aetheroleum-first-version_en.pdf"},
    {"id":"7537","name":"Superseded community herbal monograph on Calendula officinalis L., flos - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2018-06-14T02:09:21Z","reference_number":"EMEA/HMPC/179281/2007Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-calendula-officinalis-l-flos-first-version_en.pdf"},
    {"id":"7551","name":"Final Community herbal monograph on Fucus vesiculosus L., thallus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-08-06T02:00:00Z","last_updated_date":"2014-08-06T02:00:00Z","reference_number":"EMA/HMPC/313674/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-fucus-vesiculosus-l-thallus_en.pdf"},
    {"id":"7662","name":"Draft community herbal monograph on Foeniculum vulgare Miller subsp.\n\nvulgare var. dulce (Miller) Thellung, fructus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-10-26T02:00:00Z","last_updated_date":"2006-10-26T02:00:00Z","reference_number":"EMEA/HMPC/263293/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus_en.pdf"},
    {"id":"7736","name":"Draft community herbal monograph on Salix, cortex","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-09-07T02:00:00Z","last_updated_date":"2007-09-07T02:00:00Z","reference_number":"EMEA/HMPC/295338/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-salix-cortex_en.pdf"},
    {"id":"7954","name":"Superseded community herbal monograph on Trigonella foenumgraecum L., semen","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2022-08-30T01:00:00Z","last_updated_date":"2022-08-30T01:00:00Z","reference_number":"EMA/HMPC/146221/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-trigonella-foenumgraecum-l-semen_en.pdf"},
    {"id":"7967","name":"Draft Community herbal monograph on Sisymbrium officinale (L.) Scop., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-01-15 - 2014-04-15","first_published_date":"2014-01-17T02:00:00Z","last_updated_date":"2014-01-17T02:00:00Z","reference_number":"EMA/HMPC/280193/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-sisymbrium-officinale-l-scop-herba_en.pdf"},
    {"id":"8275","name":"Superseded final Community herbal monograph on Rhodiola rosea - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T16:00:00Z","last_updated_date":"2024-05-23T16:00:00Z","reference_number":"EMA/HMPC/232091/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-rhodiola-rosea-first-version_en.pdf"},
    {"id":"8365","name":"Final Community herbal monograph on Passiflora incarnata L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-06-18T12:05:00Z","last_updated_date":"2014-06-18T12:05:00Z","reference_number":"EMA/HMPC/669740/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-passiflora-incarnata-l-herba_en.pdf"},
    {"id":"8582","name":"Superseded community herbal monograph on Ruscus aculeatus L, rhizome","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2019-05-02T17:00:00Z","reference_number":"EMEA/HMPC/261938/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-ruscus-aculeatus-l-rhizome_en.pdf"},
    {"id":"8614","name":"Superseded community herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne, radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMEA/HMPC/251323/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-harpagophytum-procumbens-dc-andor-harpagophytum-zeyheri-decne-radix_en.pdf"},
    {"id":"9174","name":"Final Community herbal monograph on Rubus idaeus L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T11:00:00Z","last_updated_date":"2014-03-21T11:00:00Z","reference_number":"EMA/HMPC/44211/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-rubus-idaeus-l-folium_en.pdf"},
    {"id":"9179","name":"Draft community herbal monograph on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl., semen","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-04-15 - 2011-08-15","first_published_date":"2011-04-20T04:00:00Z","last_updated_date":"2011-04-20T04:00:00Z","reference_number":"EMA/HMPC/722367/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-cola-nitida-vent-schott-et-endl-and-its-varieties-and-cola-acuminata-p-beauv-schott-et-endl-semen_en.pdf"},
    {"id":"9197","name":"Draft community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-01-14T00:09:21Z","last_updated_date":"2009-01-14T00:09:21Z","reference_number":"EMEA/HMPC/212895/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf"},
    {"id":"9202","name":"Superseded community herbal monograph on Ribes nigrum L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2010-06-30T02:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"EMA/HMPC/142986/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-ribes-nigrum-l-folium_en.pdf"},
    {"id":"9439","name":"Draft community herbal monograph on Quercus robur L., Quercus petraea (Matt.) Liebl. and Quercus pubescens Willd., cortex","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-01-14 - 2010-05-15","first_published_date":"2010-03-08T02:00:00Z","last_updated_date":"2010-03-08T02:00:00Z","reference_number":"EMA/HMPC/3203/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-quercus-robur-l-quercus-petraea-matt-liebl-and-quercus-pubescens-willd-cortex_en.pdf"},
    {"id":"9479","name":"Draft Community herbal monograph on Ginkgo biloba L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-02-15 - 2014-06-15","first_published_date":"2014-02-14T02:00:00Z","last_updated_date":"2014-02-14T02:00:00Z","reference_number":"EMA/HMPC/321097/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-ginkgo-biloba-l-folium_en.pdf"},
    {"id":"9715","name":"Draft Community herbal monograph on Plantago ovata Forskk., semen","type":"herbal-monograph","status":"Draft","consultation_date":"","first_published_date":"2016-01-21T01:00:00Z","last_updated_date":"2016-01-21T01:00:00Z","reference_number":"EMEA/HMPC/340861/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-plantago-ovata-forskk-semen_en.pdf"},
    {"id":"9740","name":"Final Community herbal monograph on Chamaemelum nobile (L.) All., flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T17:20:00Z","last_updated_date":"2012-01-20T17:20:00Z","reference_number":"EMA/HMPC/560734/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-chamaemelum-nobile-l-all-flos_en.pdf"},
    {"id":"9750","name":"Draft community herbal monograph on Primula veris L., Primula elatior (L.) Hill, flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-03-08T01:00:00Z","last_updated_date":"2007-03-08T01:00:00Z","reference_number":"MEA/HMPC/64684/2007 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-primula-veris-l-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"9764","name":"Draft Community herbal monograph on Lavandula angustifolia P. Mill., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-02-15 - 2011-08-15","first_published_date":"2011-02-11T02:00:00Z","last_updated_date":"2011-06-16T04:00:00Z","reference_number":"EMA/HMPC/734125/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-lavandula-angustifolia-p-mill-flos_en.pdf"},
    {"id":"9865","name":"Final Community herbal monograph on Melissa officinalis L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-08-05T17:00:00Z","last_updated_date":"2013-08-05T17:00:00Z","reference_number":"EMA/HMPC/196745/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-melissa-officinalis-l-folium_en.pdf"},
    {"id":"9918","name":"Draft community herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne, radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-01-10T01:00:00Z","last_updated_date":"2008-01-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-harpagophytum-procumbens-dc-andor-harpagophytum-zeyheri-decne-radix_en.pdf"},
    {"id":"10139","name":"Draft Community herbal monograph on Grindelia robusta Nutt., Grindelia squarrosa (Pursh) Dunal, Grindelia humilis Hook. et Arn., Grindelia camporum Greene, herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2012-04-15 - 2012-08-15","first_published_date":"2012-05-16T04:00:00Z","last_updated_date":"2012-05-16T04:00:00Z","reference_number":"EMA/HMPC/748220/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-grindelia-robusta-nutt-grindelia-squarrosa-pursh-dunal-grindelia-humilis-hook-et-arn-grindelia-camporum-greene-herba_en.pdf"},
    {"id":"10192","name":"Draft community herbal monograph on Peumus boldus Molina, folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2008-05-08T02:09:21Z","reference_number":"EMEA/HMPC/591648/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-peumus-boldus-molina-folium_en.pdf"},
    {"id":"10537","name":"Superseded community herbal monograph on Hypericum perforatum L., herba (traditional use)","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2009-12-21T00:09:00Z","last_updated_date":"2023-02-22T00:09:00Z","reference_number":"EMEA/HMPC/745582/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-hypericum-perforatum-l-herba-traditional-use_en.pdf"},
    {"id":"10576","name":"Draft community herbal monograph on Fumaria officinalis L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-02-15 - 2011-06-15","first_published_date":"2011-02-11T02:00:00Z","last_updated_date":"2011-02-11T02:00:00Z","reference_number":"EMA/HMPC/574766/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-fumaria-officinalis-l-herba_en.pdf"},
    {"id":"10640","name":"Superseded community herbal monograph on Cynara scolymus L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T01:00:00Z","last_updated_date":"2011-12-21T01:00:00Z","reference_number":"EMA/HMPC/150218/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-cynara-scolymus-l-folium_en.pdf"},
    {"id":"10737","name":"Final community herbal monograph on Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-04-29T14:45:00Z","last_updated_date":"2014-04-29T14:45:00Z","reference_number":"EMA/HMPC/283630/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"10808","name":"Superseded community herbal monograph on Hedera helix L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-04-19T02:00:00Z","last_updated_date":"2016-01-18T01:00:00Z","reference_number":"EMA/HMPC/289430/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-hedera-helix-l-folium_en.pdf"},
    {"id":"10957","name":"Superseded Community herbal monograph on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-01-21T11:20:00Z","last_updated_date":"2016-01-21T11:20:00Z","reference_number":"EMEA/HMPC/244569/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf"},
    {"id":"11094","name":"Final community herbal monograph on Vitex agnus-castus L., fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-31T01:00:00Z","last_updated_date":"2011-01-31T01:00:00Z","reference_number":"EMA/HMPC/144006/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-vitex-agnus-castus-l-fructus_en.pdf"},
    {"id":"11117","name":"Draft community herbal monograph on Sambucus nigra L., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-09-07T02:09:21Z","last_updated_date":"2007-09-07T02:09:21Z","reference_number":"EMEA/HMPC/283166/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-sambucus-nigra-l-flos_en.pdf"},
    {"id":"11235","name":"Draft community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-02-15 - 2011-06-15","first_published_date":"2011-02-11T02:00:00Z","last_updated_date":"2011-02-11T02:00:00Z","reference_number":"EMA/HMPC/563408/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-agropyron-repens-l-p-beauv-rhizoma_en.pdf"},
    {"id":"11556","name":"Superseded Community herbal monograph on Salvia officinalis L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2017-07-13T02:00:00Z","reference_number":"EMA/HMPC/331653/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-salvia-officinalis-l-folium_en.pdf"},
    {"id":"11885","name":"Superseded community herbal monograph on Orthosiphon stamineus Benth., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/281496/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-orthosiphon-stamineus-benth-folium_en.pdf"},
    {"id":"12034","name":"Final community herbal monograph on Fumaria officinalis L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-12-06T16:50:00Z","last_updated_date":"2024-02-21T16:10:00Z","reference_number":"EMA/HMPC/574766/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-fumaria-officinalis-l-herba_en.pdf"},
    {"id":"12226","name":"Superseded Community herbal monograph on Mentha x piperita L., aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"MEA/HMPC/349466/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-mentha-x-piperita-l-aetheroleum_en.pdf"},
    {"id":"12234","name":"Superseded final Community herbal monograph on Panax ginseng C.A. Meyer, radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-05-22T02:00:00Z","last_updated_date":"2024-07-12T12:36:00Z","reference_number":"EMA/HMPC/321233/2012 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-panax-ginseng-ca-meyer-radix_en.pdf"},
    {"id":"12314","name":"Final community herbal monograph on Foeniculum vulgare Miller subsp.\n\nvulgare var. vulgare, aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/263292/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-aetheroleum_en.pdf"},
    {"id":"12687","name":"Final Community herbal monograph on Primula veris L. and / or Primula elatior (L.) Hill, radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T01:00:00Z","last_updated_date":"2013-03-04T01:00:00Z","reference_number":"EMA/HMPC/104095/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-primula-veris-l-and-or-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"12822","name":"Superseded community herbal monograph on Foeniculum vulgare Miller subsp.vulgare var. dulce (Miller) Thellung, fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-08-06T02:00:00Z","last_updated_date":"2024-03-07T02:00:00Z","reference_number":"EMEA/HMPC/263293/2006 Corr","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-foeniculum-vulgare-miller-subspvulgare-var-dulce-miller-thellung-fructus_en.pdf"},
    {"id":"12840","name":"Superseded final community herbal monograph on Pimpinella anisum L., fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2014-06-17T02:09:21Z","reference_number":"EMEA/HMPC/137423/2006 Corr","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-pimpinella-anisum-l-fructus_en.pdf"},
    {"id":"12849","name":"Draft European Union herbal monograph on Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-02-10 - 2015-05-15","first_published_date":"2011-02-11T02:00:00Z","last_updated_date":"2015-02-10T15:40:00Z","reference_number":"EMA/HMPC/84990/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"12930","name":"Draft Community herbal monograph on Mentha x piperita L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/193909/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-mentha-x-piperita-l-folium_en.pdf"},
    {"id":"13075","name":"Final community herbal monograph on Eucalyptus globulus Labill., folium","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2013-04-19T12:00:00Z","last_updated_date":"2013-04-19T12:00:00Z","reference_number":"EMA/HMPC/892618/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-eucalyptus-globulus-labill-folium_en.pdf"},
    {"id":"13123","name":"Superseded community herbal monograph on Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-09-07T02:00:00Z","last_updated_date":"2007-09-07T02:00:00Z","reference_number":"EMEA/HMPC/143370/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"13164","name":"Superseded community herbal monograph on Centaurium erythraea Rafn, herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2009-03-12T00:09:21Z","last_updated_date":"2016-01-28T00:09:21Z","reference_number":"EMEA/HMPC/105536/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-centaurium-erythraea-rafn-herba_en.pdf"},
    {"id":"13293","name":"Superseded final community herbal monograph on Aesculus hippocastanum L., semen - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2020-04-23T02:00:00Z","reference_number":"EMEA/HMPC/225319/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-aesculus-hippocastanum-l-semen-first-version_en.pdf"},
    {"id":"13307","name":"Superseded community herbal monograph on Peumus boldus Molina, folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2009-01-14T00:09:21Z","last_updated_date":"2017-01-12T10:25:00Z","reference_number":"EMEA/HMPC/591648/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-peumus-boldus-molina-folium_en.pdf"},
    {"id":"13399","name":"Superseded Community herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-04-19T02:00:00Z","last_updated_date":"2018-04-11T14:00:00Z","reference_number":"EMA/HMPC/573460/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-1_en.pdf"},
    {"id":"13579","name":"Draft Community herbal monograph on Rhamnus purshianus D.C., cortex","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-03-08T00:09:21Z","last_updated_date":"2007-03-08T00:09:21Z","reference_number":"EMEA/HMPC/513579/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf"},
    {"id":"13658","name":"Draft Community herbal monograph on Phaseolus vulgaris L., fructus sine semine","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-03-12 - 2013-07-15","first_published_date":"2013-05-14T04:00:00Z","last_updated_date":"2013-05-14T04:00:00Z","reference_number":"EMA/HMPC/317319/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-phaseolus-vulgaris-l-fructus-sine-semine_en.pdf"},
    {"id":"14139","name":"Superseded community herbal monograph on Curcuma longa L., rhizoma - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2010-02-04T01:00:00Z","last_updated_date":"2010-02-04T01:00:00Z","reference_number":"EMA/HMPC/456845/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-curcuma-longa-l-rhizoma-first-version_en.pdf"},
    {"id":"14258","name":"Final community herbal monograph on Hamamelis virginiana L., cortex","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2019-12-04T02:00:00Z","reference_number":"EMA/HMPC/114583/2008 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-cortex_en.pdf"},
    {"id":"14369","name":"Draft community herbal monograph on Juniperus communis L., aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-05-15 - 2010-08-15","first_published_date":"2010-05-28T04:00:00Z","last_updated_date":"2010-05-28T04:00:00Z","reference_number":"EMA/HMPC/12402/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-juniperus-communis-l-aetheroleum_en.pdf"},
    {"id":"14414","name":"Draft Community herbal monograph on Capsicum annuum L.\n\nvar. minimum (Miller) Heiser and small fruited varieties of\n\nCapsicum frutescens L., fructus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-09-12 - 2014-12-15","first_published_date":"2014-09-12T04:00:00Z","last_updated_date":"2014-09-12T04:00:00Z","reference_number":"EMA/HMPC/674139/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-capsicum-annuum-l-var-minimum-miller-heiser-and-small-fruited-varieties-capsicum-frutescens-l-fructus_en.pdf"},
    {"id":"14615","name":"Superseded final Community herbal monograph on Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"EMA/HMPC/130042/2010, Corr 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"14644","name":"Final community herbal monograph on Urtica dioica L.; Urtica urens L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-17T01:00:00Z","last_updated_date":"2011-01-17T01:00:00Z","reference_number":"EMA/HMPC/508015/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-folium_en.pdf"},
    {"id":"14686","name":"Draft community herbal monograph on Salvia officinalis L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-01-14T01:00:00Z","last_updated_date":"2009-01-14T01:00:00Z","reference_number":"EMEA/HMPC/331653/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-salvia-officinalis-l-folium_en.pdf"},
    {"id":"15297","name":"Final European Union herbal monograph on Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T13:00:00Z","last_updated_date":"2015-04-09T13:00:00Z","reference_number":"EMA/HMPC/320930/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-melaleuca-alternifolia-maiden-and-betch-cheel-m-linariifolia-smith-m-dissitiflora-f-mueller-and-or-other-species-melaleuca-aetheroleum-first-version_en.pdf"},
    {"id":"15373","name":"Draft European Union herbal monograph on Vaccinium myrtillus L., fructus recens","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-02-09 - 2015-05-15","first_published_date":"2015-02-09T12:30:00Z","last_updated_date":"2015-02-09T12:30:00Z","reference_number":"EMA/HMPC/375808/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-vaccinium-myrtillus-l-fructus-recens_en.pdf"},
    {"id":"15401","name":"Draft Community herbal monograph on Marrubium vulgare L., herba - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-01-15 - 2013-04-15","first_published_date":"2013-01-28T02:00:00Z","last_updated_date":"2013-01-28T02:00:00Z","reference_number":"EMA/HMPC/604271/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-marrubium-vulgare-l-herba-first-version_en.pdf"},
    {"id":"15491","name":"Draft Community herbal monograph on Cetraria islandica (L.) Acharius s.l., thallus - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-05-19 - 2014-08-31","first_published_date":"2014-05-19T20:45:00Z","last_updated_date":"2014-05-19T20:45:00Z","reference_number":"EMA/HMPC/678891/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-cetraria-islandica-l-acharius-sl-thallus-first-version_en.pdf"},
    {"id":"15740","name":"Superseded final Community herbal monograph on Aesculus hippocastanum L., cortex - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-06-27T16:15:00Z","last_updated_date":"2012-06-27T16:15:00Z","reference_number":"EMA/HMPC/354156/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-aesculus-hippocastanum-l-cortex-first-version_en.pdf"},
    {"id":"16097","name":"Draft community herbal monograph on Hamamelis virginiana L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/114586/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-hamamelis-virginiana-l-folium_en.pdf"},
    {"id":"16212","name":"Final community herbal monograph on Tanacetum parthenium (L.) Schulz Bip., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-06-20T02:00:00Z","reference_number":"EMA/HMPC/587578/200","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-tanacetum-parthenium-l-schulz-bip-herba_en.pdf"},
    {"id":"16247","name":"Superseded final community herbal monograph on Valeriana officinalis L., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2006-10-26T02:09:21Z","last_updated_date":"2016-04-27T02:09:21Z","reference_number":"EMEA/HMPC/340719/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-valeriana-officinalis-l-radix_en.pdf"},
    {"id":"16327","name":"Final community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2020-04-08T01:00:00Z","reference_number":"EMA/HMPC/212895/2008 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf"},
    {"id":"16367","name":"Superseded final community herbal monograph on Linum usitatissimum L., semen","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2006-10-26T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMEA/HMPC/340849/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf"},
    {"id":"16431","name":"Draft Community herbal monograph on Commiphora molmol Engler, gummi-resina","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-09-01 - 2010-03-15","first_published_date":"2010-11-16T02:00:00Z","last_updated_date":"2010-11-16T02:00:00Z","reference_number":"EMA/HMPC/96911/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-commiphora-molmol-engler-gummi-resina_en.pdf"},
    {"id":"16437","name":"Superseded - Final Community herbal monograph on Aloe barbadensis Miller and on Aloe (various species, mainly Aloe ferox Miller and its hybrids)","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2006-10-26T02:00:00Z","last_updated_date":"2017-04-10T02:00:00Z","reference_number":"EMEA/HMPC/76310/2006 Corrigendum","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-aloe-barbadensis-miller-and-aloe-various-species-mainly-aloe-ferox-miller-and-its-hybrids_en.pdf"},
    {"id":"16576","name":"Draft community herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L., oleum - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-04-15 - 2011-08-15","first_published_date":"2011-04-20T04:00:00Z","last_updated_date":"2011-04-20T04:00:00Z","reference_number":"EMA/HMPC/277792/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-oenothera-biennis-l-oenothera-lamarckiana-l-oleum-first-version_en.pdf"},
    {"id":"16715","name":"Superseded community herbal monograph on Rosmarinus officinalis L., aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2024-09-20T01:00:00Z","reference_number":"EMA/HMPC/235453/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-rosmarinus-officinalis-l-aetheroleum_en.pdf"}    {"id":"16924","name":"Superseded final community herbal monograph on Echinacea purpurea (L.) Moench, herba recens","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2015-04-13T02:09:21Z","reference_number":"EMEA/HMPC/104945/2006 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-echinacea-purpurea-l-moench-herba-recens_en.pdf"},
    {"id":"17070","name":"Draft Community herbal monograph on Rheum palmatum L. and Rheum officinale Baillon, radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2007-07-05T02:09:21Z","reference_number":"EMEA/HMPC/189624/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-rheum-palmatum-l-and-rheum-officinale-baillon-radix_en.pdf"},
    {"id":"17095","name":"Final Community herbal monograph on Levisticum officinale Koch, radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T16:00:00Z","last_updated_date":"2013-02-22T16:00:00Z","reference_number":"EMA/HMPC/524621/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-levisticum-officinale-koch-radix_en.pdf"},
    {"id":"17174","name":"Final Community herbal monograph on Achillea millefolium L., flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-09-30T02:00:00Z","last_updated_date":"2011-09-30T02:00:00Z","reference_number":"EMA/HMPC/143949/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-achillea-millefolium-l-flos_en.pdf"},
    {"id":"17411","name":"Draft community herbal monograph on Calendula officinalis L., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2007-07-05T02:09:21Z","reference_number":"EMEA/HMPC/179281/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-calendula-officinalis-l-flos_en.pdf"},
    {"id":"17466","name":"Final Community herbal monograph on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich), rhizoma","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T13:00:00Z","last_updated_date":"2014-05-12T13:00:00Z","reference_number":"EMA/HMPC/604600/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-curcuma-xanthorrhiza-roxb-c-xanthorrhiza-d-dietrich-rhizoma_en.pdf"},
    {"id":"17638","name":"Draft community herbal monograph on Aesculus hippocastanum L., semen","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/225319/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-aesculus-hippocastanum-l-semen_en.pdf"},
    {"id":"17923","name":"Draft community herbal monograph on Arctium lappa L., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-01-14 - 2010-06-15","first_published_date":"2010-03-08T02:00:00Z","last_updated_date":"2010-03-08T02:00:00Z","reference_number":"EMA/HMPC/246763/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-arctium-lappa-l-radix_en.pdf"},
    {"id":"18043","name":"Draft Community herbal monograph on Eucalyptus globulus Labill., Eucalyptus polybractea R.T. Baker and/or Eucalyptus smithii R.T. Baker, aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-05-14 - 2013-11-15","first_published_date":"2013-07-31T20:30:00Z","last_updated_date":"2013-07-31T20:30:00Z","reference_number":"EMA/HMPC/307781/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-and-or-eucalyptus-smithii-rt-baker-aetheroleum_en.pdf"},
    {"id":"18234","name":"Final Community herbal monograph on Primula veris L. and / or Primula elatior (L.) Hill, flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T01:00:00Z","last_updated_date":"2013-03-04T01:00:00Z","reference_number":"EMA/HMPC/136582/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-primula-veris-l-and-or-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"18239","name":"Draft community herbal monograph on Betula pendula Roth; Betula pubescens Ehrh., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-05-08T02:09:21Z","last_updated_date":"2007-05-08T02:09:21Z","reference_number":"EMEA/HMPC/260019/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-betula-pendula-roth-betula-pubescens-ehrh-folium_en.pdf"},
    {"id":"18347","name":"Draft community herbal monograph on Cinnamomum verum J. S. Presl (Cinnamomum zeylanicum Nees), cortex","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-08-15 - 2010-12-15","first_published_date":"2010-08-20T04:00:00Z","last_updated_date":"2010-08-20T04:00:00Z","reference_number":"EMA/HMPC/246774/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-cinnamomum-verum-j-s-presl-cinnamomum-zeylanicum-nees-cortex_en.pdf"},
    {"id":"19266","name":"Final community herbal monograph on Ilex paraguariensis St. Hil., folium - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2011-01-28T01:00:00Z","reference_number":"EMA/HMPC/580539/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-ilex-paraguariensis-st-hil-folium-first-version_en.pdf"},
    {"id":"19299","name":"Final Community herbal monograph on Marrubium vulgare L., herba - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-08-01T17:00:00Z","last_updated_date":"2013-08-01T17:00:00Z","reference_number":"EMA/HMPC/604271/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-marrubium-vulgare-l-herba-first-version_en.pdf"},
    {"id":"19429","name":"Superseded final community herbal monograph on Thymus vulgaris L. and Thymus zygis L, herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T00:09:21Z","last_updated_date":"2014-06-03T01:09:21Z","reference_number":"EMEA/HMPC/234113/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba_en.pdf"},
    {"id":"19539","name":"Draft community herbal monograph on Arctostaphylos uvae ursi (L.) Spreng, folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-08-15 - 2010-12-15","first_published_date":"2010-08-18T04:00:00Z","last_updated_date":"2010-08-18T04:00:00Z","reference_number":"EMA/HMPC/573460/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-arctostaphylos-uvae-ursi-l-spreng-folium_en.pdf"},
    {"id":"19550","name":"Draft Community herbal monograph on Echinacea purpurea (l.) Moench., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-07-16T02:09:21Z","last_updated_date":"2009-07-16T02:09:21Z","reference_number":"EMEA/HMPC/577784/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-echinacea-purpurea-l-moench-radix_en.pdf"},
    {"id":"19827","name":"Superseded final community herbal monograph on Plantago afra L. et Plantago indica L., semen","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2006-10-26T02:09:21Z","last_updated_date":"2013-07-29T02:09:21Z","reference_number":"EMEA/HMPC/340865/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf"},
    {"id":"19841","name":"Final European Union herbal monograph on Hieracium pilosella L., herba cum radice - Superseded","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2015-06-17T13:25:00Z","last_updated_date":"2025-02-26T13:25:00Z","reference_number":"EMA/HMPC/680374/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-hieracium-pilosella-l-herba-cum-radice-superseded_en.pdf"},
    {"id":"19995","name":"Draft community herbal monograph on Passiflora incarnata L, herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-03-08T00:09:21Z","last_updated_date":"2007-03-08T00:09:21Z","reference_number":"EMEA/HMPC/230962/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-passiflora-incarnata-l-herba_en.pdf"},
    {"id":"20235","name":"Draft Community herbal monograph on Rubus idaeus L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-03-12 - 2013-09-15","first_published_date":"2013-05-03T04:00:00Z","last_updated_date":"2013-05-03T04:00:00Z","reference_number":"EMA/HMPC/44211/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-rubus-idaeus-l-folium_en.pdf"},
    {"id":"20252","name":"Final community herbal monograph on Juglans regia L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-01-17T01:00:00Z","last_updated_date":"2014-01-17T01:00:00Z","reference_number":"EMA/HMPC/346737/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-juglans-regia-l-folium_en.pdf"},
    {"id":"20311","name":"Draft Community herbal monograph on Zingiberis rhizoma","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-08-15 - 2011-12-15","first_published_date":"2011-09-20T04:00:00Z","last_updated_date":"2011-09-20T04:00:00Z","reference_number":"EMA/HMPC/749154/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-zingiberis-rhizoma_en.pdf"},
    {"id":"20439","name":"Final European Union herbal monograph on Eschscholzia californica Cham., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/HMPC/680372/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-eschscholzia-californica-cham-herba_en.pdf"},
    {"id":"20670","name":"Draft community herbal monograph on Cynara scolymus L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-01-15 - 2011-04-15","first_published_date":"2011-01-18T02:00:00Z","last_updated_date":"2011-01-18T02:00:00Z","reference_number":"EMA/HMPC/150218/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-cynara-scolymus-l-folium_en.pdf"},
    {"id":"20855","name":"Final European Union herbal monograph on Sisymbrium officinale (L.) Scop., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-10-30T01:00:00Z","last_updated_date":"2014-10-30T01:00:00Z","reference_number":"EMA/HMPC/280193/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-sisymbrium-officinale-l-scop-herba_en.pdf"},
    {"id":"21221","name":"Draft European Union herbal monograph on Carum carvi L., fructus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-12-22 - 2015-03-15","first_published_date":"2014-12-22T18:30:00Z","last_updated_date":"2014-12-22T18:30:00Z","reference_number":"EMA/HMPC/715092/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-carum-carvi-l-fructus_en.pdf"},
    {"id":"21300","name":"Draft Community herbal monograph on Barbados aloes (Aloe barbadensis) and cape aloes (Aloe capensis)","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-03-09T01:00:00Z","last_updated_date":"2006-03-09T01:00:00Z","reference_number":"EMEA/HMPC/76310/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-barbados-aloes-aloe-barbadensis-and-cape-aloes-aloe-capensis_en.pdf"},
    {"id":"21368","name":"Community herbal monograph on Cinnamomum verum J.S. Presl, cortex","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2011-08-05T02:00:00Z","reference_number":"EMA/HMPC/246774/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/community-herbal-monograph-cinnamomum-verum-js-presl-cortex_en.pdf"},
    {"id":"21513","name":"Superseded community herbal monograph on Hypericum perforatum L., herba (well-established medicinal use)","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2009-12-21T00:09:00Z","last_updated_date":"2023-02-22T00:09:00Z","reference_number":"EMA/HMPC/101304/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-hypericum-perforatum-l-herba-well-established-medicinal-use_en.pdf"},
    {"id":"21528","name":"Draft community herbal monograph on Ribes nigrum L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/HMPC/142986/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-ribes-nigrum-l-folium_en.pdf"},
    {"id":"21622","name":"Draft community herbal monograph on Thymus vulgaris L. and Thymus zygis L, herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-05-08T02:09:21Z","last_updated_date":"2007-05-08T02:09:21Z","reference_number":"EMEA/HMPC/234113/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba_en.pdf"},
    {"id":"21694","name":"Final European Union herbal monograph on Betula pendula Roth; Betula pubescens Ehrh., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/HMPC/573241/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-betula-pendula-roth-betula-pubescens-ehrh-folium_en.pdf"},
    {"id":"21762","name":"Draft Community herbal monograph on Hieracium pilosella L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-08-04 - 2014-10-31","first_published_date":"2014-08-04T16:30:00Z","last_updated_date":"2014-08-04T16:30:00Z","reference_number":"EMA/HMPC/680374/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-hieracium-pilosella-l-herba_en.pdf"},
    {"id":"21765","name":"Final community herbal monograph on Syzygium aromaticum (L.) Merill et L. M. Perry, floris aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T01:00:00Z","last_updated_date":"2011-12-21T01:00:00Z","reference_number":"EMA/HMPC/534924/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-syzygium-aromaticum-l-merill-et-l-m-perry-floris-aetheroleum_en.pdf"},
    {"id":"21835","name":"Superseded community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2022-10-03T01:00:00Z","reference_number":"EMA/HMPC/563408/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-agropyron-repens-l-p-beauv-rhizoma_en.pdf"},
    {"id":"21902","name":"Final community herbal monograph on Hamamelis virginiana L., folium cortex aut ramunculus destillatum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMA/HMPC/114584/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium-cortex-aut-ramunculus-destillatum_en.pdf"},
    {"id":"22632","name":"Final community herbal monograph on Taraxacum officinale Weber ex Wigg., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMA/HMPC/212895/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-folium_en.pdf"},
    {"id":"22715","name":"Draft community herbal monograph on Avena sativa L., fructus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-31T00:09:21Z","last_updated_date":"2007-10-31T00:09:21Z","reference_number":"EMEA/HMPC/368600/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-avena-sativa-l-fructus_en.pdf"},
    {"id":"22880","name":"Superseded community herbal monograph on Melissa officinalis L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"EMEA/HMPC/5341/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-melissa-officinalis-l-folium_en.pdf"},
    {"id":"22944","name":"Draft Community herbal monograph on Solanum dulcamara L., stipites","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2012-04-15 - 2012-08-15","first_published_date":"2012-05-10T04:00:00Z","last_updated_date":"2012-05-10T04:00:00Z","reference_number":"EMA/HMPC/734361/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-solanum-dulcamara-l-stipites_en.pdf"},
    {"id":"23018","name":"Draft community herbal monograph on Verbascum thapsus L., V. densiflorum Bertol (V. thapsiforme Schrad), and V. phlomoides L., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/HMPC/395213/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-verbascum-thapsus-l-v-densiflorum-bertol-v-thapsiforme-schrad-and-v-phlomoides-l-flos_en.pdf"},
    {"id":"23088","name":"Draft community herbal monograph on Althaea officinalis L., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2008-07-03T02:09:21Z","reference_number":"EMEA/HMPC/98717/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-althaea-officinalis-l-radix_en.pdf"},
    {"id":"23334","name":"Community herbal monograph on Cinnamomum verum J.S. Presl, corticis aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2011-08-05T02:00:00Z","reference_number":"EMA/HMPC/706229/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/community-herbal-monograph-cinnamomum-verum-js-presl-corticis-aetheroleum_en.pdf"},
    {"id":"23394","name":"Final Community herbal monograph on Lavandula angustifolia Miller, aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-06-13T18:00:00Z","last_updated_date":"2012-06-13T18:00:00Z","reference_number":"EMA/HMPC/143181/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-lavandula-angustifolia-miller-aetheroleum_en.pdf"},
    {"id":"23908","name":"Draft Community herbal monograph on Echinaceae angustifolia DC., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-04-15 - 2011-08-15","first_published_date":"2011-04-13T04:00:00Z","last_updated_date":"2011-04-13T04:00:00Z","reference_number":"EMA/HMPC/688216/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-echinaceae-angustifolia-dc-radix_en.pdf"},
    {"id":"23958","name":"Draft community herbal monograph on Orthosiphon stamineus Benth., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-07-16T02:09:21Z","last_updated_date":"2009-07-16T02:09:21Z","reference_number":"EMEA/HMPC/281496/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-orthosiphon-stamineus-benth-folium_en.pdf"},
    {"id":"23989","name":"Draft Community herbal monograph on Rhodiola rosea - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-08-15 - 2011-12-15","first_published_date":"2011-09-20T04:00:00Z","last_updated_date":"2011-09-20T04:00:00Z","reference_number":"EMA/HMPC/232091/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-rhodiola-rosea-first-version_en.pdf"},
    {"id":"24178","name":"Superseded community herbal monograph on Rosmarinus officinalis L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2024-09-26T01:00:00Z","reference_number":"EMA/HMPC/13633/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-rosmarinus-officinalis-l-folium_en.pdf"},
    {"id":"24243","name":"Draft Community herbal monograph on Mentha x piperita L., aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-05-08T02:00:00Z","last_updated_date":"2007-05-08T02:00:00Z","reference_number":"EMEA/HMPC/349466/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-mentha-x-piperita-l-aetheroleum_en.pdf"},
    {"id":"24262","name":"Draft Community herbal monograph on Cichorium intybus L., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2012-05-22 - 2012-10-15","first_published_date":"2012-06-15T15:00:00Z","last_updated_date":"2012-06-15T15:00:00Z","reference_number":"EMA/HMPC/121816/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-cichorium-intybus-l-radix_en.pdf"},
    {"id":"24276","name":"Draft community herbal monograph on Urtica dioica L., Urtica urens L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-05-08T02:00:00Z","last_updated_date":"2008-05-08T02:00:00Z","reference_number":"EMEA/HMPC/508015/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-folium_en.pdf"},
    {"id":"24280","name":"Final  European Union herbal monograph on Symphytum officinale L., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-06-05T02:00:00Z","last_updated_date":"2015-06-05T02:00:00Z","reference_number":"EMA/HMPC/572846/2009 Corr 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-symphytum-officinale-l-radix_en.pdf"},
    {"id":"24363","name":"Superseded Community herbal monograph on Echinacea pallida (Nutt.) Nutt., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:09:21Z","last_updated_date":"2018-08-14T02:09:21Z","reference_number":"EMEA/HMPC/332350/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-echinacea-pallida-nutt-nutt-radix_en.pdf"},
    {"id":"24685","name":"Final Community herbal monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-08-24T17:00:00Z","last_updated_date":"2012-08-24T17:00:00Z","reference_number":"EMA/HMPC/571119/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf"},
    {"id":"24796","name":"Draft community herbal monograph on Psyllium seed (Plantago afra et Plantago indica, semen)","type":"herbal-monograph","status":"Draft","consultation_date":"","first_published_date":"2005-10-24T02:09:21Z","last_updated_date":"2005-10-24T02:09:21Z","reference_number":"EMEA/HMPC/340865/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-psyllium-seed-plantago-afra-et-plantago-indica-semen_en.pdf"},
    {"id":"24988","name":"Draft Community herbal monograph on Senna leaf (Sennae folium)","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-01-11T00:09:21Z","last_updated_date":"2006-01-11T00:09:21Z","reference_number":"EMEA/HMPC/51869/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-senna-leaf-sennae-folium_en.pdf"},
    {"id":"24999","name":"Superseded community herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-08-06T02:09:21Z","last_updated_date":"2024-03-07T17:13:00Z","reference_number":" EMEA/HMPC/263293/2006 Corr","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf"},
    {"id":"25079","name":"Superseded Community herbal monograph on Urtica dioica L., Urtica urens L., their hybrids or their mixtures, radix - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-11-05T12:20:00Z","last_updated_date":"2025-03-12T12:20:00Z","reference_number":"EMA/HMPC/461160/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-their-hybrids-or-their-mixtures-radix-first-version_en.pdf"},
    {"id":"25163","name":"Draft Community herbal monograph on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-09-13 - 2012-02-15","first_published_date":"2011-10-20T04:00:00Z","last_updated_date":"2011-10-20T04:00:00Z","reference_number":"EMA/HMPC/337066/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-or-their-mixtures-flos-first-version_en.pdf"},
    {"id":"25285","name":"Final Community herbal monograph on Pimpinella anisum L., fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-06-17T02:00:00Z","last_updated_date":"2014-06-17T02:00:00Z","reference_number":"EMA/HMPC/321184/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-pimpinella-anisum-l-fructus_en.pdf"},
    {"id":"25565","name":"Final community herbal monograph on Lavandula angustifolia P. Mill., flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-06-13T17:00:00Z","last_updated_date":"2012-06-13T17:00:00Z","reference_number":"EMA/HMPC/734125/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-lavandula-angustifolia-p-mill-flos_en.pdf"},
    {"id":"25790","name":"Final community herbal monograph on Juniperus communis L., aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/HMPC/12402/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-juniperus-communis-l-aetheroleum_en.pdf"},
    {"id":"25955","name":"Draft Community herbal monograph on Crataegus spp., folium cum flore","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-10-14 - 2015-01-15","first_published_date":"2014-10-14T04:00:00Z","last_updated_date":"2014-10-14T04:00:00Z","reference_number":"EMA/HMPC/159075/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-crataegus-spp-folium-cum-flore_en.pdf"},
    {"id":"26088","name":"Superseded community herbal monograph on Equisetum arvense L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2016-03-17T01:09:21Z","reference_number":"EMEA/HMPC/394894/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-equisetum-arvense-l-herba_en.pdf"},
    {"id":"26104","name":"Final community herbal monograph on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl., semen","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-02-07T01:00:00Z","last_updated_date":"2012-02-07T01:00:00Z","reference_number":"EMA/HMPC/722367/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-cola-nitida-vent-schott-et-endl-and-its-varieties-and-cola-acuminata-p-beauv-schott-et-endl-semen_en.pdf"},
    {"id":"26144","name":"Draft Community herbal monograph on Levisticum officinale Koch, radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2012-03-27 - 2012-08-15","first_published_date":"2012-05-03T17:41:00Z","last_updated_date":"2012-05-03T17:41:00Z","reference_number":"EMA/HMPC/524621/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-levisticum-officinale-koch-radix_en.pdf"},
    {"id":"26243","name":"Superseded community herbal monograph on Pelargonium sidoides DC and / or Pelargonium reniforme Curt., radix - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-02-04T12:30:00Z","last_updated_date":"2018-08-20T13:30:00Z","reference_number":"EMA/HMPC/560961/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-pelargonium-sidoides-dc-and-or-pelargonium-reniforme-curt-radix-first-version_en.pdf"},
    {"id":"26259","name":"Draft Community herbal monograph on Curcuma xanthorrhiza roxb., rhizoma","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-06-19 - 2013-09-15","first_published_date":"2013-06-19T04:00:00Z","last_updated_date":"2013-06-19T04:00:00Z","reference_number":"EMA/HMPC/604600/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-curcuma-xanthorrhiza-roxb-rhizoma_en.pdf"},
    {"id":"26262","name":"Draft community herbal monograph on Centaurium erythraea Rafn., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2008-07-03T02:09:21Z","reference_number":"EMEA/HMPC/105536/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-centaurium-erythraea-rafn-herba_en.pdf"},
    {"id":"26403","name":"Draft Community herbal monograph on Cucurbita pepo L., semen","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-09-01 - 2012-02-15","first_published_date":"2011-10-17T04:00:00Z","last_updated_date":"2011-10-17T04:00:00Z","reference_number":"EMA/HMPC/136024/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-cucurbita-pepo-l-semen_en.pdf"},
    {"id":"26439","name":"Final community herbal monograph on Avena sativa L., fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/368600/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-avena-sativa-l-fructus_en.pdf"},
    {"id":"26553","name":"Final Community herbal monograph on Cichorium intybus L., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-03-14T16:00:00Z","last_updated_date":"2013-03-14T16:00:00Z","reference_number":"EMA/HMPC/121816/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-cichorium-intybus-l-radix_en.pdf"},
    {"id":"26609","name":"Final community herbal monograph on Humulus lupulus L., flos - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-08-07T02:00:00Z","last_updated_date":"2014-08-07T02:00:00Z","reference_number":"EMA/HMPC/682384/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"27125","name":"Draft Community herbal monograph on frangula bark (frangulae cortex)","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-03-09T01:00:00Z","last_updated_date":"2006-03-09T01:00:00Z","reference_number":"EMEA/HMPC/76307/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-frangula-bark-frangulae-cortex_en.pdf"},
    {"id":"27226","name":"Superseded final Community herbal monograph on Rhamnus frangula L., cortex - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2006-10-26T02:00:00Z","last_updated_date":"2006-10-26T02:00:00Z","reference_number":"EMEA/HMPC/76307/2006 Corrigendum","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-rhamnus-frangula-l-cortex-first-version_en.pdf"},
    {"id":"27371","name":"Draft Community herbal monograph on Eschscholzia californica Cham., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-07-31 - 2014-10-31","first_published_date":"2014-07-31T21:15:00Z","last_updated_date":"2014-07-31T21:15:00Z","reference_number":"EMA/HMPC/680372/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-eschscholzia-californica-cham-herba_en.pdf"},
    {"id":"27388","name":"Superseded community herbal monograph on Sambucus nigra L., flos - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2018-06-27T02:09:21Z","reference_number":"EMEA/HMPC/283166/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-sambucus-nigra-l-flos-first-version_en.pdf"},
    {"id":"27559","name":"Final Community herbal monograph on Ononis spinosa L., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-05-28T02:00:00Z","last_updated_date":"2014-05-28T02:00:00Z","reference_number":"EMA/HMPC/138319/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-ononis-spinosa-l-radix_en.pdf"},
    {"id":"27789","name":"Superseded community herbal monograph on Olea europaea L., folium - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-04-18T17:30:00Z","last_updated_date":"2012-04-18T17:30:00Z","reference_number":"EMA/HMPC/430507/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf"},
    {"id":"27848","name":"Final community herbal monograph on Quercus robur L., Quercus petraea. (Matt.) Liebl., Quercus pubescens Willd., cortex","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2011-01-28T01:00:00Z","reference_number":"EMA/HMPC/3203/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-quercus-robur-l-quercus-petraea-matt-liebl-quercus-pubescens-willd-cortex_en.pdf"},
    {"id":"28139","name":"Draft community herbal monograph on Urtica dioica L. and Urtica urens L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-09-07T02:00:00Z","last_updated_date":"2007-09-07T02:00:00Z","reference_number":"EMEA/HMPC/170261/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-urtica-dioica-l-and-urtica-urens-l-herba_en.pdf"},
    {"id":"28188","name":"Draft Community herbal monograph on Paullinia cupana Kunth ex H.B.K. var. sorbilis (Mart.) Ducke, semen - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2012-06-15 - 2012-10-15","first_published_date":"2012-06-25T14:07:00Z","last_updated_date":"2012-06-25T14:07:00Z","reference_number":"EMA/HMPC/897344/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-paullinia-cupana-kunth-ex-hbk-var-sorbilis-mart-ducke-semen-first-version_en.pdf"},
    {"id":"28190","name":"Superseded community herbal monograph on Melilotus officinalis (L.) Lam., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2018-04-23T02:00:00Z","reference_number":"EMEA/HMPC/354177/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"28435","name":"Superseded final community herbal monograph on Achillea millefolium L., herba - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-09-30T02:00:00Z","last_updated_date":"2011-09-30T02:00:00Z","reference_number":"EMA/HMPC/290284/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-achillea-millefolium-l-herba-first-version_en.pdf"},
    {"id":"28561","name":"Draft community herbal monograph on Ispaghula husk (Plantago ovate, tegumentum)","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-10-24T02:00:00Z","last_updated_date":"2005-10-24T02:00:00Z","reference_number":"EMEA/HMPC/340857/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-ispaghula-husk-plantago-ovate-tegumentum_en.pdf"},
    {"id":"28565","name":"European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-04-09 - 2015-07-15","first_published_date":"2015-04-09T04:00:00Z","last_updated_date":"2015-04-09T04:00:00Z","reference_number":"EMA/HMPC/712511/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-epilobium-angustifolium-l-and-or-epilobium-parviflorum-schreb-herba_en.pdf"},
    {"id":"28566","name":"Final community herbal monograph on Filipendula ulmaria (L.) Maxim., flos - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-09-29T02:00:00Z","last_updated_date":"2011-09-29T02:00:00Z","reference_number":"EMA/HMPC/434894/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-filipendula-ulmaria-l-maxim-flos-first-version_en.pdf"},
    {"id":"28740","name":"Draft community herbal monograph on Foeniculum vulgare Miller subsp.\n\nvulgare var. vulgare, aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-10-26T02:00:00Z","last_updated_date":"2006-10-26T02:00:00Z","reference_number":"EMEA/HMPC/263292/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-aetheroleum_en.pdf"},
    {"id":"28923","name":"Draft Community herbal monograph on Lavandula angustifolia Mill., aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-02-15 - 2011-08-15","first_published_date":"2011-02-11T02:00:00Z","last_updated_date":"2011-06-16T04:00:00Z","reference_number":"EMA/HMPC/143181/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-lavandula-angustifolia-mill-aetheroleum_en.pdf"},
    {"id":"28972","name":"Draft community herbal monograph on Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria (L.)), herba - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-01-15 - 2011-04-15","first_published_date":"2011-01-26T02:00:00Z","last_updated_date":"2011-01-26T02:00:00Z","reference_number":"EMA/HMPC/434881/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-filipendula-ulmaria-l-maxim-spiraea-ulmaria-l-herba-first-version_en.pdf"},
    {"id":"28996","name":"Draft community herbal monograph on Primula veris L., Primula elatior (L.) Hill, radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-03-08T01:00:00Z","last_updated_date":"2007-03-08T01:00:00Z","reference_number":"MEA/HMPC/143370/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-primula-veris-l-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"29043","name":"Draft community herbal monograph on Hypericum perforatum L., herba - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/101304/2008 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-hypericum-perforatum-l-herba-first-version_en.pdf"},
    {"id":"29095","name":"Final community herbal monograph on Arctium lappa L., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"EMA/HMPC/246763/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-arctium-lappa-l-radix_en.pdf"},
    {"id":"29120","name":"Draft community herbal monograph on Pimpinella anisum L., fructus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-09-15T02:09:21Z","last_updated_date":"2006-09-15T02:09:21Z","reference_number":"EMEA/HMPC/137423/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-pimpinella-anisum-l-fructus_en.pdf"},
    {"id":"29155","name":"Final community herbal monograph on Phaseolus vulgaris L., fructus sine semine","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-01-17T16:00:00Z","last_updated_date":"2014-01-17T16:00:00Z","reference_number":"EMA/HMPC/317319/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-phaseolus-vulgaris-l-fructus-sine-semine_en.pdf"},
    {"id":"29242","name":"Draft community herbal monograph on Humulus lupulus L., flos - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/513617/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-humulus-lupulus-l-flos-first-version_en.pdf"},
    {"id":"29374","name":"Final community herbal monograph on Solidago virgaurea L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/285758/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-solidago-virgaurea-l-herba_en.pdf"},
    {"id":"29382","name":"Draft Community herbal monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-08-15 - 2011-11-15","first_published_date":"2011-08-19T04:00:00Z","last_updated_date":"2011-08-19T04:00:00Z","reference_number":"EMA/HMPC/571119/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-glycyrrhiza-glabra-l-and-or-glycyrrhiza-inflata-bat-and-or-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf"},
    {"id":"29398","name":"Draft Community herbal monograph on Senna pods, Alexandrian (Sennae fructus acutifoliae) and Senna pods, Tinnevelly (Sennae fructus angustifoliae)","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-01-11T00:09:21Z","last_updated_date":"2006-01-11T00:09:21Z","reference_number":"EMEA/HMPC/51871/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-senna-pods-alexandrian-sennae-fructus-acutifoliae-and-senna-pods-tinnevelly-sennae-fructus-angustifoliae_en.pdf"}    {"id":"29686","name":"Draft community herbal monograph on Avena sativa L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-31T00:09:21Z","last_updated_date":"2007-10-31T00:09:21Z","reference_number":"EMEA/HMPC/202966/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-avena-sativa-l-herba_en.pdf"},
    {"id":"29903","name":"Final community herbal monograph on Leonurus cardiaca L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/HMPC/127428/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-leonurus-cardiaca-l-herba_en.pdf"},
    {"id":"29936","name":"Draft community herbal monograph on Rosmarinus officinalis L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/HMPC/13633/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-rosmarinus-officinalis-l-folium_en.pdf"},
    {"id":"29969","name":"Superseded Community herbal monograph on Gentiana Lutea L., radix  - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2010-03-08T01:00:00Z","last_updated_date":"2019-04-30T01:00:00Z","reference_number":"EMA/HMPC/578324/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-gentiana-lutea-l-radix-first-version_en.pdf"},
    {"id":"30049","name":"Draft community herbal monograph on Trigonella foenumgraecum L., semen","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-05-15 - 2010-09-15","first_published_date":"2010-06-10T04:00:00Z","last_updated_date":"2010-06-10T04:00:00Z","reference_number":"EMA/HMPC/146221/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-trigonella-foenumgraecum-l-semen_en.pdf"},
    {"id":"30225","name":"Draft community herbal monograph on Chamaemelum nobile (L.) All., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-02-15 - 2011-06-15","first_published_date":"2011-02-14T02:00:00Z","last_updated_date":"2011-02-14T02:00:00Z","reference_number":"EMA/HMPC/560734/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-chamaemelum-nobile-l-all-flos_en.pdf"},
    {"id":"30320","name":"Draft community herbal monograph on Melissa officinalis L., leaf","type":"herbal-monograph","status":"Draft","consultation_date":"","first_published_date":"2016-01-21T01:00:00Z","last_updated_date":"2016-01-21T01:00:00Z","reference_number":"EMEA/HMPC/5341/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-melissa-officinalis-l-leaf_en.pdf"},
    {"id":"30442","name":"Final Community herbal monograph on Thymus vulgaris L., Thymus zygis Loefl. ex. L., aetheroleum - Superseded","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/HMPC/131901/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-thymus-vulgaris-l-thymus-zygis-loefl-ex-l-aetheroleum-superseded_en.pdf"},
    {"id":"30547","name":"Superseded Community herbal monograph on Cassia senna L, fructus and Cassia angustifolia Vahl, fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2006-10-26T02:09:00Z","last_updated_date":"2006-10-26T02:09:00Z","reference_number":"EMEA/HMPC/51871/2006 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-cassia-senna-l-fructus-and-cassia-angustifolia-vahl-fructus_en.pdf"},
    {"id":"30563","name":"Draft Community herbal monograph on Olea europaea L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-02-15 - 2011-08-15","first_published_date":"2011-02-11T02:00:00Z","last_updated_date":"2011-06-16T04:00:00Z","reference_number":"EMA/HMPC/430507/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-olea-europaea-l-folium_en.pdf"},
    {"id":"30608","name":"Final Community herbal monograph on Arnica montana L., flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/HMPC/198793/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-arnica-montana-l-flos_en.pdf"},
    {"id":"30803","name":"Final Community herbal monograph on Plantago ovata Forssk., semen","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T15:30:00Z","last_updated_date":"2013-07-23T15:30:00Z","reference_number":"EMA/HMPC/304390/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-ovata-forssk-semen_en.pdf"},
    {"id":"30856","name":"Final Community herbal monograph on Fraxinus excelsior L. or\n\nFraxinus angustifolia Vahl, folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T16:40:00Z","last_updated_date":"2012-06-18T16:40:00Z","reference_number":"EMA/HMPC/239271/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-fraxinus-excelsior-l-or-fraxinus-angustifolia-vahl-folium_en.pdf"},
    {"id":"31201","name":"Draft community herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-09-17T02:09:21Z","last_updated_date":"2009-09-17T02:09:21Z","reference_number":"EMEA/HMPC/600717/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-first-version_en.pdf"},
    {"id":"31369","name":"Draft community herbal monograph on Echinacea purpurea (L.) Moench, herba recens","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-03-08T00:09:21Z","last_updated_date":"2007-03-08T00:09:21Z","reference_number":"EMEA/HMPC/104945/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-echinacea-purpurea-l-moench-herba-recens_en.pdf"},
    {"id":"31481","name":"Draft community herbal monograph on Solidago virgaurea L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/HMPC/285758/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-solidago-virgaurea-l-herba_en.pdf"},
    {"id":"31497","name":"Draft Community herbal monograph on Agrimonia eupatoria L., herba - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-05-23 - 2014-08-31","first_published_date":"2014-05-23T04:00:00Z","last_updated_date":"2014-05-23T04:00:00Z","reference_number":"EMA/HMPC/680597/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-agrimonia-eupatoria-l-herba-first-version_en.pdf"},
    {"id":"31503","name":"Draft Community herbal monograph on Pelargonium sidoides DC and / or Pelargonium reniforme Curt., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-03-31 - 2011-08-15","first_published_date":"2011-04-26T04:00:00Z","last_updated_date":"2011-04-26T04:00:00Z","reference_number":"EMA/HMPC/560961/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-pelargonium-sidoides-dc-and-or-pelargonium-reniforme-curt-radix_en.pdf"},
    {"id":"31554","name":"Final Community herbal monograph on Capsella bursa-pastoris (L.) Medikus, herba  - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T15:30:00Z","last_updated_date":"2011-12-22T15:30:00Z","reference_number":"EMA/HMPC/262766/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-capsella-bursa-pastoris-l-medikus-herba-first-version_en.pdf"},
    {"id":"31635","name":"Draft community herbal monograph on Artemisia absinthium L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/234463/2008 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-artemisia-absinthium-l-herba_en.pdf"},
    {"id":"31739","name":"Superseded community herbal monograph on Vitis vinifera L., folium - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"EMA/HMPC/16635/2009 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-vitis-vinifera-l-folium-first-version_en.pdf"},
    {"id":"31819","name":"Draft community herbal monograph on Juniperus communis L., pseudo-fructus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-01-14T01:00:00Z","last_updated_date":"2009-01-14T01:00:00Z","reference_number":"EMEA/HMPC/441929/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-juniperus-communis-l-pseudo-fructus_en.pdf"},
    {"id":"32152","name":"Draft Community herbal monograph on Ononis spinosa L., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-08-19 - 2013-12-15","first_published_date":"2013-08-19T17:59:00Z","last_updated_date":"2013-08-19T17:59:00Z","reference_number":"EMA/HMPC/138317/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-ononis-spinosa-l-radix_en.pdf"},
    {"id":"32345","name":"Final European Union herbal monograph on Cetraria islandica (L.) Acharius s.l., thallus - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-02-11T11:45:00Z","last_updated_date":"2015-02-11T11:45:00Z","reference_number":"EMA/HMPC/678891/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cetraria-islandica-l-acharius-sl-thallus-first-version_en.pdf"},
    {"id":"32486","name":"Final community herbal monograph on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2014-10-06T02:09:21Z","reference_number":"EMEA/HMPC/244569/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf-0"},
    {"id":"32516","name":"Draft community herbal monograph on Curcuma longa L., rhizoma","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-11-06T00:09:21Z","last_updated_date":"2008-11-06T00:09:21Z","reference_number":"EMEA/HMPC/456845/2008 Corr","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-curcuma-longa-l-rhizoma_en.pdf"},
    {"id":"32567","name":"Final European Union herbal monograph on Agrimonia eupatoria L., herba - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T13:00:00Z","last_updated_date":"2015-04-09T13:00:00Z","reference_number":"EMA/HMPC/680597/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-agrimonia-eupatoria-l-herba-first-version_en.pdf"},
    {"id":"32909","name":"Draft community herbal monograph on Tanacetum parthenium (L.) Schulz Bip., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-05-15 - 2010-08-15","first_published_date":"2010-05-28T04:00:00Z","last_updated_date":"2010-05-28T04:00:00Z","reference_number":"EMA/HMPC/587578/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-tanacetum-parthenium-l-schulz-bip-herba_en.pdf"},
    {"id":"33012","name":"Final Community herbal monograph on Commiphora molmol Engler, gummi-resina","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T15:00:00Z","last_updated_date":"2011-12-22T15:00:00Z","reference_number":"EMA/HMPC/96911/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-commiphora-molmol-engler-gummi-resina_en.pdf"},
    {"id":"33175","name":"Draft community herbal monograph on Syzygium aromaticum (L.) Merill et L. M. Perry, floris aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-01-27 - 2011-06-15","first_published_date":"2011-02-10T02:00:00Z","last_updated_date":"2011-02-10T02:00:00Z","reference_number":"EMA/HMPC/534924/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-syzygium-aromaticum-l-merill-et-l-m-perry-floris-aetheroleum_en.pdf"},
    {"id":"33250","name":"Draft Community herbal monograph on Matricaria recutita L., flos - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-07-24 - 2014-10-31","first_published_date":"2014-07-24T19:50:00Z","last_updated_date":"2014-07-24T19:50:00Z","reference_number":"EMA/HMPC/55843/2011 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-matricaria-recutita-l-flos-first-version_en.pdf"},
    {"id":"33319","name":"Final community herbal monograph on Avena sativa L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/202966/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-avena-sativa-l-herba_en.pdf"},
    {"id":"33473","name":"Draft community herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-10-26T02:09:21Z","last_updated_date":"2006-10-26T02:09:21Z","reference_number":"EMEA/HMPC/137428/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf"},
    {"id":"33749","name":"Superseded community herbal monograph on Primula veris L. and Primula elatior (L.) Hill, flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-09-07T02:00:00Z","last_updated_date":"2007-09-07T02:00:00Z","reference_number":"EMEA/HMPC/64684/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-primula-veris-l-and-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"33786","name":"Superseded community herbal monograph on Plantago ovata Forssk., semen","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2006-10-26T02:00:00Z","last_updated_date":"2013-07-23T02:00:00Z","reference_number":"EMEA/HMPC/340861/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-plantago-ovata-forssk-semen_en.pdf"},
    {"id":"33839","name":"Final community herbal monograph on Viola tricolor L.","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/HMPC/131734/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-viola-tricolor-l_en.pdf"},
    {"id":"34150","name":"Draft Community herbal monograph on Rosa centifolia L.; Rosa gallica L.; Rosa damascena Mill., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-12-20 - 2014-04-15","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2013-12-20T13:00:00Z","reference_number":"EMA/HMPC/137299/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-rosa-centifolia-l-rosa-gallica-l-rosa-damascena-mill-flos_en.pdf"},
    {"id":"34180","name":"Draft community herbal monograph on Ruscus aculeatus L, rhizome - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-09-07T02:00:00Z","last_updated_date":"2007-09-07T02:00:00Z","reference_number":"EMEA/HMPC/261938/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-ruscus-aculeatus-l-rhizome-first-version_en.pdf"},
    {"id":"34412","name":"Superseded community herbal monograph on Urtica dioica L. and Urtica urens L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2025-03-07T02:00:00Z","reference_number":"EMEA/HMPC/170261/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-herba_en.pdf"},
    {"id":"34430","name":"Superseded Community herbal monograph on Rheum palmatum L. and Rheum officinale Baillon, radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T00:09:00Z","last_updated_date":"2020-08-18T00:09:00Z","reference_number":"EMEA/HMPC/189624/2007Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-rheum-palmatum-l-and-rheum-officinale-baillon-radix_en.pdf"},
    {"id":"34762","name":"Final Community herbal monograph on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-07-10T14:00:00Z","last_updated_date":"2012-07-10T14:00:00Z","reference_number":"EMA/HMPC/337066/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-or-their-mixtures-flos-first-version_en.pdf"},
    {"id":"34864","name":"Final Community herbal monograph on Plantago ovata Forssk., seminis tegumentum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T16:00:00Z","last_updated_date":"2013-07-23T16:00:00Z","reference_number":"EMA/HMPC/199774/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-ovata-forssk-seminis-tegumentum_en.pdf"},
    {"id":"34940","name":"Draft community herbal monograph on Pimpinella anisum L., aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-09-15T02:09:21Z","last_updated_date":"2006-09-15T02:09:21Z","reference_number":"EMEA/HMPC/263273/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-pimpinella-anisum-l-aetheroleum_en.pdf"},
    {"id":"35031","name":"Draft community herbal monograph on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2007-07-05T02:09:21Z","reference_number":"EMEA/HMPC/244569/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf"},
    {"id":"35051","name":"Superseded Community herbal monograph on Vitex agnus-castus L., fructus - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2018-10-10T02:00:00Z","reference_number":"EMA/HMPC/144006/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-vitex-agnus-castus-l-fructus-first-version_en.pdf"},
    {"id":"35113","name":"Superseded community herbal monograph on Althaea officinalis L., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2009-05-14T02:09:21Z","last_updated_date":"2016-11-04T14:47:00Z","reference_number":"EMEA/HMPC/98717/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-althaea-officinalis-l-radix_en.pdf"},
    {"id":"35207","name":"Draft Community herbal monograph on Origanum dictamnus L., herba - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2012-12-15 - 2013-04-15","first_published_date":"2013-02-04T13:35:00Z","last_updated_date":"2013-02-04T13:35:00Z","reference_number":"EMA/HMPC/200429/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-origanum-dictamnus-l-herba-first-version_en.pdf"},
    {"id":"35329","name":"Final Community herbal monograph on Echinacea angustifolia DC., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T16:30:00Z","last_updated_date":"2012-05-29T16:30:00Z","reference_number":"EMA/HMPC/688216/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-echinacea-angustifolia-dc-radix_en.pdf"},
    {"id":"35557","name":"Superseded - Community herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2018-07-03T02:00:00Z","reference_number":"EMA/HMPC/600717/2007 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-first-version_en.pdf"},
    {"id":"35674","name":"Draft community herbal monograph on Hamamelis virginiana L., cortex","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-11-06T00:09:21Z","last_updated_date":"2008-11-06T00:09:21Z","reference_number":"EMEA/HMPC/114583/2008 Corr","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-hamamelis-virginiana-l-cortex_en.pdf"},
    {"id":"35828","name":"Draft Community herbal monograph on Thymus vulgaris L. and Thymus zygis Loefl. ex L., aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-05-14T02:09:21Z","last_updated_date":"2009-05-14T02:09:21Z","reference_number":"EMEA/HMPC/131901/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-loefl-ex-l-aetheroleum_en.pdf"},
    {"id":"35846","name":"Superseded final community herbal monograph on Verbascum thapsus L., V. densiflorum Bertol and V. phlomoides L., flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/HMPC/395213/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-verbascum-thapsus-l-v-densiflorum-bertol-and-v-phlomoides-l-flos_en.pdf"},
    {"id":"36082","name":"Draft Community herbal monograph on Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-monograph","status":"Draft","consultation_date":"2013-03-12 - 2013-07-15","first_published_date":"2013-04-19T04:00:00Z","last_updated_date":"2013-04-19T04:00:00Z","reference_number":"EMA/HMPC/283630/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"36545","name":"Final Community herbal monograph on Pimpinella anisum L., aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-06-18T02:00:00Z","last_updated_date":"2014-06-18T02:00:00Z","reference_number":"EMEA/HMPC/321185/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-pimpinella-anisum-l-aetheroleum_en.pdf"},
    {"id":"36665","name":"Draft European Union herbal monograph on Carum carvi L. aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2014-12-22 - 2015-03-15","first_published_date":"2014-12-22T18:15:00Z","last_updated_date":"2014-12-22T18:15:00Z","reference_number":"EMA/HMPC/715094/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"36787","name":"Final Community herbal monograph on Cucurbita pepo L., semen","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/HMPC/136024/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-cucurbita-pepo-l-semen_en.pdf"},
    {"id":"36826","name":"Final Community herbal monograph on Paullinia cupana Kunth ex H.B.K. var. sorbilis (Mart.) Ducke, semen - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/HMPC/897344/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-paullinia-cupana-kunth-ex-hbk-var-sorbilis-mart-ducke-semen-first-version_en.pdf"},
    {"id":"36854","name":"Superseded final community herbal monograph on ,Passiflora incarnate L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-09-07T02:09:21Z","last_updated_date":"2014-06-18T02:09:21Z","reference_number":"EMEA/HMPC/230962/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-passiflora-incarnate-l-herba_en.pdf"},
    {"id":"36931","name":"Superseded community herbal monograph on Juniperus communis L., pseudo-fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2023-06-13T01:00:00Z","reference_number":"EMA/HMPC/441929/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-juniperus-communis-l-pseudo-fructus_en.pdf"},
    {"id":"36997","name":"Draft community herbal monograph on Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria (L.)), flos - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-01-15 - 2011-04-15","first_published_date":"2011-01-26T02:00:00Z","last_updated_date":"2011-01-26T02:00:00Z","reference_number":"EMA/HMPC/434894/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-filipendula-ulmaria-l-maxim-spiraea-ulmaria-l-flos-first-version_en.pdf"},
    {"id":"37180","name":"Draft community herbal monograph on Leonurus cardiaca L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-05-15 - 2010-08-15","first_published_date":"2010-05-26T04:00:00Z","last_updated_date":"2010-05-26T04:00:00Z","reference_number":"EMA/HMPC/127428/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-leonurus-cardiaca-l-herba_en.pdf"},
    {"id":"37246","name":"Superseded Community herbal monograph on Rhamnus purshianus D.C., cortex","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-09-07T02:09:00Z","last_updated_date":"2007-09-07T02:09:00Z","reference_number":"EMEA/HMPC/513579/2006Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf"},
    {"id":"37289","name":"Superseded community herbal monograph on Betula pendula Roth; Betula pubescens Ehrh., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2007-05-08T02:09:21Z","last_updated_date":"2015-03-13T01:09:21Z","reference_number":"EMEA/HMPC/260019/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-betula-pendula-roth-betula-pubescens-ehrh-folium_en.pdf"},
    {"id":"37339","name":"Draft community herbal monograph on Vitis vinifera L. var. tinctoria, folium (red vine leaf)","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2009-11-12 - 2010-04-15","first_published_date":"2009-12-21T01:09:21Z","last_updated_date":"2010-01-22T01:00:00Z","reference_number":"EMA/HMPC/16635/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-vitis-vinifera-l-var-tinctoria-folium-red-vine-leaf_en.pdf"},
    {"id":"37573","name":"Final community herbal monograph on Linum usitatissimum L., semen","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-07-13T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMA/HMPC/377675/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf"},
    {"id":"37637","name":"Final Community herbal monograph on Grindelia robusta Nutt., Grindelia squarrosa (Pursh) Dunal, Grindelia humilis Hook. et Arn., Grindelia camporum Greene, herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-03-11T11:00:00Z","last_updated_date":"2013-03-11T11:00:00Z","reference_number":"EMA/HMPC/748220/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-grindelia-robusta-nutt-grindelia-squarrosa-pursh-dunal-grindelia-humilis-hook-et-arn-grindelia-camporum-greene-herba_en.pdf"},
    {"id":"37885","name":"Final Community herbal monograph on Thymus vulgaris L. and Thymus zygis L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-06-02T02:00:00Z","last_updated_date":"2014-06-02T02:00:00Z","reference_number":"EMA/HMPC/342332/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba_en.pdf"},
    {"id":"38079","name":"Draft community herbal monograph on Ilex paraguariensis St. Hil., folium - First time","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/HMPC/580539/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-ilex-paraguariensis-st-hil-folium-first-time_en.pdf"},
    {"id":"38325","name":"Superseded final community herbal monograph on Humulus lupulus L., flos - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2008-07-11T02:00:00Z","last_updated_date":"2014-08-07T02:00:00Z","reference_number":"EMEA/HMPC/513617/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-humulus-lupulus-l-flos-first-version_en.pdf"},
    {"id":"38480","name":"Draft Community herbal monograph on Achillea millefolium L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-11-15 - 2011-02-15","first_published_date":"2010-11-09T02:00:00Z","last_updated_date":"2010-11-09T02:00:00Z","reference_number":"EMA/HMPC/290284/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-achillea-millefolium-l-herba_en.pdf"},
    {"id":"38585","name":"Final European Union herbal monograph on Capsicum annuum L. var. minimum (Miller) Heiser and small fruited varieties of Capsicum frutescens L., fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/HMPC/674139/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-capsicum-annuum-l-var-minimum-miller-heiser-and-small-fruited-varieties-capsicum-frutescens-l-fructus_en.pdf"},
    {"id":"38841","name":"Draft community herbal monograph on Rosmarinus officinalis L., aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/HMPC/235453/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-rosmarinus-officinalis-l-aetheroleum_en.pdf"},
    {"id":"38845","name":"Draft Community herbal monograph on Fucus vesiculosus L., thallus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-08-19 - 2013-11-15","first_published_date":"2013-08-19T04:00:00Z","last_updated_date":"2013-08-19T04:00:00Z","reference_number":"EMA/HMPC/313674/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-fucus-vesiculosus-l-thallus_en.pdf"},
    {"id":"38878","name":"Draft community herbal monograph on Cinnamomum verum J.S. Presl (Cinnamomum zeylanicum Nees), aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-08-15 - 2010-12-15","first_published_date":"2010-08-20T04:00:00Z","last_updated_date":"2010-08-20T04:00:00Z","reference_number":"EMA/HMPC/706229/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-cinnamomum-verum-js-presl-cinnamomum-zeylanicum-nees-aetheroleum_en.pdf"},
    {"id":"38939","name":"Superseded Community herbal monograph on Cassia senna L. and Cassia angustifolia Vahl, folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2006-10-26T02:09:00Z","last_updated_date":"2006-10-26T02:09:00Z","reference_number":"EMEA/HMPC/51869/2006 Corrigendum","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-cassia-senna-l-and-cassia-angustifolia-vahl-folium_en.pdf"},
    {"id":"40023","name":"Draft community herbal monograph on Echinacea pallida Nutt., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/332350/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-echinacea-pallida-nutt-radix_en.pdf"},
    {"id":"40445","name":"Final Community herbal monograph on Plantago afra L. et Plantago indica L., semen","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-07-29T15:30:00Z","last_updated_date":"2013-07-29T15:30:00Z","reference_number":"EMA/HMPC/599747/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf"},
    {"id":"40615","name":"Final community herbal monograph on Hamamelis virginiana L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMA/HMPC/114586/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-hamamelis-virginiana-l-folium_en.pdf"},
    {"id":"40681","name":"Draft Community herbal monograph on Achillea millefolium L., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2010-11-15 - 2011-02-15","first_published_date":"2010-11-09T02:00:00Z","last_updated_date":"2010-11-09T02:00:00Z","reference_number":"EMA/HMPC/143949/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-achillea-millefolium-l-flos_en.pdf"},
    {"id":"40707","name":"Draft community herbal monograph on Fraxinus excelsior L. and Fraxinus angustifolia Vahl, folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-08-15 - 2011-11-15","first_published_date":"2011-08-30T04:00:00Z","last_updated_date":"2011-08-30T04:00:00Z","reference_number":"EMA/HMPC/239271/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-fraxinus-excelsior-l-and-fraxinus-angustifolia-vahl-folium_en.pdf"},
    {"id":"40736","name":"Draft Community herbal monograph on Plantaginis lanceolatae folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2011-01-15 - 2011-04-15","first_published_date":"2011-01-26T02:00:00Z","last_updated_date":"2011-01-26T02:00:00Z","reference_number":"EMA/HMPC/437858/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-plantaginis-lanceolatae-folium_en.pdf"},
    {"id":"40800","name":"Draft community herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-05-14T02:09:21Z","last_updated_date":"2009-05-14T02:09:21Z","reference_number":"EMEA/HMPC/585558/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos_en.pdf"},
    {"id":"40946","name":"Superseded community herbal monograph on Echinacea purpurea (L.) Moench, radix - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2011-01-28T01:00:00Z","reference_number":"EMA/HMPC/577784/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-echinacea-purpurea-l-moench-radix-first-version_en.pdf"},
    {"id":"41408","name":"Final Community herbal monograph on Eucalyptus globulus Labill., Eucalyptus polybractea R.T. Baker and/or Eucalyptus smithii R.T. Baker, aetheroleum - Superseded","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2025-02-28T02:00:00Z","reference_number":"EMA/HMPC/307781/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-or-eucalyptus-smithii-rt-baker-aetheroleum-superseded_en.pdf"},
    {"id":"41655","name":"Draft Community herbal monograph on Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2013-08-21 - 2013-12-15","first_published_date":"2013-08-21T04:00:00Z","last_updated_date":"2013-08-21T04:00:00Z","reference_number":"EMA/HMPC/320930/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-community-herbal-monograph-melaleuca-alternifolia-maiden-and-betch-cheel-m-linariifolia-smith-m-dissitiflora-f-mueller-and-or-other-species-melaleuca-aetheroleum-first-version_en.pdf"},
    {"id":"43721","name":"Draft European Union herbal monograph on Rhamnus frangula L., cortex - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2019-02-15 - 2019-05-15","first_published_date":"2019-02-15T10:00:00Z","last_updated_date":"2019-02-15T10:00:00Z","reference_number":"EMA/HMPC/726261/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-rhamnus-frangula-l-cortex-revision-1_en.pdf"},
    {"id":"43859","name":"Superseded European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T18:32:00Z","last_updated_date":"2018-08-20T18:32:00Z","reference_number":"EMA/HMPC/560961/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-european-union-herbal-monograph-pelargonium-sidoides-dc-andor-pelargonium-reniforme-curt-radix-first-version_en.pdf"},
    {"id":"43863","name":"Final European Union herbal monograph on Malva sylvestris L., flos - First version","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2019-03-19T12:26:00Z","last_updated_date":"2019-03-19T12:26:00Z","reference_number":"EMA/HMPC/749511/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-malva-sylvestris-l-flos-first-version_en.pdf"},
    {"id":"44419","name":"European Union herbal monograph on Ruscus aculeatus L., rhizoma - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2019-05-02T17:39:00Z","last_updated_date":"2019-05-02T17:39:00Z","reference_number":"EMA/HMPC/188804/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-ruscus-aculeatus-l-rhizoma-revision-1_en.pdf"},
    {"id":"44728","name":"Draft European Union herbal monograph on Mentha x piperita L., aetheroleum - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2019-06-15 - 2019-09-15","first_published_date":"2019-06-18T10:47:00Z","last_updated_date":"2019-06-18T10:47:00Z","reference_number":"EMA/HMPC/522410/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-mentha-x-piperita-l-aetheroleum-revision-1_en.pdf"},
    {"id":"44737","name":"Draft European Union herbal monograph on Aesculus hippocastanum L., semen - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2019-06-15 - 2019-09-15","first_published_date":"2019-06-18T16:03:00Z","last_updated_date":"2019-06-18T16:03:00Z","reference_number":"EMA/HMPC/628242/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-aesculus-hippocastanum-l-semen-revision-1_en.pdf"},
    {"id":"45692","name":"Draft European Union herbal monograph on Rhamnus purshiana DC., cortex - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2019-10-15 - 2020-01-15","first_published_date":"2019-10-15T11:03:00Z","last_updated_date":"2019-10-15T11:03:00Z","reference_number":"EMA/HMPC/726270/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-rhamnus-purshiana-dc-cortex-revision-1_en.pdf"},
    {"id":"45693","name":"Draft European Union herbal monograph on Rheum palmatum L. and Rheum officinale Baillon, radix - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2019-10-15 - 2020-01-15","first_published_date":"2019-10-15T11:03:00Z","last_updated_date":"2019-10-15T11:03:00Z","reference_number":"EMA/HMPC/113700/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-rheum-palmatum-l-and-rheum-officinale-baillon-radix-revision-1_en.pdf"},
    {"id":"45694","name":"Draft European Union herbal monograph on Tanacetum parthenium (L.) Schultz Bip., herba - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2019-10-15 - 2020-01-15","first_published_date":"2019-10-15T11:03:00Z","last_updated_date":"2019-10-15T11:03:00Z","reference_number":"EMA/HMPC/48715/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-tanacetum-parthenium-l-schultz-bip-herba-revision-1_en.pdf"},
    {"id":"45695","name":"Draft European Union herbal monograph on Thymus vulgaris L., Thymus zygis L., aetheroleum - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2019-10-15 - 2020-01-15","first_published_date":"2019-10-15T11:03:00Z","last_updated_date":"2019-10-15T11:03:00Z","reference_number":"EMA/HMPC/59032/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-thymus-vulgaris-l-thymus-zygis-l-aetheroleum-revision-1_en.pdf"},
    {"id":"46228","name":"European Union herbal monograph on Rhamnus frangula L., cortex - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2019-12-04T09:00:00Z","last_updated_date":"2019-12-04T09:00:00Z","reference_number":"EMA/HMPC/726261/2016 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-rhamnus-frangula-l-cortex-revision-1_en.pdf"},
    {"id":"46339","name":"Draft European Union herbal monograph on Herniaria glabra L., H. hirsuta L., H. incana Lam., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2019-12-19 - 2020-03-15","first_published_date":"2019-12-19T12:39:00Z","last_updated_date":"2019-12-19T12:39:00Z","reference_number":"EMA/HMPC/554043/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-herniaria-glabra-l-h-hirsuta-l-h-incana-lam-herba_en.pdf"},
    {"id":"47300","name":"Final European Union herbal monograph on Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl), fructus - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T16:11:00Z","last_updated_date":"2020-04-02T16:11:00Z","reference_number":"EMA/HMPC/228761/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-fructus-revision-1_en.pdf"},
    {"id":"47305","name":"Final European Union herbal monograph on Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl), folium- Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T16:45:00Z","last_updated_date":"2020-04-02T16:45:00Z","reference_number":"EMA/HMPC/625849/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-folium-revision-1_en.pdf"},
    {"id":"47463","name":"European Union herbal monograph on Aesculus hippocastanum L., semen Final - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2020-04-23T13:35:00Z","last_updated_date":"2020-04-23T13:35:00Z","reference_number":"EMA/HMPC/628242/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf"}    {"id":"47497","name":"Final European Union herbal monograph on Allium sativum L., bulbus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2020-04-28T10:43:00Z","last_updated_date":"2020-04-28T10:43:00Z","reference_number":"EMA/HMPC/7685/2013 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-allium-sativum-l-bulbus_en.pdf"},
    {"id":"47561","name":"Final European Union herbal monograph on Pistacia lentiscus L., resin (mastic)","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2020-05-05T11:02:00Z","last_updated_date":"2020-05-05T11:02:00Z","reference_number":"EMA/HMPC/46758/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-pistacia-lentiscus-l-resin-mastic_en.pdf"},
    {"id":"47797","name":"Draft European Union herbal monograph on Species amarae","type":"herbal-monograph","status":"Draft","consultation_date":"2020-05-31 - 2020-08-31","first_published_date":"2020-05-28T16:45:00Z","last_updated_date":"2020-05-28T16:45:00Z","reference_number":"EMA/HMPC/44543/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-species-amarae_en.pdf"},
    {"id":"48413","name":"European Union herbal monograph on Mentha x piperita L., aetheroleum - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T08:47:00Z","last_updated_date":"2020-07-24T08:47:00Z","reference_number":"EMA/HMPC/522410/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-mentha-x-piperita-l-aetheroleum-revision-1_en.pdf"},
    {"id":"48419","name":"European Union herbal monograph on Mentha x piperita L., folium - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T16:08:00Z","last_updated_date":"2020-07-24T16:08:00Z","reference_number":"EMA/HMPC/572705/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-mentha-x-piperita-l-folium-revision-1_en.pdf"},
    {"id":"48424","name":"Final European Union herbal monograph on Rhamnus purshiana DC., cortex - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2020-07-27T09:52:00Z","last_updated_date":"2020-07-27T09:52:00Z","reference_number":"EMA/HMPC/726270/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rhamnus-purshiana-dc-cortex-revision-1_en.pdf"},
    {"id":"48621","name":"Final European Union herbal monograph on Rheum palmatum L. and Rheum officinale Baillon, radix – Revision 1","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2020-08-18T15:49:00Z","last_updated_date":"2020-08-18T15:49:00Z","reference_number":"EMA/HMPC/113700/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rheum-palmatum-l-and-rheum-officinale-baillon-radix-revision-1_en.pdf"},
    {"id":"48635","name":"Final European Union herbal monograph on Herniaria glabra L., H. hirsuta L., H. incana Lam., herba","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T14:43:00Z","last_updated_date":"2020-08-19T14:43:00Z","reference_number":"EMA/HMPC/554043/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-herniaria-glabra-l-h-hirsuta-l-h-incana-lam-herba_en.pdf"},
    {"id":"48870","name":"Final European Union herbal monograph on Thymus vulgaris L., Thymus zygis L., aetheroleum - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2020-09-21T15:57:00Z","last_updated_date":"2020-09-21T15:57:00Z","reference_number":"EMA/HMPC/59032/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-thymus-vulgaris-l-thymus-zygis-l-aetheroleum-revision-1_en.pdf"},
    {"id":"48971","name":"Draft European Union herbal monograph on Menyanthes trifoliata L., folium","type":"herbal-monograph","status":"Draft","consultation_date":"","first_published_date":"2020-10-09T09:19:00Z","last_updated_date":"2020-10-09T09:19:00Z","reference_number":"EMA/HMPC/637833/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-menyanthes-trifoliata-l-folium_en.pdf"},
    {"id":"50010","name":"Draft European Union herbal monograph on Orthosiphon aristatus (Blume) Miq. var. aristatus, folium - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2021-02-01 - 2021-04-30","first_published_date":"2021-02-01T11:41:00Z","last_updated_date":"2021-02-01T11:41:00Z","reference_number":"EMA/HMPC/486551/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-orthosiphon-aristatus-blume-miq-var-aristatus-folium-revision-1_en.pdf"},
    {"id":"50676","name":"Final European Union herbal monograph on Species amarae","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2021-03-23T11:38:00Z","last_updated_date":"2021-03-23T11:38:00Z","reference_number":"EMA/HMPC/44543/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-species-amarae_en.pdf"},
    {"id":"50713","name":"Final European Union herbal monograph on Species sedativae","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2021-03-25T16:44:00Z","last_updated_date":"2021-03-25T16:44:00Z","reference_number":"EMA/HMPC/438183/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-species-sedativae_en.pdf"},
    {"id":"50877","name":"Draft European Union herbal monograph on Trigonella foenum-graecum L., semen - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2021-04-15 - 2021-07-15","first_published_date":"2021-04-16T10:59:00Z","last_updated_date":"2021-04-16T10:59:00Z","reference_number":"EMA/HMPC/179591/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-trigonella-foenum-graecum-l-semen-revision-1_en.pdf"},
    {"id":"51312","name":"Draft European Union herbal monograph on Vaccinium macrocarpon Aiton, fructus - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2021-05-31 - 2021-08-31","first_published_date":"2021-05-31T19:39:00Z","last_updated_date":"2021-05-31T19:39:00Z","reference_number":"EMA/HMPC/49135/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-vaccinium-macrocarpon-aiton-fructus-first-version_en.pdf"},
    {"id":"51315","name":"Draft European Union herbal monograph on Taraxacum officinale F.H. Wigg., radix - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2021-05-31 - 2021-08-31","first_published_date":"2021-05-31T19:48:00Z","last_updated_date":"2021-05-31T19:48:00Z","reference_number":"EMA/HMPC/475726/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-taraxacum-officinale-fh-wigg-radix-first-version_en.pdf"},
    {"id":"52158","name":"Draft European Union herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2021-07-31 - 2021-10-31","first_published_date":"2021-07-30T15:27:00Z","last_updated_date":"2021-07-30T15:27:00Z","reference_number":"EMA/HMPC/114726/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-agropyron-repens-l-p-beauv-rhizoma-revision-1_en.pdf"},
    {"id":"52223","name":"Final European Union herbal monograph on Aloysia citrodora Paláu (syn. Aloysia triphylla (L'Hér.) Kuntze; Verbena triphylla L'Hér.; Lippia citriodora Kunth), folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2021-08-16T10:42:00Z","last_updated_date":"2021-08-16T10:42:00Z","reference_number":"EMA/HMPC/376770/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloysia-citrodora-palau-syn-aloysia-triphylla-lher-kuntze-verbena-triphylla-lher-lippia-citriodora-kunth-folium_en.pdf"},
    {"id":"52950","name":"Draft European Union herbal monograph on Centella asiatica (L.) Urb., herba - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2021-10-31 - 2022-01-31","first_published_date":"2021-10-29T15:07:00Z","last_updated_date":"2021-10-29T15:07:00Z","reference_number":"EMA/HMPC/489142/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-centella-asiatica-l-urb-herba-revision-1_en.pdf"},
    {"id":"57014","name":"Final European Union herbal monograph on Rosmarinus officinalis L., aetheroleum - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2022-12-15 - 2023-03-15","first_published_date":"2022-12-15T11:00:00Z","last_updated_date":"2024-09-20T11:17:00Z","reference_number":"EMA/HMPC/513893/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rosmarinus-officinalis-l-aetheroleum-revision-1_en.pdf"},
    {"id":"59541","name":"Final European Union herbal monograph on Rhodiola rosea L., rhizoma et radix - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2023-08-02T16:19:00Z","last_updated_date":"2024-05-21T13:46:00Z","reference_number":"EMA/HMPC/24177/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rhodiola-rosea-l-rhizoma-et-radix-revision-1_en.pdf"},
    {"id":"60629","name":"Draft European Union herbal monograph on Species digestivae","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2021-07-31 - 2021-10-31","first_published_date":"2021-07-30T10:37:00Z","last_updated_date":"2021-07-30T10:37:00Z","reference_number":"EMA/HMPC/180400/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-species-digestivae_en.pdf"},
    {"id":"63620","name":"Final European Union herbal monograph on Urtica dioica L.; Urtica urens L., radix - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T15:22:57Z","last_updated_date":"2025-03-12T13:18:00Z","reference_number":"EMA/HMPC/322646/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-urtica-dioica-l-urtica-urens-l-radix-revision-1_en.pdf"},
    {"id":"63623","name":"Draft European Union herbal monograph on Prunus avium L.; Prunus cerasus L., peduncle - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2024-06-15 - 2024-09-15","first_published_date":"2024-06-14T16:30:00Z","last_updated_date":"2024-06-14T16:30:00Z","reference_number":"EMA/HMPC/379866/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-prunus-avium-l-prunus-cerasus-l-peduncle-first-version_en.pdf"},
    {"id":"63626","name":"Final European Union herbal monograph on Urtica dioica L.; Urtica urens L., herba - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T16:30:05Z","last_updated_date":"2025-03-07T16:00:00Z","reference_number":"EMA/HMPC/261302/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-urtica-dioica-l-urtica-urens-l-herba-revision-1_en.pdf"},
    {"id":"63640","name":"Final European Union herbal monograph on Zingiber officinale Roscoe, rhizoma - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"2024-06-15 - 2024-09-15","first_published_date":"2024-06-14T17:21:06Z","last_updated_date":"2025-06-19T11:02:00Z","reference_number":"EMA/HMPC/885789/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-zingiber-officinale-roscoe-rhizoma-revision-1_en.pdf"},
    {"id":"66936","name":"Final European Union herbal monograph on Prunus avium L.; Prunus cerasus L., peduncle","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2025-02-25T11:57:59Z","last_updated_date":"2025-02-25T11:57:59Z","reference_number":"EMA/HMPC/379866/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-prunus-avium-l-prunus-cerasus-l-peduncle_en.pdf"},
    {"id":"66979","name":"Final European Union herbal monograph on Pilosella officinarum Vall. (syn Hieracium pilosella L.), herba cum radice - Revision 1","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2025-02-26T09:40:10Z","last_updated_date":"2025-02-26T09:40:10Z","reference_number":"EMA/HMPC/493453/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-pilosella-officinarum-vall-syn-hieracium-pilosella-l-herba-cum-radice-revision-1_en.pdf"},
    {"id":"67061","name":"Final European Union herbal monograph on Eucalyptus globulus Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker, aetheroleum - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T15:45:54Z","last_updated_date":"2025-02-28T15:45:54Z","reference_number":"EMA/HMPC/320292/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-eucalyptus-smithii-rt-baker-aetheroleum-revision-1_en.pdf"},
    {"id":"68513","name":"Draft European Union herbal monograph on Ononis spinosa L., radix - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2025-06-01 - 2025-08-31","first_published_date":"2025-06-02T09:54:43Z","last_updated_date":"2025-06-02T09:54:43Z","reference_number":"EMA/HMPC/584455/2023 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-ononis-spinosa-l-radix-revision-1_en.pdf"},
    {"id":"72560","name":"Draft European Union herbal monograph on Ribes nigrum L., folium - Revision 2","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2026-02-15 - 2026-05-15","first_published_date":"2026-02-16T08:53:54Z","last_updated_date":"2026-02-16T08:53:54Z","reference_number":"EMA/HMPC/296855/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-ribes-nigrum-l-folium-revision-2_en.pdf"},
    {"id":"73918","name":"Draft European Union herbal monograph on Glycine max (L.) Merr., lecithinum","type":"herbal-monograph","status":"Draft: consultation open","consultation_date":"2026-06-01 - 2026-08-31","first_published_date":"2026-06-01T10:52:34Z","last_updated_date":"2026-06-01T10:52:34Z","reference_number":"EMA/HMPC/216490/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-glycine-max-l-merr-lecithinum_en.pdf"},
    {"id":"5131","name":"Draft Community list entry on Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum - First version","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"2013-08-21 - 2013-12-15","first_published_date":"2013-08-21T04:00:00Z","last_updated_date":"2013-08-21T04:00:00Z","reference_number":"EMA/HMPC/281620/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-community-list-entry-melaleuca-alternifolia-maiden-and-betch-cheel-m-linariifolia-smith-m-dissitiflora-f-mueller-and-or-other-species-melaleuca-aetheroleum-first-version_en.pdf"},
    {"id":"14107","name":"Draft European Union list entry on Sideritis scardica Griseb., herba","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"2015-07-27 - 2015-10-31","first_published_date":"2015-07-27T15:00:00Z","last_updated_date":"2015-07-27T15:00:00Z","reference_number":"EMA/HMPC/150543/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-european-union-list-entry-sideritis-scardica-griseb-herba_en.pdf"},
    {"id":"17949","name":"Draft Community list entry on Thymus vulgaris L. and Thymus zygis Loefl. ex L., aetheroleum","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"2010-01-14 - 2010-05-15","first_published_date":"2010-02-12T02:09:21Z","last_updated_date":"2010-02-12T02:09:21Z","reference_number":"EMA/HMPC/255527/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-community-list-entry-thymus-vulgaris-l-and-thymus-zygis-loefl-ex-l-aetheroleum_en.pdf"},
    {"id":"19122","name":"Draft entry to list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products: Linseed (linum, semen)","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-10-24T02:00:00Z","last_updated_date":"2005-10-24T02:00:00Z","reference_number":"EMEA/HMPC/340854/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-entry-list-herbal-substances-preparations-and-combinations-thereof-use-traditional-herbal-medicinal-products-linseed-linum-semen_en.pdf"},
    {"id":"21884","name":"Draft entry to list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products: Valerian root (valeriana, radix)","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-10-24T02:09:21Z","last_updated_date":"2005-10-24T02:09:21Z","reference_number":"EMEA/HMPC/340779/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-entry-list-herbal-substances-preparations-and-combinations-thereof-use-traditional-herbal-medicinal-products-valerian-root-valeriana-radix_en.pdf"},
    {"id":"26425","name":"Draft European Union list entry on Valeriana officinalis L., radix","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"2015-07-22 - 2015-10-31","first_published_date":"2015-07-23T20:15:00Z","last_updated_date":"2015-07-23T20:15:00Z","reference_number":"EMA/HMPC/150849/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-european-union-list-entry-valeriana-officinalis-l-radix_en.pdf"},
    {"id":"26836","name":"Draft Community list entry on Mentha x piperita L., aetheroleum","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-05-08T02:00:00Z","last_updated_date":"2008-05-08T02:00:00Z","reference_number":"EMEA/HMPC/189245/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-community-list-entry-mentha-x-piperita-l-aetheroleum_en.pdf"},
    {"id":"27203","name":"Draft community list entry on Calendula officinalis L., flos","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2007-07-05T02:09:21Z","reference_number":"EMEA/HMPC/179283/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-community-list-entry-calendula-officinalis-l-flos_en.pdf"},
    {"id":"27646","name":"Draft community list entry on Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung, fructus","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-10-26T02:09:21Z","last_updated_date":"2006-10-26T02:09:21Z","reference_number":"EMEA/HMPC/428963/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-community-list-entry-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus_en.pdf"},
    {"id":"27671","name":"Draft community list entry on Vitis vinifera var. Tinctoria L., folium","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"2010-01-14 - 2010-05-15","first_published_date":"2010-02-12T02:09:21Z","last_updated_date":"2010-02-12T02:09:21Z","reference_number":"EMA/HMPC/5816/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-community-list-entry-vitis-vinifera-var-tinctoria-l-folium_en.pdf"},
    {"id":"29801","name":"Draft community list entry on Echinacea purpurea (L.) Moench, herba recens","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-05-08T02:09:21Z","last_updated_date":"2007-05-08T02:09:21Z","reference_number":"EMEA/HMPC/189629/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-community-list-entry-echinacea-purpurea-l-moench-herba-recens_en.pdf"},
    {"id":"31680","name":"Draft community list entry on Hamamelis virginiana L., folium et cortex aut ramunculus destillatum","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"2009-11-12 - 2010-06-15","first_published_date":"2010-03-23T02:00:00Z","last_updated_date":"2010-03-23T02:00:00Z","reference_number":"EMA/HMPC/704562/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-community-list-entry-hamamelis-virginiana-l-folium-et-cortex-aut-ramunculus-destillatum_en.pdf"},
    {"id":"35993","name":"Draft revised entry to list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products: Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2014-10-28T15:00:00Z","reference_number":"EMA/HMPC/680616/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-revised-entry-list-herbal-substances-preparations-and-combinations-thereof-use-traditional-herbal-medicinal-products-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf"},
    {"id":"36005","name":"Draft community list entry on Pimpinella anisum L., fructus","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2007-07-05T02:09:21Z","reference_number":"EMEA/HMPC/297757/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-community-list-entry-pimpinella-anisum-l-fructus_en.pdf"},
    {"id":"44726","name":"Draft European Union list entry on Mentha x piperita L., aetheroleum - Revision 1","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"2019-06-15 - 2019-09-15","first_published_date":"2019-06-18T10:43:00Z","last_updated_date":"2019-06-18T10:43:00Z","reference_number":"EMA/HMPC/679997/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-european-union-list-entry-mentha-x-piperita-l-aetheroleum-revision-1_en.pdf"},
    {"id":"46651","name":"Draft European Union list entry on Achillea millefolium L., herba - Revision 1","type":"herbal-list-entry","status":"Draft: consultation closed","consultation_date":"2020-02-01 - 2020-04-30","first_published_date":"2020-01-31T17:31:00Z","last_updated_date":"2020-01-31T17:31:00Z","reference_number":"EMA/HMPC/376417/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-european-union-list-entry-achillea-millefolium-l-herba-revision-1_en.pdf"},
    {"id":"48412","name":"European Union list entry on Mentha x piperita L., aetheroleum - Revision 1","type":"herbal-list-entry","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T15:43:00Z","last_updated_date":"2020-07-24T15:43:00Z","reference_number":"EMA/HMPC/679997/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/european-union-list-entry-mentha-x-piperita-l-aetheroleum-revision-1_en.pdf"},
    {"id":"57025","name":"Draft European Union list entry on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus - Revision 1","type":"herbal-list-entry","status":"Draft","consultation_date":"2022-12-15 - 2023-03-15","first_published_date":"2022-12-15T10:19:00Z","last_updated_date":"2022-12-15T10:19:00Z","reference_number":"EMA/HMPC/372843/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-european-union-list-entry-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus-revision-1_en.pdf"},
    {"id":"57026","name":"Draft European Union list entry on Foeniculum vulgare Miller subsp. vulgare var. dulce (Mill.) Batt. & Trab., fructus - Revision 1","type":"herbal-list-entry","status":"Draft","consultation_date":"2022-12-15 - 2023-03-15","first_published_date":"2022-12-15T10:26:00Z","last_updated_date":"2022-12-15T10:26:00Z","reference_number":"EMA/HMPC/372840/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-list-entry/draft-european-union-list-entry-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf"},
    {"id":"2870","name":"Draft European Union herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos – Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2017-12-15 - 2018-03-15","first_published_date":"2017-12-08T19:35:00Z","last_updated_date":"2017-12-08T19:35:00Z","reference_number":"EMA/HMPC/327107/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"2906","name":"Final European Union herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-07-03T02:00:00Z","last_updated_date":"2018-07-03T02:00:00Z","reference_number":"EMA/HMPC/48745/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf"},
    {"id":"3208","name":"Draft European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-10-14 - 2016-01-15","first_published_date":"2015-10-14T14:35:00Z","last_updated_date":"2015-10-14T14:35:00Z","reference_number":"EMA/HMPC/41108/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-helichrysum-arenarium-l-moench-flos_en.pdf"},
    {"id":"3356","name":"Final European Union herbal monograph on Echinacea pallida (Nutt.) Nutt., radix - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-08-14T12:00:00Z","last_updated_date":"2018-08-14T12:00:00Z","reference_number":"EMA/HMPC/737380/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-echinacea-pallida-nutt-nutt-radix-revision-1_en.pdf"},
    {"id":"3428","name":"Final European Union herbal monograph on Artemisia absinthium L., herba - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2017-10-05T02:00:00Z","last_updated_date":"2020-04-08T02:00:00Z","reference_number":"EMA/HMPC/751490/2016 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-artemisia-absinthium-l-herba-revision-1_en.pdf"},
    {"id":"3985","name":"Final European Union herbal monograph on Serenoa repens (W. Bartram) Small, fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-01-14T01:00:00Z","last_updated_date":"2016-01-14T01:00:00Z","reference_number":"EMA/HMPC/280079/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-serenoa-repens-w-bartram-small-fructus_en.pdf"},
    {"id":"4363","name":"Draft European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeheyri Decne., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2016-02-15 - 2016-05-15","first_published_date":"2016-02-15T13:00:00Z","last_updated_date":"2016-02-15T13:00:00Z","reference_number":"EMA/HMPC/627057/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-harpagophytum-procumbens-dc-and-or-harpagophytum-zeheyri-decne-radix_en.pdf"},
    {"id":"4619","name":"Draft European Union herbal monograph on Pistacia lentiscus L., resin (mastic)","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-07-22 - 2015-10-31","first_published_date":"2015-07-22T13:30:00Z","last_updated_date":"2015-07-22T13:30:00Z","reference_number":"EMA/HMPC/46758/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-pistacia-lentiscus-l-resin-mastic_en.pdf"},
    {"id":"6299","name":"Superseded European Union herbal monograph on Hedera helix L., folium - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-01-18T01:00:00Z","last_updated_date":"2018-08-13T02:00:00Z","reference_number":"EMA/HMPC/586888/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-european-union-herbal-monograph-hedera-helix-l-folium-revision-1_en.pdf"},
    {"id":"8186","name":"Final European Union herbal monograph on Ricinus communis L., oleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-03-01T01:00:00Z","last_updated_date":"2016-03-01T01:00:00Z","reference_number":"EMA/HMPC/572974/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-ricinus-communis-l-oleum_en.pdf"},
    {"id":"8347","name":"Final European Union herbal monograph on Polygonum aviculare L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-05-23T18:15:00Z","last_updated_date":"2016-05-23T18:15:00Z","reference_number":"EMA/HMPC/143658/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-polygonum-aviculare-l-herba_en.pdf"},
    {"id":"8507","name":"Final European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-05-23T12:50:00Z","last_updated_date":"2016-05-23T12:50:00Z","reference_number":"EMA/HMPC/41108/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-helichrysum-arenarium-l-moench-flos_en.pdf"},
    {"id":"8902","name":"Final European Union herbal monograph on Salvia officinalis L., folium - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2017-07-13T02:00:00Z","last_updated_date":"2017-07-13T02:00:00Z","reference_number":"EMA/HMPC/277152/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-salvia-officinalis-l-folium-revision-1_en.pdf"},
    {"id":"9478","name":"Final European Union herbal monograph on Equisetum arvense L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-03-17T01:00:00Z","reference_number":"EMA/HMPC/278091/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-equisetum-arvense-l-herba_en.pdf"},
    {"id":"9536","name":"Draft European Union herbal monograph on Valeriana officinalis L.,  aetheroleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-07-22 - 2015-10-31","first_published_date":"2015-07-23T04:00:00Z","last_updated_date":"2015-07-23T04:00:00Z","reference_number":"EMA/HMPC/278053/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-valeriana-officinalis-l-aetheroleum_en.pdf"},
    {"id":"9685","name":"Draft European Union herbal monograph on Vitis vinifera L., folium","type":"herbal-monograph","status":"unknown","consultation_date":"2016-12-15 - 2017-03-15","first_published_date":"2016-12-15T11:54:00Z","last_updated_date":"2016-12-15T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-vitis-vinifera-l-folium_en.pdf"},
    {"id":"9880","name":"Final European Union herbal monograph on Matricaria recutita L., aetheroleum - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-04-05T02:00:00Z","last_updated_date":"2016-04-05T02:00:00Z","reference_number":"EMA/HMPC/278814/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-matricaria-recutita-l-aetheroleum-first-version_en.pdf"},
    {"id":"10685","name":"Final European Union herbal monograph on Glycine max (L.) Merr., lecithinum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2017-11-20T01:00:00Z","last_updated_date":"2017-11-20T01:00:00Z","reference_number":"EMA/HMPC/220599/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-glycine-max-l-merr-lecithinum_en.pdf"},
    {"id":"11069","name":"Draft European Union herbal monograph on Melilotus officinalis (L.) Lam., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2017-04-12 - 2017-07-16","first_published_date":"2017-04-12T17:13:00Z","last_updated_date":"2017-04-12T17:13:00Z","reference_number":"EMA/HMPC/44166/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"11363","name":"Draft European Union herbal monograph on Althaea officinalis L., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-12-11 - 2016-03-15","first_published_date":"2015-12-11T19:20:00Z","last_updated_date":"2015-12-11T19:20:00Z","reference_number":"EMA/HMPC/436679/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-althaea-officinalis-l-radix_en.pdf"},
    {"id":"13718","name":"Draft European Union herbal monograph on Species diureticae","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2016-10-28 - 2017-01-28","first_published_date":"2016-10-28T04:00:00Z","last_updated_date":"2016-10-28T04:00:00Z","reference_number":"EMA/HMPC/224755/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-species-diureticae_en.pdf"},
    {"id":"14401","name":"Final European Union herbal monograph on Species diureticae","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/HMPC/224755/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-species-diureticae_en.pdf"},
    {"id":"14617","name":"Draft European Union herbal monograph on Gentiana lutea L., radix – Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2018-04-11 - 2018-07-15","first_published_date":"2018-04-11T04:00:00Z","last_updated_date":"2018-04-11T04:00:00Z","reference_number":"EMA/607861/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-gentiana-lutea-l-radix-revision-1_en.pdf"},
    {"id":"15006","name":"Draft European Union herbal monograph on Malva sylvestris L., flos - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2018-06-30 - 2018-09-15","first_published_date":"2018-07-02T04:00:00Z","last_updated_date":"2018-07-02T04:00:00Z","reference_number":"EMA/HMPC/749511/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-malva-sylvestris-l-flos-first-version_en.pdf"},
    {"id":"15012","name":"Final European Union herbal monograph on Hedera helix  L., folium  - Revision 2","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2018-08-13T13:47:00Z","last_updated_date":"2018-08-13T13:47:00Z","reference_number":"EMA/HMPC/325716/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-hedera-helix-l-folium-revision-2_en.pdf"},
    {"id":"15809","name":"European Union herbal monograph on Centaurium erythraea Rafn. s.l., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"EMA/HMPC/277493/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-centaurium-erythraea-rafn-sl-herba_en.pdf"},
    {"id":"17920","name":"Final European Union herbal monograph on Carum carvi L., aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/HMPC/715094/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"18097","name":"Final European Union herbal monograph on Calendula officinalis L., flos - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-06-14T15:00:00Z","last_updated_date":"2018-06-14T15:00:00Z","reference_number":"EMA/HMPC/437450/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-calendula-officinalis-l-flos-revision-1_en.pdf"},
    {"id":"18138","name":"Final European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium - Revision 2","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T14:00:00Z","last_updated_date":"2018-04-11T14:00:00Z","reference_number":"EMA/HMPC/750269/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-2_en.pdf"},
    {"id":"18170","name":"Draft European Union herbal monograph on Ricinus communis L., oleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-07-22 - 2015-10-31","first_published_date":"2015-07-22T04:00:00Z","last_updated_date":"2015-07-22T04:00:00Z","reference_number":"EMA/HMPC/572974/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-ricinus-communis-l-oleum_en.pdf"},
    {"id":"18219","name":"Draft European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2017-04-12 - 2017-07-16","first_published_date":"2017-04-12T16:08:00Z","last_updated_date":"2017-04-12T16:08:00Z","reference_number":"EMA/HMPC/750269/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium_en.pdf"},
    {"id":"19131","name":"Draft European Union herbal monograph on Equisetum arvense L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-07-27 - 2015-10-31","first_published_date":"2015-07-27T14:00:00Z","last_updated_date":"2015-07-27T14:00:00Z","reference_number":"EMA/HMPC/278091/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-equisetum-arvense-l-herba_en.pdf"},
    {"id":"19230","name":"Draft European Union herbal monograph on Hypericum perforatum L., herba (traditional use) - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2018-03-08 - 2018-06-15","first_published_date":"2018-03-08T10:35:00Z","last_updated_date":"2018-03-08T10:35:00Z","reference_number":"EMA/HMPC/45508/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-hypericum-perforatum-l-herba-traditional-use-revision-1_en.pdf"},
    {"id":"19659","name":"Final  European Union herbal monograph on Althaea officinalis L., radix","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2016-11-04T14:59:00Z","last_updated_date":"2016-11-04T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-althaea-officinalis-l-radix_en.pdf"},
    {"id":"20244","name":"Draft European Union herbal monograph on Origanum majorana L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2016-02-15 - 2016-05-15","first_published_date":"2016-02-15T18:15:00Z","last_updated_date":"2016-02-15T18:15:00Z","reference_number":"EMA/HMPC/166517/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-origanum-majorana-l-herba_en.pdf"},
    {"id":"20305","name":"Final European Union herbal monograph on Matricaria recutita L., flos - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-04-05T17:30:00Z","last_updated_date":"2016-04-05T17:30:00Z","reference_number":"EMA/HMPC/55843/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-matricaria-recutita-l-flos-first-version_en.pdf"},
    {"id":"20451","name":"Draft European Union herbal monograph on Silybum marianum (L.) Gaertn., fructus","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T17:01:00Z","last_updated_date":"2016-11-07T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-silybum-marianum-l-gaertn-fructus_en.pdf"},
    {"id":"20698","name":"Final European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-01-13T16:10:00Z","last_updated_date":"2016-01-13T16:10:00Z","reference_number":"EMA/HMPC/712511/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf"},
    {"id":"21542","name":"Draft European Union herbal monograph on Prunus africana (Hook f.) Kalkm., cortex","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-03-15","first_published_date":"2015-12-15T18:30:00Z","last_updated_date":"2015-12-15T18:30:00Z","reference_number":"EMA/HMPC/680626/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-prunus-africana-hook-f-kalkm-cortex_en.pdf"},
    {"id":"22231","name":"Final European Union herbal monograph on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis raeseri Boiss. & Heldr.; Sideritis syriaca L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/HMPC/39453/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-sideritis-scardica-griseb-sideritis-clandestina-bory-chaub-hayek-sideritis-raeseri-boiss-heldr-sideritis-syriaca-l-herba_en.pdf"},
    {"id":"22443","name":"Final European Union herbal monograph on Melilotus officinalis (L.) Lam., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-04-23T16:10:00Z","last_updated_date":"2018-04-23T16:10:00Z","reference_number":"EMA/HMPC/44166/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"22711","name":"Draft European Union herbal monograph on Glycine max (L.) Merr., oleum","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2016-07-25 - 2016-10-31","first_published_date":"2016-07-25T16:30:00Z","last_updated_date":"2016-07-25T16:30:00Z","reference_number":"EMA/HMPC/338914/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-glycine-max-l-merr-oleum_en.pdf"},
    {"id":"23174","name":"Draft European Union herbal monograph on Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl), folium – Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2017-10-12 - 2018-01-12","first_published_date":"2017-10-12T14:30:00Z","last_updated_date":"2017-10-12T14:30:00Z","reference_number":"EMA/HMPC/625849/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-folium-revision-1_en.pdf"},
    {"id":"23591","name":"Final European Union herbal monograph on Vitis vinifera L., folium - Revision 1","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2018-01-05T01:00:00Z","last_updated_date":"2018-01-05T01:00:00Z","reference_number":"EMA/HMPC/464684/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitis-vinifera-l-folium-revision-1_en.pdf"},
    {"id":"24722","name":"Final European Union herbal monograph on Glycine max (L.) Merr., oleum raffinatum","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2017-03-03T10:19:00Z","last_updated_date":"2017-03-03T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-glycine-max-l-merr-oleum-raffinatum_en.pdf"},
    {"id":"26022","name":"Final European Union herbal monograph on Vaccinium myrtillus L., fructus recens","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"EMA/HMPC/375808/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vaccinium-myrtillus-l-fructus-recens_en.pdf"},
    {"id":"26694","name":"Superseded final community herbal monograph on Valeriana officinalis L., radix  (Valerianae aetheroleum)","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-06-20T02:00:00Z","last_updated_date":"2016-06-20T02:00:00Z","reference_number":"EMEA/HMPC/340719/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-community-herbal-monograph-valeriana-officinalis-l-radix-valerianae-aetheroleum_en.pdf"},
    {"id":"26830","name":"Draft European Union herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2017-08-04 - 2017-11-04","first_published_date":"2017-08-04T19:30:00Z","last_updated_date":"2017-08-04T19:30:00Z","reference_number":"EMA/HMPC/48745/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf"},
    {"id":"27379","name":"Final European Union herbal monograph onEchinacea purpurea (L.) Moench, radix – Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2017-08-11T02:00:00Z","last_updated_date":"2017-08-11T02:00:00Z","reference_number":"EMA/HMPC/424583/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-onechinacea-purpurea-l-moench-radix-revision-1_en.pdf"}    {"id":"28030","name":"Final European Union herbal monograph on Ribes nigrum L., folium","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T10:03:00Z","last_updated_date":"2017-12-19T10:03:00Z","reference_number":"EMA/HMPC/745353/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-ribes-nigrum-l-folium_en.pdf"},
    {"id":"28037","name":"Superseded final European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-08-20T02:00:00Z","last_updated_date":"2024-07-12T02:00:00Z","reference_number":"EMA/HMPC/444244/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-final-european-union-herbal-monograph-pelargonium-sidoides-dc-or-pelargonium-reniforme-curt-radix-revision-1_en.pdf"},
    {"id":"28420","name":"Draft European Union herbal monograph on Ribes nigrum L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2017-02-28 - 2017-06-01","first_published_date":"2017-02-28T11:24:00Z","last_updated_date":"2017-02-28T11:24:00Z","reference_number":"EMA/HMPC/745353/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-ribes-nigrum-l-folium_en.pdf"},
    {"id":"28839","name":"Final European Union herbal monograph on Peumus boldus Molina, folium","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2017-01-12T10:48:00Z","last_updated_date":"2017-01-12T10:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-peumus-boldus-molina-folium_en.pdf"},
    {"id":"29728","name":"Final European Union herbal monograph on Salix [various species including S. purpurea L., S. daphnoides Vill., S. fragilis L.], cortex","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2017-07-07T02:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMA/HMPC/80630/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-cortex_en.pdf"},
    {"id":"30227","name":"Final European Union herbal monograph on Sambucus nigra L., flos - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-06-27T17:00:00Z","last_updated_date":"2018-06-27T17:00:00Z","reference_number":"EMA/HMPC/611512/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-sambucus-nigra-l-flos-revision-1_en.pdf"},
    {"id":"30234","name":"Superseded Community herbal monograph on Salix [various species including S. purpurea L., S. daphnoides Vill., S. fragilis L.], cortex","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2009-01-14T01:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMEA/HMPC/295338/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-cortex_en.pdf"},
    {"id":"30352","name":"Draft European Union herbal monograph on Mentha x piperita L., folium - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2017-02-23 - 2017-05-31","first_published_date":"2017-02-23T18:58:00Z","last_updated_date":"2017-03-08T18:58:00Z","reference_number":"EMA/HMPC/572705/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-mentha-x-piperita-l-folium-revision-1_en.pdf"},
    {"id":"30411","name":"Draft European Union herbal monograph on Valeriana officinalis L., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-07-22 - 2015-10-31","first_published_date":"2015-07-23T20:15:00Z","last_updated_date":"2015-07-23T20:15:00Z","reference_number":"EMA/HMPC/150848/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf"},
    {"id":"30518","name":"Superseded European Union herbal monograph on Artemisia absinthium L., herba - First version","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2017-10-05T02:00:00Z","reference_number":"EMEA/HMPC/234463/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-european-union-herbal-monograph-artemisia-absinthium-l-herba-first-version_en.pdf"},
    {"id":"31600","name":"Final European Union herbal monograph on Origanum majorana L., herba","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T11:35:00Z","last_updated_date":"2016-11-15T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-origanum-majorana-l-herba_en.pdf"},
    {"id":"31957","name":"Draft European Union herbal monograph on Silybum marianum (L.) Gaertn., fructus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-07-22 - 2015-10-31","first_published_date":"2015-07-23T14:50:00Z","last_updated_date":"2015-07-23T14:50:00Z","reference_number":"EMA/HMPC/294187/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-silybum-marianum-l-gaertn-fructus_en.pdf-0"},
    {"id":"32230","name":"Final European Union herbal monograph on Valeriana officinalis L., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-04-27T12:30:00Z","last_updated_date":"2017-11-09T13:03:00Z","reference_number":"EMA/HMPC/150848/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf"},
    {"id":"33251","name":"Final European Union herbal monograph on Carum carvi L., fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/HMPC/715092/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-carum-carvi-l-fructus_en.pdf"},
    {"id":"33480","name":"Draft European Union herbal monograph on Fragaria vesca L., Fragaria moschata Weston, Fragaria viridis Weston and Fragaria x ananassa (Weston) Duchesne ex Rozier, folium - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2018-04-11 - 2018-07-15","first_published_date":"2018-04-11T14:30:00Z","last_updated_date":"2018-04-11T14:30:00Z","reference_number":"EMA/HMPC/432278/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-and-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium-first-version_en.pdf"},
    {"id":"33511","name":"Draft European Union herbal monograph on Ruscus aculeatus L. rhizoma- Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2018-03-08 - 2018-06-15","first_published_date":"2018-03-08T10:30:00Z","last_updated_date":"2018-03-08T10:30:00Z","reference_number":"EMA/188804/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-ruscus-aculeatus-l-rhizoma-revision-1_en.pdf"},
    {"id":"34305","name":"Draft European Union herbal monograph on Glycine max (L.) Merr., lecithin","type":"herbal-monograph","status":"Draft","consultation_date":"2016-07-27 - 2016-10-31","first_published_date":"2016-07-27T17:40:00Z","last_updated_date":"2016-07-27T17:40:00Z","reference_number":"EMA/HMPC/220599/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-glycine-max-l-merr-lecithin_en.pdf"},
    {"id":"35028","name":"Draft European Union herbal monograph on Pelargonium sidoides DC and / or Pelargonium reniforme Curt., radix","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-10-26 - 2016-01-31","first_published_date":"2015-10-26T02:00:00Z","last_updated_date":"2015-10-26T02:00:00Z","reference_number":"EMA/HMPC/444244/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-pelargonium-sidoides-dc-and-or-pelargonium-reniforme-curt-radix_en.pdf"},
    {"id":"35308","name":"Final European Union herbal monograph on Crataegus spp., folium cum flore","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"EMA/HMPC/159075/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-crataegus-spp-folium-cum-flore_en.pdf"},
    {"id":"37220","name":"Draft European Union herbal monograph on Malva sylvestris L. and/or Malva neglecta Wallr., folium - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2018-06-30 - 2018-09-15","first_published_date":"2018-07-02T04:00:00Z","last_updated_date":"2018-07-02T04:00:00Z","reference_number":"EMA/HMPC/749510/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-malva-sylvestris-l-and-or-malva-neglecta-wallr-folium-first-version_en.pdf"},
    {"id":"37762","name":"Final European Union herbal monograph on Valeriana officinalis L., aetheroleum","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-04-27T12:00:00Z","last_updated_date":"2016-06-20T12:00:00Z","reference_number":"EMA/HMPC/278053/2015 corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-aetheroleum_en.pdf"},
    {"id":"38420","name":"Final European Union herbal monograph on Prunus africana (Hook f.) Kalkm., cortex","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2017-09-01T02:00:00Z","last_updated_date":"2017-09-01T02:00:00Z","reference_number":"EMA/HMPC/680626/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-prunus-africana-hook-f-kalkm-cortex_en.pdf"},
    {"id":"38800","name":"Draft European Union herbal monograph on Salvia officinalis L., folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2016-02-15 - 2016-05-15","first_published_date":"2016-02-15T13:00:00Z","last_updated_date":"2016-02-15T13:00:00Z","reference_number":"EMA/HMPC/277152/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-salvia-officinalis-l-folium_en.pdf"},
    {"id":"39196","name":"Final European Union herbal monograph on Verbascum thapsus L., V. densiflorum Bertol. (V. thapsiforme Schrad) and V. phlomoides L., flos","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T02:00:00Z","last_updated_date":"2018-06-22T02:00:00Z","reference_number":"EMA/HMPC/611537/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-verbascum-thapsus-l-v-densiflorum-bertol-v-thapsiforme-schrad-and-v-phlomoides-l-flos_en.pdf"},
    {"id":"39273","name":"Final European Union herbal monograph on Vaccinium myrtillus L., fructus siccus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"EMA/HMPC/678995/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vaccinium-myrtillus-l-fructus-siccus_en.pdf"},
    {"id":"39278","name":"Draft European Union herbal monograph on Allium sativum L., bulbus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2016-07-25 - 2016-10-31","first_published_date":"2016-07-25T19:00:00Z","last_updated_date":"2016-07-25T19:00:00Z","reference_number":"EMA/HMPC/7685/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-allium-sativum-l-bulbus_en.pdf"},
    {"id":"39731","name":"Final Community herbal monograph on Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-06-09T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"EMA/HMPC/84990/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"40004","name":"Final European Union herbal monograph on Olea europaea L., folium - First version","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T01:00:00Z","last_updated_date":"2018-01-04T01:00:00Z","reference_number":"EMA/HMPC/359238/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf"},
    {"id":"40636","name":"Final European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMA/HMPC/627057/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-harpagophytum-procumbens-dc-andor-harpagophytum-zeyheri-decne-radix_en.pdf"},
    {"id":"40706","name":"Final European Union herbal monograph on Aloe barbadensis Mill. and on Aloe (various species, mainly Aloe ferox Mill. and its hybrids), folii succus siccatus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2017-04-10T02:00:00Z","last_updated_date":"2017-04-10T02:00:00Z","reference_number":"EMA/HMPC/625788/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf"},
    {"id":"41093","name":"Draft European Union herbal monograph on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis raeseri Boiss. & Heldr.; Sideritis syriaca L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-07-27 - 2015-10-31","first_published_date":"2015-07-27T15:00:00Z","last_updated_date":"2015-07-27T15:00:00Z","reference_number":"EMA/HMPC/39453/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-sideritis-scardica-griseb-sideritis-clandestina-bory-chaub-hayek-sideritis-raeseri-boiss-heldr-sideritis-syriaca-l-herba_en.pdf"},
    {"id":"41630","name":"Draft European Union herbal monograph on Polygonum aviculare L., herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2015-10-19 - 2016-01-15","first_published_date":"2015-10-19T14:50:00Z","last_updated_date":"2015-10-19T14:50:00Z","reference_number":"EMA/HMPC/143658/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-polygonum-aviculare-l-herba_en.pdf"},
    {"id":"41873","name":"Draft European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), rhizome – Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2017-12-15 - 2018-03-15","first_published_date":"2017-12-08T18:35:00Z","last_updated_date":"2017-12-08T18:35:00Z","reference_number":"EMA/HMPC/329755/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-curcuma-longa-l-c-domestica-valeton-rhizome-revision-1_en.pdf"},
    {"id":"42087","name":"Final European Union herbal monograph on Silybum marianum (L.) Gaertn., fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-09-19T02:00:00Z","last_updated_date":"2018-09-19T02:00:00Z","reference_number":"EMA/HMPC/294187/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-silybum-marianum-l-gaertn-fructus_en.pdf"},
    {"id":"42256","name":"Final European Union herbal monograph on Vitex agnus-castus L., fructus - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-10-10T11:18:00Z","last_updated_date":"2018-10-10T11:18:00Z","reference_number":"EMA/HMPC/606742/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf"},
    {"id":"42260","name":"Final European Union herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L., oleum - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2018-10-10T12:53:00Z","last_updated_date":"2018-10-10T12:53:00Z","reference_number":"EMA/HMPC/753041/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-oenothera-biennis-l-oenothera-lamarckiana-l-oleum-revision-1_en.pdf"},
    {"id":"43475","name":"Final European Union herbal monograph on Curcuma longa L., rhizoma - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2019-01-24T16:25:00Z","last_updated_date":"2019-01-24T16:25:00Z","reference_number":"EMA/HMPC/329755/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf"},
    {"id":"43659","name":"Final European Union herbal monograph on Cynara cardunculus L. (syn. Cynara scolymus L.), folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2019-02-07T12:05:00Z","last_updated_date":"2019-02-07T12:05:00Z","reference_number":"EMA/HMPC/194014/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cynara-cardunculus-l-syn-cynara-scolymus-l-folium_en.pdf"},
    {"id":"44061","name":"Final European Union herbal monograph on Malva sylvestris L. and/or Malva neglecta Wallr., folium - First version","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2019-03-19T16:22:00Z","last_updated_date":"2019-03-19T16:22:00Z","reference_number":"EMA/HMPC/749510/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-malva-sylvestris-l-andor-malva-neglecta-wallr-folium-first-version_en.pdf"},
    {"id":"44326","name":"Superseded Community herbal monograph on Salix [various species including S. purpurea L., S. daphnoides Vill., S. fragilis L.], cortex","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2009-09-26T10:12:00Z","last_updated_date":"2019-04-24T11:15:00Z","reference_number":"EMEA/HMPC/295338/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/superseded-community-herbal-monograph-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-cortex_en.pdf-0"},
    {"id":"44404","name":"European herbal monograph on Gentiana Lutea L., radix - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2019-04-30T14:43:00Z","last_updated_date":"2019-04-30T14:43:00Z","reference_number":"EMA/HMPC/607861/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-herbal-monograph-gentiana-lutea-l-radix-revision-1_en.pdf"},
    {"id":"44510","name":"Final European Union herbal monograph on Fragaria vesca L., Fragaria moschata Weston, Fragaria viridis Weston and Fragaria x ananassa (Weston) Duchesne ex Rozier, folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2019-05-15T17:46:00Z","last_updated_date":"2019-05-15T17:46:00Z","reference_number":"EMA/HMPC/432278/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-and-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium_en.pdf"},
    {"id":"46508","name":"Final European Union herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos - Revision 1","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T15:42:00Z","last_updated_date":"2020-01-23T15:42:00Z","reference_number":"EMA/HMPC/327107/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"47790","name":"Draft European Union herbal monograph on Species sedativae","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2020-05-31 - 2020-08-31","first_published_date":"2020-05-29T13:22:00Z","last_updated_date":"2020-05-29T13:22:00Z","reference_number":"EMA/HMPC/438183/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-species-sedativae_en.pdf"},
    {"id":"47820","name":"Draft European Union herbal monograph on Aloysia citrodora Paláu (syn. Aloysia triphylla (L'Hér.) Kuntze; Verbena triphylla L'Hér.; Lippia citriodora Kunth), folium","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2020-05-31 - 2020-08-31","first_published_date":"2020-05-29T13:28:00Z","last_updated_date":"2020-05-29T13:28:00Z","reference_number":"EMA/HMPC/376770/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-aloysia-citrodora-palau-syn-aloysia-triphylla-lher-kuntze-verbena-triphylla-lher-lippia-citriodora-kunth-folium_en.pdf"},
    {"id":"48616","name":"Final European Union herbal monograph on Tanacetum parthenium (L.) Schulz Bip., herba - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2020-08-14T11:44:00Z","last_updated_date":"2020-08-14T11:44:00Z","reference_number":"EMA/HMPC/48715/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-tanacetum-parthenium-l-schulz-bip-herba-revision-1_en.pdf"},
    {"id":"51966","name":"Final European Union herbal monograph on Menyanthes trifoliata L., folium","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2021-07-20T13:10:00Z","last_updated_date":"2021-07-20T13:10:00Z","reference_number":"EMA/HMPC/637833/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-menyanthes-trifoliata-l-folium_en.pdf"},
    {"id":"53419","name":"European Union herbal monograph on Orthosiphon aristatus (Blume) Miq. var. aristatus, folium - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2021-12-08T13:53:00Z","last_updated_date":"2021-12-08T13:53:00Z","reference_number":"EMA/HMPC/486551/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-orthosiphon-aristatus-blume-miq-var-aristatus-folium-revision-1_en.pdf"},
    {"id":"55310","name":"Final European Union herbal monograph on Taraxacum officinale F.H. Wigg., radix","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2022-06-21T13:16:00Z","last_updated_date":"2022-06-21T13:16:00Z","reference_number":"EMA/HMPC/475726/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-taraxacum-officinale-fh-wigg-radix_en.pdf"},
    {"id":"55878","name":"Final European Union herbal monograph on Juniperus communis L., pseudo-fructus (galbulus) - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"2022-08-31 - 2022-11-30","first_published_date":"2022-08-31T17:47:00Z","last_updated_date":"2023-06-13T13:04:00Z","reference_number":"EMA/HMPC/241320/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-juniperus-communis-l-pseudo-fructus-galbulus-revision-1_en.pdf"},
    {"id":"55884","name":"European Union herbal monograph on Trigonella foenum-graecum L., semen - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2022-08-30T10:52:00Z","last_updated_date":"2022-08-30T10:52:00Z","reference_number":"EMA/HMPC/179591/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-trigonella-foenum-graecum-l-semen-revision-1_en.pdf"},
    {"id":"55888","name":"Final European Union herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus  - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"2022-08-31 - 2022-11-30","first_published_date":"2022-08-31T18:51:00Z","last_updated_date":"2024-03-01T12:11:00Z","reference_number":"EMEA/HMPC/372841/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus-revision-1_en.pdf"},
    {"id":"55895","name":"Final European Union herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. dulce (Mill.) Batt. & Trab., fructus - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"2022-08-31 - 2022-11-30","first_published_date":"2022-08-31T11:09:00Z","last_updated_date":"2024-03-01T12:31:00Z","reference_number":"EMEA/HMPC/372839/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf"},
    {"id":"55943","name":"European Union herbal monograph on Centella asiatica (L.) Urb., herba - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2022-09-02T09:43:00Z","last_updated_date":"2022-09-02T09:43:00Z","reference_number":"EMA/HMPC/489142/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-centella-asiatica-l-urb-herba-revision-1_en.pdf"},
    {"id":"56280","name":"European Union herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2022-10-03T12:13:00Z","last_updated_date":"2022-10-03T12:13:00Z","reference_number":"EMA/HMPC/114726/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-agropyron-repens-l-p-beauv-rhizoma-revision-1_en.pdf"},
    {"id":"56509","name":"Draft European Union herbal monograph on Fumaria officinalis L., herba – Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2022-10-31 - 2023-01-31","first_published_date":"2022-10-31T10:35:00Z","last_updated_date":"2022-10-31T10:35:00Z","reference_number":"EMA/HMPC/367011/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-fumaria-officinalis-l-herba-revision-1_en.pdf"},
    {"id":"56719","name":"European Union herbal monograph on Species digestivae","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2022-11-21T09:29:00Z","last_updated_date":"2022-11-21T09:29:00Z","reference_number":"EMA/HMPC/180400/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-species-digestivae_en.pdf"},
    {"id":"57017","name":"Final European Union herbal monograph on Rosmarinus officinalis L., folium - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2022-12-15 - 2023-03-15","first_published_date":"2022-12-15T17:32:00Z","last_updated_date":"2024-09-26T12:43:00Z","reference_number":"EMA/HMPC/513940/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rosmarinus-officinalis-l-folium-revision-1_en.pdf"},
    {"id":"57694","name":"Draft European Union herbal monograph on Cnicus benedictus L., herba","type":"herbal-monograph","status":"Draft","consultation_date":"","first_published_date":"2023-02-16T13:09:00Z","last_updated_date":"2023-02-16T13:09:00Z","reference_number":"EMA/HMPC/32402/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-cnicus-benedictus-l-herba_en.pdf"},
    {"id":"57754","name":"Final European Union herbal monograph on Vaccinium macrocarpon Aiton, fructus","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T12:00:00Z","last_updated_date":"2023-02-21T12:00:00Z","reference_number":"EMA/HMPC/49135/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vaccinium-macrocarpon-aiton-fructus_en.pdf"},
    {"id":"57775","name":"Final European Union herbal monograph on Hypericum perforatum L., herba - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2023-02-22T10:37:00Z","last_updated_date":"2023-02-22T10:37:00Z","reference_number":"EMA/HMPC/7695/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-hypericum-perforatum-l-herba-revision-1_en.pdf"},
    {"id":"58167","name":"Draft European Union herbal monograph on Aesculus hippocastanum L., cortex - Revision 1","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2023-03-27T15:33:00Z","last_updated_date":"2023-03-27T15:33:00Z","reference_number":"EMA/HMPC/596130/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-aesculus-hippocastanum-l-cortex-revision-1_en.pdf"},
    {"id":"58954","name":"Draft European Union herbal monograph on Panax ginseng C.A.Mey., radix - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2023-10-19 - 2024-01-15","first_published_date":"2023-06-15T13:43:00Z","last_updated_date":"2023-10-25T12:14:00Z","reference_number":"EMA/HMPC/27744/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-panax-ginseng-camey-radix-revision-1_en.pdf"},
    {"id":"60442","name":"Final European Union herbal monograph on Pelargonium sidoides DC; Pelargonium reniforme Curt., radix - Revision 2","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2023-10-16T18:11:00Z","last_updated_date":"2024-07-12T16:03:00Z","reference_number":"EMA/HMPC/648100/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-pelargonium-sidoides-dc-pelargonium-reniforme-curt-radix-revision-2_en.pdf"},
    {"id":"61782","name":"Final European Union herbal monograph on Cnicus benedictus L., herba","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2024-01-16T14:31:28Z","last_updated_date":"2024-01-16T14:31:28Z","reference_number":"EMA/HMPC/32402/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cnicus-benedictus-l-herba_en.pdf"},
    {"id":"62244","name":"Final European Union herbal monograph on Fumaria officinalis L., herba - Revision 1","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T15:59:31Z","last_updated_date":"2024-02-21T15:59:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-fumaria-officinalis-l-herba-revision-1_en.pdf"},
    {"id":"62945","name":"Draft European Union herbal monograph on Eucalyptus globulus Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker, aetheroleum - Revision 1","type":"herbal-monograph","status":"Draft","consultation_date":"","first_published_date":"2024-04-15T10:44:30Z","last_updated_date":"2024-04-15T10:44:30Z","reference_number":"EMA/HMPC/320292/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-eucalyptus-smithii-rt-baker-aetheroleum-revision-1_en.pdf"},
    {"id":"62948","name":"Draft European Union herbal monograph on Pilosella officinarum Vall. (syn Hieracium pilosella L.), herba cum radice - Revision 1","type":"herbal-monograph","status":"Draft","consultation_date":"","first_published_date":"2024-04-15T11:01:15Z","last_updated_date":"2024-04-15T11:01:15Z","reference_number":"EMA/HMPC/493453/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-pilosella-officinarum-vall-syn-hieracium-pilosella-l-herba-cum-radice-revision-1_en.pdf"},
    {"id":"63191","name":"Final European Union herbal monograph on Aesculus hippocastanum L., cortex - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2024-05-07T14:40:41Z","last_updated_date":"2024-05-07T14:40:41Z","reference_number":"EMA/HMPC/596130/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aesculus-hippocastanum-l-cortex-revision-1_en.pdf"},
    {"id":"63643","name":"Draft public statement on Tribulus terrestris L., herba - First version","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2024-06-15 - 2024-09-15","first_published_date":"2024-06-14T17:31:55Z","last_updated_date":"2024-06-14T17:31:55Z","reference_number":"EMA/HMPC/308436/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-public-statement-tribulus-terrestris-l-herba-first-version_en.pdf"},
    {"id":"64113","name":"Final European Union herbal monograph on Panax ginseng C.A.Mey., radix - Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"","first_published_date":"2024-07-12T15:48:00Z","last_updated_date":"2024-07-12T15:48:00Z","reference_number":"EMA/HMPC/27744/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-panax-ginseng-camey-radix-revision-1_en.pdf"},
    {"id":"64577","name":"Final European Union herbal monograph on Cisti cretici herba – First version","type":"herbal-monograph","status":"Adopted","consultation_date":"2024-08-15 - 2024-11-15","first_published_date":"2024-08-14T16:25:58Z","last_updated_date":"2025-04-30T15:38:00Z","reference_number":"EMA/HMPC/150763/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cisti-cretici-herba-first-version_en.pdf"},
    {"id":"64581","name":"Final European Union herbal monograph on plantaginis lanceolatae folium – Revision 1","type":"herbal-monograph","status":"Adopted","consultation_date":"2024-08-15 - 2024-11-15","first_published_date":"2024-08-14T16:43:37Z","last_updated_date":"2025-10-20T09:36:00Z","reference_number":"EMA/HMPC/887979/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-plantaginis-lanceolatae-folium-revision-1_en.pdf"},
    {"id":"64890","name":"Final European Union herbal monograph on Artemisia absinthium L., herba","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2024-09-18T11:10:00Z","last_updated_date":"2024-09-18T11:10:00Z","reference_number":"EMA/HMPC/751490/2016 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-artemisia-absinthium-l-herba_en.pdf"},
    {"id":"66162","name":"Draft European Union herbal monograph on Species pectorales","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2024-12-15 - 2025-03-15","first_published_date":"2024-12-16T16:14:42Z","last_updated_date":"2024-12-16T16:14:42Z","reference_number":"EMA/HMPC/239465/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-species-pectorales_en.pdf"},
    {"id":"66790","name":"Draft European Union herbal monograph on Hypericum perforatum L, herba and Cimicifuga racemosa (L.) Nutt., rhizoma","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2025-02-15 - 2025-05-15","first_published_date":"2025-02-14T15:25:35Z","last_updated_date":"2025-02-14T15:25:35Z","reference_number":"EMA/HMPC/884573/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-hypericum-perforatum-l-herba-cimicifuga-racemosa-l-nutt-rhizoma_en.pdf"},
    {"id":"67838","name":"Draft European Union herbal monograph on Crataegus monogyna Jacq. (Lindm.), C. laevigata (Poir.) DC. or their hybrids; C. pentagyna Waldst. et Kit. ex Willd.; C. azarolus L.","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2025-04-15 - 2025-07-15","first_published_date":"2025-04-15T11:52:54Z","last_updated_date":"2025-04-15T11:52:54Z","reference_number":"EMA/HMPC/234781/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-crataegus-monogyna-jacq-lindm-c-laevigata-poir-dc-or-their-hybrids-c-pentagyna-waldst-et-kit-ex-willd-c-azarolus-l_en.pdf"},
    {"id":"67841","name":"Draft European Union herbal monograph on Arnica montana L., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2025-04-15 - 2025-07-15","first_published_date":"2025-04-15T12:07:17Z","last_updated_date":"2025-04-15T12:07:17Z","reference_number":"EMA/HMPC/524586/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-arnica-montana-l-flos_en.pdf"},
    {"id":"67845","name":"Draft European Union herbal monograph on Allium sativum L., bulbus","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2025-04-15 - 2025-07-15","first_published_date":"2025-04-15T12:17:44Z","last_updated_date":"2025-04-15T12:17:44Z","reference_number":"EMA/HMPC/329435/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-allium-sativum-l-bulbus_en.pdf-0"},
    {"id":"69608","name":"Draft public statement on Cannabis sativa L., flos","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2025-08-01 - 2025-10-31","first_published_date":"2025-08-01T10:41:13Z","last_updated_date":"2025-08-01T10:41:13Z","reference_number":"EMA/HMPC/69833/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-public-statement-cannabis-sativa-l-flos_en.pdf"},
    {"id":"69609","name":"Draft European Union herbal monograph on Glycyrrhiza glabra L.; Gycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix  – Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2025-08-01 - 2025-10-31","first_published_date":"2025-08-01T11:08:14Z","last_updated_date":"2025-08-01T11:08:14Z","reference_number":"EMA/HMPC/108399/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-glycyrrhiza-glabra-l-gycyrrhiza-inflata-bat-glycyrrhiza-uralensis-fisch-radix-revision-1_en.pdf"},
    {"id":"69612","name":"Draft European Union herbal monograph on Fragaria vesca L.; Fragaria moschata Weston; Fragaria viridis Weston; Fragaria x ananassa (Weston) Duchesne ex Rozier, folium - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2025-08-01 - 2025-10-31","first_published_date":"2025-08-01T11:35:08Z","last_updated_date":"2025-08-01T11:35:08Z","reference_number":"EMA/HMPC/10134/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium-revision-1_en.pdf"},
    {"id":"69615","name":"Draft European Union herbal monograph on Species diureticae - Revision 1","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2025-08-01 - 2025-10-31","first_published_date":"2025-08-01T11:59:47Z","last_updated_date":"2025-08-01T11:59:47Z","reference_number":"EMA/HMPC/85836/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-species-diureticae-revision-1_en.pdf"},
    {"id":"70199","name":"Final European Union herbal monograph on Species pectorales - First version","type":"herbal-monograph","status":"unknown","consultation_date":"","first_published_date":"2025-09-22T10:51:12Z","last_updated_date":"2025-09-22T10:51:12Z","reference_number":"EMA/HMPC/239465/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-species-pectorales-first-version_en.pdf"},
    {"id":"70558","name":"Draft European Union herbal monograph on Zea mays L., stigma","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2025-10-15 - 2026-01-15","first_published_date":"2025-10-15T09:24:37Z","last_updated_date":"2025-10-15T09:24:37Z","reference_number":"EMA/HMPC/509424/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-zea-mays-l-stigma_en.pdf"},
    {"id":"73036","name":"Call for scientific data for the periodic review of the monograph on Absinthii herba","type":"herbal-monograph","status":"Draft: consultation closed","consultation_date":"2026-03-15 - 2026-06-15","first_published_date":"2026-03-16T11:35:10Z","last_updated_date":"2026-03-16T11:35:10Z","reference_number":"EMA/HMPC/57665/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-monograph/call-scientific-data-periodic-review-monograph-absinthii-herba_en.pdf"},
    {"id":"2403","name":"Superseded assessment report on Salix [various species including S. purpurea L., S. daphnoides Vill., S. fragilis L.], cortex","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-09-26T02:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMEA/HMPC/295337/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-cortex_en.pdf"},
    {"id":"3301","name":"Assessment report on Polypodium vulgare L., rhizoma","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/600669/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-polypodium-vulgare-l-rhizoma_en.pdf"},
    {"id":"3335","name":"Final assessment report on Eucalyptus globulus Labill., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-04-19T12:00:00Z","last_updated_date":"2013-04-19T12:00:00Z","reference_number":"EMA/HMPC/892615/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-eucalyptus-globulus-labill-folium_en.pdf"},
    {"id":"3607","name":"Final assessment report on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis raeseri Boiss. & Heldr.; Sideritis syriaca L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/HMPC/39455/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-sideritis-scardica-griseb-sideritis-clandestina-bory-chaub-hayek-sideritis-raeseri-boiss-heldr-sideritis-syriaca-l-herba_en.pdf"},
    {"id":"3848","name":"Superseded assessment report on Olea europaea L., folium - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-04-18T17:30:00Z","last_updated_date":"2012-04-18T17:30:00Z","reference_number":"EMA/HMPC/430506/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-olea-europaea-l-folium-first-version_en.pdf"},
    {"id":"3893","name":"Final assessment report on Sambucus nigra L., fructus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-04-29T02:00:00Z","last_updated_date":"2014-04-29T02:00:00Z","reference_number":"EMA/HMPC/44208/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-sambucus-nigra-l-fructus_en.pdf"},
    {"id":"3938","name":"Draft assessment report on Valeriana officinalis L., radix and Humulus lupulus L., flos – Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2017-12-08T18:35:00Z","last_updated_date":"2017-12-08T18:35:00Z","reference_number":"EMA/HMPC/441766/2017EMA/HMPC/441766/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"3997","name":"Final assessment report on Salvia fruticosa Mill., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-07-01T02:00:00Z","last_updated_date":"2016-07-01T02:00:00Z","reference_number":"EMA/HMPC/599992/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-salvia-fruticosa-mill-folium_en.pdf"},
    {"id":"4052","name":"Final assessment report on Passiflora incarnata L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-06-18T12:05:00Z","last_updated_date":"2014-06-18T12:05:00Z","reference_number":"EMA/HMPC/669738/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-passiflora-incarnata-l-herba_en.pdf"},
    {"id":"4093","name":"Superseded assessment report on Vitex agnus-castus L., fructus - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2018-10-10T02:00:00Z","reference_number":"EMA/HMPC/144003/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-vitex-agnus-castus-l-fructus-first-version_en.pdf"},
    {"id":"4099","name":"Superseded assessment report on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne, radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-03-12T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMEA/HMPC/251324/2006 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-harpagophytum-procumbens-dc-andor-harpagophytum-zeyheri-decne-radix_en.pdf"},
    {"id":"4209","name":"Final assessment report on Polygonum aviculare L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-05-23T18:15:00Z","last_updated_date":"2016-05-23T18:15:00Z","reference_number":"EMA/HMPC/143659/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-polygonum-aviculare-l-herba_en.pdf"},
    {"id":"4633","name":"Final assessment report on Chamaemelum nobile (L.) All., flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T17:20:00Z","last_updated_date":"2012-01-20T17:20:00Z","reference_number":"EMA/HMPC/560906/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-chamaemelum-nobile-l-all-flos_en.pdf"},
    {"id":"4696","name":"Draft assessment report on Prunus africana (Hook f.) Kalkm., cortex","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-12-15T01:00:00Z","last_updated_date":"2015-12-15T01:00:00Z","reference_number":"EMA/HMPC/680624/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-prunus-africana-hook-f-kalkm-cortex_en.pdf"}    {"id":"4946","name":"Draft assessment report on Malva sylvestris L. and/or Malva neglecta Wallr., folium and Malva sylvestris L., flos - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"EMA/HMPC/749518","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-malva-sylvestris-l-andor-malva-neglecta-wallr-folium-and-malva-sylvestris-l-flos-first-version_en.pdf"},
    {"id":"4949","name":"Final assessment report on on Filipendula ulmaria (L.) Maxim., herba and Filipendula ulmaria (L.) Maxim., flos  - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-09-29T02:00:00Z","last_updated_date":"2011-09-29T02:00:00Z","reference_number":"EMA/HMPC/434892/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-filipendula-ulmaria-l-maxim-herba-and-filipendula-ulmaria-l-maxim-flos-first-version_en.pdf"},
    {"id":"5089","name":"Final assessment report on Eucalytus globulus Labill., Eucalyptus polybractea R.T. Baker and/or Eucalyptus smithii R.T. Baker, aetheroleum - Superseded","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2025-02-28T02:00:00Z","reference_number":"EMA/HMPC/307782/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-eucalytus-globulus-labill-eucalyptus-polybractea-rt-baker-or-eucalyptus-smithii-rt-baker-aetheroleum-superseded_en.pdf"},
    {"id":"5231","name":"Draft assessment report on Crataegus spp., folium cum flore","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-10-14T02:00:00Z","last_updated_date":"2014-10-14T02:00:00Z","reference_number":"EMA/HMPC/159076/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-crataegus-spp-folium-cum-flore_en.pdf"},
    {"id":"5638","name":"Second draft assessment report on Urtica dioica L., Urtica urens L., their hybrids or their mixtures, radix - First version","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-19T04:00:00Z","last_updated_date":"2011-10-19T04:00:00Z","reference_number":"EMA/HMPC/461156/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/second-draft-assessment-report-urtica-dioica-l-urtica-urens-l-their-hybrids-or-their-mixtures-radix-first-version_en.pdf"},
    {"id":"5951","name":"Superseded assessment report on Verbascum thapsus L., V. densiflorum Bertol; V. phlomoides L., flos with traditional use","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/HMPC/395206/2007 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-verbascum-thapsus-l-v-densiflorum-bertol-v-phlomoides-l-flos-traditional-use_en.pdf"},
    {"id":"6045","name":"Final assessment report on Carum carvi L.,fructus and Carum carvi L., aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/HMPC/715093/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-carum-carvi-lfructus-and-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"6117","name":"Draft assessment report on Plantaginis lanceolatae folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/HMPC/437859/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-plantaginis-lanceolatae-folium_en.pdf"},
    {"id":"6204","name":"Draft assessment report on Allium cepa L., bulbus","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-08-18T02:00:00Z","last_updated_date":"2011-08-18T02:00:00Z","reference_number":"EMA/HMPC/347195/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-allium-cepa-l-bulbus_en.pdf"},
    {"id":"6209","name":"Draft assessment report on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2015-04-09T02:00:00Z","reference_number":"EMA/HMPC/712510/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf"},
    {"id":"6264","name":"Superseded assessment report on Rhamnus purshianus D.C. and Rhamni purshianae cortex - Cascara and herbal preparation(s) thereof with well-established use and traditional use","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-06-05T02:09:00Z","last_updated_date":"2008-06-05T02:09:00Z","reference_number":"EMEA/HMPC/513580/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-rhamnus-purshianus-dc-and-rhamni-purshianae-cortex-cascara-and-herbal-preparations-thereof-well-established-use-and-traditional-use_en.pdf"},
    {"id":"6406","name":"Final assessment report on Cucurbita pepo L., semen","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/HMPC/136022/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-cucurbita-pepo-l-semen_en.pdf"},
    {"id":"6409","name":"Final  assessment report on Myroxylon balsamum (L.) Harms var. pereirae (Royle) Harms, balsamum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/HMPC/712648/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-myroxylon-balsamum-l-harms-var-pereirae-royle-harms-balsamum_en.pdf"},
    {"id":"6523","name":"Draft assessment report on Tilia tomentosa Moench, flos","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-10-20T02:00:00Z","last_updated_date":"2011-10-20T02:00:00Z","reference_number":"EMA/HMPC/346780/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-tilia-tomentosa-moench-flos_en.pdf"},
    {"id":"6626","name":"Final assessment report on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMA/HMPC/627058/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-harpagophytum-procumbens-dc-andor-harpagophytum-zeyheri-decne-radix_en.pdf"},
    {"id":"6638","name":"Supersede list of references supporting the assessment of Olea europaea L., folium - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-04-18T17:30:00Z","last_updated_date":"2012-04-18T17:30:00Z","reference_number":"EMA/HMPC/430505/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/supersede-list-references-supporting-assessment-olea-europaea-l-folium-first-version_en.pdf"},
    {"id":"6683","name":"Draft assessment report on Hieracium pilosella L., herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2014-08-04T02:00:00Z","last_updated_date":"2014-08-04T02:00:00Z","reference_number":"EMA/HMPC/680373/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-hieracium-pilosella-l-herba_en.pdf"},
    {"id":"6700","name":"Assessment report on Solidago virgaurea L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/285759/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-solidago-virgaurea-l-herba_en.pdf"},
    {"id":"6747","name":"Final assessment report on Sambucus nigra L., flos - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-06-27T17:00:00Z","last_updated_date":"2018-06-27T17:00:00Z","reference_number":"EMA/HMPC/611504/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-sambucus-nigra-l-flos-revision-1_en.pdf"},
    {"id":"6885","name":"Final assessment report on Angelica sinensis (Oliv.) Diels, radix - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-11-25T01:00:00Z","last_updated_date":"2013-11-25T01:00:00Z","reference_number":"EMA/HMPC/614586/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-angelica-sinensis-oliv-diels-radix-first-version_en.pdf"},
    {"id":"6987","name":"Draft assessment report on Myroxylon balsamum (L.) Harms var. pereirae (Royle) Harms, balsamum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"EMA/HMPC/712648/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-myroxylon-balsamum-l-harms-var-pereirae-royle-harms-balsamum_en.pdf"},
    {"id":"7002","name":"Final assessment report on Cimicifuga racemosa (L.) Nutt., rhizome - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-07-03T02:00:00Z","last_updated_date":"2018-07-03T02:00:00Z","reference_number":"EMA/HMPC/48744/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf"},
    {"id":"7067","name":"Draft assessment report on Cynara scolymus L., folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-01-18T01:00:00Z","last_updated_date":"2011-01-18T01:00:00Z","reference_number":"EMA/HMPC/150209/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-cynara-scolymus-l-folium_en.pdf"},
    {"id":"7205","name":"Draft assessment report on Salvia officinalis L., folium and Salvia officinalis L., aetheroleum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2016-02-15T12:00:00Z","last_updated_date":"2016-02-15T12:00:00Z","reference_number":"EMA/HMPC/150801/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-salvia-officinalis-l-folium-and-salvia-officinalis-l-aetheroleum_en.pdf"},
    {"id":"7249","name":"Final assessment report on Solanum dulcamara L., stipites","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T01:00:00Z","last_updated_date":"2013-02-15T01:00:00Z","reference_number":"EMA/HMPC/734363/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-solanum-dulcamara-l-stipites_en.pdf"},
    {"id":"7456","name":"Final assessment report on Agrimonia eupatoria L., herba - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T13:00:00Z","last_updated_date":"2015-04-09T13:00:00Z","reference_number":"EMA/HMPC/680595/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-agrimonia-eupatoria-l-herba-first-version_en.pdf"},
    {"id":"7776","name":"Assessment report on hamamelis virginiana l., cortex hamamelis virginiana l., folium hamamelis virginiana l., folium et cortex aut ramunculus destillatum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMA/HMPC/114585/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-hamamelis-virginiana-l-cortex-hamamelis-virginiana-l-folium-hamamelis-virginiana-l-folium-et-cortex-aut-ramunculus-destillatum_en.pdf"},
    {"id":"7778","name":"Final assessment report on Citrus bergamia Risso et Poiteau, aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-08-28T13:45:00Z","last_updated_date":"2012-08-28T13:45:00Z","reference_number":"EMA/HMPC/56155/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-citrus-bergamia-risso-et-poiteau-aetheroleum_en.pdf"},
    {"id":"7916","name":"Draft assessment report on Commiphora molmol Engler, gummi-resina","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2010-11-16T01:00:00Z","last_updated_date":"2010-11-16T01:00:00Z","reference_number":"EMA/HMPC/96910/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-commiphora-molmol-engler-gummi-resina_en.pdf"},
    {"id":"7965","name":"Superseded assessment report for the development of a community monograph and for inclusion of herbal substance(s), preparation(s) or combinations thereof in the list Eleutherococcus senticosus (Ruppr. et Maxim.) Maxim.,...","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2014-10-06T02:09:21Z","reference_number":"EMEA/HMPC/232403/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-development-community-monograph-and-inclusion-herbal-substances-preparations-or-combinations-thereof-list-eleutherococcus-senticosus-ruppr-et-maxim-maxim_en.pdf"},
    {"id":"7981","name":"Superseded assessment report on Valeriana officinalis L., radix (Valerianae aetheroleum)","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-06-20T02:00:00Z","last_updated_date":"2016-06-20T02:00:00Z","reference_number":"EMEA/HMPC/167391/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-valeriana-officinalis-l-radix-valerianae-aetheroleum_en.pdf"},
    {"id":"7983","name":"Draft assessment report on Origanum dictamnus L., herba - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-02-04T12:35:00Z","last_updated_date":"2013-02-04T12:35:00Z","reference_number":"EMA/HMPC/200431/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-origanum-dictamnus-l-herba-first-version_en.pdf"},
    {"id":"8048","name":"Draft assessment report on Fumaria officinalis L., herba","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2011-02-15 - 2011-06-15","first_published_date":"2011-04-04T04:00:00Z","last_updated_date":"2011-04-04T04:00:00Z","reference_number":"EMA/HMPC/576232/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-fumaria-officinalis-l-herba_en.pdf"},
    {"id":"8065","name":"Draft assessment report on Origanum majorana L., herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2016-02-15T17:15:00Z","last_updated_date":"2016-02-15T17:15:00Z","reference_number":"EMA/HMPC/63479/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-origanum-majorana-l-herba_en.pdf"},
    {"id":"8348","name":"Draft assessment report on Rosa centifolia L.; Rosa gallica L.; Rosa damascena Mill., flos","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/HMPC/137298/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-rosa-centifolia-l-rosa-gallica-l-rosa-damascena-mill-flos_en.pdf"},
    {"id":"8553","name":"Superseded final assessment report on Rhodiola rosea  - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T16:00:00Z","last_updated_date":"2024-05-23T16:00:00Z","reference_number":"EMA/HMPC/232100/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-final-assessment-report-rhodiola-rosea-first-version_en.pdf"},
    {"id":"8568","name":"Superseded assessment report on Plantago ovate Forssk., seminis tegumentum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMEA/HMPC/165838/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-plantago-ovate-forssk-seminis-tegumentum_en.pdf"},
    {"id":"8595","name":"Final assessment report on Chelidonium majus L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/HMPC/369801/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-chelidonium-majus-l-herba_en.pdf"},
    {"id":"8647","name":"Final assessment report on Ilex paraguariensis St. Hilaire, folium - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-02-14T01:00:00Z","last_updated_date":"2011-02-14T01:00:00Z","reference_number":"EMA/HMPC/580545/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-ilex-paraguariensis-st-hilaire-folium-first-version_en.pdf"},
    {"id":"8670","name":"Draft assessment report on Vaccinium myrtillus L., fructus","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-02-09T01:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMA/HMPC/555161/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-vaccinium-myrtillus-l-fructus_en.pdf"},
    {"id":"8783","name":"Superseded assessment report on Valeriana officinalis L., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-11-29T00:09:21Z","last_updated_date":"2016-04-28T01:09:21Z","reference_number":"EMEA/HMPC/167391/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-valeriana-officinalis-l-radix_en.pdf"},
    {"id":"8824","name":"Draft assessment report on Achillea millefolium L., herba","type":"herbal-report","status":"Draft","consultation_date":"2010-11-15 - 2011-02-15","first_published_date":"2010-11-09T02:00:00Z","last_updated_date":"2010-11-09T02:00:00Z","reference_number":"EMA/HMPC/290309/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-achillea-millefolium-l-herba_en.pdf"},
    {"id":"8941","name":"Superseded assessment report on Mentha x piperita L., aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/349465/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-mentha-x-piperita-l-aetheroleum_en.pdf"},
    {"id":"9239","name":"Final assessment report on Serenoa repens (W. Bartram) Small, fructus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-03-30T02:00:00Z","last_updated_date":"2016-03-30T02:00:00Z","reference_number":"EMA/HMPC/137250/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-serenoa-repens-w-bartram-small-fructus_en.pdf"},
    {"id":"9251","name":"Draft assessment report on Helichrysum arenarium (L.) Moench, flos","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-10-14T12:35:00Z","last_updated_date":"2015-10-14T12:35:00Z","reference_number":"EMA/HMPC/41109/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-helichrysum-arenarium-l-moench-flos_en.pdf"},
    {"id":"9489","name":"Final assessment report on Cichorium intybus L., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-03-14T16:00:00Z","last_updated_date":"2013-03-14T16:00:00Z","reference_number":"EMA/HMPC/113041/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-cichorium-intybus-l-radix_en.pdf"},
    {"id":"9591","name":"Draft assessment report on Primula veris L. and / or Primula elatior (L.) Hill, flos","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMEA/HMPC/64683/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-primula-veris-l-and-or-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"9646","name":"Draft assessment report on Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-04-19T02:00:00Z","last_updated_date":"2013-04-19T02:00:00Z","reference_number":"EMA/HMPC/283629/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"9719","name":"Draft assessment report on Eschscholzia californica Cham., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2014-07-31T19:15:00Z","last_updated_date":"2014-07-31T19:15:00Z","reference_number":"EMA/HMPC/680375/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-eschscholzia-californica-cham-herba_en.pdf"},
    {"id":"9765","name":"Draft assessment report on Glycine max (L.) Merr., lecithin","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2016-07-27T15:40:00Z","last_updated_date":"2016-07-27T15:40:00Z","reference_number":"EMA/HMPC/220598/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-glycine-max-l-merr-lecithin_en.pdf"},
    {"id":"9947","name":"Final assessment report on Carum carvi L., fructus and Carum carvi L., aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/HMPC/715093/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-carum-carvi-l-fructus-and-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"10021","name":"Superseded final assessment report on Aesculus hippocastanum L., cortex","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-27T16:15:00Z","last_updated_date":"2012-06-27T16:15:00Z","reference_number":"EMA/HMPC/354157/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-final-assessment-report-aesculus-hippocastanum-l-cortex_en.pdf"},
    {"id":"10030","name":"Superseded assessment report on Plantago ovata Forssk., semen","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2013-07-23T02:00:00Z","reference_number":"EMEA/HMPC/166377/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-plantago-ovata-forssk-semen_en.pdf"},
    {"id":"10093","name":"Draft assessment report on Piper methysticum G. Forst., rhizoma","type":"herbal-report","status":"unknown","consultation_date":"2016-12-15 - 2017-03-15","first_published_date":"2016-12-15T11:35:00Z","last_updated_date":"2016-12-15T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-piper-methysticum-g-forst-rhizoma_en.pdf"},
    {"id":"10244","name":"Final assessment report on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-08-24T17:00:00Z","last_updated_date":"2013-04-02T15:00:00Z","reference_number":"EMA/HMPC/571122/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf"},
    {"id":"10296","name":"Final assessment report on Plantago ovata Forssk., seminis tegumentum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T16:00:00Z","last_updated_date":"2013-07-23T16:00:00Z","reference_number":"EMA/HMPC/199775/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-plantago-ovata-forssk-seminis-tegumentum_en.pdf"},
    {"id":"10300","name":"Draft assessment report on Capsella bursa-pastoris (L.) Medikus, herba - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-01-18T01:00:00Z","last_updated_date":"2011-01-18T01:00:00Z","reference_number":"EMA/HMPC/262767/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-capsella-bursa-pastoris-l-medikus-herba-first-version_en.pdf"},
    {"id":"10495","name":"Final assessment report on Urtica dioica L., Urtica urens L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-01-17T01:00:00Z","last_updated_date":"2011-01-17T01:00:00Z","reference_number":"EMA/HMPC/508013/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-urtica-dioica-l-urtica-urens-l-folium_en.pdf"},
    {"id":"10518","name":"Final assessment report on Symphytum officinale L., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-06-05T02:00:00Z","last_updated_date":"2015-06-05T02:00:00Z","reference_number":"EMA/HMPC/572844/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-symphytum-officinale-l-radix_en.pdf"},
    {"id":"10534","name":"Superseded assessment report on Foeniculum vulgare Miller","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T00:09:00Z","last_updated_date":"2024-03-07T17:15:00Z","reference_number":"EMEA/HMPC/137426/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-foeniculum-vulgare-miller_en.pdf"},
    {"id":"10709","name":"Final assessment report on Thymus vulgaris L., Thymus zygis Loefl. ex. L., aetheroleum - Superseded","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/HMPC/131903/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-thymus-vulgaris-l-thymus-zygis-loefl-ex-l-aetheroleum-superseded_en.pdf"},
    {"id":"10758","name":"Final assessment report on Calendula officinalis L., flos - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-06-14T15:00:00Z","last_updated_date":"2018-06-14T15:00:00Z","reference_number":"EMA/HMPC/603409/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-calendula-officinalis-l-flos-revision-1_en.pdf"},
    {"id":"10865","name":"Draft assessment report on Grindelia robusta Nutt., Grindelia squarrosa (Pursh) Dunal, Grindelia humilis Hook. et Arn., Grindelia camporum Greene, herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2012-05-16T02:00:00Z","last_updated_date":"2012-05-16T02:00:00Z","reference_number":"EMA/HMPC/748218/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-grindelia-robusta-nutt-grindelia-squarrosa-pursh-dunal-grindelia-humilis-hook-et-arn-grindelia-camporum-greene-herba_en.pdf"},
    {"id":"10924","name":"Draft assessment report on Chelidonium majus L., herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-01-18T01:00:00Z","last_updated_date":"2011-01-18T01:00:00Z","reference_number":"EMA/HMPC/369801/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-chelidonium-majus-l-herba_en.pdf"},
    {"id":"11401","name":"Final assessment report on Rosa gallica L., Rosa centifolia L., Rosa damascena Mill., flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-09-10T02:00:00Z","last_updated_date":"2014-09-10T02:00:00Z","reference_number":"EMA/HMPC/137298/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-rosa-gallica-l-rosa-centifolia-l-rosa-damascena-mill-flos_en.pdf"},
    {"id":"11597","name":"Draft assessment report on Malva sylvestris L. and/or Malva neglecta Wallr., folium and Malva sylvestris L., flos - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"EMA/HMPC/749518","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-malva-sylvestris-l-andor-malva-neglecta-wallr-folium-and-malva-sylvestris-l-flos-first-version_en.pdf-0"},
    {"id":"11612","name":"Draft assessment report on Olea europaea L., folium","type":"herbal-report","status":"Draft","consultation_date":"2011-02-15 - 2011-06-15","first_published_date":"2011-07-14T04:00:00Z","last_updated_date":"2011-07-14T04:00:00Z","reference_number":"EMA/HMPC/430506/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-olea-europaea-l-folium_en.pdf"},
    {"id":"11886","name":"Final assessment report on Verbascum thapsus L., V. densiflorum Bertol. (V. thapsiforme Schrad) and V. phlomoides L., flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T02:00:00Z","last_updated_date":"2018-06-22T02:00:00Z","reference_number":"EMA/HMPC/611531/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-verbascum-thapsus-l-v-densiflorum-bertol-v-thapsiforme-schrad-and-v-phlomoides-l-flos_en.pdf"},
    {"id":"11994","name":"Final assessment report on Eschscholzia californica Cham., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/HMPC/680375/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-eschscholzia-californica-cham-herba_en.pdf"},
    {"id":"12000","name":"Final assessment report on Valeriana officinalis L., radix and Valeriana officinalis L., aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-04-27T12:30:00Z","last_updated_date":"2016-04-27T12:30:00Z","reference_number":"EMA/HMPC/150846/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-valeriana-officinalis-l-radix-and-valeriana-officinalis-l-aetheroleum_en.pdf"},
    {"id":"12017","name":"Final assessment report on Plantago lanceolata L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T01:00:00Z","last_updated_date":"2012-02-24T01:00:00Z","reference_number":"EMA/HMPC/437859/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-plantago-lanceolata-l-folium_en.pdf"},
    {"id":"12074","name":"Draft assessment report on Curcuma xanthorrhiza roxb., rhizoma","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-06-19T02:00:00Z","last_updated_date":"2013-06-19T02:00:00Z","reference_number":"EMA/HMPC/604598/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-curcuma-xanthorrhiza-roxb-rhizoma_en.pdf"},
    {"id":"12351","name":"Final assessment report on Echinacea purpurea (L.) Moench., herba recens","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-04-13T02:00:00Z","last_updated_date":"2015-04-13T02:00:00Z","reference_number":"EMA/HMPC/557979/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-echinacea-purpurea-l-moench-herba-recens_en.pdf"},
    {"id":"12442","name":"Superseded final assessment report on Tanacetum parthenium (L.) Schulz Bip., herba -First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-06-20T02:00:00Z","last_updated_date":"2020-08-14T02:00:00Z","reference_number":"EMA/HMPC/587579/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-final-assessment-report-tanacetum-parthenium-l-schulz-bip-herba-first-version_en.pdf"},
    {"id":"12452","name":"Draft assessment report on Cimicifuga racemosa (L.) Nutt., rhizome - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2017-08-04T02:00:00Z","last_updated_date":"2017-08-04T02:00:00Z","reference_number":"EMA/HMPC/48744/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf"},
    {"id":"12661","name":"Final assessment report on Hieracium pilosella L., herba cum radice - Superseded","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2015-06-17T13:25:00Z","last_updated_date":"2025-02-26T13:25:00Z","reference_number":"EMA/HMPC/680373/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-hieracium-pilosella-l-herba-cum-radice-superseded_en.pdf"},
    {"id":"13050","name":"Assessment report on Linum usitatissimum L., semen","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-07-13T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMA/HMPC/377674/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-linum-usitatissimum-l-semen_en.pdf"},
    {"id":"13060","name":"Draft assessment report on Hedera helix L., folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2010-03-08T01:00:00Z","last_updated_date":"2015-02-12T01:00:00Z","reference_number":"EMA/HMPC/586887/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-hedera-helix-l-folium_en.pdf"},
    {"id":"13219","name":"Draft assessment report on Silybum marianum (L.) Gaertn., fructus","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-07-23T12:50:00Z","last_updated_date":"2015-07-23T12:50:00Z","reference_number":"EMA/HMPC/294188/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-silybum-marianum-l-gaertn-fructus_en.pdf"},
    {"id":"13259","name":"Final assessment report on Pimpinella anisum L., fructus and Pimpinella anisum L., aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-06-18T02:00:00Z","last_updated_date":"2014-06-18T02:00:00Z","reference_number":"EMEA/HMPC/321181/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-pimpinella-anisum-l-fructus-and-pimpinella-anisum-l-aetheroleum_en.pdf"},
    {"id":"13263","name":"Draft assessment report on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix  - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-08-19T02:00:00Z","last_updated_date":"2011-08-19T02:00:00Z","reference_number":"EMA/HMPC/571122/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf"},
    {"id":"13269","name":"Draft assessment report on Trigonella foenum-graecum L., semen","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2010-05-15 - 2010-09-15","first_published_date":"2010-06-10T04:00:00Z","last_updated_date":"2010-06-10T04:00:00Z","reference_number":"EMA/HMPC/146220/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-trigonella-foenum-graecum-l-semen_en.pdf"},
    {"id":"13517","name":"Superseded assessment report on Cassia senna L. and Cassia angustifolia Vahl, folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-04-27T02:09:00Z","last_updated_date":"2007-04-27T02:09:00Z","reference_number":"EMEA/HMPC/51868/2006 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-cassia-senna-l-and-cassia-angustifolia-vahl-folium_en.pdf"},
    {"id":"13531","name":"Draft assessment report on Rhodiola rosea - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-09-20T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"EMA/HMPC/232100/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-rhodiola-rosea-first-version_en.pdf"},
    {"id":"13563","name":"Superseded assessment report on Arctostaphylos uva-ursi (L.) Spreng., folium - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2018-04-11T14:00:00Z","reference_number":"EMA/HMPC/573462/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-arctostaphylos-uva-ursi-l-spreng-folium-revision-1_en.pdf"},
    {"id":"13742","name":"Final assessment report on Capsicum annuum L. var. minimum (Miller) Heiser and small fruited varieties of Capsicum frutescens L., fructus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/HMPC/674138/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-capsicum-annuum-l-var-minimum-miller-heiser-and-small-fruited-varieties-capsicum-frutescens-l-fructus_en.pdf"},
    {"id":"14101","name":"Draft assessment report on Pelargonium sidoides DC and / or Pelargonium reniforme Curt., radix","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-10-26T01:00:00Z","last_updated_date":"2015-10-26T01:00:00Z","reference_number":"EMA/HMPC/444251/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-pelargonium-sidoides-dc-and-or-pelargonium-reniforme-curt-radix_en.pdf"},
    {"id":"14115","name":"Superseded assessment report on Curcuma longa L., rhizoma - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-02-04T01:00:00Z","last_updated_date":"2010-02-04T01:00:00Z","reference_number":"EMEA/HMPC/456848/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-curcuma-longa-l-rhizoma-first-version_en.pdf"},
    {"id":"14146","name":"Final assessment report on Echinacea angustifolia DC., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T16:30:00Z","last_updated_date":"2012-05-29T16:30:00Z","reference_number":"EMA/HMPC/688212/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-echinacea-angustifolia-dc-radix_en.pdf"},
    {"id":"14175","name":"Draft assessment report on Cichorium intybus L., radix","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2012-06-15T13:00:00Z","last_updated_date":"2012-06-15T13:00:00Z","reference_number":"EMA/HMPC/113041/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-cichorium-intybus-l-radix_en.pdf"},
    {"id":"14293","name":"Draft assessment report on Gentiana lutea L., radix – Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/607863/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-gentiana-lutea-l-radix-revision-1_en.pdf"},
    {"id":"14345","name":"Draft assessment report on Cimicifuga racemosa (L.) Nutt., rhizome - First version","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-09-17T02:09:21Z","last_updated_date":"2009-09-17T02:09:21Z","reference_number":"EMEA/HMPC/3968/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-cimicifuga-racemosa-l-nutt-rhizome-first-version_en.pdf"},
    {"id":"14356","name":"Draft assessment report on on Agrimonia eupatoria L., herba - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/HMPC/680595/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-agrimonia-eupatoria-l-herba-first-version_en.pdf"},
    {"id":"14446","name":"Draft assessment report on Levisticum officinale Koch, radix","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2012-05-03T15:41:00Z","last_updated_date":"2012-05-03T15:41:00Z","reference_number":"EMA/HMPC/524623/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-levisticum-officinale-koch-radix_en.pdf"},
    {"id":"14583","name":"Draft assessment report on Paeonia lactiflora Pall. and Paeonia veitchii Lynch, radix (Paeoniae radix rubra)","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2016-02-16T01:00:00Z","last_updated_date":"2016-02-16T01:00:00Z","reference_number":"EMA/HHMP/762953/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-paeonia-lactiflora-pall-and-paeonia-veitchii-lynch-radix-paeoniae-radix-rubra_en.pdf"},
    {"id":"14690","name":"Draft assessment report on Rubus idaeus L., folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/HMPC/44209/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-rubus-idaeus-l-folium_en.pdf"},
    {"id":"15089","name":"Final assessment report on Echinacea purpurea (L.) Moench, radix – Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-08-11T02:00:00Z","last_updated_date":"2017-08-11T02:00:00Z","reference_number":"EMA/HMPC/424584/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-echinacea-purpurea-l-moench-radix-revision-1_en.pdf"},
    {"id":"15114","name":"Draft assessment report on Symphytum officinale L., radix","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-08-19T02:00:00Z","last_updated_date":"2011-08-19T02:00:00Z","reference_number":"EMA/HMPC/572844/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-symphytum-officinale-l-radix_en.pdf"},
    {"id":"15172","name":"Superseded assessment report on Echinacea purpurea (L.) Moench, radix - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-02-10T01:00:00Z","last_updated_date":"2011-02-10T01:00:00Z","reference_number":"EMA/HMPC/577786/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-echinacea-purpurea-l-moench-radix-first-version_en.pdf"},
    {"id":"15248","name":"Draft assessment report on Vitis vinifera L., folium","type":"herbal-report","status":"unknown","consultation_date":"2016-12-15 - 2017-03-15","first_published_date":"2016-12-15T11:54:00Z","last_updated_date":"2016-12-15T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-vitis-vinifera-l-folium_en.pdf"}    {"id":"15532","name":"Draft assessment report on Paeonia lactiflora Pallas, radix (Paeoniae radix alba)","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2016-02-16T16:10:00Z","last_updated_date":"2016-02-16T16:10:00Z","reference_number":"EMA/HHMP/762954/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-paeonia-lactiflora-pallas-radix-paeoniae-radix-alba_en.pdf"},
    {"id":"15540","name":"Final assessment report on Thymus vulgaris L., vulgaris zygis L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-06-02T02:00:00Z","last_updated_date":"2014-06-02T02:00:00Z","reference_number":"EMA/HMPC/342334/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-thymus-vulgaris-l-vulgaris-zygis-l-herba_en.pdf"},
    {"id":"15775","name":"Superseded assessment report on Primula veris L., primula elatior (L.) Hill, radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-11-24T01:00:00Z","last_updated_date":"2008-11-24T01:00:00Z","reference_number":"EMEA/HMPC/144474/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-primula-veris-l-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"15825","name":"Draft assessment report on Sambucus nigra L., fructus","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-04-19T02:00:00Z","last_updated_date":"2013-04-19T02:00:00Z","reference_number":"EMA/HMPC/44208/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-sambucus-nigra-l-fructus_en.pdf"},
    {"id":"15898","name":"Final assessment report on Humulus lupulus L., flos - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-08-07T02:00:00Z","last_updated_date":"2014-08-07T02:00:00Z","reference_number":"EMA/HMPC/418902/2005","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"15900","name":"Draft assessment report on Echinaceae angustifolia DC., radix","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-07-28T02:00:00Z","last_updated_date":"2011-07-28T02:00:00Z","reference_number":"EMA/HMPC/688212/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-echinaceae-angustifolia-dc-radix_en.pdf"},
    {"id":"15924","name":"Final assessment report on Uncaria tomentosa (Willd. ex Schult.) DC., cortex","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMA/HMPC/259598/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-uncaria-tomentosa-willd-ex-schult-dc-cortex_en.pdf"},
    {"id":"15960","name":"Final assessment report on Paeonia lactiflora Pall. and/or Paeonia veitchii Lynch, radix (Paeoniae radix rubra)","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2017-04-25T17:35:00Z","last_updated_date":"2017-04-28T12:47:00Z","reference_number":"EMA/HHMP/762953/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-paeonia-lactiflora-pall-andor-paeonia-veitchii-lynch-radix-paeoniae-radix-rubra_en.pdf"},
    {"id":"16027","name":"Superseded assessment report on Passiflora incarnate L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-11-15T00:09:21Z","last_updated_date":"2014-06-19T01:09:21Z","reference_number":"EMEA/HMPC/230961/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-passiflora-incarnate-l-herba_en.pdf"},
    {"id":"16084","name":"Final assessment report on Melilotus officinalis (L.) Lam., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-04-23T16:10:00Z","last_updated_date":"2018-04-23T16:10:00Z","reference_number":"EMA/HMPC/44165/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"16674","name":"Final assessment report on Levisticum officinale Koch, radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T16:00:00Z","last_updated_date":"2013-02-22T16:00:00Z","reference_number":"EMA/HMPC/524623/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-levisticum-officinale-koch-radix_en.pdf"},
    {"id":"16694","name":"Draft assessment report on Matricaria recutita L., flos and Matricaria recutita L., aetheroleum - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2014-07-24T02:00:00Z","last_updated_date":"2014-07-24T02:00:00Z","reference_number":"EMA/HMPC/55837/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-matricaria-recutita-l-flos-and-matricaria-recutita-l-aetheroleum-first-version_en.pdf"},
    {"id":"16711","name":"Draft assessment report on Zingiberis rhizoma","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-09-20T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"EMA/HMPC/577856/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-zingiberis-rhizoma_en.pdf"},
    {"id":"16712","name":"Draft assessment report on Fucus vesiculosus L., thallus","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-08-19T02:00:00Z","last_updated_date":"2013-08-19T02:00:00Z","reference_number":"EMA/HMPC/313675/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-fucus-vesiculosus-l-thallus_en.pdf"},
    {"id":"16830","name":"Draft assessment report on Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-08-21T02:00:00Z","last_updated_date":"2013-08-21T02:00:00Z","reference_number":"EMA/HMPC/320932/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-melaleuca-alternifolia-maiden-and-betch-cheel-m-linariifolia-smith-m-dissitiflora-f-mueller-andor-other-species-melaleuca-aetheroleum-first-version_en.pdf"},
    {"id":"16863","name":"Final assessment report on Fraxinus excelsior L. or Fraxinus angustifolia Vahl, folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T16:40:00Z","last_updated_date":"2012-06-18T16:40:00Z","reference_number":"EMA/HMPC/239269/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-fraxinus-excelsior-l-or-fraxinus-angustifolia-vahl-folium_en.pdf"},
    {"id":"16941","name":"Draft assessment report on Fraxinus excelsior L. and Fraxinus angustifolia Vahl, folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-08-30T02:00:00Z","last_updated_date":"2011-08-30T02:00:00Z","reference_number":"EMA/HMPC/239269/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-fraxinus-excelsior-l-and-fraxinus-angustifolia-vahl-folium_en.pdf"},
    {"id":"17044","name":"Draft assessment report on Ricinus communis L., oleum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-07-22T02:00:00Z","last_updated_date":"2015-07-22T02:00:00Z","reference_number":"EMA/HMPC/572973/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-ricinus-communis-l-oleum_en.pdf"},
    {"id":"17072","name":"Final assessment report on Hedera helix  L., folium  - Revision 2","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2018-08-13T13:47:00Z","last_updated_date":"2018-08-13T13:47:00Z","reference_number":"EMA/HMPC/325715/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-hedera-helix-l-folium-revision-2_en.pdf"},
    {"id":"17467","name":"Superseded assessment report on Echinacea purpurea (L.) Moench., herba recens","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-03-06T00:09:21Z","last_updated_date":"2015-04-14T01:09:21Z","reference_number":"EMEA/HMPC/104918/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-echinacea-purpurea-l-moench-herba-recens_en.pdf"},
    {"id":"17508","name":"Final assessment report on Plantago ovata Forskk., semen","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T15:30:00Z","last_updated_date":"2013-07-23T15:30:00Z","reference_number":"EMA/HMPC/304360/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-plantago-ovata-forskk-semen_en.pdf"},
    {"id":"17652","name":"Final assessment report on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny), herba cum flore","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-10-13T11:40:00Z","last_updated_date":"2011-10-13T11:40:00Z","reference_number":"EMA/HMPC/131735/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-viola-tricolor-l-andor-subspecies-viola-arvensis-murray-gaud-and-viola-vulgaris-koch-oborny-herba-cum-flore_en.pdf"},
    {"id":"17809","name":"Final assessment report on Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-04-29T14:45:00Z","last_updated_date":"2014-04-29T14:45:00Z","reference_number":"EMA/HPC/283629/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"17855","name":"Draft assessment report on Hypericum perforatum L., herba - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2018-03-08T01:00:00Z","last_updated_date":"2018-03-08T01:00:00Z","reference_number":"EMA/HMPC/244315/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-hypericum-perforatum-l-herba-revision-1_en.pdf"},
    {"id":"17964","name":"Superseded assessment report on Vitis vinifera L., folium - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/16633/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-vitis-vinifera-l-folium-first-version_en.pdf"},
    {"id":"18045","name":"Superseded assessment report on Althaea officinalis L., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-05-14T02:09:21Z","last_updated_date":"2016-11-04T14:29:00Z","reference_number":"EMEA/HMPC/98718/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-althaea-officinalis-l-radix_en.pdf"},
    {"id":"18105","name":"Final assessment report on Vaccinium myrtillus L., fructus recens and Vaccinium myrtillus L., fructus siccus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"EMA/HMPC/555161/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-vaccinium-myrtillus-l-fructus-recens-and-vaccinium-myrtillus-l-fructus-siccus_en.pdf"},
    {"id":"18374","name":"Final assessment report on Pimpinella anisum L., fructus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-06-17T02:00:00Z","last_updated_date":"2014-06-17T02:00:00Z","reference_number":"EMEA/HMPC/321181/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-pimpinella-anisum-l-fructus_en.pdf"},
    {"id":"18379","name":"Superseded assessment report on Rhamnus frangula L., cortex - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/76306/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-rhamnus-frangula-l-cortex-first-version_en.pdf"},
    {"id":"18415","name":"Draft assessment report on Silybum marianum (L.) Gaertn., fructus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T16:59:00Z","last_updated_date":"2016-11-07T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-silybum-marianum-l-gaertn-fructus_en.pdf-0"},
    {"id":"18756","name":"Final assessment report on Primula veris L. and / or Primula elatior (L.) Hill, flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T01:00:00Z","last_updated_date":"2013-03-04T01:00:00Z","reference_number":"EMA/HMPC/136583/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-primula-veris-l-and-or-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"18818","name":"Superseded assessment report on Ruscus aculeatus L., rhizoma","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2019-05-02T17:00:00Z","reference_number":"EMEA/HMPC/261939/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-ruscus-aculeatus-l-rhizoma_en.pdf"},
    {"id":"18973","name":"Draft assessment report on Viscum album L., herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-10-20T11:30:00Z","last_updated_date":"2011-10-20T11:30:00Z","reference_number":"EMA/HMPC/246778/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-viscum-album-l-herba_en.pdf"},
    {"id":"19512","name":"Final assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich), rhizoma","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T13:00:00Z","last_updated_date":"2014-05-12T13:00:00Z","reference_number":"EMA/HMPC/604598/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-curcuma-xanthorrhiza-roxb-c-xanthorrhiza-d-dietrich-rhizoma_en.pdf"},
    {"id":"19889","name":"Final assessment report on Sisymbrium officinale (L.) Scop., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-10-30T01:00:00Z","last_updated_date":"2014-10-30T01:00:00Z","reference_number":"EMA/HMPC/280194/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-sisymbrium-officinale-l-scop-herba_en.pdf"},
    {"id":"19940","name":"Final assessment report on Primula veris L. and / or Primula elatior (L.) Hill, radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T01:00:00Z","last_updated_date":"2013-03-04T01:00:00Z","reference_number":"EMA/HMPC/113577/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-primula-veris-l-and-or-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"19992","name":"Draft assessment report on Capsicum annuum L.\n\nvar. minimum (Miller) Heiser and small fruited varieties of\n\nCapsicum frutescens L., fructus","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2014-09-12T02:00:00Z","last_updated_date":"2014-09-12T02:00:00Z","reference_number":"EMA/HMPC/674138/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-capsicum-annuum-l-var-minimum-miller-heiser-and-small-fruited-varieties-capsicum-frutescens-l-fructus_en.pdf"},
    {"id":"20104","name":"Assessment report on Cinnamomum verum J. S. Presl, cortex and corticis aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2011-08-05T02:00:00Z","reference_number":"EMA/HMPC/246773/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-cinnamomum-verum-j-s-presl-cortex-and-corticis-aetheroleum_en.pdf"},
    {"id":"20258","name":"Draft assessment report on Leonurus cardiaca L., herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2010-05-26T02:00:00Z","last_updated_date":"2010-05-26T02:00:00Z","reference_number":"EMA/HMPC/127430/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-leonurus-cardiaca-l-herba_en.pdf"},
    {"id":"20594","name":"Draft assessment report on Cetraria islandica (L.) Acharius s.l., thallus - First version","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2014-05-19T02:00:00Z","last_updated_date":"2014-05-19T02:00:00Z","reference_number":"EMA/HMPC/36866/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-cetraria-islandica-l-acharius-sl-thallus-first-version_en.pdf"},
    {"id":"20929","name":"Superseded assessment report on Centaurium erythraea Rafn s. L. including C. majus (H. et L.) Zeltner and C. suffruticosum (griseb.) Ronn., herba, for the development of a community herbal monograph","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-03-12T00:09:21Z","last_updated_date":"2016-01-28T00:09:21Z","reference_number":"EMEA/HMPC/105535/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-centaurium-erythraea-rafn-s-l-including-c-majus-h-et-l-zeltner-and-c-suffruticosum-griseb-ronn-herba-development-community-herbal-monograph_en.pdf"},
    {"id":"21066","name":"Superseded assessment report on Echinacea pallida (nutt.) nutt., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:09:21Z","last_updated_date":"2018-08-14T02:09:21Z","reference_number":"EMEA/HMPC/332358/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-echinacea-pallida-nutt-nutt-radix_en.pdf"},
    {"id":"21121","name":"Draft assessment report on Arnica montana L., flos","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-08-22T02:00:00Z","last_updated_date":"2013-08-22T02:00:00Z","reference_number":"EMA/HMPC/198794/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-arnica-montana-l-flos_en.pdf"},
    {"id":"21163","name":"Superseded assessment report for the development of community herbal monographs and for inclusion of herbal substance(s), preparation(s) or combinations thereof in the community list Calendula officinalis L., flos - Firs...","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-03-06T00:09:21Z","last_updated_date":"2018-06-15T01:09:21Z","reference_number":"EMEA/HMPC/179282/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-development-community-herbal-monographs-and-inclusion-herbal-substances-preparations-or-combinations-thereof-community-list-calendula-officinalis-l-flos-firs_en.pdf"},
    {"id":"21354","name":"Final assessment report on Ginkgo biloba L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2015-04-08T02:00:00Z","reference_number":"EMA/HMPC/321095/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-ginkgo-biloba-l-folium_en.pdf"},
    {"id":"21494","name":"Draft Assessment report on Valeriana officinalis L., radix and Humulus lupulus L., flos","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-05-14T02:09:21Z","last_updated_date":"2009-05-14T02:09:21Z","reference_number":"EMEA/HMPC/215214/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos_en.pdf"},
    {"id":"21530","name":"Final assessment report on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-10-06T02:00:00Z","last_updated_date":"2014-10-06T02:00:00Z","reference_number":"EMA/HMPC/680615/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf"},
    {"id":"21638","name":"Superseded assessment report on Primula veris L. and / or Primula elatior (L.) Hill, flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMA/HMPC/64683/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-primula-veris-l-and-or-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"21663","name":"Final assessment report on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl., semen","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-02-07T01:00:00Z","last_updated_date":"2012-02-07T01:00:00Z","reference_number":"EMA/HMPC/722365/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-cola-nitida-vent-schott-et-endl-and-its-varieties-and-cola-acuminata-p-beauv-schott-et-endl-semen_en.pdf"},
    {"id":"21813","name":"Final assessment report on Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-06-09T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"EMA/HMPC/85124/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"21960","name":"Final assessment report on Matricaria recutita L., flos and Matricaria recutita L., aetheroleum - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-04-05T02:00:00Z","last_updated_date":"2016-04-05T02:00:00Z","reference_number":"EMA/HMPC/55837/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-matricaria-recutita-l-flos-and-matricaria-recutita-l-aetheroleum-first-version_en.pdf"},
    {"id":"21975","name":"Final assessment report on Paeonia lactiflora Pall. and/or Paeonia veitchii Lynch, radix (Paeoniae radix rubra)","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2017-04-25T17:35:00Z","last_updated_date":"2017-04-25T17:35:00Z","reference_number":"EMA/HHMP/762953/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-paeonia-lactiflora-pall-andor-paeonia-veitchii-lynch-radix-paeoniae-radix-rubra_en.pdf-0"},
    {"id":"22000","name":"Final assessment report on Cetraria islandica (L.) Acharius s.l., thallus - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-11T11:45:00Z","last_updated_date":"2015-02-11T11:45:00Z","reference_number":"EMA/HMPC/36866/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-cetraria-islandica-l-acharius-sl-thallus-first-version_en.pdf"},
    {"id":"22496","name":"Final assessment report on Ricinus communis L., oleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-03-01T01:00:00Z","last_updated_date":"2016-03-01T01:00:00Z","reference_number":"EMA/HMPC/572973/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-ricinus-communis-l-oleum_en.pdf"},
    {"id":"22506","name":"Final assessment report on Euphrasia officinalis L. and Euphrasia rostkoviana Hayne, herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/246799/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-euphrasia-officinalis-l-and-euphrasia-rostkoviana-hayne-herba_en.pdf"},
    {"id":"22546","name":"Superseded assessment report on Urtica dioica L., and Urtica urens L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2025-03-07T02:00:00Z","reference_number":"EMEA/HMPC/168380/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-urtica-dioica-l-urtica-urens-l-herba_en.pdf"},
    {"id":"22624","name":"Draft assessment report on Pelargonium sidoides DC and / or Pelargonium reniforme Curt., radix","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-06-20T02:00:00Z","last_updated_date":"2011-06-20T02:00:00Z","reference_number":"EMA/HMPC/560962/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-pelargonium-sidoides-dc-and-or-pelargonium-reniforme-curt-radix_en.pdf-0"},
    {"id":"22683","name":"Final assessment report on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-07-10T14:00:00Z","last_updated_date":"2012-07-10T14:00:00Z","reference_number":"EMA/HMPC/337067/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-or-their-mixtures-flos-first-version_en.pdf"},
    {"id":"22736","name":"Final assessment report on Taraxacum officinale Weber ex Wigg., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMA/HMPC/579634/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-taraxacum-officinale-weber-ex-wigg-folium_en.pdf"},
    {"id":"22815","name":"Draft assessment report on Marrubium vulgare L., herba - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-01-28T01:00:00Z","last_updated_date":"2013-01-28T01:00:00Z","reference_number":"EMA/HMPC/604273/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-marrubium-vulgare-l-herba-first-version_en.pdf"},
    {"id":"22900","name":"Superseded assessment report on Hypericum perforatum L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-12-21T00:09:00Z","last_updated_date":"2023-02-22T00:09:00Z","reference_number":"EMA/HMPC/101303/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-hypericum-perforatum-l-herba_en.pdf"},
    {"id":"23026","name":"Draft assessment report on Polygonum aviculare L., herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-10-19T12:50:00Z","last_updated_date":"2015-10-19T12:50:00Z","reference_number":"EMA/HMPC/143659/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-polygonum-aviculare-l-herba_en.pdf"},
    {"id":"23126","name":"Superseded assessment report on Urtica dioica L., Urtica urens L., their hybrids or their mixtures, radix - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-11-05T12:20:00Z","last_updated_date":"2025-03-12T12:20:00Z","reference_number":"EMA/HMPC/461156/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-urtica-dioica-l-urtica-urens-l-their-hybrids-or-their-mixtures-radix-first-version_en.pdf"},
    {"id":"23268","name":"Superseded final assessment report on Achillea millefolium L., herba - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-09-30T02:00:00Z","last_updated_date":"2011-09-30T02:00:00Z","reference_number":"EMA/HMPC/290309/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-final-assessment-report-achillea-millefolium-l-herba-first-version_en.pdf"},
    {"id":"23331","name":"Draft assessment report on Phaseolus vulgaris L., fructus sine semine","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-05-14T02:00:00Z","last_updated_date":"2013-05-14T02:00:00Z","reference_number":"EMA/HMPC/317317/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-phaseolus-vulgaris-l-fructus-sine-semine_en.pdf"},
    {"id":"23562","name":"Superseded assessment report on Betula pendula Roth; Betula pubescens Ehrh., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2015-03-13T01:09:21Z","reference_number":"EMEA/HMPC/260018/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-betula-pendula-roth-betula-pubescens-ehrh-folium_en.pdf"},
    {"id":"23620","name":"Addendum to assessment report on Commiphora molmol Engler, gummi-resina","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-09-05T17:30:00Z","last_updated_date":"2018-09-05T17:30:00Z","reference_number":"EMA/HMPC/364552/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-commiphora-molmol-engler-gummi-resina_en.pdf"},
    {"id":"23645","name":"Superseded assessment report on Trigonella foenum-graecum L., semen","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-08-30T02:00:00Z","last_updated_date":"2022-08-30T02:00:00Z","reference_number":"EMA/HMPC/146220/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-trigonella-foenum-graecum-l-semen_en.pdf"},
    {"id":"23952","name":"Superseded assessment report on Melissa officinalis L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"EMEA/HMPC/5342/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-melissa-officinalis-l-folium_en.pdf"},
    {"id":"24076","name":"Final assessment report on Ribes nigrum L., folium - revision 1","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T10:20:00Z","last_updated_date":"2017-12-19T10:20:00Z","reference_number":"EMA/HMPC/745347/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-ribes-nigrum-l-folium-revision-1_en.pdf"},
    {"id":"24166","name":"Superseded final assessment report for the development of community monographs and for inclusion of herbal substance(s), preparation(s) or combinations thereof in the list for Thymus vulgaris L., Thymus zygis L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2014-06-03T01:09:21Z","reference_number":"EMEA/HMPC/234073/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-final-assessment-report-development-community-monographs-and-inclusion-herbal-substances-preparations-or-combinations-thereof-list-thymus-vulgaris-l-thymus-zygis-l-herba_en.pdf"},
    {"id":"24279","name":"Superseded final assessment report on Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"EMA/HMPC/130038/2010, Corr 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-final-assessment-report-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"24535","name":"Superseded assessment report on Orthosiphon stamineus Benth., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-05-30T02:00:00Z","last_updated_date":"2011-05-30T02:00:00Z","reference_number":"EMA/HMPC/135701/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-orthosiphon-stamineus-benth-folium_en.pdf"},
    {"id":"24546","name":"Final assessment report on Juglans regia L., folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2014-01-17T01:00:00Z","last_updated_date":"2014-01-17T01:00:00Z","reference_number":"EMA/HMPC/346740/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-juglans-regia-l-folium_en.pdf"},
    {"id":"24715","name":"Draft assessment report on Althaea officinalis L., radix","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-12-11T18:20:00Z","last_updated_date":"2015-12-11T18:20:00Z","reference_number":"EMA/HMPC/436680/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-althaea-officinalis-l-radix_en.pdf"},
    {"id":"24848","name":"Final assessment report on Fumaria officinalis L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-12-06T16:50:00Z","last_updated_date":"2024-02-21T16:10:00Z","reference_number":"EMA/HMPC/576232/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-fumaria-officinalis-l-herba_en.pdf"},
    {"id":"24981","name":"Draft assessment report on Ononis spinosa L., radix","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-08-19T02:00:00Z","last_updated_date":"2013-08-19T02:00:00Z","reference_number":"EMA/HMPC/138316/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-ononis-spinosa-l-radix_en.pdf"},
    {"id":"25299","name":"Superseded assessment report on Rosmarinus officinalis L., aetheroleum and Rosmarinus officinalis L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-02-03T01:00:00Z","last_updated_date":"2024-09-20T01:00:00Z","reference_number":"EMA/HMPC/13631/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-rosmarinus-officinalis-l-aetheroleum-rosmarinus-officinalis-l-folium_en.pdf"},
    {"id":"25376","name":"Superseded final assessment report on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-08-20T02:00:00Z","last_updated_date":"2024-07-12T02:00:00Z","reference_number":"EMA/HMPC/444251/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-final-assessment-report-pelargonium-sidoides-dc-or-pelargonium-reniforme-curt-radix-revision-1_en.pdf"},
    {"id":"25598","name":"Superseded assessment report on Cassia senna L, fructus and Cassia angustifolia Vahl, fructus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-04-27T02:09:00Z","last_updated_date":"2007-04-27T02:09:00Z","reference_number":"EMEA/HMPC/51870/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-cassia-senna-l-fructus-and-cassia-angustifolia-vahl-fructus_en.pdf"},
    {"id":"25636","name":"Final assessment report on Lavandula angustifolia Miller, aetheroleum and Lavandula angustifolia Miller, flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-13T18:00:00Z","last_updated_date":"2012-06-13T18:00:00Z","reference_number":"EMA/HMPC/143183/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-lavandula-angustifolia-miller-aetheroleum-and-lavandula-angustifolia-miller-flos_en.pdf"},
    {"id":"25672","name":"Final assessment report on Commiphora molmol Engler, gummi-resina","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T15:00:00Z","last_updated_date":"2011-12-22T15:00:00Z","reference_number":"EMA/HMPC/96910/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-commiphora-molmol-engler-gummi-resina_en.pdf"},
    {"id":"25675","name":"Draft assessment report on Arctostaphylos uva-ursi (L.) Spreng., folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2017-04-12T14:08:00Z","last_updated_date":"2017-04-12T14:08:00Z","reference_number":"EMA/HMPC/750266/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-arctostaphylos-uva-ursi-l-spreng-folium_en.pdf"},
    {"id":"25677","name":"Draft assessment report on Euphrasia officinalis L. and Euphrasia rostkoviana Hayne, herba","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2010-01-15 - 2010-04-15","first_published_date":"2010-02-12T01:09:21Z","last_updated_date":"2010-02-12T01:09:21Z","reference_number":"EMA/HMPC/246799/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-euphrasia-officinalis-l-and-euphrasia-rostkoviana-hayne-herba_en.pdf"},
    {"id":"25804","name":"Superseded assessment report for the development of community monographs and for inclusion of herbal substance(s), preparation(s) or combinations thereof in the list Humulus lupulus L., flos - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-07-11T02:00:00Z","last_updated_date":"2014-08-07T02:00:00Z","reference_number":"EMEA/HMPC/513618/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-development-community-monographs-and-inclusion-herbal-substances-preparations-or-combinations-thereof-list-humulus-lupulus-l-flos-first-version_en.pdf"},
    {"id":"25857","name":"Draft assessment report on Cinnamomum verum J. S. Presl (Cinnamomum zeylanicum Nees), cortex and corticis aetheroleum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2010-08-20T02:00:00Z","last_updated_date":"2010-08-20T02:00:00Z","reference_number":"EMA/HMPC/246773/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-cinnamomum-verum-j-s-presl-cinnamomum-zeylanicum-nees-cortex-and-corticis-aetheroleum_en.pdf"},
    {"id":"26049","name":"Final assessment report on Paeonia lactiflora Pallas, radix (Paeoniae radix alba)","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2017-04-25T16:47:00Z","last_updated_date":"2017-04-25T16:47:00Z","reference_number":"EMA/HHMP/150787/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-paeonia-lactiflora-pallas-radix-paeoniae-radix-alba_en.pdf"},
    {"id":"26291","name":"Draft assessment report on Pimpinella anisum L.","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-06-17T02:09:21Z","last_updated_date":"2008-06-17T02:09:21Z","reference_number":"EMEA/HMPC/137421/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-pimpinella-anisum-l_en.pdf"},
    {"id":"26329","name":"Final assessment report on Peumus boldus Molina, folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2017-01-12T10:48:00Z","last_updated_date":"2017-01-12T10:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-peumus-boldus-molina-folium_en.pdf"},
    {"id":"26338","name":"Final assessment report on Allium cepa L., bulbus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T18:00:00Z","last_updated_date":"2012-05-29T18:00:00Z","reference_number":"EMA/HMPC/347195/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-allium-cepa-l-bulbus_en.pdf"},
    {"id":"26454","name":"Draft assessment report on Glycine max (L.) Merr., oleum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2016-07-25T02:00:00Z","last_updated_date":"2016-07-25T02:00:00Z","reference_number":"EMA/HMPC/338915/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-glycine-max-l-merr-oleum_en.pdf"},
    {"id":"26687","name":"Superseded assessment report on Pimpinella anisum  L.","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-06-17T02:00:00Z","last_updated_date":"2014-06-17T02:00:00Z","reference_number":"EMEA/HMPC/137421/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-pimpinella-anisum-l_en.pdf"},
    {"id":"26711","name":"Draft assessment report on Harpagophytum procumbens DC. and/or Harpagophytum zeheyri Decne., radix","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2016-02-15T12:00:00Z","last_updated_date":"2016-02-15T12:00:00Z","reference_number":"EMA/HMPC/627058/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-harpagophytum-procumbens-dc-andor-harpagophytum-zeheyri-decne-radix_en.pdf"},
    {"id":"26873","name":"Superseded assessment report on Salvia officinalis L., folium and Salvia officinalis L., aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2017-07-13T02:00:00Z","reference_number":"EMA/HMPC/330383/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-salvia-officinalis-l-folium-and-salvia-officinalis-l-aetheroleum_en.pdf"},
    {"id":"26890","name":"Superseded assessment report on Hedera helix L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T01:00:00Z","last_updated_date":"2016-01-18T01:00:00Z","reference_number":"EMA/HMPC/289432/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-hedera-helix-l-folium_en.pdf"},
    {"id":"27006","name":"Superseded assessment report for the development of community monographs and for inclusion of  herbal substance(s), preparation(s) or combinations thereof in the list Melilotus officinalis (L.) Lam., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2018-04-23T02:00:00Z","reference_number":"EMEA/HMPC/354183/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-development-community-monographs-and-inclusion-herbal-substances-preparations-or-combinations-thereof-list-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"27165","name":"Superseded assessment report on Cynara scolymus L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T01:00:00Z","last_updated_date":"2011-12-21T01:00:00Z","reference_number":"EMA/HMPC/150209/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-cynara-scolymus-l-folium_en.pdf"},
    {"id":"27533","name":"Draft assessment report on Salvia fruticosa Mill., folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"EMA/HMPC/599992/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-salvia-fruticosa-mill-folium_en.pdf"},
    {"id":"27564","name":"Final assessment report on Matricaria recutita L., flos and Matricaria recutita L., aetheroleum - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-04-05T17:30:00Z","last_updated_date":"2016-04-05T17:30:00Z","reference_number":"EMA/HMPC/55837/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-matricaria-recutita-l-flos-and-matricaria-recutita-l-aetheroleum-first-version_en.pdf-0"},
    {"id":"27699","name":"Final assessment report on Capsella bursa-pastoris (L.) Medikus, herba  - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T15:30:00Z","last_updated_date":"2011-12-22T15:30:00Z","reference_number":"EMA/HMPC/262767/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-capsella-bursa-pastoris-l-medikus-herba-first-version_en.pdf"}    {"id":"27953","name":"Final assessment report on Ononis spinosa L., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-05-28T02:00:00Z","last_updated_date":"2014-05-28T02:00:00Z","reference_number":"EMA/HMPC/138316/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-ononis-spinosa-l-radix_en.pdf"},
    {"id":"28004","name":"Superseded assessment report on Linum usitatissimum L., semen","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2006-10-25T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMEA/HMPC/167395/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-linum-usitatissimum-l-semen_en.pdf"},
    {"id":"28076","name":"Superseded assessment report on Artemisia absinthium L., herba - First version","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2017-10-05T02:00:00Z","reference_number":"EMEA/HMPC/234444/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-artemisia-absinthium-l-herba-first-version_en.pdf"},
    {"id":"28150","name":"Draft assessment report on Juglans regia L., folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-01-25T01:00:00Z","last_updated_date":"2013-01-25T01:00:00Z","reference_number":"EMA/HMPC/346740/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-juglans-regia-l-folium_en.pdf"},
    {"id":"28468","name":"Final assessment report on Paullinia cupana Kunth ex H.B.K. var. sorbilis (Mart.) Ducke, semen - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/HMPC/897384/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-paullinia-cupana-kunth-ex-hbk-var-sorbilis-mart-ducke-semen-first-version_en.pdf"},
    {"id":"28734","name":"Assessment report on Avena sativa L., herba and Avena sativa L., fructus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/202967/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-avena-sativa-l-herba-and-avena-sativa-l-fructus_en.pdf"},
    {"id":"28781","name":"Final assessment report on Helichrysum arenarium (L.) Moench, flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-05-23T12:50:00Z","last_updated_date":"2016-05-23T12:50:00Z","reference_number":"EMA/HMPC/41109/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-helichrysum-arenarium-l-moench-flos_en.pdf"},
    {"id":"29411","name":"Final assessment report on Potentilla erecta (L.) Raeusch., rhizoma","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-03-16T01:00:00Z","last_updated_date":"2011-03-16T01:00:00Z","reference_number":"EMA/HMPC/5511/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-potentilla-erecta-l-raeusch-rhizoma_en.pdf"},
    {"id":"29522","name":"Draft assessment report on Fragaria vesca L., Fragaria moschata Weston, Fragaria viridis Weston and Fragaria x ananassa (Weston) Duchesne ex Rozier, folium - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2018-04-11T12:30:00Z","last_updated_date":"2018-04-11T12:30:00Z","reference_number":"EMA/HMPC/432276/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-and-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium-first-version_en.pdf"},
    {"id":"29548","name":"Final  assessment report on Althaea officinalis L., radix","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2016-11-04T15:05:00Z","last_updated_date":"2016-11-04T15:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-althaea-officinalis-l-radix_en.pdf"},
    {"id":"29587","name":"Draft assessment report on Paullinia cupana Kunth ex H.B.K. var. sorbilis (Mart.) Ducke, semen - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2012-06-25T12:12:00Z","last_updated_date":"2012-06-25T12:12:00Z","reference_number":"EMA/HMPC/897384/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-paullinia-cupana-kunth-ex-hbk-var-sorbilis-mart-ducke-semen-first-version_en.pdf"},
    {"id":"29828","name":"Final assessment report on Syzygium aromaticum (L.) Merill et L.M. Perry, flos and Syzygium aromaticum (L.) Merill et L.M. Perry, floris aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T01:00:00Z","last_updated_date":"2011-12-21T01:00:00Z","reference_number":"EMA/HMPC/534946/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-syzygium-aromaticum-l-merill-et-lm-perry-flos-and-syzygium-aromaticum-l-merill-et-lm-perry-floris-aetheroleum_en.pdf"},
    {"id":"29891","name":"Draft assessment report on Serenoa repens (W. Bartram) Small, fructus","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2014-12-22T17:40:00Z","last_updated_date":"2014-12-22T17:40:00Z","reference_number":"EMA/HMPC/137250/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-serenoa-repens-w-bartram-small-fructus_en.pdf"},
    {"id":"29916","name":"Draft assessment report on Panax ginseng C.A. Meyer, radix","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-04-16T02:00:00Z","last_updated_date":"2013-04-16T02:00:00Z","reference_number":"EMA/HMPC/321232/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-panax-ginseng-ca-meyer-radix_en.pdf"},
    {"id":"30022","name":"Draft assessment report on Carum carvi L., fructus and Carum carvi L. aetheroleum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2014-12-22T17:15:00Z","last_updated_date":"2014-12-22T17:15:00Z","reference_number":"EMA/HMPC/715093/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-carum-carvi-l-fructus-and-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"30041","name":"Superseded assessment report on Juniperi pseudo-fructus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-02-16T01:00:00Z","last_updated_date":"2023-06-13T01:00:00Z","reference_number":"EMA/HMPC/441930/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-juniperi-pseudo-fructus_en.pdf"},
    {"id":"30101","name":"Assessment report on Plantago ovata Forssk., seminis tegumentum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2013-07-23T02:00:00Z","reference_number":"EMEA/HMPC/165838/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-plantago-ovata-forssk-seminis-tegumentum_en.pdf"},
    {"id":"30283","name":"Final assessment report on Fucus vesiculosus L., thallus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-07-23T02:00:00Z","last_updated_date":"2015-07-23T02:00:00Z","reference_number":"EMA/HMPC/313675/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-fucus-vesiculosus-l-thallus_en.pdf"},
    {"id":"30374","name":"Final assessment report on Prunus africana (Hook f.) Kalkm., cortex","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-09-01T02:00:00Z","last_updated_date":"2017-09-01T02:00:00Z","reference_number":"EMA/HMPC/680624/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-prunus-africana-hook-f-kalkm-cortex_en.pdf"},
    {"id":"30655","name":"Draft assessment report on Vaccinium myrtillus L., fructus recens","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-02-09T01:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMA/HMPC/555161/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-vaccinium-myrtillus-l-fructus-recens_en.pdf"},
    {"id":"30847","name":"Final assessment report on Equisetum arvense L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-03-17T01:00:00Z","reference_number":"EMA/HMPC/278089/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-equisetum-arvense-l-herba_en.pdf"},
    {"id":"30919","name":"Draft assessment report on Melilotus officinalis (L.) Lam., herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2017-04-12T15:13:00Z","last_updated_date":"2017-04-12T15:13:00Z","reference_number":"EMA/HMPC/44165/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"30936","name":"Draft assessment report on Curcuma longa L. (C. domestica Valeton), rhizome – Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"EMA/HMPC/749518/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-curcuma-longa-l-c-domestica-valeton-rhizome-revision-1_en.pdf"},
    {"id":"31218","name":"Superseded assessment report on Zingiber officinale Roscoe, rhizoma","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-04T02:00:00Z","last_updated_date":"2025-06-19T02:00:00Z","reference_number":"EMA/HMPC/577856/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-zingiber-officinale-roscoe-rhizoma_en.pdf"},
    {"id":"31418","name":"Draft assessment report on Ginkgo biloba L., folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2014-02-14T01:00:00Z","last_updated_date":"2014-02-14T01:00:00Z","reference_number":"EMA/HMPC/321095/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-ginkgo-biloba-l-folium_en.pdf"},
    {"id":"31458","name":"Superseded assessment report for the development of community monographs and for inclusion of herbal substance(s), preparation(s) or combinations thereof in the list: Sambucus nigra L., flos - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2018-06-27T02:09:21Z","reference_number":"EMEA/HMPC/283170/2007Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-development-community-monographs-and-inclusion-herbal-substances-preparations-or-combinations-thereof-list-sambucus-nigra-l-flos-first-version_en.pdf"},
    {"id":"31516","name":"Superseded assessment report on Peumus boldus Molina, folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-01-14T00:09:21Z","last_updated_date":"2017-01-12T10:09:00Z","reference_number":"EMEA/HMPC/591131/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-peumus-boldus-molina-folium_en.pdf"},
    {"id":"31610","name":"Final assessment report on Tilia tomentosa Moench, flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-07-09T18:50:00Z","last_updated_date":"2012-07-09T18:50:00Z","reference_number":"EMA/HMPC/346780/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-tilia-tomentosa-moench-flos_en.pdf"},
    {"id":"31725","name":"Draft assessment report on Aesculus hippocastanum L., cortex","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-10-26T12:37:02Z","last_updated_date":"2011-10-26T12:37:02Z","reference_number":"EMA/HMPC/354157/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-aesculus-hippocastanum-l-cortex_en.pdf"},
    {"id":"31884","name":"Draft assessment report on Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl), folium and fructus – Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2017-10-12T02:00:00Z","last_updated_date":"2017-10-12T02:00:00Z","reference_number":"EMA/HMPC/228759/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-folium-and-fructus-revision-1_en.pdf"},
    {"id":"31976","name":"Final assessment report on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-01-13T16:10:00Z","last_updated_date":"2016-01-13T16:10:00Z","reference_number":"EMA/HMPC/712510/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf"},
    {"id":"32188","name":"Final assessment report on Marrubium vulgare L., herba - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-08-01T17:00:00Z","last_updated_date":"2013-08-01T17:00:00Z","reference_number":"EMA/HMPC/604273/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-marrubium-vulgare-l-herba-first-version_en.pdf"},
    {"id":"32190","name":"Final assessment report on Taraxacum officinale Weber ex Wigg., radix cum herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMA/HMPC/212897/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf"},
    {"id":"32252","name":"Draft assessment report on Eucalyptus globulus Labill., folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2012-06-21T16:01:00Z","last_updated_date":"2012-06-21T16:01:00Z","reference_number":"EMA/HMPC/892615/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-eucalyptus-globulus-labill-folium_en.pdf"},
    {"id":"32534","name":"Final assessment report on Valeriana officinalis L., radix and Valeriana officinalis L., aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-04-27T12:00:00Z","last_updated_date":"2016-06-20T12:00:00Z","reference_number":"EMA/HMPC/150846/2015 corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-valeriana-officinalis-l-radix-and-valeriana-officinalis-l-aetheroleum_en.pdf-0"},
    {"id":"32647","name":"Final assessment report on Melissa officinalis L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-08-05T17:00:00Z","last_updated_date":"2013-08-05T17:00:00Z","reference_number":"EMA/HMPC/196746/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-melissa-officinalis-l-folium_en.pdf"},
    {"id":"32665","name":"Final assessment report on Salix [various species including S. purpurea L., S. daphnoides Vill., S. fragilis L.], cortex","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-07-07T02:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMA/HMPC/80628/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-cortex_en.pdf"},
    {"id":"32694","name":"Draft assessment report on Carum carvi L., fructus and Carum carvi L. aetheroleum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2014-12-22T17:30:00Z","last_updated_date":"2014-12-22T17:30:00Z","reference_number":"EMA/HMPC/715093/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-carum-carvi-l-fructus-and-carum-carvi-l-aetheroleum_en.pdf-0"},
    {"id":"32840","name":"Draft assessment report on Achillea millefolium L., flos","type":"herbal-report","status":"Draft","consultation_date":"2010-11-15 - 2011-02-15","first_published_date":"2010-11-09T02:00:00Z","last_updated_date":"2010-11-09T02:00:00Z","reference_number":"EMA/HMPC/149343/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-achillea-millefolium-l-flos_en.pdf"},
    {"id":"32942","name":"Final assessment report on Echinacea pallida (Nutt.) Nutt., radix - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-08-14T12:00:00Z","last_updated_date":"2018-08-14T12:00:00Z","reference_number":"EMA/HMPC/737379/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-echinacea-pallida-nutt-nutt-radix-revision-1_en.pdf"},
    {"id":"32953","name":"Final assessment report on Arnica montana L., flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/HMPC/198794/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-arnica-montana-l-flos_en.pdf"},
    {"id":"32997","name":"Superseded assessment report on Ribes nigrum L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-06-30T02:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"EMA/HMPC/142989/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-ribes-nigrum-l-folium_en.pdf"},
    {"id":"33243","name":"Superseded assessment report on Valeriana officinalis L., radix and Humulus lupulus L., flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-09-02T02:00:00Z","last_updated_date":"2010-09-02T02:00:00Z","reference_number":"EMA/HMPC/215214/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos_en.pdf"},
    {"id":"33337","name":"Superseded assessment report on Agropyron repens (L.) P. Beauv., rhizoma","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2022-10-03T01:00:00Z","reference_number":"EMA/HMPC/563395/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-agropyron-repens-l-p-beauv-rhizoma_en.pdf"},
    {"id":"33391","name":"Draft assessment report on Chamaemelum nobile (L.) All., flos","type":"herbal-report","status":"Draft","consultation_date":"2011-02-15 - 2011-06-15","first_published_date":"2011-03-02T02:00:00Z","last_updated_date":"2011-03-02T02:00:00Z","reference_number":"EMA/HMPC/560906/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-chamaemelum-nobile-l-all-flos_en.pdf"},
    {"id":"33467","name":"Superseded assessment report for rhubarb (Rhei radix)","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-06-05T02:09:00Z","last_updated_date":"2020-08-18T02:09:00Z","reference_number":"EMEA/HMPC/189626/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-rhubarb-rhei-radix_en.pdf"},
    {"id":"33493","name":"Final assessment report on Glycine max (L.) Merr., lecithinum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-11-20T01:00:00Z","last_updated_date":"2017-11-20T01:00:00Z","reference_number":"EMA/HMPC/220598/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-glycine-max-l-merr-lecithinum_en.pdf"},
    {"id":"33494","name":"Final assessment report on Plantago afra L. et Plantago indica L., semen","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-07-29T15:30:00Z","last_updated_date":"2013-07-29T15:30:00Z","reference_number":"EMA/HMPC/599745/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-plantago-afra-l-et-plantago-indica-l-semen_en.pdf"},
    {"id":"33524","name":"Final assessment report on Aloe barbadensis Mill. and on Aloe (various species, mainly Aloe ferox Mill. and its hybrids), folii succus siccatus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-04-10T02:00:00Z","last_updated_date":"2017-04-10T02:00:00Z","reference_number":"EMA/HMPC/759585/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf"},
    {"id":"33652","name":"Draft assessment report on Ruscus aculeatus L. rhizome - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2018-03-08T09:30:00Z","last_updated_date":"2018-03-08T09:30:00Z","reference_number":"EMA/188805/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-ruscus-aculeatus-l-rhizome-revision-1_en.pdf"},
    {"id":"33834","name":"Final assessment report on Quercus robur L., Quercus petraea. (Matt.) Liebl., Quercus pubescens Willd., cortex","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-05-18T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMA/HMPC/3206/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-quercus-robur-l-quercus-petraea-matt-liebl-quercus-pubescens-willd-cortex_en.pdf"},
    {"id":"34208","name":"Draft assessment report on Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-report","status":"Draft","consultation_date":"2011-05-15 - 2011-08-15","first_published_date":"2011-05-30T04:00:00Z","last_updated_date":"2015-02-10T02:00:00Z","reference_number":"EMA/HMPC/85124/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"34716","name":"Final assessment report on Rubus idaeus L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T11:00:00Z","last_updated_date":"2014-03-21T11:00:00Z","reference_number":"EMA/HMPC/44209/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-rubus-idaeus-l-folium_en.pdf"},
    {"id":"34723","name":"Draft assessment report on Sisymbrium officinale (L.) Scop., herba","type":"herbal-report","status":"Draft","consultation_date":"2014-01-15 - 2014-04-15","first_published_date":"2014-01-17T02:00:00Z","last_updated_date":"2014-01-17T02:00:00Z","reference_number":"EMA/HMPC/280194/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-sisymbrium-officinale-l-scop-herba_en.pdf"},
    {"id":"34849","name":"Final assessment report on Crataegus spp., folium cum flore","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"EMA/HMPC/159076/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-crataegus-spp-folium-cum-flore_en.pdf"},
    {"id":"35016","name":"Draft assessment report on Pistacia lentiscus L., resin (mastic)","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-07-22T11:30:00Z","last_updated_date":"2015-07-22T11:30:00Z","reference_number":"EMA/HMPC/46756/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-pistacia-lentiscus-l-resin-mastic_en.pdf"},
    {"id":"35045","name":"Draft assessment report on Syzygium aromaticum (L.) Merill et L.M. Perry, flos and Syzygium aromaticum (L.) Merill et L.M. Perry, floris aetheroleum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-03-28T02:00:00Z","last_updated_date":"2011-03-28T02:00:00Z","reference_number":"EMA/HMPC/534946/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-syzygium-aromaticum-l-merill-et-lm-perry-flos-and-syzygium-aromaticum-l-merill-et-lm-perry-floris-aetheroleum_en.pdf"},
    {"id":"35114","name":"Draft assessment report on Cucurbita pepo L., semen","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/HMPC/136022/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-cucurbita-pepo-l-semen_en.pdf"},
    {"id":"35235","name":"Draft assessment report on Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria (L.)), herba and Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria (L.)), flos - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/HMPC/434892/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-filipendula-ulmaria-l-maxim-spiraea-ulmaria-l-herba-and-filipendula-ulmaria-l-maxim-spiraea-ulmaria-l-flos-first-version_en.pdf"},
    {"id":"35287","name":"Superseded - Assessment report on Cimicifuga racemosa (L.) Nutt., rhizome - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-05-16T02:00:00Z","last_updated_date":"2018-07-03T02:00:00Z","reference_number":"EMA/HMPC/3968/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-cimicifuga-racemosa-l-nutt-rhizome-first-version_en.pdf"},
    {"id":"35700","name":"Final assessment report on Viscum album L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-08-01T17:05:00Z","last_updated_date":"2013-08-01T17:05:00Z","reference_number":"EMA/HMPC/246778/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-viscum-album-l-herba_en.pdf"},
    {"id":"35848","name":"Final assessment report on Betula pendula Roth; Betula pubescens Ehrh., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/HMPC/573240/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-betula-pendula-roth-betula-pubescens-ehrh-folium_en.pdf"},
    {"id":"35894","name":"Final assessment report on Phaseolus vulgaris L., fructus sine semine","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2014-01-17T16:00:00Z","last_updated_date":"2014-01-17T16:00:00Z","reference_number":"EMA/HMPC/317317/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-phaseolus-vulgaris-l-fructus-sine-semine_en.pdf"},
    {"id":"35901","name":"Final assessment report on Origanum dictamnus L., herba - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-08-05T02:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"EMA/HMPC/200431/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-origanum-dictamnus-l-herba-first-version_en.pdf"},
    {"id":"36051","name":"Draft assessment report on Ribes nigrum L., folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2017-02-28T10:25:00Z","last_updated_date":"2017-02-28T10:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-ribes-nigrum-l-folium_en.pdf"},
    {"id":"36141","name":"Final assessment report on Grindelia robusta Nutt., Grindelia squarrosa (Pursh) Dunal, Grindelia humilis Hook. et Arn., Grindelia camporum Greene, herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-03-11T11:00:00Z","last_updated_date":"2013-03-11T11:00:00Z","reference_number":"EMA/HMPC/748218/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-grindelia-robusta-nutt-grindelia-squarrosa-pursh-dunal-grindelia-humilis-hook-et-arn-grindelia-camporum-greene-herba_en.pdf"},
    {"id":"36280","name":"Draft assessment report on Glycine max (L.) Merr., semen - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2017-02-28T01:00:00Z","last_updated_date":"2017-02-28T01:00:00Z","reference_number":"EMA/HMPC/461813/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-glycine-max-l-merr-semen-first-version_en.pdf"},
    {"id":"36404","name":"Draft assessment report on Vitex agnus-castus L., fructus - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2009-09-17T02:09:00Z","last_updated_date":"2009-09-17T02:09:00Z","reference_number":"EMEA/HMPC/144003/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-vitex-agnus-castus-l-fructus-first-version_en.pdf"},
    {"id":"36468","name":"Draft assessment report on Agropyron repens (L.) P. Beauv., rhizoma","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"EMA/HMPC/563395/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-agropyron-repens-l-p-beauv-rhizoma_en.pdf"},
    {"id":"36668","name":"Draft assessment report on Species diureticae","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/HMPC/224754/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-species-diureticae_en.pdf"},
    {"id":"36868","name":"Draft assessment report on Andrographis paniculata Nees, folium - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-01-25T01:00:00Z","last_updated_date":"2013-01-25T01:00:00Z","reference_number":"EMA/HMPC/320433/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-andrographis-paniculata-nees-folium-first-version_en.pdf"},
    {"id":"36874","name":"Final assessment report on Origanum majorana L., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T11:30:00Z","last_updated_date":"2016-11-15T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-origanum-majorana-l-herba_en.pdf"},
    {"id":"36907","name":"Draft assessment report on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-10-20T02:00:00Z","last_updated_date":"2011-10-20T02:00:00Z","reference_number":"EMA/HMPC/337067/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-or-their-mixtures-flos-first-version_en.pdf"},
    {"id":"37142","name":"Draft Assessment report on Arctostaphylos uvae ursi (L.) Spreng, folium","type":"herbal-report","status":"Draft","consultation_date":"2010-08-15 - 2010-12-15","first_published_date":"2010-08-18T04:00:00Z","last_updated_date":"2010-08-18T04:00:00Z","reference_number":"EMA/HMPC/573462/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-arctostaphylos-uvae-ursi-l-spreng-folium_en.pdf"},
    {"id":"37263","name":"Superseded final assessment report on Plantago afra L., et Plantago indica L., semen","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T00:09:21Z","last_updated_date":"2013-07-29T14:00:00Z","reference_number":"EMEA/HMPC/167338/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-final-assessment-report-plantago-afra-l-et-plantago-indica-l-semen_en.pdf"},
    {"id":"37301","name":"Final assessment report on Olea europaea L., folium - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-01-04T01:00:00Z","last_updated_date":"2018-01-04T01:00:00Z","reference_number":"EMA/HMPC/359236/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-olea-europaea-l-folium-first-version_en.pdf"},
    {"id":"37322","name":"Superseded assessment report on Gentiana Lutea L., radix  - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-03-05T01:00:00Z","last_updated_date":"2019-04-30T01:00:00Z","reference_number":"EMA/HMPC/578322/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-gentiana-lutea-l-radix-first-version_en.pdf"},
    {"id":"37416","name":"Superseded assessment report on Oenothera biennis L., Oenothera lamarckiana L., oleum - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2012-04-02T11:26:00Z","last_updated_date":"2018-10-10T11:26:00Z","reference_number":"EMA/HMPC/277791/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-oenothera-biennis-l-oenothera-lamarckiana-l-oleum-first-version_en.pdf"},
    {"id":"37432","name":"Final assessment report on Vitis vinifera L., folium - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-01-05T01:00:00Z","last_updated_date":"2018-01-05T01:00:00Z","reference_number":"EMA/HMPC/464682/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-vitis-vinifera-l-folium-revision-1_en.pdf"},
    {"id":"37458","name":"Final assessment report on Salvia officinalis L., folium and Salvia officinalis L., aetheroleum - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-07-13T02:00:00Z","last_updated_date":"2017-07-13T02:00:00Z","reference_number":"EMA/HMPC/150801/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-salvia-officinalis-l-folium-and-salvia-officinalis-l-aetheroleum-revision-1_en.pdf"},
    {"id":"37739","name":"Draft assessment report on Uncaria tomentosa (Willd. ex Schult.) DC., cortex","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-04-15T11:00:00Z","last_updated_date":"2015-04-15T11:00:00Z","reference_number":"EMA/HMPC/259598/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-uncaria-tomentosa-willd-ex-schult-dc-cortex_en.pdf"},
    {"id":"37756","name":"Draft assessment report on Echinacea purpurea (L.) Moench, radix","type":"herbal-report","status":"unknown","consultation_date":"2016-12-15 - 2017-03-15","first_published_date":"2016-12-15T11:00:00Z","last_updated_date":"2016-12-15T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-echinacea-purpurea-l-moench-radix_en.pdf"},
    {"id":"37823","name":"Draft assessment report on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl., semen","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-07-28T02:00:00Z","last_updated_date":"2011-07-28T02:00:00Z","reference_number":"EMA/HMPC/722365/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-cola-nitida-vent-schott-et-endl-and-its-varieties-and-cola-acuminata-p-beauv-schott-et-endl-semen_en.pdf"},
    {"id":"38086","name":"Superseded final assessment report on Panax ginseng C.A. Meyer, radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2014-05-22T02:00:00Z","last_updated_date":"2024-07-12T02:00:00Z","reference_number":"EMA/HMPC/321232/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-final-assessment-report-panax-ginseng-ca-meyer-radix_en.pdf"},
    {"id":"38133","name":"Final assessment report on Species diureticae","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/HMPC/224754/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-species-diureticae_en.pdf"},
    {"id":"38213","name":"Final assessment report on Achillea millefolium L., flos","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-09-30T02:00:00Z","last_updated_date":"2011-09-30T02:00:00Z","reference_number":"EMA/HMPC/149343/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-achillea-millefolium-l-flos_en.pdf"},
    {"id":"38483","name":"Draft assessment report on Urtica dioica L., Urtica urens L., their hybrids or their mixtures, radix - First version","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/HMPC/461156/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-urtica-dioica-l-urtica-urens-l-their-hybrids-or-their-mixtures-radix-first-version_en.pdf"},
    {"id":"38624","name":"Draft assessment report on Citrus bergamia Risso et Poiteau, aetheroleum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-10-19T18:30:00Z","last_updated_date":"2011-10-19T18:30:00Z","reference_number":"EMA/HMPC/56155/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-citrus-bergamia-risso-et-poiteau-aetheroleum_en.pdf"},
    {"id":"38792","name":"Superseded - Assessment report on Aloe barabadensis Miller and Aloe (various species, mainly Aloe ferox Miller and its hybrids)","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2017-04-10T02:00:00Z","reference_number":"EMEA/HMPC/76313/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-aloe-barabadensis-miller-and-aloe-various-species-mainly-aloe-ferox-miller-and-its-hybrids_en.pdf"},
    {"id":"38883","name":"Addendum to assessment report on Polypodium vulgare L., rhizoma","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-08-16T13:00:00Z","last_updated_date":"2018-08-16T13:00:00Z","reference_number":"EMA/HMPC/627591/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-polypodium-vulgare-l-rhizoma_en.pdf"},
    {"id":"39344","name":"Final assessment report on Andrographis paniculata Nees, folium - First version","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2014-06-10T02:00:00Z","last_updated_date":"2014-08-28T13:05:00Z","reference_number":"EMA/HMPC/320433/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-andrographis-paniculata-nees-folium-first-version_en.pdf"},
    {"id":"39353","name":"Superseded assessment report on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T01:00:00Z","last_updated_date":"2018-08-20T02:00:00Z","reference_number":"EMA/HMPC/560962/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-pelargonium-sidoides-dc-andor-pelargonium-reniforme-curt-radix-first-version_en.pdf"},
    {"id":"39388","name":"Final assessment report on Arctium lappa L., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"EMA/HMPC/246764/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-arctium-lappa-l-radix_en.pdf"},
    {"id":"39527","name":"Superseded assessment report on Aesculus hippocastanum L., semen - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2020-04-23T02:00:00Z","reference_number":"EMEA/HMPC/225304/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-aesculus-hippocastanum-l-semen-first-version_en.pdf"},
    {"id":"39684","name":"Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae Rhizoma (black cohosh, root)","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2007-05-08T02:09:21Z","last_updated_date":"2007-05-08T02:09:21Z","reference_number":"EMEA/HMPC/269258/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-case-reports-connected-herbal-medicinal-products-containing-cimicifugae-racemosae-rhizoma-black-cohosh-root_en.pdf"},
    {"id":"40237","name":"Superseded assessment report on Hedera helix L., folium - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-01-18T01:00:00Z","last_updated_date":"2018-08-13T02:00:00Z","reference_number":"EMA/HMPC/586887/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-hedera-helix-l-folium-revision-1_en.pdf"},
    {"id":"40277","name":"Superseded assessment report on Mentha x piperita L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/193910/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-mentha-x-piperita-l-folium_en.pdf"},
    {"id":"40395","name":"Draft assessment report on Solanum dulcamara L., stipites","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2012-05-10T02:00:00Z","last_updated_date":"2012-05-10T02:00:00Z","reference_number":"EMA/HMPC/734363/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-solanum-dulcamara-l-stipites_en.pdf"},
    {"id":"40412","name":"Final assessment report on Leonurus cardiaca L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/HMPC/127430/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-leonurus-cardiaca-l-herba_en.pdf"},
    {"id":"40493","name":"Draft assessment report on Eucalyptus globulus Labill., E. polybractea R.T. Baker and E. smithii R.T. Baker., aetheroleum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2013-07-31T18:30:00Z","last_updated_date":"2013-07-31T18:30:00Z","reference_number":"EMA/HMPC/307782/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-eucalyptus-globulus-labill-e-polybractea-rt-baker-and-e-smithii-rt-baker-aetheroleum_en.pdf"}    {"id":"40540","name":"Draft assessment report on Lavandula angustifolia Mill., aetheroleum and Lavandula angustifolia Mill., flos","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2011-06-16T02:00:00Z","last_updated_date":"2011-06-16T02:00:00Z","reference_number":"EMA/HMPC/143183/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-lavandula-angustifolia-mill-aetheroleum-and-lavandula-angustifolia-mill-flos_en.pdf"},
    {"id":"40671","name":"Superseded assessment report for the development of community monographs and for inclusion of herbal substance(s), preparation(s) or combinations thereof in the list Equisetum arvense L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2016-03-17T01:09:21Z","reference_number":"EMEA/HMPC/394895/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-development-community-monographs-and-inclusion-herbal-substances-preparations-or-combinations-thereof-list-equisetum-arvense-l-herba_en.pdf"},
    {"id":"40713","name":"Superseded assessment report on Centella asiatica (L.) Urban, herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-09-02T17:50:00Z","last_updated_date":"2022-09-02T17:50:00Z","reference_number":"EMA/HMPC/291177/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/superseded-assessment-report-centella-asiatica-l-urban-herba_en.pdf"},
    {"id":"40855","name":"Final assessment report on Piper methysticum G. Forst., rhizoma","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-04-13T02:00:00Z","last_updated_date":"2018-04-13T02:00:00Z","reference_number":"EMA/HMPC/450589/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-piper-methysticum-g-forst-rhizoma_en.pdf"},
    {"id":"41112","name":"Final assessment report on Glycine max (L.) Merr., semen - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-07-31T02:00:00Z","last_updated_date":"2018-07-31T02:00:00Z","reference_number":"EMA/HMPC/461813/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-glycine-max-l-merr-semen-first-version_en.pdf"},
    {"id":"41178","name":"Final assessment report on Glycine max (L.) Merr., oleum\n\nraffinatum","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2017-03-03T10:19:00Z","last_updated_date":"2017-03-03T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-glycine-max-l-merr-oleum-raffinatum_en.pdf"},
    {"id":"41210","name":"Final Assessment report on Juniperus communis L., aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/HMPC/12401/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-juniperus-communis-l-aetheroleum_en.pdf"},
    {"id":"41479","name":"Draft assessment report on Allium sativum L., bulbus","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2016-07-25T02:00:00Z","last_updated_date":"2016-07-25T02:00:00Z","reference_number":"EMA/HMPC/7686/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-allium-sativum-l-bulbus_en.pdf"},
    {"id":"41500","name":"Draft  assessment report Hypericum perforatum L., herba - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/101303/2008 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-hypericum-perforatum-l-herba-first-version_en.pdf"},
    {"id":"41599","name":"Draft assessment report on Valeriana officinalis L., radix and Valeriana officinalis L., aetheroleum","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2015-07-23T02:00:00Z","last_updated_date":"2015-07-23T02:00:00Z","reference_number":"EMA/HMPC/150846/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-valeriana-officinalis-l-radix-and-valeriana-officinalis-l-aetheroleum_en.pdf"},
    {"id":"41627","name":"Final assessment report on Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T13:00:00Z","last_updated_date":"2015-04-09T13:00:00Z","reference_number":"EMA/HMPC/320932/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-melaleuca-alternifolia-maiden-and-betch-cheel-m-linariifolia-smith-m-dissitiflora-f-mueller-andor-other-species-melaleuca-aetheroleum-first-version_en.pdf"},
    {"id":"41676","name":"Final assessment report on Primula veris L., and Primula elatior (L.) Hill, flos’ - Superseded","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2010-04-09T02:00:00Z","last_updated_date":"2010-04-09T02:00:00Z","reference_number":"EMA/HMPC/405544/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-primula-veris-l-and-primula-elatior-l-hill-flos-superseded_en.pdf"},
    {"id":"41697","name":"Final assessment report on Artemisia absinthium L., herba - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2017-10-05T02:00:00Z","last_updated_date":"2017-10-05T02:00:00Z","reference_number":"EMA/HMPC/751484/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-artemisia-absinthium-l-herba-revision-1_en.pdf"},
    {"id":"41753","name":"Final assessment report on Arctostaphylos uva-ursi (L.) Spreng., folium - Revision 2","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T14:00:00Z","last_updated_date":"2018-04-11T14:00:00Z","reference_number":"EMA/HMPC/750266/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-arctostaphylos-uva-ursi-l-spreng-folium-revision-2_en.pdf"},
    {"id":"41781","name":"Assessment report on Centaurium erythraea Rafn. s.l., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"EMA/HMPC/277491/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-centaurium-erythraea-rafn-sl-herba_en.pdf"},
    {"id":"42072","name":"Final assessment report on Silybum marianum (L.) Gaertn., fructus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-09-19T02:00:00Z","last_updated_date":"2018-09-19T02:00:00Z","reference_number":"EMA/HMPC/294188/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-silybum-marianum-l-gaertn-fructus_en.pdf"},
    {"id":"42106","name":"Addendum to assessment report on Avena sativa L., herba and Avena sativa L., fructus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2018-09-18T02:00:00Z","last_updated_date":"2018-09-18T02:00:00Z","reference_number":"EMA/HMPC/732731/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-avena-sativa-l-herba-and-avena-sativa-l-fructus_en.pdf"},
    {"id":"42257","name":"Final assessment report on Vitex agnus-castus L., fructus - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-10-10T11:21:00Z","last_updated_date":"2018-10-10T11:21:00Z","reference_number":"EMA/HMPC/606741/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-vitex-agnus-castus-l-fructus-revision-1_en.pdf"},
    {"id":"42262","name":"Final assessment report on Oenothera biennis L., Oenothera lamarckiana L., oleum - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2018-10-10T12:58:00Z","last_updated_date":"2018-10-10T12:58:00Z","reference_number":"EMA/HMPC/753042/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-oenothera-biennis-l-oenothera-lamarckiana-l-oleum-revision-1_en.pdf"},
    {"id":"43478","name":"Final assessment report on Curcuma longa L., rhizoma - Revision 1","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2019-01-24T16:30:00Z","last_updated_date":"2019-01-24T16:30:00Z","reference_number":"EMA/HMPC/749518/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-curcuma-longa-l-rhizoma-revision-1_en.pdf"},
    {"id":"43661","name":"Final assessment report on Cynara cardunculus L. (syn. Cynara scolymus L.), folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-02-07T12:09:00Z","last_updated_date":"2019-02-07T12:09:00Z","reference_number":"EMA/HMPC/194013/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-cynara-cardunculus-l-syn-cynara-scolymus-l-folium_en.pdf"},
    {"id":"43720","name":"Draft assessment report on Rhamnus frangula L., cortex - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2019-02-15T12:40:00Z","last_updated_date":"2019-02-15T12:40:00Z","reference_number":"EMA/HMPC/483550/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-rhamnus-frangula-l-cortex-revision-1_en.pdf"},
    {"id":"43866","name":"Final assessment report on Malva sylvestris L. and/or Malva neglecta Wallr., folium and Malva sylvestris L., flos - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-03-19T12:41:00Z","last_updated_date":"2019-03-19T12:41:00Z","reference_number":"EMA/HMPC/749518/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-malva-sylvestris-l-andor-malva-neglecta-wallr-folium-and-malva-sylvestris-l-flos-first-version_en.pdf"},
    {"id":"44066","name":"Final assessment report on Malva sylvestris L. and/or Malva neglecta Wallr., folium and Malva sylvestris L., flos - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-03-19T17:05:00Z","last_updated_date":"2019-03-19T17:05:00Z","reference_number":"EMA/HMPC/749518/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-malva-sylvestris-l-andor-malva-neglecta-wallr-folium-and-malva-sylvestris-l-flos-first-version_en.pdf-0"},
    {"id":"44320","name":"Addendum to Assessment report on Echinacea angustifolia, radix - First review","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-04-23T14:48:00Z","last_updated_date":"2019-04-23T14:48:00Z","reference_number":"EMA/HMPC/637898/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-echinacea-angustifolia-radix-first-review_en.pdf"},
    {"id":"44327","name":"Addendum to Assessment report on Potentialla erecta (L.) Raeusch., rhizoma - First review","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2019-04-24T10:53:00Z","last_updated_date":"2019-04-24T10:53:00Z","reference_number":"EMA/HMPC/554898/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-potentialla-erecta-l-raeusch-rhizoma-first-review_en.pdf"},
    {"id":"44328","name":"Addendum to Assessment report on Achillea millefolium L., flos - First review","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2019-04-24T11:00:00Z","last_updated_date":"2019-04-24T11:00:00Z","reference_number":"EMA/HMPC/630682/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-achillea-millefolium-l-flos-first-review_en.pdf"},
    {"id":"44329","name":"Addendum to Assessment report on Capsella bursa-pastoris (L.) Medikus, herba - First review","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2019-04-24T11:04:00Z","last_updated_date":"2019-04-24T11:04:00Z","reference_number":"EMA/HMPC/638288/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-capsella-bursa-pastoris-l-medikus-herba-first-review_en.pdf"},
    {"id":"44330","name":"Addendum to Assessment report on Phaseolus vulgaris L., fructus sine semine - First review","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2019-04-24T11:09:00Z","last_updated_date":"2019-04-24T11:09:00Z","reference_number":"EMA/HMPC/554879/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-phaseolus-vulgaris-l-fructus-sine-semine-first-review_en.pdf"},
    {"id":"44393","name":"Addendum to assessment report on Leonurus cardiaca L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-04-29T14:30:00Z","last_updated_date":"2019-04-29T14:30:00Z","reference_number":"EMA/HMPC/553980/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-leonurus-cardiaca-l-herba_en.pdf"},
    {"id":"44407","name":"Assessment report on Gentiana lutea L., radix - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-04-30T14:54:00Z","last_updated_date":"2019-04-30T14:54:00Z","reference_number":"EMA/HMPC/607863/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-gentiana-lutea-l-radix-revision-1_en.pdf"},
    {"id":"44421","name":"Final assessment report on Ruscus aculeatus L. rhizoma - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-05-02T17:42:00Z","last_updated_date":"2019-05-02T17:42:00Z","reference_number":"EMA/HMPC/188805/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-ruscus-aculeatus-l-rhizoma-revision-1_en.pdf"},
    {"id":"44508","name":"Final assessment report on Fragaria vesca L., Fragaria moschata Weston, Fragaria viridis Weston and Fragaria x ananassa (Weston) Duchesne ex Rozier, folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-05-15T17:44:00Z","last_updated_date":"2019-05-15T17:44:00Z","reference_number":"EMA/HMPC/432276/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-and-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium_en.pdf"},
    {"id":"44729","name":"Draft assessment report on Mentha x piperita L., folium and aetheroleum - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2019-06-18T08:49:00Z","last_updated_date":"2019-06-18T08:49:00Z","reference_number":"EMA/HMPC/522409/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-mentha-x-piperita-l-folium-and-aetheroleum-revision-1_en.pdf"},
    {"id":"44738","name":"Draft assessment report on Aesculus hippocastanum L., semen - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2019-06-18T14:06:00Z","last_updated_date":"2019-06-18T14:06:00Z","reference_number":"EMA/HMPC/638245/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-aesculus-hippocastanum-l-semen-revision-1_en.pdf"},
    {"id":"45684","name":"Draft assessment report on Rhamnus purshiana DC., cortex - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2019-10-15T09:00:00Z","last_updated_date":"2019-10-15T09:00:00Z","reference_number":"EMA/HMPC/909434/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-rhamnus-purshiana-dc-cortex-revision-1_en.pdf"},
    {"id":"45685","name":"Draft assessment report on Rheum palmatum L. and Rheum officinale Baillon, radix - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2019-10-15T09:00:00Z","last_updated_date":"2019-10-15T09:00:00Z","reference_number":"EMA/HMPC/113701/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-rheum-palmatum-l-and-rheum-officinale-baillon-radix-revision-1_en.pdf"},
    {"id":"45686","name":"Draft assessment report on Tanacetum parthenium (L.) Schultz Bip., herba - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2019-10-15T09:00:00Z","last_updated_date":"2019-10-15T09:00:00Z","reference_number":"EMA/HMPC/48716/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-tanacetum-parthenium-l-schultz-bip-herba-revision-1_en.pdf"},
    {"id":"45687","name":"Draft assessment report on Thymus vulgaris L., Thymus zygis L., aetheroleum - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2019-10-15T09:00:00Z","last_updated_date":"2019-10-15T09:00:00Z","reference_number":"EMA/HMPC/52980/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-thymus-vulgaris-l-thymus-zygis-l-aetheroleum-revision-1_en.pdf"},
    {"id":"46226","name":"Assessment report on Rhamnus frangula L., cortex - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-12-04T02:00:00Z","last_updated_date":"2019-12-04T02:00:00Z","reference_number":"EMA/HMPC/483550/2018 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-rhamnus-frangula-l-cortex-revision-1_en.pdf"},
    {"id":"46231","name":"Addendum to assessment report on Hamamelis virginiana L., folium et cortex aut ramunculus destillatum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-12-04T11:45:00Z","last_updated_date":"2019-12-04T11:45:00Z","reference_number":"EMA/HMPC/638015/2018 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-hamamelis-virginiana-l-folium-et-cortex-aut-ramunculus-destillatum_en.pdf"},
    {"id":"46239","name":"Addendum to assessment report on Potentialla erecta (L.) Raeusch., rhizoma","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-12-05T11:50:00Z","last_updated_date":"2019-12-05T11:50:00Z","reference_number":"EMA/HMPC/554898/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-potentialla-erecta-l-raeusch-rhizoma_en.pdf"},
    {"id":"46259","name":"Addendum to assessment report on Hamamelis virginiana L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2019-12-09T13:43:00Z","last_updated_date":"2019-12-09T13:43:00Z","reference_number":"EMA/HMPC/637991/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-hamamelis-virginiana-l-folium_en.pdf"},
    {"id":"46337","name":"Draft assessment report on Herniariae glabra L.; Herniariae hirsuta L.; Herniariae incana LAM., herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2019-12-19T11:15:00Z","last_updated_date":"2019-12-19T11:15:00Z","reference_number":"EMA/HMPC/554033/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-herniariae-glabra-l-herniariae-hirsuta-l-herniariae-incana-lam-herba_en.pdf"},
    {"id":"46496","name":"Addendum to assessment report on Quercus robur L., Quercus petraea. (Matt.) Liebl., Quercus pubescens Willd., cortex","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T12:41:00Z","last_updated_date":"2020-01-23T12:41:00Z","reference_number":"EMA/HMPC/645526/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-quercus-robur-l-quercus-petraea-matt-liebl-quercus-pubescens-willd-cortex_en.pdf"},
    {"id":"46505","name":"Final assessment report on Valeriana officinalis L., radix and Humulus lupulus L., flos - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-01-23T15:35:00Z","last_updated_date":"2020-01-23T15:35:00Z","reference_number":"EMA/HMPC/441766/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"46653","name":"Draft assessment report on Achillea millefolium L., herba - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2020-01-31T16:44:00Z","last_updated_date":"2020-01-31T16:44:00Z","reference_number":"EMA/HMPC/376415/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-achillea-millefolium-l-herba-revision-1_en.pdf"},
    {"id":"46662","name":"Addendum to final assessment report on Taraxacum officinale Weber ex Wigg., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-02-03T12:20:00Z","last_updated_date":"2020-02-03T12:20:00Z","reference_number":"EMA/HMPC/514842/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-final-assessment-report-taraxacum-officinale-weber-ex-wigg-folium_en.pdf"},
    {"id":"47322","name":"Addendum to Assessment report on Arctium lappa L., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T12:06:00Z","last_updated_date":"2020-04-03T12:06:00Z","reference_number":"EMA/HMPC/509409/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-arctium-lappa-l-radix_en.pdf"},
    {"id":"47385","name":"Addendum to Assessment report on Taraxacum officinale Weber ex Wigg., radix cum herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2020-04-08T15:06:00Z","last_updated_date":"2020-04-08T15:06:00Z","reference_number":"EMA/HMPC/514844/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf"},
    {"id":"47386","name":"Addendum to Assessment report on Artemisia absinthium L., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2020-04-08T15:12:00Z","last_updated_date":"2020-04-08T15:12:00Z","reference_number":"EMA/HMPC/13144/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-artemisia-absinthium-l-herba_en.pdf"},
    {"id":"47461","name":"Assessment report on Aesculus hippocastanum L., semen Final - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-04-23T13:23:00Z","last_updated_date":"2020-04-23T13:23:00Z","reference_number":"EMA/HMPC/638244/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf"},
    {"id":"47494","name":"Final assessment report on Allium sativum L., bulbus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-04-28T10:37:00Z","last_updated_date":"2020-04-28T10:37:00Z","reference_number":"EMA/HMPC/7686/2013 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-allium-sativum-l-bulbus_en.pdf"},
    {"id":"47495","name":"Final assessment report on Allium sativum L., bulbus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-04-28T10:37:00Z","last_updated_date":"2020-04-28T10:37:00Z","reference_number":"EMA/HMPC/7686/2013 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-allium-sativum-l-bulbus_en.pdf-0"},
    {"id":"47562","name":"Final assessment report on Pistacia lentiscus L., resin (mastic)","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2020-05-05T11:04:00Z","last_updated_date":"2020-05-05T11:04:00Z","reference_number":"EMA/HMPC/46756/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-pistacia-lentiscus-l-resin-mastic_en.pdf"},
    {"id":"47792","name":"Draft assessment report on Species sedativae","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2020-05-29T11:30:00Z","last_updated_date":"2020-05-29T11:30:00Z","reference_number":"EMA/HMPC/438185/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-species-sedativae_en.pdf"},
    {"id":"47798","name":"Draft assessment report on Species amarae","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2020-05-28T14:45:00Z","last_updated_date":"2020-05-28T14:45:00Z","reference_number":"EMA/HMPC/749723/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-species-amarae_en.pdf"},
    {"id":"47818","name":"Draft assessment report on Aloysia citrodora Paláu (syn. Aloysia triphylla (L'Hér.) Kuntze; Verbena triphylla L'Hér.; Lippia citriodora Kunth), folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2020-05-29T11:30:00Z","last_updated_date":"2020-05-29T11:30:00Z","reference_number":"EMA/HMPC/376761/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-aloysia-citrodora-palau-syn-aloysia-triphylla-lher-kuntze-verbena-triphylla-lher-lippia-citriodora-kunth-folium_en.pdf"},
    {"id":"48414","name":"Assessment report on Mentha x piperita L., folium and aetheroleum - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T15:48:00Z","last_updated_date":"2020-07-24T15:48:00Z","reference_number":"EMA/HMPC/522409/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-mentha-x-piperita-l-folium-and-aetheroleum-revision-1_en.pdf"},
    {"id":"48422","name":"Final assessment report on Rhamnus purshiana DC., cortex - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-07-27T09:48:00Z","last_updated_date":"2020-07-27T09:48:00Z","reference_number":"EMA/HMPC/909434/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-rhamnus-purshiana-dc-cortex-revision-1_en.pdf"},
    {"id":"48501","name":"Addendum to assessment report on Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria L.), flos - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-07-30T17:16:00Z","last_updated_date":"2020-07-30T17:16:00Z","reference_number":"EMA/HMPC/232764/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-filipendula-ulmaria-l-maxim-spiraea-ulmaria-l-flos-first-version_en.pdf"},
    {"id":"48507","name":"Addendum to Assessment report on Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria L.), herba - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-07-30T17:20:00Z","last_updated_date":"2020-07-30T17:20:00Z","reference_number":"EMA/HMPC/595722/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-filipendula-ulmaria-l-maxim-spiraea-ulmaria-l-herba-first-version_en.pdf"},
    {"id":"48614","name":"Final assessment report on Tanacetum parthenium (L.) Schulz Bip., herba - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-14T11:37:00Z","last_updated_date":"2020-08-14T11:37:00Z","reference_number":"EMA/HMPC/48716/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-tanacetum-parthenium-l-schulz-bip-herba-revision-1_en.pdf"},
    {"id":"48619","name":"Final assessment report on Rheum palmatum L. and Rheum officinale Baillon, radix – Revision 1","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2020-08-18T15:46:00Z","last_updated_date":"2020-08-18T15:46:00Z","reference_number":"EMA/HMPC/113701/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-rheum-palmatum-l-and-rheum-officinale-baillon-radix-revision-1_en.pdf"},
    {"id":"48636","name":"Final assessment report on Herniaria glabra L., H. hirsuta L., H. incana Lam., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T14:46:00Z","last_updated_date":"2020-08-19T14:46:00Z","reference_number":"EMA/HMPC/554033/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-herniaria-glabra-l-h-hirsuta-l-h-incana-lam-herba_en.pdf"},
    {"id":"48869","name":"Final assessment report on Thymus vulgaris L., Thymus zygis L., aetheroleum - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-09-21T15:55:00Z","last_updated_date":"2020-09-21T15:55:00Z","reference_number":"EMA/HMPC/52980/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-thymus-vulgaris-l-thymus-zygis-l-aetheroleum-revision-1_en.pdf"},
    {"id":"48969","name":"Draft assessment report on Menyanthes trifoliata L., folium","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2020-10-09T09:15:00Z","last_updated_date":"2020-10-09T09:15:00Z","reference_number":"EMA/HMPC/637830/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-menyanthes-trifoliata-l-folium_en.pdf"},
    {"id":"49397","name":"Addendum to Assessment report Juniperus communis L., aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-04-08T15:12:00Z","last_updated_date":"2020-11-27T11:15:00Z","reference_number":"EMA/HMPC/616091/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-juniperus-communis-l-aetheroleum_en.pdf"},
    {"id":"49419","name":"Final assessment report on Achillea millefolium L., herba - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2020-12-03T02:00:00Z","last_updated_date":"2020-12-03T02:00:00Z","reference_number":"EMA/HMPC/376415/2019 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-achillea-millefolium-l-herba-revision-1_en.pdf"},
    {"id":"49533","name":"Addendum to assessment report on Carum carvi L., fructus and aetheroleum","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2020-12-11T15:12:00Z","last_updated_date":"2020-12-11T15:12:00Z","reference_number":"EMA/HMPC/351955/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-carum-carvi-l-fructus-and-aetheroleum_en.pdf"},
    {"id":"49546","name":"Addendum to assessment report on Chamaemelum nobile (L.) All. (Anthemis nobilis L.), flos","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2020-12-14T15:12:00Z","last_updated_date":"2020-12-14T15:12:00Z","reference_number":"EMA/HMPC/439694/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-chamaemelum-nobile-l-all-anthemis-nobilis-l-flos_en.pdf"},
    {"id":"49663","name":"Addendum to assessment report on Solanum dulcamara L., stipites","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T15:12:00Z","last_updated_date":"2020-12-21T15:12:00Z","reference_number":"EMA/HMPC/489234/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-solanum-dulcamara-l-stipites_en.pdf"},
    {"id":"49965","name":"Addendum - Final assessment report on Syzygium aromaticum (L.) Merill et L.M. Perry, flos and Syzygium aromaticum (L.) Merill et L.M. Perry, floris aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-01-28T14:13:00Z","last_updated_date":"2021-01-28T14:13:00Z","reference_number":"EMA/HMPC/475451/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-final-assessment-report-syzygium-aromaticum-l-merill-et-lm-perry-flos-and-syzygium-aromaticum-l-merill-et-lm-perry-floris-aetheroleum_en.pdf"},
    {"id":"50008","name":"Draft assessment report on Orthosiphon aristatus (Blume) Miq. var. aristatus, folium - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2021-02-01T10:40:00Z","last_updated_date":"2021-02-01T10:40:00Z","reference_number":"EMA/HMPC/486549/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-orthosiphon-aristatus-blume-miq-var-aristatus-folium-revision-1_en.pdf"},
    {"id":"50015","name":"Draft assessment report on Salvia miltiorrhiza Bunge, radix et rhizoma - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2021-02-01T11:30:00Z","last_updated_date":"2021-02-01T11:30:00Z","reference_number":"EMA/HMPC/509932/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-salvia-miltiorrhiza-bunge-radix-et-rhizoma-first-version_en.pdf"},
    {"id":"50146","name":"Addendum to Assessment report on Lavandula angustifolia Mill. (L. officinalis Chaix), flos","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2021-02-11T16:51:00Z","last_updated_date":"2021-02-11T16:51:00Z","reference_number":"EMA/HMPC/487394/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-lavandula-angustifolia-mill-l-officinalis-chaix-flos_en.pdf"},
    {"id":"50677","name":"Final assessment report on Species amarae","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-03-23T11:43:00Z","last_updated_date":"2021-03-23T11:43:00Z","reference_number":"EMA/HMPC/749723/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-species-amarae_en.pdf"},
    {"id":"50711","name":"Final assessment report on Species sedativae","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-03-25T16:37:00Z","last_updated_date":"2021-03-25T16:37:00Z","reference_number":"EMA/HMPC/438185/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-species-sedativae_en.pdf"},
    {"id":"50782","name":"Addendum to assessment report on Cinnamomum verum J.S. Presl, cortex","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-04-09T10:46:00Z","last_updated_date":"2021-04-09T10:46:00Z","reference_number":"EMA/HMPC/601683/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-cinnamomum-verum-js-presl-cortex_en.pdf"},
    {"id":"50878","name":"Draft Assessment report on Trigonella foenum-graecum L., semen - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2021-04-16T08:59:00Z","last_updated_date":"2021-04-16T08:59:00Z","reference_number":"EMA/HMPC/179590/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-trigonella-foenum-graecum-l-semen-revision-1_en.pdf"},
    {"id":"50885","name":"Second draft assessment report on Hypericum perforatum L., herba - Revision 1","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2021-04-15 - 2021-07-15","first_published_date":"2021-04-16T12:35:00Z","last_updated_date":"2021-04-16T12:35:00Z","reference_number":"EMA/HMPC/244315/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/second-draft-assessment-report-hypericum-perforatum-l-herba-revision-1_en.pdf"},
    {"id":"50986","name":"Addendum to assessment report on Cinnamomum verum J.S. Presl, corticis aetheroleum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-04-26T11:19:00Z","last_updated_date":"2021-04-26T11:19:00Z","reference_number":"EMA/HMPC/601695/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-cinnamomum-verum-js-presl-corticis-aetheroleum_en.pdf"},
    {"id":"51310","name":"Draft assessment report on Vaccinium macrocarpon Aiton, fructus - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2021-05-31T17:38:00Z","last_updated_date":"2021-05-31T17:38:00Z","reference_number":"EMA/HMPC/517879/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-vaccinium-macrocarpon-aiton-fructus-first-version_en.pdf"},
    {"id":"51314","name":"Draft Assessment report on Taraxacum officinale F.H. Wigg., radix - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2021-05-31T17:47:00Z","last_updated_date":"2021-05-31T17:47:00Z","reference_number":"EMA/HMPC/475725/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-taraxacum-officinale-fh-wigg-radix-first-version_en.pdf"},
    {"id":"51318","name":"Draft assessment report on Saccharomyces cerevisiae CBS 5926 - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2021-05-31T18:02:00Z","last_updated_date":"2021-05-31T18:02:00Z","reference_number":"EMA/HMPC/625623/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-saccharomyces-cerevisiae-cbs-5926-first-version_en.pdf"},
    {"id":"51629","name":"Addendum to Assessment report on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl., semen","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T09:51:00Z","last_updated_date":"2021-06-28T09:51:00Z","reference_number":"EMA/HMPC/357351/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-cola-nitida-vent-schott-et-endl-and-its-varieties-and-cola-acuminata-p-beauv-schott-et-endl-semen_en.pdf"},
    {"id":"51658","name":"Addendum to Final assessment report on Ilex paraguariensis St. Hilaire, folium - First version - Following consultation","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-06-29T11:57:00Z","last_updated_date":"2021-06-29T11:57:00Z","reference_number":"EMA/HMPC/599113/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-final-assessment-report-ilex-paraguariensis-st-hilaire-folium-first-version-following-consultation_en.pdf"},
    {"id":"51968","name":"Final assessment report on Menyanthes trifoliata L., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-07-20T14:31:00Z","last_updated_date":"2021-07-20T14:31:00Z","reference_number":"EMA/HMPC/637830/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-menyanthes-trifoliata-l-folium_en.pdf"},
    {"id":"52152","name":"Draft assessment report on Species digestivae","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2021-07-31 - 2021-10-31","first_published_date":"2021-07-30T10:31:00Z","last_updated_date":"2021-07-30T10:31:00Z","reference_number":"EMA/HMPC/607773/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-species-digestivae_en.pdf"},
    {"id":"52156","name":"Draft assessment report on Agropyron repens (L.) P. Beauv., rhizoma - Revision 1","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2021-07-31 - 2021-10-31","first_published_date":"2021-07-30T15:21:00Z","last_updated_date":"2021-07-30T15:21:00Z","reference_number":"EMA/HMPC/113793/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-agropyron-repens-l-p-beauv-rhizoma-revision-1_en.pdf"},
    {"id":"52220","name":"Final assessment report on Aloysia citrodora Paláu (syn. Aloysia triphylla (L’Hér.) Kuntze; Verbena triphylla L’Hér.; Lippia citriodora Kunth), folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-08-16T10:22:00Z","last_updated_date":"2021-08-16T10:22:00Z","reference_number":"EMA/HMPC/376761/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-aloysia-citrodora-palau-syn-aloysia-triphylla-lher-kuntze-verbena-triphylla-lher-lippia-citriodora-kunth-folium_en.pdf"},
    {"id":"52316","name":"Addendum to assessment report on Serenoa repens (W. Bartram) Small (Sabal serrulata (Michaux) Nichols), fructus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2021-09-01T13:08:00Z","last_updated_date":"2021-09-01T13:08:00Z","reference_number":"EMA/HMPC/602363/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-serenoa-repens-w-bartram-small-sabal-serrulata-michaux-nichols-fructus_en.pdf"},
    {"id":"52939","name":"Draft assessment report on Centella asiatica (L.) Urb., herba - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2021-10-29T10:08:00Z","last_updated_date":"2021-10-29T10:08:00Z","reference_number":"EMA/HMPC/489140/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-centella-asiatica-l-urb-herba-revision-1_en.pdf"},
    {"id":"53332","name":"Addendum to the assessment report on Solidago virgaurea L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-11-29T17:20:00Z","last_updated_date":"2021-11-29T17:20:00Z","reference_number":"EMA/HMPC/637909/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-solidago-virgaurea-l-herba_en.pdf"},
    {"id":"53420","name":"Final assessment report on Orthosiphon aristatus (Blume) Miq. var. aristatus, folium - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2021-12-08T13:56:00Z","last_updated_date":"2021-12-08T13:56:00Z","reference_number":"EMA/HMPC/486549/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-orthosiphon-aristatus-blume-miq-var-aristatus-folium-revision-1_en.pdf"},
    {"id":"54396","name":"Addendum to assessment report on Cetraria islandica (L.) Acharius s.l., thallus - First version","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T14:40:00Z","last_updated_date":"2022-03-08T14:40:00Z","reference_number":"EMA/HMPC/502105/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-cetraria-islandica-l-acharius-sl-thallus-first-version_en.pdf"},
    {"id":"54465","name":"Addendum to Assessment report on Levisticum officinale W.D.J. Koch, radix","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-15T11:03:00Z","last_updated_date":"2022-03-15T11:03:00Z","reference_number":"EMA/HMPC/500504/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-levisticum-officinale-wdj-koch-radix_en.pdf"},
    {"id":"54481","name":"Addendum to Assessment report on Grindelia robusta Nutt., Grindelia squarrosa (Pursh) Dunal, Grindelia humilis Hook. et Arn., Grindelia camporum Greene, herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T13:55:00Z","last_updated_date":"2022-03-16T13:55:00Z","reference_number":"EMA/HMPC/515836/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-grindelia-robusta-nutt-grindelia-squarrosa-pursh-dunal-grindelia-humilis-hook-et-arn-grindelia-camporum-greene-herba_en.pdf"},
    {"id":"54482","name":"Addendum to Assessment report on Eucalyptus globulus Labill., folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T14:05:00Z","last_updated_date":"2022-03-16T14:05:00Z","reference_number":"EMA/HMPC/679833/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-eucalyptus-globulus-labill-folium_en.pdf"},
    {"id":"54483","name":"Addendum to Assessment report on Fraxinus excelsior L. or Fraxinus angustifolia Vahl, folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T14:10:00Z","last_updated_date":"2022-03-16T14:10:00Z","reference_number":"EMA/HMPC/690227/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-fraxinus-excelsior-l-or-fraxinus-angustifolia-vahl-folium_en.pdf"}    {"id":"54484","name":"Addendum to Assessment report on Cucurbita pepo L., semen","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T14:15:00Z","last_updated_date":"2022-03-16T14:15:00Z","reference_number":"EMA/HMPC/367273/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-cucurbita-pepo-l-semen_en.pdf"},
    {"id":"54485","name":"Addendum to Assessment report on Fucus vesiculosus L., thallus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T14:20:00Z","last_updated_date":"2022-03-16T14:20:00Z","reference_number":"EMA/HMPC/681054/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-fucus-vesiculosus-l-thallus_en.pdf"},
    {"id":"54516","name":"Addendum to Assessment report on Cichorium intybus L., radix","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-18T11:19:00Z","last_updated_date":"2022-03-18T11:19:00Z","reference_number":"EMA/HMPC/639126/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-cichorium-intybus-l-radix_en.pdf"},
    {"id":"54577","name":"Addendum to Assessment report on Origanum dictamnus L., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T09:53:00Z","last_updated_date":"2022-03-25T09:53:00Z","reference_number":"EMA/HMPC/515985/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-origanum-dictamnus-l-herba_en.pdf"},
    {"id":"54578","name":"Addendum to Assessment report on Origanum dictamnus L., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T09:57:00Z","last_updated_date":"2022-03-25T09:57:00Z","reference_number":"EMA/HMPC/515985/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-origanum-dictamnus-l-herba_en.pdf-0"},
    {"id":"54588","name":"Addendum to Assessment report on Urtica dioica L., Urtica urens L., folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T11:30:00Z","last_updated_date":"2022-03-25T11:30:00Z","reference_number":"EMA/HMPC/489006/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-urtica-dioica-l-urtica-urens-l-folium_en.pdf"},
    {"id":"54592","name":"Addendum to Assessment report on Marrubium vulgare L., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T11:59:00Z","last_updated_date":"2022-03-25T11:59:00Z","reference_number":"EMA/HMPC/493697/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-marrubium-vulgare-l-herba_en.pdf"},
    {"id":"54714","name":"Addendum to Assessment report on Rhamnus frangula L., cortex","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T10:22:00Z","last_updated_date":"2022-04-11T10:22:00Z","reference_number":"EMA/HMPC/172961/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-rhamnus-frangula-l-cortex_en.pdf"},
    {"id":"54715","name":"Addendum to Assessment report on Aloe barbadensis Mill. and Aloe (various species, mainly Aloe ferox Mill. and its hybrids), folii succus siccatus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T11:52:00Z","last_updated_date":"2022-04-11T11:52:00Z","reference_number":"EMA/HMPC/2199/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf"},
    {"id":"54716","name":"Addendum to Assessment report on Rheum palmatum L. and Rheum officinale Baillon, radix","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T12:17:00Z","last_updated_date":"2022-04-11T12:17:00Z","reference_number":"EMA/HMPC/172974/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-rheum-palmatum-l-and-rheum-officinale-baillon-radix_en.pdf"},
    {"id":"54717","name":"Addendum to Assessment report on Cassia senna L., Cassia angustifolia Vahl, fructus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T12:21:00Z","last_updated_date":"2022-04-11T12:21:00Z","reference_number":"EMA/HMPC/18311/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-cassia-senna-l-cassia-angustifolia-vahl-fructus_en.pdf"},
    {"id":"54749","name":"Addendum to Assessment report on Rhamnus purshianus D.C., cortex","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-04-13T10:16:00Z","last_updated_date":"2022-04-13T10:16:00Z","reference_number":"EMA/HMPC/172975/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-rhamnus-purshianus-dc-cortex_en.pdf"},
    {"id":"54750","name":"Addendum to Assessment report on Cassia senna L., Cassia angustifolia Vahl, folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-04-13T10:34:00Z","last_updated_date":"2022-04-13T10:34:00Z","reference_number":"EMA/HMPC/18310/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-cassia-senna-l-cassia-angustifolia-vahl-folium_en.pdf"},
    {"id":"55307","name":"Final assessment report on Taraxacum officinale F.H. Wigg., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-06-21T13:05:00Z","last_updated_date":"2022-06-21T13:05:00Z","reference_number":"EMA/HMPC/475725/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-taraxacum-officinale-fh-wigg-radix_en.pdf"},
    {"id":"55770","name":"Assessment report on Salvia miltiorrhiza Bunge, radix et rhizoma","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-08-03T11:33:00Z","last_updated_date":"2022-08-03T11:33:00Z","reference_number":"EMA/HMPC/509932/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-salvia-miltiorrhiza-bunge-radix-et-rhizoma_en.pdf"},
    {"id":"55794","name":"Assessment report on Saccharomyces cerevisiae CBS 5926","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-08-08T10:37:00Z","last_updated_date":"2022-08-08T10:37:00Z","reference_number":"EMA/HMPC/625623/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-saccharomyces-cerevisiae-cbs-5926_en.pdf"},
    {"id":"55879","name":"Final assessment report on Juniperus communis L., pseudo-fructus (galbulus) - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"2022-08-31 - 2022-11-30","first_published_date":"2022-08-31T17:50:00Z","last_updated_date":"2023-06-13T13:13:00Z","reference_number":"EMA/HMPC/241319/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-juniperus-communis-l-pseudo-fructus-galbulus-revision-1_en.pdf"},
    {"id":"55886","name":"Assessment report on Trigonella foenum-graecum L., semen - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-08-30T10:56:00Z","last_updated_date":"2022-08-30T10:56:00Z","reference_number":"EMA/HMPC/179590/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-trigonella-foenum-graecum-l-semen-revision-1_en.pdf"},
    {"id":"55890","name":"Final assessment report on Foeniculum vulgare Miller subsp. vulgare var. vulgare and Foeniculum vulgare Miller subsp. vulgare var. dulce (Mill.) Batt. & Trab., fructus - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T16:59:00Z","last_updated_date":"2024-03-01T12:14:00Z","reference_number":"EMA/HMPC/240553/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf"},
    {"id":"55893","name":"Final assessment report on Foeniculum vulgare Miller subsp. vulgare var. vulgare, aetheroleum - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T10:54:00Z","last_updated_date":"2024-07-18T15:37:00Z","reference_number":"EMA/HMPC/271394/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-aetheroleum-revision-1_en.pdf"},
    {"id":"55896","name":"Final assessment report on Foeniculum vulgare Miller subsp. vulgare var. vulgare and Foeniculum vulgare Miller subsp. vulgare var. dulce (Mill.) Batt. & Trab., fructus - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T11:12:00Z","last_updated_date":"2024-03-01T12:32:00Z","reference_number":"EMA/HMPC/240553/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf-0"},
    {"id":"55945","name":"Assessment report on Centella asiatica (L.) Urb., herba - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-09-02T09:48:00Z","last_updated_date":"2022-09-02T09:48:00Z","reference_number":"EMA/HMPC/489140/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-centella-asiatica-l-urb-herba-revision-1_en.pdf"},
    {"id":"56189","name":"Addendum to Assessment report on Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-09-26T16:02:00Z","last_updated_date":"2022-09-26T16:02:00Z","reference_number":"EMA/HMPC/30571/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"56282","name":"Assessment report on Agropyron repens (L.) P. Beauv., rhizoma - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2022-10-03T12:17:00Z","last_updated_date":"2022-10-03T12:17:00Z","reference_number":"EMA/HMPC/113793/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-agropyron-repens-l-p-beauv-rhizoma-revision-1_en.pdf"},
    {"id":"56511","name":"Draft Assessment report on Fumaria officinalis L. herba– Revision 1","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2022-10-31 - 2023-01-31","first_published_date":"2022-10-31T10:49:00Z","last_updated_date":"2022-10-31T10:49:00Z","reference_number":"EMA/HMPC/367013/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-fumaria-officinalis-l-herba-revision-1_en.pdf"},
    {"id":"56532","name":"Addendum to Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich), rhizoma","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-11-04T15:08:00Z","last_updated_date":"2022-11-04T15:08:00Z","reference_number":"EMA/HMPC/166164/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-curcuma-xanthorrhiza-roxb-c-xanthorrhiza-d-dietrich-rhizoma_en.pdf"},
    {"id":"56533","name":"Addendum to Assessment report on Juglans regia L., folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-11-04T15:16:00Z","last_updated_date":"2022-11-04T15:16:00Z","reference_number":"EMA/HMPC/693261/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-juglans-regia-l-folium_en.pdf"},
    {"id":"56680","name":"Addendum to Assessment report on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T14:09:00Z","last_updated_date":"2022-11-17T14:09:00Z","reference_number":"EMA/HMPC/615965/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf"},
    {"id":"56717","name":"Assessment report on Species digestivae","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-11-21T09:24:00Z","last_updated_date":"2022-11-21T09:24:00Z","reference_number":"EMA/HMPC/607773/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-species-digestivae_en.pdf"},
    {"id":"56720","name":"Addendum to Assessment report on Eschscholzia californica Cham., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2022-11-21T10:16:00Z","last_updated_date":"2022-11-21T10:16:00Z","reference_number":"EMA/HMPC/648153/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-eschscholzia-californica-cham-herba_en.pdf"},
    {"id":"57016","name":"Final assessment report on Rosmarinus officinalis L., aetheroleum and Rosmarinus officinalis L., folium - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2022-12-15T16:28:00Z","last_updated_date":"2024-09-20T11:18:00Z","reference_number":"EMA/HMPC/681037/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-rosmarinus-officinalis-l-aetheroleum-rosmarinus-officinalis-l-folium-revision-1_en.pdf"},
    {"id":"57663","name":"Addendum to Assessment report on Paullinia cupana Kunth (syn. Paullinia sorbilis Mart.), semen","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T13:16:00Z","last_updated_date":"2023-02-14T13:16:00Z","reference_number":"EMA/HMPC/684020/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-paullinia-cupana-kunth-syn-paullinia-sorbilis-mart-semen_en.pdf"},
    {"id":"57677","name":"Addendum to Assessment report on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne, flos","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-02-15T14:43:00Z","last_updated_date":"2023-02-15T14:43:00Z","reference_number":"EMA/HMPC/176303/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-flos_en.pdf"},
    {"id":"57695","name":"Draft assessment report on Cnicus benedictus L., herba","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2023-02-16T13:11:00Z","last_updated_date":"2023-02-16T13:11:00Z","reference_number":"EMA/HMPC/648162/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-cnicus-benedictus-l-herba_en.pdf"},
    {"id":"57725","name":"Addendum to Assessment report on Agrimonia eupatoria L., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-02-20T10:22:00Z","last_updated_date":"2023-02-20T10:22:00Z","reference_number":"EMA/HMPC/626568/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-agrimonia-eupatoria-l-herba_en.pdf"},
    {"id":"57756","name":"Final assessment report on Vaccinium macrocarpon Aiton, fructus","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T12:07:00Z","last_updated_date":"2023-02-21T12:07:00Z","reference_number":"EMA/HMPC/517879/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-vaccinium-macrocarpon-aiton-fructus_en.pdf"},
    {"id":"57777","name":"Final assessment report on Hypericum perforatum L., herba - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-02-22T10:43:00Z","last_updated_date":"2023-02-22T10:43:00Z","reference_number":"EMA/HMPC/244315/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-hypericum-perforatum-l-herba-revision-1_en.pdf"},
    {"id":"58166","name":"Draft assessment report on Aesculus hippocastanum L., cortex - Revision 1","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-03-27T15:30:00Z","last_updated_date":"2023-03-27T15:30:00Z","reference_number":"EMA/HMPC/596131/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-aesculus-hippocastanum-l-cortex-revision-1_en.pdf"},
    {"id":"58560","name":"Addendum to Assessment report on Helichrysum arenarium (L.) Moench, flos","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-05-02T14:40:00Z","last_updated_date":"2023-05-02T14:40:00Z","reference_number":"EMA/HMPC/709373/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-helichrysum-arenarium-l-moench-flos_en.pdf"},
    {"id":"58955","name":"Draft assessment report on Panax ginseng C.A.Mey., radix - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"2023-10-19 - 2024-01-15","first_published_date":"2023-06-15T13:48:00Z","last_updated_date":"2023-10-25T12:15:00Z","reference_number":"EMA/HMPC/27745/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-panax-ginseng-camey-radix-revision-1_en.pdf"},
    {"id":"59013","name":"Addendum to Assessment report on Ricinus communis L., oleum","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T15:15:00Z","last_updated_date":"2023-06-21T15:15:00Z","reference_number":"EMA/HMPC/883123/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-ricinus-communis-l-oleum_en.pdf"},
    {"id":"59015","name":"Addendum to Assesment report on Sisymbrium officinale (L.) Scop., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T15:20:00Z","last_updated_date":"2023-06-21T15:20:00Z","reference_number":"EMA/HMPC/261330/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assesment-report-sisymbrium-officinale-l-scop-herba_en.pdf"},
    {"id":"59114","name":"Addendum to assessment report on Vaccinium myrtillus L., fructus recens and Vaccinium myrtillus L., fructus siccus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-06-27T12:55:00Z","last_updated_date":"2023-06-27T12:55:00Z","reference_number":"EMA/HMPC/883967/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-vaccinium-myrtillus-l-fructus-recens-and-vaccinium-myrtillus-l-fructus-siccus_en.pdf"},
    {"id":"59115","name":"Addendum to assessment report on Rubus idaeus L., folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-06-27T13:13:00Z","last_updated_date":"2023-06-27T13:13:00Z","reference_number":"EMA/HMPC/767595/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-rubus-idaeus-l-folium_en.pdf"},
    {"id":"59532","name":"Addendum to Assessment report on Capsicum annuum L. var. minimum (Miller) Heiser, fructus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-07-31T15:03:00Z","last_updated_date":"2023-07-31T15:03:00Z","reference_number":"EMA/HMPC/104943/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-capsicum-annuum-l-var-minimum-miller-heiser-fructus_en.pdf"},
    {"id":"59537","name":"Addendum to Assessment report on Melaleuca alternifolia (Maiden and Betche) Cheel; Melaleuca linariifolia Smith; Melaleuca dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-08-02T13:52:00Z","last_updated_date":"2023-08-02T13:52:00Z","reference_number":"EMA/HMPC/765808/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-melaleuca-alternifolia-maiden-and-betche-cheel-melaleuca-linariifolia-smith-melaleuca-dissitiflora-f-mueller-andor-other-species-melaleuca-aetheroleum_en.pdf"},
    {"id":"59540","name":"Addendum to assessment report on Origanum majorana L., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2023-08-02T16:11:00Z","last_updated_date":"2023-08-02T16:11:00Z","reference_number":"EMA/HMPC/765801/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-origanum-majorana-l-herba_en.pdf"},
    {"id":"59542","name":"Final assessment report on Rhodiola rosea L., rhizoma et radix - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-05-21T16:21:00Z","last_updated_date":"2024-05-21T16:21:00Z","reference_number":"EMA/HMPC/24186/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-rhodiola-rosea-l-rhizoma-et-radix-revision-1_en.pdf"},
    {"id":"60441","name":"Final assessment report on Pelargonium sidoides DC; Pelargonium reniforme Curt., radix - Revision 2","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2023-10-16T16:02:00Z","last_updated_date":"2024-07-12T16:01:00Z","reference_number":"EMA/HMPC/765656/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-pelargonium-sidoides-dc-pelargonium-reniforme-curt-radix-revision-2_en.pdf"},
    {"id":"60647","name":"Addendum to Assessment report on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny)","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2021-07-01T12:59:00Z","last_updated_date":"2021-07-01T12:59:00Z","reference_number":"EMA/HMPC/472964/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-viola-tricolor-l-and-or-subspecies-viola-arvensis-murray-gaud-and-viola-vulgaris-koch-oborny_en.pdf"},
    {"id":"61639","name":"Addendum to assessment report on Prunus africana (Hook f.) Kalkm., cortex","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T13:48:34Z","last_updated_date":"2024-01-05T13:48:34Z","reference_number":"EMA/HMPC/321020/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-prunus-africana-hook-f-kalkm-cortex_en.pdf"},
    {"id":"61640","name":"Addendum to assessment report on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis raeseri Boiss. & Heldr.; Sideritis syriaca L., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T13:55:56Z","last_updated_date":"2024-01-05T13:55:56Z","reference_number":"EMA/HMPC/320997/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-sideritis-scardica-griseb-sideritis-clandestina-bory-chaub-hayek-sideritis-raeseri-boiss-heldr-sideritis-syriaca-l-herba_en.pdf"},
    {"id":"61641","name":"Addendum to assessment report on Rosa centifolia L.; Rosa gallica L.; Rosa damascena Mill., flos","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T14:05:03Z","last_updated_date":"2024-01-05T14:05:03Z","reference_number":"EMA/HMPC/320996/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-rosa-centifolia-l-rosa-gallica-l-rosa-damascena-mill-flos_en.pdf"},
    {"id":"61784","name":"Final assessment report on Cnicus benedictus L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-01-16T14:36:36Z","last_updated_date":"2024-01-16T14:36:36Z","reference_number":"EMA/HMPC/648162/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-cnicus-benedictus-l-herba_en.pdf"},
    {"id":"62246","name":"Final assessment report on Fumaria officinalis L., herba - Revision 1","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T16:02:02Z","last_updated_date":"2024-02-21T16:02:02Z","reference_number":"EMA/HMPC/367013/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-fumaria-officinalis-l-herba-revision-1_en.pdf"},
    {"id":"62445","name":"Addendum to Assessment report on Silybum marianum L. Gaertn., fructus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2024-03-05T17:03:09Z","last_updated_date":"2024-03-05T17:03:09Z","reference_number":"EMA/HMPC/509451/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-silybum-marianum-l-gaertn-fructus_en.pdf"},
    {"id":"62457","name":"Addendum to Assessment report on Symphytum officinale L., radix","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-03-11T09:10:51Z","last_updated_date":"2024-03-11T09:10:51Z","reference_number":"EMA/HMPC/313662/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-symphytum-officinale-l-radix_en.pdf"},
    {"id":"62946","name":"Draft assessment report on Eucalytus globulus Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker, aetheroleum - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2024-04-15T10:47:39Z","last_updated_date":"2024-04-15T10:47:39Z","reference_number":"EMA/HMPC/320282/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-eucalytus-globulus-labill-eucalyptus-polybractea-rt-baker-eucalyptus-smithii-rt-baker-aetheroleum-revision-1_en.pdf"},
    {"id":"62949","name":"Draft assessment report on Pilosella officinarum Vall. (syn Hieracium pilosella L.), herba cum radice - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2024-04-15T11:04:01Z","last_updated_date":"2024-04-15T11:04:01Z","reference_number":"EMA/HMPC/493454/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-pilosella-officinarum-vall-syn-hieracium-pilosella-l-herba-cum-radice-revision-1_en.pdf"},
    {"id":"63120","name":"Addendum to Assessment report on Malva sylvestris L., flos","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2024-05-02T09:00:00Z","last_updated_date":"2024-05-02T09:00:00Z","reference_number":"EMA/HMPC/408278/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-malva-sylvestris-l-flos_en.pdf"},
    {"id":"63146","name":"Final addendum to Assessment report on Malva sylvestris L.; Malva neglecta Wallr., folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-05-02T14:35:00Z","last_updated_date":"2024-05-02T14:35:00Z","reference_number":"EMA/HMPC/408283/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-addendum-assessment-report-malva-sylvestris-l-malva-neglecta-wallr-folium_en.pdf"},
    {"id":"63192","name":"Final assessment report on Aesculus hippocastanum L., cortex - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-05-07T14:42:32Z","last_updated_date":"2024-05-07T14:42:32Z","reference_number":"EMA/HMPC/596131/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-aesculus-hippocastanum-l-cortex-revision-1_en.pdf"},
    {"id":"63618","name":"Final assessment report on Urtica dioica L.; Urtica urens L., radix - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T15:19:17Z","last_updated_date":"2025-03-12T13:18:00Z","reference_number":"EMA/HMPC/322627/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-urtica-dioica-l-urtica-urens-l-radix-revision-1_en.pdf"},
    {"id":"63621","name":"Draft assessment report on Prunus avium L.; Prunus cerasus L., peduncle - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2024-06-14T15:33:13Z","last_updated_date":"2024-06-14T15:33:13Z","reference_number":"EMA/HMPC/379865/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-prunus-avium-l-prunus-cerasus-l-peduncle-first-version_en.pdf"},
    {"id":"63624","name":"Final assessment report on Urtica dioica L.; Urtica urens L., herba - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T15:40:54Z","last_updated_date":"2025-03-07T16:05:00Z","reference_number":"EMA/HMPC/261303/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-urtica-dioica-l-urtica-urens-l-herba-revision-1_en.pdf"},
    {"id":"63637","name":"Final assessment report on Zingiber officinale Roscoe, rhizoma - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T17:19:08Z","last_updated_date":"2025-06-19T11:04:00Z","reference_number":"EMA/HMPC/765220/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-zingiber-officinale-roscoe-rhizoma-revision-1_en.pdf"},
    {"id":"63641","name":"Draft assessment report on Tribulus terrestris L., herba - First version","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2024-06-14T17:29:38Z","last_updated_date":"2024-06-14T17:29:38Z","reference_number":"EMA/HMPC/886105/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-tribulus-terrestris-l-herba-first-version_en.pdf"},
    {"id":"64110","name":"Final assessment report on Panax ginseng C.A.Mey., radix - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-07-12T15:44:00Z","last_updated_date":"2024-07-12T15:44:00Z","reference_number":"EMA/HMPC/27745/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-panax-ginseng-camey-radix-revision-1_en.pdf"},
    {"id":"64575","name":"Final assessment report on Cisti cretici herba – First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-08-14T16:19:30Z","last_updated_date":"2025-04-30T15:40:00Z","reference_number":"EMA/HMPC/150765/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-cisti-cretici-herba-first-version_en.pdf"},
    {"id":"64579","name":"Final assessment report on plantaginis lanceolatae folium – Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-08-14T16:40:52Z","last_updated_date":"2025-10-20T09:38:00Z","reference_number":"EMA/HMPC/887981/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-plantaginis-lanceolatae-folium-revision-1_en.pdf"},
    {"id":"64739","name":"Final addendum to assessment report on Pistacia lentiscus L., resina (mastic)","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-09-06T12:44:00Z","last_updated_date":"2024-09-06T12:44:00Z","reference_number":"EMA/HMPC/32686/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-addendum-assessment-report-pistacia-lentiscus-l-resina-mastic_en.pdf"},
    {"id":"64740","name":"Final addendum to assessment report on Glycine max (L.) Merr., oleum raffinatum","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2024-09-06T13:02:00Z","last_updated_date":"2024-09-06T13:02:00Z","reference_number":"EMA/HMPC/237034/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-addendum-assessment-report-glycine-max-l-merr-oleum-raffinatum_en.pdf"},
    {"id":"64893","name":"Final assessment report on Artemisia absinthium L., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2024-09-18T11:15:00Z","last_updated_date":"2024-09-18T11:15:00Z","reference_number":"EMA/HMPC/751484/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-artemisia-absinthium-l-herba_en.pdf"},
    {"id":"64894","name":"Addendum to Assessment report on Artemisia absinthium L., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2024-09-18T11:16:00Z","last_updated_date":"2024-09-18T11:16:00Z","reference_number":"EMA/HMPC/13144/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-artemisia-absinthium-l-herba_en.pdf-0"},
    {"id":"66684","name":"Addendum to Assessment report on Peumus boldus Molina, folium","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-02-11T16:29:17Z","last_updated_date":"2025-02-11T16:29:17Z","reference_number":"EMA/HMPC/329351/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-peumus-boldus-molina-folium_en.pdf"},
    {"id":"66792","name":"Draft assessment report on Hypericum perforatum L., herba and Cimicifuga racemosa (L.) Nutt., rhizoma","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T15:29:25Z","last_updated_date":"2025-02-14T15:29:25Z","reference_number":"EMA/HMPC/107224/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-hypericum-perforatum-l-herba-cimicifuga-racemosa-l-nutt-rhizoma_en.pdf"},
    {"id":"66939","name":"Final assessment report on Prunus avium L.; Prunus cerasus L., peduncle","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-02-25T12:01:50Z","last_updated_date":"2025-02-25T12:01:50Z","reference_number":"EMA/HMPC/379865/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-prunus-avium-l-prunus-cerasus-l-peduncle_en.pdf"},
    {"id":"66940","name":"Final public statement on Tribulus terrestris L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-02-25T12:11:00Z","last_updated_date":"2025-02-25T12:11:00Z","reference_number":"EMA/HMPC/308436/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-public-statement-tribulus-terrestris-l-herba_en.pdf"},
    {"id":"66941","name":"Final assessment report on Tribulus terrestris L., herba","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-02-25T12:12:09Z","last_updated_date":"2025-02-25T12:12:09Z","reference_number":"EMA/HMPC/886105/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-tribulus-terrestris-l-herba_en.pdf"},
    {"id":"66977","name":"Final assessment report on Pilosella officinarum Vall. (syn Hieracium pilosella L.), herba cum radice - Revision 1","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-02-26T09:37:50Z","last_updated_date":"2025-02-26T09:37:50Z","reference_number":"EMA/HMPC/493454/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-pilosella-officinarum-vall-syn-hieracium-pilosella-l-herba-cum-radice-revision-1_en.pdf"},
    {"id":"67059","name":"Final assessment report on Eucalyptus globulus Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker, aetheroleum - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T15:42:58Z","last_updated_date":"2025-02-28T15:42:58Z","reference_number":"EMA/HMPC/320282/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-eucalyptus-smithii-rt-baker-aetheroleum-revision-1_en.pdf"},
    {"id":"67238","name":"Addendum to assessment report on Linum usitatissimum L., semen","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-03-12T16:28:20Z","last_updated_date":"2025-03-12T16:28:20Z","reference_number":"EMA/HMPC/416377/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-linum-usitatissimum-l-semen_en.pdf"},
    {"id":"67242","name":"Addendum to Assessment report on Polypodium vulgare L. rhizoma","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T10:38:53Z","last_updated_date":"2025-03-13T10:38:53Z","reference_number":"EMA/HMPC/438158/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-polypodium-vulgare-l-rhizoma_en.pdf-0"},
    {"id":"67260","name":"Addendum to Assessment report on Sambucus nigra L., flos","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T15:44:31Z","last_updated_date":"2025-03-13T15:44:31Z","reference_number":"EMA/HMPC/438159/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-sambucus-nigra-l-flos_en.pdf"},
    {"id":"67262","name":"Addendum to Assessment report on Verbascum thapsus L.; V. densiflorum Bertol. (V.,thapsiforme Schrad); V. phlomoides L., flos","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T15:48:44Z","last_updated_date":"2025-03-13T15:48:44Z","reference_number":"EMA/HMPC/438161/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-verbascum-thapsus-l-v-densiflorum-bertol-vthapsiforme-schrad-v-phlomoides-l-flos_en.pdf"},
    {"id":"67264","name":"Addendum to Assessment report on Avena sativa L., herba and Avena sativa L., fructus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T15:53:33Z","last_updated_date":"2025-03-13T15:53:33Z","reference_number":"EMA/HMPC/331773/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-avena-sativa-l-herba-avena-sativa-l-fructus_en.pdf"},
    {"id":"67265","name":"Addendum to Assessment report on Cynara cardunculus L. (syn. C. scolymus L.), folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T15:57:36Z","last_updated_date":"2025-03-13T15:57:36Z","reference_number":"EMA/HMPC/432136/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-cynara-cardunculus-l-syn-c-scolymus-l-folium_en.pdf"},
    {"id":"67266","name":"Addendum to Assessment report on Olea europaea L., folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T16:03:49Z","last_updated_date":"2025-03-13T16:03:49Z","reference_number":"EMA/HMPC/432213/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-olea-europaea-l-folium_en.pdf"},
    {"id":"67840","name":"Draft assessment report on Crataegus monogyna Jacq. (Lindm.), C. laevigata (Poir.) DC. or their hybrids; C. pentagyna Waldst. et Kit. ex Willd.; C. azarolus L.","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2025-04-15 - 2025-07-15","first_published_date":"2025-04-15T11:59:21Z","last_updated_date":"2025-04-15T11:59:21Z","reference_number":"EMA/HMPC/116318/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-crataegus-monogyna-jacq-lindm-c-laevigata-poir-dc-or-their-hybrids-c-pentagyna-waldst-et-kit-ex-willd-c-azarolus-l_en.pdf"},
    {"id":"67844","name":"Draft assessment report on Arnica montana L., flos","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2025-04-15 - 2025-07-15","first_published_date":"2025-04-15T12:12:06Z","last_updated_date":"2025-04-15T12:12:06Z","reference_number":"EMA/HMPC/432016/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-arnica-montana-l-flos_en.pdf-0"},
    {"id":"67847","name":"Draft assessment report on Allium sativum L., bulbus","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2025-04-15 - 2025-07-15","first_published_date":"2025-04-15T12:21:38Z","last_updated_date":"2025-04-15T12:21:38Z","reference_number":"EMA/HMPC/329433/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-allium-sativum-l-bulbus_en.pdf-0"},
    {"id":"68043","name":"Addendum to Assessment report on Gentiana lutea L., radix","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-04-30T15:53:04Z","last_updated_date":"2025-04-30T15:53:04Z","reference_number":"EMA/HMPC/3544/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-gentiana-lutea-l-radix_en.pdf"},
    {"id":"68044","name":"Addendum to Assessment report on Humulus lupulus L., flos","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-04-30T15:55:43Z","last_updated_date":"2025-04-30T15:55:43Z","reference_number":"EMA/HMPC/8694/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-humulus-lupulus-l-flos_en.pdf"},
    {"id":"68045","name":"Addendum to assessment report on Melilotus officinalis (L.) Lam., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-04-30T15:57:51Z","last_updated_date":"2025-04-30T15:57:51Z","reference_number":"EMA/HMPC/419121/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"68046","name":"Addendum to Assessment report on Arctostaphylos uva-ursi (L.) Spreng., folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-04-30T16:00:12Z","last_updated_date":"2025-04-30T16:00:12Z","reference_number":"EMA/HMPC/320360/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-arctostaphylos-uva-ursi-l-spreng-folium_en.pdf"},
    {"id":"68511","name":"Draft assessment report on Ononis spinosa L., radix - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2025-06-02T09:36:44Z","last_updated_date":"2025-06-02T09:36:44Z","reference_number":"EMA/HMPC/584453/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-ononis-spinosa-l-radix-revision-1_en.pdf"},
    {"id":"68803","name":"Final addendum to assessment report on Vitis vinifera L., folium - Revision 1","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-06-18T11:13:19Z","last_updated_date":"2025-06-18T11:13:19Z","reference_number":"EMA/HMPC/432223/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-addendum-assessment-report-vitis-vinifera-l-folium-revision-1_en.pdf"},
    {"id":"69611","name":"Draft assessment report on on Glycyrrhiza glabra L.; Gycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2025-08-01T11:14:09Z","last_updated_date":"2025-08-01T11:14:09Z","reference_number":"EMA/HMPC/108395/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-glycyrrhiza-glabra-l-gycyrrhiza-inflata-bat-glycyrrhiza-uralensis-fisch-radix-revision-1_en.pdf"},
    {"id":"69613","name":"Draft assessment report on Fragaria vesca L.; Fragaria moschata Weston; Fragaria viridis Weston; Fragaria x ananassa (Weston) Duchesne ex Rozier, folium - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2025-08-01T11:37:31Z","last_updated_date":"2025-08-01T11:37:31Z","reference_number":"EMA/HMPC/10132/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium-revision-1_en.pdf"},
    {"id":"69616","name":"Draft assessment report on Species diureticae - Revision 1","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2025-08-01T12:02:11Z","last_updated_date":"2025-08-01T12:02:11Z","reference_number":"EMA/HMPC/85831/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-species-diureticae-revision-1_en.pdf"}    {"id":"70201","name":"Final assessment report on Species pectorales - First version","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-09-22T10:56:28Z","last_updated_date":"2025-09-22T10:56:28Z","reference_number":"EMA/HMPC/189454/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-species-pectorales-first-version_en.pdf"},
    {"id":"70432","name":"Addendum to Assessment report on Calendula officinalis L., flos - Revision 1","type":"herbal-report","status":"Adopted","consultation_date":"","first_published_date":"2025-10-03T11:08:57Z","last_updated_date":"2025-10-03T11:08:57Z","reference_number":"EMA/HMPC/12880/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-calendula-officinalis-l-flos-revision-1_en.pdf"},
    {"id":"70559","name":"Draft assessment report on Zea mays L., stigma","type":"herbal-report","status":"Draft: consultation closed","consultation_date":"2025-10-15 - 2026-01-15","first_published_date":"2025-10-15T09:30:13Z","last_updated_date":"2025-10-15T09:30:13Z","reference_number":"EMA/HMPC/509423/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-zea-mays-l-stigma_en.pdf"},
    {"id":"70782","name":"Addendum to Assessment report on Primula veris L. Primula elatior (L.) Hill, flos","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T10:51:17Z","last_updated_date":"2025-10-23T10:51:17Z","reference_number":"EMA/HMPC/216179/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-primula-veris-l-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"70783","name":"Addendum to Assessment report on Primula veris L.; Primula elatior (L.) Hill, radix","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T10:53:52Z","last_updated_date":"2025-10-23T10:53:52Z","reference_number":"EMA/HMPC/216180/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-primula-veris-l-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"71594","name":"Addendum to Assessment report on Althaea officinalis L., radix","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-12-08T16:42:02Z","last_updated_date":"2025-12-08T16:42:02Z","reference_number":"EMA/HMPC/301260/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-althaea-officinalis-l-radix_en.pdf"},
    {"id":"71596","name":"Addendum to Assessment report on Carum carvi L., aetheroleum","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-12-08T16:45:36Z","last_updated_date":"2026-02-09T15:44:00Z","reference_number":"EMA/HMPC/296779/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"71597","name":"Addendum to Assessment report on Carum carvi L., fructus","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2025-12-08T16:48:26Z","last_updated_date":"2026-02-09T15:42:00Z","reference_number":"EMA/HMPC/296784/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-carum-carvi-l-fructus_en.pdf"},
    {"id":"72356","name":"Final addendum to assessment report on Curcuma longa L., rhizoma","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T16:12:32Z","last_updated_date":"2026-02-10T11:22:00Z","reference_number":"EMA/HMPC/81467/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/final-addendum-assessment-report-curcuma-longa-l-rhizoma_en.pdf"},
    {"id":"72503","name":"Addendum to assessment report on Cimicifuga racemosa (L.) Nutt., rhizoma","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2026-02-11T11:04:51Z","last_updated_date":"2026-02-11T11:04:51Z","reference_number":"EMA/HMPC/8411/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-cimicifuga-racemosa-l-nutt-rhizoma_en.pdf"},
    {"id":"72504","name":"Addendum to assessment report on Oenothera biennis L.; Oenothera lamarckiana L., oleum","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2026-02-11T11:08:45Z","last_updated_date":"2026-02-11T11:08:45Z","reference_number":"EMA/HMPC/297627/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-oenothera-biennis-l-oenothera-lamarckiana-l-oleum_en.pdf"},
    {"id":"72559","name":"Draft assessment report on Ribes nigrum L., folium - Revision 2","type":"herbal-report","status":"Draft","consultation_date":"","first_published_date":"2026-02-16T08:45:06Z","last_updated_date":"2026-02-16T08:45:06Z","reference_number":"EMA/HMPC/296856/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-ribes-nigrum-l-folium-revision-2_en.pdf"},
    {"id":"73491","name":"Addendum to assessment report on Ruscus aculeatus L., rhizoma - Revision 1","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2026-04-17T15:53:11Z","last_updated_date":"2026-04-17T15:53:11Z","reference_number":"EMA/HMPC/139333/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-ruscus-aculeatus-l-rhizoma-revision-1_en.pdf"},
    {"id":"73505","name":"Addendum to assessment report on Centaurium erythraea Rafn. s.l., herba","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2026-04-21T15:20:38Z","last_updated_date":"2026-04-21T15:20:38Z","reference_number":"EMA/HMPC/8050/2026","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-centaurium-erythraea-rafn-sl-herba_en.pdf"},
    {"id":"73701","name":"Addendum to assessment report on Hamamelis virginiana L., folium et cortex aut ramunculus destillatum","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2026-05-11T13:40:59Z","last_updated_date":"2026-05-11T13:40:59Z","reference_number":"EMA/HMPC/359574/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-hamamelis-virginiana-l-folium-et-cortex-aut-ramunculus-destillatum_en.pdf-0"},
    {"id":"73702","name":"Addendum to assessment report on Hamamelis virginiana L., folium","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2026-05-11T13:42:52Z","last_updated_date":"2026-05-11T13:42:52Z","reference_number":"EMA/HMPC/359553/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-hamamelis-virginiana-l-folium_en.pdf-0"},
    {"id":"73703","name":"Addendum to assessment report on Hamamelis virginiana L., folium et cortex aut ramunculus destillatum","type":"herbal-report","status":"unknown","consultation_date":"","first_published_date":"2026-05-11T13:44:51Z","last_updated_date":"2026-05-11T13:44:51Z","reference_number":"EMA/HMPC/359539/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-hamamelis-virginiana-l-folium-et-cortex-aut-ramunculus-destillatum_en.pdf-1"},
    {"id":"73917","name":"Draft assessment report on Glycine max (L.) Merr., lecithinum","type":"herbal-report","status":"Draft: consultation open","consultation_date":"2026-06-01 - 2026-08-31","first_published_date":"2026-06-01T10:51:13Z","last_updated_date":"2026-06-01T10:51:13Z","reference_number":"EMA/HMPC/216488/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-glycine-max-l-merr-lecithinum_en.pdf"},
    {"id":"2483","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a Community herbal monograph on Trigonella foenum-graecum L., semen","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2022-08-30T02:00:00Z","last_updated_date":"2022-08-30T02:00:00Z","reference_number":"EMA/HMPC/64602/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-trigonella-foenum-graecum-l-semen_en.pdf"},
    {"id":"3270","name":"Opinion of HMPC on a Community herbal monograph on Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T01:00:00Z","last_updated_date":"2013-03-04T01:00:00Z","reference_number":"EMA/HMPC/332113/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"3556","name":"Opinion of the HMPC on a Community herbal monograph on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-10-06T02:00:00Z","last_updated_date":"2014-10-06T02:00:00Z","reference_number":"EMA/HMPC/176672/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf"},
    {"id":"3793","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Betula pendula Roth; Betula pubescens Ehrh., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2015-03-13T01:09:21Z","reference_number":"EMEA/HMPC/453698/2007EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-betula-pendula-roth-betula-pubescens-ehrh-folium_en.pdf"},
    {"id":"3988","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Fucus vesicolosus L., thallus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-10-10T02:00:00Z","last_updated_date":"2014-10-10T02:00:00Z","reference_number":"EMA/HMPC/283231/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-fucus-vesicolosus-l-thallus_en.pdf"},
    {"id":"4098","name":"Opinion of the Committee on Herbal Medicinal Products on a Community herbal monograph on Cinnamomum verum J.S. Presl, cortex","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2011-08-05T02:00:00Z","reference_number":"EMA/HMPC/258018/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-cinnamomum-verum-js-presl-cortex_en.pdf"},
    {"id":"4265","name":"Superseded opinion of the HMPC on a community herbal monograph on Hedera helix L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T01:00:00Z","last_updated_date":"2016-01-18T01:00:00Z","reference_number":"EMA/HMPC/258019/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-hedera-helix-l-folium_en.pdf"},
    {"id":"4285","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Urtica dioica l.; Urtica urens L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2025-03-07T02:00:00Z","reference_number":"EMEA/HMPC/187995/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-herba_en.pdf"},
    {"id":"4310","name":"Final opinion of the HMPC on a Community herbal monograph on Solanum dulcamara L., stipites","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T01:00:00Z","last_updated_date":"2013-02-15T01:00:00Z","reference_number":"EMA/HMPC/26000/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-community-herbal-monograph-solanum-dulcamara-l-stipites_en.pdf"},
    {"id":"4673","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2014-10-06T02:09:21Z","reference_number":"EMEA/HMPC/590998/2007/EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf"},
    {"id":"4707","name":"Opinion of the HMPC on a Community herbal monograph on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-07-10T14:00:00Z","last_updated_date":"2012-07-10T14:00:00Z","reference_number":"EMA/HMPC/332115/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-or-their-mixtures-flos-first-version_en.pdf"},
    {"id":"4766","name":"Superseded opinion of the HMPC on a Community herbal monograph on Aesculus hippocastanum L., cortex","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-06-27T16:15:00Z","last_updated_date":"2012-06-27T16:15:00Z","reference_number":"EMA/HMPC/332116/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-aesculus-hippocastanum-l-cortex_en.pdf"},
    {"id":"5384","name":"Opinion of the HMPC on a Community herbal monograph on Arnica montana L., flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/HMPC/283229/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-arnica-montana-l-flos_en.pdf"},
    {"id":"5453","name":"Superseded opinion of the HMPC on a Community herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L., oleum - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-04-02T11:26:00Z","last_updated_date":"2018-10-10T11:26:00Z","reference_number":"EMA/HMPC/888907/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-oenothera-biennis-l-oenothera-lamarckiana-l-oleum-first-version_en.pdf"},
    {"id":"6226","name":"Opinion of the HMPC on a European Union herbal monograph on Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T13:00:00Z","last_updated_date":"2015-04-09T13:00:00Z","reference_number":"EMA/HMPC/711718/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-melaleuca-alternifolia-maiden-and-betch-cheel-m-linariifolia-smith-m-dissitiflora-f-mueller-andor-other-species-melaleuca-aetheroleum-first-version_en.pdf"},
    {"id":"6353","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Gentiana Lutea L., radix  - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-03-05T01:00:00Z","last_updated_date":"2019-04-30T01:00:00Z","reference_number":"EMA/HMPC/678928/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-gentiana-lutea-l-radix-first-version_en.pdf"},
    {"id":"7004","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Avena sativa L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/305008/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-avena-sativa-l-herba_en.pdf"},
    {"id":"7712","name":"Opinion of the Committee on Herbal Medicinal products on a community herbal monograph for Linum usitatissimum L., semen","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-07-13T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMA/HMPC/165016/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf"},
    {"id":"7911","name":"Opinion of the HMPC on a Community herbal monograph on Ononis spinosa L., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-05-28T02:00:00Z","last_updated_date":"2014-05-28T02:00:00Z","reference_number":"EMA/HMPC/283233/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-ononis-spinosa-l-radix_en.pdf"},
    {"id":"7957","name":"Opinion of the HMPC on a European Union herbal monograph on Althaea officinalis L., radix","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2016-11-04T15:14:00Z","last_updated_date":"2016-11-04T15:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-althaea-officinalis-l-radix_en.pdf"},
    {"id":"8046","name":"Opinion of the HMPC on a European Union herbal monograph on Carum carvi L., fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/HMPC/454922/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-carum-carvi-l-fructus_en.pdf"},
    {"id":"8662","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Equisetum arvense L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2016-03-17T01:09:21Z","reference_number":"EMEA/HMPC/305044/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-equisetum-arvense-l-herba_en.pdf"},
    {"id":"9352","name":"Final opinion of the HMPC on a European Union herbal monograph on Artemisia absinthium L., herba - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-10-05T02:00:00Z","last_updated_date":"2017-10-05T02:00:00Z","reference_number":"EMA/HMPC/319051/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-artemisia-absinthium-l-herba-revision-1_en.pdf"},
    {"id":"9616","name":"Opinion of the HMPC on a European Union herbal monograph on Valeriana officinalis L., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-04-27T12:30:00Z","last_updated_date":"2016-04-27T12:30:00Z","reference_number":"EMA/HMPC/74082/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf"},
    {"id":"9751","name":"Superseded opinion of the HMPC on a Community herbal monograph on Mentha x piperita L., aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/HMPC/453712/2007EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-mentha-x-piperita-l-aetheroleum_en.pdf"},
    {"id":"9780","name":"Opinion of the HMPC on a Community herbal monograph on Fraxinus excelsior L. or Fraxinus angustifolia Vahl, folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T16:40:00Z","last_updated_date":"2012-06-18T16:40:00Z","reference_number":"EMA/HMPC/216953/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-fraxinus-excelsior-l-or-fraxinus-angustifolia-vahl-folium_en.pdf"},
    {"id":"9944","name":"Superseded opinion of the HMPC on a Community herbal monograph on Juniperi pseudo-fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-02-16T01:00:00Z","last_updated_date":"2023-06-13T01:00:00Z","reference_number":"EMA/HMPC/678925/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-juniperi-pseudo-fructus_en.pdf"},
    {"id":"10059","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung, fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2024-03-07T02:00:00Z","reference_number":"EMEA/HMPC/280074/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus_en.pdf"},
    {"id":"10239","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Polypodium vulgare L., rhizoma","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/589447/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-polypodium-vulgare-l-rhizoma_en.pdf"},
    {"id":"10510","name":"Opinion of the HMPC on a European Union herbal monograph on Echinacea purpurea (L.) Moench, radix – Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-08-11T02:00:00Z","last_updated_date":"2017-08-11T02:00:00Z","reference_number":"EMA/HMPC/319071/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-echinacea-purpurea-l-moench-radix-revision-1_en.pdf"},
    {"id":"10532","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Plantago ovata Forssk., seminis tegumentum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2006-07-13T02:00:00Z","last_updated_date":"2013-07-23T02:00:00Z","reference_number":"EMEA/HMPC/353208/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-plantago-ovata-forssk-seminis-tegumentum_en.pdf"},
    {"id":"10559","name":"Superseded - Opinion of the Committee on Herbal Medicinal Products on a Community herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-05-16T02:00:00Z","last_updated_date":"2018-07-03T02:00:00Z","reference_number":"EMA/HMPC/756918/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-first-version_en.pdf"},
    {"id":"10753","name":"Opinion of the HMPC on a European Union herbal monograph on Vaccinium myrtillus L., fructus recens","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"EMA/HMPC/642019/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-vaccinium-myrtillus-l-fructus-recens_en.pdf"},
    {"id":"10817","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Calendula offilinalis L., flos - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-03-06T00:09:21Z","last_updated_date":"2018-06-15T01:09:21Z","reference_number":"EMEA/HMPC/590995/2007/EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-calendula-offilinalis-l-flos-first-version_en.pdf"},
    {"id":"10952","name":"Superseded opinion of the HMPC on a community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2022-10-03T01:00:00Z","reference_number":"EMA/HMPC/888911/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-agropyron-repens-l-p-beauv-rhizoma_en.pdf"},
    {"id":"11056","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Peumus boldus Molina, folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2009-01-15T00:09:21Z","last_updated_date":"2017-01-12T10:29:00Z","reference_number":"EMEA/HMPC/11543/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-peumus-boldus-molina-folium_en.pdf"},
    {"id":"11148","name":"Opinion of the HMPC on a European Union herbal monograph on  Eschscholzia californica Cham., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/HMPC/61600/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-eschscholzia-californica-cham-herba_en.pdf"},
    {"id":"11174","name":"Opinion of the HMPC on a community herbal monograph on Phaseolus vulgaris L., fructus sine semine","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2014-01-17T16:00:00Z","last_updated_date":"2014-01-17T16:00:00Z","reference_number":"EMA/HMPC/695911/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-phaseolus-vulgaris-l-fructus-sine-semine_en.pdf"},
    {"id":"11212","name":"Final opinion of the HMPC on Hedera helix  L., folium  - Revision 2","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2018-08-13T13:47:00Z","last_updated_date":"2018-08-13T13:47:00Z","reference_number":"EMA/HMPC/769686/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-hedera-helix-l-folium-revision-2_en.pdf"},
    {"id":"11579","name":"Superseded opinion of the HMPC on a community herbal monograph on Tanacetum parthenium (L.) Shulz Bip., herba - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-06-20T02:00:00Z","last_updated_date":"2020-08-14T02:00:00Z","reference_number":"EMA/HMPC/757136/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-tanacetum-parthenium-l-shulz-bip-herba-first-version_en.pdf"},
    {"id":"12316","name":"Opinion of the HMPC on a Community herbal monograph on Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2016-06-09T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"EMA/HMPC/244307/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"12542","name":"Opinion of the HMPC on a Community herbal monograph on Cichorium intybus L., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-03-14T16:00:00Z","last_updated_date":"2013-03-14T16:00:00Z","reference_number":"EMA/HMPC/M/H/0126","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-cichorium-intybus-l-radix_en.pdf"},
    {"id":"12583","name":"Opinion of the HMPC on a European Union herbal monograph on Hieracium pilosella L., herba cum radice - Superseded","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2015-06-17T13:25:00Z","last_updated_date":"2025-02-26T13:25:00Z","reference_number":"EMA/HMPC/165127/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-hieracium-pilosella-l-herba-cum-radice-superseded_en.pdf"},
    {"id":"12967","name":"Opinion of the HMPC on a community herbal monograph on Plantago lanceolata L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T01:00:00Z","last_updated_date":"2012-02-24T01:00:00Z","reference_number":"EMA/HMPC/888909/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-plantago-lanceolata-l-folium_en.pdf"},
    {"id":"13284","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Althaea officinalis L., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2009-07-14T02:09:21Z","last_updated_date":"2016-11-04T14:54:00Z","reference_number":"EMEA/HMPC/109223/2009EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-althaea-officinalis-l-radix_en.pdf"},
    {"id":"13314","name":"Superseded opinion of the HMPC on a Community herbal monograph on Zingiber officinale Roscoe, rhizoma","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2012-06-04T02:00:00Z","last_updated_date":"2025-06-19T02:00:00Z","reference_number":"EMA/HMPC/216956/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-zingiber-officinale-roscoe-rhizoma_en.pdf"},
    {"id":"13321","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMEA/HMPC/583003/2009EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf"},
    {"id":"14177","name":"Opinion of the HMPC on a European Union herbal monograph on Peumus boldus, Molina, folium","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2017-01-12T10:48:00Z","last_updated_date":"2017-01-12T10:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-peumus-boldus-molina-folium_en.pdf"},
    {"id":"14475","name":"HMPC positive opinion on Community herbal monograph on Chamaemelum nobile (L.) All., flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T17:20:00Z","last_updated_date":"2012-01-20T17:20:00Z","reference_number":"EMA/HMPC/888905/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/hmpc-positive-opinion-community-herbal-monograph-chamaemelum-nobile-l-all-flos_en.pdf"},
    {"id":"14526","name":"Opinion of the HMPC on a Community herbal monograph on Levisticum officinale Koch, radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T16:00:00Z","last_updated_date":"2013-02-22T16:00:00Z","reference_number":"EMA/HMPC/M/H/0123","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-levisticum-officinale-koch-radix_en.pdf"},
    {"id":"14593","name":"Opinion of the HMPC on an European Union herbal monograph on Ribes nigrum L., folium","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T10:34:00Z","last_updated_date":"2017-12-19T10:34:00Z","reference_number":"EMA/HMPC/615038/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-ribes-nigrum-l-folium_en.pdf"},
    {"id":"15005","name":"Opinion of the HMPC on a community herbal monograph on Melissa officinalis L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-08-05T17:00:00Z","last_updated_date":"2013-08-05T17:00:00Z","reference_number":"EMA/HMPC/M/H/0130","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-melissa-officinalis-l-folium_en.pdf"},
    {"id":"15535","name":"Superseded opinion of the HMPC on a community herbal monograph on Ribes nigrum L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-06-30T02:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"EMA/HMPC/615038/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-ribes-nigrum-l-folium_en.pdf"},
    {"id":"15633","name":"Superseded opinion of the HMPC on a Community herbal monograph on Plantago ovata Forssk., semen","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2006-07-13T02:00:00Z","last_updated_date":"2013-07-23T02:00:00Z","reference_number":"EMEA/HMPC/353198/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-plantago-ovata-forssk-semen_en.pdf"},
    {"id":"15773","name":"Opinion of the HMPC on a Community herbal monograph on Filipendula ulmaria (L.) Maxim., herba - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-09-29T02:00:00Z","last_updated_date":"2011-09-29T02:00:00Z","reference_number":"EMA/HMPC/544938/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-filipendula-ulmaria-l-maxim-herba-first-version_en.pdf"},
    {"id":"15845","name":"Superseded opinion of the HMPC on a Community herbal monograph on Cassia senna L, fructus and Cassia angustifolia Vahl, fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2006-09-07T02:09:00Z","last_updated_date":"2006-09-07T02:09:00Z","reference_number":"EMEA/HMPC/429430/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-cassia-senna-l-fructus-and-cassia-angustifolia-vahl-fructus_en.pdf"},
    {"id":"15867","name":"Superseded opinion of the HMPC on a Community herbal monograph on Rhodiola rosea  - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T16:00:00Z","last_updated_date":"2024-05-23T16:00:00Z","reference_number":"EMA/HMPC/216955/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-rhodiola-rosea-first-version_en.pdf"},
    {"id":"15977","name":"Superseded final opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Plantago afra L. et Plantago indica L., semen","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2006-07-13T02:09:21Z","last_updated_date":"2013-07-29T02:09:21Z","reference_number":"EMEA/HMPC/353137/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-final-opinion-committee-herbal-medicinal-products-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf"},
    {"id":"15985","name":"Opinion of the HMPC on a Community herbal monograph on Achillea millefolium L., flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T15:35:00Z","last_updated_date":"2012-11-16T15:35:00Z","reference_number":"EMA/HMPC/544939/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-achillea-millefolium-l-flos_en.pdf"},
    {"id":"16038","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Eucalyptus globulus Labill., Eucalyptus polybractea R.T. Baker and/or Eucalyptus smithii R.T. Baker, aetheroleum - Superseded","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2025-02-28T02:00:00Z","reference_number":"EMA/HMPC/283230/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-or-eucalyptus-smithii-rt-baker-aetheroleum-superseded_en.pdf"},
    {"id":"16188","name":"Superseded opinion of the HMPC on a Community herbal monograph on Rhamnus purshianus D.C., cortex","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-09-07T02:09:00Z","last_updated_date":"2007-09-07T02:09:00Z","reference_number":"EMEA/HMPC/405547/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf"},
    {"id":"16295","name":"Opinion of the HMPC on a European Union herbal monograph on Salix [various species including S. purpurea L., S. daphnoides Vill., S. fragilis L.], cortex","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-07-07T02:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMA/HMPC/66094/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-cortex_en.pdf"},
    {"id":"16435","name":"Opinion of the HMPC on a Community herbal monograph on Paullina cupana Kunth ex H.G.K. var sorbilis (Mart.) Ducke, semen - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/HMPC/2603/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-paullina-cupana-kunth-ex-hgk-var-sorbilis-mart-ducke-semen-first-version_en.pdf"},
    {"id":"16454","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Commiphora molmol Engler, gummi-resina","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T15:00:00Z","last_updated_date":"2011-12-22T15:00:00Z","reference_number":"EMA/HMPC/544935/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-commiphora-molmol-engler-gummi-resina_en.pdf"},
    {"id":"17205","name":"Opinion of the HMPC on a Community herbal on Origanum dictamus L., herba - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-08-05T02:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"EMA/HMPC/420310/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-origanum-dictamus-l-herba-first-version_en.pdf"},
    {"id":"17211","name":"Final opinion of the HMPC on a  Community herbal monograph on Thymus vulgaris L., Thymus zygis L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-06-02T02:00:00Z","last_updated_date":"2014-06-02T02:00:00Z","reference_number":"EMA/HMPC/695924/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-community-herbal-monograph-thymus-vulgaris-l-thymus-zygis-l-herba_en.pdf"},
    {"id":"17294","name":"Opinion of the HMPC on a Community herbal monograph on Plantago ovata Forssk., semen","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T15:30:00Z","last_updated_date":"2013-07-23T15:30:00Z","reference_number":"EMA/HMPC/742264/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-plantago-ovata-forssk-semen_en.pdf"},
    {"id":"17426","name":"Opinion of the HMPC on a Community herbal monograph on Grindelia robusta Nutt., Grindelia squarrosa (Pursh) Dunal, Grindelia humilis Hook. et Arn., Grindelia camporum Greene, herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-03-14T14:30:00Z","last_updated_date":"2013-03-14T14:30:00Z","reference_number":"EMA/HMPC/M/H/0124","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-grindelia-robusta-nutt-grindelia-squarrosa-pursh-dunal-grindelia-humilis-hook-et-arn-grindelia-camporum-greene-herba_en.pdf"},
    {"id":"17670","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-04-29T14:45:00Z","last_updated_date":"2014-04-29T14:45:00Z","reference_number":"EMA/HPC/695912/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"17842","name":"Final opinion of the HMPC on a European Union herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-07-03T02:00:00Z","last_updated_date":"2018-07-03T02:00:00Z","reference_number":"EMA/HMPC/195629/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf"},
    {"id":"17967","name":"Opinion of the Committee on Herbal Medicinal Products on a European Union herbal monograph on Betula pendula Roth; Betula pubescens Ehrh., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/HMPC/711682/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-european-union-herbal-monograph-betula-pendula-roth-betula-pubescens-ehrh-folium_en.pdf"},
    {"id":"18068","name":"Opinion of the HMPC on a European Union herbal monograph on Serenoa repens (W. Bartram) Small, fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-01-14T01:00:00Z","last_updated_date":"2016-01-14T01:00:00Z","reference_number":"EMA/HMPC/642021/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-serenoa-repens-w-bartram-small-fructus_en.pdf"},
    {"id":"18236","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Curcuma longa L., rhizoma - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-02-04T01:00:00Z","last_updated_date":"2010-02-04T01:00:00Z","reference_number":"EMEA/HMPC/678921/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-curcuma-longa-l-rhizoma-first-version_en.pdf"},
    {"id":"18398","name":"Opinion of the HMPC on a Community herbal monograph on Echinacea angustifolia DC., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T16:30:00Z","last_updated_date":"2012-05-29T16:30:00Z","reference_number":"EMA/HMPC/216954/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-echinacea-angustifolia-dc-radix_en.pdf"},
    {"id":"18661","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Panax ginseng C.A.Meyer, radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-10-10T02:00:00Z","last_updated_date":"2024-07-12T02:00:00Z","reference_number":"EMA/HMPC/270952/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-panax-ginseng-cameyer-radix_en.pdf"},
    {"id":"18799","name":"Superseded opinion of the HMPC on a community herbal monograph on Vitis vinifera L. folium - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/458286/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-vitis-vinifera-l-folium-first-version_en.pdf"},
    {"id":"18903","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Pimpinella anisum L., aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-06-18T02:00:00Z","last_updated_date":"2014-06-18T02:00:00Z","reference_number":"EMEA/HMPC/695922/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-pimpinella-anisum-l-aetheroleum_en.pdf"},
    {"id":"19364","name":"Superseded opinion of the HMPC on a Community herbal monograph on Mentha x piperita L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/189852/2008/EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-mentha-x-piperita-l-folium_en.pdf"},
    {"id":"19431","name":"Opinion of the HMPC on a European Union herbal monograph on Ricinus communis L., oleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-03-11T12:31:00Z","last_updated_date":"2016-03-11T12:31:00Z","reference_number":"EMA/HMPC/74516/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-ricinus-communis-l-oleum_en.pdf"},
    {"id":"19499","name":"Opinion of the HMPC on Marrubium vulgare L., herba - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-08-01T17:00:00Z","last_updated_date":"2013-08-01T17:00:00Z","reference_number":"EMA/HMPC/420311/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-marrubium-vulgare-l-herba-first-version_en.pdf"},
    {"id":"19672","name":"Opinion of the HMPC on a Community herbal monograph on Filipendula ulmaria (L.) Maxim., flos - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-09-29T02:00:00Z","last_updated_date":"2011-09-29T02:00:00Z","reference_number":"EMA/HMPC/544937/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-filipendula-ulmaria-l-maxim-flos-first-version_en.pdf"},
    {"id":"19754","name":"Superseded opinion of the HMPC on a community herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-02-28T16:15:00Z","last_updated_date":"2018-04-11T14:00:00Z","reference_number":"EMA/HMPC/888910/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-1_en.pdf"}    {"id":"19988","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Capsella bursa-pastoris (L.) Medikus, herba  - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T15:30:00Z","last_updated_date":"2011-12-22T15:30:00Z","reference_number":"EMA/HMPC/544936/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-capsella-bursa-pastoris-l-medikus-herba-first-version_en.pdf"},
    {"id":"20333","name":"Opinion of the HMPC on a Community herbal monograph on Humulus lupulus L., flos - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-10-09T02:00:00Z","last_updated_date":"2014-10-09T02:00:00Z","reference_number":"EMA/HMPC/283232/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"20358","name":"Superseded opinion of the HMPC on a community herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-09-02T02:00:00Z","last_updated_date":"2010-09-02T02:00:00Z","reference_number":"EMA/HMPC/282834/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos_en.pdf"},
    {"id":"21296","name":"Superseded opinion of the Committee on Herbal Medicinal products on a community herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne, radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMEA/HMPC/584717/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-harpagophytum-procumbens-dc-andor-harpagophytum-zeyheri-decne-radix_en.pdf"},
    {"id":"21499","name":"Opinion of the HMPC on a Community herbal monograph on Cucurbita pepo L, semen","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/HMPC/742266/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-cucurbita-pepo-l-semen_en.pdf"},
    {"id":"21723","name":"Superseded opinion of the committee on herbal medicinal products on a community herbal monograph on Echinacea purpurea (L.) Moench., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-03-06T00:09:21Z","last_updated_date":"2015-04-14T01:09:21Z","reference_number":"EMEA/HMPC/453709/2007EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-echinacea-purpurea-l-moench-herba_en.pdf"},
    {"id":"21730","name":"Opinion of the HMPC on a European Union herbal monograph on Glycine max (L.) Merr., lecithinum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-11-20T01:00:00Z","last_updated_date":"2017-11-20T01:00:00Z","reference_number":"EMA/HMPC/66450/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-glycine-max-l-merr-lecithinum_en.pdf"},
    {"id":"21767","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Valeriana officinalis L., radix (Valerianae aetheroleum)","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-06-20T02:00:00Z","last_updated_date":"2016-06-20T02:00:00Z","reference_number":"EMEA/HMPC/313368/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-valeriana-officinalis-l-radix-valerianae-aetheroleum_en.pdf"},
    {"id":"21823","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Taraxacum officinale Weber ex Wigg., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMEA/HMPC/583004/2009EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-folium_en.pdf"},
    {"id":"22223","name":"Superseded opinion of the HMPC on a Community herbal monograph on Cassia senna L. et Cassia angustifolia Vahl, folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2006-09-07T02:09:00Z","last_updated_date":"2006-09-07T02:09:00Z","reference_number":"EMEA/HMPC/429415/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-cassia-senna-l-et-cassia-angustifolia-vahl-folium_en.pdf"},
    {"id":"22279","name":"Opinion of the HMPC on a European Union herbal monograph on Matricaria recutita L., aetheroleum - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-04-05T02:00:00Z","last_updated_date":"2016-04-05T02:00:00Z","reference_number":"EMA/HMPC/458822/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-matricaria-recutita-l-aetheroleum-first-version_en.pdf"},
    {"id":"22292","name":"Opinion of the HMPC on a European Union herbal monograph on Prunus africana (Hook f.) Kalkm., cortex","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-09-01T02:00:00Z","last_updated_date":"2017-09-01T02:00:00Z","reference_number":"EMA/HMPC/481429/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-prunus-africana-hook-f-kalkm-cortex_en.pdf"},
    {"id":"22513","name":"Opinion of the HMPC on a Community herbal monograph on Eucalyptus globulus Labill., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-04-19T12:00:00Z","last_updated_date":"2013-04-19T12:00:00Z","reference_number":"EMA/HMPC/26002/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-eucalyptus-globulus-labill-folium_en.pdf"},
    {"id":"22601","name":"Opinion of the HMPC on a European Union herbal monograph on Calendula officinalis L., flos - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-06-14T15:00:00Z","last_updated_date":"2018-06-14T15:00:00Z","reference_number":"EMA/HMPC/195714/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-calendula-officinalis-l-flos-revision-1_en.pdf"},
    {"id":"23189","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Thymus vulgaris L. and Thymus zygis L, herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T00:09:21Z","last_updated_date":"2014-06-03T01:09:21Z","reference_number":"EMEA/HMPC/453713/2007EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba_en.pdf"},
    {"id":"23319","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Artemisia absinthium L., herba - First version","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2017-10-05T02:00:00Z","reference_number":"EMEA/HMPC/375221/2009EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-artemisia-absinthium-l-herba-first-version_en.pdf"},
    {"id":"23452","name":"Opinion of the HMPC on a European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-01-13T16:10:00Z","last_updated_date":"2016-01-13T16:10:00Z","reference_number":"EMA/HMPC/774041/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf"},
    {"id":"23533","name":"Superseded opinion of the HMPC on a Community herbal monograph on Rosmarinus officinalis L., aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-02-03T01:00:00Z","last_updated_date":"2024-09-20T01:00:00Z","reference_number":"EMA/HMPC/457054/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-rosmarinus-officinalis-l-aetheroleum_en.pdf"},
    {"id":"23669","name":"Final opinion of the HMPC on a European Union herbal monograph on Aloe barbadensis Mill. and on Aloe (various species, mainly Aloe ferox Mill. and its hybrids), folii succus siccatus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-04-10T02:00:00Z","last_updated_date":"2017-04-10T02:00:00Z","reference_number":"EMA/HMPC/28044/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf"},
    {"id":"23748","name":"Superseded opinion of the HMPC on a Community herbal monograph on Achillea millefolium L., herba - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T15:35:00Z","last_updated_date":"2012-11-16T15:35:00Z","reference_number":"EMA/HMPC/544934/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-achillea-millefolium-l-herba-first-version_en.pdf"},
    {"id":"23935","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Hypericum perforatum L., herba (well-established medicinal use)","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2009-12-21T00:09:00Z","last_updated_date":"2023-02-22T00:09:00Z","reference_number":"EMA/HMPC/678923/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-hypericum-perforatum-l-herba-well-established-medicinal-use_en.pdf"},
    {"id":"24019","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Passiflora incarnata L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-07-24T16:40:00Z","last_updated_date":"2014-07-24T16:40:00Z","reference_number":"EMA/HMPC/283334/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-passiflora-incarnata-l-herba_en.pdf"},
    {"id":"24154","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Pimpinella anisum L., aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2014-06-18T02:09:21Z","reference_number":"EMEA/HMPC/286986/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-pimpinella-anisum-l-aetheroleum_en.pdf"},
    {"id":"24173","name":"Opinion of the HMPC on a Community herbal monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-08-24T17:00:00Z","last_updated_date":"2012-08-24T17:00:00Z","reference_number":"EMA/HMPC/331117/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf"},
    {"id":"24436","name":"Superseded opinion of the committee on herbal medicinal products on a community herbal monograph on Salvia officinalis L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2017-07-13T02:00:00Z","reference_number":"EMA/HMPC/583001/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-salvia-officinalis-l-folium_en.pdf"},
    {"id":"24443","name":"Opinion of the HMPC on a European Union herbal monograph on Vaccinium myrtillus L., fructus siccus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"EMA/HMPC/642020/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-vaccinium-myrtillus-l-fructus-siccus_en.pdf"},
    {"id":"24814","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Salix [various species including S. purpurea L.; S. daphnoides Vill.; S. fragilis L.], cortex","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"EMEA/HMPC/66094/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-cortex_en.pdf"},
    {"id":"25552","name":"Opinion of the HMPC on a Community herbal monograph on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P.Beauv.) Schott et Endl., semen","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-02-07T01:00:00Z","last_updated_date":"2012-02-07T01:00:00Z","reference_number":"EMA/HMPC/888906/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-cola-nitida-vent-schott-et-endl-and-its-varieties-and-cola-acuminata-pbeauv-schott-et-endl-semen_en.pdf"},
    {"id":"25666","name":"Superseded opinion of the HMPC on a community herbal monograph on Cynara scolymus L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T01:00:00Z","last_updated_date":"2011-12-21T01:00:00Z","reference_number":"EMA/HMPC/749911/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-cynara-scolymus-l-folium_en.pdf"},
    {"id":"25942","name":"Superseded opinion of the HMPC on a Community herbal monograph on Rhamnus frangula L., cortex - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2006-09-07T02:00:00Z","last_updated_date":"2006-09-07T02:00:00Z","reference_number":"EMEA/HMPC/429405/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-rhamnus-frangula-l-cortex-first-version_en.pdf"},
    {"id":"26059","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. vulgare, aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2024-07-19T02:00:00Z","reference_number":"EMEA/HMPC/280059/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-aetheroleum_en.pdf"},
    {"id":"26180","name":"Final opinion of the HMPC on a European Union herbal monograph on Origanum majorana L., herba","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T11:09:00Z","last_updated_date":"2016-11-15T11:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-origanum-majorana-l-herba_en.pdf"},
    {"id":"26268","name":"Opinion of the Committee on Herbal Medicinal Products on a Community herbal monograph on Arctium lappa L., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"EMA/HMPC/573551/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-arctium-lappa-l-radix_en.pdf"},
    {"id":"26308","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Fumaria officinalis L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-12-07T01:00:00Z","last_updated_date":"2011-12-07T01:00:00Z","reference_number":"EMA/HMPC/749912/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-fumaria-officinalis-l-herba_en.pdf"},
    {"id":"26348","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Pimpinella anisum L., fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2014-06-17T02:09:21Z","reference_number":"EMEA/HMPC/286974/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-pimpinella-anisum-l-fructus_en.pdf"},
    {"id":"26363","name":"Superseded opinion of the HMPC on a Community herbal monograph on Rosmarinus officinalis L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-02-03T01:00:00Z","last_updated_date":"2024-09-26T01:00:00Z","reference_number":"EMA/HMPC/457257/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-rosmarinus-officinalis-l-folium_en.pdf"},
    {"id":"26660","name":"Opinion of the HMPC on a European Union herbal monograph on Vitis vinifera L., folium - Revision 1","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2018-01-05T01:00:00Z","last_updated_date":"2018-01-05T01:00:00Z","reference_number":"EMA/HMPC/338763/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-vitis-vinifera-l-folium-revision-1_en.pdf"},
    {"id":"26822","name":"Opinion of the HMPC on a European Union herbal monograph on Matricaria recutita L., flos - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-04-05T17:30:00Z","last_updated_date":"2016-04-05T17:30:00Z","reference_number":"EMA/HMPC/M/H/170","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-matricaria-recutita-l-flos-first-version_en.pdf"},
    {"id":"26847","name":"Final opinion of the HMPC on a European Union herbal monograph on Melilotus officinalis (L.) Lam., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-04-23T16:10:00Z","last_updated_date":"2018-04-23T16:10:00Z","reference_number":"EMA/HMPC/M/H/0214","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"27358","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Centaurum erythraea Rafn, herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2009-03-12T00:09:21Z","last_updated_date":"2016-01-28T00:09:21Z","reference_number":"EMEA/HMPC/109227/2009EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-centaurum-erythraea-rafn-herba_en.pdf"},
    {"id":"27687","name":"Opinion of the HMPC on a Community herbal monograph on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny), herba cum flore","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-10-13T11:40:00Z","last_updated_date":"2011-10-13T11:40:00Z","reference_number":"EMA/HMPC/757226/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-viola-tricolor-l-andor-subspecies-viola-arvensis-murray-gaud-and-viola-vulgaris-koch-oborny-herba-cum-flore_en.pdf"},
    {"id":"27773","name":"Opinion of the HMPC on a Community herbal monograph on Pimpinella anisum L., fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-06-17T02:00:00Z","last_updated_date":"2014-06-17T02:00:00Z","reference_number":"EMA/HMPC/321184/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-pimpinella-anisum-l-fructus_en.pdf"},
    {"id":"27919","name":"Opinion of the HMPC on a European Union herbal monograph on Polygonum aviculare L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-05-23T18:15:00Z","last_updated_date":"2016-05-23T18:15:00Z","reference_number":"EMA/HMPC/244313/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-polygonum-aviculare-l-herba_en.pdf"},
    {"id":"28084","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Hamamelis virginiana L., cortex","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMEA/HMPC/582862/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-hamamelis-virginiana-l-cortex_en.pdf"},
    {"id":"28182","name":"Opinion of the HMPC on a European Union herbal monograph on Carum carvi L., aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/HMPC/454921/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"28305","name":"Opinion of the HMPC on a European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMA/HMPC/469777/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-harpagophytum-procumbens-dc-andor-harpagophytum-zeyheri-decne-radix_en.pdf"},
    {"id":"28330","name":"Opinion of the HMPC on a Community herbal monograph on Juniperus communis L., aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/HMPC/756995/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-juniperus-communis-l-aetheroleum_en.pdf"},
    {"id":"28390","name":"Superseded opinion of the Committee on Herbal Medicinal products on a community herbal monograph for Linum usitatissimum L., semen","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2006-07-13T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMEA/HMPC/353205/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf"},
    {"id":"28663","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Melilotus officinalis (L.) Lam., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/HMPC/305054/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"28751","name":"Opinion of the Committee on Herbal Medicinal Products on a Community herbal monograph on Potentilla erecta (L.) Raeusch., rhizoma","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-03-16T01:00:00Z","last_updated_date":"2011-03-16T01:00:00Z","reference_number":"EMA/HMPC/757185/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-potentilla-erecta-l-raeusch-rhizoma_en.pdf"},
    {"id":"29219","name":"Final opinion of the HMPC on a European Union herbal monograph on Glycine max (L.) Merr., oleum raffinatum","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2017-03-03T10:19:00Z","last_updated_date":"2017-03-03T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-glycine-max-l-merr-oleum-raffinatum_en.pdf"},
    {"id":"29239","name":"Opinion of the HMPC on a Community herbal monograph on Lavandula angustifolia Miller, aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-06-13T18:00:00Z","last_updated_date":"2012-06-13T18:00:00Z","reference_number":"EMA/HMPC/216952/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-lavandula-angustifolia-miller-aetheroleum_en.pdf"},
    {"id":"29448","name":"Opinion of the HMPC on a European Union herbal monograph on Ginkgo biloba L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2015-04-08T02:00:00Z","reference_number":"EMA/HMPC/61601/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-ginkgo-biloba-l-folium_en.pdf"},
    {"id":"29667","name":"Superseded - Opinion of the HMPC on a Community herbal monograph on Aloe barbadensis Miller and Aloe (various species, mainly Aloe ferox Miller and its hybrids)","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2006-09-07T02:00:00Z","last_updated_date":"2017-04-10T02:00:00Z","reference_number":"EMEA/HMPC/429376/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-aloe-barbadensis-miller-and-aloe-various-species-mainly-aloe-ferox-miller-and-its-hybrids_en.pdf"},
    {"id":"29946","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Hamamelis virginiana L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMEA/HMPC/582863/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-hamamelis-virginiana-l-folium_en.pdf"},
    {"id":"30139","name":"Superseded opinion of the Committee on Herbal Medicinal products on a community herbal monograph on Aesculus Hippocastanum L., semen - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2020-04-23T02:00:00Z","reference_number":"EMEA/HMPC/438817/2009EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-aesculus-hippocastanum-l-semen-first-version_en.pdf"},
    {"id":"30259","name":"Superseded opinion of the HMPC on a European Union herbal monograph on Hedera helix L., folium - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-01-18T01:00:00Z","last_updated_date":"2018-08-13T02:00:00Z","reference_number":"EMA/HMPC/777865/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-european-union-herbal-monograph-hedera-helix-l-folium-revision-1_en.pdf"},
    {"id":"30281","name":"Draft Community herbal monograph on Panax ginseng C.A. Meyer, radix","type":"herbal-opinion","status":"Draft: consultation closed","consultation_date":"2013-04-15 - 2013-07-15","first_published_date":"2013-04-16T04:00:00Z","last_updated_date":"2013-04-16T04:00:00Z","reference_number":"EMA/HMPC/321233/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/draft-community-herbal-monograph-panax-ginseng-ca-meyer-radix_en.pdf"},
    {"id":"30322","name":"Opinion of the HMPC on a Community herbal monograph on Plantago ovata Forssk., seminis tegumentum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T16:00:00Z","last_updated_date":"2013-07-23T16:00:00Z","reference_number":"EMA/HMPC/742490/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-plantago-ovata-forssk-seminis-tegumentum_en.pdf"},
    {"id":"30511","name":"Opinion of the HMPC on a community herbal monograph on Syzygium aromaticum (L.) Merill et L. M. Perry, floris aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T01:00:00Z","last_updated_date":"2011-12-21T01:00:00Z","reference_number":"EMA/HMPC/749910/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-syzygium-aromaticum-l-merill-et-l-m-perry-floris-aetheroleum_en.pdf"},
    {"id":"30630","name":"Opinion of the HMPC on a Community herbal monograph on Plantago afra L. et Plantago indica L., semen","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-07-29T15:30:00Z","last_updated_date":"2013-07-29T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf"},
    {"id":"30780","name":"Opinion of the HMPC on a European Union herbal monograph on Sisymbrium officinale (L.) Scop., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-10-30T01:00:00Z","last_updated_date":"2014-10-30T01:00:00Z","reference_number":"EMA/HMPC/600047/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-sisymbrium-officinale-l-scop-herba_en.pdf"},
    {"id":"30893","name":"Opinion of the HMPC on a European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T13:28:00Z","last_updated_date":"2016-10-07T13:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-harpagophytum-procumbens-dc-andor-harpagophytum-zeyheri-decne-radix_en.pdf-0"},
    {"id":"30912","name":"Opinion of HMPC on a Community herbal monograph on Primula veris L. and Primula elatior (L.) Hill, flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T01:00:00Z","last_updated_date":"2013-03-04T01:00:00Z","reference_number":"EMA/HMPC/332112/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-primula-veris-l-and-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"31226","name":"Superseded opinion of the HMPC on a Community herbal monograph on Salix [various species including S. purpurea L., S. daphnoides Vill., S. fragilis L.], cortex","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2009-09-26T02:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMEA/HMPC/11545/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-cortex_en.pdf"},
    {"id":"31255","name":"Opinion of the HMPC on a European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium - Revision 2","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T14:00:00Z","last_updated_date":"2018-04-11T14:00:00Z","reference_number":"EMA/HMPC/M/H/0217","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-2_en.pdf"},
    {"id":"31322","name":"Superseded opinion of the HMPC on Urtica dioica L., Urtica urens L. their hybrids or their mixtures, radix - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-11-05T12:20:00Z","last_updated_date":"2025-03-12T12:20:00Z","reference_number":"EMA/HMPC/627569/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-urtica-dioica-l-urtica-urens-l-their-hybrids-or-their-mixtures-radix-first-version_en.pdf"},
    {"id":"31360","name":"Opinion of the HMPC on a European Union herbal monograph on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis raeseri Boiss. & Heldr.; Sideritis syriaca L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/HMPC/80270/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-sideritis-scardica-griseb-sideritis-clandestina-bory-chaub-hayek-sideritis-raeseri-boiss-heldr-sideritis-syriaca-l-herba_en.pdf"},
    {"id":"31809","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Sambucus nigra L., flos - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"EMA/HMPC/195730/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-sambucus-nigra-l-flos-revision-1_en.pdf"},
    {"id":"32172","name":"Opinion of the HMPC on a European Union herbal monograph on Species diureticae","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/HMPC/171225/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-species-diureticae_en.pdf"},
    {"id":"32400","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Hypericum perforatum L., herba (traditional use)","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2009-12-21T00:09:00Z","last_updated_date":"2023-02-22T00:09:00Z","reference_number":"EMEA/HMPC/752903/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-hypericum-perforatum-l-herba-traditional-use_en.pdf"},
    {"id":"32526","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Orthosiphon stamineus Benth., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-05-30T02:00:00Z","last_updated_date":"2011-05-30T02:00:00Z","reference_number":"EMA/HMPC/153982/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-orthosiphon-stamineus-benth-folium_en.pdf"},
    {"id":"32963","name":"Opinion of the Committee on Herbal Medicinal Products on a Community herbal monograph on Cinnamomum verum J.S. Presl, corticis aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2011-08-05T02:00:00Z","reference_number":"EMA/HMPC/258017/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-cinnamomum-verum-js-presl-corticis-aetheroleum_en.pdf"},
    {"id":"33104","name":"Superseded opinion of the HMPC on a European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-08-20T02:00:00Z","last_updated_date":"2024-07-12T02:00:00Z","reference_number":"EMA/HMPC/378804/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-european-union-herbal-monograph-pelargonium-sidoides-dc-or-pelargonium-reniforme-curt-radix-revision-1_en.pdf"},
    {"id":"33226","name":"Opinion of the HMPC on a European Union herbal monograph on Capsicum annuum L. var. minimum (Miller) Heiser and small fruited varieties of Capsicum frutescens L., fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/HMPC/292904/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-capsicum-annuum-l-var-minimum-miller-heiser-and-small-fruited-varieties-capsicum-frutescens-l-fructus_en.pdf"},
    {"id":"33259","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Passiflora incarnata L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-09-03T02:09:21Z","last_updated_date":"2007-09-03T02:09:21Z","reference_number":"EMEA/HMPC/405535/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-passiflora-incarnata-l-herba_en.pdf"},
    {"id":"33448","name":"Superseded opinion of the HMPC on a Community herbal monograph on Olea europaea L., folium - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-04-18T17:30:00Z","last_updated_date":"2012-04-18T17:30:00Z","reference_number":"EMA/HMPC/888908/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf"},
    {"id":"33606","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph  on Valeriana officinalis L., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2006-07-13T02:09:21Z","last_updated_date":"2016-04-27T02:09:21Z","reference_number":"EMEA/HMPC/313368/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-valeriana-officinalis-l-radix_en.pdf"},
    {"id":"34073","name":"Superseded opinion of the HMPC on a Community herbal monograph on Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"EMA/HMPC/332110/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"34085","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Solidago virgaurea L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/305296/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-solidago-virgaurea-l-herba_en.pdf"},
    {"id":"34329","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Hamamelis virginiana L., folium et cortex aut ramunculus destillatum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMEA/HMPC/582868/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-hamamelis-virginiana-l-folium-et-cortex-aut-ramunculus-destillatum_en.pdf"},
    {"id":"34450","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Leonurus cardiaca L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/HMPC/573554/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-leonurus-cardiaca-l-herba_en.pdf"},
    {"id":"34588","name":"Superseded opinion of the HMPC on a Community herbal monograph on Echinacea purpurea (L.) Moench, radix - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-02-10T01:00:00Z","last_updated_date":"2011-02-10T01:00:00Z","reference_number":"EMA/HMPC/153975/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-echinacea-purpurea-l-moench-radix-first-version_en.pdf"},
    {"id":"34676","name":"Superseded opinion of the community on herbal medicinal products on a community herbal monograph on Verbascum thapsus L., V. densiflorum Bertol and V. phlomoides L., flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/HMPC/188000/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-community-herbal-medicinal-products-community-herbal-monograph-verbascum-thapsus-l-v-densiflorum-bertol-and-v-phlomoides-l-flos_en.pdf"},
    {"id":"34975","name":"Superseded opinion of the HMPC on a Community herbal monograph on Rheum palmatum L. and Rheum officinale Baillon, radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T00:09:00Z","last_updated_date":"2020-08-18T00:09:00Z","reference_number":"EMEA/HMPC/494334/2007EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-rheum-palmatum-l-and-rheum-officinale-baillon-radix_en.pdf"},
    {"id":"35312","name":"Superseded opinion of the HMPC on a Community herbal monograph on Pelargonium sidoides DC and / or Pelargonium reniforme Curt., radix - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-02-04T12:30:00Z","last_updated_date":"2018-08-20T13:30:00Z","reference_number":"EMA/HMPC/742263/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-pelargonium-sidoides-dc-and-or-pelargonium-reniforme-curt-radix-first-version_en.pdf"},
    {"id":"35475","name":"Opinion of the HMPC on a Community herbal monograph on Ilex paraguariensis St. Hilaire, folium - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-02-14T01:00:00Z","last_updated_date":"2011-02-14T01:00:00Z","reference_number":"EMA/HMPC/282494/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-ilex-paraguariensis-st-hilaire-folium-first-version_en.pdf"},
    {"id":"35551","name":"Opinion of the HMPC on a Community herbal monograph on Thymus vulgaris L., Thymus zygis Loefl. ex. L., aetheroleum - Superseded","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/HMPC/25419/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-thymus-vulgaris-l-thymus-zygis-loefl-ex-l-aetheroleum-superseded_en.pdf"},
    {"id":"35570","name":"Opinion of the HMPC on a European Union herbal monograph on Agrimonia eupatoria L., herba - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T13:00:00Z","last_updated_date":"2015-04-09T13:00:00Z","reference_number":"EMA/HMPC/61599/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-agrimonia-eupatoria-l-herba-first-version_en.pdf"},
    {"id":"35701","name":"Opinion of the HMPC on a European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-05-23T12:50:00Z","last_updated_date":"2016-05-23T12:50:00Z","reference_number":"EMA/HMPC/244312/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-helichrysum-arenarium-l-moench-flos_en.pdf"},
    {"id":"36049","name":"Opinion of the HMPC on a European Union herbal monograph on Centaurium erythraea Rafn. s.l., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"EMA/HMPC/642018/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-centaurium-erythraea-rafn-sl-herba_en.pdf"},
    {"id":"36225","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Melissa officinalis L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"EMEA/HMPC/453710/2007EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-melissa-officinalis-l-folium_en.pdf"},
    {"id":"36431","name":"Superseded final opinion of the HMPC on a Community herbal monograph on Thymus vulgaris L., Thymus zygis L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"EMEA/HMPC/453713/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-final-opinion-hmpc-community-herbal-monograph-thymus-vulgaris-l-thymus-zygis-l-herba_en.pdf"},
    {"id":"37253","name":"Opinion of the HMPC on a European Union herbal monograph on Crataegus spp., folium cum flore","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"EMA/HMPC/244297/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-crataegus-spp-folium-cum-flore_en.pdf"},
    {"id":"37377","name":"Opinion of the HMPC on a European Union herbal monograph on Salvia officinalis L., folium - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-07-13T02:00:00Z","last_updated_date":"2017-07-13T02:00:00Z","reference_number":"EMA/HMPC/531445/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-salvia-officinalis-l-folium-revision-1_en.pdf"},
    {"id":"37647","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Echinacea pallida (Nutt.) Nutt., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:09:21Z","last_updated_date":"2018-08-14T02:09:21Z","reference_number":"EMEA/HMPC/375219/2009EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-echinacea-pallida-nutt-nutt-radix_en.pdf"},
    {"id":"37653","name":"Opinion of the HMPC on a European Union herbal monograph on Verbascum thapsus L., V. densiflorum Bertol. (V. thapsiforme Schrad) and V. phlomoides L., flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T02:00:00Z","last_updated_date":"2018-06-22T02:00:00Z","reference_number":"EMA/HMPC/195735/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-verbascum-thapsus-l-v-densiflorum-bertol-v-thapsiforme-schrad-and-v-phlomoides-l-flos_en.pdf"},
    {"id":"38155","name":"Superseded opinion of the HMPC on a Community herbal monograph on Humulus lupulus L., flos - First version","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2016-01-21T01:00:00Z","last_updated_date":"2016-01-21T01:00:00Z","reference_number":"EMEA/HMPC/591021/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-humulus-lupulus-l-flos-first-version_en.pdf"},
    {"id":"38504","name":"Opinion of the HMPC on a community herbal monograph on Juglans regia L., folium","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2014-01-17T01:00:00Z","last_updated_date":"2014-01-17T01:00:00Z","reference_number":"EMA/HMPC/420309/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-juglans-regia-l-folium_en.pdf"},
    {"id":"38691","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Ruscus aculeatus L, rhizome","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2019-05-02T17:00:00Z","reference_number":"EMEA/HMPC/188003/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-ruscus-aculeatus-l-rhizome_en.pdf"}    {"id":"38929","name":"Opinion of the Committee on Herbal Medicinal Products on a Community herbal monograph on Quercus robur L., Quercus petraea. (Matt.) Liebl., Quercus pubescens Willd., cortex","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-05-18T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMA/HMPC/757063/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-quercus-robur-l-quercus-petraea-matt-liebl-quercus-pubescens-willd-cortex_en.pdf"},
    {"id":"38973","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Avena sativa L., fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/304988/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-avena-sativa-l-fructus_en.pdf"},
    {"id":"39375","name":"Superseded opinion of the HMPC on a Community herbal monograph on Vitex agnus-castus L., fructus - First version","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2018-10-10T02:00:00Z","reference_number":"EMA/HMPC/756507/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-hmpc-community-herbal-monograph-vitex-agnus-castus-l-fructus-first-version_en.pdf"},
    {"id":"39450","name":"Opinion of the HMPC on a European Union herbal monograph on Equisetum arvense L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-03-17T01:00:00Z","reference_number":"EMA/HMPC/72954/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-equisetum-arvense-l-herba_en.pdf"},
    {"id":"39733","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2024-03-07T17:15:21Z","reference_number":"EMEA/HMPC/280074/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf"},
    {"id":"39784","name":"Opinion of the HMPC on a European Union herbal monograph on Symphytum officinale L., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-06-05T02:00:00Z","last_updated_date":"2015-06-05T02:00:00Z","reference_number":"EMA/HMPC/292905/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-symphytum-officinale-l-radix_en.pdf"},
    {"id":"39820","name":"Final opinion of the HMPC on a Community herbal monograph on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich), rhizoma","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T13:00:00Z","last_updated_date":"2014-05-12T13:00:00Z","reference_number":"EMA/HMPC/55203/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-community-herbal-monograph-curcuma-xanthorrhiza-roxb-c-xanthorrhiza-d-dietrich-rhizoma_en.pdf"},
    {"id":"39838","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2007-09-07T02:00:00Z","last_updated_date":"2007-09-07T02:00:00Z","reference_number":"EMEA/HMPC/405542/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"40537","name":"Opinion of the HMPC on a community herbal monograph on Rubus idaeus L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T11:00:00Z","last_updated_date":"2014-03-21T11:00:00Z","reference_number":"EMA/HMPC/54389/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-rubus-idaeus-l-folium_en.pdf"},
    {"id":"40659","name":"Final opinion of the HMPC on a European Union herbal monograph on Echinacea pallida (Nutt.) Nutt., radix - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-08-14T12:00:00Z","last_updated_date":"2018-08-14T12:00:00Z","reference_number":"EMA/HMPC/482923/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-echinacea-pallida-nutt-nutt-radix-revision-1_en.pdf"},
    {"id":"40748","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Urtica dioica L., Urtica urens L., folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-01-17T01:00:00Z","last_updated_date":"2011-01-17T01:00:00Z","reference_number":"EMA/HMPC/375218/2009EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-folium_en.pdf"},
    {"id":"40771","name":"Opinion of the HMPC on a Community herbal monograph on Rosa gallica L., Rosa centifolia L., Rosa damascena Mill., flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-09-10T02:00:00Z","last_updated_date":"2014-09-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-rosa-gallica-l-rosa-centifolia-l-rosa-damascena-mill-flos_en.pdf"},
    {"id":"40943","name":"Opinion of the Committee on Herbal Medicinal Products on a European Union herbal monograph on Valeriana officinalis L., aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-04-27T12:00:00Z","last_updated_date":"2016-04-27T12:00:00Z","reference_number":"EMA/HMPC/74067/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-european-union-herbal-monograph-valeriana-officinalis-l-aetheroleum_en.pdf"},
    {"id":"41302","name":"Final Opinion of the committee on herbal medicinal products on a  European Union herbal monograph on Echinacea purpurea (L.) Moench., herba recens","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-04-13T02:00:00Z","last_updated_date":"2015-04-13T02:00:00Z","reference_number":"EMA/HMPC/712219/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-committee-herbal-medicinal-products-european-union-herbal-monograph-echinacea-purpurea-l-moench-herba-recens_en.pdf"},
    {"id":"41307","name":"Superseded opinion of the committee on herbal medicinal products on a community herbal monograph on Primula veris L., Primula elatior (L.) Hill, flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-04-09T02:00:00Z","last_updated_date":"2010-04-09T02:00:00Z","reference_number":"EMA/HMPC/405544/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-primula-veris-l-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"41405","name":"Opinion of the HMPC on a Community herbal monograph on Lavandula angustifolia P. Mill., flos","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-06-13T17:00:00Z","last_updated_date":"2012-06-13T17:00:00Z","reference_number":"EMA/HMPC/216951/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-lavandula-angustifolia-p-mill-flos_en.pdf"},
    {"id":"41681","name":"Opinion of the HMPC on a European Union herbal monograph on Olea europaea L., folium - First version","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T01:00:00Z","last_updated_date":"2018-01-04T01:00:00Z","reference_number":"EMA/HMPC/65917/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf"},
    {"id":"42103","name":"Opinion of the HMPC on a European Union herbal monograph on Silybum marianum (L.) Gaertn., fructus","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2018-09-19T02:00:00Z","last_updated_date":"2018-09-19T02:00:00Z","reference_number":"EMA/HMPC/318925/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-silybum-marianum-l-gaertn-fructus_en.pdf"},
    {"id":"42255","name":"Final Opinion of the HMPC on a Community herbal monograph on Vitex agnus-castus L., fructus - Revision 1","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T11:16:00Z","last_updated_date":"2018-10-10T11:16:00Z","reference_number":"EMA/HMPC/M/H/0218","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-community-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf"},
    {"id":"42261","name":"Final opinion of the HMPC on a Community herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L., oleum - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-10-10T12:56:00Z","last_updated_date":"2018-10-10T12:56:00Z","reference_number":"EMA/HMPC/490645/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-community-herbal-monograph-oenothera-biennis-l-oenothera-lamarckiana-l-oleum-revision-1_en.pdf"},
    {"id":"43476","name":"Opinion of the HMPC on a European Union herbal monograph on Curcuma longa L., rhizoma - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2019-01-24T16:27:00Z","last_updated_date":"2019-01-24T16:27:00Z","reference_number":"EMA/507445/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf"},
    {"id":"43660","name":"Opinion of the HMPC on a European Union herbal monograph on Cynara cardunculus L. (syn. Cynara scolymus L.), folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2019-02-07T12:07:00Z","last_updated_date":"2019-02-07T12:07:00Z","reference_number":"EMA/HMPC/195635/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-cynara-cardunculus-l-syn-cynara-scolymus-l-folium_en.pdf"},
    {"id":"43864","name":"Opinion of the HMPC on a European Union herbal monograph on Malva sylvestris L., flos - First version","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2019-03-19T12:31:00Z","last_updated_date":"2019-03-19T12:31:00Z","reference_number":"EMA/HMPC/28616/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-malva-sylvestris-l-flos-first-version_en.pdf"},
    {"id":"44064","name":"Opinion of the HMPC on a European Union herbal monograph on Malva sylvestris L. and/or Malva neglecta Wallr., folium - First version","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2019-03-19T17:00:00Z","last_updated_date":"2019-03-19T17:00:00Z","reference_number":"EMA/HMPC/28616/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-malva-sylvestris-l-andor-malva-neglecta-wallr-folium-first-version_en.pdf"},
    {"id":"44405","name":"Opinion of the HMPC on a European Union herbal monograph on Gentiana lutea L., radix - Revision 1","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2019-04-30T14:48:00Z","last_updated_date":"2019-04-30T14:48:00Z","reference_number":"EMA/HMPC/125353/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-gentiana-lutea-l-radix-revision-1_en.pdf"},
    {"id":"44420","name":"Opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Ruscus aculeatus L, rhizome - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2019-05-02T17:40:00Z","last_updated_date":"2019-05-02T17:40:00Z","reference_number":"EMA/HMPC/135945/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-committee-herbal-medicinal-products-community-herbal-monograph-ruscus-aculeatus-l-rhizome-revision-1_en.pdf"},
    {"id":"44507","name":"Opinion of the HMPC on a European Union herbal monograph on Fragaria vesca L., Fragaria moschata Weston, Fragaria viridis Weston and Fragaria x ananassa (Weston) Duchesne ex Rozier, folium","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2019-05-15T17:43:00Z","last_updated_date":"2019-05-15T17:43:00Z","reference_number":"EMA/HMPC/811721/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-and-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium_en.pdf"},
    {"id":"46230","name":"Opinion of the HMPC on a European Union herbal monograph on Rhamnus frangula L. cortex","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2019-12-04T02:00:00Z","last_updated_date":"2019-12-04T02:00:00Z","reference_number":"EMA/HMPC/523330/2019 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-rhamnus-frangula-l-cortex_en.pdf"},
    {"id":"46507","name":"Opinion of the HMPC on a community herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos - Revision 1","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T15:38:00Z","last_updated_date":"2020-01-23T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"46650","name":"Draft European Union herbal monograph on Achillea millefolium L., herba - Revision 1","type":"herbal-opinion","status":"Draft: consultation closed","consultation_date":"2020-01-30 - 2020-04-30","first_published_date":"2020-01-31T17:16:00Z","last_updated_date":"2020-01-31T17:16:00Z","reference_number":"EMA/HMPC/376416/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/draft-european-union-herbal-monograph-achillea-millefolium-l-herba-revision-1_en.pdf"},
    {"id":"47303","name":"Opinion of the HMPC on a European Union herbal monograph on Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl), fructus - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T16:17:00Z","last_updated_date":"2020-04-02T16:17:00Z","reference_number":"EMA/HMPC/454272/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-fructus-revision-1_en.pdf"},
    {"id":"47308","name":"Opinion of the HMPC on a European Union herbal monograph on Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl), folium- Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T16:49:00Z","last_updated_date":"2020-04-02T16:49:00Z","reference_number":"EMA/HMPC/453968/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-folium-revision-1_en.pdf"},
    {"id":"47465","name":"Opinion of the HMPC on a European Union herbal monograph on Aesculus hippocastanum L., semen - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-04-23T13:40:00Z","last_updated_date":"2020-04-23T13:40:00Z","reference_number":"EMA/HMPC/22334/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-aesculus-hippocastanum-l-semen-revision-1_en.pdf"},
    {"id":"47564","name":"Final opinion of the HMPC on a European Union herbal monograph on Pistacia lentiscus L., resin (mastic)","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2020-05-05T11:07:00Z","last_updated_date":"2020-05-05T11:07:00Z","reference_number":"EMA/HMPC/74864/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-pistacia-lentiscus-l-resin-mastic_en.pdf"},
    {"id":"48416","name":"Opinion of the HMPC on changes to be introduced into an entry in the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products - Mentha x piperita L., aetheroleum","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T08:47:00Z","last_updated_date":"2020-07-24T08:47:00Z","reference_number":"EMA/HMPC/229263/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-changes-be-introduced-entry-list-herbal-substances-preparations-and-combinations-thereof-use-traditional-herbal-medicinal-products-mentha-x-piperita-l-aetheroleum_en.pdf"},
    {"id":"48417","name":"Opinion of the HMPC on a European Union herbal monograph on Mentha x piperita L., aetheroleum - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T01:00:00Z","last_updated_date":"2020-07-24T01:00:00Z","reference_number":"EMA/HMPC/22236/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-mentha-x-piperita-l-aetheroleum-revision-1_en.pdf"},
    {"id":"48420","name":"Opinion of the HMPC on a European Union herbal monograph on Mentha x piperita L., folium - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T16:09:00Z","last_updated_date":"2020-07-24T16:09:00Z","reference_number":"EMA/HMPC/226633/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-mentha-x-piperita-l-folium-revision-1_en.pdf"},
    {"id":"48425","name":"Final opinion of the HMPC on a European Union herbal monograph on Rhamnus purshiana DC., cortex - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-07-27T10:04:00Z","last_updated_date":"2020-07-27T10:04:00Z","reference_number":"EMA/HMPC/254847/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-rhamnus-purshiana-dc-cortex-revision-1_en.pdf"},
    {"id":"48615","name":"Opinion of the HMPC on a European Union herbal monograph on Tanacetum parthenium (L.) Shulz Bip., herba - Revision 1","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2020-08-14T11:40:00Z","last_updated_date":"2020-08-14T11:40:00Z","reference_number":"EMA/HMPC/400955/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-tanacetum-parthenium-l-shulz-bip-herba-revision-1_en.pdf"},
    {"id":"48623","name":"Opinion of the HMPC on a European Union herbal monograph on Rheum palmatum L. and Rheum officinale Baillon, radix","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2020-08-18T15:56:00Z","last_updated_date":"2020-08-18T15:56:00Z","reference_number":"EMA/HMPC/257645/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-rheum-palmatum-l-and-rheum-officinale-baillon-radix_en.pdf"},
    {"id":"48638","name":"Opinion of the HMPC on a European Union herbal monograph on Herniariae glabra L.; Herniariae hirsuta L.; Herniariae incana Lam., herba","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T14:49:00Z","last_updated_date":"2020-08-19T14:49:00Z","reference_number":"EMA/HMPC/378594/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-herniariae-glabra-l-herniariae-hirsuta-l-herniariae-incana-lam-herba_en.pdf"},
    {"id":"48872","name":"Opinion of the HMPC on a European Union herbal monograph on Thymus vulgaris L., Thymus zygis L., aetheroleum - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-09-21T16:00:00Z","last_updated_date":"2020-09-21T16:00:00Z","reference_number":"EMA/HMPC/394930/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-thymus-vulgaris-l-thymus-zygis-l-aetheroleum-revision-1_en.pdf"},
    {"id":"49420","name":"Final European Union herbal monograph on Achillea millefolium L., herba - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-12-03T16:16:00Z","last_updated_date":"2020-12-03T16:16:00Z","reference_number":"EMA/HMPC/376416/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-european-union-herbal-monograph-achillea-millefolium-l-herba-revision-1_en.pdf"},
    {"id":"49422","name":"Final opinion of the HMPC on a Community herbal monograph on Achillea millefolium L., herba - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-12-03T15:35:00Z","last_updated_date":"2020-12-03T15:35:00Z","reference_number":"EMA/HMPC/539154/2020 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-community-herbal-monograph-achillea-millefolium-l-herba-revision-1_en.pdf"},
    {"id":"50679","name":"Opinion of the HMPC on a European Union herbal monograph on Species amarae","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2021-03-23T11:46:00Z","last_updated_date":"2021-03-23T11:46:00Z","reference_number":"EMA/HMPC/649746/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-species-amarae_en.pdf"},
    {"id":"50715","name":"Opinion of the HMPC on a European Union herbal monograph on Species sedativae","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2021-03-25T16:48:00Z","last_updated_date":"2021-03-25T16:48:00Z","reference_number":"EMA/HMPC/660334/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-species-sedativae_en.pdf"},
    {"id":"50883","name":"Second draft European Union herbal monograph on Hypericum perforatum L., herba (traditional use) - Revision 1","type":"herbal-opinion","status":"Draft: consultation closed","consultation_date":"2021-04-15 - 2021-07-15","first_published_date":"2021-04-16T12:29:00Z","last_updated_date":"2021-04-16T12:29:00Z","reference_number":"EMA/HMPC/7695/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/second-draft-european-union-herbal-monograph-hypericum-perforatum-l-herba-traditional-use-revision-1_en.pdf"},
    {"id":"51004","name":"Opinion of the HMPC on a European Union herbal monograph on Allium sativum L., bulbus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2021-04-29T15:01:00Z","last_updated_date":"2021-04-29T15:01:00Z","reference_number":"EMA/HMPC/171136/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-allium-sativum-l-bulbus_en.pdf"},
    {"id":"51967","name":"Opinion of the HMPC on a European Union herbal monograph on Menyanthes trifoliata L., folium","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2021-07-20T13:25:00Z","last_updated_date":"2021-07-20T13:25:00Z","reference_number":"EMA/HMPC/379267/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-menyanthes-trifoliata-l-folium_en.pdf"},
    {"id":"52221","name":"Opinion of the HMPC on a European Union herbal monograph on Aloysia citrodora Paláu (syn. Aloysia triphylla (L’Hér.) Kuntze; Verbena triphylla L’Hér.; Lippia citriodora Kunth), folium","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2021-08-16T10:25:00Z","last_updated_date":"2021-08-16T10:25:00Z","reference_number":"EMA/HMPC/32590/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-aloysia-citrodora-palau-syn-aloysia-triphylla-lher-kuntze-verbena-triphylla-lher-lippia-citriodora-kunth-folium_en.pdf"},
    {"id":"53493","name":"Final opinion of the HMPC on a European Union herbal monograph on Orthosiphon aristatus (Blume) Miq. var. aristatus, folium - Revision 1","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T13:56:00Z","last_updated_date":"2021-12-14T13:56:00Z","reference_number":"EMA/HMPC/629762/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-orthosiphon-aristatus-blume-miq-var-aristatus-folium-revision-1_en.pdf"},
    {"id":"55308","name":"Opinion of the HMPC on a European Union herbal monograph on Taraxacum officinale F.H. Wigg., radix","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2022-06-21T13:11:00Z","last_updated_date":"2022-06-21T13:11:00Z","reference_number":"EMA/HMPC/747402/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-taraxacum-officinale-fh-wigg-radix_en.pdf"},
    {"id":"55885","name":"Opinion of the HMPC on a European Union herbal monograph on Trigonella foenum-graecum L., semen - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2022-08-30T10:54:00Z","last_updated_date":"2022-08-30T10:54:00Z","reference_number":"EMA/HMPC/755473/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-trigonella-foenum-graecum-l-semen-revision-1_en.pdf"},
    {"id":"55944","name":"Opinion of the HMPC on a European Union herbal monograph on Centella asiatica (L.) Urb., herba - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2022-09-02T09:46:00Z","last_updated_date":"2022-09-02T09:46:00Z","reference_number":"EMA/HMPC/592095/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-centella-asiatica-l-urb-herba-revision-1_en.pdf"},
    {"id":"56281","name":"Opinion of the HMPC on a European Union herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2022-10-03T12:15:00Z","last_updated_date":"2022-10-03T12:15:00Z","reference_number":"EMA/HMPC/613365/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-agropyron-repens-l-p-beauv-rhizoma-revision-1_en.pdf"},
    {"id":"56718","name":"Opinion of the HMPC on a European Union herbal monograph on Species digestivae","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2022-11-21T09:27:00Z","last_updated_date":"2022-11-21T09:27:00Z","reference_number":"MA/HMPC/820644/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-species-digestivae_en.pdf"},
    {"id":"57755","name":"Opinion of the HMPC on a European Union herbal monograph on Vaccinium macrocarpon Aiton, fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T12:04:00Z","last_updated_date":"2023-02-21T12:04:00Z","reference_number":"EMA/HMPC/15740/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-vaccinium-macrocarpon-aiton-fructus_en.pdf"},
    {"id":"57776","name":"Opinion of the HMPC on a European Union herbal monograph on Hypericum perforatum L., herba - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2023-02-22T10:41:00Z","last_updated_date":"2023-02-22T10:41:00Z","reference_number":"EMA/HMPC/71074/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-hypericum-perforatum-l-herba-revision-1_en.pdf"},
    {"id":"58937","name":"Final opinion of the HMPC on a European Union herbal monograph on Juniperus communis L., galbulus (pseudo- fructus) - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T14:40:00Z","last_updated_date":"2023-06-13T14:40:00Z","reference_number":"EMA/HMPC/170276/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-juniperus-communis-l-galbulus-pseudo-fructus-revision-1_en.pdf"},
    {"id":"61783","name":"Opinion of the HMPC on a European Union herbal monograph on Cnicus benedictus L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2024-01-16T14:34:10Z","last_updated_date":"2024-01-16T14:34:10Z","reference_number":"EMA/HMPC/M/H/0259","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-cnicus-benedictus-l-herba_en.pdf"},
    {"id":"62245","name":"Final Opinion of the HMPC on a European Union herbal monograph on Fumaria officinalis L., herba - Revision 1","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T16:00:30Z","last_updated_date":"2024-02-21T16:00:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-fumaria-officinalis-l-herba-revision-1_en.pdf"},
    {"id":"62394","name":"Opinion of the HMPC on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2024-03-01T12:15:46Z","last_updated_date":"2024-03-01T12:15:46Z","reference_number":"EMA/HMPC/76353/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf"},
    {"id":"62397","name":"Opinion of the HMPC on Foeniculum vulgare Miller subsp. vulgare var. dulce (Mill.) Batt. & Trab., fructus","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2024-03-01T12:34:21Z","last_updated_date":"2024-03-01T12:34:21Z","reference_number":"EMA/HMPC/76532/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus_en.pdf"},
    {"id":"63193","name":"Opinion of the HMPC on a Community herbal monograph on Aesculus hippocastanum L., cortex - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2024-05-07T14:49:53Z","last_updated_date":"2024-05-07T14:49:53Z","reference_number":"EMA/HMPC/567149/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-community-herbal-monograph-aesculus-hippocastanum-l-cortex-revision-1_en.pdf"},
    {"id":"63281","name":"Opinion of the HMPC on a European Union herbal monograph on Rhodiola rosea L., rhizoma et radix","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2024-05-21T13:51:00Z","last_updated_date":"2024-05-21T13:51:00Z","reference_number":"EMA/HMPC/148107/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-rhodiola-rosea-l-rhizoma-et-radix_en.pdf"},
    {"id":"64111","name":"Opinion of the HMPC on a European Union herbal monograph on Panax ginseng C.A.Mey., radix","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2024-07-12T15:46:00Z","last_updated_date":"2024-07-12T15:46:00Z","reference_number":"EMA/HMPC/289958/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-panax-ginseng-camey-radix_en.pdf"},
    {"id":"64117","name":"Opinion of the HMPC on a European Union herbal monograph on Pelargonium sidoides DC; Pelargonium reniforme Curt., radix - Revision 2","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T16:06:00Z","last_updated_date":"2024-07-12T16:06:00Z","reference_number":"EMA/HMPC/319732/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-pelargonium-sidoides-dc-pelargonium-reniforme-curt-radix-revision-2_en.pdf"},
    {"id":"64891","name":"Final opinion of the HMPC on a European Union herbal monograph on Artemisia absinthium L., herba","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2024-09-18T11:12:00Z","last_updated_date":"2024-09-18T11:12:00Z","reference_number":"EMA/HMPC/319051/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-artemisia-absinthium-l-herba_en.pdf"},
    {"id":"64967","name":"Final opinion of the HMPC on a European Union herbal monograph on Rosmarinus officinalis L., aetheroleum","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T11:21:00Z","last_updated_date":"2024-09-20T11:21:00Z","reference_number":"EMA/HMPC/307667/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-rosmarinus-officinalis-l-aetheroleum_en.pdf"},
    {"id":"65044","name":"Final opinion of the HMPC on a European Union herbal monograph on Rosmarinus officinalis L., folium - Revision 1","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2024-09-26T12:46:00Z","last_updated_date":"2024-09-26T12:46:00Z","reference_number":"EMA/HMPC/317755/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-rosmarinus-officinalis-l-folium-revision-1_en.pdf"},
    {"id":"66937","name":"Final opinion of the HMPC on a European Union herbal monograph on Prunus avium L.; Prunus cerasus L., peduncle","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2025-02-25T11:59:29Z","last_updated_date":"2025-02-25T11:59:29Z","reference_number":"EMA/HMPC/560880/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-prunus-avium-l-prunus-cerasus-l-peduncle_en.pdf"},
    {"id":"66980","name":"Final opinion of the HMPC on a European Union herbal monograph on Pilosella officinarum Vall. (syn Hieracium pilosella L.), herba cum radice - Revision 1","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2025-02-26T09:56:44Z","last_updated_date":"2025-02-26T09:56:44Z","reference_number":"EMA/HMPC/564085/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-pilosella-officinarum-vall-syn-hieracium-pilosella-l-herba-cum-radice-revision-1_en.pdf"},
    {"id":"67063","name":"Final opinion of the HMPC on a European Union herbal monograph on Eucalyptus globulus Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker, aetheroleum - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T15:48:41Z","last_updated_date":"2025-02-28T15:48:41Z","reference_number":"EMA/HMPC/563195/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-eucalyptus-smithii-rt-baker-aetheroleum-revision-1_en.pdf"},
    {"id":"67156","name":"Final opinion of the HMPC on a European Union herbal monograph on Urtica dioica L.; Urtica urens L., herba","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2025-03-07T16:07:29Z","last_updated_date":"2025-03-07T16:07:29Z","reference_number":"EMA/HMPC/48112/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-urtica-dioica-l-urtica-urens-l-herba_en.pdf"},
    {"id":"67231","name":"Final opinion of the HMPC on a European Union herbal monograph on Urtica dioica L.; Urtica urens L., radix - Revision 1","type":"herbal-opinion","status":"Adopted","consultation_date":"","first_published_date":"2025-03-12T13:19:19Z","last_updated_date":"2025-03-12T13:19:19Z","reference_number":"EMA/HMPC/48523/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/final-opinion-hmpc-european-union-herbal-monograph-urtica-dioica-l-urtica-urens-l-radix-revision-1_en.pdf"},
    {"id":"68041","name":"Opinion of the HMPC on a European Union herbal monograph on Cistus creticus L., herba","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2025-04-30T15:41:43Z","last_updated_date":"2025-04-30T15:41:43Z","reference_number":"EMA/HMPC/116483/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-cistus-creticus-l-herba_en.pdf"},
    {"id":"68828","name":"Opinion of the HMPC on a European Union herbal monograph on Zingiber officinale Roscoe, rhizoma","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2025-06-19T11:05:22Z","last_updated_date":"2025-06-19T11:05:22Z","reference_number":"EMA/HMPC/169170/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-zingiber-officinale-roscoe-rhizoma_en.pdf"},
    {"id":"70200","name":"Opinion of the HMPC on a European Union herbal monograph on Species pectorales - First version","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2025-09-22T10:53:52Z","last_updated_date":"2025-09-22T10:53:52Z","reference_number":"EMA/HMPC/301711/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-species-pectorales-first-version_en.pdf"},
    {"id":"70656","name":"Opinion of the HMPC on a European Union herbal monograph on Plantago lanceolata L., folium","type":"herbal-opinion","status":"unknown","consultation_date":"","first_published_date":"2025-10-20T09:39:15Z","last_updated_date":"2025-10-20T09:39:15Z","reference_number":"EMA/HMPC/261836/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-opinion/opinion-hmpc-european-union-herbal-monograph-plantago-lanceolata-l-folium_en.pdf"},
    {"id":"2408","name":"Superseded list of references supporting the assessment report on: Foeniculum vulgare Miller subsp. vulgare var. vulgare Foeniculum vulgare Miller subsp. vulgare var. dulce","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2024-03-07T17:14:00Z","reference_number":"EMEA/HMPC/456740/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-foeniculum-vulgare-miller-subsp-vulgare-var-dulce_en.pdf"},
    {"id":"2594","name":"Final list of references supporting the assessment of Grindelia robusta Nutt., Grindelia squarrosa (Pursh) Dunal, Grindelia humilis Hook. et Arn., Grindelia camporum Greene, herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-03-11T11:00:00Z","last_updated_date":"2013-03-11T11:00:00Z","reference_number":"EMA/HMPC/748221/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-grindelia-robusta-nutt-grindelia-squarrosa-pursh-dunal-grindelia-humilis-hook-et-arn-grindelia-camporum-greene-herba_en.pdf"},
    {"id":"2738","name":"Draft list of references supporting the assessment of Origanum dictamnus L., herba - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-02-04T12:35:00Z","last_updated_date":"2013-02-04T12:35:00Z","reference_number":"EMA/HMPC/200427/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-origanum-dictamnus-l-herba-first-version_en.pdf"},
    {"id":"2802","name":"Superseded list of references supporting the assessment report on: Centauri herba Centaurium erythraea Rafn, herba (centaury herb)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2009-03-12T00:09:21Z","last_updated_date":"2016-01-28T00:09:21Z","reference_number":"EMEA/HMPC/105618/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-centauri-herba-centaurium-erythraea-rafn-herba-centaury-herb_en.pdf"},
    {"id":"2971","name":"Draft list of references supporting the assessment of Valeriana officinalis L., radix and Valeriana officinalis L., aetheroleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-07-23T02:00:00Z","last_updated_date":"2015-07-23T02:00:00Z","reference_number":"EMA/HMPC/150847/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-valeriana-officinalis-l-radix-and-valeriana-officinalis-l-aetheroleum_en.pdf"},
    {"id":"2996","name":"Draft list of references for assessment of: Polypodii rhizoma Polypodium vulgare L., rhizoma (polypody rhizome)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-05-08T02:00:00Z","last_updated_date":"2008-05-08T02:00:00Z","reference_number":"EMEA/HMPC/600670/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-polypodii-rhizoma-polypodium-vulgare-l-rhizoma-polypody-rhizome_en.pdf"},
    {"id":"2998","name":"Draft list of references supporting the assessment of Commiphora molmol Engler, gummi-resina","type":"herbal-references","status":"Draft","consultation_date":"2010-09-01 - 2010-03-15","first_published_date":"2010-11-16T02:00:00Z","last_updated_date":"2010-11-16T02:00:00Z","reference_number":"EMA/HMPC/16634/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-commiphora-molmol-engler-gummi-resina_en.pdf"},
    {"id":"3053","name":"Draft list of references supporting the assessment of Fumaria officinalis L., herba","type":"herbal-references","status":"Draft","consultation_date":"2011-02-15 - 2011-06-15","first_published_date":"2011-04-04T04:00:00Z","last_updated_date":"2011-04-04T04:00:00Z","reference_number":"EMA/HMPC/576233/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-fumaria-officinalis-l-herba_en.pdf"},
    {"id":"3211","name":"Final list of references supporting the assessment of Urtica dioica L.; Urtica urens L., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-01-17T01:00:00Z","last_updated_date":"2011-01-17T01:00:00Z","reference_number":"EMA/HMPC/4252/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-urtica-dioica-l-urtica-urens-l-folium_en.pdf"},
    {"id":"3318","name":"Draft list of references supporting the assessment of Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl), folium and fructus – Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2017-10-12T02:00:00Z","last_updated_date":"2017-10-12T02:00:00Z","reference_number":"EMA/HMPC/228760/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-folium-and-fructus-revision-1_en.pdf"},
    {"id":"3458","name":"Superseded list of references supporting the assessment of Centella asiatica (L.) Urban, herba","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T17:50:00Z","last_updated_date":"2022-09-02T17:50:00Z","reference_number":"EMA/HMPC/291180/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-centella-asiatica-l-urban-herba_en.pdf"},
    {"id":"3736","name":"Draft list of references for assessment of Cimicifugae rhizoma Cimicifuga racemosa (L.) Nutt., rhizoma (black cohosh) - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-09-17T02:09:21Z","last_updated_date":"2009-09-17T02:09:21Z","reference_number":"EMEA/HMPC/102303/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-cimicifugae-rhizoma-cimicifuga-racemosa-l-nutt-rhizoma-black-cohosh-first-version_en.pdf"},
    {"id":"3866","name":"Draft list of references supporting the assessment of Cimicifuga racemosa (L.) Nutt., rhizome - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2017-08-04T02:00:00Z","last_updated_date":"2017-08-04T02:00:00Z","reference_number":"EMA/HMPC/193919/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf"},
    {"id":"3896","name":"Draft list of references supporting the assessment of Ribes nigrum L., folium","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2017-02-28T10:27:00Z","last_updated_date":"2017-02-28T10:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-ribes-nigrum-l-folium_en.pdf"},
    {"id":"4123","name":"Draft list of references supporting the assessment of Levisticum officinale Koch, radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2012-05-03T15:41:00Z","last_updated_date":"2012-05-03T15:41:00Z","reference_number":"EMA/HMPC/524626/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-levisticum-officinale-koch-radix_en.pdf"},
    {"id":"4311","name":"Final list of references supporting the assessment Symphytum officinale L., radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-06-05T02:00:00Z","last_updated_date":"2015-06-05T02:00:00Z","reference_number":"EMA/HMPC/572845/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-symphytum-officinale-l-radix_en.pdf"},
    {"id":"4325","name":"Final list of references supporting the assessment of Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T13:00:00Z","last_updated_date":"2015-04-09T13:00:00Z","reference_number":"EMA/HMPC/320929/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-melaleuca-alternifolia-maiden-and-betch-cheel-m-linariifolia-smith-m-dissitiflora-f-mueller-andor-other-species-melaleuca-aetheroleum-first-version_en.pdf"},
    {"id":"4491","name":"Draft list of references supporting the assessment of Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2015-04-09T02:00:00Z","reference_number":"EMA/HMPC/712512/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf"},
    {"id":"4599","name":"Draft list of references for assessment of: Betulae folium Betula pendula Roth; Betula pubescens Ehrh. (birch leaf)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-05-08T02:09:21Z","last_updated_date":"2007-05-08T02:09:21Z","reference_number":"EMEA/HMPC/207742/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-betulae-folium-betula-pendula-roth-betula-pubescens-ehrh-birch-leaf_en.pdf"},
    {"id":"4611","name":"Final list of references supporting the assessment of Thymus vulgaris L., Thymus zygis Loefl. ex. L., aetheroleum - Superseded","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/HMPC/131905/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-thymus-vulgaris-l-thymus-zygis-loefl-ex-l-aetheroleum-superseded_en.pdf"},
    {"id":"4687","name":"Final list of references supporting the assessment of Glycine max (L.) Merr., lecithinum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2017-11-20T01:00:00Z","last_updated_date":"2017-11-20T01:00:00Z","reference_number":"EMA/HMPC/338889/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-glycine-max-l-merr-lecithinum_en.pdf"}    {"id":"4743","name":"Draft list of references supporting the assessment of Syzygium aromaticum (L.) Merill et L.M. Perry, flos and Syzygium aromaticum (L.) Merill et L.M. Perry, floris aetheroleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-03-28T02:00:00Z","last_updated_date":"2011-03-28T02:00:00Z","reference_number":"EMA/HMPC/534948/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-syzygium-aromaticum-l-merill-et-lm-perry-flos-and-syzygium-aromaticum-l-merill-et-lm-perry-floris-aetheroleum_en.pdf"},
    {"id":"4773","name":"Superseded  list of references supporting the assessment report on: Valeriana officinalis L., radix (EMEA/HMPC/167391/2006)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2007-11-29T00:09:21Z","last_updated_date":"2016-04-28T01:09:21Z","reference_number":"EMEA/HMPC/167392/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-valeriana-officinalis-l-radix-emeahmpc1673912006_en.pdf"},
    {"id":"4877","name":"Final list of references supporting the assessment of Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-10-06T02:00:00Z","last_updated_date":"2014-10-06T02:00:00Z","reference_number":"EMA/HMPC/680617/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf"},
    {"id":"4906","name":"Draft list of references supporting the assessment of Valeriana officinalis L., radix and Humulus lupulus L., flos – Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2017-12-08T18:35:00Z","last_updated_date":"2017-12-08T18:35:00Z","reference_number":"EMA/HMPC/441802/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"4908","name":"List of references supporting the assessment report on: Solidaginis virgaureae herba Solidago virgaurea L., herba (European goldenrod)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/434192/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-report-solidaginis-virgaureae-herba-solidago-virgaurea-l-herba-european-goldenrod_en.pdf"},
    {"id":"5339","name":"Final list of references supporting the assessment of Polygonum aviculare L., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-05-23T18:15:00Z","last_updated_date":"2016-05-23T18:15:00Z","reference_number":"EMA/HMPC/143657/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-polygonum-aviculare-l-herba_en.pdf"},
    {"id":"5401","name":"Final list of references supporting the assessment of Species diureticae","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/HMPC/358625/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-species-diureticae_en.pdf"},
    {"id":"5440","name":"Draft list of references for assessment of Menthae piperitae folium and Mentha x piperita L. (peppermint leaf)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/262645/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-menthae-piperitae-folium-and-mentha-x-piperita-l-peppermint-leaf_en.pdf"},
    {"id":"5454","name":"Final list of references supporting the assessment of Arnica montana L., flos","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/HMPC/198792/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-arnica-montana-l-flos_en.pdf"},
    {"id":"5462","name":"Draft list of references supporting the assessment of Helichrysum arenarium (L.) Moench, flos","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-10-14T12:35:00Z","last_updated_date":"2015-10-14T12:35:00Z","reference_number":"EMA/HMPC/144093/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-helichrysum-arenarium-l-moench-flos_en.pdf"},
    {"id":"5591","name":"Superseded list of references supporting the assessment report on: Betulae folium Betula pendula Roth; Betula pubescens Ehrh., folium (birch leaf)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2007-05-08T02:09:21Z","last_updated_date":"2015-03-13T01:09:21Z","reference_number":"EMEA/HMPC/207742/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-betulae-folium-betula-pendula-roth-betula-pubescens-ehrh-folium-birch-leaf_en.pdf"},
    {"id":"5607","name":"Final list of references supporting the assessment of Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis raeseri Boiss. & Heldr.; Sideritis syriaca L., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/HMPC/39454/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-sideritis-scardica-griseb-sideritis-clandestina-bory-chaub-hayek-sideritis-raeseri-boiss-heldr-sideritis-syriaca-l-herba_en.pdf"},
    {"id":"5632","name":"List of references supporting the assessment of Angelica sinensis (Oliv.) Diels, radix - First version","type":"herbal-references","status":"Draft","consultation_date":"2012-12-15 - 2013-04-15","first_published_date":"2012-12-10T18:00:00Z","last_updated_date":"2012-12-10T18:00:00Z","reference_number":"EMA/HMPC/681358/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-angelica-sinensis-oliv-diels-radix-first-version_en.pdf"},
    {"id":"5921","name":"Final list of references supporting the assessment of Carum carvi L.,fructus and Carum carvi L., aetheroleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/HMPC/242200/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-carum-carvi-lfructus-and-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"5979","name":"Final list of references supporting the assessment of Paeonia lactiflora Pall. and/or Paeonia veitchii Lynch, radix (Paeoniae radix rubra)","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2017-04-25T17:35:00Z","last_updated_date":"2017-04-25T17:35:00Z","reference_number":"EMA/HMPC/762955/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-paeonia-lactiflora-pall-andor-paeonia-veitchii-lynch-radix-paeoniae-radix-rubra_en.pdf"},
    {"id":"6025","name":"Final list of references supporting the assessment of Juniperus communis L., aetheroleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/HMPC/12399/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-juniperus-communis-l-aetheroleum_en.pdf"},
    {"id":"6064","name":"Superseded list of references supporting the assessment of Rosmarinus officinalis L., aetheroleum and Rosmarinus officinalis L., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-02-03T01:00:00Z","last_updated_date":"2024-09-20T01:00:00Z","reference_number":"EMA/HMPC/13632/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-rosmarinus-officinalis-l-aetheroleum-rosmarinus-officinalis-l-folium_en.pdf"},
    {"id":"6165","name":"Draft list of references for assessment of Urticae radix: Urtica dioica L., Urtica urens L. (nettle root) - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/HMPC/461158/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-urticae-radix-urtica-dioica-l-urtica-urens-l-nettle-root-first-version_en.pdf"},
    {"id":"6360","name":"Final list of references supporting the assessment report on: Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-04-29T14:45:00Z","last_updated_date":"2014-04-29T14:45:00Z","reference_number":"EMA/HPC/7702/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-report-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"6565","name":"Draft list of references supporting the assessment of Symphytum officinale L., radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-08-19T02:00:00Z","last_updated_date":"2011-08-19T02:00:00Z","reference_number":"EMA/HMPC/572845/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-symphytum-officinale-l-radix_en.pdf"},
    {"id":"6653","name":"Draft list of references supporting the assessment of Althaea officinalis L., radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-12-11T18:20:00Z","last_updated_date":"2015-12-11T18:20:00Z","reference_number":"EMA/HMPC/436678/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-althaea-officinalis-l-radix_en.pdf"},
    {"id":"6731","name":"Final list of references supporting the assessment of Pimpinella anisum L., fructus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-06-17T02:00:00Z","last_updated_date":"2014-06-17T02:00:00Z","reference_number":"EMEA/HMPC/321182/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-pimpinella-anisum-l-fructus_en.pdf"},
    {"id":"6832","name":"Draft list of references supporting the assessment of Pelargonium sidoides DC and / or Pelargonium reniforme Curt., radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-10-26T01:00:00Z","last_updated_date":"2015-10-26T01:00:00Z","reference_number":"EMA/HMPC/444243/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-pelargonium-sidoides-dc-and-or-pelargonium-reniforme-curt-radix_en.pdf"},
    {"id":"6878","name":"Final list of references supporting the assessment of Eucalyptus globulus Labill., Eucalyptus polybractea R.T. Baker and/or Eucalyptus smithii R.T. Baker, aetheroleum - Superseded","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2025-02-28T02:00:00Z","reference_number":"EMA/HMPC/307783/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-or-eucalyptus-smithii-rt-baker-aetheroleum-superseded_en.pdf"},
    {"id":"7025","name":"Draft list of references for assessment of Rhei radix Rheum palmatum L. and Rheum officinale Baillon (rhubarb)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2007-07-05T02:09:21Z","reference_number":"EMEA/HMPC/189625/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-rhei-radix-rheum-palmatum-l-and-rheum-officinale-baillon-rhubarb_en.pdf"},
    {"id":"7182","name":"Draft list of references supporting the assessment of Phaseolus vulgaris L., fructus sine semine","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-05-14T02:00:00Z","last_updated_date":"2013-05-14T02:00:00Z","reference_number":"EMA/HMPC/317318/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-phaseolus-vulgaris-l-fructus-sine-semine_en.pdf"},
    {"id":"7273","name":"Draft list of references supporting the assessment of Capsella bursa-pastoris (L.) Medikus, herba - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-01-18T01:00:00Z","last_updated_date":"2011-01-18T01:00:00Z","reference_number":"EMA/HMPC/369803/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-capsella-bursa-pastoris-l-medikus-herba-first-version_en.pdf"},
    {"id":"7319","name":"Draft list of references supporting the assessment of Cynara scolymus L., folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-01-18T01:00:00Z","last_updated_date":"2011-01-18T01:00:00Z","reference_number":"EMA/HMPC/150213/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-cynara-scolymus-l-folium_en.pdf"},
    {"id":"7375","name":"List of references supporting the assessment of Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-01-13T16:10:00Z","last_updated_date":"2016-01-13T16:10:00Z","reference_number":"EMA/HMPC/712512/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf"},
    {"id":"7622","name":"Draft list of references supporting the assessment of Rosa centifolia L.; Rosa gallica L.; Rosa damascena Mill., flos","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/HMPC/137300/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-rosa-centifolia-l-rosa-gallica-l-rosa-damascena-mill-flos_en.pdf"},
    {"id":"7623","name":"Superseded list of references supporting the assessment report on: Menthae piperitae folium Mentha x piperita L., folium (peppermint leaf)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/262645/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-menthae-piperitae-folium-mentha-x-piperita-l-folium-peppermint-leaf_en.pdf"},
    {"id":"7728","name":"Draft list of references supporting the assessment of Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca, aetheroleum - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-08-21T02:00:00Z","last_updated_date":"2013-08-21T02:00:00Z","reference_number":"EMA/HMPC/320929/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-melaleuca-alternifolia-maiden-and-betch-cheel-m-linariifolia-smith-m-dissitiflora-f-mueller-andor-other-species-melaleuca-aetheroleum-first-version_en.pdf"},
    {"id":"7758","name":"Draft list of references supporting the assessment of Carum carvi L., fructus and Carum carvi L. aetheroleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2014-12-22T17:30:00Z","last_updated_date":"2014-12-22T17:30:00Z","reference_number":"EMA/HMPC/242200/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-carum-carvi-l-fructus-and-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"7797","name":"Superseded list of references supporting the assessment report on: Valeriana officinalis L., radix (EMEA/HMPC/167391/2006) (Valerianae aetheroleum)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-06-20T02:00:00Z","last_updated_date":"2016-06-20T02:00:00Z","reference_number":"EMEA/HMPC/167392/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-valeriana-officinalis-l-radix-emeahmpc1673912006-valerianae-aetheroleum_en.pdf"},
    {"id":"7805","name":"Draft list of references for assessment of: Rusci aculeati rhizome Ruscus aculeatus L., rhizome (butcher's broom) - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-09-07T02:00:00Z","last_updated_date":"2007-09-07T02:00:00Z","reference_number":"EMEA/HMPC/372915/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-rusci-aculeati-rhizome-ruscus-aculeatus-l-rhizome-butchers-broom-first-version_en.pdf"},
    {"id":"7806","name":"Superseded list of bibliographic references supporting the HMPC assessment report on Linum usitatissimum L. semen (EMEA/HMPC/167395/2006)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2006-10-25T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"WC500059161.pdf","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-bibliographic-references-supporting-hmpc-assessment-report-linum-usitatissimum-l-semen-emeahmpc1673952006_en.pdf"},
    {"id":"7856","name":"Final list of references supporting the assessment of Tilia tomentosa Moench, flos","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-07-09T18:50:00Z","last_updated_date":"2012-07-09T18:50:00Z","reference_number":"EMA/HMPC/346776/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-tilia-tomentosa-moench-flos_en.pdf"},
    {"id":"8203","name":"Final list of references supporting the assessment of Ricinus communis L., oleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-03-01T01:00:00Z","last_updated_date":"2016-03-01T01:00:00Z","reference_number":"EMA/HMPC/572975/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-ricinus-communis-l-oleum_en.pdf"},
    {"id":"8224","name":"Final list of references supporting the assessment of Calendula officinalis L., flos - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-06-14T15:00:00Z","last_updated_date":"2018-06-14T15:00:00Z","reference_number":"EMA/HMPC/603407/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-calendula-officinalis-l-flos-revision-1_en.pdf"},
    {"id":"8424","name":"Superseded list of references supporting the assessment of Zingiber officinale Roscoe, rhizoma","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2012-06-04T02:00:00Z","last_updated_date":"2025-06-19T02:00:00Z","reference_number":"EMA/HMPC/577857/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-zingiber-officinale-roscoe-rhizoma_en.pdf"},
    {"id":"8593","name":"List of references supporting the assessment report on: Polypodii rhizoma Polypodium vulgare L., rhizoma (polypody rhizome)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/600670/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-report-polypodii-rhizoma-polypodium-vulgare-l-rhizoma-polypody-rhizome_en.pdf"},
    {"id":"8721","name":"Draft list of references supporting the assessment of Marrubium vulgare L., herba - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-01-28T01:00:00Z","last_updated_date":"2013-01-28T01:00:00Z","reference_number":"EMA/HMPC/604272/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-marrubium-vulgare-l-herba-first-version_en.pdf"},
    {"id":"8781","name":"Draft list of references supporting the assessment of Fraxinus excelsior L. and Fraxinus angustifolia Vahl, folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-08-30T02:00:00Z","last_updated_date":"2011-08-30T02:00:00Z","reference_number":"EMA/HMPC/239270/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-fraxinus-excelsior-l-and-fraxinus-angustifolia-vahl-folium_en.pdf"},
    {"id":"8794","name":"Draft list of references supporting the assessment of Gentiana lutea L., radix – Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/607862/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-gentiana-lutea-l-radix-revision-1_en.pdf"},
    {"id":"8875","name":"Draft list of references supporting the assessment of Paeonia lactiflora Pallas, radix (Paeoniae radix alba)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-02-16T16:10:00Z","last_updated_date":"2016-02-16T16:10:00Z","reference_number":"EMA/HMPC/150788/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-paeonia-lactiflora-pallas-radix-paeoniae-radix-alba_en.pdf"},
    {"id":"9005","name":"Draft list of references for assessment of: Hamamelis cortex, Hamamelis folium, Hamamelis folium et cortex, distillate Hamamelis virginiana L. (hamamelis bark, hamamelis leaf, hamamelis distillate)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/115209/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-hamamelis-cortex-hamamelis-folium-hamamelis-folium-et-cortex-distillate-hamamelis-virginiana-l-hamamelis-bark-hamamelis-leaf-hamamelis-distillate_en.pdf"},
    {"id":"9025","name":"Final list of references supporting the assessment of Salvia fruticosa Mill., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-07-01T02:00:00Z","last_updated_date":"2016-07-01T02:00:00Z","reference_number":"EMA/HMPC/440074/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-salvia-fruticosa-mill-folium_en.pdf"},
    {"id":"9134","name":"Final list of references supporting the assessment of Filipendula ulmaria (L.) Maxim., herba and Filipendula ulmaria (L.) Maxim., flos - First version","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2011-09-29T02:00:00Z","last_updated_date":"2011-09-29T02:00:00Z","reference_number":"EMA/HMPC/759656/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-filipendula-ulmaria-l-maxim-herba-and-filipendula-ulmaria-l-maxim-flos-first-version_en.pdf"},
    {"id":"9256","name":"Superseded list of references supporting the assessment of Hedera helix L., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T01:00:00Z","last_updated_date":"2016-01-18T01:00:00Z","reference_number":"EMA/HMPC/289429/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-hedera-helix-l-folium_en.pdf"},
    {"id":"9563","name":"Draft list of references supporting the assessment of Eucalyptus globulus Labill., folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2012-06-21T16:01:00Z","last_updated_date":"2012-06-21T16:01:00Z","reference_number":"EMA/HMPC/892623/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-eucalyptus-globulus-labill-folium_en.pdf"},
    {"id":"9628","name":"Draft list of references supporting the assessment of  Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"EMEA/HMPC/111736/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"9675","name":"Draft list of references supporting the assessment of Paeonia lactiflora Pall. and Paeonia veitchii Lynch, radix (Paeoniae radix rubra)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-02-16T01:00:00Z","last_updated_date":"2016-02-16T01:00:00Z","reference_number":"EMA/HMPC/762955/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-paeonia-lactiflora-pall-and-paeonia-veitchii-lynch-radix-paeoniae-radix-rubra_en.pdf"},
    {"id":"9676","name":"Final list of references supporting the assessment of Peumus boldus Molina, folium","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2017-01-12T10:48:00Z","last_updated_date":"2017-01-12T10:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-peumus-boldus-molina-folium_en.pdf"},
    {"id":"9934","name":"Draft list of references for assessment of: Salicis cortex Salix sp (willow bark)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-09-07T02:00:00Z","last_updated_date":"2007-09-07T02:00:00Z","reference_number":"EMEA/HMPC/394997/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-salicis-cortex-salix-sp-willow-bark_en.pdf"},
    {"id":"9987","name":"Draft list of references supporting the assessment of Olea europaea L., folium","type":"herbal-references","status":"Draft","consultation_date":"2011-02-15 - 2011-06-15","first_published_date":"2011-07-14T04:00:00Z","last_updated_date":"2011-07-14T04:00:00Z","reference_number":"EMA/HMPC/430505/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-olea-europaea-l-folium_en.pdf"},
    {"id":"10354","name":"Draft list of references supporting the assessment of Polygonum aviculare L., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-10-19T12:50:00Z","last_updated_date":"2015-10-19T12:50:00Z","reference_number":"EMA/HMPC/143657/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-polygonum-aviculare-l-herba_en.pdf"},
    {"id":"10562","name":"Final list of references supporting the assessment of Pimpinella anisum L., fructus and Pimpinella anisum L., aetheroleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-06-18T02:00:00Z","last_updated_date":"2014-06-18T02:00:00Z","reference_number":"EMEA/HMPC/321182/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-pimpinella-anisum-l-fructus-and-pimpinella-anisum-l-aetheroleum_en.pdf"},
    {"id":"10615","name":"Draft list of references for assessment of: Taraxaci folium Taraxacum officinale Weber ex Wigg., folium (dandelion leaf)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-01-14T00:09:21Z","last_updated_date":"2009-01-14T00:09:21Z","reference_number":"EMEA/HMPC/579635/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-taraxaci-folium-taraxacum-officinale-weber-ex-wigg-folium-dandelion-leaf_en.pdf"},
    {"id":"10843","name":"Final list of references supporting the assessment of Althaea officinalis L., radix","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2016-11-04T15:07:00Z","last_updated_date":"2016-11-04T15:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-althaea-officinalis-l-radix_en.pdf"},
    {"id":"10906","name":"Draft list of references supporting the assessment of Chelidonium majus L., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-01-18T01:00:00Z","last_updated_date":"2011-01-18T01:00:00Z","reference_number":"EMA/HMPC/369803/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-chelidonium-majus-l-herba_en.pdf"},
    {"id":"11004","name":"Final list of references supporting the assessment of Euphrasia officinalis L. and Euphrasia rostkoviana Hayne, herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/246817/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-euphrasia-officinalis-l-and-euphrasia-rostkoviana-hayne-herba_en.pdf"},
    {"id":"11043","name":"Draft list of references supporting the assessment of Citrus bergamia Risso et Poiteau, aetheroleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-10-19T18:30:05Z","last_updated_date":"2011-10-19T18:30:05Z","reference_number":"EMA/HMPC/56157/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-citrus-bergamia-risso-et-poiteau-aetheroleum_en.pdf"},
    {"id":"11058","name":"List of references supporting the assessment of Phaseolus vulgaris L., fructus sine semine","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2014-01-17T16:00:00Z","last_updated_date":"2014-01-17T16:00:00Z","reference_number":"EMA/HMPC/317318/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-phaseolus-vulgaris-l-fructus-sine-semine_en.pdf"},
    {"id":"11144","name":"Final list of references supporting the assessment of Andrographis paniculata Nees, folium - First version","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2014-06-10T02:00:00Z","last_updated_date":"2014-08-28T13:05:00Z","reference_number":"EMA/HMPC/320452/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-andrographis-paniculata-nees-folium-first-version_en.pdf"},
    {"id":"11161","name":"Draft list of references supporting the assessment of Echinacea purpurea (L.) Moench, radix","type":"herbal-references","status":"unknown","consultation_date":"2016-12-15 - 2017-03-15","first_published_date":"2016-12-15T11:00:00Z","last_updated_date":"2016-12-15T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-echinacea-purpurea-l-moench-radix_en.pdf"},
    {"id":"11249","name":"Draft list of references for assessment of: Hippocastani semen Aesculus hippocastanum L., semen (horse chestnut seed)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/225629/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-hippocastani-semen-aesculus-hippocastanum-l-semen-horse-chestnut-seed_en.pdf"},
    {"id":"11336","name":"Draft list of references supporting the assessment of Adhatoda vasica Nees, folium - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-01-24T01:00:00Z","last_updated_date":"2013-01-24T01:00:00Z","reference_number":"EMA/HMPC/681469/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-adhatoda-vasica-nees-folium-first-version_en.pdf"},
    {"id":"11649","name":"Superseded list of references supporting the assessment report on: Equiseti herba Equisetum arvense L., herba (horsetail)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2016-03-17T01:09:21Z","reference_number":"EMEA/HMPC/394897/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-equiseti-herba-equisetum-arvense-l-herba-horsetail_en.pdf"},
    {"id":"11677","name":"Draft list of references supporting the assessment of Curcuma longa L. (C. domestica Valeton), rhizome – Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"EMA/434955/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-curcuma-longa-l-c-domestica-valeton-rhizome-revision-1_en.pdf"},
    {"id":"11695","name":"Draft list of references supporting the assessment of Malva sylvestris L. and/or Malva neglecta Wallr., folium and Malva sylvestris L., flos - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"EMA/HMPC/749540/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-malva-sylvestris-l-andor-malva-neglecta-wallr-folium-and-malva-sylvestris-l-flos-first-version_en.pdf"},
    {"id":"11909","name":"Draft list of references supporting the assessment of Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-08-19T02:00:00Z","last_updated_date":"2011-08-19T02:00:00Z","reference_number":"EMA/HMPC/571121/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf"},
    {"id":"11963","name":"Superseded list of references supporting the assessment of Vitex agnus-castus L., fructus - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2018-10-10T02:00:00Z","reference_number":"EMA/HMPC/144004/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-vitex-agnus-castus-l-fructus-first-version_en.pdf"},
    {"id":"11995","name":"Draft list of references supporting the assessment of Cinnamomum verum J. S. Presl, (Cinnamomum zeylanicum Nees), cortex and corticis aetheroleum: Cinnamomi cortex and Cinnamomi corticis aetheroleum\n\n(Cinnamon and Cinnam...","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2010-08-20T02:00:00Z","last_updated_date":"2010-08-20T02:00:00Z","reference_number":"EMA/HMPC/246775/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-cinnamomum-verum-j-s-presl-cinnamomum-zeylanicum-nees-cortex-and-corticis-aetheroleum-cinnamomi-cortex-and-cinnamomi-corticis-aetheroleum-cinnamon-and_en.pdf"},
    {"id":"12095","name":"Draft list of references for assessment of: Solidaginis virgaureae herba Solidago virgaurea L. (European goldenrod)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/HMPC/434192/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-solidaginis-virgaureae-herba-solidago-virgaurea-l-european-goldenrod_en.pdf"},
    {"id":"12401","name":"Draft list of references supporting the assessment of Trigonella foenum-graecum L., semen","type":"herbal-references","status":"Draft","consultation_date":"2010-05-15 - 2010-09-15","first_published_date":"2010-06-10T04:00:00Z","last_updated_date":"2010-06-10T04:00:00Z","reference_number":"EMA/HMPC/574496/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-trigonella-foenum-graecum-l-semen_en.pdf"},
    {"id":"12487","name":"Draft list of references for assessment of Mate folium Ilex paraguariensis St. Hil., folium - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/HMPC/580546/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-mate-folium-ilex-paraguariensis-st-hil-folium-first-version_en.pdf"},
    {"id":"12662","name":"Final list of references supporting the assessment of Eucalyptus globulus Labill., folium","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2013-04-19T12:00:00Z","last_updated_date":"2013-04-19T12:00:00Z","reference_number":"EMA/HMPC/892623/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-eucalyptus-globulus-labill-folium_en.pdf"},
    {"id":"12799","name":"Superseded list of references supporting the HMPC Assessment Report on Plantago ovata Forssk., semen (EMEA/HMPC/166377/2006)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2013-07-23T02:00:00Z","reference_number":"EMEA/HMPC/166377/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-hmpc-assessment-report-plantago-ovata-forssk-semen-emeahmpc1663772006_en.pdf"},
    {"id":"12914","name":"Draft list of references for assessment of: Curcumae longae rhizoma Curcuma longa L., rhizoma (turmeric root)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-11-06T00:09:21Z","last_updated_date":"2008-11-06T00:09:21Z","reference_number":"EMEA/HMPC/456910/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-curcumae-longae-rhizoma-curcuma-longa-l-rhizoma-turmeric-root_en.pdf"},
    {"id":"13051","name":"Final list of references supporting the assessment of Origanum dictamnus L., herba - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-08-05T02:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"EMA/HMPC/200427/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-origanum-dictamnus-l-herba-first-version_en.pdf"},
    {"id":"13161","name":"Final list of references supporting the assessment of Primula veris L. and / or Primula elatior (L.) Hill, radix","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2013-03-04T01:00:00Z","last_updated_date":"2013-03-04T01:00:00Z","reference_number":"EMA/HMPC/113665/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-primula-veris-l-and-or-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"13221","name":"Draft list of references supporting the assessment of Cichorium intybus L., radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2012-06-15T13:00:00Z","last_updated_date":"2012-06-15T13:00:00Z","reference_number":"EMA/HMPC/113046/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-cichorium-intybus-l-radix_en.pdf"},
    {"id":"13351","name":"Final list of references supporting the assessment of Crataegus spp., folium cum flore","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"EMA/HMPC/378548/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-crataegus-spp-folium-cum-flore_en.pdf"},
    {"id":"13390","name":"Superseded list of references supporting the assessment report on: Lupuli flos Humulus lupulus L., flos (hop strobiles) - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-07-11T02:00:00Z","last_updated_date":"2014-08-07T02:00:00Z","reference_number":"EMEA/HMPC/262640/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-lupuli-flos-humulus-lupulus-l-flos-hop-strobiles-first-version_en.pdf"},
    {"id":"13445","name":"Final list of references supporting the assessment of Echinacea pallida (Nutt.) Nutt., radix - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-08-14T12:00:00Z","last_updated_date":"2018-08-14T12:00:00Z","reference_number":"EMA/HMPC/737378/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-echinacea-pallida-nutt-nutt-radix-revision-1_en.pdf"},
    {"id":"13462","name":"Draft list of references for assessment of: Urticae folium Urtica dioica L.; Urtica urens L., folium (nettle leaf)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-05-08T02:00:00Z","last_updated_date":"2008-05-08T02:00:00Z","reference_number":"EMEA/HMPC/4252/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-urticae-folium-urtica-dioica-l-urtica-urens-l-folium-nettle-leaf_en.pdf"},
    {"id":"13475","name":"Superseded final list of references for assessment of: Hippocastani semen  Aesculus hippocastanum L., semen (horse chestnut seed) - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2020-04-23T02:00:00Z","reference_number":"EMEA/HMPC/225629/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-final-list-references-assessment-hippocastani-semen-aesculus-hippocastanum-l-semen-horse-chestnut-seed-first-version_en.pdf"},
    {"id":"13576","name":"Final list of references supporting the assessment of Uncaria tomentosa (Willd. ex Schult.) DC., cortex","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMA/HMPC/259599/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-uncaria-tomentosa-willd-ex-schult-dc-cortex_en.pdf"},
    {"id":"13869","name":"Draft list of references supporting the assessment of Fucus vesiculosus L., thallus","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-08-19T02:00:00Z","last_updated_date":"2013-08-19T02:00:00Z","reference_number":"EMA/HMPC/313673/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-fucus-vesiculosus-l-thallus_en.pdf"},
    {"id":"13913","name":"Final list of references supporting the assessment of Taraxacum officinale Weber ex Wigg., radix cum herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMA/HMPC/212894/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf"},
    {"id":"14238","name":"List of references supporting the assessment of Sisymbrium officinale (L.) Scop., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-10-30T01:00:00Z","last_updated_date":"2014-10-30T01:00:00Z","reference_number":"EMA/HMPC/280195/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-sisymbrium-officinale-l-scop-herba_en.pdf"},
    {"id":"14278","name":"Final list of references supporting the assessment of Withania somnifera (L.) Dunal, radix - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/HMPC/733313/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-withania-somnifera-l-dunal-radix-first-version_en.pdf"},
    {"id":"14476","name":"Draft list of references for assessment of: Valerianae radix and Lupuli flos Valerian officinalis L. and Humulus lupulus L. (valerian root and hop strobiles)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-05-14T02:09:21Z","last_updated_date":"2009-05-14T02:09:21Z","reference_number":"EMEA/HMPC/216362/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-valerianae-radix-and-lupuli-flos-valerian-officinalis-l-and-humulus-lupulus-l-valerian-root-and-hop-strobiles_en.pdf"},
    {"id":"14596","name":"List of references supporting the assessment report on: Avenae herba and Avenae fructus Avena sativa  L. (oat herb and oat fruit)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/260098/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-report-avenae-herba-and-avenae-fructus-avena-sativa-l-oat-herb-and-oat-fruit_en.pdf"},
    {"id":"14668","name":"Draft list of references supporting the assessment of Hypericum perforatum L., herba - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2018-03-08T01:00:00Z","last_updated_date":"2018-03-08T01:00:00Z","reference_number":"EMA/HMPC/45511/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-hypericum-perforatum-l-herba-revision-1_en.pdf"},
    {"id":"14861","name":"Draft list of references supporting the assessment of Eucalyptus globulus Labill., Eucalyptus polybractea R.T. Baker and/or Eucalyptus smithii R.T. Baker, aetheroleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-07-31T18:30:00Z","last_updated_date":"2013-07-31T18:30:00Z","reference_number":"EMA/HMPC/307783/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-andor-eucalyptus-smithii-rt-baker-aetheroleum_en.pdf"},
    {"id":"15088","name":"Draft list of references supporting the assessment of Crataegus spp., folium cum flore","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-10-14T02:00:00Z","last_updated_date":"2014-10-14T02:00:00Z","reference_number":"EMA/HMPC/378548/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-crataegus-spp-folium-cum-flore_en.pdf"},
    {"id":"15092","name":"Superseded list of references supporting the assessment of Vitis vinifera L., folium - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/16634/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-vitis-vinifera-l-folium-first-version_en.pdf"},
    {"id":"15098","name":"Superseded list of references supporting the assessment report on: Salviae folium and Salviae aetheroleum: Salvia officinalis L., folium and Salvia officinalis L., aetheroleum: (Sage leaf and Sage oil)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2017-07-13T02:00:00Z","reference_number":"EMA/HMPC/331645/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-salviae-folium-and-salviae-aetheroleum-salvia-officinalis-l-folium-and-salvia-officinalis-l-aetheroleum-sage-leaf-and-sage-oil_en.pdf"},
    {"id":"15283","name":"List of references supporting the assessment of Centaurium erythraea Rafn. s.l., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"EMA/HMPC/277492/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-centaurium-erythraea-rafn-sl-herba_en.pdf"}    {"id":"15381","name":"Draft list of references supporting the assessment of Achillea millefolium L., herba","type":"herbal-references","status":"Draft","consultation_date":"2010-11-15 - 2011-02-15","first_published_date":"2010-11-09T02:00:00Z","last_updated_date":"2010-11-09T02:00:00Z","reference_number":"EMA/HMPC/290282/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-achillea-millefolium-l-herba_en.pdf"},
    {"id":"15518","name":"Final list of references supporting the assessment of Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-08-24T17:00:00Z","last_updated_date":"2013-04-02T15:40:00Z","reference_number":"EMA/HMPC/571121/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf"},
    {"id":"15550","name":"Superseded list of references supporting the assessment of Agropyron repens (L.) P. Beauv., rhizoma","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2022-10-03T01:00:00Z","reference_number":"EMA/HMPC/563402/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-agropyron-repens-l-p-beauv-rhizoma_en.pdf"},
    {"id":"15647","name":"Draft list of references for assessment of: Pimpinella anisum L., fructus and aetheroleum (aniseed and anise oil)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-09-07T02:09:21Z","last_updated_date":"2007-09-07T02:09:21Z","reference_number":"EMEA/HMPC/359388/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-pimpinella-anisum-l-fructus-and-aetheroleum-aniseed-and-anise-oil_en.pdf"},
    {"id":"15683","name":"Draft list of references supporting the assessment of Viscum album L., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-10-20T11:30:10Z","last_updated_date":"2011-10-20T11:30:10Z","reference_number":"EMA/HMPC/246781/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-viscum-album-l-herba_en.pdf"},
    {"id":"15686","name":"Draft list of references supporting the assessment of Glycine max (L.) Merr., semen - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2017-02-28T01:00:00Z","last_updated_date":"2017-02-28T01:00:00Z","reference_number":"EMA/607531/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-glycine-max-l-merr-semen-first-version_en.pdf"},
    {"id":"15763","name":"Superseded final list of references supporting the assessment report on: Thymi herba Thymus vulgaris L.; Thymus zygis L. (thyme herb)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2014-06-03T01:09:21Z","reference_number":"EMEA/HMPC/207858/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-final-list-references-supporting-assessment-report-thymi-herba-thymus-vulgaris-l-thymus-zygis-l-thyme-herb_en.pdf"},
    {"id":"15838","name":"Superseded list of references supporting the assessment of Ribes nigrum L., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2010-06-30T02:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"EMA/HMPC/143130/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-ribes-nigrum-l-folium_en.pdf"},
    {"id":"15962","name":"Superseded final list of references supporting the assessment of Aesculus hippocastanum L., cortex - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-06-27T16:15:00Z","last_updated_date":"2012-06-27T16:15:00Z","reference_number":"EMA/HMPC/354158/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-final-list-references-supporting-assessment-aesculus-hippocastanum-l-cortex-first-version_en.pdf"},
    {"id":"16164","name":"Superseded list of references supporting the assessment of Rhamni purshianae cortex and Rhamnus purshianus D.C. (cascara)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-06-05T02:09:00Z","last_updated_date":"2008-06-05T02:09:00Z","reference_number":"EMEA/HMPC/513578/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-rhamni-purshianae-cortex-and-rhamnus-purshianus-dc-cascara_en.pdf"},
    {"id":"16463","name":"Draft list of references supporting the assessment of Tanacetum parthenium (L.) Schulz Bip.","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/HMPC/587580/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-tanacetum-parthenium-l-schulz-bip_en.pdf"},
    {"id":"16578","name":"Final list of references supporting the assessment of Fucus vesiculosus L., thallus","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2014-08-06T02:00:00Z","last_updated_date":"2014-08-06T02:00:00Z","reference_number":"EMA/HMPC/313673/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-fucus-vesiculosus-l-thallus_en.pdf"},
    {"id":"16616","name":"Final list of references supporting the assessment of Echinacea angustifolia DC., radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T16:30:00Z","last_updated_date":"2012-05-29T16:30:00Z","reference_number":"EMA/HMPC/688215/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-echinacea-angustifolia-dc-radix_en.pdf"},
    {"id":"16987","name":"Final list of references supporting the assessment of Thymus vulgaris L. and Thymus zygis L., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-06-02T02:00:00Z","last_updated_date":"2014-06-02T02:00:00Z","reference_number":"EMA/HMPC/342335/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-thymus-vulgaris-l-and-thymus-zygis-l-herba_en.pdf"},
    {"id":"17086","name":"Draft list of references for assessment of Hedera helix L., folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2010-03-08T01:00:00Z","last_updated_date":"2015-02-12T01:00:00Z","reference_number":"EMA/HMPC/706540/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-hedera-helix-l-folium_en.pdf"},
    {"id":"17433","name":"Final list of references supporting the assessment of Levisticum officinale Koch, radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T16:00:00Z","last_updated_date":"2013-02-22T16:00:00Z","reference_number":"EMA/HMPC/524626/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-levisticum-officinale-koch-radix_en.pdf"},
    {"id":"17450","name":"Final list of references supporting the assessment of Paullinia cupana Kunth ex H.B.K. var. sorbilis (Mart.) Ducke, semen - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/HMPC/897341/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-paullinia-cupana-kunth-ex-hbk-var-sorbilis-mart-ducke-semen-first-version_en.pdf"},
    {"id":"17460","name":"Draft list of references supporting the assessment of Carum carvi L., fructus and Carum carvi L. aetheroleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2014-12-22T17:15:00Z","last_updated_date":"2014-12-22T17:15:00Z","reference_number":"EMA/HMPC/242200/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-carum-carvi-l-fructus-and-carum-carvi-l-aetheroleum_en.pdf-0"},
    {"id":"17488","name":"Draft list of references supporting the assessment of Achillea millefolium L., flos","type":"herbal-references","status":"Draft","consultation_date":"2010-11-15 - 2011-02-15","first_published_date":"2010-11-09T02:00:00Z","last_updated_date":"2010-11-09T02:00:00Z","reference_number":"EMA/HMPC/149469/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-achillea-millefolium-l-flos_en.pdf"},
    {"id":"17781","name":"Draft list of references for assessment of: Verbasci flos Verbascum Sp., flos (mullein flower)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/HMPC/395238/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-verbasci-flos-verbascum-sp-flos-mullein-flower_en.pdf"},
    {"id":"17992","name":"Final list of references supporting the assessment of Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich), rhizoma","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T13:00:00Z","last_updated_date":"2014-05-12T13:00:00Z","reference_number":"EMA/HMPC/604598/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-curcuma-xanthorrhiza-roxb-c-xanthorrhiza-d-dietrich-rhizoma_en.pdf"},
    {"id":"18060","name":"Draft list of references for assessment of Menthae piperitae aetheroleum\n\nMentha x piperita L. (peppermint oil)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/199469/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-menthae-piperitae-aetheroleum-mentha-x-piperita-l-peppermint-oil_en.pdf"},
    {"id":"18187","name":"Draft list of references supporting the assessment of Valeriana officinalis L., radix and Valeriana officinalis L., aetheroleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-07-23T02:00:00Z","last_updated_date":"2015-07-23T02:00:00Z","reference_number":"EMA/HMPC/150847/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-valeriana-officinalis-l-radix-and-valeriana-officinalis-l-aetheroleum_en.pdf-0"},
    {"id":"18259","name":"Superseded - List of references supporting the HMPC assessment report on Aloe barbadensis Miller and Aloe (various species, mainly Aloe ferox Miller and its hybrids)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2017-04-10T02:00:00Z","reference_number":"EMEA/HMPC/76313/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-hmpc-assessment-report-aloe-barbadensis-miller-and-aloe-various-species-mainly-aloe-ferox-miller-and-its-hybrids_en.pdf"},
    {"id":"18363","name":"Draft list of references supporting the assessment of Solanum dulcamara L., stipites","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2012-05-10T02:00:00Z","last_updated_date":"2012-05-10T02:00:00Z","reference_number":"EMA/HMPC/734362/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-solanum-dulcamara-l-stipites_en.pdf"},
    {"id":"18426","name":"List of references supporting the assessment of Ricinus communis L., oleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-07-22T02:00:00Z","last_updated_date":"2015-07-22T02:00:00Z","reference_number":"EMA/HMPC/572975/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-ricinus-communis-l-oleum_en.pdf"},
    {"id":"18458","name":"Final  list of references supporting the assessment of Myroxylon balsamum (L.) Harms var. pereirae (Royle) Harms, balsamum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/HMPC/712650/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-myroxylon-balsamum-l-harms-var-pereirae-royle-harms-balsamum_en.pdf"},
    {"id":"18539","name":"Final list of references supporting the assessment of Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMA/HMPC/627059/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-harpagophytum-procumbens-dc-andor-harpagophytum-zeyheri-decne-radix_en.pdf"},
    {"id":"18546","name":"Draft list of references supporting the assessment of Malva sylvestris L. and/or Malva neglecta Wallr., folium and Malva sylvestris L., flos - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"EMA/HMPC/749540/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-malva-sylvestris-l-andor-malva-neglecta-wallr-folium-and-malva-sylvestris-l-flos-first-version_en.pdf-0"},
    {"id":"18578","name":"Superseded list of references supporting the assessment report on: Verbasci flos Verbascum thapsus L., V. densiflorum Bertol. and V. phlomoides L., flos (mullein flower)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/HMPC/395238/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-verbasci-flos-verbascum-thapsus-l-v-densiflorum-bertol-and-v-phlomoides-l-flos-mullein-flower_en.pdf"},
    {"id":"18629","name":"Final list of references supporting the assessment of Sambucus nigra L., fructus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-04-29T02:00:00Z","last_updated_date":"2014-04-29T02:00:00Z","reference_number":"EMA/HMPC/44212/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-sambucus-nigra-l-fructus_en.pdf"},
    {"id":"18745","name":"Final list of references supporting the assessment of Cucurbita pepo L., semen","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/HMPC/136023/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-cucurbita-pepo-l-semen_en.pdf"},
    {"id":"18753","name":"Final list of references supporting the assessment report on: Passiflorae herba Passiflora incarnata L., herba (passion flower)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-06-18T12:05:00Z","last_updated_date":"2014-06-18T12:05:00Z","reference_number":"EMA/HMPC/669739/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-report-passiflorae-herba-passiflora-incarnata-l-herba-passion-flower_en.pdf"},
    {"id":"18972","name":"Draft list of references supporting the assessment of Ruscus aculeatus L. rhizoma - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2018-03-08T09:30:00Z","last_updated_date":"2018-03-08T09:30:00Z","reference_number":"EMA/188806/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-ruscus-aculeatus-l-rhizoma-revision-1_en.pdf"},
    {"id":"19045","name":"Draft list of references for assessment of Vitex agnus-castus L., fructus Agni casti fructus (agnus castus fruit) - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-09-17T02:09:00Z","last_updated_date":"2009-09-17T02:09:00Z","reference_number":"EMEA/HMPC/144004/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-vitex-agnus-castus-l-fructus-agni-casti-fructus-agnus-castus-fruit-first-version_en.pdf"},
    {"id":"19126","name":"Final list of references supporting the assessment of Artemisia absinthium L., herba - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2017-10-05T02:00:00Z","last_updated_date":"2017-10-05T02:00:00Z","reference_number":"EMA/HMPC/186849/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-artemisia-absinthium-l-herba-revision-1_en.pdf"},
    {"id":"19134","name":"Draft list of references supporting the assessment of Thymus vulgaris L. and Thymus zygis L., herba","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"EMEA/HMPC/207858/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-thymus-vulgaris-l-and-thymus-zygis-l-herba_en.pdf"},
    {"id":"19220","name":"Draft list of references supporting the assessment of Primula veris L. and / or Primula elatior (L.) Hill, flos","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMEA/HMPC/111633/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-primula-veris-l-and-or-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"19239","name":"List of references supporting the assessment of Juglans regia L., folium","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2014-01-17T01:00:00Z","last_updated_date":"2014-01-17T01:00:00Z","reference_number":"EMA/HMPC/346742/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-juglans-regia-l-folium_en.pdf"},
    {"id":"19251","name":"Draft list of references supporting the assessment of Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-04-19T02:00:00Z","last_updated_date":"2013-04-19T02:00:00Z","reference_number":"EMA/HMPC/7702/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"19398","name":"Final list of references supporting the assessment of Potentilla erecta (L.) Raeusch., rhizoma","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-03-16T01:00:00Z","last_updated_date":"2011-03-16T01:00:00Z","reference_number":"EMA/HMPC/5517/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-potentilla-erecta-l-raeusch-rhizoma_en.pdf"},
    {"id":"19565","name":"Final list of references supporting the assessment of Solanum dulcamara L., stipites","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2013-02-15T01:00:00Z","last_updated_date":"2013-02-15T01:00:00Z","reference_number":"EMA/HMPC/734362/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-solanum-dulcamara-l-stipites_en.pdf"},
    {"id":"19794","name":"Final list of references supporting the assessment of Arctostaphylos uva-ursi (L.) Spreng., folium - Revision 2","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T14:00:00Z","last_updated_date":"2018-04-11T14:00:00Z","reference_number":"EMA/HMPC/750270/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-arctostaphylos-uva-ursi-l-spreng-folium-revision-2_en.pdf"},
    {"id":"19900","name":"Final list of references supporting the assessment of Valeriana officinalis L., radix and Valeriana officinalis L., aetheroleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-04-27T12:30:00Z","last_updated_date":"2016-04-27T12:30:00Z","reference_number":"EMA/HMPC/150847/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-valeriana-officinalis-l-radix-and-valeriana-officinalis-l-aetheroleum_en.pdf"},
    {"id":"20046","name":"Final list of references supporting the assessment of Plantago afra L. et Plantago indica L., semen","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-07-29T15:30:00Z","last_updated_date":"2013-07-29T15:30:00Z","reference_number":"EMA/HMPC/599746/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-plantago-afra-l-et-plantago-indica-l-semen_en.pdf"},
    {"id":"20090","name":"Final list of references supporting the assessment of Hedera helix L., folium - Revision 2","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2018-08-13T13:47:00Z","last_updated_date":"2018-08-13T13:47:00Z","reference_number":"EMA/HMPC/325719/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-hedera-helix-l-folium-revision-2_en.pdf"},
    {"id":"20111","name":"Final list of references supporting the assessment of Plantago ovata Forssk., semen","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T15:30:00Z","last_updated_date":"2013-07-23T15:30:00Z","reference_number":"EMA/HMPC/304361/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-plantago-ovata-forssk-semen_en.pdf"},
    {"id":"20162","name":"Final list of references supporting the assessment of Helichrysum arenarium (L.) Moench, flos","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-05-23T12:50:00Z","last_updated_date":"2016-05-23T12:50:00Z","reference_number":"EMA/HMPC/144093/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-helichrysum-arenarium-l-moench-flos_en.pdf"},
    {"id":"20300","name":"List of references supporting the assessment of Withania somnifera (L.) Dunal, radix - First version","type":"herbal-references","status":"Draft","consultation_date":"2012-12-15 - 2013-04-15","first_published_date":"2012-12-10T02:00:00Z","last_updated_date":"2012-12-10T02:00:00Z","reference_number":"EMA/HMPC/733313/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-withania-somnifera-l-dunal-radix-first-version_en.pdf"},
    {"id":"20384","name":"Final list of references supporting the assessment of Capsicum annuum L. var. minimum (Miller) Heiser and small fruited varieties of Capsicum frutescens L., fructus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/HMPC/36892/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-capsicum-annuum-l-var-minimum-miller-heiser-and-small-fruited-varieties-capsicum-frutescens-l-fructus_en.pdf"},
    {"id":"20835","name":"List of bibliographic references supporting the HMPC assessment report\n\non Plantago ovata Forssk., seminis tegumentum (EMEA/HMPC/165838/2006)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2013-07-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-bibliographic-references-supporting-hmpc-assessment-report-plantago-ovata-forssk-seminis-tegumentum-emeahmpc1658382006_en.pdf"},
    {"id":"20903","name":"Final list of references supporting the assessment of Carum carvi L., fructus and Carum carvi L., aetheroleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/HMPC/242200/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-carum-carvi-l-fructus-and-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"20908","name":"Final list of references supporting the assessment report on: Betulae folium Betula pendula Roth; Betula pubescens Ehrh., folium (birch leaf)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/HMPC/573239/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-report-betulae-folium-betula-pendula-roth-betula-pubescens-ehrh-folium-birch-leaf_en.pdf"},
    {"id":"20960","name":"Final list of references supporting the assessment of Piper methysticum G. Forst., rhizoma","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-04-13T02:00:00Z","last_updated_date":"2018-04-13T02:00:00Z","reference_number":"EMA/HMPC/450587/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-piper-methysticum-g-forst-rhizoma_en.pdf"},
    {"id":"21010","name":"Draft list of references for assessment of: Euphrasiae herba Euphrasia officinalis L.and Euphrasia rostkoviana Hayne, herba (eyebright herb)","type":"herbal-references","status":"Draft","consultation_date":"2010-01-15 - 2010-04-15","first_published_date":"2010-02-12T01:09:21Z","last_updated_date":"2010-02-12T01:09:21Z","reference_number":"EMA/HMPC/246817/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-euphrasiae-herba-euphrasia-officinalis-land-euphrasia-rostkoviana-hayne-herba-eyebright-herb_en.pdf"},
    {"id":"21092","name":"Final list of references supporting the assessment of Achillea millefolium L., flos","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2011-09-30T02:00:00Z","last_updated_date":"2011-09-30T02:00:00Z","reference_number":"EMA/HMPC/149469/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-achillea-millefolium-l-flos_en.pdf"},
    {"id":"21151","name":"Final list of references supporting the assessment of Chamaemelum nobile (L.) All., flos","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T17:20:00Z","last_updated_date":"2012-01-20T17:20:00Z","reference_number":"EMA/HMPC/560733/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-chamaemelum-nobile-l-all-flos_en.pdf"},
    {"id":"21525","name":"Draft list of references for assessment of Quercus robur L., Quercus petrea.(Matt.) Liebl. and Quercus pubescens Willd., Quercus cortex (oak bark)","type":"herbal-references","status":"Draft","consultation_date":"2010-01-14 - 2010-05-15","first_published_date":"2010-03-08T02:00:00Z","last_updated_date":"2010-03-08T02:00:00Z","reference_number":"EMA/HMPC/3205/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-quercus-robur-l-quercus-petreamatt-liebl-and-quercus-pubescens-willd-quercus-cortex-oak-bark_en.pdf"},
    {"id":"21527","name":"Final list of references supporting the assessment of Ilex paraguariensis St. Hilaire, folium - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-02-14T01:00:00Z","last_updated_date":"2011-02-14T01:00:00Z","reference_number":"EMA/HMPC/580546/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-ilex-paraguariensis-st-hilaire-folium-first-version_en.pdf"},
    {"id":"21565","name":"Draft list of references supporting the assessment of Juniperus communis L., aetheroleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/HMPC/12399/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-juniperus-communis-l-aetheroleum_en.pdf"},
    {"id":"21585","name":"Superseded final list of bibliographic references supporting the HMPC Assessment Report on Plantago afra L. Plantago indica L. semen (EMEA/HMPC/167338/2006)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T00:09:21Z","last_updated_date":"2013-07-29T14:00:00Z","reference_number":"EMEA/HMPC/167338/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-final-list-bibliographic-references-supporting-hmpc-assessment-report-plantago-afra-l-plantago-indica-l-semen-emeahmpc1673382006_en.pdf"},
    {"id":"21670","name":"Final list of references supporting the assessment of Agrimonia eupatoria L., herba - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T13:00:00Z","last_updated_date":"2015-04-09T13:00:00Z","reference_number":"EMA/HMPC/18031/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-agrimonia-eupatoria-l-herba-first-version_en.pdf"},
    {"id":"21802","name":"Draft list of references supporting the assessment of Salvia officinalis L., folium and Salvia officinalis L., aetheroleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-02-15T12:00:00Z","last_updated_date":"2016-02-15T12:00:00Z","reference_number":"EMA/HMPC/277151/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-salvia-officinalis-l-folium-and-salvia-officinalis-l-aetheroleum_en.pdf"},
    {"id":"21910","name":"Superseded list of references supporting the assessment of Plantago ovate Forssk., seminis tegumentum","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMEA/HMPC/165838/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-plantago-ovate-forssk-seminis-tegumentum_en.pdf"},
    {"id":"21992","name":"Final list of references supporting the assessment of Citrus bergamia Risso et Poiteau, aetheroleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-08-28T13:45:00Z","last_updated_date":"2012-08-28T13:45:00Z","reference_number":"EMA/HMPC/56157/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-citrus-bergamia-risso-et-poiteau-aetheroleum_en.pdf"},
    {"id":"22133","name":"Draft list of references supporting the assessment report on: Lupuli flos Humulus lupulus L., flos (hop strobiles) - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/262640/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-report-lupuli-flos-humulus-lupulus-l-flos-hop-strobiles-first-version_en.pdf"},
    {"id":"22179","name":"Draft list of references for assessment of Echinaceae purpureae radix Echinacea purpurea (L.) Moench., radix (purple coneflower root)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-07-16T02:09:21Z","last_updated_date":"2009-07-16T02:09:21Z","reference_number":"EMEA/HMPC/577790/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-echinaceae-purpureae-radix-echinacea-purpurea-l-moench-radix-purple-coneflower-root_en.pdf"},
    {"id":"22565","name":"Draft list of references supporting the assessment of Chamaemelum nobile (L.) All., flos","type":"herbal-references","status":"Draft","consultation_date":"2011-02-15 - 2011-06-15","first_published_date":"2011-03-02T02:00:00Z","last_updated_date":"2011-03-02T02:00:00Z","reference_number":"EMA/HMPC/560733/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-chamaemelum-nobile-l-all-flos_en.pdf"},
    {"id":"22697","name":"Superseded list of references supporting the assessment of Orthosiphon stamineus Benth., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-05-30T02:00:00Z","last_updated_date":"2011-05-30T02:00:00Z","reference_number":"EMA/HMPC/281529/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-orthosiphon-stamineus-benth-folium_en.pdf"},
    {"id":"22790","name":"Draft list of references for assessment of: Althaeae radix Althaea officinalis L., radix (marshmallow root)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2008-07-03T02:09:21Z","reference_number":"EMEA/HMPC/98716/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-althaeae-radix-althaea-officinalis-l-radix-marshmallow-root_en.pdf"},
    {"id":"23059","name":"Superseded list of references supporting the assessment on: Primulae radix Primula veris L. and Primula elatior (L.) Hill, radix (primula root)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-11-28T01:00:00Z","last_updated_date":"2008-11-28T01:00:00Z","reference_number":"EMEA/HMPC/111736/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-primulae-radix-primula-veris-l-and-primula-elatior-l-hill-radix-primula-root_en.pdf"},
    {"id":"23131","name":"Draft list of references for assessment of: Gentianae radix Gentiana lutea L., radix (gentian root) - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-03-12T00:09:21Z","last_updated_date":"2009-03-12T00:09:21Z","reference_number":"EMEA/HMPC/578323/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-gentianae-radix-gentiana-lutea-l-radix-gentian-root-first-version_en.pdf"},
    {"id":"23173","name":"Superseded final list of references supporting the assessment of Rhodiola rosea - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T16:00:00Z","last_updated_date":"2024-05-23T16:00:00Z","reference_number":"EMA/HMPC/232102/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-final-list-references-supporting-assessment-rhodiola-rosea-first-version_en.pdf"},
    {"id":"23227","name":"Final list of references supporting the assessment of Prunus africana (Hook f.) Kalkm., cortex","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2017-09-01T02:00:00Z","last_updated_date":"2017-09-01T02:00:00Z","reference_number":"EMA/HMPC/680625/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-prunus-africana-hook-f-kalkm-cortex_en.pdf"},
    {"id":"23403","name":"Draft list of references supporting the assessment of Hieracium pilosella L., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2014-08-04T02:00:00Z","last_updated_date":"2014-08-04T02:00:00Z","reference_number":"EMA/HMPC/35510/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-hieracium-pilosella-l-herba_en.pdf"},
    {"id":"23466","name":"Draft list of references supporting the assessment report on: Boldi folium Peumus boldus Molina, folium (boldo leaf)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2008-05-08T02:09:21Z","reference_number":"EMEA/HMPC/591649/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-report-boldi-folium-peumus-boldus-molina-folium-boldo-leaf_en.pdf"},
    {"id":"23475","name":"Final list of references supporting the assessment of Fumaria officinalis L., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-12-06T16:50:00Z","last_updated_date":"2024-02-21T16:10:00Z","reference_number":"EMA/HMPC/576233/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-fumaria-officinalis-l-herba_en.pdf"},
    {"id":"23699","name":"Final list of references supporting the assessment of Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-06-09T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"EMA/HMPC/85125/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"23805","name":"Final list of references supporting the assessment of Serenoa repens (W. Bartram) Small, fructus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-03-30T02:00:00Z","last_updated_date":"2016-03-30T02:00:00Z","reference_number":"EMA/HMPC/280080/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-serenoa-repens-w-bartram-small-fructus_en.pdf"},
    {"id":"23840","name":"Draft list of references for assessment of: Taraxaci radix cum herba Taraxacum officinale Weber ex Wigg., radix cum herba (dandelion root and herb)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-01-14T00:09:21Z","last_updated_date":"2009-01-14T00:09:21Z","reference_number":"EMEA/HMPC/212894/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-taraxaci-radix-cum-herba-taraxacum-officinale-weber-ex-wigg-radix-cum-herba-dandelion-root-and-herb_en.pdf"},
    {"id":"23889","name":"Draft list of references supporting the assessment of Grindelia robusta Nutt., Grindelia squarrosa (Pursh) Dunal, Grindelia humilis Hook. et Arn., Grindelia camporum Greene, herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2012-05-16T02:00:00Z","last_updated_date":"2012-05-16T02:00:00Z","reference_number":"EMA/HMPC/748221/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-grindelia-robusta-nutt-grindelia-squarrosa-pursh-dunal-grindelia-humilis-hook-et-arn-grindelia-camporum-greene-herba_en.pdf"},
    {"id":"24518","name":"Draft list of references supporting the assessment of Arctostaphylos uvae ursi (L.) Spreng, folium","type":"herbal-references","status":"Draft","consultation_date":"2010-08-15 - 2010-12-15","first_published_date":"2010-08-18T04:00:00Z","last_updated_date":"2010-08-18T04:00:00Z","reference_number":"EMA/HMPC/573461/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-arctostaphylos-uvae-ursi-l-spreng-folium_en.pdf"},
    {"id":"24858","name":"Superseded - List of references supporting the assessment of Cimicifuga racemosa (L.) Nutt., rhizome - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-05-16T02:00:00Z","last_updated_date":"2018-07-03T02:00:00Z","reference_number":"EMA/HMPC/102303/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-cimicifuga-racemosa-l-nutt-rhizome-first-version_en.pdf"},
    {"id":"24972","name":"Draft list of references supporting the assessment of Andrographis paniculata Nees, folium - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-01-25T01:00:00Z","last_updated_date":"2013-01-25T01:00:00Z","reference_number":"EMA/HMPC/320452/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-andrographis-paniculata-nees-folium-first-version_en.pdf"},
    {"id":"25014","name":"Draft list of references supporting the assessment on Allium cepa L., bulbus","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-08-18T02:00:00Z","last_updated_date":"2011-08-18T02:00:00Z","reference_number":"EMA/HMPC/347199/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-allium-cepa-l-bulbus_en.pdf"},
    {"id":"25028","name":"List of references supporting the assessment of Linum usitatissimum L., semen","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-07-13T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMA/HMPC/377676/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-linum-usitatissimum-l-semen_en.pdf"},
    {"id":"25048","name":"Draft list of references supporting the public statement of Picrorhiza kurroa Royle ex Benth, radix","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2014-07-31T02:00:00Z","last_updated_date":"2014-07-31T02:00:00Z","reference_number":"EMA/HMPC/252875/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-public-statement-picrorhiza-kurroa-royle-ex-benth-radix_en.pdf"},
    {"id":"25059","name":"Final list of references supporting the assessment of Eschscholzia californica Cham., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/HMPC/35559/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-eschscholzia-californica-cham-herba_en.pdf"},
    {"id":"25134","name":"Draft list of references for assessment of: Avenae herba and fructus Avena sativa L. (oat herb and fruit)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-10-22T02:09:21Z","last_updated_date":"2007-10-22T02:09:21Z","reference_number":"EMEA/HMPC/260098/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-avenae-herba-and-fructus-avena-sativa-l-oat-herb-and-fruit_en.pdf"},
    {"id":"25259","name":"Final list of references supporting the assessment of Chelidonium majus L., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/HMPC/369803/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-chelidonium-majus-l-herba_en.pdf"},
    {"id":"25281","name":"Draft list of references for assessment of Rhamnus purshianus D.C.","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-03-08T00:09:21Z","last_updated_date":"2007-03-08T00:09:21Z","reference_number":"EMEA/HMPC/513578/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-rhamnus-purshianus-dc_en.pdf"},
    {"id":"25421","name":"Draft list of references supporting the assessment of Serenoa repens (W. Bartram) Small, fructus","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2014-12-22T17:40:00Z","last_updated_date":"2014-12-22T17:40:00Z","reference_number":"EMA/HMPC/280080/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-serenoa-repens-w-bartram-small-fructus_en.pdf"},
    {"id":"25464","name":"Draft list of references for assessment of: Eleutherococci radix Eleutherococcus senticosus (Rupr. et Maxim.) Maxim. (eleutherococcus root)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2007-07-05T02:09:21Z","reference_number":"EMEA/249428/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-eleutherococci-radix-eleutherococcus-senticosus-rupr-et-maxim-maxim-eleutherococcus-root_en.pdf"},
    {"id":"25469","name":"Superseded list of references supporting the HMPC assessment report on Gentianae radix, Gentiana lutea L., radix (gentian root)  - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2010-03-08T01:00:00Z","last_updated_date":"2019-04-30T01:00:00Z","reference_number":"EMA/HMPC/578323/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-hmpc-assessment-report-gentianae-radix-gentiana-lutea-l-radix-gentian-root-first-version_en.pdf"},
    {"id":"25492","name":"Draft list of references supporting the assessment of Eschscholzia californica Cham., herba","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2014-07-31T19:15:00Z","last_updated_date":"2014-07-31T19:15:00Z","reference_number":"EMA/HMPC/35559/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-eschscholzia-californica-cham-herba_en.pdf"},
    {"id":"25496","name":"Draft list of references supporting the assessment of Myroxylon balsamum (L.) Harms var. pereirae (Royle) Harms, balsamum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"EMA/HMPC/712650/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-myroxylon-balsamum-l-harms-var-pereirae-royle-harms-balsamum_en.pdf"},
    {"id":"25608","name":"Draft list of references supporting the assessment of Species diureticae","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/HMPC/358625/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-species-diureticae_en.pdf"},
    {"id":"25754","name":"Final list of references supporting the assessment of Echinacea purpurea (L.) Moench, radix – Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2017-08-11T02:00:00Z","last_updated_date":"2017-08-11T02:00:00Z","reference_number":"EMA/HMPC/424585/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-echinacea-purpurea-l-moench-radix-revision-1_en.pdf"},
    {"id":"25812","name":"List of references supporting the assessment of Oenothera biennis L.; Oenothera lamarckiana L., oleum - First version","type":"herbal-references","status":"Draft","consultation_date":"2011-02-15 - 2011-06-15","first_published_date":"2011-07-14T04:00:00Z","last_updated_date":"2011-07-14T04:00:00Z","reference_number":"EMA/HMPC/277817/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-oenothera-biennis-l-oenothera-lamarckiana-l-oleum-first-version_en.pdf"},
    {"id":"25836","name":"Superseded list of references supporting the assessment of Urtica dioica L., Urtica urens L., their hybrids or their mixtures, radix - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-11-05T12:20:00Z","last_updated_date":"2025-03-12T12:20:00Z","reference_number":"EMA/HMPC/461158/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-urtica-dioica-l-urtica-urens-l-their-hybrids-or-their-mixtures-radix-first-version_en.pdf"}    {"id":"25841","name":"Final list of references supporting the assessment of Rubus idaeus L., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T11:00:00Z","last_updated_date":"2014-03-21T11:00:00Z","reference_number":"EMA/HMPC/44210/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-rubus-idaeus-l-folium_en.pdf"},
    {"id":"25892","name":"Final list of references supporting the assessment of Leonurus cardiaca L., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/HMPC/127429/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-leonurus-cardiaca-l-herba_en.pdf"},
    {"id":"25909","name":"Final list of references supporting the assessment of Salvia officinalis L., folium and Salvia officinalis L., aetheroleum - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2017-07-13T02:00:00Z","last_updated_date":"2017-07-13T02:00:00Z","reference_number":"MA/HMPC/277151/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-salvia-officinalis-l-folium-and-salvia-officinalis-l-aetheroleum-revision-1_en.pdf"},
    {"id":"26113","name":"Draft list of references supporting the assessment of Ononis spinosa L., radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-08-19T02:00:00Z","last_updated_date":"2013-08-19T02:00:00Z","reference_number":"EMA/HMPC/138319/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-ononis-spinosa-l-radix_en.pdf"},
    {"id":"26123","name":"Draft list of references supporting the assessment of Aesculus hippocastanum L., cortex","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-10-26T12:30:03Z","last_updated_date":"2011-10-26T12:30:03Z","reference_number":"EMA/HMPC/354158/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-aesculus-hippocastanum-l-cortex_en.pdf"},
    {"id":"26364","name":"Draft list of references supporting the assessment of Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis raeseri Boiss. & Heldr.; Sideritis syriaca L., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-07-27T13:00:00Z","last_updated_date":"2015-07-27T13:00:00Z","reference_number":"EMA/HMPC/39454/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-sideritis-scardica-griseb-sideritis-clandestina-bory-chaub-hayek-sideritis-raeseri-boiss-heldr-sideritis-syriaca-l-herba_en.pdf"},
    {"id":"26377","name":"Draft list of references supporting the assessment of Origanum majorana L., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-02-15T17:15:00Z","last_updated_date":"2016-02-15T17:15:00Z","reference_number":"EMA/HMPC/63480/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-origanum-majorana-l-herba_en.pdf"},
    {"id":"26426","name":"Final list of references supporting the assessment of Taraxacum officinale Weber ex Wigg., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMA/HMPC/579635/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-taraxacum-officinale-weber-ex-wigg-folium_en.pdf"},
    {"id":"26508","name":"Draft list of references supporting the assessment report on: Passiflorae herba Passiflora incarnate L., herba (passion flower)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-01-21T01:00:00Z","last_updated_date":"2016-01-21T01:00:00Z","reference_number":"EMEA/HMPC/111180/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-report-passiflorae-herba-passiflora-incarnate-l-herba-passion-flower_en.pdf"},
    {"id":"26524","name":"Superseded list of references supporting the HMPC assessment on Rhamnus frangula L., cortex - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/76306/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-hmpc-assessment-rhamnus-frangula-l-cortex-first-version_en.pdf"},
    {"id":"26686","name":"Draft list of references supporting the assessment of Panax ginseng C.A. Meyer, radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-04-16T02:00:00Z","last_updated_date":"2013-04-16T02:00:00Z","reference_number":"EMA/HMPC/321234/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-panax-ginseng-ca-meyer-radix_en.pdf"},
    {"id":"26706","name":"Final list of references supporting the assessment of Plantago ovata Forssk., seminis tegumentum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T16:00:00Z","last_updated_date":"2013-07-23T16:00:00Z","reference_number":"EMA/HMPC/199776/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-plantago-ovata-forssk-seminis-tegumentum_en.pdf"},
    {"id":"26733","name":"Draft list of references supporting the assessment of Cucurbita pepo L., semen","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/HMPC/136023/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-cucurbita-pepo-l-semen_en.pdf"},
    {"id":"26863","name":"Draft list of references for assessment of: Absinthii herba Artemisia absinthium L., herba (wormwood herb)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/234497/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-absinthii-herba-artemisia-absinthium-l-herba-wormwood-herb_en.pdf"},
    {"id":"26891","name":"Superseded list of references supporting the assessment of Valeriana officinalis L., radix and Humulus lupulus L., flos","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2010-09-02T02:00:00Z","last_updated_date":"2010-09-02T02:00:00Z","reference_number":"EMA/HMPC/216362/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos_en.pdf"},
    {"id":"26911","name":"Superseded list of bibliographic references supporting the HMPC assessment report on Cassia senna L. and Cassia angustifolia Vahl, folium (EMEA/HMPC/51868/2006) and the HMPC assessment report on Cassia senna L., fructus and Cassia ...","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2007-04-27T02:09:00Z","last_updated_date":"2007-04-27T02:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-bibliographic-references-supporting-hmpc-assessment-report-cassia-senna-l-and-cassia-angustifolia-vahl-folium-emeahmpc518682006-and-hmpc-assessment-report-cassia-senna-l-fructus-and_en.pdf"},
    {"id":"27223","name":"Final list of references supporting the assessment of Allium cepa L., bulbus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T18:00:00Z","last_updated_date":"2012-05-29T18:00:00Z","reference_number":"EMA/HMPC/347199/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-allium-cepa-l-bulbus_en.pdf"},
    {"id":"27279","name":"Draft list of references supporting the assessment of Silybum marianum (L.) Gaertn., fructus","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T17:01:00Z","last_updated_date":"2016-11-07T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-silybum-marianum-l-gaertn-fructus_en.pdf"},
    {"id":"27390","name":"Draft list of references for assessment of: Juniperi fructus Juniperus communis L., fructus (Juniper berry)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-01-14T01:00:00Z","last_updated_date":"2009-01-14T01:00:00Z","reference_number":"EMEA/HMPC/442959/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-juniperi-fructus-juniperus-communis-l-fructus-juniper-berry_en.pdf"},
    {"id":"27443","name":"Final list of references supporting the assessment of Fraxinus excelsior L. and Fraxinus angustifolia Vahl, folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T16:40:00Z","last_updated_date":"2012-06-18T16:40:00Z","reference_number":"EMA/HMPC/239270/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-fraxinus-excelsior-l-and-fraxinus-angustifolia-vahl-folium_en.pdf"},
    {"id":"27512","name":"Final list of references supporting the assessment of Plantago lanceolata L., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T01:00:00Z","last_updated_date":"2012-02-24T01:00:00Z","reference_number":"EMA/HMPC/437860/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-plantago-lanceolata-l-folium_en.pdf"},
    {"id":"27543","name":"Draft list of references supporting the assessment of Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria (L.)), herba and Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria (L.)), flos  - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/HMPC/759656/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-filipendula-ulmaria-l-maxim-spiraea-ulmaria-l-herba-and-filipendula-ulmaria-l-maxim-spiraea-ulmaria-l-flos-first-version_en.pdf"},
    {"id":"27590","name":"Draft list of references for assessment of Arctium lappa L. Arctii radix (burdock root)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2010-03-08T01:00:00Z","last_updated_date":"2010-03-08T01:00:00Z","reference_number":"EMA/HMPC/246770/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-arctium-lappa-l-arctii-radix-burdock-root_en.pdf"},
    {"id":"27663","name":"Superseded list of references supporting the assessment report on: Calendulae flos Calendula officinalis L. (calendula flower) - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-03-06T00:09:21Z","last_updated_date":"2018-06-15T01:09:21Z","reference_number":"EMEA/HMPC/261882/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-calendulae-flos-calendula-officinalis-l-calendula-flower-first-version_en.pdf"},
    {"id":"27678","name":"Superseded final list of references supporting the assessment of Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-08-20T02:00:00Z","last_updated_date":"2024-07-12T02:00:00Z","reference_number":"EMA/HMPC/444243/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-final-list-references-supporting-assessment-pelargonium-sidoides-dc-or-pelargonium-reniforme-curt-radix-revision-1_en.pdf"},
    {"id":"27779","name":"Superseded final list of references supporting the assessment of Panax ginseng C.A. Meyer, radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-05-22T02:00:00Z","last_updated_date":"2024-07-12T02:00:00Z","reference_number":"EMA/HMPC/321234/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-final-list-references-supporting-assessment-panax-ginseng-ca-meyer-radix_en.pdf"},
    {"id":"27871","name":"Superseded list of references supporting the assessment report on: Hyperici herba, Hypericum perforatum L., herba (St. John’s wort)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2009-12-21T00:09:00Z","last_updated_date":"2023-02-22T00:09:00Z","reference_number":"EMA/HMPC/101620/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-hyperici-herba-hypericum-perforatum-l-herba-st-johns-wort_en.pdf"},
    {"id":"27962","name":"Draft list of references for assessment of: Vitis viniferae folium Vitis vinifera L. var. tinctoria, folium (red vine leaf)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-12-21T00:09:21Z","last_updated_date":"2009-12-21T00:09:21Z","reference_number":"EMA/HMPC/16634/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-vitis-viniferae-folium-vitis-vinifera-l-var-tinctoria-folium-red-vine-leaf_en.pdf"},
    {"id":"27983","name":"Final list of references supporting the public statement of Picrorhiza kurroa Royle ex Benth, radix","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2015-02-18T01:00:00Z","last_updated_date":"2015-02-18T01:00:00Z","reference_number":"EMA/HMPC/252875/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-public-statement-picrorhiza-kurroa-royle-ex-benth-radix_en.pdf"},
    {"id":"28040","name":"Draft list of references supporting the assessment of Leonurus cardiaca L., herba\n\nLeonuri cardiacae herba, \n\n(motherwort)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2010-05-26T02:00:00Z","last_updated_date":"2010-05-26T02:00:00Z","reference_number":"EMA/HMPC/127429/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-leonurus-cardiaca-l-herba-leonuri-cardiacae-herba-motherwort_en.pdf"},
    {"id":"28054","name":"Draft list of references supporting the assessment of\n\nArctostaphylos uva-ursi (L.) Spreng., folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2017-04-12T14:08:00Z","last_updated_date":"2017-04-12T14:08:00Z","reference_number":"EMA/HMPC/750270/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-arctostaphylos-uva-ursi-l-spreng-folium_en.pdf"},
    {"id":"28453","name":"Final list of references supporting the assessment of Adhatoda vasica Nees, folium - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/HMPC/681469/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-adhatoda-vasica-nees-folium-first-version_en.pdf"},
    {"id":"28664","name":"Superseded final list of references supporting the assessment of Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"EMA/HMPC/130045/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-final-list-references-supporting-assessment-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"28717","name":"Final list of references supporting the assessment of Melissa officinalis L., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-08-05T17:00:00Z","last_updated_date":"2013-08-05T17:00:00Z","reference_number":"EMA/HMPC/196744/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-melissa-officinalis-l-folium_en.pdf"},
    {"id":"28722","name":"Draft list of references for assessment of Orthosiphonis staminei folium Orthosiphon stamineus Benth., folium (Java tea)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-07-16T02:09:21Z","last_updated_date":"2009-07-16T02:09:21Z","reference_number":"EMEA/HMPC/281529/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-orthosiphonis-staminei-folium-orthosiphon-stamineus-benth-folium-java-tea_en.pdf"},
    {"id":"28983","name":"List of references for assessment of: Thymi aetheroleum Thymus vulgaris L.; Thymus zygis L., aetheroleum (thyme essential oil)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2009-05-14T02:09:21Z","last_updated_date":"2009-05-14T02:09:21Z","reference_number":"EMEA/HMPC/131905/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-assessment-thymi-aetheroleum-thymus-vulgaris-l-thymus-zygis-l-aetheroleum-thyme-essential-oil_en.pdf"},
    {"id":"28991","name":"Final list of references supporting the assessment of Humulus lupulus L., flos - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-08-07T02:00:00Z","last_updated_date":"2014-08-07T02:00:00Z","reference_number":"EMA/HMPC/682386/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"29031","name":"Final list of references supporting the assessment of Syzygium aromaticum (L.) Merill et L.M. Perry, flos and Syzygium aromaticum (L.) Merill et L.M. Perry, floris aetheroleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T01:00:00Z","last_updated_date":"2011-12-21T01:00:00Z","reference_number":"EMA/HMPC/534948/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-syzygium-aromaticum-l-merill-et-lm-perry-flos-and-syzygium-aromaticum-l-merill-et-lm-perry-floris-aetheroleum_en.pdf"},
    {"id":"29221","name":"List of references supporting the assessment of Cinnamomum verum J. S. Presl, cortex and corticis aetheroleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2011-08-05T02:00:00Z","reference_number":"EMA/HMPC/246775/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-cinnamomum-verum-j-s-presl-cortex-and-corticis-aetheroleum_en.pdf"},
    {"id":"29358","name":"Draft list of references supporting the assessment of Agropyron repens (L.) P. Beauv., rhizoma","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"EMA/HMPC/563402/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-agropyron-repens-l-p-beauv-rhizoma_en.pdf"},
    {"id":"29399","name":"Draft list of references supporting the assessment of Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl., semen","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-07-28T02:00:00Z","last_updated_date":"2011-07-28T02:00:00Z","reference_number":"EMA/HMPC/722366/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-cola-nitida-vent-schott-et-endl-and-its-varieties-and-cola-acuminata-p-beauv-schott-et-endl-semen_en.pdf"},
    {"id":"29468","name":"Draft list of references for assessment of Rosmarini aetheroleum; Rosmarini folium Rosmarinus officinalis L., aetheroleum; Rosmarinus officinalis L., folium (rosemary oil; rosemary leaf)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/HMPC/13632/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-rosmarini-aetheroleum-rosmarini-folium-rosmarinus-officinalis-l-aetheroleum-rosmarinus-officinalis-l-folium-rosemary-oil-rosemary-leaf_en.pdf"},
    {"id":"29698","name":"Superseded list of references supporting the assessment report on: Sambuci flos Sambucus nigra L., flos (elder flower) - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2018-06-27T02:09:21Z","reference_number":"EMEA/HMPC/283842/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-sambuci-flos-sambucus-nigra-l-flos-elder-flower-first-version_en.pdf"},
    {"id":"29711","name":"Draft list of references supporting the assessment on Rhodiola rosea  - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-09-20T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"EMA/HMPC/232102/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-rhodiola-rosea-first-version_en.pdf"},
    {"id":"29719","name":"Superseded list of references supporting the assessment of Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix - First version","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2013-02-15T01:00:00Z","last_updated_date":"2018-08-20T02:00:00Z","reference_number":"EMA/HMPC/560963/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-pelargonium-sidoides-dc-andor-pelargonium-reniforme-curt-radix-first-version_en.pdf"},
    {"id":"29871","name":"Draft list of references supporting the assessment of Curcuma xanthorrhiza roxb., rhizoma","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-06-19T02:00:00Z","last_updated_date":"2013-06-19T02:00:00Z","reference_number":"EMA/HMPC/604598/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-curcuma-xanthorrhiza-roxb-rhizoma_en.pdf"},
    {"id":"29894","name":"Final list of references supporting the assessment of Salix [various species including S. purpurea L., S. daphnoides Vill., S. fragilis L.], cortex","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2017-07-07T02:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMA/HMPC/80629/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-cortex_en.pdf"},
    {"id":"30027","name":"Draft list of references supporting the assessment of Glycine max (L.) Merr., lecithin","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-07-27T15:40:00Z","last_updated_date":"2016-07-27T15:40:00Z","reference_number":"EMA/HMPC/338889/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-glycine-max-l-merr-lecithin_en.pdf"},
    {"id":"30296","name":"Draft list of references supporting the assessment of Silybum marianum (L.) Gaertn., fructus","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-07-23T12:50:00Z","last_updated_date":"2015-07-23T12:50:00Z","reference_number":"EMA/HMPC/278220/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-silybum-marianum-l-gaertn-fructus_en.pdf-0"},
    {"id":"30381","name":"Draft list of references supporting the assessment of Prunus africana (Hook f.) Kalkm., cortex","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-12-15T01:00:00Z","last_updated_date":"2015-12-15T01:00:00Z","reference_number":"EMA/HMPC/680625/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-prunus-africana-hook-f-kalkm-cortex_en.pdf"},
    {"id":"30571","name":"Draft list of references supporting the assessment of Melilotus officinalis (L.) Lam., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2017-04-12T15:13:00Z","last_updated_date":"2017-04-12T15:13:00Z","reference_number":"EMA/HMPC/350533/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"30743","name":"Final list of references supporting the assessment of Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl., semen","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-02-07T01:00:00Z","last_updated_date":"2012-02-07T01:00:00Z","reference_number":"EMA/HMPC/722366/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-cola-nitida-vent-schott-et-endl-and-its-varieties-and-cola-acuminata-p-beauv-schott-et-endl-semen_en.pdf"},
    {"id":"30991","name":"Superseded list of references for assessment of: Harpagophyti radix Harpagophytum procumbens DC.; Harpagophytum zeyheri Decne (devil's claw root)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2009-03-12T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMEA/HMPC/476255/2007 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-assessment-harpagophyti-radix-harpagophytum-procumbens-dc-harpagophytum-zeyheri-decne-devils-claw-root_en.pdf"},
    {"id":"31052","name":"Superseded list of references supporting the assessment of  Echinacea purpurea (L.) Moench, radix - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-02-10T01:00:00Z","last_updated_date":"2011-02-10T01:00:00Z","reference_number":"EMA/HMPC/577790/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-echinacea-purpurea-l-moench-radix-first-version_en.pdf"},
    {"id":"31073","name":"Draft list of references supporting the assessment of Ginkgo biloba L., folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2014-02-14T01:00:00Z","last_updated_date":"2014-02-14T01:00:00Z","reference_number":"EMA/HMPC/321096/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-ginkgo-biloba-l-folium_en.pdf"},
    {"id":"31084","name":"Final list of references supporting the assessment of Olea europaea L., folium - First version","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T01:00:00Z","last_updated_date":"2018-01-04T01:00:00Z","reference_number":"EMA/HMPC/359237/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-olea-europaea-l-folium-first-version_en.pdf"},
    {"id":"31465","name":"Superseded list of references supporting the assessment report on: Passiflorae herba Passiflora incarnate L., herba (passion flower)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-11-15T00:09:21Z","last_updated_date":"2014-06-19T01:09:21Z","reference_number":"EMEA/HMPC/111180/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-passiflorae-herba-passiflora-incarnate-l-herba-passion-flower_en.pdf"},
    {"id":"31612","name":"Superseded list of references supporting the assessment of Hedera helix L., folium - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-01-18T01:00:00Z","last_updated_date":"2018-08-13T02:00:00Z","reference_number":"EMA/HMPC/706540/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-hedera-helix-l-folium-revision-1_en.pdf"},
    {"id":"31714","name":"Superseded list of references supporting the assessment of Trigonella foenum-graecum L., semen","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2022-08-30T02:00:00Z","last_updated_date":"2022-08-30T02:00:00Z","reference_number":"EMA/HMPC/146222/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-trigonella-foenum-graecum-l-semen_en.pdf"},
    {"id":"31718","name":"Draft list of references supporting the assessment of Harpagophytum procumbens DC. and/or Harpagophytum zeheyri Decne., radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-02-15T12:00:00Z","last_updated_date":"2016-02-15T12:00:00Z","reference_number":"EMA/HMPC/627059/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-harpagophytum-procumbens-dc-andor-harpagophytum-zeheyri-decne-radix_en.pdf"},
    {"id":"31720","name":"Draft list of references supporting the assessment of Paullinia cupana Kunth ex H.B.K. var. sorbilis (Mart.) Ducke, semen - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2012-06-25T12:12:00Z","last_updated_date":"2012-06-25T12:12:00Z","reference_number":"EMA/HMPC/897341/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-paullinia-cupana-kunth-ex-hbk-var-sorbilis-mart-ducke-semen-first-version_en.pdf"},
    {"id":"31735","name":"Superseded list of references supporting the assessment report on: Urticae herba Urtica dioica L.; Urtica urens","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2025-03-07T02:00:00Z","reference_number":"EMEA/HMPC/366106/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-urticae-herba-urtica-dioica-l-urtica-urens_en.pdf"},
    {"id":"31921","name":"Draft list of references supporting the assessment of Plantaginis lanceolatae folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/HMPC/437860/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-plantaginis-lanceolatae-folium_en.pdf"},
    {"id":"31941","name":"Draft list of references supporting the assessment of Fragaria vesca L., Fragaria moschata Weston, Fragaria viridis Weston and Fragaria x ananassa (Weston) Duchesne ex Rozier, folium - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2018-04-11T12:30:00Z","last_updated_date":"2018-04-11T12:30:00Z","reference_number":"EMA/HMPC/432277/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-and-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium-first-version_en.pdf"},
    {"id":"32218","name":"Draft list of references supporting the assessment of Salvia fruticosa Mill., folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-12-09T10:00:00Z","last_updated_date":"2015-12-09T10:00:00Z","reference_number":"EMA/HMPC/599993/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-salvia-fruticosa-mill-folium_en.pdf"},
    {"id":"32254","name":"Final list of references supporting the assessment of Equisetum arvense L. herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-03-17T01:00:00Z","reference_number":"EMA/HMPC/278090/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-equisetum-arvense-l-herba_en.pdf"},
    {"id":"32447","name":"Draft list of references for assessment of: Ribis nigri folium Ribes nigrum L., folium (blackcurrant leaf)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/HMPC/143130/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-ribis-nigri-folium-ribes-nigrum-l-folium-blackcurrant-leaf_en.pdf"},
    {"id":"32448","name":"Draft list of references supporting the assessment of Sisymbrium officinale (L.) Scop., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2014-01-17T01:00:00Z","last_updated_date":"2014-01-17T01:00:00Z","reference_number":"EMA/HMPC/280195/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-sisymbrium-officinale-l-scop-herba_en.pdf"},
    {"id":"32496","name":"Final list of references supporting the assessment of Quercus robur L., Quercus petraea. (Matt.) Liebl., Quercus pubescens Willd., cortex","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-05-18T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMA/HMPC/3205/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-quercus-robur-l-quercus-petraea-matt-liebl-quercus-pubescens-willd-cortex_en.pdf"},
    {"id":"32506","name":"List of references supporting the assessment report on: Anisi fructus and Anisi aetheroleum Pimpinella anisum L., fructus and Pimpinella anisum L., aetheroleum (aniseed and anise oil)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-06-12T02:00:00Z","last_updated_date":"2014-06-17T02:00:00Z","reference_number":"EMEA/HMPC/359388/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-report-anisi-fructus-and-anisi-aetheroleum-pimpinella-anisum-l-fructus-and-pimpinella-anisum-l-aetheroleum-aniseed-and-anise-oil_en.pdf"},
    {"id":"32908","name":"Draft list of references for assessment of: Salviae folium Salvia officinalis L., folium (sage leaf)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2009-01-14T01:00:00Z","last_updated_date":"2009-01-14T01:00:00Z","reference_number":"EMEA/HMPC/331645/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-salviae-folium-salvia-officinalis-l-folium-sage-leaf_en.pdf"},
    {"id":"32916","name":"Final list of references supporting the assessment of Vaccinium myrtillus L., fructus recens and Vaccinium myrtillus L., fructus siccus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"EMA/HMPC/678996/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-vaccinium-myrtillus-l-fructus-recens-and-vaccinium-myrtillus-l-fructus-siccus_en.pdf"},
    {"id":"33317","name":"Draft list of references for assessment of Melissa officinalis L., leaf","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-01-21T01:00:00Z","last_updated_date":"2016-01-21T01:00:00Z","reference_number":"EMEA/HMPC/207739/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-melissa-officinalis-l-leaf_en.pdf"},
    {"id":"33564","name":"Draft list of references supporting the assessment of Glycine max (L.) Merr., oleum","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-07-25T02:00:00Z","last_updated_date":"2016-07-25T02:00:00Z","reference_number":"EMA/HMPC/338916/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-glycine-max-l-merr-oleum_en.pdf"},
    {"id":"33589","name":"Draft list of references for assessment of: Centaurii herba Centaurium erythraea Rafn., herba (centaury herb)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2008-07-03T02:09:21Z","reference_number":"EMEA/HMPC/105618/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-centaurii-herba-centaurium-erythraea-rafn-herba-centaury-herb_en.pdf"},
    {"id":"33614","name":"Final list of references supporting the assessment of Ribes nigrum L., folium - revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T10:03:00Z","last_updated_date":"2017-12-19T10:03:00Z","reference_number":"EMA/HMPC/745349/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-ribes-nigrum-l-folium-revision-1_en.pdf"},
    {"id":"33622","name":"Final list of references supporting the assessment of Verbascum thapsus L., V. densiflorum Bertol. (V. thapsiforme Schrad), and V. phlomoides L., flos","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T02:00:00Z","last_updated_date":"2018-06-22T02:00:00Z","reference_number":"EMA/HMPC/611532/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-verbascum-thapsus-l-v-densiflorum-bertol-v-thapsiforme-schrad-and-v-phlomoides-l-flos_en.pdf"},
    {"id":"33811","name":"Superseded list of references supporting the assessment report on: Anisi fructus and Anisi aetheroleum Pimpinella anisum L., fructus and Pimpinella anisum L., aetheroleum (aniseed and anise oil)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-06-12T02:09:21Z","last_updated_date":"2014-06-18T02:09:21Z","reference_number":"EMEA/HMPC/359388/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-anisi-fructus-and-anisi-aetheroleum-pimpinella-anisum-l-fructus-and-pimpinella-anisum-l-aetheroleum-aniseed-and-anise-oil_en.pdf"},
    {"id":"33863","name":"Supserseded list of references supporting the assessment report on Menthae piperitae aetheroleum Mentha x piperita L., aetheroleum (peppermint oil)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/199469/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/supserseded-list-references-supporting-assessment-report-menthae-piperitae-aetheroleum-mentha-x-piperita-l-aetheroleum-peppermint-oil_en.pdf"},
    {"id":"34164","name":"Final list of references supporting the assessment of Lavandula angustifolia Miller, aetheroleum and Lavandula angustifolia Miller, flos","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-06-13T18:00:00Z","last_updated_date":"2012-06-13T18:00:00Z","reference_number":"EMA/HMPC/143182/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-lavandula-angustifolia-miller-aetheroleum-and-lavandula-angustifolia-miller-flos_en.pdf"},
    {"id":"34303","name":"Final list of references supporting the assessment of Rosa gallica L., Rosa centifolia L., Rosa damascena Mill., flos","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-09-10T02:00:00Z","last_updated_date":"2014-09-10T02:00:00Z","reference_number":"EMA/HMPC/137300/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-rosa-gallica-l-rosa-centifolia-l-rosa-damascena-mill-flos_en.pdf"},
    {"id":"34371","name":"Superseded list of references supporting the assessment report on: Echinaceae purpureae herba Echinacea purpurea (L.) Moench (purple coneflower herb)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-03-06T00:09:21Z","last_updated_date":"2015-04-14T01:09:21Z","reference_number":"EMEA/HMPC/111536/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-echinaceae-purpureae-herba-echinacea-purpurea-l-moench-purple-coneflower-herb_en.pdf"},
    {"id":"34377","name":"Superseded list of references supporting the assessment report on: Eleutherococci radix,  Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix  (eleutherococcus root)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2014-10-06T02:09:21Z","reference_number":"EMEA/249428/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-eleutherococci-radix-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix-eleutherococcus-root_en.pdf"},
    {"id":"34562","name":"Draft list of references supporting the assessment of Agrimonia eupatoria L., herba - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/HMPC/18031/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-agrimonia-eupatoria-l-herba-first-version_en.pdf"},
    {"id":"34613","name":"Superseded list of references supporting the assessment report on Absinthii herba  Artemisia absinthium L., herba (wormwood) - First version","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2017-10-05T02:00:00Z","reference_number":"EMEA/HMPC/234497/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-absinthii-herba-artemisia-absinthium-l-herba-wormwood-first-version_en.pdf"},
    {"id":"34641","name":"Final list of references supporting the assessment of Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-07-10T14:00:00Z","last_updated_date":"2012-07-10T14:00:00Z","reference_number":"EMA/HMPC/337076/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-or-their-mixtures-flos-first-version_en.pdf"},
    {"id":"34700","name":"Superseded list of references supporting the assessment report on: Rusci aculeati rhizoma Ruscus aculeatus L., rhizoma (butcher's broom)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2019-05-02T17:00:00Z","reference_number":"EMEA/HMPC/372915/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-rusci-aculeati-rhizoma-ruscus-aculeatus-l-rhizoma-butchers-broom_en.pdf"},
    {"id":"34890","name":"Superseded list of references supporting the assessment of Cynara scolymus L., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T01:00:00Z","last_updated_date":"2011-12-21T01:00:00Z","reference_number":"EMA/HMPC/150213/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-cynara-scolymus-l-folium_en.pdf"},
    {"id":"34957","name":"Superseded list of references supporting the assessment report on: Althaeae radix Althaea officinalis L., radix (marshmallow root)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2009-05-14T02:09:21Z","last_updated_date":"2016-11-04T14:42:00Z","reference_number":"EMEA/HMPC/98716/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-althaeae-radix-althaea-officinalis-l-radix-marshmallow-root_en.pdf"},
    {"id":"35057","name":"Draft list of references supporting the assessment of Tilia tomentosa Moench, flos","type":"herbal-references","status":"Draft","consultation_date":"2011-09-13 - 2012-02-15","first_published_date":"2011-10-20T04:00:00Z","last_updated_date":"2011-10-20T04:00:00Z","reference_number":"EMA/HMPC/346776/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-tilia-tomentosa-moench-flos_en.pdf"},
    {"id":"35080","name":"Draft list of references supporting the assessment of Rubus idaeus L., folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/HMPC/44210/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-rubus-idaeus-l-folium_en.pdf"},
    {"id":"35121","name":"Draft list of references for assessment of: Harpagophyti radix Harpagophytum procumbens DC.; Harpagophytum zeyheri Decne (devil's claw root)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-01-10T01:00:00Z","last_updated_date":"2008-01-10T01:00:00Z","reference_number":"EMEA/HMPC/476255/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-harpagophyti-radix-harpagophytum-procumbens-dc-harpagophytum-zeyheri-decne-devils-claw-root_en.pdf"},
    {"id":"35139","name":"Draft list of references supporting the assessment of Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl), folium and fructus – Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2017-10-12T13:00:00Z","last_updated_date":"2017-10-12T13:00:00Z","reference_number":"EMA/HMPC/228760/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-folium-and-fructus-revision-1_en.pdf-0"},
    {"id":"35196","name":"Draft list of references supporting the assessment of Allium sativum L., bulbus","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2016-07-25T02:00:00Z","last_updated_date":"2016-07-25T02:00:00Z","reference_number":"EMA/HMPC/7687/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-allium-sativum-l-bulbus_en.pdf"},
    {"id":"35219","name":"Draft list of references for assessment of: Urticae herba Urtica dioica L.; Urtica urens L., herba (nettle herb)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-09-07T02:00:00Z","last_updated_date":"2007-09-07T02:00:00Z","reference_number":"EMEA/HMPC/366106/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-urticae-herba-urtica-dioica-l-urtica-urens-l-herba-nettle-herb_en.pdf"},
    {"id":"35256","name":"Draft list of references for assessment of: Sambuci flos Sambucus nigra L. flos (elder flower)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-09-07T02:09:21Z","last_updated_date":"2007-09-07T02:09:21Z","reference_number":"EMEA/HMPC/283842/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-sambuci-flos-sambucus-nigra-l-flos-elder-flower_en.pdf"},
    {"id":"35261","name":"Superseded list of references supporting the assessment report of Pimpinella anisum L., fructus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-01-20T01:00:00Z","last_updated_date":"2016-01-20T01:00:00Z","reference_number":"EMEA/HMPC/359388/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-pimpinella-anisum-l-fructus_en.pdf"},
    {"id":"35263","name":"Draft list of references supporting the assessment of Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-references","status":"Draft","consultation_date":"2011-05-15 - 2011-08-15","first_published_date":"2011-05-30T04:00:00Z","last_updated_date":"2015-02-10T02:00:00Z","reference_number":"EMA/HMPC/85125/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"35498","name":"Final list of references supporting the assessment of Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny), herba cum flore","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-10-13T11:40:00Z","last_updated_date":"2011-10-13T11:40:00Z","reference_number":"EMA/HMPC/131736/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-viola-arvensis-murray-gaud-and-viola-vulgaris-koch-oborny-herba-cum-flore_en.pdf"},
    {"id":"35501","name":"Final list of references supporting the assessment of Hieracium pilosella L., herba cum radice - Superseded","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2015-06-17T13:25:00Z","last_updated_date":"2025-02-26T13:25:00Z","reference_number":"EMA/HMPC/35510/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-hieracium-pilosella-l-herba-cum-radice-superseded_en.pdf"}    {"id":"35574","name":"Draft list of references supporting the assessment of Potentilla erecta (L.) Raeusch., rhizome","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/HMPC/5517/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-potentilla-erecta-l-raeusch-rhizome_en.pdf"},
    {"id":"35600","name":"Draft list of references supporting the assessment of Matricaria recutita L., flos and Matricaria recutita L., aetheroleum - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2014-07-24T02:00:00Z","last_updated_date":"2014-07-24T02:00:00Z","reference_number":"EMA/HMPC/55810/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-matricaria-recutita-l-flos-and-matricaria-recutita-l-aetheroleum-first-version_en.pdf"},
    {"id":"35639","name":"Superseded list of references supporting the assessment report on: Meliloti herba Melilotus officinalis (L.) Lam. (melilot)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2018-04-23T02:00:00Z","reference_number":"EMEA/HMPC/476396/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-meliloti-herba-melilotus-officinalis-l-lam-melilot_en.pdf"},
    {"id":"36211","name":"Draft list of references supporting the assessment of Viola tricolor L.","type":"herbal-references","status":"Draft","consultation_date":"2010-05-15 - 2010-08-15","first_published_date":"2010-05-28T04:00:00Z","last_updated_date":"2010-05-28T04:00:00Z","reference_number":"EMA/HMPC/131736/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-viola-tricolor-l_en.pdf"},
    {"id":"36336","name":"Draft list of references supporting the assessment of Vaccinium myrtillus L., fructus","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-02-09T01:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMA/HMPC/678996/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-vaccinium-myrtillus-l-fructus_en.pdf"},
    {"id":"36493","name":"Draft list of references for assessment of Meliloti herba Melilotus officinalis (L.) Lam. (melilot)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/HMPC/476396/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-meliloti-herba-melilotus-officinalis-l-lam-melilot_en.pdf"},
    {"id":"36552","name":"Final list of references supporting the assessment of Assessment report on Arctium lappa L., radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"EMA/HMPC/246770/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-assessment-report-arctium-lappa-l-radix_en.pdf"},
    {"id":"36676","name":"Draft list of references supporting the assessment report on Echinaceae pallidae radix Echinacea pallida (Nutt.) Nutt., radix (pale coneflower root)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/332366/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-report-echinaceae-pallidae-radix-echinacea-pallida-nutt-nutt-radix-pale-coneflower-root_en.pdf"},
    {"id":"36758","name":"Final list of references supporting the assessment of Valeriana officinalis L., radix and Valeriana officinalis L., aetheroleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-04-27T12:00:00Z","last_updated_date":"2016-06-20T12:00:00Z","reference_number":"EMA/HMPC/150847/2015 corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-valeriana-officinalis-l-radix-and-valeriana-officinalis-l-aetheroleum_en.pdf-0"},
    {"id":"36822","name":"Final list of references supporting the assessment of Glycine max (L.) Merr., oleum raffinatum","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2017-03-03T10:19:00Z","last_updated_date":"2017-03-03T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-glycine-max-l-merr-oleum-raffinatum_en.pdf"},
    {"id":"36831","name":"Draft list of references supporting the assessment of Pistacia lentiscus L., resin (mastic)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-07-22T02:00:00Z","last_updated_date":"2015-07-22T10:20:00Z","reference_number":"EMA/HMPC/46757/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-pistacia-lentiscus-l-resin-mastic_en.pdf"},
    {"id":"36930","name":"Draft list of references supporting the assessment of Sambucus nigra L., fructus","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-04-19T02:00:00Z","last_updated_date":"2013-04-19T02:00:00Z","reference_number":"EMA/HMPC/44212/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-sambucus-nigra-l-fructus_en.pdf"},
    {"id":"36955","name":"Superseded final list of references supporting the assessment of Achillea millefolium L., herba - First version","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2011-09-30T02:00:00Z","last_updated_date":"2011-09-30T02:00:00Z","reference_number":"EMA/HMPC/290282/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-final-list-references-supporting-assessment-achillea-millefolium-l-herba-first-version_en.pdf"},
    {"id":"36958","name":"Final list of references supporting the assessment of Glycine max (L.) Merr., semen - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-07-31T02:00:00Z","last_updated_date":"2018-07-31T02:00:00Z","reference_number":"EMA/HMPC/607531/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-glycine-max-l-merr-semen-first-version_en.pdf"},
    {"id":"37020","name":"Superseded list of references supporting the assessment report on: Melissae folium Melissa officinalis L. (melissa leaf)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"EMEA/HMPC/207739/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-melissae-folium-melissa-officinalis-l-melissa-leaf_en.pdf"},
    {"id":"37065","name":"Draft list of references supporting the assessment of Cetraria islandica (L.) Acharius s.l., thallus - First version","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2014-05-19T02:00:00Z","last_updated_date":"2014-05-19T02:00:00Z","reference_number":"EMA/HMPC/36865/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-cetraria-islandica-l-acharius-sl-thallus-first-version_en.pdf"},
    {"id":"37356","name":"Draft list of references supporting the assessment of Piper methysticum G. Forst., rhizoma","type":"herbal-references","status":"unknown","consultation_date":"2016-12-15 - 2017-03-15","first_published_date":"2016-12-15T11:35:00Z","last_updated_date":"2016-12-15T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-piper-methysticum-g-forst-rhizoma_en.pdf"},
    {"id":"37358","name":"Final list of references supporting the assessment of Sambucus nigra L. - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-06-27T17:00:00Z","last_updated_date":"2018-06-27T17:00:00Z","reference_number":"EMA/HMPC/611509/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-sambucus-nigra-l-revision-1_en.pdf"},
    {"id":"37408","name":"Superseded list of references for assessment of: Boldi folium Peumus boldus Molina, folium (boldo leaf)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2009-01-14T00:09:21Z","last_updated_date":"2017-01-12T10:12:00Z","reference_number":"EMEA/HMPC/591649/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-assessment-boldi-folium-peumus-boldus-molina-folium-boldo-leaf_en.pdf"},
    {"id":"37418","name":"Draft list of references supporting the assessment of Vaccinium myrtillus L., fructus","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-02-09T01:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMA/HMPC/678996/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-vaccinium-myrtillus-l-fructus_en.pdf-0"},
    {"id":"37564","name":"Final list of references supporting the assessment of Ononis spinosa L., radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2014-05-28T02:00:00Z","last_updated_date":"2014-05-28T02:00:00Z","reference_number":"EMA/HMPC/138319/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-ononis-spinosa-l-radix_en.pdf"},
    {"id":"37572","name":"Final list of references supporting the assessment of Vitis vinifera L., folium - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2018-01-05T01:00:00Z","last_updated_date":"2018-01-05T01:00:00Z","reference_number":"EMA/HMPC/464683/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-vitis-vinifera-l-folium-revision-1_en.pdf"},
    {"id":"37645","name":"Final list of references supporting the assessment of Origanum majorana L., herba","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T11:32:00Z","last_updated_date":"2016-11-15T11:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-origanum-majorana-l-herba_en.pdf"},
    {"id":"37714","name":"Draft list of references supporting the assessment of Juglans regia L., folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-01-25T01:00:00Z","last_updated_date":"2013-01-25T01:00:00Z","reference_number":"EMA/HMPC/346742/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-juglans-regia-l-folium_en.pdf"},
    {"id":"37845","name":"Superseded list of references for assessment of: Rhei radix Rheum palmatum L.; Rheum officinale Baillon (rhubarb)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2008-06-05T02:09:00Z","last_updated_date":"2020-08-18T02:09:00Z","reference_number":"EMEA/HMPC/189625/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-assessment-rhei-radix-rheum-palmatum-l-rheum-officinale-baillon-rhubarb_en.pdf"},
    {"id":"37850","name":"Final list of references supporting the assessment report on: Hamamelidis cortex, Hamamelidis folium, Hamamelidis folium et cortex aut ramunculus destillatum; Hamamelis virginiana L. (hamamelis bark, hamamelis leaf, hama...","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMA/HMPC/115209/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-report-hamamelidis-cortex-hamamelidis-folium-hamamelidis-folium-et-cortex-aut-ramunculus-destillatum-hamamelis-virginiana-l-hamamelis-bark-hamamelis-leaf_en.pdf"},
    {"id":"38101","name":"Draft list of references supporting the assessment of Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-10-20T02:00:00Z","last_updated_date":"2011-10-20T02:00:00Z","reference_number":"EMA/HMPC/337076/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-or-their-mixtures-flos-first-version_en.pdf"},
    {"id":"38128","name":"Final list of references supporting the assessment of Echinacea purpurea (L.) Moench., herba recens","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-04-13T02:00:00Z","last_updated_date":"2015-04-13T02:00:00Z","reference_number":"EMA/HMPC/261891/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-echinacea-purpurea-l-moench-herba-recens_en.pdf"},
    {"id":"38463","name":"Final list of references supporting the assessment of Angelica sinensis (Oliv.) Diels, radix - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-11-25T01:00:00Z","last_updated_date":"2013-11-25T01:00:00Z","reference_number":"EMA/HMPC/681358/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-angelica-sinensis-oliv-diels-radix-first-version_en.pdf"},
    {"id":"38477","name":"Superseded list of references supporting the assessment of Juniperi pseudo-fructus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-02-16T01:00:00Z","last_updated_date":"2023-06-13T01:00:00Z","reference_number":"EMA/HMPC/442959/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-juniperi-pseudo-fructus_en.pdf"},
    {"id":"38569","name":"Superseded list of references supporting the assessment of Salix [various species including S. purpurea L., S. daphnoides Vill., S. fragilis L.], cortex","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2009-09-26T02:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMEA/HMPC/394997/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-salix-various-species-including-s-purpurea-l-s-daphnoides-vill-s-fragilis-l-cortex_en.pdf"},
    {"id":"38660","name":"Draft list of references supporting the assessment of Lavandula angustifolia Mill., aetheroleum and Lavandula angustifolia Mill., flos","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-06-16T02:00:00Z","last_updated_date":"2011-06-16T02:00:00Z","reference_number":"EMA/HMPC/143182/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-lavandula-angustifolia-mill-aetheroleum-and-lavandula-angustifolia-mill-flos_en.pdf"},
    {"id":"38735","name":"Final list of references supporting the assessment of Viscum album L., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-08-01T17:05:00Z","last_updated_date":"2013-08-01T17:05:00Z","reference_number":"EMEA/HMPC/246781/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-viscum-album-l-herba_en.pdf"},
    {"id":"38736","name":"Superseded list of references supporting the assessment report on Curcumae longae rhizoma Curcuma longa L., rhizoma (turmeric root) -  First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2010-02-04T01:00:00Z","last_updated_date":"2010-02-04T01:00:00Z","reference_number":"EMA/HMPC/456910/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-curcumae-longae-rhizoma-curcuma-longa-l-rhizoma-turmeric-root-first-version_en.pdf"},
    {"id":"39119","name":"Final list of references supporting the assessment of Primula veris L. and / or Primula elatior (L.) Hill, flos","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2013-03-04T01:00:00Z","last_updated_date":"2013-03-04T01:00:00Z","reference_number":"EMA/HMPC/136584/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-primula-veris-l-and-or-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"39132","name":"Final list of references supporting the assessment of Ginkgo biloba L., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2015-04-08T02:00:00Z","reference_number":"EMA/HMPC/321096/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-ginkgo-biloba-l-folium_en.pdf"},
    {"id":"39308","name":"Draft list of references supporting the assessment of Echinaceae angustifolia DC., radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-07-28T02:00:00Z","last_updated_date":"2011-07-28T02:00:00Z","reference_number":"EMA/HMPC/688215/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-echinaceae-angustifolia-dc-radix_en.pdf"},
    {"id":"39466","name":"Final list of references supporting the assessment of Cimicifuga racemosa (L.) Nutt., rhizoma - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-07-03T02:00:00Z","last_updated_date":"2018-07-03T02:00:00Z","reference_number":"EMA/HMPC/193919/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-cimicifuga-racemosa-l-nutt-rhizoma-revision-1_en.pdf"},
    {"id":"39661","name":"Superseded list of references supporting the assessment of Primulae flos Primula veris L.  and Primula elatior (L.) Hill (primula flower)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2010-04-09T02:00:00Z","last_updated_date":"2010-04-09T02:00:00Z","reference_number":"EMA/HMPC/111633/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-primulae-flos-primula-veris-l-and-primula-elatior-l-hill-primula-flower_en.pdf"},
    {"id":"39810","name":"Final list of references supporting the assessment of Cichorium intybus L., radix","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-03-14T16:00:00Z","last_updated_date":"2013-03-14T16:00:00Z","reference_number":"EMA/HMPC/113046/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-cichorium-intybus-l-radix_en.pdf"},
    {"id":"39870","name":"Draft list of references supporting the assessment of Arnica montana L., flos","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2013-08-22T02:00:00Z","last_updated_date":"2013-08-22T02:00:00Z","reference_number":"EMA/HMPC/198792/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-arnica-montana-l-flos_en.pdf"},
    {"id":"39950","name":"Final list of references supporting the assessment of Commiphora molmol Engler, gummi-resina","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T15:00:00Z","last_updated_date":"2011-12-22T15:00:00Z","reference_number":"EMA/HMPC/16634/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-commiphora-molmol-engler-gummi-resina_en.pdf"},
    {"id":"40002","name":"Draft European Union herbal monograph on Echinacea purpurea (L.) Moench, radix","type":"herbal-references","status":"unknown","consultation_date":"2016-12-15 - 2017-03-15","first_published_date":"2016-12-15T11:00:00Z","last_updated_date":"2016-12-15T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-european-union-herbal-monograph-echinacea-purpurea-l-moench-radix_en.pdf"},
    {"id":"40042","name":"Draft list of references supporting the assessment of Pelargonium sidoides DC and / or Pelargonium reniforme Curt., radix","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-06-20T02:00:00Z","last_updated_date":"2011-06-20T02:00:00Z","reference_number":"EMA/HMPC/560963/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-pelargonium-sidoides-dc-and-or-pelargonium-reniforme-curt-radix_en.pdf-0"},
    {"id":"40096","name":"Draft list of references supporting the assessment on Zingiberis rhizoma","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-09-20T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"EMA/HMPC/577856/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-zingiberis-rhizoma_en.pdf"},
    {"id":"40100","name":"Final list of references supporting the assessment of Capsella bursa-pastoris (L.) Medikus, herba  - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T15:30:00Z","last_updated_date":"2011-12-22T15:30:00Z","reference_number":"EMA/HMPC/543735/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-capsella-bursa-pastoris-l-medikus-herba-first-version_en.pdf"},
    {"id":"40507","name":"Draft list of references for assessment of: Echinaceae purpureae herba Echinacea purpurea (L.) Moench (purple coneflower herb)","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2007-03-08T00:09:21Z","last_updated_date":"2007-03-08T00:09:21Z","reference_number":"EMEA/HMPC/111536/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-echinaceae-purpureae-herba-echinacea-purpurea-l-moench-purple-coneflower-herb_en.pdf"},
    {"id":"40528","name":"Superseded list of references supporting the assessment of Oenothera biennis L.; Oenothera lamarckiana L., oleum - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2012-04-02T11:26:00Z","last_updated_date":"2018-10-10T11:26:00Z","reference_number":"EMA/HMPC/277817/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-oenothera-biennis-l-oenothera-lamarckiana-l-oleum-first-version_en.pdf"},
    {"id":"40560","name":"Draft list of references supporting the assessment of Uncaria tomentosa (Willd. ex Schult.) DC., cortex","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-04-15T11:00:00Z","last_updated_date":"2015-04-15T11:00:00Z","reference_number":"EMA/HMPC/259599/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-uncaria-tomentosa-willd-ex-schult-dc-cortex_en.pdf"},
    {"id":"40612","name":"Second draft list of references supporting the assessment of Urtica dioica L., Urtica urens L., their hybrids or their mixtures, radix - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2011-10-19T17:00:00Z","last_updated_date":"2011-10-19T17:00:00Z","reference_number":"EMA/HMPC/461158/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/second-draft-list-references-supporting-assessment-urtica-dioica-l-urtica-urens-l-their-hybrids-or-their-mixtures-radix-first-version_en.pdf"},
    {"id":"40627","name":"Draft list of references for assessment of: Hyperici herba  Hypericum perforatum L.  (St. John´s wort) - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/101620/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-hyperici-herba-hypericum-perforatum-l-st-johns-wort-first-version_en.pdf"},
    {"id":"40632","name":"Draft list of references supporting the assessment of Capsicum annuum L. var. minimum (Miller) Heiser and small fruited varieties of Capsicum frutescens L., fructus","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2014-09-12T02:00:00Z","last_updated_date":"2014-09-12T02:00:00Z","reference_number":"EMA/HMPC/36892/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-capsicum-annuum-l-var-minimum-miller-heiser-and-small-fruited-varieties-capsicum-frutescens-l-fructus_en.pdf"},
    {"id":"40804","name":"Superseded final list of references supporting the assessment of Tanacetum parthenium (L.) Schulz Bip., herba - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-06-20T02:00:00Z","last_updated_date":"2020-08-14T02:00:00Z","reference_number":"EMA/HMPC/587580/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-final-list-references-supporting-assessment-tanacetum-parthenium-l-schulz-bip-herba-first-version_en.pdf"},
    {"id":"40837","name":"Final list of references supporting the assessment of Aloe barbadensis Mill. and Aloe (various species, mainly Aloe ferox Mill. and its hybrids), folii succus siccatus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2017-04-10T02:00:00Z","last_updated_date":"2017-04-10T02:00:00Z","reference_number":"EMEA/HMPC/759584/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf"},
    {"id":"40893","name":"Final list of references supporting the assessment of Matricaria recutita L., flos and Matricaria recutita L., aetheroleum","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2016-04-05T02:00:00Z","last_updated_date":"2016-04-05T02:00:00Z","reference_number":"EMA/HMPC/55810/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-matricaria-recutita-l-flos-and-matricaria-recutita-l-aetheroleum_en.pdf"},
    {"id":"41032","name":"Superseded list of references supporting the assessment report on Echinaceae pallidae Radix Echinacea pallida (Nutt.) Nutt., radix (pale coneflower root)","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:09:21Z","last_updated_date":"2018-08-14T02:09:21Z","reference_number":"EMEA/HMPC/332366/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-report-echinaceae-pallidae-radix-echinacea-pallida-nutt-nutt-radix-pale-coneflower-root_en.pdf"},
    {"id":"41117","name":"Draft list of references supporting the assessment of Vitis\n\nvinifera L., folium","type":"herbal-references","status":"unknown","consultation_date":"2016-12-15 - 2017-03-15","first_published_date":"2016-12-15T11:54:00Z","last_updated_date":"2016-12-15T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-vitis-vinifera-l-folium_en.pdf"},
    {"id":"41139","name":"Superseded list of references supporting the assessment of Arctostaphylos uva-ursi (L.) Spreng., folium - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2018-04-11T14:00:00Z","reference_number":"EMA/HMPC/573461/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/superseded-list-references-supporting-assessment-arctostaphylos-uva-ursi-l-spreng-folium-revision-1_en.pdf"},
    {"id":"41773","name":"Final list of references supporting the assessment of Cetraria islandica (L.) Acharius s.l., thallus - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2015-02-11T11:45:00Z","last_updated_date":"2015-02-11T11:45:00Z","reference_number":"EMA/HMPC/36865/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-cetraria-islandica-l-acharius-sl-thallus-first-version_en.pdf"},
    {"id":"41860","name":"Final list of references supporting the assessment of Matricaria recutita L., flos and Matricaria recutita L., aetheroleum - First version","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2016-04-05T17:30:00Z","last_updated_date":"2016-04-05T17:30:00Z","reference_number":"EMA/HMPC/55810/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-matricaria-recutita-l-flos-and-matricaria-recutita-l-aetheroleum-first-version_en.pdf"},
    {"id":"41893","name":"Final list of references supporting the assessment of Paeonia lactiflora Pallas, radix (Paeoniae radix alba)","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2017-04-25T16:47:00Z","last_updated_date":"2017-04-25T16:47:00Z","reference_number":"EMA/HMPC/150788/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-paeonia-lactiflora-pallas-radix-paeoniae-radix-alba_en.pdf"},
    {"id":"41916","name":"Final list of references supporting the assessment of Marrubium vulgare L., herba  - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2013-08-01T17:00:00Z","last_updated_date":"2013-08-01T17:00:00Z","reference_number":"EMA/HMPC/604272/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-marrubium-vulgare-l-herba-first-version_en.pdf"},
    {"id":"42008","name":"Final list of references supporting the assessment of Melilotus officinalis (L.) Lam., herba","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2018-04-23T16:10:00Z","last_updated_date":"2018-04-23T16:10:00Z","reference_number":"EMA/HMPC/350533/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-melilotus-officinalis-l-lam-herba_en.pdf"},
    {"id":"42137","name":"Final list of references supporting the assessment of Silybum marianum (L.) Gaertn., fructus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-09-19T02:00:00Z","last_updated_date":"2018-09-19T02:00:00Z","reference_number":"EMA/HMPC/278220/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-silybum-marianum-l-gaertn-fructus_en.pdf"},
    {"id":"42258","name":"Final list of references supporting the assessment of Vitex agnus-castus L., fructus - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T11:26:00Z","last_updated_date":"2018-10-10T11:26:00Z","reference_number":"EMA/HMPC/795807/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-vitex-agnus-castus-l-fructus-revision-1_en.pdf"},
    {"id":"42263","name":"Final list of references supporting the assessment of Oenothera biennis L.; Oenothera lamarckiana L., oleum - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2018-10-10T13:00:00Z","last_updated_date":"2018-10-10T13:00:00Z","reference_number":"EMA/HMPC/753040/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-oenothera-biennis-l-oenothera-lamarckiana-l-oleum-revision-1_en.pdf"},
    {"id":"43477","name":"Final list of references supporting the assessment of Curcuma longa L., rhizoma - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2019-01-24T16:28:00Z","last_updated_date":"2019-01-24T16:28:00Z","reference_number":"EMA/434955/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-curcuma-longa-l-rhizoma-revision-1_en.pdf"},
    {"id":"43662","name":"Final list of references supporting the assessment of Cynara cardunculus L. (syn. Cynara scolymus L.), folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2019-02-07T12:10:00Z","last_updated_date":"2019-02-07T12:10:00Z","reference_number":"EMA/HMPC/194012/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-cynara-cardunculus-l-syn-cynara-scolymus-l-folium_en.pdf"},
    {"id":"43722","name":"Draft list of references supporting the assessment of Rhamnus frangula L., cortex - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T12:45:00Z","last_updated_date":"2019-02-15T12:45:00Z","reference_number":"EMA/HMPC/909254/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-rhamnus-frangula-l-cortex-revision-1_en.pdf"},
    {"id":"43865","name":"Final list of references supporting the assessment of Malva sylvestris L. and/or Malva neglecta Wallr., folium and Malva sylvestris L., flos - First version","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2019-03-19T12:36:00Z","last_updated_date":"2019-03-19T12:36:00Z","reference_number":"EMA/HMPC/749540/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-malva-sylvestris-l-andor-malva-neglecta-wallr-folium-and-malva-sylvestris-l-flos-first-version_en.pdf"},
    {"id":"44065","name":"Final list of references supporting the assessment of Malva sylvestris L. and/or Malva neglecta Wallr., folium and Malva sylvestris L., flos - First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2019-03-19T17:03:00Z","last_updated_date":"2019-03-19T17:03:00Z","reference_number":"EMA/HMPC/749540/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-malva-sylvestris-l-andor-malva-neglecta-wallr-folium-and-malva-sylvestris-l-flos-first-version_en.pdf-0"},
    {"id":"44406","name":"List of references supporting the assessment of Gentiana lutea L., radix - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2019-04-30T14:52:00Z","last_updated_date":"2019-04-30T14:52:00Z","reference_number":"EMA/HMPC/607862/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-gentiana-lutea-l-radix-revision-1_en.pdf"},
    {"id":"44422","name":"List of references supporting the assessment of Ruscus aculeatus L., rhizoma - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2019-05-02T17:44:00Z","last_updated_date":"2019-05-02T17:44:00Z","reference_number":"EMA/HMPC/188806/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-ruscus-aculeatus-l-rhizoma-revision-1_en.pdf"},
    {"id":"44509","name":"Final list of references supporting the assessment of Fragaria vesca L., Fragaria moschata Weston, Fragaria viridis Weston and Fragaria x ananassa (Weston) Duchesne ex Rozier, folium","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2019-05-15T17:45:00Z","last_updated_date":"2019-05-15T17:45:00Z","reference_number":"EMA/HMPC/432277/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-and-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium_en.pdf"},
    {"id":"44727","name":"Draft list of references supporting the assessment of Mentha x piperita L., folium and aetheroleum - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2019-06-18T08:46:00Z","last_updated_date":"2019-06-18T08:46:00Z","reference_number":"EMA/HMPC/522408/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-mentha-x-piperita-l-folium-and-aetheroleum-revision-1_en.pdf"},
    {"id":"44736","name":"Draft list of references supporting the assessment of Aesculus hippocastanum L., semen - Revision 1","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2019-06-15 - 2019-09-15","first_published_date":"2019-06-18T16:01:00Z","last_updated_date":"2019-06-18T16:01:00Z","reference_number":"EMA/HMPC/638245/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-aesculus-hippocastanum-l-semen-revision-1_en.pdf"},
    {"id":"45688","name":"Draft list of references supporting the assessment of Rhamnus purshiana DC., cortex - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2019-10-15T09:00:00Z","last_updated_date":"2019-10-15T09:00:00Z","reference_number":"EMA/HMPC/14806/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-rhamnus-purshiana-dc-cortex-revision-1_en.pdf"},
    {"id":"45689","name":"Draft list of references supporting the assessment of Rheum palmatum L. and Rheum officinale Baillon, radix - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2019-10-15T09:00:00Z","last_updated_date":"2019-10-15T09:00:00Z","reference_number":"EMA/HMPC/113699/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-rheum-palmatum-l-and-rheum-officinale-baillon-radix-revision-1_en.pdf"},
    {"id":"45690","name":"Draft list of references supporting the assessment of Tanacetum parthenium (L.) Schultz Bip., herba - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2019-10-15T09:00:00Z","last_updated_date":"2019-10-15T09:00:00Z","reference_number":"EMA/HMPC/48714/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-tanacetum-parthenium-l-schultz-bip-herba-revision-1_en.pdf"},
    {"id":"45691","name":"Draft list of references supporting the assessment of Thymus vulgaris L., Thymus zygis L., aetheroleum - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2019-10-15T09:00:00Z","last_updated_date":"2019-10-15T09:00:00Z","reference_number":"EMA/HMPC/52978/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-thymus-vulgaris-l-thymus-zygis-l-aetheroleum-revision-1_en.pdf"},
    {"id":"46227","name":"List of references supporting the assessment of Rhamnus frangula L., cortex - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2019-12-04T12:45:00Z","last_updated_date":"2019-12-04T12:45:00Z","reference_number":"EMA/HMPC/909254/2019 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-rhamnus-frangula-l-cortex-revision-1_en.pdf"},
    {"id":"46338","name":"Draft list of references supporting the assessment of Herniaria glabra L., H. hirsuta L., H. incana Lam., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2019-12-19T11:18:00Z","last_updated_date":"2019-12-19T11:18:00Z","reference_number":"EMA/HMPC/554034/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-herniaria-glabra-l-h-hirsuta-l-h-incana-lam-herba_en.pdf"},
    {"id":"46511","name":"List of references supporting the assessment of Valeriana officinalis L., radix and Humulus lupulus L., flos - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T15:53:00Z","last_updated_date":"2020-01-23T15:53:00Z","reference_number":"EMA/HMPC/441802/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"46652","name":"Draft list of references supporting the assessment of Achillea millefolium L., herba - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2020-01-31T16:40:00Z","last_updated_date":"2020-01-31T16:40:00Z","reference_number":"EMA/HMPC/509104/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-achillea-millefolium-l-herba-revision-1_en.pdf"},
    {"id":"47301","name":"Final list of references supporting the assessment of Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl) 1, folium and fructus- Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T16:13:00Z","last_updated_date":"2020-04-02T16:13:00Z","reference_number":"EMA/HMPC/228760/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-1-folium-and-fructus-revision-1_en.pdf"},
    {"id":"47306","name":"Final list of references supporting the assessment of Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl) 1, folium and fructus- Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T16:46:00Z","last_updated_date":"2020-04-02T16:46:00Z","reference_number":"EMA/HMPC/228760/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-1-folium-and-fructus-revision-1_en.pdf-0"},
    {"id":"47462","name":"List of references supporting the assessment of Aesculus hippocastanum L., semen Final - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2020-04-23T13:25:00Z","last_updated_date":"2020-04-23T13:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf"},
    {"id":"47496","name":"Final list of references supporting the assessment of Allium sativum L., bulbus","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2020-04-28T10:38:00Z","last_updated_date":"2020-04-28T10:38:00Z","reference_number":"EMA/HMPC/7687/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-allium-sativum-l-bulbus_en.pdf"},
    {"id":"47563","name":"Final list of references supporting the assessment of Pistacia lentiscus L., resin (mastic)","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2020-05-05T11:05:00Z","last_updated_date":"2020-05-05T11:05:00Z","reference_number":"EMA/HMPC/46757/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-pistacia-lentiscus-l-resin-mastic_en.pdf"},
    {"id":"47789","name":"Draft list of references supporting the assessment of Species sedativae","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2020-05-29T02:00:00Z","last_updated_date":"2020-05-29T02:00:00Z","reference_number":"EMA/HMPC/735707/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-species-sedativae_en.pdf"},
    {"id":"47796","name":"Draft list of references supporting the assessment of Species amarae","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2020-05-28T14:45:00Z","last_updated_date":"2020-05-28T14:45:00Z","reference_number":"EMA/HMPC/97854/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-species-amarae_en.pdf"},
    {"id":"47819","name":"Draft list of references supporting the assessment of Aloysia citrodora Paláu (syn. Aloysia triphylla (L'Hér.) Kuntze; Verbena triphylla L'Hér.; Lippia citriodora Kunth), folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2020-05-29T02:00:00Z","last_updated_date":"2020-05-29T02:00:00Z","reference_number":"EMA/HMPC/643161/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-aloysia-citrodora-palau-syn-aloysia-triphylla-lher-kuntze-verbena-triphylla-lher-lippia-citriodora-kunth-folium_en.pdf"},
    {"id":"48415","name":"List of references supporting the assessment of Mentha x piperita L., folium and aetheroleum - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T08:47:00Z","last_updated_date":"2020-07-24T08:47:00Z","reference_number":"EMA/HMPC/522408/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-mentha-x-piperita-l-folium-and-aetheroleum-revision-1_en.pdf"},
    {"id":"48423","name":"Final list of references supporting the assessment of Rhamnus purshiana DC., cortex - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2020-07-27T09:50:00Z","last_updated_date":"2020-07-27T09:50:00Z","reference_number":"EMA/HMPC/14806/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-rhamnus-purshiana-dc-cortex-revision-1_en.pdf"},
    {"id":"48613","name":"Final list of references supporting the assessment of Tanacetum parthenium (L.) Schultz Bip., herba - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2020-08-14T11:32:00Z","last_updated_date":"2020-08-14T11:32:00Z","reference_number":"EMA/HMPC/48714/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-tanacetum-parthenium-l-schultz-bip-herba-revision-1_en.pdf"},
    {"id":"48620","name":"Final list of references supporting the assessment of Rheum palmatum L. and Rheum officinale Baillon, radix – Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2020-08-18T15:48:00Z","last_updated_date":"2020-08-18T15:48:00Z","reference_number":"EMA/HMPC/113699/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-rheum-palmatum-l-and-rheum-officinale-baillon-radix-revision-1_en.pdf"},
    {"id":"48637","name":"Final list of references supporting the assessment of Herniaria glabra L., H. hirsuta L., H. incana Lam., herba","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T14:47:00Z","last_updated_date":"2020-08-19T14:47:00Z","reference_number":"EMA/HMPC/554034/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-herniaria-glabra-l-h-hirsuta-l-h-incana-lam-herba_en.pdf"},
    {"id":"48871","name":"Final List of references supporting the assessment of Thymus vulgaris L., Thymus zygis L., aetheroleum - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2020-09-21T15:59:00Z","last_updated_date":"2020-09-21T15:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-thymus-vulgaris-l-thymus-zygis-l-aetheroleum-revision-1_en.pdf"},
    {"id":"48970","name":"Draft list of references supporting the assessment of Menyanthes trifoliata L., folium","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2020-10-09T09:17:00Z","last_updated_date":"2020-10-09T09:17:00Z","reference_number":"EMA/HMPC/884830/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-menyanthes-trifoliata-l-folium_en.pdf"},
    {"id":"49421","name":"Final list of references supporting the assessment of Achillea millefolium L., herba - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2020-12-03T16:40:00Z","last_updated_date":"2020-12-03T16:40:00Z","reference_number":"EMA/HMPC/509104/2019 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-achillea-millefolium-l-herba-revision-1_en.pdf"}    {"id":"50009","name":"Draft list of references supporting the assessment of Orthosiphon aristatus (Blume) Miq. var. aristatus, folium - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2021-02-01T10:40:00Z","last_updated_date":"2021-02-01T10:40:00Z","reference_number":"EMA/HMPC/486553/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-orthosiphon-aristatus-blume-miq-var-aristatus-folium-revision-1_en.pdf"},
    {"id":"50016","name":"Draft list of references supporting the assessment of Salvia miltiorrhiza Bunge, radix et rhizoma - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2021-02-01T11:30:00Z","last_updated_date":"2021-02-01T11:30:00Z","reference_number":"EMA/HMPC/509927/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-salvia-miltiorrhiza-bunge-radix-et-rhizoma-first-version_en.pdf"},
    {"id":"50678","name":"Final list of references supporting the assessment of Species amarae","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2021-03-23T11:45:00Z","last_updated_date":"2021-03-23T11:45:00Z","reference_number":"EMA/HMPC/97854/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-species-amarae_en.pdf"},
    {"id":"50712","name":"Final list of references supporting the assessment of Species sedativae","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2021-03-25T16:42:00Z","last_updated_date":"2021-03-25T16:42:00Z","reference_number":"EMA/HMPC/735707/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-species-sedativae_en.pdf"},
    {"id":"50879","name":"Draft List of references supporting the assessment of Trigonella foenum-graecum L., semen - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2021-04-16T08:59:00Z","last_updated_date":"2021-04-16T08:59:00Z","reference_number":"EMA/HMPC/371216/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-trigonella-foenum-graecum-l-semen-revision-1_en.pdf"},
    {"id":"50884","name":"Second draft list of references supporting the assessment of Hypericum perforatum L., herba - Revision 1","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2021-04-15 - 2021-07-15","first_published_date":"2021-04-16T12:31:00Z","last_updated_date":"2021-04-16T12:31:00Z","reference_number":"EMA/HMPC/45511/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/second-draft-list-references-supporting-assessment-hypericum-perforatum-l-herba-revision-1_en.pdf"},
    {"id":"51313","name":"Draft List of references supporting the assessment of Vaccinium macrocarpon Aiton, fructus - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2021-05-31T17:39:00Z","last_updated_date":"2021-05-31T17:39:00Z","reference_number":"EMA/HMPC/551668/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-vaccinium-macrocarpon-aiton-fructus-first-version_en.pdf"},
    {"id":"51316","name":"Draft list of references supporting the assessment of Taraxacum officinale F.H. Wigg., radix - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2021-05-31T17:48:00Z","last_updated_date":"2021-05-31T17:48:00Z","reference_number":"EMA/HMPC/475727/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-taraxacum-officinale-fh-wigg-radix-first-version_en.pdf"},
    {"id":"51319","name":"Draft list of references supporting the assessment of Saccharomyces cerevisiae CBS 5926 - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2021-05-31T18:03:00Z","last_updated_date":"2021-05-31T18:03:00Z","reference_number":"EMA/HMPC/625624/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-saccharomyces-cerevisiae-cbs-5926-first-version_en.pdf"},
    {"id":"51969","name":"Final list of references supporting the assessment of Menyanthes trifoliata L., folium","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2021-07-20T14:35:00Z","last_updated_date":"2021-07-20T14:35:00Z","reference_number":"EMA/HMPC/884830/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-menyanthes-trifoliata-l-folium_en.pdf"},
    {"id":"52153","name":"Draft list of references supporting the assessment of Species digestivae","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2021-07-31 - 2021-10-31","first_published_date":"2021-07-30T10:43:00Z","last_updated_date":"2021-07-30T10:43:00Z","reference_number":"EMA/HMPC/638030/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-species-digestivae_en.pdf"},
    {"id":"52157","name":"Draft list of references supporting the assessment of Agropyron repens (L.) P. Beauv., rhizoma - Revision 1","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2021-07-31 - 2021-10-31","first_published_date":"2021-07-30T15:25:00Z","last_updated_date":"2021-07-30T15:25:00Z","reference_number":"EMA/HMPC/117128/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-agropyron-repens-l-p-beauv-rhizoma-revision-1_en.pdf"},
    {"id":"52222","name":"Final list of references supporting the assessment of Aloysia citrodora Paláu (syn. Aloysia triphylla (L’Hér.) Kuntze; Verbena triphylla L’Hér.; Lippia citriodora Kunth), folium","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2021-08-16T10:40:00Z","last_updated_date":"2021-08-16T10:40:00Z","reference_number":"EMA/HMPC/643161/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-aloysia-citrodora-palau-syn-aloysia-triphylla-lher-kuntze-verbena-triphylla-lher-lippia-citriodora-kunth-folium_en.pdf"},
    {"id":"52948","name":"Draft list of references supporting the assessment of Centella asiatica (L.) Urb., herba - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T11:58:00Z","last_updated_date":"2021-10-29T11:58:00Z","reference_number":"EMA/HMPC/489143/2020 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-centella-asiatica-l-urb-herba-revision-1_en.pdf"},
    {"id":"53421","name":"Final list of references supporting the assessment of Orthosiphon aristatus (Blume) Miq. var. aristatus, folium - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2021-12-08T14:01:00Z","last_updated_date":"2021-12-08T14:01:00Z","reference_number":"EMA/HMPC/486553/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-orthosiphon-aristatus-blume-miq-var-aristatus-folium-revision-1_en.pdf"},
    {"id":"55309","name":"Final list of references supporting the assessment of  Taraxacum officinale F.H. Wigg., radix","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2022-06-21T13:14:00Z","last_updated_date":"2022-06-21T13:14:00Z","reference_number":"EMA/HMPC/475727/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-taraxacum-officinale-fh-wigg-radix_en.pdf"},
    {"id":"55771","name":"List of references supporting the assessment of Salvia miltiorrhiza Bunge, radix et rhizoma","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2022-08-03T11:42:00Z","last_updated_date":"2022-08-03T11:42:00Z","reference_number":"EMA/HMPC/509927/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-salvia-miltiorrhiza-bunge-radix-et-rhizoma_en.pdf"},
    {"id":"55793","name":"List of references supporting the assessment of Saccharomyces cerevisiae CBS 5926","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2022-08-08T10:32:00Z","last_updated_date":"2022-08-08T10:32:00Z","reference_number":"EMA/HMPC/625624/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-saccharomyces-cerevisiae-cbs-5926_en.pdf"},
    {"id":"55880","name":"Final list of references supporting the assessment of Juniperus communis L., pseudo-fructus (galbulus) - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"2022-08-31 - 2022-11-30","first_published_date":"2022-08-31T17:54:00Z","last_updated_date":"2023-06-13T13:14:00Z","reference_number":"EMA/HMPC/241321/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-juniperus-communis-l-pseudo-fructus-galbulus-revision-1_en.pdf"},
    {"id":"55887","name":"List of references supporting the assessment of Trigonella foenum-graecum L., semen - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2022-08-30T10:58:00Z","last_updated_date":"2022-08-30T10:58:00Z","reference_number":"EMA/HMPC/371216/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-trigonella-foenum-graecum-l-semen-revision-1_en.pdf"},
    {"id":"55889","name":"Final list of references supporting the assessment of Foeniculum vulgare Miller subsp. vulgare var. vulgare and var. dulce (Mill.) Batt. & Trab., fructus - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T16:55:00Z","last_updated_date":"2024-03-01T12:13:00Z","reference_number":"EMA/HMPC/372844/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf"},
    {"id":"55894","name":"Final list of references supporting the assessment of Foeniculum vulgare Miller subsp. vulgare var. vulgare, aetheroleum - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2022-08-31T10:58:00Z","last_updated_date":"2024-07-18T15:39:00Z","reference_number":"EMA/HMPC/271393/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-aetheroleum-revision-1_en.pdf"},
    {"id":"55897","name":"Final list of references supporting the assessment of Foeniculum vulgare Miller subsp. vulgare var. vulgare and var. dulce (Mill.) Batt. & Trab., fructus - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T11:15:00Z","last_updated_date":"2024-03-01T12:33:00Z","reference_number":"EMA/HMPC/372844/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf-0"},
    {"id":"55947","name":"List of references supporting the assessment of Centella asiatica (L.) Urb., herba - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2022-09-02T09:50:00Z","last_updated_date":"2022-09-02T09:50:00Z","reference_number":"EMA/HMPC/489143/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-centella-asiatica-l-urb-herba-revision-1_en.pdf"},
    {"id":"56283","name":"List of references supporting the assessment of Agropyron repens (L.) P. Beauv., rhizoma - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2022-10-03T12:18:00Z","last_updated_date":"2022-10-03T12:18:00Z","reference_number":"EMA/HMPC/117128/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-agropyron-repens-l-p-beauv-rhizoma-revision-1_en.pdf"},
    {"id":"56510","name":"Draft List of references supporting the assessment of Fumaria officinalis L., herba – Revision 1","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2022-10-31 - 2023-01-31","first_published_date":"2022-10-31T10:39:00Z","last_updated_date":"2022-10-31T10:39:00Z","reference_number":"EMA/HMPC/367012/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-fumaria-officinalis-l-herba-revision-1_en.pdf"},
    {"id":"56716","name":"List of references supporting the assessment of Species digestivae","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2022-11-21T09:17:00Z","last_updated_date":"2022-11-21T09:17:00Z","reference_number":"EMA/HMPC/638030/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/list-references-supporting-assessment-species-digestivae_en.pdf"},
    {"id":"57015","name":"Final list of references supporting the assessment of Rosmarinus officinalis L., aetheroleum and Rosmarinus officinalis L., folium - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2022-12-15T16:25:00Z","last_updated_date":"2024-09-20T11:18:00Z","reference_number":"EMA/HMPC/648117/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-rosmarinus-officinalis-l-aetheroleum-rosmarinus-officinalis-l-folium-revision-1_en.pdf"},
    {"id":"57696","name":"Draft list of references supporting the assessment of Cnicus benedictus L., herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2023-02-16T13:13:00Z","last_updated_date":"2023-02-16T13:13:00Z","reference_number":"EMA/HMPC/32403/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-cnicus-benedictus-l-herba_en.pdf"},
    {"id":"57757","name":"Final list of references supporting the assessment of Vaccinium macrocarpon Aiton, fructus","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T12:09:00Z","last_updated_date":"2023-02-21T12:09:00Z","reference_number":"EMA/HMPC/551668/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-vaccinium-macrocarpon-aiton-fructus_en.pdf"},
    {"id":"57778","name":"Final list of references supporting the assessment of Hypericum perforatum L., herba - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2023-02-22T10:47:00Z","last_updated_date":"2023-02-22T10:47:00Z","reference_number":"EMA/HMPC/45511/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-hypericum-perforatum-l-herba-revision-1_en.pdf"},
    {"id":"58165","name":"Draft list of references supporting the assessment of Aesculus hippocastanum L., cortex - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2023-03-27T15:25:00Z","last_updated_date":"2023-03-27T15:25:00Z","reference_number":"EMA/HMPC/596129/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-aesculus-hippocastanum-l-cortex-revision-1_en.pdf"},
    {"id":"58956","name":"Draft list of references supporting the assessment of Panax ginseng C.A. Mey., radix - Revision 1","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2023-10-19 - 2024-01-15","first_published_date":"2023-06-15T13:50:00Z","last_updated_date":"2023-10-25T12:16:00Z","reference_number":"EMA/HMPC/27746/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-panax-ginseng-ca-mey-radix-revision-1_en.pdf"},
    {"id":"59543","name":"Final list of references supporting the assessment of Rhodiola rosea L., rhizoma et radix - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2023-08-02T16:23:00Z","last_updated_date":"2024-05-21T13:49:00Z","reference_number":"EMA/HMPC/24189/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-rhodiola-rosea-l-rhizoma-et-radix-revision-1_en.pdf"},
    {"id":"60443","name":"Final list of references supporting the assessment of Pelargonium sidoides DC; Pelargonium reniforme Curt., radix - Revision 2","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2023-10-16T16:15:00Z","last_updated_date":"2024-07-12T16:04:00Z","reference_number":"EMA/HMPC/765658/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-pelargonium-sidoides-dc-pelargonium-reniforme-curt-radix-revision-2_en.pdf"},
    {"id":"60576","name":"Draft list of references supporting the assessment of Equisetum arvense L. herba","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2015-07-27T12:00:00Z","last_updated_date":"2015-07-27T12:00:00Z","reference_number":"EMA/HMPC/278090/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-equisetum-arvense-l-herba_en.pdf"},
    {"id":"61785","name":"Final list of references supporting the assessment of Cnicus benedictus L., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2024-01-16T14:38:32Z","last_updated_date":"2024-01-16T14:38:32Z","reference_number":"EMA/HMPC/32403/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-cnicus-benedictus-l-herba_en.pdf"},
    {"id":"62243","name":"Final list of references supporting the assessment of Fumaria officinalis L., herba - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T15:57:15Z","last_updated_date":"2024-02-21T15:57:15Z","reference_number":"EMA/HMPC/367012/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-fumaria-officinalis-l-herba-revision-1_en.pdf"},
    {"id":"62947","name":"Draft list of references supporting the assessment of Eucalyptus globulus Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker, aetheroleum - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2024-04-15T10:49:24Z","last_updated_date":"2024-04-15T10:49:24Z","reference_number":"EMA/HMPC/320286/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-eucalyptus-smithii-rt-baker-aetheroleum-revision-1_en.pdf"},
    {"id":"62950","name":"Draft list of references supporting the assessment of Pilosella officinarum Vall. (syn Hieracium pilosella L.), herba cum radice - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2024-04-15T11:05:58Z","last_updated_date":"2024-04-15T11:05:58Z","reference_number":"EMA/HMPC/103855/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-pilosella-officinarum-vall-syn-hieracium-pilosella-l-herba-cum-radice-revision-1_en.pdf"},
    {"id":"63194","name":"Final list of references supporting the assessment of Aesculus hippocastanum L., cortex - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2024-05-07T14:51:05Z","last_updated_date":"2024-05-07T14:51:05Z","reference_number":"EMA/HMPC/596129/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-aesculus-hippocastanum-l-cortex-revision-1_en.pdf"},
    {"id":"63619","name":"Final list of references supporting the assessment of Urtica dioica L.; Urtica urens L., radix - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T15:21:36Z","last_updated_date":"2025-03-12T13:18:00Z","reference_number":"EMA/HMPC/322630/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-urtica-dioica-l-urtica-urens-l-radix-revision-1_en.pdf"},
    {"id":"63622","name":"Draft list of references supporting the assessment of Prunus avium L.; Prunus cerasus L., peduncle - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2024-06-14T15:34:50Z","last_updated_date":"2024-06-14T15:34:50Z","reference_number":"EMA/HMPC/379867/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-prunus-avium-l-prunus-cerasus-l-peduncle-first-version_en.pdf"},
    {"id":"63625","name":"Final list of references supporting the assessment of Urtica dioica L.; Urtica urens L., herba - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T15:42:11Z","last_updated_date":"2025-03-07T16:00:00Z","reference_number":"EMA/HMPC/261304/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-urtica-dioica-l-urtica-urens-l-herba-revision-1_en.pdf"},
    {"id":"63638","name":"Final list of references supporting the assessment of Zingiber officinale Roscoe, rhizoma - Revision 1","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T17:20:20Z","last_updated_date":"2025-06-19T11:03:00Z","reference_number":"EXT/HMPC/29299/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-zingiber-officinale-roscoe-rhizoma-revision-1_en.pdf"},
    {"id":"63642","name":"Draft list of references supporting the assessment of Tribulus terrestris L., herba - First version","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2024-06-14T17:30:53Z","last_updated_date":"2024-06-14T17:30:53Z","reference_number":"EMA/HMPC/308434/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-tribulus-terrestris-l-herba-first-version_en.pdf"},
    {"id":"64108","name":"Final list of references supporting the assessment of Panax ginseng C.A.Mey., radix - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:41:00Z","last_updated_date":"2024-07-12T15:41:00Z","reference_number":"EMA/HMPC/27746/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-panax-ginseng-camey-radix-revision-1_en.pdf"},
    {"id":"64576","name":"Final list of references supporting the assessment of Cisti cretici herba – First version","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2024-08-14T16:23:46Z","last_updated_date":"2025-04-30T15:40:00Z","reference_number":"EMA/HMPC/150764/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-cisti-cretici-herba-first-version_en.pdf"},
    {"id":"64580","name":"Final list of references supporting the assessment of plantaginis lanceolatae folium – Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2024-08-14T16:42:12Z","last_updated_date":"2025-10-20T09:37:00Z","reference_number":"EMA/HMPC/887980/2022","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-plantaginis-lanceolatae-folium-revision-1_en.pdf"},
    {"id":"64892","name":"Final list of references supporting the assessment of Artemisia absinthium L., herba","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2024-09-18T11:13:00Z","last_updated_date":"2024-09-18T11:13:00Z","reference_number":"EMA/HMPC/186849/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-artemisia-absinthium-l-herba_en.pdf"},
    {"id":"66161","name":"Draft list of references supporting the assessment of Species pectorales","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2024-12-15 - 2025-03-15","first_published_date":"2024-12-16T16:13:53Z","last_updated_date":"2024-12-16T16:13:53Z","reference_number":"EMA/HMPC/462140/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-species-pectorales_en.pdf"},
    {"id":"66791","name":"Draft list of references supporting the assessment of Hypericum perforatum L., herba and Cimicifuga racemosa (L.) Nutt., rhizoma","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T15:28:00Z","last_updated_date":"2025-02-14T15:28:00Z","reference_number":"EMA/HMPC/201618/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-hypericum-perforatum-l-herba-cimicifuga-racemosa-l-nutt-rhizoma_en.pdf"},
    {"id":"66938","name":"Final list of references supporting the assessment of Prunus avium L.; Prunus cerasus L., peduncle","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2025-02-25T12:00:39Z","last_updated_date":"2025-02-25T12:00:39Z","reference_number":"EMA/HMPC/379867/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-prunus-avium-l-prunus-cerasus-l-peduncle_en.pdf"},
    {"id":"66942","name":"Final list of references supporting the assessment of Tribulus terrestris L., herba","type":"herbal-references","status":"Adopted","consultation_date":"","first_published_date":"2025-02-25T12:13:15Z","last_updated_date":"2025-02-25T12:13:15Z","reference_number":"EMA/HMPC/308434/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-tribulus-terrestris-l-herba_en.pdf"},
    {"id":"66978","name":"Final list of references supporting the assessment of Pilosella officinarum Vall. (syn Hieracium pilosella L.), herba cum radice - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2025-02-26T09:39:20Z","last_updated_date":"2025-02-26T09:39:20Z","reference_number":"EMA/HMPC/103855/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-pilosella-officinarum-vall-syn-hieracium-pilosella-l-herba-cum-radice-revision-1_en.pdf"},
    {"id":"67060","name":"Final list of references supporting the assessment of Eucalyptus globulus Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker, aetheroleum - Revision 1","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T15:44:16Z","last_updated_date":"2025-02-28T15:44:16Z","reference_number":"EMA/HMPC/320286/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-eucalyptus-smithii-rt-baker-aetheroleum-revision-1_en.pdf"},
    {"id":"67839","name":"Draft list of references supporting the assessment of Crataegus monogyna Jacq. (Lindm.), C. laevigata (Poir.) DC. or their hybrids; C. pentagyna Waldst. et Kit. ex Willd.; C. azarolus L.","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2025-04-15 - 2025-07-15","first_published_date":"2025-04-15T11:56:40Z","last_updated_date":"2025-04-15T11:56:40Z","reference_number":"EMA/HMPC/234780/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-crataegus-monogyna-jacq-lindm-c-laevigata-poir-dc-or-their-hybrids-c-pentagyna-waldst-et-kit-ex-willd-c-azarolus-l_en.pdf"},
    {"id":"67842","name":"Draft list of references supporting the assessment of Arnica montana L., flos","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2025-04-15 - 2025-07-15","first_published_date":"2025-04-15T12:10:21Z","last_updated_date":"2025-04-15T12:10:21Z","reference_number":"EMA/HMPC/524584/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-arnica-montana-l-flos_en.pdf-0"},
    {"id":"67846","name":"Draft list of references supporting the assessment of Allium sativum L., bulbus","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2025-04-15 - 2025-07-15","first_published_date":"2025-04-15T12:19:41Z","last_updated_date":"2025-04-15T12:19:41Z","reference_number":"EMA/HMPC/329434/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-allium-sativum-l-bulbus_en.pdf-0"},
    {"id":"68512","name":"Draft list of references assessment of Ononis spinosa L., radix - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2025-06-02T09:53:49Z","last_updated_date":"2025-06-02T09:53:49Z","reference_number":"EMA/HMPC/584454/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-assessment-ononis-spinosa-l-radix-revision-1_en.pdf"},
    {"id":"69610","name":"Draft list of references supporting the assessment of Glycyrrhiza glabra L.; Gycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2025-08-01T11:11:53Z","last_updated_date":"2025-08-01T11:11:53Z","reference_number":"EMA/HMPC/528923/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-glycyrrhiza-glabra-l-gycyrrhiza-inflata-bat-glycyrrhiza-uralensis-fisch-radix-revision-1_en.pdf"},
    {"id":"69614","name":"Draft list of references supporting the assessment of Fragaria vesca L.; Fragaria moschata Weston; Fragaria viridis Weston; Fragaria x ananassa (Weston) Duchesne ex Rozier, folium - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2025-08-01T11:40:04Z","last_updated_date":"2025-08-01T11:40:04Z","reference_number":"EMA/HMPC/10133/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium-revision-1_en.pdf"},
    {"id":"69617","name":"Draft list of references supporting the assessment of Species diureticae - Revision 1","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2025-08-01T12:03:35Z","last_updated_date":"2025-08-01T12:03:35Z","reference_number":"EMA/HMPC/85835/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-species-diureticae-revision-1_en.pdf"},
    {"id":"70202","name":"Final list of references supporting the assessment of Species pectorales - First version","type":"herbal-references","status":"unknown","consultation_date":"","first_published_date":"2025-09-22T10:59:19Z","last_updated_date":"2025-09-22T10:59:19Z","reference_number":"EMA/HMPC/462140/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/final-list-references-supporting-assessment-species-pectorales-first-version_en.pdf"},
    {"id":"70560","name":"Draft list of references supporting the assessment of Zea mays, L., stigma","type":"herbal-references","status":"Draft: consultation closed","consultation_date":"2025-10-15 - 2026-01-15","first_published_date":"2025-10-15T09:32:16Z","last_updated_date":"2025-10-15T09:32:16Z","reference_number":"EMA/HMPC/509422/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-zea-mays-l-stigma_en.pdf"},
    {"id":"72561","name":"Draft list of references supporting the assessment of Ribes nigrum L., folium - Revision 2","type":"herbal-references","status":"Draft","consultation_date":"","first_published_date":"2026-02-16T08:51:35Z","last_updated_date":"2026-02-16T08:51:35Z","reference_number":"EMA/HMPC/296854/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-ribes-nigrum-l-folium-revision-2_en.pdf"},
    {"id":"73916","name":"Draft list of references supporting the assessment of Glycine max (L.) Merr., lecithinum","type":"herbal-references","status":"Draft: consultation open","consultation_date":"2026-06-01 - 2026-08-31","first_published_date":"2026-06-01T10:48:01Z","last_updated_date":"2026-06-01T10:48:01Z","reference_number":"EMA/HMPC/216489/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-references/draft-list-references-supporting-assessment-glycine-max-l-merr-lecithinum_en.pdf"},
    {"id":"2764","name":"Overview of comments received on Community herbal monograph on Ononis spinosa L., radix","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2014-05-28T02:00:00Z","last_updated_date":"2014-05-28T02:00:00Z","reference_number":"EMA/HMPC/35010/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-ononis-spinosa-l-radix_en.pdf"},
    {"id":"2988","name":"Overview of comments received on Community herbal monograph on Levisticum officinale Koch, radix","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2013-02-22T16:00:00Z","last_updated_date":"2013-02-22T16:00:00Z","reference_number":"EMEA/HMPC/411398/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-levisticum-officinale-koch-radix_en.pdf"},
    {"id":"3091","name":"Overview of comments received on European Union herbal monograph on Matricaria recutita L., aetheroleum - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2016-04-05T02:00:00Z","last_updated_date":"2016-04-05T02:00:00Z","reference_number":"EMA/HMPC/706537/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-matricaria-recutita-l-aetheroleum-first-version_en.pdf"},
    {"id":"3418","name":"Superseded opinion of the Committee on Herbal Medicinal Products on a community herbal monograph on Sambucus nigra L., flos - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2018-06-27T02:09:21Z","reference_number":"EMEA/HMPC/188139/2008EN","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-opinion-committee-herbal-medicinal-products-community-herbal-monograph-sambucus-nigra-l-flos-first-version_en.pdf"},
    {"id":"3489","name":"Overview of comments received on Community herbal monograph on Eucalyptus globulus Labill., Eucalyptus polybractea R.T. Baker and/or Eucalyptus smithii R.T. Baker, aetheroleum - Superseded","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2025-02-28T02:00:00Z","reference_number":"EMA/HMPC/32373/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-or-eucalyptus-smithii-rt-baker-aetheroleum-superseded_en.pdf"},
    {"id":"3618","name":"Overview of comments received on European Union herbal monograph on Matricaria recutita L., flos - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2016-04-05T17:30:00Z","last_updated_date":"2016-04-05T17:30:00Z","reference_number":"EMA/HMPC/706538/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-matricaria-recutita-l-flos-first-version_en.pdf"},
    {"id":"3638","name":"Overview of comments on draft Community herbal monograph on Lavandula angustifolia Miller, aetheroleum","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2012-06-13T18:00:00Z","last_updated_date":"2012-06-13T18:00:00Z","reference_number":"EMA/HMPC/734381/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-draft-community-herbal-monograph-lavandula-angustifolia-miller-aetheroleum_en.pdf"},
    {"id":"3755","name":"Superseded overview of comments received on 'Community herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne, radix' (EMEA/HMPC/251323/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMEA/HMPC/454136/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-harpagophytum-procumbens-dc-andor-harpagophytum-zeyheri-decne-radix-emeahmpc2513232006_en.pdf"},
    {"id":"3913","name":"Overview of comments received on reflection paper on ethanol content in herbal medicinal products and traditional herbal medicinal products used in children","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2010-02-01T01:00:00Z","last_updated_date":"2010-02-01T01:00:00Z","reference_number":"EMA/HMPC/427952/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-reflection-paper-ethanol-content-herbal-medicinal-products-and-traditional-herbal-medicinal-products-used-children_en.pdf"},
    {"id":"4235","name":"Superseded overview of comments received on Community herbal monograph on Rhodiola rosea - First version","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T16:00:00Z","last_updated_date":"2024-05-23T16:00:00Z","reference_number":"EMA/HMPC/26431/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-rhodiola-rosea-first-version_en.pdf"},
    {"id":"4395","name":"Superseded overview of comments received on 'Community herbal monograph on Equisetum arvense L., herba' (EMEA/HMPC/394894/2007)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2016-03-17T01:09:21Z","reference_number":"EMEA/HMPC/230479/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-equisetum-arvense-l-herba-emeahmpc3948942007_en.pdf"},
    {"id":"4623","name":"Overview of comments received on community herbal monograph on Leonurus cardiaca L., herba","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/HMPC/561942/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-leonurus-cardiaca-l-herba_en.pdf"},
    {"id":"4669","name":"Final overview of comments received on European Union herbal monograph on Ginkgo biloba L., folium","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2015-04-08T02:00:00Z","reference_number":"EMA/HMPC/586885/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-received-european-union-herbal-monograph-ginkgo-biloba-l-folium_en.pdf"},
    {"id":"4760","name":"Overview of comments received on Community herbal monograph on Olea europaea L., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2012-04-18T17:30:00Z","last_updated_date":"2012-04-18T17:30:00Z","reference_number":"EMA/HMPC/736741/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-olea-europaea-l-folium_en.pdf"},
    {"id":"4880","name":"Superseded overview of comments received on 'Community herbal monograph on Sambucus nigra L., flos' - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2018-06-27T02:09:21Z","reference_number":"EMEA/HMPC/66605/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-sambucus-nigra-l-flos-first-version_en.pdf"},
    {"id":"5518","name":"Superseded overview of comments received on Community herbal monograph on Rosmarinus officinalis L., aetheroleum","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-02-03T01:00:00Z","last_updated_date":"2024-09-20T01:00:00Z","reference_number":"EMA/HMPC/254083/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-rosmarinus-officinalis-l-aetheroleum_en.pdf"},
    {"id":"5887","name":"Overview of comments received on Community herbal monograph on Filipendula ulmaria (L.) Maxim., herba - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-09-29T02:00:00Z","last_updated_date":"2011-09-29T02:00:00Z","reference_number":"EMA/HMPC/326670/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-filipendula-ulmaria-l-maxim-herba-first-version_en.pdf"},
    {"id":"6492","name":"Overview of comments received on Public statement on Sambucus nigra L., fructus","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2014-04-29T02:00:00Z","last_updated_date":"2014-04-29T02:00:00Z","reference_number":"EMA/HMPC/551899/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-public-statement-sambucus-nigra-l-fructus_en.pdf"},
    {"id":"6563","name":"Superseded overview of comments received on 'Community herbal monograph on \n\nPimpinella anisum L., aetheroleum' (EMEA/HMPC/263273/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-06-12T02:09:21Z","last_updated_date":"2014-06-18T02:09:21Z","reference_number":"EMEA/HMPC/286756/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-pimpinella-anisum-l-aetheroleum-emeahmpc2632732006_en.pdf"},
    {"id":"6644","name":"Superseded overview of comments received on community herbal monograph and community list entry on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus and on a  community herbal monograph and community list entry on Foen...","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2024-03-07T17:15:00Z","reference_number":"EMEA/HMPC/200856/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-community-list-entry-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus-community-herbal-monograph-community-list-entry-foen_en.pdf"},
    {"id":"6963","name":"Overview of comments on European Union herbal monograph on Harpagophytum procumbens DC. and /or Harpagophytum zeyheri Decne., radix (EMA/HMPC/627057/2015)","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMA/HMPC/354205/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-european-union-herbal-monograph-harpagophytum-procumbens-dc-and-or-harpagophytum-zeyheri-decne-radix-emahmpc6270572015_en.pdf"},
    {"id":"7773","name":"Overview of comments received on Community herbal monograph on Plantago lanceolata L., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2012-02-24T01:00:00Z","last_updated_date":"2012-02-24T01:00:00Z","reference_number":"EMA/HMPC/353910/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-plantago-lanceolata-l-folium_en.pdf"},
    {"id":"8070","name":"Final overview of comments received on Public statement on Paeonia lactiflora Pallas, radix (Paeoniae radix alba)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2017-04-25T16:47:00Z","last_updated_date":"2017-04-25T16:47:00Z","reference_number":"EMA/HMPC/610809/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-received-public-statement-paeonia-lactiflora-pallas-radix-paeoniae-radix-alba_en.pdf"},
    {"id":"8874","name":"Superseded overview of comments received on 'Community herbal monograph on salix, cortex' (EMEA/HMPC/295338/2007)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2009-09-26T02:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMEA/HMPC/451855/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-salix-cortex-emeahmpc2953382007_en.pdf"},
    {"id":"9080","name":"Superseded overview of comments received on Community herbal monograph on Orthosiphon stamineus Benth., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-05-30T02:00:00Z","last_updated_date":"2011-05-30T02:00:00Z","reference_number":"EMA/HMPC/143067/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-orthosiphon-stamineus-benth-folium_en.pdf"},
    {"id":"9148","name":"Superseded overview of comments received on 'Community herbal monograph on Cassia senna L., fructus and Cassia angustifolia Vahl, fructus' (EMEA/HMPC/51871/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2007-04-27T02:09:00Z","last_updated_date":"2007-04-27T02:09:00Z","reference_number":"EMEA/HMPC/237716/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-cassia-senna-l-fructus-and-cassia-angustifolia-vahl-fructus-emeahmpc518712006_en.pdf"},
    {"id":"10068","name":"Superseded overview of comments received on Community herbal monograph on Zingiber officinale Roscoe, rhizoma","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2012-06-04T02:00:00Z","last_updated_date":"2025-06-19T02:00:00Z","reference_number":"EMA/HMPC/44043/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-zingiber-officinale-roscoe-rhizoma_en.pdf"},
    {"id":"10223","name":"Superseded overview of comments received on Community herbal monograph on Vitis vinifera L., folium - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/276427/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-vitis-vinifera-l-folium-first-version_en.pdf"},
    {"id":"10233","name":"Overview of comments received on 'Community herbal monograph on Avena sativa L., herba' (EMEA/HMPC/202966/2007)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/225877/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-avena-sativa-l-herba-emeahmpc2029662007_en.pdf"},
    {"id":"10429","name":"Superseded overview of comments received on 'Community herbal monograph on Mentha x piperita L., aetheroleum' (EMEA/HMPC/349466/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/494410/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-mentha-x-piperita-l-aetheroleum-emeahmpc3494662006_en.pdf"},
    {"id":"10552","name":"Overview of comments received on Community herbal monograph on Commiphora molmol Engler, gummi-resina","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T15:00:00Z","last_updated_date":"2011-12-22T15:00:00Z","reference_number":"EMA/HMPC/354015/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-commiphora-molmol-engler-gummi-resina_en.pdf"},
    {"id":"10783","name":"Overview of comments received on European Union herbal monograph Valeriana officinalis L., radix","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2016-04-27T12:30:00Z","last_updated_date":"2016-04-27T12:30:00Z","reference_number":"EMA/HMPC/759056/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf"},
    {"id":"11173","name":"Superseded overview of comments received on Community herbal monograph on Rosmarinus officinalis L., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-02-03T01:00:00Z","last_updated_date":"2024-09-26T01:00:00Z","reference_number":"EMA/HMPC/254082/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-rosmarinus-officinalis-l-folium_en.pdf"}    {"id":"11181","name":"Overview of comments received on Community herbal monograph on Solanum dulcamara L., stipites (EMA/HMPC/734361/2011)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2013-02-15T01:00:00Z","last_updated_date":"2013-02-15T01:00:00Z","reference_number":"EMA/HMPC/697749/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-solanum-dulcamara-l-stipites-emahmpc7343612011_en.pdf"},
    {"id":"11194","name":"Overview of comments received on 'Community herbal monograph on Solidago virgaurea L., herba' (EMEA/HMPC/285758/2007)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/102215/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-solidago-virgaurea-l-herba-emeahmpc2857582007_en.pdf"},
    {"id":"11364","name":"Superseded overview of comments received on 'Community herbal monograph on Cassia senna L. and Cassia angustifolia Vahl, folium' (EMEA/HMPC/51869/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2007-04-27T02:09:00Z","last_updated_date":"2007-04-27T02:09:00Z","reference_number":"EMEA/HMPC/237669/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-cassia-senna-l-and-cassia-angustifolia-vahl-folium-emeahmpc518692006_en.pdf"},
    {"id":"11402","name":"Overview of comments received on Community herbal monograph on Cinnamomum verum J. S. Presl, cortex (EMA/HMPC/246774/2009)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2011-08-05T02:00:00Z","reference_number":"EMA/HMPC/31666/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-cinnamomum-verum-j-s-presl-cortex-emahmpc2467742009_en.pdf"},
    {"id":"11473","name":"Overview of comments received on European Union herbal monograph and European Union list entry on Crataegus spp., folium cum flore","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"EMA/HMPC/150876/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-and-european-union-list-entry-crataegus-spp-folium-cum-flore_en.pdf"},
    {"id":"11535","name":"Overview of comments received on HMPC draft procedure for calls for scientific data for use in HMPC assessment work (EMEA/HMPC/1004/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2006-10-26T02:09:21Z","last_updated_date":"2006-10-26T02:09:21Z","reference_number":"EMEA/HMPC/309487/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-hmpc-draft-procedure-calls-scientific-data-use-hmpc-assessment-work-emeahmpc10042006_en.pdf"},
    {"id":"11929","name":"Draft overview of comments received on European Union herbal monograph on Silybum marianum (L.) Gaertn., fructus (EMA/HMPC/229413/2016)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T17:07:00Z","last_updated_date":"2016-11-07T17:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/draft-overview-comments-received-european-union-herbal-monograph-silybum-marianum-l-gaertn-fructus-emahmpc2294132016_en.pdf"},
    {"id":"12406","name":"Superseded overview of comments received on Community herbal monograph on Echinacea purpurea (L.) Moench, radix - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-02-10T01:00:00Z","last_updated_date":"2011-02-10T01:00:00Z","reference_number":"EMA/HMPC/7084/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-echinacea-purpurea-l-moench-radix-first-version_en.pdf"},
    {"id":"12655","name":"Overview of comments received on Community herbal monograph on Aesculus hippocastanum L., cortex","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2012-06-27T16:15:00Z","last_updated_date":"2012-06-27T16:15:00Z","reference_number":"EMA/HMPC/198422/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-aesculus-hippocastanum-l-cortex_en.pdf"},
    {"id":"13710","name":"Superseded overview of comments received on community herbal monograph on Althaea officinalis L., radix","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2009-05-14T02:09:21Z","last_updated_date":"2016-11-04T14:49:00Z","reference_number":"EMEA/HMPC/2920/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-althaea-officinalis-l-radix_en.pdf"},
    {"id":"13958","name":"Overview of comments on draft assessment report on Cetraria islandica (L.) Acharius s.l., thallus - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2015-02-11T11:45:00Z","last_updated_date":"2015-02-11T11:45:00Z","reference_number":"EMA/HMPC/572698/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-draft-assessment-report-cetraria-islandica-l-acharius-sl-thallus-first-version_en.pdf"},
    {"id":"14646","name":"Superseded final overview of comments received on 'Community herbal monograph on Plantago afra L. et Plantago indica L., semen' (EMEA/HMPC/340865/2005)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2007-02-28T00:09:21Z","last_updated_date":"2013-07-29T14:00:00Z","reference_number":"EMEA/HMPC/65063/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-final-overview-comments-received-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen-emeahmpc3408652005_en.pdf"},
    {"id":"14724","name":"Overview of comments received on reflection paper on the reasons and timelines for revision of final Community herbal monographs and Community list entries (EMEA/HMPC/326440/2008)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/370642/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-reflection-paper-reasons-and-timelines-revision-final-community-herbal-monographs-and-community-list-entries-emeahmpc3264402008_en.pdf"},
    {"id":"14962","name":"Superseded overview of comments received on ‘Community herbal monograph on Humulus lupulus L., flos’ - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-07-11T02:00:00Z","last_updated_date":"2014-08-07T02:00:00Z","reference_number":"EMEA/HMPC/577303/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-humulus-lupulus-l-flos-first-version_en.pdf"},
    {"id":"15189","name":"Superseded overview of comments received on Community herbal monograph on Trigonella foenum-graecum L., semen","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2022-08-30T02:00:00Z","last_updated_date":"2022-08-30T02:00:00Z","reference_number":"EMA/HMPC/729635/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-trigonella-foenum-graecum-l-semen_en.pdf"},
    {"id":"15192","name":"Overview of comments received on 'community herbal monograph on Avena sativa L., fructus' (EMEA/HMPC/368600/2007)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/HMPC/225876/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-avena-sativa-l-fructus-emeahmpc3686002007_en.pdf"},
    {"id":"15750","name":"Overview of comments received on 'Community herbal monograph on Peumus boldus Molina, folium'","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2009-01-14T00:09:21Z","last_updated_date":"2009-01-14T00:09:21Z","reference_number":"EMEA/HMPC/559459/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-peumus-boldus-molina-folium_en.pdf"},
    {"id":"15803","name":"Overview of comments received on draft guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-01-10T01:00:00Z","last_updated_date":"2008-01-10T01:00:00Z","reference_number":"EMEA/HMPC/539645/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-draft-guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products-first-version_en.pdf"},
    {"id":"15854","name":"Superseded overview of comments received on Community herbal monograph on Pelargonium sidoides DC and / or Pelargonium reniforme Curt., radix - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2013-02-04T12:30:00Z","last_updated_date":"2018-08-20T13:30:00Z","reference_number":"EMA/HMPC/748350/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-pelargonium-sidoides-dc-and-or-pelargonium-reniforme-curt-radix-first-version_en.pdf"},
    {"id":"15920","name":"Superseded overview of comments received on ‘Community herbal monograph on Passiflora incarnate L., herba’ (EMEA/HMPC/230962/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-11-15T00:09:21Z","last_updated_date":"2014-06-19T01:09:21Z","reference_number":"EMEA/HMPC/383450/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-passiflora-incarnate-l-herba-emeahmpc2309622006_en.pdf"},
    {"id":"16098","name":"Overview of comments received on European Union herbal monograph on Carum carvi L., aetheroleum","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/HMPC/562782/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-carum-carvi-l-aetheroleum_en.pdf"},
    {"id":"16315","name":"Superseded overview of comments received on  'Community herbal monograph on  Linum usitatissimum L., semen'  EMEA/HMPC/340849/2005","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2006-10-25T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMEA/HMPC/66042/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-linum-usitatissimum-l-semen-emeahmpc3408492005_en.pdf"},
    {"id":"16668","name":"Overview of comments received on Community herbal monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2012-08-24T17:00:00Z","last_updated_date":"2014-04-02T15:40:00Z","reference_number":"EMA/HMPC/48932/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf"},
    {"id":"16965","name":"Overview of comments received on Community herbal monograph on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny), herba cum flore","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-10-13T11:40:00Z","last_updated_date":"2011-10-13T11:40:00Z","reference_number":"EMA/HMPC/564527/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-viola-tricolor-l-andor-subspecies-viola-arvensis-murray-gaud-and-viola-vulgaris-koch-oborny-herba-cum-flore_en.pdf"},
    {"id":"17013","name":"Overview of comments received on Community herbal monograph on Cucurbita pepo L, semen","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/HMPC/196724/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-cucurbita-pepo-l-semen_en.pdf"},
    {"id":"17875","name":"Superseded overview of comments received on Community Herbal Monograph on Melissa officinalis L., folium (EMEA/HMPC/5341/2007)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"EMEA/HMPC/499295/2007 Corr","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-melissa-officinalis-l-folium-emeahmpc53412007_en.pdf"},
    {"id":"18752","name":"Overview of comments received on European Union herbal monograph on Symphytum officinale L., radix","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2015-06-05T02:00:00Z","last_updated_date":"2015-06-05T02:00:00Z","reference_number":"EMA/HMPC/44385/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-symphytum-officinale-l-radix_en.pdf"},
    {"id":"18968","name":"Superseded overview of comments received on Community herbal monograph on Tanacetum parthenium (L) Schulz Bip., herba - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-06-20T02:00:00Z","last_updated_date":"2020-08-14T02:00:00Z","reference_number":"EMA/HMPC/563270/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-tanacetum-parthenium-l-schulz-bip-herba-first-version_en.pdf"},
    {"id":"19077","name":"Overview of comments received on Syzygium aromaticum (L.) Merill et L. M. Perry, floris aetheroleum","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-12-21T01:00:00Z","last_updated_date":"2011-12-21T01:00:00Z","reference_number":"EMA/HMPC/504510/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-syzygium-aromaticum-l-merill-et-l-m-perry-floris-aetheroleum_en.pdf"},
    {"id":"19201","name":"Overview of comments received on 'Community herbal monograph on calendula officinalis L., flos' EMEA/HMPC/179281/2007","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-03-06T00:09:21Z","last_updated_date":"2008-03-06T00:09:21Z","reference_number":"EMEA/HMPC/590044/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-calendula-officinalis-l-flos-emeahmpc1792812007_en.pdf"},
    {"id":"19289","name":"Superseded overview of comments received on 'Community herbal monograph on Centaurium erythraea Rafn, herba' (EMEA/HMPC/105536/2008)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2009-03-12T00:09:21Z","last_updated_date":"2016-01-28T00:09:21Z","reference_number":"EMEA/HMPC/664610/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-centaurium-erythraea-rafn-herba-emeahmpc1055362008_en.pdf"},
    {"id":"19532","name":"Superseded final overview of comments received on 'Community herbal monograph on Thymus vulgaris L. and Thymus zygis L., herba' EMEA/HMPC/234113/2006","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2014-06-03T01:09:21Z","reference_number":"EMEA/HMPC/489157/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-final-overview-comments-received-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba-emeahmpc2341132006_en.pdf"},
    {"id":"19800","name":"Superseded overview of comments received on ‘Community herbal monograph on Primula veris L., Primula elatior (L.) Hill, flos","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2010-04-09T02:00:00Z","last_updated_date":"2010-04-09T02:00:00Z","reference_number":"EMA/HMPC/373075/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-primula-veris-l-primula-elatior-l-hill-flos_en.pdf"},
    {"id":"19832","name":"Superseded overview of comments received on Community herbal monograph on Vitex agnus-castus L., fructus (EMA/HMPC/144006/2009) - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2018-10-10T02:00:00Z","reference_number":"EMA/HMPC/278781/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-vitex-agnus-castus-l-fructus-emahmpc1440062009-first-version_en.pdf"},
    {"id":"20327","name":"Superseded overview of comments received on 'Community herbal monograph on ruscus aculeatus L., rhizoma' (EMEA/HMPC/261938/2007)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2019-05-02T17:00:00Z","reference_number":"EMEA/HMPC/112990/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-ruscus-aculeatus-l-rhizoma-emeahmpc2619382007_en.pdf"},
    {"id":"20411","name":"Overview of comments received on Community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMA/HMPC/400536/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf"},
    {"id":"20986","name":"Overview of comments received on community herbal monograph on Curcuma longa L., rhizoma - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2010-02-04T01:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"EMA/HMPC/401918/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-curcuma-longa-l-rhizoma-first-version_en.pdf"},
    {"id":"21234","name":"Superseded overview of comments received on Community herbal monograph on Cynara scolymus L., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-12-21T01:00:00Z","last_updated_date":"2011-12-21T01:00:00Z","reference_number":"EMA/HMPC/350089/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-cynara-scolymus-l-folium_en.pdf"},
    {"id":"21618","name":"Overview of comments received on public statement on Viscum album L., herba","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2013-08-01T17:05:00Z","last_updated_date":"2013-08-01T17:05:00Z","reference_number":"EMA/HMPC/196894/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-public-statement-viscum-album-l-herba_en.pdf"},
    {"id":"21708","name":"Overview of comments received on European Union herbal monograph on Eschscholzia californica Cham., herba","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/HMPC/726116/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-eschscholzia-californica-cham-herba_en.pdf"},
    {"id":"22265","name":"Superseded overview of comments received on 'Community herbal monograph on Echinacea purpurea L., herba recens' EMEA/HMPC/104945/2006\n\n\n\nSuperseded overview of comments received on 'Community herbal list entry Echinacea ...","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-03-06T00:09:21Z","last_updated_date":"2015-04-14T01:09:21Z","reference_number":"EMEA/HMPC/475463/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-echinacea-purpurea-l-herba-recens-emeahmpc1049452006-superseded-overview-comments-received-community-herbal-list-entry-echinacea_en.pdf"},
    {"id":"22573","name":"Overview of comments received on draft public statement on Piper methysticum G. Forst., rhizoma","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T02:00:00Z","last_updated_date":"2018-04-13T02:00:00Z","reference_number":"EMA/HMPC/326583/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-draft-public-statement-piper-methysticum-g-forst-rhizoma_en.pdf"},
    {"id":"22805","name":"Overview of comments received on European Union herbal monograph on Serenoa repens (W. Bartram) Small, fructus","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T02:00:00Z","last_updated_date":"2016-03-30T02:00:00Z","reference_number":"EMA/HMPC/278488/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-serenoa-repens-w-bartram-small-fructus_en.pdf"},
    {"id":"23208","name":"Overview of comments received on Community herbal monograph on Urtica dioica L.; Urtica urens L., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-01-17T01:00:00Z","last_updated_date":"2011-01-17T01:00:00Z","reference_number":"EMA/HMPC/584060/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-folium_en.pdf"},
    {"id":"23573","name":"Final overview of comments received on European Union herbal monograph on Glycine max (L.) Merr., lecithinum (EMA/HMPC/220599/2016)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T01:00:00Z","last_updated_date":"2017-11-20T01:00:00Z","reference_number":"EMA/HMPC/748525/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-received-european-union-herbal-monograph-glycine-max-l-merr-lecithinum-emahmpc2205992016_en.pdf"},
    {"id":"24099","name":"Overview of comments received on 'Procedure on the publication of Committee on Herbal Medicinal Products public statements when Community herbal monographs on herbal substances, preparations and/or combinations thereof a...","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-07-20T02:00:00Z","last_updated_date":"2011-07-20T02:00:00Z","reference_number":"EMA/HMPC/495353/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-procedure-publication-committee-herbal-medicinal-products-public-statements-when-community-herbal-monographs-herbal-substances-preparations-andor-combinations-thereof_en.pdf"},
    {"id":"24561","name":"Overview of comments received on European Union herbal monograph on Carum carvi L., fructus","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2015-09-10T02:00:00Z","last_updated_date":"2015-09-10T02:00:00Z","reference_number":"EMA/HMPC/268114/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-carum-carvi-l-fructus_en.pdf"},
    {"id":"25093","name":"Superseded overview of comments received on 'Community herbal monograph on Melilotus officinalis (L.) Lam., herba' (EMEA/HMPC/220828/2008)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2018-04-23T02:00:00Z","reference_number":"EMEA/HMPC/220828/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-melilotus-officinalis-l-lam-herba-emeahmpc2208282008_en.pdf"},
    {"id":"25348","name":"Overview of comments received on draft Community herbal monograph on Potentilla erecta (L.) Raeusch., rhizoma (EMEA/HMPC/5513/2010)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-03-16T01:00:00Z","last_updated_date":"2011-03-16T01:00:00Z","reference_number":"EMA/HMPC/527028/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-draft-community-herbal-monograph-potentilla-erecta-l-raeusch-rhizoma-emeahmpc55132010_en.pdf"},
    {"id":"25699","name":"Superseded overview of comments received on ‘Community herbal monograph on Salvia officinalis L., folium’","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2017-07-13T02:00:00Z","reference_number":"EMA/HMPC/443915/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-salvia-officinalis-l-folium_en.pdf"},
    {"id":"26254","name":"Superseded overview of comments received on 'Community herbal monograph on Rhamnus frangula L. (Frangula alnus Miller), cortex' - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/342513/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-rhamnus-frangula-l-frangula-alnus-miller-cortex-first-version_en.pdf"},
    {"id":"26255","name":"Overview of comments received on Community herbal monograph on Arctium lappa L., radix","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"EMA/HMPC/559432/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-arctium-lappa-l-radix_en.pdf"},
    {"id":"26368","name":"Superseded overview of comments received on Community herbal monograph on Juniperi pseudo-fructus","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-02-16T01:00:00Z","last_updated_date":"2023-06-13T01:00:00Z","reference_number":"EMA/HMPC/421352/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-juniperi-pseudo-fructus_en.pdf"},
    {"id":"26559","name":"Overview of comments received on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2012-07-10T14:00:00Z","last_updated_date":"2012-07-10T14:00:00Z","reference_number":"EMA/HMPC/198518/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-or-their-mixtures-flos-first-version_en.pdf"},
    {"id":"27137","name":"Superseded overview of comments received on 'Community herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. vulgare, aetheroleum' EMEA/HMPC/263292/2006","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2024-07-19T01:00:00Z","reference_number":"EMEA/HMPC/200857/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-aetheroleum-emea-hmpc-263292-2006_en.pdf"},
    {"id":"27563","name":"Superseded overview of comments on Community herbal monograph on Rhamnus purshianus D.C., cortex (EMEA/HMPC/513579/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-06-05T02:09:00Z","last_updated_date":"2008-06-05T02:09:00Z","reference_number":"EMEA/HMPC/369020/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-community-herbal-monograph-rhamnus-purshianus-dc-cortex-emeahmpc5135792006_en.pdf"},
    {"id":"27593","name":"Superseded - Overview of comments received on 'Community herbal monograph on Aloe' EMEA/HMPC/76310/2006","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2017-04-10T02:00:00Z","reference_number":"EMEA/HMPC/342482/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-aloe-emeahmpc763102006_en.pdf"},
    {"id":"27753","name":"Overview of comments received on Community herbal monograph on Thymus vulgaris L. and Thymus zygis L., herba and Primula veris L. and Primula elatior (L.) Hill, radix","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-07-25T02:00:00Z","reference_number":"EMA/HMPC/897630/2011, Corr 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-thymus-vulgaris-l-and-thymus-zygis-l-herba-and-primula-veris-l-and-primula-elatior-l-hill-radix_en.pdf"},
    {"id":"27874","name":"Overview of comments received on the draft Community herbal monograph on Echinacea angustifolia DC., radix","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2012-05-29T16:30:00Z","last_updated_date":"2012-05-29T16:30:00Z","reference_number":"EMA/HMPC/729132/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-draft-community-herbal-monograph-echinacea-angustifolia-dc-radix_en.pdf"},
    {"id":"28140","name":"Superseded overview of comments received on 'community herbal monograph on Valeriana officinalis L., radix' EMEA/HMPC/340719/2005 (Valerianae aetheroleum)","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2016-06-20T02:00:00Z","last_updated_date":"2016-06-20T02:00:00Z","reference_number":"EMEA/HMPC/50774/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-valeriana-officinalis-l-radix-emeahmpc3407192005-valerianae-aetheroleum_en.pdf"},
    {"id":"28162","name":"Overview of comments received on Community herbal monograph on Achillea millefolium L., flos","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-09-30T02:00:00Z","last_updated_date":"2011-09-30T02:00:00Z","reference_number":"EMA/HMPC/238586/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-achillea-millefolium-l-flos_en.pdf"},
    {"id":"28185","name":"Superseded final overview of comments received on European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix - Revision 1","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2018-08-20T02:00:00Z","last_updated_date":"2024-07-12T02:00:00Z","reference_number":"EMA/HMPC/444243/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-final-overview-comments-received-european-union-herbal-monograph-pelargonium-sidoides-dc-or-pelargonium-reniforme-curt-radix-revision-1_en.pdf"},
    {"id":"28571","name":"Overview of comments received on European Union herbal monograph and European Union herbal list entry on Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other spe(..) - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2015-04-09T13:00:00Z","last_updated_date":"2015-04-09T13:00:00Z","reference_number":"EMA/HMPC/166767/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-and-european-union-herbal-list-entry-melaleuca-alternifolia-maiden-and-betch-cheel-m-linariifolia-smith-m-dissitiflora-f-mueller-andor-other_en.pdf"},
    {"id":"28584","name":"Overview of comments on draft Community herbal monograph on Lavandula angustifolia P. Mill., flos","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2012-06-13T17:00:00Z","last_updated_date":"2012-06-13T17:00:00Z","reference_number":"EMA/HMPC/734383/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-draft-community-herbal-monograph-lavandula-angustifolia-p-mill-flos_en.pdf"},
    {"id":"28827","name":"Final overview of comments received on European Union herbal monograph on Species diureticae","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/HMPC/81744/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-received-european-union-herbal-monograph-species-diureticae_en.pdf"},
    {"id":"28865","name":"Superseded overview of comments received on community herbal monograph on Hypericum perforatum L., herba","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2009-12-21T00:09:00Z","last_updated_date":"2023-02-22T00:09:00Z","reference_number":"EMA/HMPC/258853/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-hypericum-perforatum-l-herba_en.pdf"},
    {"id":"29123","name":"Overview of comments received on “Reflection paper on Polycyclic Aromatic Hydrocarbons in herbal medicinal products/traditional herbal medicinal products” (EMA/HMPC/300551/2015)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T18:14:00Z","last_updated_date":"2017-12-19T18:14:00Z","reference_number":"EMA/HMPC/679440/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-reflection-paper-polycyclic-aromatic-hydrocarbons-herbal-medicinal-productstraditional-herbal-medicinal-products-emahmpc3005512015_en.pdf"},
    {"id":"29176","name":"Superseded overview of comments on draft Community herbal monograph on Rheum palmatum L., and Rheum officinale Baillon, radix EMEA/HMPC/189624/2007","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-06-05T02:09:00Z","last_updated_date":"2020-08-18T02:09:00Z","reference_number":"EMEA/HMPC/494207/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-draft-community-herbal-monograph-rheum-palmatum-l-and-rheum-officinale-baillon-radix-emeahmpc1896242007_en.pdf"},
    {"id":"29745","name":"Overview of comments received on procedure on management of proposals submitted by interested parties for community list entries or community herbal monographs (EMEA/HMPC/328575/2007) - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-05-08T02:00:00Z","last_updated_date":"2008-05-08T02:00:00Z","reference_number":"EMEA/HMPC/191615/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-procedure-management-proposals-submitted-interested-parties-community-list-entries-or-community-herbal-monographs-emeahmpc3285752007-revision-1_en.pdf"},
    {"id":"30090","name":"Superseded overview of comments received on community herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2010-09-02T02:00:00Z","last_updated_date":"2010-09-02T02:00:00Z","reference_number":"EMA/HMPC/132077/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos_en.pdf"},
    {"id":"30136","name":"Superseded overview of comments received on Community herbal monograph on Achillea millefolium L., herba - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-09-30T02:00:00Z","last_updated_date":"2011-09-30T02:00:00Z","reference_number":"EMA/HMPC/238500/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-achillea-millefolium-l-herba-first-version_en.pdf"},
    {"id":"30174","name":"Overview of comments received on Community herbal monograph on Juniperus communis L., aetheroleum","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/HMPC/563725/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-juniperus-communis-l-aetheroleum_en.pdf"},
    {"id":"30410","name":"Final overview of comments received on European Union herbal monograph on Salvia officinalis L., folium (EMA/HMPC/277152/2015) - Revision 1","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2017-07-13T02:00:00Z","last_updated_date":"2017-07-13T02:00:00Z","reference_number":"EMA/HMPC/360238/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-received-european-union-herbal-monograph-salvia-officinalis-l-folium-emahmpc2771522015-revision-1_en.pdf"},
    {"id":"30684","name":"Superseded overview of comments received on Community herbal monograph on plantago ovata Forssk., semen (EMEA/HMPC/340861/2005)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2013-07-23T02:00:00Z","reference_number":"EMEA/HMPC/65636/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-plantago-ovata-forssk-semen-emeahmpc3408612005_en.pdf"},
    {"id":"31174","name":"Overview of comments received on guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2013-05-13T12:30:00Z","last_updated_date":"2013-05-13T12:30:00Z","reference_number":"EMA/HMPC/768094/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products-revision-1_en.pdf"},
    {"id":"31466","name":"Overview of comments received on Community herbal monograph on Quercus robur L., Quercus petraea. (Matt.) Liebl., Quercus pubescens Willd., cortex","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-05-18T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMA/HMPC/564675/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-quercus-robur-l-quercus-petraea-matt-liebl-quercus-pubescens-willd-cortex_en.pdf"},
    {"id":"31638","name":"Superseded overview of comments received on 'Community herbal monograph on Plantago ovata Forssk., seminis tegumentum' (EMEA/HMPC/340857/2005)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2013-07-23T02:00:00Z","reference_number":"EMEA/HMPC/65916/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-plantago-ovata-forssk-seminis-tegumentum-emeahmpc3408572005_en.pdf"},
    {"id":"31651","name":"Overview of comments received on Community herbal monograph on Camellia sinensis (L.) Kuntze, non fermentatum folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2014-04-29T14:45:00Z","last_updated_date":"2014-04-29T14:45:00Z","reference_number":"EMA/HMPC/555110/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-camellia-sinensis-l-kuntze-non-fermentatum-folium_en.pdf"},
    {"id":"31818","name":"Superseded overview of comments received on public statement on Centella asiatica (L.) Urban, herba","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T17:50:00Z","last_updated_date":"2022-09-02T17:50:00Z","reference_number":"EMA/HMPC/573720/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-public-statement-centella-asiatica-l-urban-herba_en.pdf"},
    {"id":"32170","name":"Overview of comments received on European Union herbal monograph on Capsicum annuum L. var. minimum (Miller) Heiser and small fruited varieties of Capsicum frutescens L., fructus (EMA/HMPC/674139/2013)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/HMPC/41015/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-capsicum-annuum-l-var-minimum-miller-heiser-and-small-fruited-varieties-capsicum-frutescens-l-fructus-emahmpc6741392013_en.pdf"},
    {"id":"32927","name":"Superseded overview of comments received on Community herbal monograph on Gentiana lutea L., radix - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2010-03-08T01:00:00Z","last_updated_date":"2010-03-08T01:00:00Z","reference_number":"EMA/HMPC/573967/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-gentiana-lutea-l-radix-first-version_en.pdf"},
    {"id":"33133","name":"Superseded overview of comments received on Community herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2018-04-11T14:00:00Z","reference_number":"EMA/HMPC/46410/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-1_en.pdf"},
    {"id":"33551","name":"Superseded overview of comments received on 'Betula pendula Roth; Betula pubescens Ehrh., folium' (EMEA/HMPC/260019/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2007-05-08T02:09:21Z","last_updated_date":"2015-03-13T01:09:21Z","reference_number":"EMEA/HMPC/488559/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-betula-pendula-roth-betula-pubescens-ehrh-folium-emeahmpc2600192006_en.pdf"},
    {"id":"33579","name":"Overview of comments received on Community herbal monograph on Fucus vesiculosus L., thallus","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2014-08-06T02:00:00Z","last_updated_date":"2014-08-06T02:00:00Z","reference_number":"EMA/HMPC/94567/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-fucus-vesiculosus-l-thallus_en.pdf"},
    {"id":"33874","name":"Superseded overview of comments received on 'Community herbal monograph on Pimpinella anisum L., fructus' (EMEA/HMPC/137423/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-06-12T02:09:21Z","last_updated_date":"2014-06-17T02:09:21Z","reference_number":"EMEA/HMPC/286755/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-pimpinella-anisum-l-fructus-emeahmpc1374232006_en.pdf"},
    {"id":"33998","name":"Overview of comments received on the draft Public Statement on Chelidonium majus L., herba","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/HMPC/352591/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-draft-public-statement-chelidonium-majus-l-herba_en.pdf"},
    {"id":"34052","name":"Superseded overview of comments received on community herbal monograph on Aesculus hippocastanum L., semen - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2020-04-23T02:00:00Z","reference_number":"EMEA/HMPC/262723/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-aesculus-hippocastanum-l-semen-first-version_en.pdf"},
    {"id":"34263","name":"Overview of comments received on European Union herbal monograph on Hedera helix L., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2016-01-18T01:00:00Z","last_updated_date":"2016-01-18T01:00:00Z","reference_number":"EMA/HMPC/624379/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-hedera-helix-l-folium_en.pdf"},
    {"id":"34386","name":"Overview of comments received on Community herbal monograph on Arnica montana L., flos","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/HMPC/36949/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-arnica-montana-l-flos_en.pdf"},
    {"id":"34620","name":"Superseded overview of comments received on Community herbal monograph on Hedera helix L., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2012-01-19T01:00:00Z","last_updated_date":"2016-01-18T01:00:00Z","reference_number":"EMA/HMPC/570419/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-hedera-helix-l-folium_en.pdf"},
    {"id":"34876","name":"Superseded overview of comments received on Community herbal monograph on Ribes nigrum L., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2010-06-30T02:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"EMA/HMPC/5687/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-ribes-nigrum-l-folium_en.pdf"},
    {"id":"34985","name":"Overview of comments received on European Union herbal monograph Prunus africana (Hook f.) Kalkm., cortex (EMA/HMPC/680626/2013)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2017-09-01T02:00:00Z","last_updated_date":"2017-09-01T02:00:00Z","reference_number":"EMA/HMPC/246260/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-prunus-africana-hook-f-kalkm-cortex-emahmpc6806262013_en.pdf"},
    {"id":"35561","name":"Superseded - Overview of comments received on Community herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-05-16T02:00:00Z","last_updated_date":"2018-07-03T02:00:00Z","reference_number":"EMA/HMPC/439318/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-first-version_en.pdf"},
    {"id":"36229","name":"Overview of comments received on Community herbal monograph on Thymus vulgaris L., Thymus zygis Loefl. ex. L., aetheroleum - Superseded","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/638578/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-thymus-vulgaris-l-thymus-zygis-loefl-ex-l-aetheroleum-superseded_en.pdf"},
    {"id":"37254","name":"Superseded overview of comments received on Community herbal monograph on Urtica dioica L., Urtica urens L. their hybrids or their mixtures, radix - First version","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2012-11-05T12:20:00Z","last_updated_date":"2025-03-12T12:20:00Z","reference_number":"EMA/HMPC/203843/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-their-hybrids-or-their-mixtures-radix-first-version_en.pdf"},
    {"id":"37596","name":"Overview of comments received on 'community herbal monograph on Verbascum thapsus L., V. densiflorum Bertol., and V. phlomoides L., flos' (EMEA/HMPC/395213/2007)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/HMPC/87230/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-verbascum-thapsus-l-v-densiflorum-bertol-and-v-phlomoides-l-flos-emeahmpc3952132007_en.pdf"},
    {"id":"38060","name":"Final overview of comments received on European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium (EMA/HMPC/750269/2016) - Revision 2","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2018-04-11T14:00:00Z","last_updated_date":"2018-04-11T14:00:00Z","reference_number":"EMA/HMPC/589805/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-received-european-union-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-emahmpc7502692016-revision-2_en.pdf"},
    {"id":"38344","name":"Final overview of comments received on European Union herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizoma- Revision 1","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2018-07-03T02:00:00Z","last_updated_date":"2018-07-03T02:00:00Z","reference_number":"EMA/HMPC/193919/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-received-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizoma-revision-1_en.pdf"},
    {"id":"38429","name":"Superseded overview of comments on 'Community herbal monograph and list entry on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix' (EMEA/HMPC/244569/2006) and (EMEA/HMPC/83756/2007)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-05-08T02:09:21Z","last_updated_date":"2014-10-06T02:09:21Z","reference_number":"EMEA/HMPC/591758/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-community-herbal-monograph-and-list-entry-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix-emeahmpc2445692006-and-emeahmpc837562007_en.pdf"},
    {"id":"38582","name":"Superseded overview of comments received on 'Community herbal monograph on Primula veris L., primula elatior (L.) Hill, radix' (EMEA/HMPC/143370/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-11-01T01:00:00Z","last_updated_date":"2008-11-01T01:00:00Z","reference_number":"EMEA/HMPC/373077/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-primula-veris-l-primula-elatior-l-hill-radix-emeahmpc1433702006_en.pdf"}    {"id":"38837","name":"Superseded overview of comments received on 'Community herbal monograph on Mentha x piperita L., folium' (EMEA/HMPC/193909/2007)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/101815/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-mentha-x-piperita-l-folium-emeahmpc1939092007_en.pdf"},
    {"id":"39747","name":"Final overview of comments received on Public statement on Paeonia lactiflora Pall. and/or Paeonia veitchii Lynch, radix (Paeoniae radix rubra)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2017-04-25T17:35:00Z","last_updated_date":"2017-04-25T17:35:00Z","reference_number":"EMA/HMPC/610812/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-received-public-statement-paeonia-lactiflora-pall-andor-paeonia-veitchii-lynch-radix-paeoniae-radix-rubra_en.pdf"},
    {"id":"39972","name":"Superseded overview of comments received on 'Community herbal monograph on Urtica dioica L. and Urtica urens L., herba' (EMEA/HMPC/170261/2006)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2025-03-07T02:00:00Z","reference_number":"EMEA/HMPC/4251/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-herba-emea-hmpc-170261-2006_en.pdf"},
    {"id":"40044","name":"Final overview of comments received on European Union herbal monograph on Althaea officinalis L., radix (EMA/HMPC/436679/2015)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2016-11-04T15:12:00Z","last_updated_date":"2016-11-04T15:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-received-european-union-herbal-monograph-althaea-officinalis-l-radix-emahmpc4366792015_en.pdf"},
    {"id":"40536","name":"Superseded overview of comments received on 'community herbal monograph on Valeriana officinalis L., radix' EMEA/HMPC/340719/2005","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2016-04-28T01:09:21Z","reference_number":"EMEA/HMPC/50774/2006","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-overview-comments-received-community-herbal-monograph-valeriana-officinalis-l-radix-emeahmpc3407192005_en.pdf"},
    {"id":"40863","name":"Overview of comments received on Community herbal monograph on Ilex paraguariensis St. Hilaire, folium - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-02-14T01:00:00Z","last_updated_date":"2011-02-14T01:00:00Z","reference_number":"EMA/HMPC/139995/2010","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-ilex-paraguariensis-st-hilaire-folium-first-version_en.pdf"},
    {"id":"40915","name":"Overview of comments received on Community herbal monograph on Filipendula ulmaria (L.) Maxim., flos - First version","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2011-09-29T02:00:00Z","last_updated_date":"2011-09-29T02:00:00Z","reference_number":"EMA/HMPC/326673/2011","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-filipendula-ulmaria-l-maxim-flos-first-version_en.pdf"},
    {"id":"41565","name":"Overview of comments received on community herbal monograph on Hamamelis virginiana L., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMA/HMPC/280729/2009","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-hamamelis-virginiana-l-folium_en.pdf"},
    {"id":"41930","name":"Superseded final overview of comments received on draft Community herbal monograph on Panax ginseng C.A. Meyer, radix","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2014-05-22T02:00:00Z","last_updated_date":"2024-07-12T02:00:00Z","reference_number":"EMA/HMPC/679424/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/superseded-final-overview-comments-received-draft-community-herbal-monograph-panax-ginseng-ca-meyer-radix_en.pdf"},
    {"id":"42094","name":"Final overview of comments on second draft European Union herbal monograph on Silybum marianum (L.) Gaertn., fructus (EMA/HMPC/294187/2013)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2018-09-19T02:00:00Z","last_updated_date":"2018-09-19T02:00:00Z","reference_number":"EMA/HMPC/772735/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-second-draft-european-union-herbal-monograph-silybum-marianum-l-gaertn-fructus-emahmpc2941872013_en.pdf"},
    {"id":"44423","name":"Overview of comments received on European Union herbal monograph on Ruscus aculeatus L., rhizoma (EMA/HMPC/188804/2017) - Revision 1","type":"herbal-comments","status":"Adopted","consultation_date":"","first_published_date":"2019-05-02T17:46:00Z","last_updated_date":"2019-05-02T17:46:00Z","reference_number":"EMA/HMPC/573003/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-ruscus-aculeatus-l-rhizoma-emahmpc1888042017-revision-1_en.pdf"},
    {"id":"44511","name":"Overview of comments received on draft Fragaria vesca L.; Fragaria moschata Weston; Fragaria viridis Weston; Fragaria x ananassa (Weston) Duchesne ex Rozier, folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2019-05-15T17:47:00Z","last_updated_date":"2019-05-15T17:47:00Z","reference_number":"EMA/HMPC/638127/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-draft-fragaria-vesca-l-fragaria-moschata-weston-fragaria-viridis-weston-fragaria-x-ananassa-weston-duchesne-ex-rozier-folium_en.pdf"},
    {"id":"46229","name":"Overview of comments received on European Union herbal monograph on Rhamnus frangula L., cortex (EMA/HMPC/726261/2016) - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2019-12-04T17:46:00Z","last_updated_date":"2019-12-04T17:46:00Z","reference_number":"EMA/HMPC/370682/2019 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-rhamnus-frangula-l-cortex-emahmpc7262612016-revision-1_en.pdf"},
    {"id":"46509","name":"Overview of comments received on community herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T15:48:00Z","last_updated_date":"2020-01-23T15:48:00Z","reference_number":"EMA/HMPC/495797/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-community-herbal-monograph-valeriana-officinalis-l-radix-and-humulus-lupulus-l-flos-revision-1_en.pdf"},
    {"id":"47304","name":"Overview of comments received on European Union herbal monographs on Senna alexandrina Mill., folium (EMA/HMPC/625849/2015) and Senna alexandrina Mill., fructus (EMA/HMPC/228761/2016) - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2020-04-02T16:19:00Z","last_updated_date":"2020-04-02T16:19:00Z","reference_number":"EMA/HMPC/265637/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monographs-senna-alexandrina-mill-folium-emahmpc6258492015-and-senna-alexandrina-mill-fructus-emahmpc2287612016-revision-1_en.pdf"},
    {"id":"47309","name":"Overview of comments received on European Union herbal monographs on Senna alexandrina Mill., folium (EMA/HMPC/625849/2015) and Senna alexandrina Mill., fructus (EMA/HMPC/228761/2016) - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2020-04-02T16:52:00Z","last_updated_date":"2020-04-02T16:52:00Z","reference_number":"EMA/HMPC/265637/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monographs-senna-alexandrina-mill-folium-emahmpc6258492015-and-senna-alexandrina-mill-fructus-emahmpc2287612016-revision-1_en.pdf-0"},
    {"id":"47464","name":"Overview of comments received on European Union herbal monograph on Aesculus hippocastanum L., semen (EMA/HMPC/628242/2018) Final - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2020-04-23T13:38:00Z","last_updated_date":"2020-04-23T13:38:00Z","reference_number":"EMA/HMPC/611976/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-aesculus-hippocastanum-l-semen-emahmpc6282422018-final-revision-1_en.pdf"},
    {"id":"47498","name":"Overview of comments received on European Union herbal monograph on Allium sativum L., bulbus EMA/HMPC/7685/2013)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2020-04-28T10:44:00Z","last_updated_date":"2020-04-28T10:44:00Z","reference_number":"EMA/HMPC/48689/2017 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-allium-sativum-l-bulbus-emahmpc76852013_en.pdf"},
    {"id":"48612","name":"Overview of comments received on 'Draft European Union herbal monograph on Tanacetum parthenium (L.) Schultz Bip., herba - Revision 1'","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2020-08-14T11:20:00Z","last_updated_date":"2020-08-14T11:20:00Z","reference_number":"EMA/HMPC/358928/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-draft-european-union-herbal-monograph-tanacetum-parthenium-l-schultz-bip-herba-revision-1_en.pdf"},
    {"id":"48622","name":"Overview of comments received on European Union herbal monograph on Rheum palmatum L. and Rheum officinale Baillon, radix - Draft Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2020-08-18T15:54:00Z","last_updated_date":"2020-08-18T15:54:00Z","reference_number":"EMA/HMPC/106851/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-rheum-palmatum-l-and-rheum-officinale-baillon-radix-draft-revision-1_en.pdf"},
    {"id":"48639","name":"Overview of comments received on European Union herbal monograph on Herniaria glabra L., H. hirsuta L., H. incana Lam., herba","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T14:50:00Z","last_updated_date":"2020-08-19T14:50:00Z","reference_number":"EMA/HMPC/229208/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-herniaria-glabra-l-h-hirsuta-l-h-incana-lam-herba_en.pdf"},
    {"id":"50680","name":"Overview of comments received on European Union Draft Herbal Monograph on Species amarae (EMA/HMPC/44543/2018)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2021-03-23T11:48:00Z","last_updated_date":"2021-03-23T11:48:00Z","reference_number":"EMA/HMPC/487459/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-draft-herbal-monograph-species-amarae-emahmpc445432018_en.pdf"},
    {"id":"50714","name":"Overview of comments received on European Union Draft Herbal Monograph on Species sedativae (EMA/HMPC/438183/2017)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2021-03-25T16:47:00Z","last_updated_date":"2021-03-25T16:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-draft-herbal-monograph-species-sedativae-emahmpc4381832017_en.pdf"},
    {"id":"53422","name":"Overview of comments received on European Union herbal monograph on Orthosiphon aristatus (Blume) Miq. var. aristatus, folium - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T14:07:00Z","last_updated_date":"2021-12-08T14:07:00Z","reference_number":"EMA/HMPC/363594/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-orthosiphon-aristatus-blume-miq-var-aristatus-folium-revision-1_en.pdf"},
    {"id":"54310","name":"Overview of comments received on the draft revised Public statement on the use of herbal medicinal products containing estragole (EMA/HMPC/137212/2005 Rev 1 – 2nd Draft)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2022-03-01T14:15:00Z","last_updated_date":"2022-03-01T14:15:00Z","reference_number":"EMA/HMPC/482974/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-draft-revised-public-statement-use-herbal-medicinal-products-containing-estragole-emahmpc1372122005-rev-1-2nd-draft_en.pdf"},
    {"id":"57758","name":"Overview of comments received on European Union herbal monograph on Vaccinium macrocarpon Aiton, fructus (EMA/HMPC/49135/2017)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2023-02-21T12:11:00Z","last_updated_date":"2023-02-21T12:11:00Z","reference_number":"EMA/HMPC/679981/2021","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-vaccinium-macrocarpon-aiton-fructus-emahmpc491352017_en.pdf"},
    {"id":"57779","name":"Overview of comments received on European Union herbal monograph on Hypericum perforatum L., herba (traditional use) (EMA/HMPC/45508/2017) - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2023-02-22T10:49:00Z","last_updated_date":"2023-02-22T10:49:00Z","reference_number":"EMA/HMPC/536348/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-hypericum-perforatum-l-herba-traditional-use-emahmpc455082017-revision-1_en.pdf"},
    {"id":"57780","name":"Overview of comments received on European Union herbal monograph on Hypericum perforatum L., herba (well-established use and traditional use) (EMA/HMPC/7695/2021) - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2023-02-22T10:51:00Z","last_updated_date":"2023-02-22T10:51:00Z","reference_number":"EMA/HMPC/72258/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-hypericum-perforatum-l-herba-well-established-use-and-traditional-use-emahmpc76952021-revision-1_en.pdf"},
    {"id":"62395","name":"Overview of comments received on European Union herbal monographs on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus and Foeniculum vulgare Miller subsp. vulgare var. dulce (Mill.) Batt. & Trab., fructus","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T12:17:30Z","last_updated_date":"2024-03-01T12:17:30Z","reference_number":"EMA/HMPC/324960/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monographs-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus_en.pdf"},
    {"id":"62398","name":"Overview of comments received on European Union herbal monographs on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus and Foeniculum vulgare Miller subsp. vulgare var. dulce (Mill.) Batt. & Trab., fructus","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T12:35:50Z","last_updated_date":"2024-03-01T12:35:50Z","reference_number":"EMA/HMPC/324960/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monographs-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus_en.pdf-0"},
    {"id":"63283","name":"Overview of comments received on European Union herbal monograph on Rhodiola rosea L., rhizoma et radix","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2024-05-21T13:53:00Z","last_updated_date":"2024-05-21T13:53:00Z","reference_number":"EMA/HMPC/509547/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-rhodiola-rosea-l-rhizoma-et-radix_en.pdf"},
    {"id":"64119","name":"Overview of comments received on European Union herbal monograph on Pelargonium sidoides DC; Pelargonium reniforme Curt., radix - Revision 2","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T16:07:00Z","last_updated_date":"2024-07-12T16:07:00Z","reference_number":"EMA/HMPC/108559/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-pelargonium-sidoides-dc-pelargonium-reniforme-curt-radix-revision-2_en.pdf"},
    {"id":"64205","name":"Overview of comments received on public statement on Foeniculum vulgare Miller subsp. vulgare var. vulgare, aetheroleum (EMA/HMPC/522456/2021)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2024-07-18T15:41:00Z","last_updated_date":"2024-07-18T15:41:00Z","reference_number":"EMA/HMPC/324881/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-public-statement-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-aetheroleum-ema-hmpc-522456-2021_en.pdf"},
    {"id":"64968","name":"Overview of comments received on European Union herbal monograph on Rosmarinus officinalis L., aetheroleum (EMA/HMPC/513893/2021)","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T11:23:00Z","last_updated_date":"2024-09-20T11:23:00Z","reference_number":"EMA/HMPC/322623/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-rosmarinus-officinalis-l-aetheroleum-ema-hmpc-513893-2021_en.pdf"},
    {"id":"67062","name":"Final overview of comments received on European Union herbal monograph on Eucalyptus globulus Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker, aetheroleum - Revision 1","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T15:47:33Z","last_updated_date":"2025-02-28T15:47:33Z","reference_number":"EMA/HMPC/418628/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/final-overview-comments-received-european-union-herbal-monograph-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-eucalyptus-smithii-rt-baker-aetheroleum-revision-1_en.pdf"},
    {"id":"68042","name":"Overview of comments received on European Union herbal monograph on Cistus creticus L., herba","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2025-04-30T15:43:22Z","last_updated_date":"2025-04-30T15:43:22Z","reference_number":"EMA/HMPC/9713/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-cistus-creticus-l-herba_en.pdf"},
    {"id":"68829","name":"Overview of comments received on European Union herbal monograph on Zingiber officinale Roscoe, rhizoma","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2025-06-19T11:06:55Z","last_updated_date":"2025-06-19T11:06:55Z","reference_number":"EMA/HMPC/524702/2024","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-zingiber-officinale-roscoe-rhizoma_en.pdf"},
    {"id":"70657","name":"Overview of comments received on European Union herbal monograph on Plantago lanceolata L., folium","type":"herbal-comments","status":"unknown","consultation_date":"","first_published_date":"2025-10-20T09:42:00Z","last_updated_date":"2025-10-20T09:42:00Z","reference_number":"EMA/HMPC/5153/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-comments/overview-comments-received-european-union-herbal-monograph-plantago-lanceolata-l-folium_en.pdf"},
    {"id":"2907","name":"Javanese turmeric: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T01:00:00Z","last_updated_date":"2016-12-02T01:00:00Z","reference_number":"EMA/654803/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/javanese-turmeric-summary-public_en.pdf"},
    {"id":"3378","name":"Bladderwrack: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T17:31:00Z","last_updated_date":"2016-12-02T17:31:00Z","reference_number":"EMA/661584/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/bladderwrack-summary-public_en.pdf"},
    {"id":"3661","name":"Ginkgo leaf - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-12-14T01:00:00Z","reference_number":"EMA/HMPC/324406/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/ginkgo-leaf-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/ginkgo-leaf-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/ginkgo-leaf-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/ginkgo-leaf-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/ginkgo-leaf-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/ginkgo-leaf-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/ginkgo-leaf-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/ginkgo-leaf-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/ginkgo-leaf-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/ginkgo-leaf-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/ginkgo-leaf-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/ginkgo-leaf-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/ginkgo-leaf-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/ginkgo-leaf-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/ginkgo-leaf-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/ginkgo-leaf-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/ginkgo-leaf-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/ginkgo-leaf-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/ginkgo-leaf-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/ginkgo-leaf-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/ginkgo-leaf-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/ginkgo-leaf-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/ginkgo-leaf-summary-public_sv.pdf"}},
    {"id":"3732","name":"Fresh Billberry Fruit - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"EMA/680058/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/fresh-billberry-fruit-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/fresh-billberry-fruit-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/fresh-billberry-fruit-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/fresh-billberry-fruit-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/fresh-billberry-fruit-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/fresh-billberry-fruit-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/fresh-billberry-fruit-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/fresh-billberry-fruit-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/fresh-billberry-fruit-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/fresh-billberry-fruit-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/fresh-billberry-fruit-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/fresh-billberry-fruit-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/fresh-billberry-fruit-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/fresh-billberry-fruit-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/fresh-billberry-fruit-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/fresh-billberry-fruit-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/fresh-billberry-fruit-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/fresh-billberry-fruit-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/fresh-billberry-fruit-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/fresh-billberry-fruit-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/fresh-billberry-fruit-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/fresh-billberry-fruit-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/fresh-billberry-fruit-summary-public_sv.pdf"}},
    {"id":"5511","name":"Thyme and primula root: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"EMA/262389/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/thyme-and-primula-root-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/thyme-and-primula-root-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/thyme-and-primula-root-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/thyme-and-primula-root-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/thyme-and-primula-root-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/thyme-and-primula-root-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/thyme-and-primula-root-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/thyme-and-primula-root-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/thyme-and-primula-root-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/thyme-and-primula-root-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/thyme-and-primula-root-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/thyme-and-primula-root-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/thyme-and-primula-root-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/thyme-and-primula-root-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/thyme-and-primula-root-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/thyme-and-primula-root-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/thyme-and-primula-root-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/thyme-and-primula-root-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/thyme-and-primula-root-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/thyme-and-primula-root-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/thyme-and-primula-root-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/thyme-and-primula-root-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/thyme-and-primula-root-summary-public_sv.pdf"}},
    {"id":"6057","name":"Saw palmetto fruit: summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T17:00:00Z","last_updated_date":"2016-04-28T17:00:00Z","reference_number":"EMA/823974/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/saw-palmetto-fruit-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/saw-palmetto-fruit-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/saw-palmetto-fruit-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/saw-palmetto-fruit-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/saw-palmetto-fruit-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/saw-palmetto-fruit-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/saw-palmetto-fruit-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/saw-palmetto-fruit-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/saw-palmetto-fruit-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/saw-palmetto-fruit-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/saw-palmetto-fruit-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/saw-palmetto-fruit-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/saw-palmetto-fruit-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/saw-palmetto-fruit-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/saw-palmetto-fruit-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/saw-palmetto-fruit-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/saw-palmetto-fruit-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/saw-palmetto-fruit-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/saw-palmetto-fruit-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/saw-palmetto-fruit-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/saw-palmetto-fruit-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/saw-palmetto-fruit-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/saw-palmetto-fruit-summary-public_sv.pdf"}},
    {"id":"6197","name":"Ispaghula seed - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"EMA/HMPC/313692/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/ispaghula-seed-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/ispaghula-seed-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/ispaghula-seed-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/ispaghula-seed-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/ispaghula-seed-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/ispaghula-seed-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/ispaghula-seed-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/ispaghula-seed-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/ispaghula-seed-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/ispaghula-seed-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/ispaghula-seed-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/ispaghula-seed-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/ispaghula-seed-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/ispaghula-seed-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/ispaghula-seed-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/ispaghula-seed-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/ispaghula-seed-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/ispaghula-seed-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/ispaghula-seed-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/ispaghula-seed-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/ispaghula-seed-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/ispaghula-seed-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/ispaghula-seed-summary-public_sv.pdf"}},
    {"id":"6259","name":"Ginseng root: Assessment Report Summary for the Public (ARSP)","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T12:16:00Z","last_updated_date":"2026-03-12T12:16:00Z","reference_number":"EMA/HMPC/387747/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/ginseng-root-assessment-report-summary-public-arsp_en.pdf"},
    {"id":"6342","name":"Soya-bean oil: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-05-11T02:00:00Z","last_updated_date":"2017-05-11T02:00:00Z","reference_number":"EMA/93396/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/soya-bean-oil-summary-public_en.pdf"},
    {"id":"6528","name":"Matricaria oil - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-04-05T02:00:00Z","last_updated_date":"2016-04-05T02:00:00Z","reference_number":"EMA/487922/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/matricaria-oil-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/matricaria-oil-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/matricaria-oil-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/matricaria-oil-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/matricaria-oil-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/matricaria-oil-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/matricaria-oil-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/matricaria-oil-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/matricaria-oil-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/matricaria-oil-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/matricaria-oil-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/matricaria-oil-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/matricaria-oil-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/matricaria-oil-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/matricaria-oil-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/matricaria-oil-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/matricaria-oil-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/matricaria-oil-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/matricaria-oil-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/matricaria-oil-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/matricaria-oil-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/matricaria-oil-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/matricaria-oil-summary-public_sv.pdf"}},
    {"id":"7304","name":"Grapevine leaf - Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2018-01-03T12:00:00Z","last_updated_date":"2018-01-03T12:00:00Z","reference_number":"EMA/381757/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/grapevine-leaf-summary-public_en.pdf"},
    {"id":"8133","name":"Marshmallow root: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T01:00:00Z","last_updated_date":"2016-12-02T01:00:00Z","reference_number":"EMA/570566/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/marshmallow-root-summary-public_en.pdf"},
    {"id":"8504","name":"Eucalyptus leaf - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"EMA/HMPC/300235/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/eucalyptus-leaf-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/eucalyptus-leaf-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/eucalyptus-leaf-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/eucalyptus-leaf-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/eucalyptus-leaf-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/eucalyptus-leaf-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/eucalyptus-leaf-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/eucalyptus-leaf-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/eucalyptus-leaf-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/eucalyptus-leaf-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/eucalyptus-leaf-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/eucalyptus-leaf-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/eucalyptus-leaf-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/eucalyptus-leaf-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/eucalyptus-leaf-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/eucalyptus-leaf-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/eucalyptus-leaf-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/eucalyptus-leaf-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/eucalyptus-leaf-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/eucalyptus-leaf-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/eucalyptus-leaf-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/eucalyptus-leaf-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/eucalyptus-leaf-summary-public_sv.pdf"}},
    {"id":"8845","name":"Matricaria flower - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-04-05T17:30:00Z","last_updated_date":"2016-04-05T17:30:00Z","reference_number":"EMA/490629/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/matricaria-flower-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/matricaria-flower-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/matricaria-flower-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/matricaria-flower-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/matricaria-flower-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/matricaria-flower-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/matricaria-flower-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/matricaria-flower-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/matricaria-flower-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/matricaria-flower-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/matricaria-flower-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/matricaria-flower-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/matricaria-flower-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/matricaria-flower-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/matricaria-flower-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/matricaria-flower-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/matricaria-flower-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/matricaria-flower-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/matricaria-flower-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/matricaria-flower-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/matricaria-flower-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/matricaria-flower-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/matricaria-flower-summary-public_sv.pdf"}},
    {"id":"9044","name":"Sandy everlasting: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"EMA/269745/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/sandy-everlasting-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/sandy-everlasting-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/sandy-everlasting-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/sandy-everlasting-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/sandy-everlasting-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/sandy-everlasting-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/sandy-everlasting-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/sandy-everlasting-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/sandy-everlasting-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/sandy-everlasting-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/sandy-everlasting-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/sandy-everlasting-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/sandy-everlasting-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/sandy-everlasting-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/sandy-everlasting-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/sandy-everlasting-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/sandy-everlasting-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/sandy-everlasting-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/sandy-everlasting-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/sandy-everlasting-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/sandy-everlasting-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/sandy-everlasting-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/sandy-everlasting-summary-public_sv.pdf"}},
    {"id":"9438","name":"Anise oil: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-10-06T02:00:00Z","last_updated_date":"2016-10-06T02:00:00Z","reference_number":"EMA/412178/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/anise-oil-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/anise-oil-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/anise-oil-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/anise-oil-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/anise-oil-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/anise-oil-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/anise-oil-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/anise-oil-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/anise-oil-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/anise-oil-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/anise-oil-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/anise-oil-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/anise-oil-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/anise-oil-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/anise-oil-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/anise-oil-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/anise-oil-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/anise-oil-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/anise-oil-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/anise-oil-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/anise-oil-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/anise-oil-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/anise-oil-summary-public_sv.pdf"}},
    {"id":"9669","name":"Valerian essential oil: summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T17:00:00Z","last_updated_date":"2016-04-28T17:00:00Z","reference_number":"EMA/154066/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/valerian-essential-oil-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/valerian-essential-oil-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/valerian-essential-oil-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/valerian-essential-oil-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/valerian-essential-oil-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/valerian-essential-oil-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/valerian-essential-oil-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/valerian-essential-oil-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/valerian-essential-oil-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/valerian-essential-oil-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/valerian-essential-oil-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/valerian-essential-oil-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/valerian-essential-oil-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/valerian-essential-oil-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/valerian-essential-oil-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/valerian-essential-oil-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/valerian-essential-oil-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/valerian-essential-oil-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/valerian-essential-oil-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/valerian-essential-oil-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/valerian-essential-oil-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/valerian-essential-oil-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/valerian-essential-oil-summary-public_sv.pdf"}},
    {"id":"9837","name":"Capsicum - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"EMA/HMPC/331421/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/capsicum-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/capsicum-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/capsicum-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/capsicum-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/capsicum-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/capsicum-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/capsicum-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/capsicum-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/capsicum-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/capsicum-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/capsicum-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/capsicum-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/capsicum-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/capsicum-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/capsicum-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/capsicum-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/capsicum-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/capsicum-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/capsicum-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/capsicum-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/capsicum-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/capsicum-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/capsicum-summary-public_sv.pdf"}},
    {"id":"10560","name":"Valerian root: Assessment Report Summary for the Public (ARSP)","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T17:00:00Z","last_updated_date":"2026-03-11T16:51:00Z","reference_number":"EMA/HMPC/387742/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/valerian-root-assessment-report-summary-public-arsp_en.pdf"},
    {"id":"10884","name":"Bearberry leaf: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2018-04-10T02:00:00Z","reference_number":"EMA/181295/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/bearberry-leaf-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/bearberry-leaf-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/bearberry-leaf-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/bearberry-leaf-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/bearberry-leaf-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/bearberry-leaf-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/bearberry-leaf-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/bearberry-leaf-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/bearberry-leaf-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/bearberry-leaf-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/bearberry-leaf-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/bearberry-leaf-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/bearberry-leaf-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/bearberry-leaf-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/bearberry-leaf-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/bearberry-leaf-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/bearberry-leaf-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/bearberry-leaf-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/bearberry-leaf-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/bearberry-leaf-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/bearberry-leaf-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/bearberry-leaf-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/bearberry-leaf-summary-public_sv.pdf"}},
    {"id":"11190","name":"Purple coneflower herb - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-10-20T12:45:00Z","last_updated_date":"2016-02-17T11:55:00Z","reference_number":"EMA/481797/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/purple-coneflower-herb-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/purple-coneflower-herb-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/purple-coneflower-herb-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/purple-coneflower-herb-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/purple-coneflower-herb-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/purple-coneflower-herb-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/purple-coneflower-herb-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/purple-coneflower-herb-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/purple-coneflower-herb-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/purple-coneflower-herb-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/purple-coneflower-herb-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/purple-coneflower-herb-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/purple-coneflower-herb-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/purple-coneflower-herb-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/purple-coneflower-herb-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/purple-coneflower-herb-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/purple-coneflower-herb-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/purple-coneflower-herb-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/purple-coneflower-herb-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/purple-coneflower-herb-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/purple-coneflower-herb-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/purple-coneflower-herb-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/purple-coneflower-herb-summary-public_sv.pdf"}},
    {"id":"12558","name":"Mullein Flower: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2018-07-25T16:06:00Z","last_updated_date":"2018-07-25T16:06:00Z","reference_number":"EMA/269687/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/mullein-flower-summary-public_en.pdf"},
    {"id":"13194","name":"Tea tree oil: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T12:16:00Z","last_updated_date":"2017-03-09T12:16:00Z","reference_number":"EMA/814441/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/tea-tree-oil-summary-public_en.pdf"},
    {"id":"13265","name":"Lavender oil - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"EMA/HMPC/530968/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/lavender-oil-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/lavender-oil-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/lavender-oil-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/lavender-oil-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/lavender-oil-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/lavender-oil-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/lavender-oil-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/lavender-oil-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/lavender-oil-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/lavender-oil-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/lavender-oil-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/lavender-oil-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/lavender-oil-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/lavender-oil-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/lavender-oil-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/lavender-oil-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/lavender-oil-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/lavender-oil-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/lavender-oil-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/lavender-oil-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/lavender-oil-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/lavender-oil-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/lavender-oil-summary-public_sv.pdf"}},
    {"id":"13613","name":"Horsetail herb: summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T17:00:00Z","last_updated_date":"2016-04-28T17:00:00Z","reference_number":"EMA/147173/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/horsetail-herb-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/horsetail-herb-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/horsetail-herb-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/horsetail-herb-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/horsetail-herb-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/horsetail-herb-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/horsetail-herb-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/horsetail-herb-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/horsetail-herb-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/horsetail-herb-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/horsetail-herb-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/horsetail-herb-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/horsetail-herb-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/horsetail-herb-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/horsetail-herb-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/horsetail-herb-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/horsetail-herb-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/horsetail-herb-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/horsetail-herb-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/horsetail-herb-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/horsetail-herb-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/horsetail-herb-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/horsetail-herb-summary-public_sv.pdf"}},
    {"id":"13990","name":"Willow bark: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/97861/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/willow-bark-summary-public_en.pdf"},
    {"id":"14333","name":"White horehound - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-10-10T02:00:00Z","last_updated_date":"2014-10-10T02:00:00Z","reference_number":"EMA/HMPC/446032/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/white-horehound-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/white-horehound-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/white-horehound-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/white-horehound-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/white-horehound-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/white-horehound-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/white-horehound-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/white-horehound-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/white-horehound-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/white-horehound-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/white-horehound-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/white-horehound-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/white-horehound-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/white-horehound-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/white-horehound-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/white-horehound-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/white-horehound-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/white-horehound-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/white-horehound-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/white-horehound-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/white-horehound-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/white-horehound-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/white-horehound-summary-public_sv.pdf"}},
    {"id":"14926","name":"Willow herb - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-02-10T01:00:00Z","last_updated_date":"2016-02-10T01:00:00Z","reference_number":"EMA/822538/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/willow-herb-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/willow-herb-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/willow-herb-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/willow-herb-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/willow-herb-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/willow-herb-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/willow-herb-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/willow-herb-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/willow-herb-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/willow-herb-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/willow-herb-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/willow-herb-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/willow-herb-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/willow-herb-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/willow-herb-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/willow-herb-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/willow-herb-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/willow-herb-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/willow-herb-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/willow-herb-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/willow-herb-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/willow-herb-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/willow-herb-summary-public_sv.pdf"}},
    {"id":"15041","name":"Aloes: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-07-06T02:00:00Z","last_updated_date":"2017-07-06T02:00:00Z","reference_number":"EMA/807482/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/aloes-summary-public_en.pdf"},
    {"id":"15138","name":"Iceland moss: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T12:16:00Z","last_updated_date":"2017-03-09T12:16:00Z","reference_number":"EMA/812331/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/iceland-moss-summary-public_en.pdf"},
    {"id":"15889","name":"Blackcurrant leaf: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2018-03-13T01:00:00Z","last_updated_date":"2018-03-13T01:00:00Z","reference_number":"EMA/643910/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/blackcurrant-leaf-summary-public_en.pdf"},
    {"id":"15892","name":"Psyllium seed - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"EMA/HMPC/322933/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/psyllium-seed-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/psyllium-seed-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/psyllium-seed-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/psyllium-seed-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/psyllium-seed-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/psyllium-seed-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/psyllium-seed-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/psyllium-seed-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/psyllium-seed-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/psyllium-seed-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/psyllium-seed-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/psyllium-seed-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/psyllium-seed-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/psyllium-seed-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/psyllium-seed-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/psyllium-seed-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/psyllium-seed-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/psyllium-seed-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/psyllium-seed-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/psyllium-seed-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/psyllium-seed-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/psyllium-seed-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/psyllium-seed-summary-public_sv.pdf"}},
    {"id":"17224","name":"Purple coneflower root: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-08-17T02:00:00Z","last_updated_date":"2017-08-17T02:00:00Z","reference_number":"EMA/377966/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/purple-coneflower-root-summary-public_en.pdf"},
    {"id":"17845","name":"Melissa leaf - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"EMA/HMPC/310761/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/melissa-leaf-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/melissa-leaf-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/melissa-leaf-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/melissa-leaf-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/melissa-leaf-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/melissa-leaf-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/melissa-leaf-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/melissa-leaf-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/melissa-leaf-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/melissa-leaf-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/melissa-leaf-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/melissa-leaf-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/melissa-leaf-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/melissa-leaf-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/melissa-leaf-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/melissa-leaf-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/melissa-leaf-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/melissa-leaf-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/melissa-leaf-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/melissa-leaf-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/melissa-leaf-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/melissa-leaf-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/melissa-leaf-summary-public_sv.pdf"}},
    {"id":"18176","name":"Eleutherococcus root - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-02-10T01:00:00Z","last_updated_date":"2016-02-10T01:00:00Z","reference_number":"EMA/283374/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/eleutherococcus-root-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/eleutherococcus-root-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/eleutherococcus-root-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/eleutherococcus-root-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/eleutherococcus-root-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/eleutherococcus-root-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/eleutherococcus-root-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/eleutherococcus-root-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/eleutherococcus-root-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/eleutherococcus-root-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/eleutherococcus-root-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/eleutherococcus-root-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/eleutherococcus-root-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/eleutherococcus-root-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/eleutherococcus-root-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/eleutherococcus-root-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/eleutherococcus-root-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/eleutherococcus-root-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/eleutherococcus-root-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/eleutherococcus-root-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/eleutherococcus-root-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/eleutherococcus-root-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/eleutherococcus-root-summary-public_sv.pdf"}},
    {"id":"18344","name":"Arctic root - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"EMA/HMPC/289537/2012","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/arctic-root-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/arctic-root-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/arctic-root-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/arctic-root-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/arctic-root-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/arctic-root-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/arctic-root-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/arctic-root-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/arctic-root-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/arctic-root-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/arctic-root-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/arctic-root-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/arctic-root-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/arctic-root-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/arctic-root-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/arctic-root-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/arctic-root-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/arctic-root-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/arctic-root-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/arctic-root-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/arctic-root-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/arctic-root-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/arctic-root-summary-public_sv.pdf"}},
    {"id":"18497","name":"Chicory root - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"EMA/HMPC/286842/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/chicory-root-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/chicory-root-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/chicory-root-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/chicory-root-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/chicory-root-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/chicory-root-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/chicory-root-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/chicory-root-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/chicory-root-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/chicory-root-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/chicory-root-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/chicory-root-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/chicory-root-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/chicory-root-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/chicory-root-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/chicory-root-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/chicory-root-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/chicory-root-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/chicory-root-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/chicory-root-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/chicory-root-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/chicory-root-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/chicory-root-summary-public_sv.pdf"}},
    {"id":"18857","name":"Foeniculum vulgare miller subsp. vulgare var. dulce (Miller) Thellung, fructus Fennel fruit, sweet: HMPC assessment report summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2010-02-16T00:09:21Z","last_updated_date":"2010-02-16T00:09:21Z","reference_number":"EMA/HMPC/411665/2008","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_fr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc-assessment-report-summary-public_sv.pdf"}},
    {"id":"19056","name":"Boldo leaf: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T12:16:00Z","last_updated_date":"2017-03-09T12:16:00Z","reference_number":"EMA/810459/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/boldo-leaf-summary-public_en.pdf"},
    {"id":"19113","name":"Woody nightshade stem - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"EMA/HMPC/261736/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/woody-nightshade-stem-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/woody-nightshade-stem-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/woody-nightshade-stem-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/woody-nightshade-stem-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/woody-nightshade-stem-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/woody-nightshade-stem-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/woody-nightshade-stem-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/woody-nightshade-stem-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/woody-nightshade-stem-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/woody-nightshade-stem-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/woody-nightshade-stem-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/woody-nightshade-stem-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/woody-nightshade-stem-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/woody-nightshade-stem-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/woody-nightshade-stem-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/woody-nightshade-stem-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/woody-nightshade-stem-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/woody-nightshade-stem-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/woody-nightshade-stem-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/woody-nightshade-stem-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/woody-nightshade-stem-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/woody-nightshade-stem-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/woody-nightshade-stem-summary-public_sv.pdf"}},
    {"id":"20331","name":"Agrimony - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"EMA/HMPC/332849/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/agrimony-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/agrimony-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/agrimony-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/agrimony-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/agrimony-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/agrimony-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/agrimony-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/agrimony-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/agrimony-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/agrimony-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/agrimony-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/agrimony-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/agrimony-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/agrimony-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/agrimony-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/agrimony-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/agrimony-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/agrimony-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/agrimony-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/agrimony-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/agrimony-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/agrimony-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/agrimony-summary-public_sv.pdf"}},
    {"id":"22003","name":"Eucalyptus oil: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T12:23:00Z","last_updated_date":"2016-12-05T12:23:00Z","reference_number":"EMA/HMPC/288003/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/eucalyptus-oil-summary-public_en.pdf"},
    {"id":"22985","name":"Aniseed: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-10-06T02:00:00Z","last_updated_date":"2016-10-06T02:00:00Z","reference_number":"EMA/305345/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/aniseed-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/aniseed-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/aniseed-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/aniseed-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/aniseed-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/aniseed-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/aniseed-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/aniseed-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/aniseed-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/aniseed-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/aniseed-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/aniseed-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/aniseed-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/aniseed-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/aniseed-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/aniseed-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/aniseed-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/aniseed-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/aniseed-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/aniseed-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/aniseed-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/aniseed-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/aniseed-summary-public_sv.pdf"}},
    {"id":"23677","name":"Ispaghula husk - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"EMA/HMPC/313600/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/ispaghula-husk-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/ispaghula-husk-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/ispaghula-husk-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/ispaghula-husk-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/ispaghula-husk-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/ispaghula-husk-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/ispaghula-husk-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/ispaghula-husk-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/ispaghula-husk-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/ispaghula-husk-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/ispaghula-husk-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/ispaghula-husk-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/ispaghula-husk-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/ispaghula-husk-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/ispaghula-husk-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/ispaghula-husk-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/ispaghula-husk-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/ispaghula-husk-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/ispaghula-husk-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/ispaghula-husk-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/ispaghula-husk-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/ispaghula-husk-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/ispaghula-husk-summary-public_sv.pdf"}},
    {"id":"24803","name":"Primula flower: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-10-06T02:00:00Z","last_updated_date":"2016-10-06T02:00:00Z","reference_number":"EMA/423706/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/primula-flower-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/primula-flower-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/primula-flower-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/primula-flower-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/primula-flower-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/primula-flower-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/primula-flower-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/primula-flower-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/primula-flower-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/primula-flower-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/primula-flower-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/primula-flower-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/primula-flower-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/primula-flower-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/primula-flower-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/primula-flower-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/primula-flower-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/primula-flower-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/primula-flower-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/primula-flower-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/primula-flower-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/primula-flower-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/primula-flower-summary-public_sv.pdf"}},
    {"id":"25308","name":"Ivy leaf - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-02-10T01:00:00Z","last_updated_date":"2018-10-01T17:37:00Z","reference_number":"EMA/821305/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/ivy-leaf-summary-public_en.pdf"},
    {"id":"25706","name":"Comfrey root - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-12-07T01:00:00Z","reference_number":"EMA/HMPC/333915/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/comfrey-root-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/comfrey-root-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/comfrey-root-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/comfrey-root-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/comfrey-root-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/comfrey-root-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/comfrey-root-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/comfrey-root-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/comfrey-root-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/comfrey-root-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/comfrey-root-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/comfrey-root-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/comfrey-root-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/comfrey-root-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/comfrey-root-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/comfrey-root-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/comfrey-root-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/comfrey-root-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/comfrey-root-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/comfrey-root-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/comfrey-root-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/comfrey-root-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/comfrey-root-summary-public_sv.pdf"}},
    {"id":"25873","name":"Rose flower: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-07-06T02:00:00Z","last_updated_date":"2017-07-06T02:00:00Z","reference_number":"EMA/237220/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/rose-flower-summary-public_en.pdf"},
    {"id":"26275","name":"Caraway oil - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-10-20T12:45:00Z","last_updated_date":"2015-10-20T12:45:00Z","reference_number":"EMA/499012/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/caraway-oil-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/caraway-oil-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/caraway-oil-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/caraway-oil-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/caraway-oil-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/caraway-oil-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/caraway-oil-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/caraway-oil-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/caraway-oil-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/caraway-oil-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/caraway-oil-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/caraway-oil-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/caraway-oil-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/caraway-oil-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/caraway-oil-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/caraway-oil-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/caraway-oil-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/caraway-oil-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/caraway-oil-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/caraway-oil-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/caraway-oil-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/caraway-oil-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/caraway-oil-summary-public_sv.pdf"}},
    {"id":"28357","name":"Black cohosh: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2018-07-26T02:00:00Z","last_updated_date":"2018-07-26T02:00:00Z","reference_number":"EMA/265439/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/black-cohosh-summary-public_en.pdf"},
    {"id":"28974","name":"Primula root: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-10-06T02:00:00Z","last_updated_date":"2016-10-06T02:00:00Z","reference_number":"EMA/424238/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/primula-root-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/primula-root-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/primula-root-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/primula-root-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/primula-root-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/primula-root-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/primula-root-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/primula-root-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/primula-root-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/primula-root-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/primula-root-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/primula-root-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/primula-root-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/primula-root-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/primula-root-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/primula-root-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/primula-root-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/primula-root-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/primula-root-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/primula-root-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/primula-root-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/primula-root-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/primula-root-summary-public_sv.pdf"}},
    {"id":"29115","name":"Guarana seed - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"EMA/HMPC/284498/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/guarana-seed-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/guarana-seed-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/guarana-seed-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/guarana-seed-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/guarana-seed-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/guarana-seed-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/guarana-seed-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/guarana-seed-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/guarana-seed-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/guarana-seed-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/guarana-seed-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/guarana-seed-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/guarana-seed-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/guarana-seed-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/guarana-seed-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/guarana-seed-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/guarana-seed-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/guarana-seed-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/guarana-seed-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/guarana-seed-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/guarana-seed-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/guarana-seed-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/guarana-seed-summary-public_sv.pdf"}},
    {"id":"29615","name":"Castor oil: summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T17:00:00Z","last_updated_date":"2016-04-28T17:00:00Z","reference_number":"EMA/108531/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/castor-oil-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/castor-oil-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/castor-oil-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/castor-oil-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/castor-oil-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/castor-oil-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/castor-oil-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/castor-oil-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/castor-oil-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/castor-oil-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/castor-oil-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/castor-oil-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/castor-oil-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/castor-oil-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/castor-oil-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/castor-oil-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/castor-oil-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/castor-oil-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/castor-oil-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/castor-oil-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/castor-oil-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/castor-oil-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/castor-oil-summary-public_sv.pdf"}},
    {"id":"29740","name":"Raspberry leaf: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-07-06T02:00:00Z","last_updated_date":"2017-07-06T02:00:00Z","reference_number":"EMA/237849/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/raspberry-leaf-summary-public_en.pdf"},
    {"id":"29913","name":"Arnica flower: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T01:00:00Z","last_updated_date":"2016-12-02T01:00:00Z","reference_number":"EMA/654173/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/arnica-flower-summary-public_en.pdf"},
    {"id":"29987","name":"Restharrow root: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T12:16:00Z","last_updated_date":"2017-03-09T12:16:00Z","reference_number":"EMA/815130/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/restharrow-root-summary-public_en.pdf"},
    {"id":"30405","name":"Hop strobile: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-10-06T02:00:00Z","last_updated_date":"2016-10-06T02:00:00Z","reference_number":"EMA/304459/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/hop-strobile-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/hop-strobile-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/hop-strobile-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/hop-strobile-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/hop-strobile-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/hop-strobile-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/hop-strobile-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/hop-strobile-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/hop-strobile-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/hop-strobile-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/hop-strobile-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/hop-strobile-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/hop-strobile-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/hop-strobile-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/hop-strobile-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/hop-strobile-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/hop-strobile-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/hop-strobile-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/hop-strobile-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/hop-strobile-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/hop-strobile-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/hop-strobile-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/hop-strobile-summary-public_sv.pdf"}},
    {"id":"34012","name":"Centaury - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-02-10T01:00:00Z","last_updated_date":"2016-02-10T01:00:00Z","reference_number":"EMA/824095/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/centaury-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/centaury-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/centaury-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/centaury-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/centaury-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/centaury-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/centaury-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/centaury-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/centaury-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/centaury-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/centaury-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/centaury-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/centaury-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/centaury-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/centaury-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/centaury-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/centaury-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/centaury-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/centaury-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/centaury-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/centaury-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/centaury-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/centaury-summary-public_sv.pdf"}},
    {"id":"34362","name":"Dittany of Crete herb - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-10-10T02:00:00Z","last_updated_date":"2014-10-10T02:00:00Z","reference_number":"EMA/HMPC/441263/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/dittany-crete-herb-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/dittany-crete-herb-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/dittany-crete-herb-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/dittany-crete-herb-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/dittany-crete-herb-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/dittany-crete-herb-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/dittany-crete-herb-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/dittany-crete-herb-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/dittany-crete-herb-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/dittany-crete-herb-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/dittany-crete-herb-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/dittany-crete-herb-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/dittany-crete-herb-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/dittany-crete-herb-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/dittany-crete-herb-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/dittany-crete-herb-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/dittany-crete-herb-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/dittany-crete-herb-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/dittany-crete-herb-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/dittany-crete-herb-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/dittany-crete-herb-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/dittany-crete-herb-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/dittany-crete-herb-summary-public_sv.pdf"}},
    {"id":"34373","name":"Hawthorn leaf and flower: summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"EMA/268358/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/hawthorn-leaf-and-flower-summary-public_sv.pdf"}},
    {"id":"34822","name":"California poppy - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"EMA/HMPC/334023/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/california-poppy-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/california-poppy-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/california-poppy-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/california-poppy-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/california-poppy-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/california-poppy-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/california-poppy-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/california-poppy-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/california-poppy-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/california-poppy-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/california-poppy-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/california-poppy-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/california-poppy-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/california-poppy-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/california-poppy-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/california-poppy-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/california-poppy-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/california-poppy-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/california-poppy-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/california-poppy-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/california-poppy-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/california-poppy-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/california-poppy-summary-public_sv.pdf"}},
    {"id":"35272","name":"Birch leaf - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-10-20T12:45:00Z","last_updated_date":"2015-10-20T12:45:00Z","reference_number":"EMA/482160/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/birch-leaf-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/birch-leaf-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/birch-leaf-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/birch-leaf-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/birch-leaf-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/birch-leaf-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/birch-leaf-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/birch-leaf-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/birch-leaf-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/birch-leaf-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/birch-leaf-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/birch-leaf-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/birch-leaf-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/birch-leaf-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/birch-leaf-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/birch-leaf-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/birch-leaf-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/birch-leaf-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/birch-leaf-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/birch-leaf-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/birch-leaf-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/birch-leaf-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/birch-leaf-summary-public_sv.pdf"}}    {"id":"35488","name":"Linseed - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-10-20T12:45:00Z","last_updated_date":"2016-02-03T11:45:00Z","reference_number":"EMA/492394/2015 Corr.","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/linseed-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/linseed-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/linseed-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/linseed-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/linseed-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/linseed-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/linseed-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/linseed-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/linseed-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/linseed-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/linseed-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/linseed-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/linseed-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/linseed-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/linseed-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/linseed-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/linseed-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/linseed-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/linseed-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/linseed-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/linseed-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/linseed-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/linseed-summary-public_sv.pdf"}},
    {"id":"35937","name":"Soya-bean lecithin - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2018-01-05T11:35:00Z","last_updated_date":"2018-01-05T11:35:00Z","reference_number":"EMA/90100/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/soya-bean-lecithin-summary-public_en.pdf"},
    {"id":"36700","name":"Melilot: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2018-04-24T18:33:00Z","last_updated_date":"2018-04-24T18:33:00Z","reference_number":"EMA/795143/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/melilot-summary-public_en.pdf"},
    {"id":"37216","name":"Ginger rhizoma: Assessment Report Summary for the Public (ARSP)","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2026-03-12T02:00:00Z","reference_number":"EMA/HMPC/387775/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/ginger-rhizoma-assessment-report-summary-public-arsp_en.pdf"},
    {"id":"37365","name":"Wormwood herb : Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-10-02T18:33:00Z","last_updated_date":"2017-10-02T18:33:00Z","reference_number":"EMA/366468/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/wormwood-herb-summary-public_en.pdf"},
    {"id":"37587","name":"Mouse-ear hawkweed: Assessment Report Summary for the Public (ARSP)","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2026-03-12T16:30:00Z","reference_number":"EMA/HMPC/387725/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/mouse-ear-hawkweed-assessment-report-summary-public-arsp_en.pdf"},
    {"id":"38072","name":"Diuretic herbal tea combinations: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2017-07-06T02:00:00Z","last_updated_date":"2017-07-06T02:00:00Z","reference_number":"EMA/236406/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/diuretic-herbal-tea-combinations-summary-public_en.pdf"},
    {"id":"39127","name":"Olive leaf - Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2017-12-20T10:31:00Z","last_updated_date":"2017-12-20T10:31:00Z","reference_number":"EMA/94696/2017","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/olive-leaf-summary-public_en.pdf"},
    {"id":"39354","name":"Ironwort: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-11-11T01:00:00Z","last_updated_date":"2016-11-11T01:00:00Z","reference_number":"EMA/115825/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/ironwort-summary-public_en.pdf"},
    {"id":"39577","name":"Dried bilberry fruit - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"EMA/685398/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/dried-bilberry-fruit-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/dried-bilberry-fruit-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/dried-bilberry-fruit-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/dried-bilberry-fruit-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/dried-bilberry-fruit-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/dried-bilberry-fruit-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/dried-bilberry-fruit-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/dried-bilberry-fruit-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/dried-bilberry-fruit-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/dried-bilberry-fruit-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/dried-bilberry-fruit-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/dried-bilberry-fruit-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/dried-bilberry-fruit-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/dried-bilberry-fruit-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/dried-bilberry-fruit-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/dried-bilberry-fruit-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/dried-bilberry-fruit-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/dried-bilberry-fruit-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/dried-bilberry-fruit-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/dried-bilberry-fruit-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/dried-bilberry-fruit-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/dried-bilberry-fruit-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/dried-bilberry-fruit-summary-public_sv.pdf"}},
    {"id":"39640","name":"Devil’s claw root: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T01:00:00Z","last_updated_date":"2016-12-02T01:00:00Z","reference_number":"EMA/571858/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/devils-claw-root-summary-public_en.pdf"},
    {"id":"39877","name":"Calendula Flower: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"EMA/267467/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/calendula-flower-summary-public_en.pdf"},
    {"id":"40085","name":"Marjoram: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T01:00:00Z","last_updated_date":"2016-12-02T01:00:00Z","reference_number":"EMA/653011/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/marjoram-summary-public_en.pdf"},
    {"id":"40398","name":"Passion flower: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-10-06T02:00:00Z","last_updated_date":"2016-10-06T02:00:00Z","reference_number":"EMA/275240/2014","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/passion-flower-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/passion-flower-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/passion-flower-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/passion-flower-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/passion-flower-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/passion-flower-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/passion-flower-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/passion-flower-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/passion-flower-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/passion-flower-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/passion-flower-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/passion-flower-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/passion-flower-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/passion-flower-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/passion-flower-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/passion-flower-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/passion-flower-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/passion-flower-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/passion-flower-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/passion-flower-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/passion-flower-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/passion-flower-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/passion-flower-summary-public_sv.pdf"}},
    {"id":"40460","name":"Valeriana officinalis  L., Radix (valerian root): HMPC assessment report summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2010-02-16T01:00:00Z","last_updated_date":"2010-02-16T01:00:00Z","reference_number":"EMA/HMPC/575871/2007","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_fr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/valeriana-officinalis-l-radix-valerian-root-hmpc-assessment-report-summary-public_sv.pdf"}},
    {"id":"40605","name":"Elder flower: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2018-07-26T02:00:00Z","last_updated_date":"2018-07-26T02:00:00Z","reference_number":"EMA/269235/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/elder-flower-summary-public_en.pdf"},
    {"id":"40819","name":"Walnut leaf - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2014-10-10T02:00:00Z","last_updated_date":"2014-10-10T02:00:00Z","reference_number":"EMA/HMPC/432131/2013","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/walnut-leaf-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/walnut-leaf-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/walnut-leaf-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/walnut-leaf-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/walnut-leaf-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/walnut-leaf-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/walnut-leaf-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/walnut-leaf-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/walnut-leaf-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/walnut-leaf-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/walnut-leaf-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/walnut-leaf-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/walnut-leaf-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/walnut-leaf-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/walnut-leaf-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/walnut-leaf-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/walnut-leaf-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/walnut-leaf-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/walnut-leaf-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/walnut-leaf-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/walnut-leaf-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/walnut-leaf-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/walnut-leaf-summary-public_sv.pdf"}},
    {"id":"41484","name":"Knotgrass herb: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"EMA/270540/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/knotgrass-herb-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/knotgrass-herb-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/knotgrass-herb-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/knotgrass-herb-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/knotgrass-herb-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/knotgrass-herb-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/knotgrass-herb-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/knotgrass-herb-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/knotgrass-herb-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/knotgrass-herb-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/knotgrass-herb-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/knotgrass-herb-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/knotgrass-herb-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/knotgrass-herb-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/knotgrass-herb-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/knotgrass-herb-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/knotgrass-herb-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/knotgrass-herb-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/knotgrass-herb-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/knotgrass-herb-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/knotgrass-herb-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/knotgrass-herb-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/knotgrass-herb-summary-public_sv.pdf"}},
    {"id":"41892","name":"Caraway fruit - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2015-10-20T12:45:00Z","last_updated_date":"2016-02-17T12:05:00Z","reference_number":"EMA/498568/2015","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/caraway-fruit-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/caraway-fruit-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/caraway-fruit-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/caraway-fruit-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/caraway-fruit-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/caraway-fruit-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/caraway-fruit-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/caraway-fruit-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/caraway-fruit-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/caraway-fruit-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/caraway-fruit-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/caraway-fruit-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/caraway-fruit-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/caraway-fruit-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/caraway-fruit-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/caraway-fruit-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/caraway-fruit-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/caraway-fruit-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/caraway-fruit-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/caraway-fruit-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/caraway-fruit-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/caraway-fruit-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/caraway-fruit-summary-public_sv.pdf"}},
    {"id":"42005","name":"Thyme: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"EMA/307113/20166","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/thyme-summary-public_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/herbal-summary/thyme-summary-public_bg.pdf","es":"https://www.ema.europa.eu/es/documents/herbal-summary/thyme-summary-public_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/herbal-summary/thyme-summary-public_cs.pdf","da":"https://www.ema.europa.eu/da/documents/herbal-summary/thyme-summary-public_da.pdf","de":"https://www.ema.europa.eu/de/documents/herbal-summary/thyme-summary-public_de.pdf","et":"https://www.ema.europa.eu/et/documents/herbal-summary/thyme-summary-public_et.pdf","el":"https://www.ema.europa.eu/el/documents/herbal-summary/thyme-summary-public_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/herbal-summary/thyme-summary-public_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/herbal-summary/thyme-summary-public_hr.pdf","it":"https://www.ema.europa.eu/it/documents/herbal-summary/thyme-summary-public_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/herbal-summary/thyme-summary-public_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/herbal-summary/thyme-summary-public_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/herbal-summary/thyme-summary-public_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/herbal-summary/thyme-summary-public_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/herbal-summary/thyme-summary-public_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/herbal-summary/thyme-summary-public_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/herbal-summary/thyme-summary-public_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/herbal-summary/thyme-summary-public_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/herbal-summary/thyme-summary-public_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/herbal-summary/thyme-summary-public_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/herbal-summary/thyme-summary-public_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/herbal-summary/thyme-summary-public_sv.pdf"}},
    {"id":"42049","name":"Pale coneflower root - Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2018-09-19T17:14:00Z","last_updated_date":"2018-10-08T14:49:00Z","reference_number":"EMA/421887/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/pale-coneflower-root-summary-public_en.pdf"},
    {"id":"42068","name":"Pelargonium root: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2018-09-18T02:00:00Z","last_updated_date":"2018-09-18T02:00:00Z","reference_number":"EMA/421085/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/pelargonium-root-summary-public_en.pdf"},
    {"id":"42357","name":"Evening primrose oil: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2018-10-17T16:49:00Z","last_updated_date":"2018-10-17T16:49:00Z","reference_number":"EMA/422144/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/evening-primrose-oil-summary-public_en.pdf"},
    {"id":"43723","name":"Turmeric: Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T13:03:00Z","last_updated_date":"2019-02-14T13:03:00Z","reference_number":"EMA/697301/20188","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/turmeric-summary-public_en.pdf"},
    {"id":"43724","name":"Milkthistle fruit : Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-02-14T14:02:00Z","last_updated_date":"2019-02-14T14:02:00Z","reference_number":"EMA/415131/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/milkthistle-fruit-summary-public_en.pdf"},
    {"id":"44021","name":"Artichoke leaf: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-03-13T12:07:00Z","last_updated_date":"2019-03-13T12:07:00Z","reference_number":"EMA/268161/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/artichoke-leaf-summary-public_en.pdf"},
    {"id":"44321","name":"Mallow leaf: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-04-23T15:19:00Z","last_updated_date":"2019-04-23T15:19:00Z","reference_number":"EMA/834778/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/mallow-leaf-summary-public_en.pdf"},
    {"id":"44479","name":"Malva sylvestris L., flos : Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-05-10T13:54:00Z","last_updated_date":"2019-05-10T13:54:00Z","reference_number":"EMA/836527/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/malva-sylvestris-l-flos-summary-public_en.pdf"},
    {"id":"45305","name":"Wild strawberry leaf : Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T15:55:00Z","last_updated_date":"2019-08-22T15:55:00Z","reference_number":"EMA/833739/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/wild-strawberry-leaf-summary-public_en.pdf"},
    {"id":"45306","name":"Gentian root: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T16:16:00Z","last_updated_date":"2019-08-22T16:16:00Z","reference_number":"EMA/836995/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/gentian-root-summary-public_en.pdf"},
    {"id":"45307","name":"Butcher’s broom: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T16:38:00Z","last_updated_date":"2019-08-22T16:38:00Z","reference_number":"EMA/845547/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/butchers-broom-summary-public_en.pdf"},
    {"id":"45308","name":"Green bean pods: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T16:46:00Z","last_updated_date":"2019-08-22T16:46:00Z","reference_number":"EMA/166144/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/green-bean-pods-summary-public_en.pdf"},
    {"id":"45309","name":"Yarrow flower: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T16:56:00Z","last_updated_date":"2019-08-22T16:56:00Z","reference_number":"EMA/165822/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/yarrow-flower-summary-public_en.pdf"},
    {"id":"45310","name":"Motherwort: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T17:09:00Z","last_updated_date":"2019-08-22T17:09:00Z","reference_number":"EMA/165476/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/motherwort-summary-public_en.pdf"},
    {"id":"45311","name":"Polypody rhizome: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T17:19:00Z","last_updated_date":"2019-08-22T17:19:00Z","reference_number":"EMA/164380/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/polypody-rhizome-summary-public_en.pdf"},
    {"id":"45317","name":"Shepherd’s purse: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-23T14:24:00Z","last_updated_date":"2019-08-23T14:24:00Z","reference_number":"EMA/164805/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/shepherds-purse-summary-public_en.pdf"},
    {"id":"45318","name":"Myrrh: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-23T14:49:00Z","last_updated_date":"2019-08-23T14:49:00Z","reference_number":"EMA/164109/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/myrrh-summary-public_en.pdf"},
    {"id":"45319","name":"Oat herb: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-23T15:04:00Z","last_updated_date":"2019-08-23T15:04:00Z","reference_number":"EMA/163549/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/oat-herb-summary-public_en.pdf"},
    {"id":"45320","name":"Oat grain: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-08-23T15:21:00Z","last_updated_date":"2019-08-23T15:21:00Z","reference_number":"EMA/163216/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/oat-grain-summary-public_en.pdf"},
    {"id":"46224","name":"Frangula bark : Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-12-03T17:30:00Z","last_updated_date":"2019-12-03T17:30:00Z","reference_number":"EMA/535762/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/frangula-bark-summary-public_en.pdf"},
    {"id":"46258","name":"Tormentillae rhizoma: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T11:14:00Z","last_updated_date":"2019-12-09T11:14:00Z","reference_number":"EMA/166412/2019","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/tormentillae-rhizoma-summary-public_en.pdf"},
    {"id":"46676","name":"Valerian root and hop strobile: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2020-02-05T17:30:00Z","last_updated_date":"2020-02-05T17:30:00Z","reference_number":"EMA/539891/2019 ","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/valerian-root-and-hop-strobile-summary-public_en.pdf"},
    {"id":"46870","name":"Agnus castus fruit: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:58:00Z","last_updated_date":"2020-02-25T09:58:00Z","reference_number":"EMA/266692/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/agnus-castus-fruit-summary-public_en.pdf"},
    {"id":"47302","name":"Final assessment report on Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl) 1, folium and fructus - Revision 1","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T16:15:00Z","last_updated_date":"2020-04-02T16:15:00Z","reference_number":"EMA/HMPC/228759/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/final-assessment-report-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-1-folium-and-fructus-revision-1_en.pdf"},
    {"id":"47307","name":"Final assessment report on Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl) 1, folium and fructus - Revision 1","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T16:48:00Z","last_updated_date":"2020-04-02T16:48:00Z","reference_number":"EMA/HMPC/228759/2016","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/final-assessment-report-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-1-folium-and-fructus-revision-1_en.pdf-0"},
    {"id":"48411","name":"Horse-chestnut seed: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T09:58:00Z","last_updated_date":"2020-07-24T09:58:00Z","reference_number":"EMA/60766/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/horse-chestnut-seed-summary-public_en.pdf"},
    {"id":"48455","name":"Rhubarb root : Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:09:00Z","last_updated_date":"2020-07-28T14:09:00Z","reference_number":"EMA/279244/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/rhubarb-root-summary-public_en.pdf"},
    {"id":"48458","name":"Senna leaf : Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T15:06:00Z","last_updated_date":"2020-07-28T15:06:00Z","reference_number":"EMA/697536/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/senna-leaf-summary-public_en.pdf"},
    {"id":"48464","name":"Cascara : Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T16:47:00Z","last_updated_date":"2020-07-28T16:47:00Z","reference_number":"EMA/272383/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/cascara-summary-public_en.pdf"},
    {"id":"48465","name":"Senna pods : Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T17:04:00Z","last_updated_date":"2020-07-28T17:04:00Z","reference_number":"EMA/697392/2018","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/senna-pods-summary-public_en.pdf"},
    {"id":"48725","name":"Peppermint leaf: Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2020-08-31T16:47:00Z","last_updated_date":"2020-08-31T16:47:00Z","reference_number":"EMA/60946/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/peppermint-leaf-summary-public_en.pdf"},
    {"id":"48817","name":"Peppermint oil: Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2020-09-16T16:47:00Z","last_updated_date":"2020-09-16T16:47:00Z","reference_number":"EMA/55625/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/peppermint-oil-summary-public_en.pdf"},
    {"id":"49007","name":"Rupturewort: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2020-10-14T15:09:00Z","last_updated_date":"2020-10-14T15:09:00Z","reference_number":"EMA/382941/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/rupturewort-summary-public_en.pdf"},
    {"id":"49012","name":"Thyme oil: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2020-10-15T15:09:00Z","last_updated_date":"2020-10-15T15:09:00Z","reference_number":"EMA/380605/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/thyme-oil-summary-public_en.pdf"},
    {"id":"49061","name":"Feverfew herb: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2020-10-20T15:09:00Z","last_updated_date":"2020-10-20T15:09:00Z","reference_number":"EMA/380074/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/feverfew-herb-summary-public_en.pdf"},
    {"id":"49447","name":"Yarrow herb: Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2020-12-03T15:12:00Z","last_updated_date":"2020-12-03T15:12:00Z","reference_number":"EMA/513753/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/yarrow-herb-summary-public_en.pdf"},
    {"id":"52900","name":"Species amarae: Summary for the public","type":"herbal-summary","status":"unknown","consultation_date":"","first_published_date":"2021-10-26T10:50:00Z","last_updated_date":"2021-10-26T10:50:00Z","reference_number":"EMA/631843/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/species-amarae-summary-public_en.pdf"},
    {"id":"52936","name":"Species sedativae: Summary for the public","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2021-10-28T16:57:00Z","last_updated_date":"2021-10-28T16:57:00Z","reference_number":"EMA/645615/2020","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/species-sedativae-summary-public_en.pdf"},
    {"id":"66160","name":"Draft assessment report on Species pectorales","type":"herbal-summary","status":"Draft: consultation closed","consultation_date":"2024-12-15 - 2025-03-15","first_published_date":"2024-12-16T16:12:38Z","last_updated_date":"2024-12-16T16:12:38Z","reference_number":"EMA/HMPC/189454/2023","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/draft-assessment-report-species-pectorales_en.pdf"},
    {"id":"72975","name":"Holy thistle (St. Benedict's thistle): Assessment Report Summary for the Public (ARSP)","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T15:11:32Z","last_updated_date":"2026-03-12T15:11:32Z","reference_number":"EMA/HMPC/387758/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/holy-thistle-st-benedicts-thistle-assessment-report-summary-public-arsp_en.pdf"},
    {"id":"72986","name":"Rosemary oil: Assessment Report Summary for the Public (ARSP)","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T16:26:07Z","last_updated_date":"2026-03-12T16:26:07Z","reference_number":"EMA/HMPC/387788/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/rosemary-oil-assessment-report-summary-public-arsp_en.pdf"},
    {"id":"72987","name":"Rosemary leaf: Assessment Report Summary for the Public (ARSP)","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T16:32:54Z","last_updated_date":"2026-03-12T16:32:54Z","reference_number":"EMA/HMPC/387754/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/rosemary-leaf-assessment-report-summary-public-arsp_en.pdf"},
    {"id":"72989","name":"Fenugreek seed: Assessment Report Summary for the Public (ARSP)","type":"herbal-summary","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T16:53:29Z","last_updated_date":"2026-03-12T16:53:29Z","reference_number":"EMA/HMPC/387796/2025","document_url":"https://www.ema.europa.eu/en/documents/herbal-summary/fenugreek-seed-assessment-report-summary-public-arsp_en.pdf"},
    {"id":"3427","name":"Better vigilance for health protection and innovation","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2015-06-23T12:17:00Z","last_updated_date":"2015-06-23T12:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/better-vigilance-health-protection-and-innovation_en.pdf"},
    {"id":"3779","name":"Advanced-therapy medicinal products and the CAT","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2016-11-08T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/advanced-therapy-medicinal-products-and-cat_en.pdf"},
    {"id":"4385","name":"Enpr-EMA European Network of Paediatric Research at the European Medicines Agency","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2012-05-21T12:05:00Z","last_updated_date":"2015-09-18T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/enpr-ema-european-network-paediatric-research-european-medicines-agency_en.pdf"},
    {"id":"7347","name":"European Medicines Agency 20th anniversary book","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2015-03-18T12:00:00Z","last_updated_date":"2015-03-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/european-medicines-agency-20th-anniversary-book_en.pdf"},
    {"id":"8391","name":"Pharmacovigilance: Information systems and services","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2015-06-23T12:17:00Z","last_updated_date":"2015-06-23T12:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/pharmacovigilance-information-systems-and-services_en.pdf"},
    {"id":"9611","name":"Overview of the European Medicines Agency’s role, activities and priorities for 2015","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2015-05-18T18:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/overview-european-medicines-agencys-role-activities-and-priorities-2015_en.pdf"},
    {"id":"9736","name":"Human medicines highlights 2016","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2017-01-17T16:00:00Z","last_updated_date":"2017-01-19T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/human-medicines-highlights-2016_en.pdf"},
    {"id":"9782","name":"European Medicines Agency 1995-2015 - Working together for safe and effective medicines","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2015-05-18T18:17:00Z","last_updated_date":"2015-05-18T18:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/european-medicines-agency-1995-2015-working-together-safe-and-effective-medicines_en.pdf"},
    {"id":"10635","name":"Veterinary medicines highlights 2015","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T13:00:00Z","last_updated_date":"2016-01-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/veterinary-medicines-highlights-2015_en.pdf"},
    {"id":"12365","name":"Biological medicinal products","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2016-11-08T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/biological-medicinal-products_en.pdf"},
    {"id":"12537","name":"Better medicines for children","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T01:00:00Z","last_updated_date":"2015-05-18T18:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/better-medicines-children_en.pdf"},
    {"id":"12950","name":"The European regulatory system for medicines","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2014-08-26T12:00:00Z","last_updated_date":"2024-11-07T13:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/european-regulatory-system-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/leaflet/european-regulatory-system-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/leaflet/european-regulatory-system-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/leaflet/european-regulatory-system-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/leaflet/european-regulatory-system-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/leaflet/european-regulatory-system-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/leaflet/european-regulatory-system-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/leaflet/european-regulatory-system-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/leaflet/european-regulatory-system-medicines_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/leaflet/european-regulatory-system-medicines_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/leaflet/european-regulatory-system-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/leaflet/european-regulatory-system-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/leaflet/european-regulatory-system-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/leaflet/european-regulatory-system-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/leaflet/european-regulatory-system-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/leaflet/european-regulatory-system-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/leaflet/european-regulatory-system-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/leaflet/european-regulatory-system-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/leaflet/european-regulatory-system-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/leaflet/european-regulatory-system-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/leaflet/european-regulatory-system-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/leaflet/european-regulatory-system-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/leaflet/european-regulatory-system-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/leaflet/european-regulatory-system-medicines_sv.pdf","is":"https://www.ema.europa.eu/is/documents/leaflet/european-regulatory-system-medicines_is.pdf","no":"https://www.ema.europa.eu/no/documents/leaflet/european-regulatory-system-medicines_no.pdf"}},
    {"id":"13412","name":"Orphan-medicinal-product designation","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2015-05-18T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/orphan-medicinal-product-designation_en.pdf"},
    {"id":"14504","name":"Did you know? You can report side effects yourself","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2014-10-06T15:00:00Z","last_updated_date":"2014-10-06T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_bg.pdf","es":"https://www.ema.europa.eu/es/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_cs.pdf","da":"https://www.ema.europa.eu/da/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_da.pdf","de":"https://www.ema.europa.eu/de/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_de.pdf","et":"https://www.ema.europa.eu/et/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_et.pdf","el":"https://www.ema.europa.eu/el/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_hr.pdf","it":"https://www.ema.europa.eu/it/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_sv.pdf","is":"https://www.ema.europa.eu/is/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_is.pdf","no":"https://www.ema.europa.eu/no/documents/leaflet/did-you-know-you-can-report-side-effects-yourself_no.pdf"}},
    {"id":"14597","name":"Applying for European Union marketing authorisation for medicinal products for human use","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2015-05-18T18:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/applying-european-union-marketing-authorisation-medicinal-products-human-use_en.pdf"},
    {"id":"14671","name":"Supporting regulatory science outside the EU - The Article 58 procedure","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2015-05-18T18:17:00Z","last_updated_date":"2015-05-18T18:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/supporting-regulatory-science-outside-eu-article-58-procedure_en.pdf"},
    {"id":"15084","name":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2017-09-26T12:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/european-network-centres-pharmacoepidemiology-and-pharmacovigilance_en.pdf"},
    {"id":"15291","name":"Annual training day for patients and healthcare professionals","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2018-06-21T13:00:00Z","last_updated_date":"2018-06-21T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/annual-training-day-patients-and-healthcare-professionals_en.pdf"},
    {"id":"16362","name":"Veterinary medicines highlights 2016","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2017-01-25T15:30:00Z","last_updated_date":"2017-01-26T18:24:00Z","reference_number":"Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/leaflet/veterinary-medicines-highlights-2016_en.pdf"},
    {"id":"17154","name":"EMA tools available to medicine’s developers from the academic sector","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2018-07-06T14:30:00Z","last_updated_date":"2020-10-19T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/ema-tools-available-medicines-developers-academic-sector_en.pdf"},
    {"id":"17705","name":"The EU clinical trial portal and database","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2016-09-23T13:20:00Z","last_updated_date":"2016-09-23T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/eu-clinical-trial-portal-and-database_en.pdf"},
    {"id":"17883","name":"European Union enlargement programme","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T11:30:00Z","last_updated_date":"2013-05-22T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/european-union-enlargement-programme_en.pdf"},
    {"id":"18695","name":"Improving medicines for older people","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2013-05-22T12:00:00Z","last_updated_date":"2013-05-22T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/improving-medicines-older-people_en.pdf"},
    {"id":"20000","name":"Biosimilar medicinal products","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2013-05-22T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/biosimilar-medicinal-products_en.pdf"},
    {"id":"20705","name":"Biosimilars in the EU - Information guide for healthcare professionals","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2017-05-05T14:00:00Z","last_updated_date":"2023-11-13T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_bg.pdf","es":"https://www.ema.europa.eu/es/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_cs.pdf","da":"https://www.ema.europa.eu/da/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_da.pdf","de":"https://www.ema.europa.eu/de/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_de.pdf","et":"https://www.ema.europa.eu/et/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_et.pdf","el":"https://www.ema.europa.eu/el/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_hr.pdf","it":"https://www.ema.europa.eu/it/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_sv.pdf"}},
    {"id":"21316","name":"Pharmacovigilance","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2015-05-18T18:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/pharmacovigilance_en.pdf"},
    {"id":"21787","name":"The European innovation offices network - innovators meet regulators","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T12:00:00Z","last_updated_date":"2018-04-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/european-innovation-offices-network-innovators-meet-regulators_en.pdf"},
    {"id":"22110","name":"Infographic: Medicines for use outside the EU – EU-M4all","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2020-07-24T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/infographic-medicines-use-outside-eu-eu-m4all_en.pdf"},
    {"id":"23335","name":"Healthy animals, healthy people - leaflet","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2017-08-21T13:10:00Z","last_updated_date":"2017-08-21T13:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/healthy-animals-healthy-people-leaflet_en.pdf"},
    {"id":"24739","name":"Info sheet - Orphan medicines in the EU","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2017-12-21T15:00:00Z","last_updated_date":"2026-02-27T11:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/info-sheet-orphan-medicines-eu_en.pdf"},
    {"id":"26121","name":"Connecting the dots - Towards global knowledge of the international medicine regulatory landscape: mapping of international initiatives","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2016-10-13T16:30:00Z","last_updated_date":"2017-01-09T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/connecting-dots-towards-global-knowledge-international-medicine-regulatory-landscape-mapping-international-initiatives_en.pdf"},
    {"id":"27073","name":"Enabling science that works for patients – leaflet","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2017-08-10T12:00:00Z","last_updated_date":"2017-10-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/enabling-science-works-patients-leaflet_en.pdf"},
    {"id":"28107","name":"Environmental risk-assessment of medicines","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T11:30:00Z","last_updated_date":"2015-05-18T18:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/environmental-risk-assessment-medicines_en.pdf"},
    {"id":"29501","name":"Early access to medicines - Development support and regulatory tools","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T18:30:00Z","last_updated_date":"2016-11-08T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/early-access-medicines-development-support-and-regulatory-tools_en.pdf"},
    {"id":"29742","name":"Human medicines highlights 2015","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T11:00:00Z","last_updated_date":"2016-01-11T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/human-medicines-highlights-2015_en.pdf"},
    {"id":"29749","name":"The work of the European Medicines Agency - Vital for EU public and animal health and the pharmaceutical industry","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2016-10-11T14:45:00Z","last_updated_date":"2016-10-11T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/work-european-medicines-agency-vital-eu-public-and-animal-health-and-pharmaceutical-industry_en.pdf"},
    {"id":"30012","name":"Business pipeline","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2015-05-18T18:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/business-pipeline_en.pdf"}    {"id":"35703","name":"EU Clinical Trials Register","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2013-05-22T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/eu-clinical-trials-register_en.pdf"},
    {"id":"35889","name":"Career opportunities at the European Medicines Agency","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2015-05-18T18:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/career-opportunities-european-medicines-agency_en.pdf"},
    {"id":"37105","name":"PRIME – Paving the way for promising medicines for patients - Factsheet","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2024-10-10T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/prime-paving-way-promising-medicines-patients-factsheet_en.pdf"},
    {"id":"37880","name":"Applying for EU marketing authorisation for medicinal products for veterinary use","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2015-05-18T18:17:00Z","last_updated_date":"2015-05-18T18:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/applying-eu-marketing-authorisation-medicinal-products-veterinary-use_en.pdf"},
    {"id":"38356","name":"1 year anniversary of clinical data publication","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2017-10-20T16:30:00Z","last_updated_date":"2017-10-20T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/1-year-anniversary-clinical-data-publication_en.pdf"},
    {"id":"41430","name":"Scientific advice and protocol assistance","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2013-05-22T12:00:00Z","last_updated_date":"2016-11-08T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/scientific-advice-and-protocol-assistance_en.pdf"},
    {"id":"41766","name":"International Cooperation - European Medicines Agency","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2015-05-18T18:17:00Z","last_updated_date":"2015-05-18T18:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/international-cooperation-european-medicines-agency_en.pdf"},
    {"id":"42728","name":"Spark building - what you need to know","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2018-11-20T17:19:00Z","last_updated_date":"2018-11-20T17:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/spark-building-what-you-need-know_en.pdf"},
    {"id":"43726","name":"Amsterdam hotels for EMA 2019","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2019-02-14T14:40:00Z","last_updated_date":"2019-08-08T09:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/amsterdam-hotels-ema-2019_en.pdf"},
    {"id":"45081","name":"Public engagement highlights of 2019 - Academia","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2019-03-10T11:30:00Z","last_updated_date":"2020-09-24T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2019-academia_en.pdf"},
    {"id":"45702","name":"Responsible use of antibiotics protects animals and people - 2011-2021 Sales of antibiotics for veterinary use are down - Infographic","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2019-10-15T14:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/responsible-use-antibiotics-protects-animals-and-people-2011-2021-sales-antibiotics-veterinary-use-are-down-infographic_en.pdf"},
    {"id":"45752","name":"Infographic on the 1,000 GCP inspections requested by the CHMP","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T09:22:00Z","last_updated_date":"2019-10-18T09:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/infographic-1000-gcp-inspections-requested-chmp_en.pdf"},
    {"id":"45755","name":"Ebola vaccine development 2014-2019","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2019-11-27T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/ebola-vaccine-development-2014-2019_en.pdf"},
    {"id":"45953","name":"EMA Regulatory Science to 2025 - Five goals","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2019-11-11T14:20:00Z","last_updated_date":"2019-11-14T13:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/ema-regulatory-science-2025-five-goals_en.pdf"},
    {"id":"46044","name":"Antimicrobial resistance - Infocards","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T11:59:00Z","last_updated_date":"2022-11-18T11:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/antimicrobial-resistance-infocards_en.pdf"},
    {"id":"46196","name":"EMA Regulatory Science to 2025 - Four goals for veterinary medicines regulation","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2019-11-28T14:00:00Z","last_updated_date":"2019-11-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/ema-regulatory-science-2025-four-goals-veterinary-medicines-regulation_en.pdf"},
    {"id":"46204","name":"World AIDS Day – Communities make the difference","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2019-11-29T14:23:00Z","last_updated_date":"2019-11-29T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/world-aids-day-communities-make-difference_en.pdf"},
    {"id":"47468","name":"Info-card for patients: Reporting suspected side effects of medicines in patients with COVID-19","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2020-04-23T16:56:00Z","last_updated_date":"2021-01-20T17:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_bg.pdf","es":"https://www.ema.europa.eu/es/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_cs.pdf","da":"https://www.ema.europa.eu/da/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_da.pdf","de":"https://www.ema.europa.eu/de/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_de.pdf","et":"https://www.ema.europa.eu/et/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_et.pdf","el":"https://www.ema.europa.eu/el/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_hr.pdf","it":"https://www.ema.europa.eu/it/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/leaflet/info-card-patients-reporting-suspected-side-effects-medicines-patients-covid-19_sv.pdf"}},
    {"id":"47469","name":"Info-card for healthcare professional: Reporting suspected side effects of medicines in patients with COVID-19","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2020-04-23T16:59:00Z","last_updated_date":"2020-04-23T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_bg.pdf","es":"https://www.ema.europa.eu/es/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_cs.pdf","da":"https://www.ema.europa.eu/da/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_da.pdf","de":"https://www.ema.europa.eu/de/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_de.pdf","et":"https://www.ema.europa.eu/et/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_et.pdf","el":"https://www.ema.europa.eu/el/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_hr.pdf","it":"https://www.ema.europa.eu/it/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/leaflet/info-card-healthcare-professional-reporting-suspected-side-effects-medicines-patients-covid-19_sv.pdf"}},
    {"id":"47890","name":"Infographic - Fast-track procedures for treatments and vaccines for COVID-19","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2020-06-08T16:00:00Z","last_updated_date":"2020-06-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/infographic-fast-track-procedures-treatments-and-vaccines-covid-19_en.pdf"},
    {"id":"47947","name":"Public engagement highlights 2016","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2020-06-11T10:46:00Z","last_updated_date":"2020-06-11T10:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2016_en.pdf"},
    {"id":"47948","name":"Public engagement highlights 2017","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2020-06-11T10:47:00Z","last_updated_date":"2020-06-11T10:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2017_en.pdf"},
    {"id":"47951","name":"Public engagement highlights 2018","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2020-06-11T10:49:00Z","last_updated_date":"2020-06-11T10:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2018_en.pdf"},
    {"id":"47952","name":"Public engagement highlights 2019","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2020-06-11T10:50:00Z","last_updated_date":"2020-06-11T10:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2019_en.pdf"},
    {"id":"48101","name":"Development of regulatory science strategy to 2025","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T15:43:00Z","last_updated_date":"2020-06-23T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/development-regulatory-science-strategy-2025_en.pdf"},
    {"id":"49802","name":"EU-M4all - Promoting parallel application for EU-M4all opinion and centralised marketing authorisation procedure","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2021-01-14T09:54:00Z","last_updated_date":"2021-01-14T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/eu-m4all-promoting-parallel-application-eu-m4all-opinion-and-centralised-marketing-authorisation-procedure_en.pdf"},
    {"id":"50904","name":"Public engagement highlights 2020","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2021-04-19T15:45:00Z","last_updated_date":"2021-04-19T15:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2020_en.pdf"},
    {"id":"54879","name":"Public engagement highlights 2021","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2022-05-03T09:34:00Z","last_updated_date":"2022-05-03T09:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2021_en.pdf"},
    {"id":"55541","name":"Factsheet: Towards better prevention of medicine shortages","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T11:38:00Z","last_updated_date":"2022-07-14T11:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/factsheet-towards-better-prevention-medicine-shortages_en.pdf"},
    {"id":"55542","name":"Info-cards: What can you do when it comes to shortages of medicines?","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T11:59:00Z","last_updated_date":"2022-07-14T11:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/info-cards-what-can-you-do-when-it-comes-shortages-medicines_en.pdf"},
    {"id":"56713","name":"Info cards: Preventing antimicrobial resistance together (EMA/ICMRA)","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2022-11-21T12:30:00Z","last_updated_date":"2022-11-21T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/info-cards-preventing-antimicrobial-resistance-together-emaicmra_en.pdf"},
    {"id":"58154","name":"Public engagement highlights 2022","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T14:02:00Z","last_updated_date":"2024-03-22T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2022_en.pdf"},
    {"id":"58501","name":"Info-cards: Every Dose Counts to protect public health","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T12:11:00Z","last_updated_date":"2023-04-24T12:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/info-cards-every-dose-counts-protect-public-health_en.pdf"},
    {"id":"59067","name":"Letter of Support for Forskolin-Induced Swelling (FIS) Assay: Biomarker for Cystic Fibrosis Transmembrane Conductance Regulator Protein (CFTR)","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T10:29:00Z","last_updated_date":"2023-06-23T10:29:00Z","reference_number":"EMADOC-1700519818-1037383","document_url":"https://www.ema.europa.eu/en/documents/leaflet/letter-support-forskolin-induced-swelling-fis-assay-biomarker-cystic-fibrosis-transmembrane-conductance-regulator-protein-cftr_en.pdf"},
    {"id":"59072","name":"Infosheet: EMA review of real-world data studies from September 2021 to February 2024","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T11:52:00Z","last_updated_date":"2024-08-01T11:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/infosheet-ema-review-real-world-data-studies-september-2021-february-2024_en.pdf"},
    {"id":"60440","name":"Letter of Support for World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR)","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2023-10-16T15:22:00Z","last_updated_date":"2023-10-16T15:22:00Z","reference_number":"EMADOC-1700519818-1173599","document_url":"https://www.ema.europa.eu/en/documents/leaflet/letter-support-world-federation-hemophilia-wfh-gene-therapy-registry-gtr_en.pdf"},
    {"id":"60976","name":"Responsible use of antimicrobials protects people, animals and the future","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2023-11-20T11:59:18Z","last_updated_date":"2023-11-20T11:59:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/responsible-use-antimicrobials-protects-people-animals-and-future_en.pdf"},
    {"id":"63371","name":"Public engagement highlights 2023","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2024-05-29T15:40:57Z","last_updated_date":"2024-05-29T15:40:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2023_en.pdf"},
    {"id":"68341","name":"Public engagement highlights 2024","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2025-05-19T11:46:21Z","last_updated_date":"2025-05-19T11:46:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2024_en.pdf"},
    {"id":"70133","name":"Quick guide to competing interests for EMA experts","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2025-09-17T15:54:32Z","last_updated_date":"2025-09-17T15:54:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/quick-guide-competing-interests-ema-experts_en.pdf"},
    {"id":"71266","name":"Antimicrobial resistance – Act Now: Protect our present, secure our future","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2025-11-21T10:13:00Z","last_updated_date":"2025-11-21T10:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/antimicrobial-resistance-act-now-protect-our-present-secure-our-future_en.pdf"},
    {"id":"73337","name":"Public engagement highlights 2025","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T15:18:56Z","last_updated_date":"2026-04-07T15:18:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2025_en.pdf"},
    {"id":"73998","name":"Infosheet: EMA review of real-world data studies from September 2021 to February 2026","type":"leaflet","status":"unknown","consultation_date":"","first_published_date":"2026-06-08T10:16:42Z","last_updated_date":"2026-06-08T10:16:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/leaflet/infosheet-ema-review-real-world-data-studies-september-2021-february-2026_en.pdf"},
    {"id":"3128","name":"Opinion of the CVMP on the establishment of maximum residue limits: Derquantel","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/CVMP/261782/2010","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-derquantel_en.pdf"},
    {"id":"3185","name":"Opinion of the CVMP on the establishment of maximum residue limits: Triclabendazole","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-09-08T19:00:00Z","last_updated_date":"2014-09-08T19:00:00Z","reference_number":"EMA/CVMP/649894/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-triclabendazole_en.pdf"},
    {"id":"3877","name":"Opinion of the CVMP on the establishment of maximum residue limits: Lasalocid","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-03-22T01:00:00Z","last_updated_date":"2012-03-22T01:00:00Z","reference_number":"EMA/CVMP/754527/2010","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-lasalocid_en.pdf"},
    {"id":"3901","name":"Opinion of the CVMP on the establishment of maximum residue limits: Diclazuril","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-03-14T12:30:00Z","last_updated_date":"2013-03-14T12:30:00Z","reference_number":"EMA/CVMP/183880/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-diclazuril_en.pdf"},
    {"id":"4019","name":"Opinion of the CVMP on the establishment of maximum residue limits: Propyl 4-hydroxybenzoate and its sodium salt","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-09-09T18:15:00Z","last_updated_date":"2015-09-09T18:15:00Z","reference_number":"EMA/CVMP/633015/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-propyl-4-hydroxybenzoate-and-its-sodium-salt_en.pdf"},
    {"id":"4501","name":"Opinion of the CVMP on the establishment of maximum residue limits: Monepantel","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-03-22T01:00:00Z","last_updated_date":"2012-03-22T01:00:00Z","reference_number":"EMA/CVMP/165867/2011-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-monepantel_en.pdf"},
    {"id":"4545","name":"Opinion of the CVMP on the establishment of maximum residue limits: Tildipirosin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-04-14T15:30:00Z","last_updated_date":"2014-04-14T15:30:00Z","reference_number":"EMA/CVMP/440151/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-tildipirosin_en.pdf"},
    {"id":"5305","name":"Opinion of the Committee for Medicinal Products for Veterinary Use on the establishment of maximum residue limits: Aluminium salicylate, basic","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-12-12T15:16:00Z","last_updated_date":"2016-12-12T15:16:00Z","reference_number":"EMA/CVMP/453264/2016","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-committee-medicinal-products-veterinary-use-establishment-maximum-residue-limits-aluminium-salicylate-basic_en.pdf"},
    {"id":"5536","name":"Opinion of the CVMP on the establishment of maximum residue limits: Tulathromycin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-03-10T16:00:00Z","last_updated_date":"2015-03-10T16:00:00Z","reference_number":"EMA/CVMP/303753/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-tulathromycin_en.pdf"},
    {"id":"5874","name":"Opinion of the CVMP on the establishment of maximum residue limits: Eprinomectin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-07-07T02:00:00Z","last_updated_date":"2016-07-07T02:00:00Z","reference_number":"EMA/CVMP/779112/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-eprinomectin_en.pdf"},
    {"id":"6103","name":"Opinion of the CVMP on the establishment of maximum residue limits: Sisapronil","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-12-11T11:17:00Z","last_updated_date":"2015-12-11T11:17:00Z","reference_number":"EMA/CVMP/259372/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-sisapronil_en.pdf"},
    {"id":"6215","name":"Opinion of the CVMP on the establishment of maximum residue limits: Monepantel","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-09-16T12:12:00Z","last_updated_date":"2013-09-16T12:12:00Z","reference_number":"EMA/CVMP/219741/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-monepantel_en.pdf-0"},
    {"id":"6239","name":"Opinion of the CVMP on the establishment of maximum residue limits: Sodium Salicylate","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/CVMP/13789/2010","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-sodium-salicylate_en.pdf"},
    {"id":"6635","name":"Opinion of the CVMP on the establishment of maximum residue limits: Lufenuron","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-02-04T11:10:00Z","last_updated_date":"2015-02-04T11:10:00Z","reference_number":"EMA/CVMP/651823/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-lufenuron_en.pdf"},
    {"id":"6707","name":"Opinion of the CVMP on the establishment of MRL: Double-stranded ribonucleic acid homologous to viral ribonucleic acid coding for part of the coat protein and part of the intergenic region of the  Israel Acute Paralysis Virus","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-07-30T19:00:00Z","last_updated_date":"2013-07-30T19:00:00Z","reference_number":"EMA/CVMP/594122/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-mrl-double-stranded-ribonucleic-acid-homologous-viral-ribonucleic-acid-coding-part-coat-protein-part-intergenic-region-israel-acute-paralysis-virus_en.pdf"},
    {"id":"7975","name":"Opinion of the CVMP on the establishment of maximum residue limits: Tulathromycin (modification of ADI and MRL)","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-04-28T15:53:00Z","last_updated_date":"2015-04-28T15:53:00Z","reference_number":"EMA/CVMP/380415/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-tulathromycin-modification-adi-and-mrl_en.pdf"},
    {"id":"9036","name":"Opinion of the CVMP on the establishment of maximum residue limits: Diclazuril","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-03-17T15:30:00Z","last_updated_date":"2014-03-17T15:30:00Z","reference_number":"EMA/CVMP/13722/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-diclazuril_en.pdf-0"},
    {"id":"9283","name":"Opinion of the CVMP on the establishment of maximum residue limits: Phenoxymethylpenicillin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-03-22T01:00:00Z","last_updated_date":"2012-03-22T01:00:00Z","reference_number":"EMA/CVMP/447493/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-phenoxymethylpenicillin_en.pdf"},
    {"id":"9537","name":"Opinion of the CVMP on the establishment of maximum residue limits: Prednisolone","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-07-30T19:45:00Z","last_updated_date":"2013-07-30T19:45:00Z","reference_number":"EMA/CVMP/382060/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-prednisolone_en.pdf"},
    {"id":"10344","name":"Opinion of the CVMP on the establishment of maximum residue limits: Triptorelin acetate","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-04-14T15:30:00Z","last_updated_date":"2014-04-14T15:30:00Z","reference_number":"EMA/CVMP/383203/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-triptorelin-acetate_en.pdf"},
    {"id":"10470","name":"Opinion of the CVMP on the establishment of maximum residue limits: Barium selenate","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-04-28T15:34:00Z","last_updated_date":"2015-04-28T15:34:00Z","reference_number":"EMA/CVMP/176966/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-barium-selenate_en.pdf"},
    {"id":"10697","name":"Opinion of the CVMP on the establishment of maximum residue limits: Fluazuron","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-05-03T19:00:00Z","last_updated_date":"2018-05-03T19:00:00Z","reference_number":"EMA/CVMP/616458/2017","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-fluazuron_en.pdf"},
    {"id":"12071","name":"Opinion of the CVMP on the establishment of maximum residue limits: Clodronic acid","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-09-09T18:15:00Z","last_updated_date":"2015-09-09T18:15:00Z","reference_number":"EMA/CVMP/239251/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-clodronic-acid_en.pdf"},
    {"id":"12159","name":"Opinion of the CVMP on the establishment of maximum residue limits: Eprinomectin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-09-05T14:30:00Z","last_updated_date":"2018-09-05T14:30:00Z","reference_number":"EMA/CVMP/698003/2017","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-eprinomectin_en.pdf-0"},
    {"id":"12215","name":"Opinion of the CVMP on the establishment of maximum residue limits: Azamethiphos","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-06-15T16:00:00Z","last_updated_date":"2012-06-15T16:00:00Z","reference_number":"EMA/CVMP/149845/2011 – Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-azamethiphos_en.pdf"},
    {"id":"12844","name":"Opinion of the CVMP on the establishment of maximum residue limits: Porcine prolactin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-09-05T14:30:00Z","last_updated_date":"2018-09-05T14:30:00Z","reference_number":"EMA/CVMP/698114/2017","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-porcine-prolactin_en.pdf"},
    {"id":"13039","name":"Opinion of the CVMP on the establishment of maximum residue limits: Gamithromycin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-03-10T16:00:00Z","last_updated_date":"2015-03-10T16:00:00Z","reference_number":"EMA/CVMP/350420/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-gamithromycin_en.pdf"},
    {"id":"13152","name":"Opinion of the CVMP on the establishment of maximum residue limits: Copper carbonate","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T12:10:00Z","last_updated_date":"2016-05-27T12:10:00Z","reference_number":"EMA/CVMP/758984/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-copper-carbonate_en.pdf"},
    {"id":"14239","name":"Opinion of the CVMP on the establishment of maximum residue limits: Virginiamycin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-09-09T18:15:00Z","last_updated_date":"2015-09-09T18:15:00Z","reference_number":"EMA/CVMP/643808/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-virginiamycin_en.pdf"},
    {"id":"14481","name":"Opinion of the CVMP on the establishment of maximum residue limits: Methylprednisolone","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-03-22T01:00:00Z","last_updated_date":"2012-03-22T01:00:00Z","reference_number":"EMA/CVMP/822069/2010-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-methylprednisolone_en.pdf"},
    {"id":"14678","name":"Opinion of the CVMP on the establishment of maximum residue limits: Isoeugenol","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CVMP/518785/2010","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-isoeugenol_en.pdf"},
    {"id":"15104","name":"Opinion of the CVMP on the establishment of maximum residue limits: Tildipirosin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-10-26T19:38:55Z","last_updated_date":"2010-10-26T19:38:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-tildipirosin_en.pdf-0"},
    {"id":"16858","name":"Opinion of the CVMP on the establishment of maximum residue limits: Altrenogest","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-03-22T01:00:00Z","last_updated_date":"2012-03-22T01:00:00Z","reference_number":"EMA/CVMP/687242/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-altrenogest_en.pdf"},
    {"id":"16887","name":"Opinion of the CVMP on the establishment of maximum residue limits: Monensin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T17:00:00Z","last_updated_date":"2013-02-08T17:00:00Z","reference_number":"EMA/CVMP/804330/2011- Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-monensin_en.pdf"},
    {"id":"19099","name":"Opinion of the CVMP on the establishment of maximum residue limits: Potassium selenate, sodium selenate, sodium selenite","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-04-28T15:53:00Z","last_updated_date":"2015-04-28T15:53:00Z","reference_number":"EMA/CVMP/666932/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-potassium-selenate-sodium-selenate-sodium-selenite_en.pdf"},
    {"id":"19734","name":"Opinion of the CVMP on the establishment of maximum residue limits: Valnemulin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-10-26T19:38:00Z","last_updated_date":"2010-10-26T19:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-valnemulin_en.pdf"},
    {"id":"20621","name":"Opinion of the CVMP on the establishment of maximum residue limits: Sodium salicylate","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-01-22T10:10:00Z","last_updated_date":"2013-01-22T10:10:00Z","reference_number":"EMA/CVMP/63588/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-sodium-salicylate_en.pdf-0"},
    {"id":"21080","name":"Opinion of the Committee for Medicinal Products for Veterinary Use on the establishment of maximum residue limits: Hydrocortisone aceponate","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-09-21T15:32:00Z","last_updated_date":"2016-09-21T15:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-committee-medicinal-products-veterinary-use-establishment-maximum-residue-limits-hydrocortisone-aceponate_en.pdf"},
    {"id":"21582","name":"Opinion of the CVMP on the establishment of maximum residue limits: Rafoxanide","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-09-08T19:00:00Z","last_updated_date":"2014-09-08T19:00:00Z","reference_number":"EMA/CVMP/672931/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-rafoxanide_en.pdf"},
    {"id":"21648","name":"Opinion of the CVMP on the establishment of maximum residue limits: Fluralaner ( EMEA/V/MRL/004380/FULL/0001)","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-02-17T11:00:00Z","last_updated_date":"2017-02-17T11:00:00Z","reference_number":"EMA/CVMP/615777/2016","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-fluralaner-emea-v-mrl-004380-full-0001_en.pdf"},
    {"id":"22074","name":"Opinion of the CVMP on the establishment of maximum residue limits: Clorsulon","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-06-15T16:00:00Z","last_updated_date":"2012-06-15T16:00:00Z","reference_number":"EMA/CVMP/915840/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-clorsulon_en.pdf"},
    {"id":"22155","name":"Opinion of the CVMP on the establishment of maximum residue limits: Ivermectin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-06-17T13:50:00Z","last_updated_date":"2014-06-17T13:50:00Z","reference_number":"EMA/CVMP/497546/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-ivermectin_en.pdf"},
    {"id":"22586","name":"Opinion of the CVMP on the establishment of maximum residue limits: Tylvalosin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-09-09T18:15:00Z","last_updated_date":"2015-09-09T18:15:00Z","reference_number":"EMA/CVMP/380629/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-tylvalosin_en.pdf"},
    {"id":"23487","name":"Opinion of the CVMP on the establishment of maximum residue limits: Monepantel","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CVMP/569128/2010","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-monepantel_en.pdf-1"},
    {"id":"23671","name":"Opinion of the CVMP on the establishment of maximum residue limits: Lasalocid","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-02-17T12:40:00Z","last_updated_date":"2015-02-17T12:40:00Z","reference_number":"EMA/CVMP/154734/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-lasalocid_en.pdf-0"},
    {"id":"23692","name":"Opinion of the CVMP on the establishment of maximum residue limits: Diethylene glycol monoethyl ether","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T12:00:00Z","last_updated_date":"2015-10-20T12:00:00Z","reference_number":"EMA/CVMP/36684/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-diethylene-glycol-monoethyl-ether_en.pdf"},
    {"id":"23942","name":"Opinion of the CVMP on the establishment of maximum residue limits: Triclabendazole","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-04-13T15:35:00Z","last_updated_date":"2012-04-13T15:35:00Z","reference_number":"EMA/CVMP/848821/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-triclabendazole_en.pdf-0"},
    {"id":"24156","name":"Opinion of the CVMP on the establishment of maximum residue limits: Closantel","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-04-23T02:00:00Z","last_updated_date":"2012-04-23T02:00:00Z","reference_number":"EMA/CVMP/846763/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-closantel_en.pdf"},
    {"id":"26039","name":"Opinion of the CVMP on the establishment of maximum residue limits: Fenbendazole","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-01-22T10:10:00Z","last_updated_date":"2013-01-22T10:10:00Z","reference_number":"EMA/CVMP/845730/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-fenbendazole_en.pdf"},
    {"id":"28023","name":"Opinion of the Committee for CVMP on the establishment of maximum residue limits: Rafoxanide","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-05-03T19:00:00Z","last_updated_date":"2016-05-03T19:00:00Z","reference_number":"EMA/CVMP/705308/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-committee-cvmp-establishment-maximum-residue-limits-rafoxanide_en.pdf"},
    {"id":"28354","name":"Opinion of the CVMP on the establishment of maximum residue limits: Nitroxinil","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-05-23T17:39:00Z","last_updated_date":"2012-05-23T17:39:00Z","reference_number":"EMA/CVMP/848524/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-nitroxinil_en.pdf"},
    {"id":"29453","name":"Opinion of the CVMP on the establishment of maximum residue limits: Hexaflumuron","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-09-09T18:15:00Z","last_updated_date":"2015-09-09T18:15:00Z","reference_number":"EMA/CVMP/347690/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-hexaflumuron_en.pdf"},
    {"id":"29863","name":"Opinion of the CVMP on the establishment of maximum residue limits: Octenidine dihydrochloride","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-03-22T01:00:00Z","last_updated_date":"2012-03-22T01:00:00Z","reference_number":"EMA/CVMP/61867/2011-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-octenidine-dihydrochloride_en.pdf"},
    {"id":"30354","name":"Opinion of the CVMP on the establishment of maximum residue limits: Eprinomectin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-02-17T12:40:00Z","last_updated_date":"2015-02-17T12:40:00Z","reference_number":"EMA/CVMP/293995/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-eprinomectin_en.pdf-1"},
    {"id":"30360","name":"Final opinion of the CVMP on the establishment of maximum residue limits: Neomycin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-11-27T15:45:00Z","last_updated_date":"2013-11-27T15:45:00Z","reference_number":"EMA/CVMP/840899/2011 Final, Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/final-opinion-cvmp-establishment-maximum-residue-limits-neomycin_en.pdf"},
    {"id":"30851","name":"Opinion of the CVMP on the establishment of maximum residue limits: Doxycycline","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-03-10T16:00:00Z","last_updated_date":"2015-03-10T16:00:00Z","reference_number":"EMA/CVMP/347869/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-doxycycline_en.pdf"},
    {"id":"30876","name":"Opinion of the CVMP on the establishment of maximum residue limits: Gentamicin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-03-22T15:30:00Z","last_updated_date":"2016-03-22T15:30:00Z","reference_number":"EMA/CVMP/619915/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-gentamicin_en.pdf"}    {"id":"32274","name":"Opinion of the Committee for Medicinal Products for Veterinary Use on the establishment of maximum residue limits: Gamithromycin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2017-01-12T17:52:00Z","last_updated_date":"2017-01-12T17:52:00Z","reference_number":"EMA/CVMP/454065/2016","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-committee-medicinal-products-veterinary-use-establishment-maximum-residue-limits-gamithromycin_en.pdf"},
    {"id":"32847","name":"Opinion of the CVMP on the establishment of maximum residue limits: Closantel","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-09-08T19:00:00Z","last_updated_date":"2014-09-08T19:00:00Z","reference_number":"EMA/CVMP/741512/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-closantel_en.pdf-0"},
    {"id":"33111","name":"Opinion of the CVMP on the establishment of maximum residue limits: Purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids (as potassium salts)","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-02-17T17:30:00Z","last_updated_date":"2016-02-17T17:30:00Z","reference_number":"EMA/CVMP/245930/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-purified-semi-solid-extract-humulus-lupulus-l-containing-approximately-48-beta-acids-potassium-salts_en.pdf"},
    {"id":"34950","name":"Opinion of the CVMP on the establishment of maximum residue limits: Phoxim","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-01-22T10:10:00Z","last_updated_date":"2013-01-22T10:10:00Z","reference_number":"EMA/CVMP/78444/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-phoxim_en.pdf"},
    {"id":"35560","name":"Opinion of the CVMP on the establishment of maximum residue limits: Solvent naphtha, light aromatic","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-05-03T18:00:00Z","last_updated_date":"2018-05-03T18:00:00Z","reference_number":"EMA/CVMP/617222/2017","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-solvent-naphtha-light-aromatic_en.pdf"},
    {"id":"36182","name":"Opinion of the CVMP on the establishment of maximum residue limits: Manganese carbonate","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-11-27T15:45:00Z","last_updated_date":"2013-11-27T15:45:00Z","reference_number":"EMA/CVMP/14468/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-manganese-carbonate_en.pdf"},
    {"id":"36471","name":"Opinion of the Committee for Medicinal Products for Veterinary Use on the establishment of maximum residue limits: Bromelain","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-02-02T09:50:00Z","last_updated_date":"2018-02-02T09:50:00Z","reference_number":"EMA/CVMP/255492/2017","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-committee-medicinal-products-veterinary-use-establishment-maximum-residue-limits-bromelain_en.pdf"},
    {"id":"37258","name":"Opinion of the CVMP on the establishment of maximum residue limits: Methylprednisolone","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2010-10-26T19:38:54Z","last_updated_date":"2010-10-26T19:38:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-methylprednisolone_en.pdf-0"},
    {"id":"37599","name":"Opinion of the CVMP on the establishment of maximum residue limits: Methylprednisolone","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-03-10T16:00:00Z","last_updated_date":"2015-03-10T16:00:00Z","reference_number":"EMA/CVMP/339063/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-methylprednisolone_en.pdf-1"},
    {"id":"38384","name":"Opinion of the CVMP on the establishment of maximum residue limits: Butafosfan","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-03-17T15:30:00Z","last_updated_date":"2014-03-17T15:30:00Z","reference_number":"EMA/CVMP/250946/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-butafosfan_en.pdf"},
    {"id":"38676","name":"Opinion of the CVMP on the establishment of maximum residue limits: Tulathromycin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-02-17T12:40:00Z","last_updated_date":"2015-02-17T12:40:00Z","reference_number":"EMA/CVMP/604655/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-tulathromycin_en.pdf-0"},
    {"id":"39018","name":"Opinion of the CVMP on the establishment of maximum residue limits: Chloroform","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-03-17T15:30:00Z","last_updated_date":"2014-03-17T15:30:00Z","reference_number":"EMA/CVMP/317099/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-chloroform_en.pdf"},
    {"id":"39075","name":"Opinion of the Committee for Medicinal Products for Veterinary Use on the establishment of maximum residue limits: Monepantel","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2016-11-16T14:24:00Z","last_updated_date":"2016-11-16T14:24:00Z","reference_number":"EMA/CVMP/322539/2016","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-committee-medicinal-products-veterinary-use-establishment-maximum-residue-limits-monepantel_en.pdf"},
    {"id":"39846","name":"Opinion of the CVMP on the establishment of maximum residue limits: Cabergoline","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-09-08T19:00:00Z","last_updated_date":"2014-09-08T19:00:00Z","reference_number":"EMA/CVMP/660284/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-cabergoline_en.pdf"},
    {"id":"39909","name":"Opinion of the CVMP on the establishment of maximum residue limits: Eprinomectin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2013-03-21T17:00:00Z","last_updated_date":"2013-03-21T17:00:00Z","reference_number":"EMA/CVMP/205176/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-eprinomectin_en.pdf-2"},
    {"id":"39926","name":"Opinion of the CVMP on the establishment of maximum residue limits: Pegylated bovine granulocyte colony stimulating factor","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T17:12:00Z","last_updated_date":"2012-05-25T17:12:00Z","reference_number":"EMA/CVMP/293093/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-pegylated-bovine-granulocyte-colony-stimulating-factor_en.pdf"},
    {"id":"40685","name":"Opinion of the CVMP on the establishment of maximum residue limits: Aluminium salicylate, basic","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2015-09-17T16:50:00Z","last_updated_date":"2015-09-17T16:50:00Z","reference_number":"EMA/CVMP/587830/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-aluminium-salicylate-basic_en.pdf"},
    {"id":"40861","name":"Opinion of the Committee for Medicinal Products for Veterinary Use on the establishment of maximum residue limits: Alarelin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-02-02T09:50:00Z","last_updated_date":"2018-02-02T09:50:00Z","reference_number":"EMA/CVMP/185578/2017","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-committee-medicinal-products-veterinary-use-establishment-maximum-residue-limits-alarelin_en.pdf"},
    {"id":"41758","name":"Opinion of the CVMP on the establishment of maximum residue limits: Clorsulon","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2014-09-08T19:00:00Z","last_updated_date":"2014-09-08T19:00:00Z","reference_number":"EMA/CVMP/741367/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-clorsulon_en.pdf-0"},
    {"id":"42353","name":"Opinion of the CVMP on the establishment of maximum residue limits: Isoflurane","type":"mrl-opinion","status":"unknown","consultation_date":"","first_published_date":"2018-10-17T10:40:00Z","last_updated_date":"2018-10-17T10:40:00Z","reference_number":"EMA/CVMP/103565/2018","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-isoflurane_en.pdf"},
    {"id":"47667","name":"Opinion of the CVMP on the establishment of maximum residue limits: Bambermycin","type":"mrl-opinion","status":"unknown","consultation_date":"","first_published_date":"2020-05-14T14:50:00Z","last_updated_date":"2020-05-14T14:50:00Z","reference_number":"EMA/CVMP/202283/2019","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-bambermycin_en.pdf"},
    {"id":"47745","name":"Opinion of the CVMP on the establishment of maximum residue limits: Ciclesonide","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2020-05-20T16:14:00Z","last_updated_date":"2020-05-20T16:14:00Z","reference_number":"EMA/CVMP/101968/2019","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-ciclesonide_en.pdf"},
    {"id":"48237","name":"Opinion of the CVMP on the establishment of maximum residue limits: Ketoprofen","type":"mrl-opinion","status":"unknown","consultation_date":"","first_published_date":"2020-07-06T15:37:00Z","last_updated_date":"2020-07-06T15:37:00Z","reference_number":"EMA/CVMP/94867/2020","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-ketoprofen_en.pdf"},
    {"id":"50389","name":"Opinion of the CVMP on the establishment of maximum residue limits: Bupivacaine","type":"mrl-opinion","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T10:11:00Z","last_updated_date":"2021-03-04T10:11:00Z","reference_number":"EMA/CVMP/278194/2020","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-bupivacaine_en.pdf"},
    {"id":"50391","name":"Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (EMEA/V/MRL/003649/EXTN/0003)","type":"mrl-opinion","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T10:18:00Z","last_updated_date":"2021-03-04T10:18:00Z","reference_number":"EMA/94693/2021","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-lidocaine-emea-v-mrl-003649-extn-0003_en.pdf"},
    {"id":"50705","name":"Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (porcine) (EMEA/V/MRL/003649/EXTN/0002)","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2021-03-25T14:49:00Z","last_updated_date":"2021-03-25T14:49:00Z","reference_number":"EMA/CVMP/358731/2020","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-lidocaine-porcine-emea-v-mrl-003649-extn-0002_en.pdf"},
    {"id":"50903","name":"Opinion of the CVMP on the establishment of maximum residue limits : Imidacloprid","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2021-04-19T14:06:00Z","last_updated_date":"2021-04-19T14:06:00Z","reference_number":"EMA/CVMP/446874/2020","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-imidacloprid_en.pdf"},
    {"id":"51093","name":"Opinion of the CVMP on the establishment of maximum residue limits: Bupivacaine","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2021-05-06T09:30:00Z","last_updated_date":"2021-05-06T09:30:00Z","reference_number":"EMA/CVMP/70565/2020","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-bupivacaine_en.pdf-0"},
    {"id":"52146","name":"Opinion of the CVMP on the establishment of maximum residue limits: Paromomycin","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2021-07-29T14:04:00Z","last_updated_date":"2021-07-29T14:04:00Z","reference_number":"EMA/CVMP/56181/2018","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-paromomycin_en.pdf"},
    {"id":"55436","name":"Opinion of the CVMP on the establishment of maximum residue limits : Bambermycin (EXTN/0002)","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2022-07-01T13:51:00Z","last_updated_date":"2022-07-01T13:51:00Z","reference_number":"EMA/CVMP/371780/2021","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-bambermycin-extn0002_en.pdf"},
    {"id":"60890","name":"Opinion of the CVMP on the establishment of maximum residue limits: Praziquantel","type":"mrl-opinion","status":"unknown","consultation_date":"","first_published_date":"2023-11-13T12:35:00Z","last_updated_date":"2023-11-13T12:35:00Z","reference_number":"EMA/484831/2023","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-praziquantel_en.pdf"},
    {"id":"65879","name":"Opinion of the CVMP on the establishment of maximum residue limits: Toltrazuril","type":"mrl-opinion","status":"unknown","consultation_date":"","first_published_date":"2024-11-29T10:52:52Z","last_updated_date":"2024-11-29T10:52:52Z","reference_number":"EMA/CVMP/683921/2021","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-toltrazuril_en.pdf"},
    {"id":"65883","name":"Opinion of the CVMP on the establishment of maximum residue limits: Ketoprofen","type":"mrl-opinion","status":"unknown","consultation_date":"","first_published_date":"2024-11-29T11:27:23Z","last_updated_date":"2024-11-29T11:27:23Z","reference_number":"EMA/CVMP/206677/2023","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-ketoprofen_en.pdf-0"},
    {"id":"66263","name":"Opinion of the CVMP on the establishment of maximum residue limits: Rafoxanide","type":"mrl-opinion","status":"unknown","consultation_date":"","first_published_date":"2025-01-07T17:15:45Z","last_updated_date":"2025-01-07T17:15:45Z","reference_number":"EMA/CVMP/152100/2023","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-rafoxanide_en.pdf-0"},
    {"id":"72879","name":"Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (EMEA/V/MRL/003649/MODF/0004)","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T15:09:03Z","last_updated_date":"2026-04-21T09:00:00Z","reference_number":"EMA/CVMP/330013/2025","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-lidocaine-emea-v-mrl-003649-modf-0004_en.pdf"},
    {"id":"72880","name":"Opinion of the CVMP on the establishment of maximum residue limits: Fluralaner ( EMEA/V/MRL/004380/EXTN/0002)","type":"mrl-opinion","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T15:11:47Z","last_updated_date":"2026-03-06T15:11:47Z","reference_number":"EMA/CVMP/27344/2025","document_url":"https://www.ema.europa.eu/en/documents/mrl-opinion/opinion-cvmp-establishment-maximum-residue-limits-fluralaner-emea-v-mrl-004380-extn-0002_en.pdf"},
    {"id":"27730","name":"Divergent position on a CVMP opinion on the establishment of maximum residue limits: For extension of fluazuron for fin fish (automatic extrapolation to milk)","type":"mrl-divergent-opinion","status":"Adopted","consultation_date":"","first_published_date":"2018-05-03T19:00:00Z","last_updated_date":"2018-05-03T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-divergent-opinion/divergent-position-cvmp-opinion-establishment-maximum-residue-limits-extension-fluazuron-fin-fish-automatic-extrapolation-milk_en.pdf"},
    {"id":"40648","name":"Divergent opinion on maximum residue limits of 'Purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids (as potassium salts)'","type":"mrl-divergent-opinion","status":"unknown","consultation_date":"","first_published_date":"2016-02-17T01:00:00Z","last_updated_date":"2016-02-17T17:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-divergent-opinion/divergent-opinion-maximum-residue-limits-purified-semi-solid-extract-humulus-lupulus-l-containing-approximately-48-beta-acids-potassium-salts_en.pdf"},
    {"id":"2391","name":"Oxyclozanide: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-02-01T01:00:00Z","last_updated_date":"1998-02-01T01:00:00Z","reference_number":"EMEA/MRL/340/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxyclozanide-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"2395","name":"Bromide, sodium salt: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-03-01T01:00:00Z","last_updated_date":"1997-03-01T01:00:00Z","reference_number":"EMEA/MRL/182/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bromide-sodium-salt-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"2409","name":"Majoranae herba: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/455/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/majoranae-herba-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"2447","name":"Florfenicol: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/florfenicol-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"2467","name":"Salviae folium: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T01:00:00Z","last_updated_date":"1997-11-01T01:00:00Z","reference_number":"EMEA/MRL/283/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/salviae-folium-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"2559","name":"Novobiocin: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/MRL/610/99-FINAL CORRIGENDUM","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/novobiocin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"2592","name":"Tosylchloramide sodium (extension to horses): Summary Report (3) – Committee for Medicinal Products for Veterinary use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-07-01T02:00:00Z","last_updated_date":"2005-07-01T02:00:00Z","reference_number":"EMEA/CVMP/220264/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tosylchloramide-sodium-extension-horses-summary-report-3-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"2615","name":"Cefacetrile: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-07-01T02:00:00Z","last_updated_date":"2000-07-01T02:00:00Z","reference_number":"EMEA/MRL/754/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefacetrile-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"2692","name":"Erythromycin, Erythromycin thiocyante, Erythromycin stearate: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-11-28T01:00:00Z","last_updated_date":"2000-11-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/erythromycin-erythromycin-thiocyante-erythromycin-stearate-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"2841","name":"Frangulae cortex: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/715/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/frangulae-cortex-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"2969","name":"Thymol: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-03-01T00:09:21Z","last_updated_date":"1996-03-01T00:09:21Z","reference_number":"EMEA/MRL/075/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thymol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3002","name":"Viscum album: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/680/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/viscum-album-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3107","name":"Coumafos: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"EMEA/MRL69/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/coumafos-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3183","name":"Cinnamomi cassiae aetheroleum: Summary report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-05-10T02:00:00Z","last_updated_date":"2012-05-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cinnamomi-cassiae-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3260","name":"Neomycin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-03-01T01:00:00Z","last_updated_date":"2000-03-01T01:00:00Z","reference_number":"EMEA/MRL/730/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/neomycin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3352","name":"Amprolium: Summary report (2) Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"EMEA/MRL/767/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/amprolium-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3471","name":"Substances used in homeopathic veterinary medicines:  European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-11-21T01:00:00Z","last_updated_date":"2013-11-21T01:00:00Z","reference_number":"EMEA/CVMP/016/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/substances-used-homeopathic-veterinary-medicines-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"3507","name":"Eucalyptus globulus (Use in veterinary homeopathy): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/688/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/eucalyptus-globulus-use-veterinary-homeopathy-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3584","name":"Florfenicol (Extension to all food producing species): Summary report (6) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/822/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/florfenicol-extension-all-food-producing-species-summary-report-6-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3594","name":"Aesculus Hippocastanum (use in veterinary homeopathy): Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/681/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/aesculus-hippocastanum-use-veterinary-homeopathy-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3614","name":"Peforelin - Summary report of the CVMP on the establishment of maximum residue limits","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-03-29T02:00:00Z","last_updated_date":"2012-03-29T02:00:00Z","reference_number":"EMEA/CVMP/111444/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/peforelin-summary-report-cvmp-establishment-maximum-residue-limits_en.pdf"},
    {"id":"3669","name":"Streptomycin and dihydrostreptomycin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/008/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/streptomycin-and-dihydrostreptomycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3748","name":"Ketamine: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-12-01T01:00:00Z","last_updated_date":"1997-12-01T01:00:00Z","reference_number":"EMEEA/MRL/315/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ketamine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3805","name":"Difloxacin (Modification): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-01-01T01:00:00Z","last_updated_date":"1997-01-01T01:00:00Z","reference_number":"EMEA/MRL/154/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/difloxacin-modification-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3823","name":"Alphacypermethrin: Summary Report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/402/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/alphacypermethrin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3834","name":"Omeprazole: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-06-01T02:00:00Z","last_updated_date":"2002-06-01T02:00:00Z","reference_number":"EMEA/MRL/841/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/omeprazole-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3968","name":"Tilmicosin (pigs and sheep tissues): Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-26T01:00:00Z","last_updated_date":"1999-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tilmicosin-pigs-and-sheep-tissues-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3980","name":"2-Aminoethanol glucuronate: Summary report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/567/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/2-aminoethanol-glucuronate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4064","name":"Meloxicam: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-06-01T02:00:00Z","last_updated_date":"1997-06-01T02:00:00Z","reference_number":"EMEA/MRL/236/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/meloxicam-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4103","name":"Gamithromycin (all ruminants except bovine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2017-01-10T16:32:00Z","last_updated_date":"2017-01-10T16:32:00Z","reference_number":"EMA/CVMP/454092/2016","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gamithromycin-all-ruminants-except-bovine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"4243","name":"Amitraz (Pigs): Summary report (3) Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-03-01T01:00:00Z","last_updated_date":"1996-03-01T01:00:00Z","reference_number":"EMEA/MRL/078/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/amitraz-pigs-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4320","name":"Diclazuril (Extension to all ruminants and porcine species): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-05-01T02:00:00Z","last_updated_date":"2004-05-01T02:00:00Z","reference_number":"EMEA/MRL/895/04-Final-rev","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diclazuril-extension-all-ruminants-and-porcine-species-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4326","name":"Amitraz (Extrapolation to goats): Summary report (4) Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/872/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/amitraz-extrapolation-goats-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4339","name":"Angelicae radix aetheroleum: Summary report  Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/412/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/angelicae-radix-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4389","name":"Medroxyprogesterone: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-07-01T02:00:00Z","last_updated_date":"1996-07-01T02:00:00Z","reference_number":"EMEA/MRL/0129/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/medroxyprogesterone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4467","name":"Xylazine hydrochloride (extension to dairy cows): Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-04-01T02:00:00Z","last_updated_date":"2002-04-01T02:00:00Z","reference_number":"EMEA/MRL/836/02-FINAL-corrigendum","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/xylazine-hydrochloride-extension-dairy-cows-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4490","name":"Sodium cetostearyl sulphate: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:09:21Z","last_updated_date":"1998-06-01T02:09:21Z","reference_number":"EMEA/MRL/449/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-cetostearyl-sulphate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4502","name":"Linear alkyl benzene sulphonic acids: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-07-01T02:00:00Z","last_updated_date":"2000-07-01T02:00:00Z","reference_number":"EMEA/MRL/755/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/linear-alkyl-benzene-sulphonic-acids-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4547","name":"Malic acid: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-18T01:00:00Z","last_updated_date":"1997-02-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/malic-acid-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4586","name":"Flubendazole: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flubendazole-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4604","name":"Cyromazine: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"EMEA/MRL/770/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cyromazine-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4690","name":"Permethrin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-03-01T01:00:00Z","last_updated_date":"1998-03-01T01:00:00Z","reference_number":"EMEA/MRL/112/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/permethrin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4695","name":"Nitroxinil (extrapolation of maximum residue limits (MRLs) to bovine and ovine milk): European public MRL assessment report (EPMAR)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T12:16:00Z","last_updated_date":"2012-03-15T12:16:00Z","reference_number":"EMA/CVMP/813401/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/nitroxinil-extrapolation-maximum-residue-limits-mrls-bovine-and-ovine-milk-european-public-mrl-assessment-report-epmar_en.pdf"},
    {"id":"4697","name":"Clorsulon: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/590/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clorsulon-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4714","name":"Clenbuterol: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-02-01T01:00:00Z","last_updated_date":"2000-02-01T01:00:00Z","reference_number":"EMEA/MRL/723/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clenbuterol-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4756","name":"Cinnamomi ceylanici aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/416/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cinnamomi-ceylanici-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4820","name":"Tiamulin (extension to rabbits): Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T00:09:21Z","last_updated_date":"2000-01-01T00:09:21Z","reference_number":"EMEA/MRL/724/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tiamulin-extension-rabbits-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"4890","name":"Azamethiphos (extension to fin fish): European public maximum-residue-limit assessment report (EPMAR)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-11T18:17:00Z","last_updated_date":"2023-11-23T18:17:00Z","reference_number":"EMA/CVMP/88291/2011-corr 1","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/azamethiphos-extension-fin-fish-european-public-maximum-residue-limit-assessment-report-epmar_en.pdf"},
    {"id":"4966","name":"Benzocaine (extension to Salmonidae): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-11-01T01:00:00Z","last_updated_date":"2001-11-01T01:00:00Z","reference_number":"EMEA/MRL/811/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/benzocaine-extension-salmonidae-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5035","name":"Cloprostenol and r-cloprostenol: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-04-01T02:00:00Z","last_updated_date":"1997-04-01T02:00:00Z","reference_number":"EMEA/MRL/202/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cloprostenol-and-r-cloprostenol-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5070","name":"Polysulphated glycosaminoglycan: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/024/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/polysulphated-glycosaminoglycan-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5130","name":"Diclofenac: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-09-01T02:00:00Z","last_updated_date":"2003-09-01T02:00:00Z","reference_number":"EMEA/MRL/885/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diclofenac-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5157","name":"Purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids (as potassium salts): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2016-02-16T15:54:00Z","last_updated_date":"2017-01-13T16:48:00Z","reference_number":"EMA/CVMP/245941/2015 Corr.","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/purified-semi-solid-extract-humulus-lupulus-l-containing-approximately-48-beta-acids-potassium-salts-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"5382","name":"Phenoxymethylpenicillin (eggs): European Public MRL Assessment Report (EPMAR) - Committee for Medicinal Products for Veterinary Use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-02-20T15:00:00Z","last_updated_date":"2012-02-20T15:00:00Z","reference_number":"EMA/CVMP/796083/2010","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phenoxymethylpenicillin-eggs-european-public-mrl-assessment-report-epmar-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"5385","name":"Oxibendazole: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxibendazole-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5409","name":"Harpagophytum procumbens: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/670/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/harpagophytum-procumbens-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5451","name":"Dihydrostreptomycin (Extrapolation to all ruminants): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-07-01T02:00:00Z","last_updated_date":"2005-07-01T02:00:00Z","reference_number":"EMEA/CVMP/211249/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dihydrostreptomycin-extrapolation-all-ruminants-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5552","name":"Thymi aetheroleum: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:09:21Z","last_updated_date":"1998-05-01T02:09:21Z","reference_number":"EMEA/MRL/411/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thymi-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5616","name":"Methylprednisolone: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-10-01T02:00:00Z","last_updated_date":"1999-10-01T02:00:00Z","reference_number":"EMEA/MRL/703/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/methylprednisolone-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5860","name":"Tricaine mesilate: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/586/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tricaine-mesilate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5888","name":"Paromomycin (Extension to all food producing species): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/825/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/paromomycin-extension-all-food-producing-species-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5975","name":"Amitraz (Bees): Summary report (2) Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/572/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/amitraz-bees-summary-report-2-committee-veterinary-medicinal-products_en.pdf"}    {"id":"6004","name":"Tiamulin: Summary Report (3) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2008-11-01T00:09:21Z","last_updated_date":"2008-11-01T00:09:21Z","reference_number":"EMEA/MRL/747/00-FINAL-REV","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tiamulin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6010","name":"Isoflurane: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-05-01T02:00:00Z","last_updated_date":"1997-05-01T02:00:00Z","reference_number":"EMEA/MRL/222/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/isoflurane-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6068","name":"Rafoxanide: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/636/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rafoxanide-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6147","name":"Thiamphenicol: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiamphenicol-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6156","name":"Fluazuron (All ruminants, except bovine and ovine, and fin fish): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2018-05-02T15:00:00Z","last_updated_date":"2018-05-02T15:00:00Z","reference_number":"EMA/CVMP/456716/2017","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fluazuron-all-ruminants-except-bovine-ovine-fin-fish-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"6182","name":"Potassium nitrate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-01T02:00:00Z","last_updated_date":"1997-07-01T02:00:00Z","reference_number":"EMEA/MRL/232/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/potassium-nitrate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6201","name":"Phenoxymethylpenicillin: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-10-01T02:00:00Z","last_updated_date":"1999-10-01T02:00:00Z","reference_number":"EMEA/MRL/697/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phenoxymethylpenicillin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6207","name":"Norgestomet: Summary Report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-01-01T01:00:00Z","last_updated_date":"2005-01-01T01:00:00Z","reference_number":"EMEA/CVMP/208625/2004-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/norgestomet-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6288","name":"Tiaprost: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T00:09:21Z","last_updated_date":"1999-02-01T00:09:21Z","reference_number":"EMEA/MRL/502/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tiaprost-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6294","name":"Thiamphenicol (extension to pigs): Summary Report (5) – Committee for Medicinal Products for Veterinary use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-01-01T00:09:21Z","last_updated_date":"2005-01-01T00:09:21Z","reference_number":"EMEA/CVMP/2316/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiamphenicol-extension-pigs-summary-report-5-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"6391","name":"Flumequine (Extension to bovine milk and turkey): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-11-01T01:00:00Z","last_updated_date":"1999-11-01T01:00:00Z","reference_number":"EMEA/MRL/707/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flumequine-extension-bovine-milk-and-turkey-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6397","name":"Peracetic acid: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-02-01T01:00:00Z","last_updated_date":"1996-02-01T01:00:00Z","reference_number":"EMEA/MRL/060/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/peracetic-acid-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6442","name":"Dexamethasone: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-03-01T01:00:00Z","last_updated_date":"1997-03-01T01:00:00Z","reference_number":"EMEA/MRL/195/97-CORRIGENDUM","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dexamethasone-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6526","name":"Paromomycin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/718/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/paromomycin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6602","name":"Meloxicam (Extension to horses): Summary report (6) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-03-01T01:00:00Z","last_updated_date":"2002-03-01T01:00:00Z","reference_number":"EMEA/MRL/833/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/meloxicam-extension-horses-summary-report-6-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6650","name":"Human menopausal urinary gonadotrophin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/human-menopausal-urinary-gonadotrophin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6687","name":"Romifidine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/romifidine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6730","name":"Diethylene glycol monoethyl ether: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/488/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diethylene-glycol-monoethyl-ether-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6765","name":"Mebendazole: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/625/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/mebendazole-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6822","name":"Altrenogest: Summary Report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-02-01T01:00:00Z","last_updated_date":"2002-02-01T01:00:00Z","reference_number":"EMEA/MRL/831/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/altrenogest-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6894","name":"Spectinomycin: Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-09-01T02:00:00Z","last_updated_date":"2001-09-01T02:00:00Z","reference_number":"EMEA/MRL/802/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/spectinomycin-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6951","name":"8-hydroxyquinoline: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/464/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/8-hydroxyquinoline-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6998","name":"Ginseng (Extension of use): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-09-01T02:00:00Z","last_updated_date":"2006-09-01T02:00:00Z","reference_number":"EMEA/CVMP/352217/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ginseng-extension-use-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7180","name":"Colistin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-07-23T02:00:00Z","last_updated_date":"2002-07-23T02:00:00Z","reference_number":"EMEA/MRL/016/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/colistin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7186","name":"Oxibendazole: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-10-01T02:00:00Z","last_updated_date":"1997-10-01T02:00:00Z","reference_number":"EMEA/MRL/268/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxibendazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7246","name":"Propane, n-butane, isobutane: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/031/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/propane-n-butane-isobutane-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7316","name":"2-Aminoethanol: Summary Report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-01-01T01:00:00Z","last_updated_date":"1998-01-01T01:00:00Z","reference_number":"EMEA/MRL/331/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/2-aminoethanol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7376","name":"Coco alkyl dimethyl betaines: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/396/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/coco-alkyl-dimethyl-betaines-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7525","name":"Gentamicin: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-11-01T01:00:00Z","last_updated_date":"2001-11-01T01:00:00Z","reference_number":"EMEA/MRL/803/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gentamicin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7549","name":"Flubendazole: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-10-01T02:00:00Z","last_updated_date":"1997-10-01T02:00:00Z","reference_number":"EMEA/MRL/267/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flubendazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7567","name":"Iron fumarate: European Public MRL Assessment Report (EPMAR) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2009-06-30T02:00:00Z","last_updated_date":"2009-06-30T02:00:00Z","reference_number":"EMEA/CVMP/168439/2008","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/iron-fumarate-european-public-mrl-assessment-report-epmar-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7607","name":"Ivermectin (deer): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-12-01T01:00:00Z","last_updated_date":"1996-12-01T01:00:00Z","reference_number":"EMEA/MRL/179/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ivermectin-deer-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7685","name":"Mepivacaine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-05-01T02:00:00Z","last_updated_date":"1999-05-01T02:00:00Z","reference_number":"EMEA/MRL/585/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/mepivacaine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7703","name":"Terebinthinae aetheroleum rectificatum: Summary Report  – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:09:21Z","last_updated_date":"1998-04-01T02:09:21Z","reference_number":"EMEA/MRL/397/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/terebinthinae-aetheroleum-rectificatum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7721","name":"Dapsone: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"1996-05-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dapsone-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7764","name":"Tildipirosin (bovine, caprine and porcine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-03-27T16:30:00Z","last_updated_date":"2014-03-27T16:30:00Z","reference_number":"EMA/CVMP/684147/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tildipirosin-bovine-caprine-and-porcine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"7833","name":"Barium selenate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/580/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/barium-selenate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7851","name":"Fenvalerate: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-05-01T02:00:00Z","last_updated_date":"2006-05-01T02:00:00Z","reference_number":"EMEA/CVMP/167406/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fenvalerate-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7875","name":"Tylosin: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tylosin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7909","name":"Melissae folium: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T01:00:00Z","last_updated_date":"1997-11-01T01:00:00Z","reference_number":"EMEA/MRL/287/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/melissae-folium-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7996","name":"Ricini oleum: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/399/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ricini-oleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8039","name":"Cefquinome (Extension to pigs): Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/405/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefquinome-extension-pigs-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8069","name":"Quillaia saponins: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-02-01T01:00:00Z","last_updated_date":"1996-02-01T01:00:00Z","reference_number":"EMEA/MRL/055/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/quillaia-saponins-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8127","name":"Spectinomycin (Extension to all food producing species): Summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/826/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/spectinomycin-extension-all-food-producing-species-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8194","name":"Flubendazole (Extension to turkeys): Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/576/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flubendazole-extension-turkeys-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8237","name":"Carprofen: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-11-01T01:00:00Z","last_updated_date":"2004-11-01T01:00:00Z","reference_number":"EMEA/MRL/914/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/carprofen-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8346","name":"Centellae asiaticae extractum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"EMEA/MRL/494/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/centellae-asiaticae-extractum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8357","name":"Hyperici oleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/359/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hyperici-oleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8426","name":"Manganese carbonate (all food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-11-12T12:33:00Z","last_updated_date":"2013-11-12T12:33:00Z","reference_number":"EMA/CVMP/685072/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/manganese-carbonate-all-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"8438","name":"Levamisole: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/levamisole-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8475","name":"Nicoboxil: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/466/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/nicoboxil-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8482","name":"Cloprostenol and r-cloprostenol (extension to goats): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-05-01T02:00:00Z","last_updated_date":"2004-05-01T02:00:00Z","reference_number":"EMEA/MRL/898/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cloprostenol-and-r-cloprostenol-extension-goats-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8560","name":"Polyethylene glycols (including polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 1000, polyethylene glycol 1500, polyethylene glycol 1540, polyethyle...","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/034/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/polyethylene-glycols-including-polyethylene-glycol-200-polyethylene-glycol-300-polyethylene-glycol-400-polyethylene-glycol-600-polyethylene-glycol-1000-polyethylene-glycol-1500-polyethylene-glycol_en.pdf"},
    {"id":"8581","name":"Chloroform (all mammalian food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-26T12:30:00Z","last_updated_date":"2014-02-26T12:30:00Z","reference_number":"EMA/CVMP/350579/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/chloroform-all-mammalian-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"8771","name":"Deslorelin acetate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-02-01T01:00:00Z","last_updated_date":"2002-02-01T01:00:00Z","reference_number":"EMEA/MRL/830/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/deslorelin-acetate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8867","name":"Ginseng: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/669/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ginseng-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8898","name":"Echinacea (Use in veterinary homeopathy): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/687/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/echinacea-use-veterinary-homeopathy-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"8933","name":"Flugestone acetate: Summary report  (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-05-01T02:00:00Z","last_updated_date":"2005-05-01T02:00:00Z","reference_number":"EMEA/CVMP/139560/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flugestone-acetate-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9000","name":"Rafoxanide (bovine and ovine milk): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-08-18T02:00:00Z","last_updated_date":"2014-08-18T02:00:00Z","reference_number":"EMA/CVMP/592866/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rafoxanide-bovine-and-ovine-milk-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"9069","name":"Bituminosulfonates, ammonium and sodium salts (Extension to dairy cattle): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-09-01T02:00:00Z","last_updated_date":"2004-09-01T02:00:00Z","reference_number":"EMEA/MRL/910/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bituminosulfonates-ammonium-and-sodium-salts-extension-dairy-cattle-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9124","name":"Abamectin (Revision of the acceptable daily intake): Summary Report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-05-01T02:00:00Z","last_updated_date":"2002-05-01T02:00:00Z","reference_number":"EMEA/MRL/838/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/abamectin-revision-acceptable-daily-intake-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9181","name":"Toltrazuril: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"2019-11-27T13:40:00Z","reference_number":"EMEA/MRL/314/97 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/toltrazuril-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9225","name":"Dicyclanil (Modification of the MRL for fat): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-05-01T02:00:00Z","last_updated_date":"2000-05-01T02:00:00Z","reference_number":"EMEA/MRL/739/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dicyclanil-modification-mrl-fat-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9384","name":"Furazolidone: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-01-01T01:00:00Z","last_updated_date":"1997-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/furazolidone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9477","name":"Triclabendazole: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/triclabendazole-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9483","name":"Moxidectin (Modification of the ADI and extension to bovine milk): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-02-01T01:00:00Z","last_updated_date":"2001-02-01T01:00:00Z","reference_number":"EMEA/MRL/777/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/moxidectin-modification-adi-and-extension-bovine-milk-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9508","name":"Baquiloprim: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-02-01T01:00:00Z","last_updated_date":"1996-02-01T01:00:00Z","reference_number":"EMEA/MRL/048/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/baquiloprim-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9535","name":"Clorsulon (cattle): European Public MRL Assessment Report (EPMAR) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2008-08-04T02:00:00Z","last_updated_date":"2008-08-04T02:00:00Z","reference_number":"EMEA/CVMP/358525/2008","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clorsulon-cattle-european-public-mrl-assessment-report-epmar-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9588","name":"Cyromazine: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/MRL/606/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cyromazine-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9644","name":"Triclabendazole (all ruminants milk): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-08-18T02:00:00Z","last_updated_date":"2014-08-18T02:00:00Z","reference_number":"EMA/CVMP/649781/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/triclabendazole-all-ruminants-milk-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"9654","name":"Lasalocid sodium (Extension to eggs): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-07-01T02:00:00Z","last_updated_date":"2006-07-01T02:00:00Z","reference_number":"EMEA/CVMP/46049/2006-FINAL-corr","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lasalocid-sodium-extension-eggs-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9826","name":"Amitraz (cattle and sheep): Summary report (2)  – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/330/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/amitraz-cattle-and-sheep-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9850","name":"Aminosidine: Summary report (1)  – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-11-28T01:00:00Z","last_updated_date":"2000-11-28T01:00:00Z","reference_number":"EMEA/MRL/050/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/aminosidine-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9893","name":"Imidocarb (Extension to sheep): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-07-01T02:00:00Z","last_updated_date":"2003-07-01T02:00:00Z","reference_number":"EMEA/MRL/881/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/imidocarb-extension-sheep-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9923","name":"Butafosfan: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/630/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/butafosfan-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"9974","name":"Difloxacin (Extension to swine and cattle): Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-11-01T01:00:00Z","last_updated_date":"1998-11-01T01:00:00Z","reference_number":"EMEA/MRL/525/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/difloxacin-extension-swine-and-cattle-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10094","name":"Calcium hypophosphite and other calcium salts: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"1996-05-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/calcium-hypophosphite-and-other-calcium-salts-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10110","name":"Rosmarini aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/290/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rosmarini-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10174","name":"Isoxsuprine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-09-01T02:00:00Z","last_updated_date":"1996-09-01T02:00:00Z","reference_number":"EMEA/MRL/123/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/isoxsuprine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10270","name":"Oxfendazole: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-06-01T02:00:00Z","last_updated_date":"1997-06-01T02:00:00Z","reference_number":"EMEA/MRL/194/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxfendazole-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10359","name":"Alphacypermethrin: Summary Report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-06-01T02:00:00Z","last_updated_date":"2003-06-01T02:00:00Z","reference_number":"EMEA/MRL/879/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/alphacypermethrin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10411","name":"Spiramycin (Extension to pigs): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/MRL/618/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/spiramycin-extension-pigs-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10412","name":"Diethylene glycol monoethyl ether (All food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-10-15T12:20:00Z","last_updated_date":"2015-10-15T12:20:00Z","reference_number":"EMA/CVMP/36933/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diethylene-glycol-monoethyl-ether-all-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"10487","name":"Kanamycin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-10-01T02:00:00Z","last_updated_date":"2003-10-01T02:00:00Z","reference_number":"EMEA/MRL/886/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/kanamycin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10583","name":"Fenbendazole: European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-01-16T16:00:00Z","last_updated_date":"2013-01-16T16:00:00Z","reference_number":"EMA/CVMP/914694/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fenbendazole-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"10586","name":"Danofloxacin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-25T02:00:00Z","last_updated_date":"1996-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/danofloxacin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10616","name":"Monepantel (ovine and caprine; extension of provisional MRLs): European Public MRL Assessment Report (2) (EPMAR) - Committee for Medicinal Products for Veterinary Use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2011-05-16T02:00:00Z","last_updated_date":"2011-05-16T02:00:00Z","reference_number":"EMA/CVMP/306267/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/monepantel-ovine-and-caprine-extension-provisional-mrls-european-public-mrl-assessment-report-2-epmar-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"10645","name":"Dinoprost tromethamine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"1996-05-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dinoprost-tromethamine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10656","name":"Terebinthinae laricina: Summary Report  – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:09:21Z","last_updated_date":"1998-04-01T02:09:21Z","reference_number":"EMEA/MRL/398/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/terebinthinae-laricina-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10690","name":"Cinchonae cortex: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/711/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cinchonae-cortex-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10743","name":"Cypermethrin (Extension to salmonidae): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-01-01T01:00:00Z","last_updated_date":"2003-01-01T01:00:00Z","reference_number":"EMEA/MRL/861/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cypermethrin-extension-salmonidae-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10762","name":"Bismuth subnitrate (Extension to intramammary administration): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-10-01T02:00:00Z","last_updated_date":"1999-10-01T02:00:00Z","reference_number":"EMEA/MRL/705/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bismuth-subnitrate-extension-intramammary-administration-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10787","name":"Anisi stellati fructus: Summary report  Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/710/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/anisi-stellati-fructus-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10796","name":"Altrenogest (equidae and porcine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-02-20T15:00:00Z","last_updated_date":"2012-02-20T15:00:00Z","reference_number":"EMA/CVMP/487477/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/altrenogest-equidae-and-porcine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"10874","name":"Copper chloride, copper gluconate, copper heptanoate, copper oxide, copper methionate, copper sulphate and dicopper oxide: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/431/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/copper-chloride-copper-gluconate-copper-heptanoate-copper-oxide-copper-methionate-copper-sulphate-and-dicopper-oxide-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10886","name":"Procaine: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-01-01T01:00:00Z","last_updated_date":"1998-01-01T01:00:00Z","reference_number":"EMEA/MRL/217/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/procaine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10947","name":"Medicago sativa extractum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/453/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/medicago-sativa-extractum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10965","name":"Allium Cepa: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/660/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/allium-cepa-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"10977","name":"Teflubenzuron: Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/547/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/teflubenzuron-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11033","name":"Tosylchloramide sodium (extension to bovine): Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-03-01T01:00:00Z","last_updated_date":"2001-03-01T01:00:00Z","reference_number":"EMEA/MRL/782/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tosylchloramide-sodium-extension-bovine-summary-report-2-committee-veterinary-medicinal-products_en.pdf"}    {"id":"11075","name":"Papain: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/036/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/papain-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11081","name":"Atropa belladonna: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-12-01T01:00:00Z","last_updated_date":"1998-12-01T01:00:00Z","reference_number":"EMEA/MRL/540/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/atropa-belladonna-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11099","name":"Pirlimycin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/460/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/pirlimycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11129","name":"Sodium nitrite: Summary Report – Committee for Medicinal Products for Veterinary use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-04-01T02:00:00Z","last_updated_date":"2006-04-01T02:00:00Z","reference_number":"EMEA/CVMP/116350/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-nitrite-summary-report-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"11319","name":"Fenvalerate: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-05-01T02:00:00Z","last_updated_date":"2002-05-01T02:00:00Z","reference_number":"EMEA/MRL/840/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fenvalerate-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11337","name":"Pregnant mare serum gonadotrophin (PMSG): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/pregnant-mare-serum-gonadotrophin-pmsg-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11347","name":"Levomethadone: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/583/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/levomethadone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11406","name":"Ruscus aculeatus: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/569/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ruscus-aculeatus-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11424","name":"Denaverine hydrochloride: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-12-01T01:00:00Z","last_updated_date":"1997-12-01T01:00:00Z","reference_number":"EMEA/MRL/307/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/denaverine-hydrochloride-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11481","name":"Difloxacin (Extension to all food producing species): Summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/819/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/difloxacin-extension-all-food-producing-species-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11487","name":"Doramectin (Extension to deer): Summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"EMEA/MRL/773/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/doramectin-extension-deer-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11523","name":"Potassium aspartate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-01T02:00:00Z","last_updated_date":"1997-07-01T02:00:00Z","reference_number":"EMEA/MRL/240/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/potassium-aspartate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11569","name":"Levamisole: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/levamisole-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11576","name":"Morantel (Extension to all ruminants): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-06-01T02:00:00Z","last_updated_date":"2005-06-01T02:00:00Z","reference_number":"EMEA/CVMP/36147/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/morantel-extension-all-ruminants-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11667","name":"Teflubenzuron: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-05-01T02:00:00Z","last_updated_date":"1997-05-01T02:00:00Z","reference_number":"EMEA/MRL/221/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/teflubenzuron-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11868","name":"Valnemulin (rabbits)European public MRL assessment report (EPMAR)Committee for Medicinal Products for Veterinary Use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/CVMP/137196/2009","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/valnemulin-rabbitseuropean-public-mrl-assessment-report-epmarcommittee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"11973","name":"Coriandri aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/409/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/coriandri-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12048","name":"Hydrogen peroxide: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-02-01T01:00:00Z","last_updated_date":"1996-02-01T01:00:00Z","reference_number":"EMEA/MRL/061/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hydrogen-peroxide-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12054","name":"Erythromycin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/720/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/erythromycin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12166","name":"Acetyl Cysteine: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-14T02:00:00Z","last_updated_date":"1996-05-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/acetyl-cysteine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12196","name":"Aristolochia: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-10-01T02:00:00Z","last_updated_date":"1997-10-01T02:00:00Z","reference_number":"EMEA/MRL/271/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/aristolochia-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12292","name":"Virola sebifera: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/604/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/virola-sebifera-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12325","name":"Permethrin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-07-01T02:00:00Z","last_updated_date":"2000-07-01T02:00:00Z","reference_number":"EMEA/MRL/751/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/permethrin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12337","name":"Tilmicosin (extension to chicken): Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-03-01T00:09:21Z","last_updated_date":"1998-03-01T00:09:21Z","reference_number":"EMEA/MRL/390/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tilmicosin-extension-chicken-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12421","name":"Florfenicol (Extension to chicken): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/589/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/florfenicol-extension-chicken-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12471","name":"Enrofloxacin (Extension to sheep, rabbits and lactating cows): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/389/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/enrofloxacin-extension-sheep-rabbits-and-lactating-cows-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12547","name":"Etamiphylline camsylate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-04-01T02:00:00Z","last_updated_date":"1996-04-01T02:00:00Z","reference_number":"EMEA/MRL/085/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/etamiphylline-camsylate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12724","name":"Toltrazuril (extension for pigs): Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/MRL/620/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/toltrazuril-extension-pigs-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12736","name":"Progesterone: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-12-21T01:00:00Z","last_updated_date":"2004-12-21T01:00:00Z","reference_number":"EMEA/MRL/146/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/progesterone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12759","name":"Dicyclanil: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/573/99-FINAL-CORRIGENDUM","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dicyclanil-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12828","name":"Butorphanol tartrate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-01-01T01:00:00Z","last_updated_date":"1998-01-01T01:00:00Z","reference_number":"EMEA/MRL/323/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/butorphanol-tartrate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12965","name":"Matricaria Recutita: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-11-01T01:00:00Z","last_updated_date":"1999-11-01T01:00:00Z","reference_number":"EMEA/MRL/706/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/matricaria-recutita-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12993","name":"Sorbitan trioleate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-04-01T02:00:00Z","last_updated_date":"2001-04-01T02:00:00Z","reference_number":"EMEA/MRL/783/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sorbitan-trioleate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13101","name":"Prednisolone (as free alcohol): Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/629/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/prednisolone-free-alcohol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13154","name":"Bromelain (porcine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2018-01-31T18:00:00Z","last_updated_date":"2018-01-31T18:00:00Z","reference_number":"EMA/CVMP/208391/2017","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bromelain-porcine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"13303","name":"Flunixin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/661/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flunixin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13425","name":"Echinacea purpurea: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-08-10T02:00:00Z","last_updated_date":"1998-08-10T02:00:00Z","reference_number":"EMEA/MRL/357/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/echinacea-purpurea-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13498","name":"Tylvalosin (acetylisovaleryltylosin) (modification of the acceptable daily intake, ADI): European Public MRL Assessment Report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2007-11-28T00:09:21Z","last_updated_date":"2007-11-28T00:09:21Z","reference_number":"EMEA/CVMP/469245/2007-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tylvalosin-acetylisovaleryltylosin-modification-acceptable-daily-intake-adi-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"13573","name":"Lincomycin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"EMEA/MRL/497/98-FINAL-corr","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lincomycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13585","name":"Sarafloxacin (salmonidae): Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-01-01T01:00:00Z","last_updated_date":"1997-01-01T01:00:00Z","reference_number":"EMEA/MRL/160/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sarafloxacin-salmonidae-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13587","name":"Sodium salicylate: European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-01-16T16:00:00Z","last_updated_date":"2013-01-16T16:00:00Z","reference_number":"EMA/CVMP/71291/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-salicylate-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"13603","name":"Oxolinic acid:  European public maximum-residue-limit assessment report (3) (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-11-21T01:00:00Z","last_updated_date":"2013-11-21T01:00:00Z","reference_number":"EMEA/MRL/845/02- FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxolinic-acid-european-public-maximum-residue-limit-assessment-report-3-epmar-cvmp_en.pdf"},
    {"id":"13671","name":"Wool alcohols: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/450/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/wool-alcohols-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13735","name":"Selenicereus grandiflorus: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/601/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/selenicereus-grandiflorus-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13775","name":"Lobeline: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-03-01T01:00:00Z","last_updated_date":"1996-03-01T01:00:00Z","reference_number":"EMEA/MRL/070/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lobeline-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13787","name":"Carazolol (Extension to cattle): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/442/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/carazolol-extension-cattle-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13811","name":"Citronellae aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-04T01:00:00Z","last_updated_date":"2015-05-01T02:00:00Z","reference_number":"EMEA/MRL/408/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/citronellae-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13854","name":"Carprofen: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/042/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/carprofen-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13927","name":"Strychni semen: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/566/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/strychni-semen-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13957","name":"Deltamethrin (Extension to fin fish): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-03-01T01:00:00Z","last_updated_date":"2000-03-01T01:00:00Z","reference_number":"EMEA/MRL/731/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/deltamethrin-extension-fin-fish-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13987","name":"Turnera diffusa: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:09:21Z","last_updated_date":"1999-08-01T02:09:21Z","reference_number":"EMEA/MRL/678/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/turnera-diffusa-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14086","name":"Sodium chlorite: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-chlorite-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14141","name":"Lauri fructus: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/565/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lauri-fructus-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14153","name":"Ivermectin (Extension to deer): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/487/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ivermectin-extension-deer-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14243","name":"Diflubenzuron: Call for scientific data for use in CVMP assessment work of diflubenzuron: review of the CVMP opinion for the establishment of maximum residue limits","type":"mrl-report","status":"Draft: consultation closed","consultation_date":"2014-06-10 - 2014-09-30","first_published_date":"2014-06-10T20:25:00Z","last_updated_date":"2014-06-10T20:25:00Z","reference_number":"EMA/CVMP/337469/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diflubenzuron-call-scientific-data-use-cvmp-assessment-work-diflubenzuron-review-cvmp-opinion-establishment-maximum-residue-limits_en.pdf"},
    {"id":"14273","name":"Benzalkonium chloride: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-12-01T01:00:00Z","last_updated_date":"1997-12-01T01:00:00Z","reference_number":"EMEA/MRL/306/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/benzalkonium-chloride-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14434","name":"Dexpanthenol: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-09-01T02:00:00Z","last_updated_date":"2001-09-01T02:00:00Z","reference_number":"EMEA/MRL/799/01","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dexpanthenol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14439","name":"Quatresin: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-01T02:00:00Z","last_updated_date":"1996-06-01T02:00:00Z","reference_number":"EMEA/MRL/097/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/quatresin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14447","name":"Sisapronil (bovine and caprine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-12-10T10:23:00Z","last_updated_date":"2015-12-10T10:23:00Z","reference_number":"EMA/CVMP/262442/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sisapronil-bovine-and-caprine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"14482","name":"Diethylene glycol monoethyl ether (Extension to all ruminants): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-09-01T02:00:00Z","last_updated_date":"2005-09-01T02:00:00Z","reference_number":"EMEA/CVMP/244224/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diethylene-glycol-monoethyl-ether-extension-all-ruminants-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14512","name":"Polyethylene glycol stearates and polyethylene glycol 15 hydroxystearate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-06-01T02:00:00Z","last_updated_date":"2003-06-01T02:00:00Z","reference_number":"EMEA/MRL/392/98-FINAL-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/polyethylene-glycol-stearates-and-polyethylene-glycol-15-hydroxystearate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14760","name":"Isoeugenol (fin fish): European Public MRL Assessment Report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2011-05-16T02:00:00Z","last_updated_date":"2020-11-27T12:46:00Z","reference_number":"EMA/CVMP/405186/2010 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/isoeugenol-fin-fish-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"14765","name":"Thiamphenicol (extension to pigs, sheep and fin fish): Summary Report (3) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:09:21Z","last_updated_date":"1998-09-01T02:09:21Z","reference_number":"EMEA/MRL/505/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiamphenicol-extension-pigs-sheep-and-fin-fish-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14860","name":"Strychnine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"EMEA/MRL/504/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/strychnine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14942","name":"Clorsulon: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-10-25T02:00:00Z","last_updated_date":"1999-10-25T02:00:00Z","reference_number":"EMEA/MRL/037/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clorsulon-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14953","name":"Lincomycin (Extension to all food producing species): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/824/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lincomycin-extension-all-food-producing-species-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14993","name":"Mineral hydrocarbons: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/CVMP/069/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/mineral-hydrocarbons-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15039","name":"Hydrochlorothiazide: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/582/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hydrochlorothiazide-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15186","name":"Dimethyl and diethyl phthalates: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-03-27T01:00:00Z","last_updated_date":"2002-03-27T01:00:00Z","reference_number":"EMEA/MRL/049/95-CORRIGENDUM","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dimethyl-and-diethyl-phthalates-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15311","name":"Nonivamide: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/467/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/nonivamide-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15410","name":"Fluazuron: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-03-01T01:00:00Z","last_updated_date":"2005-03-01T01:00:00Z","reference_number":"EMEA/MRL/77290/05-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fluazuron-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15514","name":"Phoxim (Extension to laying hens): Summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-06-01T02:00:00Z","last_updated_date":"2003-06-01T02:00:00Z","reference_number":"EMEA/MRL/880/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phoxim-extension-laying-hens-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15583","name":"Josamycin (Pigs): Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/461/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/josamycin-pigs-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15584","name":"Norgestomet:  European public maximum-residue-limit assessment report (1) (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-11-21T01:00:00Z","last_updated_date":"2013-11-21T01:00:00Z","reference_number":"EMEA/MRL/468/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/norgestomet-european-public-maximum-residue-limit-assessment-report-1-epmar-cvmp_en.pdf"},
    {"id":"15600","name":"Enrofloxacin (Extension to all food producing species): Summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/820/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/enrofloxacin-extension-all-food-producing-species-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15635","name":"Sulfogaiacol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/539/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sulfogaiacol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15696","name":"Coumafos: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/489/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/coumafos-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15807","name":"Closantel (bovine and ovine milk): European public MRL assessment report (EPMAR)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-04-13T15:45:00Z","last_updated_date":"2012-04-13T15:45:00Z","reference_number":"EMA/CVMP/813350/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/closantel-bovine-and-ovine-milk-european-public-mrl-assessment-report-epmar_en.pdf"},
    {"id":"15948","name":"Tosylchloramide sodium: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/570/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tosylchloramide-sodium-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16048","name":"Sulphur (Extension to all food producing species): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-11-01T01:00:00Z","last_updated_date":"2002-11-01T01:00:00Z","reference_number":"EMEA/MRL/853/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sulphur-extension-all-food-producing-species-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16176","name":"Tau fluvalinate: Revised Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/021-REV1/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tau-fluvalinate-revised-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16205","name":"Harunga madagascariensis: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/598/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/harunga-madagascariensis-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16282","name":"Somatolsalm: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-02T01:00:00Z","last_updated_date":"1997-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/somatolsalm-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16339","name":"Alarelin (all food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2018-01-31T18:00:00Z","last_updated_date":"2018-01-31T18:00:00Z","reference_number":"EMA/CVMP/156095/2017","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/alarelin-all-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"16403","name":"Octenidine dihydrochloride: European public MRL assessment report (EPMAR) - Committee for Medicinal Products for Veterinary Use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-03-14T01:00:00Z","last_updated_date":"2012-03-14T01:00:00Z","reference_number":"EMA/CVMP/735219/2009","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/octenidine-dihydrochloride-european-public-mrl-assessment-report-epmar-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"16447","name":"Clenbuterol hydrochloride: Summary report  (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/030/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clenbuterol-hydrochloride-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16462","name":"Tolfenamic acid: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-04-01T02:00:00Z","last_updated_date":"1997-04-01T02:00:00Z","reference_number":"EMEA/MRL/183/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tolfenamic-acid-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16658","name":"Zinc salts: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-01T02:00:00Z","last_updated_date":"1996-06-01T02:00:00Z","reference_number":"EMEA/MRL/113/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/zinc-salts-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16728","name":"Oxolinic acid (Extension to all food producing species): Summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-02-01T01:00:00Z","last_updated_date":"2005-02-01T01:00:00Z","reference_number":"EMEA/CVMP/41090/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxolinic-acid-extension-all-food-producing-species-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16740","name":"Gonadotrophin releasing hormone (Gonadorelin): Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gonadotrophin-releasing-hormone-gonadorelin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16758","name":"Eprinomectin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-01T02:00:00Z","last_updated_date":"1996-06-01T02:00:00Z","reference_number":"EMEA/MRL/114/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/eprinomectin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16781","name":"Doxycycline hyclate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-01T02:00:00Z","last_updated_date":"1996-06-01T02:00:00Z","reference_number":"EMEA/MRL/101/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/doxycycline-hyclate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16847","name":"Cypermethrin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/403/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cypermethrin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16860","name":"Tylosin (extension to all food producing species): Summary Report (5) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T00:09:21Z","last_updated_date":"2002-01-01T00:09:21Z","reference_number":"EMEA/MRL/829/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tylosin-extension-all-food-producing-species-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16925","name":"Porcine prolactin (porcine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2018-08-01T14:20:00Z","last_updated_date":"2018-08-01T14:20:00Z","reference_number":"EMA/CVMP/405782/2018","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/porcine-prolactin-porcine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"16942","name":"Magnesium and its compounds: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/039/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/magnesium-and-its-compounds-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16991","name":"Abamectin (Extension to sheep): Summary Report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-05-01T02:00:00Z","last_updated_date":"2002-05-01T02:00:00Z","reference_number":"EMEA/MRL/813/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/abamectin-extension-sheep-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17101","name":"Azaperone: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-01-01T01:00:00Z","last_updated_date":"1998-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/azaperone-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17165","name":"Danofloxacin (Extension to all food producing species): Summary report (6) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/818/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/danofloxacin-extension-all-food-producing-species-summary-report-6-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17215","name":"Flugestone acetate: Summary report (1)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-12-01T01:00:00Z","last_updated_date":"1999-12-01T01:00:00Z","reference_number":"EMEA/MRL/374/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flugestone-acetate-summary-report-1_en.pdf"}    {"id":"17231","name":"Oxalic acid: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-12-01T01:00:00Z","last_updated_date":"2003-12-01T01:00:00Z","reference_number":"EMEA/MRL/891/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxalic-acid-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17321","name":"Baquiloprim: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-04-01T02:00:00Z","last_updated_date":"1997-04-01T02:00:00Z","reference_number":"EMEA/MRL/199/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/baquiloprim-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17323","name":"Methylprednisolone (bovine milk after provisional MRLs): European Public MRL Assessment Report (EPMAR) - Committee for Medicinal Products for Veterinary Use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-02-20T15:00:00Z","last_updated_date":"2012-02-20T15:00:00Z","reference_number":"EMA/CVMP/664126/2010","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/methylprednisolone-bovine-milk-after-provisional-mrls-european-public-mrl-assessment-report-epmar-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"17328","name":"Netobimin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/556/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/netobimin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17345","name":"Trichlormethiazide (extension to dairy cows): Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-07-01T02:00:00Z","last_updated_date":"2002-07-01T02:00:00Z","reference_number":"EMEA/MRL/844/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/trichlormethiazide-extension-dairy-cows-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17371","name":"Lasalocid sodium: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-10-01T02:00:00Z","last_updated_date":"2004-10-01T02:00:00Z","reference_number":"EMEA/MRL/912/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lasalocid-sodium-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17387","name":"Ceftiofur (Modification of MRLs for bovine species): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-04-01T02:00:00Z","last_updated_date":"2002-04-01T02:00:00Z","reference_number":"EMEA/MRL/835/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ceftiofur-modification-mrls-bovine-species-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17394","name":"Oxfendazole, fenbendazole, febantel: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-28T01:00:00Z","last_updated_date":"1997-11-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxfendazole-fenbendazole-febantel-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17430","name":"Oxytocin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-18T01:00:00Z","last_updated_date":"1997-02-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxytocin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17496","name":"Sorbitan sesquioleate: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-04-01T02:00:00Z","last_updated_date":"2004-04-01T02:00:00Z","reference_number":"EMEA/MRL/900/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sorbitan-sesquioleate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17581","name":"Altrenogest: Summary Report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-12-01T01:00:00Z","last_updated_date":"1999-12-01T01:00:00Z","reference_number":"EMEA/MRL/175/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/altrenogest-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17591","name":"Boric acid and borates: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-14T02:00:00Z","last_updated_date":"1996-05-14T02:00:00Z","reference_number":"EMEA/CVMP/025/MRL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/boric-acid-and-borates-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17622","name":"Apramycin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-09-01T02:00:00Z","last_updated_date":"1997-09-01T02:00:00Z","reference_number":"EMEA/MRL/181/97","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/apramycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17661","name":"Melatonin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/melatonin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17695","name":"Cefacetrile: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-05-01T02:00:00Z","last_updated_date":"2001-05-01T02:00:00Z","reference_number":"EMEA/MRL/784/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefacetrile-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17713","name":"Sarafloxacin (salmonidae): Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-23T02:00:00Z","last_updated_date":"1996-05-23T02:00:00Z","reference_number":"EMEA/MRL/349/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sarafloxacin-salmonidae-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17736","name":"Phenoxymethylpenicillin (Extension to poultry): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-01-01T01:00:00Z","last_updated_date":"2005-01-01T01:00:00Z","reference_number":"EMEA/CVMP/2021/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phenoxymethylpenicillin-extension-poultry-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17771","name":"Tylvalosin (eggs): European public MRL assessment report (EPMAR)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-09-08T16:35:00Z","last_updated_date":"2015-09-08T16:35:00Z","reference_number":"EMA/CVMP/380628/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tylvalosin-eggs-european-public-mrl-assessment-report-epmar_en.pdf"},
    {"id":"17775","name":"Toltrazuril (extension to cattle and extrapolation to all mammalian food-producing species and poultry): Summary Report (5) – Committee for Medicinal Products for Veterinary use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-09-01T02:00:00Z","last_updated_date":"2005-09-01T02:00:00Z","reference_number":"EMEA/CVMP/278616/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/toltrazuril-extension-cattle-and-extrapolation-all-mammalian-food-producing-species-and-poultry-summary-report-5-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"17814","name":"Diclazuril: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-04-01T02:00:00Z","last_updated_date":"1996-04-01T02:00:00Z","reference_number":"EMEA/MRL/086/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diclazuril-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17850","name":"Imidocarb: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/444/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/imidocarb-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17891","name":"Mercaptamine hydrochloride: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-11-01T01:00:00Z","last_updated_date":"1998-11-01T01:00:00Z","reference_number":"EMEA/MRL/518/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/mercaptamine-hydrochloride-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"17916","name":"Acetylisovaleryltylosin: Summary Report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-10-01T02:00:00Z","last_updated_date":"1999-10-01T02:00:00Z","reference_number":"EMEA/MRL/702/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/acetylisovaleryltylosin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18004","name":"Enilconazole: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"EMEA/MRL/496/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/enilconazole-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18009","name":"Moxidectin (Extension to ovine milk): Summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-07-01T02:00:00Z","last_updated_date":"2004-07-01T02:00:00Z","reference_number":"EMEA/MRL/906/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/moxidectin-extension-ovine-milk-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18057","name":"Tilmicosin (extension to turkey): Summary Report (6) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-12-01T00:09:21Z","last_updated_date":"2000-12-01T00:09:21Z","reference_number":"EMEA/MRL/764/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tilmicosin-extension-turkey-summary-report-6-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18094","name":"Cetrimide: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-03-01T01:00:00Z","last_updated_date":"1996-03-01T01:00:00Z","reference_number":"EMEA/MRL/073/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cetrimide-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18117","name":"Hypericum perforatum (Use in veterinary homeopathy): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/690/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hypericum-perforatum-use-veterinary-homeopathy-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18277","name":"Carazolol (Extension to cattle): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/592/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/carazolol-extension-cattle-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18290","name":"Alphacypermethrin: Summary Report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-09-01T02:00:00Z","last_updated_date":"2001-09-01T02:00:00Z","reference_number":"EMEA/MRL/800/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/alphacypermethrin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18373","name":"Ethanol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-24T02:00:00Z","last_updated_date":"1997-07-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ethanol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18402","name":"Salicylic acid, sodium salicylate, aluminium salicylate, basic, and methyl salicylate: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-11-01T01:00:00Z","last_updated_date":"1999-11-01T01:00:00Z","reference_number":"EMEA/MRL/696/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/salicylic-acid-sodium-salicylate-aluminium-salicylate-basic-and-methyl-salicylate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18425","name":"Tanninum: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-02-01T01:00:00Z","last_updated_date":"1998-02-01T01:00:00Z","reference_number":"EMEA/MRL/353/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tanninum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18472","name":"Neomycin, including framycetin and soframycin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/006/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/neomycin-including-framycetin-and-soframycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18627","name":"Calcium pantothenate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-06-01T02:00:00Z","last_updated_date":"2001-06-01T02:00:00Z","reference_number":"EMEA/MRL/790/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/calcium-pantothenate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18773","name":"Hesperidin and hesperidin methyl chalcone: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-01T02:00:00Z","last_updated_date":"1996-06-01T02:00:00Z","reference_number":"EMEA/MRL/109/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hesperidin-and-hesperidin-methyl-chalcone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18778","name":"Gentamicin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-03-01T01:00:00Z","last_updated_date":"2000-03-01T01:00:00Z","reference_number":"EMEA/MRL/729/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gentamicin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18912","name":"Bronopol: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-06-01T02:00:00Z","last_updated_date":"2001-06-01T02:00:00Z","reference_number":"EMEA/MRL/791/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bronopol-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18946","name":"Febantel: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-06-01T02:00:00Z","last_updated_date":"1997-06-01T02:00:00Z","reference_number":"EMEA/MRL/192/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/febantel-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19054","name":"Clavulanic acid: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-10-01T02:00:00Z","last_updated_date":"1996-10-01T02:00:00Z","reference_number":"EMEA/MRL/152/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clavulanic-acid-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19060","name":"Tetracaine: Summary Report  – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-06-01T02:09:21Z","last_updated_date":"1997-06-01T02:09:21Z","reference_number":"EMEA/MRL/219/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tetracaine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19078","name":"Polyoxyl castor oil, polyoxyl hydrogenated castor oil: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/MRL/614/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/polyoxyl-castor-oil-polyoxyl-hydrogenated-castor-oil-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19108","name":"Acetylisovaleryltylosin: Summary Report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-07-01T02:00:00Z","last_updated_date":"2004-07-01T02:00:00Z","reference_number":"EMEA/MRL/909/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/acetylisovaleryltylosin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19154","name":"Josamycin (Chicken): Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/011/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/josamycin-chicken-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19189","name":"Emamectin (Extension to fin fish): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-02-01T01:00:00Z","last_updated_date":"2003-02-01T01:00:00Z","reference_number":"EMEA/MRL/863/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/emamectin-extension-fin-fish-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19221","name":"Diclazuril (Rabbits): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T17:30:00Z","last_updated_date":"2014-02-20T17:30:00Z","reference_number":"EMA/CVMP/605156/20123","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diclazuril-rabbits-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"19249","name":"1-Methyl-2-pyrrolidone: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"EMEA/MRL/493/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/1-methyl-2-pyrrolidone-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19255","name":"Symphyti radix: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/649/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/symphyti-radix-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19261","name":"Oleyloleate: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/445/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oleyloleate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19295","name":"Dexamethasone (Extrapolation to goats): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/874/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dexamethasone-extrapolation-goats-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19301","name":"Albendazole oxide: Summary Report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/555/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/albendazole-oxide-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19306","name":"Danofloxacin (Extension to pigs): Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/458/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/danofloxacin-extension-pigs-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19372","name":"Tiludronic acid (extension to poultry species): European Public MRL Assessment Report (EPMAR) – Committee for Medicinal Products for Veterinary use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2009-06-30T02:00:00Z","last_updated_date":"2009-06-30T02:00:00Z","reference_number":"EMEA/CVMP/92734/2008","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tiludronic-acid-extension-poultry-species-european-public-mrl-assessment-report-epmar-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"19400","name":"Sambuci flos: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T01:00:00Z","last_updated_date":"1997-11-01T01:00:00Z","reference_number":"EMEA/MRL/284/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sambuci-flos-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19457","name":"Triptorelin acetate (all food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-03-27T16:30:00Z","last_updated_date":"2014-03-27T16:30:00Z","reference_number":"EMA/CVMP/382140/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/triptorelin-acetate-all-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"19502","name":"Methylprednisolone: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-07-01T02:00:00Z","last_updated_date":"2001-07-01T02:00:00Z","reference_number":"EMEA/MRL/798/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/methylprednisolone-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19562","name":"Cefoperazone: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-07-01T02:00:00Z","last_updated_date":"2000-07-01T02:00:00Z","reference_number":"EMEA/MRL/748/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefoperazone-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19574","name":"Decoquinate: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-11-28T01:00:00Z","last_updated_date":"2000-11-28T01:00:00Z","reference_number":"EMEA/MRL/017/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/decoquinate-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19613","name":"Tiludronic acid, disodium salt: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"EMEA/MRL/774/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tiludronic-acid-disodium-salt-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19619","name":"Netobimin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-21T02:00:00Z","last_updated_date":"1996-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/netobimin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19635","name":"Gentamicin (all mammalian food producing species and fin fish): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2016-03-22T13:45:00Z","last_updated_date":"2016-03-22T13:45:00Z","reference_number":"EMA/CVMP/619817/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gentamicin-all-mammalian-food-producing-species-and-fin-fish-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"19664","name":"Enrofloxacin (Extension to sheep): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/MRL/574/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/enrofloxacin-extension-sheep-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19676","name":"Hydroxyethylsalicylate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-04-01T02:00:00Z","last_updated_date":"2002-04-01T02:00:00Z","reference_number":"EMEA/MRL/837/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hydroxyethylsalicylate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19692","name":"Fenbendazole (extrapolation to all ruminants): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"unknown","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/866/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fenbendazole-extrapolation-all-ruminants-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19701","name":"Triclabendazole: Summary Report (3) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T00:09:21Z","last_updated_date":"1997-11-01T00:09:21Z","reference_number":"EMEA/MRL/196/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/triclabendazole-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19744","name":"Iron dichloride and iron sulphate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/383/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/iron-dichloride-and-iron-sulphate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19762","name":"Gamithromycin (Bovine species): European Public MRL Assessment Report (EPMAR) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/CVMP/567075/2008","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gamithromycin-bovine-species-european-public-mrl-assessment-report-epmar-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19815","name":"Amitraz (Bees): Summary report (1)  – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-01T01:00:00Z","last_updated_date":"1997-02-01T01:00:00Z","reference_number":"EMEA/MRL/187/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/amitraz-bees-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19839","name":"Pyrantel embonate: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-11-01T01:00:00Z","last_updated_date":"1998-11-01T01:00:00Z","reference_number":"EMEA?MRL/491/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/pyrantel-embonate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19904","name":"n-Butanol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-01-01T01:00:00Z","last_updated_date":"1997-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/n-butanol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19955","name":"Allantoin: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-10-01T02:00:00Z","last_updated_date":"2001-10-01T02:00:00Z","reference_number":"EMEA/MRL/804/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/allantoin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20020","name":"Cefalonium: Summary report  (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-09-01T02:00:00Z","last_updated_date":"2002-09-01T02:00:00Z","reference_number":"EMEA/MRL/839/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefalonium-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20185","name":"Lachnanthes tinctoria: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/671/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lachnanthes-tinctoria-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20214","name":"Cefquinome: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-10-25T02:00:00Z","last_updated_date":"1999-10-25T02:00:00Z","reference_number":"EMEA/MRL/005/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefquinome-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20220","name":"Carprofen: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/528/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/carprofen-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20243","name":"Mebendazole: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-03-01T01:00:00Z","last_updated_date":"2001-03-01T01:00:00Z","reference_number":"EMEA/MRL/781/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/mebendazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20314","name":"Chlorhexidine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-01T02:00:00Z","last_updated_date":"1996-06-01T02:00:00Z","reference_number":"EMEA/MRL/107/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/chlorhexidine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20370","name":"Humic acids and their sodium salts: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/554/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/humic-acids-and-their-sodium-salts-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20410","name":"Lauri folii aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/564/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lauri-folii-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20454","name":"Lini oleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-09-01T02:00:00Z","last_updated_date":"1997-09-01T02:00:00Z","reference_number":"EMEA/MRL/263/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lini-oleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20519","name":"Flugestone acetate: Note regarding the establishment of maximum residue limits","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-01-01T01:00:00Z","last_updated_date":"2003-01-01T01:00:00Z","reference_number":"EMEA-V-8486-03","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flugestone-acetate-note-regarding-establishment-maximum-residue-limits_en.pdf"},
    {"id":"20593","name":"Vetrabutine hydrochloride: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/510/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/vetrabutine-hydrochloride-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20761","name":"Benzyl alcohol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-01-01T01:00:00Z","last_updated_date":"1997-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/benzyl-alcohol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20777","name":"Balsamum peruvianum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/356/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/balsamum-peruvianum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20789","name":"Halofuginone: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-06-01T02:00:00Z","last_updated_date":"2000-06-01T02:00:00Z","reference_number":"EMEA/MRL/741/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/halofuginone-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20824","name":"Amprolium: Summary report (1) Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-12-01T01:00:00Z","last_updated_date":"1999-12-01T01:00:00Z","reference_number":"EMEA/MRL/721/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/amprolium-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20830","name":"Apocynum cannabinum: Summary report  Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/596/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/apocynum-cannabinum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20848","name":"Deltamethrin (Extrapolation to all ruminants): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/893/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/deltamethrin-extrapolation-all-ruminants-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20861","name":"Penethamate (Hydriodide): Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-18T01:00:00Z","last_updated_date":"1997-02-18T01:00:00Z","reference_number":"EMEA/CVMP/022-REV1/MRL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/penethamate-hydriodide-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20879","name":"Lespedeza capitata: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/419/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lespedeza-capitata-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20982","name":"Beclometasone dipropionate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/905/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/beclometasone-dipropionate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"21015","name":"Aluminium Distearate, Hydroxide Acetate, Phosphate,Tristearate: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/393/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/aluminium-distearate-hydroxide-acetate-phosphatetristearate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"21039","name":"Cabergoline (bovine): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-08-18T02:00:00Z","last_updated_date":"2014-08-18T02:00:00Z","reference_number":"EMA/CVMP/656490/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cabergoline-bovine-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"21108","name":"L-Tartaric acid: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-24T02:00:00Z","last_updated_date":"1997-07-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/l-tartaric-acid-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"21140","name":"Eprinomectin (extention to ovine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-03-05T10:05:00Z","last_updated_date":"2013-03-05T10:05:00Z","reference_number":"EMA/CVMP/29109/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/eprinomectin-extention-ovine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"21168","name":"Ketoprofen: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/020/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ketoprofen-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"21229","name":"Sodium dichloroisocyanurate: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-dichloroisocyanurate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"21231","name":"Eprinomectin (ovine and caprine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-10T18:10:00Z","last_updated_date":"2015-02-10T18:10:00Z","reference_number":"EMA/CVMP/293891/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/eprinomectin-ovine-caprine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"21264","name":"Praziquantel: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-09-01T02:00:00Z","last_updated_date":"1996-09-01T02:00:00Z","reference_number":"EMEA/MRL/141/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/praziquantel-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"21282","name":"Chloramphenicol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"1996-05-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/chloramphenicol-summary-report-committee-veterinary-medicinal-products_en.pdf"}    {"id":"21288","name":"Phoxim: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/509/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phoxim-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"21539","name":"Emamectin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/546/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/emamectin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"21557","name":"Carbetocin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-02-01T01:00:00Z","last_updated_date":"1996-02-01T01:00:00Z","reference_number":"EMEA/MRL/054/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/carbetocin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"21592","name":"Fluralaner (poultry): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2017-02-16T14:00:00Z","last_updated_date":"2017-02-16T14:00:00Z","reference_number":"EMA/CVMP/567262/2016","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fluralaner-poultry-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"21650","name":"Piceae turiones recentes extractum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-07-01T02:00:00Z","last_updated_date":"2005-07-01T02:00:00Z","reference_number":"EMEA/CVMP/219201/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/piceae-turiones-recentes-extractum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22123","name":"Carazolol: Summary report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-05-10T02:00:00Z","last_updated_date":"2012-05-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/carazolol-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22126","name":"Propylene glycol: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-07-01T02:00:00Z","last_updated_date":"1996-07-01T02:00:00Z","reference_number":"EMEA/MRL/130/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/propylene-glycol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22173","name":"Deltamethrin: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-04-01T02:00:00Z","last_updated_date":"2001-04-01T02:00:00Z","reference_number":"EMEA/MRL/779/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/deltamethrin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22253","name":"Deltamethrin (Extension to fin fish): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-06-01T02:00:00Z","last_updated_date":"2001-06-01T02:00:00Z","reference_number":"EMEA/MRL/792/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/deltamethrin-extension-fin-fish-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22338","name":"Ronidazole: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ronidazole-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22350","name":"Cypermethrin (Extension to salmonidae): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-07-01T02:00:00Z","last_updated_date":"2001-07-01T02:00:00Z","reference_number":"EMEA/MRL/797/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cypermethrin-extension-salmonidae-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22362","name":"Florfenicol (Extension to fish): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-01T02:00:00Z","last_updated_date":"1997-07-01T02:00:00Z","reference_number":"EMEA/MRL/251/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/florfenicol-extension-fish-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22374","name":"Flugestone acetate: Summary report  (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-12-01T01:00:00Z","last_updated_date":"2002-12-01T01:00:00Z","reference_number":"EMEA/MRL/859/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flugestone-acetate-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22386","name":"Spectinomycin (sheep and chicken eggs): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/623/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/spectinomycin-sheep-and-chicken-eggs-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22434","name":"Phenol: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/040/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phenol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22518","name":"Aluminium salicylate, basic (bovine, caprine, Equidae and rabbit):  European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-09-17T13:00:00Z","last_updated_date":"2015-09-17T13:00:00Z","reference_number":"EMA/CVMP/587362/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/aluminium-salicylate-basic-bovine-caprine-equidae-and-rabbit-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"22534","name":"Jecoris oleum: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/MRL/613/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/jecoris-oleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22603","name":"Hexaflumuron (Fin fish): European public MRL assessment report (EPMAR)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-09-08T16:35:00Z","last_updated_date":"2015-09-08T16:35:00Z","reference_number":"EMA/CVMP/347671/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hexaflumuron-fin-fish-european-public-mrl-assessment-report-epmar_en.pdf"},
    {"id":"22641","name":"Cefquinome (Extension to pigs): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/545/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefquinome-extension-pigs-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22755","name":"Juniperi fructus: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/562/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/juniperi-fructus-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22803","name":"Monepantel (caprine and ovine milk): European public maximum-residue-limit assessment report (4) (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-05-24T13:15:00Z","last_updated_date":"2013-05-24T13:15:00Z","reference_number":"EMA/CVMP/741250/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/monepantel-caprine-and-ovine-milk-european-public-maximum-residue-limit-assessment-report-4-epmar-cvmp_en.pdf"},
    {"id":"22859","name":"Clodronic acid (in the form of disodium salt) (Equidae): European public MRL assessment report (EPMAR)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-09-08T16:35:00Z","last_updated_date":"2015-09-08T16:35:00Z","reference_number":"EMA/CVMP/239233/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clodronic-acid-form-disodium-salt-equidae-european-public-mrl-assessment-report-epmar_en.pdf"},
    {"id":"22882","name":"Flumethrin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/469/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flumethrin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22898","name":"Difloxacin (Extension to swine and cattle): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-06-01T02:00:00Z","last_updated_date":"2000-06-01T02:00:00Z","reference_number":"EMEA/MRL/740/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/difloxacin-extension-swine-and-cattle-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22932","name":"Sodium hypophosphite: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/44698-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-hypophosphite-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23002","name":"Sulfonamides: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/026/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sulfonamides-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23040","name":"Betaine Glucuronate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/568/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/betaine-glucuronate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23082","name":"Methylprednisolone (bovine milk)\n\nEuropean public MRL assessment report (EPMAR)\n\nCommittee for Medicinal Products for Veterinary Use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/CVMP/339442/2009","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/methylprednisolone-bovine-milk-european-public-mrl-assessment-report-epmar-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"23100","name":"Tilmicosin (extension to rabbbits): Summary Report (5) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-10-01T02:09:21Z","last_updated_date":"1999-10-01T02:09:21Z","reference_number":"EMEA/MRL/704/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tilmicosin-extension-rabbbits-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23137","name":"Cupressi aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/632/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cupressi-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23326","name":"Tilmicosin (extension to chicken): Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T00:09:21Z","last_updated_date":"1997-11-01T00:09:21Z","reference_number":"EMEA/MRL/318/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tilmicosin-extension-chicken-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23449","name":"Doramectin (Extension to deer including reindeer): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/637/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/doramectin-extension-deer-including-reindeer-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23484","name":"Florfenicol (Extension to pigs): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/591/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/florfenicol-extension-pigs-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23491","name":"Moxidectin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-01-01T01:00:00Z","last_updated_date":"1997-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/moxidectin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23509","name":"Piperazine: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"EMEA/MRL/771/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/piperazine-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23516","name":"Chlormadinone: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-05-01T02:00:00Z","last_updated_date":"2000-05-01T02:00:00Z","reference_number":"EMEA/MRL/694/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/chlormadinone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23641","name":"Cefazolin: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-24T02:00:00Z","last_updated_date":"1997-07-24T02:00:00Z","reference_number":"EMEA/MRL/0126/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefazolin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23647","name":"Corticotrophin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-12-01T01:00:00Z","last_updated_date":"1997-12-01T01:00:00Z","reference_number":"EMEA/MRL/308/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/corticotrophin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23693","name":"Cefalonium: Summary report  (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/646/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefalonium-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23723","name":"Oxyclozanide (Extrapolation to all ruminants): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/889/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxyclozanide-extrapolation-all-ruminants-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23817","name":"Dihydrostreptomycin (Extrapolation to rabbits): summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-12-01T01:00:00Z","last_updated_date":"2006-12-01T01:00:00Z","reference_number":"EMEA/CVMP/463923/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dihydrostreptomycin-extrapolation-rabbits-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23829","name":"1-Methyl-2-pyrrolidone: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2008-05-01T02:00:00Z","last_updated_date":"2008-05-01T02:00:00Z","reference_number":"EMEA/MRL/615/99-FINAL-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/1-methyl-2-pyrrolidone-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23887","name":"Okoubaka aubrevillei: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/673/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/okoubaka-aubrevillei-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23921","name":"Tulathromycin (modification of the microbiological ADI and MRLs in bovine and porcine species) – after provisional maximum residue limits (MRLs): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-04-07T12:40:00Z","last_updated_date":"2015-04-07T12:40:00Z","reference_number":"EMA/CVMP/380257/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tulathromycin-modification-microbiological-adi-and-mrls-bovine-and-porcine-species-after-provisional-maximum-residue-limits-mrls-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"23950","name":"Albendazole sulphoxide: Summary Report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-01T02:00:00Z","last_updated_date":"1996-06-01T02:00:00Z","reference_number":"EMEA/MRL/094/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/albendazole-sulphoxide-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"23956","name":"Tiliae flos: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T00:09:21Z","last_updated_date":"1997-11-01T00:09:21Z","reference_number":"EMEA/MRL/285/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tiliae-flos-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24054","name":"Urginea maritima: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/603/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/urginea-maritima-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24092","name":"Cyfluthrin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-07-01T02:00:00Z","last_updated_date":"2000-07-01T02:00:00Z","reference_number":"EMEA/MRL/746/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cyfluthrin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24119","name":"Camphora (use in veterinary homeopathy): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/684/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/camphora-use-veterinary-homeopathy-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24160","name":"Millefolii herba: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-10-01T02:00:00Z","last_updated_date":"1999-10-01T02:00:00Z","reference_number":"EMEA/MRL/288/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/millefolii-herba-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24217","name":"Paracetamol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/551/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/paracetamol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24270","name":"Menthae piperitae aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/420/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/menthae-piperitae-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24310","name":"Azagly-nafarelin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-02-01T01:00:00Z","last_updated_date":"2002-02-01T01:00:00Z","reference_number":"EMEA/MRL/832/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/azagly-nafarelin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24351","name":"Tiamulin: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:09:21Z","last_updated_date":"2017-05-05T16:00:00Z","reference_number":"EMEA/MRL/578/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tiamulin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24394","name":"Thiabendazole (extrapolation to goats): Summary Report (3) – Committee for Medicinal Products for Veterinary use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:09:21Z","last_updated_date":"2004-06-01T02:09:21Z","reference_number":"EMEA/MRL/868/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiabendazole-extrapolation-goats-summary-report-3-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"24411","name":"Quercus cortex: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T01:00:00Z","last_updated_date":"1997-11-01T01:00:00Z","reference_number":"EMEA/MRL/282/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/quercus-cortex-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24575","name":"Tylosin: Summary Report (3) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-04-01T02:09:21Z","last_updated_date":"1997-04-01T02:09:21Z","reference_number":"EMEA/MRL/205/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tylosin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24592","name":"Thiabendazole: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiabendazole-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24784","name":"Phytolacca americana: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/600/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phytolacca-americana-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24790","name":"Bacitracin (Extension to rabbits): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-11-01T01:00:00Z","last_updated_date":"2002-11-01T01:00:00Z","reference_number":"EMEA/MRL/857/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bacitracin-extension-rabbits-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24913","name":"Propetamphos: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/626/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/propetamphos-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24926","name":"Doramectin (Modification for cattle): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-01T01:00:00Z","last_updated_date":"1997-02-01T01:00:00Z","reference_number":"EMEA/MRL/136/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/doramectin-modification-cattle-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"24976","name":"Vincamine: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/587/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/vincamine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25011","name":"Altrenogest: Summary Report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL904/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/altrenogest-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25109","name":"Prethcamide (crothetamide and cropropamide): Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/385/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/prethcamide-crothetamide-and-cropropamide-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25162","name":"Polyethylene glycol 7 glyceryl cocoate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/395/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/polyethylene-glycol-7-glyceryl-cocoate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25168","name":"Carlinae radix: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/631/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/carlinae-radix-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25174","name":"Thiomersal and timerfonate: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-10-01T02:09:21Z","last_updated_date":"1996-10-01T02:09:21Z","reference_number":"EMEA/MRL/140/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiomersal-and-timerfonate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25241","name":"Agnus castus: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/658/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/agnus-castus-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25349","name":"Diflubenzuron: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-11-01T01:00:00Z","last_updated_date":"1998-11-01T01:00:00Z","reference_number":"EMEA/MRL/486/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diflubenzuron-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25367","name":"Thiopental sodium: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-11-01T00:09:21Z","last_updated_date":"1999-11-01T00:09:21Z","reference_number":"EMEA/MRL/708/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiopental-sodium-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25385","name":"Rifaximin (Extension to topical use): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/443/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rifaximin-extension-topical-use-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25404","name":"Urticae herba: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-10-01T02:00:00Z","last_updated_date":"1999-10-01T02:00:00Z","reference_number":"EMEA/MRL/286/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/urticae-herba-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25504","name":"Glycerol formal: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-01T02:00:00Z","last_updated_date":"1996-06-01T02:00:00Z","reference_number":"EMEA/MRL/108/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/glycerol-formal-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25573","name":"Vitamin A: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-03-01T01:00:00Z","last_updated_date":"1998-03-01T01:00:00Z","reference_number":"EMEA/MRL/365/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/vitamin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25604","name":"Menbutone: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-01T02:00:00Z","last_updated_date":"1996-06-01T02:00:00Z","reference_number":"EMEA/MRL/106/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/menbutone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25610","name":"Progesterone: Note regarding the establishment of maximum residue limits  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-03-01T01:00:00Z","last_updated_date":"2004-03-01T01:00:00Z","reference_number":"EMEA/CVMP/015/04","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/progesterone-note-regarding-establishment-maximum-residue-limits-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25656","name":"Hydrogen peroxide: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hydrogen-peroxide-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25719","name":"Imidocarb: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-05-01T02:00:00Z","last_updated_date":"2001-05-01T02:00:00Z","reference_number":"EMEA/MRL/785/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/imidocarb-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25810","name":"Nitroxinil: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-07T02:00:00Z","last_updated_date":"1999-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/nitroxinil-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25839","name":"Dembrexine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-04-01T02:00:00Z","last_updated_date":"1996-04-01T02:00:00Z","reference_number":"EMEA/MRL/080/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dembrexine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25868","name":"Human chorionic gonadotrophin (HCG): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-17T02:00:00Z","last_updated_date":"1996-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/human-chorionic-gonadotrophin-hcg-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25908","name":"Aloe vera gel: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/650/99","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/aloe-vera-gel-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25935","name":"Butafosfan (all mammalian food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T17:30:00Z","last_updated_date":"2014-02-20T17:30:00Z","reference_number":"EMA/CVMP/335153/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/butafosfan-all-mammalian-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"25972","name":"Cinnamomi cassiae cortex: Summary report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-05-10T02:00:00Z","last_updated_date":"2012-05-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cinnamomi-cassiae-cortex-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26047","name":"Cobalt carbonate, cobalt dichloride, cobalt gluconate, cobalt oxide, cobalt sulphate and cobalt trioxide: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/387/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cobalt-carbonate-cobalt-dichloride-cobalt-gluconate-cobalt-oxide-cobalt-sulphate-and-cobalt-trioxide-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26106","name":"Ceftiofur (Extension to ovine and extrapolation to all mammalian species): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-03-01T01:00:00Z","last_updated_date":"2006-03-01T01:00:00Z","reference_number":"EMEA/CVMP/80785/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ceftiofur-extension-ovine-and-extrapolation-all-mammalian-species-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26131","name":"Potassium selenate (all food producing species) Sodium selenate (all food producing species) Sodium selenite (all food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-04-07T12:40:00Z","last_updated_date":"2015-04-07T12:40:00Z","reference_number":"EMA/CVMP/187590/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/potassium-selenate-all-food-producing-species-sodium-selenate-all-food-producing-species-sodium-selenite-all-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"26142","name":"Crataegus: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/666/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/crataegus-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26166","name":"Carvi aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/414/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/carvi-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26248","name":"Boldo folium: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/548/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/boldo-folium-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26373","name":"Streptomycin: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-02-01T01:00:00Z","last_updated_date":"2002-02-01T01:00:00Z","reference_number":"EMEA/MRL/809/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/streptomycin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26475","name":"Brotizolam: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-14T02:00:00Z","last_updated_date":"1996-05-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/brotizolam-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26480","name":"Toltrazuril (extension for cattle): Summary Report (4) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/907/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/toltrazuril-extension-cattle-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26511","name":"Penethamate (Extension to pigs): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/577/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/penethamate-extension-pigs-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26512","name":"Aloes: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/549/99","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/aloes-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26548","name":"Rifaximin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-12-01T01:00:00Z","last_updated_date":"1997-12-01T01:00:00Z","reference_number":"EMEA/MRL/309/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rifaximin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26625","name":"Morantel:  European public maximum-residue-limit assessment report (2) (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-11-21T01:00:00Z","last_updated_date":"2013-11-21T01:00:00Z","reference_number":"EMEA/MRL/875/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/morantel-european-public-maximum-residue-limit-assessment-report-2-epmar-cvmp_en.pdf"},
    {"id":"26635","name":"Azamethiphos: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/001/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/azamethiphos-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26640","name":"Albendazole: Summary Report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-12-01T01:00:00Z","last_updated_date":"1997-12-01T01:00:00Z","reference_number":"EMEA/MRL/247/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/albendazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf"}    {"id":"26655","name":"Metamizole: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/529/98-FINAL-CORRIGENDUM","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/metamizole-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26835","name":"Gentamicin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/003/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gentamicin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26869","name":"Methyl nicotinate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/465/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/methyl-nicotinate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26875","name":"Florfenicol (Extension to fish): Summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-10-01T02:00:00Z","last_updated_date":"2000-10-01T02:00:00Z","reference_number":"EMEA/MRL/760/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/florfenicol-extension-fish-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26893","name":"Dihydrostreptomycin: summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-02-01T01:00:00Z","last_updated_date":"2002-02-01T01:00:00Z","reference_number":"EMEA/MRL/810/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dihydrostreptomycin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26905","name":"Febantel (Extrapolation to all ruminants): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/867/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/febantel-extrapolation-all-ruminants-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26973","name":"Ceftiofur: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-05-04T02:00:00Z","last_updated_date":"1999-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ceftiofur-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"26991","name":"Bronopol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/459/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bronopol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27051","name":"Penethamate (Extension to all mammalian species): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-12-01T01:00:00Z","last_updated_date":"2004-12-01T01:00:00Z","reference_number":"EMEA/MRL/913/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/penethamate-extension-all-mammalian-species-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27081","name":"Norgestomet: Note regarding establishment of maximum residue limits - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1993-01-01T01:00:00Z","last_updated_date":"2009-11-04T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/norgestomet-note-regarding-establishment-maximum-residue-limits-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27155","name":"Praziquantel (Extension to sheep milk): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-11-01T01:00:00Z","last_updated_date":"1998-11-01T01:00:00Z","reference_number":"EMEA/MRL/523/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/praziquantel-extension-sheep-milk-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27253","name":"Piperazine: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-05-01T02:00:00Z","last_updated_date":"1999-05-01T02:00:00Z","reference_number":"EMEA/MRL/531/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/piperazine-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27341","name":"Hamamelis virginiana: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-02-01T01:00:00Z","last_updated_date":"1998-02-01T01:00:00Z","reference_number":"EMEA/MRL/358/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hamamelis-virginiana-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27365","name":"Thuja occidentalis: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:09:21Z","last_updated_date":"1999-04-01T02:09:21Z","reference_number":"EMEA/MRL/602/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thuja-occidentalis-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27442","name":"Solvent naphtha, light aromatic (All food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2018-05-02T15:00:00Z","last_updated_date":"2018-05-02T15:00:00Z","reference_number":"EMA/CVMP/243810/2018","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/solvent-naphtha-light-aromatic-all-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"27522","name":"Oxolinic acid: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"EMEA/MRL/501/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxolinic-acid-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27651","name":"Flugestone acetate: Summary report (2)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-03-01T01:00:00Z","last_updated_date":"2001-03-01T01:00:00Z","reference_number":"EMEA/MRL/780/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flugestone-acetate-summary-report-2_en.pdf"},
    {"id":"27652","name":"Levothyroxine: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/319/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/levothyroxine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27733","name":"Menthol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/045/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/menthol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27816","name":"Sinapis nigrae semen: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:09:21Z","last_updated_date":"1998-06-01T02:09:21Z","reference_number":"EMEA/MRL/421/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sinapis-nigrae-semen-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27839","name":"Bellis perennis: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/663/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bellis-perennis-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28070","name":"Cefapirin: Summary report  (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-02-01T01:00:00Z","last_updated_date":"2001-02-01T01:00:00Z","reference_number":"EMEA/MRL/745/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefapirin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28216","name":"Trichlormethiazide: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/515/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/trichlormethiazide-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28316","name":"Colchicine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-10T01:00:00Z","last_updated_date":"1997-02-10T01:00:00Z","reference_number":"EMEA/MRL/044/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/colchicine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28365","name":"Meloxicam: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/571/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/meloxicam-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28418","name":"Nafcillin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-01-01T01:00:00Z","last_updated_date":"1997-01-01T01:00:00Z","reference_number":"EMEA/MRL/147/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/nafcillin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28425","name":"Fenpipramide hydrochloride: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/581/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fenpipramide-hydrochloride-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28478","name":"Rafoxanide: European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2016-05-03T13:02:00Z","last_updated_date":"2016-05-03T13:02:00Z","reference_number":"EMA/CVMP/700819/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rafoxanide-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"28569","name":"Chloroform: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-07-01T02:00:00Z","last_updated_date":"1996-07-01T02:00:00Z","reference_number":"EMEA/MRL/118/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/chloroform-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28605","name":"Kanamycin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/514/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/kanamycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28681","name":"Ivermectin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-18T01:00:00Z","last_updated_date":"1997-02-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ivermectin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28693","name":"Cypermethrin: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-04-01T02:00:00Z","last_updated_date":"2003-04-01T02:00:00Z","reference_number":"EMEA/MRL/876/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cypermethrin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28760","name":"Acetylsalicylic acid, sodium acetylsalicylate, acetylsalicylic acid dl-lysine and carbasalate calcium: Summary report (1) Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-11-01T01:00:00Z","last_updated_date":"1999-11-01T01:00:00Z","reference_number":"EMEA/MRL/695/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/acetylsalicylic-acid-sodium-acetylsalicylate-acetylsalicylic-acid-dl-lysine-and-carbasalate-calcium-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28762","name":"Eprinomectin: European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2016-07-01T17:58:00Z","last_updated_date":"2016-07-01T17:58:00Z","reference_number":"EMA/CVMP/779158/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/eprinomectin-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"28765","name":"Bacitracin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"EMEA/MRL/768/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bacitracin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28772","name":"Sulphur: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sulphur-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28778","name":"Capsici fructus acer: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/560/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/capsici-fructus-acer-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28822","name":"Oxolinic acid (Extension to bovine): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-12-01T01:00:00Z","last_updated_date":"2003-12-01T01:00:00Z","reference_number":"EMEA/MRL/892/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxolinic-acid-extension-bovine-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28880","name":"Dapsone: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"1996-05-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dapsone-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28967","name":"Betaine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-09-01T02:00:00Z","last_updated_date":"1997-09-01T02:00:00Z","reference_number":"EMEA/MRL/261/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/betaine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29014","name":"Iodine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/iodine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29020","name":"Solidago virgaurea: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/677/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/solidago-virgaurea-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29126","name":"Flumequine: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-03T01:00:00Z","last_updated_date":"1998-10-20T02:00:00Z","reference_number":"EMEA/MRL/104/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flumequine-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29143","name":"Double-stranded ribonucleic acid homologous to viral ribonucleic acid coding for part of the coat protein and part of the intergenic region of the Israel acute-paralysis virus (bees): European public MRL report","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-07-25T12:00:00Z","last_updated_date":"2013-07-25T12:00:00Z","reference_number":"EMA/CVMP/430890/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/double-stranded-ribonucleic-acid-homologous-viral-ribonucleic-acid-coding-part-coat-protein-part-intergenic-region-israel-acute-paralysis-virus-bees-european-public-mrl-report_en.pdf"},
    {"id":"29263","name":"Praziquantel (Extension to horses): Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-01-01T01:00:00Z","last_updated_date":"1998-01-01T01:00:00Z","reference_number":"EMEA/MRL/337/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/praziquantel-extension-horses-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29324","name":"Diazinon (Diampylate): Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"1996-05-15T02:00:00Z","reference_number":"EMEA/MRL/059/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diazinon-diampylate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29356","name":"Pirlimycin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/719/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/pirlimycin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29380","name":"Prunus laurocerasus: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/675/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/prunus-laurocerasus-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29386","name":"Spectinomycin (cattle, pigs, and poultry): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-03-01T01:00:00Z","last_updated_date":"2000-03-01T01:00:00Z","reference_number":"EMEA/MRL/726/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/spectinomycin-cattle-pigs-and-poultry-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29392","name":"Oxytetracycline, tetracycline, chlortetracycline: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/023/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxytetracycline-tetracycline-chlortetracycline-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29413","name":"Clorsulon (bovine milk): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-08-18T02:00:00Z","last_updated_date":"2014-08-18T02:00:00Z","reference_number":"EMA/CVMP/752339/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clorsulon-bovine-milk-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"29503","name":"Meloxicam (Extension to bovine milk): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/635/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/meloxicam-extension-bovine-milk-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29551","name":"Recommendation for the inclusion in Annex II of Council Regulation (EEC) 2377/90 of: Substances with an E number - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/CVMP/020-REV2/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/recommendation-inclusion-annex-ii-council-regulation-eec-237790-substances-e-number-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29644","name":"Gingko biloba: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/668/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gingko-biloba-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29657","name":"Propyl 4-hydroxybenzoate and its sodium salt (all food producing species): European public MRL assessment report (EPMAR)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-09-08T16:35:00Z","last_updated_date":"2015-09-08T16:35:00Z","reference_number":"EMA/CVMP/632934/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/propyl-4-hydroxybenzoate-and-its-sodium-salt-all-food-producing-species-european-public-mrl-assessment-report-epmar_en.pdf"},
    {"id":"29674","name":"Hydroxybenzoic acid esters and their sodium salts: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-02-01T01:00:00Z","last_updated_date":"1996-02-01T01:00:00Z","reference_number":"EMEA/MRL/051/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hydroxybenzoic-acid-esters-and-their-sodium-salts-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29744","name":"Sodium salicylate - European Public MRL Assessment Report (EPMAR) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2010-11-12T01:00:00Z","last_updated_date":"2010-11-12T01:00:00Z","reference_number":"EMA/CVMP/529651/2009","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-salicylate-european-public-mrl-assessment-report-epmar-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29813","name":"Doxycycline: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-10-01T02:00:00Z","last_updated_date":"1997-10-01T02:00:00Z","reference_number":"EMEA/MRL/270/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/doxycycline-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29883","name":"Phytomenadione (Vitamin K1) and menadione (Vitamin K3): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/447/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phytomenadione-vitamin-k1-and-menadione-vitamin-k3-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29924","name":"Lecirelin (LE): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-18T01:00:00Z","last_updated_date":"1997-02-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lecirelin-le-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30019","name":"Doxapram: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/533/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/doxapram-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30076","name":"Tulathromycin: Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-01-01T00:09:21Z","last_updated_date":"2004-01-01T00:09:21Z","reference_number":"EMEA/MRL/894/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tulathromycin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30081","name":"Cyfluthrin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T01:00:00Z","last_updated_date":"1997-11-01T01:00:00Z","reference_number":"EMEA/MRL/028/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cyfluthrin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30158","name":"Chlorocresol (4-chloro-3-methylphenol): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-03-01T01:00:00Z","last_updated_date":"1996-03-01T01:00:00Z","reference_number":"EMEA/MRL/074/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/chlorocresol-4-chloro-3-methylphenol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30205","name":"Gamithromycin (bovine species):  European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-11-21T01:00:00Z","last_updated_date":"2013-11-21T01:00:00Z","reference_number":"EMEA/CVMP/268818/2007","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gamithromycin-bovine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"30222","name":"Vedaprofen: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/038/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/vedaprofen-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30264","name":"Rafoxanide: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"EMEA/MRL/775/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rafoxanide-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30293","name":"Diflubenzuron: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/MRL/621/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diflubenzuron-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30371","name":"Albendazole: Summary Report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-25T02:00:00Z","last_updated_date":"1998-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/albendazole-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30377","name":"Avilamycin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2007-03-01T01:00:00Z","last_updated_date":"2007-03-01T01:00:00Z","reference_number":"EMEA/CVMP/102152/2007-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/avilamycin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30383","name":"Rosmarini folium: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T01:00:00Z","last_updated_date":"1997-11-01T01:00:00Z","reference_number":"EMEA/MRL/289/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rosmarini-folium-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30426","name":"Amitraz (cattle and sheep): Summary report (1)  – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-03-01T01:00:00Z","last_updated_date":"1996-03-01T01:00:00Z","reference_number":"EMEA/MRL/077/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/amitraz-cattle-and-sheep-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30472","name":"Eprinomectin (Modification): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-10-01T02:00:00Z","last_updated_date":"1998-10-01T02:00:00Z","reference_number":"EMEA/MRL/520/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/eprinomectin-modification-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30746","name":"Menthae arvensis aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-05-01T02:00:00Z","last_updated_date":"2001-05-01T02:00:00Z","reference_number":"EMEA/MRL/787/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/menthae-arvensis-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30752","name":"Bituminosulfonates, ammonium and sodium salts: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/511/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bituminosulfonates-ammonium-and-sodium-salts-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30859","name":"Oxytetracycline, tetracycline, chlortetracycline: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxytetracycline-tetracycline-chlortetracycline-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30895","name":"Morantel: Note regarding the establishment of maximum residue limits - Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-01-01T01:00:00Z","last_updated_date":"2004-01-01T01:00:00Z","reference_number":"EMEA-V-139723-04","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/morantel-note-regarding-establishment-maximum-residue-limits-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30928","name":"Chlorpromazine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-06-01T02:00:00Z","last_updated_date":"1996-06-01T02:00:00Z","reference_number":"EMEA/MRL/111/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/chlorpromazine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"30982","name":"Papaverine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/033/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/papaverine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31000","name":"Nitrofurans: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/nitrofurans-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31022","name":"Silybum marianum: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:09:21Z","last_updated_date":"1999-08-01T02:09:21Z","reference_number":"EMEA/MRL/665/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/silybum-marianum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31057","name":"Adonis Vernalis: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-12-01T01:00:00Z","last_updated_date":"1998-12-01T01:00:00Z","reference_number":"EMEA/MRL/543/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/adonis-vernalis-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31154","name":"Cypermethrin (Extrapolation to all ruminants): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/890/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cypermethrin-extrapolation-all-ruminants-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31177","name":"Pancreatin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"EMEA/MRL/062/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/pancreatin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31245","name":"Doxycycline (all food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-24T12:00:00Z","last_updated_date":"2015-02-24T12:00:00Z","reference_number":"EMA/CVMP/347870/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/doxycycline-all-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"31253","name":"Lavandulae aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/633/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lavandulae-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31271","name":"Oxytetracycline, tetracycline, chlortetracycline: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxytetracycline-tetracycline-chlortetracycline-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31284","name":"Closantel (bovine and ovine milk): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-08-18T02:00:00Z","last_updated_date":"2014-08-18T02:00:00Z","reference_number":"EMA/CVMP/751522/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/closantel-bovine-and-ovine-milk-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"31320","name":"Moxidectin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-09-01T02:00:00Z","last_updated_date":"1996-09-01T02:00:00Z","reference_number":"EMEA/MRL/139/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/moxidectin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31333","name":"Dinoprost: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-06-01T02:00:00Z","last_updated_date":"1997-06-01T02:00:00Z","reference_number":"EMEA/MRL/228/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dinoprost-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31356","name":"Cypermethrin (Extension to salmonidae): Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/436/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cypermethrin-extension-salmonidae-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31380","name":"Foeniculi aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/418/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/foeniculi-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31452","name":"Amitraz : Summary report (1) Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-01-01T01:00:00Z","last_updated_date":"1997-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/amitraz-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31475","name":"Cefacetrile: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"EMEA/MRL/499/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefacetrile-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31487","name":"Monepantel (Ovine and caprine): European Public MRL Assessment Report (1) (EPMAR) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2009-06-30T02:00:00Z","last_updated_date":"2009-06-30T02:00:00Z","reference_number":"EMEA/CVMP/165324/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/monepantel-ovine-and-caprine-european-public-mrl-assessment-report-1-epmar-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31511","name":"Phoxim (Extension to sheep): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-04-01T02:00:00Z","last_updated_date":"2000-04-01T02:00:00Z","reference_number":"EMEA/MRL/735/00-corrigendum","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phoxim-extension-sheep-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31528","name":"Morantel: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-11-01T01:00:00Z","last_updated_date":"1998-11-01T01:00:00Z","reference_number":"EMEA/MRL/490/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/morantel-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31640","name":"Monepantel (bovine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T11:10:00Z","last_updated_date":"2016-11-15T11:10:00Z","reference_number":"EMA/CVMP/351687/2016","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/monepantel-bovine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"31688","name":"Condurango cortex: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/14/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/condurango-cortex-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31879","name":"Tildipirosin\n\nEuropean public MRL assessment report (EPMAR)\n\nCommittee for Medicinal Products for Veterinary Use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/CVMP/709377/2009","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tildipirosin-european-public-mrl-assessment-report-epmar-committee-medicinal-products-veterinary-use_en.pdf"}    {"id":"31893","name":"Diclazuril (extension to poultry): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-03-05T10:05:00Z","last_updated_date":"2013-03-05T10:05:00Z","reference_number":"EMA/CVMP/165950/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diclazuril-extension-poultry-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"31930","name":"Toltrazuril (extension for pigs): Summary Report (3) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-06-01T02:00:00Z","last_updated_date":"2000-06-01T02:00:00Z","reference_number":"EMEA/MRL/743/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/toltrazuril-extension-pigs-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31959","name":"Monepantel (caprine and ovine species): European public MRL assessment report (3) (EPMAR) - Committee for Medicinal Products for Veterinary Use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T09:56:00Z","last_updated_date":"2012-03-01T09:56:00Z","reference_number":"EMA/CVMP/165324/2008","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/monepantel-caprine-and-ovine-species-european-public-mrl-assessment-report-3-epmar-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"31960","name":"3,5-Diiodo-L-thyrosine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/320/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/35-diiodo-l-thyrosine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31981","name":"Eprinomectin (Fin fish; extrapolation to horses and rabbits): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2018-08-01T14:20:00Z","last_updated_date":"2018-08-01T14:20:00Z","reference_number":"EMA/CVMP/607398/2017","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/eprinomectin-fin-fish-extrapolation-horses-and-rabbits-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"32008","name":"Vitamin D: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-03-01T01:00:00Z","last_updated_date":"1998-03-01T01:00:00Z","reference_number":"EMEA/MRL/366/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/vitamin-d-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32049","name":"Thiamphenicol (extension to pigs and extrapolation to all food producing species): Summary Report (6) – Committee for Medicinal Products for Veterinary use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-05-01T02:09:21Z","last_updated_date":"2006-05-01T02:09:21Z","reference_number":"EMEA/CVMP/162614/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiamphenicol-extension-pigs-and-extrapolation-all-food-producing-species-summary-report-6-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"32073","name":"Butafosfan (Extension to lactating cows): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-04-01T02:00:00Z","last_updated_date":"2000-04-01T02:00:00Z","reference_number":"EMEA/MRL/734/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/butafosfan-extension-lactating-cows-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32091","name":"Cardiospermum halicacabum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/664/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cardiospermum-halicacabum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32150","name":"Cimicifugae racemosae rhizoma: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-05-01T02:00:00Z","last_updated_date":"1999-05-01T02:00:00Z","reference_number":"EMEA/MRL/563/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cimicifugae-racemosae-rhizoma-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32178","name":"Manganese compounds: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-12-01T01:00:00Z","last_updated_date":"1997-12-01T01:00:00Z","reference_number":"EMEA/MRL/334/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/manganese-compounds-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32214","name":"Trimethoprim: Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-09-01T02:09:21Z","last_updated_date":"1997-09-01T02:09:21Z","reference_number":"EMEA/MRL/255/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/trimethoprim-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32275","name":"Trimethoprim: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/trimethoprim-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32311","name":"Firocoxib: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-10-01T02:00:00Z","last_updated_date":"2006-10-01T02:00:00Z","reference_number":"EMEA/CVMP/383063/2006-Final","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/firocoxib-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32335","name":"Convallaria majalis: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-12-01T01:00:00Z","last_updated_date":"1998-12-01T01:00:00Z","reference_number":"EMEA/MRL/541/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/convallaria-majalis-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32510","name":"Piperonyl butoxide: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/537/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/piperonyl-butoxide-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32538","name":"Anisi aetheroleum: Summary report  Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/413/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/anisi-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32568","name":"Doramectin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/doramectin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32603","name":"Sarafloxacin: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-23T02:09:21Z","last_updated_date":"1996-05-23T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sarafloxacin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32621","name":"Ketoprofen Extension to pigs): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-03-01T01:00:00Z","last_updated_date":"1996-03-01T01:00:00Z","reference_number":"EMEA/MRL/076/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ketoprofen-extension-pigs-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32667","name":"Potassium glucuronate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-01T02:00:00Z","last_updated_date":"1997-07-01T02:00:00Z","reference_number":"EMEA/MRL/238/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/potassium-glucuronate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32753","name":"Spiramycin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-19T01:00:00Z","last_updated_date":"1997-02-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/spiramycin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32764","name":"Furosemide: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-09-01T02:00:00Z","last_updated_date":"1999-09-01T02:00:00Z","reference_number":"EMEA/MRL/644/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/furosemide-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32780","name":"Flubendazole (Extrapolation to poultry): Summary report  (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-07-01T02:00:00Z","last_updated_date":"2006-07-01T02:00:00Z","reference_number":"EMEA/CVMP/33128/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flubendazole-extrapolation-poultry-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32811","name":"Heptaminol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/043/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/heptaminol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32831","name":"Cefazolin (Extension to sheep and goats): Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-09-01T02:00:00Z","last_updated_date":"1997-09-01T02:00:00Z","reference_number":"EMEA/MRL/257/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefazolin-extension-sheep-and-goats-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32874","name":"Flumequine: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/624/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flumequine-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32932","name":"Phoxim (pigs): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-07-01T02:00:00Z","last_updated_date":"2000-07-01T02:00:00Z","reference_number":"EMEA/MRL/752/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phoxim-pigs-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"32967","name":"Doramectin (Pigs and sheep): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-01T01:00:00Z","last_updated_date":"1997-02-01T01:00:00Z","reference_number":"EMEA/MRL/186/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/doramectin-pigs-sheep-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33009","name":"Ivermectin (all mammalian food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2014-05-20T14:00:00Z","last_updated_date":"2014-05-20T14:00:00Z","reference_number":"EMA/CVMP/294840/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ivermectin-all-mammalian-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"33061","name":"Phoxim (Extension to laying hens): Summary report (6) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-01-01T01:00:00Z","last_updated_date":"2005-01-01T01:00:00Z","reference_number":"EMEA/CVMP/6745/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phoxim-extension-laying-hens-summary-report-6-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33088","name":"Betamethasone: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEa/MRL/605/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/betamethasone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33124","name":"Dimetridazole: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"1996-05-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dimetridazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33141","name":"Sodium glycerophosphate: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-11-01T01:00:00Z","last_updated_date":"1998-11-01T01:00:00Z","reference_number":"EMEA/MRL/522/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-glycerophosphate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33172","name":"Fenbendazole: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"unknown","consultation_date":"","first_published_date":"1997-06-01T02:00:00Z","last_updated_date":"1997-06-01T02:00:00Z","reference_number":"EMEA/MRL/193/97/-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fenbendazole-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33205","name":"Clavulanic acid: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-02-01T01:00:00Z","last_updated_date":"2001-02-01T01:00:00Z","reference_number":"EMEA/MRL/776/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clavulanic-acid-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33241","name":"Xylazine hydrochloride: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/MRL/611/99-FINAL-corrigendum","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/xylazine-hydrochloride-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33332","name":"Acetylisovaleryltylosin: Summary Report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-07-01T02:00:00Z","last_updated_date":"2001-07-01T02:00:00Z","reference_number":"EMEA/MRL/794/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/acetylisovaleryltylosin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33346","name":"Aluminium salicylate basic (Extension to oral use in cattle): Summary Report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-06-01T02:00:00Z","last_updated_date":"2002-06-01T02:00:00Z","reference_number":"EMEA/MRL/796/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/aluminium-salicylate-basic-extension-oral-use-cattle-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33353","name":"Syzygium cumini: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/679/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/syzygium-cumini-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33478","name":"Benzocaine: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-06-13T02:00:00Z","last_updated_date":"2002-06-13T02:00:00Z","reference_number":"EMEA/MRL/218/97","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/benzocaine-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33623","name":"Alfaprostol (Extension to rabbits): Summary Report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-04T01:00:00Z","last_updated_date":"2015-05-01T02:00:00Z","reference_number":"EMEA/MRL/440/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/alfaprostol-extension-rabbits-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33629","name":"Dimetridazole: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"1996-05-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dimetridazole-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33670","name":"Tilmicosin (extension to all food producing species): Summary Report (7) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T00:09:21Z","last_updated_date":"2002-01-01T00:09:21Z","reference_number":"EMEA/MRL/827/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tilmicosin-extension-all-food-producing-species-summary-report-7-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33711","name":"Dexamethasone: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-28T01:00:00Z","last_updated_date":"1997-11-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dexamethasone-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33761","name":"Phoxim: European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-01-16T16:00:00Z","last_updated_date":"2013-01-16T16:00:00Z","reference_number":"EMA/CVMP/52331/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phoxim-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"33794","name":"Piperazine: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-11-01T01:00:00Z","last_updated_date":"2001-11-01T01:00:00Z","reference_number":"EMEA/MRL/807/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/piperazine-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33841","name":"Atropine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-10-01T02:00:00Z","last_updated_date":"1998-10-01T02:00:00Z","reference_number":"EMEA/MRL/517/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/atropine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33848","name":"Lasalocid (modification of the ADI and MRLs in poultry): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-10T18:10:00Z","last_updated_date":"2015-02-10T18:10:00Z","reference_number":"EMA/CVMP/769137/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lasalocid-modification-adi-and-mrls-poultry-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"33880","name":"Tylosin (extension to eggs): Summary Report (4) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-03-01T00:09:21Z","last_updated_date":"2000-03-01T00:09:21Z","reference_number":"EMEA/MRL/732/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tylosin-extension-eggs-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33894","name":"Dinoprostone: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2007-06-01T02:00:00Z","last_updated_date":"2007-06-01T02:00:00Z","reference_number":"EMEA/CVMP/235871/2007","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dinoprostone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33900","name":"Closantel: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"1996-05-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/closantel-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33913","name":"Linear alkyl benzene sulphonic acids (Extension to sheep): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-07-01T02:00:00Z","last_updated_date":"2004-07-01T02:00:00Z","reference_number":"EMEA/MRL/908/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/linear-alkyl-benzene-sulphonic-acids-extension-sheep-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33964","name":"Alfaprostol: Summary Report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-07-01T02:00:00Z","last_updated_date":"1996-07-01T02:00:00Z","reference_number":"EMEA/MRL/115/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/alfaprostol-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33968","name":"Ketanserin tartrate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ketanserin-tartrate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34115","name":"Metamizole: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-06-01T02:00:00Z","last_updated_date":"2003-06-01T02:00:00Z","reference_number":"EMEA/MRL/878/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/metamizole-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34140","name":"Vedaprofen: Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-10-01T02:00:00Z","last_updated_date":"1996-10-01T02:00:00Z","reference_number":"EMEA/MRL/144/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/vedaprofen-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34156","name":"Luprostiol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-04-01T02:00:00Z","last_updated_date":"1997-04-01T02:00:00Z","reference_number":"EMEA/MRL/200/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/luprostiol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34169","name":"Tilmicosin: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tilmicosin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34185","name":"Carazolol: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"2012-05-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/carazolol-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34297","name":"Enrofloxacin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/enrofloxacin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34315","name":"Manganese carbonate:  European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-11-21T01:00:00Z","last_updated_date":"2013-11-21T01:00:00Z","reference_number":"EMA/CVMP/14468/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/manganese-carbonate-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"34354","name":"Oxfendazole, fenbendazole, febantel: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxfendazole-fenbendazole-febantel-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34383","name":"Lincomycin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-07-01T02:00:00Z","last_updated_date":"2000-07-01T02:00:00Z","reference_number":"EMEA/MRL/749/00-FINAL-corr","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lincomycin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34390","name":"Potassium and sodium salts of selenium: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-10-01T02:00:00Z","last_updated_date":"1997-10-01T02:00:00Z","reference_number":"EMEA/MRL/249/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/potassium-and-sodium-salts-selenium-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34406","name":"Doramectin (Modification of the MRLs): Summary report (6) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-07-01T02:00:00Z","last_updated_date":"2006-07-01T02:00:00Z","reference_number":"EMEA/CVMP/126676/6/2006-Final","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/doramectin-modification-mrls-summary-report-6-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34507","name":"Spiramycin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-24T02:00:00Z","last_updated_date":"1997-07-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/spiramycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34521","name":"Triclabendazole: Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-25T02:00:00Z","last_updated_date":"1998-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/triclabendazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34526","name":"Thiamylal: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-12-01T00:09:21Z","last_updated_date":"1999-12-01T00:09:21Z","reference_number":"EMEA/MRL/724/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiamylal-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34544","name":"Erythromycin (Extension to all food producing species): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/821/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/erythromycin-extension-all-food-producing-species-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34602","name":"Rifaximin: Revised Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/007-REV 1/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rifaximin-revised-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34604","name":"Derquantel - European Public MRL Assessment Report (EPMAR) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2010-11-12T01:00:00Z","last_updated_date":"2010-11-12T01:00:00Z","reference_number":"EMA/CVMP/529651/2009","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/derquantel-european-public-mrl-assessment-report-epmar-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34726","name":"Hydrocortisone aceponate: European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2016-09-20T18:00:00Z","last_updated_date":"2016-09-20T18:00:00Z","reference_number":"EMA/CVMP/89165/2016","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hydrocortisone-aceponate-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"34741","name":"Phloroglucinol trimethylphloroglucinol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/046/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phloroglucinol-trimethylphloroglucinol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34765","name":"Eucalyptii aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/417/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/eucalyptii-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34783","name":"Ivermectin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ivermectin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34889","name":"Lidocaine: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/584/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lidocaine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34964","name":"Cefalexin: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/627/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefalexin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35015","name":"Policresulen (metacresol sulphonic acid-formaldehyde): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/035/095","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/policresulen-metacresol-sulphonic-acid-formaldehyde-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35084","name":"Oxidation products of terebinthinae oleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/400/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxidation-products-terebinthinae-oleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35090","name":"Citri aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/407/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/citri-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35112","name":"Hydrochloric acid:  European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-11-21T01:00:00Z","last_updated_date":"2013-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hydrochloric-acid-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"35185","name":"Calendulae flos: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-05-01T02:00:00Z","last_updated_date":"1999-05-01T02:00:00Z","reference_number":"EMEA/MRL/559/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/calendulae-flos-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35217","name":"Neomycin (including framycetin) (all food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-11-12T12:33:00Z","last_updated_date":"2013-11-12T12:33:00Z","reference_number":"EMA/CVMP/561830/2010","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/neomycin-including-framycetin-all-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"35279","name":"Moxidectin (Extension to horses): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/594/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/moxidectin-extension-horses-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35297","name":"Hydrocortisone: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-03-01T01:00:00Z","last_updated_date":"1998-03-01T01:00:00Z","reference_number":"EMEA/MRL/377/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hydrocortisone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35321","name":"Calcium glucoheptonate, calcium glucono glucoheptonate, calcium gluconolactate, calcium glutamate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/350/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/calcium-glucoheptonate-calcium-glucono-glucoheptonate-calcium-gluconolactate-calcium-glutamate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35356","name":"Bromhexine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-11-01T01:00:00Z","last_updated_date":"1998-11-01T01:00:00Z","reference_number":"EMEA/MRL/503/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bromhexine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35432","name":"Danofloxacin (Extension to milk): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-12-01T01:00:00Z","last_updated_date":"1998-12-01T01:00:00Z","reference_number":"EMEA/MRL/507/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/danofloxacin-extension-milk-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35455","name":"Lactic acid: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lactic-acid-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35466","name":"Halofuginone: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-11-01T01:00:00Z","last_updated_date":"1998-11-01T01:00:00Z","reference_number":"EMEA/MRL/485/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/halofuginone-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35558","name":"Thiabendazole: Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-10-01T02:09:21Z","last_updated_date":"1997-10-01T02:09:21Z","reference_number":"EMEA/MRL/269/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiabendazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35575","name":"Polyoxyethylene sorbitan monooleate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-09-01T02:00:00Z","last_updated_date":"2005-09-01T02:00:00Z","reference_number":"EMEA/CVMP/263823/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/polyoxyethylene-sorbitan-monooleate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35610","name":"Cymiazole: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-03-01T01:00:00Z","last_updated_date":"1996-03-01T01:00:00Z","reference_number":"EMEA/MRL/067/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cymiazole-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35704","name":"Streptomycin (Extrapolation to all ruminants and rabbits): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-12-01T01:00:00Z","last_updated_date":"2006-12-01T01:00:00Z","reference_number":"EMEA/CVMP/506164/2006-Final","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/streptomycin-extrapolation-all-ruminants-and-rabbits-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35822","name":"Cypermethrin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-09-01T02:00:00Z","last_updated_date":"2001-09-01T02:00:00Z","reference_number":"EMEA/MRL/801/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cypermethrin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35904","name":"Bromide, potassium salt: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/538/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bromide-potassium-salt-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"35936","name":"Tulathromycin (ovine and caprine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-24T12:00:00Z","last_updated_date":"2015-02-24T12:00:00Z","reference_number":"EMA/CVMP/131462/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tulathromycin-ovine-and-caprine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"36094","name":"Lufenuron (fin fish): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-01-14T17:10:00Z","last_updated_date":"2015-01-14T17:10:00Z","reference_number":"EMA/CVMP/651740/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lufenuron-fin-fish-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"36168","name":"Ruta graveolens: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/542/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ruta-graveolens-summary-report-committee-veterinary-medicinal-products_en.pdf"}    {"id":"36261","name":"Acetylsalicylic acid, sodium acetylsalicylate, acetylsalicylic acid dl-lysine and carbasalate calcium (Extension to all food producing species): Summary report (2) CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-01-01T01:00:00Z","last_updated_date":"2003-01-01T01:00:00Z","reference_number":"EMEA/MRL/860/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/acetylsalicylic-acid-sodium-acetylsalicylate-acetylsalicylic-acid-dl-lysine-carbasalate-calcium-extension-all-food-producing-species-summary-report-2-cvmp_en.pdf"},
    {"id":"36266","name":"Etiproston tromethamine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/etiproston-tromethamine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36284","name":"Sodium salicylates (extension to oral use in bovine and porcine): Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-02-01T01:00:00Z","last_updated_date":"2004-02-01T01:00:00Z","reference_number":"EMEA/MRL/897/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-salicylates-extension-oral-use-bovine-and-porcine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36312","name":"Monensin: European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-02-05T12:30:00Z","last_updated_date":"2013-02-05T12:30:00Z","reference_number":"EMA/CVMP/78198/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/monensin-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"36332","name":"Bismuth subnitrate, bismuth subcarbonate, bismuth subgallate, bismuth subsalicylate: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-04-01T02:00:00Z","last_updated_date":"1997-04-01T02:00:00Z","reference_number":"EMEA/MRL/201/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bismuth-subnitrate-bismuth-subcarbonate-bismuth-subgallate-bismuth-subsalicylate-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36435","name":"Sodium 2-methyl-2-phenoxy-propanoate: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/438/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-2-methyl-2-phenoxy-propanoate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36473","name":"Gamithromycin (porcine): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-24T12:00:00Z","last_updated_date":"2015-02-24T12:00:00Z","reference_number":"EMA/CVMP/350415/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gamithromycin-porcine-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"36488","name":"Rhei radix: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-11-01T01:00:00Z","last_updated_date":"1999-11-01T01:00:00Z","reference_number":"EMEA/MRL/648/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rhei-radix-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36491","name":"Tulathromycin (modification of the microbiological ADI and MRLs in bovine and porcine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-10T18:10:00Z","last_updated_date":"2015-02-10T18:10:00Z","reference_number":"EMA/CVMP/598235/2013","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tulathromycin-modification-microbiological-adi-and-mrls-bovine-and-porcine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"36494","name":"Folic acid: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-09-01T02:00:00Z","last_updated_date":"1997-09-01T02:00:00Z","reference_number":"EMEA/MRL/262/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/folic-acid-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36500","name":"Abamectin (Extension to sheep): Summary Report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/692/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/abamectin-extension-sheep-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36512","name":"Diclofenac (2) Bovine milk - European Public MRL Assessment Report (EPMAR) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/CVMP/67421/2009","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diclofenac-2-bovine-milk-european-public-mrl-assessment-report-epmar-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36565","name":"Penicillins: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/penicillins-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36598","name":"Sulfonamides: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sulfonamides-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36604","name":"Nickel gluconate and nickel sulphate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/454/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/nickel-gluconate-and-nickel-sulphate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36616","name":"Aqua Levici: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-12-01T01:00:00Z","last_updated_date":"1998-12-01T01:00:00Z","reference_number":"EMEA/MRL/544/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/aqua-levici-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36627","name":"Thiamphenicol: Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-10-01T02:09:21Z","last_updated_date":"1997-10-01T02:09:21Z","reference_number":"EMEA/MRL/256/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/thiamphenicol-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36679","name":"Meloxicam (Extension to pigs): Summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-12-01T01:00:00Z","last_updated_date":"2000-12-01T01:00:00Z","reference_number":"EMEA/MRL/765/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/meloxicam-extension-pigs-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36742","name":"Artemisia abrotanum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/682/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/artemisia-abrotanum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36779","name":"Cyhalothrin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-04-01T02:00:00Z","last_updated_date":"2001-04-01T02:00:00Z","reference_number":"EMEA/MRL/699/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cyhalothrin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36851","name":"Neomycin: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/816/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/neomycin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36875","name":"Buserelin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-14T02:00:00Z","last_updated_date":"1996-05-14T02:00:00Z","reference_number":"EMEA/MRL/019/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/buserelin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36900","name":"Natamycin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-02-01T01:00:00Z","last_updated_date":"1998-02-01T01:00:00Z","reference_number":"EMEA/MRL/342/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/natamycin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37057","name":"Tilmicosin (extension to milk): Summary Report (4) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-04-01T02:09:21Z","last_updated_date":"2000-04-01T02:09:21Z","reference_number":"EMEA/MRL/736/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tilmicosin-extension-milk-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37085","name":"Dicyclanil: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-03-01T01:00:00Z","last_updated_date":"2000-03-01T01:00:00Z","reference_number":"EMEA/MRL/733/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dicyclanil-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37091","name":"Phoxim (Extension to sheep): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-07-01T02:00:00Z","last_updated_date":"2000-07-01T02:00:00Z","reference_number":"EMEA/MRL/756/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/phoxim-extension-sheep-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37178","name":"Apramycin: Summary report (2) Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/526/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/apramycin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37213","name":"Euphrasia officinalis: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/667/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/euphrasia-officinalis-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37231","name":"Flumequine (Extension to all food producing species): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/823/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flumequine-extension-all-food-producing-species-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37332","name":"Marbofloxacin: Summary report  (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-10-01T02:00:00Z","last_updated_date":"1999-10-01T02:00:00Z","reference_number":"EMEA/MRL/693/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/marbofloxacin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37402","name":"Acetylisovaleryltylosin: Summary Report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2005-03-01T01:00:00Z","last_updated_date":"2005-03-01T01:00:00Z","reference_number":"EMEA/CVMP/77339/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/acetylisovaleryltylosin-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37453","name":"Ammonium chloride : Summary report  Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/394/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ammonium-chloride-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37514","name":"Prednisolone (Equidae): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2013-07-25T12:00:00Z","last_updated_date":"2013-07-25T12:00:00Z","reference_number":"EMA/CVMP/78357/2012","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/prednisolone-equidae-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"37577","name":"Decoquinate: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/722/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/decoquinate-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37623","name":"Marbofloxacin: Summary report  (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-03-01T01:00:00Z","last_updated_date":"1996-03-01T01:00:00Z","reference_number":"EMEA/MRL/079/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/marbofloxacin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37652","name":"Trimethoprim (extension to all food producing species): Summary Report (3) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T00:09:21Z","last_updated_date":"2002-01-01T00:09:21Z","reference_number":"EMEA/MRL/828/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/trimethoprim-extension-all-food-producing-species-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37665","name":"Hippocastani semen: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/MRL/558/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hippocastani-semen-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37694","name":"2-pyrrolidone: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/457/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/2-pyrrolidone-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37706","name":"Cyfluthrin (Extrapolation to caprine species): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2009-06-30T02:00:00Z","last_updated_date":"2009-06-30T02:00:00Z","reference_number":"EMEA/CVMP/606552/2007","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cyfluthrin-extrapolation-caprine-species-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37731","name":"Clazuril: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/371/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clazuril-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37751","name":"Polyoxyethylene sorbitan monooleate and trioleate - Summary report of the CVMP on the establishment of maximum residue limits","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-03-29T02:00:00Z","last_updated_date":"2012-03-29T02:00:00Z","reference_number":"EMEA/CVMP/72503/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/polyoxyethylene-sorbitan-monooleate-and-trioleate-summary-report-cvmp-establishment-maximum-residue-limits_en.pdf"},
    {"id":"37754","name":"Oxolinic acid: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-07-01T02:00:00Z","last_updated_date":"2000-07-01T02:00:00Z","reference_number":"EMEA/MRL/753/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxolinic-acid-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37820","name":"Lasalocid sodium (Extension to eggs): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2007-05-01T02:00:00Z","last_updated_date":"2007-05-01T02:00:00Z","reference_number":"EMEA/CVMP/201708/2007-FINAL-corr","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lasalocid-sodium-extension-eggs-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37858","name":"Terpin hydrate: Summary Report  – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:09:21Z","last_updated_date":"1998-04-01T02:09:21Z","reference_number":"EMEA/MRL/372/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/terpin-hydrate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37889","name":"Monensin (Cattle, including dairy cows): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2007-05-01T02:00:00Z","last_updated_date":"2007-05-01T02:00:00Z","reference_number":"EMEA/CVMP/185123/2007-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/monensin-cattle-including-dairy-cows-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37938","name":"Ailanthus altissima: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/ 659/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ailanthus-altissima-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"37959","name":"Methylprednisolone (Equidae): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-24T12:00:00Z","last_updated_date":"2015-02-24T12:00:00Z","reference_number":"EMA/CVMP/339062/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/methylprednisolone-equidae-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"38045","name":"Enrofloxacin (Modification for bovine, porcine and poultry): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/388/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/enrofloxacin-modification-bovine-porcine-and-poultry-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38051","name":"Firocoxib: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2006-06-01T02:00:00Z","reference_number":"EMEA/CVMP/228774/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/firocoxib-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38119","name":"Melissae aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"EMEA/MRL/281/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/melissae-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38123","name":"Parconazole: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"EMEA/MRL/351/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/parconazole-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38148","name":"Streptomycin and dihydrostreptomycin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-04-01T02:00:00Z","last_updated_date":"2000-04-01T02:00:00Z","reference_number":"EMEA/MRL/728/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/streptomycin-and-dihydrostreptomycin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38210","name":"Aluminium salicylate, basic (bovine, caprine, Equidae and rabbit) – after provisional maximum residue limits (MRLs): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2016-12-12T10:20:00Z","last_updated_date":"2016-12-12T10:20:00Z","reference_number":"EMA/CVMP/454104/2016","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/aluminium-salicylate-basic-bovine-caprine-equidae-and-rabbit-after-provisional-maximum-residue-limits-mrls-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"38212","name":"Hamamelis virginiana (Use in veterinary homeopathy): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/689/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hamamelis-virginiana-use-veterinary-homeopathy-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38323","name":"Valnemulin: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/339/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/valnemulin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38341","name":"Diprophylline: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/386/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diprophylline-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38402","name":"Ivermectin (Modification of Maximum Residue Limits): Summary report (5) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-11-01T01:00:00Z","last_updated_date":"2004-11-01T01:00:00Z","reference_number":"EMEA/MRL/915/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ivermectin-modification-maximum-residue-limits-summary-report-5-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38411","name":"Bacitracin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/451/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bacitracin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38446","name":"Mecillinam: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-07-01T02:00:00Z","last_updated_date":"1998-07-01T02:00:00Z","reference_number":"EMEA/MRL/462/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/mecillinam-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38494","name":"Spectinomycin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/spectinomycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38499","name":"Abamectin: Summary Report (1) Updated - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2002-05-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/abamectin-summary-report-1-updated-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38708","name":"Penethamate (Hydriodide): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1995-01-01T01:00:00Z","last_updated_date":"1995-01-01T01:00:00Z","reference_number":"EMEA/MRL/022-REV2/95","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/penethamate-hydriodide-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38714","name":"Cetostearyl alcohol: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-06-01T02:00:00Z","last_updated_date":"1998-06-01T02:00:00Z","reference_number":"EMEA/MRL/448/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cetostearyl-alcohol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38786","name":"Calendula officinalis (use in veterinary homeopathy): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/683/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/calendula-officinalis-use-veterinary-homeopathy-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"38927","name":"Azaperone: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T01:00:00Z","last_updated_date":"1997-11-01T01:00:00Z","reference_number":"EMEA/MRL/300/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/azaperone-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39073","name":"Matricariae flos: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T01:00:00Z","last_updated_date":"1997-11-01T01:00:00Z","reference_number":"EMEA/MRL/280/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/matricariae-flos-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39091","name":"Myristicae aetheroleum: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/410/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/myristicae-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39096","name":"Lectin extracted from red kidney beans, phaseolus vulgaris, (Porcine species): European Public MRL Assessment Report (EPMAR) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2008-09-01T02:00:00Z","last_updated_date":"2008-09-01T02:00:00Z","reference_number":"EMEA/CVMP/491626/2007","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lectin-extracted-red-kidney-beans-phaseolus-vulgaris-porcine-species-european-public-mrl-assessment-report-epmar-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39149","name":"Neostigmine: Summary report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-12-01T01:00:00Z","last_updated_date":"1996-12-01T01:00:00Z","reference_number":"EMEA/MRL/161/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/neostigmine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39161","name":"Hexetidine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-04-01T02:00:00Z","last_updated_date":"1998-04-01T02:00:00Z","reference_number":"EMEA/MRL/382/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/hexetidine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39211","name":"Arnica montana: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-12-01T01:00:00Z","last_updated_date":"1999-12-01T01:00:00Z","reference_number":"EMEA/MRL/647/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/arnica-montana-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39252","name":"Potassium glycerophosphate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-01T02:00:00Z","last_updated_date":"1997-07-01T02:00:00Z","reference_number":"EMEA/MRL/239/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/potassium-glycerophosphate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39348","name":"Virginiamycin (Poultry): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-09-08T16:35:00Z","last_updated_date":"2015-09-08T16:35:00Z","reference_number":"EMA/CVMP/643658/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/virginiamycin-poultry-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"39395","name":"Danofloxacin Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-09-01T02:00:00Z","last_updated_date":"1997-09-01T02:00:00Z","reference_number":"EMEA/MRL/254/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/danofloxacin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39399","name":"Lasalocid (bovine species): European public MRL assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-02-21T09:40:00Z","last_updated_date":"2012-02-21T09:40:00Z","reference_number":"EMA/CVMP/504089/2010","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lasalocid-bovine-species-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"39405","name":"Triclabendazole (extrapolation to bovine and ovine milk): European public MRL assessment report (EPMAR)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T13:30:00Z","last_updated_date":"2012-03-26T13:30:00Z","reference_number":"EMA/CVMP/8136/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/triclabendazole-extrapolation-bovine-and-ovine-milk-european-public-mrl-assessment-report-epmar_en.pdf"},
    {"id":"39459","name":"Triclabendazole (modification of maximum residue limits): Summary Report (4) – Committee for Medicinal Products for Veterinary use","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-06-01T02:09:21Z","last_updated_date":"2006-06-01T02:09:21Z","reference_number":"EMEA/CVMP/320386/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/triclabendazole-modification-maximum-residue-limits-summary-report-4-committee-medicinal-products-veterinary-use_en.pdf"},
    {"id":"39465","name":"Detomidine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-15T02:00:00Z","last_updated_date":"1996-05-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/detomidine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39586","name":"Ammonium lauryl sulphate: Summary report  Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-05-01T02:00:00Z","last_updated_date":"2001-05-01T02:00:00Z","reference_number":"EMEA/MRL/786/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ammonium-lauryl-sulphate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39603","name":"Difloxacin: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-02-11T01:00:00Z","last_updated_date":"1997-02-11T01:00:00Z","reference_number":"EMEA/MRL/029/95-Rev5","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/difloxacin-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39614","name":"Ergometrine maleate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/MRL/237/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ergometrine-maleate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39623","name":"Barium selenate (all food producing species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2015-04-07T12:40:00Z","last_updated_date":"2015-04-07T12:40:00Z","reference_number":"EMA/CVMP/160082/2014","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/barium-selenate-all-food-producing-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"39680","name":"Cefoperazone: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-10-01T02:00:00Z","last_updated_date":"1998-10-01T02:00:00Z","reference_number":"EMEA/MRL/512/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefoperazone-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39700","name":"Flunixin (extension to horses): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-06-01T02:00:00Z","last_updated_date":"2000-06-01T02:00:00Z","reference_number":"EMEA/MRL/744/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flunixin-extension-horses-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39720","name":"Meloxicam (Extrapolation to rabbits and goats): Summary report (7) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-05-01T02:00:00Z","last_updated_date":"2006-05-01T02:00:00Z","reference_number":"EMEA/CVMP/152255/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/meloxicam-extrapolation-rabbits-and-goats-summary-report-7-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39726","name":"Fluazuron: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2006-04-01T02:00:00Z","last_updated_date":"2006-04-01T02:00:00Z","reference_number":"EMEA/CVMP/126892/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fluazuron-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39730","name":"Pegylated bovine granulocyte colony stimulating factor (PEGbG-CSF) (bovine species): European public MRL assessment report (EPMAR)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T12:16:00Z","last_updated_date":"2012-03-15T12:16:00Z","reference_number":"EMA/CVMP/190918/2010","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/pegylated-bovine-granulocyte-colony-stimulating-factor-pegbg-csf-bovine-species-european-public-mrl-assessment-report-epmar_en.pdf"},
    {"id":"39791","name":"Ceftiofur: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/498/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ceftiofur-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39803","name":"D-phe6-luteinizing-hormone-releasing-hormone: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-12-01T01:00:00Z","last_updated_date":"1996-12-01T01:00:00Z","reference_number":"EMEA/MRL/159/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/d-phe6-luteinizing-hormone-releasing-hormone-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39833","name":"Albendazole: Summary Report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/865/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/albendazole-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39874","name":"Azamethiphos: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-01-01T01:00:00Z","last_updated_date":"1999-01-01T01:00:00Z","reference_number":"EMEA/MRL/527/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/azamethiphos-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39881","name":"Tulathromycin: Summary Report (1) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-06-01T02:09:21Z","last_updated_date":"2002-06-01T02:09:21Z","reference_number":"EMEA/MRL/842/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tulathromycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39899","name":"Cinnamomi ceylanici cortex: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/713/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cinnamomi-ceylanici-cortex-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39924","name":"Lobaria pulmonaria: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/MRL/672/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lobaria-pulmonaria-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39975","name":"Deltamethrin: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-04-01T02:00:00Z","last_updated_date":"1999-04-01T02:00:00Z","reference_number":"EMEA/MRL/530/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/deltamethrin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40047","name":"Meloxicam (Modification for bovine): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/MRL/634/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/meloxicam-modification-bovine-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40086","name":"Chlorphenamine: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/MRL/513/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/chlorphenamine-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40098","name":"Oestradiol: Summary Report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oestradiol-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40136","name":"Amitraz : Summary report (2) Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-01-01T01:00:00Z","last_updated_date":"1997-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/amitraz-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40201","name":"Alfacalcidol: Summary Report  - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-03-01T01:00:00Z","last_updated_date":"1998-03-01T01:00:00Z","reference_number":"EMEA/MRL/381/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/alfacalcidol-summary-report-committee-veterinary-medicinal-products_en.pdf"}    {"id":"40241","name":"Cefapirin: Summary report  (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-07-01T02:00:00Z","last_updated_date":"1996-07-01T02:00:00Z","reference_number":"EMEA/MRL/0128/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefapirin-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40427","name":"Tilmicosin (extension to bovine milk): Summary Report (3) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:09:21Z","last_updated_date":"1999-06-01T02:09:21Z","reference_number":"EMEA/MRL/619/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tilmicosin-extension-bovine-milk-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40444","name":"Oxfendazole (Extrapolation to all ruminants): Summary report (4) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/MRL/888/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxfendazole-extrapolation-all-ruminants-summary-report-4-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40448","name":"Clorsulon (bovine milk): European public maximum-residue-limit assessment report (EPMAR)","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-11T18:17:00Z","last_updated_date":"2012-06-11T18:17:00Z","reference_number":"EMA/CVMP/813332/2011","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/clorsulon-bovine-milk-european-public-maximum-residue-limit-assessment-report-epmar_en.pdf"},
    {"id":"40513","name":"Flumethrin (Extension to sheep): Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-04-01T02:00:00Z","last_updated_date":"2000-04-01T02:00:00Z","reference_number":"EMEA/MRL/737/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/flumethrin-extension-sheep-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40524","name":"Etamsylate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"EMEA/MRL/500/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/etamsylate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40530","name":"2-Aminoethyl dihydrogenphosphate: Summary report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-02-01T01:00:00Z","last_updated_date":"1998-02-01T01:00:00Z","reference_number":"EMEA/MRL/352/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/2-aminoethyl-dihydrogenphosphate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40631","name":"Nafcillin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2001-04-01T02:00:00Z","last_updated_date":"2001-04-01T02:00:00Z","reference_number":"EMEA/MRL/750/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/nafcillin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40723","name":"Moxidectin (Extension to horses): Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-01T02:00:00Z","last_updated_date":"1997-07-01T02:00:00Z","reference_number":"EMEA/MRL/250/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/moxidectin-extension-horses-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40729","name":"Tylosin: Summary Report (2) – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-23T02:00:00Z","last_updated_date":"1996-05-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/tylosin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40782","name":"Serenoa repens: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:09:21Z","last_updated_date":"1999-08-01T02:09:21Z","reference_number":"EMEA/MRL/676/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/serenoa-repens-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40794","name":"Butylscopolaminium bromide: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T01:00:00Z","last_updated_date":"1997-11-01T01:00:00Z","reference_number":"EMEA/MRL/244/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/butylscopolaminium-bromide-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40841","name":"Toldimfos: Summary Report – Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1999-12-01T01:00:00Z","last_updated_date":"1999-12-01T01:00:00Z","reference_number":"EMEA/MRL/717/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/toldimfos-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40847","name":"Metronidazole: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1997-07-01T02:00:00Z","last_updated_date":"1997-07-01T02:00:00Z","reference_number":"EMEA/MRL/173/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/metronidazole-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40898","name":"Gentianae radix: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2000-01-01T01:00:00Z","last_updated_date":"2000-01-01T01:00:00Z","reference_number":"EMEA/MRL/716/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/gentianae-radix-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"41026","name":"Fenvalerate: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2004-03-01T01:00:00Z","last_updated_date":"2004-03-01T01:00:00Z","reference_number":"EMEA/MRL/899/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fenvalerate-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"41039","name":"Dimetridazole: Summary report (1) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-05-05T02:00:00Z","last_updated_date":"1996-05-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/dimetridazole-summary-report-1-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"41062","name":"Caryophylli aetheroleum: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-05-01T02:00:00Z","last_updated_date":"1998-05-01T02:00:00Z","reference_number":"EMEA/MRL/406/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/caryophylli-aetheroleum-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"41073","name":"Copper carbonate: European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2016-05-26T19:45:00Z","last_updated_date":"2016-05-26T19:45:00Z","reference_number":"EMA/CVMP/758734/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/copper-carbonate-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"41074","name":"Oxyclozanide: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/MRL/817/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/oxyclozanide-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"41142","name":"Ronidazole: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ronidazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"41146","name":"Permethrin: Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-09-01T02:00:00Z","last_updated_date":"2002-09-01T02:00:00Z","reference_number":"EMEA/MRL/843/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/permethrin-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"41194","name":"Chrysanthemi cinerariifolii flos and pyrethrum extract: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1998-02-01T01:00:00Z","last_updated_date":"1998-02-01T01:00:00Z","reference_number":"EMEA/MRL/362/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/chrysanthemi-cinerariifolii-flos-and-pyrethrum-extract-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"41263","name":"Fertirelin acetate: Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"1996-01-01T01:00:00Z","last_updated_date":"1996-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/fertirelin-acetate-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"41298","name":"Nafcillin (Extension to all ruminants): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-11-01T01:00:00Z","last_updated_date":"2003-11-01T01:00:00Z","reference_number":"EMEA/MRL/887/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/nafcillin-extension-all-ruminants-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"41316","name":"Cefquinome (Extension to horses): Summary report (3) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2003-07-01T02:00:00Z","last_updated_date":"2003-07-01T02:00:00Z","reference_number":"EMEA/MRL/883/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/cefquinome-extension-horses-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"42351","name":"Isoflurane (porcine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2018-10-16T17:11:00Z","last_updated_date":"2018-10-16T17:11:00Z","reference_number":"EMA/CVMP/60621/2018","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/isoflurane-porcine-species-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"47666","name":"Bambermycin (rabbit): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2020-05-14T14:35:00Z","last_updated_date":"2020-05-14T14:35:00Z","reference_number":"EMA/CVMP/211307/2019","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bambermycin-rabbit-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"47678","name":"Ciclesonide (equidae): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2020-05-15T14:38:00Z","last_updated_date":"2020-05-15T14:38:00Z","reference_number":"EMA/CVMP/101968/2019","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ciclesonide-equidae-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"47835","name":"Bovine casein hydrolysate : Summary of assessment undertaken to determine whether the substance may be entered into the list of biological substances considered as not requiring an MRL evaluation","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T17:27:00Z","last_updated_date":"2020-05-29T17:27:00Z","reference_number":"EMA/2278/2020","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bovine-casein-hydrolysate-summary-assessment-undertaken-determine-whether-substance-may-be-entered-list-biological-substances-considered-not-requiring-mrl-evaluation_en.pdf"},
    {"id":"48200","name":"Ketoprofen (Bovine, Porcine and Equidae): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2020-07-02T14:00:00Z","last_updated_date":"2020-07-02T14:00:00Z","reference_number":"EMA/CVMP/94885/2020","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ketoprofen-bovine-porcine-and-equidae-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"48569","name":"Diflubenzuron (Salmonidae): European public MRL assessment report (EPMAR)","type":"mrl-report","status":"unknown","consultation_date":"","first_published_date":"2020-08-07T15:43:00Z","last_updated_date":"2020-08-07T15:43:00Z","reference_number":"EMA/CVMP/115336/2018 ","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/diflubenzuron-salmonidae-european-public-mrl-assessment-report-epmar_en.pdf"},
    {"id":"50013","name":"Recombinant bovine IL-8: Summary of assessment undertaken to determine whether the substance may be entered into the list of biological substances considered as not requiring an MRL evaluation","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T11:16:00Z","last_updated_date":"2021-02-01T11:16:00Z","reference_number":"EMA/CVMP/608257/2020","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/recombinant-bovine-il-8-summary-assessment-undertaken-determine-whether-substance-may-be-entered-list-biological-substances-considered-not-requiring-mrl-evaluation_en.pdf"},
    {"id":"50319","name":"Bupivacaine (bovine species): European Public MRL Assessment Report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2021-03-01T12:24:00Z","last_updated_date":"2021-03-01T12:24:00Z","reference_number":"EMA/CVMP/96709/2021","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bupivacaine-bovine-species-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"50330","name":"Lidocaine (bovine): European Public MRL Assessment Report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2021-03-01T16:06:00Z","last_updated_date":"2024-09-16T16:53:00Z","reference_number":"EMA/CVMP/94655/2021 Corr.","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lidocaine-bovine-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"50665","name":"Lidocaine (porcine species): European Public MRL Assessment Report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2021-03-22T12:02:00Z","last_updated_date":"2024-09-16T16:51:00Z","reference_number":"EMA/CVMP/393160/2020 Corr.","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/lidocaine-porcine-species-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"50902","name":"Imidacloprid (fin fish): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2021-04-19T12:42:00Z","last_updated_date":"2021-04-19T12:42:00Z","reference_number":"EMA/CVMP/223046/2021","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/imidacloprid-fin-fish-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"50993","name":"Bupivacaine (porcine species): Summary report - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2021-04-28T10:41:00Z","last_updated_date":"2021-04-28T10:41:00Z","reference_number":"EMA/CVMP/89867/2020","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bupivacaine-porcine-species-summary-report-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"51252","name":"Paromomycin (tissues and eggs of all food producing species): European public MRL assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2021-05-25T11:56:00Z","last_updated_date":"2021-05-25T11:56:00Z","reference_number":"EMA/CVMP/56180/2018","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/paromomycin-tissues-and-eggs-all-food-producing-species-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"55326","name":"Bambermycin (poultry): European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2022-06-23T11:52:00Z","last_updated_date":"2022-06-23T11:52:00Z","reference_number":"EMA/CVMP/123880/2021","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/bambermycin-poultry-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"60892","name":"Praziquantel (fin fish): European public MRL assessment report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2023-11-07T12:51:00Z","last_updated_date":"2023-11-07T12:51:00Z","reference_number":"EMA/CVMP/483968/2023","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/praziquantel-fin-fish-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"61062","name":"Varroa destructor calmodulin gene-specific double-stranded interfering RNA EP15: Summary of assessment undertaken to determine whether substance may be entered into the of chemical-unlike biological substances considered as not requiring an MRL assessment","type":"mrl-report","status":"unknown","consultation_date":"","first_published_date":"2023-11-23T11:12:06Z","last_updated_date":"2023-11-23T11:12:06Z","reference_number":"EMA/CVMP/449785/2023","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/varroa-destructor-calmodulin-gene-specific-double-stranded-interfering-rna-ep15-summary-assessment-undertaken-determine-whether-substance-may-be-entered-chemical-unlike-biological-substances_en.pdf"},
    {"id":"63116","name":"Ketoprofen : call for scientific data for use in CVMP assessment work of ketoprofen: review of the CVMP opinion for the establishment of maximum residue limits","type":"mrl-report","status":"Draft: consultation closed","consultation_date":"2024-04-30 - 2024-08-31","first_published_date":"2024-04-30T16:24:59Z","last_updated_date":"2024-04-30T16:24:59Z","reference_number":"EMA/CVMP/151185/2024","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ketoprofen-call-scientific-data-use-cvmp-assessment-work-ketoprofen-review-cvmp-opinion-establishment-maximum-residue-limits_en.pdf"},
    {"id":"63343","name":"Sodium salicylate (poultry other than turkey): European Public MRL Assessment Report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2024-05-28T14:53:21Z","last_updated_date":"2024-05-28T14:53:21Z","reference_number":"EMA/CVMP/189263/2024","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/sodium-salicylate-poultry-other-turkey-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"65855","name":"Ketoprofen (poultry): European Public MRL Assessment Report (EPMAR) - CVMP","type":"mrl-report","status":"unknown","consultation_date":"","first_published_date":"2024-11-28T10:33:52Z","last_updated_date":"2024-11-28T10:33:52Z","reference_number":"EMA/CVMP/505842/2023","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ketoprofen-poultry-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"65856","name":"Toltrazuril (poultry eggs): European Public MRL Assessment Report (EPMAR) - CVMP","type":"mrl-report","status":"unknown","consultation_date":"","first_published_date":"2024-11-28T10:35:29Z","last_updated_date":"2024-11-28T10:35:29Z","reference_number":"EMA/CVMP/511158/2023","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/toltrazuril-poultry-eggs-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"66251","name":"Rafoxanide (bovine and ovine milk): European Public MRL Assessment Report (EPMAR) - CVMP","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2025-01-07T11:01:18Z","last_updated_date":"2025-01-07T11:01:18Z","reference_number":"EMA/CVMP/81060/2023","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/rafoxanide-bovine-ovine-milk-european-public-mrl-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"69680","name":"Ketoprofen: European public maximum-residue-limit assessment report (EPMAR) - CVMP","type":"mrl-report","status":"unknown","consultation_date":"","first_published_date":"2025-08-06T16:15:22Z","last_updated_date":"2025-08-06T16:15:22Z","reference_number":"EMA/CVMP/490617/2024","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/ketoprofen-european-public-maximum-residue-limit-assessment-report-epmar-cvmp_en.pdf"},
    {"id":"70066","name":"Colistin: Summary report (2) - Committee for Veterinary Medicinal Products","type":"mrl-report","status":"Adopted","consultation_date":"","first_published_date":"2002-01-01T14:49:19Z","last_updated_date":"2002-01-01T14:49:19Z","reference_number":"EMEA/MRL/815/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/mrl-report/colistin-summary-report-2-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"5602","name":"Amoxicillin (extension to eggs) - Summary opinion of the committee for medicinal products for veterinary use on the establishment of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2006-09-15T02:00:00Z","last_updated_date":"2006-09-15T02:00:00Z","reference_number":"EMEA/CVMP/330177/2006","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/amoxicillin-extension-eggs-summary-opinion-committee-medicinal-products-veterinary-use-establishment-maximum-residue-limits_en.pdf"},
    {"id":"11165","name":"Ovotransferrin - Summary opinion of the CVMP on the establishment of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2018-07-20T16:30:00Z","last_updated_date":"2018-07-20T16:30:00Z","reference_number":"EMA/CVMP/452246/2018","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/ovotransferrin-summary-opinion-cvmp-establishment-maximum-residue-limits_en.pdf"},
    {"id":"26610","name":"Josamycin - Summary opinion of the Committee for Medicinal Products for Veterinary use on the establishment of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2002-03-15T01:00:00Z","last_updated_date":"2002-03-15T01:00:00Z","reference_number":"EMEA/CVMP/238/02","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/josamycin-summary-opinion-committee-medicinal-products-veterinary-use-establishment-maximum-residue-limits_en.pdf"},
    {"id":"30878","name":"Oxytetracycline (Extension to honey bees) - Summary opinion of the Committee for Medicinal Products for Veterinary use on the establishment of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2008-11-14T01:00:00Z","last_updated_date":"2008-11-14T01:00:00Z","reference_number":"EMEA/CVMP/581586/2008","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/oxytetracycline-extension-honey-bees-summary-opinion-committee-medicinal-products-veterinary-use-establishment-maximum-residue-limits_en.pdf"},
    {"id":"31863","name":"Diflubenzuron - Summary opinion of the CVMP on the establishment of maximum residue limits (2018)","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2018-03-16T16:30:00Z","last_updated_date":"2018-03-16T16:30:00Z","reference_number":"EMA/CVMP/153976/2018","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/diflubenzuron-summary-opinion-cvmp-establishment-maximum-residue-limits-2018_en.pdf"},
    {"id":"35117","name":"Diflubenzuron - Summary opinion of the CVMP on the establishment of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2015-05-08T18:00:00Z","last_updated_date":"2015-05-08T18:00:00Z","reference_number":"EMA/CVMP/259781/2015","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/diflubenzuron-summary-opinion-cvmp-establishment-maximum-residue-limits_en.pdf"},
    {"id":"45662","name":"Dicyclanil - Summary opinion of the CVMP on the establishment of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2019-10-11T15:00:00Z","last_updated_date":"2019-10-11T15:00:00Z","reference_number":"EMA/CVMP/516225/2019","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/dicyclanil-summary-opinion-cvmp-establishment-maximum-residue-limits_en.pdf"},
    {"id":"48057","name":"Bupivacaine - Summary opinion of the CVMP on the establishment of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2020-06-19T13:54:00Z","last_updated_date":"2020-06-19T13:54:00Z","reference_number":"EMA/CVMP/278195/2020","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/bupivacaine-summary-opinion-cvmp-establishment-maximum-residue-limits_en.pdf"},
    {"id":"50653","name":"Bambermycin (poultry) - Summary opinion of the CVMP on the establishment of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2021-03-19T12:00:00Z","last_updated_date":"2021-07-16T15:03:00Z","reference_number":"EMA/CVMP/378788/2021","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/bambermycin-poultry-summary-opinion-cvmp-establishment-maximum-residue-limits_en.pdf"},
    {"id":"56051","name":"Praziquantel (all ruminants except bovine, Equidae, fin fish) - Summary opinion of the CVMP on the establishment of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2022-09-09T16:00:00Z","last_updated_date":"2022-09-09T16:00:00Z","reference_number":"EMA/CVMP/706481/2022","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/praziquantel-all-ruminants-except-bovine-equidae-fin-fish-summary-opinion-cvmp-establishment-maximum-residue-limits_en.pdf"},
    {"id":"60290","name":"Opinion of the CVMP on the establishment of maximum residue limits: Sodium salicylate","type":"mrl-summary","status":"unknown","consultation_date":"","first_published_date":"2023-10-06T14:42:00Z","last_updated_date":"2023-10-06T14:42:00Z","reference_number":"EMA/CVMP/406220/2023","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/opinion-cvmp-establishment-maximum-residue-limits-sodium-salicylate_en.pdf"},
    {"id":"65579","name":"Ketoprofen (all ruminants, porcine and Equidae) - Summary opinion of the CVMP on the extension of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2024-11-08T13:30:27Z","last_updated_date":"2024-11-12T13:23:00Z","reference_number":"EMA/CVMP/495258/2024","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/ketoprofen-all-ruminants-porcine-equidae-summary-opinion-cvmp-extension-maximum-residue-limits_en.pdf"},
    {"id":"66784","name":"Fluralaner (Salmonidae and other fin fish)  - Summary opinion of the CVMP on the extension of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2025-02-14T15:00:00Z","last_updated_date":"2025-02-14T15:00:00Z","reference_number":"EMA/29093/2025","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/fluralaner-salmonidae-other-fin-fish-summary-opinion-cvmp-extension-maximum-residue-limits_en.pdf"},
    {"id":"68332","name":"Lidocaine (Porcine) - Summary opinion of the CVMP on the modification of maximum residue limits","type":"mrl-summary","status":"Adopted","consultation_date":"","first_published_date":"2025-05-16T15:02:04Z","last_updated_date":"2025-12-05T14:21:49Z","reference_number":"EMA/CVMP/380363/2025","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/lidocaine-porcine-summary-opinion-cvmp-modification-maximum-residue-limits_en.pdf"},
    {"id":"74265","name":"Recombinant equine Chorionic Gonadotropin (reCG): Summary of assessment","type":"mrl-summary","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T10:57:24Z","last_updated_date":"2026-06-25T10:57:24Z","reference_number":"EMA/CVMP/5612/2026","document_url":"https://www.ema.europa.eu/en/documents/mrl-summary/recombinant-equine-chorionic-gonadotropin-recg-summary-assessment_en.pdf"},
    {"id":"2502","name":"Questions and answers on the safety of Acomplia (Rimonabant)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/330598/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-safety-acomplia-rimonabant_en.pdf"},
    {"id":"2572","name":"Explanatory note on scientific considerations regarding the licensing of pandemic A(H1N1)v vaccines","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/608259/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/explanatory-note-scientific-considerations-regarding-licensing-pandemic-ah1n1v-vaccines_en.pdf"},
    {"id":"2645","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Zometa (zoledronic acid)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/831243/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa-zoledronic-acid_sv.pdf"}},
    {"id":"2810","name":"Questions and answers on the withdrawal of the marketing authorisation application for Restaysis (ciclosporin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/275525/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-restaysis-ciclosporin_sv.pdf"}},
    {"id":"2828","name":"Questions and answers on the withdrawal of the marketing application for Voraxaze","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-06-02T02:00:00Z","last_updated_date":"2008-06-02T02:00:00Z","reference_number":"EMEA/287136/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-voraxaze_sv.pdf"}},
    {"id":"2921","name":"Questions and answers on the supply shortage of Simponi pre-filled pens","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-02-18T13:27:23Z","last_updated_date":"2011-02-18T13:27:23Z","reference_number":"EMA/126688/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-supply-shortage-simponi-pre-filled-pens_en.pdf"},
    {"id":"3132","name":"Questions and answers on the withdrawal of the marketing authorisation application for Aripiprazole Mylan (aripiprazole)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"EMA/55039/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_sv.pdf"}},
    {"id":"3229","name":"Questions and answers on the withdrawal of the marketing authorisation application for Bosatria (mepolizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-08-20T02:00:00Z","last_updated_date":"2009-08-20T02:00:00Z","reference_number":"EMEA/505188/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-bosatria-mepolizumab_sv.pdf"}},
    {"id":"3424","name":"Questions and answers on withdrawal of the marketing authorisation application for Hyalograft C autograft (characterised viable autologous chondrocytes expanded in vitro, seeded and cultured on a hyaluronan-based scaffol...","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-02-26T01:00:00Z","last_updated_date":"2013-05-14T02:00:00Z","reference_number":"EMA/52320/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-hyalograft-c-autograft-characterised-viable-autologous-chondrocytes-expanded-vitro-seeded-and-cultured-hyaluronan-based-scaffol_sv.pdf"}},
    {"id":"3548","name":"Questions and answers on the withdrawal of the marketing authorisation application for Docetaxel Mylan (docetaxel)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/166011/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-mylan-docetaxel_sv.pdf"}},
    {"id":"3745","name":"Questions and answers on the withdrawal of the marketing authorisation application for Luveniq","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-10-24T02:00:00Z","last_updated_date":"2011-10-24T02:00:00Z","reference_number":"EMA/CHMP/835463/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-luveniq_sv.pdf"}},
    {"id":"4018","name":"Questions and answers on the withdrawal of the marketing authorisation application for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T01:00:00Z","last_updated_date":"2008-01-24T01:00:00Z","reference_number":"EMEA/4193/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_sv.pdf"}},
    {"id":"4030","name":"Questions and answers on the EMEA's action regarding the safety of Champix","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T01:00:00Z","last_updated_date":"2007-12-14T01:00:00Z","reference_number":"EMEA/595658/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-emeas-action-regarding-safety-champix_en.pdf"},
    {"id":"4167","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Imagify","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-08-28T02:00:00Z","last_updated_date":"2014-08-28T02:00:00Z","reference_number":"EMA/483508/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-imagify_en.pdf"},
    {"id":"4198","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Tyverb (lapatinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-03-16T01:00:00Z","last_updated_date":"2012-03-16T01:00:00Z","reference_number":"EMA/169461/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tyverb-lapatinib_sv.pdf"}},
    {"id":"4210","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Loulla","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-02-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-loulla_sv.pdf"}},
    {"id":"4309","name":"Questions and answers on the recommendation to suspend the marketing authorisation for Raptiva","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T00:09:21Z","last_updated_date":"2009-02-19T00:09:21Z","reference_number":"EMEA/CHMP/15525/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-suspend-marketing-authorisation-raptiva_en.pdf"},
    {"id":"4345","name":"Further questions and answers on the follow-up to the Viracept recall","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-07-26T02:00:00Z","last_updated_date":"2007-07-26T02:00:00Z","reference_number":"EMEA/337440/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/further-questions-and-answers-follow-viracept-recall_en.pdf"},
    {"id":"4476","name":"Questions and answers on the withdrawal of the marketing application for\n\nTheraloc","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"EMEA/651597/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-theraloc_sv.pdf"}},
    {"id":"4478","name":"Questions and answers on Neupro (rotigotine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-06-18T02:00:00Z","last_updated_date":"2008-06-18T02:00:00Z","reference_number":"EMEA/265069/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-neupro-rotigotine_en.pdf"},
    {"id":"4702","name":"Questions and answers on the Committee for Medicinal Products for Human Use recommendation on nimesulide-containing medicines","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-09-21T02:09:21Z","last_updated_date":"2007-09-21T02:09:21Z","reference_number":"EMEA/430988/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-committee-medicinal-products-human-use-recommendation-nimesulide-containing-medicines_en.pdf"},
    {"id":"4796","name":"Questions and Answers on the review of non-selective NSAIDs","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2006-09-26T02:09:21Z","last_updated_date":"2006-09-26T02:09:21Z","reference_number":"EMEA/376641/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-non-selective-nsaids_en.pdf"},
    {"id":"4970","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Alpheon","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-06-28T02:09:21Z","last_updated_date":"2006-06-28T02:09:21Z","reference_number":"EMEA/190896/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_en.pdf"},
    {"id":"5059","name":"Questions and answers on abacavir and the risk of heart attack","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-04-02T02:00:00Z","last_updated_date":"2008-04-02T02:00:00Z","reference_number":"EMEA/142884/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-abacavir-and-risk-heart-attack_en.pdf"},
    {"id":"5133","name":"Questions and answers on the withdrawal of the marketing authorisation application for Biferonex (interferon beta-1a)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:00:00Z","last_updated_date":"2009-07-02T02:00:00Z","reference_number":"EMEA/372952/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-biferonex-interferon-beta-1a_sv.pdf"}},
    {"id":"5149","name":"Questions and answers on the withdrawal of the marketing authorisation application for Pioglitazone ratiopharm GmbH","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T13:21:00Z","last_updated_date":"2012-04-30T13:21:00Z","reference_number":"EMA/281360/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm-gmbh_sv.pdf"}},
    {"id":"5240","name":"Questions and answers on the withdrawal of the marketing authorisation application for Ozespa","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-01-31T01:00:00Z","last_updated_date":"2011-01-31T01:00:00Z","reference_number":"EMA/40202/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ozespa_sv.pdf"}},
    {"id":"5258","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for NovoNorm/Prandin","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-10-18T02:00:00Z","last_updated_date":"2006-10-18T02:00:00Z","reference_number":"EMEA/405238/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novonormprandin_sv.pdf"}},
    {"id":"5324","name":"Questions and answers on the Withdrawal of the application for a change to the marketing authorisation for Firazyr (icatibant)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/95900/2014 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-firazyr-icatibant_en.pdf"},
    {"id":"5407","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Ceprotin (human protein C)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2014-11-21T13:00:00Z","reference_number":"EMA/706787/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ceprotin-human-protein-c_sv.pdf"}},
    {"id":"5429","name":"Questions and answers on the review of Tygacil (tigecycline)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-02-18T01:00:00Z","last_updated_date":"2011-02-18T01:00:00Z","reference_number":"EMA/121925/2011 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-tygacil-tigecycline_en.pdf"},
    {"id":"5471","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Zavesca","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-03-19T01:00:00Z","last_updated_date":"2008-03-19T01:00:00Z","reference_number":"EMEA/121008/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zavesca_sv.pdf"}},
    {"id":"5566","name":"Questions and answers on withdrawal of the marketing authorisation applications for Issarlos (strontium ranelate / cholecalciferol)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/249569/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-applications-issarlos-strontium-ranelate-cholecalciferol_en.pdf"},
    {"id":"5605","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Tasigna (nilotinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/362590/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tasigna-nilotinib_en.pdf"},
    {"id":"5651","name":"Questions and answers on the withdrawal of the application for  the marketing authorisation for Qinprezo (vosaroxin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T12:43:00Z","last_updated_date":"2017-05-19T12:43:00Z","reference_number":"EMA/249992/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-qinprezo-vosaroxin_sv.pdf"}},
    {"id":"5716","name":"Questions and answers on recommendation for the refusal of the marketing authorisation  for  Rhucin : Common name: recombinant human C1 inhibitor","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-03-19T00:09:21Z","last_updated_date":"2008-03-19T00:09:21Z","reference_number":"EMEA/CHMP/143105/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-rhucin-common-name-recombinant-human-c1-inhibitor_en.pdf"}    {"id":"5816","name":"Questions and answers on the withdrawal of the marketing authorisation application for OraNera","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-03-22T01:00:00Z","last_updated_date":"2013-03-22T01:00:00Z","reference_number":"EMA/179232/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oranera_en.pdf"},
    {"id":"6416","name":"Questions and answers on the review of Protelos and Osseor (strontium ranelate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-03-16T11:00:00Z","last_updated_date":"2012-03-16T11:00:00Z","reference_number":"EMA/183047/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-protelos-and-osseor-strontium-ranelate_en.pdf"},
    {"id":"6520","name":"Questions and answers on the withdrawal of the marketing authorisation application for Enpaxiq (pacritinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/192276/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-enpaxiq-pacritinib_sv.pdf"}},
    {"id":"6543","name":"Questions and Answers on the suspension of Hexavac","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2005-09-20T02:00:00Z","last_updated_date":"2005-09-20T02:00:00Z","reference_number":"EMEA/304888/2005","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-suspension-hexavac_en.pdf"},
    {"id":"6551","name":"Questions and answers on the withdrawal of the marketing authorisation application for Pemetrexed ditromethamine Hospira","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2016-10-14T14:00:00Z","reference_number":"EMA/659373/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_sv.pdf"}},
    {"id":"6618","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Protelos (strontium ranelate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/232003/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-protelos-strontium-ranelate_sv.pdf"}},
    {"id":"6943","name":"Questions and answers on the withdrawal of the marketing authorisation application for Oncophage (vitespen)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-12-21T00:09:21Z","last_updated_date":"2009-12-21T00:09:21Z","reference_number":"EMA/830607/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-oncophage-vitespen_sv.pdf"}},
    {"id":"6973","name":"Questions and answers on the addition of a contraindication for Velcade (bortezomib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-03-20T01:00:00Z","last_updated_date":"2008-03-20T01:00:00Z","reference_number":"EMEA/CHMP/138387/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-addition-contraindication-velcade-bortezomib_en.pdf"},
    {"id":"7003","name":"Questions and answers on the withdrawal of the marketing application for Lenalidomide Celgene Europe","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/294089/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lenalidomide-celgene-europe_sv.pdf"}},
    {"id":"7023","name":"Questions and answers on the withdrawal of the marketing authorisation application for Zemfirza (cediranib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2016-10-14T14:00:00Z","reference_number":"EMA/656265/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zemfirza-cediranib_sv.pdf"}},
    {"id":"7171","name":"Withdrawal of the marketing authorisation application for Winfuran (nalfurafine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-01-24T01:00:00Z","reference_number":"EMA/33514/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/withdrawal-marketing-authorisation-application-winfuran-nalfurafine_sv.pdf"}},
    {"id":"7317","name":"Questions and answers on the withdrawal of the marketing authorisation application for Omontys","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/384566/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-omontys_en.pdf"},
    {"id":"7391","name":"Questions and answers on the withdrawal of the marketing authorisation application for Emerflu [pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)]","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/792246/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_sv.pdf"}},
    {"id":"7747","name":"Questions and answers on the withdrawal of the marketing authorisation application for Contusugene Ladenovec Gendux (contusugene ladenovec)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/448660/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-contusugene-ladenovec-gendux-contusugene-ladenovec_sv.pdf"}},
    {"id":"7994","name":"Questions and answers on the cessation of supply of Regranex (becaplermin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/CHMP/386043/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-cessation-supply-regranex-becaplermin_en.pdf"},
    {"id":"8139","name":"Questions and answers on the marketing authorisation  for  vectibix : International non-proprietary name (INN): panitumumab","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-09-20T02:09:21Z","last_updated_date":"2007-09-20T02:09:21Z","reference_number":"EMEA/405113/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-marketing-authorisation-vectibix-international-non-proprietary-name-inn-panitumumab_en.pdf"},
    {"id":"8147","name":"Questions and answers on the withdrawal of the marketing application for orBec","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-06-05T02:00:00Z","last_updated_date":"2008-06-05T02:00:00Z","reference_number":"EMEA/266786/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orbec_sv.pdf"}},
    {"id":"8207","name":"Questions and answers on recommendation for the refusal of the marketing authorisation  for  sovrima  International non-proprietary name (INN): idebenone","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:09:21Z","last_updated_date":"2008-07-24T02:09:21Z","reference_number":"EMEA/359839/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-sovrima-international-non-proprietary-name-inn-idebenone_en.pdf"},
    {"id":"8541","name":"Questions and answers on the withdrawal of the marketing authorisation application for Ibandronic Acid Hexal","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-08-22T02:00:00Z","last_updated_date":"2011-08-22T02:00:00Z","reference_number":"EMA/685524/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ibandronic-acid-hexal_sv.pdf"}},
    {"id":"8612","name":"Questions and answers on the withdrawal of the marketing authorisation application for Cokiera (dasabuvir / ombitasvir / paritaprevir / ritonavir)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/541043/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cokiera-dasabuvir-ombitasvir-paritaprevir-ritonavir_sv.pdf"}},
    {"id":"8705","name":"Questions and answers on the withdrawal of the marketing application for Vitragan","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-05-24T02:00:00Z","last_updated_date":"2007-05-24T02:00:00Z","reference_number":"EMEA/195786/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vitragan_sv.pdf"}},
    {"id":"8853","name":"Questions and answers on withdrawal of marketing application for Ximelagatran Astrazeneca 36 mg film coated tablets","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-02-23T01:00:00Z","last_updated_date":"2006-02-23T01:00:00Z","reference_number":"EMEA/60465/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ximelagatran-astrazeneca-36-mg-film-coated-tablets_en.pdf"},
    {"id":"8862","name":"Questions and answers on the withdrawal of the marketing authorisation application for Raxone","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T02:00:00Z","last_updated_date":"2013-04-26T02:00:00Z","reference_number":"EMA/242206/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raxone_sv.pdf"}},
    {"id":"9082","name":"Questions and answers on vaccines for the pandemic (H1N1) 2009 ('swine flu')","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/601321/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-vaccines-pandemic-h1n1-2009-swine-flu_en.pdf"},
    {"id":"9161","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Invega","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/2672/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-invega_sv.pdf"}},
    {"id":"9212","name":"Questions and answers on positive opinion on the marketing authorisation for Fampyra (fampridine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/395076/2011 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-marketing-authorisation-fampyra-fampridine_en.pdf"},
    {"id":"9379","name":"Questions and answers on withdrawal of marketing application for Retaane","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-03-23T01:00:00Z","last_updated_date":"2006-03-23T01:00:00Z","reference_number":"EMEA/98712/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retaane_sv.pdf"}},
    {"id":"9492","name":"Questions and answers on the withdrawal of the marketing application for  Multaq","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/389502/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-multaq_sv.pdf"}},
    {"id":"9733","name":"Questions and answers on the review of Ixiaro (Japanese encephalitis vaccine)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T14:00:00Z","last_updated_date":"2012-03-16T14:00:00Z","reference_number":"EMA/173541/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-ixiaro-japanese-encephalitis-vaccine_en.pdf"},
    {"id":"9792","name":"Questions and answers on the withdrawal of the marketing application for Aquilda","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-06-09T02:00:00Z","last_updated_date":"2008-06-09T02:00:00Z","reference_number":"EMEA/277960/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aquilda_en.pdf"},
    {"id":"9799","name":"Questions and answers on the review of pioglitazone-containing medicines (Actos, Glustin, Competact, Glubrava and Tandemact)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-07-21T02:00:00Z","last_updated_date":"2011-07-21T02:00:00Z","reference_number":"EMA/CHMP/562496/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-pioglitazone-containing-medicines-actos-glustin-competact-glubrava-and-tandemact_en.pdf"},
    {"id":"9846","name":"Questions and answers on vaccines for the H1N1 ('swine flu') pandemic","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-07-24T02:09:21Z","last_updated_date":"2009-07-24T02:09:21Z","reference_number":"EMEA/461476/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-vaccines-h1n1-swine-flu-pandemic_en.pdf"},
    {"id":"9952","name":"Questions and answers on HBVAXPRO and Procomvax","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-05-04T02:00:00Z","last_updated_date":"2006-05-04T02:00:00Z","reference_number":"EMEA/CHMP/153090/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-hbvaxpro-and-procomvax_en.pdf"},
    {"id":"10156","name":"Questions and answers on the safety of Protelos/Osseor (strontium ranelate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-11-16T00:09:21Z","last_updated_date":"2007-11-16T00:09:21Z","reference_number":"EMEA/534613/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-safety-protelososseor-strontium-ranelate_en.pdf"},
    {"id":"10475","name":"Questions and answers on recommendation for the refusal of the marketing authorisation  for  opgenra: International non-proprietary name (INN): eptotermin alfa","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:09:21Z","last_updated_date":"2008-06-26T02:09:21Z","reference_number":"EMEA/308379/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-opgenra-international-non-proprietary-name-inn-eptotermin-alfa_en.pdf"},
    {"id":"10594","name":"Questions and answers on the review of centrally authorised medicines with ingredients manufactured at Roche Carolina Inc., Florence, United States","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T17:00:00Z","last_updated_date":"2012-07-20T17:00:00Z","reference_number":"EMA/476366/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-centrally-authorised-medicines-ingredients-manufactured-roche-carolina-inc-florence-united-states_en.pdf"},
    {"id":"10657","name":"Inovelon: Questions and answers on the outcome of an extension of indication application for Inovelon (rufinamide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-02-08T10:53:00Z","last_updated_date":"2017-02-08T10:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_en.pdf"},
    {"id":"10659","name":"Questions and answers on the withdrawal of the marketing authorisation application for Repaglinide Sun (repaglinide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-04-28T02:00:00Z","last_updated_date":"2010-04-28T02:00:00Z","reference_number":"EMA/211132/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-repaglinide-sun-repaglinide_sv.pdf"}},
    {"id":"10889","name":"Questions and answers on the withdrawal of the marketing application for Advexin","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-02-11T01:00:00Z","last_updated_date":"2009-02-11T01:00:00Z","reference_number":"EMEA/690893/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-advexin_sv.pdf"}},
    {"id":"10972","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Opdivo (nivolumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T01:00:00Z","last_updated_date":"2018-01-26T01:00:00Z","reference_number":"EMA/51006/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opdivo-nivolumab_en.pdf"},
    {"id":"10993","name":"Recommendations on the use of Caelyx (doxorubicin hydrochloride)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-11-22T16:59:00Z","last_updated_date":"2011-11-22T16:59:00Z","reference_number":"EMA/914175/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/recommendations-use-caelyx-doxorubicin-hydrochloride_en.pdf"},
    {"id":"11010","name":"Questions and answers on the outcome of extension of indication application for Exjade","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/254004/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-outcome-extension-indication-application-exjade_en.pdf"},
    {"id":"11197","name":"Questions and answers on the review of Multaq (dronedarone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-09-22T02:00:00Z","last_updated_date":"2011-09-22T02:00:00Z","reference_number":"EMA/CHMP/706259/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-multaq-dronedarone_en.pdf"},
    {"id":"11342","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Tygacil","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/245771/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tygacil_sv.pdf"}},
    {"id":"11361","name":"Questions and answers on the ongoing review of Gilenya (fingolimod)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-01-20T10:57:33Z","last_updated_date":"2012-01-20T10:57:33Z","reference_number":"EMA/43541/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-ongoing-review-gilenya-fingolimod_en.pdf"},
    {"id":"11392","name":"Questions and answers on the shortages of Cerezyme and Fabrazyme","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:09:21Z","last_updated_date":"2009-06-25T02:09:21Z","reference_number":"EMEA/388773/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-shortages-cerezyme-and-fabrazyme_en.pdf"},
    {"id":"11638","name":"Questions and answers on 'mock-up' pandemic flu vaccines","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T01:00:00Z","last_updated_date":"2006-12-15T01:00:00Z","reference_number":"EMEA/501557/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-mock-pandemic-flu-vaccines_en.pdf"},
    {"id":"11845","name":"Questions and answers on drug interactions between Victrelis (boceprevir) and ritonavir-boosted HIV protease inhibitors","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T17:07:13Z","last_updated_date":"2012-02-16T17:07:13Z","reference_number":"EMA/CHMP/117973/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-drug-interactions-between-victrelis-boceprevir-and-ritonavir-boosted-hiv-protease-inhibitors_en.pdf"},
    {"id":"11932","name":"Questions and answers on the withdrawal of the marketing authorisation application for Ramvocid (oritavancin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/554626/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ramvocid-oritavancin_sv.pdf"}},
    {"id":"12115","name":"Questions and answers on withdrawal of the marketing authorisation application for Zenhale","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zenhale_sv.pdf"}},
    {"id":"12121","name":"Shortage of Caelyx (doxorubicin hydrochloride)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-09-09T15:19:00Z","last_updated_date":"2011-09-09T15:19:00Z","reference_number":"EMA/718827/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/shortage-caelyx-doxorubicin-hydrochloride_en.pdf"},
    {"id":"12262","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Abilify (aripiprazole)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-01-05T01:00:00Z","last_updated_date":"2010-01-05T01:00:00Z","reference_number":"EMA/809491/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-abilify-aripiprazole_sv.pdf"}},
    {"id":"12577","name":"Questions and answers on the withdrawal of the marketing authorisation application for Zunrisa (casopitant)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/652773/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zunrisa-casopitant_sv.pdf"}},
    {"id":"12592","name":"Questions and answers on the withdrawal of the marketing application for Lacosamide Pain UCB Pharma","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-11-04T01:00:00Z","last_updated_date":"2008-11-04T01:00:00Z","reference_number":"EMEA/522632/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-lacosamide-pain-ucb-pharma_sv.pdf"}},
    {"id":"12643","name":"Questions and answers on the review of Revlimid (lenalidomide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/766672/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-revlimid-lenalidomide_en.pdf"},
    {"id":"12769","name":"Questions and answers on the shortages of Cerezyme and Fabrazyme - Update","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-08-14T02:00:00Z","last_updated_date":"2009-08-14T02:00:00Z","reference_number":"EMEA/510766/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-shortages-cerezyme-and-fabrazyme-update_en.pdf"},
    {"id":"12899","name":"Questions and answers on the withdrawal of the marketing authorisation application for Fluad Paediatric (influenza vaccine, surface antigen, inactivated, adjuvanted)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-02-21T11:30:00Z","last_updated_date":"2012-04-24T12:30:00Z","reference_number":"EMA/CHMP/114709/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fluad-paediatric-influenza-vaccine-surface-antigen-inactivated-adjuvanted_sv.pdf"}},
    {"id":"12903","name":"Questions and answers on the regulation of advanced therapy medicinal products","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-01-16T00:09:21Z","last_updated_date":"2009-01-16T00:09:21Z","reference_number":"EMEA/14327/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-regulation-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"12913","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Tysabri (natalizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/322273/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tysabri-natalizumab_en.pdf"},
    {"id":"12960","name":"Questions and answers on the withdrawal of the marketing authorisation\n\nfor Ixempra","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-05-20T02:00:00Z","last_updated_date":"2009-05-20T02:00:00Z","reference_number":"EMEA/196121/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ixempra_sv.pdf"}},
    {"id":"13005","name":"Questions and answers on the risk of fever with Pandemrix in young children","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-12-04T00:09:21Z","last_updated_date":"2009-12-04T00:09:21Z","reference_number":"EMEA/780391/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-risk-fever-pandemrix-young-children_en.pdf"},
    {"id":"13226","name":"Questions and answers on withdrawal of marketing application for Surfaxin","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-06-29T02:00:00Z","last_updated_date":"2006-06-29T02:00:00Z","reference_number":"EMEA/CHMP/220307/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-surfaxin_sv.pdf"}},
    {"id":"13427","name":"Questions and answers on the withdrawal of the marketing authorisation application for Factive (gemifloxacin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2009-07-01T02:00:00Z","reference_number":"EMEA/409402/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_sv.pdf"}},
    {"id":"13558","name":"Questions and answers on the withdrawal of the marketing authorisation application for Mersarex (iclaprim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/727640/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mersarex-iclaprim_sv.pdf"}},
    {"id":"13778","name":"Questions and answers on the review aliskiren-containing medicines","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T12:00:00Z","last_updated_date":"2012-02-17T12:00:00Z","reference_number":"EMA/113677/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-aliskiren-containing-medicines_en.pdf"},
    {"id":"13891","name":"Questions and answers on the withdrawal of the marketing authorisation application for Egrifta (tesamorelin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-07-18T02:00:00Z","last_updated_date":"2012-07-18T02:00:00Z","reference_number":"EMA/CHMP/475021/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egrifta-tesamorelin_sv.pdf"}},
    {"id":"14118","name":"Questions and answers on the withdrawal of the marketing authorisation application for Zioxtenzo (pegfilgrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/47326/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zioxtenzo-pegfilgrastim_sv.pdf"}},
    {"id":"14355","name":"Final recommendations on 12 centrally authorised medicines manufactured at Ben Venue Laboratories","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T18:00:00Z","last_updated_date":"2012-02-22T13:40:00Z","reference_number":"EMA/106872/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/final-recommendations-12-centrally-authorised-medicines-manufactured-ben-venue-laboratories_en.pdf"},
    {"id":"14431","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Arzerra (ofatumumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"EMA/847130/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-arzerra-ofatumumab_sv.pdf"}},
    {"id":"14557","name":"Questions and answers on the review of MabThera (rituximab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-05-25T12:00:00Z","last_updated_date":"2012-05-25T12:00:00Z","reference_number":"EMA/CHMP/337123/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-mabthera-rituximab_en.pdf"},
    {"id":"14666","name":"Questions and answers on final recommendations on Caelyx and Ceplene manufactured at Ben Venue Laboratories","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-03-16T11:00:00Z","last_updated_date":"2012-03-16T11:00:00Z","reference_number":"EMA/178766/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-final-recommendations-caelyx-and-ceplene-manufactured-ben-venue-laboratories_en.pdf"},
    {"id":"14960","name":"Questions and answers on the positive opinion on the marketing authorisation for Ninlaro (ixazomib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/615008/2016 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-marketing-authorisation-ninlaro-ixazomib_en.pdf"},
    {"id":"14978","name":"Questions and answers on the supply situation of Caelyx","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/254938/2013 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-supply-situation-caelyx_en.pdf"},
    {"id":"15151","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for Natalizumab Elan Pharma 300 mg","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/310856/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-natalizumab-elan-pharma-300-mg_en.pdf"},
    {"id":"15378","name":"Questions and answers on the positive opinion on the marketing authorisation for Deltyba (delamanid): Outcome of re-examination","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T13:00:00Z","last_updated_date":"2013-11-22T13:00:00Z","reference_number":"EMA/713953/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-marketing-authorisation-deltyba-delamanid-outcome-re-examination_en.pdf"},
    {"id":"15465","name":"Questions and answers on the withdrawal of the marketing authorisation application for Comfyde","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-01-27T00:09:21Z","last_updated_date":"2010-01-27T00:09:21Z","reference_number":"EMA/32301/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-comfyde_sv.pdf"}},
    {"id":"15594","name":"Questions and answers on recommendation for the refusal of the marketing authorisation  for  Mycograb","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2007-03-23T00:09:21Z","last_updated_date":"2007-03-23T00:09:21Z","reference_number":"EMEA/129723/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-mycograb_en.pdf"},
    {"id":"15621","name":"Questions and answers on the withdrawal of the marketing authorisation for Ibuprofen/Diphenhydramine Hydrochloride Wyeth","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-01-28T01:00:00Z","last_updated_date":"2010-01-28T01:00:00Z","reference_number":"EMA/23377/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-ibuprofendiphenhydramine-hydrochloride-wyeth_sv.pdf"}},
    {"id":"15645","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Eviplera (emtricitabine / rilpivirine / tenofovir disoproxil)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/CHMP/447729/2013 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-eviplera-emtricitabine-rilpivirine-tenofovir-disoproxil_en.pdf"},
    {"id":"15726","name":"Questions and answers on the use of angiotensin ii receptor antagonists during pregnancy","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/218318/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-use-angiotensin-ii-receptor-antagonists-during-pregnancy_en.pdf"},
    {"id":"15762","name":"Questions and answers on the review of Gilenya - Outcome of a procedure under Article 20 of Regulation (EC) No 726/2004","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-04-20T12:00:00Z","last_updated_date":"2012-04-20T12:00:00Z","reference_number":"EMA/254587/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-gilenya-outcome-procedure-under-article-20-regulation-ec-no-7262004_en.pdf"},
    {"id":"15843","name":"Questions and answers on the withdrawal of the marketing authorisation application for Heplisav (hepatitis B (rDNA) vaccine, adjuvanted)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T13:00:00Z","last_updated_date":"2014-02-21T13:00:00Z","reference_number":"EMA/92957/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-heplisav-hepatitis-b-rdna-vaccine-adjuvanted_sv.pdf"}},
    {"id":"15874","name":"Questions and answers on recommendation for the refusal of the marketing authorisation  for  Cimzia","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-11-15T00:09:21Z","last_updated_date":"2007-11-15T00:09:21Z","reference_number":"EMEA/518720/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-cimzia_en.pdf"},
    {"id":"15878","name":"Questions and answers on the withdrawal of the marketing authorisation application for Clopidogrel Teva Pharma (clopidogrel)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-06-24T02:00:00Z","last_updated_date":"2009-06-24T02:00:00Z","reference_number":"EMEA/254399/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel_sv.pdf"}},
    {"id":"16043","name":"Question and answers on the CVMP guideline on testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestations in dogs and cats (EMEA/CVMP/005/00-Rev 2)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-03-16T01:00:00Z","last_updated_date":"2012-07-25T12:00:00Z","reference_number":"EMEA/CVMP/EWP/82829/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/question-and-answers-cvmp-guideline-testing-and-evaluation-efficacy-antiparasitic-substances-treatment-and-prevention-tick-and-flea-infestations-dogs-and-cats-emeacvmp00500-rev-2_en.pdf"},
    {"id":"16229","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for DepoCyte","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-06-29T02:00:00Z","last_updated_date":"2006-06-29T02:00:00Z","reference_number":"EMEA/349192/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_et.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-depocyte_sv.pdf"}},
    {"id":"16260","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Effentora (fentanyl)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/447220/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-effentora-fentanyl_sv.pdf"}},
    {"id":"16270","name":"Questions and answers on the withdrawal of the marketing authorisation application for Ratioepo (epoetin theta)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-03-22T01:00:00Z","last_updated_date":"2010-03-22T01:00:00Z","reference_number":"EMA/146533/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ratioepo-epoetin-theta_en.pdf"},
    {"id":"16384","name":"Questions and answers on the withdrawal of the application for a scientific opinion for Globorix","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-10-24T02:00:00Z","last_updated_date":"2007-10-24T02:00:00Z","reference_number":"EMEA/475076/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-scientific-opinion-globorix_en.pdf"},
    {"id":"16583","name":"Questions and answers on the withdrawal of the marketing authorisation application for Begedina (begelomab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T11:14:00Z","last_updated_date":"2017-01-17T10:14:00Z","reference_number":"EMA/491291/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-begedina-begelomab_sv.pdf"}},
    {"id":"16595","name":"Questions and answers on the withdrawal of the marketing application for Cylatron","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-03-27T01:00:00Z","last_updated_date":"2009-03-27T01:00:00Z","reference_number":"EMEA/156698/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cylatron_sv.pdf"}},
    {"id":"16720","name":"Questions and answers on the withdrawal of the application to change the marketing authorisation application for Draxxin","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-02-20T01:00:00Z","last_updated_date":"2007-02-20T01:00:00Z","reference_number":"EMEA/CVMP/58270/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-application-draxxin_en.pdf"},
    {"id":"16759","name":"Questions and answers on the recall of Viracept","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:09:21Z","last_updated_date":"2007-06-06T02:09:21Z","reference_number":"EMEA/251718/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recall-viracept_en.pdf"},
    {"id":"16793","name":"Questions and answers on the addition of contraindications for Fareston (toremifene)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T00:09:21Z","last_updated_date":"2009-01-23T00:09:21Z","reference_number":"EMEA/45331/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-addition-contraindications-fareston-toremifene_en.pdf"},
    {"id":"16797","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Translarna (ataluren)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/185561/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-translarna-ataluren_en.pdf"},
    {"id":"16883","name":"Questions and answers on the withdrawal of the marketing application for Garenoxacin mesylate","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-08-16T02:09:21Z","last_updated_date":"2007-08-16T02:09:21Z","reference_number":"EMEA/374268/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-garenoxacin-mesylate_sv.pdf"}},
    {"id":"17011","name":"Questions and answers on the withdrawal of the marketing application for Kiacta","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-04-08T02:00:00Z","last_updated_date":"2008-04-08T02:00:00Z","reference_number":"EMEA/136938/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-kiacta_sv.pdf"}},
    {"id":"17192","name":"Questions and Answers on ketoprofen, ketorolac and piroxicam","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-09-26T02:00:00Z","last_updated_date":"2006-09-26T02:00:00Z","reference_number":"EMEA/377567/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-ketoprofen-ketorolac-and-piroxicam_en.pdf"},
    {"id":"17306","name":"Questions and answers on the withdrawal of the marketing authorisation application for Pioglitazone Teva Generics","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T13:20:00Z","last_updated_date":"2012-04-30T13:20:00Z","reference_number":"EMA/282199/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-teva-generics_sv.pdf"}},
    {"id":"17377","name":"Withdrawal of the marketing authorisation application for Doxorubicin SUN","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/CHMP/647763/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/withdrawal-marketing-authorisation-application-doxorubicin-sun_sv.pdf"}}    {"id":"17674","name":"Questions and answers on the withdrawal of the marketing authorisation application for Tekinex","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-01-31T01:00:00Z","last_updated_date":"2011-01-31T01:00:00Z","reference_number":"EMA/13310/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tekinex_sv.pdf"}},
    {"id":"17945","name":"Questions and answers on the withdrawal of the marketing authorisation application for Balimek (binimetinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-03-27T17:07:00Z","reference_number":"EMA/41972/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-balimek-binimetinib_sv.pdf"}},
    {"id":"17977","name":"Questions and answers on updated recommendations on the use of Caelyx (doxorubicin hydrochloride)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-10-30T14:05:12Z","last_updated_date":"2012-10-30T14:05:12Z","reference_number":"EMA/664564/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-updated-recommendations-use-caelyx-doxorubicin-hydrochloride_en.pdf"},
    {"id":"18052","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Qtern (saxagliptin / dapagliflozin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"EMA/251728/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qtern-saxagliptin-dapagliflozin_en.pdf"},
    {"id":"18218","name":"Questions and answers on the withdrawal of the marketing application for\n\nVekacia","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-12-02T01:00:00Z","last_updated_date":"2008-12-02T01:00:00Z","reference_number":"EMEA/611497/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vekacia_sv.pdf"}},
    {"id":"18240","name":"Questions and answers on the review of Conbriza (bazedoxifene), PecFent (fentanyl) and Torisel (temsirolimus)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T17:02:17Z","last_updated_date":"2012-07-20T17:02:17Z","reference_number":"EMA/483755/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-conbriza-bazedoxifene-pecfent-fentanyl-and-torisel-temsirolimus_en.pdf"},
    {"id":"18273","name":"Questions and answers on the shortage of Increlex","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/250270/2013 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-shortage-increlex_en.pdf"},
    {"id":"18282","name":"Questions and Answers on the EMEA's action regarding the safety of Ketek (telithromycin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-01-27T01:00:00Z","last_updated_date":"2006-01-27T01:00:00Z","reference_number":"EMEA/31861/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-emeas-action-regarding-safety-ketek-telithromycin_en.pdf"},
    {"id":"18358","name":"Questions and answers on the withdrawal of the marketing authorisation application for Ogivri (trastuzumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:12:00Z","last_updated_date":"2017-09-15T14:12:00Z","reference_number":"EMA/564631/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ogivri-trastuzumab_sv.pdf"}},
    {"id":"18465","name":"Questions and answers on the withdrawal of the marketing authorisation application for Tyvaso","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tyvaso_sv.pdf"}},
    {"id":"18484","name":"Questions and answers on the withdrawal of the marketing application for Arxxant","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-03-22T01:00:00Z","last_updated_date":"2007-03-22T01:00:00Z","reference_number":"EMEA/117441/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-arxxant_sv.pdf"}},
    {"id":"18586","name":"Questions and answers on the withdrawal of the marketing authorisation application for Brilence","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-06-29T02:00:00Z","last_updated_date":"2010-06-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-brilence_en.pdf"},
    {"id":"18634","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Osseor (strontium ranelate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/232003/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-osseor-strontium-ranelate_sv.pdf"}},
    {"id":"19114","name":"Questions and answers on the positive opinion  for  Thalidomide Pharmion","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/543524/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-thalidomide-pharmion_en.pdf"},
    {"id":"19158","name":"Questions and answers on the withdrawal of the marketing authorisation application for Kyndrisa (drisapersen)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T17:00:00Z","last_updated_date":"2016-06-30T17:00:00Z","reference_number":"EMA/430531/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_sv.pdf"}},
    {"id":"19394","name":"Questions and answers on epoetins and the risk of tumour growth and blood clots in the veins","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:09:21Z","last_updated_date":"2008-06-26T02:09:21Z","reference_number":"EMEA/CHMP/333962/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-epoetins-and-risk-tumour-growth-and-blood-clots-veins_en.pdf"},
    {"id":"19454","name":"Questions and answers on the positive opinion  for  Revlimid","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2007-03-22T00:09:21Z","last_updated_date":"2007-03-22T00:09:21Z","reference_number":"EMEA/121873/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-revlimid_en.pdf"},
    {"id":"19496","name":"Questions and answers on the CHMP review of the recommendations on the use of pandemic H1N1 vaccines","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-10-23T02:09:21Z","last_updated_date":"2009-10-23T02:09:21Z","reference_number":"EMEA/666809/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-chmp-review-recommendations-use-pandemic-h1n1-vaccines_en.pdf"},
    {"id":"19526","name":"Questions and Answers on the EMEA review of cardiovascular and gastrointestinal safety and serious skin reactions with non-selective NSAIDs","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2005-10-17T02:00:00Z","last_updated_date":"2005-10-17T02:00:00Z","reference_number":"EMEA/300095/2005","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-emea-review-cardiovascular-and-gastrointestinal-safety-and-serious-skin-reactions-non-selective-nsaids_en.pdf"},
    {"id":"19722","name":"Questions and answers on the withdrawal of the marketing application for  Retisert","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-09-03T02:00:00Z","last_updated_date":"2007-09-03T02:00:00Z","reference_number":"EMEA/342023/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-retisert_sv.pdf"}},
    {"id":"20349","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Aranesp (darbepoetin alfa)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"EMA/165563/2018 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-aranesp-darbepoetin-alfa_sv.pdf"}},
    {"id":"20462","name":"Questions and answers on the withdrawal of the marketing authorisation application for Topotecan SUN","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"EMA/121971/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-topotecan-sun_sv.pdf"}},
    {"id":"20608","name":"Questions and answers on the withdrawal of the marketing authorisation application for Docetaxel Sun (docetaxel)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/396891/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-docetaxel-sun-docetaxel_sv.pdf"}},
    {"id":"21069","name":"Questions and answers on the expression of the strength for Halaven (eribulin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T13:00:00Z","last_updated_date":"2012-02-17T13:00:00Z","reference_number":"EMA/105039/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-expression-strength-halaven-eribulin_en.pdf"},
    {"id":"21124","name":"Questions and Answers on non-selective NSAIDs CHMP review of safety of non-selective NSAIDs","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2005-08-02T02:00:00Z","last_updated_date":"2005-08-02T02:00:00Z","reference_number":"EMEA/250423/2005","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-non-selective-nsaids-chmp-review-safety-non-selective-nsaids_en.pdf"},
    {"id":"21254","name":"Questions and answers on the review of RotaTeq (rotavirus vaccine, live, oral)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-09-23T02:00:00Z","last_updated_date":"2010-09-23T02:00:00Z","reference_number":"EMA/588405/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-rotateq-rotavirus-vaccine-live-oral_en.pdf"},
    {"id":"21269","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Solumarv (human insulin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/CHMP/761027/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solumarv-human-insulin_sv.pdf"}},
    {"id":"21347","name":"Questions and answers on the CVMP positive opinions for avian influenza vaccines for use in birds","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-07-21T02:00:00Z","last_updated_date":"2006-07-21T02:00:00Z","reference_number":"EMEA/281078/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-cvmp-positive-opinions-avian-influenza-vaccines-use-birds_en.pdf"},
    {"id":"21478","name":"Questions and answers on the withdrawal of the marketing authorisation application for Zafiride (NGR-human tumour necrosis factor alpha)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"EMA/393395/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis-factor-alpha_sv.pdf"}},
    {"id":"21654","name":"Questions and answers on the withdrawal of the marketing authorisation application for Plivensia (sirukumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2018-02-05T13:00:00Z","reference_number":"EMA/727596/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-plivensia-sirukumab_sv.pdf"}},
    {"id":"21722","name":"Questions and answers on the review of Avastin (bevacizumab) in the treatment of metastatic breast cancer","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-12-16T01:00:00Z","last_updated_date":"2010-12-16T01:00:00Z","reference_number":"EMA/CHMP/804031/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-avastin-bevacizumab-treatment-metastatic-breast-cancer_en.pdf"},
    {"id":"21738","name":"Questions and answers on the review of Vimpat (lacosamide) 15-mg/ml syrup","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-09-22T02:00:00Z","last_updated_date":"2011-09-22T02:00:00Z","reference_number":"EMA/CHMP/762478/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-vimpat-lacosamide-15-mgml-syrup_en.pdf"},
    {"id":"21805","name":"Questions and answers on the withdrawal of the marketing authorisation application for Zactima (vandetanib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/726915/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-zactima-vandetanib_en.pdf"},
    {"id":"22103","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for NovoSeven","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-04-27T02:00:00Z","last_updated_date":"2006-04-27T02:00:00Z","reference_number":"EMEA/133892/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-novoseven_sv.pdf"}},
    {"id":"22381","name":"Questions and answers on the withdrawal of the marketing authorisation application for Joicela (lumiracoxib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/361680/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joicela-lumiracoxib_sv.pdf"}},
    {"id":"22397","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Macugen (pegaptanib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/CHMP/563649/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-macugen-pegaptanib_en.pdf"},
    {"id":"22525","name":"Questions and answers on the lack of sterility assurance with DepoCyte (cytarabine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-08-24T13:15:00Z","last_updated_date":"2012-08-24T13:15:00Z","reference_number":"EMA/552200/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-lack-sterility-assurance-depocyte-cytarabine_en.pdf"},
    {"id":"22630","name":"Questions and answers on the withdrawal of the marketing authorisation application for SecreFlo (secretin human)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-09-24T02:00:00Z","last_updated_date":"2012-09-24T02:00:00Z","reference_number":"EMA/CHMP/602611/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-secreflo-secretin-human_sv.pdf"}},
    {"id":"22638","name":"Questions and answers on the withdrawal of the marketing authorisation application for Lunivia (eszopiclone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-06-24T02:00:00Z","last_updated_date":"2009-06-24T02:00:00Z","reference_number":"EMEA/307582/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-lunivia-eszopiclone_sv.pdf"}},
    {"id":"22654","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Teysuno (tegafur/gimeracil/oteracil)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"EMA/37171/2015","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-teysuno-tegafurgimeraciloteracil_sv.pdf"}},
    {"id":"22989","name":"Questions and answers on the withdrawal of the marketing authorisation application for IXinity","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/379048/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ixinity_sv.pdf"}},
    {"id":"23098","name":"Questions and answers on the withdrawal of the marketing authorisation application for Opsiria (sirolimus)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/358774/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opsiria-sirolimus_sv.pdf"}},
    {"id":"23340","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Velcade (bortezomib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-07-31T17:45:00Z","last_updated_date":"2012-07-31T17:45:00Z","reference_number":"EMA/454020/2012 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-velcade-bortezomib_sv.pdf"}},
    {"id":"23428","name":"Questions and answers on the withdrawal of the marketing authorisation application for Corluxin (mifepristone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/261739/2015","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-corluxin-mifepristone_sv.pdf"}},
    {"id":"23514","name":"Questions and answers on the possible risk of liver injury with Multaq (dronedarone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/48911/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-possible-risk-liver-injury-multaq-dronedarone_en.pdf"},
    {"id":"23598","name":"Questions and answers on withdrawal of the marketing authorisation application for Rasival (aliskiren / valsartan)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-09-28T02:00:00Z","last_updated_date":"2010-09-28T02:00:00Z","reference_number":"EMA/584655/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rasival-aliskiren-valsartan_sv.pdf"}},
    {"id":"23905","name":"Questions and answers on the marketing authorisation for Opgenra","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-10-23T02:00:00Z","last_updated_date":"2008-10-23T02:00:00Z","reference_number":"EMEA/CHMP/559257/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-marketing-authorisation-opgenra_en.pdf"},
    {"id":"24035","name":"Questions and answers on the withdrawal of the marketing authorisation application for Epostim (epoetin alfa)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-04-19T02:00:00Z","last_updated_date":"2011-04-19T02:00:00Z","reference_number":"EMA/287731/2011 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_sv.pdf"}},
    {"id":"24168","name":"Questions and answers on the withdrawal of the marketing authorisation application for Beprana (naproxcinod)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/364651/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-beprana-naproxcinod_sv.pdf"}},
    {"id":"24258","name":"Questions and answers on the withdrawal of the marketing authorisation application for Keytruda (pembrolizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/727539/2017 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-keytruda-pembrolizumab_sv.pdf"}},
    {"id":"24559","name":"Questions and answers on the shortage of Vistide","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-02-28T12:00:00Z","last_updated_date":"2013-02-28T12:00:00Z","reference_number":"EMA/101129/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-shortage-vistide_en.pdf"},
    {"id":"24600","name":"Questions and answers on shortcomings in quality assurance at Ben Venue Laboratories","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-12-13T17:00:00Z","last_updated_date":"2011-12-13T17:00:00Z","reference_number":"EMA/946321/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-shortcomings-quality-assurance-ben-venue-laboratories_en.pdf"},
    {"id":"24760","name":"Questions and answers on the withdrawal of the marketing authorisation application for Pioglitazone ratiopharm","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T13:00:00Z","last_updated_date":"2012-07-12T13:00:00Z","reference_number":"EMA/281372/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratiopharm_sv.pdf"}},
    {"id":"24834","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Zometa","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-01-17T01:00:00Z","last_updated_date":"2008-01-17T01:00:00Z","reference_number":"EMEA/31266/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zometa_sv.pdf"}},
    {"id":"24901","name":"Questions and answers on the withdrawal of the marketing application for Riquent","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-10-18T02:00:00Z","last_updated_date":"2006-10-18T02:00:00Z","reference_number":"EMEA/410799/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-riquent_sv.pdf"}},
    {"id":"24994","name":"Questions and answers on the precautionary recall of batches of clopidogrel-containing medicines","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-03-25T01:00:00Z","last_updated_date":"2010-03-25T01:00:00Z","reference_number":"EMA/179698/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-precautionary-recall-batches-clopidogrel-containing-medicines_en.pdf"},
    {"id":"25038","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Isomarv (human insulin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/CHMP/800910/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-isomarv-human-insulin_sv.pdf"}},
    {"id":"25121","name":"Questions and answers on the withdrawal of the marketing application for Iplex","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-06-26T02:00:00Z","last_updated_date":"2007-06-26T02:00:00Z","reference_number":"EMEA/111199/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-iplex_sv.pdf"}},
    {"id":"25149","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Adempas (riociguat)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/560099/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-adempas-riociguat_en.pdf"},
    {"id":"25449","name":"Questions and answers on the withdrawal of the marketing authorisation application for Opdivo (nivolumab) (II/0039)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/504630/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opdivo-nivolumab-ii0039_en.pdf"},
    {"id":"26090","name":"Questions and answers on the withdrawal of application for a change to the marketing authorisation for Sutent (sunitinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/504631/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-sutent-sunitinib_sv.pdf"}},
    {"id":"26292","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Zydelig (idelalisib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-02-23T13:00:00Z","last_updated_date":"2018-02-23T13:00:00Z","reference_number":"EMA/109876/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-zydelig-idelalisib_en.pdf"},
    {"id":"26400","name":"Questions and answers on the positive opinion on the marketing authorisation for Sialanar (glycopyrronium bromide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/500080/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-marketing-authorisation-sialanar-glycopyrronium-bromide_en.pdf"},
    {"id":"26414","name":"Questions and answers on withdrawal of the application for a change to the marketing authorisation for Exelon and Prometax (rivastigmine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-05-21T02:00:00Z","reference_number":"EMA/226251/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_sv.pdf"}},
    {"id":"26478","name":"Questions and answers on the withdrawal of the\n\nmarketing authorisation application for Ethyl Eicosapent soft gelatin capsules (ethyl eicosapent)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/830917/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ethyl-eicosapent-soft-gelatin-capsules-ethyl-eicosapent_en.pdf"},
    {"id":"26578","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for Vedrop International non-proprietary name (INN): tocofersolan","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T00:09:21Z","last_updated_date":"2009-01-22T00:09:21Z","reference_number":"EMEA/30797/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-vedrop-international-non-proprietary-name-inn-tocofersolan_en.pdf"},
    {"id":"26620","name":"Questions and answers on the positive opinion on the marketing authorisation for Translarna (ataluren)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/299027/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-marketing-authorisation-translarna-ataluren_en.pdf"},
    {"id":"26652","name":"Questions and answers on the assessment of the deficiencies in the safety reporting system at Roche Registration Ltd","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-10-23T14:00:00Z","last_updated_date":"2023-09-25T14:00:00Z","reference_number":"EMA/681227/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-assessment-deficiencies-safety-reporting-system-roche-registration-ltd_en.pdf"},
    {"id":"26707","name":"Questions and answers on the review of Ketek (telithromycin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-03-30T02:09:21Z","last_updated_date":"2007-03-30T02:09:21Z","reference_number":"EMEA/140996/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-ketek-telithromycin_en.pdf"},
    {"id":"26806","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Exelon and Prometax (rivastigmine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2013-12-20T13:00:00Z","reference_number":"EMA/780804/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-exelon-and-prometax-rivastigmine_sv.pdf-0"}},
    {"id":"26951","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Ditelos (strontium ranelate / cholecalciferol)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/249569/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ditelos-strontium-ranelate-cholecalciferol_en.pdf"},
    {"id":"27119","name":"Questions and answers on the supply shortage of Vfend (voriconazole)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-03-08T11:00:00Z","last_updated_date":"2012-03-08T11:00:00Z","reference_number":"EMA/152112/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-supply-shortage-vfend-voriconazole_en.pdf"},
    {"id":"27536","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Combimarv (human insulin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/CHMP/800908/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-combimarv-human-insulin_sv.pdf"}},
    {"id":"27592","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Ruvise","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/38204/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ruvise_sv.pdf"}},
    {"id":"27605","name":"Questions and answers on the withdrawal of the marketing application for Sinerem","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/599866/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-sinerem_sv.pdf"}},
    {"id":"27703","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Rienso (ferumoxytol)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/119454/2015","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-rienso-ferumoxytol_en.pdf"},
    {"id":"27774","name":"Questions and answers on endotoxins in dialysis solutions produced at Baxter manufacturing plant","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/48881/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_en.pdf"},
    {"id":"27818","name":"Questions and answers on the withdrawal of the marketing authorisation application for Cavoley (pegfilgrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/822769/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_sv.pdf"}},
    {"id":"27830","name":"Questions and answers on the withdrawal of the marketing application for Synordia","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-12-14T01:00:00Z","last_updated_date":"2006-12-14T01:00:00Z","reference_number":"EMEA/490683/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-synordia_sv.pdf"}},
    {"id":"28006","name":"Questions and answers on recommendation for refusal for a  change to the marketing authorisation  for  Tarceva","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2006-07-27T02:09:21Z","last_updated_date":"2006-07-27T02:09:21Z","reference_number":"EMEA/284207/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-change-marketing-authorisation-tarceva_en.pdf"},
    {"id":"28148","name":"Questions and answers on the review of Rotarix (rotavirus vaccine, live)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/CHMP/460465/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-rotarix-rotavirus-vaccine-live_en.pdf"},
    {"id":"28160","name":"Questions and answers on the withdrawal of the marketing authorisation application for Blectifor (caffeine citrate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/188385/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-blectifor-caffeine-citrate_sv.pdf"}},
    {"id":"28229","name":"Questions and answers on the review of medicines for which studies have been conducted at Texas-based Cetero Research facility","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-09-21T16:45:00Z","last_updated_date":"2012-09-21T16:45:00Z","reference_number":"EMA/483755/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-medicines-which-studies-have-been-conducted-texas-based-cetero-research-facility_en.pdf"},
    {"id":"28265","name":"Questions and answers on recommendation for the refusal of the marketing authorisation  for  Mylotarg : International non-proprietary name (INN): gemtuzumab ozogamicin","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-09-20T02:09:21Z","last_updated_date":"2007-09-20T02:09:21Z","reference_number":"EMEA/318553/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-mylotarg-international-non-proprietary-name-inn-gemtuzumab-ozogamicin_en.pdf"},
    {"id":"28274","name":"Questions and answers on the withdrawal of the marketing authorisation application for Neocepri (folic acid)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-06-17T02:00:00Z","last_updated_date":"2015-01-12T14:30:00Z","reference_number":"EMA/303644/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neocepri-folic-acid_en.pdf"},
    {"id":"28752","name":"Questions and answers on the withdrawal of the marketing application for Spanidin","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/309003/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-spanidin_sv.pdf"}},
    {"id":"28776","name":"Questions and answers on the withdrawal of the marketing application for DuoCover","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-06-09T02:00:00Z","last_updated_date":"2010-03-31T02:00:00Z","reference_number":"EMEA/270168/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duocover_sv.pdf"}},
    {"id":"28937","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Fanaptum","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/172695/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fanaptum_sv.pdf"}},
    {"id":"29140","name":"Questions and answers on the recommendation to suspend the marketing authorisation of Ionsys","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-11-21T00:09:21Z","last_updated_date":"2008-11-21T00:09:21Z","reference_number":"EMEA/CHMP/609856/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-suspend-marketing-authorisation-ionsys_en.pdf"},
    {"id":"29379","name":"Questions and answers on withdrawal of marketing application for Orathecin","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-01-23T01:00:00Z","last_updated_date":"2006-01-23T01:00:00Z","reference_number":"EMEA/282451/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orathecin_sv.pdf"}},
    {"id":"29439","name":"Questions and answers on the withdrawal of the marketing application for Vorinostat MSD","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-03-10T01:00:00Z","last_updated_date":"2009-03-10T01:00:00Z","reference_number":"EMEA/90664/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vorinostat-msd_sv.pdf"}},
    {"id":"29705","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Revlimid (lenalidomide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T02:00:00Z","last_updated_date":"2012-07-24T02:00:00Z","reference_number":"EMA/414386/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-revlimid-lenalidomide_sv.pdf"}},
    {"id":"29764","name":"Questions and answers on withdrawal of the application for a change to the marketing authorisation for Qutenza (capsaicin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-04-16T02:00:00Z","last_updated_date":"2012-04-16T02:00:00Z","reference_number":"EMA/212297/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-qutenza-capsaicin_sv.pdf"}},
    {"id":"29806","name":"Questions and answers on recommendation for the refusal of the marketing authorisation  for Mycograb","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2006-11-16T00:09:21Z","last_updated_date":"2006-11-16T00:09:21Z","reference_number":"EMEA/454649/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-mycograb_en.pdf-0"},
    {"id":"29905","name":"Shortage of Apidra (insulin glulisine) cartridges","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-09-22T18:08:00Z","last_updated_date":"2011-09-22T18:08:00Z","reference_number":"EMA/CHMP/769286/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/shortage-apidra-insulin-glulisine-cartridges_en.pdf"},
    {"id":"30213","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Jenzyl (ridaforolimus)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2013-02-18T15:20:00Z","reference_number":"EMA/807998/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-jenzyl-ridaforolimus_sv.pdf"}},
    {"id":"30232","name":"Questions and answers on the withdrawal of the marketing application\n\nfor Aflunov","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/306731/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-aflunov_sv.pdf"}},
    {"id":"30449","name":"Questions and answers on recommendation for the refusal of the marketing authorisation  for  vectibix","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-05-24T02:09:21Z","last_updated_date":"2009-05-24T02:09:21Z","reference_number":"EMEA/219924/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-vectibix_en.pdf"},
    {"id":"30555","name":"Questions and answers on the withdrawal of the marketing authorisation application for Faldaprevir Boehringer Ingelheim (faldaprevir)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/354906/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-faldaprevir-boehringer-ingelheim-faldaprevir_sv.pdf"}},
    {"id":"30594","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Intrinsa (testosterone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-10-26T02:00:00Z","last_updated_date":"2010-10-26T02:00:00Z","reference_number":"EMA/632261/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-intrinsa-testosterone_sv.pdf"}}    {"id":"30604","name":"Questions and answers on recommendation for refusal of marketing authorisation  for  Valdoxan/Thymanax","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2006-07-27T02:09:21Z","last_updated_date":"2006-07-27T02:09:21Z","reference_number":"EMEA/267703/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-valdoxanthymanax_en.pdf"},
    {"id":"30896","name":"Questions and answers on the withdrawal of the marketing application for Gastromotal","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-11-16T01:00:00Z","last_updated_date":"2007-11-16T01:00:00Z","reference_number":"EMEA/519568/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-gastromotal_sv.pdf"}},
    {"id":"31047","name":"Questions and answers on the withdrawal of the marketing authorisation application for Janacti and related names","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-11-22T01:00:00Z","last_updated_date":"2011-11-22T01:00:00Z","reference_number":"EMA/897336/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-janacti-and-related-names_en.pdf"},
    {"id":"31128","name":"Questions and answers on the withdrawal of the marketing authorisation application for Megestrol Alkermes (megestrol)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-03-20T01:00:00Z","last_updated_date":"2012-03-20T01:00:00Z","reference_number":"EMA/190839/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-megestrol-alkermes-megestrol_sv.pdf"}},
    {"id":"31166","name":"Questions and answers on the updated recommendations for Fabrazyme treatment","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/603545/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-updated-recommendations-fabrazyme-treatment_en.pdf"},
    {"id":"31339","name":"Questions and answers on the withdrawal of the marketing application for Vibativ","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-11-28T01:00:00Z","last_updated_date":"2008-11-28T01:00:00Z","reference_number":"EMEA/586612/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-vibativ_sv.pdf"}},
    {"id":"31342","name":"Questions and answers on the withdrawal of the marketing authorisation application for Alendronic Acid/Colecalciferol Mylan (alendronic acid and colecalciferol)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T13:04:00Z","last_updated_date":"2017-02-02T12:04:00Z","reference_number":"EMA/354096/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-alendronic-acidcolecalciferol-mylan-alendronic-acid-and-colecalciferol_sv.pdf"}},
    {"id":"31435","name":"Questions and answers on the withdrawal of the marketing application for Exulett","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-10-07T02:00:00Z","last_updated_date":"2008-10-07T02:00:00Z","reference_number":"EMEA/477488/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-exulett_sv.pdf"}},
    {"id":"31471","name":"Questions and Answers on COX-2 Inhibitors - Update","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2005-06-27T02:09:21Z","last_updated_date":"2005-06-27T02:09:21Z","reference_number":"EMEA/210745/2005 corr","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-cox-2-inhibitors-update_en.pdf"},
    {"id":"31611","name":"Questions and answers on the outcome of an application for Xgeva to be used in patients with castration-resistant prostate cancer at high risk of spreading to the bones","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T15:00:00Z","last_updated_date":"2013-10-25T15:00:00Z","reference_number":"EMA/655170/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-outcome-application-xgeva-be-used-patients-castration-resistant-prostate-cancer-high-risk-spreading-bones_en.pdf"},
    {"id":"31646","name":"Questions and answers on the withdrawal of the marketing authorisation application for Graspa (eryaspase)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/817193/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-eryaspase_sv.pdf"}},
    {"id":"32029","name":"Questions and answers on withdrawal of marketing authorisation application for Cerepro","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMA/152214/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cerepro_sv.pdf"}},
    {"id":"32310","name":"Questions and answers on the withdrawal of the marketing application for Pristiqs","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-04-04T02:00:00Z","last_updated_date":"2008-04-04T02:00:00Z","reference_number":"EMEA/CHMP/125421/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-pristiqs_en.pdf"},
    {"id":"32312","name":"Questions and answers on the withdrawal of the marketing authorisation application for VeraSeal (human fibrinogen / human thrombin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/679015/2015","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-veraseal-human-fibrinogen-human-thrombin_sv.pdf"}},
    {"id":"32329","name":"Questions and answers on atryn","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2006-06-02T02:09:21Z","last_updated_date":"2006-06-02T02:09:21Z","reference_number":"EMEA/191862/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-atryn_en.pdf"},
    {"id":"32342","name":"Questions and answers on the positive opinion on the marketing authorisation of Glybera (alipogene tiparvovec)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T14:14:49Z","last_updated_date":"2012-07-20T14:14:49Z","reference_number":"EMA/470328/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-positive-opinion-marketing-authorisation-glybera-alipogene-tiparvovec_en.pdf"},
    {"id":"32406","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Glivec","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-11-16T01:00:00Z","last_updated_date":"2006-11-16T01:00:00Z","reference_number":"EMEA/452758/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-glivec_en.pdf"},
    {"id":"32421","name":"Questions and answers on the withdrawal of the marketing authorisation application for Opdivo (nivolumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/586431/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opdivo-nivolumab_en.pdf"},
    {"id":"32444","name":"Questions and answers on the withdrawal of the marketing application for DuoPlavin","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-06-09T02:00:00Z","last_updated_date":"2010-03-31T02:00:00Z","reference_number":"EMEA/279720/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-duoplavin_sv.pdf"}},
    {"id":"32445","name":"Questions and answers on the review of Zerit (stavudine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-02-18T13:27:00Z","last_updated_date":"2011-02-18T13:27:00Z","reference_number":"EMA/127094/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-zerit-stavudine_en.pdf"},
    {"id":"32573","name":"Questions and answers on the withdrawal of the marketing authorisation application for Vynfinit (vintafolide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2015-01-12T14:30:00Z","reference_number":"EMA/302516/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynfinit-vintafolide_en.pdf"},
    {"id":"32815","name":"Questions and answers on the withdrawal of the marketing authorisation application for Xegafri (rociletinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/352428/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xegafri-rociletinib_sv.pdf"}},
    {"id":"32946","name":"Questions and answers on the withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/822770/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_sv.pdf"}},
    {"id":"33215","name":"Questions and answers on the withdrawal of the marketing authorisation application for Elmisol (levamisole)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"EMA/CHMP/380586/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-elmisol-levamisole_sv.pdf"}},
    {"id":"33275","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for  Mylotarg","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/37537/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-mylotarg_en.pdf"},
    {"id":"33460","name":"Questions and answers on positive opinion on a change to the marketing authorisation for Avastin (bevacizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/295613/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-change-marketing-authorisation-avastin-bevacizumab_en.pdf"},
    {"id":"33537","name":"Questions and answers on the withdrawal of the marketing authorisation application for Desloratadine Krka","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-11-17T01:00:00Z","last_updated_date":"2011-11-17T01:00:00Z","reference_number":"EMA/CHMP/839195/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-desloratadine-krka_en.pdf"},
    {"id":"33553","name":"Questions and answers on the recall of Vimpat 15-mg/ml syrup (lacosamide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP//559522/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recall-vimpat-15-mgml-syrup-lacosamide_en.pdf"},
    {"id":"33568","name":"Questions and answers on the positive opinion on the change to the marketing authorisation for Vectibix (panitumumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T20:03:33Z","last_updated_date":"2011-06-24T20:03:33Z","reference_number":"EMA/CHMP/486351/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-change-marketing-authorisation-vectibix-panitumumab_en.pdf"},
    {"id":"33697","name":"Questions and answers on the withdrawal of the marketing authorisation application for Ertapenem Hospira (ertapenem)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"EMA/610687/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ertapenem-hospira-ertapenem_sv.pdf"}},
    {"id":"33855","name":"Questions and answers on the withdrawal of the marketing authorisation application for Duloxetine Sandoz (duloxetine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/249807/2015","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-duloxetine-sandoz-duloxetine_sv.pdf"}},
    {"id":"33931","name":"Questions and answers on the withdrawal of the marketing application\n\nfor Ellefore","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-11-12T01:00:00Z","last_updated_date":"2008-11-12T01:00:00Z","reference_number":"EMEA/544525/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ellefore_sv.pdf"}},
    {"id":"34146","name":"Questions and answers on recommendation for the refusal of the marketing authorisation  for  Natalizumab Elan Pharma","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-11-15T00:09:21Z","last_updated_date":"2007-11-15T00:09:21Z","reference_number":"EMEA/530964/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-authorisation-natalizumab-elan-pharma_en.pdf"},
    {"id":"34182","name":"Inovelon: Questions and answers on the outcome of an extension of indication application for Inovelon (rufinamide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-02-08T10:51:00Z","last_updated_date":"2017-02-08T10:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/inovelon-questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_sv.pdf"}},
    {"id":"34198","name":"Questions and answers on the marketing authorisation for Ceplene","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:09:21Z","last_updated_date":"2008-07-24T02:09:21Z","reference_number":"EMEA/398628/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-marketing-authorisation-ceplene_en.pdf"},
    {"id":"34464","name":"Questions and answers on the application of the so-called 'Sunset clause' to centrally authorised medicinal products","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2006-02-23T01:00:00Z","last_updated_date":"2006-02-23T01:00:00Z","reference_number":"EMEA/180079/2005","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-application-so-called-sunset-clause-centrally-authorised-medicinal-products_en.pdf"},
    {"id":"34706","name":"Overview of comments received on questions and answers on notification to the EMEA of actual marketing and cessation of placing on the market for centrally authorised medicinal products","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-02-23T01:00:00Z","last_updated_date":"2006-02-23T01:00:00Z","reference_number":"EMEA/424223/2005","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/overview-comments-received-questions-and-answers-notification-emea-actual-marketing-and-cessation-placing-market-centrally-authorised-medicinal-products_en.pdf"},
    {"id":"34719","name":"PRAC recommends restriction in the use of Protelos / Osseor: Questions and answers","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-04-12T14:00:00Z","last_updated_date":"2013-04-12T14:00:00Z","reference_number":"EMA/220628/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/prac-recommends-restriction-use-protelos-osseor-questions-and-answers_en.pdf"},
    {"id":"34874","name":"Questions and answers on the withdrawal of the marketing authorisation application for Folcepri (etarfolatide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T02:00:00Z","last_updated_date":"2015-01-12T14:30:00Z","reference_number":"EMA/303643/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-folcepri-etarfolatide_en.pdf"},
    {"id":"35663","name":"Questions and answers on the follow-up to the contamination of Viracept (nelfinavir) with ethyl mesilate","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:09:21Z","last_updated_date":"2008-07-24T02:09:21Z","reference_number":"EMEA/CHMP/375807/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-follow-contamination-viracept-nelfinavir-ethyl-mesilate_en.pdf"},
    {"id":"35690","name":"Questions and answers on the withdrawal of the marketing authorisation application for Kepnetic (aceneuramic acid)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kepnetic-aceneuramic-acid_en.pdf"},
    {"id":"35795","name":"Questions and answers on the withdrawal of the marketing authorisation application for Tigecycline Accord (tigecycline)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/589782/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-tigecycline-accord-tigecycline_sv.pdf"}},
    {"id":"35817","name":"Questions and answers on the withdrawal of the marketing authorisation application for Pioglitazone ratio","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T02:00:00Z","last_updated_date":"2012-07-12T02:00:00Z","reference_number":"EMA/281366/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_sv.pdf"}},
    {"id":"36056","name":"Questions and answers on the suspension of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-09-23T02:00:00Z","last_updated_date":"2010-09-23T02:00:00Z","reference_number":"EMA/CHMP/586211/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-suspension-rosiglitazone-containing-medicines-avandia-avandamet-and-avaglim_en.pdf"},
    {"id":"36071","name":"Questions and answers on the withdrawal of the marketing authorisation application for Graspa (L-asparaginase)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T14:00:00Z","last_updated_date":"2018-06-29T14:00:00Z","reference_number":"EMA/431413/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-graspa-l-asparaginase_sv.pdf"}},
    {"id":"36263","name":"Questions and answers on the withdrawal of the marketing authorisation application for Raligize (axalimogene filolisbac)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/499771/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-raligize-axalimogene-filolisbac_sv.pdf"}},
    {"id":"36290","name":"Questions and answers on the CHMP recommendation to allow Viracept back onto the market","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2007-09-20T02:00:00Z","reference_number":"EMEA/413449/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-chmp-recommendation-allow-viracept-back-market_en.pdf"},
    {"id":"36363","name":"Questions and answers on the withdrawal of the marketing authorisation application for Recothrom (thrombin alfa)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/828729/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-recothrom-thrombin-alfa_sv.pdf"}},
    {"id":"36380","name":"Questions and answers on the review of Pandemrix influenza vaccine (H1N1) (split virion, inactivated, adjuvanted) A/California/7/2009 (H1N1)v like strain (X-179A)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-07-21T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/CHMP/562838/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-pandemrix-influenza-vaccine-h1n1-split-virion-inactivated-adjuvanted-acalifornia72009-h1n1v-strain-x-179a_en.pdf"},
    {"id":"36458","name":"Questions and answers on the follow-up to the Viracept recall","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-06-21T02:00:00Z","last_updated_date":"2007-06-21T02:00:00Z","reference_number":"EMEA/276379/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-follow-viracept-recall_en.pdf"},
    {"id":"36548","name":"Questions and answers on the withdrawal of the marketing authorisation application for Fulphila (pegfilgrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2018-05-29T02:00:00Z","reference_number":"EMA/577551/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fulphila-pegfilgrastim_sv.pdf"}},
    {"id":"36632","name":"Questions and answers on the withdrawal of the marketing authorisation application for Opaxio (paclitaxel poliglumex)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/654674/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_sv.pdf"}},
    {"id":"36852","name":"Questions and answers on the withdrawal of the marketing authorisation application for Infinia (alpha-1-antitrypsin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/440995/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-infinia-alpha-1-antitrypsin_sv.pdf"}},
    {"id":"37163","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Belviq","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/309180/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-belviq_en.pdf"},
    {"id":"37308","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Viagra","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/609574/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-viagra_en.pdf"},
    {"id":"37313","name":"Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-10-23T02:09:21Z","last_updated_date":"2008-10-23T02:09:21Z","reference_number":"EMEA/537153/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-suspend-marketing-authorisation-acomplia-rimonabant_en.pdf"},
    {"id":"37349","name":"Questions and answers on the benefits and risks of rosiglitazone and pioglitazone","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-10-18T02:00:00Z","last_updated_date":"2007-10-18T02:00:00Z","reference_number":"EMEA/484464/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-benefits-and-risks-rosiglitazone-and-pioglitazone_en.pdf"},
    {"id":"37410","name":"Questions and answers on the use of phosphates in eye drops","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T13:00:00Z","last_updated_date":"2012-12-14T13:00:00Z","reference_number":"EMA/CHMP/753373/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-use-phosphates-eye-drops_en.pdf"},
    {"id":"37423","name":"Questions and answers on the withdrawal of the marketing application for\n\nOrplatna","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-10-17T02:00:00Z","last_updated_date":"2008-10-17T02:00:00Z","reference_number":"EMEA/404511/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-orplatna_sv.pdf"}},
    {"id":"37450","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Votrient (pazopanib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/232003/2014 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-votrient-pazopanib_en.pdf"},
    {"id":"37502","name":"Questions and answers on the withdrawal of the application for change to the marketing authorisation for  Nutropinaq","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/166909/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-nutropinaq_sv.pdf"}},
    {"id":"37506","name":"Questions and answers on the outcome of extension of indication application for Kogenate Bayer and Helixate Nexgen (octocog alfa)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-03-22T17:12:00Z","last_updated_date":"2012-03-22T17:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-outcome-extension-indication-application-kogenate-bayer-and-helixate-nexgen-octocog-alfa_en.pdf"},
    {"id":"37684","name":"Questions and answers on the positive opinion on the marketing authorisation for Bronchitol (mannitol)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-10-21T13:59:25Z","last_updated_date":"2011-10-21T13:59:25Z","reference_number":"EMA/CHMP/834308/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-marketing-authorisation-bronchitol-mannitol_en.pdf"},
    {"id":"37724","name":"Questions and answers on the review of Regranex (becaplermin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-02-18T01:00:00Z","last_updated_date":"2010-02-18T01:00:00Z","reference_number":"EMA/312452/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-regranex-becaplermin_en.pdf"},
    {"id":"37888","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Stalevo","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-03-19T01:00:00Z","last_updated_date":"2009-03-19T01:00:00Z","reference_number":"EMEA/151362/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-stalevo_en.pdf"},
    {"id":"38025","name":"Questions and answers on the outcome of an extension of indication application for Inovelon (rufinamide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T10:35:00Z","last_updated_date":"2017-02-08T10:35:00Z","reference_number":"EMA/848709/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-outcome-extension-indication-application-inovelon-rufinamide_en.pdf"},
    {"id":"38036","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Erbitux (cetuximab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-10-12T02:00:00Z","last_updated_date":"2012-10-12T02:00:00Z","reference_number":"EMA/608075/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-erbitux-cetuximab_sv.pdf"}},
    {"id":"38175","name":"Questions and answers on the withdrawal of the marketing authorisation application for Xgeva (denosumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/47097/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-xgeva-denosumab_sv.pdf"}},
    {"id":"38292","name":"Questions and answers on the outcome of application to extend use of Menveo in children less than two years","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/253316/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-outcome-application-extend-use-menveo-children-less-two-years_en.pdf"},
    {"id":"38296","name":"Questions and answers on the withdrawal of the marketing application for Scintimun","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2010-03-15T01:00:00Z","reference_number":"EMEA/189992/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-scintimun_sv.pdf"}},
    {"id":"38345","name":"Likely shortage of Caelyx (doxorubicin hydrochloride)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-08-08T02:00:00Z","last_updated_date":"2011-08-08T02:00:00Z","reference_number":"EMA/615191/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/likely-shortage-caelyx-doxorubicin-hydrochloride_en.pdf"},
    {"id":"38348","name":"Questions and answers on the outcome of an application an application to extend use of Abilify in schizophrenia to 13 and 14 year olds","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-10-13T02:00:00Z","reference_number":"EMA/610465/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_en.pdf"},
    {"id":"38505","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Opatanol","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-02-23T01:00:00Z","last_updated_date":"2006-02-23T01:00:00Z","reference_number":"EMEA/60142/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opatanol_sv.pdf"}},
    {"id":"38534","name":"Overview of comments received on questions and answers on the application of the so-called 'Sunset clause' to centrally authorised medicinal products","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-02-23T01:00:00Z","last_updated_date":"2006-02-23T01:00:00Z","reference_number":"EMEA/424409/2005","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/overview-comments-received-questions-and-answers-application-so-called-sunset-clause-centrally-authorised-medicinal-products_en.pdf"},
    {"id":"38617","name":"Questions and answers on the withdrawal of the marketing application for Ramelteon","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-10-07T02:00:00Z","last_updated_date":"2008-10-07T02:00:00Z","reference_number":"EMEA/CHMP/502946/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-ramelteon_sv.pdf"}},
    {"id":"38646","name":"Questions and answers on the withdrawal of the marketing authorisation application for Egranli (balugrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2015-02-16T01:00:00Z","reference_number":"EMA/705109/2014","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-egranli-balugrastim_sv.pdf"}},
    {"id":"38664","name":"Outcome of review of new safety data on insulin glargine","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/329790/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/outcome-review-new-safety-data-insulin-glargine_en.pdf"},
    {"id":"38872","name":"Questions and answers on the withdrawal of the marketing authorisation application for Nenad (lisuride)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/830685/2009","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-nenad-lisuride_sv.pdf"}},
    {"id":"38970","name":"Questions and answers on the withdrawal of the marketing authorisation application for Mulsevo (semuloparin sodium)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"EMA/453098/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-mulsevo-semuloparin-sodium_en.pdf"},
    {"id":"39062","name":"Questions and answers on the withdrawal of the marketing authorisation application for Solithromycin Triskel EU Services (solithromycin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/249992/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-solithromycin-triskel-eu-services-solithromycin_sv.pdf"}},
    {"id":"39244","name":"Questions and answers on the withdrawal of the marketing authorisation application for Kyomarc (bevacizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kyomarc-bevacizumab_en.pdf"},
    {"id":"39254","name":"Questions and answers on the review of Tysabri (natalizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-01-21T01:00:00Z","last_updated_date":"2010-01-21T01:00:00Z","reference_number":"EMA/27573/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-tysabri-natalizumab_en.pdf"},
    {"id":"39374","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Neofordex","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-11-20T01:00:00Z","reference_number":"EMEA/H/C/002418","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-neofordex_sv.pdf"}},
    {"id":"39451","name":"Questions and answers on ongoing review of aliskiren-containing medicines","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-12-22T17:00:00Z","last_updated_date":"2011-12-22T17:00:00Z","reference_number":"EMA/990270/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-ongoing-review-aliskiren-containing-medicines_en.pdf"},
    {"id":"39670","name":"Questions and answers on withdrawal of the marketing authorisation application for Rotigotine Mylan (rotigotine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T01:00:00Z","last_updated_date":"2018-07-11T02:00:00Z","reference_number":"EMA/43037/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-rotigotine-mylan-rotigotine_sv.pdf"}},
    {"id":"39817","name":"Questions and answers on Exubera","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-06-17T02:09:21Z","last_updated_date":"2008-06-17T02:09:21Z","reference_number":"EMEA/289739/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-exubera_en.pdf"},
    {"id":"39885","name":"Questions and answers on the withdrawal of the marketing-authorisation application for Memantine FGK","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-04-10T02:00:00Z","reference_number":"EMA/19257/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-memantine-fgk_sv.pdf"}},
    {"id":"40045","name":"Questions and answers on the withdrawal of the marketing authorisation application for Ketoconazole AID-SCFM (ketoconazole)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-03-27T01:00:00Z","reference_number":"EMA/194831/2015","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ketoconazole-aid-scfm-ketoconazole_sv.pdf"}},
    {"id":"40204","name":"Questions and answers on the withdrawal of the marketing application for\n\nDiractin","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-08-21T02:00:00Z","last_updated_date":"2008-08-21T02:00:00Z","reference_number":"EMEA/402553/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-diractin_sv.pdf"}},
    {"id":"40313","name":"Questions and answers on the withdrawal of the marketing authorisation application for Aripiprazole Mylan (aripiprazole)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/324241/2015","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-aripiprazole-mylan-aripiprazole_sv.pdf-0"}},
    {"id":"40410","name":"Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Taxotere/Docetaxel Winthrop","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T00:09:21Z","last_updated_date":"2008-11-20T00:09:21Z","reference_number":"EMEA/610140/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-taxoteredocetaxel-winthrop_sv.pdf"}},
    {"id":"40602","name":"Questions and answers on the withdrawal of a change to the marketing authorisation for Evoltra","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/138069/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-change-marketing-authorisation-evoltra_sv.pdf"}},
    {"id":"40644","name":"Questions and answers on withdrawal of marketing authorisation application for Joulferon","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-04-29T02:00:00Z","last_updated_date":"2010-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-joulferon_sv.pdf"}},
    {"id":"40744","name":"Questions and answers on the withdrawal of the marketing authorisation application for Kalbitor","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2012-02-09T15:43:00Z","reference_number":"EMA/888548/2011","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-kalbitor_sv.pdf"}},
    {"id":"40940","name":"Questions and answers on Tysabri and liver injury","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2008-03-20T00:09:21Z","last_updated_date":"2008-03-20T00:09:21Z","reference_number":"EMEA/CHMP/145908/2008","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-tysabri-and-liver-injury_en.pdf"},
    {"id":"40989","name":"Questions and answers on recommendation for refusal of marketing application for Atryn","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2006-02-23T00:09:21Z","last_updated_date":"2006-02-23T00:09:21Z","reference_number":"EMEA/62022/2006","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-recommendation-refusal-marketing-application-atryn_en.pdf"},
    {"id":"41019","name":"Questions and answers on the outcome of an extension of indication application for Lysodren (mitotane)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/323929/2013","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-outcome-extension-indication-application-lysodren-mitotane_en.pdf"},
    {"id":"41052","name":"Questions and answers on the withdrawal of the marketing authorisation application for Qizenday (biotin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2017-12-14T01:00:00Z","last_updated_date":"2018-02-06T01:00:00Z","reference_number":"EMA/821654/2017","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-qizenday-biotin_sv.pdf"}},
    {"id":"41087","name":"Questions and answers on the review of bleeding risk with Pradaxa (dabigatran etexilate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-05-25T13:59:00Z","last_updated_date":"2012-05-25T13:59:00Z","reference_number":"EMA/CHMP/333240/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-bleeding-risk-pradaxa-dabigatran-etexilate_en.pdf"},
    {"id":"41106","name":"Questions and answers on the withdrawal of the marketing authorisation for Prohippur (sodium benzoate)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T14:00:00Z","last_updated_date":"2018-04-27T14:00:00Z","reference_number":"EMA/258015/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-prohippur-sodium-benzoate_sv.pdf"}}    {"id":"41127","name":"Questions and answers on the review of Doribax (doripenem)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T12:00:00Z","last_updated_date":"2014-10-17T12:00:00Z","reference_number":"EMA/CHMP/411815/2012","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-review-doribax-doripenem_en.pdf"},
    {"id":"41541","name":"Questions and answers on the withdrawal of the marketing application for  Cerepro","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/318692/2007","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-application-cerepro_sv.pdf"}},
    {"id":"41703","name":"Questions and answers on withdrawal of marketing authorisation application for Sliwens (eplivanserin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2010-01-20T01:00:00Z","last_updated_date":"2010-01-20T01:00:00Z","reference_number":"EMA/23705/2010","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-sliwens-eplivanserin_sv.pdf"}},
    {"id":"41802","name":"Questions and answers on the withdrawal of the marketing authorisation application for Arikayce (amikacin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T14:00:00Z","last_updated_date":"2016-10-14T11:15:00Z","reference_number":"EMA/430267/2016","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-arikayce-amikacin_sv.pdf"}},
    {"id":"42066","name":"Questions and answers on the withdrawal of the marketing authorisation application for Treprostinil SciPharm Sà rl (treprostinil)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/622813/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-treprostinil-scipharm-sa-rl-treprostinil_en.pdf"},
    {"id":"42139","name":"Questions and answers on Entolimod TMC","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-09-26T17:42:00Z","last_updated_date":"2018-09-26T17:42:00Z","reference_number":"EMA/632431/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-entolimod-tmc_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-entolimod-tmc_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-entolimod-tmc_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-entolimod-tmc_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-entolimod-tmc_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-entolimod-tmc_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-entolimod-tmc_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-entolimod-tmc_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-entolimod-tmc_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-entolimod-tmc_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-entolimod-tmc_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-entolimod-tmc_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-entolimod-tmc_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-entolimod-tmc_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-entolimod-tmc_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-entolimod-tmc_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-entolimod-tmc_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-entolimod-tmc_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-entolimod-tmc_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-entolimod-tmc_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-entolimod-tmc_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-entolimod-tmc_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-entolimod-tmc_sv.pdf"}},
    {"id":"42701","name":"Questions and answers on the withdrawal of application for a change to the marketing authorisation for Tecentriq (atezolizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T11:26:00Z","last_updated_date":"2018-11-16T11:26:00Z","reference_number":"EMA/798527/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tecentriq-atezolizumab_en.pdf"},
    {"id":"42708","name":"Questions and answers on the positive opinion on the change to the marketing authorisation for Blincyto (blinatumomab)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T13:00:00Z","last_updated_date":"2018-11-16T13:00:00Z","reference_number":"EMA/800602/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-positive-opinion-change-marketing-authorisation-blincyto-blinatumomab_en.pdf"},
    {"id":"43055","name":"Questions and answers on the withdrawal of the marketing authorisation application for Fyzoclad (adalimumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2019-01-15T16:54:00Z","reference_number":"EMA/866697/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-fyzoclad-adalimumab_sv.pdf"}},
    {"id":"43063","name":"Questions and answers on the withdrawal of the marketing authorisation application for Canakinumab Novartis (canakinumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/865778/2018","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_sv.pdf"}},
    {"id":"43577","name":"Questions and answers on the withdrawal of the marketing authorisation application for Cavoley (pegfilgrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T16:22:00Z","last_updated_date":"2019-04-05T09:48:00Z","reference_number":"EMA/912779/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_sv.pdf-0"}},
    {"id":"43579","name":"Questions and answers on the withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T16:39:00Z","last_updated_date":"2019-04-05T09:24:00Z","reference_number":"EMA/912780/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_sv.pdf-0"}},
    {"id":"43608","name":"Questions and answers on the withdrawal of the marketing authorisation application for Vynpenta (avacopan)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T12:55:00Z","last_updated_date":"2020-05-15T02:00:00Z","reference_number":"EMA/38410/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_sv.pdf"}},
    {"id":"43957","name":"Questions and answers on the withdrawal of the marketing authorisation application for Epjevy (pacritinib citrate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-03-01T12:42:00Z","last_updated_date":"2019-03-01T12:42:00Z","reference_number":"EMA/142005/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-epjevy-pacritinib-citrate_en.pdf"},
    {"id":"44602","name":"Questions and answers on the withdrawal of the marketing authorisation application for Ambrisentan Zentiva (ambrisentan)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T16:27:00Z","last_updated_date":"2019-05-29T16:27:00Z","reference_number":"EMA/249121/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-ambrisentan-zentiva-ambrisentan_en.pdf"},
    {"id":"44621","name":"Questions and answers on the withdrawal of the marketing authorisation application for Radicava (edaravone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T19:00:00Z","last_updated_date":"2019-05-29T19:00:00Z","reference_number":"EMA/293450/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-radicava-edaravone_sv.pdf"}},
    {"id":"44939","name":"Questions and answers on the withdrawal of the marketing authorisation application for ABP 710 (infliximab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T12:00:00Z","last_updated_date":"2019-06-28T12:00:00Z","reference_number":"EMA/357148/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-abp-710-infliximab_en.pdf"},
    {"id":"45744","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Xyndari (glutamine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T16:23:00Z","last_updated_date":"2019-10-18T16:23:00Z","reference_number":"EMA/521995/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xyndari-glutamine_sv.pdf"}},
    {"id":"45745","name":"Questions and answers on the approval of the marketing authorisation for Evenity (romosozumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T16:46:00Z","last_updated_date":"2019-10-18T16:46:00Z","reference_number":"EMA/565564/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-approval-marketing-authorisation-evenity-romosozumab_en.pdf"},
    {"id":"45749","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Nuzyra (omadacycline)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T17:54:00Z","last_updated_date":"2019-10-18T17:54:00Z","reference_number":"EMA/556620/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_sv.pdf"}},
    {"id":"45758","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Ekesivy (diclofenamide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T11:04:00Z","last_updated_date":"2019-10-18T11:04:00Z","reference_number":"EMA/560142/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-ekesivy-diclofenamide_sv.pdf"}},
    {"id":"45952","name":"Responses to questions raised at the Bravecto petition hand over","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-11-08T15:29:00Z","last_updated_date":"2019-11-08T15:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/responses-questions-raised-bravecto-petition-hand-over_en.pdf"},
    {"id":"46020","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Linhaliq (ciprofloxacin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T13:37:00Z","last_updated_date":"2019-11-15T13:37:00Z","reference_number":"EMA/610519/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-linhaliq-ciprofloxacin_sv.pdf"}},
    {"id":"46022","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Luxceptar (viable T-cells)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T14:43:00Z","last_updated_date":"2019-11-15T14:43:00Z","reference_number":"EMA/603662/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-luxceptar-viable-t-cells_sv.pdf"}},
    {"id":"46023","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Opsumit (macitentan)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T14:51:00Z","last_updated_date":"2019-11-15T14:51:00Z","reference_number":"EMA/613378/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-opsumit-macitentan_sv.pdf"}},
    {"id":"46642","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Keytruda (pembrolizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-01-31T09:29:00Z","last_updated_date":"2020-03-19T17:08:00Z","reference_number":"EMA/673300/2019","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-keytruda-pembrolizumab_sv.pdf"}},
    {"id":"46645","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Idhifa (enasidenib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-01-31T10:03:00Z","last_updated_date":"2020-01-31T10:03:00Z","reference_number":"EMA/47029/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_sv.pdf"}},
    {"id":"46899","name":"Withdrawal of application to change the marketing authorisation for Opdivo (nivolumab) and Yervoy (ipilimumab)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2020-02-28T11:02:00Z","last_updated_date":"2020-02-28T11:02:00Z","reference_number":"EMA/92336/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_sv.pdf"}},
    {"id":"46902","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Axumin (fluciclovine (18F)) (II-11)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T11:12:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/88420/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-axumin-fluciclovine-18f-ii-11_sv.pdf"}},
    {"id":"47166","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Doxorubicin Hydrochloride Tillomed (doxorubicin hydrochloride pegylated liposomal concentrate  for dispersion for infusion, 2 mg/ml)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T13:40:00Z","last_updated_date":"2020-03-27T13:40:00Z","reference_number":"EMA/142714/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-doxorubicin-hydrochloride-tillomed-doxorubicin-hydrochloride-pegylated-liposomal-concentrate-dispersion-infusion-2-mgml_sv.pdf"}},
    {"id":"47222","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Rituximab Mabion","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-03-30T15:32:00Z","last_updated_date":"2020-06-24T02:00:00Z","reference_number":"EMA/163447/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rituximab-mabion_sv.pdf"}},
    {"id":"47549","name":"Questions and answers on the use of Keytruda alone in non-small cell lung cancer with low levels of PD-L1","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/233126/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-use-keytruda-alone-non-small-cell-lung-cancer-low-levels-pd-l1_sv.pdf"}},
    {"id":"47803","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Fingolimod Mylan (fingolimod)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/256974/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-fingolimod-mylan-fingolimod_sv.pdf"}},
    {"id":"47806","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Erlotinib Accord (erlotinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T17:08:00Z","last_updated_date":"2020-05-29T17:08:00Z","reference_number":"EMA/278694/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-erlotinib-accord-erlotinib_en.pdf"},
    {"id":"47811","name":"Questions and answers on the use of Vokanamet in diabetic kidney disease","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-06-02T08:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-use-vokanamet-diabetic-kidney-disease_en.pdf"},
    {"id":"47817","name":"Questions and answers on the use of Trumenba in children between 1 and 9 years of age","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/147694/2020 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-use-trumenba-children-between-1-and-9-years-age_en.pdf"},
    {"id":"48129","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Sondelbay (teriparatide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-09-28T15:47:00Z","reference_number":"EMA/338421/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sondelbay-teriparatide_sv.pdf"}},
    {"id":"48142","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Zemdri (plazomicin)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/333752/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zemdri-plazomicin_en.pdf"},
    {"id":"48144","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Xiidra","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-07-14T16:23:00Z","reference_number":"EMA/334810/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_sv.pdf"}},
    {"id":"48381","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Rayoqta (abicipar pegol)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T12:12:00Z","last_updated_date":"2020-07-24T12:12:00Z","reference_number":"EMA/389021/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-rayoqta-abicipar-pegol_sv.pdf"}},
    {"id":"48388","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Abilify MyCite (aripiprazole)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T09:27:00Z","last_updated_date":"2020-07-24T09:27:00Z","reference_number":"EMA/390789/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_sv.pdf"}},
    {"id":"48389","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Abilify MyCite (aripiprazole)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T09:27:00Z","last_updated_date":"2020-07-24T09:27:00Z","reference_number":"EMA/390789/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-abilify-mycite-aripiprazole_en.pdf-0"},
    {"id":"48397","name":"Questions and answers on the use of Votubia in children from 6 months of age","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T12:05:00Z","last_updated_date":"2020-07-24T12:05:00Z","reference_number":"EMA/393579/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-use-votubia-children-6-months-age_sv.pdf"}},
    {"id":"48847","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Upkanz (deferiprone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-09-18T17:53:00Z","last_updated_date":"2020-09-18T17:53:00Z","reference_number":"EMA/463431/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-upkanz-deferiprone_sv.pdf"}},
    {"id":"49233","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Puldysa (idebenone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T14:05:00Z","last_updated_date":"2020-11-13T14:05:00Z","reference_number":"EMA/594092/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-puldysa-idebenone_sv.pdf"}},
    {"id":"49239","name":"Questions and answers on the withdrawal of application for the marketing authorisation for Roctavian (valoctocogene roxaparvovec)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T14:52:00Z","last_updated_date":"2020-11-13T14:52:00Z","reference_number":"EMA/592291/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-roctavian-valoctocogene-roxaparvovec_en.pdf"},
    {"id":"49240","name":"Questions and answers on the withdrawal for the marketing authorisation of Tibsovo (ivosidenib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T14:44:00Z","last_updated_date":"2021-04-16T15:04:00Z","reference_number":"EMA/577847/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_sv.pdf"}},
    {"id":"49536","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Artobend (autologous human chondrocytes in vitro expanded)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/661149/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-artobend-autologous-human-chondrocytes-vitro-expanded_en.pdf"},
    {"id":"49992","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Dexamethasone Taw (dexamethasone phosphate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-01-29T15:41:00Z","last_updated_date":"2021-01-29T15:41:00Z","reference_number":"EMA/49981/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dexamethasone-taw-dexamethasone-phosphate_sv.pdf"}},
    {"id":"50012","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for for Tecentriq (atezolizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-02-01T10:55:00Z","last_updated_date":"2021-02-01T10:55:00Z","reference_number":"EMA/47544/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tecentriq-atezolizumab_en.pdf-0"},
    {"id":"50718","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for for Brilique (ticagrelor)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-03-26T16:54:00Z","last_updated_date":"2021-05-25T17:25:00Z","reference_number":"EMA/170569/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-brilique-ticagrelor_sv.pdf"}},
    {"id":"51591","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Esbriet (pirfenidone) (II-69)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-06-25T16:25:00Z","last_updated_date":"2021-06-25T16:25:00Z","reference_number":"EMA/354062/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-esbriet-pirfenidone-ii-69_sv.pdf"}},
    {"id":"52032","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Tecentriq (atezolizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-07-23T18:35:00Z","last_updated_date":"2021-07-23T18:35:00Z","reference_number":"EMA/409715/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-tecentriq-atezolizumab_en.pdf-1"},
    {"id":"52462","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Livmarli (maralixibat chloride)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/507929/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-livmarli-maralixibat-chloride_sv.pdf"}},
    {"id":"52466","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Oportuzumab monatox DLRC Pharma Services (oportuzumab monatox)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/508191/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-oportuzumab-monatox-dlrc-pharma-services-oportuzumab-monatox_sv.pdf"}},
    {"id":"52472","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Teriparatide Cinnagen (teriparatide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T16:15:00Z","last_updated_date":"2021-09-17T16:15:00Z","reference_number":"EMA/509904/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-teriparatide-cinnagen-teriparatide_en.pdf"},
    {"id":"52478","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Sildenafil FGK (sildenafil)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T16:56:00Z","last_updated_date":"2021-09-17T16:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sildenafil-fgk-sildenafil_sv.pdf"}},
    {"id":"52813","name":"Questions and answers on end of rolling review for CureVac’s COVID-19 vaccine (CVnCoV)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-10-12T15:05:00Z","last_updated_date":"2021-10-12T15:05:00Z","reference_number":"EMA/576752/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-end-rolling-review-curevacs-covid-19-vaccine-cvncov_en.pdf"},
    {"id":"52855","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Zynyz","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-10-15T09:14:00Z","last_updated_date":"2021-10-15T09:14:00Z","reference_number":"EMA/577902/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zynyz_sv.pdf"}},
    {"id":"52971","name":"Questions and answers on end of rolling review for antibodies bamlanivimab and etesevimab for COVID-19","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-11-02T15:05:00Z","last_updated_date":"2021-11-02T15:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-end-rolling-review-antibodies-bamlanivimab-and-etesevimab-covid-19_en.pdf"},
    {"id":"53080","name":"Questions and answers on the withdrawal for the marketing authorisation of Flynpovi (eflornithine / sulindac)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T15:57:00Z","last_updated_date":"2021-11-12T15:57:00Z","reference_number":"EMA/627715/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_cs.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-flynpovi-eflornithine-sulindac_sv.pdf"}},
    {"id":"53105","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Cervarix (human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed))","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T11:13:00Z","last_updated_date":"2021-11-12T11:13:00Z","reference_number":"EMA/627371/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-cervarix-human-papillomavirus-vaccine-types-16-18-recombinant-adjuvanted-adsorbed_sv.pdf"}},
    {"id":"53547","name":"Questions and answers on the withdrawal for the marketing authorisation of Zektayos-Hepjuvo (obeticholic acid)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2021-12-17T10:28:00Z","last_updated_date":"2022-04-08T14:25:00Z","reference_number":"EMA/747864/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-zektayos-hepjuvo-obeticholic-acid_sv.pdf"}},
    {"id":"53576","name":"Questions and answers on the refusal of the marketing authorisation for Aduhelm (aducanumab)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T08:59:00Z","last_updated_date":"2022-02-25T12:05:00Z","reference_number":"EMA/750220/2021 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-refusal-marketing-authorisation-aduhelm-aducanumab_en.pdf"},
    {"id":"53953","name":"Questions and answers on the withdrawal for the marketing authorisation of Tookad (padelifporfin) (II-13)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T14:21:00Z","last_updated_date":"2022-01-28T14:21:00Z","reference_number":"EMA/748951/2021","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tookad-padelifporfin-ii-13_en.pdf"},
    {"id":"53958","name":"Questions and answers on the withdrawal for the marketing authorisation of  Brilique (ticagrelor)  (II-49)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T15:04:00Z","last_updated_date":"2022-01-28T15:04:00Z","reference_number":"EMA/10049/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-brilique-ticagrelor-ii-49_en.pdf"},
    {"id":"53973","name":"Questions and answers on the withdrawal for the marketing authorisation of Abylqis (Arachis hypogaea extract)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T19:17:00Z","last_updated_date":"2022-11-23T09:37:00Z","reference_number":"EMA/45097/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-abylqis-arachis-hypogaea-extract_sv.pdf"}},
    {"id":"53991","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Aliqopa (copanlisib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T12:00:00Z","last_updated_date":"2022-01-28T12:00:00Z","reference_number":"EMA/38839/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aliqopa-copanlisib_sv.pdf"}},
    {"id":"54562","name":"Questions and answers on the outcome of assessment on use of Vyxeos liposomal in the treatment of relapsed or refractory acute myeloid leukaemia (II-18-G)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T16:59:00Z","last_updated_date":"2022-03-25T16:59:00Z","reference_number":"EMA/179542/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-outcome-assessment-use-vyxeos-liposomal-treatment-relapsed-or-refractory-acute-myeloid-leukaemia-ii-18-g_en.pdf"},
    {"id":"54585","name":"Questions and answers on the withdrawal for the marketing authorisation of Dimherity (dimethyl fumarate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T10:40:00Z","last_updated_date":"2022-11-03T10:04:00Z","reference_number":"EMA/173087/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-dimherity-dimethyl-fumarate_sv.pdf"}},
    {"id":"54786","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Miplyffa (arimoclomol)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T12:00:00Z","last_updated_date":"2022-04-22T12:00:00Z","reference_number":"EMA/219136/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-miplyffa-arimoclomol_sv.pdf"}},
    {"id":"54791","name":"Questions and answers on the refusal of the marketing authorisation for Flynpovi  (eflornithine / sulindac)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T09:17:00Z","last_updated_date":"2021-07-23T09:17:00Z","reference_number":"EMA/350828/2021 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-refusal-marketing-authorisation-flynpovi-eflornithine-sulindac_en.pdf"},
    {"id":"54795","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Neffy (adrenaline)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T12:00:00Z","last_updated_date":"2022-05-20T16:36:00Z","reference_number":"EMA/222587/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-neffy-adrenaline_sv.pdf"}},
    {"id":"54798","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Aduhelm (aducanumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T10:53:00Z","last_updated_date":"2022-04-22T10:53:00Z","reference_number":"EMA/225498/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-aduhelm-aducanumab_sv.pdf"}},
    {"id":"55022","name":"Questions and answers on the withdrawal for the marketing authorisation of HemAryo (eptacog alfa (activated))","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-09-27T09:28:00Z","reference_number":"EMA/267926/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hemaryo-eptacog-alfa-activated_sv.pdf"}},
    {"id":"55038","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Sitoiganap (allogeneic and autologous haptenised and irradiated cells and cell lysates derived from glioma)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T10:53:00Z","last_updated_date":"2022-05-20T10:53:00Z","reference_number":"EMA/266354/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sitoiganap-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma_sv.pdf"}},
    {"id":"55624","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Imcivree (setmelanotide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T15:52:00Z","last_updated_date":"2022-09-28T10:26:00Z","reference_number":"EMA/687359/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imcivree-setmelanotide_sv.pdf"}},
    {"id":"55637","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Parsaclisib Incyte Biosciences Distribution B.V. (parsaclisib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T12:00:00Z","last_updated_date":"2022-11-08T14:41:00Z","reference_number":"EMA/641196/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-parsaclisib-incyte-biosciences-distribution-bv-parsaclisib_sv.pdf"}},
    {"id":"55841","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Sevsury (surufatinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-08-19T10:53:00Z","last_updated_date":"2022-11-16T11:20:00Z","reference_number":"EMA/685599/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-sevsury-surufatinib_sv.pdf"}},
    {"id":"55842","name":"Questions and answers on the withdrawal for the marketing authorisation of Exkivity (mobocertinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-08-19T09:37:00Z","last_updated_date":"2022-11-24T12:12:00Z","reference_number":"EMA/665807/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-exkivity-mobocertinib_sv.pdf"}},
    {"id":"56413","name":"Questions and answers on the withdrawal for the marketing authorisation of Hervelous (trastuzumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-10-14T11:43:00Z","last_updated_date":"2022-12-13T12:00:00Z","reference_number":"EMA/807465/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-hervelous-trastuzumab_sv.pdf"}},
    {"id":"56416","name":"Questions and answers on the withdrawal for the marketing authorisation of Tuznue (trastuzumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-10-14T11:55:00Z","last_updated_date":"2022-12-13T15:28:00Z","reference_number":"EMA/807453/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-tuznue-trastuzumab_sv.pdf"}},
    {"id":"56578","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Orepaxam (treprostinil diolamine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T14:57:00Z","last_updated_date":"2022-11-11T14:57:00Z","reference_number":"EMA/861343/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-orepaxam-treprostinil-diolamine_en.pdf"},
    {"id":"56579","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Ilaris (canakinumab) (II-0075)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T15:52:00Z","last_updated_date":"2023-02-23T10:43:00Z","reference_number":"EMEA/H/C/001109/II/75","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-ilaris-canakinumab-ii-0075_sv.pdf"}},
    {"id":"56587","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Gavreto (pralsetinib) (II-0002-G)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T08:58:00Z","last_updated_date":"2023-02-02T16:37:00Z","reference_number":"EMA/876364/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gavreto-pralsetinib-ii-0002-g_sv.pdf"}},
    {"id":"56589","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Febseltiq (infigratinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T09:11:00Z","last_updated_date":"2023-01-30T10:11:00Z","reference_number":"EMA/870501/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-febseltiq-infigratinib_sv.pdf"}},
    {"id":"56994","name":"Questions and answers on the withdrawal for the marketing authorisation of Imbarkyd (bardoxolone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T11:34:00Z","last_updated_date":"2023-02-07T12:34:00Z","reference_number":"EMA/913652/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-imbarkyd-bardoxolone_sv.pdf"}},
    {"id":"57032","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Olumiant (baricitinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2023-02-02T13:08:00Z","reference_number":"EMA/931846/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_sv.pdf"}},
    {"id":"57379","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Imbruvica (ibrutinib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/933469/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-imbruvica-ibrutinib_en.pdf"},
    {"id":"57809","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Buvidal (buprenorphine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-02-24T12:00:00Z","last_updated_date":"2023-06-14T12:36:00Z","reference_number":"EMA/76139/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-buvidal-buprenorphine_sv.pdf"}},
    {"id":"57842","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Garsun (artesunate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-03-01T11:46:00Z","last_updated_date":"2023-03-01T11:46:00Z","reference_number":"EMA/939492/2022","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-garsun-artesunate_sv.pdf"}},
    {"id":"58228","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Raltegravir Viatris (raltegravir)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-04-21T14:42:00Z","reference_number":"EMA/141471/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-raltegravir-viatris-raltegravir_sv.pdf"}},
    {"id":"58232","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Feraheme (ferumoxytol)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T16:47:00Z","last_updated_date":"2023-07-11T13:54:00Z","reference_number":"EMA/142149/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-feraheme-ferumoxytol_sv.pdf"}},
    {"id":"58519","name":"Questions and answers on Vey Tosal 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats and associated names (butafosfan, cyanocobalamin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-04-25T12:12:00Z","last_updated_date":"2023-04-25T12:12:00Z","reference_number":"EMA/144351/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-vey-tosal-100-mgml-005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_sv.pdf"}},
    {"id":"58526","name":"Questions and answers on Catophos 100 mg/ml+0.05 mg/ml solution for injection for horses, cattle, dogs and cats and associated names (butafosfan, cyanocobalamin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-04-25T17:26:00Z","last_updated_date":"2023-04-25T17:26:00Z","reference_number":"EMA/144348/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-catophos-100-mgml005-mgml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names-butafosfan-cyanocobalamin_sv.pdf"}},
    {"id":"58540","name":"Questions and answers on the outcome of assessment on use of Epidyolex (cannabidiol)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2023-04-28T08:40:00Z","last_updated_date":"2023-04-28T08:40:00Z","reference_number":"EMA/186960/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-outcome-assessment-use-epidyolex-cannabidiol_en.pdf"},
    {"id":"58542","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Lumevoq (lenadogene nolparvovec)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-04-26T16:27:00Z","last_updated_date":"2023-04-26T16:27:00Z","reference_number":"EMA/186712/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lumevoq-lenadogene-nolparvovec_sv.pdf"}},
    {"id":"58788","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Asimtufii (aripiprazole)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T12:00:00Z","last_updated_date":"2023-07-07T16:23:00Z","reference_number":"EMA/225109/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-asimtufii-aripiprazole_sv.pdf"}},
    {"id":"58791","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Susvimo (Port Delivery System with ranibizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T13:46:00Z","last_updated_date":"2023-05-26T13:46:00Z","reference_number":"EMA/224686/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-susvimo-port-delivery-system-ranibizumab_sv.pdf"}},
    {"id":"59054","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Zefylti (filgrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T12:00:00Z","last_updated_date":"2023-08-30T14:56:00Z","reference_number":"EMA/278188/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-zefylti-filgrastim_sv.pdf"}}    {"id":"59058","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Dyrupeg (pegfilgrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T12:00:00Z","last_updated_date":"2023-06-23T12:00:00Z","reference_number":"EMA/274951/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-dyrupeg-pegfilgrastim_sv.pdf"}},
    {"id":"59075","name":"Outcome of application to extend use of Ofev (nintedanib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T12:44:00Z","last_updated_date":"2023-06-23T12:44:00Z","reference_number":"EMA/279846/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/outcome-application-extend-use-ofev-nintedanib_en.pdf"},
    {"id":"59116","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Lagevrio (molnupiravir)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-06-27T13:48:00Z","last_updated_date":"2023-08-09T10:46:00Z","reference_number":"EMA/290450/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lagevrio-molnupiravir_sv.pdf"}},
    {"id":"59431","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Gazyvaro (obinutuzumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T13:46:00Z","last_updated_date":"2023-10-04T16:43:00Z","reference_number":"EMEA/328985/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-gazyvaro-obinutuzumab_sv.pdf"}},
    {"id":"59450","name":"Questions and asnwers on the withdrawal of application for the marketing authorisation of Jesduvroq (daprodustat)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T10:47:00Z","last_updated_date":"2023-12-13T09:23:00Z","reference_number":"EMA/329320/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-asnwers-withdrawal-application-marketing-authorisation-jesduvroq-daprodustat_sv.pdf"}},
    {"id":"59608","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Lutholaz (pegfilgrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-08-18T12:44:00Z","last_updated_date":"2023-11-07T15:08:00Z","reference_number":"EMA/352990/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-lutholaz-pegfilgrastim_sv.pdf"}},
    {"id":"59984","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Skycovion (COVID-19 vaccine [recombinant, adjuvanted])","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T15:24:00Z","last_updated_date":"2025-01-22T14:25:34Z","reference_number":"EMA/405317/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-skycovion-covid-19-vaccine-recombinant-adjuvanted_sv.pdf"}},
    {"id":"59998","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Iclusig","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T12:00:00Z","last_updated_date":"2023-11-30T18:23:00Z","reference_number":"EMA/406725/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-iclusig_sv.pdf"}},
    {"id":"60024","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Vivjoa (oteseconazole)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T10:59:00Z","last_updated_date":"2023-10-23T16:04:00Z","reference_number":"EMA/388456/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-vivjoa-oteseconazole_sv.pdf"}},
    {"id":"60410","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Jivadco (trastuzumab duocarmazine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-11-23T12:00:00Z","reference_number":"EMA/456294/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-jivadco-trastuzumab-duocarmazine_sv.pdf"}},
    {"id":"60411","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Sugammadex Lorien (sugammadex)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2024-02-08T10:50:00Z","reference_number":"EMA/450337/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-sugammadex-lorien-sugammadex_sv.pdf"}},
    {"id":"60413","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for RoActemra (tocilizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-11-07T17:43:00Z","reference_number":"EMA/452221/2023 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-roactemra-tocilizumab_sv.pdf"}},
    {"id":"60831","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Vijoice (alpelisib)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T15:40:00Z","last_updated_date":"2024-03-14T10:45:00Z","reference_number":"EMA/492147/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_sv.pdf"}},
    {"id":"60908","name":"Questions and answers on the outcome of assessment on use of Moventig (naloxegol) in treatment of constipation due to opioids","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-11-13T16:19:00Z","last_updated_date":"2023-11-13T16:19:00Z","reference_number":"EMA/488713/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-outcome-assessment-use-moventig-naloxegol-treatment-constipation-due-opioids_en.pdf"},
    {"id":"61024","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Bylvay (odevixibat) ","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2023-11-20T17:21:35Z","last_updated_date":"2023-11-20T17:21:35Z","reference_number":"EMA/492792/2023","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-change-marketing-authorisation-bylvay-odevixibat_en.pdf"},
    {"id":"62691","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Orencia (abatacept)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T17:40:53Z","last_updated_date":"2024-04-08T10:46:00Z","reference_number":"EMA/111484/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-orencia-abatacept_sv.pdf"}},
    {"id":"62699","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Adcetris (brentuximab vedotin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T10:38:13Z","last_updated_date":"2024-07-18T12:16:00Z","reference_number":"EMA/116069/2024 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-adcetris-brentuximab-vedotin_sv.pdf"}},
    {"id":"62704","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Ontilyv (opicapone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T12:08:28Z","last_updated_date":"2024-09-18T13:00:00Z","reference_number":"EMA/122577/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ontilyv-opicapone_sv.pdf"}},
    {"id":"62705","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Ongentys (opicapone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T12:16:42Z","last_updated_date":"2024-09-18T12:42:00Z","reference_number":"EMA/114749/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ongentys-opicapone_sv.pdf"}},
    {"id":"63090","name":"Questions and answers on the withdrawal of application for the marketing authorisation of GeGant (germanium [68Ge] chloride /gallium [68Ga] chloride)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2025-02-26T13:44:00Z","reference_number":"EMA/171931/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-gegant-germanium-68ge-chloride-gallium-68ga-chloride_sv.pdf"}},
    {"id":"63419","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Kinharto (omecamtiv mecarbil)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T13:00:00Z","last_updated_date":"2024-09-30T10:55:00Z","reference_number":"EMA/239769/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-kinharto-omecamtiv-mecarbil_fi.pdf"}},
    {"id":"63422","name":"Questions and answers on the outcome of assessment to extend the use of Valdoxan (agomelatine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T12:00:22Z","last_updated_date":"2024-05-31T12:00:22Z","reference_number":"EMA/248654/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-outcome-assessment-extend-use-valdoxan-agomelatine_en.pdf"},
    {"id":"63430","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Scenesse (afamelanotide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T10:46:54Z","last_updated_date":"2026-03-05T15:33:00Z","reference_number":"EMA/243052/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-scenesse-afamelanotide_sv.pdf"}},
    {"id":"63792","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Dabigatran etexilate Teva","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/296655/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dabigatran-etexilate-teva_en.pdf"},
    {"id":"64337","name":"Questions and answers on the outcome of assessment to extend the use of Wegovy (semaglutide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-07-26T11:22:43Z","last_updated_date":"2024-07-26T11:22:43Z","reference_number":"EMA/340123/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-outcome-assessment-extend-use-wegovy-semaglutide_en.pdf"},
    {"id":"64956","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Durysta (bimatoprost intracameral implant)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T11:11:11Z","last_updated_date":"2024-12-16T15:01:24Z","reference_number":"EMA/433446/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-durysta-bimatoprost-intracameral-implant_sv.pdf"}},
    {"id":"64960","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Tecentriq (II-81)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T09:54:40Z","last_updated_date":"2024-09-20T09:54:40Z","reference_number":"EMA/426039/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tecentriq-ii-81_en.pdf"},
    {"id":"64962","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Sialanar (glycopyrronium bromide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T10:31:24Z","last_updated_date":"2024-09-20T10:31:24Z","reference_number":"EMA/429177/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-sialanar-glycopyrronium-bromide_en.pdf"},
    {"id":"65317","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Apremilast Viatris (apremilast)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T11:11:01Z","last_updated_date":"2025-01-06T13:04:00Z","reference_number":"EMA/469906/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-apremilast-viatris-apremilast_sv.pdf"}},
    {"id":"65344","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Epixram ","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2025-01-09T14:11:48Z","reference_number":"EMA/475293/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-epixram_sv.pdf"}},
    {"id":"65647","name":"Questions and answers on: the approval of the marketing authorisation for Leqembi (lecanemab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-11-14T16:25:39Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/36867/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-approval-marketing-authorisation-leqembi-lecanemab_en.pdf"},
    {"id":"65659","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Izelvay","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2025-02-04T16:20:00Z","reference_number":"EMA/522714/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-izelvay_sv.pdf"}},
    {"id":"65667","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Inaqovi (II-0002)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2025-06-17T09:41:00Z","reference_number":"EMA/521354/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_de.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-inaqovi-ii-0002_sv.pdf"}},
    {"id":"66099","name":"Questions and answers on the outcome of assessment on use of Mounjaro in treatment of obstructive sleep apnoea","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2024-12-13T09:36:14Z","last_updated_date":"2024-12-13T09:36:14Z","reference_number":"EMA/576853/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-outcome-assessment-use-mounjaro-treatment-obstructive-sleep-apnoea_en.pdf"},
    {"id":"66548","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Nugalviq (govorestat)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2026-06-04T13:20:00Z","reference_number":"EMA/33759/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nugalviq-govorestat_sv.pdf"}},
    {"id":"66550","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Datopotamab deruxtecan Daiichi Sankyo  (datopotamab deruxtecan)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-11-11T13:15:00Z","reference_number":"EMA/34483/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-datopotamab-deruxtecan-daiichi-sankyo-datopotamab-deruxtecan_sv.pdf"}},
    {"id":"67032","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Rilonacept FGK Representative Service GmbH (rilonacept)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T12:01:05Z","last_updated_date":"2025-07-04T16:00:00Z","reference_number":"EMA/64310/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-rilonacept-fgk-representative-service-gmbh-rilonacept_sv.pdf"}},
    {"id":"67039","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Pelgraz Paediatric (pegfilgrastim)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T10:19:50Z","last_updated_date":"2025-06-04T10:19:50Z","reference_number":"EMA/67546/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-pelgraz-paediatric-pegfilgrastim_sv.pdf"}},
    {"id":"67048","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Bimervax (COVID-19 vaccine (recombinant, adjuvanted)) (II-0016)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T11:48:46Z","last_updated_date":"2025-02-28T11:48:46Z","reference_number":"EMA/66891/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-bimervax-covid-19-vaccine-recombinant-adjuvanted-ii-0016_en.pdf"},
    {"id":"67050","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Dupixent (dupilumab) (II-0083)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T11:51:01Z","last_updated_date":"2025-11-07T11:40:00Z","reference_number":"EMA/68277/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-dupixent-dupilumab-ii-0083_sv.pdf"}},
    {"id":"67499","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Cinainu (extracts from Allium cepa (onion) fresh bulb and Citrus limon (lemon) fresh fruit, Paullinia cupana (guarana) seed, and Theobroma cacao (cocoa) seed)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-05-26T12:00:00Z","reference_number":"EMA/90850/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_sv.pdf"}},
    {"id":"67519","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Amyvid (florbetapir (18F)) (II-0046)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-05-28T12:00:00Z","reference_number":"EMA/100425/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-amyvid-florbetapir-18f-ii-0046_sv.pdf"}},
    {"id":"67525","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Insulin Human Rechon (insulin human)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T11:05:51Z","last_updated_date":"2025-03-28T11:05:51Z","reference_number":"EMA/100240/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-human-rechon-insulin-human_en.pdf"},
    {"id":"67993","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Ngenla (somatrogon) (II-16)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-04-25T14:25:01Z","last_updated_date":"2025-04-25T14:25:01Z","reference_number":"EMA/134483/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-ngenla-somatrogon-ii-16_en.pdf"},
    {"id":"67994","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Dazluma (troriluzole hydrochloride monohydrate)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2026-06-24T17:00:00Z","reference_number":"EMA/128274/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-dazluma-troriluzole-hydrochloride-monohydrate_sv.pdf"}},
    {"id":"68395","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for Lutathera (lutetium (177Lu) oxodotreotide) (II-52)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T09:29:10Z","last_updated_date":"2025-06-27T15:06:00Z","reference_number":"EMA/164684/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-ii-52_sv.pdf"}},
    {"id":"68397","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Teriparatide Ascend (teriparatide)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T09:44:17Z","last_updated_date":"2025-05-23T09:44:17Z","reference_number":"EMA/168367/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-teriparatide-ascend-teriparatide_en.pdf"},
    {"id":"69001","name":"Questions and answers on the outcome of assessment on use of Revolade in treatment of severe aplastic anaemia in children","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2025-06-27T10:49:36Z","last_updated_date":"2025-08-27T12:56:00Z","reference_number":"EMA/203280/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-outcome-assessment-use-revolade-treatment-severe-aplastic-anaemia-children_sv.pdf"}},
    {"id":"69445","name":"Questions and answers on the refusal of the marketing authorisation for Elevidys (delandistrogene moxeparvovec)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T15:51:05Z","last_updated_date":"2025-10-20T16:37:00Z","reference_number":"EMA/237523/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_sv.pdf"}},
    {"id":"69448","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Nidlegy (bifikafusp alfa / onfekafusp alfa)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T15:59:17Z","last_updated_date":"2025-10-01T14:22:00Z","reference_number":"EMA/CHMP/242757/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nidlegy-bifikafusp-alfa-onfekafusp-alfa_sv.pdf"}},
    {"id":"69455","name":"Questions and answers on the outcome of assessment on use of Neuraceq to monitor treatment response","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T12:24:24Z","last_updated_date":"2025-07-25T12:24:24Z","reference_number":"EMA/310493/2020","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-outcome-assessment-use-neuraceq-monitor-treatment-response_en.pdf"},
    {"id":"69473","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Aplidin (plitidepsin)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T09:28:40Z","last_updated_date":"2025-10-06T16:25:00Z","reference_number":"EMA/243003/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-aplidin-plitidepsin_sv.pdf"}},
    {"id":"69488","name":"Questions and answers on the approval of the marketing authorisation for Kisunla (donanemab) - Outcome of re-examination","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T11:06:57Z","last_updated_date":"2025-07-25T11:06:57Z","reference_number":"EMA/239081/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-approval-marketing-authorisation-kisunla-donanemab-outcome-re-examination_en.pdf"},
    {"id":"69501","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Ifinwil (eflornithine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T14:45:39Z","last_updated_date":"2025-07-25T14:45:39Z","reference_number":"EMA/238203/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-ifinwil-eflornithine_en.pdf"},
    {"id":"69843","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Amtagvi (lifileucel)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-08-22T12:00:08Z","last_updated_date":"2025-10-23T13:55:00Z","reference_number":"EMA/241567/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-amtagvi-lifileucel_sv.pdf"}},
    {"id":"69844","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Fanskya (Mozafancogene autotemcel)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-08-22T12:00:11Z","last_updated_date":"2025-10-27T15:20:00Z","reference_number":"EMA/270385/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_sv.pdf"}},
    {"id":"69855","name":"Questions and answers on the approval of the marketing authorisation for Winlevi (clascoterone)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-08-26T14:00:00Z","last_updated_date":"2025-08-26T14:00:00Z","reference_number":"EMA/277213/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-approval-marketing-authorisation-winlevi-clascoterone_en.pdf"},
    {"id":"70171","name":"Questions and answer on the outcome of assessment on use of Lutathera in treatment of gastro-entero-pancreatic neuroendocrine tumours in adolescents","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2025-11-12T16:08:00Z","reference_number":"EMA/299422/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answer-outcome-assessment-use-lutathera-treatment-gastro-entero-pancreatic-neuroendocrine-tumours-adolescents_sv.pdf"}},
    {"id":"70177","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Omforro (midazolam)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T08:47:25Z","last_updated_date":"2025-12-16T12:38:08Z","reference_number":"EMA/300796/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-omforro-midazolam_sv.pdf"}},
    {"id":"70178","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Tuzodi (midazolam)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T08:48:57Z","last_updated_date":"2025-12-04T09:27:00Z","reference_number":"EMA/301698/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-tuzodi-midazolam_sv.pdf"}},
    {"id":"70531","name":"Questions and answers on the refusal of the marketing authorisation for Syfovre (pegcetacoplan)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-10-10T17:53:42Z","last_updated_date":"2025-10-30T17:15:00Z","reference_number":"EMA/432931/2024","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_sv.pdf"}},
    {"id":"70602","name":"Questions and answers on the withdrawal of Hydrocortisone Aguettant ","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-10-17T14:30:46Z","last_updated_date":"2025-10-17T14:30:46Z","reference_number":"EMA/318340/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-hydrocortisone-aguettant_en.pdf"},
    {"id":"71170","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Ohtuvayre (ensifentrine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-11-14T10:49:24Z","last_updated_date":"2025-11-14T10:49:24Z","reference_number":"EMA/363153/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-ohtuvayre-ensifentrine_en.pdf"},
    {"id":"71178","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Insulin Aspart Injection (insulin aspart)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-11-14T11:52:27Z","last_updated_date":"2026-06-05T09:00:00Z","reference_number":"EMA/356296/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-insulin-aspart-injection-insulin-aspart_sv.pdf"}},
    {"id":"71179","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Nurzigma (pridopidine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-11-14T12:18:10Z","last_updated_date":"2026-01-09T11:18:08Z","reference_number":"EMA/358840/2025","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_sv.pdf"}},
    {"id":"71716","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Jelrix (cartilage-forming cells, autologous)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T10:34:35Z","last_updated_date":"2026-04-15T16:10:00Z","reference_number":"EMEA/H/C/004594","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_sv.pdf"}},
    {"id":"72374","name":"Questions and answers on the approval of the marketing authorisation for Rezurock (belumosudil)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T11:16:33Z","last_updated_date":"2026-01-30T11:16:33Z","reference_number":"EMEA/H/C/006421","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-approval-marketing-authorisation-rezurock-belumosudil_en.pdf"},
    {"id":"72384","name":"Questions and answers on the outcome of assessment on use of Mounjaro in treatment of heart failure with preserved ejection fraction in adults with obesity","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T12:00:00Z","last_updated_date":"2026-01-30T12:00:00Z","reference_number":"EMA/18704/2026","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-outcome-assessment-use-mounjaro-treatment-heart-failure-preserved-ejection-fraction-adults-obesity_en.pdf"},
    {"id":"72727","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Zumrad (sasanlimab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-02-27T18:19:38Z","last_updated_date":"2026-02-27T18:19:38Z","reference_number":"EMA/40388/2026","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-zumrad-sasanlimab_en.pdf"},
    {"id":"73231","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Blarcamesine Anavex (blarcamesine)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T08:45:23Z","last_updated_date":"2026-06-25T11:00:03Z","reference_number":"EMA/70818/2026","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-blarcamesine-anavex-blarcamesine_sv.pdf"}},
    {"id":"73560","name":"Withdrawal of application to change the marketing authorisation for Pluvicto (lutetium (177Lu) vipivotide tetraxetan) (VR-0000288073)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-06-11T10:55:00Z","reference_number":"EMA/VR/0000288073","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_da.pdf","de":"https://www.ema.europa.eu/de/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_de.pdf","et":"https://www.ema.europa.eu/et/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_et.pdf","el":"https://www.ema.europa.eu/el/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medicine-qa/withdrawal-application-change-marketing-authorisation-pluvicto-lutetium-177lu-vipivotide-tetraxetan-vr-0000288073_sv.pdf"}},
    {"id":"73563","name":"Withdrawal of application for the marketing authorisation of Viokat (diazoxide choline)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-04-24T12:00:00Z","reference_number":"EMA/88113/2026","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/withdrawal-application-marketing-authorisation-viokat-diazoxide-choline_en.pdf"},
    {"id":"73807","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Orblid (bevacizumab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T15:22:44Z","last_updated_date":"2026-05-22T15:22:44Z","reference_number":"EMEA/H/C/006392","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-orblid-bevacizumab_en.pdf"},
    {"id":"73828","name":"Questions and answers on the withdrawal of application for the marketing authorisation of Veblocema (infliximab)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T10:58:36Z","last_updated_date":"2026-05-22T10:58:36Z","reference_number":"EMA/114092/2026","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-veblocema-infliximab_en.pdf"},
    {"id":"74313","name":"Outcome of assessment on use of Mounjaro to reduce the risk of serious events affecting the heart and blood circulation","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMA/140483/2026 ","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/outcome-assessment-use-mounjaro-reduce-risk-serious-events-affecting-heart-blood-circulation_en.pdf"},
    {"id":"74319","name":"Questions and answers on the approval of the marketing authorisation for Daybu (trofinetide)","type":"medicine-qa","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMA/143256/2026","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-approval-marketing-authorisation-daybu-trofinetide_en.pdf"},
    {"id":"74332","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for BiResp Spiromax (WS-2806-G)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T16:16:54Z","last_updated_date":"2026-06-26T16:16:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-biresp-spiromax-ws-2806-g_en.pdf"},
    {"id":"74334","name":"Questions and answers on the withdrawal of application to change the marketing authorisation for DuoResp Spiromax (WS-2806-G)","type":"medicine-qa","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T16:26:07Z","last_updated_date":"2026-06-26T16:26:07Z","reference_number":"EMA/145433/2026","document_url":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-change-marketing-authorisation-duoresp-spiromax-ws-2806-g_en.pdf"},
    {"id":"3383","name":"Annex VIII - List of cilostazol-containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-05-28T11:15:00Z","last_updated_date":"2017-07-26T13:30:00Z","reference_number":"EMA/294357/2014 correction 2*","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-viii-list-cilostazol-containing-medicinal-products-european-union_en.pdf"},
    {"id":"5161","name":"Annex XI -List of Numeta G16%E medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-09-30T13:00:00Z","last_updated_date":"2014-09-30T13:00:00Z","reference_number":"EMA/490500/2014","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-xi-list-numeta-g16e-medicinal-products-european-union_en.pdf"},
    {"id":"12322","name":"Annex IV - List of thiocolchicoside-containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-01-29T13:00:00Z","last_updated_date":"2019-12-12T10:23:00Z","reference_number":"EMA/48333/2014 Corr.2","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-iv-list-thiocolchicoside-containing-medicinal-products-european-union_en.pdf"},
    {"id":"14432","name":"Annex II - List of trimetazidine containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T11:30:00Z","last_updated_date":"2017-05-31T12:45:00Z","reference_number":"EMA/701561/2013 Corr.4","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-ii-list-trimetazidine-containing-medicinal-products-european-union_en.pdf"},
    {"id":"16778","name":"Annex V - List of hydroxyethyl starch (HES)-containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-01-29T13:00:00Z","last_updated_date":"2025-05-28T11:10:00Z","reference_number":"EMA/48335/2014 corr. 7","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-v-list-hydroxyethyl-starch-hes-containing-medicinal-products-european-union_en.xlsx"},
    {"id":"19838","name":"Annex II - List of trimetazidine containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T11:30:00Z","last_updated_date":"2017-05-31T12:43:00Z","reference_number":"EMA/701561/2013 Corr.4","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-ii-list-trimetazidine-containing-medicinal-products-european-union_en.xls"},
    {"id":"22836","name":"Annex XIII - List of Valproate and related substances in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2015-01-28T10:00:00Z","last_updated_date":"2023-04-26T11:10:00Z","reference_number":"EMA/11799/2015 Corr. 5","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-xiii-list-valproate-and-related-substances-european-union_en.xlsx"},
    {"id":"24031","name":"Annex IV - List of thiocolchicoside-containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-01-29T13:00:00Z","last_updated_date":"2019-12-12T10:22:00Z","reference_number":"EMA/48333/2014 Corr.2","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-iv-list-thiocolchicoside-containing-medicinal-products-european-union_en.xls"},
    {"id":"24164","name":"Annex IX - List of combined hormonal contraceptives containing chlormadinone in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-06-25T14:00:00Z","last_updated_date":"2023-06-26T16:32:00Z","reference_number":"EMA/344487/2014 Corr. 8","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-ix-list-combined-hormonal-contraceptives-containing-chlormadinone-european-union_en.pdf"},
    {"id":"25940","name":"Annex XIII - List of Valproate and related substances in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2015-01-28T10:00:00Z","last_updated_date":"2023-04-26T11:10:00Z","reference_number":"EMA/11799/2015 Corr. 5","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-xiii-list-valproate-related-substances-european-union_en.pdf"},
    {"id":"26862","name":"Annex VI - List of flupirtine-containing medicinal products in the EU","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-02-26T15:00:00Z","last_updated_date":"2017-09-27T12:30:00Z","reference_number":"EMA/68528/2014 CORRECTION 4*","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-vi-list-flupirtine-containing-medicinal-products-eu_en.pdf"},
    {"id":"28391","name":"Annex IX - List of combined hormonal contraceptives containing chlormadinone in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-06-25T14:00:00Z","last_updated_date":"2023-06-26T16:32:00Z","reference_number":"EMA/344487/2014 Corr.8","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-ix-list-combined-hormonal-contraceptives-containing-chlormadinone-european-union_en.xlsx"},
    {"id":"31997","name":"Annex XI - List of Numeta G16%E medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-09-30T13:00:00Z","last_updated_date":"2014-09-30T13:00:00Z","reference_number":"EMA/490500/2014","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-xi-list-numeta-g16e-medicinal-products-european-union_en.xls"},
    {"id":"34798","name":"Annex V - List of hydroxyethyl starch (HES)-containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-01-29T13:00:00Z","last_updated_date":"2025-05-28T11:10:00Z","reference_number":"EMA/48335/2014 corr. 7","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-v-list-hydroxyethyl-starch-hes-containing-medicinal-products-european-union_en.pdf"},
    {"id":"35194","name":"Annex VIII - List of cilostazol-containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-05-28T11:15:00Z","last_updated_date":"2017-07-26T13:30:00Z","reference_number":"EMA/294357/2014 correction 2*","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-viii-list-cilostazol-containing-medicinal-products-european-union_en.xls"},
    {"id":"35485","name":"Annex I - List of cyproterone-acetate / ethinylestradiol-containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2013-08-09T13:00:00Z","last_updated_date":"2019-06-26T15:29:00Z","reference_number":"EMA/483088/2013 correction 15*","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-i-list-cyproterone-acetate-ethinylestradiol-containing-medicinal-products-european-union_en.xls"},
    {"id":"37807","name":"Annex VI - List of flupirtine-containing medicinal products in the EU","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2014-02-26T15:00:00Z","last_updated_date":"2017-09-27T12:30:00Z","reference_number":"EMA/68528/2014 CORRECTION 4*","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-vi-list-flupirtine-containing-medicinal-products-eu_en.xls"},
    {"id":"40144","name":"Annex I - List of cyproterone-acetate / ethinylestradiol-containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2013-08-09T13:00:00Z","last_updated_date":"2019-06-26T15:29:00Z","reference_number":"EMA/483088/2013 corr. 15*","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-i-list-cyproterone-acetate-ethinylestradiol-containing-medicinal-products-european-union_en.pdf"},
    {"id":"42142","name":"Annex XIV - List of Retinoid-containing medicinal products and related substances (acitretin, alitretinoin and isotretinoin) in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2018-09-28T13:15:00Z","last_updated_date":"2023-04-26T11:10:00Z","reference_number":"EMA/580272/2018","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-xiv-list-retinoid-containing-medicinal-products-and-related-substances-acitretin-alitretinoin-and-isotretinoin-european-union_en.pdf"},
    {"id":"42143","name":"Annex XIV - List of Retinoid-containing medicinal products and related substances (acitretin, alitretinoin and isotretinoin) in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2018-09-28T13:19:00Z","last_updated_date":"2023-04-26T11:10:00Z","reference_number":"EMA/580272/2018","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-xiv-list-retinoid-containing-medicinal-products-and-related-substances-acitretin-alitretinoin-and-isotretinoin-european-union_en.xlsx"},
    {"id":"42471","name":"List of medicinal products under additional monitoring","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2013-06-23T14:11:00Z","last_updated_date":"2026-06-25T10:00:00Z","reference_number":"EMA/245297/2013 Rev. 145","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/list-medicinal-products-under-additional-monitoring_en.pdf"},
    {"id":"42472","name":"List of medicinal products under additional monitoring","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2013-04-25T12:13:00Z","last_updated_date":"2026-06-25T10:00:15Z","reference_number":"EMA/245297/2013 Rev. 145","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/list-medicinal-products-under-additional-monitoring_en.xlsx"}    {"id":"63366","name":"Annex XV - List of topiramate containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2024-05-29T14:43:00Z","last_updated_date":"2024-06-26T16:12:00Z","reference_number":"EMA/227981/2024","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-xv-list-topiramate-containing-medicinal-products-european-union_en.pdf"},
    {"id":"63367","name":"Annex XV - List of topiramate containing medicinal products in the European Union","type":"additional-monitoring","status":"unknown","consultation_date":"","first_published_date":"2024-05-29T14:48:57Z","last_updated_date":"2024-06-26T16:11:00Z","reference_number":"EMA/227981/2024","document_url":"https://www.ema.europa.eu/en/documents/additional-monitoring/annex-xv-list-topiramate-containing-medicinal-products-european-union_en.xlsx"},
    {"id":"2471","name":"Minutes of thalidomide follow-up meeting with patients’ and victims’ organisations","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T10:57:00Z","last_updated_date":"2011-10-25T14:15:00Z","reference_number":"EMA/743134/2011 Corr 2","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-thalidomide-follow-meeting-patients-and-victims-organisations_en.pdf"},
    {"id":"2568","name":"Minutes of the 91st meeting of the Management Board: 17 March 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-05-04T18:30:00Z","last_updated_date":"2016-05-04T18:30:00Z","reference_number":"EMA/MB/206400/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-91st-meeting-management-board-17-march-2016_en.pdf"},
    {"id":"2586","name":"Minutes of the paediatric anticoagulation therapy expert meeting 6 November 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-07-08T19:00:00Z","last_updated_date":"2013-07-08T19:00:00Z","reference_number":"EMA/715924/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-paediatric-anticoagulation-therapy-expert-meeting-6-november-2012_en.pdf"},
    {"id":"2640","name":"Minutes of the CHMP meeting 12-15 September 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-10-20T12:00:00Z","last_updated_date":"2016-10-20T12:00:00Z","reference_number":"EMA/CHMP/680764/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-12-15-september-2016_en.pdf"},
    {"id":"2673","name":"Minutes of the EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) together with all other eligible organisations - meeting of 30 November 2010","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-03-02T01:00:00Z","last_updated_date":"2011-03-02T01:00:00Z","reference_number":"EMA/790515/10","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-together-all-other-eligible-organisations-meeting-30-november-2010_en.pdf"},
    {"id":"2686","name":"Minutes of the sixty-second meeting of the Management Board: 4-5 March 2009","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2009-04-09T02:09:21Z","last_updated_date":"2009-04-09T02:09:21Z","reference_number":"EMEA/MB/144834/2009/EN/Adopted","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-sixty-second-meeting-management-board-4-5-march-2009_sv.pdf"}},
    {"id":"2851","name":"Minutes of the PRAC meeting 7-10 July 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-09-22T12:00:00Z","last_updated_date":"2014-09-22T12:00:00Z","reference_number":"EMA/PRAC/501208/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-july-2014_en.pdf"},
    {"id":"2857","name":"Workshop on regulatory and scientific issues related to the Investigation of medicinal products intended for neonatal use - Neonates Workshop - Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2006-11-07T00:09:21Z","last_updated_date":"2006-11-07T00:09:21Z","reference_number":"EMEA/484678/2006","document_url":"https://www.ema.europa.eu/en/documents/minutes/workshop-regulatory-and-scientific-issues-related-investigation-medicinal-products-intended-neonatal-use-neonates-workshop-minutes_en.pdf"},
    {"id":"2878","name":"Minutes of the CVMP meeting of 7-9 November 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-12-11T11:50:00Z","last_updated_date":"2017-12-11T11:50:00Z","reference_number":"EMA/CVMP/809166/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-7-9-november-2017_en.pdf"},
    {"id":"2923","name":"Minutes - PDCO minutes of the 11-13 February 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-03-30T13:25:00Z","last_updated_date":"2015-03-30T13:25:00Z","reference_number":"EMA/PDCO/97803/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-11-13-february-2015-meeting_en.pdf"},
    {"id":"2937","name":"Minutes - PDCO minutes of the 14-16 January 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-03-16T11:05:00Z","last_updated_date":"2015-03-16T11:05:00Z","reference_number":"EMA/PDCO/17136/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-14-16-january-2015-meeting_en.pdf"},
    {"id":"2942","name":"Minutes of the CVMP meeting of 6-8 October 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-11-09T17:50:00Z","last_updated_date":"2015-11-09T17:50:00Z","reference_number":"EMA/CVMP/729333/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-6-8-october-2015_en.pdf"},
    {"id":"2947","name":"Minutes of the CAT meeting August 2017 (written procedure)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-10-03T16:30:00Z","last_updated_date":"2017-10-03T16:30:00Z","reference_number":"EMA/CAT/652287/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-august-2017-written-procedure_en.pdf"},
    {"id":"2977","name":"Minutes of the HMPC 17-18 July 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-10-18T15:25:00Z","last_updated_date":"2017-10-18T15:25:00Z","reference_number":"EMA/HMPC/630124/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-17-18-july-2017-meeting_en.pdf"},
    {"id":"2991","name":"Minutes of the PRAC meeting 13-16 May 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-06-24T12:30:00Z","last_updated_date":"2013-06-24T12:30:00Z","reference_number":"EMA/PRAC/336080/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-13-16-may-2013_en.pdf"},
    {"id":"3037","name":"Minutes of the CVMP meeting of 14-16 June 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-07-20T14:20:00Z","last_updated_date":"2016-07-20T14:20:00Z","reference_number":"EMA/CVMP/476383/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-14-16-june-2016_en.pdf"},
    {"id":"3238","name":"Minutes of the PRAC meeting 2-5 December 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-01-17T16:25:00Z","last_updated_date":"2014-01-29T13:30:00Z","reference_number":"EMA/PRAC/807963/2013 Corr","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-2-5-december-2013_en.pdf"},
    {"id":"3265","name":"CHMP ORGAM minutes for the meeting on 12 February 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-04-06T12:07:00Z","last_updated_date":"2018-04-06T12:07:00Z","reference_number":"EMA/106932/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-12-february-2018_en.pdf"},
    {"id":"3403","name":"Minutes of the COMP meeting 19-21 April 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-06-03T11:55:00Z","last_updated_date":"2016-06-03T11:55:00Z","reference_number":"EMA/COMP/278477/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-19-21-april-2016_en.pdf"},
    {"id":"3616","name":"Minutes of the European Medicines Agency/European network for Health Technology Assessment dialogue meeting - December 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-02-03T14:00:00Z","last_updated_date":"2014-02-03T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-dialogue-meeting-december-2013_en.pdf"},
    {"id":"3720","name":"Minutes of European Union (EU) International Organization for Standardization (ISO) identification of medicinal products (IDMP) task force meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-07-14T02:00:00Z","last_updated_date":"2015-07-14T02:00:00Z","reference_number":"EMA/403761/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-eu-international-organization-standardization-iso-identification-medicinal-products-idmp-task-force-meeting_en.pdf"},
    {"id":"3752","name":"Minutes of the 87th meeting of the Management Board: 19 March 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T13:00:00Z","last_updated_date":"2015-05-06T13:00:00Z","reference_number":"EMA/MB/178925/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-87th-meeting-management-board-19-march-2015_en.pdf"},
    {"id":"3837","name":"Minutes - PDCO minutes of the 17-19 July 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-08-16T11:30:00Z","last_updated_date":"2013-08-16T11:30:00Z","reference_number":"EMA/PDCO/435734/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-17-19-july-2013-meeting_en.pdf"},
    {"id":"3847","name":"Minutes - PDCO minutes of the 10-12 December 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-01-26T11:05:00Z","last_updated_date":"2015-01-26T11:05:00Z","reference_number":"EMA/PDCO/764791/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-10-12-december-2014-meeting_en.pdf"},
    {"id":"3905","name":"Minutes of the COMP meeting 2-4 September 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-10-30T17:20:00Z","last_updated_date":"2014-11-03T10:55:00Z","reference_number":"EMA/COMP/427307/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-2-4-september-2014_en.pdf"},
    {"id":"3971","name":"Minutes of the 77th meeting of the Management Board: 4 October 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/MB/653638/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-77th-meeting-management-board-4-october-2012_en.pdf"},
    {"id":"4048","name":"Minutes of the PRAC meeting 8-11 June 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-07-21T11:00:00Z","last_updated_date":"2015-07-21T11:00:00Z","reference_number":"EMA/PRAC/443961/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-june-2015_en.pdf"},
    {"id":"4074","name":"Minutes - PDCO minutes of the 6-8 June 2012 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-07-18T20:14:42Z","last_updated_date":"2012-07-18T20:14:42Z","reference_number":"EMA/PDCO/347509/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-6-8-june-2012-meeting_en.pdf"},
    {"id":"4253","name":"Minutes of the CAT meeting 15-17 March 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T16:28:00Z","last_updated_date":"2017-05-19T16:28:00Z","reference_number":"EMA/CAT/313544/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-17-march-2017_en.pdf"},
    {"id":"4373","name":"Minutes - PRAC meeting 1-3 October 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-11-07T15:55:00Z","last_updated_date":"2012-11-07T15:55:00Z","reference_number":"EMA/PRAC/635842/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-1-3-october-2012_en.pdf"},
    {"id":"4376","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting -  March 2011","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-march-2011_en.pdf"},
    {"id":"4397","name":"Minutes of the COMP meeting of 3-5 October 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-11-20T17:30:00Z","last_updated_date":"2017-11-20T17:30:00Z","reference_number":"EMA/COMP/649605/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-3-5-october-2017_en.pdf"},
    {"id":"4445","name":"Minutes of the European network of paediatric research and the European Medicines Agency Coordinating Group (Enpr-EMA CG) teleconference meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T16:45:00Z","last_updated_date":"2015-12-08T16:45:00Z","reference_number":"EMA/701987/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-and-european-medicines-agency-coordinating-group-enpr-ema-cg-teleconference-meeting_en.pdf"},
    {"id":"4466","name":"Minutes - Industry stakeholder meeting on Brexit and operation of the centralised procedure for human medicinal products","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T17:30:00Z","last_updated_date":"2018-05-02T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-industry-stakeholder-meeting-brexit-and-operation-centralised-procedure-human-medicinal-products_en.pdf"},
    {"id":"4468","name":"Minutes of the PRAC meeting 6-9 January 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-02-19T12:55:00Z","last_updated_date":"2014-02-25T09:50:00Z","reference_number":"EMA/PRAC/96908/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-6-9-january-2014_en.pdf"},
    {"id":"4536","name":"Minutes of the fourth meeting of the EMEA Human Scientific Committees’ Working Party with with Patients’ and Consumers’ Organisations (PCWP)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/604758/2007","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-fourth-meeting-emea-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp_en.pdf"},
    {"id":"4555","name":"Minutes of the CVMP meeting of 8-10 September 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-10-14T15:15:00Z","last_updated_date":"2015-10-14T15:15:00Z","reference_number":"EMA/CVMP/661152/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-september-2015_en.pdf"},
    {"id":"4578","name":"Minutes of the COMP meeting 6-8 December 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-27T17:30:00Z","last_updated_date":"2017-02-27T17:30:00Z","reference_number":"EMA/COMP/816520/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-6-8-december-2016_en.pdf"},
    {"id":"4704","name":"Minutes of the CVMP meeting of 7-9 October 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-11-11T11:00:00Z","last_updated_date":"2014-11-11T11:00:00Z","reference_number":"EMA/CVMP/682233/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-7-9-october-2014_en.pdf"},
    {"id":"4709","name":"Minutes of Joint meeting of Good-clinical-practice compliance Inspectors Working Group and eClinical Forum representatives on electronic data capture systems and investigator site eSource readiness","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-01-10T10:59:00Z","last_updated_date":"2014-01-10T10:59:00Z","reference_number":"EMA/INS/GCP/504197/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-joint-meeting-good-clinical-practice-compliance-inspectors-working-group-eclinical-forum-representatives-electronic-data-capture-systems-investigator-site-esource-readiness_en.pdf"},
    {"id":"4783","name":"Minutes of the COMP meeting 5-6 February 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-04-08T12:00:00Z","last_updated_date":"2013-04-08T12:00:00Z","reference_number":"EMA/COMP/18213/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-5-6-february-2013_en.pdf"},
    {"id":"4965","name":"Minutes of the CHMP meeting 25-28 January 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-03-04T15:00:00Z","last_updated_date":"2016-03-04T15:00:00Z","reference_number":"EMA/CHMP/162442/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-25-28-january-2016_en.pdf"},
    {"id":"5011","name":"Minutes of the European Medicines Agency/European network for Health Technology Assessment dialogue meeting - May 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T11:00:00Z","last_updated_date":"2014-07-11T13:55:00Z","reference_number":"EMA/299386/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-dialogue-meeting-may-2014_en.pdf"},
    {"id":"5015","name":"Minutes of the CVMP meeting of 4-6 October 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T15:43:00Z","last_updated_date":"2016-11-14T15:43:00Z","reference_number":"EMA/CVMP/737245/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-4-6-october-2016_en.pdf"},
    {"id":"5031","name":"Minutes of the CAT meeting 15-17 February 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-04T19:25:00Z","last_updated_date":"2017-05-04T19:25:00Z","reference_number":"EMA/CAT/278840/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-17-february-2017_en.pdf"},
    {"id":"5109","name":"Minutes - PDCO minutes of the 23 – 26 January 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-04-10T18:30:00Z","last_updated_date":"2018-04-10T18:30:00Z","reference_number":"EMA/PDCO/49067/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-23-26-january-2018-meeting_en.pdf"},
    {"id":"5259","name":"Minutes of the CAT meeting 17-18 July 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-10-03T19:00:00Z","last_updated_date":"2014-10-03T19:00:00Z","reference_number":"EMA/CAT/580044/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-17-18-july-2014_en.pdf"},
    {"id":"5322","name":"Minutes - PDCO minutes of the 11-13 November 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-12-11T16:55:00Z","last_updated_date":"2015-12-11T16:55:00Z","reference_number":"EMA/PDCO/750371/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-11-13-november-2015-meeting_en.pdf"},
    {"id":"5331","name":"Minutes of the 75th meeting of the Management Board: 21-22 March 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-06-14T16:30:00Z","last_updated_date":"2012-06-14T16:30:00Z","reference_number":"EMA/MB/221361/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-75th-meeting-management-board-21-22-march-2012_sv.pdf"}},
    {"id":"5351","name":"CHMP ORGAM minutes for the meeting on 18 June 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-07-31T16:10:00Z","last_updated_date":"2018-07-31T16:10:00Z","reference_number":"EMA/CHMP/442690/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-18-june-2018_en.pdf"},
    {"id":"5472","name":"Minutes of the 79th meeting of the Management Board: 21-22 March 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-06-18T19:00:00Z","last_updated_date":"2013-06-18T19:00:00Z","reference_number":"EMA/MB/195991/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-79th-meeting-management-board-21-22-march-2013_en.pdf"},
    {"id":"5495","name":"Minutes of the COMP meeting of 17-19 April 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-06-28T18:18:00Z","last_updated_date":"2018-06-28T18:18:00Z","reference_number":"EMA/COMP/171165/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-17-19-april-2018_en.pdf"},
    {"id":"5636","name":"Minutes of the CHMP meeting 22-25 April 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T16:00:00Z","last_updated_date":"2014-05-23T16:00:00Z","reference_number":"EMA/CHMP/263230/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-april-2014_en.pdf"},
    {"id":"5647","name":"Presentation - Pharmacovigilance legislation - what has been achieved and future priorities. Scanning the horizon for 2016 – 2018 (Peter Arlett)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-pharmacovigilance-legislation-what-has-been-achieved-and-future-priorities-scanning-horizon-2016-2018-peter-arlett_en.pdf"},
    {"id":"5653","name":"Minutes of the HMPC 9-10 March 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-05-19T11:56:00Z","last_updated_date":"2015-05-19T11:56:00Z","reference_number":"EMA/HMPC/301016/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-9-10-march-2015-meeting_en.pdf"},
    {"id":"5706","name":"Minutes - Healthcare Professionals Working Group (HCPWG) meeting 27 Feb 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/255634/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-healthcare-professionals-working-group-hcpwg-meeting-27-feb-2013_en.pdf"},
    {"id":"5868","name":"Minutes of the COMP meeting 10-12 November 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T17:40:00Z","last_updated_date":"2015-12-18T17:40:00Z","reference_number":"EMA/COMP/734238/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-12-november-2015_en.pdf"},
    {"id":"6012","name":"Minutes of the CVMP meeting of 10-12 April 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-18T17:20:00Z","last_updated_date":"2017-05-18T17:20:00Z","reference_number":"EMA/CVMP/301142/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-12-april-2017_en.pdf"},
    {"id":"6032","name":"Minutes of the drafting meeting on the framework for the interaction between the Agency and Healthcare Professionals' Organisations","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2010-09-22T02:00:00Z","last_updated_date":"2010-09-22T02:00:00Z","reference_number":"EMA/424967/2010","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-drafting-meeting-framework-interaction-between-agency-and-healthcare-professionals-organisations_en.pdf"},
    {"id":"6084","name":"Presentation - Harnessing mobile apps and social media for product safety(Phil Tregunno)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-harnessing-mobile-apps-and-social-media-product-safetyphil-tregunno_en.pdf"},
    {"id":"6220","name":"Minutes of the PRAC meeting 5-8 February 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-04-06T18:35:00Z","last_updated_date":"2018-04-06T18:35:00Z","reference_number":"EMA/PRAC/218598/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-5-8-february-2018_en.pdf"},
    {"id":"6340","name":"Minutes of the CVMP meeting of 19-21 April 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-05-20T17:50:00Z","last_updated_date":"2016-05-20T17:50:00Z","reference_number":"EMA/CVMP/340807/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-19-21-april-2016_en.pdf"},
    {"id":"6343","name":"Minutes of the CHMP meeting 17-20 February 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-03-25T13:15:00Z","last_updated_date":"2014-03-25T13:15:00Z","reference_number":"EMA/CHMP/120991/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-17-20-february-2014_en.pdf"},
    {"id":"6370","name":"Minutes of the CAT meeting 16-17 July 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T14:30:00Z","last_updated_date":"2015-10-02T14:30:00Z","reference_number":"EMA/CAT/484983/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-16-17-july-2015_en.pdf"},
    {"id":"6514","name":"Minutes of the CVMP meeting of 14-16 March 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T13:05:00Z","last_updated_date":"2017-04-20T13:05:00Z","reference_number":"EMA/CVMP/250608/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-14-16-march-2017_en.pdf"},
    {"id":"6542","name":"Minutes of the COMP meeting of 13-15 February 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-04-30T17:46:00Z","last_updated_date":"2018-05-15T12:52:00Z","reference_number":"EMA/COMP/40855/2018 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-13-15-february-2018_en.pdf"},
    {"id":"6556","name":"Presentation - 3-year report on European Union pharmacovigilance activities (Helen Lee)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-3-year-report-european-union-pharmacovigilance-activities-helen-lee_en.pdf"},
    {"id":"6576","name":"Minutes - PDCO minutes of the 13-15 March 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-04-22T12:20:00Z","last_updated_date":"2013-04-22T12:20:00Z","reference_number":"EMA/PDCO/154253/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-13-15-march-2013-meeting_en.pdf"},
    {"id":"6600","name":"Minutes of the CHMP meeting 20-23 July 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T12:03:00Z","last_updated_date":"2015-10-02T12:03:00Z","reference_number":"EMA/630733/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-20-23-july-2015_en.pdf"},
    {"id":"6611","name":"Minutes of the 98th meeting of the Management Board: 13-14 December 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-02-27T12:45:00Z","last_updated_date":"2018-02-27T12:45:00Z","reference_number":"EMA/MB/701078/2017 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-98th-meeting-management-board-13-14-december-2017_en.pdf"},
    {"id":"6775","name":"Minutes of the second joint meeting of the EMEA Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) and the EMEA/CHMP working group with Healthcare Professionals' Organisations (HCP WG...","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-09-12T02:00:00Z","last_updated_date":"2008-09-12T02:00:00Z","reference_number":"EMEA/301606/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-second-joint-meeting-emea-scientific-committees-working-party-patients-consumers-organisations-pcwp-emea-chmp-working-group-healthcare-professionals-organisations-hcp-wg_en.pdf"},
    {"id":"6936","name":"Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-12-18T13:00:00Z","last_updated_date":"2017-12-18T13:00:00Z","reference_number":"EMA/785044/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting_en.pdf"},
    {"id":"7039","name":"Minutes of the PRAC meeting 27-30 November 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-01-31T17:23:00Z","last_updated_date":"2018-01-31T17:23:00Z","reference_number":"EMA/PRAC/64990/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-27-30-november-2017_en.pdf"},
    {"id":"7224","name":"Minutes - PDCO minutes of the 9-11 January 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T12:50:00Z","last_updated_date":"2013-02-15T12:50:00Z","reference_number":"EMA/PDCO/9311/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-9-11-january-2013-meeting_en.pdf"},
    {"id":"7274","name":"Minutes of the CVMP meeting of 8-10 December 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-01-25T17:30:00Z","last_updated_date":"2016-01-25T17:30:00Z","reference_number":"EMA/CVMP/48390/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-december-2015_en.pdf"},
    {"id":"7489","name":"Minutes of the second meeting of the EMEA Human Scientific Committees’ Working Party with with Patients’ and Consumers’ Organisations (PCWP)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2007-06-18T02:00:00Z","last_updated_date":"2007-06-18T02:00:00Z","reference_number":"EMEA/211974/2007","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-second-meeting-emea-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp_en.pdf"},
    {"id":"7540","name":"Minutes of the European network of paediatric research at the European Medicines Agency coordinating group members meeting - 6 October 2016","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-11-24T17:25:00Z","last_updated_date":"2016-11-24T17:25:00Z","reference_number":"EMA/683953/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-agency-coordinating-group-members-meeting-6-october-2016_en.pdf"},
    {"id":"7630","name":"Minutes of the CAT meeting 15-16 June 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-09-05T12:45:00Z","last_updated_date":"2017-09-05T12:45:00Z","reference_number":"EMA/CAT/581913/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-16-june-2017_en.pdf"},
    {"id":"7698","name":"Minutes of the Healthcare Professionals' Organisations Working Group, 4 March 2011","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"EMA/231456/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-healthcare-professionals-organisations-working-group-4-march-2011_en.pdf"},
    {"id":"7713","name":"Minutes - PDCO minutes of the  6-8 February 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T12:30:00Z","last_updated_date":"2013-03-25T12:30:00Z","reference_number":"EMA/PDCO/61365/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-6-8-february-2013-meeting_en.pdf"},
    {"id":"7817","name":"Minutes of the COMP meeting 11-13 November 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-12-23T13:25:00Z","last_updated_date":"2014-12-23T13:25:00Z","reference_number":"EMA/COMP/638338/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-11-13-november-2014_en.pdf"},
    {"id":"7867","name":"Minutes - PDCO minutes of the 29 May-01 June 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T14:00:00Z","last_updated_date":"2018-07-25T14:00:00Z","reference_number":"EMA/PDCO/372867/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-29-may-01-june-2018-meeting_en.pdf"},
    {"id":"8055","name":"Minutes of the second PCWP meeting with all eligible patients’ and consumers’ organisations, 8 Dec 2009","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"EMA/63330/2010","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-second-pcwp-meeting-all-eligible-patients-and-consumers-organisations-8-dec-2009_en.pdf"},
    {"id":"8064","name":"Minutes - PDCO minutes of the 12-15 September 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-11-30T11:35:00Z","last_updated_date":"2017-11-30T11:35:00Z","reference_number":"EMA/PDCO/612728/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-12-15-september-2017-meeting_en.pdf"},
    {"id":"8112","name":"Minutes - EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting (27 June 2017)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"EMA/355452/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-27-june-2017_en.pdf"},
    {"id":"8208","name":"Minutes of the European Medicines Agency/European network for Health Technology Assessment dialogue meeting - December 2016","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T11:17:00Z","last_updated_date":"2017-05-12T11:17:00Z","reference_number":"EMA/826577/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-dialogue-meeting-december-2016_en.pdf"},
    {"id":"8290","name":"Minutes of the COMP meeting 21-23 March 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-05-10T17:10:00Z","last_updated_date":"2016-05-10T17:10:00Z","reference_number":"EMA/COMP/201580/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-21-23-march-2016_en.pdf"},
    {"id":"8332","name":"Minutes of the PRAC meeting 3-6 November 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-12-15T13:10:00Z","last_updated_date":"2014-12-15T13:10:00Z","reference_number":"EMA/PRAC/778401/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-3-6-november-2014_en.pdf"},
    {"id":"8382","name":"Minutes - PDCO minutes of the 20-23 March 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-05-16T18:00:00Z","last_updated_date":"2018-05-16T18:00:00Z","reference_number":"EMA/PDCO/187894/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-20-23-march-2018-meeting_en.pdf"},
    {"id":"8420","name":"Minutes of the 81st meeting of the Management Board: 3 October 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-12-04T17:00:00Z","last_updated_date":"2013-12-04T17:00:00Z","reference_number":"EMA/MB/584118/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-81st-meeting-management-board-3-october-2013_en.pdf"},
    {"id":"8468","name":"Minutes of the CVMP meeting of 9-11 December 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-01-20T10:35:00Z","last_updated_date":"2015-01-20T10:35:00Z","reference_number":"EMA/CVMP/25865/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-9-11-december-2014_en.pdf"},
    {"id":"8587","name":"Minutes of the CHMP meeting 16-19 December 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-01-28T15:00:00Z","last_updated_date":"2014-01-28T15:00:00Z","reference_number":"EMA/CHMP/723655/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-16-19-december-2013_en.pdf"},
    {"id":"8627","name":"CHMP ORGAM minutes for the meeting on 10 July 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-08-04T16:00:00Z","last_updated_date":"2017-08-04T16:00:00Z","reference_number":"EMA/CHMP/468845/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-10-july-2017_en.pdf"},
    {"id":"9062","name":"Minutes of the 74th meeting of the Management Board: 15 December 2011","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"EMA/MB/33634/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-74th-meeting-management-board-15-december-2011_sv.pdf"}},
    {"id":"9070","name":"CHMP ORGAM minutes for the meeting on 10 April  2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-11T17:04:00Z","last_updated_date":"2017-05-11T17:04:00Z","reference_number":"EMA/CHMP/267964/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-10-april-2017_en.pdf"},
    {"id":"9079","name":"CHMP ORGAM minutes for the meeting on 3 October 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-10-20T12:00:00Z","last_updated_date":"2016-10-20T12:00:00Z","reference_number":"EMA/CHMP/676249/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-3-october-2016_en.pdf"},
    {"id":"9087","name":"Meeting summary - European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T17:30:00Z","last_updated_date":"2018-06-27T17:30:00Z","reference_number":"EMA/259214/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-human-scientific-committees-working-parties-patients-consumers-organisations-pcwp-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf"},
    {"id":"9123","name":"Minutes of the CAT meeting 6-8 September 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-11-06T16:00:00Z","last_updated_date":"2017-11-06T16:00:00Z","reference_number":"EMA/CAT/602703/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-6-8-september-2017_en.pdf"}    {"id":"9162","name":"Minutes of the European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations meeting: Election of co-chair","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-12-11T10:30:00Z","last_updated_date":"2013-12-11T10:30:00Z","reference_number":"EMA/696950/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-meeting-election-co-chair_en.pdf"},
    {"id":"9165","name":"Minutes of the PRAC meeting 08-11 February 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-04-08T12:00:00Z","last_updated_date":"2016-04-08T12:00:00Z","reference_number":"EMA/PRAC/251925/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-08-11-february-2016_en.pdf"},
    {"id":"9180","name":"Minutes of the CAT meeting 11–12 December 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-01-28T16:15:00Z","last_updated_date":"2015-01-28T16:15:00Z","reference_number":"EMA/CAT/14963/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-11-12-december-2014_en.pdf"},
    {"id":"9429","name":"Minutes - Meeting with Alliance for Regenerative Medicine","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-02-06T13:00:00Z","last_updated_date":"2018-02-06T13:00:00Z","reference_number":"EMA/37264/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-meeting-alliance-regenerative-medicine_en.pdf"},
    {"id":"9465","name":"Minutes of the CHMP meeting 20-23 March 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-02T16:40:00Z","last_updated_date":"2017-05-04T12:00:00Z","reference_number":"EMA/254538/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-20-23-march-2017_en.pdf"},
    {"id":"9545","name":"Minutes of the PRAC meeting 7-10 October 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T18:20:00Z","last_updated_date":"2013-11-22T12:59:30Z","reference_number":"EMA/PRAC/708968/2013 Corr","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-october-2013_en.pdf"},
    {"id":"9610","name":"Minutes of the European Union International Organisation for Standardization (ISO) identification of medicinal products (IDMP) task force meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-03-15T15:00:00Z","last_updated_date":"2016-03-15T15:00:00Z","reference_number":"EMA/155769/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-international-organisation-standardization-iso-identification-medicinal-products-idmp-task-force-meeting_en.pdf"},
    {"id":"9657","name":"Minutes - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting_en.pdf"},
    {"id":"9724","name":"Minutes of the CHMP meeting 28-31 May 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-07-30T18:42:00Z","last_updated_date":"2018-07-30T18:42:00Z","reference_number":"EMA/CHMP/442216/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-28-31-may-2018_en.pdf"},
    {"id":"9761","name":"Minutes of the PRAC meeting 10-13 June 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-07-24T18:40:00Z","last_updated_date":"2013-07-24T18:40:00Z","reference_number":"EMA/PRAC/430682/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-10-13-june-2013_en.pdf"},
    {"id":"9770","name":"Minutes of the expert meeting on specific immunotherapy","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-06-21T02:00:00Z","last_updated_date":"2011-06-21T02:00:00Z","reference_number":"EMA/414476/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-expert-meeting-specific-immunotherapy_en.pdf"},
    {"id":"9853","name":"Minutes of the Patients’ and Consumers’ Working Party and Healthcare Professionals Working Party joint meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-12-11T10:30:00Z","last_updated_date":"2013-12-11T10:30:00Z","reference_number":"EMA/618027/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-patients-and-consumers-working-party-and-healthcare-professionals-working-party-joint-meeting_en.pdf"},
    {"id":"9868","name":"Minutes of the PRAC meeting 14-17 March 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-05-03T15:00:00Z","last_updated_date":"2016-05-03T15:00:00Z","reference_number":"EMA/PRAC/259752/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-14-17-march-2016_en.pdf"},
    {"id":"9960","name":"Minutes of the COMP meeting 14-16 April 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-05-20T16:30:00Z","last_updated_date":"2015-05-20T16:30:00Z","reference_number":"EMA/COMP/209468/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-16-april-2015_en.pdf"},
    {"id":"10031","name":"Minutes - PDCO minutes of the 12-15 December 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-02-22T11:30:00Z","last_updated_date":"2018-02-22T11:30:00Z","reference_number":"EMA/PDCO/830920/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-12-15-december-2017-meeting_en.pdf"},
    {"id":"10231","name":"Minutes of the CAT meeting 12-14 July 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-10-03T16:30:00Z","last_updated_date":"2017-10-03T16:30:00Z","reference_number":"EMA/CAT/651213/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-12-14-july-2017_en.pdf"},
    {"id":"10322","name":"Minutes of the COMP meeting 16-18 February 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-04-05T12:25:00Z","last_updated_date":"2016-04-05T12:25:00Z","reference_number":"EMA/COMP/240468/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-18-february-2016_en.pdf"},
    {"id":"10329","name":"Minutes of the HMPC 30-31 May 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T18:15:00Z","last_updated_date":"2016-07-22T18:15:00Z","reference_number":"EMA/HMPC/434600/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-30-31-may-2016-meeting_en.pdf"},
    {"id":"10337","name":"Minutes of the CHMP meeting 18-21 April 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-06-07T19:00:00Z","last_updated_date":"2017-06-07T19:00:00Z","reference_number":"EMA/317902/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-18-21-april-2017_en.pdf"},
    {"id":"10469","name":"Minutes of the 95th meeting of the Management Board: 16 March 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-03T16:35:00Z","last_updated_date":"2017-05-03T16:35:00Z","reference_number":"EMA/MB/183915/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-95th-meeting-management-board-16-march-2017_en.pdf"},
    {"id":"10521","name":"Minutes of the HMPC 27-28 January 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-03-18T17:45:00Z","last_updated_date":"2015-03-18T17:45:00Z","reference_number":"EMA/HMPC/168048/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-27-28-january-2015-meeting_en.pdf"},
    {"id":"10596","name":"Minutes of the CVMP meeting of 13-15 March 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-04-24T19:30:00Z","last_updated_date":"2018-04-24T19:30:00Z","reference_number":"EMA/CVMP/246666/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-13-15-march-2018_en.pdf"},
    {"id":"10648","name":"Minutes of the COMP meeting of 30-31 October 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-01-29T18:20:00Z","last_updated_date":"2018-01-29T18:20:00Z","reference_number":"EMA/COMP/708746/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-30-31-october-2017_en.pdf"},
    {"id":"10702","name":"Minutes - PDCO minutes of the 10-12 April 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-05-29T18:40:00Z","last_updated_date":"2013-05-29T18:40:00Z","reference_number":"EMA/PDCO/215721/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-10-12-april-2013-meeting_en.pdf"},
    {"id":"10809","name":"Minutes of the HMPC 16-17 September 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-11-26T15:45:00Z","last_updated_date":"2013-11-26T15:45:00Z","reference_number":"EMA/HMPC/708071/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-16-17-september-2013-meeting_en.pdf"},
    {"id":"10861","name":"Minutes of the HMPC 20-21 November 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-03-15T16:00:00Z","last_updated_date":"2018-03-15T16:00:00Z","reference_number":"EMA/HMPC/124848/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-20-21-november-2017-meeting_en.pdf"},
    {"id":"11086","name":"Minutes of the 83rd meeting of the Management Board: 19-20 March 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-05-27T11:30:00Z","last_updated_date":"2014-05-27T11:30:00Z","reference_number":"EMA/MB/169928/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-83rd-meeting-management-board-19-20-march-2014_en.pdf"},
    {"id":"11184","name":"Minutes of the CHMP meeting 16-19 November 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T15:35:00Z","last_updated_date":"2015-12-18T15:35:00Z","reference_number":"EMA/CHMP/851760/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-16-19-november-2015_en.pdf"},
    {"id":"11236","name":"Minutes of the PRAC meeting 11-14 June 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-08-10T16:30:00Z","last_updated_date":"2018-08-10T16:30:00Z","reference_number":"EMA/PRAC/400242/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-11-14-june-2018_en.pdf"},
    {"id":"11276","name":"Minutes of the CAT meeting 3-4 November 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-01-05T10:00:00Z","last_updated_date":"2017-01-05T10:00:00Z","reference_number":"EMA/CAT/2434/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-3-4-november-2016_en.pdf"},
    {"id":"11360","name":"Minutes of the HMPC 21-22 November 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-21T16:30:00Z","last_updated_date":"2017-02-21T16:30:00Z","reference_number":"EMA/HMPC/85652/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-21-22-november-2016-meeting_en.pdf"},
    {"id":"11395","name":"Minutes of the European network of paediatric research at the European Medicines Agency coordinating group teleconference - 21 January 2015","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-03-09T16:00:00Z","last_updated_date":"2015-03-09T16:00:00Z","reference_number":"EMA/52510/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-agency-coordinating-group-teleconference-21-january-2015_en.pdf"},
    {"id":"11474","name":"Draft minutes of the focus group meeting on Pharmacokinetic / Pharmacodynamic (PK/PD) modelling in veterinary medicines","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-09-24T02:09:21Z","last_updated_date":"2008-09-24T02:09:21Z","reference_number":"EMEA/CVMP/EWP/503528/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/draft-minutes-focus-group-meeting-pharmacokinetic-pharmacodynamic-pkpd-modelling-veterinary-medicines_en.pdf"},
    {"id":"11525","name":"Minutes of the European network of paediatric research-European Medicines working groups meeting 23 January 2014","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T16:00:00Z","last_updated_date":"2014-03-21T16:00:00Z","reference_number":"EMA/126483/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-working-groups-meeting-23-january-2014_en.pdf"},
    {"id":"11701","name":"Minutes of the COMP meeting 17-19 January 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-27T17:30:00Z","last_updated_date":"2017-02-27T17:30:00Z","reference_number":"EMA/COMP/33182/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-17-19-january-2017_en.pdf"},
    {"id":"11748","name":"Minutes - PDCO minutes of the 13–15 August 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-09-16T13:40:00Z","last_updated_date":"2014-09-16T13:40:00Z","reference_number":"EMA/PDCO/491868/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-13-15-august-2014-meeting_en.pdf"},
    {"id":"11762","name":"Minutes - COMP meeting 10-11 July 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-09-24T13:53:00Z","last_updated_date":"2012-10-01T13:53:00Z","reference_number":"EMA/COMP/404711/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-11-july-2012_en.pdf"},
    {"id":"11807","name":"CHMP ORGAM minutes for the meeting on 22 May 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T16:00:00Z","last_updated_date":"2018-06-19T16:00:00Z","reference_number":"EMA/CHMP/356853/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-22-may-2018_en.pdf"},
    {"id":"11837","name":"Minutes of the CAT meeting 8-9 December 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-20T12:20:00Z","last_updated_date":"2017-02-20T12:20:00Z","reference_number":"EMA/CAT/117531/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-8-9-december-2016_en.pdf"},
    {"id":"11870","name":"Highlights of the European Medicines Agency industry platform meeting on paediatric medicines held on 11 May 2015","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-07-14T13:00:00Z","last_updated_date":"2015-07-14T13:00:00Z","reference_number":"EMA/327077/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-european-medicines-agency-industry-platform-meeting-paediatric-medicines-held-11-may-2015_en.pdf"},
    {"id":"11958","name":"Minutes of the CVMP meeting of 17-19 April 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-05-30T15:55:00Z","last_updated_date":"2018-05-30T15:55:00Z","reference_number":"EMA/CVMP/327674/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-17-19-april-2018_en.pdf"},
    {"id":"12210","name":"Minutes - PDCO minutes of the 6-8 November 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-12-13T12:25:00Z","last_updated_date":"2013-12-13T12:25:00Z","reference_number":"EMA/PDCO/641214/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-6-8-november-2013-meeting_en.pdf"},
    {"id":"12218","name":"Minutes of the CHMP meeting 25-28 April 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-06-01T14:00:00Z","last_updated_date":"2017-01-20T16:03:00Z","reference_number":"EMA/CHMP/363014/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-25-28-april-2016_en.pdf"},
    {"id":"12287","name":"Minutes - Annual Patients/Consumers Working Party (PCWP) and Healthcare Professionals Working Group (HCP WG) joint meeting, 16 June 2011","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2011-08-22T02:00:00Z","last_updated_date":"2011-08-22T02:00:00Z","reference_number":"EMA/613261/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-annual-patientsconsumers-working-party-pcwp-and-healthcare-professionals-working-group-hcp-wg-joint-meeting-16-june-2011_en.pdf"},
    {"id":"12369","name":"Minutes of the PRAC meeting 4-7 November 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-12-17T11:00:00Z","last_updated_date":"2013-12-17T11:00:00Z","reference_number":"EMA/PRAC/729184/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-4-7-november-2013_en.pdf"},
    {"id":"12456","name":"Minutes of the seventh meeting of the EMEA Human Scientific Committees’ Working Party with with Patients’ and Consumers’ Organisations (PCWP)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/595521/08","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-seventh-meeting-emea-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp_en.pdf"},
    {"id":"12502","name":"Minutes - PDCO minutes of the 4-6 December 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-01-28T17:35:00Z","last_updated_date":"2014-01-28T17:35:00Z","reference_number":"EMA/PDCO/750981/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-4-6-december-2013-meeting_en.pdf"},
    {"id":"12533","name":"Minutes of the COMP meeting 6-8 October 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-11-26T15:50:00Z","last_updated_date":"2016-01-20T15:10:00Z","reference_number":"EMA/COMP/664502/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-6-8-october-2015_en.pdf"},
    {"id":"12545","name":"Minutes - PDCO minutes of the 20-22 July 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-08-22T13:30:00Z","last_updated_date":"2016-08-22T13:30:00Z","reference_number":"EMA/PDCO/452922/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-20-22-july-2016-meeting_en.pdf"},
    {"id":"12596","name":"Minutes of the PRAC meeting 26-29 November 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-01-23T12:30:00Z","last_updated_date":"2013-02-06T14:10:00Z","reference_number":"EMA/36832/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-26-29-november-2012_en.pdf"},
    {"id":"12606","name":"Presentation - Welcome and Introduction (Guido Rasi)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-welcome-and-introduction-guido-rasi_en.pdf"},
    {"id":"12621","name":"Minutes of the tenth EMA human scientific committees' working party with patients' and consumers' organisations (PCWP) meeting of 16 June 2010","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2010-08-20T02:00:00Z","last_updated_date":"2010-08-20T02:00:00Z","reference_number":"EMA/405307/2010","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-tenth-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-16-june-2010_en.pdf"},
    {"id":"12659","name":"Minutes of the CHMP meeting 22-25 January 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-03-08T12:19:00Z","last_updated_date":"2018-03-08T12:19:00Z","reference_number":"EMA/108712/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-january-2018_en.pdf"},
    {"id":"12678","name":"Minutes of the CAT meeting 16-17 January 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-03-12T12:20:00Z","last_updated_date":"2014-03-12T12:20:00Z","reference_number":"EMA/CAT/95789/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-16-17-january-2014_en.pdf"},
    {"id":"12730","name":"Minutes of the first meeting of the EMEA Scientific Committees’ Working Party with with Patients’ and Consumers’ Organisations (PCWP) with all eligible Patients’ and Consumers’ Organisations","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-09-30T02:00:00Z","last_updated_date":"2008-09-30T02:00:00Z","reference_number":"EMEA/302414/2008 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-first-meeting-emea-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-all-eligible-patients-and-consumers-organisations_en.pdf"},
    {"id":"12763","name":"List of participants - Tenth Stakeholder Forum on the Pharmacovigilance legislation","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/list-participants-tenth-stakeholder-forum-pharmacovigilance-legislation_en.pdf"},
    {"id":"12991","name":"Minutes of the CHMP meeting 23-26 June 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-08-07T18:30:00Z","last_updated_date":"2014-08-07T18:30:00Z","reference_number":"EMA/CHMP/413428/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-23-26-june-2014_en.pdf"},
    {"id":"13073","name":"Minutes of the PRAC meeting 8-11 April 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-06-05T13:50:00Z","last_updated_date":"2013-06-05T13:50:00Z","reference_number":"EMA/PRAC/332071/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-april-2013_en.pdf"},
    {"id":"13117","name":"Minutes of the CVMP meeting of 7-9 July 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-09-14T18:30:00Z","last_updated_date":"2015-09-14T18:30:00Z","reference_number":"EMA/CVMP/600373/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-7-9-july-2015_en.pdf"},
    {"id":"13119","name":"Minutes of the COMP meeting 5-6 December 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-01-23T15:40:00Z","last_updated_date":"2013-02-13T11:00:00Z","reference_number":"EMA/COMP/722237/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-5-6-december-2012_en.pdf"},
    {"id":"13131","name":"Minutes of the COMP meeting 7-9 January 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-03-12T12:10:00Z","last_updated_date":"2014-03-12T12:10:00Z","reference_number":"EMA/COMP/14515/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-7-9-january-2014_en.pdf"},
    {"id":"13145","name":"Minutes of the CAT meeting 19-20 February 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-04-01T12:55:00Z","last_updated_date":"2015-04-01T12:55:00Z","reference_number":"EMA/CAT/199284/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-19-20-february-2015_en.pdf"},
    {"id":"13224","name":"Minutes of the CAT meeting 18-20 April 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-08-23T15:19:00Z","last_updated_date":"2018-08-23T15:19:00Z","reference_number":"EMA/CAT/252351/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-20-april-2018_en.pdf"},
    {"id":"13271","name":"Minutes of the 84th meeting of the Management Board: 12 June 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T17:50:00Z","last_updated_date":"2014-09-01T17:50:00Z","reference_number":"EMA/MB/325638/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-84th-meeting-management-board-12-june-2014_en.pdf"},
    {"id":"13361","name":"Minutes of Enpr-EMA Coordinating Group meeting with Chairs of the working groups","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-03-06T01:00:00Z","last_updated_date":"2017-03-06T01:00:00Z","reference_number":"EMA/45320/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-meeting-chairs-working-groups_en.pdf"},
    {"id":"13363","name":"Minutes of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - 4 March 2015","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-06-19T18:58:00Z","last_updated_date":"2015-06-19T18:58:00Z","reference_number":"EMA/14656/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-4-march-2015_en.pdf"},
    {"id":"13435","name":"Minutes of the 89th meeting of the Management Board","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T10:30:00Z","last_updated_date":"2015-11-16T10:30:00Z","reference_number":"EMA/MB/313663/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-89th-meeting-management-board_en.pdf"},
    {"id":"13437","name":"Minutes of the sixty-first meeting of the Management Board: 11 December 2008","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2009-01-28T00:09:21Z","last_updated_date":"2009-01-28T00:09:21Z","reference_number":"EMEA/MB/671250/2008 Adopted","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-sixty-first-meeting-management-board-11-december-2008_en.pdf"},
    {"id":"13661","name":"Presentation - Epidemiology as an enabler for health (Alison Cave)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-epidemiology-enabler-health-alison-cave_en.pdf"},
    {"id":"13673","name":"Minutes - European network of paediatric research and the European Medicines Agency Coordinating Group meeting with chairs of the Working Groups","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-and-european-medicines-agency-coordinating-group-meeting-chairs-working-groups_en.pdf"},
    {"id":"13679","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting -  May 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"EMA/297283/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-may-2013_en.pdf"},
    {"id":"13703","name":"Minutes of the European Medicines Agency Human Scientific Committees’ Working Party with Patients’ and Consumers’ organisations (PCWP) meeting with all eligible organisations","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"EMA/1639/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations_en.pdf"},
    {"id":"13753","name":"Minutes - PDCO minutes of the 9-11 December 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-02-09T01:00:00Z","last_updated_date":"2016-02-09T01:00:00Z","reference_number":"EMA/PDCO/835743/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-9-11-december-2015-meeting_en.pdf"},
    {"id":"13818","name":"Minutes - PDCO minutes of the 16-19 May 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2017-08-01T18:00:00Z","reference_number":"EMA/PDCO/307150/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-16-19-may-2017-meeting_en.pdf"},
    {"id":"13857","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting -  February 2010","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-february-2010_en.pdf"},
    {"id":"13935","name":"Minutes of the CHMP meeting 20-23 October 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-11-27T17:50:00Z","last_updated_date":"2014-11-27T17:50:00Z","reference_number":"EMA/679758/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-20-23-october-2014_en.pdf"},
    {"id":"13941","name":"Minutes of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) 25 February 2014 joint meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"EMA/155728/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-25-february-2014-joint-meeting_en.pdf"},
    {"id":"13982","name":"Report of the expert meeting on paediatric asthma, 20 October 2010","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T17:01:00Z","last_updated_date":"2012-11-23T17:01:00Z","reference_number":"EMA/726030/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/report-expert-meeting-paediatric-asthma-20-october-2010_en.pdf"},
    {"id":"13991","name":"Minutes of the PRAC meeting 3-6 March 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-04-28T11:30:00Z","last_updated_date":"2014-04-28T11:30:00Z","reference_number":"EMA/PRAC/253432/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-3-6-march-2014_en.pdf"},
    {"id":"14016","name":"Minutes of the CAT meeting 22-23 March 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-05-03T16:40:00Z","last_updated_date":"2016-05-03T16:40:00Z","reference_number":"EMA/CAT/310689/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-22-23-march-2016_en.pdf"},
    {"id":"14038","name":"Minutes of the PRAC meeting 5-8 March 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-05-08T19:06:00Z","last_updated_date":"2018-05-08T19:06:00Z","reference_number":"EMA/288259/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-5-8-march-2018_en.pdf"},
    {"id":"14214","name":"Minutes of the CHMP meeting 18-21 July 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-09-23T13:35:00Z","last_updated_date":"2016-09-23T13:35:00Z","reference_number":"EMA/CHMP/623490/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-18-21-july-2016_en.pdf"},
    {"id":"14236","name":"Minutes of the Healthcare Professionals' Organisations Working Group meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-12-19T01:00:00Z","last_updated_date":"2011-12-19T01:00:00Z","reference_number":"EMA/873439/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-healthcare-professionals-organisations-working-group-meeting_en.pdf"},
    {"id":"14287","name":"Minutes of the CHMP meeting 09-12 October 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-11-23T15:01:00Z","last_updated_date":"2017-11-23T15:01:00Z","reference_number":"EMA/CHMP/762846/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-09-12-october-2017_en.pdf"},
    {"id":"14289","name":"Minutes of the 67th meeting of the Management Board: 10 June 2010","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2010-08-19T02:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/MB/404038/2010","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-67th-meeting-management-board-10-june-2010_sv.pdf"}},
    {"id":"14321","name":"Minutes of the HMPC 27-28 March 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-07-05T13:30:00Z","last_updated_date":"2017-07-05T13:30:00Z","reference_number":"EMA/HMPC/347754/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-27-28-march-2017-meeting_en.pdf"},
    {"id":"14387","name":"Inventory of EU PV & PE research centres in ENCePP - Minutes of working group 4","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/462010/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/inventory-eu-pv-pe-research-centres-encepp-minutes-working-group-4_en.pdf"},
    {"id":"14517","name":"Minutes - PDCO minutes of the 24-27 January 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-27T17:18:00Z","last_updated_date":"2017-02-27T17:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-24-27-january-2017-meeting_en.pdf"},
    {"id":"14527","name":"Minutes - PDCO minutes of the 15-17 January 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-03-05T17:15:00Z","last_updated_date":"2014-03-05T17:15:00Z","reference_number":"EMA/PDCO/798803/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-15-17-january-2014-meeting_en.pdf"},
    {"id":"14587","name":"Minutes of the PRAC meeting 3-6 July 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-09-22T19:30:00Z","last_updated_date":"2017-09-22T19:30:00Z","reference_number":"EMA/PRAC/631448/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-3-6-july-2017_en.pdf"},
    {"id":"14647","name":"Minutes - PDCO minutes of the 7-9 October 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:57:00Z","last_updated_date":"2015-11-23T16:57:00Z","reference_number":"EMA/PDCO/662503/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-7-9-october-2015-meeting_en.pdf"},
    {"id":"14731","name":"Minutes of the PRAC meeting 06-09 June 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T17:00:00Z","last_updated_date":"2016-08-26T17:00:00Z","reference_number":"EMA/PRAC/460046/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-06-09-june-2016_en.pdf"},
    {"id":"14756","name":"Minutes of the HMPC 6-7 July 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-10-12T18:40:00Z","last_updated_date":"2015-10-12T18:40:00Z","reference_number":"EMA/HMPC/645800/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-6-7-july-2015-meeting_en.pdf"},
    {"id":"14769","name":"Minutes of the European Medicines Agency Human Scientific Committees’ Working Party with Healthcare Professionals’ Organisations meeting: Election of co-chair","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-12-11T10:30:00Z","last_updated_date":"2013-12-11T10:30:00Z","reference_number":"EMA/697021/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-healthcare-professionals-organisations-meeting-election-co-chair_en.pdf"},
    {"id":"14813","name":"Minutes of the HMPC 11-12 November 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-02-03T12:00:00Z","last_updated_date":"2014-02-03T12:00:00Z","reference_number":"EMA/HMPC/742564/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-11-12-november-2013-meeting_en.pdf"},
    {"id":"15008","name":"Minutes of the eleventh EMA human scientific committees' working party with patients' and consumers' organisations (PCWP) meeting of 08 September 2010","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2010-11-22T01:00:00Z","last_updated_date":"2010-11-22T01:00:00Z","reference_number":"EMA/575467/2010","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-eleventh-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-08-september-2010_en.pdf"},
    {"id":"15058","name":"Minutes of the 86th meeting of the Management Board: 17-18 December 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-03-26T14:10:00Z","last_updated_date":"2015-03-26T14:10:00Z","reference_number":"EMA/MB/791352/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-86th-meeting-management-board-17-18-december-2014_en.pdf"},
    {"id":"15124","name":"Minutes of the Patients' and Consumers’ Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint meeting - June 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"EMA/362080/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-meeting-june-2013_en.pdf"},
    {"id":"15222","name":"Minutes - Veterinary focus group meeting with stakeholders: revision of the reflection paper on anthelmintic resistance","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"EMA/CVMP/EWP/412810/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-veterinary-focus-group-meeting-stakeholders-revision-reflection-paper-anthelmintic-resistance_en.pdf"},
    {"id":"15241","name":"Minutes of the CHMP meeting 29 March - 1 April 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-05-03T14:45:00Z","last_updated_date":"2016-05-03T14:45:00Z","reference_number":"EMA/312797/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-29-march-1-april-2016_en.pdf"}    {"id":"15279","name":"Minutes of the European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting of 13 September 2011","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"EMA/545841/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-13-september-2011_en.pdf"},
    {"id":"15361","name":"Minutes of the CAT meeting 16-17 June 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T18:25:00Z","last_updated_date":"2016-07-22T18:25:00Z","reference_number":"EMA/CAT/503591/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-16-17-june-2016_en.pdf"},
    {"id":"15638","name":"Minutes - COMP meeting 6-7 November 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-12-19T16:01:01Z","last_updated_date":"2012-12-19T16:01:01Z","reference_number":"EMA/COMP/648772/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-6-7-november-2012_en.pdf"},
    {"id":"15705","name":"Minutes of the PRAC meeting 26-29 September 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-21T13:20:00Z","last_updated_date":"2017-02-21T13:20:00Z","reference_number":"EMA/PRAC/123588/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-26-29-september-2016_en.pdf"},
    {"id":"15771","name":"Minutes - PDCO minutes of the 13-16 December 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-20T12:35:00Z","last_updated_date":"2017-02-20T12:35:00Z","reference_number":"EMA/PDCO/860428/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-13-16-december-2016-meeting_en.pdf"},
    {"id":"15772","name":"Minutes of the 80th meeting of the Management Board: 13 June 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-08-06T14:00:00Z","last_updated_date":"2013-08-06T14:00:00Z","reference_number":"EMA/MB/367978/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-80th-meeting-management-board-13-june-2013_en.pdf"},
    {"id":"15778","name":"Minutes of the PRAC meeting 1-4 December 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-01-14T16:55:00Z","last_updated_date":"2015-01-14T16:55:00Z","reference_number":"EMA/PRAC/786812/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-1-4-december-2014_en.pdf"},
    {"id":"15837","name":"Minutes of the EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations - December 2013","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T13:30:00Z","last_updated_date":"2014-02-07T13:30:00Z","reference_number":"EMA/792279/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations-december-2013_en.pdf"},
    {"id":"15853","name":"Minutes - Highlights from the 11th EMA Industry Platform meeting on the operation of EU pharmacovigilance legislation","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T16:03:00Z","last_updated_date":"2017-07-25T16:03:00Z","reference_number":"EMA/369620/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-highlights-11th-ema-industry-platform-meeting-operation-eu-pharmacovigilance-legislation_en.pdf"},
    {"id":"15956","name":"Minutes of the PRAC meeting 4-7 March 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T10:38:00Z","last_updated_date":"2013-04-26T10:38:00Z","reference_number":"EMA/248666/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-4-7-march-2013_en.pdf"},
    {"id":"16032","name":"Minutes of the COMP meeting 13-15 June 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-08-03T15:30:00Z","last_updated_date":"2017-08-03T15:30:00Z","reference_number":"EMA/COMP/375607/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-13-15-june-2017_en.pdf"},
    {"id":"16189","name":"Minutes of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - 4 June 2015","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-09-01T02:00:00Z","last_updated_date":"2015-09-01T02:00:00Z","reference_number":"EMA/167556/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-4-june-2015_en.pdf"},
    {"id":"16442","name":"Minutes from the Joint Meeting Patients & Consumers Organisations (PCO) and Committee on Herbal Medicinal Products (HMPC) held on 13 March 2009 on the content and publication of HMPC documents","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2010-06-14T02:00:00Z","last_updated_date":"2010-06-14T02:00:00Z","reference_number":"EMA/220282/2009","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-joint-meeting-patients-consumers-organisations-pco-committee-herbal-medicinal-products-hmpc-held-13-march-2009-content-publication-hmpc-documents_en.pdf"},
    {"id":"16483","name":"Minutes of the HMPC 28-29 September 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-12-07T14:32:00Z","last_updated_date":"2015-12-07T14:32:00Z","reference_number":"EMA/HMPC/814611/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-28-29-september-2015-meeting_en.pdf"},
    {"id":"16501","name":"Minutes - PDCO minutes of the 10-12 September 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-10-16T12:55:00Z","last_updated_date":"2014-10-16T12:55:00Z","reference_number":"EMA/PDCO/544529/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-10-12-september-2014-meeting_en.pdf"},
    {"id":"16650","name":"Minutes of the CHMP meeting 22-25 February 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-04-06T13:50:00Z","last_updated_date":"2016-04-06T13:50:00Z","reference_number":"EMA/CHMP/244718/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-february-2016_en.pdf"},
    {"id":"16700","name":"Minutes - PDCO minutes of the 16-18 July 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-08-15T13:38:00Z","last_updated_date":"2014-08-15T13:38:00Z","reference_number":"EMA/427398/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-16-18-july-2014-meeting_en.pdf"},
    {"id":"16719","name":"Highlights from the eighth European Medicines Agency Industry Platform meeting on the operation of European Union pharmacovigilance legislation - 1 July 2016","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-08-16T11:10:00Z","last_updated_date":"2016-08-16T11:10:00Z","reference_number":"EMA/459864/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-eighth-european-medicines-agency-industry-platform-meeting-operation-european-union-pharmacovigilance-legislation-1-july-2016_en.pdf"},
    {"id":"16790","name":"Minutes of the PRAC meeting 2-5 September 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-10-21T13:35:00Z","last_updated_date":"2013-10-21T13:35:00Z","reference_number":"EMA/PRAC/586155/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-2-5-september-2013_en.pdf"},
    {"id":"16816","name":"Minutes of the CVMP meeting of 8-10 November 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-12-09T15:22:00Z","last_updated_date":"2016-12-09T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-november-2016_en.pdf"},
    {"id":"16944","name":"Minutes of the COMP meeting 9-11 December 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-22T01:00:00Z","reference_number":"EMA/COMP/727397/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-9-11-december-2014_en.pdf"},
    {"id":"17073","name":"Minutes - PDCO minutes of the 30 March-1 April 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-05-20T16:05:00Z","last_updated_date":"2016-05-20T16:05:00Z","reference_number":"EMA/PDCO/230626/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-30-march-1-april-2016-meeting_en.pdf"},
    {"id":"17193","name":"Highlights - Second industry stakeholder platform on the operation of European Union pharmacovigilance legislation","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMA/38167/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-second-industry-stakeholder-platform-operation-european-union-pharmacovigilance-legislation_en.pdf"},
    {"id":"17197","name":"Minutes of the Healthcare Professionals' Working Group meeting of 8 May 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-08-14T14:00:00Z","last_updated_date":"2012-08-14T14:00:00Z","reference_number":"EMA/432052/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-healthcare-professionals-working-group-meeting-8-may-2012_en.pdf"},
    {"id":"17235","name":"Minutes of the CAT meeting 19-20 June 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-07-30T11:40:00Z","last_updated_date":"2014-07-30T11:40:00Z","reference_number":"EMA/CAT/449117/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-19-20-june-2014_en.pdf"},
    {"id":"17350","name":"Minutes - PDCO minutes of the 15-17 July 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-08-17T16:40:00Z","last_updated_date":"2015-08-17T16:40:00Z","reference_number":"EMA/PDCO/471874/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-15-17-july-2015-meeting_en.pdf"},
    {"id":"17564","name":"Minutes of the CAT meeting 13-15 July 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-09-26T02:00:00Z","last_updated_date":"2016-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-13-15-july-2016_en.pdf"},
    {"id":"17565","name":"Minutes of the European Medicines Agency - Payer Community meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-12-06T17:27:00Z","last_updated_date":"2017-12-06T17:27:00Z","reference_number":"EMA/615275/2017 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-payer-community-meeting_en.pdf"},
    {"id":"17660","name":"CHMP ORGAM minutes for the meeting on 16 April 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-06-08T14:30:00Z","last_updated_date":"2018-06-08T14:30:00Z","reference_number":"EMA/CHMP/257951/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-16-april-2018_en.pdf"},
    {"id":"17722","name":"Minutes of the EMA Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP) meeting - 4 June 2015","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-09-01T02:00:00Z","last_updated_date":"2015-09-01T02:00:00Z","reference_number":"EMA/377881/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-meeting-4-june-2015_en.pdf"},
    {"id":"17753","name":"EMEA/CHMP working group with Healthcare Professionals' Organisations  Wednesday, 24 October 2007  - Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-01-31T01:00:00Z","last_updated_date":"2008-01-31T01:00:00Z","reference_number":"EMEA/514084/2007","document_url":"https://www.ema.europa.eu/en/documents/minutes/emea-chmp-working-group-healthcare-professionals-organisations-wednesday-24-october-2007-minutes_en.pdf"},
    {"id":"17924","name":"Minutes of the COMP meeting 7-9 January 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-02-18T11:35:00Z","last_updated_date":"2015-02-18T16:50:00Z","reference_number":"EMA/COMP/780484/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-7-9-january-2015_en.pdf"},
    {"id":"18010","name":"Minutes of the CAT meeting 13-14 February 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T17:35:00Z","last_updated_date":"2014-03-24T17:35:00Z","reference_number":"EMA/CAT/163913/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-13-14-february-2014_en.pdf"},
    {"id":"18064","name":"Minutes of the CAT meeting 30-31 October 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T14:55:00Z","last_updated_date":"2018-01-26T14:55:00Z","reference_number":"EMA/CAT/52359/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-30-31-october-2017_en.pdf"},
    {"id":"18086","name":"Minutes of the CVMP meeting of 12-14 July 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-09-19T17:25:00Z","last_updated_date":"2016-09-19T17:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-12-14-july-2016_en.pdf"},
    {"id":"18142","name":"Minutes of the 69th meeting of the Management Board: 16 December 2010","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-02-11T01:00:00Z","last_updated_date":"2011-02-11T01:00:00Z","reference_number":"EMA/MB/808316/2010 corr.","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-69th-meeting-management-board-16-december-2010_sv.pdf"}},
    {"id":"18163","name":"Minutes - PDCO minutes of the 8-10 October 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-11-18T10:35:00Z","last_updated_date":"2014-11-18T10:35:00Z","reference_number":"EMA/PDCO/609719/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-8-10-october-2014-meeting_en.pdf"},
    {"id":"18237","name":"Minutes - PDCO minutes of the 26-29 June 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-08-06T13:45:00Z","last_updated_date":"2018-08-06T13:45:00Z","reference_number":"EMA/PDCO/437683/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-26-29-june-2018-meeting_en.pdf"},
    {"id":"18267","name":"Minutes - PDCO minutes of the 18-21 July 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-10-10T17:13:00Z","last_updated_date":"2017-10-10T17:13:00Z","reference_number":"EMA/PDCO/460837/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-18-21-july-2017-meeting_en.pdf"},
    {"id":"18285","name":"Minutes of the HMPC 30 June-1 July 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-10-16T11:10:00Z","last_updated_date":"2014-10-16T11:10:00Z","reference_number":"EMA/HMPC/441024/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-30-june-1-july-2014-meeting_en.pdf"},
    {"id":"18339","name":"Minutes of the CAT meeting 16-17 October 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-12-02T17:15:00Z","last_updated_date":"2014-12-02T17:15:00Z","reference_number":"EMA/CAT/737852/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-16-17-october-2014_en.pdf"},
    {"id":"18369","name":"Minutes of the COMP meeting 10-12 May 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T11:15:00Z","last_updated_date":"2017-07-21T11:15:00Z","reference_number":"EMA/COMP/294665/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-12-may-2017_en.pdf"},
    {"id":"18440","name":"Minutes of the European Union International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) / substance, product, organisation and referential data (SPOR) task force meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-12-20T17:00:00Z","last_updated_date":"2017-12-20T17:00:00Z","reference_number":"EMA/839613/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-international-organization-standardization-iso-identification-medicinal-products-idmp-substance-product-organisation-and-referential-data-spor-task-force-meeting_en.pdf"},
    {"id":"18466","name":"Minutes - PDCO minutes of the 5-7 September 2012 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-10-11T13:35:00Z","last_updated_date":"2012-10-11T13:35:00Z","reference_number":"EMA/PDCO/565104/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-5-7-september-2012-meeting_en.pdf"},
    {"id":"18515","name":"Minutes - PDCO minutes of the 24-26 February 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-04-13T15:40:00Z","last_updated_date":"2016-04-13T15:40:00Z","reference_number":"EMA/PDCO/150499/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-24-26-february-2016-meeting_en.pdf"},
    {"id":"18557","name":"Minutes of the COMP meeting 1-3 September 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T12:08:00Z","last_updated_date":"2015-10-23T12:08:00Z","reference_number":"EMA/COMP/583387/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-1-3-september-2015_en.pdf"},
    {"id":"18599","name":"Minutes of the CVMP meeting of 4-6 November 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-12-11T15:00:00Z","last_updated_date":"2015-12-11T15:00:00Z","reference_number":"EMA/CVMP/829802/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-4-6-november-2015_en.pdf"},
    {"id":"18643","name":"Minutes of the 2017 annual members meeting of the European network of paediatric research at the European Medicines Agency (Enpr-EMA)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T12:45:00Z","last_updated_date":"2017-07-24T12:45:00Z","reference_number":"EMA/329833/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-2017-annual-members-meeting-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"18649","name":"Minutes of CHMP written procedure 14-17 August 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T17:25:00Z","last_updated_date":"2017-10-24T17:25:00Z","reference_number":"EMA/CHMP/467690/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-written-procedure-14-17-august-2017_en.pdf"},
    {"id":"18735","name":"Minutes of the COMP meeting 14-16 June 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-08-25T12:30:00Z","last_updated_date":"2016-08-25T12:30:00Z","reference_number":"EMA/COMP/404281/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-16-june-2016_en.pdf"},
    {"id":"18758","name":"Minutes of the PRAC meeting 5-8 October 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-11-27T14:52:00Z","last_updated_date":"2015-11-27T14:52:00Z","reference_number":"EMA/PRAC/725044/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-5-8-october-2015_en.pdf"},
    {"id":"18801","name":"EMEA/CHMP working group with Healthcare Professionals' Organisations  Friday, 16 March 2007  - Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-06-01T02:00:00Z","last_updated_date":"2008-06-01T02:00:00Z","reference_number":"EMEA/129522/2007","document_url":"https://www.ema.europa.eu/en/documents/minutes/emea-chmp-working-group-healthcare-professionals-organisations-friday-16-march-2007-minutes_en.pdf"},
    {"id":"18938","name":"Minutes of the European Network of Paediatric Research at the European Medicines Agency Coordinating Group meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-10-23T13:25:00Z","last_updated_date":"2013-10-23T13:25:00Z","reference_number":"EMA/543361/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-agency-coordinating-group-meeting_en.pdf"},
    {"id":"19118","name":"Minutes of the CAT meeting 13-14 March 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-04-30T16:30:00Z","last_updated_date":"2014-04-30T16:30:00Z","reference_number":"EMA/CAT/252280/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-13-14-march-2014_en.pdf"},
    {"id":"19203","name":"Minutes of the CAT meeting 6-7 October 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T15:55:00Z","last_updated_date":"2016-11-24T15:55:00Z","reference_number":"EMA/CAT/783686/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-6-7-october-2016_en.pdf"},
    {"id":"19244","name":"Minutes of the PRAC meeting 6-9 July 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-09-23T11:20:00Z","last_updated_date":"2015-09-23T11:20:00Z","reference_number":"EMA/PRAC/269153/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-6-9-july-2015_en.pdf"},
    {"id":"19302","name":"Minutes of the CVMP meeting of 5-7 December 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-01-19T15:45:00Z","last_updated_date":"2018-01-19T15:45:00Z","reference_number":"EMA/CVMP/30112/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-5-7-december-2017_en.pdf"},
    {"id":"19324","name":"Minutes of the CHMP meeting 12-15 December 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-08T17:53:00Z","last_updated_date":"2017-02-09T17:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-12-15-december-2016_en.pdf"},
    {"id":"19381","name":"Minutes of the EMA Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP) meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-08-22T02:00:00Z","last_updated_date":"2016-08-22T02:00:00Z","reference_number":"EMA/418148/20166","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-meeting_en.pdf"},
    {"id":"19501","name":"Minutes of the COMP meeting 4-6 October 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T16:50:00Z","last_updated_date":"2016-11-15T16:50:00Z","reference_number":"EMA/COMP/653816/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-4-6-october-2016_en.pdf"},
    {"id":"19633","name":"Minutes of the PRAC meeting 6-9 February 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T13:03:00Z","last_updated_date":"2017-05-05T13:03:00Z","reference_number":"EMA/PRAC/286717/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-6-9-february-2017_en.pdf"},
    {"id":"19811","name":"Minutes of the sixth European network of paediatric research at the European Medicines Agency coordinating group meeting - 27 June 2014","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-02-02T15:00:00Z","last_updated_date":"2015-02-02T15:00:00Z","reference_number":"EMA/410668/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-sixth-european-network-paediatric-research-european-medicines-agency-coordinating-group-meeting-27-june-2014_en.pdf"},
    {"id":"19870","name":"Minutes of the 92nd meeting of the Management Board","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-07-29T19:10:00Z","last_updated_date":"2016-09-23T19:10:00Z","reference_number":"EMA/MB/421228/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-92nd-meeting-management-board_en.pdf"},
    {"id":"19881","name":"Minutes of the PRAC meeting 3-6 April 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-06-02T19:00:00Z","last_updated_date":"2017-06-02T19:00:00Z","reference_number":"EMA/PRAC/271304/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-3-6-april-2017_en.pdf"},
    {"id":"19994","name":"Minutes Annual Patients/Consumers Working Party (PCWP) and Healthcare Professionals Working Group (HCP WG) joint meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"EMA/210985/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-annual-patientsconsumers-working-party-pcwp-and-healthcare-professionals-working-group-hcp-wg-joint-meeting_en.pdf"},
    {"id":"20019","name":"Minutes of the 88th meeting of the Management Board: 11 June 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-07-30T16:00:00Z","last_updated_date":"2015-07-30T16:00:00Z","reference_number":"EMA/MB/313120/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-88th-meeting-management-board-11-june-2015_en.pdf"},
    {"id":"20196","name":"Minutes of the sixth meeting of the EMEA Human Scientific Committees’ Working Party with with Patients’ and Consumers’ Organisations (PCWP)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/516924/08","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-sixth-meeting-emea-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp_en.pdf"},
    {"id":"20432","name":"Minutes of the CHMP meeting 23-26 May 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-06-30T18:36:00Z","last_updated_date":"2016-06-30T18:36:00Z","reference_number":"EMA/445754/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-23-26-may-2016_en.pdf"},
    {"id":"20437","name":"Minutes - PDCO minutes of the 20-23 February 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-05-16T18:00:00Z","last_updated_date":"2018-05-16T18:00:00Z","reference_number":"EMA/PDCO/113780/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-20-23-february-2018-meeting_en.pdf"},
    {"id":"20499","name":"Minutes of the CVMP meeting of 8-10 April 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T17:30:00Z","last_updated_date":"2015-05-11T17:30:00Z","reference_number":"EMA/294611/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-april-2015_en.pdf"},
    {"id":"20616","name":"Minutes of the CAT meeting 6-8 December 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-02-13T12:20:00Z","last_updated_date":"2018-02-13T12:20:00Z","reference_number":"EMA/CAT/92967/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-6-8-december-2017_en.pdf"},
    {"id":"20662","name":"Minutes of the CHMP meeting 15-18 May 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T19:00:00Z","last_updated_date":"2018-02-01T18:00:00Z","reference_number":"EMA/CHMP/262210/2017 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-15-18-may-2017_en.pdf"},
    {"id":"20674","name":"Minutes - European Union International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) task force meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/871857/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-international-organization-standardization-iso-identification-medicinal-products-idmp-task-force-meeting_en.pdf"},
    {"id":"20743","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting - May 2015","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-07-01T12:50:00Z","last_updated_date":"2015-07-01T12:50:00Z","reference_number":"EMA/353327/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-may-2015_en.pdf"},
    {"id":"20797","name":"Presentation - Scientific advice delivers planning during development (Spiros Vamvakas)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-scientific-advice-delivers-planning-during-development-spiros-vamvakas_en.pdf"},
    {"id":"20847","name":"Minutes of the PRAC meeting 6-9 March 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T15:56:00Z","last_updated_date":"2017-05-05T15:56:00Z","reference_number":"EMA/PRAC/287540/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-6-9-march-2017_en.pdf"},
    {"id":"20920","name":"Minutes of the seventh annual European network of paediatric research at the  European Medicines Agency (Enpr-EMA) members face to face  meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-08-05T13:30:00Z","last_updated_date":"2015-08-05T13:30:00Z","reference_number":"EMA/366838/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-seventh-annual-european-network-paediatric-research-european-medicines-agency-enpr-ema-members-face-face-meeting_en.pdf"},
    {"id":"20925","name":"Minutes of the European Medicines Agency/European network for Health Technology Assessment dialogue meeting - December 2017","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-04-16T15:00:00Z","last_updated_date":"2018-04-16T15:00:00Z","reference_number":"EMA/845953/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-dialogue-meeting-december-2017_en.pdf"},
    {"id":"20926","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting -  February 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-february-2012_en.pdf"},
    {"id":"20932","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting -  June 2010","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-june-2010_en.pdf"},
    {"id":"21006","name":"Minutes of the European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting on 6 June 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-07-02T17:00:00Z","last_updated_date":"2013-07-02T17:00:00Z","reference_number":"EMA/263690/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-6-june-2013_en.pdf"},
    {"id":"21011","name":"Minutes - PDCO minutes of the 22-24 June 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-08-04T12:35:00Z","last_updated_date":"2016-08-04T12:35:00Z","reference_number":"EMA/PDCO/436533/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-22-24-june-2016-meeting_en.pdf"},
    {"id":"21023","name":"Minutes of the CAT meeting 20-21 April 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T11:20:00Z","last_updated_date":"2016-06-02T11:20:00Z","reference_number":"EMA/CAT/379547/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-20-21-april-2016_en.pdf"},
    {"id":"21025","name":"Minutes - PDCO minutes of the 9-11 October 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-11-14T11:55:00Z","last_updated_date":"2013-11-14T11:55:00Z","reference_number":"EMA/PDCO/592586/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-9-11-october-2013-meeting_en.pdf"},
    {"id":"21113","name":"Minutes of the CHMP meeting 11-14 September 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T17:58:00Z","last_updated_date":"2017-11-07T11:02:00Z","reference_number":"EMA/CHMP/479458/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-11-14-september-2017_en.pdf"},
    {"id":"21149","name":"Minutes of the CVMP meeting of 14-16 February 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T13:10:00Z","last_updated_date":"2017-03-17T13:10:00Z","reference_number":"EMA/CVMP/179328/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-14-16-february-2017_en.pdf"},
    {"id":"21198","name":"CHMP ORGAM minutes for the meeting on 13 March 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-04-25T16:23:00Z","last_updated_date":"2017-04-25T16:23:00Z","reference_number":"EMA/CHMP/174289/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-13-march-2017_en.pdf"},
    {"id":"21315","name":"Minutes - EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"EMA/779124/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations_en.pdf"},
    {"id":"21356","name":"Minutes of the HMPC 1-2 February 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-04-18T12:00:00Z","last_updated_date":"2016-04-18T12:00:00Z","reference_number":"EMA/HMPC/252822/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-1-2-february-2016-meeting_en.pdf"},
    {"id":"21508","name":"Minutes of the CVMP meeting of 6-8 December 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T16:15:00Z","last_updated_date":"2017-01-30T16:15:00Z","reference_number":"EMA/CVMP/35323/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-6-8-december-2016_en.pdf"},
    {"id":"21518","name":"Focus group meeting - Revision of bioequivalence guideline - Minutes of the meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2009-07-08T02:09:21Z","last_updated_date":"2009-07-08T02:09:21Z","reference_number":"EMEA/CVMP/EWP/290174/2009","document_url":"https://www.ema.europa.eu/en/documents/minutes/focus-group-meeting-revision-bioequivalence-guideline-minutes-meeting_en.pdf"},
    {"id":"21526","name":"Minutes of the Extraordinary Management Board meeting for the building approval process of EMA premises in Amsterdam: 28 February 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-04-05T19:10:00Z","last_updated_date":"2018-04-05T19:10:00Z","reference_number":"EMA/MB/102052/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-extraordinary-management-board-meeting-building-approval-process-ema-premises-amsterdam-28-february-2018_en.pdf"},
    {"id":"21680","name":"Minutes of the PRAC meeting 28 November - 1 December 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-04-10T11:40:00Z","last_updated_date":"2017-04-10T11:40:00Z","reference_number":"EMA/PRAC/237221/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-28-november-1-december-2016_en.pdf"},
    {"id":"21757","name":"Minutes of the CHMP meeting 17-20 March 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-04-28T18:20:00Z","last_updated_date":"2014-04-28T18:20:00Z","reference_number":"EMA/CHMP/189248/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-17-20-march-2014_en.pdf"},
    {"id":"21785","name":"Minutes of the COMP meeting 17-19 March 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-04-22T12:30:00Z","last_updated_date":"2015-04-22T12:30:00Z","reference_number":"EMA/COMP/105033/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-17-19-march-2015_en.pdf"},
    {"id":"21880","name":"Minutes of the COMP meeting 16-17 April 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T15:05:00Z","last_updated_date":"2013-05-31T15:05:00Z","reference_number":"EMA/COMP/165816/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-17-april-2013_en.pdf"},
    {"id":"21948","name":"Minutes of the COMP meeting 13-14 May 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-08-14T16:25:00Z","last_updated_date":"2014-08-14T16:25:00Z","reference_number":"EMA/COMP/220006/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-13-14-may-2014_en.pdf"},
    {"id":"21959","name":"Minutes of the CVMP meeting of 11-13 March 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-04-15T13:55:00Z","last_updated_date":"2014-04-15T13:55:00Z","reference_number":"EMA/CVMP/212566/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-11-13-march-2014_en.pdf"},
    {"id":"22035","name":"Minutes of the European Medicines Agency/European network for Health Technology Assessment dialogue meeting - December 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-03-03T11:00:00Z","last_updated_date":"2015-03-03T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-dialogue-meeting-december-2014_en.pdf"},
    {"id":"22119","name":"Minutes of the CVMP meeting of 9-11 September 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-10-14T13:40:00Z","last_updated_date":"2014-10-14T13:40:00Z","reference_number":"EMA/CVMP/540437/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-9-11-september-2014_en.pdf"}    {"id":"22189","name":"Minute of the European Medicines Agency/European Network for Health Technology Assessment meeting - November 2015","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-02-12T13:20:00Z","last_updated_date":"2016-02-12T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minute-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-november-2015_en.pdf"},
    {"id":"22198","name":"Minutes of the PRAC meeting 6-9 January 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T15:05:00Z","last_updated_date":"2015-02-27T15:05:00Z","reference_number":"EMA/PRAC/54777/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-6-9-january-2015_en.pdf"},
    {"id":"22259","name":"Minutes of the eighth meeting of the EMEA Human Scientific Committees’ Working Party with with Patients’ and Consumers’ Organisations (PCWP)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2009-04-08T02:00:00Z","last_updated_date":"2009-04-08T02:00:00Z","reference_number":"EMEA/146988/2009","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-eighth-meeting-emea-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp_en.pdf"},
    {"id":"22276","name":"Minutes of the PRAC meeting 6-9 October 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-11-26T16:35:00Z","last_updated_date":"2014-11-26T16:35:00Z","reference_number":"EMA/PRAC/730503/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-6-9-october-2014_en.pdf"},
    {"id":"22301","name":"Minutes of the COMP meeting 6-8 September 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-10-18T18:50:00Z","last_updated_date":"2016-10-18T18:50:00Z","reference_number":"EMA/COMP/590983/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-6-8-september-2016_en.pdf"},
    {"id":"22321","name":"Minutes of the sixty-third meeting of the Management Board: 11 June 2009","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/MB/366757/2009/EN/Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-sixty-third-meeting-management-board-11-june-2009_sv.pdf"}},
    {"id":"22407","name":"Minutes of the ninth meeting of the EMA Human Scientific Committees’ Working Party with Patients' and Consumers' Organisations (PCWP), 30 September 2009","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMA/625710/2009","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ninth-meeting-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-30-september-2009_en.pdf"},
    {"id":"22560","name":"Independence & Transparency - Minutes of working group 2","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-04-28T02:00:00Z","last_updated_date":"2008-04-28T02:00:00Z","reference_number":"EMEA/230056/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/independence-transparency-minutes-working-group-2_en.pdf"},
    {"id":"22592","name":"Minutes of the PRAC meeting 04-08 July 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-09-23T02:00:00Z","last_updated_date":"2016-09-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-04-08-july-2016_en.pdf"},
    {"id":"22619","name":"Minutes of the CHMP meeting 23-26 January 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-03-21T11:00:00Z","last_updated_date":"2017-03-21T11:00:00Z","reference_number":"EMA/CHMP/133033/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-23-26-january-2017_en.pdf"},
    {"id":"22628","name":"Minutes of the CVMP meeting of 13-15 February 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T14:35:00Z","last_updated_date":"2018-03-23T14:35:00Z","reference_number":"EMA/CVMP/93469/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-13-15-february-2018_en.pdf"},
    {"id":"22699","name":"Minutes - PDCO minutes of the 20-22 May 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T14:15:00Z","last_updated_date":"2015-06-26T14:15:00Z","reference_number":"EMA/PDCO/340491/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-20-22-may-2015-meeting_en.pdf"},
    {"id":"22878","name":"Minutes of the CAT meeting 15–16 January 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T15:30:00Z","last_updated_date":"2015-03-06T15:30:00Z","reference_number":"EMA/CAT/37348/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-16-january-2015_en.pdf"},
    {"id":"22886","name":"Minutes of the 93rd meeting of the Management Board","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-11-16T17:30:00Z","last_updated_date":"2016-11-16T17:30:00Z","reference_number":"EMA/MB/489158/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-93rd-meeting-management-board_en.pdf"},
    {"id":"22924","name":"Minutes - Ninth industry stakeholder platform on the operation of EU pharmacovigilance (highlights)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T01:00:00Z","last_updated_date":"2017-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ninth-industry-stakeholder-platform-operation-eu-pharmacovigilance-highlights_en.pdf"},
    {"id":"23054","name":"Minutes of the CAT meeting 18-20 January 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-03-14T17:00:00Z","last_updated_date":"2017-03-14T17:00:00Z","reference_number":"EMA/CAT/176510/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-20-january-2017_en.pdf"},
    {"id":"23135","name":"Minutes of the PRAC meeting 11-14 April 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T19:25:00Z","last_updated_date":"2016-06-02T19:25:00Z","reference_number":"EMA/PRAC/319149/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-11-14-april-2016_en.pdf"},
    {"id":"23180","name":"Minutes of the COMP meeting 14-16 February 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-04T16:02:00Z","last_updated_date":"2017-05-04T16:02:00Z","reference_number":"EMA/COMP/97842/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-16-february-2017_en.pdf"},
    {"id":"23351","name":"Minutes of the HMPC 29-30 January 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-05-28T14:00:00Z","last_updated_date":"2018-05-28T14:00:00Z","reference_number":"EMA/HMPC/146940/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-29-30-january-2018-meeting_en.pdf"},
    {"id":"23356","name":"Minutes of the CHMP meeting 19–22 May 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T16:20:00Z","last_updated_date":"2014-07-01T16:20:00Z","reference_number":"EMA/CHMP/329259/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-may-2014_en.pdf"},
    {"id":"23409","name":"Minutes of the CVMP meeting of 6-8 May 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-06-10T16:42:00Z","last_updated_date":"2014-06-10T16:42:00Z","reference_number":"EMA/CVMP/337845/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-6-8-may-2014_en.pdf"},
    {"id":"23456","name":"Minutes of the CAT meeting 4-6 October 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-12-18T17:55:00Z","last_updated_date":"2017-12-18T17:55:00Z","reference_number":"EMA/CAT/837016/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-4-6-october-2017_en.pdf"},
    {"id":"23503","name":"Minutes - PDCO minutes of the 19-21 March 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-05-05T11:30:00Z","last_updated_date":"2014-05-05T11:30:00Z","reference_number":"EMA/PDCO/129787/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-19-21-march-2014-meeting_en.pdf"},
    {"id":"23821","name":"Minutes - PDCO minutes of the 17 - 19 August 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-10-12T17:01:00Z","last_updated_date":"2016-10-12T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-17-19-august-2016-meeting_en.pdf"},
    {"id":"23856","name":"Minutes of the Enpr-EMA Coordinating Group (CG) meeting 23 January 2014","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T17:45:00Z","last_updated_date":"2014-03-21T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-cg-meeting-23-january-2014_en.pdf"},
    {"id":"23871","name":"Minutes of European Medicines Agency Human Scientific Committees’ Working Party with Patients’ and Consumers’ Organisations meeting with all eligible organisations: 30 November 2012 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-02-12T01:00:00Z","last_updated_date":"2013-02-12T01:00:00Z","reference_number":"EMA/774808/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-meeting-all-eligible-organisations-30-november-2012-meeting_en.pdf"},
    {"id":"24055","name":"Minutes of the COMP meeting 8-10 July 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-10-07T14:10:00Z","last_updated_date":"2014-10-07T14:10:00Z","reference_number":"EMA/COMP/357442/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-8-10-july-2014_en.pdf"},
    {"id":"24067","name":"Minutes of the 208th CVMP meeting of 10-12 December 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-01-28T15:00:00Z","last_updated_date":"2014-01-28T15:00:00Z","reference_number":"EMA/CVMP/31508/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-208th-cvmp-meeting-10-12-december-2013_en.pdf"},
    {"id":"24146","name":"Minutes of the PRAC meeting 4-7 May 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-06-25T13:10:00Z","last_updated_date":"2015-06-25T13:10:00Z","reference_number":"EMA/PRAC/59170/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-4-7-may-2015_en.pdf"},
    {"id":"24153","name":"Minutes of the CAT meeting 15-16 April 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-06-02T16:15:00Z","last_updated_date":"2014-06-02T16:15:00Z","reference_number":"EMA/CAT/315050/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-16-april-2014_en.pdf"},
    {"id":"24163","name":"Minutes of the COMP meeting of 13-15 March 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-05-28T14:00:00Z","last_updated_date":"2018-05-28T14:00:00Z","reference_number":"EMA/COMP/150160/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-13-15-march-2018_en.pdf"},
    {"id":"24165","name":"Minutes of the CAT meeting 12-13 May 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-07-02T12:00:00Z","last_updated_date":"2015-07-02T12:00:00Z","reference_number":"EMA/CAT/331519/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-12-13-may-2015_en.pdf"},
    {"id":"24211","name":"Minutes of the CHMP meeting 11-14 December 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T12:00:00Z","last_updated_date":"2018-02-12T12:00:00Z","reference_number":"EMA/CHMP/847042/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-11-14-december-2017_en.pdf"},
    {"id":"24257","name":"Minutes of the CAT meeting 12-13 December 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-01-28T15:00:00Z","last_updated_date":"2014-01-28T15:00:00Z","reference_number":"EMA/CAT/30564/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-12-13-december-2013_en.pdf"},
    {"id":"24313","name":"Minutes of the CVMP meeting of 13-15 June 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-07-13T13:30:00Z","last_updated_date":"2017-07-13T13:30:00Z","reference_number":"EMA/CVMP/440948/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-13-15-june-2017_en.pdf"},
    {"id":"24393","name":"Minutes of the 2016 annual face to face meeting of the Enpr-EMA Coordinating Group members - 3 June 2016","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T13:45:00Z","last_updated_date":"2016-10-28T13:45:00Z","reference_number":"EMA/403089/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-2016-annual-face-face-meeting-enpr-ema-coordinating-group-members-3-june-2016_en.pdf"},
    {"id":"24432","name":"Minutes of the European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - 16 September 20...","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"EMA/563152/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-16-september-20_en.pdf"},
    {"id":"24611","name":"Minutes of the joint meeting of the EMA Scientific Committees’ Working Party with Patients’ and Consumers’ Organisations (PCWP) and the EMA/CHMP Working Group with Healthcare Professionals’ Organisations (HCP WG)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"EMA/149325/2010","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-joint-meeting-ema-scientific-committees-working-party-patients-consumers-organisations-pcwp-ema-chmp-working-group-healthcare-professionals-organisations-hcp-wg_en.pdf"},
    {"id":"24651","name":"Minutes of the CVMP meeting of 15-17 January 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T13:00:00Z","last_updated_date":"2018-02-23T13:00:00Z","reference_number":"EMA/CVMP/93469/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-15-17-january-2018_en.pdf"},
    {"id":"24791","name":"Minutes - EU IDMP/SPOR Task Force meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/476463/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-eu-idmpspor-task-force-meeting_en.pdf"},
    {"id":"24795","name":"CHMP ORGAM minutes for the meeting on 15 January 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-02-19T12:00:00Z","last_updated_date":"2018-02-19T12:00:00Z","reference_number":"EMA/48249/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-15-january-2018_en.pdf"},
    {"id":"24833","name":"Minutes of the European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting on 3 June 2015","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-08-10T18:30:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"EMA/167759/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-3-june-2015_en.pdf"},
    {"id":"24856","name":"Minutes of the CVMP meeting of 5-7 May 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-06-05T14:00:00Z","last_updated_date":"2015-06-05T14:00:00Z","reference_number":"EMA/CVMP/368443/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-5-7-may-2015_en.pdf"},
    {"id":"25117","name":"Minutes of the 96th meeting of the Management Board: 14-15 June 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-08-01T11:30:00Z","last_updated_date":"2017-08-01T11:30:00Z","reference_number":"EMA/MB/383134/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-96th-meeting-management-board-14-15-june-2017_en.pdf"},
    {"id":"25190","name":"CHMP ORGAM minutes for the meeting on 28 October 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-11-21T12:58:00Z","last_updated_date":"2016-11-21T12:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-28-october-2016_en.pdf"},
    {"id":"25207","name":"Minutes of the Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Group (HCPWG) joint meeting - February 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-05-24T18:00:00Z","last_updated_date":"2013-05-24T18:00:00Z","reference_number":"EMA/228576/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-group-hcpwg-joint-meeting-february-2013_en.pdf"},
    {"id":"25250","name":"Minutes of the sixth meeting of the EMEA/CHMP working group with Healthcare Professionals' Organisations EMEA, 30th October 2008","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-10-30T01:00:00Z","last_updated_date":"2008-10-30T01:00:00Z","reference_number":"EMEA/591309/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-sixth-meeting-emea-chmp-working-group-healthcare-professionals-organisations-emea-30th-october-2008_en.pdf"},
    {"id":"25271","name":"Minutes of the CVMP meeting of 19-21 June 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-07-23T16:30:00Z","last_updated_date":"2018-07-23T16:30:00Z","reference_number":"EMA/CVMP/495564/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-19-21-june-2018_en.pdf"},
    {"id":"25274","name":"Report: Workshop on paediatric formulations for assessors in national regulatory agencies","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"EMA/455844/2010","document_url":"https://www.ema.europa.eu/en/documents/minutes/report-workshop-paediatric-formulations-assessors-national-regulatory-agencies_en.pdf"},
    {"id":"25313","name":"Minutes of the PRAC meeting 30 August - 2 September 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T10:06:00Z","last_updated_date":"2016-11-15T10:06:00Z","reference_number":"EMA/PRAC/693633/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-30-august-2-september-2016_en.pdf"},
    {"id":"25316","name":"Minutes of the HMPC 24 November 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-02-05T14:45:00Z","last_updated_date":"2015-02-05T14:45:00Z","reference_number":"EMA/HMPC/769631/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-24-november-2014-meeting_en.pdf"},
    {"id":"25537","name":"Minutes of the CHMP meeting 18-21 May 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T12:05:00Z","last_updated_date":"2015-06-30T12:05:00Z","reference_number":"EMA/CHMP/425257/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-18-21-may-2015_en.pdf"},
    {"id":"25549","name":"Presentation - Pharmacovigilance impact evaluation – for better pharmacovigilance (Almath Spooner)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-pharmacovigilance-impact-evaluation-better-pharmacovigilance-almath-spooner_en.pdf"},
    {"id":"25589","name":"Minutes of the CHMP meeting 23-26 February 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T18:50:00Z","last_updated_date":"2015-04-09T18:50:00Z","reference_number":"EMA/CHMP/203276/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-23-26-february-2015_en.pdf"},
    {"id":"25743","name":"Minutes of the CHMP meeting 25-28 June 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-09-11T18:28:00Z","last_updated_date":"2018-09-11T18:28:00Z","reference_number":"EMA/519677/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-25-28-june-2018_en.pdf"},
    {"id":"25783","name":"Minutes of the twelfth European Medicines Agency (EMA) Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting of 22-23 February 2011","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-05-23T02:00:00Z","last_updated_date":"2011-05-23T02:00:00Z","reference_number":"EMA/9241/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-twelfth-european-medicines-agency-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-22-23-february-2011_en.pdf"},
    {"id":"25896","name":"Minutes of the COMP meeting of 19-21 June 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-08-17T11:40:00Z","last_updated_date":"2018-08-17T11:40:00Z","reference_number":"EMA/COMP/417627/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-19-21-june-2018_en.pdf"},
    {"id":"25979","name":"Minutes - Tenth industry stakeholder platform on the operation of pharmacovigilance in the European Union","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T18:30:00Z","last_updated_date":"2017-05-16T18:30:00Z","reference_number":"EMA/80558/20177","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-tenth-industry-stakeholder-platform-operation-pharmacovigilance-european-union_en.pdf"},
    {"id":"26016","name":"Minutes of the CHMP meeting 10-13 October 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-11-21T15:30:00Z","last_updated_date":"2016-11-21T15:30:00Z","reference_number":"EMA/CHMP/611664/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-10-13-october-2016_en.pdf"},
    {"id":"26132","name":"Minutes of the PRAC meeting 9-12 April 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-06-11T18:56:00Z","last_updated_date":"2018-06-11T18:56:00Z","reference_number":"EMA/PRAC/288660/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-april-2018_en.pdf"},
    {"id":"26141","name":"Minutes of the extraordinary meeting of the Management Board on 1 October 2015 for the appointment of the Executive Director","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T10:30:00Z","last_updated_date":"2015-11-16T10:30:00Z","reference_number":"EMA/MB/517093/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-extraordinary-meeting-management-board-1-october-2015-appointment-executive-director_en.pdf"},
    {"id":"26199","name":"Minutes of the CVMP meeting of 8-10 April 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T17:50:00Z","last_updated_date":"2014-05-12T17:50:00Z","reference_number":"EMA/CVMP/275244/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-april-2014_en.pdf"},
    {"id":"26258","name":"Minutes of the PRAC meeting 2-5 May 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-06-30T17:20:00Z","last_updated_date":"2017-06-30T17:20:00Z","reference_number":"EMA/PRAC/419638/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-2-5-may-2017_en.pdf"},
    {"id":"26278","name":"Minutes of the COMP meeting 10-12 June 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-08-14T16:25:00Z","last_updated_date":"2014-08-14T16:25:00Z","reference_number":"EMA/COMP/295834/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-12-june-2014_en.pdf"},
    {"id":"26463","name":"Minutes - PDCO minutes of the 12-14 November 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-12-15T13:10:00Z","last_updated_date":"2014-12-15T13:10:00Z","reference_number":"EMA/PDCO/697054/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-12-14-november-2014-meeting_en.pdf"},
    {"id":"26499","name":"CHMP ORGAM minutes for the meeting on 4 September 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-11-28T13:00:00Z","last_updated_date":"2017-11-28T13:00:00Z","reference_number":"EMA/606018/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-4-september-2017_en.pdf"},
    {"id":"26537","name":"Minutes of the PRAC meeting 3-6 February 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-03-18T12:45:00Z","last_updated_date":"2014-03-18T12:45:00Z","reference_number":"EMA/158631/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-3-6-february-2014_en.pdf"},
    {"id":"26547","name":"Minutes - PDCO minutes of the 7-9 November 2012 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-12-18T18:00:00Z","last_updated_date":"2012-12-18T18:00:00Z","reference_number":"EMA/638304/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-7-9-november-2012-meeting_en.pdf"},
    {"id":"26558","name":"CHMP ORGAM minutes for the meeting on 4 December 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-01-22T14:30:00Z","last_updated_date":"2018-01-22T14:30:00Z","reference_number":"EMA/828521/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-4-december-2017_en.pdf"},
    {"id":"26564","name":"Minutes of the CAT meeting 15-16 February 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-05-02T15:30:00Z","last_updated_date":"2018-05-02T15:30:00Z","reference_number":"EMA/CAT/271970/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-16-february-2018_en.pdf"},
    {"id":"26597","name":"Minutes - PDCO minutes of the 18-20 June 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-07-29T13:00:00Z","last_updated_date":"2014-07-29T13:00:00Z","reference_number":"EMA/PDCO/364111/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-18-20-june-2014-meeting_en.pdf"},
    {"id":"26598","name":"Minutes of the CAT meeting 10-11 December 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-02-05T13:50:00Z","last_updated_date":"2016-02-05T13:50:00Z","reference_number":"EMA/CAT/77433/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-10-11-december-2015_en.pdf"},
    {"id":"26751","name":"Minutes of the COMP meeting 11 - 13 July 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-09-26T02:00:00Z","last_updated_date":"2016-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-11-13-july-2016_en.pdf"},
    {"id":"26787","name":"Minutes of the CAT meeting 15-16 October 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-12-02T18:30:00Z","last_updated_date":"2015-12-02T18:30:00Z","reference_number":"EMA/CAT/816010/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-16-october-2015_en.pdf"},
    {"id":"26801","name":"Minutes - PDCO minutes of the 15-17 August 2012 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-09-13T11:17:00Z","last_updated_date":"2012-09-13T11:17:00Z","reference_number":"EMA/528504/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-15-17-august-2012-meeting_en.pdf"},
    {"id":"26834","name":"Minutes of the COMP meeting 11-12 March 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-04-28T11:40:00Z","last_updated_date":"2014-04-28T11:40:00Z","reference_number":"EMA/COMP/74734/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-11-12-march-2014_en.pdf"},
    {"id":"26954","name":"Minutes of the CHMP meeting 19-22 February 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-04-06T02:00:00Z","last_updated_date":"2018-04-06T02:00:00Z","reference_number":"EMA/CHMP/56177/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-february-2018_en.pdf"},
    {"id":"27016","name":"Minutes of the PRAC meeting 29 August -1 September 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-10-20T19:30:00Z","last_updated_date":"2017-10-20T19:30:00Z","reference_number":"EMA/PRAC/701894/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-29-august-1-september-2017_en.pdf"},
    {"id":"27027","name":"Minutes of the CAT meeting 16-17 April 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-06-08T12:00:00Z","last_updated_date":"2015-06-08T12:00:00Z","reference_number":"EMA/CAT/260206/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-16-17-april-2015_en.pdf"},
    {"id":"27028","name":"Final summary record – EDC systems and risk-based monitoring in Clinical Trials","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-06-26T18:20:00Z","last_updated_date":"2017-06-26T18:20:00Z","reference_number":"EMA/729273/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/final-summary-record-edc-systems-and-risk-based-monitoring-clinical-trials_en.pdf"},
    {"id":"27043","name":"Minutes of the PRAC meeting 4-7 February 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-03-15T16:00:00Z","last_updated_date":"2013-03-15T16:00:00Z","reference_number":"EMA/162000/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-4-7-february-2013_en.pdf"},
    {"id":"27252","name":"CHMP ORGAM minutes for the meeting on 12 June 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-08-04T16:00:00Z","last_updated_date":"2017-08-04T16:00:00Z","reference_number":"EMA/402672/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-12-june-2017_en.pdf"},
    {"id":"27261","name":"Minutes of the joint European Medicines Agency / Food and Drug Administration workshop for paediatric Gaucher disease type I: exploring the way forward, 17-18 September 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-11-28T01:00:00Z","last_updated_date":"2012-11-28T01:00:00Z","reference_number":"EMA/610397/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-joint-european-medicines-agency-food-and-drug-administration-workshop-paediatric-gaucher-disease-type-i-exploring-way-forward-17-18-september-2012_en.pdf"},
    {"id":"27296","name":"Report of the first meeting of the EMEA Human Scientific Committees’ Working Party with with Patients’ and Consumers’ Organisations (PCWP)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2006-12-13T01:00:00Z","last_updated_date":"2006-12-13T01:00:00Z","reference_number":"EMEA/66146/2007","document_url":"https://www.ema.europa.eu/en/documents/minutes/report-first-meeting-emea-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp_en.pdf"},
    {"id":"27318","name":"Highlights from the workshop on methods for efficacy studies in the everyday practice","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-11-27T11:20:00Z","last_updated_date":"2013-12-10T16:16:00Z","reference_number":"EMA/717922/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-workshop-methods-efficacy-studies-everyday-practice_en.pdf"},
    {"id":"27476","name":"Minutes of the European network of paediatric research at the European Medicines Agency coordinating group teleconference - 24 October 2014","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-02-16T16:30:00Z","last_updated_date":"2015-02-16T16:30:00Z","reference_number":"EMA/664345/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-agency-coordinating-group-teleconference-24-october-2014_en.pdf"},
    {"id":"27519","name":"Minutes - PDCO minutes of the 24-27 April 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-07-10T16:55:00Z","last_updated_date":"2018-07-10T16:55:00Z","reference_number":"EMA/PDCO/263134/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-24-27-april-2018-meeting_en.pdf"},
    {"id":"27527","name":"Minutes of the HMPC 11-12 July 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T13:00:00Z","last_updated_date":"2016-10-03T13:00:00Z","reference_number":"EMA/HMPC/626954/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-11-12-july-2016-meeting_en.pdf"},
    {"id":"27571","name":"Minutes of the PRAC meeting 5-8 May 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-06-30T12:50:00Z","last_updated_date":"2014-06-30T12:50:00Z","reference_number":"EMA/PRAC/324055/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-5-8-may-2014_en.pdf"},
    {"id":"27621","name":"Minutes of the CHMP meeting 23-26 March 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-04-27T16:07:00Z","last_updated_date":"2015-04-27T16:07:00Z","reference_number":"EMA/223528/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-23-26-march-2015_en.pdf"},
    {"id":"27644","name":"Minutes of the seventh annual European network of paediatric research at the  European Medicines Agency (Enpr-EMA) coordinating group (CG) face to face meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-08-05T13:30:00Z","last_updated_date":"2015-08-05T13:30:00Z","reference_number":"EMA/367915/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-seventh-annual-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-cg-face-face-meeting_en.pdf"},
    {"id":"27758","name":"Minutes of the PRAC meeting 9-12 January 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-04-11T17:50:00Z","last_updated_date":"2017-04-11T17:50:00Z","reference_number":"EMA/PRAC/243286/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-january-2017_en.pdf"},
    {"id":"27787","name":"Minutes of the CAT meeting 17 - 19 January 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-03-28T11:20:00Z","last_updated_date":"2018-03-28T11:20:00Z","reference_number":"EMA/CAT/197934/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-17-19-january-2018_en.pdf"},
    {"id":"27829","name":"Minutes of the CAT meeting 21-22 January 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-03-15T15:15:00Z","last_updated_date":"2016-03-15T15:15:00Z","reference_number":"EMA/CAT/169534/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-21-22-january-2016_en.pdf"},
    {"id":"27838","name":"Minutes - European Union International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) / Substance, Product, Organisation and Referential data (SPOR) task force meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-02T02:00:00Z","last_updated_date":"2017-05-02T02:00:00Z","reference_number":"EMA/186147/20177","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-international-organization-standardization-iso-identification-medicinal-products-idmp-substance-product-organisation-and-referential-data-spor-task-force-meeting_en.pdf-0"},
    {"id":"27849","name":"Minutes of the 100th meeting of the Management Board: 6-7 June 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-08-23T16:00:00Z","last_updated_date":"2018-08-23T16:00:00Z","reference_number":"EMA/MB/395034/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-100th-meeting-management-board-6-7-june-2018_en.pdf"},
    {"id":"27965","name":"Minutes of the 85th meeting of the Management Board: 2 October 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-12-16T19:00:00Z","last_updated_date":"2014-12-16T19:00:00Z","reference_number":"EMA/MB/612373/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-85th-meeting-management-board-2-october-2014_en.pdf"},
    {"id":"28191","name":"Minutes of the PRAC meeting 14-17 May 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-07-09T11:16:00Z","last_updated_date":"2018-07-09T11:16:00Z","reference_number":"EMA/PRAC/394603/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-14-17-may-2018_en.pdf"},
    {"id":"28204","name":"Minutes of the Healthcare Professionals' Organisations Working Group (HCP WG), 28 October 2010","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"EMA/760667/2010","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-healthcare-professionals-organisations-working-group-hcp-wg-28-october-2010_en.pdf"},
    {"id":"28242","name":"Minutes of the COMP meeting 10-12 December 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-03-12T12:10:00Z","last_updated_date":"2014-03-12T12:10:00Z","reference_number":"EMA/COMP/687306/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-12-december-2013_en.pdf"}    {"id":"28309","name":"Minutes of the HMPC 18-19 September 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-12-21T12:00:00Z","last_updated_date":"2017-12-21T12:00:00Z","reference_number":"EMA/HMPC/767522/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-18-19-september-2017-meeting_en.pdf"},
    {"id":"28344","name":"Minutes - PDCO minutes of the 12-14 June 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-07-29T16:00:00Z","last_updated_date":"2013-07-29T16:00:00Z","reference_number":"EMA/PDCO/356146/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-12-14-june-2013-meeting_en.pdf"},
    {"id":"28471","name":"Minutes of the CHMP meeting 20-23 February 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-04-18T10:30:00Z","last_updated_date":"2017-04-18T10:30:00Z","reference_number":"EMA/CHMP/196172/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-20-23-february-2017_en.pdf"},
    {"id":"28540","name":"Minutes of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting 20 September 2017","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T02:00:00Z","last_updated_date":"2017-10-26T02:00:00Z","reference_number":"EMA/626905/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-20-september-2017_en.pdf"},
    {"id":"28600","name":"Minutes of the PRAC meeting 10-13 June 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-07-21T12:50:00Z","last_updated_date":"2014-07-21T12:50:00Z","reference_number":"EMA/PRAC/438418/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-10-13-june-2014_en.pdf"},
    {"id":"28621","name":"Minutes of the 68th meeting of the Management Board: 7 October 2010","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/MB/628133/2010","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-68th-meeting-management-board-7-october-2010_sv.pdf"}},
    {"id":"28785","name":"Minutes of the CAT meeting 10-12 May 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-08-09T11:30:00Z","last_updated_date":"2017-08-09T11:30:00Z","reference_number":"EMA/CAT/305411/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-10-12-may-2017_en.pdf"},
    {"id":"28786","name":"Minutes of the European Medicines Agency and European Network for Health Technology Assessment meeting -  November 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-and-european-network-health-technology-assessment-meeting-november-2012_en.pdf"},
    {"id":"28793","name":"Minutes of the COMP meeting 10-12 February 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-03-26T17:00:00Z","last_updated_date":"2015-03-26T17:00:00Z","reference_number":"EMA/COMP/25297/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-12-february-2015_en.pdf"},
    {"id":"29157","name":"Minutes of the HMPC 19-20 September 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-12-20T11:00:00Z","last_updated_date":"2016-12-20T11:00:00Z","reference_number":"EMA/HMPC/790627/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-19-20-september-2016-meeting_en.pdf"},
    {"id":"29169","name":"Minutes of the CAT meeting 18-19 February 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-04-06T18:10:00Z","last_updated_date":"2016-04-06T18:10:00Z","reference_number":"EMA/CAT/246676/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-19-february-2016_en.pdf"},
    {"id":"29181","name":"Minutes - PDCO minutes of the 18-20 March 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-04-20T13:30:00Z","last_updated_date":"2015-04-20T13:30:00Z","reference_number":"EMA/PDCO/178890/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-18-20-march-2015-meeting_en.pdf"},
    {"id":"29192","name":"Minutes of the 76th meeting of the Management Board: 7 June 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-09-12T12:30:00Z","last_updated_date":"2012-09-12T12:30:00Z","reference_number":"EMA/MB/394635/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-76th-meeting-management-board-7-june-2012_en.pdf"},
    {"id":"29260","name":"Minutes of the CVMP meeting of 17-19 January 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T10:20:00Z","last_updated_date":"2017-02-24T10:20:00Z","reference_number":"EMA/CVMP/126626/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-17-19-january-2017_en.pdf"},
    {"id":"29332","name":"Minutes of the 97th meeting of the Management Board: 5 October 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-11-30T12:40:00Z","last_updated_date":"2017-11-30T12:40:00Z","reference_number":"EMA/MB/660406/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-97th-meeting-management-board-5-october-2017_en.pdf"},
    {"id":"29346","name":"Minutes - COMP meeting on 4-5 September 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-10-25T14:05:00Z","last_updated_date":"2012-10-25T14:05:00Z","reference_number":"EMA/COMP/471400/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-4-5-september-2012_en.pdf"},
    {"id":"29403","name":"Minutes of the CVMP meeting of 5-7 September 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-10-23T17:30:00Z","last_updated_date":"2017-10-23T17:30:00Z","reference_number":"EMA/CVMP/659549/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-5-7-september-2017_en.pdf"},
    {"id":"29450","name":"Minutes of the 66th meeting of the Management Board: 17-18 March 2010","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/MB/194352/2010","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-66th-meeting-management-board-17-18-march-2010_sv.pdf"}},
    {"id":"29480","name":"Minutes of the CHMP meeting 23-26 April 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-06-15T19:10:00Z","last_updated_date":"2018-06-15T19:10:00Z","reference_number":"EMA/CHMP/356536/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-23-26-april-2018_en.pdf"},
    {"id":"29499","name":"Minutes of the 94th meeting of the Management Board: 14-15 December 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-07T18:00:00Z","last_updated_date":"2017-02-07T18:00:00Z","reference_number":"EMA/MB/862367/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-94th-meeting-management-board-14-15-december-2016_en.pdf"},
    {"id":"29502","name":"Minutes of the CAT meeting 18-19 September 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-12-02T17:15:00Z","last_updated_date":"2014-12-02T17:15:00Z","reference_number":"EMA/CAT/737694/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-19-september-2014_en.pdf"},
    {"id":"29506","name":"CHMP ORGAM minutes for the meeting on 30 October 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-11-28T13:00:00Z","last_updated_date":"2017-11-28T13:00:00Z","reference_number":"EMA/CHMP/734503/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-30-october-2017_en.pdf"},
    {"id":"29510","name":"Minutes of the audiovisual-open-tender site visit (supply, installation and maintenance of audiovisual equipment and consumables including on-site technical support - EMA/2012/21/IS)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-11-28T16:07:00Z","last_updated_date":"2012-11-28T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-audiovisual-open-tender-site-visit-supply-installation-and-maintenance-audiovisual-equipment-and-consumables-including-site-technical-support-ema201221is_en.pdf"},
    {"id":"29588","name":"Minutes of the COMP meeting 5-7 September 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-10-18T19:35:00Z","last_updated_date":"2017-10-18T19:35:00Z","reference_number":"EMA/COMP/583563/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-5-7-september-2017_en.pdf"},
    {"id":"29635","name":"Minutes - PDCO minutes of the 21-24 February 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-04T17:42:00Z","last_updated_date":"2017-05-04T17:42:00Z","reference_number":"EMA/PDCO/123280/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-21-24-february-2017-meeting_en.pdf"},
    {"id":"29658","name":"Minutes - PDCO minutes of the 3-5 October 2012 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-11-15T12:03:00Z","last_updated_date":"2012-11-15T12:03:00Z","reference_number":"EMA/638304/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-3-5-october-2012-meeting_en.pdf"},
    {"id":"29672","name":"Minutes of the European Medicines Agency Human Scientific Committee’s Working Party with Healthcare Professionals’ Organisations (HCPWP) meeting on 5 June 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-07-12T17:00:00Z","last_updated_date":"2013-07-12T17:00:00Z","reference_number":"EMA/361720/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-meeting-5-june-2013_en.pdf"},
    {"id":"30071","name":"Minutes - PDCO minutes of the 25-27 May 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-07-06T16:13:00Z","last_updated_date":"2016-07-06T16:13:00Z","reference_number":"EMA/PDCO/316468/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-25-27-may-2016-meeting_en.pdf"},
    {"id":"30126","name":"CHMP ORGAM minutes for the meeting on 5 December 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-12-22T18:00:00Z","last_updated_date":"2016-12-22T18:00:00Z","reference_number":"EMA/CHMP/858237/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-5-december-2016_en.pdf"},
    {"id":"30186","name":"Minutes of the PRAC meeting 29-31 October 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-12-03T18:00:00Z","last_updated_date":"2012-12-03T18:00:00Z","reference_number":"EMA/PRAC/771924/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-29-31-october-2012_en.pdf"},
    {"id":"30190","name":"Minutes of the HMPC 26-27 March 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T13:15:00Z","last_updated_date":"2019-04-23T13:15:00Z","reference_number":"EMA/HMPC/269869/2018 - corr. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-26-27-march-2018-meeting_en.pdf"},
    {"id":"30250","name":"Minutes of the CHMP meeting 22-25 September 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-10-30T18:20:00Z","last_updated_date":"2014-10-30T18:20:00Z","reference_number":"EMA/CHMP/614190/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-september-2014_en.pdf"},
    {"id":"30298","name":"CHMP ORGAM minutes for the meeting on 8 May 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-06-13T02:00:00Z","last_updated_date":"2017-06-13T02:00:00Z","reference_number":"EMA/CHMP/312260/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-8-may-2017_en.pdf"},
    {"id":"30314","name":"Minutes of the PRAC meeting 10-13 May 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-07-01T18:00:00Z","last_updated_date":"2016-07-01T18:00:00Z","reference_number":"EMA/PRAC/457201/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-10-13-may-2016_en.pdf"},
    {"id":"30369","name":"Minutes of the HMPC 30-31 January 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-22T16:50:00Z","last_updated_date":"2017-05-22T16:50:00Z","reference_number":"EMA/HMPC/220735/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-30-31-january-2017-meeting_en.pdf"},
    {"id":"30424","name":"Minutes - PDCO minutes of the 4-6 July 2012 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T17:45:00Z","last_updated_date":"2012-08-23T17:45:00Z","reference_number":"EMA/PDCO/422131/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-4-6-july-2012-meeting_en.pdf"},
    {"id":"30453","name":"Minutes of the CHMP meeting 21-24 July 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-10-13T16:00:00Z","last_updated_date":"2014-10-13T16:00:00Z","reference_number":"EMA/CHMP/471144/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-21-24-july-2014_en.pdf"},
    {"id":"30480","name":"Minutes of the PRAC meeting 24-27 October 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-22T13:00:00Z","last_updated_date":"2017-02-22T13:00:00Z","reference_number":"EMA/PRAC/127425/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-24-27-october-2016_en.pdf"},
    {"id":"30513","name":"Minutes of the COMP meeting 19-21 January 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-03-03T16:03:00Z","last_updated_date":"2016-03-09T16:03:00Z","reference_number":"EMA/COMP/39793/2016 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-19-21-january-2016_en.pdf"},
    {"id":"30545","name":"Summary of discussions - Workshop on generation and use of Health Based Exposure Limits (HBEL)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:30:00Z","last_updated_date":"2017-08-04T15:30:00Z","reference_number":"EMA/410936/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/summary-discussions-workshop-generation-and-use-health-based-exposure-limits-hbel_en.pdf"},
    {"id":"30617","name":"Minutes of the CAT meeting 08-09 September 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-10-24T17:50:00Z","last_updated_date":"2016-10-24T17:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-08-09-september-2016_en.pdf"},
    {"id":"30667","name":"Minutes of the first joint meeting of the EMEA Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) and the EMEA/CHMP working group with Healthcare Professionals' Organisations (HCP WG)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2007-10-24T02:00:00Z","last_updated_date":"2007-10-24T02:00:00Z","reference_number":"EMEA/258866/2007","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-first-joint-meeting-emea-scientific-committees-working-party-patients-consumers-organisations-pcwp-emea-chmp-working-group-healthcare-professionals-organisations-hcp-wg_en.pdf"},
    {"id":"30984","name":"Minutes of the European Medicines Agency/European network for Health Technology Assessment dialogue meeting - June 2017","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T13:00:00Z","last_updated_date":"2017-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-dialogue-meeting-june-2017_en.pdf"},
    {"id":"30992","name":"Minutes - PDCO minutes of the 9-11 September 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T18:00:00Z","last_updated_date":"2015-10-20T18:00:00Z","reference_number":"EMA/PDCO/596621/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-9-11-september-2015-meeting_en.pdf"},
    {"id":"31024","name":"Minutes of the Extraordinary Management Board meeting for the building approval process of EMA premises in Amsterdam: 6 February 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-04-05T19:10:00Z","last_updated_date":"2018-04-05T19:10:00Z","reference_number":"EMA/MB/84505/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-extraordinary-management-board-meeting-building-approval-process-ema-premises-amsterdam-6-february-2018_en.pdf"},
    {"id":"31066","name":"Minutes of the CVMP meeting of 3-5 October 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-11-20T17:30:00Z","last_updated_date":"2017-11-20T17:30:00Z","reference_number":"EMA/CVMP/750093/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-3-5-october-2017_en.pdf"},
    {"id":"31112","name":"Minutes - PDCO minutes of the 7-10 November 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-01-05T14:49:00Z","last_updated_date":"2018-01-05T14:49:00Z","reference_number":"EMA/PDCO/738440/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-7-10-november-2017-meeting_en.pdf"},
    {"id":"31215","name":"Minutes - EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting (15 March 2017)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/182189/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-15-march-2017_en.pdf"},
    {"id":"31228","name":"Minutes of the CAT meeting 17-18 September 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-11-05T10:25:00Z","last_updated_date":"2015-11-05T10:25:00Z","reference_number":"EMA/CAT/723417/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-17-18-september-2015_en.pdf"},
    {"id":"31256","name":"Minutes of the CVMP meeting of 3-5 June 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-07-11T16:20:00Z","last_updated_date":"2014-07-11T16:20:00Z","reference_number":"EMA/CVMP/415698/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-3-5-june-2014_en.pdf"},
    {"id":"31261","name":"Minutes of the HMPC 29-30 May 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-08-16T12:39:00Z","last_updated_date":"2017-08-16T12:39:00Z","reference_number":"EMA/HMPC/461658/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-29-30-may-2017-meeting_en.pdf"},
    {"id":"31407","name":"Minutes of the European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - 3 June 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"EMA/335623/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-3-june-2014_en.pdf"},
    {"id":"31431","name":"Minutes of the CVMP meeting of 10-12 March 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-04-15T17:40:00Z","last_updated_date":"2015-04-15T17:40:00Z","reference_number":"EMA/CVMP/234214/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-12-march-2015_en.pdf"},
    {"id":"31491","name":"Minutes of the CHMP meeting 20-23 January 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-02-26T12:20:00Z","last_updated_date":"2014-02-26T12:20:00Z","reference_number":"EMA/CHMP/59462/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-20-23-january-2014_en.pdf"},
    {"id":"31571","name":"Meeting summary - Tripartite meeting held between the PMDA, EMA, and FDA in Kyoto, Japan to discuss convergence on approaches for the evaluation of antibacterial drugs","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-11-17T13:00:00Z","last_updated_date":"2017-11-17T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-tripartite-meeting-held-between-pmda-ema-fda-kyoto-japan-discuss-convergence-approaches-evaluation-antibacterial-drugs_en.pdf"},
    {"id":"31706","name":"Minutes of the sixty-fourth meeting of the Management Board: 1 October 2009","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2009-11-13T00:09:21Z","last_updated_date":"2009-11-13T00:09:21Z","reference_number":"EMEA/MB/642672/2009/EN/Adopted","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-sixty-fourth-meeting-management-board-1-october-2009_sv.pdf"}},
    {"id":"32196","name":"Minutes - PDCO minutes of the 10-13 October 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-12-21T16:40:00Z","last_updated_date":"2017-12-21T16:40:00Z","reference_number":"EMA/PDCO/675083/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-10-13-october-2017-meeting_en.pdf"},
    {"id":"32380","name":"Minutes of the CVMP meeting of 17-19 May 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2016-06-17T17:00:00Z","reference_number":"EMA/CVMP/413001/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-17-19-may-2016_en.pdf"},
    {"id":"32523","name":"Minutes of the COMP meeting 11-13 June 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T12:20:00Z","last_updated_date":"2013-07-24T18:45:00Z","reference_number":"EMA/COMP/302197/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-11-13-june-2013_en.pdf"},
    {"id":"32727","name":"Minutes of the COMP meeting 12-13 March 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-05-06T16:46:00Z","last_updated_date":"2013-05-06T16:46:00Z","reference_number":"EMA/COMP/83433/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-12-13-march-2013_en.pdf"},
    {"id":"32766","name":"Minutes of the HMPC 5-6 May 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-07-11T16:10:00Z","last_updated_date":"2014-07-11T16:10:00Z","reference_number":"EMA/HMPC/316498/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-5-6-may-2014-meeting_en.pdf"},
    {"id":"32923","name":"Minutes of the COMP meeting 14-15 March 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-06-01T17:40:00Z","last_updated_date":"2017-06-01T17:40:00Z","reference_number":"EMA/COMP/174237/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-15-march-2017_en.pdf"},
    {"id":"32952","name":"Minutes of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"EMA/528328/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf"},
    {"id":"32964","name":"Minutes of the HMPC 24-25 March 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-05-15T02:00:00Z","last_updated_date":"2014-05-15T02:00:00Z","reference_number":"EMA/HMPC/289059/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-24-25-march-2014-meeting_en.pdf"},
    {"id":"33146","name":"Minutes of European Union International Organization for Standardization (ISO) for the identification of medicinal products (IDMP)task force meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-10-29T16:00:00Z","last_updated_date":"2015-10-29T16:00:00Z","reference_number":"EMA/645750/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-international-organization-standardization-iso-identification-medicinal-products-idmptask-force-meeting_en.pdf"},
    {"id":"33153","name":"Minutes of the CHMP meeting 7-10 November 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-01-11T17:00:00Z","last_updated_date":"2017-01-11T17:00:00Z","reference_number":"EMA/CHMP/788305/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-7-10-november-2016_en.pdf"},
    {"id":"33197","name":"Presentation - Update on the follow up actions from the Risk Minimisation Measures Workshop in 2015 (Jamie Wilkinson)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-update-follow-actions-risk-minimisation-measures-workshop-2015-jamie-wilkinson_en.pdf"},
    {"id":"33227","name":"Minutes of the CHMP meeting 19-22 June 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-08-01T17:35:00Z","last_updated_date":"2017-08-01T17:35:00Z","reference_number":"EMA/CHMP/468829/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-june-2017_en.pdf"},
    {"id":"33245","name":"Minutes of the COMP meeting 11-13 July 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T16:05:00Z","last_updated_date":"2017-09-28T16:05:00Z","reference_number":"EMA/COMP/440281/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-11-13-july-2017_en.pdf"},
    {"id":"33263","name":"Minutes of the HMPC 29-30 September 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-12-03T01:00:00Z","last_updated_date":"2014-12-03T01:00:00Z","reference_number":"EMA/HMPC/624810/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-29-30-september-2014-meeting_en.pdf"},
    {"id":"33371","name":"Minutes of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting 9 March 2016","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-26T02:00:00Z","reference_number":"EMA/183905/2016 corr.","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-9-march-2016_en.pdf"},
    {"id":"33399","name":"Minutes of the PRAC meeting 9-12 February 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T10:35:00Z","last_updated_date":"2015-03-27T10:35:00Z","reference_number":"EMA/PRAC/147021/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-february-2015_en.pdf"},
    {"id":"33426","name":"Minutes of the COMP meeting 8-10 December 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T17:45:00Z","last_updated_date":"2016-02-04T17:45:00Z","reference_number":"EMA/COMP/803062/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-8-10-december-2015_en.pdf"},
    {"id":"33449","name":"CHMP ORGAM minutes for the meeting on 13 February 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-03-28T10:50:00Z","last_updated_date":"2017-03-28T10:50:00Z","reference_number":"EMA/CHMP/139584/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-13-february-2017_en.pdf"},
    {"id":"33454","name":"Minutes - PRAC meeting 3-5 September 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-10-05T13:59:00Z","last_updated_date":"2012-10-05T13:59:00Z","reference_number":"EMA/PRAC/571481/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-3-5-september-2012_en.pdf"},
    {"id":"33466","name":"Minutes of the 73rd meeting of the Management Board: 6 October 2011","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-12-07T13:00:00Z","last_updated_date":"2011-12-07T13:00:00Z","reference_number":"EMA/MB/828587/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-73rd-meeting-management-board-6-october-2011_sv.pdf"}},
    {"id":"33468","name":"Minutes of the CAT meeting 14-16 March 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-07-19T13:50:00Z","last_updated_date":"2018-07-19T13:50:00Z","reference_number":"EMA/CAT/172804/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-14-16-march-2018_en.pdf"},
    {"id":"33474","name":"Minutes of the CVMP meeting of 11-13 July 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-09-19T12:41:00Z","last_updated_date":"2017-09-19T12:41:00Z","reference_number":"EMA/CVMP/587890/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-11-13-july-2017_en.pdf"},
    {"id":"33481","name":"Minutes of the COMP meeting 14-16 July 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-09-10T12:15:00Z","last_updated_date":"2015-09-10T12:15:00Z","reference_number":"EMA/COMP/475182/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-16-july-2015_en.pdf"},
    {"id":"33722","name":"Minutes of EU ISO IDMP Task Force meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T02:00:00Z","last_updated_date":"2015-06-18T02:00:00Z","reference_number":"EMA/236653/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-eu-iso-idmp-task-force-meeting_en.pdf"},
    {"id":"33748","name":"Meeting summary - Patients and Consumers Working Party (PCWP) meeting with all EMA eligible patient/consumer organisations","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T16:26:00Z","last_updated_date":"2017-12-11T16:26:00Z","reference_number":"EMA/757232/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-patients-consumers-working-party-pcwp-meeting-all-ema-eligible-patient-consumer-organisations_en.pdf"},
    {"id":"33763","name":"Minutes of the European Medicines Agency/CHMP Working Group with Healthcare Professionals’ Organisations (HCP WG)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2010-01-20T00:09:21Z","last_updated_date":"2010-01-20T00:09:21Z","reference_number":"EMA/712326/2009","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-chmp-working-group-healthcare-professionals-organisations-hcp-wg_en.pdf"},
    {"id":"33772","name":"Minutes of the Joint meeting of the EMA Scientific Committees’ Working Party with Patients’ and Consumers’ Organisations (PCWP) and the EMA/CHMP Working Group with Healthcare Professionals’ Organisations (HCP WG) meeting...","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-09-12T02:00:00Z","last_updated_date":"2008-09-12T02:00:00Z","reference_number":"EMEA/301606/08","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-joint-meeting-ema-scientific-committees-working-party-patients-consumers-organisations-pcwp-ema-chmp-working-group-healthcare-professionals-organisations-hcp-wg-meeting_en.pdf-0"},
    {"id":"33814","name":"Minutes - PDCO minutes of the 21-23 May 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-06-26T18:40:00Z","last_updated_date":"2014-06-26T18:40:00Z","reference_number":"EMA/PDCO/290625/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-21-23-may-2014-meeting_en.pdf"},
    {"id":"33818","name":"Minutes of the COMP meeting of 5-7 December 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-02-13T09:54:00Z","last_updated_date":"2018-02-13T09:54:00Z","reference_number":"EMA/COMP/730551/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-5-7-december-2017_en.pdf"},
    {"id":"33849","name":"Minutes of the CVMP meeting of 19-21 January 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T16:25:00Z","last_updated_date":"2016-02-26T16:25:00Z","reference_number":"EMA/CVMP/145891/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-19-21-january-2016_en.pdf"},
    {"id":"33994","name":"Minutes - PDCO minutes of the 17-19 June 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-07-20T17:26:00Z","last_updated_date":"2015-07-20T17:26:00Z","reference_number":"EMA/PDCO/351567/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-17-19-june-2015-meeting_en.pdf"},
    {"id":"34039","name":"Minutes of the CAT meeting 15-16 May 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T16:20:00Z","last_updated_date":"2014-07-01T16:20:00Z","reference_number":"EMA/CAT/378521/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-16-may-2014_en.pdf"},
    {"id":"34098","name":"Minutes of the CVMP meeting of 4-6 November 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-12-15T13:10:00Z","last_updated_date":"2014-12-15T13:10:00Z","reference_number":"EMA/CVMP/768792/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-4-6-november-2014_en.pdf"},
    {"id":"34177","name":"Minutes of the CHMP meeting 06-09 November 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-01-08T15:11:00Z","last_updated_date":"2018-01-08T15:11:00Z","reference_number":"EMA/829219/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-06-09-november-2017_en.pdf"},
    {"id":"34223","name":"Minutes - PDCO minutes of the 12-14 August 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-09-17T12:55:00Z","last_updated_date":"2015-09-28T17:15:00Z","reference_number":"EMA/PDCO/547310/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-12-14-august-2015-meeting_en.pdf"},
    {"id":"34295","name":"Minutes of the 72nd meeting of the Management Board: 8-9 June 2011","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2011-08-16T02:00:00Z","reference_number":"EMA/MB/465305/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-72nd-meeting-management-board-8-9-june-2011_en.pdf"},
    {"id":"34306","name":"Minutes of the CHMP meeting 19-22 March 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-05-31T12:00:00Z","last_updated_date":"2018-05-31T12:00:00Z","reference_number":"EMA/273672/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-march-2018_en.pdf"},
    {"id":"34385","name":"Minutes - PDCO minutes of the 15-17 April 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-06-01T17:00:00Z","last_updated_date":"2015-06-01T17:00:00Z","reference_number":"EMA/PDCO/243363/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-15-17-april-2015-meeting_en.pdf"},
    {"id":"34414","name":"Minutes of the PRAC meeting 7-10 September 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-10-30T16:10:00Z","last_updated_date":"2015-10-30T16:10:00Z","reference_number":"EMA/PRAC/722174/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-september-2015_en.pdf"},
    {"id":"34493","name":"Minutes of the CHMP meeting 22-25 June 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-07-28T13:02:00Z","last_updated_date":"2015-07-28T13:02:00Z","reference_number":"EMA/CHMP/502563/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-june-2015_en.pdf"},
    {"id":"34574","name":"EMEA/CHMP working group with Healthcare Professionals' Organisations  Wednesday, 31 January 2008  - Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-06-05T02:00:00Z","last_updated_date":"2008-06-05T02:00:00Z","reference_number":"EMEA/58588/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/emea-chmp-working-group-healthcare-professionals-organisations-wednesday-31-january-2008-minutes_en.pdf"},
    {"id":"34609","name":"Minutes of the European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting of 7 May 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-07-06T14:00:00Z","last_updated_date":"2012-07-06T14:00:00Z","reference_number":"EMA/296167/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-7-may-2012_en.pdf"},
    {"id":"34651","name":"Minutes of the CVMP meeting of 13-15 January 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-02-20T18:15:00Z","last_updated_date":"2015-02-20T18:15:00Z","reference_number":"EMA/CVMP/96522/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-13-15-january-2015_en.pdf"},
    {"id":"34749","name":"Minutes - PDCO minutes of the 15-18 August 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-10-10T17:13:00Z","last_updated_date":"2017-10-10T17:13:00Z","reference_number":"EMA/PDCO/531408/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-15-18-august-2017-meeting_en.pdf"}    {"id":"34893","name":"CHMP ORGAM minutes for the meeting on 16 July 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-07-31T17:30:00Z","last_updated_date":"2018-07-31T17:30:00Z","reference_number":"EMA/CHMP/523753/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-16-july-2018_en.pdf"},
    {"id":"34941","name":"Presentation - SCOPE activities report (J. Raine)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-scope-activities-report-j-raine_en.pdf"},
    {"id":"35003","name":"Minutes of the fifth meeting of the EMEA Human Scientific Committees’ Working Party with with Patients’ and Consumers’ Organisations (PCWP)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-06-30T02:00:00Z","last_updated_date":"2008-06-30T02:00:00Z","reference_number":"EMEA/122940/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-fifth-meeting-emea-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp_en.pdf"},
    {"id":"35004","name":"Minutes of the COMP meeting 12-13 May 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-06-23T12:30:00Z","last_updated_date":"2015-07-02T12:10:00Z","reference_number":"EMA/COMP/253668/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-12-13-may-2015_en.pdf"},
    {"id":"35014","name":"Minutes of the second 2017 meeting of the coordinating group of the European network of paediatric research at the European Medicines Agency (Enpr-EMA)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T12:45:00Z","last_updated_date":"2017-07-24T12:45:00Z","reference_number":"EMA/329838/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-second-2017-meeting-coordinating-group-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"35062","name":"Minutes - PDCO minutes of the 20-23 June 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-08-03T16:30:00Z","last_updated_date":"2017-08-03T16:30:00Z","reference_number":"EMA/PDCO/396495/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-20-23-june-2017-meeting_en.pdf"},
    {"id":"35071","name":"Minutes of the CAT meeting 18-20 May 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-07-07T19:20:00Z","last_updated_date":"2016-07-07T19:20:00Z","reference_number":"EMA/CAT/472337/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-20-may-2016_en.pdf"},
    {"id":"35125","name":"Minutes of the HMPC 23-24 November 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-02-11T14:45:00Z","last_updated_date":"2016-02-11T14:45:00Z","reference_number":"EMA/HMPC/85759/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-23-24-november-2015-meeting_en.pdf"},
    {"id":"35152","name":"Informal CVMP meeting, Athens, 20 and 21 May 2003: Future strategy on antimicrobial resistance","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2003-06-20T02:09:21Z","last_updated_date":"2003-06-20T02:09:21Z","reference_number":"EMEA/CVMP/558/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/minutes/informal-cvmp-meeting-athens-20-21-may-2003-future-strategy-antimicrobial-resistance_en.pdf"},
    {"id":"35204","name":"Minutes of the European Medicines Agency/European Federation of Pharmaceutical Industries and Associations second workshop on adaptive design in confirmatory trials","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2010-03-30T02:00:00Z","last_updated_date":"2010-03-30T02:00:00Z","reference_number":"EMA/779520/2009","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-federation-pharmaceutical-industries-and-associations-second-workshop-adaptive-design-confirmatory-trials_en.pdf"},
    {"id":"35224","name":"Minutes of the PRAC meeting 25-29 September 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-11-24T18:00:00Z","last_updated_date":"2017-11-24T18:00:00Z","reference_number":"EMA/PRAC/782068/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-25-29-september-2017_en.pdf"},
    {"id":"35300","name":"Minutes of the COMP meeting 3-4 September 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-10-17T11:13:00Z","last_updated_date":"2013-10-17T11:13:00Z","reference_number":"EMA/COMP/432621/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-3-4-september-2013_en.pdf"},
    {"id":"35385","name":"Minutes of the PRAC meeting 30 November - 3 December 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T10:45:00Z","last_updated_date":"2016-02-03T10:45:00Z","reference_number":"EMA/PRAC/75116/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-30-november-3-december-2015_en.pdf"},
    {"id":"35465","name":"Presentation - Experience from the PROTECT project (Xavier Kurz)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-experience-protect-project-xavier-kurz_en.pdf"},
    {"id":"35522","name":"Minutes of the PRAC meeting 6-9 June 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-07-27T16:20:00Z","last_updated_date":"2017-07-27T16:20:00Z","reference_number":"EMA/PRAC/478147/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-6-9-june-2017_en.pdf"},
    {"id":"35787","name":"Minutes - PDCO minutes of the 7-9 August 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-09-25T16:00:00Z","last_updated_date":"2013-09-25T16:00:00Z","reference_number":"EMA/PDCO/485847/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-7-9-august-2013-meeting_en.pdf"},
    {"id":"35800","name":"Minutes of the COMP meeting 14-15 May 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-07-02T11:20:00Z","last_updated_date":"2013-07-02T11:20:00Z","reference_number":"EMA/COMP/248636/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-15-may-2013_en.pdf"},
    {"id":"35867","name":"Minutes of the PRAC meeting 23-26 October 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-01-05T17:03:00Z","last_updated_date":"2018-01-05T17:03:00Z","reference_number":"EMA/PRAC/782491/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-23-26-october-2017_en.pdf"},
    {"id":"35876","name":"Minutes of the COMP meeting 9-11 July 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-10-17T11:13:00Z","last_updated_date":"2013-10-17T11:13:00Z","reference_number":"EMA/COMP/366326/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-9-11-july-2013_en.pdf"},
    {"id":"35886","name":"Minutes of the CAT meeting 12-13 November 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T18:00:00Z","last_updated_date":"2015-12-21T18:00:00Z","reference_number":"EMA/CAT/859727/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-12-13-november-2015_en.pdf"},
    {"id":"35970","name":"Minutes of the annual European network of paediatric research at the European Medicines Agency members meeting - 26 June 2014","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2015-02-02T15:00:00Z","last_updated_date":"2015-02-02T15:00:00Z","reference_number":"EMA/408421/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-annual-european-network-paediatric-research-european-medicines-agency-members-meeting-26-june-2014_en.pdf"},
    {"id":"35976","name":"Minutes of the 78th meeting of the Management Board: 13 December 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/MB/810387/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-78th-meeting-management-board-13-december-2012_en.pdf"},
    {"id":"36036","name":"Minutes - PRAC inaugural plenary meeting 19-20 July 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-09-07T13:11:00Z","last_updated_date":"2012-09-07T13:11:00Z","reference_number":"EMA/PRAC/520121/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-inaugural-plenary-meeting-19-20-july-2012_en.pdf"},
    {"id":"36213","name":"EMEA/CHMP working group with Healthcare Professionals' Organisations  Friday, 17 November 2006  - Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2007-03-16T01:00:00Z","last_updated_date":"2007-03-16T01:00:00Z","reference_number":"EMEA/470546/2006","document_url":"https://www.ema.europa.eu/en/documents/minutes/emea-chmp-working-group-healthcare-professionals-organisations-friday-17-november-2006-minutes_en.pdf"},
    {"id":"36237","name":"Minutes of the 82nd meeting of the Management Board: 11-12 December 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-03-04T10:30:00Z","last_updated_date":"2014-03-04T10:30:00Z","reference_number":"EMA/MB/723234/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-82nd-meeting-management-board-11-12-december-2013_en.pdf"},
    {"id":"36287","name":"Minutes - PDCO minutes of the 21-24 March 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-05-11T11:30:00Z","last_updated_date":"2017-05-11T11:30:00Z","reference_number":"EMA/PDCO/193146/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-21-24-march-2017-meeting_en.pdf"},
    {"id":"36360","name":"Minutes of the COMP meeting 8-9 April 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-06-16T18:45:00Z","last_updated_date":"2014-06-18T13:50:00Z","reference_number":"EMA/COMP/151064/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-8-9-april-2014_en.pdf"},
    {"id":"36384","name":"Minutes of the  third joint meeting of the EMEA Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) and the EMEA/CHMP working group with Healthcare Professionals' Organisations (HCP WG...","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2009-06-09T02:00:00Z","last_updated_date":"2009-06-09T02:00:00Z","reference_number":"EMEA/358876/2009","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-third-joint-meeting-emea-scientific-committees-working-party-patients-consumers-organisations-pcwp-emea-chmp-working-group-healthcare-professionals-organisations-hcp-wg_en.pdf"},
    {"id":"36588","name":"Minutes of the European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) with all eligible organisations","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMA/545922/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-all-eligible-organisations_en.pdf"},
    {"id":"36608","name":"Minutes of the CAT meeting 18-19 June 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-07-30T16:10:00Z","last_updated_date":"2015-07-30T16:10:00Z","reference_number":"EMA/CAT/512537/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-19-june-2015_en.pdf"},
    {"id":"36621","name":"EMEA/CHMP/EWP Workshop: Slowing the Progression of Neurodegenerative Diseases: Medicinal Products (MP) Clinical Development - Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2006-12-14T00:09:21Z","last_updated_date":"2006-12-14T00:09:21Z","reference_number":"EMEA/512562/2006","document_url":"https://www.ema.europa.eu/en/documents/minutes/emea-chmp-ewp-workshop-slowing-progression-neurodegenerative-diseases-medicinal-products-mp-clinical-development-minutes_en.pdf"},
    {"id":"36633","name":"Minutes of the PRAC meeting 11-14 January 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-03-03T11:00:00Z","last_updated_date":"2016-03-03T11:00:00Z","reference_number":"EMA/PRAC/92676/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-11-14-january-2016_en.pdf"},
    {"id":"36724","name":"Inventory of EU data sources and methodological approaches for multi-source studies - Minutes of working group 3","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-06-09T02:00:00Z","last_updated_date":"2008-06-09T02:00:00Z","reference_number":"EMEA/382114/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/inventory-eu-data-sources-and-methodological-approaches-multi-source-studies-minutes-working-group-3_en.pdf"},
    {"id":"36780","name":"Minutes of the EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations (30 November 2016)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"EMA/801985/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations-30-november-2016_en.pdf"},
    {"id":"36833","name":"Minutes of the Joint meeting of the EMA Scientific Committees’ Working Party with Patients’ and Consumers’ Organisations (PCWP) and the EMA/CHMP Working Group with Healthcare Professionals’ Organisations (HCP WG) meeting...","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2007-10-27T02:00:00Z","last_updated_date":"2007-10-27T02:00:00Z","reference_number":"EMEA/258866/2007","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-joint-meeting-ema-scientific-committees-working-party-patients-consumers-organisations-pcwp-ema-chmp-working-group-healthcare-professionals-organisations-hcp-wg-meeting_en.pdf"},
    {"id":"36878","name":"Minutes of the 71st extraordinary meeting of the Management Board: 5 May 2011","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-06-16T02:00:00Z","last_updated_date":"2011-06-16T02:00:00Z","reference_number":"EMA/MB/417000/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-71st-extraordinary-meeting-management-board-5-may-2011_en.pdf"},
    {"id":"36924","name":"Minutes of the Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Group (HCPWG) joint meeting: September 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T17:00:00Z","last_updated_date":"2012-11-26T17:00:00Z","reference_number":"EMA/685483/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-group-hcpwg-joint-meeting-september-2012_en.pdf"},
    {"id":"37082","name":"Minutes of the CVMP meeting of 16-18 February 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-03-23T16:40:00Z","last_updated_date":"2016-03-23T16:40:00Z","reference_number":"EMA/CVMP/199920/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-16-18-february-2016_en.pdf"},
    {"id":"37141","name":"Minutes of the COMP meeting 17-19 May 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-06-30T16:36:00Z","last_updated_date":"2016-06-30T16:36:00Z","reference_number":"EMA/COMP/339164/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-17-19-may-2016_en.pdf"},
    {"id":"37299","name":"Research standards and PhV and PhEpi guidances -Minutes of working group 1","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2008-08-11T02:00:00Z","last_updated_date":"2008-08-11T02:00:00Z","reference_number":"EMEA/279618/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/research-standards-and-phv-and-phepi-guidances-minutes-working-group-1_en.pdf"},
    {"id":"37366","name":"Minutes of the COMP meeting 4-6 February 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-04-28T11:40:00Z","last_updated_date":"2014-04-28T11:40:00Z","reference_number":"EMA/COMP/77369/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-4-6-february-2014_en.pdf"},
    {"id":"37368","name":"Minutes of the 2016 annual meeting of Enpr-EMA members - 3 June 2016","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T13:45:00Z","last_updated_date":"2016-10-28T13:45:00Z","reference_number":"EMA/520986/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-2016-annual-meeting-enpr-ema-members-3-june-2016_en.pdf"},
    {"id":"37477","name":"Minutes of the third meeting of the EMEA Human Scientific Committees’ Working Party with with Patients’ and Consumers’ Organisations (PCWP)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2007-09-24T02:00:00Z","last_updated_date":"2007-09-24T02:00:00Z","reference_number":"EMEA/439453/2007","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-third-meeting-emea-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp_en.pdf"},
    {"id":"37597","name":"Minutes of the 5-7 December 2012 PDCO meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-01-17T15:34:00Z","last_updated_date":"2013-01-17T15:34:00Z","reference_number":"EMA/638304/2008","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-5-7-december-2012-pdco-meeting_en.pdf"},
    {"id":"37646","name":"Minutes of the COMP meeting 3-4 November 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-01-10T16:15:00Z","last_updated_date":"2017-01-10T16:15:00Z","reference_number":"EMA/COMP/704981/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-3-4-november-2016_en.pdf"},
    {"id":"37733","name":"Minutes - PDCO minutes of the 27-29 April 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-06-01T14:15:00Z","last_updated_date":"2016-06-01T14:15:00Z","reference_number":"EMA/PDCO/244355/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-27-29-april-2016-meeting_en.pdf"},
    {"id":"37774","name":"Minutes - PDCO minutes of the 27-29 January 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-03-03T16:03:00Z","last_updated_date":"2016-03-03T16:03:00Z","reference_number":"EMA/PDCO/79065/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-27-29-january-2016-meeting_en.pdf"},
    {"id":"37876","name":"Minutes of the CVMP meeting of 10-11 May 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-06-16T19:15:00Z","last_updated_date":"2017-06-16T19:15:00Z","reference_number":"EMA/CVMP/376100/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-11-may-2017_en.pdf"},
    {"id":"37879","name":"Minutes of the 210th CVMP meeting of 11-13 February 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-03-20T14:05:00Z","last_updated_date":"2014-03-20T14:05:00Z","reference_number":"EMA/CVMP/149513/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-210th-cvmp-meeting-11-13-february-2014_en.pdf"},
    {"id":"37972","name":"Minutes of the CHMP meeting 19-22 January 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-03-04T01:00:00Z","last_updated_date":"2015-03-04T01:00:00Z","reference_number":"EMA/CHMP/68245/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-january-2015_en.pdf"},
    {"id":"38000","name":"Minutes of the HMPC 4-5 April 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-06-13T11:30:00Z","last_updated_date":"2016-06-13T11:30:00Z","reference_number":"EMA/HMPC/385080/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-4-5-april-2016-meeting_en.pdf"},
    {"id":"38049","name":"Minutes of the PRAC meeting 7-10 April 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-05-22T15:30:00Z","last_updated_date":"2014-05-22T15:30:00Z","reference_number":"EMA/PRAC/210690/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-april-2014_en.pdf"},
    {"id":"38058","name":"Presentation - Lifecycle pharmacovigilance planning for public health: key to product development and safe and effective use of products (Peter Arlett)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/presentation-lifecycle-pharmacovigilance-planning-public-health-key-product-development-and-safe-and-effective-use-products-peter-arlett_en.pdf"},
    {"id":"38127","name":"Minutes of the CAT meeting 10-12 April 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-06-21T14:30:00Z","last_updated_date":"2018-01-26T14:51:00Z","reference_number":"EMA/CAT/393097/2017 Corr.","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-10-12-april-2017_en.pdf"},
    {"id":"38326","name":"Summary report - EMA / European Biopharmaceutical Enterprises (EBE) fifth annual regulatory conference on optimising the development of advanced therapies to meet patient needs","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T16:00:00Z","last_updated_date":"2017-02-03T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/summary-report-ema-european-biopharmaceutical-enterprises-ebe-fifth-annual-regulatory-conference-optimising-development-advanced-therapies-meet-patient-needs_en.pdf"},
    {"id":"38397","name":"Minutes of the COMP meeting 7-9 October 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T15:50:00Z","last_updated_date":"2014-11-21T15:50:00Z","reference_number":"EMA/COMP/575359/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-7-9-october-2014_en.pdf"},
    {"id":"38410","name":"Minutes of the COMP meeting 10-11 April 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-06-13T17:10:00Z","last_updated_date":"2017-06-13T17:10:00Z","reference_number":"EMA/COMP/238488/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-11-april-2017_en.pdf"},
    {"id":"38543","name":"Minutes of expert meeting on clinical investigation of new drugs for the treatment of chronic hepatitis C in the paediatric population: Monday 4 April 2011","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T03:00:00Z","last_updated_date":"2011-07-12T03:00:00Z","reference_number":"EMA/251093/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-expert-meeting-clinical-investigation-new-drugs-treatment-chronic-hepatitis-c-paediatric-population-monday-4-april-2011_en.pdf"},
    {"id":"38638","name":"Minutes of the CVMP meeting of 15-17 March 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-04-27T19:15:00Z","last_updated_date":"2016-04-27T19:15:00Z","reference_number":"EMA/CVMP/283054/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-15-17-march-2016_en.pdf"},
    {"id":"38755","name":"Minutes of the CVMP meeting of 23-25 May 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-06-27T16:30:00Z","last_updated_date":"2018-06-27T16:30:00Z","reference_number":"EMA/CVMP/303818/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-23-25-may-2018_en.pdf"},
    {"id":"38779","name":"Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, 25 October 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-12-18T13:40:00Z","last_updated_date":"2017-12-18T13:40:00Z","reference_number":"EMA/743801/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting-25-october-2017_en.pdf"},
    {"id":"38992","name":"Meeting summary - Second tripartite meeting held between EMA, PMDA and FDA to discuss regulatory approaches for the evaluation of antibacterial agents","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-06-12T12:30:00Z","last_updated_date":"2017-06-12T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-second-tripartite-meeting-held-between-ema-pmda-fda-discuss-regulatory-approaches-evaluation-antibacterial-agents_en.pdf"},
    {"id":"39114","name":"Minutes - PDCO minutes of the 15-17 May 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-06-27T12:00:00Z","last_updated_date":"2013-06-27T12:00:00Z","reference_number":"EMA/PDCO/296162/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-15-17-may-2013-meeting_en.pdf"},
    {"id":"39116","name":"Minutes of the COMP meeting 16-18 June 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T15:43:00Z","last_updated_date":"2015-07-27T15:43:00Z","reference_number":"EMA/COMP/326071/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-18-june-2015_en.pdf"},
    {"id":"39192","name":"Minutes of the European Network of Paediatric Research at the European Medicines Agency members meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-10-23T13:25:00Z","last_updated_date":"2013-10-23T13:25:00Z","reference_number":"EMA/543324/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-agency-members-meeting_en.pdf"},
    {"id":"39239","name":"Minutes - PDCO minutes of the 12-14 February 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-04-02T13:05:00Z","last_updated_date":"2014-04-02T13:05:00Z","reference_number":"EMA/PDCO/60343/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-12-14-february-2014-meeting_en.pdf"},
    {"id":"39324","name":"Minutes of the COMP meeting 8-9 January 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T12:04:00Z","last_updated_date":"2013-02-15T12:04:00Z","reference_number":"EMA/COMP/790271/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-8-9-january-2013_en.pdf"},
    {"id":"39414","name":"Minutes - PDCO minutes of the 11-13 September 2013 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-10-18T12:00:00Z","last_updated_date":"2013-10-18T12:00:00Z","reference_number":"EMA/PDCO/556160/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-11-13-september-2013-meeting_en.pdf"},
    {"id":"39423","name":"Minutes - COMP meeting of 3-5 October 2012","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T13:30:00Z","last_updated_date":"2012-11-23T13:30:00Z","reference_number":"EMA/COMP/589195/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-3-5-october-2012_en.pdf"},
    {"id":"39431","name":"Minutes of the CHMP meeting 21-24 September 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-10-29T12:30:00Z","last_updated_date":"2015-10-29T12:30:00Z","reference_number":"EMA/CHMP/696163/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-21-24-september-2015_en.pdf"},
    {"id":"39443","name":"Minutes of the CHMP meeting 20-23 April 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T18:50:00Z","last_updated_date":"2015-05-22T18:50:00Z","reference_number":"EMA/CHMP/290828/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-20-23-april-2015_en.pdf"},
    {"id":"39449","name":"Minutes of the CVMP meeting of 8-10 July 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-09-19T16:00:00Z","last_updated_date":"2014-09-19T16:00:00Z","reference_number":"EMA/CVMP/557195/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-july-2014_en.pdf"},
    {"id":"39473","name":"Minutes of the PRAC meeting 8-11 July 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T10:41:00Z","last_updated_date":"2013-10-11T16:00:00Z","reference_number":"EMA/PRAC/509108/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-july-2013_en.pdf"},
    {"id":"39509","name":"Minutes of the PRAC meeting 9-12 March 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-04-20T14:20:00Z","last_updated_date":"2015-04-20T14:20:00Z","reference_number":"EMA/PRAC/257790/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-march-2015_en.pdf"},
    {"id":"39528","name":"Minutes - PDCO minutes of the 12-14 October 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-01-11T12:00:00Z","last_updated_date":"2017-01-11T12:00:00Z","reference_number":"EMA/PDCO/674356/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-12-14-october-2016-meeting_en.pdf"},
    {"id":"39539","name":"Minutes of the CAT meeting 19-20 March 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-04-29T12:00:00Z","last_updated_date":"2015-04-29T12:00:00Z","reference_number":"EMA/CAT/267023/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-19-20-march-2015_en.pdf"},
    {"id":"39687","name":"Minutes of the PRAC meeting 8-11 January 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-03-02T16:53:00Z","last_updated_date":"2018-03-02T16:53:00Z","reference_number":"EMA/PRAC/71458/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-january-2018_en.pdf"},
    {"id":"39690","name":"Minutes of the CHMP meeting 14-17 December 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-02-08T15:40:00Z","last_updated_date":"2016-02-08T15:40:00Z","reference_number":"EMA/CHMP/71842/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-14-17-december-2015_en.pdf"},
    {"id":"39762","name":"Hearing with interested parties - Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2006-01-12T01:00:00Z","last_updated_date":"2006-01-12T01:00:00Z","reference_number":"EMEA/HMPC/405043/2005","document_url":"https://www.ema.europa.eu/en/documents/minutes/hearing-interested-parties-minutes_en.pdf"},
    {"id":"39844","name":"Minutes of the HMPC 4-5 May 2015 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-07-13T12:58:00Z","last_updated_date":"2015-07-13T12:58:00Z","reference_number":"EMA/HMPC/465862/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-4-5-may-2015-meeting_en.pdf"},
    {"id":"39872","name":"Minutes of the 65th meeting of the Management Board: 10 December 2009","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2010-04-07T02:00:00Z","last_updated_date":"2010-04-07T02:00:00Z","reference_number":"EMA/MB/806136/2009","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-65th-meeting-management-board-10-december-2009_sv.pdf"}},
    {"id":"39996","name":"Minutes of the PRAC meeting 7-10 April 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-05-20T16:30:00Z","last_updated_date":"2015-05-20T16:30:00Z","reference_number":"EMA/PRAC/332948/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-april-2015_en.pdf"},
    {"id":"40040","name":"Minutes of the COMP meeting of 16-18 January 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-03-26T18:59:00Z","last_updated_date":"2018-03-26T18:59:00Z","reference_number":"EMA/COMP/31472/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-18-january-2018_en.pdf"},
    {"id":"40112","name":"Minutes of the CAT meeting 23-25 May 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-08-23T15:19:00Z","last_updated_date":"2018-08-23T15:19:00Z","reference_number":"EMA/CAT/354919/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-23-25-may-2018_en.pdf"},
    {"id":"40227","name":"Minutes of the COMP meeting 8-10 October 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T10:10:00Z","last_updated_date":"2013-11-18T10:10:00Z","reference_number":"EMA/COMP/548719/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-8-10-october-2013_en.pdf"},
    {"id":"40393","name":"Minutes of the CVMP meeting of 2-4 June 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-07-14T13:25:00Z","last_updated_date":"2015-07-14T13:25:00Z","reference_number":"MA/CVMP/368443/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-2-4-june-2015_en.pdf"},
    {"id":"40433","name":"09 June 2009 minutes: Joint meeting with HCP and WG","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2009-06-09T02:00:00Z","last_updated_date":"2009-06-09T02:00:00Z","reference_number":"EMEA/358876/2009","document_url":"https://www.ema.europa.eu/en/documents/minutes/09-june-2009-minutes-joint-meeting-hcp-and-wg_en.pdf"},
    {"id":"40544","name":"Minutes of the 99th meeting of the Management Board: 15 March 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T13:30:00Z","last_updated_date":"2018-04-27T13:30:00Z","reference_number":"EMA/MB/167407/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-99th-meeting-management-board-15-march-2018_en.pdf"},
    {"id":"40565","name":"Minutes of the CHMP meeting 15-18 December 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-02-04T12:50:00Z","last_updated_date":"2015-02-04T12:50:00Z","reference_number":"EMA/45338/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-15-18-december-2014_en.pdf"},
    {"id":"40595","name":"Minutes of the 209th CVMP meeting of 14-16 January 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T16:30:00Z","last_updated_date":"2014-02-21T16:30:00Z","reference_number":"EMA/CVMP/95628/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-209th-cvmp-meeting-14-16-january-2014_en.pdf"},
    {"id":"40647","name":"Minutes of the 70th meeting of the Management Board: 16-17 March 2011","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/MB/232704/2011","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_bg.pdf","es":"https://www.ema.europa.eu/es/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_cs.pdf","da":"https://www.ema.europa.eu/da/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_da.pdf","de":"https://www.ema.europa.eu/de/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_de.pdf","et":"https://www.ema.europa.eu/et/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_et.pdf","el":"https://www.ema.europa.eu/el/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_fr.pdf","it":"https://www.ema.europa.eu/it/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/minutes/minutes-70th-meeting-management-board-16-17-march-2011_sv.pdf"}},
    {"id":"40684","name":"Summary - European Medicines Agency workshop with European Union pharmaceutical industry associations on the implementation of Article 57(2), second subparagraph of Regulation (EC) No.726/2004","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2012-07-06T17:00:00Z","last_updated_date":"2012-07-06T17:00:00Z","reference_number":"EMA/322628/2012","document_url":"https://www.ema.europa.eu/en/documents/minutes/summary-european-medicines-agency-workshop-european-union-pharmaceutical-industry-associations-implementation-article-572-second-subparagraph-regulation-ec-no7262004_en.pdf"},
    {"id":"40772","name":"Minutes - PDCO minutes of the 8-11 November 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-02-06T15:26:00Z","last_updated_date":"2017-02-06T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-8-11-november-2016-meeting_en.pdf"},
    {"id":"40778","name":"Minutes of the European Medicines Agency Human Scientific Committees’ Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting February 2014","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T13:40:00Z","last_updated_date":"2014-04-28T13:40:00Z","reference_number":"EMA/116971/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-february-2014_en.pdf"},
    {"id":"40832","name":"Minutes of the CHMP meeting 17-20 July 2017","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T14:00:00Z","last_updated_date":"2017-09-28T14:00:00Z","reference_number":"EMA/CHMP/605853/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-17-20-july-2017_en.pdf"},
    {"id":"40870","name":"Minutes - PDCO minutes of the 23-25 April 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-06-11T13:05:00Z","last_updated_date":"2014-06-11T13:05:00Z","reference_number":"EMA/PDCO/212992/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-23-25-april-2014-meeting_en.pdf"},
    {"id":"40982","name":"Minutes of the HMPC 27-28 January 2014 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-04-03T13:00:00Z","last_updated_date":"2014-04-03T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-27-28-january-2014-meeting_en.pdf"},
    {"id":"41011","name":"Minutes - PDCO minutes of the 24-27 July 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-08-28T18:00:00Z","last_updated_date":"2018-08-28T18:00:00Z","reference_number":"EMA/PDCO/514093/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-24-27-july-2018-meeting_en.pdf"},
    {"id":"41099","name":"Minutes of the PRAC meeting 3-6 November 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-01-08T17:15:00Z","last_updated_date":"2016-01-08T17:15:00Z","reference_number":"EMA/PRAC/799709/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-3-6-november-2015_en.pdf"},
    {"id":"41186","name":"Minutes of the CAT meeting 13-14 November 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-01-06T16:26:00Z","last_updated_date":"2015-01-06T16:26:00Z","reference_number":"EMA/CAT/786798/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-13-14-november-2014_en.pdf"}    {"id":"41297","name":"Minutes - PDCO minutes of the 14 - 16 September 2016 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-12-15T12:00:00Z","last_updated_date":"2016-12-15T12:00:00Z","reference_number":"EMA/PDCO/612683/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-14-16-september-2016-meeting_en.pdf"},
    {"id":"41301","name":"Minutes of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting (20 September 2016)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"EMA/625038/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-20-september-2016_en.pdf"},
    {"id":"41391","name":"Minutes of the CHMP meeting 19-22 October 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-11-25T14:35:00Z","last_updated_date":"2015-11-25T14:35:00Z","reference_number":"EMA/CHMP/771530/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-october-2015_en.pdf"},
    {"id":"41572","name":"Minutes of the CHMP meeting 17-20 November 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-12-22T10:30:00Z","last_updated_date":"2014-12-22T10:30:00Z","reference_number":"EMA/785545/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-17-20-november-2014_en.pdf"},
    {"id":"41626","name":"Minutes of the CHMP meeting 20-23 June 2016","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-07-29T02:00:00Z","last_updated_date":"2016-07-29T02:00:00Z","reference_number":"EMA/CHMP/498012/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-20-23-june-2016_en.pdf"},
    {"id":"41722","name":"Minutes of the COMP meeting 5-6 November 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-01-13T15:15:00Z","last_updated_date":"2014-01-13T15:15:00Z","reference_number":"EMA/COMP/622526/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-5-6-november-2013_en.pdf"},
    {"id":"41761","name":"Minutes of the PRAC meeting 8-11 September 2014","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2014-10-21T20:10:00Z","last_updated_date":"2014-10-21T20:10:00Z","reference_number":"EMA/PRAC/608832/2014","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-september-2014_en.pdf"},
    {"id":"41782","name":"Minutes of the CVMP meeting of 10-12 February 2015","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2015-03-16T16:56:00Z","last_updated_date":"2015-03-16T16:56:00Z","reference_number":"EMA/CVMP/163850/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-12-february-2015_en.pdf"},
    {"id":"41822","name":"Minutes of the COMP meeting of 22-24 May 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-08-17T11:40:00Z","last_updated_date":"2018-08-17T11:40:00Z","reference_number":"EMA/COMP/316876/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-22-24-may-2018_en.pdf"},
    {"id":"41912","name":"Minutes of the CVMP meeting of 6-8 September","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-10-18T17:28:00Z","last_updated_date":"2016-10-18T17:28:00Z","reference_number":"EMA/CVMP/657341/2016","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-6-8-september_en.pdf"},
    {"id":"42002","name":"Minutes - PDCO minutes of the 18-21 April 2017 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2017-06-26T17:53:00Z","last_updated_date":"2017-06-26T17:53:00Z","reference_number":"EMA/PDCO/246316/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-18-21-april-2017-meeting_en.pdf"},
    {"id":"42013","name":"Minutes of the 90th meeting of the Management Board","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2016-02-15T17:20:00Z","last_updated_date":"2016-02-15T17:20:00Z","reference_number":"EMA/MB/858667/2015","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-90th-meeting-management-board_en.pdf"},
    {"id":"42043","name":"Minutes - Third industry stakeholder platform on research and development support","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-09-18T16:00:00Z","last_updated_date":"2018-09-18T16:00:00Z","reference_number":"EMA/365499/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-third-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"42151","name":"Minutes of the CVMP meeting of 17-19 July 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-01T10:55:00Z","last_updated_date":"2018-10-01T10:55:00Z","reference_number":"EMA/CVMP455551/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-17-19-july-2018_en.pdf"},
    {"id":"42155","name":"Minutes of the PRAC meeting 9-12 July 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-01T15:51:00Z","last_updated_date":"2018-10-01T15:51:00Z","reference_number":"EMA/PRAC/576790/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-july-2018_en.pdf"},
    {"id":"42157","name":"Minutes of the CAT meeting 18-20 July 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-01T15:33:00Z","last_updated_date":"2018-10-01T15:33:00Z","reference_number":"EMA/CAT/665989/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-20-july-2018_en.pdf"},
    {"id":"42181","name":"Minutes of the CHMP meeting 23-26 July 2018","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-10-03T12:11:00Z","last_updated_date":"2018-10-05T16:00:00Z","reference_number":"EMA/CHMP/633386/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-23-26-july-2018_en.pdf"},
    {"id":"42188","name":"Minutes of the HMPC 23-24 July 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-03T16:17:00Z","last_updated_date":"2018-12-17T13:15:00Z","reference_number":"EMA/HMPC/672621/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-23-24-july-2018-meeting_en.pdf"},
    {"id":"42237","name":"Minutes of the CAT written procedure 15-17 August 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-09T11:47:00Z","last_updated_date":"2018-10-09T11:47:00Z","reference_number":"EMA/CAT/568714/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-written-procedure-15-17-august-2018_en.pdf"},
    {"id":"42343","name":"Minutes - PDCO minutes of the 21-24 August 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-15T14:53:00Z","last_updated_date":"2018-10-15T14:53:00Z","reference_number":"EMA/PDCO/582591/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-21-24-august-2018-meeting_en.pdf"},
    {"id":"42383","name":"Minutes - European Union (EU) International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) / Substance, Product, Organisation and Referential data (SPOR) task force meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T15:20:00Z","last_updated_date":"2018-10-19T15:20:00Z","reference_number":"EMA/239218/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-eu-international-organization-standardization-iso-identification-medicinal-products-idmp-substance-product-organisation-and-referential-data-spor-task-force-meeting_en.pdf"},
    {"id":"42395","name":"Minutes of the CAT meeting 20-22 June 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T16:26:00Z","last_updated_date":"2018-10-19T16:26:00Z","reference_number":"EMA/CAT/724555/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-20-22-june-2018_en.pdf"},
    {"id":"42397","name":"Minutes -  European Union International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) / Substance, Product, Organisation and Referential data (SPOR) task force meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:41:00Z","last_updated_date":"2018-10-19T16:41:00Z","reference_number":"EMA/471122/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-international-organization-standardization-iso-identification-medicinal-products-idmp-substance-product-organisation-and-referential-data-spor-task-force-meeting_en.pdf-1"},
    {"id":"42405","name":"Minutes of the CVMP meeting of 11-13 September 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T17:32:00Z","last_updated_date":"2018-10-19T17:32:00Z","reference_number":"EMA/CVMP/574963/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-11-13-september-2018_en.pdf"},
    {"id":"42443","name":"Minutes of the PRAC meeting 3-6 September 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-26T17:11:00Z","last_updated_date":"2018-10-26T17:11:00Z","reference_number":"EMA/PRAC/675727/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-3-6-september-2018_en.pdf"},
    {"id":"42483","name":"Minutes - Technical Anonymisation Group (TAG): First meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T13:07:00Z","last_updated_date":"2018-10-30T13:07:00Z","reference_number":"EMA/797384/2017","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-technical-anonymisation-group-tag-first-meeting_en.pdf"},
    {"id":"42518","name":"Minutes of the CHMP meeting 17-20 September 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-31T16:57:00Z","last_updated_date":"2018-10-31T16:57:00Z","reference_number":"EMA/CHMP/765541/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-17-20-september-2018_en.pdf"},
    {"id":"42520","name":"CHMP ORGAM minutes for the meeting on 10 September 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-10-31T17:14:00Z","last_updated_date":"2018-10-31T17:14:00Z","reference_number":"EMA/628721/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-10-september-2018_en.pdf"},
    {"id":"42583","name":"Minutes of the COMP meeting of 17-19 July 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-11-08T12:00:00Z","last_updated_date":"2018-11-08T12:00:00Z","reference_number":"EMA/COMP/425925/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-17-19-july-2018_en.pdf"},
    {"id":"42614","name":"Minutes of the CVMP meeting of 9-11 October 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-11-09T14:50:00Z","last_updated_date":"2018-11-09T14:50:00Z","reference_number":"EMA/CVMP/680007/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-9-11-october-2018_en.pdf"},
    {"id":"42651","name":"Meeting summary - European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-11-12T14:47:00Z","last_updated_date":"2018-11-12T14:47:00Z","reference_number":"EMA/717595/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-human-scientific-committees-working-parties-patients-consumers-organisations-pcwp_en.pdf"},
    {"id":"42656","name":"CHMP ORGAM minutes for the meeting on 8 October 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-11-12T18:12:00Z","last_updated_date":"2018-11-12T18:12:00Z","reference_number":"EMA/CHMP/752743/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-8-october-2018_en.pdf"},
    {"id":"42693","name":"Meeting summary - EMA Human Scientific’ Committees Working Party with Patients’ and Consumers’ Organisations (PCWP) and with Healthcare Professionals’ Organisations (HCPWP) (25 September 2018)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-11-15T15:03:00Z","last_updated_date":"2018-11-15T15:03:00Z","reference_number":"EMA/717794/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-ema-human-scientific-committees-working-party-patients-consumers-organisations-pcwp-healthcare-professionals-organisations-hcpwp-25-september-2018_en.pdf"},
    {"id":"42727","name":"Minutes of the HMPC 4-5 June 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-11-20T16:07:00Z","last_updated_date":"2018-11-20T16:07:00Z","reference_number":"EMA/HMPC/510355/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-4-5-june-2018-meeting_en.pdf"},
    {"id":"42819","name":"Minutes of the European Medicines Agency/European network for Health Technology Assessment dialogue meeting - July 2018","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-11-27T15:00:00Z","last_updated_date":"2018-11-27T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-dialogue-meeting-july-2018_en.pdf"},
    {"id":"42885","name":"Minutes of the CHMP meeting 15-18 October 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-11-29T11:23:00Z","last_updated_date":"2018-11-29T11:23:00Z","reference_number":"EMA/CHMP/821741/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-15-18-october-2018_en.pdf"},
    {"id":"42887","name":"Minutes of the PRAC meeting 1-4 October 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-11-29T18:20:00Z","last_updated_date":"2018-11-29T18:20:00Z","reference_number":"EMA/PRAC/752056/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-1-4-october-2018_en.pdf"},
    {"id":"42926","name":"Meeting summary - EMA Human Scientific’ Committees Working Party with Healthcare Professionals’ Organisations (HCPWP) 26 September 2018","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-12-04T17:30:00Z","last_updated_date":"2018-12-04T17:30:00Z","reference_number":"EMA/721409/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-ema-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-26-september-2018_en.pdf"},
    {"id":"42930","name":"Minutes of the Enpr-EMA Coordinating Group and networks meeting on 22 October 2018","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2018-12-04T17:45:00Z","last_updated_date":"2018-12-04T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-and-networks-meeting-22-october-2018_en.pdf"},
    {"id":"42969","name":"Minutes of the 101st meeting of the Management Board: 4 October 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-12-10T12:43:00Z","last_updated_date":"2018-12-10T12:43:00Z","reference_number":"EMA/MB/690649/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-101st-meeting-management-board-4-october-2018_en.pdf"},
    {"id":"42978","name":"Minutes of the CVMP meeting of 6-8 November 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-12-10T15:26:00Z","last_updated_date":"2018-12-10T15:26:00Z","reference_number":"EMA/CVMP/745459/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-6-8-november-2018_en.pdf"},
    {"id":"43020","name":"Minutes - PDCO minutes of the 18-21 September 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-12-12T17:16:00Z","last_updated_date":"2018-12-12T17:16:00Z","reference_number":"EMA/PDCO/644788/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-18-21-september-2018-meeting_en.pdf"},
    {"id":"43069","name":"Minutes of the CAT meeting 12-14 September 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T11:45:00Z","last_updated_date":"2018-12-14T11:45:00Z","reference_number":"EMA/CAT/868466/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-12-14-september-2018_en.pdf"},
    {"id":"43204","name":"Minutes of the PRAC meeting 29-31 October 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-12-20T18:10:00Z","last_updated_date":"2018-12-20T18:10:00Z","reference_number":"EMA/PRAC/822441/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-29-31-october-2018_en.pdf"},
    {"id":"43226","name":"Minutes of the CHMP meeting 12-15 November 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T11:58:00Z","last_updated_date":"2019-01-07T11:58:00Z","reference_number":"EMA/890274/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-12-15-november-2018_en.pdf"},
    {"id":"43228","name":"CHMP ORGAM minutes for the meeting on 5 November 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T12:05:00Z","last_updated_date":"2019-01-07T12:05:00Z","reference_number":"EMA/854939/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-5-november-2018_en.pdf"},
    {"id":"43229","name":"Minutes of the CAT meeting 10-12 October 2018","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T13:34:00Z","last_updated_date":"2019-01-07T13:34:00Z","reference_number":"EMA/CAT/895611/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-10-12-october-2018_en.pdf"},
    {"id":"43365","name":"Minutes of the CAT meeting 7-8 November 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-01-15T16:36:00Z","last_updated_date":"2019-01-15T16:36:00Z","reference_number":"EMA/CAT/7336/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-7-8-november-2018_en.pdf"},
    {"id":"43509","name":"CHMP ORGAM minutes for the meeting on 4 December 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T11:25:00Z","last_updated_date":"2019-01-28T11:25:00Z","reference_number":"EMA/32432/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-4-december-2018_en.pdf"},
    {"id":"43620","name":"Minutes of the CVMP meeting of 4-6 December 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T17:41:00Z","last_updated_date":"2019-02-01T17:41:00Z","reference_number":"EMA/CVMP/805493/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-4-6-december-2018_en.pdf"},
    {"id":"43627","name":"Minutes - PDCO minutes of the 16-19 October 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T10:09:00Z","last_updated_date":"2019-02-18T10:54:00Z","reference_number":"EMA/PDCO/724133/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-16-19-october-2018-meeting_en.pdf"},
    {"id":"43686","name":"Minutes of the PRAC meeting 26-29 November 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-02-08T16:45:00Z","last_updated_date":"2019-02-08T16:45:00Z","reference_number":"EMA/PRAC/109243/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-26-29-november-2018_en.pdf"},
    {"id":"43725","name":"HMA-EMA Joint Task Force on big data: Summary report","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T11:00:00Z","last_updated_date":"2019-02-15T11:00:00Z","reference_number":"EMA/105321/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/hma-ema-joint-task-force-big-data-summary-report_en.pdf"},
    {"id":"43781","name":"Minutes of the COMP meeting 6-8 November 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-02-18T16:32:00Z","last_updated_date":"2019-02-18T16:32:00Z","reference_number":"EMA/COMP/712920/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-6-8-november-2018_en.pdf"},
    {"id":"43862","name":"Minutes of the HMPC 19-20 November 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-02-21T12:15:00Z","last_updated_date":"2019-02-21T12:15:00Z","reference_number":"EMA/HMPC/22535/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-19-20-november-2018-meeting_en.pdf"},
    {"id":"43867","name":"Minutes of the CHMP meeting 10-13 December 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-02-21T13:31:00Z","last_updated_date":"2019-02-21T13:31:00Z","reference_number":"EMA/131655/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-10-13-december-2018_en.pdf"},
    {"id":"43868","name":"Minutes of the COMP meeting 9-11 October 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-02-21T13:39:00Z","last_updated_date":"2019-02-21T13:39:00Z","reference_number":"EMA/COMP/701293/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-9-11-october-2018_en.pdf"},
    {"id":"43872","name":"Minutes of the 102nd meeting of the Management Board","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-02-22T10:25:00Z","last_updated_date":"2019-02-22T10:25:00Z","reference_number":"EMA/MB/877601/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-102nd-meeting-management-board_en.pdf"},
    {"id":"43875","name":"Minutes of the COMP meeting 4-6 December 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-02-22T14:24:00Z","last_updated_date":"2019-02-22T14:24:00Z","reference_number":"EMA/COMP/792954/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-4-6-december-2018_en.pdf"},
    {"id":"43959","name":"Minutes of the CVMP meeting of 22-24 January 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T11:16:00Z","last_updated_date":"2019-03-01T11:16:00Z","reference_number":"EMA/CVMP/22361/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-22-24-january-2019_en.pdf"},
    {"id":"43964","name":"Minutes of the CAT meeting 5-7 December 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T16:02:00Z","last_updated_date":"2019-03-01T16:02:00Z","reference_number":"EMA/CAT/153883/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-5-7-december-2018_en.pdf"},
    {"id":"44103","name":"Minutes of the PRAC meeting 14-17 January 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-03-25T17:03:00Z","last_updated_date":"2019-03-25T17:03:00Z","reference_number":"EMA/PRAC/190876/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-14-17-january-2019_en.pdf"},
    {"id":"44104","name":"Minutes - PDCO minutes of the 13-16 November 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-03-25T17:33:00Z","last_updated_date":"2019-03-25T17:33:00Z","reference_number":"EMA/PDCO/800778/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-13-16-november-2018-meeting_en.pdf"},
    {"id":"44162","name":"Minutes of the CHMP meeting 28-31 January 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-04-01T17:26:00Z","last_updated_date":"2019-04-01T17:26:00Z","reference_number":"EMA/CHMP/172951/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-28-31-january-2019_en.pdf"},
    {"id":"44165","name":"Minutes of the CVMP meeting of 19-21 February 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-04-02T15:35:00Z","last_updated_date":"2019-04-02T15:35:00Z","reference_number":"EMA/CVMP/117144/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-19-21-february-2019_en.pdf"},
    {"id":"44168","name":"Minutes - PDCO minutes of the 11-14 December 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-04-03T16:35:00Z","last_updated_date":"2019-04-03T16:35:00Z","reference_number":"EMA/PDCO/877036/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-11-14-december-2018-meeting_en.pdf"},
    {"id":"44188","name":"Minutes of the PRAC meeting 11-14 February 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-04-08T17:40:00Z","last_updated_date":"2019-04-08T17:40:00Z","reference_number":"EMA/ PRAC/216303/ 2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-11-14-february-2019_en.pdf"},
    {"id":"44285","name":"Minutes of the COMP meeting 22-24 January 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-04-17T10:58:00Z","last_updated_date":"2019-04-17T10:58:00Z","reference_number":"EMA/COMP/32255/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-22-24-january-2019_en.pdf"},
    {"id":"44288","name":"Minutes of the CAT meeting 23-25 January 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-04-17T11:24:00Z","last_updated_date":"2019-04-17T11:24:00Z","reference_number":"EMA/CAT/232013/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-23-25-january-2019_en.pdf"},
    {"id":"44311","name":"Minutes of the CHMP meeting 25-28 February 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-04-17T17:15:00Z","last_updated_date":"2019-04-17T17:15:00Z","reference_number":"EMA/210804/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-25-28-february-2019_en.pdf"},
    {"id":"44430","name":"Minutes - European Union (EU) International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) / Substance, Product, Organisation and Referential data (SPOR) task force meeting (Dec 2018)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-05-06T10:49:00Z","last_updated_date":"2019-05-06T10:49:00Z","reference_number":"EMA/881990/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-eu-international-organization-standardization-iso-identification-medicinal-products-idmp-substance-product-organisation-and-referential-data-spor-task-force-meeting-dec-2018_en.pdf"},
    {"id":"44488","name":"Minutes of the COMP meeting 19-21 February 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-05-13T19:07:00Z","last_updated_date":"2019-05-13T19:07:00Z","reference_number":"EMA/COMP/126402/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-19-21-february-2019_en.pdf"},
    {"id":"44582","name":"Minutes of the CHMP meeting 25-28 March 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-05-23T17:33:00Z","last_updated_date":"2019-05-23T17:33:00Z","reference_number":"EMA/CHMP/269728/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-25-28-march-2019_en.pdf"},
    {"id":"44654","name":"Minutes of the CAT meeting 20-22 March 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-06-05T10:34:00Z","last_updated_date":"2019-06-05T10:34:00Z","reference_number":"EMA/CAT/305462/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-20-22-march-2019_en.pdf"},
    {"id":"44655","name":"Minutes of the COMP meeting 19-21 March 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-06-05T10:51:00Z","last_updated_date":"2019-06-05T10:51:00Z","reference_number":"EMA/COMP/305701/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-19-21-march-2019_en.pdf"},
    {"id":"44699","name":"Minutes of the 103rd meeting of the Management Board: 21 March 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-06-14T08:31:00Z","last_updated_date":"2019-06-14T08:31:00Z","reference_number":"EMA/MB/188256/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-103rd-meeting-management-board-21-march-2019_en.pdf"},
    {"id":"44740","name":"CHMP ORGAM minutes for the meeting on 21 January 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-06-18T17:54:00Z","last_updated_date":"2019-06-18T17:54:00Z","reference_number":"EMA/CHMP/332463/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-21-january-2019_en.pdf"},
    {"id":"44741","name":"CHMP ORGAM minutes for the meeting on 18 February 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-06-18T17:57:00Z","last_updated_date":"2019-06-18T17:57:00Z","reference_number":"EMA/CHMP/343726/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-18-february-2019_en.pdf"},
    {"id":"44776","name":"CHMP ORGAM minutes for the meeting on 18 March 2019","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-06-20T16:41:00Z","last_updated_date":"2019-06-20T16:41:00Z","reference_number":"EMA/CHMP/349981/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-18-march-2019_en.pdf"},
    {"id":"44861","name":"Minutes of the CHMP meeting 23-26 April 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T09:47:00Z","last_updated_date":"2019-06-25T09:47:00Z","reference_number":"EMA/CHMP/341563/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-23-26-april-2019_en.pdf"},
    {"id":"44913","name":"Minutes of the Enpr-EMA Coordinating Group and networks meeting on 19 February 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-06-27T15:30:00Z","last_updated_date":"2019-06-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-and-networks-meeting-19-february-2019_en.pdf"},
    {"id":"44982","name":"Minutes of the PRAC meeting 12-15 March 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-07-03T13:32:00Z","last_updated_date":"2019-07-03T13:32:00Z","reference_number":"EMA/PRAC/235021/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-12-15-march-2019_en.pdf"},
    {"id":"45027","name":"Minutes of the CVMP meeting of 19-21 March 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-07-10T13:11:00Z","last_updated_date":"2019-07-10T13:11:00Z","reference_number":"EMA/CVMP/229277/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-19-21-march-2019_en.pdf"},
    {"id":"45028","name":"Minutes of the CVMP meeting of 15-16 April 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-07-10T13:13:00Z","last_updated_date":"2019-07-10T13:13:00Z","reference_number":"EMA/CVMP/281537/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-15-16-april-2019_en.pdf"},
    {"id":"45029","name":"Minutes of the CVMP meeting of 21-22 May 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-07-10T13:16:00Z","last_updated_date":"2019-07-10T13:16:00Z","reference_number":"EMA/345458/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-21-22-may-2019_en.pdf"},
    {"id":"45049","name":"Minutes - PDCO minutes of the 29 January - 1 February 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-07-12T12:20:00Z","last_updated_date":"2019-07-12T12:20:00Z","reference_number":"EMA/PDCO/56017/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-29-january-1-february-2019-meeting_en.pdf"},
    {"id":"45061","name":"Minutes of the CAT meeting 20-22 February 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-07-15T11:26:00Z","last_updated_date":"2019-07-15T11:26:00Z","reference_number":"EMA/CAT/400411/2019 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-20-22-february-2019_en.pdf"},
    {"id":"45094","name":"Minutes of the European Medicines Agency and European Union payer community meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-07-19T11:14:00Z","last_updated_date":"2019-07-19T11:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-and-european-union-payer-community-meeting_en.pdf"},
    {"id":"45116","name":"Minutes of the CHMP meeting 27-29 May 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-07-24T14:26:00Z","last_updated_date":"2019-07-24T14:26:00Z","reference_number":"EMA/CHMP/378959/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-27-29-may-2019_en.pdf"},
    {"id":"45184","name":"Minutes - European Union (EU) International Organization for Standardization (ISO) for the identification of medicinal products (IDMP)/Substance, Product, Organisation and Referential data (SPOR) task force meeting (May 2019)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-08-01T10:52:00Z","last_updated_date":"2019-08-01T10:52:00Z","reference_number":"EMA/404389/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-eu-international-organization-standardization-iso-identification-medicinal-products-idmpsubstance-product-organisation-and-referential-data-spor-task-force-meeting-may-2019_en.pdf"},
    {"id":"45203","name":"Minutes of the COMP meeting 15-17 April 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-08-06T12:57:00Z","last_updated_date":"2019-08-06T12:57:00Z","reference_number":"EMA/COMP/245908/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-15-17-april-2019_en.pdf"},
    {"id":"45213","name":"Minutes - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-08-08T11:43:00Z","last_updated_date":"2019-08-08T11:43:00Z","reference_number":"EMA/385512/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting_en.pdf-0"},
    {"id":"45217","name":"CHMP ORGAM minutes for the meeting on 20 May 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-08-08T12:49:00Z","last_updated_date":"2019-08-08T12:49:00Z","reference_number":"EMA/CHMP/445958/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-20-may-2019_en.pdf"},
    {"id":"45218","name":"CHMP ORGAM minutes for the meeting on 17 June 2019","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-08-08T13:01:00Z","last_updated_date":"2019-08-08T13:01:00Z","reference_number":"EMA/CHMP/447862/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-17-june-2019_en.pdf"},
    {"id":"45220","name":"CHMP ORGAM minutes for the meeting on 15 July 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-08-08T13:05:00Z","last_updated_date":"2019-08-08T13:05:00Z","reference_number":"EMA/CHMP/401816/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-15-july-2019_en.pdf"},
    {"id":"45232","name":"CHMP ORGAM minutes for the meeting on 15 April 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-08-12T09:22:00Z","last_updated_date":"2019-09-16T10:31:00Z","reference_number":"EMA/CHMP/447252/2019 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-15-april-2019_en.pdf"},
    {"id":"45249","name":"Minutes - PDCO minutes of the 26 February-01 March 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-08-13T17:51:00Z","last_updated_date":"2019-08-13T17:51:00Z","reference_number":"EMA/PDCO/149030/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-26-february-01-march-2019-meeting_en.pdf"},
    {"id":"45327","name":"Minutes of the CAT meeting 16-17 April 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-08-26T11:50:00Z","last_updated_date":"2019-08-26T11:50:00Z","reference_number":"EMA/CAT/233992/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-16-17-april-2019_en.pdf"},
    {"id":"45355","name":"Minutes of the CAT meeting 22-24 May 2019","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-08-30T09:59:00Z","last_updated_date":"2019-08-30T09:59:00Z","reference_number":"EMA/CAT/290589/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-22-24-may-2019_en.pdf"},
    {"id":"45415","name":"Minutes of the COMP meeting 21-23 May 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-09-11T12:11:00Z","last_updated_date":"2019-09-11T12:11:00Z","reference_number":"EMA/COMP/288904/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-21-23-may-2019_en.pdf"}    {"id":"45435","name":"Minutes of the CAT meeting 19-21 June 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-09-12T16:51:00Z","last_updated_date":"2019-09-12T16:51:00Z","reference_number":"EMA/CAT/499958/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-19-21-june-2019_en.pdf"},
    {"id":"45528","name":"Minutes of the CHMP meeting 24-27 June 2019","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-09-27T10:18:00Z","last_updated_date":"2019-10-02T16:33:00Z","reference_number":"EMA/CHMP/486041/2019 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-24-27-june-2019_en.pdf"},
    {"id":"45529","name":"Minutes of the PRAC meeting 08-11 April 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-09-27T10:54:00Z","last_updated_date":"2019-09-27T10:54:00Z","reference_number":"EMA/PRAC/527155/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-08-11-april-2019_en.pdf"},
    {"id":"45547","name":"Minutes of the COMP meeting 18-20 June 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-02T13:52:00Z","last_updated_date":"2019-10-02T13:52:00Z","reference_number":"EMA/COMP/347785/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-18-20-june-2019_en.pdf"},
    {"id":"45566","name":"Minutes of the European Medicines Agency/European network for Health Technology Assessment dialogue meeting - December 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-08T10:32:00Z","last_updated_date":"2019-10-08T10:32:00Z","reference_number":"EMA/832382/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-dialogue-meeting-december-2018_en.pdf"},
    {"id":"45571","name":"Minutes - PDCO minutes of the 23-26 April 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-04T15:22:00Z","last_updated_date":"2019-10-04T15:22:00Z","reference_number":"EMA/PDCO/239430/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-23-26-april-2019-meeting_en.pdf"},
    {"id":"45586","name":"Minutes of the 104th meeting of the Management Board","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-07T18:07:00Z","last_updated_date":"2019-10-07T18:07:00Z","reference_number":"EMA/MB/335139/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-104th-meeting-management-board_en.pdf"},
    {"id":"45590","name":"Minutes - PDCO minutes of the 26-29 March 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-08T14:09:00Z","last_updated_date":"2019-10-08T14:09:00Z","reference_number":"EMA/PDCO/196583/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-26-29-march-2019-meeting_en.pdf"},
    {"id":"45678","name":"Minutes of the CHMP meeting 22-25 July 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-14T15:33:00Z","last_updated_date":"2019-10-14T15:33:00Z","reference_number":"EMA/CHMP/535736/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-july-2019_en.pdf"},
    {"id":"45731","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting - July 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-17T11:09:00Z","last_updated_date":"2019-10-17T11:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-july-2019_en.pdf"},
    {"id":"45734","name":"Minutes of the CVMP meeting of 18-20 June 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-17T13:13:00Z","last_updated_date":"2019-10-17T13:13:00Z","reference_number":"EMA/CVMP/403401/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-18-20-june-2019_en.pdf"},
    {"id":"45735","name":"Minutes of the CVMP meeting of 16-18 July 2019","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-10-17T13:15:00Z","last_updated_date":"2019-10-17T13:15:00Z","reference_number":"EMA/CVMP/498139/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-16-18-july-2019_en.pdf"},
    {"id":"45736","name":"Minutes of the CVMP meeting of 10-12 September 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-17T13:16:00Z","last_updated_date":"2019-10-17T13:16:00Z","reference_number":"EMA/CVMP/550956/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-12-september-2019_en.pdf"},
    {"id":"45740","name":"Minutes of the PRAC meeting 13-16 May 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-17T15:07:00Z","last_updated_date":"2019-10-17T15:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-13-16-may-2019_en.pdf"},
    {"id":"45763","name":"Minutes of the HMPC 14-16 January 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-10-21T09:54:00Z","last_updated_date":"2019-10-21T09:54:00Z","reference_number":"EMA/HMPC/278211/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-14-16-january-2019-meeting_en.pdf"},
    {"id":"45876","name":"Meeting summary - European Medicines Agency (EMA) Joint Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) meetingPrimary tabs","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-11-04T09:05:00Z","last_updated_date":"2019-11-04T09:05:00Z","reference_number":"EMA/527554/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-joint-patients-consumers-pcwp-healthcare-professionals-hcpwp-meetingprimary-tabs_en.pdf"},
    {"id":"45877","name":"Meeting summary - European Medicines Agency (EMA) Healthcare Professionals' Working Party (HCPWP) meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-11-04T09:09:00Z","last_updated_date":"2019-11-04T09:09:00Z","reference_number":"EMA/527554/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-healthcare-professionals-working-party-hcpwp-meeting_en.pdf"},
    {"id":"45878","name":"Meeting summary - European Medicines Agency (EMA) Patients' and Consumers' Working Party meeting (PCWP)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-11-04T09:22:00Z","last_updated_date":"2019-11-04T09:22:00Z","reference_number":"EMA/546723/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-patients-consumers-working-party-meeting-pcwp_en.pdf"},
    {"id":"45891","name":"Meeting summary - EMA, Food and Drug Administration (FDA) and Pharmaceuticals and Medical Devices Agency (PMDA)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-11-06T13:30:00Z","last_updated_date":"2019-11-06T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-ema-food-drug-administration-fda-pharmaceuticals-medical-devices-agency-pmda_en.pdf"},
    {"id":"45894","name":"Minutes of CHMP written procedure 19-22 August 2019","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-11-06T11:14:00Z","last_updated_date":"2019-11-06T11:14:00Z","reference_number":"EMA/CHMP/536511/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-written-procedure-19-22-august-2019_en.pdf"},
    {"id":"46015","name":"Minutes of the PRAC meeting 11-14 June 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T12:12:00Z","last_updated_date":"2019-11-13T12:12:00Z","reference_number":"EMA/PRAC/616893/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-11-14-june-2019_en.pdf"},
    {"id":"46045","name":"CHMP ORGAM minutes for the meeting on 7 October 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T16:32:00Z","last_updated_date":"2019-11-15T16:32:00Z","reference_number":"EMA/CHMP/547872/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-7-october-2019_en.pdf"},
    {"id":"46061","name":"Minutes of the CHMP meeting 16-19 September 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-11-19T13:51:00Z","last_updated_date":"2019-11-19T13:51:00Z","reference_number":"EMA/CHMP/599241/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-16-19-september-2019_en.pdf"},
    {"id":"46110","name":"Minutes of the CAT meeting 17-19 July 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-11-22T11:52:00Z","last_updated_date":"2019-11-22T11:52:00Z","reference_number":"EMA/CAT/633465/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-17-19-july-2019_en.pdf"},
    {"id":"46202","name":"Minutes - PDCO minutes of the 27-29 May 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-11-29T11:39:00Z","last_updated_date":"2019-11-29T11:39:00Z","reference_number":"EMA/PDCO/297694/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-27-29-may-2019-meeting_en.pdf"},
    {"id":"46203","name":"Minutes - PDCO minutes of the 25-28 June 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-11-29T11:42:00Z","last_updated_date":"2019-11-29T11:42:00Z","reference_number":"EMA/PDCO/366850/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-25-28-june-2019-meeting_en.pdf"},
    {"id":"46295","name":"Minutes of the 105th meeting of the Management Board: 3 October 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-12-11T14:41:00Z","last_updated_date":"2019-12-11T14:41:00Z","reference_number":"EMA/MB/542228/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-105th-meeting-management-board-3-october-2019_en.pdf"},
    {"id":"46351","name":"Meeting summary - Annual Patients and Consumers Working Party (PCWP) and Healthcare Professionals Working Party (HCPWP) meeting with all eligible organisations","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2019-12-19T16:34:00Z","last_updated_date":"2019-12-19T16:34:00Z","reference_number":"EMA/527554/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-annual-patients-consumers-working-party-pcwp-healthcare-professionals-working-party-hcpwp-meeting-all-eligible-organisations_en.pdf"},
    {"id":"46354","name":"Minutes of the PRAC meeting 8-11 July 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-12-19T18:07:00Z","last_updated_date":"2019-12-19T18:07:00Z","reference_number":"EMA/PRAC/692665/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-july-2019_en.pdf"},
    {"id":"46355","name":"Minutes of the COMP meeting 16-18 July 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-12-19T18:13:00Z","last_updated_date":"2019-12-19T18:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-18-july-2019_en.pdf"},
    {"id":"46365","name":"Minutes of the CVMP meeting of 8-10 October 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-12-20T11:20:00Z","last_updated_date":"2019-12-20T11:20:00Z","reference_number":"EMA/CVMP/597241/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-october-2019_en.pdf"},
    {"id":"46366","name":"Minutes of the CVMP meeting of 5-7 November 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-12-20T11:20:00Z","last_updated_date":"2019-12-20T11:20:00Z","reference_number":"EMA/CVMP/657101/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-5-7-november-2019_en.pdf"},
    {"id":"46380","name":"Minutes of the CHMP meeting 14-17 October 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2019-12-20T16:27:00Z","last_updated_date":"2019-12-20T16:27:00Z","reference_number":"EMA/CHMP/653549/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-14-17-october-2019_en.pdf"},
    {"id":"46403","name":"Minutes of the COMP meeting 10-12 September 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-01-09T15:45:00Z","last_updated_date":"2020-01-09T15:45:00Z","reference_number":"EMA/COMP/499116/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-12-september-2019_en.pdf"},
    {"id":"46434","name":"Minutes of the CAT meeting 11-13 September 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-01-15T15:45:00Z","last_updated_date":"2020-01-15T15:45:00Z","reference_number":"EMA/CAT/14825/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-11-13-september-2019_en.pdf"},
    {"id":"46590","name":"Minutes of the CHMP meeting 11-14 November 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-01-28T09:57:00Z","last_updated_date":"2020-01-28T09:57:00Z","reference_number":"EMA/CHMP/5161/2020 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-11-14-november-2019_en.pdf"},
    {"id":"46606","name":"Minutes of the CAT meeting 9-11 October 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-01-29T11:21:00Z","last_updated_date":"2020-01-29T11:21:00Z","reference_number":"EMA/CAT/40164/2020 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-9-11-october-2019_en.pdf"},
    {"id":"46607","name":"Minutes of the HMPC 8-10 July 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-01-29T11:27:00Z","last_updated_date":"2020-01-29T11:27:00Z","reference_number":"EMA/HMPC/530624/2019 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-8-10-july-2019-meeting_en.pdf"},
    {"id":"46613","name":"Minutes of the HMPC 13-15 May 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-01-29T14:49:00Z","last_updated_date":"2020-01-29T14:49:00Z","reference_number":"EMA/HMPC/403891/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-13-15-may-2019-meeting_en.pdf"},
    {"id":"46616","name":"Minutes of the COMP meeting 8-10 October 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-01-29T16:55:00Z","last_updated_date":"2020-01-29T16:55:00Z","reference_number":"EMA/COMP/550965/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-8-10-october-2019_en.pdf"},
    {"id":"46669","name":"Minutes of the PRAC meeting 2-5 September 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-02-04T14:13:00Z","last_updated_date":"2020-02-04T14:13:00Z","reference_number":"EMA/PRAC/60629/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-2-5-september-2019_en.pdf"},
    {"id":"46670","name":"Minutes of the CVMP meeting of 3-5 December 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-02-04T14:26:00Z","last_updated_date":"2020-02-04T14:26:00Z","reference_number":"EMA/CVMP/36283/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-3-5-december-2019_en.pdf"},
    {"id":"46694","name":"Minutes - PDCO minutes of the 17-20 September 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-02-10T14:27:00Z","last_updated_date":"2020-02-10T14:27:00Z","reference_number":"EMA/PDCO/519055/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-17-20-september-2019-meeting_en.pdf"},
    {"id":"46695","name":"Minutes - PDCO minutes of the 23-26 July 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-02-10T14:29:00Z","last_updated_date":"2020-02-10T14:29:00Z","reference_number":"EMA/PDCO/417613/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-23-26-july-2019-meeting_en.pdf"},
    {"id":"46806","name":"Minutes of the PRAC meeting 30 September-03 October 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-02-19T16:27:00Z","last_updated_date":"2020-02-19T16:27:00Z","reference_number":"EMA/PRAC/89165/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-30-september-03-october-2019_en.pdf"},
    {"id":"46855","name":"Minutes of the COMP meeting 5-7 November 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-02-25T08:16:00Z","last_updated_date":"2020-02-25T08:16:00Z","reference_number":"EMA/COMP/597430/2019 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-5-7-november-2019_en.pdf"},
    {"id":"46856","name":"Minutes - European Union (EU) International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) / Substance, Product, Organisation and Referential data (SPOR) task force meeting (Oct 2019)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T10:49:00Z","last_updated_date":"2020-03-03T10:03:00Z","reference_number":"EMA/580947/2019 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-eu-international-organization-standardization-iso-identification-medicinal-products-idmp-substance-product-organisation-and-referential-data-spor-task-force-meeting-oct-2019_en.pdf"},
    {"id":"46909","name":"Minutes of the PRAC meeting 28-31 October  2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-02-28T13:26:00Z","last_updated_date":"2020-02-28T13:26:00Z","reference_number":"EMA/PRAC/107813/2020 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-28-31-october-2019_en.pdf"},
    {"id":"46931","name":"Minutes of the CHMP meeting 9-12 December 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-03T11:39:00Z","last_updated_date":"2020-03-03T11:39:00Z","reference_number":"EMA/CHMP/71515/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-9-12-december-2019_en.pdf"},
    {"id":"46948","name":"Minutes of the CVMP meeting of 21-23 January 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-05T15:45:00Z","last_updated_date":"2020-03-05T15:45:00Z","reference_number":"EMA/CVMP/86082/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-21-23-january-2020_en.pdf"},
    {"id":"46949","name":"Minutes of the 106th meeting of the Management Board: 18-19 December 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-05T15:59:00Z","last_updated_date":"2020-03-05T15:59:00Z","reference_number":"EMA/MB/542228/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-106th-meeting-management-board-18-19-december-2019_en.pdf"},
    {"id":"46988","name":"Minutes of the CAT meeting 06-08 November 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-10T11:29:00Z","last_updated_date":"2020-03-10T11:29:00Z","reference_number":"EMA/CAT/48305/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-06-08-november-2019_en.pdf"},
    {"id":"46989","name":"Minutes of the CAT meeting 4-6 December 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-10T11:34:00Z","last_updated_date":"2020-03-10T11:34:00Z","reference_number":"EMA/CAT/127341/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-4-6-december-2019_en.pdf"},
    {"id":"46991","name":"Minutes of the CAT meeting 22-24 January 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-10T14:18:00Z","last_updated_date":"2020-03-10T14:18:00Z","reference_number":"EMA/CAT/127419/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-22-24-january-2020_en.pdf"},
    {"id":"47055","name":"Minutes - PDCO minutes of the 15-18 October 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-19T13:36:00Z","last_updated_date":"2020-03-19T13:36:00Z","reference_number":"EMA/PDCO/523933/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-15-18-october-2019-meeting_en.pdf"},
    {"id":"47096","name":"Minutes - PDCO minutes of the 12-15 November 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-23T14:09:00Z","last_updated_date":"2020-03-23T14:09:00Z","reference_number":"EMA/PDCO/615413/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-12-15-november-2019-meeting_en.pdf"},
    {"id":"47197","name":"Minutes of the COMP meeting 3-5 December 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T13:10:00Z","last_updated_date":"2020-03-27T13:10:00Z","reference_number":"EMA/COMP/655129/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-3-5-december-2019_en.pdf"},
    {"id":"47211","name":"Minutes of the HMPC 23-25 September 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T13:42:00Z","last_updated_date":"2020-03-30T13:42:00Z","reference_number":"EMA/HMPC/563130/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-23-25-september-2019-meeting_en.pdf"},
    {"id":"47221","name":"CHMP ORGAM minutes for the meeting on 2 December 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T15:04:00Z","last_updated_date":"2020-03-30T15:04:00Z","reference_number":"EMA/CHMP/654738/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-2-december-2019_en.pdf"},
    {"id":"47280","name":"Minutes of the CVMP meeting of 18-20 February 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T16:14:00Z","last_updated_date":"2020-04-01T16:14:00Z","reference_number":"EMA/CVMP/142728/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-18-20-february-2020_en.pdf"},
    {"id":"47299","name":"Minutes of the CHMP meeting 27-30 January 2020","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2020-04-02T15:43:00Z","last_updated_date":"2020-04-02T15:43:00Z","reference_number":"EMA/CHMP/114813/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-27-30-january-2020_en.pdf"},
    {"id":"47311","name":"Minutes of the HMPC 18-20 November 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T09:00:00Z","last_updated_date":"2020-04-03T09:00:00Z","reference_number":"EMA/HMPC/32208/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-18-20-november-2019-meeting_en.pdf"},
    {"id":"47343","name":"Minutes of the COMP meeting 20-22 January 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T17:49:00Z","last_updated_date":"2020-04-03T17:49:00Z","reference_number":"EMA/COMP/33629/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-20-22-january-2020_en.pdf"},
    {"id":"47455","name":"Meeting summary - PCWP/HCPWP joint meeting on 3-4 March 2020","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2020-04-22T14:43:00Z","last_updated_date":"2020-04-22T14:43:00Z","reference_number":"EMA/527554/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-joint-meeting-3-4-march-2020_en.pdf"},
    {"id":"47467","name":"CHMP ORGAM minutes for the meeting on 9 September 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-04-23T15:04:00Z","last_updated_date":"2020-04-23T15:04:00Z","reference_number":"EMA/CHMP/121051/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-9-september-2019_en.pdf"},
    {"id":"47551","name":"Minutes of the CVMP meeting of 17-18 March 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T17:50:00Z","last_updated_date":"2020-04-30T17:50:00Z","reference_number":"EMA/CVMP/220479/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-17-18-march-2020_en.pdf"},
    {"id":"47566","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting - November 2019","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2020-05-05T15:30:00Z","last_updated_date":"2020-05-05T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-november-2019_en.pdf"},
    {"id":"47587","name":"CHMP ORGAM minutes for the meeting on 17 February 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-05-07T12:40:00Z","last_updated_date":"2020-05-07T12:40:00Z","reference_number":"EMA/244237/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-17-february-2020_en.pdf"},
    {"id":"47653","name":"Minutes of the Enpr-EMA Coordinating Group & networks meeting on 21 February 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-05-13T11:30:00Z","last_updated_date":"2020-05-13T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-networks-meeting-21-february-2020_en.pdf"},
    {"id":"47655","name":"Minutes of the CAT meeting 18-20 March 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-05-13T11:20:00Z","last_updated_date":"2020-05-13T11:20:00Z","reference_number":"EMA/CAT/257145/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-20-march-2020_en.pdf"},
    {"id":"47679","name":"Minutes of the COMP meeting 17-19 March 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-05-15T15:28:00Z","last_updated_date":"2020-05-15T15:28:00Z","reference_number":"EMA/COMP/155348/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-17-19-march-2020_en.pdf"},
    {"id":"47688","name":"Minutes of the HMPC 13-15 January 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-05-18T14:18:00Z","last_updated_date":"2020-05-18T14:18:00Z","reference_number":"EMA/HMPC/176153/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-13-15-january-2020-meeting_en.pdf"},
    {"id":"47697","name":"Minutes of the CAT meeting 19-21 February 2020","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T15:35:00Z","last_updated_date":"2020-05-18T15:35:00Z","reference_number":"EMA/CAT/98684/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-19-21-february-2020_en.pdf"},
    {"id":"47784","name":"Minutes of the PRAC meeting 25-28 November 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-05-27T17:21:00Z","last_updated_date":"2020-05-27T17:21:00Z","reference_number":"EMA/PRAC/287927/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-25-28-november-2019_en.pdf"},
    {"id":"47795","name":"Minutes of the CHMP meeting 24-27 February 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-05-28T14:10:00Z","last_updated_date":"2020-05-28T14:10:00Z","reference_number":"EMA/CHMP/225128/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-24-27-february-2020_en.pdf"},
    {"id":"47833","name":"Minutes of the 107th meeting of the Management Board: 19 March 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T17:07:00Z","last_updated_date":"2020-05-29T17:07:00Z","reference_number":"EMA/MB/152592/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-107th-meeting-management-board-19-march-2020_en.pdf"},
    {"id":"47836","name":"Minutes of the CVMP meeting of 21-23 April 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T17:44:00Z","last_updated_date":"2020-05-29T17:44:00Z","reference_number":"EMA/CVMP/271198/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-21-23-april-2020_en.pdf"},
    {"id":"47842","name":"Minutes of the PRAC meeting 13-16 January 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-03T12:28:00Z","last_updated_date":"2020-06-03T12:28:00Z","reference_number":"EMA/PRAC/297855/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-13-16-january-2020_en.pdf"},
    {"id":"47850","name":"Minutes of the CAT meeting 22-24 April 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-04T14:17:00Z","last_updated_date":"2020-06-04T14:17:00Z","reference_number":"EMA/CAT/297683/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-22-24-april-2020_en.pdf"},
    {"id":"47883","name":"Minutes of the COMP meeting 18-20 February 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-05T11:32:00Z","last_updated_date":"2020-06-05T11:32:00Z","reference_number":"EMA/COMP/86291/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-18-20-february-2020_en.pdf"},
    {"id":"47901","name":"Minutes of the COMP meeting 21-23 April 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-09T16:09:00Z","last_updated_date":"2020-06-09T16:09:00Z","reference_number":"EMA/COMP/238684/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-21-23-april-2020_en.pdf"},
    {"id":"47924","name":"Minutes of the HMPC 2-4 March 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T11:54:00Z","last_updated_date":"2020-06-10T11:54:00Z","reference_number":"EMA/HMPC/265856/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-2-4-march-2020-meeting_en.pdf"},
    {"id":"48040","name":"Minutes of the CHMP meeting 23-26 March 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-17T14:55:00Z","last_updated_date":"2020-06-17T14:55:00Z","reference_number":"EMA/CHMP/267750/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-23-26-march-2020_en.pdf"},
    {"id":"48045","name":"Minutes of the HMPC 24-25 September 2018 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-18T10:08:00Z","last_updated_date":"2020-06-18T10:08:00Z","reference_number":"EMA/HMPC/813680/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-24-25-september-2018-meeting_en.pdf"},
    {"id":"48112","name":"Minutes of the CHMP meeting 28-30 April 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-24T16:23:00Z","last_updated_date":"2020-06-24T16:23:00Z","reference_number":"EMA/CHMP/299360/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-28-30-april-2020_en.pdf"},
    {"id":"48119","name":"Minutes of the COMP meeting 18-20 May 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-25T11:09:00Z","last_updated_date":"2020-06-25T11:09:00Z","reference_number":"EMA/COMP/287867/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-18-20-may-2020_en.pdf"},
    {"id":"48147","name":"Minutes of the CVMP meeting of 18-20 May 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T09:49:00Z","last_updated_date":"2020-06-26T09:49:00Z","reference_number":"EMA/CVMP/326595/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-18-20-may-2020_en.pdf"},
    {"id":"48179","name":"Minutes of the CAT meeting 18-20 May 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-06-29T11:57:00Z","last_updated_date":"2020-06-29T11:57:00Z","reference_number":"EMA/CAT/345764/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-20-may-2020_en.pdf"},
    {"id":"48202","name":"Minutes - PDCO minutes of the 28-31 January 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-07-02T15:25:00Z","last_updated_date":"2020-07-02T15:25:00Z","reference_number":"EMA/PDCO/52138/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-28-31-january-2020-meeting_en.pdf"},
    {"id":"48203","name":"Minutes - PDCO minutes of the 09-11 December 2019 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-07-02T16:16:00Z","last_updated_date":"2020-07-02T16:16:00Z","reference_number":"EMA/PDCO/682483/2019","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-09-11-december-2019-meeting_en.pdf"},
    {"id":"48331","name":"Minutes - PDCO minutes of the 25-28 February 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-07-20T10:52:00Z","last_updated_date":"2020-07-20T10:52:00Z","reference_number":"EMA/PDCO/104692/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-25-28-february-2020-meeting_en.pdf"},
    {"id":"48372","name":"Minutes of the HMPC 4-6 May 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-07-23T12:08:00Z","last_updated_date":"2020-07-23T12:08:00Z","reference_number":"EMA/HMPC/290980/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-4-6-may-2020-meeting_en.pdf"},
    {"id":"48410","name":"Minutes of the CAT meeting 17-19 June 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T15:07:00Z","last_updated_date":"2020-07-24T15:07:00Z","reference_number":"EMA/CAT/401853/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-17-19-june-2020_en.pdf"},
    {"id":"48457","name":"Minutes of the PRAC meeting 10-13 February 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T15:09:00Z","last_updated_date":"2020-07-28T15:09:00Z","reference_number":"EMA/PRAC/404462/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-10-13-february-2020_en.pdf"},
    {"id":"48572","name":"Minutes of the COMP meeting 16-18 June 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-08-07T16:50:00Z","last_updated_date":"2020-08-07T16:50:00Z","reference_number":"EMA/COMP/346343/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-18-june-2020_en.pdf"},
    {"id":"48601","name":"Meeting summary - PCWP/HCPWP joint meeting on 24 June 2020","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2020-08-13T11:52:00Z","last_updated_date":"2020-08-13T11:52:00Z","reference_number":"EMA/313114/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-joint-meeting-24-june-2020_en.pdf"},
    {"id":"48602","name":"Meeting summary - PCWP/HCPWP joint meeting on 2 June 2020","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2020-08-13T11:55:00Z","last_updated_date":"2020-08-13T11:55:00Z","reference_number":"EMA/313148/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-joint-meeting-2-june-2020_en.pdf"},
    {"id":"48696","name":"Minutes of the CHMP meeting 25-28 May 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-08-26T16:33:00Z","last_updated_date":"2020-08-26T16:33:00Z","reference_number":"EMA/CHMP/365761/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-25-28-may-2020_en.pdf"},
    {"id":"48718","name":"Minutes - PDCO minutes of the 24-27 March 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-08-28T12:42:00Z","last_updated_date":"2020-08-28T12:42:00Z","reference_number":"EMA/PDCO/164431/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-24-27-march-2020-meeting_en.pdf"},
    {"id":"48719","name":"Minutes - PDCO minutes of the 28-30 April 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-08-28T12:50:00Z","last_updated_date":"2020-08-28T12:50:00Z","reference_number":"EMA/PDCO/173462/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-28-30-april-2020-meeting_en.pdf"}    {"id":"48722","name":"Minutes - PDCO minutes of the 26-29 May 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-08-28T16:29:00Z","last_updated_date":"2020-08-28T16:29:00Z","reference_number":"EMA/PDCO/295795/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-26-29-may-2020-meeting_en.pdf"},
    {"id":"48724","name":"Minutes - PDCO minutes of the 23-26 June 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-08-28T17:58:00Z","last_updated_date":"2020-08-28T17:58:00Z","reference_number":"EMA/PDCO/341309/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-23-26-june-2020-meeting_en.pdf"},
    {"id":"48727","name":"Minutes of the PRAC meeting 9-12 March 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-08-31T15:37:00Z","last_updated_date":"2020-08-31T15:37:00Z","reference_number":"EMA/PRAC/457964/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-march-2020_en.pdf"},
    {"id":"48744","name":"Minutes of the CVMP meeting of 16-18 June 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-09-03T11:01:00Z","last_updated_date":"2020-09-03T11:01:00Z","reference_number":"EMA/CVMP/452643/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-16-18-june-2020_en.pdf"},
    {"id":"48760","name":"Minutes of the Extraordinary Management Board meeting for the nomination of the Executive Director: 25 June 2020","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2020-09-04T16:08:00Z","last_updated_date":"2020-09-04T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-extraordinary-management-board-meeting-nomination-executive-director-25-june-2020_en.pdf"},
    {"id":"48769","name":"Minutes of the 108th meeting of the Management Board: 11 June 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-09-09T09:00:00Z","last_updated_date":"2020-09-09T09:00:00Z","reference_number":"EMA/MB/318294/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-108th-meeting-management-board-11-june-2020_en.pdf"},
    {"id":"48863","name":"Minutes of the CVMP meeting of 14-16 July 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T14:30:00Z","last_updated_date":"2020-09-18T14:30:00Z","reference_number":"EMA/CVMP/473597/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-14-16-july-2020_en.pdf"},
    {"id":"48867","name":"Minutes of the CAT meeting 12-14 August 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-09-21T15:29:00Z","last_updated_date":"2020-09-21T15:29:00Z","reference_number":"EMA/CAT/495907/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-12-14-august-2020_en.pdf"},
    {"id":"48893","name":"Minutes of the CHMP meeting  22-25 June 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-09-25T16:12:00Z","last_updated_date":"2020-09-25T16:12:00Z","reference_number":"EMA/CHMP/475571/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-june-2020_en.pdf"},
    {"id":"48904","name":"Minutes of the CAT meeting 15-17 July 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-09-29T09:22:00Z","last_updated_date":"2020-09-29T09:22:00Z","reference_number":"EMA/CAT/510852/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-17-july-2020_en.pdf"},
    {"id":"49005","name":"Minutes of the PRAC meeting 14-17 April 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-10-14T13:40:00Z","last_updated_date":"2020-10-14T13:40:00Z","reference_number":"EMA/PRAC/546361/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-14-17-april-2020_en.pdf"},
    {"id":"49006","name":"Minutes of the COMP meeting 14-16 July 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-10-14T13:47:00Z","last_updated_date":"2020-10-14T13:47:00Z","reference_number":"EMA/COMP/381675/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-16-july-2020_en.pdf"},
    {"id":"49038","name":"Minutes of the CVMP meeting of 8-9 September 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T11:58:00Z","last_updated_date":"2020-10-16T11:58:00Z","reference_number":"EMA/CVMP/527316/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-9-september-2020_en.pdf"},
    {"id":"49122","name":"Minutes of the European networkof paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T16:00:00Z","last_updated_date":"2020-10-23T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-networkof-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting_en.pdf"},
    {"id":"49140","name":"Minutes of the CAT meeting 9-11 September 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-10-27T16:42:00Z","last_updated_date":"2020-10-27T16:42:00Z","reference_number":"EMA/CAT/572076/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-9-11-september-2020_en.pdf"},
    {"id":"49157","name":"Minutes of the HMPC 6-8 July 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-10-29T12:23:00Z","last_updated_date":"2020-10-29T12:23:00Z","reference_number":"EMA/HMPC/404030/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-6-8-july-2020-meeting_en.pdf"},
    {"id":"49158","name":"Minutes of the CHMP meeting 20-23 July 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-10-29T16:49:00Z","last_updated_date":"2020-10-29T16:49:00Z","reference_number":"EMA/CHMP/558121/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-20-23-july-2020_en.pdf"},
    {"id":"49184","name":"Minutes - PDCO minutes of the 21-24 July 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-11-05T15:52:00Z","last_updated_date":"2020-11-05T15:52:00Z","reference_number":"EMA/PDCO/541950/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-21-24-july-2020-meeting_en.pdf"},
    {"id":"49224","name":"Minutes of the COMP meeting 8-10 September 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-11-12T09:18:00Z","last_updated_date":"2020-11-12T09:18:00Z","reference_number":"EMA/COMP/486363/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-8-10-september-2020_en.pdf"},
    {"id":"49229","name":"Minutes of the CVMP meeting of 6-7 October 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-11-12T09:34:00Z","last_updated_date":"2020-11-12T09:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-6-7-october-2020_en.pdf"},
    {"id":"49272","name":"Meeting highlights - 15th industry stakeholder platform - Operation of European Union (EU) pharmacovigilance","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2020-11-18T15:40:00Z","last_updated_date":"2020-11-18T15:40:00Z","reference_number":"EMA/582239/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-highlights-15th-industry-stakeholder-platform-operation-european-union-eu-pharmacovigilance_en.pdf"},
    {"id":"49293","name":"Minutes of the PRAC meeting 11-14 May 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T17:00:00Z","last_updated_date":"2020-11-19T17:00:00Z","reference_number":"EMA/PRAC/624022/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-11-14-may-2020_en.pdf"},
    {"id":"49414","name":"Minutes of the PRAC meeting 08 – 11 June 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-12-01T14:46:00Z","last_updated_date":"2020-12-01T14:46:00Z","reference_number":"EMA/PRAC/645617/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-08-11-june-2020_en.pdf"},
    {"id":"49415","name":"Minutes of the CAT meeting 7-9 October 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-12-01T15:11:00Z","last_updated_date":"2020-12-01T15:11:00Z","reference_number":"EMA/CAT/647967/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-7-9-october-2020_en.pdf"},
    {"id":"49427","name":"Minutes of CHMP written procedure 17-20 August 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-12-02T17:02:00Z","last_updated_date":"2020-12-02T17:02:00Z","reference_number":"EMA/CHMP/624647/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-written-procedure-17-20-august-2020_en.pdf"},
    {"id":"49488","name":"Minutes of the HMPC 21-23 September 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-12-09T14:32:00Z","last_updated_date":"2020-12-09T14:32:00Z","reference_number":"EMA/HMPC/539421/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-21-23-september-2020-meeting_en.pdf"},
    {"id":"49512","name":"Minutes of the PRAC meeting 6-9 July 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-12-10T12:31:00Z","last_updated_date":"2020-12-10T12:31:00Z","reference_number":"EMA/PRAC/672654/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-6-9-july-2020_en.pdf"},
    {"id":"49564","name":"Minutes - PDCO minutes of the 13-16 October 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-12-14T18:03:00Z","last_updated_date":"2020-12-14T18:03:00Z","reference_number":"EMA/PDCO/555707/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-13-16-october-2020-meeting_en.pdf"},
    {"id":"49565","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting - July 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-12-15T11:46:00Z","last_updated_date":"2020-12-15T11:46:00Z","reference_number":"EMA/386443/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-july-2020_en.pdf"},
    {"id":"49588","name":"Minutes of the 109th meeting of the Management Board: 1 October 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-12-15T16:15:00Z","last_updated_date":"2020-12-15T16:15:00Z","reference_number":"EMA/MB/519858/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-109th-meeting-management-board-1-october-2020_en.pdf"},
    {"id":"49644","name":"Minutes of the PRAC meeting 31 August-3 September 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-12-18T14:35:00Z","last_updated_date":"2020-12-18T14:35:00Z","reference_number":"EMA/PRAC/698632/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-31-august-3-september-2020_en.pdf"},
    {"id":"49696","name":"Minutes of the PRAC meeting 28 September - 1 October 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2020-12-31T17:31:00Z","last_updated_date":"2020-12-31T17:31:00Z","reference_number":"EMA/PRAC/708023/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-28-september-1-october-2020_en.pdf"},
    {"id":"49709","name":"Minutes - PDCO minutes of the 1-4 September 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-04T17:53:00Z","last_updated_date":"2021-01-04T17:53:00Z","reference_number":"EMA/PDCO/466199/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-1-4-september-2020-meeting_en.pdf"},
    {"id":"49710","name":"Minutes of the CHMP meeting 14-17 September 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-05T10:16:00Z","last_updated_date":"2021-01-15T10:49:00Z","reference_number":"EMA/CHMP/625456/2020 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-14-17-september-2020_en.pdf"},
    {"id":"49725","name":"Minutes of the COMP meeting 6-8 October 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-05T17:21:00Z","last_updated_date":"2021-01-05T17:21:00Z","reference_number":"EMA/COMP/556648/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-6-8-october-2020_en.pdf"},
    {"id":"49727","name":"Minutes of the CHMP meeting 12-15 October 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-06T10:45:00Z","last_updated_date":"2021-01-06T10:45:00Z","reference_number":"EMA/CHMP/708154/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-12-15-october-2020_en.pdf"},
    {"id":"49742","name":"Minutes of the CHMP meeting 9-12 November 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-07T13:02:00Z","last_updated_date":"2021-01-07T13:02:00Z","reference_number":"EMA/CHMP/708314/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-9-12-november-2020_en.pdf"},
    {"id":"49743","name":"Minutes of the CVMP meeting of 3-5 November 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-07T14:31:00Z","last_updated_date":"2021-01-07T14:31:00Z","reference_number":"EMA/CVMP/666630/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-3-5-november-2020_en.pdf"},
    {"id":"49763","name":"Minutes of the PRAC meeting 26-29 October 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-08T17:07:00Z","last_updated_date":"2021-01-08T17:07:00Z","reference_number":"EMA/PRAC/12790/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-26-29-october-2020_en.pdf"},
    {"id":"49929","name":"Minutes - PDCO minutes of the 10-13 November 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-25T12:00:00Z","last_updated_date":"2021-01-25T12:00:00Z","reference_number":"EMA/PDCO/615662/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-10-13-november-2020-meeting_en.pdf"},
    {"id":"49944","name":"CHMP ORGAM minutes for the meeting on 16 March 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-27T09:18:00Z","last_updated_date":"2021-01-27T09:18:00Z","reference_number":"EMA/CHMP/51258/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-16-march-2020_en.pdf"},
    {"id":"49945","name":"Meeting summary - PCWP/HCPWP meeting with all eligible organisations: COVID-19 pandemic update","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2021-01-27T09:32:00Z","last_updated_date":"2021-01-27T09:32:00Z","reference_number":"EMA/693425/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-meeting-all-eligible-organisations-covid-19-pandemic-update_en.pdf"},
    {"id":"49946","name":"CHMP ORGAM minutes for the meeting on 20 April 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-27T11:07:00Z","last_updated_date":"2021-01-27T11:07:00Z","reference_number":"EMA/CHMP/54321/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-20-april-2020_en.pdf"},
    {"id":"49950","name":"CHMP ORGAM minutes for the meeting on 18 May 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-27T13:41:00Z","last_updated_date":"2021-01-27T13:41:00Z","reference_number":"EMA/CHMP/56041/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-18-may-2020_en.pdf"},
    {"id":"49975","name":"CHMP ORGAM minutes for the meeting on 4 November 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-29T09:23:00Z","last_updated_date":"2021-01-29T09:23:00Z","reference_number":"EMA/CHMP/421790/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-4-november-2019_en.pdf"},
    {"id":"49976","name":"CHMP ORGAM minutes for the meeting on 4 November 2019","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-01-29T09:23:00Z","last_updated_date":"2021-01-29T09:23:00Z","reference_number":"EMA/CHMP/421790/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-4-november-2019_en.pdf-0"},
    {"id":"50023","name":"Minutes of the HMPC 16-18 November 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T15:58:00Z","last_updated_date":"2021-02-01T15:58:00Z","reference_number":"EMA/HMPC/654096/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-16-18-november-2020-meeting_en.pdf"},
    {"id":"50038","name":"Minutes of the COMP meeting 3-5 November 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-02-03T09:11:00Z","last_updated_date":"2021-02-03T09:11:00Z","reference_number":"EMA/COMP/611950/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-3-5-november-2020_en.pdf"},
    {"id":"50053","name":"Minutes of the CAT meeting 4-6 November 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-02-03T15:56:00Z","last_updated_date":"2021-02-03T15:56:00Z","reference_number":"EMA/CAT/69678/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-4-6-november-2020_en.pdf"},
    {"id":"50102","name":"CHMP ORGAM minutes for the meeting on 20 January 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-02-08T16:46:00Z","last_updated_date":"2021-02-08T16:46:00Z","reference_number":"EMA/CHMP/29856/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-20-january-2020_en.pdf"},
    {"id":"50116","name":"Minutes - Oncology focus group meeting on 25 April 2007","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2021-02-10T12:57:00Z","last_updated_date":"2021-02-10T12:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-oncology-focus-group-meeting-25-april-2007_en.pdf"},
    {"id":"50184","name":"Minutes of the PRAC meeting 23-26 November 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T12:41:00Z","last_updated_date":"2021-02-16T12:41:00Z","reference_number":"EMA/PRAC/87359/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-23-26-november-2020_en.pdf"},
    {"id":"50189","name":"Minutes of the COMP meeting 1-3 December 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T14:26:00Z","last_updated_date":"2021-02-16T14:26:00Z","reference_number":"EMA/COMP/687971/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-1-3-december-2020_en.pdf"},
    {"id":"50231","name":"Minutes of the CVMP meeting of 8-10 December 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-02-18T14:45:00Z","last_updated_date":"2021-02-18T14:45:00Z","reference_number":"EMA/CVMP/36148/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-december-2020_en.pdf"},
    {"id":"50331","name":"Minutes - PDCO minutes of the 8-11 December 2020 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-01T16:07:00Z","last_updated_date":"2021-03-01T16:07:00Z","reference_number":"EMA/PDCO/622400/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-8-11-december-2020-meeting_en.pdf"},
    {"id":"50355","name":"Minutes of the CVMP meeting of 19-20 January 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-02T11:03:00Z","last_updated_date":"2021-03-02T11:03:00Z","reference_number":"EMA/CVMP/99479/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-19-20-january-2021_en.pdf"},
    {"id":"50356","name":"Minutes of the CHMP meeting 7-10 December 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-02T11:15:00Z","last_updated_date":"2021-03-02T11:15:00Z","reference_number":"EMA/CHMP/81765/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-7-10-december-2020_en.pdf"},
    {"id":"50367","name":"Minutes of the 110th meeting of the Management Board: 16-17 December 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-02T16:08:00Z","last_updated_date":"2021-03-02T16:08:00Z","reference_number":"EMA/MB/695181/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-110th-meeting-management-board-16-17-december-2020_en.pdf"},
    {"id":"50399","name":"Minutes of the CHMP meeting 25-29 January 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T13:50:00Z","last_updated_date":"2021-03-04T13:50:00Z","reference_number":"EMA/CHMP/128746/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-25-29-january-2021_en.pdf"},
    {"id":"50508","name":"CHMP ORGAM minutes for the meeting on 13 July 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-10T11:43:00Z","last_updated_date":"2021-03-10T11:43:00Z","reference_number":"EMA/CHMP/381251/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-13-july-2020_en.pdf"},
    {"id":"50522","name":"Minutes of the COMP meeting 19-21 January 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-11T09:39:00Z","last_updated_date":"2021-03-11T09:39:00Z","reference_number":"EMA/COMP/64530/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-19-21-january-2021_en.pdf"},
    {"id":"50567","name":"Minutes of the HMPC 11-13 January 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T11:28:00Z","last_updated_date":"2021-03-16T11:28:00Z","reference_number":"EMA/HMPC/62722/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-11-13-january-2021-meeting_en.pdf"},
    {"id":"50585","name":"Minutes of the CAT meeting 2-4 December 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T14:59:00Z","last_updated_date":"2021-03-16T14:59:00Z","reference_number":"EMA/CAT/162004/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-2-4-december-2020_en.pdf"},
    {"id":"50627","name":"CHMP ORGAM minutes for the meeting on 7 September 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T15:55:00Z","last_updated_date":"2021-03-17T15:55:00Z","reference_number":"EMA/471512/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-7-september-2020_en.pdf"},
    {"id":"50629","name":"Minutes - PDCO minutes of the 26-29 January 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T16:02:00Z","last_updated_date":"2021-03-17T16:02:00Z","reference_number":"EMA/PDCO/74936/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-26-29-january-2021-meeting_en.pdf"},
    {"id":"50656","name":"Minutes of the CAT meeting 20-22 January 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-19T13:52:00Z","last_updated_date":"2021-03-19T13:52:00Z","reference_number":"EMA/CAT/166763/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-20-22-january-2021_en.pdf"},
    {"id":"50703","name":"Minutes - European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting (March 2021)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2021-03-25T15:58:00Z","last_updated_date":"2021-03-25T15:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting-march-2021_en.pdf"},
    {"id":"50729","name":"Minutes of the CVMP meeting of 16-17 February 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T13:53:00Z","last_updated_date":"2021-03-26T13:53:00Z","reference_number":"EMA/CVMP/162693/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-16-17-february-2021_en.pdf"},
    {"id":"50977","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting - December 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-04-26T09:11:00Z","last_updated_date":"2021-04-26T09:11:00Z","reference_number":"EMA/694619/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-december-2020_en.pdf"},
    {"id":"51007","name":"CHMP ORGAM minutes for the meeting on 3 November 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-04-30T08:52:00Z","last_updated_date":"2021-08-16T16:56:00Z","reference_number":"EMA/CHMP/586023/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-3-november-2020_en.pdf"},
    {"id":"51043","name":"Minutes of the CHMP meeting 22-25 February 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-05-03T14:31:00Z","last_updated_date":"2021-05-03T14:31:00Z","reference_number":"EMA/CHMP/176288/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-february-2021_en.pdf"},
    {"id":"51045","name":"Minutes of the COMP meeting 16-18 February 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-05-03T16:34:00Z","last_updated_date":"2021-05-03T16:34:00Z","reference_number":"EMA/COMP/129196/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-18-february-2021_en.pdf"},
    {"id":"51047","name":"Minutes of the CVMP meeting of 16-18 March 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-05-03T17:14:00Z","last_updated_date":"2021-05-03T17:14:00Z","reference_number":"EMA/CVMP/212369/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-16-18-march-2021_en.pdf"},
    {"id":"51062","name":"Minutes of the COMP meeting 16-18 March 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-05-04T12:49:00Z","last_updated_date":"2021-05-04T12:49:00Z","reference_number":"EMA/COMP/180661/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-18-march-2021_en.pdf"},
    {"id":"51086","name":"Minutes - PDCO minutes of the 23-26 February 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-05-05T16:42:00Z","last_updated_date":"2021-05-05T16:42:00Z","reference_number":"EMA/PDCO/138740/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-23-26-february-2021_en.pdf"},
    {"id":"51089","name":"Minutes of the CAT meeting 17-19 February 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-05-05T16:57:00Z","last_updated_date":"2021-05-05T16:57:00Z","reference_number":"EMA/CAT/250178/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-17-19-february-2021_en.pdf"},
    {"id":"51152","name":"Minutes - PDCO minutes of the 23-26 March 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-05-12T17:02:00Z","last_updated_date":"2021-05-12T17:02:00Z","reference_number":"EMA/PDCO/193094/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-23-26-march-2021-meeting_en.pdf"},
    {"id":"51155","name":"Minutes of the CHMP meeting 22-25 March 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-05-17T09:57:00Z","last_updated_date":"2021-05-17T09:57:00Z","reference_number":"EMA/CHMP/258452/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-march-2021_en.pdf"},
    {"id":"51264","name":"Minutes of the 111th meeting of the Management Board: 11 March 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-05-25T16:50:00Z","last_updated_date":"2021-05-25T16:50:00Z","reference_number":"EMA/MB/153834/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-111th-meeting-management-board-11-march-2021_en.pdf"},
    {"id":"51296","name":"Meeting Summary - PCWP HCPWP joint meeting March 2021","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2021-05-31T09:44:00Z","last_updated_date":"2021-05-31T09:44:00Z","reference_number":"EMA/158664/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-joint-meeting-march-2021_en.pdf"},
    {"id":"51303","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting - April 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-01T09:00:00Z","last_updated_date":"2021-06-01T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-april-2021_en.pdf"},
    {"id":"51321","name":"Minutes of the HMPC 1-3 March 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-01T09:45:00Z","last_updated_date":"2021-06-01T09:45:00Z","reference_number":"EMA/HMPC/177648/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-1-3-march-2021-meeting_en.pdf"},
    {"id":"51361","name":"Minutes of the CHMP meeting 19-22 April 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-04T09:47:00Z","last_updated_date":"2021-06-04T09:47:00Z","reference_number":"EMA/CHMP/294837/2021 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-april-2021_en.pdf"},
    {"id":"51422","name":"Minutes of the COMP meeting 13-15 April 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-11T15:42:00Z","last_updated_date":"2021-06-11T15:42:00Z","reference_number":"EMA/COMP/222143/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-13-15-april-2021_en.pdf"},
    {"id":"51481","name":"Minutes of the CAT meeting 17-18 March 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T10:21:00Z","last_updated_date":"2021-06-18T10:21:00Z","reference_number":"EMA/CAT/172956/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-17-18-march-2021_en.pdf"},
    {"id":"51509","name":"Minutes of the CAT meeting 14-16 April 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T16:53:00Z","last_updated_date":"2021-06-18T16:53:00Z","reference_number":"EMA/CAT/224917/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-14-16-april-2021_en.pdf"},
    {"id":"51582","name":"Minutes of the CVMP meeting of 13-15 April 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-24T12:31:00Z","last_updated_date":"2021-06-24T12:31:00Z","reference_number":"EMA/CVMP/267193/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-13-15-april-2021_en.pdf"},
    {"id":"51597","name":"Meeting summary - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint virtual meeting on 1-2 June 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-24T17:12:00Z","last_updated_date":"2021-06-24T17:12:00Z","reference_number":"EMA/314725/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-virtual-meeting-1-2-june-2021_en.pdf"},
    {"id":"51622","name":"Minutes of the Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (Dec 2020)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T16:08:00Z","last_updated_date":"2021-06-25T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-substance-product-organisation-and-referential-data-spor-task-force-meeting-dec-2020_en.pdf"},
    {"id":"51624","name":"Minutes of the Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (Sept 2020)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T16:17:00Z","last_updated_date":"2021-06-25T16:17:00Z","reference_number":"EMA/523839/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-substance-product-organisation-and-referential-data-spor-task-force-meeting-sept-2020_en.pdf"},
    {"id":"51625","name":"Minutes of the Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (Jul 2020)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T16:23:00Z","last_updated_date":"2021-06-25T16:23:00Z","reference_number":"EMA/345505/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-substance-product-organisation-and-referential-data-spor-task-force-meeting-jul-2020_en.pdf"},
    {"id":"51627","name":"Minutes of the Substance, Product, Organisation and Referential data (SPOR) Task Force meeting (Apr 2020)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T16:31:00Z","last_updated_date":"2021-06-25T16:31:00Z","reference_number":"EMA/316413/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-substance-product-organisation-and-referential-data-spor-task-force-meeting-apr-2020_en.pdf"},
    {"id":"51687","name":"Minutes - PDCO minutes of the 20-23 April 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T15:37:00Z","last_updated_date":"2021-06-30T15:37:00Z","reference_number":"EMA/PDCO/245494/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-20-23-april-2021-meeting_en.pdf"},
    {"id":"51699","name":"Minutes of the CVMP meeting of 10-12 May 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T17:15:00Z","last_updated_date":"2021-06-30T17:15:00Z","reference_number":"EMA/CVMP/339658/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-12-may-2021_en.pdf"},
    {"id":"51898","name":"Minutes of the COMP meeting 10-12 May 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-07-09T14:34:00Z","last_updated_date":"2021-07-09T14:34:00Z","reference_number":"EMA/COMP/292909/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-12-may-2021_en.pdf"},
    {"id":"51899","name":"Minutes of the CAT meeting 10-12 May 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-07-09T14:42:00Z","last_updated_date":"2021-07-09T14:42:00Z","reference_number":"EMA/CAT/275464/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-10-12-may-2021_en.pdf"},
    {"id":"51902","name":"Minutes of the CHMP meeting 17-20 May 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-07-09T15:53:00Z","last_updated_date":"2021-07-09T15:53:00Z","reference_number":"EMA/CHMP/350170/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-17-20-may-2021_en.pdf"},
    {"id":"51916","name":"Minutes of the European Medicines Agency and European Union payer community meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2021-07-12T17:15:00Z","last_updated_date":"2021-07-12T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-and-european-union-payer-community-meeting_en.pdf-0"},
    {"id":"51926","name":"Minutes of the Extraordinary Management Board meeting on CTIS audit","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-07-14T12:48:00Z","last_updated_date":"2021-07-14T12:48:00Z","reference_number":"EMA/MB/243718/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-extraordinary-management-board-meeting-ctis-audit_en.pdf"},
    {"id":"51941","name":"Minutes - European Union (EU) International Organization for Standardization (ISO) for the identification of medicinal products (IDMP) / Substance, Product, Organisation and Referential data (SPOR) task force meeting (April 2021)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2021-07-15T10:49:00Z","last_updated_date":"2021-07-15T10:49:00Z","reference_number":"EMA/384689/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-union-eu-international-organization-standardization-iso-identification-medicinal-products-idmp-substance-product-organisation-and-referential-data-spor-task-force-meeting-april-2021_en.pdf"}    {"id":"52089","name":"Minutes of the HMPC 3-5 May 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-07-27T10:40:00Z","last_updated_date":"2021-07-27T10:40:00Z","reference_number":"EMA/HMPC/300189/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-3-5-may-2021-meeting_en.pdf"},
    {"id":"52155","name":"Minutes of the CVMP meeting of 15-17 June 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-07-30T09:38:00Z","last_updated_date":"2021-07-30T09:38:00Z","reference_number":"EMA/CVMP/397071/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-15-17-june-2021_en.pdf"},
    {"id":"52173","name":"Minutes of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting on 29 June 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-08-02T17:33:00Z","last_updated_date":"2021-08-02T17:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-networks-meeting-29-june-2021_en.pdf"},
    {"id":"52211","name":"Minutes of the CHMP meeting 21-24 June 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-08-11T10:57:00Z","last_updated_date":"2021-08-11T10:57:00Z","reference_number":"EMA/CHMP/442451/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-21-24-june-2021_en.pdf"},
    {"id":"52224","name":"CHMP ORGAM minutes for the meeting on 5 October 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-08-16T16:27:00Z","last_updated_date":"2021-08-16T16:27:00Z","reference_number":"EMA/526005/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-5-october-2020_en.pdf"},
    {"id":"52231","name":"CHMP ORGAM minutes for the meeting on 30 November 2020","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-08-17T15:20:00Z","last_updated_date":"2021-08-17T15:20:00Z","reference_number":"EMA/CHMP/647319/2020","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-30-november-2020_en.pdf"},
    {"id":"52234","name":"CHMP ORGAM minutes for the meeting on 18 January 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-08-17T15:52:00Z","last_updated_date":"2021-08-17T15:52:00Z","reference_number":"EMA/CHMP/34231/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-orgam-minutes-meeting-18-january-2021_en.pdf"},
    {"id":"52329","name":"Minutes of the 112th meeting of the Management Board: 17 June 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-09-03T09:45:00Z","last_updated_date":"2021-09-03T09:45:00Z","reference_number":"EMA/MB/345297/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-112th-meeting-management-board-17-june-2021_en.pdf"},
    {"id":"52469","name":"Minutes of the CVMP meeting of 13-15 July 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-09-16T15:42:00Z","last_updated_date":"2021-09-16T15:42:00Z","reference_number":"EMA/CVMP/500685/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-13-15-july-2021_en.pdf"},
    {"id":"52535","name":"Minutes of the COMP meeting 15-17 June 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-09-21T15:57:00Z","last_updated_date":"2021-09-21T15:57:00Z","reference_number":"EMA/COMP/359170/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-15-17-june-2021_en.pdf"},
    {"id":"52566","name":"Minutes of the PRAC meeting 11-14 January 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T08:52:00Z","last_updated_date":"2021-09-23T08:52:00Z","reference_number":"EMA/PRAC/532676/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-11-14-january-2021_en.pdf"},
    {"id":"52683","name":"Minutes of the COMP meeting 13-15 July 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-09-30T10:19:00Z","last_updated_date":"2021-09-30T10:19:00Z","reference_number":"EMA/COMP/424709/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-13-15-july-2021_en.pdf"},
    {"id":"52706","name":"Minutes of the HMPC 5-7 July 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-10-01T16:02:00Z","last_updated_date":"2021-10-01T16:02:00Z","reference_number":"EMA/HMPC/413456/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-5-7-july-2021-meeting_en.pdf"},
    {"id":"52772","name":"Minutes of CHMP written procedure 16-19 August 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-10-07T15:59:00Z","last_updated_date":"2021-10-07T15:59:00Z","reference_number":"EMA/CHMP/528074/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-written-procedure-16-19-august-2021_en.pdf"},
    {"id":"52773","name":"Minutes of the CHMP meeting 19-22 July 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-10-07T16:03:00Z","last_updated_date":"2021-10-07T16:03:00Z","reference_number":"EMA/CHMP/562166/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-july-2021_en.pdf"},
    {"id":"52865","name":"Minutes of the CVMP meeting of 7-9 September 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T11:12:00Z","last_updated_date":"2021-10-15T11:12:00Z","reference_number":"EMA/562594/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-7-9-september-2021_en.pdf"},
    {"id":"52925","name":"Minutes of the COMP meeting 7-9 September 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-10-27T17:21:00Z","last_updated_date":"2021-10-27T17:21:00Z","reference_number":"EMA/COMP/525993/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-7-9-september-2021_en.pdf"},
    {"id":"53007","name":"Meeting summary - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting on 21-22 September 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T15:43:00Z","last_updated_date":"2021-11-05T15:43:00Z","reference_number":"EMA/314725/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting-21-22-september-2021_en.pdf"},
    {"id":"53071","name":"Minutes of the CHMP meeting 13-16 September 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-11-11T14:02:00Z","last_updated_date":"2021-11-11T14:02:00Z","reference_number":"EMA/621477/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-13-16-september-2021_en.pdf"},
    {"id":"53117","name":"Minutes of the CVMP meeting of 5-7 October 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T10:09:00Z","last_updated_date":"2021-11-15T10:09:00Z","reference_number":"EMA/CVMP/622424/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-5-7-october-2021_en.pdf"},
    {"id":"53132","name":"Minutes - PDCO minutes of the 22-25 June 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T17:52:00Z","last_updated_date":"2021-11-15T17:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-22-25-june-2021-meeting_en.pdf"},
    {"id":"53302","name":"Minutes of the CAT meeting 16-18 June 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-11-29T11:14:00Z","last_updated_date":"2021-11-29T11:14:00Z","reference_number":"EMA/CAT/349953/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-16-18-june-2021_en.pdf"},
    {"id":"53303","name":"Minutes of the CAT meeting 14-16 July 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-11-29T11:28:00Z","last_updated_date":"2021-11-29T11:28:00Z","reference_number":"EMA/CAT/407165/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-14-16-july-2021_en.pdf"},
    {"id":"53304","name":"Minutes of the CAT written procedure 11-13 August 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-11-29T11:35:00Z","last_updated_date":"2021-11-29T11:35:00Z","reference_number":"EMA/CAT/458500/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-written-procedure-11-13-august-2021_en.pdf"},
    {"id":"53367","name":"Highlights - 16th industry stakeholder platform - operation of European Union (EU) pharmacovigilance","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2021-12-06T12:27:00Z","last_updated_date":"2021-12-10T08:43:00Z","reference_number":"EMA/582239/2021 Corr.","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-16th-industry-stakeholder-platform-operation-european-union-eu-pharmacovigilance_en.pdf"},
    {"id":"53385","name":"CHMP PROM minutes for the meeting on 15 February 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T11:57:00Z","last_updated_date":"2021-12-07T11:57:00Z","reference_number":"EMA/CHMP/96864/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-15-february-2021_en.pdf"},
    {"id":"53387","name":"CHMP PROM minutes for the meeting on 15 March 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T12:38:00Z","last_updated_date":"2021-12-07T12:38:00Z","reference_number":"EMA/CHMP/161669/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-15-march-2021_en.pdf"},
    {"id":"53391","name":"CHMP PROM minutes for the meeting on 12 April 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T13:55:00Z","last_updated_date":"2021-12-07T13:55:00Z","reference_number":"EMA/CHMP/210409/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-12-april-2021_en.pdf"},
    {"id":"53394","name":"CHMP PROM minutes for the meeting on 10 May 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T14:25:00Z","last_updated_date":"2021-12-07T14:25:00Z","reference_number":"EMA/CHMP/268010/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-10-may-2021_en.pdf"},
    {"id":"53395","name":"CHMP PROM minutes for the meeting on 14 June 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T14:34:00Z","last_updated_date":"2021-12-07T14:34:00Z","reference_number":"EMA/CHMP/336435/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-14-june-2021_en.pdf"},
    {"id":"53401","name":"Minutes of the HMPC  20-22 September 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-07T16:46:00Z","last_updated_date":"2021-12-07T16:46:00Z","reference_number":"EMA/HMPC/568018/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-20-22-september-2021-meeting_en.pdf"},
    {"id":"53424","name":"Minutes of the CHMP meeting 11-14 October 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-09T09:15:00Z","last_updated_date":"2021-12-09T09:15:00Z","reference_number":"EMA/CHMP/711196/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-11-14-october-2021_en.pdf"},
    {"id":"53487","name":"Minutes of the COMP meeting 5-7 October 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-14T12:35:00Z","last_updated_date":"2021-12-14T12:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-5-7-october-2021_en.pdf"},
    {"id":"53571","name":"Minutes of the CVMP meeting of 3-4 November 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-16T17:53:00Z","last_updated_date":"2021-12-16T17:53:00Z","reference_number":"EMA/CVMP/728802/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-3-4-november-2021_en.pdf"},
    {"id":"53603","name":"Minutes of the CHMP meeting 8-11 November 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-20T11:26:00Z","last_updated_date":"2021-12-20T11:26:00Z","reference_number":"EMA/CHMP/759951/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-8-11-november-2021_en.pdf"},
    {"id":"53605","name":"Minutes of the PRAC meeting 8-11 February 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-12-20T12:51:00Z","last_updated_date":"2021-12-20T12:51:00Z","reference_number":"EMA/PRAC/696693/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-february-2021_en.pdf"},
    {"id":"53645","name":"Meeting summary - Annual Patients and Consumers Working Party (PCWP) and Healthcare Professionals Working Party (HCPWP) meeting with all eligible organisations (24 Nov 2021)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-01-06T09:24:00Z","last_updated_date":"2022-01-06T09:24:00Z","reference_number":"EMA/775191/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-annual-patients-consumers-working-party-pcwp-healthcare-professionals-working-party-hcpwp-meeting-all-eligible-organisations-24-nov-2021_en.pdf"},
    {"id":"53677","name":"Minutes - DARWIN EU Advisory Board meeting: 20 September 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-11T09:27:00Z","last_updated_date":"2022-01-11T09:27:00Z","reference_number":"EMA/371416/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-meeting-20-september-2021_en.pdf"},
    {"id":"53679","name":"Minutes - DARWIN EU Advisory Board meeting: 28 June 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-11T09:36:00Z","last_updated_date":"2022-01-11T09:36:00Z","reference_number":"EMA/371416/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-meeting-28-june-2021_en.pdf"},
    {"id":"53713","name":"Minutes of the CAT meeting 8-10 September 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-14T11:28:00Z","last_updated_date":"2022-01-14T11:28:00Z","reference_number":"EMA/CAT/515396/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-8-10-september-2021_en.pdf"},
    {"id":"53716","name":"Minutes of the CAT meeting 6-8 October 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-14T11:58:00Z","last_updated_date":"2022-01-14T11:58:00Z","reference_number":"EMA/CAT/574435/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-6-8-october-2021_en.pdf"},
    {"id":"53825","name":"Minutes of the 113th meeting of the Management Board: 7 October 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T17:40:00Z","last_updated_date":"2022-01-18T17:40:00Z","reference_number":"EMA/MB/571618/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-113th-meeting-management-board-7-october-2021_en.pdf"},
    {"id":"53827","name":"CHMP PROM minutes for the meeting on 12 July 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-19T09:14:00Z","last_updated_date":"2022-01-19T09:14:00Z","reference_number":"EMA/CHMP/397322/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-12-july-2021_en.pdf"},
    {"id":"53828","name":"CHMP PROM minutes for the meeting on 6 September 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-19T09:17:00Z","last_updated_date":"2022-01-19T09:17:00Z","reference_number":"EMA/CHMP/499778/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-6-september-2021_en.pdf"},
    {"id":"53857","name":"CHMP PROM minutes for the meeting on 3 November 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-20T12:43:00Z","last_updated_date":"2022-01-20T12:43:00Z","reference_number":"EMA/CHMP/620080/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-3-november-2021_en.pdf"},
    {"id":"53858","name":"CHMP PROM minutes for the meeting on 4 October 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-20T12:46:00Z","last_updated_date":"2022-01-20T12:46:00Z","reference_number":"EMA/CHMP/562180/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-4-october-2021_en.pdf"},
    {"id":"53873","name":"Minutes of the COMP meeting on 3 - 5 November 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-21T13:24:00Z","last_updated_date":"2022-01-21T13:24:00Z","reference_number":"EMA/COMP/647448/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-3-5-november-2021_en.pdf"},
    {"id":"53982","name":"Minutes of the CVMP meeting of 7-9 December 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T10:23:00Z","last_updated_date":"2022-01-28T10:23:00Z","reference_number":"EMA/CVMP/31894/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-7-9-december-2021_en.pdf"},
    {"id":"54060","name":"Minutes of the HMPC 22-24 November 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-02-03T15:20:00Z","last_updated_date":"2022-02-03T15:20:00Z","reference_number":"EMA/HMPC/734733/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-22-24-november-2021-meeting_en.pdf"},
    {"id":"54097","name":"Minutes of the PRAC meeting 8-11 March 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-02-08T09:00:00Z","last_updated_date":"2022-02-08T09:00:00Z","reference_number":"EMA/PRAC/73527/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-march-2021_en.pdf"},
    {"id":"54099","name":"Minutes of the CHMP meeting 13-16 December 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-02-08T10:34:00Z","last_updated_date":"2022-02-08T10:34:00Z","reference_number":"EMA/CHMP/782804/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-13-16-december-2021_en.pdf"},
    {"id":"54107","name":"Minutes - Committee for Advanced Therapies (CAT) meeting with interested parties - October 2021","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T17:29:00Z","last_updated_date":"2022-02-08T17:29:00Z","reference_number":"EMA/582731/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-committee-advanced-therapies-cat-meeting-interested-parties-october-2021_en.pdf"},
    {"id":"54127","name":"CHMP PROM minutes for the meeting on 6 December 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-02-10T14:44:00Z","last_updated_date":"2022-02-10T14:44:00Z","reference_number":"EMA/CHMP/724020/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-6-december-2021_en.pdf"},
    {"id":"54128","name":"Minutes of the PRAC meeting 6-9 April 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-02-10T14:51:00Z","last_updated_date":"2022-03-21T09:21:00Z","reference_number":"EMA/PRAC/89475/2022 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-6-9-april-2021_en.pdf"},
    {"id":"54241","name":"Minutes - PDCO minutes of the 20-23 July 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-02-21T15:31:00Z","last_updated_date":"2022-02-21T15:31:00Z","reference_number":"EMA/PDCO/429998/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-20-23-july-2021-meeting_en.pdf"},
    {"id":"54259","name":"CHMP PROM minutes for the meeting on 17 January 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-02-23T09:56:00Z","last_updated_date":"2022-02-23T09:56:00Z","reference_number":"EMA/CHMP/25624/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-17-january-2022_en.pdf"},
    {"id":"54282","name":"Minutes of the CVMP meeting of 18-19 January 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-02-24T16:11:00Z","last_updated_date":"2022-02-24T16:11:00Z","reference_number":"EMA/CVMP/101771/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-18-19-january-2022_en.pdf"},
    {"id":"54334","name":"Minutes - DARWIN EU Advisory Board meeting: 12 November 2021","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-03-02T17:11:00Z","last_updated_date":"2022-03-02T17:11:00Z","reference_number":"EMA/745207/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-meeting-12-november-2021_en.pdf"},
    {"id":"54340","name":"Minutes - PDCO minutes of the 7-10 September 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-02T17:22:00Z","last_updated_date":"2022-03-02T17:22:00Z","reference_number":"EMA/PDCO/521274/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-7-10-september-2021-meeting_en.pdf"},
    {"id":"54398","name":"Minutes of the COMP meeting on 7-9 December 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-08T16:15:00Z","last_updated_date":"2022-03-08T16:15:00Z","reference_number":"EMA/COMP/778269/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-7-9-december-2021_en.pdf"},
    {"id":"54399","name":"Minutes of the COMP meeting on 7-9 December 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-08T16:15:00Z","last_updated_date":"2022-03-08T16:15:00Z","reference_number":"EMA/COMP/778269/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-7-9-december-2021_en.pdf-0"},
    {"id":"54424","name":"Minutes - PDCO minutes of the 12-15 October 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-11T14:36:00Z","last_updated_date":"2022-03-11T14:36:00Z","reference_number":"EMA/PDCO/601596/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-12-15-october-2021-meeting_en.pdf"},
    {"id":"54487","name":"Minutes of the CHMP meeting  24-27 January 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-16T15:51:00Z","last_updated_date":"2022-03-16T15:51:00Z","reference_number":"EMA/CHMP/95406/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-24-27-january-2022_en.pdf"},
    {"id":"54540","name":"Minutes of the COMP meeting on 18-20 January 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-22T14:34:00Z","last_updated_date":"2022-03-22T14:34:00Z","reference_number":"EMA/COMP/63104/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-18-20-january-2022_en.pdf"},
    {"id":"54541","name":"Minutes - PDCO minutes of the 9-12 November 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-22T14:42:00Z","last_updated_date":"2022-03-22T14:42:00Z","reference_number":"EMA/PDCO/687396/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-9-12-november-2021-meeting_en.pdf"},
    {"id":"54552","name":"Minutes of the CAT meeting 8-10 December 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-24T15:12:00Z","last_updated_date":"2022-03-24T15:12:00Z","reference_number":"EMA/CAT/752469/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-8-10-december-2021_en.pdf"},
    {"id":"54553","name":"Minutes - PDCO minutes of the 14-17 December 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-24T15:20:00Z","last_updated_date":"2022-03-24T15:20:00Z","reference_number":"EMA/PDCO/780332/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-14-17-december-2021-meeting_en.pdf"},
    {"id":"54559","name":"CHMP PROM minutes for the meeting on 14 February 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-24T16:47:00Z","last_updated_date":"2022-03-24T16:47:00Z","reference_number":"EMA/CHMP/97882/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-14-february-2022_en.pdf"},
    {"id":"54568","name":"Minutes of the CVMP meeting of 15-16 February 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T08:30:00Z","last_updated_date":"2022-03-25T08:30:00Z","reference_number":"EMA/CVMP/157941/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-15-16-february-2022_en.pdf"},
    {"id":"54679","name":"PDCO meeting report of opinions on paediatric investigation plans and other activities 18-21 January 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-04-05T15:59:00Z","last_updated_date":"2022-04-05T15:59:00Z","reference_number":"EMA/PDCO/64920/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-meeting-report-opinions-paediatric-investigation-plans-other-activities-18-21-january-2022_en.pdf"},
    {"id":"54687","name":"Minutes of the COMP meeting on 15-17 February 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-04-06T14:48:00Z","last_updated_date":"2022-04-06T14:48:00Z","reference_number":"EMA/COMP/204288/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-15-17-february-2022_en.pdf"},
    {"id":"54723","name":"Minutes - Enpr-EMA Coordinating Group and networks meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T16:15:00Z","last_updated_date":"2022-04-11T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-and-networks-meeting_en.pdf"},
    {"id":"54736","name":"Meeting summary - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting on 2-3 March 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-04-12T15:19:00Z","last_updated_date":"2022-04-12T15:19:00Z","reference_number":"EMA/775191/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting-2-3-march-2022_en.pdf"},
    {"id":"54765","name":"Minutes of the 114th meeting of the Management Board: 15-16 December 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-04-20T12:57:00Z","last_updated_date":"2022-04-20T12:57:00Z","reference_number":"EMA/MB/761948/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-114th-meeting-management-board-15-16-december-2021_en.pdf"},
    {"id":"54790","name":"Minutes of the CVMP meeting of 15-16 March 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T09:18:00Z","last_updated_date":"2022-04-22T09:18:00Z","reference_number":"EMA/CVMP/214973/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-15-16-march-2022_en.pdf"},
    {"id":"54875","name":"Minutes of the CHMP meeting 21-24 February 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-02T15:49:00Z","last_updated_date":"2022-05-02T15:49:00Z","reference_number":"EMA/CHMP/149023/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-21-24-february-2022_en.pdf"},
    {"id":"54892","name":"Minutes of the PRAC meeting 7-10 June 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-04T15:56:00Z","last_updated_date":"2022-05-04T15:56:00Z","reference_number":"EMA/PRAC/139868/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-june-2021_en.pdf"},
    {"id":"54893","name":"PDCO minutes of the 18-21 January 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-04T16:00:00Z","last_updated_date":"2022-05-04T16:00:00Z","reference_number":"EMA/PDCO/54982/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-18-21-january-2022-meeting_en.pdf"},
    {"id":"54909","name":"Minutes of the HMPC 24-26 January 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-06T09:36:00Z","last_updated_date":"2022-05-06T09:36:00Z","reference_number":"EMA/HMPC/82262/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-24-26-january-2022-meeting_en.pdf"},
    {"id":"54910","name":"PDCO minutes of the 22-25 February 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-06T09:45:00Z","last_updated_date":"2022-09-19T09:37:00Z","reference_number":"EMA/PDCO/134913/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-22-25-february-2022-meeting_en.pdf"},
    {"id":"54927","name":"Minutes of the PRAC meeting 5-8 July 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-10T12:18:00Z","last_updated_date":"2022-05-10T12:18:00Z","reference_number":"EMA/PRAC/171547/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-5-8-july-2021_en.pdf"},
    {"id":"54956","name":"Minutes of the PRAC meeting 5 August 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-12T16:27:00Z","last_updated_date":"2022-05-12T16:27:00Z","reference_number":"EMA/PRAC/178649/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-5-august-2021_en.pdf"},
    {"id":"55026","name":"Minutes of the HMPC 28-30 March 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-19T17:06:00Z","last_updated_date":"2022-05-19T17:06:00Z","reference_number":"EMA/HMPC/218711/2022 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-28-30-march-2022-meeting_en.pdf"},
    {"id":"55027","name":"Minutes of the CVMP meeting of 11-13 April 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-19T17:10:00Z","last_updated_date":"2022-05-19T17:10:00Z","reference_number":"EMA/CVMP/260411/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-11-13-april-2022_en.pdf"},
    {"id":"55103","name":"Minutes - DARWIN EU Advisory Board meeting: 16 February 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-05-25T16:37:00Z","last_updated_date":"2022-05-25T16:37:00Z","reference_number":"EMA/191243/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-meeting-16-february-2022_en.pdf"},
    {"id":"55114","name":"Minutes of the CAT meeting 3-5 November 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-31T11:17:00Z","last_updated_date":"2022-05-31T11:17:00Z","reference_number":"EMA/CAT/636354/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-3-5-november-2021_en.pdf"},
    {"id":"55115","name":"Minutes of the CHMP meeting 21-24 March 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-05-31T11:28:00Z","last_updated_date":"2022-05-31T11:28:00Z","reference_number":"EMA/CHMP/214270/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-21-24-march-2022_en.pdf"},
    {"id":"55130","name":"PDCO minutes of the 22-25 March 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-03T15:57:00Z","last_updated_date":"2022-09-19T09:41:00Z","reference_number":"EMA/PDCO/202678/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-22-25-march-2022-meeting_en.pdf"},
    {"id":"55138","name":"Agenda of the PRAC meeting 7-10 June 2022","type":"minutes","status":"Draft","consultation_date":"","first_published_date":"2022-06-07T13:04:00Z","last_updated_date":"2022-06-07T13:04:00Z","reference_number":"EMA/PRAC/246158/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/agenda-prac-meeting-7-10-june-2022_en.pdf"},
    {"id":"55170","name":"Minutes - Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-09T14:35:00Z","last_updated_date":"2022-06-09T14:35:00Z","reference_number":"EMA/127956/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-meeting-executive-steering-group-shortages-safety-medicinal-products-mssg_en.pdf"},
    {"id":"55187","name":"Minutes of the CAT meeting 19-21 January 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-10T12:53:00Z","last_updated_date":"2022-06-10T12:53:00Z","reference_number":"EMA/CAT/47833/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-19-21-january-2022_en.pdf"},
    {"id":"55188","name":"Minutes of the CAT meeting 16-17 February 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-10T12:56:00Z","last_updated_date":"2022-06-10T12:56:00Z","reference_number":"EMA/CAT/110649/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-16-17-february-2022_en.pdf"},
    {"id":"55189","name":"Minutes of the CAT meeting 16-18 March 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-10T13:02:00Z","last_updated_date":"2022-06-10T13:02:00Z","reference_number":"EMA/CAT/186491/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-16-18-march-2022_en.pdf"},
    {"id":"55190","name":"Minutes of the CAT meeting 11-13 April 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-10T13:03:00Z","last_updated_date":"2022-06-10T13:03:00Z","reference_number":"EMA/CAT/184995/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-11-13-april-2022_en.pdf"},
    {"id":"55214","name":"Minutes of the COMP meeting on 15-17 March 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-13T12:14:00Z","last_updated_date":"2022-09-22T15:33:00Z","reference_number":"EMA/COMP/157930/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-15-17-march-2022_en.pdf"},
    {"id":"55232","name":"Minutes - Big Data Steering Group and industry stakeholders meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-14T11:49:00Z","last_updated_date":"2022-06-14T11:49:00Z","reference_number":"EMA/562407/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-big-data-steering-group-and-industry-stakeholders-meeting_en.pdf"},
    {"id":"55255","name":"Minutes of the COMP meeting on 11-13 April 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-16T10:15:00Z","last_updated_date":"2022-06-16T10:15:00Z","reference_number":"EMA/COMP/214405/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-11-13-april-2022_en.pdf"},
    {"id":"55257","name":"Minutes of the 115th meeting of the Management Board: 16-17 March 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-16T10:41:00Z","last_updated_date":"2022-06-16T10:41:00Z","reference_number":"EMA/MB/169135/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-115th-meeting-management-board-16-17-march-2022_en.pdf"},
    {"id":"55258","name":"Minutes - PDCO minutes of the 19-22 April 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-16T12:05:00Z","last_updated_date":"2022-06-16T12:05:00Z","reference_number":"EMA/PDCO/247621/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-19-22-april-2022-meeting_en.pdf"},
    {"id":"55270","name":"Minutes of the CHMP meeting 19-22 April 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-17T11:30:00Z","last_updated_date":"2022-06-17T11:30:00Z","reference_number":"EMA/CHMP/253483/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-april-2022_en.pdf"}    {"id":"55353","name":"Minutes of the CVMP meeting of 10-12 May 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T10:14:00Z","last_updated_date":"2022-06-24T10:14:00Z","reference_number":"EMA/CVMP/587361/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-12-may-2022_en.pdf"},
    {"id":"55430","name":"Minutes of the CAT meeting 11-13 May 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-07-01T11:30:00Z","last_updated_date":"2022-07-01T11:30:00Z","reference_number":"EMA/CAT/275668/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-11-13-may-2022_en.pdf"},
    {"id":"55516","name":"Minutes - DARWIN EU Advisory Board meeting: 20 April 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-07-12T11:41:00Z","last_updated_date":"2022-07-12T11:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-meeting-20-april-2022_en.pdf"},
    {"id":"55518","name":"Minutes of the CHMP meeting 16-19 May 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-07-12T11:50:00Z","last_updated_date":"2022-07-12T11:50:00Z","reference_number":"EMA/CHMP/511583/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-16-19-may-2022_en.pdf"},
    {"id":"55536","name":"Minutes – ad-hoc TC of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-07-13T17:21:00Z","last_updated_date":"2022-07-13T17:21:00Z","reference_number":"EMA/365445/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ad-hoc-tc-executive-steering-group-shortages-safety-medicinal-products-mssg_en.pdf"},
    {"id":"55539","name":"Meeting summary - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting on 1-2 June 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T11:36:00Z","last_updated_date":"2022-07-14T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting-1-2-june-2022_en.pdf"},
    {"id":"55564","name":"Meeting summary - First industry standing group (ISG) meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-07-18T09:43:00Z","last_updated_date":"2022-07-18T09:43:00Z","reference_number":"EMA/775191/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-first-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"55598","name":"Minutes of the PRAC meeting 30 August - 2 September 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-07-20T09:21:00Z","last_updated_date":"2022-07-20T09:21:00Z","reference_number":"EMA/PRAC/233544/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-30-august-2-september-2021_en.pdf"},
    {"id":"55607","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (7 June 2022)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-07-21T09:47:00Z","last_updated_date":"2022-07-21T09:47:00Z","reference_number":"EMA/562731/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-7-june-2022_en.pdf"},
    {"id":"55609","name":"PCDO minutes of the 17-20 May 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-07-21T11:29:00Z","last_updated_date":"2022-07-21T11:29:00Z","reference_number":"EMA/PDCO/561127/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/pcdo-minutes-17-20-may-2022-meeting_en.pdf"},
    {"id":"55613","name":"Minutes of the HMPC 16-18 May 2022 meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-07-21T14:09:00Z","last_updated_date":"2022-07-21T14:09:00Z","reference_number":"EMA/HMPC/563158/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-16-18-may-2022-meeting_en.pdf"},
    {"id":"55620","name":"Minutes of the PRAC meeting 27-30 September 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-07-21T15:15:00Z","last_updated_date":"2022-07-21T15:15:00Z","reference_number":"EMA/PRAC/244588/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-27-30-september-2021_en.pdf"},
    {"id":"55662","name":"Minutes of the CAT meeting 15-17 June 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T14:18:00Z","last_updated_date":"2022-07-22T14:18:00Z","reference_number":"EMA/CAT/600000/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-17-june-2022_en.pdf"},
    {"id":"55711","name":"Minutes of the Cancer Medicines Forum - 31st March 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-07-27T17:58:00Z","last_updated_date":"2023-03-24T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-31st-march-2022_en.pdf"},
    {"id":"55757","name":"Minutes of the PRAC meeting 25-28 October 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-08-02T10:33:00Z","last_updated_date":"2022-08-02T10:33:00Z","reference_number":"EMA/PRAC/648171/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-25-28-october-2021_en.pdf"},
    {"id":"55769","name":"PCDO minutes of the 21-24 June 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-08-02T17:07:00Z","last_updated_date":"2022-08-02T17:07:00Z","reference_number":"EMA/PDCO/625532/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/pcdo-minutes-21-24-june-2022-meeting_en.pdf"},
    {"id":"55773","name":"Highlights from the seventh Nitrosamine Implementation Oversight Group (NIOG) meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-08-03T11:54:00Z","last_updated_date":"2022-08-03T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-seventh-nitrosamine-implementation-oversight-group-niog-meeting_en.pdf"},
    {"id":"55816","name":"CHMP PROM minutes for the meeting on 14 March 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-08-12T09:33:00Z","last_updated_date":"2022-08-12T09:33:00Z","reference_number":"EMA/CHMP/154439/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-14-march-2022_en.pdf"},
    {"id":"55818","name":"CHMP PROM minutes for the meeting on 11 April 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-08-12T11:12:00Z","last_updated_date":"2022-08-12T11:12:00Z","reference_number":"EMA/CHMP/213136/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-11-april-2022_en.pdf"},
    {"id":"55820","name":"CHMP PROM agenda for the meeting on 10 May 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-08-12T16:01:00Z","last_updated_date":"2022-08-12T16:01:00Z","reference_number":"EMA/CHMP/228709/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-agenda-meeting-10-may-2022_en.pdf"},
    {"id":"55821","name":"CHMP PROM minutes for the meeting on 10 May 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-08-12T16:19:00Z","last_updated_date":"2023-01-27T12:44:00Z","reference_number":"EMA/CHMP/259930/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-10-may-2022_en.pdf"},
    {"id":"55823","name":"CHMP PROM minutes for the meeting on 13 June 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-08-12T16:39:00Z","last_updated_date":"2022-08-12T16:39:00Z","reference_number":"EMA/CHMP/288113/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-13-june-2022_en.pdf"},
    {"id":"55839","name":"Minutes of the CHMP meeting 20-23 June 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-08-18T11:00:00Z","last_updated_date":"2022-08-18T11:00:00Z","reference_number":"EMA/CHMP/624461/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-20-23-june-2022_en.pdf"},
    {"id":"55950","name":"Minutes - Enpr-EMA Coordinating Group meeting (June 2022)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T16:12:00Z","last_updated_date":"2022-09-02T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-meeting-june-2022_en.pdf"},
    {"id":"56068","name":"Minutes - Highlight report from the 8th Industry stakeholder platform on research and development support","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-09-13T09:46:00Z","last_updated_date":"2022-09-13T09:46:00Z","reference_number":"EMA/644334/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-highlight-report-8th-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"56087","name":"Event summary - Workshop on the guidance on the protection of personal data and commercially confidential information (CCI) in documents submitted or uploaded via CTIS","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:53:00Z","last_updated_date":"2022-09-12T16:53:00Z","reference_number":"EMA/652218/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/event-summary-workshop-guidance-protection-personal-data-and-commercially-confidential-information-cci-documents-submitted-or-uploaded-ctis_en.pdf"},
    {"id":"56088","name":"Minutes of the COMP meeting on 12-14 July 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T17:02:00Z","last_updated_date":"2022-10-21T17:04:00Z","reference_number":"EMA/COMP/646322/2022 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-12-14-july-2022_en.pdf"},
    {"id":"56117","name":"Minutes of the CVMP meeting of 12-14 July 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T09:12:00Z","last_updated_date":"2022-09-16T09:12:00Z","reference_number":"EMA/CVMP/726655/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-12-14-july-2022_en.pdf"},
    {"id":"56121","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (7 July 2022)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T09:37:00Z","last_updated_date":"2022-09-16T09:37:00Z","reference_number":"EMA/568151/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-7-july-2022_en.pdf"},
    {"id":"56122","name":"Minutes -  Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (25 July 2022)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T09:49:00Z","last_updated_date":"2022-09-16T09:49:00Z","reference_number":"EMA/662292/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-25-july-2022_en.pdf"},
    {"id":"56123","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (2 September 2022)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T09:56:00Z","last_updated_date":"2022-09-16T09:56:00Z","reference_number":"EMA/722467/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-2-september-2022_en.pdf"},
    {"id":"56166","name":"Minutes of the CAT meeting 13-15 July 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-09-22T15:42:00Z","last_updated_date":"2022-09-22T15:42:00Z","reference_number":"EMA/CAT/646878/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-13-15-july-2022_en.pdf"},
    {"id":"56167","name":"Minutes of the CAT meeting 10-12 August 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-09-22T15:45:00Z","last_updated_date":"2022-09-22T15:45:00Z","reference_number":"EMA/CAT/691207/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-10-12-august-2022_en.pdf"},
    {"id":"56175","name":"Minutes of the HMPC 18-20 July 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-09-23T15:30:00Z","last_updated_date":"2022-09-23T15:30:00Z","reference_number":"EMA/HMPC/662996/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-18-20-july-2022-meeting_en.pdf"},
    {"id":"56195","name":"Minutes of the CHMP meeting 18-21 July 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-09-27T10:39:00Z","last_updated_date":"2022-09-27T10:39:00Z","reference_number":"EMA/CHMP/685582/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-18-21-july-2022_en.pdf"},
    {"id":"56312","name":"Minutes of the PRAC meeting 29 November - 2 December 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-04T13:25:00Z","last_updated_date":"2022-10-04T13:25:00Z","reference_number":"EMA/PRAC/699734/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-29-november-2-december-2021_en.pdf"},
    {"id":"56313","name":"Minutes of CHMP written procedure 16-19 August 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-04T13:38:00Z","last_updated_date":"2022-10-04T13:38:00Z","reference_number":"EMA/CHMP/722907/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-written-procedure-16-19-august-2022_en.pdf"},
    {"id":"56315","name":"Meeting summary - Patients and Consumers Working Party (PCWP) meeting on 22 September 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T15:07:00Z","last_updated_date":"2022-10-04T15:07:00Z","reference_number":"EMA/793804/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-patients-consumers-working-party-pcwp-meeting-22-september-2022_en.pdf"},
    {"id":"56316","name":"Meeting summary - Healthcare Professionals Working Party (HCPWP) meeting on 22 September 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T15:12:00Z","last_updated_date":"2022-10-04T15:12:00Z","reference_number":"EMA/792740/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-healthcare-professionals-working-party-hcpwp-meeting-22-september-2022_en.pdf"},
    {"id":"56317","name":"Meeting summary - PCWP/HCPWP joint meeting on 22 September 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T15:13:00Z","last_updated_date":"2022-10-04T15:13:00Z","reference_number":"EMA/792889/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-joint-meeting-22-september-2022_en.pdf"},
    {"id":"56331","name":"PDCO minutes of the 19-22 July 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-06T12:21:00Z","last_updated_date":"2022-10-06T12:21:00Z","reference_number":"EMA/PDCO/674607/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-19-22-july-2022-meeting_en.pdf"},
    {"id":"56335","name":"Minutes - DARWIN EU Advisory Board meeting: 6 July 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-06T11:41:00Z","last_updated_date":"2022-10-06T11:41:00Z","reference_number":"EMA/629004/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-meeting-6-july-2022_en.pdf"},
    {"id":"56336","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (14 September 2022)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-06T14:15:00Z","last_updated_date":"2022-10-06T14:15:00Z","reference_number":"EMA/767250/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-14-september-2022_en.pdf"},
    {"id":"56346","name":"Minutes of the PRAC meeting 10-13 January 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-07T13:33:00Z","last_updated_date":"2022-10-07T13:33:00Z","reference_number":"EMA/PRAC/780026/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-10-13-january-2022_en.pdf"},
    {"id":"56360","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting - June 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-11T16:58:00Z","last_updated_date":"2022-10-11T16:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-june-2022_en.pdf"},
    {"id":"56372","name":"Minutes of the 116th meeting of the Management Board: 15-16 June 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-12T14:35:00Z","last_updated_date":"2022-10-12T14:35:00Z","reference_number":"EMA/MB/592684/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-116th-meeting-management-board-15-16-june-2022_en.pdf"},
    {"id":"56407","name":"Minutes of the CVMP meeting of 6-8 September 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T08:52:00Z","last_updated_date":"2022-10-14T08:52:00Z","reference_number":"EMA/CVMP/799298/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-6-8-september-2022_en.pdf"},
    {"id":"56454","name":"Minutes of the COMP meeting 6-8 September 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-21T14:57:00Z","last_updated_date":"2022-10-21T14:57:00Z","reference_number":"EMA/COMP/772376/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-6-8-september-2022_en.pdf"},
    {"id":"56479","name":"PDCO minutes of the 6-9 September 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-26T10:56:00Z","last_updated_date":"2022-10-26T10:56:00Z","reference_number":"EMA/PDCO/775544/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-6-9-september-2022-meeting_en.pdf"},
    {"id":"56498","name":"Minutes of the CAT meeting 7-9 September 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-10-28T09:39:00Z","last_updated_date":"2022-10-28T09:39:00Z","reference_number":"EMA/CAT/760739/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-7-9-september-2022_en.pdf"},
    {"id":"56526","name":"Minutes of the CHMP meeting 12-15 September 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-03T14:34:00Z","last_updated_date":"2022-11-03T14:34:00Z","reference_number":"EMA/CHMP/787052/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-12-15-september-2022_en.pdf"},
    {"id":"56528","name":"Minutes of the Cancer Medicines Forum - 26 February 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T14:55:00Z","last_updated_date":"2024-04-12T14:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-26-february-2024_en.pdf"},
    {"id":"56535","name":"Minutes of the PRAC meeting 7-10 February 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-07T10:33:00Z","last_updated_date":"2022-11-07T10:33:00Z","reference_number":"EMA/PRAC/822311/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-february-2022_en.pdf"},
    {"id":"56608","name":"Meeting summary - Industry Standing Group (ISG) meeting on EMA’s extended mandate","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-11-14T09:58:00Z","last_updated_date":"2022-11-14T09:58:00Z","reference_number":"EMA/790948/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-industry-standing-group-isg-meeting-emas-extended-mandate_en.pdf"},
    {"id":"56636","name":"Minutes of the CAT meeting 5-7 October 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-15T17:18:00Z","last_updated_date":"2022-11-15T17:18:00Z","reference_number":"EMA/CAT/822776/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-5-7-october-2022_en.pdf"},
    {"id":"56679","name":"Minutes of the COMP meeting 4-6 October 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-17T13:05:00Z","last_updated_date":"2022-11-17T13:05:00Z","reference_number":"EMA/COMP/835868/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-4-6-october-2022_en.pdf"},
    {"id":"56702","name":"CHMP PROM minutes for the meeting on 11 July 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-17T17:35:00Z","last_updated_date":"2022-11-17T17:35:00Z","reference_number":"EMA/CHMP/636662/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-11-july-2022_en.pdf"},
    {"id":"56703","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (5 October 2022)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-17T17:41:00Z","last_updated_date":"2022-11-17T17:41:00Z","reference_number":"EMA/768375/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-5-october-2022_en.pdf"},
    {"id":"56704","name":"Minutes of the CVMP meeting of 4-6 October 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-18T08:26:00Z","last_updated_date":"2022-11-18T08:26:00Z","reference_number":"EMA/CVMP/871224/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-4-6-october-2022_en.pdf"},
    {"id":"56727","name":"PDCO minutes of the 11-14 October 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-21T16:00:00Z","last_updated_date":"2022-11-21T16:00:00Z","reference_number":"EMA/PDCO/850696/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-11-14-october-2022-meeting_en.pdf"},
    {"id":"56731","name":"Minutes of the PRAC meeting 7-10 March 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-22T09:22:00Z","last_updated_date":"2022-11-22T09:22:00Z","reference_number":"EMA/PRAC/856951/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-march-2022_en.pdf"},
    {"id":"56744","name":"CHMP PROM minutes for the meeting on 5 September 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-22T14:53:00Z","last_updated_date":"2022-11-22T14:53:00Z","reference_number":"EMA/CHMP/726358/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-5-september-2022_en.pdf"},
    {"id":"56745","name":"CHMP PROM agenda for the meeting on 5 September 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-22T14:53:00Z","last_updated_date":"2022-11-22T14:53:00Z","reference_number":"EMA/CHMP/670236/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-agenda-meeting-5-september-2022_en.pdf"},
    {"id":"56754","name":"Minutes of the CHMP meeting 10-13 October 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-11-23T12:02:00Z","last_updated_date":"2022-11-23T12:02:00Z","reference_number":"EMA/CHMP/851047/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-10-13-october-2022_en.pdf"},
    {"id":"56866","name":"Minutes of the HMPC 19-21 September 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-12-02T13:52:00Z","last_updated_date":"2022-12-02T13:52:00Z","reference_number":"EMA/HMPC/792083/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-19-21-september-2022-meeting_en.pdf"},
    {"id":"56980","name":"Meeting highlights - Second European Medicines Agency and Affordable Medicines Europe bilateral meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T15:15:00Z","last_updated_date":"2022-12-13T15:15:00Z","reference_number":"EMA/88147/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-highlights-second-european-medicines-agency-and-affordable-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"57053","name":"Meeting summary - Third Industry Standing Group (ISG) meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T16:06:00Z","last_updated_date":"2022-12-15T16:06:00Z","reference_number":"EMA/790948/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-third-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"57057","name":"Minutes of the CVMP meeting of 8-10 November 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-12-15T16:45:00Z","last_updated_date":"2022-12-15T16:45:00Z","reference_number":"EMA/CVMP/924173/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-november-2022_en.pdf"},
    {"id":"57098","name":"Meeting highlights - First European Medicines Agency - Vaccines Europe meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-12-20T10:00:00Z","last_updated_date":"2023-01-13T15:08:00Z","reference_number":"EMA/775191/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-highlights-first-european-medicines-agency-vaccines-europe-meeting_en.pdf"},
    {"id":"57108","name":"Minutes of the CAT meeting 3-4 November 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-12-21T13:06:00Z","last_updated_date":"2022-12-21T13:06:00Z","reference_number":"EMA/CAT/867072/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-3-4-november-2022_en.pdf"},
    {"id":"57162","name":"Minutes of the 117th meeting of the Management Board: 6 October 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-05T10:35:00Z","last_updated_date":"2023-01-05T10:35:00Z","reference_number":"EMA/MB/815892/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-117th-meeting-management-board-6-october-2022_en.pdf"},
    {"id":"57164","name":"PDCO minutes of the 8-11 November 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-05T10:49:00Z","last_updated_date":"2023-01-05T10:49:00Z","reference_number":"EMA/PDCO/903993/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-8-11-november-2022-meeting_en.pdf"},
    {"id":"57171","name":"Meeting summary - PCWP/HCPWP annual meeting with all eligible organisations - 15 November 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T10:15:00Z","last_updated_date":"2023-01-09T10:15:00Z","reference_number":"EMA/775191/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-annual-meeting-all-eligible-organisations-15-november-2022_en.pdf"},
    {"id":"57194","name":"Minutes of the COMP meeting 8-10 November 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T11:14:00Z","last_updated_date":"2023-01-20T12:27:00Z","reference_number":"EMA/COMP/897858/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-8-10-november-2022_en.pdf"},
    {"id":"57199","name":"CHMP PROM minutes for the meeting on 31 October 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T12:27:00Z","last_updated_date":"2023-01-10T12:27:00Z","reference_number":"EMA/CHMP/855932/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-31-october-2022_en.pdf"},
    {"id":"57268","name":"CHMP PROM minutes for the meeting on 3 October 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T15:56:00Z","last_updated_date":"2023-01-12T15:56:00Z","reference_number":"EMA/CHMP/795987/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-3-october-2022_en.pdf"},
    {"id":"57316","name":"Minutes of the CHMP meeting 7-10 November 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-17T17:58:00Z","last_updated_date":"2023-01-17T17:58:00Z","reference_number":"EMA/CHMP/907832/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-7-10-november-2022_en.pdf"},
    {"id":"57318","name":"Minutes of the PRAC meeting 4-7 April 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-18T11:52:00Z","last_updated_date":"2023-01-18T11:52:00Z","reference_number":"EMA/PRAC/955041/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-4-7-april-2022_en.pdf"},
    {"id":"57396","name":"Minutes of the CVMP meeting of 8-10 November 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-26T12:29:00Z","last_updated_date":"2023-01-26T12:29:00Z","reference_number":"EMA/CVMP/924173/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-november-2022_en.pdf-0"},
    {"id":"57397","name":"Minutes of the CVMP meeting of 6-8 December 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-26T12:33:00Z","last_updated_date":"2023-01-26T12:33:00Z","reference_number":"EMA/CVMP/30338/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-6-8-december-2022_en.pdf"},
    {"id":"57447","name":"CHMP PROM minutes for the meeting on 5 December 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-30T12:38:00Z","last_updated_date":"2023-01-30T12:38:00Z","reference_number":"EMA/CHMP/923033/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-5-december-2022_en.pdf"},
    {"id":"57482","name":"Minutes of the HMPC 21-23 November 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-01-31T14:07:00Z","last_updated_date":"2023-01-31T14:07:00Z","reference_number":"EMA/HMPC/917662/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-21-23-november-2022-meeting_en.pdf"},
    {"id":"57489","name":"Minutes – Ad-hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-02-01T10:39:00Z","last_updated_date":"2023-02-01T10:39:00Z","reference_number":"EMA/14491/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ad-hoc-executive-steering-group-shortages-safety-medicinal-products-mssg_en.pdf"},
    {"id":"57491","name":"Minutes of the COMP meeting 6-8 December 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-01T11:52:00Z","last_updated_date":"2023-02-01T11:52:00Z","reference_number":"EMA/COMP/946245/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-6-8-december-2022_en.pdf"},
    {"id":"57497","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (11 November 2022)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-02-01T17:45:00Z","last_updated_date":"2023-02-01T17:45:00Z","reference_number":"EMA/803437/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-11-november-2022_en.pdf"},
    {"id":"57512","name":"Minutes of the PRAC meeting 29 August - 1 September 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-02T17:10:00Z","last_updated_date":"2023-02-02T17:10:00Z","reference_number":"EMA/PRAC/938468/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-29-august-1-september-2022_en.pdf"},
    {"id":"57520","name":"Minutes of the PRAC meeting 2-5 May 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-06T09:56:00Z","last_updated_date":"2023-02-06T09:56:00Z","reference_number":"EMA/PRAC/955173/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-2-5-may-2022_en.pdf"},
    {"id":"57568","name":"PDCO minutes of the 13-16 December 2022 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-08T11:49:00Z","last_updated_date":"2023-02-08T11:49:00Z","reference_number":"EMA/PDCO/3263/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-13-16-december-2022-meeting_en.pdf"},
    {"id":"57570","name":"Minutes of the CHMP meeting 12-15 December 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-08T14:35:00Z","last_updated_date":"2023-02-08T14:35:00Z","reference_number":"EMA/CHMP/1738/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-12-15-december-2022_en.pdf"},
    {"id":"57571","name":"Minutes of the CAT meeting 7-9 December 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-08T14:53:00Z","last_updated_date":"2023-02-08T14:53:00Z","reference_number":"EMA/CAT/946084/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-7-9-december-2022_en.pdf"},
    {"id":"57578","name":"Minutes - DARWIN EU Advisory Board meeting: 8 September 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-08T15:41:00Z","last_updated_date":"2023-02-08T15:41:00Z","reference_number":"EMA/757688/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-meeting-8-september-2022_en.pdf"},
    {"id":"57719","name":"Minutes of the PRAC meeting 26-29 September 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T15:56:00Z","last_updated_date":"2023-02-17T15:56:00Z","reference_number":"EMA/PRAC/947562/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-26-29-september-2022_en.pdf"},
    {"id":"57761","name":"Minutes of the COMP meeting 17-19 January 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T13:37:00Z","last_updated_date":"2023-02-21T13:37:00Z","reference_number":"EMA/COMP/49263/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-17-19-january-2023_en.pdf"},
    {"id":"57816","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (26 January 2023)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T11:03:00Z","last_updated_date":"2023-02-24T11:03:00Z","reference_number":"EMA/36866/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-26-january-2023_en.pdf"},
    {"id":"57818","name":"Minutes of the CVMP meeting of 17-18 January 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T12:53:00Z","last_updated_date":"2023-02-24T12:53:00Z","reference_number":"EMA/72724/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-17-18-january-2023_en.pdf"},
    {"id":"57894","name":"PDCO minutes of the 17-20 January 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-03-06T17:20:00Z","last_updated_date":"2023-03-06T17:20:00Z","reference_number":"EMA/PDCO/51475/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-17-20-january-2023-meeting_en.pdf"},
    {"id":"58070","name":"Minutes of the HMPC 23-25 January 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-03-20T16:45:00Z","last_updated_date":"2023-03-20T16:45:00Z","reference_number":"EMA/HMPC/49161/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-23-25-january-2023-meeting_en.pdf"},
    {"id":"58071","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (23 February 2023)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-03-20T14:06:00Z","last_updated_date":"2023-03-20T14:06:00Z","reference_number":"EMA/81607/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-23-february-2023_en.pdf"},
    {"id":"58108","name":"Minutes - Enpr-EMA Coordinating Group meeting (February 2023)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-03-22T16:12:00Z","last_updated_date":"2023-03-22T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-meeting-february-2023_en.pdf"},
    {"id":"58139","name":"Minutes of the Cancer Medicines Forum - 20 December 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T10:41:00Z","last_updated_date":"2023-03-24T10:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-20-december-2022_en.pdf"}    {"id":"58220","name":"Meeting Summary of the Medicine Shortages (SPOC) Working Party 13 December 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T12:39:00Z","last_updated_date":"2023-03-30T12:39:00Z","reference_number":"EMA/24017/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-13-december-2022_en.pdf"},
    {"id":"58222","name":"Meeting Summary of the Medicine Shortages (SPOC) Working Party 18 January 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T12:44:00Z","last_updated_date":"2023-03-30T12:44:00Z","reference_number":"EMA/64146/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-18-january-2023_en.pdf"},
    {"id":"58224","name":"Meeting Summary of the Medicine Shortages (SPOC) Working Party 15 February 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T12:49:00Z","last_updated_date":"2023-03-30T12:49:00Z","reference_number":"EMA/76218/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-15-february-2023_en.pdf"},
    {"id":"58247","name":"Minutes of the CVMP meeting of 14-15 February 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T11:11:00Z","last_updated_date":"2023-04-28T16:28:00Z","reference_number":"EMA/CVMP/134248/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-14-15-february-2023_en.pdf"},
    {"id":"58254","name":"Minutes of the PRAC meeting 7-10 June 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T14:59:00Z","last_updated_date":"2023-03-31T14:59:00Z","reference_number":"EMA/PRAC/88337/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-june-2022_en.pdf"},
    {"id":"58255","name":"Minutes of the PRAC meeting 24-27 October 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T15:13:00Z","last_updated_date":"2023-03-31T15:13:00Z","reference_number":"EMA/PRAC/56404/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-24-27-october-2022_en.pdf"},
    {"id":"58267","name":"Minutes of the PRAC meeting 4-7 July 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T17:52:00Z","last_updated_date":"2023-03-31T17:52:00Z","reference_number":"EMA/PRAC/145325/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-4-7-july-2022_en.pdf"},
    {"id":"58271","name":"Minutes of the PRAC meeting 28 November - 1 December 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-04-03T16:11:00Z","last_updated_date":"2023-04-24T11:29:00Z","reference_number":"EMA/PRAC/135553/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-28-november-1-december-2022_en.pdf"},
    {"id":"58354","name":"Minutes of the CHMP meeting 23-26 January 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-04-14T14:37:00Z","last_updated_date":"2023-04-14T14:37:00Z","reference_number":"EMA/CHMP/58860/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-23-26-january-2023_en.pdf"},
    {"id":"58403","name":"Minutes of the CAT meeting 18-19 January 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-04-18T13:07:00Z","last_updated_date":"2023-04-18T13:07:00Z","reference_number":"EMA/CAT/36517/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-19-january-2023_en.pdf"},
    {"id":"58404","name":"Minutes of the CAT meeting 15-16 February 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-04-18T13:09:00Z","last_updated_date":"2023-04-18T13:09:00Z","reference_number":"EMA/CAT/79091/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-16-february-2023_en.pdf"},
    {"id":"58408","name":"PDCO minutes of the 21-24 February 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-04-18T14:18:00Z","last_updated_date":"2023-04-18T14:18:00Z","reference_number":"EMA/PDCO/108345/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-21-24-february-2023-meeting_en.pdf"},
    {"id":"58495","name":"Minutes of the COMP meeting 14-16 February 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-04-21T16:26:00Z","last_updated_date":"2023-04-21T16:26:00Z","reference_number":"EMA/COMP/88477/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-16-february-2023_en.pdf"},
    {"id":"58502","name":"Minutes of the CHMP meeting 20-23 February 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-04-24T12:21:00Z","last_updated_date":"2023-04-24T12:21:00Z","reference_number":"EMA/CHMP/112518/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-20-23-february-2023_en.pdf"},
    {"id":"58503","name":"Meeting summary - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T13:52:00Z","last_updated_date":"2023-04-24T13:52:00Z","reference_number":"EMA/89221/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting_en.pdf"},
    {"id":"58505","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (15 March 2023)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-04-24T15:33:00Z","last_updated_date":"2023-04-24T15:33:00Z","reference_number":"EMA/118057/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-15-march-2023_en.pdf"},
    {"id":"58552","name":"Minutes of the CVMP meeting of 21-22 March 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-04-28T16:22:00Z","last_updated_date":"2023-04-28T16:22:00Z","reference_number":"EMA/CVMP/188158/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-21-22-march-2023_en.pdf"},
    {"id":"58565","name":"Minutes of the PRAC meeting 9 - 12 January 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-03T10:06:00Z","last_updated_date":"2023-05-03T10:06:00Z","reference_number":"EMA/PRAC/141718/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-january-2023_en.pdf"},
    {"id":"58566","name":"Minutes of the COMP meeting 21-23 March 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-03T10:15:00Z","last_updated_date":"2023-05-03T10:15:00Z","reference_number":"EMA/COMP/151364/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-21-23-march-2023_en.pdf"},
    {"id":"58580","name":"Meeting Summary of the Medicine Shortages (SPOC) Working Party 21 March 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-05-04T08:55:00Z","last_updated_date":"2023-05-04T08:55:00Z","reference_number":"EMA/137098/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-21-march-2023_en.pdf"},
    {"id":"58623","name":"PDCO minutes of the 28-31 March 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T11:28:00Z","last_updated_date":"2023-05-11T11:28:00Z","reference_number":"EMA/PDCO/164725/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-28-31-march-2023-meeting_en.pdf"},
    {"id":"58624","name":"Minutes of the 118th meeting of the Management Board: 14-15 December 2022","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T11:38:00Z","last_updated_date":"2023-05-11T11:38:00Z","reference_number":"EMA/MB/17597/2023 corr. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-118th-meeting-management-board-14-15-december-2022_en.pdf"},
    {"id":"58723","name":"Minutes of the PRAC meeting 6-9 February 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-17T15:40:00Z","last_updated_date":"2023-05-17T15:40:00Z","reference_number":"EMA/PRAC/185211/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-6-9-february-2023_en.pdf"},
    {"id":"58728","name":"Minutes of the CHMP meeting 27-30 March 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-22T11:04:00Z","last_updated_date":"2023-05-22T11:04:00Z","reference_number":"EMA/CHMP/165710/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-27-30-march-2023_en.pdf"},
    {"id":"58744","name":"Minutes of the HMPC 13-15 March 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-23T17:27:00Z","last_updated_date":"2023-05-23T17:27:00Z","reference_number":"EMA/HMPC/135921/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-13-15-march-2023-meeting_en.pdf"},
    {"id":"58747","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (20 April 2023)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-24T10:02:00Z","last_updated_date":"2023-05-24T10:02:00Z","reference_number":"EMA/177968/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-20-april-2023_en.pdf"},
    {"id":"58795","name":"Minutes of the CVMP meeting of 18-20 April 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-26T11:03:00Z","last_updated_date":"2023-05-26T11:03:00Z","reference_number":"EMA/CVMP/221092/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-18-20-april-2023_en.pdf"},
    {"id":"58826","name":"CHMP PROM minutes for the meeting on 16 January 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-31T12:42:00Z","last_updated_date":"2023-05-31T12:42:00Z","reference_number":"EMA/CHMP/22030/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-16-january-2023_en.pdf"},
    {"id":"58839","name":"CHMP PROM minutes for the meeting on 13 February 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-05-31T15:08:00Z","last_updated_date":"2023-05-31T15:08:00Z","reference_number":"EMA/CHMP/68823/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-13-february-2023_en.pdf"},
    {"id":"58883","name":"Meeting Summary - Medicine Shortages (SPOC) Working Party: 18 April 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-06-08T11:15:00Z","last_updated_date":"2023-06-08T11:15:00Z","reference_number":"EMA/226828/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-18-april-2023_en.pdf"},
    {"id":"58891","name":"PDCO minutes of the 24-26 April 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-06-08T13:28:00Z","last_updated_date":"2023-06-08T13:28:00Z","reference_number":"EMA/PDCO/213935/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-24-26-april-2023-meeting_en.pdf"},
    {"id":"58901","name":"Minutes of the COMP meeting 18-20 April 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-06-09T11:14:00Z","last_updated_date":"2023-06-09T11:14:00Z","reference_number":"EMA/COMP/200366/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-18-20-april-2023_en.pdf"},
    {"id":"58903","name":"Minutes of the 119th meeting of the Management Board: 16 March 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-06-09T11:35:00Z","last_updated_date":"2023-06-09T11:35:00Z","reference_number":"EMA/MB/225645/2023 corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-119th-meeting-management-board-16-march-2023_en.pdf"},
    {"id":"58916","name":"Minutes of the CAT meeting 22-23 March 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-06-12T11:27:00Z","last_updated_date":"2023-06-12T11:27:00Z","reference_number":"EMA/CAT/143498/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-22-23-march-2023_en.pdf"},
    {"id":"58987","name":"Minutes of the CAT meeting 19-21 April 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-06-19T14:24:00Z","last_updated_date":"2023-06-19T14:24:00Z","reference_number":"EMA/CAT/184641/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-19-21-april-2023_en.pdf"},
    {"id":"59026","name":"Minutes of the PRAC meeting 13-16 March 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-06-22T08:39:00Z","last_updated_date":"2023-06-22T08:39:00Z","reference_number":"EMA/PRAC/236189/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-13-16-march-2023_en.pdf"},
    {"id":"59035","name":"Minutes of the COMP meeting 15-17 May 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-06-22T11:38:00Z","last_updated_date":"2023-06-22T11:38:00Z","reference_number":"EMA/COMP/248545/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-15-17-may-2023_en.pdf"},
    {"id":"59073","name":"Minutes of the CVMP meeting 15-16 May 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T12:18:00Z","last_updated_date":"2023-06-23T12:18:00Z","reference_number":"EMA/CVMP/270634/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-15-16-may-2023_en.pdf"},
    {"id":"59090","name":"Minutes of the Cancer Medicines Forum - March 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-06-26T11:43:00Z","last_updated_date":"2023-06-26T11:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-march-2023_en.pdf"},
    {"id":"59274","name":"PDCO minutes of the 23-26 May 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-07-06T11:43:00Z","last_updated_date":"2023-07-06T11:43:00Z","reference_number":"EMA/PDCO/258156/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-23-26-may-2023-meeting_en.pdf"},
    {"id":"59288","name":"Minutes of the CHMP meeting 24-26 April 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-07-07T08:43:00Z","last_updated_date":"2023-07-07T08:43:00Z","reference_number":"EMA/CHMP/217936/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-24-26-april-2023_en.pdf"},
    {"id":"59301","name":"Minutes of the PRAC meeting 11-14 April 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-07-07T13:47:00Z","last_updated_date":"2023-07-07T13:47:00Z","reference_number":"EMA/PRAC/280418/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-11-14-april-2023_en.pdf"},
    {"id":"59302","name":"CHMP PROM minutes for the meeting on 15 May 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-07-07T14:30:00Z","last_updated_date":"2023-07-07T14:30:00Z","reference_number":"EMA/CHMP/229678/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-15-may-2023_en.pdf"},
    {"id":"59305","name":"CHMP PROM minutes for the meeting on 12 June 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-07-07T15:55:00Z","last_updated_date":"2023-07-07T15:55:00Z","reference_number":"EMA/CHMP/266883/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-12-june-2023_en.pdf"},
    {"id":"59363","name":"Minutes of the CHMP meeting 22-25 May 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-07-17T10:18:00Z","last_updated_date":"2023-07-17T10:18:00Z","reference_number":"EMA/CHMP/262270/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-may-2023_en.pdf"},
    {"id":"59372","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (19 June 2023)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-07-17T15:16:00Z","last_updated_date":"2023-07-17T15:16:00Z","reference_number":"EMA/280935/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-19-june-2023_en.pdf"},
    {"id":"59446","name":"Minutes of the CVMP meeting 13-15 June 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-21T12:00:00Z","reference_number":"EMA/CVMP/321089/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-13-15-june-2023_en.pdf"},
    {"id":"59465","name":"Highlights - Second European Medicines Agency & MedTech Europe bilateral meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T17:39:00Z","last_updated_date":"2023-07-21T17:39:00Z","reference_number":"EMA/157298/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-second-european-medicines-agency-medtech-europe-bilateral-meeting_en.pdf"},
    {"id":"59468","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting - November 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-07-24T13:55:00Z","last_updated_date":"2023-07-24T13:55:00Z","reference_number":"EMA/908798/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-november-2022_en.pdf"},
    {"id":"59469","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting - March 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-07-24T13:56:00Z","last_updated_date":"2023-07-24T13:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agencyeuropean-network-health-technology-assessment-meeting-march-2023_en.pdf"},
    {"id":"59471","name":"Minutes - Enpr-EMA Coordinating Group and networks meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-07-24T14:07:00Z","last_updated_date":"2023-08-02T09:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-and-networks-meeting_en.pdf-0"},
    {"id":"59499","name":"Minutes of the HMPC 10-12 May 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-07-25T15:20:00Z","last_updated_date":"2023-07-25T15:20:00Z","reference_number":"EMA/HMPC/238217/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-10-12-may-2023-meeting_en.pdf"},
    {"id":"59501","name":"Minutes - Executive Steering Group on Shortages of Medical Devices (MDSSG) (19 June 2023)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-07-25T13:52:00Z","last_updated_date":"2023-07-25T13:52:00Z","reference_number":"EMA/291443/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-medical-devices-mdssg-19-june-2023_en.pdf"},
    {"id":"59539","name":"Minutes of the COMP meeting 13-15 June 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-08-02T15:41:00Z","last_updated_date":"2023-08-02T15:41:00Z","reference_number":"EMA/COMP/281453/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-13-15-june-2023_en.pdf"},
    {"id":"59611","name":"Minutes of the CAT meeting 15-17 May 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-08-18T15:17:00Z","last_updated_date":"2023-08-18T15:17:00Z","reference_number":"EMA/CAT/368362/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-17-may-2023_en.pdf"},
    {"id":"59612","name":"Meeting summary of the Medicine Shortages (SPOC) Working Party 24 May 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-08-21T16:22:00Z","last_updated_date":"2023-08-21T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-24-may-2023_en.pdf"},
    {"id":"59613","name":"Meeting summary of the Medicine Shortages (SPOC) Working Party meeting 16 June 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-08-21T16:23:00Z","last_updated_date":"2023-08-21T16:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-16-june-2023_en.pdf"},
    {"id":"59627","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (14 July 2023)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-08-25T10:02:00Z","last_updated_date":"2023-08-25T10:02:00Z","reference_number":"EMA/323383/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-14-july-2023_en.pdf"},
    {"id":"59635","name":"PDCO minutes of the 20-23 June 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-08-25T13:40:00Z","last_updated_date":"2023-08-25T13:40:00Z","reference_number":"EMA/PDCO/308544/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-20-23-june-2023-meeting_en.pdf"},
    {"id":"59876","name":"Minutes of the PRAC meeting 10-12 May 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-08-31T16:56:00Z","last_updated_date":"2023-08-31T16:56:00Z","reference_number":"EMA/PRAC/332783/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-10-12-may-2023_en.pdf"},
    {"id":"59892","name":"Minutes of the PRAC meeting 5-8 June 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-09-04T15:47:00Z","last_updated_date":"2023-09-04T15:47:00Z","reference_number":"EMA/PRAC/337931/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-5-8-june-2023_en.pdf"},
    {"id":"59909","name":"Minutes of the CHMP meeting 19-22 June 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-09-07T10:06:00Z","last_updated_date":"2023-09-07T10:06:00Z","reference_number":"EMA/CHMP/311397/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-june-2023_en.pdf"},
    {"id":"59999","name":"PDCO minutes of the 18-21 July 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T17:43:00Z","last_updated_date":"2023-09-14T17:43:00Z","reference_number":"EMA/PDCO/352213/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-18-21-july-2023-meeting_en.pdf"},
    {"id":"60017","name":"Minutes of the CVMP meeting 11-13 July 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T09:34:00Z","last_updated_date":"2023-09-15T09:34:00Z","reference_number":"EMA/CVMP/400608/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-11-13-july-2023_en.pdf"},
    {"id":"60032","name":"Minutes of the 120th meeting of the Management Board: 7-8 June 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T15:25:00Z","last_updated_date":"2023-09-15T15:25:00Z","reference_number":"EMA/MB/257775/2023 corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-120th-meeting-management-board-7-8-june-2023_en.pdf"},
    {"id":"60055","name":"Minutes of the COMP meeting 11-13 July 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T09:25:00Z","last_updated_date":"2023-09-19T09:25:00Z","reference_number":"EMA/COMP/353726/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-11-13-july-2023_en.pdf"},
    {"id":"60056","name":"Minutes of the CAT meeting 12-14 July 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-09-19T12:13:00Z","last_updated_date":"2023-09-19T12:13:00Z","reference_number":"EMA/CAT/421568/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-12-14-july-2023_en.pdf"},
    {"id":"60100","name":"Meeting summary - Patients and Consumers Working Party (PCWP) meeting - 27 June 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-09-21T14:59:00Z","last_updated_date":"2023-09-21T14:59:00Z","reference_number":"EMA/89221/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-patients-consumers-working-party-pcwp-meeting-27-june-2023_en.pdf"},
    {"id":"60101","name":"Meeting summary - Healthcare Professionals' Working Party (HCPWP) meeting - 27 June 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-09-21T15:08:00Z","last_updated_date":"2023-09-21T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-healthcare-professionals-working-party-hcpwp-meeting-27-june-2023_en.pdf"},
    {"id":"60102","name":"Meeting summary - Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting - 28 June 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-09-21T15:13:00Z","last_updated_date":"2023-09-21T15:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting-28-june-2023_en.pdf"},
    {"id":"60103","name":"Minutes of the HMPC 17-19 July 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-09-21T15:20:00Z","last_updated_date":"2023-09-21T15:20:00Z","reference_number":"EMA/HMPC/345565/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-17-19-july-2023-meeting_en.pdf"},
    {"id":"60104","name":"Minutes of the PRAC Meeting 3-6 July 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-09-21T15:40:00Z","last_updated_date":"2023-09-21T15:40:00Z","reference_number":"EMA/PRAC/397811/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-3-6-july-2023_en.pdf"},
    {"id":"60108","name":"Minutes of the CAT meeting 9-11 August 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-09-22T09:29:00Z","last_updated_date":"2023-09-22T09:29:00Z","reference_number":"EMA/CAT/421621/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-9-11-august-2023_en.pdf"},
    {"id":"60285","name":"Minutes of the CHMP meeting 17-20 July 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-10-06T13:17:00Z","last_updated_date":"2023-10-06T13:17:00Z","reference_number":"EMA/CHMP/353930/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-17-20-july-2023_en.pdf"},
    {"id":"60412","name":"Minutes of the COMP meeting 5-7 September 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T09:34:00Z","last_updated_date":"2023-10-13T09:34:00Z","reference_number":"EMA/COMP/422323/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-5-7-september-2023_en.pdf"},
    {"id":"60444","name":"Minutes of the CVMP meeting 5-7 September 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-10-16T16:44:00Z","last_updated_date":"2023-10-16T16:44:00Z","reference_number":"EMA/CVMP/445464/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-5-7-september-2023_en.pdf"},
    {"id":"60480","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-10-24T17:23:00Z","last_updated_date":"2023-10-24T17:23:00Z","reference_number":"EMA/424026/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg_en.pdf"},
    {"id":"60499","name":"CHMP PROM minutes for the meeting 10 July 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-10-27T10:19:00Z","last_updated_date":"2023-10-27T10:19:00Z","reference_number":"EMA/459840/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-10-july-2023_en.pdf"},
    {"id":"60500","name":"CHMP PROM minutes for the meeting on 4 September 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-10-27T10:23:00Z","last_updated_date":"2023-10-27T10:23:00Z","reference_number":"EMA/459382/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-4-september-2023_en.pdf"},
    {"id":"60501","name":"PDCO minutes of the 5-8 September 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-10-27T10:34:00Z","last_updated_date":"2023-10-27T10:34:00Z","reference_number":"EMA/PDCO/424082/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-5-8-september-2023-meeting_en.pdf"},
    {"id":"60505","name":"Minutes of PRAC meeting on 28-31 August 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-10-27T13:56:00Z","last_updated_date":"2023-10-27T13:56:00Z","reference_number":"EMA/PRAC/452701/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-28-31-august-2023_en.pdf"},
    {"id":"60506","name":"Meeting summary of the Medicine Shortages (SPOC) Working Party 6 July 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-10-30T09:06:00Z","last_updated_date":"2023-10-30T09:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-6-july-2023_en.pdf"},
    {"id":"60519","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 29 September 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-11-03T15:32:00Z","last_updated_date":"2023-11-03T15:32:00Z","reference_number":"EMA/130876/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-29-september-2023_en.pdf"},
    {"id":"60572","name":"Minutes of the PRAC meeting 7-10 January 2013","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2013-02-26T11:55:00Z","last_updated_date":"2013-02-26T11:55:00Z","reference_number":"EMA/91065/2013","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-january-2013_en.pdf"},
    {"id":"60593","name":"Minutes of the COMP meeting 11-13 September 2018","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2018-12-06T11:59:00Z","last_updated_date":"2018-12-06T11:59:00Z","reference_number":"EMA/COMP/506115/2018","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-11-13-september-2018_en.pdf"},
    {"id":"60655","name":"Minutes - PDCO minutes of the 18-21 May 2021 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2021-08-27T16:58:00Z","last_updated_date":"2021-08-27T16:58:00Z","reference_number":"EMA/PDCO/298607/2021","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-18-21-may-2021-meeting_en.pdf"},
    {"id":"60670","name":"Minutes of the PRAC meeting 3-6 May 2021","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2022-03-24T15:00:00Z","last_updated_date":"2022-03-24T15:00:00Z","reference_number":"EMA/PRAC/121854/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-3-6-may-2021_en.pdf"},
    {"id":"60736","name":"Minutes of the CAT meeting 15 June 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-08-17T16:25:00Z","last_updated_date":"2023-08-17T16:25:00Z","reference_number":"EMA/CAT/367824/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-june-2023_en.pdf"},
    {"id":"60762","name":"Minutes of CHMP written procedure 14-17August 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-10-09T16:22:00Z","last_updated_date":"2023-10-09T16:22:00Z","reference_number":"EMA/CHMP/378018/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-written-procedure-14-17august-2023_en.pdf"},
    {"id":"60768","name":"Minutes of the CAT meeting 06-08 September 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-10-19T14:41:00Z","last_updated_date":"2023-10-19T14:41:00Z","reference_number":"EMA/CAT/412887/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-06-08-september-2023_en.pdf"},
    {"id":"60771","name":"Highlights of EMA - Thalassaemia International Federation (TIF) bilateral meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-10-23T14:31:00Z","last_updated_date":"2023-10-23T14:31:00Z","reference_number":"EMA/473390/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-ema-thalassaemia-international-federation-tif-bilateral-meeting_en.pdf"},
    {"id":"60960","name":"Minutes of the CVMP meeting 3-5 October 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-11-20T11:20:19Z","last_updated_date":"2023-11-20T11:20:19Z","reference_number":"EMA/CVMP/510377/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-3-5-october-2023_en.pdf"},
    {"id":"60965","name":"Meeting summary - PCWP/HCPWP joint meeting (19-20 September 2023)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-11-23T16:24:15Z","last_updated_date":"2023-11-23T16:24:15Z","reference_number":"EMA/89221/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-joint-meeting-19-20-september-2023_en.pdf"},
    {"id":"60966","name":"Minutes of the CAT meeting 4-6 October 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-11-23T16:42:16Z","last_updated_date":"2023-11-23T16:42:16Z","reference_number":"EMA/CAT/456007/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-4-6-october-2023_en.pdf"},
    {"id":"60986","name":"Highlights – 6th Industry Standing Group (ISG) meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-11-24T17:03:39Z","last_updated_date":"2023-12-21T10:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-6th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"60996","name":"Minutes of the CHMP meeting 11-14 September 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-11-27T16:16:10Z","last_updated_date":"2023-11-27T16:16:10Z","reference_number":"EMA/CHMP/439990/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-11-14-september-2023_en.pdf"},
    {"id":"61013","name":"PDCO minutes of the 10-13 October 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-11-28T14:10:23Z","last_updated_date":"2023-11-28T14:10:23Z","reference_number":"EMA/PDCO/479731/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-10-13-october-2023-meeting_en.pdf"},
    {"id":"61034","name":"Meeting summary of the Medicine Shortages (SPOC) Working Party meeting 12 September 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-11-29T12:01:33Z","last_updated_date":"2023-11-29T12:01:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-12-september-2023_en.pdf"},
    {"id":"61270","name":"Meeting Summary of the Medicine Shortages (SPOC) Working Party 26-27 October 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T13:49:35Z","last_updated_date":"2023-12-06T13:49:35Z","reference_number":"EMA/497161/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-26-27-october-2023_en.pdf"},
    {"id":"61324","name":"Minutes of the HMPC 18-20 September 2023 meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T16:36:10Z","last_updated_date":"2023-12-07T16:36:10Z","reference_number":"EMA/HMPC/452624/2023 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-18-20-september-2023-meeting_en.pdf"}    {"id":"61329","name":"Minutes of the PRAC meeting on 25-28 September 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-11-30T09:08:27Z","last_updated_date":"2023-11-30T09:08:27Z","reference_number":"EMA/PRAC/497911/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-25-28-september-2023_en.pdf"},
    {"id":"61381","name":"Minutes - DARWIN EU Advisory Board meeting: 6 February 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T12:27:39Z","last_updated_date":"2023-12-12T12:27:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-meeting-6-february-2023_en.pdf"},
    {"id":"61392","name":"Minutes of the CHMP meeting 09-12 October 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T16:56:55Z","last_updated_date":"2023-12-12T16:56:55Z","reference_number":"EMA/CHMP/492427/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-09-12-october-2023_en.pdf"},
    {"id":"61425","name":"Minutes of the 121st meeting of the Management Board: 5 October 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-12-14T16:10:32Z","last_updated_date":"2023-12-14T16:10:32Z","reference_number":"EMA/MB/490331/2023 corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-121st-meeting-management-board-5-october-2023_en.pdf"},
    {"id":"61445","name":"Minutes of the CVMP meeting 7-9 November 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-12-21T11:33:00Z","last_updated_date":"2023-12-21T11:33:00Z","reference_number":"EMA/556288/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-7-9-november-2023_en.pdf"},
    {"id":"61549","name":"CHMP PROM minutes for the meeting on 30 October 2023","type":"minutes","status":"Draft","consultation_date":"","first_published_date":"2023-12-20T15:44:23Z","last_updated_date":"2023-12-20T15:44:23Z","reference_number":"EMA/CHMP/571146/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-30-october-2023_en.pdf"},
    {"id":"61554","name":"CHMP PROM minutes for the meeting on 12 October 2023","type":"minutes","status":"Draft","consultation_date":"","first_published_date":"2023-12-20T09:31:42Z","last_updated_date":"2023-12-20T09:31:42Z","reference_number":"EMA/568436/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-12-october-2023_en.pdf"},
    {"id":"61560","name":"CHMP PROM minutes for the meeting on 4 December 2023","type":"minutes","status":"Draft","consultation_date":"","first_published_date":"2023-12-21T11:30:54Z","last_updated_date":"2023-12-21T11:30:54Z","reference_number":"EMA/CHMP/573158/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-4-december-2023_en.pdf"},
    {"id":"61563","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 23 November 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T12:41:47Z","last_updated_date":"2023-12-21T12:41:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-23-november-2023_en.pdf"},
    {"id":"61567","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 30 October 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-12-21T13:25:57Z","last_updated_date":"2023-12-21T13:25:57Z","reference_number":"EMA/130876/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-30-october-2023_en.pdf"},
    {"id":"61605","name":"Minutes of the COMP meeting 7-9 November 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-12-22T15:43:43Z","last_updated_date":"2023-12-22T15:43:43Z","reference_number":"EMA/COMP/525730/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-7-9-november-2023_en.pdf"},
    {"id":"61617","name":"Minutes of the COMP meeting 3-5 October 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2023-12-22T17:10:30Z","last_updated_date":"2023-12-22T17:10:30Z","reference_number":"EMA/COMP/464039/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-3-5-october-2023_en.pdf"},
    {"id":"61708","name":"Minutes of the PRAC meeting on 23-26 October 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-01-10T16:14:05Z","last_updated_date":"2024-01-10T16:14:05Z","reference_number":"EMA/PRAC/565432/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-23-26-october-2023_en.pdf"},
    {"id":"61710","name":"Minutes of the CHMP meeting 06-09 November 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-01-10T17:04:33Z","last_updated_date":"2024-01-10T17:04:33Z","reference_number":"EMA/CHMP/530441/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-06-09-november-2023_en.pdf"},
    {"id":"61721","name":"Meeting summary of the of the Medicine Shortages (SPOC) Working Party 20 November 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T12:59:04Z","last_updated_date":"2024-01-11T12:59:04Z","reference_number":"EMA/557090/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-20-november-2023_en.pdf"},
    {"id":"61762","name":"PDCO minutes of the 7-10 November 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-01-15T13:52:21Z","last_updated_date":"2024-01-15T13:52:21Z","reference_number":"EMA/PDCO/531147/2023 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-7-10-november-2023-meeting_en.pdf"},
    {"id":"61792","name":"Meeting highlights - second EMA-EUCOPE bilateral meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-01-17T12:36:39Z","last_updated_date":"2024-01-17T12:36:39Z","reference_number":"EMA/513750/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-highlights-second-ema-eucope-bilateral-meeting_en.pdf"},
    {"id":"61810","name":"Meeting summary - PCWP/HCPWP and all eligible organisations meeting (Nov 2023)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-01-19T11:33:22Z","last_updated_date":"2024-01-19T11:33:22Z","reference_number":"EMA/510807/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-all-eligible-organisations-meeting-nov-2023_en.pdf"},
    {"id":"61871","name":"Minutes of the CAT meeting 30-31 October 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-01-24T14:11:32Z","last_updated_date":"2024-01-24T14:11:32Z","reference_number":"EMA/CAT/501779/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-30-31-october-2023_en.pdf"},
    {"id":"61896","name":"Minutes - Enpr-EMA Coordinating Group and networks meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-01-25T16:26:34Z","last_updated_date":"2024-01-25T16:26:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-and-networks-meeting_en.pdf-1"},
    {"id":"61897","name":"Minutes of the CVMP meeting 5-7 December 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-01-25T16:45:14Z","last_updated_date":"2024-01-25T16:45:14Z","reference_number":"EMA/24929/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-5-7-december-2023_en.pdf"},
    {"id":"61919","name":"Minutes of the CAT meeting 6-8 December 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-01-26T15:07:13Z","last_updated_date":"2024-01-26T15:07:13Z","reference_number":"EMA/CAT/38816/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-6-8-december-2023_en.pdf"},
    {"id":"61960","name":"PDCO minutes of the 12-15 December 2023 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-01-31T10:33:04Z","last_updated_date":"2024-01-31T10:33:04Z","reference_number":"EMA/PDCO/586488/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-12-15-december-2023-meeting_en.pdf"},
    {"id":"61968","name":"Minutes of the COMP meeting 5-7 December 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-01-31T16:21:48Z","last_updated_date":"2024-01-31T16:21:48Z","reference_number":"EMA/COMP/582760/2023 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-5-7-december-2023_en.pdf"},
    {"id":"61970","name":"Minutes of the PRAC meeting on 27-30 November 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-02-01T09:00:36Z","last_updated_date":"2024-02-28T09:03:00Z","reference_number":"EMA/PRAC/25440/2024 Corr 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-27-30-november-2023_en.pdf"},
    {"id":"61987","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 13 December 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-02-02T12:18:07Z","last_updated_date":"2024-02-02T12:18:07Z","reference_number":"EMA/568691/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-13-december-2023_en.pdf"},
    {"id":"62029","name":"Minutes of the HMPC meeting 20-22 November 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-02-07T16:59:37Z","last_updated_date":"2024-02-07T16:59:37Z","reference_number":"EMA/HMPC/566870/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-20-22-november-2023_en.pdf"},
    {"id":"62060","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 5 December 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-02-09T11:59:14Z","last_updated_date":"2024-02-09T11:59:14Z","reference_number":"EMA/130876/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-5-december-2023_en.pdf"},
    {"id":"62061","name":"Meeting summary of the Medicine Shortages (SPOC) Working Party 14 December 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-02-09T12:27:50Z","last_updated_date":"2024-02-09T12:27:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-14-december-2023_en.pdf"},
    {"id":"62125","name":"Minutes of the European Medicines Agency/European Network for Health Technology Assessment meeting - September 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-02-13T15:58:43Z","last_updated_date":"2024-02-13T15:58:43Z","reference_number":"EMA/421707/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency-european-network-health-technology-assessment-meeting-september-2023_en.pdf"},
    {"id":"62279","name":"Minutes of the CVMP meeting 16-17 January 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T10:54:42Z","last_updated_date":"2024-02-23T10:54:42Z","reference_number":"EMA/67783/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-16-17-january-2024_en.pdf"},
    {"id":"62315","name":"Minutes of the CAT meeting 17-19 January 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-02-28T08:48:46Z","last_updated_date":"2024-06-12T12:23:00Z","reference_number":"EMA/CAT/85207/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-17-19-january-2024_en.pdf"},
    {"id":"62346","name":"Minutes of the Cancer Medicines Forum","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T15:25:27Z","last_updated_date":"2024-02-28T15:25:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum_en.pdf"},
    {"id":"62388","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (29 January 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T10:11:35Z","last_updated_date":"2024-03-01T10:11:35Z","reference_number":"EMA/43606/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-29-january-2024_en.pdf"},
    {"id":"62433","name":"CHMP PROM minutes for the meeting on 15 January 2024","type":"minutes","status":"Draft","consultation_date":"","first_published_date":"2024-03-05T11:18:25Z","last_updated_date":"2024-03-05T11:18:25Z","reference_number":"EMA/CHMP/51462/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-15-january-2024_en.pdf"},
    {"id":"62434","name":"CHMP PROM minutes for the meeting on 12 February 2024","type":"minutes","status":"Draft","consultation_date":"","first_published_date":"2024-03-05T11:21:10Z","last_updated_date":"2024-03-05T11:21:10Z","reference_number":"EMA/CHMP/82768/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-12-february-2024_en.pdf"},
    {"id":"62435","name":"Minutes of the COMP meeting 16-18 January 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-03-05T11:39:39Z","last_updated_date":"2024-03-05T11:39:39Z","reference_number":"EMA/COMP/47120/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-18-january-2024_en.pdf"},
    {"id":"62442","name":"Minutes of the PRAC meeting 8-11 January 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-03-05T16:42:58Z","last_updated_date":"2024-03-05T16:42:58Z","reference_number":"EMA/PRAC/68905/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-january-2024_en.pdf"},
    {"id":"62455","name":"Minutes of the CHMP meeting 11-14 December 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-03-06T16:38:10Z","last_updated_date":"2024-03-06T16:38:10Z","reference_number":"EMA/CHMP/3867/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-11-14-december-2023_en.pdf"},
    {"id":"62465","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 30 January 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-03-07T11:57:18Z","last_updated_date":"2024-03-07T11:57:18Z","reference_number":"EMA/51677/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-30-january-2024_en.pdf"},
    {"id":"62530","name":"Minutes of the CHMP meeting 22-25 January 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-03-11T11:26:36Z","last_updated_date":"2024-03-11T11:26:36Z","reference_number":"EMA/CHMP/57124/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-january-2024_en.pdf"},
    {"id":"62554","name":"Minutes – DARWIN EU Advisory Board - 24 May 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T14:25:03Z","last_updated_date":"2024-03-12T14:25:03Z","reference_number":"EMA/238242/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-24-may-2023_en.pdf"},
    {"id":"62585","name":"PDCO minutes of the 16-19 January 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-03-13T10:15:34Z","last_updated_date":"2024-03-13T10:15:34Z","reference_number":"EMA/PDCO/46434/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-16-19-january-2024_en.pdf"},
    {"id":"62593","name":"Meeting summary - Medicine Shortages (SPOC) Working Party (22 January 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T12:13:39Z","last_updated_date":"2024-03-13T12:13:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-22-january-2024_en.pdf"},
    {"id":"62619","name":"Meeting summary - Joint Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-03-15T15:48:57Z","last_updated_date":"2024-03-15T15:48:57Z","reference_number":"EMA/79367/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-joint-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-meeting_en.pdf"},
    {"id":"62720","name":"Minutes of the CVMP meeting 13-15 February 2024","type":"minutes","status":"Draft","consultation_date":"","first_published_date":"2024-03-22T17:04:26Z","last_updated_date":"2024-03-22T17:04:26Z","reference_number":"EMA/CVMP/111854/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-13-15-february-2024_en.pdf"},
    {"id":"62750","name":"Minutes of the HMPC meeting 29-31 January 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-03-26T15:21:09Z","last_updated_date":"2024-03-26T15:21:09Z","reference_number":"EMA/HMPC/85397/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-29-31-january-2024_en.pdf"},
    {"id":"62789","name":"Minutes of the COMP meeting 13-15 February 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-03T12:44:05Z","last_updated_date":"2024-04-03T12:44:05Z","reference_number":"EMA/COMP/87308/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-13-15-february-2024_en.pdf"},
    {"id":"62829","name":"PDCO minutes of the 20-23 February 2024 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-04T15:46:09Z","last_updated_date":"2024-04-04T15:46:09Z","reference_number":"EMA/PDCO/98496/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-20-23-february-2024-meeting_en.pdf"},
    {"id":"62872","name":"Minutes of the PRAC meeting 5-8 February 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-09T12:13:12Z","last_updated_date":"2024-04-09T12:13:12Z","reference_number":"EMA/PRAC/122241/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-5-8-february-2024_en.pdf"},
    {"id":"62917","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 26 February 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-11T14:14:28Z","last_updated_date":"2024-04-16T11:34:00Z","reference_number":"EMA/51677/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-26-february-2024_en.pdf"},
    {"id":"62938","name":"Minutes of the 122nd meeting of the Management Board, 13-14 December 2023","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-12T13:53:55Z","last_updated_date":"2024-04-12T13:53:55Z","reference_number":"EMA/MB/87010/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-122nd-meeting-management-board-13-14-december-2023_en.pdf"},
    {"id":"62941","name":"Minutes - Committee for Advanced Therapies (CAT) meeting with interested parties - May 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T16:05:00Z","last_updated_date":"2024-04-12T16:05:00Z","reference_number":"EMA/397814/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-committee-advanced-therapies-cat-meeting-interested-parties-may-2023_en.pdf"},
    {"id":"62963","name":"Meeting Summary of the Medicine Shortages SPOC Working Party - 14 February 2024","type":"minutes","status":"Draft","consultation_date":"","first_published_date":"2024-04-15T16:55:07Z","last_updated_date":"2024-04-15T16:55:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-14-february-2024_en.pdf"},
    {"id":"63000","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (19 March 2024)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-18T11:18:02Z","last_updated_date":"2024-04-18T11:18:02Z","reference_number":"EMA/118868/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-19-march-2024_en.pdf"},
    {"id":"63012","name":"Minutes of the CHMP meeting 19-22 February 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-19T14:24:47Z","last_updated_date":"2024-04-19T14:24:47Z","reference_number":"EMA/CHMP/106558/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-february-2024_en.pdf"},
    {"id":"63081","name":"Minutes of the CVMP meeting 12-13 March 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T09:14:06Z","last_updated_date":"2024-04-26T09:14:06Z","reference_number":"EMA/CVMP/162270/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-12-13-march-2024_en.pdf"},
    {"id":"63096","name":"Minutes - Enpr-EMA Coordinating Group meeting (March 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-04-29T09:06:12Z","last_updated_date":"2024-04-29T09:06:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-meeting-march-2024_en.pdf"},
    {"id":"63103","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 22 March 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-29T16:16:00Z","last_updated_date":"2024-04-29T16:16:00Z","reference_number":"EMA/51677/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-22-march-2024_en.pdf"},
    {"id":"63107","name":"Minutes of the CAT meeting 13-15 March 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-29T17:30:00Z","last_updated_date":"2024-04-29T17:30:00Z","reference_number":"EMA/CAT/128490/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-13-15-march-2024_en.pdf"},
    {"id":"63119","name":"Minutes of the CAT meeting 14-16 February 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-04-30T17:20:00Z","last_updated_date":"2024-04-30T17:20:00Z","reference_number":"EMA/CAT/185591/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-14-16-february-2024_en.pdf"},
    {"id":"63171","name":"Minutes of the COMP meeting 12-14 March 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-05-06T13:38:00Z","last_updated_date":"2024-05-06T13:38:00Z","reference_number":"EMA/COMP/141681/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-12-14-march-2024_en.pdf"},
    {"id":"63209","name":"Minutes of the PRAC meeting 4-7 March 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-05-14T14:24:00Z","last_updated_date":"2024-05-14T14:24:00Z","reference_number":"EMA/PRAC/163432/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-4-7-march-2024_en.pdf"},
    {"id":"63234","name":"Meeting Summary of the Medicine Shortages (SPOC) Working Party - 14 March 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T12:26:00Z","last_updated_date":"2024-05-16T12:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-14-march-2024_en.pdf"},
    {"id":"63235","name":"PDCO minutes of the 19-22 March 2024 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-05-16T14:08:00Z","last_updated_date":"2024-05-16T14:08:00Z","reference_number":"EMA/PDCO/140329/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-19-22-march-2024-meeting_en.pdf"},
    {"id":"63338","name":"Minutes - DARWIN EU Advisory Board - 11 December 2023","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T14:15:02Z","last_updated_date":"2024-05-28T14:15:02Z","reference_number":"EMA/565691/2023","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-11-december-2023_en.pdf"},
    {"id":"63437","name":"Minutes of the CVMP meeting 16-18 April 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:47:00Z","last_updated_date":"2024-05-31T12:47:00Z","reference_number":"EMA/CVMP/239662/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-16-18-april-2024_en.pdf"},
    {"id":"63550","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 22 April 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-10T15:07:37Z","last_updated_date":"2024-06-10T15:07:37Z","reference_number":"EMA/51677/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-22-april-2024_en.pdf"},
    {"id":"63577","name":"Minutes of the HMPC meeting 18-20 March 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-12T10:30:00Z","last_updated_date":"2024-06-12T10:30:00Z","reference_number":"EMA/HMPC/152252/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-18-20-march-2024_en.pdf"},
    {"id":"63580","name":"Meeting Summary - Medicine Shortages  (SPOC) Working Party - 15-16 April 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-06-12T11:05:00Z","last_updated_date":"2024-06-12T11:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-15-16-april-2024_en.pdf"},
    {"id":"63581","name":"CHMP PROM minutes for the meeting on 11 March 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-12T11:59:20Z","last_updated_date":"2024-06-12T11:59:20Z","reference_number":"EMA/CHMP/174396/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-11-march-2024_en.pdf"},
    {"id":"63582","name":"Minutes of the CHMP meeting 18-21 March 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-12T12:10:00Z","last_updated_date":"2024-06-12T12:10:00Z","reference_number":"EMA/CHMP/165603/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-18-21-march-2024_en.pdf"},
    {"id":"63583","name":"Minutes of the PRAC meeting 8-11 April 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-12T12:17:00Z","last_updated_date":"2024-06-12T12:17:00Z","reference_number":"EMA/PRAC/262385/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-april-2024_en.pdf"},
    {"id":"63591","name":"Summary report -  - Biannual Big Data Steering Group and industry stakeholders meeting 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-12T16:20:00Z","last_updated_date":"2024-06-12T16:20:00Z","reference_number":"EMA/255630/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/summary-report-biannual-big-data-steering-group-industry-stakeholders-meeting-2024_en.pdf"},
    {"id":"63594","name":"Minutes of the CAT meeting 17-19 April 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T09:43:00Z","last_updated_date":"2024-06-14T09:43:00Z","reference_number":"EMA/CAT/279597/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-17-19-april-2024_en.pdf"},
    {"id":"63595","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (12 April 2024)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T10:17:00Z","last_updated_date":"2024-06-14T10:17:00Z","reference_number":"EMA/156992/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-12-april-2024_en.pdf"},
    {"id":"63596","name":"Minutes of the COMP meeting 16-18 April 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T10:55:00Z","last_updated_date":"2024-06-14T10:55:00Z","reference_number":"EMA/COMP/223043/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-18-april-2024_en.pdf"},
    {"id":"63614","name":"Minutes – Ad-hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - April 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-14T14:15:00Z","last_updated_date":"2024-06-14T14:15:00Z","reference_number":"EMA/128602/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ad-hoc-executive-steering-group-shortages-safety-medicinal-products-mssg-april-2024_en.pdf"},
    {"id":"63661","name":"PDCO minutes of the 23-26 April 2024 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-18T11:30:47Z","last_updated_date":"2024-06-18T11:30:47Z","reference_number":"EMA/PDCO/222146/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-23-26-april-2024-meeting_en.pdf"},
    {"id":"63663","name":"Minutes of the 123rd meeting of the Management Board on 21 March 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T12:02:06Z","last_updated_date":"2024-06-18T12:02:06Z","reference_number":"EMA/MB/158744/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-123rd-meeting-management-board-21-march-2024_en.pdf"},
    {"id":"63721","name":"Minutes - Enpr-EMA Coordinating Group and networks meeting - June 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-06-12T14:50:17Z","last_updated_date":"2024-06-12T14:50:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-networks-meeting-june-2024_en.pdf"},
    {"id":"63788","name":"Minutes of the CVMP meeting 21-22 May 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T11:00:00Z","last_updated_date":"2024-06-28T11:00:00Z","reference_number":"EMA/CVMP/285480/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-21-22-may-2024_en.pdf"},
    {"id":"63943","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 27 May 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-07-08T10:48:13Z","last_updated_date":"2024-07-08T10:48:13Z","reference_number":"EMA/51677/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-27-may-2024_en.pdf-0"},
    {"id":"63969","name":"Minutes of the PRAC meeting 13-16 May 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-07-09T14:17:37Z","last_updated_date":"2025-04-09T11:39:27Z","reference_number":"EMA/PRAC/303038/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-13-16-may-2024_en.pdf"},
    {"id":"64021","name":"Minutes of the Cancer Medicines Forum - May 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-07-11T11:14:00Z","last_updated_date":"2024-07-11T11:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-may-2024_en.pdf"},
    {"id":"64152","name":"Meeting summary - Medicine Shortages (SPOC) Working Party meeting on 22 May 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T11:25:48Z","last_updated_date":"2024-07-15T11:25:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-22-may-2024_en.pdf"},
    {"id":"64181","name":"PDCO minutes of the 28-31 May 2024 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-07-16T17:06:28Z","last_updated_date":"2024-07-16T17:06:28Z","reference_number":"EMA/PDCO/274736/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-28-31-may-2024-meeting_en.pdf"},
    {"id":"64186","name":"Minutes of the COMP meeting 21-23 May 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-07-17T16:16:33Z","last_updated_date":"2024-07-17T16:16:33Z","reference_number":"EMA/COMP/259816/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-21-23-may-2024_en.pdf"},
    {"id":"64211","name":"CHMP PROM minutes for the meeting on 15 April 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-07-19T10:52:08Z","last_updated_date":"2024-07-19T10:52:08Z","reference_number":"EMA/CHMP/254908/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-15-april-2024_en.pdf"},
    {"id":"64292","name":"Meeting summary - Patients and Consumers Working Party (PCWP) meeting (2 July 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-07-24T14:15:01Z","last_updated_date":"2024-07-24T14:15:01Z","reference_number":"EMA/308177/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-patients-consumers-working-party-pcwp-meeting-2-july-2024_en.pdf"},
    {"id":"64293","name":"Meeting summary - Patients and Consumers Working Party (PCWP) and Healthcare Professionals Working Party (HCPWP) meeting (2-3 July 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-07-24T14:18:21Z","last_updated_date":"2024-07-24T14:18:21Z","reference_number":"EMA/308177/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-patients-consumers-working-party-pcwp-healthcare-professionals-working-party-hcpwp-meeting-2-3-july-2024_en.pdf"},
    {"id":"64316","name":"Meeting summary - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting (July 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-07-25T15:04:06Z","last_updated_date":"2024-07-25T15:04:06Z","reference_number":"EMA/308177/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting-july-2024_en.pdf"},
    {"id":"64317","name":"Minutes of the CVMP meeting 18-19 June 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-07-25T15:11:30Z","last_updated_date":"2024-07-25T15:11:30Z","reference_number":"EMA/CVMP/333236/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-18-19-june-2024_en.pdf"},
    {"id":"64379","name":"Minutes of the COMP meeting on 14-16 June 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T17:23:04Z","last_updated_date":"2022-07-22T17:23:04Z","reference_number":"EMA/COMP/605337/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-16-june-2022_en.pdf"},
    {"id":"64380","name":"Minutes of the COMP meeting on 10-12 May 2022","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2022-07-21T11:11:11Z","last_updated_date":"2022-07-21T11:11:11Z","reference_number":"EMA/COMP/260156/2022","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-12-may-2022_en.pdf"},
    {"id":"64518","name":"Minutes of the HMPC meeting 27-29 May 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-08-06T11:54:25Z","last_updated_date":"2024-08-06T11:54:25Z","reference_number":"EMA/HMPC/278637/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-27-29-may-2024_en.pdf"},
    {"id":"64531","name":"Minutes of the CHMP meeting 22-25 April 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-08-07T13:04:06Z","last_updated_date":"2024-08-07T13:04:06Z","reference_number":"EMA/CHMP/222148/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-april-2024_en.pdf"},
    {"id":"64555","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 24 June 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-08-12T14:27:39Z","last_updated_date":"2024-08-12T14:27:39Z","reference_number":"EMA/296385/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-24-june-2024_en.pdf"},
    {"id":"64559","name":"Minutes – HMA-EMA joint Big Data Steering Group teleconference - 27 May 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-08-13T12:14:47Z","last_updated_date":"2024-08-13T12:14:47Z","reference_number":"EMA/51677/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-27-may-2024_en.pdf"},
    {"id":"64560","name":"Highlights - First EMA-Animal Health Europe annual bilateral meeting July 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-08-13T12:19:21Z","last_updated_date":"2024-08-13T12:19:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-first-ema-animal-health-europe-annual-bilateral-meeting-july-2024_en.pdf"}    {"id":"64605","name":"Minutes of the PRAC meeting 10-13 June 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-08-21T10:26:52Z","last_updated_date":"2024-08-21T10:26:52Z","reference_number":"EMA/PRAC/343192/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-10-13-june-2024_en.pdf"},
    {"id":"64614","name":"Minutes of the COMP meeting 18-20 June 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-08-22T13:45:29Z","last_updated_date":"2024-08-22T13:45:29Z","reference_number":"EMA/COMP/307965/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-18-20-june-2024_en.pdf"},
    {"id":"64651","name":"Meeting summary - Medicine Shortages (SPOC) Working Party meeting on 20 June 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-08-28T16:19:43Z","last_updated_date":"2024-08-28T16:19:43Z","reference_number":"EMA/344742/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-20-june-2024_en.pdf"},
    {"id":"64682","name":"PDCO minutes of the 25-28 June 2024 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-09-02T16:31:40Z","last_updated_date":"2024-09-02T16:31:40Z","reference_number":"EMA/PDCO/321477/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-25-28-june-2024-meeting_en.pdf"},
    {"id":"64780","name":"Minutes of the PRAC meeting 8-11 July 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-09-10T16:08:58Z","last_updated_date":"2024-09-10T16:08:58Z","reference_number":"EMA/PRAC/337971/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-july-2024_en.pdf"},
    {"id":"64841","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (26 June 2024)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-09-13T09:11:24Z","last_updated_date":"2024-09-13T09:11:24Z","reference_number":"EMA/296817/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-26-june-2024_en.pdf"},
    {"id":"64901","name":"Minutes – Ad-hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (July 2024)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-09-18T14:33:07Z","last_updated_date":"2024-09-18T14:33:07Z","reference_number":"EMA/307188/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ad-hoc-executive-steering-group-shortages-safety-medicinal-products-mssg-july-2024_en.pdf"},
    {"id":"64921","name":"Minutes of the CVMP meeting 16-18 July 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-09-19T09:32:29Z","last_updated_date":"2024-09-19T09:32:29Z","reference_number":"EMA/CVMP/423075/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-16-18-july-2024_en.pdf"},
    {"id":"64986","name":"Minutes of the 124th meeting of the Management Board: 12-13 June 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T17:31:53Z","last_updated_date":"2024-09-20T17:31:53Z","reference_number":"EMA/MB/312765/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-124th-meeting-management-board-12-13-june-2024_en.pdf"},
    {"id":"64997","name":"CHMP PROM minutes for the meeting on 17 June 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-09-23T15:31:26Z","last_updated_date":"2024-09-23T15:31:26Z","reference_number":"EMA/CHMP/280125/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-17-june-2024_en.pdf"},
    {"id":"65033","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 19 July 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-09-25T13:13:24Z","last_updated_date":"2024-09-25T13:13:24Z","reference_number":"EMA/339502/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-19-july-2024_en.pdf"},
    {"id":"65116","name":"Meeting Summary of the Medicine Shortages SPOC Working Party meeting on 17 July 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T14:28:14Z","last_updated_date":"2024-10-02T14:28:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-17-july-2024_en.pdf"},
    {"id":"65121","name":"CHMP PROM minutes for the meeting on 15 July 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-10-02T16:10:49Z","last_updated_date":"2024-10-02T16:10:49Z","reference_number":"EMA/CHMP/330703/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-15-july-2024_en.pdf"},
    {"id":"65122","name":"Minutes of the COMP meeting 16-18 July 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-10-03T11:30:18Z","last_updated_date":"2024-10-03T11:30:18Z","reference_number":"EMA/COMP/350725/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-16-18-july-2024_en.pdf"},
    {"id":"65148","name":"PDCO minutes of the 23-26 July 2024 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T10:32:00Z","last_updated_date":"2024-10-04T10:32:00Z","reference_number":"EMA/PDCO/364965/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-23-26-july-2024-meeting_en.pdf"},
    {"id":"65209","name":"Minutes of the HMPC meeting 22-24 July 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-10-07T11:00:00Z","last_updated_date":"2024-10-07T11:00:00Z","reference_number":"EMA/HMPC/372968/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-22-24-july-2024_en.pdf"},
    {"id":"65323","name":"Minutes of the COMP meeting 10-12 September 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-10-17T12:15:00Z","last_updated_date":"2024-10-17T12:15:00Z","reference_number":"EMA/COMP/446111/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-12-september-2024_en.pdf"},
    {"id":"65364","name":"Minutes of the CAT meeting 22-24 May 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-10-22T15:23:43Z","last_updated_date":"2024-10-22T15:23:43Z","reference_number":"EMA/CAT/248714/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-22-24-may-2024_en.pdf"},
    {"id":"65365","name":"Minutes of the CAT meeting 19-21 June 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-10-22T15:25:09Z","last_updated_date":"2024-10-22T15:25:09Z","reference_number":"EMA/CAT/490675/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-19-21-june-2024_en.pdf"},
    {"id":"65366","name":"Minutes of the CAT meeting 17-19 July 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-10-22T15:26:15Z","last_updated_date":"2024-10-22T15:26:15Z","reference_number":"EMA/CAT/493244/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-17-19-july-2024_en.pdf"},
    {"id":"65460","name":"Minutes of the PRAC meeting 2-5 September 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-10-28T17:28:00Z","last_updated_date":"2025-04-09T11:43:12Z","reference_number":"EMA/PRAC/468455/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-2-5-september-2024_en.pdf"},
    {"id":"65532","name":"Minutes - PDCO minutes of the 3-6 September 2024 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-04T16:13:14Z","last_updated_date":"2024-11-04T16:13:14Z","reference_number":"EMA/PDCO/435411/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-3-6-september-2024-meeting_en.xlsx"},
    {"id":"65533","name":"Minutes of the CHMP meeting 27-30 May 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-04T16:25:33Z","last_updated_date":"2024-11-04T16:25:33Z","reference_number":"EMA/CHMP/285355/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-27-30-may-2024_en.pdf"},
    {"id":"65545","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (18 September 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-11-05T11:22:20Z","last_updated_date":"2024-11-05T11:22:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-18-september-2024_en.pdf"},
    {"id":"65566","name":"Meeting Summary of the Medicine Shortages SPOC Working Party meeting - 11 September 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-11-07T17:04:22Z","last_updated_date":"2024-11-07T17:04:22Z","reference_number":"EMA/453004/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-11-september-2024_en.pdf"},
    {"id":"65616","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 6 September 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-13T16:09:03Z","last_updated_date":"2024-11-13T16:09:03Z","reference_number":"EMA/423417/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-6-september-2024_en.pdf"},
    {"id":"65624","name":"CHMP PROM minutes for the meeting on 09 September 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-14T10:18:22Z","last_updated_date":"2024-11-14T10:18:22Z","reference_number":"EMA/CHMP/465101/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-09-september-2024_en.pdf"},
    {"id":"65633","name":"Minutes of the CAT meeting 11-12 September 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-14T12:28:51Z","last_updated_date":"2024-11-14T12:28:51Z","reference_number":"EMA/CAT/533443/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-11-12-september-2024_en.pdf"},
    {"id":"65728","name":"Minutes of the COMP meeting 08-10 October 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-20T15:19:11Z","last_updated_date":"2024-11-20T15:19:11Z","reference_number":"EMA/COMP/489105/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-08-10-october-2024_en.pdf"},
    {"id":"65774","name":"Meeting Summary of the Medicine Shortages (SPOC) Working Party meeting 7-8 October 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-11-22T14:34:36Z","last_updated_date":"2024-11-22T14:34:36Z","reference_number":"EMA/513605/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-7-8-october-2024_en.pdf"},
    {"id":"65800","name":"Minutes of the HMPC meeting 23-25 September 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-25T13:53:29Z","last_updated_date":"2024-11-25T13:53:29Z","reference_number":"EMA/HMPC/478382/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-23-25-september-2024_en.pdf"},
    {"id":"65825","name":"Minutes of the PRAC meeting on 30 September - 03 October 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-27T09:54:39Z","last_updated_date":"2024-11-27T09:54:39Z","reference_number":"EMA/PRAC/532125/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-30-september-03-october-2024_en.pdf"},
    {"id":"65840","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 19 July 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-27T15:57:44Z","last_updated_date":"2024-11-27T15:57:44Z","reference_number":"EMA/339502/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-19-july-2024_en.pdf-0"},
    {"id":"65841","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 4 October 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-27T16:00:02Z","last_updated_date":"2024-11-27T16:00:02Z","reference_number":"EMA/478208/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-4-october-2024_en.pdf"},
    {"id":"65865","name":"Minutes of the CAT meeting 9-11 October 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-28T13:43:54Z","last_updated_date":"2024-11-28T13:43:54Z","reference_number":"EMA/CAT/554433/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-9-11-october-2024_en.pdf"},
    {"id":"65866","name":"Minutes of the CHMP meeting 24-27 June 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-11-28T14:33:01Z","last_updated_date":"2024-11-28T14:33:01Z","reference_number":"EMA/CHMP/330692/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-24-27-june-2024_en.pdf"},
    {"id":"65888","name":"Minutes - PDCO minutes of the 15-18 October 2024 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-12-02T11:31:05Z","last_updated_date":"2024-12-02T11:31:05Z","reference_number":"EMA/PDCO/505016/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-15-18-october-2024-meeting_en.xlsx"},
    {"id":"65972","name":"Meeting Summary - PCWP/HCPWP and all eligible organisations meeting (November 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T13:44:05Z","last_updated_date":"2024-12-05T13:44:05Z","reference_number":"EMA/526113/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-all-eligible-organisations-meeting-november-2024_en.pdf"},
    {"id":"66041","name":"Minutes - Enpr-EMA Coordinating Group and networks meeting (October 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T11:42:26Z","last_updated_date":"2024-12-10T11:42:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-networks-meeting-october-2024_en.pdf"},
    {"id":"66050","name":"Minutes - Cancer Medicines Forum: October 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T13:36:09Z","last_updated_date":"2024-12-10T13:36:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-october-2024_en.pdf"},
    {"id":"66085","name":"Minutes - Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (November 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2024-12-12T12:54:30Z","last_updated_date":"2024-12-12T12:54:30Z","reference_number":"EMA/538724 /2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-meeting-executive-steering-group-shortages-safety-medicinal-products-mssg-november-2024_en.pdf"},
    {"id":"66119","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 15 November 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T14:41:47Z","last_updated_date":"2024-12-13T14:41:47Z","reference_number":"EMA/548191/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-15-november-2024_en.pdf"},
    {"id":"66183","name":"Minutes of the CHMP meeting 22-25 July 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-12-18T09:25:27Z","last_updated_date":"2024-12-18T09:25:27Z","reference_number":"EMA/CHMP/376395/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-july-2024_en.pdf"},
    {"id":"66221","name":"Minutes of the COMP meeting 5-7 November 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2024-12-19T11:10:00Z","last_updated_date":"2024-12-19T11:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-5-7-november-2024_en.pdf"},
    {"id":"66281","name":"Minutes of the CAT meeting 6-8 November 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-09T15:53:08Z","last_updated_date":"2025-01-09T15:53:08Z","reference_number":"EMA/CAT/8204/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-6-8-november-2024_en.pdf"},
    {"id":"66282","name":"Minutes of the CHMP written procedure 19-22 August 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-09T15:59:40Z","last_updated_date":"2025-01-09T15:59:40Z","reference_number":"EMA/CHMP/414791/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-written-procedure-19-22-august-2024_en.pdf"},
    {"id":"66287","name":"Minutes of the 125th meeting of the EMA Management Board: 3 October 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-10T14:41:11Z","last_updated_date":"2025-01-10T14:41:11Z","reference_number":"EMA/MB/449773/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-125th-meeting-ema-management-board-3-october-2024_en.pdf"},
    {"id":"66290","name":"Meeting summary - Medicine Shortages (SPOC) Working Party 6 November 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-01-10T14:53:49Z","last_updated_date":"2025-01-10T14:53:49Z","reference_number":"EMA/565505/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-6-november-2024_en.pdf"},
    {"id":"66292","name":"Minutes of the CHMP meeting 16-19 September 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-10T16:21:35Z","last_updated_date":"2025-01-10T16:21:35Z","reference_number":"EMA/CHMP/463417/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-16-19-september-2024_en.pdf"},
    {"id":"66297","name":"Minutes - PDCO minutes of the 12-15 November 2024 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-13T15:28:25Z","last_updated_date":"2025-03-05T13:37:00Z","reference_number":"EMA/PDCO/554314/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-12-15-november-2024-meeting_en.xlsx"},
    {"id":"66309","name":"Minutes - HMA-EMA joint Big Data Steering Group teleconference - 11 December 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-14T14:44:16Z","last_updated_date":"2025-02-17T17:04:00Z","reference_number":"EMA/475371/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-big-data-steering-group-teleconference-11-december-2024_en.pdf"},
    {"id":"66314","name":"Minutes of the PRAC meeting 28-31 October 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-15T12:33:07Z","last_updated_date":"2025-04-09T11:46:47Z","reference_number":"EMA/PRAC/583624/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-28-31-october-2024_en.pdf"},
    {"id":"66370","name":"CHMP PROM minutes for the meeting on 02 December 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-20T11:27:56Z","last_updated_date":"2025-01-20T11:27:56Z","reference_number":"EMA/CHMP/558008/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-02-december-2024_en.pdf"},
    {"id":"66446","name":"Minutes of the CVMP meeting 3-5 December 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-24T13:07:50Z","last_updated_date":"2025-01-24T13:07:50Z","reference_number":"EMA/CVMP/15527/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-3-5-december-2024_en.pdf"},
    {"id":"66482","name":"Minutes of the HMPC meeting 18-20 November 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-28T14:10:00Z","last_updated_date":"2025-01-30T11:00:20Z","reference_number":"EMA/HMPC/589139/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-18-20-november-2024_en.pdf"},
    {"id":"66484","name":"Minutes of the CAT meeting 4-6 December 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-01-28T14:20:35Z","last_updated_date":"2025-03-24T11:44:00Z","reference_number":"EMA/CAT/36325/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-4-6-december-2024_en.pdf"},
    {"id":"66575","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (11 December 2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-02-03T14:58:14Z","last_updated_date":"2025-02-11T14:11:30Z","reference_number":"EMA/576985/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-11-december-2024_en.pdf"},
    {"id":"66626","name":"CHMP PROM minutes for the meeting on 04 November 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-02-06T15:32:20Z","last_updated_date":"2025-02-06T15:32:20Z","reference_number":"EMA/CHMP/510871/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-04-november-2024_en.pdf"},
    {"id":"66645","name":"Minutes of the PRAC meeting 25-28 November 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-02-10T12:58:24Z","last_updated_date":"2025-04-09T11:45:04Z","reference_number":"EMA/PRAC/592992/2024 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-25-28-november-2024_en.pdf"},
    {"id":"66646","name":"Meeting Summary - Medicine Shortages SPOC Working Party 5 December 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T13:15:52Z","last_updated_date":"2025-02-10T13:15:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-5-december-2024_en.pdf"},
    {"id":"66677","name":"Minutes of the COMP meeting 3-5 December 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-02-11T14:14:05Z","last_updated_date":"2025-02-21T11:58:13Z","reference_number":"EMA/COMP/588348/2024 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-3-5-december-2024_en.pdf"},
    {"id":"66734","name":"Minutes - PDCO minutes of the 10-13 December 2024 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-02-13T13:46:34Z","last_updated_date":"2025-02-13T13:46:34Z","reference_number":"EMA/PDCO/554314/2024\t","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-10-13-december-2024-meeting_en.xlsx"},
    {"id":"66893","name":"Minutes - DARWIN EU Advisory Board - 3 May 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-02-20T11:00:00Z","last_updated_date":"2025-02-20T11:00:00Z","reference_number":"EMA/244079/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-3-may-2024_en.pdf"},
    {"id":"66906","name":"Minutes of the CVMP meeting 14-15 January 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-02-20T15:30:41Z","last_updated_date":"2025-02-20T15:30:41Z","reference_number":"EMA/CVMP/54921/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-14-15-january-2025_en.pdf"},
    {"id":"66914","name":"Minutes of the CVMP meeting 10-12 September 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-02-21T12:00:42Z","last_updated_date":"2025-02-21T12:00:42Z","reference_number":"EMA/CVMP/49328/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-12-september-2024_en.pdf"},
    {"id":"66915","name":"Minutes of the CVMP meeting 8-10 October 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-02-21T12:05:48Z","last_updated_date":"2025-02-21T12:05:48Z","reference_number":"EMA/CVMP/49655/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-10-october-2024_en.pdf"},
    {"id":"66916","name":"CHMP PROM minutes for the meeting on 07 October 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-02-21T12:16:04Z","last_updated_date":"2025-02-21T12:16:04Z","reference_number":"EMA/CHMP/464338/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-07-october-2024_en.pdf"},
    {"id":"67029","name":"Minutes of the CAT meeting 22-24 January 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-02-27T17:41:40Z","last_updated_date":"2025-02-27T17:41:40Z","reference_number":"EMA/CAT/73821/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-22-24-january-2025_en.pdf"},
    {"id":"67030","name":"Minutes of the COMP meeting 21-23 January 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-02-27T17:54:23Z","last_updated_date":"2025-02-27T17:54:23Z","reference_number":"EMA/COMP/48379/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-21-23-january-2025_en.pdf"},
    {"id":"67131","name":"Minutes of the CHMP meeting 11-14 November 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-03-07T10:43:08Z","last_updated_date":"2025-03-07T10:43:08Z","reference_number":"EMA/CHMP/561524/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-11-14-november-2024_en.pdf"},
    {"id":"67155","name":"Minutes of the CHMP meeting on 14-17 October 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-03-07T15:54:55Z","last_updated_date":"2025-03-07T15:54:55Z","reference_number":"EMA/CHMP/503277/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-14-17-october-2024_en.pdf"},
    {"id":"67167","name":"Minutes of the 126th meeting of the EMA Management Board: 11 - 12 December 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-03-10T13:33:52Z","last_updated_date":"2025-03-10T13:33:52Z","reference_number":"EMA/MB/580677/2024","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-126th-meeting-ema-management-board-11-12-december-2024_en.pdf"},
    {"id":"67178","name":"Minutes of the Cancer Medicines Forum - December 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T11:14:15Z","last_updated_date":"2025-03-11T11:14:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-december-2024_en.pdf"},
    {"id":"67219","name":"Minutes of the PRAC meeting 13-16 January 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-03-12T10:26:42Z","last_updated_date":"2025-03-26T13:05:00Z","reference_number":"EMA/PRAC/67596/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-13-16-january-2025_en.pdf"},
    {"id":"67230","name":"Minutes - PDCO minutes of the 28-31 January 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-03-12T12:21:02Z","last_updated_date":"2025-03-12T12:21:02Z","reference_number":"EMA/PDCO/55457/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-28-31-january-2025-meeting_en.xlsx"},
    {"id":"67236","name":"Summary of the Medicine Shortages SPOC Working Party meeting on 21 January 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-03-12T15:22:42Z","last_updated_date":"2025-03-12T15:22:42Z","reference_number":"EMA/55604/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/summary-medicine-shortages-spoc-working-party-meeting-21-january-2025_en.pdf"},
    {"id":"67365","name":"Minutes of the HMPC meeting 20-22 January 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-03-20T12:36:00Z","last_updated_date":"2025-03-20T12:36:00Z","reference_number":"EMA/HMPC/60660/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-20-22-january-2025_en.pdf"},
    {"id":"67431","name":"Minutes of the CVMP meeting 11-12 February 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-03-25T11:40:52Z","last_updated_date":"2025-03-25T11:40:52Z","reference_number":"EMA/CVMP/90258/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-11-12-february-2025_en.pdf"},
    {"id":"67506","name":"Minutes of the COMP meeting 18-19 February 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-03-27T16:17:39Z","last_updated_date":"2025-03-27T16:17:39Z","reference_number":"EMA/COMP/77527/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-18-19-february-2025_en.pdf"},
    {"id":"67574","name":"Minutes of the CAT meeting 19-21 February 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-04-01T12:32:45Z","last_updated_date":"2025-04-01T12:32:45Z","reference_number":"EMA/CAT/115813/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-19-21-february-2025_en.pdf"},
    {"id":"67582","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (26 February 2025)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-04-01T16:07:46Z","last_updated_date":"2025-04-01T16:07:46Z","reference_number":"EMA/72023/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-26-february-2025_en.pdf"},
    {"id":"67605","name":"Meeting summary of the Medicine Shortages SPOC Working Party 18 February 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-04-02T17:00:00Z","last_updated_date":"2025-04-02T17:00:00Z","reference_number":"EMA/97390/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-18-february-2025_en.pdf"},
    {"id":"67722","name":"Minutes of the PRAC meeting 10-13 February 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-04-09T16:48:12Z","last_updated_date":"2025-04-09T16:48:12Z","reference_number":"EMA/PRAC/111789/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-10-13-february-2025_en.pdf"},
    {"id":"67733","name":"Minutes - PDCO minutes of the 25-28 February 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-04-10T14:33:10Z","last_updated_date":"2025-04-10T14:33:10Z","reference_number":"EMA/PDCO/90562/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-25-28-february-2025-meeting_en.xlsx"},
    {"id":"67869","name":"Minutes of the CVMP meeting 11-13 March 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-04-16T11:41:52Z","last_updated_date":"2025-04-16T11:41:52Z","reference_number":"EMA/CVMP/125927/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-11-13-march-2025_en.pdf"},
    {"id":"68010","name":"Minutes of the CAT meeting 19-21 March 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-04-28T15:23:38Z","last_updated_date":"2025-04-28T15:23:38Z","reference_number":"EMA/CAT/141549/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-19-21-march-2025_en.pdf"},
    {"id":"68025","name":"Meeting summary - Medicine Shortages (SPOC) Working Party 18 March 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-04-29T13:59:58Z","last_updated_date":"2025-04-29T13:59:58Z","reference_number":"EMA/125235/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-18-march-2025_en.pdf"},
    {"id":"68107","name":"Minutes of the COMP meeting 18-20 March 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-05-06T09:37:29Z","last_updated_date":"2025-05-06T09:37:29Z","reference_number":"EMA/COMP/146311/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-18-20-march-2025_en.pdf"},
    {"id":"68110","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (April 2025)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-05-06T11:42:58Z","last_updated_date":"2025-05-06T11:42:58Z","reference_number":"EMA/114435/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-april-2025_en.pdf"},
    {"id":"68114","name":"Meeting summary - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting on 1-2 April 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-05-06T14:11:57Z","last_updated_date":"2025-05-06T14:11:57Z","reference_number":"EMA/115618/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-european-medicines-agency-ema-patients-consumers-pcwp-healthcare-professionals-hcpwp-working-parties-joint-meeting-1-2-april-2025_en.pdf"},
    {"id":"68119","name":"HMA-EMA joint Network Data Steering Group kick-off meeting, 28-29 January 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-05-06T15:21:05Z","last_updated_date":"2025-05-06T15:21:05Z","reference_number":"EMA/46938/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/hma-ema-joint-network-data-steering-group-kick-meeting-28-29-january-2025_en.pdf"},
    {"id":"68120","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 4 March 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-05-06T15:21:07Z","last_updated_date":"2025-05-06T15:21:07Z","reference_number":"EMA/87142/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-4-march-2025_en.pdf"},
    {"id":"68121","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 31 March 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-05-06T15:21:10Z","last_updated_date":"2025-05-06T15:21:10Z","reference_number":"EMA/122343/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-31-march-2025_en.pdf"},
    {"id":"68123","name":"HMA-EMA joint Network Data Steering Group kick-off meeting - 28/29 January 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-05-06T15:21:05Z","last_updated_date":"2025-05-06T15:21:05Z","reference_number":"EMA/46938/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/hma-ema-joint-network-data-steering-group-kick-meeting-28-29-january-2025_en.pdf-0"},
    {"id":"68151","name":"Minutes - Enpr-EMA Coordinating Group meeting (March, April)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-05-07T16:14:58Z","last_updated_date":"2025-05-07T16:14:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-meeting-march-april_en.pdf"},
    {"id":"68158","name":"Minutes of the PRAC meeting 10-13 March 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-05-08T10:16:12Z","last_updated_date":"2025-05-08T10:16:12Z","reference_number":"EMA/PRAC/132323/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-10-13-march-2025_en.pdf"},
    {"id":"68215","name":"Minutes - PDCO minutes of the 25-28 March 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-05-12T10:54:02Z","last_updated_date":"2025-05-12T10:54:02Z","reference_number":"EMA/PDCO/122939/2025\t","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-25-28-march-2025-meeting_en.xlsx"},
    {"id":"68237","name":"Minutes of the HMPC meeting 17-19 March 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-05-12T16:06:01Z","last_updated_date":"2025-05-12T16:06:01Z","reference_number":"EMA/HMPC/125295/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-17-19-march-2025_en.pdf"},
    {"id":"68420","name":"Minutes of the Cancer Medicines Forum - March 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T14:29:01Z","last_updated_date":"2025-05-23T14:29:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-march-2025_en.pdf"},
    {"id":"68421","name":"Minutes of the 127th meeting of the EMA Management Board: 13 March 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T14:36:20Z","last_updated_date":"2025-05-23T14:36:20Z","reference_number":"EMA/MB/87893/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-127th-meeting-ema-management-board-13-march-2025_en.pdf"}    {"id":"68474","name":"Minutes of the CHMP meeting 9-12 December 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-05-27T15:30:00Z","last_updated_date":"2025-05-27T15:30:00Z","reference_number":"EMA/CHMP/23329/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-9-12-december-2024_en.pdf"},
    {"id":"68489","name":"Minutes of the CHMP meeting 27-30 January 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-05-28T14:29:02Z","last_updated_date":"2025-06-05T10:51:00Z","reference_number":"EMA/CHMP/57306/2025 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-27-30-january-2025_en.pdf"},
    {"id":"68490","name":"Annex to 27-30 January 2025 CHMP Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-05-28T14:31:55Z","last_updated_date":"2025-05-28T14:31:55Z","reference_number":"EMA/CHMP/40629/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/annex-27-30-january-2025-chmp-minutes_en.xlsx"},
    {"id":"68532","name":"Meeting summary - Medicine shortages (SPOC) working party 10-11 April 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-06-02T16:59:04Z","last_updated_date":"2025-06-02T16:59:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-10-11-april-2025_en.pdf"},
    {"id":"68535","name":"Minutes of the CAT meeting 14-16 April 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-06-02T17:16:51Z","last_updated_date":"2025-06-02T17:16:51Z","reference_number":"EMA/CAT/186753/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-14-16-april-2025_en.pdf"},
    {"id":"68572","name":"Minutes of the PRAC meeting 07-10 April 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-06-04T11:39:48Z","last_updated_date":"2025-06-04T11:39:48Z","reference_number":"EMA/PRAC/169632/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-07-10-april-2025_en.pdf"},
    {"id":"68581","name":"Minutes - PDCO minutes of the 22-25 April 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-06-05T10:58:23Z","last_updated_date":"2025-06-05T10:58:23Z","reference_number":"EMA/PDCO/154148/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-22-25-april-2025-meeting_en.xlsx"},
    {"id":"68670","name":"Minutes of the COMP meeting 14-15 April 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-06-10T15:40:19Z","last_updated_date":"2025-06-10T15:40:19Z","reference_number":"EMA/COMP/144968/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-15-april-2025_en.xlsx"},
    {"id":"68774","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 30 April 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:21:11Z","last_updated_date":"2025-06-16T15:21:11Z","reference_number":"EMA/156282/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-30-april-2025_en.pdf"},
    {"id":"68962","name":"Minutes of the CVMP meeting 5-7 November 2024","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-06-25T15:31:59Z","last_updated_date":"2025-06-25T15:31:59Z","reference_number":"EMA/CVMP/197226/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-5-7-november-2024_en.pdf"},
    {"id":"68963","name":"Minutes of the CVMP meeting 8-9 April 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-06-25T15:35:21Z","last_updated_date":"2025-06-25T15:35:21Z","reference_number":"EMA/CVMP/198789/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-8-9-april-2025_en.pdf"},
    {"id":"68964","name":"Minutes of the CVMP meeting 13-15 May 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-06-25T15:39:35Z","last_updated_date":"2025-06-25T15:39:35Z","reference_number":"EMA/CVMP/199015/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-13-15-may-2025_en.pdf"},
    {"id":"68999","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 21 May 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-06-27T09:06:42Z","last_updated_date":"2025-06-27T09:06:42Z","reference_number":"EMA/171299/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-21-may-2025_en.pdf"},
    {"id":"69070","name":"Minutes of the COMP meeting 13-15 May 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-07-01T15:54:43Z","last_updated_date":"2025-07-01T15:54:43Z","reference_number":"EMA/COMP/187294/2025\t","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-13-15-may-2025_en.xlsx"},
    {"id":"69113","name":"Minutes of the PRAC meeting 5-8 May 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-07-04T16:35:00Z","last_updated_date":"2025-07-04T16:35:00Z","reference_number":"EMA/PRAC/199835/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-5-8-may-2025_en.pdf"},
    {"id":"69136","name":"Meeting summary of the Medicine Shortages SPOC Working Party meeting on 13 May 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-07-07T13:13:28Z","last_updated_date":"2025-07-07T13:13:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-13-may-2025_en.pdf"},
    {"id":"69164","name":"CHMP PROM minutes for the meeting on 20 January 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-07-08T13:58:05Z","last_updated_date":"2025-07-08T13:58:05Z","reference_number":"EMA/CHMP/82016/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-20-january-2025_en.pdf"},
    {"id":"69165","name":"Minutes of the CAT meeting 14-16 May 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-07-08T14:09:39Z","last_updated_date":"2025-07-08T14:09:39Z","reference_number":"EMA/CAT/223455/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-14-16-may-2025_en.pdf"},
    {"id":"69166","name":"Minutes of the CHMP meeting 24-27 February 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-07-08T14:35:00Z","last_updated_date":"2025-07-08T14:35:00Z","reference_number":"EMA/CHMP/91836/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-24-27-february-2025_en.pdf"},
    {"id":"69167","name":"Annex to 24-27 February 2025 CHMP Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-07-08T14:32:00Z","last_updated_date":"2025-07-08T14:32:00Z","reference_number":"EMA/CHMP/79634/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/annex-24-27-february-2025-chmp-minutes_en.xlsx"},
    {"id":"69170","name":"Minutes - PDCO minutes of the 20-23 May 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-07-08T15:09:43Z","last_updated_date":"2025-07-08T15:09:43Z","reference_number":"EMA/PDCO/187768/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-20-23-may-2025-meeting_en.xlsx"},
    {"id":"69204","name":"Minutes of the HMPC meeting 5-7 May 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-07-09T16:30:00Z","last_updated_date":"2025-07-09T16:30:00Z","reference_number":"EMA/HMPC/187311/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-5-7-may-2025_en.pdf"},
    {"id":"69430","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 28 May 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-07-24T11:59:56Z","last_updated_date":"2025-07-24T11:59:56Z","reference_number":"EMA/198426/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-28-may-2025_en.pdf"},
    {"id":"69431","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 27 June 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-07-24T12:03:26Z","last_updated_date":"2025-07-24T12:03:26Z","reference_number":"EMA/198426/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-27-june-2025_en.pdf"},
    {"id":"69711","name":"Minutes of the COMP meeting 10-12 June 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T16:37:58Z","last_updated_date":"2025-08-12T16:37:58Z","reference_number":"EMA/COMP/267913/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-10-12-june-2025_en.xlsx"},
    {"id":"69744","name":"CHMP PROM minutes for the meeting on 17 February 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-08-14T15:55:18Z","last_updated_date":"2025-08-14T15:55:18Z","reference_number":"EMA/82017/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-17-february-2025_en.pdf"},
    {"id":"69745","name":"Minutes of the CHMP meeting 22-25 April 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-08-14T16:02:06Z","last_updated_date":"2025-08-14T16:02:06Z","reference_number":"EMA/CHMP/157675/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-22-25-april-2025_en.pdf"},
    {"id":"69746","name":"Annex to 22-25 April 2025 CHMP Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-08-14T16:03:34Z","last_updated_date":"2025-08-14T16:03:34Z","reference_number":"EMA/CHMP/143165/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/annex-22-25-april-2025-chmp-minutes_en.xlsx"},
    {"id":"69758","name":"Minutes of the PRAC meeting 2-5 June 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-08-19T11:15:48Z","last_updated_date":"2025-11-04T16:18:00Z","reference_number":"EMA/PRAC/238878/2025 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-2-5-june-2025_en.pdf"},
    {"id":"69761","name":"CHMP PROM minutes for the meeting on 14 April 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-08-19T11:28:25Z","last_updated_date":"2025-08-19T11:28:25Z","reference_number":"EMA/137922/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-14-april-2025_en.pdf"},
    {"id":"69800","name":"Annex to 24-27 March 2025 CHMP Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-08-20T15:23:15Z","last_updated_date":"2025-08-20T15:23:15Z","reference_number":"EMA/CHMP/111642/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/annex-24-27-march-2025-chmp-minutes_en.xlsx"},
    {"id":"69801","name":"Minutes of the CHMP meeting 24-27 March 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-08-20T15:23:14Z","last_updated_date":"2025-08-20T15:23:14Z","reference_number":"EMA/149300/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-24-27-march-2025_en.pdf"},
    {"id":"69838","name":"Annex to 19-22 May 2025 CHMP Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-08-21T16:05:25Z","last_updated_date":"2025-08-21T16:05:25Z","reference_number":"EMA/CHMP/177215/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/annex-19-22-may-2025-chmp-minutes_en.xlsx"},
    {"id":"69839","name":"Minutes of the CHMP meeting 19-22 May 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-08-21T16:13:56Z","last_updated_date":"2026-02-16T17:22:04Z","reference_number":"EMA/206317/2025 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-19-22-may-2025_en.pdf"},
    {"id":"69853","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 23 July 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-08-25T16:37:47Z","last_updated_date":"2025-08-25T16:37:47Z","reference_number":"EMA/241125/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-23-july-2025_en.pdf"},
    {"id":"69866","name":"Minutes - PDCO minutes of the 17-20 June 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-08-27T14:30:00Z","last_updated_date":"2025-08-27T14:30:00Z","reference_number":"EMA/PDCO/217586/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-17-20-june-2025-meeting_en.xlsx"},
    {"id":"69900","name":"Summary report - Annual Network Data Steering Group and industry stakeholders meeting 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-08-28T16:29:36Z","last_updated_date":"2025-08-28T16:29:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/summary-report-annual-network-data-steering-group-industry-stakeholders-meeting-2025_en.pdf"},
    {"id":"69909","name":"Minutes of the CAT meeting 11-13 June 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-08-29T15:16:52Z","last_updated_date":"2025-08-29T15:16:52Z","reference_number":"EMA/CAT/280856/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-11-13-june-2025_en.pdf"},
    {"id":"70044","name":"Minutes of the PRAC meeting 7-10 July 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-09-10T11:58:45Z","last_updated_date":"2025-11-04T16:09:00Z","reference_number":"EMA/272191/2025 Corr.","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-july-2025_en.pdf"},
    {"id":"70142","name":"Minutes of the Cancer Medicines Forum - June 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-09-18T12:17:33Z","last_updated_date":"2025-09-18T12:17:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-june-2025_en.pdf"},
    {"id":"70209","name":"CHMP PROM minutes for the meeting on 17 March 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-09-22T12:14:06Z","last_updated_date":"2025-09-22T12:14:06Z","reference_number":"EMA/CHMP/96050/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-17-march-2025_en.pdf"},
    {"id":"70245","name":"Minutes of the 128th meeting of the EMA Management Board: 11-12 June 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-09-24T10:35:55Z","last_updated_date":"2025-09-24T10:35:55Z","reference_number":"EMA/MB/189883/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-128th-meeting-ema-management-board-11-12-june-2025_en.pdf"},
    {"id":"70294","name":"Minutes - PDCO minutes of the 22-25 July 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-09-26T12:45:54Z","last_updated_date":"2025-09-26T12:45:54Z","reference_number":"EMA/PDCO/263801/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-22-25-july-2025-meeting_en.xlsx"},
    {"id":"70307","name":"Minutes of the COMP meeting 15-17 July 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-09-26T16:47:50Z","last_updated_date":"2025-09-26T16:47:50Z","reference_number":"EMA/COMP/275500/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-15-17-july-2025_en.xlsx"},
    {"id":"70321","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 17 July 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-09-29T14:57:25Z","last_updated_date":"2025-09-29T14:57:25Z","reference_number":"EMA/241078/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-17-july-2025_en.pdf"},
    {"id":"70327","name":"Minutes of the HMPC meeting 7-9 July 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-09-29T16:03:24Z","last_updated_date":"2025-09-29T16:03:24Z","reference_number":"EMA/HMPC/244166/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-7-9-july-2025_en.pdf"},
    {"id":"70375","name":"Minutes of the CAT meeting 16-18 July 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-09-30T16:25:00Z","last_updated_date":"2025-09-30T16:25:00Z","reference_number":"EMA/CAT/315554/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-16-18-july-2025_en.pdf"},
    {"id":"70377","name":"Minutes of the CAT meeting 12-14 August 2025 - written procedure","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-09-30T16:35:11Z","last_updated_date":"2025-09-30T16:35:11Z","reference_number":"EMA/CAT/315756/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-12-14-august-2025-written-procedure_en.pdf"},
    {"id":"70406","name":"Minutes - Enpr-EMA Coordinating Group & networks meeting - June 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T13:53:40Z","last_updated_date":"2025-10-02T13:53:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-enpr-ema-coordinating-group-networks-meeting-june-2025_en.pdf"},
    {"id":"70433","name":"Meeting summary of the Medicine Shortages SPOC Working party on 14 July 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T11:11:19Z","last_updated_date":"2025-10-03T11:11:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-14-july-2025_en.pdf"},
    {"id":"70442","name":"Meeting summary - PCWP meeting, HCPWP meeting, joint PCWP/HCPWP meeting - 23-24 September 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T15:41:27Z","last_updated_date":"2025-10-03T15:41:27Z","reference_number":"EMA/307703/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-meeting-hcpwp-meeting-joint-pcwp-hcpwp-meeting-23-24-september-2025_en.pdf"},
    {"id":"70475","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 16 September 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-10-07T15:58:39Z","last_updated_date":"2025-10-07T15:58:39Z","reference_number":"EMA/309999/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-16-september-2025_en.pdf"},
    {"id":"70481","name":"Minutes of the CHMP written procedure 18-21 August 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-10-07T16:51:10Z","last_updated_date":"2025-10-07T16:51:10Z","reference_number":"EMA/CHMP/285053/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-written-procedure-18-21-august-2025_en.pdf"},
    {"id":"70598","name":"Minutes of the CVMP meeting 9-10 September 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T13:27:42Z","last_updated_date":"2025-10-16T13:27:42Z","reference_number":"EMA/CVMP/324854/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-9-10-september-2025_en.pdf"},
    {"id":"70599","name":" Minutes of the CVMP meeting 10-12 June 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T13:28:41Z","last_updated_date":"2025-10-16T13:28:41Z","reference_number":"EMA/CVMP/324851/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-12-june-2025_en.pdf"},
    {"id":"70622","name":"Minutes of the CVMP meeting 15-17 July 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T11:03:08Z","last_updated_date":"2025-10-17T11:03:08Z","reference_number":"EMA/334046/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-15-17-july-2025_en.pdf"},
    {"id":"70750","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (24 September 2025)","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T10:19:28Z","last_updated_date":"2025-10-22T10:19:28Z","reference_number":"EMA/310935/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-24-september-2025_en.pdf"},
    {"id":"70788","name":"Minutes of the COMP meeting 9-11 September 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T16:07:41Z","last_updated_date":"2025-10-23T16:07:41Z","reference_number":"EMA/COMP/312031/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-9-11-september-2025_en.xlsx"},
    {"id":"70819","name":"Minutes of the PRAC meeting 1-4 September 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-10-24T14:04:25Z","last_updated_date":"2025-10-24T14:04:25Z","reference_number":"EMA/PRAC/326133/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-1-4-september-2025_en.pdf"},
    {"id":"70944","name":"Highlights - European Medicines Agency (EMA) and European Association of Urology (EAU) bilateral meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-10-30T15:21:18Z","last_updated_date":"2025-11-14T11:20:31Z","reference_number":"EMA/342496/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-european-medicines-agency-ema-european-association-urology-eau-bilateral-meeting_en.pdf"},
    {"id":"70982","name":"Meeting Summary - Medicine Shortages (SPOC) Working Party 10 September 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-11-03T17:09:15Z","last_updated_date":"2025-11-03T17:09:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-10-september-2025_en.pdf"},
    {"id":"71009","name":"Minutes - PDCO minutes of the 9-12 September 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-11-05T14:04:19Z","last_updated_date":"2025-11-05T14:04:19Z","reference_number":"EMA/PDCO/309796/2025 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-9-12-september-2025-meeting_en.xlsx"},
    {"id":"71163","name":"Minutes of the CVMP meeting 7-9 October 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T10:09:52Z","last_updated_date":"2025-11-14T10:09:52Z","reference_number":"EMA/352482/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-7-9-october-2025_en.pdf"},
    {"id":"71273","name":"Minutes of the HMPC meeting 22-24 September 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-11-21T10:31:46Z","last_updated_date":"2025-11-21T10:31:46Z","reference_number":"EMA/HMPC/336824/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-22-24-september-2025_en.pdf"},
    {"id":"71275","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 20 October 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-11-21T10:56:39Z","last_updated_date":"2025-11-21T10:56:39Z","reference_number":"EMA/337800/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-20-october-2025_en.pdf"},
    {"id":"71276","name":"Minutes of the PRAC meeting 29 September - 2 October 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-11-21T11:00:13Z","last_updated_date":"2025-11-21T11:00:13Z","reference_number":"EMA/PRAC/352486/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-29-september-2-october-2025_en.pdf"},
    {"id":"71327","name":"Minutes of the COMP meeting 7-8 October 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T11:03:57Z","last_updated_date":"2025-11-25T11:03:57Z","reference_number":"EMA/COMP/337975/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-7-8-october-2025_en.xlsx"},
    {"id":"71337","name":"Minutes of the Cancer Medicines Forum - September 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T15:39:09Z","last_updated_date":"2025-11-25T15:39:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-september-2025_en.pdf"},
    {"id":"71340","name":"Minutes - DARWIN EU Advisory Board - 25 November 2024","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T10:20:25Z","last_updated_date":"2025-11-26T10:20:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-25-november-2024_en.pdf"},
    {"id":"71342","name":"Minutes - DARWIN EU Advisory Board - 20 January 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T10:23:56Z","last_updated_date":"2025-11-26T10:23:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-darwin-eu-advisory-board-20-january-2025_en.pdf"},
    {"id":"71387","name":"Summary notes - HMA-EMA group focused on AI with industry stakeholders kick-off meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T11:25:58Z","last_updated_date":"2025-11-28T11:25:58Z","reference_number":"EMA/366155/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/summary-notes-hma-ema-group-focused-ai-industry-stakeholders-kick-meeting_en.pdf"},
    {"id":"71392","name":"Minutes - PDCO minutes of the 14-17 October 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-11-28T14:32:18Z","last_updated_date":"2025-11-28T14:32:18Z","reference_number":"EMA/PDCO/345180/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-14-17-october-2025-meeting_en.xlsx"},
    {"id":"71403","name":"Meeting Summary - Medicine Shortages SPOC Working Party 14-15 October 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T15:14:49Z","last_updated_date":"2025-11-28T15:14:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-14-15-october-2025_en.pdf"},
    {"id":"71410","name":"Minutes - Management Board meeting: 2 October 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-12-01T10:34:10Z","last_updated_date":"2025-12-01T10:34:10Z","reference_number":"EMA/MB/313357/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-management-board-meeting-2-october-2025_en.pdf"},
    {"id":"71465","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 6 October 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-12-03T09:32:00Z","last_updated_date":"2025-12-03T09:32:00Z","reference_number":"EMA/323786/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-6-october-2025_en.pdf"},
    {"id":"71627","name":"Meeting summary - PCWP/HCPWP and all eligible organisations meeting 18 November 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T15:50:10Z","last_updated_date":"2025-12-09T15:50:10Z","reference_number":"EMA/364256/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-pcwp-hcpwp-all-eligible-organisations-meeting-18-november-2025_en.pdf"},
    {"id":"71646","name":"Minutes of the CAT meeting 10-12 September 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-12-10T14:43:46Z","last_updated_date":"2026-03-11T16:28:00Z","reference_number":"EMA/CAT/387156/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-10-12-september-2025_en.pdf"},
    {"id":"71647","name":"Minutes of the CAT meeting 8-9 October 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-12-10T14:47:06Z","last_updated_date":"2025-12-10T14:47:06Z","reference_number":"EMA/CAT/383728/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-8-9-october-2025_en.pdf"},
    {"id":"71747","name":"Minutes of the CVMP meeting 4-6 November 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T16:53:48Z","last_updated_date":"2025-12-12T16:53:48Z","reference_number":"EMA/380332/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-4-6-november-2025_en.pdf"},
    {"id":"71836","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 20 November 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2025-12-18T10:19:17Z","last_updated_date":"2025-12-18T10:19:17Z","reference_number":"EMA/367781/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-20-november-2025_en.pdf"},
    {"id":"71841","name":"Minutes of the PRAC meeting 27 - 30 October 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-12-18T12:16:18Z","last_updated_date":"2025-12-18T12:16:18Z","reference_number":"EMA/PRAC/375420/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-27-30-october-2025_en.pdf"},
    {"id":"71908","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 6 November 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2025-12-22T11:43:05Z","last_updated_date":"2025-12-22T11:43:05Z","reference_number":"EMA/323786/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-6-november-2025_en.pdf"},
    {"id":"71945","name":"\tMeeting summary - Medicine Shortages (SPOC) Working Party meeting on 11 November 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T11:50:12Z","last_updated_date":"2026-01-06T11:50:12Z","reference_number":"EMA/377966/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-11-november-2025_en.pdf"},
    {"id":"72068","name":"Minutes of the COMP meeting 4-6 November 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T14:51:59Z","last_updated_date":"2026-01-15T14:51:59Z","reference_number":"EMA/COMP/369218/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-4-6-november-2025_en.xlsx"},
    {"id":"72077","name":"Minutes - PDCO minutes of the 11-14 November 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-01-15T16:42:09Z","last_updated_date":"2026-01-15T16:42:09Z","reference_number":"EMA/PDCO/371360/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pdco-minutes-11-14-november-2025-meeting_en.xlsx"},
    {"id":"72081","name":"Minutes - Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP) (2023)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:15:52Z","last_updated_date":"2026-01-16T09:15:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-meeting-ctti-fda-patient-engagement-collaborative-pec-ema-patients-consumers-working-party-pcwp-2023_en.pdf"},
    {"id":"72085","name":"\tMinutes - Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP) (2024)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:21:58Z","last_updated_date":"2026-01-16T09:21:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-meeting-ctti-fda-patient-engagement-collaborative-pec-ema-patients-consumers-working-party-pcwp-2024_en.pdf"},
    {"id":"72090","name":"\tMinutes - Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP) (2025)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:28:07Z","last_updated_date":"2026-01-16T09:28:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-meeting-ctti-fda-patient-engagement-collaborative-pec-ema-patients-consumers-working-party-pcwp-2025_en.pdf"},
    {"id":"72153","name":"Highlights - Fourth European Medicines Agency (EMA) and European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) bilateral meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T11:07:36Z","last_updated_date":"2026-01-20T11:07:36Z","reference_number":"EMA/387096/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-fourth-european-medicines-agency-ema-european-confederation-pharmaceutical-entrepreneurs-eucope-bilateral-meeting_en.pdf"},
    {"id":"72283","name":"Minutes of the CAT meeting 5-7 November 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-01-27T11:32:44Z","last_updated_date":"2026-03-11T16:30:00Z","reference_number":"EMA/CAT/7940/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-5-7-november-2025_en.pdf"},
    {"id":"72336","name":"Minutes of the HMPC meeting 17-19 November 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-01-28T16:28:03Z","last_updated_date":"2026-01-28T16:28:03Z","reference_number":"EMA/HMPC/377649/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-17-19-november-2025_en.pdf"},
    {"id":"72338","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 8 December 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-01-28T16:54:44Z","last_updated_date":"2026-01-28T16:54:44Z","reference_number":"EMA/323786/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-8-december-2025_en.pdf"},
    {"id":"72382","name":"Highlights of the meeting on the impact of chemical and environmental policies on the healthcare sector and availability of medicines","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T12:08:26Z","last_updated_date":"2026-01-30T12:08:26Z","reference_number":"EMA/14601/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-meeting-impact-chemical-environmental-policies-healthcare-sector-availability-medicines_en.pdf"},
    {"id":"72400","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 17 December 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-02-02T14:44:18Z","last_updated_date":"2026-02-02T14:44:18Z","reference_number":"EMA/397090/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-17-december-2025_en.pdf"},
    {"id":"72429","name":"Minutes of the CAT meeting 3-5 December 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-05T14:44:53Z","last_updated_date":"2026-03-11T16:31:00Z","reference_number":"EMA/CAT/29045/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-3-5-december-2025_en.pdf"},
    {"id":"72451","name":"Highlights – 1st European Medicine Agency (EMA) and European Respiratory Society (ERS) bilateral meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-02-06T16:08:00Z","last_updated_date":"2026-02-06T16:08:00Z","reference_number":"EMA/15211/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-1st-european-medicine-agency-ema-european-respiratory-society-ers-bilateral-meeting_en.pdf"},
    {"id":"72460","name":"Minutes of the COMP meeting 2-3 December 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-09T17:07:06Z","last_updated_date":"2026-02-09T17:07:06Z","reference_number":"EMA/COMP/393493/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-2-3-december-2025_en.xlsx"},
    {"id":"72488","name":"Minutes of the CHMP meeting 16-19 June 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T14:19:38Z","last_updated_date":"2026-02-10T14:19:38Z","reference_number":"EMA/CHMP/221169/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-16-19-june-2025_en.pdf"},
    {"id":"72489","name":"Annex to 16-19 June 2025 CHMP Minutes","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T14:20:54Z","last_updated_date":"2026-02-10T14:20:54Z","reference_number":"EMA/CHMP/210151/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/annex-16-19-june-2025-chmp-minutes_en.xlsx"},
    {"id":"72516","name":"Minutes - 2025 annual internal meeting of the members and Coordinating Group of the European network of paediatric research at the EMA (EnprEMA)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-02-11T16:49:05Z","last_updated_date":"2026-02-11T16:49:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-2025-annual-internal-meeting-members-coordinating-group-european-network-paediatric-research-ema-enprema_en.pdf"}    {"id":"72518","name":"Minutes of the CHMP meeting 21-24 July 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-11T17:22:35Z","last_updated_date":"2026-02-16T17:23:11Z","reference_number":"EMA/CHMP/319030/2025 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-21-24-july-2025_en.pdf"},
    {"id":"72519","name":"Annex to 21-24 July 2025 CHMP Minutes","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-11T17:22:37Z","last_updated_date":"2026-02-11T17:22:37Z","reference_number":"EMA/CHMP/247275/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/annex-21-24-july-2025-chmp-minutes_en.xlsx"},
    {"id":"72525","name":"Minutes of the PRAC meeting 24 - 27 November 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-12T11:00:00Z","last_updated_date":"2026-02-12T11:00:00Z","reference_number":"EMA/PRAC/21905/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-24-27-november-2025_en.pdf"},
    {"id":"72565","name":"PDCO minutes of the 9-12 December 2025 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-16T10:30:17Z","last_updated_date":"2026-02-16T10:30:17Z","reference_number":"EMA/PDCO/6360/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-9-12-december-2025-meeting_en.xlsx"},
    {"id":"72566","name":"Minutes -  HMA-EMA joint Network Data Steering Group meeting - 13 January 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-16T10:35:22Z","last_updated_date":"2026-02-16T10:35:22Z","reference_number":"EMA/8958/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-13-january-2026_en.pdf"},
    {"id":"72636","name":"Minutes of the CVMP meeting 2-4 December 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-20T16:10:05Z","last_updated_date":"2026-02-20T16:10:05Z","reference_number":"EMA/34873/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-2-4-december-2025_en.pdf"},
    {"id":"72637","name":"Minutes of the CVMP meeting 13-15 January 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-20T16:13:15Z","last_updated_date":"2026-02-20T16:13:15Z","reference_number":"EMA/33615/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-13-15-january-2026_en.pdf"},
    {"id":"72683","name":"Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 30 January 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-25T09:06:25Z","last_updated_date":"2026-02-25T09:06:25Z","reference_number":"EMA/27137/20266","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-30-january-2026_en.pdf"},
    {"id":"72684","name":"Minutes of the Cancer Medicines Forum - December 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-02-25T10:42:16Z","last_updated_date":"2026-02-25T10:42:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-december-2025_en.pdf"},
    {"id":"72723","name":"Minutes of the Management Board meeting: 17-18 December 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-02-26T16:15:15Z","last_updated_date":"2026-02-26T16:15:15Z","reference_number":"EMA/MB/389167/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-management-board-meeting-17-18-december-2025_en.pdf"},
    {"id":"72758","name":"Summary notes - Meeting of the HMA-EMA group focused on AI with industry stakeholders - February 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-02-27T15:44:33Z","last_updated_date":"2026-02-27T15:44:33Z","reference_number":"EMA/40804/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/summary-notes-meeting-hma-ema-group-focused-ai-industry-stakeholders-february-2026_en.pdf"},
    {"id":"72760","name":"Minutes - PCWP and HCPWP joint meeting February 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-03-02T09:51:57Z","last_updated_date":"2026-03-02T09:51:57Z","reference_number":"EMA/025717/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-pcwp-hcpwp-joint-meeting-february-2026_en.pdf"},
    {"id":"72765","name":"Minutes - Healthcare Professionals' Working Party (HCPWP) plenary meeting - 3 February 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-03-02T10:04:49Z","last_updated_date":"2026-03-02T10:04:49Z","reference_number":"EMA/025717/2026 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-healthcare-professionals-working-party-hcpwp-plenary-meeting-3-february-2026_en.pdf"},
    {"id":"72806","name":"Meeting Summary - Medicine Shortages SPOC Working Party meeting 20 January 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-03-03T16:15:21Z","last_updated_date":"2026-03-03T16:15:21Z","reference_number":"EMA/38413/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-20-january-2026_en.pdf"},
    {"id":"72812","name":"Minutes of the CAT meeting 21-23 January 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-03-04T09:20:00Z","last_updated_date":"2026-03-11T16:31:00Z","reference_number":"EMA/CAT/48944/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-21-23-january-2026_en.pdf"},
    {"id":"72882","name":"Minutes of the HMPC meeting 19-21 January 2026","type":"minutes","status":"Draft","consultation_date":"","first_published_date":"2026-03-06T15:25:25Z","last_updated_date":"2026-03-06T15:25:25Z","reference_number":"EMA/HMPC/33287/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-19-21-january-2026_en.pdf"},
    {"id":"72949","name":"Minutes of the PRAC meeting 12 - 15 January 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T15:11:40Z","last_updated_date":"2026-03-11T15:11:40Z","reference_number":"EMA/PRAC/46601/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-12-15-january-2026_en.pdf"},
    {"id":"72955","name":"Minutes of the COMP meeting 20-22 January 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T16:50:34Z","last_updated_date":"2026-03-11T16:50:34Z","reference_number":"EMA/COMP/28033/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-20-22-january-2026_en.xlsx"},
    {"id":"72996","name":"Minutes - HMA-EMA joint Network Data Steering Group meeting - 11 February 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-03-13T09:29:29Z","last_updated_date":"2026-03-13T09:29:29Z","reference_number":"EMA/37722/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-11-february-2026_en.pdf"},
    {"id":"73022","name":"Meeting summary -  EMA - Alzheimer Europe (AE) bilateral meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-03-16T09:54:05Z","last_updated_date":"2026-03-16T09:54:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-ema-alzheimer-europe-ae-bilateral-meeting_en.pdf"},
    {"id":"73046","name":"PDCO minutes of the 27-30 January 2026 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-03-16T14:31:50Z","last_updated_date":"2026-03-16T14:31:50Z","reference_number":"EMA/PDCO/32217/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-27-30-january-2026-meeting_en.xlsx"},
    {"id":"73172","name":"Minutes – Ad hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 5 March 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T15:27:21Z","last_updated_date":"2026-03-24T15:27:21Z","reference_number":"EMA/54093/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-ad-hoc-executive-steering-group-shortages-safety-medicinal-products-mssg-5-march-2026_en.pdf"},
    {"id":"73181","name":"Minutes of the CAT meeting 18-20 February 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T16:38:25Z","last_updated_date":"2026-03-24T16:38:25Z","reference_number":"EMA/CAT/70533/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-20-february-2026_en.pdf"},
    {"id":"73288","name":"Minutes - Medicine Shortages SPOC Working Party meeting 17 February 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T09:08:29Z","last_updated_date":"2026-04-01T09:08:29Z","reference_number":"EMA/55346/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-medicine-shortages-spoc-working-party-meeting-17-february-2026_en.pdf"},
    {"id":"73309","name":"Minutes of the COMP meeting 17-19 February 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-04-01T16:46:24Z","last_updated_date":"2026-04-01T16:46:24Z","reference_number":"EMA/COMP/50319/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-17-19-february-2026_en.xlsx"},
    {"id":"73320","name":"Highlights - EMA - European Alliance of Associations for Rheumatology (EULAR) bilateral meeting - March 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T13:16:36Z","last_updated_date":"2026-04-07T13:16:36Z","reference_number":"EMA/73196/2026 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-ema-european-alliance-associations-rheumatology-eular-bilateral-meeting-march-2026_en.pdf"},
    {"id":"73324","name":"CHMP PROM minutes for the meeting on 12 May 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-04-07T13:48:16Z","last_updated_date":"2026-04-08T09:30:00Z","reference_number":"EMA/CHMP/158851/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-12-may-2025_en.pdf"},
    {"id":"73325","name":"CHMP PROM minutes for the meeting on 10 June 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-04-07T13:49:11Z","last_updated_date":"2026-04-08T09:30:00Z","reference_number":"EMA/CHMP/196245/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-10-june-2025_en.pdf"},
    {"id":"73326","name":"CHMP PROM minutes for the meeting on 14 July 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-04-07T13:57:31Z","last_updated_date":"2026-04-08T09:30:00Z","reference_number":"EMA/CHMP/230038/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-14-july-2025_en.pdf"},
    {"id":"73327","name":"CHMP PROM minutes for the meeting on 8 September 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-04-07T14:00:21Z","last_updated_date":"2026-04-08T09:30:00Z","reference_number":"EMA/CHMP/266703/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-8-september-2025_en.pdf"},
    {"id":"73328","name":"CHMP PROM minutes for the meeting on 6 October 2025","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-04-07T14:02:37Z","last_updated_date":"2026-04-08T09:30:00Z","reference_number":"EMA/CHMP/323082/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-6-october-2025_en.pdf"},
    {"id":"73334","name":"Minutes of PRAC meeting on 9-12 February 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T14:35:41Z","last_updated_date":"2026-04-07T14:35:41Z","reference_number":"EMA/PRAC/59896/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-february-2026_en.pdf"},
    {"id":"73422","name":"PDCO minutes of the 24-27 February 2026 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-04-13T09:47:31Z","last_updated_date":"2026-04-13T09:47:31Z","reference_number":"EMA/PDCO/57380/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-24-27-february-2026-meeting_en.xlsx"},
    {"id":"73478","name":"Minutes - HMA-EMA joint Network Data Steering Group meeting - 9 March 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-04-16T16:40:46Z","last_updated_date":"2026-04-16T16:40:46Z","reference_number":"EMA/61118/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-9-march-2026_en.pdf"},
    {"id":"73573","name":"Minutes of the CVMP meeting 10-12 February 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T15:41:48Z","last_updated_date":"2026-04-24T15:41:48Z","reference_number":"EMA/CVMP/32668/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-12-february-2026_en.pdf"},
    {"id":"73574","name":"Minutes - Executive steering group on shortages and safety of medicinal products (MSSG) - 23 March 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-04-24T16:18:35Z","last_updated_date":"2026-04-24T16:18:35Z","reference_number":"EMA/71929/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-23-march-2026_en.pdf"},
    {"id":"73588","name":"Highlights - EMA and European Association of Nuclear Medicine (EANM) bilateral meeting","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-04-30T11:36:37Z","last_updated_date":"2026-04-30T11:36:37Z","reference_number":"EMA/92825/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/highlights-ema-european-association-nuclear-medicine-eanm-bilateral-meeting_en.pdf"},
    {"id":"73592","name":"Summary - European Medicines Agency meeting with senior representatives of pharmaceutical companies","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-04-30T15:27:20Z","last_updated_date":"2026-04-30T15:27:20Z","reference_number":"EMA/93685/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/summary-european-medicines-agency-meeting-senior-representatives-pharmaceutical-companies_en.pdf"},
    {"id":"73599","name":"CHMP PROM minutes for the meeting on 3 November 2025","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-04-30T17:28:12Z","last_updated_date":"2026-04-30T17:28:12Z","reference_number":"EMA/CHMP/348962/2025","document_url":"https://www.ema.europa.eu/en/documents/minutes/chmp-prom-minutes-meeting-3-november-2025_en.pdf"},
    {"id":"73608","name":"Minutes - Executive Steering Group on Shortages of Medical Devices (MDSSG) (23 March 2026)","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-05-04T17:06:53Z","last_updated_date":"2026-05-04T17:06:53Z","reference_number":"EMA/77340/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-medical-devices-mdssg-23-march-2026_en.pdf"},
    {"id":"73609","name":"Minutes of the Management Board meeting: 12 March 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-05-04T17:14:43Z","last_updated_date":"2026-05-04T17:14:43Z","reference_number":"EMA/MB/57340/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-management-board-meeting-12-march-2026_en.pdf"},
    {"id":"73611","name":"Meeting summary - Medicine Shortages SPOC Working Party meeting 16-17 March 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-05-04T17:31:02Z","last_updated_date":"2026-05-04T17:31:02Z","reference_number":"EMA/77606/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/meeting-summary-medicine-shortages-spoc-working-party-meeting-16-17-march-2026_en.pdf"},
    {"id":"73625","name":"Minutes of the COMP meeting 17-18 March 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-05-05T16:14:08Z","last_updated_date":"2026-05-05T16:14:08Z","reference_number":"EMA/COMP/76108/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-17-18-march-2026_en.xlsx"},
    {"id":"73626","name":"Minutes of the CAT meeting 18-20 March 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-05-05T16:19:09Z","last_updated_date":"2026-05-05T16:19:09Z","reference_number":"EMA/CAT/96509/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-18-20-march-2026_en.pdf"},
    {"id":"73636","name":"Minutes of PRAC meeting on 9-12 March 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-05-06T17:08:03Z","last_updated_date":"2026-05-06T17:08:03Z","reference_number":"EMA/PRAC/91330/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-march-2026_en.pdf"},
    {"id":"73686","name":"PDCO minutes of the 24-27 March 2026 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-05-08T16:34:33Z","last_updated_date":"2026-05-08T16:34:33Z","reference_number":"EMA/PDCO/82444/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-24-27-march-2026-meeting_en.xlsx"},
    {"id":"73700","name":"Minutes of the HMPC meeting 2-4 March 2026","type":"minutes","status":"Draft","consultation_date":"","first_published_date":"2026-05-11T12:10:53Z","last_updated_date":"2026-05-11T12:10:53Z","reference_number":"EMA/HMPC/62790/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hmpc-meeting-2-4-march-2026_en.pdf"},
    {"id":"73829","name":"Minutes – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) 24 April 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T11:48:10Z","last_updated_date":"2026-05-22T11:48:10Z","reference_number":"EMA/95527/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-executive-steering-group-shortages-safety-medicinal-products-mssg-24-april-2026_en.pdf"},
    {"id":"73908","name":"Minutes of the COMP meeting 14-16 April 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-05-29T13:42:44Z","last_updated_date":"2026-05-29T13:42:44Z","reference_number":"EMA/COMP/96186/2026\t","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-comp-meeting-14-16-april-2026_en.xlsx"},
    {"id":"73914","name":"Minutes - HMA-EMA joint Network Data Steering Group meeting - 15 April 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-06-01T10:18:06Z","last_updated_date":"2026-06-01T10:18:06Z","reference_number":"EMA/88790/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-15-april-2026_en.pdf"},
    {"id":"73965","name":"PDCO minutes of the 21-24 April 2026 meeting","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-06-03T17:31:38Z","last_updated_date":"2026-06-03T17:31:38Z","reference_number":"EMA/PDCO/106454/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/pdco-minutes-21-24-april-2026-meeting_en.xlsx"},
    {"id":"73996","name":"Minutes of PRAC meeting on 7-10 April 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-06-08T09:03:28Z","last_updated_date":"2026-06-08T09:03:28Z","reference_number":"EMA/PRAC/117688/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-april-2026_en.pdf"},
    {"id":"74040","name":"Minutes - Cancer Medicines Forum: March 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-06-10T11:30:37Z","last_updated_date":"2026-06-10T11:30:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cancer-medicines-forum-march-2026_en.pdf"},
    {"id":"74041","name":"Minutes of the CAT meeting 15-17 April 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-06-10T11:57:22Z","last_updated_date":"2026-06-10T11:57:22Z","reference_number":"EMA/CAT/128640/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cat-meeting-15-17-april-2026_en.pdf"},
    {"id":"74094","name":"Minutes of the CVMP meeting 10-12 March 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-06-15T11:56:34Z","last_updated_date":"2026-06-15T11:56:34Z","reference_number":"EMA/127395/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-cvmp-meeting-10-12-march-2026_en.pdf"},
    {"id":"74126","name":"Minutes - Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - May 2026","type":"minutes","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T17:01:18Z","last_updated_date":"2026-06-16T17:01:18Z","reference_number":"EMA/139091/2026","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-meeting-executive-steering-group-shortages-safety-medicinal-products-mssg-may-2026_en.pdf"},
    {"id":"74180","name":"Minutes - HMA-EMA joint Network Data Steering Group meeting - 21 May 2026","type":"minutes","status":"Adopted","consultation_date":"","first_published_date":"2026-06-22T16:24:20Z","last_updated_date":"2026-06-22T16:24:20Z","reference_number":"EMA/127390/2026 ","document_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-hma-ema-joint-network-data-steering-group-meeting-21-may-2026_en.pdf"},
    {"id":"2630","name":"News bulletin for small and medium-sized enterprises - Issue 22","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-12-17T09:43:00Z","last_updated_date":"2012-12-17T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-22_en.pdf"},
    {"id":"3006","name":"What's new in pharmacovigilance - QPPV Update - Issue 3 - 2017","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2017-12-21T12:00:00Z","last_updated_date":"2017-12-21T12:00:00Z","reference_number":"Issue 3 - 2017","document_url":"https://www.ema.europa.eu/en/documents/newsletter/whats-new-pharmacovigilance-qppv-update-issue-3-2017_en.pdf"},
    {"id":"3056","name":"Human medicines highlights - September 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-10-07T16:30:00Z","last_updated_date":"2014-10-07T16:30:00Z","reference_number":"Issue 67","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2014_en.pdf"},
    {"id":"3136","name":"News bulletin for small and medium-sized enterprises - Issue 32","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-07-30T10:40:00Z","last_updated_date":"2015-07-30T10:40:00Z","reference_number":"Issue 32","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-32_en.pdf"},
    {"id":"3371","name":"Human medicines highlights - January 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-02-06T12:10:00Z","last_updated_date":"2015-02-06T12:10:00Z","reference_number":"Issue 71","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-january-2015_en.pdf"},
    {"id":"3802","name":"Public bulletin: Veterinary pharmacovigilance 2016","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T15:30:00Z","last_updated_date":"2017-02-24T15:30:00Z","reference_number":"EMA/568976/2016","document_url":"https://www.ema.europa.eu/en/documents/newsletter/public-bulletin-veterinary-pharmacovigilance-2016_en.pdf"},
    {"id":"4597","name":"Human medicines highlights - April 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-05-07T13:40:00Z","last_updated_date":"2013-05-07T13:40:00Z","reference_number":"Issue 51","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-april-2013_en.pdf"},
    {"id":"5010","name":"News bulletin for small and medium-sized enterprises - Issue 7","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2009-04-01T02:00:00Z","last_updated_date":"2009-04-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-7_en.pdf"},
    {"id":"5172","name":"Human medicines highlights - August 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-09-05T13:10:00Z","last_updated_date":"2014-09-05T13:10:00Z","reference_number":"Issue 66","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-august-2014_en.pdf"},
    {"id":"5247","name":"News bulletin for small and medium-sized enterprises - Issue 27","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-03-31T13:10:00Z","last_updated_date":"2014-03-31T13:10:00Z","reference_number":"Issue 27","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-27_en.pdf"},
    {"id":"5309","name":"Human medicines highlights - May 2012","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-06-01T17:10:00Z","last_updated_date":"2012-06-01T17:10:00Z","reference_number":"Issue 40","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-may-2012_en.pdf"},
    {"id":"5320","name":"News bulletin for small and medium-sized enterprises - Issue 2","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2007-09-01T02:00:00Z","last_updated_date":"2007-09-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-2_en.pdf"},
    {"id":"5410","name":"Human medicines highlights - December 2012","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T12:59:00Z","last_updated_date":"2013-01-11T12:59:00Z","reference_number":"Issue 47","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-december-2012_en.pdf"},
    {"id":"5571","name":"European network of paediatric research at the European Medicines Agency newsletter: January 2016","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T17:00:00Z","last_updated_date":"2016-03-14T17:00:00Z","reference_number":"EMA/61510/2016 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/newsletter/european-network-paediatric-research-european-medicines-agency-newsletter-january-2016_en.pdf"},
    {"id":"6185","name":"What’s new in pharmacovigilance - QPPV Update - Issue 1 - 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-07-31T13:30:00Z","last_updated_date":"2018-07-31T13:30:00Z","reference_number":"Issue 1","document_url":"https://www.ema.europa.eu/en/documents/newsletter/whats-new-pharmacovigilance-qppv-update-issue-1-2018_en.pdf"},
    {"id":"6692","name":"What's new in pharmacovigilance - QPPV Update - Issue 2 - 2017","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2017-08-09T15:55:00Z","last_updated_date":"2017-08-09T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/whats-new-pharmacovigilance-qppv-update-issue-2-2017_en.pdf"},
    {"id":"7046","name":"News bulletin for small and medium-sized enterprises - Issue 25","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-10-08T16:58:00Z","last_updated_date":"2013-10-08T16:58:00Z","reference_number":"Issue 25","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-25_en.pdf"},
    {"id":"7259","name":"European network of paediatric research at the European Medicines Agency newsletter: December 2016","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T17:00:00Z","last_updated_date":"2017-01-04T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/european-network-paediatric-research-european-medicines-agency-newsletter-december-2016_en.pdf"},
    {"id":"7624","name":"News bulletin for small and medium-sized enterprises - Issue 39","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T11:20:00Z","last_updated_date":"2017-05-16T11:20:00Z","reference_number":"Issue 39","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-39_en.pdf"},
    {"id":"7910","name":"News bulletin for small and medium-sized enterprises - Issue 42","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-02-06T13:30:00Z","last_updated_date":"2018-02-06T13:30:00Z","reference_number":"Issue 42","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-42_en.pdf"},
    {"id":"8067","name":"News bulletin for small and medium-sized enterprises - Issue 14","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T02:00:00Z","last_updated_date":"2010-12-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-14_en.pdf"},
    {"id":"8212","name":"News bulletin for small and medium-sized enterprises - Issue 41","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2017-11-07T14:47:00Z","last_updated_date":"2017-11-07T14:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-41_en.pdf"},
    {"id":"8240","name":"Human medicines highlights - March 2012","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-04-04T13:45:00Z","last_updated_date":"2012-04-04T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-march-2012_en.pdf"},
    {"id":"8925","name":"News bulletin for pharmacovigilance programme update - Issue 6","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-12-21T15:45:00Z","last_updated_date":"2015-12-21T15:45:00Z","reference_number":"Issue 6","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-pharmacovigilance-programme-update-issue-6_en.pdf"},
    {"id":"9388","name":"What's new in pharmacovigilance - QPPV Update - Issue 3","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2016-12-22T12:30:00Z","last_updated_date":"2016-12-22T12:30:00Z","reference_number":"Issue 3","document_url":"https://www.ema.europa.eu/en/documents/newsletter/whats-new-pharmacovigilance-qppv-update-issue-3_en.pdf"},
    {"id":"9589","name":"News bulletin for small and medium-sized enterprises - Issue 1","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2007-05-01T02:00:00Z","last_updated_date":"2007-05-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-1_en.pdf"},
    {"id":"9599","name":"News bulletin for small and medium-sized enterprises - Issue 16","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2011-06-30T02:00:00Z","last_updated_date":"2011-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-16_en.pdf"},
    {"id":"9898","name":"News bulletin for small and medium-sized enterprises - Issue 34","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T17:00:00Z","last_updated_date":"2016-01-25T17:00:00Z","reference_number":"Issue 34","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-34_en.pdf"},
    {"id":"10066","name":"Human medicines highlights - April 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T17:30:00Z","last_updated_date":"2014-05-08T17:30:00Z","reference_number":"Issue 61","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-april-2014_en.pdf"},
    {"id":"10766","name":"Human medicines highlights - February 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-03-06T15:30:00Z","last_updated_date":"2015-03-06T15:30:00Z","reference_number":"Issue 72","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-february-2015_en.pdf"},
    {"id":"10948","name":"News bulletin for small and medium-sized enterprises - Issue 44","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-08-09T19:00:00Z","last_updated_date":"2018-08-09T19:00:00Z","reference_number":"Issue 44","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-44_en.pdf"},
    {"id":"11134","name":"News bulletin for small and medium-sized enterprises - Issue 43","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-05-14T16:27:00Z","last_updated_date":"2018-05-14T16:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-43_en.pdf"},
    {"id":"11180","name":"News bulletin for pharmacovigilance programme update - Issue 2","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T17:40:00Z","last_updated_date":"2014-12-11T17:40:00Z","reference_number":"Issue 2","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-pharmacovigilance-programme-update-issue-2_en.pdf"},
    {"id":"12191","name":"News bulletin for small and medium-sized enterprises - Issue 12","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-12_en.pdf"},
    {"id":"12324","name":"News bulletin for small and medium-sized enterprises - Issue 4","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2008-06-01T02:00:00Z","last_updated_date":"2008-06-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-4_en.pdf"},
    {"id":"12546","name":"News bulletin for small and medium-sized enterprises - Issue 38","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T16:38:00Z","last_updated_date":"2017-02-02T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-38_en.pdf"},
    {"id":"12631","name":"News bulletin for small and medium-sized enterprises - Issue 11","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2010-03-29T02:00:00Z","last_updated_date":"2010-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-11_en.pdf"},
    {"id":"12836","name":"News bulletin for small and medium-sized enterprises - Issue 15","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2011-03-21T01:00:00Z","last_updated_date":"2011-03-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-15_en.pdf"},
    {"id":"13128","name":"News bulletin for small and medium-sized enterprises - Issue 8","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2008-06-01T02:00:00Z","last_updated_date":"2008-06-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-8_en.pdf"},
    {"id":"13378","name":"News bulletin for small and medium-sized enterprises - Issue 6","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2008-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-6_en.pdf"},
    {"id":"13615","name":"Human medicines highlights - February 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-03-07T18:00:00Z","last_updated_date":"2013-03-07T18:00:00Z","reference_number":"Issue 49","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-february-2013_en.pdf"},
    {"id":"13764","name":"News bulletin for small and medium-sized enterprises - Issue 33","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-10-20T17:37:00Z","last_updated_date":"2015-10-20T17:37:00Z","reference_number":"Issue 33","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-33_en.pdf"},
    {"id":"13835","name":"Human medicines highlights - October 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T12:00:00Z","last_updated_date":"2013-11-12T12:00:00Z","reference_number":"Issue 56","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-october-2013_en.pdf"}    {"id":"14339","name":"News bulletin for small and medium-sized enterprises - Issue 30","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-01-28T16:25:00Z","last_updated_date":"2015-01-28T16:25:00Z","reference_number":"Issue 30","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-30_en.pdf"},
    {"id":"14508","name":"Human medicines highlights - September 2011","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T15:33:00Z","last_updated_date":"2011-10-06T15:33:00Z","reference_number":"Issue 32","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2011_en.pdf"},
    {"id":"16095","name":"News bulletin for pharmacovigilance programme update - Issue 3","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-03-31T14:40:00Z","last_updated_date":"2015-03-31T14:40:00Z","reference_number":"Issue 3","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-pharmacovigilance-programme-update-issue-3_en.pdf"},
    {"id":"16196","name":"News bulletin for small and medium-sized enterprises - Issue 17","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2011-09-19T02:00:00Z","last_updated_date":"2011-09-19T17:50:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-17_en.pdf"},
    {"id":"16604","name":"Human medicines highlights - June 2012","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-07-03T18:00:15Z","last_updated_date":"2012-07-03T18:00:15Z","reference_number":"Issue 41","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-june-2012_en.pdf"},
    {"id":"16807","name":"News bulletin for small and medium-sized enterprises - Issue 20","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-07-11T16:05:00Z","last_updated_date":"2012-07-11T16:05:00Z","reference_number":"Issue 20","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-20_en.pdf"},
    {"id":"16822","name":"Human medicines highlights - November 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-12-10T15:40:00Z","last_updated_date":"2015-12-10T15:40:00Z","reference_number":"Issue 81","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-2015_en.pdf"},
    {"id":"17334","name":"Human medicines highlights - May 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-06-05T17:00:00Z","last_updated_date":"2015-06-05T17:00:00Z","reference_number":"Issue 75","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-may-2015_en.pdf"},
    {"id":"17966","name":"Human medicines highlights - December 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2016-01-15T15:10:00Z","last_updated_date":"2016-01-15T15:10:00Z","reference_number":"Issue 82","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-december-2015_en.pdf"},
    {"id":"18027","name":"What's new in pharmacovigilance - QPPV Update - Issue 1 - 2017","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2017-04-11T19:30:00Z","last_updated_date":"2017-04-11T19:30:00Z","reference_number":"Issue 1 - 2017","document_url":"https://www.ema.europa.eu/en/documents/newsletter/whats-new-pharmacovigilance-qppv-update-issue-1-2017_en.pdf"},
    {"id":"18995","name":"News bulletin for small and medium-sized enterprises - Issue 21","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-09-13T15:27:00Z","last_updated_date":"2012-09-13T15:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-21_en.pdf"},
    {"id":"19348","name":"European network of paediatric research-European Medicines Agency newsletter December 2012","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T16:00:00Z","last_updated_date":"2014-03-21T16:00:00Z","reference_number":"EMA/805975/2012","document_url":"https://www.ema.europa.eu/en/documents/newsletter/european-network-paediatric-research-european-medicines-agency-newsletter-december-2012_en.pdf"},
    {"id":"21166","name":"What's new in pharmacovigilance - QPPV Update - Issue 1","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T15:37:00Z","last_updated_date":"2016-04-29T15:37:00Z","reference_number":"Issue 1","document_url":"https://www.ema.europa.eu/en/documents/newsletter/whats-new-pharmacovigilance-qppv-update-issue-1_en.pdf"},
    {"id":"22083","name":"Human medicines highlights - November 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-12-05T17:45:00Z","last_updated_date":"2013-12-05T17:45:00Z","reference_number":"Issue 57","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-2013_en.pdf"},
    {"id":"22151","name":"News bulletin for small and medium-sized enterprises - Issue 5","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2008-09-01T02:00:00Z","last_updated_date":"2008-09-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-5_en.pdf"},
    {"id":"22449","name":"Human medicines highlights - June 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-07-09T18:10:00Z","last_updated_date":"2013-07-09T18:10:00Z","reference_number":"Issue 53","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-june-2013_en.pdf"},
    {"id":"22454","name":"News bulletin for small and medium-sized enterprises - Issue 37","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T16:10:00Z","last_updated_date":"2016-10-27T16:10:00Z","reference_number":"Issue 37","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-37_en.pdf"},
    {"id":"23159","name":"Human medicines highlights - July 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-08-06T12:00:00Z","last_updated_date":"2013-08-06T12:00:00Z","reference_number":"Issue 54","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-july-2013_en.pdf"},
    {"id":"23175","name":"Human medicines highlights - September 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-10-15T16:26:00Z","last_updated_date":"2015-10-15T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2015_en.pdf"},
    {"id":"23414","name":"Human medicines highlights - June 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T17:55:00Z","last_updated_date":"2014-07-08T17:55:00Z","reference_number":"Issue 64","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-june-2014_en.pdf"},
    {"id":"24158","name":"Human medicines highlights - October 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-11-06T12:00:00Z","last_updated_date":"2014-11-06T12:00:00Z","reference_number":"Issue 68","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-october-2014_en.pdf"},
    {"id":"24409","name":"Human medicines highlights - August 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-08-06T18:38:00Z","last_updated_date":"2018-08-06T18:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-august-2018_en.pdf"},
    {"id":"24763","name":"Human medicines highlights - November 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T12:45:00Z","last_updated_date":"2014-12-12T12:45:00Z","reference_number":"Issue 69","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-2014_en.pdf"},
    {"id":"24863","name":"News bulletin for pharmacovigilance programme update - Issue 1","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-08-06T12:35:00Z","last_updated_date":"2014-08-06T12:35:00Z","reference_number":"Issue 1","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-pharmacovigilance-programme-update-issue-1_en.pdf"},
    {"id":"24958","name":"News bulletin for small and medium-sized enterprises - Issue 9","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2000-10-19T02:00:00Z","last_updated_date":"2000-10-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-9_en.pdf"},
    {"id":"25305","name":"Human medicines highlights - November 2012","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-12-05T11:15:00Z","last_updated_date":"2012-12-05T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-2012_en.pdf"},
    {"id":"25473","name":"Human medicines highlights - August 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-09-08T16:50:00Z","last_updated_date":"2015-09-08T16:50:00Z","reference_number":"Issue 78","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-august-2015_en.pdf"},
    {"id":"25714","name":"Public bulletin: Veterinary pharmacovigilance 2017","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-03-22T16:15:00Z","last_updated_date":"2018-03-22T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/public-bulletin-veterinary-pharmacovigilance-2017_en.pdf"},
    {"id":"26052","name":"News bulletin for small and medium-sized enterprises - Issue 24","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-07-08T11:40:00Z","last_updated_date":"2013-07-08T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-24_en.pdf"},
    {"id":"26505","name":"Human medicines highlights - June 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T17:35:00Z","last_updated_date":"2018-06-19T17:35:00Z","reference_number":"Issue 111","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-june-2018_en.pdf"},
    {"id":"27009","name":"News bulletin for small and medium-sized enterprises - Issue 36","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2016-08-03T18:05:00Z","last_updated_date":"2016-08-03T18:05:00Z","reference_number":"Issue 36","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-36_en.pdf"},
    {"id":"27057","name":"Human medicines highlights - January 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-01-05T13:15:00Z","last_updated_date":"2018-01-05T13:15:00Z","reference_number":"Issue 106","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-january-2018_en.pdf"},
    {"id":"27218","name":"News bulletin for pharmacovigilance programme update - Issue 4","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-07-03T11:00:00Z","last_updated_date":"2015-07-03T11:00:00Z","reference_number":"Issue 4","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-pharmacovigilance-programme-update-issue-4_en.pdf"},
    {"id":"28028","name":"Human medicines highlights - September 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-10-04T16:50:00Z","last_updated_date":"2013-10-04T16:50:00Z","reference_number":"Issue 55","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2013_en.pdf"},
    {"id":"29639","name":"Human medicines highlights - October 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-11-10T12:20:00Z","last_updated_date":"2015-11-10T12:20:00Z","reference_number":"Issue 80","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-october-2015_en.pdf"},
    {"id":"30171","name":"News bulletin for small and medium-sized enterprises - Issue 29","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-10-17T18:20:00Z","last_updated_date":"2014-10-17T18:20:00Z","reference_number":"Issue 29","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-29_en.pdf"},
    {"id":"30613","name":"Human medicines highlights - July 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-08-07T18:00:00Z","last_updated_date":"2014-08-07T18:00:00Z","reference_number":"Issue 65","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-july-2014_en.pdf"},
    {"id":"30703","name":"European network of paediatric research at the European Medicines Agency newsletter: February 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T11:15:00Z","last_updated_date":"2015-03-10T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/european-network-paediatric-research-european-medicines-agency-newsletter-february-2015_en.pdf"},
    {"id":"31307","name":"Human medicines highlights - January 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-02-04T16:55:00Z","last_updated_date":"2014-02-04T16:55:00Z","reference_number":"Issue 59","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-january-2014_en.pdf"},
    {"id":"31724","name":"News bulletin for pharmacovigilance programme update - Issue 5","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-10-13T16:35:00Z","last_updated_date":"2015-10-13T16:35:00Z","reference_number":"Issue 5","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-pharmacovigilance-programme-update-issue-5_en.pdf"},
    {"id":"31927","name":"Human medicines highlights - August 2016","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T13:36:00Z","last_updated_date":"2016-09-08T13:36:00Z","reference_number":"Issue 90","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-august-2016_en.pdf"},
    {"id":"32517","name":"European Network of Paediatric Research at the European Medicines Agency newsletter: December 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-01-16T17:15:00Z","last_updated_date":"2014-01-16T17:15:00Z","reference_number":"EMA/807762/2013","document_url":"https://www.ema.europa.eu/en/documents/newsletter/european-network-paediatric-research-european-medicines-agency-newsletter-december-2013_en.pdf"},
    {"id":"32554","name":"Human medicines highlights - January 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-02-05T14:52:00Z","last_updated_date":"2013-02-05T14:52:00Z","reference_number":"Issue 48","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-january-2013_en.pdf"},
    {"id":"32776","name":"Human medicines highlights - September 2012","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-10-04T11:45:00Z","last_updated_date":"2012-10-04T11:45:00Z","reference_number":"Issue 44","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2012_en.pdf"},
    {"id":"33335","name":"What's new in pharmacovigilance - QPPV Update - Issue 2","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2016-08-09T12:35:00Z","last_updated_date":"2016-08-09T12:35:00Z","reference_number":"Issue 2","document_url":"https://www.ema.europa.eu/en/documents/newsletter/whats-new-pharmacovigilance-qppv-update-issue-2_en.pdf"},
    {"id":"33507","name":"Human medicines highlights - August 2012","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-09-04T12:30:00Z","last_updated_date":"2012-09-04T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-august-2012_en.pdf"},
    {"id":"33563","name":"Human medicines highlights - May 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-06-06T17:35:00Z","last_updated_date":"2014-06-06T17:35:00Z","reference_number":"Issue 63","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-may-2014_en.pdf"},
    {"id":"33611","name":"News bulletin for small and medium-sized enterprises - Issue 18","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2011-12-21T16:50:00Z","last_updated_date":"2011-12-21T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-18_en.pdf"},
    {"id":"33911","name":"Human medicines highlights - March 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-04-04T17:20:00Z","last_updated_date":"2014-04-04T17:20:00Z","reference_number":"Issue 61","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-march-2014_en.pdf"},
    {"id":"34321","name":"News bulletin for small and medium-sized enterprises - Issue 26","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-01-07T17:37:00Z","last_updated_date":"2014-01-07T17:37:00Z","reference_number":"Issue 26","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-26_en.pdf"},
    {"id":"34780","name":"News bulletin for small and medium-sized enterprises - Issue 31","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-04-15T16:20:00Z","last_updated_date":"2015-04-15T16:20:00Z","reference_number":"Issue 31","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-31_en.pdf"},
    {"id":"35511","name":"Human medicines highlights - July 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-07-10T13:12:00Z","last_updated_date":"2018-07-10T13:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-july-2018_en.pdf"},
    {"id":"35540","name":"News bulletin for small and medium-sized enterprises - Issue 13","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2010-09-13T02:00:00Z","last_updated_date":"2010-09-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-13_en.pdf"},
    {"id":"35550","name":"Human medicines highlights - December 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-01-15T15:00:00Z","last_updated_date":"2015-01-15T15:00:00Z","reference_number":"Issue 70","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-december-2014_en.pdf"},
    {"id":"36395","name":"News bulletin for small and medium-sized enterprises - Issue 10","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2009-12-17T00:09:21Z","last_updated_date":"2009-12-17T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-10_en.pdf"},
    {"id":"37341","name":"News bulletin for small and medium-sized enterprises - Issue 23","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T11:20:00Z","last_updated_date":"2013-03-25T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-23_en.pdf"},
    {"id":"38006","name":"Human medicines highlights - April 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-05-08T16:20:00Z","last_updated_date":"2015-05-08T16:20:00Z","reference_number":"Issue 74","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-april-2015_en.pdf"},
    {"id":"38424","name":"Human medicines highlights - November 2011","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2011-12-02T13:13:00Z","last_updated_date":"2011-12-02T13:13:00Z","reference_number":"Issue 34","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-2011_en.pdf"},
    {"id":"39046","name":"Human medicines highlights - February 2014","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-03-05T16:50:00Z","last_updated_date":"2014-03-05T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-february-2014_en.pdf"},
    {"id":"39232","name":"News bulletin for small and medium-sized enterprises - Issue 40","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2017-07-27T16:10:00Z","last_updated_date":"2017-07-27T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-40_en.pdf"},
    {"id":"39621","name":"Human medicines highlights - April 2012","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:15:00Z","last_updated_date":"2012-05-10T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-april-2012_en.pdf"},
    {"id":"39683","name":"News bulletin for small and medium-sized enterprises - Issue 35","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T15:26:00Z","last_updated_date":"2016-04-29T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-35_en.pdf"},
    {"id":"39932","name":"Human medicines highlights - March 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T11:00:00Z","last_updated_date":"2013-04-08T11:00:00Z","reference_number":"Issue 50","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-march-2013_en.pdf"},
    {"id":"40054","name":"News bulletin for small and medium-sized enterprises - Issue 3","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2008-02-01T01:00:00Z","last_updated_date":"2008-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-3_en.pdf"},
    {"id":"40336","name":"Human medicines highlights - December 2013","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-01-10T14:43:00Z","last_updated_date":"2014-01-10T14:43:00Z","reference_number":"Issue 58","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-december-2013_en.pdf"},
    {"id":"40657","name":"News bulletin for small and medium-sized enterprises - Issue 19","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2012-03-14T15:35:00Z","last_updated_date":"2012-03-14T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-19_en.pdf"},
    {"id":"40753","name":"Human medicines highlights - September 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-09-07T16:10:00Z","last_updated_date":"2018-09-07T16:10:00Z","reference_number":"Issue 114","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2018_en.pdf"},
    {"id":"41166","name":"European network of paediatric research at the European Medicines Agency newsletter: 2017","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T10:59:00Z","last_updated_date":"2018-03-02T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/european-network-paediatric-research-european-medicines-agency-newsletter-2017_en.pdf"},
    {"id":"41632","name":"News bulletin for small and medium-sized enterprises - Issue 28","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2014-06-30T16:23:00Z","last_updated_date":"2014-06-30T16:23:00Z","reference_number":"Issue 28","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-28_en.pdf"},
    {"id":"41905","name":"Human medicines highlights - March 2015","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2015-04-01T17:25:00Z","last_updated_date":"2015-04-01T17:25:00Z","reference_number":"Issue 73","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-march-2015_en.pdf"},
    {"id":"42238","name":"Human medicines highlights - October 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-10-09T12:58:00Z","last_updated_date":"2018-10-09T12:58:00Z","reference_number":"Issue 115","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-october-2018_en.pdf"},
    {"id":"42612","name":"Human medicines highlights - November 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T14:42:00Z","last_updated_date":"2018-11-22T12:00:00Z","reference_number":"Issue 116","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-2018_en.pdf"},
    {"id":"42764","name":"News bulletin for small and medium-sized enterprises - Issue 45","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T12:12:00Z","last_updated_date":"2018-11-23T12:12:00Z","reference_number":"Issue 45","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-45_en.pdf"},
    {"id":"42965","name":"Human medicines highlights - December 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-12-07T17:15:00Z","last_updated_date":"2018-12-07T17:15:00Z","reference_number":"Issue 117","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-december-2018_en.pdf"},
    {"id":"43109","name":"European network of paediatric research at the European Medicines Agency newsletter: 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2018-12-17T17:37:00Z","last_updated_date":"2018-12-17T17:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/european-network-paediatric-research-european-medicines-agency-newsletter-2018_en.pdf"},
    {"id":"43225","name":"What’s new in pharmacovigilance - QPPV Update - Issue 2 - 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T11:53:00Z","last_updated_date":"2019-01-07T11:53:00Z","reference_number":"Issue 2","document_url":"https://www.ema.europa.eu/en/documents/newsletter/whats-new-pharmacovigilance-qppv-update-issue-2-2018_en.pdf"},
    {"id":"43355","name":"Human medicines highlights - January 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-01-14T15:40:00Z","last_updated_date":"2019-01-14T15:40:00Z","reference_number":"Issue 118","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-january-2019_en.pdf"},
    {"id":"43702","name":"Human medicines highlights - February 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-02-13T14:20:00Z","last_updated_date":"2019-02-13T14:20:00Z","reference_number":"Issue 119","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-february-2019_en.pdf"},
    {"id":"43982","name":"Human medicines highlights - March 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-03-06T16:04:00Z","last_updated_date":"2019-03-06T16:04:00Z","reference_number":"Issue 120","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-march-2019_en.pdf"},
    {"id":"43990","name":"News bulletin for small and medium-sized enterprises - Issue 46","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-03-08T08:43:00Z","last_updated_date":"2019-03-08T08:43:00Z","reference_number":"Issue 46","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-46_en.pdf"},
    {"id":"44254","name":"Human medicines highlights - April 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T14:05:00Z","last_updated_date":"2019-04-12T14:05:00Z","reference_number":"Issue 121","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-april-2019_en.pdf"},
    {"id":"44290","name":"Public bulletin: Veterinary pharmacovigilance 2018","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-04-17T12:04:00Z","last_updated_date":"2019-05-17T09:15:00Z","reference_number":"EMA/CVMP/809750/2018","document_url":"https://www.ema.europa.eu/en/documents/newsletter/public-bulletin-veterinary-pharmacovigilance-2018_en.pdf"},
    {"id":"44473","name":"Human medicines highlights - May 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-05-10T10:38:00Z","last_updated_date":"2019-05-10T10:38:00Z","reference_number":"Issue 122","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-may-2019_en.pdf"},
    {"id":"44668","name":"Human medicines highlights - June 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-06-06T12:35:00Z","last_updated_date":"2019-06-06T12:35:00Z","reference_number":"Issue 123","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-june-2019_en.pdf"},
    {"id":"45003","name":"Human medicines highlights - July 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-07-05T15:05:00Z","last_updated_date":"2019-07-24T16:38:00Z","reference_number":"Issue 124","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-july-2019_en.pdf"},
    {"id":"45229","name":"What’s new in pharmacovigilance - QPPV Update - Issue 1 - 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-08-09T16:28:00Z","last_updated_date":"2019-08-09T16:28:00Z","reference_number":"Issue 1 - 2019","document_url":"https://www.ema.europa.eu/en/documents/newsletter/whats-new-pharmacovigilance-qppv-update-issue-1-2019_en.pdf"},
    {"id":"45248","name":"Human medicines highlights - August 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-08-13T17:41:00Z","last_updated_date":"2019-08-13T17:41:00Z","reference_number":"Issue 125","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-august-2019_en.pdf"},
    {"id":"45323","name":"News bulletin for small and medium-sized enterprises - Issue 47","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-08-26T09:21:00Z","last_updated_date":"2019-08-26T09:21:00Z","reference_number":"Issue 47","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-47_en.pdf"},
    {"id":"45414","name":"Human medicines highlights - September 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-09-11T11:16:00Z","last_updated_date":"2019-09-11T11:16:00Z","reference_number":"Issue 126","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2019_en.pdf"},
    {"id":"45575","name":"Human medicines highlights - October 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-10-07T13:05:00Z","last_updated_date":"2019-10-07T13:05:00Z","reference_number":"Issue 127","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-october-2019_en.pdf"},
    {"id":"45909","name":"Human medicines highlights - November 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-11-07T10:39:00Z","last_updated_date":"2019-11-07T10:39:00Z","reference_number":"Issue 128","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-2019_en.pdf"},
    {"id":"46278","name":"Human medicines highlights - December 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2019-12-10T11:55:00Z","last_updated_date":"2019-12-10T11:55:00Z","reference_number":"Issue 129","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-december-2019_en.pdf"},
    {"id":"46452","name":"Human medicines highlights - January 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-01-17T14:08:00Z","last_updated_date":"2020-01-17T14:08:00Z","reference_number":"Issue 130","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-january-2020_en.pdf"},
    {"id":"46609","name":"News bulletin for small and medium-sized enterprises - Issue 48","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-01-29T14:25:00Z","last_updated_date":"2020-01-29T14:25:00Z","reference_number":"Issue 48","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-48_en.pdf"},
    {"id":"46699","name":"Human medicines highlights - February 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-02-10T15:48:00Z","last_updated_date":"2020-02-10T15:48:00Z","reference_number":"Issue 131","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-february-2020_en.pdf"},
    {"id":"47001","name":"Human medicines highlights - March 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-03-11T15:46:00Z","last_updated_date":"2020-03-11T15:46:00Z","reference_number":"Issue 132","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-march-2020_en.pdf"},
    {"id":"47402","name":"Human medicines highlights - April 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-04-14T14:58:00Z","last_updated_date":"2020-04-14T14:58:00Z","reference_number":"Issue 133","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-april-2020_en.pdf"},
    {"id":"47589","name":"News bulletin for small and medium-sized enterprises - Issue 49","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T14:51:00Z","last_updated_date":"2020-05-07T14:51:00Z","reference_number":"Issue 49","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-49_en.pdf"},
    {"id":"47640","name":"Public bulletin: Veterinary pharmacovigilance 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-05-11T15:56:00Z","last_updated_date":"2020-05-11T15:56:00Z","reference_number":"EMA/CVMP/PhVWP/33617/2020","document_url":"https://www.ema.europa.eu/en/documents/newsletter/public-bulletin-veterinary-pharmacovigilance-2019_en.pdf"},
    {"id":"47641","name":"Human medicines highlights - May 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-05-11T16:00:00Z","last_updated_date":"2020-05-11T16:00:00Z","reference_number":"Issue 134","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-may-2020_en.pdf"}    {"id":"47642","name":"Public bulletin: Veterinary pharmacovigilance 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-05-11T15:56:00Z","last_updated_date":"2020-05-11T15:56:00Z","reference_number":"EMA/CVMP/PhVWP/33617/2020","document_url":"https://www.ema.europa.eu/en/documents/newsletter/public-bulletin-veterinary-pharmacovigilance-2019_en.pdf-0"},
    {"id":"47889","name":"Human medicines highlights - June 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-06-08T12:28:00Z","last_updated_date":"2020-06-08T12:28:00Z","reference_number":"Issue 135","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-june-2020_en.pdf"},
    {"id":"48218","name":"Clinical Trials Information System (CTIS) highlights - June 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-07-03T11:35:00Z","last_updated_date":"2020-07-03T11:35:00Z","reference_number":"Issue 1","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-information-system-ctis-highlights-june-2020_en.pdf"},
    {"id":"48269","name":"Human medicines highlights - July 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-07-09T10:09:00Z","last_updated_date":"2020-07-09T10:09:00Z","reference_number":"Issue 136","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-july-2020_en.pdf"},
    {"id":"48306","name":"Veterinary Medicines Regulation highlights - Issue 1","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-07-17T10:37:00Z","last_updated_date":"2020-07-17T10:37:00Z","reference_number":"Issue 1","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicines-regulation-highlights-issue-1_en.pdf"},
    {"id":"48571","name":"Human medicines highlights - August 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-08-07T16:44:00Z","last_updated_date":"2020-08-07T16:44:00Z","reference_number":"Issue 137","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-august-2020_en.pdf"},
    {"id":"48756","name":"Human medicines highlights - September 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-09-04T09:06:00Z","last_updated_date":"2020-09-04T09:06:00Z","reference_number":"Issue 138","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2020_en.pdf"},
    {"id":"48778","name":"News bulletin for small and medium-sized enterprises - Issue 50","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-09-10T12:12:00Z","last_updated_date":"2020-09-10T12:12:00Z","reference_number":"Issue 50","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-50_en.pdf"},
    {"id":"48996","name":"Human medicines highlights - October 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-10-12T14:52:00Z","last_updated_date":"2020-10-12T14:52:00Z","reference_number":"Issue 139","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-october-2020_en.pdf"},
    {"id":"49164","name":"Veterinary Medicines Regulation highlights - Issue 2","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-10-30T15:35:00Z","last_updated_date":"2020-10-30T15:35:00Z","reference_number":"Issue 2","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicines-regulation-highlights-issue-2_en.pdf"},
    {"id":"49209","name":"Human medicines highlights - November 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-11-11T14:11:00Z","last_updated_date":"2020-11-11T14:11:00Z","reference_number":"Issue 140","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-2020_en.pdf"},
    {"id":"49486","name":"Clinical Trials Information System (CTIS) highlights - December 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-12-09T11:48:00Z","last_updated_date":"2020-12-09T11:48:00Z","reference_number":"Issue 2","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-information-system-ctis-highlights-december-2020_en.pdf"},
    {"id":"49504","name":"Human medicines highlights - December 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-12-10T10:38:00Z","last_updated_date":"2020-12-10T10:38:00Z","reference_number":"Issue 141","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-december-2020_en.pdf"},
    {"id":"49603","name":"Enpr-EMA newsletter 2020","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T10:24:00Z","last_updated_date":"2020-12-17T10:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/enpr-ema-newsletter-2020_en.pdf"},
    {"id":"49790","name":"Human medicines highlights - January 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-01-13T10:08:00Z","last_updated_date":"2021-01-13T10:08:00Z","reference_number":"Issue 142","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-january-2021_en.pdf"},
    {"id":"49838","name":"News bulletin for small and medium-sized enterprises - Issue 51","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-01-19T14:36:00Z","last_updated_date":"2021-01-19T14:36:00Z","reference_number":"Issue 51","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-51_en.pdf"},
    {"id":"49966","name":"Veterinary Medicinal Products Regulation highlights - Issue 3","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-01-28T14:28:00Z","last_updated_date":"2021-01-28T14:28:00Z","reference_number":"Issue 3","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicinal-products-regulation-highlights-issue-3_en.pdf"},
    {"id":"50043","name":"Human medicines highlights - February 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-02-03T12:51:00Z","last_updated_date":"2021-02-03T12:51:00Z","reference_number":"Issue 143","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-february-2021_en.pdf"},
    {"id":"50637","name":"Human medicines highlights - March 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-03-18T12:13:00Z","last_updated_date":"2021-03-18T12:13:00Z","reference_number":"Issue 144","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-march-2021_en.pdf"},
    {"id":"50751","name":"Veterinary Medicinal Products Regulation highlights - Issue 4","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-03-31T14:43:00Z","last_updated_date":"2021-03-31T14:43:00Z","reference_number":"Issue 4","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicinal-products-regulation-highlights-issue-4_en.pdf"},
    {"id":"50817","name":"Human medicines highlights - April 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T09:55:00Z","last_updated_date":"2021-04-14T09:55:00Z","reference_number":"Issue 145","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-april-2021_en.pdf"},
    {"id":"50910","name":"News bulletin for small and medium-sized enterprises - Issue 52","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-04-19T17:25:00Z","last_updated_date":"2021-04-19T17:25:00Z","reference_number":"Issue 52","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-52_en.pdf"},
    {"id":"51295","name":"Human medicines highlights - May 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-05-31T09:38:00Z","last_updated_date":"2021-05-31T09:38:00Z","reference_number":"Issue 146","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-may-2021_en.pdf"},
    {"id":"51320","name":"Veterinary Medicinal Products Regulation highlights - Issue 5","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-05-31T18:12:00Z","last_updated_date":"2021-05-31T18:12:00Z","reference_number":"Issue 5","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicinal-products-regulation-highlights-issue-5_en.pdf"},
    {"id":"51360","name":"Human medicines highlights - June 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-06-04T09:33:00Z","last_updated_date":"2021-06-04T09:33:00Z","reference_number":"Issue 147","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-june-2021_en.pdf"},
    {"id":"51559","name":"Clinical Trials Information System (CTIS) highlights - June 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-06-23T15:23:00Z","last_updated_date":"2021-07-30T10:29:00Z","reference_number":"Issue 3","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-information-system-ctis-highlights-june-2021_en.pdf"},
    {"id":"51841","name":"Human medicines highlights - July 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T12:51:00Z","last_updated_date":"2021-07-06T12:51:00Z","reference_number":"Issue 148","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-july-2021_en.pdf"},
    {"id":"52140","name":"News bulletin for small and medium-sized enterprises - Issue 53","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-07-29T09:56:00Z","last_updated_date":"2021-07-29T09:56:00Z","reference_number":"Issue 53","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-53_en.pdf"},
    {"id":"52150","name":"Veterinary Medicinal Products Regulation highlights - Issue 6","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-07-29T15:36:00Z","last_updated_date":"2021-07-29T15:36:00Z","reference_number":"Issue 6","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicinal-products-regulation-highlights-issue-6_en.pdf"},
    {"id":"52201","name":"Human medicines highlights - August 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-08-05T14:25:00Z","last_updated_date":"2021-08-05T14:25:00Z","reference_number":"Issue 149","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-august-2021_en.pdf"},
    {"id":"52204","name":"Clinical Trials Information System (CTIS) highlights - August 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-08-06T10:43:00Z","last_updated_date":"2021-08-06T10:43:00Z","reference_number":"Issue 4","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-information-system-ctis-highlights-august-2021_en.pdf"},
    {"id":"52356","name":"Human medicines highlights - September 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-09-07T13:24:00Z","last_updated_date":"2021-09-07T13:24:00Z","reference_number":"Issue 150","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2021_en.pdf"},
    {"id":"52707","name":"Veterinary Medicinal Products Regulation highlights - Issue 7","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T16:09:00Z","last_updated_date":"2021-10-01T16:09:00Z","reference_number":"Issue 7","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicinal-products-regulation-highlights-issue-7_en.pdf"},
    {"id":"52775","name":"Human medicines highlights - October 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-10-07T16:30:00Z","last_updated_date":"2021-10-07T16:30:00Z","reference_number":"Issue 151","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-october-2021_en.pdf"},
    {"id":"52882","name":"Clinical Trials Information System (CTIS) highlights - October 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-10-18T16:09:00Z","last_updated_date":"2021-10-18T16:09:00Z","reference_number":"Issue 5","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-information-system-ctis-highlights-october-2021_en.pdf"},
    {"id":"53056","name":"Human medicines highlights - November 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-11-11T10:24:00Z","last_updated_date":"2021-11-11T10:24:00Z","reference_number":"Issue 152","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-2021_en.pdf"},
    {"id":"53331","name":"Veterinary Medicinal Products Regulation highlights - Issue 8","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T16:11:00Z","last_updated_date":"2021-11-29T16:11:00Z","reference_number":"Issue 8","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicinal-products-regulation-highlights-issue-8_en.pdf"},
    {"id":"53377","name":"Human medicines highlights - December 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-12-06T17:00:00Z","last_updated_date":"2021-12-06T17:00:00Z","reference_number":"Issue 153","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-december-2021_en.pdf"},
    {"id":"53449","name":"Clinical Trials Information System (CTIS) highlights - December 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-12-13T15:07:00Z","last_updated_date":"2021-12-13T15:07:00Z","reference_number":"Issue 6","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-information-system-ctis-highlights-december-2021_en.pdf"},
    {"id":"53462","name":"News bulletin for small and medium-sized enterprises - Issue 54","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T10:00:00Z","last_updated_date":"2021-12-14T10:00:00Z","reference_number":"Issue 54","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-54_en.pdf"},
    {"id":"53606","name":"Enpr-EMA newsletter 2021","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2021-12-20T13:23:00Z","last_updated_date":"2021-12-20T13:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/enpr-ema-newsletter-2021_en.pdf"},
    {"id":"53717","name":"Human medicines highlights - January 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T12:12:00Z","last_updated_date":"2022-01-14T12:12:00Z","reference_number":"Issue 154","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-january-2022_en.pdf"},
    {"id":"53936","name":"Clinical Trials Information System (CTIS) highlights - January 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-01-27T09:22:00Z","last_updated_date":"2022-01-27T09:22:00Z","reference_number":"Issue 7","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-information-system-ctis-highlights-january-2022_en.pdf"},
    {"id":"54074","name":"Human medicines highlights - February 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-02-04T13:27:00Z","last_updated_date":"2022-02-04T13:27:00Z","reference_number":"Issue 155","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-february-2022_en.pdf"},
    {"id":"54092","name":"CTIS newsflash - 4 February 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-02-07T11:49:00Z","last_updated_date":"2022-02-07T11:49:00Z","reference_number":"EMA/70002/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-4-february-2022_en.pdf"},
    {"id":"54095","name":"Veterinary Medicinal Products Regulation highlights - Issue 9","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-02-07T16:15:00Z","last_updated_date":"2022-02-07T16:15:00Z","reference_number":"Issue 9","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicinal-products-regulation-highlights-issue-9_en.pdf"},
    {"id":"54162","name":"Big Data highlights - Issue 1","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-02-15T10:14:00Z","last_updated_date":"2022-02-15T10:14:00Z","reference_number":"Issue 1","document_url":"https://www.ema.europa.eu/en/documents/newsletter/big-data-highlights-issue-1_en.pdf"},
    {"id":"54185","name":"CTIS newsflash - 11 February 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-02-15T15:49:00Z","last_updated_date":"2022-02-15T15:49:00Z","reference_number":"EMA/83300/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-11-february-2022_en.pdf"},
    {"id":"54258","name":"CTIS newsflash - 18 February 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T09:35:00Z","last_updated_date":"2022-02-23T09:35:00Z","reference_number":"EMA/104967/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-18-february-2022_en.pdf"},
    {"id":"54320","name":"CTIS newsflash - 25 February 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-03-01T16:06:00Z","last_updated_date":"2022-03-01T16:06:00Z","reference_number":"EMA/119802/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-25-february-2022_en.pdf"},
    {"id":"54362","name":"Human medicines highlights - March 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-03-07T13:52:00Z","last_updated_date":"2022-03-07T13:52:00Z","reference_number":"Issue 156","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-march-2022_en.pdf"},
    {"id":"54370","name":"CTIS newsflash - 4 March 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T09:33:00Z","last_updated_date":"2022-03-08T09:33:00Z","reference_number":"EMA/131960/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-4-march-2022_en.pdf"},
    {"id":"54447","name":"CTIS newsflash - 11 March 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T16:35:00Z","last_updated_date":"2022-03-14T16:35:00Z","reference_number":"EMA/149078/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-11-march-2022_en.pdf"},
    {"id":"54532","name":"CTIS newsflash - 18 March 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-03-21T16:26:00Z","last_updated_date":"2022-03-21T16:26:00Z","reference_number":"EMA/168795/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-18-march-2022_en.pdf"},
    {"id":"54594","name":"Clinical Trials Highlights - March 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T14:47:00Z","last_updated_date":"2022-03-25T14:47:00Z","reference_number":"Issue 8","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-highlights-march-2022_en.pdf"},
    {"id":"54598","name":"CTIS newsflash - 25 March 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-03-28T13:36:00Z","last_updated_date":"2022-03-28T13:36:00Z","reference_number":"EMA/183329/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-25-march-2022_en.pdf"},
    {"id":"54680","name":"CTIS newsflash - 1 April 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-04-05T16:11:00Z","last_updated_date":"2022-04-05T16:11:00Z","reference_number":"EMA/193739/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-1-april-2022_en.pdf"},
    {"id":"54724","name":"Human medicines highlights - April 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T16:22:00Z","last_updated_date":"2022-04-11T16:22:00Z","reference_number":"Isssue 157","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-april-2022_en.pdf"},
    {"id":"54725","name":"CTIS newsflash - 8 April 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T16:30:00Z","last_updated_date":"2022-04-11T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-8-april-2022_en.pdf"},
    {"id":"54823","name":"CTIS newsflash - 22 April 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-04-25T14:39:00Z","last_updated_date":"2022-04-25T14:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-22-april-2022_en.pdf"},
    {"id":"54973","name":"Veterinary Medicinal Products Regulation highlights - Issue 10","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-05-17T13:41:00Z","last_updated_date":"2022-05-17T13:41:00Z","reference_number":"Issue 10","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicinal-products-regulation-highlights-issue-10_en.pdf"},
    {"id":"54979","name":"News bulletin for small and medium-sized enterprises - Issue 55","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-05-17T16:38:00Z","last_updated_date":"2022-05-17T16:38:00Z","reference_number":"Issue 55","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-55_en.pdf"},
    {"id":"55081","name":"Big Data highlights - Issue 2","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-05-24T14:43:00Z","last_updated_date":"2022-05-24T14:43:00Z","reference_number":"Issue 2","document_url":"https://www.ema.europa.eu/en/documents/newsletter/big-data-highlights-issue-2_en.pdf"},
    {"id":"55092","name":"Clinical Trials Highlights - May 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-05-25T08:29:00Z","last_updated_date":"2022-05-25T08:29:00Z","reference_number":"Issue 9","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-highlights-may-2022_en.pdf"},
    {"id":"55143","name":"Human medicines highlights - June 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-06-08T09:31:00Z","last_updated_date":"2022-06-08T09:31:00Z","reference_number":"Isssue 159","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-june-2022_en.pdf"},
    {"id":"55565","name":"Human medicines highlights - July 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-07-18T09:47:00Z","last_updated_date":"2022-07-18T09:47:00Z","reference_number":"Isssue 160","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-july-2022_en.pdf"},
    {"id":"55680","name":"Clinical Trials Highlights - July 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-07-25T14:25:00Z","last_updated_date":"2022-07-25T14:25:00Z","reference_number":"Issue 10","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-highlights-july-2022_en.pdf"},
    {"id":"55685","name":"Digital Application Dataset Integration (DADI) newsletter - Issue 1","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-07-26T10:20:00Z","last_updated_date":"2022-07-26T10:20:00Z","reference_number":"Issue 1","document_url":"https://www.ema.europa.eu/en/documents/newsletter/digital-application-dataset-integration-dadi-newsletter-issue-1_en.pdf"},
    {"id":"55763","name":"News bulletin for small and medium-sized enterprises - Issue 56","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-08-02T14:33:00Z","last_updated_date":"2022-08-02T14:33:00Z","reference_number":"Issue 56","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-56_en.pdf"},
    {"id":"55791","name":"Human medicines highlights - August 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-08-08T10:24:00Z","last_updated_date":"2022-08-08T10:24:00Z","reference_number":"Issue 161","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-august-2022_en.pdf"},
    {"id":"55994","name":"Big Data highlights - Issue 3","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-08-06T09:48:00Z","last_updated_date":"2022-08-06T09:48:00Z","reference_number":"Issue 3","document_url":"https://www.ema.europa.eu/en/documents/newsletter/big-data-highlights-issue-3_en.pdf"},
    {"id":"56194","name":"Veterinary Medicinal Products Regulation highlights - Issue 11","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T10:39:00Z","last_updated_date":"2022-09-27T10:39:00Z","reference_number":"Issue 11","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicinal-products-regulation-highlights-issue-11_en.pdf"},
    {"id":"56375","name":"Human medicines highlights - September 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-10-12T17:59:00Z","last_updated_date":"2022-10-12T17:59:00Z","reference_number":"Issue 162","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2022_en.pdf"},
    {"id":"56376","name":"Human medicines highlights - September 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-10-12T17:59:00Z","last_updated_date":"2022-10-12T17:59:00Z","reference_number":"Issue 162","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2022_en.pdf-0"},
    {"id":"56449","name":"Clinical Trials Highlights - October 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-10-21T09:34:00Z","last_updated_date":"2022-10-21T09:34:00Z","reference_number":"Issue 11","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-highlights-october-2022_en.pdf"},
    {"id":"56607","name":"Human medicines highlights - November 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-11-14T11:46:00Z","last_updated_date":"2022-11-14T11:46:00Z","reference_number":"Issue 163","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-2022_en.pdf"},
    {"id":"56946","name":"Human medicines highlights - December 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T09:34:00Z","last_updated_date":"2022-12-13T09:34:00Z","reference_number":"Issue 164","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-december-2022_en.pdf"},
    {"id":"57013","name":"Big Data highlights - Issue 4","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T16:14:00Z","last_updated_date":"2022-12-14T16:14:00Z","reference_number":"Issue 4","document_url":"https://www.ema.europa.eu/en/documents/newsletter/big-data-highlights-issue-4_en.pdf"},
    {"id":"57099","name":"Clinical Trials Highlights - December 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-12-20T10:15:00Z","last_updated_date":"2022-12-21T10:17:00Z","reference_number":"Issue 12","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-highlights-december-2022_en.pdf"},
    {"id":"57106","name":"Electronic Application Form (eAF) newsletter - Issue 2","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-12-21T11:27:00Z","last_updated_date":"2023-01-10T17:35:00Z","reference_number":"Issue 2","document_url":"https://www.ema.europa.eu/en/documents/newsletter/electronic-application-form-eaf-newsletter-issue-2_en.pdf"},
    {"id":"57146","name":"CTIS newsflash - 5 December 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T15:45:00Z","last_updated_date":"2022-12-22T15:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-5-december-2022_en.pdf"},
    {"id":"57147","name":"CTIS newsflash - 12 December 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T15:47:00Z","last_updated_date":"2022-12-22T15:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-12-december-2022_en.pdf"},
    {"id":"57165","name":"CTIS newsflash - 22 December 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-01-05T10:57:00Z","last_updated_date":"2023-01-05T10:57:00Z","reference_number":"EMA/940077/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-22-december-2022_en.pdf"},
    {"id":"57179","name":"CTIS newsflash - 6 January 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T11:52:00Z","last_updated_date":"2023-01-09T11:52:00Z","reference_number":"EMA/957698/2022","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-6-january-2023_en.pdf"},
    {"id":"57225","name":"Human medicines highlights - January 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-01-11T15:43:00Z","last_updated_date":"2023-01-18T15:46:00Z","reference_number":"Issue 165","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-january-2023_en.pdf"},
    {"id":"57230","name":"News bulletin for small and medium-sized enterprises - Issue 57","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T09:37:00Z","last_updated_date":"2023-01-12T09:37:00Z","reference_number":"Issue 57","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-57_en.pdf"},
    {"id":"57282","name":"CTIS newsflash – 13 January 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-01-13T15:17:00Z","last_updated_date":"2023-01-13T15:17:00Z","reference_number":"EMA/6441/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-13-january-2023_en.pdf"},
    {"id":"57350","name":"CTIS newsflash – 20 January 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-01-23T09:24:00Z","last_updated_date":"2023-01-23T09:24:00Z","reference_number":"EMA/23426/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-20-january-2023_en.pdf"},
    {"id":"57470","name":"CTIS newsflash - 27 January 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T11:10:00Z","last_updated_date":"2023-01-31T11:10:00Z","reference_number":"EMA/36776/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-27-january-2023_en.pdf"},
    {"id":"57517","name":"CTIS newsflash - 3 February 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-02-03T13:05:00Z","last_updated_date":"2023-02-03T13:05:00Z","reference_number":"EMA/47266/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-3-february-2023_en.pdf"},
    {"id":"57524","name":"Human medicines highlights - February 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-02-06T10:35:00Z","last_updated_date":"2023-02-06T10:35:00Z","reference_number":"Issue 166","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-february-2023_en.pdf"},
    {"id":"57619","name":"CTIS newsflash - 10 February 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T12:10:00Z","last_updated_date":"2023-02-13T12:10:00Z","reference_number":"EMA/58602/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-10-february-2023_en.pdf"},
    {"id":"57732","name":"CTIS newsflash - 17 February 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-02-20T12:07:00Z","last_updated_date":"2023-02-20T12:07:00Z","reference_number":"EMA/69125/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-17-february-2023_en.pdf"},
    {"id":"57735","name":"Clinical Trials Highlights - February 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-02-20T12:55:00Z","last_updated_date":"2023-02-20T12:55:00Z","reference_number":"Issue 13","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-highlights-february-2023_en.pdf"},
    {"id":"57828","name":"CTIS newsflash - 24 February 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-02-27T10:35:00Z","last_updated_date":"2023-02-27T10:35:00Z","reference_number":"EMA/78479/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-24-february-2023_en.pdf"},
    {"id":"57871","name":"CTIS newsflash - 3 March 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-03-03T10:38:00Z","last_updated_date":"2023-03-03T10:38:00Z","reference_number":"EMA/89888/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-3-march-2023_en.pdf"},
    {"id":"57961","name":"Human medicines highlights - March 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T09:12:00Z","last_updated_date":"2023-03-09T09:12:00Z","reference_number":"Issue 167","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-march-2023_en.pdf"},
    {"id":"57987","name":"CTIS newsflash - 10 March 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-03-10T11:39:00Z","last_updated_date":"2023-03-10T11:39:00Z","reference_number":"EMA/103161/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-10-march-2023_en.pdf"},
    {"id":"58062","name":"CTIS newsflash – 17 March 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-03-17T15:04:00Z","last_updated_date":"2023-03-17T15:04:00Z","reference_number":"EMA/114900/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-17-march-2023_en.pdf"},
    {"id":"58164","name":"CTIS newsflash – 24 March 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-03-27T12:50:00Z","last_updated_date":"2023-03-27T12:50:00Z","reference_number":"EMA/127714/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-24-march-2023_en.pdf"}    {"id":"58241","name":"Big Data highlights - Issue 5","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T10:27:00Z","last_updated_date":"2023-03-31T10:27:00Z","reference_number":"Issue 5","document_url":"https://www.ema.europa.eu/en/documents/newsletter/big-data-highlights-issue-5_en.pdf"},
    {"id":"58259","name":"CTIS newsflash – 31 March 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T16:15:00Z","last_updated_date":"2023-03-31T16:15:00Z","reference_number":"EMA/141792/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-31-march-2023_en.pdf"},
    {"id":"58316","name":"Human medicines highlights - April 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-04-12T11:42:00Z","last_updated_date":"2023-04-12T11:42:00Z","reference_number":"Issue 168","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-april-2023_en.pdf"},
    {"id":"58355","name":"CTIS newsflash - 14 April 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-04-14T15:13:00Z","last_updated_date":"2023-04-14T15:13:00Z","reference_number":"EMA/155249/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-14-april-2023_en.pdf"},
    {"id":"58499","name":"CTIS newsflash - 21 April 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T11:36:00Z","last_updated_date":"2023-04-24T11:36:00Z","reference_number":"EMA/171343/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-21-april-2023_en.pdf"},
    {"id":"58506","name":"Clinical Trials Highlights - April 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T15:31:00Z","last_updated_date":"2023-04-24T15:31:00Z","reference_number":"Issue 14","document_url":"https://www.ema.europa.eu/en/documents/newsletter/clinical-trials-highlights-april-2023_en.pdf"},
    {"id":"58546","name":"News bulletin for small and medium-sized enterprises - Issue 58","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-04-28T10:13:00Z","last_updated_date":"2023-04-28T10:13:00Z","reference_number":"Issue 58","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-58_en.pdf"},
    {"id":"58555","name":"CTIS newsflash - 28 April 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-04-28T16:56:00Z","last_updated_date":"2023-04-28T16:56:00Z","reference_number":"EMA/184144/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-28-april-2023_en.pdf"},
    {"id":"58599","name":"CTIS newsflash - 5 May 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-05-08T16:46:00Z","last_updated_date":"2023-05-08T16:46:00Z","reference_number":"EMA/186032/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-5-may-2023_en.pdf"},
    {"id":"58620","name":"Human medicines highlights - June 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-06-16T15:41:00Z","last_updated_date":"2023-06-16T15:41:00Z","reference_number":"Issue 170","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-june-2023_en.pdf"},
    {"id":"58694","name":"Electronic Application Form (eAF) - Product Management Service (PMS) newsletter - Issue 3","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-05-15T17:00:00Z","last_updated_date":"2023-05-15T17:00:00Z","reference_number":"Issue 3","document_url":"https://www.ema.europa.eu/en/documents/newsletter/electronic-application-form-eaf-product-management-service-pms-newsletter-issue-3_en.pdf"},
    {"id":"58696","name":"CTIS newsflash - 12 May 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-05-16T10:16:00Z","last_updated_date":"2023-05-16T10:16:00Z","reference_number":"EMA/209485/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-12-may-2023_en.pdf"},
    {"id":"58815","name":"CTIS newsflash - 26 May 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-05-30T17:39:00Z","last_updated_date":"2023-05-30T17:39:00Z","reference_number":"EMA/220482/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-26-may-2023_en.pdf"},
    {"id":"58857","name":"Veterinary Medicines Highlights - Issue 12","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-06-02T10:33:00Z","last_updated_date":"2023-06-02T10:33:00Z","reference_number":"Issue 12","document_url":"https://www.ema.europa.eu/en/documents/newsletter/veterinary-medicines-highlights-issue-12_en.pdf"},
    {"id":"58918","name":"CTIS newsflash - 9 June 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-06-12T11:44:00Z","last_updated_date":"2023-06-12T11:44:00Z","reference_number":"EMA/231823/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-9-june-2023_en.pdf"},
    {"id":"58981","name":"Human medicines highlights - May 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-05-11T16:00:00Z","last_updated_date":"2023-05-11T16:00:00Z","reference_number":"Issue 169","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-may-2023_en.pdf"},
    {"id":"59271","name":"CTIS newsflash – 23 June 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T17:22:00Z","last_updated_date":"2023-07-05T17:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-23-june-2023_en.pdf"},
    {"id":"59340","name":"CTIS newsflash - 7 July 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T13:45:00Z","last_updated_date":"2023-07-12T13:45:00Z","reference_number":"EMA/293590/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-7-july-2023_en.pdf"},
    {"id":"59359","name":"Human medicines highlights - July 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-07-17T09:33:00Z","last_updated_date":"2023-07-17T09:33:00Z","reference_number":"Issue 171","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-july-2023_en.pdf"},
    {"id":"59466","name":"CTIS newsflash - 21 July 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-07-24T11:06:00Z","last_updated_date":"2023-07-24T11:06:00Z","reference_number":"EMA/293653/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-21-july-2023_en.pdf"},
    {"id":"59503","name":"News bulletin for small and medium-sized enterprises - Issue 59","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-07-26T10:45:00Z","last_updated_date":"2023-07-26T10:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-59_en.pdf"},
    {"id":"59556","name":"CTIS newsflash - 4 August 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-08-04T16:29:00Z","last_updated_date":"2023-08-04T16:29:00Z","reference_number":"EMA/339073/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-4-august-2023_en.pdf"},
    {"id":"59595","name":"Human medicines highlights - August 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-08-14T14:44:00Z","last_updated_date":"2023-08-14T14:44:00Z","reference_number":"Issue 172","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-august-2023_en.pdf"},
    {"id":"59609","name":"CTIS newsflash – 18 August 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-08-18T13:56:00Z","last_updated_date":"2023-08-18T13:56:00Z","reference_number":"EMA/356297/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-18-august-2023_en.pdf"},
    {"id":"59889","name":"CTIS newsflash - 1 September 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-09-04T11:29:00Z","last_updated_date":"2023-09-04T11:29:00Z","reference_number":"EMA/376569/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-1-september-2023_en.pdf"},
    {"id":"59931","name":"Human medicines highlights - September 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-09-11T16:06:00Z","last_updated_date":"2023-09-11T16:06:00Z","reference_number":"Issue 173","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-september-2023_en.pdf"},
    {"id":"60034","name":"CTIS newsflash - 15 September 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T16:16:00Z","last_updated_date":"2023-09-15T16:16:00Z","reference_number":"EMA/397022/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-15-september-2023_en.pdf"},
    {"id":"60367","name":"Human medicines highlights - October 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-10-11T17:54:00Z","last_updated_date":"2023-10-11T17:54:00Z","reference_number":"Issue 174","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-october-2023_en.pdf"},
    {"id":"60605","name":"Enpr-EMA newsletter 2019","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T15:49:00Z","last_updated_date":"2020-01-24T15:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/enpr-ema-newsletter-2019_en.pdf"},
    {"id":"60752","name":"CTIS newsflash - 29 September 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-10-02T18:23:00Z","last_updated_date":"2023-10-02T18:23:00Z","reference_number":"EMA/416454/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-29-september-2023_en.pdf"},
    {"id":"60775","name":"CTIS newsflash – 13 October 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-10-30T09:22:00Z","last_updated_date":"2023-10-30T09:22:00Z","reference_number":"EMA/440825/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-13-october-2023_en.pdf"},
    {"id":"60776","name":"CTIS newsflash – 27 October 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-10-30T09:23:00Z","last_updated_date":"2023-10-30T09:23:00Z","reference_number":"EMA/471461/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-27-october-2023_en.pdf"},
    {"id":"60869","name":"CTIS newsflash – 10 November 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T16:48:00Z","last_updated_date":"2023-11-10T16:48:00Z","reference_number":"EMA/486111/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-10-november-2023_en.pdf"},
    {"id":"60984","name":"Enpr-EMA newsletter 2022","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-11-24T16:42:27Z","last_updated_date":"2023-11-24T16:42:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/enpr-ema-newsletter-2022_en.pdf"},
    {"id":"60990","name":"News bulletin for small and medium-sized enterprises - Issue 60","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-11-20T13:56:37Z","last_updated_date":"2023-11-20T13:56:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/news-bulletin-small-and-medium-sized-enterprises-issue-60_en.pdf"},
    {"id":"61253","name":"CTIS newsflash – 24 November 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T15:25:51Z","last_updated_date":"2023-12-05T15:25:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-24-november-2023_en.pdf"},
    {"id":"61388","name":"CTIS newsflash - 8 December 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T16:08:39Z","last_updated_date":"2023-12-12T16:08:39Z","reference_number":"EMA/536032/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-8-december-2023_en.pdf"},
    {"id":"61420","name":"Human medicines highlights - November-December 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2023-12-14T14:32:46Z","last_updated_date":"2023-12-14T14:32:46Z","reference_number":"Issue 175","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-november-december-2023_en.pdf"},
    {"id":"61664","name":"CTIS newsflash – 22 December 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-01-08T16:05:19Z","last_updated_date":"2024-01-08T16:05:19Z","reference_number":"EMA/564292/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-22-december-2023_en.pdf"},
    {"id":"61736","name":"Human medicines highlights - January 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T15:04:00Z","last_updated_date":"2024-01-11T15:04:00Z","reference_number":"Issue 176","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-january-2024_en.pdf"},
    {"id":"61823","name":"CTIS newsflash – 12 January 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T13:59:09Z","last_updated_date":"2024-01-22T13:59:09Z","reference_number":"EMA/586501/2023","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-12-january-2024_en.pdf"},
    {"id":"61945","name":"CTIS newsflash - 26 January 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-01-29T16:41:45Z","last_updated_date":"2024-01-29T16:41:45Z","reference_number":"EMA/20807/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-26-january-2024_en.pdf"},
    {"id":"61995","name":"Enpr-EMA newsletter 2023","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-02-05T13:05:17Z","last_updated_date":"2024-02-05T13:05:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/enpr-ema-newsletter-2023_en.pdf"},
    {"id":"62056","name":"Human medicines highlights - February 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-02-08T16:29:17Z","last_updated_date":"2024-02-08T16:29:17Z","reference_number":"Issue 177","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-february-2024_en.pdf"},
    {"id":"62068","name":"CTIS newsflash - 9 February 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-02-12T09:39:21Z","last_updated_date":"2024-02-12T09:39:21Z","reference_number":"EMA/43654/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-9-february-2024_en.pdf"},
    {"id":"62393","name":"CTIS newsflash - 23 february 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T11:51:32Z","last_updated_date":"2024-03-01T11:51:32Z","reference_number":"EMA/62843/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-23-february-2024_en.pdf"},
    {"id":"62525","name":"CTIS newsflash - 8 March 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T10:33:51Z","last_updated_date":"2024-03-11T10:33:51Z","reference_number":"EMA/84206/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-8-march-2024_en.pdf"},
    {"id":"62586","name":"Human medicines highlights - March 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T10:24:26Z","last_updated_date":"2024-03-13T10:24:26Z","reference_number":"Issue 178","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-march-2024_en.pdf"},
    {"id":"62710","name":"CTIS newsflash - 22 March 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T13:45:46Z","last_updated_date":"2024-03-22T13:45:46Z","reference_number":"EMA/106948/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-22-march-2024_en.pdf"},
    {"id":"62901","name":"Human medicines highlights - April 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T11:21:34Z","last_updated_date":"2024-04-11T11:21:34Z","reference_number":"Issue 179","document_url":"https://www.ema.europa.eu/en/documents/newsletter/human-medicines-highlights-april-2024_en.pdf"},
    {"id":"62996","name":"CTIS newsflash - 5 April 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-04-18T09:54:48Z","last_updated_date":"2024-04-18T09:54:48Z","reference_number":"EMA/128274/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-5-april-2024_en.pdf"},
    {"id":"63038","name":"CTIS newsflash - 22 April 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-04-22T16:14:56Z","last_updated_date":"2024-04-22T16:14:56Z","reference_number":"EMA/147229/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-22-april-2024_en.pdf"},
    {"id":"63166","name":"CTIS newsflash – 3 May 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-05-06T10:32:00Z","last_updated_date":"2024-05-06T10:32:00Z","reference_number":"EMA/174397/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-3-may-2024_en.pdf"},
    {"id":"63280","name":"CTIS newsflash - 17 May 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-05-21T13:18:23Z","last_updated_date":"2024-05-21T13:18:23Z","reference_number":"EMA/162262/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-17-may-2024_en.pdf"},
    {"id":"63448","name":" CTIS newsflash - 31 May 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-06-03T09:44:01Z","last_updated_date":"2024-06-03T09:44:01Z","reference_number":"EMA/240597/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-31-may-2024_en.pdf"},
    {"id":"63656","name":"CTIS newsflash – 14 June 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-06-17T16:23:00Z","last_updated_date":"2024-06-17T16:23:00Z","reference_number":"EMA/264069/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-14-june-2024_en.pdf"},
    {"id":"63802","name":"CTIS newsflash - 28 June 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T13:56:58Z","last_updated_date":"2024-06-28T13:56:58Z","reference_number":"EMA/291916/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-28-june-2024_en.pdf"},
    {"id":"64190","name":"CTIS newsflash - 12 July 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-07-18T10:36:23Z","last_updated_date":"2024-07-18T10:36:23Z","reference_number":"EMA/303545/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-12-july-2024_en.pdf"},
    {"id":"64353","name":"CTIS newsflash - 26 July 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-07-29T09:47:05Z","last_updated_date":"2024-07-29T09:47:05Z","reference_number":"EMA/334159/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-26-july-2024_en.pdf"},
    {"id":"64573","name":"CTIS newsflash - 9 August 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-08-14T15:28:49Z","last_updated_date":"2024-08-14T15:28:49Z","reference_number":"EMA/325160/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-9-august-2024_en.pdf"},
    {"id":"64770","name":"CTIS newsflash - 10 September 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-09-10T11:26:52Z","last_updated_date":"2024-09-10T11:26:52Z","reference_number":"EMA/374537/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-10-september-2024_en.pdf"},
    {"id":"65035","name":"CTIS newsflash - 24 September 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-09-25T14:20:00Z","last_updated_date":"2024-09-25T14:20:00Z","reference_number":"EMA/421508/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-24-september-2024_en.pdf"},
    {"id":"65273","name":"CTIS newsflash - 8 October 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-10-10T15:32:15Z","last_updated_date":"2024-10-10T15:32:15Z","reference_number":"EMA/441928/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-8-october-2024_en.pdf"},
    {"id":"65551","name":"CTIS newsflash - 22 October 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-11-05T17:01:00Z","last_updated_date":"2024-11-05T17:01:00Z","reference_number":"EMA/469994/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-22-october-2024_en.pdf"},
    {"id":"65552","name":"CTIS newsflash - 5 November 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-11-05T17:02:26Z","last_updated_date":"2024-11-05T17:02:26Z","reference_number":"EMA/501426/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-5-november-2024_en.pdf"},
    {"id":"65726","name":"CTIS newsflash - 19 November 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-11-20T13:13:37Z","last_updated_date":"2024-11-20T13:13:37Z","reference_number":"EMA/514303/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-19-november-2024_en.pdf"},
    {"id":"65941","name":"CTIS newsflash - 3 December 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-12-04T12:32:41Z","last_updated_date":"2024-12-04T12:32:41Z","reference_number":"EMA/541301/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-3-december-2024_en.pdf"},
    {"id":"66166","name":"CTIS newsflash - 17 December 2024","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2024-12-17T12:34:47Z","last_updated_date":"2024-12-17T12:34:47Z","reference_number":"EMA/559561/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-17-december-2024_en.pdf"},
    {"id":"66303","name":"CTIS newsflash - 14 January 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-01-14T11:26:22Z","last_updated_date":"2025-01-14T11:26:22Z","reference_number":"EMA/582910/2024","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-14-january-2025_en.pdf"},
    {"id":"66486","name":"CTIS newsflash – 28 January 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-01-28T15:00:00Z","last_updated_date":"2025-01-28T15:00:00Z","reference_number":"EMA/7145/2025","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-28-january-2025_en.pdf"},
    {"id":"66682","name":"CTIS newsflash – 11 February 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-02-11T16:00:00Z","last_updated_date":"2025-02-11T16:00:00Z","reference_number":"EMA/37270/2025","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-11-february-2025_en.pdf"},
    {"id":"66973","name":"CTIS newsflash - 25 February 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T16:09:05Z","last_updated_date":"2025-02-25T16:09:05Z","reference_number":"EMA/36861/2025","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-25-february-2025_en.pdf"},
    {"id":"67232","name":"CTIS newsflash - 11 March 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-03-12T14:15:41Z","last_updated_date":"2025-03-12T14:15:41Z","reference_number":"EMA/72075/2025","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-11-march-2025_en.pdf"},
    {"id":"67443","name":"CTIS newsflash - 25 March 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-03-25T16:18:29Z","last_updated_date":"2025-03-25T16:18:29Z","reference_number":"EMA/90566/2025","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-25-march-2025_en.pdf"},
    {"id":"67702","name":"CTIS newsflash – 8 April 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-04-08T15:57:44Z","last_updated_date":"2025-04-08T15:57:44Z","reference_number":"EMA/108619/2025","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-8-april-2025_en.pdf"},
    {"id":"68032","name":"CTIS newsflash - 29 April 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-04-29T16:50:56Z","last_updated_date":"2025-04-29T16:50:56Z","reference_number":"EMA/124649/2025","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-29-april-2025_en.pdf"},
    {"id":"68345","name":"CTIS newsflash - 16 May 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-05-19T15:11:40Z","last_updated_date":"2025-05-19T15:11:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-16-may-2025_en.pdf"},
    {"id":"68472","name":"CTIS newsflash - 27 May 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-05-27T14:52:47Z","last_updated_date":"2025-05-27T14:52:47Z","reference_number":"EMA/175583/2025","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-27-may-2025_en.pdf"},
    {"id":"68712","name":"CTIS newsflash - 10 June 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-06-12T11:54:25Z","last_updated_date":"2025-06-12T11:54:25Z","reference_number":"EMA/179146/2025","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-10-june-2025_en.pdf"},
    {"id":"68974","name":"CTIS newsflash – 24 June 2025","type":"newsletter","status":"unknown","consultation_date":"","first_published_date":"2025-06-25T17:28:17Z","last_updated_date":"2025-06-25T17:28:17Z","reference_number":"EMA/198062/2025","document_url":"https://www.ema.europa.eu/en/documents/newsletter/ctis-newsflash-24-june-2025_en.pdf"},
    {"id":"2405","name":"EU/3/09/688: Public summary of positive opinion for orphan designation of patupilone for the treatment of fallopian tube cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2015-02-12T00:09:21Z","reference_number":"EMEA/COMP/582074/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309688-public-summary-positive-opinion-orphan-designation-patupilone-treatment-fallopian-tube-cancer_en.pdf"},
    {"id":"2421","name":"EU/3/01/024: Public summary of positive opinion for orphan designation of ribavirin for the treatment of haemorrhagic fever with renal syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T00:00:00Z","last_updated_date":"2011-05-07T01:00:00Z","reference_number":"EMEA/COMP/125/04draft","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301024-public-summary-positive-opinion-orphan-designation-ribavirin-treatment-haemorrhagic-fever-renal-syndrome_en.pdf"},
    {"id":"2425","name":"EU/3/09/625: Public summary of positive opinion for orphan designation of\n\nguanabenz for the treatment of traumatic spinal cord injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-12T02:00:00Z","last_updated_date":"2009-05-12T02:00:00Z","reference_number":"EMEA/COMP/163720/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309625-public-summary-positive-opinion-orphan-designation-guanabenz-treatment-traumatic-spinal-cord-injury_en.pdf"},
    {"id":"2427","name":"EU/3/05/262: Public summary of positive opinion for orphan designation of titanium dioxide and bisoctrizole for the treatment of ultraviolet-A- and visible-light-induced photosensitivity disorders (chronic actinic dermat...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-07-01T02:00:00Z","last_updated_date":"2013-07-31T02:00:00Z","reference_number":"EMEA/COMP/25343/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305262-public-summary-positive-opinion-orphan-designation-titanium-dioxide-and-bisoctrizole-treatment-ultraviolet-and-visible-light-induced-photosensitivity-disorders-chronic-actinic-dermat_en.pdf"},
    {"id":"2450","name":"EU/3/08/542: Public summary of positive opinion for orphan designation of ribonucleotide reductase R2 specific phosphorothioate oligonucleotide for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/184075/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308542-public-summary-positive-opinion-orphan-designation-ribonucleotide-reductase-r2-specific-phosphorothioate-oligonucleotide-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"2462","name":"EU/3/12/969: Public summary of opinion on orphan designation: Allogeneic human dendritic cells derived from a CD34+ progenitor cell line for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-06T16:00:00Z","last_updated_date":"2014-10-08T16:00:00Z","reference_number":"EMA/COMP/67860/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312969-public-summary-opinion-orphan-designation-allogeneic-human-dendritic-cells-derived-cd34-progenitor-cell-line-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"2474","name":"EU/3/11/874 Public summary of opinion on orphan designation: Human embryonic stem-cell-derived retinal pigment epithelial cells for the treatment of Stargardt’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2023-07-19T09:20:00Z","reference_number":"EMA/COMP/247172/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311874-public-summary-opinion-orphan-designation-human-embryonic-stem-cell-derived-retinal-pigment-epithelial-cells-treatment-stargardts-disease_en.pdf"},
    {"id":"2514","name":"EU/3/06/355: Public summary of positive opinion for orphan designation of zosuquidar trihydrochloride for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/24493/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306355-public-summary-positive-opinion-orphan-designation-zosuquidar-trihydrochloride-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"2518","name":"EU/3/15/1558: Public summary of opinion on orphan designation: Three chimeric human/murine monoclonal antibodies against the Ebola (Zaire) surface glycoprotein for the treatment for Ebola virus disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-18T10:00:00Z","last_updated_date":"2015-11-18T10:00:00Z","reference_number":"EMA/COMP/610640/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151558-public-summary-opinion-orphan-designation-three-chimeric-humanmurine-monoclonal-antibodies-against-ebola-zaire-surface-glycoprotein-treatment-ebola-virus-disease_en.pdf"},
    {"id":"2522","name":"EU/3/16/1771: Public summary of positive opinion for orphan designation of adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene for treatment of glycogen storage disease type Ia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T14:43:00Z","last_updated_date":"2016-12-14T14:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161771-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-glucose-6-phosphatase-gene-treatment-glycogen-storage-disease-type-ia_en.pdf"},
    {"id":"2523","name":"EU/3/02/095: Public summary of positive opinion of iodine (131I) chimeric IgG monoclonal antibody cG250 for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-06T01:00:00Z","last_updated_date":"2014-06-18T02:00:00Z","reference_number":"EMEA/COMP/77/02 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302095-public-summary-positive-opinion-iodine-131i-chimeric-igg-monoclonal-antibody-cg250-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"2524","name":"EU/3/10/753: Public summary of opinion on orphan designation 6alpha-ethyl-chenodeoxycholic acid for treatment of primary biliary cirrhosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-05T02:00:00Z","last_updated_date":"2010-08-05T02:00:00Z","reference_number":"EMA/COMP/235947/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310753-public-summary-opinion-orphan-designation-6alpha-ethyl-chenodeoxycholic-acid-treatment-primary-biliary-cirrhosis_en.pdf"},
    {"id":"2526","name":"EU/3/16/1692: Public summary of opinion on orphan designation: 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt for the treatment of idiopathic pulmonar...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T00:00:00Z","last_updated_date":"2016-09-06T00:00:00Z","reference_number":"EMA/COMP/446359/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161692-public-summary-opinion-orphan-designation-3-4-1h-imidazol-1-ylmethylphenyl-5-2-methylpropylthiophene-2-n-butyloxylcarbamate-sulphonamide-sodium-salt-treatment-idiopathic-pulmonar_en.pdf"},
    {"id":"2529","name":"EU/3/03/153: Public summary of positive opinion for orphan designation of herpes simplex virus lacking infected cell protein 34.5 for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-10-23T02:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMEA/COMP/1327/03 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303153-public-summary-positive-opinion-orphan-designation-herpes-simplex-virus-lacking-infected-cell-protein-345-treatment-glioma_en.pdf"},
    {"id":"2535","name":"EU/3/14/1287: Public summary of opinion on orphan designation: Beloranib for the treatment of Prader-Willi syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"EMA/COMP/223562/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141287-public-summary-opinion-orphan-designation-beloranib-treatment-prader-willi-syndrome_en.pdf"},
    {"id":"2560","name":"EU/3/11/876: Public summary of opinion on orphan designation: Viral vector containing DNA encoding the human SMN protein for the treatment of 5q spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2011-07-12T02:00:00Z","reference_number":"EMA/COMP/247581/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311876-public-summary-opinion-orphan-designation-viral-vector-containing-dna-encoding-human-smn-protein-treatment-5q-spinal-muscular-atrophy_en.pdf"},
    {"id":"2582","name":"EU/3/09/620: Public summary of positive opinion for orphan designation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate for the treatment of myelofibrosis secondary to ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-04-28T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMEA/COMP/95887/2009 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309620-public-summary-positive-opinion-orphan-designation-r-3-4-7h-pyrrolo23-dpyrimidin-4-yl-1h-pyrazol-1-yl-3-cyclopentylpropanenitrile-phosphate-treatment-myelofibrosis-secondary_en.pdf"},
    {"id":"2587","name":"EU/3/16/1722 : Public summary of opinion on orphan designation: Masitinib mesilate for treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161722-public-summary-opinion-orphan-designation-masitinib-mesilate-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"2610","name":"EU/3/15/1565: Public summary of opinion on orphan designation: 2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-18T11:00:00Z","last_updated_date":"2015-11-18T11:00:00Z","reference_number":"EMA/COMP/614807/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151565-public-summary-opinion-orphan-designation-2-chloro-n6-3-iodobenzyladenosine-5-n-methyluronamide-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"2612","name":"EU/3/10/819: Public summary of opinion on orphan designation: Human heterologous liver cells (for infusion) for the treatment of hyperargininaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-19T01:00:00Z","last_updated_date":"2011-01-19T01:00:00Z","reference_number":"EMA/COMP/636058/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310819-public-summary-opinion-orphan-designation-human-heterologous-liver-cells-infusion-treatment-hyperargininaemia_en.pdf"}    {"id":"2637","name":"EU/3/03/138: Public summary of positive opinion for orphan designation of α-1-acid glycoprotein for the treatment of tricyclic antidepressants poisoning","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-04-09T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/311/03 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303138-public-summary-positive-opinion-orphan-designation-i-1-acid-glycoprotein-treatment-tricyclic-antidepressants-poisoning_en.pdf"},
    {"id":"2644","name":"EU/3/14/1355: Public summary of opinion on orphan designation: Selinexor for the treatment of plasma cell myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2021-06-07T09:47:00Z","reference_number":"EMA/COMP/637070/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141355-public-summary-opinion-orphan-designation-selinexor-treatment-plasma-cell-myeloma_en.pdf"},
    {"id":"2657","name":"EU/3/06/357: Public summary of positive opinion for orphan designation\n\nof 2'-O-methyl-phosphorothioate oligonucleotide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/1250/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306357-public-summary-positive-opinion-orphan-designation-2-o-methyl-phosphorothioate-oligonucleotide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"2727","name":"EU/3/05/269: Public summary of positive opinion for orphan designation of tipifarnib for the treatment of acute myeloid leukemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-06-01T02:00:00Z","last_updated_date":"2005-06-01T02:00:00Z","reference_number":"EMEA/COMP/42098/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305269-public-summary-positive-opinion-orphan-designation-tipifarnib-treatment-acute-myeloid-leukemia_en.pdf"},
    {"id":"2783","name":"EU/3/08/568: Public summary of positive opinion for orphan designation of N'-(5-chloro-2-hydroxy-3-methylbenzylidene)-2,4-dihydroxybenzhydrazide for the treatment of partial deep dermal and full thickness burn wounds","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2011-04-06T02:00:00Z","reference_number":"EMEA/COMP/456630/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308568-public-summary-positive-opinion-orphan-designation-n-5-chloro-2-hydroxy-3-methylbenzylidene-24-dihydroxybenzhydrazide-treatment-partial-deep-dermal-and-full-thickness-burn-wounds_en.pdf"},
    {"id":"2787","name":"EU/3/17/1872: Public summary of opinion on orphan designation: Chimeric locked nucleic acid deoxynucleoside phosphorothioate-linked oligonucleotide inhibitor directed against microRNA-155-5p for the treatment of cutaneou...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-06-29T02:00:00Z","last_updated_date":"2022-06-22T14:45:00Z","reference_number":"EMA/274810/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171872-public-summary-opinion-orphan-designation-chimeric-locked-nucleic-acid-deoxynucleoside-phosphorothioate-linked-oligonucleotide-inhibitor-directed-against-microrna-155-5p-treatment-cutaneou_en.pdf"},
    {"id":"2824","name":"EU/3/09/704: Public summary of opinion on orphan designation of givinostat for the treatment of systemic-onset juvenile idiopathic arthritis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2013-06-25T02:00:00Z","reference_number":"EMA/COMP/769050/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309704-public-summary-opinion-orphan-designation-givinostat-treatment-systemic-onset-juvenile-idiopathic-arthritis_en.pdf"},
    {"id":"2825","name":"EU/3/16/1793: Public summary of positive opinion for orphan designation of zinc gluconate for treatment of facioscapulohumeral muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T15:43:00Z","last_updated_date":"2016-12-14T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161793-public-summary-positive-opinion-orphan-designation-zinc-gluconate-treatment-facioscapulohumeral-muscular-dystrophy_en.pdf"},
    {"id":"2849","name":"EU/3/12/1080 : Public summary of opinion on orphan designation: 4-(4-{[2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-25T12:00:00Z","last_updated_date":"2018-11-22T12:00:00Z","reference_number":"EMA/COMP/720294/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121080-public-summary-opinion-orphan-designation-4-4-2-4-chlorophenyl-44-dimethylcyclohex-1-en-1-ylmethylpiperazin-1-yl-n-3-nitro-4-tetrahydro-2h-pyran-4-ylmethylaminophenylsulfonyl-2-1h_en.pdf"},
    {"id":"2892","name":"EU/3/09/615: Public summary of positive opinion for orphan designation of N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase for the treatment of mucopolysaccharidosis type IVA (M...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-30T00:00:00Z","last_updated_date":"2011-03-19T00:00:00Z","reference_number":"EMEA/COMP/118069/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309615-public-summary-positive-opinion-orphan-designation-n-terminal-hexaglutamine-tagged-recombinant-human-n-acetylgalactosamine-6-sulfate-sulfatase-treatment-mucopolysaccharidosis-type-iva-m_en.pdf"},
    {"id":"2900","name":"EU/3/13/1134: Public summary of opinion on orphan designation: Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene for the treatment of adenosine-deaminase-deficient severe combined i...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2013-06-25T19:00:00Z","reference_number":"EMA/COMP/277074/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131134-public-summary-opinion-orphan-designation-autologous-cd34-cells-transduced-lentiviral-vector-containing-human-ada-gene-treatment-adenosine-deaminase-deficient-severe-combined-i_en.pdf"},
    {"id":"2934","name":"EU/3/09/613: Public summary of positive opinion for orphan designation of tobramycin (inhalation use) for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2018-02-09T01:00:00Z","reference_number":"EMEA/COMP/15451/2009 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309613-public-summary-positive-opinion-orphan-designation-tobramycin-inhalation-use-treatment-pseudomonas-aeruginosa-lung-infection-cystic-fibrosis_en.pdf"},
    {"id":"2952","name":"EU/3/09/679: Public summary of positive opinion for orphan designation of 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione for the treatment of progressive supranuclear palsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2013-10-18T01:09:21Z","reference_number":"EMEA/COMP/591799/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309679-public-summary-positive-opinion-orphan-designation-4-benzyl-2-naphtalen-1-yl-124-thiadiazolidine-35-dione-treatment-progressive-supranuclear-palsy_en.pdf"},
    {"id":"2961","name":"EU/3/16/1616: Public summary of opinion on orphan designation: Diclofenamide for the treatment of periodic paralysis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/COMP/61828/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161616-public-summary-opinion-orphan-designation-diclofenamide-treatment-periodic-paralysis_en.pdf"},
    {"id":"2968","name":"EU/3/14/1350: Public summary of opinion on orphan designation: Recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor for the treatment of tenosynovial giant cell...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/553659/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141350-public-summary-opinion-orphan-designation-recombinant-human-monoclonal-antibody-igg1-kappa-class-against-human-macrophage-colony-stimulating-factor-treatment-tenosynovial-giant-cell_en.pdf"},
    {"id":"2974","name":"C(2005)1171: Public summary of negative opinion for orphan designation of sudismase for the treatment of active phase of Peyronie's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-27T02:00:00Z","last_updated_date":"2005-10-27T02:00:00Z","reference_number":"EMEA/COMP/268676/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/c20051171-public-summary-negative-opinion-orphan-designation-sudismase-treatment-active-phase-peyronies-disease_en.pdf"},
    {"id":"2979","name":"EU/3/14/1271: Public summary of opinion on orphan designation of 177Lu-tetraxetan-tetulomab for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/COMP/239252/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141271-public-summary-opinion-orphan-designation-177lu-tetraxetan-tetulomab-treatment-follicular-lymphoma_en.pdf"},
    {"id":"3014","name":"EU/3/05/274: Public summary of positive opinion for orphan designation of melatonin for the treatment of non-24-hour sleep-wake disorders in blind people with no light perception","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-27T02:00:00Z","last_updated_date":"2014-06-19T02:00:00Z","reference_number":"EMEA/COMP/138419/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305274-public-summary-positive-opinion-orphan-designation-melatonin-treatment-non-24-hour-sleep-wake-disorders-blind-people-no-light-perception_en.pdf"},
    {"id":"3038","name":"EU/3/06/364: Public summary of positive opinion for orphan designation of sorafenib tosylate for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2018-01-31T13:30:00Z","reference_number":"EMEA/COMP/95269/2006 Rev3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306364-public-summary-positive-opinion-orphan-designation-sorafenib-tosylate-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"3072","name":"EU/3/01/030: Public summary of positive opinion for orphan designation\n\nof 8-cyclopentyl-1,3-dipropylxanthine for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/22868/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301030-public-summary-positive-opinion-orphan-designation-8-cyclopentyl-13-dipropylxanthine-treatment-cystic-fibrosis_en.pdf"},
    {"id":"3108","name":"EU/3/15/1553: Public summary of opinion on orphan designation: Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor for the treatment of primary mediastinal l...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2015-11-16T01:00:00Z","reference_number":"EMA/COMP/597518/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151553-public-summary-opinion-orphan-designation-autologous-t-cells-transduced-retroviral-vector-encoding-anti-cd19-cd28cd3-zeta-chimeric-antigen-receptor-treatment-primary-mediastinal-l_en.pdf"},
    {"id":"3129","name":"EU/3/12/951: Public summary of opinion on orphan designation: Sodium phenylbutyrate for the treatment of carbamoyl-phosphate-synthase-1","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T01:00:00Z","last_updated_date":"2017-08-09T02:00:00Z","reference_number":"EMA/COMP/43230/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312951-public-summary-opinion-orphan-designation-sodium-phenylbutyrate-treatment-carbamoyl-phosphate-synthase-1_en.pdf"},
    {"id":"3130","name":"EU/3/08/601: Public summary of positive opinion for orphan designation of milatuzumab for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/COMP/609983/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308601-public-summary-positive-opinion-orphan-designation-milatuzumab-treatment-multiple-myeloma_en.pdf"},
    {"id":"3147","name":"EU/3/00/005: Public summary of positive opinion for orphan designation of gemtuzumab ozogamicin for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-11-08T00:00:00Z","last_updated_date":"2013-06-19T14:00:00Z","reference_number":"EMEA/COMP/375/04 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300005-public-summary-positive-opinion-orphan-designation-gemtuzumab-ozogamicin-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"3152","name":"EU/3/07/490: Public summary of positive opinion for orphan designation of human autologous bone-forming cells derived from bone marrow stem cells for treatment of non-traumatic osteonecrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-17T01:00:00Z","last_updated_date":"2008-01-17T01:00:00Z","reference_number":"EMEA/COMP/440983/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307490-public-summary-positive-opinion-orphan-designation-human-autologous-bone-forming-cells-derived-bone-marrow-stem-cells-treatment-non-traumatic-osteonecrosis_en.pdf"},
    {"id":"3178","name":"EU/3/18/2004: Public summary of opinion on orphan designation: Tazemetostat for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-08T02:00:00Z","last_updated_date":"2018-05-08T02:00:00Z","reference_number":"EMA/111685/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182004-public-summary-opinion-orphan-designation-tazemetostat-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"3186","name":"EU/3/02/100: Public summary of positive opinion for orphan designation of recombinant human alpha-1 antitrypsin for the treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-04T16:09:00Z","last_updated_date":"2014-01-13T05:09:00Z","reference_number":"EMEA/COMP/681/02 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302100-public-summary-positive-opinion-orphan-designation-recombinant-human-alpha-1-antitrypsin-treatment-emphysema-secondary-congenital-alpha-1-antitrypsin-deficiency_en.pdf"},
    {"id":"3189","name":"EU/3/11/882: Public summary of opinion on orphan designation: Fresolimumab for the treatment of focal segmental glomerulosclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"EMA/COMP/407696/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311882-public-summary-opinion-orphan-designation-fresolimumab-treatment-focal-segmental-glomerulosclerosis_en.pdf"},
    {"id":"3248","name":"EU/3/17/1942: Public summary of opinion on orphan designation: N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin)benzamide for the treatment of peripheral T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-15T01:00:00Z","last_updated_date":"2018-01-15T01:00:00Z","reference_number":"EMA/694349/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171942-public-summary-opinion-orphan-designation-n-2-aminophenyl-4-1-13-dimethyl-1h-pyrazol-4-ylmethylpiperidinbenzamide-treatment-peripheral-t-cell-lymphoma_en.pdf"},
    {"id":"3257","name":"EU/3/13/1209: Public summary of opinion on orphan designation: Nitric oxide for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-23T01:00:00Z","last_updated_date":"2014-01-23T01:00:00Z","reference_number":"EMA/COMP/710260/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131209-public-summary-opinion-orphan-designation-nitric-oxide-treatment-cystic-fibrosis_en.pdf"},
    {"id":"3273","name":"EU/3/09/698: Public summary of positive opinion for orphan designation of\n\npegylated carboxyhaemoglobin for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-12-08T00:09:21Z","last_updated_date":"2009-12-08T00:09:21Z","reference_number":"EMA/COMP/654109/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309698-public-summary-positive-opinion-orphan-designation-pegylated-carboxyhaemoglobin-treatment-sickle-cell-disease_en.pdf"},
    {"id":"3278","name":"EU/3/18/1996: Public summary of opinion on orphan designation: Melatonin for the treatment of neonatal encephalopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-15T02:00:00Z","last_updated_date":"2018-05-15T02:00:00Z","reference_number":"EMA/141281/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181996-public-summary-opinion-orphan-designation-melatonin-treatment-neonatal-encephalopathy_en.pdf"},
    {"id":"3323","name":"EU/3/02/102: Public summary of positive opinion for orphan designation of mitotane for the treatment of adrenal cortical carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T01:00:00Z","last_updated_date":"2014-06-19T02:00:00Z","reference_number":"EMEA/COMP/966/02 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302102-public-summary-positive-opinion-orphan-designation-mitotane-treatment-adrenal-cortical-carcinoma_en.pdf"},
    {"id":"3333","name":"EU/3/15/1603: Public summary of opinion on orphan designation: Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T01:00:00Z","reference_number":"EMA/COMP/848213/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151603-public-summary-opinion-orphan-designation-live-attenuated-listeria-monocytogenes-delta-actadelta-inlb-strain-expressing-human-mesothelin-treatment-pancreatic-cancer_en.pdf"},
    {"id":"3348","name":"EU/3/10/834: Public summary of opinion on orphan designation: Human plasmin for the treatment of acute peripheral arterial occlusion","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-04T01:00:00Z","last_updated_date":"2018-03-12T12:45:00Z","reference_number":"EMA/COMP/760969/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310834-public-summary-opinion-orphan-designation-human-plasmin-treatment-acute-peripheral-arterial-occlusion_en.pdf"},
    {"id":"3404","name":"EU/3/17/1906: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector serotype 5 carrying the gene for the human frataxin protein for the treatment of Friedreich’s ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/498738/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171906-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-serotype-5-carrying-gene-human-frataxin-protein-treatment-friedreichs-ataxia_en.pdf"},
    {"id":"3408","name":"EU/3/14/1379: Public summary of opinion on orphan designation: Dantrolene sodium for the treatment of malignant hyperthermia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2015-01-16T01:00:00Z","reference_number":"EMA/COMP/652841/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141379-public-summary-opinion-orphan-designation-dantrolene-sodium-treatment-malignant-hyperthermia_en.pdf"},
    {"id":"3430","name":"EU/3/12/1051: Public summary of opinion on orphan designation: Recombinant human lecithin cholesterol acyltransferase for the treatment of lecithin-cholesterol-acyltransferase deficiency","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2012-11-16T01:00:00Z","reference_number":"EMA/COMP/613087/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121051-public-summary-opinion-orphan-designation-recombinant-human-lecithin-cholesterol-acyltransferase-treatment-lecithin-cholesterol-acyltransferase-deficiency_en.pdf"},
    {"id":"3456","name":"EU/3/16/1643: Public summary of opinion on orphan designation: Autologous stromal vascular cell fraction from adipose tissue for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-31T02:00:00Z","last_updated_date":"2020-08-13T02:00:00Z","reference_number":"EMA/COMP/236625/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161643-public-summary-opinion-orphan-designation-autologous-stromal-vascular-cell-fraction-adipose-tissue-treatment-systemic-sclerosis_en.pdf"},
    {"id":"3495","name":"EU/3/07/507: Public summary of positive opinion for orphan designation of doxorubicin hydrochloride (drug eluting beads) for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"EMEA/COMP/489044/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307507-public-summary-positive-opinion-orphan-designation-doxorubicin-hydrochloride-drug-eluting-beads-treatment-glioma_en.pdf"},
    {"id":"3500","name":"EU/3/07/464: Public summary of positive opinion for orphan designation of panobinostat lactate for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-22T00:00:00Z","last_updated_date":"2015-02-11T16:00:00Z","reference_number":"EMA/COMP/286087/2007 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307464-public-summary-positive-opinion-orphan-designation-panobinostat-lactate-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"3501","name":"EU/3/11/928: Public summary of opinion on orphan designation: Cysteamine for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"EMA/COMP/870559/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311928-public-summary-opinion-orphan-designation-cysteamine-treatment-cystic-fibrosis_en.pdf"},
    {"id":"3549","name":"EU/3/07/436: Public summary of positive opinion for orphan designation of eptacog alfa (activated) for the treatment of post-neonatal intracerebral haemorrhage","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T01:00:00Z","last_updated_date":"2011-09-05T02:00:00Z","reference_number":"EMEA/COMP/60645/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307436-public-summary-positive-opinion-orphan-designation-eptacog-alfa-activated-treatment-post-neonatal-intracerebral-haemorrhage_en.pdf"},
    {"id":"3553","name":"EU/3/11/908: Public summary of opinion on orphan designation: Kifunensine for the treatment of gamma sarcoglycanopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2014-06-19T02:00:00Z","reference_number":"EMA/COMP/657804/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311908-public-summary-opinion-orphan-designation-kifunensine-treatment-gamma-sarcoglycanopathy_en.pdf"},
    {"id":"3574","name":"EU/3/15/1448: Public summary of opinion on orphan designation: 505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase for the treatment of facioscapulohumeral muscular ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2015-04-09T02:00:00Z","reference_number":"EMA/COMP/31818/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151448-public-summary-opinion-orphan-designation-505-amino-acid-protein-corresponding-amino-acids-2-506-wild-type-human-histidyl-trna-synthetase-treatment-facioscapulohumeral-muscular_en.pdf"},
    {"id":"3575","name":"EU/3/15/1476: Public summary of positive opinion for orphan designation of 1-(4-(N-glycylamido)phenyl)-3-trifluoromethyl-5-(phenanthren-2-yl)-pyrazole-hydrochloride for the treatment of tularaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-21T14:00:00Z","last_updated_date":"2015-05-21T14:00:00Z","reference_number":"EMA/COMP/211415/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151476-public-summary-positive-opinion-orphan-designation-1-4-n-glycylamidophenyl-3-trifluoromethyl-5-phenanthren-2-yl-pyrazole-hydrochloride-treatment-tularaemia_en.pdf"},
    {"id":"3649","name":"EU/3/17/1887: Public summary of opinion on orphan designation: Synthetic glucagon analogue modified to contain 7 amino acid substitutions for the treatment of congenital hyperinsulinism","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T02:00:00Z","last_updated_date":"2017-07-17T02:00:00Z","reference_number":"EMA/326123/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171887-public-summary-opinion-orphan-designation-synthetic-glucagon-analogue-modified-contain-7-amino-acid-substitutions-treatment-congenital-hyperinsulinism_en.pdf"},
    {"id":"3659","name":"EU/3/11/898: Public summary of opinion on orphan designation: Sirolimus for the treatment of chronic non-infectious uveitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2022-08-30T11:55:00Z","reference_number":"EMA/COMP/508827/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311898-public-summary-opinion-orphan-designation-sirolimus-treatment-chronic-non-infectious-uveitis_en.pdf"},
    {"id":"3667","name":"EU/3/15/1478: Public summary of positive opinion for orphan designation of Rimeporide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-21T14:00:00Z","last_updated_date":"2015-05-21T14:00:00Z","reference_number":"EMA/COMP/211156/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151478-public-summary-positive-opinion-orphan-designation-rimeporide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"3668","name":"EU/3/09/714: Public summary of opinion on orphan designation of Streptococcus pyogenes Su strain cells treated with benzylpenicillin for the treatment of congenital lymphatic malformations","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2011-09-06T02:00:00Z","reference_number":"EMA/743702/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309714-public-summary-opinion-orphan-designation-streptococcus-pyogenes-su-strain-cells-treated-benzylpenicillin-treatment-congenital-lymphatic-malformations_en.pdf"},
    {"id":"3670","name":"EU/3/13/1174: Public summary of opinion on orphan designation: Trans-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine bis-hydrochloride for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-12T02:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMA/COMP/432481/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131174-public-summary-opinion-orphan-designation-trans-n1-1r2s-2-phenylcyclopropylcyclohexane-14-diamine-bis-hydrochloride-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"3678","name":"EU/3/16/1615: Public summary of opinion on orphan designation: 2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/COMP/72050/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161615-public-summary-opinion-orphan-designation-2-ethylbutyl-2s-2-s-2r3s4r5r-5-4-aminopyrrolo21-f124triazin-7-yl-5-cyano-34-dihydroxytetrahydrofuran-2-ylmethoxyphenoxyphosphoryl_en.pdf"},
    {"id":"3680","name":"EU/3/05/279: Public summary of positive opinion for orphan designation of (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone for ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMEA/COMP/122781/2005 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305279-public-summary-positive-opinion-orphan-designation-e-1s4s10s21r-7-z-ethylidene-421-diisopropyl-2-oxa-1213-dithia-582023-tetraazabicyclo876tricos-16-ene-3691922-pentone_en.pdf"},
    {"id":"3719","name":"EU/3/02/125: Public summary of positive opinion for orphan designation of monoclonal antibody to human interleukin-6 for the treatment of post-transplant lymphoproliferative disorders","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T03:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"EMEA/COMP/2832/02","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302125-public-summary-positive-opinion-orphan-designation-monoclonal-antibody-human-interleukin-6-treatment-post-transplant-lymphoproliferative-disorders_en.pdf"},
    {"id":"3776","name":"EU/3/16/1673: Public summary of opinion on orphan designation: Pyridoxine and L-pyroglutamic acid for the treatment of fragile X syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/396049/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161673-public-summary-opinion-orphan-designation-pyridoxine-and-l-pyroglutamic-acid-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"3778","name":"EU/3/14/1410: Public summary of opinion on orphan designation: Recombinant human aspartylglucosaminidase for the treatment of aspartylglucosaminuria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2021-06-25T01:00:00Z","reference_number":"EMA/COMP/10141/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141410-public-summary-opinion-orphan-designation-recombinant-human-aspartylglucosaminidase-treatment-aspartylglucosaminuria_en.pdf"},
    {"id":"3789","name":"EU/3/13/1196: Public summary of opinion on orphan designation:\n\nAutologous CD34+ cells transduced with a lentiviral vector containing the human Wiskott-Aldrich syndrome gene for the treatment of Wiskott-Aldrich syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-10-31T01:00:00Z","last_updated_date":"2013-10-31T01:00:00Z","reference_number":"EMA/COMP/553057/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131196-public-summary-opinion-orphan-designation-autologous-cd34-cells-transduced-lentiviral-vector-containing-human-wiskott-aldrich-syndrome-gene-treatment-wiskott-aldrich-syndrome_en.pdf"},
    {"id":"3824","name":"EU/3/12/1081 : Public summary of opinion on orphan designation: Triheptanoin for the treatment of very-long-chain 3-hydroxyacyl-CoA-dehydrogenase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-25T12:00:00Z","last_updated_date":"2016-08-12T16:00:00Z","reference_number":"EMA/COMP/744220/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121081-public-summary-opinion-orphan-designation-triheptanoin-treatment-very-long-chain-3-hydroxyacyl-coa-dehydrogenase-deficiency_en.pdf"},
    {"id":"3871","name":"EU/3/12/996: Public summary of opinion on orphan designation: N-Hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide for the treatment of meningioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-04T17:00:00Z","last_updated_date":"2012-07-04T17:00:00Z","reference_number":"EMA/COMP/285075/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312996-public-summary-opinion-orphan-designation-n-hydroxy-4-3-methyl-2-s-phenyl-butyrylamino-benzamide-treatment-meningioma_en.pdf"},
    {"id":"3874","name":"EU/3/16/1612: Public summary of opinion on orphan designation: Methyl 3-((2R)-2-hydroxy-4-(((((S)-1-methoxy-1-oxopropan-2-yl) amino)(phenoxy)phosphoryl)oxy)-3,3-dimethylbutanamido)propanoate for the treatment of pantothe...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2020-08-13T02:00:00Z","reference_number":"EMA/COMP/63648/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161612-public-summary-opinion-orphan-designation-methyl-3-2r-2-hydroxy-4-s-1-methoxy-1-oxopropan-2-yl-aminophenoxyphosphoryloxy-33-dimethylbutanamidopropanoate-treatment-pantothe_en.pdf"},
    {"id":"3890","name":"EU/3/11/937: Public summary of opinion on orphan designation: Alpha-tocotrienol quinone for the treatment of Leigh syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/COMP/870527/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311937-public-summary-opinion-orphan-designation-alpha-tocotrienol-quinone-treatment-leigh-syndrome_en.pdf"},
    {"id":"3934","name":"EU/3/03/176: Public summary of positive opinion for orphan designation of recombinant antibody derivative against human CD19 and CD3 for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T00:00:00Z","last_updated_date":"2014-05-12T18:30:00Z","reference_number":"EMA/COMP/381/2004 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303176-public-summary-positive-opinion-orphan-designation-recombinant-antibody-derivative-against-human-cd19-and-cd3-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"3936","name":"EU/3/10/772: Public summary of opinion on orphan designation: Adenovirus-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase and sulfatase modifying factor 1 cDNAs for the treatment o...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2015-05-13T16:00:00Z","reference_number":"EMA/COMP/360494/2010 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310772-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-10-carrying-human-n-sulfoglucosamine-sulfohydrolase-and-sulfatase-modifying-factor-1-cdnas-treatment-o_en.pdf"},
    {"id":"3946","name":"EU/3/10/764: Public summary of opinion on orphan designation of everolimus for the treatment of tuberous sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-11T01:31:00Z","last_updated_date":"2023-09-15T00:31:00Z","reference_number":"EMA/COMP/306721/2010 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-10-764-public-summary-opinion-orphan-designation-everolimus-treatment-tuberous-sclerosis_en.pdf"},
    {"id":"3959","name":"EU/3/14/1246: Public summary of opinion on orphan designation: 68Ga-2,2'-(7-(4-((S)-1-((4S,7S,10S,13R,16S,19R)-4-((R)-1-amino-3-(4-hydroxyphenyl) ...diacetic acid for the diagnosis of gastro-entero-pancreatic neuroendocr...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-02T19:00:00Z","last_updated_date":"2014-04-02T19:00:00Z","reference_number":"EMA/COMP/35993/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141246-public-summary-opinion-orphan-designation-68ga-22-7-4-s-1-4s7s10s13r16s19r-4-r-1-amino-3-4-hydroxyphenyl-diacetic-acid-diagnosis-gastro-entero-pancreatic-neuroendocr_en.pdf"},
    {"id":"3982","name":"EU/3/14/1296: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene for the treatment of catecholaminergic polymorphic ventricular tachy...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMA/COMP/374390/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141296-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-containing-human-cardiac-calsequestrin-gene-treatment-catecholaminergic-polymorphic-ventricular-tachy_en.pdf"},
    {"id":"4011","name":"EU/3/14/1406: Public summary of opinion on orphan designation: Chenodeoxycholic acid for the treatment of inborn errors in primary bile acid synthesis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMA/COMP/744266/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141406-public-summary-opinion-orphan-designation-chenodeoxycholic-acid-treatment-inborn-errors-primary-bile-acid-synthesis_en.pdf"},
    {"id":"4024","name":"EU/3/09/675: Public summary of positive opinion for orphan designation of sequence-modified recombinant human factor VIIa for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2016-01-19T13:30:00Z","reference_number":"EMEA/COMP/462157/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309675-public-summary-positive-opinion-orphan-designation-sequence-modified-recombinant-human-factor-viia-treatment-haemophilia_en.pdf"},
    {"id":"4033","name":"EU/3/14/1415: Public summary of opinion on orphan designation: Adenoviral vector serotype 5 containing the vascular endothelial growth factor D isoform (preprocessed short form) from a CMV promoter for the treatment of p...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/COMP/786970/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141415-public-summary-opinion-orphan-designation-adenoviral-vector-serotype-5-containing-vascular-endothelial-growth-factor-d-isoform-preprocessed-short-form-cmv-promoter-treatment-p_en.pdf"},
    {"id":"4060","name":"EU/3/15/1549: Public summary of opinion on orphan designation: Synthetic peptide L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glu...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2015-11-16T01:00:00Z","reference_number":"EMA/COMP/615274/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151549-public-summary-opinion-orphan-designation-synthetic-peptide-l-cysteine-l-cysteinylglycyl-l-glutaminyl-l-arginyl-l-alpha-glutamyl-l-threonyl-l-prolyl-l-alpha-glutamylglycyl-l-alanyl-l-alpha_en.pdf"},
    {"id":"4114","name":"EU/3/05/284: Public summary of positive opinion for orphan designation of sodium butyrate (rectal use) for the prevention of radiation proctitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-06-29T02:00:00Z","last_updated_date":"2005-06-29T02:00:00Z","reference_number":"EMEA/COMP/140439/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305284-public-summary-positive-opinion-orphan-designation-sodium-butyrate-rectal-use-prevention-radiation-proctitis_en.pdf"},
    {"id":"4137","name":"EU/3/16/1700: Public summary of opinion on orphan designation: Mifamurtide for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/449076/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161700-public-summary-opinion-orphan-designation-mifamurtide-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"4153","name":"EU/3/11/889: Public summary of opinion on orphan designation: Pegylated recombinant Erwinia chrysanthemi L-asparaginase for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/COMP/406337/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311889-public-summary-opinion-orphan-designation-pegylated-recombinant-erwinia-chrysanthemi-l-asparaginase-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"4162","name":"EU/3/00/014: Iloprost for the treatment of primary and of the following forms of secondary pulmonary hypertension: connective tissue disease pulmonary hypertension, drug-induced pulmonary hypertension, portopulmonary hyp...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-12T00:00:00Z","last_updated_date":"2013-10-08T15:00:00Z","reference_number":"EMEA/COMP/617901/2008 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300014-iloprost-treatment-primary-and-following-forms-secondary-pulmonary-hypertension-connective-tissue-disease-pulmonary-hypertension-drug-induced-pulmonary-hypertension-portopulmonary-hyp_en.pdf"},
    {"id":"4225","name":"EU/3/01/075: Public summary of positive opinion for orphan designation of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2009-09-21T02:00:00Z","reference_number":"EMEA/COMP/14442/2003 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301075-public-summary-positive-opinion-orphan-designation-denileukin-diftitox-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"4226","name":"EU/3/16/1686: Public summary of opinion on orphan designation: Recombinant humanised monoclonal IgG2 lambda antibody against human\n\nsclerostin for the treatment of osteogenesis imperfecta","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/382728/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161686-public-summary-opinion-orphan-designation-recombinant-humanised-monoclonal-igg2-lambda-antibody-against-human-sclerostin-treatment-osteogenesis-imperfecta_en.pdf"},
    {"id":"4231","name":"EU/3/09/650: Public summary of positive opinion for orphan designation\n\nof blinatumomab for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2014-05-08T17:00:00Z","reference_number":"EMA/COMP/364669/2009 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309650-public-summary-positive-opinion-orphan-designation-blinatumomab-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"4237","name":"EU/3/08/597: Public summary of positive opinion for orphan designation\n\nof 2,3,4,5 tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole dihydrochloride for the treatment of Huntington’s diseas...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMA/COMP/628335/2008 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308597-public-summary-positive-opinion-orphan-designation-2345-tetrahydro-28-dimethyl-5-2-6-methyl-3-pyridinylethyl-1h-pyrido43-bindole-dihydrochloride-treatment-huntingtons-diseas_en.pdf"},
    {"id":"4261","name":"EU/3/04/225: Public summary of positive opinion for orphan designation of sodium dichloroactetate for the treatment of systemic monochloroacetate poisoning","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/77724/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304225-public-summary-positive-opinion-orphan-designation-sodium-dichloroactetate-treatment-systemic-monochloroacetate-poisoning_en.pdf"},
    {"id":"4268","name":"EU/3/15/1482: Public summary of positive opinion for orphan designation of Adeno-associated viral vector serotype 5 containing the human CHM gene for the treatment of choroideremia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T18:00:00Z","last_updated_date":"2015-05-22T18:00:00Z","reference_number":"EMA/COMP/209763/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151482-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-serotype-5-containing-human-chm-gene-treatment-choroideremia_en.pdf"},
    {"id":"4334","name":"EU/3/11/946: Public summary of positive opinion for orphan designation: Recombinant homodimer of the human annexin V for the prevention of ischaemia/reperfusion injury associated with solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2014-04-01T18:00:00Z","reference_number":"EMA/COMP/923118/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311946-public-summary-positive-opinion-orphan-designation-recombinant-homodimer-human-annexin-v-prevention-ischaemiareperfusion-injury-associated-solid-organ-transplantation_en.pdf"},
    {"id":"4343","name":"EU/3/13/1182: Public summary of opinion on orphan designation: Cladribine for the treatment of mastocytosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-16T02:00:00Z","last_updated_date":"2013-09-16T02:00:00Z","reference_number":"EMA/COMP/439251/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131182-public-summary-opinion-orphan-designation-cladribine-treatment-mastocytosis_en.pdf"},
    {"id":"4372","name":"EU/3/04/222: Public summary of positive opinion for orphan designation of pancreatic enzymes (cross linked enzyme crystal lipase, protease, amylase) \n\nfor the treatment of malabsorption due to exocrine pancreatic enzyme ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMEA/COMP/77766/2004 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304222-public-summary-positive-opinion-orphan-designation-pancreatic-enzymes-cross-linked-enzyme-crystal-lipase-protease-amylase-treatment-malabsorption-due-exocrine-pancreatic-enzyme_en.pdf"},
    {"id":"4387","name":"EU/3/15/1510: Public summary of opinion on orphan designation: Edaravone for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2015-07-27T02:00:00Z","reference_number":"EMA/COMP/351114/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151510-public-summary-opinion-orphan-designation-edaravone-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"4407","name":"EU/3/02/107: Public summary of positive opinion for orphan designation of purified bromelain for the treatment of partial deep dermal and full thickness burns","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-08T00:00:00Z","last_updated_date":"2023-02-15T14:00:00Z","reference_number":"EMEA/COMP/1413/02 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302107-public-summary-positive-opinion-orphan-designation-purified-bromelain-treatment-partial-deep-dermal-and-full-thickness-burns_en.pdf"},
    {"id":"4442","name":"Public summary of positive opinion for orphan designation of trabedersen for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2014-04-03T16:00:00Z","reference_number":"EMEA/COMP/373187/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-positive-opinion-orphan-designation-trabedersen-treatment-pancreatic-cancer_en.pdf"},
    {"id":"4455","name":"EU/3/09/692: Public summary of positive opinion for orphan designation of\n\n16-base single-stranded PNA oligonucleotide linked to a 7-aminoacid peptide for the treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2014-04-01T18:00:00Z","reference_number":"EMA/COMP/654094/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309692-public-summary-positive-opinion-orphan-designation-16-base-single-stranded-pna-oligonucleotide-linked-7-aminoacid-peptide-treatment-neuroblastoma_en.pdf"},
    {"id":"4498","name":"EU/3/16/1634: Public summary of opinion on orphan designation: Glucopyranosyl lipid A stable emulsion and recombinant New York oesophageal squamous cell carcinoma-1 protein for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-02T02:00:00Z","last_updated_date":"2019-10-15T02:00:00Z","reference_number":"EMA/COMP/159769/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161634-public-summary-opinion-orphan-designation-glucopyranosyl-lipid-stable-emulsion-and-recombinant-new-york-oesophageal-squamous-cell-carcinoma-1-protein-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"4508","name":"EU/3/07/501: Public summary of positive opinion for orphan designation of olaparib for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2018-05-28T17:00:00Z","reference_number":"EMEA/COMP/510787/2007 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307501-public-summary-positive-opinion-orphan-designation-olaparib-treatment-ovarian-cancer_en.pdf"},
    {"id":"4519","name":"EU/3/17/1884: Public summary of opinion on orphan designation: Recombinant human factor IX protein modified with three point mutations for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T02:00:00Z","last_updated_date":"2017-07-17T02:00:00Z","reference_number":"EMA/COMP/336095/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171884-public-summary-opinion-orphan-designation-recombinant-human-factor-ix-protein-modified-three-point-mutations-treatment-haemophilia-b_en.pdf"},
    {"id":"4552","name":"EU/3/07/472: Public summary of positive opinion for orphan designation of cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyryl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"EMEA/COMP/167445/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307472-public-summary-positive-opinion-orphan-designation-cyclo-ez-2s3r4r-3-hydroxy-4-methyl-2-methylaminonona-68-dienoyl-l-2-aminobutyryl-n-methyl-glycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l_en.pdf"},
    {"id":"4605","name":"EU/3/10/804: Public summary of opinion on orphan designation methylthioninium for the treatment of progressive supranuclear palsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-15T01:00:00Z","last_updated_date":"2014-01-13T16:00:00Z","reference_number":"EMA/606348/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310804-public-summary-opinion-orphan-designation-methylthioninium-treatment-progressive-supranuclear-palsy_en.pdf"},
    {"id":"4612","name":"EU/3/15/1527: Public summary of opinion on orphan designation: Hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]acetate for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T02:00:00Z","last_updated_date":"2015-08-18T02:00:00Z","reference_number":"EMA/COMP/431631/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151527-public-summary-opinion-orphan-designation-hydrocinnamate-orn-pro-dcha-trp-argacetate-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"4622","name":"EU/3/08/530: Public summary of positive opinion for orphan designation of heterologous human adult liver derived stem cells for the treatment of ornithine-transcarbamylase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/2482/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308530-public-summary-positive-opinion-orphan-designation-heterologous-human-adult-liver-derived-stem-cells-treatment-ornithine-transcarbamylase-deficiency_en.pdf"},
    {"id":"4638","name":"EU/3/12/999: Public summary of opinion on orphan designation: Letermovir for the treatment of cytomegalovirus disease in patients with impaired cell mediated immunity","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-04T17:00:00Z","last_updated_date":"2013-06-19T14:00:00Z","reference_number":"EMA/COMP/416248/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312999-public-summary-opinion-orphan-designation-letermovir-treatment-cytomegalovirus-disease-patients-impaired-cell-mediated-immunity_en.pdf"},
    {"id":"4661","name":"EU/3/07/508: Public summary of positive opinion for orphan designation of chimeric-anti-interleukin 6 monoclonal antibody for the treatment of Castleman’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2014-07-11T14:02:00Z","reference_number":"EMEA/COMP/147287/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307508-public-summary-positive-opinion-orphan-designation-chimeric-anti-interleukin-6-monoclonal-antibody-treatment-castlemans-disease_en.pdf"},
    {"id":"4679","name":"EU/3/10/784: Public summary of opinion on orphan designation: Recombinant porcine factor VIII (B-domain-deleted) for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/COMP/394028/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310784-public-summary-opinion-orphan-designation-recombinant-porcine-factor-viii-b-domain-deleted-treatment-haemophilia_en.pdf"},
    {"id":"4706","name":"EU/3/10/727: Public summary of opinion on orphan designation: Lentiviral vector containing the human MYO7A gene for the treatment of retinitis pigmentosa in Usher syndrome 1B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMA/COMP/23512/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310727-public-summary-opinion-orphan-designation-lentiviral-vector-containing-human-myo7a-gene-treatment-retinitis-pigmentosa-usher-syndrome-1b_en.pdf"},
    {"id":"4726","name":"EU/3/00/013: Public summary of positive opinion for orphan designation of ethyl eicosopentaenoate for the treatment of Huntington's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T01:00:00Z","last_updated_date":"2006-01-04T01:00:00Z","reference_number":"EMEA/COMP/208510/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300013-public-summary-positive-opinion-orphan-designation-ethyl-eicosopentaenoate-treatment-huntingtons-disease_en.pdf"},
    {"id":"4747","name":"EU/3/18/1980: Public summary of opinion on orphan designation: Levosimendan for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/71249/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181980-public-summary-opinion-orphan-designation-levosimendan-treatment-amyotrophic-lateral-sclerosis_en.pdf"}    {"id":"4774","name":"EU/3/15/1468: Public summary of positive opinion for orphan designation of  adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene for the treatment of Gaucher disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-19T02:00:00Z","reference_number":"EMA/COMP/125699/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151468-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-containing-human-glucocerebrosidase-gene-treatment-gaucher-disease_en.pdf"},
    {"id":"4802","name":"EU/3/15/1575: Public summary of opinion on orphan designation: Humanised fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain for the prevention of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/COMP/697070/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151575-public-summary-opinion-orphan-designation-humanised-fusion-protein-consisting-extracellular-domain-cd24-linked-igg1-fc-domain-prevention-graft-versus-host-disease_en.pdf"},
    {"id":"4824","name":"EU/3/17/1835: Public summary of opinion on orphan designation: Ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the COL7A1 gene for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/68550/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171835-public-summary-opinion-orphan-designation-ex-vivo-expanded-autologous-keratinocytes-transduced-retroviral-vector-containing-col7a1-gene-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"4830","name":"EU/3/16/1651: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector serotype 9 carrying the gene for the human E6-AP ubiquitin protein ligase for the treatment of Angelman syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2016-05-30T02:00:00Z","reference_number":"EMA/COMP/235552/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161651-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-serotype-9-carrying-gene-human-e6-ap-ubiquitin-protein-ligase-treatment-angelman-syndrome_en.pdf"},
    {"id":"4851","name":"EU/3/09/635: Public summary of positive opinion for orphan designation of treprostinil diethanolamine for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-09T02:00:00Z","last_updated_date":"2009-06-09T02:00:00Z","reference_number":"EMEA/COMP/228584/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309635-public-summary-positive-opinion-orphan-designation-treprostinil-diethanolamine-treatment-systemic-sclerosis_en.pdf"},
    {"id":"4868","name":"EU/3/07/487: Public summary of positive opinion for orphan designation of 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indol for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/141024/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307487-public-summary-positive-opinion-orphan-designation-4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido54-bindol-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"4874","name":"EU/3/05/263: Public summary of positive opinion for orphan designation of dimethyl sulfoxide for the treatment of severe closed traumatic brain injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-07-01T02:00:00Z","last_updated_date":"2005-07-01T02:00:00Z","reference_number":"EMEA/COMP/159828/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305263-public-summary-positive-opinion-orphan-designation-dimethyl-sulfoxide-treatment-severe-closed-traumatic-brain-injury_en.pdf"},
    {"id":"4886","name":"EU/3/16/1653: Public summary of opinion on orphan designation: Resiquimod for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-31T02:00:00Z","last_updated_date":"2016-05-31T02:00:00Z","reference_number":"EMA/COMP/240708/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161653-public-summary-opinion-orphan-designation-resiquimod-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"4891","name":"EU/3/06/396: Public summary of positive opinion for orphan designation of\n\ncardiotrophin-1 for the prevention of the ischemia/reperfusion injury associated with solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/188219/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306396-public-summary-positive-opinion-orphan-designation-cardiotrophin-1-prevention-ischemiareperfusion-injury-associated-solid-organ-transplantation_en.pdf"},
    {"id":"4912","name":"EU/3/04/191: Public summary of positive opinion for orphan designation of ethanol (96 per cent) (gel for injection) for the treatment of congenital venous malformations","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-04-28T02:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"EMEA/COMP/71/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304191-public-summary-positive-opinion-orphan-designation-ethanol-96-cent-gel-injection-treatment-congenital-venous-malformations_en.pdf"},
    {"id":"4954","name":"EU/3/04/220: Public summary of positive opinion for orphan designation of anti epidermal growth factor receptor antibody h-R3 for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-10-01T02:00:00Z","last_updated_date":"2004-10-01T02:00:00Z","reference_number":"EMEA/COMP/380/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304220-public-summary-positive-opinion-orphan-designation-anti-epidermal-growth-factor-receptor-antibody-h-r3-treatment-glioma_en.pdf"},
    {"id":"5017","name":"EU/3/13/1190: Public summary of opinion on orphan designation:\n\nRecombinant human monoclonal IgM antibody targeting glucose regulated protein 78 for the treatment of plasma cell myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-10-31T01:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMA/COMP/560011/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131190-public-summary-opinion-orphan-designation-recombinant-human-monoclonal-igm-antibody-targeting-glucose-regulated-protein-78-treatment-plasma-cell-myeloma_en.pdf"},
    {"id":"5019","name":"EU/3/08/588: Public summary of positive opinion for orphan designation of recombinant human ADAMTS-13 for the treatment of thrombotic thrombocytopenic purpura","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/COMP/547396/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308588-public-summary-positive-opinion-orphan-designation-recombinant-human-adamts-13-treatment-thrombotic-thrombocytopenic-purpura_en.pdf"},
    {"id":"5054","name":"EU/3/09/638: Public summary of positive opinion for orphan designation of humanised IgG4 monoclonal antibody to the human toll-like receptor type 2 for the prevention of ischaemia/reperfusion injury in solid organ transp...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-09T02:00:00Z","last_updated_date":"2013-03-19T13:30:00Z","reference_number":"EMA/COMP/224347/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309638-public-summary-positive-opinion-orphan-designation-humanised-igg4-monoclonal-antibody-human-toll-receptor-type-2-prevention-ischaemiareperfusion-injury-solid-organ-transp_en.pdf"},
    {"id":"5095","name":"EU/3/14/1272: Public summary of opinion on orphan designation of recombinant human alpha 1 chain homotrimer of type VII collagen for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/COMP/258960/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141272-public-summary-opinion-orphan-designation-recombinant-human-alpha-1-chain-homotrimer-type-vii-collagen-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"5186","name":"EU/3/16/1704: Public summary of opinion on orphan designation: Sirolimus for the treatment of sporadic lymphangioleiomyomatosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/451315/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161704-public-summary-opinion-orphan-designation-sirolimus-treatment-sporadic-lymphangioleiomyomatosis_en.pdf"},
    {"id":"5188","name":"EU/3/03/140: Public summary of positive opinion for orphan designation of tobramycin (inhalation powder) for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-03-07T01:00:00Z","last_updated_date":"2023-07-31T01:00:00Z","reference_number":"EMEA/COMP/4684/03 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303140-public-summary-positive-opinion-orphan-designation-tobramycin-inhalation-powder-treatment-pseudomonas-aeruginosa-lung-infection-cystic-fibrosis_en.pdf"},
    {"id":"5190","name":"EU/3/18/1983: Public summary of opinion on orphan designation: Pyridoxal 5'-phosphate for the treatment of pyridoxamine 5'-phosphate oxidase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/67937/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181983-public-summary-opinion-orphan-designation-pyridoxal-5-phosphate-treatment-pyridoxamine-5-phosphate-oxidase-deficiency_en.pdf"},
    {"id":"5198","name":"EU/3/11/886: Public summary of opinion on orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt for the treatment of post-polycythaemia vera myelofibrosi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2013-06-20T13:00:00Z","reference_number":"EMA/COMP/407857/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311886-public-summary-opinion-orphan-designation-n-cyanomethyl-4-2-4-morpholin-4-ylphenylaminopyrimidin-4-ylbenzamide-dihydrochloride-salt-treatment-post-polycythaemia-vera-myelofibrosi_en.pdf"},
    {"id":"5212","name":"EU/3/04/213: Public summary of positive opinion for orphan designation of mepolizumab for the treatment of hypereosinophilic syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2020-10-23T02:00:00Z","reference_number":"EMEA/COMP/292/04 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304213-public-summary-positive-opinion-orphan-designation-mepolizumab-treatment-hypereosinophilic-syndrome_en.pdf"},
    {"id":"5242","name":"EU/3/08/591: Public summary of positive opinion for orphan designation of 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMEA/COMP/556772/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308591-public-summary-positive-opinion-orphan-designation-5-ethylsulfonyl-2-naphthalen-2-ylbenzodoxazole-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"5253","name":"EU/3/06/409: Public summary of  positive opinion for orphan designation of  l-asparaginase encapsulated in erythrocytes  for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/359204/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306409-public-summary-positive-opinion-orphan-designation-l-asparaginase-encapsulated-erythrocytes-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"5283","name":"EU/3/14/1307: Public summary of opinion on orphan designation: Retinol for the prevention of bronchopulmonary dysplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/COMP/443084/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141307-public-summary-opinion-orphan-designation-retinol-prevention-bronchopulmonary-dysplasia_en.pdf"},
    {"id":"5311","name":"EU/3/16/1627: Public summary of opinion on orphan designation: Allogeneic Epstein-Barr virus specific cytotoxic T lymphocytes for the treatment of post-transplant lymphoproliferative disorder","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-03T18:30:00Z","last_updated_date":"2016-05-03T18:30:00Z","reference_number":"EMA/COMP/151270/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161627-public-summary-opinion-orphan-designation-allogeneic-epstein-barr-virus-specific-cytotoxic-t-lymphocytes-treatment-post-transplant-lymphoproliferative-disorder_en.pdf"},
    {"id":"5354","name":"EU/3/07/467: Public summary of positive opinion for orphan designation of eltrombopag olamine for the treatment of idiopathic thrombocytopenic purpura","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2012-01-12T01:00:00Z","reference_number":"EMEA/COMP/287945/2007 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307467-public-summary-positive-opinion-orphan-designation-eltrombopag-olamine-treatment-idiopathic-thrombocytopenic-purpura_en.pdf"},
    {"id":"5357","name":"EU/3/17/1960: Public summary of opinion on orphan designation: Ciclopirox for the treatment of congenital erythropoietic porphyria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-14T01:00:00Z","last_updated_date":"2018-03-14T01:00:00Z","reference_number":"EMA/844079/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171960-public-summary-opinion-orphan-designation-ciclopirox-treatment-congenital-erythropoietic-porphyria_en.pdf"},
    {"id":"5411","name":"EU/3/16/1739: Public summary of positive opinion for orphan designation of a non-covalent trimer of tumour necrosis factor fused to an antibody specific to the extra-domain B of fibronectin in single-chain variable fragm...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/628407/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161739-public-summary-positive-opinion-orphan-designation-non-covalent-trimer-tumour-necrosis-factor-fused-antibody-specific-extra-domain-b-fibronectin-single-chain-variable-fragm_en.pdf"},
    {"id":"5422","name":"EU/3/12/1073 : Public summary of opinion on orphan designation: Maytansinoid-conjugated human monoclonal antibody against mesothelin for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-24T13:15:00Z","last_updated_date":"2018-10-24T16:30:00Z","reference_number":"EMA/COMP/744111/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121073-public-summary-opinion-orphan-designation-maytansinoid-conjugated-human-monoclonal-antibody-against-mesothelin-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"5442","name":"EU/3/13/1139: Public summary of opinion on orphan designation: Sodium chlorite for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T14:00:00Z","last_updated_date":"2013-09-09T14:00:00Z","reference_number":"EMA/COMP/317798/2013 Corr.","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131139-public-summary-opinion-orphan-designation-sodium-chlorite-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"5467","name":"EU/3/16/1821: Public summary of opinion on orphan designation:\n\nLeuprorelin acetate for the treatment of congenital hypogonadotropic hypogonadism","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/5459/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161821-public-summary-opinion-orphan-designation-leuprorelin-acetate-treatment-congenital-hypogonadotropic-hypogonadism_en.pdf"},
    {"id":"5485","name":"EU/3/15/1513: Public summary of opinion on orphan designation: Doxorubicin for the treatment of hepatoblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T14:00:00Z","last_updated_date":"2015-08-18T14:00:00Z","reference_number":"EMA/COMP/433087/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151513-public-summary-opinion-orphan-designation-doxorubicin-treatment-hepatoblastoma_en.pdf"},
    {"id":"5487","name":"EU/3/17/1866: Public summary of opinion on orphan designation: Human normal immunoglobulin for treatment in organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/203453/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171866-public-summary-opinion-orphan-designation-human-normal-immunoglobulin-treatment-organ-transplantation_en.pdf"},
    {"id":"5540","name":"EU/3/07/479: Public summary of positive opinion for orphan designation of N-adamantanyl-N'-Geranyl-ethylenediamine for the treatment of tuberculosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/144397/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307479-public-summary-positive-opinion-orphan-designation-n-adamantanyl-n-geranyl-ethylenediamine-treatment-tuberculosis_en.pdf"},
    {"id":"5567","name":"EU/3/11/888: Public summary of opinion on orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt for the treatment of primary myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2013-06-20T13:00:00Z","reference_number":"EMA/COMP/407883/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311888-public-summary-opinion-orphan-designation-n-cyanomethyl-4-2-4-morpholin-4-ylphenylaminopyrimidin-4-ylbenzamide-dihydrochloride-salt-treatment-primary-myelofibrosis_en.pdf"},
    {"id":"5577","name":"EU/3/16/1675: Public summary of opinion on orphan designation: Citric acid monohydrate for the treatment of acute liver failure","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/384853/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161675-public-summary-opinion-orphan-designation-citric-acid-monohydrate-treatment-acute-liver-failure_en.pdf"},
    {"id":"5615","name":"EU/3/18/1982: Public summary of opinion on orphan designation: N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide for the treatment of pulmonary arterial hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/64185/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181982-public-summary-opinion-orphan-designation-n-tert-butylcarbamoyl-5-cyano-2-4-difluoromethoxy-11-biphenyl-3-yloxybenzenesulfonamide-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"5627","name":"Public summary of positive opinion for orphan designation of forodesine hydrochloride for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-13T00:00:00Z","last_updated_date":"2007-12-13T00:00:00Z","reference_number":"EMEA/COMP/452604/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-positive-opinion-orphan-designation-forodesine-hydrochloride-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"5644","name":"EU3/03/152: Public summary of positive opinion for orphan designation of\n\nengineered protein inhibitor of human neutrophil elastase for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/3795/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303152-public-summary-positive-opinion-orphan-designation-engineered-protein-inhibitor-human-neutrophil-elastase-treatment-cystic-fibrosis_en.pdf"},
    {"id":"5686","name":"EU/3/01/067: Public summary of positive opinion for orphan designation of thalidomide for the treatment of  multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2018-07-18T02:00:00Z","reference_number":"EMEA/COMP/263/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301067-public-summary-positive-opinion-orphan-designation-thalidomide-treatment-multiple-myeloma_en.pdf"},
    {"id":"5698","name":"EU/3/05/308: Public summary of positive opinion for orphan designation of sapropterin for the treatment of hyperphenylalaninemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T00:00:00Z","last_updated_date":"2011-03-29T01:00:00Z","reference_number":"EMEA/COMP/247606/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305308-public-summary-positive-opinion-orphan-designation-sapropterin-treatment-hyperphenylalaninemia_en.pdf"},
    {"id":"5703","name":"EU/3/16/1679: Public summary of opinion on orphan designation: Eflornithine for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/387500/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161679-public-summary-opinion-orphan-designation-eflornithine-treatment-glioma_en.pdf"},
    {"id":"5714","name":"EU/3/12/1048: Public summary of opinion on orphan designation: Mixture of two allogeneic human pancreatic-cancer cell lines stably transduced with a retroviral vector encoding the murine alpha-(1,3)-galactosyltransferase...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2018-01-23T01:00:00Z","reference_number":"EMA/COMP/625102/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121048-public-summary-opinion-orphan-designation-mixture-two-allogeneic-human-pancreatic-cancer-cell-lines-stably-transduced-retroviral-vector-encoding-murine-alpha-13-galactosyltransferase_en.pdf"},
    {"id":"5733","name":"EU/3/16/1644: Public summary of opinion on orphan designation: Brincidofovir for the prevention of cytomegalovirus disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2016-05-30T02:00:00Z","reference_number":"EMA/COMP/246858/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161644-public-summary-opinion-orphan-designation-brincidofovir-prevention-cytomegalovirus-disease_en.pdf"},
    {"id":"5760","name":"EU/3/12/1000: Public summary of opinion on orphan designation: Polyinosine-polycytidylic acid coupled with the polycationic polyethyleneimine for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-04T17:00:00Z","last_updated_date":"2013-09-23T17:00:00Z","reference_number":"EMA/COMP/286701/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121000-public-summary-opinion-orphan-designation-polyinosine-polycytidylic-acid-coupled-polycationic-polyethyleneimine-treatment-pancreatic-cancer_en.pdf"},
    {"id":"5765","name":"EU/3/15/1588: Public summary of opinion on orphan designation: (R)-1-[1-(4-acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea for the treatme...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2023-04-04T12:39:00Z","reference_number":"EMA/COMP/793612/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151588-public-summary-opinion-orphan-designation-r-1-1-4-acetoxy-33-dimethyl-2-oxo-butyl-2-oxo-5-pyridin-2-yl-23-dihydro-1h-benzoe14diazepin-3-yl-3-3-methylamino-phenyl-urea-treatme_en.pdf"},
    {"id":"5766","name":"EU/3/13/1111: Public summary of opinion on orphan designation:\n\nGevokizumab for the treatment of chronic non-infectious uveitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2018-07-18T02:00:00Z","reference_number":"EMA/COMP/105735/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131111-public-summary-opinion-orphan-designation-gevokizumab-treatment-chronic-non-infectious-uveitis_en.pdf"},
    {"id":"5768","name":"EU/3/07/524: Public summary of positive opinion for orphan designation of (R)-2-Methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl] phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole for the treatment of tuber...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2014-06-18T13:30:00Z","reference_number":"EMEA/COMP/578275/2007 Rev.","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307524-public-summary-positive-opinion-orphan-designation-r-2-methyl-6-nitro-2-4-4-4-trifluoromethoxyphenoxypiperidin-1-yl-phenoxymethyl-23-dihydroimidazo21-boxazole-treatment-tuber_en.pdf"},
    {"id":"5796","name":"EU/3/06/416: Public summary of positive opinion for orphan designation of antisense oligonucleotide 5'-d[P-Thio] (CCCTG CTCCC CCCTG GCTCC)-3' for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMEA/COMP/173924/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306416-public-summary-positive-opinion-orphan-designation-antisense-oligonucleotide-5-dp-thio-ccctg-ctccc-ccctg-gctcc-3-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"5823","name":"EU/3/13/1206: Public summary of opinion on orphan designation: Synthetic 12 amino acid peptide designed after subcommissural organ-spondin for the treatment of spinal cord injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2013-12-02T01:00:00Z","reference_number":"EMA/COMP/631492/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131206-public-summary-opinion-orphan-designation-synthetic-12-amino-acid-peptide-designed-after-subcommissural-organ-spondin-treatment-spinal-cord-injury_en.pdf"},
    {"id":"5833","name":"EU/3/07/463: Public summary of positive opinion for orphan designation of pyridoxalated hemoglobin polyoxyethylene for the treatment of cardiogenic shock","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/165527/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307463-public-summary-positive-opinion-orphan-designation-pyridoxalated-hemoglobin-polyoxyethylene-treatment-cardiogenic-shock_en.pdf"},
    {"id":"5861","name":"EU/3/16/1800: Public summary of opinion on orphan designation: Dantrolene sodium for the treatment of Wolfram syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/756214/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161800-public-summary-opinion-orphan-designation-dantrolene-sodium-treatment-wolfram-syndrome_en.pdf"},
    {"id":"5870","name":"EU/3/08/552: Public summary of positive opinion for orphan designation of pegylated recombinant factor VIIa for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMEA/COMP/204660/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308552-public-summary-positive-opinion-orphan-designation-pegylated-recombinant-factor-viia-treatment-haemophilia-b_en.pdf"},
    {"id":"5876","name":"EU/3/12/1069: Public summary of opinion on orphan designation: Adeno-associated viral vector encoding an inducible short hairpin RNA targeting claudin-5 (prior to administration of 17-dimethylaminoethylamino-17-demethocy...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2016-10-21T02:00:00Z","reference_number":"EMA/COMP/655660/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121069-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-encoding-inducible-short-hairpin-rna-targeting-claudin-5-prior-administration-17-dimethylaminoethylamino-17-demethocy_en.pdf"},
    {"id":"5893","name":"EU/3/05/344: Public summary of positive opinion for orphan designation of vandetanib for the treatment of medullary thyroid carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-08-08T02:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/COMP/20891/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305344-public-summary-positive-opinion-orphan-designation-vandetanib-treatment-medullary-thyroid-carcinoma_en.pdf"},
    {"id":"5894","name":"EU/03/11/926: Public summary of opinion on orphan designation: Recombinant human minibody against complement component C5 for the treatment of primary membranoproliferative glomerulonephritis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2014-01-22T16:00:00Z","reference_number":"EMA/COMP/791225/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu0311926-public-summary-opinion-orphan-designation-recombinant-human-minibody-against-complement-component-c5-treatment-primary-membranoproliferative-glomerulonephritis_en.pdf"},
    {"id":"5897","name":"EU/3/16/1666: Public summary of opinion on orphan designation: Rimiducid for treatment of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2022-04-07T02:00:00Z","reference_number":"EMA/COMP/308001/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161666-public-summary-opinion-orphan-designation-rimiducid-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"5904","name":"EU/3/06/369: Public summary of positive opinion for orphan designation of\n\nbilayer engineered skin composed of keratinocytes from the patient (autologous) and fibroblasts from a donor (allogeneic) embedded in a plasma ma...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2015-03-11T01:00:00Z","reference_number":"EMEA/COMP/126215/2006 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306369-public-summary-positive-opinion-orphan-designation-bilayer-engineered-skin-composed-keratinocytes-patient-autologous-and-fibroblasts-donor-allogeneic-embedded-plasma-ma_en.pdf"},
    {"id":"5920","name":"EU/3/15/1443: Public summary of opinion on orphan designation: Recombinant human glutamate oxaloacetate transaminase 1 for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2021-04-07T14:33:00Z","reference_number":"EMA/COMP/26647/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151443-public-summary-opinion-orphan-designation-recombinant-human-glutamate-oxaloacetate-transaminase-1-treatment-glioma_en.pdf"},
    {"id":"5932","name":"EU/3/15/1533: Public summary of opinion on orphan designation: Human allogeneic bone-marrow-derived osteoblastic cells for the treatment of osteogenesis imperfecta","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/495514/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151533-public-summary-opinion-orphan-designation-human-allogeneic-bone-marrow-derived-osteoblastic-cells-treatment-osteogenesis-imperfecta_en.pdf"},
    {"id":"5957","name":"EU/3/09/663: Public summary of positive opinion for orphan designation of adeno-associated viral vector containing modified U1 snRNA for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"EMA/COMP/448951/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309663-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-containing-modified-u1-snrna-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"6021","name":"EU/3/15/1466: Public summary of positive opinion for orphan designation of ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL7A1-encoding retroviral vector for the treat...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/116155/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151466-public-summary-positive-opinion-orphan-designation-ex-vivo-expanded-autologous-human-keratinocytes-containing-epidermal-stem-cells-transduced-col7a1-encoding-retroviral-vector-treat_en.pdf"},
    {"id":"6030","name":"EU/3/17/1941: Public summary of opinion on orphan designation:\n\nDiazoxide choline for the treatment of Prader-Willi syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-12T01:00:00Z","last_updated_date":"2018-01-12T01:00:00Z","reference_number":"EMA/699103/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171941-public-summary-opinion-orphan-designation-diazoxide-choline-treatment-prader-willi-syndrome_en.pdf"},
    {"id":"6037","name":"EU/3/12/1075 : Public summary of opinion on orphan designation: Cyclo(-gamma-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt for ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-24T13:15:00Z","last_updated_date":"2013-01-24T13:15:00Z","reference_number":"EMA/COMP/744439/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121075-public-summary-opinion-orphan-designation-cyclo-gamma-aminobutyryl-l-phenylalanyl-l-tryptophanyl-d-tryptophanyl-l-lysyl-l-threonyl-l-phenylalanyl-n-3-carboxypropyl-glycine-amide-acetate-salt_en.pdf"},
    {"id":"6071","name":"EU/3/16/1788: Public summary of positive opinion for orphan designation of sodium benzoate for the treatment of N-acetylglutamate synthase deficiency","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T15:43:00Z","last_updated_date":"2016-12-14T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161788-public-summary-positive-opinion-orphan-designation-sodium-benzoate-treatment-n-acetylglutamate-synthase-deficiency_en.pdf"},
    {"id":"6130","name":"EU/3/08/547: Public summary of positive opinion for orphan designation of anti-von Willebrand aptamer for the treatment of thrombotic thrombocytopenic purpura","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/COMP/205588/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308547-public-summary-positive-opinion-orphan-designation-anti-von-willebrand-aptamer-treatment-thrombotic-thrombocytopenic-purpura_en.pdf"},
    {"id":"6135","name":"EU/3/04/245: Public summary of positive opinion for orphan designation of aplidine for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-11T02:00:00Z","last_updated_date":"2005-10-11T02:00:00Z","reference_number":"EMEA/COMP/127243/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304245-public-summary-positive-opinion-orphan-designation-aplidine-treatment-multiple-myeloma_en.pdf"},
    {"id":"6136","name":"EU/3/12/1017: Public summary of opinion on orphan designation: Talarozole for the treatment of recessive X-linked ichthyosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2016-01-19T14:00:00Z","reference_number":"EMA/COMP/391930/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121017-public-summary-opinion-orphan-designation-talarozole-treatment-recessive-x-linked-ichthyosis_en.pdf"},
    {"id":"6157","name":"EU/3/13/1227: Public summary of opinion on orphan designation: Adenovirus-specific T-cells derived from allogeneic donor leukocytes, expanded ex vivo, for the treatment of adenovirus infection in allogeneic haematopoieti...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"EMA/COMP/4626/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131227-public-summary-opinion-orphan-designation-adenovirus-specific-t-cells-derived-allogeneic-donor-leukocytes-expanded-ex-vivo-treatment-adenovirus-infection-allogeneic-haematopoieti_en.pdf"},
    {"id":"6160","name":"EU/3/09/674: Public summary of positive opinion for orphan designation of recombinant human serum amyloid P for the prevention of scarring post glaucoma filtration surgery","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2014-04-03T18:00:00Z","reference_number":"EMEA/COMP/478310/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309674-public-summary-positive-opinion-orphan-designation-recombinant-human-serum-amyloid-p-prevention-scarring-post-glaucoma-filtration-surgery_en.pdf"},
    {"id":"6187","name":"EU/3/05/289: Public summary of positive opinion for orphan designation of pegylated arginine deiminase for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-07-26T02:00:00Z","last_updated_date":"2005-07-26T02:00:00Z","reference_number":"EMEA/167975/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305289-public-summary-positive-opinion-orphan-designation-pegylated-arginine-deiminase-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"6212","name":"EU/3/15/1540: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene for the treatment of mucopolysaccharidosis type II (Hunter's syndrom...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/493900/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151540-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-containing-human-iduronate-2-sulfatase-gene-treatment-mucopolysaccharidosis-type-ii-hunters-syndrom_en.pdf"},
    {"id":"6213","name":"EU/3/07/502: Public summary of positive opinion for orphan designation of picoplatin for the treatment of small-cell lung cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2014-04-01T18:00:00Z","reference_number":"EMEA/COMP/473073/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307502-public-summary-positive-opinion-orphan-designation-picoplatin-treatment-small-cell-lung-cancer_en.pdf"},
    {"id":"6219","name":"EU/3/04/221: Public summary of positive opinion for orphan designation\n\nof 5,10-methylene-tetrahydrofolic acid for the treatment of pancreatic cancer in combination with 5-fluorouracil","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/389/04 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304221-public-summary-positive-opinion-orphan-designation-510-methylene-tetrahydrofolic-acid-treatment-pancreatic-cancer-combination-5-fluorouracil_en.pdf"},
    {"id":"6225","name":"EU/3/07/460: Public summary of positive opinion for orphan designation of arsenic trioxide for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2010-03-15T01:00:00Z","reference_number":"EMEA/COMP/95792/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307460-public-summary-positive-opinion-orphan-designation-arsenic-trioxide-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"6242","name":"EU/3/18/2030: Public summary of opinion on orphan designation: 20-hydroxyecdysone for treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-21T18:21:00Z","last_updated_date":"2018-08-21T18:21:00Z","reference_number":"EMA/382043/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182030-public-summary-opinion-orphan-designation-20-hydroxyecdysone-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"6254","name":"EU/3/18/2031: Public summary of opinion on orphan designation: Argon for the treatment of perinatal asphyxia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-22T11:52:00Z","last_updated_date":"2018-08-22T11:52:00Z","reference_number":"EMA/395053/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182031-public-summary-opinion-orphan-designation-argon-treatment-perinatal-asphyxia_en.pdf"},
    {"id":"6272","name":"EU/3/11/895: Public summary of opinion on orphan designation: Hydroxy-propyl-beta-cyclodextrin for the treatment of Niemann-Pick disease, type C","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMA/COMP/546608/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311895-public-summary-opinion-orphan-designation-hydroxy-propyl-beta-cyclodextrin-treatment-niemann-pick-disease-type-c_en.pdf"},
    {"id":"6281","name":"EU/3/16/1775: Public summary of positive opinion for orphan designation of alpha-tocopherol for the treatment of facioscapulohumeral muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T14:41:00Z","last_updated_date":"2016-12-14T14:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161775-public-summary-positive-opinion-orphan-designation-alpha-tocopherol-treatment-facioscapulohumeral-muscular-dystrophy_en.pdf"},
    {"id":"6293","name":"EU/3/16/1659: Public summary of opinion on orphan designation: Arimoclomol citrate for the treatment of inclusion body myositis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2022-07-19T11:28:00Z","reference_number":"EMA/COMP/306904/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161659-public-summary-opinion-orphan-designation-arimoclomol-citrate-treatment-inclusion-body-myositis_en.pdf"},
    {"id":"6314","name":"EU/3/10/827: Public summary of opinion on orphan designation: Recombinant human lysosomal acid lipase for the treatment of lysosomal acid lipase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2015-03-24T13:00:00Z","reference_number":"EMA/COMP/662892/2010 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310827-public-summary-opinion-orphan-designation-recombinant-human-lysosomal-acid-lipase-treatment-lysosomal-acid-lipase-deficiency_en.pdf"},
    {"id":"6317","name":"EU/3/05/281: Public summary of positive opinion of interferon gamma for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2007-05-30T02:00:00Z","reference_number":"EMEA/COMP/130719/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305281-public-summary-positive-opinion-interferon-gamma-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"6320","name":"EU/3/09/701: Public summary of opinion on orphan designation of 2-iminobiotin for the treatment of perinatal asphyxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMA/COMP/761401/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309701-public-summary-opinion-orphan-designation-2-iminobiotin-treatment-perinatal-asphyxia_en.pdf"},
    {"id":"6334","name":"EU/3/16/1760: Public summary of positive opinion for orphan designation of radio-iodinated (131I) anti-CD45 murine monoclonal antibody for treatment in haematopoietic stem cell transplantation","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161760-public-summary-positive-opinion-orphan-designation-radio-iodinated-131i-anti-cd45-murine-monoclonal-antibody-treatment-haematopoietic-stem-cell-transplantation_en.pdf"},
    {"id":"6354","name":"EU/3/13/1122: Public summary of opinion on orphan designation: R,S-O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxime dihydrochloride for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-05-14T12:00:00Z","last_updated_date":"2015-03-24T11:00:00Z","reference_number":"EMA/COMP/185530/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131122-public-summary-opinion-orphan-designation-rs-o-3-piperidino-2-hydroxy-1-propyl-nicotinic-acid-amidoxime-dihydrochloride-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"6359","name":"EU/3/10/783: Public summary of opinion on orphan designation: Recombinant fusion protein consisting of human coagulation factor VIII attached to the Fc domain of human IgG1 for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"EMA/COMP/367483/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310783-public-summary-opinion-orphan-designation-recombinant-fusion-protein-consisting-human-coagulation-factor-viii-attached-fc-domain-human-igg1-treatment-haemophilia_en.pdf"},
    {"id":"6380","name":"EU/3/04/233: Public summary of positive opinion for orphan designation of adeno-associated viral vector containing the human gamma sarcoglycan gene for the treatment of gamma sarcoglycanopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-11T02:00:00Z","last_updated_date":"2014-06-18T02:00:00Z","reference_number":"EMEA/COMP/336675/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304233-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-containing-human-gamma-sarcoglycan-gene-treatment-gamma-sarcoglycanopathy_en.pdf"},
    {"id":"6382","name":"EU/3/10/790: Public summary of opinion on orphan designation: Ambrisentan for the treatment idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2011-09-05T02:00:00Z","reference_number":"EMA/COMP/450736/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310790-public-summary-opinion-orphan-designation-ambrisentan-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"6410","name":"EU/3/05/300: Public summary of positive opinion for orphan designation of nemorubicin hydrochloride for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-27T02:00:00Z","last_updated_date":"2005-10-27T02:00:00Z","reference_number":"EMEA/COMP/202152/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305300-public-summary-positive-opinion-orphan-designation-nemorubicin-hydrochloride-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"6418","name":"EU/3/06/389: Public summary of positive opinion for orphan designation of lestaurtinib for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-24T00:00:00Z","last_updated_date":"2015-05-08T19:00:00Z","reference_number":"EMEA/COMP/279986/2006 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306389-public-summary-positive-opinion-orphan-designation-lestaurtinib-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"6424","name":"EU/3/05/340: Public summary of positive opinion for imatinib mesilate for the treatment of myelodysplastic / myeloproliferative diseases","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMA/COMP/386759/2005 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305340-public-summary-positive-opinion-imatinib-mesilate-treatment-myelodysplastic-myeloproliferative-diseases_en.pdf"},
    {"id":"6452","name":"EU/3/15/1457: Public summary of positive opinion for orphan designation of [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride for the treatment of t...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2022-02-02T02:00:00Z","reference_number":"EMA/COMP/125607/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151457-public-summary-positive-opinion-orphan-designation-5-5-chloro-1h-pyrrolo23-bpyridin-3-ylmethyl-pyridin-2-yl-6-trifluoromethyl-pyridin-3-ylmethyl-amine-hydrochloride-treatment-t_en.pdf"},
    {"id":"6460","name":"EU/3/08/569: Public summary of positive opinion for orphan designation of pegylated L-asparaginase for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2013-03-13T01:00:00Z","reference_number":"EMEA/COMP/456792/2008 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308569-public-summary-positive-opinion-orphan-designation-pegylated-l-asparaginase-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"6531","name":"EU/3/07/492: Public summary of positive opinion of iodine (131I) chlorotoxin for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2011-09-06T02:00:00Z","reference_number":"EMEA/COMP/467543/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307492-public-summary-positive-opinion-iodine-131i-chlorotoxin-treatment-glioma_en.pdf"},
    {"id":"6533","name":"EU/3/14/1363: Public summary of opinion on orphan designation: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T14:00:00Z","last_updated_date":"2015-06-08T15:00:00Z","reference_number":"EMA/COMP/653297/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141363-public-summary-opinion-orphan-designation-4-1s4s-5-4-4-oxazol-2-ylphenoxyphenylmethyl-25-diazabicyclo221hept-2-ylmethylbenzoic-acid-treatment-cystic-fibrosis_en.pdf"},
    {"id":"6560","name":"EU/3/16/1730 : Public summary of opinion on orphan designation: Sodium benzoate for the treatment of ornithine translocase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161730-public-summary-opinion-orphan-designation-sodium-benzoate-treatment-ornithine-translocase-deficiency_en.pdf"},
    {"id":"6639","name":"EU/3/06/395: Public summary of positive opinion for orphan designation of aviptadil for the treatment of acute lung injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2009-04-02T02:00:00Z","reference_number":"EMEA/COMP/187221/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306395-public-summary-positive-opinion-orphan-designation-aviptadil-treatment-acute-lung-injury_en.pdf"},
    {"id":"6643","name":"EU/3/16/1826: Public summary of opinion on orphan designation: Recombinant IgG degrading enzyme of Streptococcus pyogenes for the prevention of graft rejection following solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"EMA/15862/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161826-public-summary-opinion-orphan-designation-recombinant-igg-degrading-enzyme-streptococcus-pyogenes-prevention-graft-rejection-following-solid-organ-transplantation_en.pdf"},
    {"id":"6668","name":"EU/3/09/626: Public summary of  positive opinion for orphan designation of lintuzumab for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-12T02:00:00Z","last_updated_date":"2011-11-11T01:00:00Z","reference_number":"EMEA/COMP/161876/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309626-public-summary-positive-opinion-orphan-designation-lintuzumab-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"6691","name":"EU/3/11/909: Public summary of opinion on orphan designation: Macitentan for the treatment of pulmonary arterial hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2015-03-23T17:00:00Z","reference_number":"EMA/COMP/635474/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311909-public-summary-opinion-orphan-designation-macitentan-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"6693","name":"EU/3/02/093: Public summary of positive opinion for orphan designation of beclomethasone 17,21-dipropionate (oral use) for the treatment of intestinal graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2011-06-20T02:00:00Z","reference_number":"EMEA/COMP/93/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302093-public-summary-positive-opinion-orphan-designation-beclomethasone-1721-dipropionate-oral-use-treatment-intestinal-graft-versus-host-disease_en.pdf"}    {"id":"6720","name":"EU/3/15/1589: Public summary of opinion on orphan designation: Glibenclamide for the treatment of neonatal diabetes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/COMP/796201/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151589-public-summary-opinion-orphan-designation-glibenclamide-treatment-neonatal-diabetes_en.pdf"},
    {"id":"6725","name":"EU/03/14/1273: Public summary of opinion on orphan designation of autologous dendritic cells pulsed with RNA from glioma stem cells for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/COMP/228647/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu03141273-public-summary-opinion-orphan-designation-autologous-dendritic-cells-pulsed-rna-glioma-stem-cells-treatment-glioma_en.pdf"},
    {"id":"6795","name":"EU/3/16/1619: Public summary of opinion on orphan designation: DNA plasmid encoding a recombinant fusion protein consisting of the extracellular domain of human TNFα p55 receptor linked to the human IgG1 Fc domain for t...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/COMP/61236/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161619-public-summary-opinion-orphan-designation-dna-plasmid-encoding-recombinant-fusion-protein-consisting-extracellular-domain-human-tnfi-p55-receptor-linked-human-igg1-fc-domain-t_en.pdf"},
    {"id":"6804","name":"EU/3/01/083: Public summary of positive opinion for orphan designation of adenovirus-mediated Herpes simplex virus - thymidine kinase (HSV-tk) gene for the treatment of high-grade glioma with subsequent use of ganciclovi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-06T01:00:00Z","last_updated_date":"2014-04-01T14:30:00Z","reference_number":"EMA/COMP/68/02 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301083-public-summary-positive-opinion-orphan-designation-adenovirus-mediated-herpes-simplex-virus-thymidine-kinase-hsv-tk-gene-treatment-high-grade-glioma-subsequent-use-ganciclovi_en.pdf"},
    {"id":"6813","name":"EU/3/12/976: Public summary of opinion on orphan designation: Antisense oligonucleotide targeted to the SMN2 gene for the treatment of 5q spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-30T02:00:00Z","last_updated_date":"2012-04-30T02:00:00Z","reference_number":"EMA/COMP/136041/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312976-public-summary-opinion-orphan-designation-antisense-oligonucleotide-targeted-smn2-gene-treatment-5q-spinal-muscular-atrophy_en.pdf"},
    {"id":"6818","name":"EU/3/17/1901: Public summary of opinion on orphan designation: Itraconazole for the treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2023-07-27T02:00:00Z","reference_number":"EMA/475685/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171901-public-summary-opinion-orphan-designation-itraconazole-treatment-naevoid-basal-cell-carcinoma-syndrome-gorlin-syndrome_en.pdf"},
    {"id":"6823","name":"EU/3/10/789: Public summary of opinion on orphan designation: 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide for the treatment of medulloblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2014-04-01T18:00:00Z","reference_number":"EMA/COMP/483832/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310789-public-summary-opinion-orphan-designation-16-base-single-stranded-peptide-nucleic-acid-oligonucleotide-linked-7-amino-acid-peptide-treatment-medulloblastoma_en.pdf"},
    {"id":"6846","name":"EU/3/08/536: Public summary of positive opinion for orphan designation of chimeric antibody to mesothelin for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2016-08-11T02:00:00Z","reference_number":"EMEA/COMP/72873/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308536-public-summary-positive-opinion-orphan-designation-chimeric-antibody-mesothelin-treatment-pancreatic-cancer_en.pdf"},
    {"id":"6849","name":"Public summary of opinion on orphan designation: Zoledronic acid for the treatment of complex regional pain syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T02:00:00Z","last_updated_date":"2013-04-23T02:00:00Z","reference_number":"EMA/COMP/102965/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-zoledronic-acid-treatment-complex-regional-pain-syndrome_en.pdf"},
    {"id":"6852","name":"EU/3/01/023: Public summary of positive opinion for orphan designation of pegvisomant for the treatment of acromegaly","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T00:00:00Z","last_updated_date":"2013-02-27T13:00:00Z","reference_number":"EMEA/COMP/1282/03 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301023-public-summary-positive-opinion-orphan-designation-pegvisomant-treatment-acromegaly_en.pdf"},
    {"id":"6873","name":"EU/3/13/1197: Public summary of opinion on orphan designation: Autologous ex-vivo-expanded leucocytes treated with 5-aza-2’-deoxycytidine for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-11-28T01:00:00Z","last_updated_date":"2013-11-28T01:00:00Z","reference_number":"EMA/COMP/627216/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131197-public-summary-opinion-orphan-designation-autologous-ex-vivo-expanded-leucocytes-treated-5-aza-2-deoxycytidine-treatment-glioma_en.pdf"},
    {"id":"6876","name":"EU/3/06/376: Public summary of positive opinion for orphan designation of recombinant P-selectin glycoprotein immunoglobulin for the prevention of post transplantation graft dysfunction","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-24T00:00:00Z","last_updated_date":"2011-06-01T01:00:00Z","reference_number":"EMEA/COMP/133194/2006draft","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306376-public-summary-positive-opinion-orphan-designation-recombinant-p-selectin-glycoprotein-immunoglobulin-prevention-post-transplantation-graft-dysfunction_en.pdf"},
    {"id":"6908","name":"EU/3/11/849: Public summary of positive opinion for orphan designation: (S)-{8-fluoro-2-2[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3, 4-dihydro-4-quinazolinyl} acetic acid for the preve...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2013-06-19T12:00:00Z","reference_number":"EMA/COMP/57753/2011 rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311849-public-summary-positive-opinion-orphan-designation-s-8-fluoro-2-24-3-methoxyphenyl-1-piperazinyl-3-2-methoxy-5-trifluoromethyl-phenyl-3-4-dihydro-4-quinazolinyl-acetic-acid-preve_en.pdf"},
    {"id":"6910","name":"EU/3/13/1146: Public summary of opinion on orphan designation: Unoprostone isopropyl for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T14:00:00Z","last_updated_date":"2016-08-11T14:00:00Z","reference_number":"EMA/COMP/318070/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131146-public-summary-opinion-orphan-designation-unoprostone-isopropyl-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"6919","name":"EU/3/13/1101: Public summary of positive opinion of progesterone for the treatment of moderate and severe traumatic brain injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T11:00:00Z","last_updated_date":"2014-10-16T12:00:00Z","reference_number":"EMA/COMP/29206/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131101-public-summary-positive-opinion-progesterone-treatment-moderate-and-severe-traumatic-brain-injury_en.pdf"},
    {"id":"6928","name":"EU/3/05/267: Public summary of positive opinion for orphan designation of (Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysyccina...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2016-09-30T02:00:00Z","reference_number":"EMEA/COMP/216994/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305267-public-summary-positive-opinion-orphan-designation-z-n-2-diethylaminoethyl-5-5-fluoro-2-oxo-12-dihydro-3h-indol-3-ylidenemethyl-24-dimethyl-1h-pyrrole-3-carboxamide-s-2-hydroxysyccina_en.pdf"},
    {"id":"6933","name":"EU/3/08/584: Public summary of positive opinion for orphan designation of palifosfamide for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2016-01-14T01:00:00Z","reference_number":"EMEA/COMP/563399/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308584-public-summary-positive-opinion-orphan-designation-palifosfamide-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"6969","name":"EU/3/16/1763: Public summary of positive opinion for orphan designation of tadekinig alfa for the treatment of haemophagocytic lymphohistiocytosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/615105/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161763-public-summary-positive-opinion-orphan-designation-tadekinig-alfa-treatment-haemophagocytic-lymphohistiocytosis_en.pdf"},
    {"id":"6975","name":"EU/3/15/1511: Public summary of opinion on orphan designation: Human plasminogen for the treatment of plasminogen deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T14:00:00Z","last_updated_date":"2015-08-18T14:00:00Z","reference_number":"EMA/COMP/426689/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151511-public-summary-opinion-orphan-designation-human-plasminogen-treatment-plasminogen-deficiency_en.pdf"},
    {"id":"6984","name":"EU/3/17/1851: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype rh.10 expressing beta-galactosidase for the treatment of GM1 gangliosidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/152998/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171851-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-rh10-expressing-beta-galactosidase-treatment-gm1-gangliosidosis_en.pdf"},
    {"id":"6990","name":"EU/3/18/2023: Public summary of opinion on orphan designation: H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-225-Actinium for the treatment of glioma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-24T11:27:00Z","last_updated_date":"2018-07-24T11:27:00Z","reference_number":"EMA/273099/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182023-public-summary-opinion-orphan-designation-h-arg-pro-lys-pro-gln-gln-phe-2thi-gly-leu-meto2-nh2-dota-225-actinium-treatment-glioma_en.pdf"},
    {"id":"6992","name":"EU/3/07/468: Public summary of positive opinion for orphan designation of dihydroartemisin, piperaquine for the treatment of malaria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-07-29T02:00:00Z","last_updated_date":"2011-09-05T02:00:00Z","reference_number":"EMEA/COMP/97615/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307468-public-summary-positive-opinion-orphan-designation-dihydroartemisin-piperaquine-treatment-malaria_en.pdf"},
    {"id":"7014","name":"EU/3/18/2040: Public summary of opinion on orphan designation: Recombinant human placental growth factor for the treatment of pre eclampsia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-22T12:02:00Z","last_updated_date":"2018-08-22T12:02:00Z","reference_number":"EMA/396455/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182040-public-summary-opinion-orphan-designation-recombinant-human-placental-growth-factor-treatment-pre-eclampsia_en.pdf"},
    {"id":"7071","name":"EU/3/15/1604: Public summary of opinion on orphan designation: Two allogeneic irradiated pancreatic tumour cell lines for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T01:00:00Z","reference_number":"EMA/COMP/847393/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151604-public-summary-opinion-orphan-designation-two-allogeneic-irradiated-pancreatic-tumour-cell-lines-treatment-pancreatic-cancer_en.pdf"},
    {"id":"7097","name":"EU/3/09/717: Public summary of opinion on orphan designation of ecopipam for the treatment of Lesch-Nyhan disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:00:00Z","last_updated_date":"2010-03-03T01:00:00Z","reference_number":"EU/3/09/717","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309717-public-summary-opinion-orphan-designation-ecopipam-treatment-lesch-nyhan-disease_en.pdf"},
    {"id":"7100","name":"EU/3/13/1151: Public summary of opinion on orphan designation: Belinostat for the treatment of malignant thymoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T14:30:00Z","last_updated_date":"2014-02-07T13:30:00Z","reference_number":"EMA/COMP/411546/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131151-public-summary-opinion-orphan-designation-belinostat-treatment-malignant-thymoma_en.pdf"},
    {"id":"7105","name":"EU/3/12/1055: Public summary of opinion on orphan designation: Belinostat for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic / disseminated)","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2012-11-16T01:00:00Z","reference_number":"EMA/COMP/613019/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121055-public-summary-opinion-orphan-designation-belinostat-treatment-peripheral-t-cell-lymphoma-nodal-other-extranodal-and-leukaemic-disseminated_en.pdf"},
    {"id":"7119","name":"EU/3/15/1451: Public summary of positive opinion for orphan designation of 5'-ASCSASTSCSASGSTSCSTSGSASUSASASGSCSTSA-3' for the treatment of alport syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2023-06-05T02:00:00Z","reference_number":"EMA/COMP/127039/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151451-public-summary-positive-opinion-orphan-designation-5-ascsastscsasgstscstsgsasusasasgscstsa-3-treatment-alport-syndrome_en.pdf"},
    {"id":"7138","name":"EU/3/04/187: Public summary of positive opinion for orphan designation of human monoclonal hepatitis B immunoglobulins for the prevention of hepatitis B re-infection following liver transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-07-10T02:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/COMP/29/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304187-public-summary-positive-opinion-orphan-designation-human-monoclonal-hepatitis-b-immunoglobulins-prevention-hepatitis-b-re-infection-following-liver-transplantation_en.pdf"},
    {"id":"7144","name":"EU/3/03/165: Public summary of positive opinion for orphan designation of \n\nnolatrexed for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-23T00:00:00Z","last_updated_date":"2007-02-23T00:00:00Z","reference_number":"EMEA/COMP/1384/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303165-public-summary-positive-opinion-orphan-designation-nolatrexed-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"7147","name":"EU/3/13/1152: Public summary of opinion on orphan designation: (1-Methyl-2-nitro-1H-imidazole-5-yl)methyl N,N’-bis(2-bromoethyl)diamidophosphate for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-16T13:00:00Z","last_updated_date":"2017-10-19T13:00:00Z","reference_number":"EMA/COMP/402338/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131152-public-summary-opinion-orphan-designation-1-methyl-2-nitro-1h-imidazole-5-ylmethyl-nn-bis2-bromoethyldiamidophosphate-treatment-pancreatic-cancer_en.pdf"},
    {"id":"7156","name":"EU/3/11/864: Public summary of opinion on orphan designation: Adeno-associated viral vector containing the human ARSB gene for the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/COMP/158082/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311864-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-containing-human-arsb-gene-treatment-mucopolysaccharidosis-vi-maroteaux-lamy-syndrome_en.pdf"},
    {"id":"7164","name":"EU/3/01/034: Public summary of positive opinion for orphan designation of gusperimus trihydrochloride for the treatment of Wegener’s granulomatosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T00:00:00Z","last_updated_date":"2011-11-19T00:00:00Z","reference_number":"EMEA/COMP/169/04 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301034-public-summary-positive-opinion-orphan-designation-gusperimus-trihydrochloride-treatment-wegeners-granulomatosis_en.pdf"},
    {"id":"7201","name":"EU/3/11/857: Public summary of positive opinion for orphan designation:  Synthetic double-stranded siRNA oligonucleotide directed against transthyretin mRNA for the treatment of transthyretin-mediated amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/82557/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311857-public-summary-positive-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-transthyretin-mrna-treatment-transthyretin-mediated-amyloidosis_en.pdf"},
    {"id":"7233","name":"EU/3/06/406: Public summary of positive opinion for orphan designation of arimoclomol for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2022-07-19T11:29:00Z","reference_number":"EMA/COMP/225724/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306406-public-summary-positive-opinion-orphan-designation-arimoclomol-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"7236","name":"EU/3/18/2014: Public summary of opinion on orphan designation: 1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-6-yl)ethan-1-one for the treatment of Stargardt'...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T18:30:00Z","last_updated_date":"2018-07-23T18:30:00Z","reference_number":"EMA/270132/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182014-public-summary-opinion-orphan-designation-1-3-4-34-difluoro-2-trifluoromethylphenylpiperidine-1-carbonyl-1h4h5h6h7h-pyrazolo34-cpyridin-6-ylethan-1-one-treatment-stargardt_en.pdf"},
    {"id":"7270","name":"EU/3/07/477: Public summary of positive opinion for orphan designation of 4-Amino-1-[5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-arabinofuranosyl]-2(1H)-pyrimidinone for the treatment of hepat...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-22T01:00:00Z","last_updated_date":"2008-01-22T01:00:00Z","reference_number":"EMEA/COMP/388117/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307477-public-summary-positive-opinion-orphan-designation-4-amino-1-5-o-2r4s-2-oxido-4-4-pyridinyl-132-dioxaphosphorinan-2-yl-i2-d-arabinofuranosyl-21h-pyrimidinone-treatment-hepat_en.pdf"},
    {"id":"7288","name":"EU/3/16/1660: Public summary of opinion on orphan designation: Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene for the treatment of beta thalassaemia intermedia and major","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"EMA/COMP/309791/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161660-public-summary-opinion-orphan-designation-autologous-cd34-cells-transduced-lentiviral-vector-encoding-human-beta-globin-gene-treatment-beta-thalassaemia-intermedia-and-major_en.pdf"},
    {"id":"7326","name":"EU/3/15/1506: Public summary of opinion on orphan designation: Antisense oligonucleotide directed against TGF-β2 mRNA for the prevention of scarring post glaucoma filtration surgery","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2015-07-27T02:00:00Z","reference_number":"EMA/COMP/348492/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151506-public-summary-opinion-orphan-designation-antisense-oligonucleotide-directed-against-tgf-i22-mrna-prevention-scarring-post-glaucoma-filtration-surgery_en.pdf"},
    {"id":"7328","name":"EU/3/09/693: Public summary of positive opinion for orphan designation of1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:00Z","last_updated_date":"2009-12-07T00:09:00Z","reference_number":"EMA/COMP/662923/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309693-public-summary-positive-opinion-orphan-designation-of1-cyclopropyl-3-3-5-morpholin-4-ylmethyl-1h-benzoimidazol-2-yl-1h-pyrazol-4-yl-urea-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"7337","name":"EU/3/16/1695: Public summary of opinion on orphan designation: Autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo for the treatment of extranodal NK/T-cell ly...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2020-05-25T02:00:00Z","reference_number":"EMA/COMP/442574/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161695-public-summary-opinion-orphan-designation-autologous-epstein-barr-virus-specific-t-cells-derived-peripheral-blood-mononuclear-cells-expanded-ex-vivo-treatment-extranodal-nkt-cell-ly_en.pdf"},
    {"id":"7357","name":"EU/3/11/920: Public summary of opinion on orphan designation: Gallium (68Ga)-pasireotide tetraxetan for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2011-11-23T16:00:00Z","reference_number":"EMA/COMP/780536/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311920-public-summary-opinion-orphan-designation-gallium-68ga-pasireotide-tetraxetan-diagnosis-gastro-entero-pancreatic-neuroendocrine-tumours_en.pdf"},
    {"id":"7366","name":"EU/3/13/1173: Public summary of opinion on orphan designation: Idelalisib for the treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-12T02:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/COMP/434308/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131173-public-summary-opinion-orphan-designation-idelalisib-treatment-chronic-lymphocytic-leukaemia-small-lymphocytic-lymphoma_en.pdf"},
    {"id":"7417","name":"EU/3/16/1617: Public summary of opinion on orphan designation: Venetoclax for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/COMP/72835/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161617-public-summary-opinion-orphan-designation-venetoclax-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"7475","name":"EU/3/14/1280: Public summary of opinion on orphan designation of autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene for the treatment of mucopolysaccharidosis IIIA (Sanfilippo A sy...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/COMP/251189/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141280-public-summary-opinion-orphan-designation-autologous-cd34-cells-transduced-lentiviral-vector-containing-human-sgsh-gene-treatment-mucopolysaccharidosis-iiia-sanfilippo-sy_en.pdf"},
    {"id":"7519","name":"EU/3/16/1647: Public summary of opinion on orphan designation: Fluocinolone acetonide for the treatment of non-infectious uveitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2017-08-16T02:00:00Z","reference_number":"EMA/COMP/242323/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161647-public-summary-opinion-orphan-designation-fluocinolone-acetonide-treatment-non-infectious-uveitis_en.pdf"},
    {"id":"7528","name":"EU/3/17/1922: Public summary of opinion on orphan designation : Entospletinib for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T11:37:00Z","last_updated_date":"2018-01-08T11:37:00Z","reference_number":"EMA/623204/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171922-public-summary-opinion-orphan-designation-entospletinib-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"7543","name":"EU/3/07/482: Public summary of positive opinion for orphan designation of sulfonated monophosphorylated mannose oligosaccharide for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/135044/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307482-public-summary-positive-opinion-orphan-designation-sulfonated-monophosphorylated-mannose-oligosaccharide-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"7573","name":"EU/3/04/193: Public summary of positive opinion for orphan designation of anti-epithelial cell adhesion molecule / anti-CD3 monoclonal antibody for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-27T02:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMEA/COMP/69/2004 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304193-public-summary-positive-opinion-orphan-designation-anti-epithelial-cell-adhesion-molecule-anti-cd3-monoclonal-antibody-treatment-ovarian-cancer_en.pdf"},
    {"id":"7594","name":"EU/3/17/1913: Public summary of opinion on orphan designation: Teicoplanin for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/489706/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171913-public-summary-opinion-orphan-designation-teicoplanin-treatment-cystic-fibrosis_en.pdf"},
    {"id":"7626","name":"EU/3/05/275: Public summary of positive opinion for orphan designation of estradiol hemihydrate and progesterone for the prevention of  bronchopulmonary dysplasia in premature neonates of less than 30 weeks of gestationa...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-01T01:00:00Z","last_updated_date":"2011-11-18T01:00:00Z","reference_number":"EMEA/COMP/216883/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305275-public-summary-positive-opinion-orphan-designation-estradiol-hemihydrate-and-progesterone-prevention-bronchopulmonary-dysplasia-premature-neonates-less-30-weeks-gestationa_en.pdf"},
    {"id":"7632","name":"EU/3/08/564: Public summary of positive opinion for orphan designation\n\nof avian polyclonal IgY antibody against Pseudomonas aeruginosa for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/456746/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308564-public-summary-positive-opinion-orphan-designation-avian-polyclonal-igy-antibody-against-pseudomonas-aeruginosa-treatment-cystic-fibrosis_en.pdf"},
    {"id":"7652","name":"EU/3/14/1384: Public summary of positive opinion for orphan designation: ((E)-1-(4'-chlorophenyl)-3-(4-hydroxy-3-metoxyphenyl)prop-2-en-1-one) for the treatment of WHIM syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-02-26T18:00:00Z","reference_number":"EMA/COMP/735797/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141384-public-summary-positive-opinion-orphan-designation-e-1-4-chlorophenyl-3-4-hydroxy-3-metoxyphenylprop-2-en-1-one-treatment-whim-syndrome_en.pdf"},
    {"id":"7673","name":"EU/3/05/324: Public summary of positive opinion for orphan designation of levamisol hydrochloride for the treatment of nephrotic syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-08-08T02:00:00Z","last_updated_date":"2006-08-08T02:00:00Z","reference_number":"EMEA/COMP/315311/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305324-public-summary-positive-opinion-orphan-designation-levamisol-hydrochloride-treatment-nephrotic-syndrome_en.pdf"},
    {"id":"7675","name":"EU/3/10/762: Public summary of opinion on orphan designation of Bosutinib for the treatment of chronic myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-11T01:31:00Z","last_updated_date":"2013-06-19T13:15:00Z","reference_number":"EMA/COMP/327056/2010 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310762-public-summary-opinion-orphan-designation-bosutinib-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"7708","name":"EU/3/07/445: Public summary of positive opinion for orphan designation of antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT) for the prevention of corneal graft rejection","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-12T00:00:00Z","last_updated_date":"2007-12-12T00:00:00Z","reference_number":"EMEA/COMP/108186/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307445-public-summary-positive-opinion-orphan-designation-antisense-oligonucleotide-tatccggagggctcgccatgctgct-prevention-corneal-graft-rejection_en.pdf"},
    {"id":"7709","name":"EU/3/17/1904: Public summary of opinion on orphan designation: Picropodophyllin for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/494333/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171904-public-summary-opinion-orphan-designation-picropodophyllin-treatment-glioma_en.pdf"},
    {"id":"7826","name":"EU/3/13/1118: Public summary of opinion on orphan designation:\n\nRecombinant human tripeptidyl-peptidase 1 for the treatment of neuronal ceroid lipofuscinosis type 2","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2013-04-05T02:00:00Z","reference_number":"EMA/COMP/92274/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131118-public-summary-opinion-orphan-designation-recombinant-human-tripeptidyl-peptidase-1-treatment-neuronal-ceroid-lipofuscinosis-type-2_en.pdf"},
    {"id":"7861","name":"EU/3/17/1896: Public summary of opinion on orphan designation: Sirolimus for the treatment of pachyonychia congenita","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2017-08-14T16:54:00Z","last_updated_date":"2017-08-14T16:54:00Z","reference_number":"EMA/391493/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171896-public-summary-opinion-orphan-designation-sirolimus-treatment-pachyonychia-congenita_en.pdf"},
    {"id":"7869","name":"EU/3/01/040: Public summary of positive opinion for orphan designation of fomepizole for the treatment of methanol poisoning","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-24T00:00:00Z","last_updated_date":"2011-05-06T01:00:00Z","reference_number":"EMEA/COMP/1288/03draft","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301040-public-summary-positive-opinion-orphan-designation-fomepizole-treatment-methanol-poisoning_en.pdf"},
    {"id":"7886","name":"EU/3/17/1939: Public summary of opinion on orphan designation:\n\nC1-esterase-inhibitor human for treatment in solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-12T01:00:00Z","last_updated_date":"2018-01-12T01:00:00Z","reference_number":"EMA/690959/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171939-public-summary-opinion-orphan-designation-c1-esterase-inhibitor-human-treatment-solid-organ-transplantation_en.pdf"},
    {"id":"7899","name":"EU/3/00/004: Public summary of positive opinion for orphan designation of fluorouracil for the treatment of glioblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/258143/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300004-public-summary-positive-opinion-orphan-designation-fluorouracil-treatment-glioblastoma_en.pdf"},
    {"id":"7914","name":"EU/3/07/465: Committee for Orphan Medicinal ProductsPublic summary of positive opinion for orphan designation of L-threo-3,4-dihydroxyphenylserine for the treatment of orthostatic hypotension in patients with pure auto...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-08-28T02:00:00Z","last_updated_date":"2022-01-28T02:00:00Z","reference_number":"EMEA/COMP/519317/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307465-committee-orphan-medicinal-productspublic-summary-positive-opinion-orphan-designation-l-threo-34-dihydroxyphenylserine-treatment-orthostatic-hypotension-patients-pure-auto_en.pdf"},
    {"id":"7915","name":"EU/3/18/1986: Public summary of opinion on orphan designation: Seletalisib for the treatment of activated phosphoinositide 3-kinase delta syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/52868/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181986-public-summary-opinion-orphan-designation-seletalisib-treatment-activated-phosphoinositide-3-kinase-delta-syndrome_en.pdf"},
    {"id":"7923","name":"EU/3/12/984: Public summary of opinion on orphan designation: 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T13:00:00Z","last_updated_date":"2015-03-10T12:00:00Z","reference_number":"EMA/COMP/219979/2012 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312984-public-summary-opinion-orphan-designation-1-3r-3-4-amino-3-4-phenoxyphenyl-1h-pyrazolo34-dpyrimidin-1-yl-1-piperidinyl-2-propen-1-one-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"7924","name":"EU/3/14/1235: Public summary of opinion on orphan designation: Mixture of recombinant human IgG1 monoclonal antibodies against human cytomegalovirus envelope glycoproteins for the prevention of congenital cytomegalovirus...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-01T03:00:00Z","last_updated_date":"2015-05-08T03:00:00Z","reference_number":"EMA/COMP/29801/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141235-public-summary-opinion-orphan-designation-mixture-recombinant-human-igg1-monoclonal-antibodies-against-human-cytomegalovirus-envelope-glycoproteins-prevention-congenital-cytomegalovirus_en.pdf"},
    {"id":"7970","name":"EU/3/17/1850: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase for treatment of ornithine transcarbamylase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/159927/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171850-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-lk03-encoding-human-ornithine-transcarbamylase-treatment-ornithine-transcarbamylase-deficiency_en.pdf"},
    {"id":"7976","name":"EU/3/18/2009: Public summary of opinion on orphan designation: Autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T13:00:00Z","last_updated_date":"2022-08-17T16:42:00Z","reference_number":"EMA/198204/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182009-public-summary-opinion-orphan-designation-autologous-dendritic-cells-pulsed-killed-ovarian-cancer-cells-and-matured-tlr3-ligand-ex-vivo-treatment-ovarian-cancer_en.pdf"},
    {"id":"7979","name":"EU/3/14/1266: Public summary of opinion on orphan designation: Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 for the treatment of B-lymphoblastic leukae...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-06-04T02:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMA/COMP/157129/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141266-public-summary-opinion-orphan-designation-autologous-t-cells-transduced-lentiviral-vector-containing-chimeric-antigen-receptor-directed-against-cd19-treatment-b-lymphoblastic-leukae_en.pdf"},
    {"id":"7985","name":"EU/3/05/331: Public summary of positive opinion for orphan designation of recombinant microbial lipase for the treatment of malabsorption due to exocrine pancreatic enzyme insufficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-03-13T00:00:00Z","last_updated_date":"2013-03-01T13:00:00Z","reference_number":"EMEA/COMP/315315/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305331-public-summary-positive-opinion-orphan-designation-recombinant-microbial-lipase-treatment-malabsorption-due-exocrine-pancreatic-enzyme-insufficiency_en.pdf"},
    {"id":"8023","name":"EU/3/16/1778: Public summary of positive opinion for orphan designation of budesonide for the treatment of primary IgA nephropathy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T15:43:00Z","last_updated_date":"2016-12-13T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161778-public-summary-positive-opinion-orphan-designation-budesonide-treatment-primary-iga-nephropathy_en.pdf"},
    {"id":"8081","name":"EU/3/13/1189: Public summary of opinion on orphan designation:\n\nMexiletine hydrochloride for the treatment of myotonic disorders","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-10-31T01:00:00Z","last_updated_date":"2013-10-31T01:00:00Z","reference_number":"EMA/COMP/554729/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131189-public-summary-opinion-orphan-designation-mexiletine-hydrochloride-treatment-myotonic-disorders_en.pdf"},
    {"id":"8100","name":"EU/3/11/877: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 9 containing the human sulfamidase gene for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2011-07-12T02:00:00Z","reference_number":"EMA/COMP/290516/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311877-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-containing-human-sulfamidase-gene-treatment-mucopolysaccharidosis-type-iiia-sanfilippo-syndrome_en.pdf"},
    {"id":"8102","name":"EU/3/07/459: Public summary of positive opinion for orphan designation of \n\n1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride for the treatment of narcolepsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-12T01:00:00Z","last_updated_date":"2007-12-12T01:00:00Z","reference_number":"EMEA/COMP/246680/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307459-public-summary-positive-opinion-orphan-designation-1-3-3-4-chlorophenylpropoxypropylpiperidine-hydrochloride-treatment-narcolepsy_en.pdf"},
    {"id":"8107","name":"EU/3/17/1849: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene for treatment of Fabry disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/159926/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171849-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-alpha-galactosidase-gene-treatment-fabry-disease_en.pdf"},
    {"id":"8119","name":"EU/3/12/1019: Public summary of opinion on orphan designation: Ramucirumab for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2016-08-11T16:00:00Z","reference_number":"EMA/COMP/358556/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121019-public-summary-opinion-orphan-designation-ramucirumab-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"8143","name":"EU/3/17/1830: Public summary of opinion on orphan designation: 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/80870/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171830-public-summary-opinion-orphan-designation-5-46-dimorpholino-135-triazin-2-yl-4-trifluoromethylpyridin-2-amine-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"8178","name":"EU/3/17/1910: Public summary of opinion on orphan designation: Sirolimus for the treatment of tuberous sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/507442/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171910-public-summary-opinion-orphan-designation-sirolimus-treatment-tuberous-sclerosis_en.pdf"},
    {"id":"8202","name":"EU/3/18/2022: Public summary of opinion on orphan designation: Glucagon analogue linked to a human immunoglobulin Fc fragment for the treatment of congenital hyperinsulinism","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-24T12:51:00Z","last_updated_date":"2018-07-24T12:51:00Z","reference_number":"EMA/271839/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182022-public-summary-opinion-orphan-designation-glucagon-analogue-linked-human-immunoglobulin-fc-fragment-treatment-congenital-hyperinsulinism_en.pdf"},
    {"id":"8225","name":"EU/3/04/201: Public summary of positive opinion for orphan designation: Vascular endothelial growth factor-D gene in an adenoviral vector for use with a collagen collar for the prevention of stenosis in synthetic grafts ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-12-06T00:00:00Z","last_updated_date":"2014-04-03T16:00:00Z","reference_number":"EMA/COMP/260/04 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304201-public-summary-positive-opinion-orphan-designation-vascular-endothelial-growth-factor-d-gene-adenoviral-vector-use-collagen-collar-prevention-stenosis-synthetic-grafts_en.pdf"},
    {"id":"8231","name":"EU/3/03/145: Public summary of positive opinion for orphan designation of rubitecan for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-06-23T02:00:00Z","last_updated_date":"2003-06-23T02:00:00Z","reference_number":"EMEA/COMP/1227/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303145-public-summary-positive-opinion-orphan-designation-rubitecan-treatment-pancreatic-cancer_en.pdf"},
    {"id":"8259","name":"EU/3/17/1956: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene for the treatment of mucopolysaccharidosis...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-13T01:00:00Z","last_updated_date":"2023-09-12T01:00:00Z","reference_number":"EMA/843195/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-17-1956-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-2-6-encoding-zinc-finger-nucleases-and-human-iduronate-2-sulfatase-gene-treatment-mucopolysaccharidosis_en.pdf"},
    {"id":"8263","name":"EU/3/12/1042: Public summary of opinion on orphan designation: Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes for the prevention of cytomegalovirus disease in patient...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-26T16:30:00Z","last_updated_date":"2013-06-25T02:00:00Z","reference_number":"EMA/COMP/524463/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121042-public-summary-opinion-orphan-designation-covalently-closed-dna-plasmids-coding-cytomegalovirus-phosphoprotein-65-and-glycoprotein-b-genes-prevention-cytomegalovirus-disease-patient_en.pdf"},
    {"id":"8266","name":"EU/3/14/1388: Public summary of positive opinion for orphan designation: Allogeneic bone marrow derived mesenchymal cells expanded ex vivo in synthetic media for the prevention of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-02-26T18:00:00Z","reference_number":"EMA/COMP/732370/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141388-public-summary-positive-opinion-orphan-designation-allogeneic-bone-marrow-derived-mesenchymal-cells-expanded-ex-vivo-synthetic-media-prevention-graft-versus-host-disease_en.pdf"},
    {"id":"8270","name":"EU/3/10/748: Public summary of positive opinion for Pravastatin / zoledronic acid for the treatment of Hutchinson-Gilford progeria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMA/COMP/165397/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310748-public-summary-positive-opinion-pravastatin-zoledronic-acid-treatment-hutchinson-gilford-progeria_en.pdf"},
    {"id":"8273","name":"EU/3/06/354: Public summary of positive opinion for orphan designation of Oxalobacter formigenes strain HC-1 for the treatment of primary hyperoxaluria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2013-06-26T02:00:00Z","reference_number":"EMA/COMP/24465/2006 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306354-public-summary-positive-opinion-orphan-designation-oxalobacter-formigenes-strain-hc-1-treatment-primary-hyperoxaluria_en.pdf"},
    {"id":"8288","name":"EU/3/12/1038: Public summary of opinion on orphan designation: Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-27T16:00:00Z","last_updated_date":"2012-09-27T16:00:00Z","reference_number":"EMA/COMP/509830/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121038-public-summary-opinion-orphan-designation-recombinant-anti-cd3-bi-single-chain-fv-diphtheria-toxin-fusion-protein-treatment-peripheral-t-cell-lymphoma-nodal-other-extranodal-and-leukaemi_en.pdf"},
    {"id":"8312","name":"EU/3/17/1874: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector serotype 6 encoding the B-domain-deleted human factor VIII for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-06-29T02:00:00Z","last_updated_date":"2017-06-29T02:00:00Z","reference_number":"EMA/260421/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171874-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-serotype-6-encoding-b-domain-deleted-human-factor-viii-treatment-haemophilia_en.pdf"},
    {"id":"8355","name":"EU/3/15/1546: Public summary of opinion on orphan designation: Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2 for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2017-02-07T15:32:00Z","reference_number":"EMA/COMP/494057/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151546-public-summary-opinion-orphan-designation-allogeneic-umbilical-cord-blood-cells-treated-ex-vivo-1616-dimethyl-prostaglandin-e2-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"8369","name":"EU/3/07/430: Public summary of positive opinion for orphan designation of artesunate for the treatment of malaria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2008-07-10T02:00:00Z","reference_number":"EMEA/COMP/96483/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307430-public-summary-positive-opinion-orphan-designation-artesunate-treatment-malaria_en.pdf"},
    {"id":"8371","name":"EU/3/14/1330: Public summary of opinion on orphan designation: Lentiviral vector containing the human liver and erythroid pyruvate kinase (PKLR) gene for the treatment of pyruvate kinase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2014-10-02T02:00:00Z","reference_number":"EMA/COMP/436864/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141330-public-summary-opinion-orphan-designation-lentiviral-vector-containing-human-liver-and-erythroid-pyruvate-kinase-pklr-gene-treatment-pyruvate-kinase-deficiency_en.pdf"},
    {"id":"8385","name":"EU/3/16/1685: Public summary of opinion on orphan designation: Molgramostim for the treatment of acute respiratory distress syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/396041/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161685-public-summary-opinion-orphan-designation-molgramostim-treatment-acute-respiratory-distress-syndrome_en.pdf"},
    {"id":"8389","name":"EU/3/12/1063: Public summary of opinion on orphan designation: Panobinostat for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2015-02-11T01:00:00Z","reference_number":"EMA/COMP/683787/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121063-public-summary-opinion-orphan-designation-panobinostat-treatment-multiple-myeloma_en.pdf"},
    {"id":"8408","name":"EU/3/13/1184: Public summary of opinion on orphan designation: (1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-2-yl)-β-D-galactopyranosyl]-4-O-(α-L-fucopyranosyl)-5-orothylamido-cyclohexane-1-car...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-16T02:00:00Z","last_updated_date":"2013-09-16T02:00:00Z","reference_number":"EMA/COMP/432735/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131184-public-summary-opinion-orphan-designation-1r3r4r5s-3-o-2-o-benzoyl-3-o-sodium2s-3-cyclohexyl-propanoate-2-yl-i2-d-galactopyranosyl-4-o-i-l-fucopyranosyl-5-orothylamido-cyclohexane-1-car_en.pdf"},
    {"id":"8415","name":"EU/3/00/003: Public summary of positive opinion for orphan designation of α -Galactosidase A for the treatment of Fabry disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T01:00:00Z","last_updated_date":"2011-11-18T01:00:00Z","reference_number":"EMEA/COMP/616497/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300003-public-summary-positive-opinion-orphan-designation-i-galactosidase-treatment-fabry-disease_en.pdf"},
    {"id":"8422","name":"Public summary of negative opinion for orphan designation of capsaicin\n\nfor the treatment of painful HIV-associated neuropathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/COMP/223599/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-capsaicin-treatment-painful-hiv-associated-neuropathy_en.pdf"},
    {"id":"8423","name":"EU/3/15/1504: Public summary of opinion on orphan designation: Obinutuzumab for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2015-07-27T02:00:00Z","reference_number":"EMA/COMP/346519/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151504-public-summary-opinion-orphan-designation-obinutuzumab-treatment-follicular-lymphoma_en.pdf"},
    {"id":"8444","name":"EU/3/05/290 - Public summary of positive opinion for orphan designation of humanised antibody fragment (Ep-CAM)-truncated Pseudomonas exotoxin A fusion protein for the treatment of Ep-CAM-positive squamous cell carcinoma...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T00:00:00Z","last_updated_date":"2005-12-12T00:00:00Z","reference_number":"EMEA/COMP/163688/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305290-public-summary-positive-opinion-orphan-designation-humanised-antibody-fragment-ep-cam-truncated-pseudomonas-exotoxin-fusion-protein-treatment-ep-cam-positive-squamous-cell-carcinoma_en.pdf"},
    {"id":"8509","name":"EU/3/17/1846: Public summary of opinion on orphan designation: Vemurafenib for the treatment of Erdheim-Chester disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/72440/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171846-public-summary-opinion-orphan-designation-vemurafenib-treatment-erdheim-chester-disease_en.pdf"},
    {"id":"8528","name":"EU/3/13/1234: Public summary of opinion on orphan designation: N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide benzenesulfonic acid salt for the treatment of chronic lymphocytic leu...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T01:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMA/COMP/9979/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131234-public-summary-opinion-orphan-designation-n-3-5-fluoro-2-4-2-methoxyethoxyphenylaminopyrimidin-4-ylaminophenylacrylamide-benzenesulfonic-acid-salt-treatment-chronic-lymphocytic-leu_en.pdf"}    {"id":"8531","name":"EU/3/16/1670: Public summary of opinion on orphan designation: Vemurafenib for treatment of Langerhans’ cell histiocytosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-22T02:00:00Z","last_updated_date":"2016-06-22T02:00:00Z","reference_number":"EMA/COMP/313647/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161670-public-summary-opinion-orphan-designation-vemurafenib-treatment-langerhans-cell-histiocytosis_en.pdf"},
    {"id":"8544","name":"EU/3/10/729: Public summary of opinion on orphan designation: (1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)-bicyclo[2.2.1]hept-5-ene-2-carboxamide benzoate for the ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2011-11-18T12:16:00Z","reference_number":"EMA/COMP/23533/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310729-public-summary-opinion-orphan-designation-1s-2s-3r-4r-3-5-fluoro-2-3-methyl-4-4-methylpiperazin-1-yl-phenylamino-pyrimidin-4-ylamino-bicyclo221hept-5-ene-2-carboxamide-benzoate_en.pdf"},
    {"id":"8547","name":"EU/3/11/911: Public summary of opinion on orphan designation: Recombinant human galactocerebrosidase for the treatment of globoid cell leukodystrophy (Krabbe disease)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2020-08-12T02:00:00Z","reference_number":"EMA/COMP/584544/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311911-public-summary-opinion-orphan-designation-recombinant-human-galactocerebrosidase-treatment-globoid-cell-leukodystrophy-krabbe-disease_en.pdf"},
    {"id":"8548","name":"EU/3/07/483: Public summary of positive opinion for orphan designation of\n\namonafide L-malate for the the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMEA/COMP/129879/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307483-public-summary-positive-opinion-orphan-designation-amonafide-l-malate-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"8549","name":"EU/3/16/1735 : Public summary of opinion on orphan designation: Zoledronic acid for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161735-public-summary-opinion-orphan-designation-zoledronic-acid-treatment-glioma_en.pdf"},
    {"id":"8601","name":"EU/3/15/1484: Public summary of positive opinion for orphan designation of Nitric oxide for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T14:00:00Z","last_updated_date":"2015-05-22T14:00:00Z","reference_number":"EMA/COMP/207860/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151484-public-summary-positive-opinion-orphan-designation-nitric-oxide-treatment-cystic-fibrosis_en.pdf"},
    {"id":"8604","name":"EU/3/04/211: Public summary of positive opinion for orphan designation of defibrotide for the prevention of hepatic veno-occlusive disease (VOD)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T00:00:00Z","last_updated_date":"2005-12-12T00:00:00Z","reference_number":"EMEA/COMP/312/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304211-public-summary-positive-opinion-orphan-designation-defibrotide-prevention-hepatic-veno-occlusive-disease-vod_en.pdf"},
    {"id":"8615","name":"EU/3/05/315: Public summary of positive opinion for orphan designationof (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl] butanamidefor the treatment of progressive myoclonic epilepsies","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2022-11-08T02:00:00Z","reference_number":"EMEA/COMP/247530/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305315-public-summary-positive-opinion-orphan-designationof-2s-2-4r-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl-butanamidefor-treatment-progressive-myoclonic-epilepsies_en.pdf"},
    {"id":"8636","name":"EU/3/14/1300: Public summary of opinion on orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain for the...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T17:30:00Z","last_updated_date":"2015-03-24T16:30:00Z","reference_number":"EMA/COMP/365538/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141300-public-summary-opinion-orphan-designation-recombinant-fusion-protein-consisting-modified-form-extracellular-domain-human-activin-receptor-iib-linked-human-igg1-fc-domain_en.pdf"},
    {"id":"8651","name":"EU/3/17/1833: Public summary of opinion on orphan designation: Autologous T-cells transduced with lentiviral vector encoding an anti-SLAMF7 CD28/CD3-zeta chimeric antigen receptor for the treatment of plasma cell myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/85419/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171833-public-summary-opinion-orphan-designation-autologous-t-cells-transduced-lentiviral-vector-encoding-anti-slamf7-cd28cd3-zeta-chimeric-antigen-receptor-treatment-plasma-cell-myeloma_en.pdf"},
    {"id":"8652","name":"EU/3/02/127: Public summary of positive opinion for orphan designation of cholic acid for the treatment of inborn errors in primary-bile-acid synthesis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2013-10-10T02:00:00Z","reference_number":"EMEA/COMP/2692/02 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302127-public-summary-positive-opinion-orphan-designation-cholic-acid-treatment-inborn-errors-primary-bile-acid-synthesis_en.pdf"},
    {"id":"8663","name":"EU/3/17/1879: Public summary of opinion on orphan designation: Asp-Arg-Val-Tyr-Ile-His-Pro for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T02:00:00Z","last_updated_date":"2017-07-17T02:00:00Z","reference_number":"EMA/329481/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171879-public-summary-opinion-orphan-designation-asp-arg-val-tyr-ile-his-pro-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"8667","name":"EU/3/09/715: Public summary of opinion on orphan designation of benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] for the treatment of acute ly...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMA/COMP/804144/2009 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309715-public-summary-opinion-orphan-designation-benzamide-3-2-imidazo12-bpyridazin-3-ylethynyl-4-methyl-n-4-4-methyl-1-piperazinylmethyl-3-trifluoromethylphenyl-treatment-acute-ly_en.pdf"},
    {"id":"8684","name":"EU/3/13/1125: Public summary of opinion on orphan designation: (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-05-14T15:00:00Z","last_updated_date":"2021-05-31T17:28:00Z","reference_number":"EMA/COMP/175315/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131125-public-summary-opinion-orphan-designation-s-3-1-9h-purin-6-ylaminoethyl-8-chloro-2-phenylisoquinolin-12h-one-treatment-chronic-lymphocytic-leukaemiasmall-lymphocytic-lymphoma_en.pdf"},
    {"id":"8688","name":"EU/3/11/870: Public summary of opinion on orphan designation: S-Nitrosoglutathione for the treatment of pre-eclampsia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-31T02:00:00Z","last_updated_date":"2011-05-31T02:00:00Z","reference_number":"EMA/COMP/172586/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311870-public-summary-opinion-orphan-designation-s-nitrosoglutathione-treatment-pre-eclampsia_en.pdf"},
    {"id":"8725","name":"EU/3/09/616: Public summary of positive opinion for orphan designation\n\nof (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMEA/COMP/107945/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309616-public-summary-positive-opinion-orphan-designation-6r-4567-tetrahydro-n6-propyl-26-benzothiazolediamine-dihydrochloride-monohydrate-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"8740","name":"EU/3/13/1176: Public summary of opinion on orphan designation: Human allogeneic bone-marrow-derived osteoblastic-like cells for the treatment of non-traumatic osteonecrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-13T02:00:00Z","last_updated_date":"2013-09-13T02:00:00Z","reference_number":"EMA/COMP/439952/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131176-public-summary-opinion-orphan-designation-human-allogeneic-bone-marrow-derived-osteoblastic-cells-treatment-non-traumatic-osteonecrosis_en.pdf"},
    {"id":"8756","name":"EU/3/11/941: Public summary of positive opinion for orphan designation: Lipopolysaccharide of Ochrobactrum intermedium for the prevention of sepsis in at-risk premature infants of less than or equal to 32 weeks of gestat...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2014-10-08T16:00:00Z","reference_number":"EMA/COMP/938586/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311941-public-summary-positive-opinion-orphan-designation-lipopolysaccharide-ochrobactrum-intermedium-prevention-sepsis-risk-premature-infants-less-or-equal-32-weeks-gestat_en.pdf"},
    {"id":"8790","name":"EU/3/13/1107: Public summary of opinion on orphan designation:\n\nRecombinant adeno-associated viral vector containing the human retinoschisin gene for the treatment of X-linked juvenile retinoschisis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2013-04-05T02:00:00Z","reference_number":"EMA/COMP/94352/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131107-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-containing-human-retinoschisin-gene-treatment-x-linked-juvenile-retinoschisis_en.pdf"},
    {"id":"8811","name":"EU/3/15/1441: Public summary of opinion on orphan designation: 5-hydroxymethyl-2-furfural for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2016-02-10T01:00:00Z","reference_number":"EMA/COMP/48633/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151441-public-summary-opinion-orphan-designation-5-hydroxymethyl-2-furfural-treatment-sickle-cell-disease_en.pdf"},
    {"id":"8833","name":"EU/3/00/008: Public summary of positive opinion for orphan designation of arsenic trioxide for the treatment of acute promyelocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-04T02:00:00Z","last_updated_date":"2013-10-17T18:00:00Z","reference_number":"EMEA/COMP/9747/2003 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300008-public-summary-positive-opinion-orphan-designation-arsenic-trioxide-treatment-acute-promyelocytic-leukaemia_en.pdf"},
    {"id":"8846","name":"EU/3/17/1969: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits for the treatment of GM2 gangliosidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-13T01:00:00Z","last_updated_date":"2018-03-13T01:00:00Z","reference_number":"EMA/826135/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171969-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-serotype-21-encoding-human-beta-hexosaminidase-alpha-and-beta-subunits-treatment-gm2-gangliosidosis_en.pdf"},
    {"id":"8856","name":"EU/3/04/243: Public summary of positive opinion for orphan designation of alpha-1 antitrypsin (inhalation use) for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2013-02-07T01:00:00Z","reference_number":"EMA/COMP/109837/2004 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304243-public-summary-positive-opinion-orphan-designation-alpha-1-antitrypsin-inhalation-use-treatment-cystic-fibrosis_en.pdf"},
    {"id":"8917","name":"EU/3/12/1021: Public summary of opinion on orphan designation: 1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene for the prevention of poliomyelitis in patients with immunodeficiencies deemed a...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-08-31T12:30:00Z","last_updated_date":"2013-03-12T11:30:00Z","reference_number":"EMA/COMP/446487/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121021-public-summary-opinion-orphan-designation-1-2-chloro-4-methoxyphenoxymethyl-4-26-dichlorophenoxymethylbenzene-prevention-poliomyelitis-patients-immunodeficiencies-deemed_en.pdf"},
    {"id":"8939","name":"EU/3/14/1333: Public summary of opinion on orphan designation: Lumacaftor/ivacaftor for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"EMA/COMP/440253/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141333-public-summary-opinion-orphan-designation-lumacaftorivacaftor-treatment-cystic-fibrosis_en.pdf"},
    {"id":"8966","name":"EU/3/14/1249: Public summary of opinion on orphan designation: Phosphorothioate oligonucleotide targeted to apolipoprotein C-III for the treatment of familial chylomicronaemia syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-03T12:00:00Z","last_updated_date":"2014-04-03T12:00:00Z","reference_number":"EMA/COMP/30845/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141249-public-summary-opinion-orphan-designation-phosphorothioate-oligonucleotide-targeted-apolipoprotein-c-iii-treatment-familial-chylomicronaemia-syndrome_en.pdf"},
    {"id":"8969","name":"EU/3/11/850: Public summary of positive opinion for orphan designation: Darinaparsin for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"EMA/COMP/71586/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311850-public-summary-positive-opinion-orphan-designation-darinaparsin-treatment-peripheral-t-cell-lymphoma-nodal-other-extranodal-and-leukaemicdisseminated_en.pdf"},
    {"id":"9006","name":"EU/3/13/1219: Public summary of opinion on orphan designation: Fenfluramine hydrochloride for the treatment of Dravet syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-23T01:00:00Z","last_updated_date":"2020-11-06T01:00:00Z","reference_number":"EMA/COMP/700717/2013 Corr.","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131219-public-summary-opinion-orphan-designation-fenfluramine-hydrochloride-treatment-dravet-syndrome_en.pdf"},
    {"id":"9009","name":"EU/3/12/1096: Public summary of opinion on orphan designation: Terguride for the treatment of systemic sclerosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2021-03-22T01:00:00Z","reference_number":"EMA/COMP/2116/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121096-public-summary-opinion-orphan-designation-terguride-treatment-systemic-sclerosis_en.pdf"},
    {"id":"9010","name":"EU/3/10/780: Public summary of opinion on orphan designation: Forodesine for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2010-10-18T02:00:00Z","reference_number":"EMA/COMP/397978/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310780-public-summary-opinion-orphan-designation-forodesine-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"9012","name":"EU/3/13/1193: Public summary of opinion on orphan designation:\n\n3,5-diiodothyropropionic acid for the treatment of Allan-Herndon-Dudley syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-10-31T01:00:00Z","last_updated_date":"2013-10-31T01:00:00Z","reference_number":"EMA/COMP/562044/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131193-public-summary-opinion-orphan-designation-35-diiodothyropropionic-acid-treatment-allan-herndon-dudley-syndrome_en.pdf"},
    {"id":"9033","name":"EU/3/01/020: Public summary of positive opinion for orphan designation of ibuprofen for the treatment of patent ductus arteriosus","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMEA/COMP/158/04 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301020-public-summary-positive-opinion-orphan-designation-ibuprofen-treatment-patent-ductus-arteriosus_en.pdf"},
    {"id":"9046","name":"EU/3/04/212: Public summary of positive opinion for orphan designation of defibrotide for the treatment of hepatic veno-occlusive disease (VOD)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T00:00:00Z","last_updated_date":"2013-11-11T12:00:00Z","reference_number":"EMEA/COMP/313/2004 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304212-public-summary-positive-opinion-orphan-designation-defibrotide-treatment-hepatic-veno-occlusive-disease-vod_en.pdf"},
    {"id":"9073","name":"EU/3/16/1614: Public summary of opinion on orphan designation: Tolfenamic acid for the treatment of behavioural variant frontotemporal dementia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/COMP/75479/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161614-public-summary-opinion-orphan-designation-tolfenamic-acid-treatment-behavioural-variant-frontotemporal-dementia_en.pdf"},
    {"id":"9085","name":"EU/3/16/1622: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 5 containing a B-domain deleted variant of human coagulation factor VIII gene for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"EMA/COMP/163486/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161622-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-5-containing-b-domain-deleted-variant-human-coagulation-factor-viii-gene-treatment-haemophilia_en.pdf"},
    {"id":"9088","name":"EU/3/08/560: Public summary of positive opinion for orphan designationof (-)-(2R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate for the treatment of moderate and severe closed traumatic brai...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2013-11-28T11:53:00Z","reference_number":"EMEA/COMP/449352/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308560-public-summary-positive-opinion-orphan-designationof-2r-3-2-hydroxymethylindanyl-4-oxy-phenyl-444-trifluorobutane-1-sulfonate-treatment-moderate-and-severe-closed-traumatic-brai_en.pdf"},
    {"id":"9094","name":"EU/3/04/204: Public summary of positive opinion for orphan designation of aztreonam lysinate (inhalation use) for the treatment of gram negative bacterial lung infection in cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2019-10-16T02:00:00Z","reference_number":"EMEA/COMP/296/04 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304204-public-summary-positive-opinion-orphan-designation-aztreonam-lysinate-inhalation-use-treatment-gram-negative-bacterial-lung-infection-cystic-fibrosis_en.pdf"},
    {"id":"9112","name":"EU/3/06/382: Public summary of positive opinion for orphan designation of pazopanib hydrochloride for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-20T00:00:00Z","last_updated_date":"2011-06-01T01:00:00Z","reference_number":"EMEA/COMP/156129/2006draft","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306382-public-summary-positive-opinion-orphan-designation-pazopanib-hydrochloride-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"9113","name":"EU/3/14/1354: Public summary of opinion on orphan designation: Selinexor for the treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/COMP/637216/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141354-public-summary-opinion-orphan-designation-selinexor-treatment-chronic-lymphocytic-leukaemia-small-lymphocytic-lymphoma_en.pdf"},
    {"id":"9116","name":"EU/3/16/1746: Public summary of positive opinion for orphan designation of carbamazepine for the treatment of metaphyseal chondrodysplasia, Schmid type","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/623846/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161746-public-summary-positive-opinion-orphan-designation-carbamazepine-treatment-metaphyseal-chondrodysplasia-schmid-type_en.pdf"},
    {"id":"9142","name":"EU/3/09/643: Public summary of positive opinion for orphan designation of desipramine chlorhydrate for the treatment of Rett syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2017-08-16T02:00:00Z","reference_number":"EMEA/COMP/295146/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309643-public-summary-positive-opinion-orphan-designation-desipramine-chlorhydrate-treatment-rett-syndrome_en.pdf"},
    {"id":"9164","name":"EU/3/10/842: Public summary of opinion on orphan designation: Nimorazole for the treatment of squamous cell carcinoma of the head and neck in patients undergoing radiotherapy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-04T01:00:00Z","last_updated_date":"2011-03-04T01:00:00Z","reference_number":"EMA/COMP/740415/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310842-public-summary-opinion-orphan-designation-nimorazole-treatment-squamous-cell-carcinoma-head-and-neck-patients-undergoing-radiotherapy_en.pdf"},
    {"id":"9268","name":"EU/3/01/035: Public summary of positive opinion for orphan designation of levodopa / carbidopa (gastroenteral use) for the treatment of advanced idiopathic Parkinson’s disease with severe motor fluctuations and not respo...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T00:00:00Z","last_updated_date":"2016-01-19T12:00:00Z","reference_number":"EMEA/COMP/197/04 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301035-public-summary-positive-opinion-orphan-designation-levodopa-carbidopa-gastroenteral-use-treatment-advanced-idiopathic-parkinsons-disease-severe-motor-fluctuations-and-not-respo_en.pdf"},
    {"id":"9280","name":"EU/3/05/271: Public summary of positive opinion for orphan designation of paromomycin sulfate for the treatment of visceral leishmaniasis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-07-01T02:00:00Z","last_updated_date":"2011-05-19T01:00:00Z","reference_number":"EMEA/COMP/131770/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305271-public-summary-positive-opinion-orphan-designation-paromomycin-sulfate-treatment-visceral-leishmaniasis_en.pdf"},
    {"id":"9286","name":"EU/3/06/387: Public summary of positive opinion for orphan designation of amikacin sulfate (liposomal) for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMEA/COMP/428207/2006 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306387-public-summary-positive-opinion-orphan-designation-amikacin-sulfate-liposomal-treatment-pseudomonas-aeruginosa-lung-infection-cystic-fibrosis_en.pdf"},
    {"id":"9299","name":"EU/3/01/066: Public summary of positive opinion for orphan designation of thalidomide for the treatment of erythema nodosum lepra or type II lepra reactions.","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-20T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/COMP/1287/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301066-public-summary-positive-opinion-orphan-designation-thalidomide-treatment-erythema-nodosum-lepra-or-type-ii-lepra-reactions_en.pdf"},
    {"id":"9311","name":"EU/3/05/276 - Public summary of positive opinion for orphan designation of humanised agonistic anti-CD28 monoclonal antibody for the treatment of B-cell chronic lymphocytic leukemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-07-01T02:00:00Z","last_updated_date":"2005-07-01T02:00:00Z","reference_number":"EMEA/COMP/85958/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305276-public-summary-positive-opinion-orphan-designation-humanised-agonistic-anti-cd28-monoclonal-antibody-treatment-b-cell-chronic-lymphocytic-leukemia_en.pdf"},
    {"id":"9320","name":"EU/3/17/1962: Public summary of opinion on orphan designation: Humanised Fc-engineered monoclonal antibody against CD19 for the treatment of IgG4-related disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-12T01:00:00Z","last_updated_date":"2018-03-12T01:00:00Z","reference_number":"EMA/828791/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171962-public-summary-opinion-orphan-designation-humanised-fc-engineered-monoclonal-antibody-against-cd19-treatment-igg4-related-disease_en.pdf"},
    {"id":"9322","name":"EU/3/16/1761: Public summary of positive opinion for orphan designation of self-complementary adeno-associated viral vector serotype 9 containing the SGSH gene for the treatment of mucopolysaccharidosis type IIIA (Sanfil...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/629533/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161761-public-summary-positive-opinion-orphan-designation-self-complementary-adeno-associated-viral-vector-serotype-9-containing-sgsh-gene-treatment-mucopolysaccharidosis-type-iiia-sanfil_en.pdf"},
    {"id":"9343","name":"EU/3/09/721: Public summary of opinion on orphan designation of panobinostat for the treatment of Hodgkin’s lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:00:00Z","last_updated_date":"2015-02-11T12:13:00Z","reference_number":"EMA/COMP/817766/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309721-public-summary-opinion-orphan-designation-panobinostat-treatment-hodgkins-lymphoma_en.pdf"},
    {"id":"9363","name":"EU/3/15/1584: Public summary of opinion on orphan designation: Variant of recombinant human fibroblast growth factor 19 for the treatment of primary sclerosing cholangitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/COMP/791407/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151584-public-summary-opinion-orphan-designation-variant-recombinant-human-fibroblast-growth-factor-19-treatment-primary-sclerosing-cholangitis_en.pdf"},
    {"id":"9383","name":"EU/3/15/1568: Public summary of opinion on orphan designation:\n\nInterferon alfa-n3 for the treatment of Middle East respiratory syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-05T01:00:00Z","last_updated_date":"2016-01-05T01:00:00Z","reference_number":"EMA/COMP/698747/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151568-public-summary-opinion-orphan-designation-interferon-alfa-n3-treatment-middle-east-respiratory-syndrome_en.pdf"},
    {"id":"9394","name":"EU/3/12/1036 : Public summary of opinion on orphan designation:Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt for the treatment of familial chylomicronaem...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-05T01:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMA/COMP/527251/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121036-public-summary-opinion-orphan-designationtrans-4-4-5-6-trifluoromethyl-3-pyridinylamino-2-pyridinylphenyl-cyclohexane-acetic-acid-sodium-salt-treatment-familial-chylomicronaem_en.pdf"},
    {"id":"9396","name":"EU/3/01/079: Public summary of positive opinion for orphan designation of sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleoyl phosphatidylglycerol and palmitic acid for the treatment of acute lung injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2011-03-10T01:00:00Z","reference_number":"EMEA/COMP/48/02 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301079-public-summary-positive-opinion-orphan-designation-sinapultide-dipalmitoylphosphatidylcholine-palmitoyl-oleoyl-phosphatidylglycerol-and-palmitic-acid-treatment-acute-lung-injury_en.pdf"},
    {"id":"9397","name":"EU/3/10/755: Public summary of opinion on orphan designation: Octenidine dihydrochloride for the prevention of late-onset sepsis in premature infants of less than or equal to 32 weeks of gestational age","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-05T02:00:00Z","last_updated_date":"2010-08-05T02:00:00Z","reference_number":"EMA/COMP/264905/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310755-public-summary-opinion-orphan-designation-octenidine-dihydrochloride-prevention-late-onset-sepsis-premature-infants-less-or-equal-32-weeks-gestational-age_en.pdf"},
    {"id":"9401","name":"EU/3/16/1676: Public summary of opinion on orphan designation: Cyclocreatine for the treatment of creatine deficiency syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2019-07-09T12:00:00Z","reference_number":"EMA/396044/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161676-public-summary-opinion-orphan-designation-cyclocreatine-treatment-creatine-deficiency-syndromes_en.pdf"},
    {"id":"9402","name":"EU/3/05/336: Public summary of positive opinion for orphan designation of brostallicin for the treatment of soft-tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2013-07-08T02:00:00Z","reference_number":"EMEA/COMP/383867/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305336-public-summary-positive-opinion-orphan-designation-brostallicin-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"9412","name":"EU/3/16/1818: Public summary of opinion on orphan designation: Human hepatoma cell line HepaRG in bioartificial liver for the treatment of acute liver failure","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"EMA/3424/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161818-public-summary-opinion-orphan-designation-human-hepatoma-cell-line-heparg-bioartificial-liver-treatment-acute-liver-failure_en.pdf"},
    {"id":"9427","name":"EU/3/10/781: Public summary of opinion on orphan designation: Glutathione-pegylated liposomal doxorubicin hydrochloride for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMA/COMP/360648/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310781-public-summary-opinion-orphan-designation-glutathione-pegylated-liposomal-doxorubicin-hydrochloride-treatment-glioma_en.pdf"},
    {"id":"9436","name":"EU/3/06/393: Public summary of positive opinion for orphan designation\n\nof autologous CD34+ cells transfected with retroviral vector containing the human gp91 (phox) gene for the treatment of chronic granulomatous diseas...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/278975/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306393-public-summary-positive-opinion-orphan-designation-autologous-cd34-cells-transfected-retroviral-vector-containing-human-gp91-phox-gene-treatment-chronic-granulomatous-diseas_en.pdf"},
    {"id":"9493","name":"EU/3/16/1727 : Public summary of opinion on orphan designation: Recombinant human interleukin-12 for treatment of acute radiation syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161727-public-summary-opinion-orphan-designation-recombinant-human-interleukin-12-treatment-acute-radiation-syndrome_en.pdf"},
    {"id":"9497","name":"EU/3/13/1226: Public summary of opinion on orphan designation: (6aS)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol for the treatment of dystrophic myotonia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"EMA/COMP/18322/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131226-public-summary-opinion-orphan-designation-6as-110-dimethoxy-6-methyl-566a7-tetrahydro-4h-dibenzodegquinoline-29-diol-treatment-dystrophic-myotonia_en.pdf"},
    {"id":"9524","name":"EU/3/05/316: Public summary of positive opinion for orphan designation\n\nof 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide for the treatment of pulmonary arterial hypertension and chr...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMEA/COMP/247593/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305316-public-summary-positive-opinion-orphan-designation-2-4-56-diphenylpyrazin-2-ylisopropylaminobutoxy-n-methylsulfonylacetamide-treatment-pulmonary-arterial-hypertension-and-chr_en.pdf"},
    {"id":"9530","name":"EU/3/06/388: Public summary of positive opinion for orphan designationof becatecarin for the treatment of cancers of the biliary tree","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/226408/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306388-public-summary-positive-opinion-orphan-designationof-becatecarin-treatment-cancers-biliary-tree_en.pdf"},
    {"id":"9618","name":"EU/3/03/163: Public summary of positive opinion for orphan designation of 5,6,7,8 tetrahydrobiopterin for the treatment of hyperphenylalaninemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-23T00:00:00Z","last_updated_date":"2007-02-23T00:00:00Z","reference_number":"EMEA/COMP/1387/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303163-public-summary-positive-opinion-orphan-designation-5678-tetrahydrobiopterin-treatment-hyperphenylalaninemia_en.pdf"},
    {"id":"9642","name":"EU/3/04/230: Public summary of positive opinion for orphan designation of dexamethasone sodium phosphate encapsulated in human erythrocytes for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T01:00:00Z","last_updated_date":"2010-02-22T00:00:00Z","reference_number":"EMEA/COMP/77487/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304230-public-summary-positive-opinion-orphan-designation-dexamethasone-sodium-phosphate-encapsulated-human-erythrocytes-treatment-cystic-fibrosis_en.pdf"},
    {"id":"9670","name":"EU/3/17/1859: Public summary of opinion on orphan designation: Phosphoinositide 3-kinase gamma peptide for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/143975/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171859-public-summary-opinion-orphan-designation-phosphoinositide-3-kinase-gamma-peptide-treatment-cystic-fibrosis_en.pdf"},
    {"id":"9671","name":"EU/3/12/1029: Public summary of opinion on orphan designation: Humanised monoclonal antibody against epidermal-growth-factor receptor for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-26T16:30:00Z","last_updated_date":"2013-09-23T14:30:00Z","reference_number":"EMA/COMP/526571/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121029-public-summary-opinion-orphan-designation-humanised-monoclonal-antibody-against-epidermal-growth-factor-receptor-treatment-glioma_en.pdf"},
    {"id":"9674","name":"EU/3/13/1222: Public summary of opinion on orphan designation: Amatuximab for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"EMA/COMP/7038/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131222-public-summary-opinion-orphan-designation-amatuximab-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"9677","name":"EU/3/11/853: Public summary of positive opinion for orphan designation:  Ombrabulin for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2014-06-19T02:00:00Z","reference_number":"EMA/COMP/69581/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311853-public-summary-positive-opinion-orphan-designation-ombrabulin-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"9684","name":"EU/3/03/162: Public summary of positive opinion for orphan designation of  yttrium (90Y) antiferritin polyclonal antibodies for the treatment of Hodgkin lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2013-06-20T13:00:00Z","reference_number":"EMEA/COMP/384/04 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303162-public-summary-positive-opinion-orphan-designation-yttrium-90y-antiferritin-polyclonal-antibodies-treatment-hodgkin-lymphoma_en.pdf"},
    {"id":"9743","name":"EU/3/08/543: Public summary of positive opinion for orphan designation of sarsasapogenin for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-28T02:00:00Z","last_updated_date":"2012-09-06T17:34:00Z","reference_number":"EMEA/COMP/202469/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308543-public-summary-positive-opinion-orphan-designation-sarsasapogenin-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"9774","name":"EU/3/05/323: Public summary of positive opinion for orphan designation of bacterial lipase for the treatment of malabsorption due to exocrine pancreatic enzyme insufficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-02-09T00:00:00Z","last_updated_date":"2006-02-09T00:00:00Z","reference_number":"EMEA/COMP/317739/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305323-public-summary-positive-opinion-orphan-designation-bacterial-lipase-treatment-malabsorption-due-exocrine-pancreatic-enzyme-insufficiency_en.pdf"},
    {"id":"9797","name":"EU/3/05/335: Public summary of positive opinion for orphan designation of human Staphylococcus aureus polyclonal immunoglobulin and human Staphylococcus epidermidis polyclonal immunoglobulin for the prevention of late on...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/367733/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305335-public-summary-positive-opinion-orphan-designation-human-staphylococcus-aureus-polyclonal-immunoglobulin-and-human-staphylococcus-epidermidis-polyclonal-immunoglobulin-prevention-late_en.pdf"},
    {"id":"9803","name":"EU/3/09/676: Public summary of positive opinion for orphan designation of sequence-modified recombinant human factor VIIa for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2016-01-19T13:30:00Z","reference_number":"EMEA/COMP/462126/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309676-public-summary-positive-opinion-orphan-designation-sequence-modified-recombinant-human-factor-viia-treatment-haemophilia-b_en.pdf"},
    {"id":"9806","name":"EU/3/13/1228: Public summary of opinion on orphan designation: Obeticholic acid for the treatment of primary sclerosing cholangitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T01:00:00Z","last_updated_date":"2022-05-10T01:00:00Z","reference_number":"EMA/COMP/18109/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131228-public-summary-opinion-orphan-designation-obeticholic-acid-treatment-primary-sclerosing-cholangitis_en.pdf"},
    {"id":"9916","name":"EU/3/01/046: Public summary of positive opinion for orphan designation of thalidomide for the treatment of graft versus host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/1289/2003 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301046-public-summary-positive-opinion-orphan-designation-thalidomide-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"9928","name":"EU/3/07/456: Public summary of positive opinion for orphan designation of rilonacept for the treatment of cryopirin-associated periodic syndromes (Familial Cold Urticaria Syndrome (FCUS), Muckle-Wells Syndrome (MWS), and...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2014-10-17T01:00:00Z","reference_number":"EMEA/COMP/170868/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307456-public-summary-positive-opinion-orphan-designation-rilonacept-treatment-cryopirin-associated-periodic-syndromes-familial-cold-urticaria-syndrome-fcus-muckle-wells-syndrome-mws-and_en.pdf"},
    {"id":"9959","name":"EU/3/17/1943: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector serotype 9 containing human iduronate-2-sulfatase gene for the treatment of mucopolysaccharidosis type II (Hunter’s...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-15T01:00:00Z","last_updated_date":"2018-01-15T01:00:00Z","reference_number":"EMA/694657/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171943-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-serotype-9-containing-human-iduronate-2-sulfatase-gene-treatment-mucopolysaccharidosis-type-ii-hunters_en.pdf"},
    {"id":"9995","name":"EU/3/18/2021: Public summary of opinion on orphan designation: Equine immunoglobulin F(ab’)2 fragments targeting Shiga toxin for the prevention of haemolytic uraemic syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-24T11:27:00Z","last_updated_date":"2018-07-24T11:27:00Z","reference_number":"EMA/265927/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182021-public-summary-opinion-orphan-designation-equine-immunoglobulin-fab2-fragments-targeting-shiga-toxin-prevention-haemolytic-uraemic-syndrome_en.pdf"},
    {"id":"9997","name":"EU/3/11/903: Public summary of opinion on orphan designation: Genetically modified Lactococcus lactis bacteria containing the human trefoil factor 1 gene for the prevention of oral mucositis in head and neck cancer patie...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/COMP/659769/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311903-public-summary-opinion-orphan-designation-genetically-modified-lactococcus-lactis-bacteria-containing-human-trefoil-factor-1-gene-prevention-oral-mucositis-head-and-neck-cancer-patie_en.pdf"},
    {"id":"10017","name":"EU/3/07/447: Public summary of positive opinion for orphan designation of \n\nnilotinib hydrochloride monohydrate for the treatment of gastrointestinal stromal tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2015-02-10T01:00:00Z","reference_number":"EMA/COMP/93604/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307447-public-summary-positive-opinion-orphan-designation-nilotinib-hydrochloride-monohydrate-treatment-gastrointestinal-stromal-tumours_en.pdf"},
    {"id":"10063","name":"EU/3/16/1707: Public summary of opinion on orphan designation: Sodium benzoate for the treatment of citrullinaemia type 1","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/450240/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161707-public-summary-opinion-orphan-designation-sodium-benzoate-treatment-citrullinaemia-type-1_en.pdf"},
    {"id":"10064","name":"EU/3/09/646: Public summary of positive opinion for orphan designation of talampanel for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-07-08T02:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/COMP/290916/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309646-public-summary-positive-opinion-orphan-designation-talampanel-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"10112","name":"EU/3/10/760: Public summary of opinion on orphan designation of (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-11T01:31:00Z","last_updated_date":"2013-03-12T11:00:00Z","reference_number":"EMA/COMP/325300/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310760-public-summary-opinion-orphan-designation-3s-3-4-7-aminocarbonyl-2h-indazol-2-yl-phenyl-piperidine-tosylate-monohydrate-salt-treatment-ovarian-cancer_en.pdf"},
    {"id":"10116","name":"EU/3/08/576: Public summary of positive opinion for orphan designation ofcarglumic acid for the treatment of methylmalonic acidaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2021-06-09T15:05:00Z","reference_number":"EMEA/COMP/481269/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308576-public-summary-positive-opinion-orphan-designation-ofcarglumic-acid-treatment-methylmalonic-acidaemia_en.pdf"},
    {"id":"10126","name":"EU/3/11/867: Public summary of opinion on orphan designation: Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2 for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-30T02:00:00Z","last_updated_date":"2019-08-30T15:00:00Z","reference_number":"EMA/COMP/156244/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311867-public-summary-opinion-orphan-designation-allogeneic-umbilical-cord-blood-cells-treated-ex-vivo-1616-dimethyl-prostaglandin-e2-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"10140","name":"Public summary of positive opinion for orphan designation of deoxyribose phosphorothioate (5’-tct-ccc-agc-gtg-cgc-cat-3’) for the treatment of  multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T00:00:00Z","last_updated_date":"2013-04-09T02:00:00Z","reference_number":"EMA/COMP/11100/2003 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-positive-opinion-orphan-designation-deoxyribose-phosphorothioate-5-tct-ccc-agc-gtg-cgc-cat-3-treatment-multiple-myeloma_en.pdf"},
    {"id":"10146","name":"EU/3/13/1194: Public summary of opinion on orphan designation:\n\nNaproxcinod for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-10-31T01:00:00Z","last_updated_date":"2018-01-23T01:00:00Z","reference_number":"EMA/COMP/553063/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131194-public-summary-opinion-orphan-designation-naproxcinod-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"10168","name":"Public summary of negative opinion for orphan designation\n\nof 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]-methyl]tetrahydro-\n\nN-hydroxy-2H-pyran-4-carboxamide for prevention of graft rejection after liver transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2009-09-17T02:00:00Z","reference_number":"EMEA/COMP/67000/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-4-4-4-chlorophenoxyphenylsulfonyl-methyltetrahydro-n-hydroxy-2h-pyran-4-carboxamide-prevention-graft-rejection-after-liver-transplantation_en.pdf"},
    {"id":"10190","name":"EU/3/11/861: Public summary of opinion on orphan designation: 9-cis-Retinyl acetate for the treatment of Leber’s congenital amauro","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2012-01-04T01:00:00Z","reference_number":"EMA/COMP/171945/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311861-public-summary-opinion-orphan-designation-9-cis-retinyl-acetate-treatment-lebers-congenital-amauro_en.pdf"},
    {"id":"10226","name":"EU/3/11/900: Public summary of opinion on orphan designation: 20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate for the treatment o...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/COMP/635479/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311900-public-summary-opinion-orphan-designation-20-pentaerythritol-poly-oxy-12-ethanediyl-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine-10-14-bipiperidine-1-carboxylate-treatment-o_en.pdf"},
    {"id":"10255","name":"EU/3/18/2020: Public summary of opinion on orphan designation: Daratumumab for the treatment of AL amyloidosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T18:30:00Z","last_updated_date":"2018-07-23T18:30:00Z","reference_number":"EMA/271688/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182020-public-summary-opinion-orphan-designation-daratumumab-treatment-al-amyloidosis_en.pdf"},
    {"id":"10284","name":"EU/3/17/1952: Public summary of opinion on orphan designation: Modified messenger ribonucleic acid encoding human argininosuccinate lyase enzyme encapsulated into lipid nanoparticles for the treatment of argininosuccinic...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-23T14:42:00Z","last_updated_date":"2018-01-23T14:42:00Z","reference_number":"EMA/750696/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171952-public-summary-opinion-orphan-designation-modified-messenger-ribonucleic-acid-encoding-human-argininosuccinate-lyase-enzyme-encapsulated-lipid-nanoparticles-treatment-argininosuccinic_en.pdf"},
    {"id":"10285","name":"EU/3/15/1507: Public summary of opinion on orphan designation: 3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid for the treatment of non-infectious uveitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2015-07-27T02:00:00Z","reference_number":"EMA/COMP/348507/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151507-public-summary-opinion-orphan-designation-3-2356-tetrafluoro-3-trifluoromethoxybiphenyl-4-ylcarbamoylthiophene-2-carboxylic-acid-treatment-non-infectious-uveitis_en.pdf"},
    {"id":"10304","name":"EU/3/16/1668: Public summary of opinion on orphan designation: Sodium nitrite and ethylenediaminetetraacetic acid for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-22T02:00:00Z","last_updated_date":"2016-06-22T02:00:00Z","reference_number":"EMA/COMP/307213/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161668-public-summary-opinion-orphan-designation-sodium-nitrite-and-ethylenediaminetetraacetic-acid-treatment-cystic-fibrosis_en.pdf"},
    {"id":"10309","name":"EU/3/08/574: Public summary of positive opinion for orphan designation of autologous urothelial and smooth muscle cells for the treatment of spinal cord injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2012-05-24T13:54:00Z","reference_number":"EMEA/COMP/480031/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308574-public-summary-positive-opinion-orphan-designation-autologous-urothelial-and-smooth-muscle-cells-treatment-spinal-cord-injury_en.pdf"},
    {"id":"10315","name":"EU/3/14/1292: Public summary of opinion on orphan designation: Carboxy pyrrolidine hexanoyl pyrrolidine carboxylate for the treatment of AL amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T02:00:00Z","last_updated_date":"2019-07-09T12:00:00Z","reference_number":"EMA/COMP/360624/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141292-public-summary-opinion-orphan-designation-carboxy-pyrrolidine-hexanoyl-pyrrolidine-carboxylate-treatment-al-amyloidosis_en.pdf"},
    {"id":"10316","name":"EU/3/16/1702: Public summary of opinion on orphan designation: Recombinant human monoclonal antibody to insulin receptor for the treatment of congenital hyperinsulinism","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/447608/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161702-public-summary-opinion-orphan-designation-recombinant-human-monoclonal-antibody-insulin-receptor-treatment-congenital-hyperinsulinism_en.pdf"},
    {"id":"10348","name":"EU/3/08/532: Public summary of positive opinion for orphan designation of filgrastim for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMEA/COMP/84439/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308532-public-summary-positive-opinion-orphan-designation-filgrastim-treatment-amyotrophic-lateral-sclerosis_en.pdf"}    {"id":"10360","name":"EU/3/16/1729 : Public summary of opinion on orphan designation: Sodium benzoate for the treatment of lysinuric protein intolerance","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161729-public-summary-opinion-orphan-designation-sodium-benzoate-treatment-lysinuric-protein-intolerance_en.pdf"},
    {"id":"10363","name":"EU/3/15/1479: Public summary of positive opinion for orphan designation of Recombinant monoclonal IgG1 antibody against T-cell immune response cDNA 7 for the prevention of graft rejection following solid organ transplant...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T13:00:00Z","last_updated_date":"2015-05-22T13:00:00Z","reference_number":"EMA/COMP/207644/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151479-public-summary-positive-opinion-orphan-designation-recombinant-monoclonal-igg1-antibody-against-t-cell-immune-response-cdna-7-prevention-graft-rejection-following-solid-organ-transplant_en.pdf"},
    {"id":"10368","name":"EU/3/12/959: Public summary of opinion on orphan designation: Vincaleukoblastin-23-oic acid, O4-deacetyl-, 2-[(2-mercaptoethoxy)carbonyl]hydrazide, disulfide with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]ami...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T01:00:00Z","last_updated_date":"2016-10-21T02:00:00Z","reference_number":"EMA/COMP/862757/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312959-public-summary-opinion-orphan-designation-vincaleukoblastin-23-oic-acid-o4-deacetyl-2-2-mercaptoethoxycarbonylhydrazide-disulfide-n-4-2-amino-34-dihydro-4-oxo-6-pteridinylmethylami_en.pdf"},
    {"id":"10370","name":"EU/3/16/1669: Public summary of opinion on orphan designation: Temsirolimus for the treatment of adrenoleukodystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-22T02:00:00Z","last_updated_date":"2016-06-22T02:00:00Z","reference_number":"EMA/COMP/313675/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161669-public-summary-opinion-orphan-designation-temsirolimus-treatment-adrenoleukodystrophy_en.pdf"},
    {"id":"10371","name":"EU/3/01/028: Public summary of positive opinion of inolimomab for treatment of graft versus host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2008-08-18T02:00:00Z","reference_number":"EMEA/COMP/12306/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301028-public-summary-positive-opinion-inolimomab-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"10374","name":"EU/3/13/1099: Public summary of positive opinion of recombinant adeno-associated viral vector containing the human CNGB3 gene for the treatment of achromatopsia caused by mutations in the CNGB3 gene","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T11:00:00Z","last_updated_date":"2013-03-04T11:00:00Z","reference_number":"EMA/COMP/31465/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131099-public-summary-positive-opinion-recombinant-adeno-associated-viral-vector-containing-human-cngb3-gene-treatment-achromatopsia-caused-mutations-cngb3-gene_en.pdf"},
    {"id":"10377","name":"EU/3/09/687: Public summary of positive opinion for orphan designation of patupilone for the treatment of primary peritoneal cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2015-02-12T00:09:21Z","reference_number":"EMEA/COMP/582084/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309687-public-summary-positive-opinion-orphan-designation-patupilone-treatment-primary-peritoneal-cancer_en.pdf"},
    {"id":"10434","name":"EU/3/05/325: Public summary of positive opinion for orphan designation of mannitolum for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-28T02:00:00Z","last_updated_date":"2013-09-19T02:00:00Z","reference_number":"EMEA/COMP/318112/2005 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305325-public-summary-positive-opinion-orphan-designation-mannitolum-treatment-cystic-fibrosis_en.pdf"},
    {"id":"10462","name":"EU/3/05/304: Public summary of positive opinion for orphan designation of imatinib mesilate for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2015-02-10T01:00:00Z","reference_number":"EMA/COMP/244140/2005 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305304-public-summary-positive-opinion-orphan-designation-imatinib-mesilate-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"10493","name":"EU/3/07/480: Public summary of positive opinion for orphan designation of naptumomab estafenatox for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-22T00:00:00Z","last_updated_date":"2011-11-11T16:00:00Z","reference_number":"EMEA/COMP/353198/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307480-public-summary-positive-opinion-orphan-designation-naptumomab-estafenatox-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"10499","name":"EU/3/04/256: Public summary of positive opinion for orphan designation\n\nof 17-allylamino-17-demethoxygeldanamycin for the treatment of chronic myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2011-03-25T01:00:00Z","reference_number":"EMEA/COMP/192872/2004 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304256-public-summary-positive-opinion-orphan-designation-17-allylamino-17-demethoxygeldanamycin-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"10501","name":"EU/3/10/756: Public summary of opinion on orphan designation: Tranilast for the prevention of scarring post glaucoma filtration surgery","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-06T02:00:00Z","last_updated_date":"2010-08-06T02:00:00Z","reference_number":"EMA/COMP/234320/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310756-public-summary-opinion-orphan-designation-tranilast-prevention-scarring-post-glaucoma-filtration-surgery_en.pdf"},
    {"id":"10524","name":"EU/3/16/1766: Public summary of positive opinion for orphan designation of venetoclax for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/623825/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161766-public-summary-positive-opinion-orphan-designation-venetoclax-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"10565","name":"EU/3/16/1733 : Public summary of opinion on orphan designation: Temozolomide for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161733-public-summary-opinion-orphan-designation-temozolomide-treatment-glioma_en.pdf"},
    {"id":"10597","name":"EU/3/01/058: Public summary of positive opinion for orphan designation of repertaxin l-lysinate salt for the prevention of delayed graft function in organ transplant","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMEA/COMP/261/2004 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301058-public-summary-positive-opinion-orphan-designation-repertaxin-l-lysinate-salt-prevention-delayed-graft-function-organ-transplant_en.pdf"},
    {"id":"10608","name":"EU/3/18/2036: Public summary of opinion on orphan designation: L-cystine bis(N'-methylpiperazide) for the treatment of cystinuria","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-21T12:50:00Z","last_updated_date":"2018-08-21T12:50:00Z","reference_number":"EMA/378641/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182036-public-summary-opinion-orphan-designation-l-cystine-bisn-methylpiperazide-treatment-cystinuria_en.pdf"},
    {"id":"10628","name":"EU/3/08/565: Public summary of positive opinion for orphan designation of drotrecogin alfa (activated) for the treatment of acute respiratory distress syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-24T01:00:00Z","last_updated_date":"2021-09-21T10:11:00Z","reference_number":"EMEA/COMP/441380/2008 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308565-public-summary-positive-opinion-orphan-designation-drotrecogin-alfa-activated-treatment-acute-respiratory-distress-syndrome_en.pdf"},
    {"id":"10658","name":"EU/3/11/873: Public summary of opinion on orphan designation: Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2014-04-01T18:00:00Z","reference_number":"EMA/COMP/247220/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311873-public-summary-opinion-orphan-designation-human-dermal-fibroblasts-cultured-bioresorbable-polyglactin-mesh-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"10670","name":"EU/3/12/1061: Public summary of opinion on orphan designation: Tralokinumab for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2016-10-21T02:00:00Z","reference_number":"EMA/COMP/656472/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121061-public-summary-opinion-orphan-designation-tralokinumab-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"10674","name":"EU/3/16/1677: Public summary of opinion on orphan designation: Diclofenamide for the treatment of periodic paralysis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/393522/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161677-public-summary-opinion-orphan-designation-diclofenamide-treatment-periodic-paralysis_en.pdf"},
    {"id":"10677","name":"EU/3/13/1135: Public summary of opinion on orphan designation: Recombinant human nerve growth factor for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2015-05-13T19:00:00Z","reference_number":"EMA/COMP/272347/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131135-public-summary-opinion-orphan-designation-recombinant-human-nerve-growth-factor-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"10723","name":"EU/3/15/1518: Public summary of opinion on orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T14:00:00Z","last_updated_date":"2015-08-18T14:00:00Z","reference_number":"EMA/COMP/426684/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151518-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-2-containing-human-rpe65-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"10748","name":"EU/3/14/1391: Public summary of positive opinion for orphan designation: 5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-2-pyrimidinamine for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2016-02-10T18:00:00Z","reference_number":"EMA/COMP/744278/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141391-public-summary-positive-opinion-orphan-designation-5-8-methyl-9-1-methylethyl-2-4-morpholinyl-9h-purin-6-yl-2-pyrimidinamine-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"10749","name":"EU/3/06/426: Public summary of positive opinion for orphan designation of fenretinide for the treatment of primary malignant bone tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2011-03-25T01:00:00Z","reference_number":"EMEA/COMP/96682/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306426-public-summary-positive-opinion-orphan-designation-fenretinide-treatment-primary-malignant-bone-tumours_en.pdf"},
    {"id":"10785","name":"EU/3/14/1239: Public summary of opinion on orphan designation: 11-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-aza-cyclopentadecane-13,15-di...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-01T14:30:00Z","last_updated_date":"2014-04-01T14:30:00Z","reference_number":"EMA/COMP/26019/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141239-public-summary-opinion-orphan-designation-11-4-dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy-2-ethyl-3410-trihydroxy-3568101214-heptamethyl-1-oxa-6-aza-cyclopentadecane-1315-di_en.pdf"},
    {"id":"10793","name":"EU/3/09/681: Public summary of positive opinion for orphan designation of 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide for the treatment of Huntington’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-16T00:09:21Z","last_updated_date":"2009-11-16T00:09:21Z","reference_number":"EMEA/COMP/589945/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309681-public-summary-positive-opinion-orphan-designation-6-chloro-2349-tetrahydro-1h-carbazole-1-carboxamide-treatment-huntingtons-disease_en.pdf"},
    {"id":"10798","name":"EU/3/10/809: Public summary of opinion on orphan designation Nanoparticle albumin-bound paclitaxel for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2013-03-11T17:15:00Z","reference_number":"EMA/606364/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310809-public-summary-opinion-orphan-designation-nanoparticle-albumin-bound-paclitaxel-treatment-pancreatic-cancer_en.pdf"},
    {"id":"10811","name":"EU/3/08/585: Public summary of positive opinion for orphan designation of\n\ndaunorubicin (liposomal) for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2009-09-17T02:00:00Z","reference_number":"EMEA/COMP/558087/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308585-public-summary-positive-opinion-orphan-designation-daunorubicin-liposomal-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"10814","name":"EU/3/15/1607: Public summary of opinion on orphan designation: Entolimod for the treatment of acute radiation syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2020-05-07T01:00:00Z","reference_number":"EMA/COMP/866871/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151607-public-summary-opinion-orphan-designation-entolimod-treatment-acute-radiation-syndrome_en.pdf"},
    {"id":"10829","name":"EU/3/05/311: Public summary of positive opinion for orphan designation of troxacitabine for the treatment acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/221755/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305311-public-summary-positive-opinion-orphan-designation-troxacitabine-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"10851","name":"EU/3/13/1160: Public summary of opinion on orphan designation: Idelalisib for the treatment of lymphoplasmacytic lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-22T17:30:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/COMP/400941/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131160-public-summary-opinion-orphan-designation-idelalisib-treatment-lymphoplasmacytic-lymphoma_en.pdf"},
    {"id":"10864","name":"EU/3/10/747: Public summary of positive opinion for N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"EMA/COMP/164828/2010 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310747-public-summary-positive-opinion-n-2-chloro-4-67-dimethoxy-4-quinolyloxyphenyl-n-5-methyl-3-isoxazolyl-urea-hydrochloride-monohydrate-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"10887","name":"EU/3/13/1165: Public summary of opinion on orphan designation: Heterologous human adult liver-derived progenitor cells for the treatment of N-acetylglutamate-synthetase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-22T17:30:00Z","last_updated_date":"2013-08-22T17:30:00Z","reference_number":"EMA/COMP/413218/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131165-public-summary-opinion-orphan-designation-heterologous-human-adult-liver-derived-progenitor-cells-treatment-n-acetylglutamate-synthetase-deficiency_en.pdf"},
    {"id":"10896","name":"EU/3/16/1694: Public summary of opinion on orphan designation: Autologous CD4+ and CD8+ T cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/451054/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161694-public-summary-opinion-orphan-designation-autologous-cd4-and-cd8-t-cells-transduced-lentiviral-vector-containing-affinity-enhanced-t-cell-receptor-targeting-new-york-esophageal-antigen_en.pdf"},
    {"id":"10907","name":"EU/3/11/905: Public summary of opinion on orphan designation: Kifunensine for the treatment of alpha sarcoglycanopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2014-06-19T02:00:00Z","reference_number":"EMA/COMP/657806/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311905-public-summary-opinion-orphan-designation-kifunensine-treatment-alpha-sarcoglycanopathy_en.pdf"},
    {"id":"10926","name":"EU/3/05/341: Public summary of positive opinion of imexon for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-08-08T02:00:00Z","last_updated_date":"2018-10-04T11:38:00Z","reference_number":"EMEA/COMP/22896/2006 Correction 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305341-public-summary-positive-opinion-imexon-treatment-ovarian-cancer_en.pdf"},
    {"id":"10942","name":"EU/3/08/590: Public summary of positive opinion for orphan designationof2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate t...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2019-08-30T15:00:00Z","reference_number":"EMEA/COMP/546580/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308590-public-summary-positive-opinion-orphan-designationof2-3-4-5-2-3-fluorophenylamino-2-oxoethyl-1h-pyrazol-3-ylamino-quinazolin-7-yloxypropylethylaminoethyl-dihydrogen-phosphate-t_en.pdf"},
    {"id":"10963","name":"EU/3/16/1691: Public summary of opinion on orphan designation: 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid for the treatment of Huntington's disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2018-05-29T02:00:00Z","reference_number":"EMA/COMP/451043/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161691-public-summary-opinion-orphan-designation-2-4-1-methyl-4-pyridin-4-yl-1h-pyrazol-3-yl-phenoxymethyl-quinoline-succinic-acid-treatment-huntingtons-disease_en.pdf"},
    {"id":"11003","name":"EU/3/04/216: Public summary of positive opinion for orphan designation of sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleoyl phosphatidylglycerol and palmitic acid for the prevention of respiratory distress sy...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"EMEA/COMP/376/04 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304216-public-summary-positive-opinion-orphan-designation-sinapultide-dipalmitoylphosphatidylcholine-palmitoyl-oleoyl-phosphatidylglycerol-and-palmitic-acid-prevention-respiratory-distress-sy_en.pdf"},
    {"id":"11009","name":"EU/3/06/404: Public summary of positive opinion for orphan designation\n\nof adenoviral vector containing human p53 gene for the treatment of Li-Fraumeni syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2009-04-02T02:00:00Z","reference_number":"EMEA/COMP/177051/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306404-public-summary-positive-opinion-orphan-designation-adenoviral-vector-containing-human-p53-gene-treatment-li-fraumeni-syndrome_en.pdf"},
    {"id":"11039","name":"EU/3/08/593: Public summary of positive opinion for orphan designation of N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-himerized anti-CD138 IgG4 monoclonal antibody for the treatment of multiple...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/COMP/568150/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308593-public-summary-positive-opinion-orphan-designation-n2-deacetyl-n2-4-methyl-4-oxobuthyldithio-1-oxopentyl-maytansine-himerized-anti-cd138-igg4-monoclonal-antibody-treatment-multiple_en.pdf"},
    {"id":"11084","name":"EU/3/11/940: Public summary of positive opinion for orphan designation: Chimeric locked nucleic acid-deoxynucleoside phosphorothioate-linked oligonucleotide directed against microRNA-451 for the treatment of polycythaemi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2017-05-17T16:00:00Z","reference_number":"EMA/COMP/922838/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311940-public-summary-positive-opinion-orphan-designation-chimeric-locked-nucleic-acid-deoxynucleoside-phosphorothioate-linked-oligonucleotide-directed-against-microrna-451-treatment-polycythaemi_en.pdf"},
    {"id":"11164","name":"EU/3/12/979: Public summary of opinion on orphan designation: Sodium thiosulfate for the treatment of calciphylaxis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-30T02:00:00Z","last_updated_date":"2012-04-30T02:00:00Z","reference_number":"EMA/COMP/142664/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312979-public-summary-opinion-orphan-designation-sodium-thiosulfate-treatment-calciphylaxis_en.pdf"},
    {"id":"11201","name":"EU/3/17/1926: Public summary of opinion on orphan designation : Ofranergene obadenovec for the treatment of ovarian cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T11:37:00Z","last_updated_date":"2022-09-26T11:37:00Z","reference_number":"EMA/632137/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171926-public-summary-opinion-orphan-designation-ofranergene-obadenovec-treatment-ovarian-cancer_en.pdf"},
    {"id":"11227","name":"EU/3/07/455: Public summary of positive opinion for orphan designation of ciclosporin for the prevention of corneal graft rejection","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMEA/COMP/466593/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307455-public-summary-positive-opinion-orphan-designation-ciclosporin-prevention-corneal-graft-rejection_en.pdf"},
    {"id":"11256","name":"EU/3/02/085: Public summary of positive opinion for orphan designation of carmustine (solution for intratumoural injection) for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-23T00:00:00Z","last_updated_date":"2013-10-18T01:00:00Z","reference_number":"EMEA/COMP/46/2002 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302085-public-summary-positive-opinion-orphan-designation-carmustine-solution-intratumoural-injection-treatment-glioma_en.pdf"},
    {"id":"11263","name":"EU/3/15/1523: Public summary of opinion on orphan designation: Inecalcitol for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T02:00:00Z","last_updated_date":"2015-08-18T02:00:00Z","reference_number":"EMA/COMP/431519/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151523-public-summary-opinion-orphan-designation-inecalcitol-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"11272","name":"EU/3/10/815: Public summary of opinion on orphan designation: Sildenafil citrate for the treatment of postcardiotomy right ventricular failure","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/COMP/579361/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310815-public-summary-opinion-orphan-designation-sildenafil-citrate-treatment-postcardiotomy-right-ventricular-failure_en.pdf"},
    {"id":"11288","name":"EU/3/14/1244: Public summary of opinion on orphan designation: Ruxolitinib for the treatment of polycythaemia vera","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-02T18:00:00Z","last_updated_date":"2015-05-08T18:00:00Z","reference_number":"EMA/COMP/30457/2014 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141244-public-summary-opinion-orphan-designation-ruxolitinib-treatment-polycythaemia-vera_en.pdf"},
    {"id":"11344","name":"EU/3/13/1147: Public summary of opinion on orphan designation: Granulocyte-macrophage colony-stimulating factor for the treatment of pulmonary alveolar proteinosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T14:30:00Z","last_updated_date":"2015-03-12T13:30:00Z","reference_number":"EMA/COMP/413549/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131147-public-summary-opinion-orphan-designation-granulocyte-macrophage-colony-stimulating-factor-treatment-pulmonary-alveolar-proteinosis_en.pdf"},
    {"id":"11407","name":"EU/3/14/1316: Public summary of opinion on orphan designation: Recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-01T02:00:00Z","last_updated_date":"2014-10-01T02:00:00Z","reference_number":"EMA/COMP/434800/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141316-public-summary-opinion-orphan-designation-recombinant-factor-viia-modified-three-terminal-repeats-derived-i2-chain-human-chorionic-gonadotropin-treatment-haemophilia_en.pdf"},
    {"id":"11416","name":"EU/3/16/1682: Public summary of opinion on orphan designation: Melatonin for the treatment of necrotising enterocolitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-08-02T17:30:00Z","last_updated_date":"2016-08-02T17:30:00Z","reference_number":"EMA/COMP/391425/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161682-public-summary-opinion-orphan-designation-melatonin-treatment-necrotising-enterocolitis_en.pdf"},
    {"id":"11436","name":"EU/3/16/1765: Public summary of positive opinion for orphan designation of ubiquinol for the treatment of primary coenzyme Q10 deficiency syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/620954/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161765-public-summary-positive-opinion-orphan-designation-ubiquinol-treatment-primary-coenzyme-q10-deficiency-syndrome_en.pdf"},
    {"id":"11468","name":"EU/3/02/101: Public summary of positive opinion for orphan designation of pseudomonas exotoxin (domains II/III)-interleukin 13 chimeric protein for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T00:00:00Z","last_updated_date":"2016-10-20T14:00:00Z","reference_number":"EMEA/COMP/612/02 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302101-public-summary-positive-opinion-orphan-designation-pseudomonas-exotoxin-domains-iiiii-interleukin-13-chimeric-protein-treatment-glioma_en.pdf"},
    {"id":"11503","name":"EU/3/15/1487: Public summary of opinion on orphan designation: Reduced oxidised N-acetyl heparin for the treatment of plasma cell myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2021-09-02T02:00:00Z","reference_number":"EMA/COMP/281341/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151487-public-summary-opinion-orphan-designation-reduced-oxidised-n-acetyl-heparin-treatment-plasma-cell-myeloma_en.pdf"},
    {"id":"11512","name":"EU/3/14/1299: Public summary of opinion on orphan designation: Riociguat for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T17:30:00Z","last_updated_date":"2014-09-01T17:30:00Z","reference_number":"EMA/COMP/359772/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141299-public-summary-opinion-orphan-designation-riociguat-treatment-systemic-sclerosis_en.pdf"},
    {"id":"11529","name":"EU/3/04/238: Public summary of positive opinion for orphan designation of recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3 for the treatment of leprechaunism","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-20T00:00:00Z","last_updated_date":"2011-06-22T01:00:00Z","reference_number":"EMEA/COMP/77797/2004 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304238-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-irecombinant-human-insulin-growth-factor-binding-protein-3-treatment-leprechaunism_en.pdf"},
    {"id":"11538","name":"EU/3/17/1836: Public summary of opinion on orphan designation: Fenfluramine hydrochloride for the treatment of Lennox-Gastaut syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/71973/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171836-public-summary-opinion-orphan-designation-fenfluramine-hydrochloride-treatment-lennox-gastaut-syndrome_en.pdf"},
    {"id":"11570","name":"EU/3/17/1897: Public summary of opinion on orphan designation: Tirapazamine for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2017-08-14T16:54:00Z","last_updated_date":"2017-08-14T16:54:00Z","reference_number":"EMA/410458/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171897-public-summary-opinion-orphan-designation-tirapazamine-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"11595","name":"EU/3/07/521: Public summary of positive opinion for orphan designation of H-Arg-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt & H-Tyr-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt for the treatment of TERT positive...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-10-21T02:00:00Z","last_updated_date":"2010-03-15T01:00:00Z","reference_number":"EMEA/COMP/161880/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307521-public-summary-positive-opinion-orphan-designation-h-arg-leu-phe-phe-tyr-arg-lys-ser-val-oh-acetate-salt-h-tyr-leu-phe-phe-tyr-arg-lys-ser-val-oh-acetate-salt-treatment-tert-positive_en.pdf"},
    {"id":"11620","name":"EU/3/05/339: Public summary of positive opinion for orphan designation of dasatinib for the treatment of chronic myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T00:00:00Z","last_updated_date":"2017-02-09T00:00:00Z","reference_number":"EMEA/COMP/386800/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305339-public-summary-positive-opinion-orphan-designation-dasatinib-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"11622","name":"EU/3/10/829: Public summary of opinion on orphan designation: Tesetaxel for the treatment of gastric cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"EMA/COMP/671327/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310829-public-summary-opinion-orphan-designation-tesetaxel-treatment-gastric-cancer_en.pdf"},
    {"id":"11637","name":"EU/3/16/1645: Public summary of opinion on orphan designation: Cannabidiol for the prevention of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2016-05-30T02:00:00Z","reference_number":"EMA/COMP/252372/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161645-public-summary-opinion-orphan-designation-cannabidiol-prevention-graft-versus-host-disease_en.pdf"},
    {"id":"11664","name":"EU/3/15/1602: Public summary of opinion on orphan designation: Live attenuated Listeria monocytogenes transfected with plasmids encoding the HPV-16E7 protein fused to a truncated fragment of the Lm protein listeriolysin ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T01:00:00Z","reference_number":"EMA/COMP/861603/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151602-public-summary-opinion-orphan-designation-live-attenuated-listeria-monocytogenes-transfected-plasmids-encoding-hpv-16e7-protein-fused-truncated-fragment-lm-protein-listeriolysin_en.pdf"},
    {"id":"11678","name":"EU/3/07/520: Public summary of positive opinion for orphan designation of\n\nhuman papilloma virus type 16 E6/E7 synthetic long peptides for the treatment of epithelial neoplasia of the vulva positive for human papilloma v...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2013-06-26T02:00:00Z","reference_number":"EMEA/COMP/170034/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307520-public-summary-positive-opinion-orphan-designation-human-papilloma-virus-type-16-e6e7-synthetic-long-peptides-treatment-epithelial-neoplasia-vulva-positive-human-papilloma-v_en.pdf"},
    {"id":"11710","name":"EU/3/12/970: Public summary of opinion on orphan designation: 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T11:45:00Z","last_updated_date":"2015-03-25T10:45:00Z","reference_number":"EMA/61726/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312970-public-summary-opinion-orphan-designation-6-ethynyl-1-pentan-3-yl-1h-imidazo45-bpyrazin-23h-one-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"11739","name":"EU/3/10/736: Public summary of opinion on orphan designation: Glyceryl tri-(4-phenylbutyrate) for the treatment of argininosuccinic aciduria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/COMP/123458/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310736-public-summary-opinion-orphan-designation-glyceryl-tri-4-phenylbutyrate-treatment-argininosuccinic-aciduria_en.pdf"},
    {"id":"11763","name":"EU/3/10/726: Public summary of opinion on orphan designation: Taliglucerase alfa for the treatment of Gaucher disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2011-03-10T01:00:00Z","reference_number":"EMA/COMP/38662/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310726-public-summary-opinion-orphan-designation-taliglucerase-alfa-treatment-gaucher-disease_en.pdf"},
    {"id":"11764","name":"EU/3/06/402: Public summary of positive opinion for orphan designation of opebacan for the treatment of meningococcal disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/427851/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306402-public-summary-positive-opinion-orphan-designation-opebacan-treatment-meningococcal-disease_en.pdf"},
    {"id":"11800","name":"EU/3/08/537: Public summary of positive opinion for orphan designation of autologous urothelial and smooth muscle cells for the treatment of spina bifida","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMEA/COMP/49041/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308537-public-summary-positive-opinion-orphan-designation-autologous-urothelial-and-smooth-muscle-cells-treatment-spina-bifida_en.pdf"},
    {"id":"11829","name":"EU/3/07/510: Public summary of positive opinion for orphan designation of artesunate for the treatment of malaria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"EMEA/COMP/486932/2007 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307510-public-summary-positive-opinion-orphan-designation-artesunate-treatment-malaria_en.pdf"},
    {"id":"11866","name":"EU/3/08/604: Public summary of positive opinion for orphan designation of recombinant human minibody against complement component C5 fused with RGD-motif for prevention of the ischaemia/reperfusion injury associated with...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2014-01-22T01:00:00Z","reference_number":"EMA/COMP/609861/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308604-public-summary-positive-opinion-orphan-designation-recombinant-human-minibody-against-complement-component-c5-fused-rgd-motif-prevention-ischaemiareperfusion-injury-associated_en.pdf"},
    {"id":"11876","name":"EU/3/13/1100: Public summary of positive opinion of humanised IgG1 kappa antibody against serum amyloid A and AL amyloid for the treatment of amyloid light-chain amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T11:00:00Z","last_updated_date":"2015-05-13T12:00:00Z","reference_number":"EMA/COMP/29473/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131100-public-summary-positive-opinion-humanised-igg1-kappa-antibody-against-serum-amyloid-and-al-amyloid-treatment-amyloid-light-chain-amyloidosis_en.pdf"},
    {"id":"11928","name":"EU/3/12/1009: Public summary of opinion on orphan designation: Givinostat for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2012-07-24T16:00:00Z","reference_number":"EMA/350443/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121009-public-summary-opinion-orphan-designation-givinostat-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"11930","name":"EU/3/08/603: Public summary of positive opinion for orphan designation of pralatrexate for the treatment of non-papillary transitional cell carcinoma of the urinary bladder","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2011-04-06T02:00:00Z","reference_number":"EMEA/COMP/667375/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308603-public-summary-positive-opinion-orphan-designation-pralatrexate-treatment-non-papillary-transitional-cell-carcinoma-urinary-bladder_en.pdf"},
    {"id":"12018","name":"EU/3/15/1548: Public summary of opinion on orphan designation: Ovine specific immunoglobulin (Fab) fragments raised against Vipera berus venom for the treatment of snakebite envenomation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2015-11-16T01:00:00Z","reference_number":"EMA/COMP/615279/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151548-public-summary-opinion-orphan-designation-ovine-specific-immunoglobulin-fab-fragments-raised-against-vipera-berus-venom-treatment-snakebite-envenomation_en.pdf"},
    {"id":"12031","name":"EU/3/08/599: Public summary of positive opinion for orphan designation of\n\nexon 51 specific phosphorothioate oligonucleotide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMEA/COMP/628120/2008 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308599-public-summary-positive-opinion-orphan-designation-exon-51-specific-phosphorothioate-oligonucleotide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"12036","name":"EU/3/05/285: Public summary of positive opinion for orphan designation of bimosiamose disodium for the treatment of acute lung injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-06-29T02:00:00Z","last_updated_date":"2005-06-29T02:00:00Z","reference_number":"EMEA/COMP/139723/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305285-public-summary-positive-opinion-orphan-designation-bimosiamose-disodium-treatment-acute-lung-injury_en.pdf"},
    {"id":"12045","name":"EU/3/13/1109: Public summary of opinion on orphan designation:4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2013-04-05T02:00:00Z","reference_number":"EMA/COMP/95768/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131109-public-summary-opinion-orphan-designation4-2-6-methylpyridin-2-yl-56-dihydro-4h-pyrrolo12-bpyrazol-3-yl-quinoline-6-carboxamide-monohydrate-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"12097","name":"EU/3/15/1460: Public summary of positive opinion for orphan designation of lenvatinib for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/132959/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151460-public-summary-positive-opinion-orphan-designation-lenvatinib-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"12119","name":"EU/3/14/1327: Public summary of opinion on orphan designation: S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-ar...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2014-10-02T02:00:00Z","reference_number":"EMA/COMP/452195/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141327-public-summary-opinion-orphan-designation-s3s13-cyclod-tyrolsyl-l-isoleucyl-l-cysteinyl-l-valyl-1-methyl-l-tryptophyl-l-glutaminyl-l-aspartyl-l-tryptophyl-n-methyl-l-glycyl-l-alanyl-l_en.pdf"},
    {"id":"12190","name":"EU/3/06/375: Public summary of positive opinion for orphan designation of nilotinib for the treatment of chronic myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T00:00:00Z","last_updated_date":"2020-01-20T00:00:00Z","reference_number":"EMEA/COMP/137639/2006 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306375-public-summary-positive-opinion-orphan-designation-nilotinib-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"12197","name":"EU/3/10/807: Public summary of opinion on orphan designation methylthioninium for the treatment of frontotemporal dementia with parkinsonism-17","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-15T01:00:00Z","last_updated_date":"2014-01-13T16:00:00Z","reference_number":"EMA/606352/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310807-public-summary-opinion-orphan-designation-methylthioninium-treatment-frontotemporal-dementia-parkinsonism-17_en.pdf"},
    {"id":"12213","name":"EU/3/15/1594: Public summary of opinion on orphan designation: Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin for treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2016-02-03T01:00:00Z","reference_number":"EMA/COMP/778963/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151594-public-summary-opinion-orphan-designation-live-attenuated-listeria-monocytogenes-delta-actadelta-inlb-strain-expressing-human-mesothelin-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"12239","name":"EU/3/12/1050: Public summary of opinion on orphan designation: [2-Cyano-3-cyclopropyl-3-hydroxy-N-(3-methyl-4-trifluoromethylphenyl)prop-2-enamide] for the treatment of traumatic spinal-cord injury","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2012-11-16T01:00:00Z","reference_number":"EMA/COMP/629399/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121050-public-summary-opinion-orphan-designation-2-cyano-3-cyclopropyl-3-hydroxy-n-3-methyl-4-trifluoromethylphenylprop-2-enamide-treatment-traumatic-spinal-cord-injury_en.pdf"},
    {"id":"12242","name":"EU/3/16/1787: Public summary of positive opinion for orphan designation of sodium benzoate for the treatment of argininosuccinic aciduria","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T16:26:00Z","last_updated_date":"2016-12-14T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161787-public-summary-positive-opinion-orphan-designation-sodium-benzoate-treatment-argininosuccinic-aciduria_en.pdf"},
    {"id":"12253","name":"EU/3/16/1628: Public summary of opinion on orphan designation: Diaspirin cross-linked haemoglobin for the treatment of oesophageal cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-02T02:00:00Z","last_updated_date":"2016-05-02T02:00:00Z","reference_number":"EMA/COMP/166535/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161628-public-summary-opinion-orphan-designation-diaspirin-cross-linked-haemoglobin-treatment-oesophageal-cancer_en.pdf"},
    {"id":"12310","name":"EU/3/15/1519: Public summary of opinion on orphan designation: Allogeneic human adult stem cells, isolated from skeletal muscle and expanded ex vivo for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T14:00:00Z","last_updated_date":"2015-08-18T14:00:00Z","reference_number":"EMA/COMP/426687/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151519-public-summary-opinion-orphan-designation-allogeneic-human-adult-stem-cells-isolated-skeletal-muscle-and-expanded-ex-vivo-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"12327","name":"EU/3/16/1683: Public summary of opinion on orphan designation: Melatonin for the treatment of neonatal sepsis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/391429/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161683-public-summary-opinion-orphan-designation-melatonin-treatment-neonatal-sepsis_en.pdf"},
    {"id":"12330","name":"EU/3/06/381: Public summary of positive opinion for orphan designation of\n\nhuman monoclonal antibody against Pseudomonas aeruginosa serotype O11\n\nfor the treatment of pneumonia caused by serotype O11 Pseudomonas aerugino...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMEA/COMP/428324/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306381-public-summary-positive-opinion-orphan-designation-human-monoclonal-antibody-against-pseudomonas-aeruginosa-serotype-o11-treatment-pneumonia-caused-serotype-o11-pseudomonas-aerugino_en.pdf"},
    {"id":"12354","name":"EU/3/15/1536: Public summary of opinion on orphan designation: Recombinant human acid ceramidase for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/500571/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151536-public-summary-opinion-orphan-designation-recombinant-human-acid-ceramidase-treatment-cystic-fibrosis_en.pdf"},
    {"id":"12356","name":"EU/3/05/265: Public summary of positive opinion for orphan designation of ciclosporin (inhalation use) for treatment of graft rejection after lung transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T00:00:00Z","last_updated_date":"2016-10-22T01:00:00Z","reference_number":"EMEA/COMP/42154/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305265-public-summary-positive-opinion-orphan-designation-ciclosporin-inhalation-use-treatment-graft-rejection-after-lung-transplantation_en.pdf"},
    {"id":"12373","name":"EU/3/17/1869: Public summary of opinion on orphan designation: Rituximab for treatment in solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/203464/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171869-public-summary-opinion-orphan-designation-rituximab-treatment-solid-organ-transplantation_en.pdf"},
    {"id":"12387","name":"EU/3/08/596: Public summary of positive opinion for orphan designation of monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E for the treatment of Hodgkin lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMEA/COMP/547302/2008 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308596-public-summary-positive-opinion-orphan-designation-monoclonal-antibody-against-human-cd30-covalently-linked-cytotoxin-monomethylauristatin-e-treatment-hodgkin-lymphoma_en.pdf"},
    {"id":"12392","name":"EU/3/08/553: Public summary of positive opinion for orphan designation of recombinant fusion protein of circularly-permuted IL-4 and pseudomonas exotoxin A, [IL-4(38-37)-PE38KDEL] for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2008-08-18T02:00:00Z","reference_number":"EMEA/COMP/202184/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308553-public-summary-positive-opinion-orphan-designation-recombinant-fusion-protein-circularly-permuted-il-4-and-pseudomonas-exotoxin-il-438-37-pe38kdel-treatment-glioma_en.pdf"},
    {"id":"12400","name":"EU/3/13/1110: Public summary of opinion on orphan designation:\n\nRecombinant human heat-shock protein 70 for the treatment of Niemann-Pick’s disease type C","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2017-08-14T02:00:00Z","reference_number":"EMA/COMP/105680/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131110-public-summary-opinion-orphan-designation-recombinant-human-heat-shock-protein-70-treatment-niemann-picks-disease-type-c_en.pdf"},
    {"id":"12411","name":"EU/3/14/1274: Public summary of opinion on orphan designation of paclitaxel-succinate-Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMA/COMP/252166/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141274-public-summary-opinion-orphan-designation-paclitaxel-succinate-arg-arg-leu-ser-tyr-ser-arg-arg-arg-phe-treatment-glioma_en.pdf"},
    {"id":"12441","name":"EU/3/13/1119: Public summary of opinion on orphan designation: Lenvatinib for the treatment of follicular thyroid cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-05-14T12:00:00Z","last_updated_date":"2013-10-22T12:00:00Z","reference_number":"EMA/COMP/193931/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131119-public-summary-opinion-orphan-designation-lenvatinib-treatment-follicular-thyroid-cancer_en.pdf"},
    {"id":"12467","name":"EU/3/12/982: Public summary of opinion on orphan designation: Dipalmitoylphosphatidylcholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, sodium salt, synthetic surfactant protein C analogue and synthetic surfacta...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-30T02:00:00Z","last_updated_date":"2012-04-30T02:00:00Z","reference_number":"EMA/COMP/135935/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312982-public-summary-opinion-orphan-designation-dipalmitoylphosphatidylcholine-1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol-sodium-salt-synthetic-surfactant-protein-c-analogue-and-synthetic_en.pdf"},
    {"id":"12477","name":"EU/3/06/417: Public summary of positive opinion for orphan designation of human interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and non-glycosylated) (inhalation use) for the treatment of renal ce...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/432982/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306417-public-summary-positive-opinion-orphan-designation-human-interleukin-2-glycosylated-tetrasaccharide-glycosylated-trisaccharide-and-non-glycosylated-inhalation-use-treatment-renal-ce_en.pdf"}    {"id":"12513","name":"EU/3/07/499: Public summary of positive opinion for orphan designation of terguride for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/155342/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307499-public-summary-positive-opinion-orphan-designation-terguride-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"12525","name":"EU/3/08/577: Public summary of positive opinion for orphan designation ofcarglumic acid for the treatment of propionic acidaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2021-06-09T15:05:00Z","reference_number":"EMEA/COMP/481242/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308577-public-summary-positive-opinion-orphan-designation-ofcarglumic-acid-treatment-propionic-acidaemia_en.pdf"},
    {"id":"12531","name":"EU/3/03/136: Public summary of positive opinion for orphan designation of iodine (131I) tositumomab for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T00:00:00Z","last_updated_date":"2015-05-09T01:00:00Z","reference_number":"EMEA/COMP/3/03/Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303136-public-summary-positive-opinion-orphan-designation-iodine-131i-tositumomab-treatment-follicular-lymphoma_en.pdf"},
    {"id":"12541","name":"EU/3/09/709: Public summary of opinion on orphan designation of recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T00:09:21Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/COMP/728150/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309709-public-summary-opinion-orphan-designation-recombinant-fusion-protein-consisting-extracellular-portion-cd95-fused-fc-part-human-igg1-molecule-treatment-glioma_en.pdf"},
    {"id":"12543","name":"EU/3/07/511: Public summary of positive opinion for orphan designation of3-methoxy-pregnenolone for the treatment of spinal cord injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2008-07-02T02:00:00Z","reference_number":"EMEA/COMP/473266/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307511-public-summary-positive-opinion-orphan-designation-of3-methoxy-pregnenolone-treatment-spinal-cord-injury_en.pdf"},
    {"id":"12593","name":"EU/3/09/628: Public summary of positive opinion for orphan designation  of mercaptopurine (oral suspension) for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-12T02:00:00Z","last_updated_date":"2013-09-19T02:00:00Z","reference_number":"EMEA/COMP/157866/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309628-public-summary-positive-opinion-orphan-designation-mercaptopurine-oral-suspension-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"12677","name":"EU/3/17/1958: Public summary of opinion on orphan designation: Allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 for treatment in haematopoietic stem cell transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-14T01:00:00Z","last_updated_date":"2021-03-22T01:00:00Z","reference_number":"EMA/5288/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171958-public-summary-opinion-orphan-designation-allogeneic-umbilical-cord-blood-cd34-cells-cultured-ex-vivo-notch-ligand-delta1-treatment-haematopoietic-stem-cell-transplantation_en.pdf"},
    {"id":"12712","name":"EU/3/04/227: Public summary of  positive opinion for orphan designation  of  l, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane  for treatment to mobilize progenitor cells prior to stem cell tran...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2021-08-10T12:24:00Z","reference_number":"EMEA/COMP/77477/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304227-public-summary-positive-opinion-orphan-designation-l-1-14-phenylenebis-methylene-bis-14811-tetraazacyclotetradecane-treatment-mobilize-progenitor-cells-prior-stem-cell-tran_en.pdf"},
    {"id":"12754","name":"EU/3/04/215: Public summary of positive opinion for orphan designation of porfimer sodium (for use with photodynamic therapy) for the treatment of cholangiocarcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-11-22T00:00:00Z","last_updated_date":"2013-04-09T02:00:00Z","reference_number":"EMA/COMP/369/2004 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304215-public-summary-positive-opinion-orphan-designation-porfimer-sodium-use-photodynamic-therapy-treatment-cholangiocarcinoma_en.pdf"},
    {"id":"12786","name":"EU/3/12/983: Public summary of opinion on orphan designation: Heterologous human adult liver-derived stem cells for the treatment of acute liver failure","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T13:00:00Z","last_updated_date":"2012-06-18T13:00:00Z","reference_number":"EMA/COMP/222564/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312983-public-summary-opinion-orphan-designation-heterologous-human-adult-liver-derived-stem-cells-treatment-acute-liver-failure_en.pdf"},
    {"id":"12798","name":"EU/3/12/965: Public summary of opinion on orphan designation: Ketoconazole for the treatment of Cushing’s syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2015-03-12T16:30:00Z","reference_number":"EMA/COMP/66372/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312965-public-summary-opinion-orphan-designation-ketoconazole-treatment-cushings-syndrome_en.pdf"},
    {"id":"12829","name":"EU/3/10/738: Public summary of opinion on orphan designation: Glyceryl tri-(4-phenylbutyrate) for the treatment of ornithine translocase deficiency (hyperornithinaemia-hyperammonaemia homocitrullinuria (HHH) syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/COMP/123548/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310738-public-summary-opinion-orphan-designation-glyceryl-tri-4-phenylbutyrate-treatment-ornithine-translocase-deficiency-hyperornithinaemia-hyperammonaemia-homocitrullinuria-hhh-syndrome_en.pdf"},
    {"id":"12873","name":"EU/3/14/1389: Public summary of positive opinion for orphan designation: Adeno-associated viral vector serotype rh.rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA for the treatment of mucopolysaccharidosi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-05-13T19:00:00Z","reference_number":"EMA/COMP/730599/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141389-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-serotype-rhrh10-carrying-human-n-sulfoglucosamine-sulfohydrolase-cdna-treatment-mucopolysaccharidosi_en.pdf"},
    {"id":"12885","name":"EU/3/09/699: Public summary of positive opinion for orphan designation of\n\nrecombinant chimeric monoclonal antibody against CD20 for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T02:09:21Z","last_updated_date":"2010-03-15T02:09:21Z","reference_number":"EMEA/COMP/663075/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309699-public-summary-positive-opinion-orphan-designation-recombinant-chimeric-monoclonal-antibody-against-cd20-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"12908","name":"EU/3/15/1544: Public summary of opinion on orphan designation: 2-(2-phenylvinyl)-4-[4- methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/508499/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151544-public-summary-opinion-orphan-designation-2-2-phenylvinyl-4-4-methylpiperazin-1-yl-6-5-methyl-2h-pyrazol-3-yl-amino-pyrimidine-l-tartrate-salt-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"12911","name":"EU/3/11/913: Public summary of opinion on orphan designation: Resminostat for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/COMP/584371/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311913-public-summary-opinion-orphan-designation-resminostat-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"12949","name":"EU/3/12/1092: Public summary of opinion on orphan designation: Chimeric monoclonal antibody against claudin 6 for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2021-04-08T01:00:00Z","reference_number":"EMA/COMP/794326/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121092-public-summary-opinion-orphan-designation-chimeric-monoclonal-antibody-against-claudin-6-treatment-ovarian-cancer_en.pdf"},
    {"id":"12998","name":"EU/3/11/948: Public summary of positive opinion for orphan designation: Sodium phenylbutyrate for the treatment of 5q spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2012-02-13T15:00:00Z","reference_number":"EMA/COMP/928645/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311948-public-summary-positive-opinion-orphan-designation-sodium-phenylbutyrate-treatment-5q-spinal-muscular-atrophy_en.pdf"},
    {"id":"13015","name":"EU/3/15/1521: Public summary of opinion on orphan designation: Artesunate for the treatment of malaria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T14:00:00Z","last_updated_date":"2015-08-18T14:00:00Z","reference_number":"EMA/COMP/422819/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151521-public-summary-opinion-orphan-designation-artesunate-treatment-malaria_en.pdf"},
    {"id":"13038","name":"EU/3/15/1475: Public summary of positive opinion for orphan designation of 1-(4-(N-glycylamido)phenyl)-3-trifluoromethyl-5-(phenanthren-2-yl)-pyrazole-hydrochloride for the treatment of cryptococcosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-21T14:00:00Z","last_updated_date":"2015-05-21T14:00:00Z","reference_number":"EMA/COMP/211408/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151475-public-summary-positive-opinion-orphan-designation-1-4-n-glycylamidophenyl-3-trifluoromethyl-5-phenanthren-2-yl-pyrazole-hydrochloride-treatment-cryptococcosis_en.pdf"},
    {"id":"13048","name":"EU/3/09/700: Public summary of positive opinion for orphan designation of\n\nvaccinia GM-CSF/TK-deactivated virus for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-12-08T00:09:21Z","last_updated_date":"2011-11-18T13:30:00Z","reference_number":"EMA/COMP/650791/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309700-public-summary-positive-opinion-orphan-designation-vaccinia-gm-csftk-deactivated-virus-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"13068","name":"EU/3/10/761: Public summary of opinion on orphan designation of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-11T01:31:00Z","last_updated_date":"2013-03-12T14:00:00Z","reference_number":"EMA/COMP/325798/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310761-public-summary-opinion-orphan-designation-3-6-1-22-difluorobenzo-d-13-dioxol-5-ylcyclopropanecarboxamido-3-methylpyridin-2-ylbenzoic-acid-treatment-cystic-fibrosis_en.pdf"},
    {"id":"13076","name":"EU/3/18/2001: Public summary of opinion on orphan designation: Recombinant modified ricin toxin A-chain subunit for the prevention of ricin poisoning","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"EMA/125875/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182001-public-summary-opinion-orphan-designation-recombinant-modified-ricin-toxin-chain-subunit-prevention-ricin-poisoning_en.pdf"},
    {"id":"13099","name":"EU/3/10/775: Public summary of opinion on orphan designation: Autologous bone-marrow-derived mononuclear-cell fraction for the treatment of thromboangiitis obliterans (Buerger’s disease)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/377668/2010 Re. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310775-public-summary-opinion-orphan-designation-autologous-bone-marrow-derived-mononuclear-cell-fraction-treatment-thromboangiitis-obliterans-buergers-disease_en.pdf"},
    {"id":"13112","name":"EU/3/17/1947: Public summary of opinion on orphan designation: 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione for the treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-23T14:42:00Z","last_updated_date":"2018-01-23T14:42:00Z","reference_number":"EMA/757596/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171947-public-summary-opinion-orphan-designation-2-isopropyl-3h-naphtho12-dimidazole-45-dione-treatment-mitochondrial-encephalomyopathy-lactic-acidosis-and-stroke-episodes_en.pdf"},
    {"id":"13120","name":"EU/3/13/1144: Public summary of opinion on orphan designation: Recombinant human alpha-N-acetylglucosaminidase for the treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T14:00:00Z","last_updated_date":"2017-10-19T14:00:00Z","reference_number":"EMA/COMP/317797/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131144-public-summary-opinion-orphan-designation-recombinant-human-alpha-n-acetylglucosaminidase-treatment-mucopolysaccharidosis-type-iiib-sanfilippo-b-syndrome_en.pdf"},
    {"id":"13129","name":"EU/3/16/1629: Public summary of opinion on orphan designation: Exenatide for the treatment of idiopathic intracranial hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-02T02:00:00Z","last_updated_date":"2016-05-02T02:00:00Z","reference_number":"EMA/COMP/168618/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161629-public-summary-opinion-orphan-designation-exenatide-treatment-idiopathic-intracranial-hypertension_en.pdf"},
    {"id":"13143","name":"EU/3/09/725: Public summary of opinion on orphan designation RNA, [P-deoxy-P-(dimethylamino)] (2',3'-dideoxy-2',3'-imino-2',3'-seco) (2'a→5') (C-m5U-m5U-A-C-AG-G-C-m5U-C-C-A-A-m5U-A-G-m5U-G-G-m5U-C-A-G-m5U), 5' [P-[4-[[2-[2-(2- hydroxyethoxy)ethoxy]ethoxy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:00:00Z","last_updated_date":"2021-02-03T01:00:00Z","reference_number":"EU/3/09/725","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-09-725-public-summary-opinion-orphan-designation-rna-p-deoxy-p-dimethylamino-23-dideoxy-23-imino-23-seco-2a-5-c-m5u-m5u-c-ag-g-c-m5u-c-c-m5u-g-m5u-g-g-m5u-c-g-m5u-5-p-4-2-2-2_en.pdf"},
    {"id":"13148","name":"EU/3/17/1894: Public summary of opinion on orphan designation: Recombinant human antibody directed against misfolded human superoxide dismutase 1 for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2017-08-14T16:54:00Z","last_updated_date":"2017-08-14T16:54:00Z","reference_number":"EMA/395085/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171894-public-summary-opinion-orphan-designation-recombinant-human-antibody-directed-against-misfolded-human-superoxide-dismutase-1-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"13173","name":"EU/3/12/957: Public summary of opinion on orphan designation: Autologous haematopoietic cells genetically modified with a lentiviral vector containing the human gp91(phox) gene for the treatment of X-linked chronic granu...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T01:00:00Z","last_updated_date":"2012-03-01T01:00:00Z","reference_number":"EMA/COMP/969323/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312957-public-summary-opinion-orphan-designation-autologous-haematopoietic-cells-genetically-modified-lentiviral-vector-containing-human-gp91phox-gene-treatment-x-linked-chronic-granu_en.pdf"},
    {"id":"13181","name":"EU/3/01/052: Public summary of positive opinion for orphan designation of seocalcitol for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-11-08T00:00:00Z","last_updated_date":"2004-11-08T00:00:00Z","reference_number":"EMEA/COMP/1291/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301052-public-summary-positive-opinion-orphan-designation-seocalcitol-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"13243","name":"EU/3/04/260: Public summary of positive opinion for orphan designation of recombinant human α-mannosidase for the treatment of α-mannosidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-07-01T02:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMEA/COMP/194136/2004 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304260-public-summary-positive-opinion-orphan-designation-recombinant-human-i-mannosidase-treatment-i-mannosidosis_en.pdf"},
    {"id":"13250","name":"EU/3/10/812: Public summary of opinion on orphan designation: Recombinant fusion protein consisting of the extracellular portion of human activin receptor IIB linked to the human IgG1 Fc domain for the treatment of Duche...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMA/COMP/602192/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310812-public-summary-opinion-orphan-designation-recombinant-fusion-protein-consisting-extracellular-portion-human-activin-receptor-iib-linked-human-igg1-fc-domain-treatment-duche_en.pdf"},
    {"id":"13264","name":"EU/3/15/1551: Public summary of opinion on orphan designation: Recombinant human IgG1 kappa light chain monoclonal antibody targeting plasma kallikrein for the treatment of hereditary angioedema","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2015-11-16T01:00:00Z","reference_number":"EMA/COMP/603277/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151551-public-summary-opinion-orphan-designation-recombinant-human-igg1-kappa-light-chain-monoclonal-antibody-targeting-plasma-kallikrein-treatment-hereditary-angioedema_en.pdf"},
    {"id":"13281","name":"EU/3/16/1720 : Public summary of opinion on orphan designation: Fimaporfin for the treatment of cholangiocarcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-10T14:03:00Z","last_updated_date":"2016-10-10T14:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161720-public-summary-opinion-orphan-designation-fimaporfin-treatment-cholangiocarcinoma_en.pdf"},
    {"id":"13327","name":"EU/3/07/476: Public summary of positive opinion for orphan designation of 5'-O-(trans-9\"-octadecenoyl)-1-àŸ-D-arabinofuranosyl cytosine for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2014-05-08T02:00:00Z","reference_number":"EMEA/COMP/127723/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307476-public-summary-positive-opinion-orphan-designation-5-o-trans-9-octadecenoyl-1-ay-d-arabinofuranosyl-cytosine-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"13334","name":"EU/3/14/1331: Public summary of opinion on orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain for the...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMA/COMP/435101/2014 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141331-public-summary-opinion-orphan-designation-recombinant-fusion-protein-consisting-modified-form-extracellular-domain-human-activin-receptor-iib-linked-human-igg1-fc-domain_en.pdf"},
    {"id":"13339","name":"EU/3/15/1512: Public summary of opinion on orphan designation: Anti-H5N1 equine immunoglobulin F(ab')2 fragments for the treatment of avian influenza","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T14:00:00Z","last_updated_date":"2015-08-18T14:00:00Z","reference_number":"EMA/COMP/433479/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151512-public-summary-opinion-orphan-designation-anti-h5n1-equine-immunoglobulin-fab2-fragments-treatment-avian-influenza_en.pdf"},
    {"id":"13346","name":"EU/3/13/1216: Public summary of opinion on orphan designation: (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-22T01:00:00Z","last_updated_date":"2014-01-22T01:00:00Z","reference_number":"EMA/COMP/697127/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131216-public-summary-opinion-orphan-designation-4r5r-1-4-4-33-dibutyl-7-dimethylamino-2345-tetrahydro-4-hydroxy-11-dioxido-1-benzothiepin-5-ylphenoxymethylphenylmethyl-4-aza-1-azoniabi_en.pdf"},
    {"id":"13364","name":"EU/3/14/1357: Public summary of opinion on orphan designation: Imatinib for the treatment of acute respiratory distress syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/COMP/660447/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141357-public-summary-opinion-orphan-designation-imatinib-treatment-acute-respiratory-distress-syndrome_en.pdf"},
    {"id":"13374","name":"EU/3/01/039: Public summary of positive opinion for orphan designation of ecteinascidin 743 for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T01:00:00Z","last_updated_date":"2007-12-04T01:00:00Z","reference_number":"EMEA/COMP/1292/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301039-public-summary-positive-opinion-orphan-designation-ecteinascidin-743-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"13379","name":"EU/3/18/1997: Public summary of opinion on orphan designation: Miransertib for the treatment of Proteus syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-15T02:00:00Z","last_updated_date":"2018-05-15T02:00:00Z","reference_number":"EMA/119696/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181997-public-summary-opinion-orphan-designation-miransertib-treatment-proteus-syndrome_en.pdf"},
    {"id":"13382","name":"EU/3/14/1252: Public summary of opinion on orphan designation: Cysteamine bitartrate for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-06T02:00:00Z","last_updated_date":"2014-05-06T02:00:00Z","reference_number":"EMA/COMP/93499/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141252-public-summary-opinion-orphan-designation-cysteamine-bitartrate-treatment-pancreatic-cancer_en.pdf"},
    {"id":"13415","name":"EU/3/16/1823: Public summary of opinion on orphan designation: Pioglitazone hydrochloride for the treatment of sudden sensorineural hearing loss","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/5816/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161823-public-summary-opinion-orphan-designation-pioglitazone-hydrochloride-treatment-sudden-sensorineural-hearing-loss_en.pdf"},
    {"id":"13431","name":"EU/3/08/554: Public summary of positive opinion for orphan designation of beraprost sodium (modified release tablet) for the treatment of pulmonary arterial hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2020-02-11T02:00:00Z","reference_number":"EMA/COMP/369082/2008 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308554-public-summary-positive-opinion-orphan-designation-beraprost-sodium-modified-release-tablet-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"13461","name":"EU/3/18/1992: Public summary of opinion on orphan designation: Efgartigimod alfa for the treatment of myasthenia gravis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"EMA/139668/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181992-public-summary-opinion-orphan-designation-efgartigimod-alfa-treatment-myasthenia-gravis_en.pdf"},
    {"id":"13468","name":"EU/3/07/453: Public summary of positive opinion for orphan designation of recombinant fusion protein consisting of human coagulation factor IX  attached to the Fc domain of human IgG1 for the treatment of haemophilia B (...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2011-03-10T01:00:00Z","reference_number":"EMEA/COMP/138804/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307453-public-summary-positive-opinion-orphan-designation-recombinant-fusion-protein-consisting-human-coagulation-factor-ix-attached-fc-domain-human-igg1-treatment-haemophilia-b_en.pdf"},
    {"id":"13527","name":"C(2005)1884: Public summary of negative opinion for orphan designation of ibuprofen L-lysinate for the treatment of patent ductus arteriosus in premature neonates\n\nof less than 34 weeks of gestational age","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-11T02:00:00Z","last_updated_date":"2005-10-11T02:00:00Z","reference_number":"EMEA/COMP/130896/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/c20051884-public-summary-negative-opinion-orphan-designation-ibuprofen-l-lysinate-treatment-patent-ductus-arteriosus-premature-neonates-less-34-weeks-gestational-age_en.pdf"},
    {"id":"13539","name":"EU/3/02/092: Public summary of positive opinion for orphan designation of 4-(3,5-bis-(hydroxy-phenyl)-1,2,4) triazol-1-yl)-benzoic acid for the treatment of chronic iron overload requiring chelation therapy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2016-09-30T02:00:00Z","reference_number":"EMEA/COMP/50/02 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302092-public-summary-positive-opinion-orphan-designation-4-35-bis-hydroxy-phenyl-124-triazol-1-yl-benzoic-acid-treatment-chronic-iron-overload-requiring-chelation-therapy_en.pdf"},
    {"id":"13547","name":"EU/3/15/1458: Public summary of positive opinion for orphan designation of humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4 for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/118047/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151458-public-summary-positive-opinion-orphan-designation-humanised-anti-folate-receptor-1-monoclonal-antibody-conjugated-maytansinoid-dm4-treatment-ovarian-cancer_en.pdf"},
    {"id":"13556","name":"EU/3/01/018: Public summary of positive opinion for orphan designation of recombinant human acid α-glucosidase for the treatment of glycogen storage disease type II (Pompe’s disease)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2016-08-10T14:00:00Z","reference_number":"EMEA/COMP/1277/03 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301018-public-summary-positive-opinion-orphan-designation-recombinant-human-acid-i-glucosidase-treatment-glycogen-storage-disease-type-ii-pompes-disease_en.pdf"},
    {"id":"13568","name":"EU/3/03/147: Public summary of positive opinion for orphan designation of amiloride hydrochloride dihydrate for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2009-09-17T02:00:00Z","reference_number":"EMEA/COMP/1186/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303147-public-summary-positive-opinion-orphan-designation-amiloride-hydrochloride-dihydrate-treatment-cystic-fibrosis_en.pdf"},
    {"id":"13631","name":"EU/3/01/073: Public summary of positive opinion for orphan designation of recombinant human monoclonal antibody to hsp90 for the treatment of invasive fungal infections","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-12T00:00:00Z","last_updated_date":"2015-02-12T13:00:00Z","reference_number":"EMA/COMP/97241/2009 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301073-public-summary-positive-opinion-orphan-designation-recombinant-human-monoclonal-antibody-hsp90-treatment-invasive-fungal-infections_en.pdf"},
    {"id":"13638","name":"C(2004) 3227: Public summary of negative opinion for orphan designation of histamine dihydrochloride for the treatment of malignant melanoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-03-16T00:00:00Z","last_updated_date":"2005-03-16T00:00:00Z","reference_number":"EMEA/COMP/17/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/c2004-3227-public-summary-negative-opinion-orphan-designation-histamine-dihydrochloride-treatment-malignant-melanoma_en.pdf"},
    {"id":"13641","name":"EU/3/10/825: Public summary of opinion on orphan designation: Ovine anti-colchicine polyclonal antibody fragments for the treatment of colchicine poisoning","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2013-06-25T02:00:00Z","reference_number":"EMA/COMP/662959/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310825-public-summary-opinion-orphan-designation-ovine-anti-colchicine-polyclonal-antibody-fragments-treatment-colchicine-poisoning_en.pdf"},
    {"id":"13644","name":"EU/3/06/392: Public summary of positive opinion for orphan designation of\n\nhuman monoclonal antibody against inhibitory killer cell lg-like receptors for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2014-01-13T15:30:00Z","reference_number":"EMEA/COMP/174047/2008 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306392-public-summary-positive-opinion-orphan-designation-human-monoclonal-antibody-against-inhibitory-killer-cell-lg-receptors-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"13666","name":"EU/3/12/955: Public summary of opinion on orphan designation: Doxycycline hyclate for the treatment of familial amyloid polyneuropathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/COMP/15933/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312955-public-summary-opinion-orphan-designation-doxycycline-hyclate-treatment-familial-amyloid-polyneuropathy_en.pdf"},
    {"id":"13683","name":"EU/3/06/380: Public summary of positive opinion for orphan designation of\n\ndiphenylcyclopropenone for the treatment of alopecia universalis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2013-09-23T02:00:00Z","reference_number":"EMEA/COMP/428296/2006 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306380-public-summary-positive-opinion-orphan-designation-diphenylcyclopropenone-treatment-alopecia-universalis_en.pdf"},
    {"id":"13691","name":"EU/3/13/1158: Public summary of opinion on orphan designation: Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes for the treatment of ataxia telangiectasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-16T02:00:00Z","last_updated_date":"2013-08-16T02:00:00Z","reference_number":"EMA/COMP/417562/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131158-public-summary-opinion-orphan-designation-dexamethasone-sodium-phosphate-encapsulated-human-autologous-erythrocytes-treatment-ataxia-telangiectasia_en.pdf"},
    {"id":"13694","name":"EU/3/15/1495: Public summary of opinion on orphan designation: Triheptanoin for the treatment of glucose transporter type-1 deficiency syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"EMA/COMP/269979/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151495-public-summary-opinion-orphan-designation-triheptanoin-treatment-glucose-transporter-type-1-deficiency-syndrome_en.pdf"},
    {"id":"13695","name":"EU/3/17/1883: Public summary of opinion on orphan designation: Pentamer formyl thiophene acetic acid for the treatment of Creutzfeldt-Jakob disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T02:00:00Z","last_updated_date":"2017-07-17T02:00:00Z","reference_number":"EMA/312774/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171883-public-summary-opinion-orphan-designation-pentamer-formyl-thiophene-acetic-acid-treatment-creutzfeldt-jakob-disease_en.pdf"},
    {"id":"13696","name":"EU/3/03/183: Public summary of positive opinion for orphan designation of temocillin sodium for the treatment of Burkholderia cepacia lung infection in cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-09-23T02:00:00Z","last_updated_date":"2014-07-14T14:00:00Z","reference_number":"EMA/COMP/42574/2004 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303183-public-summary-positive-opinion-orphan-designation-temocillin-sodium-treatment-burkholderia-cepacia-lung-infection-cystic-fibrosis_en.pdf"},
    {"id":"13704","name":"EU/3/11/933: Public summary of opinion on orphan designation: Nanoliposomal irinotecan for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMA/COMP/853906/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311933-public-summary-opinion-orphan-designation-nanoliposomal-irinotecan-treatment-pancreatic-cancer_en.pdf"},
    {"id":"13741","name":"EU/3/05/309: Public summary of positive opinion for orphan designation of sodium valproate for the treatment of 5q spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T01:00:00Z","last_updated_date":"2014-01-13T01:00:00Z","reference_number":"EMEA/COMP/245336/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305309-public-summary-positive-opinion-orphan-designation-sodium-valproate-treatment-5q-spinal-muscular-atrophy_en.pdf"},
    {"id":"13755","name":"EU/3/12/1027: Public summary of opinion on orphan designation: Human apotransferrin for the treatment of congenital hypotransferrinaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-08-31T12:30:00Z","last_updated_date":"2012-08-31T12:30:00Z","reference_number":"EMA/COMP/424419/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121027-public-summary-opinion-orphan-designation-human-apotransferrin-treatment-congenital-hypotransferrinaemia_en.pdf"},
    {"id":"13760","name":"EU/3/13/1103: Public summary of positive opinion of treprostinil sodium for the treatment of chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T11:00:00Z","last_updated_date":"2013-03-04T11:00:00Z","reference_number":"EMA/COMP/20734/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131103-public-summary-positive-opinion-treprostinil-sodium-treatment-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"13782","name":"EU/3/16/1796: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 encoding engineered rhodopsin DNA-binding repressor and human rhodopsin expression cassettes for the treatment of re...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/747470/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161796-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-encoding-engineered-rhodopsin-dna-binding-repressor-and-human-rhodopsin-expression-cassettes-treatment-re_en.pdf"},
    {"id":"13791","name":"EU/3/10/811: Public summary of opinion on orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate for the treatment o...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2013-04-09T02:00:00Z","reference_number":"EMA/COMP/601719/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310811-public-summary-opinion-orphan-designation-n-tert-butyl-3-5-methyl-2-4-2-pyrrolidin-1-ylethoxyphenylaminopyrimidin-4-ylamino-benzenesulfonamide-dihydrochloride-monohydrate-treatment-o_en.pdf"},
    {"id":"13819","name":"EU/3/13/1102: Public summary of positive opinion of Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys for the treatment of high-altitude pulmonary oedema","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T11:00:00Z","last_updated_date":"2013-03-04T11:00:00Z","reference_number":"EMA/COMP/39571/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131102-public-summary-positive-opinion-cyclo-cys-gly-gln-arg-glu-thr-pro-glu-gly-ala-glu-ala-lys-pro-trp-tyr-cys-treatment-high-altitude-pulmonary-oedema_en.pdf"},
    {"id":"13825","name":"EU/3/06/367: Public summary of positive opinion for orphan designation of parathyroid hormone (1-34) transglutaminase fusion protein fibrin matrix complex for the treatment of solitary bone cysts","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/107517/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306367-public-summary-positive-opinion-orphan-designation-parathyroid-hormone-1-34-transglutaminase-fusion-protein-fibrin-matrix-complex-treatment-solitary-bone-cysts_en.pdf"},
    {"id":"13837","name":"EU/3/12/1057: Public summary of opinion on orphan designation: Naloxone hydrochloride dihydrate for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2012-12-12T01:00:00Z","reference_number":"EMA/COMP/684045/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121057-public-summary-opinion-orphan-designation-naloxone-hydrochloride-dihydrate-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"13862","name":"EU/3/16/1667: Public summary of opinion on orphan designation: Rovalpituzumab tesirine for the treatment of small cell lung cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"EMA/COMP/303792/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161667-public-summary-opinion-orphan-designation-rovalpituzumab-tesirine-treatment-small-cell-lung-cancer_en.pdf"},
    {"id":"13896","name":"EU/3/06/386: Public summary of positive opinion for orphan designation\n\nof 4-[123I] iodo-L-phenylalanine for the diagnosis of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/159728/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306386-public-summary-positive-opinion-orphan-designation-4-123i-iodo-l-phenylalanine-diagnosis-glioma_en.pdf"},
    {"id":"13898","name":"EU/3/13/1223: Public summary of opinion on orphan designation: Inecalcitol for the treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"EMA/COMP/16735/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131223-public-summary-opinion-orphan-designation-inecalcitol-treatment-chronic-lymphocytic-leukaemia-small-lymphocytic-lymphoma_en.pdf"},
    {"id":"13946","name":"EU/3/05/313: Public summary of positive opinion for orphan designation of autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene for the treatment of severe combined immunodeficienc...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T00:00:00Z","last_updated_date":"2015-03-11T01:00:00Z","reference_number":"EMEA/COMP/247430/2005 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305313-public-summary-positive-opinion-orphan-designation-autologous-cd34-cells-transfected-retroviral-vector-containing-adenosine-deaminase-gene-treatment-severe-combined-immunodeficienc_en.pdf"},
    {"id":"13955","name":"EU/3/12/952: Public summary of opinion on orphan designation: Nimorazole maleate for the treatment of squamous cell carcinoma of the head and neck in patients undergoing radiotherapy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T01:00:00Z","last_updated_date":"2012-03-01T01:00:00Z","reference_number":"EMA/COMP/41124/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312952-public-summary-opinion-orphan-designation-nimorazole-maleate-treatment-squamous-cell-carcinoma-head-and-neck-patients-undergoing-radiotherapy_en.pdf"},
    {"id":"13964","name":"EU/3/04/192: Public summary of positive opinion for orphan designation of 3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2013-09-17T02:00:00Z","reference_number":"EMEA/COMP/81/04 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304192-public-summary-positive-opinion-orphan-designation-3-4aminoisoindoline-1-one-1-piperidine-26-dione-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"13988","name":"EU/3/15/1528: Public summary of opinion on orphan designation: Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene for the treatment of primary hyperoxaluria type 1","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T02:00:00Z","last_updated_date":"2015-08-18T02:00:00Z","reference_number":"EMA/COMP/430728/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151528-public-summary-opinion-orphan-designation-synthetic-double-stranded-rna-oligonucleotide-specific-hydroxyacid-oxidase-1-gene-treatment-primary-hyperoxaluria-type-1_en.pdf"},
    {"id":"14023","name":"EU/3/13/1215: Public summary of opinion on orphan designation: (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-22T01:00:00Z","last_updated_date":"2022-06-14T01:00:00Z","reference_number":"EMA/COMP/699781/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131215-public-summary-opinion-orphan-designation-4r5r-1-4-4-33-dibutyl-7-dimethylamino-2345-tetrahydro-4-hydroxy-11-dioxido-1-benzothiepin-5-ylphenoxymethylphenylmethyl-4-aza-1-azoniabi_en.pdf"},
    {"id":"14053","name":"EU/3/13/1225: Public summary of opinion on orphan designation: Lonafarnib for the treatment of hepatitis delta virus infection","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"EMA/COMP/18107/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131225-public-summary-opinion-orphan-designation-lonafarnib-treatment-hepatitis-delta-virus-infection_en.pdf"},
    {"id":"14068","name":"EU/3/03/185: Public summary  of positive opinion for orphan designation of tacrolimus hydrate for the treatment of vernal keratoconjunctivitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-04-26T02:00:00Z","last_updated_date":"2010-10-14T02:00:00Z","reference_number":"EMEA/COMP/1610/03 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303185-public-summary-positive-opinion-orphan-designation-tacrolimus-hydrate-treatment-vernal-keratoconjunctivitis_en.pdf"},
    {"id":"14102","name":"EU/3/14/1403: Public summary of opinion on orphan designation: Plerixafor for the treatment of WHIM syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/COMP/735793/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141403-public-summary-opinion-orphan-designation-plerixafor-treatment-whim-syndrome_en.pdf"},
    {"id":"14143","name":"EU/3/14/1267: Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against transthyretin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-06-04T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"EMA/COMP/160178/2014  Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141267-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-transthyretin-mrna-and-covalently-linked-ligand-containing-three-n_en.pdf"},
    {"id":"14156","name":"EU/3/15/1436: Public summary of opinion on orphan designation: Lactobacillus reuteri for the prevention of necrotising enterocolitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2015-04-09T02:00:00Z","reference_number":"EMA/COMP/48621/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151436-public-summary-opinion-orphan-designation-lactobacillus-reuteri-prevention-necrotising-enterocolitis_en.pdf"},
    {"id":"14179","name":"EU/3/16/1703: Public summary of opinion on orphan designation: Setmelanotide for the treatment of pro-opiomelanocortin deficiency","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/446373/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161703-public-summary-opinion-orphan-designation-setmelanotide-treatment-pro-opiomelanocortin-deficiency_en.pdf"},
    {"id":"14181","name":"EU/3/05/288: Public summary of positive opinion for orphan designation of 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine x HC1 for the treatment of Huntington's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-04T02:00:00Z","last_updated_date":"2013-06-19T12:30:00Z","reference_number":"EMEA/COMP/167453/2005 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305288-public-summary-positive-opinion-orphan-designation-4-3-methylsulfonylphenyl-1-propylpiperidine-x-hc1-treatment-huntingtons-disease_en.pdf"},
    {"id":"14188","name":"EU/3/11/860: Public summary of opinion on orphan designation: Adeno-associated viral vector containing the human NADH-dehydrogenase-4 gene for the treatment of Leber's hereditary optic neuropathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2013-10-07T18:00:00Z","reference_number":"EMA/COMP/154900/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311860-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-containing-human-nadh-dehydrogenase-4-gene-treatment-lebers-hereditary-optic-neuropathy_en.pdf"},
    {"id":"14206","name":"EU/3/04/208: Public summary of positive opinion for orphan designation of acetylsalicylic acid for the treatment of polycythemia vera","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-12-06T01:00:00Z","last_updated_date":"2004-12-06T01:00:00Z","reference_number":"EMEA/COMP/311/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304208-public-summary-positive-opinion-orphan-designation-acetylsalicylic-acid-treatment-polycythemia-vera_en.pdf"},
    {"id":"14259","name":"EU/3/16/1827: Public summary of opinion on orphan designation: Trans-resveratrol for the treatment of spinocerebellar ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/15858/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161827-public-summary-opinion-orphan-designation-trans-resveratrol-treatment-spinocerebellar-ataxia_en.pdf"},
    {"id":"14261","name":"EU/3/11/945: Public summary of positive opinion for orphan designation: Ornithine phenylacetate for the treatment of acute liver failure","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2014-10-16T16:00:00Z","reference_number":"EMA/COMP/929338/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311945-public-summary-positive-opinion-orphan-designation-ornithine-phenylacetate-treatment-acute-liver-failure_en.pdf"},
    {"id":"14310","name":"EU/3/06/371: Public summary of positive opinion for orphan designation of\n\nheparin sodium for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/126010/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306371-public-summary-positive-opinion-orphan-designation-heparin-sodium-treatment-cystic-fibrosis_en.pdf"},
    {"id":"14320","name":"EU/3/14/1424: Public summary of opinion on orphan designation: Humanised Fc engineered monoclonal antibody against CD19 for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2015-03-06T12:00:00Z","reference_number":"EMA/COMP/793170/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141424-public-summary-opinion-orphan-designation-humanised-fc-engineered-monoclonal-antibody-against-cd19-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"14334","name":"EU/3/04/249: Public summary of positive opinion for orphan designation of recombinant histidine tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-06T00:00:00Z","last_updated_date":"2011-06-01T01:00:00Z","reference_number":"EMEA/COMP/5142/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304249-public-summary-positive-opinion-orphan-designation-recombinant-histidine-tagged-idiotype-immunoglobulin-fab-fragment-clonal-b-cell-receptors-treatment-follicular-lymphoma_en.pdf"},
    {"id":"14340","name":"EU/3/07/481: Public summary of positive opinion for orphan designation of R-salbutamol sulphate for the treatment of cutaneous forms of lupus erythematosus","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2008-07-02T02:00:00Z","reference_number":"EMEA/COMP/390202/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307481-public-summary-positive-opinion-orphan-designation-r-salbutamol-sulphate-treatment-cutaneous-forms-lupus-erythematosus_en.pdf"},
    {"id":"14351","name":"EU/3/06/420: Public summary of positive opinion for orphan designation of temsirolimus for the treatment of mantle cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2019-08-30T14:30:00Z","reference_number":"EMEA/COMP/195543/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306420-public-summary-positive-opinion-orphan-designation-temsirolimus-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"14362","name":"EU/3/07/446: Public summary of positive opinion for orphan designation of autologous CD34+ cells transfected with lentiviral vector containing the human arylsulfatase A cDNA for the treatment of metachromatic leukodystro...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2015-03-11T01:00:00Z","reference_number":"EMEA/COMP/143211/2008 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307446-public-summary-positive-opinion-orphan-designation-autologous-cd34-cells-transfected-lentiviral-vector-containing-human-arylsulfatase-cdna-treatment-metachromatic-leukodystro_en.pdf"},
    {"id":"14375","name":"EU/3/10/749: Public summary of positive opinion for Recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMA/COMP/164768/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310749-public-summary-positive-opinion-recombinant-human-anti-interferon-gamma-monoclonal-antibody-treatment-haemophagocytic-lymphohistiocytosis_en.pdf"},
    {"id":"14393","name":"EU/3/09/666: Public summary of positive opinion for orphan designation of\n\neicosapentaenoic acid for the treatment of familial adenomatous polyposis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2009-10-20T02:00:00Z","reference_number":"EMEA/COMP/454132/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309666-public-summary-positive-opinion-orphan-designation-eicosapentaenoic-acid-treatment-familial-adenomatous-polyposis_en.pdf"},
    {"id":"14400","name":"EU/3/16/1635: Public summary of opinion on orphan designation: N-acetyl-D-mannosamine monohydrate for the treatment of GNE myopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"EMA/COMP/172186/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161635-public-summary-opinion-orphan-designation-n-acetyl-d-mannosamine-monohydrate-treatment-gne-myopathy_en.pdf"},
    {"id":"14417","name":"EU/3/09/622: Public summary of positive opinion for orphan designation of N-(5-tert-butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt for the t...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-08T02:00:00Z","last_updated_date":"2009-04-08T02:00:00Z","reference_number":"EMEA/COMP/26165/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309622-public-summary-positive-opinion-orphan-designation-n-5-tert-butylisoxazol-3-yl-n-4-7-2-morpholin-4-ylethoxy-imidazo21-b13benzothiazol-2-ylphenylurea-di-hydrochloride-salt-t_en.pdf"}    {"id":"14430","name":"EU/3/15/1597: Public summary of opinion on orphan designation: Sodium (2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1(2H)-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl ((2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9(6H)-yl)-3-hydroxytet...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2016-02-03T01:00:00Z","reference_number":"EMA/COMP/790054/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151597-public-summary-opinion-orphan-designation-sodium-2r3s5r-5-4-amino-2-oxo-135-triazin-12h-yl-2-hydroxymethyltetrahydrofuran-3-yl-2r3s5r-5-2-amino-6-oxo-1h-purin-96h-yl-3-hydroxytet_en.pdf"},
    {"id":"14449","name":"EU/3/13/1199: Public summary of opinion on orphan designation: Sorafenib tosylate for the treatment of follicular thyroid cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/COMP/637636/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131199-public-summary-opinion-orphan-designation-sorafenib-tosylate-treatment-follicular-thyroid-cancer_en.pdf"},
    {"id":"14462","name":"EU/3/14/1324: Public summary of opinion on orphan designation: 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide for the treatment of small cell lung cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2014-10-02T02:00:00Z","reference_number":"EMA/COMP/457059/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141324-public-summary-opinion-orphan-designation-2-2-methyl-5-nitro-1h-imidazol-1-ylethylsulfamide-treatment-small-cell-lung-cancer_en.pdf"},
    {"id":"14469","name":"EU/3/08/563: Public summary of positive opinion for orphan designation of recombinant derivative of C3 transferase for the treatment of traumatic spinal cord injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMEA/COMP/449959/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308563-public-summary-positive-opinion-orphan-designation-recombinant-derivative-c3-transferase-treatment-traumatic-spinal-cord-injury_en.pdf"},
    {"id":"14490","name":"EU/3/10/802: Public summary of opinion on orphan designation\n\n2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-15T01:00:00Z","last_updated_date":"2011-11-11T01:00:00Z","reference_number":"EMA/606370/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310802-public-summary-opinion-orphan-designation-2-2-chlorophenyl-4-3-dimethylaminophenyl-5-methyl-1h-pyrazolo43-cpyridine-362h5h-dione-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"14491","name":"EU/3/14/1364: Public summary of opinion on orphan designation: Olaptesed pegol for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/COMP/652858/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141364-public-summary-opinion-orphan-designation-olaptesed-pegol-treatment-glioma_en.pdf"},
    {"id":"14540","name":"EU/3/14/1380: Public summary of opinion on orphan designation: Ataluren for the treatment of mucopolysaccharidosis type I","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2018-02-22T01:00:00Z","reference_number":"EMA/COMP/638269/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141380-public-summary-opinion-orphan-designation-ataluren-treatment-mucopolysaccharidosis-type-i_en.pdf"},
    {"id":"14559","name":"EU/3/05/330: Public summary of positive opinion for orphan designation of tilarginine acetate for the treatment of cardiogenic shock","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/315304/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305330-public-summary-positive-opinion-orphan-designation-tilarginine-acetate-treatment-cardiogenic-shock_en.pdf"},
    {"id":"14566","name":"EU/3/08/567: Public summary of positive opinion for orphan designation of miltefosine for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/456657/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308567-public-summary-positive-opinion-orphan-designation-miltefosine-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"14578","name":"EU/3/08/602: Public summary of positive opinion for orphan designation of milatuzumab for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/COMP/593994/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308602-public-summary-positive-opinion-orphan-designation-milatuzumab-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"14585","name":"EU/3/09/708: Public summary of opinion on orphan designation of pegylated recombinant phenylalanine ammonia lyase for the treatment of hyperphenylalaninaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/COMP/748610/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309708-public-summary-opinion-orphan-designation-pegylated-recombinant-phenylalanine-ammonia-lyase-treatment-hyperphenylalaninaemia_en.pdf"},
    {"id":"14602","name":"EU/3/04/217: Public summary of positive opinion for orphan designation of sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleoyl hosphatidylglycerol and palmitic acid for the treatment of respiratory distress synd...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"EMEA/COMP/370/04 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304217-public-summary-positive-opinion-orphan-designation-sinapultide-dipalmitoylphosphatidylcholine-palmitoyl-oleoyl-hosphatidylglycerol-and-palmitic-acid-treatment-respiratory-distress-synd_en.pdf"},
    {"id":"14605","name":"EU/3/17/1895: Public summary of opinion on orphan designation: Retinol for the prevention of retinopathy of prematurity","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2017-08-15T16:00:00Z","last_updated_date":"2017-08-15T16:00:00Z","reference_number":"EMA/402226/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171895-public-summary-opinion-orphan-designation-retinol-prevention-retinopathy-prematurity_en.pdf"},
    {"id":"14626","name":"Public summary of opinion on orphan designation: Tariquidar for the treatment of P-gp positive breast cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-09-06T02:00:00Z","last_updated_date":"2012-09-06T02:00:00Z","reference_number":"EMA/COMP/444415/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-tariquidar-treatment-p-gp-positive-breast-cancer_en.pdf"},
    {"id":"14660","name":"EU/3/15/1452: Public summary of positive opinion for orphan designation of tideglusib for the treatment of fragile X syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/123657/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151452-public-summary-positive-opinion-orphan-designation-tideglusib-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"14699","name":"EU/3/06/368: Public summary of positive opinion for orphan designation of 1-deoxygalactonojirimycin hydrochloride for the treatment of Fabry disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2014-05-08T02:00:00Z","reference_number":"EMEA/COMP/139954/2006 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306368-public-summary-positive-opinion-orphan-designation-1-deoxygalactonojirimycin-hydrochloride-treatment-fabry-disease_en.pdf"},
    {"id":"14701","name":"EU/3/15/1515: Public summary of opinion on orphan designation: Synthetic hypericin for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T02:00:00Z","last_updated_date":"2015-08-18T02:00:00Z","reference_number":"EMA/COMP/432824/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151515-public-summary-opinion-orphan-designation-synthetic-hypericin-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"14726","name":"EU/3/13/1140: Public summary of opinion on orphan designation: Expanded human allogeneic neural retinal progenitor cells extracted from neural retina for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T14:00:00Z","last_updated_date":"2013-07-11T14:00:00Z","reference_number":"EMA/COMP/307446/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131140-public-summary-opinion-orphan-designation-expanded-human-allogeneic-neural-retinal-progenitor-cells-extracted-neural-retina-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"14734","name":"EU/3/18/2010: Public summary of opinion on orphan designation: Branaplam for the treatment of spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T13:00:00Z","last_updated_date":"2018-05-17T13:00:00Z","reference_number":"EMA/197899/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182010-public-summary-opinion-orphan-designation-branaplam-treatment-spinal-muscular-atrophy_en.pdf"},
    {"id":"14746","name":"EU/3/02/097: Public summary of positive opinion for orphan designation of humanized anti-KSA monoclonal antibody-human interleukin-2 fusion protein for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-05-23T02:00:00Z","last_updated_date":"2003-05-23T02:00:00Z","reference_number":"EMEA/COMP/47/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302097-public-summary-positive-opinion-orphan-designation-humanized-anti-ksa-monoclonal-antibody-human-interleukin-2-fusion-protein-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"14757","name":"EU/3/15/1444: Public summary of opinion on orphan designation: Mazindol for the treatment of narcolepsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2018-05-29T02:00:00Z","reference_number":"EMA/COMP/43664/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151444-public-summary-opinion-orphan-designation-mazindol-treatment-narcolepsy_en.pdf"},
    {"id":"14759","name":"EU/3/02/115: Public summary of positive opinion for orphan designation of (-)-17-(cyclopropylmethyl)-3,14 àŸ-dihydroxy-4,5 α-epoxy-6àŸ-[N-methyl-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (intravenous use) fo...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-09T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/COMP/78338/2004 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302115-public-summary-positive-opinion-orphan-designation-17-cyclopropylmethyl-314-ay-dihydroxy-45-i-epoxy-6ay-n-methyl-trans-3-3-furyl-acrylamido-morphinan-hydrochloride-intravenous-use-fo_en.pdf"},
    {"id":"14764","name":"EU/3/17/1848: Public summary of opinion on orphan designation: Acetylleucine for the treatment of Niemann-Pick disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/142313/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171848-public-summary-opinion-orphan-designation-acetylleucine-treatment-niemann-pick-disease_en.pdf"},
    {"id":"14791","name":"EU/3/12/1012: Public summary of opinion on orphan designation: 2S, 4R ketoconazole for treatment of Cushing's syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2012-07-24T16:00:00Z","reference_number":"EMA/COMP/357657/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121012-public-summary-opinion-orphan-designation-2s-4r-ketoconazole-treatment-cushings-syndrome_en.pdf"},
    {"id":"14833","name":"EU/3/15/1508: Public summary of opinion on orphan designation: Triheptanoin for the treatment of very long-chain acyl-CoA dehydrogenase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2015-07-27T02:00:00Z","reference_number":"EMA/COMP/345427/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151508-public-summary-opinion-orphan-designation-triheptanoin-treatment-very-long-chain-acyl-coa-dehydrogenase-deficiency_en.pdf"},
    {"id":"14867","name":"EU/3/18/2016: Public summary of opinion on orphan designation: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor for the treatment of follicular lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-24T12:51:00Z","last_updated_date":"2022-02-21T12:51:00Z","reference_number":"EMA/262875/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182016-public-summary-opinion-orphan-designation-autologous-cd4-and-cd8-t-cells-expressing-cd19-specific-chimeric-antigen-receptor-treatment-follicular-lymphoma_en.pdf"},
    {"id":"14892","name":"EU/3/12/994: Public summary of opinion on orphan designation: Yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10 for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T16:55:00Z","last_updated_date":"2012-06-18T16:55:00Z","reference_number":"EMA/COMP/203343/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312994-public-summary-opinion-orphan-designation-yttrium-90y-dtpa-radiolabelled-chimeric-monoclonal-antibody-against-frizzled-homologue-10-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"14912","name":"EU/3/01/061: Public summary of positive opinion for imatinib mesilate for the treatment of malignant gastrointestinal stromal tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T01:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMA/COMP/10367/2003 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301061-public-summary-positive-opinion-imatinib-mesilate-treatment-malignant-gastrointestinal-stromal-tumours_en.pdf"},
    {"id":"14915","name":"EU/3/13/1155: Public summary of opinion on orphan designation: Allogeneic motor-neurone progenitor cells derived from human embryonic stem cells for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-16T13:00:00Z","last_updated_date":"2013-08-16T13:00:00Z","reference_number":"EMA/COMP/413414/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131155-public-summary-opinion-orphan-designation-allogeneic-motor-neurone-progenitor-cells-derived-human-embryonic-stem-cells-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"14947","name":"EU/3/14/1418: Public summary of opinion on orphan designation: A lentiviral vector pseudotyped by the New-Jersey serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I an...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/COMP/786967/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141418-public-summary-opinion-orphan-designation-lentiviral-vector-pseudotyped-new-jersey-serotype-vesicular-stomatitis-virus-g-protein-encoding-antigen-derived-tax-hbz-p12i_en.pdf"},
    {"id":"14955","name":"EU/3/12/1023: Public summary of opinion on orphan designation: Metreleptin for the treatment of Barraquer-Simons syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-08-31T12:30:00Z","last_updated_date":"2015-05-13T12:30:00Z","reference_number":"EMA/COMP/440571/2012 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121023-public-summary-opinion-orphan-designation-metreleptin-treatment-barraquer-simons-syndrome_en.pdf"},
    {"id":"14973","name":"EU/3/10/843: Public summary of opinion on orphan designation:  Allogeneic aortic endothelial cells cultured in a porcine gelatin matrix for the prevention of arteriovenous access failure in haemodialysis patients","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-04T01:00:00Z","last_updated_date":"2017-05-17T16:00:00Z","reference_number":"EMA/COMP/831251/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310843-public-summary-opinion-orphan-designation-allogeneic-aortic-endothelial-cells-cultured-porcine-gelatin-matrix-prevention-arteriovenous-access-failure-haemodialysis-patients_en.pdf"},
    {"id":"14981","name":"EU/3/08/592: Public summary of positive opinion for orphan designation of murine anti-CD22 antibody variable region fused to truncated Pseudomonas exotoxin 38 for the treatment of hairy cell leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2009-09-17T02:00:00Z","reference_number":"EMEA/COMP/546613/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308592-public-summary-positive-opinion-orphan-designation-murine-anti-cd22-antibody-variable-region-fused-truncated-pseudomonas-exotoxin-38-treatment-hairy-cell-leukaemia_en.pdf"},
    {"id":"14994","name":"EU/3/13/1178: Public summary of opinion on orphan designation: Pegylated recombinant anti-Pseudomonas aeruginosa PcrV Fab’ antibody for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-13T02:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMA/COMP/440852/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131178-public-summary-opinion-orphan-designation-pegylated-recombinant-anti-pseudomonas-aeruginosa-pcrv-fab-antibody-treatment-pseudomonas-aeruginosa-lung-infection-cystic-fibrosis_en.pdf"},
    {"id":"14995","name":"EU/3/18/2026: Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2'-fluoro a...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T18:30:00Z","last_updated_date":"2018-07-23T18:30:00Z","reference_number":"EMA/275373/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182026-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-targeted-against-transthyretin-mrna-six-phosphorothioate-linkages-backbone-and-nine-2-fluoro_en.pdf"},
    {"id":"15050","name":"EU/3/15/1562: Public summary of opinion on orphan designation: A highly purified formulation of Staphylococcus aureus protein A for the treatment of immune thrombocytopenia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-18T11:00:00Z","last_updated_date":"2015-11-18T11:00:00Z","reference_number":"EMA/COMP/614801/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151562-public-summary-opinion-orphan-designation-highly-purified-formulation-staphylococcus-aureus-protein-treatment-immune-thrombocytopenia_en.pdf"},
    {"id":"15068","name":"EU/3/06/384: Public summary of positive opinion for orphan designation ofhuman telomerase reverse transcriptase peptide (611-626) for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2023-08-08T12:59:00Z","reference_number":"EMEA/COMP/177332/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306384-public-summary-positive-opinion-orphan-designation-ofhuman-telomerase-reverse-transcriptase-peptide-611-626-treatment-pancreatic-cancer_en.pdf"},
    {"id":"15074","name":"EU/3/02/131: Public summary of positive opinion for orphan designation of sodium oxybate for the treatment of narcolepsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2016-09-30T02:00:00Z","reference_number":"EMEA/COMP/32860/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302131-public-summary-positive-opinion-orphan-designation-sodium-oxybate-treatment-narcolepsy_en.pdf"},
    {"id":"15091","name":"EU/3/08/572: Public summary of positive opinion for orphan designation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate for the treatment of chronic idiopathic myelofib...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMEA/COMP/488810/2008 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308572-public-summary-positive-opinion-orphan-designation-r-3-4-7h-pyrrolo23-dpyrimidin-4-yl-1h-pyrazol-1-yl-3-cyclopentylpropanenitrile-phosphate-treatment-chronic-idiopathic-myelofib_en.pdf"},
    {"id":"15134","name":"EU/3/09/645: Public summary of positive opinion for orphan designation of octreotide hydrochloride (lipid depot solution) for the treatment of acromegaly","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2024-09-18T02:00:00Z","reference_number":"EMEA/COMP/296368/2009 Rev.2 Corr.","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-09-645-public-summary-positive-opinion-orphan-designation-octreotide-hydrochloride-lipid-depot-solution-treatment-acromegaly_en.pdf"},
    {"id":"15141","name":"EU/3/05/270: Public summary of positive opinion for orphan designation of autologous tumor-derived gp96 heat shock protein-peptide complex for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-08T00:00:00Z","last_updated_date":"2003-01-08T00:00:00Z","reference_number":"EMEA/COMP/216828/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305270-public-summary-positive-opinion-orphan-designation-autologous-tumor-derived-gp96-heat-shock-protein-peptide-complex-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"15173","name":"EU/3/14/1417: Public summary of opinion on orphan designation: A lentiviral vector pseudotyped by the Indiana serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/COMP/786963/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141417-public-summary-opinion-orphan-designation-lentiviral-vector-pseudotyped-indiana-serotype-vesicular-stomatitis-virus-g-protein-encoding-antigen-derived-tax-hbz-p12i-and-p_en.pdf"},
    {"id":"15211","name":"EU/3/16/1642: Public summary of opinion on orphan designation: Autologous dermal fibroblasts genetically modified ex vivo with a lentiviral vector containing the human COL7A1 gene for the treatment of epidermolysis bullo...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2016-05-30T02:00:00Z","reference_number":"EMA/COMP/252366/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161642-public-summary-opinion-orphan-designation-autologous-dermal-fibroblasts-genetically-modified-ex-vivo-lentiviral-vector-containing-human-col7a1-gene-treatment-epidermolysis-bullo_en.pdf"},
    {"id":"15216","name":"EU/3/16/1807: Public summary of opinion on orphan designation: Udenafil for the treatment of functional single ventricle congenital heart disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/754417/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161807-public-summary-opinion-orphan-designation-udenafil-treatment-functional-single-ventricle-congenital-heart-disease_en.pdf"},
    {"id":"15233","name":"EU/3/13/1180: Public summary of opinion on orphan designation: Apremilast for the treatment of Behà§et’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-13T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"EMA/COMP/433213/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131180-public-summary-opinion-orphan-designation-apremilast-treatment-behassets-disease_en.pdf"},
    {"id":"15271","name":"EU/3/16/1792: Public summary of positive opinion for orphan designation of valproic acid for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T12:31:00Z","last_updated_date":"2016-12-14T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161792-public-summary-positive-opinion-orphan-designation-valproic-acid-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"15277","name":"EU/3/15/1469: Public summary of positive opinion for orphan designation of human reovirus type 3 dearing strain for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/116982/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151469-public-summary-positive-opinion-orphan-designation-human-reovirus-type-3-dearing-strain-treatment-ovarian-cancer_en.pdf"},
    {"id":"15305","name":"EU/3/08/600: Public summary of positive opinion for orphan designation of\n\nhuman anti-intercellular adhesion molecule-1 monoclonal antibody for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2009-06-15T02:00:00Z","reference_number":"EMEA/COMP/543593/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308600-public-summary-positive-opinion-orphan-designation-human-anti-intercellular-adhesion-molecule-1-monoclonal-antibody-treatment-multiple-myeloma_en.pdf"},
    {"id":"15308","name":"EU/3/17/1905: Public summary of opinion on orphan designation: Purified pasteurised and freeze-dried cell-wall fragments from Mycobacterium tuberculosis strain RUTI for the treatment of tuberculosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/496597/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171905-public-summary-opinion-orphan-designation-purified-pasteurised-and-freeze-dried-cell-wall-fragments-mycobacterium-tuberculosis-strain-ruti-treatment-tuberculosis_en.pdf"},
    {"id":"15334","name":"EU/3/13/1200: Public summary of opinion on orphan designation: Sorafenib tosylate for the treatment of papillary thyroid cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/COMP/637634/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131200-public-summary-opinion-orphan-designation-sorafenib-tosylate-treatment-papillary-thyroid-cancer_en.pdf"},
    {"id":"15342","name":"EU/3/15/1471: Public summary of opinion on orphan designation: Trientine tetrahydrochloride for the treatment of Wilson's di","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T02:00:00Z","last_updated_date":"2017-10-03T02:00:00Z","reference_number":"EMA/COMP/132991/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151471-public-summary-opinion-orphan-designation-trientine-tetrahydrochloride-treatment-wilsons-di_en.pdf"},
    {"id":"15354","name":"EU/3/07/462: Public summary of positive opinion for orphan designation of recombinant human soluble Fc-gamma receptor II b for the treatment of idiopathic thrombocytopenic purpura","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2019-10-16T02:00:00Z","reference_number":"EMEA/COMP/143892/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307462-public-summary-positive-opinion-orphan-designation-recombinant-human-soluble-fc-gamma-receptor-ii-b-treatment-idiopathic-thrombocytopenic-purpura_en.pdf"},
    {"id":"15366","name":"EU/3/12/1014: Public summary of opinion on orphan designation: Talarozole for the treatment of keratinopathic ichthyosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2016-01-19T15:00:00Z","reference_number":"EMA/COMP/392964/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121014-public-summary-opinion-orphan-designation-talarozole-treatment-keratinopathic-ichthyosis_en.pdf"},
    {"id":"15382","name":"EU/3/17/1855: Public summary of opinion on orphan designation: Cannabidiol for the treatment of Lennox-Gastaut syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/143020/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171855-public-summary-opinion-orphan-designation-cannabidiol-treatment-lennox-gastaut-syndrome_en.pdf"},
    {"id":"15394","name":"EU/3/17/1842: Public summary of opinion on orphan designation: Recombinant human club cell 10 KDa protein for the treatment of bronchiolitis obliterans syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/72259/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171842-public-summary-opinion-orphan-designation-recombinant-human-club-cell-10-kda-protein-treatment-bronchiolitis-obliterans-syndrome_en.pdf"},
    {"id":"15431","name":"EU/3/17/1854: Public summary of opinion on orphan designation: Autologous adipose tissue-derived mesenchymal stem cells for the treatment of thromboangiitis obliterans (Buerger's disease)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/138358/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171854-public-summary-opinion-orphan-designation-autologous-adipose-tissue-derived-mesenchymal-stem-cells-treatment-thromboangiitis-obliterans-buergers-disease_en.pdf"},
    {"id":"15433","name":"EU/3/15/1541: Public summary of opinion on orphan designation: Ibrutinib for the treatment of marginal zone lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2021-11-23T02:00:00Z","reference_number":"EMA/COMP/508544/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151541-public-summary-opinion-orphan-designation-ibrutinib-treatment-marginal-zone-lymphoma_en.pdf"},
    {"id":"15525","name":"EU/3/06/408: Public summary of positive opinion for orphan designation of\n\nhuman cytomegalovirus immunoglobulin for the prevention of congenital cytomegalovirus infection following primary cytomegalovirus infection","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/178305/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306408-public-summary-positive-opinion-orphan-designation-human-cytomegalovirus-immunoglobulin-prevention-congenital-cytomegalovirus-infection-following-primary-cytomegalovirus-infection_en.pdf"},
    {"id":"15622","name":"EU/3/09/659: Public summary of positive opinion for orphan designation of tosedostat for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMEA/COMP/395735/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309659-public-summary-positive-opinion-orphan-designation-tosedostat-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"15634","name":"EU/3/17/1914 : Public summary of opinion on orphan designation : (S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid for the treatment of primary scl...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T15:38:00Z","last_updated_date":"2018-01-08T15:38:00Z","reference_number":"EMA/629138/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171914-public-summary-opinion-orphan-designation-s-3-s-2-2-26-difluorophenylamino-2-oxoacetamidopropanamido-4-oxo-5-2356-tetrafluorophenoxypentanoic-acid-treatment-primary-scl_en.pdf"},
    {"id":"15655","name":"EU/3/09/654: Public summary of positive opinion for orphan designation of hypothiocyanite / lactoferrin for the treatment","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-13T02:00:00Z","last_updated_date":"2010-10-13T02:00:00Z","reference_number":"EMEA/COMP/392984/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309654-public-summary-positive-opinion-orphan-designation-hypothiocyanite-lactoferrin-treatment_en.pdf"},
    {"id":"15662","name":"EU/3/13/1131: Public summary of opinion on orphan designation: Recombinant human CXCL8 mutant for the treatment of cystic fibrosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2013-06-25T19:00:00Z","reference_number":"EMA/COMP/272544/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131131-public-summary-opinion-orphan-designation-recombinant-human-cxcl8-mutant-treatment-cystic-fibrosis_en.pdf"},
    {"id":"15684","name":"EU/3/15/1455: Public summary of positive opinion for orphan designation of human plasma-derived alpha-1 proteinase inhibitor for the treatment of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/127023/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151455-public-summary-positive-opinion-orphan-designation-human-plasma-derived-alpha-1-proteinase-inhibitor-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"15688","name":"EU/3/08/562: Public summary of positive opinion for orphan designation of topotecan hydrochloride (liposomal) for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/450103/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308562-public-summary-positive-opinion-orphan-designation-topotecan-hydrochloride-liposomal-treatment-glioma_en.pdf"},
    {"id":"15738","name":"EU/3/05/337: Public summary of positive opinion for orphan designation of heparin sodium (inhalation use) for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-08-08T02:00:00Z","last_updated_date":"2014-01-22T01:00:00Z","reference_number":"EMEA/COMP/383545/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305337-public-summary-positive-opinion-orphan-designation-heparin-sodium-inhalation-use-treatment-cystic-fibrosis_en.pdf"},
    {"id":"15761","name":"EU/3/16/1610: Public summary of opinion on orphan designation: Arsenic trioxide for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-04-06T02:00:00Z","reference_number":"EMA/COMP/72409/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161610-public-summary-opinion-orphan-designation-arsenic-trioxide-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"15805","name":"EU/3/14/1298: Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine r...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T17:30:00Z","last_updated_date":"2014-09-01T17:30:00Z","reference_number":"EMA/COMP/360842/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141298-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-antithrombin-mrna-and-covalently-linked-ligand-containing-three-n_en.pdf"},
    {"id":"15855","name":"EU/3/06/398: Public summary of positive opinion for orphan designation of\n\nH-Val-Ile-Val-Lys-Leu-Ile-Pro-Ser-Thr-Ser-Ser-Ala-Val-Asp-Thr-Pro-Tyr-Leu-Asp-Ile-Thr-Tyr-His-Phe-Val-Ala-Gln-Arg-Leu-Pro-Leu-OH for the treatmen...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/229279/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306398-public-summary-positive-opinion-orphan-designation-h-val-ile-val-lys-leu-ile-pro-ser-thr-ser-ser-ala-val-asp-thr-pro-tyr-leu-asp-ile-thr-tyr-his-phe-val-ala-gln-arg-leu-pro-leu-oh-treatmen_en.pdf"},
    {"id":"15868","name":"EU/3/02/109: Public summary of positive opinion for orphan designation of oregovomab for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2007-05-30T02:00:00Z","reference_number":"EMEA/COMP/1517/02 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302109-public-summary-positive-opinion-orphan-designation-oregovomab-treatment-ovarian-cancer_en.pdf"},
    {"id":"15931","name":"EU/3/01/042: Public summary of positive opinion for orphan designation\n\nof human engineered monoclonal antibody specific for transforming growth factor β2 (CAT-152) for the prevention of scarring in glaucoma filtration ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2011-05-05T02:00:00Z","reference_number":"EMEA/COMP/220/04draft Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301042-public-summary-positive-opinion-orphan-designation-human-engineered-monoclonal-antibody-specific-transforming-growth-factor-i22-cat-152-prevention-scarring-glaucoma-filtration_en.pdf"},
    {"id":"15947","name":"EU/3/17/1937: Public summary of opinion on orphan designation: 4-Amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-15T01:00:00Z","last_updated_date":"2018-01-15T01:00:00Z","reference_number":"EMA/689758/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171937-public-summary-opinion-orphan-designation-4-amino-1-1s4r5s-2-fluoro-45-dihydroxy-3-hydroxymethylcyclopent-2-en-1-ylpyrimidin-2-one-treatment-pancreatic-cancer_en.pdf"},
    {"id":"15953","name":"EU/3/08/558: Public summary of positive opinion for orphan designation of sapacitabine for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/369006/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308558-public-summary-positive-opinion-orphan-designation-sapacitabine-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"15976","name":"EU/3/16/1620: Public summary of opinion on orphan designation: Allogeneic fetal human retinal progenitor cells expanded ex vivo for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/COMP/64103/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161620-public-summary-opinion-orphan-designation-allogeneic-fetal-human-retinal-progenitor-cells-expanded-ex-vivo-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"15995","name":"EU/3/09/633: Public summary of positive opinion for orphan designation of L-asparaginase encapsulated in erythrocytes for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-05T02:00:00Z","last_updated_date":"2009-06-05T02:00:00Z","reference_number":"EMEA/COMP/218226/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309633-public-summary-positive-opinion-orphan-designation-l-asparaginase-encapsulated-erythrocytes-treatment-pancreatic-cancer_en.pdf"},
    {"id":"15997","name":"EU/3/17/1839: Public summary of opinion on orphan designation: Iodine (131I) murine IgG1 monoclonal antibody against CD276 for the treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/69663/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171839-public-summary-opinion-orphan-designation-iodine-131i-murine-igg1-monoclonal-antibody-against-cd276-treatment-neuroblastoma_en.pdf"},
    {"id":"16023","name":"EU/3/07/458: Public summary of positive opinion for orphan designation of fampridine for the treatment of Guillain-Barrà© syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-17T00:00:00Z","last_updated_date":"2016-01-20T00:00:00Z","reference_number":"EMEA/COMP/246654/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307458-public-summary-positive-opinion-orphan-designation-fampridine-treatment-guillain-barrac-syndrome_en.pdf"},
    {"id":"16025","name":"EU/3/14/1409: Public summary of opinion on orphan designation: Pegylated recombinant arginine deiminase for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/COMP/793173/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141409-public-summary-opinion-orphan-designation-pegylated-recombinant-arginine-deiminase-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"16035","name":"EU/3/09/644: Public summary of positive opinion for orphan designation of murine monoclonal antibody to GD2 for the treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2011-03-28T02:00:00Z","reference_number":"EMEA/COMP/292651/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309644-public-summary-positive-opinion-orphan-designation-murine-monoclonal-antibody-gd2-treatment-neuroblastoma_en.pdf"},
    {"id":"16039","name":"EU/3/16/1657: Public summary of opinion on orphan designation: (R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride for the treatment of biliary tract ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"EMA/COMP/309638/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161657-public-summary-opinion-orphan-designation-r-6-2-fluorophenyl-n-3-2-2-methoxyethylaminoethylphenyl-56-dihydrobenzohquinazolin-2-amine-dihydrochloride-treatment-biliary-tract_en.pdf"},
    {"id":"16057","name":"EU/3/15/1488: Public summary of opinion on orphan designation: {2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl]-(3H-benzo[f]azepin-4-yl)}-N,N-dipropylcarboxamide for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2017-08-10T02:00:00Z","reference_number":"EMA/COMP/269491/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151488-public-summary-opinion-orphan-designation-2-amino-8-4-pyrrolidinylcarbonylphenyl-3h-benzofazepin-4-yl-nn-dipropylcarboxamide-treatment-ovarian-cancer_en.pdf"},
    {"id":"16071","name":"EU/3/17/1862: Public summary of opinion on orphan designation: Autologous adult bone marrow-derived non-expanded CD133+haematopoietic stem cells for the treatment of Asherman's syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/206895/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171862-public-summary-opinion-orphan-designation-autologous-adult-bone-marrow-derived-non-expanded-cd133haematopoietic-stem-cells-treatment-ashermans-syndrome_en.pdf"},
    {"id":"16083","name":"EU/3/13/1145: Public summary of opinion on orphan designation: Genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T14:00:00Z","last_updated_date":"2013-07-11T14:00:00Z","reference_number":"EMA/COMP/303494/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131145-public-summary-opinion-orphan-designation-genetically-modified-serotype-53-adenovirus-coding-granulocyte-macrophage-colony-stimulating-factor-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"16108","name":"EU/3/03/137: Public summary of positive opinion for orphan designation of tositumomab for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T00:00:00Z","last_updated_date":"2015-05-09T01:00:00Z","reference_number":"EMEA/COMP/4/2003 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303137-public-summary-positive-opinion-orphan-designation-tositumomab-treatment-follicular-lymphoma_en.pdf"},
    {"id":"16126","name":"EU/3/15/1454: Public summary of positive opinion for orphan designation of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one for the treatment of Netherton syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/116731/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151454-public-summary-positive-opinion-orphan-designation-6-ethoxy-7-methoxy-2-2-methylsulfanylphenyl-31-benzoxazin-4-one-treatment-netherton-syndrome_en.pdf"},
    {"id":"16127","name":"EU/3/13/1117: Public summary of opinion on orphan designation:\n\nRamiprilat for the treatment of Stargardt’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2013-04-05T02:00:00Z","reference_number":"EMA/COMP/92888/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131117-public-summary-opinion-orphan-designation-ramiprilat-treatment-stargardts-disease_en.pdf"},
    {"id":"16128","name":"EU/3/06/385: Public summary of positive opinion for orphan designation\n\nof 2-(4-(diethylamino) phenyl)-6-methyl-2H-benzo[d][1,2,3] triazol-5-amine\n\nfor the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/176490/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306385-public-summary-positive-opinion-orphan-designation-2-4-diethylamino-phenyl-6-methyl-2h-benzod123-triazol-5-amine-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"16141","name":"EU/3/09/706: Public summary of opinion on orphan designation of lithium citrate tetrahydrate (in reverse-micelle formulation) for the treatment of Huntington’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/COMP/770586/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309706-public-summary-opinion-orphan-designation-lithium-citrate-tetrahydrate-reverse-micelle-formulation-treatment-huntingtons-disease_en.pdf"},
    {"id":"16179","name":"EU/3/13/1128: Public summary of opinion on orphan designation: N-[2,6-bis(1-methylethyl)phenyl]-N’-[[1-[4-(dimethylamino) phenyl]cyclopentyl]methyl]urea, hydrochloride salt for the treatment of adrenocortical carcinoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2013-06-25T19:00:00Z","reference_number":"EMA/COMP/277098/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131128-public-summary-opinion-orphan-designation-n-26-bis1-methylethylphenyl-n-1-4-dimethylamino-phenylcyclopentylmethylurea-hydrochloride-salt-treatment-adrenocortical-carcinoma_en.pdf"},
    {"id":"16183","name":"EU/3/15/1570: Public summary of opinion on orphan designation: Azacitidine for the treatment of nasopharyngeal carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T15:31:00Z","last_updated_date":"2017-02-08T15:31:00Z","reference_number":"EMA/COMP/696429/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151570-public-summary-opinion-orphan-designation-azacitidine-treatment-nasopharyngeal-carcinoma_en.pdf"},
    {"id":"16197","name":"EU/3/14/1382: Public summary of positive opinion for orphan designation:  Allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2022-09-16T18:00:00Z","reference_number":"EMA/COMP/724271/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141382-public-summary-positive-opinion-orphan-designation-allogeneic-cd34-cells-expanded-ex-vivo-aryl-hydrocarbon-receptor-antagonist-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"16198","name":"EU/3/10/777: Public summary of opinion on orphan designation: Cyclic pyranopterin monophosphate for the treatment of molybdenum-cofactor deficiency type A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2015-03-25T12:15:00Z","reference_number":"EMA/COMP/403557/2010 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310777-public-summary-opinion-orphan-designation-cyclic-pyranopterin-monophosphate-treatment-molybdenum-cofactor-deficiency-type_en.pdf"},
    {"id":"16235","name":"EU/3/09/713: Public summary of opinion on orphan designation of Veltuzumab for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2020-03-06T01:00:00Z","reference_number":"EMA/742740/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309713-public-summary-opinion-orphan-designation-veltuzumab-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"16246","name":"EU/3/14/1338: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene for the treatment of Crigler-Najjar syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/558518/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141338-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-ugt1a1-gene-treatment-crigler-najjar-syndrome_en.pdf"},
    {"id":"16249","name":"EU/3/16/1648: Public summary of opinion on orphan designation: Human/murine chimeric monoclonal antibody against endoglin for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2016-05-30T02:00:00Z","reference_number":"EMA/COMP/247747/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161648-public-summary-opinion-orphan-designation-humanmurine-chimeric-monoclonal-antibody-against-endoglin-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"16263","name":"EU/3/01/044: Public summary of positive opinion for orphan designation of human alpha1-proteinase inhibitor (respiratory use) for the treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-24T00:00:00Z","last_updated_date":"2011-05-06T01:00:00Z","reference_number":"EMEA/COMP/221/04draft","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301044-public-summary-positive-opinion-orphan-designation-human-alpha1-proteinase-inhibitor-respiratory-use-treatment-emphysema-secondary-congenital-alpha-1-antitrypsin-deficiency_en.pdf"},
    {"id":"16281","name":"EU/3/12/973: Public summary of opinion on orphan designation: Recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type VII (Sly syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T11:45:00Z","last_updated_date":"2015-05-27T11:45:00Z","reference_number":"EMA/COMP/73113/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312973-public-summary-opinion-orphan-designation-recombinant-human-beta-glucuronidase-treatment-mucopolysaccharidosis-type-vii-sly-syndrome_en.pdf"},
    {"id":"16283","name":"EU/3/17/1964: Public summary of opinion on orphan designation: Itacitinib for treatment of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-13T01:00:00Z","last_updated_date":"2018-03-13T01:00:00Z","reference_number":"EMA/4237/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171964-public-summary-opinion-orphan-designation-itacitinib-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"16288","name":"EU/3/12/949: Public summary of opinion on orphan designation: Sodium phenylbutyrate for the treatment of citrullinaemia type 1","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T01:00:00Z","last_updated_date":"2017-08-09T02:00:00Z","reference_number":"EMA/COMP/43229/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312949-public-summary-opinion-orphan-designation-sodium-phenylbutyrate-treatment-citrullinaemia-type-1_en.pdf"},
    {"id":"16304","name":"EU/3/12/966: Public summary of opinion on orphan designation:\n\n(1-Methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T11:45:00Z","last_updated_date":"2016-10-21T12:00:00Z","reference_number":"EMA/COMP/67848/2012 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312966-public-summary-opinion-orphan-designation-1-methyl-2-nitro-1h-imidazole-5-ylmethyl-nn-bis2-bromoethyl-diamidophosphate-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"16306","name":"EU/3/06/377: Public summary of positive opinion for orphan designation of mecasermin rinfabate for the treatment of patients with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2009-04-02T02:00:00Z","reference_number":"EMEA/COMP/309736/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306377-public-summary-positive-opinion-orphan-designation-mecasermin-rinfabate-treatment-patients-growth-hormone-gh-gene-deletion-who-have-developed-neutralizing-antibodies-gh_en.pdf"}    {"id":"16317","name":"EU/3/13/1167: Public summary of opinion on orphan designation: Heterologous human adult liver-derived progenitor cells for the treatment of ornithine-translocase deficiency (hyperornithinaemia-hyperammonaemia-homocitrull...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-22T17:30:00Z","last_updated_date":"2013-08-22T17:30:00Z","reference_number":"EMA/COMP/413224/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131167-public-summary-opinion-orphan-designation-heterologous-human-adult-liver-derived-progenitor-cells-treatment-ornithine-translocase-deficiency-hyperornithinaemia-hyperammonaemia-homocitrull_en.pdf"},
    {"id":"16324","name":"EU/3/05/327: Public summary of positive opinion for orphan designation of oligonucleotide phosphorothioate (TAAACGTTATAACGTTATGACGTCAT), sodium salt for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T00:00:00Z","last_updated_date":"2006-01-04T00:00:00Z","reference_number":"EMEA/COMP/317431/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305327-public-summary-positive-opinion-orphan-designation-oligonucleotide-phosphorothioate-taaacgttataacgttatgacgtcat-sodium-salt-treatment-glioma_en.pdf"},
    {"id":"16336","name":"EU/3/13/1133: Public summary of opinion on orphan designation: Maribavir for the treatment of cytomegalovirus disease in patients with impaired cell mediated immunity","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2013-06-25T19:00:00Z","reference_number":"EMA/COMP/258956/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131133-public-summary-opinion-orphan-designation-maribavir-treatment-cytomegalovirus-disease-patients-impaired-cell-mediated-immunity_en.pdf"},
    {"id":"16349","name":"EU/3/10/759: Public summary of opinion on orphan designation: Pomalidomide for the treatment of post-essential thrombocythaemia myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-06T02:00:00Z","last_updated_date":"2017-02-10T12:39:00Z","reference_number":"EMA/COMP/249478/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310759-public-summary-opinion-orphan-designation-pomalidomide-treatment-post-essential-thrombocythaemia-myelofibrosis_en.pdf"},
    {"id":"16357","name":"EU/3/07/443: Public summary of positive opinion for orphan designation of elafin for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2008-07-02T02:00:00Z","reference_number":"EMEA/COMP/570727/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307443-public-summary-positive-opinion-orphan-designation-elafin-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"16370","name":"EU/3/11/883: Public summary of opinion on orphan designation: Low molecular weight dextran sulfate as treatment for mobilisation of progenitor cells prior to stem cell transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2011-11-18T16:00:00Z","reference_number":"EMA/COMP/406657/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311883-public-summary-opinion-orphan-designation-low-molecular-weight-dextran-sulfate-treatment-mobilisation-progenitor-cells-prior-stem-cell-transplantation_en.pdf"},
    {"id":"16381","name":"EU/3/12/1087: Public summary of opinion on orphan designation: Recombinant modified human growth hormone for the treatment of growth-hormone deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2013-03-01T01:00:00Z","reference_number":"EMA/COMP/810031/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121087-public-summary-opinion-orphan-designation-recombinant-modified-human-growth-hormone-treatment-growth-hormone-deficiency_en.pdf"},
    {"id":"16406","name":"EU/3/01/021: Public summary of positive opinion for imatinib mesilate for treatment of chronic myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2015-02-10T01:00:00Z","reference_number":"EMEA/COMP/10370/2003 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301021-public-summary-positive-opinion-imatinib-mesilate-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"16439","name":"EU/3/15/1580: Public summary of opinion on orphan designation: N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4 methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide for treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/COMP/698281/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151580-public-summary-opinion-orphan-designation-n-5-35-difluorobenzyl-1h-indazol-3-yl-4-4-methylpiperazin-1-yl-2-tetrahydro-2h-pyran-4-ylaminobenzamide-treatment-neuroblastoma_en.pdf"},
    {"id":"16449","name":"EU/3/11/863: Public summary of opinion on orphan designation: Recombinant fusion protein linking human coagulation factor VIIa with human albumin for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-31T02:00:00Z","last_updated_date":"2011-05-31T02:00:00Z","reference_number":"EMA/COMP/158306/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311863-public-summary-opinion-orphan-designation-recombinant-fusion-protein-linking-human-coagulation-factor-viia-human-albumin-treatment-haemophilia-b_en.pdf"},
    {"id":"16503","name":"EU/3/16/1689: Public summary of opinion on orphan designation: Teriparatide for the treatment of hypoparathyroidism","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/383047/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161689-public-summary-opinion-orphan-designation-teriparatide-treatment-hypoparathyroidism_en.pdf"},
    {"id":"16508","name":"EU/3/16/1779: Public summary of positive opinion for orphan designation of human monoclonal antibody against activin A for the treatment of fibrodysplasia ossificans progressiva","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T16:22:00Z","last_updated_date":"2016-12-14T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161779-public-summary-positive-opinion-orphan-designation-human-monoclonal-antibody-against-activin-treatment-fibrodysplasia-ossificans-progressiva_en.pdf"},
    {"id":"16523","name":"EU/3/10/750: Public summary of positive opinion for Rifapentine for the treatment of tuberculosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2013-04-09T02:00:00Z","reference_number":"EMA/COMP/165383/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310750-public-summary-positive-opinion-rifapentine-treatment-tuberculosis_en.pdf"},
    {"id":"16558","name":"EU/3/09/691: Public summary of positive opinion for orphan designation of human anthrax immunoglobulin for the treatment of inhalation anthrax disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2016-08-12T01:09:21Z","reference_number":"EMEA/COMP/578967/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309691-public-summary-positive-opinion-orphan-designation-human-anthrax-immunoglobulin-treatment-inhalation-anthrax-disease_en.pdf"},
    {"id":"16573","name":"EU/3/14/1369: Public summary of opinion on orphan designation: Siponimod for the treatment of dermatomyositis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2018-03-12T01:00:00Z","reference_number":"EMA/COMP/660609/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141369-public-summary-opinion-orphan-designation-siponimod-treatment-dermatomyositis_en.pdf"},
    {"id":"16580","name":"EU/3/11/866: Public summary of opinion on orphan designation: Allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2 for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-30T02:00:00Z","last_updated_date":"2017-02-07T15:28:00Z","reference_number":"EMA/COMP/152131/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311866-public-summary-opinion-orphan-designation-allogeneic-bone-marrow-stem-cells-treated-ex-vivo-1616-dimethyl-prostaglandin-e2-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"16586","name":"EU/3/04/209: Public summary of positive opinion for orphan designation of ciclosporin (inhalation use) for the prevention of graft rejection after lung transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-13T00:00:00Z","last_updated_date":"2011-06-28T01:00:00Z","reference_number":"EMEA/COMP/298/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304209-public-summary-positive-opinion-orphan-designation-ciclosporin-inhalation-use-prevention-graft-rejection-after-lung-transplantation_en.pdf"},
    {"id":"16589","name":"EU/3/16/1608: Public summary of opinion on orphan designation: S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-ar...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-04-06T02:00:00Z","reference_number":"EMA/COMP/75894/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161608-public-summary-opinion-orphan-designation-s3s13-cyclod-tyrolsyl-l-isoleucyl-l-cysteinyl-l-valyl-1-methyl-l-tryptophyl-l-glutaminyl-l-aspartyl-l-tryptophyl-n-methyl-l-glycyl-l-alanyl-l_en.pdf"},
    {"id":"16593","name":"EU/3/18/2000: Public summary of opinion on orphan designation: Recombinant human acid alpha-glucosidase for the treatment of glycogen storage disease type II (Pompe's disease)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-15T02:00:00Z","last_updated_date":"2023-05-30T02:00:00Z","reference_number":"EMA/139657/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182000-public-summary-opinion-orphan-designation-recombinant-human-acid-alpha-glucosidase-treatment-glycogen-storage-disease-type-ii-pompes-disease_en.pdf"},
    {"id":"16619","name":"EU/3/14/1255: Public summary of opinion on orphan designation: Volasertib for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-06T02:00:00Z","last_updated_date":"2014-05-06T02:00:00Z","reference_number":"EMA/COMP/93562/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141255-public-summary-opinion-orphan-designation-volasertib-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"16627","name":"EU/3/18/2033: Public summary of opinion on orphan designation: Codon-optimised human ornithine transcarbamylase mRNA complexed with lipid-based nanoparticles for the treatment of ornithine transcarbamylase deficiency","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-21T18:32:00Z","last_updated_date":"2018-08-21T18:32:00Z","reference_number":"EMA/395377/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182033-public-summary-opinion-orphan-designation-codon-optimised-human-ornithine-transcarbamylase-mrna-complexed-lipid-based-nanoparticles-treatment-ornithine-transcarbamylase-deficiency_en.pdf"},
    {"id":"16645","name":"EU/3/18/1993: Public summary of opinion on orphan designation: Gemfibrozil for the treatment of neuronal ceroid lipofuscinosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-14T02:00:00Z","last_updated_date":"2018-05-14T02:00:00Z","reference_number":"EMA/120664/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181993-public-summary-opinion-orphan-designation-gemfibrozil-treatment-neuronal-ceroid-lipofuscinosis_en.pdf"},
    {"id":"16666","name":"EU/3/14/1238: Public summary of opinion on orphan designation: Eculizumab for the prevention of delayed graft function after solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-01T14:00:00Z","last_updated_date":"2017-05-17T14:00:00Z","reference_number":"EMA/COMP/36006/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141238-public-summary-opinion-orphan-designation-eculizumab-prevention-delayed-graft-function-after-solid-organ-transplantation_en.pdf"},
    {"id":"16670","name":"EU/3/02/106: Public summary of positive opinion for orphan designation of antisense NF-kBp65 oligonucleotide for the treatment of active ulcerative colitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-23T00:00:00Z","last_updated_date":"2015-03-23T13:30:00Z","reference_number":"EMA/COMP/1500/2002 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302106-public-summary-positive-opinion-orphan-designation-antisense-nf-kbp65-oligonucleotide-treatment-active-ulcerative-colitis_en.pdf"},
    {"id":"16731","name":"EU/3/13/1126: Public summary of opinion on orphan designation: Mexiletine hydrochloride for the treatment of non-dystrophic myotonia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2013-06-25T19:00:00Z","reference_number":"EMA/COMP/277084/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131126-public-summary-opinion-orphan-designation-mexiletine-hydrochloride-treatment-non-dystrophic-myotonia_en.pdf"},
    {"id":"16732","name":"EU/3/16/1621: Public summary of opinion on orphan designation: Delta-9-tetrahydrocannabinol and cannabidiol from extracts of the Cannabis sativa L. plant for the treatment glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/COMP/72100/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161621-public-summary-opinion-orphan-designation-delta-9-tetrahydrocannabinol-and-cannabidiol-extracts-cannabis-sativa-l-plant-treatment-glioma_en.pdf"},
    {"id":"16765","name":"EU/3/07/516: Public summary of positive opinion for orphan designation of recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3 for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2013-03-13T01:00:00Z","reference_number":"EMEA/COMP/130384/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307516-public-summary-positive-opinion-orphan-designation-recombinant-human-histone-h13-and-recombinant-human-n-bis-met-histone-h13-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"16770","name":"EU/3/09/707: Public summary of opinion on orphan designation of macitentan for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMA/COMP/750700/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309707-public-summary-opinion-orphan-designation-macitentan-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"16837","name":"EU/3/12/1040: Public summary of opinion on orphan designation: (2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)ace...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-26T16:30:00Z","last_updated_date":"2012-09-26T16:30:00Z","reference_number":"EMA/COMP/526568/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121040-public-summary-opinion-orphan-designation-2s-2-2r-2-33-dibutyl-7-methylthio-11-dioxido-5-phenyl-2345-tetrahydro-125-benzothiadiazepin-8-yloxyacetylamino-2-4-hydroxyphenylace_en.pdf"},
    {"id":"16843","name":"EU/3/12/1058: Public summary of opinion on orphan designation: IL-12-secreting dendritic cells, loaded with autologous tumour lysate for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2012-12-12T01:00:00Z","reference_number":"EMA/COMP/657711/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121058-public-summary-opinion-orphan-designation-il-12-secreting-dendritic-cells-loaded-autologous-tumour-lysate-treatment-glioma_en.pdf"},
    {"id":"16870","name":"EU/3/12/993: Public summary of opinion on orphan designation: N-hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide for the treatment of neurofibromatosis type 2","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T16:55:00Z","last_updated_date":"2012-06-18T16:55:00Z","reference_number":"EMA/COMP/216967/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312993-public-summary-opinion-orphan-designation-n-hydroxy-4-3-methyl-2-s-phenyl-butyrylamino-benzamide-treatment-neurofibromatosis-type-2_en.pdf"},
    {"id":"16879","name":"EU/3/13/1143: Public summary of opinion on orphan designation: Immortalised human C3A hepatoblastoma cells for the treatment of acute liver failure","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T14:00:00Z","last_updated_date":"2013-07-11T14:00:00Z","reference_number":"EMA/COMP/304298/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131143-public-summary-opinion-orphan-designation-immortalised-human-c3a-hepatoblastoma-cells-treatment-acute-liver-failure_en.pdf"},
    {"id":"16880","name":"EU/3/15/1563: Public summary of opinion on orphan designation: Recombinant human interleukin-3 truncated diphtheria toxin fusion protein for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-18T11:00:00Z","last_updated_date":"2015-11-18T11:00:00Z","reference_number":"EMA/COMP/603715/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151563-public-summary-opinion-orphan-designation-recombinant-human-interleukin-3-truncated-diphtheria-toxin-fusion-protein-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"16881","name":"EU/3/12/1098: Public summary of opinion on orphan designation: Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor for the treatment of ret...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2013-03-01T01:00:00Z","reference_number":"EMA/COMP/808529/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121098-public-summary-opinion-orphan-designation-encapsulated-human-retinal-pigment-epithelial-cell-line-transfected-plasmid-vector-expressing-human-ciliary-neurotrophic-factor-treatment-ret_en.pdf"},
    {"id":"16938","name":"EU/3/13/1172: Public summary of opinion on orphan designation: Idelalisib for the treatment of nodal marginal-zone lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-12T02:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/COMP/434307/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131172-public-summary-opinion-orphan-designation-idelalisib-treatment-nodal-marginal-zone-lymphoma_en.pdf"},
    {"id":"16992","name":"EU/3/16/1757: Public summary of positive opinion for orphan designation of n-[(2S)-5-{[(1R, 2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide, bis-to...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/620940/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161757-public-summary-positive-opinion-orphan-designation-n-2s-5-1r-2s-2-4-fluorophenylcyclopropylamino-1-4-methylpiperazin-1-yl-1-oxopentan-2-yl-4-1h-123-triazol-1-ylbenzamide-bis_en.pdf"},
    {"id":"16997","name":"EU/3/03/180: Public summary of positive opinion for orphan designation\n\nof 4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid\n\nfor the treatment of chronic iron overload requiring chelation therapy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/1593/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303180-public-summary-positive-opinion-orphan-designation-45-dihydro-2-24-dihydroxyphenyl-4-methylthiazole-4s-carboxylic-acid-treatment-chronic-iron-overload-requiring-chelation-therapy_en.pdf"},
    {"id":"16999","name":"EU/3/10/826: Public summary of opinion on orphan designation: Para-aminosalicylic acid for the treatment of tuberculosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2014-10-16T18:00:00Z","reference_number":"EMA/COMP/671320/2010 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310826-public-summary-opinion-orphan-designation-para-aminosalicylic-acid-treatment-tuberculosis_en.pdf"},
    {"id":"17018","name":"EU/3/14/1257: Public summary of opinion on orphan designation: Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene for the treatment of recombination-activating gene 1 deficient seve...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-07T02:00:00Z","last_updated_date":"2014-05-07T02:00:00Z","reference_number":"EMA/COMP/89818/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141257-public-summary-opinion-orphan-designation-autologous-cd34-cells-transduced-lentiviral-vector-containing-human-rag1-gene-treatment-recombination-activating-gene-1-deficient-seve_en.pdf"},
    {"id":"17020","name":"EU/3/01/050: Public summary of positive opinion for orphan designation of zinc acetate dihydrate for the treatment of Wilson's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T01:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMA/COMP/1293/2003 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301050-public-summary-positive-opinion-orphan-designation-zinc-acetate-dihydrate-treatment-wilsons-disease_en.pdf"},
    {"id":"17023","name":"EU/3/10/810: Public summary of opinion on orphan designation N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate for the treatment of...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2013-04-09T02:00:00Z","reference_number":"EMA/COMP/601661/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310810-public-summary-opinion-orphan-designation-n-tert-butyl-3-5-methyl-2-4-2-pyrrolidin-1-ylethoxyphenylaminopyrimidin-4-ylamino-benzenesulfonamide-dihydrochloride-monohydrate-treatment_en.pdf"},
    {"id":"17033","name":"EU/3/17/1955: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene for the treatment of mucopolysaccharidosis t...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-12T01:00:00Z","last_updated_date":"2023-09-12T01:00:00Z","reference_number":"EMA/839607/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-17-1955-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-2-6-encoding-zinc-finger-nucleases-and-human-alpha-l-iduronidase-gene-treatment-mucopolysaccharidosis-t_en.pdf"},
    {"id":"17037","name":"EU/3/05/328: Public summary of positive opinion for orphan designation\n\nof (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone for ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMEA/COMP/317921/2005 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305328-public-summary-positive-opinion-orphan-designation-e-1s4s10s21r-7-z-ethylidene-421-diisopropyl-2-oxa-1213-dithia-582023-tetraazabicyclo876tricos-16-ene-3691922-pentone_en.pdf"},
    {"id":"17054","name":"EU/3/14/1243: Public summary of opinion on orphan designation: Recombinant human acid ceramidase for the treatment of Farber disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-02T17:00:00Z","last_updated_date":"2015-05-13T17:00:00Z","reference_number":"EMA/COMP/32699/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141243-public-summary-opinion-orphan-designation-recombinant-human-acid-ceramidase-treatment-farber-disease_en.pdf"},
    {"id":"17103","name":"EU/3/15/1585: Public summary of opinion on orphan designation: Sirolimus for the treatment of beta-thalassaemia intermedia and major","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/COMP/789714/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151585-public-summary-opinion-orphan-designation-sirolimus-treatment-beta-thalassaemia-intermedia-and-major_en.pdf"},
    {"id":"17117","name":"EU/3/07/493: Public summary of  positive opinion for orphan designation of isofagomine tartrate for the treatment of Gaucher disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-08-12T02:00:00Z","last_updated_date":"2010-03-15T01:00:00Z","reference_number":"EMEA/COMP/488315/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307493-public-summary-positive-opinion-orphan-designation-isofagomine-tartrate-treatment-gaucher-disease_en.pdf"},
    {"id":"17162","name":"EU/3/12/1035: Public summary of opinion on orphan designation: Recombinant human monoclonal antibody against activin receptor type IIB for the treatment of inclusion-body myositis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-27T16:00:00Z","last_updated_date":"2018-10-24T16:30:00Z","reference_number":"EMA/COMP/525531/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121035-public-summary-opinion-orphan-designation-recombinant-human-monoclonal-antibody-against-activin-receptor-type-iib-treatment-inclusion-body-myositis_en.pdf"},
    {"id":"17179","name":"EU/3/11/914: Public summary of opinion on orphan designation: Smilagenin for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2013-11-25T01:00:00Z","reference_number":"EMA/COMP/584436/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311914-public-summary-opinion-orphan-designation-smilagenin-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"17187","name":"EU/3/10/734: Public summary of opinion on orphan designation: Glyceryl tri-(4-phenylbutyrate) for the treatment of ornithine carbamoyltransferase  deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/COMP/123283/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310734-public-summary-opinion-orphan-designation-glyceryl-tri-4-phenylbutyrate-treatment-ornithine-carbamoyltransferase-deficiency_en.pdf"},
    {"id":"17204","name":"EU/3/12/1060: Public summary of opinion on orphan designation: Ixazomib for the treatment of systemic light chain amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMA/COMP/682970/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121060-public-summary-opinion-orphan-designation-ixazomib-treatment-systemic-light-chain-amyloidosis_en.pdf"},
    {"id":"17213","name":"EU/3/18/2015: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing a functional copy of the codon-optimised F8 cDNA encoding the B-domain deleted human coagulation factor V...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T17:07:00Z","last_updated_date":"2018-07-23T17:07:00Z","reference_number":"EMA/270813/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182015-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-functional-copy-codon-optimised-f8-cdna-encoding-b-domain-deleted-human-coagulation-factor-v_en.pdf"},
    {"id":"17219","name":"EU/3/09/697: Public summary of positive opinion for orphan designation of\n\nN-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide for the treatment of naevoid basa...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-12-08T00:09:21Z","last_updated_date":"2015-02-10T13:00:00Z","reference_number":"EMA/COMP/658320/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309697-public-summary-positive-opinion-orphan-designation-n-6-cis-26-dimethylmorpholin-4-ylpyridine-3-yl-2-methyl-4-trifluoromethoxy11-biphenyl-3-carboxamide-treatment-naevoid-basa_en.pdf"},
    {"id":"17255","name":"EU/3/18/2028: Public summary of opinion on orphan designation: (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochlo...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-21T12:33:00Z","last_updated_date":"2021-06-01T13:56:00Z","reference_number":"EMA/381666/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182028-public-summary-opinion-orphan-designation-r-1-3-aminomethyl-phenyl-n-5-3-cyanophenylcyclopropylmethylaminomethyl-2-fluorophenyl-3-trifluoromethyl-1h-pyrazole-5-carboxamide-dihydrochlo_en.pdf"},
    {"id":"17284","name":"EU/3/17/1841: Public summary of opinion on orphan designation: Propranolol hydrochloride for the treatment of von Hippel-Lindau disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/80340/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171841-public-summary-opinion-orphan-designation-propranolol-hydrochloride-treatment-von-hippel-lindau-disease_en.pdf"},
    {"id":"17335","name":"EU/3/09/670: Public summary of positive opinion for orphan designation of pasireotide for the treatment of acromegaly","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMA/COMP/454500/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309670-public-summary-positive-opinion-orphan-designation-pasireotide-treatment-acromegaly_en.pdf"},
    {"id":"17340","name":"EU/3/10/769: Public summary of opinion on orphan designation: 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene for the treat...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMA/COMP/360348/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310769-public-summary-opinion-orphan-designation-11-2-pyrrolidin-1-yl-ethoxy-1419-dioxa-5726-triaza-tetracyclo19311261812-heptacosa-125226358101227162123-decaene-treat_en.pdf"},
    {"id":"17341","name":"EU/3/05/332: Public summary of positive opinion for orphan designation\n\nof 1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine for the treatment acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-02-09T01:00:00Z","last_updated_date":"2006-02-09T01:00:00Z","reference_number":"EMEA/COMP/355971/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305332-public-summary-positive-opinion-orphan-designation-12-bismethylsulphonyl-1-2-chloroethyl-2-methylaminocarbonylhydrazine-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"17344","name":"EU/3/16/1774: Public summary of positive opinion for orphan designation of allogeneic peripheral blood mononuclear cells incubated ex-vivo with 16, 16-dimethyl prostaglandin E2 and dexamethasone for treatment in haematop...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T15:43:00Z","last_updated_date":"2022-08-10T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161774-public-summary-positive-opinion-orphan-designation-allogeneic-peripheral-blood-mononuclear-cells-incubated-ex-vivo-16-16-dimethyl-prostaglandin-e2-and-dexamethasone-treatment-haematop_en.pdf"},
    {"id":"17362","name":"EU/3/16/1713 : Public summary of opinion on orphan designation: 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide for the treatment of scedosporiosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161713-public-summary-opinion-orphan-designation-2-15-dimethyl-3-phenyl-1h-pyrrol-2-yl-n-4-4-5-fluoro-pyrimidin-2-ylpiperazin-1-yl-phenyl-2-oxo-acetamide-treatment-scedosporiosis_en.pdf"},
    {"id":"17366","name":"EU/3/14/1408: Public summary of opinion on orphan designation: 5,5’-(4-(trifluromethyl)benzylazanediyl)bis(methylene)diquinolin-8-ol for the\n\ntreatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/COMP/722699/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141408-public-summary-opinion-orphan-designation-55-4-trifluromethylbenzylazanediylbismethylenediquinolin-8-ol-treatment-glioma_en.pdf"},
    {"id":"17374","name":"EU/3/15/1576: Public summary of opinion on orphan designation: (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide for the treatment ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/COMP/699954/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151576-public-summary-opinion-orphan-designation-5s8s10ar-n-benzhydryl-5-s-2-methylaminopropanamido-3-3-methylbutanoyl-6-oxodecahydropyrrolo12-a15diazocine-8-carboxamide-treatment_en.pdf"},
    {"id":"17385","name":"EU/3/17/1873: Public summary of opinion on orphan designation: Poly(oxy-1,2-ethanediyl),.alpha.-hydro-.omega.-hydroxy-,15,15'-diester with N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-.al...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-06-29T02:00:00Z","last_updated_date":"2017-06-29T02:00:00Z","reference_number":"EMA/272964/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171873-public-summary-opinion-orphan-designation-polyoxy-12-ethanediylalpha-hydro-omega-hydroxy-1515-diester-n-acetyl-l-isoleucyl-l-cysteinyl-l-valyl-1-methyl-l-tryptophyl-l-glutaminyl-l-al_en.pdf"},
    {"id":"17461","name":"EU/3/04/214: Public summary of positive opinion for orphan designation of midostaurin for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-11T02:00:00Z","last_updated_date":"2015-02-10T01:00:00Z","reference_number":"EMEA/COMP/374/2004 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304214-public-summary-positive-opinion-orphan-designation-midostaurin-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"17479","name":"EU/3/08/581: Public summary of positive opinion for orphan designation of ofatumumab for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMEA/COMP/480244/2008 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308581-public-summary-positive-opinion-orphan-designation-ofatumumab-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"17493","name":"EU/3/17/1881: Public summary of opinion on orphan designation: Decitabine and tetrahydrouridine for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T02:00:00Z","last_updated_date":"2017-07-17T02:00:00Z","reference_number":"EMA/324973/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171881-public-summary-opinion-orphan-designation-decitabine-and-tetrahydrouridine-treatment-sickle-cell-disease_en.pdf"},
    {"id":"17511","name":"EU/3/15/1583: Public summary of opinion on orphan designation: 2-Amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy)phenyl]thio]phenyl]ethyl]-1,3-propanediol hydrochloride for the prevention of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2018-01-22T01:00:00Z","reference_number":"EMA/COMP/791411/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151583-public-summary-opinion-orphan-designation-2-amino-2-2-2-chloro-4-3-phenylmethoxyphenylthiophenylethyl-13-propanediol-hydrochloride-prevention-graft-versus-host-disease_en.pdf"},
    {"id":"17542","name":"EU/3/16/1738: Public summary of positive opinion for orphan designation of 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide for the treatment of invasive a...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/628404/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161738-public-summary-positive-opinion-orphan-designation-2-15-dimethyl-3-phenyl-1h-pyrrol-2-yl-n-4-4-5-fluoro-pyrimidin-2-ylpiperazin-1-yl-phenyl-2-oxo-acetamide-treatment-invasive_en.pdf"},
    {"id":"17603","name":"EU/3/08/586): Public summary of positive opinion for orphan designation of RNA, [P-deoxy-P-(dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco) (2'a→5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/COMP/567030/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308586-public-summary-positive-opinion-orphan-designation-rna-p-deoxy-p-dimethylamino23-dideoxy-23-imino-23-seco-2aa5c-m5u-c-c-c-m5u-c-g-g-g-m5u-g-g-c-m5u-m5u-m5u_en.pdf"},
    {"id":"17606","name":"EU/3/15/1557: Public summary of opinion on orphan designation: Sirolimus for the treatment of tuberous sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-18T11:00:00Z","last_updated_date":"2015-11-18T11:00:00Z","reference_number":"EMA/COMP/608871/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151557-public-summary-opinion-orphan-designation-sirolimus-treatment-tuberous-sclerosis_en.pdf"},
    {"id":"17610","name":"EU/3/13/1108: Public summary of opinion on orphan designation:\n\n2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2013-04-05T02:00:00Z","reference_number":"EMA/COMP/86745/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131108-public-summary-opinion-orphan-designation-2-4-methoxy-3-2-m-tolyl-ethoxy-benzoylamino-indan-2-carboxylic-acid-treatment-systemic-sclerosis_en.pdf"},
    {"id":"17613","name":"EU/3/01/057: Public summary of positive opinion for orphan designation of porcine lung surfactant for treatment of acute lung injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-06-01T02:00:00Z","last_updated_date":"2005-06-01T02:00:00Z","reference_number":"EMEA/COMP/255/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301057-public-summary-positive-opinion-orphan-designation-porcine-lung-surfactant-treatment-acute-lung-injury_en.pdf"},
    {"id":"17673","name":"EU/3/07/433: Public summary of positive opinion for orphan designation of HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS) for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2016-10-20T02:00:00Z","reference_number":"EMEA/COMP/96943/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307433-public-summary-positive-opinion-orphan-designation-hla-class-iii-binding-tumour-associated-peptides-adf-apo-ccn-guc-k67-met-mmp-muc-rgs-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"17686","name":"EU/3/10/794: Public summary of opinion on orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate for the treatment o...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2013-04-09T02:00:00Z","reference_number":"EMA/COMP/477791/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310794-public-summary-opinion-orphan-designation-n-tert-butyl-3-5-methyl-2-4-2-pyrrolidin-1-ylethoxyphenylaminopyrimidin-4-ylamino-benzenesulfonamide-dihydrochloride-monohydrate-treatment-o_en.pdf"},
    {"id":"17701","name":"EU/3/05/268: Public summary of positive opinion for orphan designation of (Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysyccina...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2016-09-30T02:00:00Z","reference_number":"EMEA/COMP/216937/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305268-public-summary-positive-opinion-orphan-designation-z-n-2-diethylaminoethyl-5-5-fluoro-2-oxo-12-dihydro-3h-indol-3-ylidenemethyl-24-dimethyl-1h-pyrrole-3-carboxamide-s-2-hydroxysyccina_en.pdf"},
    {"id":"17756","name":"EU/3/13/1141: Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against the keratin 6a N171K mutation for the treatment of pachyonychia congenita","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T14:00:00Z","last_updated_date":"2013-07-30T14:00:00Z","reference_number":"EMA/COMP/318074/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131141-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-keratin-6a-n171k-mutation-treatment-pachyonychia-congenita_en.pdf"},
    {"id":"17792","name":"EU/3/02/105: Public summary of positive opinion for orphan designation of carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]\n\nphenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester (amelubant)\n\nfor t...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T00:00:00Z","last_updated_date":"2005-11-29T00:00:00Z","reference_number":"EMEA/COMP/1071/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302105-public-summary-positive-opinion-orphan-designation-carbamic-acid-4-3-4-1-4-hydroxyphenyl-1-methylethyl-phenoxymethylphenylmethoxy-phenyliminomethyl-ethyl-ester-amelubant-t_en.pdf"},
    {"id":"17798","name":"EU/3/02/091: Public summary of positive opinion for orphan designation of TGF-β2-specific phosphorothioate antisense oligodeoxynucleotide for the treatment of high-grate glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-08T01:00:00Z","last_updated_date":"2014-04-03T16:00:00Z","reference_number":"EMEA/COMP/78/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302091-public-summary-positive-opinion-orphan-designation-tgf-i22-specific-phosphorothioate-antisense-oligodeoxynucleotide-treatment-high-grate-glioma_en.pdf"},
    {"id":"17836","name":"EU/3/12/990: Public summary of opinion on orphan designation: Vosaroxin for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T16:55:00Z","last_updated_date":"2012-06-18T16:55:00Z","reference_number":"EMA/COMP/222562/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312990-public-summary-opinion-orphan-designation-vosaroxin-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"17838","name":"EU/3/06/379: Public summary of positive opinion for orphan designation of\n\ndiphenylcyclopropenone for the treatment of alopecia totalis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2013-09-19T02:00:00Z","reference_number":"EMEA/COMP/428277/2006 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306379-public-summary-positive-opinion-orphan-designation-diphenylcyclopropenone-treatment-alopecia-totalis_en.pdf"},
    {"id":"17880","name":"EU/3/08/549: Public summary of positive opinion for orphan designation of NGR-human tumour necrosis factor for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/185263/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308549-public-summary-positive-opinion-orphan-designation-ngr-human-tumour-necrosis-factor-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"17895","name":"EU/3/11/925: Public summary of opinion on orphan designation: Mifepristone for the treatment of hypercortisolism (Cushing’s syndrome) of endogenous origin","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/COMP/793876/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311925-public-summary-opinion-orphan-designation-mifepristone-treatment-hypercortisolism-cushings-syndrome-endogenous-origin_en.pdf"},
    {"id":"17898","name":"EU/3/05/297: Public summary of positive opinion for orphan designation of adeno-associated viral vector containing modified U7 snRNA gene for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-11T02:00:00Z","last_updated_date":"2005-10-11T02:00:00Z","reference_number":"EMEA/COMP/203896/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305297-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-containing-modified-u7-snrna-gene-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"17925","name":"EU/3/12/1064: Public summary of opinion on orphan designation: Alisertib for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2017-02-07T17:38:00Z","reference_number":"EMA/COMP/663000/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121064-public-summary-opinion-orphan-designation-alisertib-treatment-ovarian-cancer_en.pdf"},
    {"id":"17931","name":"EU/3/11/871: Public summary of opinion on orphan designation: Salirasib for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2017-10-19T02:00:00Z","reference_number":"EMA/COMP/227845/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311871-public-summary-opinion-orphan-designation-salirasib-treatment-pancreatic-cancer_en.pdf"},
    {"id":"17935","name":"EU/3/14/1381: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human MD1 gene for treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2015-01-16T01:00:00Z","reference_number":"EMA/COMP/660615/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141381-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-md1-gene-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"18023","name":"EU/3/01/055: Public summary of positive opinion for orphan designation of cladribine (subcutaneous use) for the treatment of indolent non-Hodgkin’s lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T00:00:00Z","last_updated_date":"2014-06-19T01:00:00Z","reference_number":"EMEA/COMP/1317/03 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301055-public-summary-positive-opinion-orphan-designation-cladribine-subcutaneous-use-treatment-indolent-non-hodgkins-lymphoma_en.pdf"},
    {"id":"18031","name":"EU/3/16/1646: Public summary of opinion on orphan designation: Combination of 4-hydroxyandrostenedione, Serenoa serrulata fruit extract and alpha lipoic acid for the treatment of multiple symmetric lipomatosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-31T02:00:00Z","last_updated_date":"2016-05-31T02:00:00Z","reference_number":"EMA/COMP/242793/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161646-public-summary-opinion-orphan-designation-combination-4-hydroxyandrostenedione-serenoa-serrulata-fruit-extract-and-alpha-lipoic-acid-treatment-multiple-symmetric-lipomatosis_en.pdf"},
    {"id":"18067","name":"EU/03/14/1277: Public summary of opinion on orphan designation of plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a non-viral, cationic lipid based gene transfer age...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/COMP/255560/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu03141277-public-summary-opinion-orphan-designation-plasmid-dna-encoding-human-cystic-fibrosis-transmembrane-conductance-regulator-gene-complexed-non-viral-cationic-lipid-based-gene-transfer-age_en.pdf"},
    {"id":"18074","name":"EU/3/15/1481: Public summary of positive opinion for orphan designation of Phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis(1,1-dimethylethyl) monohydrochloride for the treatment of Huntington’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T14:00:00Z","last_updated_date":"2017-10-19T14:00:00Z","reference_number":"EMA/COMP/205588/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151481-public-summary-positive-opinion-orphan-designation-phenol-4-2-aminomethyl-4-thiazolyl-26-bis11-dimethylethyl-monohydrochloride-treatment-huntingtons-disease_en.pdf"},
    {"id":"18104","name":"EU/3/11/934: Public summary of opinion on orphan designation: 4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2018-02-22T01:00:00Z","reference_number":"EMA/COMP/870315/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311934-public-summary-opinion-orphan-designation-4-9-3s-tetrahydro-3-furanyl-8-246-trifluorophenylamino-9h-purin-2-ylamino-trans-cyclohexanol-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"18106","name":"EU/3/09/630: Public summary of positive opinion for orphan designation of skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vector for the treatment of dystrophic epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-12T02:00:00Z","last_updated_date":"2014-10-07T02:00:00Z","reference_number":"EMEA/COMP/148489/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309630-public-summary-positive-opinion-orphan-designation-skin-equivalent-graft-genetically-corrected-col7a1-encoding-sin-retroviral-vector-treatment-dystrophic-epidermolysis-bullosa_en.pdf"},
    {"id":"18135","name":"EU/3/06/353: Public summary of positive opinion for orphan designation\n\nof 26 base single stranded phosphodiester DNA oligonucleotide for the  treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMEA/COMP/25490/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306353-public-summary-positive-opinion-orphan-designation-26-base-single-stranded-phosphodiester-dna-oligonucleotide-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"18164","name":"EU/3/16/1721 : Public summary of opinion on orphan designation: L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser for the prevention of graft loss in pancreatic islet transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161721-public-summary-opinion-orphan-designation-l-pyr-l-glu-l-gln-l-leu-l-glu-l-arg-l-ala-l-leu-l-asn-l-ser-l-ser-prevention-graft-loss-pancreatic-islet-transplantation_en.pdf"},
    {"id":"18169","name":"EU/3/14/1253: Public summary of opinion on orphan designation: Ex-vivo cultured human mesenchymal stromal cells for the prevention of graft rejection following solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-06T02:00:00Z","last_updated_date":"2014-05-06T02:00:00Z","reference_number":"EMA/COMP/90111/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141253-public-summary-opinion-orphan-designation-ex-vivo-cultured-human-mesenchymal-stromal-cells-prevention-graft-rejection-following-solid-organ-transplantation_en.pdf"},
    {"id":"18199","name":"EU/3/13/1154: Public summary of opinion on orphan designation: Fosbretabulin tromethamine for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T14:30:00Z","last_updated_date":"2021-09-02T14:30:00Z","reference_number":"EMA/COMP/417559/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131154-public-summary-opinion-orphan-designation-fosbretabulin-tromethamine-treatment-ovarian-cancer_en.pdf"},
    {"id":"18213","name":"EU/3/18/1972: Public summary of opinion on orphan designation: 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/60711/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181972-public-summary-opinion-orphan-designation-1-4-4-fluoro-2-methyl-1h-indol-5-yloxy-6-methoxyquinolin-7-yloxymethylcyclopropanamine-dihydrochloride-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"18224","name":"EU/3/09/703: Public summary of opinion on orphan designation of brivudine for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/COMP/768295/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309703-public-summary-opinion-orphan-designation-brivudine-treatment-pancreatic-cancer_en.pdf"},
    {"id":"18243","name":"EU/3/16/1813: Public summary of opinion on orphan designation: Autologous dendritic cells incubated ex vivo with zebularine and factor VIII for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"EMA/5825/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161813-public-summary-opinion-orphan-designation-autologous-dendritic-cells-incubated-ex-vivo-zebularine-and-factor-viii-treatment-haemophilia_en.pdf"},
    {"id":"18253","name":"EU/3/07/489: Public summary of positive opinion for orphan designation of ciclosporin for the treatment of Herpes simplex virus stromal keratitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMEA/COMP/440430/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307489-public-summary-positive-opinion-orphan-designation-ciclosporin-treatment-herpes-simplex-virus-stromal-keratitis_en.pdf"},
    {"id":"18265","name":"EU/3/07/497: Public summary of positive opinion for orphan designation of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMEA/COMP/132644/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307497-public-summary-positive-opinion-orphan-designation-4-35-bistrimethylsilylbenzamido-benzoic-acid-treatment-hepatocellular-carcinoma_en.pdf"}    {"id":"18299","name":"Public summary of opinion on orphan designation: Gastrin 17C diphtheria toxoid conjugate for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-05T02:00:00Z","last_updated_date":"2010-08-05T02:00:00Z","reference_number":"EMA/COMP/110198/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-gastrin-17c-diphtheria-toxoid-conjugate-treatment-pancreatic-cancer_en.pdf"},
    {"id":"18355","name":"EU/3/05/305: Public summary of positive opinion for imatinib mesilate for the treatment of dermatofibrosarcoma protuberans","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMA/COMP/244136/2005 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305305-public-summary-positive-opinion-imatinib-mesilate-treatment-dermatofibrosarcoma-protuberans_en.pdf"},
    {"id":"18367","name":"EU/3/05/301: Public summary of positive opinion for orphan designation of chimeric monoclonal antibody to shiga-toxin 1 and 2 for the treatment of shiga-toxin producing bacterial infection","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-02-09T00:00:00Z","last_updated_date":"2013-02-27T13:00:00Z","reference_number":"EMEA/COMP/246642/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305301-public-summary-positive-opinion-orphan-designation-chimeric-monoclonal-antibody-shiga-toxin-1-and-2-treatment-shiga-toxin-producing-bacterial-infection_en.pdf"},
    {"id":"18407","name":"EU/3/06/403: Public summary of positive opinion for orphan designation\n\nof 5-(2,6-Difluoro-phenoxy)-3(R,S)-{2(S)-[2(S)-(3-methoxycarbonyl-2(S)-{3-methyl-2(S)-[(quinoline-2-carbonyl)-amino]-butyrylamino}-propionylamino)-3...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-22T02:00:00Z","last_updated_date":"2015-05-08T03:00:00Z","reference_number":"EMEA/COMP/358708/2006 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306403-public-summary-positive-opinion-orphan-designation-5-26-difluoro-phenoxy-3rs-2s-2s-3-methoxycarbonyl-2s-3-methyl-2s-quinoline-2-carbonyl-amino-butyrylamino-propionylamino-3_en.pdf"},
    {"id":"18438","name":"EU/3/16/1701: Public summary of opinion on orphan designation: Poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-, amide with arginase 1 [cobalt cofactor] (synthetic human) (1:10), trimer for the treatment of...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/450723/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161701-public-summary-opinion-orphan-designation-polyoxy-12-ethanediyl-alpha-carboxymethyl-omega-methoxy-amide-arginase-1-cobalt-cofactor-synthetic-human-110-trimer-treatment_en.pdf"},
    {"id":"18475","name":"EU/3/15/1501: Public summary of opinion on orphan designation: Adeno-associated viral vector containing the human factor IX gene for treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2017-10-19T02:00:00Z","reference_number":"EMA/COMP/360279/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151501-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-containing-human-factor-ix-gene-treatment-haemophilia-b_en.pdf"},
    {"id":"18495","name":"EU/3/08/559: Public summary of positive opinion for orphan designation of\n\nbosentan for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2014-05-08T02:00:00Z","reference_number":"EMEA/COMP/364120/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308559-public-summary-positive-opinion-orphan-designation-bosentan-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"18501","name":"EU/3/02/118: Public summary of positive opinion for orphan designation of recombinant glycoprotein gp350 of Epstein-Barr virus for the prevention of post-transplantation lympho-proliferative disorders","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2002-12-17T00:00:00Z","last_updated_date":"2002-12-17T00:00:00Z","reference_number":"EMEA/COMP/2207/02","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302118-public-summary-positive-opinion-orphan-designation-recombinant-glycoprotein-gp350-epstein-barr-virus-prevention-post-transplantation-lympho-proliferative-disorders_en.pdf"},
    {"id":"18542","name":"EU/3/04/242: Public summary of positive opinion for orphan designation of N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole for the treatment of mastocytosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-26T02:00:00Z","last_updated_date":"2005-10-26T02:00:00Z","reference_number":"EMEA/COMP/100459/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304242-public-summary-positive-opinion-orphan-designation-n-methyl-diazacyclohexyl-methylbenzamide-azaphenyl-aminothiopyrrole-treatment-mastocytosis_en.pdf"},
    {"id":"18585","name":"EU/3/12/1011: Public summary of opinion on orphan designation: Levoglutamide for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2012-07-24T16:00:00Z","reference_number":"EMA/COMP/381822/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121011-public-summary-opinion-orphan-designation-levoglutamide-treatment-sickle-cell-disease_en.pdf"},
    {"id":"18616","name":"EU/3/10/745: Public summary of positive opinion for Dexamethasone (40 mg tablet) for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/COMP/168763/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310745-public-summary-positive-opinion-dexamethasone-40-mg-tablet-treatment-multiple-myeloma_en.pdf"},
    {"id":"18632","name":"EU/3/04/259: Public summary of positive opinion for orphan designation of acetylcysteine for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/199698/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304259-public-summary-positive-opinion-orphan-designation-acetylcysteine-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"18656","name":"EU/3/17/1834: Public summary of opinion on orphan designation: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetat...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/83325/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171834-public-summary-opinion-orphan-designation-cyclol-alanyl-l-seryl-l-isoleucyl-l-prolyl-l-prolyl-l-glutaminyl-l-lysyl-l-tyrosyl-d-prolyl-l-prolyl-2s-2-aminodecanoyl-l-alpha-glutamyl-l_en.pdf"},
    {"id":"18676","name":"EU/3/16/1764: Public summary of positive opinion for orphan designation of tetrofosmin for the diagnosis of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/COMP/611816/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161764-public-summary-positive-opinion-orphan-designation-tetrofosmin-diagnosis-glioma_en.pdf"},
    {"id":"18689","name":"EU/3/14/1309: Public summary of opinion on orphan designation: 17α,21-dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-01T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMA/COMP/431749/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141309-public-summary-opinion-orphan-designation-17i-21-dihydroxy-16i-methyl-pregna-14911-triene-320-dione-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"18693","name":"EU/3/16/1772: Public summary of positive opinion for orphan designation of adeno-associated viral vector serotype 8 containing the human UGT1A1 genefor the treatment of Crigler-Najjar syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T15:43:00Z","last_updated_date":"2021-02-03T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161772-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-ugt1a1-genefor-treatment-crigler-najjar-syndrome_en.pdf"},
    {"id":"18705","name":"EU/3/11/856: Public summary of positive opinion for orphan designation:  Recombinant thymidine phosphorylase encapsulated in autologous erythrocytes for the treatment of mitochondrial neurogastrointestinal encephalomyopa...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"EMA/COMP/89527/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311856-public-summary-positive-opinion-orphan-designation-recombinant-thymidine-phosphorylase-encapsulated-autologous-erythrocytes-treatment-mitochondrial-neurogastrointestinal-encephalomyopa_en.pdf"},
    {"id":"18706","name":"EU/3/16/1791: Public summary of positive opinion for orphan designation of vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions, for the treatment of ovarian cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T10:54:00Z","last_updated_date":"2016-12-14T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161791-public-summary-positive-opinion-orphan-designation-vaccine-consisting-5-survivin-peptides-different-human-leukocyte-antigen-restrictions-treatment-ovarian-cancer_en.pdf"},
    {"id":"18711","name":"EU/3/12/1091: Public summary of opinion on orphan designation: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene for treatment of beta thalassaemia int...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2022-11-30T01:00:00Z","reference_number":"EMA/COMP/2193/2013 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121091-public-summary-opinion-orphan-designation-autologous-cd34-haematopoietic-stem-cells-transduced-lentiviral-vector-encoding-human-betaa-t87q-globin-gene-treatment-beta-thalassaemia-int_en.pdf"},
    {"id":"18719","name":"EU/3/17/1861: Public summary of opinion on orphan designation: (S)-8-{2-amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester for the tre...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/211274/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171861-public-summary-opinion-orphan-designation-s-8-2-amino-6-1-5-chloro-biphenyl-2-yl-r-222-trifluoro-ethoxy-pyrimidin-4-yl-28-diaza-spiro45decane-3-carboxylic-acid-ethyl-ester-tre_en.pdf"},
    {"id":"18723","name":"EU/3/04/223: Public summary of positive opinion for orphan designation of heparin sodium for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-07-01T14:06:00Z","last_updated_date":"2017-02-10T13:06:00Z","reference_number":"EMEA/COMP/169351/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304223-public-summary-positive-opinion-orphan-designation-heparin-sodium-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"18755","name":"EU/3/08/575: Public summary of positive opinion for orphan designation ofcarglumic acid for the treatment of isovaleric acidaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2021-06-09T15:00:00Z","reference_number":"EMEA/COMP/481646/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308575-public-summary-positive-opinion-orphan-designation-ofcarglumic-acid-treatment-isovaleric-acidaemia_en.pdf"},
    {"id":"18764","name":"EU/3/16/1755: Public summary of positive opinion for orphan designation of melatonin for the treatment of Smith-Magenis syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/619571/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161755-public-summary-positive-opinion-orphan-designation-melatonin-treatment-smith-magenis-syndrome_en.pdf"},
    {"id":"18807","name":"EU/3/03/155: Public summary of positive opinion for orphan designation of murine anti-idiotypic antibody against OC125 antibody against CA125 antigen for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T01:00:00Z","last_updated_date":"2014-01-13T15:30:00Z","reference_number":"EMEA/COMP/1376/03 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303155-public-summary-positive-opinion-orphan-designation-murine-anti-idiotypic-antibody-against-oc125-antibody-against-ca125-antigen-treatment-ovarian-cancer_en.pdf"},
    {"id":"18811","name":"EU/3/16/1743: Public summary of positive opinion for orphan designation of autologous mononuclear cells derived from human cord blood for the treatment of neonatal encephalopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/629725/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161743-public-summary-positive-opinion-orphan-designation-autologous-mononuclear-cells-derived-human-cord-blood-treatment-neonatal-encephalopathy_en.pdf"},
    {"id":"18825","name":"EU/3/08/582: Public summary of positive opinion for orphan designation of recombinant human heparan-N-sulfatase for the treatment of mucopolysaccharidosis III, type A (Sanfilippo A syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2021-09-02T02:00:00Z","reference_number":"EMEA/COMP/488980/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308582-public-summary-positive-opinion-orphan-designation-recombinant-human-heparan-n-sulfatase-treatment-mucopolysaccharidosis-iii-type-sanfilippo-syndrome_en.pdf"},
    {"id":"18837","name":"EU/3/12/1077 : Public summary of opinion on orphan designation: Exon-52-specific phosphorothioate oligonucleotide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-25T12:00:00Z","last_updated_date":"2013-01-25T12:00:00Z","reference_number":"EMA/COMP/740574/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121077-public-summary-opinion-orphan-designation-exon-52-specific-phosphorothioate-oligonucleotide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"18860","name":"EU/3/11/872: Public summary of opinion on orphan designation: Sulfonated monophosphorylated mannose oligosaccharide for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2013-06-26T02:00:00Z","reference_number":"EMA/COMP/228635/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311872-public-summary-opinion-orphan-designation-sulfonated-monophosphorylated-mannose-oligosaccharide-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"18885","name":"EU/3/17/1953: Public summary of opinion on orphan designation: Pegunigalsidase alfa for the treatment of Fabry disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-23T14:42:00Z","last_updated_date":"2023-05-08T14:42:00Z","reference_number":"EMA/757900/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171953-public-summary-opinion-orphan-designation-pegunigalsidase-alfa-treatment-fabry-disease_en.pdf"},
    {"id":"18918","name":"EU/3/01/019: Public summary of positive opinion for orphan designation of bosentan for the treatment of pulmonary arterial hypertension and chronic  thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T00:00:00Z","last_updated_date":"2013-02-27T15:00:00Z","reference_number":"EMEA/COMP/1280/2003 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301019-public-summary-positive-opinion-orphan-designation-bosentan-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"18920","name":"Public summary of negative opinion on orphan designation: 20% intravenous fat emulsion consisting of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/211260/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-20-intravenous-fat-emulsion-consisting-20-soybean-oil-12-egg-yolk-phospholipids-225-glycerin-and-water-injection_en.pdf"},
    {"id":"18975","name":"EU/3/03/151: Public summary of positive opinion for orphan designation of aplidine for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T00:00:00Z","last_updated_date":"2011-09-06T01:00:00Z","reference_number":"EMEA/COMP/378/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303151-public-summary-positive-opinion-orphan-designation-aplidine-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"18980","name":"EU/3/14/1416: Public summary of opinion on orphan designation: Chimeric monoclonal antibody to O-acetyl-GD2 antigen for the treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/COMP/786549/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141416-public-summary-opinion-orphan-designation-chimeric-monoclonal-antibody-o-acetyl-gd2-antigen-treatment-neuroblastoma_en.pdf"},
    {"id":"18981","name":"EU/3/02/088: Public summary of positive opinion for orphan designation of colistimethate sodium for the treatment of Pseudomonas aeruginosa lung infection (including colonisation) in cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-08T00:00:00Z","last_updated_date":"2011-11-19T00:00:00Z","reference_number":"EMEA/COMP/75/02 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302088-public-summary-positive-opinion-orphan-designation-colistimethate-sodium-treatment-pseudomonas-aeruginosa-lung-infection-including-colonisation-cystic-fibrosis_en.pdf"},
    {"id":"18999","name":"EU/3/07/435: Public summary of positive opinion for orphan designation of recombinant human C1-inhibitor for the prevention of delayed graft function in organ transplant","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"EMEA/COMP/13308/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307435-public-summary-positive-opinion-orphan-designation-recombinant-human-c1-inhibitor-prevention-delayed-graft-function-organ-transplant_en.pdf"},
    {"id":"19029","name":"EU/3/08/541: Public summary of positive opinion for orphan designation of [Nle4, D-Phe7]-alpha-melanocyte stimulating hormone for the treatment of erythropoietic protoporphyria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMEA/COMP/160599/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308541-public-summary-positive-opinion-orphan-designation-nle4-d-phe7-alpha-melanocyte-stimulating-hormone-treatment-erythropoietic-protoporphyria_en.pdf"},
    {"id":"19037","name":"EU/3/10/739: Public summary of opinion on orphan designation: Glyceryl tri-(4-phenylbutyrate) for the treatment of citrullinaemia type 2","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/COMP/122534/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310739-public-summary-opinion-orphan-designation-glyceryl-tri-4-phenylbutyrate-treatment-citrullinaemia-type-2_en.pdf"},
    {"id":"19057","name":"EU/3/09/724: Public summary of opinion on orphan designation of recombinant human monoclonal antibody to human interleukin (IL)-17A of the IgG1/k class for the treatment of chronic non-infectious uveitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMA/COMP/822954/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309724-public-summary-opinion-orphan-designation-recombinant-human-monoclonal-antibody-human-interleukin-il-17a-igg1k-class-treatment-chronic-non-infectious-uveitis_en.pdf"},
    {"id":"19061","name":"EU/3/15/1566: Public summary of opinion on orphan designation: Autologous human peripheral blood Vdelta1+ T lymphocytes activated in vitro by cytokine and monoclonal antibody treatment for the treatment of chronic lympho...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2015-11-16T01:00:00Z","reference_number":"EMA/COMP/611679/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151566-public-summary-opinion-orphan-designation-autologous-human-peripheral-blood-vdelta1-t-lymphocytes-activated-vitro-cytokine-and-monoclonal-antibody-treatment-treatment-chronic-lympho_en.pdf"},
    {"id":"19066","name":"EU/3/08/544: Public summary of positive opinion for orphan designation of omigapil maleate for congenital muscular dystrophy with merosin (laminin alpha 2) deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2011-04-12T02:00:00Z","reference_number":"EMEA/COMP/204694/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308544-public-summary-positive-opinion-orphan-designation-omigapil-maleate-congenital-muscular-dystrophy-merosin-laminin-alpha-2-deficiency_en.pdf"},
    {"id":"19090","name":"EU/3/08/611: Public summary of positive opinion for orphan designation of recombinant human hepatocarcinoma-intestine-pancreas / pancreatic associated protein for the treatment of acute liver failure","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/COMP/668440/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308611-public-summary-positive-opinion-orphan-designation-recombinant-human-hepatocarcinoma-intestine-pancreas-pancreatic-associated-protein-treatment-acute-liver-failure_en.pdf"},
    {"id":"19136","name":"EU/3/12/977: Public summary of opinion on orphan designation: Linsitinib for the treatment of adrenal cortical carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-30T02:00:00Z","last_updated_date":"2013-03-11T16:30:00Z","reference_number":"EMA/COMP/142178/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312977-public-summary-opinion-orphan-designation-linsitinib-treatment-adrenal-cortical-carcinoma_en.pdf"},
    {"id":"19143","name":"EU/3/01/072: Public summary of positive opinion for orphan designation of apomorphine (oromucosal use) for the treatment of off-periods in Parkinson’s disease not responding adequately to other existing therapies","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T00:00:00Z","last_updated_date":"2011-06-01T01:00:00Z","reference_number":"EMEA/COMP/209/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301072-public-summary-positive-opinion-orphan-designation-apomorphine-oromucosal-use-treatment-periods-parkinsons-disease-not-responding-adequately-other-existing-therapies_en.pdf"},
    {"id":"19155","name":"EU/3/14/1237: Public summary of opinion on orphan designation: Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-01T14:00:00Z","last_updated_date":"2014-04-01T14:00:00Z","reference_number":"EMA/COMP/36001/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141237-public-summary-opinion-orphan-designation-gallium-ga-68-n-4710-tricarboxymethyl-14710-tetraazacyclododec-1-ylacetyl-d-phenylalanyl-l-cysteinyl-l-tyrosyl-d-tryptophanyl-l-lysyl-l-threoninyl_en.pdf"},
    {"id":"19207","name":"EU/3/04/240: Public summary of positive opinion for orphan designation of rufinamide for the treatment of Lennox-Gastaut syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T00:00:00Z","last_updated_date":"2019-02-20T00:00:00Z","reference_number":"EMEA/122307/2004 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304240-public-summary-positive-opinion-orphan-designation-rufinamide-treatment-lennox-gastaut-syndrome_en.pdf"},
    {"id":"19210","name":"EU/3/00/002: Public summary of opinion on orphan designation: alpha-galactosidase A for the treatment of Fabry disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2011-11-18T01:00:00Z","reference_number":"EMA/COMP/235368/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300002-public-summary-opinion-orphan-designation-alpha-galactosidase-treatment-fabry-disease_en.pdf"},
    {"id":"19235","name":"EU/3/16/1806: Public summary of opinion on orphan designation: Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene for the treatment of neuronal ceroid lipofuscinosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2023-06-20T01:00:00Z","reference_number":"EMA/758036/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161806-public-summary-opinion-orphan-designation-recombinant-self-complementary-adeno-associated-viral-vector-serotype-9-containing-human-cln3-gene-treatment-neuronal-ceroid-lipofuscinosis_en.pdf"},
    {"id":"19240","name":"EU/3/17/1931: Public summary of opinion on orphan designation: Siplizumab for the treatment in solid organ transplantation","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T15:45:00Z","last_updated_date":"2018-01-09T15:45:00Z","reference_number":"EMA/632175/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171931-public-summary-opinion-orphan-designation-siplizumab-treatment-solid-organ-transplantation_en.pdf"},
    {"id":"19250","name":"EU/3/15/1561: Public summary of opinion on orphan designation: Ataluren for the treatment of aniridia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-18T11:00:00Z","last_updated_date":"2015-11-18T11:00:00Z","reference_number":"EMA/COMP/607054/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151561-public-summary-opinion-orphan-designation-ataluren-treatment-aniridia_en.pdf"},
    {"id":"19274","name":"EU/3/15/1573: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 encoding the human ATP7B gene under the control of the human alpha-1 antitrypsin promoter for the treatment of Wilso...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/COMP/698735/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151573-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-encoding-human-atp7b-gene-under-control-human-alpha-1-antitrypsin-promoter-treatment-wilso_en.pdf"},
    {"id":"19303","name":"EU/3/12/1094: Public summary of opinion on orphan designation: Modified recombinant human C-type natriuretic peptide for the treatment of achondroplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2013-03-01T01:00:00Z","reference_number":"EMA/COMP/795251/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121094-public-summary-opinion-orphan-designation-modified-recombinant-human-c-type-natriuretic-peptide-treatment-achondroplasia_en.pdf"},
    {"id":"19319","name":"EU/3/01/022: Public summary of positive opinion for orphan designation of laronidase for the treatment of mucopolysaccharidosis, type I","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2013-07-08T02:00:00Z","reference_number":"EMEA/COMP/1279/03 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301022-public-summary-positive-opinion-orphan-designation-laronidase-treatment-mucopolysaccharidosis-type-i_en.pdf"},
    {"id":"19413","name":"EU/3/13/1112: Public summary of opinion on orphan designation: Poloxamer 188 for the treatment of sickle-cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/COMP/89560/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131112-public-summary-opinion-orphan-designation-poloxamer-188-treatment-sickle-cell-disease_en.pdf"},
    {"id":"19440","name":"EU/3/10/813: Public summary of opinion on orphan designation: Recombinant human arylsulfatase A for the treatment of metachromatic leukodystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/COMP/601606/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310813-public-summary-opinion-orphan-designation-recombinant-human-arylsulfatase-treatment-metachromatic-leukodystrophy_en.pdf"},
    {"id":"19484","name":"EU/3/16/1693 : Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/446355/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161693-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-27m8-containing-chrimsonr-tdtomato-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"19487","name":"EU/3/13/1191: Public summary of opinion on orphan designation:\n\nL-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser for the treatment of sarcoidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-10-31T01:00:00Z","last_updated_date":"2013-10-31T01:00:00Z","reference_number":"EMA/COMP/554715/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131191-public-summary-opinion-orphan-designation-l-pyr-l-glu-l-gln-l-leu-l-glu-l-arg-l-ala-l-leu-l-asn-l-ser-l-ser-treatment-sarcoidosis_en.pdf"},
    {"id":"19488","name":"EU/3/03/156: Public summary of positive opinion for orphan designation of prasterone for the treatment of adrenal insufficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-11-07T00:00:00Z","last_updated_date":"2003-11-07T00:00:00Z","reference_number":"EMEA/COMP/1257/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303156-public-summary-positive-opinion-orphan-designation-prasterone-treatment-adrenal-insufficiency_en.pdf"},
    {"id":"19489","name":"EU/3/11/858: Public summary of positive opinion for orphan designation:  R-baclofen for the treatment of fragile X syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"EMA/COMP/72554/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311858-public-summary-positive-opinion-orphan-designation-r-baclofen-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"19531","name":"EU/3/15/1509: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 9 containing the human SMN gene for the treatment of spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2015-07-27T02:00:00Z","reference_number":"EMA/COMP/351110/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151509-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-containing-human-smn-gene-treatment-spinal-muscular-atrophy_en.pdf"},
    {"id":"19549","name":"EU/3/14/1365: Public summary of opinion on orphan designation: Recombinant human pentraxin-2 for the treatment of post-polycythaemia vera myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2020-06-08T01:00:00Z","reference_number":"EMA/COMP/660441/2014 Corr.","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141365-public-summary-opinion-orphan-designation-recombinant-human-pentraxin-2-treatment-post-polycythaemia-vera-myelofibrosis_en.pdf"},
    {"id":"19556","name":"EU/3/04/247: Public summary of positive opinion for orphan designation of 17-allylamino-17-demethoxygeldanamycin for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2011-03-25T01:00:00Z","reference_number":"EMEA/COMP/143416/2004 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304247-public-summary-positive-opinion-orphan-designation-17-allylamino-17-demethoxygeldanamycin-treatment-multiple-myeloma_en.pdf"},
    {"id":"19571","name":"EU/3/13/1231: Public summary of opinion on orphan designation: (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T01:00:00Z","last_updated_date":"2014-03-24T01:00:00Z","reference_number":"EMA/COMP/3530/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131231-public-summary-opinion-orphan-designation-2r3r4s5r-2-6-amino-9h-purin-9-yl-5-1r3s-3-2-5-tert-butyl-1h-benzodimidazol-2-ylethylcyclobutylisopropyl-aminomethyltetrahydrofuran_en.pdf"},
    {"id":"19596","name":"EU/3/06/428: Public summary of positive opinion for orphan designation of forodesine hydrochloride for the treatment of cutaneous T cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-13T00:00:00Z","last_updated_date":"2007-12-13T00:00:00Z","reference_number":"EMEA/COMP/465553/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306428-public-summary-positive-opinion-orphan-designation-forodesine-hydrochloride-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"19615","name":"EU/03/11/927: Public summary of opinion on orphan designation: Sinapultide, dipalmitoylphosphatidylcholine palmitoyl-oleoyl phosphatidylglycerol, sodium salt and palmitic acid for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2011-11-23T16:00:00Z","reference_number":"EMA/COMP/793892/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu0311927-public-summary-opinion-orphan-designation-sinapultide-dipalmitoylphosphatidylcholine-palmitoyl-oleoyl-phosphatidylglycerol-sodium-salt-and-palmitic-acid-treatment-cystic-fibrosis_en.pdf"},
    {"id":"19626","name":"EU/3/17/1870: Public summary of opinion on orphan designation: Thymidine and deoxycytidine for treatment of mitochondrial DNA depletion syndrome, myopathic form","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/210409/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171870-public-summary-opinion-orphan-designation-thymidine-and-deoxycytidine-treatment-mitochondrial-dna-depletion-syndrome-myopathic-form_en.pdf"},
    {"id":"19630","name":"EU/3/12/997: Public summary of opinion on orphan designation: N-Hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide for the treatment of schwannoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-04T17:00:00Z","last_updated_date":"2012-07-04T17:00:00Z","reference_number":"EMA/COMP/285070/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312997-public-summary-opinion-orphan-designation-n-hydroxy-4-3-methyl-2-s-phenyl-butyrylamino-benzamide-treatment-schwannoma_en.pdf"},
    {"id":"19688","name":"EU/3/04/186: Public summary of positive opinion for orphan designation of treosulfan for the conditioning treatment prior to haematopoietic progenitor cell transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-11-22T00:00:00Z","last_updated_date":"2019-08-30T14:00:00Z","reference_number":"EMEA/COMP/371/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304186-public-summary-positive-opinion-orphan-designation-treosulfan-conditioning-treatment-prior-haematopoietic-progenitor-cell-transplantation_en.pdf"},
    {"id":"19717","name":"EU/3/17/1911: Public summary of opinion on orphan designation: Sodium 2-hydroxylinoleate for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/480448/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171911-public-summary-opinion-orphan-designation-sodium-2-hydroxylinoleate-treatment-pancreatic-cancer_en.pdf"},
    {"id":"19738","name":"EU/3/04/199: Public summary of positive opinion for orphan designation of tetrahydrobiopterin for the treatment of hyperphenylalaninemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2011-05-19T01:00:00Z","reference_number":"EMEA/COMP/258/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304199-public-summary-positive-opinion-orphan-designation-tetrahydrobiopterin-treatment-hyperphenylalaninemia_en.pdf"},
    {"id":"19740","name":"EU/3/17/1950: Public summary of opinion on orphan designation: Adenovirus associated viral vector serotype 8 containing the human AIPL1 gene for the treatment of Leber’s congenital amaurosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T10:44:00Z","last_updated_date":"2018-01-24T10:44:00Z","reference_number":"EMA/754024/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171950-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-8-containing-human-aipl1-gene-treatment-lebers-congenital-amaurosis_en.pdf"},
    {"id":"19761","name":"EU/3/15/1547: Public summary of opinion on orphan designation: Mazindol for the treatment of narcolepsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2015-11-16T01:00:00Z","reference_number":"EMA/COMP/623175/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151547-public-summary-opinion-orphan-designation-mazindol-treatment-narcolepsy_en.pdf"},
    {"id":"19772","name":"EU/3/10/787: Public summary of opinion on orphan designation: (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt for the treatment of mantle-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"EMA/COMP/476246/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310787-public-summary-opinion-orphan-designation-3s-3-4-7-aminocarbonyl-2h-indazol-2-yl-phenyl-piperidine-tosylate-monohydrate-salt-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"19784","name":"EU/3/10/806: Public summary of opinion on orphan designation methylthioninium for the treatment of progressive non-fluent aphasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-15T01:00:00Z","last_updated_date":"2014-01-13T16:00:00Z","reference_number":"EMA/606351/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310806-public-summary-opinion-orphan-designation-methylthioninium-treatment-progressive-non-fluent-aphasia_en.pdf"},
    {"id":"19785","name":"EU/3/04/257: Public summary of positive opinion for orphan designation of recombinant human bile salt-stimulated lipase for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-11T02:00:00Z","last_updated_date":"2016-08-10T15:00:00Z","reference_number":"EMA/COMP/7913/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304257-public-summary-positive-opinion-orphan-designation-recombinant-human-bile-salt-stimulated-lipase-treatment-cystic-fibrosis_en.pdf"},
    {"id":"19797","name":"EU/3/05/264: Public summary of positive opinion for orphan designation of cholest-4-en-3-one, oxime for the treatment of 5 q spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-11T02:00:00Z","last_updated_date":"2005-10-11T02:00:00Z","reference_number":"EMEA/COMP/42161/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305264-public-summary-positive-opinion-orphan-designation-cholest-4-en-3-one-oxime-treatment-5-q-spinal-muscular-atrophy_en.pdf"},
    {"id":"19805","name":"EU/3/14/1262: Public summary of opinion on orphan designation: Recombinant human surfactant protein D for the prevention of bronchopulmonary dysplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-06-05T02:00:00Z","last_updated_date":"2014-06-05T02:00:00Z","reference_number":"EMA/COMP/92638/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141262-public-summary-opinion-orphan-designation-recombinant-human-surfactant-protein-d-prevention-bronchopulmonary-dysplasia_en.pdf"},
    {"id":"19817","name":"EU/3/14/1265: Public summary of opinion on orphan designation: Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-06-04T02:00:00Z","last_updated_date":"2014-06-04T02:00:00Z","reference_number":"EMA/COMP/151282/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141265-public-summary-opinion-orphan-designation-genetically-modified-serotype-53-adenovirus-coding-granulocyte-macrophage-colony-stimulating-factor-treatment-ovarian-cancer_en.pdf"},
    {"id":"19844","name":"EU/3/10/778: Public summary of opinion on orphan designation: Cysteamine bitartrate (gastroresistant) for the treatment of cystinosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2013-10-10T12:17:00Z","reference_number":"EMA/COMP/405606/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310778-public-summary-opinion-orphan-designation-cysteamine-bitartrate-gastroresistant-treatment-cystinosis_en.pdf"},
    {"id":"19846","name":"EU/3/18/2002: Public summary of opinion on orphan designation: Ribavirin for the treatment of Crimean-Congo haemorrhagic fever","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-15T02:00:00Z","last_updated_date":"2018-05-15T02:00:00Z","reference_number":"EMA/132079/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182002-public-summary-opinion-orphan-designation-ribavirin-treatment-crimean-congo-haemorrhagic-fever_en.pdf"},
    {"id":"19857","name":"EU/3/02/094: Public summary of positive opinion for orphan designation of chimeric IgG monoclonal antibody cG250 for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-08-01T02:00:00Z","last_updated_date":"2021-09-02T02:00:00Z","reference_number":"EMEA/COMP/76/02 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302094-public-summary-positive-opinion-orphan-designation-chimeric-igg-monoclonal-antibody-cg250-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"19869","name":"EU/3/07/491: Public summary of positive opinion of interferon gamma for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2013-03-01T01:00:00Z","reference_number":"EMEA/COMP/468704/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307491-public-summary-positive-opinion-interferon-gamma-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"19871","name":"EU/3/12/980: Public summary of opinion on orphan designation: Genistein sodium salt dihydrate for the treatment of mucopolysaccharidosis type III (Sanfilippo syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-30T02:00:00Z","last_updated_date":"2012-04-30T02:00:00Z","reference_number":"EMA/COMP/136271/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312980-public-summary-opinion-orphan-designation-genistein-sodium-salt-dihydrate-treatment-mucopolysaccharidosis-type-iii-sanfilippo-syndrome_en.pdf"},
    {"id":"19882","name":"EU/3/16/1711: Public summary of opinion on orphan designation : Volanesorsen sodium for the treatment of familial partial lipodystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-05T02:00:00Z","last_updated_date":"2016-09-05T02:00:00Z","reference_number":"EMA/COMP/444302/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161711-public-summary-opinion-orphan-designation-volanesorsen-sodium-treatment-familial-partial-lipodystrophy_en.pdf"},
    {"id":"19885","name":"EU/3/09/647: Public summary of positive opinion for orphan designation of (S)-3-(OH)-desazadesferrithiocin-polyether, magnesium salt for the treatment of chronic iron overload requiring chelation therapy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2009-09-11T02:00:00Z","reference_number":"EMEA/COMP/390293/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309647-public-summary-positive-opinion-orphan-designation-s-3-oh-desazadesferrithiocin-polyether-magnesium-salt-treatment-chronic-iron-overload-requiring-chelation-therapy_en.pdf"},
    {"id":"19943","name":"EU/3/06/407: Public summary of positive opinion for orphan designation of heparin-binding epidermal growth factor-like growth factor (HB-EGF), amino acids 74-148 for the prevention of necrotizing enterocolitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2014-01-13T01:00:00Z","reference_number":"EMEA/COMP/183997/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306407-public-summary-positive-opinion-orphan-designation-heparin-binding-epidermal-growth-factor-growth-factor-hb-egf-amino-acids-74-148-prevention-necrotizing-enterocolitis_en.pdf"},
    {"id":"19944","name":"EU/3/13/1229: Public summary of opinion on orphan designation: Autologous dendritic cells pulsed with allogeneic tumour cell lysate for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T01:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMA/COMP/17038/2014 REv. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131229-public-summary-opinion-orphan-designation-autologous-dendritic-cells-pulsed-allogeneic-tumour-cell-lysate-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"19947","name":"Public summary of negative opinion for orphan designation: 3-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine hydrochloride for the treatment of narcolepsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/751496/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-3-3-methanesulfonyl-phenyl-1-propyl-piperidine-hydrochloride-treatment-narcolepsy_en.pdf"},
    {"id":"19981","name":"EU/3/14/1278: Public summary of opinion on orphan designation of adeno-associated viral vector serotype 2 containing the human CHM gene encoding human Rab escort protein 1 for the treatment of choroideraemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2015-06-08T02:00:00Z","reference_number":"EMA/COMP/223562/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141278-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-2-containing-human-chm-gene-encoding-human-rab-escort-protein-1-treatment-choroideraemia_en.pdf"},
    {"id":"19998","name":"EU/3/16/1697: Public summary of opinion on orphan designation: Brincidofovir for the treatment of adenovirus infection in immunocompromised patients","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/437325/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161697-public-summary-opinion-orphan-designation-brincidofovir-treatment-adenovirus-infection-immunocompromised-patients_en.pdf"},
    {"id":"20010","name":"EU/3/13/1203: Public summary of opinion on orphan designation: Ibrutinib for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2021-11-23T01:00:00Z","reference_number":"EMA/COMP/629119/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131203-public-summary-opinion-orphan-designation-ibrutinib-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"20026","name":"EU/3/15/1526: Public summary of opinion on orphan designation: Triheptanoin for the treatment of carnitine palmitoyltransferase II deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T02:00:00Z","last_updated_date":"2015-08-18T02:00:00Z","reference_number":"EMA/COMP/432848/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151526-public-summary-opinion-orphan-designation-triheptanoin-treatment-carnitine-palmitoyltransferase-ii-deficiency_en.pdf"},
    {"id":"20028","name":"EU/3/17/1949: Public summary of opinion on orphan designation: Acetylleucine for the treatment of GM2 gangliosidosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T10:44:00Z","last_updated_date":"2018-01-24T10:44:00Z","reference_number":"EMA/755224/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171949-public-summary-opinion-orphan-designation-acetylleucine-treatment-gm2-gangliosidosis_en.pdf"},
    {"id":"20039","name":"EU/3/17/1900: Public summary of opinion on orphan designation: Asunercept for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/508069/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171900-public-summary-opinion-orphan-designation-asunercept-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"20106","name":"EU/3/01/076: Public summary of positive opinion for orphan designation of octovalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine for the prevention of Pseudomonas aeruginosa infections in patients w...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/86914/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301076-public-summary-positive-opinion-orphan-designation-octovalent-pseudomonas-aeruginosa-o-polysaccharide-toxin-conjugate-vaccine-prevention-pseudomonas-aeruginosa-infections-patients-w_en.pdf"},
    {"id":"20146","name":"EU/3/14/1289: Public summary of opinion on orphan designation: Recombinant human alpha-1-microglobulin for the treatment of pre-eclampsia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-16T02:00:00Z","last_updated_date":"2014-07-16T02:00:00Z","reference_number":"EMA/COMP/322623/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141289-public-summary-opinion-orphan-designation-recombinant-human-alpha-1-microglobulin-treatment-pre-eclampsia_en.pdf"},
    {"id":"20170","name":"EU/3/14/1373: Public summary of opinion on orphan designation: (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide for the treatment of gra...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T14:00:00Z","last_updated_date":"2015-01-15T14:00:00Z","reference_number":"EMA/COMP/637490/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141373-public-summary-opinion-orphan-designation-2r3s-2-4-cyclopentylaminophenyl-1-2-fluoro-6-methylbenzoylpiperidine-3-carboxylic-acid4-methyl-3-trifluoromethylphenylamide-treatment-gra_en.pdf"},
    {"id":"20200","name":"EU/3/13/1137: Public summary of opinion on orphan designation: 4,6,4’-trimethylangelicin for the treatment of cystic fibrosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T14:00:00Z","last_updated_date":"2013-07-11T14:00:00Z","reference_number":"EMA/COMP/309118/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131137-public-summary-opinion-orphan-designation-464-trimethylangelicin-treatment-cystic-fibrosis_en.pdf"},
    {"id":"20201","name":"EU/3/11/922: Public summary of opinion on orphan designation: Human platelet antigen-1a immunoglobulin for the prevention of fetal and neonatal alloimmune thrombocytopenia due to human platelet antigen-1a incompatibility","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2011-11-23T16:00:00Z","reference_number":"EMA/COMP/793874/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311922-public-summary-opinion-orphan-designation-human-platelet-antigen-1a-immunoglobulin-prevention-fetal-and-neonatal-alloimmune-thrombocytopenia-due-human-platelet-antigen-1a-incompatibility_en.pdf"},
    {"id":"20218","name":"EU/3/14/1387: Public summary of positive opinion for orphan designation: Exisulind for the treatment of familial cerebral cavernous malformations","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-02-26T18:00:00Z","reference_number":"EMA/COMP/733137/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141387-public-summary-positive-opinion-orphan-designation-exisulind-treatment-familial-cerebral-cavernous-malformations_en.pdf"},
    {"id":"20251","name":"EU/3/15/1598: Public summary of opinion on orphan designation: 2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate for the treatment of Charcot-Marie-Tooth disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2016-02-03T01:00:00Z","reference_number":"EMA/COMP/792973/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151598-public-summary-opinion-orphan-designation-2-2-chlorobenzylidenehydrazinecarboximidamide-acetate-treatment-charcot-marie-tooth-disease_en.pdf"}    {"id":"20277","name":"EU/3/03/169: Public summary of positive on orphan designation of human immunoglobulin for the treatment of dermatomyositis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-11T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/COMP/1442/2004 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303169-public-summary-positive-orphan-designation-human-immunoglobulin-treatment-dermatomyositis_en.pdf"},
    {"id":"20281","name":"EU/3/14/1372: Public summary of opinion on orphan designation: (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide for the treatment of mic...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T14:00:00Z","last_updated_date":"2015-01-15T14:00:00Z","reference_number":"EMA/COMP/637435/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141372-public-summary-opinion-orphan-designation-2r3s-2-4-cyclopentylaminophenyl-1-2-fluoro-6-methylbenzoylpiperidine-3-carboxylic-acid4-methyl-3-trifluoromethylphenylamide-treatment-mic_en.pdf"},
    {"id":"20295","name":"EU/3/07/473: Public summary of positive opinion for orphan designation of aviptadil for the treatment of sarcoidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-22T00:00:00Z","last_updated_date":"2008-01-22T00:00:00Z","reference_number":"EMEA/COMP/371789/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307473-public-summary-positive-opinion-orphan-designation-aviptadil-treatment-sarcoidosis_en.pdf"},
    {"id":"20334","name":"EU/3/06/358: Public summary of positive opinion for orphan designation of human monoclonal antibody against HLA-DR for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/56003/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306358-public-summary-positive-opinion-orphan-designation-human-monoclonal-antibody-against-hla-dr-treatment-multiple-myeloma_en.pdf"},
    {"id":"20343","name":"EU/3/05/342: Public summary of positive opinion for orphan designation of denufosol tetrasodium for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-04T02:00:00Z","last_updated_date":"2016-10-21T14:30:00Z","reference_number":"EMA/COMP/22635/2006 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305342-public-summary-positive-opinion-orphan-designation-denufosol-tetrasodium-treatment-cystic-fibrosis_en.pdf"},
    {"id":"20356","name":"EU/3/01/038: Public summary of positive opinion for orphan designation of retroviral gamma c cDNA containing vector for the treatment of severe combined immunodeficiency (SCID)-Xl disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/257219/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301038-public-summary-positive-opinion-orphan-designation-retroviral-gamma-c-cdna-containing-vector-treatment-severe-combined-immunodeficiency-scid-xl-disease_en.pdf"},
    {"id":"20392","name":"EU/3/08/612: Public summary of positive opinion for orphan designation of recombinant human proinsulin for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-19T02:00:00Z","last_updated_date":"2010-03-15T02:00:00Z","reference_number":"EMEA/COMP/566957/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308612-public-summary-positive-opinion-orphan-designation-recombinant-human-proinsulin-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"20395","name":"EU/3/18/1976: Public summary of opinion on orphan designation: Allogeneic CD4+ and CD25+ T lymphocytes ex vivo incubated with GP120 for the treatment in haematopoietic stem cell transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/63455/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181976-public-summary-opinion-orphan-designation-allogeneic-cd4-and-cd25-t-lymphocytes-ex-vivo-incubated-gp120-treatment-haematopoietic-stem-cell-transplantation_en.pdf"},
    {"id":"20416","name":"C(2002) 2822: Public summary of negative opinion for orphan designation of chlorproguanil hydrochloride and dapsone for the treatment of acute uncomplicated Plasmodium falciparum malaria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-08T00:00:00Z","last_updated_date":"2003-01-08T00:00:00Z","reference_number":"EMEA/COMP/1073/02 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/c2002-2822-public-summary-negative-opinion-orphan-designation-chlorproguanil-hydrochloride-and-dapsone-treatment-acute-uncomplicated-plasmodium-falciparum-malaria_en.pdf"},
    {"id":"20452","name":"EU/3/14/1404: Public summary of opinion on orphan designation: 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one for the treatment of multiple system atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/COMP/722694/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141404-public-summary-opinion-orphan-designation-1-2-isopropoxyethyl-2-thioxo-1235-tetrahydro-pyrrolo32-d-pyrimidin-4-one-treatment-multiple-system-atrophy_en.pdf"},
    {"id":"20456","name":"EU/3/12/950: Public summary of opinion on orphan designation: Sodium phenylbutyrate for the treatment of ornithine-transcarbamylase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T01:00:00Z","last_updated_date":"2017-08-09T02:00:00Z","reference_number":"EMA/COMP/43232/2012 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312950-public-summary-opinion-orphan-designation-sodium-phenylbutyrate-treatment-ornithine-transcarbamylase-deficiency_en.pdf"},
    {"id":"20463","name":"EU/3/17/1867: Public summary of opinion on orphan designation: Modified messenger ribonucleic acid encoding human ornithine transcarbamylase enzyme encapsulated into lipid nanoparticles for the treatment of ornithine tra...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/195824/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171867-public-summary-opinion-orphan-designation-modified-messenger-ribonucleic-acid-encoding-human-ornithine-transcarbamylase-enzyme-encapsulated-lipid-nanoparticles-treatment-ornithine-tra_en.pdf"},
    {"id":"20475","name":"EU/3/15/1431: Public summary of opinion on orphan designation: 3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid for the treatment of hereditary a...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2017-04-25T02:00:00Z","reference_number":"EMA/COMP/48508/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151431-public-summary-opinion-orphan-designation-3-2-4-carbamimidoyl-phenylcarbamoyl-5-methoxy-4-vinyl-phenyl-6-cyclopropylmethyl-carbamoyl-pyridine-2-carboxylic-acid-treatment-hereditary_en.pdf"},
    {"id":"20487","name":"EU/3/13/1159: Public summary of opinion on orphan designation: Idelalisib for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-22T17:30:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/COMP/400936/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131159-public-summary-opinion-orphan-designation-idelalisib-treatment-follicular-lymphoma_en.pdf"},
    {"id":"20490","name":"EU/3/09/637: Public summary of positive opinion for orphan designation\n\nof 2',3',5'-tri-O-acetyluridine for the treatment of 5-fluorouracil overdose","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-09T02:09:21Z","last_updated_date":"2009-06-09T02:09:21Z","reference_number":"EMEA/COMP/231352/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309637-public-summary-positive-opinion-orphan-designation-235-tri-o-acetyluridine-treatment-5-fluorouracil-overdose_en.pdf"},
    {"id":"20491","name":"EU/3/12/1025: Public summary of opinion on orphan designation: Metreleptin for the treatment of Berardinelli-Seip syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-08-31T12:30:00Z","last_updated_date":"2015-05-13T12:30:00Z","reference_number":"EMA/COMP/440572/2012 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121025-public-summary-opinion-orphan-designation-metreleptin-treatment-berardinelli-seip-syndrome_en.pdf"},
    {"id":"20515","name":"EU/3/12/975: Public summary of opinion on orphan designation: Carbetocin for the treatment of Prader-Willi syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T11:45:00Z","last_updated_date":"2012-04-19T11:45:00Z","reference_number":"EMA/COMP/69949/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312975-public-summary-opinion-orphan-designation-carbetocin-treatment-prader-willi-syndrome_en.pdf"},
    {"id":"20530","name":"EU/3/09/634: Public summary of positive opinion for orphan designation of S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinyl-GNNDESNISFKEK for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-09T02:00:00Z","last_updated_date":"2009-06-09T02:00:00Z","reference_number":"EMEA/COMP/216741/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309634-public-summary-positive-opinion-orphan-designation-s-23-bispalmitoyloxy-2r-propyl-cysteinyl-gnndesnisfkek-treatment-pancreatic-cancer_en.pdf"},
    {"id":"20533","name":"EU/3/12/985: Public summary of opinion on orphan designation: Recombinant human methionine proinsulin for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T16:55:00Z","last_updated_date":"2012-06-18T16:55:00Z","reference_number":"EMA/COMP/204100/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312985-public-summary-opinion-orphan-designation-recombinant-human-methionine-proinsulin-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"20534","name":"EU/3/13/1185: Eculizumab for the treatment of neuromyelitis optica spectrum disorders","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-14T12:00:00Z","last_updated_date":"2019-06-14T12:00:00Z","reference_number":"EMADOC-628903358-745","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131185-eculizumab-treatment-neuromyelitis-optica-spectrum-disorders_en.pdf"},
    {"id":"20611","name":"EU/3/07/514: Public summary of positive opinion for orphan designation of (1R,2R)-octanoic acid[2-(2',3'-dihydro-benzo[1,4] dioxin-6'-yl)-2-hydroxy-\n\n1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt for the trea...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMEA/COMP/472719/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307514-public-summary-positive-opinion-orphan-designation-1r2r-octanoic-acid2-23-dihydro-benzo14-dioxin-6-yl-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl-amide-l-tartaric-acid-salt-trea_en.pdf"},
    {"id":"20631","name":"Public summary of opinion on orphan designation: Molgramostim for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-05T02:00:00Z","last_updated_date":"2010-08-05T02:00:00Z","reference_number":"EMA/COMP/327903/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-molgramostim-treatment-cystic-fibrosis_en.pdf"},
    {"id":"20636","name":"EU/3/14/1412: Public summary of opinion on orphan designation: Herpes simplex type 1 virus containing cellular B-myb gene as tumour-specific promoter for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/COMP/797466/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141412-public-summary-opinion-orphan-designation-herpes-simplex-type-1-virus-containing-cellular-b-myb-gene-tumour-specific-promoter-treatment-pancreatic-cancer_en.pdf"},
    {"id":"20649","name":"EU/3/18/2029: Public summary of opinion on orphan designation: 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one for the treatment of tuberculosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-21T12:43:00Z","last_updated_date":"2018-08-21T12:43:00Z","reference_number":"EMA/395070/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182029-public-summary-opinion-orphan-designation-2-2s-2-methyl-14-dioxa-8-azaspiro45dec-8-yl-8-nitro-6-trifluoromethyl-4h-13-benzothiazin-4-one-treatment-tuberculosis_en.pdf"},
    {"id":"20672","name":"EU/3/04/236: Public summary of opinion on orphan designation: Recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3 for the treatment of Type A extreme insulin resi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-06-21T02:00:00Z","last_updated_date":"2011-06-21T02:00:00Z","reference_number":"EMA/COMP/77786/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304236-public-summary-opinion-orphan-designation-recombinant-human-insulin-growth-factor-irecombinant-human-insulin-growth-factor-binding-protein-3-treatment-type-extreme-insulin-resi_en.pdf"},
    {"id":"20685","name":"EU/3/13/1171: Public summary of opinion on orphan designation: Autologous regulatory T cells with an immunophenotype of CD4+CD25hiFoxP3+ for the prevention of rejection following solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"EMA/COMP/442069/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131171-public-summary-opinion-orphan-designation-autologous-regulatory-t-cells-immunophenotype-cd4cd25hifoxp3-prevention-rejection-following-solid-organ-transplantation_en.pdf"},
    {"id":"20708","name":"EU/3/09/685: Public summary of positive opinion for orphan designation ofN-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:00Z","last_updated_date":"2020-08-12T00:09:00Z","reference_number":"EMEA/COMP/577406/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309685-public-summary-positive-opinion-orphan-designation-ofn-2s-23-dihydroxypropyl-3-2-fluoro-4-iodophenylaminoisonicotinamide-hydrochloride-treatment-pancreatic-cancer_en.pdf"},
    {"id":"20712","name":"EU/3/10/796: Public summary of opinion on orphan designation: Recombinant humanised anti-human interleukin-1 beta monoclonal antibody for the treatment of Behà§et’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2018-07-18T02:00:00Z","reference_number":"EMA/COMP/451283/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310796-public-summary-opinion-orphan-designation-recombinant-humanised-anti-human-interleukin-1-beta-monoclonal-antibody-treatment-behassets-disease_en.pdf"},
    {"id":"20717","name":"EU/3/10/765: Public summary of opinion on orphan designation of Midostaurin for the treatment of mastocytosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-11T01:31:00Z","last_updated_date":"2015-02-11T00:31:00Z","reference_number":"EMA/COMP/323341/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310765-public-summary-opinion-orphan-designation-midostaurin-treatment-mastocytosis_en.pdf"},
    {"id":"20739","name":"EU/3/13/1166: Public summary of opinion on orphan designation: Heterologous human adult liver-derived progenitor cells for the treatment of citrullinaemia type 2","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-22T17:30:00Z","last_updated_date":"2013-08-22T17:30:00Z","reference_number":"EMA/COMP/413220/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131166-public-summary-opinion-orphan-designation-heterologous-human-adult-liver-derived-progenitor-cells-treatment-citrullinaemia-type-2_en.pdf"},
    {"id":"20778","name":"EU/3/12/986: Public summary of opinion on orphan designation: Pomalidomide for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T16:55:00Z","last_updated_date":"2015-06-08T16:55:00Z","reference_number":"EMA/COMP/216971/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312986-public-summary-opinion-orphan-designation-pomalidomide-treatment-systemic-sclerosis_en.pdf"},
    {"id":"20795","name":"EU/3/07/517: Public summary of positive opinion for orphan designation of N-[4-(3-amino-1H-indazol-4 yl)phenyl]-N’-(2-fluoro-5-methylphenyl) urea for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2016-02-10T13:30:00Z","reference_number":"EMA/COMP/524080/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307517-public-summary-positive-opinion-orphan-designation-n-4-3-amino-1h-indazol-4-ylphenyl-n-2-fluoro-5-methylphenyl-urea-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"20801","name":"EU/3/09/658: Public summary of positive opinion for orphan designation of tamibarotene for the treatment of acute promyelocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2013-07-31T02:00:00Z","reference_number":"EMA/COMP/361520/2009 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309658-public-summary-positive-opinion-orphan-designation-tamibarotene-treatment-acute-promyelocytic-leukaemia_en.pdf"},
    {"id":"20816","name":"EU/3/09/702: Public summary of opinion on orphan designation of beta-artemether / lumefantrine (powder for oral suspension) for the treatment of malaria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/COMP/767660/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309702-public-summary-opinion-orphan-designation-beta-artemether-lumefantrine-powder-oral-suspension-treatment-malaria_en.pdf"},
    {"id":"20891","name":"EU/3/06/365: Public summary of positive opinion for orphan designation of temsirolimus for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2018-01-22T18:45:00Z","reference_number":"EMEA/COMP/107472/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306365-public-summary-positive-opinion-orphan-designation-temsirolimus-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"20923","name":"EU/3/08/555: Public summary of positive opinion for orphan designation of vincristine sulphate liposomes for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2011-06-21T02:00:00Z","reference_number":"EMEA/COMP/449452/2008 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308555-public-summary-positive-opinion-orphan-designation-vincristine-sulphate-liposomes-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"20928","name":"EU/3/16/1633: Public summary of opinion on orphan designation: Fosbretabulin tromethamine for the treatment of gastro-entero-pancreatic neuroendocrine tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"EMA/COMP/172769/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161633-public-summary-opinion-orphan-designation-fosbretabulin-tromethamine-treatment-gastro-entero-pancreatic-neuroendocrine-tumours_en.pdf"},
    {"id":"20980","name":"EU/3/12/1062: Public summary of opinion on orphan designation: Chimeric monoclonal antibody against GD2 for the treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2012-12-12T01:00:00Z","reference_number":"EMA/COMP/663138/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121062-public-summary-opinion-orphan-designation-chimeric-monoclonal-antibody-against-gd2-treatment-neuroblastoma_en.pdf"},
    {"id":"21012","name":"EU/3/14/1358: Public summary of opinion on orphan designation: Recombinant human pentraxin-2 for the treatment of post-essential thrombocythaemia myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/COMP/660436/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141358-public-summary-opinion-orphan-designation-recombinant-human-pentraxin-2-treatment-post-essential-thrombocythaemia-myelofibrosis_en.pdf"},
    {"id":"21043","name":"EU/3/05/314: Public summary of positive opinion for orphan designation\n\nof (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol for the treatment of tuberculosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2014-04-01T17:10:00Z","reference_number":"EMA/COMP/247350/2005 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305314-public-summary-positive-opinion-orphan-designation-1r2s-6-bromo-alpha-2-dimethylaminoethyl-2-methoxy-alpha-1-naphthyl-beta-phenyl-3-quinolineethanol-treatment-tuberculosis_en.pdf"},
    {"id":"21048","name":"EU/3/07/442: Public summary of positive opinion for orphan designation of enzastraurin hydrochloride for the treatment of diffuse large B cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2023-09-12T16:21:00Z","reference_number":"EMEA/COMP/94131/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-07-442-public-summary-positive-opinion-orphan-designation-enzastraurin-hydrochloride-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"21055","name":"EU/3/15/1442: Public summary of opinion on orphan designation: Fibrinogen-coated albumin spheres for the treatment of Ebola virus disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2015-04-09T02:00:00Z","reference_number":"EMA/COMP/55779/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151442-public-summary-opinion-orphan-designation-fibrinogen-coated-albumin-spheres-treatment-ebola-virus-disease_en.pdf"},
    {"id":"21070","name":"EU/3/10/728: Public summary of opinion on orphan designation: Davunetide for the treatment of progressive supranuclear palsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2013-06-25T02:00:00Z","reference_number":"EMA/COMP/23524/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310728-public-summary-opinion-orphan-designation-davunetide-treatment-progressive-supranuclear-palsy_en.pdf"},
    {"id":"21100","name":"EU/3/09/722: Public summary of opinion on orphan designation of pixantrone dimaleate for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMA/COMP/814908/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309722-public-summary-opinion-orphan-designation-pixantrone-dimaleate-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"21158","name":"EU/3/04/189: Public summary of positive opinion for orphan designation of idebenone for the treatment of Friedreich’s ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-10T00:00:00Z","last_updated_date":"2011-04-12T01:00:00Z","reference_number":"EMEA/COMP/72/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304189-public-summary-positive-opinion-orphan-designation-idebenone-treatment-friedreichs-ataxia_en.pdf"},
    {"id":"21162","name":"EU/3/10/832: Public summary of opinion on orphan designation: Deferiprone for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-04T01:00:00Z","last_updated_date":"2011-03-04T01:00:00Z","reference_number":"EMA/COMP/740288/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310832-public-summary-opinion-orphan-designation-deferiprone-treatment-sickle-cell-disease_en.pdf"},
    {"id":"21223","name":"EU/3/12/1079 : Public summary of opinion on orphan designation: Artesunate for the treatment of malaria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-25T12:00:00Z","last_updated_date":"2013-01-25T12:00:00Z","reference_number":"EMA/COMP/732365/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121079-public-summary-opinion-orphan-designation-artesunate-treatment-malaria_en.pdf"},
    {"id":"21225","name":"EU/3/17/1970: Public summary of opinion on orphan designation: Sirolimus for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-14T01:00:00Z","last_updated_date":"2018-03-14T01:00:00Z","reference_number":"EMA/826628/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171970-public-summary-opinion-orphan-designation-sirolimus-treatment-sickle-cell-disease_en.pdf"},
    {"id":"21268","name":"EU/3/14/1361: Public summary of opinion on orphan designation: 1-(6-Benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T14:00:00Z","last_updated_date":"2020-12-14T14:00:00Z","reference_number":"EMA/COMP/646194/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141361-public-summary-opinion-orphan-designation-1-6-benzothiazolylsulfonyl-5-chloro-1h-indole-2-butanoic-acid-treatment-systemic-sclerosis_en.pdf"},
    {"id":"21276","name":"EU/3/07/478: Public summary of positive opinion for orphan designation of N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide for the treatment of Hodgkin's lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2022-05-10T02:00:00Z","reference_number":"EMEA/COMP/389996/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307478-public-summary-positive-opinion-orphan-designation-n-2-amino-phenyl-4-4-pyridin-3-yl-pyrimidin-2-ylamino-methyl-benzamide-treatment-hodgkins-lymphoma_en.pdf"},
    {"id":"21338","name":"EU/3/14/1261: Public summary of opinion on orphan designation: Caffeine citrate for the prevention of bronchopulmonary dysplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-06-05T02:00:00Z","last_updated_date":"2014-06-05T02:00:00Z","reference_number":"EMA/COMP/89532/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141261-public-summary-opinion-orphan-designation-caffeine-citrate-prevention-bronchopulmonary-dysplasia_en.pdf"},
    {"id":"21341","name":"EU/3/10/767: Public summary of opinion on orphan designation: 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene for the treat...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMA/COMP/360315/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310767-public-summary-opinion-orphan-designation-11-2-pyrrolidin-1-yl-ethoxy-1419-dioxa-5726-triaza-tetracyclo19311261812-heptacosa-125226358101227162123-decaene-treat_en.pdf"},
    {"id":"21351","name":"EU/3/07/439: Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class for the treatment of cryopirin-associated periodic syndromes (Familial Cold  Urticaria Syndrome (FCUS), Muckle-Wells Syndrome (MWS)...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-08T02:00:00Z","last_updated_date":"2015-02-12T01:00:00Z","reference_number":"EMEA/COMP/104059/2008 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307439-recombinant-human-monoclonal-antibody-human-il-1beta-igg1k-class-treatment-cryopirin-associated-periodic-syndromes-familial-cold-urticaria-syndrome-fcus-muckle-wells-syndrome-mws_en.pdf"},
    {"id":"21373","name":"EU/3/14/1362: Public summary of opinion on orphan designation: 1-(6-Benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T14:00:00Z","last_updated_date":"2015-01-15T14:00:00Z","reference_number":"EMA/COMP/646696/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141362-public-summary-opinion-orphan-designation-1-6-benzothiazolylsulfonyl-5-chloro-1h-indole-2-butanoic-acid-treatment-systemic-sclerosis_en.pdf"},
    {"id":"21397","name":"EU/3/12/1002: Public summary of opinion on orphan designation: Adenovirus-associated vector containing human Fas-c gene for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-04T17:00:00Z","last_updated_date":"2022-09-26T17:00:00Z","reference_number":"EMA/COMP/268035/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121002-public-summary-opinion-orphan-designation-adenovirus-associated-vector-containing-human-fas-c-gene-treatment-glioma_en.pdf"},
    {"id":"21418","name":"EU/3/10/773: Public summary of opinion on orphan designation: Allogeneic T cells encoding an exogenous TK gene for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2010-10-18T02:00:00Z","reference_number":"EMA/COMP/395841/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310773-public-summary-opinion-orphan-designation-allogeneic-t-cells-encoding-exogenous-tk-gene-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"21427","name":"EU/3/16/1671: Public summary of opinion on orphan designation: C2'-O-(2-Methoxyethyl) phosphorothioate antisense oligonucleotide targeting the growth hormone receptor for the treatment of acromegaly","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/380897/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161671-public-summary-opinion-orphan-designation-c2-o-2-methoxyethyl-phosphorothioate-antisense-oligonucleotide-targeting-growth-hormone-receptor-treatment-acromegaly_en.pdf"},
    {"id":"21461","name":"EU/3/12/998: Public summary of opinion on orphan designation: Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene for the treatment of Wiskott-Aldrich syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-04T17:00:00Z","last_updated_date":"2015-03-11T16:00:00Z","reference_number":"EMA/COMP/278945/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312998-public-summary-opinion-orphan-designation-autologous-cd34-cells-transfected-lentiviral-vector-containing-wiskott-aldrich-syndrome-protein-gene-treatment-wiskott-aldrich-syndrome_en.pdf"},
    {"id":"21468","name":"EU/3/13/1124: Public summary of opinion on orphan designation: 2-Hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick disease, type C","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-05-14T13:30:00Z","last_updated_date":"2015-03-25T12:30:00Z","reference_number":"EMA/COMP/189520/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131124-public-summary-opinion-orphan-designation-2-hydroxypropyl-i2-cyclodextrin-treatment-niemann-pick-disease-type-c_en.pdf"},
    {"id":"21492","name":"EU/3/16/1751: Public summary of positive opinion for orphan designation of fenretinide for the treatment of peripheral T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2022-01-19T01:00:00Z","reference_number":"EMA/622420/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161751-public-summary-positive-opinion-orphan-designation-fenretinide-treatment-peripheral-t-cell-lymphoma_en.pdf"},
    {"id":"21538","name":"EU/3/16/1804: Public summary of opinion on orphan designation: Pegylated recombinant human interleukin-10 for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/758032/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161804-public-summary-opinion-orphan-designation-pegylated-recombinant-human-interleukin-10-treatment-pancreatic-cancer_en.pdf"},
    {"id":"21547","name":"EU/3/12/988: Public summary of opinion on orphan designation: Halofuginone hydrobromide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T13:00:00Z","last_updated_date":"2015-03-23T12:00:00Z","reference_number":"EMA/COMP/203967/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312988-public-summary-opinion-orphan-designation-halofuginone-hydrobromide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"21580","name":"EU/3/04/226: Public summary of positive opinion for orphan designation: Recombinant human interleukin-21 for the treatment of renal-cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-10-01T02:00:00Z","last_updated_date":"2014-10-16T11:30:00Z","reference_number":"EMA/COMP/366/2004 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304226-public-summary-positive-opinion-orphan-designation-recombinant-human-interleukin-21-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"21632","name":"EU/3/16/1737: Public summary of positive opinion for orphan designation of (E)-(6-((N-methyl-((3-methylbenzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl phosphate, bis ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/623833/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161737-public-summary-positive-opinion-orphan-designation-e-6-n-methyl-3-methylbenzofuran-2-ylmethylamino-3-oxoprop-1-en-1-yl-2-oxo-34-dihydro-18-naphthyridin-12h-ylmethyl-phosphate-bis_en.pdf"},
    {"id":"21656","name":"EU/03/11/917: Public summary of opinion on orphan designation: Adeno-associated viral vector containing the human alpha-N-acetylglucosaminidase gene for the treatment of mucopolysaccharidosis type IIIB (Sanfilippo B synd...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2011-11-23T16:00:00Z","reference_number":"EMA/COMP/793344/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu0311917-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-containing-human-alpha-n-acetylglucosaminidase-gene-treatment-mucopolysaccharidosis-type-iiib-sanfilippo-b-synd_en.pdf"},
    {"id":"21664","name":"EU/3/14/1430: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human factor-VII gene for the treatment of congenital factor VII deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2015-03-06T12:00:00Z","reference_number":"EMA/COMP/10146/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141430-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-factor-vii-gene-treatment-congenital-factor-vii-deficiency_en.pdf"},
    {"id":"21668","name":"EU/3/17/1963: Public summary of opinion on orphan designation: Hydroxychloroquine sulphate for the treatment of LIPIN1 disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-13T01:00:00Z","last_updated_date":"2018-03-13T01:00:00Z","reference_number":"EMA/4249/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171963-public-summary-opinion-orphan-designation-hydroxychloroquine-sulphate-treatment-lipin1-disease_en.pdf"},
    {"id":"21676","name":"EU/3/14/1283: Public summary of opinion on orphan designation: Mixture of two adeno-associated viral vectors of serotye 8 containing the 5’-half sequence of human ABCA4 gene and the 3’-half sequence of human ABCA4 gene f...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-16T02:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMA/COMP/318161/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141283-public-summary-opinion-orphan-designation-mixture-two-adeno-associated-viral-vectors-serotye-8-containing-5-half-sequence-human-abca4-gene-and-3-half-sequence-human-abca4-gene-f_en.pdf"},
    {"id":"21704","name":"EU/03/14/1275: Public summary of opinion on orphan designation of aganirsen for the treatment of central retinal vein occlusion","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/COMP/256922/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu03141275-public-summary-opinion-orphan-designation-aganirsen-treatment-central-retinal-vein-occlusion_en.pdf"},
    {"id":"21736","name":"EU/3/17/1831: Public summary of opinion on orphan designation: 505 amino acid protein, corresponding to amino acids 2-506 of the wild-type human histidyl-tRNA synthetase for the treatment of limb-girdle muscular dystroph...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/85417/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171831-public-summary-opinion-orphan-designation-505-amino-acid-protein-corresponding-amino-acids-2-506-wild-type-human-histidyl-trna-synthetase-treatment-limb-girdle-muscular-dystroph_en.pdf"},
    {"id":"21740","name":"EU/3/07/512: Public summary of positive opinion for orphan designation\n\nof 17-(allylamino)-17-demethoxygeldanamycin hydroquinone hydrochloride\n\nfor the treatment of malignant gastrointestinal stromal tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2011-03-25T01:00:00Z","reference_number":"EMEA/COMP/473573/2007 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307512-public-summary-positive-opinion-orphan-designation-17-allylamino-17-demethoxygeldanamycin-hydroquinone-hydrochloride-treatment-malignant-gastrointestinal-stromal-tumours_en.pdf"},
    {"id":"21761","name":"EU/3/06/362: Public summary of positive opinion for orphan designation of\n\nhuman heterologous liver cells (for infusion) for the treatment of acute liver failure","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/96573/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306362-public-summary-positive-opinion-orphan-designation-human-heterologous-liver-cells-infusion-treatment-acute-liver-failure_en.pdf"},
    {"id":"21795","name":"EU/3/11/855: Public summary of positive opinion for orphan designation: Recombinant fusion protein linking human coagulation factor VIIa with human albumin for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"EMA/COMP/76909/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311855-public-summary-positive-opinion-orphan-designation-recombinant-fusion-protein-linking-human-coagulation-factor-viia-human-albumin-treatment-haemophilia_en.pdf"},
    {"id":"21806","name":"EU/3/12/1074 : Public summary of opinion on orphan designation: Alisertib for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic / disseminated)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-24T13:15:00Z","last_updated_date":"2017-02-07T17:44:00Z","reference_number":"EMA/COMP/743664/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121074-public-summary-opinion-orphan-designation-alisertib-treatment-peripheral-t-cell-lymphoma-nodal-other-extranodal-and-leukaemic-disseminated_en.pdf"},
    {"id":"21814","name":"EU/3/03/133: Public summary of positive opinion for orphan designation of icatibant acetate for treatment of angioedema","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-04-09T02:00:00Z","last_updated_date":"2013-09-24T01:00:00Z","reference_number":"EMEA/COMP/86/03 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303133-public-summary-positive-opinion-orphan-designation-icatibant-acetate-treatment-angioedema_en.pdf"},
    {"id":"21819","name":"EU/3/16/1613: Public summary of opinion on orphan designation: Tolfenamic acid for the treatment of progressive supranuclear palsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/COMP/75475/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161613-public-summary-opinion-orphan-designation-tolfenamic-acid-treatment-progressive-supranuclear-palsy_en.pdf"},
    {"id":"21822","name":"EU/3/16/1799: Public summary of opinion on orphan designation: Cabiralizumab for the treatment of tenosynovial giant cell tumour, localised and diffuse type","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2020-08-12T01:00:00Z","reference_number":"EMA/753362/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161799-public-summary-opinion-orphan-designation-cabiralizumab-treatment-tenosynovial-giant-cell-tumour-localised-and-diffuse-type_en.pdf"},
    {"id":"21826","name":"EU/3/16/1759: Public summary of positive opinion for orphan designation of recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter for the treatmen...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/614751/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161759-public-summary-positive-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-encoding-human-micro-dystrophin-gene-under-control-muscle-specific-promoter-treatmen_en.pdf"},
    {"id":"21831","name":"EU/3/06/394: Public summary of positive opinion for orphan designation of autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2012-06-14T02:00:00Z","reference_number":"EMEA/COMP/280125/2006 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306394-public-summary-positive-opinion-orphan-designation-autologous-tumor-derived-immunoglobulin-idiotype-coupled-keyhole-limpet-haemocyanin-treatment-follicular-lymphoma_en.pdf"},
    {"id":"21856","name":"EU/3/14/1293: Public summary of opinion on orphan designation: Recombinant monoclonal antibody to human serum amyloid P component for the treatment of AL amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T17:00:00Z","last_updated_date":"2019-07-09T12:00:00Z","reference_number":"EMA/COMP/360634/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141293-public-summary-opinion-orphan-designation-recombinant-monoclonal-antibody-human-serum-amyloid-p-component-treatment-al-amyloidosis_en.pdf"},
    {"id":"21879","name":"EU/3/10/763: Public summary of opinion on orphan designation of Dexamethasone (intravitreal implant) for the treatment of non-infectious uveitis affecting the posterior segment of the eye","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-11T01:31:00Z","last_updated_date":"2010-11-19T00:31:00Z","reference_number":"EMA/COMP/319872/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310763-public-summary-opinion-orphan-designation-dexamethasone-intravitreal-implant-treatment-non-infectious-uveitis-affecting-posterior-segment-eye_en.pdf"},
    {"id":"21901","name":"EU/3/17/1885: Public summary of opinion on orphan designation: Sildenafil for the treatment of congenital diaphragmatic hernia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T02:00:00Z","last_updated_date":"2017-07-17T02:00:00Z","reference_number":"EMA/336708/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171885-public-summary-opinion-orphan-designation-sildenafil-treatment-congenital-diaphragmatic-hernia_en.pdf"},
    {"id":"21912","name":"EU/3/12/1034: Public summary of opinion on orphan designation: Humanised monoclonal antibody against P-selectin for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-26T16:30:00Z","last_updated_date":"2012-09-26T16:30:00Z","reference_number":"EMA/COMP/516702/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121034-public-summary-opinion-orphan-designation-humanised-monoclonal-antibody-against-p-selectin-treatment-sickle-cell-disease_en.pdf"},
    {"id":"21938","name":"EU/3/17/1890: Public summary of opinion on orphan designation: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2017-08-14T16:54:00Z","last_updated_date":"2022-02-21T16:54:00Z","reference_number":"EMA/407154/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171890-public-summary-opinion-orphan-designation-autologous-cd4-and-cd8-t-cells-expressing-cd19-specific-chimeric-antigen-receptor-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"21990","name":"EU/3/00/007: Public summary of positive opinion for orphan designation of N-carbamyl-L-glutamic acid for the treatment of N-acetylglutamate synthetase (NAGS) deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T00:00:00Z","last_updated_date":"2014-07-25T17:00:00Z","reference_number":"EMEA/COMP/239830/2008 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300007-public-summary-positive-opinion-orphan-designation-n-carbamyl-l-glutamic-acid-treatment-n-acetylglutamate-synthetase-nags-deficiency_en.pdf"},
    {"id":"22011","name":"EU/3/17/1923: Public summary of opinion on orphan designation: Glasdegib maleate for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T15:45:00Z","last_updated_date":"2018-01-09T15:45:00Z","reference_number":"EMA/623187/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171923-public-summary-opinion-orphan-designation-glasdegib-maleate-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"22012","name":"EU/3/13/1168: Public summary of opinion on orphan designation: Ex-vivo-expanded autologous human corneal epithelium containing stem cells for the treatment of limbal-stem-cell deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-16T02:00:00Z","last_updated_date":"2013-08-16T02:00:00Z","reference_number":"EMA/COMP/417565/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131168-public-summary-opinion-orphan-designation-ex-vivo-expanded-autologous-human-corneal-epithelium-containing-stem-cells-treatment-limbal-stem-cell-deficiency_en.pdf"},
    {"id":"22034","name":"EU/3/12/1085 : Public summary of opinion on orphan designation: Voclosporin for the treatment of non-infectious uveitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-25T12:00:00Z","last_updated_date":"2013-01-25T12:00:00Z","reference_number":"EMA/COMP/728485/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121085-public-summary-opinion-orphan-designation-voclosporin-treatment-non-infectious-uveitis_en.pdf"},
    {"id":"22037","name":"EU/3/02/096: Public summary of positive opinion for orphan designation of nitisinone for the treatment of alkaptonuria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-06T00:00:00Z","last_updated_date":"2014-07-11T19:00:00Z","reference_number":"EMEA/COMP/140/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302096-public-summary-positive-opinion-orphan-designation-nitisinone-treatment-alkaptonuria_en.pdf"},
    {"id":"22040","name":"EU/3/11/865: Public summary of opinion on orphan designation: 9-cis-Retinyl acetate for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2012-01-04T01:00:00Z","reference_number":"EMA/COMP/167703/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311865-public-summary-opinion-orphan-designation-9-cis-retinyl-acetate-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"22051","name":"EU/3/09/716: Public summary of opinion on orphan designation of benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] for the treatment of chronic ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMA/COMP/804530/2009 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309716-public-summary-opinion-orphan-designation-benzamide-3-2-imidazo12-bpyridazin-3-ylethynyl-4-methyl-n-4-4-methyl-1-piperazinylmethyl-3-trifluoromethylphenyl-treatment-chronic_en.pdf"},
    {"id":"22052","name":"EU/3/12/962: Public summary of opinion on orphan designation: Chimeric monoclonal antibody against kappa myeloma antigen for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-06T18:00:00Z","last_updated_date":"2015-06-08T18:00:00Z","reference_number":"EMA/COMP/67144/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312962-public-summary-opinion-orphan-designation-chimeric-monoclonal-antibody-against-kappa-myeloma-antigen-treatment-multiple-myeloma_en.pdf"},
    {"id":"22064","name":"EU/3/14/1242: Public summary of opinion on orphan designation: 3-Chloro-4-fluorophenyl-[4-fluoro-4-{[(5-methylpyrimidin-2-ylmethyl) amino]methyl}piperidin-1-yl]methanone for the treatment of Rett syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-02T14:00:00Z","last_updated_date":"2014-04-02T14:00:00Z","reference_number":"EMA/COMP/29766/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141242-public-summary-opinion-orphan-designation-3-chloro-4-fluorophenyl-4-fluoro-4-5-methylpyrimidin-2-ylmethyl-aminomethylpiperidin-1-ylmethanone-treatment-rett-syndrome_en.pdf"},
    {"id":"22106","name":"EU/3/14/1256: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human GUCY2D gene for the treatment of Leber’s congenital amaurosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-07T02:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/COMP/97253/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141256-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-gucy2d-gene-treatment-lebers-congenital-amaurosis_en.pdf"},
    {"id":"22140","name":"EU/3/16/1724 : Public summary of opinion on orphan designation: Nintedanib for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161724-public-summary-opinion-orphan-designation-nintedanib-treatment-systemic-sclerosis_en.pdf"},
    {"id":"22144","name":"EU/3/07/494: Public summary of opinion on orphan designation ofLenalidomide for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMEA/COMP/439851/2007 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307494-public-summary-opinion-orphan-designation-oflenalidomide-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"22205","name":"EU/3/07/440: Public summary of positive opinion for orphan designation of recombinant adeno-associated viral vector containing human alpha-1 antitripsin gene for the treatment of congenital alpha-1 antitrypsin deficiency...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2011-04-08T01:00:00Z","reference_number":"EMEA/COMP/29331/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307440-public-summary-positive-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-containing-human-alpha-1-antitripsin-gene-treatment-congenital-alpha-1-antitrypsin-deficiency_en.pdf"},
    {"id":"22227","name":"EU/3/10/836: Public summary of opinion on orphan designation: Paquinimod for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2011-03-07T01:00:00Z","reference_number":"EMA/COMP/760844/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310836-public-summary-opinion-orphan-designation-paquinimod-treatment-systemic-sclerosis_en.pdf"},
    {"id":"22230","name":"EU/3/18/1989: Public summary of opinion on orphan designation: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide for the treatment of C3...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-08T02:00:00Z","last_updated_date":"2018-05-08T02:00:00Z","reference_number":"EMA/117486/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181989-public-summary-opinion-orphan-designation-2s4r-1-2-3-acetyl-5-2-methylpyrimidine-5-yl-1h-indazol-1-ylacetyl-n-6-bromopyridine-2-yl-4-fluoropyrrolidine-2-carboxamide-treatment-c3_en.pdf"},
    {"id":"22247","name":"EU/3/09/636: Public summary of positive opinion for orphan designation of dexamethasone phosphate (iontophoretic solution, ocular use) for the treatment of corneal graft rejection","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-09T02:00:00Z","last_updated_date":"2016-10-21T02:00:00Z","reference_number":"EMEA/COMP/226334/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309636-public-summary-positive-opinion-orphan-designation-dexamethasone-phosphate-iontophoretic-solution-ocular-use-treatment-corneal-graft-rejection_en.pdf"}    {"id":"22248","name":"EU/3/15/1462: Public summary of positive opinion for orphan designation of sodium 3-[(4aR,6R,7R,7aS)-7-hydroxy-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo [3,2-d][1,3,2] dioxaphosphinin-6-yl]-2-bromo-6-phenyl-5H...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/132966/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151462-public-summary-positive-opinion-orphan-designation-sodium-3-4ar6r7r7as-7-hydroxy-2-oxido-2-sulfanylidene-4a677a-tetrahydro-4h-furo-32-d132-dioxaphosphinin-6-yl-2-bromo-6-phenyl-5h_en.pdf"},
    {"id":"22249","name":"EU/3/16/1802: Public summary of opinion on orphan designation: Ivosidenib for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/741003/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161802-public-summary-opinion-orphan-designation-ivosidenib-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"22267","name":"EU/3/12/1082 : Public summary of opinion on orphan designation: Triheptanoin for the treatment of long-chain 3-hydroxyacyl-CoA-dehydrogenase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-25T12:00:00Z","last_updated_date":"2016-08-11T16:10:00Z","reference_number":"EMA/COMP/744105/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121082-public-summary-opinion-orphan-designation-triheptanoin-treatment-long-chain-3-hydroxyacyl-coa-dehydrogenase-deficiency_en.pdf"},
    {"id":"22281","name":"EU/3/13/1186: Public summary of opinion on orphan designation: Idelalisib for the treatment of extranodal marginal-zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-16T02:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/COMP/434309/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131186-public-summary-opinion-orphan-designation-idelalisib-treatment-extranodal-marginal-zone-lymphoma-mucosa-associated-lymphoid-tissue-malt-lymphoma_en.pdf"},
    {"id":"22311","name":"EU/3/03/172: Public summary of positive opinion for orphan designation of trientine dihydrochloride for the treatment of Wilson's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-04-26T02:00:00Z","last_updated_date":"2014-10-08T01:00:00Z","reference_number":"EMEA/COMP/1469/03 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303172-public-summary-positive-opinion-orphan-designation-trientine-dihydrochloride-treatment-wilsons-disease_en.pdf"},
    {"id":"22332","name":"EU/3/03/154: Public summary of positive opinion for orphan designation of hydroxyurea for the treatment of sickle cell syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2017-08-11T02:00:00Z","reference_number":"EMEA/COMP/1465/03 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303154-public-summary-positive-opinion-orphan-designation-hydroxyurea-treatment-sickle-cell-syndrome_en.pdf"},
    {"id":"22334","name":"EU/3/12/1070: Public summary of opinion on orphan designation: Recombinant human dyskerin for the treatment of dyskeratosis congenita","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2012-12-12T01:00:00Z","reference_number":"EMA/COMP/684469/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121070-public-summary-opinion-orphan-designation-recombinant-human-dyskerin-treatment-dyskeratosis-congenita_en.pdf"},
    {"id":"22343","name":"EU/3/09/648: Public summary of positive opinion for orphan designation of\n\nafamelanotide for the treatment of solar urticaria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2013-07-08T02:00:00Z","reference_number":"EMEA/COMP/386616/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309648-public-summary-positive-opinion-orphan-designation-afamelanotide-treatment-solar-urticaria_en.pdf"},
    {"id":"22353","name":"EU/3/15/1535: Public summary of opinion on orphan designation: Fibrinogen-coated albumin spheres for the treatment of acute radiation syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/508238/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151535-public-summary-opinion-orphan-designation-fibrinogen-coated-albumin-spheres-treatment-acute-radiation-syndrome_en.pdf"},
    {"id":"22356","name":"EU/3/08/531: Public summary of positive opinion for orphan designation of ascorbic acid for the treatment of Charcot-Marie-Tooth disease type 1A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2014-04-01T18:00:00Z","reference_number":"EMEA/COMP/265714/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308531-public-summary-positive-opinion-orphan-designation-ascorbic-acid-treatment-charcot-marie-tooth-disease-type-1a_en.pdf"},
    {"id":"22371","name":"EU/3/15/1450: Public summary of positive opinion for orphan designation of gallium (68Ga)-edotreotide for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/125762/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151450-public-summary-positive-opinion-orphan-designation-gallium-68ga-edotreotide-diagnosis-gastro-entero-pancreatic-neuroendocrine-tumours_en.pdf"},
    {"id":"22382","name":"EU/3/14/1328: Public summary of opinion on orphan designation: 4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2014-10-02T02:00:00Z","reference_number":"EMA/COMP/457064/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141328-public-summary-opinion-orphan-designation-4-2r3s4r5s-4-4-chloro-2-fluoro-phenyl-3-3-chloro-2-fluoro-phenyl-4-cyano-5-22-dimethyl-propyl-pyrrolidine-2-carbonyl-amino-3-methoxy-benzoic_en.pdf"},
    {"id":"22410","name":"Public summary of negative opinion for orphan designation of tramadol hydrochloride for the treatment of painful HIV-associated neuropathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/COMP/223605/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-tramadol-hydrochloride-treatment-painful-hiv-associated-neuropathy_en.pdf"},
    {"id":"22412","name":"EU/3/14/1250: Public summary of opinion on orphan designation: Phosphorothioate oligonucleotide targeted to transthyretin for the treatment of ATTR amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-06T02:00:00Z","last_updated_date":"2014-05-06T02:00:00Z","reference_number":"EMA/COMP/95948/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141250-public-summary-opinion-orphan-designation-phosphorothioate-oligonucleotide-targeted-transthyretin-treatment-attr-amyloidosis_en.pdf"},
    {"id":"22433","name":"EU/3/18/2007: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene for the treatment of glycogen storage disease type II (Pompe's dise...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T13:00:00Z","last_updated_date":"2018-05-17T13:00:00Z","reference_number":"EMA/184668/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182007-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-acid-alpha-glucosidase-gene-treatment-glycogen-storage-disease-type-ii-pompes-dise_en.pdf"},
    {"id":"22442","name":"EU/3/16/1718 : Public summary of opinion on orphan designation: Cannabidiol for the treatment of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161718-public-summary-opinion-orphan-designation-cannabidiol-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"22447","name":"(EU/3/10/770: Public summary of opinion on orphan designation: 1-[2-(Benzo[1,2,5]thiadiazol-5-ylamino)-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMA/COMP/396281/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310770-public-summary-opinion-orphan-designation-1-2-benzo125thiadiazol-5-ylamino-6-26-dichloro-phenyl-pyrido23-dpyrimidin-7-yl-3-tert-butyl-urea-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"22514","name":"EU/3/06/391: Public summary of positive opinion for orphan designation of amphotericin B (for inhalation use) for the prevention of pulmonary fungal infections in patients deemed at risk","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMEA/COMP/199044/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306391-public-summary-positive-opinion-orphan-designation-amphotericin-b-inhalation-use-prevention-pulmonary-fungal-infections-patients-deemed-risk_en.pdf"},
    {"id":"22556","name":"EU/3/16/1795: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human CNGA3 gene under the control of a cone arrestin promoter for the treatment of achromatopsia cau...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/746037/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161795-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-cnga3-gene-under-control-cone-arrestin-promoter-treatment-achromatopsia-cau_en.pdf"},
    {"id":"22583","name":"EU/3/08/605: Public summary of positive opinion for orphan designation of recombinant human monoclonal antibody to human Nogo-A protein of the IgG4/k class for the treatment of spinal cord injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2019-10-16T16:00:00Z","reference_number":"EMEA/COMP/623774/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308605-public-summary-positive-opinion-orphan-designation-recombinant-human-monoclonal-antibody-human-nogo-protein-igg4k-class-treatment-spinal-cord-injury_en.pdf"},
    {"id":"22584","name":"EU/3/17/1894: Public summary of opinion on orphan designation: recombinant human antibody directed against misfolded human superoxide dismutase 1 for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2017-09-13T11:28:00Z","last_updated_date":"2017-09-13T11:28:00Z","reference_number":"EMA/395085/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171894-public-summary-opinion-orphan-designation-recombinant-human-antibody-directed-against-misfolded-human-superoxide-dismutase-1-treatment-amyotrophic-lateral-sclerosis_en.pdf-0"},
    {"id":"22598","name":"EU/3/15/1590: Public summary of opinion on orphan designation: Recombinant human monoclonal IgG1 antibody against programmed death ligand-1 for the treatment of Merkel cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2019-10-15T01:00:00Z","reference_number":"EMA/COMP/778956/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151590-public-summary-opinion-orphan-designation-recombinant-human-monoclonal-igg1-antibody-against-programmed-death-ligand-1-treatment-merkel-cell-carcinoma_en.pdf"},
    {"id":"22611","name":"EU/3/04/234: Public summary of positive opinion for orphan designation of sitaxentan sodium for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T00:00:00Z","last_updated_date":"2016-09-30T12:00:00Z","reference_number":"EMEA/COMP/69492/04 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304234-public-summary-positive-opinion-orphan-designation-sitaxentan-sodium-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"22618","name":"EU/3/12/978: Public summary of opinion on orphan designation: Melatonin for the treatment of perinatal asphyxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-30T02:00:00Z","last_updated_date":"2012-04-30T02:00:00Z","reference_number":"EMA/COMP/142943/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312978-public-summary-opinion-orphan-designation-melatonin-treatment-perinatal-asphyxia_en.pdf"},
    {"id":"22622","name":"EU/3/16/1731 : Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against delta-aminolevulinic acid synthase 1 mRNA, covalently linked to a ligand containing three N...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-11T02:00:00Z","last_updated_date":"2016-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161731-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-delta-aminolevulinic-acid-synthase-1-mrna-covalently-linked-ligand-containing-three_en.pdf"},
    {"id":"22629","name":"EU/3/05/346: Public summary of positive opinion for orphan designation of E. Coli heat-shock protein 70 with bovine retinal S-antigen for the treatment of autoimmune uveitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-08-08T02:00:00Z","last_updated_date":"2006-08-08T02:00:00Z","reference_number":"EMEA/COMP/414021/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305346-public-summary-positive-opinion-orphan-designation-e-coli-heat-shock-protein-70-bovine-retinal-s-antigen-treatment-autoimmune-uveitis_en.pdf"},
    {"id":"22633","name":"EU/3/16/1618: Public summary of opinion on orphan designation: N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d]pyrimidin-4-amine for treatment of glioma for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/COMP/72380/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161618-public-summary-opinion-orphan-designation-n-4-methoxyphenyl-n26-trimethylfuro23-dpyrimidin-4-amine-treatment-glioma-treatment-glioma_en.pdf"},
    {"id":"22637","name":"EU/3/14/1305: Public summary of opinion on orphan designation: Humanised recombinant monoclonal antibody against epidermal growth factor receptor conjugated to maleimidocaproyl monomethylauristatin F for the treatment of...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T02:00:00Z","last_updated_date":"2019-10-15T02:00:00Z","reference_number":"EMA/COMP/363867/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141305-public-summary-opinion-orphan-designation-humanised-recombinant-monoclonal-antibody-against-epidermal-growth-factor-receptor-conjugated-maleimidocaproyl-monomethylauristatin-f-treatment_en.pdf"},
    {"id":"22664","name":"EU/3/08/579: Public summary of positive opinion for orphan designation of\n\nex vivo expanded autologous human corneal epithelium containing stem cells for the treatment of corneal lesions, with associated corneal (limbal)...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMEA/COMP/482413/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308579-public-summary-positive-opinion-orphan-designation-ex-vivo-expanded-autologous-human-corneal-epithelium-containing-stem-cells-treatment-corneal-lesions-associated-corneal-limbal_en.pdf"},
    {"id":"22668","name":"EU/3/10/774: Public summary of opinion on orphan designation: Allogeneic human dermal fibroblasts for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2012-02-09T12:00:00Z","reference_number":"EMA/COMP/360580/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310774-public-summary-opinion-orphan-designation-allogeneic-human-dermal-fibroblasts-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"22675","name":"EU/3/09/651: Public summary of positive opinion for orphan designation of\n\nciclosporin (eye drops, solution) for the treatment of atopic  keratoconjunctivitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2009-04-02T02:00:00Z","reference_number":"EMEA/COMP/386330/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309651-public-summary-positive-opinion-orphan-designation-ciclosporin-eye-drops-solution-treatment-atopic-keratoconjunctivitis_en.pdf"},
    {"id":"22680","name":"EU/3/14/1374: Public summary of opinion on orphan designation: (3S)-1-azabicyclo[2.2.2]oct-3-yl{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate for the treatment of Gaucher disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T14:00:00Z","last_updated_date":"2015-01-15T14:00:00Z","reference_number":"EMA/COMP/645261/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141374-public-summary-opinion-orphan-designation-3s-1-azabicyclo222oct-3-yl2-2-4-fluorophenyl-13-thiazol-4-ylpropan-2-ylcarbamate-treatment-gaucher-disease_en.pdf"},
    {"id":"22698","name":"EU/3/17/1888: Public summary of opinion on orphan designation: Tripotassium citrate monohydrate and potassium hydrogen carbonate for the treatment of distal renal tubular acidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T02:00:00Z","last_updated_date":"2017-07-17T02:00:00Z","reference_number":"EMA/333697/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171888-public-summary-opinion-orphan-designation-tripotassium-citrate-monohydrate-and-potassium-hydrogen-carbonate-treatment-distal-renal-tubular-acidosis_en.pdf"},
    {"id":"22705","name":"EU/3/15/1497: Public summary of opinion on orphan designation: 5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride for the treatment of Huntington’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"EMA/COMP/276402/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151497-public-summary-opinion-orphan-designation-57-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline-hydrochloride-treatment-huntingtons-disease_en.pdf"},
    {"id":"22739","name":"EU/3/18/1975: Public summary of opinion on orphan designation: Adenovirus-associated viral vector serotype 8 containing the human RPGR gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/56962/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181975-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-8-containing-human-rpgr-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"22749","name":"EU/3/13/1177: Public summary of opinion on orphan designation: Chimaeric monoclonal antibody against claudin-18 splice variant 2 for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-13T02:00:00Z","last_updated_date":"2013-09-13T02:00:00Z","reference_number":"EMA/COMP/438204/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131177-public-summary-opinion-orphan-designation-chimaeric-monoclonal-antibody-against-claudin-18-splice-variant-2-treatment-pancreatic-cancer_en.pdf"},
    {"id":"22759","name":"EU/3/11/852: Public summary of positive opinion for orphan designation:  Human anthrax monoclonal antibody for the treatment of inhalation anthrax disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2016-08-11T02:00:00Z","reference_number":"EMA/COMP/65174/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311852-public-summary-positive-opinion-orphan-designation-human-anthrax-monoclonal-antibody-treatment-inhalation-anthrax-disease_en.pdf"},
    {"id":"22784","name":"EU/3/01/048: Public summary of positive opinion for orphan designation of ziconotide (intraspinal use) for the treatment of chronic pain requiring intraspinal analgesia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMEA/COMP/252/04 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301048-public-summary-positive-opinion-orphan-designation-ziconotide-intraspinal-use-treatment-chronic-pain-requiring-intraspinal-analgesia_en.pdf"},
    {"id":"22797","name":"EU/3/14/1341: Public summary of opinion on orphan designation: Cysteamine hydrochloride for the treatment of cystinosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/552795/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141341-public-summary-opinion-orphan-designation-cysteamine-hydrochloride-treatment-cystinosis_en.pdf"},
    {"id":"22831","name":"EU/3/04/253: Public summary of positive opinion for orphan designation of Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-06T00:00:00Z","last_updated_date":"2009-11-19T00:00:00Z","reference_number":"EMEA/COMP/152720/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304253-public-summary-positive-opinion-orphan-designation-val-leu-gln-glu-leu-asn-val-thr-val-pr1-nanopeptide-sequence-169-177-proteinase-3-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"22838","name":"EU/3/18/2039: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene for the treatment of mucopolysaccharidosis type I","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-22T11:49:00Z","last_updated_date":"2018-08-22T11:49:00Z","reference_number":"EMA/373289/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182039-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-serotype-9-containing-human-iduronidase-gene-treatment-mucopolysaccharidosis-type-i_en.pdf"},
    {"id":"22849","name":"EU/3/06/419: Public summary of positive opinion for orphan designation of paclitaxel (liposomal) for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2009-04-02T02:00:00Z","reference_number":"EMEA/COMP/177295/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306419-public-summary-positive-opinion-orphan-designation-paclitaxel-liposomal-treatment-pancreatic-cancer_en.pdf"},
    {"id":"22856","name":"EU/3/02/119: Public summary of positive opinion for orphan designation of iodine (131I) anti-nucleohistone H1 chimeric biotinylated monoclonal antibody for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-05-26T02:00:00Z","last_updated_date":"2016-10-20T02:00:00Z","reference_number":"EMEA/COMP/2410/02/Rev 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302119-public-summary-positive-opinion-orphan-designation-iodine-131i-anti-nucleohistone-h1-chimeric-biotinylated-monoclonal-antibody-treatment-glioma_en.pdf"},
    {"id":"22861","name":"EU/3/14/1342: Public summary of opinion on orphan designation: Glucagon for the treatment of congenital hyperinsulinism","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/546576/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141342-public-summary-opinion-orphan-designation-glucagon-treatment-congenital-hyperinsulinism_en.pdf"},
    {"id":"22895","name":"EU/3/16/1816: Public summary of opinion on orphan designation: Genetically modified adeno-associated viral vector serotype 9 expressing shRNA as well as a codon-optimised shRNA-insensitive wildtype PABPN1 for the treatme...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/4674/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161816-public-summary-opinion-orphan-designation-genetically-modified-adeno-associated-viral-vector-serotype-9-expressing-shrna-well-codon-optimised-shrna-insensitive-wildtype-pabpn1-treatme_en.pdf"},
    {"id":"22906","name":"EU/3/12/1076: Public summary of opinion on orphan designation: Allopurinol sodium for the treatment of perinatal asphyxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-21T01:00:00Z","last_updated_date":"2014-10-01T02:00:00Z","reference_number":"EMA/COMP/721436/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121076-public-summary-opinion-orphan-designation-allopurinol-sodium-treatment-perinatal-asphyxia_en.pdf"},
    {"id":"22908","name":"EU/3/15/1439: Public summary of opinion on orphan designation: Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2015-04-09T02:00:00Z","reference_number":"EMA/COMP/55787/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151439-public-summary-opinion-orphan-designation-allogeneic-cd4-and-cd8-t-lymphocytes-ex-vivo-incubated-synthetic-peptides-viral-antigens-cytomegalovirus-adenovirus-and-epstein-barr-virus_en.pdf"},
    {"id":"22928","name":"EU/3/11/885: Public summary of opinion on orphan designation: Mixture of seven synthetic fragments consisting of p21 RAS peptides for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2011-08-16T02:00:00Z","reference_number":"EMA/COMP/404700/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311885-public-summary-opinion-orphan-designation-mixture-seven-synthetic-fragments-consisting-p21-ras-peptides-treatment-pancreatic-cancer_en.pdf"},
    {"id":"22937","name":"EU/3/04/205: Public summary of positive opinion for orphan designation of suberoylanilide hydroxamic acid for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-11T02:00:00Z","last_updated_date":"2013-03-12T12:30:00Z","reference_number":"EMA/COMP/372/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304205-public-summary-positive-opinion-orphan-designation-suberoylanilide-hydroxamic-acid-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"22942","name":"EU/3/16/1654: Public summary of opinion on orphan designation: S-acetyl-(S)-4'-phosphopantetheine, calcium salt for the treatment of pantothenate-kinase-associated neurodegeneration","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-31T02:00:00Z","last_updated_date":"2016-05-31T02:00:00Z","reference_number":"EMA/COMP/240716/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161654-public-summary-opinion-orphan-designation-s-acetyl-s-4-phosphopantetheine-calcium-salt-treatment-pantothenate-kinase-associated-neurodegeneration_en.pdf"},
    {"id":"22955","name":"EU/3/09/656: Public summary of positive opinion for orphan designation of recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2011-05-31T02:00:00Z","reference_number":"EMEA/COMP/395524/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309656-public-summary-positive-opinion-orphan-designation-recombinant-histidine-tagged-idiotype-immunoglobulin-fab-fragment-clonal-b-cell-receptors-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"22979","name":"EU/3/15/1530: Public summary of opinion on orphan designation: Beloranib for the treatment of craniopharyngioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"EMA/COMP/422821/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151530-public-summary-opinion-orphan-designation-beloranib-treatment-craniopharyngioma_en.pdf"},
    {"id":"22995","name":"EU/3/14/1247: Public summary of opinion on orphan designation: Autologous dendritic cells pulsed with tumour antigen-derived synthetic peptides (MAGE-1, HER-2, AIM-2, TRP-2, gp-100, and interleukin-13 receptor alpha) for...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-02T19:15:00Z","last_updated_date":"2014-04-02T19:15:00Z","reference_number":"EMA/COMP/22964/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141247-public-summary-opinion-orphan-designation-autologous-dendritic-cells-pulsed-tumour-antigen-derived-synthetic-peptides-mage-1-her-2-aim-2-trp-2-gp-100-and-interleukin-13-receptor-alpha_en.pdf"},
    {"id":"22996","name":"EU/3/00/006: Public summary of positive opinion for orphan designation\n\nof 1,5-(butylimino)-1,5-dideoxy, D-glucitol for the treatment of Gaucher disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2013-02-27T01:00:00Z","reference_number":"EMA/COMP/239490/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300006-public-summary-positive-opinion-orphan-designation-15-butylimino-15-dideoxy-d-glucitol-treatment-gaucher-disease_en.pdf"},
    {"id":"23005","name":"EU/3/11/942: Public summary of positive opinion for orphan designation: Liposomal combination of cytarabine and daunorubicin for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2014-10-08T16:00:00Z","reference_number":"EMA/COMP/911703/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311942-public-summary-positive-opinion-orphan-designation-liposomal-combination-cytarabine-and-daunorubicin-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"23025","name":"EU/3/13/1218: Public summary of opinion on orphan designation: Recombinant human type I pancreatic elastase for the prevention of arteriovenous access dysfunction in haemodialysis patients","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-23T01:00:00Z","last_updated_date":"2019-07-09T11:00:00Z","reference_number":"EMA/COMP/708390/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131218-public-summary-opinion-orphan-designation-recombinant-human-type-i-pancreatic-elastase-prevention-arteriovenous-access-dysfunction-haemodialysis-patients_en.pdf"},
    {"id":"23042","name":"EU/3/18/2016: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 9 containing the human CLN1 gene for the treatment of neuronal ceroid lipofuscinosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T17:07:00Z","last_updated_date":"2018-07-23T17:07:00Z","reference_number":"EMA/270942/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182016-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-containing-human-cln1-gene-treatment-neuronal-ceroid-lipofuscinosis_en.pdf"},
    {"id":"23052","name":"EU/3/01/074: Public summary of positive opinion for orphan designation of halofuginone hydrobromide for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2009-06-15T02:00:00Z","reference_number":"EMEA/COMP/271/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301074-public-summary-positive-opinion-orphan-designation-halofuginone-hydrobromide-treatment-systemic-sclerosis_en.pdf"},
    {"id":"23105","name":"EU/3/13/1202: Public summary of opinion on orphan designation: Tivantinib for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2018-01-23T01:00:00Z","reference_number":"EMA/COMP/630515/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131202-public-summary-opinion-orphan-designation-tivantinib-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"23109","name":"EU/3/17/1921 : Public summary of opinion on orphan designation : Cannabidivarin for the treatment of Rett syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T15:38:00Z","last_updated_date":"2018-01-08T15:38:00Z","reference_number":"EMA/632070/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171921-public-summary-opinion-orphan-designation-cannabidivarin-treatment-rett-syndrome_en.pdf"},
    {"id":"23112","name":"EU/3/13/1221: Public summary of opinion on orphan designation: Humanised monoclonal modified IgG4 antibody with bispecific structure targeting factors IX, IXa, X and Xa for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-23T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMA/COMP/701408/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131221-public-summary-opinion-orphan-designation-humanised-monoclonal-modified-igg4-antibody-bispecific-structure-targeting-factors-ix-ixa-x-and-xa-treatment-haemophilia_en.pdf"},
    {"id":"23128","name":"EU/3/14/1339: Public summary of opinion on orphan designation: Cannabidiol for the treatment of Dravet syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/557465/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141339-public-summary-opinion-orphan-designation-cannabidiol-treatment-dravet-syndrome_en.pdf"},
    {"id":"23160","name":"EU/3/12/1028: Public summary of opinion on orphan designation: (2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acet...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-08-30T18:40:00Z","last_updated_date":"2012-08-30T18:40:00Z","reference_number":"EMA/COMP/426291/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121028-public-summary-opinion-orphan-designation-2s-2-2r-2-33-dibutyl-7-methylthio-11-dioxido-5-phenyl-2345-tetrahydro-125-benzothiadiazepin-8-yloxyacetylamino-2-4-hydroxyphenylacet_en.pdf"},
    {"id":"23221","name":"EU/3/16/1812: Public summary of opinion on orphan designation: Antroquinonol for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"EMA/15467/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161812-public-summary-opinion-orphan-designation-antroquinonol-treatment-pancreatic-cancer_en.pdf"},
    {"id":"23231","name":"EU/3/13/1224: Public summary of opinion on orphan designation: Sodium nitrite for the treatment of aneurysmal subarachnoid haemorrhage","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"EMA/COMP/13642/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131224-public-summary-opinion-orphan-designation-sodium-nitrite-treatment-aneurysmal-subarachnoid-haemorrhage_en.pdf"},
    {"id":"23246","name":"EU/3/10/792: Public summary of opinion on orphan designation: Maytansinoid-conjugated humanised monoclonal antibody against CD56 for the treatment of small-cell lung cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2015-03-06T13:30:00Z","reference_number":"EMA/COMP/477962/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310792-public-summary-opinion-orphan-designation-maytansinoid-conjugated-humanised-monoclonal-antibody-against-cd56-treatment-small-cell-lung-cancer_en.pdf"},
    {"id":"23258","name":"EU/3/16/1636: Public summary of opinion on orphan designation: Sindbis virus envelope pseudotyped lentiviral vector encoding New York oesophageal squamous cell carcinoma-1 protein for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2019-10-15T02:00:00Z","reference_number":"EMA/COMP/159761/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161636-public-summary-opinion-orphan-designation-sindbis-virus-envelope-pseudotyped-lentiviral-vector-encoding-new-york-oesophageal-squamous-cell-carcinoma-1-protein-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"23285","name":"EU/3/09/719: Public summary of opinion on orphan designation of givinostat for the treatment of polycythaemia vera","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:00:00Z","last_updated_date":"2010-03-03T01:00:00Z","reference_number":"EU/3/09/719","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309719-public-summary-opinion-orphan-designation-givinostat-treatment-polycythaemia-vera_en.pdf"},
    {"id":"23290","name":"EU/3/07/454: Public summary of positive opinion for orphan designation of recombinant adeno-associated viral vector containing human acid alpha-glucosidase-gene for the treatment of glycogen storage disease type II (Pomp...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T00:00:00Z","last_updated_date":"2011-04-08T01:00:00Z","reference_number":"EMA/COMP/243140/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307454-public-summary-positive-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-containing-human-acid-alpha-glucosidase-gene-treatment-glycogen-storage-disease-type-ii-pomp_en.pdf"},
    {"id":"23315","name":"EU/3/11/862: Public summary of opinion on orphan designation: Apomorphine hydrochloride for the treatment of moderate and severe traumatic brain injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/COMP/158697/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311862-public-summary-opinion-orphan-designation-apomorphine-hydrochloride-treatment-moderate-and-severe-traumatic-brain-injury_en.pdf"},
    {"id":"23330","name":"EU/3/16/1805: Public summary of opinion on orphan designation: Propranolol for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/754433/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161805-public-summary-opinion-orphan-designation-propranolol-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"23370","name":"EU/3/04/202: Public summary of positive opinion for orphan designation of\n\nHLA-A2 restricted CD8 T-cell line expressing MART-1 T-cell receptor for the treatment of MART-1 positive malignant melanoma in HLA-A2 positive pa...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2009-06-15T02:00:00Z","reference_number":"EMEA/COMP/297/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304202-public-summary-positive-opinion-orphan-designation-hla-a2-restricted-cd8-t-cell-line-expressing-mart-1-t-cell-receptor-treatment-mart-1-positive-malignant-melanoma-hla-a2-positive-pa_en.pdf"},
    {"id":"23398","name":"EU/3/09/695: Public summary of positive opinion for orphan designation of8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one mono-hydrochloride for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:00Z","last_updated_date":"2009-12-07T00:09:00Z","reference_number":"EMA/COMP/662971/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309695-public-summary-positive-opinion-orphan-designation-of8-4-1-aminocyclobutylphenyl-9-phenyl-124-triazolo34-f16naphthyridin-32h-one-mono-hydrochloride-treatment-ovarian-cancer_en.pdf"},
    {"id":"23404","name":"EU/3/03/141: Public summary of positive opinion for orphan designation \n\nof 2-chloro-9-[2-deoxy-2’-fluoro-àŸ-D-arabinofuranosyl]adenine\n\nfor the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMEA/COMP/792/03 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303141-public-summary-positive-opinion-orphan-designation-2-chloro-9-2-deoxy-2-fluoro-ay-d-arabinofuranosyladenine-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"23411","name":"EU/3/05/306: Public summary of positive opinion for imatinib mesilate for the treatment of mastocytosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T01:00:00Z","last_updated_date":"2015-02-10T01:00:00Z","reference_number":"EMEA/COMP/244165/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305306-public-summary-positive-opinion-imatinib-mesilate-treatment-mastocytosis_en.pdf"},
    {"id":"23434","name":"EU/3/15/1517: Public summary of opinion on orphan designation: 2-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]na...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T14:00:00Z","last_updated_date":"2015-08-18T14:00:00Z","reference_number":"EMA/COMP/432053/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151517-public-summary-opinion-orphan-designation-2-3-4-3-aminopropylaminobutylaminopropylamino-n-5s5as8ar9r-9-4-hydroxy-35-dimethoxyphenyl-8-oxo-55a688a9-hexahydrofuro3467na_en.pdf"},
    {"id":"23440","name":"EU/3/15/1543: Public summary of opinion on orphan designation: (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride for the treatment of mitochondrial encephalomyopathy, lactic acid...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/508508/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151543-public-summary-opinion-orphan-designation-s-6-hydroxy-2578-tetramethyl-n-r-piperidin-3-ylchroman-2-carboxamide-hydrochloride-treatment-mitochondrial-encephalomyopathy-lactic-acid_en.pdf"},
    {"id":"23441","name":"EU/3/12/1031: Public summary of opinion on orphan designation: Ketoconazole for the treatment of Cushing’s syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-26T16:30:00Z","last_updated_date":"2012-09-26T16:30:00Z","reference_number":"EMA/COMP/528385/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121031-public-summary-opinion-orphan-designation-ketoconazole-treatment-cushings-syndrome_en.pdf"},
    {"id":"23454","name":"EU/3/13/1127: Public summary of opinion on orphan designation: Inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukaemia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2013-06-25T19:00:00Z","reference_number":"EMA/COMP/268991/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131127-public-summary-opinion-orphan-designation-inotuzumab-ozogamicin-treatment-b-cell-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"23490","name":"EU/3/14/1405: Public summary of opinion on orphan designation: Autologous collagen type II-specific regulatory T cells for the treatment ofnon-infectious uveitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2019-11-19T01:00:00Z","reference_number":"EMA/COMP/736522/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141405-public-summary-opinion-orphan-designation-autologous-collagen-type-ii-specific-regulatory-t-cells-treatment-ofnon-infectious-uveitis_en.pdf"},
    {"id":"23547","name":"EU/3/15/1435: Public summary of opinion on orphan designation: Nitroglycerin for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2015-04-08T02:00:00Z","reference_number":"EMA/COMP/50020/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151435-public-summary-opinion-orphan-designation-nitroglycerin-treatment-systemic-sclerosis_en.pdf"},
    {"id":"23552","name":"EU/3/07/496: Public summary of positive opinion for orphan designation of mercaptopurine (oral liquid) for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2014-01-22T01:00:00Z","reference_number":"EMEA/COMP/469508/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307496-public-summary-positive-opinion-orphan-designation-mercaptopurine-oral-liquid-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"23557","name":"EU/3/10/83: Public summary of opinion on orphan designation: Autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin for the treatment of mantle cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-04T01:00:00Z","last_updated_date":"2011-11-18T01:00:00Z","reference_number":"EMA/COMP/758068/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu31083-public-summary-opinion-orphan-designation-autologous-tumour-derived-immunoglobulin-idiotype-coupled-keyhole-limpet-hemocyanin-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"23565","name":"EU/3/07/485: Public summary of positive opinion for orphan designation of alvocidib for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMA/COMP/36797/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307485-public-summary-positive-opinion-orphan-designation-alvocidib-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"23572","name":"EU/3/14/1392: Public summary of positive opinion for orphan designation: 5-bromo-N-(prop-2-yn-1-yl)-2-(1H-1,2,4-triazol-1-yl)pyrimidine-4,6-diamine for the treatment of Huntington’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-02-26T18:00:00Z","reference_number":"EMA/COMP/724036/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141392-public-summary-positive-opinion-orphan-designation-5-bromo-n-prop-2-yn-1-yl-2-1h-124-triazol-1-ylpyrimidine-46-diamine-treatment-huntingtons-disease_en.pdf"},
    {"id":"23629","name":"EU/3/09/631: Public summary of positive opinion for orphan designation of talampanel for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-12T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMEA/COMP/160717/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309631-public-summary-positive-opinion-orphan-designation-talampanel-treatment-glioma_en.pdf"},
    {"id":"23637","name":"EU/3/16/1784: Public summary of positive opinion for orphan designation of particles comprised of methacrylic acid based co-polymer, cross-linked with a bi-functional cross-linker, purified to bind L-phenylalanine and L-...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T15:43:00Z","last_updated_date":"2016-12-13T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161784-public-summary-positive-opinion-orphan-designation-particles-comprised-methacrylic-acid-based-co-polymer-cross-linked-bi-functional-cross-linker-purified-bind-l-phenylalanine-and-l_en.pdf"},
    {"id":"23672","name":"EU/3/09/667: Public summary of positive opinion for orphan designation of\n\nexpanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue for the treatment of anal fistula","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2013-06-25T02:00:00Z","reference_number":"EMA/COMP/472601/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309667-public-summary-positive-opinion-orphan-designation-expanded-human-allogeneic-mesenchymal-adult-stem-cells-extracted-adipose-tissue-treatment-anal-fistula_en.pdf"},
    {"id":"23675","name":"EU/3/18/1998: Public summary of opinion on orphan designation: Patidegib for the treatment of naevoid basal-cell carcinoma syndrome (Gorlin\n\nsyndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-08T02:00:00Z","last_updated_date":"2018-05-08T02:00:00Z","reference_number":"EMA/116423/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181998-public-summary-opinion-orphan-designation-patidegib-treatment-naevoid-basal-cell-carcinoma-syndrome-gorlin-syndrome_en.pdf"},
    {"id":"23691","name":"EU/3/17/1934: Public summary of opinion on orphan designation: (R)-troloxamide quinone for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-15T01:00:00Z","last_updated_date":"2018-01-15T01:00:00Z","reference_number":"EMA/693845/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171934-public-summary-opinion-orphan-designation-r-troloxamide-quinone-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"23704","name":"EU/3/05/318: Public summary of positive opinion for orphan designation of recombinant modified vaccinia virus Ankara expressing tuberculosis antigen 85A for the prevention of tuberculosis disease in Bacille-Calmette-Guà©...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"EMA/COMP/317369/2005 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305318-public-summary-positive-opinion-orphan-designation-recombinant-modified-vaccinia-virus-ankara-expressing-tuberculosis-antigen-85a-prevention-tuberculosis-disease-bacille-calmette-guac_en.pdf"},
    {"id":"23717","name":"EU/3/01/033: Public summary of positive opinion for orphan designation of ranpirnase for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T00:00:00Z","last_updated_date":"2010-11-19T00:00:00Z","reference_number":"EMA/COMP/1290/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301033-public-summary-positive-opinion-orphan-designation-ranpirnase-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"23735","name":"EU/3/01/029: Public summary of positive opinion for orphan designation of ribavirin for the treatment of adenovirus infection in immunocompromised patients","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T00:00:00Z","last_updated_date":"2011-05-07T01:00:00Z","reference_number":"EMEA/COMP/1278/03draft","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301029-public-summary-positive-opinion-orphan-designation-ribavirin-treatment-adenovirus-infection-immunocompromised-patients_en.pdf"},
    {"id":"23756","name":"EU/3/16/1661: Public summary of opinion on orphan designation: Fc- and CDR-modified humanised monoclonal antibody against C5 for the treatment of paroxysmal nocturnal haemoglobinuria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"EMA/COMP/306911/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161661-public-summary-opinion-orphan-designation-fc-and-cdr-modified-humanised-monoclonal-antibody-against-c5-treatment-paroxysmal-nocturnal-haemoglobinuria_en.pdf"},
    {"id":"23802","name":"EU/3/15/1446: Public summary of opinion on orphan designation: N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulphate salt for the treatment of progressive supranuclear palsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2015-04-09T02:00:00Z","reference_number":"EMA/COMP/43938/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151446-public-summary-opinion-orphan-designation-n-3-4-3-diisobutylaminopropylpiperazin-1-ylpropyl-1h-benzodimidazol-2-amine-disulphate-salt-treatment-progressive-supranuclear-palsy_en.pdf"},
    {"id":"23842","name":"EU/3/17/1889: Public summary of opinion on orphan designation: (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine for the treatment of ...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2017-08-14T16:54:00Z","last_updated_date":"2017-08-14T16:54:00Z","reference_number":"EMA/407025/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171889-public-summary-opinion-orphan-designation-s-1-4-fluorophenyl-1-2-4-6-1-methyl-1h-pyrazol-4-ylpyrrolo21-f124triazin-4-ylpiperazin-ylpyrimidin-5-ylethan-1-amine-treatment_en.pdf"},
    {"id":"23863","name":"EU/3/05/273: Public summary of positive opinion for orphan designation of ambrisentan for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2018-07-18T02:00:00Z","reference_number":"EMEA/COMP/130938/2005 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305273-public-summary-positive-opinion-orphan-designation-ambrisentan-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"23891","name":"EU/3/13/1136: Public summary of opinion on orphan designation: 5-[1-(2,6-dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride for the treatment of 5q spinal muscular atrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2013-10-07T18:00:00Z","reference_number":"EMA/COMP/276580/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131136-public-summary-opinion-orphan-designation-5-1-26-dichlorobenzylpiperidin-4-ylmethoxyquinazoline-24-diamine-dihydrochloride-treatment-5q-spinal-muscular-atrophy_en.pdf"},
    {"id":"23902","name":"EU/3/16/1749: Public summary of positive opinion for orphan designation of crenolanib besylate for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/628439/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161749-public-summary-positive-opinion-orphan-designation-crenolanib-besylate-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"23938","name":"EU/3/04/200: (2-aminoethyl) carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-bezyloxy benzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclop...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-09-03T02:00:00Z","last_updated_date":"2017-08-16T12:00:00Z","reference_number":"EMA/COMP/44039/2004 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304200-2-aminoethyl-carbamic-acid-2r5s8s11s14r17s19as-11-4-aminobutyl-5-benzyl-8-4-bezyloxy-benzyl-14-1h-indol-3-ylmethyl-4710131619-hexaoxo-17-phenyloctadecahydro-3a69121518-hexaazacyclop_en.pdf"}    {"id":"23955","name":"EU/3/15/1449: Public summary of opinion on orphan designation: Myriocin for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2015-04-09T02:00:00Z","reference_number":"EMA/COMP/43665/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151449-public-summary-opinion-orphan-designation-myriocin-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"23971","name":"EU/3/15/1560: Public summary of opinion on orphan designation: N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-18T11:00:00Z","last_updated_date":"2021-09-02T11:00:00Z","reference_number":"EMA/COMP/603544/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151560-public-summary-opinion-orphan-designation-n-2-4z7z10z13z16z19z-docosa-4710131619-hexaenamidoethyl-2-hydroxybenzamide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"23978","name":"EU/3/14/1390: Public summary of positive opinion for orphan designation: Bevacizumab for the treatment of hereditary haemorrhagic telangiectasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-02-26T18:00:00Z","reference_number":"EMA/COMP/736554/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141390-public-summary-positive-opinion-orphan-designation-bevacizumab-treatment-hereditary-haemorrhagic-telangiectasia_en.pdf"},
    {"id":"24046","name":"EU/3/07/466: Public summary of positive opinion for orphan designation of L-threo-3,4-dihydroxyphenylserine for the treatment of orthostatic hypotension in patients with multiple system atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-08-28T02:00:00Z","last_updated_date":"2022-01-28T02:00:00Z","reference_number":"EMEA/COMP/364826/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307466-public-summary-positive-opinion-orphan-designation-l-threo-34-dihydroxyphenylserine-treatment-orthostatic-hypotension-patients-multiple-system-atrophy_en.pdf"},
    {"id":"24063","name":"EU/3/05/283: Public summary of positive opinion for orphan designation of recombinant megakaryopoiesis-stimulating protein for the treatment of idiopathic thrombocytopenic purpura","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-06-29T02:00:00Z","last_updated_date":"2019-02-20T12:00:00Z","reference_number":"EMEA/COMP/122763/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305283-public-summary-positive-opinion-orphan-designation-recombinant-megakaryopoiesis-stimulating-protein-treatment-idiopathic-thrombocytopenic-purpura_en.pdf"},
    {"id":"24100","name":"EU/3/18/1995: Public summary of opinion on orphan designation: Larotrectinib for the treatment of salivary gland cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-08T02:00:00Z","last_updated_date":"2019-10-24T02:00:00Z","reference_number":"EMA/126933/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181995-public-summary-opinion-orphan-designation-larotrectinib-treatment-salivary-gland-cancer_en.pdf"},
    {"id":"24172","name":"EU/3/08/598: Public summary of positive opinion for orphan designation of\n\nexon 44 specific phosphorothioate oligonucleotide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2013-10-17T14:00:00Z","reference_number":"EMEA/COMP/624299/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308598-public-summary-positive-opinion-orphan-designation-exon-44-specific-phosphorothioate-oligonucleotide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"24175","name":"EU/3/14/1396: Public summary of opinion on orphan designation: Adenovirus serotype 5 containing partial E1A deletion and an integrin-binding domain for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T01:00:00Z","last_updated_date":"2015-02-26T01:00:00Z","reference_number":"EMA/COMP/728498/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141396-public-summary-opinion-orphan-designation-adenovirus-serotype-5-containing-partial-e1a-deletion-and-integrin-binding-domain-treatment-glioma_en.pdf"},
    {"id":"24195","name":"EU/3/15/1537: Public summary of opinion on orphan designation: Verucerfont for the treatment of congenital adrenal hyperplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2016-02-10T01:00:00Z","reference_number":"EMA/COMP/508881/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151537-public-summary-opinion-orphan-designation-verucerfont-treatment-congenital-adrenal-hyperplasia_en.pdf"},
    {"id":"24213","name":"EU/3/15/1453: Public summary of positive opinion for orphan designation of  chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA for the treatment of Huntington’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/125750/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151453-public-summary-positive-opinion-orphan-designation-chimeric-2-o-2-methoxyethyl-modified-oligonucleotide-targeted-huntingtin-rna-treatment-huntingtons-disease_en.pdf"},
    {"id":"24261","name":"EU/3/15/1592: Public summary of opinion on orphan designation: [4-aminobutanoic acid-glycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-ly...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2016-02-03T01:00:00Z","reference_number":"EMA/COMP/794903/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151592-public-summary-opinion-orphan-designation-4-aminobutanoic-acid-glycyl-l-glutaminyl-l-arginyl-l-alpha-glutamyl-l-threonyl-l-prolyl-l-alpha-glutamylglycyl-l-alanyl-l-alpha-glutamyl-l-alanyl-l_en.pdf"},
    {"id":"24283","name":"EU/3/03/174: Public summary of positive opinion for orphan designation of\n\ngimatecan for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2009-09-21T02:00:00Z","reference_number":"EMEA/COMP/1536/03 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303174-public-summary-positive-opinion-orphan-designation-gimatecan-treatment-glioma_en.pdf"},
    {"id":"24361","name":"EU/03/11/916: Public summary of opinion on orphan designation: 2-hydroxyoleic acid for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2011-11-23T16:00:00Z","reference_number":"EMA/COMP/780686/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu0311916-public-summary-opinion-orphan-designation-2-hydroxyoleic-acid-treatment-glioma_en.pdf"},
    {"id":"24362","name":"EU/3/14/1284: Public summary of opinion on orphan designation: Isavuconazonium sulfate for the treatment of invasive aspergillosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-16T02:00:00Z","last_updated_date":"2014-07-16T02:00:00Z","reference_number":"EMA/COMP/306060/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141284-public-summary-opinion-orphan-designation-isavuconazonium-sulfate-treatment-invasive-aspergillosis_en.pdf"},
    {"id":"24378","name":"EU/3/18/2038: Public summary of opinion on orphan designation: Palovarotene for the treatment of multiple osteochondromas","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-21T19:07:00Z","last_updated_date":"2021-10-19T14:48:00Z","reference_number":"EMA/371472/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182038-public-summary-opinion-orphan-designation-palovarotene-treatment-multiple-osteochondromas_en.pdf"},
    {"id":"24416","name":"EU/3/13/1123: Public summary of opinion on orphan designation: Nintedanib for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-05-14T13:00:00Z","last_updated_date":"2020-06-09T12:00:00Z","reference_number":"EMA/COMP/194212/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131123-public-summary-opinion-orphan-designation-nintedanib-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"24422","name":"EU/3/09/621: Public summary of positive opinion for orphan designation\n\nof 2,2-dimethylbutyric acid, sodium salt for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-08T02:00:00Z","last_updated_date":"2015-03-20T01:00:00Z","reference_number":"EMEA/COMP/82515/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309621-public-summary-positive-opinion-orphan-designation-22-dimethylbutyric-acid-sodium-salt-treatment-sickle-cell-disease_en.pdf"},
    {"id":"24493","name":"EU/3/09/642: Public summary of positive opinion for orphan designation of chimeric-anti-interleukin-6 monoclonal antibody for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMEA/COMP/291681/2009 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309642-public-summary-positive-opinion-orphan-designation-chimeric-anti-interleukin-6-monoclonal-antibody-treatment-multiple-myeloma_en.pdf"},
    {"id":"24499","name":"EU/3/04/254: Public summary of positive opinion for orphan designation of Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-06T00:00:00Z","last_updated_date":"2009-11-19T00:00:00Z","reference_number":"EMEA/COMP/152574/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304254-public-summary-positive-opinion-orphan-designation-val-leu-gln-glu-leu-asn-val-thr-val-pr1-nanopeptide-sequence-169-177-proteinase-3-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"24563","name":"EU/3/04/246: Public summary of positive opinion for orphan designation of valproic acid, sodium for the treatment of familial adenomatous polyposis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T00:00:00Z","last_updated_date":"2014-01-13T15:30:00Z","reference_number":"EMEA/COMP/109745/2004, Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304246-public-summary-positive-opinion-orphan-designation-valproic-acid-sodium-treatment-familial-adenomatous-polyposis_en.pdf"},
    {"id":"24581","name":"EU/3/02/108: Public summary of positive opinion for orphan designation of myristoylated-peptidyl-recombinant SCR1-3 of human complement receptor type I for the prevention of post transplantation graft dysfunction","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"A/COMP/1498/02 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302108-public-summary-positive-opinion-orphan-designation-myristoylated-peptidyl-recombinant-scr1-3-human-complement-receptor-type-i-prevention-post-transplantation-graft-dysfunction_en.pdf"},
    {"id":"24591","name":"EU/3/17/1957: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene for the treatment of Huntington's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-12T01:00:00Z","last_updated_date":"2018-03-12T01:00:00Z","reference_number":"EMA/828668/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171957-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-5-encoding-microrna-targeted-human-huntingtin-gene-treatment-huntingtons-disease_en.pdf"},
    {"id":"24612","name":"EU/3/11/923: Public summary of opinion on orphan designation: L-cysteine, L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2020-12-04T16:00:00Z","reference_number":"EMA/COMP/793868/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311923-public-summary-opinion-orphan-designation-l-cysteine-l-leucyl-l-alpha-glutamyl-l-alpha-glutamyl-l-lysyl-l-lysylglycyl-l-asparaginyl-l-tyrosyl-l-valyl-l-valyl-l-threonyl-l-alpha-aspartyl-l_en.pdf"},
    {"id":"24646","name":"EU/3/08/527: Public summary of positive opinion for orphan designation of recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class for the treatment of systemic-onset juvenile idiopathic arthritis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2015-02-12T13:00:00Z","reference_number":"EMEA/COMP/103869/2008 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308527-public-summary-positive-opinion-orphan-designation-recombinant-human-monoclonal-antibody-human-il-1beta-igg1k-class-treatment-systemic-onset-juvenile-idiopathic-arthritis_en.pdf"},
    {"id":"24652","name":"EU/3/08/580: Public summary of positive opinion for orphan designation of filgrastim for the treatment of spinal cord injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMEA/COMP/488916/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308580-public-summary-positive-opinion-orphan-designation-filgrastim-treatment-spinal-cord-injury_en.pdf"},
    {"id":"24661","name":"EU/3/11/935: Public summary of opinion on orphan designation: Interferon gamma for the treatment of Friedreich's ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"EMA/COMP/849100/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311935-public-summary-opinion-orphan-designation-interferon-gamma-treatment-friedreichs-ataxia_en.pdf"},
    {"id":"24677","name":"EU/3/09/624: Public summary of positive opinion for orphan designation of autologous tumour-derived gp96 heat shock protein-peptide complex for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-12T02:00:00Z","last_updated_date":"2009-05-12T02:00:00Z","reference_number":"EMEA/COMP/157828/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309624-public-summary-positive-opinion-orphan-designation-autologous-tumour-derived-gp96-heat-shock-protein-peptide-complex-treatment-glioma_en.pdf"},
    {"id":"24678","name":"EU/3/15/1572: Public summary of opinion on orphan designation: Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor for the treatment of chronic lymphocytic l...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/COMP/697123/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151572-public-summary-opinion-orphan-designation-autologous-t-cells-transduced-retroviral-vector-encoding-anti-cd19-cd28cd3-zeta-chimeric-antigen-receptor-treatment-chronic-lymphocytic-l_en.pdf"},
    {"id":"24694","name":"EU/3/05/329: Public summary of positive opinion for orphan designation of peptide 144 TGF-beta1-inhibitor (TSLDASIIWAMMQN) treatment of localised scleroderma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/317440/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305329-public-summary-positive-opinion-orphan-designation-peptide-144-tgf-beta1-inhibitor-tsldasiiwammqn-treatment-localised-scleroderma_en.pdf"},
    {"id":"24701","name":"EU/3/10/828: Public summary of opinion on orphan designation: Silibinin-C-2',3-dihydrogensuccinate, disodium salt for the prevention of recurrent hepatitis C in liver transplant recipients","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"EMA/COMP/642562/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310828-public-summary-opinion-orphan-designation-silibinin-c-23-dihydrogensuccinate-disodium-salt-prevention-recurrent-hepatitis-c-liver-transplant-recipients_en.pdf"},
    {"id":"24706","name":"EU/3/02/113: Public summary of positive opinion for orphan designation of mitotane for the treatment of adrenal cortical carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T01:00:00Z","last_updated_date":"2005-11-29T01:00:00Z","reference_number":"EMEA/COMP/1640/02 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302113-public-summary-positive-opinion-orphan-designation-mitotane-treatment-adrenal-cortical-carcinoma_en.pdf"},
    {"id":"24714","name":"EU/3/11/944: Public summary of positive opinion for orphan designation: N,N'-bis(2-mercaptoethyl)isophthalamide for the treatment of mercury toxicity","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2015-03-24T15:00:00Z","reference_number":"EMA/COMP/929337/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311944-public-summary-positive-opinion-orphan-designation-nn-bis2-mercaptoethylisophthalamide-treatment-mercury-toxicity_en.pdf"},
    {"id":"24730","name":"EU/3/07/449: Public summary of positive opinion for orphan designation of everolimus for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMEA/COMP/202020/2007 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307449-public-summary-positive-opinion-orphan-designation-everolimus-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"24747","name":"EU/3/17/1876: Public summary of opinion on orphan designation: Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-06-29T02:00:00Z","last_updated_date":"2017-06-29T02:00:00Z","reference_number":"EMA/259560/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171876-public-summary-opinion-orphan-designation-sodium-1r3r4r5s-3-2-n-acetylamino-2-deoxy-3-o-1s-1-carboxylato-2-cyclohexylethyl-beta-d-galactopyranosyloxy-4-6-deoxy-alpha-l-galactopyranosyl_en.pdf"},
    {"id":"24798","name":"EU/3/10/816: Public summary of opinion on orphan designation: 7-Beta-hydroxy cholesteryl-3-beta-oleate for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-19T01:00:00Z","last_updated_date":"2011-01-19T01:00:00Z","reference_number":"EMA/COMP/663050/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310816-public-summary-opinion-orphan-designation-7-beta-hydroxy-cholesteryl-3-beta-oleate-treatment-glioma_en.pdf"},
    {"id":"24854","name":"EU/3/00/012: Public summary of positive opinion for orphan designation of nitisinone for the treatment of tyrosinaemia type 1","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T00:00:00Z","last_updated_date":"2015-05-09T01:00:00Z","reference_number":"EMEA/COMP/97363/2009 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300012-public-summary-positive-opinion-orphan-designation-nitisinone-treatment-tyrosinaemia-type-1_en.pdf"},
    {"id":"24867","name":"EU/3/04/228: Public summary of positive opinion for orphan designation: Homoharringtonine for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2016-08-10T02:00:00Z","reference_number":"EMEA/COMP/204749/2004 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304228-public-summary-positive-opinion-orphan-designation-homoharringtonine-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"24872","name":"EU/3/16/1734 : Public summary of opinion on orphan designation: Valproic acid for the treatment of McArdle’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161734-public-summary-opinion-orphan-designation-valproic-acid-treatment-mcardles-disease_en.pdf"},
    {"id":"24881","name":"EU/3/13/1204: Public summary of opinion on orphan designation: Sirolimus for the prevention of arteriovenous access dysfunction in patients undergoing surgical creation of an arteriovenous access for haemodialysis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2013-12-02T01:00:00Z","reference_number":"EMA/COMP/629568/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131204-public-summary-opinion-orphan-designation-sirolimus-prevention-arteriovenous-access-dysfunction-patients-undergoing-surgical-creation-arteriovenous-access-haemodialysis_en.pdf"},
    {"id":"24911","name":"EU/3/16/1798: Public summary of opinion on orphan designation: Avelumab for the treatment of gastric cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2019-10-15T01:00:00Z","reference_number":"EMA/753360/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161798-public-summary-opinion-orphan-designation-avelumab-treatment-gastric-cancer_en.pdf"},
    {"id":"24940","name":"EU/3/17/1893: Public summary of opinion on orphan designation: Polyphenyl(disodium 3-O-sulfo-beta-D-glucopyranuronate)-(1->3)-beta-D-galactopyranoside for the treatment of anti-MAG neuropathy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2017-08-16T11:30:00Z","last_updated_date":"2017-08-16T11:30:00Z","reference_number":"EMA/407016/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171893-public-summary-opinion-orphan-designation-polyphenyldisodium-3-o-sulfo-beta-d-glucopyranuronate-1-3-beta-d-galactopyranoside-treatment-anti-mag-neuropathy_en.pdf"},
    {"id":"24980","name":"EU/3/16/1723 : Public summary of opinion on orphan designation: Methotrexate for the treatment of alkaptonuria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161723-public-summary-opinion-orphan-designation-methotrexate-treatment-alkaptonuria_en.pdf"},
    {"id":"25000","name":"EU/3/18/1977: Public summary of opinion on orphan designation: Cannabidivarin for treatment of fragile X syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/COMP/69020/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181977-public-summary-opinion-orphan-designation-cannabidivarin-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"25046","name":"EU/3/05/320: Public summary of positive opinion for orphan designation of imatinib mesilate for the treatment of chronic eosinophilic leukaemia and the hypereosinophilic syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T01:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMA/COMP/275619/2005 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305320-public-summary-positive-opinion-orphan-designation-imatinib-mesilate-treatment-chronic-eosinophilic-leukaemia-and-hypereosinophilic-syndrome_en.pdf"},
    {"id":"25051","name":"EU/3/01/069: Public summary of positive opinion for orphan designation of phenylephrine hydrochloride for the treatment of ileal pouch anal anastomosis related faecal incontinence","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/268/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301069-public-summary-positive-opinion-orphan-designation-phenylephrine-hydrochloride-treatment-ileal-pouch-anal-anastomosis-related-faecal-incontinence_en.pdf"},
    {"id":"25060","name":"EU/3/06/378: Public summary of positive opinion for orphan designation of mecasermin rinfabate for the treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/309707/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306378-public-summary-positive-opinion-orphan-designation-mecasermin-rinfabate-treatment-primary-insulin-growth-factor-1-deficiency-due-molecular-or-genetic-defects_en.pdf"},
    {"id":"25065","name":"EU/3/15/1567: Public summary of opinion on orphan designation:\n\nRecombinant human interleukin-3 truncated diphtheria toxin fusion protein for treatment of blastic plasmacytoid dendritic cell neoplasm","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-05T01:00:00Z","last_updated_date":"2016-01-05T01:00:00Z","reference_number":"EMA/COMP/698904/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151567-public-summary-opinion-orphan-designation-recombinant-human-interleukin-3-truncated-diphtheria-toxin-fusion-protein-treatment-blastic-plasmacytoid-dendritic-cell-neoplasm_en.pdf"},
    {"id":"25075","name":"EU/3/10/782: Public summary of opinion on orphan designation: Nafamostat mesilate for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2010-10-18T02:00:00Z","reference_number":"EMA/COMP/394803/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310782-public-summary-opinion-orphan-designation-nafamostat-mesilate-treatment-cystic-fibrosis_en.pdf"},
    {"id":"25102","name":"EU/3/11/879: Public summary of opinion on orphan designation: Chimeric monoclonal antibody against GD2 for the treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2011-07-12T02:00:00Z","reference_number":"EMA/COMP/300521/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311879-public-summary-opinion-orphan-designation-chimeric-monoclonal-antibody-against-gd2-treatment-neuroblastoma_en.pdf"},
    {"id":"25145","name":"EU/3/07/525: Public summary of  positive opinion for orphan designation of  iodine (131I) iobenguane  for the treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2008-07-10T02:00:00Z","reference_number":"EMEA/COMP/19760/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307525-public-summary-positive-opinion-orphan-designation-iodine-131i-iobenguane-treatment-neuroblastoma_en.pdf"},
    {"id":"25165","name":"EU/3/13/1175: Public summary of opinion on orphan designation: Tolvaptan for the treatment of autosomal dominant polycystic kidney disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-13T02:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/COMP/444684/2013 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131175-public-summary-opinion-orphan-designation-tolvaptan-treatment-autosomal-dominant-polycystic-kidney-disease_en.pdf"},
    {"id":"25197","name":"EU/3/04/241: Public summary of positive opinion for orphan designation: Pirfenidone for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMEA/COMP/198295/2004 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304241-public-summary-positive-opinion-orphan-designation-pirfenidone-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"25203","name":"EU/3/04/196: Public summary of positive opinion for orphan designation of ciclosporin for the treatment of atopic keratoconjunctivits","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-22T00:00:00Z","last_updated_date":"2008-01-22T00:00:00Z","reference_number":"EMEA/COMP/328/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304196-public-summary-positive-opinion-orphan-designation-ciclosporin-treatment-atopic-keratoconjunctivits_en.pdf"},
    {"id":"25222","name":"EU/3/17/1843: Public summary of opinion on orphan designation: Soluble recombinant human fibroblast growth factor receptor 3 for the treatment of achondroplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2023-03-24T02:00:00Z","reference_number":"EMA/69647/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171843-public-summary-opinion-orphan-designation-soluble-recombinant-human-fibroblast-growth-factor-receptor-3-treatment-achondroplasia_en.pdf"},
    {"id":"25223","name":"Public summary of negative opinion for orphan designation of mycobacterial cell wall complex for superficial bladder cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-14T01:00:00Z","last_updated_date":"2003-01-14T01:00:00Z","reference_number":"EMEA/COMP/2370/02","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-mycobacterial-cell-wall-complex-superficial-bladder-cancer_en.pdf"},
    {"id":"25240","name":"EU/3/15/1532: Public summary of opinion on orphan designation: Insulin human for the treatment of short bowel syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/507070/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151532-public-summary-opinion-orphan-designation-insulin-human-treatment-short-bowel-syndrome_en.pdf"},
    {"id":"25256","name":"EU/3/10/735: Public summary of opinion on orphan designation: Glyceryl tri-(4-phenylbutyrate) for the treatment of citrullinaemia type 1","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/123430/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310735-public-summary-opinion-orphan-designation-glyceryl-tri-4-phenylbutyrate-treatment-citrullinaemia-type-1_en.pdf"},
    {"id":"25265","name":"EU/3/12/1084 : Public summary of opinion on orphan designation: Erdosteine for the treatment of lead toxicity","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-25T12:00:00Z","last_updated_date":"2013-01-25T12:00:00Z","reference_number":"EMA/COMP/732940/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121084-public-summary-opinion-orphan-designation-erdosteine-treatment-lead-toxicity_en.pdf"},
    {"id":"25291","name":"EU/3/14/1422: Public summary of opinion on orphan designation: Chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2 for the treatment of mucopolysaccharidosis ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2015-03-06T12:00:00Z","reference_number":"EMA/COMP/793141/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141422-public-summary-opinion-orphan-designation-chimeric-fusion-protein-recombinant-human-alpha-n-acetylglucosaminidase-and-human-insulin-growth-factor-2-treatment-mucopolysaccharidosis_en.pdf"},
    {"id":"25315","name":"EU/3/07/495: Public summary of positive opinion for orphan designation of  methotrexate (oral liquid) for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2014-07-11T02:00:00Z","reference_number":"EMEA/COMP/469498/2007 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307495-public-summary-positive-opinion-orphan-designation-methotrexate-oral-liquid-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"25326","name":"EU/3/17/1852: Public summary of opinion on orphan designation: Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haema...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/154018/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171852-public-summary-opinion-orphan-designation-allogeneic-ex-vivo-expanded-umbilical-cord-blood-derived-haematopoietic-cd34-progenitor-cells-and-allogeneic-non-expanded-umbilical-cord-blood_en.pdf"},
    {"id":"25327","name":"EU/3/07/506: Public summary of positive opinion for orphan designation of heterologous human adult liver-derived stem cells for the treatment of Crigler-Najjar syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2013-03-01T01:00:00Z","reference_number":"EMEA/COMP/482272/2007 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307506-public-summary-positive-opinion-orphan-designation-heterologous-human-adult-liver-derived-stem-cells-treatment-crigler-najjar-syndrome_en.pdf"},
    {"id":"25330","name":"EU/3/12/1022: Public summary of opinion on orphan designation: Metreleptin for the treatment of familial partial lipodystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-08-31T12:30:00Z","last_updated_date":"2015-05-13T12:30:00Z","reference_number":"EMA/COMP/440577/2012 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121022-public-summary-opinion-orphan-designation-metreleptin-treatment-familial-partial-lipodystrophy_en.pdf"},
    {"id":"25331","name":"EU/3/17/1948: Public summary of opinion on orphan designation: 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl for the treatment of familial cerebral cavernous malformation","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-23T14:42:00Z","last_updated_date":"2018-01-23T14:42:00Z","reference_number":"EMA/754098/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171948-public-summary-opinion-orphan-designation-4-hydroxy-2266-tetramethylpiperidine-n-oxyl-treatment-familial-cerebral-cavernous-malformation_en.pdf"},
    {"id":"25337","name":"EU/3/15/1483: Public summary of positive opinion for orphan designation of Xenon for the treatment of perinatal asphyxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T14:00:00Z","last_updated_date":"2015-05-22T14:00:00Z","reference_number":"EMA/COMP/212804/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151483-public-summary-positive-opinion-orphan-designation-xenon-treatment-perinatal-asphyxia_en.pdf"},
    {"id":"25355","name":"EU/3/02/104: Public summary of positive opinion for orphan designation of miltefosine for the treatment of visceral  leishmaniasis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-06-11T02:00:00Z","last_updated_date":"2003-06-11T02:00:00Z","reference_number":"EMEA/COMP/965/02 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302104-public-summary-positive-opinion-orphan-designation-miltefosine-treatment-visceral-leishmaniasis_en.pdf"},
    {"id":"25399","name":"EU/3/10/824: Public summary of opinion on orphan designation: N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2020-08-12T01:00:00Z","reference_number":"EMA/COMP/642226/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310824-public-summary-opinion-orphan-designation-n-2s-23-dihydroxypropyl-3-2-fluoro-4-iodophenylamino-isonicotinamide-hydrochloride-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"25456","name":"EU/03/11/919: Public summary of opinion on orphan designation: Clonidine hydrochloride for the prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2015-03-12T16:00:00Z","reference_number":"EMA/COMP/780548/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu0311919-public-summary-opinion-orphan-designation-clonidine-hydrochloride-prevention-oral-mucositis-head-and-neck-cancer-patients-undergoing-radiation-therapy_en.pdf"},
    {"id":"25493","name":"EU/3/06/374: Public summary of positive opinion for orphan designation of methoxsalen for the treatment of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMEA/COMP/132163/2006 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306374-public-summary-positive-opinion-orphan-designation-methoxsalen-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"25530","name":"EU/3/13/1207: Public summary of opinion on orphan designation: Trebananib for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2013-12-02T01:00:00Z","reference_number":"EMA/COMP/630502/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131207-public-summary-opinion-orphan-designation-trebananib-treatment-ovarian-cancer_en.pdf"},
    {"id":"25540","name":"EU/3/11/859: [N-((2S,3R,3aS,3'R,4a'R,6S,6a'R,6b'S,7aR,12a'S,12b'S,Z)-3,6,11',12b'-tetramethyl-2',3a,3',4,4',4a',5,5',6,6',6a',6b',7,7a,7',8',10',12',12a',12b'-icosahydro-1'H,3H-spiro[furo[3,2-b]pyridine-2,9'-naphtho[2,1-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2013-07-31T02:00:00Z","reference_number":"EMA/COMP/158609/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311859-n-2s3r3as3r4ar6s6ar6bs7ar12as12bsz-361112b-tetramethyl-23a3444a55666a6b77a78101212a12b-icosahydro-1h3h-spirofuro32-bpyridine-29-naphtho21_en.pdf"},
    {"id":"25558","name":"EU/3/11/894: Public summary of opinion on orphan designation: Everolimus for the treatment of gastric cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2015-02-09T14:30:00Z","reference_number":"EMA/COMP/546609/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311894-public-summary-opinion-orphan-designation-everolimus-treatment-gastric-cancer_en.pdf"},
    {"id":"25581","name":"EU/3/10/730: Public summary of opinion on orphan designation: Raloxifene hydrochloride for the treatment of hereditary haemorrhagic telangiectasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2010-06-24T02:00:00Z","reference_number":"EMA/COMP/90982/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310730-public-summary-opinion-orphan-designation-raloxifene-hydrochloride-treatment-hereditary-haemorrhagic-telangiectasia_en.pdf"},
    {"id":"25602","name":"EU/3/15/1559: Public summary of opinion on orphan designation: 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-18T11:00:00Z","last_updated_date":"2015-11-18T11:00:00Z","reference_number":"EMA/COMP/609748/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151559-public-summary-opinion-orphan-designation-2-2-chlorophenyl-4-3-dimethylaminophenyl-5-methyl-1h-pyrazolo43-cpyridine-362h5h-dione-treatment-systemic-sclerosis_en.pdf"},
    {"id":"25613","name":"EU/3/14/1407: Public summary of opinion on orphan designation: Allogeneic adipose-derived adult mesenchymal stem cells contained in a\n\nfibrin-based bioengineered dermis for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/COMP/744641/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141407-public-summary-opinion-orphan-designation-allogeneic-adipose-derived-adult-mesenchymal-stem-cells-contained-fibrin-based-bioengineered-dermis-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"25655","name":"EU/3/14/1401: Public summary of opinion on orphan designation: Riluzole for the treatment of traumatic spinal cord injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/COMP/744269/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141401-public-summary-opinion-orphan-designation-riluzole-treatment-traumatic-spinal-cord-injury_en.pdf"},
    {"id":"25660","name":"EU/3/11/875: Public summary of opinion on orphan designation: Metronidazole for the treatment of pouchitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2011-07-12T02:00:00Z","reference_number":"EMA/COMP/247584/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311875-public-summary-opinion-orphan-designation-metronidazole-treatment-pouchitis_en.pdf"},
    {"id":"25676","name":"EU/3/15/1486: Public summary of positive opinion for orphan designation of Recombinant human mesencephalic astrocyte-derived neurotrophic factor for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T14:00:00Z","last_updated_date":"2015-05-22T14:00:00Z","reference_number":"EMA/COMP/209499/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151486-public-summary-positive-opinion-orphan-designation-recombinant-human-mesencephalic-astrocyte-derived-neurotrophic-factor-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"25679","name":"EU/3/13/1161: Public summary of opinion on orphan designation: Heterologous human adult liver-derived progenitor cells for the treatment of carbamoyl-phosphate-synthase-1 deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T14:30:00Z","last_updated_date":"2013-08-21T14:30:00Z","reference_number":"EMA/COMP/413210/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131161-public-summary-opinion-orphan-designation-heterologous-human-adult-liver-derived-progenitor-cells-treatment-carbamoyl-phosphate-synthase-1-deficiency_en.pdf"},
    {"id":"25707","name":"EU/3/12/1015: Public summary of opinion on orphan designation: Eculizumab for the treatment of infection-associated haemolytic uraemic syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2016-01-19T15:00:00Z","reference_number":"EMA/COMP/381629/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121015-public-summary-opinion-orphan-designation-eculizumab-treatment-infection-associated-haemolytic-uraemic-syndrome_en.pdf"},
    {"id":"25710","name":"EU/3/14/1366: Public summary of opinion on orphan designation: Recombinant human pentraxin-2 for the treatment of primary myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/COMP/660445/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141366-public-summary-opinion-orphan-designation-recombinant-human-pentraxin-2-treatment-primary-myelofibrosis_en.pdf"},
    {"id":"25711","name":"EU/3/10/779: Public summary of opinion on orphan designation: Eflornithine for the treatment of familial adenomatous polyposis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2010-10-18T02:00:00Z","reference_number":"EMA/COMP/363907/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310779-public-summary-opinion-orphan-designation-eflornithine-treatment-familial-adenomatous-polyposis_en.pdf"},
    {"id":"25742","name":"EU/3/02/099: Public summary of positive opinion for orphan designation of bryostatin-1 for the treatment of oesophageal cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-23T00:00:00Z","last_updated_date":"2007-02-23T00:00:00Z","reference_number":"EMEA/COMP/613/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302099-public-summary-positive-opinion-orphan-designation-bryostatin-1-treatment-oesophageal-cancer_en.pdf"},
    {"id":"25760","name":"EU/3/17/1907: Public summary of opinion on orphan designation: Recombinant fragment of human surfactant protein-D for the prevention of bronchopulmonary dysplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/507449/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171907-public-summary-opinion-orphan-designation-recombinant-fragment-human-surfactant-protein-d-prevention-bronchopulmonary-dysplasia_en.pdf"},
    {"id":"25791","name":"EU/3/15/1525: Public summary of opinion on orphan designation: Triheptanoin for the treatment of mitochondrial trifunctional protein deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T16:00:00Z","last_updated_date":"2015-12-18T16:00:00Z","reference_number":"EMA/COMP/432828/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151525-public-summary-opinion-orphan-designation-triheptanoin-treatment-mitochondrial-trifunctional-protein-deficiency_en.pdf"},
    {"id":"25805","name":"EU/3/14/1411: Public summary of opinion on orphan designation: Pentosan polysulfate sodium for the treatment of interstitial cystitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2017-06-19T02:00:00Z","reference_number":"EMA/COMP/10142/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141411-public-summary-opinion-orphan-designation-pentosan-polysulfate-sodium-treatment-interstitial-cystitis_en.pdf"},
    {"id":"25828","name":"EU/3/04/237: Public summary of positive opinion for orphan designation of recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3 for the treatment of Rabson Mendnhal...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-20T00:00:00Z","last_updated_date":"2011-06-22T01:00:00Z","reference_number":"EMEA/COMP/77791/2004 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304237-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-irecombinant-human-insulin-growth-factor-binding-protein-3-treatment-rabson-mendnhal_en.pdf"},
    {"id":"25837","name":"EU/3/17/1968: Public summary of opinion on orphan designation: Pyrazolo[1,5-a]pyrimidine, 3-[4-chloro-2-(4-morpholinyl)-5-thiazolyl]-7-(1-ethylpropyl)-2,5-dimethyl-pyrazolo[1,3-a]pyrimidine for the treatment of congenita...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-12T01:00:00Z","last_updated_date":"2018-03-12T01:00:00Z","reference_number":"EMA/COMP/840575/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171968-public-summary-opinion-orphan-designation-pyrazolo15-apyrimidine-3-4-chloro-2-4-morpholinyl-5-thiazolyl-7-1-ethylpropyl-25-dimethyl-pyrazolo13-apyrimidine-treatment-congenita_en.pdf"},
    {"id":"25843","name":"EU/3/16/1794: Public summary of opinion on orphan designation: 68Ga-DOTA-pABzA-DIG-dPhe-Gln-Trp-Ala-Val-Gly-His-NHCH[(CH2-CH(CH3)2]2 for the diagnosis of gastrointestinal stromal tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/745295/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161794-public-summary-opinion-orphan-designation-68ga-dota-pabza-dig-dphe-gln-trp-ala-val-gly-his-nhchch2-chch322-diagnosis-gastrointestinal-stromal-tumours_en.pdf"},
    {"id":"25871","name":"EU/3/14/1370: Public summary of opinion on orphan designation: Siponimod for the treatment of polymyositis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2018-03-12T01:00:00Z","reference_number":"EMA/COMP/660610/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141370-public-summary-opinion-orphan-designation-siponimod-treatment-polymyositis_en.pdf"},
    {"id":"25885","name":"EU/3/07/450: Public summary of positive opinion for orphan designation of 5(S)-(2'-hydroxy ethoxy)-20(S)-camptothecin for the treatment of osteosarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2017-08-14T02:00:00Z","reference_number":"EMEA/COMP/148165/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307450-public-summary-positive-opinion-orphan-designation-5s-2-hydroxy-ethoxy-20s-camptothecin-treatment-osteosarcoma_en.pdf"},
    {"id":"25907","name":"EU/3/04/210: Public summary of positive opinion for orphan designation of ciclosporin for the treatment of bronchiolitis obliterans syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-13T00:00:00Z","last_updated_date":"2018-10-12T11:10:00Z","reference_number":"EMEA/COMP/293/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304210-public-summary-positive-opinion-orphan-designation-ciclosporin-treatment-bronchiolitis-obliterans-syndrome_en.pdf"},
    {"id":"25915","name":"EU/3/17/1946: Public summary of opinion on orphan designation:  (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide for the treatment of p...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T10:44:00Z","last_updated_date":"2018-01-24T10:44:00Z","reference_number":"EMA/753055/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171946-public-summary-opinion-orphan-designation-2s4r-1-2-3-acetyl-5-2-methylpyrimidine-5-yl-1h-indazol-1-ylacetyl-n-6-bromopyridine-2-yl-4-fluoropyrrolidine-2-carboxamide-treatment-p_en.pdf"},
    {"id":"25916","name":"EU/3/09/720: Public summary of opinion on orphan designation of lentiviral vector containing the human ABCA4 gene for the treatment of Stargardt’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMA/COMP/814184/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309720-public-summary-opinion-orphan-designation-lentiviral-vector-containing-human-abca4-gene-treatment-stargardts-disease_en.pdf"},
    {"id":"25936","name":"EU/3/06/424: Public summary of positive opinion for orphan designation of thiotepa for the conditioning treatment prior to haematopoietic progenitor cell transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2014-01-22T01:00:00Z","reference_number":"EMA/COMP/504488/2006 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306424-public-summary-positive-opinion-orphan-designation-thiotepa-conditioning-treatment-prior-haematopoietic-progenitor-cell-transplantation_en.pdf"},
    {"id":"25946","name":"EU/3/10/838: Public summary of opinion on orphan designation: Plitidepsin for the treatment of post-essential thrombocythaemia myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2011-09-06T02:00:00Z","reference_number":"EMA/COMP/740407/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310838-public-summary-opinion-orphan-designation-plitidepsin-treatment-post-essential-thrombocythaemia-myelofibrosis_en.pdf"},
    {"id":"25988","name":"EU/3/12/1039: Public summary of opinion on orphan designation: Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-27T16:00:00Z","last_updated_date":"2012-09-27T16:00:00Z","reference_number":"EMA/COMP/509614/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121039-public-summary-opinion-orphan-designation-recombinant-anti-cd3-bi-single-chain-fv-diphtheria-toxin-fusion-protein-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"25989","name":"EU/3/13/1150: Public summary of opinion on orphan designation: Moxetumomab pasudotox for the treatment of B-lymphoblastic leukaemia / lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-22T17:30:00Z","last_updated_date":"2022-07-25T12:38:00Z","reference_number":"EMA/COMP/413548/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131150-public-summary-opinion-orphan-designation-moxetumomab-pasudotox-treatment-b-lymphoblastic-leukaemia-lymphoma_en.pdf"},
    {"id":"26020","name":"EU/3/14/1343: Public summary of opinion on orphan designation: Immunoglobulin G1, anti-(human tumour-associated calcium signal transducer 2)(human-Mus musculus monoclonal hRS7 heavy chain), disulfide with human-Mus muscu...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/552859/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141343-public-summary-opinion-orphan-designation-immunoglobulin-g1-anti-human-tumour-associated-calcium-signal-transducer-2human-mus-musculus-monoclonal-hrs7-heavy-chain-disulfide-human-mus-muscu_en.pdf"},
    {"id":"26021","name":"EU/3/08/571: Public summary of positive opinion for orphan designation of recombinant human minibody against complement component C5 for the treatment of atypical haemolytic uraemic syndrome (aHUS) associated with an inh...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2014-01-22T01:00:00Z","reference_number":"EMA/COMP/363566/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308571-public-summary-positive-opinion-orphan-designation-recombinant-human-minibody-against-complement-component-c5-treatment-atypical-haemolytic-uraemic-syndrome-ahus-associated-inh_en.pdf"}    {"id":"26043","name":"EU/3/17/1886: Public summary of opinion on orphan designation: Sirolimus for the treatment of tuberous sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T02:00:00Z","last_updated_date":"2017-07-17T02:00:00Z","reference_number":"EMA/329992/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171886-public-summary-opinion-orphan-designation-sirolimus-treatment-tuberous-sclerosis_en.pdf"},
    {"id":"26046","name":"EU/3/14/1351: Public summary of opinion on orphan designation: Recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23 for the treatment of X-linked hypophosphataemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/551233/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141351-public-summary-opinion-orphan-designation-recombinant-human-monoclonal-igg1-antibody-fibroblast-growth-factor-23-treatment-x-linked-hypophosphataemia_en.pdf"},
    {"id":"26066","name":"EU/3/10/740: Public summary of opinion on orphan designation\n\nPerifosine for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/COMP/90859/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310740-public-summary-opinion-orphan-designation-perifosine-treatment-multiple-myeloma_en.pdf"},
    {"id":"26067","name":"EU/3/17/1829: Public summary of opinion on orphan designation: 26 base synthetic single-stranded fully phosphorothioated 2'-O-methyl-RNA and DNA mixmer oligonucleotide-based compound for the treatment of Dravet syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/81619/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171829-public-summary-opinion-orphan-designation-26-base-synthetic-single-stranded-fully-phosphorothioated-2-o-methyl-rna-and-dna-mixmer-oligonucleotide-based-compound-treatment-dravet-syndrome_en.pdf"},
    {"id":"26097","name":"EU/3/16/1717 : Public summary of opinion on orphan designation: Autologous mesenchymal stromal cells on a decellularised tracheal scaffold from a cadaveric donor for the treatment of tracheal stenosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161717-public-summary-opinion-orphan-designation-autologous-mesenchymal-stromal-cells-decellularised-tracheal-scaffold-cadaveric-donor-treatment-tracheal-stenosis_en.pdf"},
    {"id":"26156","name":"EU/3/11/912: Public summary of opinion on orphan designation: Reparixin for the prevention of graft loss in pancreatic islet transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMA/COMP/584413/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311912-public-summary-opinion-orphan-designation-reparixin-prevention-graft-loss-pancreatic-islet-transplantation_en.pdf"},
    {"id":"26159","name":"EU/3/16/1753: Public summary of positive opinion for orphan designation of haematopoietic stem cells modified with a lentiviral vector containing the CD18 gene for the treatment of leukocyte adhesion deficiency type I","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/623403/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161753-public-summary-positive-opinion-orphan-designation-haematopoietic-stem-cells-modified-lentiviral-vector-containing-cd18-gene-treatment-leukocyte-adhesion-deficiency-type-i_en.pdf"},
    {"id":"26186","name":"EU/3/15/1601: Public summary of opinion on orphan designation: Sodium benzoate for the treatment of argininosuccinic aciduria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T01:00:00Z","reference_number":"EMA/COMP/851584/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151601-public-summary-opinion-orphan-designation-sodium-benzoate-treatment-argininosuccinic-aciduria_en.pdf"},
    {"id":"26206","name":"EU/3/13/1201: Public summary of opinion on orphan designation: Defibrotide for the prevention of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2013-12-02T01:00:00Z","reference_number":"EMA/COMP/627684/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131201-public-summary-opinion-orphan-designation-defibrotide-prevention-graft-versus-host-disease_en.pdf"},
    {"id":"26213","name":"EU/3/01/068: Public summary of positive opinion for orphan designation of thalidomide for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/262/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301068-public-summary-positive-opinion-orphan-designation-thalidomide-treatment-multiple-myeloma_en.pdf"},
    {"id":"26252","name":"EU/3/18/1988: Public summary of opinion on orphan designation: (R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-5-yl)phenyl)-N,N,N-tri...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/60696/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181988-public-summary-opinion-orphan-designation-r-2-5-cyano-2-6-methoxycarbonyl-7-methyl-3-oxo-8-3-trifluoromethylphenyl-2358-tetrahydro-124triazolo43-apyrimidine-5-ylphenyl-nnn-tri_en.pdf"},
    {"id":"26310","name":"EU/3/16/1705: Public summary of opinion on orphan designation: Sodium benzoate for the treatment of ornithine transcarbamylase deficiency","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/450237/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161705-public-summary-opinion-orphan-designation-sodium-benzoate-treatment-ornithine-transcarbamylase-deficiency_en.pdf"},
    {"id":"26311","name":"EU/3/14/1377: Public summary of opinion on orphan designation: Chloroquine for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2015-01-16T01:00:00Z","reference_number":"EMA/COMP/652852/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141377-public-summary-opinion-orphan-designation-chloroquine-treatment-glioma_en.pdf"},
    {"id":"26372","name":"EU/3/14/1288: Public summary of opinion on orphan designation: Norursodeoxycholic acid for the treatment of primary sclerosing cholangitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-16T02:00:00Z","last_updated_date":"2014-07-16T02:00:00Z","reference_number":"EMA/COMP/322667/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141288-public-summary-opinion-orphan-designation-norursodeoxycholic-acid-treatment-primary-sclerosing-cholangitis_en.pdf"},
    {"id":"26374","name":"EU/3/11/929: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human AIPL1 gene for the treatment of Leber’s congenital amaurosis type 4","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMA/COMP/870326/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311929-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-aipl1-gene-treatment-lebers-congenital-amaurosis-type-4_en.pdf"},
    {"id":"26422","name":"EU/3/02/086: Public summary of positive opinion for orphan designation of porfimer sodium (for use with photodynamic therapy) for the treatment of high-grade dysplasia in Barrett’s oesophagus","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T00:00:00Z","last_updated_date":"2013-06-20T13:00:00Z","reference_number":"EMEA/COMP/69/02 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302086-public-summary-positive-opinion-orphan-designation-porfimer-sodium-use-photodynamic-therapy-treatment-high-grade-dysplasia-barretts-oesophagus_en.pdf"},
    {"id":"26444","name":"EU/3/17/1967: Public summary of opinion on orphan designation: N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-\n\n(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt for the\n\ntreatment of congenital adrenal hyper...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-13T01:00:00Z","last_updated_date":"2018-03-13T01:00:00Z","reference_number":"EMA/848721/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171967-public-summary-opinion-orphan-designation-n-26-bis1-methylethylphenyl-n-1-4-dimethylaminophenylcyclopentylmethylurea-hydrochloride-salt-treatment-congenital-adrenal-hyper_en.pdf"},
    {"id":"26469","name":"EU/3/07/498: Public summary of positive opinion for orphan designation of polihexanide for the treatment of Acanthamoeba keratitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2008-07-02T02:00:00Z","reference_number":"EMEA/COMP/466752/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307498-public-summary-positive-opinion-orphan-designation-polihexanide-treatment-acanthamoeba-keratitis_en.pdf"},
    {"id":"26470","name":"EU/3/13/1148: Public summary of opinion on orphan designation: Autologous bone-marrow-derived mesenchymal stromal cells secreting neurotrophic factors for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-16T02:00:00Z","last_updated_date":"2013-08-16T02:00:00Z","reference_number":"EMA/COMP/417227/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131148-public-summary-opinion-orphan-designation-autologous-bone-marrow-derived-mesenchymal-stromal-cells-secreting-neurotrophic-factors-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"26477","name":"EU/3/16/1630: Public summary of opinion on orphan designation: Fenretinide for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-03T02:00:00Z","last_updated_date":"2022-01-19T02:00:00Z","reference_number":"EMA/COMP/172183/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161630-public-summary-opinion-orphan-designation-fenretinide-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"26491","name":"EU/3/15/1587: Public summary of opinion on orphan designation: Combretastatin A1 diphosphate for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/COMP/791083/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151587-public-summary-opinion-orphan-designation-combretastatin-a1-diphosphate-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"26542","name":"EU/3/02/117: Public summary of positive opinion for orphan designation of boswellia serrata resin extract for the treatment of peritumoral oedema derived from brain tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-23T00:00:00Z","last_updated_date":"2007-02-23T00:00:00Z","reference_number":"EMEA/COMP/2247/02 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302117-public-summary-positive-opinion-orphan-designation-boswellia-serrata-resin-extract-treatment-peritumoral-oedema-derived-brain-tumours_en.pdf"},
    {"id":"26543","name":"EU/3/13/1195: Public summary of opinion on orphan designation:Antisense oligonucleotide targeting the F508delta mutation of CFTR for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-10-31T01:00:00Z","last_updated_date":"2020-12-18T11:00:00Z","reference_number":"EMA/COMP/562059/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131195-public-summary-opinion-orphan-designationantisense-oligonucleotide-targeting-f508delta-mutation-cftr-treatment-cystic-fibrosis_en.pdf"},
    {"id":"26544","name":"EU/3/16/1786: Public summary of positive opinion for orphan designation of recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein for the treatmen...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T15:43:00Z","last_updated_date":"2016-12-14T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161786-public-summary-positive-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-serotype-2-carrying-gene-human-aromatic-l-amino-acid-decarboxylase-protein-treatmen_en.pdf"},
    {"id":"26561","name":"EU/3/13/1179: Public summary of opinion on orphan designation: Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains for the treatment of growth-hormone deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-13T02:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/COMP/440859/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131179-public-summary-opinion-orphan-designation-recombinant-human-growth-hormone-modified-fusion-two-hydrophilic-polypeptide-chains-treatment-growth-hormone-deficiency_en.pdf"},
    {"id":"26580","name":"Public summary of opinion on orphan designation: Nalbuphine hydrochloride for the treatment of uraemic pruritus","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/504453/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-nalbuphine-hydrochloride-treatment-uraemic-pruritus_en.pdf"},
    {"id":"26594","name":"EU/3/12/1072: Public summary of opinion on orphan designation: Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotropic factor for the treatment of macu...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2012-12-12T01:00:00Z","reference_number":"EMA/COMP/682942/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121072-public-summary-opinion-orphan-designation-encapsulated-human-retinal-pigment-epithelial-cell-line-transfected-plasmid-vector-expressing-human-ciliary-neurotropic-factor-treatment-macu_en.pdf"},
    {"id":"26616","name":"EU/3/12/1032: Public summary of opinion on orphan designation: Vatreptacog alfa (activated) for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-27T16:00:00Z","last_updated_date":"2015-03-06T15:00:00Z","reference_number":"EMA/COMP/527610/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121032-public-summary-opinion-orphan-designation-vatreptacog-alfa-activated-treatment-haemophilia-b_en.pdf"},
    {"id":"26628","name":"EU/3/13/1113: Public summary of opinion on orphan designation:\n\nMurine IgM monoclonal antibody binding to alpha beta T-cell receptor for the prevention of graft rejection following solid-organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2015-06-08T02:00:00Z","reference_number":"EMA/COMP/105743/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131113-public-summary-opinion-orphan-designation-murine-igm-monoclonal-antibody-binding-alpha-beta-t-cell-receptor-prevention-graft-rejection-following-solid-organ-transplantation_en.pdf"},
    {"id":"26646","name":"EU/3/13/1105: Public summary of positive opinion of humanised monoclonal antibody against myostatin for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T11:00:00Z","last_updated_date":"2020-10-23T11:00:00Z","reference_number":"EMA/COMP/34464/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131105-public-summary-positive-opinion-humanised-monoclonal-antibody-against-myostatin-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"26698","name":"EU/3/11/892: Public summary of opinion on orphan designation: 5-[1-(2,6-dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride for the treatment of 5q spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2011-09-21T02:00:00Z","reference_number":"EMA/COMP/512027/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311892-public-summary-opinion-orphan-designation-5-1-26-dichlorobenzylpiperidin-4-ylmethoxyquinazoline-24-diamine-dihydrochloride-treatment-5q-spinal-muscular-atrophy_en.pdf"},
    {"id":"26729","name":"EU/3/16/1650: Public summary of opinion on orphan designation: N-carboxymethyl-glycyl-L-threonyl-L-histidyl-L-3,3-diphenylalanyl-L-piperidincarboxy-3-yl-L-arginyl-L-S-methylthio-cystyl-L-arginyl-L-tryptophyl-aminohexanyl...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2017-08-10T02:00:00Z","reference_number":"EMA/COMP/235594/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161650-public-summary-opinion-orphan-designation-n-carboxymethyl-glycyl-l-threonyl-l-histidyl-l-33-diphenylalanyl-l-piperidincarboxy-3-yl-l-arginyl-l-s-methylthio-cystyl-l-arginyl-l-tryptophyl_en.pdf"},
    {"id":"26742","name":"EU/03/14/1279: Public summary of opinion on orphan designation of 4-(4-methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid for the prevention of scarring post glaucoma filtration surgery","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/COMP/226099/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu03141279-public-summary-opinion-orphan-designation-4-4-methoxy-phenylamino-6-methylcarbamyl-quinoline-3-carboxylic-acid-prevention-scarring-post-glaucoma-filtration-surgery_en.pdf"},
    {"id":"26752","name":"EU/3/09/682: Public summary of positive opinion for orphan designation of anti-EphA2 monoclonal antibody conjugated to maleimidocaproyl monomethylauristatin phenylalanine for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-17T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/COMP/578019/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309682-public-summary-positive-opinion-orphan-designation-anti-epha2-monoclonal-antibody-conjugated-maleimidocaproyl-monomethylauristatin-phenylalanine-treatment-ovarian-cancer_en.pdf"},
    {"id":"26754","name":"EU/3/16/1801: Public summary of opinion on orphan designation: Ibudilast for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/756482/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161801-public-summary-opinion-orphan-designation-ibudilast-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"26780","name":"EU/3/03/175: Public summary of positive opinion for orphan designation: Recombinant antibody derivative against human CD19 and CD3 for the treatment of mantle-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-11-05T00:00:00Z","last_updated_date":"2014-05-12T13:15:00Z","reference_number":"EMA/COMP/43398/2004 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303175-public-summary-positive-opinion-orphan-designation-recombinant-antibody-derivative-against-human-cd19-and-cd3-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"26798","name":"EU/3/01/081: Public summary of positive opinion for orphan designation of fumagillin for the treatment of diarrhoea associated with intestinal microsporidial infection","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2016-08-10T02:00:00Z","reference_number":"EMA/COMP/82/2002 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301081-public-summary-positive-opinion-orphan-designation-fumagillin-treatment-diarrhoea-associated-intestinal-microsporidial-infection_en.pdf"},
    {"id":"26811","name":"EU/3/09/653: Public summary of positive opinion for orphan designation of\n\neculizumab for the treatment of atypical haemolytic uraemic syndrome (aHUS)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMEA/COMP/364582/2009 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309653-public-summary-positive-opinion-orphan-designation-eculizumab-treatment-atypical-haemolytic-uraemic-syndrome-ahus_en.pdf"},
    {"id":"26817","name":"EU/3/05/291: Public summary of positive opinion for orphan designation of human monoclonal antibody against HLA-DR for the treatment of Hodgkin’s lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/192749/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305291-public-summary-positive-opinion-orphan-designation-human-monoclonal-antibody-against-hla-dr-treatment-hodgkins-lymphoma_en.pdf"},
    {"id":"26845","name":"EU/3/09/640: Public summary of positive opinion for orphan designation of pegylated recombinant human factor IX for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-09T02:00:00Z","last_updated_date":"2017-08-03T02:00:00Z","reference_number":"EMEA/COMP/214529/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309640-public-summary-positive-opinion-orphan-designation-pegylated-recombinant-human-factor-ix-treatment-haemophilia-b_en.pdf"},
    {"id":"26886","name":"Public summary of opinion on orphan designation: Sodium ascorbate and menadione sodium bisulfite for the treatment of autosomal dominant polycystic kidney disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/COMP/736555/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-sodium-ascorbate-and-menadione-sodium-bisulfite-treatment-autosomal-dominant-polycystic-kidney-disease_en.pdf"},
    {"id":"26896","name":"EU/3/10/841: Public summary of opinion on orphan designation: Tasimelteon for the treatment of non-24-hour sleep-wake disorder in blind people with no light perception","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/COMP/740405/2010 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310841-public-summary-opinion-orphan-designation-tasimelteon-treatment-non-24-hour-sleep-wake-disorder-blind-people-no-light-perception_en.pdf"},
    {"id":"26923","name":"EU/3/04/198: Public summary of positive opinion for orphan designation of human monoclonal antibody against CD4 for the treatment of cutaneous T cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2011-03-10T01:00:00Z","reference_number":"EMEA/COMP/135/04 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304198-public-summary-positive-opinion-orphan-designation-human-monoclonal-antibody-against-cd4-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"26933","name":"EU/3/14/1321: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene for the treatment of Crigler-Najjar syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-01T02:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/COMP/457011/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141321-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-ugt1a1-gene-treatment-crigler-najjar-syndrome_en.pdf"},
    {"id":"26942","name":"EU/3/16/1655: Public summary of opinion on orphan designation: Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu, Ser-Gly-Gln-Ala-Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-Pro-Ser-Cys-Leu-Glu-Ser, Arg-Ser-Asp-Glu-Leu-Val-Arg-His-His-Asn-Met...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2016-05-30T02:00:00Z","reference_number":"EMA/COMP/240771/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161655-public-summary-opinion-orphan-designation-tyr-met-phe-pro-asn-ala-pro-tyr-leu-ser-gly-gln-ala-tyr-met-phe-pro-asn-ala-pro-tyr-leu-pro-ser-cys-leu-glu-ser-arg-ser-asp-glu-leu-val-arg-his-his_en.pdf"},
    {"id":"26956","name":"EU/3/15/1538: Public summary of opinion on orphan designation: Fixed-dose combination of fosfomycin disodium and tobramycin for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/501084/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151538-public-summary-opinion-orphan-designation-fixed-dose-combination-fosfomycin-disodium-and-tobramycin-treatment-cystic-fibrosis_en.pdf"},
    {"id":"26987","name":"EU/3/13/1220: Public summary of opinion on orphan designation: Poly[2-[(4-{[1-carboxy-2-(hexadecylcarbamoyl)ethyl]sulfanyl}-2,3-bis({2-[((2S)-2-(2-{[(2R)-2-carbamoyl-(2-{[(2S)-1-ethoxy-3-(3-hydroxy-4oxo-1,4-dihydropyridi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-23T01:00:00Z","last_updated_date":"2015-06-08T02:00:00Z","reference_number":"EMA/COMP/698335/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131220-public-summary-opinion-orphan-designation-poly2-4-1-carboxy-2-hexadecylcarbamoylethylsulfanyl-23-bis2-2s-2-2-2r-2-carbamoyl-2-2s-1-ethoxy-3-3-hydroxy-4oxo-14-dihydropyridi_en.pdf"},
    {"id":"27034","name":"EU/3/08/608: Public summary of positive opinion for orphan designation of yttrium (90Y)-DOTA-radiolabelled humanized monoclonal antibody against mucin 1 for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-26T02:00:00Z","last_updated_date":"2020-03-06T02:00:00Z","reference_number":"EMEA/COMP/671125/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308608-public-summary-positive-opinion-orphan-designation-yttrium-90y-dota-radiolabelled-humanized-monoclonal-antibody-against-mucin-1-treatment-pancreatic-cancer_en.pdf"},
    {"id":"27039","name":"EU/3/04/231: Public summary of positive opinion for orphan designation of deferoxamine mesilate for the treatment of traumatic spinal-cord injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMEA/COMP/178558/2004 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304231-public-summary-positive-opinion-orphan-designation-deferoxamine-mesilate-treatment-traumatic-spinal-cord-injury_en.pdf"},
    {"id":"27063","name":"EU/3/06/422: Public summary of positive opinion for orphan designation of paclitaxel (micellar) for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2018-10-04T11:42:00Z","reference_number":"EMEA/COMP/453951/2006 Correction 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306422-public-summary-positive-opinion-orphan-designation-paclitaxel-micellar-treatment-ovarian-cancer_en.pdf"},
    {"id":"27085","name":"EU/3/10/785: Public summary of opinion on orphan designation: Vorinostat for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2013-03-12T13:30:00Z","reference_number":"EMA/381200/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310785-public-summary-opinion-orphan-designation-vorinostat-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"27098","name":"EU/3/17/1965: Public summary of opinion on orphan designation: Metformin and L-citrulline for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-12T01:00:00Z","last_updated_date":"2018-03-12T01:00:00Z","reference_number":"EMA/848685/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171965-public-summary-opinion-orphan-designation-metformin-and-l-citrulline-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"27106","name":"EU/3/05/293: Public summary of positive opinion for orphan designation of nelarabine for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMEA/COMP/163494/2005 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305293-public-summary-positive-opinion-orphan-designation-nelarabine-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"27131","name":"EU/3/04/251: Public summary of positive opinion for orphan designation of N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole for the treatment of malignant gastro intestinal stromal tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-06T00:00:00Z","last_updated_date":"2006-01-06T00:00:00Z","reference_number":"EMEA/COMP/155795/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304251-public-summary-positive-opinion-orphan-designation-n-methyl-diazacyclohexyl-methylbenzamide-azaphenyl-aminothiopyrrole-treatment-malignant-gastro-intestinal-stromal-tumours_en.pdf"},
    {"id":"27173","name":"EU/3/05/307: Public summary of positive opinion for orphan designation of mecasermin for the treatment of primary growth hormone insensitivity syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-04T02:00:00Z","last_updated_date":"2009-11-19T00:00:00Z","reference_number":"EMEA/COMP/247635/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305307-public-summary-positive-opinion-orphan-designation-mecasermin-treatment-primary-growth-hormone-insensitivity-syndrome_en.pdf"},
    {"id":"27186","name":"Public summary of opinion on orphan designation: Lentiviral vector expressing the truncated form of human tyrosine hydroxylase gene, human aromatic L amino-acid decarboxylase gene, human GTP-cyclohydrolase 1 gene","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-03-30T18:30:00Z","last_updated_date":"2012-03-30T18:30:00Z","reference_number":"EMA/COMP/139305/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-lentiviral-vector-expressing-truncated-form-human-tyrosine-hydroxylase-gene-human-aromatic-l-amino-acid-decarboxylase-gene-human-gtp-cyclohydrolase-1-gene_en.pdf"},
    {"id":"27194","name":"EU/3/18/2012: Public summary of opinion on orphan designation: Genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII for treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T13:00:00Z","last_updated_date":"2018-05-17T13:00:00Z","reference_number":"EMA/188612/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182012-public-summary-opinion-orphan-designation-genetically-modified-replication-incompetent-herpes-simplex-virus-1-expressing-collagen-vii-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"27222","name":"EU/3/18/1987: Public summary of opinion on orphan designation: Vocimagene amiretrorepvec for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/62737/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181987-public-summary-opinion-orphan-designation-vocimagene-amiretrorepvec-treatment-glioma_en.pdf"},
    {"id":"27243","name":"EU/3/08/610: Public summary of positive opinion for orphan designation of\n\ncyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt for the treatment o...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMEA/COMP/11538/2009 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308610-public-summary-positive-opinion-orphan-designation-cyclopropane-11-dicarboxylic-acid-4-67-dimethoxy-quinolin-4-yloxy-phenyl-amide-4-fluoro-phenyl-amide-l-malate-salt-treatment-o_en.pdf"},
    {"id":"27266","name":"EU/3/14/1332: Public summary of opinion on orphan designation: Macromolecular conjugate of heparin sodium on a polymer backbone for the prevention of ischaemia/reperfusion injury associated with solid organ transplantati...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2014-10-02T02:00:00Z","reference_number":"EMA/COMP/452094/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141332-public-summary-opinion-orphan-designation-macromolecular-conjugate-heparin-sodium-polymer-backbone-prevention-ischaemiareperfusion-injury-associated-solid-organ-transplantati_en.pdf"},
    {"id":"27332","name":"EU/3/12/963: Public summary of opinion on orphan designation: Chlormethine for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-06T18:00:00Z","last_updated_date":"2015-03-23T17:00:00Z","reference_number":"EMA/COMP/60984/2012 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312963-public-summary-opinion-orphan-designation-chlormethine-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"27356","name":"EU/3/13/1214: Public summary of opinion on orphan designation: (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-22T01:00:00Z","last_updated_date":"2021-09-08T01:00:00Z","reference_number":"EMA/COMP/696783/2013 Corr.","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131214-public-summary-opinion-orphan-designation-4r5r-1-4-4-33-dibutyl-7-dimethylamino-2345-tetrahydro-4-hydroxy-11-dioxido-1-benzothiepin-5-ylphenoxymethylphenylmethyl-4-aza-1-azoniabi_en.pdf"},
    {"id":"27386","name":"EU/3/14/1251: Public summary of opinion on orphan designation: Recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan for the treatment of glycogen st...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-06T02:00:00Z","last_updated_date":"2014-05-06T02:00:00Z","reference_number":"EMA/COMP/96508/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141251-public-summary-opinion-orphan-designation-recombinant-human-alpha-glucosidase-conjugated-multiple-copies-synthetic-bismannose-6-phosphate-tetra-mannose-glycan-treatment-glycogen-st_en.pdf"},
    {"id":"27397","name":"EU/3/16/1824: Public summary of opinion on orphan designation: Pr-D-Cys-Met-Pip-Arg-Leu-Arg-Sar-Cys-Lys-Arg-Pro-Tyr-Tle-Leu-OH for the treatment of perinatal asphyxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/5833/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161824-public-summary-opinion-orphan-designation-pr-d-cys-met-pip-arg-leu-arg-sar-cys-lys-arg-pro-tyr-tle-leu-oh-treatment-perinatal-asphyxia_en.pdf"},
    {"id":"27469","name":"EU/3/02/111: Public summary of positive opinion for orphan designation of benzoic acid, sodium salt for the treatment of non-ketotic hyperglycinaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-08T00:00:00Z","last_updated_date":"2003-01-08T00:00:00Z","reference_number":"EMEA/COMP/1639/02 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302111-public-summary-positive-opinion-orphan-designation-benzoic-acid-sodium-salt-treatment-non-ketotic-hyperglycinaemia_en.pdf"},
    {"id":"27496","name":"EU/3/16/1748: Public summary of positive opinion for orphan designation of crenolanib besylate for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/629727/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161748-public-summary-positive-opinion-orphan-designation-crenolanib-besylate-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"27514","name":"EU/3/15/1595: Public summary of opinion on orphan designation: Live attenuated Listeria monocytogenes bioengineered with a chimeric human epidermal growth factor receptor 2 fused to a truncated form of the Lm protein lis...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2016-02-03T01:00:00Z","reference_number":"EMA/COMP/780391/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151595-public-summary-opinion-orphan-designation-live-attenuated-listeria-monocytogenes-bioengineered-chimeric-human-epidermal-growth-factor-receptor-2-fused-truncated-form-lm-protein-lis_en.pdf"},
    {"id":"27574","name":"EU/3/15/1438: Public summary of opinion on orphan designation: Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus ...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T02:00:00Z","last_updated_date":"2015-05-19T02:00:00Z","reference_number":"EMA/COMP/55786/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151438-public-summary-opinion-orphan-designation-allogeneic-cd4-and-cd8-t-lymphocytes-ex-vivo-incubated-synthetic-peptides-viral-antigens-cytomegalovirus-adenovirus-and-epstein-barr-virus_en.pdf"},
    {"id":"27576","name":"EU/3/08/535: Public summary of positive opinion for orphan designation of humanised monoclonal antibody to the folate receptor alpha for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/48649/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308535-public-summary-positive-opinion-orphan-designation-humanised-monoclonal-antibody-folate-receptor-alpha-treatment-ovarian-cancer_en.pdf"},
    {"id":"27577","name":"EU/3/13/1138: Public summary of opinion on orphan designation: Copper meso-5,15-bis[3-[(1,2-dicarba-closo-dodecaboranyl)methoxy]phenyl]-meso-10,20-dinitroporphyrin for the treatment of squamous cell carcinoma of the head...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T14:00:00Z","last_updated_date":"2015-03-23T13:00:00Z","reference_number":"EMA/COMP/309838/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131138-public-summary-opinion-orphan-designation-copper-meso-515-bis3-12-dicarba-closo-dodecaboranylmethoxyphenyl-meso-1020-dinitroporphyrin-treatment-squamous-cell-carcinoma-head_en.pdf"},
    {"id":"27587","name":"EU/3/11/902: Public summary of opinion on orphan designation: Eflornithine for the treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/COMP/660536/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311902-public-summary-opinion-orphan-designation-eflornithine-treatment-neuroblastoma_en.pdf"},
    {"id":"27606","name":"EU/3/14/1340: Public summary of opinion on orphan designation: Cultured allogeneic corneal limbal stem cells for the treatment of limbal stem cell deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/557523/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141340-public-summary-opinion-orphan-designation-cultured-allogeneic-corneal-limbal-stem-cells-treatment-limbal-stem-cell-deficiency_en.pdf"},
    {"id":"27623","name":"EU/3/06/413: Public summary of positive opinion for orphan designation of budesonide (oral use) for the treatment of Graft-versus-Host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-20T00:00:00Z","last_updated_date":"2011-06-21T01:00:00Z","reference_number":"EMEA/COMP/405290/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306413-public-summary-positive-opinion-orphan-designation-budesonide-oral-use-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"27700","name":"EU/3/01/062: Public summary of positive opinion for orphan designation of idebenone for the treatment of Friedreich’s ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-11T02:00:00Z","last_updated_date":"2005-10-11T02:00:00Z","reference_number":"EMEA/COMP/266/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301062-public-summary-positive-opinion-orphan-designation-idebenone-treatment-friedreichs-ataxia_en.pdf"},
    {"id":"27710","name":"EU/3/01/043: Public summary of positive opinion for orphan designation of human milk fat globule 1/Yttrium (90Y) human milk fat globule 1-S-p-isothiocyanatobenzyl-diethylenetriaminepentaacetic acid for the treatment of o...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-06-02T02:00:00Z","last_updated_date":"2004-06-02T02:00:00Z","reference_number":"EMEA/COMP/1286/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301043-public-summary-positive-opinion-orphan-designation-human-milk-fat-globule-1yttrium-90y-human-milk-fat-globule-1-s-p-isothiocyanatobenzyl-diethylenetriaminepentaacetic-acid-treatment-o_en.pdf"},
    {"id":"27744","name":"EU/3/13/1187: Public summary of opinion on orphan designation: Idelalisib for the treatment of splenic marginal-zone lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-16T02:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/COMP/434311/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131187-public-summary-opinion-orphan-designation-idelalisib-treatment-splenic-marginal-zone-lymphoma_en.pdf"},
    {"id":"27766","name":"EU/3/12/972: Public summary of opinion on orphan designation: Sialic acid for treatment of GNE myopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T11:45:00Z","last_updated_date":"2017-05-05T11:45:00Z","reference_number":"EMA/159934/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312972-public-summary-opinion-orphan-designation-sialic-acid-treatment-gne-myopathy_en.pdf"},
    {"id":"27784","name":"EU/3/14/1258: Public summary of opinion on orphan designation: Doxorubicin(6-maleimidocaproyl)hydrazone for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-07T02:00:00Z","last_updated_date":"2023-06-06T02:00:00Z","reference_number":"EMA/COMP/89615/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141258-public-summary-opinion-orphan-designation-doxorubicin6-maleimidocaproylhydrazone-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"27788","name":"EU/3/09/669: Public summary of positive opinion for orphan designation of low molecular weight dextran sulfate for the prevention of graft rejection during pancreatic islet transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2011-11-18T16:00:00Z","reference_number":"EMEA/COMP/439787/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309669-public-summary-positive-opinion-orphan-designation-low-molecular-weight-dextran-sulfate-prevention-graft-rejection-during-pancreatic-islet-transplantation_en.pdf"},
    {"id":"27800","name":"EU/3/09/677 - Public summary of positive opinion for orphan designation of human tumour necrosis factor alpha-derived peptide Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys for the treatment of acute...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2009-10-20T02:00:00Z","reference_number":"EMEA/COMP/442408/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309677-public-summary-positive-opinion-orphan-designation-human-tumour-necrosis-factor-alpha-derived-peptide-cys-gly-gln-arg-glu-thr-pro-glu-gly-ala-glu-ala-lys-pro-trp-tyr-cys-treatment-acute_en.pdf"},
    {"id":"27806","name":"EU/3/14/1385: Public summary of positive opinion for orphan designation: Heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-02-26T18:00:00Z","reference_number":"EMA/COMP/733185/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141385-public-summary-positive-opinion-orphan-designation-heat-killed-mycobacterium-obuense-whole-cell-treatment-pancreatic-cancer_en.pdf"},
    {"id":"27840","name":"EU/3/13/1156: Public summary of opinion on orphan designation: Recombinant human monoclonal antibody against hepatitis-B virus for the prevention of hepatitis-B re-infection following liver transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-22T17:30:00Z","last_updated_date":"2015-03-12T16:30:00Z","reference_number":"EMA/COMP/401189/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131156-public-summary-opinion-orphan-designation-recombinant-human-monoclonal-antibody-against-hepatitis-b-virus-prevention-hepatitis-b-re-infection-following-liver-transplantation_en.pdf"},
    {"id":"27853","name":"EU/3/13/1192: Public summary of opinion on orphan designation:\n\nZoledronic acid for the treatment of complex regional pain syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-10-31T01:00:00Z","last_updated_date":"2013-10-31T01:00:00Z","reference_number":"EMA/COMP/554682/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131192-public-summary-opinion-orphan-designation-zoledronic-acid-treatment-complex-regional-pain-syndrome_en.pdf"},
    {"id":"27875","name":"EU/3/14/1301: Public summary of opinion on orphan designation: Humanised anti-alpha ν beta 6 monoclonal antibody for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T02:00:00Z","last_updated_date":"2014-09-01T02:00:00Z","reference_number":"EMA/COMP/374511/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141301-public-summary-opinion-orphan-designation-humanised-anti-alpha-i-12-beta-6-monoclonal-antibody-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"27889","name":"EU/3/16/1732 : Public summary of opinion on orphan designation: Synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid for the treatment of amyotrophic lateral scler...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161732-public-summary-opinion-orphan-designation-synthetic-ribonucleic-acid-oligonucleotide-directed-against-superoxide-dismutase-1-messenger-ribonucleic-acid-treatment-amyotrophic-lateral-scler_en.pdf"},
    {"id":"27890","name":"EU/3/06/359: Public summary of positive opinion for orphan designation of adeno-associated viral vector containing the human calpain 3 gene for the treatment of calpainopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-24T01:00:00Z","last_updated_date":"2014-06-18T02:00:00Z","reference_number":"EMEA/COMP/96343/2006 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306359-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-containing-human-calpain-3-gene-treatment-calpainopathy_en.pdf"},
    {"id":"27902","name":"EU/3/18/2024: Public summary of opinion on orphan designation: Itraconazole for the prevention of invasive aspergillosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-24T11:27:00Z","last_updated_date":"2018-07-24T11:27:00Z","reference_number":"EMA/272912/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182024-public-summary-opinion-orphan-designation-itraconazole-prevention-invasive-aspergillosis_en.pdf"},
    {"id":"27918","name":"EU/3/13/1153: Public summary of opinion on orphan designation: Daratumumab for the treatment of plasma-cell myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-16T02:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/COMP/400238/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131153-public-summary-opinion-orphan-designation-daratumumab-treatment-plasma-cell-myeloma_en.pdf"},
    {"id":"27937","name":"EU/3/17/1935: Public summary of opinion on orphan designation: 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene for the treatment of non-traumatic subarachnoid haemorrhage","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-15T01:00:00Z","last_updated_date":"2018-01-15T01:00:00Z","reference_number":"EMA/COMP/685526/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171935-public-summary-opinion-orphan-designation-14-diamino-23-dicyano-14-bis2-aminophenylthiobutadiene-treatment-non-traumatic-subarachnoid-haemorrhage_en.pdf"},
    {"id":"27941","name":"EU/3/11/899: Public summary of opinion on orphan designation: 2,2'-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid for the treatment of multiple myel...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMA/COMP/635488/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311899-public-summary-opinion-orphan-designation-22-2-1r-1-25-dichlorobenzoylaminoacetylamino-3-methylbutyl-5-oxo-132-dioxaborolane-44-diyldiacetic-acid-treatment-multiple-myel_en.pdf"},
    {"id":"27951","name":"EU/3/09/632: Public summary of positive opinion for orphan designation\n\nof adeno-associated viral vector containing porphobilinogen deaminase gene\n\nfor the treatment of acute intermittent porphyria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-12T02:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"EMA/COMP/147330/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309632-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-containing-porphobilinogen-deaminase-gene-treatment-acute-intermittent-porphyria_en.pdf"},
    {"id":"27963","name":"EU/3/13/1115: Public summary of opinion on orphan designation:1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one for the treatment of mantle-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/COMP/101688/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131115-public-summary-opinion-orphan-designation1-3r-3-4-amino-3-4-phenoxyphenyl-1h-pyrazolo34-dpyrimidin-1-yl-1-piperidinyl-2-propen-1-one-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"27978","name":"EU/3/15/1491: Public summary of opinion on orphan designation: Triamcinolone acetonide for the treatment of non-infectious Adeno-associated viral vector serotype 9 containing the human HGSNAT gene for the treatment of mu...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"EMA/COMP/280636/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151491-public-summary-opinion-orphan-designation-triamcinolone-acetonide-treatment-non-infectious-adeno-associated-viral-vector-serotype-9-containing-human-hgsnat-gene-treatment-mu_en.pdf"},
    {"id":"27984","name":"EU/3/09/673: Public summary of positive opinion for orphan designation of recombinant antibody construct against human CD30 and CD16A for the treatment of Hodgkin’s lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2009-10-20T02:00:00Z","reference_number":"EMEA/COMP/475406/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309673-public-summary-positive-opinion-orphan-designation-recombinant-antibody-construct-against-human-cd30-and-cd16a-treatment-hodgkins-lymphoma_en.pdf"},
    {"id":"27997","name":"EU/3/17/1863: Public summary of opinion on orphan designation: Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturati...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/208155/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171863-public-summary-opinion-orphan-designation-autologous-t-lymphocyte-enriched-population-cells-transduced-lentiviral-vector-encoding-chimeric-antigen-receptor-targeting-human-b-cell-maturati_en.pdf"},
    {"id":"28013","name":"EU/3/06/427: Public summary of positive opinion for orphan designation of fenretinide for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2011-03-25T01:00:00Z","reference_number":"EMA/COMP/96616/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306427-public-summary-positive-opinion-orphan-designation-fenretinide-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"28020","name":"EU/3/09/618: Public summary of positive opinion for orphan designation\n\nof allogeneic ex-vivo-expanded umbilical-cord blood cells for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-20T01:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMEA/COMP/15535/2009 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309618-public-summary-positive-opinion-orphan-designation-allogeneic-ex-vivo-expanded-umbilical-cord-blood-cells-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"28025","name":"EU/3/02/112: Public summary of positive opinion for orphan designation of\n\ndoxorubicin carbon/iron magnetically targeted microparticles for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/2020/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302112-public-summary-positive-opinion-orphan-designation-doxorubicin-carboniron-magnetically-targeted-microparticles-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"28041","name":"EU/3/16/1790: Public summary of positive opinion for orphan designation of Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Gly-Gly-Asp-Leu-Leu-Pro-Arg-Gly-Ser for the treatment of Huntington’s disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T12:46:00Z","last_updated_date":"2016-12-14T12:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161790-public-summary-positive-opinion-orphan-designation-tyr-gly-arg-lys-lys-arg-arg-gln-arg-arg-gly-gly-asp-leu-leu-pro-arg-gly-ser-treatment-huntingtons-disease_en.pdf"},
    {"id":"28055","name":"EU/3/00/011: Public summary of positive opinion for orphan designation of busulfan (intravenous use) for the conditioning treatment prior to haematopoietic-progenitor-cell transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2013-07-31T02:00:00Z","reference_number":"EMEA/COMP/243537/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300011-public-summary-positive-opinion-orphan-designation-busulfan-intravenous-use-conditioning-treatment-prior-haematopoietic-progenitor-cell-transplantation_en.pdf"}    {"id":"28057","name":"EU/3/13/1114: Public summary of opinion on orphan designation: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl] aceta...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-08T12:50:00Z","last_updated_date":"2013-04-08T12:50:00Z","reference_number":"EMA/COMP/105652/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131114-public-summary-opinion-orphan-designation-cyclol-alanyl-l-seryl-l-isoleucyl-l-prolyl-l-prolyl-l-glutaminyl-l-lysyl-l-tyrosyl-d-prolyl-l-prolyl-2s-2-aminodecanoyl-l-alpha-glutamyl-l-threonyl_en.pdf"},
    {"id":"28097","name":"EU/3/16/1631: Public summary of opinion on orphan designation: Florilglutamic acid (18F) for the diagnosis of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-02T02:00:00Z","last_updated_date":"2016-05-02T02:00:00Z","reference_number":"EMA/COMP/172323/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161631-public-summary-opinion-orphan-designation-florilglutamic-acid-18f-diagnosis-glioma_en.pdf"},
    {"id":"28115","name":"EU/3/15/1596: Public summary of opinion on orphan designation: Bilayer engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts for the treatment of partial deep dermal and full ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2016-02-03T01:00:00Z","reference_number":"EMA/COMP/796203/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151596-public-summary-opinion-orphan-designation-bilayer-engineered-collagen-hydrogel-based-skin-graft-composed-autologous-keratinocytes-and-fibroblasts-treatment-partial-deep-dermal-and-full_en.pdf"},
    {"id":"28122","name":"EU/3/06/366: Public summary of positive opinion for orphan designation of tobramycin (liposomal) for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2013-03-14T11:00:00Z","reference_number":"EMEA/COMP/105966/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306366-public-summary-positive-opinion-orphan-designation-tobramycin-liposomal-treatment-pseudomonas-aeruginosa-lung-infection-cystic-fibrosis_en.pdf"},
    {"id":"28142","name":"EU/3/18/2003: Public summary of opinion on orphan designation: Ribavirin for the treatment of Lassa fever","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-15T02:00:00Z","last_updated_date":"2018-05-15T02:00:00Z","reference_number":"EMA/132080/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182003-public-summary-opinion-orphan-designation-ribavirin-treatment-lassa-fever_en.pdf"},
    {"id":"28143","name":"EU/3/10/830: Public summary of opinion on orphan designation: Veliparib for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2013-03-14T11:00:00Z","reference_number":"EMA/COMP/668370/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310830-public-summary-opinion-orphan-designation-veliparib-treatment-ovarian-cancer_en.pdf"},
    {"id":"28146","name":"EU/3/08/566: Public summary of positive opinion for orphan designation of levofloxacin hemihydrate for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2018-02-09T01:00:00Z","reference_number":"EMEA/COMP/450243/2008 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308566-public-summary-positive-opinion-orphan-designation-levofloxacin-hemihydrate-treatment-cystic-fibrosis_en.pdf"},
    {"id":"28156","name":"EU/3/11/938: Public summary of positive opinion for orphan designation: Adeno-associated viral vector containing the human factor IX gene for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2013-03-11T13:30:00Z","reference_number":"EMA/COMP/911845/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311938-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-containing-human-factor-ix-gene-treatment-haemophilia-b_en.pdf"},
    {"id":"28240","name":"EU/3/09/671: Public summary of positive opinion for orphan designation of pasireotide for the treatment of Cushing’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2022-06-14T01:00:00Z","reference_number":"EMEA/COMP/455317/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309671-public-summary-positive-opinion-orphan-designation-pasireotide-treatment-cushings-disease_en.pdf"},
    {"id":"28252","name":"EU/3/18/2037: Public summary of opinion on orphan designation: Omaveloxolone for treatment of Friedreich's ataxia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-22T12:01:00Z","last_updated_date":"2018-08-22T12:01:00Z","reference_number":"EMA/395368/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182037-public-summary-opinion-orphan-designation-omaveloxolone-treatment-friedreichs-ataxia_en.pdf"},
    {"id":"28254","name":"EU/3/09/718: Public summary of opinion on orphan designation of fingolimod for the treatment of chronic inflammatory demyelinating polyneuropathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T14:43:00Z","last_updated_date":"2017-02-07T14:43:00Z","reference_number":"EMA/COMP/831319/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309718-public-summary-opinion-orphan-designation-fingolimod-treatment-chronic-inflammatory-demyelinating-polyneuropathy_en.pdf"},
    {"id":"28259","name":"EU/3/03/139: Public summary of positive opinion for orphan designation of bosentan for treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2014-05-08T18:00:00Z","reference_number":"EMEA/COMP/270/03 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303139-public-summary-positive-opinion-orphan-designation-bosentan-treatment-systemic-sclerosis_en.pdf"},
    {"id":"28276","name":"EU/3/09/661: Public summary of positive opinion for orphan designation: (S)-ethyl 2-amino-3-(4-(2-amino-6(-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate for the tr...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/142686/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309661-public-summary-positive-opinion-orphan-designation-s-ethyl-2-amino-3-4-2-amino-6-1-4-chloro-2-3-methyl-1h-pyrazol-1-ylphenyl-222-trifluoroethoxypyrimidin-4-ylphenylpropanoate-tr_en.pdf"},
    {"id":"28280","name":"EU/3/06/410: Public summary of positive opinion for orphan designation of\n\ndoxorubicin hydrochloride (liposomal) for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2009-04-02T02:00:00Z","reference_number":"EMEA/COMP/41533/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306410-public-summary-positive-opinion-orphan-designation-doxorubicin-hydrochloride-liposomal-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"28290","name":"EU/3/12/1024: Public summary of opinion on orphan designation: Metreleptin for the treatment of Lawrence syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-08-31T12:30:00Z","last_updated_date":"2015-05-13T12:30:00Z","reference_number":"EMA/COMP/440579/2012 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121024-public-summary-opinion-orphan-designation-metreleptin-treatment-lawrence-syndrome_en.pdf"},
    {"id":"28291","name":"EU/3/13/1230: Public summary of opinion on orphan designation: (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T01:00:00Z","last_updated_date":"2014-03-24T01:00:00Z","reference_number":"EMA/COMP/5578/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131230-public-summary-opinion-orphan-designation-2r3r4s5r-2-6-amino-9h-purin-9-yl-5-1r3s-3-2-5-tert-butyl-1h-benzodimidazol-2-ylethylcyclobutylisopropyl-aminomethyltetrahydrofuran_en.pdf"},
    {"id":"28341","name":"EU/3/03/181: Public summary of positive opinion for orphan designation of N-acetylsarcosyl-glycyl-L-valyl-D-allo-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-propyl-N-ethylamide for the treatment of soft tissu...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/1574/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303181-public-summary-positive-opinion-orphan-designation-n-acetylsarcosyl-glycyl-l-valyl-d-allo-isoleucyl-l-threonyl-l-norvalyl-l-isoleucyl-l-arginyl-l-propyl-n-ethylamide-treatment-soft-tissu_en.pdf"},
    {"id":"28347","name":"EU/3/05/266: Public summary of positive opinion for orphan designation of ciclosporin (inhalation use) for the prevention of graft rejection after lung transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T00:00:00Z","last_updated_date":"2016-10-22T01:00:00Z","reference_number":"EMEA/COMP/42149/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305266-public-summary-positive-opinion-orphan-designation-ciclosporin-inhalation-use-prevention-graft-rejection-after-lung-transplantation_en.pdf"},
    {"id":"28364","name":"EU/3/15/1606: Public summary of opinion on orphan designation: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate for the treatment of s...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2019-10-24T01:00:00Z","reference_number":"EMA/COMP/844899/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151606-public-summary-opinion-orphan-designation-s-n-5-r-2-25-difluorophenylpyrrolidin-1-ylpyrazolo15-apyrimidin-3-yl-3-hydroxypyrrolidine-1-carboxamide-hydrogen-sulfate-treatment-s_en.pdf"},
    {"id":"28370","name":"EU/3/01/082: Public summary of positive opinion for orphan designation \n\nof 2-chloro-9-[2-deoxy-2-fluoro-àŸ-D-arabinofuranosyl]adenine for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2016-08-10T02:00:00Z","reference_number":"EMEA/COMP/66/02 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301082-public-summary-positive-opinion-orphan-designation-2-chloro-9-2-deoxy-2-fluoro-ay-d-arabinofuranosyladenine-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"28383","name":"EU/3/08/528: Public summary of positive opinion for orphan designation of lumiliximab for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/36761/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308528-public-summary-positive-opinion-orphan-designation-lumiliximab-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"28387","name":"EU/3/16/1769: Public summary of positive opinion for orphan designation of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde for the treatment of sickle cell disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T15:43:00Z","last_updated_date":"2016-12-14T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161769-public-summary-positive-opinion-orphan-designation-2-hydroxy-6-2-1-isopropyl-1h-pyrazol-5-ylpyridin-3-ylmethoxybenzaldehyde-treatment-sickle-cell-disease_en.pdf"},
    {"id":"28445","name":"EU/3/10/766: Public summary of opinion on orphan designation of Pyr-His-Trp-Ser-Tyr-D-Lys(doxorubicinylglutarate)-Leu-Arg-Pro-Gly-NH2, acetate salt for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-11T01:31:00Z","last_updated_date":"2017-08-16T12:55:00Z","reference_number":"EMA/COMP/320551/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310766-public-summary-opinion-orphan-designation-pyr-his-trp-ser-tyr-d-lysdoxorubicinylglutarate-leu-arg-pro-gly-nh2-acetate-salt-treatment-ovarian-cancer_en.pdf"},
    {"id":"28451","name":"EU/3/10/803: Public summary of opinion on orphan designation chimeric monoclonal antibody against claudin-18 splice variant 2 for the treatment of gastric cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-15T01:00:00Z","last_updated_date":"2010-12-15T01:00:00Z","reference_number":"EMA/579374/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310803-public-summary-opinion-orphan-designation-chimeric-monoclonal-antibody-against-claudin-18-splice-variant-2-treatment-gastric-cancer_en.pdf"},
    {"id":"28466","name":"EU/3/16/1714 : Public summary of opinion on orphan designation: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-paromamine sulfate for the treatment of mucopolysaccharidosis type I","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-11T19:05:00Z","last_updated_date":"2016-10-11T19:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161714-public-summary-opinion-orphan-designation-6-r-methyl-5-o-5-amino-56-dideoxy-i-l-talofuranosyl-paromamine-sulfate-treatment-mucopolysaccharidosis-type-i_en.pdf"},
    {"id":"28512","name":"EU/3/07/504: Public summary of  positive opinion for orphan designation: Irinotecan hydrochloride (drug-eluting beads) for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-01T02:00:00Z","last_updated_date":"2017-04-25T02:00:00Z","reference_number":"EMA/COMP/539060/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307504-public-summary-positive-opinion-orphan-designation-irinotecan-hydrochloride-drug-eluting-beads-treatment-glioma_en.pdf"},
    {"id":"28551","name":"EU/3/02/110: Public summary of positive opinion for orphan designation of thymalfasin for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-08T01:00:00Z","last_updated_date":"2003-01-08T01:00:00Z","reference_number":"EMEA/COMP/1477/02 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302110-public-summary-positive-opinion-orphan-designation-thymalfasin-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"28597","name":"EU/3/15/1470: Public summary of positive opinion for orphan designation of  5,10,15,20-tetrakis(2,6-difluoro-3-N-methylsulfamoylphenyl)bacteriochlorin for the treatment of biliary tract cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/126073/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151470-public-summary-positive-opinion-orphan-designation-5101520-tetrakis26-difluoro-3-n-methylsulfamoylphenylbacteriochlorin-treatment-biliary-tract-cancer_en.pdf"},
    {"id":"28618","name":"EU/3/14/1414: Public summary of opinion on orphan designation: Sodium thiosulfate for the treatment for calciphylaxis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/COMP/786341/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141414-public-summary-opinion-orphan-designation-sodium-thiosulfate-treatment-calciphylaxis_en.pdf"},
    {"id":"28623","name":"EU/3/01/063: Public summary of positive opinion for orphan designation of deoxyribose phosphorothioate (5’-tct-ccc-agc-gtg-cgc-cat-3’) for the treatment of chronic lymphocytic leukemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-01-06T00:00:00Z","last_updated_date":"2013-04-09T02:00:00Z","reference_number":"EMA/COMP/10718/2003 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301063-public-summary-positive-opinion-orphan-designation-deoxyribose-phosphorothioate-5-tct-ccc-agc-gtg-cgc-cat-3-treatment-chronic-lymphocytic-leukemia_en.pdf"},
    {"id":"28638","name":"EU/3/16/1776: Public summary of positive opinion for orphan designation of ascorbic acid for the treatment of facioscapulohumeral muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T14:28:00Z","last_updated_date":"2016-12-14T14:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161776-public-summary-positive-opinion-orphan-designation-ascorbic-acid-treatment-facioscapulohumeral-muscular-dystrophy_en.pdf"},
    {"id":"28670","name":"EU/3/07/431: Public summary of positive opinion for orphan designation of autologous dendritic cells pulsed with autologous tumour cell lysate for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2013-03-01T01:00:00Z","reference_number":"EMA/COMP/96767/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307431-public-summary-positive-opinion-orphan-designation-autologous-dendritic-cells-pulsed-autologous-tumour-cell-lysate-treatment-glioma_en.pdf"},
    {"id":"28708","name":"EU/3/15/1593: Public summary of opinion on orphan designation: Imetelstat sodium for the treatment of myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2016-02-03T01:00:00Z","reference_number":"EMA/COMP/777525/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151593-public-summary-opinion-orphan-designation-imetelstat-sodium-treatment-myelofibrosis_en.pdf"},
    {"id":"28736","name":"EU/3/12/1059: Public summary of opinion on orphan designation: Milciclib maleate for treatment of malignant thymoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-07-09T02:00:00Z","last_updated_date":"2021-03-22T02:00:00Z","reference_number":"EMA/COMP/655696/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121059-public-summary-opinion-orphan-designation-milciclib-maleate-treatment-malignant-thymoma_en.pdf"},
    {"id":"28829","name":"EU/3/13/1170: Public summary of opinion on orphan designation: Octreotide acetate (oral use) for treatment of acromegaly","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-12T02:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/COMP/443659/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131170-public-summary-opinion-orphan-designation-octreotide-acetate-oral-use-treatment-acromegaly_en.pdf"},
    {"id":"28830","name":"EU/3/15/1586: Public summary of opinion on orphan designation: Recombinant human nerve growth factor for the treatment of neurotrophic keratitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/COMP/793645/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151586-public-summary-opinion-orphan-designation-recombinant-human-nerve-growth-factor-treatment-neurotrophic-keratitis_en.pdf"},
    {"id":"28844","name":"EU/3/11/930: Public summary of opinion on orphan designation: Resminostat for the treatment of Hodgkin’s lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"EMA/COMP/862754/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311930-public-summary-opinion-orphan-designation-resminostat-treatment-hodgkins-lymphoma_en.pdf"},
    {"id":"28855","name":"EU/3/18/2032: Public summary of opinion on orphan designation: Carmustine for treatment in haematopoietic stem cell transplantation","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-21T12:47:00Z","last_updated_date":"2018-08-21T12:47:00Z","reference_number":"EMA/355631/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182032-public-summary-opinion-orphan-designation-carmustine-treatment-haematopoietic-stem-cell-transplantation_en.pdf"},
    {"id":"28909","name":"EU/3/17/1936: Public summary of opinion on orphan designation: 1-[4-Bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea for the treatment of gastrointestinal stromal tum...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-15T01:00:00Z","last_updated_date":"2018-01-15T01:00:00Z","reference_number":"EMA/689763/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171936-public-summary-opinion-orphan-designation-1-4-bromo-5-1-ethyl-7-methylamino-2-oxo-12-dihydro-16-naphthyridin-3-yl-2-fluorophenyl-3-phenylurea-treatment-gastrointestinal-stromal-tum_en.pdf"},
    {"id":"28924","name":"EU/3/03/178: Public summary of positive opinion for orphan designation of sildenafil citrate for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T00:00:00Z","last_updated_date":"2016-01-20T00:00:00Z","reference_number":"EMEA/COMP/1572/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303178-public-summary-positive-opinion-orphan-designation-sildenafil-citrate-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"28960","name":"EU/3/01/071: Public summary of positive opinion for orphan designation of stiripentol for the treatment of severe myoclonic epilepsy in infancy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-31T02:00:00Z","last_updated_date":"2017-02-08T01:00:00Z","reference_number":"EMEA/COMP/269/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301071-public-summary-positive-opinion-orphan-designation-stiripentol-treatment-severe-myoclonic-epilepsy-infancy_en.pdf"},
    {"id":"29025","name":"EU/3/11/901: Public summary of opinion on orphan designation: Dinaciclib for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2022-02-25T02:00:00Z","reference_number":"EMA/COMP/635476/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311901-public-summary-opinion-orphan-designation-dinaciclib-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"29062","name":"EU/3/03/134: Public summary of  positive opinion for orphan designation  of  iodine (123I) serum amyloid P  for the diagnosis of the extent of histologically proven amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2016-08-10T02:00:00Z","reference_number":"EMEA/COMP/126/03 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303134-public-summary-positive-opinion-orphan-designation-iodine-123i-serum-amyloid-p-diagnosis-extent-histologically-proven-amyloidosis_en.pdf"},
    {"id":"29068","name":"EU/3/08/548: Public summary of positive opinion for orphan designation of\n\ncarfilzomib for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2014-07-11T02:00:00Z","reference_number":"EMEA/COMP/196439/2008 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308548-public-summary-positive-opinion-orphan-designation-carfilzomib-treatment-multiple-myeloma_en.pdf"},
    {"id":"29073","name":"EU/3/17/1933: Public summary of opinion on orphan designation: (1'R,6'R)-3-(benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione for the treatment of systemic scler...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-15T01:00:00Z","last_updated_date":"2018-01-15T01:00:00Z","reference_number":"EMA/676126/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171933-public-summary-opinion-orphan-designation-1r6r-3-benzylamine-6-hydroxy-3-methyl-4-pentyl-6-prop-1-en-2-yl-11-bicyclohexane-236-triene-25-dione-treatment-systemic-scler_en.pdf"},
    {"id":"29074","name":"EU/3/06/423: Public summary of positive opinion for orphan designation of tazarotene for the treatment of congenital ichthyoses","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMEA/COMP/495692/2006 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306423-public-summary-positive-opinion-orphan-designation-tazarotene-treatment-congenital-ichthyoses_en.pdf"},
    {"id":"29076","name":"EU/3/12/1093: Public summary of opinion on orphan designation: 1,2:5,6-Dianhydrogalactitol for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2013-03-01T01:00:00Z","reference_number":"EMA/COMP/848/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121093-public-summary-opinion-orphan-designation-1256-dianhydrogalactitol-treatment-glioma_en.pdf"},
    {"id":"29141","name":"EU/3/18/1984: Public summary of opinion on orphan designation: Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 for the treatment of primary IgA nephropathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/64972/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181984-public-summary-opinion-orphan-designation-recombinant-human-monoclonal-antibody-against-mannan-binding-lectin-associated-serine-protease-2-treatment-primary-iga-nephropathy_en.pdf"},
    {"id":"29151","name":"EU/3/11/906: Public summary of opinion on orphan designation: Kifunensine for the treatment of beta sarcoglycanopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2014-06-19T02:00:00Z","reference_number":"EMA/COMP/657805/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311906-public-summary-opinion-orphan-designation-kifunensine-treatment-beta-sarcoglycanopathy_en.pdf"},
    {"id":"29165","name":"EU/3/09/683: Public summary of positive opinion for orphan designation of cholic acid for the treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:00Z","last_updated_date":"2015-09-28T19:25:00Z","reference_number":"EMEA/COMP/590369/2009 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309683-public-summary-positive-opinion-orphan-designation-cholic-acid-treatment-inborn-errors-primary-bile-acid-synthesis-responsive-treatment-cholic-acid_en.pdf"},
    {"id":"29173","name":"EU/3/14/1352: Public summary of opinion on orphan designation: Raxibacumab for the treatment of inhalation anthrax disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/560216/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141352-public-summary-opinion-orphan-designation-raxibacumab-treatment-inhalation-anthrax-disease_en.pdf"},
    {"id":"29178","name":"EU/3/10/771: Public summary of opinion on orphan designation: Abarelix for the treatment of low-flow priapism","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"EMA/COMP/411127/2010 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310771-public-summary-opinion-orphan-designation-abarelix-treatment-low-flow-priapism_en.pdf"},
    {"id":"29184","name":"EU/3/10/822: Public summary of opinion on orphan designation: Lentiviral vector carrying the Fanconi anaemia-A (FANCA) gene for the treatment of Fanconi anaemia type A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMA/COMP/662962/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310822-public-summary-opinion-orphan-designation-lentiviral-vector-carrying-fanconi-anaemia-fanca-gene-treatment-fanconi-anaemia-type_en.pdf"},
    {"id":"29199","name":"EU/3/03/161: Public summary of positive opinion for orphan designation of antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT) for treatment of  neovascular glaucoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-04-26T02:00:00Z","last_updated_date":"2004-04-26T02:00:00Z","reference_number":"EMEA/COMP/1421/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303161-public-summary-positive-opinion-orphan-designation-antisense-oligonucleotide-tatccggagggctcgccatgctgct-treatment-neovascular-glaucoma_en.pdf"},
    {"id":"29227","name":"EU/3/12/1005: Public summary of opinion on orphan designation: Talarozole for the treatment of autosomal recessive congenital ichthyosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2016-01-19T15:00:00Z","reference_number":"EMA/COMP/393059/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121005-public-summary-opinion-orphan-designation-talarozole-treatment-autosomal-recessive-congenital-ichthyosis_en.pdf"},
    {"id":"29238","name":"EU/3/14/1425: Public summary of opinion on orphan designation: Ceftriaxone for the treatment of spinocerebellar ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2015-03-06T12:00:00Z","reference_number":"EMA/COMP/785809/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141425-public-summary-opinion-orphan-designation-ceftriaxone-treatment-spinocerebellar-ataxia_en.pdf"},
    {"id":"29254","name":"EU/3/17/1929 : Public summary of opinion on orphan designation : Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8 for the treatment of mastocytosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T15:38:00Z","last_updated_date":"2018-01-08T15:38:00Z","reference_number":"EMA/632174/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171929-public-summary-opinion-orphan-designation-recombinant-monoclonal-antibody-sialic-acid-binding-ig-lectin-8-treatment-mastocytosis_en.pdf"},
    {"id":"29262","name":"EU/3/16/1736: Public summary of positive opinion for orphan designation of (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/628398/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161736-public-summary-positive-opinion-orphan-designation-6ar10ar-3-11-dimethylheptyl-delta-8-tetrahydrocannabinol-9-carboxylic-acid-treatment-cystic-fibrosis_en.pdf"},
    {"id":"29274","name":"EU/3/15/1459: Public summary of positive opinion for orphan designation of  enoxacin for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/125722/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151459-public-summary-positive-opinion-orphan-designation-enoxacin-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"29280","name":"EU/3/18/1999: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector containing a codon-optimized Padua derivative of human coagulation factor IX cDNA for the treatment of haemophilia ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"EMA/139261/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181999-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-containing-codon-optimized-padua-derivative-human-coagulation-factor-ix-cdna-treatment-haemophilia_en.pdf"},
    {"id":"29289","name":"EU/3/12/1020: Public summary of opinion on orphan designation: Recombinant human pentraxin-2 for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-08-30T18:40:00Z","last_updated_date":"2014-05-12T18:40:00Z","reference_number":"EMA/COMP/441505/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121020-public-summary-opinion-orphan-designation-recombinant-human-pentraxin-2-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"29304","name":"EU/3/14/1297: Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine r...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T17:30:00Z","last_updated_date":"2014-09-01T17:30:00Z","reference_number":"EMA/COMP/360847/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141297-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-antithrombin-mrna-and-covalently-linked-ligand-containing-three-n_en.pdf"},
    {"id":"29312","name":"EU/3/11/936: Public summary of opinion on orphan designation: Human haptoglobin for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"EMA/COMP/845929/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311936-public-summary-opinion-orphan-designation-human-haptoglobin-treatment-sickle-cell-disease_en.pdf"},
    {"id":"29318","name":"EU/3/11/910: Public summary of opinion on orphan designation: NH2-Cys-Ser-Ser-Val-Thr-Ala-Trp-Thr-T","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/COMP/659363/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311910-public-summary-opinion-orphan-designation-nh2-cys-ser-ser-val-thr-ala-trp-thr-t_en.pdf"},
    {"id":"29327","name":"EU/3/16/1611: Public summary of opinion on orphan designation: Ex-vivo-expanded autologous fibroblasts transduced with lentiviral vector containing the COL7A1 gene for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-04-06T02:00:00Z","reference_number":"EMA/COMP/68326/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161611-public-summary-opinion-orphan-designation-ex-vivo-expanded-autologous-fibroblasts-transduced-lentiviral-vector-containing-col7a1-gene-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"29338","name":"EU/3/16/1709: Public summary of opinion on orphan designation: Sodium hypochlorite for the treatment of partial deep dermal and full thickness burns","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/451349/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161709-public-summary-opinion-orphan-designation-sodium-hypochlorite-treatment-partial-deep-dermal-and-full-thickness-burns_en.pdf"},
    {"id":"29344","name":"EU/3/14/1360: Public summary of opinion on orphan designation: A combination of H-Lys-Lys-Gly-Pro-Arg-Cys(SH)-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys-OH and H-Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-A...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T14:00:00Z","last_updated_date":"2015-01-15T14:00:00Z","reference_number":"EMA/COMP/654941/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141360-public-summary-opinion-orphan-designation-combination-h-lys-lys-gly-pro-arg-cyssh-leu-thr-arg-tyr-tyr-ser-ser-phe-val-asn-met-glu-gly-lys-lys-oh-and-h-lys-lys-gly-asp-asn-ile-met-val-thr-phe_en.pdf"},
    {"id":"29349","name":"EU/3/00/009: Public summary of positive opinion for orphan designation of thalidomide for the treatment of erythema nodosum leprosum (ENL) or type II lepra reactions","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/244358/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300009-public-summary-positive-opinion-orphan-designation-thalidomide-treatment-erythema-nodosum-leprosum-enl-or-type-ii-lepra-reactions_en.pdf"},
    {"id":"29357","name":"EU/3/16/1624: Public summary of opinion on orphan designation: Acalabrutinib for the treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-02T02:00:00Z","last_updated_date":"2016-05-02T02:00:00Z","reference_number":"EMA/COMP/153504/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161624-public-summary-opinion-orphan-designation-acalabrutinib-treatment-chronic-lymphocytic-leukaemia-small-lymphocytic-lymphoma_en.pdf"},
    {"id":"29368","name":"EU/3/09/694: Public summary of positive opinion for orphan designation of\n\n6-thioguanine (oral liquid) for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2013-11-29T00:09:21Z","reference_number":"EMA/COMP/654040/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309694-public-summary-positive-opinion-orphan-designation-6-thioguanine-oral-liquid-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"29388","name":"EU/3/12/1071: Public summary of opinion on orphan designation: Canakinumab for the treatment of tumour necrosis factor receptor-associated periodic syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-17T01:00:00Z","last_updated_date":"2016-01-14T01:00:00Z","reference_number":"EMA/COMP/663189/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121071-public-summary-opinion-orphan-designation-canakinumab-treatment-tumour-necrosis-factor-receptor-associated-periodic-syndrome_en.pdf"},
    {"id":"29419","name":"EU/03/14/1269: Public summary of opinion on orphan designation of lutetium (177Lu) edotreotide for the treatment of gastro-entero-pancreatic neuroendocrine tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/COMP/258942/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu03141269-public-summary-opinion-orphan-designation-lutetium-177lu-edotreotide-treatment-gastro-entero-pancreatic-neuroendocrine-tumours_en.pdf"},
    {"id":"29423","name":"EU/3/03/149: Public summary of positive opinion for orphan designation of cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate for the treatment of pa...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2009-09-21T02:00:00Z","reference_number":"EMEA/COMP/1194/03 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303149-public-summary-positive-opinion-orphan-designation-cytochrome-p450-isoform-2b1-gene-transfected-human-embryonic-kidney-293-cells-encapsulated-polymeric-cellulose-sulphate-treatment-pa_en.pdf"},
    {"id":"29429","name":"EU/3/10/846: Public summary of opinion on orphan designation: Paclitaxel (aqueous gel) for the treatment of oesophagus carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-04T01:00:00Z","last_updated_date":"2011-03-04T01:00:00Z","reference_number":"EMA/COMP/16280/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310846-public-summary-opinion-orphan-designation-paclitaxel-aqueous-gel-treatment-oesophagus-carcinoma_en.pdf"},
    {"id":"29434","name":"EU/3/02/128: Public summary of positive opinion for orphan designation of carboxypeptidase G2 for the adjunctive treatment in patients at risk of methotrexate toxicity","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T00:00:00Z","last_updated_date":"2015-05-14T01:00:00Z","reference_number":"EMEA/COMP/32880/02 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302128-public-summary-positive-opinion-orphan-designation-carboxypeptidase-g2-adjunctive-treatment-patients-risk-methotrexate-toxicity_en.pdf"},
    {"id":"29455","name":"EU/3/09/623: Public summary of positive opinion for orphan designation\n\nof autologous haematopoietic stem cells transduced with lentiviral vector\n\nencoding the human beta-globin gene for the treatment of beta thalassaemi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-12T02:00:00Z","last_updated_date":"2009-05-12T02:00:00Z","reference_number":"EMEA/COMP/156099/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309623-public-summary-positive-opinion-orphan-designation-autologous-haematopoietic-stem-cells-transduced-lentiviral-vector-encoding-human-beta-globin-gene-treatment-beta-thalassaemi_en.pdf"},
    {"id":"29460","name":"EU/3/14/1368: Public summary of opinion on orphan designation: Palovarotene for the treatment of fibrodysplasia ossificans progressiva","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/COMP/637026/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141368-public-summary-opinion-orphan-designation-palovarotene-treatment-fibrodysplasia-ossificans-progressiva_en.pdf"},
    {"id":"29462","name":"EU/3/04/250: Public summary of positive opinion for orphan designation of recombinant histidine tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors for the treatment of mantle cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-06T00:00:00Z","last_updated_date":"2011-06-01T01:00:00Z","reference_number":"EMEA/COMP/157071/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304250-public-summary-positive-opinion-orphan-designation-recombinant-histidine-tagged-idiotype-immunoglobulin-fab-fragment-clonal-b-cell-receptors-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"29495","name":"EU/3/15/1433: Public summary of opinion on orphan designation: Sevuparin sodium for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2015-04-08T02:00:00Z","reference_number":"EMA/COMP/48629/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151433-public-summary-opinion-orphan-designation-sevuparin-sodium-treatment-sickle-cell-disease_en.pdf"},
    {"id":"29500","name":"EU/3/12/1001: Public summary of opinion on orphan designation: 1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl] thieno [3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl) urea for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-04T17:00:00Z","last_updated_date":"2015-06-08T14:30:00Z","reference_number":"EMA/COMP/280092/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121001-public-summary-opinion-orphan-designation-1-4-4-amino-7-1-2-hydroxyethyl-1h-pyrazol-4-yl-thieno-32-cpyridin-3-ylphenyl-3-3-fluorophenyl-urea-treatment-ovarian-cancer_en.pdf"},
    {"id":"29523","name":"EU/3/09/668: Public summary of positive opinion for orphan designation of human C1 inhibitor for the treatment of angioedema caused by C1 inhibitor deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMEA/COMP/470276/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309668-public-summary-positive-opinion-orphan-designation-human-c1-inhibitor-treatment-angioedema-caused-c1-inhibitor-deficiency_en.pdf"},
    {"id":"29533","name":"EU/3/14/1423: Public summary of opinion on orphan designation: Synthetic signal peptide of human mucin-1 (amino acids 1-21) for the treatment of plasma cell myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2015-03-26T12:00:00Z","reference_number":"EMA/COMP/787373/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141423-public-summary-opinion-orphan-designation-synthetic-signal-peptide-human-mucin-1-amino-acids-1-21-treatment-plasma-cell-myeloma_en.pdf"},
    {"id":"29554","name":"EU/3/16/1745: Public summary of positive opinion for orphan designation of autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 for the treatment of diffuse la...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMA/623799/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161745-public-summary-positive-opinion-orphan-designation-autologous-t-cells-transduced-lentiviral-vector-containing-chimeric-antigen-receptor-directed-against-cd19-treatment-diffuse-la_en.pdf"},
    {"id":"29580","name":"EU/3/07/434: Public summary of positive opinion for orphan designation of idebenone for the treatment of Leber's hereditary optic neuropathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2011-04-11T02:00:00Z","reference_number":"EMEA/COMP/96073/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307434-public-summary-positive-opinion-orphan-designation-idebenone-treatment-lebers-hereditary-optic-neuropathy_en.pdf"},
    {"id":"29584","name":"EU/3/13/1213: Public summary of opinion on orphan designation: Lactobacillus acidophilus and Bifidobacterium bifidum for the prevention of necrotising enterocolitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-23T01:00:00Z","last_updated_date":"2014-01-23T01:00:00Z","reference_number":"EMA/COMP/703237/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131213-public-summary-opinion-orphan-designation-lactobacillus-acidophilus-and-bifidobacterium-bifidum-prevention-necrotising-enterocolitis_en.pdf"},
    {"id":"29599","name":"EU/3/11/881: Public summary of opinion on orphan designation: Acadesine for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2013-07-31T12:15:00Z","reference_number":"EMA/COMP/417459/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311881-public-summary-opinion-orphan-designation-acadesine-treatment-multiple-myeloma_en.pdf"},
    {"id":"29618","name":"EU/3/08/551: Public summary of positive opinion for orphan designation of pegylated recombinant factor VIIa for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMEA/COMP/204668/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308551-public-summary-positive-opinion-orphan-designation-pegylated-recombinant-factor-viia-treatment-haemophilia_en.pdf"},
    {"id":"29629","name":"EU/3/17/1882: Public summary of opinion on orphan designation: Ibutamoren mesilate for the treatment of growth hormone deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T02:00:00Z","last_updated_date":"2017-07-17T02:00:00Z","reference_number":"EMA/325369/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171882-public-summary-opinion-orphan-designation-ibutamoren-mesilate-treatment-growth-hormone-deficiency_en.pdf"},
    {"id":"29649","name":"EU/3/01/078: Public summary of opinion on orphan designation: iduronate-2-sulfatase for the treatment of mucopolysaccharidosis, type II (Hunter Syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2017-02-08T01:00:00Z","reference_number":"EMA/COMP/1281/2003 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301078-public-summary-opinion-orphan-designation-iduronate-2-sulfatase-treatment-mucopolysaccharidosis-type-ii-hunter-syndrome_en.pdf"},
    {"id":"29680","name":"EU/3/05/347: Public summary of positive opinion for orphan designation of human monoclonal antibody against HLA-DR for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/414041/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305347-public-summary-positive-opinion-orphan-designation-human-monoclonal-antibody-against-hla-dr-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"29699","name":"EU/3/10/844: Public summary of opinion on orphan designation: Axitinib for the treatment of renal-cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-04T01:00:00Z","last_updated_date":"2012-12-03T01:00:00Z","reference_number":"EMA/COMP/2608/2011, Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310844-public-summary-opinion-orphan-designation-axitinib-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"29710","name":"EU/3/03/144: Public summary of positive opinion for orphan designation of liarozole for the treatment of congenital ichthyoses","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-09-26T02:00:00Z","last_updated_date":"2016-08-10T02:00:00Z","reference_number":"EMEA/COMP/1185/03 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303144-public-summary-positive-opinion-orphan-designation-liarozole-treatment-congenital-ichthyoses_en.pdf"},
    {"id":"29716","name":"EU/3/04/239: Public summary of positive opinion for orphan designation of deuterium oxide for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T01:00:00Z","last_updated_date":"2005-11-29T01:00:00Z","reference_number":"EMEA/COMP/69735/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304239-public-summary-positive-opinion-orphan-designation-deuterium-oxide-treatment-pancreatic-cancer_en.pdf"},
    {"id":"29765","name":"EU/3/02/098: Public summary of positive opinion for orphan designation of epothilone B for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-06-11T02:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMEA/COMP/81/02 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302098-public-summary-positive-opinion-orphan-designation-epothilone-b-treatment-ovarian-cancer_en.pdf"},
    {"id":"29786","name":"EU/3/12/1030: Public summary of opinion on orphan designation: Vatreptacog alfa (activated) for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-27T16:00:00Z","last_updated_date":"2015-03-06T15:00:00Z","reference_number":"EMA/COMP/527614/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121030-public-summary-opinion-orphan-designation-vatreptacog-alfa-activated-treatment-haemophilia_en.pdf"},
    {"id":"29805","name":"EU/3/14/1264: Public summary of opinion on orphan designation: Ibrutinib for the treatment of treatment of lymphoplasmacytic lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-06-04T02:00:00Z","last_updated_date":"2014-06-04T02:00:00Z","reference_number":"EMA/COMP/172279/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141264-public-summary-opinion-orphan-designation-ibrutinib-treatment-treatment-lymphoplasmacytic-lymphoma_en.pdf"},
    {"id":"29827","name":"EU/3/15/1461: Public summary of positive opinion for orphan designation of recombinant human monoclonal antibody binding to vascular adhesion protein-1 for the treatment of primary sclerosing cholangitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/132952/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151461-public-summary-positive-opinion-orphan-designation-recombinant-human-monoclonal-antibody-binding-vascular-adhesion-protein-1-treatment-primary-sclerosing-cholangitis_en.pdf"},
    {"id":"29842","name":"EU/3/05/348: Public summary of positive opinion for orphan designation of purified inactivated Japanese encephalitis SA14-4-2 virus vaccine for the prevention of Japanese encephalitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"EMEA/COMP/24246/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305348-public-summary-positive-opinion-orphan-designation-purified-inactivated-japanese-encephalitis-sa14-4-2-virus-vaccine-prevention-japanese-encephalitis_en.pdf"},
    {"id":"29846","name":"EU/3/12/991: Public summary of opinion on orphan designation: Exon-45-specific phosphorothioate oligonucleotide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T13:00:00Z","last_updated_date":"2012-06-18T13:00:00Z","reference_number":"EMA/COMP/193672/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312991-public-summary-opinion-orphan-designation-exon-45-specific-phosphorothioate-oligonucleotide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"29850","name":"EU/3/05/321: Public Summary of opinion on orphan designation: (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2013-03-11T12:15:00Z","reference_number":"EMA/COMP/245993/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305321-public-summary-opinion-orphan-designation-1r2r4s-4-2r-2-3s6r7e9r10r12r14s15e17e19e21s23s26r27r34as-927-dihydroxy-1021-dimethoxy-6812142026-hexamethyl_en.pdf"}    {"id":"29885","name":"EU/3/10/757: Public summary of opinion on orphan designation for pomalidomide for the treatment of primary myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-06T02:00:00Z","last_updated_date":"2017-02-10T12:26:00Z","reference_number":"EMA/COMP/249369/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310757-public-summary-opinion-orphan-designation-pomalidomide-treatment-primary-myelofibrosis_en.pdf"},
    {"id":"29886","name":"EU/3/15/1539: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human MTM1 gene for the treatment of X-linked myotubular myopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/500586/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151539-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-containing-human-mtm1-gene-treatment-x-linked-myotubular-myopathy_en.pdf"},
    {"id":"29889","name":"EU/3/03/132: Public summary of positive opinion for orphan designation of caffeine citrate for the treatment of primary apnoea of premature newborns","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-03-07T00:00:00Z","last_updated_date":"2019-07-11T00:00:00Z","reference_number":"EMEA/COMP/5/03 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303132-public-summary-positive-opinion-orphan-designation-caffeine-citrate-treatment-primary-apnoea-premature-newborns_en.pdf"},
    {"id":"29902","name":"Public summary of negative opinion for orphan designation of naltrexone for the treatment of fibromyalgia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T15:43:00Z","last_updated_date":"2016-12-13T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-naltrexone-treatment-fibromyalgia_en.pdf"},
    {"id":"29937","name":"EU/3/12/958: Public summary of opinion on orphan designation: N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine and folic acid","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T01:00:00Z","last_updated_date":"2012-11-12T01:00:00Z","reference_number":"EMA/COMP/853895/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312958-public-summary-opinion-orphan-designation-n-4-2-amino-34-dihydro-4-oxo-6-pteridinylmethylaminobenzoyl-d-gamma-glutamyl-2s-2-amino-beta-alanyl-l-alpha-aspartyl-l-cysteine-and-folic-acid_en.pdf"},
    {"id":"29942","name":"EU/3/06/415: Public summary of positive opinion for orphan designation of ciclosporin (implant) for the prevention of rejection of corneal transplant","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2010-03-15T01:00:00Z","reference_number":"EMEA/COMP/191077/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306415-public-summary-positive-opinion-orphan-designation-ciclosporin-implant-prevention-rejection-corneal-transplant_en.pdf"},
    {"id":"29952","name":"EU/3/05/277: Public summary of positive opinion for orphan designation of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-04T02:00:00Z","last_updated_date":"2017-05-17T12:30:00Z","reference_number":"EMEA/COMP/123054/2005 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305277-public-summary-positive-opinion-orphan-designation-3-5-2-fluoro-phenyl-124oxadiazole-3-yl-benzoic-acid-treatment-cystic-fibrosis_en.pdf"},
    {"id":"29953","name":"EU/3/16/1822: Public summary of opinion on orphan designation: Pentosan polysulfate sodium for the treatment of interstitial cystitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/5068/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161822-public-summary-opinion-orphan-designation-pentosan-polysulfate-sodium-treatment-interstitial-cystitis_en.pdf"},
    {"id":"29968","name":"EU/3/14/1317: Public summary of opinion on orphan designation: (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-01T02:00:00Z","last_updated_date":"2014-10-01T02:00:00Z","reference_number":"EMA/COMP/433733/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141317-public-summary-opinion-orphan-designation-z-3-3-35-bistrifluoromethylphenyl-1h-124-triazol-1-yl-n-pyrazin-2-ylacrylohydrazide-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"30001","name":"EU/3/03/157: Public summary of positive opinion for orphan designation of recombinant dog gastric lipase for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-10-29T00:00:00Z","last_updated_date":"2003-10-29T00:00:00Z","reference_number":"EMEA/COMP/1464/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303157-public-summary-positive-opinion-orphan-designation-recombinant-dog-gastric-lipase-treatment-cystic-fibrosis_en.pdf"},
    {"id":"30058","name":"EU/3/16/1741: Public summary of positive opinion for orphan designation of adeno-associated viral vector serotype 5 containing the human RLBP1 gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/620229/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161741-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-serotype-5-containing-human-rlbp1-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"30063","name":"EU/3/04/235: Public summary of positive opinion for orphan designation of recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3 for treatment of Type B extreme insu...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-20T00:00:00Z","last_updated_date":"2011-06-22T01:00:00Z","reference_number":"EMEA/COMP/77803/2004 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304235-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-irecombinant-human-insulin-growth-factor-binding-protein-3-treatment-type-b-extreme-insu_en.pdf"},
    {"id":"30069","name":"EU/3/06/356: Public summary of positive opinion for orphan designation of 4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-24T02:00:00Z","last_updated_date":"2011-04-04T02:00:00Z","reference_number":"EMEA/COMP/26820/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306356-public-summary-positive-opinion-orphan-designation-4-amino-5-oxo-4-pyridinium-1-ylmethyl-proline-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"30092","name":"EU/3/14/1304: Public summary of opinion on orphan designation: Eculizumab for the treatment myasthenia gravis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T02:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/COMP/374393/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141304-public-summary-opinion-orphan-designation-eculizumab-treatment-myasthenia-gravis_en.pdf"},
    {"id":"30094","name":"EU/3/17/1845: Public summary of opinion on orphan designation: Thalidomide for the treatment of hereditary haemorrhagic telangiectasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/72429/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171845-public-summary-opinion-orphan-designation-thalidomide-treatment-hereditary-haemorrhagic-telangiectasia_en.pdf"},
    {"id":"30105","name":"EU/3/17/1915: Public summary of opinion on orphan designation : 2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine for the treatment of Charcot-Marie-Tooth disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T11:37:00Z","last_updated_date":"2018-01-08T11:37:00Z","reference_number":"EMA/620625/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171915-public-summary-opinion-orphan-designation-2-n-2-hydroxyethyl-n-4-methoxybenzenesulfonylamino-n-4-chlorocinnamyl-n-methylbenzylamine-treatment-charcot-marie-tooth-disease_en.pdf"},
    {"id":"30140","name":"EU/3/01/036: Public summary of positive opinion for orphan designation of recombinant human C1-inhibitor for the treatment of angioedema caused by C1 inhibitor deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/COMP/182/04 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301036-public-summary-positive-opinion-orphan-designation-recombinant-human-c1-inhibitor-treatment-angioedema-caused-c1-inhibitor-deficiency_en.pdf"},
    {"id":"30151","name":"EU/3/08/578: Public summary of positive opinion for orphan designation of\n\ncysteamine hydrochloride for the treatment of cystinosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/COMP/488783/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308578-public-summary-positive-opinion-orphan-designation-cysteamine-hydrochloride-treatment-cystinosis_en.pdf"},
    {"id":"30168","name":"EU/3/05/302: Public summary of positive opinion for orphan designation of extract of Sorghum bicolour leaf, Pterocarpus osun stem, Piper guineense seed and Caryophylli flower for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-27T02:00:00Z","last_updated_date":"2005-10-27T02:00:00Z","reference_number":"EMEA/COMP/241141/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305302-public-summary-positive-opinion-orphan-designation-extract-sorghum-bicolour-leaf-pterocarpus-osun-stem-piper-guineense-seed-and-caryophylli-flower-treatment-sickle-cell-disease_en.pdf"},
    {"id":"30175","name":"EU/3/05/295: Public summary of positive opinion for orphan designation of hepatitis C immunoglobulin for the prevention of recurrent hepatitis C virus induced liver disease in liver transplant recipients","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2008-08-18T02:00:00Z","reference_number":"EMEA/COMP/193391/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305295-public-summary-positive-opinion-orphan-designation-hepatitis-c-immunoglobulin-prevention-recurrent-hepatitis-c-virus-induced-liver-disease-liver-transplant-recipients_en.pdf"},
    {"id":"30187","name":"C(2002) 355: Public summary of negative opinion for orphan designation of ibritumomab tiuxetan for use with 90Yttrium for the treatment of B-cell non-Hodgkin’s lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2009-09-17T02:00:00Z","reference_number":"EMEA/COMP/73/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/c2002-355-public-summary-negative-opinion-orphan-designation-ibritumomab-tiuxetan-use-90yttrium-treatment-b-cell-non-hodgkins-lymphoma_en.pdf"},
    {"id":"30202","name":"EU/3/12/1090: Public summary of opinion on orphan designation: Recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem-cell antigen for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMA/COMP/1814/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121090-public-summary-opinion-orphan-designation-recombinant-human-monoclonal-antibody-igg1-kappa-class-against-prostate-stem-cell-antigen-treatment-pancreatic-cancer_en.pdf"},
    {"id":"30209","name":"EU/3/10/797: Public summary of opinion on orphan designation: Recombinant humanised monoclonal antibody to human Nogo-A protein of the IgG1/kappa class for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"EMA/COMP/454762/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310797-public-summary-opinion-orphan-designation-recombinant-humanised-monoclonal-antibody-human-nogo-protein-igg1kappa-class-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"30256","name":"EU/3/14/1323: Public summary of opinion on orphan designation: [5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2014-10-02T02:00:00Z","reference_number":"EMA/COMP/434969/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141323-public-summary-opinion-orphan-designation-5-amino-1-4-fluoro-phenyl-1h-pyrazol-4-yl-3-23-dihydroxy-propoxy-phenyl-methanone-treatment-pancreatic-cancer_en.pdf"},
    {"id":"30265","name":"EU/3/16/1747: Public summary of positive opinion for orphan designation of chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/629529/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161747-public-summary-positive-opinion-orphan-designation-chemically-modified-human-recombinant-sulfamidase-treatment-mucopolysaccharidosis-type-iiia-sanfilippo-syndrome_en.pdf"},
    {"id":"30308","name":"EU/3/16/1710: Public summary of opinion on orphan designation: Triheptanoin for the treatment of McArdle’s disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/447479/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161710-public-summary-opinion-orphan-designation-triheptanoin-treatment-mcardles-disease_en.pdf"},
    {"id":"30325","name":"EU/3/15/1582: Public summary of opinion on orphan designation: Humanised monoclonal antibody of the IgG4 kappa isotype targeting CD47 for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/COMP/696064/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151582-public-summary-opinion-orphan-designation-humanised-monoclonal-antibody-igg4-kappa-isotype-targeting-cd47-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"30355","name":"EU/3/12/1006: Public summary of opinion on orphan designation: Doxorubicin (administered after synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine) for the treatmen...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-17T01:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"EMA/COMP/350454/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121006-public-summary-opinion-orphan-designation-doxorubicin-administered-after-synthetic-double-stranded-sirna-oligonucleotide-directed-against-claudin-5-complexed-polyethyleneimine-treatmen_en.pdf"},
    {"id":"30372","name":"EU/3/10/742: Public summary of opinion on orphan designation: 2-Methoxymethyl-2-hydroxymethyl-1-azabicyclo[2,2,2]octan-3-one for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2010-06-24T02:00:00Z","reference_number":"EMA/COMP/91045/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310742-public-summary-opinion-orphan-designation-2-methoxymethyl-2-hydroxymethyl-1-azabicyclo222octan-3-one-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"30388","name":"EU/3/13/1181: Public summary of opinion on orphan designation: Budesonide for the treatment of eosinophilic oesophagitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-13T02:00:00Z","last_updated_date":"2013-09-13T02:00:00Z","reference_number":"EMA/COMP/433918/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131181-public-summary-opinion-orphan-designation-budesonide-treatment-eosinophilic-oesophagitis_en.pdf"},
    {"id":"30391","name":"EU/3/11/869: Public summary of opinion on orphan designation: Lisuride hydrogen maleate for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-31T02:00:00Z","last_updated_date":"2013-04-09T02:00:00Z","reference_number":"EMA/COMP/172578/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311869-public-summary-opinion-orphan-designation-lisuride-hydrogen-maleate-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"30396","name":"EU/3/06/361: Public summary of positive opinion for orphan designation of\n\nglutathione for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMEA/COMP/106028/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306361-public-summary-positive-opinion-orphan-designation-glutathione-treatment-cystic-fibrosis_en.pdf"},
    {"id":"30399","name":"EU/3/16/1767: Public summary of positive opinion for orphan designation of venetoclax for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/623817/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161767-public-summary-positive-opinion-orphan-designation-venetoclax-treatment-multiple-myeloma_en.pdf"},
    {"id":"30409","name":"EU/3/04/258: Public summary of positive opinion for orphan designation of L-asparaginase for the treatment of acute lymphoblastic leukemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-07-26T02:00:00Z","last_updated_date":"2016-02-10T01:00:00Z","reference_number":"EMEA/COMP/193911/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304258-public-summary-positive-opinion-orphan-designation-l-asparaginase-treatment-acute-lymphoblastic-leukemia_en.pdf"},
    {"id":"30417","name":"EU/3/17/1891: Public summary of opinion on orphan designation: Bacillus subtilis oxalate decarboxylase for the treatment of primary hyperoxaluria","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2017-08-15T16:00:00Z","last_updated_date":"2017-08-15T16:00:00Z","reference_number":"EMA/402771/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171891-public-summary-opinion-orphan-designation-bacillus-subtilis-oxalate-decarboxylase-treatment-primary-hyperoxaluria_en.pdf"},
    {"id":"30459","name":"EU/3/14/1245: Public summary of opinion on orphan designation: Pioglitazone for the treatment of adrenoleukodystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-02T18:20:00Z","last_updated_date":"2014-04-02T18:20:00Z","reference_number":"EMA/COMP/31500/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141245-public-summary-opinion-orphan-designation-pioglitazone-treatment-adrenoleukodystrophy_en.pdf"},
    {"id":"30461","name":"Public summary of negative opinion for orphan designation of chelidonii radix special liquid extract for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/472841/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-chelidonii-radix-special-liquid-extract-treatment-pancreatic-cancer_en.pdf"},
    {"id":"30471","name":"EU/3/14/1427: Public summary of opinion on orphan designation: Recombinant human alkaline phosphatase for the treatment of hypophosphatasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2015-03-06T12:00:00Z","reference_number":"EMA/COMP/787358/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141427-public-summary-opinion-orphan-designation-recombinant-human-alkaline-phosphatase-treatment-hypophosphatasia_en.pdf"},
    {"id":"30477","name":"EU/3/04/229: Public summary of positive opinion for orphan designation of doxorubicin polyisohexylcyanoacrylate nanoparticles for treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2019-07-09T11:40:00Z","reference_number":"EMEA/69677/2004 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304229-public-summary-positive-opinion-orphan-designation-doxorubicin-polyisohexylcyanoacrylate-nanoparticles-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"30484","name":"EU/3/14/1310: Public summary of opinion on orphan designation: (3S)-1-azabicyclo[2.2.2]oct-3-yl{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate for the treatment of Fabry disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/COMP/431240/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141310-public-summary-opinion-orphan-designation-3s-1-azabicyclo222oct-3-yl2-2-4-fluorophenyl-13-thiazol-4-ylpropan-2-ylcarbamate-treatment-fabry-disease_en.pdf"},
    {"id":"30536","name":"EU/3/16/1744: Public summary of positive opinion for orphan designation of autologous mononuclear cells derived from human cord blood for the treatment of periventricular leukomalacia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMA/628394/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161744-public-summary-positive-opinion-orphan-designation-autologous-mononuclear-cells-derived-human-cord-blood-treatment-periventricular-leukomalacia_en.pdf"},
    {"id":"30537","name":"EU/3/10/776: Public summary of opinion on orphan designation: Autologous dendritic cells pulsed with recombinant human-fusion protein (mucin 1 − glutathione S transferase) coupled to oxidised polymannose for the treatm...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2013-10-17T17:00:00Z","reference_number":"EMA/COMP/400483/2010 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310776-public-summary-opinion-orphan-designation-autologous-dendritic-cells-pulsed-recombinant-human-fusion-protein-mucin-1-glutathione-s-transferase-coupled-oxidised-polymannose-treatm_en.pdf"},
    {"id":"30541","name":"EU/3/05/303: Public summary of positive opinion for orphan designation ofhuman autologous mesenchymal adult stem cells extracted from adipose tissuefor the treatment of anal fistula","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2022-07-01T02:00:00Z","reference_number":"EMA/COMP/223443/2005 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305303-public-summary-positive-opinion-orphan-designation-ofhuman-autologous-mesenchymal-adult-stem-cells-extracted-adipose-tissuefor-treatment-anal-fistula_en.pdf"},
    {"id":"30559","name":"EU/3/15/1500: Public summary of opinion on orphan designation: Synthetic 47-amino-acid N-myristoylated lipopeptide, derived from the preS region of hepatitis B virus for the treatment of hepatitis delta virus infection","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2015-07-27T02:00:00Z","reference_number":"EMA/COMP/360280/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151500-public-summary-opinion-orphan-designation-synthetic-47-amino-acid-n-myristoylated-lipopeptide-derived-pres-region-hepatitis-b-virus-treatment-hepatitis-delta-virus-infection_en.pdf"},
    {"id":"30586","name":"EU/3/05/322: Public summary of positive opinion for orphan designation of alfimeprase for the treatment of acute peripheral arterial occlusion","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/315314/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305322-public-summary-positive-opinion-orphan-designation-alfimeprase-treatment-acute-peripheral-arterial-occlusion_en.pdf"},
    {"id":"30592","name":"EU/3/09/665: Public summary of positive opinion for orphan designation of allogeneic ex-vivo-expanded umbilical-cord blood cells for the treatment of chronic myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMEA/COMP/478187/2009 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309665-public-summary-positive-opinion-orphan-designation-allogeneic-ex-vivo-expanded-umbilical-cord-blood-cells-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"30603","name":"EU/3/12/967: Public summary of opinion on orphan designation: Sodium nitrite for the treatment of pulmonary arterial hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-06T18:00:00Z","last_updated_date":"2012-07-06T18:00:00Z","reference_number":"EMA/COMP/68665/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312967-public-summary-opinion-orphan-designation-sodium-nitrite-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"30627","name":"EU/3/12/1068: Public summary of opinion on orphan designation: Melarsoprol for treatment of African trypanosomiasis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2012-12-12T01:00:00Z","reference_number":"EMA/COMP/684363/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121068-public-summary-opinion-orphan-designation-melarsoprol-treatment-african-trypanosomiasis_en.pdf"},
    {"id":"30629","name":"EU/3/15/1574: Public summary of opinion on orphan designation: 4’-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2’-(ethoxymethyl)-[1,1’-biphenyl]-2-sulfonamide for the treatment o...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/COMP/696157/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151574-public-summary-opinion-orphan-designation-4-2-butyl-4-oxo-13-diazaspiro44non-1-en-3-ylmethyl-n-45-dimethyl-3-isoxazolyl-2-ethoxymethyl-11-biphenyl-2-sulfonamide-treatment-o_en.pdf"},
    {"id":"30663","name":"EU/3/04/224: Public summary of positive opinion for orphan designation of\n\nhomoharringtonine for treatment of chronic myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2016-08-10T02:00:00Z","reference_number":"EMA/COMP/44012/2004 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304224-public-summary-positive-opinion-orphan-designation-homoharringtonine-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"30708","name":"EU/3/09/705: Public summary of opinion on orphan designation of human monoclonal antibody against Pseudomonas aeruginosa IATS-O1 for the treatment of pneumonia caused by serotype O1 Pseudomonas aeruginosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2021-02-03T01:00:00Z","reference_number":"EMA/768546/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309705-public-summary-opinion-orphan-designation-human-monoclonal-antibody-against-pseudomonas-aeruginosa-iats-o1-treatment-pneumonia-caused-serotype-o1-pseudomonas-aeruginosa_en.pdf"},
    {"id":"30710","name":"EU/3/05/278: Public summary of positive opinion for orphan designation of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-04T02:00:00Z","last_updated_date":"2015-03-10T13:00:00Z","reference_number":"EMEA/COMP/122996/2005 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305278-public-summary-positive-opinion-orphan-designation-3-5-2-fluoro-phenyl-124oxadiazole-3-yl-benzoic-acid-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"30729","name":"EU/3/17/1916: Public summary of opinion on orphan designation: 5-amino-1-(2-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl 1H-indol-2-yl ketone mono[(S)-2-hydroxysuccinate] for the treatment of biliary tract cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-10T10:25:00Z","last_updated_date":"2018-01-10T10:25:00Z","reference_number":"EMA/620630/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171916-public-summary-opinion-orphan-designation-5-amino-1-2-methyl-1h-benzodimidazol-5-yl-1h-pyrazol-4-yl-1h-indol-2-yl-ketone-monos-2-hydroxysuccinate-treatment-biliary-tract-cancer_en.pdf"},
    {"id":"30765","name":"EU/3/06/414: Public summary of positive opinion for orphan designation of catumaxomab for the treatment of gastric cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-24T00:00:00Z","last_updated_date":"2014-02-08T00:00:00Z","reference_number":"EMEA/COMP/188397/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306414-public-summary-positive-opinion-orphan-designation-catumaxomab-treatment-gastric-cancer_en.pdf"},
    {"id":"30776","name":"EU/3/16/1637: Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalact...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-02T02:00:00Z","last_updated_date":"2016-05-02T02:00:00Z","reference_number":"EMA/COMP/172901/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161637-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-hydroxyacid-oxidase-1-mrna-and-covalently-linked-ligand-containing-three-n_en.pdf"},
    {"id":"30796","name":"EU/3/15/1531: Public summary of opinion on orphan designation: Sarizotan hydrochloride for the treatment of Rett syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T02:00:00Z","last_updated_date":"2015-08-18T02:00:00Z","reference_number":"EMA/COMP/430803/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151531-public-summary-opinion-orphan-designation-sarizotan-hydrochloride-treatment-rett-syndrome_en.pdf"},
    {"id":"30798","name":"EU/3/08/607: Public summary of positive opinion for orphan designation of type I native bovine skin collagen for treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/COMP/541000/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308607-public-summary-positive-opinion-orphan-designation-type-i-native-bovine-skin-collagen-treatment-systemic-sclerosis_en.pdf"},
    {"id":"30809","name":"EU/3/14/1420: Public summary of opinion on orphan designation: Emtricitabine for the treatment of Aicardi-Goutià¨res syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2015-03-06T12:00:00Z","reference_number":"EMA/COMP/797337/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141420-public-summary-opinion-orphan-designation-emtricitabine-treatment-aicardi-goutiares-syndrome_en.pdf"},
    {"id":"30815","name":"EU/3/15/1503: Public summary of opinion on orphan designation: Allogeneic ex-vivo-expanded human umbilical cord blood-derived mesenchymal stem cells for the prevention of bronchopulmonary dysplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2015-07-27T02:00:00Z","reference_number":"EMA/COMP/359112/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151503-public-summary-opinion-orphan-designation-allogeneic-ex-vivo-expanded-human-umbilical-cord-blood-derived-mesenchymal-stem-cells-prevention-bronchopulmonary-dysplasia_en.pdf"},
    {"id":"30833","name":"EU/3/14/1315: Public summary of opinion on orphan designation: Recombinant human apolipoprotein A-I in a complex with phospholipids for the treatment of apolipoprotein A-I deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-01T02:00:00Z","last_updated_date":"2014-10-01T02:00:00Z","reference_number":"EMA/COMP/434437/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141315-public-summary-opinion-orphan-designation-recombinant-human-apolipoprotein-i-complex-phospholipids-treatment-apolipoprotein-i-deficiency_en.pdf"},
    {"id":"30834","name":"EU/3/07/457: Public summary of positive opinion for orphan designation of lusupultide for the treatment of aspiration pneumonitis requiring intubation and mechanical ventilation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/241008/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307457-public-summary-positive-opinion-orphan-designation-lusupultide-treatment-aspiration-pneumonitis-requiring-intubation-and-mechanical-ventilation_en.pdf"},
    {"id":"30841","name":"EU/3/03/148: Public summary of positive opinion for orphan designation of chimeric-ant-interleukin-6 monoclonal antibody for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-07-08T02:00:00Z","last_updated_date":"2011-11-11T01:00:00Z","reference_number":"EMEA/COMP/1193/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303148-public-summary-positive-opinion-orphan-designation-chimeric-ant-interleukin-6-monoclonal-antibody-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"30863","name":"EU/3/14/1367: Public summary of opinion on orphan designation: Bazedoxifene acetate for the treatment of hereditary haemorrhagic telangiectasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/COMP/639353/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141367-public-summary-opinion-orphan-designation-bazedoxifene-acetate-treatment-hereditary-haemorrhagic-telangiectasia_en.pdf"},
    {"id":"30864","name":"EU/3/16/1698 : Public summary of opinion on orphan designation: Dimethyl fumarate for the treatment of bullous pemphigoid","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/446350/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161698-public-summary-opinion-orphan-designation-dimethyl-fumarate-treatment-bullous-pemphigoid_en.pdf"},
    {"id":"30906","name":"EU/3/11/884: Public summary of opinion on orphan designation: Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-α-as...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2011-08-16T02:00:00Z","reference_number":"EMA/COMP/420755/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311884-public-summary-opinion-orphan-designation-methyl-o-4-o-2-2-2-2-n-1r-1-4-aminoiminomethylphenylmethyl-2-oxo-2-1-piperidinylethyl-n2-4-methoxy-236-trimethylphenylsulfonyl-l-i_en.pdf"},
    {"id":"30946","name":"EU/3/03/135: Public summary of positive opinion for orphan designation of decitabine for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2007-05-30T02:00:00Z","reference_number":"EMEA/COMP/2/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303135-public-summary-positive-opinion-orphan-designation-decitabine-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"30972","name":"EU/3/16/1797: Public summary of opinion on orphan designation: Arsenic trioxide for the treatment of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/744548/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161797-public-summary-opinion-orphan-designation-arsenic-trioxide-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"30973","name":"EU/3/14/1306: Public summary of opinion on orphan designation: Cysteamine bitartrate for the treatment of Huntington’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T02:00:00Z","last_updated_date":"2014-09-01T02:00:00Z","reference_number":"EMA/COMP/359565/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141306-public-summary-opinion-orphan-designation-cysteamine-bitartrate-treatment-huntingtons-disease_en.pdf"},
    {"id":"30976","name":"EU/3/16/1652: Public summary of opinion on orphan designation: Recombinant human cerebral dopamine neurotrophic factor for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2016-05-30T02:00:00Z","reference_number":"EMA/COMP/235531/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161652-public-summary-opinion-orphan-designation-recombinant-human-cerebral-dopamine-neurotrophic-factor-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"30979","name":"EU/3/14/1322: Public summary of opinion on orphan designation: Humanised IgG1 monoclonal antibody against human KIR3DL2 for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-01T02:00:00Z","last_updated_date":"2014-10-01T02:00:00Z","reference_number":"EMA/COMP/457016/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141322-public-summary-opinion-orphan-designation-humanised-igg1-monoclonal-antibody-against-human-kir3dl2-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"31013","name":"EU/3/13/1232: Public summary of opinion on orphan designation: Allantoin for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T01:00:00Z","last_updated_date":"2015-03-11T01:00:00Z","reference_number":"EMA/COMP/1161/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131232-public-summary-opinion-orphan-designation-allantoin-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"31028","name":"EU/3/02/121: Public summary of positive opinion for orphan designation of 5-aminolevulinic acid hydrochloride for the intra-operative photodynamic diagnosis of residual glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T01:00:00Z","last_updated_date":"2007-12-04T01:00:00Z","reference_number":"EMEA/COMP/2390/02 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302121-public-summary-positive-opinion-orphan-designation-5-aminolevulinic-acid-hydrochloride-intra-operative-photodynamic-diagnosis-residual-glioma_en.pdf"},
    {"id":"31056","name":"EU/3/10/805: Public summary of opinion on orphan designation methylthioninium for the treatment of behavioural variant frontotemporal dementia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-15T01:00:00Z","last_updated_date":"2014-01-13T16:20:00Z","reference_number":"EMA/606354/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310805-public-summary-opinion-orphan-designation-methylthioninium-treatment-behavioural-variant-frontotemporal-dementia_en.pdf"},
    {"id":"31075","name":"EU/3/09/689: Public summary of positive opinion for orphan designation of peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis for the treatment of myastheni...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2014-10-07T17:00:00Z","reference_number":"EMEA/COMP/586062/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309689-public-summary-positive-opinion-orphan-designation-peptides-mimicking-antigen-receptors-autoimmune-b-cells-and-autoimmune-t-cells-associated-myasthenia-gravis-treatment-myastheni_en.pdf"},
    {"id":"31132","name":"EU/3/10/786: Public summary of opinion on orphan designation: Heat-killed Mycobacterium vaccae (whole cell) for the treatment of tuberculosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2012-02-09T12:00:00Z","reference_number":"EMA/COMP/382074/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310786-public-summary-opinion-orphan-designation-heat-killed-mycobacterium-vaccae-whole-cell-treatment-tuberculosis_en.pdf"},
    {"id":"31151","name":"EU/3/12/1097: Public summary of opinion on orphan designation: Lenalidomide for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2013-03-01T01:00:00Z","reference_number":"EMA/COMP/808519/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121097-public-summary-opinion-orphan-designation-lenalidomide-treatment-follicular-lymphoma_en.pdf"},
    {"id":"31165","name":"EU/3/16/1728 : Public summary of opinion on orphan designation: Recombinant humanised monoclonal antibody against human complement component C5a for the treatment of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2017-10-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161728-public-summary-opinion-orphan-designation-recombinant-humanised-monoclonal-antibody-against-human-complement-component-c5a-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"31168","name":"EU/3/14/1376: Public summary of opinion on orphan designation: Arimoclomol citrate for the treatment of Niemann-Pick disease, type C","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2015-01-16T01:00:00Z","reference_number":"EMA/COMP/637387/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141376-public-summary-opinion-orphan-designation-arimoclomol-citrate-treatment-niemann-pick-disease-type-c_en.pdf"},
    {"id":"31169","name":"EU/3/12/1037: Public summary of opinion on orphan designation: Elotuzumab for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-26T16:30:00Z","last_updated_date":"2016-05-23T16:30:00Z","reference_number":"EMA/COMP/528459/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121037-public-summary-opinion-orphan-designation-elotuzumab-treatment-multiple-myeloma_en.pdf"},
    {"id":"31170","name":"EU/3/09/712: Public summary of opinion on orphan designation of recombinant kallikrein inhibitor for the treatment of Netherton syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2012-05-04T14:00:00Z","reference_number":"EMA/744660/2009 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309712-public-summary-opinion-orphan-designation-recombinant-kallikrein-inhibitor-treatment-netherton-syndrome_en.pdf"},
    {"id":"31208","name":"EU/3/14/1346: Public summary of opinion on orphan designation: Oxalobacter formigenes strain HC-1 for the treatment of short bowel syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/552880/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141346-public-summary-opinion-orphan-designation-oxalobacter-formigenes-strain-hc-1-treatment-short-bowel-syndrome_en.pdf"},
    {"id":"31229","name":"EU/3/12/968: Public summary of opinion on orphan designation: Human monoclonal antibody targeting Staphylococcus aureus alpha-toxin for the treatment of pneumonia caused by Staphylococcus aureus","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-06T18:00:00Z","last_updated_date":"2014-10-16T18:00:00Z","reference_number":"EMA/COMP/64665/2012 rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312968-public-summary-opinion-orphan-designation-human-monoclonal-antibody-targeting-staphylococcus-aureus-alpha-toxin-treatment-pneumonia-caused-staphylococcus-aureus_en.pdf"},
    {"id":"31235","name":"EU/3/12/989: Public summary of opinion on orphan designation: 2-Allyl-1-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one for the treatmen...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T13:00:00Z","last_updated_date":"2015-05-27T13:00:00Z","reference_number":"EMA/COMP/223438/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312989-public-summary-opinion-orphan-designation-2-allyl-1-6-1-hydroxy-1-methylethylpyridin-2-yl-6-4-4-methylpiperazin-1-ylphenylamino-12-dihydro-3h-pyrazolo34-dpyrimidin-3-one-treatmen_en.pdf"},
    {"id":"31250","name":"EU/3/13/1212: Public summary of opinion on orphan designation: Ibrutinib for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-23T01:00:00Z","last_updated_date":"2021-11-23T01:00:00Z","reference_number":"EMA/COMP/708125/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131212-public-summary-opinion-orphan-designation-ibrutinib-treatment-follicular-lymphoma_en.pdf"},
    {"id":"31259","name":"EU/3/10/818: Public summary of opinion on orphan designation: Human heterologous liver cells (for infusion) for the treatment of citrullinaemia type 1","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-19T01:00:00Z","last_updated_date":"2011-01-19T01:00:00Z","reference_number":"EMA/COMP/636230/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310818-public-summary-opinion-orphan-designation-human-heterologous-liver-cells-infusion-treatment-citrullinaemia-type-1_en.pdf"},
    {"id":"31277","name":"EU/3/05/298: Public summary of positive opinion for orphan designation of  mifepristone for the treatment of Cushing's syndrome secondary to ectopic ACTH secretion","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-11T02:00:00Z","last_updated_date":"2017-02-10T12:56:00Z","reference_number":"EMEA/COMP/216615/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305298-public-summary-positive-opinion-orphan-designation-mifepristone-treatment-cushings-syndrome-secondary-ectopic-acth-secretion_en.pdf"},
    {"id":"31289","name":"EU/3/06/425: Public summary of positive opinion for orphan designation of complement factor H for the treatment of atypical haemolytic uraemic syndrome associated with an inherited abnormality of the complement system","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2013-10-17T18:00:00Z","reference_number":"EMEA/COMP/521235/2006 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306425-public-summary-positive-opinion-orphan-designation-complement-factor-h-treatment-atypical-haemolytic-uraemic-syndrome-associated-inherited-abnormality-complement-system_en.pdf"},
    {"id":"31299","name":"EU/3/11/931: Public summary of opinion on orphan designation: Plerixafor for adjunctive treatment to cytotoxic therapy in acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMA/COMP/862747/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311931-public-summary-opinion-orphan-designation-plerixafor-adjunctive-treatment-cytotoxic-therapy-acute-myeloid-leukaemia_en.pdf"},
    {"id":"31336","name":"EU/3/16/1712 : Public summary of opinion on orphan designation: 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-10-04T02:00:00Z","last_updated_date":"2016-10-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161712-public-summary-opinion-orphan-designation-2-2-ethyl-6-4-2-3-hydroxyazetidin-1-yl-2-oxoethyl-piperazin-1-yl-8-methylimidazo12-alphapyridin-3-yl-methylamino-4-4-fluorophenyl-thiazole_en.pdf"},
    {"id":"31341","name":"EU/3/01/053: Public summary of positive opinion for orphan designation of beraprost sodium for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T00:00:00Z","last_updated_date":"2006-01-04T00:00:00Z","reference_number":"EMEA/COMP/14511/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301053-public-summary-positive-opinion-orphan-designation-beraprost-sodium-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"31358","name":"EU/3/18/1981: Public summary of opinion on orphan designation: Mertansine functionalised gold nanoconjugate for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2020-05-20T02:00:00Z","reference_number":"EMA/71251/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181981-public-summary-opinion-orphan-designation-mertansine-functionalised-gold-nanoconjugate-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"31432","name":"EU/3/11/924: Public summary of opinion on orphan designation: Lenalidomide for the treatment of mantle cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2011-11-23T16:00:00Z","reference_number":"EMA/COMP/793867/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311924-public-summary-opinion-orphan-designation-lenalidomide-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"31462","name":"EU/3/09/723: Public summary of opinion on orphan designation of recombinant fusion protein linking human coagulation factor IX with human albumin for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:00:00Z","last_updated_date":"2010-03-03T01:00:00Z","reference_number":"EU/3/09/723","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309723-public-summary-opinion-orphan-designation-recombinant-fusion-protein-linking-human-coagulation-factor-ix-human-albumin-treatment-haemophilia-b_en.pdf"},
    {"id":"31492","name":"EU/3/16/1783: Public summary of positive opinion for orphan designation of N-(5-(6-chloro-2,2-difluorobenzo[d][1,3]dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide for the treatment of acute pancreatitis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T15:43:00Z","last_updated_date":"2016-12-13T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161783-public-summary-positive-opinion-orphan-designation-n-5-6-chloro-22-difluorobenzod13dioxol-5-ylpyrazin-2-yl-2-fluoro-6-methylbenzamide-treatment-acute-pancreatitis_en.pdf"},
    {"id":"31507","name":"EU/3/12/1003: Public summary of opinion on orphan designation: Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA for the treatment of adrenoleukodystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-04T17:00:00Z","last_updated_date":"2022-04-04T16:00:00Z","reference_number":"EMA/COMP/282979/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121003-public-summary-opinion-orphan-designation-autologous-haematopoietic-stem-cells-transduced-lentiviral-vector-lenti-d-encoding-human-abcd1-cdna-treatment-adrenoleukodystrophy_en.pdf"},
    {"id":"31515","name":"EU/3/15/1489: Public summary of opinion on orphan designation: Fusion proteins composed by a genetically modified cholera toxin subunit A1, peptides from the acetylcholine receptor alpha chain and a dimer of the D fragme...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"EMA/COMP/269696/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151489-public-summary-opinion-orphan-designation-fusion-proteins-composed-genetically-modified-cholera-toxin-subunit-a1-peptides-acetylcholine-receptor-alpha-chain-and-dimer-d-fragme_en.pdf"},
    {"id":"31518","name":"EU/3/14/1276: Public summary of opinion on orphan designation of isavuconazonium sulfate for the treatment of mucormycosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/COMP/230820/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141276-public-summary-opinion-orphan-designation-isavuconazonium-sulfate-treatment-mucormycosis_en.pdf"},
    {"id":"31535","name":"EU/3/03/168: Public summary of positive opinion for orphan designation of herpes simplex 1 virus-thymidine kinase and truncated low affinity nerve growth factor receptor transfected donor lymphocytes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T00:00:00Z","last_updated_date":"2006-01-04T00:00:00Z","reference_number":"EMEA/COMP/1441/2003","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303168-public-summary-positive-opinion-orphan-designation-herpes-simplex-1-virus-thymidine-kinase-and-truncated-low-affinity-nerve-growth-factor-receptor-transfected-donor-lymphocytes_en.pdf"},
    {"id":"31551","name":"EU/3/16/1716 : Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161716-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-containing-human-mini-dystrophin-gene-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"31564","name":"EU/3/07/432: Public summary of positive opinion for orphan designation of ex-vivo cultured adult human mesenchymal stem cells for the treatment of graft-versus-host-disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2013-06-19T14:00:00Z","reference_number":"EMEA/COMP/29248/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307432-public-summary-positive-opinion-orphan-designation-ex-vivo-cultured-adult-human-mesenchymal-stem-cells-treatment-graft-versus-host-disease_en.pdf"}    {"id":"31566","name":"EU/3/14/1311: Public summary of opinion on orphan designation: Gevokizumab for the treatment of Schnitzler syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2018-07-18T02:00:00Z","reference_number":"EMA/COMP/436241/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141311-public-summary-opinion-orphan-designation-gevokizumab-treatment-schnitzler-syndrome_en.pdf"},
    {"id":"31572","name":"EU/3/14/1248: Public summary of opinion on orphan designation: N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-carbamoyl}-methyl)-2-[2-(2-fluoro-phenyl)-ethylamino]-N-isobutyl-acetamide for the treatment of optic ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-03T12:00:00Z","last_updated_date":"2015-06-08T12:00:00Z","reference_number":"EMA/COMP/23335/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141248-public-summary-opinion-orphan-designation-n-carbamoylmethyl-3-2-oxo-pyrrolidin-1-yl-propyl-carbamoyl-methyl-2-2-2-fluoro-phenyl-ethylamino-n-isobutyl-acetamide-treatment-optic_en.pdf"},
    {"id":"31575","name":"EU/3/04/248: Public summary of positive opinion for orphan designation of recombinant histidine tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-06T00:00:00Z","last_updated_date":"2011-06-01T01:00:00Z","reference_number":"EMEA/COMP/157098/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304248-public-summary-positive-opinion-orphan-designation-recombinant-histidine-tagged-idiotype-immunoglobulin-fab-fragment-clonal-b-cell-receptors-treatment-multiple-myeloma_en.pdf"},
    {"id":"31591","name":"EU/3/14/1400: Public summary of opinion on orphan designation: (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-\n\ncarboxylic acid-L-lysine for the treatment of neurotrophic keratitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T01:00:00Z","last_updated_date":"2015-02-26T01:00:00Z","reference_number":"EMA/COMP/734950/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141400-public-summary-opinion-orphan-designation-1s4r5r7s-34-dibenzyl-2-oxo-68-dioxa-3-azabyciclo321octane-7-carboxylic-acid-l-lysine-treatment-neurotrophic-keratitis_en.pdf"},
    {"id":"31594","name":"EU/3/16/1632: Public summary of opinion on orphan designation: Florilglutamic acid (18F) for diagnosis of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-02T02:00:00Z","last_updated_date":"2016-05-02T02:00:00Z","reference_number":"EMA/COMP/172321/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161632-public-summary-opinion-orphan-designation-florilglutamic-acid-18f-diagnosis-hepatocellular-carcinoma_en.pdf"},
    {"id":"31605","name":"EU/3/10/746: Public summary of positive opinion: Maytansinoid-conjugated humanised monoclonal antibody against CD56 for the treatment of Merkel-cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2015-03-06T13:30:00Z","reference_number":"EMA/COMP/164684/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310746-public-summary-positive-opinion-maytansinoid-conjugated-humanised-monoclonal-antibody-against-cd56-treatment-merkel-cell-carcinoma_en.pdf"},
    {"id":"31642","name":"EU/3/09/617: Public summary of positive opinion for orphan designation\n\nof 2,2-dimethylbutyric acid, sodium salt for the treatment of beta thalassaemia intermedia and major","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2015-03-20T01:00:00Z","reference_number":"EMEA/COMP/45098/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309617-public-summary-positive-opinion-orphan-designation-22-dimethylbutyric-acid-sodium-salt-treatment-beta-thalassaemia-intermedia-and-major_en.pdf"},
    {"id":"31658","name":"EU/3/16/1756: Public summary of positive opinion for orphan designation of mogamulizumab for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMA/616732/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161756-public-summary-positive-opinion-orphan-designation-mogamulizumab-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"31673","name":"EU/3/17/1828: Public summary of opinion on orphan designation: 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/83404/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171828-public-summary-opinion-orphan-designation-1-22-difluoro-2h-13-benzodioxol-5-yl-n-1-2r-23-dihydroxypropyl-6-fluoro-2-1-hydroxy-2-methylpropan-2-yl-1h-indol-5-ylcyclopropane-1-carboxamide_en.pdf"},
    {"id":"31683","name":"EU/3/15/1473: Public summary of positive opinion for orphan designation of Lenalidomide for the treatment of marginal zone lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-21T14:00:00Z","last_updated_date":"2015-05-21T14:00:00Z","reference_number":"EMA/COMP/210061/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151473-public-summary-positive-opinion-orphan-designation-lenalidomide-treatment-marginal-zone-lymphoma_en.pdf"},
    {"id":"31711","name":"EU/3/09/627: Public summary of positive opinion for orphan designation of lintuzumab for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-12T02:00:00Z","last_updated_date":"2011-11-11T01:00:00Z","reference_number":"EMEA/COMP/161880/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309627-public-summary-positive-opinion-orphan-designation-lintuzumab-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"31747","name":"EU/3/07/522: Public summary of positive opinion for (manganese, dichloro [(4aR, 13aR, 17aR, 21aR)-1, 2, 3, 4, 4a, 5, 6, 12, 13, 13a, 14, 15, 16, 17, 17a, 18, 19, 20, 21, 21a-eicosahydro-11, 7-nitrilo-7H-dibenzo[ b,h] [1,...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/COMP/577300/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307522-public-summary-positive-opinion-manganese-dichloro-4ar-13ar-17ar-21ar-1-2-3-4-4a-5-6-12-13-13a-14-15-16-17-17a-18-19-20-21-21a-eicosahydro-11-7-nitrilo-7h-dibenzo-bh-1_en.pdf"},
    {"id":"31749","name":"EU/3/13/1188: Public summary of opinion on orphan designation:\n\nRecombinant fusion protein linking coagulation factor VIIa with albumin for the treatment of congenital factor VII deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-10-31T01:00:00Z","last_updated_date":"2013-10-31T01:00:00Z","reference_number":"EMA/COMP/556625/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131188-public-summary-opinion-orphan-designation-recombinant-fusion-protein-linking-coagulation-factor-viia-albumin-treatment-congenital-factor-vii-deficiency_en.pdf"},
    {"id":"31752","name":"EU/3/18/1991: Public summary of opinion on orphan designation: Docosahexaenoic acid ethyl ester for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"EMA/125843/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181991-public-summary-opinion-orphan-designation-docosahexaenoic-acid-ethyl-ester-treatment-sickle-cell-disease_en.pdf"},
    {"id":"31753","name":"EU/3/07/474: Public summary of positive opinion for orphan designation of alpha-1proteinase inhibitor (inhalation use) for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-17T01:00:00Z","last_updated_date":"2008-01-17T01:00:00Z","reference_number":"EMEA/351455/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307474-public-summary-positive-opinion-orphan-designation-alpha-1proteinase-inhibitor-inhalation-use-treatment-cystic-fibrosis_en.pdf"},
    {"id":"31758","name":"EU/3/04/206: Public summary of positive opinion for orphan designation of muramyl tripeptide phosphatidyl ethanolamine for the treatment of osteosarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2019-07-11T02:00:00Z","reference_number":"EMEA/COMP/373/04 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304206-public-summary-positive-opinion-orphan-designation-muramyl-tripeptide-phosphatidyl-ethanolamine-treatment-osteosarcoma_en.pdf"},
    {"id":"31764","name":"EU/3/01/056: Public summary of positive opinion for orphan designation: Recombinant human acid sphingomyelinase for the treatment of Niemann-Pick disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/142984/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301056-public-summary-positive-opinion-orphan-designation-recombinant-human-acid-sphingomyelinase-treatment-niemann-pick-disease_en.pdf"},
    {"id":"31788","name":"EU/3/16/1688: Public summary of opinion on orphan designation: Setmelanotide for the treatment of Prader-Willi syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/383369/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161688-public-summary-opinion-orphan-designation-setmelanotide-treatment-prader-willi-syndrome_en.pdf"},
    {"id":"31789","name":"EU/3/12/1046: Public summary of opinion on orphan designation: Mavoglurant for treatment of fragile-X syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T17:00:00Z","last_updated_date":"2015-02-10T17:00:00Z","reference_number":"EMA/COMP/613861/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121046-public-summary-opinion-orphan-designation-mavoglurant-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"31806","name":"EU/3/03/179: Public summary of positive opinion for orphan designation of recombinant human factor XIII (composed of two A subunits) for the treatment of hereditary factor-XIII deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T00:00:00Z","last_updated_date":"2014-01-13T01:00:00Z","reference_number":"EMA/COMP/1590/2003, Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303179-public-summary-positive-opinion-orphan-designation-recombinant-human-factor-xiii-composed-two-subunits-treatment-hereditary-factor-xiii-deficiency_en.pdf"},
    {"id":"31826","name":"EU/3/14/1393: Public summary of positive opinion for orphan designation: Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor for the treatment of diffuse lar...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-02-26T18:00:00Z","reference_number":"EMA/COMP/736525/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141393-public-summary-positive-opinion-orphan-designation-autologous-t-cells-transduced-retroviral-vector-encoding-anti-cd19-cd28cd3-zeta-chimeric-antigen-receptor-treatment-diffuse-lar_en.pdf"},
    {"id":"31850","name":"EU/3/17/1899: Public summary of opinion on orphan designation: Antisense oligonucleotide targeting exon 13 in the USH2A gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/508063/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171899-public-summary-opinion-orphan-designation-antisense-oligonucleotide-targeting-exon-13-ush2a-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"31892","name":"EU/3/14/1313: Public summary of opinion on orphan designation: (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/COMP/433740/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141313-public-summary-opinion-orphan-designation-z-3-3-35-bistrifluoromethylphenyl-1h-124-triazol-1-yl-n-pyrazin-2-ylacrylohydrazide-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"31906","name":"EU/3/01/084: Public summary of positive opinion for orphan designation ofazacitidine for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2019-02-20T02:00:00Z","reference_number":"EMA/COMP/89/2002 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301084-public-summary-positive-opinion-orphan-designation-ofazacitidine-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"31920","name":"EU/3/16/1662: Public summary of opinion on orphan designation: H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-22T02:00:00Z","last_updated_date":"2016-06-22T02:00:00Z","reference_number":"EMA/COMP/310646/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161662-public-summary-opinion-orphan-designation-h-phe-ser-arg-tyr-ala-arg-oh-acetate-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"31944","name":"EU/3/14/1281: Public summary of opinion on orphan designation: 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropanecarboxamide for th...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/COMP/304418/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141281-public-summary-opinion-orphan-designation-1-22-difluoro-13-benzodioxol-5-yl-n-1-2r-23-dihydroxypropyl-6-fluoro-2-1-hydroxy-2-methylpropan-2-yl-1h-indol-5-ylcyclopropanecarboxamide-th_en.pdf"},
    {"id":"31995","name":"EU/3/06/351: Public summary of positive opinion for orphan designation of miglustat for the treatment of Niemann-Pick disease, type C","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-08-24T02:00:00Z","last_updated_date":"2019-02-20T01:00:00Z","reference_number":"EMEA/COMP/25188/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306351-public-summary-positive-opinion-orphan-designation-miglustat-treatment-niemann-pick-disease-type-c_en.pdf"},
    {"id":"32005","name":"EU/3/13/1106: Public summary of positive opinion of L-asparaginase encapsulated in erythrocytes for the treatment acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T11:00:00Z","last_updated_date":"2013-03-04T11:00:00Z","reference_number":"EMA/COMP/38578/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131106-public-summary-positive-opinion-l-asparaginase-encapsulated-erythrocytes-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"32014","name":"EU/3/08/606: Public summary of positive opinion for orphan designation of recombinant human residue 41 glutamic acid to glutamine variant of interferon-alfa-2b for the treatment of Behà§et’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-06-29T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMEA/COMP/612595/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308606-public-summary-positive-opinion-orphan-designation-recombinant-human-residue-41-glutamic-acid-glutamine-variant-interferon-alfa-2b-treatment-behassets-disease_en.pdf"},
    {"id":"32051","name":"EU/3/13/1130: Public summary of opinion on orphan designation: Recombinant human transglutaminase 1 encapsulated into liposomes for the treatment of transglutaminase-1-deficient autosomal recessive congenital ichthyosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2013-06-25T19:00:00Z","reference_number":"EMA/COMP/273194/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131130-public-summary-opinion-orphan-designation-recombinant-human-transglutaminase-1-encapsulated-liposomes-treatment-transglutaminase-1-deficient-autosomal-recessive-congenital-ichthyosis_en.pdf"},
    {"id":"32060","name":"EU/3/06/360: Public summary of positive opinion for orphan designation of ciclosporin for the treatment of vernal keratoconjunctivitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-24T00:00:00Z","last_updated_date":"2015-05-14T01:00:00Z","reference_number":"EMEA/COMP/107514/2006 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306360-public-summary-positive-opinion-orphan-designation-ciclosporin-treatment-vernal-keratoconjunctivitis_en.pdf"},
    {"id":"32079","name":"EU/3/09/684: Public summary of positive opinion for orphan designation of masitinib mesilate for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2009-11-18T00:09:21Z","reference_number":"EMEA/COMP/575646/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309684-public-summary-positive-opinion-orphan-designation-masitinib-mesilate-treatment-pancreatic-cancer_en.pdf"},
    {"id":"32098","name":"EU/3/16/1708: Public summary of opinion on orphan designation: Sodium benzoate for the treatment of hyperargininaemia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/450251/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161708-public-summary-opinion-orphan-designation-sodium-benzoate-treatment-hyperargininaemia_en.pdf"},
    {"id":"32115","name":"EU/3/12/1065: Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine (prior to administration of doxorubicin) for the ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"EMA/COMP/678670/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121065-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-claudin-5-complexed-polyethyleneimine-prior-administration-doxorubicin_en.pdf"},
    {"id":"32123","name":"EU/3/15/1493: Public summary of opinion on orphan designation: Allopurinol sodium for the treatment of perinatal asphyxia myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"EMA/COMP/269967/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151493-public-summary-opinion-orphan-designation-allopurinol-sodium-treatment-perinatal-asphyxia-myeloma_en.pdf"},
    {"id":"32127","name":"EU 3/03/164: Public summary of positive opinion for orphan designation of α-1-acid glycoprotein for the treatment of cocaine poisoning","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-04-26T02:00:00Z","last_updated_date":"2011-03-25T01:00:00Z","reference_number":"EMA/COMP/234392/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-303164-public-summary-positive-opinion-orphan-designation-i-1-acid-glycoprotein-treatment-cocaine-poisoning_en.pdf"},
    {"id":"32130","name":"EU/3/15/1569: Public summary of opinion on orphan designation: Pentetrazol for the treatment of idiopathic hypersomnia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2020-12-10T01:00:00Z","reference_number":"EMA/COMP/699946/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151569-public-summary-opinion-orphan-designation-pentetrazol-treatment-idiopathic-hypersomnia_en.pdf"},
    {"id":"32151","name":"EU/3/12/1008: Public summary of opinion on orphan designation: Human erythrocytes encapsulating inositol hexaphosphate for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2012-07-24T16:00:00Z","reference_number":"EMA/COMP/350652/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121008-public-summary-opinion-orphan-designation-human-erythrocytes-encapsulating-inositol-hexaphosphate-treatment-sickle-cell-disease_en.pdf"},
    {"id":"32159","name":"EU/3/15/1498: Public summary of opinion on orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide for treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2020-04-16T02:00:00Z","reference_number":"EMA/COMP/274375/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151498-public-summary-opinion-orphan-designation-2-7-ethoxy-4-3-fluorophenyl-1-oxophthalazin-21h-yl-n-methyl-n-2-methylbenzodoxazol-6-yl-acetamide-treatment-cystic-fibrosis_en.pdf"},
    {"id":"32198","name":"EU/3/07/505: Public summary of positive opinion of acute respiratory distress syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2018-10-11T09:43:00Z","reference_number":"EMA/396437/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307505-public-summary-positive-opinion-acute-respiratory-distress-syndrome_en.pdf"},
    {"id":"32243","name":"C(2005)2034: Public summary of negative opinion for orphan designation of ibuprofen L-lysinate for the prevention of patent ductus arteriosus in premature neonates of less than 34 weeks of gestational age","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-11T02:00:00Z","last_updated_date":"2005-10-11T02:00:00Z","reference_number":"EMEA/COMP/130770/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/c20052034-public-summary-negative-opinion-orphan-designation-ibuprofen-l-lysinate-prevention-patent-ductus-arteriosus-premature-neonates-less-34-weeks-gestational-age_en.pdf"},
    {"id":"32278","name":"EU/3/14/1254: Public summary of opinion on orphan designation: Eculizumab for the prevention of graft rejection following solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-06T02:00:00Z","last_updated_date":"2018-05-22T11:31:00Z","reference_number":"EMA/COMP/89171/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141254-public-summary-opinion-orphan-designation-eculizumab-prevention-graft-rejection-following-solid-organ-transplantation_en.pdf"},
    {"id":"32302","name":"EU/3/13/1205: Public summary of opinion on orphan designation: Human monoclonal antibody against human interleukin 13 for the treatment of eosinophilic oesophagitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2022-08-30T11:42:00Z","reference_number":"EMA/COMP/637681/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131205-public-summary-opinion-orphan-designation-human-monoclonal-antibody-against-human-interleukin-13-treatment-eosinophilic-oesophagitis_en.pdf"},
    {"id":"32392","name":"EU/3/12/1004: Public summary of opinion on orphan designation: Ramucirumab for the treatment of gastric cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2016-01-19T15:00:00Z","reference_number":"EMA/COMP/337338/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121004-public-summary-opinion-orphan-designation-ramucirumab-treatment-gastric-cancer_en.pdf"},
    {"id":"32393","name":"EU/3/08/589: Public summary of positive opinion for orphan designation of yttrium (90Y) edotreotide for the treatment of gastro-entero-pancreatic neuroendocrine tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2018-05-29T02:00:00Z","reference_number":"EMEA/COMP/547022/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308589-public-summary-positive-opinion-orphan-designation-yttrium-90y-edotreotide-treatment-gastro-entero-pancreatic-neuroendocrine-tumours_en.pdf"},
    {"id":"32398","name":"EU/3/12/1053: Public summary of opinion on orphan designation\n\nLurbinectedin for the treatment of ovarian cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2012-11-16T01:00:00Z","reference_number":"EMA/COMP/624614/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121053-public-summary-opinion-orphan-designation-lurbinectedin-treatment-ovarian-cancer_en.pdf"},
    {"id":"32423","name":"EU/3/14/1428: Public summary of opinion on orphan designation: Sodium valproate for the treatment of Wolfram syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2015-03-06T12:00:00Z","reference_number":"EMA/COMP/787361/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141428-public-summary-opinion-orphan-designation-sodium-valproate-treatment-wolfram-syndrome_en.pdf"},
    {"id":"32435","name":"EU/3/03/173: Public summary of positive opinion for orphan designation of vasoactive intestinal peptide for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/1537/03 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303173-public-summary-positive-opinion-orphan-designation-vasoactive-intestinal-peptide-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"32441","name":"EU/3/04/203: Public summary of positive opinion for orphan designation of 5'CTG CCA CGT TCT CCT GC-(2' methoxy)A-(2' methoxy)C-(2'methoxy)C-3' for the treatment of myasthenia gravis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-06T02:00:00Z","last_updated_date":"2019-08-30T14:00:00Z","reference_number":"EMEA/COMP/245/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304203-public-summary-positive-opinion-orphan-designation-5ctg-cca-cgt-tct-cct-gc-2-methoxya-2-methoxyc-2methoxyc-3-treatment-myasthenia-gravis_en.pdf"},
    {"id":"32449","name":"EU/3/15/1520: Public summary of opinion on orphan designation: Cannabidiol for the treatment of perinatal asphyxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T14:00:00Z","last_updated_date":"2015-08-18T14:00:00Z","reference_number":"EMA/COMP/427063/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151520-public-summary-opinion-orphan-designation-cannabidiol-treatment-perinatal-asphyxia_en.pdf"},
    {"id":"32458","name":"EU/3/04/244: Public summary of positive opinion for orphan designation of alpha-1 antitrypsin (inhalation use) for the treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2013-02-07T01:00:00Z","reference_number":"EMA/COMP/109743/2004 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304244-public-summary-positive-opinion-orphan-designation-alpha-1-antitrypsin-inhalation-use-treatment-emphysema-secondary-congenital-alpha-1-antitrypsin-deficiency_en.pdf"},
    {"id":"32474","name":"EU/3/08/550: Public summary of positive opinion for orphan designation of \n\nnimotuzumab for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2008-08-18T02:00:00Z","reference_number":"EMEA/COMP/196682/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308550-public-summary-positive-opinion-orphan-designation-nimotuzumab-treatment-pancreatic-cancer_en.pdf"},
    {"id":"32477","name":"EU/3/14/1397: Public summary of opinion on orphan designation: Amikacin sulfate for the treatment of Pseudomonas aeuriginosa lung infection\n\nin cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T01:00:00Z","last_updated_date":"2015-02-26T01:00:00Z","reference_number":"EMA/COMP/736592/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141397-public-summary-opinion-orphan-designation-amikacin-sulfate-treatment-pseudomonas-aeuriginosa-lung-infection-cystic-fibrosis_en.pdf"},
    {"id":"32518","name":"EU/3/10/795: Public summary of opinion on orphan designation: Pralatrexate for the treatment of Hodgkin’s lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2010-10-14T02:00:00Z","reference_number":"EMA/COMP/471332/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310795-public-summary-opinion-orphan-designation-pralatrexate-treatment-hodgkins-lymphoma_en.pdf"},
    {"id":"32527","name":"EU/3/09/655: Public summary of positive opinion for orphan designation of octocog alfa (liposomal) for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2013-07-08T17:00:00Z","reference_number":"EMEA/COMP/364727/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309655-public-summary-positive-opinion-orphan-designation-octocog-alfa-liposomal-treatment-haemophilia_en.pdf"},
    {"id":"32533","name":"EU/3/06/373: Public summary of positive opinion for orphan designation of mecasermin for the treatment of primary insulin-like growth factor-1 deficiencydue to molecular or genetic defects","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-11-19T00:00:00Z","reference_number":"EMEA/COMP/133160/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306373-public-summary-positive-opinion-orphan-designation-mecasermin-treatment-primary-insulin-growth-factor-1-deficiencydue-molecular-or-genetic-defects_en.pdf"},
    {"id":"32536","name":"EU/3/17/1945: Public summary of opinion on orphan designation: Tiratricol for the treatment of Allan-Herndon-Dudley syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-15T01:00:00Z","last_updated_date":"2018-01-15T01:00:00Z","reference_number":"EMA/695502/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171945-public-summary-opinion-orphan-designation-tiratricol-treatment-allan-herndon-dudley-syndrome_en.pdf"},
    {"id":"32540","name":"EU/3/13/1104: Public summary of positive opinion of terguride for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-04T11:00:00Z","last_updated_date":"2013-11-25T01:00:00Z","reference_number":"EMA/COMP/27796/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131104-public-summary-positive-opinion-terguride-treatment-systemic-sclerosis_en.pdf"},
    {"id":"32555","name":"EU/3/14/1413: Public summary of opinion on orphan designation: Allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells / allogeneic, umbilical cord blood-derived, non-expanded, haematopoie...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2018-01-23T01:00:00Z","reference_number":"EMA/COMP/786995/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141413-public-summary-opinion-orphan-designation-allogeneic-umbilical-cord-blood-derived-ex-vivo-expanded-haematopoietic-cd133-cells-allogeneic-umbilical-cord-blood-derived-non-expanded-haematopoie_en.pdf"},
    {"id":"32562","name":"EU/3/05/282: Public summary of positive opinion for orphan designation of miltefosine for the treatment of Acanthamoeba keratitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2014-01-10T01:00:00Z","reference_number":"EMEA/COMP/139086/2005 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305282-public-summary-positive-opinion-orphan-designation-miltefosine-treatment-acanthamoeba-keratitis_en.pdf"},
    {"id":"32575","name":"EU/3/15/1492: Public summary of opinion on orphan designation:  AASSGVSTPGSAGHDIITEQPRS for the treatment of Huntington’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"EMA/COMP/275974/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151492-public-summary-opinion-orphan-designation-aassgvstpgsaghdiiteqprs-treatment-huntingtons-disease_en.pdf"},
    {"id":"32594","name":"EU/3/15/1522: Public summary of opinion on orphan designation: Humanised IgG4 monoclonal antibody against extracellular tau for the treatment of progressive supranuclear palsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T14:00:00Z","last_updated_date":"2015-08-18T14:00:00Z","reference_number":"EMA/COMP/430864/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151522-public-summary-opinion-orphan-designation-humanised-igg4-monoclonal-antibody-against-extracellular-tau-treatment-progressive-supranuclear-palsy_en.pdf"},
    {"id":"32615","name":"EU/3/07/486: Public summary of positive opinion for orphan designation of adenovirus associated viral vector serotype 4 containing the human RPE65 gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMEA/COMP/440597/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307486-public-summary-positive-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-4-containing-human-rpe65-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"32626","name":"EU/3/12/1016: Public summary of opinion on orphan designation: 16-base single-stranded peptide nucleic acid oligonucleotide linked to 7-amino acid peptide for the treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2014-04-01T16:00:00Z","reference_number":"EMA/COMP/393098/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121016-public-summary-opinion-orphan-designation-16-base-single-stranded-peptide-nucleic-acid-oligonucleotide-linked-7-amino-acid-peptide-treatment-neuroblastoma_en.pdf"},
    {"id":"32638","name":"EU/3/04/194: Public summary of positive opinion for orphan designation of adeno-associated viral vector expressing lipoprotein lipase for treatment of lipoprotein-lipase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-03-07T01:00:00Z","last_updated_date":"2021-05-21T02:00:00Z","reference_number":"EMEA/COMP/83/2004 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304194-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-expressing-lipoprotein-lipase-treatment-lipoprotein-lipase-deficiency_en.pdf"},
    {"id":"32661","name":"EU/3/02/126: Public summary of positive opinion for orphan designation of recombinant inhibitor of human plasma kallikrein for the treatment of angioedema","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMEA/COMP/2714/02 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302126-public-summary-positive-opinion-orphan-designation-recombinant-inhibitor-human-plasma-kallikrein-treatment-angioedema_en.pdf"},
    {"id":"32673","name":"EU/3/12/956: Public summary of opinion on orphan designation: Human monoclonal antibody against Fas ligand for the treatment of pemphigus","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T01:00:00Z","last_updated_date":"2012-03-01T01:00:00Z","reference_number":"EMA/982984/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312956-public-summary-opinion-orphan-designation-human-monoclonal-antibody-against-fas-ligand-treatment-pemphigus_en.pdf"},
    {"id":"32675","name":"EU/3/03/182: Public summary of positive opinion for orphan designation of 5-methyl-pyridine-2-sulfonic acid 6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-\n\n(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide sodium salt (...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T00:00:00Z","last_updated_date":"2015-03-24T00:00:00Z","reference_number":"EMEA/COMP/1563/03 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303182-public-summary-positive-opinion-orphan-designation-5-methyl-pyridine-2-sulfonic-acid-6-2-hydroxyethoxy-5-2-methoxyphenoxy-2-2-1h-tetrazol-5-yl-pyridin-4-yl-pyrimidin-4-ylamide-sodium-salt_en.pdf"},
    {"id":"32679","name":"EU/3/12/1043: Public summary of opinion on orphan designation: N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine to be used with fo...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-27T16:00:00Z","last_updated_date":"2021-12-07T16:00:00Z","reference_number":"EMA/COMP/554957/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121043-public-summary-opinion-orphan-designation-n-4-2-amino-34-dihydro-4-oxo-6-pteridinylmethylaminobenzoyl-d-gamma-glutamyl-2s-2-amino-beta-alanyl-l-alpha-aspartyl-l-cysteine-be-used-fo_en.pdf"},
    {"id":"32710","name":"EU/3/06/349: Public summary of positive opinion for orphan designation of apomorphine hydrochloride (inhalation use) for the treatment of off-periods in Parkinson’s disease not responding to oral treatment","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-08-24T02:00:00Z","last_updated_date":"2006-08-24T02:00:00Z","reference_number":"EMEA/COMP/25291/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306349-public-summary-positive-opinion-orphan-designation-apomorphine-hydrochloride-inhalation-use-treatment-periods-parkinsons-disease-not-responding-oral-treatment_en.pdf"},
    {"id":"32720","name":"EU/3/17/1918: Public summary of opinion on orphan designation: Autologous ex vivo expanded peripheral polyclonal lymphocytes enriched in activated natural killer cells for the treatment of multiple myeloma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-10T10:25:00Z","last_updated_date":"2018-01-10T10:25:00Z","reference_number":"EMA/617444/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171918-public-summary-opinion-orphan-designation-autologous-ex-vivo-expanded-peripheral-polyclonal-lymphocytes-enriched-activated-natural-killer-cells-treatment-multiple-myeloma_en.pdf"},
    {"id":"32733","name":"EU/3/12/1045: Public summary of opinion on orphan designation: Alpha-1 proteinase inhibitor (for inhalation use) for the treatment of cystic fibrosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T17:00:00Z","last_updated_date":"2012-11-16T17:00:00Z","reference_number":"EMA/COMP/612138/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121045-public-summary-opinion-orphan-designation-alpha-1-proteinase-inhibitor-inhalation-use-treatment-cystic-fibrosis_en.pdf"},
    {"id":"32767","name":"EU/3/16/1785: Public summary of positive opinion for orphan designation of R-azasetron besylate for the treatment of sudden sensorineural hearing loss","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T15:43:00Z","last_updated_date":"2016-12-13T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161785-public-summary-positive-opinion-orphan-designation-r-azasetron-besylate-treatment-sudden-sensorineural-hearing-loss_en.pdf"},
    {"id":"32769","name":"EU/3/17/1930: Public summary of opinion on orphan designation: Seladelpar for the treatment of primary biliary cholangitis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-10T10:25:00Z","last_updated_date":"2018-01-10T10:25:00Z","reference_number":"EMA/634183/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171930-public-summary-opinion-orphan-designation-seladelpar-treatment-primary-biliary-cholangitis_en.pdf"},
    {"id":"32804","name":"EU/3/07/437: Public summary of positive opinion for orphan designation of idebenone for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2011-04-11T02:00:00Z","reference_number":"EMEA/COMP/466948/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307437-public-summary-positive-opinion-orphan-designation-idebenone-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"32834","name":"EU/3/16/1706: Public summary of opinion on orphan designation: Sodium benzoate for the treatment of carbamoyl-phosphate synthase-1 deficiency","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/449116/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161706-public-summary-opinion-orphan-designation-sodium-benzoate-treatment-carbamoyl-phosphate-synthase-1-deficiency_en.pdf"},
    {"id":"32849","name":"EU/3/03/170: Public summary of positive opinion for orphan designation of human immunoglobulin for the treatment of polymyositis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-04-26T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMEA/COMP/1443/2003 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303170-public-summary-positive-opinion-orphan-designation-human-immunoglobulin-treatment-polymyositis_en.pdf"},
    {"id":"32866","name":"EU/3/10/754: Public summary of opinion on orphan designation: Heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device ade from alpha-calcium sulphate hemihydrate) for the treatment of tr...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-05T02:00:00Z","last_updated_date":"2021-02-03T02:00:00Z","reference_number":"EMA/COMP/269110/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310754-public-summary-opinion-orphan-designation-heparin-activated-recombinant-human-fibroblast-growth-factor-1-biodegradable-device-ade-alpha-calcium-sulphate-hemihydrate-treatment-tr_en.pdf"},
    {"id":"32870","name":"EU/3/15/1599: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype rh10 containing the human factor IX gene for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2022-10-11T01:00:00Z","reference_number":"EMA/COMP/776835/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151599-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-rh10-containing-human-factor-ix-gene-treatment-haemophilia-b_en.pdf"},
    {"id":"32882","name":"EU/3/15/1472: Public summary of positive opinion for orphan designation of Fluciclovine (18F) for the diagnosis of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-21T14:00:00Z","last_updated_date":"2015-05-21T14:00:00Z","reference_number":"EMA/COMP/212725/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151472-public-summary-positive-opinion-orphan-designation-fluciclovine-18f-diagnosis-glioma_en.pdf"},
    {"id":"32950","name":"EU/3/08/570: Public summary of positive opinion for orphan designation of recombinant human CXCL8 mutant for the prevention of delayed graft function after solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2009-04-02T02:00:00Z","reference_number":"EMEA/COMP/364246/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308570-public-summary-positive-opinion-orphan-designation-recombinant-human-cxcl8-mutant-prevention-delayed-graft-function-after-solid-organ-transplantation_en.pdf"},
    {"id":"32957","name":"Public summary of opinion on orphan designation: Nabilone for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"EMA/COMP/924925/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-nabilone-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"32995","name":"EU/3/16/1674: Public summary of opinion on orphan designation: Allogeneic donor-derived ex-vivo expanded T lymphocytes transduced with a retroviral vector containing inducible caspase 9 and truncated CD19 for treatment i...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2022-04-07T02:00:00Z","reference_number":"EMA/COMP/388379/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161674-public-summary-opinion-orphan-designation-allogeneic-donor-derived-ex-vivo-expanded-t-lymphocytes-transduced-retroviral-vector-containing-inducible-caspase-9-and-truncated-cd19-treatment-i_en.pdf"},
    {"id":"33013","name":"EU/3/18/1994: Public summary of opinion on orphan designation:\n\nIvosidenib for the treatment of biliary tract cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-08T02:00:00Z","last_updated_date":"2018-05-08T02:00:00Z","reference_number":"EMA/126932/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181994-public-summary-opinion-orphan-designation-ivosidenib-treatment-biliary-tract-cancer_en.pdf"},
    {"id":"33078","name":"EU/3/03/159: Public summary of positive opinion for orphan designation of recombinant human insulin-like growth factor-I / recombinant human insulin-like growth factor binding protein-3 for the treatment of primary growt...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2011-06-21T02:00:00Z","reference_number":"EMEA/COMP/1338/03 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303159-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i-recombinant-human-insulin-growth-factor-binding-protein-3-treatment-primary-growt_en.pdf"},
    {"id":"33101","name":"EU/3/01/037 : Public summary of positive opinion for orphan designation of humanised anti-HM1.24 monoclonal antibody for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-04-28T02:00:00Z","last_updated_date":"2005-04-28T02:00:00Z","reference_number":"EMEA/COMP/11030/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301037-public-summary-positive-opinion-orphan-designation-humanised-anti-hm124-monoclonal-antibody-treatment-multiple-myeloma_en.pdf"},
    {"id":"33112","name":"EU/3/01/051: Public summary of positive opinion for orphan designation\n\nof 1,3-propanedisulfonic acid, disodium salt for the treatment of systemic secondary amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2013-09-19T02:00:00Z","reference_number":"EMEA/COMP/249/04 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301051-public-summary-positive-opinion-orphan-designation-13-propanedisulfonic-acid-disodium-salt-treatment-systemic-secondary-amyloidosis_en.pdf"},
    {"id":"33130","name":"EU/3/07/513: Public summary of positive opinion for orphan designation of (S)-2-nitro-6-(4-trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine for the treatment of tuberculosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2008-07-02T02:00:00Z","reference_number":"EMEA/COMP/489102/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307513-public-summary-positive-opinion-orphan-designation-s-2-nitro-6-4-trifluoromethoxybenzyloxy-67-dihydro-5h-imidazo21-b-13-oxazine-treatment-tuberculosis_en.pdf"},
    {"id":"33136","name":"EU/3/08/534: Public summary of positive opinion for orphan designation of allogeneic human umbilical cord tissue-derived cells for treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/48111/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308534-public-summary-positive-opinion-orphan-designation-allogeneic-human-umbilical-cord-tissue-derived-cells-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"33139","name":"EU/3/11/893: Public summary of opinion on orphan designation: Cardiotrophin-1 for the treatment of acute liver failure","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2011-09-21T02:00:00Z","reference_number":"EMA/COMP/512020/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311893-public-summary-opinion-orphan-designation-cardiotrophin-1-treatment-acute-liver-failure_en.pdf"},
    {"id":"33174","name":"EU/3/15/1516: Public summary of opinion on orphan designation: Modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full len...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T02:00:00Z","last_updated_date":"2015-08-18T02:00:00Z","reference_number":"EMA/COMP/272314/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151516-public-summary-opinion-orphan-designation-modified-adenovirus-serotype-535-containing-cmv-promoter-driven-transgene-cassette-human-transgenes-membrane-bound-cd40-ligand-and-full-len_en.pdf"},
    {"id":"33193","name":"EU/3/08/595: Public summary of positive opinion for orphan designation of monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E for the treatment of anaplastic large cell lympho...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMEA/COMP/547229/2008 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308595-public-summary-positive-opinion-orphan-designation-monoclonal-antibody-against-human-cd30-covalently-linked-cytotoxin-monomethylauristatin-e-treatment-anaplastic-large-cell-lympho_en.pdf"},
    {"id":"33199","name":"EU/3/09/654: Public summary of positive opinion for orphan designation of hypothiocyanite / lactoferrin for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2013-03-19T13:30:00Z","reference_number":"EMA/COMP/392984/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309654-public-summary-positive-opinion-orphan-designation-hypothiocyanite-lactoferrin-treatment-cystic-fibrosis_en.pdf"},
    {"id":"33211","name":"EU/3/12/1066: Public summary of opinion on orphan designation: Tafamidis for treatment of senile systemic amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2012-12-12T01:00:00Z","reference_number":"EMA/COMP/678671/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121066-public-summary-opinion-orphan-designation-tafamidis-treatment-senile-systemic-amyloidosis_en.pdf"},
    {"id":"33220","name":"EU/3/15/1490: Public summary of opinion on orphan designation: Triamcinolone acetonide for the treatment of non-infectious uveitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"EMA/COMP/281345/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151490-public-summary-opinion-orphan-designation-triamcinolone-acetonide-treatment-non-infectious-uveitis_en.pdf"},
    {"id":"33229","name":"EU/3/05/310: Public summary of positive opinion for orphan designation of treprostinil diethanolamine (oral use) for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"EMEA/COMP/221562/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305310-public-summary-positive-opinion-orphan-designation-treprostinil-diethanolamine-oral-use-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"33232","name":"EU/3/16/1699: Public summary of opinion on orphan designation: Mifamurtide for the treatment of echinococcosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/448143/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161699-public-summary-opinion-orphan-designation-mifamurtide-treatment-echinococcosis_en.pdf"},
    {"id":"33242","name":"EU/3/12/1083 : Public summary of opinion on orphan designation: Humanised single-chain monoclonal antibody against CD37 for the treatment chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-25T12:00:00Z","last_updated_date":"2013-07-08T13:00:00Z","reference_number":"EMA/COMP/741023/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121083-public-summary-opinion-orphan-designation-humanised-single-chain-monoclonal-antibody-against-cd37-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"33260","name":"EU/3/12/1095: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase-alpha gene for the treatment of mucopolysaccharidosis type IIIB (Sanfil...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/COMP/805822/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121095-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-containing-human-n-acetylglucosaminidase-alpha-gene-treatment-mucopolysaccharidosis-type-iiib-sanfil_en.pdf"},
    {"id":"33264","name":"EU/3/09/614: Public summary of positive opinion for orphan designation of mifepristone for the treatment of endogenous hypercortisolism (Cushing’s syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/COMP/50998/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309614-public-summary-positive-opinion-orphan-designation-mifepristone-treatment-endogenous-hypercortisolism-cushings-syndrome_en.pdf"}    {"id":"33269","name":"EU/3/14/1334: Public summary of opinion on orphan designation: (3S)-(+)-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one for the treatment of fragile X syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/555975/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141334-public-summary-opinion-orphan-designation-3s-5-chloro-2-methoxyphenyl-13-dihydro-3-fluoro-6-trifluoromethyl-2h-indol-2-one-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"33270","name":"EU/3/09/686: Public summary of positive opinion for orphan designation of NGR-human tumour necrosis factor for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2009-11-18T00:09:21Z","reference_number":"EMEA/COMP/577663/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309686-public-summary-positive-opinion-orphan-designation-ngr-human-tumour-necrosis-factor-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"33278","name":"EU/3/18/2005: Public summary of opinion on orphan designation: Tazemetostat for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-15T02:00:00Z","last_updated_date":"2018-05-15T02:00:00Z","reference_number":"EMA/111729/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182005-public-summary-opinion-orphan-designation-tazemetostat-treatment-follicular-lymphoma_en.pdf"},
    {"id":"33284","name":"EU/3/14/1270: Public summary of opinion on orphan designation of(5R,5aR,8aR,9S)-9-[[4,6-O-[(R)-Ethylidene]-β-D-glucopyranosyl]-oxy]-5-(4-({[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]carbonyl}oxy)-3,5-dimethoxyphenyl)-5,8,...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-10T02:00:00Z","last_updated_date":"2014-07-10T02:00:00Z","reference_number":"EMA/COMP/234508/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141270-public-summary-opinion-orphan-designation-of5r5ar8ar9s-9-46-o-r-ethylidene-i2-d-glucopyranosyl-oxy-5-4-22-dimethyl-13-dioxolan-4-ylmethoxycarbonyloxy-35-dimethoxyphenyl-58_en.pdf"},
    {"id":"33286","name":"EU/3/10/820: Public summary of opinion on orphan designation: Human heterologous liver cells (for infusion) for the treatment of argininosuccinic aciduria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"EMA/COMP/636096/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310820-public-summary-opinion-orphan-designation-human-heterologous-liver-cells-infusion-treatment-argininosuccinic-aciduria_en.pdf"},
    {"id":"33287","name":"EU/3/12/974: Public summary of opinion on orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene for the treatment of primary hyperoxaluria type 1","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T11:45:00Z","last_updated_date":"2013-03-11T14:00:00Z","reference_number":"EMA/64512/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312974-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-5-containing-human-alanine-glyoxylate-aminotransferase-gene-treatment-primary-hyperoxaluria-type-1_en.pdf"},
    {"id":"33289","name":"EU/3/01/031: Public summary of positive opinion for orphan designation of arsenic trioxide for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-04T02:00:00Z","last_updated_date":"2010-03-15T01:00:00Z","reference_number":"EMEA/COMP/118/04 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301031-public-summary-positive-opinion-orphan-designation-arsenic-trioxide-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"33323","name":"EU/3/16/1770: Public summary of positive opinion for orphan designation of 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride for the treatment of adrenoleukodystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T15:43:00Z","last_updated_date":"2016-12-13T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161770-public-summary-positive-opinion-orphan-designation-5-4-2-5-1-hydroxyethyl-2-pyridinylethoxybenzyl-24-thiazolidinedione-hydrochloride-treatment-adrenoleukodystrophy_en.pdf"},
    {"id":"33342","name":"EU/3/16/1820: Public summary of opinion on orphan designation: Hydroxychloroquine for treatment of antiphospholipid syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/4539/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161820-public-summary-opinion-orphan-designation-hydroxychloroquine-treatment-antiphospholipid-syndrome_en.pdf"},
    {"id":"33357","name":"EU/3/14/1348: Public summary of opinion on orphan designation: Recombinant human bone morphogenetic protein 4 for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/553420/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141348-public-summary-opinion-orphan-designation-recombinant-human-bone-morphogenetic-protein-4-treatment-glioma_en.pdf"},
    {"id":"33372","name":"EU/3/16/1825: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector serotype 9 containing the human N-alpha-acetylglucosaminidase gene for the treatment of mucopolysaccharidosis type ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"EMA/15565/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161825-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-serotype-9-containing-human-n-alpha-acetylglucosaminidase-gene-treatment-mucopolysaccharidosis-type_en.pdf"},
    {"id":"33395","name":"EU/3/03/143: Public summary of positive opinion for orphan designation\n\nof 5-10-methylene-tetrahydrofolate for the treatment of pancreatic cancer in combination with 5-fluorouracil","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/1098/03 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303143-public-summary-positive-opinion-orphan-designation-5-10-methylene-tetrahydrofolate-treatment-pancreatic-cancer-combination-5-fluorouracil_en.pdf"},
    {"id":"33437","name":"EU/3/11/891: Public summary of opinion on orphan designation: Human anthrax monoclonal antibody for post-exposure prophylaxis of inhalation anthrax disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2016-08-11T02:00:00Z","reference_number":"EMA/COMP/144916/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311891-public-summary-opinion-orphan-designation-human-anthrax-monoclonal-antibody-post-exposure-prophylaxis-inhalation-anthrax-disease_en.pdf"},
    {"id":"33488","name":"EU/3/14/1291: Public summary of opinion on orphan designation: Rilotumumab for the treatment of gastric cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T17:00:00Z","last_updated_date":"2014-09-01T17:00:00Z","reference_number":"EMA/COMP/358832/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141291-public-summary-opinion-orphan-designation-rilotumumab-treatment-gastric-cancer_en.pdf"},
    {"id":"33490","name":"EU/3/12/971: Public summary of opinion on orphan designation: Heterologous human adult liver-derived stem cells for the treatment of carbamoyl-phosphate synthase-1 deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T11:45:00Z","last_updated_date":"2012-04-19T11:45:00Z","reference_number":"EMA/COMP/62441/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312971-public-summary-opinion-orphan-designation-heterologous-human-adult-liver-derived-stem-cells-treatment-carbamoyl-phosphate-synthase-1-deficiency_en.pdf"},
    {"id":"33498","name":"EU/3/16/1623: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 encoding human ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"EMA/COMP/164905/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161623-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-8-encoding-human-ornithine-transcarbamylase-treatment-ornithine-transcarbamylase-deficiency_en.pdf"},
    {"id":"33508","name":"EU/3/10/752: Public summary of positive opinion for Velaglucerase alfa for the treatment of Gaucher disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2022-09-09T02:00:00Z","reference_number":"EMA/COMP/169787/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310752-public-summary-positive-opinion-velaglucerase-alfa-treatment-gaucher-disease_en.pdf"},
    {"id":"33509","name":"EU/3/08/587: Public summary of positive opinion for orphan designation of cenersen for the treatment chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMEA/COMP/547158/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308587-public-summary-positive-opinion-orphan-designation-cenersen-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"33533","name":"EU/3/07/448: Public summary of positive opinion for orphan designation of talactoferrinum alpha for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/COMP/206437/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307448-public-summary-positive-opinion-orphan-designation-talactoferrinum-alpha-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"33535","name":"EU/3/17/1860: Public summary of opinion on orphan designation: Poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/143980/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171860-public-summary-opinion-orphan-designation-poly-cyclodextrin-bis-cysteine-peg3400-camptothecin-conjugate-treatment-ovarian-cancer_en.pdf"},
    {"id":"33598","name":"EU/3/18/1973: Public summary of opinion on orphan designation: 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide targeting exon 13 in the USH2A gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-10T02:00:00Z","last_updated_date":"2018-04-10T02:00:00Z","reference_number":"EMA/56907/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181973-public-summary-opinion-orphan-designation-2-o-2-methoxyethyl-modified-antisense-oligonucleotide-targeting-exon-13-ush2a-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"33619","name":"EU/3/15/1564: Public summary of opinion on orphan designation: Dronabinol and cannabidiol for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-18T11:00:00Z","last_updated_date":"2015-11-18T11:00:00Z","reference_number":"EMA/COMP/607076/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151564-public-summary-opinion-orphan-designation-dronabinol-and-cannabidiol-treatment-glioma_en.pdf"},
    {"id":"33634","name":"EU/3/16/1815: Public summary of opinion on orphan designation: Fluticasone propionate for the treatment of eosinophilic oesophagitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/4662/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161815-public-summary-opinion-orphan-designation-fluticasone-propionate-treatment-eosinophilic-oesophagitis_en.pdf"},
    {"id":"33641","name":"EU/3/07/444: Public summary of positive opinion for orphan designation of pralatrexate for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2011-04-07T02:00:00Z","reference_number":"EMEA/COMP/107558/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307444-public-summary-positive-opinion-orphan-designation-pralatrexate-treatment-peripheral-t-cell-lymphoma-nodal-other-extranodal-and-leukaemicdisseminated_en.pdf"},
    {"id":"33663","name":"EU/3/15/1432: Public summary of opinion on orphan designation: 2'-O-methyl phosphorothioate RNA oligonucleotide, 5'-m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3' for the treatment of Huntington's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2015-04-08T02:00:00Z","reference_number":"EMA/COMP/24679/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151432-public-summary-opinion-orphan-designation-2-o-methyl-phosphorothioate-rna-oligonucleotide-5-m5cugm5cugm5cugm5cugm5cugm5cugm5cug-3-treatment-huntingtons-disease_en.pdf"},
    {"id":"33681","name":"EU/3/16/1690: Public summary of opinion on orphan designation: 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7 amino acid peptide for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-09-06T02:00:00Z","reference_number":"EMA/COMP/451052/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161690-public-summary-opinion-orphan-designation-16-base-single-stranded-peptide-nucleic-acid-oligonucleotide-linked-7-amino-acid-peptide-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"33754","name":"EU/3/17/1917: Public summary of opinion on orphan designation: Adenoviral vector of serotype 5 modified to contain a chimeric sequence consisting of a minimal urokinase-type plasminogen activator receptor promoter preced...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T15:45:00Z","last_updated_date":"2018-01-09T15:45:00Z","reference_number":"EMA/618135/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171917-public-summary-opinion-orphan-designation-adenoviral-vector-serotype-5-modified-contain-chimeric-sequence-consisting-minimal-urokinase-type-plasminogen-activator-receptor-promoter-preced_en.pdf"},
    {"id":"33817","name":"EU/3/03/167: Public summary of positive opinion for orphan designation of H-Tyrosine-Glycine-Phenylalanine-Glycine-Glycine-OH for the treatment of chronic idiopathic myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2009-09-21T02:00:00Z","reference_number":"EMEA/COMP/1579/2003 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303167-public-summary-positive-opinion-orphan-designation-h-tyrosine-glycine-phenylalanine-glycine-glycine-oh-treatment-chronic-idiopathic-myelofibrosis_en.pdf"},
    {"id":"33840","name":"EU/3/10/833: Public summary of opinion on orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes) for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-04T01:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMA/COMP/754491/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310833-public-summary-opinion-orphan-designation-doxorubicin-hydrochloride-heat-sensitive-liposomes-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"33844","name":"EU/3/10/731: Public summary of opinion on orphan designation: Bafetinib for the treatment of chronic myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2013-07-31T02:00:00Z","reference_number":"EMA/COMP/90894/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310731-public-summary-opinion-orphan-designation-bafetinib-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"33902","name":"EU/3/11/943: Public summary of positive opinion for orphan designation: Mogamulizumab for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2012-05-04T14:00:00Z","reference_number":"EMA/COMP/938736/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311943-public-summary-positive-opinion-orphan-designation-mogamulizumab-treatment-peripheral-t-cell-lymphoma-nodal-other-extranodal-and-leukaemicdisseminated_en.pdf"},
    {"id":"33915","name":"EU/3/16/1664: Public summary of opinion on orphan designation: Polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase for treatment of homocystinuria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"EMA/COMP/309791/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161664-public-summary-opinion-orphan-designation-polyethylene-glycol-modified-human-recombinant-truncated-cystathionine-beta-synthase-treatment-homocystinuria_en.pdf"},
    {"id":"33927","name":"EU/3/16/1768: Public summary of positive opinion for orphan designation of xenon for the treatment of ischaemia reperfusion injury associated with cardiac arrest","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/622430/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161768-public-summary-positive-opinion-orphan-designation-xenon-treatment-ischaemia-reperfusion-injury-associated-cardiac-arrest_en.pdf"},
    {"id":"33934","name":"EU/3/15/1505: Public summary of opinion on orphan designation: Obinutuzumab for the treatment of marginal zone lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2016-10-20T02:00:00Z","reference_number":"EMA/COMP/350571/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151505-public-summary-opinion-orphan-designation-obinutuzumab-treatment-marginal-zone-lymphoma_en.pdf"},
    {"id":"33939","name":"EU/3/17/1864: Public summary of opinion on orphan designation: Emeramide for the prevention of mercury toxicity","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/208446/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171864-public-summary-opinion-orphan-designation-emeramide-prevention-mercury-toxicity_en.pdf"},
    {"id":"33969","name":"EU/3/15/1534: Public summary of opinion on orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid for the treatment of Rett syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2015-10-02T02:00:00Z","reference_number":"EMA/COMP/494145/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151534-public-summary-opinion-orphan-designation-glycyl-l-2-methylprolyl-l-glutamic-acid-treatment-rett-syndrome_en.pdf"},
    {"id":"34017","name":"EU/3/18/2034: Public summary of opinion on orphan designation: Deferiprone for the treatment of neurodegeneration with brain iron accumulation","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-21T12:45:00Z","last_updated_date":"2018-08-21T12:45:00Z","reference_number":"EMA/355632/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182034-public-summary-opinion-orphan-designation-deferiprone-treatment-neurodegeneration-brain-iron-accumulation_en.pdf"},
    {"id":"34045","name":"EU/3/14/1320: Public summary of opinion on orphan designation: Recombinant human diamine oxidase for the treatment of mastocytosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-01T02:00:00Z","last_updated_date":"2014-10-01T02:00:00Z","reference_number":"EMA/COMP/452146/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141320-public-summary-opinion-orphan-designation-recombinant-human-diamine-oxidase-treatment-mastocytosis_en.pdf"},
    {"id":"34057","name":"EU/3/13/1217: Public summary of opinion on orphan designation: (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabi...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-22T01:00:00Z","last_updated_date":"2022-06-14T01:00:00Z","reference_number":"EMA/COMP/700146/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131217-public-summary-opinion-orphan-designation-4r5r-1-4-4-33-dibutyl-7-dimethylamino-2345-tetrahydro-4-hydroxy-11-dioxido-1-benzothiepin-5-ylphenoxymethylphenylmethyl-4-aza-1-azoniabi_en.pdf"},
    {"id":"34063","name":"EU/3/14/1419: Public summary of opinion on orphan designation: Tenofovir disoproxil fumarate for the treatment of Aicardi-Goutià¨res syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/COMP/797338/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141419-public-summary-opinion-orphan-designation-tenofovir-disoproxil-fumarate-treatment-aicardi-goutiares-syndrome_en.pdf"},
    {"id":"34072","name":"EU/3/15/1524: Public summary of opinion on orphan designation: Triheptanoin for the treatment of long-chain 3-hydroxyacyl-coA dehydrogenase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T02:00:00Z","last_updated_date":"2015-08-18T02:00:00Z","reference_number":"EMA/COMP/432825/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151524-public-summary-opinion-orphan-designation-triheptanoin-treatment-long-chain-3-hydroxyacyl-coa-dehydrogenase-deficiency_en.pdf"},
    {"id":"34074","name":"EU/3/04/252: Public summary of positive opinion for orphan designation of Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3) for the treatment of chronic myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-06T00:00:00Z","last_updated_date":"2009-11-19T00:00:00Z","reference_number":"EMEA/COMP/152652/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304252-public-summary-positive-opinion-orphan-designation-val-leu-gln-glu-leu-asn-val-thr-val-pr1-nanopeptide-sequence-169-177-proteinase-3-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"34089","name":"EU/3/16/1658: Public summary of opinion on orphan designation: 4-[(2E)-1-oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2017-08-16T02:00:00Z","reference_number":"EMA/COMP/314054/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161658-public-summary-opinion-orphan-designation-4-2e-1-oxo-3-266-trimethyl-1-cyclohexen-1-yl-2-propen-1-yl-1-piperazinecarboxamide-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"34190","name":"EU/3/12/1054: Public summary of opinion on orphan designation: Obinutuzumab for the treatment of chronic lymphocytic leukaemia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/COMP/612787/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121054-public-summary-opinion-orphan-designation-obinutuzumab-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"34222","name":"EU/3/07/441: Public summary of positive opinion for orphan designation of hydrocortisone (modified release tablet) for the treatment of adrenal insufficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2020-10-20T16:00:00Z","reference_number":"EMEA/COMP/57720/2007 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307441-public-summary-positive-opinion-orphan-designation-hydrocortisone-modified-release-tablet-treatment-adrenal-insufficiency_en.pdf"},
    {"id":"34246","name":"EU/3/15/1496: Public summary of opinion on orphan designation: Trehalose for the treatment of oculopharyngeal muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"EMA/COMP/280663/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151496-public-summary-opinion-orphan-designation-trehalose-treatment-oculopharyngeal-muscular-dystrophy_en.pdf"},
    {"id":"34247","name":"EU/3/12/1007: Public summary of opinion on orphan designation: 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (after administration of adeno-associated viral vector encoding an inducible short hairpin RNA targetin...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-17T01:00:00Z","last_updated_date":"2016-08-11T02:00:00Z","reference_number":"EMA/COMP/357653/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121007-public-summary-opinion-orphan-designation-17-dimethylaminoethylamino-17-demethoxygeldanamycin-after-administration-adeno-associated-viral-vector-encoding-inducible-short-hairpin-rna-targetin_en.pdf"},
    {"id":"34260","name":"EU/3/06/350: Public summary of positive opinion for orphan designation of alpha-1 proteinase inhibitor for the treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2009-09-17T02:00:00Z","reference_number":"EMEA/COMP/17827/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306350-public-summary-positive-opinion-orphan-designation-alpha-1-proteinase-inhibitor-treatment-emphysema-secondary-congenital-alpha-1-antitrypsin-deficiency_en.pdf"},
    {"id":"34267","name":"EU/3/07/451: Public summary of positive opinion for orphan designation of cisplatin (liposomal) for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T00:00:00Z","last_updated_date":"2007-12-04T00:00:00Z","reference_number":"EMEA/COMP/167850/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307451-public-summary-positive-opinion-orphan-designation-cisplatin-liposomal-treatment-pancreatic-cancer_en.pdf"},
    {"id":"34309","name":"EU/3/15/1434: Public summary of opinion on orphan designation: Chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-08T02:00:00Z","last_updated_date":"2021-06-25T02:00:00Z","reference_number":"EMA/COMP/49562/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151434-public-summary-opinion-orphan-designation-chimeric-group-b-adenovirus-11p3-deletions-e3-and-e4-regions-treatment-ovarian-cancer_en.pdf"},
    {"id":"34314","name":"EU/3/04/207: Public summary of positive opinion for orphan designation of sorafenib tosylate for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2016-08-10T14:30:00Z","reference_number":"EMEA/COMP/294/04 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304207-public-summary-positive-opinion-orphan-designation-sorafenib-tosylate-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"34323","name":"EU/3/10/758: Public summary of opinion on orphan designation: Pomalidomide for the treatment of post-polycythaemia vera myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-08-06T13:32:00Z","last_updated_date":"2017-02-10T12:32:00Z","reference_number":"EMA/COMP/249456/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310758-public-summary-opinion-orphan-designation-pomalidomide-treatment-post-polycythaemia-vera-myelofibrosis_en.pdf"},
    {"id":"34334","name":"EU/3/13/1116: Public summary of opinion on orphan designation:Mepolizumab for the treatment of Churg-Strauss syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T02:00:00Z","last_updated_date":"2020-10-23T02:00:00Z","reference_number":"EMA/COMP/95498/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131116-public-summary-opinion-orphan-designationmepolizumab-treatment-churg-strauss-syndrome_en.pdf"},
    {"id":"34344","name":"EU/3/13/1233: Public summary of opinion on orphan designation: Allogeneic bone-marrow-derived ex-vivo-expanded multipotent adult progenitor cells for the prevention of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T01:00:00Z","last_updated_date":"2014-03-24T01:00:00Z","reference_number":"EMA/COMP/1978/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131233-public-summary-opinion-orphan-designation-allogeneic-bone-marrow-derived-ex-vivo-expanded-multipotent-adult-progenitor-cells-prevention-graft-versus-host-disease_en.pdf"},
    {"id":"34380","name":"EU/3/14/1303: Public summary of opinion on orphan designation: Cediranib for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T02:00:00Z","last_updated_date":"2014-09-01T02:00:00Z","reference_number":"EMA/COMP/359488/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141303-public-summary-opinion-orphan-designation-cediranib-treatment-ovarian-cancer_en.pdf"},
    {"id":"34415","name":"EU/3/11/932: Public summary of opinion on orphan designation: Pegylated proline-interferon alpha-2b for the treatment of polycythaemia vera","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"EMA/COMP/862741/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311932-public-summary-opinion-orphan-designation-pegylated-proline-interferon-alpha-2b-treatment-polycythaemia-vera_en.pdf"},
    {"id":"34432","name":"EU/3/15/1591: Public summary of opinion on orphan designation: Synthetic peptide L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glu...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2016-02-03T01:00:00Z","reference_number":"EMA/COMP/794963/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151591-public-summary-opinion-orphan-designation-synthetic-peptide-l-cysteine-l-cysteinylglycyl-l-glutaminyl-l-arginyl-l-alpha-glutamyl-l-threonyl-l-prolyl-l-alpha-glutamylglycyl-l-alanyl-l-alpha_en.pdf"},
    {"id":"34443","name":"EU/3/10/821: Public summary of opinion on orphan designation: Human heterologous liver cells (for infusion) for the treatment of carbamoyl-phosphate synthase-1 deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"EMA/COMP/636271/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310821-public-summary-opinion-orphan-designation-human-heterologous-liver-cells-infusion-treatment-carbamoyl-phosphate-synthase-1-deficiency_en.pdf"},
    {"id":"34456","name":"EU/3/09/711: Public summary of opinion on orphan designation of recombinant human vascular endothelial growth factor for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/749030/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309711-public-summary-opinion-orphan-designation-recombinant-human-vascular-endothelial-growth-factor-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"34459","name":"EU/3/01/059: Public summary of positive opinion for orphan designation of dexrazoxane for the treatment of anthracycline extravasation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2016-09-30T02:00:00Z","reference_number":"EMEA/COMP/256/2004 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301059-public-summary-positive-opinion-orphan-designation-dexrazoxane-treatment-anthracycline-extravasation_en.pdf"},
    {"id":"34510","name":"EU/3/12/987: Public summary of opinion on orphan designation: (E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl-sulfone sodium salt for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T13:00:00Z","last_updated_date":"2021-10-27T11:30:00Z","reference_number":"EMA/COMP/217857/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312987-public-summary-opinion-orphan-designation-e-246-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl-sulfone-sodium-salt-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"34512","name":"EU/3/02/103: Public summary of positive opinion for orphan designation of recombinant human porphobilinogen deaminase for the treatment of acute intermittent porphyria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-01-08T00:00:00Z","last_updated_date":"2020-08-12T00:00:00Z","reference_number":"EMEA/COMP/843/02 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302103-public-summary-positive-opinion-orphan-designation-recombinant-human-porphobilinogen-deaminase-treatment-acute-intermittent-porphyria_en.pdf"},
    {"id":"34516","name":"EU/3/10/737: Public summary of opinion on orphan designation: Glyceryl tri-(4-phenylbutyrate) for the treatment of hyperargininaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/COMP/123476/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310737-public-summary-opinion-orphan-designation-glyceryl-tri-4-phenylbutyrate-treatment-hyperargininaemia_en.pdf"},
    {"id":"34551","name":"EU/3/15/1437: Public summary of opinion on orphan designation: Alvocidib for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2015-04-09T02:00:00Z","reference_number":"EMA/COMP/24067/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151437-public-summary-opinion-orphan-designation-alvocidib-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"34561","name":"EU/3/06/383: Public summary of positive opinion for orphan designation of siplizumab for the treatment of T-cell and NK-cell neoplasms","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2013-04-09T02:00:00Z","reference_number":"EMA/COMP/110465/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306383-public-summary-positive-opinion-orphan-designation-siplizumab-treatment-t-cell-and-nk-cell-neoplasms_en.pdf"},
    {"id":"34568","name":"EU/3/14/1260: Public summary of opinion on orphan designation: Fixed-dose combination of (R-S) baclofen, naltrexone hydrochloride and D-sorbitol for the treatment of Charcot-Marie-Tooth disease type 1A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-07T02:00:00Z","last_updated_date":"2014-05-07T02:00:00Z","reference_number":"EMA/COMP/94332/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141260-public-summary-opinion-orphan-designation-fixed-dose-combination-r-s-baclofen-naltrexone-hydrochloride-and-d-sorbitol-treatment-charcot-marie-tooth-disease-type-1a_en.pdf"},
    {"id":"34569","name":"EU/3/00/001: Public summary of positive opinion for orphan designation of somatropin for AIDS wasting","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T01:00:00Z","last_updated_date":"2011-05-06T02:00:00Z","reference_number":"EMEA/COMP/259802/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300001-public-summary-positive-opinion-orphan-designation-somatropin-aids-wasting_en.pdf"},
    {"id":"34607","name":"EU/3/07/461: Public summary of positive opinion for orphan designation of human plasminogen for the treatment of ligneous conjunctivitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-17T01:00:00Z","last_updated_date":"2008-01-17T01:00:00Z","reference_number":"EMEA/COMP/285792/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307461-public-summary-positive-opinion-orphan-designation-human-plasminogen-treatment-ligneous-conjunctivitis_en.pdf"},
    {"id":"34616","name":"EU/3/10/744: Public summary of positive opinion on orphan designation Adrenomedullin for the treatment of acute lung injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2011-11-18T01:00:00Z","reference_number":"EMA/COMP/169921/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310744-public-summary-positive-opinion-orphan-designation-adrenomedullin-treatment-acute-lung-injury_en.pdf"},
    {"id":"34627","name":"EU/3/16/1663: Public summary of opinion on orphan designation: Pentosan polysulfate sodium for the treatment of interstitial cystitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-22T02:00:00Z","last_updated_date":"2016-06-22T02:00:00Z","reference_number":"EMA/COMP/310632/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161663-public-summary-opinion-orphan-designation-pentosan-polysulfate-sodium-treatment-interstitial-cystitis_en.pdf"},
    {"id":"34648","name":"EU/3/09/652: Public summary of positive opinion for orphan designation of ciprofloxacin (liposomal) for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2009-09-11T02:00:00Z","reference_number":"EMEA/COMP/362878/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309652-public-summary-positive-opinion-orphan-designation-ciprofloxacin-liposomal-treatment-cystic-fibrosis_en.pdf"},
    {"id":"34650","name":"EU/3/15/1499: Public summary of opinion on orphan designation: Adult human bone-marrow-derived, ex-vivo-expanded, pooled allogeneic mesenchymal stromal cells for treatment of thromboangiitis obliterans (Buerger's disease...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"EMA/COMP/274387/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151499-public-summary-opinion-orphan-designation-adult-human-bone-marrow-derived-ex-vivo-expanded-pooled-allogeneic-mesenchymal-stromal-cells-treatment-thromboangiitis-obliterans-buergers-disease_en.pdf"},
    {"id":"34668","name":"EU/3/10/837: Public summary of opinion on orphan designation: Plitidepsin for the treatment of primary myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2011-09-06T02:00:00Z","reference_number":"EMA/COMP/740395/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310837-public-summary-opinion-orphan-designation-plitidepsin-treatment-primary-myelofibrosis_en.pdf"},
    {"id":"34693","name":"EU/3/14/1314: Public summary of opinion on orphan designation: Recombinant human apolipoprotein A-I in a complex with phospholipids for the treatment of ATP-binding cassette transporter A1 deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/COMP/434435/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141314-public-summary-opinion-orphan-designation-recombinant-human-apolipoprotein-i-complex-phospholipids-treatment-atp-binding-cassette-transporter-a1-deficiency_en.pdf"},
    {"id":"34708","name":"EU/3/16/1752: Public summary of positive opinion for orphan designation of human monoclonal IgG1 antibody against tissue factor pathway inhibitor for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"EMA/615269/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161752-public-summary-positive-opinion-orphan-designation-human-monoclonal-igg1-antibody-against-tissue-factor-pathway-inhibitor-treatment-haemophilia_en.pdf"},
    {"id":"34709","name":"EU/3/18/2013: Public summary of opinion on orphan designation: Polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T13:00:00Z","last_updated_date":"2018-05-17T13:00:00Z","reference_number":"EMA/178440/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182013-public-summary-opinion-orphan-designation-polatuzumab-vedotin-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"34760","name":"EU/3/16/1817: Public summary of opinion on orphan designation: Human donor haematopoietic stem and progenitor cells that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/4679/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161817-public-summary-opinion-orphan-designation-human-donor-haematopoietic-stem-and-progenitor-cells-have-been-treated-ex-vivo-protein-transduction-domain-hiv-1-transactivation-protein_en.pdf"},
    {"id":"34771","name":"EU/3/02/124: Public summary of positive opinion for orphan designation of 3,4 diaminopyridine phosphate for the treatment of Lambert-Eaton myasthenic syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/2732/02 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302124-public-summary-positive-opinion-orphan-designation-34-diaminopyridine-phosphate-treatment-lambert-eaton-myasthenic-syndrome_en.pdf"},
    {"id":"34772","name":"EU/3/12/995: Public summary of opinion on orphan designation: Pegylated recombinant factor VIII for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T16:55:00Z","last_updated_date":"2012-06-18T16:55:00Z","reference_number":"EMA/COMP/215112/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312995-public-summary-opinion-orphan-designation-pegylated-recombinant-factor-viii-treatment-haemophilia_en.pdf"},
    {"id":"34777","name":"EU/3/09/641: Public summary of positive opinion for orphan designation of\n\nalicaforsen for the treatment of pouchitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-09T02:00:00Z","last_updated_date":"2013-09-19T02:00:00Z","reference_number":"EMEA/COMP/241184/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309641-public-summary-positive-opinion-orphan-designation-alicaforsen-treatment-pouchitis_en.pdf"},
    {"id":"34823","name":"EU/3/17/1971: Public summary of opinion on orphan designation: Vatiquinone for the treatment of RARS2 syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-12T01:00:00Z","last_updated_date":"2018-03-12T01:00:00Z","reference_number":"EMA/829780/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171971-public-summary-opinion-orphan-designation-vatiquinone-treatment-rars2-syndrome_en.pdf"},
    {"id":"34836","name":"EU/3/15/1480: Public summary of positive opinion for orphan designation of Rintatolimod for the treatment of Ebola virus disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T13:00:00Z","last_updated_date":"2015-05-22T13:00:00Z","reference_number":"EMA/COMP/204227/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151480-public-summary-positive-opinion-orphan-designation-rintatolimod-treatment-ebola-virus-disease_en.pdf"},
    {"id":"34840","name":"EU/3/00/015: Public summary of positive opinion for orphan designation of xaliproden hydrochloride for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-12T00:00:00Z","last_updated_date":"2011-05-07T01:00:00Z","reference_number":"EMEA/COMP/1275/03 draft Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300015-public-summary-positive-opinion-orphan-designation-xaliproden-hydrochloride-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"34862","name":"EU/3/18/1978: Public summary of opinion on orphan designation: Flucytosine for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-10T02:00:00Z","last_updated_date":"2018-04-10T02:00:00Z","reference_number":"EMA/64659/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181978-public-summary-opinion-orphan-designation-flucytosine-treatment-glioma_en.pdf"},
    {"id":"34863","name":"EU/3/10/799: Public summary of opinion on orphan designation: Tecovirimat for the treatment of cowpox infection","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2012-05-04T14:00:00Z","reference_number":"EMA/COMP/486458/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310799-public-summary-opinion-orphan-designation-tecovirimat-treatment-cowpox-infection_en.pdf"},
    {"id":"34865","name":"EU/3/01/027: Public summary of positive opinion for orphan designation of ibuprofen for the prevention of patent ductus arteriosus in premature neonates of less than 34 weeks of gestational age","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/161/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301027-public-summary-positive-opinion-orphan-designation-ibuprofen-prevention-patent-ductus-arteriosus-premature-neonates-less-34-weeks-gestational-age_en.pdf"},
    {"id":"34897","name":"EU/3/15/1552: Public summary of opinion on orphan designation: Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor for the treatment of mantle cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2015-11-16T01:00:00Z","reference_number":"EMA/COMP/596693/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151552-public-summary-opinion-orphan-designation-autologous-t-cells-transduced-retroviral-vector-encoding-anti-cd19-cd28cd3-zeta-chimeric-antigen-receptor-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"34916","name":"EU/3/14/1353: Public summary of opinion on orphan designation: Mexiletine hydrochloride for the treatment of myotonic disorders","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/COMP/660449/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141353-public-summary-opinion-orphan-designation-mexiletine-hydrochloride-treatment-myotonic-disorders_en.pdf"},
    {"id":"34929","name":"EU/3/14/1268: Public summary of opinion on orphan designation: Humanised monoclonal antibody against CD38 for the treatment of plasma cell myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-06-04T02:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMA/COMP/171715/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141268-public-summary-opinion-orphan-designation-humanised-monoclonal-antibody-against-cd38-treatment-plasma-cell-myeloma_en.pdf"},
    {"id":"34963","name":"EU/3/11/878: Public summary of opinion on orphan designation: Allogeneic T cells encoding an exogenous TK gene for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2011-07-12T02:00:00Z","reference_number":"EMA/COMP/291801/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311878-public-summary-opinion-orphan-designation-allogeneic-t-cells-encoding-exogenous-tk-gene-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"34984","name":"EU/3/13/1211: Public summary of opinion on orphan designation: Allogeneic and autologous haptenised and irradiated cells and cell lysates derived from glioma for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-22T01:00:00Z","last_updated_date":"2014-01-22T01:00:00Z","reference_number":"EMA/COMP/704856/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131211-public-summary-opinion-orphan-designation-allogeneic-and-autologous-haptenised-and-irradiated-cells-and-cell-lysates-derived-glioma-treatment-glioma_en.pdf"},
    {"id":"34989","name":"EU/3/10/791: Public summary of opinion on orphan designation: Ciclosporin for the treatment of moderate and severe closed traumatic brain injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2013-03-19T13:30:00Z","reference_number":"EMA/COMP/479449/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310791-public-summary-opinion-orphan-designation-ciclosporin-treatment-moderate-and-severe-closed-traumatic-brain-injury_en.pdf"},
    {"id":"35005","name":"EU/3/12/1078 : Public summary of opinion on orphan designation: Exon-55-specific phosphorothioate oligonucleotide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-25T12:00:00Z","last_updated_date":"2013-01-25T12:00:00Z","reference_number":"EMA/COMP/740569/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121078-public-summary-opinion-orphan-designation-exon-55-specific-phosphorothioate-oligonucleotide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"35024","name":"EU/3/14/1336: Public summary of opinion on orphan designation: (S)-6-Hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride for the treatment of Leigh syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/557459/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141336-public-summary-opinion-orphan-designation-s-6-hydroxy-2578-tetramethyl-n-r-piperidin-3-ylchroman-2-carboxamide-hydrochloride-treatment-leigh-syndrome_en.pdf"},
    {"id":"35049","name":"EU/3/14/1282: Public summary of opinion on orphan designation: Mixture of two adeno-associated viral vectors serotype 8 containing the 5’-half sequence of human MYO7A gene and the 3’-half sequence of human MYO7A gene for...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-16T02:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMA/COMP/319754/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141282-public-summary-opinion-orphan-designation-mixture-two-adeno-associated-viral-vectors-serotype-8-containing-5-half-sequence-human-myo7a-gene-and-3-half-sequence-human-myo7a-gene_en.pdf"},
    {"id":"35055","name":"EU/3/05/286: Public summary of positive opinion for orphan designation of N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-07-26T02:00:00Z","last_updated_date":"2005-07-26T02:00:00Z","reference_number":"EMEA/COMP/163647/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305286-public-summary-positive-opinion-orphan-designation-n-methyl-diazacyclohexyl-methylbenzamide-azaphenyl-aminothiopyrrole-treatment-multiple-myeloma_en.pdf"},
    {"id":"35115","name":"EU/3/10/733: Public summary of opinion on orphan designation: Glyceryl tri-(4-phenylbutyrate) for the treatment of carbamoyl-phosphate synthase-1 deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/COMP/110042/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310733-public-summary-opinion-orphan-designation-glyceryl-tri-4-phenylbutyrate-treatment-carbamoyl-phosphate-synthase-1-deficiency_en.pdf"},
    {"id":"35122","name":"EU/3/16/1803: Public summary of opinion on orphan designation: Metformin for the treatment of progressive myoclonic epilepsy type 2 (Lafora disease)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/741007/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161803-public-summary-opinion-orphan-designation-metformin-treatment-progressive-myoclonic-epilepsy-type-2-lafora-disease_en.pdf"},
    {"id":"35129","name":"EU/3/01/077: Public summary of positive opinion for orphan designation of [gly2]-recombinant human glucagon-like peptide for the treatment of short-bowel syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2022-09-09T01:00:00Z","reference_number":"EMA/COMP/247424/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301077-public-summary-positive-opinion-orphan-designation-gly2-recombinant-human-glucagon-peptide-treatment-short-bowel-syndrome_en.pdf"},
    {"id":"35135","name":"EU/3/15/1477: Public summary of positive opinion for orphan designation of Human reovirus type-3 Dearing strain for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-21T14:00:00Z","last_updated_date":"2015-05-21T14:00:00Z","reference_number":"EMA/COMP/212797/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151477-public-summary-positive-opinion-orphan-designation-human-reovirus-type-3-dearing-strain-treatment-pancreatic-cancer_en.pdf"}    {"id":"35157","name":"EU/3/17/1909: Public summary of opinion on orphan designation: Salmonella typhi Ty21a strain transfected with a plasmid vector encoding the human vascular endothelial growth factor receptor 2 for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/507448/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171909-public-summary-opinion-orphan-designation-salmonella-typhi-ty21a-strain-transfected-plasmid-vector-encoding-human-vascular-endothelial-growth-factor-receptor-2-treatment-glioma_en.pdf"},
    {"id":"35173","name":"EU/3/15/1571: Public summary of opinion on orphan designation: Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor for the treatment of acute lymphoblastic l...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/COMP/697370/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151571-public-summary-opinion-orphan-designation-autologous-t-cells-transduced-retroviral-vector-encoding-anti-cd19-cd28cd3-zeta-chimeric-antigen-receptor-treatment-acute-lymphoblastic-l_en.pdf"},
    {"id":"35223","name":"EU/3/13/1164: Public summary of opinion on orphan designation: Heterologous human adult liver-derived progenitor cells for the treatment of hyperargininaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T14:30:00Z","last_updated_date":"2013-08-21T14:30:00Z","reference_number":"EMA/COMP/413217/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131164-public-summary-opinion-orphan-designation-heterologous-human-adult-liver-derived-progenitor-cells-treatment-hyperargininaemia_en.pdf"},
    {"id":"35244","name":"EU/3/09/619: Public summary of positive opinion for orphan designation of allogeneic ex vivo expanded umbilical cord blood cells for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-20T01:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMEA/COMP/15606/2009 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309619-public-summary-positive-opinion-orphan-designation-allogeneic-ex-vivo-expanded-umbilical-cord-blood-cells-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"35253","name":"EU/3/10/848: Public summary of opinion on orphan designation: Sodium thiosulfate for the treatment of calciphylaxis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2021-02-03T13:30:00Z","reference_number":"EMA/COMP/5844/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310848-public-summary-opinion-orphan-designation-sodium-thiosulfate-treatment-calciphylaxis_en.pdf"},
    {"id":"35268","name":"EU/3/15/1467: Public summary of positive opinion for orphan designation of ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL17A1-encoding retroviral vector for the trea...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/116151/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151467-public-summary-positive-opinion-orphan-designation-ex-vivo-expanded-autologous-human-keratinocytes-containing-epidermal-stem-cells-transduced-col17a1-encoding-retroviral-vector-trea_en.pdf"},
    {"id":"35269","name":"EU/3/12/1026: Public summary of opinion on orphan designation: Hexasodium phytate for the treatment of calciphylaxis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-08-31T12:30:00Z","last_updated_date":"2012-08-31T12:30:00Z","reference_number":"EMA/COMP/443783/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121026-public-summary-opinion-orphan-designation-hexasodium-phytate-treatment-calciphylaxis_en.pdf"},
    {"id":"35276","name":"EU/3/18/1990: Public summary of opinion on orphan designation: Dimethyl fumarate for the treatment of Friedreich's ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-15T02:00:00Z","last_updated_date":"2018-05-15T02:00:00Z","reference_number":"EMA/117924/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181990-public-summary-opinion-orphan-designation-dimethyl-fumarate-treatment-friedreichs-ataxia_en.pdf"},
    {"id":"35278","name":"EU/3/16/1684: Public summary of opinion on orphan designation: Modified mRNA encoding the UGT1A1 protein for the treatment of Crigler-Najjar syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/391433/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161684-public-summary-opinion-orphan-designation-modified-mrna-encoding-ugt1a1-protein-treatment-crigler-najjar-syndrome_en.pdf"},
    {"id":"35282","name":"EU/3/17/1903: Public summary of opinion on orphan designation: Odiparcil for the treatment of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/476085/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171903-public-summary-opinion-orphan-designation-odiparcil-treatment-mucopolysaccharidosis-type-vi-maroteaux-lamy-syndrome_en.pdf"},
    {"id":"35305","name":"EU/3/11/896: Public summary of opinion on orphan designation: Multilamellar microvesicle comprising phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and cholesterol f...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2022-04-06T02:00:00Z","reference_number":"EMA/COMP/512931/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311896-public-summary-opinion-orphan-designation-multilamellar-microvesicle-comprising-phosphatidylcholine-sphingomyelin-phosphatidylethanolamine-phosphatidylserine-phosphatidylinositol-and_en.pdf"},
    {"id":"35317","name":"EU/3/13/1163: Public summary of opinion on orphan designation: Heterologous human adult liver-derived progenitor cells for the treatment of argininosuccinic aciduria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T14:30:00Z","last_updated_date":"2013-08-21T14:30:00Z","reference_number":"EMA/COMP/413216/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131163-public-summary-opinion-orphan-designation-heterologous-human-adult-liver-derived-progenitor-cells-treatment-argininosuccinic-aciduria_en.pdf"},
    {"id":"35320","name":"EU/3/15/1465: Public summary of positive opinion for orphan designation of ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a LAMB3-encoding retroviral vector for the treatm...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/116169/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151465-public-summary-positive-opinion-orphan-designation-ex-vivo-expanded-autologous-human-keratinocytes-containing-epidermal-stem-cells-transduced-lamb3-encoding-retroviral-vector-treatm_en.pdf"},
    {"id":"35325","name":"EU/3/10/823: Public summary of opinion on orphan designation: Lomitapide for the treatment of familial chylomicronaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMA/COMP/639953/2010 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310823-public-summary-opinion-orphan-designation-lomitapide-treatment-familial-chylomicronaemia_en.pdf"},
    {"id":"35344","name":"EU/3/06/363: Public summary of positive opinion for orphan designation\n\nof 4-[131I] iodo-L-phenylalanine for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/96512/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306363-public-summary-positive-opinion-orphan-designation-4-131i-iodo-l-phenylalanine-treatment-glioma_en.pdf"},
    {"id":"35362","name":"EU/3/08/594: Public summary of positive opinion for orphan designation of recombinant human tissue non-specific alkaline phosphatase - Fc - deca-aspartate fusion protein for the treatment of hypophosphatasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2015-03-26T16:00:00Z","reference_number":"EMEA/COMP/547061/2008 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308594-public-summary-positive-opinion-orphan-designation-recombinant-human-tissue-non-specific-alkaline-phosphatase-fc-deca-aspartate-fusion-protein-treatment-hypophosphatasia_en.pdf"},
    {"id":"35400","name":"EU/3/12/964: Public summary of opinion on orphan designation: Oleylphosphocholine for the treatment of leishmaniasis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"EMA/COMP/73109/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312964-public-summary-opinion-orphan-designation-oleylphosphocholine-treatment-leishmaniasis_en.pdf"},
    {"id":"35430","name":"EU/3/17/1892: Public summary of opinion on orphan designation: Oxymetazoline hydrochloride for the treatment of spinal cord injury","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2017-08-15T16:00:00Z","last_updated_date":"2017-08-15T16:00:00Z","reference_number":"EMA/404401/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171892-public-summary-opinion-orphan-designation-oxymetazoline-hydrochloride-treatment-spinal-cord-injury_en.pdf"},
    {"id":"35464","name":"EU/3/18/1979: Public summary of opinion on orphan designation: Human monoclonal IgG2 antibody against tissue factor pathway inhibitor for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2020-03-26T14:00:00Z","reference_number":"EMA/67933/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181979-public-summary-opinion-orphan-designation-human-monoclonal-igg2-antibody-against-tissue-factor-pathway-inhibitor-treatment-haemophilia_en.pdf"},
    {"id":"35482","name":"EU/3/15/1545: Public summary of opinion on orphan designation: CD33-directed antibody-drug conjugate consisting of an antibody conjugated to a DNA cross-linking pyrrolobenzodiazepine dimer drug for the treatment of acute...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2019-07-09T12:00:00Z","reference_number":"EMA/COMP/508236/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151545-public-summary-opinion-orphan-designation-cd33-directed-antibody-drug-conjugate-consisting-antibody-conjugated-dna-cross-linking-pyrrolobenzodiazepine-dimer-drug-treatment-acute_en.pdf"},
    {"id":"35533","name":"EU/3/08/533: Public summary of positive opinion for orphan designation of recombinant human monoclonal antibody against transforming growth factor beta-1, 2 and 3 for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"EMEA/COMP/84123/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308533-public-summary-positive-opinion-orphan-designation-recombinant-human-monoclonal-antibody-against-transforming-growth-factor-beta-1-2-and-3-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"35544","name":"EU/3/09/657: Public summary of positive opinion for orphan designation of recombinant human N-acetylgalactosamine-6-sulfatase for the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2014-07-14T02:00:00Z","reference_number":"EMEA/COMP/361236/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309657-public-summary-positive-opinion-orphan-designation-recombinant-human-n-acetylgalactosamine-6-sulfatase-treatment-mucopolysaccharidosis-type-iva-morquio-syndrome_en.pdf"},
    {"id":"35577","name":"EU/3/14/1345: Public summary of opinion on orphan designation: Osilodrostat for the treatment of Cushing's syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/552875/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141345-public-summary-opinion-orphan-designation-osilodrostat-treatment-cushings-syndrome_en.pdf"},
    {"id":"35582","name":"EU/3/15/1474: Public summary of positive opinion for orphan designation of Ecothiopate iodide for the treatment of Stargardt’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-21T14:00:00Z","last_updated_date":"2015-05-21T14:00:00Z","reference_number":"EMA/COMP/211400/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151474-public-summary-positive-opinion-orphan-designation-ecothiopate-iodide-treatment-stargardts-disease_en.pdf"},
    {"id":"35585","name":"EU/3/10/732: Public summary of opinion on orphan designation: Entinostat for the treatment of Hodgkin’s lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2015-05-27T13:15:00Z","reference_number":"EMA/COMP/90806/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310732-public-summary-opinion-orphan-designation-entinostat-treatment-hodgkins-lymphoma_en.pdf"},
    {"id":"35592","name":"EU/3/07/526: Public summary of positive opinion for orphan designation of N- (2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"EMEA/COMP/577292/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307526-public-summary-positive-opinion-orphan-designation-n-2-amino-phenyl-4-4-pyridin-3-yl-pyrimidin-2-ylamino-methyl-benzamide-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"35613","name":"EU/3/16/1639: Public summary of opinion on orphan designation: (1E,6E)-1,7-bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione for the treatment of X-linked spinal and bulbar muscular atrophy (Kennedy’s ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-31T02:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"EMA/COMP/254125/2016 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161639-public-summary-opinion-orphan-designation-1e6e-17-bis34-dimethoxyphenyl-4-cyclobutylmethyl-16-heptadiene-35-dione-treatment-x-linked-spinal-and-bulbar-muscular-atrophy-kennedys_en.pdf"},
    {"id":"35649","name":"EU/3/18/1985: Public summary of opinion on orphan designation: Rusalatide acetate for the treatment of acute radiation syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/52859/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181985-public-summary-opinion-orphan-designation-rusalatide-acetate-treatment-acute-radiation-syndrome_en.pdf"},
    {"id":"35659","name":"EU/3/11/939: Public summary of positive opinion for orphan designation: Brentuximab vedotin for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMA/COMP/923105/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311939-public-summary-positive-opinion-orphan-designation-brentuximab-vedotin-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"35687","name":"EU/3/06/400: Public summary of positive opinion for orphan designation of metastable technetium 99 [99mTc] demogastrin 2 for the diagnosis of medullary thyroid carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2011-04-12T02:00:00Z","reference_number":"EMEA/COMP/194130/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306400-public-summary-positive-opinion-orphan-designation-metastable-technetium-99-99mtc-demogastrin-2-diagnosis-medullary-thyroid-carcinoma_en.pdf"},
    {"id":"35688","name":"EU/3/13/1183: Public summary of opinion on orphan designation: Sacrosidase for the treatment of congenital sucrase-isomaltase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-16T02:00:00Z","last_updated_date":"2014-04-03T16:00:00Z","reference_number":"EMA/COMP/440861/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131183-public-summary-opinion-orphan-designation-sacrosidase-treatment-congenital-sucrase-isomaltase-deficiency_en.pdf"},
    {"id":"35693","name":"EU/3/12/1088: Public summary of opinion on orphan designation: Allogeneic motor-neuron progenitor cells derived from human embryonic stem cells for the treatment of 5q spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2013-03-01T01:00:00Z","reference_number":"EMA/COMP/2194/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121088-public-summary-opinion-orphan-designation-allogeneic-motor-neuron-progenitor-cells-derived-human-embryonic-stem-cells-treatment-5q-spinal-muscular-atrophy_en.pdf"},
    {"id":"35698","name":"EU/3/17/1847: Public summary of opinion on orphan designation: (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclo...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/140581/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171847-public-summary-opinion-orphan-designation-3r4s5r-n-3r6s-6-carbamoyltetrahydro-2h-pyran-3-yl-6-chloro-4-2-chloro-3-fluoropyridin-4-yl-44-dimethyl-2-oxo-12-dihydrodispirocyclo_en.pdf"},
    {"id":"35777","name":"EU/3/03/171: Public summary of positive opinion for orphan designation of trabectedin for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-10-01T03:00:00Z","last_updated_date":"2019-11-27T01:00:00Z","reference_number":"EMEA/COMP/1463/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303171-public-summary-positive-opinion-orphan-designation-trabectedin-treatment-ovarian-cancer_en.pdf"},
    {"id":"35833","name":"EU/3/16/1625: Public summary of opinion on orphan designation: Acalabrutinib for the treatment of mantle cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"EMA/COMP/150795/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161625-public-summary-opinion-orphan-designation-acalabrutinib-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"35858","name":"EU/3/01/080: Public summary of positive opinion for orphan designation of human engineered monoclonal antibody specific for transforming growth factor àŸ1 (TGF- àŸ1) for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-23T01:00:00Z","last_updated_date":"2007-02-23T01:00:00Z","reference_number":"EMEA/COMP/74/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301080-public-summary-positive-opinion-orphan-designation-human-engineered-monoclonal-antibody-specific-transforming-growth-factor-ay1-tgf-ay1-treatment-systemic-sclerosis_en.pdf"},
    {"id":"35868","name":"EU/3/11/854: Public summary of positive opinion for orphan designation:  Vorinostat for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2013-03-12T13:30:00Z","reference_number":"EMA/COMP/69541/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311854-public-summary-positive-opinion-orphan-designation-vorinostat-treatment-multiple-myeloma_en.pdf"},
    {"id":"35869","name":"EU/3/15/1542: Public summary of opinion on orphan designation: 2’-deoxyguanosylyl-(3’,5’-phosphoryl)-2’-deoxythymidylyl-(3’,5’-phosphoryl)- 2’-deoxyguanosylyl-(3’,5’-phosphoryl)-2’-deoxycytidylyl-(3’,5’-phosphoryl)-2’-de...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-02T02:00:00Z","last_updated_date":"2016-10-21T02:00:00Z","reference_number":"EMA/COMP/508488/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151542-public-summary-opinion-orphan-designation-2-deoxyguanosylyl-35-phosphoryl-2-deoxythymidylyl-35-phosphoryl-2-deoxyguanosylyl-35-phosphoryl-2-deoxycytidylyl-35-phosphoryl-2-de_en.pdf"},
    {"id":"35888","name":"EU/3/14/1402: Public summary of opinion on orphan designation: Benserazide hydrochloride for the treatment of beta thalassaemia intermedia and major","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/COMP/736552/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141402-public-summary-opinion-orphan-designation-benserazide-hydrochloride-treatment-beta-thalassaemia-intermedia-and-major_en.pdf"},
    {"id":"35914","name":"EU/3/17/1832: Public summary of opinion on orphan designation: Alpha-tocopherol and ascorbic acid for treatment of fragile X syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/83323/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171832-public-summary-opinion-orphan-designation-alpha-tocopherol-and-ascorbic-acid-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"35930","name":"EU/3/12/1044: Public summary of opinion on orphan designation: Folic acid to be used with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-26T16:30:00Z","last_updated_date":"2017-02-07T15:30:00Z","reference_number":"EMA/COMP/554946/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121044-public-summary-opinion-orphan-designation-folic-acid-be-used-n-4-2-amino-34-dihydro-4-oxo-6-pteridinylmethylaminobenzoyl-d-gamma-glutamyl-2s-2-amino-beta-alanyl-l-alpha-aspartyl-l_en.pdf"},
    {"id":"35945","name":"EU/3/05/299: Public summary of positive opinion for orphan designation of 4-imino-1, 3-diazobicyclo-[3.1.0]-hexan-2-one for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T01:00:00Z","last_updated_date":"2005-11-29T01:00:00Z","reference_number":"EMEA/COMP/202020/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305299-public-summary-positive-opinion-orphan-designation-4-imino-1-3-diazobicyclo-310-hexan-2-one-treatment-pancreatic-cancer_en.pdf"},
    {"id":"35981","name":"EU/3/01/032: Public summary of positive opinion for orphan designation of arsenic trioxide for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-04T02:00:00Z","last_updated_date":"2010-03-15T01:00:00Z","reference_number":"EMA/COMP/10959/2003 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301032-public-summary-positive-opinion-orphan-designation-arsenic-trioxide-treatment-multiple-myeloma_en.pdf"},
    {"id":"35998","name":"EU/3/16/1672: Public summary of opinion on orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/384024/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161672-public-summary-opinion-orphan-designation-3-5-amino-2-methyl-4-oxoquinazolin-34h-ylpiperidine-26-dione-hydrochloride-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"36004","name":"EU/3/16/1725 : Public summary of opinion on orphan designation: Public summary of opinion on orphan designation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161725-public-summary-opinion-orphan-designation-public-summary-opinion-orphan-designation_en.pdf"},
    {"id":"36014","name":"EU/3/17/1925 : Public summary of opinion on orphan designation : Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F for the treatment of multiple my...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T15:38:00Z","last_updated_date":"2018-01-08T15:38:00Z","reference_number":"EMA/632132/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171925-public-summary-opinion-orphan-designation-humanised-monoclonal-antibody-targeting-b-cell-maturation-antigen-conjugated-maleimidocaproyl-monomethyl-auristatin-f-treatment-multiple-my_en.pdf"},
    {"id":"36019","name":"EU/3/16/1777: Public summary of positive opinion for orphan designation of brincidofovir for the treatment of smallpox","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T15:43:00Z","last_updated_date":"2016-12-14T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161777-public-summary-positive-opinion-orphan-designation-brincidofovir-treatment-smallpox_en.pdf"},
    {"id":"36059","name":"EU/3/01/026: Committee for Orphan Medicinal Products Public summary of positive opinion for orphan designation of L-lysine-N-acetyl-L-cysteinate for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-13T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMEA/COMP/10863/2003","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301026-committee-orphan-medicinal-products-public-summary-positive-opinion-orphan-designation-l-lysine-n-acetyl-l-cysteinate-treatment-cystic-fibrosis_en.pdf"},
    {"id":"36070","name":"EU/3/08/529: Public summary of positive opinion for orphan designation of tretazicar for the treatment of visceral leishmaniasis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2013-07-08T02:00:00Z","reference_number":"EMEA/COMP/40892/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308529-public-summary-positive-opinion-orphan-designation-tretazicar-treatment-visceral-leishmaniasis_en.pdf"},
    {"id":"36072","name":"EU/3/12/1076 : Public summary of opinion on orphan designation: Allopurinol sodium for the treatment of perinatal asphyxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-01-25T12:00:00Z","last_updated_date":"2014-10-08T13:00:00Z","reference_number":"EMA/COMP/721436/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121076-public-summary-opinion-orphan-designation-allopurinol-sodium-treatment-perinatal-asphyxia_en.pdf-0"},
    {"id":"36076","name":"EU/3/00/016: Public summary of positive opinion for orphan designation of lusupultide for the treatment of acute respiratory distress syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/1274/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300016-public-summary-positive-opinion-orphan-designation-lusupultide-treatment-acute-respiratory-distress-syndrome_en.pdf"},
    {"id":"36086","name":"EU/3/07/438: Public summary of positive opinion for orphan designation of zanolimumab for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2011-03-10T01:00:00Z","reference_number":"EMEA/COMP/110319/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307438-public-summary-positive-opinion-orphan-designation-zanolimumab-treatment-peripheral-t-cell-lymphoma-nodal-other-extranodal-and-leukaemicdisseminated_en.pdf"},
    {"id":"36103","name":"EU/3/16/1762: Public summary of positive opinion for orphan designation of synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker for the treatment of paroxysmal nocturnal hae...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2022-02-01T01:00:00Z","reference_number":"EMA/620104/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161762-public-summary-positive-opinion-orphan-designation-synthetic-15-amino-acid-macrocyclic-peptide-acylated-polyethyleneglycol-palmitoylated-linker-treatment-paroxysmal-nocturnal-hae_en.pdf"},
    {"id":"36111","name":"EU/3/12/981: Public summary of opinion on orphan designation: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene for the treatment of Leber’s congenital amaurosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-30T02:00:00Z","last_updated_date":"2012-04-30T02:00:00Z","reference_number":"EMA/COMP/142986/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312981-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-2-containing-human-rpe65-gene-treatment-lebers-congenital-amaurosis_en.pdf"},
    {"id":"36138","name":"EU/3/10/743: Public summary of positive opinion for Pagibaximab for the prevention of sepsis caused by Gram-positive pathogens in premature infants less than or equal to 34 weeks of gestational age","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2012-02-02T12:09:00Z","reference_number":"EMA/COMP/164788/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310743-public-summary-positive-opinion-pagibaximab-prevention-sepsis-caused-gram-positive-pathogens-premature-infants-less-or-equal-34-weeks-gestational-age_en.pdf"},
    {"id":"36170","name":"EU/3/12/1013: Public summary of opinion on orphan designation: Recombinant human interleukin-7 for the treatment of progressive multifocal leukoencephalopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2014-07-14T16:00:00Z","reference_number":"EMA/COMP/383327/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121013-public-summary-opinion-orphan-designation-recombinant-human-interleukin-7-treatment-progressive-multifocal-leukoencephalopathy_en.pdf"},
    {"id":"36175","name":"EU/3/03/177: Public summary of positive opinion for orphan designation of 3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMEA/COMP/388/2004 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303177-public-summary-positive-opinion-orphan-designation-3-4aminoisoindoline-1-one-1-piperidine-26-dione-treatment-multiple-myeloma_en.pdf"},
    {"id":"36197","name":"EU/3/05/345: Public summary of positive opinion for orphan designation of lentiviral vector containing the human Wiskott Aldrich syndrome protein gene for the treatment of Wiskott Aldrich syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2014-06-19T02:00:00Z","reference_number":"EMEA/COMP/24267/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305345-public-summary-positive-opinion-orphan-designation-lentiviral-vector-containing-human-wiskott-aldrich-syndrome-protein-gene-treatment-wiskott-aldrich-syndrome_en.pdf"},
    {"id":"36343","name":"EU/3/12/1033: Public summary of opinion on orphan designation: N-butyldeoxygalactonojirimycin for the treatment of Fabry disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-27T16:00:00Z","last_updated_date":"2015-03-24T15:00:00Z","reference_number":"EMA/COMP/528478/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121033-public-summary-opinion-orphan-designation-n-butyldeoxygalactonojirimycin-treatment-fabry-disease_en.pdf"},
    {"id":"36352","name":"EU/3/15/1514: Public summary of opinion on orphan designation: Lanreotide acetate for the treatment of autosomal dominant polycystic kidney disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T02:00:00Z","last_updated_date":"2015-08-18T02:00:00Z","reference_number":"EMA/COMP/432098/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151514-public-summary-opinion-orphan-designation-lanreotide-acetate-treatment-autosomal-dominant-polycystic-kidney-disease_en.pdf"},
    {"id":"36356","name":"EU/3/01/041: Public summary of positive opinion for orphan designation of recombinant human alpha-1 antitrypsin for the treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/272/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301041-public-summary-positive-opinion-orphan-designation-recombinant-human-alpha-1-antitrypsin-treatment-emphysema-secondary-congenital-alpha-1-antitrypsin-deficiency_en.pdf"},
    {"id":"36389","name":"EU/3/03/184: Public summary of positive opinion for orphan designation of cilengitide for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-07-08T02:00:00Z","last_updated_date":"2013-04-09T02:00:00Z","reference_number":"EMA/COMP/326/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303184-public-summary-positive-opinion-orphan-designation-cilengitide-treatment-glioma_en.pdf"},
    {"id":"36407","name":"EU/3/08/545: Public summary of positive opinion for orphan designation of [Nle4, D-Phe7]-alpha-melanocyte stimulating hormone for the treatment of congenital erythropoietic porphyria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2009-09-17T02:00:00Z","reference_number":"EMEA/COMP/160499/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308545-public-summary-positive-opinion-orphan-designation-nle4-d-phe7-alpha-melanocyte-stimulating-hormone-treatment-congenital-erythropoietic-porphyria_en.pdf"},
    {"id":"36412","name":"EU/3/14/1371: Public summary of opinion on orphan designation: Humanised IgG1 monoclonal antibody against human eotaxin-2 for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2015-01-16T01:00:00Z","reference_number":"EMA/COMP/647258/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141371-public-summary-opinion-orphan-designation-humanised-igg1-monoclonal-antibody-against-human-eotaxin-2-treatment-systemic-sclerosis_en.pdf"},
    {"id":"36438","name":"EU/3/17/1938: Public summary of opinion on orphan designation: Antisense oligonucleotide targeting exon 73 in the COL7A1 gene for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-15T01:00:00Z","last_updated_date":"2018-01-15T01:00:00Z","reference_number":"EMA/690435/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171938-public-summary-opinion-orphan-designation-antisense-oligonucleotide-targeting-exon-73-col7a1-gene-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"36452","name":"EU/3/02/129: Public summary of positive opinion for orphan designation of\n\nG17(9) gastrin-diphtheria toxoid conjugate for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2009-09-21T02:00:00Z","reference_number":"EMEA/COMP/2393/03 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302129-public-summary-positive-opinion-orphan-designation-g179-gastrin-diphtheria-toxoid-conjugate-treatment-pancreatic-cancer_en.pdf"},
    {"id":"36482","name":"EU/3/07/475: Public summary of positive opinion for orphan designation of alginate oligosaccharide (G-block) fragment for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2009-09-17T02:00:00Z","reference_number":"EMEA/COMP/164923/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307475-public-summary-positive-opinion-orphan-designation-alginate-oligosaccharide-g-block-fragment-treatment-cystic-fibrosis_en.pdf"},
    {"id":"36495","name":"EU/3/16/1609: Public summary of opinion on orphan designation: Humanised IgG4 monoclonal antibody against total complement component 1, subcomponent s for the treatment of autoimmune haemolytic anaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-04-06T02:00:00Z","reference_number":"EMA/COMP/68353/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161609-public-summary-opinion-orphan-designation-humanised-igg4-monoclonal-antibody-against-total-complement-component-1-subcomponent-s-treatment-autoimmune-haemolytic-anaemia_en.pdf"},
    {"id":"36585","name":"EU/3/17/1928: Public summary of opinion on orphan designation : Recombinant adeno-associated viral vector serotype 5 encoding Staphylococcus aureus Cas9 endonuclease and two guide RNAs complementary to two regions of int...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T11:37:00Z","last_updated_date":"2018-01-08T11:37:00Z","reference_number":"EMA/632147/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171928-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-serotype-5-encoding-staphylococcus-aureus-cas9-endonuclease-and-two-guide-rnas-complementary-two-regions_en.pdf"},
    {"id":"36612","name":"EU/03/11/921: Public summary of opinion on orphan designation: Glycosylation independent lysosomal targeting (GILT)-tagged recombinant human acid alpha glucosidase for the treatment of glycogen storage disease type II (P...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2011-11-23T16:00:00Z","reference_number":"EMA/COMP/782044/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu0311921-public-summary-opinion-orphan-designation-glycosylation-independent-lysosomal-targeting-gilt-tagged-recombinant-human-acid-alpha-glucosidase-treatment-glycogen-storage-disease-type-ii-p_en.pdf"},
    {"id":"36637","name":"EU/3/07/500: Public summary of positive opinion for orphan designation of recombinant human rod-derived cone viability factor for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2015-03-06T01:00:00Z","reference_number":"EMEA/COMP/473374/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307500-public-summary-positive-opinion-orphan-designation-recombinant-human-rod-derived-cone-viability-factor-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"36642","name":"EU/3/14/1347: Public summary of opinion on orphan designation: Pyridoxal 5'-phosphate for the treatment of pyridoxamine 5'-phosphate oxidase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/551205/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141347-public-summary-opinion-orphan-designation-pyridoxal-5-phosphate-treatment-pyridoxamine-5-phosphate-oxidase-deficiency_en.pdf"},
    {"id":"36643","name":"EU/3/07/488: Public summary of positive opinion for orphan designation of everolimus for the treatment of gastro-entero-pancreatic neuroendocrine tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"EMEA/COMP/467747/2007 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307488-public-summary-positive-opinion-orphan-designation-everolimus-treatment-gastro-entero-pancreatic-neuroendocrine-tumours_en.pdf"},
    {"id":"36649","name":"EU/3/05/280: Public summary of positive opinion for orphan designation of\n\nacadesine for the treatment B-cell chronic lymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2013-07-31T02:00:00Z","reference_number":"EMEA/COMP/121542/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305280-public-summary-positive-opinion-orphan-designation-acadesine-treatment-b-cell-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"36670","name":"EU/3/14/1429: Public summary of opinion on orphan designation: N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride for the treatment o...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2015-03-06T12:00:00Z","reference_number":"EMA/COMP/793190/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141429-public-summary-opinion-orphan-designation-n-methyl-4-4-3-methylmethylsulfonylaminopyrazin-2-ylmethylamino-5-trifluoromethylpyrimidin-2-ylaminobenzamide-hydrochloride-treatment-o_en.pdf"},
    {"id":"36671","name":"EU/3/17/1853: Public summary of opinion on orphan designation: Antisense oligonucleotide targeting the USH2A gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/138353/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171853-public-summary-opinion-orphan-designation-antisense-oligonucleotide-targeting-ush2a-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"36705","name":"EU/3/17/1954: Public summary of opinion on orphan designation: Venetoclax for the treatment of mantle cell lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-23T14:42:00Z","last_updated_date":"2018-01-23T14:42:00Z","reference_number":"EMA/742235/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171954-public-summary-opinion-orphan-designation-venetoclax-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"36713","name":"EU/3/09/710: Public summary of opinion on orphan designation of recombinant human elafin for the treatment of oesophagus carcinoma\n\nOn","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/COMP/750556/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309710-public-summary-opinion-orphan-designation-recombinant-human-elafin-treatment-oesophagus-carcinoma_en.pdf"},
    {"id":"36732","name":"EU/3/04/190: Public summary of positive opinion for orphan designation of ethanol (96 per cent) (gel for injection) for the treatment of congenital lymphatic  malformations","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-04-28T02:00:00Z","last_updated_date":"2016-01-14T01:00:00Z","reference_number":"EMEA/COMP/70/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304190-public-summary-positive-opinion-orphan-designation-ethanol-96-cent-gel-injection-treatment-congenital-lymphatic-malformations_en.pdf"},
    {"id":"36749","name":"EU/3/17/1858: Public summary of opinion on orphan designation: Megestrol acetate for the treatment of granulosa cell tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/143101/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171858-public-summary-opinion-orphan-designation-megestrol-acetate-treatment-granulosa-cell-tumours_en.pdf"},
    {"id":"36757","name":"EU/3/11/890: Public summary of opinion on orphan designation: Peretinoin for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2011-08-16T02:00:00Z","reference_number":"EMA/COMP/406301/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311890-public-summary-opinion-orphan-designation-peretinoin-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"36802","name":"EU/3/06/405: Public summary of positive opinion for orphan designation\n\nof genetically modified allogenic (human) tumour cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based dou...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/222234/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306405-public-summary-positive-opinion-orphan-designation-genetically-modified-allogenic-human-tumour-cells-expression-il-7-gm-csf-cd80-and-cd154-fixed-combination-dna-based-dou_en.pdf"},
    {"id":"36811","name":"EU/3/05/333: Public summary of positive opinion for orphan designation of eptacog alpha (activated) for the treatment of diffuse alveolar haemorrhage","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-01T01:00:00Z","last_updated_date":"2021-09-21T11:18:00Z","reference_number":"EMEA/COMP/370803/2005 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305333-public-summary-positive-opinion-orphan-designation-eptacog-alpha-activated-treatment-diffuse-alveolar-haemorrhage_en.pdf"},
    {"id":"36877","name":"EU/3/14/1383: Public summary of positive opinion for orphan designation: Single-chain urokinase plasminogen activator for the treatment of pleural empyema","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-02-26T18:00:00Z","reference_number":"EMA/COMP/735886/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141383-public-summary-positive-opinion-orphan-designation-single-chain-urokinase-plasminogen-activator-treatment-pleural-empyema_en.pdf"},
    {"id":"36879","name":"EU/3/16/1656: Public summary of opinion on orphan designation: Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu, Ser-Gly-Gln-Ala-Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-Pro-Ser-Cys-Leu-Glu-Ser, Arg-Ser-Asp-Glu-Leu-Val-Arg-His-His-Asn-Met...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2016-05-30T02:00:00Z","reference_number":"EMA/COMP/254123/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161656-public-summary-opinion-orphan-designation-tyr-met-phe-pro-asn-ala-pro-tyr-leu-ser-gly-gln-ala-tyr-met-phe-pro-asn-ala-pro-tyr-leu-pro-ser-cys-leu-glu-ser-arg-ser-asp-glu-leu-val-arg-his-his_en.pdf"},
    {"id":"36912","name":"EU/3/07/509: Public summary of positive opinion for orphan designation of azacitidine for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2019-02-20T02:00:00Z","reference_number":"EMEA/COMP/479331/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307509-public-summary-positive-opinion-orphan-designation-azacitidine-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"36964","name":"EU/3/08/546: Public summary of positive opinion for orphan designation of alpha-1 proteinase inhibitor (for inhalation use) for the treatment of congenital alpha-1 antitrypsin deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2013-10-17T16:00:00Z","reference_number":"EMA/COMP/211433/2008 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308546-public-summary-positive-opinion-orphan-designation-alpha-1-proteinase-inhibitor-inhalation-use-treatment-congenital-alpha-1-antitrypsin-deficiency_en.pdf"},
    {"id":"37030","name":"EU/3/18/2027: Public summary of opinion on orphan designation: Three human monoclonal antibodies against the EBOV glycoprotein for the treatment of Ebola virus disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T17:07:00Z","last_updated_date":"2018-07-23T17:07:00Z","reference_number":"EMA/270111/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182027-public-summary-opinion-orphan-designation-three-human-monoclonal-antibodies-against-ebov-glycoprotein-treatment-ebola-virus-disease_en.pdf"},
    {"id":"37048","name":"EU/3/14/1335: Public summary of opinion on orphan designation: (S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile for the treatment of pemphigus","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2018-02-22T13:00:00Z","reference_number":"EMA/COMP/557455/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141335-public-summary-opinion-orphan-designation-s-2-1-6-amino-5-cyanopyrimidin-4-ylaminoethyl-4-oxo-3-phenyl-34-dihydropyrrolo21-f124triazine-5-carbonitrile-treatment-pemphigus_en.pdf"},
    {"id":"37059","name":"EU/3/17/1924: Public summary of opinion on orphan designation: Glucopyranosyl lipid A stable emulsion for the treatment of follicular lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T15:45:00Z","last_updated_date":"2019-10-15T15:45:00Z","reference_number":"EMA/COMP/632529/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171924-public-summary-opinion-orphan-designation-glucopyranosyl-lipid-stable-emulsion-treatment-follicular-lymphoma_en.pdf"},
    {"id":"37066","name":"EU/3/17/1878: Public summary of opinion on orphan designation: Ursodeoxycholic acid for the treatment of Niemann-Pick disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-06-29T02:00:00Z","last_updated_date":"2017-06-29T02:00:00Z","reference_number":"EMA/270550/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171878-public-summary-opinion-orphan-designation-ursodeoxycholic-acid-treatment-niemann-pick-disease_en.pdf"},
    {"id":"37093","name":"EU/3/15/1456: Public summary of positive opinion for orphan designation of recombinant human club cell 10 KDa protein for the prevention of bronchopulmonary dysplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/123186/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151456-public-summary-positive-opinion-orphan-designation-recombinant-human-club-cell-10-kda-protein-prevention-bronchopulmonary-dysplasia_en.pdf"},
    {"id":"37094","name":"EU/3/12/1089: Public summary of opinion on orphan designation: Choline tetrathiomolybdate for the treatment of Wilson’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2015-03-11T01:00:00Z","reference_number":"EMA/COMP/795268/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121089-public-summary-opinion-orphan-designation-choline-tetrathiomolybdate-treatment-wilsons-disease_en.pdf"},
    {"id":"37121","name":"EU/3/16/1811: Public summary of opinion on orphan designation: 5-Aminolevulinic acid for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/14622/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161811-public-summary-opinion-orphan-designation-5-aminolevulinic-acid-treatment-glioma_en.pdf"},
    {"id":"37126","name":"EU/3/00/010: Public summary of positive opinion for orphan designation of anagrelide hydrochloride for the treatment of essential thrombocythaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2017-02-08T01:00:00Z","reference_number":"EMEA/COMP/237387/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300010-public-summary-positive-opinion-orphan-designation-anagrelide-hydrochloride-treatment-essential-thrombocythaemia_en.pdf"},
    {"id":"37156","name":"EU/3/07/519: Public summary of positive opinion for orphan designation of maribavir for the prevention of cytomegalovirus (CMV) disease in patients with impaired cell mediated immunity deemed at risk","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2011-05-31T02:00:00Z","reference_number":"EMEA/COMP/157555/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307519-public-summary-positive-opinion-orphan-designation-maribavir-prevention-cytomegalovirus-cmv-disease-patients-impaired-cell-mediated-immunity-deemed-risk_en.pdf"},
    {"id":"37167","name":"EU/3/01/064: Public summary of positive opinion for orphan designation of abetimus sodium for the treatment of lupus nephritis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T00:00:00Z","last_updated_date":"2011-05-31T02:00:00Z","reference_number":"EMEA/COMP/267/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301064-public-summary-positive-opinion-orphan-designation-abetimus-sodium-treatment-lupus-nephritis_en.pdf"},
    {"id":"37195","name":"EU/3/07/470: Public summary of positive opinion for orphan designation of human heterologous liver cells (for infusion) for the treatment of ornithine-transcarbamylase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-22T01:00:00Z","last_updated_date":"2008-01-22T01:00:00Z","reference_number":"EMEA/COMP/353161/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307470-public-summary-positive-opinion-orphan-designation-human-heterologous-liver-cells-infusion-treatment-ornithine-transcarbamylase-deficiency_en.pdf"},
    {"id":"37201","name":"EU/3/01/060: Public summary of positive opinion for orphan designation of pemetrexed disodium for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-03T00:00:00Z","last_updated_date":"2011-05-07T01:00:00Z","reference_number":"EMEA/COMP/1294/03draft","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301060-public-summary-positive-opinion-orphan-designation-pemetrexed-disodium-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"37218","name":"EU/3/11/868: Public summary of opinion on orphan designation: Lenalidomide for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-05-30T02:00:00Z","last_updated_date":"2011-05-30T02:00:00Z","reference_number":"EMA/COMP/156241/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311868-public-summary-opinion-orphan-designation-lenalidomide-treatment-diffuse-large-b-cell-lymphoma_en.pdf"}    {"id":"37314","name":"EU/3/17/1961: Public summary of opinion on orphan designation: Gilteritinib for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-13T01:00:00Z","last_updated_date":"2018-03-13T01:00:00Z","reference_number":"EMA/846386/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171961-public-summary-opinion-orphan-designation-gilteritinib-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"37371","name":"EU/3/17/1912: Public summary of opinion on orphan designation: Tacrolimus for the treatment of pulmonary arterial hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/495732/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171912-public-summary-opinion-orphan-designation-tacrolimus-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"37374","name":"EU/3/16/1773: Public summary of positive opinion for orphan designation of allogenic cytomegalovirus-specific cytotoxic T lymphocytes for the treatment of cytomegalovirus infections in patients with impaired cell-mediate...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T15:43:00Z","last_updated_date":"2022-09-16T15:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161773-public-summary-positive-opinion-orphan-designation-allogenic-cytomegalovirus-specific-cytotoxic-t-lymphocytes-treatment-cytomegalovirus-infections-patients-impaired-cell-mediate_en.pdf"},
    {"id":"37380","name":"EU/3/06/411: Public summary of positive opinion for orphan designation of recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule for the prevention of gra...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2009-04-02T02:00:00Z","reference_number":"EMEA/COMP/200084/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306411-public-summary-positive-opinion-orphan-designation-recombinant-fusion-protein-consisting-extracellular-portion-cd95-fused-fc-part-human-igg1-molecule-prevention-gra_en.pdf"},
    {"id":"37397","name":"EU/3/09/696: Public summary of positive opinion for orphan designation of\n\nhuman MHC non-restricted cytotoxic T-cell line for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-12-08T00:09:21Z","last_updated_date":"2013-06-19T14:00:00Z","reference_number":"EMEA/COMP/652787/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309696-public-summary-positive-opinion-orphan-designation-human-mhc-non-restricted-cytotoxic-t-cell-line-treatment-ovarian-cancer_en.pdf"},
    {"id":"37425","name":"EU/3/09/664: Public summary of positive opinion for orphan designation of allogeneic ex-vivo-expanded umbilical-cord blood cells for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMEA/COMP/467478/2009 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309664-public-summary-positive-opinion-orphan-designation-allogeneic-ex-vivo-expanded-umbilical-cord-blood-cells-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"37451","name":"EU/3/18/2017: Public summary of opinion on orphan designation: Ambroxol hydrochloride for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-24T11:27:00Z","last_updated_date":"2018-07-24T11:27:00Z","reference_number":"EMA/270990/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182017-public-summary-opinion-orphan-designation-ambroxol-hydrochloride-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"37492","name":"Public summary of negative opinion for orphan designation of melatonin for the treatment of partial deep dermal and full thickness burns","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-11T02:00:00Z","last_updated_date":"2018-04-11T02:00:00Z","reference_number":"EMA/57238/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-melatonin-treatment-partial-deep-dermal-and-full-thickness-burns_en.pdf"},
    {"id":"37494","name":"EU/3/08/583: Public summary of positive opinion for orphan designation of gadodiamide (liposomal) for the adjunctive treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/COMP/560580/2008draft","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308583-public-summary-positive-opinion-orphan-designation-gadodiamide-liposomal-adjunctive-treatment-glioma_en.pdf"},
    {"id":"37500","name":"EU/3/10/840: Public summary of opinion on orphan designation: Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3 for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2013-03-13T01:00:00Z","reference_number":"EMA/COMP/740425/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310840-public-summary-opinion-orphan-designation-recombinant-human-histone-h13-and-recombinant-human-n-bis-met-histone-h13-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"37503","name":"EU/3/16/1641: Public summary of opinion on orphan designation: Antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA for the treatment of Leb...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-31T02:00:00Z","last_updated_date":"2016-05-31T02:00:00Z","reference_number":"EMA/COMP/248706/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161641-public-summary-opinion-orphan-designation-antisense-oligonucleotide-complementary-exonic-splicer-enhancer-sequence-intron-26-centrosomal-protein-290-pre-mrna-treatment-leb_en.pdf"},
    {"id":"37505","name":"EU/3/10/793: Public summary of opinion on orphan designation: N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide for the treatment of Friedreich’s ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2010-10-14T02:00:00Z","reference_number":"EMA/COMP/455242/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310793-public-summary-opinion-orphan-designation-n-6-2-aminophenylamino-6-oxohexyl-4-methylbenzamide-treatment-friedreichs-ataxia_en.pdf"},
    {"id":"37511","name":"EU/3/17/1932: Public summary of opinion on orphan designation : Synthetic cyclic 8 amino acid analogue of human unacylated ghrelin for the treatment of Prader-Willi syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T11:37:00Z","last_updated_date":"2018-01-08T11:37:00Z","reference_number":"EMA/COMP/632552/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171932-public-summary-opinion-orphan-designation-synthetic-cyclic-8-amino-acid-analogue-human-unacylated-ghrelin-treatment-prader-willi-syndrome_en.pdf"},
    {"id":"37583","name":"EU/3/02/122: Public summary of positive opinion for orphan designation of etilefrine for the treatment of low flow priapism","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2002-12-13T01:00:00Z","last_updated_date":"2013-06-25T02:00:00Z","reference_number":"EMA/COMP/27070/2002 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302122-public-summary-positive-opinion-orphan-designation-etilefrine-treatment-low-flow-priapism_en.pdf"},
    {"id":"37601","name":"EU/3/17/1837: Public summary of opinion on orphan designation: Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2 for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/80317/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171837-public-summary-opinion-orphan-designation-humanised-igg4-monoclonal-antibody-human-toll-receptor-type-2-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"37616","name":"EU/3/15/1440: Public summary of opinion on orphan designation: Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus ...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T02:00:00Z","last_updated_date":"2015-05-19T02:00:00Z","reference_number":"EMA/COMP/55791/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151440-public-summary-opinion-orphan-designation-allogeneic-cd4-and-cd8-t-lymphocytes-ex-vivo-incubated-synthetic-peptides-viral-antigens-cytomegalovirus-adenovirus-and-epstein-barr-virus_en.pdf"},
    {"id":"37658","name":"EU/3/17/1868: Public summary of opinion on orphan designation: N-[(1R)-1-Phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}quinazolin-2-amine for the treatment of fragile X syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/195839/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171868-public-summary-opinion-orphan-designation-n-1r-1-phenylethyl-6-1h-pyrazolo34-dpyrimidin-4-ylquinazolin-2-amine-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"37687","name":"EU/3/17/1875: Public summary of opinion on orphan designation: Recombinant human interleukin-7 fused to a hybrid crystallisable fragment region of a human antibody for treatment of idiopathic CD4 lymphocytopenia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-06-29T02:00:00Z","last_updated_date":"2017-06-29T02:00:00Z","reference_number":"EMA/276567/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171875-public-summary-opinion-orphan-designation-recombinant-human-interleukin-7-fused-hybrid-crystallisable-fragment-region-human-antibody-treatment-idiopathic-cd4-lymphocytopenia_en.pdf"},
    {"id":"37700","name":"EU/3/08/557: Public summary of positive opinion for orphan designation of sapacitabine for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/369045/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308557-public-summary-positive-opinion-orphan-designation-sapacitabine-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"37721","name":"EU/3/15/1581: Public summary of opinion on orphan designation: Sodium phenylbutyrate for the treatment of pyruvate dehydrogenase complex deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/COMP/699685/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-15-1581-public-summary-opinion-orphan-designation-sodium-phenylbutyrate-treatment-pyruvate-dehydrogenase-complex-deficiency_en.pdf"},
    {"id":"37725","name":"EU/3/07/452: Public summary of positive opinion for orphan designation of R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea for the treatment of gastric carcino...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/COMP/165106/2007","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307452-public-summary-positive-opinion-orphan-designation-r-1-23-dihydro-2-oxo-1-pivaloylmethyl-5-2-pyridyl-1-h-14-benzodiazepin-3-yl-3-3-methylaminophenylurea-treatment-gastric-carcino_en.pdf"},
    {"id":"37770","name":"EU/3/13/1121: Public summary of opinion on orphan designation: Lenvatinib for the treatment of papillary thyroid cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-05-14T12:00:00Z","last_updated_date":"2013-10-22T12:00:00Z","reference_number":"EMA/COMP/193646/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131121-public-summary-opinion-orphan-designation-lenvatinib-treatment-papillary-thyroid-cancer_en.pdf"},
    {"id":"37812","name":"EU/3/18/2035: Public summary of opinion on orphan designation: Efpegsomatropin for the treatment of growth hormone deficiency","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-08-21T12:49:00Z","last_updated_date":"2018-08-21T12:49:00Z","reference_number":"EMA/380699/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182035-public-summary-opinion-orphan-designation-efpegsomatropin-treatment-growth-hormone-deficiency_en.pdf"},
    {"id":"37830","name":"EU/3/14/1290: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 2 containing the human REP1 gene for the treatment of choroideraemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2015-06-08T02:00:00Z","reference_number":"EMA/COMP/296144/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141290-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-2-containing-human-rep1-gene-treatment-choroideraemia_en.pdf"},
    {"id":"37831","name":"EU/3/17/1840: Public summary of opinion on orphan designation: N-(4-(1-cyanocyclopentyl)phenyl)-2-(4-pyridinylmethyl)amino-3-pyridinecarboxamide methanesulfonate for the treatment of gastric cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/72986/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171840-public-summary-opinion-orphan-designation-n-4-1-cyanocyclopentylphenyl-2-4-pyridinylmethylamino-3-pyridinecarboxamide-methanesulfonate-treatment-gastric-cancer_en.pdf"},
    {"id":"37837","name":"EU/3/11/904: Public summary of opinion on orphan designation: Heterologous human adult liver-derived stem cells for the treatment of ornithine transcarbamylase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/COMP/661152/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311904-public-summary-opinion-orphan-designation-heterologous-human-adult-liver-derived-stem-cells-treatment-ornithine-transcarbamylase-deficiency_en.pdf"},
    {"id":"37848","name":"EU/3/14/1359: Public summary of opinion on orphan designation: Pentosan polysulfate sodium for the treatment of mucopolysaccharidosis type I","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/COMP/638790/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141359-public-summary-opinion-orphan-designation-pentosan-polysulfate-sodium-treatment-mucopolysaccharidosis-type-i_en.pdf"},
    {"id":"37869","name":"EU/3/03/142: Public summary of positive opinion of iodine ( 131I) anti-CEA sheep-human chimeric monoclonal antibody for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-05-21T02:00:00Z","last_updated_date":"2011-09-06T02:00:00Z","reference_number":"EMEA/COMP/892/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303142-public-summary-positive-opinion-iodine-131i-anti-cea-sheep-human-chimeric-monoclonal-antibody-treatment-pancreatic-cancer_en.pdf"},
    {"id":"37940","name":"EU/3/14/1326: Public summary of opinion on orphan designation: Vector based on an adeno-associated virus serotype 2 backbone, pseudo-serotyped with a type 8 capsid, which carries the coding sequence of the human TYMP gen...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2014-10-02T02:00:00Z","reference_number":"EMA/COMP/432877/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141326-public-summary-opinion-orphan-designation-vector-based-adeno-associated-virus-serotype-2-backbone-pseudo-serotyped-type-8-capsid-which-carries-coding-sequence-human-tymp-gen_en.pdf"},
    {"id":"37942","name":"EU/3/12/1018: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector containing human acid alfa-glucosidase-gene for the treatment of glycogen storage disease type II (Pompe's disease)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2012-07-24T16:00:00Z","reference_number":"EMA/COMP/381188/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121018-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-containing-human-acid-alfa-glucosidase-gene-treatment-glycogen-storage-disease-type-ii-pompes-disease_en.pdf"},
    {"id":"37967","name":"EU/3/17/1871: Public summary of opinion on orphan designation: 225Ac-lintuzumab for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-06-30T02:00:00Z","last_updated_date":"2017-06-30T02:00:00Z","reference_number":"EMA/261867/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171871-public-summary-opinion-orphan-designation-225ac-lintuzumab-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"37977","name":"EU/3/01/070: Public summary of positive opinion for orphan designation of celecoxib for the treatment of familial adenomatous polyposis (FAP)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2009-06-15T02:00:00Z","reference_number":"EMEA/COMP/264/04","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301070-public-summary-positive-opinion-orphan-designation-celecoxib-treatment-familial-adenomatous-polyposis-fap_en.pdf"},
    {"id":"37988","name":"EU/3/07/471: Public summary of positive opinion for orphan designation of human coagulation factor X for the treatment of hereditary factor X deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/COMP/138276/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307471-public-summary-positive-opinion-orphan-designation-human-coagulation-factor-x-treatment-hereditary-factor-x-deficiency_en.pdf"},
    {"id":"38012","name":"EU/3/04/219: Public summary of positive opinion for orphan designation of HLA-B27-derived peptide (amino acid 125-138) for the treatment of autoimmune uveitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-06-09T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"EMEA/COMP/391/2004 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304219-public-summary-positive-opinion-orphan-designation-hla-b27-derived-peptide-amino-acid-125-138-treatment-autoimmune-uveitis_en.pdf"},
    {"id":"38019","name":"EU/3/16/1696: Public summary of opinion on orphan designation: Autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo for the treatment of post-transplant lymphop...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2020-05-25T02:00:00Z","reference_number":"EMA/COMP/449979/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161696-public-summary-opinion-orphan-designation-autologous-epstein-barr-virus-specific-t-cells-derived-peripheral-blood-mononuclear-cells-expanded-ex-vivo-treatment-post-transplant-lymphop_en.pdf"},
    {"id":"38039","name":"EU/3/06/370: Public summary of positive opinion for orphan designation of decitabine for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2013-09-19T02:00:00Z","reference_number":"EMEA/COMP/137787/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306370-public-summary-positive-opinion-orphan-designation-decitabine-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"38105","name":"EU/3/07/515: Public summary of positive opinion for orphan designation of tegafur, gimeracil, oteracil potassium for the treatment of gastric cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2011-03-28T02:00:00Z","reference_number":"EMEA/COMP/152488/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307515-public-summary-positive-opinion-orphan-designation-tegafur-gimeracil-oteracil-potassium-treatment-gastric-cancer_en.pdf"},
    {"id":"38154","name":"EU/3/10/847: Public summary of opinion on orphan designation: Pegylated B-domain-deleted sequence-modified recombinant human factor VIII for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2011-11-18T13:30:00Z","reference_number":"EMA/COMP/14316/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310847-public-summary-opinion-orphan-designation-pegylated-b-domain-deleted-sequence-modified-recombinant-human-factor-viii-treatment-haemophilia_en.pdf"},
    {"id":"38181","name":"EU/3/03/150: Public summary of positive opinion for orphan designation of adenovirus-interferon gamma - coding DNA sequence for the treatment of cutaneous T cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-10-23T02:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/COMP/1326/2003 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303150-public-summary-positive-opinion-orphan-designation-adenovirus-interferon-gamma-coding-dna-sequence-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"38223","name":"EU/3/08/539: Public summary of positive opinion for orphan designation of ammonium tetrathiomolybdate for the treatment of Wilson’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2008-07-10T02:00:00Z","reference_number":"EMEA/COMP/82161/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308539-public-summary-positive-opinion-orphan-designation-ammonium-tetrathiomolybdate-treatment-wilsons-disease_en.pdf"},
    {"id":"38233","name":"EU/3/17/1865: Public summary of opinion on orphan designation: Estetrol for the treatment of neonatal encephalopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-13T02:00:00Z","last_updated_date":"2017-05-13T02:00:00Z","reference_number":"EMA/227698/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171865-public-summary-opinion-orphan-designation-estetrol-treatment-neonatal-encephalopathy_en.pdf"},
    {"id":"38237","name":"EU/3/01/054: Public summary of positive opinion for orphan designation of sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleyl phosphatidylglycerol and palmitic acid for the treatment of meconium aspiration syndr...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/257/04 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301054-public-summary-positive-opinion-orphan-designation-sinapultide-dipalmitoylphosphatidylcholine-palmitoyl-oleyl-phosphatidylglycerol-and-palmitic-acid-treatment-meconium-aspiration-syndr_en.pdf"},
    {"id":"38243","name":"EU/3/09/662: Public summary of positive opinion for orphan designationof 26 base single stranded phosphodiester DNA oligonucleotide for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMEA/COMP/445179/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309662-public-summary-positive-opinion-orphan-designationof-26-base-single-stranded-phosphodiester-dna-oligonucleotide-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"38271","name":"EU/3/14/1294: Public summary of opinion on orphan designation: Sodium acetate salt of the synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH for the treatment of necrotising soft tissue infections","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T17:00:00Z","last_updated_date":"2015-05-13T17:00:00Z","reference_number":"EMA/COMP/357055/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141294-public-summary-opinion-orphan-designation-sodium-acetate-salt-synthetic-peptide-h-d-ala-ser-pro-met-leu-val-ala-tyr-asp-d-ala-oh-treatment-necrotising-soft-tissue-infections_en.pdf"},
    {"id":"38281","name":"EU/3/14/1259: Public summary of opinion on orphan designation: Amikacin sulfate for the treatment of nontuberculous mycobacterial lung disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-07T02:00:00Z","last_updated_date":"2014-10-08T02:00:00Z","reference_number":"EMA/COMP/97247/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141259-public-summary-opinion-orphan-designation-amikacin-sulfate-treatment-nontuberculous-mycobacterial-lung-disease_en.pdf"},
    {"id":"38294","name":"EU/3/05/312: Public sumary of opinion  on orphan designation: (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentao...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2013-03-11T12:15:00Z","reference_number":"EMA/COMP/246033/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305312-public-sumary-opinion-orphan-designation-1r2r4s-4-2r-2-3s6r7e9r10r12r14s15e17e19e21s23s26r27r34as-927-dihydroxy-1021-dimethoxy-6812142026-hexamethyl-15112829-pentao_en.pdf"},
    {"id":"38301","name":"EU/3/16/1640: Public summary of opinion on orphan designation: 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate for the tre...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-31T02:00:00Z","last_updated_date":"2016-05-31T02:00:00Z","reference_number":"EMA/COMP/254160/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161640-public-summary-opinion-orphan-designation-2-methyl-1-4-6-trifluoromethylpyridin-2-yl-6-2-trifluoromethylpyridin-4-ylamino-135-triazin-2-ylaminopropan-2-ol-methanesulfonate-tre_en.pdf"},
    {"id":"38305","name":"EU/3/07/469: Public summary of positive opinion for orphan designation of ciprofloxacin (inhalation use) for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-06-15T02:00:00Z","last_updated_date":"2011-11-18T01:00:00Z","reference_number":"EMEA/COMP/287903/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307469-public-summary-positive-opinion-orphan-designation-ciprofloxacin-inhalation-use-treatment-cystic-fibrosis_en.pdf"},
    {"id":"38317","name":"EU/3/08/609: Public summary of positive opinion for orphan designation of adeno-associated viral vector serotype 5 containing the human ABCA4 gene for the treatment of Stargardt’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-03-20T01:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMEA/COMP/567050/2008 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308609-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-serotype-5-containing-human-abca4-gene-treatment-stargardts-disease_en.pdf"},
    {"id":"38335","name":"EU/3/04/218: Public summary of positive opinion for orphan designation of (R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate for treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMEA/COMP/379/2004 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304218-public-summary-positive-opinion-orphan-designation-r-s-3-bromomethyl-3-butanol-1-yl-diphosphate-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"38352","name":"EU/3/05/338: Public summary of positive opinion for orphan designation of dasatinib for the treatment of acute lymphoblastic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-28T00:00:00Z","last_updated_date":"2017-02-09T00:00:00Z","reference_number":"EMEA/COMP/386781/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305338-public-summary-positive-opinion-orphan-designation-dasatinib-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"38364","name":"EU/3/05/294: Public summary of positive opinion for orphan designation of soluble yeast beta-1,3/1,6- glucan for the prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-06-26T02:00:00Z","last_updated_date":"2011-04-07T02:00:00Z","reference_number":"EMA/COMP/167667/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305294-public-summary-positive-opinion-orphan-designation-soluble-yeast-beta-1316-glucan-prevention-oral-mucositis-head-and-neck-cancer-patients-undergoing-radiation-therapy_en.pdf"},
    {"id":"38367","name":"EU/3/15/1445: Public summary of opinion on orphan designation: Ulocuplumab for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2015-04-09T02:00:00Z","reference_number":"EMA/COMP/26034/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151445-public-summary-opinion-orphan-designation-ulocuplumab-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"38375","name":"EU/3/16/1814: Public summary of opinion on orphan designation: Doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin for the treatment of malignant mes...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"EMA/19916/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161814-public-summary-opinion-orphan-designation-doxorubicin-hydrochloride-lipid-based-pegylated-nanoparticle-modified-31-aminoacid-peptide-targeting-nucleolin-treatment-malignant-mes_en.pdf"},
    {"id":"38390","name":"EU/3/14/1302: Public summary of opinion on orphan designation: Oxytocin for the treatment of Prader-Willi syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T17:30:00Z","last_updated_date":"2014-09-01T17:30:00Z","reference_number":"EMA/COMP/364093/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141302-public-summary-opinion-orphan-designation-oxytocin-treatment-prader-willi-syndrome_en.pdf"},
    {"id":"38404","name":"EU/3/14/1286: Public summary of opinion on orphan designation: Humanised Fc engineered monoclonal antibody against CD19 for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-16T02:00:00Z","last_updated_date":"2014-07-16T02:00:00Z","reference_number":"EMA/COMP/317254/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141286-public-summary-opinion-orphan-designation-humanised-fc-engineered-monoclonal-antibody-against-cd19-treatment-chronic-lymphocytic-leukaemiasmall-lymphocytic-lymphoma_en.pdf"},
    {"id":"38450","name":"EU/3/13/1157: Public summary of opinion on orphan designation: (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-16T13:00:00Z","last_updated_date":"2021-05-31T18:00:00Z","reference_number":"EMA/COMP/411861/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131157-public-summary-opinion-orphan-designation-s-3-1-9h-purin-6-ylaminoethyl-8-chloro-2-phenylisoquinolin-12h-one-treatment-follicular-lymphoma_en.pdf"},
    {"id":"38464","name":"EU/3/07/518: Public summary of positive opinion for orphan designation of methyl 4, 6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3, 4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate for the treatment of pulmonary arteria...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2022-06-14T17:00:00Z","reference_number":"EMEA/COMP/35953/2008 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307518-public-summary-positive-opinion-orphan-designation-methyl-4-6-diamino-2-1-2-fluorobenzyl-1h-pyrazolo-3-4-bpyridine-3-yl-5-pyrimidinylmethylcarbamate-treatment-pulmonary-arteria_en.pdf"},
    {"id":"38467","name":"EU/3/17/1920: Public summary of opinion on orphan designation : Cannabidiol for the treatment of West syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T15:38:00Z","last_updated_date":"2018-01-08T15:38:00Z","reference_number":"EMA/625004/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171920-public-summary-opinion-orphan-designation-cannabidiol-treatment-west-syndrome_en.pdf"},
    {"id":"38527","name":"EU/3/15/1502: Public summary of opinion on orphan designation: Trehalose for the treatment of spinocerebellar ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2015-07-27T02:00:00Z","reference_number":"EMA/COMP/345422/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151502-public-summary-opinion-orphan-designation-trehalose-treatment-spinocerebellar-ataxia_en.pdf"},
    {"id":"38571","name":"EU/3/12/1056: Public summary of opinion on orphan designation: Liposomal daunorubicin for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"EMA/COMP/615285/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121056-public-summary-opinion-orphan-designation-liposomal-daunorubicin-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"38584","name":"EU/3/13/1142: Public summary of opinion on orphan designation: Adenovirus associated viral vector serotype 5 containing the human pde6β gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T14:00:00Z","last_updated_date":"2015-03-10T13:00:00Z","reference_number":"EMA/COMP/307456/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131142-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-5-containing-human-pde6i2-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"38623","name":"EU/3/03/158: Public summary of positive opinion for orphan designation of recombinant human arylsulfatase A for the treatment of metachromatic leukodystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2011-11-18T13:30:00Z","reference_number":"EMEA/COMP/1378/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303158-public-summary-positive-opinion-orphan-designation-recombinant-human-arylsulfatase-treatment-metachromatic-leukodystrophy_en.pdf"},
    {"id":"38674","name":"EU/3/04/232: Public summary of positive opinion for orphan designation of biotinylated anti-tenascin monoclonal antibody for use with 90-Yttrium for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T00:00:00Z","last_updated_date":"2006-01-04T00:00:00Z","reference_number":"EMEA/COMP/122308/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304232-public-summary-positive-opinion-orphan-designation-biotinylated-anti-tenascin-monoclonal-antibody-use-90-yttrium-treatment-glioma_en.pdf"},
    {"id":"38680","name":"EU/3/05/296: Public summary of positive opinion for orphan designation of hydrocortisone (modified release tablet) for the treatment of congenital adrenal hyperplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2021-06-14T14:06:00Z","reference_number":"EMEA/COMP/216596/2005 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305296-public-summary-positive-opinion-orphan-designation-hydrocortisone-modified-release-tablet-treatment-congenital-adrenal-hyperplasia_en.pdf"},
    {"id":"38720","name":"EU/3/18/2006: Public summary of opinion on orphan designation: Tazemetostat for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"EMA/112323/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182006-public-summary-opinion-orphan-designation-tazemetostat-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"38723","name":"EU/3/14/1295: Public summary of opinion on orphan designation: Marizomib for the treatment of plasma cell myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-01T02:00:00Z","last_updated_date":"2015-03-26T01:00:00Z","reference_number":"EMA/COMP/360650/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141295-public-summary-opinion-orphan-designation-marizomib-treatment-plasma-cell-myeloma_en.pdf"},
    {"id":"38864","name":"EU/3/12/1086: Public summary of opinion on orphan designation: Eflornithine in combination with sulindac for the treatment of familial adenomatous polyposis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-03-01T01:00:00Z","last_updated_date":"2013-03-01T01:00:00Z","reference_number":"EMA/COMP/798800/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121086-public-summary-opinion-orphan-designation-eflornithine-combination-sulindac-treatment-familial-adenomatous-polyposis_en.pdf"},
    {"id":"38871","name":"EU/3/16/1808: Public summary of opinion on orphan designation: (6aR, 10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydro-cannabinol-9-carboxylic acid for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"EMA/14165/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161808-public-summary-opinion-orphan-designation-6ar-10ar-3-11-dimethylheptyl-delta-8-tetrahydro-cannabinol-9-carboxylic-acid-treatment-systemic-sclerosis_en.pdf"},
    {"id":"38882","name":"EU/3/11/907: Public summary of opinion on orphan designation: Kifunensine for the treatment of delta sarcoglycanopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2014-06-19T02:00:00Z","reference_number":"EMA/COMP/657803/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311907-public-summary-opinion-orphan-designation-kifunensine-treatment-delta-sarcoglycanopathy_en.pdf"},
    {"id":"38892","name":"EU/3/05/317: Public summary of positive opinion for orphan designation of a mixture of anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein for the treatment of graft-ve...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-10-27T02:00:00Z","last_updated_date":"2013-03-19T13:30:00Z","reference_number":"EMA/COMP/241073/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305317-public-summary-positive-opinion-orphan-designation-mixture-anti-cd3-mab-spv-t3a-ricin-chain-fusion-protein-and-anti-cd7-mab-wt1-ricin-chain-fusion-protein-treatment-graft-ve_en.pdf"},
    {"id":"38894","name":"EU/3/12/1049: Public summary of opinion on orphan designation: Rucaparib for the treatment of ovarian cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2019-02-19T01:00:00Z","reference_number":"EMA/COMP/613865/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121049-public-summary-opinion-orphan-designation-rucaparib-treatment-ovarian-cancer_en.pdf"},
    {"id":"38937","name":"EU/3/16/1758: Public summary of positive opinion for orphan designation of p-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/629732/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161758-public-summary-positive-opinion-orphan-designation-p-ethoxy-growth-factor-receptor-bound-protein-2-antisense-oligonucleotide-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"38945","name":"EU/3/04/255: Public summary of positive opinion for orphan designation of sabarubicin for the treatment of small cell lung cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/157131/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304255-public-summary-positive-opinion-orphan-designation-sabarubicin-treatment-small-cell-lung-cancer_en.pdf"},
    {"id":"38948","name":"EU/3/15/1554: Public summary of opinion on orphan designation: Nimodipine for the treatment of aneurysmal subarachnoid haemorrhage","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2015-11-16T01:00:00Z","reference_number":"EMA/COMP/602415/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151554-public-summary-opinion-orphan-designation-nimodipine-treatment-aneurysmal-subarachnoid-haemorrhage_en.pdf"},
    {"id":"38964","name":"EU/3/12/1047: Public summary of opinion on orphan designation: Asp-Arg-Val-Tyr-Ile-His-Pro for the treatment of acute lung injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"EMA/COMP/629946/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121047-public-summary-opinion-orphan-designation-asp-arg-val-tyr-ile-his-pro-treatment-acute-lung-injury_en.pdf"},
    {"id":"38978","name":"EU/3/05/272: Public summary of positive opinion for orphan designation: Histamine dihydrochloride for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-03-07T00:00:00Z","last_updated_date":"2019-02-20T16:00:00Z","reference_number":"EMA/COMP/86675/2005 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305272-public-summary-positive-opinion-orphan-designation-histamine-dihydrochloride-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"39001","name":"EU/3/12/1041: Public summary of opinion on orphan designation: (2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)ace...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-09-26T16:30:00Z","last_updated_date":"2012-09-26T16:30:00Z","reference_number":"EMA/COMP/526570/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121041-public-summary-opinion-orphan-designation-2s-2-2r-2-33-dibutyl-7-methylthio-11-dioxido-5-phenyl-2345-tetrahydro-125-benzothiadiazepin-8-yloxyacetylamino-2-4-hydroxyphenylace_en.pdf"},
    {"id":"39003","name":"EU/3/10/788: Public summary of opinion on orphan designation: (S)-10-[(dimethylamino)methyl]-4-ethyl-9-hydroxy-4-O-[alpha-(2”, 4”, 5”, 7”-tetranitro-9”-fluorenylideneaminooxy)propionyl]-1H-pyrano[3’, 4’, 6’, 7’]indolizin...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2010-10-14T02:00:00Z","reference_number":"EMA/COMP/479464/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310788-public-summary-opinion-orphan-designation-s-10-dimethylaminomethyl-4-ethyl-9-hydroxy-4-o-alpha-2-4-5-7-tetranitro-9-fluorenylideneaminooxypropionyl-1h-pyrano3-4-6-7indolizin_en.pdf"},
    {"id":"39061","name":"EU/3/02/120: Public summary of positive opinion for orphan designation of duramycin for treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T01:00:00Z","last_updated_date":"2005-12-12T01:00:00Z","reference_number":"EMEA/COMP/26147/02 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302120-public-summary-positive-opinion-orphan-designation-duramycin-treatment-cystic-fibrosis_en.pdf"},
    {"id":"39065","name":"EU/3/10/808: Public summary of opinion on orphan designation Murine monoclonal antibody against CD26 for the treatment of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-15T01:00:00Z","last_updated_date":"2014-01-22T01:00:00Z","reference_number":"EMA/COMP/604454/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310808-public-summary-opinion-orphan-designation-murine-monoclonal-antibody-against-cd26-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"39067","name":"EU/3/02/114: Public summary of positive opinion for orphan designation of myristoylated-peptidyl-recombinant human CD59 for the treatment of paroxysmal nocturnal haemoglobinuria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"EMEA/COMP/1641/02 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302114-public-summary-positive-opinion-orphan-designation-myristoylated-peptidyl-recombinant-human-cd59-treatment-paroxysmal-nocturnal-haemoglobinuria_en.pdf"},
    {"id":"39083","name":"EU/3/14/1263: Public summary of opinion on orphan designation: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene for the treatment of sickle cell dise...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-06-04T02:00:00Z","last_updated_date":"2021-12-07T01:00:00Z","reference_number":"EMA/COMP/172803/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141263-public-summary-opinion-orphan-designation-autologous-cd34-haematopoietic-stem-cells-transduced-lentiviral-vector-encoding-human-beta-t87q-globin-gene-treatment-sickle-cell-dise_en.pdf"},
    {"id":"39113","name":"EU/3/03/160: Public summary of positive opinion for orphan designation of antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT) for the treatment of retinopathy of prematurity","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-04-26T02:00:00Z","last_updated_date":"2004-04-26T02:00:00Z","reference_number":"EMEA/COMP/1440/03","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303160-public-summary-positive-opinion-orphan-designation-antisense-oligonucleotide-tatccggagggctcgccatgctgct-treatment-retinopathy-prematurity_en.pdf"},
    {"id":"39137","name":"EU/3/05/287: Public summary of positive opinion for orphan designation of bovine bile extract for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-03-07T00:00:00Z","last_updated_date":"2007-03-07T00:00:00Z","reference_number":"EMEA/COMP/166638/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305287-public-summary-positive-opinion-orphan-designation-bovine-bile-extract-treatment-pancreatic-cancer_en.pdf"},
    {"id":"39159","name":"EU/3/12/1010: Public summary of opinion on orphan designation: Ataluren for treatment of Becker muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-07-24T16:00:00Z","last_updated_date":"2015-03-23T15:00:00Z","reference_number":"EMA/COMP/357359/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121010-public-summary-opinion-orphan-designation-ataluren-treatment-becker-muscular-dystrophy_en.pdf"},
    {"id":"39180","name":"EU/3/14/1399: Public summary of opinion on orphan designation: Edaravone for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T01:00:00Z","last_updated_date":"2015-02-26T01:00:00Z","reference_number":"EMA/COMP/744271/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141399-public-summary-opinion-orphan-designation-edaravone-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"39204","name":"EU/3/06/429: Public summary of positive opinion for orphan designation of recombinant modified vaccinia Ankara expressing human 5T4  for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T00:00:00Z","last_updated_date":"2007-12-04T00:00:00Z","reference_number":"EMEA/COMP/495766/2006","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306429-public-summary-positive-opinion-orphan-designation-recombinant-modified-vaccinia-ankara-expressing-human-5t4-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"39223","name":"EU/3/03/146: Public summary of positive opinion for orphan designation of aldesleukin (inhalation use) for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-23T01:00:00Z","last_updated_date":"2007-02-23T01:00:00Z","reference_number":"EMEA/COMP/1228/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303146-public-summary-positive-opinion-orphan-designation-aldesleukin-inhalation-use-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"39235","name":"EU/3/05/292: Public summary of positive opinion for orphan designation of\n\nH-D-Asp-D-Gln-D-Ser-D-Arg-D-Pro-D-Val-D-Gln-D-Pro-D-Phe-D-Leu-D-Asn-D-Leu-D-Thr-D-Thr-D-Pro-D-Arg-D-Lys-D-Pro-D-Arg-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2013-10-17T14:00:00Z","reference_number":"EMEA/COMP/216808/2005 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305292-public-summary-positive-opinion-orphan-designation-h-d-asp-d-gln-d-ser-d-arg-d-pro-d-val-d-gln-d-pro-d-phe-d-leu-d-asn-d-leu-d-thr-d-thr-d-pro-d-arg-d-lys-d-pro-d-arg-d-pro-d-pro-d-arg-d-arg_en.pdf"},
    {"id":"39251","name":"EU/3/14/1240: Public summary of opinion on orphan designation: Cysteamine for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-01T15:30:00Z","last_updated_date":"2014-04-01T15:30:00Z","reference_number":"EMA/COMP/27210/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141240-public-summary-opinion-orphan-designation-cysteamine-treatment-cystic-fibrosis_en.pdf"},
    {"id":"39267","name":"EU/3/15/1556: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector expressing the human CNGA3 gene for the treatment of achromatopsia caused by mutations in the CNGA3 gene","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2015-11-16T01:00:00Z","reference_number":"EMA/COMP/603631/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151556-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-expressing-human-cnga3-gene-treatment-achromatopsia-caused-mutations-cnga3-gene_en.pdf"},
    {"id":"39270","name":"EU/3/02/116: Public summary of positive opinion for orphan designation of autologous renal tumour vaccine for the treatment of renal cell carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T00:00:00Z","last_updated_date":"2006-01-04T00:00:00Z","reference_number":"EMEA/COMP/2188/02 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302116-public-summary-positive-opinion-orphan-designation-autologous-renal-tumour-vaccine-treatment-renal-cell-carcinoma_en.pdf"},
    {"id":"39287","name":"EU/3/07/503: Public summary of positive opinion for orphan designation of recombinant human hepatitis C monoclonal antibody against C4 region of E1 for the prevention of recurrent hepatitis C virus induced liver disease ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2008-08-18T02:00:00Z","reference_number":"EMEA/COMP/135814/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307503-public-summary-positive-opinion-orphan-designation-recombinant-human-hepatitis-c-monoclonal-antibody-against-c4-region-e1-prevention-recurrent-hepatitis-c-virus-induced-liver-disease_en.pdf"},
    {"id":"39293","name":"EU/3/04/188: Public summary of positive opinion for orphan designation of N-3[[4(aminoiminomethyl)benzoyl]amino]propyl]-1-[[2,4-dichloro-3-[[2,4-dimethyl-8-quinolinyl)oxy]methyl] phenyl]sulphonyl]-(2S)-2-pyrrolidinecarbo...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-02-23T00:00:00Z","last_updated_date":"2007-02-23T00:00:00Z","reference_number":"EMEA/COMP/30/04 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304188-public-summary-positive-opinion-orphan-designation-n-34aminoiminomethylbenzoylaminopropyl-1-24-dichloro-3-24-dimethyl-8-quinolinyloxymethyl-phenylsulphonyl-2s-2-pyrrolidinecarbo_en.pdf"},
    {"id":"39330","name":"EU/3/16/1754: Public summary of positive opinion for orphan designation of lutetium-177(3+), S2,S7-cyclo[N-{4,7,10-tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl}-4-chloro-L-phenylalanyl-D-cysteinyl-4-[(4S)-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMA/615260/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161754-public-summary-positive-opinion-orphan-designation-lutetium-1773-s2s7-cyclon-4710-tricarboxymethyl-14710-tetraaza-cyclododecan-1-yl-acetyl-4-chloro-l-phenylalanyl-d-cysteinyl-4-4s_en.pdf"},
    {"id":"39339","name":"EU/3/16/1819: Public summary of opinion on orphan designation: Humanised IgG1 monoclonal antibody against the receptor-binding site of human placental growth factor for the treatment of medulloblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"EMA/4405/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161819-public-summary-opinion-orphan-designation-humanised-igg1-monoclonal-antibody-against-receptor-binding-site-human-placental-growth-factor-treatment-medulloblastoma_en.pdf"},
    {"id":"39340","name":"EU/3/01/025: Public summary of positive opinion for orphan designation of N-acetylgalactosamine-4-sulfatase for the treatment of mucopolysaccharidosis, type VI (Maroteaux-Lamy syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-20T00:00:00Z","last_updated_date":"2016-02-11T00:00:00Z","reference_number":"EMA/COMP/1276/2003 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301025-public-summary-positive-opinion-orphan-designation-n-acetylgalactosamine-4-sulfatase-treatment-mucopolysaccharidosis-type-vi-maroteaux-lamy-syndrome_en.pdf"},
    {"id":"39342","name":"EU/3/16/1626: Public summary of opinion on orphan designation: Acalabrutinib for the treatment of lymphoplasmacytic lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"EMA/COMP/150815/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161626-public-summary-opinion-orphan-designation-acalabrutinib-treatment-lymphoplasmacytic-lymphoma_en.pdf"},
    {"id":"39390","name":"EU/3/13/1169: Public summary of opinion on orphan designation: Lipid-complexed cisplatin for the treatment of osteosarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-09-12T02:00:00Z","last_updated_date":"2013-09-12T02:00:00Z","reference_number":"EMA/COMP/443340/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131169-public-summary-opinion-orphan-designation-lipid-complexed-cisplatin-treatment-osteosarcoma_en.pdf"}    {"id":"39415","name":"EU/3/05/326: Public summary of positive opinion for orphan designation of peptide 144 TGF-beta1-inhibitor (TSLDASIIWAMMQN) for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"EMEA/COMP/315308/2005 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305326-public-summary-positive-opinion-orphan-designation-peptide-144-tgf-beta1-inhibitor-tsldasiiwammqn-treatment-systemic-sclerosis_en.pdf"},
    {"id":"39446","name":"EU/3/00/017: Public summary of positive opinion for orphan designation ofarsenic trioxide for the treatment of acute promyelocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/COMP/259719/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu300017-public-summary-positive-opinion-orphan-designation-ofarsenic-trioxide-treatment-acute-promyelocytic-leukaemia_en.pdf"},
    {"id":"39468","name":"EU/3/16/1681: Public summary of opinion on orphan designation: Humanised monoclonal antibody targeting interleukin-15 for the treatment of eosinophilic oesophagitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/392522/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161681-public-summary-opinion-orphan-designation-humanised-monoclonal-antibody-targeting-interleukin-15-treatment-eosinophilic-oesophagitis_en.pdf"},
    {"id":"39519","name":"EU/3/14/1308: Public summary of opinion on orphan designation: Sodium ascorbate and menadione sodium bisulfite for the treatment of autosomal dominant polycystic liver disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/COMP/443070/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141308-public-summary-opinion-orphan-designation-sodium-ascorbate-and-menadione-sodium-bisulfite-treatment-autosomal-dominant-polycystic-liver-disease_en.pdf"},
    {"id":"39530","name":"EU/3/12/953: Public summary of opinion on orphan designation: (1S,3S)-3-amino-4-(difluoromethylene) cyclopentanecarboxylic acid hydrochloride for the treatment of West syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T01:00:00Z","last_updated_date":"2012-03-01T01:00:00Z","reference_number":"EMA/COMP/41120/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312953-public-summary-opinion-orphan-designation-1s3s-3-amino-4-difluoromethylene-cyclopentanecarboxylic-acid-hydrochloride-treatment-west-syndrome_en.pdf"},
    {"id":"39538","name":"EU/3/08/540: Public summary of positive opinion for orphan designation of omigapil maleate for the treatment of congenital muscular dystrophy with collagen VI deficiency (Ullrich Syndrome and Bethlem Myopathy)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2011-04-12T02:00:00Z","reference_number":"EMEA/COMP/204727/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308540-public-summary-positive-opinion-orphan-designation-omigapil-maleate-treatment-congenital-muscular-dystrophy-collagen-vi-deficiency-ullrich-syndrome-and-bethlem-myopathy_en.pdf"},
    {"id":"39556","name":"EU/3/16/1750: Public summary of positive opinion for orphan designation of exendin (9-39) for the treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"EMA/622426/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161750-public-summary-positive-opinion-orphan-designation-exendin-9-39-treatment-noninsulinoma-pancreatogenous-hypoglycaemia-syndrome_en.pdf"},
    {"id":"39566","name":"EU/3/03/166: Public summary of positive opinion for orphan designation ofeculizumab for the treatment of paroxysmal nocturnal haemoglobinuria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2019-08-30T14:00:00Z","reference_number":"EMEA/COMP/1523/03 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu303166-public-summary-positive-opinion-orphan-designation-ofeculizumab-treatment-paroxysmal-nocturnal-haemoglobinuria_en.pdf"},
    {"id":"39568","name":"EU/3/15/1485: Public summary of positive opinion for orphan designation of Sodium 2-hydroxylinoleate for the treatment of neuroblastoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T14:00:00Z","last_updated_date":"2015-05-22T14:00:00Z","reference_number":"EMA/COMP/209764/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151485-public-summary-positive-opinion-orphan-designation-sodium-2-hydroxylinoleate-treatment-neuroblastoma_en.pdf"},
    {"id":"39570","name":"EU/3/17/1838: Public summary of opinion on orphan designation: Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2 for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/80315/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171838-public-summary-opinion-orphan-designation-humanised-igg4-monoclonal-antibody-human-toll-receptor-type-2-treatment-pancreatic-cancer_en.pdf"},
    {"id":"39572","name":"EU/3/07/523: Public summary of positive opinion for orphan designation of lutetium (177Lu)-N-[(4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-07-10T02:00:00Z","last_updated_date":"2011-11-18T16:00:00Z","reference_number":"EMEA/COMP/19906/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307523-public-summary-positive-opinion-orphan-designation-lutetium-177lu-n-4710-tricarboxymethyl-14710-tetraazacyclododec-1-ylacetyl-d-phenylalanyl-l-cysteinyl-l-tyrosyl-d-tryptophanyl-l-lysyl_en.pdf"},
    {"id":"39609","name":"EU/3/10/798: Public summary of opinion on orphan designation: Synthetic double-stranded short interfering RNA oligonucleotide directed against proopiomelanocortin for the treatment of adrenocorticotropin-dependent Cushin...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-14T02:00:00Z","last_updated_date":"2013-02-28T12:01:00Z","reference_number":"EMA/COMP/477182/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310798-public-summary-opinion-orphan-designation-synthetic-double-stranded-short-interfering-rna-oligonucleotide-directed-against-proopiomelanocortin-treatment-adrenocorticotropin-dependent-cushin_en.pdf"},
    {"id":"39627","name":"EU/3/01/045: Public summary of positive opinion for orphan designation of betaine anhydrous for the treatment of homocystinuria","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2011-03-25T01:00:00Z","reference_number":"EMEA/COMP/1353/03 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301045-public-summary-positive-opinion-orphan-designation-betaine-anhydrous-treatment-homocystinuria_en.pdf"},
    {"id":"39668","name":"EU/3/09/649: Public summary of positive opinion for orphan designation of allogeneic ex-vivo-expanded umbilical-cord blood cells for the treatment of Hodgkin’s lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMEA/COMP/364682/2009 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309649-public-summary-positive-opinion-orphan-designation-allogeneic-ex-vivo-expanded-umbilical-cord-blood-cells-treatment-hodgkins-lymphoma_en.pdf"},
    {"id":"39685","name":"EU/3/10/835: Public summary of opinion on orphan designation: Maytansinoid-conjugated humanised monoclonal antibody against CD56 for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-04T01:00:00Z","last_updated_date":"2015-03-06T13:30:00Z","reference_number":"EMA/COMP/757716/2010 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310835-public-summary-opinion-orphan-designation-maytansinoid-conjugated-humanised-monoclonal-antibody-against-cd56-treatment-multiple-myeloma_en.pdf"},
    {"id":"39701","name":"EU/3/15/1529: Public summary of opinion on orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid for the treatment of fragile X syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-18T14:00:00Z","last_updated_date":"2015-08-18T14:00:00Z","reference_number":"EMA/COMP/425722/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151529-public-summary-opinion-orphan-designation-glycyl-l-2-methylprolyl-l-glutamic-acid-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"39707","name":"EU/3/16/1782: Public summary of positive opinion for orphan designation of L-selenomethionine for the treatment of facioscapulohumeral muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T13:06:00Z","last_updated_date":"2016-12-14T13:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161782-public-summary-positive-opinion-orphan-designation-l-selenomethionine-treatment-facioscapulohumeral-muscular-dystrophy_en.pdf"},
    {"id":"39714","name":"EU/3/06/352: Public summary of positive opinion for orphan designation of 26 base single stranded phosphodiester DNA oligonucleotide for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2011-05-18T02:00:00Z","reference_number":"EMEA/COMP/25354/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306352-public-summary-positive-opinion-orphan-designation-26-base-single-stranded-phosphodiester-dna-oligonucleotide-treatment-pancreatic-cancer_en.pdf"},
    {"id":"39743","name":"EU/3/10/741: Public summary of opinion on orphan designation: Pralatrexate for the treatment of cutaneous T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2011-03-10T01:00:00Z","reference_number":"EMA/COMP/90948/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310741-public-summary-opinion-orphan-designation-pralatrexate-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"39757","name":"EU/3/12/992: Public summary of opinion on orphan designation: Exon-53-specific phosphorothioate oligonucleotide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-06-18T13:00:00Z","last_updated_date":"2012-06-18T13:00:00Z","reference_number":"EMA/COMP/193933/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312992-public-summary-opinion-orphan-designation-exon-53-specific-phosphorothioate-oligonucleotide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"39780","name":"EU/3/12/954: Public summary of opinion on orphan designation: S[+] apomorphine for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T01:00:00Z","last_updated_date":"2012-03-28T16:30:00Z","reference_number":"EMA/COMP/5395/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312954-public-summary-opinion-orphan-designation-s-apomorphine-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"39795","name":"EU/3/13/1162: Public summary of opinion on orphan designation: Heterologous human adult liver-derived progenitor cells for the treatment of citrullinaemia type 1","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T14:30:00Z","last_updated_date":"2013-08-21T14:30:00Z","reference_number":"EMA/COMP/413213/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131162-public-summary-opinion-orphan-designation-heterologous-human-adult-liver-derived-progenitor-cells-treatment-citrullinaemia-type-1_en.pdf"},
    {"id":"39798","name":"EU/3/02/087: Public summary of positive opinion for orphan designation of eflornithine hydrochloride for the treatment of Familial Adenomatous Polyposis (FAP)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T01:00:00Z","last_updated_date":"2005-11-29T01:00:00Z","reference_number":"EMEA/COMP/91/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302087-public-summary-positive-opinion-orphan-designation-eflornithine-hydrochloride-treatment-familial-adenomatous-polyposis-fap_en.pdf"},
    {"id":"39893","name":"EU/3/07/484: Public summary of positive opinion for orphan designation of adenovirus associated viral vector serotype 4 containing the human RPE65 gene for treatment of Leber's congenital amaurosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-01-22T01:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"EMEA/COMP/440649/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu307484-public-summary-positive-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-4-containing-human-rpe65-gene-treatment-lebers-congenital-amaurosis_en.pdf"},
    {"id":"39902","name":"EU/3/14/1241: Public summary of opinion on orphan designation: Asp-Arg-Val-Tyr-Ile-His-Pro for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-01T16:00:00Z","last_updated_date":"2014-04-01T16:00:00Z","reference_number":"EMA/COMP/29754/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141241-public-summary-opinion-orphan-designation-asp-arg-val-tyr-ile-his-pro-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"39905","name":"EU/3/16/1665: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector containing the human RPGR gene for the treatment of retinitis pigmentosa caused by mutations in the RPGR gene","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-22T02:00:00Z","last_updated_date":"2016-06-22T02:00:00Z","reference_number":"EMA/COMP/314134/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161665-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-containing-human-rpgr-gene-treatment-retinitis-pigmentosa-caused-mutations-rpgr-gene_en.pdf"},
    {"id":"39937","name":"EU/3/09/672: Public summary of opinion on orphan designation for pomalidomide for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2023-09-13T11:12:00Z","reference_number":"EMEA/COMP/474084/2009 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-09-672-public-summary-opinion-orphan-designation-pomalidomide-treatment-multiple-myeloma_en.pdf"},
    {"id":"39939","name":"EU/3/13/1210: Public summary of opinion on orphan designation: Recombinant human parathyroid hormone for the treatment of hypoparathyroidism","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-23T01:00:00Z","last_updated_date":"2015-06-08T02:00:00Z","reference_number":"EMA/COMP/712586/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131210-public-summary-opinion-orphan-designation-recombinant-human-parathyroid-hormone-treatment-hypoparathyroidism_en.pdf"},
    {"id":"39946","name":"EU/3/17/1856: Public summary of opinion on orphan designation: Inebilizumab for the treatment of neuromyelitis optica spectrum disorders","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2022-05-19T02:00:00Z","reference_number":"EMA/144977/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171856-public-summary-opinion-orphan-designation-inebilizumab-treatment-neuromyelitis-optica-spectrum-disorders_en.pdf"},
    {"id":"39954","name":"C(2004) 356/3: Public summary of negative opinion for orphan designation of midazolam hydrochloride (for oromucosal use) for the treatment of seizures which continue for at least five minutes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-12-12T01:00:00Z","last_updated_date":"2005-12-12T01:00:00Z","reference_number":"EMEA/COMP/85/2004","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/c2004-3563-public-summary-negative-opinion-orphan-designation-midazolam-hydrochloride-oromucosal-use-treatment-seizures-which-continue-least-five-minutes_en.pdf"},
    {"id":"39974","name":"EU/3/14/1325: Public summary of opinion on orphan designation: Obinutuzumab for the treatment of diffuse large B-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2014-10-02T02:00:00Z","reference_number":"EMA/COMP/452142/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141325-public-summary-opinion-orphan-designation-obinutuzumab-treatment-diffuse-large-b-cell-lymphoma_en.pdf"},
    {"id":"39988","name":"EU/3/02/090: Public summary of positive opinion for orphan designation of human transferrin conjugated to mutant diphtheria toxin for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T01:00:00Z","last_updated_date":"2007-12-04T01:00:00Z","reference_number":"EMEA/COMP/49/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302090-public-summary-positive-opinion-orphan-designation-human-transferrin-conjugated-mutant-diphtheria-toxin-treatment-glioma_en.pdf"},
    {"id":"40007","name":"EU/3/09/690: Public summary of positive opinion for orphan designation of human anthrax immunoglobulin for the post-exposure prophylaxis of inhalation anthrax disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2016-08-12T01:09:21Z","reference_number":"EMEA/COMP/577283/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309690-public-summary-positive-opinion-orphan-designation-human-anthrax-immunoglobulin-post-exposure-prophylaxis-inhalation-anthrax-disease_en.pdf"},
    {"id":"40017","name":"EU/3/05/343: Public summary of positive opinion for orphan designation of enzastaurin hydrochloride for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2006-08-08T02:00:00Z","last_updated_date":"2006-08-08T02:00:00Z","reference_number":"EMEA/COMP/383664/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305343-public-summary-positive-opinion-orphan-designation-enzastaurin-hydrochloride-treatment-glioma_en.pdf"},
    {"id":"40033","name":"EU/3/14/1318: Public summary of opinion on orphan designation: Ulinastatin for the treatment of acute pancreatitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-01T02:00:00Z","last_updated_date":"2014-10-01T02:00:00Z","reference_number":"EMA/COMP/443087/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141318-public-summary-opinion-orphan-designation-ulinastatin-treatment-acute-pancreatitis_en.pdf"},
    {"id":"40057","name":"EU/3/13/1120: Public summary of opinion on orphan designation: 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-05-14T12:00:00Z","last_updated_date":"2013-05-14T12:00:00Z","reference_number":"EMA/COMP/175329/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131120-public-summary-opinion-orphan-designation-4-2-6-methylpyridin-2-yl-56-dihydro-4h-pyrrolo12-bpyrazol-3-yl-quinoline-6-carboxamide-monohydrate-treatment-glioma_en.pdf"},
    {"id":"40109","name":"EU/3/15/1579: Public summary of opinion on orphan designation: Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor for the treatment of follicular lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/COMP/696766/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151579-public-summary-opinion-orphan-designation-autologous-t-cells-transduced-retroviral-vector-encoding-anti-cd19-cd28cd3-zeta-chimeric-antigen-receptor-treatment-follicular-lymphoma_en.pdf"},
    {"id":"40130","name":"EU/3/05/261: Public summary of positive opinion for orphan designation of fluocinolone acetonide (prolonged-release intravitreal implant) for the treatment of non-infectious uveitis affecting the posterior segment of the...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-05-30T02:00:00Z","last_updated_date":"2007-05-30T02:00:00Z","reference_number":"EMEA/COMP/33483/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305261-public-summary-positive-opinion-orphan-designation-fluocinolone-acetonide-prolonged-release-intravitreal-implant-treatment-non-infectious-uveitis-affecting-posterior-segment_en.pdf"},
    {"id":"40215","name":"EU/3/13/1208: Public summary of opinion on orphan designation: Soraprazan for the treatment of Stargardt’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2013-12-02T01:00:00Z","reference_number":"EMA/COMP/631348/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131208-public-summary-opinion-orphan-designation-soraprazan-treatment-stargardts-disease_en.pdf"},
    {"id":"40240","name":"EU/3/11/887: Public summary of opinion on orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt for the treatment of post-essential thrombocythaemia myel...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-08-16T02:00:00Z","last_updated_date":"2013-06-20T13:00:00Z","reference_number":"EMA/COMP/407852/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311887-public-summary-opinion-orphan-designation-n-cyanomethyl-4-2-4-morpholin-4-ylphenylaminopyrimidin-4-ylbenzamide-dihydrochloride-salt-treatment-post-essential-thrombocythaemia-myel_en.pdf"},
    {"id":"40258","name":"EU/3/11/947: Public summary of positive opinion for orphan designation: Recombinant protein consisting of modified human growth hormone releasing hormone and the translocation and endopeptidase domains of botulinum toxin...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T15:00:00Z","last_updated_date":"2012-02-01T15:00:00Z","reference_number":"EMA/COMP/928881/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311947-public-summary-positive-opinion-orphan-designation-recombinant-protein-consisting-modified-human-growth-hormone-releasing-hormone-and-translocation-and-endopeptidase-domains-botulinum-toxin_en.pdf"},
    {"id":"40266","name":"EU/3/05/334: Public summary of positive opinion for orphan designation of human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor-binding domain fusion protein for the treatment of X-linked hypohidrotic...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"EMEA/COMP/367775/2005","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305334-public-summary-positive-opinion-orphan-designation-human-immunoglobulin-g1-constant-region-human-ectodysplasin-a1-receptor-binding-domain-fusion-protein-treatment-x-linked-hypohidrotic_en.pdf"},
    {"id":"40344","name":"EU/3/09/629: Public summary of positive opinion for orphan designation of nanobody directed towards the human A1 domain of von Willebrand factor for the treatment of thrombotic thrombocytopenic purpura","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-05-12T02:00:00Z","last_updated_date":"2011-04-06T02:00:00Z","reference_number":"EMEA/COMP/146358/2009","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309629-public-summary-positive-opinion-orphan-designation-nanobody-directed-towards-human-a1-domain-von-willebrand-factor-treatment-thrombotic-thrombocytopenic-purpura_en.pdf"},
    {"id":"40354","name":"EU/03/11/915: Public summary of opinion on orphan designation: 1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H- pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2015-06-08T12:00:00Z","reference_number":"EMA/COMP/793147/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu0311915-public-summary-opinion-orphan-designation-1-4-4-amino-7-1-2-hydroxyethyl-1h-pyrazol-4-ylthieno32-cpyridin-3-ylphenyl-3-3-fluorophenylurea-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"40357","name":"EU/3/09/680: Public summary of positive opinion for orphan designation of 5'-O-(trans-9''-octadecenoyl)-1-beta-D-2'-deoxy-2',2'-difluorocytidine for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2013-06-24T02:00:00Z","reference_number":"EMA/COMP/577495/2009 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309680-public-summary-positive-opinion-orphan-designation-5-o-trans-9-octadecenoyl-1-beta-d-2-deoxy-22-difluorocytidine-treatment-pancreatic-cancer_en.pdf"},
    {"id":"40359","name":"Public summary of opinion on orphan designation: 5-chloro-N2-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N4-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine for the treatment of non-small cell lung cancer (NSCLC) ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/COMP/88624/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-5-chloro-n2-2-isopropoxy-5-methyl-4-4-piperidinylphenyl-n4-2-isopropylsulfonylphenyl-24-pyrimidinediamine-treatment-non-small-cell-lung-cancer-nsclc_en.pdf"},
    {"id":"40361","name":"EU/3/17/1919: Public summary of opinion on orphan designation: Bitopertin for the treatment of beta thalassaemia intermedia and major","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-10T10:25:00Z","last_updated_date":"2018-10-24T16:00:00Z","reference_number":"EMA/624094/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171919-public-summary-opinion-orphan-designation-bitopertin-treatment-beta-thalassaemia-intermedia-and-major_en.pdf"},
    {"id":"40420","name":"EU/3/12/1067: Public summary of opinion on orphan designation: Erdosteine for the treatment of mercury toxicity","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T01:00:00Z","last_updated_date":"2012-12-12T01:00:00Z","reference_number":"EMA/COMP/682684/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3121067-public-summary-opinion-orphan-designation-erdosteine-treatment-mercury-toxicity_en.pdf"},
    {"id":"40431","name":"EU/3/10/845: Public summary of opinion on orphan designation: Dry extract from Birch bark (DER 0.1-0.2:1), extraction solvent n-heptane 95% (V/V) for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-04T01:00:00Z","last_updated_date":"2012-06-28T18:00:00Z","reference_number":"EMA/COMP/10735/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310845-public-summary-opinion-orphan-designation-dry-extract-birch-bark-der-01-021-extraction-solvent-n-heptane-95-vv-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"40459","name":"EU/3/18/2025: Public summary of opinion on orphan designation: Modified mRNA encoding human methylmalonyl-coenzyme A mutase encapsulated into lipid nanoparticles for the treatment of methylmalonic acidaemia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T18:30:00Z","last_updated_date":"2023-06-26T18:30:00Z","reference_number":"EMA/275363/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182025-public-summary-opinion-orphan-designation-modified-mrna-encoding-human-methylmalonyl-coenzyme-mutase-encapsulated-lipid-nanoparticles-treatment-methylmalonic-acidaemia_en.pdf"},
    {"id":"40476","name":"EU/3/13/1129: Public summary of opinion on orphan designation: Allogeneic bone-marrow-derived mesenchymal cells expanded ex vivo in synthetic media for the treatment of graft-versus-host disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2013-07-09T11:00:00Z","reference_number":"EMA/COMP/268935/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131129-public-summary-opinion-orphan-designation-allogeneic-bone-marrow-derived-mesenchymal-cells-expanded-ex-vivo-synthetic-media-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"40491","name":"EU/3/10/768: Public summary of opinion on orphan designation: 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene for the treat...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-10-18T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMA/COMP/360298/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310768-public-summary-opinion-orphan-designation-11-2-pyrrolidin-1-yl-ethoxy-1419-dioxa-5726-triaza-tetracyclo19311261812-heptacosa-125226358101227162123-decaene-treat_en.pdf"},
    {"id":"40512","name":"EU/3/14/1312: Public summary of opinion on orphan designation: Recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin for the treatment of congenital factor...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/COMP/434796/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141312-public-summary-opinion-orphan-designation-recombinant-factor-viia-modified-three-terminal-repeats-derived-i2-chain-human-chorionic-gonadotropin-treatment-congenital-factor_en.pdf"},
    {"id":"40532","name":"EU/3/17/1902: Public summary of opinion on orphan designation: N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide for the treatment o...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/557429/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171902-public-summary-opinion-orphan-designation-n-2-6-26-dichloro-35-dimethoxyphenylcarbamoylmethylaminopyrimidin-4-ylamino-5-4-ethylpiperazin-1-ylphenylprop-2-enamide-treatment-o_en.pdf"},
    {"id":"40555","name":"EU/3/02/123: Public summary of positive opinion for orphan designation of anti-CD147 murine monoclonal IgM for the treatment of Graft versus Host Disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2003-07-07T02:00:00Z","last_updated_date":"2003-07-07T02:00:00Z","reference_number":"EMEA/COMP/2391/02/Rev 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302123-public-summary-positive-opinion-orphan-designation-anti-cd147-murine-monoclonal-igm-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"40558","name":"EU/3/11/918: Public summary of opinion on orphan designation: Brivanib alaninate for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-11-23T16:00:00Z","last_updated_date":"2013-06-25T02:00:00Z","reference_number":"EMA/COMP/780640/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311918-public-summary-opinion-orphan-designation-brivanib-alaninate-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"40567","name":"EU/3/08/573: Public summary of positive opinion for orphan designation of adeno-associated viral vector containing the human alpha sarcoglycan gene\n\nfor the treatment of alpha sarcoglycanopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2014-06-18T02:00:00Z","reference_number":"EMEA/COMP/479941/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308573-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-containing-human-alpha-sarcoglycan-gene-treatment-alpha-sarcoglycanopathy_en.pdf"},
    {"id":"40634","name":"EU/3/12/961: Public summary of opinion on orphan designation: Doxycycline hyclate for the treatment of systemic amyloidosis caused by beta-2 microglobulin","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T11:45:00Z","last_updated_date":"2012-04-19T11:45:00Z","reference_number":"EMA/COMP/58844/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312961-public-summary-opinion-orphan-designation-doxycycline-hyclate-treatment-systemic-amyloidosis-caused-beta-2-microglobulin_en.pdf"},
    {"id":"40673","name":"EU/3/16/1726 : Public summary of opinion on orphan designation: Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues for the treatment of glycogen storage disease type II (Pompe’s diseas...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161726-public-summary-opinion-orphan-designation-recombinant-human-acid-alpha-glucosidase-conjugated-mannose-6-phosphate-analogues-treatment-glycogen-storage-disease-type-ii-pompes-diseas_en.pdf"},
    {"id":"40682","name":"EU/3/14/1375: Public summary of opinion on orphan designation: Pro-Pro-Thr-Val-Pro-Thr-Arg for treatment of xeroderma pigmentosum","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2022-02-25T01:00:00Z","reference_number":"EMA/COMP/660612/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141375-public-summary-opinion-orphan-designation-pro-pro-thr-val-pro-thr-arg-treatment-xeroderma-pigmentosum_en.pdf"},
    {"id":"40698","name":"EU/3/14/1378: Public summary of opinion on orphan designation: Diaspirin cross-linked haemoglobin for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2015-01-16T01:00:00Z","reference_number":"EMA/COMP/652847/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141378-public-summary-opinion-orphan-designation-diaspirin-cross-linked-haemoglobin-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"40699","name":"EU/3/09/639: Public summary of positive opinion for orphan designation\n\nof 4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo[b,e][1,4] diazepin-11-one for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-09T02:00:00Z","last_updated_date":"2013-10-17T13:25:00Z","reference_number":"EMEA/COMP/24006/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309639-public-summary-positive-opinion-orphan-designation-468-trihydroxy-10-3711-trimethyldodeca-2610-trienyl-510-dihydrodibenzobe14-diazepin-11-one-treatment-glioma_en.pdf"},
    {"id":"40704","name":"EU/3/13/1149: Public summary of opinion on orphan designation: Human haemin for the prevention of ischaemia reperfusion injury associated with solid-organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-08-22T17:30:00Z","last_updated_date":"2013-08-22T17:30:00Z","reference_number":"EMA/COMP/399770/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3131149-public-summary-opinion-orphan-designation-human-haemin-prevention-ischaemia-reperfusion-injury-associated-solid-organ-transplantation_en.pdf"},
    {"id":"40712","name":"EU/3/06/418: Public summary of positive opinion of iodine (131I) anti-tenascin monoclonal antibody 81C6 for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-06-15T02:00:00Z","last_updated_date":"2016-02-10T01:00:00Z","reference_number":"EMEA/COMP/221961/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306418-public-summary-positive-opinion-iodine-131i-anti-tenascin-monoclonal-antibody-81c6-treatment-glioma_en.pdf"},
    {"id":"40727","name":"EU/3/11/851: Public summary of positive opinion for orphan designation:  Glufosfamide for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMA/COMP/45835/2011 ev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311851-public-summary-positive-opinion-orphan-designation-glufosfamide-treatment-pancreatic-cancer_en.pdf"},
    {"id":"40743","name":"EU/3/16/1742: Public summary of positive opinion for orphan designation of acebutolol hydrochloride for the treatment of Smith-Magenis syndrome\n\nOn","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/619426/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161742-public-summary-positive-opinion-orphan-designation-acebutolol-hydrochloride-treatment-smith-magenis-syndrome_en.pdf"},
    {"id":"40756","name":"EU/3/15/1600: Public summary of opinion on orphan designation: Sodium benzoate for the treatment of hyperargininaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T01:00:00Z","reference_number":"EMA/COMP/851574/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151600-public-summary-opinion-orphan-designation-sodium-benzoate-treatment-hyperargininaemia_en.pdf"},
    {"id":"40758","name":"EU/3/17/1857: Public summary of opinion on orphan designation: Ketoconazole for the treatment of granulosa cell tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/143113/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171857-public-summary-opinion-orphan-designation-ketoconazole-treatment-granulosa-cell-tumours_en.pdf"},
    {"id":"40792","name":"EU/3/15/1578: Public summary of opinion on orphan designation: \n\nAdenovirus associated viral vector serotype 8 containing the human CNGB3 gene for the treatment of achromatopsia caused by mutations in the CNGB3 gene","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMA/COMP/699673/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151578-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-8-containing-human-cngb3-gene-treatment-achromatopsia-caused-mutations-cngb3-gene_en.pdf"},
    {"id":"40818","name":"EU/3/09/678: Public summary of positive opinion for orphan designation\n\nof (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-20T02:00:00Z","last_updated_date":"2014-01-22T01:00:00Z","reference_number":"EMEA/COMP/444936/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu309678-public-summary-positive-opinion-orphan-designation-trans-3-56-dihydro-4h-pyrrolo321-ijquinolin-1yl-4-1h-indol-3-yl-pyrrolidine-2-5-dione-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"40831","name":"EU/3/14/1386: Public summary of positive opinion for orphan designation: 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-02-26T18:00:00Z","reference_number":"EMA/COMP/725365/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141386-public-summary-positive-opinion-orphan-designation-2-hydroxymethyl-2-methoxymethyl-1-azabicyclo222octan-3-one-treatment-ovarian-cancer_en.pdf"},
    {"id":"40883","name":"EU/3/10/814: Public summary of opinion on orphan designation: Recombinant human von Willebrand factor for the treatment of von Willebrand disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/COMP/578646/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310814-public-summary-opinion-orphan-designation-recombinant-human-von-willebrand-factor-treatment-von-willebrand-disease_en.pdf"},
    {"id":"40910","name":"EU/3/06/390: Public summary of positive opinion for orphan designation of 4-amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride for the treatment of moderate and severe traumatic brain injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-02-24T01:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMEA/COMP/275889/2006draft","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306390-public-summary-positive-opinion-orphan-designation-4-amino-6rs-5678-tetrahydro-l-biopterin-dihydrochloride-treatment-moderate-and-severe-traumatic-brain-injury_en.pdf"},
    {"id":"40922","name":"EU/3/06/399: Public summary of positive opinion for orphan designation of mecasermin rinfabate for the prevention of retinopathy of prematurity in neonates of less than 32 weeks of gestational age","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/COMP/63851/2008","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306399-public-summary-positive-opinion-orphan-designation-mecasermin-rinfabate-prevention-retinopathy-prematurity-neonates-less-32-weeks-gestational-age_en.pdf"},
    {"id":"40926","name":"EU/3/17/1951: Public summary of opinion on orphan designation: Agammaglobulinaemia tyrosine kinase for the treatment of pemphigus","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T10:44:00Z","last_updated_date":"2018-01-24T10:44:00Z","reference_number":"EMA/COMP/737372/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171951-public-summary-opinion-orphan-designation-agammaglobulinaemia-tyrosine-kinase-treatment-pemphigus_en.pdf"},
    {"id":"40933","name":"EU/3/10/839: Public summary of opinion on orphan designation: Plitidepsin for the treatment of post-polycythaemia vera myelofibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2011-09-06T02:00:00Z","reference_number":"EMA/COMP/740417/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310839-public-summary-opinion-orphan-designation-plitidepsin-treatment-post-polycythaemia-vera-myelofibrosis_en.pdf"},
    {"id":"40934","name":"EU/3/06/412: Public summary of positive opinion for orphan designation\n\nof 4,7,10,13,16,19-docosahexaenoic acid for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2013-07-08T02:00:00Z","reference_number":"EMEA/COMP/197064/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306412-public-summary-positive-opinion-orphan-designation-4710131619-docosahexaenoic-acid-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"40939","name":"EU/3/11/897: Public summary of opinion on orphan designation: N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide for the treatment of tuberculosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMA/COMP/547013/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311897-public-summary-opinion-orphan-designation-n-5s-3-3-fluoro-4-thiomorpholin-4-ylphenyl-2-oxo-13-oxazolidin-5-ylmethylacetamide-treatment-tuberculosis_en.pdf"},
    {"id":"40951","name":"EU/3/17/1944: Public summary of opinion on orphan designation: Tamoxifen citrate for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-15T01:00:00Z","last_updated_date":"2018-01-15T01:00:00Z","reference_number":"EMA/696120/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171944-public-summary-opinion-orphan-designation-tamoxifen-citrate-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"40954","name":"EU/3/05/319: Public summary of positive opinion for orphan designation of human Staphylococcus aureus immunoglobulin for the treatment of Staphylococcus aureus bacteraemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2008-08-18T02:00:00Z","last_updated_date":"2008-08-18T02:00:00Z","reference_number":"EMEA/COMP/317953/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305319-public-summary-positive-opinion-orphan-designation-human-staphylococcus-aureus-immunoglobulin-treatment-staphylococcus-aureus-bacteraemia_en.pdf"},
    {"id":"40964","name":"EU/3/10/817: Public summary of opinion on orphan designation: Adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin / adeno-associated viral vector containing a rhodopsin gene for the treatmen...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-01-19T01:00:00Z","last_updated_date":"2011-01-19T01:00:00Z","reference_number":"EMA/COMP/671325/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu310817-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-containing-dna-encoding-rnai-targeting-rhodopsin-adeno-associated-viral-vector-containing-rhodopsin-gene-treatmen_en.pdf"},
    {"id":"40990","name":"EU/3/16/1687: Public summary of opinion on orphan designation: Recombinant protein derived from the saliva of the Ornithodoros moubata tick for the treatment of Guillain-Barrà© syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/380759/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161687-public-summary-opinion-orphan-designation-recombinant-protein-derived-saliva-ornithodoros-moubata-tick-treatment-guillain-barrac-syndrome_en.pdf"},
    {"id":"41002","name":"EU/3/02/089: Public summary of positive opinion for orphan designation of granulocyte macrophage colony stimulating factor receptor antagonist for the treatment of juvenile myelomonocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T00:00:00Z","last_updated_date":"2005-11-29T00:00:00Z","reference_number":"EMEA/COMP/67/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302089-public-summary-positive-opinion-orphan-designation-granulocyte-macrophage-colony-stimulating-factor-receptor-antagonist-treatment-juvenile-myelomonocytic-leukaemia_en.pdf"},
    {"id":"41023","name":"EU/3/18/1974: Public summary of opinion on orphan designation: 6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate for the treatment of acute ...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-10T02:00:00Z","last_updated_date":"2018-04-10T02:00:00Z","reference_number":"EMA/65622/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3181974-public-summary-opinion-orphan-designation-6-1r2s-2-aminocyclohexylamino-7-fluoro-4-1-methyl-1h-pyrazol-4-yl-12-dihydro-3h-pyrrolo34-cpyridin-3-one-monocitrate-treatment-acute_en.pdf"},
    {"id":"41124","name":"EU/3/16/1680: Public summary of opinion on orphan designation: Humanised anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorders","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2016-07-26T02:00:00Z","reference_number":"EMA/COMP/395313/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161680-public-summary-opinion-orphan-designation-humanised-anti-il-6-receptor-monoclonal-antibody-treatment-neuromyelitis-optica-spectrum-disorders_en.pdf"},
    {"id":"41140","name":"EU/3/18/2011: Public summary of opinion on orphan designation: Burosumab for the treatment of phosphaturic mesenchymal tumour","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T13:00:00Z","last_updated_date":"2018-05-17T13:00:00Z","reference_number":"EMA/179384/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182011-public-summary-opinion-orphan-designation-burosumab-treatment-phosphaturic-mesenchymal-tumour_en.pdf"},
    {"id":"41152","name":"EU/3/17/1844: Public summary of opinion on orphan designation: Tauroursodeoxycholic acid for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T02:00:00Z","last_updated_date":"2017-03-31T02:00:00Z","reference_number":"EMA/72424/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171844-public-summary-opinion-orphan-designation-tauroursodeoxycholic-acid-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"41153","name":"EU/3/02/130: Public summary of positive opinion for orphan designation of\n\nG17(9) gastrin-diphtheria toxoid conjugate for the treatment of gastric  cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2009-09-21T02:00:00Z","reference_number":"EMEA/COMP/2994/03 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu302130-public-summary-positive-opinion-orphan-designation-g179-gastrin-diphtheria-toxoid-conjugate-treatment-gastric-cancer_en.pdf"},
    {"id":"41172","name":"EU/3/01/047: Public summary of positive opinion for orphan designation of thalidomide for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-10-15T02:00:00Z","last_updated_date":"2009-10-15T02:00:00Z","reference_number":"EMEA/COMP/11249/2003 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu301047-public-summary-positive-opinion-orphan-designation-thalidomide-treatment-multiple-myeloma_en.pdf"},
    {"id":"41266","name":"EU/3/17/1898: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype Anc80 containing the truncated human ATP7B gene under the control of the human alpha-1 antitrypsin promoter for the tr...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2017-10-17T02:00:00Z","reference_number":"EMA/508058/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171898-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-anc80-containing-truncated-human-atp7b-gene-under-control-human-alpha-1-antitrypsin-promoter-tr_en.pdf"},
    {"id":"41280","name":"EU/3/04/197: Public summary of positive opinion for orphan designation of treprostinil sodium (inhalation use) for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"EMEA/COMP/137/04 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu304197-public-summary-positive-opinion-orphan-designation-treprostinil-sodium-inhalation-use-treatment-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension_en.pdf"},
    {"id":"41310","name":"EU/3/06/397: Public summary of positive opinion for orphan designation of cholest-4-en-3-one, oxime for treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"EMEA/COMP/279844/2006 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu306397-public-summary-positive-opinion-orphan-designation-cholest-4-en-3-one-oxime-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"41321","name":"EU/3/14/1394: Public summary of positive opinion for orphan designation: Pegylated recombinant human hyaluronidase PH20 for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T18:00:00Z","last_updated_date":"2015-02-26T18:00:00Z","reference_number":"EMA/COMP/733378/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141394-public-summary-positive-opinion-orphan-designation-pegylated-recombinant-human-hyaluronidase-ph20-treatment-pancreatic-cancer_en.pdf"},
    {"id":"41329","name":"EU/3/11/880: Public summary of opinion on orphan designation: Genetically modified human adenovirus encoding human PH20 hyaluronidase for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2013-07-31T12:15:00Z","reference_number":"EMA/COMP/309860/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu311880-public-summary-opinion-orphan-designation-genetically-modified-human-adenovirus-encoding-human-ph20-hyaluronidase-treatment-pancreatic-cancer_en.pdf"},
    {"id":"41331","name":"EU/3/08/538: Public summary of positive opinion for orphan designation of amrubicin hydrochloride for the treatment of small-cell lung cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2016-08-11T02:00:00Z","reference_number":"EMEA/COMP/93021/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308538-public-summary-positive-opinion-orphan-designation-amrubicin-hydrochloride-treatment-small-cell-lung-cancer_en.pdf"},
    {"id":"41357","name":"EU/3/14/1236: Public summary of opinion on orphan designation: Diacerein for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-31T03:00:00Z","last_updated_date":"2014-03-31T03:00:00Z","reference_number":"EMA/COMP/26852/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141236-public-summary-opinion-orphan-designation-diacerein-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"41400","name":"EU/3/14/1398: Public summary of opinion on orphan designation: Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T01:00:00Z","last_updated_date":"2015-02-26T01:00:00Z","reference_number":"EMA/COMP/744276/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141398-public-summary-opinion-orphan-designation-genetically-modified-serotype-53-adenovirus-coding-granulocyte-macrophage-colony-stimulating-factor-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"41425","name":"EU/3/14/1344: Public summary of opinion on orphan designation: Nitric oxide for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/560372/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141344-public-summary-opinion-orphan-designation-nitric-oxide-treatment-cystic-fibrosis_en.pdf"},
    {"id":"41458","name":"EU/3/12/960: Public summary of opinion on orphan designation: Glucagon for the treatment of congenital hyperinsulinism","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T11:45:00Z","last_updated_date":"2012-04-19T11:45:00Z","reference_number":"EMA/COMP/61086/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu312960-public-summary-opinion-orphan-designation-glucagon-treatment-congenital-hyperinsulinism_en.pdf"},
    {"id":"41505","name":"EU/3/18/2019: Public summary of opinion on orphan designation: Bardoxolone methyl for the treatment of Alport syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T17:07:00Z","last_updated_date":"2018-07-23T17:07:00Z","reference_number":"EMA/266267/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182019-public-summary-opinion-orphan-designation-bardoxolone-methyl-treatment-alport-syndrome_en.pdf"}    {"id":"41532","name":"EU/3/14/1395: Public summary of opinion on orphan designation: Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-26T01:00:00Z","last_updated_date":"2015-02-26T01:00:00Z","reference_number":"EMA/COMP/730059/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141395-public-summary-opinion-orphan-designation-allogeneic-ex-vivo-generated-natural-killer-cells-cd34-umbilical-cord-blood-progenitor-cells-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"41607","name":"EU/3/17/1880: Public summary of opinion on orphan designation: Avacopan for the treatment of C3 glomerulopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T02:00:00Z","last_updated_date":"2017-07-17T02:00:00Z","reference_number":"EMA/323352/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171880-public-summary-opinion-orphan-designation-avacopan-treatment-c3-glomerulopathy_en.pdf"},
    {"id":"41639","name":"EU/3/15/1447: Public summary of opinion on orphan designation: Olaratumab for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-09T02:00:00Z","last_updated_date":"2020-01-15T02:00:00Z","reference_number":"EMA/COMP/25527/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151447-public-summary-opinion-orphan-designation-olaratumab-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"41652","name":"EU/3/17/1959: Public summary of opinion on orphan designation: Cannabidiol for the treatment of tuberous sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-12T01:00:00Z","last_updated_date":"2018-03-12T01:00:00Z","reference_number":"EMA/5287/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171959-public-summary-opinion-orphan-designation-cannabidiol-treatment-tuberous-sclerosis_en.pdf"},
    {"id":"41658","name":"EU/3/15/1605: Public summary of opinion on orphan designation: Synthetic double-stranded oligomer specific to the SERPINA1 gene and containing a cholesterol-conjugated, acyclic nucleobase analogue for the treatment of co...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"EMA/COMP/852267/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151605-public-summary-opinion-orphan-designation-synthetic-double-stranded-oligomer-specific-serpina1-gene-and-containing-cholesterol-conjugated-acyclic-nucleobase-analogue-treatment-co_en.pdf"},
    {"id":"41663","name":"EU/3/14/1319: Public summary of opinion on orphan designation: Recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-01T02:00:00Z","last_updated_date":"2014-10-01T02:00:00Z","reference_number":"EMA/COMP/434793/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141319-public-summary-opinion-orphan-designation-recombinant-factor-viia-modified-three-terminal-repeats-derived-i2-chain-human-chorionic-gonadotropin-treatment-haemophilia-b_en.pdf"},
    {"id":"41702","name":"EU/3/14/1337: Public summary of opinion on orphan designation: Acamprosate calcium for the treatment of fragile X syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2014-11-12T13:00:00Z","reference_number":"EMA/COMP/556117/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141337-public-summary-opinion-orphan-designation-acamprosate-calcium-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"41718","name":"EU/3/14/1285: Public summary of opinion on orphan designation: Afamelanotide for the treatment of familial benign chronic pemphigus (Hailey-Hailey disease)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/COMP/317253/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141285-public-summary-opinion-orphan-designation-afamelanotide-treatment-familial-benign-chronic-pemphigus-hailey-hailey-disease_en.pdf"},
    {"id":"41728","name":"EU/3/16/1649: Public summary of opinion on orphan designation: Humanised recombinant IgG4 anti-human tau antibody for the treatment of progressive supranuclear palsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2020-04-01T02:00:00Z","reference_number":"EMA/COMP/241978/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161649-public-summary-opinion-orphan-designation-humanised-recombinant-igg4-anti-human-tau-antibody-treatment-progressive-supranuclear-palsy_en.pdf"},
    {"id":"41737","name":"EU/3/16/1719 : Public summary of opinion on orphan designation: Cisplatin for the treatment of malignant mesothelioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161719-public-summary-opinion-orphan-designation-cisplatin-treatment-malignant-mesothelioma_en.pdf"},
    {"id":"41751","name":"EU/3/16/1781: Public summary of positive opinion for orphan designation of live-attenuated non-replicative Pseudomonas aeruginosa strain expressing large T antigen of Merkel cell polyomavirus for the treatment of Merkel ...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T13:10:00Z","last_updated_date":"2016-12-14T13:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161781-public-summary-positive-opinion-orphan-designation-live-attenuated-non-replicative-pseudomonas-aeruginosa-strain-expressing-large-t-antigen-merkel-cell-polyomavirus-treatment-merkel_en.pdf"},
    {"id":"41762","name":"EU/3/17/1966: Public summary of opinion on orphan designation: N-(bromoacetyl)-3,3-dinitroazetidine for the treatment of small cell lung cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-12T01:00:00Z","last_updated_date":"2018-03-12T01:00:00Z","reference_number":"EMA/COMP/840557/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171966-public-summary-opinion-orphan-designation-n-bromoacetyl-33-dinitroazetidine-treatment-small-cell-lung-cancer_en.pdf"},
    {"id":"41775","name":"EU/3/16/1638: Public summary of opinion on orphan designation: Ubenimex for the treatment of pulmonary arterial hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-02T02:00:00Z","last_updated_date":"2016-05-02T02:00:00Z","reference_number":"EMA/COMP/167823/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161638-public-summary-opinion-orphan-designation-ubenimex-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"41828","name":"EU/3/17/1877: Public summary of opinion on orphan designation: Tamoxifen citrate for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-06-29T02:00:00Z","last_updated_date":"2017-06-29T02:00:00Z","reference_number":"EMA/COMP/277117/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3171877-public-summary-opinion-orphan-designation-tamoxifen-citrate-treatment-cystic-fibrosis_en.pdf"},
    {"id":"41841","name":"EU/3/16/1715 : Public summary of opinion on orphan designation: Adenovirus-associated viral vector serotype 5 containing the human RPGR gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T02:00:00Z","last_updated_date":"2016-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161715-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-5-containing-human-rpgr-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"41881","name":"EU/3/16/1809: Public summary of opinion on orphan designation: [5,10,15,20-tetrakis(4-carboxyphenyl)-21H,23H-porphine]manganese(III) chloride for the treatment of Cockayne syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-11T02:00:00Z","last_updated_date":"2017-07-11T02:00:00Z","reference_number":"EMA/5008/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161809-public-summary-opinion-orphan-designation-5101520-tetrakis4-carboxyphenyl-21h23h-porphinemanganeseiii-chloride-treatment-cockayne-syndrome_en.pdf"},
    {"id":"41898","name":"EU/3/15/1464: Public summary of positive opinion for orphan designation of  autologous adipose tissue-derived stromal vascular fraction cells for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2015-05-11T02:00:00Z","reference_number":"EMA/COMP/125714/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151464-public-summary-positive-opinion-orphan-designation-autologous-adipose-tissue-derived-stromal-vascular-fraction-cells-treatment-systemic-sclerosis_en.pdf"},
    {"id":"41899","name":"EU/3/14/1329: Public summary of opinion on orphan designation: Variant of recombinant human fibroblast growth factor 19 for the treatment of primary biliary cirrhosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2014-10-02T02:00:00Z","reference_number":"EMA/COMP/440234/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3141329-public-summary-opinion-orphan-designation-variant-recombinant-human-fibroblast-growth-factor-19-treatment-primary-biliary-cirrhosis_en.pdf"},
    {"id":"41957","name":"EU/3/15/1577: Public summary of opinion on orphan designation: \n\nAdenovirus associated viral vector serotype 5 containing the human RPE65 gene for the treatment of Leber’s congenital amaurosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMA/COMP/699951/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3151577-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-5-containing-human-rpe65-gene-treatment-lebers-congenital-amaurosis_en.pdf"},
    {"id":"42027","name":"EU/3/18/2008: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1 for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-17T13:00:00Z","last_updated_date":"2018-05-17T13:00:00Z","reference_number":"EMA/184161/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182008-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-encoding-mirna-against-human-superoxide-dismutase-1-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"42033","name":"EU/3/16/1780: Public summary of positive opinion for orphan designation of ibrutinib for the treatment of graft-versus-host disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T15:36:00Z","last_updated_date":"2021-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161780-public-summary-positive-opinion-orphan-designation-ibrutinib-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"42259","name":"EU/3/18/2044: Public summary of orphan designation: Allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded for the treatment of graft-versus-host disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T12:48:00Z","last_updated_date":"2018-10-10T12:48:00Z","reference_number":"EMA/453202/2018 Corr. 2","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182044-public-summary-orphan-designation-allogeneic-bone-marrow-derived-mesenchymal-stromal-cells-ex-vivo-expanded-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"42284","name":"EU/3/18/2053: Public summary of opinion on orphan designation: Tamibarotene for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-10T21:51:00Z","last_updated_date":"2018-10-10T21:51:00Z","reference_number":"EMA/452780/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182053-public-summary-opinion-orphan-designation-tamibarotene-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"42285","name":"EU/3/18/2045: Public summary of opinion on orphan designation: Ex-vivo fused autologous human bone marrow-derived mesenchymal stem cell with allogenic human myoblast for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-10T22:03:00Z","last_updated_date":"2018-10-10T22:03:00Z","reference_number":"EMA/468680/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182045-public-summary-opinion-orphan-designation-ex-vivo-fused-autologous-human-bone-marrow-derived-mesenchymal-stem-cell-allogenic-human-myoblast-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"42286","name":"EU/3/18/2051: Public summary of opinion on orphan designation: Synthetic antisense oligonucleotide directed against human dystrophin pre-mRNA for treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-10T22:11:00Z","last_updated_date":"2018-10-10T22:11:00Z","reference_number":"EMA/468719/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182051-public-summary-opinion-orphan-designation-synthetic-antisense-oligonucleotide-directed-against-human-dystrophin-pre-mrna-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"42287","name":"EU/3/18/2043: Public summary of opinion on orphan designation: Combination of carboplatin and sodium valproate for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T09:36:00Z","last_updated_date":"2018-10-11T09:36:00Z","reference_number":"EMA/437307/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182043-public-summary-opinion-orphan-designation-combination-carboplatin-and-sodium-valproate-treatment-glioma_en.pdf"},
    {"id":"42288","name":"EU/3/18/2054: Public summary of opinion on orphan designation: Tetracosactide for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T09:47:00Z","last_updated_date":"2018-10-11T09:47:00Z","reference_number":"EMA/468032/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182054-public-summary-opinion-orphan-designation-tetracosactide-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"42289","name":"EU/3/18/2050: Public summary of opinion on orphan designation: Selumetinib for the treatment of neurofibromatosis type 1","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T09:56:00Z","last_updated_date":"2018-10-11T09:56:00Z","reference_number":"EMA/464911/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182050-public-summary-opinion-orphan-designation-selumetinib-treatment-neurofibromatosis-type-1_en.pdf"},
    {"id":"42290","name":"EU/3/18/2042: Public summary of opinion on orphan designation: Adenovirus associated viral vector serotype 2/8 containing the human CNGA3 gene for the treatment of achromatopsia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T10:03:00Z","last_updated_date":"2018-10-11T10:03:00Z","reference_number":"EMA/470290/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182042-public-summary-opinion-orphan-designation-adenovirus-associated-viral-vector-serotype-28-containing-human-cnga3-gene-treatment-achromatopsia_en.pdf"},
    {"id":"42291","name":"EU/3/18/2041: Public summary of opinion on orphan designation: 2ʹ-O-(2-methoxyethyl) antisense oligonucleotide targeting microtubule-associated protein tau pre-mRNA for the treatment of behavioural variant frontotemporal dementia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T09:10:00Z","last_updated_date":"2018-10-11T09:10:00Z","reference_number":"EMA/470356/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-18-2041-public-summary-opinion-orphan-designation-2-o-2-methoxyethyl-antisense-oligonucleotide-targeting-microtubule-associated-protein-tau-pre-mrna-treatment-behavioural-variant-frontotemporal_en.pdf"},
    {"id":"42292","name":"EU/3/18/2048: Public summary of opinion on orphan designation: N-acetylgalactosamine-conjugated synthetic double-stranded oligomer specific to serpin family A member 1 gene for the treatment of congenital alpha-1 antitrypsin deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T11:35:00Z","last_updated_date":"2018-10-11T11:35:00Z","reference_number":"EMA/454554/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182048-public-summary-opinion-orphan-designation-n-acetylgalactosamine-conjugated-synthetic-double-stranded-oligomer-specific-serpin-family-member-1-gene-treatment-congenital-alpha-1-antitrypsin_en.pdf"},
    {"id":"42293","name":"EU/3/18/2052: Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T11:41:00Z","last_updated_date":"2018-10-11T11:41:00Z","reference_number":"EMA/451140/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182052-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-lactate-dehydrogenase-mrna-and-containing-four-modified-nucleosides-which-form_en.pdf"},
    {"id":"42294","name":"EU/3/18/2046: Public summary of opinion on orphan designation: Givinostat for the treatment of Becker muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T11:49:00Z","last_updated_date":"2018-10-11T11:49:00Z","reference_number":"EMA/465065/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182046-public-summary-opinion-orphan-designation-givinostat-treatment-becker-muscular-dystrophy_en.pdf"},
    {"id":"42295","name":"Public summary of negative opinion for orphan designation of melatonin for the treatment of non-traumatic subarachnoid haemorrhage","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T12:03:00Z","last_updated_date":"2018-10-11T12:03:00Z","reference_number":"EMA/138943/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-melatonin-treatment-non-traumatic-subarachnoid-haemorrhage_en.pdf"},
    {"id":"42296","name":"EU/3/16/1800: Public summary of opinion on orphan designation: Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1 for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T12:08:00Z","last_updated_date":"2018-10-11T12:08:00Z","reference_number":"EMA/454552/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3161800-public-summary-opinion-orphan-designation-recombinant-human-ectonucleotide-pyrophosphatasephosphodiesterase-1-fused-fc-fragment-igg1-treatment-ectonucleotide-pyrophosphatasephosphodiesterase_en.pdf"},
    {"id":"42297","name":"EU/3/18/2047: Public summary of opinion on orphan designation: Liposomal mannose-1-phosphate for the treatment of phosphomannomutase 2-congenital disorder of glycosylation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-11T12:20:00Z","last_updated_date":"2018-10-11T12:20:00Z","reference_number":"EMA/438554/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182047-public-summary-opinion-orphan-designation-liposomal-mannose-1-phosphate-treatment-phosphomannomutase-2-congenital-disorder-glycosylation_en.pdf"},
    {"id":"43155","name":"EU/3/18/2077: Public summary of opinion on orphan designation: Melatonin for the treatment of acute radiation syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T13:32:00Z","last_updated_date":"2018-12-19T13:32:00Z","reference_number":"EMA/678539/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182077-public-summary-opinion-orphan-designation-melatonin-treatment-acute-radiation-syndrome_en.pdf"},
    {"id":"43158","name":"EU/3/18/2066: Public summary of opinion on orphan designation: Pemigatinib for the treatment of biliary tract cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T13:55:00Z","last_updated_date":"2018-12-19T13:55:00Z","reference_number":"EMA/532482/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182066-public-summary-opinion-orphan-designation-pemigatinib-treatment-biliary-tract-cancer_en.pdf"},
    {"id":"43159","name":"EU/3/18/2069: Public summary of opinion on orphan designation: Tilorone for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T14:10:00Z","last_updated_date":"2018-12-19T14:10:00Z","reference_number":"EMA/521619/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182069-public-summary-opinion-orphan-designation-tilorone-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"43160","name":"EU/3/18/2068: Public summary of opinion on orphan designation: Somapacitan for the treatment of growth hormone deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T14:30:00Z","last_updated_date":"2018-12-19T14:30:00Z","reference_number":"EMA/534113/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182068-public-summary-opinion-orphan-designation-somapacitan-treatment-growth-hormone-deficiency_en.pdf"},
    {"id":"43162","name":"EU/3/18/2067: Public summary of opinion on orphan designation: Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1 for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T15:29:00Z","last_updated_date":"2018-12-19T15:29:00Z","reference_number":"EMA/534117/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182067-public-summary-opinion-orphan-designation-recombinant-human-ectonucleotide-pyrophosphatasephosphodiesterase-1-fused-fc-fragment-igg1-treatment-ectonucleotide-pyrophosphatasephosphodiesterase_en.pdf"},
    {"id":"43163","name":"EU/3/18/2061: Public summary of opinion on orphan designation: Autologous glioma tumour cells treated with antisense molecule directed against the insulin-like growth factor type 1 receptor for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T16:44:00Z","last_updated_date":"2018-12-19T16:44:00Z","reference_number":"EMA/514590/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182061-public-summary-opinion-orphan-designation-autologous-glioma-tumour-cells-treated-antisense-molecule-directed-against-insulin-growth-factor-type-1-receptor-treatment-glioma_en.pdf"},
    {"id":"43164","name":"EU/3/18/2057: Public summary of opinion on orphan designation: 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt for the treatment of acute myeloid le","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T16:51:00Z","last_updated_date":"2022-11-22T15:35:00Z","reference_number":"EMA/521611/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182057-public-summary-opinion-orphan-designation-1-2-hydroxyethyl-8-5-4-methylpiperazin-1-yl-2-trifluoromethoxy-phenylamino-45-dihydro-1h-pyrazolo43-hquinazoline-3-carboxamide-fumarate-salt_en.pdf"},
    {"id":"43166","name":"EU/3/18/2055: Public summary of opinion on orphan designation: (3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T17:12:00Z","last_updated_date":"2018-12-19T17:12:00Z","reference_number":"EMA/514601/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182055-public-summary-opinion-orphan-designation-3r3as9r9as9bs-3-dimethylaminomethyl-9-hydroxy-69-dimethyl-33a457899a-octahydroazuleno45-bfuran-29bh-one-fumarate-treatment-glioma_en.pdf"},
    {"id":"43167","name":"EU/3/18/2060: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype hu68 containing the human SMN1 gene for the treatment of spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T17:20:00Z","last_updated_date":"2021-01-07T09:40:00Z","reference_number":"EMA/530909/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182060-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-hu68-containing-human-smn1-gene-treatment-spinal-muscular-atrophy_en.pdf"},
    {"id":"43170","name":"EU/3/18/2064: Public summary of opinion on orphan designation: Copanlisib for the treatment of marginal zone lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T17:32:00Z","last_updated_date":"2018-12-19T17:32:00Z","reference_number":"EMA/533263/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182064-public-summary-opinion-orphan-designation-copanlisib-treatment-marginal-zone-lymphoma_en.pdf"},
    {"id":"43171","name":"EU/3/18/2056: Public summary of opinion on orphan designation: (S)-(−)ypropanoic acid for the treatment of idiopathic pulmonary fibro-3-(4-aminophenyl)-2-methoxsis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T17:38:00Z","last_updated_date":"2018-12-19T17:38:00Z","reference_number":"EMA/521616/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-18-2056-public-summary-opinion-orphan-designation-s-ypropanoic-acid-treatment-idiopathic-pulmonary-fibro-3-4-aminophenyl-2-methoxsis_en.pdf"},
    {"id":"43173","name":"EU/3/18/2065: Public summary of opinion on orphan designation: Obiltoxaximab for the treatment of anthrax","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T17:47:00Z","last_updated_date":"2018-12-19T17:47:00Z","reference_number":"EMA/532463/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182065-public-summary-opinion-orphan-designation-obiltoxaximab-treatment-anthrax_en.pdf"},
    {"id":"43186","name":"EU/3/18/2063: Public summary of opinion on orphan designation: CD34+ haematopoietic stem and progenitor cells with CD3+ T-cells for treatment in solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-20T10:09:00Z","last_updated_date":"2018-12-20T10:09:00Z","reference_number":"EMA/533264/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182063-public-summary-opinion-orphan-designation-cd34-haematopoietic-stem-and-progenitor-cells-cd3-t-cells-treatment-solid-organ-transplantation_en.pdf"},
    {"id":"43187","name":"EU/3/18/2059: Public summary of opinion on orphan designation: Acetylleucine for the treatment of spinocerebellar ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-20T10:19:00Z","last_updated_date":"2018-12-20T10:19:00Z","reference_number":"EMA/530908/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182059-public-summary-opinion-orphan-designation-acetylleucine-treatment-spinocerebellar-ataxia_en.pdf"},
    {"id":"43188","name":"EU/3/18/2062: Public summary of opinion on orphan designation: Bertilimumab for the treatment of bullous pemphigoid","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-20T10:27:00Z","last_updated_date":"2018-12-20T10:27:00Z","reference_number":"EMA/533268/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182062-public-summary-opinion-orphan-designation-bertilimumab-treatment-bullous-pemphigoid_en.pdf"},
    {"id":"43189","name":"EU/3/18/2052: Public summary of opinion on orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-12-20T10:36:00Z","last_updated_date":"2022-10-21T10:46:00Z","reference_number":"EMA/530846/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182052-public-summary-opinion-orphan-designation-1-3-methylbutanoyl-l-aspartyl-l-threonyl-l-histidyl-l-phenylalanyl-l-prolyl-l-cystinyl-l-isoleucyl-n6-s-4-carboxy-4-palmitamidobutanoyl-l-lysinyl-l_en.pdf"},
    {"id":"43211","name":"EU/3/18/2074: Public summary of opinion on orphan designation: Avapritinib for the treatment of mastocytosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-04T13:05:00Z","last_updated_date":"2019-01-04T13:05:00Z","reference_number":"EMA/674141/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182074-public-summary-opinion-orphan-designation-avapritinib-treatment-mastocytosis_en.pdf"},
    {"id":"43305","name":"EU/3/18/2075: Public summary of positive opinion for orphan designation: Gefinitib for the treatment of Fanconi anaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-10T16:07:00Z","last_updated_date":"2019-01-10T16:07:00Z","reference_number":"EMA/674771/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182075-public-summary-positive-opinion-orphan-designation-gefinitib-treatment-fanconi-anaemia_en.pdf"},
    {"id":"43306","name":"EU/3/18/2078: Public summary of opinion on orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG for treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-10T16:27:00Z","last_updated_date":"2019-01-10T16:27:00Z","reference_number":"EMA/678538/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182078-public-summary-opinion-orphan-designation-peptides-ymfpnapyl-sgqaymfpnapylpscles-rsdelvrhhnmhqrnmtkl-and-pgcnkryfklshlqmhsrkhtg-treatment-multiple-myeloma_en.pdf"},
    {"id":"43307","name":"EU/3/18/2076: Public summary of opinion on orphan designation: Glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan..","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-10T16:41:00Z","last_updated_date":"2020-02-03T17:08:00Z","reference_number":"EMA/658184/2018 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182076-public-summary-opinion-orphan-designation-glycine-l-alanine-l-arginine-l-aspartic-acid-l-cysteine-l-glutamic-acid-l-histidine-l-lysine-monohydrate-l-methionine-l-phenylalanine-l-proline-l_en.pdf"},
    {"id":"43308","name":"EU/3/18/2079: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coag...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-10T17:06:00Z","last_updated_date":"2019-01-10T17:06:00Z","reference_number":"EMA/661289/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182079-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-containing-bioengineered-capsid-and-codon-optimised-expression-cassette-drive-expression-sq-form-b-domain_en.pdf"},
    {"id":"43309","name":"EU/3/18/2073: Public summary of opinion on orphan designation: Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA for the treatment of mucopolysac...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-10T17:43:00Z","last_updated_date":"2019-01-10T17:43:00Z","reference_number":"EMA/650328/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182073-public-summary-opinion-orphan-designation-autologous-cd34-haematopoietic-stem-and-progenitor-cells-genetically-modified-lentiviral-vector-idua-lv-encoding-alpha-l-iduronidase-cdna-treatment_en.pdf"},
    {"id":"43310","name":"EU/3/18/2070: Public summary of opinion on orphan designation: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid for the treatment of dermatomyositis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-10T17:51:00Z","last_updated_date":"2019-01-10T17:51:00Z","reference_number":"EMA/688517/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182070-public-summary-opinion-orphan-designation-6ar10ar-3-11-dimethylheptyl-delta8-tetrahydro-cannabinol-9-carboxylic-acid-treatment-dermatomyositis_en.pdf"},
    {"id":"43311","name":"EU/3/18/2071: Public summary of opinion on orphan designation: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile for the treatment of medullary t...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T10:53:00Z","last_updated_date":"2019-01-11T10:53:00Z","reference_number":"EMA/680129/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182071-public-summary-opinion-orphan-designation-6-2-hydroxy-2-methylpropoxy-4-6-6-6-methoxypyridin-3-ylmethyl-36-diazabicyclo311heptan-3-ylpyridin-3-ylpyrazolo15-apyridine-3-carbonitrile-treatment_en.pdf"},
    {"id":"43314","name":"EU/3/18/2080: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T11:11:00Z","last_updated_date":"2019-01-11T11:11:00Z","reference_number":"EMA/667696/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182080-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-serotype-s3-containing-codon-optimised-expression-cassette-encoding-human-coagulation-factor-ix-variant_en.pdf"},
    {"id":"43318","name":"(2018)2354: Public summary of negative opinion for orphan designation: Autologous skeletal myoblasts expanded ex vivo for the treatment of oculopharyngeal muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T11:20:00Z","last_updated_date":"2019-01-11T11:20:00Z","reference_number":"EMA/689216/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/20182354-public-summary-negative-opinion-orphan-designation-autologous-skeletal-myoblasts-expanded-ex-vivo-treatment-oculopharyngeal-muscular-dystrophy_en.pdf"},
    {"id":"43325","name":"EU/3/18/2072: Public summary of opinion on orphan designation: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T11:44:00Z","last_updated_date":"2019-01-11T11:44:00Z","reference_number":"EMA/680124/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182072-public-summary-opinion-orphan-designation-6-r-methyl-5-o-5-amino-56-dideoxy-alpha-l-talofuranosyl-paromamine-sulfate-treatment-cystic-fibrosis_en.pdf"},
    {"id":"43706","name":"EU/3/18/2096: Public summary of opinion on orphan designation: Imlifidase for the treatment of anti-glomerular basement membrane disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-13T16:13:00Z","last_updated_date":"2019-02-13T16:13:00Z","reference_number":"EMA/770508/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182096-public-summary-opinion-orphan-designation-imlifidase-treatment-anti-glomerular-basement-membrane-disease_en.pdf"},
    {"id":"43794","name":"EU/3/18/2082: Public summary of opinion on orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride for the treatment of Kabuki syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T13:15:00Z","last_updated_date":"2022-11-22T14:44:00Z","reference_number":"EMA/765042/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182082-public-summary-opinion-orphan-designation-5-1r2r-2-cyclopropylmethylaminocyclopropyl-n-tetrahydro-2h-pyran-4-ylthiophene-3-carboxamide-monohydrochloride-treatment-kabuki-syndrome_en.pdf"},
    {"id":"43798","name":"EU/3/18/2081: Public summary of opinion on orphan designation: 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T13:44:00Z","last_updated_date":"2019-02-19T13:44:00Z","reference_number":"EMA/762979/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182081-public-summary-opinion-orphan-designation-3-3-35-dimethyl-1h-pyrazol-4-ylpropoxy-4-fluorobenzoic-acid_en.pdf"},
    {"id":"43801","name":"EU/3/18/2100: Public summary of opinion on orphan designation: Propagermanium for the treatment of focal segmental glomerulosclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T15:20:00Z","last_updated_date":"2019-02-19T15:20:00Z","reference_number":"EMA/760205/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182100-public-summary-opinion-orphan-designation-propagermanium-treatment-focal-segmental-glomerulosclerosis_en.pdf"},
    {"id":"43802","name":"EU/3/18/2086: Public summary of opinion on orphan designation: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-glutamyl-L-threonyl]acetate for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T15:44:00Z","last_updated_date":"2019-02-19T15:44:00Z","reference_number":"EMA/750426/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182086-public-summary-opinion-orphan-designation-cyclol-alanyl-l-seryl-l-isoleucyl-l-prolyl-l-prolyl-l-glutaminyl-l-lysyl-l-tyrosyl-d-prolyl-l-prolyl-2s-2-aminodecanoyl-l-glutamyl-l-threonylacetate_en.pdf"},
    {"id":"43803","name":"EU/3/18/2091: Public summary of opinion on orphan designation: Glucagon for the treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T16:10:00Z","last_updated_date":"2019-02-19T16:10:00Z","reference_number":"EMA/769575/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182091-public-summary-opinion-orphan-designation-glucagon-treatment-noninsulinoma-pancreatogenous-hypoglycaemia-syndrome_en.pdf"},
    {"id":"43804","name":"EU/3/18/2093: Public summary of opinion on orphan designation: Human apotransferrin for the treatment of beta-thalassaemia intermedia and major","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T16:28:00Z","last_updated_date":"2019-02-19T16:28:00Z","reference_number":"EMA/776428/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182093-public-summary-opinion-orphan-designation-human-apotransferrin-treatment-beta-thalassaemia-intermedia-and-major_en.pdf"},
    {"id":"43806","name":"EU/3/18/2090: Public summary of opinion on orphan designation: Fidanacogene elaparvovec for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T17:21:00Z","last_updated_date":"2019-02-19T17:21:00Z","reference_number":"EMA/755561/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182090-public-summary-opinion-orphan-designation-fidanacogene-elaparvovec-treatment-haemophilia-b_en.pdf"},
    {"id":"43808","name":"EU/3/18/2102: Public summary of opinion on orphan designation: Apraglutide for the treatment of short bowel syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T17:52:00Z","last_updated_date":"2019-02-19T17:52:00Z","reference_number":"EMA/747281/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182102-public-summary-opinion-orphan-designation-apraglutide-treatment-short-bowel-syndrome_en.pdf"},
    {"id":"43809","name":"EU/3/18/2097: Public summary of opinion on orphan designation: Larotrectinib for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T18:19:00Z","last_updated_date":"2019-10-24T17:00:00Z","reference_number":"EMA/776178/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182097-public-summary-opinion-orphan-designation-larotrectinib-treatment-glioma_en.pdf"},
    {"id":"43816","name":"EU/3/18/2085: Public summary of opinion on orphan designation: Autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:12:00Z","last_updated_date":"2019-02-20T12:12:00Z","reference_number":"EMA/747621/2018 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182085-public-summary-opinion-orphan-designation-autologous-human-adipose-perivascular-stromal-cells-genetically-modified-secrete-soluble-tumour-necrosis-factor-related-apoptosis-inducing-ligand_en.pdf"},
    {"id":"43886","name":"EU/3/18/2098: Public summary of opinion on orphan designation: Larotrectinib for the treatment of papillary thyroid cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-02-22T11:37:00Z","last_updated_date":"2019-10-24T17:00:00Z","reference_number":"EMA/776179/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182098-public-summary-opinion-orphan-designation-larotrectinib-treatment-papillary-thyroid-cancer_en.pdf"},
    {"id":"43887","name":"EU/3/18/2083: Public summary of opinion on orphan designation: Allogeneic faecal microbiota, pooled for the treatment of graft-versus-host disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T11:59:00Z","last_updated_date":"2019-02-25T11:59:00Z","reference_number":"EMA/763197/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182083-public-summary-opinion-orphan-designation-allogeneic-faecal-microbiota-pooled-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"43888","name":"EU/3/18/2099: Public summary of opinion on orphan designation: Lisocabtagene maraleucel for the treatment of primary mediastinal large B-cell lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T12:22:00Z","last_updated_date":"2022-02-21T13:35:00Z","reference_number":"EMA/759232/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182099-public-summary-opinion-orphan-designation-lisocabtagene-maraleucel-treatment-primary-mediastinal-large-b-cell-lymphoma_en.pdf"},
    {"id":"43889","name":"EU/3/18/2094: Public summary of opinion on orphan designation: Anti-GD2 monoclonal antibody 3F8 humanised for the treatment of neuroblastoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T12:34:00Z","last_updated_date":"2019-02-25T12:34:00Z","reference_number":"EMA/769941/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182094-public-summary-opinion-orphan-designation-anti-gd2-monoclonal-antibody-3f8-humanised-treatment-neuroblastoma_en.pdf"},
    {"id":"43890","name":"EU/3/18/2089: Public summary of opinion on orphan designation: Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T12:44:00Z","last_updated_date":"2019-02-25T12:44:00Z","reference_number":"EMA/754017/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182089-public-summary-opinion-orphan-designation-ex-vivo-fused-normal-allogeneic-human-myoblast-autologous-human-myoblast-derived-duchenne-muscular-dystrophy-affected-donor-treatment-duchenne_en.pdf"},
    {"id":"43891","name":"EU/3/18/2088: Public summary of opinion on orphan designation: Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T13:13:00Z","last_updated_date":"2019-02-25T13:13:00Z","reference_number":"EMA/754015/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182088-public-summary-opinion-orphan-designation-ex-vivo-fused-normal-allogeneic-human-myoblast-another-normal-allogeneic-human-myoblast-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"43892","name":"EU/3/18/2087: Public summary of opinion on orphan designation: Etamsylate for the treatment of hereditary haemorrhagic telangiectasia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T13:23:00Z","last_updated_date":"2019-02-25T13:23:00Z","reference_number":"EMA/750060/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182087-public-summary-opinion-orphan-designation-etamsylate-treatment-hereditary-haemorrhagic-telangiectasia_en.pdf"},
    {"id":"43894","name":"EU/3/18/2092: Public summary of opinion on orphan designation: H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-213-bismuth for the treatment of glioma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T15:21:00Z","last_updated_date":"2019-02-25T15:21:00Z","reference_number":"EMA/776530/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182092-public-summary-opinion-orphan-designation-h-arg-pro-lys-pro-gln-gln-phe-2thi-gly-leu-meto2-nh2-dota-213-bismuth-treatment-glioma_en.pdf"},
    {"id":"43895","name":"EU/3/18/2095: Public summary of opinion on orphan designation: Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp for the treatment of multiple system atrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T15:33:00Z","last_updated_date":"2019-02-25T15:33:00Z","reference_number":"EMA/776496/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182095-public-summary-opinion-orphan-designation-ile-ser-ile-thr-glu-ile-lys-gly-val-ile-val-his-arg-ile-glu-thr-ile-leu-phe-lys-lys-lys-lys-glu-met-pro-ser-glu-glu-gly-tyr-gln-asp-treatment_en.pdf"},
    {"id":"43896","name":"EU/3/18/2084: Public summary of opinion on orphan designation: Anetumab ravtansine for the treatment of ovarian cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T15:43:00Z","last_updated_date":"2022-02-01T11:19:00Z","reference_number":"EMA/765821/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182084-public-summary-opinion-orphan-designation-anetumab-ravtansine-treatment-ovarian-cancer_en.pdf"},
    {"id":"43985","name":"EU/3/18/2115: Public summary of opinion on orphan designation: Human anti-promyostatin monoclonal antibody for the treatment of spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-07T09:56:00Z","last_updated_date":"2019-03-07T09:56:00Z","reference_number":"EMA/832992/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182115-public-summary-opinion-orphan-designation-human-anti-promyostatin-monoclonal-antibody-treatment-spinal-muscular-atrophy_en.pdf"},
    {"id":"43986","name":"EU/3/18/2117: Public summary of opinion on orphan designation: Ivacaftor, potassium(benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl) cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide, tezacaftor","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-07T11:11:00Z","last_updated_date":"2019-03-07T11:11:00Z","reference_number":"EMA/828863/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182117-public-summary-opinion-orphan-designation-ivacaftor-potassiumbenzenesulfonyl6-3-2-1-trifluoromethyl-cyclopropylethoxy-1h-pyrazol-1-yl-2-4s-224-trimethylpyrrolidin-1-ylpyridin-3_en.pdf"},
    {"id":"43987","name":"EU/3/18/2116: Public summary of opinion on orphan designation: Ivacaftor, N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, tezacaftor","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-07T11:47:00Z","last_updated_date":"2019-03-07T11:47:00Z","reference_number":"EMA/828204/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182116-public-summary-opinion-orphan-designation-ivacaftor-n-13-dimethyl-1h-pyrazole-4-sulfonyl-6-3-333-trifluoro-22-dimethylpropoxy-1h-pyrazol-1-yl-2-4s-224-trimethylpyrrolidin-1-ylpyridine-3_en.pdf"},
    {"id":"43988","name":"EU/3/18/2108: Public summary of opinion on orphan designation: Adeno-associated viral vector expressing human 21-hydroxylase","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-07T11:52:00Z","last_updated_date":"2019-03-07T11:52:00Z","reference_number":"EMA/818775/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182108-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-expressing-human-21-hydroxylase_en.pdf"},
    {"id":"43992","name":"EU/3/18/2110: Public summary of opinion on orphan designation: Afatinib for the treatment of Fanconi anaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-08T10:06:00Z","last_updated_date":"2019-03-08T10:06:00Z","reference_number":"EMA/829563/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182110-public-summary-opinion-orphan-designation-afatinib-treatment-fanconi-anaemia_en.pdf"},
    {"id":"43993","name":"EU/3/18/2121: Public summary of opinion on orphan designation: Sodium 2-hydroxylinoleate for the treatment of biliary tract cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-08T10:22:00Z","last_updated_date":"2019-03-08T10:22:00Z","reference_number":"EMA/833241/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182121-public-summary-opinion-orphan-designation-sodium-2-hydroxylinoleate-treatment-biliary-tract-cancer_en.pdf"},
    {"id":"43994","name":"EU/3/18/2113: Public summary of opinion on orphan designation: Bromelain for the treatment of pseudomyxoma peritonei","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-08T10:32:00Z","last_updated_date":"2019-03-08T10:32:00Z","reference_number":"EMA/818577/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182113-public-summary-opinion-orphan-designation-bromelain-treatment-pseudomyxoma-peritonei_en.pdf"},
    {"id":"43996","name":"EU/3/18/2107: Public summary of opinion on orphan designation: Acetylcysteine for the treatment of pseudomyxoma peritonei","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-08T11:50:00Z","last_updated_date":"2019-03-08T11:50:00Z","reference_number":"EMA/818573/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182107-public-summary-opinion-orphan-designation-acetylcysteine-treatment-pseudomyxoma-peritonei_en.pdf"},
    {"id":"43997","name":"EU/3/18/2109: Public summary of opinion on orphan designation: Adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylase for the treatment of phenylalanine hydroxylase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-08T12:49:00Z","last_updated_date":"2023-08-08T13:08:00Z","reference_number":"EMA/830775/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182109-public-summary-opinion-orphan-designation-adeno-associated-virus-serotype-hsc15-expressing-human-phenylalanine-hydroxylase-treatment-phenylalanine-hydroxylase-deficiency_en.pdf"},
    {"id":"44002","name":"EU/3/18/2112: Public summary of opinion on orphan designation: Bifunctional fusion protein composed of two extracellular domains of transforming growth factor beta receptor II fused with a human immunoglobulin G1 monoclonal antibody","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-11T09:24:00Z","last_updated_date":"2022-02-07T08:45:00Z","reference_number":"EMA/838048/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182112-public-summary-opinion-orphan-designation-bifunctional-fusion-protein-composed-two-extracellular-domains-transforming-growth-factor-beta-receptor-ii-fused-human-immunoglobulin-g1-monoclonal_en.pdf"},
    {"id":"44003","name":"EU/3/18/2111: Public summary of opinion on orphan designation: Allogeneic ABCB5-positive limbal stem cells for the treatment of limbal stem cell deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-11T09:48:00Z","last_updated_date":"2019-03-11T09:48:00Z","reference_number":"EMA/833462/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182111-public-summary-opinion-orphan-designation-allogeneic-abcb5-positive-limbal-stem-cells-treatment-limbal-stem-cell-deficiency_en.pdf"},
    {"id":"44004","name":"EU/3/18/2104: Public summary of opinion on orphan designation: (4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1)) for treatment of C3 glomerulopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-11T10:07:00Z","last_updated_date":"2019-03-11T10:07:00Z","reference_number":"EMA/830788/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182104-public-summary-opinion-orphan-designation-4-2s4s-4-ethoxy-1-5-methoxy-7-methyl-1h-indol-4-ylmethylpiperidin-2-ylbenzoic-acid-hydrogen-chloride11-treatment-c3-glomerulopathy_en.pdf"},
    {"id":"44005","name":"EU/3/18/2118: Public summary of opinion on orphan designation: Lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-11T10:14:00Z","last_updated_date":"2019-03-11T10:14:00Z","reference_number":"EMA/806419/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182118-public-summary-opinion-orphan-designation-lonafarnib-treatment-hutchinson-gilford-progeria-syndrome_en.pdf"},
    {"id":"44007","name":"EU/3/18/2119: Public summary of opinion on orphan designation: Marizomib for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-12T10:57:00Z","last_updated_date":"2019-03-12T10:57:00Z","reference_number":"EMA/806418/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182119-public-summary-opinion-orphan-designation-marizomib-treatment-glioma_en.pdf"},
    {"id":"44008","name":"EU/3/18/2103: Public summary of opinion on orphan designation: (2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-12T11:29:00Z","last_updated_date":"2019-03-12T11:29:00Z","reference_number":"EMA/830039/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182103-public-summary-opinion-orphan-designation-2s-2-2r-2-33-dibutyl-7-methylthio-11-dioxido-5-phenyl-2345-tetrahydro-125-benzothiadiazepin-8-yloxyacetylamino-2-4-hydroxyphenylacetylaminobutanoic_en.pdf"},
    {"id":"44009","name":"EU/3/18/2105: Public summary of opinion on orphan designation: 6,8-bis(benzylthio)octanoic acid for treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-12T11:43:00Z","last_updated_date":"2019-03-12T11:43:00Z","reference_number":"EMA/840548/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182105-public-summary-opinion-orphan-designation-68-bisbenzylthiooctanoic-acid-treatment-pancreatic-cancer_en.pdf"}    {"id":"44010","name":"EU/3/18/2123: Public summary of opinion on orphan designation: 6,8-bis(benzylthio)octanoic acid for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-12T12:05:00Z","last_updated_date":"2019-03-12T12:05:00Z","reference_number":"EMA/841154/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182123-public-summary-opinion-orphan-designation-68-bisbenzylthiooctanoic-acid-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"44011","name":"EU/3/18/2106: Public summary of opinion on orphan designation: 6-fluoro-9-methyl-9H-pyrido[3,4-b]-indole for the treatment of sudden sensorineural hearing loss","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-12T14:24:00Z","last_updated_date":"2019-03-12T14:24:00Z","reference_number":"EMA/830798/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182106-public-summary-opinion-orphan-designation-6-fluoro-9-methyl-9h-pyrido34-b-indole-treatment-sudden-sensorineural-hearing-loss_en.pdf"},
    {"id":"44012","name":"EU/3/18/2114: Public summary of opinion on orphan designation: C1 esterase inhibitor (human) for treatment in solid organ transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-12T14:33:00Z","last_updated_date":"2019-03-12T14:33:00Z","reference_number":"EMA/840912/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182114-public-summary-opinion-orphan-designation-c1-esterase-inhibitor-human-treatment-solid-organ-transplantation_en.pdf"},
    {"id":"44117","name":"EU/3/18/2126: Public summary of opinion on orphan designation: Human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment for the treatment of short bowel syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T14:51:00Z","last_updated_date":"2019-03-27T14:51:00Z","reference_number":"EMADOC-628903358-224","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182126-public-summary-opinion-orphan-designation-human-glucagon-peptide-2-analogue-linked-human-immunoglobulin-fc-fragment-treatment-short-bowel-syndrome_en.pdf"},
    {"id":"44118","name":"EU/3/18/2125: Public summary of opinion on orphan designation: Benserazide hydrochloride for treatment of sickle cell disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T15:06:00Z","last_updated_date":"2019-03-27T15:06:00Z","reference_number":"EMADOC-628903358-223","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182125-public-summary-opinion-orphan-designation-benserazide-hydrochloride-treatment-sickle-cell-disease_en.pdf"},
    {"id":"44119","name":"EU/3/18/2124: Public summary of opinion on orphan designation: Acetylleucine for treatment of ataxia telangiectasia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T15:22:00Z","last_updated_date":"2019-03-27T15:22:00Z","reference_number":"EMADOC-628903358-222","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182124-public-summary-opinion-orphan-designation-acetylleucine-treatment-ataxia-telangiectasia_en.pdf"},
    {"id":"44121","name":"EU/3/18/2132: Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues for the treatment of beta-thalas","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T15:40:00Z","last_updated_date":"2019-03-27T15:40:00Z","reference_number":"EMADOC-628903358-225","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182132-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-tmprss6-mrna-and-covalently-linked-ligand-containing-three-n-acetylgalactosamine_en.pdf"},
    {"id":"44122","name":"EU/3/18/2127: Public summary of opinion on orphan designation: Melatonin for the treatment of perinatal asphyxia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T15:50:00Z","last_updated_date":"2019-03-27T15:50:00Z","reference_number":"EMADOC-628903358-228","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182127-public-summary-opinion-orphan-designation-melatonin-treatment-perinatal-asphyxia_en.pdf"},
    {"id":"44125","name":"EU/3/18/2133: Public summary of opinion on orphan designation: Vinorelbine tartrate for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T16:42:00Z","last_updated_date":"2019-03-27T16:42:00Z","reference_number":"EMADOC-628903358-229","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182133-public-summary-opinion-orphan-designation-vinorelbine-tartrate-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"44126","name":"EU/3/18/2131: Public summary of opinion on orphan designation: Rozanolixizumab for the treatment of immune thrombocytopenia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T16:50:00Z","last_updated_date":"2023-05-08T10:05:00Z","reference_number":"EMADOC-628903358-230","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182131-public-summary-opinion-orphan-designation-rozanolixizumab-treatment-immune-thrombocytopenia_en.pdf"},
    {"id":"44127","name":"EU/3/18/2130: Public summary of opinion on orphan designation: Ralinepag for the treatment of pulmonary arterial hypertension","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T17:05:00Z","last_updated_date":"2019-03-27T17:05:00Z","reference_number":"EMADOC-628903358-231","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182130-public-summary-opinion-orphan-designation-ralinepag-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"44128","name":"EU/3/18/2129: Public summary of opinion on orphan designation: Miglustat for the treatment of glycogen storage disease type II (Pompe's disease)","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T17:22:00Z","last_updated_date":"2023-03-24T13:54:00Z","reference_number":"EMADOC-628903358-232","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182129-public-summary-opinion-orphan-designation-miglustat-treatment-glycogen-storage-disease-type-ii-pompes-disease_en.pdf"},
    {"id":"44129","name":"EU/3/18/2128: Public summary of opinion on orphan designation: Mercaptamine-pantetheine disulfide for the treatment of Rett syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T17:40:00Z","last_updated_date":"2019-03-27T17:40:00Z","reference_number":"EMADOC-628903358-233","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3182128-public-summary-opinion-orphan-designation-mercaptamine-pantetheine-disulfide-treatment-rett-syndrome_en.pdf"},
    {"id":"44189","name":"EU/3/19/2143: Public summary of opinion on orphan designation for lurbinectedin for the treatment of small cell lung cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T09:26:00Z","last_updated_date":"2019-04-09T09:26:00Z","reference_number":"EMADOC-628903358-445","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192143-public-summary-opinion-orphan-designation-lurbinectedin-treatment-small-cell-lung-cancer_en.pdf"},
    {"id":"44191","name":"EU/3/19/2139: Public summary of opinion on orphan designation for autologous adult live cultured osteoblasts for the treatment of non-traumatic osteonecrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T10:11:00Z","last_updated_date":"2019-04-09T10:11:00Z","reference_number":"EMADOC-628903358-443","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192139-public-summary-opinion-orphan-designation-autologous-adult-live-cultured-osteoblasts-treatment-non-traumatic-osteonecrosis_en.pdf"},
    {"id":"44192","name":"EU/3/19/2140: Public summary of opinion on orphan designation for humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase for the treatment of mucopolysaccharidosis type II (Hunter’s syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T10:36:00Z","last_updated_date":"2019-04-09T10:36:00Z","reference_number":"EMADOC-628903358-444","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192140-public-summary-opinion-orphan-designation-humanised-igg1-monoclonal-antibody-targeting-human-transferrin-receptor-conjugated-human-iduronate-2-sulfatase-treatment-mucopolysaccharidosis-type_en.pdf"},
    {"id":"44194","name":"EU/3/19/2134: Public summary of opinion on orphan designation for 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester for the treatment of infantile neuroaxonal dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T11:15:00Z","last_updated_date":"2019-04-09T11:15:00Z","reference_number":"EMADOC-628903358-447","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192134-public-summary-opinion-orphan-designation-9-cis-12-cis-1111-d2-linoleic-acid-ethyl-ester-treatment-infantile-neuroaxonal-dystrophy_en.pdf"},
    {"id":"44198","name":"EU/3/19/2141: Public summary of opinion on orphan designation for lentiviral vector encoding human coagulation factor IX for treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T16:28:00Z","last_updated_date":"2019-04-09T16:28:00Z","reference_number":"EMADOC-628903358-448","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192141-public-summary-opinion-orphan-designation-lentiviral-vector-encoding-human-coagulation-factor-ix-treatment-haemophilia-b_en.pdf"},
    {"id":"44199","name":"EU/3/19/2142: Public summary of opinion on orphan designation for losartan for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T16:40:00Z","last_updated_date":"2019-04-09T16:40:00Z","reference_number":"EMADOC-628903358-449","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192142-public-summary-opinion-orphan-designation-losartan-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"44200","name":"EU/3/19/2144: Public summary of opinion on orphan designation for poly(N-acetyl, N-arginyl)glucosamine for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T17:25:00Z","last_updated_date":"2019-04-09T17:25:00Z","reference_number":"EMADOC-628903358-451","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192144-public-summary-opinion-orphan-designation-polyn-acetyl-n-arginylglucosamine-treatment-cystic-fibrosis_en.pdf"},
    {"id":"44201","name":"EU/3/19/2135: Public summary of opinion on orphan designation for allogeneic cultured postnatal thymus-derived tissue for the treatment of DiGeorge syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T17:35:00Z","last_updated_date":"2019-04-09T17:35:00Z","reference_number":"EMADOC-628903358-452","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192135-public-summary-opinion-orphan-designation-allogeneic-cultured-postnatal-thymus-derived-tissue-treatment-digeorge-syndrome_en.pdf"},
    {"id":"44202","name":"EU/3/19/2136: Public summary of opinion on orphan designation for allogeneic cultured postnatal thymus-derived tissue for the treatment of CHARGE syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T17:58:00Z","last_updated_date":"2019-04-09T17:58:00Z","reference_number":"EMADOC-628903358-453","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192136-public-summary-opinion-orphan-designation-allogeneic-cultured-postnatal-thymus-derived-tissue-treatment-charge-syndrome_en.pdf"},
    {"id":"44203","name":"EU/3/19/2137: Public summary of opinion on orphan designation for allogeneic cultured postnatal thymus-derived tissue for the treatment of severe combined immunodeficiency due to FOXN1 deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T18:06:00Z","last_updated_date":"2019-04-09T18:06:00Z","reference_number":"EMADOC-628903358-454","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192137-public-summary-opinion-orphan-designation-allogeneic-cultured-postnatal-thymus-derived-tissue-treatment-severe-combined-immunodeficiency-due-foxn1-deficiency_en.pdf"},
    {"id":"44449","name":"EU/3/19/2146: Public summary of opinion on orphan designation: 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]-2-propen-1-one for the treatment of biliary tract cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-05-07T12:43:00Z","last_updated_date":"2019-05-07T12:43:00Z","reference_number":"EMADOC-628903358-644","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192146-public-summary-opinion-orphan-designation-1-3s-3-4-amino-3-35-dimethoxyphenylethynyl-1h-pyrazolo34-dpyrimidin-1-ylpyrrolidin-1-yl-2-propen-1-one-treatment-biliary-tract-cancer_en.pdf"},
    {"id":"44450","name":"EU/3/19/2149: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype rh10 containing the human cholesterol 24-hydroxylase gene for the treatment of Huntington's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-05-07T12:58:00Z","last_updated_date":"2019-05-07T12:58:00Z","reference_number":"EMADOC-628903358-641","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192149-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-rh10-containing-human-cholesterol-24-hydroxylase-gene-treatment-huntingtons-disease_en.pdf"},
    {"id":"44451","name":"EU/3/19/2151: Public summary of opinion on orphan designation: Marzeptacog alfa (activated) for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-05-07T14:57:00Z","last_updated_date":"2019-05-07T14:57:00Z","reference_number":"EMADOC-628903358-643","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192151-public-summary-opinion-orphan-designation-marzeptacog-alfa-activated-treatment-haemophilia-b_en.pdf"},
    {"id":"44452","name":"EU/3/19/2150: Public summary of opinion on orphan designation: Codon-optimised human cystic fibrosis transmembrane conductance","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-05-07T15:05:00Z","last_updated_date":"2023-07-21T12:44:00Z","reference_number":"EMADOC-628903358-642","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192150-public-summary-opinion-orphan-designation-codon-optimised-human-cystic-fibrosis-transmembrane-conductance_en.pdf"},
    {"id":"44453","name":"EU/3/19/2147: Public summary of opinion on orphan designation: 2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy}phenyl)-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-05-07T15:17:00Z","last_updated_date":"2019-05-07T15:17:00Z","reference_number":"EMADOC-628903358-646","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192147-public-summary-opinion-orphan-designation-2-3-2-chloro-4-5-cyclopropyl-3-26-dichlorophenyl-12-oxazol-4-ylmethoxyphenyl-3-hydroxyazetidin-1-ylpyridine-4-carboxylic-acid-2-amino-2_en.pdf"},
    {"id":"44454","name":"EU/3/19/2148: Public summary of opinion on orphan designation: 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one for the treatment of Friedreich’s ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-05-07T15:42:00Z","last_updated_date":"2019-05-07T15:42:00Z","reference_number":"EMADOC-628903358-645","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192148-public-summary-opinion-orphan-designation-4-hydroxy-6-2-4-trifluoromethylphenylethylpyridazin-32h-one-treatment-friedreichs-ataxia_en.pdf"},
    {"id":"44700","name":"EU/3/19/2152: Public summary of opinion on orphan designation: 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1h-pyrazol-1-yl)propanoic acid for the treatment of Stargardt's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-14T11:01:00Z","last_updated_date":"2023-04-13T15:53:00Z","reference_number":"EMADOC-628903358-740","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192152-public-summary-opinion-orphan-designation-3-3-35-bistrifluoromethylphenyl-1h-pyrazol-1-ylpropanoic-acid-treatment-stargardts-disease_en.pdf"},
    {"id":"44701","name":"EU/3/19/2153: Public summary of opinion on orphan designation: Autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes for the treatment of spinal cord injury","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-14T11:03:00Z","last_updated_date":"2019-06-14T11:03:00Z","reference_number":"EMADOC-628903358-741","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192153-public-summary-opinion-orphan-designation-autologous-human-bone-marrow-derived-haematopoietic-and-mesenchymal-stem-cells-depleted-erythrocytes-monocytes-and-lymphocytes-treatment-spinal-cord_en.pdf"},
    {"id":"44702","name":"EU/3/19/2154: Public summary of opinion on orphan designation: Balipodect for the treatment of fragile X syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-14T11:04:00Z","last_updated_date":"2019-06-14T11:04:00Z","reference_number":"EMADOC-628903358-742","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192154-public-summary-opinion-orphan-designation-balipodect-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"44703","name":"EU/3/19/2155: Public summary of opinion on orphan designation: Human culture expanded autologous mesenchymal stromal cells for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-14T11:05:00Z","last_updated_date":"2019-06-14T11:05:00Z","reference_number":"EMADOC-628903358-747","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192155-public-summary-opinion-orphan-designation-human-culture-expanded-autologous-mesenchymal-stromal-cells-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"44704","name":"EU/3/19/2156: Public summary of opinion on orphan designation: Modified messenger ribonucleic acid encoding human propionyl-coenzyme A carboxylase alpha and beta subunits encapsulated into lipid nanoparticle for the treatment of propionic acidaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-14T11:06:00Z","last_updated_date":"2019-06-14T11:06:00Z","reference_number":"EMADOC-628903358-743","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192156-public-summary-opinion-orphan-designation-modified-messenger-ribonucleic-acid-encoding-human-propionyl-coenzyme-carboxylase-alpha-and-beta-subunits-encapsulated-lipid-nanoparticle-treatment_en.pdf"},
    {"id":"44705","name":"EU/3/19/2157: Public summary of opinion on orphan designation: Sodium benzoate, sodium phenylacetate for the treatment of ornithine transcarbamylase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-14T11:07:00Z","last_updated_date":"2019-06-14T11:07:00Z","reference_number":"EMADOC-628903358-744","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192157-public-summary-opinion-orphan-designation-sodium-benzoate-sodium-phenylacetate-treatment-ornithine-transcarbamylase-deficiency_en.pdf"},
    {"id":"44714","name":"Public summary of negative opinion on orphan designation: Diacerein for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-14T15:41:00Z","last_updated_date":"2019-06-14T15:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-diacerein-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"45223","name":"EU/3/19/2158: Public summary of opinion on orphan designation: (S)-3-((3-(1-((6-(3,4-Dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium for the treatment of pulmonary arterial hypertension","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-09T11:11:00Z","last_updated_date":"2019-08-09T11:11:00Z","reference_number":"EMADOC-628903358-939","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192158-public-summary-opinion-orphan-designation-s-3-3-1-6-34-dimethoxyphenylpryazin-2-ylaminoethylphenylcarbamoyl-5-methylpridin-1-ium-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"45224","name":"EU/3/19/2159: Public summary of opinion on orphan designation: (S)-5-(1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethylamino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-09T11:40:00Z","last_updated_date":"2019-08-09T11:40:00Z","reference_number":"EMADOC-628903358-937","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192159-public-summary-opinion-orphan-designation-s-5-1-6-chloro-2-oxo-12-dihydroquinolin-3-ylethylamino-1-methyl-6-oxo-16-dihydropyridine-2-carbonitrile-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"45225","name":"EU/3/19/2160: Public summary of opinion on orphan designation: Allogeneic skin-derived ABCB5-positive mesenchymal stem cells for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-09T12:02:00Z","last_updated_date":"2019-08-09T12:02:00Z","reference_number":"EMADOC-628903358-933","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192160-public-summary-opinion-orphan-designation-allogeneic-skin-derived-abcb5-positive-mesenchymal-stem-cells-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"45226","name":"EU/3/19/2161: Public summary of opinion on orphan designation: Diacerein for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-09T14:38:00Z","last_updated_date":"2019-08-09T14:38:00Z","reference_number":"EMADOC-628903358-934","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192161-public-summary-opinion-orphan-designation-diacerein-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"45227","name":"EU/3/19/2162: Public summary of opinion on orphan designation: Emixustat hydrochloride for the treatment of Stargardt’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-09T14:55:00Z","last_updated_date":"2019-08-09T14:55:00Z","reference_number":"EMADOC-628903358-936","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192162-public-summary-opinion-orphan-designation-emixustat-hydrochloride-treatment-stargardts-disease_en.pdf"},
    {"id":"45228","name":"EU/3/19/2164: Public summary of opinion on orphan designation: Relacorilant for the treatment of Cushing’s syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-09T15:58:00Z","last_updated_date":"2019-08-09T15:58:00Z","reference_number":"EMADOC-628903358-935","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192164-public-summary-opinion-orphan-designation-relacorilant-treatment-cushings-syndrome_en.pdf"},
    {"id":"45234","name":"EU/3/19/2165: Public summary of opinion on orphan designation: Sodium benzoate, sodium phenylacetate for the treatment of citrullinaemia type 1","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-12T15:16:00Z","last_updated_date":"2019-08-12T15:16:00Z","reference_number":"EMADOC-628903358-941","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192165-public-summary-opinion-orphan-designation-sodium-benzoate-sodium-phenylacetate-treatment-citrullinaemia-type-1_en.pdf"},
    {"id":"45235","name":"EU/3/19/2166: Public summary of opinion on orphan designation: Sodium benzoate, sodium phenylacetate for the treatment of carbamoyl-phosphate synthase-1 deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-12T15:25:00Z","last_updated_date":"2019-08-12T15:25:00Z","reference_number":"EMADOC-628903358-940","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192166-public-summary-opinion-orphan-designation-sodium-benzoate-sodium-phenylacetate-treatment-carbamoyl-phosphate-synthase-1-deficiency_en.pdf"},
    {"id":"45236","name":"EU/3/19/2167: Public summary of opinion on orphan designation: Zanubrutinib for the treatment of lymphoplasmatic lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-12T15:46:00Z","last_updated_date":"2019-08-12T15:46:00Z","reference_number":"EMADOC-628903358-942","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192167-public-summary-opinion-orphan-designation-zanubrutinib-treatment-lymphoplasmatic-lymphoma_en.pdf"},
    {"id":"45512","name":"EU/3/19/2180: Public summary of opinion on orphan designation: 2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-09-24T13:41:00Z","last_updated_date":"2019-09-24T13:41:00Z","reference_number":"EMADOC-628903358-1136","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192180-public-summary-opinion-orphan-designation-2-hydroxymethyl-2-methoxymethyl-1-azabicyclo222octan-3-one-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"45513","name":"EU/3/19/2181: Public summary of opinion on orphan designation: 7-Ethyl-10-hydroxy-camptothecin for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-09-24T14:41:00Z","last_updated_date":"2019-09-24T14:41:00Z","reference_number":"EMADOC-628903358-1135","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192181-public-summary-opinion-orphan-designation-7-ethyl-10-hydroxy-camptothecin-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"45514","name":"EU/3/19/2183: Public summary of opinion on orphan designation: Mavorixafor for the treatment of WHIM syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-09-24T14:58:00Z","last_updated_date":"2019-09-24T14:58:00Z","reference_number":"EMADOC-628903358-1133","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192183-public-summary-opinion-orphan-designation-mavorixafor-treatment-whim-syndrome_en.pdf"},
    {"id":"45515","name":"EU/3/19/2184: Public summary of opinion on orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide for the treatment of neurofibromatosis type 1","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-09-24T15:13:00Z","last_updated_date":"2019-09-24T15:13:00Z","reference_number":"EMADOC-628903358-1132","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192184-public-summary-opinion-orphan-designation-n-r-23-dihydroxypropoxyl-34-difluro-2-2-fluoro-4-iodo-phenylamino-benzamide-treatment-neurofibromatosis-type-1_en.pdf"},
    {"id":"45519","name":"EU/3/19/2187: Public summary of opinion on orphan designation: Recombinant mutated extracellular domain of the human acetylcholine receptor subunit alpha1 for the treatment of myasthenia gravis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-09-24T16:04:00Z","last_updated_date":"2019-09-24T16:04:00Z","reference_number":"EMADOC-628903358-1129","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192187-public-summary-opinion-orphan-designation-recombinant-mutated-extracellular-domain-human-acetylcholine-receptor-subunit-alpha1-treatment-myasthenia-gravis_en.pdf"},
    {"id":"45524","name":"EU/3/19/2182: Public summary of opinion on orphan designation: Elafibranor for the treatment of primary biliary cholangitis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-09-25T13:38:00Z","last_updated_date":"2019-09-25T13:38:00Z","reference_number":"EMADOC-628903358-1134","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192182-public-summary-opinion-orphan-designation-elafibranor-treatment-primary-biliary-cholangitis_en.pdf"},
    {"id":"45525","name":"EU/3/19/2185: Public summary of opinion on orphan designation: Parsaclisib for the treatment of marginal zone lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-09-25T13:42:00Z","last_updated_date":"2022-12-13T09:21:00Z","reference_number":"EMADOC-628903358-1131","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192185-public-summary-opinion-orphan-designation-parsaclisib-treatment-marginal-zone-lymphoma_en.pdf"},
    {"id":"45548","name":"EU/3/19/2168: Public summary of opinion on orphan designation: (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidine-3-yl)chroman-2-carboxamide hydrochloride for the treatment of maternally inherited diabetes and deafness","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-02T16:30:00Z","last_updated_date":"2019-10-02T16:30:00Z","reference_number":"EMADOC-628903358-1034","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192168-public-summary-opinion-orphan-designation-s-6-hydroxy-2578-tetramethyl-n-r-piperidine-3-ylchroman-2-carboxamide-hydrochloride-treatment-maternally-inherited-diabetes-and-deafness_en.pdf"},
    {"id":"45549","name":"EU/3/19/2169: Public summary of opinion on orphan designation: Reldesemtiv for the treatment of spinal muscular atrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-02T16:57:00Z","last_updated_date":"2019-10-02T16:57:00Z","reference_number":"EMADOC-628903358-1039","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192169-public-summary-opinion-orphan-designation-reldesemtiv-treatment-spinal-muscular-atrophy_en.pdf"},
    {"id":"45551","name":"EU/3/19/2170: Public summary of opinion on orphan designation: 2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride for the treatment of beta-thalassaemia intermedia and major","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-02T17:11:00Z","last_updated_date":"2019-10-02T17:11:00Z","reference_number":"EMADOC-628903358-1042","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192170-public-summary-opinion-orphan-designation-2-2-2-1h-benzimidazol-2-ylethylaminoethyl-n-3-fluoropyridin-2-ylmethyl-13-oxazole-4-carboxamide-trihydrochloride-treatment-beta-thalassaemia_en.pdf"},
    {"id":"45558","name":"EU/3/19/2171: Public summary of opinion on orphan designation: 5'-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-sp-dA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3' for the treatment of centronuclear myopathies","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-03T13:12:00Z","last_updated_date":"2019-10-03T13:12:00Z","reference_number":"EMADOC-628903358-1035","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192171-public-summary-opinion-orphan-designation-5-cetg-sp-cet5meu-sp-cet5meu-sp-dt-sp-da-sp-dt-sp-dt-sp-da-sp-dt-sp-da-sp-dg-sp-dg-sp-dg-sp-cet5mec-sp-cet5meu-sp-cet5meu-3-treatment-centronuclear_en.pdf"},
    {"id":"45574","name":"EU/3/19/2172: Public summary of opinion on orphan designation: Gaboxadol monohydrate for the treatment of Angelman syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-07T10:12:00Z","last_updated_date":"2019-10-07T10:12:00Z","reference_number":"EMADOC-628903358-1033","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192172-public-summary-opinion-orphan-designation-gaboxadol-monohydrate-treatment-angelman-syndrome_en.pdf"},
    {"id":"45638","name":"EU/3/19/2174: Public summary of opinion on orphan designation: Rasagiline for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-10T15:34:00Z","last_updated_date":"2019-10-10T15:34:00Z","reference_number":"EMADOC-628903358-1037","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192174-public-summary-opinion-orphan-designation-rasagiline-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"45641","name":"EU/3/19/2175: Public summary of opinion on orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid derived from AAV-rh74 and a codon-optimised expression cassette to drive...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-10T15:42:00Z","last_updated_date":"2019-10-10T15:42:00Z","reference_number":"EMADOC-628903358-1040","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192175-public-summary-opinion-orphan-designation-recombinant-adeno-associated-viral-vector-containing-bioengineered-capsid-derived-aav-rh74-and-codon-optimised-expression-cassette-drive_en.pdf"},
    {"id":"45666","name":"EU/3/19/2176: Public summary of opinion on orphan designation: Recombinant human coagulation factor VIII Fc - von Willebrand factor - XTEN fusion protein for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-14T14:52:00Z","last_updated_date":"2019-10-14T14:52:00Z","reference_number":"EMADOC-628903358-1041","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192176-public-summary-opinion-orphan-designation-recombinant-human-coagulation-factor-viii-fc-von-willebrand-factor-xten-fusion-protein-treatment-haemophilia_en.pdf"},
    {"id":"45669","name":"EU/3/19/2177: Public summary of opinion on orphan designation: Regorafenib for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-14T15:02:00Z","last_updated_date":"2022-12-20T14:44:00Z","reference_number":"EMADOC-628903358-1038","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192177-public-summary-opinion-orphan-designation-regorafenib-treatment-glioma_en.pdf"},
    {"id":"45676","name":"EU/3/19/2178: Public summary of opinion on orphan designation: Sodium benzoate, sodium phenylacetate for the treatment of argininosuccinic aciduria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-14T15:21:00Z","last_updated_date":"2019-10-14T15:21:00Z","reference_number":"EMADOC-628903358-1043","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192178-public-summary-opinion-orphan-designation-sodium-benzoate-sodium-phenylacetate-treatment-argininosuccinic-aciduria_en.pdf"},
    {"id":"45677","name":"EU/3/19/2179: Public summary of opinion on orphan designation: Sodium benzoate, sodium phenylacetate for the treatment of hyperargininaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-14T15:38:00Z","last_updated_date":"2019-10-14T15:38:00Z","reference_number":"EMADOC-628903358-1044","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192179-public-summary-opinion-orphan-designation-sodium-benzoate-sodium-phenylacetate-treatment-hyperargininaemia_en.pdf"},
    {"id":"46415","name":"EU/3/08/595: Public summary of positive opinion for orphan designation of monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E (brentuximab vedotin) for the treatment of peripheral T-cell lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T13:48:00Z","last_updated_date":"2020-01-14T13:48:00Z","reference_number":"EMADOC-628903358-1297","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308595-public-summary-positive-opinion-orphan-designation-monoclonal-antibody-against-human-cd30-covalently-linked-cytotoxin-monomethylauristatin-e-brentuximab-vedotin-treatment-peripheral-t-cell_en.pdf"},
    {"id":"46416","name":"EU/3/19/2188: Public summary of positive opinion for orphan designation of temozolomide for the treatment of neuroblastoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T14:17:00Z","last_updated_date":"2020-01-14T14:17:00Z","reference_number":"EMADOC-628903358-1310","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192188-public-summary-positive-opinion-orphan-designation-temozolomide-treatment-neuroblastoma_en.pdf"},
    {"id":"46417","name":"EU/3/19/2189: Public summary of positive opinion for orphan designation of gallium citrate for the treatment of cystic fibrosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T14:43:00Z","last_updated_date":"2020-01-14T14:43:00Z","reference_number":"EMADOC-628903358-1309","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192189-public-summary-positive-opinion-orphan-designation-gallium-citrate-treatment-cystic-fibrosis_en.pdf"},
    {"id":"46418","name":"EU/3/19/2190: Public summary of positive opinion for orphan designation of peginterferon lambda-1a for the treatment of hepatitis D virus infection","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T14:56:00Z","last_updated_date":"2020-01-14T14:56:00Z","reference_number":"EMADOC-628903358-1306","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192190-public-summary-positive-opinion-orphan-designation-peginterferon-lambda-1a-treatment-hepatitis-d-virus-infection_en.pdf"},
    {"id":"46419","name":"EU/3/19/2191: Public summary of positive opinion for orphan designation of relacorilant for the treatment of pancreatic cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T15:11:00Z","last_updated_date":"2020-01-14T15:11:00Z","reference_number":"EMADOC-628903358-1308","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192191-public-summary-positive-opinion-orphan-designation-relacorilant-treatment-pancreatic-cancer_en.pdf"},
    {"id":"46421","name":"EU/3/05/269: Public summary of positive opinion for orphan designation of setmelanotide for the treatment of Bardet Biedl syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T15:34:00Z","last_updated_date":"2020-01-14T15:34:00Z","reference_number":"EMADOC-628903358-1304","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu305269-public-summary-positive-opinion-orphan-designation-setmelanotide-treatment-bardet-biedl-syndrome_en.pdf"},
    {"id":"46426","name":"EU/3/19/2193: Public summary of positive opinion for orphan designation of acetazolamide for the treatment of periodic paralysis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T16:23:00Z","last_updated_date":"2020-01-14T16:23:00Z","reference_number":"EMADOC-628903358-1303","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192193-public-summary-positive-opinion-orphan-designation-acetazolamide-treatment-periodic-paralysis_en.pdf"},
    {"id":"46429","name":"EU/3/19/2194: Public summary of positive opinion for orphan designation of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine for congenital adrenal hyperplasia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T16:38:00Z","last_updated_date":"2020-01-14T16:38:00Z","reference_number":"EMADOC-628903358-1302","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192194-public-summary-positive-opinion-orphan-designation-4-2-chloro-4-methoxy-5-methylphenyl-n-1s-2-cyclopropyl-1-3-fluoro-4-methylphenylethyl-5-methyl-n-2-propynyl-13-thiazol-2-amine-congenital_en.pdf"},
    {"id":"46437","name":"EU/3/19/2189: Public summary of positive opinion for orphan designation of 1-(2,2-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine hydrochloride for the treatment of Rett syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-16T11:50:00Z","last_updated_date":"2020-01-16T11:50:00Z","reference_number":"EMADOC-628903358-1301","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192189-public-summary-positive-opinion-orphan-designation-1-22-diphenyltetrahydrofuran-3-yl-nn-dimethylmethanamine-hydrochloride-treatment-rett-syndrome_en.pdf"},
    {"id":"46438","name":"EU/3/19/2196: Public summary of positive opinion for orphan designation of recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene for the treatment of neuronal ceroid lipofuscinosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-16T12:05:00Z","last_updated_date":"2020-01-16T12:05:00Z","reference_number":"EMADOC-628903358-1300","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192196-public-summary-positive-opinion-orphan-designation-recombinant-self-complementary-adeno-associated-viral-vector-serotype-9-containing-human-cln3-gene-treatment-neuronal-ceroid-lipofuscinosis_en.pdf"},
    {"id":"46439","name":"EU/3/19/2197: Public summary of positive opinion for orphan designation of recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene for the treatment of neuronal ceroid lipofuscinosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-16T12:25:00Z","last_updated_date":"2020-01-16T12:25:00Z","reference_number":"EMADOC-628903358-1299","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192197-public-summary-positive-opinion-orphan-designation-recombinant-self-complementary-adeno-associated-viral-vector-serotype-9-containing-human-cln6-gene-treatment-neuronal-ceroid-lipofuscinosis_en.pdf"},
    {"id":"46441","name":"EU/3/19/2198: Public summary of positive opinion for orphan designation of adenoviral vector serotype 5 encoding the human interleukin-12 p70 transgene under the control of activator ligand veledimex for the treatment of glioma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-16T16:29:00Z","last_updated_date":"2022-03-21T15:43:00Z","reference_number":"EMADOC-628903358-1298","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192198-public-summary-positive-opinion-orphan-designation-adenoviral-vector-serotype-5-encoding-human-interleukin-12-p70-transgene-under-control-activator-ligand-veledimex-treatment-glioma_en.pdf"},
    {"id":"46442","name":"EU/3/19/2201: Public summary of positive opinion for orphan designation of poly(oxy-1,2-ethanediyl), alpha-hydro-omega-hydroxy-,15,15'-diester with N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophylgl","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-16T17:07:00Z","last_updated_date":"2020-01-16T17:07:00Z","reference_number":"EMADOC-628903358-1305","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192201-public-summary-positive-opinion-orphan-designation-polyoxy-12-ethanediyl-alpha-hydro-omega-hydroxy-1515-diester-n-acetyl-l-isoleucyl-l-cysteinyl-l-valyl-1-methyl-l-tryptophyl-l-glutaminyl-l_en.pdf"},
    {"id":"46443","name":"EU/3/08/595: Public summary of positive opinion for orphan designation of monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E (brentuximab vedotin) for the treatment of peripheral T-cell lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-16T17:17:00Z","last_updated_date":"2020-01-16T17:17:00Z","reference_number":"EMADOC-628903358-1297","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu308595-public-summary-positive-opinion-orphan-designation-monoclonal-antibody-against-human-cd30-covalently-linked-cytotoxin-monomethylauristatin-e-brentuximab-vedotin-treatment-peripheral-t-cell_en.pdf-0"},
    {"id":"46445","name":"EU/3/19/2199: Public summary of positive opinion for orphan designation of veledimex for the treatment of glioma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-16T10:58:00Z","last_updated_date":"2022-03-21T15:46:00Z","reference_number":"EMADOC-628903358-1296","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192199-public-summary-positive-opinion-orphan-designation-veledimex-treatment-glioma_en.pdf"},
    {"id":"46446","name":"EU/3/19/2200: Public summary of positive opinion for orphan designation of clofazimine for the treatment of nontuberculous mycobacterial lung disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-01-16T11:08:00Z","last_updated_date":"2020-01-16T11:08:00Z","reference_number":"EMADOC-628903358-1295","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192200-public-summary-positive-opinion-orphan-designation-clofazimine-treatment-nontuberculous-mycobacterial-lung-disease_en.pdf"},
    {"id":"46472","name":"EU/3/19/2202: Public summary of positive opinion for orphan designation of (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[ 19.3.1.1(2,6).1(8,12)]heptacosa- 1(25),2(26),3,5,8(27),9,11,16,21,23-decaene–citric acid for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-21T14:36:00Z","last_updated_date":"2020-01-21T14:36:00Z","reference_number":"EMADOC-628903358-1516","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192202-public-summary-positive-opinion-orphan-designation-16e-14-methyl-20-oxa-571426-tetraazatetracyclo-19311261812heptacosa-12522635827911162123-decaene-citric-acid-treatment-glioma_en.pdf"},
    {"id":"46475","name":"EU/3/19/2203: Public summary of positive opinion for orphan designation of (S)-2-Isobutyrylamino-pentanedioic acid 5-amide 1-{[(2S,5S,8S,11R,12S,15S,18S,21R)-2,8-bis-((S)-sec-butyl)-21-hydroxy-5-(4-hydroxy-benzyl) (...)for the treatment of Netherton","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-21T15:43:00Z","last_updated_date":"2020-01-21T15:43:00Z","reference_number":"EMADOC-628903358-1521","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192203-public-summary-positive-opinion-orphan-designation-s-2-isobutyrylamino-pentanedioic-acid-5-amide-1-2s5s8s11r12s15s18s21r-28-bis-s-sec-butyl-21-hydroxy-5-4-hydroxy-benzyl-treatment-netherton_en.pdf"},
    {"id":"46476","name":"EU/3/19/2204: Public summary of positive opinion for orphan designation of 18-(p-(131I)-Iodophenyl)octadecyl phosphocholine for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-21T16:19:00Z","last_updated_date":"2020-01-21T16:19:00Z","reference_number":"EMADOC-628903358-1514","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192204-public-summary-positive-opinion-orphan-designation-18-p-131i-iodophenyloctadecyl-phosphocholine-treatment-multiple-myeloma_en.pdf"},
    {"id":"46477","name":"EU/3/19/2205: Public summary of positive opinion for orphan designation of 2-(3-(4-(1H-Indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide-methane sulfonic acid salt for the treatment of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-21T16:42:00Z","last_updated_date":"2020-01-21T16:42:00Z","reference_number":"EMADOC-628903358-1520","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192205-public-summary-positive-opinion-orphan-designation-2-3-4-1h-indazol-5-ylaminoquinazolin-2-ylphenoxy-n-isopropylacetamide-methane-sulfonic-acid-salt-treatment-graft-versus-host-disease_en.pdf"},
    {"id":"46478","name":"EU/3/19/2206: Public summary of positive opinion for orphan designation of 2'-O-(2-Methoxyethyl)-d-ribose antisense oligonucleotide targeting glial fibrillary acidic protein messenger ribonucleic acid for the treatment of Alexander disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-21T16:59:00Z","last_updated_date":"2020-01-21T16:59:00Z","reference_number":"EMADOC-628903358-1522","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192206-public-summary-positive-opinion-orphan-designation-2-o-2-methoxyethyl-d-ribose-antisense-oligonucleotide-targeting-glial-fibrillary-acidic-protein-messenger-ribonucleic-acid-treatment_en.pdf"},
    {"id":"46479","name":"EU/3/19/2207: Public summary of positive opinion for orphan designation of 4-Oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-(...) for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-21T17:11:00Z","last_updated_date":"2020-01-21T17:11:00Z","reference_number":"EMADOC-628903358-1511","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192207-public-summary-positive-opinion-orphan-designation-4-oxo-4h-chromene-2-carboxylic-acid-2-2-4-2-67-dimethoxy-34-dihydro-1h-isoquinolin-2-yl-ethyl-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"46480","name":"EU/3/19/2208: Public summary of positive opinion for orphan designation of combination of two adeno-associated viral vectors of serotype 8 containing the 5'- and the 3'- (...) of human ABCA4 fused to inteins for the treatment of Stargardt’s disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-22T10:14:00Z","last_updated_date":"2020-01-22T10:14:00Z","reference_number":"EMADOC-628903358-1519","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192208-public-summary-positive-opinion-orphan-designation-combination-two-adeno-associated-viral-vectors-serotype-8-containing-5-and-3-human-abca4-fused-inteins-treatment-stargardts-disease_en.pdf"},
    {"id":"46481","name":"EU/3/19/2209: Public summary of positive opinion for orphan designation of anti-neonatal Fc receptor human monoclonal antibody for the prevention of haemolytic disease of the foetus and newborn","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-22T11:12:00Z","last_updated_date":"2020-01-22T11:12:00Z","reference_number":"EMADOC-628903358-1510","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192209-public-summary-positive-opinion-orphan-designation-anti-neonatal-fc-receptor-human-monoclonal-antibody-prevention-haemolytic-disease-foetus-and-newborn_en.pdf"},
    {"id":"46482","name":"EU/3/19/2210: Public summary of positive opinion for orphan designation of autologous CD34+ hematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the bcl11a gene for the treatment of beta-thalassaemia intermedia and major","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-22T11:45:00Z","last_updated_date":"2020-01-22T11:45:00Z","reference_number":"EMADOC-628903358-1532","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192210-public-summary-positive-opinion-orphan-designation-autologous-cd34-hematopoietic-stem-cells-crispr-edited-erythroid-enhancer-region-bcl11a-gene-treatment-beta-thalassaemia-intermedia-and_en.pdf"},
    {"id":"46484","name":"EU/3/19/2211: Public summary of positive opinion for orphan designation of besilesomab for treatment in haematopoietic stem cell transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-22T14:13:00Z","last_updated_date":"2020-01-22T14:13:00Z","reference_number":"EMADOC-628903358-1509","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192211-public-summary-positive-opinion-orphan-designation-besilesomab-treatment-haematopoietic-stem-cell-transplantation_en.pdf"},
    {"id":"46485","name":"EU/3/19/2212: Public summary of positive opinion for orphan designation of leriglitazone for the treatment of Friedreich’s ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-22T14:27:00Z","last_updated_date":"2020-01-22T14:27:00Z","reference_number":"EMADOC-628903358-1523","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192212-public-summary-positive-opinion-orphan-designation-leriglitazone-treatment-friedreichs-ataxia_en.pdf"},
    {"id":"46486","name":"EU/3/19/2213: Public summary of positive opinion for orphan designation of lonapegsomatropin for the treatment of growth hormone deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-22T14:57:00Z","last_updated_date":"2020-01-22T14:57:00Z","reference_number":"EMADOC-628903358-1517","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192213-public-summary-positive-opinion-orphan-designation-lonapegsomatropin-treatment-growth-hormone-deficiency_en.pdf"},
    {"id":"46495","name":"EU/3/19/2214: Public summary of positive opinion for orphan designation of nirogacestat for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-23T12:18:00Z","last_updated_date":"2020-01-23T12:18:00Z","reference_number":"EMADOC-628903358-1513","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192214-public-summary-positive-opinion-orphan-designation-nirogacestat-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"46498","name":"EU/3/19/2215: Public summary of positive opinion for orphan designation of paclitaxel for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-23T14:05:00Z","last_updated_date":"2020-01-23T14:05:00Z","reference_number":"EMADOC-628903358-1512","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192215-public-summary-positive-opinion-orphan-designation-paclitaxel-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"46499","name":"EU/3/19/2216: Public summary of positive opinion for orphan designation of 4-Oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-(...) for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-23T14:26:00Z","last_updated_date":"2020-01-23T14:26:00Z","reference_number":"EMADOC-628903358-1508","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192216-public-summary-positive-opinion-orphan-designation-4-oxo-4h-chromene-2-carboxylic-acid-2-2-4-2-67-dimethoxy-34-dihydro-1h-isoquinolin-2-yl-ethyl-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"46506","name":"EU/3/19/2217: Public summary of positive opinion for orphan designation of propranolol hydrochloride for the treatment of retinopathy of prematurity","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-23T14:40:00Z","last_updated_date":"2020-01-23T14:40:00Z","reference_number":"EMADOC-628903358-1518","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192217-public-summary-positive-opinion-orphan-designation-propranolol-hydrochloride-treatment-retinopathy-prematurity_en.pdf"},
    {"id":"46734","name":"EU/3/19/2218: Public summary of opinion on orphan designation: (2S,3R,4R,5S)-2-(Hydroxymethyl)-1-pentylpiperidine-3,4,5-triol for the treatment of GM2 gangliosidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-12T02:00:00Z","last_updated_date":"2020-02-12T02:00:00Z","reference_number":"EMADOC-628903358-1573 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192218-public-summary-opinion-orphan-designation-2s3r4r5s-2-hydroxymethyl-1-pentylpiperidine-345-triol-treatment-gm2-gangliosidosis_en.pdf"},
    {"id":"46735","name":"EU/3/19/2219: Public summary of opinion on orphan designation: 4-((E)-(5-(2-(2-((S)-2-((S)-1-(L-threonyl-L-lysyl)pyrrolidine-2-carboxamido)-5-guanidinopentanamido)acetamido)-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-12T02:00:00Z","last_updated_date":"2020-02-12T02:00:00Z","reference_number":"EMADOC-628903358-1566","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192219-public-summary-opinion-orphan-designation-4-e-5-2-2-s-2-s-1-l-threonyl-l-lysylpyrrolidine-2-carboxamido-5-guanidinopentanamidoacetamido_en.pdf"},
    {"id":"46737","name":"EU/3/19/2220: Public summary of opinion on orphan designation: Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3zeta chimeric antigen receptor and cultured","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-13T02:00:00Z","last_updated_date":"2020-02-13T02:00:00Z","reference_number":"EMADOC-628903358-1571","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192220-public-summary-opinion-orphan-designation-autologous-peripheral-blood-t-cells-cd4-and-cd8-selected-and-cd3-and-cd28-activated-transduced-retroviral-vector-expressing-anti-cd19-cd28cd3zeta_en.pdf"},
    {"id":"46738","name":"EU/3/19/2221: Public summary of opinion on orphan designation: Camsirubicin for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-13T02:00:00Z","last_updated_date":"2020-02-13T02:00:00Z","reference_number":"EMADOC-628903358-1569 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192221-public-summary-opinion-orphan-designation-camsirubicin-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"46739","name":"EU/3/19/2222: Public summary of opinion on orphan designation: Chimeric fibril-reactive IgG1k monoclonal antibody 11-1F4 for the treatment of AL amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-13T02:00:00Z","last_updated_date":"2020-02-13T02:00:00Z","reference_number":"EMADOC-628903358-1572","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192222-public-summary-opinion-orphan-designation-chimeric-fibril-reactive-igg1k-monoclonal-antibody-11-1f4-treatment-al-amyloidosis_en.pdf"}    {"id":"46740","name":"EU/3/19/2223: Public summary of opinion on orphan designation: Exendin (9-39) for the treatment of congenital hyperinsulinism","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-13T02:00:00Z","last_updated_date":"2020-02-13T02:00:00Z","reference_number":"EMADOC-628903358-1570","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192223-public-summary-opinion-orphan-designation-exendin-9-39-treatment-congenital-hyperinsulinism_en.pdf"},
    {"id":"46741","name":"EU/3/19/2224: Public summary of opinion on orphan designation: Ganaxolone for the treatment of CDKL5 deficiency disorder","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-13T02:00:00Z","last_updated_date":"2020-02-13T02:00:00Z","reference_number":"EMADOC-628903358-1568","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192224-public-summary-opinion-orphan-designation-ganaxolone-treatment-cdkl5-deficiency-disorder_en.pdf"},
    {"id":"46744","name":"EU/3/19/2225: Public summary of opinion on orphan designation: Replication-incompetent, non-integrating, herpes simplex virus 1 vector expressing the human transglutaminase-1 enzyme for the treatment of autosomal recessive congenital ichthyosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-13T02:00:00Z","last_updated_date":"2020-02-13T02:00:00Z","reference_number":"MADOC-628903358-156","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192225-public-summary-opinion-orphan-designation-replication-incompetent-non-integrating-herpes-simplex-virus-1-vector-expressing-human-transglutaminase-1-enzyme-treatment-autosomal-recessive_en.pdf"},
    {"id":"46844","name":"EU/3/19/2226: Public summary of positive opinion for orphan designation: (E)-2-((2S,4S)-4-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-10-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-24T02:00:00Z","last_updated_date":"2020-02-24T02:00:00Z","reference_number":"EMADOC-628903358-1671","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192226-public-summary-positive-opinion-orphan-designation-e-2-2s4s-4-2r4s5s6s-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yloxy-2512-trihydroxy-7-methoxy-611-dioxo-1234611-hexahydrotetracen-2_en.pdf"},
    {"id":"46845","name":"EU/3/19/2227: Public summary of opinion on orphan designation: 2-(Isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-02-24T15:50:00Z","last_updated_date":"2020-02-24T15:50:00Z","reference_number":"EMADOC-628903358-1672 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192227-public-summary-opinion-orphan-designation-2-isopropylamino-3-methyl-5-6-methyl-5-2-1-methyl-1h-pyrazol-4ylpyridin-4-yloxypyridin-2-ylpyrimidin-43h-one_en.pdf"},
    {"id":"46846","name":"EU/3/19/2228: Public summary of opinion on orphan designation: 5,7-Dichloro-2-((ethylamino)methyl)-8-hydroxy-3-methylquinazolin-4(3H)one mesilate for the treatment of multiple system atrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T15:50:00Z","last_updated_date":"2020-02-25T15:50:00Z","reference_number":"EMADOC-628903358-1673 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192228-public-summary-opinion-orphan-designation-57-dichloro-2-ethylaminomethyl-8-hydroxy-3-methylquinazolin-43hone-mesilate-treatment-multiple-system-atrophy_en.pdf"},
    {"id":"46847","name":"EU/3/19/2229: Public summary of opinion on orphan designation: Adeno-associated virus vector encoding human phenylalanine hydroxylase for the treatment of phenylalanine hydroxylase deficiency","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T15:50:00Z","last_updated_date":"2020-02-25T15:50:00Z","reference_number":"EMADOC-628903358-1674","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192229-public-summary-opinion-orphan-designation-adeno-associated-virus-vector-encoding-human-phenylalanine-hydroxylase-treatment-phenylalanine-hydroxylase-deficiency_en.pdf"},
    {"id":"46848","name":"EU/3/19/2229: Public summary of opinion on orphan designation: Efgartigimod alfa for the treatment of immune thrombocytopenia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T15:50:00Z","last_updated_date":"2020-02-25T15:50:00Z","reference_number":"EMADOC-628903358-1668 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192229-public-summary-opinion-orphan-designation-efgartigimod-alfa-treatment-immune-thrombocytopenia_en.pdf"},
    {"id":"46849","name":"EU/3/19/2231: Public summary of opinion on orphan designation: H-Leu-Pro-Pro-Leu-Pro-Tyr-Pro-OH for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T15:50:00Z","last_updated_date":"2020-02-25T15:50:00Z","reference_number":"EMADOC-628903358-1675 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192231-public-summary-opinion-orphan-designation-h-leu-pro-pro-leu-pro-tyr-pro-oh-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"46850","name":"EU/3/19/2232: Public summary of opinion on orphan designation: Lactobacillus plantarum for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T15:50:00Z","last_updated_date":"2020-02-25T15:50:00Z","reference_number":"EMADOC-628903358-1669","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192232-public-summary-opinion-orphan-designation-lactobacillus-plantarum-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"46851","name":"EU/3/19/2233: Public summary of opinion on orphan designation: Navitoclax for the treatment of myelofibrosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T15:50:00Z","last_updated_date":"2020-02-25T15:50:00Z","reference_number":"EMADOC-628903358-1678 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192233-public-summary-opinion-orphan-designation-navitoclax-treatment-myelofibrosis_en.pdf"},
    {"id":"46852","name":"EU/3/19/2234: Public summary of opinion on orphan designation: Pamrevlumab for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T15:50:00Z","last_updated_date":"2020-02-25T15:50:00Z","reference_number":"EMADOC-628903358-1670 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192234-public-summary-opinion-orphan-designation-pamrevlumab-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"46853","name":"EU/3/19/2235: Public summary of opinion on orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against SERPINA1 mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T15:50:00Z","last_updated_date":"2020-02-25T15:50:00Z","reference_number":"EMADOC-628903358-1679 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192235-public-summary-opinion-orphan-designation-synthetic-double-stranded-sirna-oligonucleotide-directed-against-serpina1-mrna-and-containing-four-modified-nucleosides-which-form-ligand-cluster_en.pdf"},
    {"id":"46854","name":"Public summary of negative opinion for orphan designation of naltrexone for the treatment of fibromyalgia (Nov 2019)","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-02-24T15:43:00Z","last_updated_date":"2020-02-24T15:43:00Z","reference_number":"EMADOC-628903358-1680 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-naltrexone-treatment-fibromyalgia-nov-2019_en.pdf"},
    {"id":"47567","name":"EU/3/20/2247: Public summary of positive opinion for orphan designation of 2-((4S)-6-(4-Chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide monohydrate for the treatment of myelofibrosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-05T15:56:00Z","last_updated_date":"2020-05-05T15:56:00Z","reference_number":"EMADOC-628903358-1937","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202247-public-summary-positive-opinion-orphan-designation-2-4s-6-4-chlorophenyl-1-methyl-4h-benzocisoxazolo45-eazepin-4-ylacetamide-monohydrate-treatment-myelofibrosis_en.pdf"},
    {"id":"47568","name":"EU/3/20/2248: Public summary of positive opinion for orphan designation of adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA for the treatment of Fabry disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-05T16:30:00Z","last_updated_date":"2020-05-05T16:30:00Z","reference_number":"EMADOC-628903358-1939","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202248-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-serotype-s3-encoding-human-alpha-galactosidase-cdna-treatment-fabry-disease_en.pdf"},
    {"id":"47569","name":"EU/3/20/2249: Public summary of positive opinion for orphan designation of adeno-associated virus serotype 8 containing the human RdCVF sequence and the human RdCVFL sequence for the treatment of inherited retinal dystrophies","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-05T16:54:00Z","last_updated_date":"2020-05-05T16:54:00Z","reference_number":"EMADOC-628903358-1941","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202249-public-summary-positive-opinion-orphan-designation-adeno-associated-virus-serotype-8-containing-human-rdcvf-sequence-and-human-rdcvfl-sequence-treatment-inherited-retinal-dystrophies_en.pdf"},
    {"id":"47570","name":"EU/3/20/2250: Public summary of positive opinion for orphan designation of adeno-associated virus serotype rh74 containing the human micro-dystrophin gene for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-05T17:37:00Z","last_updated_date":"2020-05-05T17:37:00Z","reference_number":"EMADOC-628903358-1934","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202250-public-summary-positive-opinion-orphan-designation-adeno-associated-virus-serotype-rh74-containing-human-micro-dystrophin-gene-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"47573","name":"EU/3/20/2251: Public summary of positive opinion for orphan designation of artesunate for the treatment of malaria","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-06T10:26:00Z","last_updated_date":"2020-05-06T10:26:00Z","reference_number":"EMADOC-628903358-1935","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202251-public-summary-positive-opinion-orphan-designation-artesunate-treatment-malaria_en.pdf"},
    {"id":"47574","name":"EU/3/20/2258: Public summary of positive opinion for orphan designation of sutimlimab for the treatment of immune thrombocytopenia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-06T10:42:00Z","last_updated_date":"2020-05-06T10:42:00Z","reference_number":"EMADOC-628903358-1940","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202258-public-summary-positive-opinion-orphan-designation-sutimlimab-treatment-immune-thrombocytopenia_en.pdf"},
    {"id":"47575","name":"EU/3/20/2257: Public summary of positive opinion for orphan designation of sintilimab for the treatment of peripheral T-cell lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-06T10:53:00Z","last_updated_date":"2020-05-06T10:53:00Z","reference_number":"EMADOC-628903358-1938","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202257-public-summary-positive-opinion-orphan-designation-sintilimab-treatment-peripheral-t-cell-lymphoma_en.pdf"},
    {"id":"47576","name":"EU/3/20/2256: Public summary of positive opinion for orphan designation of reldesmetiv for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-06T11:07:00Z","last_updated_date":"2020-05-06T11:07:00Z","reference_number":"EMADOC-628903358-1930","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202256-public-summary-positive-opinion-orphan-designation-reldesmetiv-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"47578","name":"EU/3/20/2255: Public summary of positive opinion for orphan designation of luspatercept for the treatment of myelofibrosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-06T11:17:00Z","last_updated_date":"2020-05-06T11:17:00Z","reference_number":"EMADOC-628903358-1936","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202255-public-summary-positive-opinion-orphan-designation-luspatercept-treatment-myelofibrosis_en.pdf"},
    {"id":"47579","name":"EU/3/20/2254: Public summary of positive opinion for orphan designation of combination of three adeno-associated viral vectors of serotype 8 containing the 5'-, the body- and the 3'- coding sequences of human CEP290 fused to inteins for the treatment of i","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-06T11:31:00Z","last_updated_date":"2020-05-06T11:31:00Z","reference_number":"EMADOC-628903358-1933","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202254-public-summary-positive-opinion-orphan-designation-combination-three-adeno-associated-viral-vectors-serotype-8-containing-5-body-and-3-coding-sequences-human-cep290-fused-inteins-treatment-i_en.pdf"},
    {"id":"47580","name":"EU/3/20/2253: Public summary of positive opinion for orphan designation of autologous skin equivalent graft composed of keratinocytes and fibroblasts genetically corrected by CRISPR/Cas9-mediated excision of mutation-carrying COL7A1 exon 80 for the treatm","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-06T11:48:00Z","last_updated_date":"2020-05-06T11:48:00Z","reference_number":"EMADOC-628903358-1929","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202253-public-summary-positive-opinion-orphan-designation-autologous-skin-equivalent-graft-composed-keratinocytes-and-fibroblasts-genetically-corrected-crisprcas9-mediated-excision-mutation_en.pdf"},
    {"id":"47581","name":"EU/3/20/2252: Public summary of positive opinion for orphan designation of autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor for B-cell maturation antigen for the treatment of multiple myel","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-06T11:59:00Z","last_updated_date":"2020-05-06T11:59:00Z","reference_number":"EMADOC-628903358-1931","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202252-public-summary-positive-opinion-orphan-designation-autologous-human-t-cells-genetically-modified-ex-vivo-lentiviral-vector-encoding-chimeric-antigen-receptor-b-cell-maturation-antigen_en.pdf"},
    {"id":"47583","name":"Public summary of negative opinion for orphan designation of melatonin, sorafenib for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-05-06T12:07:00Z","last_updated_date":"2020-05-06T12:07:00Z","reference_number":"EMADOC-628903358-1932","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-negative-opinion-orphan-designation-melatonin-sorafenib-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"47662","name":"EU/3/19/2236: Public summary of opinion on orphan designation for dimethyl fumarate for the treatment of adrenoleukodystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-14T12:27:00Z","last_updated_date":"2020-05-14T12:27:00Z","reference_number":"EMADOC-628903358-1823","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192236-public-summary-opinion-orphan-designation-dimethyl-fumarate-treatment-adrenoleukodystrophy_en.pdf"},
    {"id":"47673","name":"EU/3/19/2237: Public summary of opinion on orphan designation for 2-(3,7-Dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone for the treatment of Huntington's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-15T10:33:00Z","last_updated_date":"2020-05-15T10:33:00Z","reference_number":"EMADOC-628903358-1822","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192237-public-summary-opinion-orphan-designation-2-37-dimethyl-octa-2-6-dienyl-6-ethylamino-3-hydroxy-5-pentyl-14benzoquinone-treatment-huntingtons-disease_en.pdf"},
    {"id":"47700","name":"EU/3/19/2238: Public summary of opinion on orphan designation for adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene for the treatment of mucopolysaccharidosis type IVA (Morquio A Syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-19T09:16:00Z","last_updated_date":"2020-05-19T09:16:00Z","reference_number":"EMADOC-628903358-1821","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192238-public-summary-opinion-orphan-designation-adeno-associated-virus-serotype-9-vector-containing-human-n-acetylgalactosamine-6-sulfate-sulfatase-gene-treatment-mucopolysaccharidosis-type-iva_en.pdf"},
    {"id":"47701","name":"EU/3/19/2239: Public summary of opinion on orphan designation for tripotassium citrate monohydrate and potassium hydrogen carbonate for the treatment of cystinuria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-19T09:24:00Z","last_updated_date":"2020-05-19T09:24:00Z","reference_number":"EMADOC-628903358-1824","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192239-public-summary-opinion-orphan-designation-tripotassium-citrate-monohydrate-and-potassium-hydrogen-carbonate-treatment-cystinuria_en.pdf"},
    {"id":"47702","name":"EU/3/19/2240: Public summary of opinion on orphan designation for nicardipine for the treatment of non-traumatic subarachnoid haemorrhage","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-19T09:53:00Z","last_updated_date":"2020-05-19T09:53:00Z","reference_number":"EMADOC-628903358-1825","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192240-public-summary-opinion-orphan-designation-nicardipine-treatment-non-traumatic-subarachnoid-haemorrhage_en.pdf"},
    {"id":"47704","name":"EU/3/19/2241: Public summary of opinion on orphan designation for adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA for the treatment of Fabry disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-19T10:49:00Z","last_updated_date":"2020-05-19T10:49:00Z","reference_number":"EMADOC-628903358-1826","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192241-public-summary-opinion-orphan-designation-adeno-associated-virus-serotype-26-encoding-human-alpha-galactosidase-cdna-treatment-fabry-disease_en.pdf"},
    {"id":"47705","name":"EU/3/19/2242: Public summary of opinion on orphan designation for autologous CD34+ hematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-19T11:02:00Z","last_updated_date":"2020-05-19T11:02:00Z","reference_number":"EMADOC-628903358-1827","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192242-public-summary-opinion-orphan-designation-autologous-cd34-hematopoietic-stem-cells-crispr-edited-erythroid-enhancer-region-bcl11a-gene-treatment-sickle-cell-disease_en.pdf"},
    {"id":"47707","name":"EU/3/19/2243: Public summary of opinion on orphan designation for motixafortide for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-19T11:21:00Z","last_updated_date":"2020-05-19T11:21:00Z","reference_number":"EMADOC-628903358-1828","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192243-public-summary-opinion-orphan-designation-motixafortide-treatment-pancreatic-cancer_en.pdf"},
    {"id":"47736","name":"EU/3/19/2244: Public summary of opinion on orphan designation for ziritaxestat for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-20T10:16:00Z","last_updated_date":"2020-05-20T10:16:00Z","reference_number":"EMADOC-628903358-1830","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192244-public-summary-opinion-orphan-designation-ziritaxestat-treatment-systemic-sclerosis_en.pdf"},
    {"id":"47738","name":"EU/3/19/2245: Public summary of opinion on orphan designation for setmelanotide for the treatment of Alström syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-20T11:24:00Z","last_updated_date":"2020-05-20T11:24:00Z","reference_number":"EMADOC-628903358-1829","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192245-public-summary-opinion-orphan-designation-setmelanotide-treatment-alstrom-syndrome_en.pdf"},
    {"id":"47739","name":"EU/3/19/2246: Public summary of opinion on orphan designation for romilkimab for the treatment of systemic sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-20T11:38:00Z","last_updated_date":"2020-05-20T11:38:00Z","reference_number":"EMADOC-628903358-1831","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3192246-public-summary-opinion-orphan-designation-romilkimab-treatment-systemic-sclerosis_en.pdf"},
    {"id":"48580","name":"EU/3/20/2265: Public summary of positive opinion for orphan designation of cusatuzumab for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-11T13:59:00Z","last_updated_date":"2020-08-11T13:59:00Z","reference_number":"EMADOC-628903358-2219","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202265-public-summary-positive-opinion-orphan-designation-cusatuzumab-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"48581","name":"EU/3/20/2266: Public summary of positive opinion for orphan designation of DNA plasmid encoding IL-12 p35 and p40 genes for the treatment of ovarian cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-11T14:38:00Z","last_updated_date":"2020-08-11T14:38:00Z","reference_number":"EMADOC-628903358-2218","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202266-public-summary-positive-opinion-orphan-designation-dna-plasmid-encoding-il-12-p35-and-p40-genes-treatment-ovarian-cancer_en.pdf"},
    {"id":"48583","name":"EU/3/20/2267: Public summary of positive opinion for orphan designation of Adeno-associated viral vector serotype 3B encoding human multidrug resistance protein 3A for the treatment of progressive familial intrahepatic cholestasis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-11T14:49:00Z","last_updated_date":"2020-08-11T14:49:00Z","reference_number":"EMADOC-628903358-2220","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202267-public-summary-positive-opinion-orphan-designation-adeno-associated-viral-vector-serotype-3b-encoding-human-multidrug-resistance-protein-3a-treatment-progressive-familial-intrahepatic_en.pdf"},
    {"id":"48584","name":"EU/3/20/2259: Public summary of opinion on orphan designation for 2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate for the treatment of pancreatic cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-12T10:36:00Z","last_updated_date":"2023-02-16T15:14:00Z","reference_number":"EMADOC-628903358-2107","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202259-public-summary-opinion-orphan-designation-2-hydroxy-nnn-trimethylethan-1-aminium-z-4-5-3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidenemethylfuran-2-ylbenzoate-treatment-pancreatic-cancer_en.pdf"},
    {"id":"48585","name":"EU/3/20/2260: Public summary of opinion on orphan designation for allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus for treatment in haematopoietic stem cell...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-12T10:45:00Z","last_updated_date":"2020-08-12T10:45:00Z","reference_number":"EMADOC-628903358-2106","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202260-public-summary-opinion-orphan-designation-allogeneic-multi-virus-specific-t-lymphocytes-targeting-bk-virus-cytomegalovirus-human-herpesvirus-6-epstein-barr-virus-and-adenovirus-treatment_en.pdf"},
    {"id":"48586","name":"EU/3/20/2261: Public summary of opinion on orphan designation for asciminib for the treatment of chronic myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-12T11:05:00Z","last_updated_date":"2020-08-12T11:05:00Z","reference_number":"EMADOC-628903358-2104","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202261-public-summary-opinion-orphan-designation-asciminib-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"48587","name":"EU/3/20/2262: Public summary of opinion on orphan designation for fosgemcitabine palabenamide for the treatment of biliary tract cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-12T11:49:00Z","last_updated_date":"2020-08-12T11:49:00Z","reference_number":"EMADOC-628903358-2105","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202262-public-summary-opinion-orphan-designation-fosgemcitabine-palabenamide-treatment-biliary-tract-cancer_en.pdf"},
    {"id":"48588","name":"EU/3/20/2263: Public summary of opinion on orphan designation for losmapimod for the treatment of facioscapulohumeral muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-12T12:02:00Z","last_updated_date":"2020-08-12T12:02:00Z","reference_number":"EMADOC-628903358-2102","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202263-public-summary-opinion-orphan-designation-losmapimod-treatment-facioscapulohumeral-muscular-dystrophy_en.pdf"},
    {"id":"48589","name":"EU/3/20/2264: Public summary of opinion on orphan designation for trifarotene for the treatment of autosomal recessive congenital ichthyosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-12T12:13:00Z","last_updated_date":"2022-06-07T10:51:00Z","reference_number":"EMADOC-628903358-2103","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202264-public-summary-opinion-orphan-designation-trifarotene-treatment-autosomal-recessive-congenital-ichthyosis_en.pdf"},
    {"id":"48590","name":"EU/3/20/2268: Public summary of positive opinion for orphan designation of florbetaben (18F) for the diagnosis of AL amyloidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-12T13:32:00Z","last_updated_date":"2020-08-12T13:32:00Z","reference_number":"EMADOC-628903358-2227","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202268-public-summary-positive-opinion-orphan-designation-florbetaben-18f-diagnosis-al-amyloidosis_en.pdf"},
    {"id":"48591","name":"EU/3/20/2270: Public summary of positive opinion for orphan designation of mitapivat sulfate for the treatment of pyruvate kinase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-12T13:44:00Z","last_updated_date":"2020-08-12T13:44:00Z","reference_number":"EMADOC-628903358-2222","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202270-public-summary-positive-opinion-orphan-designation-mitapivat-sulfate-treatment-pyruvate-kinase-deficiency_en.pdf"},
    {"id":"48592","name":"EU/3/20/2271: Public summary of positive opinion for orphan designation of haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-12T13:55:00Z","last_updated_date":"2020-08-12T13:55:00Z","reference_number":"EMADOC-628903358-2223","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202271-public-summary-positive-opinion-orphan-designation-haematopoietic-stem-cells-and-blood-progenitors-umbilical-cord-derived-expanded-1r-4r-n1-2-benzyl-7-2-methyl-2h-tetrazol-5-yl-9h-pyrimido45_en.pdf"},
    {"id":"48603","name":"EU/3/20/2272: Public summary of positive opinion for orphan designation of rozanolixizumab for the treatment of myasthenia gravis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-13T16:08:00Z","last_updated_date":"2020-08-13T16:08:00Z","reference_number":"EMADOC-628903358-2224","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202272-public-summary-positive-opinion-orphan-designation-rozanolixizumab-treatment-myasthenia-gravis_en.pdf"},
    {"id":"48604","name":"EU/3/20/2273: Public summary of positive opinion for orphan designation of 18-(p-(131I)-Iodophenyl)octadecyl phosphocholine for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-13T16:33:00Z","last_updated_date":"2020-08-13T16:33:00Z","reference_number":"EMADOC-628903358-2225","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202273-public-summary-positive-opinion-orphan-designation-18-p-131i-iodophenyloctadecyl-phosphocholine-treatment-multiple-myeloma_en.pdf"},
    {"id":"48607","name":"EU/3/20/2274: Public summary of positive opinion for orphan designation of adeno-associated virus vector serotype hu37 encoding human factor VIII for the treatment of haemophilia A","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-13T16:44:00Z","last_updated_date":"2020-08-13T16:44:00Z","reference_number":"EMADOC-628903358-2226","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202274-public-summary-positive-opinion-orphan-designation-adeno-associated-virus-vector-serotype-hu37-encoding-human-factor-viii-treatment-haemophilia_en.pdf"},
    {"id":"48608","name":"EU/3/20/2275: Public summary of positive opinion for orphan designation of glucagon analogue linked to a human immunoglobulin Fc fragment for the treatment of insulin autoimmune syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-13T17:02:00Z","last_updated_date":"2020-08-13T17:02:00Z","reference_number":"EMADOC-628903358-2228","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202275-public-summary-positive-opinion-orphan-designation-glucagon-analogue-linked-human-immunoglobulin-fc-fragment-treatment-insulin-autoimmune-syndrome_en.pdf"},
    {"id":"48626","name":"EU/3/20/2276: Public summary of opinion on orphan designation: Methotrexate for the treatment of retinal detachment","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T11:01:00Z","last_updated_date":"2020-08-19T11:01:00Z","reference_number":"EMADOC-628903358-2378","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202276-public-summary-opinion-orphan-designation-methotrexate-treatment-retinal-detachment_en.pdf"},
    {"id":"48627","name":"EU/3/20/2277: Public summary of opinion on orphan designation: Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T11:09:00Z","last_updated_date":"2020-08-19T11:09:00Z","reference_number":"EMADOC-628903358-2369","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202277-public-summary-opinion-orphan-designation-autologous-t-lymphocyte-enriched-population-cells-transduced-lentiviral-vector-encoding-chimeric-antigen-receptor-targeting-human-b-cell-maturation_en.pdf"},
    {"id":"48628","name":"EU/3/20/2278: Public summary of opinion on orphan designation:Rilzabrutinib for the treatment of immune thrombocytopenia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T11:50:00Z","last_updated_date":"2020-08-19T11:50:00Z","reference_number":"EMADOC-628903358-2371","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202278-public-summary-opinion-orphan-designationrilzabrutinib-treatment-immune-thrombocytopenia_en.pdf"},
    {"id":"48629","name":"EU/3/20/2279 : Public summary of opinion on orphan designation: Lumacaftor for the treatment of non-traumatic subarachnoid haemorrhage","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T12:04:00Z","last_updated_date":"2020-08-19T12:04:00Z","reference_number":"EMADOC-628903358-2372","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202279-public-summary-opinion-orphan-designation-lumacaftor-treatment-non-traumatic-subarachnoid-haemorrhage_en.pdf"},
    {"id":"48631","name":"EU/3/20/2280: Public summary of opinion on orphan designation: Lutetium (177Lu) lilotomab satetraxetan for the treatment of marginal zone lymphoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T12:41:00Z","last_updated_date":"2020-08-19T12:41:00Z","reference_number":"EMADOC-628903358-2370","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202280-public-summary-opinion-orphan-designation-lutetium-177lu-lilotomab-satetraxetan-treatment-marginal-zone-lymphoma_en.pdf"},
    {"id":"48632","name":"EU/3/20/2281: Public summary of opinion on orphan designation: (4-{(2S,4S)-4-Ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1)) for the treatment of paroxysmal nocturnal haemoglobinuria","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T12:51:00Z","last_updated_date":"2020-08-19T12:51:00Z","reference_number":"EMADOC-628903358-2373","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202281-public-summary-opinion-orphan-designation-4-2s4s-4-ethoxy-1-5-methoxy-7-methyl-1h-indol-4-ylmethylpiperidin-2-ylbenzoic-acid-hydrogen-chloride11-treatment-paroxysmal-nocturnal_en.pdf"},
    {"id":"48633","name":"EU/3/20/2282 : Public summary of opinion on orphan designation: Viltolarsen for the treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T13:07:00Z","last_updated_date":"2020-08-19T13:07:00Z","reference_number":"EMADOC-628903358-2374","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202282-public-summary-opinion-orphan-designation-viltolarsen-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"48640","name":"EU/3/20/2283: Public summary of opinion on orphan designation: Ile-Ala-Leu-Ile-Leu-Glu-Pro-Ile-Cys-Cys-Gln-Glu-Arg-Ala-Ala-(discrete-polyethylene glycol)24 for the treatment of neonatal encephalopathy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T17:38:00Z","last_updated_date":"2020-08-19T17:38:00Z","reference_number":"EMADOC-628903358-2375","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202283-public-summary-opinion-orphan-designation-ile-ala-leu-ile-leu-glu-pro-ile-cys-cys-gln-glu-arg-ala-ala-discrete-polyethylene-glycol24-treatment-neonatal-encephalopathy_en.pdf"},
    {"id":"48641","name":"EU/3/20/2284: Public summary of opinion on orphan designation: Sodium phenylbutyrate, tauroursodeoxycholic acid for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T17:51:00Z","last_updated_date":"2020-08-19T17:51:00Z","reference_number":"EMADOC-628903358-2376","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202284-public-summary-opinion-orphan-designation-sodium-phenylbutyrate-tauroursodeoxycholic-acid-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"48642","name":"EU/3/20/2285 : Public summary of opinion on orphan designation: 1-((2S,4S)-2-((((S)-(4-Bromophenoxy)(((S)-1-oxo-1-(((S)-pentan-2-yl)oxy)propan-2-yl)amino)phosphoryl)oxy)methyl)-1,3-dioxolan-4-yl)-2-oxo-1,2-dihydropyrimidin-4-aminium chloride for the treat","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T18:03:00Z","last_updated_date":"2020-08-19T18:03:00Z","reference_number":"EMADOC-628903358-2379","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202285-public-summary-opinion-orphan-designation-1-2s4s-2-s-4-bromophenoxys-1-oxo-1-s-pentan-2-yloxypropan-2-ylaminophosphoryloxymethyl-13-dioxolan-4-yl-2-oxo-12-dihydropyrimidin-4-aminium-chloride_en.pdf"},
    {"id":"48643","name":"EU/3/20/2286: Public summary of opinion on orphan designation: Autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding an affinity enhanced T cell receptor specific to MAGE-A4 for the treatment of soft tissue sarcoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T18:14:00Z","last_updated_date":"2020-08-19T18:14:00Z","reference_number":"EMADOC-628903358-2380","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202286-public-summary-opinion-orphan-designation-autologous-cd4-and-cd8-t-cells-transduced-lentiviral-vector-encoding-affinity-enhanced-t-cell-receptor-specific-mage-a4-treatment-soft-tissue_en.pdf"},
    {"id":"48644","name":"EU/3/20/2287: Public summary of opinion on orphan designation: Adeno-associated virus serotype 9 containing the human ASPA gene for the treatment of Canavan disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2020-08-19T18:25:00Z","last_updated_date":"2020-08-19T18:25:00Z","reference_number":"EMADOC-628903358-2377","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202287-public-summary-opinion-orphan-designation-adeno-associated-virus-serotype-9-containing-human-aspa-gene-treatment-canavan-disease_en.pdf"},
    {"id":"48874","name":"EU/3/20/2288: Public summary of opinion on orphan designation for Magrolimab for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-22T10:33:00Z","last_updated_date":"2020-09-22T10:33:00Z","reference_number":"EMADOC-628903358-2476","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202288-public-summary-opinion-orphan-designation-magrolimab-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"48875","name":"EU/3/20/2289: Public summary of opinion on orphan designation for Nomacopan for the treatment of bullous pemphigoid","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-22T10:56:00Z","last_updated_date":"2020-09-22T10:56:00Z","reference_number":"EMADOC-628903358-2477","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202289-public-summary-opinion-orphan-designation-nomacopan-treatment-bullous-pemphigoid_en.pdf"},
    {"id":"48876","name":"EU/3/20/2290: Public summary of opinion on orphan designation for Stiripentol for the treatment of primary hyperoxaluria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-22T11:03:00Z","last_updated_date":"2020-09-22T11:03:00Z","reference_number":"EMADOC-628903358-2478","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202290-public-summary-opinion-orphan-designation-stiripentol-treatment-primary-hyperoxaluria_en.pdf"},
    {"id":"48877","name":"EU/3/20/2291: Public summary of opinion on orphan designation for Onfekafusp alfa for the treatment of glioma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-22T11:31:00Z","last_updated_date":"2020-09-22T11:31:00Z","reference_number":"EMADOC-628903358-2479","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202291-public-summary-opinion-orphan-designation-onfekafusp-alfa-treatment-glioma_en.pdf"},
    {"id":"48882","name":"EU/3/20/2292: Public summary of opinion on orphan designation for Anti-CD123 IgG1 humanised monoclonal antibody conjugated to N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-23T15:43:00Z","last_updated_date":"2020-09-23T15:43:00Z","reference_number":"EMADOC-628903358-2480","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202292-public-summary-opinion-orphan-designation-anti-cd123-igg1-humanised-monoclonal-antibody-conjugated-n1-2-25-dioxo-25-dihydro-1h-pyrrol-1-ylethyl-n6-s-1-s-1-3-s-8-methoxy-6-oxo-111212a13_en.pdf"},
    {"id":"48883","name":"EU/3/20/2293: Public summary of opinion on orphan designation for (+)-Epicatechin for the treatment of Becker muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-23T15:54:00Z","last_updated_date":"2020-09-23T15:54:00Z","reference_number":"EMADOC-628903358-2482","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202293-public-summary-opinion-orphan-designation-epicatechin-treatment-becker-muscular-dystrophy_en.pdf"},
    {"id":"48884","name":"EU/3/20/2294: Public summary of opinion on orphan designation for Sodium cromoglicate for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-23T16:02:00Z","last_updated_date":"2020-09-23T16:02:00Z","reference_number":"EMADOC-628903358-2481","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202294-public-summary-opinion-orphan-designation-sodium-cromoglicate-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"48887","name":"EU/3/20/2295: Public summary of opinion on orphan designation for Lys40(NODAGA-68Ga)NH2-exendin-4 for the diagnosis of insulinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-24T12:31:00Z","last_updated_date":"2020-09-24T12:31:00Z","reference_number":"EMADOC-628903358-2483","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202295-public-summary-opinion-orphan-designation-lys40nodaga-68ganh2-exendin-4-diagnosis-insulinoma_en.pdf"},
    {"id":"48888","name":"EU/3/20/2296: Public summary of opinion on orphan designation for Axicabtagene ciloleucel for the treatment of marginal zone lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-24T14:40:00Z","last_updated_date":"2020-09-24T14:40:00Z","reference_number":"EMADOC-628903358-2484","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202296-public-summary-opinion-orphan-designation-axicabtagene-ciloleucel-treatment-marginal-zone-lymphoma_en.pdf"},
    {"id":"49280","name":"EU/3/20/2299: Public summary of opinion on orphan designation: C-type natriuretic peptide conjugated to multi-arm polyethylene glycol carrier through a cleavable linker for the treatment of achondroplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2617","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202299-public-summary-opinion-orphan-designation-c-type-natriuretic-peptide-conjugated-multi-arm-polyethylene-glycol-carrier-through-cleavable-linker-treatment-achondroplasia_en.pdf"},
    {"id":"49281","name":"EU/3/20/2300: Public summary of opinion on orphan designation: Fasudil hydrochloride for the treatment of non-traumatic subarachnoid haemorrhage","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2616","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202300-public-summary-opinion-orphan-designation-fasudil-hydrochloride-treatment-non-traumatic-subarachnoid-haemorrhage_en.pdf"},
    {"id":"49282","name":"EU/3/20/2301: Public summary of opinion on orphan designation: Pegylated adrenomedullin for the treatment of acute respiratory distress syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2618","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202301-public-summary-opinion-orphan-designation-pegylated-adrenomedullin-treatment-acute-respiratory-distress-syndrome_en.pdf"},
    {"id":"49284","name":"EU/3/20/2302: Public summary of opinion on orphan designation: Triheptanoin for the treatment of carnitine-acylcarnitine translocase deficiency","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2624","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202302-public-summary-opinion-orphan-designation-triheptanoin-treatment-carnitine-acylcarnitine-translocase-deficiency_en.pdf"},
    {"id":"49285","name":"EU/3/20/2303: Public summary of opinion on orphan designation: Adeno-associated viral vector expressing acid alpha-glucosidase gene for the treatment of glycogen storage disease type II (Pompe's disease)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2619","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202303-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-expressing-acid-alpha-glucosidase-gene-treatment-glycogen-storage-disease-type-ii-pompes-disease_en.pdf"},
    {"id":"49286","name":"EU/3/20/2304: Public summary of opinion on orphan designation: Maralixibat chloride for the treatment of biliary atresia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2620","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202304-public-summary-opinion-orphan-designation-maralixibat-chloride-treatment-biliary-atresia_en.pdf"},
    {"id":"49287","name":"EU/3/20/2305: Public summary of opinion on orphan designation: Imetelstat sodium for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2621","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202305-public-summary-opinion-orphan-designation-imetelstat-sodium-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"49288","name":"EU/3/20/2306: Public summary of opinion on orphan designation: Retinol palmitate for the prevention of bronchopulmonary dysplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2622","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202306-public-summary-opinion-orphan-designation-retinol-palmitate-prevention-bronchopulmonary-dysplasia_en.pdf"},
    {"id":"49289","name":"EU/3/20/2307: Public summary of opinion on orphan designation: Tinostamustine for the treatment of T-cell prolymphocytic leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2623","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202307-public-summary-opinion-orphan-designation-tinostamustine-treatment-t-cell-prolymphocytic-leukaemia_en.pdf"},
    {"id":"49290","name":"Public summary of opinion on orphan designation: Melatonin for the treatment of intracerebral haemorrhage","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2614","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-melatonin-treatment-intracerebral-haemorrhage_en.pdf"},
    {"id":"49291","name":"Public summary of opinion on orphan designation: Benzyl benzoate, beta-caryophyllene, cineole, cinnamaldehyde, cinnamyl acetate, linalool, trans-2-methoxycinnamaldehyde for the treatment of eumycetoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T01:00:00Z","last_updated_date":"2020-11-19T01:00:00Z","reference_number":"EMADOC-628903358-2613","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/public-summary-opinion-orphan-designation-benzyl-benzoate-beta-caryophyllene-cineole-cinnamaldehyde-cinnamyl-acetate-linalool-trans-2-methoxycinnamaldehyde-treatment-eumycetoma_en.pdf"},
    {"id":"49300","name":"EU/3/20/2308: Public summary of opinion on orphan designation: Allogeneic umbilical cord tissue-derived mesenchymal stromal cells ex vivo expanded for the prevention of bronchopulmonary dysplasia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-24T01:00:00Z","last_updated_date":"2020-11-24T01:00:00Z","reference_number":"EMADOC-628903358-2736","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202308-public-summary-opinion-orphan-designation-allogeneic-umbilical-cord-tissue-derived-mesenchymal-stromal-cells-ex-vivo-expanded-prevention-bronchopulmonary-dysplasia_en.pdf"},
    {"id":"49301","name":"EU/3/20/2309: Public summary of opinion on orphan designation: Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-beta-D-galactopyranosyl) sulfane for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2737","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202309-public-summary-opinion-orphan-designation-bis-3-deoxy-3-4-3-fluorophenyl-1h-123-triazol-1-yl-beta-d-galactopyranosyl-sulfane-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"49303","name":"EU/3/20/2310: Public summary of opinion on orphan designation: Adeno-associated virus serotype 2/8 vector containing the human PDE6A gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2738","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202310-public-summary-opinion-orphan-designation-adeno-associated-virus-serotype-28-vector-containing-human-pde6a-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"49304","name":"EU/3/20/2311: Public summary of opinion on orphan designation: Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2739","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202311-public-summary-opinion-orphan-designation-sodium-4-e-3-4-fluorophenyl-3-4-3-morpholin-4-yl-prop1ynylphenylallyloxy-2-methylphenoxyacetate_en.pdf"},
    {"id":"49305","name":"EU/3/20/2312: Public summary of opinion on orphan designation: Allogeneic hepatoblastoma cells encapsulated in alginate, ex vivo expanded for the treatment of acute liver failure","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2740","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202312-public-summary-opinion-orphan-designation-allogeneic-hepatoblastoma-cells-encapsulated-alginate-ex-vivo-expanded-treatment-acute-liver-failure_en.pdf"},
    {"id":"49306","name":"EU/3/20/2313: Public summary of opinion on orphan designation: 2-(2-(18F)fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine for the diagnosis of progressive supranuclear palsy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2756","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202313-public-summary-opinion-orphan-designation-2-2-18ffluoropyridin-4-yl-9h-pyrrolo23-b45-cdipyridine-diagnosis-progressive-supranuclear-palsy_en.pdf"},
    {"id":"49307","name":"EU/3/20/2314: Public summary of opinion on orphan designation: Humanised IgG1 monoclonal antibody against human eotaxin-2 for the treatment of primary sclerosing cholangitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2741","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202314-public-summary-opinion-orphan-designation-humanised-igg1-monoclonal-antibody-against-human-eotaxin-2-treatment-primary-sclerosing-cholangitis_en.pdf"},
    {"id":"49308","name":"EU/3/20/2315: Public summary of opinion on orphan designation: Pentosan polysulfate sodium for the treatment of mucopolysaccharidosis type VI","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2742","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202315-public-summary-opinion-orphan-designation-pentosan-polysulfate-sodium-treatment-mucopolysaccharidosis-type-vi_en.pdf"},
    {"id":"49309","name":"EU/3/20/2316: Public summary of opinion on orphan designation: Protein-based delivery vector carrying a DNA payload encoding an RNA-guided nuclease that targets stx genes of Shiga toxin-producing Escherichia coli","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2743","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202316-public-summary-opinion-orphan-designation-protein-based-delivery-vector-carrying-dna-payload-encoding-rna-guided-nuclease-targets-stx-genes-shiga-toxin-producing-escherichia-coli_en.pdf"},
    {"id":"49337","name":"EU/3/20/2317: Public summary of opinion on orphan designation: Allogeneic T-cell precursors, mobilised peripheral blood-derived, ex vivo cultured for treatment in haematopoietic stem cell transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2744","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202317-public-summary-opinion-orphan-designation-allogeneic-t-cell-precursors-mobilised-peripheral-blood-derived-ex-vivo-cultured-treatment-haematopoietic-stem-cell-transplantation_en.pdf"},
    {"id":"49338","name":"EU/3/20/2318: Public summary of opinion on orphan designation: Dextran sulfate low molecular weight for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2745","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202318-public-summary-opinion-orphan-designation-dextran-sulfate-low-molecular-weight-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"49339","name":"EU/3/20/2319: Public summary of opinion on orphan designation: Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2746","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202319-public-summary-opinion-orphan-designation-sodium-4-e-3-4-fluorophenyl-3-4-3-morpholin-4-yl-prop1ynylphenylallyloxy-2-methylphenoxyacetate_en.pdf"},
    {"id":"49340","name":"EU/3/20/2320: Public summary of opinion on orphan designation: Copper histidinate for the treatment of Menkes disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2748","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202320-public-summary-opinion-orphan-designation-copper-histidinate-treatment-menkes-disease_en.pdf"},
    {"id":"49341","name":"EU/3/20/2321: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 3B encoding shortened human ATP7B for the treatment of Wilson's disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2747","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202321-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-3b-encoding-shortened-human-atp7b-treatment-wilsons-disease_en.pdf"}    {"id":"49342","name":"EU/3/20/2322: Public summary of opinion on orphan designation: 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-yl-methyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7H-imidazo(1,5-a)pyrazin-8-one for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2022-11-08T11:05:00Z","reference_number":"EMADOC-628903358-2749","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202322-public-summary-opinion-orphan-designation-6-3s4s-4-methyl-1-pyrimidin-2-yl-methylpyrrolidin-3-yl-3-tetrahydropyran-4-yl-7h-imidazo15-apyrazin-8-one-treatment-sickle-cell-disease_en.pdf"},
    {"id":"49343","name":"EU/3/20/2323: Public summary of opinion on orphan designation: Trehalose for the treatment of mucopolysaccharidosis type III","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2750","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202323-public-summary-opinion-orphan-designation-trehalose-treatment-mucopolysaccharidosis-type-iii_en.pdf"},
    {"id":"49344","name":"EU/3/20/2324: Public summary of opinion on orphan designation: 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile for the treatment of von Hippel-Lindau disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2751","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202324-public-summary-opinion-orphan-designation-3-1s2s3r-23-difluoro-1-hydroxy-7-methylsulfonyl-23-dihydro-1h-inden-4-yloxy-5-fluorobenzonitrile-treatment-von-hippel-lindau-disease_en.pdf"},
    {"id":"49345","name":"EU/3/20/2325: Public summary of opinion on orphan designation: Venglustat for the treatment of GM2 gangliosidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2752","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202325-public-summary-opinion-orphan-designation-venglustat-treatment-gm2-gangliosidosis_en.pdf"},
    {"id":"49346","name":"EU/3/20/2326: Public summary of opinion on orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta for the treatment of Gaucher disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2753","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202326-public-summary-opinion-orphan-designation-autologous-cd34-cells-transduced-lentiviral-vector-encoding-glucosylceramidase-beta-treatment-gaucher-disease_en.pdf"},
    {"id":"49347","name":"EU/3/20/2327: Public summary of opinion on orphan designation: Autologous T cells transduced with lentiviral vector containing a tandem chimeric antigen receptor directed against CD20 and CD19","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2754","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202327-public-summary-opinion-orphan-designation-autologous-t-cells-transduced-lentiviral-vector-containing-tandem-chimeric-antigen-receptor-directed-against-cd20-and-cd19_en.pdf"},
    {"id":"49348","name":"EU/3/20/2328: Public summary of opinion on orphan designation: Human frataxin fused to TAT cell-penetrating peptide for the treatment of Friedreich's ataxia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2020-11-25T01:00:00Z","reference_number":"EMADOC-628903358-2755","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202328-public-summary-opinion-orphan-designation-human-frataxin-fused-tat-cell-penetrating-peptide-treatment-friedreichs-ataxia_en.pdf"},
    {"id":"49349","name":"EU/3/20/2329: Public summary of opinion on orphan designation: Infigratinib for the treatment of cholangiocarcinoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-25T01:00:00Z","last_updated_date":"2022-11-08T10:44:00Z","reference_number":"EMADOC-628903358-2757","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202329-public-summary-opinion-orphan-designation-infigratinib-treatment-cholangiocarcinoma_en.pdf"},
    {"id":"50120","name":"EU/3/20/2330: Public summary of opinion on orphan designation:1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-11T01:00:00Z","last_updated_date":"2021-02-11T01:00:00Z","reference_number":"EMADOC-628903358-3059","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202330-public-summary-opinion-orphan-designation1-3-methylbutanoyl-l-aspartyl-l-threonyl-l-histidyl-l-phenylalanyl-l-prolyl-l-cystinyl-l-isoleucyl-n6-s-4-carboxy-4-palmitamidobutanoyl-l-lysinyl-l_en.pdf"},
    {"id":"50121","name":"EU/3/20/2331: Public summary of opinion on orphan designation: Teclistamab for the treatment of multiple myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-11T01:00:00Z","last_updated_date":"2022-07-22T11:13:00Z","reference_number":"EMADOC-628903358-3061","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202331-public-summary-opinion-orphan-designation-teclistamab-treatment-multiple-myeloma_en.pdf"},
    {"id":"50123","name":"EU/3/20/2332: Public summary of opinion on orphan designation: Retigabine for the treatment of KCNQ2 developmental and epileptic encephalopathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-12T01:00:00Z","last_updated_date":"2021-02-12T01:00:00Z","reference_number":"EMADOC-628903358-3060","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202332-public-summary-opinion-orphan-designation-retigabine-treatment-kcnq2-developmental-and-epileptic-encephalopathy_en.pdf"},
    {"id":"50124","name":"EU/3/20/2333: Public summary of opinion on orphan designation: Tipifarnib for the treatment of peripheral T-cell lymphoma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-12T01:00:00Z","last_updated_date":"2021-02-12T01:00:00Z","reference_number":"EMADOC-628903358-3041","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202333-public-summary-opinion-orphan-designation-tipifarnib-treatment-peripheral-t-cell-lymphoma_en.pdf"},
    {"id":"50125","name":"EU/3/20/2334: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene for the treatment of aspartylglucosaminuria","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-12T01:00:00Z","last_updated_date":"2021-02-12T01:00:00Z","reference_number":"EMADOC-628903358-3040","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202334-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-encoding-codon-optimised-human-aspartylglucosaminidase-transgene-treatment-aspartylglucosaminuria_en.pdf"},
    {"id":"50126","name":"EU/3/20/2335: Public summary of opinion on orphan designation: (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-15T01:00:00Z","last_updated_date":"2021-02-15T01:00:00Z","reference_number":"EMADOC-628903358-3042","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202335-public-summary-opinion-orphan-designation-s-1-5-23-dihydro-14dioxino23-bpyridin-7-ylsulfonyl-3456-tetrahydropyrrolo34-cpyrrol-21h-yl-3-hydroxy-2-phenylpropan-1-one-treatment-sickle-cell_en.pdf"},
    {"id":"50127","name":"EU/3/20/2336: Public summary of opinion on orphan designation: (4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1)) for the treatment of primary IgA nephropathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-15T01:00:00Z","last_updated_date":"2021-02-15T01:00:00Z","reference_number":"EMADOC-628903358-3043","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202336-public-summary-opinion-orphan-designation-4-2s4s-4-ethoxy-1-5-methoxy-7-methyl-1h-indol-4-ylmethylpiperidin-2-ylbenzoic-acid-hydrogen-chloride11-treatment-primary-iga-nephropathy_en.pdf"},
    {"id":"50128","name":"EU/3/20/2337: Public summary of opinion on orphan designation: Ribitol for the treatment of limb-girdle muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-25T01:00:00Z","last_updated_date":"2021-05-25T01:00:00Z","reference_number":"EMADOC-628903358-3044","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202337-public-summary-opinion-orphan-designation-ribitol-treatment-limb-girdle-muscular-dystrophy_en.pdf"},
    {"id":"50129","name":"EU/3/20/2338: Public summary of opinion on orphan designation: Decitabine, tetrahydrouridine for the treatment of sickle cell disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-15T01:00:00Z","last_updated_date":"2021-02-15T01:00:00Z","reference_number":"EMADOC-628903358-3045","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202338-public-summary-opinion-orphan-designation-decitabine-tetrahydrouridine-treatment-sickle-cell-disease_en.pdf"},
    {"id":"50130","name":"EU/3/20/2339: Public summary of opinion on orphan designation: Leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-25T01:00:00Z","last_updated_date":"2021-05-25T01:00:00Z","reference_number":"EMADOC-628903358-3046","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202339-public-summary-opinion-orphan-designation-leniolisib-treatment-activated-phosphoinositide-3-kinase-delta-syndrome-apds_en.pdf"},
    {"id":"50131","name":"EU/3/20/2340: Public summary of opinion on orphan designation: 2-(2-(18F)fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine for the diagnosis of corticobasal degeneration","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-15T01:00:00Z","last_updated_date":"2021-02-15T01:00:00Z","reference_number":"EMADOC-628903358-3048","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202340-public-summary-opinion-orphan-designation-2-2-18ffluoropyridin-4-yl-9h-pyrrolo23-b45-cdipyridine-diagnosis-corticobasal-degeneration_en.pdf"},
    {"id":"50132","name":"EU/3/20/2341: Public summary of opinion on orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha for the treatment of Fabry disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T01:00:00Z","last_updated_date":"2021-02-16T01:00:00Z","reference_number":"EMADOC-628903358-3047","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202341-public-summary-opinion-orphan-designation-autologous-cd34-cells-transduced-lentiviral-vector-encoding-galactosidase-alpha-treatment-fabry-disease_en.pdf"},
    {"id":"50133","name":"EU/3/20/2342: Public summary of opinion on orphan designation: Highly branched poly(beta-amino ester) complexed with a nanoplasmid containing the human COL7A1 gene for the treatment of epidermolysis bullosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T01:00:00Z","last_updated_date":"2021-02-16T01:00:00Z","reference_number":"EMADOC-628903358-3049","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202342-public-summary-opinion-orphan-designation-highly-branched-polybeta-amino-ester-complexed-nanoplasmid-containing-human-col7a1-gene-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"50134","name":"EU/3/20/2343: Public summary of opinion on orphan designation: Retifanlimab for the treatment of anal cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T01:00:00Z","last_updated_date":"2021-02-16T01:00:00Z","reference_number":"EMADOC-628903358-3050","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202343-public-summary-opinion-orphan-designation-retifanlimab-treatment-anal-cancer_en.pdf"},
    {"id":"50135","name":"EU/3/20/2344: Public summary of opinion on orphan designation: Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T01:00:00Z","last_updated_date":"2021-02-16T01:00:00Z","reference_number":"EMADOC-628903358-3051","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202344-public-summary-opinion-orphan-designation-autologous-peripheral-blood-t-cells-cd4-and-cd8-selected-and-cd3-and-cd28-activated-transduced-retroviral-vector-expressing-anti-cd19-cd28cd3-zeta_en.pdf"},
    {"id":"50136","name":"EU/3/20/2345: Public summary of opinion on orphan designation: Sparsentan for the treatment of primary IgA nephropathy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T01:00:00Z","last_updated_date":"2021-02-16T01:00:00Z","reference_number":"EMADOC-628903358-3052","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202345-public-summary-opinion-orphan-designation-sparsentan-treatment-primary-iga-nephropathy_en.pdf"},
    {"id":"50138","name":"EU/3/20/2346: Public summary of opinion on orphan designation: Adeno-associated virus serotype hu68 containing the human GLB1 gene for the treatment of GM1 gangliosidosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T01:00:00Z","last_updated_date":"2021-02-16T01:00:00Z","reference_number":"EMADOC-628903358-3053","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202346-public-summary-opinion-orphan-designation-adeno-associated-virus-serotype-hu68-containing-human-glb1-gene-treatment-gm1-gangliosidosis_en.pdf"},
    {"id":"50139","name":"EU/3/20/2347: Public summary of opinion on orphan designation: Trehalose for the treatment of neuronal ceroid lipofuscinosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T01:00:00Z","last_updated_date":"2021-02-16T01:00:00Z","reference_number":"EMADOC-628903358-3054","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202347-public-summary-opinion-orphan-designation-trehalose-treatment-neuronal-ceroid-lipofuscinosis_en.pdf"},
    {"id":"50140","name":"EU/3/20/2348: Public summary of opinion on orphan designation: Poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-, amide with cystathionine γ-lyase [pyridoxal 5’-phosphate cofactor] (synthetic engineered human)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-18T01:00:00Z","last_updated_date":"2021-02-18T01:00:00Z","reference_number":"EMADOC-628903358-3055","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-20-2348-public-summary-opinion-orphan-designation-polyoxy-12-ethanediyl-alpha-carboxymethyl-omega-methoxy-amide-cystathionine-g-lyase-pyridoxal-5-phosphate-cofactor-synthetic-engineered-human_en.pdf"},
    {"id":"50141","name":"EU/3/20/2349: Public summary of opinion on orphan designation: Miglustat for the treatment of neuronal ceroid lipofuscinosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-18T01:00:00Z","last_updated_date":"2021-02-18T01:00:00Z","reference_number":"EMADOC-628903358-3056","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202349-public-summary-opinion-orphan-designation-miglustat-treatment-neuronal-ceroid-lipofuscinosis_en.pdf"},
    {"id":"50142","name":"EU/3/20/2350: Public summary of opinion on orphan designation: Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-18T01:00:00Z","last_updated_date":"2021-02-18T01:00:00Z","reference_number":"EMADOC-628903358-3058","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202350-public-summary-opinion-orphan-designation-polyoxy-12-ethanediyl-alpha-hydro-omega-methoxy-ether-n-2-6-1-3-3-23-dihydroxypropoxypropylamino-3-oxopropyl-25-dioxo-3_en.pdf"},
    {"id":"50143","name":"EU/3/20/2351: Public summary of opinion on orphan designation: Adeno-associated virus serotype 5 containing the human RDH12 gene for the treatment of RDH12 mutation associated retinal dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-18T01:00:00Z","last_updated_date":"2021-02-18T01:00:00Z","reference_number":"EMADOC-628903358-3057","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202351-public-summary-opinion-orphan-designation-adeno-associated-virus-serotype-5-containing-human-rdh12-gene-treatment-rdh12-mutation-associated-retinal-dystrophy_en.pdf"},
    {"id":"50163","name":"EU/3/20/2352: Public summary of opinion on orphan designation: (R)‑tetrahydrofuran‑3‑yl 4‑(6‑(5‑(4‑ethoxy‑1‑isopropylpiperidin‑4‑yl)pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate for the treatment of fibrodysplasia ossi","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T10:57:00Z","last_updated_date":"2021-02-15T10:57:00Z","reference_number":"EMADOC-628903358-3454","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-20-2352-public-summary-opinion-orphan-designation-r-tetrahydrofuran-3-yl-4-6-5-4-ethoxy-1-isopropylpiperidin-4-ylpyridin-2-ylpyrrolo12-bpyridazin-4-ylpiperazine-1-carboxylate-sesquisuccinate_en.pdf"},
    {"id":"50164","name":"EU/3/20/2353: Public summary of opinion on orphan designation - Zanidatamab for the treatment of gastric cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T11:29:00Z","last_updated_date":"2021-02-15T11:29:00Z","reference_number":"EMADOC-628903358-3455","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202353-public-summary-opinion-orphan-designation-zanidatamab-treatment-gastric-cancer_en.pdf"},
    {"id":"50165","name":"EU/3/20/2354: Public summary of opinion on orphan designation - Alisitol, retinol palmitate, zinc gluconate for the treatment of microvillus inclusion disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T12:09:00Z","last_updated_date":"2021-02-15T12:09:00Z","reference_number":"EMADOC-628903358-3456","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202354-public-summary-opinion-orphan-designation-alisitol-retinol-palmitate-zinc-gluconate-treatment-microvillus-inclusion-disease_en.pdf"},
    {"id":"50166","name":"EU/3/20/2355: Public summary of opinion on orphan designation - Anti-(pancreatic adenocarcinoma upregulated factor) IgG1 humanised monoclonal antibody for the treatment of pancreatic cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T12:21:00Z","last_updated_date":"2021-02-15T12:21:00Z","reference_number":"EMADOC-628903358-3457","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202355-public-summary-opinion-orphan-designation-anti-pancreatic-adenocarcinoma-upregulated-factor-igg1-humanised-monoclonal-antibody-treatment-pancreatic-cancer_en.pdf"},
    {"id":"50167","name":"EU/3/20/2356: Public summary of opinion on orphan designation - Autologous CD34+ cells transduced ex vivo with a lentiviral vector containing a modified gamma-globin gene for the treatment of sickle cell disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T12:32:00Z","last_updated_date":"2022-09-16T14:59:00Z","reference_number":"EMADOC-628903358-3459","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202356-public-summary-opinion-orphan-designation-autologous-cd34-cells-transduced-ex-vivo-lentiviral-vector-containing-modified-gamma-globin-gene-treatment-sickle-cell-disease_en.pdf"},
    {"id":"50168","name":"EU/3/20/2357: Public summary of opinion on orphan designation - Tislelizumab for the treatment of oesophageal cancer","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T12:41:00Z","last_updated_date":"2021-02-15T12:41:00Z","reference_number":"EMADOC-628903358-3458","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202357-public-summary-opinion-orphan-designation-tislelizumab-treatment-oesophageal-cancer_en.pdf"},
    {"id":"50169","name":"EU/3/20/2358: Public summary of opinion on orphan designation - L-pyroglutamyl-L-asparaginyl-L-prolyl-D-tyrosyl-D-tryptophan amide for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T12:58:00Z","last_updated_date":"2021-02-15T12:58:00Z","reference_number":"EMADOC-628903358-3460","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202358-public-summary-opinion-orphan-designation-l-pyroglutamyl-l-asparaginyl-l-prolyl-d-tyrosyl-d-tryptophan-amide-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"50170","name":"EU/3/20/2359: Public summary of opinion for orphan designation - Adeno-associated viral vector serotype 9 expressing codon-optimized human GRN gene for the treatment of frontotemporal dementia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T14:31:00Z","last_updated_date":"2021-02-15T14:31:00Z","reference_number":"EMADOC-628903358-3461","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202359-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-expressing-codon-optimized-human-grn-gene-treatment-frontotemporal-dementia_en.pdf"},
    {"id":"50172","name":"EU/3/20/2360: Public summary of opinion for orphan designation - Triheptanoin for the treatment of carnitine palmitoyltransferase I deficiency","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T16:03:00Z","last_updated_date":"2021-02-15T16:03:00Z","reference_number":"EMADOC-628903358-3462","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202360-public-summary-opinion-orphan-designation-triheptanoin-treatment-carnitine-palmitoyltransferase-i-deficiency_en.pdf"},
    {"id":"50173","name":"EU/3/20/2361: Public summary of opinion for orphan designation - Perflubron for the treatment of congenital pulmonary hypoplasia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T16:47:00Z","last_updated_date":"2021-02-15T16:47:00Z","reference_number":"EMADOC-628903358-3463","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202361-public-summary-opinion-orphan-designation-perflubron-treatment-congenital-pulmonary-hypoplasia_en.pdf"},
    {"id":"50174","name":"EU/3/20/2362: Public summary of opinion for orphan designation - Autologous bone marrow derived CD34+ cells transduced ex vivo with a self-inactivating lentiviral vector containing a normal version of the coding region of the IL2RG gene","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T17:01:00Z","last_updated_date":"2021-02-15T17:01:00Z","reference_number":"EMADOC-628903358-3464","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202362-public-summary-opinion-orphan-designation-autologous-bone-marrow-derived-cd34-cells-transduced-ex-vivo-self-inactivating-lentiviral-vector-containing-normal-version-coding-region-il2rg-gene_en.pdf"},
    {"id":"50175","name":"EU/3/20/2363: Public summary of opinion on orphan designation - 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxamide, sodium chloride solution 4.2% (w/v) for th","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T17:10:00Z","last_updated_date":"2021-02-15T17:10:00Z","reference_number":"EMADOC-628903358-3465","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202363-public-summary-opinion-orphan-designation-35-diamino-6-chloro-n-n-4-4-2-hexyl2s3r4r5r-23456-pentahydroxyhexylaminoethoxyphenylbutyl-carbamimidoylpyrazine-2-carboxamide-sodium-chloride_en.pdf"},
    {"id":"50176","name":"EU/3/20/2364: Public summary of opinion on orphan designation - DNA plasmid encoding human transferrin gene for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T17:20:00Z","last_updated_date":"2021-02-15T17:20:00Z","reference_number":"EMADOC-628903358-3466","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202364-public-summary-opinion-orphan-designation-dna-plasmid-encoding-human-transferrin-gene-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"51163","name":"EU/3/20/2385: Public summary of opinion on orphan designation: Rezafungin acetate for the treatment of invasive candidiasis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4019","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202385-public-summary-opinion-orphan-designation-rezafungin-acetate-treatment-invasive-candidiasis_en.pdf"},
    {"id":"51164","name":"EU/3/20/2386: Public summary of opinion on orphan designation: Calcium oxybate, magnesium oxybate, potassium oxybate, sodium oxybate for the treatment of idiopathic hypersomnia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4020","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202386-public-summary-opinion-orphan-designation-calcium-oxybate-magnesium-oxybate-potassium-oxybate-sodium-oxybate-treatment-idiopathic-hypersomnia_en.pdf"},
    {"id":"51165","name":"EU/3/20/2387: Public summary of opinion on orphan designation: Setanaxib for the treatment of primary biliary cholangitis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202387-public-summary-opinion-orphan-designation-setanaxib-treatment-primary-biliary-cholangitis_en.pdf"},
    {"id":"51166","name":"EU/3/20/2388: Public summary of opinion on orphan designation: Human laminin-111, recombinant for the treatment of congenital muscular dystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4021","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202388-public-summary-opinion-orphan-designation-human-laminin-111-recombinant-treatment-congenital-muscular-dystrophy_en.pdf"},
    {"id":"51167","name":"EU/3/20/2389: Public summary of opinion on orphan designation: Cyclo-L-glycyl-L-2-allylproline for the treatment of Angelman syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4022","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202389-public-summary-opinion-orphan-designation-cyclo-l-glycyl-l-2-allylproline-treatment-angelman-syndrome_en.pdf"},
    {"id":"51168","name":"EU/3/20/2390: Public summary of opinion on orphan designation: Rilonacept for the treatment of idiopathic pericarditis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4023","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202390-public-summary-opinion-orphan-designation-rilonacept-treatment-idiopathic-pericarditis_en.pdf"},
    {"id":"51169","name":"EU/3/20/2391: Public summary of opinion on orphan designation: Idursulfase for the treatment of mucopolysaccharidosis type II (Hunter's syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2023-01-27T13:01:00Z","reference_number":"EMADOC-628903358-4024","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202391-public-summary-opinion-orphan-designation-idursulfase-treatment-mucopolysaccharidosis-type-ii-hunters-syndrome_en.pdf"},
    {"id":"51171","name":"EU/3/20/2392: Public summary of opinion on orphan designation: Humanised IgG1K monoclonal antibody against interferon beta for the treatment of dermatomyositis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4025","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202392-public-summary-opinion-orphan-designation-humanised-igg1k-monoclonal-antibody-against-interferon-beta-treatment-dermatomyositis_en.pdf"},
    {"id":"51172","name":"EU/3/20/2393: Public summary of opinion on orphan designation: Cyclo-L-glycyl-L-2-allylproline for the treatment of Pitt-Hopkins syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4026","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202393-public-summary-opinion-orphan-designation-cyclo-l-glycyl-l-2-allylproline-treatment-pitt-hopkins-syndrome_en.pdf"},
    {"id":"51173","name":"EU/3/20/2394: Public summary of opinion on orphan designation: Cyclo-L-glycyl-L-2-allylproline for the treatment of Phelan-McDermid syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4029","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202394-public-summary-opinion-orphan-designation-cyclo-l-glycyl-l-2-allylproline-treatment-phelan-mcdermid-syndrome_en.pdf"},
    {"id":"51174","name":"EU/3/20/2395: Public summary of opinion on orphan designation: Celecoxib, ciprofloxacin for the treatment of amyotrophic lateral sclerosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4027","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202395-public-summary-opinion-orphan-designation-celecoxib-ciprofloxacin-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"51175","name":"EU/3/20/2396: Public summary of opinion on orphan designation: Alpha galactosidase A for the treatment of Fabry disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-18T01:00:00Z","last_updated_date":"2021-05-18T01:00:00Z","reference_number":"EMADOC-628903358-4028","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202396-public-summary-opinion-orphan-designation-alpha-galactosidase-treatment-fabry-disease_en.pdf"},
    {"id":"51193","name":"EU/3/20/2365: Public summary of opinion on orphan designation: Adeno-associated virus serotype rh74 containing the human sarcoglycan beta gene for the treatment of limb-girdle muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-19T15:21:00Z","last_updated_date":"2021-05-19T15:21:00Z","reference_number":"EMADOC-628903358-3736","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202365-public-summary-opinion-orphan-designation-adeno-associated-virus-serotype-rh74-containing-human-sarcoglycan-beta-gene-treatment-limb-girdle-muscular-dystrophy_en.pdf"},
    {"id":"51194","name":"EU/3/20/2367: Public summary of opinion on orphan designation: (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea fumarate for the treatment of Prader-Willi syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-19T15:36:00Z","last_updated_date":"2021-05-19T15:36:00Z","reference_number":"EMADOC-628903358-3725","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202367-public-summary-opinion-orphan-designation-r-3-1-23-dichloro-4-pyrazin-2-ylphenyl-222-trifluoroethyl-1-methyl-1-1-methylpiperidin-4-ylurea-fumarate-treatment-prader-willi-syndrome_en.pdf"},
    {"id":"51197","name":"EU/3/20/2368: Public summary of opinion on orphan designation: Human interleukin 12 fused with immunoglobulin G4 C-terminal Fc fragment for the treatment of glioma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-19T17:27:00Z","last_updated_date":"2021-05-19T17:27:00Z","reference_number":"EMADOC-628903358-3723","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202368-public-summary-opinion-orphan-designation-human-interleukin-12-fused-immunoglobulin-g4-c-terminal-fc-fragment-treatment-glioma_en.pdf"},
    {"id":"51230","name":"EU/3/20/2369: Public summary of opinion on orphan designation: Sotatercept for the treatment of pulmonary arterial hypertension","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T15:46:00Z","last_updated_date":"2021-05-21T15:46:00Z","reference_number":"EMADOC-628903358-3726","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202369-public-summary-opinion-orphan-designation-sotatercept-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"51232","name":"EU/3/20/2370: Public summary of opinion on orphan designation: Tremelimumab for the treatment of hepatocellular carcinoma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T15:58:00Z","last_updated_date":"2022-12-09T13:53:00Z","reference_number":"EMADOC-628903358-3728","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202370-public-summary-opinion-orphan-designation-tremelimumab-treatment-hepatocellular-carcinoma_en.pdf"},
    {"id":"51239","name":"EU/3/20/2371: Public summary of opinion on orphan designation: Aspacytarabine for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T16:37:00Z","last_updated_date":"2021-05-21T16:37:00Z","reference_number":"EMADOC-628903358-3735","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202371-public-summary-opinion-orphan-designation-aspacytarabine-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"51256","name":"EU/3/20/2372: Public summary of opinion on orphan designation: Dabrafenib mesylate for the treatment of glioma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-25T15:37:00Z","last_updated_date":"2021-05-25T15:37:00Z","reference_number":"EMADOC-628903358-3737","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202372-public-summary-opinion-orphan-designation-dabrafenib-mesylate-treatment-glioma_en.pdf"},
    {"id":"51257","name":"EU/3/20/2373: Public summary of opinion on orphan designation: Humanised IgG1 monoclonal antibody against the extracellular domain of receptor tyrosine kinase-like orphan receptor 1 coupled via a proteolytically cleavable maleimidocaproyl-valine-citrullin","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-25T16:01:00Z","last_updated_date":"2021-05-25T16:01:00Z","reference_number":"EMADOC-628903358-3738","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202373-public-summary-opinion-orphan-designation-humanised-igg1-monoclonal-antibody-against-extracellular-domain-receptor-tyrosine-kinase-orphan-receptor-1-coupled-proteolytically-cleavable_en.pdf"},
    {"id":"51261","name":"EU/3/20/2374: Public summary of opinion on orphan designation: Treatment of glioma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-25T16:21:00Z","last_updated_date":"2021-05-25T16:21:00Z","reference_number":"EMADOC-628903358-3739","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202374-public-summary-opinion-orphan-designation-treatment-glioma_en.pdf"},
    {"id":"51266","name":"EU/3/20/2375: Public summary of opinion on orphan designation: Treatment of Duchenne muscular dystrophy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-25T16:58:00Z","last_updated_date":"2021-05-25T16:58:00Z","reference_number":"EMADOC-628903358-3727","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202375-public-summary-opinion-orphan-designation-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"51271","name":"EU/3/20/2383: Public summary of opinion on orphan designation: Perflubron for the treatment of respiratory distress syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-26T15:57:00Z","last_updated_date":"2021-05-26T15:57:00Z","reference_number":"EMADOC-628903358-3743","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202383-public-summary-opinion-orphan-designation-perflubron-treatment-respiratory-distress-syndrome_en.pdf"},
    {"id":"51272","name":"EU/3/20/2366: Public summary of opinion on orphan designation: Autologous CD4+ and CD8+ T cells genetically modified with a lentiviral vector encoding a B-cell maturation antigen-specific chimeric antigen receptor for the treatment of multiple myeloma","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-26T16:51:00Z","last_updated_date":"2021-05-26T16:51:00Z","reference_number":"EMADOC-628903358-3724","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202366-public-summary-opinion-orphan-designation-autologous-cd4-and-cd8-t-cells-genetically-modified-lentiviral-vector-encoding-b-cell-maturation-antigen-specific-chimeric-antigen-receptor_en.pdf"},
    {"id":"51273","name":"EU/3/20/2384: Public summary of opinion on orphan designation: Sulindac for the treatment of fragile X syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-26T17:22:00Z","last_updated_date":"2021-05-26T17:22:00Z","reference_number":"EMADOC-628903358-3734","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202384-public-summary-opinion-orphan-designation-sulindac-treatment-fragile-x-syndrome_en.pdf"},
    {"id":"51274","name":"EU/3/20/2377: Public summary of opinion on orphan designation: 2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glycogen synthase 1 pre‑mRNA for the treatment of progressive myoclonic epilepsy type 2 (Lafora disease)","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-27T11:46:00Z","last_updated_date":"2021-05-27T11:46:00Z","reference_number":"EMADOC-628903358-3730","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-20-2377-public-summary-opinion-orphan-designation-2-o-2-methoxyethyl-modified-antisense-oligonucleotide-targeting-glycogen-synthase-1-pre-mrna-treatment-progressive-myoclonic-epilepsy-type-2_en.pdf"},
    {"id":"51275","name":"EU/3/20/2378: Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 9 encoding human ATP7B for the treatment of Wilson’s disease","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-27T12:42:00Z","last_updated_date":"2021-05-27T12:42:00Z","reference_number":"EMADOC-628903358-3731","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202378-public-summary-opinion-orphan-designation-adeno-associated-viral-vector-serotype-9-encoding-human-atp7b-treatment-wilsons-disease_en.pdf"},
    {"id":"51277","name":"EU/3/20/2379: Public summary of opinion on orphan designation: Synthetic oligonucleotide selectively targeting UBE3A antisense RNA transcripts for the treatment of Angelman syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-27T14:22:00Z","last_updated_date":"2021-05-27T14:22:00Z","reference_number":"EMADOC-628903358-3740","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202379-public-summary-opinion-orphan-designation-synthetic-oligonucleotide-selectively-targeting-ube3a-antisense-rna-transcripts-treatment-angelman-syndrome_en.pdf"},
    {"id":"51284","name":"EU/3/20/2380: Public summary of opinion on orphan designation: Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express beta-domain deleted human factor VIII for the treatment of haemophilia A","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-27T14:50:00Z","last_updated_date":"2022-12-05T14:09:00Z","reference_number":"EMADOC-628903358-3741","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202380-public-summary-opinion-orphan-designation-allogeneic-retinal-pigment-epithelial-cells-genetically-modified-non-viral-vector-express-beta-domain-deleted-human-factor-viii-treatment_en.pdf"},
    {"id":"51286","name":"EU/3/20/2381: Public summary of opinion on orphan designation: (S)-N-(5-(4-(1-(Benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4thiadiazol-2-yl)acetamide, hydrochloride salt for the treatment of progressive supranuclear palsy","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-27T15:38:00Z","last_updated_date":"2021-05-27T15:38:00Z","reference_number":"EMADOC-628903358-3732","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202381-public-summary-opinion-orphan-designation-s-n-5-4-1-benzod13dioxol-5-ylethylpiperazin-1-yl-134thiadiazol-2-ylacetamide-hydrochloride-salt-treatment-progressive-supranuclear-palsy_en.pdf"},
    {"id":"51287","name":"EU/3/20/2382: Public summary of opinion on orphan designation: Erlotinib for the treatment of Olmsted syndrome","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-27T16:14:00Z","last_updated_date":"2021-05-27T16:14:00Z","reference_number":"EMADOC-628903358-3742","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202382-public-summary-opinion-orphan-designation-erlotinib-treatment-olmsted-syndrome_en.pdf"},
    {"id":"51290","name":"EU/3/20/2376: Public summary of opinion on orphan designation: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide for the treatment of congenital hyperinsulinism","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2021-05-27T17:59:00Z","last_updated_date":"2021-05-27T17:59:00Z","reference_number":"EMADOC-628903358-3729","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3202376-public-summary-opinion-orphan-designation-4-3s-3-aminopyrrolidin-1-yl-6-cyano-5-35-difluorophenyl-n-2s-111-trifluoropropan-2-ylpyridine-3-carboxamide-treatment-congenital-hyperinsulinism_en.pdf"},
    {"id":"53610","name":"EU/3/21/2467: Orphan designation for the treatment of perivascular epithelioid cell tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2021-12-21T09:37:00Z","last_updated_date":"2021-12-21T09:37:00Z","reference_number":"EMADOC-628903358-6056","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu3212467-orphan-designation-treatment-perivascular-epithelioid-cell-tumours_en.pdf"},
    {"id":"60534","name":"EU/3/14/1356: Public summary of opinion on orphan designation: Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2022-02-28T01:00:00Z","reference_number":"EMA/COMP/655830/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-14-1356-public-summary-opinion-orphan-designation-donor-t-lymphocytes-depleted-ex-vivo-host-alloreactive-t-cells-using-photodynamic-treatment-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"60536","name":"EU/3/08/561: Public summary of positive opinion for orphan designationof donor lymphocyte preparation depleted of functional alloreactive T-cellsfor the prevention of Graft-versus-Host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2022-02-28T02:00:00Z","reference_number":"EMEA/COMP/308922/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-08-561-public-summary-positive-opinion-orphan-designationof-donor-lymphocyte-preparation-depleted-functional-alloreactive-t-cellsfor-prevention-graft-versus-host-disease_en.pdf"},
    {"id":"60538","name":"EU/3/13/1198: Public summary of opinion on orphan designation: Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase for the treatment of mucopolysaccharidosis type II (Hunter's syndrome)","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2022-02-18T01:00:00Z","reference_number":"EMA/COMP/629122/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-13-1198-public-summary-opinion-orphan-designation-recombinant-human-insulin-receptor-monoclonal-antibody-fused-iduronate-2-sulfatase-treatment-mucopolysaccharidosis-type-ii-hunters-syndrome_en.pdf"},
    {"id":"60541","name":"EU/3/16/1678: Public summary of opinion on orphan designation: Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment for treatment in haematopoietic stem cell transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T02:00:00Z","last_updated_date":"2022-02-28T02:00:00Z","reference_number":"EMA/COMP/391633/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-16-1678-public-summary-opinion-orphan-designation-donor-t-lymphocytes-depleted-ex-vivo-host-alloreactive-t-cells-using-photodynamic-treatment-treatment-haematopoietic-stem-cell-transplantation_en.pdf"},
    {"id":"60544","name":"EU/3/04/195: Public summary of positive opinion for orphan designation of 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol for the treatment of anaplastic thyroid cancer","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2004-11-05T01:00:00Z","last_updated_date":"2021-07-21T12:30:00Z","reference_number":"EMEA/COMP/136/04 rev. 1","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-04-195-public-summary-positive-opinion-orphan-designation-2-methoxy-5-1z-2-345-trimethoxyphenyl-ethenyl-phenol-treatment-anaplastic-thyroid-cancer_en.pdf"},
    {"id":"60546","name":"EU/3/17/1940: Public summary of opinion on orphan designation: Concizumab for the treatment of haemophilia B","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-12T01:00:00Z","last_updated_date":"2022-12-14T01:00:00Z","reference_number":"EMA/698762/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-17-1940-public-summary-opinion-orphan-designation-concizumab-treatment-haemophilia-b_en.pdf"},
    {"id":"60547","name":"EU/3/14/1421: Public summary of opinion on orphan designation: Ponatinib hydrochloride for the treatment of gastrointestinal stromal tumours","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2022-03-18T12:00:00Z","reference_number":"EMA/COMP/787355/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-14-1421-public-summary-opinion-orphan-designation-ponatinib-hydrochloride-treatment-gastrointestinal-stromal-tumours_en.pdf"},
    {"id":"60551","name":"EU/3/12/1052: Public summary of opinion on orphan designation: Humanised monoclonal IgG4 antibody against tissue-factor-pathway inhibitor for the treatment of haemophilia A","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2022-12-14T01:00:00Z","reference_number":"EMA/COMP/619502/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-12-1052-public-summary-opinion-orphan-designation-humanised-monoclonal-igg4-antibody-against-tissue-factor-pathway-inhibitor-treatment-haemophilia_en.pdf"},
    {"id":"60552","name":"EU/3/10/751: Public summary of opinion for Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA for the prevention of delayed graft function after renal transplantation","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2022-02-28T02:00:00Z","reference_number":"EMA/COMP/170167/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-10-751-public-summary-opinion-synthetic-double-stranded-sirna-oligonucleotide-directed-against-p53-mrna-prevention-delayed-graft-function-after-renal-transplantation_en.pdf"},
    {"id":"60554","name":"EU/3/14/1426: Public summary of opinion on orphan designation: Allogeneic peripheral blood mononuclear cells induced to an early apoptotic state for the prevention of graft-versus-host disease","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T12:00:00Z","last_updated_date":"2022-02-28T12:00:00Z","reference_number":"EMA/COMP/786789/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-14-1426-public-summary-opinion-orphan-designation-allogeneic-peripheral-blood-mononuclear-cells-induced-early-apoptotic-state-prevention-graft-versus-host-disease_en.pdf"},
    {"id":"60557","name":"EU/3/08/556: Public summary of positive opinion for orphan designation of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2022-08-10T10:34:00Z","reference_number":"EMA/COMP/272429/2008 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-08-556-public-summary-positive-opinion-orphan-designation-n-24-di-tert-butyl-5-hydroxyphenyl-14-dihydro-4-oxoquinoline-3-carboxamide-treatment-cystic-fibrosis_en.pdf"},
    {"id":"60560","name":"EU/3/17/1908: Public summary of opinion on orphan designation: Recombinant truncated N-terminal fragment of human lens epithelium-derived growth factor for the treatment of retinitis pigmentosa","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-17T02:00:00Z","last_updated_date":"2022-08-12T13:54:00Z","reference_number":"EMA/508066/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-17-1908-public-summary-opinion-orphan-designation-recombinant-truncated-n-terminal-fragment-human-lens-epithelium-derived-growth-factor-treatment-retinitis-pigmentosa_en.pdf"},
    {"id":"60561","name":"EU/3/16/1810: Public summary of opinion on orphan designation: 3-pentylbenzeneacetic acid sodium salt for the treatment of Alström syndrome","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2022-02-28T02:00:00Z","reference_number":"EMA/19945/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-16-1810-public-summary-opinion-orphan-designation-3-pentylbenzeneacetic-acid-sodium-salt-treatment-alstrom-syndrome_en.pdf"},
    {"id":"60564","name":"EU/3/06/401: Public summary of positive opinion for orphan designation of N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium; 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate for the treatment of familial amyloid polyne...","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2009-04-02T02:00:00Z","last_updated_date":"2021-11-25T02:00:00Z","reference_number":"EMEA/COMP/186264/2008 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-06-401-public-summary-positive-opinion-orphan-designation-n-methyl-d-23456-pentahydroxy-hexyl-ammonium-2-35-dichloro-phenyl-benzoxazole-6-carboxylate-treatment-familial-amyloid-polyne_en.pdf"},
    {"id":"60566","name":"EU/3/13/1132: Public summary of opinion on orphan designation: N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride for the treatment o...","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2013-06-25T19:00:00Z","last_updated_date":"2022-02-28T19:00:00Z","reference_number":"EMA/COMP/258965/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-13-1132-public-summary-opinion-orphan-designation-n-methyl-4-4-3-methylmethylsulfonylaminopyrazin-2-ylmethylamino-5-trifluoromethylpyrimidin-2-ylaminobenzamide-hydrochloride-treatment-o_en.pdf"},
    {"id":"60568","name":"EU/3/15/1550: Public summary of opinion on orphan designation: 3-Pentylbenzeneacetic acid sodium salt for the treatment of idiopathic pulmonary fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2022-02-28T01:00:00Z","reference_number":"EMA/COMP/614795/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-15-1550-public-summary-opinion-orphan-designation-3-pentylbenzeneacetic-acid-sodium-salt-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"60573","name":"EU/3/17/1927: Public summary of opinion on orphan designation: Pracinostat for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T15:45:00Z","last_updated_date":"2022-02-18T15:45:00Z","reference_number":"EMA/623210/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-17-1927-public-summary-opinion-orphan-designation-pracinostat-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"60574","name":"EU/3/15/1463: Public summary of positive opinion for orphan designation of melphalan flufenamide for the treatment of plasma cell myeloma","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-11T02:00:00Z","last_updated_date":"2022-07-28T14:16:00Z","reference_number":"EMA/COMP/132969/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-15-1463-public-summary-positive-opinion-orphan-designation-melphalan-flufenamide-treatment-plasma-cell-myeloma_en.pdf"},
    {"id":"60575","name":"EU/3/14/1349: Public summary of opinion on orphan designation: Recombinant human insulin receptor monoclonal antibody-fused-α-L-iduronidase for the treatment of mucopolysaccharidosis type I","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-12T13:00:00Z","last_updated_date":"2022-02-18T13:00:00Z","reference_number":"EMA/COMP/554956/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-14-1349-public-summary-opinion-orphan-designation-recombinant-human-insulin-receptor-monoclonal-antibody-fused-i-l-iduronidase-treatment-mucopolysaccharidosis-type-i_en.pdf"},
    {"id":"60596","name":"EU/3/18/2120: Public summary of opinion on orphan designation: Pevonedistat for the treatment of myelodysplastic syndromes","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-12T11:15:00Z","last_updated_date":"2022-02-18T10:33:00Z","reference_number":"EMA/806417/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-18-2120-public-summary-opinion-orphan-designation-pevonedistat-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"60600","name":"EU/3/19/2163: Public summary of opinion on orphan designation: N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide for the treatment of cystic fibrosis","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-09T15:20:00Z","last_updated_date":"2021-07-30T10:32:00Z","reference_number":"EMADOC-628903358-938","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-19-2163-public-summary-opinion-orphan-designation-n-trans-3-5-r-1-hydroxyethyl-134-oxadiazol-2-ylcyclobutyl-3-phenylisoxazole-5-carboxamide-treatment-cystic-fibrosis_en.pdf"},
    {"id":"60601","name":"EU/3/19/2186: Public summary of opinion on orphan designation: Pevonedistat for the treatment of acute myeloid leukaemia","type":"orphan-designation","status":"unknown","consultation_date":"","first_published_date":"2019-09-24T15:52:00Z","last_updated_date":"2022-02-18T10:37:00Z","reference_number":"EMADOC-628903358-1130","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-19-2186-public-summary-opinion-orphan-designation-pevonedistat-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"60602","name":"EU/3/19/2138: Public summary of opinion on orphan designation: Allogeneic anti-Epstein Barr virus cytotoxic T lymphocytes expanded ex vivo for the treatment of post-transplant lymphoproliferative disorder","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-02T15:44:00Z","last_updated_date":"2021-07-21T10:23:00Z","reference_number":"EMADOC-628903358-450","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-19-2138-public-summary-opinion-orphan-designation-allogeneic-anti-epstein-barr-virus-cytotoxic-t-lymphocytes-expanded-ex-vivo-treatment-post-transplant-lymphoproliferative-disorder_en.pdf"},
    {"id":"60617","name":"EU/3/20/2297: Public summary of opinion on orphan designation for Adeno-associated virus serotype HSC15 expressing human arylsulfatase A gene for the treatment of metachromatic leukodystrophy","type":"orphan-designation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-24T14:53:00Z","last_updated_date":"2023-07-21T12:38:00Z","reference_number":"EMADOC-628903358-2485","document_url":"https://www.ema.europa.eu/en/documents/orphan-designation/eu-3-20-2297-public-summary-opinion-orphan-designation-adeno-associated-virus-serotype-hsc15-expressing-human-arylsulfatase-gene-treatment-metachromatic-leukodystrophy_en.pdf"}    {"id":"2658","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Venclyxto (venetoclax) for the treatment of chronic lymphocytic leukaemia","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-12-21T18:00:00Z","last_updated_date":"2018-11-22T18:00:00Z","reference_number":"EMA/700601/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-venclyxto-venetoclax-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"2773","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Cyramza (ramucirumab) for the treatment of gastric cancer","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-01-30T01:00:00Z","last_updated_date":"2015-01-30T01:00:00Z","reference_number":"EMA/601520/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-cyramza-ramucirumab-treatment-gastric-cancer_en.pdf"},
    {"id":"2954","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2017-06-21T17:21:00Z","last_updated_date":"2017-06-21T17:21:00Z","reference_number":"EMA/288176/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-spinraza-nusinersen-treatment-5q-spinal-muscular-atrophy_en.pdf"},
    {"id":"2955","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Cresemba (isavuconazole) for the treatment of invasive aspergillosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-11-05T15:52:00Z","last_updated_date":"2015-11-05T15:52:00Z","reference_number":"EMA/582962/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-cresemba-isavuconazole-treatment-invasive-aspergillosis_en.pdf"},
    {"id":"3337","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Vimizim (elosulfase alfa) for the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome)","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-06-26T02:00:00Z","last_updated_date":"2014-06-26T02:00:00Z","reference_number":"EMA/COMP/139514/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-vimizim-elosulfase-alfa-treatment-mucopolysaccharidosis-type-iva-morquio-syndrome_en.pdf"},
    {"id":"3498","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2017-06-22T16:29:00Z","last_updated_date":"2017-06-22T16:29:00Z","reference_number":"EMA/291639/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-brineura-cerliponase-alfa-treatment-neuronal-ceroid-lipofuscinosis_en.pdf"},
    {"id":"3676","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Defitelio (defibrotide) for the treatment of hepatic veno-occlusive disease","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2013-11-11T12:00:00Z","last_updated_date":"2013-11-11T12:00:00Z","reference_number":"EMA/COMP/536533/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-defitelio-defibrotide-treatment-hepatic-veno-occlusive-disease_en.pdf"},
    {"id":"4644","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Kyprolis (carfilzomib) for the treatment of multiple myeloma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-12-02T01:00:00Z","last_updated_date":"2015-12-02T01:00:00Z","reference_number":"EMA/COMP/656221/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-kyprolis-carfilzomib-treatment-multiple-myeloma_en.pdf"},
    {"id":"4757","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Sylvant (siltuximab) for the treatment of Castleman’s disease","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-06-19T02:00:00Z","last_updated_date":"2014-06-19T02:00:00Z","reference_number":"EMA/COMP/211041/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-sylvant-siltuximab-treatment-castlemans-disease_en.pdf"},
    {"id":"4803","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Revestive (teduglutide) for the treatment of short-bowel syndrome","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2012-09-26T02:00:00Z","last_updated_date":"2022-09-09T02:00:00Z","reference_number":"EMA/COMP/452266/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-revestive-teduglutide-treatment-short-bowel-syndrome_en.pdf"},
    {"id":"4809","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Adcetris (brentuximab vedotin) for the treatment of Hodgkin lymphoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2012-11-28T16:01:00Z","last_updated_date":"2012-11-28T16:01:00Z","reference_number":"EMA/COMP/601841/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-adcetris-brentuximab-vedotin-treatment-hodgkin-lymphoma_en.pdf"},
    {"id":"5123","name":"Recommendation for maintenance of orphan designation at the time of addition of a new indication to the marketing authorisation: Soliris (eculizumab) for the treatment of myasthenia gravis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2017-09-26T17:00:00Z","last_updated_date":"2017-09-26T17:00:00Z","reference_number":"EMA/427360/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-addition-new-indication-marketing-authorisation-soliris-eculizumab-treatment-myasthenia-gravis_en.pdf"},
    {"id":"5207","name":"Recommendation for maintenance of orphan designation at the time of addition of a new indication to the marketing authorisation: Nexavar (sorafenib) for the treatment of follicular and papillary thyroid cancers","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/COMP/279471/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-addition-new-indication-marketing-authorisation-nexavar-sorafenib-treatment-follicular-and-papillary-thyroid-cancers_en.pdf"},
    {"id":"6677","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Deltyba (delamanid) for the treatment of tuberculosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/COMP/2642/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-deltyba-delamanid-treatment-tuberculosis_en.pdf"},
    {"id":"6971","name":"Recommendation for maintenance of orphan designation at the time of addition of new indications to the marketing authorisation: Tobi Podhaler (tobramycin) for the treatment of Pseudomonas aeruginosa lung infection in cys...","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2011-10-10T15:32:00Z","last_updated_date":"2023-07-31T15:32:00Z","reference_number":"EMA/COMP/624961/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-addition-new-indications-marketing-authorisation-tobi-podhaler-tobramycin-treatment-pseudomonas-aeruginosa-lung-infection-cys_en.pdf"},
    {"id":"7229","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMA/COMP/11127/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-esbriet-pirfenidone-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"7506","name":"Recommendation for removal of orphan designation at the time of marketing authorisation: Obizur (susoctocog alfa) for the treatment of haemophilia A","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-11-24T01:00:00Z","last_updated_date":"2015-11-24T01:00:00Z","reference_number":"EMA/COMP/656553/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-removal-orphan-designation-time-marketing-authorisation-obizur-susoctocog-alfa-treatment-haemophilia_en.pdf"},
    {"id":"7930","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Signifor (pasireotide) for the treatment of Cushing’s disease","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2012-06-29T13:38:00Z","last_updated_date":"2022-06-14T13:38:00Z","reference_number":"EMA/COMP/93349/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-signifor-pasireotide-treatment-cushings-disease_en.pdf"},
    {"id":"7946","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Chenodeoxycholic acid sigma-tau (chenodeoxycholic acid) for the treatment of inborn errors in primary bile acid synthesis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2017-05-11T11:29:00Z","last_updated_date":"2017-06-29T11:29:00Z","reference_number":"EMA/39662/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-chenodeoxycholic-acid-sigma-tau-chenodeoxycholic-acid-treatment-inborn-errors-primary-bile-acid-synthesis_en.pdf"},
    {"id":"8284","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Cholic acid FGK (cholic acid) for the treatment of inborn errors in primary bile acid synthesis responsive to treatment with ch...","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMA/COMP/777596/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-cholic-acid-fgk-cholic-acid-treatment-inborn-errors-primary-bile-acid-synthesis-responsive-treatment-ch_en.pdf"},
    {"id":"8510","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Gazyvaro (obinutuzumab) for the treatment of chronic lymphocytic leukaemia","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/COMP/345188/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-gazyvaro-obinutuzumab-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"8848","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Sirturo (bedaquiline) for the treatment of tuberculosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-03-14T17:00:00Z","last_updated_date":"2014-03-14T17:00:00Z","reference_number":"EMA/COMP/3833/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-sirturo-bedaquiline-treatment-tuberculosis_en.pdf"},
    {"id":"8888","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Besponsa (inotuzumab ozogamicin) for the treatment of B-cell acute lymphoblastic leukaemia","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2017-07-13T12:46:00Z","last_updated_date":"2017-07-13T12:46:00Z","reference_number":"EMA/320642/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-besponsa-inotuzumab-ozogamicin-treatment-b-cell-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"8963","name":"Recommendation for removal of orphan designation at the time of marketing authorisation: Cuprior (trientine tetrahydrochloride) for the treatment of Wilson's disease","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2017-10-03T19:00:00Z","last_updated_date":"2017-10-03T19:00:00Z","reference_number":"EMA/568817/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-removal-orphan-designation-time-marketing-authorisation-cuprior-trientine-tetrahydrochloride-treatment-wilsons-disease_en.pdf"},
    {"id":"9184","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Bosulif (bosutinib) for the treatment chronic myeloid leukaemia","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2013-04-11T02:00:00Z","last_updated_date":"2013-04-11T02:00:00Z","reference_number":"EMA/COMP/71582/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-bosulif-bosutinib-treatment-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"9198","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Pomalidomide Celgene (pomalidomide) for the treatment of multiple myeloma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2013-08-20T11:15:00Z","last_updated_date":"2023-09-13T11:15:00Z","reference_number":"EMA/351975/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-pomalidomide-celgene-pomalidomide-treatment-multiple-myeloma_en.pdf"},
    {"id":"9426","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Cresemba (isavuconazole) for the treatment of mucormycosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-11-05T15:52:00Z","last_updated_date":"2015-11-05T15:52:00Z","reference_number":"EMA/582963/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-cresemba-isavuconazole-treatment-mucormycosis_en.pdf"},
    {"id":"9434","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Procysbi (mercaptamine) for the treatment of cystinosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2013-10-10T02:00:00Z","last_updated_date":"2013-10-10T02:00:00Z","reference_number":"EMA/COMP/415414/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-procysbi-mercaptamine-treatment-cystinosis_en.pdf"},
    {"id":"9565","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation for Vpriv (velaglucerase alfa) for the treatment of Gaucher disease","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2010-09-13T02:00:00Z","last_updated_date":"2022-09-09T02:00:00Z","reference_number":"EMA/COMP/433831/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-vpriv-velaglucerase-alfa-treatment-gaucher-disease_en.pdf"},
    {"id":"9841","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Cometriq (cabozantinib) for the treatment of medullary thyroid carcinoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"EMA/COMP/4640/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-cometriq-cabozantinib-treatment-medullary-thyroid-carcinoma_en.pdf"},
    {"id":"10027","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Glybera (alipogene tiparvovec) for the treatment of lipoprotein-lipase deficiency","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2012-12-03T12:58:00Z","last_updated_date":"2021-05-31T12:58:00Z","reference_number":"EMA/571233/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-glybera-alipogene-tiparvovec-treatment-lipoprotein-lipase-deficiency_en.pdf"},
    {"id":"10355","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Ketoconazole HRA (ketoconazole) for the treatment of Cushing’s syndrome","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-01-30T01:00:00Z","last_updated_date":"2015-01-30T01:00:00Z","reference_number":"EMA/COMP/609790/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-ketoconazole-hra-ketoconazole-treatment-cushings-syndrome_en.pdf"},
    {"id":"10618","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Iclusig (ponatinib) for the treatment of acute lymphoblastic leukaemia and chronic myeloid leukaemia","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2013-07-31T17:25:00Z","last_updated_date":"2013-07-31T17:25:00Z","reference_number":"EMA/238239/2013 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-iclusig-ponatinib-treatment-acute-lymphoblastic-leukaemia-and-chronic-myeloid-leukaemia_en.pdf"},
    {"id":"10668","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Coagadex (human coagulation factor X) for the treatment of hereditary factor X deficiency","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-04-05T02:00:00Z","last_updated_date":"2016-04-05T02:00:00Z","reference_number":"EMA/COMP/180349/2016 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-coagadex-human-coagulation-factor-x-treatment-hereditary-factor-x-deficiency_en.pdf"},
    {"id":"10687","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Vyndaqel (N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium; 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate) for treatment ...","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T11:30:00Z","last_updated_date":"2021-11-25T11:30:00Z","reference_number":"EMA/COMP/729178/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-vyndaqel-n-methyl-d-23456-pentahydroxy-hexyl-ammonium-2-35-dichloro-phenyl-benzoxazole-6-carboxylate-treatment_en.pdf"},
    {"id":"10747","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Wakix (pitolisant) for the treatment of narcolepsy","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-04-20T15:40:00Z","last_updated_date":"2016-04-20T15:40:00Z","reference_number":"EMA/COMP/156871/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-wakix-pitolisant-treatment-narcolepsy_en.pdf"},
    {"id":"10803","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Signifor (pasireotide) for the treatment of acromegaly","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"EMA/COMP/621067/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-signifor-pasireotide-treatment-acromegaly_en.pdf"},
    {"id":"10837","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Ocaliva (obeticholic acid) for the treatment of primary biliary cirrhosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-12-19T19:00:00Z","last_updated_date":"2016-12-19T19:00:00Z","reference_number":"EMA/696815/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-ocaliva-obeticholic-acid-treatment-primary-biliary-cirrhosis_en.pdf"},
    {"id":"11341","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Kalydeco (ivacaftor) for the treatment of cystic fibrosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2012-08-31T13:20:00Z","last_updated_date":"2022-08-10T10:33:00Z","reference_number":"EMA/COMP/394533/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-kalydeco-ivacaftor-treatment-cystic-fibrosis_en.pdf"},
    {"id":"11515","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Hetlioz (tasimelteon) for the treatment of non-24-hour sleep-wake disorder","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-07-27T15:22:00Z","last_updated_date":"2015-07-27T15:22:00Z","reference_number":"EMA/COMP/321004/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-hetlioz-tasimelteon-treatment-non-24-hour-sleep-wake-disorder_en.pdf"},
    {"id":"12939","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Strimvelis (autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene) for the treatment of...","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-06-08T17:40:00Z","last_updated_date":"2016-06-08T17:40:00Z","reference_number":"EMA/COMP/260673/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-strimvelis-autologous-cd34-cells-transfected-retroviral-vector-containing-adenosine-deaminase-gene-treatment_en.pdf"},
    {"id":"13190","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Blincyto (blinatumomab) for the treatment of acute lymphoblastic leukaemia","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-12-08T11:00:00Z","last_updated_date":"2015-12-08T11:00:00Z","reference_number":"EMA/655660/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-blincyto-blinatumomab-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"13725","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Dacogen (decitabine) for the treatment of acute myeloid leukaemia","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2012-10-22T02:00:00Z","last_updated_date":"2012-10-22T02:00:00Z","reference_number":"EMA/COMP/558969/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-dacogen-decitabine-treatment-acute-myeloid-leukaemia_en.pdf"},
    {"id":"13851","name":"Recommendation for removal of orphan designation at the time of marketing authorisation: Pheburane (sodium phenylbutyrate) for the treatment of urea-cycle disorders (carbamoyl-phosphate-synthase-1 deficiency, ornithine-t...","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2013-08-08T14:00:00Z","last_updated_date":"2013-08-08T14:00:00Z","reference_number":"EMA/COMP/239416/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-removal-orphan-designation-time-marketing-authorisation-pheburane-sodium-phenylbutyrate-treatment-urea-cycle-disorders-carbamoyl-phosphate-synthase-1-deficiency-ornithine-t_en.pdf"},
    {"id":"13917","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Adempas (riociguat) for the treatment of pulmonary arterial hypertension including chronic thromboembolic pulmonary hypertensio...","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-04-24T12:30:00Z","last_updated_date":"2022-06-14T12:30:00Z","reference_number":"EMA/COMP/68649/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-adempas-riociguat-treatment-pulmonary-arterial-hypertension-including-chronic-thromboembolic-pulmonary-hypertensio_en.pdf"},
    {"id":"14709","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation Ledaga (chlormethine) for the treatment of cutaneous T-cell lymphoma","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T15:18:00Z","last_updated_date":"2017-03-16T15:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-ledaga-chlormethine-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"15040","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Orphacol (cholic acid) for the treatment of inborn errors in primary-bile-acid synthesis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2013-10-10T02:00:00Z","last_updated_date":"2013-10-10T02:00:00Z","reference_number":"EMA/COMP/10667/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-orphacol-cholic-acid-treatment-inborn-errors-primary-bile-acid-synthesis_en.pdf"},
    {"id":"15093","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Kolbam (cholic acid) for the treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/COMP/663120/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-kolbam-cholic-acid-treatment-inborn-errors-primary-bile-acid-synthesis-responsive-treatment-cholic-acid_en.pdf"},
    {"id":"15413","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Jakavi (ruxolitinib) for the treatment of chronic idiopathic myelofibrosis and myelofibrosis secondary to polycythaemia vera or...","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2013-01-24T10:23:00Z","last_updated_date":"2013-01-24T10:23:00Z","reference_number":"EMA/COMP/299582/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-jakavi-ruxolitinib-treatment-chronic-idiopathic-myelofibrosis-and-myelofibrosis-secondary-polycythaemia-vera-or_en.pdf"},
    {"id":"15751","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Plenadren (hydrocortisone) for the treatment of adrenal insufficiency","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2011-11-15T15:40:00Z","last_updated_date":"2021-11-25T15:40:00Z","reference_number":"EMA/729720/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-plenadren-hydrocortisone-treatment-adrenal-insufficiency_en.pdf"},
    {"id":"16265","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Bronchitol (mannitol) for the treatment of cystic fibrosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2012-10-30T16:23:00Z","last_updated_date":"2012-10-30T16:23:00Z","reference_number":"EMA/COMP/874717/2011  ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-bronchitol-mannitol-treatment-cystic-fibrosis_en.pdf"},
    {"id":"16296","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Ravicti (glycerol phenylbutyrate) for the treatment of urea cycle disorders [carbamoyl phosphate-synthase-1 deficiency, ornithi...","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-01-04T15:00:00Z","last_updated_date":"2016-01-04T15:00:00Z","reference_number":"EMA/COMP/658477/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-ravicti-glycerol-phenylbutyrate-treatment-urea-cycle-disorders-carbamoyl-phosphate-synthase-1-deficiency-ornithi_en.pdf"},
    {"id":"16735","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Revolade (eltrombopag olamine) for the treatment of idiopathic thrombocytopenic purpura","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2011-04-11T02:00:00Z","last_updated_date":"2011-04-11T02:00:00Z","reference_number":"EMA/COMP/378290/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-revolade-eltrombopag-olamine-treatment-idiopathic-thrombocytopenic-purpura_en.pdf"},
    {"id":"16898","name":"Recommendation for removal of orphan designation at the time of marketing authorisation: Empliciti (elotuzumab) for the treatment of multiple myeloma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-05-23T02:00:00Z","last_updated_date":"2016-05-23T02:00:00Z","reference_number":"EMA/COMP/261865/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-removal-orphan-designation-time-marketing-authorisation-empliciti-elotuzumab-treatment-multiple-myeloma_en.pdf"},
    {"id":"17027","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Zejula (niraparib) for the treatment of ovarian cancer","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2017-12-04T17:42:00Z","last_updated_date":"2017-12-04T17:42:00Z","reference_number":"EMA/712784/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-zejula-niraparib-treatment-ovarian-cancer_en.pdf"},
    {"id":"17157","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Farydak (panobinostat) for the treatment of multiple myeloma","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2015-09-14T02:00:00Z","last_updated_date":"2015-09-14T02:00:00Z","reference_number":"EMA/COMP/470322/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-farydak-panobinostat-treatment-multiple-myeloma_en.pdf"},
    {"id":"17311","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Holoclar (ex vivo expanded autologous human corneal epithelium containing stem cells) for the treatment of corneal lesions, wit...","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"EMA/15233/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-holoclar-ex-vivo-expanded-autologous-human-corneal-epithelium-containing-stem-cells-treatment-corneal-lesions-wit_en.pdf"},
    {"id":"17475","name":"Recommendation for maintenance of orphan designation at the time of addition of new indications to the marketing authorisation: Carbaglu (carglumic acid) for the treatment of isovaleric acidaemia, methylmalonic acidaemia...","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2011-10-10T15:32:00Z","last_updated_date":"2021-06-09T15:05:00Z","reference_number":"EMA/COMP/321680/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-addition-new-indications-marketing-authorisation-carbaglu-carglumic-acid-treatment-isovaleric-acidaemia-methylmalonic-acidaemia_en.pdf"},
    {"id":"17776","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: SomaKit TOC (edotreotide) for the diagnosis of gastroenteropancreatic neuroendocrine tumours","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2017-02-20T17:00:00Z","last_updated_date":"2017-02-20T17:00:00Z","reference_number":"EMA/683386/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-somakit-toc-edotreotide-diagnosis-gastroenteropancreatic-neuroendocrine-tumours_en.pdf"},
    {"id":"19335","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Para-aminosalicylic acid Lucane (para-aminosalicylic acid) for the treatment of tuberculosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T02:00:00Z","last_updated_date":"2014-10-16T02:00:00Z","reference_number":"EMA/COMP/72228/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-para-aminosalicylic-acid-lucane-para-aminosalicylic-acid-treatment-tuberculosis_en.pdf"},
    {"id":"19495","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Lenvima (lenvatinib) for the treatment of follicular and papillary thyroid cancers","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2015-06-29T02:00:00Z","last_updated_date":"2015-06-29T02:00:00Z","reference_number":"EMA/COMP/236650/2015 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-lenvima-lenvatinib-treatment-follicular-and-papillary-thyroid-cancers_en.pdf"},
    {"id":"20869","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Strensiq (asfotase alfa) for the treatment of hypophosphatasia","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-09-28T02:00:00Z","last_updated_date":"2015-09-28T02:00:00Z","reference_number":"EMA/COMP/471205/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-strensiq-asfotase-alfa-treatment-hypophosphatasia_en.pdf"},
    {"id":"21129","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Darzalex (daratumumab) for the treatment of plasma cell myeloma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-06-08T18:00:00Z","last_updated_date":"2016-06-08T18:00:00Z","reference_number":"EMA/COMP/332269/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-darzalex-daratumumab-treatment-plasma-cell-myeloma_en.pdf"},
    {"id":"21255","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Bavencio (avelumab) for the treatment of Merkel cell carcinoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"EMA/569222/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-bavencio-avelumab-treatment-merkel-cell-carcinoma_en.pdf"},
    {"id":"22048","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Lutathera (lutetium (177Lu) oxodotreotide) for the treatment of gastro-entero-pancreatic neuroendocrine tumours","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2018-01-17T12:33:00Z","last_updated_date":"2018-01-17T12:33:00Z","reference_number":"EMA/552373/2017 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-lutathera-lutetium-177lu-oxodotreotide-treatment-gastro-entero-pancreatic-neuroendocrine-tumours_en.pdf"},
    {"id":"22666","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Opsumit (macitentan) for the treatment of pulmonary arterial hypertension","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/COMP/684822/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-opsumit-macitentan-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"23530","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Kanuma (sebelipase alfa) for the treatment of lysosomal acid lipase deficiency","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-09-08T02:00:00Z","last_updated_date":"2015-09-08T02:00:00Z","reference_number":"EMA/COMP/470354/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-kanuma-sebelipase-alfa-treatment-lysosomal-acid-lipase-deficiency_en.pdf"},
    {"id":"24449","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Lartruvo (olaratumab) for the treatment of soft tissue sarcoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T16:20:00Z","last_updated_date":"2020-01-15T16:20:00Z","reference_number":"EMA/698651/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-lartruvo-olaratumab-treatment-soft-tissue-sarcoma_en.pdf"},
    {"id":"24457","name":"Recommendation for maintenance of orphan designation at the time of addition of a new indication to the marketing authorisation: Revlimid (lenalidomide) for the treatment of myelodysplastic syndromes","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T02:00:00Z","last_updated_date":"2013-07-19T02:00:00Z","reference_number":"EMA/COMP/288804/2013","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-addition-new-indication-marketing-authorisation-revlimid-lenalidomide-treatment-myelodysplastic-syndromes_en.pdf"},
    {"id":"24505","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Translarna (ataluren) for the treatment of Duchenne muscular dystrophy","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-09-04T12:00:00Z","last_updated_date":"2014-09-04T12:00:00Z","reference_number":"EMA/COMP/340003/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-translarna-ataluren-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"25572","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-12-01T01:00:00Z","last_updated_date":"2014-12-01T01:00:00Z","reference_number":"EMA/COMP/535574/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-imbruvica-ibrutinib-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"27250","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Zalmoxis (allogeneic T cells genetically modified with a retroviral vector encoding","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-09-21T02:00:00Z","last_updated_date":"2016-09-21T02:00:00Z","reference_number":"EMA/COMP/455724/2016 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-zalmoxis-allogeneic-t-cells-genetically-modified-retroviral-vector-encoding_en.pdf"},
    {"id":"27892","name":"Recommendation for maintenance of orphan designation at the time of addition of a new indication to the marketing authorisation: Soliris (eculizumab) for the treatment of atypical haemolytic uraemic syndrome","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T11:30:00Z","last_updated_date":"2011-12-21T11:33:00Z","reference_number":"EMA/COMP/792994/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-addition-new-indication-marketing-authorisation-soliris-eculizumab-treatment-atypical-haemolytic-uraemic-syndrome_en.pdf"},
    {"id":"27926","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Gazyvaro (obinutuzumab) for the treatment of follicular lymphoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-08-19T02:00:00Z","last_updated_date":"2016-08-19T02:00:00Z","reference_number":"EMA/COMP/370418/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-gazyvaro-obinutuzumab-treatment-follicular-lymphoma_en.pdf"},
    {"id":"28074","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Rydapt (midostaurin) for the treatment of acute myeloid leukaemia and mastocytosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2017-10-25T02:00:00Z","last_updated_date":"2017-10-25T02:00:00Z","reference_number":"EMA/550601/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-rydapt-midostaurin-treatment-acute-myeloid-leukaemia-and-mastocytosis_en.pdf"},
    {"id":"28759","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: NexoBrid (concentrate of proteolytic enzymes enriched in bromelain) for the treatment of partial deep dermal and full-thickness...","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2013-01-07T12:01:00Z","last_updated_date":"2023-02-15T12:01:00Z","reference_number":"EMA/COMP/631996/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-nexobrid-concentrate-proteolytic-enzymes-enriched-bromelain-treatment-partial-deep-dermal-and-full-thickness_en.pdf"},
    {"id":"29412","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Galafold (migalastat) for the treatment of Fabry disease","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-06-10T18:00:00Z","last_updated_date":"2016-06-10T18:00:00Z","reference_number":"EMA/COMP/267525/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-galafold-migalastat-treatment-fabry-disease_en.pdf"},
    {"id":"29833","name":"Recommendation for maintenance of orphan designation at the time of addition of a new indication to the marketing authorisation: Revlimid (lenalidomide) for the treatment of mantle cell lymphoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-07-20T02:00:00Z","last_updated_date":"2016-07-20T02:00:00Z","reference_number":"EMA/COMP/450189/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-addition-new-indication-marketing-authorisation-revlimid-lenalidomide-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"30118","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Mercaptopurine Nova Laboratories (mercaptopurine (oral suspension)) for the treatment of acute lymphoblastic leukaemia","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2012-04-10T17:13:00Z","last_updated_date":"2012-04-10T17:13:00Z","reference_number":"EMA/COMP/733334/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-mercaptopurine-nova-laboratories-mercaptopurine-oral-suspension-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"30172","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation : Natpar (parathyroid hormone) for the treatment of hypoparathyroidism","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2017-04-26T19:19:00Z","last_updated_date":"2017-04-26T19:19:00Z","reference_number":"EMA/172380/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-natpar-parathyroid-hormone-treatment-hypoparathyroidism_en.pdf"},
    {"id":"30642","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Cerdelga (eliglustat) for the treatment of Gaucher disease","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2015-02-17T15:20:00Z","last_updated_date":"2015-02-17T15:20:00Z","reference_number":"EMA/COMP/748368/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-cerdelga-eliglustat-treatment-gaucher-disease_en.pdf"},
    {"id":"31067","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Lynparza (olaparib) for the treatment of ovarian cancer","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-01-19T01:00:00Z","last_updated_date":"2018-05-28T02:00:00Z","reference_number":"EMA/COMP/685740/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-lynparza-olaparib-treatment-ovarian-cancer_en.pdf"},
    {"id":"31310","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Xermelo (telotristat) for the treatment of carcinoid syndrome","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2017-10-24T17:09:00Z","last_updated_date":"2017-10-24T17:09:00Z","reference_number":"EMA/550641/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-xermelo-telotristat-treatment-carcinoid-syndrome_en.pdf"},
    {"id":"31549","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Imbruvica (ibrutinib) for the treatment of mantle cell lymphoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2014-12-01T01:00:00Z","last_updated_date":"2014-12-01T01:00:00Z","reference_number":"EMA/COMP/535571/2014 ","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-imbruvica-ibrutinib-treatment-mantle-cell-lymphoma_en.pdf"},
    {"id":"31731","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Arzerra (ofatumumab) for the treatment of chronic lymphocytic leukaemia","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2011-04-11T02:00:00Z","last_updated_date":"2011-04-11T02:00:00Z","reference_number":"EMA/COMP/430552/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-arzerra-ofatumumab-treatment-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"32076","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Cystadrops (mercaptamine) for the treatment of cystinosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2017-02-22T11:10:00Z","last_updated_date":"2017-02-22T11:10:00Z","reference_number":"EMA/18807/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-cystadrops-mercaptamine-treatment-cystinosis_en.pdf"},
    {"id":"33171","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Dinutuximab beta Apeiron (dinutuximab beta) for the treatment of neuroblastoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2017-05-24T02:00:00Z","last_updated_date":"2017-05-24T02:00:00Z","reference_number":"EMA/228978/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-dinutuximab-beta-apeiron-dinutuximab-beta-treatment-neuroblastoma_en.pdf"},
    {"id":"34731","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Onivyde (irinotecan) for the treatment of pancreatic cancer","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T17:00:00Z","last_updated_date":"2016-11-11T17:00:00Z","reference_number":"EMA/COMP/639247/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-onivyde-irinotecan-treatment-pancreatic-cancer_en.pdf"},
    {"id":"36935","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Ninlaro (ixazomib) for the treatment of multiple myeloma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-12-07T12:00:00Z","last_updated_date":"2016-12-07T12:00:00Z","reference_number":"EMA/692567/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-ninlaro-ixazomib-treatment-multiple-myeloma_en.pdf"},
    {"id":"37260","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Oxervate (cenegermin) for the treatment neurotrophic keratitis","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2017-08-29T16:08:00Z","last_updated_date":"2017-08-29T16:08:00Z","reference_number":"EMA/337473/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-oxervate-cenegermin-treatment-neurotrophic-keratitis_en.pdf"},
    {"id":"37594","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Scenesse (afamelanotide) for the treatment of erythropoietic protoporphyria","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2015-02-17T15:35:00Z","last_updated_date":"2015-02-17T15:35:00Z","reference_number":"EMA/COMP/693753/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-scenesse-afamelanotide-treatment-erythropoietic-protoporphyria_en.pdf"},
    {"id":"37901","name":"Recommendation for maintenance of orphan designation at the time of addition of new indications to the marketing authorisation: Votubia (everolimus) for the treatment of tuberous sclerosis","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2011-10-10T15:32:00Z","last_updated_date":"2023-09-15T15:32:00Z","reference_number":"EMA/COMP/518763/2011","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-addition-new-indications-marketing-authorisation-votubia-everolimus-treatment-tuberous-sclerosis_en.pdf"},
    {"id":"38228","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Raxone (idebenone) for the treatment of Leber’s hereditary optic neuropathy","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-09-22T13:30:00Z","last_updated_date":"2015-09-22T13:30:00Z","reference_number":"EMA/COMP/473162/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-raxone-idebenone-treatment-lebers-hereditary-optic-neuropathy_en.pdf"},
    {"id":"38876","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Tepadina (thiotepa) for the conditioning treatment prior to haematopoietic progenitor cell transplantation","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2011-04-11T02:00:00Z","last_updated_date":"2011-04-11T02:00:00Z","reference_number":"EMA/COMP/430447/2010","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-tepadina-thiotepa-conditioning-treatment-prior-haematopoietic-progenitor-cell-transplantation_en.pdf"},
    {"id":"39152","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Unituxin (dinutuximab) for the treatment of neuroblastoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-09-08T02:00:00Z","last_updated_date":"2015-09-08T02:00:00Z","reference_number":"EMA/COMP/399837/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-unituxin-dinutuximab-treatment-neuroblastoma_en.pdf"},
    {"id":"39861","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Adcetris (brentuximab vedotin) for the treatment of anaplastic large cell lymphoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2012-11-28T16:00:00Z","last_updated_date":"2012-11-28T16:00:00Z","reference_number":"EMA/COMP/601842/2012","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-adcetris-brentuximab-vedotin-treatment-anaplastic-large-cell-lymphoma_en.pdf"},
    {"id":"41060","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Ofev (nintedanib) for the treatment of idiopathic pulmonary fibrosis","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2015-02-17T13:00:00Z","last_updated_date":"2020-06-09T13:00:00Z","reference_number":"EMA/COMP/766700/2014","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-ofev-nintedanib-treatment-idiopathic-pulmonary-fibrosis_en.pdf"},
    {"id":"41285","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Alprolix (eftrenonacog alfa) for the treatment of haemophilia B","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2016-05-30T02:00:00Z","reference_number":"EMA/COMP/259512/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-alprolix-eftrenonacog-alfa-treatment-haemophilia-b_en.pdf"},
    {"id":"41995","name":"Recommendation for maintenance of orphan designation at the time of addition of a new indication to the marketing authorisation: Imbruvica (ibrutinib) for the treatment of lymphoplasmacytic lymphoma","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2015-09-08T02:00:00Z","last_updated_date":"2015-09-14T02:00:00Z","reference_number":"EMA/COMP/396537/2015","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-addition-new-indication-marketing-authorisation-imbruvica-ibrutinib-treatment-lymphoplasmacytic-lymphoma_en.pdf"},
    {"id":"42015","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Idelvion (albutrepenonacog alfa) for the treatment of haemophilia B","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-05-31T19:50:00Z","last_updated_date":"2016-05-31T19:50:00Z","reference_number":"EMA/COMP/259510/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-idelvion-albutrepenonacog-alfa-treatment-haemophilia-b_en.pdf"}    {"id":"43893","name":"EU/3/18/2101: Public summary of opinion on orphan designation: Setmelanotide for the treatment of leptin receptor deficiency","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T13:33:00Z","last_updated_date":"2019-02-25T13:33:00Z","reference_number":"EMA/756623/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/eu3182101-public-summary-opinion-orphan-designation-setmelanotide-treatment-leptin-receptor-deficiency_en.pdf"},
    {"id":"43995","name":"EU/3/18/2122: Public summary of opinion on orphan designation: Venglustat for treatment of autosomal dominant polycystic kidney disease","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2019-03-08T11:08:00Z","last_updated_date":"2021-10-12T15:45:00Z","reference_number":"EMA/840293/2018","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/eu3182122-public-summary-opinion-orphan-designation-venglustat-treatment-autosomal-dominant-polycystic-kidney-disease_en.pdf"},
    {"id":"44193","name":"EU/3/19/2145: Public summary of opinion on orphan designation for risdiplam for the treatment of spinal muscular atrophy","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T11:06:00Z","last_updated_date":"2023-09-12T16:05:00Z","reference_number":"EMADOC-628903358-446","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/eu-3-19-2145-public-summary-opinion-orphan-designation-risdiplam-treatment-spinal-muscular-atrophy_en.pdf"},
    {"id":"44514","name":"Recommendation for maintenance of orphan designation at the time of marketing authorisation: Verkazia (ciclosporin) for the treatment of vernal keratoconjunctivitis","type":"orphan-review","status":"unknown","consultation_date":"","first_published_date":"2018-07-12T12:49:00Z","last_updated_date":"2018-07-12T12:49:00Z","reference_number":"EMA/798773/2017","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-verkazia-ciclosporin-treatment-vernal-keratoconjunctivitis_en.pdf"},
    {"id":"45577","name":"EU/3/19/2173: Public summary of opinion on orphan designation: Imidazolyl ethanamide pentandioic acid for the treatment of acute radiation syndrome","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2019-10-07T14:53:00Z","last_updated_date":"2019-10-07T14:53:00Z","reference_number":"EMADOC-628903358-1036","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/eu3192173-public-summary-opinion-orphan-designation-imidazolyl-ethanamide-pentandioic-acid-treatment-acute-radiation-syndrome_en.pdf"},
    {"id":"60540","name":"COMP assesses whether Plenadren still meets orphan designation criteria: recommendation to maintain the period of market exclusivity at 10 years: Plenadren (hydrocortisone) for the treatment of adrenal insufficiency","type":"orphan-review","status":"Adopted","consultation_date":"","first_published_date":"2016-05-03T18:00:00Z","last_updated_date":"2021-11-25T18:00:00Z","reference_number":"EMA/COMP/263073/2016","document_url":"https://www.ema.europa.eu/en/documents/orphan-review/comp-assesses-whether-plenadren-still-meets-orphan-designation-criteria-recommendation-maintain-period-market-exclusivity-10-years-plenadren-hydrocortisone-treatment-adrenal-insufficiency_en.pdf"},
    {"id":"2768","name":"Overview of comments received on 'Publication and access to clinical-trial data' (EMA/240810/2013) - from stakeholder 127 to 156","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2014-10-02T19:00:00Z","reference_number":"EMA/351881/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-publication-and-access-clinical-trial-data-ema2408102013-stakeholder-127-156_en.pdf"},
    {"id":"3050","name":"Overview of comments received on 'Guideline on the compliance of authorised equine influenza vaccines with World Organisation for Animal Health (OIE) requirements'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-11-19T12:00:00Z","last_updated_date":"2014-11-19T12:00:00Z","reference_number":"EMA/CVMP/IWP/36240/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-compliance-authorised-equine-influenza-vaccines-world-organisation-animal-health-oie-requirements_en.pdf"},
    {"id":"3619","name":"Overview of comments received on 'Vemurafenib film-coated tablets 240 mg product-specific bioequivalence guidance’ (EMA/CHMP/476248/2016)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-03-03T01:00:00Z","last_updated_date":"2017-03-03T01:00:00Z","reference_number":"EMA/CHMP/803499/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-vemurafenib-film-coated-tablets-240-mg-product-specific-bioequivalence-guidance-emachmp4762482016_en.pdf"},
    {"id":"3788","name":"Overview of comments received on 'Detailed Guide regarding the Monitoring of Medical Literature and the Entry of Relevant Information into the EudraVigilance Database by the European Medicines Agency on Literature Monito...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-05-12T14:30:00Z","last_updated_date":"2015-05-12T14:30:00Z","reference_number":"EMA/716877/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-detailed-guide-regarding-monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency-literature-monito_en.pdf"},
    {"id":"4101","name":"Overview of comments received on 'Draft guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products’ (EMA/CHMP/594085/2015)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-10-18T17:40:00Z","last_updated_date":"2016-10-18T17:40:00Z","reference_number":"EMA/242781/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-use-pharmacokinetics-and-pharmacodynamics-development-antimicrobial-medicinal-products-emachmp5940852015_en.pdf"},
    {"id":"4119","name":"Overview of comments received on 'Guideline on the procedure to be followed when a batch of a vaccine finished product is suspected to be contaminated with bovine viral diarrhoea virus’ (EMA/CVMP/IWP/205351/2006-Rev.1)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-09-17T18:35:01Z","last_updated_date":"2015-09-17T18:35:01Z","reference_number":"EMA/CVMP/IWP/342158/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-procedure-be-followed-when-batch-vaccine-finished-product-suspected-be-contaminated-bovine-viral-diarrhoea-virus-emacvmpiwp2053512006-rev1_en.pdf"},
    {"id":"4280","name":"Overview of comments received on the ‘Reflection paper on the use of methyl- and propylparaben as excipients in human medicinal products for oral use’ (EMA/CHMP/SWP/272921/2012)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-11-19T11:00:00Z","last_updated_date":"2015-11-19T11:00:00Z","reference_number":"EMA/684369/2013","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-use-methyl-and-propylparaben-excipients-human-medicinal-products-oral-use-emachmpswp2729212012_en.pdf"},
    {"id":"4318","name":"VICH GL50 Overview of comments: Harmonization of criteria to waive target animal batch safety testing for inactivated vaccines for veterinary use","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-06-27T18:00:00Z","last_updated_date":"2017-06-27T18:00:00Z","reference_number":"VICH/12/056","document_url":"https://www.ema.europa.eu/en/documents/comments/vich-gl50-overview-comments-harmonization-criteria-waive-target-animal-batch-safety-testing-inactivated-vaccines-veterinary-use_en.pdf"},
    {"id":"4342","name":"Overview of comments received on 'the guideline Core summary of product characteristics for human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94038/2007 Rev. 5) - Revision 5","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T18:00:00Z","last_updated_date":"2018-09-13T18:00:00Z","reference_number":"EMA/CHMP/BPWP/572924/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-core-summary-product-characteristics-human-normal-immunoglobulin-intravenous-administration-ivig-emachmpbpwp940382007-rev-5-revision-5_en.pdf"},
    {"id":"4711","name":"Overview of comments received on ‘Guideline on quality data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T18:21:00Z","last_updated_date":"2017-01-03T18:21:00Z","reference_number":"EMA/CVMP/QWP/472725/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-quality-data-requirements-veterinary-medicinal-products-intended-minor-use-or-minor-species-mumslimited-market_en.pdf"},
    {"id":"4744","name":"Overview of comments received on 'Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in non-surgical patients (formerly CPMP/EWP/6235/04 Rev.1)'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T15:40:00Z","last_updated_date":"2016-11-29T15:40:00Z","reference_number":"EMA/452872/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-medicinal-products-prevention-venous-thromboembolism-vte-non-surgical-patients-formerly-cpmpewp623504-rev1_en.pdf"},
    {"id":"4819","name":"Overview of comments received on 'Guideline on core SmPC for plasma-derived fibrin sealant / haemostatic products'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T12:00:00Z","last_updated_date":"2015-06-25T12:00:00Z","reference_number":"EMA/CHMP/BPWP/316655/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-core-smpc-plasma-derived-fibrin-sealant-haemostatic-products_en.pdf"},
    {"id":"4865","name":"Overview of comments received on 'Draft carglumic acid product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-04-10T15:28:00Z","last_updated_date":"2015-04-10T15:28:00Z","reference_number":"EMA/CHMP/116356/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-carglumic-acid-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"4969","name":"Overview of comments received on 'Draft guideline on implementation of risk assessment requirements to control elemental impurities in veterinary medicinal products - First version","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-12-13T12:45:00Z","last_updated_date":"2017-12-13T12:45:00Z","reference_number":"EMA/CVMP/QWP/759110/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-implementation-risk-assessment-requirements-control-elemental-impurities-veterinary-medicinal-products-first-version_en.pdf"},
    {"id":"5269","name":"Overview of comments received on draft guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin - Superseded","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2006-01-12T01:00:00Z","last_updated_date":"2006-01-12T01:00:00Z","reference_number":"EMEA//HMPC/11138/2006","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-good-agricultural-collection-practice-gacp-starting-materials-herbal-origin-superseded_en.pdf"},
    {"id":"5272","name":"Overview of comments received on 'Reflection paper on the chemical structure and properties criteria to be considered for the evaluation of new active substance (NAS) status of chemical substances'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T12:40:00Z","last_updated_date":"2016-01-19T12:40:00Z","reference_number":"EMA/839636/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-chemical-structure-and-properties-criteria-be-considered-evaluation-new-active-substance-nas-status-chemical-substances_en.pdf"},
    {"id":"5856","name":"Overview of comments received on 'Reflection paper on classification of advanced therapy medicinal products'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-06-17T14:00:00Z","last_updated_date":"2015-06-17T14:00:00Z","reference_number":"EMA/CAT/224106/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-classification-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"6061","name":"Overview of comments on 'Guideline on assessing the toxicological risk to human health and groundwater communities from veterinary pharmaceuticals in groundwater' (EMA/CVMP/ERA/103555/2015)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-04-30T13:33:00Z","last_updated_date":"2018-04-30T13:33:00Z","reference_number":"EMA/CVMP/ERA/609438/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-guideline-assessing-toxicological-risk-human-health-and-groundwater-communities-veterinary-pharmaceuticals-groundwater-emacvmpera1035552015_en.pdf"},
    {"id":"6373","name":"Overview of comments received on 'Reflection paper on the authorisation of veterinary medicinal products containing (potential) persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPv...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-05-23T11:00:00Z","last_updated_date":"2017-05-23T11:00:00Z","reference_number":"EMA/CVMP/401418/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-authorisation-veterinary-medicinal-products-containing-potential-persistent-bioaccumulative-and-toxic-pbt-or-very-persistent-and-very-bioaccumulative-vpv_en.pdf"},
    {"id":"6509","name":"Overview of comments received on 'Draft oseltamivir product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-04-10T15:28:00Z","last_updated_date":"2015-04-10T15:28:00Z","reference_number":"EMA/CHMP/116544/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-oseltamivir-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"6538","name":"Overview of comments received on 'Guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-03-26T17:00:00Z","last_updated_date":"2015-03-26T17:00:00Z","reference_number":"EMA/CHMP/BPWP/356950/2013","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-core-smpc-human-normal-immunoglobulin-subcutaneous-and-intramuscular-administration_en.pdf"},
    {"id":"6566","name":"Overview of comments received during the public consultation on ‘Reflection paper on poorly extractable and/or non-radiolabelled substances'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-03-29T11:25:00Z","last_updated_date":"2016-03-29T11:25:00Z","reference_number":"EMA/CVMP/ERA/603511/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-during-public-consultation-reflection-paper-poorly-extractable-andor-non-radiolabelled-substances_en.pdf"},
    {"id":"7005","name":"Overview of comments received on 'Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T12:00:00Z","last_updated_date":"2016-03-11T12:00:00Z","reference_number":"EMA/30262/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-duchenne-and-becker-muscular-dystrophy_en.pdf"},
    {"id":"7057","name":"Overview of comments received on Guideline on risk characterisation and assessment of maximum residue limits (MRL) for biocides","type":"comments","status":"unknown","consultation_date":"2015-01-27 - 2015-04-30","first_published_date":"2015-01-30T02:00:00Z","last_updated_date":"2015-01-30T02:00:00Z","reference_number":"EMA/CVMP/SWP/33896/2013","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-risk-characterisation-and-assessment-maximum-residue-limits-mrl-biocides_en.pdf"},
    {"id":"7618","name":"Overview of comments received on 'Guideline on safety and residue data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T18:27:00Z","last_updated_date":"2017-01-03T18:27:00Z","reference_number":"EMA/CVMP/SWP/523387/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-safety-and-residue-data-requirements-veterinary-medicinal-products-intended-minor-use-or-minor-species-mumslimited-market_en.pdf"},
    {"id":"7804","name":"Overview of comments received on 'Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-11-11T10:05:00Z","last_updated_date":"2014-11-11T10:05:00Z","reference_number":"EMA/CHMP/341511/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-medicinal-products-prevention-stroke-and-systemic-embolic-events-patients-non-valvular-atrial-fibrillation_en.pdf"},
    {"id":"7937","name":"Overview of comments received on 'Reflection paper on the use of cocrystals and other solid state forms of active substances in medicinal products’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T18:10:00Z","last_updated_date":"2015-07-16T18:10:00Z","reference_number":"EMA/CHMP/CVMP/QWP/284007/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-use-cocrystals-and-other-solid-state-forms-active-substances-medicinal-products_en.pdf"},
    {"id":"8650","name":"Overview of comments received on 'draft sorafenib product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T14:15:00Z","last_updated_date":"2015-07-07T14:15:00Z","reference_number":"EMA/CHMP/116717/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-sorafenib-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"8666","name":"Overview of comments received on 'draft capecitabine product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T14:15:00Z","last_updated_date":"2015-07-07T14:15:00Z","reference_number":"EMA/CHMP/116324/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-capecitabine-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"8747","name":"Overview of comments on EMA/641479/2014 Draft proposal for an addendum, on transparency, to the 'Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014' - Specific comments received on...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-12-03T13:30:00Z","last_updated_date":"2015-12-03T13:30:00Z","reference_number":"EMA/739152/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-ema6414792014-draft-proposal-addendum-transparency-functional-specifications-eu-portal-and-eu-database-be-audited-ema421762014-specific-comments-received_en.pdf"},
    {"id":"8761","name":"Overview of comments received on 'draft tadalafil product-specific bioequivalence guidance' - First version","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T14:15:00Z","last_updated_date":"2015-07-07T14:15:00Z","reference_number":"EMA/CHMP/116444/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-tadalafil-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"9688","name":"Overview of comments received on 'Revised recommendation for the basic surveillance of EudraVigilance Veterinary (EVVet) data for centrally\n\nauthorised products (CAPs)' (EMA/CVMP/PhVWP/171122/2016)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-06-04T14:00:01Z","last_updated_date":"2018-06-04T14:00:01Z","reference_number":"EMA/CVMP/PhVWP/519126/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-revised-recommendation-basic-surveillance-eudravigilance-veterinary-evvet-data-centrally-authorised-products-caps-emacvmpphvwp1711222016_en.pdf"},
    {"id":"9835","name":"Overview of comments received on 'Draft imatinib product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-04-10T15:28:00Z","last_updated_date":"2015-04-10T15:28:00Z","reference_number":"EMA/CHMP/116042/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-imatinib-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"9913","name":"Overview of comments received on 'Reflection paper on the risk of antimicrobial resistance transfer from companion animals'","type":"comments","status":"unknown","consultation_date":"2015-01-27 - 2015-04-30","first_published_date":"2015-01-30T02:00:00Z","last_updated_date":"2015-01-30T02:00:00Z","reference_number":"EMA/CVMP/89283/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-risk-antimicrobial-resistance-transfer-companion-animals_en.pdf"},
    {"id":"9914","name":"Overview of comments received on 'Guideline on user safety of topically administered veterinary medicinal products'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-05-07T13:45:00Z","last_updated_date":"2018-05-07T13:45:00Z","reference_number":"EMA/CVMP/SWP/30675/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-user-safety-topically-administered-veterinary-medicinal-products_en.pdf"},
    {"id":"10002","name":"Overview of comments received during the second public consultation on 'Guidance on the assessment of persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances in veterinar...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-09-17T18:05:01Z","last_updated_date":"2015-09-17T18:05:01Z","reference_number":"EMA/CVMP/ERA/74265/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-during-second-public-consultation-guidance-assessment-persistent-bioaccumulative-and-toxic-pbt-or-very-persistent-and-very-bioaccumulative-vpvb-substances-veterinar_en.pdf"},
    {"id":"10480","name":"Overview of comments received on the draft ‘Questions and Answers on Benzalkonium chloride’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/601508/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-questions-and-answers-benzalkonium-chloride_en.pdf"},
    {"id":"10529","name":"VICH GL55 Overview of comments: Harmonization of criteria to waive target animal batch safety testing for live vaccines for veterinary use - First version","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-06-27T18:00:00Z","last_updated_date":"2017-06-27T18:00:00Z","reference_number":"VICH/12/056","document_url":"https://www.ema.europa.eu/en/documents/comments/vich-gl55-overview-comments-harmonization-criteria-waive-target-animal-batch-safety-testing-live-vaccines-veterinary-use-first-version_en.pdf"},
    {"id":"10604","name":"Overview of comments on EMA/641479/2014 Draft proposal for an addendum, on transparency, to the 'Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014' - Specific comments received on...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-12-03T13:30:00Z","last_updated_date":"2015-12-03T13:30:00Z","reference_number":"EMA/739151/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-ema6414792014-draft-proposal-addendum-transparency-functional-specifications-eu-portal-and-eu-database-be-audited-ema421762014-specific-comments-received_en.pdf-0"},
    {"id":"10807","name":"Overview of comments received on 'Draft guideline for the testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestation in dogs and cats - Revision 3'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-07-25T16:09:00Z","last_updated_date":"2016-07-25T16:09:00Z","reference_number":"EMA/CVMP/EWP/495905/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-testing-and-evaluation-efficacy-antiparasitic-substances-treatment-and-prevention-tick-and-flea-infestation-dogs-and-cats-revision-3_en.pdf"},
    {"id":"10903","name":"Overview of comments received on the draft 'Questions and answers on benzoic acid and benzoates’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/349506/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-questions-and-answers-benzoic-acid-and-benzoates_en.pdf"},
    {"id":"11195","name":"Overview of comments received on Levodopa/Carbidopa/Entacapone film-coated tablet 200 mg/50 mg/200 mg, 175 mg/43.75 mg/200 mg, 150 mg/37.5 mg/200 mg, 125 mg/31.25 mg/200 mg, 100 mg/25 mg/200 mg, 75 mg/18.75 mg/200 mg and...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T17:54:00Z","last_updated_date":"2017-01-03T17:54:00Z","reference_number":"EMA/CHMP/620297/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-levodopacarbidopaentacapone-film-coated-tablet-200-mg50-mg200-mg-175-mg4375-mg200-mg-150-mg375-mg200-mg-125-mg3125-mg200-mg-100-mg25-mg200-mg-75-mg1875-mg200-mg-and_en.pdf"},
    {"id":"11265","name":"Overview of comments received on 'Paediatric addendum to the note for guidance on the clinical investigation on medicinal products in the treatment of hypertension'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-03-26T17:30:00Z","last_updated_date":"2015-03-26T17:30:00Z","reference_number":"EMA/CHMP/68390/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-paediatric-addendum-note-guidance-clinical-investigation-medicinal-products-treatment-hypertension_en.pdf"},
    {"id":"11594","name":"Overview of comments received on 'Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T16:49:00Z","last_updated_date":"2016-02-15T16:49:00Z","reference_number":"EMA/480192/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-use-minimal-residue-disease-endpoint-chronic-lymphocytic-leukaemia-studies_en.pdf"},
    {"id":"12130","name":"Overview of the comments received on draft European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Vision and Strategy 2016-2020 (EMA/326299/2015)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-02-07T15:40:00Z","last_updated_date":"2017-02-07T15:40:00Z","reference_number":"EMA/453536/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-european-surveillance-veterinary-antimicrobial-consumption-esvac-vision-and-strategy-2016-2020-ema3262992015_en.pdf"},
    {"id":"12361","name":"Overview of comments received on 'Draft guideline on clinical investigation of medicinal products for the treatment of venous thromboembolic disease'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-03-23T01:00:00Z","last_updated_date":"2016-03-23T01:00:00Z","reference_number":"EMA/129183/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-venous-thromboembolic-disease_en.pdf"},
    {"id":"12569","name":"Overview of comments received on guideline on clinical investigation of medicinal products in the treatment of hypertension (EMA/CHMP/29947/2013/Rev.4)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T12:50:00Z","last_updated_date":"2016-07-08T12:50:00Z","reference_number":"EMA/CHMP/345847/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-hypertension-emachmp299472013rev4_en.pdf"},
    {"id":"12588","name":"Overview of comments received on 'Guideline on efficacy and target animal safety data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T18:18:00Z","last_updated_date":"2017-01-03T18:18:00Z","reference_number":"EMA/CVMP/EWP/523421/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-efficacy-and-target-animal-safety-data-requirements-veterinary-medicinal-products-intended-minor-use-or-minor-species-mumslimited-market_en.pdf"},
    {"id":"13122","name":"Overview of comments received on 'Note for guidance on clinical investigation of medicinal products for treatment of asthma' - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T13:00:00Z","last_updated_date":"2015-12-15T13:00:00Z","reference_number":"EMA/CHMP/684234/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-note-guidance-clinical-investigation-medicinal-products-treatment-asthma-revision-1_en.pdf"},
    {"id":"13270","name":"Overview of comments received on 'CVMP strategy on antimicrobials 2016-2020' (EMA/CVMP/209189/2015)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T14:00:00Z","last_updated_date":"2016-10-20T14:00:00Z","reference_number":"EMA/CVMP/185871/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-cvmp-strategy-antimicrobials-2016-2020-emacvmp2091892015_en.pdf"},
    {"id":"13345","name":"Overview of comments received on “EU Medicines Agencies Network Strategy to 2020”","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/848469/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-eu-medicines-agencies-network-strategy-2020_en.pdf"},
    {"id":"13353","name":"Overview of comments received on 'Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-06-26T15:35:00Z","last_updated_date":"2018-06-26T15:35:00Z","reference_number":"EMA/CHMP/644911/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-prasugrel-hydrochloride-film-coated-tablets-5-mg-and-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"13474","name":"VICH GL50 Overview of comments: Harmonisation of criteria to waive target animal batch safety testing for inactivated vaccines for veterinary use - First version","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-05-29T12:30:00Z","last_updated_date":"2015-05-29T12:30:00Z","reference_number":"VICH GL-50","document_url":"https://www.ema.europa.eu/en/documents/comments/vich-gl50-overview-comments-harmonisation-criteria-waive-target-animal-batch-safety-testing-inactivated-vaccines-veterinary-use-first-version_en.pdf"},
    {"id":"13852","name":"Overview of comments received on 'Dabigatran etexilate, hard capsules, 75 mg, 110 mg and 150 mg product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-06-26T13:46:00Z","last_updated_date":"2018-06-26T13:46:00Z","reference_number":"EMA/CHMP/258276/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-dabigatran-etexilate-hard-capsules-75-mg-110-mg-and-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"13909","name":"Overview of comments on 'Total kidney volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD)'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-11-13T17:20:00Z","last_updated_date":"2015-11-13T17:20:00Z","reference_number":"EMA/733775/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-total-kidney-volume-tkv-prognostic-biomarker-use-clinical-trials-evaluating-patients-autosomal-dominant-polycystic-kidney-disease-adpkd_en.pdf"},
    {"id":"13912","name":"Overview of comments received by EMA on the draft Addendum of the ‘ICH E11(R1) guideline on clinical investigation of medicinal products in the paediatric population’ (EMA/CPMP/ICH/2711/1999)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-04-26T15:44:00Z","last_updated_date":"2017-04-28T18:46:00Z","reference_number":"EMA/256626/2017 Corr.","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ema-draft-addendum-ich-e11r1-guideline-clinical-investigation-medicinal-products-paediatric-population-emacpmpich27111999_en.pdf"},
    {"id":"14030","name":"Overview of comments received on 'Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T15:25:00Z","last_updated_date":"2016-05-27T15:25:00Z","reference_number":"EMA/CHMP/BWP/337128/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-process-validation-manufacture-biotechnology-derived-active-substances-and-data-be-provided-regulatory-submission_en.pdf"},
    {"id":"14112","name":"Overview of comments on 'Concept paper on the revision of the ‘Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-09-27T13:10:00Z","last_updated_date":"2017-09-27T13:10:00Z","reference_number":"EMA/CHMP/510967/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-concept-paper-revision-guideline-strategies-identify-and-mitigate-risks-first-human-clinical-trials-investigational-medicinal-products_en.pdf"},
    {"id":"14201","name":"Overview of comments received on ‘Draft guideline on the core SmPC for human Anti-D immunoglobulin for intramuscular use’ (EMA/CHMP/BPWP/29205/2005 Rev. 2)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-09-29T12:00:01Z","last_updated_date":"2016-09-29T12:00:01Z","reference_number":"EMA/CHMP/BPWP/379212/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-core-smpc-human-anti-d-immunoglobulin-intramuscular-use-emachmpbpwp292052005-rev-2_en.pdf"},
    {"id":"14611","name":"Overview of comments received on 'Gaucher disease: a strategic collaborative approach from the European Medicines Agency and Food and Drug Administration' (EMA/44410/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-06-30T19:00:00Z","last_updated_date":"2017-06-30T19:00:00Z","reference_number":"EMA/752905/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-gaucher-disease-strategic-collaborative-approach-european-medicines-agency-and-food-and-drug-administration-ema444102014_en.pdf"},
    {"id":"14811","name":"Overview of comments received on 'Guideline on the role of the pathological Complete Response (pCR) as an endpoint in neoadjuvant breast cancer studies'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-10-07T16:30:00Z","last_updated_date":"2015-10-07T16:30:00Z","reference_number":"EMA/94983/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-role-pathological-complete-response-pcr-endpoint-neoadjuvant-breast-cancer-studies_en.pdf"},
    {"id":"14902","name":"Overview of comments received on the draft 'Information in the package leaflet for aspartame'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/581993/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-information-package-leaflet-aspartame_en.pdf"},
    {"id":"15047","name":"Overview of comments received on the draft 'Questions & answers on propylene glycol and esters'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/157147/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-questions-answers-propylene-glycol-and-esters_en.pdf"},
    {"id":"15595","name":"Overview of comments received on public consultation regarding the request to the European Medicines Agency from the European Commission for a scientific opinion regarding the risks to vultures and other necrophagous bir...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T18:30:00Z","last_updated_date":"2014-12-12T18:30:00Z","reference_number":"EMA/715812/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-public-consultation-regarding-request-european-medicines-agency-european-commission-scientific-opinion-regarding-risks-vultures-and-other-necrophagous-bir_en.pdf"},
    {"id":"15890","name":"Overview of comments on EMA/641479/2014 Draft proposal for an addendum, on transparency, to the 'Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014' - Specific comments received on...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-12-03T13:30:00Z","last_updated_date":"2015-12-03T13:30:00Z","reference_number":"EMA/739150/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-ema6414792014-draft-proposal-addendum-transparency-functional-specifications-eu-portal-and-eu-database-be-audited-ema421762014-specific-comments-received_en.pdf-1"},
    {"id":"16134","name":"Overview of comments received on VICH guideline on statistical evaluation of stability data (GL 51)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-05-29T12:30:00Z","last_updated_date":"2015-05-29T12:30:00Z","reference_number":"VICH GL-51","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-vich-guideline-statistical-evaluation-stability-data-gl-51_en.pdf"},
    {"id":"16278","name":"Overview of comments received on ' Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS)' (EMA/531686/2015)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T16:25:00Z","last_updated_date":"2016-02-01T16:25:00Z","reference_number":"EMA/CHMP/131550/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis-als-ema5316862015_en.pdf"},
    {"id":"16331","name":"Overview of comments received by EMA on 'Questions and answers - ICH S9 guideline on nonclinical evaluation for anticancer pharmaceuticals - Step 2b'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-02-13T01:00:00Z","last_updated_date":"2017-02-13T01:00:00Z","reference_number":"EMA/72007/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ema-questions-and-answers-ich-s9-guideline-nonclinical-evaluation-anticancer-pharmaceuticals-step-2b_en.pdf"},
    {"id":"16519","name":"Overview of comments received on the draft 'Information in the package leaflet for fragrances containing allergens'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/579645/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-information-package-leaflet-fragrances-containing-allergens_en.pdf"},
    {"id":"16677","name":"Overview of comments received on 'Draft guideline on the testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestations in dogs and cats - Revision 1'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2007-11-12T01:00:00Z","last_updated_date":"2007-11-12T01:00:00Z","reference_number":"EMEA/CVMP/EWP/203830/2007","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-testing-and-evaluation-efficacy-antiparasitic-substances-treatment-and-prevention-tick-and-flea-infestations-dogs-and-cats-revision-1_en.pdf"},
    {"id":"16886","name":"Overview of comments received on ‘Reflection paper on microbiological aspects of herbal medicinal products and traditional herbal medicinal products’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-06-05T11:15:00Z","last_updated_date":"2015-06-05T11:15:00Z","reference_number":"EMA/HMPC/130616/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-microbiological-aspects-herbal-medicinal-products-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"16889","name":"Overview of comments received on ‘Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials’ (EMA/CHMP/BWP/534898/2008 Rev. 1) - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T15:45:00Z","last_updated_date":"2017-10-26T15:45:00Z","reference_number":"EMA/CHMP/BWP/563769/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials-emachmpbwp5348982008-rev-1-revision-1_en.pdf"},
    {"id":"16949","name":"Overview of comments received on ‘the guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)’ (EMA/CHMP/BPWP/94033/2007), Rev.3","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-07-20T16:45:00Z","last_updated_date":"2018-07-20T16:45:00Z","reference_number":"EMA/CHMP/BPWP/604687/2009","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-emachmpbpwp940332007-rev3_en.pdf"},
    {"id":"16963","name":"Overview of comments received on 'Draft guideline on non-clinical local tolerance testing of medicinal products’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-11-27T15:15:00Z","last_updated_date":"2015-11-27T15:15:00Z","reference_number":"EMA/699381/2000","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-non-clinical-local-tolerance-testing-medicinal-products_en.pdf"},
    {"id":"17152","name":"Overview of comments received on Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T16:45:00Z","last_updated_date":"2015-03-27T16:45:00Z","reference_number":"EMA/179672/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-data-requirements-intravenous-iron-based-nano-colloidal-products-developed-reference-innovator-medicinal-product_en.pdf"},
    {"id":"17559","name":"Overview of comments received on draft 'Guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food-producing animals' (E...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T14:46:00Z","last_updated_date":"2018-07-27T14:46:00Z","reference_number":"EMA/CVMP/AWP/598285/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-assessment-risk-public-health-antimicrobial-resistance-due-use-antimicrobial-veterinary-medicinal-product-food-producing-animals-e_en.pdf"},
    {"id":"17576","name":"Overview of comments received on the 'Reflection paper on anthelmintic resistance’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T16:25:00Z","last_updated_date":"2017-04-24T16:51:00Z","reference_number":"EMA/CVMP/EWP/526298/2016-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-anthelmintic-resistance_en.pdf"},
    {"id":"17773","name":"Overview of comments received on 'Publication and access to clinical-trial data' (EMA/240810/2013) - from stakeholder 157 to 169","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2014-10-02T19:00:00Z","reference_number":"EMA/354914/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-publication-and-access-clinical-trial-data-ema2408102013-stakeholder-157-169_en.pdf"},
    {"id":"17860","name":"Overview of comments received on ‘Draft Guideline on the core SmPC for human Anti-D immunoglobulin for intravenous use’ (EMA/CHMP/BPWP/319619/2005 Rev. 2)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-09-29T12:00:00Z","last_updated_date":"2016-09-29T12:00:00Z","reference_number":"EMA/CHMP/BPWP/379278/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-core-smpc-human-anti-d-immunoglobulin-intravenous-use-emachmpbpwp3196192005-rev-2_en.pdf"},
    {"id":"18451","name":"Overview of comments received on 'Qualification opinion on paediatric ulcerative colitis activity index (PUCAI)'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-01-20T17:10:00Z","last_updated_date":"2016-01-20T17:10:00Z","reference_number":"EMA/760013/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-qualification-opinion-paediatric-ulcerative-colitis-activity-index-pucai_en.pdf"},
    {"id":"18896","name":"Overview of comments received on 'Guideline on the plant testing strategy for veterinary medicinal products' (EMA/CVMP/ERA/689041/2015)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T10:00:00Z","last_updated_date":"2017-03-24T10:00:00Z","reference_number":"EMA/CVMP/ERA/8138/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-plant-testing-strategy-veterinary-medicinal-products-emacvmpera6890412015_en.pdf"},
    {"id":"18960","name":"Overview of comments received on the draft ‘Questions and answers on wheat starch (containing gluten)’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/674221/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-questions-and-answers-wheat-starch-containing-gluten_en.pdf"},
    {"id":"19062","name":"Overview of comments received on \"Qualification opinion on Proactive in chronic obstructive pulmonary disease (COPD)\"","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T13:58:00Z","last_updated_date":"2018-04-19T13:58:00Z","reference_number":"EMA/225940/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-qualification-opinion-proactive-chronic-obstructive-pulmonary-disease-copd_en.pdf"},
    {"id":"19262","name":"Overview of comments received on ‘draft sirolimus product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T14:15:00Z","last_updated_date":"2015-07-07T14:15:00Z","reference_number":"EMA/CHMP/116630/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-sirolimus-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"19553","name":"Overview of comments on 'Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products' (EMA/CAT/80183/2014)'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-07-13T02:00:00Z","last_updated_date":"2018-07-13T14:53:00Z","reference_number":"EMA/801611/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-guideline-quality-non-clinical-and-clinical-aspects-gene-therapy-medicinal-products-emacat801832014_en.pdf"},
    {"id":"19705","name":"Overview of comments received on \"Guideline on the assessment of clinical safety and efficacy in the preparation of European Union herbal monographs for well-established and traditional herbal medicinal products\"","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-11-28T12:45:00Z","last_updated_date":"2017-11-28T12:45:00Z","reference_number":"EMA/HMPC/183134/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-assessment-clinical-safety-and-efficacy-preparation-european-union-herbal-monographs-well-established-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"19746","name":"Overview of comments received on ''Draft guideline on the development of new medicinal products for the treatment of Ulcerative Colitis' (EMA/CHMP/EWP/18463/2006 Rev. 1)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T11:48:00Z","last_updated_date":"2018-07-23T11:48:00Z","reference_number":"EMA/CHMP/354664/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-development-new-medicinal-products-treatment-ulcerative-colitis-emachmpewp184632006-rev-1_en.pdf"},
    {"id":"20874","name":"Overview of comments on ‘Ticagrelor film-coated tablets 90mg product specific bioequivalence guidance’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/CHMP/206139/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-ticagrelor-film-coated-tablets-90mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"20890","name":"Overview of comments received on 'Draft posaconazole product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-04-10T15:28:00Z","last_updated_date":"2015-04-10T15:28:00Z","reference_number":"EMA/CHMP/116907/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-posaconazole-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"21515","name":"Overview of comments received on 'draft telithromycin product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T14:15:00Z","last_updated_date":"2015-07-07T14:15:00Z","reference_number":"EMA/CHMP/116814/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-telithromycin-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"21933","name":"Overview of comments received on 'Draft guideline on the clinical investigation of medicinal products to prevent development/slow progression of chronic renal insufficiency’ (EMA/CHMP/355988/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T13:46:00Z","last_updated_date":"2016-10-20T13:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-prevent-developmentslow-progression-chronic-renal-insufficiency-emachmp3559882014_en.pdf"},
    {"id":"22342","name":"Overview of comments on 'Draft qualification opinion on molecular neuroimaging of the dopamine transporter as biomarker to identify patients with early manifest Parkinsonism in Parkinson’s disease'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T17:00:00Z","last_updated_date":"2018-07-19T17:00:00Z","reference_number":"EMA/9764/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-draft-qualification-opinion-molecular-neuroimaging-dopamine-transporter-biomarker-identify-patients-early-manifest-parkinsonism-parkinsons-disease_en.pdf"},
    {"id":"22948","name":"Overview of comments received on Draft guideline on the conduct of efficacy studies for intramammary products for use in cattle - Revision 2 (first verison)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T15:30:00Z","last_updated_date":"2016-02-26T15:30:00Z","reference_number":"EMA/CVMP/EWP/335976/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-conduct-efficacy-studies-intramammary-products-use-cattle-revision-2-first-verison_en.pdf"},
    {"id":"23293","name":"Overview of comments received on the 'Draft guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances - Revision 1 (second version)'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-02-03T12:00:00Z","last_updated_date":"2016-02-03T12:00:00Z","reference_number":"EMA/CVMP/EWP/374087/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances-revision-1-second-version_en.pdf"}    {"id":"23524","name":"Overview of comments received on ‘Paediatric addendum on the CHMP guideline on clinical investigation of medicinal products for the treatment of acute heart failure’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T01:00:00Z","last_updated_date":"2016-11-18T01:00:00Z","reference_number":"EMA/CHMP/852405/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-paediatric-addendum-chmp-guideline-clinical-investigation-medicinal-products-treatment-acute-heart-failure_en.pdf"},
    {"id":"23709","name":"Overview of comments received on ' Guideline on regulatory acceptance of 3R (replacement, reduction, refinement) testing approaches' (EMA/CHMP/CVMP/JEG-3Rs/450091/2012)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T17:00:00Z","last_updated_date":"2017-02-24T17:00:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/25975/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-regulatory-acceptance-3r-replacement-reduction-refinement-testing-approaches-emachmpcvmpjeg-3rs4500912012_en.pdf"},
    {"id":"23803","name":"Overview of comments received on 'Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues' (EMEA/CHMP/BMWP/42832/2005 Rev. 1)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-03-19T11:37:00Z","last_updated_date":"2018-03-19T11:37:00Z","reference_number":"EMA/CHMP/772616/2013","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-emeachmpbmwp428322005-rev-1_en.pdf"},
    {"id":"24036","name":"Overview of comments received on “Principles on assignment of defined daily dose for animals (DDDvet) and defined course dose for animals (DCDvet)” (EMA/710019/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-06-30T16:07:00Z","last_updated_date":"2015-06-30T16:07:00Z","reference_number":"EMA/326801/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-principles-assignment-defined-daily-dose-animals-dddvet-and-defined-course-dose-animals-dcdvet-ema7100192014_en.pdf"},
    {"id":"24141","name":"Overview of comments received on 'Reflection paper on a proposal to enhance early dialogue to facilitate accelerated assessment of priority medicines (PRIME)' - List of stakeholders","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2016-03-07T12:00:00Z","reference_number":"EMA/136736/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-proposal-enhance-early-dialogue-facilitate-accelerated-assessment-priority-medicines-prime-list-stakeholders_en.pdf"},
    {"id":"24455","name":"Overview of comments on Sitagliptin film-coated tablets 25, 50 and 100 mg product-specific bioequivalence guidance","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/CHMP/162917/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-sitagliptin-film-coated-tablets-25-50-and-100-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"24668","name":"Overview of comments received on 'Publication and access to clinical-trial data' (EMA/240810/2013) - from stakeholder 109 to 126","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2014-10-02T19:00:00Z","reference_number":"EMA/349245/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-publication-and-access-clinical-trial-data-ema2408102013-stakeholder-109-126_en.pdf"},
    {"id":"24968","name":"Overview of comments received on 'Publication and access to clinical-trial data' (EMA/240810/2013) - from stakeholder 89 to 108","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2014-10-02T19:00:00Z","reference_number":"EMA/344107/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-publication-and-access-clinical-trial-data-ema2408102013-stakeholder-89-108_en.pdf"},
    {"id":"24971","name":"Overview of comments received on 'Reflection paper providing an overview of the current regulatory testing requirements for veterinary medicinal products and opportunities for implementation of the 3Rs' (EMA/CHMP/CVMP/3R...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"EMA/CHMP/CVMP/3Rs/731924/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-providing-overview-current-regulatory-testing-requirements-veterinary-medicinal-products-and-opportunities-implementation-3rs-emachmpcvmp3r_en.pdf"},
    {"id":"25044","name":"Overview of comments received on the draft 'Questions and answers on cyclodextrins'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/157146/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-questions-and-answers-cyclodextrins_en.pdf"},
    {"id":"26019","name":"Overview of comments received on the draft 'Information in the package leaflet for fructose and sorbitol'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/581887/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-information-package-leaflet-fructose-and-sorbitol_en.pdf"},
    {"id":"26359","name":"Overview of comments received on 'Guideline on clinical investigation of new medicinal products for the treatment of acute coronary syndrome'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T12:00:00Z","last_updated_date":"2017-09-26T12:00:00Z","reference_number":"EMA/CHMP/33407/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-new-medicinal-products-treatment-acute-coronary-syndrome_en.pdf"},
    {"id":"26424","name":"Overview of comments received on Paliperidone palmitate depot suspension for injection 25 mg, 50 mg, 75 mg, 100 mg and 150 mg product-specific bioequivalence guidance (EMA/CHMP/474825/2016)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-03-03T01:00:00Z","last_updated_date":"2017-03-03T01:00:00Z","reference_number":"EMA/CHMP/810545/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-paliperidone-palmitate-depot-suspension-injection-25-mg-50-mg-75-mg-100-mg-and-150-mg-product-specific-bioequivalence-guidance-emachmp4748252016_en.pdf"},
    {"id":"26619","name":"Overview of comments received on 'Vismodegib hard capsule 150 mg product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-08-03T14:00:00Z","last_updated_date":"2018-08-03T14:00:00Z","reference_number":"EMA/CHMP/398811/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-vismodegib-hard-capsule-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"27033","name":"Overview of comments received on Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function (EMA/CHMP/ 83874/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-02-02T10:09:59Z","last_updated_date":"2016-02-02T10:09:59Z","reference_number":"EMA/CHMP/725881/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function-emachmp-838742014_en.pdf"},
    {"id":"27053","name":"Overview of comments received during the first public consultation on 'Guidance on the assessment of persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances in veterinary...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-11-19T12:50:00Z","last_updated_date":"2014-11-19T12:50:00Z","reference_number":"EMA/CVMP/ERA/102239/2013","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-during-first-public-consultation-guidance-assessment-persistent-bioaccumulative-and-toxic-pbt-or-very-persistent-and-very-bioaccumulative-vpvb-substances-veterinary_en.pdf"},
    {"id":"27274","name":"Overview of comments received on 'Updated advice on the use of colistin products in animals within the European Union: development of resistance and possible impact on human and animal health' (EMA/231573/2016)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-07-27T13:00:00Z","last_updated_date":"2016-07-27T13:00:00Z","reference_number":"EMA/CVMP/CHMP/390632/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-updated-advice-use-colistin-products-animals-within-european-union-development-resistance-and-possible-impact-human-and-animal-health-ema2315732016_en.pdf"},
    {"id":"27602","name":"Overview of comments received on 'CVMP reflection paper on methods found suitable within the European Union for demonstrating freedom from extraneous agents of the seeds used for the production of immunological veterinar...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T13:05:00Z","last_updated_date":"2016-12-19T13:05:00Z","reference_number":"EMA/CVMP/IWP/65876/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-cvmp-reflection-paper-methods-found-suitable-within-european-union-demonstrating-freedom-extraneous-agents-seeds-used-production-immunological-veterinar_en.pdf"},
    {"id":"28266","name":"Overview of comments received on 'Guideline on the evaluation of medicinal products for the treatment of chronic constipation (including opioid induced constipation) and for bowel cleansing'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-09-14T18:20:00Z","last_updated_date":"2015-09-14T18:20:00Z","reference_number":"EMA/CHMP/407380/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-evaluation-medicinal-products-treatment-chronic-constipation-including-opioid-induced-constipation-and-bowel-cleansing_en.pdf"},
    {"id":"28591","name":"Overview of comments on 'Asenapine sublingual tablets 5 and 10 mg product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/162825/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-asenapine-sublingual-tablets-5-and-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"28695","name":"Comments received on 'Policy 0070 on publication and access to clinical-trial data'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2014-10-02T19:00:00Z","reference_number":"EMA/342387/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/comments-received-policy-0070-publication-and-access-clinical-trial-data_en.pdf"},
    {"id":"28968","name":"Overview of comments received on 'Reflection paper on the replacement of cell lines used for the production of immunological veterinary medicinal products’\n\n(EMA/CVMP/IWP/37620/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-09-17T18:28:01Z","last_updated_date":"2015-09-17T18:28:01Z","reference_number":"EMA/CVMP/IWP/254498/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-replacement-cell-lines-used-production-immunological-veterinary-medicinal-products-emacvmpiwp376202014_en.pdf"},
    {"id":"29006","name":"Overview of comments received on ‘Guideline on the adventitious agent safety of urine-derived medicinal products’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-05-29T12:00:00Z","last_updated_date":"2015-05-29T12:00:00Z","reference_number":"EMA/CHMP/BWP/248233/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-adventitious-agent-safety-urine-derived-medicinal-products_en.pdf"},
    {"id":"29134","name":"Overview of comments on 'Guideline on influenza vaccines – submission and procedural requirements'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-02T16:10:00Z","last_updated_date":"2015-07-02T16:10:00Z","reference_number":"EMA/230639/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-guideline-influenza-vaccines-submission-and-procedural-requirements_en.pdf"},
    {"id":"29459","name":"Overview of comments received on ‘Draft risk minimisation strategy for high strength and fixed combination insulin products, addendum to the good practice guide on risk minimisation and prevention of medication errors’ (...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-11-27T11:00:00Z","last_updated_date":"2015-11-27T11:00:00Z","reference_number":"EMA/352689/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-risk-minimisation-strategy-high-strength-and-fixed-combination-insulin-products-addendum-good-practice-guide-risk-minimisation-and-prevention-medication-errors_en.pdf"},
    {"id":"29591","name":"Overview of comments received on 'Guideline on the clinical development of medicinal products for the treatment of HIV infection'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-07-12T18:10:00Z","last_updated_date":"2016-07-12T18:10:00Z","reference_number":"EMA/CHMP/EWP/672442/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-development-medicinal-products-treatment-hiv-infection_en.pdf"},
    {"id":"29992","name":"Overview of comments received on draft guideline on similar biological medicinal products","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-12-02T10:25:00Z","last_updated_date":"2014-12-02T10:25:00Z","reference_number":"EMA/748294/2013","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-similar-biological-medicinal-products_en.pdf"},
    {"id":"30050","name":"Overview of comments received on 'Guideline on core SmPC for human plasma derived and recombinant coagulation factor IX products'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-12-22T16:30:00Z","last_updated_date":"2014-12-22T16:30:00Z","reference_number":"EMA/CHMP/BPWP/697285/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-core-smpc-human-plasma-derived-and-recombinant-coagulation-factor-ix-products_en.pdf"},
    {"id":"30208","name":"Overview of comments received on 'Procedure for the review and revision of European Union herbal monographs and European Union list entries' - Revision 2","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-08-14T13:00:00Z","last_updated_date":"2018-08-14T13:00:00Z","reference_number":"EMA/HMPC/399627/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-procedure-review-and-revision-european-union-herbal-monographs-and-european-union-list-entries-revision-2_en.pdf"},
    {"id":"30218","name":"Overview of comments received on 'Reflection paper on the use of heat treatment to inactivate retrovirus RD114 in live immunological veterinary medicinal products’ (EMA/CVMP/IWP/37924/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-09-17T18:17:01Z","last_updated_date":"2015-09-17T18:17:01Z","reference_number":"EMA/CVMP/IWP/254504/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-use-heat-treatment-inactivate-retrovirus-rd114-live-immunological-veterinary-medicinal-products-emacvmpiwp379242014_en.pdf"},
    {"id":"30359","name":"Overview of comments received on 'Reflection paper on a proposal to enhance early dialogue to facilitate accelerated assessment of priority medicines (PRIME)'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2016-03-07T12:00:00Z","reference_number":"EMA/136751/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-proposal-enhance-early-dialogue-facilitate-accelerated-assessment-priority-medicines-prime_en.pdf"},
    {"id":"30433","name":"Overview of comments received on 'Draft guideline on the chemistry of active substances for veterinary medicinal products'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-01-19T15:20:00Z","last_updated_date":"2018-01-19T15:20:00Z","reference_number":"EMA/CVMP/QWP/502315/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-chemistry-active-substances-veterinary-medicinal-products_en.pdf"},
    {"id":"31321","name":"Overview of comments received on 'Guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials - Revision 1'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-11-28T12:23:00Z","last_updated_date":"2017-11-28T12:23:00Z","reference_number":"EMA/CHMP/QWP/546045/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-requirements-chemical-and-pharmaceutical-quality-documentation-concerning-investigational-medicinal-products-clinical-trials-revision-1_en.pdf"},
    {"id":"31455","name":"Overview of comments received on 'Reflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular and metabolic diseases’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-03-29T11:25:00Z","last_updated_date":"2016-03-29T11:25:00Z","reference_number":"EMA/754705/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-assessment-cardiovascular-risk-medicinal-products-treatment-cardiovascular-and-metabolic-diseases_en.pdf"},
    {"id":"31663","name":"Overview of comments received on 'Publication and access to clinical-trial data' (EMA/240810/2013) - from stakeholder 01 to 88","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2014-10-02T19:00:00Z","reference_number":"EMA/342115/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-publication-and-access-clinical-trial-data-ema2408102013-stakeholder-01-88_en.pdf"},
    {"id":"32024","name":"Overview of comments received on 'Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities’ (EMA/CHMP/ CVMP/ SWP/169430/2012...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T02:00:00Z","last_updated_date":"2015-10-06T02:00:00Z","reference_number":"EMA/CHMP/SWP/364535/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-setting-health-based-exposure-limits-use-risk-identification-manufacture-different-medicinal-products-shared-facilities-emachmp-cvmp-swp1694302012_en.pdf"},
    {"id":"32319","name":"Overview of comments received on 'Draft guideline on influenza vaccines: non-clinical and clinical module ' (EMA/CHMP/VWP/457259/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-10-21T13:28:00Z","last_updated_date":"2016-10-21T13:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-influenza-vaccines-non-clinical-and-clinical-module-emachmpvwp4572592014_en.pdf"},
    {"id":"32549","name":"Overview of comments on guideline on core core summary of product characteristics (SmPC) and package leaflet for (99Mo/99mTc) generator","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-03-06T16:30:00Z","last_updated_date":"2015-03-06T16:30:00Z","reference_number":"EMA/416439/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-guideline-core-core-summary-product-characteristics-smpc-and-package-leaflet-99mo99mtc-generator_en.pdf"},
    {"id":"32613","name":"Overview of comments received on 'Draft guideline on the chemistry of active substances’ (EMA/CHMP/QWP/96664/2015) - First version","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-11-21T16:10:00Z","last_updated_date":"2016-11-21T16:10:00Z","reference_number":"EMA/454577/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-chemistry-active-substances-ema-chmp-qwp-96664-2015-first-version_en.pdf"},
    {"id":"32888","name":"Overview of comments received on 'Draft good practice guide on recording, coding, reporting and assessment of medication errors' (EMA/762563/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-11-27T11:00:00Z","last_updated_date":"2015-11-27T11:00:00Z","reference_number":"EMA/190895/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-good-practice-guide-recording-coding-reporting-and-assessment-medication-errors-ema7625632014_en.pdf"},
    {"id":"33134","name":"Overview of comments received by EMA on 'Draft ICH guideline E17 on general principles for planning and design of multi-regional clinical trials - Step 2b' - First version","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-02-13T01:00:00Z","last_updated_date":"2017-02-13T01:00:00Z","reference_number":"EMA/605292/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ema-draft-ich-guideline-e17-general-principles-planning-and-design-multi-regional-clinical-trials-step-2b-first-version_en.pdf"},
    {"id":"33165","name":"Overview of comments received on 'draft guideline on the development of new medicinal products for the treatment of Crohn’s Disease' (EMA/CPMP/EWP/2284/99 Rev. 2)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-07-23T11:44:58Z","last_updated_date":"2018-07-23T11:44:58Z","reference_number":"EMA/CHMP/261409/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-development-new-medicinal-products-treatment-crohns-disease-emacpmpewp228499-rev-2_en.pdf"},
    {"id":"33261","name":"Overview of comments received on 'Reflection paper on viral safety of plasma-derived medicinal products with respect to Hepatitis E virus’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-06-27T12:10:00Z","last_updated_date":"2016-06-27T12:10:00Z","reference_number":"EMA/CHMP/BWP/744742/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-viral-safety-plasma-derived-medicinal-products-respect-hepatitis-e-virus_en.pdf"},
    {"id":"33710","name":"Publication and access to clinical-trial data - Comments received from public consultation (July - September 2013)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2014-10-02T19:00:00Z","reference_number":"EMA/596658/2013","document_url":"https://www.ema.europa.eu/en/documents/comments/publication-and-access-clinical-trial-data-comments-received-public-consultation-july-september-2013_en.pdf"},
    {"id":"33829","name":"Questions and answers - Overview of comments received on ‘Draft questions and answers - ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological entities)'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-03-23T12:50:00Z","last_updated_date":"2017-03-23T12:50:00Z","reference_number":"EMA/71927/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/questions-and-answers-overview-comments-received-draft-questions-and-answers-ich-guideline-q11-development-and-manufacture-drug-substances-chemical-entities-and-biotechnological-biological-entities_en.pdf"},
    {"id":"34014","name":"Overview of comments received on 'Draft guideline on quality of transdermal patches'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2014-12-16T18:40:00Z","last_updated_date":"2014-12-16T18:40:00Z","reference_number":"EMA/CHMP/QWP/608923/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-quality-transdermal-patches_en.pdf"},
    {"id":"34452","name":"Overview of comments received on 'Draft questions and answers on sodium'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-10T02:00:00Z","last_updated_date":"2017-10-10T02:00:00Z","reference_number":"EMA/CHMP/623211/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-questions-and-answers-sodium_en.pdf"},
    {"id":"35050","name":"Overview of comments received on 'Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-09-27T13:10:00Z","last_updated_date":"2017-09-27T13:10:00Z","reference_number":"EMA/CHMP/853503/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products_en.pdf"},
    {"id":"35378","name":"Overview of comments received on 'Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-04-07T19:00:00Z","last_updated_date":"2015-04-07T19:00:00Z","reference_number":"EMA/674663/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-human-insulin-and-insulin-analogues_en.pdf"},
    {"id":"35440","name":"Overview of comments received on ICH S5 (R3) guideline on reproductive toxicology: detection of toxicity to reproduction for human pharmaceuticals (EMA/CHMP/ICH/544278/1998) - Revision 3","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-04-26T12:45:00Z","last_updated_date":"2018-04-26T12:45:00Z","reference_number":"EMA/181369/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-s5-r3-guideline-reproductive-toxicology-detection-toxicity-reproduction-human-pharmaceuticals-emachmpich5442781998-revision-3_en.pdf"},
    {"id":"35783","name":"Overview of comments received on 'Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T16:30:00Z","last_updated_date":"2018-01-24T16:30:00Z","reference_number":"EMA/CHMP/CVMP/3Rs/83712/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guidance-individual-laboratories-transfer-quality-control-methods-validated-collaborative-trials-view-implementing-3rs_en.pdf"},
    {"id":"35972","name":"Overview of comments received on 'Guideline on the clinical investigation of hepatitis B immunoglobulins'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T10:35:00Z","last_updated_date":"2015-07-24T10:35:00Z","reference_number":"EMA/CHMP/BPWP/356886/2013","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-hepatitis-b-immunoglobulins_en.pdf"},
    {"id":"36133","name":"Overview of comments received on 'Draft guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances - Revision 1 (first version)’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-03-04T16:00:00Z","last_updated_date":"2015-03-04T16:00:00Z","reference_number":"EMA/CVMP/EWP/737951/2013 ","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances-revision-1-first-version_en.pdf"},
    {"id":"36385","name":"Overview of comments on 'lenalidomide hard gelatine capsules 2.5, 5, 7.5, 10, 15 and 25mg product-specific bioequivalence guidance’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/CHMP/206166/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-lenalidomide-hard-gelatine-capsules-25-5-75-10-15-and-25mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"36411","name":"Overview of comments received on the draft 'Questions and answers on benzyl alcohol’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/349510/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-questions-and-answers-benzyl-alcohol_en.pdf"},
    {"id":"36496","name":"Overview of comments on 'Vortioxetine hydrobromide immediate release tablets 5 mg, 10 mg, 15 mg, and 20 mg; vortioxetine lactate oral drops solution 20 mg/ml product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/CHMP/260596/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-vortioxetine-hydrobromide-immediate-release-tablets-5-mg-10-mg-15-mg-and-20-mg-vortioxetine-lactate-oral-drops-solution-20-mgml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"36568","name":"Overview of comments received on the 'Guideline on the use of phthalates as excipients in human medicinal products' (EMA/CHMP/SWP/362974/2012)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T02:00:00Z","last_updated_date":"2015-10-06T02:00:00Z","reference_number":"EMA/CHMP/SWP/684886/2013","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-use-phthalates-excipients-human-medicinal-products-emachmpswp3629742012_en.pdf"},
    {"id":"36591","name":"Overview of comments received on 'Questions and answers on implementation of risk based prevention of cross contamination in production' and ‘Guideline on setting health based exposure limits for use in risk identificati...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-08-02T16:00:00Z","last_updated_date":"2018-08-02T16:00:00Z","reference_number":"EMA/411141/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-questions-and-answers-implementation-risk-based-prevention-cross-contamination-production-and-guideline-setting-health-based-exposure-limits-use-risk-identificati_en.pdf"},
    {"id":"36921","name":"Overview of comments received on 'Guideline on clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T10:35:00Z","last_updated_date":"2015-07-24T10:35:00Z","reference_number":"EMA/CHMP/BPWP/356919/2013","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-human-normal-immunoglobulin-subcutaneous-andor-intramuscular-administration_en.pdf"},
    {"id":"37538","name":"Overview of comments received on 'Guideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-11-20T11:50:00Z","last_updated_date":"2015-11-20T11:50:00Z","reference_number":"EMA/CHMP/610677/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-key-aspects-use-pharmacogenomic-methodologies-pharmacovigilance-evaluation-medicinal-products_en.pdf"},
    {"id":"37580","name":"Overview of comments received on 'Guideline on core summary of product characteristics (SmPC) for human fibrinogen products’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T10:35:00Z","last_updated_date":"2015-07-24T10:35:00Z","reference_number":"EMA/CHMP/BPWP/336355/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-core-summary-product-characteristics-smpc-human-fibrinogen-products_en.pdf"},
    {"id":"37798","name":"Overview of comments on EMA/641479/2014 Draft proposal for an addendum, on transparency, to the 'Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-12-03T13:30:00Z","last_updated_date":"2015-12-03T13:30:00Z","reference_number":"EMA/739149/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-ema6414792014-draft-proposal-addendum-transparency-functional-specifications-eu-portal-and-eu-database-be-audited-ema421762014_en.pdf"},
    {"id":"38015","name":"Overview of comments received on Pazopanib film-coated tablet 200 mg and 400 mg product-specific bioequivalence guidance","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T17:39:00Z","last_updated_date":"2017-01-03T17:39:00Z","reference_number":"EMA/CHMP/693923/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-pazopanib-film-coated-tablet-200-mg-and-400-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"38033","name":"Overview of comments received on 'Fingolimod capsules 0.5 mg product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T16:58:00Z","last_updated_date":"2017-01-03T16:58:00Z","reference_number":"EMA/CHMP/805860/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-fingolimod-capsules-05-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"38037","name":"Overview of comments received on the second draft Public statement on the use of herbal medicinal products containing toxic unsaturated pyrrolizidine alkaloids (PAs)","type":"comments","status":"unknown","consultation_date":"2014-12-22 - 2015-03-31","first_published_date":"2014-12-22T12:30:00Z","last_updated_date":"2014-12-22T12:30:00Z","reference_number":"EMA/HMPC/577756/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-second-draft-public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas_en.pdf"},
    {"id":"38047","name":"Overview of comments received on 'Draft functional specifications for the EU portal and EU database to be audited'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-12-03T13:30:00Z","last_updated_date":"2015-12-03T13:30:00Z","reference_number":"EMA/659146/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-functional-specifications-eu-portal-and-eu-database-be-audited_en.pdf"},
    {"id":"38266","name":"Overview of comments received on 'Prasugrel film-coated tablets 5 and 10 mg product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-04-07T02:00:00Z","last_updated_date":"2016-04-07T02:00:00Z","reference_number":"EMA/CHMP/162888/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-prasugrel-film-coated-tablets-5-and-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"38497","name":"Overview of comments received on 'draft sunitinib product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T14:15:00Z","last_updated_date":"2015-07-07T14:15:00Z","reference_number":"EMA/CHMP/116836/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-sunitinib-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"38785","name":"Overview of comments received on the draft 'Questions and answers on boric acid’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/735217/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-questions-and-answers-boric-acid_en.pdf"},
    {"id":"38849","name":"Overview of comments received on 'Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medici...","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2016-03-07T12:00:00Z","reference_number":"EMA/647097/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-scientific-application-and-practical-arrangements-necessary-implement-commission-regulation-ec-no-5072006-conditional-marketing-authorisation-medici_en.pdf"},
    {"id":"38884","name":"Overview of comments received on ‘Guideline on the processing of renewals in the centralised procedure","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-08-04T11:00:00Z","last_updated_date":"2016-08-04T11:00:00Z","reference_number":"EMA/723788/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-processing-renewals-centralised-procedure_en.pdf"},
    {"id":"39006","name":"Overview of comments received on '\tDraft guideline on clinical investigation of recombinant and human plasma-derived factor IX products - Revision 1'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-06-01T17:00:00Z","last_updated_date":"2015-06-01T17:00:00Z","reference_number":"EMA/CHMP/BPWP/111667/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-clinical-investigation-recombinant-human-plasma-derived-factor-ix-products-revision-1_en.pdf"},
    {"id":"39145","name":"Overview of comments received on 'Guideline on core SmPC and package leaflet for sodium fluoride (18F)' (EMA/CHMP/465616/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-20T16:45:00Z","last_updated_date":"2015-07-20T16:45:00Z","reference_number":"EMA/219347/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-core-smpc-and-package-leaflet-sodium-fluoride-18f-emachmp4656162014_en.pdf"},
    {"id":"39558","name":"Overview of comments received on 'Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-08-03T13:00:00Z","last_updated_date":"2018-08-03T13:00:00Z","reference_number":"EMA/CHMP/395071/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-cholic-acid-capsules-50-mg-and-250-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"39647","name":"Submission of comments on 'Guideline on core SmPC and Package Leaflet for sodium iodide (131I) therapy capsule' (EMA/CHMP/649301/2016)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-03-22T10:35:00Z","last_updated_date":"2018-03-22T10:35:00Z","reference_number":"EMA/630247/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/submission-comments-guideline-core-smpc-and-package-leaflet-sodium-iodide-131i-therapy-capsule-emachmp6493012016_en.pdf"},
    {"id":"39650","name":"Overview of external comments received on the 'Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus, and lupus nephritis'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T11:00:00Z","last_updated_date":"2015-03-27T11:00:00Z","reference_number":"EMA/37217/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-external-comments-received-guideline-clinical-investigation-medicinal-products-treatment-systemic-lupus-erythematosus-and-lupus-nephritis_en.pdf"},
    {"id":"39653","name":"Overview of comments received on the draft 'Questions and answers on sodium laurilsulfate’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/733748/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-questions-and-answers-sodium-laurilsulfate_en.pdf"},
    {"id":"40167","name":"Overview of comments received on draft ICH E9(R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials (EMA/CHMP/ICH/436221/2017)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-04-26T12:45:00Z","last_updated_date":"2018-04-26T12:45:00Z","reference_number":"EMA/744060/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-ich-e9r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-emachmpich4362212017_en.pdf"},
    {"id":"40183","name":"Overview of comments received on Guideline on clinical evaluation of medicinal products used in weight control - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T12:50:00Z","last_updated_date":"2016-07-08T12:50:00Z","reference_number":"EMA/414592/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-evaluation-medicinal-products-used-weight-control-revision-1_en.pdf"},
    {"id":"40403","name":"Overview of comments received on Draft guideline on the conduct of efficacy studies for intramammary products for use in cattle - Revision 2 (second version)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-01-26T17:20:00Z","last_updated_date":"2017-01-26T17:20:00Z","reference_number":"EMA/CVMP/EWP/444475/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-conduct-efficacy-studies-intramammary-products-use-cattle-revision-2-second-version_en.pdf"},
    {"id":"40495","name":"Overview of comments received on 'Draft revision of EudraVigilance access policy for medicines for human use'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-01-13T14:35:00Z","last_updated_date":"2016-01-13T14:35:00Z","reference_number":"EMA/649218/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-revision-eudravigilance-access-policy-medicines-human-use_en.pdf"},
    {"id":"40529","name":"Overview of comments received on the 'Guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-11-27T15:55:00Z","last_updated_date":"2015-11-27T15:55:00Z","reference_number":"EMA/CHMP/738839/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-juvenile-idiopathic-arthritis_en.pdf"},
    {"id":"40663","name":"Overview of comments received on 'Draft memantine product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-04-10T15:28:00Z","last_updated_date":"2015-04-10T15:28:00Z","reference_number":"EMA/CHMP/116526/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-memantine-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"40882","name":"Overview of comments received on 'Guideline on adjustment for baseline covariates'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T17:00:00Z","last_updated_date":"2015-03-27T17:00:00Z","reference_number":"EMA/40143/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-adjustment-baseline-covariates_en.pdf"},
    {"id":"41029","name":"Overview of comments received on ‘Everolimus tablets 0.25 mg, 0.5 mg, 0.75 mg and 1 mg; 2.5 mg, 5 mg and 10 mg, dispersible tablets 0.1 mg and 0.25 mg; 2 mg, 3 mg and 5 mg product-specific bioequivalence guidance’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T16:42:00Z","last_updated_date":"2017-01-03T16:42:00Z","reference_number":"EMA/CHMP/620299/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-everolimus-tablets-025-mg-05-mg-075-mg-and-1-mg-25-mg-5-mg-and-10-mg-dispersible-tablets-01-mg-and-025-mg-2-mg-3-mg-and-5-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"41258","name":"Overview of comments received on ‘Guideline on requirements for the production and control of IVMPs’ (EMA/CVMP/IWP/206555/2010-Rev.1) including Annex 2 on the approach to demonstrate freedom from extraneous agents","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T13:00:00Z","last_updated_date":"2016-12-19T13:00:00Z","reference_number":"EMA/CVMP/IWP/74071/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-requirements-production-and-control-ivmps-emacvmpiwp2065552010-rev1-including-annex-2-approach-demonstrate-freedom-extraneous-agents_en.pdf"},
    {"id":"41595","name":"Overview of comments received on 'Guideline on the environmental risk assessment of medicinal products for human use’ - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-06-02T11:20:00Z","last_updated_date":"2016-06-02T11:20:00Z","reference_number":"EMA/CHMP/SWP/96156/2016","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-environmental-risk-assessment-medicinal-products-human-use-revision-1_en.pdf"},
    {"id":"41731","name":"Overview of comments received on 'draft voriconazole product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T14:15:00Z","last_updated_date":"2015-07-07T14:15:00Z","reference_number":"EMA/CHMP/116571/2014","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-voriconazole-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"41777","name":"Overview of comments received on draft Guideline on clinical investigation of medicinal products for the treatment of chronic heart failure (CPMP/EWP/235/95, Rev.2)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T12:25:00Z","last_updated_date":"2017-09-26T12:25:00Z","reference_number":"EMA/547655/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-chronic-heart-failure-cpmpewp23595-rev2_en.pdf"},
    {"id":"41796","name":"Overview of comments received on the list of paediatric needs – Endocrinology","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-08-19T18:10:00Z","last_updated_date":"2015-08-19T18:10:00Z","reference_number":"EMA/471041/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-list-paediatric-needs-endocrinology_en.pdf"},
    {"id":"41936","name":"Overview of comments received on ‘Draft good practice guide on risk minimisation and prevention of medication errors’ (EMA/606103/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-11-27T11:00:00Z","last_updated_date":"2015-11-27T11:00:00Z","reference_number":"EMA/352692/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-good-practice-guide-risk-minimisation-and-prevention-medication-errors-ema6061032014_en.pdf"},
    {"id":"41979","name":"Overview of comments received on VICH guideline on electronic exchange of documents electronic file format (GL53)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2015-05-29T12:30:00Z","last_updated_date":"2015-05-29T12:30:00Z","reference_number":"VICH GL-53","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-vich-guideline-electronic-exchange-documents-electronic-file-format-gl53_en.pdf"},
    {"id":"42011","name":"Overview of comments received on Draft Revision of the Guideline on epidemiological data on blood transmissible infections (EMA/CHMP/BWP/548524/2008)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2016-03-01T11:13:01Z","last_updated_date":"2016-03-01T11:13:01Z","reference_number":"EMA/651460/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-revision-guideline-epidemiological-data-blood-transmissible-infections-emachmpbwp5485242008_en.pdf"},
    {"id":"42029","name":"Overview of comments received on 'Reflection paper on use of aminoglycosides in animals in the European Union: development of resistance and impact on human and animal health' (EMA/CVMP/AWP/721118/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"EMA/CVMP/AWP/726389/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-use-aminoglycosides-animals-european-union-development-resistance-and-impact-human-and-animal-health-emacvmpawp7211182014_en.pdf"},
    {"id":"42053","name":"Overview of comments received on 'Guideline on approach towards harmonisation of withdrawal periods (EMA/CVMP/SWP/735325/2012)' - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-09-21T18:00:00Z","last_updated_date":"2018-09-21T18:00:00Z","reference_number":"EMA/CVMP/SWP/81095/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-approach-towards-harmonisation-withdrawal-periods-emacvmpswp7353252012-revision-1_en.pdf"},
    {"id":"42186","name":"Review of comments submitted on the draft Qualification opinion - The European Cystic Fibrosis Society Patient Registry (ECFSPR)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-10-03T13:10:00Z","last_updated_date":"2018-10-03T13:10:00Z","reference_number":"EMA/482816/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/review-comments-submitted-draft-qualification-opinion-european-cystic-fibrosis-society-patient-registry-ecfspr_en.pdf"},
    {"id":"42236","name":"Overview of comments received on ICH guideline Q3D (R1) on elemental impurities (EMA/CHMP/ICH/353369/2013) - First version","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-10-09T11:27:00Z","last_updated_date":"2018-10-09T11:27:00Z","reference_number":"EMA/619895/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-q3d-r1-elemental-impurities-emachmpich3533692013-first-version_en.pdf"},
    {"id":"42569","name":"Overview of comments received on 'Draft guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease' (EMA/CHMP/257022/2017) - First version","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-11-07T15:17:00Z","last_updated_date":"2018-11-07T15:17:00Z","reference_number":"EMA/746314/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-clinical-evaluation-medicinal-products-indicated-prophylaxis-or-treatment-respiratory-syncytial-virus-rsv-disease-emachmp2570222017-first-version_en.pdf"},
    {"id":"42575","name":"Overview of comments received on 'Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract' (EMA/CPMP/EWP/239/95 Rev.1) - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-11-07T16:41:00Z","last_updated_date":"2018-11-07T16:41:00Z","reference_number":"EMA/CHMP/648051/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-equivalence-studies-demonstration-therapeutic-equivalence-locally-applied-locally-acting-products-gastrointestinal-tract-emacpmpewp23995-rev1-revision-1_en.pdf"},
    {"id":"42578","name":"Overview of comments received on 'Guideline on quality aspects included in the product information for vaccines for human use' (EMA/CHMP/BWP/133540/2017) - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-11-07T17:43:00Z","last_updated_date":"2018-11-07T17:43:00Z","reference_number":"EMA/CHMP/BWP/668918/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-quality-aspects-included-product-information-vaccines-human-use-emachmpbwp1335402017-revision-1_en.pdf"}    {"id":"42581","name":"Overview of comments received on 'Questions and answers on the haemagglutination inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations' (EMA/CHMP/BWP/426390/2017) - First version","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T11:27:00Z","last_updated_date":"2018-11-08T11:27:00Z","reference_number":"EMA/CHMP/BWP/652969/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-questions-and-answers-haemagglutination-inhibition-hi-test-qualification-influenza-vaccine-inactivated-seed-preparations-emachmpbwp4263902017-first-version_en.pdf"},
    {"id":"42586","name":"Overview of comments received on ‘Questions and Answers on bovine spongiform encephalopathies (BSE) and vaccines’ (EMA/CHMP/BWP/192228/2017) - Revision 1","type":"comments","status":"Adopted","consultation_date":"","first_published_date":"2018-11-08T12:00:00Z","last_updated_date":"2018-11-08T12:00:00Z","reference_number":"EMA/CHMP/BWP/637549/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-questions-and-answers-bovine-spongiform-encephalopathies-bse-and-vaccines-emachmpbwp1922282017-revision-1_en.pdf"},
    {"id":"42941","name":"Overview of comments received on the draft policy/0043: European Medicines Agency policy on access to documents","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-12-06T11:18:00Z","last_updated_date":"2018-12-06T11:18:00Z","reference_number":"EMA/768660/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-policy0043-european-medicines-agency-policy-access-documents_en.pdf"},
    {"id":"42943","name":"Overview of comments received on the output of the European Medicines Agency policy on access to documents related to medicinal products for human and veterinary use","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-12-06T11:34:00Z","last_updated_date":"2018-12-06T11:34:00Z","reference_number":"EMA/770027/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-output-european-medicines-agency-policy-access-documents-related-medicinal-products-human-and-veterinary-use_en.pdf"},
    {"id":"42944","name":"Overview of comments on the output of the European Medicines Agency policy on access to documents non-related to medicinal products for human and veterinary use","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-12-06T11:36:00Z","last_updated_date":"2018-12-06T11:36:00Z","reference_number":"EMA/770394/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-output-european-medicines-agency-policy-access-documents-non-related-medicinal-products-human-and-veterinary-use_en.pdf"},
    {"id":"43052","name":"Overview of comments received on 'Aliskiren film-coated tablet 150 mg and 300 mg product-specific bioequivalence guidance' (EMA/CHMP/291450/2018)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-12-13T18:05:00Z","last_updated_date":"2018-12-13T18:05:00Z","reference_number":"EMA/CHMP/681421/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-aliskiren-film-coated-tablet-150-mg-and-300-mg-product-specific-bioequivalence-guidance-emachmp2914502018_en.pdf"},
    {"id":"43054","name":"Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-12-13T19:19:00Z","last_updated_date":"2018-12-13T19:19:00Z","reference_number":"EMA/CHMP/681372/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-pegylated-liposomal-doxorubicin-hydrochloride-concentrate-solution-2-mgml-product-specific-bioequivalence-guidance-emachmp8007752017_en.pdf"},
    {"id":"43100","name":"Overview of comments on 'Draft guideline on clinical development of fixed combination medicinal products - Revision 2 (EMA/CHMP/281825/2015)'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-12-17T12:46:00Z","last_updated_date":"2018-12-17T12:46:00Z","reference_number":"EMA/757184/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-draft-guideline-clinical-development-fixed-combination-medicinal-products-revision-2-emachmp2818252015_en.pdf"},
    {"id":"43169","name":"Overview of comments received on 'Guideline on the conduct of bioequivalence studies for veterinary medicinal products' (EMA/CVMP/016/00-Rev.3) - Revision 3","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T16:30:00Z","last_updated_date":"2018-12-19T16:30:00Z","reference_number":"EMA/CVMP/755602/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-emacvmp01600-rev3-revision-3_en.pdf"},
    {"id":"43263","name":"Overview of comments received on guideline on assessment and control of DNA reactive (mutagenic) impurities in veterinary medicinal products (EMA/CVMP/SWP/377245/2016)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-01-09T16:00:00Z","last_updated_date":"2019-01-09T16:00:00Z","reference_number":"EMA/CVMP/SWP/610519/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-assessment-and-control-dna-reactive-mutagenic-impurities-veterinary-medicinal-products-emacvmpswp3772452016_en.pdf"},
    {"id":"43265","name":"Overview of comments received on 'Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), Bluetongue (BT) and Foot-and-Mouth disease (FMD)' - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-01-09T17:00:00Z","last_updated_date":"2019-01-09T17:00:00Z","reference_number":"EMA/CVMP/IWP/235788/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-data-requirements-multi-strain-dossiers-inactivated-vaccines-against-avian-influenza-ai-bluetongue-bt-and-foot-and-mouth-disease-fmd-revision-1_en.pdf"},
    {"id":"43411","name":"Overview of comments received on ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T16:44:00Z","last_updated_date":"2019-01-18T16:44:00Z","reference_number":"EMA/883815/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management_en.pdf"},
    {"id":"43674","name":"Overview of comments received on 'Octreotide acetate depot powder and solvent for suspension for injection 10 mg, 20 mg and 30 mg product-specific bioequivalence guidance' (EMA/CHMP/291571/2018)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-02-08T10:11:00Z","last_updated_date":"2019-02-08T10:11:00Z","reference_number":"EMA/CHMP/682121/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-octreotide-acetate-depot-powder-and-solvent-suspension-injection-10-mg-20-mg-and-30-mg-product-specific-bioequivalence-guidance-emachmp2915712018_en.pdf"},
    {"id":"43873","name":"Overview of comments received on ICH guideline M9 on biopharmaceutics classification system based biowavers (EMA/CHMP/ICH/493213/2018)","type":"comments","status":"Adopted","consultation_date":"","first_published_date":"2019-02-22T11:45:00Z","last_updated_date":"2019-02-22T11:45:00Z","reference_number":"EMA/118938/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-m9-biopharmaceutics-classification-system-based-biowavers-emachmpich4932132018_en.pdf"},
    {"id":"43944","name":"Overview of comments received on 'Draft qualification opinion on Cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry' (EMA/CHMP/SAWP/423488/2018)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-02-28T18:01:00Z","last_updated_date":"2019-02-28T18:01:00Z","reference_number":"EMA/618737/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-qualification-opinion-cellular-therapy-module-european-society-blood-marrow-transplantation-ebmt-registry-emachmpsawp4234882018_en.pdf"},
    {"id":"44000","name":"Overview of comments received on the ‘Draft guideline on the sterilisation of the medicinal product, active substance, excipients and primary container'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-03-08T15:37:00Z","last_updated_date":"2020-01-15T11:36:00Z","reference_number":"EMA/CHMP/CVMP/QWP/366428/2018 (v.3.11)","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-sterilisation-medicinal-product-active-substance-excipients-and-primary-container_en.pdf"},
    {"id":"44313","name":"Overview of comments received on draft ICH guideline S11 on nonclinical safety testing in support of development of paediatric medicines (EMA/CHMP/ICH/616110/2018)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-04-23T09:47:00Z","last_updated_date":"2019-04-23T09:47:00Z","reference_number":"EMA/213997/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-ich-guideline-s11-nonclinical-safety-testing-support-development-paediatric-medicines-emachmpich6161102018_en.pdf"},
    {"id":"44612","name":"Overview of comments on 'Stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device' (EMA/532515/2018)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T11:15:00Z","last_updated_date":"2019-05-29T11:15:00Z","reference_number":"EMA/178057/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-stride-velocity-95th-centile-secondary-endpoint-duchenne-muscular-dystrophy-measured-valid-and-suitable-wearable-device-ema5325152018_en.pdf"},
    {"id":"44967","name":"Overview of comments received during the public consultation on 'Concept paper on the need for revision of the guideline on the investigation of medicinal products in the term and preterm neonate' (EMA/PDCO/362462/2016) - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-07-01T15:30:00Z","last_updated_date":"2019-07-01T15:30:00Z","reference_number":"EMA/139606/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-during-public-consultation-concept-paper-need-revision-guideline-investigation-medicinal-products-term-and-preterm-neonate-emapdco3624622016-revision-1_en.pdf"},
    {"id":"45473","name":"Overview of comments on the draft qualification opinion on eSource Direct Data Capture (DDC)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-09-19T11:02:00Z","last_updated_date":"2019-09-19T11:02:00Z","reference_number":"EMA/179292/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-draft-qualification-opinion-esource-direct-data-capture-ddc_en.pdf"},
    {"id":"45708","name":"Overview of comments received on 'Apixaban film-coated tablet 2.5 and 5 mg product-specific bioequivalence guidance' (EMA/CHMP/291499/2018)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-10-15T14:26:00Z","last_updated_date":"2019-10-15T14:26:00Z","reference_number":"EMA/CHMP/681387/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-apixaban-film-coated-tablet-25-and-5-mg-product-specific-bioequivalence-guidance-emachmp2914992018_en.pdf"},
    {"id":"45712","name":"Overview of comments received on 'Ezetimibe tablet 10 mg product-specific bioequivalence guidance' (EMA/CHMP/802491/2018)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-10-15T14:40:00Z","last_updated_date":"2019-10-15T14:40:00Z","reference_number":"EMA/CHMP/401588/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ezetimibe-tablet-10-mg-product-specific-bioequivalence-guidance-emachmp8024912018_en.pdf"},
    {"id":"45835","name":"Overview of comments received on draft guideline on the pharmacokinetic and clinical evaluation of modified-release dosage forms","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-10-29T14:02:00Z","last_updated_date":"2019-10-29T14:02:00Z","reference_number":"EMA/CHMP/267430/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-pharmacokinetic-and-clinical-evaluation-modified-release-dosage-forms_en.pdf"},
    {"id":"45857","name":"Overview of comments received on 'Draft ICH guideline M10 on bioanalytical method validation - Step 2b'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-10-30T16:10:00Z","last_updated_date":"2019-10-30T16:10:00Z","reference_number":"EMA/485652/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-ich-guideline-m10-bioanalytical-method-validation-step-2b_en.pdf"},
    {"id":"45858","name":"Overview of comments received on 'Draft ICH guideline E19 on optimisation of safety data collection - Step 2b'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-10-30T16:17:00Z","last_updated_date":"2019-10-30T16:17:00Z","reference_number":"EMA/483343/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-ich-guideline-e19-optimisation-safety-data-collection-step-2b_en.pdf"},
    {"id":"46342","name":"Overview of comments received on 'Alectinib hard capsule 150 mg product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2019-12-19T14:05:00Z","last_updated_date":"2019-12-19T14:05:00Z","reference_number":"EMA/CHMP/582874/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-alectinib-hard-capsule-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"46588","name":"Overview of comments - 'Categorisation of antibiotics in the European Union - Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-01-28T13:00:00Z","last_updated_date":"2020-01-28T13:00:00Z","reference_number":"EMA/CVMP/CHMP/238375/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific-advice-impact-public-health-and-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"46743","name":"Overview of comments received on the draft revised Public statement on the use of herbal medicinal products containing estragole (EMA/HMPC/137212/2005 Rev 1)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-02-14T12:20:00Z","last_updated_date":"2020-02-14T12:20:00Z","reference_number":"EMA/HMPC/278706/2015","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-revised-public-statement-use-herbal-medicinal-products-containing-estragole-emahmpc1372122005-rev-1_en.pdf"},
    {"id":"46774","name":"Overview of comments received on Reflection paper on risk management requirements for elemental impurities in veterinary medicinal products (EMA/CVMP/QWP/153641/2018)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-02-17T17:39:00Z","last_updated_date":"2020-02-17T17:39:00Z","reference_number":"EMA/CVMP/QWP/434956/2019 ","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-risk-management-requirements-elemental-impurities-veterinary-medicinal-products-emacvmpqwp1536412018_en.pdf"},
    {"id":"47249","name":"Analysis and summaries of public consultation results: EMA Regulatory Science to 2025 - Strategic reflection","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-03-31T17:00:00Z","last_updated_date":"2020-04-02T15:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/analysis-and-summaries-public-consultation-results-ema-regulatory-science-2025-strategic-reflection_en.pdf"},
    {"id":"47358","name":"Overview of comments received on 'ICH guideline E8 (R1) on general considerations for clinical studies'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-04-07T11:04:00Z","last_updated_date":"2020-04-07T11:04:00Z","reference_number":"EMA/542003/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-e8-r1-general-considerations-clinical-studies_en.pdf"},
    {"id":"47400","name":"Overview of comments on the draft qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-04-14T15:32:00Z","last_updated_date":"2020-04-14T15:32:00Z","reference_number":"EMA/365402/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-draft-qualification-opinion-clinically-interpretable-treatment-effect-measures-based-recurrent-event-endpoints-allow-efficient-statistical-analyses_en.pdf"},
    {"id":"47406","name":"Overview of comments received on 'Draft procedure on management of proposals submitted by Interested Parties for European Union List Entries or European Union herbal monographs - Revision 2'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-04-15T11:10:00Z","last_updated_date":"2020-04-15T11:10:00Z","reference_number":"EMA/HMPC/453279/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-procedure-management-proposals-submitted-interested-parties-european-union-list-entries-or-european-union-herbal-monographs-revision-2_en.pdf"},
    {"id":"48081","name":"Overview of comments received on recommendations in report on lessons learnt from presence of N-nitrosamine impurities in sartan medicines","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"EMA/326173/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-recommendations-report-lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines_en.pdf"},
    {"id":"48172","name":"Overview of comments received on 'Points to consider on implications of Coronavirus disease 5 (COVID-19) on methodological aspects of ongoing clinical trials' (EMA/158330/2020)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-06-29T13:57:00Z","last_updated_date":"2020-06-29T13:57:00Z","reference_number":"EMA/204136/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-points-consider-implications-coronavirus-disease-5-covid-19-methodological-aspects-ongoing-clinical-trials-ema1583302020_en.pdf"},
    {"id":"48195","name":"Overview of comments received on 'Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation' (EMA/CHMP/458101/2016)","type":"comments","status":"Adopted","consultation_date":"","first_published_date":"2020-07-01T12:16:00Z","last_updated_date":"2020-07-01T12:16:00Z","reference_number":"EMA/CHMP/59169/2017","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-qualification-and-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-and-simulation-emachmp4581012016_en.pdf"},
    {"id":"48336","name":"Overview of comments received on the draft 'Guideline on the quality of water for pharmaceutical use' (EMA/CHMP/CVMP/QWP/496873/2018)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-07-20T17:19:00Z","last_updated_date":"2020-07-20T17:19:00Z","reference_number":"EMA/CHMP/CVMP/QWP/230700/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-quality-water-pharmaceutical-use-emachmpcvmpqwp4968732018_en.pdf"},
    {"id":"49040","name":"Overview of comments received on  ICH guideline M7 on  assessment and control of DNA reactive (mutagenic)  impurities in pharmaceuticals to limit potential  carcinogenic risk  - questions & answers  (EMA/CHMP/ICH/321999/2020)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-10-16T11:59:00Z","last_updated_date":"2020-10-16T11:59:00Z","reference_number":"EMA/538158/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-m7-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-questions-answers-emachmpich3219992020_en.pdf"},
    {"id":"49313","name":"Overview of comments received on 'Abiraterone tablets 250 mg and 500 mg product-specific bioequivalence guidance' - Revision 1","type":"comments","status":"Adopted","consultation_date":"","first_published_date":"2020-11-23T13:29:00Z","last_updated_date":"2020-11-23T13:29:00Z","reference_number":"EMA/CHMP/567816/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-abiraterone-tablets-250-mg-and-500-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"49318","name":"Overview of comments received on 'Lapatinib film-coated tablet 250 mg product-specific bioequivalence guidance - First version (1st draft)","type":"comments","status":"Adopted","consultation_date":"","first_published_date":"2020-11-23T15:46:00Z","last_updated_date":"2020-11-23T15:46:00Z","reference_number":"EMA/CHMP/567884/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-lapatinib-film-coated-tablet-250-mg-product-specific-bioequivalence-guidance-first-version-1st-draft_en.pdf"},
    {"id":"49481","name":"Overview of comments received on ICH guideline E14/S7B on clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential - questions and answers - Step 2b","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-12-08T13:15:00Z","last_updated_date":"2020-12-08T13:15:00Z","reference_number":"EMA/658070/2020 ","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-e14-s7b-clinical-nonclinical-evaluation-qt-qtc-interval-prolongation-proarrhythmic-potential-questions-answers-step-2b_en.pdf"},
    {"id":"49592","name":"Overview of comments received on 'Levothyroxine tablets 12.5 mcg, 25 mcg, 50 mcg, 75 mcg, 100 mcg (and additional strengths) and 200 mcg product-specific bioequivalence guidance'","type":"comments","status":"Adopted","consultation_date":"","first_published_date":"2020-12-16T12:55:00Z","last_updated_date":"2020-12-16T12:55:00Z","reference_number":"EMA/CHMP/532756/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-levothyroxine-tablets-125-mcg-25-mcg-50-mcg-75-mcg-100-mcg-and-additional-strengths-and-200-mcg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"49607","name":"Overview of comments received on 'Draft guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells - Revision 1'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T13:26:00Z","last_updated_date":"2020-12-17T13:26:00Z","reference_number":"EMA/34765/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-quality-non-clinical-and-clinical-aspects-medicinal-products-containing-genetically-modified-cells-revision-1_en.pdf"},
    {"id":"49793","name":"Overview of comments received on ''Reflection paper on dose optimisation of established veterinary antibiotics in the context of SPC harmonisation\"","type":"comments","status":"Adopted","consultation_date":"","first_published_date":"2021-01-13T10:28:00Z","last_updated_date":"2021-01-13T10:28:00Z","reference_number":"EMA/CVMP/117410/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-dose-optimisation-established-veterinary-antibiotics-context-spc-harmonisation_en.pdf"},
    {"id":"49943","name":"Union Product Database (UPD) Access Policy - Veterinary Medicinal Products - Policy no 0082 - Overview of comments","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-01-27T14:45:00Z","last_updated_date":"2021-01-27T14:45:00Z","reference_number":"EMA/633341/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/union-product-database-upd-access-policy-veterinary-medicinal-products-policy-no-0082-overview-comments_en.pdf"},
    {"id":"49971","name":"Overview of comments received on 'Draft Questions and answers on Data Monitoring Committees issues'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-01-29T08:56:00Z","last_updated_date":"2021-01-29T08:56:00Z","reference_number":"EMA/548893/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-questions-and-answers-data-monitoring-committees-issues_en.pdf"},
    {"id":"49983","name":"Overview of comments received on ICH guideline Q3D(R2) on elemental impurities (EMA/CHMP/ICH/353369/2013)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-01-29T10:35:00Z","last_updated_date":"2021-01-29T10:35:00Z","reference_number":"EMA/42340/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-q3dr2-elemental-impurities-emachmpich3533692013_en.pdf"},
    {"id":"50025","name":"Overview of comments received on 'CVMP strategy on antimicrobials 2021-2025'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-02-02T09:57:00Z","last_updated_date":"2021-02-02T09:57:00Z","reference_number":"EMA/CVMP/517722/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-cvmp-strategy-antimicrobials-2021-2025_en.pdf"},
    {"id":"50272","name":"Overview of comments received on “Revised guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market” EMA/CVMP/SWP/66781/2005–Rev.2","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-02-25T14:14:00Z","last_updated_date":"2021-02-25T14:14:00Z","reference_number":"EMA/CVMP/57188/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-revised-guideline-safety-and-residue-data-requirements-pharmaceutical-veterinary-medicinal-products-intended-minor-use-or-minor-species-mumslimited-market_en.pdf"},
    {"id":"50328","name":"Overview of comments received on 'Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health - First version'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-03-01T15:31:00Z","last_updated_date":"2021-03-01T15:31:00Z","reference_number":"EMA/CVMP/AWP/902538/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-use-aminopenicillins-and-their-beta-lactamase-inhibitor-combinations-animals-european-union-development-resistance-and-impact-human-and-animal-health-first_en.pdf"},
    {"id":"50337","name":"Overview of comments received on the 'Reflection paper on antimicrobial resistance in the environment: considerations for current and future risk assessment of veterinary medicinal products - First version'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-03-01T16:46:00Z","last_updated_date":"2021-03-01T16:46:00Z","reference_number":"EMA/CVMP/ERA/268948/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-antimicrobial-resistance-environment-considerations-current-and-future-risk-assessment-veterinary-medicinal-products-first-version_en.pdf"},
    {"id":"50822","name":"Overview of comments received on 'ICH reflection paper on proposed ICH guideline work to advance patient focused drug development’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T11:25:00Z","last_updated_date":"2021-04-14T11:25:00Z","reference_number":"EMA/194133/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-reflection-paper-proposed-ich-guideline-work-advance-patient-focused-drug-development_en.pdf"},
    {"id":"50886","name":"Allergen for therapy: Dermatophagoides pteronyssinus / Dermatophagoides farina (oromucosal use, products authorised via mutually recognition procedure and decentralised procedure): List of nationally authorised medicinal products -  PSUSA/00010582/202009","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-04-16T14:42:00Z","last_updated_date":"2021-04-16T14:42:00Z","reference_number":"EMA/211458/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/allergen-therapy-dermatophagoides-pteronyssinus-dermatophagoides-farina-oromucosal-use-products-authorised-mutually-recognition-procedure-and-decentralised-procedure-list-nationally-authorised_en.pdf"},
    {"id":"50939","name":"Overview of comments received on 'Public guidance - Parallel application for EU-M4all (Article 58) opinion and Centralised Marketing Authorisation procedure' (EMA/104275/2021)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-04-22T12:14:00Z","last_updated_date":"2021-04-22T12:14:00Z","reference_number":"EMA/191686/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-public-guidance-parallel-application-eu-m4all-article-58-opinion-and-centralised-marketing-authorisation-procedure-ema1042752021_en.pdf"},
    {"id":"51423","name":"Overview of comments received on 'Draft deferasirox, dispersible tablets (125 mg, 250 mg and 500 mg), film-coated tablets (90 mg, 180 mg, and 360 mg), and granules (90 mg, 180 mg and 360 mg) product-specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-06-14T10:40:00Z","last_updated_date":"2021-06-14T10:40:00Z","reference_number":"EMA/CHMP/209314/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-deferasirox-dispersible-tablets-125-mg-250-mg-500-mg-film-coated-tablets-90-mg-180-mg-360-mg-granules-90-mg-180-mg-360-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"51633","name":"Overview of comments received on Guideline on the summary of product characteristics (SPC) for veterinary medicinal products containing antimicrobial substances - Revision 1","type":"comments","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T11:39:00Z","last_updated_date":"2021-06-28T11:39:00Z","reference_number":"EMA/CVMP/692904/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-summary-product-characteristics-spc-veterinary-medicinal-products-containing-antimicrobial-substances-revision-1_en.pdf"},
    {"id":"51997","name":"Overview of comments received on the EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - obsolete","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-07-21T16:46:00Z","last_updated_date":"2021-07-21T16:46:00Z","reference_number":"EMA/358889/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-obsolete_en.pdf"},
    {"id":"52026","name":"Overview of comments received on 'Draft guideline on the use of adjuvanted veterinary vaccines - Revision 1'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-07-23T13:46:00Z","last_updated_date":"2021-07-23T13:46:00Z","reference_number":"EMA/CVMP/IWP/30398/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-use-adjuvanted-veterinary-vaccines-revision-1_en.pdf"},
    {"id":"52078","name":"Overview of comments received on 'Reflection paper on promoting the authorisation of alternatives to antimicrobials in the EU'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-07-26T14:06:00Z","last_updated_date":"2021-07-26T14:06:00Z","reference_number":"EMA/644209/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-promoting-authorisation-alternatives-antimicrobials-eu_en.pdf"},
    {"id":"52427","name":"Overview of comments received on 'Draft palbociclib hard capsule 75 mg, 100 mg and 125 mg and film-coated tablet 75 mg, 100 mg and 125 mg product-specific bioequivalence guidance - Revision 1'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-09-13T13:56:00Z","last_updated_date":"2021-09-13T13:56:00Z","reference_number":"EMA/CHMP/133838/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-palbociclib-hard-capsule-75-mg-100-mg-and-125-mg-and-film-coated-tablet-75-mg-100-mg-and-125-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"52431","name":"Overview of comments received on 'Lapatinib film-coated tablet 250 mg product-specific bioequivalence guidance - First version (1st / 2nd draft)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-09-13T14:27:00Z","last_updated_date":"2021-09-13T14:27:00Z","reference_number":"EMA/CHMP/89249/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-lapatinib-film-coated-tablet-250-mg-product-specific-bioequivalence-guidance-first-version-1st-2nd-draft_en.pdf"},
    {"id":"52507","name":"Overview of comments received on 'Reflection paper on methods found suitable within the EU for demonstrating freedom from extraneous agents of the seeds used for the production of immunological veterinary medicinal products' (Revision 1)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T15:04:00Z","last_updated_date":"2021-09-17T15:04:00Z","reference_number":"EMA/CVMP/IWP/408557/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-methods-found-suitable-within-eu-demonstrating-freedom-extraneous-agents-seeds-used-production-immunological-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"52688","name":"Overview of comments received on 'Guideline on safety and residue data requirements for applications for non-immunological veterinary medicinal products intended for limited markets submitted under Article 23 of the Regulation(EU) 2019/6 (EMA/CVMP/345237)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T08:44:00Z","last_updated_date":"2021-10-01T08:44:00Z","reference_number":"EMA/CVMP/148001/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-safety-and-residue-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulationeu_en.pdf"},
    {"id":"52689","name":"Overview of comments received on 'Guideline on efficacy and target animal safety data requirements for applications for non-immunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation (EU) 2019/6","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T08:48:00Z","last_updated_date":"2021-10-01T08:48:00Z","reference_number":"EMA/CVMP/147926/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-efficacy-and-target-animal-safety-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article_en.pdf"},
    {"id":"52690","name":"Overview of comments received on 'Guideline on data requirements for applications for immunological veterinary medicinal products intended for limited markets submitted under Article 23 of the Regulation (EU) 2019/6' (EMA/CVMP/59531/2020)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T08:51:00Z","last_updated_date":"2021-10-01T08:51:00Z","reference_number":"EMA/CVMP/147910/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-data-requirements-applications-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-20196-emacvmp595312020_en.pdf"},
    {"id":"52697","name":"Overview of comments received on draft revised Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) (EMA/HMPC/893108/2011 Rev. 1)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T12:16:00Z","last_updated_date":"2021-10-01T12:16:00Z","reference_number":"EMA/HMPC/3914/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-revised-public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-emahmpc8931082011-rev-1_en.pdf"},
    {"id":"52774","name":"Overview of comments received on 'Dasatinib film-coated tablets 20, 50, 70, 80, 100 & 140 mg and suspension 10 mg/ml product-specific bioequivalence guidance' - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-10-07T16:26:00Z","last_updated_date":"2021-10-07T16:26:00Z","reference_number":"EMA/CHMP/493940/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-dasatinib-film-coated-tablets-20-50-70-80-100-140-mg-and-suspension-10-mgml-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"53073","name":"Overview of comments received on Addendum to the ICH guideline S1B on testing for carcinogenicity of pharmaceuticals (EMA/CHMP/ICH/272147/2021)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-11-11T14:16:00Z","last_updated_date":"2021-11-11T14:16:00Z","reference_number":"EMA/628493/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-addendum-ich-guideline-s1b-testing-carcinogenicity-pharmaceuticals-emachmpich2721472021_en.pdf"},
    {"id":"53074","name":"Overview of comments received on ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products (EMA/CHMP/ICH/318372/2021)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-11-11T14:21:00Z","last_updated_date":"2021-11-11T14:21:00Z","reference_number":"EMA/628681/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-s12-nonclinical-biodistribution-considerations-gene-therapy-products-emachmpich3183722021_en.pdf"},
    {"id":"53158","name":"Overview of comments received on 'Guideline on veterinary good pharmacovigilance practices (VGVP)’ (EMA/635856/2020) - Module: Collection and recording of suspected adverse events for veterinary medicinal products","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/367323/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-veterinary-good-pharmacovigilance-practices-vgvp-ema6358562020-module-collection-and-recording-suspected-adverse-events-veterinary-medicinal-products_en.pdf"},
    {"id":"53159","name":"Overview of comments received on 'Guideline on veterinary good pharmacovigilance practices (VGVP)’ (EMA/118227/2021) - Module: Glossary","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/367598/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-veterinary-good-pharmacovigilance-practices-vgvp-ema1182272021-module-glossary_en.pdf"},
    {"id":"53160","name":"Overview of comments received on 'Guideline on veterinary good pharmacovigilance practices (VGVP)’ (EMA/328998/2021) - Module: Controls and pharmacovigilance Inspections","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/368440/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-veterinary-good-pharmacovigilance-practices-vgvp-ema3289982021-module-controls-and-pharmacovigilance-inspections_en.pdf"},
    {"id":"53161","name":"Overview of comments received on 'Guideline on veterinary good pharmacovigilance practices (VGVP)’ (EMA/257136/2021) - Module: Pharmacovigilance systems, their quality management systems and pharmacovigilance system master files","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/367990/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-veterinary-good-pharmacovigilance-practices-vgvp-ema2571362021-module-pharmacovigilance-systems-their-quality-management-systems-and-pharmacovigilance-system_en.pdf"},
    {"id":"53162","name":"Overview of comments received on 'Guideline on veterinary good pharmacovigilance practices (VGVP)’ (EMA/399713/2020) - Module: Signal Management","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/367359/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-veterinary-good-pharmacovigilance-practices-vgvp-ema3997132020-module-signal-management_en.pdf"},
    {"id":"53163","name":"Overview of comments received on 'Guideline on veterinary good pharmacovigilance practices (VGVP)’ (EMA/63454/2021) - Module: Veterinary pharmacovigilance communication","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/373229/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-veterinary-good-pharmacovigilance-practices-vgvp-ema634542021-module-veterinary-pharmacovigilance-communication_en.pdf"},
    {"id":"53417","name":"Overview of comments received on 'Draft guideline on the quality requirements for drug-device combinations - First version'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T12:08:00Z","last_updated_date":"2021-12-08T12:08:00Z","reference_number":"EMA/CHMP/QWP/BWP/725078/2021 ","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-quality-requirements-drug-device-combinations-first-version_en.pdf"},
    {"id":"53450","name":"Overview of comments received on 'Draft ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Addendum - Step 2b'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-12-13T16:00:00Z","last_updated_date":"2021-12-15T13:19:00Z","reference_number":"EMA/743397/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-ich-guideline-m7-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-addendum-step-2b_en.pdf"},
    {"id":"53600","name":"Overview of comments received on 'Draft guideline on the  summary of product characteristics for antiparasitic  veterinary medicinal products - Revision 1'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2021-12-20T09:41:00Z","last_updated_date":"2021-12-20T09:41:00Z","reference_number":"EMA/CVMP/EWP/524331/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-summary-product-characteristics-antiparasitic-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"53948","name":"Overview of comments received on draft ICH guideline Q13 on continuous manufacturing of drug substances and drug products - Step 2b","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-01-27T12:51:00Z","last_updated_date":"2022-01-27T12:51:00Z","reference_number":"EMA/771847/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-ich-guideline-q13-continuous-manufacturing-drug-substances-and-drug-products-step-2b_en.pdf"},
    {"id":"53964","name":"Overview of comments received on 'Draft revised guideline on data requirements for multi-strain dossiers for inactivated veterinary vaccines’ (EMA/CVMP/IWP/105506/2007 Rev. 2)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T18:06:00Z","last_updated_date":"2022-01-28T18:06:00Z","reference_number":"EMA/CVMP/IWP/532516/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-revised-guideline-data-requirements-multi-strain-dossiers-inactivated-veterinary-vaccines-emacvmpiwp1055062007-rev-2_en.pdf"},
    {"id":"53968","name":"Overview of comments received on the draft guideline on data requirements for vaccine platform technology master files (vPTMF) (EMA/CVMP/IWP/283631/2021)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T18:38:00Z","last_updated_date":"2022-01-28T18:38:00Z","reference_number":"EMA/CVMP/IWP/618280/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-data-requirements-vaccine-platform-technology-master-files-vptmf-emacvmpiwp2836312021_en.pdf"},
    {"id":"53970","name":"Overview of comments received on “Guideline on data requirements for vaccine antigen master files (VAMF)” (EMA/CVMP/IWP/258755/2021)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T15:06:00Z","last_updated_date":"2022-01-28T15:06:00Z","reference_number":"EMA/CVMP/IWP/544053/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-data-requirements-vaccine-antigen-master-files-vamf-emacvmpiwp2587552021_en.pdf"},
    {"id":"53977","name":"Overview of comments received on 'Draft guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials - Revision 2'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T20:19:00Z","last_updated_date":"2022-01-28T20:19:00Z","reference_number":"EMA/CHMP/QWP/693578/2021 ","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-requirements-chemical-and-pharmaceutical-quality-documentation-concerning-investigational-medicinal-products-clinical-trials-revision-2_en.pdf"},
    {"id":"53999","name":"Overview of comments received on the draft guideline on clinical trials with immunological veterinary medicinal products (IVMPs) (EMA/CVMP/IWP/260956/2021)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T11:31:00Z","last_updated_date":"2022-01-28T11:31:00Z","reference_number":"EMA/CVMP/IWP/618327/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-clinical-trials-immunological-veterinary-medicinal-products-ivmps-emacvmpiwp2609562021_en.pdf"},
    {"id":"54009","name":"Overview of comments received on the draft guideline on  data requirements for authorisation of immunological  veterinary medicinal products under exceptional circumstances (EMA/CVMP/IWP/251947/2021)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T13:58:00Z","last_updated_date":"2022-01-28T13:58:00Z","reference_number":"EMA/CVMP/IWP/618299/2021 ","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-data-requirements-authorisation-immunological-veterinary-medicinal-products-under-exceptional-circumstances-emacvmpiwp2519472021_en.pdf"},
    {"id":"54018","name":"Overview of comments received on the draft Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials (EMA/CHMP/BWP/534898/2008 Rev. 2)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T14:47:00Z","last_updated_date":"2022-01-28T14:47:00Z","reference_number":"EMA/CHMP/BWP/518880/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials-emachmpbwp5348982008-rev-2_en.pdf"},
    {"id":"54082","name":"Overview of comments received on Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94038/2007 Rev. 6)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-02-04T16:05:00Z","last_updated_date":"2022-02-04T16:05:00Z","reference_number":"EMA/30450/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-emachmpbpwp940382007-rev-6_en.pdf"},
    {"id":"54083","name":"Overview of comments received on Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94033/2007 rev. 4)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-02-04T16:16:00Z","last_updated_date":"2022-02-04T16:16:00Z","reference_number":"EMA/20937/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-emachmpbpwp940332007-rev-4_en.pdf"},
    {"id":"54243","name":"EU Common Standard for electronic product information (ePI) - categorised comments received following public consultation","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-02-22T12:00:00Z","last_updated_date":"2022-02-22T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/eu-common-standard-electronic-product-information-epi-categorised-comments-received-following-public-consultation_en.xlsx"},
    {"id":"54297","name":"Overview of comments received on the Reflection paper on the interpretation of Article 18(7) of Regulation (EU) 2019/6 (EMA/CVMP/ERA/622045/2020)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-02-25T09:40:00Z","last_updated_date":"2022-02-25T09:40:00Z","reference_number":"EMA/CVMP/ERA/768241/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-interpretation-article-187-regulation-eu-20196-emacvmpera6220452020_en.pdf"},
    {"id":"54566","name":"Overview of comments received on the \"Reflection paper on the interpretation of Article 72 of Regulation (EU) 2019/6\" (EMA/CVMP/ERA/245311/2021)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T08:02:00Z","last_updated_date":"2022-03-25T08:02:00Z","reference_number":"EMA/CVMP/ERA/56761/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-interpretation-article-72-regulation-eu-20196-emacvmpera2453112021_en.pdf"},
    {"id":"54570","name":"Overview of comments received on ‘Guideline on safety and residue data requirements for the establishment of Maximum Residue Limits in minor species’ (EMA/CVMP/345236/2020)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T10:15:00Z","last_updated_date":"2022-03-25T10:15:00Z","reference_number":"EMA/CVMP/148042/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-safety-and-residue-data-requirements-establishment-maximum-residue-limits-minor-species-emacvmp3452362020_en.pdf"},
    {"id":"54571","name":"Overview of comments received on the guideline on injection site residues (EMA/CVMP/SWP/185470/2004) - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T08:51:00Z","last_updated_date":"2022-03-25T08:51:00Z","reference_number":"EMA/CVMP/SWP/11010/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-injection-site-residues-emacvmpswp1854702004-revision-1_en.pdf"},
    {"id":"54574","name":"Overview of comments received on Guideline on determination of withdrawal periods for milk (EMA/CVMP/SWP/10941/2022) - Revision 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T08:57:00Z","last_updated_date":"2022-03-25T08:57:00Z","reference_number":"EMA/CVMP/SWP/10941/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-determination-withdrawal-periods-milk-ema-cvmp-swp-10941-2022-revision-1_en.pdf"},
    {"id":"54576","name":"Overview of comments received on the Guideline on determination of withdrawal periods for edible tissues (EMA/CVMP/SWP/735325/2012) - Revision 2","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T09:00:00Z","last_updated_date":"2022-03-25T09:00:00Z","reference_number":"EMA/CVMP/SWP/10857/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-determination-withdrawal-periods-edible-tissues-emacvmpswp7353252012-revision-2_en.pdf"},
    {"id":"54632","name":"Overview of comments received on Draft qualification opinion on Islet Autoantibodies (AAs) with answers","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-03-31T10:00:00Z","last_updated_date":"2022-03-31T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-qualification-opinion-islet-autoantibodies-aas-answers_en.pdf"},
    {"id":"54763","name":"Overview of comments received on ICH guideline Q9 (R1) on quality risk management (EMA/CHMP/ICH/24235/2006)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-04-20T12:50:00Z","last_updated_date":"2022-04-20T12:50:00Z","reference_number":"EMA/158487/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-q9-r1-quality-risk-management-emachmpich242352006_en.pdf"},
    {"id":"54812","name":"Overview of comments received on 'Draft Toolbox guidance on scientific elements and regulatory tools to support quality data packages for PRIME marketing authorisation applications' (EMA/CHMP/BWP/QWP/IWG/694114/2019)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T16:05:00Z","last_updated_date":"2022-04-22T16:05:00Z","reference_number":"EMA/CHMP/BWP/QWP/IWG/579239/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-toolbox-guidance-scientific-elements-and-regulatory-tools-support-quality-data-packages-prime-marketing-authorisation-applications-emachmpbwpqwpiwg6941142019_en.pdf"},
    {"id":"54918","name":"Overview of comments received on draft qualification opinion on IMI PREFER","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-05-06T16:15:00Z","last_updated_date":"2022-05-06T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-qualification-opinion-imi-prefer_en.pdf"},
    {"id":"55036","name":"Overview of comments received on 'Procedural advice for veterinary vaccine antigen master file (VAMF) certification’ (EMA/CVMP/127488/2021)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T10:52:00Z","last_updated_date":"2022-05-20T10:52:00Z","reference_number":"EMA/CVMP/45571/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-procedural-advice-veterinary-vaccine-antigen-master-file-vamf-certification-emacvmp1274882021_en.pdf"}    {"id":"55351","name":"Overview of comments received on 'Guideline on requirements for the production and control of immunological veterinary medicinal products’ (EMA/CVMP/IWP/206555/2010-Rev.2)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T09:32:00Z","last_updated_date":"2022-06-24T09:32:00Z","reference_number":"EMA/CVMP/IWP/157851/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-requirements-production-and-control-immunological-veterinary-medicinal-products-emacvmpiwp2065552010-rev2_en.pdf"},
    {"id":"55355","name":"Overview of comments received on the ‘Guideline on data requirements for veterinary medicinal products for the prevention of transmission of vector-borne diseases in dogs and cats’ (EMA/CVMP/EWP/278031/2015)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T10:17:00Z","last_updated_date":"2022-06-24T10:17:00Z","reference_number":"EMA/CVMP/EWP/552708/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-data-requirements-veterinary-medicinal-products-prevention-transmission-vector-borne-diseases-dogs-and-cats-emacvmpewp2780312015_en.pdf"},
    {"id":"55432","name":"Submitted comments on 'Draft guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-07-01T11:37:00Z","last_updated_date":"2022-07-01T11:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/submitted-comments-draft-guidance-procedural-aspects-consultation-european-medicines-agency-notified-body-companion-diagnostics_en.pdf"},
    {"id":"55693","name":"Submission of comments on Enroll-HD: Registry for Huntington's Disease","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-07-28T11:21:00Z","last_updated_date":"2022-07-28T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/submission-comments-enroll-hd-registry-huntingtons-disease_en.pdf"},
    {"id":"55868","name":"Overview of comments received on ICH guideline Q2(R2) on on ICH guideline on Q2(R2) validation of analytical procedures (EMA/CHMP/ICH/82072/2006)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-08-24T09:17:00Z","last_updated_date":"2022-08-24T09:17:00Z","reference_number":"EMA/678521/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-q2r2-ich-guideline-q2r2-validation-analytical-procedures-emachmpich820722006_en.pdf"},
    {"id":"55869","name":"Overview of comments received on ICH guideline Q14 on analytical procedure development (EMA/CHMP/ICH/195040/2022)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-08-24T09:29:00Z","last_updated_date":"2022-08-24T09:29:00Z","reference_number":"EMA/690538/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-q14-analytical-procedure-development-emachmpich1950402022_en.pdf"},
    {"id":"56139","name":"Overview of comments received for Prognostic Covariate Adjustment (PROCOVA™) with responses","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-09-20T14:19:00Z","last_updated_date":"2022-09-20T14:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-prognostic-covariate-adjustment-procovatm-responses_en.pdf"},
    {"id":"56398","name":"Overview of comments received on 'Reflection paper on criteria for determining that an active substance is essential when considered in the context of Article 37(2)(j) of Regulation 2019/6'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-10-14T09:30:00Z","last_updated_date":"2022-10-14T09:30:00Z","reference_number":"EMA/CVMP/352510/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-criteria-determining-active-substance-essential-when-considered-context-article-372j-regulation-20196_en.pdf"},
    {"id":"56480","name":"Overview of comments received on draft 'Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells' (EMA/CAT/CHMP/158266/2021)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-10-26T11:04:00Z","last_updated_date":"2022-10-26T11:04:00Z","reference_number":"EMA/CAT/CHMP/679290/2021","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-core-smpc-labelling-and-package-leaflet-advanced-therapy-medicinal-products-atmps-containing-genetically-modified-cells-emacatchmp1582662021_en.pdf"},
    {"id":"56989","name":"Overview of comments on 'Draft lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product specific bioequivalence guidance'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T17:18:00Z","last_updated_date":"2022-12-16T17:18:00Z","reference_number":"EMA/CHMP/839131/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-draft-lanreotide-acetate-prolonged-release-solution-injection-prefilled-syringe-60-90-and-120-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"57079","name":"Overview of comments received on Draft Qualification Opinion of the iBox Scoring System as a secondary efficacy endpoint in clinical trials investigating novel immunosuppressive medicines in kidney transplant patients","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T12:55:00Z","last_updated_date":"2022-12-16T12:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-qualification-opinion-ibox-scoring-system-secondary-efficacy-endpoint-clinical-trials-investigating-novel-immunosuppressive-medicines-kidney-transplant-patients_en.pdf"},
    {"id":"57326","name":"Overview of comments received on draft EMA / EFSA report on development of a harmonised approach to human dietary exposure","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-01-19T13:00:00Z","last_updated_date":"2023-01-19T13:00:00Z","reference_number":"EMA/CVMP/719874/2022 ","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-ema-efsa-report-development-harmonised-approach-human-dietary-exposure_en.pdf"},
    {"id":"57424","name":"Overview of comments received on CVMP guideline on NVR Art 34 for the classification of VMPs","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T10:24:00Z","last_updated_date":"2023-01-27T10:24:00Z","reference_number":"EMA/CVMP/855384/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-cvmp-guideline-nvr-art-34-classification-vmps_en.pdf"},
    {"id":"57430","name":"Overview of comments received on 'Procedural advice for vaccine platform technology master file (vPTMF) certification' (EMA/CVMP/184591/2022)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T11:27:00Z","last_updated_date":"2023-01-27T11:27:00Z","reference_number":"EMA/CVMP/695453/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-procedural-advice-vaccine-platform-technology-master-file-vptmf-certification-emacvmp1845912022_en.pdf"},
    {"id":"57432","name":"Overview of comments received on the ‘Reflection paper on resistance in ectoparasites’ (EMA/CVMP/EWP/310225/2014)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T11:43:00Z","last_updated_date":"2023-01-27T11:43:00Z","reference_number":"EMA/CVMP/EWP/483154/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-resistance-ectoparasites-emacvmpewp3102252014_en.pdf"},
    {"id":"58170","name":"Overview of comments received on ICH guideline Q5A (R2) on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-03-27T16:03:00Z","last_updated_date":"2023-03-27T16:03:00Z","reference_number":"EMA/73056/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-guideline-q5a-r2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin_en.pdf"},
    {"id":"58729","name":"Overview of comments received on 'Liposomal  amphotericin B powder for dispersion for infusion 50 mg  product-specific bioequivalence guidance’  (EMA/CHMP/559889/2021) - Rev. 1","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T11:26:00Z","last_updated_date":"2024-02-22T12:18:00Z","reference_number":"EMA/CHMP/275518/2022 Rev. 1*","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-liposomal-amphotericin-b-powder-dispersion-infusion-50-mg-product-specific-bioequivalence-guidance-ema-chmp-559889-2021-rev-1_en.pdf"},
    {"id":"59057","name":"Overview of comments received on 'Paracetamol oral use immediate release formulations product-specific bioequivalence guidance' (EMA/CHMP/356877/2022 Rev.1)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-06-22T16:16:00Z","last_updated_date":"2024-04-22T15:52:00Z","reference_number":"EMA/CHMP/758781/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-paracetamol-oral-use-immediate-release-formulations-product-specific-bioequivalence-guidance-ema-chmp-356877-2022-rev1_en.pdf"},
    {"id":"59061","name":"Overview of comments received on 'Tadalafil film-coated tablets 2.5 mg, 5 mg, 10 mg and 20 mg product-specific bioequivalence guidance' (EMA/CHMP/315234/2014 Rev.2)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-06-22T16:51:00Z","last_updated_date":"2023-06-22T16:51:00Z","reference_number":"EMA/CHMP/779867/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-tadalafil-film-coated-tablets-25-mg-5-mg-10-mg-and-20-mg-product-specific-bioequivalence-guidance-emachmp3152342014-rev2_en.pdf"},
    {"id":"59063","name":"Overview of comments received on 'Ibuprofen oral use immediate release formulations 200–800 mg productspecific bioequivalence guidance' (EMA/CHMP/356876/2017 Rev.1)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-06-22T17:03:00Z","last_updated_date":"2023-06-22T17:03:00Z","reference_number":"EMA/CHMP/735541/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ibuprofen-oral-use-immediate-release-formulations-200-800-mg-productspecific-bioequivalence-guidance-emachmp3568762017-rev1_en.pdf"},
    {"id":"59066","name":"Overview of comments received on 'Guideline on the development and data requirements of potency tests for veterinary cell-based therapy products and the relation to clinical efficacy ' (EMA/CVMP/NTWP/179287/2022)","type":"comments","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T10:29:00Z","last_updated_date":"2023-06-23T10:29:00Z","reference_number":"EMA/NTWP/85029/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-development-and-data-requirements-potency-tests-veterinary-cell-based-therapy-products-and-relation-clinical-efficacy-emacvmpntwp1792872022_en.pdf"},
    {"id":"59159","name":"Overview of comments received on ICH M13A Guideline on bioequivalence for immediate-release solid oral dosage forms","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:22:00Z","last_updated_date":"2023-06-30T14:22:00Z","reference_number":"EMA/CHMP/ICH/953493/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-m13a-guideline-bioequivalence-immediate-release-solid-oral-dosage-forms_en.pdf"},
    {"id":"59529","name":"Overview of comments on draft Qualification Opinion for Stride velocity 95th centile as a primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-07-31T12:34:00Z","last_updated_date":"2023-07-31T12:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-draft-qualification-opinion-stride-velocity-95th-centile-primary-endpoint-studies-ambulatory-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"60426","name":"Overview of comments received on 'Guideline on quality,  safety and efficacy of veterinary medicinal products  specifically designed for phage therapy'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T15:32:00Z","last_updated_date":"2023-10-13T15:32:00Z","reference_number":"EMA/CVMP/NTWP/230544/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-quality-safety-and-efficacy-veterinary-medicinal-products-specifically-designed-phage-therapy_en.pdf"},
    {"id":"60431","name":"Overview of comments - Guideline on the reporting of antimicrobial sales and use in animals at the  EU level – denominators and indicators","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T16:08:00Z","last_updated_date":"2023-10-13T16:08:00Z","reference_number":"EMA/CVMP/229549/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-guideline-reporting-antimicrobial-sales-and-use-animals-eu-level-denominators-and-indicators_en.pdf"},
    {"id":"60994","name":"Overview of comments received on 'Questions and answers on data requirements when transitioning to low global warming potential (LGWP) propellants in oral pressurised metered dose inhalers' (EMA/CHMP/83033/2023)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-11-23T15:44:33Z","last_updated_date":"2023-11-23T15:44:33Z","reference_number":"EMA/251450/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-questions-and-answers-data-requirements-when-transitioning-low-global-warming-potential-lgwp-propellants-oral-pressurised-metered-dose-inhalers-ema-chmp-83033-2023_en.pdf"},
    {"id":"61000","name":"Overview of comments received on the 'Reflection paper on the environmental risk assessment of ectoparasiticidal veterinary medicinal products used in cats and dogs'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-11-21T17:04:15Z","last_updated_date":"2023-11-21T17:04:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-environmental-risk-assessment-ectoparasiticidal-veterinary-medicinal-products-used-cats-and-dogs_en.pdf"},
    {"id":"61488","name":"Overview of comments received on Guideline on the calculation of dose factor to be submitted to the Union Product Database (UPD) (EMA/CVMP/PhVWPV/399363/2023)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-12-18T16:09:42Z","last_updated_date":"2023-12-18T16:09:42Z","reference_number":"EMA/CVMP/PhVWPV/470818/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-calculation-dose-factor-be-submitted-union-product-database-upd-ema-cvmp-phvwpv-399363-2023_en.pdf"},
    {"id":"61496","name":"Overview of comments on ICH E6 (R3) guideline","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T11:56:16Z","last_updated_date":"2023-12-22T18:00:00Z","reference_number":"EMA/553381/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-ich-e6-r3-guideline_en.pdf"},
    {"id":"61547","name":"Overview of comments received on ICH reflection paper on proposed international harmonisation of real-world evidence terminology and convergence of general principles regarding planning and reporting of studies using real-world data","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T15:33:10Z","last_updated_date":"2023-12-20T15:33:10Z","reference_number":"EMA/581874/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-reflection-paper-proposed-international-harmonisation-real-world-evidence-terminology-and-convergence-general-principles-regarding-planning-and-reporting-studies-using_en.pdf"},
    {"id":"61914","name":"Overview of comments received on Draft guideline on plasmid DNA vaccines for veterinary use","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T14:13:50Z","last_updated_date":"2024-01-26T14:13:50Z","reference_number":"EMA/CVMP/IWP/303516/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-plasmid-dna-vaccines-veterinary-use_en.pdf"},
    {"id":"61918","name":"Overview of comments received on Concept paper on the development of a guideline on determination of the need for an MRL evaluation for biological substances","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T14:57:45Z","last_updated_date":"2024-01-26T14:57:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-concept-paper-development-guideline-determination-need-mrl-evaluation-biological-substances_en.pdf"},
    {"id":"62723","name":"Overview of comments received on 'Draft guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials - first version'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-03-25T14:59:43Z","last_updated_date":"2024-03-25T14:59:43Z","reference_number":"EMA/62329/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials-first-version_en.pdf"},
    {"id":"62984","name":"Overview of comments received on 'Information for the package leaflet regarding polysorbates used as excipients in medicinal products for human use’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-04-17T09:56:33Z","last_updated_date":"2024-04-17T09:56:33Z","reference_number":"EMA/544822/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-information-package-leaflet-regarding-polysorbates-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"63434","name":"Overview of comments received on 'CHMP Reflection paper on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 3","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/BWP/245922/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-chmp-reflection-paper-creutzfeldt-jakob-disease-plasma-derived-urine-derived-medicinal-products-revision-3_en.pdf"},
    {"id":"63729","name":"Overview of comments received on draft qualification opinion for Centiloid measure of Amyloid PET to quantify brain amyloid deposition","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-06-25T09:43:31Z","last_updated_date":"2024-06-25T09:43:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-qualification-opinion-centiloid-measure-amyloid-pet-quantify-brain-amyloid-deposition_en.pdf"},
    {"id":"63808","name":"Overview of comments on 'Draft guideline on clinical investigation of recombinant and human plasma-derived factor IX products - Revision 2'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T14:00:00Z","last_updated_date":"2024-06-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-draft-guideline-clinical-investigation-recombinant-human-plasma-derived-factor-ix-products-revision-2_en.pdf"},
    {"id":"63811","name":"Overview of comments on the 'Draft guideline on core SmPC for human plasma derived and recombinant coagulation factor IX products - Revision 3'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T14:50:00Z","last_updated_date":"2024-06-28T14:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-draft-guideline-core-smpc-human-plasma-derived-recombinant-coagulation-factor-ix-products-revision-3_en.pdf"},
    {"id":"64493","name":"Overview of comments on 'ICH E2D(R1) Guideline on post-approval safety data Step 2b - Revision 1'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-08-02T12:55:54Z","last_updated_date":"2024-08-02T12:55:54Z","reference_number":"EMA/303542/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-ich-e2dr1-guideline-post-approval-safety-data-step-2b-revision-1_en.pdf"},
    {"id":"64795","name":"Overview of comments received on the ’Guideline on the environmental risk assessment of medicinal products for human use’ (EMEA/CHMP/SWP/4447/00 Rev. 1) ","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-09-11T14:25:00Z","last_updated_date":"2024-09-11T14:25:00Z","reference_number":"EMA/CHMP/422204/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-environmental-risk-assessment-medicinal-products-human-use-emea-chmp-swp-4447-00-rev-1_en.pdf"},
    {"id":"64900","name":"Implementation of comments received on the draft “Reflection paper on the use of artificial intelligence in the medicinal product lifecycle” (EMA/CHMP/CVMP/83833/2023)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-09-30T15:28:00Z","last_updated_date":"2024-09-30T15:28:00Z","reference_number":"EMA/CHMP/CVMP/83833/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/implementation-comments-received-draft-reflection-paper-use-artificial-intelligence-medicinal-product-lifecycle-ema-chmp-cvmp-83833-2023_en.pdf"},
    {"id":"65075","name":"Overview of comments received on 'Draft guideline on quality and equivalence of topical products' (EMA/CHMP/QWP/708282/2018)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-10-01T16:38:41Z","last_updated_date":"2024-10-01T16:38:41Z","reference_number":"EMA/CHMP/QWP/451535/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-quality-equivalence-topical-products-ema-chmp-qwp-708282-2018_en.pdf"},
    {"id":"65264","name":"Overview of comments received on ICH M14 Guideline on general principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-10-10T11:52:00Z","last_updated_date":"2024-10-10T11:52:00Z","reference_number":"EMA/417650/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines_en.pdf"},
    {"id":"65350","name":"Overview of comments received on guideline on safety and residue data requirements for applications for non-immunological veterinary medicinal products intended for limited markets but not eligible for authorisation under Art 23 of Reg (EU) 2019/6","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T15:10:00Z","last_updated_date":"2024-10-18T15:10:00Z","reference_number":"EMA/CVMP/SWP/46749/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-safety-residue-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-not-eligible-authorisation-under-art-23-reg_en.pdf"},
    {"id":"65806","name":"Overview of comments received on 'Guideline on stability testing for applications for variations to a marketing authorisation for veterinary medicinal products' (EMA/CVMP/QWP/515653/2023)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T14:25:42Z","last_updated_date":"2024-11-25T14:25:42Z","reference_number":"EMA/CVMP/QWP/416589/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-stability-testing-applications-variations-marketing-authorisation-veterinary-medicinal-products-ema-cvmp-qwp-515653-2023_en.pdf"},
    {"id":"66227","name":"Overview of comments received on Trametinib film-coated tablet 0.5 and 2mg product-specific bioequivalence guidance","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2024-12-19T14:07:17Z","last_updated_date":"2024-12-19T14:07:17Z","reference_number":"EMA/339228/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-trametinib-film-coated-tablet-05-2mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"66301","name":"Outcome of Public consultation on Policy 0044 - Summary of comments and EMA feedback","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-01-14T14:02:00Z","last_updated_date":"2025-01-14T14:02:00Z","reference_number":"EMA/543492/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/outcome-public-consultation-policy-0044-summary-comments-ema-feedback_en.pdf"},
    {"id":"66302","name":"Overview of comments received on the draft revision of EMA’s Policy on handling competing interests of scientific committee members and experts","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-01-14T14:02:00Z","last_updated_date":"2025-04-10T13:02:00Z","reference_number":"EMA/2304/2025 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-revision-emas-policy-handling-competing-interests-scientific-committee-members-experts_en.pdf"},
    {"id":"66451","name":"Overview of comments received on revised draft 'Guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food- producing animal species'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-01-24T15:35:31Z","last_updated_date":"2025-01-24T15:35:31Z","reference_number":"EMA/CVMP/AWP/702252/2018","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-revised-draft-guideline-assessment-risk-public-health-antimicrobial-resistance-due-use-antimicrobial-veterinary-medicinal-product-food-producing-animal-species_en.pdf"},
    {"id":"66454","name":"Overview of comments received on 'Guideline on data requirements for veterinary medicinal products for zootechnical purposes' (EMA/CVMP/EWP/37280/2023)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-01-24T15:42:19Z","last_updated_date":"2025-01-24T15:42:19Z","reference_number":"EMA/CVMP/EWP/259888/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-data-requirements-veterinary-medicinal-products-zootechnical-purposes-ema-cvmp-ewp-37280-2023_en.pdf"},
    {"id":"66624","name":"Overview of comments received on 'Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials’ (EMA/CAT/123573/2024) – second public consultation","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-02-06T13:06:03Z","last_updated_date":"2025-02-06T13:06:03Z","reference_number":"EMA/264632/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials-ema-cat-123573-2024-second-public-consultation_en.pdf"},
    {"id":"66651","name":"Overview of comments received on `Methylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidance’","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T14:39:16Z","last_updated_date":"2025-02-10T14:39:16Z","reference_number":"EMA/479935/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-methylphenidate-prolonged-release-tablet-18-mg-27-mg-36-mg-54-mg-modified-release-capsule-5-mg-10-mg-20-mg-30-mg-40-mg-50-mg-60-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"66691","name":"Overview of comments received on `Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance’ (EMA/CHMP/518671/2023)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-02-12T09:25:49Z","last_updated_date":"2025-02-12T09:25:49Z","reference_number":"EMA/479330/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-nilotinib-hard-capsules-50-150-200-mg-product-specific-bioequivalence-guidance-ema-chmp-518671-2023_en.pdf"},
    {"id":"66909","name":"Overview of comments received on ‘Guideline on the conduct of efficacy studies for intramammary products for use in cattle’ (EMA/CVMP/344/1999/Rev.3)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-02-21T11:24:57Z","last_updated_date":"2025-02-21T11:24:57Z","reference_number":"EMA/CVMP/EWP/497046/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-conduct-efficacy-studies-intramammary-products-use-cattle-ema-cvmp-344-1999-rev3_en.pdf"},
    {"id":"66913","name":"Overview of comments received on 'Guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances' (EMA/CVMP/627/2001-Rev.2)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-02-21T11:39:04Z","last_updated_date":"2025-02-21T11:39:04Z","reference_number":"EMA/CVMP/EWP/377613/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances-ema-cvmp-627-2001-rev2_en.pdf"},
    {"id":"67333","name":"Overview of comments received on the draft qualification opinion for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology (AIM-NASH) tool","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-03-20T12:00:00Z","last_updated_date":"2025-03-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-qualification-opinion-artificial-intelligence-based-measurement-non-alcoholic-steatohepatitis-histology-aim-nash-tool_en.pdf"},
    {"id":"67595","name":"Overview of comments received on Tolvaptan tablets with the dose range 7.5, 15 and 30 mg and tolvaptan tablets with the dose range 15, 30, 45, 60 and 90 mg product-specific bioequivalence guidance","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-04-02T10:50:45Z","last_updated_date":"2025-04-02T10:50:45Z","reference_number":"EMA/339228/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-tolvaptan-tablets-dose-range-75-15-30-mg-tolvaptan-tablets-dose-range-15-30-45-60-90-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"67762","name":"Overview of comments received on draft guideline on clinical investigation of medicinal products in the treatment of depression (EMA/CHMP/185423/2010, Rev.3)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-04-11T15:13:31Z","last_updated_date":"2025-04-11T15:13:31Z","reference_number":"EMA/117920/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-depression-ema-chmp-185423-2010-rev3_en.pdf"},
    {"id":"68416","name":"Overview of comments received on ICH M11 technical specification during second consultation (EMA/CHMP/ICH/778800/2022)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T14:17:41Z","last_updated_date":"2025-05-23T14:17:41Z","reference_number":"EMA/138236/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-m11-technical-specification-during-second-consultation-ema-chmp-ich-778800-2022_en.pdf"},
    {"id":"68417","name":"Overview of comments received on ICH E6(R3) guideline for good clinical practice – Annex 2 - Step 2b","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T14:22:17Z","last_updated_date":"2025-05-23T14:22:17Z","reference_number":"EMA/132793/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-e6r3-guideline-good-clinical-practice-annex-2-step-2b_en.pdf"},
    {"id":"68515","name":"Overview of comments received on 'Reflection paper on the application of Article 40(5) of Regulation (EU) 2019/6 for certain categories of variations' (EMA/CVMP/55240/2025)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-06-02T10:46:32Z","last_updated_date":"2025-06-02T10:46:32Z","reference_number":"EMA/CVMP/99773/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-reflection-paper-application-article-405-regulation-eu-2019-6-certain-categories-variations-ema-cvmp-55240-2025_en.pdf"},
    {"id":"68793","name":"Outcome of public consultation on the reflection paper use of real-world data in non-interventional studies to generate real-world evidence for regulatory purposes - Summary report of comments received during the public consultation and next steps","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-06-17T14:27:12Z","last_updated_date":"2025-06-17T14:27:12Z","reference_number":"EMA/203130/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/outcome-public-consultation-reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-regulatory-purposes-summary-report-comments-received-during-public-consultation_en.pdf"},
    {"id":"69435","name":"Overview of comments received on the\tDraft guideline for the demonstration of efficacy for veterinary medicinal products containing anticoccidial substances - Revision 1 (first version)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T10:00:00Z","last_updated_date":"2025-07-25T10:00:00Z","reference_number":"EMA/CVMP/EWP/479402/2019","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-anticoccidial-substances-revision-1-first-version_en.pdf"},
    {"id":"69436","name":"Overview of comments received on the Draft guideline for the demonstration of efficacy for veterinary medicinal products containing anticoccidial substances - Revision 1 (second version)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T10:00:00Z","last_updated_date":"2025-07-25T10:00:00Z","reference_number":"EMA/CVMP/EWP/58808/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-anticoccidial-substances-revision-1-second-version_en.pdf"},
    {"id":"69504","name":"Overview of comments received on ICH M13B guideline on bioequivalence for immediate-release solid oral dosage forms - additional strengths biowaiver (EMA/CHMP/ICH/85092/2025)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T16:18:05Z","last_updated_date":"2025-07-25T16:18:05Z","reference_number":"EMA/237572/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-m13b-guideline-bioequivalence-immediate-release-solid-oral-dosage-forms-additional-strengths-biowaiver-ema-chmp-ich-85092-2025_en.pdf"},
    {"id":"69577","name":"Overview of comments received on the “HMA/EMA guidance document on the identification of personal data and commercially confidential information within the structure of the marketing authorisation application (MAA) dossier” - public consultation","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-07-30T14:00:00Z","last_updated_date":"2025-07-30T14:00:00Z","reference_number":"EMA/401681/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-hma-ema-guidance-document-identification-personal-data-commercially-confidential-information-within-structure-marketing-authorisation-application-maa-dossier-public_en.pdf"},
    {"id":"69589","name":"Overview of comments received on ‘Dabrafenib hard capsule 50 and 75 mg product-specific bioequivalence guidance’ (EMA/CHMP/39771/2023)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-07-30T16:39:01Z","last_updated_date":"2025-07-30T16:39:01Z","reference_number":"EMA/339228/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-dabrafenib-hard-capsule-50-75-mg-product-specific-bioequivalence-guidance-ema-chmp-39771-2023_en.pdf"},
    {"id":"69606","name":"Overview of comments received on the draft qualification opinion for Simcyp Simulator","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-08-01T09:02:12Z","last_updated_date":"2025-08-01T09:02:12Z","reference_number":"EMADOC-1700519818-2115746","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-qualification-opinion-simcyp-simulator_en.pdf"},
    {"id":"69712","name":"Overview of comments received on 'Draft guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin - Revision 1'","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T16:54:22Z","last_updated_date":"2025-08-12T16:54:22Z","reference_number":"EMA/HMPC/423470/2024","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-good-agricultural-collection-practice-gacp-starting-materials-herbal-origin-revision-1_en.pdf"},
    {"id":"69893","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP Module XVI Addendum III (renumbered to Addendum I after finalisation) - Pregnancy prevention programme and other pregnancy-specific risk minimisation measures","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-08-28T15:47:18Z","last_updated_date":"2025-08-28T15:47:18Z","reference_number":"EMA/270864/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-xvi-addendum-iii-renumbered-addendum-i-after-finalisation-pregnancy-prevention-programme-other-pregnancy-specific_en.xlsx"},
    {"id":"69985","name":"Overview of comments received on \"Guideline on the requirements for demonstrating therapeutic equivalence between orally inhaled products (OIP) for asthma and  chronic obstructive pulmonary disease (COPD)\"","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T16:43:55Z","last_updated_date":"2025-09-05T16:43:55Z","reference_number":"EMA/CHMP/101453/20244","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-requirements-demonstrating-therapeutic-equivalence-between-orally-inhaled-products-oip-asthma-chronic-obstructive-pulmonary-disease-copd_en.pdf"},
    {"id":"71151","name":"Overview of comments received on ICH E21 guideline on inclusion of pregnant and breastfeeding individuals in clinical trials","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T16:27:23Z","last_updated_date":"2025-11-13T16:27:23Z","reference_number":"EMA/316356/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-e21-guideline-inclusion-pregnant-breastfeeding-individuals-clinical-trials_en.pdf"},
    {"id":"71625","name":"Overview of comments received on 'Information for the package leaflet regarding dextrans used as excipients in medicinal products for human use' (EMA/CHMP/187129/2016)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T15:09:42Z","last_updated_date":"2025-12-09T15:09:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-information-package-leaflet-regarding-dextrans-used-excipients-medicinal-products-human-use-ema-chmp-187129-2016_en.pdf"},
    {"id":"71757","name":"Overview of comments received on ICH M11 guideline","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T17:17:52Z","last_updated_date":"2023-05-24T17:17:52Z","reference_number":"EMA/CHMP/ICH/116369/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-m11-guideline_en.pdf"},
    {"id":"71761","name":"Overview of comments received on ICH M11 template","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T17:33:34Z","last_updated_date":"2023-05-24T17:33:34Z","reference_number":"EMA/CHMP/ICH/118289/2023","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-m11-template_en.pdf"},
    {"id":"71839","name":"Overview of comments received on \"Guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations\"","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2025-12-18T11:05:35Z","last_updated_date":"2025-12-18T11:05:35Z","reference_number":"(EMA/CHMP/72790/2024)","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-allergen-products-development-immunotherapy-allergy-diagnosis-moderate-low-sized-study-populations_en.pdf"},
    {"id":"72290","name":"Overview of comments received on guideline on the pharmaceutical quality of inhalation and nasal medicinal products","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T13:05:05Z","last_updated_date":"2026-01-27T13:05:05Z","reference_number":"EMA/CHMP/QWP/341175/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-pharmaceutical-quality-inhalation-nasal-medicinal-products_en.pdf"},
    {"id":"72291","name":"Overview of comments received on guideline on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease of the lower extremities","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T13:46:08Z","last_updated_date":"2026-01-27T13:46:08Z","reference_number":"EMA/372496/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-peripheral-arterial-occlusive-disease-lower-extremities_en.pdf"},
    {"id":"72307","name":"Overview of comments received on ICH M11 technical specification","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T11:06:30Z","last_updated_date":"2023-05-24T11:06:30Z","reference_number":"EMA/CHMP/ICH/778800/2022","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-m11-technical-specification_en.pdf"},
    {"id":"72323","name":"Overview of comments received on Q&A regarding co-processed excipients used in solid oral dosage forms H and V (EMA/CHMP/CVMP/QWP/422493/2024)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-01-28T13:59:22Z","last_updated_date":"2026-02-16T11:18:00Z","reference_number":"EMA/382821/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-qa-regarding-co-processed-excipients-used-solid-oral-dosage-forms-h-v-ema-chmp-cvmp-qwp-422493-2024_en.xlsx"},
    {"id":"72333","name":"Overview of comments received on on ICH Q3E guideline and supporting documentation for extractables and leachables (EMA/CHMP/ICH/236669/2025 and EMA/CHMP/ICH/236668/2025)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-01-28T15:47:34Z","last_updated_date":"2026-04-09T15:15:00Z","reference_number":"EMA/2613/2026 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-q3e-guideline-supporting-documentation-extractables-leachables-ema-chmp-ich-236669-2025-ema-chmp-ich-236668-2025_en.pdf"},
    {"id":"72410","name":"Overview of comments received on chapter 9 of guideline on epidemiological data on blood transmissible infections","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-02-04T09:12:53Z","last_updated_date":"2026-02-04T09:12:53Z","reference_number":"EMA/CHMP/BWP/548524/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-chapter-9-guideline-epidemiological-data-blood-transmissible-infections_en.xlsx"},
    {"id":"72439","name":"Comments received from public consultation on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations III: Pregnant and breastfeeding women (EMA/653036/2019)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-02-06T17:12:46Z","last_updated_date":"2026-02-06T17:12:46Z","reference_number":"EMA/473607/2020","document_url":"https://www.ema.europa.eu/en/documents/comments/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-iii-pregnant-breastfeeding-women-ema-653036-2019_en.pdf"},
    {"id":"72567","name":"Overview of comments received on ICH E20 Guideline on adaptive designs for clinical trials (EMA/CHMP/ICH/206586/2025)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-02-16T10:45:32Z","last_updated_date":"2026-02-16T10:45:32Z","reference_number":"EMA/389217/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-e20-guideline-adaptive-designs-clinical-trials-ema-chmp-ich-206586-2025_en.pdf"},
    {"id":"72618","name":"Overview of comments received on guideline on the risk management requirements for elemental impuritites in veterinary medicinal products","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-02-20T09:24:08Z","last_updated_date":"2026-02-20T09:24:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-risk-management-requirements-elemental-impuritites-veterinary-medicinal-products_en.pdf"},
    {"id":"72638","name":"Overview of comments on ICH M4Q(R2) : Guideline on the Common Technical Document for the registration of pharmaceuticals for human use - Quality - Step 2b","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-02-20T16:24:09Z","last_updated_date":"2026-02-20T16:24:09Z","reference_number":"EMA/356466/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-ich-m4qr2-guideline-common-technical-document-registration-pharmaceuticals-human-use-quality-step-2b_en.pdf"},
    {"id":"73012","name":"Overview of comments received on the draft reflection paper on the qualification of non-mutagenic impurities","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-03-13T15:10:52Z","last_updated_date":"2026-03-13T15:10:52Z","reference_number":"EMA/CHMP/41390/2026","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-reflection-paper-qualification-non-mutagenic-impurities_en.xlsx"},
    {"id":"73127","name":"Overview of comments received on the draft Qualification opinion for Molecule-independent device bridging approach (MIDBA)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-03-20T10:15:12Z","last_updated_date":"2026-03-20T10:15:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-qualification-opinion-molecule-independent-device-bridging-approach-midba_en.pdf"},
    {"id":"73230","name":"Overview of comments received on ‘Melatonin prolonged release tablets 2 mg product-specific bioequivalence guidance’ (EMA/CHMP/226444/2025)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T08:15:52Z","last_updated_date":"2026-03-27T08:15:52Z","reference_number":"EMA/32320/2026","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-melatonin-prolonged-release-tablets-2-mg-product-specific-bioequivalence-guidance-ema-chmp-226444-2025_en.pdf"},
    {"id":"73381","name":"Overview of comments received on guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Revision 2","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-04-09T13:40:04Z","last_updated_date":"2026-04-09T13:40:04Z","reference_number":"EMA/58860/2026","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-clinical-investigation-human-normal-immunoglobulin-subcutaneous-or-intramuscular-administration-scig-imig-revision-2_en.pdf"},
    {"id":"73382","name":"Overview of comments received on guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration (SCIg/IMIg) - Revision 2","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-04-09T13:45:00Z","last_updated_date":"2026-04-09T13:45:00Z","reference_number":"EMA/58859/2026","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-core-smpc-human-normal-immunoglobulin-subcutaneous-intramuscular-administration-scig-imig-revision-2_en.pdf"},
    {"id":"73731","name":"Overview of comments received on draft guideline on the development and manufacture of synthetic peptides","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-05-12T16:46:17Z","last_updated_date":"2026-05-12T16:46:17Z","reference_number":"EMA/66185/2026","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-development-manufacture-synthetic-peptides_en.pdf"},
    {"id":"73947","name":"Overview of comments received on \"Guideline on the requirements for demonstrating therapeutic equivalence between orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease (COPD)\"","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T10:36:53Z","last_updated_date":"2026-06-03T10:36:53Z","reference_number":"EMA/CHMP/225697/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-guideline-requirements-demonstrating-therapeutic-equivalence-between-orally-inhaled-products-oip-asthma-chronic-obstructive-pulmonary-disease-copd_en.pdf-0"},
    {"id":"74134","name":"Overview of comments on draft reflection paper on data recommendations for herbal medicinal products and traditional herbal medicinal products used in children and adolescents","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-06-17T10:02:50Z","last_updated_date":"2026-06-17T10:02:50Z","reference_number":"MA/HMPC/358954/2025","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-draft-reflection-paper-data-recommendations-herbal-medicinal-products-traditional-herbal-medicinal-products-used-children-adolescents_en.pdf"},
    {"id":"74248","name":"Overview of comments received on on ICH E22 guideline on general considerations for patient preference studies (EMA/CHMP/ ICH/371537/2025)","type":"comments","status":"unknown","consultation_date":"","first_published_date":"2026-06-24T13:01:30Z","last_updated_date":"2026-06-24T13:01:30Z","reference_number":"EMA/87420/2026","document_url":"https://www.ema.europa.eu/en/documents/comments/overview-comments-received-ich-e22-guideline-general-considerations-patient-preference-studies-ema-chmp-ich-371537-2025_en.pdf"},
    {"id":"2434","name":"Overview of comments received on draft guideline on the development of products for specifc immunotheray for the treatment of allergic disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-06-23T02:00:00Z","last_updated_date":"2008-06-23T02:00:00Z","reference_number":"EMEA/CHMP/EWP/330620/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-development-products-specifc-immunotheray-treatment-allergic-disease_en.pdf"},
    {"id":"2453","name":"Letter of invitation to tender - Electronic books/e-books - Lots 1&2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-03T00:00:00Z","last_updated_date":"2012-01-03T00:00:00Z","reference_number":"EMA/954391/2011","document_url":"https://www.ema.europa.eu/en/documents/other/letter-invitation-tender-electronic-bookse-books-lots-12_en.pdf"},
    {"id":"2458","name":"Joint European Commission / European Medicines Agency document: Priorities for implementation of the regulation on medicinal products for paediatric use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-01T02:00:00Z","last_updated_date":"2006-09-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/joint-european-commission-european-medicines-agency-document-priorities-implementation-regulation-medicinal-products-paediatric-use_en.pdf"},
    {"id":"2475","name":"Annex D Draft Framework Services Contract - Lot 6","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-01T02:00:00Z","last_updated_date":"2008-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-d-draft-framework-services-contract-lot-6_en.pdf"},
    {"id":"2478","name":"Overview of comments received on the Core SPC for human Anti-D immunoglobulin for intramuscular use CPMP/BPWG/574/99 Rev.1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-13T02:09:21Z","last_updated_date":"2007-07-13T02:09:21Z","reference_number":"EMEA/CHMP/BPWP/72151/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-core-spc-human-anti-d-immunoglobulin-intramuscular-use-cpmpbpwg57499-rev1_en.pdf"}    {"id":"2480","name":"Technical specifications - Annex IV - Draft framework service contract - EMA/2012/18/HR Procurement procedure for medical services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-iv-draft-framework-service-contract-ema201218hr-procurement-procedure-medical-services_en.pdf"},
    {"id":"2492","name":"Withdrawal letter : Stalevo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-stalevo_en.pdf"},
    {"id":"2517","name":"Procedural announcements - CHMP meeting 14-17 November 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-11-18T13:02:00Z","last_updated_date":"2011-11-18T13:02:00Z","reference_number":"EMA/CHMP/877159/2011","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-announcements-chmp-meeting-14-17-november-2011_en.pdf"},
    {"id":"2533","name":"Outcome of Management Board written procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/535239/2010","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-management-board-written-procedures_en.pdf"},
    {"id":"2542","name":"Management Board meeting dates 2015","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-06-19T14:30:00Z","last_updated_date":"2014-06-19T14:30:00Z","reference_number":"EMA/MB/226104/2014","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2015_en.pdf"},
    {"id":"2545","name":"Breach of trust procedure for competing interests and disclosure of confidential information by European Medicines Agency’s scientific committees’ members and experts","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-04-03T21:01:00Z","last_updated_date":"2025-12-18T10:08:00Z","reference_number":"EMA/154320/2012 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/breach-trust-procedure-competing-interests-disclosure-confidential-information-european-medicines-agencys-scientific-committees-members-experts_en.pdf"},
    {"id":"2548","name":"Declaration of interests: Nathalie Rampal Olmedo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-30T17:00:00Z","last_updated_date":"2024-07-26T17:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-nathalie-rampal-olmedo_en.pdf"},
    {"id":"2553","name":"Start of Community reviews - CHMP meeting of 22-25 April 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T17:02:00Z","last_updated_date":"2014-04-25T17:02:00Z","reference_number":"EMA/245817/2014","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-22-25-april-2014_en.pdf"},
    {"id":"2571","name":"Withdrawal letter : Taxotere","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T01:00:00Z","last_updated_date":"2008-11-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-taxotere_en.pdf"},
    {"id":"2585","name":"Questions and answers on the compassionate use of medicines in the European Union","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-01-21T00:09:21Z","last_updated_date":"2010-01-21T00:09:21Z","reference_number":"EMEA/72144/2006 (rev)","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-compassionate-use-medicines-european-union_en.pdf"},
    {"id":"2601","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes for the prevention of cytomegalovirus dis...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T12:30:00Z","last_updated_date":"2015-02-23T12:30:00Z","reference_number":"EMA/627266/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-covalently-closed-dna-plasmids-coding-cytomegalovirus-phosphoprotein-65-and-glycoprotein-b-genes-prevention-cytomegalovirus-dis_en.pdf"},
    {"id":"2608","name":"European Medicines Agency's 20th anniversary - Timeline","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-26T01:00:00Z","last_updated_date":"2015-01-29T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-20th-anniversary-timeline_en.pdf"},
    {"id":"2611","name":"Guidelines on good pharmacovigilance practices: Introductory cover note to finalisation of the first seven modules and public consultation of draft modules III and X","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:24:00Z","last_updated_date":"2012-06-25T19:24:00Z","reference_number":"EMA/426200/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-introductory-cover-note-finalisation-first-seven-modules-and-public-consultation-draft-modules-iii-and-x_en.pdf"},
    {"id":"2620","name":"Outcome of written procedures finalised during the period from 1 September 2013 to 21 November 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T11:30:00Z","last_updated_date":"2013-12-17T11:30:00Z","reference_number":"EMA/MB/622839/2013 Noted","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-1-september-2013-21-november-2013_en.pdf"},
    {"id":"2625","name":"Guideline on good pharmacovigilance practices: Introductory cover note, last updated with final new module on risk minimisation measures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T10:30:00Z","last_updated_date":"2014-02-28T10:30:00Z","reference_number":"EMA/61203/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guideline-good-pharmacovigilance-practices-introductory-cover-note-last-updated-final-new-module-risk-minimisation-measures_en.pdf"},
    {"id":"2646","name":"Letter of support for molecular imaging of the dopamine transporter biomarker as an enrichment biomarker for clinical trials for early Parkinson's disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T15:58:00Z","last_updated_date":"2016-10-07T15:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-molecular-imaging-dopamine-transporter-biomarker-enrichment-biomarker-clinical-trials-early-parkinsons-disease_en.pdf"},
    {"id":"2708","name":"Declaration of interests: Manuel Haas","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:59Z","last_updated_date":"2018-05-03T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-manuel-haas_en.pdf"},
    {"id":"2711","name":"Outcome of written procedures finalised during the period from 22 November 2013 to 21 February 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-25T13:30:00Z","last_updated_date":"2014-03-25T13:30:00Z","reference_number":"EMA/MB/9624/2014 Noted","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-22-november-2013-21-february-2014_en.pdf"},
    {"id":"2732","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T13:15:00Z","last_updated_date":"2011-12-22T13:15:00Z","reference_number":"EMA/MB/239263/2011","document_url":"https://www.ema.europa.eu/en/documents/other/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures_en.pdf"},
    {"id":"2740","name":"Khaled El Emam (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/khaled-el-emam-doi_en.pdf"},
    {"id":"2741","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting 18-21 November 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-11-27T12:25:00Z","last_updated_date":"2013-11-27T12:25:00Z","reference_number":"EMA/710483/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-18-21-november-2013_en.pdf"},
    {"id":"2747","name":"European Medicines Agency opinions on human and veterinary medicines: 1995-2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-26T01:00:00Z","last_updated_date":"2015-01-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-opinions-human-and-veterinary-medicines-1995-2014_en.pdf"},
    {"id":"2774","name":"Fourth report on the progress of interaction with patients’ and consumers’ organisations","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/MB/744981/2011","document_url":"https://www.ema.europa.eu/en/documents/other/fourth-report-progress-interaction-patients-and-consumers-organisations_en.pdf"},
    {"id":"2788","name":"Pathogen-specific database: Anthrax","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-anthrax_en.pdf"},
    {"id":"2789","name":"Summary of transfers of appropriations in the budget 2008 and 2009 - Management Board meeting: 4-5 March 2009","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-03-05T00:09:21Z","last_updated_date":"2009-03-05T00:09:21Z","reference_number":"EMEA/MB/649766/2008","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2008-and-2009-management-board-meeting-4-5-march-2009_en.pdf"},
    {"id":"2831","name":"Commission Regulation (EU) No 220/2013 of 13 March 2013 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-30T11:10:02Z","last_updated_date":"2013-03-27T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/commission-regulation-eu-no-2202013-13-march-2013-amending-council-regulation-ec-no-29795-regards-adjustment-fees-european-medicines-agency-inflation-rate_en.pdf"},
    {"id":"2835","name":"Questions and answers on the consultation procedure to the European Medicines Agency by notified bodies on an ancillary medicinal substance or an ancillary human blood derivative incorporated in a medical device","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T15:00:00Z","last_updated_date":"2024-12-17T14:20:00Z","reference_number":"EMA/144066/2021 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-consultation-procedure-european-medicines-agency-notified-bodies-ancillary-medicinal-substance-or-ancillary-human-blood-derivative-incorporated-medical-device_en.pdf"},
    {"id":"2845","name":"PDCO meeting dates for 2016, 2017 and 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T12:45:00Z","last_updated_date":"2018-03-14T16:00:00Z","reference_number":"EMA/PDCO/393174/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/pdco-meeting-dates-2016-2017-and-2018_en.pdf"},
    {"id":"2850","name":"Declaration of interests: Petri Paakkonen","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-02-02T16:56:00Z","last_updated_date":"2025-08-01T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-petri-paakkonen_en.pdf"},
    {"id":"2858","name":"eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) bulk update manager","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-10T01:00:00Z","last_updated_date":"2014-12-17T16:00:00Z","reference_number":"EMA/623491/2014","document_url":"https://www.ema.europa.eu/en/documents/other/extended-eudravigilance-medicinal-product-dictionary-xevmpd-bulk-update-manager_en.pdf"},
    {"id":"2860","name":"Position paper on the non-acceptability of replacement of pivotal clinical trials in cases of GCP non-compliance in the context of marketing authorisation applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-11-30T16:30:00Z","last_updated_date":"2015-11-30T16:30:00Z","reference_number":"EMA/448853/2015","document_url":"https://www.ema.europa.eu/en/documents/other/position-paper-non-acceptability-replacement-pivotal-clinical-trials-cases-gcp-non-compliance-context-marketing-authorisation-applications_en.pdf"},
    {"id":"2862","name":"Overview of comments received on draft scientific guidance on post-authorisation efficacy studies - First version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T18:11:00Z","last_updated_date":"2016-12-20T18:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-scientific-guidance-post-authorisation-efficacy-studies-first-version_en.pdf"},
    {"id":"2885","name":"Declaration of interests: Gonzague Huet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:05Z","last_updated_date":"2016-09-08T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-gonzague-huet_en.pdf"},
    {"id":"2895","name":"Summary on compassionate use for Tamiflu IV","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-05-06T02:00:00Z","last_updated_date":"2013-08-30T17:52:00Z","reference_number":"EMA/CHMP/780707/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-tamiflu-iv_en.pdf"},
    {"id":"2933","name":"Guidelines and concept papers adopted during the CHMP meeting 15-18 October 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T14:29:00Z","last_updated_date":"2012-10-19T14:29:00Z","reference_number":"EMA/CHMP/539798/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-15-18-october-2012_en.pdf"},
    {"id":"2950","name":"NRG position paper re-use of invented names of medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/648795/2009","document_url":"https://www.ema.europa.eu/en/documents/other/nrg-position-paper-re-use-invented-names-medicinal-products_en.pdf"},
    {"id":"3086","name":"Overview of comments received on ' Guideline on Clinical Investigation of Medicinal Products in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-22T12:00:00Z","last_updated_date":"2012-11-22T12:00:00Z","reference_number":"EMA/CHMP/700490/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease-copd_en.pdf"},
    {"id":"3087","name":"Guidelines and concept papers adopted at the CHMP meeting 22-25 April 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-29T17:40:00Z","last_updated_date":"2014-04-29T17:40:00Z","reference_number":"EMA/124006/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-chmp-meeting-22-25-april-2014_en.pdf"},
    {"id":"3090","name":"Efpia info day 2000 minus 2 - performance indicators of the Centralised Procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"1998-11-20T00:00:00Z","last_updated_date":"1998-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/efpia-info-day-2000-minus-2-performance-indicators-centralised-procedure_en.pdf"},
    {"id":"3093","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with final module VII revision 1 on PSURs and considerations I on vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-12T11:00:00Z","last_updated_date":"2013-12-12T11:00:00Z","reference_number":"EMA/757334/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-final-module-vii-revision-1-psurs-and-considerations-i-vaccines_en.pdf"},
    {"id":"3110","name":"Draft EMEA pandemic influenza crisis management plan for the evaluation and maintenance of pandemic influenza vaccines and antivirals","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-11-14T00:09:21Z","last_updated_date":"2005-11-14T00:09:21Z","reference_number":"EMEA/397403/2005","document_url":"https://www.ema.europa.eu/en/documents/other/draft-emea-pandemic-influenza-crisis-management-plan-evaluation-and-maintenance-pandemic-influenza-vaccines-and-antivirals_en.pdf"},
    {"id":"3116","name":"Overview of comments received on 'position paper on potential medication errors in the context of benefit-risk balance and risk-minimisation measures'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T16:55:00Z","last_updated_date":"2013-06-07T16:55:00Z","reference_number":"EMA/CHMP/277592/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-position-paper-potential-medication-errors-context-benefit-risk-balance-and-risk-minimisation-measures_en.pdf"},
    {"id":"3123","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 15-18 October 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-25T13:40:00Z","last_updated_date":"2012-10-25T13:40:00Z","reference_number":"EMA/CHMP/539797/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-during-chmp-meeting-15-18-october-2012_en.pdf"},
    {"id":"3124","name":"Public consultation on new EMEA transparency initiatives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2000-02-28T01:00:00Z","last_updated_date":"2000-02-28T01:00:00Z","reference_number":"EMEA/D/6135/00","document_url":"https://www.ema.europa.eu/en/documents/other/public-consultation-new-emea-transparency-initiatives_en.pdf"},
    {"id":"3137","name":"CTAG3: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on rules of engagement - Draft advice version 1.0 – including comments received on this version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-advice-european-medicines-agency-clinical-trial-advisory-group-rules-engagement-draft-advice-version-10-including-comments-received-version_en.pdf"},
    {"id":"3138","name":"Declaration of interests: Sonia Ribeiro","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-08T02:00:00Z","last_updated_date":"2025-08-01T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-sonia-ribeiro_en.pdf"},
    {"id":"3143","name":"Questions and answers on 'Guideline on the environmental risk assessment of medicinal products for human use' - First version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-11T02:00:00Z","last_updated_date":"2011-04-11T02:00:00Z","reference_number":"EMA/CHMP/SWP/44609/2010","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-guideline-environmental-risk-assessment-medicinal-products-human-use-first-version_en.pdf"},
    {"id":"3149","name":"Renewal of the Cooperation Agreement between the National Competent Authorities and the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-26T14:10:00Z","last_updated_date":"2015-03-26T14:10:00Z","reference_number":"EMA/MB/99041/2015","document_url":"https://www.ema.europa.eu/en/documents/other/renewal-cooperation-agreement-between-national-competent-authorities-and-european-medicines-agency_en.pdf"},
    {"id":"3169","name":"Letter of invitation to tender - EMA/2012/01/A-FI-AC for banking services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-21T11:51:00Z","last_updated_date":"2012-06-21T11:51:00Z","reference_number":"EMA/388284/2012","document_url":"https://www.ema.europa.eu/en/documents/other/letter-invitation-tender-ema201201a-fi-ac-banking-services_en.pdf"},
    {"id":"3171","name":"Timetable: Post-authorisation measure (PAM) Paediatric art. 46 submission - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T12:40:00Z","last_updated_date":"2025-09-24T12:12:00Z","reference_number":"EMA/267769/2016 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-post-authorisation-measure-pam-paediatric-art-46-submission-atmp_en.xlsx"},
    {"id":"3179","name":"Declaration of interests: Caroline Maignen","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-16T01:00:00Z","last_updated_date":"2015-09-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-caroline-maignen_en.pdf"},
    {"id":"3190","name":"Uppsala Monitoring Centre (UMC) reply to letter of arrangement between the European Medicines Agency and the UMC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/uppsala-monitoring-centre-umc-reply-letter-arrangement-between-european-medicines-agency-and-umc_en.pdf"},
    {"id":"3196","name":"ICH individual case safety report (ICSR) schema files","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-27T01:00:00Z","last_updated_date":"2015-10-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ich-individual-case-safety-report-icsr-schema-files_en.zip"},
    {"id":"3197","name":"European Medicines Agency splitting of the full presentation name of the medicinal product best practice: procedure and principles to handle product name in the EudraVigilance Medicinal Product Dictionary (XEVMPD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T14:00:00Z","last_updated_date":"2016-01-25T16:45:00Z","reference_number":"EMA/327516/2014 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-splitting-full-presentation-name-medicinal-product-best-practice-procedure-and-principles-handle-product-name-eudravigilance-medicinal-product-dictionary-xevmpd_en.pdf"},
    {"id":"3207","name":"Overview of comments received on 'European Medicines Agency recommendation on the procedural aspects and dossier requirements for the consultation to the European Medicines Agency by a notified body on an ancillary medic...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T16:26:00Z","last_updated_date":"2012-02-27T16:26:00Z","reference_number":"EMA/CHMP/92924/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-european-medicines-agency-recommendation-procedural-aspects-and-dossier-requirements-consultation-european-medicines-agency-notified-body-ancillary-medic_en.pdf"},
    {"id":"3213","name":"Open clinical data - benefits for public health","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T17:00:00Z","last_updated_date":"2016-10-20T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/open-clinical-data-benefits-public-health_en.pdf"},
    {"id":"3215","name":"Information on benefit-risk of medicines: patients', consumers' and healthcare professionals' expectations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-10T02:09:21Z","last_updated_date":"2009-07-10T02:09:21Z","reference_number":"EMEA/40926/2009","document_url":"https://www.ema.europa.eu/en/documents/other/information-benefit-risk-medicines-patients-consumers-and-healthcare-professionals-expectations_en.pdf"},
    {"id":"3245","name":"Conference announcement - 10 years of the Orphan Regulation in Europe","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-04T01:00:00Z","last_updated_date":"2010-02-04T01:00:00Z","reference_number":"EMA/815144/2009","document_url":"https://www.ema.europa.eu/en/documents/other/conference-announcement-10-years-orphan-regulation-europe_en.pdf"},
    {"id":"3261","name":"Letter of support to explore clinical outcomes assessments utility to measure clinical symptoms in people with autism spectrum disorders (ASD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T12:00:00Z","last_updated_date":"2015-12-09T12:00:00Z","reference_number":"EMA/794457/2015","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-explore-clinical-outcomes-assessments-utility-measure-clinical-symptoms-people-autism-spectrum-disorders-asd_en.pdf"},
    {"id":"3275","name":"Opinions on safety variations / periodic safety update reports adopted at the CHMP meeting 22-25 July 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T17:00:00Z","last_updated_date":"2013-08-21T17:00:00Z","reference_number":"EMA/CHMP/241121/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-22-25-july-2013_en.pdf"},
    {"id":"3276","name":"CTAG5: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on legal aspects - Meeting 1 summary overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag5-advice-european-medicines-agency-clinical-trial-advisory-group-legal-aspects-meeting-1-summary-overview_en.pdf"},
    {"id":"3297","name":"Declaration of interests - Paolo Rossi","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-paolo-rossi_en.pdf"},
    {"id":"3299","name":"Appendices to guideline on epidemiological data on blood transmissible infections - Revision 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-03-01T11:13:00Z","last_updated_date":"2016-03-01T11:13:00Z","reference_number":"EMA/735037/2015 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/appendices-guideline-epidemiological-data-blood-transmissible-infections-revision-1_en.doc"},
    {"id":"3302","name":"Withdrawal letter: Erbitux (cetuximab)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-12T02:00:00Z","last_updated_date":"2012-10-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-erbitux-cetuximab_en.pdf"},
    {"id":"3308","name":"Declaration of interests - David Coghill","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-david-coghill_en.pdf"},
    {"id":"3315","name":"Organisational matters: adopted at the CHMP meeting 18-21 November 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-11-27T12:25:00Z","last_updated_date":"2013-11-27T12:25:00Z","reference_number":"EMA/710477/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-adopted-chmp-meeting-18-21-november-2013_en.pdf"},
    {"id":"3317","name":"Overview of comments received on draft guideline on ankylosing spondylitis (CPMP/EWP/4891/03) - First version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/EWP/537007/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-ankylosing-spondylitis-cpmpewp489103-first-version_en.pdf"},
    {"id":"3336","name":"Kristian Svendsen (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/kristian-svendsen-cv_en.pdf"},
    {"id":"3357","name":"Overview of comments received on draft EudraVigilance access policy and implemented amendments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-08T17:50:16Z","last_updated_date":"2011-07-08T17:50:16Z","reference_number":"EMA/432253/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-eudravigilance-access-policy-and-implemented-amendments_en.pdf"},
    {"id":"3367","name":"Principal documents taken into account for the preparation of procedures for GCP inspections requested by the CHMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2022-02-18T13:35:00Z","reference_number":"EMA/30963/2022","document_url":"https://www.ema.europa.eu/en/documents/other/principal-documents-taken-account-preparation-procedures-gcp-inspections-requested-chmp_en.pdf"},
    {"id":"3373","name":"Diplomatic Notes exchanged on completion of the preparatory work 28 April 2004: European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-04-28T02:00:00Z","last_updated_date":"2004-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/diplomatic-notes-exchanged-completion-preparatory-work-28-april-2004-european-commission_en.pdf"},
    {"id":"3395","name":"Overview of comments received on “Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia”","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T17:00:00Z","last_updated_date":"2014-03-28T17:00:00Z","reference_number":"EMA/652909/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-development-medicinal-products-intended-treatment-chronic-primary-immune-thrombocytopenia_en.pdf"},
    {"id":"3401","name":"European Medicines Agency Human Scientific Committee’s Working Party with Healthcare Professionals’ Organisations (HCPWP) - List of participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T17:00:00Z","last_updated_date":"2013-07-12T17:00:00Z","reference_number":"EMA/301753/2013","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-list-participants_en.pdf"},
    {"id":"3406","name":"An overview of field safety data from the EU for Bluetongue virus vaccines serotype 8 emerging from the 2008 national vaccination campaigns","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-02-20T00:09:21Z","last_updated_date":"2009-02-20T00:09:21Z","reference_number":"EMEA/CVMP/652019/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-field-safety-data-eu-bluetongue-virus-vaccines-serotype-8-emerging-2008-national-vaccination-campaigns_en.pdf"},
    {"id":"3412","name":"Overview of comments received on HMPC guideline on the assessment of clinical safety and efficacy in the preparation of community herbal monographs for well-established and of community herbal monographs / entries to the...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-07T02:00:00Z","last_updated_date":"2006-09-07T02:00:00Z","reference_number":"EMEA/HMPC/314947/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-hmpc-guideline-assessment-clinical-safety-and-efficacy-preparation-community-herbal-monographs-well-established-and-community-herbal-monographs-entries_en.pdf"},
    {"id":"3452","name":"Reinforcing patient safety in Europe - Flyer","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-27T02:00:00Z","last_updated_date":"2011-04-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/reinforcing-patient-safety-europe-flyer_en.pdf"},
    {"id":"3461","name":"Opinions on safety variations / periodic safety update reports adopted at the CHMP meeting of 24-27 June 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-08T02:00:00Z","last_updated_date":"2013-07-09T19:30:00Z","reference_number":"EMA/CHMP/240801/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-24-27-june-2013_en.pdf"},
    {"id":"3463","name":"Statement of authority and confidentiality commitment from the United States Food and drug Administration (FDA) not publicly disclose non-public information shared by the European Commission's Directorate-General for Hea...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-23T12:00:00Z","last_updated_date":"2017-08-23T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/statement-authority-and-confidentiality-commitment-united-states-food-and-drug-administration-fda-not-publicly-disclose-non-public-information-shared-european-commissions-directorate-general-hea_en.pdf"},
    {"id":"3472","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 18-21 March 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T14:20:00Z","last_updated_date":"2013-04-04T17:49:00Z","reference_number":"EMA/CHMP/127683/2013 Corr","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-18-21-march-2013_en.pdf"},
    {"id":"3490","name":"Overview of comments received on guideline on non-clinical documentation for herbal medicinal products in applications for autorisation (bibliographical and mixed applications) and in applications for simplified registra...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-07-13T02:00:00Z","last_updated_date":"2006-07-13T02:00:00Z","reference_number":"EMEA/HMPC/132154/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-non-clinical-documentation-herbal-medicinal-products-applications-autorisation-bibliographical-and-mixed-applications-and-applications-simplified-registra_en.pdf"},
    {"id":"3494","name":"Renewal of the mandate for the Joint Expert Group on 3Rs (replacement, reduction, refinement)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/95290/2013","document_url":"https://www.ema.europa.eu/en/documents/other/renewal-mandate-joint-expert-group-3rs-replacement-reduction-refinement_en.pdf"},
    {"id":"3497","name":"Declaration of interests: Kristina Larsson","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-01T02:00:00Z","last_updated_date":"2025-08-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-kristina-larsson_en.pdf"},
    {"id":"3506","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Emtricitabine / Propan-2-yl N-[(S)-({[(2R)-1-(6-amino-9H-purin- 9-yl)propan-2-yl]-oxy}methyl)(phenoxy) phosphoryl]-Lalaninate, (2E)-but-2-ened...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/793626/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-emtricitabine-propan-2-yl-n-s-2r-1-6-amino-9h-purin-9-ylpropan-2-yl-oxymethylphenoxy-phosphoryl-lalaninate-2e-2-ened_en.pdf"},
    {"id":"3518","name":"European Commission-Japan mutual recognition agreement: Sectoral annex on good manufacturing practice for medicinal products - Fourth sub-committee meeting, 26 and 27 October 2006: Joint common statement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:00:00Z","last_updated_date":"2006-10-27T02:00:00Z","reference_number":"EMEA/INS/MRA/446188/2006","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-japan-mutual-recognition-agreement-sectoral-annex-good-manufacturing-practice-medicinal-products-fourth-sub-committee-meeting-26-and-27-october-2006-joint-common-statement_en.pdf"},
    {"id":"3546","name":"Clinical-trial advisory groups: Membership overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T13:40:00Z","last_updated_date":"2013-02-21T15:10:00Z","reference_number":"EMA/33488/2013","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trial-advisory-groups-membership-overview_en.pdf"},
    {"id":"3601","name":"Mandate of the European Innovation Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-15T16:00:00Z","last_updated_date":"2025-02-19T15:25:00Z","reference_number":"EMA/402461/2023","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-european-innovation-network_en.pdf"},
    {"id":"3624","name":"European Medicines Agency letter of arrangement with the World Health Organization (WHO) and the Uppsala Monitoring Centre (UMC) for making available EU adverse reaction reports","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-letter-arrangement-world-health-organization-who-and-uppsala-monitoring-centre-umc-making-available-eu-adverse-reaction-reports_en.pdf"},
    {"id":"3628","name":"Withdrawal letter: Osseor","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-osseor_en.pdf"},
    {"id":"3653","name":"Commission Regulation (EU) No 301/2011 of 28 March 2011 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2011-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/commission-regulation-eu-no-3012011-28-march-2011-amending-council-regulation-ec-no-29795-regards-adjustment-fees-european-medicines-agency-inflation-rate_en.pdf"},
    {"id":"3657","name":"European Commission-Japan mutual recognition agreement: Sectoral annex on good manufacturing practice - Second sub-committee meeting, 30 June 2003, joint common statement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-06-30T02:00:00Z","last_updated_date":"2003-06-30T02:00:00Z","reference_number":"EMEA/INS/MRA/JP/85/03","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-japan-mutual-recognition-agreement-sectoral-annex-good-manufacturing-practice-second-sub-committee-meeting-30-june-2003-joint-common-statement_en.pdf"},
    {"id":"3664","name":"Reminder card for Aclasta","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T13:00:00Z","last_updated_date":"2015-03-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/reminder-card-aclasta_en.pdf"},
    {"id":"3675","name":"Summary of transfers of appropriations in the budget 2009 - Management Board meeting 18 March 2010","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/MB/97480/2010","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2009-management-board-meeting-18-march-2010_en.pdf"},
    {"id":"3681","name":"Overview of comments received on draft appendix 2 to the guideline on the evaluation of anticancer medicinal products in man (CPMP/EWP/205/95 Rev.3) on confirmatory studies in haematological malignancies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-03T01:09:21Z","last_updated_date":"2010-03-03T01:09:21Z","reference_number":"EMA/574487/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-appendix-2-guideline-evaluation-anticancer-medicinal-products-man-cpmpewp20595-rev3-confirmatory-studies-haematological-malignancies_en.pdf"},
    {"id":"3700","name":"Dossier requirements for pre-submission procedure: Advanced-therapy medicinal products (ATMP) certification - Submission of application dossiers to the European Medicines Agency and members of the Committee for Advanced ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T20:00:00Z","last_updated_date":"2014-12-10T20:00:00Z","reference_number":"EMA/CAT/655614/2014","document_url":"https://www.ema.europa.eu/en/documents/other/dossier-requirements-pre-submission-procedure-advanced-therapy-medicinal-products-atmp-certification-submission-application-dossiers-european-medicines-agency-and-members-committee-advanced_en.pdf"},
    {"id":"3718","name":"Technical Specifications -  Annex VIII Test: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-viii-test-procurement-procedure-ema201401ph_en.pdf"},
    {"id":"3731","name":"Concept paper on CTD for traditional herbal medicinal products","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-03-09T01:00:00Z","last_updated_date":"2006-03-09T01:00:00Z","reference_number":"EMEA/HMPC/261344/2005","document_url":"https://www.ema.europa.eu/en/documents/other/concept-paper-ctd-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"3785","name":"Guidelines and concept papers adopted during the CHMP meeting 22-25 April 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-02T14:15:00Z","last_updated_date":"2013-05-02T14:15:00Z","reference_number":"EMA/CHMP/184562/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-22-25-april-2013_en.pdf"},
    {"id":"3818","name":"Scientific advice and protocol assistance - Adopted during the CHMP meeting 15-18 October 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T14:29:00Z","last_updated_date":"2012-10-19T14:29:00Z","reference_number":"EMA/CHMP/SAWP/667462/2012","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-15-18-october-2012_en.pdf"},
    {"id":"3830","name":"Draft appendices to draft proposal for an addendum, on transparency, to the 'Functional specifications for the European Union portal and EU database to be audited'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T13:00:00Z","last_updated_date":"2015-01-21T13:00:00Z","reference_number":"EMA/768628/2014","document_url":"https://www.ema.europa.eu/en/documents/other/draft-appendices-draft-proposal-addendum-transparency-functional-specifications-european-union-portal-and-eu-database-be-audited_en.pdf"},
    {"id":"3832","name":"Overview of comments on guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle-stimulating hormone (r-hFSH) (EMA/CHMP/BMWP/671292/2010)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-06T12:00:04Z","last_updated_date":"2013-03-06T12:00:04Z","reference_number":"EMA/92876/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-human-follicle-stimulating-hormone-r-hfsh-emachmpbmwp6712922010_en.pdf"}    {"id":"3850","name":"Overview of comments received on reflection paper on assessment of bioavailability of bound residues in food commodities of animal origin in the context of council regulation (EEC) NO 2377/90","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-09-22T02:00:00Z","last_updated_date":"2008-09-22T02:00:00Z","reference_number":"EMEA/213492/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-assessment-bioavailability-bound-residues-food-commodities-animal-origin-context-council-regulation-eec-no-237790_en.pdf"},
    {"id":"3858","name":"Legacy product data in the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-07T18:10:00Z","last_updated_date":"2013-11-07T18:10:00Z","reference_number":"EMA/656849/2013","document_url":"https://www.ema.europa.eu/en/documents/other/legacy-product-data-extended-eudravigilance-medicinal-product-dictionary-xevmpd_en.pdf"},
    {"id":"3878","name":"Overview of OMS change request process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-08-20T12:54:00Z","last_updated_date":"2019-05-06T17:49:00Z","reference_number":"EMA/440168/2018 Version 2","document_url":"https://www.ema.europa.eu/en/documents/other/overview-oms-change-request-process_en.pdf"},
    {"id":"3889","name":"Annual list of contractor modifications 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-28T17:00:00Z","last_updated_date":"2017-06-28T17:00:00Z","reference_number":"EMA/398274/2017","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contractor-modifications-2016_en.pdf"},
    {"id":"3898","name":"Annua Report 2014 - Veterinary medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-30T02:00:00Z","last_updated_date":"2015-04-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annua-report-2014-veterinary-medicines_en.pdf"},
    {"id":"3910","name":"9-10 June: Sà©minaire sur les dà©veloppements rà©cents en Pharmacovigilance europà©enne et la gestion du risque (Vukovar) - Announcement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-06-09T02:09:21Z","last_updated_date":"2008-06-09T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/9-10-june-sacminaire-sur-les-dacveloppements-raccents-en-pharmacovigilance-europacenne-et-la-gestion-du-risque-vukovar-announcement_en.pdf"},
    {"id":"3917","name":"Public summary of the evaluation of a proposed product-specific\n\nwaiver: Urofollitropin for treatment of female infertility and treatment of\n\nhypogonadotrophic hypogonadism","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T12:30:00Z","last_updated_date":"2015-02-23T12:30:00Z","reference_number":"EMA/66282/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-urofollitropin-treatment-female-infertility-and-treatment-hypogonadotrophic-hypogonadism_en.pdf"},
    {"id":"3918","name":"Rules of procedure of the Advisory Committee on Procurements and Contracts","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/269247/2012","document_url":"https://www.ema.europa.eu/en/documents/other/rules-procedure-advisory-committee-procurements-and-contracts_en.pdf"},
    {"id":"3930","name":"CTAG4: Clinical Trial Advisory Group on good analysis practice - Membership overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag4-clinical-trial-advisory-group-good-analysis-practice-membership-overview_en.pdf"},
    {"id":"3940","name":"Explanatory notes to Chapter 15 (Medicinal products GMP inspection and batch certification) of Annex 1 of EU - Swiss MRA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2002-10-22T02:00:00Z","last_updated_date":"2002-10-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-notes-chapter-15-medicinal-products-gmp-inspection-and-batch-certification-annex-1-eu-swiss-mra_en.pdf"},
    {"id":"3942","name":"Overview of comments received on 'Annex I variation application(s) content for live attenuated influenza vaccines'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-08-08T02:00:00Z","last_updated_date":"2011-08-08T02:00:00Z","reference_number":"EMA/CHMP/BWP/367594/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-annex-i-variation-applications-content-live-attenuated-influenza-vaccines_en.pdf"},
    {"id":"3954","name":"Overview of comments received on 'guideline on the treatment of premenstrual dysphoric disorder (PMDD)'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2011-08-05T02:00:00Z","reference_number":"EMA/71893/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf"},
    {"id":"3960","name":"CTAG5: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on legal aspects - Final advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag5-advice-european-medicines-agency-clinical-trial-advisory-group-legal-aspects-final-advice_en.pdf"},
    {"id":"3969","name":"Pathogen-specific database: Tularemia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-tularemia_en.pdf"},
    {"id":"4020","name":"Concept note – Focus group with invited stakeholders on field efficacy trials in the context of an EU authorisation for veterinary vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-06T02:00:00Z","last_updated_date":"2017-06-06T02:00:00Z","reference_number":"EMA/52857/2017","document_url":"https://www.ema.europa.eu/en/documents/other/concept-note-focus-group-invited-stakeholders-field-efficacy-trials-context-eu-authorisation-veterinary-vaccines_en.pdf"},
    {"id":"4061","name":"Declaration of interests: Paolo Alcini","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T11:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-paolo-alcini_en.pdf"},
    {"id":"4067","name":"Guidelines and concept papers adopted during the CHMP meeting 10-13 December 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-18T17:30:00Z","last_updated_date":"2012-12-18T17:30:00Z","reference_number":"EMA/CHMP/732294/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-10-13-december-2012_en.pdf"},
    {"id":"4080","name":"Update report on the Agency’s European Union Telematics: Operations report (December 2012)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/777362/2012","document_url":"https://www.ema.europa.eu/en/documents/other/update-report-agencys-european-union-telematics-operations-report-december-2012_en.pdf"},
    {"id":"4095","name":"Delivery time frame for the EU portal and EU database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2017-06-16T15:20:00Z","reference_number":"EMA/760345/2015","document_url":"https://www.ema.europa.eu/en/documents/other/delivery-time-frame-eu-portal-and-eu-database_en.pdf"},
    {"id":"4112","name":"Inventory of paediatric therapeutic needs - Infectious diseases","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-05-08T11:30:00Z","last_updated_date":"2014-05-08T11:30:00Z","reference_number":"EMA/PDCO/287222/2012","document_url":"https://www.ema.europa.eu/en/documents/other/inventory-paediatric-therapeutic-needs-infectious-diseases_en.pdf"},
    {"id":"4122","name":"Pathogen specific database: Botulism","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-botulism_en.pdf"},
    {"id":"4132","name":"Overview of comments received on draft guideline on multiple sclerosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-11-16T01:00:00Z","last_updated_date":"2006-11-16T01:00:00Z","reference_number":"CHMP/EWP/438043/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-multiple-sclerosis_en.pdf"},
    {"id":"4169","name":"Anti-fraud strategy revised December 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T17:00:00Z","last_updated_date":"2017-12-15T17:00:00Z","reference_number":"EMA/812072/2017","document_url":"https://www.ema.europa.eu/en/documents/other/anti-fraud-strategy-revised-december-2017_en.pdf"},
    {"id":"4174","name":"Withdrawal letter : Invega","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-12-15T01:00:00Z","last_updated_date":"2008-12-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-invega_en.pdf"},
    {"id":"4183","name":"Points to consider for assessors, inspectors and European Medicines Agency inspection coordinators on the identification of triggers for the selection of applications for routine and for-cause inspections, their investigation and scope of such inspections","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-08-20T18:30:00Z","last_updated_date":"2013-08-20T18:30:00Z","reference_number":"EMA/INS/GCP/167386/2012","document_url":"https://www.ema.europa.eu/en/documents/other/points-consider-assessors-inspectors-european-medicines-agency-inspection-coordinators-identification-triggers-selection-applications-routine-cause-inspections-their-investigation-scope-such_en.pdf"},
    {"id":"4187","name":"Jobs @EMA User guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T13:10:00Z","last_updated_date":"2018-04-18T14:00:00Z","reference_number":"EMA/847592/2017","document_url":"https://www.ema.europa.eu/en/documents/other/jobs-ema-user-guide_en.pdf"},
    {"id":"4203","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: Gems Medium Suite","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-08-07T14:15:00Z","last_updated_date":"2015-08-07T14:15:00Z","reference_number":"EMA/CHMP/737937/2014","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-gems-medium-suite_en.pdf"},
    {"id":"4233","name":"Pre-Qualification Questionnaire (PQQ) for a restricted tender procedure organised by European Medicines Agency (EMEA) maintenance of catering equipment EMEA/2008/55/ISERV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:21Z","last_updated_date":"2008-11-25T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency-emea-maintenance-catering-equipment-emea200855iserv_en.doc"},
    {"id":"4242","name":"High level business consultancy EMA/2013/23/FI - Technical specifications - Annex I costing sheet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications-annex-i-costing-sheet_en.doc"},
    {"id":"4267","name":"Working party on Herbal Medicinal Products: Points to consider on good agricultural and collection practice for starting materials of herbal origin","type":"other","status":"unknown","consultation_date":"","first_published_date":"2002-05-02T02:00:00Z","last_updated_date":"2002-05-02T02:00:00Z","reference_number":"EMEA/HMPWP/31/99 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-points-consider-good-agricultural-and-collection-practice-starting-materials-herbal-origin_en.pdf"},
    {"id":"4275","name":"Questions and answers relating to PQQ Electronic databases -11 lots","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-03T02:00:00Z","last_updated_date":"2008-07-03T02:00:00Z","reference_number":"EMEA/2008/60/DM&P","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-pqq-electronic-databases-11-lots_en.pdf"},
    {"id":"4284","name":"Technical Specifications – Annex VI Service level agreement: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"EMA/90376/2014","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-vi-service-level-agreement-procurement-procedure-ema201401ph_en.pdf"},
    {"id":"4288","name":"Start of Community reviews - CHMP meeting of 18-21 June 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T13:59:00Z","last_updated_date":"2012-06-22T13:59:00Z","reference_number":"EMA/406773/2012","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-18-21-june-2012_en.pdf"},
    {"id":"4315","name":"Overview of comments received on draft guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - First version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-10-18T02:00:00Z","last_updated_date":"2006-10-18T02:00:00Z","reference_number":"EMEA/CHMP/EWP/392476/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-juvenile-idiopathic-arthritis-first-version_en.pdf"},
    {"id":"4341","name":"Annex E Standard Timesheet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-01T02:00:00Z","last_updated_date":"2008-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-e-standard-timesheet_en.pdf"},
    {"id":"4349","name":"Opinions on safety variations / periodic safety update reports adopted at the CHMP meeting 18-21 November 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-11-27T12:25:00Z","last_updated_date":"2013-11-27T12:25:00Z","reference_number":"EMA/710491/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-18-21-november-2013_en.pdf"},
    {"id":"4359","name":"Use of eSubmission Gateway / Web Client extended to new procedure types from 1st of April 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-01T17:40:00Z","last_updated_date":"2014-04-01T17:40:00Z","reference_number":"EMA/71358/2014","document_url":"https://www.ema.europa.eu/en/documents/other/use-esubmission-gateway-web-client-extended-new-procedure-types-1st-april-2014_en.pdf"},
    {"id":"4361","name":"Referral triggered by MAH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-24T02:09:21Z","last_updated_date":"2007-10-24T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/referral-triggered-mah_en.pdf"},
    {"id":"4367","name":"Overview of comments received on draft reflection paper formulations of choice for the paediatric population","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/359361/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-reflection-paper-formulations-choice-paediatric-population_en.pdf"},
    {"id":"4380","name":"Overview of comments received on draft guideline on clinical evaluation of diagnostic agents","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-01-29T01:00:00Z","last_updated_date":"2010-01-29T01:00:00Z","reference_number":"EMA/182470/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-evaluation-diagnostic-agents_en.pdf"},
    {"id":"4382","name":"Extended EudraVigilance Medicinal Product Dictionary e-learning course presentations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T18:00:00Z","last_updated_date":"2016-02-11T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/extended-eudravigilance-medicinal-product-dictionary-e-learning-course-presentations_en.zip"},
    {"id":"4384","name":"Substance, product, organisation, referentials (SPOR) - Application program interface (API) specification (version 1.7)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-15T19:00:00Z","last_updated_date":"2017-03-15T19:00:00Z","reference_number":"EMA/241514/2016","document_url":"https://www.ema.europa.eu/en/documents/other/substance-product-organisation-referentials-spor-application-program-interface-api-specification-version-17_en.pdf"},
    {"id":"4396","name":"Questions and answers: EMA/2012/59/PD - provision of access to databases and other electronic information sources","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T12:00:00Z","last_updated_date":"2013-04-02T12:00:00Z","reference_number":"EMA/87485/2013","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-ema201259pd-provision-access-databases-and-other-electronic-information-sources_en.pdf"},
    {"id":"4403","name":"Guidelines and concept papers adopted during the CHMP meeting 12-15 March 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-16T20:03:27Z","last_updated_date":"2012-03-16T20:03:27Z","reference_number":"EMA/CHMP/162992/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-12-15-march-2012_en.pdf"},
    {"id":"4420","name":"EU Telematics systems in operation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T14:30:00Z","last_updated_date":"2017-10-30T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eu-telematics-systems-operation_en.pdf"},
    {"id":"4427","name":"PRAC strategy on measuring the impact of pharmacovigilance activities","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-04-19T10:03:00Z","last_updated_date":"2022-04-19T10:03:00Z","reference_number":"EMA/590673/2020 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/prac-strategy-measuring-impact-pharmacovigilance-activities_en.pdf"},
    {"id":"4428","name":"Incorporating patients' views during evaluation of benefit-risk by the European Medicines Agency scientific committees","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T12:00:00Z","last_updated_date":"2014-10-24T14:00:00Z","reference_number":"EMA/413422/2013 Rev1","document_url":"https://www.ema.europa.eu/en/documents/other/incorporating-patients-views-during-evaluation-benefit-risk-european-medicines-agency-scientific-committees_en.pdf"},
    {"id":"4450","name":"Organisational matters - CHMP meeting 23-26 June 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-01T16:30:00Z","last_updated_date":"2014-07-01T16:30:00Z","reference_number":"EMA/125354/2014","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-23-26-june-2014_en.pdf"},
    {"id":"4506","name":"Feedback form - Focus group on promotion of pharmacovigilance for food producing animals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/feedback-form-focus-group-promotion-pharmacovigilance-food-producing-animals_en.pdf"},
    {"id":"4511","name":"Mandate, objectives and rules of procedure for the CHMP PG Working Party","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:09:21Z","last_updated_date":"2009-06-25T02:09:21Z","reference_number":"EMEA/CHMP/125959/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-chmp-pg-working-party_en.pdf"},
    {"id":"4518","name":"Declaration of interests: Sylvie Benefice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:13Z","last_updated_date":"2015-09-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-sylvie-benefice_en.pdf"},
    {"id":"4540","name":"Opinions on safety variations adopted at the CHMP meeting 10-13 December 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-18T17:30:01Z","last_updated_date":"2012-12-18T17:30:01Z","reference_number":"EMA/CHMP/732292/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-10-13-december-2012_en.pdf"},
    {"id":"4561","name":"Internal control standards and underlying framework: strengthening control effectiveness","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"EMA/MB/602884/2015","document_url":"https://www.ema.europa.eu/en/documents/other/internal-control-standards-and-underlying-framework-strengthening-control-effectiveness_en.pdf"},
    {"id":"4563","name":"Public bulletin: Veterinary pharmacovigilance 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-02-28T15:30:00Z","last_updated_date":"2013-02-28T15:30:00Z","reference_number":"EMA/CVMP/PhVWP/717241/2012","document_url":"https://www.ema.europa.eu/en/documents/other/public-bulletin-veterinary-pharmacovigilance-2012_en.pdf"},
    {"id":"4572","name":"Download EPS - Species pictograms - Chicken","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-chicken_en.zip"},
    {"id":"4575","name":"Questions and answers relating to restricted tender procedure no. EMA/2012/43/IS – Display-screen-equipment assessments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T15:30:00Z","last_updated_date":"2013-01-03T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-restricted-tender-procedure-no-ema201243is-display-screen-equipment-assessments_en.pdf"},
    {"id":"4614","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 22-25 April 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-02T14:15:00Z","last_updated_date":"2013-05-02T14:15:00Z","reference_number":"EMA/CHMP/184563/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-during-chmp-meeting-22-25-april-2013_en.pdf"},
    {"id":"4615","name":"Workshop on in vitro cytokine release assays: Practical information","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2009-11-18T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-vitro-cytokine-release-assays-practical-information_en.pdf"},
    {"id":"4635","name":"Management Board meeting dates 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/MB/298674/2010","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2011_en.pdf"},
    {"id":"4641","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-juvenile-scleroderma-working-group-pediatric-rheumatology-european-society_en.pdf"},
    {"id":"4646","name":"Overview of comments received on draft reflection paper on markers used for quantitative and qualitative analysis of herbal medicinal products and traditional herbal medicinal products (EMEA/HMPC/253629/2007)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/HMPC/297843/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-reflection-paper-markers-used-quantitative-and-qualitative-analysis-herbal-medicinal-products-and-traditional-herbal-medicinal-products-emeahmpc2536292007_en.pdf"},
    {"id":"4667","name":"European Medicines Agency-Food and Drug Administration good-clinical-practice initiative","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-31T02:09:21Z","last_updated_date":"2009-07-31T02:09:21Z","reference_number":"EMEA/INS/GCP/541006/2008","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-food-and-drug-administration-good-clinical-practice-initiative_en.pdf"},
    {"id":"4689","name":"Overview of Staff Regulation implementing rules signed by the Management Board chair during the period from 7 October 2011 to 15 November 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/MB/723380/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-staff-regulation-implementing-rules-signed-management-board-chair-during-period-7-october-2011-15-november-2012_en.pdf"},
    {"id":"4732","name":"Public consultation on the joint heads of medicines agencies /European medicines agency training project team ‘draft strategy for regulatory and scientific training within the European regulatory network’","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-29T02:00:00Z","last_updated_date":"2009-07-29T02:00:00Z","reference_number":"EMEA/460027/2009","document_url":"https://www.ema.europa.eu/en/documents/other/public-consultation-joint-heads-medicines-agencies-european-medicines-agency-training-project-team-draft-strategy-regulatory-and-scientific-training-within-european-regulatory-network_en.pdf"},
    {"id":"4738","name":"Proposal for amendments of the Management Board rules on the Agency fees for various activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/MB/170391/2009/Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/proposal-amendments-management-board-rules-agency-fees-various-activities_en.pdf"},
    {"id":"4740","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Roxadustat for treatment of anaemia due to chronic disorders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/112432/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-roxadustat-treatment-anaemia-due-chronic-disorders_en.pdf"},
    {"id":"4758","name":"European Review System (EURS): Open invitation to Tender No. EMEA/2006/34/PM and specifications - Version 1.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-08-29T02:00:00Z","last_updated_date":"2006-08-29T02:00:00Z","reference_number":"EMEA/337919/2006","document_url":"https://www.ema.europa.eu/en/documents/other/european-review-system-eurs-open-invitation-tender-no-emea200634pm-and-specifications-version-10_en.pdf"},
    {"id":"4768","name":"Questions and answers on public consultation on implementation of transparency requirements of the European Clinical Trial Regulation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T13:00:00Z","last_updated_date":"2023-10-26T11:36:00Z","reference_number":"EMA/36398/2015","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-public-consultation-implementation-transparency-requirements-european-clinical-trial-regulation_en.pdf"},
    {"id":"4779","name":"Assessment of the paediatric needs - Diabetes (types I and II)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-07-04T02:00:00Z","last_updated_date":"2008-07-04T02:00:00Z","reference_number":"EMEA/224688/2006/rev1","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-diabetes-types-i-and-ii_en.pdf"},
    {"id":"4797","name":"Timetable: Initial (full) marketing authorisation application accelerated assessment timetables","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-05-24T19:30:00Z","last_updated_date":"2026-05-13T15:30:00Z","reference_number":"EMA/339594/2016 Rev. 16","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-initial-full-marketing-authorisation-application-accelerated-assessment-timetables_en.xlsx"},
    {"id":"4798","name":"Frequently asked questions - Travel reimbursement rules for candidates","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T14:10:00Z","last_updated_date":"2018-04-09T16:22:00Z","reference_number":"EMA/407052/2013 ","document_url":"https://www.ema.europa.eu/en/documents/other/frequently-asked-questions-travel-reimbursement-rules-candidates_en.pdf"},
    {"id":"4831","name":"EudraVigilance go-live plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-04T15:40:00Z","last_updated_date":"2017-10-16T11:30:00Z","reference_number":"EMA/399493/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-go-live-plan_en.pdf"},
    {"id":"4837","name":"Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - EMBASE","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T16:37:00Z","last_updated_date":"2024-03-25T16:30:00Z","reference_number":"EMA/517840/2015 Rev 5*","document_url":"https://www.ema.europa.eu/en/documents/other/monitoring-medical-literature-entry-relevant-information-eudravigilance-database-european-medicines-agency-embase_en.pdf"},
    {"id":"4855","name":"Lukasz Kniola (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/lukasz-kniola-doi_en.pdf"},
    {"id":"4859","name":"List of participants of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"EMA/69153/2014","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf"},
    {"id":"4871","name":"Electronic submission of medicinal product information by marketing-authorisation holders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-17T13:00:00Z","last_updated_date":"2016-02-11T12:00:00Z","reference_number":"EMA/736031/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/electronic-submission-medicinal-product-information-marketing-authorisation-holders_sv.pdf"}},
    {"id":"4896","name":"Overview of comments received on draft guideline \"guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-06-09T02:00:00Z","last_updated_date":"2006-06-09T02:00:00Z","reference_number":"EMEA/CHMP/CVMP/QWP/40728/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-guideline-specifications-test-procedures-and-acceptance-criteria-herbal-substances-herbal-preparations-and-herbal-medicinal-productstraditional-herbal_en.pdf"},
    {"id":"4926","name":"Letter of invitation to tender: Procurement procedure EMA/2013/06/PD document delivery services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T11:34:00Z","last_updated_date":"2013-10-17T11:34:00Z","reference_number":"EMA/567603/2013","document_url":"https://www.ema.europa.eu/en/documents/other/letter-invitation-tender-procurement-procedure-ema201306pd-document-delivery-services_en.pdf"},
    {"id":"4935","name":"Redistribution of the UK centrally authorised product portfolio - European Medicines Agency working groups on committees’ operational preparedness","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-04-11T16:00:00Z","last_updated_date":"2018-04-11T16:00:00Z","reference_number":"EMA/17176/2018","document_url":"https://www.ema.europa.eu/en/documents/other/redistribution-uk-centrally-authorised-product-portfolio-european-medicines-agency-working-groups-committees-operational-preparedness_en.pdf"},
    {"id":"4951","name":"List of participants - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting_en.pdf"},
    {"id":"4987","name":"External Service Providers (ESP) for Software Applications: Open Invitation to Tender - EMEA/2008/71/PM-IT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-06-19T02:00:00Z","last_updated_date":"2008-06-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/external-service-providers-esp-software-applications-open-invitation-tender-emea200871pm-it_en.pdf"},
    {"id":"4990","name":"EMA consultation on the proposal of a collaboration framework with Academia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T14:00:00Z","last_updated_date":"2016-02-01T14:00:00Z","reference_number":"EMA/791692/2015","document_url":"https://www.ema.europa.eu/en/documents/other/ema-consultation-proposal-collaboration-framework-academia_en.pdf"},
    {"id":"5018","name":"Announcement of the EMA Management Board - Confirmation of full functionality of the EudraVigilance database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T17:30:00Z","last_updated_date":"2017-05-22T17:30:00Z","reference_number":"EMA/215105/2017","document_url":"https://www.ema.europa.eu/en/documents/other/announcement-ema-management-board-confirmation-full-functionality-eudravigilance-database_en.pdf"},
    {"id":"5037","name":"List of participants - Workshop on development of antimycobacterial medicinal products (to treat Mycobacterium tuberculosis)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"EMA/632391/2016","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-workshop-development-antimycobacterial-medicinal-products-treat-mycobacterium-tuberculosis_en.pdf"},
    {"id":"5053","name":"Answer to the first request from the European Commission for scientific advice on the impact on public health and animal health of the use of antibiotics in animals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-30T14:00:00Z","last_updated_date":"2013-07-30T14:00:00Z","reference_number":"EMA/363834/2013","document_url":"https://www.ema.europa.eu/en/documents/other/answer-first-request-european-commission-scientific-advice-impact-public-health-and-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"5056","name":"Non-automatic carryover 2015 to 2016: Annex","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"Annex to EMA/MB/615629/2015","document_url":"https://www.ema.europa.eu/en/documents/other/non-automatic-carryover-2015-2016-annex_en.pdf"},
    {"id":"5066","name":"Overview of Staff Regulation implementing rules signed by the MB Chair during the period from 27 February 2014 to 13 February 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-26T14:10:00Z","last_updated_date":"2015-03-26T14:10:00Z","reference_number":"EMA/MB/665/2015","document_url":"https://www.ema.europa.eu/en/documents/other/overview-staff-regulation-implementing-rules-signed-mb-chair-during-period-27-february-2014-13-february-2015_en.pdf"},
    {"id":"5071","name":"Guide on access to unpublished documents","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T16:00:00Z","last_updated_date":"2025-10-14T16:05:00Z","reference_number":"EMA/304162/2014 Rev.8","document_url":"https://www.ema.europa.eu/en/documents/other/guide-access-unpublished-documents_en.pdf"},
    {"id":"5100","name":"Renewal of confidentiality arrangement: Letter from Ministry of Health, Labour and Welfare and Pharmaceuticals and Medical Devices Agency to European Commission and European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-02-07T12:00:00Z","last_updated_date":"2013-02-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/renewal-confidentiality-arrangement-letter-ministry-health-labour-welfare-pharmaceuticals-medical-devices-agency-european-commission-european-medicines-agency_en.pdf"},
    {"id":"5119","name":"Summaries of the presentations  - European Medicines Agency workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T17:15:00Z","last_updated_date":"2013-10-07T17:15:00Z","reference_number":"EMA/576938/2013","document_url":"https://www.ema.europa.eu/en/documents/other/summaries-presentations-european-medicines-agency-workshop-clinical-investigation-new-medicines-treatment-multiple-sclerosis_en.pdf"},
    {"id":"5126","name":"Opinions on safety variations adopted at the CHMP meeting of 22-25 April 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-02T14:15:00Z","last_updated_date":"2013-05-02T14:15:00Z","reference_number":"EMA/CHMP/184564/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-22-25-april-2013_en.pdf"},
    {"id":"5160","name":"Questions and answers on the withdrawal of the marketing authorisation application for Movectro","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"EMA/125407/2011","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-movectro_sv.pdf"}},
    {"id":"5163","name":"Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency: \n\nQuestions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-12T02:00:00Z","last_updated_date":"2017-01-05T16:34:00Z","reference_number":"EMA/848710/2016, Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency-questions-and-answers_en.pdf"},
    {"id":"5165","name":"Start of Community reviews - CHMP meeting of 12-15 March 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-16T13:01:00Z","last_updated_date":"2012-03-16T13:01:00Z","reference_number":"EMA/175904/2012","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-12-15-march-2012_en.pdf"},
    {"id":"5221","name":"Overview of comments on 'qualification opinion of low hippocampal volume (atrophy) by magnetic-resonance imaging for use in clinical trials for regulatory purpose in predementia stage of Alzheimer’s disease'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-09T11:43:00Z","last_updated_date":"2011-12-09T11:43:00Z","reference_number":"EMA/879297/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-qualification-opinion-low-hippocampal-volume-atrophy-magnetic-resonance-imaging-use-clinical-trials-regulatory-purpose-predementia-stage-alzheimers-disease_en.pdf"},
    {"id":"5236","name":"Common position between patients’, consumers, and healthcare professionals’ organisations involved in the activities of the European Medicines Agency on:\n\nSupply shortages of medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-10T16:25:00Z","last_updated_date":"2014-02-10T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/common-position-between-patients-consumers-and-healthcare-professionals-organisations-involved-activities-european-medicines-agency-supply-shortages-medicines_en.pdf"},
    {"id":"5263","name":"Practical considerations on the impact of the new pharmaceutical legislation on marketing-authorisation applications via the centralised procedure and centrally authorised medicinal products for veterinary use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-10-17T02:00:00Z","last_updated_date":"2005-10-17T02:00:00Z","reference_number":"EMEA/316976/2005","document_url":"https://www.ema.europa.eu/en/documents/other/practical-considerations-impact-new-pharmaceutical-legislation-marketing-authorisation-applications-centralised-procedure-and-centrally-authorised-medicinal-products-veterinary-use_en.pdf"},
    {"id":"5271","name":"High level business consultancy EMA/2013/23/FI - Technical specifications - Annex V reimbursement of expenses","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications-annex-v-reimbursement-expenses_en.pdf"},
    {"id":"5277","name":"European Union Telematics strategy 2014-2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-30T16:00:00Z","last_updated_date":"2014-09-30T16:00:00Z","reference_number":"EMA/289808/2014","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-telematics-strategy-2014-2016_en.pdf"},
    {"id":"5340","name":"User registration steps for EU QPPVs or trusted deputies (for the purpose of the EudraVigilance registration process) - Annex I","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T17:30:00Z","last_updated_date":"2018-03-14T11:27:00Z","reference_number":"EMA/260914/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/user-registration-steps-eu-qppvs-or-trusted-deputies-purpose-eudravigilance-registration-process-annex-i_en.pdf"}    {"id":"5374","name":"Pandemrix: Labelling","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-15T01:00:00Z","last_updated_date":"2010-02-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pandemrix-labelling_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/pandemrix-labelling_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/pandemrix-labelling_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/pandemrix-labelling_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/pandemrix-labelling_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/pandemrix-labelling_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/pandemrix-labelling_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/pandemrix-labelling_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/pandemrix-labelling_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/pandemrix-labelling_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/pandemrix-labelling_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/pandemrix-labelling_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/pandemrix-labelling_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/pandemrix-labelling_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/pandemrix-labelling_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/pandemrix-labelling_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/pandemrix-labelling_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/pandemrix-labelling_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/pandemrix-labelling_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/pandemrix-labelling_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/pandemrix-labelling_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/pandemrix-labelling_sv.pdf"}},
    {"id":"5378","name":"Veterinary information-technology and data strategy, roadmap and management overview endorsed by European Union Telematics Management Board on 28 May 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T19:30:00Z","last_updated_date":"2014-09-26T19:30:00Z","reference_number":"EMA/717773/2013","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-information-technology-and-data-strategy-roadmap-and-management-overview-endorsed-european-union-telematics-management-board-28-may-2014_en.pdf"},
    {"id":"5398","name":"Recognition criteria for self assessment - Enpr-EMA: International Pediatric Transplant Association (IPTA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2011-01-07T00:31:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-international-pediatric-transplant-association-ipta_en.pdf"},
    {"id":"5400","name":"Questions and answers: European Medicines Agency-Food and Drug Administration good-clinical-practice initiative","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-08-02T17:54:22Z","last_updated_date":"2011-08-02T17:54:22Z","reference_number":"EMA/INS/GCP/614497/2011","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-european-medicines-agency-food-and-drug-administration-good-clinical-practice-initiative_en.pdf"},
    {"id":"5406","name":"Guidelines on good pharmacovigilance practices: Introductory cover note, last updated with public consultation launch of draft modules IV and XV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-26T18:15:02Z","last_updated_date":"2012-07-26T18:15:02Z","reference_number":"EMA/500020/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-introductory-cover-note-last-updated-public-consultation-launch-draft-modules-iv-and-xv_en.pdf"},
    {"id":"5417","name":"Declaration of interests: Radhouane Cherif","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2021-06-14T17:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-radhouane-cherif_en.pdf"},
    {"id":"5423","name":"EU Telematics Strategy and Implementation Roadmap 2015 – 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T02:00:00Z","last_updated_date":"2015-08-11T02:00:00Z","reference_number":"EMA/532765/2015","document_url":"https://www.ema.europa.eu/en/documents/other/eu-telematics-strategy-and-implementation-roadmap-2015-2017_en.pdf"},
    {"id":"5424","name":"CAT meetings in 2019, 2020 and 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-06-25T18:00:00Z","last_updated_date":"2018-06-25T18:00:00Z","reference_number":"EMA/CAT/132444/2017","document_url":"https://www.ema.europa.eu/en/documents/other/cat-meetings-2019-2020-and-2021_en.pdf"},
    {"id":"5425","name":"Revised charter of tasks and responsibilities of the accounting officer","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-03-26T14:10:00Z","last_updated_date":"2015-03-26T14:10:00Z","reference_number":"EMA/MB/655670/2014","document_url":"https://www.ema.europa.eu/en/documents/other/revised-charter-tasks-and-responsibilities-accounting-officer_en.pdf"},
    {"id":"5427","name":"Opinion of the CVMP pursuant to Article 30(3) of Regulation (EC) No 716/2004 of the European Parliament and of the Council on retrovirus RD114 in live attenuated vaccines for use in animals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-14T14:23:19Z","last_updated_date":"2010-10-14T14:23:19Z","reference_number":"EMA/CVMP/433418/2010","document_url":"https://www.ema.europa.eu/en/documents/other/opinion-cvmp-pursuant-article-303-regulation-ec-no-7162004-european-parliament-and-council-retrovirus-rd114-live-attenuated-vaccines-use-animals_en.pdf"},
    {"id":"5430","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Sotagliflozin for treatment of type-2 diabetes mellitus","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T12:15:00Z","last_updated_date":"2014-12-11T12:15:00Z","reference_number":"EMA/714939/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-sotagliflozin-treatment-type-2-diabetes-mellitus_en.pdf"},
    {"id":"5464","name":"Overview of comments received on draft guideline on environmental risk assessments for medicinal products consisting of, or containing, genetically modified organisms (GMOs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-12-01T01:00:00Z","last_updated_date":"2006-12-01T01:00:00Z","reference_number":"EMEA/CHMP/BWP/480303/2006 - Corr","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-environmental-risk-assessments-medicinal-products-consisting-or-containing-genetically-modified-organisms-gmos_en.pdf"},
    {"id":"5476","name":"Opinions on annual re-assessments, 5-year renewals - Adopted at the CHMP meeting of 13-16 February 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-02-21T15:12:00Z","last_updated_date":"2012-02-21T15:12:00Z","reference_number":"EMA/CHMP/86232/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-5-year-renewals-adopted-chmp-meeting-13-16-february-2012_en.pdf"},
    {"id":"5479","name":"Invitation for expressions of interest - European Medicines Agency workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn’s disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/292143/2015","document_url":"https://www.ema.europa.eu/en/documents/other/invitation-expressions-interest-european-medicines-agency-workshop-development-new-medicinal-products-treatment-ulcerative-colitis-and-crohns-disease_en.pdf"},
    {"id":"5498","name":"Management Board meeting dates 2019 – 2021","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2018-06-11T17:00:00Z","last_updated_date":"2018-06-11T17:00:00Z","reference_number":"EMA/MB/173925/2018","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2019-2021_en.pdf"},
    {"id":"5512","name":"Booklet of the workshop on identifying opportunities for ‘big data’ in medicines development and regulatory science","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/booklet-workshop-identifying-opportunities-big-data-medicines-development-and-regulatory-science_en.pdf"},
    {"id":"5521","name":"CTAG3: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on rules of engagement - Initial discussion document","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-advice-european-medicines-agency-clinical-trial-advisory-group-rules-engagement-initial-discussion-document_en.pdf"},
    {"id":"5538","name":"Overview of comments received on draft ‘Guideline on declaration of herbal substances and herbal preparations in herbal medicinal products / traditional herbal medicinal products’ (EMEA/HMPC/CHMP/CVMP/287539/2005 Rev.1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-28T02:00:00Z","last_updated_date":"2010-04-28T02:00:00Z","reference_number":"EMA/HMPC/710724/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-declaration-herbal-substances-and-herbal-preparations-herbal-medicinal-products-traditional-herbal-medicinal-products-emeahmpcchmpcvmp2875392005-rev1_en.pdf"},
    {"id":"5546","name":"Overview of comments received on draft guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"EMEA/CHMP/EWP/EMEA/198957/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-pharmacokinetics-therapeutic-proteins_en.pdf"},
    {"id":"5562","name":"Opinions on safety variations - Adopted during the CHMP meeting 18-21 June 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T11:33:00Z","last_updated_date":"2012-06-25T11:33:00Z","reference_number":"EMA/CHMP/410511/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-during-chmp-meeting-18-21-june-2012_en.pdf"},
    {"id":"5576","name":"Outcome of written procedures finalised during the period from 13 November 2014 to 18 February 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-26T14:10:00Z","last_updated_date":"2015-03-26T14:10:00Z","reference_number":"EMA/MB/9254/2015","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-13-november-2014-18-february-2015_en.pdf"},
    {"id":"5582","name":"EMEA 2010 Priorities for Drug Safety Research: Suicidal behaviour in relation to certain drug use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-08-04T02:00:00Z","last_updated_date":"2009-08-04T02:00:00Z","reference_number":"EMEA/493798/2009","document_url":"https://www.ema.europa.eu/en/documents/other/emea-2010-priorities-drug-safety-research-suicidal-behaviour-relation-certain-drug-use_en.pdf"},
    {"id":"5596","name":"Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the European Medicines Agency in accordance with Article 57(2), second subparagraph ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-01T19:40:05Z","last_updated_date":"2011-07-01T19:40:05Z","reference_number":"EMA/399691/2011","document_url":"https://www.ema.europa.eu/en/documents/other/detailed-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-european-medicines-agency-accordance-article-572-second-subparagraph_en.pdf"},
    {"id":"5600","name":"CTAG5: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on legal aspects - Meeting 2 summary overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag5-advice-european-medicines-agency-clinical-trial-advisory-group-legal-aspects-meeting-2-summary-overview_en.pdf"},
    {"id":"5625","name":"Guidelines and concept papers adopted during the CHMP meeting 17-20 September 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-25T17:51:00Z","last_updated_date":"2012-09-25T17:51:00Z","reference_number":"EMA/CHMP/539767/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-17-20-september-2012_en.pdf"},
    {"id":"5637","name":"Letter of support for Leuven Postprandial Distress Scale (LPDS) as PRO in Postprandial Distress Syndrome (PDS)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T11:00:00Z","last_updated_date":"2015-12-15T11:00:00Z","reference_number":"EMA/794574/2015","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-leuven-postprandial-distress-scale-lpds-pro-postprandial-distress-syndrome-pds_en.pdf"},
    {"id":"5665","name":"Guidelines and concept papers adopted at the CHMP meeting 17-20 February 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-02-25T12:25:00Z","last_updated_date":"2014-02-25T12:25:00Z","reference_number":"EMA/54973/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-chmp-meeting-17-20-february-2014_en.pdf"},
    {"id":"5670","name":"Questions and answers on the impact of Mutual Recognition Agreement (MRA) between the European Union and the United States as of 9 June 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T16:20:00Z","last_updated_date":"2026-06-11T15:07:00Z","reference_number":"EMA/INS/GMP/369445/2024","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-impact-mutual-recognition-agreement-mra-between-european-union-united-states-9-june-2026_en.pdf"},
    {"id":"5673","name":"List of participants: Closed workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:57Z","last_updated_date":"2012-06-15T17:10:57Z","reference_number":"EMA/362428/2012","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-closed-workshop-biosimilar-monoclonal-antibodies-and-immunogenicity-monoclonal-antibodies_en.pdf"},
    {"id":"5687","name":"Annual list of specific contracts based on framework contracts - 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-28T17:00:00Z","last_updated_date":"2017-06-28T17:00:00Z","reference_number":"EMA/425055/2016","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-specific-contracts-based-framework-contracts-2016_en.pdf"},
    {"id":"5718","name":"Revised rules of procedure of the Management Board","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2021-10-11T15:29:00Z","reference_number":"EMA/MB/115339/2004/en/Rev.8","document_url":"https://www.ema.europa.eu/en/documents/other/revised-rules-procedure-management-board_en.pdf"},
    {"id":"5725","name":"European Medicines Agency guidance on interactions in the context of PRIME","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-05-07T17:30:00Z","last_updated_date":"2018-05-07T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-guidance-interactions-context-prime_en.pdf"},
    {"id":"5752","name":"Functional specifications for the European Union (EU) portal and EU database to be audited","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-19T16:00:00Z","last_updated_date":"2015-03-25T11:30:00Z","reference_number":"EMA/42176/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/functional-specifications-european-union-eu-portal-and-eu-database-be-audited_en.pdf"},
    {"id":"5831","name":"Response to public comments received on the inventory of paediatric therapeutic needs: gastroenterology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-28T17:20:00Z","last_updated_date":"2015-10-28T17:20:00Z","reference_number":"EMA/PDCO/470078/2015","document_url":"https://www.ema.europa.eu/en/documents/other/response-public-comments-received-inventory-paediatric-therapeutic-needs-gastroenterology_en.pdf"},
    {"id":"5842","name":"List of networks members","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-21T02:09:21Z","last_updated_date":"2009-04-21T02:09:21Z","reference_number":"EMEA/248834/2009","document_url":"https://www.ema.europa.eu/en/documents/other/list-networks-members_en.pdf"},
    {"id":"5853","name":"Ad hoc working party on Herbal Medicinal Products:  Final comments and proposals for revision of part 4 of annex to Council Directive 75/318/EEC of 20 May 1975 'clinical documentation'","type":"other","status":"unknown","consultation_date":"","first_published_date":"1998-09-17T02:00:00Z","last_updated_date":"1998-09-17T02:00:00Z","reference_number":"EMEA/HMPWP/13/99","document_url":"https://www.ema.europa.eu/en/documents/other/ad-hoc-working-party-herbal-medicinal-products-final-comments-and-proposals-revision-part-4-annex-council-directive-75318eec-20-may-1975-clinical-documentation_en.pdf"},
    {"id":"5859","name":"Letter to Sane Vax Inc. from the Committee for Medicinal Products for Human Use (CHMP) regarding Gardasil","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T16:00:00Z","last_updated_date":"2011-09-23T16:00:00Z","reference_number":"EMA/771987/2011","document_url":"https://www.ema.europa.eu/en/documents/other/letter-sane-vax-inc-committee-medicinal-products-human-use-chmp-regarding-gardasil_en.pdf"},
    {"id":"5866","name":"Organisational matters: CHMP meeting of 17-20 March 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T17:00:00Z","last_updated_date":"2014-03-24T17:00:00Z","reference_number":"EMA/CHMP/123343/2014","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-17-20-march-2014_en.pdf"},
    {"id":"5877","name":"Overview of comments received on draft guideline on the development medicinal substances contained in drug-eluting (medicinal substance-eluting) coronary stents","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/242067/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-development-medicinal-substances-contained-drug-eluting-medicinal-substance-eluting-coronary-stents_en.pdf"},
    {"id":"5896","name":"Table of recommendations - Multiple sclerosis workshop","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"EMA/651859/2017","document_url":"https://www.ema.europa.eu/en/documents/other/table-recommendations-multiple-sclerosis-workshop_en.pdf"},
    {"id":"5973","name":"What does the black triangle mean?","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-01T12:00:00Z","last_updated_date":"2013-10-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/what-does-black-triangle-mean_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/what-does-black-triangle-mean_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/what-does-black-triangle-mean_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/what-does-black-triangle-mean_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/what-does-black-triangle-mean_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/what-does-black-triangle-mean_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/what-does-black-triangle-mean_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/what-does-black-triangle-mean_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/what-does-black-triangle-mean_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/what-does-black-triangle-mean_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/what-does-black-triangle-mean_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/what-does-black-triangle-mean_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/what-does-black-triangle-mean_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/what-does-black-triangle-mean_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/what-does-black-triangle-mean_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/what-does-black-triangle-mean_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/what-does-black-triangle-mean_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/what-does-black-triangle-mean_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/what-does-black-triangle-mean_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/what-does-black-triangle-mean_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/what-does-black-triangle-mean_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/what-does-black-triangle-mean_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/what-does-black-triangle-mean_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/what-does-black-triangle-mean_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/what-does-black-triangle-mean_no.pdf"}},
    {"id":"5980","name":"Mandate of the European Medicines Agency Innovation Task Force (ITF)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-04-11T02:00:00Z","last_updated_date":"2014-09-05T13:00:00Z","reference_number":"EMA/484400/2014","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-european-medicines-agency-innovation-task-force-itf_en.pdf"},
    {"id":"5982","name":"Arepanrix: Labelling","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-29T02:00:00Z","last_updated_date":"2010-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/arepanrix-labelling_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/arepanrix-labelling_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/arepanrix-labelling_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/arepanrix-labelling_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/arepanrix-labelling_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/arepanrix-labelling_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/arepanrix-labelling_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/arepanrix-labelling_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/arepanrix-labelling_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/arepanrix-labelling_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/arepanrix-labelling_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/arepanrix-labelling_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/arepanrix-labelling_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/arepanrix-labelling_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/arepanrix-labelling_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/arepanrix-labelling_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/arepanrix-labelling_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/arepanrix-labelling_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/arepanrix-labelling_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/arepanrix-labelling_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/arepanrix-labelling_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/arepanrix-labelling_sv.pdf"}},
    {"id":"5987","name":"Organisational matters - CHMP meeting 16-19 September 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-26T17:35:00Z","last_updated_date":"2013-09-26T17:35:00Z","reference_number":"EMA/568789/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-16-19-september-2013_en.pdf"},
    {"id":"5991","name":"Appointment of European Medicines Agency Executive Director 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-01T02:00:00Z","last_updated_date":"2015-10-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/appointment-european-medicines-agency-executive-director-2015_en.pdf"},
    {"id":"5997","name":"Impact of scientific advice from the European Medicines Agency - Nature article","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-17T02:00:00Z","last_updated_date":"2015-04-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/impact-scientific-advice-european-medicines-agency-nature-article_en.pdf"},
    {"id":"6001","name":"Annex 10 Standard Profile Specification and Request Form\n\nfor Services - Procurement Procedure EMA/2012/09/IF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-10-standard-profile-specification-and-request-form-services-procurement-procedure-ema201209if_en.pdf"},
    {"id":"6058","name":"EMEA/PEG Procedure for identifying paediatric needs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-06-29T02:00:00Z","last_updated_date":"2005-06-29T02:00:00Z","reference_number":"EMEA/175192/2004/rev2","document_url":"https://www.ema.europa.eu/en/documents/other/emeapeg-procedure-identifying-paediatric-needs_en.pdf"},
    {"id":"6074","name":"Updated application software","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-29T02:00:00Z","last_updated_date":"2010-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/updated-application-software_en.zip"},
    {"id":"6109","name":"Participants list - Fourth industry stakeholder platform - operation of European Union pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T16:00:00Z","last_updated_date":"2015-06-25T16:00:00Z","reference_number":"EMA/402803/2015","document_url":"https://www.ema.europa.eu/en/documents/other/participants-list-fourth-industry-stakeholder-platform-operation-european-union-pharmacovigilance-legislation_en.pdf"},
    {"id":"6114","name":"Working groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-21T02:09:21Z","last_updated_date":"2009-04-21T02:09:21Z","reference_number":"EMEA/248833/200","document_url":"https://www.ema.europa.eu/en/documents/other/working-groups_en.pdf"},
    {"id":"6142","name":"Technical specification - Annex 10 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-10-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"6153","name":"Overview of comments received on draft guideline on criteria for requiring one additional five-year renewal for centrally authorised medicinal products (EMEA/131973/2006)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-01-29T01:00:00Z","last_updated_date":"2008-01-29T01:00:00Z","reference_number":"EMEA/29922/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-criteria-requiring-one-additional-five-year-renewal-centrally-authorised-medicinal-products-emea1319732006_en.pdf"},
    {"id":"6170","name":"Assessment of the paediatric needs - Anti-infectious therapy with focus on antimycotics, antivirals (except HIV)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-10-01T02:00:00Z","last_updated_date":"2006-10-01T02:00:00Z","reference_number":"EMEA/435350/2006","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-anti-infectious-therapy-focus-antimycotics-antivirals-except-hiv_en.pdf"},
    {"id":"6172","name":"Contractor SOP/MLM - WIN/MLM","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-01T02:00:00Z","last_updated_date":"2024-06-24T14:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/contractor-sop-mlm-win-mlm_en.zip"},
    {"id":"6251","name":"Workplan for Good Clinical Practice Inspectors Working Group (GCP IWG) for 2010","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-02-05T01:00:00Z","last_updated_date":"2010-02-05T01:00:00Z","reference_number":"EMA/INS/GCP/782669/2009","document_url":"https://www.ema.europa.eu/en/documents/other/workplan-good-clinical-practice-inspectors-working-group-gcp-iwg-2010_en.pdf"},
    {"id":"6266","name":"Format for risk-management-plan submissions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-31T13:02:00Z","last_updated_date":"2013-01-31T13:02:00Z","reference_number":"EMA/793396/2012","document_url":"https://www.ema.europa.eu/en/documents/other/format-risk-management-plan-submissions_en.pdf"},
    {"id":"6297","name":"Questions and answers relating to open tender procedure EMA/2013/06/PD – Document delivery services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-22T12:22:00Z","last_updated_date":"2013-11-20T16:30:00Z","reference_number":"EMA/645559/2013","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-tender-procedure-ema201306pd-document-delivery-services_en.pdf"},
    {"id":"6304","name":"Management Board meeting dates for 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/MB/376489/2011/Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2012_en.pdf"},
    {"id":"6335","name":"Overview of comments received on draft guideline on follow-up of patients administered with gene therapy medicinal products (EMEA/CHMP/GTWP/60436/2007)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-11-13T00:09:21Z","last_updated_date":"2009-11-13T00:09:21Z","reference_number":"EMEA/570240/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-follow-patients-administered-gene-therapy-medicinal-products-emeachmpgtwp604362007_en.pdf"},
    {"id":"6345","name":"Overview of comments received on the draft guideline on Allergen products: Production and quality issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/CHMP/BWP/596200/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-allergen-products-production-and-quality-issues_en.pdf"},
    {"id":"6355","name":"Joint audit programme for EEA GMP inspectorates: Procedure for observing inspections","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T01:00:00Z","last_updated_date":"2019-02-22T11:06:00Z","reference_number":"EMA/617616/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/joint-audit-programme-eea-gmp-inspectorates-procedure-observing-inspections_en.pdf"},
    {"id":"6368","name":"Points to consider for an EMEA communications policy","type":"other","status":"Adopted","consultation_date":"","first_published_date":"1998-05-15T02:00:00Z","last_updated_date":"1998-05-15T02:00:00Z","reference_number":"EMEA/MB/011/98 - Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/points-consider-emea-communications-policy_en.pdf"},
    {"id":"6390","name":"Overview of comments received on 'Guideline on stability testing for applications for variations to a marketing authorisation' - Revision 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-09T18:30:00Z","last_updated_date":"2014-08-20T16:10:00Z","reference_number":"EMA/CHMP/CVMP/QWP/774027/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-stability-testing-applications-variations-marketing-authorisation-revision-2_en.pdf"},
    {"id":"6483","name":"LifeGlobal Media: Consultation procedure Public Assessment Report (CPAR)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-30T11:30:00Z","last_updated_date":"2017-10-30T11:30:00Z","reference_number":"EMA/CHMP/878394/2016","document_url":"https://www.ema.europa.eu/en/documents/other/lifeglobal-media-consultation-procedure-public-assessment-report-cpar_en.pdf"},
    {"id":"6489","name":"Overview of comments received on reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in food-producing animals in the European Union: development of resistance and impact on human and animal ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-11-29T16:00:00Z","last_updated_date":"2011-11-29T16:00:00Z","reference_number":"EMA/CVMP/SAGAM/358728/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-use-macrolides-lincosamides-and-streptogramins-mls-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal_en.pdf"},
    {"id":"6497","name":"Opinions on safety variations /  periodic safety update reports adopted at the CHMP meeting of 16-19 September 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-26T17:35:00Z","last_updated_date":"2013-09-26T17:35:00Z","reference_number":"EMA/568773/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-16-19-september-2013_en.pdf"},
    {"id":"6498","name":"Outcome of the public consultation on the EU Medicines Agencies Network Strategy to 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/667824/2015","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-public-consultation-eu-medicines-agencies-network-strategy-2020_en.pdf"},
    {"id":"6504","name":"Letter of support to explore MRI methodology to be used to stratify populations of people with autism spectrum disorder (ASD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T12:00:00Z","last_updated_date":"2015-12-09T12:00:00Z","reference_number":"EMA/794542/2015","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-explore-mri-methodology-be-used-stratify-populations-people-autism-spectrum-disorder-asd_en.pdf"},
    {"id":"6506","name":"Opinions on safety variations adopted at the CHMP meeting of 21-24 May 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-29T14:16:00Z","last_updated_date":"2012-05-29T14:16:00Z","reference_number":"EMA/CHMP/273714/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-21-24-may-2012_en.pdf"},
    {"id":"6507","name":"Pathogen specific database: Q fever","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-q-fever_en.pdf"},
    {"id":"6515","name":"The European paediatric initiative: History of the Paediatric Regulation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-11T02:00:00Z","last_updated_date":"2007-07-11T02:00:00Z","reference_number":"EMEA/17967/04 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/other/european-paediatric-initiative-history-paediatric-regulation_en.pdf"},
    {"id":"6544","name":"Criteria for classification of critical medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T00:00:00Z","last_updated_date":"2018-04-20T17:00:00Z","reference_number":"EMA/314762/2013","document_url":"https://www.ema.europa.eu/en/documents/other/criteria-classification-critical-medicinal-products_en.pdf"},
    {"id":"6580","name":"Overview of comments received on reflection paper on the use of (fluoro)quinolones in food-producing animals in the European Union: development of resistance and impact on human and animal health","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-02-15T01:00:00Z","last_updated_date":"2007-02-15T01:00:00Z","reference_number":"EMEA/CVMP/SAGAM/496824/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-use-fluoroquinolones-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"6586","name":"Concept paper on the development of a Committee for Human Medicinal Products (CHMP) revised guideline on clinical evaluation of new vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-06-23T02:09:21Z","last_updated_date":"2004-06-23T02:09:21Z","reference_number":"CHMP/VEG/1820/04","document_url":"https://www.ema.europa.eu/en/documents/other/concept-paper-development-committee-human-medicinal-products-chmp-revised-guideline-clinical-evaluation-new-vaccines_en.pdf"},
    {"id":"6609","name":"Tolperisone: Product information as approved by the CHMP on 19 October 2012 pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T02:00:00Z","last_updated_date":"2012-10-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/tolperisone-product-information-approved-chmp-19-october-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"6622","name":"Letter from the Food and Drug Administration to the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-09-12T02:00:00Z","last_updated_date":"2003-09-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-food-and-drug-administration-european-commission_en.pdf"},
    {"id":"6627","name":"Chapter 1: Introduction of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-01T21:19:00Z","last_updated_date":"2012-03-05T12:00:00Z","reference_number":"EMA/717178/2011","document_url":"https://www.ema.europa.eu/en/documents/other/chapter-1-introduction-detailed-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-ema_en.pdf"},
    {"id":"6647","name":"Download EPS - Species pictograms - Pig","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-pig_en.zip"},
    {"id":"6674","name":"Opinions on safety variations adopted at the CHMP meeting of 12-15 December 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-16T13:00:00Z","last_updated_date":"2011-12-16T13:00:00Z","reference_number":"EMA/CHMP/941886/2011","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-12-15-december-2011_en.pdf"},
    {"id":"6694","name":"Enhancing quality assurance of API manufacture","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-14T02:00:00Z","last_updated_date":"2010-04-14T02:00:00Z","reference_number":"EMA/INS/GMP/232127/2010","document_url":"https://www.ema.europa.eu/en/documents/other/enhancing-quality-assurance-api-manufacture_en.pdf"},
    {"id":"6703","name":"Rare diseases, orphan medicines - Getting the facts straight","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-02-28T16:30:00Z","last_updated_date":"2018-02-28T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/rare-diseases-orphan-medicines-getting-facts-straight_en.pdf"},
    {"id":"6739","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: COOK IVF cell  media","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-08T14:00:00Z","last_updated_date":"2012-08-08T14:00:00Z","reference_number":"EMA/CHMP/100577/2012","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-cook-ivf-cell-media_en.pdf"},
    {"id":"6789","name":"Flyer - The annual European Medicines Agency review of the year and outlook for 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-27T02:00:00Z","last_updated_date":"2011-10-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/flyer-annual-european-medicines-agency-review-year-and-outlook-2012_en.pdf"},
    {"id":"6797","name":"Overview of the EudraVigilance training on electronic reporting of ICSRs in the EEA: 10-11 March 2014, London, UK","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-eudravigilance-training-electronic-reporting-icsrs-eea-10-11-march-2014-london-uk_en.pdf"},
    {"id":"6798","name":"Overview of comments received on guideline on the clinical assessment of fixed combinations of herbal substances / herbal preparations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-01-11T01:00:00Z","last_updated_date":"2006-01-11T01:00:00Z","reference_number":"EMEA/HMPC/419395/2005","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-assessment-fixed-combinations-herbal-substances-herbal-preparations_en.pdf"},
    {"id":"6805","name":"Frequently asked questions relating to the assignment and maintenance of micro-, small- or medium-sized-enterprise status by the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T02:00:00Z","last_updated_date":"2010-12-17T02:00:00Z","reference_number":"EMA/796232/2010","document_url":"https://www.ema.europa.eu/en/documents/other/frequently-asked-questions-relating-assignment-and-maintenance-micro-small-or-medium-sized-enterprise-status-european-medicines-agency_en.pdf"},
    {"id":"6810","name":"Survey 2007 on the performance of EMEA scientific procedures for medicinal products for human use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:09:21Z","last_updated_date":"2008-04-24T02:09:21Z","reference_number":"EMEA/158877/2008","document_url":"https://www.ema.europa.eu/en/documents/other/survey-2007-performance-emea-scientific-procedures-medicinal-products-human-use_en.pdf"},
    {"id":"6833","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Naloxone (hydrochloride) for treatment of opioid-induced constipation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T12:15:00Z","last_updated_date":"2014-12-12T12:15:00Z","reference_number":"EMA/461583/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-naloxone-hydrochloride-treatment-opioid-induced-constipation_en.pdf"},
    {"id":"6835","name":"Overview of comments received on guideline on repeated dose toxicity (CPMP/SWP/1042/99 Rev 1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-29T02:00:00Z","last_updated_date":"2010-11-05T01:00:00Z","reference_number":"EMA/402716/2008 Correction","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-repeated-dose-toxicity-cpmpswp104299-rev-1_en.pdf"},
    {"id":"6848","name":"Streamlining EMA public communication on medication errors","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-11-27T11:00:00Z","last_updated_date":"2015-11-27T11:00:00Z","reference_number":"EMA/787897/2015","document_url":"https://www.ema.europa.eu/en/documents/other/streamlining-ema-public-communication-medication-errors_en.pdf"},
    {"id":"6859","name":"Adempas : Product Information as approved by the CHMP on 23 June 2016, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/adempas-product-information-approved-chmp-23-june-2016-pending-endorsement-european-commission_en.pdf"},
    {"id":"6863","name":"Contact details of national competent authorities for requests of translation exemptions falling under Art. 63.3 of Directive 2001/83/EC and cases of shortages","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-19T16:30:00Z","last_updated_date":"2026-06-05T14:27:00Z","reference_number":"EMA/670900/2020 Rev.20","document_url":"https://www.ema.europa.eu/en/documents/other/contact-details-national-competent-authorities-requests-translation-exemptions-falling-under-art-633-directive-2001-83-ec-cases-shortages_en.pdf"},
    {"id":"6901","name":"Amendments to Management Board implementing rules on the Agency’s fees in relation to inflation and extrapolation of MRLs effective from 1 April 2011 - \n\nManagement Board meeting 17 March 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2011-03-29T02:00:00Z","reference_number":"EMA/MB/757388/2010","document_url":"https://www.ema.europa.eu/en/documents/other/amendments-management-board-implementing-rules-agencys-fees-relation-inflation-and-extrapolation-mrls-effective-1-april-2011-management-board-meeting-17-march-2011_en.pdf"},
    {"id":"6904","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Elbasvir for the treatment of chronic hepatitis C","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/783316/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-elbasvir-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"6913","name":"Guidelines on good pharmacovigilance practices: Introductory cover note, last updated with finalisation of modules III and IV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-13T17:00:00Z","last_updated_date":"2012-12-13T17:00:00Z","reference_number":"EMA/798404/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-introductory-cover-note-last-updated-finalisation-modules-iii-and-iv_en.pdf"},
    {"id":"6914","name":"Overview of comments received on draft guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-02-01T01:00:00Z","last_updated_date":"2010-02-01T01:00:00Z","reference_number":"EMA/818496/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-used-treatment-osteoarthritis_en.pdf"},
    {"id":"6916","name":"International Coalition of Medicines Regulatory Authorities (ICMRA) fact sheet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-20T16:00:00Z","last_updated_date":"2014-11-20T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/international-coalition-medicines-regulatory-authorities-icmra-fact-sheet_en.pdf"},
    {"id":"6917","name":"Timetable: Annual renewal application of conditional marketing authorisation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T16:00:00Z","last_updated_date":"2026-05-27T15:15:00Z","reference_number":"EMA/823131/2015 Rev. 8","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-annual-renewal-application-conditional-marketing-authorisation_en.xlsx"},
    {"id":"6918","name":"First EMEA Workshop on Advanced Therapy Medicinal Products (ATMPs) - List of participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/first-emea-workshop-advanced-therapy-medicinal-products-atmps-list-participants_en.pdf"}    {"id":"6921","name":"Rafal Swierzewski (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/rafal-swierzewski-doi_en.pdf"},
    {"id":"6959","name":"European Medicines Agency workshop on medicines for older people - Invitation for expressions of interest","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T11:40:00Z","last_updated_date":"2011-10-28T11:40:00Z","reference_number":"EMA/826786/2011","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-workshop-medicines-older-people-invitation-expressions-interest_en.pdf"},
    {"id":"6994","name":"Declaration of interests: Frances Nuttall","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:18Z","last_updated_date":"2012-08-02T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-frances-nuttall_en.pdf"},
    {"id":"7035","name":"Timetable: Post-authorisation measures (PAMs) assessed by PRAC - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T12:40:00Z","last_updated_date":"2025-11-04T16:21:00Z","reference_number":"EMA/267767/2016 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-post-authorisation-measures-pams-assessed-prac-atmp_en.xlsx"},
    {"id":"7036","name":"Guidelines and concept papers adopted during the CHMP meeting 16-19 April 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T17:30:00Z","last_updated_date":"2012-04-20T17:30:00Z","reference_number":"EMA/CHMP/213033/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-16-19-april-2012_en.pdf"},
    {"id":"7054","name":"Assessment of the paediatric needs - Migraine","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-06-02T02:00:00Z","last_updated_date":"2006-06-02T02:00:00Z","reference_number":"EMEA/224515/2006","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-migraine_en.pdf"},
    {"id":"7059","name":"Guidelines and concept papers adopted during the CHMP meeting 14-17 January 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-25T15:56:00Z","last_updated_date":"2013-01-25T15:56:00Z","reference_number":"EMA/28116/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-14-17-january-2013_en.pdf"},
    {"id":"7060","name":"Overview of comments received on draft guideline on injection site residues (EMEA/CVMP/542/03-FINAL)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-01-13T01:00:00Z","last_updated_date":"2005-01-13T01:00:00Z","reference_number":"EMEA/CVMP/209865/2004","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-injection-site-residues-emeacvmp54203-final_en.pdf"},
    {"id":"7075","name":"List of participants - EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations - December 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T13:30:00Z","last_updated_date":"2014-02-07T13:30:00Z","reference_number":"EMA/678769/2013","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations-december-2013_en.pdf"},
    {"id":"7081","name":"Benefit-risk methodology project: Reply to the comments received from Dr William Holden on the work package 2 report","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-09T17:04:05Z","last_updated_date":"2011-06-09T17:04:05Z","reference_number":"EMA/61755/2011","document_url":"https://www.ema.europa.eu/en/documents/other/benefit-risk-methodology-project-reply-comments-received-dr-william-holden-work-package-2-report_en.pdf"},
    {"id":"7092","name":"ICMRA - Mapping of supply chain/anticounterfeiting initiatives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-09T13:20:00Z","last_updated_date":"2017-01-09T13:20:00Z","reference_number":"EMA/104288/2015","document_url":"https://www.ema.europa.eu/en/documents/other/icmra-mapping-supply-chainanticounterfeiting-initiatives_en.pdf"},
    {"id":"7098","name":"Workplan for Good Clinical Practice Inspectors Working Group (GCP IWG) for 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"EMA/INS/GCP/711390/2010","document_url":"https://www.ema.europa.eu/en/documents/other/workplan-good-clinical-practice-inspectors-working-group-gcp-iwg-2011_en.pdf"},
    {"id":"7118","name":"Organisational matters: CHMP meeting of 17-20 February 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-25T12:25:00Z","last_updated_date":"2014-02-25T12:25:00Z","reference_number":"EMA/54977/2014","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-17-20-february-2014_en.pdf"},
    {"id":"7133","name":"Declaration of interests - Nicolino Ruperto","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-nicolino-ruperto_en.pdf"},
    {"id":"7159","name":"High level business consultancy EMA/2013/23/FI - Technical specifications - Annex III checklist","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications-annex-iii-checklist_en.pdf"},
    {"id":"7190","name":"Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for Ledipasvir/Sofosbuvir available for compassionate use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-02T13:00:00Z","last_updated_date":"2020-10-26T10:06:00Z","reference_number":"EMA/181959/2014","document_url":"https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distribution-and-patients-targeted-and-conditions-safety-monitoring-addressed-member-states-ledipasvirsofosbuvir-available-compassionate-use_en.pdf"},
    {"id":"7198","name":"Questions and answers relating to PQQ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-01-01T01:00:00Z","last_updated_date":"2008-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-pqq_en.pdf"},
    {"id":"7216","name":"Working party on Herbal Medicinal Products:  Comments on the Commission Regulation (EC) No. 541/95 of 10 March 1995 concerning the examination of variations to the terms of a marketing authorisation granted by a competen...","type":"other","status":"unknown","consultation_date":"","first_published_date":"1999-11-01T01:00:00Z","last_updated_date":"1999-11-01T01:00:00Z","reference_number":"EMEA/HMPWP/20/99","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-comments-commission-regulation-ec-no-54195-10-march-1995-concerning-examination-variations-terms-marketing-authorisation-granted-competen_en.pdf"},
    {"id":"7219","name":"Technical Specifications – Annex IX Template for completing the test: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-ix-template-completing-test-procurement-procedure-ema201401ph_en.xls"},
    {"id":"7228","name":"Evaluation guide for good-manufacturing-practice regulatory compliance programme: Audit checklist","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-12-21T01:00:00Z","last_updated_date":"2023-03-14T08:45:00Z","reference_number":"EMA/INS/GMP/119415/2023","document_url":"https://www.ema.europa.eu/en/documents/other/evaluation-guide-good-manufacturing-practice-regulatory-compliance-programme-audit-checklist_en.pdf"},
    {"id":"7243","name":"Consultation procedure - Public consultation regarding the request to the European Medicines Agency from the European Commission for a scientific opinion regarding the risks to vultures and other necrophagous bird popula...","type":"other","status":"Draft: consultation closed","consultation_date":"2014-09-12 - 2014-10-10","first_published_date":"2014-09-12T21:30:00Z","last_updated_date":"2014-09-12T21:30:00Z","reference_number":"EMA/545597/2014","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-procedure-public-consultation-regarding-request-european-medicines-agency-european-commission-scientific-opinion-regarding-risks-vultures-and-other-necrophagous-bird-popula_en.pdf"},
    {"id":"7247","name":"Speakers biographies - EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting: info session on antimicrobial ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/478295/2017","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-info-session-antimicrobial_en.pdf"},
    {"id":"7266","name":"Explanatory note: EudraVigilance access policy for medicines for human use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-08T17:50:18Z","last_updated_date":"2011-07-08T17:50:18Z","reference_number":"EMA/529383/2011","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-note-eudravigilance-access-policy-medicines-human-use_en.pdf"},
    {"id":"7277","name":"Statement of the European Medicines Agency position on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of human and veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-04T10:30:00Z","last_updated_date":"2011-10-04T10:30:00Z","reference_number":"EMA/470807/2011","document_url":"https://www.ema.europa.eu/en/documents/other/statement-european-medicines-agency-position-application-3rs-replacement-reduction-and-refinement-regulatory-testing-human-and-veterinary-medicinal-products_en.pdf"},
    {"id":"7279","name":"Overview of comments received on draft guideline on clinical investigation of medicinal products in the treatment of hypertension","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/CHMP/EWP/599934/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-hypertension_en.pdf"},
    {"id":"7293","name":"Type II variations (60-day procedure) and worksharing","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-24T02:09:21Z","last_updated_date":"2009-12-02T01:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/type-ii-variations-60-day-procedure-and-worksharing_en.pdf"},
    {"id":"7322","name":"Project description - Detailed information about the Instrument for Pre-accession Assistance programme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-01-01T01:00:00Z","last_updated_date":"2009-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/project-description-detailed-information-about-instrument-pre-accession-assistance-programme_en.pdf"},
    {"id":"7330","name":"CTAG5: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on legal aspects - Initial text","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag5-advice-european-medicines-agency-clinical-trial-advisory-group-legal-aspects-initial-text_en.pdf"},
    {"id":"7339","name":"ICMRA - Mapping of multinational project initiatives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-09T13:20:00Z","last_updated_date":"2017-01-09T13:20:00Z","reference_number":"EMA/563593/2016","document_url":"https://www.ema.europa.eu/en/documents/other/icmra-mapping-multinational-project-initiatives_en.pdf"},
    {"id":"7341","name":"Request for an opinion regarding the risks to vultures and other necrophagous bird populations in the Union in connection with the use of veterinary medicinal products containing the substance diclofenac","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-12T19:30:00Z","last_updated_date":"2014-09-12T19:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-opinion-regarding-risks-vultures-and-other-necrophagous-bird-populations-union-connection-use-veterinary-medicinal-products-containing-substance-diclofenac_en.pdf"},
    {"id":"7373","name":"Declaration of interests: Guy Fiems","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2015-09-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-guy-fiems_en.pdf"},
    {"id":"7397","name":"Declaration of interests: Marisa Papaluca Amati","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:15Z","last_updated_date":"2014-06-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-marisa-papaluca-amati_en.pdf"},
    {"id":"7412","name":"Questions and answers following the initial experience of the adaptive-licensing pilot project","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-11T20:05:00Z","last_updated_date":"2014-09-11T20:05:00Z","reference_number":"EMA/417706/2014 ","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-following-initial-experience-adaptive-licensing-pilot-project_en.pdf"},
    {"id":"7430","name":"Programme - Transatlantic workshop: Drug-related progressive multifocal leukoencephalopathy (PML)","type":"other","status":"Draft","consultation_date":"","first_published_date":"2011-04-05T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"EMA/262331/2011","document_url":"https://www.ema.europa.eu/en/documents/other/programme-transatlantic-workshop-drug-related-progressive-multifocal-leukoencephalopathy-pml_en.pdf"},
    {"id":"7449","name":"Pathogen specific database: Smallpox","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-smallpox_en.pdf"},
    {"id":"7451","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): Module IX – Signal management (Rev. 1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/847158/2016","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf"},
    {"id":"7453","name":"Request to assess the risk of occurrence of contamination with Mesilate Esters and related compounds in pharmaceuticals.","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/44714/2008","document_url":"https://www.ema.europa.eu/en/documents/other/request-assess-risk-occurrence-contamination-mesilate-esters-and-related-compounds-pharmaceuticals_en.pdf"},
    {"id":"7459","name":"EMEA/INFARMED/EXPERTISSUES joint workshop on cell based medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-05-25T02:09:21Z","last_updated_date":"2007-05-25T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/emeainfarmedexpertissues-joint-workshop-cell-based-medicinal-products_en.pdf"},
    {"id":"7461","name":"Committee for medicinal products for veterinary use - EMA public bulletin 2009 on veterinary pharmacovigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-17T01:09:21Z","last_updated_date":"2010-02-17T01:09:21Z","reference_number":"EMA/CVMP/PhVWP/729768/2009","document_url":"https://www.ema.europa.eu/en/documents/other/committee-medicinal-products-veterinary-use-ema-public-bulletin-2009-veterinary-pharmacovigilance_en.pdf"},
    {"id":"7507","name":"Frequently asked questions on regulatory aspects of Regulation (EC) No 1901/2006 (Paediatric Regulation) amended by Regulation (EC) No 1902/2006","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-09-02T02:00:00Z","last_updated_date":"2008-09-02T02:00:00Z","reference_number":"EMEA/520085/2006 Version 2.0","document_url":"https://www.ema.europa.eu/en/documents/other/frequently-asked-questions-regulatory-aspects-regulation-ec-no-19012006-paediatric-regulation-amended-regulation-ec-no-19022006_en.pdf"},
    {"id":"7509","name":"Implementation plan of the Summary of Product Characteristics (SmPC) guideline","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-08T01:00:00Z","last_updated_date":"2013-01-08T01:00:00Z","reference_number":"EMA/655980/2008","document_url":"https://www.ema.europa.eu/en/documents/other/implementation-plan-summary-product-characteristics-smpc-guideline_en.pdf"},
    {"id":"7512","name":"Workshop on Medicines for the Treatment of Pain in children","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-06-20T02:09:21Z","last_updated_date":"2005-06-20T02:09:21Z","reference_number":"EMEA/35431/2005","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-medicines-treatment-pain-children_en.pdf"},
    {"id":"7546","name":"EU-RMP Annex I form for 32 bit operating system  - Electronic interface for EudraVigilance (Version 5.1 – October 2013)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-07T02:00:00Z","last_updated_date":"2016-07-07T02:00:00Z","reference_number":"Version 5.1 – October 2013","document_url":"https://www.ema.europa.eu/en/documents/other/eu-rmp-annex-i-form-32-bit-operating-system-electronic-interface-eudravigilance-version-51-october-2013_en.zip"},
    {"id":"7548","name":"Revision of the Financial Regulation and its Implementing Rules","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/528780/2010","document_url":"https://www.ema.europa.eu/en/documents/other/revision-financial-regulation-and-its-implementing-rules_en.pdf"},
    {"id":"7550","name":"Opinions on annual re-assessments and five-year renewals adopted at the Committee for Medicinal Products for Human Use meeting of 19-22 September 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T15:45:00Z","last_updated_date":"2011-10-06T15:45:00Z","reference_number":"EMA/787677/2011","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-and-five-year-renewals-adopted-committee-medicinal-products-human-use-meeting-19-22-september-2011_en.pdf"},
    {"id":"7590","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: Origio","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-08T14:00:00Z","last_updated_date":"2012-08-08T14:00:00Z","reference_number":"EMEA/CHMP/461473/2007","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-origio_en.pdf"},
    {"id":"7602","name":"Questions and answers on the CVMP guideline on pharmaceutical fixed combination products (EMEA/CVMP/83804/2005)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-25T17:00:00Z","last_updated_date":"2014-05-20T16:10:00Z","reference_number":"EMA/CVMP/EWP/325284/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-cvmp-guideline-pharmaceutical-fixed-combination-products-emeacvmp838042005_en.pdf"},
    {"id":"7633","name":"User manual (EXACT): Applicant submission version 7.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-13T12:40:00Z","last_updated_date":"2015-04-13T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/user-manual-exact-applicant-submission-version-70_en.pdf"},
    {"id":"7634","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Paediatric Network of Clinical Investigation Centers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817561/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-paediatric-network-clinical-investigation-centers_en.pdf"},
    {"id":"7636","name":"List of participants - European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T17:30:00Z","last_updated_date":"2018-06-27T17:30:00Z","reference_number":"EMA/56245/2018","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf"},
    {"id":"7649","name":"Scientific advice and protocol assistance, adopted during the CHMP meeting 16-19 April 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-20T14:00:00Z","last_updated_date":"2012-04-20T14:00:00Z","reference_number":"EMA/CHMP/SAWP/261201/2012","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-16-19-april-2012_en.pdf"},
    {"id":"7678","name":"Qualification opinion list of issues - Total kidney volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-22T11:00:00Z","last_updated_date":"2015-07-22T11:00:00Z","reference_number":"EMA/CHMP/SAWP/298348/2014","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-list-issues-total-kidney-volume-tkv-prognostic-biomarker-use-clinical-trials-evaluating-patients-autosomal-dominant-polycystic-kidney-disease-adpkd_en.pdf"},
    {"id":"7725","name":"EU Regulatory Network - Challenges and Opportunities for Croatia - Announcement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eu-regulatory-network-challenges-and-opportunities-croatia-announcement_en.pdf"},
    {"id":"7730","name":"Overview of comments received on the draft revision of the guideline on the clinical development of medicinal products for the treatment of HIV infection - EMEA/CPMP/EWP/633/02 Rev. 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-02-04T01:00:00Z","last_updated_date":"2009-02-04T01:00:00Z","reference_number":"EMEA/301021/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-revision-guideline-clinical-development-medicinal-products-treatment-hiv-infection-emeacpmpewp63302-rev-2_en.pdf"},
    {"id":"7733","name":"Points to consider on good-clinical-practice inspection findings and the benefit-risk balance","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-01-29T09:42:00Z","last_updated_date":"2013-01-29T09:42:00Z","reference_number":"EMA/868942/2011","document_url":"https://www.ema.europa.eu/en/documents/other/points-consider-good-clinical-practice-inspection-findings-and-benefit-risk-balance_en.pdf"},
    {"id":"7744","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) - Authorisation status","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:01Z","last_updated_date":"2025-01-10T09:36:01Z","reference_number":"EMA/136153/2012 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-authorisation-status_en.xlsx"},
    {"id":"7745","name":"Summary of changes to the ‘External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use’ - Version 1.1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-09T01:00:00Z","last_updated_date":"2016-12-09T01:00:00Z","reference_number":"EMA/729722/2016","document_url":"https://www.ema.europa.eu/en/documents/other/summary-changes-external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-version-11_en.pdf"},
    {"id":"7786","name":"Participants list - Second industry stakeholder platform on the operation of European Union pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMA/91293/2015","document_url":"https://www.ema.europa.eu/en/documents/other/participants-list-second-industry-stakeholder-platform-operation-european-union-pharmacovigilance-legislation_en.pdf"},
    {"id":"7828","name":"Letter to European Ombudsman","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-10T16:00:00Z","last_updated_date":"2015-02-10T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-european-ombudsman_en.pdf"},
    {"id":"7847","name":"Sample EV test cases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-21T02:00:00Z","last_updated_date":"2016-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sample-ev-test-cases_en.zip"},
    {"id":"7854","name":"Overview of comments received on guideline on the investigation of drug interactions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-08-02T17:00:00Z","last_updated_date":"2013-08-02T17:00:00Z","reference_number":"EMA/CHMP/EWP/125211/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-investigation-drug-interactions_en.pdf"},
    {"id":"7868","name":"Renewal of confidentiality arrangement: Letter from European Commission and European Medicines Agency to Ministry of Health, Labour and Welfare and Pharmaceuticals and Medical Devices Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-02-07T12:00:00Z","last_updated_date":"2013-02-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/renewal-confidentiality-arrangement-letter-european-commission-european-medicines-agency-ministry-health-labour-welfare-pharmaceuticals-medical-devices-agency_en.pdf"},
    {"id":"7894","name":"Questions and answers relating to on line communications tender","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-04-04T02:00:00Z","last_updated_date":"2008-04-04T02:00:00Z","reference_number":"EMEA/139320/2008","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-line-communications-tender_en.pdf"},
    {"id":"7943","name":"Overview of comments received on reflection paper on the use of third- and fourth-generation cephalosporins in food-producing animals in the European Union: development of tesistance and impact on human and animal health","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-17T02:00:00Z","last_updated_date":"2009-04-17T02:00:00Z","reference_number":"EMEA/CVMP/SAGAM/464096/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-use-third-and-fourth-generation-cephalosporins-food-producing-animals-european-union-development-tesistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"7945","name":"EMEA conditions for informatics ( IT ) contracts","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-01T02:00:00Z","last_updated_date":"2008-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/emea-conditions-informatics-it-contracts_en.pdf"},
    {"id":"7977","name":"Organisational matters - CHMP meeting 16-19 January 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-23T17:35:00Z","last_updated_date":"2012-01-23T17:35:00Z","reference_number":"EMA/CHMP/8909/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-16-19-january-2012_en.pdf"},
    {"id":"7980","name":"Withdrawal letter : Tygacil","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-04-22T02:00:00Z","last_updated_date":"2008-04-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-tygacil_en.pdf"},
    {"id":"8011","name":"Request for an opinion regarding a request pursuant to Article-30(3) of Regulation (EC) No 726/2004 in relation to the potential risk for the consumer resulting from the use of lidocaine in food producing species","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-22T14:00:00Z","last_updated_date":"2015-04-22T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-opinion-regarding-request-pursuant-article-303-regulation-ec-no-7262004-relation-potential-risk-consumer-resulting-use-lidocaine-food-producing-species_en.pdf"},
    {"id":"8012","name":"Tolperisone: Product information as approved by the CHMP on 21 June 2012, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T12:00:00Z","last_updated_date":"2012-06-22T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/tolperisone-product-information-approved-chmp-21-june-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"8019","name":"Statement of authority and confidentiality commitment from the United States Food and Drug Administration not to publicly disclose non-public information shared by the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-09-15T02:00:00Z","last_updated_date":"2010-09-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/statement-authority-and-confidentiality-commitment-united-states-food-and-drug-administration-not-publicly-disclose-non-public-information-shared-european-medicines-agency_en.pdf"},
    {"id":"8022","name":"Public hearing on valproate - Written interventions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-02T19:30:00Z","last_updated_date":"2017-10-02T19:30:00Z","reference_number":"EMA/645752/2017","document_url":"https://www.ema.europa.eu/en/documents/other/public-hearing-valproate-written-interventions_en.pdf"},
    {"id":"8038","name":"Recognition criteria for self-assessment - European Network of Paediatric Reserach at the European Medicines Agency: European Cystic Fibrosis Society - Clinical Trials Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/867379/2011","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-reserach-european-medicines-agency-european-cystic-fibrosis-society-clinical-trials-network_en.pdf"},
    {"id":"8041","name":"Timetable: Extension application - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T16:00:00Z","last_updated_date":"2026-05-13T14:30:00Z","reference_number":"EMA/824995/2015 Rev.8","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-extension-application-atmp_en.xlsx"},
    {"id":"8042","name":"Letter of invitation to tender - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"EMA/755550/201212","document_url":"https://www.ema.europa.eu/en/documents/other/letter-invitation-tender-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"8086","name":"Annex III: Draft donation agreement - Donation of EMA assets no. EMA/2014/28/IS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-iii-draft-donation-agreement-donation-ema-assets-no-ema201428is_en.pdf"},
    {"id":"8098","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Recombinant parathyroid hormone for treatment of hypoparathyroidism","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T12:45:00Z","last_updated_date":"2014-10-21T12:45:00Z","reference_number":"EMA/485026/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-recombinant-parathyroid-hormone-treatment-hypoparathyroidism_en.pdf"},
    {"id":"8113","name":"Guidelines and concept papers adopted during the CHMP meeting 19-22 September 2011 (Corr.)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-10-18T14:56:00Z","reference_number":"EMA/764325/2011","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-19-22-september-2011-corr_en.pdf"},
    {"id":"8114","name":"Confidentiality arrangements concluded between the European Union (European Commission and European Medicines Agency) and the United States Food and Drug Administration / Department of Health and Human Services - Impleme...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-09-16T02:00:00Z","last_updated_date":"2004-09-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/confidentiality-arrangements-concluded-between-european-union-european-commission-and-european-medicines-agency-and-united-states-food-and-drug-administration-department-health-and-human-services_en.pdf"},
    {"id":"8115","name":"Recognition criteria for self assessment - Enpr-EMA: The Paediatric Trial\n\nNetwork (AMIKI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2011-01-07T00:31:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-paediatric-trial-network-amiki_en.pdf"},
    {"id":"8129","name":"Questions and answers on design-space verification","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-04T17:45:00Z","last_updated_date":"2013-11-04T17:45:00Z","reference_number":"EMA/603905/2013","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-design-space-verification_en.pdf"},
    {"id":"8163","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): Product- or population-specific considerations II: Biological medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:00:00Z","last_updated_date":"2016-08-15T12:00:00Z","reference_number":"EMA/172711/2016","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-ii-biological-medicinal-products_en.pdf"},
    {"id":"8169","name":"Outcome of the workshop on viral safety of plasma-derived medicinal products with respect to hepatitis E virus","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/774690/2014","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-workshop-viral-safety-plasma-derived-medicinal-products-respect-hepatitis-e-virus_en.pdf"},
    {"id":"8170","name":"Opinions on safety variations - Adopted at the CHMP meeting of 17-20 September 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-24T10:44:00Z","last_updated_date":"2012-09-24T10:44:00Z","reference_number":"EMA/CHMP/539766/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-17-20-september-2012_en.pdf"},
    {"id":"8174","name":"Mandate, objectives and rules of procedure for the CHMP Pharmacovigilance Working Party","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2005-06-23T02:09:21Z","last_updated_date":"2005-06-23T02:09:21Z","reference_number":"EMEA/CHMP/PhVWP/88786/04","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-chmp-pharmacovigilance-working-party_en.pdf"},
    {"id":"8175","name":"Commission Regulation (EU) 2016/461 of 30 March 2016 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T12:30:00Z","last_updated_date":"2016-04-01T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/commission-regulation-eu-2016461-30-march-2016-amending-council-regulation-ec-no-29795-regards-adjustment-fees-european-medicines-agency-inflation-rate_en.pdf"},
    {"id":"8197","name":"Workshop - the role of pharmacodynamic and pharmacokinetic measurements in the use of direct oral anticoagulants: Background document","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-11-20T11:35:00Z","last_updated_date":"2015-11-20T11:35:00Z","reference_number":"EMA/746962/2015","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-role-pharmacodynamic-and-pharmacokinetic-measurements-use-direct-oral-anticoagulants-background-document_en.pdf"},
    {"id":"8204","name":"Advanced-therapy medicinal products: Responses to list of questions/supplementary request for information/list of outstanding issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-12-06T01:00:00Z","last_updated_date":"2009-12-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advanced-therapy-medicinal-products-responses-list-questionssupplementary-request-informationlist-outstanding-issues_en.pdf"},
    {"id":"8215","name":"Extract from the published minutes of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting: Annex 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/670072/2015","document_url":"https://www.ema.europa.eu/en/documents/other/extract-published-minutes-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-annex-1_en.pdf"},
    {"id":"8218","name":"The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future Outcome of the Consultation with the EMEA’s Partners and Stakeholders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-03-04T01:00:00Z","last_updated_date":"2005-03-04T01:00:00Z","reference_number":"Ref. EMEA/83716/2004/Final","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-road-map-2010-preparing-ground-future-outcome-consultation-emeas-partners-and-stakeholders_en.pdf"},
    {"id":"8232","name":"Donation of EMA IT assets no. EMA/2016/35/IT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-29T12:45:00Z","last_updated_date":"2016-07-29T12:45:00Z","reference_number":"EMA/263097/2016","document_url":"https://www.ema.europa.eu/en/documents/other/donation-ema-it-assets-no-ema201635it_en.pdf"},
    {"id":"8241","name":"Aclasta: Product Information as approved by the CHMP on 26 March 2015, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T13:00:00Z","last_updated_date":"2015-03-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/aclasta-product-information-approved-chmp-26-march-2015-pending-endorsement-european-commission_en.pdf"},
    {"id":"8249","name":"Clarification note on the requirements for the starting materials of biological origin","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-09-22T02:09:21Z","last_updated_date":"2008-09-22T02:09:21Z","reference_number":"EMEA/CVMP/439633/2007","document_url":"https://www.ema.europa.eu/en/documents/other/clarification-note-requirements-starting-materials-biological-origin_en.pdf"},
    {"id":"8255","name":"Overview of comments on draft guideline on non-clinical and clinical development of medicinal products for the treatment of nausea and vomiting associated with cancer chemotherapy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-12-14T00:09:21Z","last_updated_date":"2006-12-14T00:09:21Z","reference_number":"EMEA/CHMP/EWP/487732/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-draft-guideline-non-clinical-and-clinical-development-medicinal-products-treatment-nausea-and-vomiting-associated-cancer-chemotherapy_en.pdf"},
    {"id":"8278","name":"Examples of prevalence sources previously considered in orphan medicinal product designation procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-18T11:40:00Z","last_updated_date":"2014-12-18T11:40:00Z","reference_number":"EMA/765701/2014","document_url":"https://www.ema.europa.eu/en/documents/other/examples-prevalence-sources-previously-considered-orphan-medicinal-product-designation-procedures_en.pdf"},
    {"id":"8302","name":"Hemoprostol : EPAR - Procedural steps taken and scientific information after authorisation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-08T02:00:00Z","last_updated_date":"2015-07-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/hemoprostol-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf"},
    {"id":"8315","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) organisations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2023-01-23T08:23:00Z","reference_number":"EMA/136156/2012 Rev. 64","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-organisations_en.xls"},
    {"id":"8317","name":"Validation issues frequently seen with initial marketing authorisation holders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T18:30:00Z","last_updated_date":"2020-08-10T11:00:00Z","reference_number":"EMA/454165/2015 Rev. 1.1","document_url":"https://www.ema.europa.eu/en/documents/other/validation-issues-frequently-seen-initial-marketing-authorisation-holders_en.pdf"},
    {"id":"8324","name":"Guidelines and concept papers adopted during the CHMP meeting 23-26 June 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T16:30:00Z","last_updated_date":"2014-07-01T16:30:00Z","reference_number":"EMA/125330/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-23-26-june-2014_en.pdf"},
    {"id":"8326","name":"Public bulletin: Veterinary pharmacovigilance 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-01T01:00:00Z","last_updated_date":"2011-03-01T01:00:00Z","reference_number":"EMA/CVMP/PhVWP/44873/2011","document_url":"https://www.ema.europa.eu/en/documents/other/public-bulletin-veterinary-pharmacovigilance-2010_en.pdf"},
    {"id":"8331","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Coagulation factor VIIa (recombinant) for treatment of congenital coagulation disorders and treatment of acquired haemophilia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T17:30:00Z","last_updated_date":"2015-05-19T17:30:00Z","reference_number":"EMA/274136/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-coagulation-factor-viia-recombinant-treatment-congenital-coagulation-disorders-and-treatment-acquired-haemophilia_en.pdf"}    {"id":"8373","name":"Reporting requirements of marketing authorisation holders in the European Union (EU) regarding suspected adverse reactions occurring with medicinal products they donate outside the EU to public health programmes against ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-27T13:03:00Z","last_updated_date":"2015-04-27T13:03:00Z","reference_number":"EMA/182873/2015","document_url":"https://www.ema.europa.eu/en/documents/other/reporting-requirements-marketing-authorisation-holders-european-union-eu-regarding-suspected-adverse-reactions-occurring-medicinal-products-they-donate-outside-eu-public-health-programmes-against_en.pdf"},
    {"id":"8387","name":"Overview of comments received on draft guideline on  carcinogenicity evaluation of medicinal products for the treatment of HIV infection","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-05-26T02:00:00Z","last_updated_date":"2009-05-26T02:00:00Z","reference_number":"EMEA/211762/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-carcinogenicity-evaluation-medicinal-products-treatment-hiv-infection_en.pdf"},
    {"id":"8395","name":"Declaration of research interests (addendum) - Jose Drabwell","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-jose-drabwell_en.pdf"},
    {"id":"8406","name":"Emerging safety issues (ESI) contact points at the national competent authority (NCA) level","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-09-01T19:30:00Z","last_updated_date":"2026-01-28T17:10:00Z","reference_number":"EMA/425422/2017 Corr.4","document_url":"https://www.ema.europa.eu/en/documents/other/emerging-safety-issues-esi-contact-points-national-competent-authority-nca-level_en.xlsx"},
    {"id":"8407","name":"Outcome of Management Board written procedures during the period from 23 February to 16 May 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/MB/375944/2011","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-management-board-written-procedures-during-period-23-february-16-may-2011_en.pdf"},
    {"id":"8427","name":"European Medicines Agency pandemic-influenza crisis management plan for the evaluation and maintenance of pandemic-influenza vaccines and antivirals","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-08-21T02:09:21Z","last_updated_date":"2006-08-21T02:09:21Z","reference_number":"EMEA/214301/2006","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-pandemic-influenza-crisis-management-plan-evaluation-and-maintenance-pandemic-influenza-vaccines-and-antivirals_en.pdf"},
    {"id":"8432","name":"Notes on a seminar involving the European Federation of Pharmaceutical Industries and Associations and the European Medicines Agency process-analytical-technology team in Ireland, 31 March - 2 April 2008","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-10-28T01:00:00Z","last_updated_date":"2008-10-28T01:00:00Z","reference_number":"EMEA/INS/575495/2008","document_url":"https://www.ema.europa.eu/en/documents/other/notes-seminar-involving-european-federation-pharmaceutical-industries-and-associations-and-european-medicines-agency-process-analytical-technology-team-ireland-31-march-2-april-2008_en.pdf"},
    {"id":"8433","name":"Declaration of interests: Birgit Breen","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-20T01:00:00Z","last_updated_date":"2017-08-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-birgit-breen_en.pdf"},
    {"id":"8460","name":"Organising committee - Joint Biologics Working Party / Quality Working Party workshop with stakeholders in relation to prior knowledge and its use in regulatory applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-07-28T18:30:00Z","last_updated_date":"2017-11-22T16:30:00Z","reference_number":"EMA/466502/2017","document_url":"https://www.ema.europa.eu/en/documents/other/organising-committee-joint-biologics-working-party-quality-working-party-workshop-stakeholders-relation-prior-knowledge-and-its-use-regulatory-applications_en.pdf"},
    {"id":"8473","name":"Renewal of confidentiality agreement: Letter from Health Canada to the European Medicines Agency and the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-15T16:30:00Z","last_updated_date":"2013-03-15T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/renewal-confidentiality-agreement-letter-health-canada-european-medicines-agency-and-european-commission_en.pdf"},
    {"id":"8474","name":"Examples of key binding elements in the paediatric investigation plan decisions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-05T13:00:00Z","last_updated_date":"2014-02-05T13:00:00Z","reference_number":"EMA/174403/2013","document_url":"https://www.ema.europa.eu/en/documents/other/examples-key-binding-elements-paediatric-investigation-plan-decisions_en.pdf"},
    {"id":"8491","name":"Summary of transfers of appropriations in budget 2017: Management Board meeting: 13-14 December 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T17:00:00Z","last_updated_date":"2017-12-15T17:00:00Z","reference_number":"EMA/MB/794050/2017","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2017-management-board-meeting-13-14-december-2017_en.pdf"},
    {"id":"8505","name":"Confidentiality arrangements concluded between the European Union (European Commission and European Medicines Agency) and the United States Food and Drug Administration / Department for Health and Human Services - Implem...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-06-18T02:09:21Z","last_updated_date":"2007-06-18T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/confidentiality-arrangements-concluded-between-european-union-european-commission-and-european-medicines-agency-and-united-states-food-and-drug-administration-department-health-and-human-services_en.pdf-0"},
    {"id":"8518","name":"Letter of invitation to tender - Provision of training courses for EMA staff (Lots 1-6)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-03T01:00:00Z","last_updated_date":"2012-01-03T01:00:00Z","reference_number":"EMA/974043/2011","document_url":"https://www.ema.europa.eu/en/documents/other/letter-invitation-tender-provision-training-courses-ema-staff-lots-1-6_en.pdf"},
    {"id":"8550","name":"Overview of comments received on the guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg): (EMA/CHMP/BPWP/94033/2007, rev. 2 formerly CPMP/BPWG/388/95 rev. 2)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-08-02T02:00:00Z","last_updated_date":"2010-08-02T02:00:00Z","reference_number":"EMA/CHMP/BPWP/604687/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-emachmpbpwp940332007-rev-2-formerly-cpmpbpwg38895-rev-2_en.pdf"},
    {"id":"8564","name":"Technical specification - Annex 6 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"EMA/193130/2012","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-6-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"8570","name":"Technical specification - Annex 9 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-9-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"8571","name":"Opinions on safety variations/PSURs adopted at the CHMP meeting 21-24 October 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T17:30:00Z","last_updated_date":"2013-10-29T17:30:00Z","reference_number":"EMA/634287/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variationspsurs-adopted-chmp-meeting-21-24-october-2013_en.pdf"},
    {"id":"8621","name":"We work together to fight antibiotic resistance keeping Europeans healthy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T11:00:00Z","last_updated_date":"2017-11-13T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/we-work-together-fight-antibiotic-resistance-keeping-europeans-healthy_en.pdf"},
    {"id":"8622","name":"Discussion paper: The European Medicines Agency Road Map to 2010: Preparing the ground for the future: Executive Summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-03-23T01:00:00Z","last_updated_date":"2004-03-23T01:00:00Z","reference_number":"EMEA/H/34163/03/Rev 2.0","document_url":"https://www.ema.europa.eu/en/documents/other/discussion-paper-european-medicines-agency-road-map-2010-preparing-ground-future-executive-summary_en.pdf"},
    {"id":"8628","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2009","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/INS/PhV/472212/2008","document_url":"https://www.ema.europa.eu/en/documents/other/work-plan-pharmacovigilance-inspectors-working-group-2009_en.pdf"},
    {"id":"8644","name":"Detailed guide regarding the monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-05-12T14:29:00Z","last_updated_date":"2015-05-12T14:29:00Z","reference_number":"EMA/161530/2014","document_url":"https://www.ema.europa.eu/en/documents/other/detailed-guide-regarding-monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency_en.pdf"},
    {"id":"8645","name":"EMA action plan for small and medium-sized enterprises (SMEs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-31T17:00:00Z","last_updated_date":"2017-05-31T17:00:00Z","reference_number":"EMA/337458/2017","document_url":"https://www.ema.europa.eu/en/documents/other/ema-action-plan-small-and-medium-sized-enterprises-smes_en.pdf"},
    {"id":"8681","name":"Committee for medicinal products for veterinary use -\n\nEMEA public bulletin 2005 on veterinary pharmacovigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-02-01T01:00:00Z","last_updated_date":"2006-02-01T01:00:00Z","reference_number":"EMEA/CVMP/226674/2005","document_url":"https://www.ema.europa.eu/en/documents/other/committee-medicinal-products-veterinary-use-emea-public-bulletin-2005-veterinary-pharmacovigilance_en.pdf"},
    {"id":"8708","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Scottish Medicines for Children Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817613/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-scottish-medicines-children-network_en.pdf"},
    {"id":"8712","name":"Amending budget 01-2012 for changes to entry grade for a post","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"EMA/MB/155755/2012","document_url":"https://www.ema.europa.eu/en/documents/other/amending-budget-01-2012-changes-entry-grade-post_en.pdf"},
    {"id":"8716","name":"Annual list of specific contracts based on framework contracts – 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-06-28T18:30:00Z","last_updated_date":"2018-06-28T18:30:00Z","reference_number":"EMA/424076/2018","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-specific-contracts-based-framework-contracts-2017_en.pdf"},
    {"id":"8722","name":"Principles for publication of agendas and minutes of EMA scientific committees","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-18T13:00:00Z","last_updated_date":"2013-12-18T13:00:00Z","reference_number":"EMA/555647/2013","document_url":"https://www.ema.europa.eu/en/documents/other/principles-publication-agendas-and-minutes-ema-scientific-committees_en.pdf"},
    {"id":"8734","name":"Questions and answers relating to open procedure – EMA 2012-37-ED Online strategy and interface design","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-27T12:50:00Z","last_updated_date":"2013-06-27T12:50:00Z","reference_number":"EMA/352562/2013","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-procedure-ema-2012-37-ed-online-strategy-and-interface-design_en.pdf"},
    {"id":"8743","name":"Letter from the European Medicines Agency to Ms M Rivasi regarding Dr Xavier Kurz","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-26T15:00:00Z","last_updated_date":"2011-10-26T15:00:00Z","reference_number":"EMA/858830/2011","document_url":"https://www.ema.europa.eu/en/documents/other/letter-european-medicines-agency-ms-m-rivasi-regarding-dr-xavier-kurz_en.pdf"},
    {"id":"8745","name":"Working party on Herbal Medicinal Products: Draft proposal for a Devil's claw root","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2000-04-04T02:00:00Z","last_updated_date":"2000-04-04T02:00:00Z","reference_number":"EMEA/HMPWP/21/00","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-draft-proposal-devils-claw-root_en.pdf"},
    {"id":"8751","name":"General principles - European Medicines Agency / Veterinary Medicines and Inspections Unit - Food and Drug Administration / Center for Veterinary Medicine - Parallel scientific-advice meetings","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-05-22T02:09:21Z","last_updated_date":"2008-05-22T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/general-principles-european-medicines-agency-veterinary-medicines-and-inspections-unit-food-and-drug-administration-center-veterinary-medicine-parallel-scientific-advice-meetings_en.pdf"},
    {"id":"8762","name":"Overview of comments received on draft Reflection Paper on the risks associated with furocoumarins contained in preparations of Angelica archangelica L.","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/HMPC/277293/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-reflection-paper-risks-associated-furocoumarins-contained-preparations-angelica-archangelica-l_en.pdf"},
    {"id":"8766","name":"Coding of indications in the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-01T17:06:00Z","last_updated_date":"2015-12-01T17:06:00Z","reference_number":"EMA/245789/2015","document_url":"https://www.ema.europa.eu/en/documents/other/coding-indications-extended-eudravigilance-medicinal-product-dictionary-xevmpd_en.pdf"},
    {"id":"8769","name":"Technical specifications - Annex VI - Service level agreement - EMA/2012/18/HR Procurement procedure for medical services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-vi-service-level-agreement-ema201218hr-procurement-procedure-medical-services_en.pdf"},
    {"id":"8780","name":"Mandate, objectives and rules of procedure for the HMPC Working Party on Community Monographs and Community List (MLWP)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-01-10T00:09:21Z","last_updated_date":"2018-03-09T16:00:00Z","reference_number":"EMA/HMPC/358825/2005","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-hmpc-working-party-community-monographs-and-community-list-mlwp_en.pdf"},
    {"id":"8785","name":"Memorandum - Expert group of quality assessors – work report","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-06T01:00:00Z","last_updated_date":"2012-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/memorandum-expert-group-quality-assessors-work-report_en.pdf"},
    {"id":"8793","name":"Small- and medium-sized-enterprises (SME) and medicines in 2014 - Marketing authorisation applications received","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/small-and-medium-sized-enterprises-sme-and-medicines-2014-marketing-authorisation-applications-received_en.pdf"},
    {"id":"8800","name":"Compliance Group mandate: Joint Audit Programme for EEA GMP Inspectorates","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T17:10:00Z","last_updated_date":"2021-03-10T10:18:00Z","reference_number":"EMA/398531/2020 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/compliance-group-mandate-joint-audit-programme-eea-gmp-inspectorates_en.pdf"},
    {"id":"8830","name":"Guidelines and concept papers adopted at the CHMP meeting 21-24 October 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T17:30:00Z","last_updated_date":"2013-10-29T17:30:00Z","reference_number":"EMA/653473/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-chmp-meeting-21-24-october-2013_en.pdf"},
    {"id":"8831","name":"Declaration of interests: Martin Harvey Allchurch","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T15:06:00Z","last_updated_date":"2025-08-01T17:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-martin-harvey-allchurch_en.pdf"},
    {"id":"8840","name":"Submission of comments form","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-02-17T14:30:00Z","last_updated_date":"2017-02-17T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/submission-comments-form_en.doc"},
    {"id":"8855","name":"Extension of the arrangement for shared non-public information regarding the influenza A (H1N1) pandemic between the European Medicines Agency and the Swiss Agency for Therapeutic Products, Swissmedic","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-02-14T16:37:01Z","last_updated_date":"2011-02-14T16:37:01Z","reference_number":"EMA/51585/2011","document_url":"https://www.ema.europa.eu/en/documents/other/extension-arrangement-shared-non-public-information-regarding-influenza-h1n1-pandemic-between-european-medicines-agency-and-swiss-agency-therapeutic-products-swissmedic_en.pdf"},
    {"id":"8868","name":"Opinions on safety variations adopted at the CHMP meeting 12-15 November 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-22T10:15:00Z","last_updated_date":"2012-11-22T10:15:00Z","reference_number":"EMA/CHMP/732275/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-12-15-november-2012_en.pdf"},
    {"id":"8872","name":"Joint Committee Opinion n.1/2011 of 8 March 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-21T01:00:00Z","last_updated_date":"2011-03-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/joint-committee-opinion-n12011-8-march-2011_en.pdf"},
    {"id":"8880","name":"Overview of comments received on draft guideline on\n\nvalidation of immunoassay for the detection of antibody to human immunodeficiency virus (anti-HIV) in plasma pools","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/CHMP/BWP/94182/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-validation-immunoassay-detection-antibody-human-immunodeficiency-virus-anti-hiv-plasma-pools_en.pdf"},
    {"id":"8918","name":"Recognition criteria for self assessment - Enpr-EMA: Children Leukemia Group (CLG)\n\nof the EORTC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2011-01-07T00:31:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-children-leukemia-group-clg-eortc_en.pdf"},
    {"id":"8922","name":"Organisational matters: CHMP meeting 21-24 October 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T17:30:00Z","last_updated_date":"2013-10-29T17:30:00Z","reference_number":"EMA/653476/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-21-24-october-2013_en.pdf"},
    {"id":"9027","name":"Annex B1 - Other criteria essential to ensure that EMA remains operational to guarantee business continuity – Summary of EMA contributions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T20:15:00Z","last_updated_date":"2017-10-03T20:15:00Z","reference_number":"EMA/606451/2017","document_url":"https://www.ema.europa.eu/en/documents/other/annex-b1-other-criteria-essential-ensure-ema-remains-operational-guarantee-business-continuity-summary-ema-contributions_en.pdf"},
    {"id":"9038","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Ceftriaxone / sulbactam for treatment of bacterial infections","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T17:30:00Z","last_updated_date":"2015-05-19T17:30:00Z","reference_number":"EMA/281072/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-ceftriaxone-sulbactam-treatment-bacterial-infections_en.pdf"},
    {"id":"9054","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Valaciclovir (hydrochloride) for treatment and prevention of Herpes simplex virus disease and treatment and prevention of Varicella Zoster vir...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-17T12:30:00Z","last_updated_date":"2015-02-17T12:30:00Z","reference_number":"EMA/99269/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-valaciclovir-hydrochloride-treatment-and-prevention-herpes-simplex-virus-disease-and-treatment-and-prevention-varicella-zoster-vir_en.pdf"},
    {"id":"9064","name":"Draft contract for external experts","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-10T12:00:00Z","last_updated_date":"2018-07-10T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/draft-contract-external-experts_en.pdf"},
    {"id":"9071","name":"Draft budget for 2010, presented to the Management Board on 10 December 2009","type":"other","status":"Draft","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMEA/MB/628139/2009","document_url":"https://www.ema.europa.eu/en/documents/other/draft-budget-2010-presented-management-board-10-december-2009_en.pdf"},
    {"id":"9072","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Solithromycin for treatment of bacterial pneumonia and treatment of\n\ngonococcal infection","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-25T12:30:00Z","last_updated_date":"2014-11-25T12:30:00Z","reference_number":"EMA/674176/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-solithromycin-treatment-bacterial-pneumonia-and-treatment-gonococcal-infection_en.pdf"},
    {"id":"9106","name":"Extension of confidentiality arrangement between the United States Food and Drug Administration and the European Commission Enterprise and Industry Directorate-General and the European Medicines Agency to exchange regula...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-09-15T02:09:21Z","last_updated_date":"2005-09-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/extension-confidentiality-arrangement-between-united-states-food-and-drug-administration-and-european-commission-enterprise-and-industry-directorate-general-and-european-medicines-agency-exchange_en.pdf"},
    {"id":"9110","name":"Opinions on consultation procedures on ancillary medicinal substances in medical devices - CHMP meeting 18-21 February 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/116578/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-consultation-procedures-ancillary-medicinal-substances-medical-devices-chmp-meeting-18-21-february-2013_en.pdf"},
    {"id":"9146","name":"Announcement - European Medicines Agency/International Federation for Animal Health Europe info day 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-02T17:00:00Z","last_updated_date":"2015-12-02T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/announcement-european-medicines-agencyinternational-federation-animal-health-europe-info-day-2016_en.pdf"},
    {"id":"9171","name":"Committee for Orphan Medicinal Products (COMP) meetings 2019, 2020 and 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-29T12:25:00Z","last_updated_date":"2019-07-31T13:25:00Z","reference_number":"EMA/COMP/115244/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/committee-orphan-medicinal-products-comp-meetings-2019-2020-and-2021_en.pdf"},
    {"id":"9172","name":"Summary of the European Union workshop on ICH Q3D from a quality perspective","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-03-08T13:00:00Z","last_updated_date":"2016-03-08T13:00:00Z","reference_number":"EMA/INS/158905/2016","document_url":"https://www.ema.europa.eu/en/documents/other/summary-european-union-workshop-ich-q3d-quality-perspective_en.pdf"},
    {"id":"9177","name":"Package leaflet: information for the patient: Fludeoxyglucose","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-14T01:00:00Z","last_updated_date":"2010-12-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/package-leaflet-information-patient-fludeoxyglucose_en.pdf"},
    {"id":"9188","name":"Availability of medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"1999-01-20T01:00:00Z","last_updated_date":"1999-01-20T01:00:00Z","reference_number":"EMEA/V2381/99","document_url":"https://www.ema.europa.eu/en/documents/other/availability-medicines_en.pdf"},
    {"id":"9201","name":"Conventional medicinal products: Full applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-25T01:09:21Z","last_updated_date":"2009-12-03T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/conventional-medicinal-products-full-applications_en.pdf"},
    {"id":"9207","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: International BFM Study Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-international-bfm-study-group_en.pdf"},
    {"id":"9218","name":"Working party on Herbal Medicinal Products: Draft proposal for a core data for Hop Strobile","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2000-03-31T02:00:00Z","last_updated_date":"2000-03-31T02:00:00Z","reference_number":"EMEA/HMPWP/20/00","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-draft-proposal-core-data-hop-strobile_en.pdf"},
    {"id":"9234","name":"Involvement of patients in Scientific Advisory Group and Ad Hoc Expert meetings at EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-26T18:00:00Z","last_updated_date":"2021-10-19T16:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/involvement-patients-scientific-advisory-group-and-ad-hoc-expert-meetings-ema_en.pdf"},
    {"id":"9238","name":"List of participants - EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting (27 June 2017)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"EMA/258524/2017","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-27-june-2017_en.pdf"},
    {"id":"9294","name":"Overview of comments received on 'Reflection paper on use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T15:45:00Z","last_updated_date":"2014-02-20T16:25:00Z","reference_number":"EMA/CVMP/AWP/257904/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-use-pleuromutilins-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"9307","name":"CTAG3: Advice to the European Medicines Agency on rules of engagement for accessing clinical-trial data - Draft 22 March 2013 version 7.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-advice-european-medicines-agency-rules-engagement-accessing-clinical-trial-data-draft-22-march-2013-version-70_en.pdf"},
    {"id":"9340","name":"Annex to the European Medicines Agency master data management roadmap","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T16:00:00Z","last_updated_date":"2015-04-29T16:00:00Z","reference_number":"EMA/187520/2015","document_url":"https://www.ema.europa.eu/en/documents/other/annex-european-medicines-agency-master-data-management-roadmap_en.pdf"},
    {"id":"9354","name":"Outcome of written procedures finalised during the period from 18 May 2012 to 19 September 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/MB/607587/2012","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-18-may-2012-19-september-2012_en.pdf"},
    {"id":"9361","name":"Working party on Herbal Medicinal Products: Comments on the European Commission guideline on dossier requirements for Type I Variations – Notice to Applicants Vol. 2A","type":"other","status":"unknown","consultation_date":"","first_published_date":"1999-11-01T01:00:00Z","last_updated_date":"1999-11-01T01:00:00Z","reference_number":"EMEA/HMPWP/22/99","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-comments-european-commission-guideline-dossier-requirements-type-i-variations-notice-applicants-vol-2a_en.pdf"},
    {"id":"9362","name":"IFAH-Europe conference room document: Outcomes of the evaluation of the European medicines agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-13T01:00:00Z","last_updated_date":"2010-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ifah-europe-conference-room-document-outcomes-evaluation-european-medicines-agency_en.pdf"},
    {"id":"9374","name":"Hemoblast Bellows - Procedural steps and scientific information after initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2021-03-15T10:20:00Z","reference_number":"EMA/CHMP/154036/2021 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/hemoblast-bellows-procedural-steps-and-scientific-information-after-initial-consultation_en.pdf"},
    {"id":"9404","name":"List of Participants - Training session for patients and consumers involved in EMA activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"EMA/702994/2014","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-training-session-patients-and-consumers-involved-ema-activities_en.pdf"},
    {"id":"9408","name":"European Medicines Agency-Food and Drug Administration good-clinical-practice initiative: Terms of engagement and procedures for participating authorities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-29T02:09:21Z","last_updated_date":"2009-07-29T02:09:21Z","reference_number":"EMEA/INS/GCP/538414/2008","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-food-and-drug-administration-good-clinical-practice-initiative-terms-engagement-and-procedures-participating-authorities_en.pdf"},
    {"id":"9411","name":"Outcome of written procedures finalised during the period from 12 May 2016 to 6 September 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:30:00Z","last_updated_date":"2016-10-07T17:30:00Z","reference_number":"EMA/MB/607820/2016","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-12-may-2016-6-september-2016_en.pdf"},
    {"id":"9422","name":"Overview of comments received on the draft guideline on clinical investigation of medicinal products in the treatment of lipid disorders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-16T16:10:00Z","last_updated_date":"2014-01-16T16:10:00Z","reference_number":"EMA/CHMP/748246/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-lipid-disorders_en.pdf"},
    {"id":"9460","name":"Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T14:00:00Z","last_updated_date":"2016-04-22T14:00:00Z","reference_number":"EMA/CHMP/292464/2014","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf"},
    {"id":"9469","name":"Background information - Symposium: Raw materials for production of cell-based and gene-therapy products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T15:00:00Z","last_updated_date":"2013-01-28T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/background-information-symposium-raw-materials-production-cell-based-and-gene-therapy-products_en.pdf"},
    {"id":"9494","name":"Overview of comments received on ‘guideline on the use of near infrared spectroscopy by the pharmaceutical industry and the data requirements for new submissions and variations’ - Revision 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-09T16:10:00Z","last_updated_date":"2012-02-09T16:10:00Z","reference_number":"EMA/CHMP/CVMP/QWP/989848/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-use-near-infrared-spectroscopy-pharmaceutical-industry-and-data-requirements-new-submissions-and-variations-revision-1_en.pdf"},
    {"id":"9503","name":"Committee for medicinal products for veterinary use -\n\nEMEA public bulletin 2004 on veterinary pharmacovigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-01-12T01:00:00Z","last_updated_date":"2005-01-12T01:00:00Z","reference_number":"EMEA/CVMP/066/05-FINAL","document_url":"https://www.ema.europa.eu/en/documents/other/committee-medicinal-products-veterinary-use-emea-public-bulletin-2004-veterinary-pharmacovigilance_en.pdf"},
    {"id":"9532","name":"Paediatric rheumatology expert group meeting - Conclusions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2011-02-16T01:00:00Z","reference_number":"EMA/89878/2010","document_url":"https://www.ema.europa.eu/en/documents/other/paediatric-rheumatology-expert-group-meeting-conclusions_en.pdf"},
    {"id":"9534","name":"Protelos / Osseor: Product information as approved by the CHMP on 15 March 2012, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-16T11:00:00Z","last_updated_date":"2012-03-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/protelos-osseor-product-information-approved-chmp-15-march-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"9543","name":"European Medicines Agency decision CW-0001-2015 of 23 July 2015 on class waivers in accordance with Regulation EC No 1901-2006 of the European Parliament and of the Council","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-23T13:00:00Z","last_updated_date":"2018-05-28T17:30:00Z","reference_number":"EMA/498952/2015","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-decision-cw-0001-2015-23-july-2015-class-waivers-accordance-regulation-ec-no-1901-2006-european-parliament-and-council_en.pdf"},
    {"id":"9552","name":"Summary - Selection and handling of the test manure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-06-23T02:09:21Z","last_updated_date":"2009-06-23T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/summary-selection-and-handling-test-manure_en.pdf"},
    {"id":"9556","name":"3.1 Annex I - Statistical analysis methods compatible with EMA bioequivalence guideline","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-09T16:00:00Z","last_updated_date":"2016-11-09T16:00:00Z","reference_number":"EMA/582648/2016","document_url":"https://www.ema.europa.eu/en/documents/other/31-annex-i-statistical-analysis-methods-compatible-ema-bioequivalence-guideline_en.pdf"},
    {"id":"9560","name":"Improving the perception and use of the Article 58 procedure- An action plan for 2015-2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/756676/2015-Rev 1","document_url":"https://www.ema.europa.eu/en/documents/other/improving-perception-and-use-article-58-procedure-action-plan-2015-2017_en.pdf"},
    {"id":"9566","name":"List of participants - Developing a framework of collaboration between EMA and academia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T13:00:00Z","last_updated_date":"2016-07-11T13:00:00Z","reference_number":"EMA/362719/2016","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-developing-framework-collaboration-between-ema-and-academia_en.pdf"},
    {"id":"9568","name":"Public hearing on quinolone and fluoroquinolone - Written interventions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-06-20T12:30:00Z","last_updated_date":"2018-06-25T14:21:00Z","reference_number":"EMA/225564/2018 Corr. *","document_url":"https://www.ema.europa.eu/en/documents/other/public-hearing-quinolone-and-fluoroquinolone-written-interventions_en.pdf"},
    {"id":"9587","name":"Summary of transfer of appropriations in the budget 2011 - Management Board meeting: 15 December 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T11:30:00Z","last_updated_date":"2011-12-20T11:30:00Z","reference_number":"EMA/MB/902314/2011","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2011-management-board-meeting-15-december-2011_en.pdf"},
    {"id":"9595","name":"EMEA meeting with interested parties and research centres on ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance) - Summary of the Outcome of the Working Groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-12-17T01:00:00Z","last_updated_date":"2007-12-17T01:00:00Z","reference_number":"EMEA/601105/2007","document_url":"https://www.ema.europa.eu/en/documents/other/emea-meeting-interested-parties-and-research-centres-encepp-european-network-centres-pharmacoepidemiology-and-pharmacovigilance-summary-outcome-working-groups_en.pdf"},
    {"id":"9596","name":"PRAC meeting dates 2012, 2013, 2014 and 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-24T01:00:00Z","last_updated_date":"2014-06-03T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/prac-meeting-dates-2012-2013-2014-and-2015_en.pdf"},
    {"id":"9624","name":"Letter from the European Commission and the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-european-commission-and-european-medicines-agency_en.pdf"},
    {"id":"9630","name":"Assessment of the paediatric needs - Psychiatry","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2007-07-27T02:00:00Z","last_updated_date":"2007-07-27T02:00:00Z","reference_number":"EMEA/288917/2007","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-psychiatry_en.pdf"},
    {"id":"9636","name":"Assessment of the paediatric needs - Cardiovascular products","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-10-01T02:00:00Z","last_updated_date":"2006-10-01T02:00:00Z","reference_number":"EMEA/439649/2006","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-cardiovascular-products_en.pdf"},
    {"id":"9648","name":"CHMP rules of procedure","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2007-03-19T01:00:00Z","last_updated_date":"2024-02-14T09:22:00Z","reference_number":"EMEA/45110/2007 – Revised 09 February 2024","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-rules-procedure_en.pdf"},
    {"id":"9653","name":"Semler - Marketing authorisations which are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation as adopted by the CHMP on 21 July 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/499744/2016","document_url":"https://www.ema.europa.eu/en/documents/other/semler-marketing-authorisations-which-are-recommended-suspension-and-marketing-authorisation-applications-which-do-not-satisfy-criteria-authorisation-adopted-chmp-21-july-2016_en.pdf"},
    {"id":"9663","name":"Download EPS - Species pictograms - Goose","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-goose_en.zip"},
    {"id":"9692","name":"Resources for issuing treatment recommendation during shortages of medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T00:00:00Z","last_updated_date":"2013-01-29T00:00:00Z","reference_number":"EMA/310484/2013","document_url":"https://www.ema.europa.eu/en/documents/other/resources-issuing-treatment-recommendation-during-shortages-medicinal-products_en.pdf"},
    {"id":"9702","name":"Overview of comments received on draft guideline on user safety for immunological veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-05-02T02:00:00Z","last_updated_date":"2007-05-02T02:00:00Z","reference_number":"EMEA/145621/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-user-safety-immunological-veterinary-medicinal-products_en.pdf"}    {"id":"9755","name":"European Medicines Agency/International Federation for Animal Health Europe info day 2014 announcement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-20T15:00:00Z","last_updated_date":"2014-01-20T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencyinternational-federation-animal-health-europe-info-day-2014-announcement_en.pdf"},
    {"id":"9786","name":"European Medicines Agency: Clarification Questions - 2 October 2006","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-10-02T02:00:00Z","last_updated_date":"2006-10-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-clarification-questions-2-october-2006_en.pdf"},
    {"id":"9798","name":"Three years of successful experience on orphan drugs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-04-28T02:00:00Z","last_updated_date":"2004-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/three-years-successful-experience-orphan-drugs_en.pdf"},
    {"id":"9834","name":"Technical specifications for open invitation to tender - Supply, installation and maintenance of audiovisual equipment and consumables including on-site technical support - EMA/2012/21/IS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-12T09:50:00Z","last_updated_date":"2012-11-30T09:50:00Z","reference_number":"EMA/565757/2012","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-supply-installation-and-maintenance-audiovisual-equipment-and-consumables-including-site-technical-support-ema201221is_en.pdf"},
    {"id":"9838","name":"Committee for medicinal products for veterinary use -\n\nEMEA public bulletin 2007 on veterinary pharmacovigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-02-18T01:00:00Z","last_updated_date":"2008-02-18T01:00:00Z","reference_number":"EMEA/CVMP/PhVWP/72829/2007","document_url":"https://www.ema.europa.eu/en/documents/other/committee-medicinal-products-veterinary-use-emea-public-bulletin-2007-veterinary-pharmacovigilance_en.pdf"},
    {"id":"9845","name":"Management Board meeting dates for 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-06-14T16:30:00Z","last_updated_date":"2012-06-14T16:30:00Z","reference_number":"EMA/MB/325685/2012","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2013_en.pdf"},
    {"id":"9847","name":"Overview of comments received on draft ESVAC reflection paper on collecting data on consumption of antimicrobial agents per animal species, on technical units of measurement and indicators for reporting consumption of an...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-15T16:35:00Z","last_updated_date":"2013-10-15T16:35:00Z","reference_number":"EMA/171117/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-esvac-reflection-paper-collecting-data-consumption-antimicrobial-agents-animal-species-technical-units-measurement-and-indicators-reporting-consumption_en.pdf"},
    {"id":"9875","name":"Overview of comments received on reflection paper on publication of the CVMP’s negative opinion and refusal to recommend the granting of a marketing authorisation for veterinary medicinal  products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-12T02:00:00Z","last_updated_date":"2007-07-12T02:00:00Z","reference_number":"EMEA/CVMP/247827/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-publication-cvmps-negative-opinion-and-refusal-recommend-granting-marketing-authorisation-veterinary-medicinal-products_en.pdf"},
    {"id":"9887","name":"Workshop on medicines for bees - Background document","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-12-11T00:09:21Z","last_updated_date":"2009-12-11T00:09:21Z","reference_number":"EMA/794320/2009","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-medicines-bees-background-document_en.pdf"},
    {"id":"9917","name":"Opinion of the Committee for Medicinal Products for Veterinary Use regarding a request pursuant to Article-30(3) of Regulation (EC) No 726/2004 in relation to the potential risk for the consumer resulting from the use of...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-22T14:00:00Z","last_updated_date":"2015-04-22T14:00:00Z","reference_number":"EMA/CVMP/124059/2015","document_url":"https://www.ema.europa.eu/en/documents/other/opinion-committee-medicinal-products-veterinary-use-regarding-request-pursuant-article-303-regulation-ec-no-7262004-relation-potential-risk-consumer-resulting-use_en.pdf"},
    {"id":"9939","name":"Letter from the European Union to Japan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-european-union-japan_en.pdf"},
    {"id":"9979","name":"Technical Specifications - Annex III Summary checklist of documents, which tenderers must submit: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-iii-summary-checklist-documents-which-tenderers-must-submit-procurement-procedure-ema201401ph_en.pdf"},
    {"id":"9988","name":"Cathal Gallagher (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cathal-gallagher-doi_en.pdf"},
    {"id":"10040","name":"Start of community reviews adopted at the Committee for Medicinal Products for Human Use meeting of 17-20 October 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-21T14:01:00Z","last_updated_date":"2011-10-21T14:01:00Z","reference_number":"EMA/851133/2011","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-adopted-committee-medicinal-products-human-use-meeting-17-20-october-2011_en.pdf"},
    {"id":"10051","name":"Speaker biographies - European Medicines Agency / health-technology-assessment-body workshop on parallel scientific advice in drug development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-25T15:00:00Z","last_updated_date":"2013-11-25T15:00:00Z","reference_number":"EMA/719506/2013","document_url":"https://www.ema.europa.eu/en/documents/other/speaker-biographies-european-medicines-agency-health-technology-assessment-body-workshop-parallel-scientific-advice-drug-development_en.pdf"},
    {"id":"10053","name":"Assessment of the paediatric needs - Rheumatology","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-06-02T02:00:00Z","last_updated_date":"2006-06-02T02:00:00Z","reference_number":"EMEA/CHMP/234105/2005","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-rheumatology_en.pdf"},
    {"id":"10058","name":"EudraVigilance access policy for medicines for human use","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-07-08T17:50:18Z","last_updated_date":"2011-08-23T17:00:00Z","reference_number":"EMA/759287/2009","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-access-policy-medicines-human-use_en.pdf"},
    {"id":"10077","name":"Core summary of product characteristics (SmPC) for fludeoxyglucose","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-14T01:00:00Z","last_updated_date":"2010-12-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/core-summary-product-characteristics-smpc-fludeoxyglucose_en.pdf"},
    {"id":"10079","name":"Decision on amending budget No 1-2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-06-21T02:00:00Z","last_updated_date":"2011-06-21T02:00:00Z","reference_number":"EMA/MB/373047/2011","document_url":"https://www.ema.europa.eu/en/documents/other/decision-amending-budget-no-1-2011_en.pdf"},
    {"id":"10134","name":"Questions and answers relating to open tender procedure –EMA/2013/23/FI – High-level business consultancy services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-13T13:20:00Z","last_updated_date":"2013-10-14T18:55:00Z","reference_number":"EMA/412192/2013","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-tender-procedure-ema201323fi-high-level-business-consultancy-services_en.pdf"},
    {"id":"10135","name":"Updated Annexes to the HMPC status report on the implementation of the provisions of Chapter 2a of Directive 2001/83/EC as amended by Directive 2004/24/EC as regards traditional herbal medicinal products (EMEA/HMPC/18721...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-08-15T02:00:00Z","last_updated_date":"2007-08-15T02:00:00Z","reference_number":"EMEA/HMPC/369288/2007","document_url":"https://www.ema.europa.eu/en/documents/other/updated-annexes-hmpc-status-report-implementation-provisions-chapter-2a-directive-200183ec-amended-directive-200424ec-regards-traditional-herbal-medicinal-products-emeahmpc18721_en.pdf"},
    {"id":"10171","name":"Questions and answers relating to tender EMEA/2009/54/IT/PM","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-11-12T01:00:00Z","last_updated_date":"2009-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-tender-emea200954itpm_en.pdf"},
    {"id":"10172","name":"Minor uses and minor species (MUMS)/limited market scheme for veterinary medicinal products - 2nd annual report (2010-2011)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/680110/2011","document_url":"https://www.ema.europa.eu/en/documents/other/minor-uses-and-minor-species-mumslimited-market-scheme-veterinary-medicinal-products-2nd-annual-report-2010-2011_en.pdf"},
    {"id":"10173","name":"Delegating the EudraVigilance registration process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T18:00:00Z","last_updated_date":"2017-05-22T17:10:00Z","reference_number":"EMA/288747/2016","document_url":"https://www.ema.europa.eu/en/documents/other/delegating-eudravigilance-registration-process_en.pdf"},
    {"id":"10180","name":"Quality Review of Documents (QRD) working group plenary meeting dates","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T16:18:00Z","last_updated_date":"2025-12-16T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/quality-review-documents-qrd-working-group-plenary-meeting-dates_en.pdf"},
    {"id":"10209","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Network of Excellence for Research in Pediatric Critical Care","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-20T13:10:00Z","last_updated_date":"2011-12-20T13:10:00Z","reference_number":"EMA/866962/2011","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-network-excellence-research-pediatric-critical-care_en.pdf"},
    {"id":"10210","name":"EU Regulatory Network - List of Participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-12-17T00:09:21Z","last_updated_date":"2008-12-17T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eu-regulatory-network-list-participants_en.pdf"},
    {"id":"10228","name":"Timetable accelerated assessment request for initial marketing authorisation applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-05-24T19:30:00Z","last_updated_date":"2026-05-13T15:00:00Z","reference_number":"EMA/347524/2016 Rev. 8","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-accelerated-assessment-request-initial-marketing-authorisation-applications_en.xlsx"},
    {"id":"10235","name":"Overview of Staff Regulation implementing rules signed by the Management Board Chair during the period from 16 November 2012 to 26 February 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-25T13:30:00Z","last_updated_date":"2014-03-25T13:30:00Z","reference_number":"EMA/MB/121745/2014","document_url":"https://www.ema.europa.eu/en/documents/other/overview-staff-regulation-implementing-rules-signed-management-board-chair-during-period-16-november-2012-26-february-2014_en.pdf"},
    {"id":"10247","name":"Overview of comments received on the draft Public statement on the use of herbal medicinal products containing toxic unsaturated pyrrolizidine alkaloids (PAs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-14T12:30:00Z","last_updated_date":"2013-11-14T12:30:00Z","reference_number":"EMEA/HMPC/411398/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas_en.pdf"},
    {"id":"10248","name":"Humenza: Labelling","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-26T01:00:00Z","last_updated_date":"2010-02-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/humenza-labelling_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/humenza-labelling_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/humenza-labelling_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/humenza-labelling_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/humenza-labelling_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/humenza-labelling_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/humenza-labelling_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/humenza-labelling_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/humenza-labelling_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/humenza-labelling_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/humenza-labelling_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/humenza-labelling_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/humenza-labelling_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/humenza-labelling_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/humenza-labelling_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/humenza-labelling_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/humenza-labelling_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/humenza-labelling_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/humenza-labelling_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/humenza-labelling_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/humenza-labelling_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/humenza-labelling_sv.pdf"}},
    {"id":"10266","name":"Overview of comments received on 'guideline on quality of oral modified-release products'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-31T17:00:00Z","last_updated_date":"2014-07-31T17:00:00Z","reference_number":"EMA/CHMP/QWP/428694/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-quality-oral-modified-release-products_en.pdf"},
    {"id":"10269","name":"Technical specification - Annex 7 Lot 2 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-7-lot-2-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"10303","name":"Overview of comments received on draft guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk - Revision 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-11-15T01:00:00Z","last_updated_date":"2007-11-15T01:00:00Z","reference_number":"EMEA/519459/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-prophylaxis-high-intra-and-post-operative-venous-thromboembolic-risk-revision-1_en.pdf"},
    {"id":"10328","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP annex I – Definitions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:18:15Z","last_updated_date":"2012-06-25T19:18:15Z","reference_number":"EMA/428732/2012","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-annex-i-definitions_en.pdf"},
    {"id":"10330","name":"Mutual recognition agreements EC - Switzerland: Questions and answers covering interpretation of Chapter 15, explanatory notes, Annex 16 and notice to applicants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2002-12-18T01:00:00Z","last_updated_date":"2002-12-18T01:00:00Z","reference_number":"EMEA/MRA/CH/84/02/Final","document_url":"https://www.ema.europa.eu/en/documents/other/mutual-recognition-agreements-ec-switzerland-questions-and-answers-covering-interpretation-chapter-15-explanatory-notes-annex-16-and-notice-applicants_en.pdf"},
    {"id":"10331","name":"List of participants - EMA/FDA/Health Canada workshop on paediatric pulmonary arterial hypertension (PAH)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-08T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"EMA/356444/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-emafdahealth-canada-workshop-paediatric-pulmonary-arterial-hypertension-pah_en.pdf"},
    {"id":"10378","name":"Policy 56: Support to staff subject to external accusations and attacks","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-05-27T13:15:00Z","last_updated_date":"2013-05-27T13:15:00Z","reference_number":"EMA/868270/2011","document_url":"https://www.ema.europa.eu/en/documents/other/policy-56-support-staff-subject-external-accusations-and-attacks_en.pdf"},
    {"id":"10401","name":"Outcome of written procedures finalised during the period from 25 May 2013 to 30 August 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-08T14:20:00Z","last_updated_date":"2013-10-08T14:20:00Z","reference_number":"EMA/MB/378130/2013","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-25-may-2013-30-august-2013_en.pdf"},
    {"id":"10402","name":"Mandate, objectives and rules of procedure for the CVMP Efficacy Working Party (EWP-V)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-10-19T02:09:00Z","last_updated_date":"2020-10-19T16:13:00Z","reference_number":"EMA/CVMP/EWP/208686/2004-Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cvmp-efficacy-working-party-ewp-v_en.pdf"},
    {"id":"10403","name":"Declaration of interests: Hans-Georg Eichler","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:00Z","last_updated_date":"2021-07-05T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-hans-georg-eichler_en.pdf"},
    {"id":"10404","name":"ICMRA - Mapping of GMP inspection initiatives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-09T13:20:00Z","last_updated_date":"2017-01-09T13:20:00Z","reference_number":"EMA/219981/2014","document_url":"https://www.ema.europa.eu/en/documents/other/icmra-mapping-gmp-inspection-initiatives_en.pdf"},
    {"id":"10428","name":"Assessment of the paediatric needs - Chemotherapy products (part II)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-06-02T02:00:00Z","last_updated_date":"2006-06-02T02:00:00Z","reference_number":"EMEA/224696/2006","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-chemotherapy-products-part-ii_en.pdf"},
    {"id":"10448","name":"Declaration of interest: Herlinde Herpoel","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-26T02:00:00Z","last_updated_date":"2016-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-herlinde-herpoel_en.pdf"},
    {"id":"10455","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: Surgiflo haemostatic matrix kit - Ferrosan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-08T14:00:00Z","last_updated_date":"2012-08-08T14:00:00Z","reference_number":"EMA/CHMP/66309/2012","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-surgiflo-haemostatic-matrix-kit-ferrosan_en.pdf"},
    {"id":"10466","name":"Overview of comments received on draft guideline on the SPC for anthelmintics","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-12T02:09:21Z","last_updated_date":"2007-07-12T02:09:21Z","reference_number":"EMEA/CVMP/EWP/413825/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-spc-anthelmintics_en.pdf"},
    {"id":"10484","name":"CTAG1: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on protecting patient confidentiality - Revised after third teleconference with comments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag1-advice-european-medicines-agency-clinical-trial-advisory-group-protecting-patient-confidentiality-revised-after-third-teleconference-comments_en.pdf"},
    {"id":"10491","name":"Action plan for implementation of the strategy for regulatory and scientific training within the European Regulatory Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-06T01:00:00Z","last_updated_date":"2012-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/action-plan-implementation-strategy-regulatory-and-scientific-training-within-european-regulatory-network_en.pdf"},
    {"id":"10500","name":"Policy 81: Document classification policy","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2016-12-15T13:15:00Z","last_updated_date":"2016-12-15T13:15:00Z","reference_number":"EMA/174602/2016","document_url":"https://www.ema.europa.eu/en/documents/other/policy-81-document-classification-policy_en.pdf"},
    {"id":"10533","name":"Decision on amending budget No 2-2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-12-22T15:00:00Z","last_updated_date":"2014-12-22T15:00:00Z","reference_number":"EMA/MB/421089/2014","document_url":"https://www.ema.europa.eu/en/documents/other/decision-amending-budget-no-2-2014_en.pdf"},
    {"id":"10539","name":"GVK Biosciences products for which the marketing authorisations are recommended for suspension by the CHMP on 22 January 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-23T13:00:00Z","last_updated_date":"2015-02-27T13:00:00Z","reference_number":"EMA/52196/2015","document_url":"https://www.ema.europa.eu/en/documents/other/gvk-biosciences-products-which-marketing-authorisations-are-recommended-suspension-chmp-22-january-2015_en.pdf"},
    {"id":"10545","name":"Technical Specifications - Annex I Costing sheet: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-i-costing-sheet-procurement-procedure-ema201401ph_en.pdf"},
    {"id":"10555","name":"Pre-Qualification Questionnaire (PQQ) for a restricted tender procedure organised by European Medicines Agency (EMEA) catering consultant EMEA/2008/45/ISERV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:21Z","last_updated_date":"2008-11-25T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency-emea-catering-consultant-emea200845iserv_en.doc"},
    {"id":"10582","name":"Overview of comments received on draft guideline on similar biological medicinal products containing recombinant erythropoietins","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/38050/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-similar-biological-medicinal-products-containing-recombinant-erythropoietins_en.pdf"},
    {"id":"10613","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Varicella-zoster virus (live, attenuated) for prevention of varicella-zoster-virus reactivation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T12:15:00Z","last_updated_date":"2014-12-12T12:15:00Z","reference_number":"EMA/757976/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-varicella-zoster-virus-live-attenuated-prevention-varicella-zoster-virus-reactivation_en.pdf"},
    {"id":"10621","name":"Compilation of Procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-11-30T01:00:00Z","last_updated_date":"2010-04-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/compilation-procedures_en.zip"},
    {"id":"10624","name":"ENCIAG Members (ENCePP Implementation Advisory Group)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-04-02T02:00:00Z","last_updated_date":"2008-04-02T02:00:00Z","reference_number":"EMEA/192773/2008","document_url":"https://www.ema.europa.eu/en/documents/other/enciag-members-encepp-implementation-advisory-group_en.pdf"},
    {"id":"10627","name":"European Medicines Agency workshop on pharmacogenomics: from science to clinical care - Invitation for expressions of interest","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T13:20:00Z","last_updated_date":"2012-05-10T17:54:00Z","reference_number":"EMA/47793/2012","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-workshop-pharmacogenomics-science-clinical-care-invitation-expressions-interest_en.pdf"},
    {"id":"10632","name":"Start of Community reviews - CHMP meeting of 22-25 July 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/458581/2013","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-22-25-july-2013_en.pdf"},
    {"id":"10647","name":"CHMP statistics: September 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-statistics-september-2015_en.pdf"},
    {"id":"10652","name":"Organisational matters - CHMP meeting 16-19 July 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-25T14:10:00Z","last_updated_date":"2012-07-25T14:10:00Z","reference_number":"EMA/CHMP/410525/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-16-19-july-2012_en.pdf"},
    {"id":"10661","name":"SPOR webinar: Using OMS & RMS data in eAF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T17:05:00Z","last_updated_date":"2017-12-01T17:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spor-webinar-using-oms-rms-data-eaf_en.pdf"},
    {"id":"10666","name":"Questions & Answers on the use of Cocktail studies for investigating in vivo drug interaction potential","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-12-13T00:09:21Z","last_updated_date":"2007-12-13T00:09:21Z","reference_number":"EMEA/CHMP/EWP/490784/2007","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-use-cocktail-studies-investigating-vivo-drug-interaction-potential_en.pdf"},
    {"id":"10675","name":"Opinions on safety variations: Adopted at the CHMP meeting of 13-16 February 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T18:50:00Z","last_updated_date":"2012-02-17T18:50:00Z","reference_number":"EMA/CHMP/86236/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-13-16-february-2012_en.pdf"},
    {"id":"10681","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP module IV – Pharmacovigilance audits","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-13T17:00:00Z","last_updated_date":"2012-12-13T17:00:00Z","reference_number":"EMA/806364/2012","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-iv-pharmacovigilance-audits_en.pdf"},
    {"id":"10689","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Clostridium difficile toxin B human monoclonal antibody for treatment of Clostridium difficile infection","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T12:30:00Z","last_updated_date":"2015-02-23T12:30:00Z","reference_number":"EMA/715190/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-clostridium-difficile-toxin-b-human-monoclonal-antibody-treatment-clostridium-difficile-infection_en.pdf"},
    {"id":"10712","name":"Mutual recognition agreements: Sectoral Annex on Good Manufacturing practices - Issues related to Investigational Medicinal Products coverage from 1 May 2004","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-05-05T02:00:00Z","last_updated_date":"2004-05-05T02:00:00Z","reference_number":"EMEA/MRA/2/04","document_url":"https://www.ema.europa.eu/en/documents/other/mutual-recognition-agreements-sectoral-annex-good-manufacturing-practices-issues-related-investigational-medicinal-products-coverage-1-may-2004_en.pdf"},
    {"id":"10721","name":"Overview of comments received on 'Guideline on the Requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled pro...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-09-20T02:00:00Z","last_updated_date":"2010-09-20T02:00:00Z","reference_number":"EMEA/CHMP/EWP/187653/2009  ","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-requirements-clinical-documentation-orally-inhaled-products-oip-including-requirements-demonstration-therapeutic-equivalence-between-two-inhaled-pro_en.pdf"},
    {"id":"10745","name":"Cover note - Revised criteria to be fulfilled by patients’ and consumers’ organisations involved in European Medicines Agency activities","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:02Z","last_updated_date":"2011-10-07T16:00:02Z","reference_number":"EMA/MB/744342/2011","document_url":"https://www.ema.europa.eu/en/documents/other/cover-note-revised-criteria-be-fulfilled-patients-and-consumers-organisations-involved-european-medicines-agency-activities_en.pdf"},
    {"id":"10760","name":"Draft European Union list entry on Crataegus spp., folium cum flore","type":"other","status":"Draft: consultation closed","consultation_date":"2015-02-09 - 2015-05-16","first_published_date":"2015-02-09T02:00:00Z","last_updated_date":"2015-02-09T02:00:00Z","reference_number":"EMA/HMPC/685372/2014","document_url":"https://www.ema.europa.eu/en/documents/other/draft-european-union-list-entry-crataegus-spp-folium-cum-flore_en.pdf"},
    {"id":"10765","name":"List of participants of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - 4 June 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-01T02:00:00Z","last_updated_date":"2015-09-01T02:00:00Z","reference_number":"EMA/167550/2015","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-4-june-2015_en.pdf"},
    {"id":"10768","name":"Overview of comments received on list of paediatric needs - Immunology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-25T02:00:00Z","last_updated_date":"2006-09-25T02:00:00Z","reference_number":"EMEA/381452/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-list-paediatric-needs-immunology_en.pdf"},
    {"id":"10772","name":"High level business consultancy EMA/2013/23/FI - Technical specifications - Annex II exclusion criteria","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications-annex-ii-exclusion-criteria_en.doc"},
    {"id":"10774","name":"Recognition criteria and quality standards for members of the European Paediatric Research Network (EnprEMA) - Final results of the Delphi surveys","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-and-quality-standards-members-european-paediatric-research-network-enprema-final-results-delphi-surveys_en.pdf"},
    {"id":"10776","name":"Questions and answers on production of water for injections by non-distillation methods – reverse osmosis and biofilms and control strategies - Final","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-02T13:21:00Z","last_updated_date":"2017-08-02T13:21:00Z","reference_number":"EMA/INS/GMP/443117/2017","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-production-water-injections-non-distillation-methods-reverse-osmosis-and-biofilms-and-control-strategies-final_en.pdf"},
    {"id":"10801","name":"Declaration of research interests (addendum) - Peter Helms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-peter-helms_en.pdf"},
    {"id":"10852","name":"Draft questions and answers on the template for the Qualified Person’s (QP's) declaration concerning good-manufacturing-practice compliance of the active substance used as starting material and verification of its supply...","type":"other","status":"Draft: consultation closed","consultation_date":"2010-12-16 - 2011-04-30","first_published_date":"2011-01-13T02:00:00Z","last_updated_date":"2011-06-20T04:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/696305/2010","document_url":"https://www.ema.europa.eu/en/documents/other/draft-questions-and-answers-template-qualified-persons-qps-declaration-concerning-good-manufacturing-practice-compliance-active-substance-used-starting-material-and-verification-its-supply_en.pdf"},
    {"id":"10856","name":"European Union Network data board - Terms of reference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-30T15:40:00Z","last_updated_date":"2018-01-16T14:33:00Z","reference_number":"EMA/231985/2016","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-network-data-board-terms-reference_en.pdf"},
    {"id":"10857","name":"Working party on Herbal Medicinal Products: Final proposal for a core data for  Isphagula Husk","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-03-27T01:00:00Z","last_updated_date":"2003-03-27T01:00:00Z","reference_number":"EMEA/HMPWP/15/00","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-isphagula-husk_en.pdf"},
    {"id":"10860","name":"European Union example instances - E2B(R3) testing files","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-27T01:00:00Z","last_updated_date":"2026-01-21T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-example-instances-e2br3-testing-files_en.zip"},
    {"id":"10891","name":"List of speakers' biographies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-09-21T19:30:00Z","last_updated_date":"2017-09-21T19:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-speakers-biographies_en.pdf"},
    {"id":"10909","name":"Joint audit programme for EEA GMP inspectorates: Observed inspection checklist","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-08-08T02:00:00Z","last_updated_date":"2019-02-22T02:00:00Z","reference_number":"EMA/170408/2018 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/joint-audit-programme-eea-gmp-inspectorates-observed-inspection-checklist_en.docx"},
    {"id":"10911","name":"Donation of European Medicines Agency assets no. EMA/2014/28/IS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/donation-european-medicines-agency-assets-no-ema201428is_en.pdf"},
    {"id":"10927","name":"Screening for adverse reactions in EudraVigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T11:25:00Z","last_updated_date":"2016-12-21T11:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf"},
    {"id":"10935","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Grazoprevir/elbasvir for the treatment of chronic hepatitis C","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/783373/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-grazoprevirelbasvir-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"10940","name":"Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - MEDLINE","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-26T17:05:00Z","last_updated_date":"2024-03-25T16:32:00Z","reference_number":"EMA/130770/2024","document_url":"https://www.ema.europa.eu/en/documents/other/monitoring-medical-literature-entry-relevant-information-eudravigilance-database-european-medicines-agency-medline_en.pdf"},
    {"id":"10949","name":"List of participants of the European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - 3 ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"EMA/291057/2014","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-3_en.pdf"},
    {"id":"10954","name":"Workshop on risk-based quality management in clinical trials 2-3 December 2013: Summaries of the presentations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T18:00:00Z","last_updated_date":"2014-07-07T18:00:00Z","reference_number":"EMA/84016/2014","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-risk-based-quality-management-clinical-trials-2-3-december-2013-summaries-presentations_en.pdf"},
    {"id":"11015","name":"Conclusions from the Paediatric Rheumatology Expert Group Meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"EMA/836276/2010","document_url":"https://www.ema.europa.eu/en/documents/other/conclusions-paediatric-rheumatology-expert-group-meeting_en.pdf"},
    {"id":"11018","name":"Letter of support to explore EEG utility to measure deficits in social recognition in people with autism spectrum disorders (ASD) and its potential to stratify patient groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T12:00:00Z","last_updated_date":"2015-12-09T12:00:00Z","reference_number":"EMA/794518/2015","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-explore-eeg-utility-measure-deficits-social-recognition-people-autism-spectrum-disorders-asd-and-its-potential-stratify-patient-groups_en.pdf"},
    {"id":"11037","name":"Analysis and Assessment of the Executive Director’s Annual Activity Report 2010","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/MB/416690/2011","document_url":"https://www.ema.europa.eu/en/documents/other/analysis-and-assessment-executive-directors-annual-activity-report-2010_en.pdf"},
    {"id":"11045","name":"Outcome of written procedures finalised during the period from 2 September to 12 November 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-22T15:00:00Z","last_updated_date":"2014-12-22T15:00:00Z","reference_number":"EMA/MB/625151/2014","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-2-september-12-november-2014_en.pdf"},
    {"id":"11051","name":"Summary on compassionate use for Daclatasvir","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T10:40:00Z","last_updated_date":"2020-10-26T11:00:00Z","reference_number":"EMA/797185/2013","document_url":"https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-daclatasvir_en.pdf"},
    {"id":"11090","name":"CTAG2: Advice to the European Medicines Agency on Clinical Trial Advisory Group on clinical-trial-data formats - Final draft advice outcome with comments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag2-advice-european-medicines-agency-clinical-trial-advisory-group-clinical-trial-data-formats-final-draft-advice-outcome-comments_en.pdf"},
    {"id":"11097","name":"UCUM units for E2B (R3) version 1.2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-07-11T14:15:00Z","last_updated_date":"2018-11-28T17:00:00Z","reference_number":"Version 1.2","document_url":"https://www.ema.europa.eu/en/documents/other/ucum-units-e2b-r3-version-12_en.xlsx"},
    {"id":"11108","name":"Paper for information (PK-PD modelling by Prof. P. Lees)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/paper-information-pk-pd-modelling-prof-p-lees_en.pdf"},
    {"id":"11111","name":"EMEA map","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-06-29T02:00:00Z","last_updated_date":"2010-04-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/emea-map_en.pdf"},
    {"id":"11120","name":"Pre-qualification questionnaire for a restricted tender procedure organised by the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-03T12:00:00Z","last_updated_date":"2013-04-03T12:00:00Z","reference_number":"EMA/2012/54/IS ","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-restricted-tender-procedure-organised-european-medicines-agency_en.doc"},
    {"id":"11138","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 16-19 December 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/730980/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-16-19-december-2013_en.pdf"},
    {"id":"11191","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) reference sources","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:01Z","last_updated_date":"2014-01-17T18:15:00Z","reference_number":"EMA/136145/2012 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-reference-sources_en.xls"}    {"id":"11219","name":"Declaration of interests: Jean-Claude Brival","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:15Z","last_updated_date":"2012-08-28T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-jean-claude-brival_en.pdf"},
    {"id":"11259","name":"Plan for implementation of the pharmacovigilance legislation by the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T10:30:00Z","last_updated_date":"2012-02-02T10:30:00Z","reference_number":"EMA/64750/2012 ","document_url":"https://www.ema.europa.eu/en/documents/other/plan-implementation-pharmacovigilance-legislation-european-medicines-agency_en.pdf"},
    {"id":"11278","name":"Mandate, objectives and rules of procedure for the CVMP Environmental Risk Assessment Working Party (ERAWP)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-12-22T01:00:00Z","last_updated_date":"2019-02-07T10:31:00Z","reference_number":"EMA/CVMP/ERA/705470/2009 - Rev.6","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cvmp-environmental-risk-assessment-working-party-erawp_en.pdf"},
    {"id":"11299","name":"Timeline: European Medicines Agency-FDA parallel scientific advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T16:30:00Z","last_updated_date":"2023-02-02T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/timeline-european-medicines-agency-fda-parallel-scientific-advice_en.pdf"},
    {"id":"11306","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) medical devices","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:01Z","last_updated_date":"2014-01-17T18:15:00Z","reference_number":"EMA/136155/2012 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-medical-devices_en.xls"},
    {"id":"11307","name":"Summary of transfers of appropriations in budgets 2017 and  2018","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2018-03-16T13:35:00Z","last_updated_date":"2018-03-16T13:35:00Z","reference_number":"EMA/MB/1127/2018 Noted","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budgets-2017-and-2018_en.pdf"},
    {"id":"11308","name":"Guidelines and concept papers adopted during the CHMP meeting 19-22 May 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-26T16:00:00Z","reference_number":"EMA/124022/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-19-22-may-2014_en.pdf"},
    {"id":"11313","name":"Lee Parker (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/lee-parker-doi_en.pdf"},
    {"id":"11324","name":"Withdrawal letter : NovoSeven","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-04-03T02:00:00Z","last_updated_date":"2006-04-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-novoseven_en.pdf"},
    {"id":"11381","name":"Overview of comments received on 'Guideline on Clinical Investigation of Medicinal Products in the treatment of epileptic disorders' (CHMP/EWP/566/98 Rev.2) - Revision 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/611366/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-chmpewp56698-rev2-revision-2_en.pdf"},
    {"id":"11396","name":"Evicel: Product information as approved by the CHMP on 15 November 2012, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-23T12:54:00Z","last_updated_date":"2012-11-23T12:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/evicel-product-information-approved-chmp-15-november-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"11432","name":"Explanatory note on fees payable to the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-22T13:15:00Z","last_updated_date":"2011-12-22T13:15:00Z","reference_number":"EMA/283580/2011","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-note-fees-payable-european-medicines-agency_en.pdf"},
    {"id":"11435","name":"Overview of Comments received on Public Statement on the use of herbal medicinal products containing estragole and on Public Statement on the use of herbal medicinal products containing methyleugenol","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-11-23T01:00:00Z","last_updated_date":"2005-11-23T01:00:00Z","reference_number":"EMEA/381090/2005","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-public-statement-use-herbal-medicinal-products-containing-estragole-and-public-statement-use-herbal-medicinal-products-containing-methyleugenol_en.pdf"},
    {"id":"11439","name":"Working party on Herbal Medicinal Products: Final concept paper on the implementation of different levels of scientific evidence in core-data for herbal drugs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-03-03T01:00:00Z","last_updated_date":"2004-03-03T01:00:00Z","reference_number":"EMEA/CPMP/HMPWP/1156/03","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-concept-paper-implementation-different-levels-scientific-evidence-core-data-herbal-drugs_en.pdf"},
    {"id":"11466","name":"Management Board meeting dates 2015-2018","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-06-16T12:00:00Z","last_updated_date":"2015-06-16T12:00:00Z","reference_number":"EMA/MB/239247/2015","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2015-2018_en.pdf"},
    {"id":"11477","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP - Product- or population-specific considerations I: Vaccines for prophylaxis against infectious diseases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-12T11:00:00Z","last_updated_date":"2013-12-12T11:00:00Z","reference_number":"EMA/756032/2013","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-product-or-population-specific-considerations-i-vaccines-prophylaxis-against-infectious-diseases_en.pdf"},
    {"id":"11504","name":"Declaration of interests - Christiane de Boeck","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-christiane-de-boeck_en.pdf"},
    {"id":"11550","name":"Work plan for the Good Clinical Practice Inspectors Working Group for 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-02-20T11:38:00Z","last_updated_date":"2012-02-20T11:38:00Z","reference_number":"EMA/INS/GCP/920415/2011","document_url":"https://www.ema.europa.eu/en/documents/other/work-plan-good-clinical-practice-inspectors-working-group-2012_en.pdf"},
    {"id":"11555","name":"Declaration of research interests (addendum) - Anne Junker","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-anne-junker_en.pdf"},
    {"id":"11565","name":"Information Management Strategy 2019-2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2019-03-08T12:29:00Z","reference_number":"EMA/502708/2018","document_url":"https://www.ema.europa.eu/en/documents/other/information-management-strategy-2019-2021_en.pdf"},
    {"id":"11566","name":"Cad a chiallaà­onn an triantà¡n dubh?","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-01T02:00:00Z","last_updated_date":"2013-10-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cad-chiallaa-onn-triantan-dubh_en.pdf"},
    {"id":"11603","name":"Guidelines and concept papers adopted during the CHMP meeting 12-15 December 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-16T13:00:00Z","last_updated_date":"2011-12-16T13:00:00Z","reference_number":"EMA/CHMP/941885/2011","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-12-15-december-2011_en.pdf"},
    {"id":"11615","name":"Good Laboratory Practice (GLP) principles in relation to advanced therapy medicinal products (ATMPs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-07-11T13:45:00Z","last_updated_date":"2017-07-11T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/good-laboratory-practice-glp-principles-relation-advanced-therapy-medicinal-products-atmps_en.pdf"},
    {"id":"11645","name":"Confidentiality arrangement: Letter from the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health and Ageing to EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-01T16:00:00Z","last_updated_date":"2012-10-01T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/confidentiality-arrangement-letter-therapeutic-goods-administration-tga-australian-government-department-health-ageing-ema_en.pdf"},
    {"id":"11650","name":"Zerit R-79 PI highlighted","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-02-18T14:06:21Z","last_updated_date":"2011-02-18T14:06:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/zerit-r-79-pi-highlighted_en.pdf"},
    {"id":"11665","name":"Explanatory note on fees payable to the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-31T12:00:00Z","last_updated_date":"2013-12-06T10:32:00Z","reference_number":"EMA/185964/2013","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-note-fees-payable-european-medicines-agency_en.pdf-0"},
    {"id":"11668","name":"Mandate, objectives and rules of procedure for the CAT Gene Therapy Temporary Working Party (GTWP)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2005-02-17T00:09:21Z","last_updated_date":"2010-08-17T01:09:21Z","reference_number":"EMA/CAT/452015/2009","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cat-gene-therapy-temporary-working-party-gtwp_en.pdf"},
    {"id":"11674","name":"Declaration of interests: Melanie Carr","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-melanie-carr_en.pdf"},
    {"id":"11703","name":"Technical specifications for open invitation to tender no. EMEA/2008/62/P&B, provision of language training for EMEA staff","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-05-03T02:00:00Z","last_updated_date":"2008-05-03T02:00:00Z","reference_number":"EMEA/183282/2008","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-no-emea200862pb-provision-language-training-emea-staff_en.pdf"},
    {"id":"11714","name":"Withdrawal letter : Docetaxel Winthrop","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T01:00:00Z","last_updated_date":"2008-11-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-docetaxel-winthrop_en.pdf"},
    {"id":"11721","name":"Report on the workshop expression of strength in the name of medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-10T01:00:00Z","last_updated_date":"2011-03-10T01:00:00Z","reference_number":"EMEA/213927/2009","document_url":"https://www.ema.europa.eu/en/documents/other/report-workshop-expression-strength-name-medicines_en.pdf"},
    {"id":"11734","name":"Assessment of the paediatric needs - Pain","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2005-06-23T02:00:00Z","last_updated_date":"2005-06-23T02:00:00Z","reference_number":"EMEA/CHMP/189220/2005","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-pain_en.pdf"},
    {"id":"11742","name":"List of participants of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting (15 March 2017)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/101021/2017","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-15-march-2017_en.pdf"},
    {"id":"11793","name":"Recognition criteria for self assessment - Enpr-EMA: Belgian Pediatric Drug Network - BPDN","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-01-07T00:31:00Z","last_updated_date":"2010-01-07T00:31:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-belgian-pediatric-drug-network-bpdn_en.pdf"},
    {"id":"11815","name":"Calcitonin: Product information as approved by the CHMP on 19 July 2012, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T17:00:00Z","last_updated_date":"2012-07-20T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/calcitonin-product-information-approved-chmp-19-july-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"11816","name":"Pathogen-specific database: Glanders and Melioidosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-glanders-and-melioidosis_en.pdf"},
    {"id":"11844","name":"Questions and Answers relating to Tender EMEA 2008 71 PM IT.","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2009-07-01T02:00:00Z","reference_number":"EMEA 2008 71 PM IT","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-tender-emea-2008-71-pm-it_en.pdf"},
    {"id":"11846","name":"Public summary of the evaluation of a proposed product-specific\n\nwaiver: Amlodipine / ramipril for treatment of hypertension","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T12:30:00Z","last_updated_date":"2015-02-23T12:30:00Z","reference_number":"EMA/50883/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-amlodipine-ramipril-treatment-hypertension_en.pdf"},
    {"id":"11855","name":"Annex to the request for a joint ECDC, EFSA and EMA scientific opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food-producing animal...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-05T01:00:00Z","last_updated_date":"2017-01-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-request-joint-ecdc-efsa-and-ema-scientific-opinion-list-outcome-indicators-regards-surveillance-antimicrobial-resistance-and-antimicrobial-consumption-humans-and-food-producing-animal_en.pdf"},
    {"id":"11874","name":"Pre-qualification questionnaire for a restricted tender procedure organised by the European Medicines Agency - ICT service desk EMA/2013/09/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-28T02:00:00Z","last_updated_date":"2013-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-restricted-tender-procedure-organised-european-medicines-agency-ict-service-desk-ema201309ict_en.doc"},
    {"id":"11880","name":"Updated application software - Determination of withdrawal periods for milk","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/updated-application-software-determination-withdrawal-periods-milk_en.zip"},
    {"id":"11914","name":"General conditions for permanent call for expression of interest for Contract Agents for temporary assignments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-12T02:00:00Z","last_updated_date":"2010-04-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/general-conditions-permanent-call-expression-interest-contract-agents-temporary-assignments_sv.pdf"}},
    {"id":"11935","name":"Tripartite meeting held between EMA, FDA and PMDA at EMA, London, on 1-2 September 2016 to discuss regulatory approaches for the evaluation of antibacterial agents","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-09-07T17:00:00Z","last_updated_date":"2016-09-07T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/tripartite-meeting-held-between-ema-fda-and-pmda-ema-london-1-2-september-2016-discuss-regulatory-approaches-evaluation-antibacterial-agents_en.pdf"},
    {"id":"11949","name":"Transfers of appropriations in the budget 2010 in accordance with Article 23 (2) of the Financial Regulation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/603657/2010","document_url":"https://www.ema.europa.eu/en/documents/other/transfers-appropriations-budget-2010-accordance-article-23-2-financial-regulation_en.pdf"},
    {"id":"11951","name":"Medication-errors workshop - Call for expressions of interest","type":"other","status":"Draft","consultation_date":"","first_published_date":"2012-10-03T02:00:00Z","last_updated_date":"2012-10-03T02:00:00Z","reference_number":"EMA/637233/2012","document_url":"https://www.ema.europa.eu/en/documents/other/medication-errors-workshop-call-expressions-interest_en.pdf"},
    {"id":"11982","name":"Summary of transfer of appropriations in the budget 2016 - Management Board meeting: 5-6 October 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:30:00Z","last_updated_date":"2016-10-07T17:30:00Z","reference_number":"EMA/MB/577322/2016","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2016-management-board-meeting-5-6-october-2016_en.pdf"},
    {"id":"11988","name":"Outcome of written procedures finalised during the period from 19 February 2015 to 8 May 2015","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-06-16T12:00:00Z","last_updated_date":"2015-06-16T12:00:00Z","reference_number":"EMA/MB/239247/2015","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-19-february-2015-8-may-2015_en.pdf"},
    {"id":"11991","name":"Overview of comments received on 'Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-30T14:15:00Z","last_updated_date":"2013-05-30T14:15:00Z","reference_number":"EMA/CHMP/47495/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-investigation-medicinal-products-prophylaxis-high-intra-and-post-operative-venous-thromboembolic-risk_en.pdf"},
    {"id":"11996","name":"Overview of comments received on draft guideline on the evaluation of medicinal products for cardiovascular disease prevention (EMEA/CHMP/EWP/311890/2007)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/357298/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-evaluation-medicinal-products-cardiovascular-disease-prevention-emeachmpewp3118902007_en.pdf"},
    {"id":"12015","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Recombinant soluble fusion protein with a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 F...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-25T12:30:00Z","last_updated_date":"2014-11-25T12:30:00Z","reference_number":"EMA/378293/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-recombinant-soluble-fusion-protein-modified-form-extracellular-domain-human-activin-receptor-iib-linked-human-igg1-f_en.pdf"},
    {"id":"12039","name":"Red SAMID - European Network of Paediatric Research at the European Medicines Agency recognition criteria for self-assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-21T16:40:00Z","last_updated_date":"2013-07-19T11:55:00Z","reference_number":"EMA/153678/2011","document_url":"https://www.ema.europa.eu/en/documents/other/red-samid-european-network-paediatric-research-european-medicines-agency-recognition-criteria-self-assessment_en.pdf"},
    {"id":"12058","name":"CPAR - updated document February","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-02-15T10:57:00Z","last_updated_date":"2017-02-16T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cpar-updated-document-february_en.pdf"},
    {"id":"12062","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue (Cx601) for treatment of anal fistulas","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-25T12:30:00Z","last_updated_date":"2014-11-25T12:30:00Z","reference_number":"EMA/674179/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-expanded-human-allogeneic-mesenchymal-adult-stem-cells-extracted-adipose-tissue-cx601-treatment-anal-fistulas_en.pdf"},
    {"id":"12067","name":"Calendar of 2009 dates for the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/386297/2008","document_url":"https://www.ema.europa.eu/en/documents/other/calendar-2009-dates-european-medicines-agency_en.pdf"},
    {"id":"12073","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency:  Newcastle Children's Cancer and Leukaemia Group Pharmacology Studies Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-newcastle-childrens-cancer-and-leukaemia-group-pharmacology-studies-group_en.pdf"},
    {"id":"12081","name":"Organisational matters: Committee for Medicinal Products for Human Use meeting 17-20 October 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-24T13:37:00Z","last_updated_date":"2011-10-24T13:37:00Z","reference_number":"EMA/CHMP/832562/2011","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-committee-medicinal-products-human-use-meeting-17-20-october-2011_en.pdf"},
    {"id":"12089","name":"VWP Conclusions from the Workshop on Co-administration of Vaccines\n\nheld on 31 Jan-1 Feb 2006","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-01-16T00:09:21Z","last_updated_date":"2007-01-16T00:09:21Z","reference_number":"EMEA/CHMP/VWP/14684/2007","document_url":"https://www.ema.europa.eu/en/documents/other/vwp-conclusions-workshop-co-administration-vaccines-held-31-jan-1-feb-2006_en.pdf"},
    {"id":"12113","name":"Mandate for the EMEA working party on herbal medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2001-11-15T12:49:21Z","last_updated_date":"2001-11-15T12:49:21Z","reference_number":"EMEA/HMPWP/76/01","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-emea-working-party-herbal-medicinal-products_en.pdf"},
    {"id":"12126","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Dupilumab for treatment of asthma","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T12:35:00Z","last_updated_date":"2014-10-21T12:35:00Z","reference_number":"EMA/511545/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-dupilumab-treatment-asthma_en.pdf"},
    {"id":"12127","name":"Functionalities in support of the medical literature monitoring service User manual: EudraVigilance ICSR Downloads and tracking spreadsheets","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-12T14:30:00Z","last_updated_date":"2024-03-25T16:56:00Z","reference_number":"EMA/274835/2015 Rev.7*","document_url":"https://www.ema.europa.eu/en/documents/other/functionalities-support-medical-literature-monitoring-service-user-manual-eudravigilance-icsr-downloads-tracking-spreadsheets_en.pdf"},
    {"id":"12151","name":"Update report on the European Medicines Agency’s European Union telematics: Operations report","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/MB/793451/2011","document_url":"https://www.ema.europa.eu/en/documents/other/update-report-european-medicines-agencys-european-union-telematics-operations-report_en.pdf"},
    {"id":"12152","name":"List of participants of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting 9 March 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"EMA/855463/2015","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-9-march-2016_en.pdf"},
    {"id":"12167","name":"Annex C - Response questionnaire Curricula Vitae","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2009-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-c-response-questionnaire-curricula-vitae_en.xls"},
    {"id":"12168","name":"Overview of comments received on 'Guideline on demonstration of target animal safety and efficacy of veterinary medicinal products intended for use in farmed finfish'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-05-17T02:00:00Z","last_updated_date":"2011-05-17T02:00:00Z","reference_number":"EMA/CVMP/EWP/324700/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-demonstration-target-animal-safety-and-efficacy-veterinary-medicinal-products-intended-use-farmed-finfish_en.pdf"},
    {"id":"12192","name":"Overview of comments received on 'reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer) as new active substance in relation to a reference active substance which is a racem...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T15:15:00Z","last_updated_date":"2012-11-21T15:15:00Z","reference_number":"EMA/355542/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-considerations-given-designation-single-stereo-isomeric-form-enantiomer-new-active-substance-relation-reference-active-substance-which-racem_en.pdf"},
    {"id":"12240","name":"Revised charter of tasks and responsibilities of the Executive Director as authorising officer","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-03-26T14:10:00Z","last_updated_date":"2015-03-26T14:10:00Z","reference_number":"EMA/MB/56129/2015","document_url":"https://www.ema.europa.eu/en/documents/other/revised-charter-tasks-and-responsibilities-executive-director-authorising-officer_en.pdf"},
    {"id":"12255","name":"Proposal of minimum (EnprEMA) criteria required for recognition","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/proposal-minimum-enprema-criteria-required-recognition_en.pdf"},
    {"id":"12256","name":"European Union - Japan orphan medicines cooperation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-30T12:33:37Z","last_updated_date":"2012-07-30T12:33:37Z","reference_number":"EMA/488924/2012","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-japan-orphan-medicines-cooperation_en.pdf"},
    {"id":"12273","name":"Mandate, objectives and rules of procedure for the EMA/CAT and Medical Devices’ Notified Body (EMA/CATNB) Collaboration Group (CG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-06T01:00:00Z","last_updated_date":"2010-12-06T01:00:00Z","reference_number":"EMA/327938/2010","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-ema-cat-medical-devices-notified-body-ema-catnb-collaboration-group-cg_en.pdf"},
    {"id":"12277","name":"Timetable: Safety signal - Assessment of responses to request for supplementary information (RSI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-02T16:15:00Z","last_updated_date":"2026-03-19T13:28:00Z","reference_number":"EMA/403963/2015 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-safety-signal-assessment-responses-request-supplementary-information-rsi_en.xlsx"},
    {"id":"12285","name":"Mandate, objectives and rules of procedure for the coordination group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-08-19T02:00:00Z","last_updated_date":"2010-08-19T02:00:00Z","reference_number":"EMA/CHMP/342584/2010","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-coordination-group_en.pdf"},
    {"id":"12296","name":"EMEA 2010 Priorities for Drug Safety Research: Long term adverse effects of immunomodulators","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-08-04T02:00:00Z","last_updated_date":"2009-08-04T02:00:00Z","reference_number":"EMEA/493705/2009","document_url":"https://www.ema.europa.eu/en/documents/other/emea-2010-priorities-drug-safety-research-long-term-adverse-effects-immunomodulators_en.pdf"},
    {"id":"12304","name":"Reflection paper on the reasons and timelines for revision of final Community herbal monographs and Community list entries","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2012-03-09T17:00:00Z","reference_number":"EMEA/HMPC/326440/2007","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-reasons-and-timelines-revision-final-community-herbal-monographs-and-community-list-entries_en.pdf"},
    {"id":"12305","name":"European Medicines Agency preparations for the impact of the 2012 Olympic Games","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T11:30:00Z","last_updated_date":"2011-12-20T11:30:00Z","reference_number":"EMA/876327/2011","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-preparations-impact-2012-olympic-games_en.pdf"},
    {"id":"12309","name":"Implementation plan for regulatory co-operation on medicinal products April 2, 2009 - Following the exchange of letters between the EU (EC and EMEA) and Health Canada (HPFB)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-08T02:09:21Z","last_updated_date":"2009-04-08T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/implementation-plan-regulatory-co-operation-medicinal-products-april-2-2009-following-exchange-letters-between-eu-ec-and-emea-and-health-canada-hpfb_en.pdf","translations":{"fr":"https://www.ema.europa.eu/fr/documents/other/implementation-plan-regulatory-co-operation-medicinal-products-april-2-2009-following-exchange-letters-between-eu-ec-and-emea-and-health-canada-hpfb_fr.pdf"}},
    {"id":"12338","name":"Planning for the implementation of the new legislation on pharmacovigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-20T01:31:00Z","last_updated_date":"2011-04-20T01:31:00Z","reference_number":"EMA/58716/2011","document_url":"https://www.ema.europa.eu/en/documents/other/planning-implementation-new-legislation-pharmacovigilance_en.pdf"},
    {"id":"12345","name":"Technical specifications - Annex IX costig scenario: Procurement procedure EMA/2013/30/IS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-14T02:00:00Z","last_updated_date":"2014-04-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-ix-costig-scenario-procurement-procedure-ema201330is_en.xls"},
    {"id":"12376","name":"Questions - Meeting of the Paediatric Diabetes Mellitus Experts Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-06T02:00:00Z","last_updated_date":"2010-05-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-meeting-paediatric-diabetes-mellitus-experts-group_en.pdf"},
    {"id":"12398","name":"Extension (Annex II) applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-25T01:09:21Z","last_updated_date":"2009-12-03T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/extension-annex-ii-applications_en.pdf"},
    {"id":"12431","name":"Designated Medical Event (DME) list","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-08-18T19:00:00Z","last_updated_date":"2020-06-16T12:40:00Z","reference_number":"EMA/326038/2020","document_url":"https://www.ema.europa.eu/en/documents/other/designated-medical-event-dme-list_en.xlsx"},
    {"id":"12436","name":"Opinions on safety variations adopted at the CHMP meeting 14-17 January 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-25T15:56:00Z","last_updated_date":"2013-01-25T15:56:00Z","reference_number":"EMA/28123/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-14-17-january-2013_en.pdf"},
    {"id":"12448","name":"Guidelines and concept papers - Adopted during the CHMP meeting 18-21 June 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T11:33:00Z","last_updated_date":"2012-06-25T11:33:00Z","reference_number":"EMA/CHMP/410509/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-18-21-june-2012_en.pdf"},
    {"id":"12482","name":"Comments received during the public consultation on Reflection paper on the risks associated with furocoumarins contained in preparations of Angelica archangelica L.","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-11-14T01:00:00Z","last_updated_date":"2007-11-14T01:00:00Z","reference_number":"EMEA/HMPC/277293/2007","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-during-public-consultation-reflection-paper-risks-associated-furocoumarins-contained-preparations-angelica-archangelica-l_en.pdf"},
    {"id":"12489","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP module VIII – Post-authorisation safety studies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:18:17Z","last_updated_date":"2012-06-25T19:18:17Z","reference_number":"EMA/428922/2012","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-viii-post-authorisation-safety-studies_en.pdf"},
    {"id":"12498","name":"Selection of members of the Technical Anonymisation Group (TAG) - Call for applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-22T16:00:00Z","last_updated_date":"2017-03-22T16:00:00Z","reference_number":"EMA/492371/2016","document_url":"https://www.ema.europa.eu/en/documents/other/selection-members-technical-anonymisation-group-tag-call-applications_en.pdf"},
    {"id":"12503","name":"Comments on paediatric investigation plan: Expected key elements and requirements for a new DTaP containing combination vaccine seeking marketing authorisation (EMA/PDCO/71162/2014)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-11-23T13:30:00Z","last_updated_date":"2015-11-23T13:30:00Z","reference_number":"EMA/48041/2015","document_url":"https://www.ema.europa.eu/en/documents/other/comments-paediatric-investigation-plan-expected-key-elements-and-requirements-new-dtap-containing-combination-vaccine-seeking-marketing-authorisation-emapdco711622014_en.pdf"},
    {"id":"12516","name":"Mandate, objectives and rules of procedure for the CVMP Pharmacovigilance Working Party (PhVWP-V)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-05-19T02:09:00Z","last_updated_date":"2025-03-21T11:15:00Z","reference_number":"EMA/CVMP/PhVWP/133883/2004 Rev.8","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-cvmp-pharmacovigilance-working-party-phvwp-v_en.pdf"},
    {"id":"12523","name":"ENCePP Scientific Convention - EU health care databases for pan-EU research - List of participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-12-08T01:00:00Z","last_updated_date":"2008-12-08T01:00:00Z","reference_number":"EMEA/657313/2008","document_url":"https://www.ema.europa.eu/en/documents/other/encepp-scientific-convention-eu-health-care-databases-pan-eu-research-list-participants_en.pdf"},
    {"id":"12524","name":"Membership at the Management Board Telematics Committee (MBTC)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/MB/751210/2011","document_url":"https://www.ema.europa.eu/en/documents/other/membership-management-board-telematics-committee-mbtc_en.pdf"},
    {"id":"12526","name":"Mandate, objectives and rules of procedure for the CVMP Ad Hoc Group on Novel Veterinary Therapies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-19T14:30:00Z","last_updated_date":"2014-06-19T14:30:00Z","reference_number":"EMA/CVMP/139369/2014 Endorsed","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cvmp-ad-hoc-group-novel-veterinary-therapies_en.pdf"},
    {"id":"12538","name":"Organisational matters: CHMP meeting of 20-23 January 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-30T11:30:00Z","last_updated_date":"2014-01-30T11:30:00Z","reference_number":"EMA/11130/2014","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-20-23-january-2014_en.pdf"},
    {"id":"12544","name":"Outlines of amendments to the Extended EudraVigilance Medicinal Product Report Message (XEVPRM) schema and EVWEB Labels","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T18:00:00Z","last_updated_date":"2014-01-31T18:00:00Z","reference_number":"EMA/21088/2014","document_url":"https://www.ema.europa.eu/en/documents/other/outlines-amendments-extended-eudravigilance-medicinal-product-report-message-xevprm-schema-and-evweb-labels_en.pdf"},
    {"id":"12561","name":"Start of Community reviews - CHMP meeting of 21-24 May 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-25T13:59:00Z","last_updated_date":"2012-05-25T13:59:00Z","reference_number":"EMA/323329/2012","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-21-24-may-2012_en.pdf"},
    {"id":"12581","name":"Summary Record - Focus Group Meeting on Substances of Animal Origin 13.00-17.00 on 30 June 2009 in room 2G - Chair: Nikolaus KriŠ¾","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-20T02:09:21Z","last_updated_date":"2009-07-20T02:09:21Z","reference_number":"EMEA/416774/2009","document_url":"https://www.ema.europa.eu/en/documents/other/summary-record-focus-group-meeting-substances-animal-origin-1300-1700-30-june-2009-room-2g-chair-nikolaus-kris-34_en.pdf"},
    {"id":"12582","name":"EBSCO Allied and the Complementary Medicine Database (AMED) journals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-05T01:00:00Z","last_updated_date":"2017-01-05T01:00:00Z","reference_number":"EMA/879143/2016","document_url":"https://www.ema.europa.eu/en/documents/other/ebsco-allied-and-complementary-medicine-database-amed-journals_en.xlsx"},
    {"id":"12586","name":"Code of conduct of the European Medicines Agency","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2005-01-01T01:00:00Z","last_updated_date":"2025-06-19T10:47:00Z","reference_number":"EMA/171864/2025","document_url":"https://www.ema.europa.eu/en/documents/other/code-conduct-european-medicines-agency_en.pdf"},
    {"id":"12601","name":"Actos: Product Information as approved by the CHMP on 20 october 2011, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-21T02:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/actos-product-information-approved-chmp-20-october-2011-pending-endorsement-european-commission_en.pdf"},
    {"id":"12625","name":"Response to the concept paper for public consultation on the Commission guideline on the format and content of applications for paediatric investigation plans","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T16:00:00Z","last_updated_date":"2014-03-21T16:00:00Z","reference_number":"EMA/803218/2013","document_url":"https://www.ema.europa.eu/en/documents/other/response-concept-paper-public-consultation-commission-guideline-format-and-content-applications-paediatric-investigation-plans_en.pdf"},
    {"id":"12628","name":"P/60/2008: European Medicines Agency decision of 8 September 2009: on a class waiver on a class of medicinal products in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amend...","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-09-08T02:09:21Z","last_updated_date":"2008-09-08T02:09:21Z","reference_number":"EMEA/386453/2008","document_url":"https://www.ema.europa.eu/en/documents/other/p602008-european-medicines-agency-decision-8-september-2009-class-waiver-class-medicinal-products-accordance-regulation-ec-no-19012006-european-parliament-and-council-amend_en.pdf"},
    {"id":"12638","name":"Outcome of written procedures during the period from 21 November 2009 to 25 February 2010 - Management Board meeting 18 March 2010","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/MB/84539/2010","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-during-period-21-november-2009-25-february-2010-management-board-meeting-18-march-2010_en.pdf"}    {"id":"12675","name":"Appendices to guideline on epidemiological data on blood transmissible infections","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-12T02:00:00Z","last_updated_date":"2010-10-12T02:00:00Z","reference_number":"EMA/CHMP/BWP/174129/2009","document_url":"https://www.ema.europa.eu/en/documents/other/appendices-guideline-epidemiological-data-blood-transmissible-infections_en.doc"},
    {"id":"12704","name":"Appointment of new Accounting Officer of the European Medicines Agency","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"EMA/MB/124276/2012","document_url":"https://www.ema.europa.eu/en/documents/other/appointment-new-accounting-officer-european-medicines-agency_en.pdf"},
    {"id":"12715","name":"Recognition criteria for self assessment - Enpr-EMA: Rà©seau d’ Investigations Pà©diatriques des Produits de Santà©","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2011-01-07T00:31:00Z","reference_number":"EMA/667796/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-racseau-d-investigations-pacdiatriques-des-produits-de-santac_en.pdf"},
    {"id":"12728","name":"Overview of comments received on 'Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products' (EMA/CVMP/ERAWP/409328/2010)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-15T16:30:00Z","last_updated_date":"2012-03-15T16:30:00Z","reference_number":"EMA/CVMP/ERA/737515/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-risk-mitigation-measures-related-environmental-risk-assessment-veterinary-medicinal-products-emacvmperawp4093282010_en.pdf"},
    {"id":"12735","name":"Summary of the evaluation of the proposed paediatric investigation plan: Humanised anti-IL-6 receptor (IL-6R) monoclonal antibody for treatment of neuromyelitis optica","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-19T02:00:00Z","last_updated_date":"2015-10-19T02:00:00Z","reference_number":"EMA/603990/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-humanised-anti-il-6-receptor-il-6r-monoclonal-antibody-treatment-neuromyelitis-optica_en.pdf"},
    {"id":"12745","name":"Performance of the Agency’s scientific procedures: Survey 2010 for medicinal products for human use - Management Board meeting 17 March 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2011-03-29T02:00:00Z","reference_number":"EMA/MB/66833/2011","document_url":"https://www.ema.europa.eu/en/documents/other/performance-agencys-scientific-procedures-survey-2010-medicinal-products-human-use-management-board-meeting-17-march-2011_en.pdf"},
    {"id":"12752","name":"CW/1/2011: EMA decision of 19 December 2011 on a class waiver on condition(s)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T15:45:00Z","last_updated_date":"2011-12-22T15:45:00Z","reference_number":"EMA/973755/2011","document_url":"https://www.ema.europa.eu/en/documents/other/cw12011-ema-decision-19-december-2011-class-waiver-conditions_en.pdf"},
    {"id":"12762","name":"Organisational matters - CHMP meeting 14-17 January 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-25T15:56:00Z","last_updated_date":"2013-01-25T15:56:00Z","reference_number":"EMA/28118/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-14-17-january-2013_en.pdf"},
    {"id":"12768","name":"Reinforcing patient safety in Europe - List of participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"EMA/370985/2011 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/other/reinforcing-patient-safety-europe-list-participants_en.pdf"},
    {"id":"12791","name":"Letter from the European Medicines Agency and the European Commission to Health Canada: Confidentiality agreement details","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-15T16:30:00Z","last_updated_date":"2013-03-15T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-european-medicines-agency-and-european-commission-health-canada-confidentiality-agreement-details_en.pdf"},
    {"id":"12808","name":"Scientific guidelines with summary-of-product-characteristics recommendations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2024-11-27T13:30:00Z","reference_number":"EMA/813125/2012 Rev.8","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-guidelines-summary-product-characteristics-recommendations_en.pdf"},
    {"id":"12824","name":"EMA business continuity planning and impact of staff retention scenarios from the EMA staff survey","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T14:15:00Z","last_updated_date":"2017-09-26T14:15:00Z","reference_number":"EMA/635491/2017","document_url":"https://www.ema.europa.eu/en/documents/other/ema-business-continuity-planning-and-impact-staff-retention-scenarios-ema-staff-survey_en.pdf"},
    {"id":"12826","name":"Overview of comments on 'guideline on pharmaceutical development of medicines for paediatric use' received during the second public consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-31T18:15:00Z","last_updated_date":"2013-07-31T18:15:00Z","reference_number":"EMA/805826/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-guideline-pharmaceutical-development-medicines-paediatric-use-received-during-second-public-consultation_en.pdf"},
    {"id":"12890","name":"Joint EMEA/EFPIA questionnaire on the new European registration system - Centralised Procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2000-03-08T00:00:00Z","last_updated_date":"2000-03-08T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/joint-emeaefpia-questionnaire-new-european-registration-system-centralised-procedure_en.pdf"},
    {"id":"12891","name":"Medicines granted a Community marketing authorisation under the centralised procedure from 1 to 29 February 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-22T10:57:00Z","last_updated_date":"2012-03-22T10:57:00Z","reference_number":"EMA/198067/2012","document_url":"https://www.ema.europa.eu/en/documents/other/medicines-granted-community-marketing-authorisation-under-centralised-procedure-1-29-february-2012_en.pdf"},
    {"id":"12893","name":"Download EPS - Species pictograms - Dog","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-dog_en.zip"},
    {"id":"12900","name":"EMEA 2010 Priorities for Drug Safety Research: Safety aspects of antipsychotics in demented patients","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-08-04T02:00:00Z","last_updated_date":"2009-08-04T02:00:00Z","reference_number":"EMEA/493730/2009","document_url":"https://www.ema.europa.eu/en/documents/other/emea-2010-priorities-drug-safety-research-safety-aspects-antipsychotics-demented-patients_en.pdf"},
    {"id":"12904","name":"Invitation to attend a meeting on 'progress in the area of antimicrobial resistance – veterinary medicines' organised by the European Medicines Agency and the Heads of Medicines Agencies (veterinary)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-01T02:00:00Z","last_updated_date":"2011-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/invitation-attend-meeting-progress-area-antimicrobial-resistance-veterinary-medicines-organised-european-medicines-agency-and-heads-medicines-agencies-veterinary_en.pdf"},
    {"id":"12937","name":"eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) user manual","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T18:00:00Z","last_updated_date":"2024-07-09T10:44:00Z","reference_number":"EMA/308954/2012 Version 5.9","document_url":"https://www.ema.europa.eu/en/documents/other/extended-eudravigilance-medicinal-product-dictionary-xevmpd-data-entry-tool-evweb-user-manual_en.pdf"},
    {"id":"12947","name":"Mandate, objectives and rules of procedure for the CHMP Biologics Working Party (BWP)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2005-01-17T01:00:00Z","last_updated_date":"2022-12-13T11:43:00Z","reference_number":"EMEA/CHMP/BWP/206296/2004 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-chmp-biologics-working-party-bwp_en.pdf"},
    {"id":"12952","name":"Speakers’ biographies - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-medicines_en.pdf"},
    {"id":"12968","name":"Decision on amending budget No 01-2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-10-17T18:30:00Z","last_updated_date":"2013-10-17T18:30:00Z","reference_number":"EMA/MB/536520/2013","document_url":"https://www.ema.europa.eu/en/documents/other/decision-amending-budget-no-01-2013_en.pdf"},
    {"id":"13004","name":"Clinical-trial advisory groups: Membership by affiliation category","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T13:40:00Z","last_updated_date":"2013-02-21T15:11:00Z","reference_number":"EMA/33489/2013","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trial-advisory-groups-membership-affiliation-category_en.pdf"},
    {"id":"13016","name":"Advisory Committee on Procurement and Contract (ACPC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/609678/201212","document_url":"https://www.ema.europa.eu/en/documents/other/advisory-committee-procurement-and-contract-acpc_en.pdf"},
    {"id":"13022","name":"Organisational matters coming out of the CHMP meeting of 16-19 April 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-04-23T02:00:00Z","last_updated_date":"2012-04-23T02:00:00Z","reference_number":"EMA/CHMP/213036/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-coming-out-chmp-meeting-16-19-april-2012_en.pdf"},
    {"id":"13025","name":"Sample profile specification and a request form for software applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2009-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sample-profile-specification-and-request-form-software-applications_en.pdf"},
    {"id":"13028","name":"Outcome of the European Medicines Agency survey on advanced-therapy-medicinal-product certification for small and medium-sized enterprises - Commission Regulations (EC) No. 1349/2007 and 668/2009","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-02-07T11:26:00Z","last_updated_date":"2013-02-07T11:26:00Z","reference_number":"EMA/66222/2012","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-european-medicines-agency-survey-advanced-therapy-medicinal-product-certification-small-and-medium-sized-enterprises-commission-regulations-ec-no-13492007-and-6682009_en.pdf"},
    {"id":"13031","name":"Amendments to Management Board implementing rules on the Agency’s fees in relation to extensions of marketing authorisation, Type II variations, annual fees, variations to plasma master files and vaccine antigen master f...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/818152/2009","document_url":"https://www.ema.europa.eu/en/documents/other/amendments-management-board-implementing-rules-agencys-fees-relation-extensions-marketing-authorisation-type-ii-variations-annual-fees-variations-plasma-master-files-and-vaccine-antigen-master-f_en.pdf"},
    {"id":"13185","name":"Tygacil renewal highlighted PI","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-02-18T14:06:01Z","last_updated_date":"2011-02-18T14:06:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/tygacil-renewal-highlighted-pi_en.pdf"},
    {"id":"13187","name":"More information on a joint meeting by TOPRA and the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-10-24T02:09:21Z","last_updated_date":"2008-10-24T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/more-information-joint-meeting-topra-and-european-medicines-agency_en.pdf"},
    {"id":"13188","name":"Timetable: Type II variation and worksharing application alternative monthly assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T14:00:00Z","last_updated_date":"2026-06-16T16:59:00Z","reference_number":"EMA/577387/2016 Rev.9","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-type-ii-variation-worksharing-application-alternative-monthly-assessment_en.xlsx"},
    {"id":"13198","name":"Rules for the implementation of Regulation (EC) No 1049/2001 on access to EMEA documents","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2007-01-11T00:09:21Z","last_updated_date":"2007-01-11T00:09:21Z","reference_number":"EMEA/MB/203359/2006 Rev 1 Adopted","document_url":"https://www.ema.europa.eu/en/documents/other/rules-implementation-regulation-ec-no-10492001-access-emea-documents_en.pdf"},
    {"id":"13252","name":"Declaration of interests - Anne Junker","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-anne-junker_en.pdf"},
    {"id":"13260","name":"Christine Fletcher (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/christine-fletcher-cv_en.pdf"},
    {"id":"13289","name":"Opinions on safety variations / periodic safety update reports adopted at the CHMP meeting of 20-23 January 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-01-30T11:30:00Z","last_updated_date":"2014-01-30T11:30:00Z","reference_number":"EMA/11129/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-20-23-january-2014_en.pdf"},
    {"id":"13308","name":"CTAG1: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on protecting patient confidentiality - Revised after first teleconference with comments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag1-advice-european-medicines-agency-clinical-trial-advisory-group-protecting-patient-confidentiality-revised-after-first-teleconference-comments_en.pdf"},
    {"id":"13340","name":"Declaration of interest: Hilde Boone","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-26T02:00:00Z","last_updated_date":"2025-08-01T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-hilde-boone_en.pdf"},
    {"id":"13354","name":"Pathogen-specific database: Introduction","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-introduction_en.pdf"},
    {"id":"13366","name":"CHMP public assessment report on the shortage of Fabrazyme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2010-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-public-assessment-report-shortage-fabrazyme_en.pdf"},
    {"id":"13384","name":"Recognition criteria for self assessment - Enpr-EMA: FIMP - MCRN (Italian Paediatric Federation- Medicines for Children Research Network)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817617/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-fimp-mcrn-italian-paediatric-federation-medicines-children-research-network_en.pdf"},
    {"id":"13405","name":"Proposal for the development of points to consider for baseline characterisation of frailty status","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-13T15:00:00Z","last_updated_date":"2013-06-13T15:00:00Z","reference_number":"EMA/335158/2013","document_url":"https://www.ema.europa.eu/en/documents/other/proposal-development-points-consider-baseline-characterisation-frailty-status_en.pdf"},
    {"id":"13452","name":"Organisational matters - CHMP meeting 14-17 November 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-11-18T13:02:00Z","last_updated_date":"2011-11-18T13:02:00Z","reference_number":"EMA/CHMP/877158/2011","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-14-17-november-2011_en.pdf"},
    {"id":"13455","name":"EMEA procedure for the collection of bank details","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-28T02:09:21Z","last_updated_date":"2006-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/emea-procedure-collection-bank-details_en.pdf"},
    {"id":"13460","name":"Technical Specifications: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"EMA/37891/2014","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-procurement-procedure-ema201401ph_en.pdf"},
    {"id":"13493","name":"Draft list of Union reference dates and frequency of submission of periodic safety update reports","type":"other","status":"Draft: consultation closed","consultation_date":"2012-04-04 - 2012-06-04","first_published_date":"2012-04-04T20:30:00Z","last_updated_date":"2012-11-05T12:00:00Z","reference_number":"EMA/228710/2012","document_url":"https://www.ema.europa.eu/en/documents/other/draft-list-union-reference-dates-frequency-submission-periodic-safety-update-reports_en.xls"},
    {"id":"13499","name":"Gilenya: Product information as approved by the CHMP on 19 April 2012, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2012-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/gilenya-product-information-approved-chmp-19-april-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"13507","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Allantoin for treatment of epidermolysis bullosa","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-25T12:30:00Z","last_updated_date":"2014-11-25T12:30:00Z","reference_number":"EMA/674171/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-allantoin-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"13508","name":"Survey results","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-08T01:00:00Z","last_updated_date":"2010-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/survey-results_en.zip"},
    {"id":"13516","name":"Arepanrix: Summary of product characteristics","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-29T02:00:00Z","last_updated_date":"2010-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/arepanrix-summary-product-characteristics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/arepanrix-summary-product-characteristics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/arepanrix-summary-product-characteristics_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/arepanrix-summary-product-characteristics_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/arepanrix-summary-product-characteristics_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/arepanrix-summary-product-characteristics_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/arepanrix-summary-product-characteristics_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/arepanrix-summary-product-characteristics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/arepanrix-summary-product-characteristics_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/arepanrix-summary-product-characteristics_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/arepanrix-summary-product-characteristics_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/arepanrix-summary-product-characteristics_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/arepanrix-summary-product-characteristics_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/arepanrix-summary-product-characteristics_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/arepanrix-summary-product-characteristics_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/arepanrix-summary-product-characteristics_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/arepanrix-summary-product-characteristics_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/arepanrix-summary-product-characteristics_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/arepanrix-summary-product-characteristics_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/arepanrix-summary-product-characteristics_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/arepanrix-summary-product-characteristics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/arepanrix-summary-product-characteristics_sv.pdf"}},
    {"id":"13532","name":"European Medicines Agency-Food and Drug Administration pilot programme for parallel assessment of quality-by-design applications: lessons learnt and questions and answers resulting from the first parallel assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-08-20T17:00:00Z","last_updated_date":"2013-08-20T17:00:00Z","reference_number":"EMA/430501/2013","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-food-and-drug-administration-pilot-programme-parallel-assessment-quality-design-applications-lessons-learnt-and-questions-and-answers-resulting-first-parallel-assessment_en.pdf"},
    {"id":"13553","name":"PROTECT: key results and recommendations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T17:00:00Z","last_updated_date":"2016-04-04T17:00:00Z","reference_number":"EMA/180815/2016","document_url":"https://www.ema.europa.eu/en/documents/other/protect-key-results-and-recommendations_en.pdf"},
    {"id":"13632","name":"Declaration of interests: Yannis Hagiyannakis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:56Z","last_updated_date":"2017-08-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-yannis-hagiyannakis_en.pdf"},
    {"id":"13634","name":"Nominations to the European Union Telematics governance bodies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-08-23T14:55:00Z","last_updated_date":"2021-02-18T13:53:00Z","reference_number":"EMA/477872/2016","document_url":"https://www.ema.europa.eu/en/documents/other/nominations-european-union-telematics-governance-bodies_en.pdf"},
    {"id":"13656","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): Module XV – Safety communication (Rev. 1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/646647/2017","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-module-xv-safety-communication-rev-1_en.pdf"},
    {"id":"13657","name":"Superseded - EMA/PDCO Summary Report on the review of the list of granted Class Waivers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-23T13:00:00Z","last_updated_date":"2025-06-03T14:31:00Z","reference_number":"EMA/PDCO/178231/2015","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-ema-pdco-summary-report-review-list-granted-class-waivers_en.pdf"},
    {"id":"13660","name":"Dates for submission of requests for ITF briefing meetings & regulatory advice\n\n2006-2008","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-27T02:00:00Z","last_updated_date":"2006-09-27T02:00:00Z","reference_number":"EMEA/385684/2006","document_url":"https://www.ema.europa.eu/en/documents/other/dates-submission-requests-itf-briefing-meetings-regulatory-advice-2006-2008_en.pdf"},
    {"id":"13662","name":"Overview of comments received on 'Reflection paper on the necessity of initiatives to stimulate the conduct of clinical studies with herbal medicinal products in the paediatric population’","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-28T10:30:00Z","last_updated_date":"2012-02-28T10:30:00Z","reference_number":"EMA/HMPC/354690/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-necessity-initiatives-stimulate-conduct-clinical-studies-herbal-medicinal-products-paediatric-population_en.pdf"},
    {"id":"13678","name":"Lukasz Kniola (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/lukasz-kniola-cv_en.pdf"},
    {"id":"13698","name":"European Medicines Agency and EUnetHTA three-year work plan","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T13:00:00Z","last_updated_date":"2013-11-19T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-and-eunethta-three-year-work-plan_en.pdf"},
    {"id":"13706","name":"Draft inventory of paediatric therapeutic needs - Endocrinology","type":"other","status":"Draft: consultation closed","consultation_date":"2015-05-08 - 2015-07-06","first_published_date":"2015-05-11T18:05:00Z","last_updated_date":"2015-06-01T18:05:00Z","reference_number":"EMA/PDCO/52553/2015 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/other/draft-inventory-paediatric-therapeutic-needs-endocrinology_en.pdf"},
    {"id":"13714","name":"Substance, product, organisation, referentials (SPOR) - Glossary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-15T19:00:00Z","last_updated_date":"2017-03-15T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/substance-product-organisation-referentials-spor-glossary_en.xlsx"},
    {"id":"13715","name":"Summary of European Union (EU) support to micro, small and medium-sized enterprises in health research: Horizon 2020 – The EU research and innovation programme for 2014-2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-21T17:38:23Z","last_updated_date":"2015-02-04T15:30:00Z","reference_number":"EMA/748291/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-european-union-eu-support-micro-small-and-medium-sized-enterprises-health-research-horizon-2020-eu-research-and-innovation-programme-2014-2020_en.pdf"},
    {"id":"13722","name":"Summary of the evaluation of the proposed paediatric investigation plan: Brodalumab for treatment of psoriasis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/615052/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-brodalumab-treatment-psoriasis_en.pdf"},
    {"id":"13728","name":"Rules for the implementation of the financial regulation applicable to the budget of the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-06-10T02:00:00Z","last_updated_date":"2014-10-08T15:00:00Z","reference_number":"EMA/MB/99010/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/rules-implementation-financial-regulation-applicable-budget-european-medicines-agency_en.pdf"},
    {"id":"13737","name":"CTAG1: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on protecting patient confidentiality - Final advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag1-advice-european-medicines-agency-clinical-trial-advisory-group-protecting-patient-confidentiality-final-advice_en.pdf"},
    {"id":"13740","name":"Declaration of interests: Nikolaus Kriz","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-08T02:00:00Z","last_updated_date":"2016-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-nikolaus-kriz_en.pdf"},
    {"id":"13747","name":"Overview of comments received on draft guideline on the specification limits for residues of metal catalysts","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-05-26T02:00:00Z","last_updated_date":"2009-05-26T02:00:00Z","reference_number":"EMEA/410412/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-specification-limits-residues-metal-catalysts_en.pdf"},
    {"id":"13797","name":"Withdrawal letter : Viagra","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-19T01:00:00Z","last_updated_date":"2008-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-viagra_en.pdf"},
    {"id":"13801","name":"List of organisations that provided comments during the public consultation on the European-Union-reference-date list","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-01T14:45:00Z","last_updated_date":"2012-11-05T11:00:02Z","reference_number":"EMA/632901/2012","document_url":"https://www.ema.europa.eu/en/documents/other/list-organisations-provided-comments-during-public-consultation-european-union-reference-date-list_en.pdf"},
    {"id":"13807","name":"Withdrawal letter: Pioglitazone Teva Generics","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T13:20:00Z","last_updated_date":"2012-04-30T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-pioglitazone-teva-generics_en.pdf"},
    {"id":"13808","name":"Questions and answers on insurance broking service","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-12-06T01:00:00Z","last_updated_date":"2007-12-06T01:00:00Z","reference_number":"EMEA/580389/2007","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-insurance-broking-service_en.pdf"},
    {"id":"13836","name":"Statement of authority and confidentiality commitment from the European Comission's Directorate-General for Health and Food Safety and the European Medicines Agency (EMA) not to publicly disclose non-public information shared by the FDA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-23T12:00:00Z","last_updated_date":"2017-08-23T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/statement-authority-confidentiality-commitment-european-comissions-directorate-general-health-food-safety-european-medicines-agency-ema-not-publicly-disclose-non-public-information-shared-fda_en.pdf"},
    {"id":"13840","name":"European Union reference instances","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-27T01:00:00Z","last_updated_date":"2017-08-02T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-reference-instances_en.zip"},
    {"id":"13856","name":"Electronic registration process – EudraVigilance registration phases I, II and III","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2019-10-31T12:00:00Z","reference_number":"EMA/101243/2016","document_url":"https://www.ema.europa.eu/en/documents/other/electronic-registration-process-eudravigilance-registration-phases-i-ii-and-iii_en.pdf"},
    {"id":"13858","name":"Questions and answers - ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological entities)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2017-10-06T19:00:00Z","last_updated_date":"2017-10-06T19:00:00Z","reference_number":"EMA/CHMP/ICH/809509/2016","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-ich-guideline-q11-development-and-manufacture-drug-substances-chemical-entities-and-biotechnological-biological-entities_en.pdf"},
    {"id":"13863","name":"Questions and answers relating to tender – Information-technology service desk - EMA-2013-09-ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-12T17:10:00Z","last_updated_date":"2013-06-19T12:10:00Z","reference_number":"EMA-2013-09-ICT","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-tender-information-technology-service-desk-ema-2013-09-ict_en.pdf"},
    {"id":"13914","name":"Tecfidera: Product Information as approved by the CHMP on 5 November 2015, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-11-09T12:54:00Z","last_updated_date":"2015-11-09T12:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/tecfidera-product-information-approved-chmp-5-november-2015-pending-endorsement-european-commission_en.pdf"},
    {"id":"13915","name":"Language skills self assessment grid","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-04-03T02:09:21Z","last_updated_date":"2007-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/language-skills-self-assessment-grid_en.pdf"},
    {"id":"13925","name":"Opinions on consultation procedures on ancillary medicinal substances in medical devices adopted at the CHMP meeting of 13-16 February 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T13:00:00Z","last_updated_date":"2012-02-17T13:00:00Z","reference_number":"EMA/113297/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-consultation-procedures-ancillary-medicinal-substances-medical-devices-adopted-chmp-meeting-13-16-february-2012_en.pdf"},
    {"id":"13929","name":"Declaration of interests: Xavier Kurz","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-16T10:30:00Z","last_updated_date":"2022-07-01T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-xavier-kurz_en.pdf"},
    {"id":"13949","name":"Mandate of the Working Group on Active Substance Master File Procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-18T18:51:00Z","last_updated_date":"2022-04-07T10:51:00Z","reference_number":"EMA/37869/2022 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-working-group-active-substance-master-file-procedures_en.pdf"},
    {"id":"13979","name":"Overview of comments received on 'Guideline for the conduct of efficacy studies for non-steroidal anti-inflammatory drugs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-24T14:25:00Z","last_updated_date":"2014-01-24T14:25:00Z","reference_number":"EMA/CVMP/EWP/391540/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-conduct-efficacy-studies-non-steroidal-anti-inflammatory-drugs_en.pdf"},
    {"id":"13996","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 21-24 May 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-31T12:30:00Z","last_updated_date":"2012-05-31T12:30:00Z","reference_number":"EMA/CHMP/273713/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-21-24-may-2012_en.pdf"},
    {"id":"13998","name":"Mandate, objectives and rules of procedure for the GMP/GDP Inspectors Working Group (GMDP IWG)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2007-08-13T02:00:00Z","last_updated_date":"2024-10-08T11:50:00Z","reference_number":"EMA/INS/GMP/426453/2024","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-gmp-gdp-inspectors-working-group-gmdp-iwg_en.pdf"},
    {"id":"14004","name":"Technical Specifications – Annex V Tenderer information form: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-v-tenderer-information-form-procurement-procedure-ema201401ph_en.pdf"},
    {"id":"14039","name":"Project description - Contribution agreement 2006/118-594 between EMEA and European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-10-05T02:09:21Z","last_updated_date":"2006-10-05T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/project-description-contribution-agreement-2006118-594-between-emea-and-european-commission_en.pdf"},
    {"id":"14054","name":"European Commission request for an update of the 2013 advice on the impact on public health and animal health of the use of antibiotics (colistin) in animals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-request-update-2013-advice-impact-public-health-and-animal-health-use-antibiotics-colistin-animals_en.pdf"},
    {"id":"14070","name":"Declaration of interests: Alexios Skarlatos","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-alexios-skarlatos_en.pdf"},
    {"id":"14074","name":"Overview of comments received on the draft guideline on reporting the results of population pharmacokinetic analyses","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-06-21T02:00:00Z","last_updated_date":"2007-06-21T02:00:00Z","reference_number":"EMEA/CHMP/EWP/260830/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-reporting-results-population-pharmacokinetic-analyses_en.pdf"},
    {"id":"14081","name":"Declaration of interests: Zaide Frias","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:00Z","last_updated_date":"2024-07-26T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-zaide-frias_en.pdf"},
    {"id":"14089","name":"The European Medicines Agency: A well-established Agency of the EU protecting human and animal health for all EU citizens","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-11T14:45:00Z","last_updated_date":"2016-10-11T14:45:00Z","reference_number":"EMA/457243/2016","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-well-established-agency-eu-protecting-human-and-animal-health-all-eu-citizens_en.pdf"},
    {"id":"14090","name":"Overview of comments received on guideline on influenza vaccines – Quality module","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-02T16:00:00Z","last_updated_date":"2014-06-02T16:00:00Z","reference_number":"EMA/CHMP/BWP/78207/2014","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-influenza-vaccines-quality-module_en.pdf"},
    {"id":"14133","name":"Terms of reference for the European Medicines Agency (EMA) / Food and Drug Administration (FDA) cluster on rare diseases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-09-26T16:00:00Z","last_updated_date":"2016-09-26T16:00:00Z","reference_number":"EMA/633705/2016","document_url":"https://www.ema.europa.eu/en/documents/other/terms-reference-european-medicines-agency-ema-food-and-drug-administration-fda-cluster-rare-diseases_en.pdf"},
    {"id":"14145","name":"Overview of comments received on draft reflection paper on stability testing of herbal medicinal products and traditional herbal medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-11-12T01:00:00Z","last_updated_date":"2010-11-12T01:00:00Z","reference_number":"EMA/HMPC/5873/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-reflection-paper-stability-testing-herbal-medicinal-products-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"14176","name":"EU influenza pandemic process map","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-08-21T02:09:21Z","last_updated_date":"2006-08-21T02:09:21Z","reference_number":"EMEA/214301/2006 Annex I","document_url":"https://www.ema.europa.eu/en/documents/other/eu-influenza-pandemic-process-map_en.pdf"},
    {"id":"14187","name":"Overview of comments received on draft guideline on cell-based medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-04-18T02:00:00Z","last_updated_date":"2008-04-18T02:00:00Z","reference_number":"EMEA/CHMP/CPWP/182901/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-cell-based-medicinal-products_en.pdf"},
    {"id":"14210","name":"Annex 09 Confidentiality Statement - Procurement Procedure EMA/2012/09/IF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-09-confidentiality-statement-procurement-procedure-ema201209if_en.pdf"},
    {"id":"14216","name":"Opinions on safety variations, CHMP meeting 19-22 September 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/768869/2011","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-chmp-meeting-19-22-september-2011_en.pdf"},
    {"id":"14270","name":"Uwe Fiedler (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/uwe-fiedler-doi_en.pdf"},
    {"id":"14274","name":"Technical specifications for open invitation to tender - EMA/2011/48/HR for provision of training courses for European Medicines Agency staff (lot 1-6)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-03T01:00:00Z","last_updated_date":"2012-02-14T12:30:00Z","reference_number":"EMA/814763/2011","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-ema201148hr-provision-training-courses-european-medicines-agency-staff-lot-1-6_en.pdf"}    {"id":"14299","name":"CHMP highlights: July 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-highlights-july-2015_en.pdf"},
    {"id":"14302","name":"List of participants - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"EMA/348113/2014","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf"},
    {"id":"14306","name":"CTAG1: Advice to the European Medicines Agency from the Clinical trial Advisory Group on Protecting patient confidentiality - Revised after 2nd teleconference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag1-advice-european-medicines-agency-clinical-trial-advisory-group-protecting-patient-confidentiality-revised-after-2nd-teleconference_en.pdf"},
    {"id":"14365","name":"Questions and answers on the ‘Note for guidance of photosafety testing’","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-11T02:00:00Z","last_updated_date":"2011-04-11T02:00:00Z","reference_number":"EMA/CHMP/SWP/336670/2010","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-note-guidance-photosafety-testing_en.pdf"},
    {"id":"14405","name":"Evidence of harm from off-label or unlicensed medicines in children","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-10-01T02:00:00Z","last_updated_date":"2004-10-01T02:00:00Z","reference_number":"EMEA/126327/2004","document_url":"https://www.ema.europa.eu/en/documents/other/evidence-harm-label-or-unlicensed-medicines-children_en.pdf"},
    {"id":"14418","name":"Timetable: Annual renewal application of conditional marketing authorisation - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T16:00:00Z","last_updated_date":"2026-05-27T15:08:00Z","reference_number":"EMA/825018/2015 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-annual-renewal-application-conditional-marketing-authorisation-atmp_en.xlsx"},
    {"id":"14435","name":"Overview of comments received on 'qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for the use of cerebrospinal-fluid amyloid beta 1-42 and t-tau and / or positron-emission-tomography amyloid...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-04T19:00:00Z","last_updated_date":"2012-04-04T19:00:00Z","reference_number":"EMA/922/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-qualification-opinion-alzheimers-disease-novel-methodologies-biomarkers-use-cerebrospinal-fluid-amyloid-beta-1-42-and-t-tau-and-or-positron-emission-tomography-amyloid_en.pdf"},
    {"id":"14444","name":"ICT service desk EMA/2013/09/ICT - Annex C - Bespoke applications in use at EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-28T02:00:00Z","last_updated_date":"2013-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ict-service-desk-ema201309ict-annex-c-bespoke-applications-use-ema_en.pdf"},
    {"id":"14452","name":"Opinions on annual reassessments, 5-year renewals adopted at the CHMP meeting of 14-17 November 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-11-24T09:32:00Z","last_updated_date":"2011-11-24T09:32:00Z","reference_number":"EMA/CHMP/877157/2011","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-reassessments-5-year-renewals-adopted-chmp-meeting-14-17-november-2011_en.pdf"},
    {"id":"14459","name":"Timetable: Marketing authorisation renewal application - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T16:00:00Z","last_updated_date":"2026-05-28T15:25:00Z","reference_number":"EMA/825017/2015 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-marketing-authorisation-renewal-application-atmp_en.xlsx"},
    {"id":"14483","name":"Orphan medicines figures 2000-2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T13:46:00Z","last_updated_date":"2026-03-03T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/orphan-medicines-figures-2000-2025_en.pdf"},
    {"id":"14509","name":"EMA-EU MSs-FDA initiative on inspections for Generic Applications: Terms of engagement and procedures for participating authorities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-18T15:15:00Z","last_updated_date":"2013-12-18T15:15:00Z","reference_number":"EMA/INS/GCP/644751/2012","document_url":"https://www.ema.europa.eu/en/documents/other/ema-eu-mss-fda-initiative-inspections-generic-applications-terms-engagement-and-procedures-participating-authorities_en.pdf"},
    {"id":"14513","name":"Timetable: Safety signal - Assessment of responses to request for supplementary information (RSI) - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T12:40:00Z","last_updated_date":"2026-03-19T13:33:00Z","reference_number":"EMA/267915/2016 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-safety-signal-assessment-responses-request-supplementary-information-rsi-atmp_en.xlsx"},
    {"id":"14533","name":"Summary of transfer of appropriations in the budget 2012 - Management Board meeting: 20-21 March 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/MB/89378/2013","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2012-management-board-meeting-20-21-march-2013_en.pdf"},
    {"id":"14538","name":"Training manual - Review of European Medicines Agency documents addressed to the general public by patients and consumers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-04T02:00:00Z","last_updated_date":"2014-01-23T13:30:00Z","reference_number":"EMA/115803/2007 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/training-manual-review-european-medicines-agency-documents-addressed-general-public-patients-and-consumers_en.pdf"},
    {"id":"14570","name":"Technical specification - Online strategy and interface design EMA/2012/37/ED","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"EMA/680395/2012","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-online-strategy-and-interface-design-ema201237ed_en.pdf"},
    {"id":"14606","name":"Technical specifications for open invitation to tender: Procurement procedure EMA/2013/06/PD document delivery services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T11:34:00Z","last_updated_date":"2013-10-17T11:34:00Z","reference_number":"EMA/567603/2013","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-procurement-procedure-ema201306pd-document-delivery-services_en.pdf"},
    {"id":"14638","name":"Action plan on activities proposed by CAT interested parties focus group on non-clinical development of advanced-therapy medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-18T13:15:00Z","last_updated_date":"2012-12-18T13:15:00Z","reference_number":"EMA/CAT/654949/2012","document_url":"https://www.ema.europa.eu/en/documents/other/action-plan-activities-proposed-cat-interested-parties-focus-group-non-clinical-development-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"14664","name":"Withdrawal letter : NovoNorm/Prandin","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:00:00Z","last_updated_date":"2006-10-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-novonormprandin_en.pdf"},
    {"id":"14674","name":"Ten years of sampling and testing of centrally authorised products: 1998-2007","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/INS/S&T/386434/2008","document_url":"https://www.ema.europa.eu/en/documents/other/ten-years-sampling-and-testing-centrally-authorised-products-1998-2007_en.pdf"},
    {"id":"14723","name":"Withdrawal letter: Cerepro","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-16T02:00:00Z","last_updated_date":"2007-07-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-cerepro_en.pdf"},
    {"id":"14728","name":"Comments received from public consultation on good\n\npharmacovigilance practices (GVP): Module V – Risk management systems (Rev. 2)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:00:00Z","last_updated_date":"2017-03-30T17:00:00Z","reference_number":"EMA/164711/2017","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-module-v-risk-management-systems-rev-2_en.pdf"},
    {"id":"14730","name":"Questions and answers on the withdrawal of the marketing authorisation application for Pioglitazone ratio","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-01T01:00:00Z","last_updated_date":"2012-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-withdrawal-marketing-authorisation-application-pioglitazone-ratio_en.pdf"},
    {"id":"14736","name":"Report on Agency's procurement procedure and proposed  improvement action plan","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T11:30:00Z","last_updated_date":"2011-12-20T11:30:00Z","reference_number":"EMA/MB/811207/2011","document_url":"https://www.ema.europa.eu/en/documents/other/report-agencys-procurement-procedure-and-proposed-improvement-action-plan_en.pdf"},
    {"id":"14738","name":"EudraVigilance high level plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-28T00:00:00Z","last_updated_date":"2017-11-22T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-high-level-plan_en.pdf"},
    {"id":"14751","name":"Hospital Sant Joan de Deu - European Network of Paediatric Research at the European Medicines Agency recognition criteria for self-assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T11:55:00Z","last_updated_date":"2013-07-19T11:55:00Z","reference_number":"EMA/219833/2013, Rev 1","document_url":"https://www.ema.europa.eu/en/documents/other/hospital-sant-joan-de-deu-european-network-paediatric-research-european-medicines-agency-recognition-criteria-self-assessment_en.pdf"},
    {"id":"14754","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP module II – Pharmacovigilance system master file","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:18:14Z","last_updated_date":"2012-06-25T19:18:14Z","reference_number":"EMA/428821/2012","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-ii-pharmacovigilance-system-master-file_en.pdf"},
    {"id":"14766","name":"Mandate, objectives and rules of procedure for the joint CVMP/CHMP working group on the application of the 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products (J3RsWG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-04T10:30:00Z","last_updated_date":"2018-03-01T18:00:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/442724/2012 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-joint-cvmpchmp-working-group-application-3rs-replacement-reduction-and-refinement-regulatory-testing-medicinal-products-j3rswg_en.pdf"},
    {"id":"14815","name":"50th orphan medicine receives positive opinion - List of orphan-designated authorised medicines (as of 6 November 2008)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-06T00:09:21Z","last_updated_date":"2008-11-06T00:09:21Z","reference_number":"EMEA/563575/08","document_url":"https://www.ema.europa.eu/en/documents/other/50th-orphan-medicine-receives-positive-opinion-list-orphan-designated-authorised-medicines-6-november-2008_en.pdf"},
    {"id":"14830","name":"Questions and answers relating to open tender procedure - EMA/2011/35/DIS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-08T17:20:00Z","last_updated_date":"2012-02-08T17:20:00Z","reference_number":"EMA/99021/2012","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-tender-procedure-ema201135dis_en.pdf"},
    {"id":"14858","name":"Declaration of interests: Peter Arlett","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T17:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-peter-arlett_en.pdf"},
    {"id":"14873","name":"General principles: European Medicines Agency-Food and Drug Administration parallel scientific advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-22T02:00:00Z","last_updated_date":"2021-08-18T08:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/general-principles-european-medicines-agency-food-and-drug-administration-parallel-scientific-advice_en.pdf"},
    {"id":"14881","name":"Recruitment for the European Medicines Agency: General conditions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-09-01T02:00:00Z","last_updated_date":"2010-09-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/recruitment-european-medicines-agency-general-conditions_en.pdf"},
    {"id":"14933","name":"Organisational matters - CHMP meeting 18-21 February 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-02-28T13:45:00Z","last_updated_date":"2013-02-28T13:45:00Z","reference_number":"EMA/CHMP/109953/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-18-21-february-2013_en.pdf"},
    {"id":"14939","name":"Opinions on safety variations adopted at the Committee for Medicinal Products for Human Use meeting of 17-20 October 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-21T14:01:00Z","last_updated_date":"2011-10-21T14:01:00Z","reference_number":"EMA/CHMP/832564/2011","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-committee-medicinal-products-human-use-meeting-17-20-october-2011_en.pdf"},
    {"id":"14945","name":"Technical specification - Annex 13 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"EMA/269479/2012","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-13-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"14966","name":"Draft revision - External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-09T01:00:00Z","last_updated_date":"2016-12-09T01:00:00Z","reference_number":"EMA/90915/2016","document_url":"https://www.ema.europa.eu/en/documents/other/draft-revision-external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use_en.pdf"},
    {"id":"14975","name":"Ad hoc working group on Herbal Medicinal Products: Proposal for a Note for guidance on non-clinical testing of herbal drug preparations with long-term marketing experience - Guidance to facilitate mutual recognition and ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"1998-09-17T02:00:00Z","last_updated_date":"1998-09-17T02:00:00Z","reference_number":"EMEA/HMPWP/11/99","document_url":"https://www.ema.europa.eu/en/documents/other/ad-hoc-working-group-herbal-medicinal-products-proposal-note-guidance-non-clinical-testing-herbal-drug-preparations-long-term-marketing-experience-guidance-facilitate-mutual-recognition-and_en.pdf"},
    {"id":"14987","name":"Ad hoc working party on Herbal Medicinal Products:  Final comments on notice to applicants volume 2B part IB1 – Summary of product characteristics","type":"other","status":"unknown","consultation_date":"","first_published_date":"1998-09-17T02:00:00Z","last_updated_date":"1998-09-17T02:00:00Z","reference_number":"EMEA/HMPWP/12/99","document_url":"https://www.ema.europa.eu/en/documents/other/ad-hoc-working-party-herbal-medicinal-products-final-comments-notice-applicants-volume-2b-part-ib1-summary-product-characteristics_en.pdf"},
    {"id":"14991","name":"Report on second workshop of the European Paediatric Research Network (EnprEMA), 16 March 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/report-second-workshop-european-paediatric-research-network-enprema-16-march-2010_en.pdf"},
    {"id":"15004","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-12-14T00:09:21Z","last_updated_date":"2010-10-12T01:00:00Z","reference_number":"EMEA/MB/818152/2009 ","document_url":"https://www.ema.europa.eu/en/documents/other/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures_en.pdf-0"},
    {"id":"15015","name":"Speaker biographies - Workshop on clinical-trial data and transparency, 22 November 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T15:00:00Z","last_updated_date":"2012-11-21T15:00:00Z","reference_number":"EMA/749769/2012","document_url":"https://www.ema.europa.eu/en/documents/other/speaker-biographies-workshop-clinical-trial-data-and-transparency-22-november-2012_en.pdf"},
    {"id":"15030","name":"EMA working group on committees’ operational preparedness for veterinary medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-16T15:00:00Z","last_updated_date":"2017-06-16T15:00:00Z","reference_number":"EMA/300988/2017","document_url":"https://www.ema.europa.eu/en/documents/other/ema-working-group-committees-operational-preparedness-veterinary-medicines_en.pdf"},
    {"id":"15032","name":"List of participants of the European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting on 3 June 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-08-10T18:30:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"EMA/167757/2015","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-3-june-2015_en.pdf"},
    {"id":"15048","name":"Enhancing good-manufacturing-practice-inspection cooperation between the European Medicines Agency and the Food and Drug Administration","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-09T14:57:10Z","last_updated_date":"2011-12-09T14:57:10Z","reference_number":"EMA/INS/GMP/942323/2011","document_url":"https://www.ema.europa.eu/en/documents/other/enhancing-good-manufacturing-practice-inspection-cooperation-between-european-medicines-agency-and-food-and-drug-administration_en.pdf"},
    {"id":"15054","name":"Guidelines and concept papers - CHMP May 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/CHMP/273711/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-chmp-may-2012_en.pdf"},
    {"id":"15055","name":"Informed consent for paediatric clinical trials in Europe 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T16:00:00Z","last_updated_date":"2023-08-09T09:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/informed-consent-paediatric-clinical-trials-europe-2015_en.pdf"},
    {"id":"15060","name":"EMA/EC website references substituting information previously available in Notice to Applicants – Chapter 7 of Volume 2A","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-13T02:00:00Z","last_updated_date":"2012-07-13T02:00:00Z","reference_number":"EMA/358526/2012","document_url":"https://www.ema.europa.eu/en/documents/other/emaec-website-references-substituting-information-previously-available-notice-applicants-chapter-7-volume-2a_en.doc"},
    {"id":"15078","name":"Guidelines and concept papers adopted during the CHMP meeting 14-17 November 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T13:02:00Z","last_updated_date":"2011-11-18T13:02:00Z","reference_number":"EMA/CHMP/877164/2011","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-14-17-november-2011_en.pdf"},
    {"id":"15100","name":"Line listing example","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-08T17:32:00Z","last_updated_date":"2017-11-08T17:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/line-listing-example_en.xlsx"},
    {"id":"15130","name":"Declaration of interests: Sylvie Beausuroy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:06Z","last_updated_date":"2017-08-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-sylvie-beausuroy_en.pdf"},
    {"id":"15166","name":"Clarification of the role of the Office of Training Steering Group in new training initiatives within the network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-06T01:00:00Z","last_updated_date":"2012-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/clarification-role-office-training-steering-group-new-training-initiatives-within-network_en.pdf"},
    {"id":"15202","name":"eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) product export tool user manual","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T12:58:00Z","last_updated_date":"2014-05-08T12:58:00Z","reference_number":"EMA/207051/2014","document_url":"https://www.ema.europa.eu/en/documents/other/extended-eudravigilance-medicinal-product-dictionary-xevmpd-product-export-tool-user-manual_en.pdf"},
    {"id":"15264","name":"Annex C - Response questionnaire - Lots 1-5","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2009-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-c-response-questionnaire-lots-1-5_en.xls"},
    {"id":"15268","name":"Proposal for the establishment of an AD hoc expert group on Veterinary Novel Therapies (ADVENT)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-19T14:30:00Z","last_updated_date":"2014-06-19T14:30:00Z","reference_number":"EMA/299310/2014 Noted","document_url":"https://www.ema.europa.eu/en/documents/other/proposal-establishment-ad-hoc-expert-group-veterinary-novel-therapies-advent_en.pdf"},
    {"id":"15284","name":"Declaration of interests: Ulrike Nagl","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:00Z","last_updated_date":"2025-08-01T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-ulrike-nagl_en.pdf"},
    {"id":"15315","name":"Overview of the training on electronic submission of information on medicines - new pharmacovigilance legislation (Art. 57, paragraph 2,\n\n2nd sub-paragraph, Regulation (EC) No. 726/2004): 20-21 February 2014, Bucharest, ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-training-electronic-submission-information-medicines-new-pharmacovigilance-legislation-art-57-paragraph-2-2nd-sub-paragraph-regulation-ec-no-7262004-20-21-february-2014-bucharest_en.pdf"},
    {"id":"15328","name":"Declaration of interests: Paolo Tomasi","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:22Z","last_updated_date":"2016-09-08T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-paolo-tomasi_en.pdf"},
    {"id":"15330","name":"Reflection paper: Chemical, pharmaceutical and biological information to be included in dossiers when process analytical technology is employed","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-03-20T01:00:00Z","last_updated_date":"2006-03-20T01:00:00Z","reference_number":"EMEA/INS/277260/200","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-chemical-pharmaceutical-and-biological-information-be-included-dossiers-when-process-analytical-technology-employed_en.pdf"},
    {"id":"15338","name":"European Commission-DG Health and Food Safety and European Medicines Agency action plan on advanced therapy medicinal products (ATMPs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-20T14:00:00Z","last_updated_date":"2020-07-10T17:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-dg-health-and-food-safety-and-european-medicines-agency-action-plan-advanced-therapy-medicinal-products-atmps_en.pdf"},
    {"id":"15341","name":"Confidentiality arrangement: Letter from EMA to the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health and Ageing","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-01T16:00:00Z","last_updated_date":"2012-10-01T16:00:00Z","reference_number":"EMEA/490079/2009","document_url":"https://www.ema.europa.eu/en/documents/other/confidentiality-arrangement-letter-ema-therapeutic-goods-administration-tga-australian-government-department-health-ageing_en.pdf"},
    {"id":"15343","name":"Paediatric Committee (PDCO) dates for 2009","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-09-23T02:00:00Z","last_updated_date":"2008-09-23T02:00:00Z","reference_number":"EMEA/PDCO/413468/2007-rev 2","document_url":"https://www.ema.europa.eu/en/documents/other/paediatric-committee-pdco-dates-2009_en.pdf"},
    {"id":"15350","name":"Letter of support for glutamate dehydrogenase, a biomarker of hepatocellular liver injury","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-28T15:55:00Z","last_updated_date":"2017-11-28T15:55:00Z","reference_number":"EMA/666090/20177","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-glutamate-dehydrogenase-biomarker-hepatocellular-liver-injury_en.pdf"},
    {"id":"15353","name":"Amendments to the Management Board implementing rules on the Agency’s fees","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T11:30:00Z","last_updated_date":"2011-12-20T11:30:00Z","reference_number":"EMA/MB/239263/2011","document_url":"https://www.ema.europa.eu/en/documents/other/amendments-management-board-implementing-rules-agencys-fees_en.pdf"},
    {"id":"15368","name":"Q&A on impact of EU-USA Mutual Recognition Agreement on marketing authorisation applications and relevant variations - Revised 1st October 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-07-28T12:30:00Z","last_updated_date":"2025-10-07T10:50:00Z","reference_number":"EMA/237558/2023","document_url":"https://www.ema.europa.eu/en/documents/other/qa-impact-eu-usa-mutual-recognition-agreement-marketing-authorisation-applications-relevant-variations-revised-1st-october-2025_en.pdf"},
    {"id":"15379","name":"Calculating 'chargeable units' for pharmacovigilance fees as specified in Regulation (EU) No 658/2014: guidance on how 'chargeable units' are derived from medicinal product information held within the 'Article 57' databa...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-21T14:00:00Z","last_updated_date":"2016-06-06T19:00:00Z","reference_number":"EMA/409768/2015","document_url":"https://www.ema.europa.eu/en/documents/other/calculating-chargeable-units-pharmacovigilance-fees-specified-regulation-eu-no-6582014-guidance-how-chargeable-units-are-derived-medicinal-product-information-held-within-article-57-databa_en.pdf"},
    {"id":"15409","name":"Tamiflu IV compassionate-use programme - Closure of programme, EMEA/H/K/002287","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-08-30T17:52:00Z","last_updated_date":"2013-08-30T17:52:00Z","reference_number":"EMEA/H/K/002287","document_url":"https://www.ema.europa.eu/en/documents/other/tamiflu-iv-compassionate-use-programme-closure-programme-emeahk002287_en.pdf"},
    {"id":"15420","name":"Working party on Herbal Medicinal Products: Final proposal for a core data for  Psyllium seed","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-03-27T01:00:00Z","last_updated_date":"2003-03-27T01:00:00Z","reference_number":"EMEA/HMPWP/13/00","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-psyllium-seed_en.pdf"},
    {"id":"15447","name":"Procedure for the appointment of the Executive Director","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/400828/2009","document_url":"https://www.ema.europa.eu/en/documents/other/procedure-appointment-executive-director_en.pdf"},
    {"id":"15468","name":"Summary Record of Focus group on promotion of pharmacovigilance for food producing animals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/summary-record-focus-group-promotion-pharmacovigilance-food-producing-animals_en.pdf"},
    {"id":"15472","name":"European Medicines Agency travel map","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-01T11:15:00Z","last_updated_date":"2014-08-01T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-travel-map_en.pdf"},
    {"id":"15475","name":"Declaration of interests: Sara Mendosa","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:17Z","last_updated_date":"2012-08-03T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-sara-mendosa_en.pdf"},
    {"id":"15508","name":"Mandate, objectives and rules of procedure for the Pharmacovigilance Inspectors Working Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-12-16T01:00:00Z","last_updated_date":"2013-07-24T19:30:00Z","reference_number":"EMA/INS/PhV/163756/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-pharmacovigilance-inspectors-working-group_en.pdf"},
    {"id":"15511","name":"Overview of comments received on guideline on determining the fate of veterinary medicinal products in manure","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-03-30T02:00:00Z","last_updated_date":"2011-03-30T02:00:00Z","reference_number":"EMA/CVMP/ERA/81952/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-determining-fate-veterinary-medicinal-products-manure_en.pdf"},
    {"id":"15517","name":"Uwe Fiedler (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/uwe-fiedler-cv_en.pdf"},
    {"id":"15521","name":"Timetable: Initial (Full) marketing authorisation application - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T16:00:00Z","last_updated_date":"2026-05-13T15:30:00Z","reference_number":"EMA/824993/2015 Rev.9","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-initial-full-marketing-authorisation-application-atmp_en.xlsx"},
    {"id":"15524","name":"Overview of comments received on 'guideline for the processing of renewals in the centralised procedure'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-02T18:27:49Z","last_updated_date":"2012-07-02T18:27:49Z","reference_number":"EMA/257975/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-processing-renewals-centralised-procedure_en.pdf"},
    {"id":"15526","name":"Annex 07 Draft Framework service contract - Procurement Procedure EMA/2012/09/IF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-07-draft-framework-service-contract-procurement-procedure-ema201209if_en.pdf"},
    {"id":"15538","name":"Highlights from the European Medicines Agency industry platform meeting held on 24 April 2015 on the operation of the centralised procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-29T13:20:00Z","last_updated_date":"2015-05-29T13:20:00Z","reference_number":"EMA/290883/2015","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-european-medicines-agency-industry-platform-meeting-held-24-april-2015-operation-centralised-procedure_en.pdf"},
    {"id":"15539","name":"ICMRA - Mapping of IT initiatives as a support to global medicines regulation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-09T13:20:00Z","last_updated_date":"2017-01-09T13:20:00Z","reference_number":"EMA/580637/2015","document_url":"https://www.ema.europa.eu/en/documents/other/icmra-mapping-it-initiatives-support-global-medicines-regulation_en.pdf"},
    {"id":"15561","name":"Article 57(2) requirements: information to marketing authorisation holders on the updated format for electronic submission of information on medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2014-01-31T18:00:00Z","reference_number":"EMA/140899/2012","document_url":"https://www.ema.europa.eu/en/documents/other/article-572-requirements-information-marketing-authorisation-holders-updated-format-electronic-submission-information-medicines_en.pdf"},
    {"id":"15570","name":"Request for CHMP Qualification Opinion - Annex 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-10T10:20:00Z","last_updated_date":"2014-02-10T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-chmp-qualification-opinion-annex-1_en.pdf"},
    {"id":"15579","name":"Summary from the workshop - Veterinary pharmacovigilance question time: better regulation for electronic reporting and periodic safety update reports (PSURs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"EMA/166976/2011","document_url":"https://www.ema.europa.eu/en/documents/other/summary-workshop-veterinary-pharmacovigilance-question-time-better-regulation-electronic-reporting-and-periodic-safety-update-reports-psurs_en.pdf"},
    {"id":"15581","name":"Statement of authority and confidentiality commitment from the European Medicines Agency not to publicly disclose non-public information shared by the United States Food and Drug Administration","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-09-15T02:00:00Z","last_updated_date":"2010-09-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/statement-authority-and-confidentiality-commitment-european-medicines-agency-not-publicly-disclose-non-public-information-shared-united-states-food-and-drug-administration_en.pdf"},
    {"id":"15652","name":"Programme - EMA workshop on qualification and reporting of physiologically-based pharmacokinetic (PBPK) modelling and simulation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:54:00Z","last_updated_date":"2016-11-17T16:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/programme-ema-workshop-qualification-and-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-and-simulation_en.pdf"},
    {"id":"15653","name":"Letter from the European Medicines Agency and the European Commission to the Food and Drug Administration","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-09-12T02:00:00Z","last_updated_date":"2003-09-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-european-medicines-agency-and-european-commission-food-and-drug-administration_en.pdf"},
    {"id":"15694","name":"Declaration of interests: Peter Richardson","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:00Z","last_updated_date":"2019-10-25T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-peter-richardson_en.pdf"},
    {"id":"15724","name":"Decision of the Management Board - On the appointment of the accounting officer of the European Medicines Agency","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T17:00:00Z","last_updated_date":"2017-03-17T17:00:00Z","reference_number":"EMA/MB/27838/2017","document_url":"https://www.ema.europa.eu/en/documents/other/decision-management-board-appointment-accounting-officer-european-medicines-agency_en.pdf"},
    {"id":"15727","name":"Pandemrix: Summary of product characteristics","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-15T01:00:00Z","last_updated_date":"2010-02-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pandemrix-summary-product-characteristics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/pandemrix-summary-product-characteristics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/pandemrix-summary-product-characteristics_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/pandemrix-summary-product-characteristics_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/pandemrix-summary-product-characteristics_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/pandemrix-summary-product-characteristics_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/pandemrix-summary-product-characteristics_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/pandemrix-summary-product-characteristics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/pandemrix-summary-product-characteristics_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/pandemrix-summary-product-characteristics_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/pandemrix-summary-product-characteristics_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/pandemrix-summary-product-characteristics_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/pandemrix-summary-product-characteristics_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/pandemrix-summary-product-characteristics_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/pandemrix-summary-product-characteristics_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/pandemrix-summary-product-characteristics_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/pandemrix-summary-product-characteristics_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/pandemrix-summary-product-characteristics_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/pandemrix-summary-product-characteristics_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/pandemrix-summary-product-characteristics_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/pandemrix-summary-product-characteristics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/pandemrix-summary-product-characteristics_sv.pdf"}},
    {"id":"15736","name":"Statistics on certificates of medicinal products 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-22T16:00:00Z","last_updated_date":"2014-12-22T16:00:00Z","reference_number":"EMA/755969/2014","document_url":"https://www.ema.europa.eu/en/documents/other/statistics-certificates-medicinal-products-2013_en.pdf"},
    {"id":"15743","name":"Guide to information on human medicines evaluated by European Medicines Agency: what the Agency publishes and when","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-05-18T12:00:00Z","last_updated_date":"2025-07-16T14:26:00Z","reference_number":"EMA/207532/2025","document_url":"https://www.ema.europa.eu/en/documents/other/guide-information-human-medicines-evaluated-european-medicines-agency-what-agency-publishes-when_en.pdf"},
    {"id":"15744","name":"Overview of comments received on the draft guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/CHMP/EWP/246228/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-role-pharmacokinetics-development-medicinal-products-paediatric-population_en.pdf"},
    {"id":"15748","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Macrogol 3350 for treatment of constipation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T12:15:00Z","last_updated_date":"2014-12-12T12:15:00Z","reference_number":"EMA/756970/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-macrogol-3350-treatment-constipation_en.pdf"},
    {"id":"15755","name":"Guidelines on good pharmacovigilance practices (GVP) - Introductory cover note, last updated with launch of public consultation of addendum I to module XVI on educational materials","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-27T12:58:00Z","last_updated_date":"2015-04-27T12:58:00Z","reference_number":"EMA/239760/2015","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-launch-public-consultation-addendum-i-module-xvi-educational-materials_en.pdf"},
    {"id":"15794","name":"Organisational matters - CHMP meeting 22-25 April 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-29T17:40:00Z","last_updated_date":"2014-05-02T12:10:00Z","reference_number":"EMA/124017/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-22-25-april-2014_en.pdf"},
    {"id":"15800","name":"Public summary of the evaluation of the proposed paediatric investigation plan: D-Argininamide, N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-, disulfide with L-cysteine (AMG 416) for treatment of ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-25T12:30:00Z","last_updated_date":"2014-11-25T12:30:00Z","reference_number":"EMA/686541/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-d-argininamide-n-acetyl-d-cysteinyl-d-alanyl-d-arginyl-d-arginyl-d-arginyl-d-alanyl-disulfide-l-cysteine-amg-416-treatment_en.pdf"},
    {"id":"15812","name":"Mandate of the European network of paediatric research-European Medicines Agency working groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T16:00:00Z","last_updated_date":"2021-03-10T16:51:00Z","reference_number":"EMA/493016/2013","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-european-network-paediatric-research-european-medicines-agency-working-groups_en.pdf"},
    {"id":"15832","name":"Mandate, objectives and rules of procedure for the CAT Cell-based Products Temporary Working Party (CPWP)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-08-12T02:00:00Z","last_updated_date":"2010-08-12T02:00:00Z","reference_number":"EMA/CAT/450145/2009","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cat-cell-based-products-temporary-working-party-cpwp_en.pdf"},
    {"id":"15885","name":"Registration of interest – EMA workshop on qualification and reporting of physiologically-based pharmacokinetic (PBPK) modelling and simulation (deadline 31 October)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:54:00Z","last_updated_date":"2016-10-11T17:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/registration-interest-ema-workshop-qualification-and-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-and-simulation-deadline-31-october_en.pdf"},
    {"id":"15937","name":"Performance indicators for the EMEA in 2003","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-04-16T02:00:00Z","last_updated_date":"2004-04-16T02:00:00Z","reference_number":"EMEA/5217/04, rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/performance-indicators-emea-2003_en.pdf"}    {"id":"15938","name":"Letter of support for skeletal muscle injury biomarkers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-19T14:00:00Z","last_updated_date":"2015-03-19T14:00:00Z","reference_number":"EMA/116308/2015","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-skeletal-muscle-injury-biomarkers_en.pdf"},
    {"id":"15988","name":"Validation checklist for initial marketing authorisation applications – immunologicals (applicable to submissions under Regulation (EU) 2019/6)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-30T12:00:00Z","last_updated_date":"2026-04-20T09:00:00Z","reference_number":"EMA/377884/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/validation-checklist-initial-marketing-authorisation-applications-immunologicals-applicable-submissions-under-regulation-eu-2019-6_en.pdf"},
    {"id":"16015","name":"Overview of comments received on Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94038/2007 rev. 3 formerly CPMP/BPWG/859/95 rev. 3)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-06T01:00:00Z","last_updated_date":"2010-12-06T01:00:00Z","reference_number":"EMA/CHMP/BPWP/375734/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-emachmpbpwp940382007-rev-3-formerly-cpmpbpwg85995-rev-3_en.pdf"},
    {"id":"16018","name":"Declaration of interests: Malcolm Godden","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:02Z","last_updated_date":"2012-08-03T13:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-malcolm-godden_en.pdf"},
    {"id":"16050","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting 27-30 May 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T13:00:00Z","last_updated_date":"2013-06-07T13:00:00Z","reference_number":"EMA/CHMP/184572/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-27-30-may-2013_en.pdf"},
    {"id":"16052","name":"Public Status Report on the Implementation of the European Risk Management Strategy (Reporting Period Mid 2005 – Mid 2007)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-26T02:09:21Z","last_updated_date":"2007-07-26T02:09:21Z","reference_number":"EMEA/168954/2007","document_url":"https://www.ema.europa.eu/en/documents/other/public-status-report-implementation-european-risk-management-strategy-reporting-period-mid-2005-mid-2007_en.pdf"},
    {"id":"16053","name":"Declaration of research interests (addendum) - Wolfgang Gopel","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-wolfgang-gopel_en.pdf"},
    {"id":"16065","name":"Overview of comments received on draft guideline on the requirements for the replacement of established Master Seeds (MS) already used in authorised immunological veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-20T02:00:00Z","last_updated_date":"2009-07-20T02:00:00Z","reference_number":"EMEA/CVMP/IWP/409485/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-requirements-replacement-established-master-seeds-ms-already-used-authorised-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"16074","name":"Timetable: Post-authorisation measure (PAM) assessed by PRAC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-02T16:15:00Z","last_updated_date":"2025-10-14T10:00:00Z","reference_number":"EMA/403287/2015 Rev.10","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-post-authorisation-measure-pam-assessed-prac_en.xlsx"},
    {"id":"16076","name":"Statement on status of revision of chapter 5 of the GMP guide concerning \"dedicated facilities\"","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-01-09T01:00:00Z","last_updated_date":"2008-01-09T01:00:00Z","reference_number":"EMEA/INS/GMP/14529/2008","document_url":"https://www.ema.europa.eu/en/documents/other/statement-status-revision-chapter-5-gmp-guide-concerning-dedicated-facilities_en.pdf"},
    {"id":"16081","name":"Declaration of interests: Andreas Pott","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:52Z","last_updated_date":"2015-09-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-andreas-pott_en.pdf"},
    {"id":"16100","name":"Overview of comments received on draft guideline safety and residue data requirements for veterinary medicinal products intended for minor uses or minor species","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-07-20T02:00:00Z","last_updated_date":"2006-07-20T02:00:00Z","reference_number":"EMEA/CVMP/SWP/401874/2005","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-safety-and-residue-data-requirements-veterinary-medicinal-products-intended-minor-uses-or-minor-species_en.pdf"},
    {"id":"16103","name":"Draft points to consider on the evidence of safety and efficacy required for well-established Herbal Medicinal Products in bibliographic applications","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"1999-10-25T02:00:00Z","last_updated_date":"1999-10-25T02:00:00Z","reference_number":"EMEA/HMPWP/23/99","document_url":"https://www.ema.europa.eu/en/documents/other/draft-points-consider-evidence-safety-and-efficacy-required-well-established-herbal-medicinal-products-bibliographic-applications_en.pdf"},
    {"id":"16116","name":"Technical specification - Annex 3 Lot 2 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-3-lot-2-external-service-providers-software-applications-ema201213ict_en.xls"},
    {"id":"16145","name":"Overview of comments received on a draft guideline on non-clinical testing for inadvertent germline transmission of gene transfer vectors(EMEA/273974/2005)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-11-16T01:00:00Z","last_updated_date":"2006-11-16T01:00:00Z","reference_number":"EMEA/360592/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-non-clinical-testing-inadvertent-germline-transmission-gene-transfer-vectorsemea2739742005_en.pdf"},
    {"id":"16147","name":"Pre-Qualification Questionnaire (PQQ) for a restricted tender procedure organised by European Medicines Agency (EMEA) provision of reception/switchboard operator services EMEA/2008/68/ISERV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:21Z","last_updated_date":"2008-11-25T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency-emea-provision-receptionswitchboard-operator-services-emea200868iserv_en.doc"},
    {"id":"16167","name":"Chapter 3.III: Practical examples of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2014-06-16T14:00:00Z","reference_number":"EMA/140557/2012 version 4.0","document_url":"https://www.ema.europa.eu/en/documents/other/chapter-3iii-practical-examples-detailed-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-ema_en.pdf"},
    {"id":"16237","name":"Technical specifications for open invitation to tender - EMA/2012/01/A-FI-AC for banking services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-21T11:51:00Z","last_updated_date":"2012-06-21T11:51:00Z","reference_number":"EMA/338770/2012","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-ema201201a-fi-ac-banking-services_en.pdf"},
    {"id":"16238","name":"Overview of comments received on draft guideline procedure for EU guidelines and related documents within the pharmaceutical legislative framework","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-06-24T02:00:00Z","last_updated_date":"2005-06-24T02:00:00Z","reference_number":"EMEA/125817/2004","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-procedure-eu-guidelines-and-related-documents-within-pharmaceutical-legislative-framework_en.pdf"},
    {"id":"16241","name":"Overview of comments received on draft guideline on the clinical evaluation of direct acting antiviral agents intended for treatment of chronic Hepatitis C (EMEA/CHMP/EWP/30039/2008)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/EWP/144962/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-evaluation-direct-acting-antiviral-agents-intended-treatment-chronic-hepatitis-c-emeachmpewp300392008_en.pdf"},
    {"id":"16255","name":"Outcome of written procedures finalised during the period from 28 February 2013 to 24 May 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-18T19:00:00Z","last_updated_date":"2013-06-18T19:00:00Z","reference_number":"EMA/MB/251156/2013","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-28-february-2013-24-may-2013_en.pdf"},
    {"id":"16275","name":"Guidelines on good pharmacovigilance practices: Introductory cover note, last updated with launch of public consultation of module VI revision 1 and module XVI","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"EMA/321625/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-introductory-cover-note-last-updated-launch-public-consultation-module-vi-revision-1-and-module-xvi_en.pdf"},
    {"id":"16276","name":"A joint meeting between TOPRA and the European Medicines Agency - Overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-10-23T02:09:21Z","last_updated_date":"2009-10-23T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/joint-meeting-between-topra-and-european-medicines-agency-overview_en.pdf"},
    {"id":"16305","name":"Start of Community reviews - CHMP meeting of 20-23 January 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-24T13:00:00Z","last_updated_date":"2014-01-24T13:00:00Z","reference_number":"EMA/39103/2014","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-20-23-january-2014_en.pdf"},
    {"id":"16308","name":"Download EPS - Species pictograms - Sheep","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-sheep_en.zip"},
    {"id":"16328","name":"Opinions on annual reassessments, 5-year renewals adopted at the CHMP meeting of 16-19 January 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-26T16:12:00Z","last_updated_date":"2012-01-26T16:12:00Z","reference_number":"EMA/CHMP/8919/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-reassessments-5-year-renewals-adopted-chmp-meeting-16-19-january-2012_en.pdf"},
    {"id":"16333","name":"Mandate, objectives and rules of procedure for the CVMP Safety Working Party (SWP-V)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2007-12-12T00:09:00Z","last_updated_date":"2021-04-07T09:14:00Z","reference_number":"EMA/CVMP/SWP/131613/2004 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cvmp-safety-working-party-swp-v_en.pdf"},
    {"id":"16343","name":"Working arrangement between the European Medicines Agency and the European Monitoring Centre for Drugs and Drug Addiction","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-06-14T02:00:00Z","last_updated_date":"2018-12-19T10:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/working-arrangement-between-european-medicines-agency-and-european-monitoring-centre-drugs-and-drug-addiction_en.pdf"},
    {"id":"16346","name":"Chapter 6: Definitions of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-01T21:19:00Z","last_updated_date":"2012-09-24T11:18:00Z","reference_number":"EMA/720203/2011","document_url":"https://www.ema.europa.eu/en/documents/other/chapter-6-definitions-detailed-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-ema_en.pdf"},
    {"id":"16389","name":"Overview of the training on electronic submission of information on medicines - new pharmacovigilance legislation (Art. 57, paragraph 2,\n\n2nd sub-paragraph, Regulation (EC) No. 726/2004): 6-7 February 2014, London, UK","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-training-electronic-submission-information-medicines-new-pharmacovigilance-legislation-art-57-paragraph-2-2nd-sub-paragraph-regulation-ec-no-7262004-6-7-february-2014-london-uk_en.pdf"},
    {"id":"16394","name":"Speaker biographies - Regulatory workshop on clinical trials designs in neuromyelitis optica and spectrum disorders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speaker-biographies-regulatory-workshop-clinical-trials-designs-neuromyelitis-optica-and-spectrum-disorders_en.pdf"},
    {"id":"16419","name":"Decision on rules concerning the handling of declared interests of national experts on secondment, trainees, interims and visiting experts of the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T10:14:00Z","last_updated_date":"2025-03-26T09:06:00Z","reference_number":"EMA/20311/2025","document_url":"https://www.ema.europa.eu/en/documents/other/decision-rules-concerning-handling-declared-interests-national-experts-secondment-trainees-interims-visiting-experts-european-medicines-agency_en.pdf"},
    {"id":"16424","name":"Overview of comments received on draft guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-10T02:00:00Z","last_updated_date":"2007-10-10T02:00:00Z","reference_number":"EMEA/CHMP/BWP/329778/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-potency-testing-cell-based-immunotherapy-medicinal-products-treatment-cancer_en.pdf"},
    {"id":"16434","name":"Public summary of the evaluation of a proposed product-specific\n\nwaiver: Abaloparatide for treatment of osteoporosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-17T12:30:00Z","last_updated_date":"2015-02-17T12:30:00Z","reference_number":"EMA/2396/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-abaloparatide-treatment-osteoporosis_en.pdf"},
    {"id":"16451","name":"Letter on the working arrangement to exchange non-public information on medical products between the European Commission's Directorate General for Health and Food Safety (DG SANTE), European Medicines Agency and the Worl...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T12:00:00Z","last_updated_date":"2015-09-22T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-working-arrangement-exchange-non-public-information-medical-products-between-european-commissions-directorate-general-health-and-food-safety-dg-sante-european-medicines-agency-and-worl_en.pdf"},
    {"id":"16478","name":"Draft inventory of paediatric therapeutic needs - Nephro-urology","type":"other","status":"Draft: consultation closed","consultation_date":"2013-08-12 - 2013-10-14","first_published_date":"2013-08-12T13:30:00Z","last_updated_date":"2013-08-12T13:30:00Z","reference_number":"EMA/PDCO/358806/2013","document_url":"https://www.ema.europa.eu/en/documents/other/draft-inventory-paediatric-therapeutic-needs-nephro-urology_en.pdf"},
    {"id":"16514","name":"Declaration of interest: Silvia Fabiani","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-26T02:00:00Z","last_updated_date":"2019-10-25T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-silvia-fabiani_en.pdf"},
    {"id":"16518","name":"Speakers’ biographies - PCWP and HCPWP joint meeting - Workshop on social media","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"EMA/554952/2016","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-pcwp-and-hcpwp-joint-meeting-workshop-social-media_en.pdf"},
    {"id":"16520","name":"Reporting side effects: Guidance for patients","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-10T16:25:00Z","last_updated_date":"2014-02-10T16:25:00Z","reference_number":"EMA/56108/2014","document_url":"https://www.ema.europa.eu/en/documents/other/reporting-side-effects-guidance-patients_en.pdf"},
    {"id":"16521","name":"Assessment of the paediatric needs - Asthma and other obstructive chronic lung diseases","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-10-01T02:00:00Z","last_updated_date":"2006-10-01T02:00:00Z","reference_number":"EMEA/439727/2006","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-asthma-and-other-obstructive-chronic-lung-diseases_en.pdf"},
    {"id":"16528","name":"Multaq: Product information as approved by the CHMP on 22 September 2011, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-28T12:15:00Z","last_updated_date":"2011-09-28T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/multaq-product-information-approved-chmp-22-september-2011-pending-endorsement-european-commission_en.pdf"},
    {"id":"16565","name":"Products for which the marketing authorisations are recommended for suspension by the CHMP on 21 May 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T14:00:00Z","last_updated_date":"2015-05-22T14:00:00Z","reference_number":"EMA/344050/2015","document_url":"https://www.ema.europa.eu/en/documents/other/products-which-marketing-authorisations-are-recommended-suspension-chmp-21-may-2015_en.pdf"},
    {"id":"16587","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 18-21 February 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-02-28T13:45:00Z","last_updated_date":"2013-02-28T13:45:00Z","reference_number":"EMA/CHMP/109945/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-during-chmp-meeting-18-21-february-2013_en.pdf"},
    {"id":"16591","name":"Overview of comments received on guideline on similar biological medicinal products containing interferon beta (EMA/CHMP/BMWP/652000/2010)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-06T12:00:01Z","last_updated_date":"2013-03-06T12:00:01Z","reference_number":"EMA/608526/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-similar-biological-medicinal-products-containing-interferon-beta-emachmpbmwp6520002010_en.pdf"},
    {"id":"16592","name":"Ad hoc working party on Herbal Medicinal Products:  Final comments on notice to applicants volume 2B part IC2 'expert report on toxico-pharmacological documentation' and part III 'toxico-pharmacological documentation'","type":"other","status":"unknown","consultation_date":"","first_published_date":"1998-09-17T02:00:00Z","last_updated_date":"1998-09-17T02:00:00Z","reference_number":"EMEA/HMPWP/10/99","document_url":"https://www.ema.europa.eu/en/documents/other/ad-hoc-working-party-herbal-medicinal-products-final-comments-notice-applicants-volume-2b-part-ic2-expert-report-toxico-pharmacological-documentation-and-part-iii-toxico-pharmacological-documentation_en.pdf"},
    {"id":"16626","name":"Overview of comments received on draft reflection paper on the use of pharmacogenetics in the pharmacokinetic evaluation of medicinal products (EMEA/128517/2006)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-05-24T02:00:00Z","last_updated_date":"2007-05-24T02:00:00Z","reference_number":"EMEA/19720/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-reflection-paper-use-pharmacogenetics-pharmacokinetic-evaluation-medicinal-products-emea1285172006_en.pdf"},
    {"id":"16629","name":"Summary of the evaluation of the proposed paediatric investigation plan: Sotagliflozin for treatment of type 1 diabetes mellitus","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-19T02:00:00Z","last_updated_date":"2015-10-19T02:00:00Z","reference_number":"EMA/628992/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-sotagliflozin-treatment-type-1-diabetes-mellitus_en.pdf"},
    {"id":"16643","name":"Outcome of Management Board written procedures during the period from 17 October 2010 to 24 November 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/MB/739297/2010","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-management-board-written-procedures-during-period-17-october-2010-24-november-2010_en.pdf"},
    {"id":"16648","name":"Request form for eligibility for double daily allowance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-05T14:30:00Z","last_updated_date":"2019-02-27T15:27:00Z","reference_number":"EMA/210753/2012","document_url":"https://www.ema.europa.eu/en/documents/other/request-form-eligibility-double-daily-allowance_en.docx"},
    {"id":"16676","name":"Declaration of interest: Thomas Castelnovo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-26T02:00:00Z","last_updated_date":"2025-08-01T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-thomas-castelnovo_en.pdf"},
    {"id":"16687","name":"Mandate, objectives and composition of the Healthcare Professionals Working Party (HCPWP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T11:55:00Z","last_updated_date":"2025-04-02T10:12:00Z","reference_number":"EMA/109592/2018 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-composition-healthcare-professionals-working-party-hcpwp_en.pdf"},
    {"id":"16691","name":"Report on the Focus Group meeting with invited stakeholders on field efficacy trials in the context of an EU authorisation for veterinary vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T13:30:00Z","last_updated_date":"2017-11-16T13:30:00Z","reference_number":"EMA/405642/2017","document_url":"https://www.ema.europa.eu/en/documents/other/report-focus-group-meeting-invited-stakeholders-field-efficacy-trials-context-eu-authorisation-veterinary-vaccines_en.pdf"},
    {"id":"16704","name":"Working party on Herbal Medicinal Products: Draft proposal for a core data for Passion flower","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2000-03-31T02:00:00Z","last_updated_date":"2000-03-31T02:00:00Z","reference_number":"EMEA/HMPWP/18/00","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-draft-proposal-core-data-passion-flower_en.pdf"},
    {"id":"16729","name":"Council Regulation (EC) No 297/95 of 10 February 1995 on fees payable to the European Agency for the Evaluation of Medicinal Products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-25T01:00:00Z","last_updated_date":"2020-05-15T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/council-regulation-ec-no-29795-10-february-1995-fees-payable-european-agency-evaluation-medicinal-products_en.pdf"},
    {"id":"16749","name":"Start of Community reviews - CHMP meeting of 24-27 June 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/384818/2013","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-24-27-june-2013_en.pdf"},
    {"id":"16783","name":"Terms of reference of the Management Board Telematics committee","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/729062/2012","document_url":"https://www.ema.europa.eu/en/documents/other/terms-reference-management-board-telematics-committee_en.pdf"},
    {"id":"16814","name":"Withdrawal letter: Protelos","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-protelos_en.pdf"},
    {"id":"16827","name":"Draft inventory of paediatric therapeutic needs - Respiratory","type":"other","status":"Draft: consultation closed","consultation_date":"2016-05-11 - 2016-07-11","first_published_date":"2016-05-11T19:20:00Z","last_updated_date":"2016-05-11T19:20:00Z","reference_number":"EMA/244726/2016","document_url":"https://www.ema.europa.eu/en/documents/other/draft-inventory-paediatric-therapeutic-needs-respiratory_en.pdf"},
    {"id":"16873","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting 22-25 April 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-29T17:40:00Z","last_updated_date":"2014-04-29T17:40:00Z","reference_number":"EMA/124014/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-22-25-april-2014_en.pdf"},
    {"id":"16876","name":"Pradaxa: Product information as approved by the CHMP on 24 May 2012, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-25T12:00:00Z","last_updated_date":"2012-05-25T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pradaxa-product-information-approved-chmp-24-may-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"16895","name":"Outcome of written procedures during the period 21 November 2017 to 21 February","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2018-03-16T13:35:00Z","last_updated_date":"2018-03-16T13:35:00Z","reference_number":"EMA/MB/114032/2018 Noted","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-during-period-21-november-2017-21-february_en.pdf"},
    {"id":"16902","name":"Workshop on the therapeutic use of bacteriophages - Summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T16:05:00Z","last_updated_date":"2015-07-09T16:05:00Z","reference_number":"EMA/389257/2015","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-therapeutic-use-bacteriophages-summary_en.pdf"},
    {"id":"16929","name":"The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future: Part II: The European Medicines Agency Road Map Implementation Plan - attachments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-03-07T01:00:00Z","last_updated_date":"2005-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-road-map-2010-preparing-ground-future-part-ii-european-medicines-agency-road-map-implementation-plan-attachments_en.pdf"},
    {"id":"16943","name":"Annex A2 - EMA technical comments on the technical requirements with respect to the candidate host member states' offers to relocate EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T20:15:00Z","last_updated_date":"2017-10-03T20:15:00Z","reference_number":"EMA/589388/2017","document_url":"https://www.ema.europa.eu/en/documents/other/annex-a2-ema-technical-comments-technical-requirements-respect-candidate-host-member-states-offers-relocate-ema_en.pdf"},
    {"id":"16970","name":"List of participants of the European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting:  wo...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"EMA/407046/2015","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-wo_en.pdf"},
    {"id":"16973","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 22-25 July 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T17:00:00Z","last_updated_date":"2013-08-21T17:00:00Z","reference_number":"EMA/CHMP/241122/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-during-chmp-meeting-22-25-july-2013_en.pdf"},
    {"id":"16982","name":"Celvapan: Summary of product characteristics","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-29T02:00:00Z","last_updated_date":"2010-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/celvapan-summary-product-characteristics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/celvapan-summary-product-characteristics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/celvapan-summary-product-characteristics_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/celvapan-summary-product-characteristics_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/celvapan-summary-product-characteristics_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/celvapan-summary-product-characteristics_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/celvapan-summary-product-characteristics_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/celvapan-summary-product-characteristics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/celvapan-summary-product-characteristics_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/celvapan-summary-product-characteristics_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/celvapan-summary-product-characteristics_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/celvapan-summary-product-characteristics_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/celvapan-summary-product-characteristics_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/celvapan-summary-product-characteristics_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/celvapan-summary-product-characteristics_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/celvapan-summary-product-characteristics_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/celvapan-summary-product-characteristics_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/celvapan-summary-product-characteristics_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/celvapan-summary-product-characteristics_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/celvapan-summary-product-characteristics_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/celvapan-summary-product-characteristics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/celvapan-summary-product-characteristics_sv.pdf"}},
    {"id":"16993","name":"Action Plan for Herbal Medicines 2010-2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-06-11T02:00:00Z","last_updated_date":"2010-06-11T02:00:00Z","reference_number":"EMA/831327/2009","document_url":"https://www.ema.europa.eu/en/documents/other/action-plan-herbal-medicines-2010-2011_en.pdf"},
    {"id":"17019","name":"List of participants - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations plenary meeting with all eligible organisations: 30 November 2012 meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-02-12T01:00:00Z","last_updated_date":"2013-02-12T01:00:00Z","reference_number":"EMA/725895/2012","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-plenary-meeting-all-eligible-organisations-30-november-2012-meeting_en.pdf"},
    {"id":"17064","name":"Utilisation of EudraGMDP database in regulatory procedures in the context of the mutual recognition agreement between Japan and the European Union - impact on good-manufacturing-practice certificates","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T15:50:00Z","last_updated_date":"2013-10-07T15:50:00Z","reference_number":"EMA/568361/2013","document_url":"https://www.ema.europa.eu/en/documents/other/utilisation-eudragmdp-database-regulatory-procedures-context-mutual-recognition-agreement-between-japan-and-european-union-impact-good-manufacturing-practice-certificates_en.pdf"},
    {"id":"17071","name":"Public bulletin: Veterinary pharmacovigilance 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T15:16:00Z","last_updated_date":"2012-03-05T15:16:00Z","reference_number":"EMA/CVMP/PhVWP/987984/2011","document_url":"https://www.ema.europa.eu/en/documents/other/public-bulletin-veterinary-pharmacovigilance-2011_en.pdf"},
    {"id":"17093","name":"Periodic safety update report (PSUR) / Periodic safety update single assessment (PSUSA) submissions and expected PRAC outcome dates for bisphosphonates and denosumab","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-13T13:00:00Z","last_updated_date":"2015-03-13T13:00:00Z","reference_number":"EMA/171030/2015","document_url":"https://www.ema.europa.eu/en/documents/other/periodic-safety-update-report-psur-periodic-safety-update-single-assessment-psusa-submissions-and-expected-prac-outcome-dates-bisphosphonates-and-denosumab_en.pdf"},
    {"id":"17133","name":"CTAG2: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on clinical-trial-data formats - meeting 1 outcome with comments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag2-advice-european-medicines-agency-clinical-trial-advisory-group-clinical-trial-data-formats-meeting-1-outcome-comments_en.pdf"},
    {"id":"17139","name":"Overview of comments received on 'Guideline on validation of bioanalytical methods' (EMEA/CHMP/EWP/192217/2009)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-08-01T02:00:00Z","last_updated_date":"2011-08-01T02:00:00Z","reference_number":"EMA/434565/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-validation-bioanalytical-methods-emeachmpewp1922172009_en.pdf"},
    {"id":"17143","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Futurenest Clinical Research","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/770017/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-futurenest-clinical-research_en.pdf"},
    {"id":"17164","name":"Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - Inclusion and exclusion criteria for processing of Individual Case Safety Reports","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-05-12T14:30:00Z","last_updated_date":"2017-01-05T16:33:00Z","reference_number":"EMA/119265/2015 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency-inclusion-and-exclusion-criteria-processing-individual-case-safety-reports_en.pdf"},
    {"id":"17202","name":"Declaration of interests: Nicholas Hywel Jarrett","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T02:00:00Z","last_updated_date":"2024-07-26T13:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-nicholas-hywel-jarrett_en.pdf"},
    {"id":"17207","name":"Extended Telematics strategy and implementation roadmap 2018-2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-25T16:30:00Z","last_updated_date":"2018-07-25T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/extended-telematics-strategy-and-implementation-roadmap-2018-2019_en.pdf"},
    {"id":"17222","name":"Outcome of Management Board written procedures during the period from 25 November 2010 to 22 February 2011  - Management Board meeting 17 March 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2011-03-29T02:00:00Z","reference_number":"EMA/MB/105462/2011","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-management-board-written-procedures-during-period-25-november-2010-22-february-2011-management-board-meeting-17-march-2011_en.pdf"},
    {"id":"17223","name":"Policy 70: European Medicines Agency policy on publication of clinical data for medicinal products for human use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2019-04-30T00:00:00Z","reference_number":"EMA/144064/2019","document_url":"https://www.ema.europa.eu/en/documents/other/policy-70-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use_en.pdf"},
    {"id":"17228","name":"Decision on setting up an Advisory Committee on Procurements and Contracts (ACPC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/269255/2012","document_url":"https://www.ema.europa.eu/en/documents/other/decision-setting-advisory-committee-procurements-and-contracts-acpc_en.pdf"},
    {"id":"17229","name":"Cover letter for change of scientific opinion holder","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-05T17:20:00Z","last_updated_date":"2014-08-05T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cover-letter-change-scientific-opinion-holder_en.doc"},
    {"id":"17230","name":"Declaration of interests: Maria Alves","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T02:00:00Z","last_updated_date":"2025-08-01T13:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-maria-alves_en.pdf"},
    {"id":"17232","name":"Mandate, objectives and rules of procedure for HMPC temporary working parties and drafting groups","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2016-08-31T18:40:00Z","reference_number":"EMEA/HMPC/410043/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-hmpc-temporary-working-parties-drafting-groups_en.pdf"},
    {"id":"17246","name":"Extension of mandate of the Acting Executive Director","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/MB/376449/2011","document_url":"https://www.ema.europa.eu/en/documents/other/extension-mandate-acting-executive-director_en.pdf"},
    {"id":"17259","name":"European Union herbal monographs: Overview of recommendations for the uses of herbal medicinal products in the paediatric population","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-08-08T11:30:00Z","last_updated_date":"2023-03-24T14:25:00Z","reference_number":"EMA/HMPC/228356/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-herbal-monographs-overview-recommendations-uses-herbal-medicinal-products-paediatric-population_en.pdf"},
    {"id":"17299","name":"Draft budget 2011 presented to the Management Board on 16 December 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-05T02:00:00Z","last_updated_date":"2011-07-05T02:00:00Z","reference_number":"EMA/MB/132206/2010 Annex I","document_url":"https://www.ema.europa.eu/en/documents/other/draft-budget-2011-presented-management-board-16-december-2010_en.pdf"},
    {"id":"17322","name":"Financial regulation applicable to the budget of the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-12-11T01:00:00Z","last_updated_date":"2014-01-23T10:27:00Z","reference_number":"EMA/MB/789566/2013","document_url":"https://www.ema.europa.eu/en/documents/other/financial-regulation-applicable-budget-european-medicines-agency_en.pdf"},
    {"id":"17402","name":"European Directorate for the Quality of Medicines and Healthcare (EDQM) participation at the CAT","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/MB/740454/2012","document_url":"https://www.ema.europa.eu/en/documents/other/european-directorate-quality-medicines-and-healthcare-edqm-participation-cat_en.pdf"},
    {"id":"17432","name":"Origio - Procedural steps and scientific information after initial consultation (archive)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2025-07-24T10:31:00Z","reference_number":"Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/origio-procedural-steps-scientific-information-after-initial-consultation-archive_en.pdf"},
    {"id":"17459","name":"Questions and Answers relating to EMEA ITT – EMEA-2004-27-PM-IT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-10-29T02:09:21Z","last_updated_date":"2004-10-29T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-emea-itt-emea-2004-27-pm-it_en.pdf"},
    {"id":"17464","name":"International Coalition of Medicines Regulatory Authorities (ICMRA) Zika virus disease press release: global medicines regulators pledge support to tackle Zika virus disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-11T12:00:00Z","last_updated_date":"2016-02-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/international-coalition-medicines-regulatory-authorities-icmra-zika-virus-disease-press-release-global-medicines-regulators-pledge-support-tackle-zika-virus-disease_en.pdf"},
    {"id":"17499","name":"List of participants - Spinal muscular atrophy stakeholder workshop","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"EMA/790303/2016","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-spinal-muscular-atrophy-stakeholder-workshop_en.pdf"},
    {"id":"17502","name":"Comments received from public consultation on good pharmacovigilance practices (GVP) - GVP Module VII – Periodic safety update report (Rev 1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-12T11:00:00Z","last_updated_date":"2013-12-12T11:00:00Z","reference_number":"EMA/646427/2013","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-vii-periodic-safety-update-report-rev-1_en.pdf"},
    {"id":"17506","name":"Technical note on the planned EudraVigilance downtime from 8 to 21 November 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-04T15:30:00Z","last_updated_date":"2017-10-04T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-note-planned-eudravigilance-downtime-8-21-november-2017_en.pdf"},
    {"id":"17523","name":"Table of recommendations – Cystic fibrosis workshop","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"EMA/511310/2017","document_url":"https://www.ema.europa.eu/en/documents/other/table-recommendations-cystic-fibrosis-workshop_en.pdf"},
    {"id":"17527","name":"Guidelines and concept papers adopted at the CHMP meeting 18-21 November 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-11-27T12:25:00Z","last_updated_date":"2013-11-27T12:25:00Z","reference_number":"EMA/710490/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-chmp-meeting-18-21-november-2013_en.pdf"},
    {"id":"17602","name":"Advanced therapy medicinal products - Key figures in 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-14T10:30:00Z","last_updated_date":"2014-02-14T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advanced-therapy-medicinal-products-key-figures-2013_en.pdf"},
    {"id":"17609","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 23-26 June 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T16:30:00Z","last_updated_date":"2014-07-01T16:30:00Z","reference_number":"EMA/125338/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-during-chmp-meeting-23-26-june-2014_en.pdf"},
    {"id":"17655","name":"Project description - Detailed information about the Instrument for Pre-accession Assistance transition assistance programme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-01-01T01:00:00Z","last_updated_date":"2008-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/project-description-detailed-information-about-instrument-pre-accession-assistance-transition-assistance-programme_en.pdf"}    {"id":"17679","name":"Mandate, objectives and rules of procedure for the joint CHMP/CVMP Quality Working Party","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-10T02:09:00Z","last_updated_date":"2019-03-06T17:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/65702/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-joint-chmpcvmp-quality-working-party_en.pdf"},
    {"id":"17683","name":"Summary of transfer of appropriations in the budget 2014 - Management Board meeting: 12 June 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-19T14:30:00Z","last_updated_date":"2014-06-19T14:30:00Z","reference_number":"EMA/MB/268686/2014 Noted","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2014-management-board-meeting-12-june-2014_en.pdf"},
    {"id":"17688","name":"Declaration of interests: Spiridon Vamvakas","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2023-08-31T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-spiridon-vamvakas_en.pdf"},
    {"id":"17689","name":"Action plan to further progress the european risk management strategy","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2005-05-04T02:00:00Z","last_updated_date":"2005-05-04T02:00:00Z","reference_number":"EMEA/115906/2005/Final","document_url":"https://www.ema.europa.eu/en/documents/other/action-plan-further-progress-european-risk-management-strategy_en.pdf"},
    {"id":"17694","name":"Procedural announcements, CHMP meeting 19-22 September 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/768879/2011","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-announcements-chmp-meeting-19-22-september-2011_en.pdf"},
    {"id":"17712","name":"Organisational matters - CHMP meeting 12-15 March 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-20T15:00:00Z","last_updated_date":"2012-03-20T15:00:00Z","reference_number":"EMA/CHMP/162996/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-12-15-march-2012_en.pdf"},
    {"id":"17721","name":"Regranex - Product information as approved by the CHMP on 18 February 2010, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-18T01:00:00Z","last_updated_date":"2010-02-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/regranex-product-information-approved-chmp-18-february-2010-pending-endorsement-european-commission_en.pdf"},
    {"id":"17741","name":"Workshop on endpoints for cystic fibrosis clinical trials - Call for expression of interest","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-02T14:00:00Z","last_updated_date":"2012-07-02T14:00:00Z","reference_number":"EMA/385817/2012","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-endpoints-cystic-fibrosis-clinical-trials-call-expression-interest_en.pdf"},
    {"id":"17757","name":"Declaration of interests: Noel Wathion","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2020-09-03T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-noel-wathion_en.pdf"},
    {"id":"17760","name":"EU Medicines Agencies Network Strategy to 2020: Working together to improve health","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/MB/151414/2015","document_url":"https://www.ema.europa.eu/en/documents/other/eu-medicines-agencies-network-strategy-2020-working-together-improve-health_en.pdf"},
    {"id":"17774","name":"Comments received from public consultation on good pharmacovigilance practices (GVP) module X – Additional monitoring","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-25T12:00:00Z","last_updated_date":"2013-04-25T12:00:00Z","reference_number":"EMA/239763/2013","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-module-x-additional-monitoring_en.pdf"},
    {"id":"17779","name":"Matching patients-friendly therapeutic areas for browse search on herbal medicines for human use with ATC therapeutic groups (level 2)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-06-28T02:00:00Z","last_updated_date":"2016-03-08T16:45:00Z","reference_number":"EMA/568320/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/matching-patients-friendly-therapeutic-areas-browse-search-herbal-medicines-human-use-atc-therapeutic-groups-level-2_en.pdf"},
    {"id":"17807","name":"Call for expressions of interest - Workshop on measuring the impact of pharmacovigilance activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T13:30:00Z","last_updated_date":"2016-04-04T13:30:00Z","reference_number":"EMA/95397/2016","document_url":"https://www.ema.europa.eu/en/documents/other/call-expressions-interest-workshop-measuring-impact-pharmacovigilance-activities_en.pdf"},
    {"id":"17826","name":"Joint audit programme for EEA GMP inspectorates: Programme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-19T02:00:00Z","last_updated_date":"2020-07-31T11:00:00Z","reference_number":"EMA/618050/2015 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/joint-audit-programme-eea-gmp-inspectorates-programme_en.pdf"},
    {"id":"17843","name":"Terms of reference for the placement of Liaison Officials at the US Food and Drug Administration and the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/terms-reference-placement-liaison-officials-us-food-and-drug-administration-and-european-medicines-agency_en.pdf"},
    {"id":"17848","name":"Declaration of research interests (addendum) - Greth Veal","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-greth-veal_en.pdf"},
    {"id":"17941","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Tobramycin for treatment of Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T11:30:00Z","last_updated_date":"2014-10-21T11:30:00Z","reference_number":"EMA/511537/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-tobramycin-treatment-pseudomonas-aeruginosa-pulmonary-infection-colonisation-patients-cystic-fibrosis_en.pdf"},
    {"id":"17948","name":"CTAG2: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on clinical-trial-data formats - meeting 2 outcome with comments and amendments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag2-advice-european-medicines-agency-clinical-trial-advisory-group-clinical-trial-data-formats-meeting-2-outcome-comments-and-amendments_en.pdf"},
    {"id":"17954","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP Module XVI Addendum I – Educational materials","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T12:30:00Z","last_updated_date":"2015-12-15T12:30:00Z","reference_number":"EMA/772528/2015","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-xvi-addendum-i-educational-materials_en.pdf"},
    {"id":"17959","name":"General comments received from public consultation on good pharmacovigilance practices","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:18:21Z","last_updated_date":"2012-06-25T19:18:21Z","reference_number":"EMA/428590/2012","document_url":"https://www.ema.europa.eu/en/documents/other/general-comments-received-public-consultation-good-pharmacovigilance-practices_en.pdf"},
    {"id":"17973","name":"Workshop on the EMEA transparency policy - List of participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"EMEA/665471/2008","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-emea-transparency-policy-list-participants_en.pdf"},
    {"id":"17975","name":"Questions and answers relating to open procedure - Online strategy and interface design - EMA 2012-37-ED","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-12T17:20:00Z","last_updated_date":"2013-06-12T17:20:00Z","reference_number":"EMA 2012-37-ED","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-procedure-online-strategy-and-interface-design-ema-2012-37-ed_en.pdf"},
    {"id":"17979","name":"Amendments to Management Board implementing rules on the Agency’s fees in relation to inflation and multistrain veterinary immunological products effective from April 2010 - Management Board meeting 18 March 2010","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/MB/818152/2009","document_url":"https://www.ema.europa.eu/en/documents/other/amendments-management-board-implementing-rules-agencys-fees-relation-inflation-and-multistrain-veterinary-immunological-products-effective-april-2010-management-board-meeting-18-march-2010_en.pdf"},
    {"id":"17983","name":"Declaration of interests: Xavier Luria","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:02Z","last_updated_date":"2012-02-29T10:07:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-xavier-luria_en.pdf"},
    {"id":"17995","name":"Declaration of interests: Claudia Galeazzo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2023-06-14T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-claudia-galeazzo_en.pdf"},
    {"id":"17999","name":"Amendment to the Agency’s internal control standard on\n\nsensitive functions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/568706/2010","document_url":"https://www.ema.europa.eu/en/documents/other/amendment-agencys-internal-control-standard-sensitive-functions_en.pdf"},
    {"id":"18070","name":"Bradley Malin (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T16:00:00Z","last_updated_date":"2017-10-31T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/bradley-malin-cv_en.pdf"},
    {"id":"18075","name":"Assessment of the paediatric needs - Epilepsy","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-09-20T02:00:00Z","last_updated_date":"2006-09-20T02:00:00Z","reference_number":"EMEA/377174/2006","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-epilepsy_en.pdf"},
    {"id":"18076","name":"List of questions: High-grade glioma expert meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-06T02:00:00Z","last_updated_date":"2011-07-06T02:00:00Z","reference_number":"EMA/608847/2010","document_url":"https://www.ema.europa.eu/en/documents/other/list-questions-high-grade-glioma-expert-meeting_en.pdf"},
    {"id":"18080","name":"CHMP statistics: June 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-statistics-june-2015_en.pdf"},
    {"id":"18111","name":"CHMP statistics: November 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-statistics-november-2015_en.pdf"},
    {"id":"18114","name":"Overview of comments received on Guidance on collection and provision of national data on antimicrobial use by animal species/categories","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-02-23T15:07:00Z","last_updated_date":"2018-02-23T15:07:00Z","reference_number":"EMA/619729/2017","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guidance-collection-and-provision-national-data-antimicrobial-use-animal-speciescategories_en.pdf"},
    {"id":"18124","name":"Overview of comments received on draft guideline on validation of immunoassay for the detection of hepatitis B virus surface antigen (HBSAG) in plasma pools","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/CHMP/BWP/94181/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-validation-immunoassay-detection-hepatitis-b-virus-surface-antigen-hbsag-plasma-pools_en.pdf"},
    {"id":"18139","name":"Overview of comments on 'qualification opinion of a novel data-driven model of disease progression and trial evaluation in mild and moderate Alzheimer’s disease'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-03T17:50:00Z","last_updated_date":"2013-10-03T17:50:00Z","reference_number":"EMA/471475/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-qualification-opinion-novel-data-driven-model-disease-progression-and-trial-evaluation-mild-and-moderate-alzheimers-disease_en.pdf"},
    {"id":"18183","name":"Declaration of interests: Heidi Janssen","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-heidi-janssen_en.pdf"},
    {"id":"18184","name":"Withdrawal letter: Intrinsa","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-26T02:00:00Z","last_updated_date":"2010-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-intrinsa_en.pdf"},
    {"id":"18186","name":"Overview of comments received on draft guideline on guideline on requirements for an authorisation under exceptional circumstances for vaccines for emergency use against bluetongue","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-17T01:00:00Z","last_updated_date":"2008-11-17T01:00:00Z","reference_number":"EMEA/CVMP/IWP/521211/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-guideline-requirements-authorisation-under-exceptional-circumstances-vaccines-emergency-use-against-bluetongue_en.pdf"},
    {"id":"18238","name":"Declaration of interests: Stiina Aarum","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-16T11:30:00Z","last_updated_date":"2013-10-16T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-stiina-aarum_en.pdf"},
    {"id":"18248","name":"Participation of patients’/consumers’ representatives as observer\n\nto the PhVWP","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/MB/752664/2009","document_url":"https://www.ema.europa.eu/en/documents/other/participation-patientsconsumers-representatives-observer-phvwp_en.pdf"},
    {"id":"18274","name":"Overview of comments received on 'guideline on quality of biological active substances produced by transgene expression in animals'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-10T17:18:00Z","last_updated_date":"2013-06-10T17:18:00Z","reference_number":"EMA/CHMP/BWP/151908/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-quality-biological-active-substances-produced-transgene-expression-animals_en.pdf"},
    {"id":"18276","name":"European Medicines Agency: Clarification Questions 21st September 2006","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-clarification-questions-21st-september-2006_en.pdf"},
    {"id":"18291","name":"Declaration of interests - Jose Drabwell","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-jose-drabwell_en.pdf"},
    {"id":"18304","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Irish Paediatric Clinical Research Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817620/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-irish-paediatric-clinical-research-network_en.pdf"},
    {"id":"18313","name":"Outline of a pilot project to rationalise international good-manufacturing-practice-inspection activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-11-06T01:00:00Z","last_updated_date":"2007-11-06T01:00:00Z","reference_number":"EMEA/INS/GMP/430438/2007","document_url":"https://www.ema.europa.eu/en/documents/other/outline-pilot-project-rationalise-international-good-manufacturing-practice-inspection-activities_en.pdf"},
    {"id":"18372","name":"eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training: frequently asked questions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2026-02-11T15:15:00Z","reference_number":"EMA/344287/2016, Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/extended-eudravigilance-medicinal-product-dictionary-xevmpd-training-frequently-asked-questions_en.pdf"},
    {"id":"18375","name":"Renewal of confidentiality agreement: Letter from the European Medicines Agency and the European Commission to Health Canada","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-15T16:30:00Z","last_updated_date":"2013-03-15T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/renewal-confidentiality-agreement-letter-european-medicines-agency-and-european-commission-health-canada_en.pdf"},
    {"id":"18387","name":"Implementing the European Medicines Agency’s road map to 2015: The Agency's contribution to science, medicines, health","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/MB/550544/2011","document_url":"https://www.ema.europa.eu/en/documents/other/implementing-european-medicines-agencys-road-map-2015-agencys-contribution-science-medicines-health_en.pdf"},
    {"id":"18410","name":"Overview of comments received on 'Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture'","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-08-17T02:00:00Z","last_updated_date":"2011-08-17T02:00:00Z","reference_number":"EMA/CHMP/BWP/453628/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-quality-aspects-isolation-candidate-influenza-vaccine-viruses-cell-culture_en.pdf"},
    {"id":"18412","name":"Nicola Orlandi (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/nicola-orlandi-cv_en.pdf"},
    {"id":"18459","name":"Register of deadlines to put a medicinal product on the market In accordance with Article 33 of the Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-05T12:15:00Z","last_updated_date":"2025-06-16T10:22:00Z","reference_number":"EMA/354670/2023","document_url":"https://www.ema.europa.eu/en/documents/other/register-deadlines-put-medicinal-product-market-accordance-article-33-regulation-ec-no-1901-2006-european-parliament-council-12-december-2006_en.pdf"},
    {"id":"18474","name":"High level business consultancy EMA/2013/23/FI - Technical specifications - Annex IX ordering process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications-annex-ix-ordering-process_en.pdf"},
    {"id":"18478","name":"Assessment of the paediatric needs - Anaesthesiology","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-10-01T02:00:00Z","last_updated_date":"2006-10-01T02:00:00Z","reference_number":"EMEA/405166/2006","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-anaesthesiology_en.pdf"},
    {"id":"18481","name":"Proceedings for the nomination of the Executive Director","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-01T16:00:00Z","last_updated_date":"2015-10-01T16:00:00Z","reference_number":"EMA/MB/452503/2015","document_url":"https://www.ema.europa.eu/en/documents/other/proceedings-nomination-executive-director_en.pdf"},
    {"id":"18482","name":"Questions and answers on implementation of risk based prevention of cross contamination in production and ‘Guideline on setting health based exposure limits for use in risk identification in the manufacture of different ...","type":"other","status":"Draft: consultation closed","consultation_date":"2017-01-09 - 2017-04-30","first_published_date":"2017-01-09T16:15:00Z","last_updated_date":"2018-04-30T21:06:00Z","reference_number":"EMA/CHMP/CVMP/SWP/246844/2018","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-implementation-risk-based-prevention-cross-contamination-production-and-guideline-setting-health-based-exposure-limits-use-risk-identification-manufacture-different_en.pdf"},
    {"id":"18489","name":"Communication from the Commission: Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation o...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-09-24T02:00:00Z","last_updated_date":"2008-09-24T02:00:00Z","reference_number":"n/a","document_url":"https://www.ema.europa.eu/en/documents/other/communication-commission-guideline-format-and-content-applications-agreement-or-modification-paediatric-investigation-plan-and-requests-waivers-or-deferrals-and-concerning-operation-o_en.pdf"},
    {"id":"18508","name":"Annex I - Summary of product characteristics for Celvapan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-10-28T00:09:21Z","last_updated_date":"2009-10-28T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-i-summary-product-characteristics-celvapan_en.pdf"},
    {"id":"18532","name":"Electronic summary of product characteristics workshop: Participation request","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T19:10:42Z","last_updated_date":"2011-07-27T19:10:42Z","reference_number":"EMA/585618/2011","document_url":"https://www.ema.europa.eu/en/documents/other/electronic-summary-product-characteristics-workshop-participation-request_en.pdf"},
    {"id":"18605","name":"EudraVigilance system components","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-system-components_en.pdf"},
    {"id":"18615","name":"Overview of comments received on ' Reflection paper on the pharmaceutical development of intravenous medicinal products containing active substances solubilised in micellar systems (non-polymeric surfactants) ' (EMA/CHMP...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-20T17:00:00Z","last_updated_date":"2012-03-20T17:00:00Z","reference_number":"EMA/CHMP/QWP/686808/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-pharmaceutical-development-intravenous-medicinal-products-containing-active-substances-solubilised-micellar-systems-non-polymeric-surfactants-emachmp_en.pdf"},
    {"id":"18625","name":"Technical specification - Annex 02 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-02-15T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-02-external-service-providers-software-applications-ema201213ict_en.xls"},
    {"id":"18631","name":"Referentials Management Services (RMS) operating model","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-01T11:05:00Z","last_updated_date":"2018-05-28T13:30:00Z","reference_number":"EMA/412376/2016","document_url":"https://www.ema.europa.eu/en/documents/other/referentials-management-services-rms-operating-model_en.pdf"},
    {"id":"18640","name":"CTAG5: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on legal aspects - Meeting 1 and 2 comments submitted","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag5-advice-european-medicines-agency-clinical-trial-advisory-group-legal-aspects-meeting-1-and-2-comments-submitted_en.pdf"},
    {"id":"18664","name":"Working party on Herbal Medicinal Products: Final proposals for comments on the Committee for Proprietary Medicinal Products (CPMP) note for guidance on stability testing after a Type II Variation to a marketing authoris...","type":"other","status":"unknown","consultation_date":"","first_published_date":"1999-11-01T01:00:00Z","last_updated_date":"1999-11-01T01:00:00Z","reference_number":"EMEA/HMPWP/21/99","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposals-comments-committee-proprietary-medicinal-products-cpmp-note-guidance-stability-testing-after-type-ii-variation-marketing-authoris_en.pdf"},
    {"id":"18679","name":"Declation of interests: Minna Leppà¤nen","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T02:00:00Z","last_updated_date":"2018-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declation-interests-minna-leppanen_en.pdf"},
    {"id":"18698","name":"Guiding principles: Processing joint Food and Drug Administration / European Medicines Agency voluntary genomic data submissions (VGDSs) within the framework of the confidentiality arrangement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-05-31T02:09:21Z","last_updated_date":"2006-05-31T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/guiding-principles-processing-joint-food-and-drug-administration-european-medicines-agency-voluntary-genomic-data-submissions-vgdss-within-framework-confidentiality-arrangement_en.pdf"},
    {"id":"18716","name":"Declaration of interests - Peter Helms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-peter-helms_en.pdf"},
    {"id":"18734","name":"Calendar of 2010 dates for the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-21T02:00:00Z","last_updated_date":"2009-07-21T02:00:00Z","reference_number":"EMEA/465056/2009","document_url":"https://www.ema.europa.eu/en/documents/other/calendar-2010-dates-european-medicines-agency_en.pdf"},
    {"id":"18751","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) substance classes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:01Z","last_updated_date":"2014-01-17T18:15:00Z","reference_number":"EMA/136147/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-substance-classes_en.xls"},
    {"id":"18770","name":"Quality control of medicinal product data submitted as per the legal requirement introduced by Article 57(2) of Regulation (EC) No. 726/2004","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-19T19:34:00Z","last_updated_date":"2025-06-10T11:38:00Z","reference_number":"EMA/661709/2014 Rev. 7","document_url":"https://www.ema.europa.eu/en/documents/other/quality-control-medicinal-product-data-submitted-legal-requirement-introduced-article-572-regulation-ec-no-726-2004_en.pdf"},
    {"id":"18808","name":"List of participants - Second stakeholders forum on the implementation\n\nof the new pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:10Z","last_updated_date":"2011-06-24T22:06:10Z","reference_number":"EMA/451672/2011","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-second-stakeholders-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"18819","name":"Declaration of interests: Isabelle Moulon","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:20Z","last_updated_date":"2016-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-isabelle-moulon_en.pdf"},
    {"id":"18822","name":"Declaration of interest: Elias Tavares","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-03-01T01:00:00Z","last_updated_date":"2025-08-01T17:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-elias-tavares_en.pdf"},
    {"id":"18836","name":"Declaration of interest: Irene Rager","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-10T01:00:00Z","last_updated_date":"2024-07-26T12:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-irene-rager_en.pdf"},
    {"id":"18843","name":"European Medicines Agency breach of trust procedure on declarations of competing interests for Management Board members","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-06-21T17:00:00Z","last_updated_date":"2023-01-04T10:08:00Z","reference_number":"EMA/MB/309079/2012 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-breach-trust-procedure-declarations-competing-interests-management-board-members_en.pdf"},
    {"id":"18849","name":"Chapter 3.II: XEVPRM detailed user guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2026-04-16T16:00:00Z","reference_number":"EMA/135580/2012 Version 3.19","document_url":"https://www.ema.europa.eu/en/documents/other/chapter-3ii-xevprm-detailed-user-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-ema_en.pdf"},
    {"id":"18931","name":"Overview of comments received on the Committee for Medicinal Products for Veterinary Use strategy on antimicrobials 2011-2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-25T03:00:00Z","last_updated_date":"2011-07-25T03:00:00Z","reference_number":"EMA/CVMP/257610/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-committee-medicinal-products-veterinary-use-strategy-antimicrobials-2011-2015_en.pdf"},
    {"id":"18935","name":"Inventory of paediatric therapeutic needs - Endocrinology","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-08-19T18:10:00Z","last_updated_date":"2015-08-19T18:10:00Z","reference_number":"EMA/PDCO/52553/2015","document_url":"https://www.ema.europa.eu/en/documents/other/inventory-paediatric-therapeutic-needs-endocrinology_en.pdf"},
    {"id":"18956","name":"Guidelines and concept papers: Adopted during the CHMP meeting 13-16 February 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T18:50:00Z","last_updated_date":"2012-02-17T18:50:00Z","reference_number":"EMA/CHMP/86231/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-13-16-february-2012_en.pdf"},
    {"id":"19016","name":"ICT service desk EMA/2013/09/ICT - Annex B - Off-the-shelf applications in use at EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-28T02:00:00Z","last_updated_date":"2013-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ict-service-desk-ema201309ict-annex-b-shelf-applications-use-ema_en.pdf"},
    {"id":"19024","name":"Declaration of interests: Patrick Le Courtois","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:10Z","last_updated_date":"2012-08-03T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-patrick-le-courtois_en.pdf"},
    {"id":"19028","name":"Worldwide Orphan Medicinal Designation workshop 10 March 2014 - Wrap up of the event","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"EMA/167060/2014","document_url":"https://www.ema.europa.eu/en/documents/other/worldwide-orphan-medicinal-designation-workshop-10-march-2014-wrap-event_en.pdf"},
    {"id":"19034","name":"Declaration of interest: Piotr Kozarewicz","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-26T02:00:00Z","last_updated_date":"2016-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-piotr-kozarewicz_en.pdf"},
    {"id":"19035","name":"Declaration of interests: Alexis Nolte","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T11:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-alexis-nolte_en.pdf"},
    {"id":"19070","name":"Workshop summary - Benefit-risk communication to medicines users: How can regulators best meet the information needs of patients and healthcare professionals?","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T15:45:00Z","last_updated_date":"2014-12-08T15:45:00Z","reference_number":"EMA/755448/2014","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-summary-benefit-risk-communication-medicines-users-how-can-regulators-best-meet-information-needs-patients-and-healthcare-professionals_en.pdf"},
    {"id":"19092","name":"Table of the amounts in euro of basic monthly salaries for contract agents for each grade and step","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T11:00:00Z","last_updated_date":"2019-03-08T11:30:00Z","reference_number":"EMA/94996/2018","document_url":"https://www.ema.europa.eu/en/documents/other/table-amounts-euro-basic-monthly-salaries-contract-agents-each-grade-and-step_en.pdf"},
    {"id":"19095","name":"Notification on authenticity of European Medicines Agency certificates","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-28T02:00:00Z","last_updated_date":"2021-05-03T14:43:00Z","reference_number":"EMA/296924/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/notification-authenticity-european-medicines-agency-certificates_en.pdf"},
    {"id":"19107","name":"Opinions on safety variations: Adopted at the CHMP meeting of 12-15 March 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-19T12:30:00Z","last_updated_date":"2012-03-19T12:30:00Z","reference_number":"EMA/CHMP/162997/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-12-15-march-2012_en.pdf"},
    {"id":"19111","name":"International Coalition of Medicines Regulatory Authorities (ICMRA) Ebola press release: medicines regulators to work together internationally to find innovative solutions to facilitate evaluation of and access to potent...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-11T12:00:00Z","last_updated_date":"2016-02-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/international-coalition-medicines-regulatory-authorities-icmra-ebola-press-release-medicines-regulators-work-together-internationally-find-innovative-solutions-facilitate-evaluation-and-access-potent_en.pdf"},
    {"id":"19119","name":"Timetable: Periodic safety update report (PSUR) and PSUR single assessment (PSUSA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-30T16:00:00Z","last_updated_date":"2025-09-23T15:00:00Z","reference_number":"EMA/251636/2015 Rev. 11","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-periodic-safety-update-report-psur-psur-single-assessment-psusa_en.xlsx"},
    {"id":"19124","name":"Fifth sub-committee meeting: Joint common statement - April 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-30T15:40:00Z","last_updated_date":"2014-09-30T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/fifth-sub-committee-meeting-joint-common-statement-april-2014_en.pdf"},
    {"id":"19132","name":"EBSCO International Pharmaceutical Abstracts (IPA) journals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-05T01:00:00Z","last_updated_date":"2024-03-19T16:12:00Z","reference_number":"EMA/879144/2016","document_url":"https://www.ema.europa.eu/en/documents/other/ebsco-international-pharmaceutical-abstracts-ipa-journals_en.xlsx"},
    {"id":"19162","name":"Specific privacy statement: Public consultation of good pharmacovigilance practices (2012-2019)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T13:19:00Z","last_updated_date":"2012-02-22T13:19:00Z","reference_number":"EMA/118632/2012","document_url":"https://www.ema.europa.eu/en/documents/other/specific-privacy-statement-public-consultation-good-pharmacovigilance-practices-2012-2019_en.pdf"},
    {"id":"19166","name":"Application form for call for expression of interest for Contract Agents for temporary assignments (English only), language versions are for reference only","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-07T02:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/application-form-call-expression-interest-contract-agents-temporary-assignments-english-only-language-versions-are-reference-only_sv.pdf"}},
    {"id":"19173","name":"List of participants - Workshop on the patient’s voice in the evaluation of medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T00:00:00Z","last_updated_date":"2013-10-29T00:00:00Z","reference_number":"EMA/489088/2013","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-workshop-patients-voice-evaluation-medicines_en.pdf"},
    {"id":"19175","name":"Vendor registration in the EudraVigilance external compliance testing environment (XCOMP)  - Registration procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2024-08-13T15:56:00Z","reference_number":"EMA/382824/2017","document_url":"https://www.ema.europa.eu/en/documents/other/vendor_registration_in_the_eudravigilance_external_compliance_testing_environment_en.pdf"},
    {"id":"19180","name":"Technical specification - Annex 8 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-8-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"19184","name":"Questions and answers relating to open procedure – European Medicines Agency 2012-37- ED online strategy and interface design","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-03T14:00:00Z","last_updated_date":"2013-07-03T14:00:00Z","reference_number":"EMA/352562/2013","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-procedure-european-medicines-agency-2012-37-ed-online-strategy-and-interface-design_en.pdf"},
    {"id":"19200","name":"Overview of comments received on procedural advice on the consultation of notified bodies in accordance with Article 9 of Regulation (EC) No. 1394/2007","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-03T01:00:00Z","last_updated_date":"2011-03-03T01:00:00Z","reference_number":"EMA/690489/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-procedural-advice-consultation-notified-bodies-accordance-article-9-regulation-ec-no-13942007_en.pdf"},
    {"id":"19217","name":"Mandate, objectives and rules of procedure for the CHMP guidelines consistency group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-02-17T01:00:00Z","last_updated_date":"2015-07-27T18:40:00Z","reference_number":"EMA/CHMP/683358/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-chmp-guidelines-consistency-group_en.pdf"},
    {"id":"19226","name":"Summary – Second stakeholder meeting on the implementation of EMA policy 0070 (on publication of clinical data for medicinal products for human use)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"EMA/600317/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-second-stakeholder-meeting-implementation-ema-policy-0070-publication-clinical-data-medicinal-products-human-use_en.pdf"}    {"id":"19231","name":"Common Repository for all veterinary submissions in the centralised procedure – statement of intent","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T12:45:00Z","last_updated_date":"2016-11-25T12:45:00Z","reference_number":"EMA/715059/2016","document_url":"https://www.ema.europa.eu/en/documents/other/common-repository-all-veterinary-submissions-centralised-procedure-statement-intent_en.pdf"},
    {"id":"19258","name":"High level business consultancy EMA/2013/23/FI - Technical specifications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"EMA/552750/2013","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications_en.pdf"},
    {"id":"19271","name":"ICMRA - Mapping of generic initiatives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-09T13:20:00Z","last_updated_date":"2017-01-09T13:20:00Z","reference_number":"EMA/275766/2014","document_url":"https://www.ema.europa.eu/en/documents/other/icmra-mapping-generic-initiatives_en.pdf"},
    {"id":"19304","name":"Online strategy and interface design EMA/2012/37/ED - Technical specification annex V - Draft framework services contract","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/online-strategy-and-interface-design-ema201237ed-technical-specification-annex-v-draft-framework-services-contract_en.pdf"},
    {"id":"19314","name":"Trimetazidine: Product information as approved by the CHMP on 21 June 2012, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T12:00:00Z","last_updated_date":"2012-06-22T12:00:00Z","reference_number":"EMA/412151/2012","document_url":"https://www.ema.europa.eu/en/documents/other/trimetazidine-product-information-approved-chmp-21-june-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"19315","name":"Appendix, on disclosure rules, to the functional specifications for the EU portal and EU database to be audited","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2024-06-18T11:00:00Z","reference_number":"EMA/228383/2015","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-disclosure-rules-functional-specifications-eu-portal-eu-database-be-audited_en.pdf"},
    {"id":"19318","name":"CHMP meeting dates 2021, 2022, 2023 and 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-04-06T14:28:00Z","last_updated_date":"2021-04-06T14:28:00Z","reference_number":"EMA/90608/2021","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-meeting-dates-2021-2022-2023-and-2024_en.pdf"},
    {"id":"19330","name":"Revised framework for interaction between the European Medicines Agency and healthcare professionals - Annex I – Action plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T13:00:00Z","last_updated_date":"2018-06-21T13:30:00Z","reference_number":"EMA/705066/2016","document_url":"https://www.ema.europa.eu/en/documents/other/revised-framework-interaction-between-european-medicines-agency-and-healthcare-professionals-annex-i-action-plan_en.pdf"},
    {"id":"19354","name":"Comments on Revision of Clinical Trials Directive 2001-20\n\nOn behalf of the European network of paediatric research at the EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T17:45:00Z","last_updated_date":"2014-03-21T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comments-revision-clinical-trials-directive-2001-20-behalf-european-network-paediatric-research-ema_en.pdf"},
    {"id":"19360","name":"Guidelines and concept papers adopted at the CHMP meeting of 16-19 December 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/730954/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-chmp-meeting-16-19-december-2013_en.pdf"},
    {"id":"19417","name":"Ad hoc working party on Herbal Medicinal Products:  Final comments for revision of notice to applicants volume 2A part 1.4.2 – Bibliographical applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"1998-09-17T02:00:00Z","last_updated_date":"1998-09-17T02:00:00Z","reference_number":"EMEA/HMPWP/6/99","document_url":"https://www.ema.europa.eu/en/documents/other/ad-hoc-working-party-herbal-medicinal-products-final-comments-revision-notice-applicants-volume-2a-part-142-bibliographical-applications_en.pdf"},
    {"id":"19420","name":"Withdrawal letter: Exelon and Prometax (rivastigmine)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2013-12-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-exelon-and-prometax-rivastigmine_en.pdf"},
    {"id":"19424","name":"European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) and Defined daily doses for animals (DDDvet) and defined course doses for animals (DCDvet) Expert Advisory Group: terms of reference 2015 - 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T16:00:00Z","last_updated_date":"2016-04-28T16:00:00Z","reference_number":"EMA/351418/2015","document_url":"https://www.ema.europa.eu/en/documents/other/european-surveillance-veterinary-antimicrobial-consumption-esvac-and-defined-daily-doses-animals-dddvet-and-defined-course-doses-animals-dcdvet-expert-advisory-group-terms-reference-2015-2017_en.pdf"},
    {"id":"19434","name":"European Medicines Agency 2011 priorities for drug safety research: Asthma treatments (long and short-acting beta agonists and anticholinergics): risk of myocardial ischaemia and long term safety, especially in children","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-07-08T02:00:00Z","last_updated_date":"2010-07-08T02:00:00Z","reference_number":"EMA/425298/2010","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-2011-priorities-drug-safety-research-asthma-treatments-long-and-short-acting-beta-agonists-and-anticholinergics-risk-myocardial-ischaemia-and-long-term-safety-especially_en.pdf"},
    {"id":"19447","name":"Overview of comments received on guideline on the documentation to be submitted for inclusion in the List of herbal substances, preparations and combinations thereof (EMEA/HMPC/107399/2005)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-24T02:09:21Z","last_updated_date":"2007-10-24T02:09:21Z","reference_number":"EMEA/HMPC/309367/2005","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-documentation-be-submitted-inclusion-list-herbal-substances-preparations-and-combinations-thereof-emeahmpc1073992005_en.pdf"},
    {"id":"19448","name":"Joint statement of the European Medicines Agency and the European Food Safety Authority on the presence of residues of phenylbutazone in horse meat","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T12:00:00Z","last_updated_date":"2013-04-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/joint-statement-european-medicines-agency-and-european-food-safety-authority-presence-residues-phenylbutazone-horse-meat_en.pdf"},
    {"id":"19453","name":"Overview of comments received on 'Questions and answers on Guideline on the environmental risk assessment of medicinal products for human use' - First version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-11T02:00:00Z","last_updated_date":"2011-04-11T02:00:00Z","reference_number":"EMA/CHMP/SWP/739571/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-questions-and-answers-guideline-environmental-risk-assessment-medicinal-products-human-use-first-version_en.pdf"},
    {"id":"19459","name":"Declaration of interests: Riccardo Ettore","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:49Z","last_updated_date":"2014-02-17T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-riccardo-ettore_en.pdf"},
    {"id":"19460","name":"Follow-up recommendations from CHMP on novel influenza (H1N1) outbreak: Tamiflu (oseltamivir); Relenza (zanamivir)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/CHMP/326095/2009","document_url":"https://www.ema.europa.eu/en/documents/other/follow-recommendations-chmp-novel-influenza-h1n1-outbreak-tamiflu-oseltamivir-relenza-zanamivir_en.pdf"},
    {"id":"19463","name":"Performance of the Agency’s scientific procedures;\n\nveterinary products - Management Board meeting 18 March 2010","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/MB/117221/2010","document_url":"https://www.ema.europa.eu/en/documents/other/performance-agencys-scientific-procedures-veterinary-products-management-board-meeting-18-march-2010_en.pdf"},
    {"id":"19492","name":"ICMRA - Mapping of pharmacovigilance initiatives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-09T13:20:00Z","last_updated_date":"2017-01-09T13:20:00Z","reference_number":"EMA/530778/2015","document_url":"https://www.ema.europa.eu/en/documents/other/icmra-mapping-pharmacovigilance-initiatives_en.pdf"},
    {"id":"19516","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) pharmaceutical dose forms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2022-11-18T08:24:00Z","reference_number":"EMA/136157/2012 Rev. 32","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-pharmaceutical-dose-forms_en.xlsx"},
    {"id":"19522","name":"Guidelines on good pharmacovigilance practices: Introductory cover note, last updated with revision of module II, launch of public consultation of P.I and information on GVP maintenance and further development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-12T02:00:00Z","last_updated_date":"2013-04-12T02:00:00Z","reference_number":"EMA/131811/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-introductory-cover-note-last-updated-revision-module-ii-launch-public-consultation-pi-and-information-gvp-maintenance-and-further-development_en.pdf"},
    {"id":"19537","name":"Final briefing book - Qualification of total kidney volume as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-22T11:00:00Z","last_updated_date":"2015-07-22T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/final-briefing-book-qualification-total-kidney-volume-prognostic-biomarker-use-clinical-trials-evaluating-patients-autosomal-dominant-polycystic-kidney-disease-adpkd_en.pdf"},
    {"id":"19589","name":"Download EPS - Species pictograms - Turkey","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-turkey_en.zip"},
    {"id":"19592","name":"Overview of comments received on 'guideline on immunogenicity assessment of monoclonal antibodies intended for in-vivo clinical use' (EMA/CHMP/BMWP/86289/2010)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:46Z","last_updated_date":"2012-06-15T17:10:46Z","reference_number":"EMA/420188/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-immunogenicity-assessment-monoclonal-antibodies-intended-vivo-clinical-use-emachmpbmwp862892010_en.pdf"},
    {"id":"19600","name":"Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - Description of the Journal/Reference databases used","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-12T14:30:00Z","last_updated_date":"2024-03-25T16:27:00Z","reference_number":"EMA/141813/2015, Rev 4*","document_url":"https://www.ema.europa.eu/en/documents/other/monitoring-medical-literature-entry-relevant-information-eudravigilance-database-european-medicines-agency-description-journal-reference-databases-used_en.pdf"},
    {"id":"19607","name":"Working party on Herbal Medicinal Products: Final proposal for a core data for Mentae piperitae aetheroleum","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-03-03T01:00:00Z","last_updated_date":"2004-03-03T01:00:00Z","reference_number":"EMEA/HMPWP/1417/02","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-mentae-piperitae-aetheroleum_en.pdf"},
    {"id":"19629","name":"Timetable: Annual reassessment - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T16:00:00Z","last_updated_date":"2026-05-27T15:12:00Z","reference_number":"EMA/825019/2015 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-annual-reassessment-atmp_en.xlsx"},
    {"id":"19640","name":"List of participants of the Vaccines Working Party closed workshop on correlates for the protection and serological assays for influenza vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-05T11:15:00Z","last_updated_date":"2013-06-05T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-vaccines-working-party-closed-workshop-correlates-protection-and-serological-assays-influenza-vaccines_en.pdf"},
    {"id":"19641","name":"3.1 Annex II - Statistical analysis of bioequivalence study example data set","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-09T16:00:00Z","last_updated_date":"2016-11-09T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/31-annex-ii-statistical-analysis-bioequivalence-study-example-data-set_en.pdf"},
    {"id":"19646","name":"Request for CHMP qualification opinion response to questions dated 11 June 2013 - Annex 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-10T10:20:00Z","last_updated_date":"2014-02-10T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-chmp-qualification-opinion-response-questions-dated-11-june-2013-annex-2_en.pdf"},
    {"id":"19647","name":"Defined daily doses for animals (DDDvet) and defined course doses for animals (DCDvet) - European Surveillance of Veterinary Antimicrobial Consumption (ESVAC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T16:00:00Z","last_updated_date":"2016-04-28T16:00:00Z","reference_number":"EMA/224954/2016","document_url":"https://www.ema.europa.eu/en/documents/other/defined-daily-doses-animals-dddvet-and-defined-course-doses-animals-dcdvet-european-surveillance-veterinary-antimicrobial-consumption-esvac_en.pdf"},
    {"id":"19675","name":"Timetable: Type II variation and worksharing application weekly assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T14:00:00Z","last_updated_date":"2026-06-16T17:00:00Z","reference_number":"EMA/577386/2016 Rev. 10","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-type-ii-variation-worksharing-application-weekly-assessment_en.xlsx"},
    {"id":"19678","name":"Withdrawal letter: Revlimid","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T02:00:00Z","last_updated_date":"2012-07-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-revlimid_en.pdf"},
    {"id":"19690","name":"Sponsor's guide to an orphan designation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-04T14:05:00Z","last_updated_date":"2015-09-04T14:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sponsors-guide-orphan-designation_en.pdf"},
    {"id":"19741","name":"Reflection paper on the further involvement of patients and consumers in\n\nthe Agency’s activities","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/MB/753771/2009","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-further-involvement-patients-and-consumers-agencys-activities_en.pdf"},
    {"id":"19742","name":"CTAG1: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on protecting patient confidentiality - Revised after first teleconference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag1-advice-european-medicines-agency-clinical-trial-advisory-group-protecting-patient-confidentiality-revised-after-first-teleconference_en.pdf"},
    {"id":"19748","name":"Letter from Health Canada to the European Medicines Agency and the European Commission: Confidentiality agreement details","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-15T16:30:00Z","last_updated_date":"2013-03-15T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-health-canada-european-medicines-agency-and-european-commission-confidentiality-agreement-details_en.pdf"},
    {"id":"19757","name":"Draft proposal for an addendum, on transparency, to the 'functional specifications for the European Union (EU) portal and EU database to be audited'","type":"other","status":"Draft: consultation closed","consultation_date":"2015-01-21 - 2015-02-18","first_published_date":"2015-01-21T02:00:00Z","last_updated_date":"2023-10-26T13:35:00Z","reference_number":"EMA/641479/2014","document_url":"https://www.ema.europa.eu/en/documents/other/draft-proposal-addendum-transparency-functional-specifications-european-union-eu-portal-and-eu-database-be-audited_en.pdf"},
    {"id":"19780","name":"EMEA Road Map: 2008 – 2009 Implementation Phase","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-11-22T01:00:00Z","last_updated_date":"2007-11-22T01:00:00Z","reference_number":"EMEA/515636/2007","document_url":"https://www.ema.europa.eu/en/documents/other/emea-road-map-2008-2009-implementation-phase_en.pdf"},
    {"id":"19809","name":"Working party on Herbal Medicinal Products: Final proposal for a core data for Linseed","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-12-17T01:00:00Z","last_updated_date":"2003-12-17T01:00:00Z","reference_number":"EMEA/HMPWP/244/03","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-linseed_en.pdf"},
    {"id":"19830","name":"Working arrangement between the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-12-22T16:26:53Z","last_updated_date":"2010-12-22T16:26:53Z","reference_number":"EMA/MB/520678/2010","document_url":"https://www.ema.europa.eu/en/documents/other/working-arrangement-between-european-medicines-agency-ema-and-european-centre-disease-prevention-and-control-ecdc_en.pdf"},
    {"id":"19836","name":"Overview of comments received on procedural advice on the certification of quality and non-clinical data for small and medium-sized enterprises developing advanced therapy medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-11-10T01:00:00Z","last_updated_date":"2010-11-10T01:00:00Z","reference_number":"EMA/CAT/45460/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-procedural-advice-certification-quality-and-non-clinical-data-small-and-medium-sized-enterprises-developing-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"19840","name":"Summary of changes to the ‘External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use’ - Version 1.2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-04-12T17:00:00Z","last_updated_date":"2017-04-12T17:00:00Z","reference_number":"EMA/243680/2017","document_url":"https://www.ema.europa.eu/en/documents/other/summary-changes-external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-version-12_en.pdf"},
    {"id":"19854","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP module IX – Signal management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:18:18Z","last_updated_date":"2012-06-25T19:18:18Z","reference_number":"EMA/428835/2012","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-ix-signal-management_en.pdf"},
    {"id":"19886","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Neocirculation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-neocirculation_en.pdf"},
    {"id":"19906","name":"EU-RMP Annex I form for 64 bit operating system  - Electronic interface for EudraVigilance (Version 5.1 – October 2013)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-07T02:00:00Z","last_updated_date":"2016-07-07T02:00:00Z","reference_number":"Version 5.1 – October 2013","document_url":"https://www.ema.europa.eu/en/documents/other/eu-rmp-annex-i-form-64-bit-operating-system-electronic-interface-eudravigilance-version-51-october-2013_en.zip"},
    {"id":"19951","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Recombinant human heparan N-sulfatase (rhHNS) for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/779395/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-recombinant-human-heparan-n-sulfatase-rhhns-treatment-mucopolysaccharidosis-type-iiia-sanfilippo-syndrome-type_en.pdf"},
    {"id":"19952","name":"Crisis simulation exercise coordinated by European Medicines Agency in October 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T12:45:00Z","last_updated_date":"2018-07-05T12:45:00Z","reference_number":"EMA/37396/2018","document_url":"https://www.ema.europa.eu/en/documents/other/crisis-simulation-exercise-coordinated-european-medicines-agency-october-2017_en.pdf"},
    {"id":"19962","name":"Overview of comments received on reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-28T13:12:00Z","last_updated_date":"2013-11-28T13:12:00Z","reference_number":"EMA/682105/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-data-requirements-intravenous-liposomal-products-developed-reference-innovator-liposomal-product_en.pdf"},
    {"id":"19975","name":"Draft inventory of paediatric therapeutic needs - Ophthalmology","type":"other","status":"Draft: consultation closed","consultation_date":"2014-05-09 - 2014-07-11","first_published_date":"2014-05-08T13:30:00Z","last_updated_date":"2014-05-08T13:30:00Z","reference_number":"EMA/PDCO/170932/2014","document_url":"https://www.ema.europa.eu/en/documents/other/draft-inventory-paediatric-therapeutic-needs-ophthalmology_en.pdf"},
    {"id":"20015","name":"Draft revision of EudraVigilance access policy for medicines for human use","type":"other","status":"Draft: consultation closed","consultation_date":"2014-08-04 - 2014-09-15","first_published_date":"2014-08-04T19:00:00Z","last_updated_date":"2014-08-04T19:00:00Z","reference_number":"EMA/759287/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/draft-revision-eudravigilance-access-policy-medicines-human-use_en.pdf"},
    {"id":"20017","name":"Countdown to July 2012 - The establishment and functioning of the Pharmacovigilance Risk Assessment Committee","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-02T10:20:10Z","last_updated_date":"2012-07-02T10:20:10Z","reference_number":"EMA/315258/2012","document_url":"https://www.ema.europa.eu/en/documents/other/countdown-july-2012-establishment-and-functioning-pharmacovigilance-risk-assessment-committee_en.pdf"},
    {"id":"20075","name":"Procedural advice for the Committee for Medicinal Products for Human Use on the need to convene a scientific advisory group or ad-hoc expert meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/CHMP/551508/2010","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-advice-committee-medicinal-products-human-use-need-convene-scientific-advisory-group-or-ad-hoc-expert-meeting_en.pdf"},
    {"id":"20079","name":"Open to tender provision of insurance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-12-01T01:00:00Z","last_updated_date":"2007-12-01T01:00:00Z","reference_number":"EMEA/562441/2007","document_url":"https://www.ema.europa.eu/en/documents/other/open-tender-provision-insurance_en.pdf"},
    {"id":"20080","name":"Summary of transfer of appropriations in the budget 2011 - Management Board meeting: 21-22 March 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"EMA/MB/115063/2012","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2011-management-board-meeting-21-22-march-2012_en.pdf"},
    {"id":"20085","name":"Letter of support for the development of a needs-based quality of life Patient Reported Outcome (PRO) measure specific to adults with plexiform neurofibromas","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T15:00:00Z","last_updated_date":"2018-01-15T15:00:00Z","reference_number":"EMA/716127/2017","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-development-needs-based-quality-life-patient-reported-outcome-pro-measure-specific-adults-plexiform-neurofibromas_en.pdf"},
    {"id":"20086","name":"CTAG2: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on clinical-trial-data formats – meeting 3 outcome with comments and amendments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag2-advice-european-medicines-agency-clinical-trial-advisory-group-clinical-trial-data-formats-meeting-3-outcome-comments-and-amendments_en.pdf"},
    {"id":"20109","name":"Conditional Marketing Authorisation - How early access to medicines has\n\nhelped patients from 2006 to 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T16:30:00Z","last_updated_date":"2017-01-23T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/conditional-marketing-authorisation-how-early-access-medicines-has-helped-patients-2006-2016_en.pdf"},
    {"id":"20119","name":"Essential considerations for successful qualification of novel methodologies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-06T15:00:00Z","last_updated_date":"2017-12-06T15:00:00Z","reference_number":"EMA/750178/2017","document_url":"https://www.ema.europa.eu/en/documents/other/essential-considerations-successful-qualification-novel-methodologies_en.pdf"},
    {"id":"20120","name":"Recommendations of the Focus Group Meeting on Substances of Animal Origin","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-20T02:09:21Z","last_updated_date":"2009-07-20T02:09:21Z","reference_number":"EMEA/413521/2009","document_url":"https://www.ema.europa.eu/en/documents/other/recommendations-focus-group-meeting-substances-animal-origin_en.pdf"},
    {"id":"20128","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Reslizumab for treatment of asthma","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/112434/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-reslizumab-treatment-asthma_en.pdf"},
    {"id":"20142","name":"Information on the Member States requirement for the nomination of a pharmacovigilance (PhV) contact person at national level","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T17:46:00Z","last_updated_date":"2025-10-01T14:15:00Z","reference_number":"EMA/INS/PhV/129721/2024, Rev 5","document_url":"https://www.ema.europa.eu/en/documents/other/information-member-states-requirement-nomination-pharmacovigilance-phv-contact-person-national-level_en.pdf"},
    {"id":"20151","name":"World Health Organization (WHO) reply to letter of arrangement between the European Medicines Agency and the WHO","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/world-health-organization-who-reply-letter-arrangement-between-european-medicines-agency-and-who_en.pdf"},
    {"id":"20209","name":"New Organisation First User EU QPPV/RP or Change of EU QPPV/RP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T18:00:00Z","last_updated_date":"2025-01-07T15:14:00Z","reference_number":"EMA/503895/2018","document_url":"https://www.ema.europa.eu/en/documents/other/new-organization-first-user-qppvrp-change-eu-qppvrp_en.pdf"},
    {"id":"20215","name":"CHMP statistics: May 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-statistics-may-2015_en.pdf"},
    {"id":"20236","name":"Terms of reference for the European Medicines Agency / Food and Drug Administration cluster on patient engagement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-22T17:00:00Z","last_updated_date":"2016-06-22T17:00:00Z","reference_number":"EMA/434415/2016","document_url":"https://www.ema.europa.eu/en/documents/other/terms-reference-european-medicines-agency-food-and-drug-administration-cluster-patient-engagement_en.pdf"},
    {"id":"20245","name":"Acceptability of IU as abbreviation for International Units in the strength of human medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T16:10:00Z","last_updated_date":"2023-03-24T14:43:00Z","reference_number":"EMA/704692/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/acceptability-iu-abbreviation-international-units-strength-human-medicinal-products_en.pdf"},
    {"id":"20247","name":"Scientific advice and protocol assistance - CHMP meeting 18-21 February 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/CHMP/SAWP/78103/2013","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-advice-and-protocol-assistance-chmp-meeting-18-21-february-2013_en.pdf"},
    {"id":"20259","name":"Overview of comments received on reflection paper on meticillin-resistant Staphylococcus pseudintermedius","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-02-10T01:00:00Z","last_updated_date":"2011-02-10T01:00:00Z","reference_number":"EMA/CVMP/SAGAM/779301/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-meticillin-resistant-staphylococcus-pseudintermedius_en.pdf"},
    {"id":"20267","name":"Overview of comments received on the guideline ''development, production, characterisation and specifications for  monoclonal antibodies and related products''","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/CHMP/BWP/651330/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-development-production-characterisation-and-specifications-monoclonal-antibodies-and-related-products_en.pdf"},
    {"id":"20279","name":"Overview of comments received on the draft guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products - First version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-05-03T02:00:00Z","last_updated_date":"2007-05-03T02:00:00Z","reference_number":"EMEA/295190/2007 Corr.","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-requirements-first-man-clinical-trials-potential-high-risk-medicinal-products-first-version_en.pdf"},
    {"id":"20287","name":"Declaration of interests: Dina Tsiambaou","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-25T01:00:00Z","last_updated_date":"2016-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-dina-tsiambaou_en.pdf"},
    {"id":"20326","name":"Noxafil : Product Information as approved by the CHMP on 23 June 2016, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/noxafil-product-information-approved-chmp-23-june-2016-pending-endorsement-european-commission_en.pdf"},
    {"id":"20329","name":"Technical specifications for open invitation to tender - EMA/2011/35/DIS -\n\nElectronic Books/E-Books – Lots 1&2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-03T01:00:00Z","last_updated_date":"2012-01-03T01:00:00Z","reference_number":"EMA/940788/2011","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-ema201135dis-electronic-bookse-books-lots-12_en.pdf"},
    {"id":"20335","name":"Expert workshop on setting specifications for biotechnological products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-22T02:00:00Z","last_updated_date":"2011-09-22T02:00:00Z","reference_number":"EMA/770060/2011","document_url":"https://www.ema.europa.eu/en/documents/other/expert-workshop-setting-specifications-biotechnological-products_en.pdf"},
    {"id":"20341","name":"Technical specification - Annex 4 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-02-15T16:30:00Z","reference_number":"EMA/207898/2012","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-4-external-service-providers-software-applications-ema201213ict_en.xls"},
    {"id":"20369","name":"Declaration of interests: Manuel Ortigà£o","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-03T02:00:00Z","last_updated_date":"2015-09-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-manuel-ortigapso_en.pdf"},
    {"id":"20378","name":"List of participants of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting 20 September 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T02:00:00Z","last_updated_date":"2017-10-26T02:00:00Z","reference_number":"EMA/457319/2017","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-20-september-2017_en.pdf"},
    {"id":"20379","name":"Report on the survey of all paediatric uses of medicinal products in Europe: Questions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-21T00:31:00Z","last_updated_date":"2011-01-21T00:31:00Z","reference_number":"EMA/761382/2010","document_url":"https://www.ema.europa.eu/en/documents/other/report-survey-all-paediatric-uses-medicinal-products-europe-questions-and-answers_en.pdf"},
    {"id":"20408","name":"Elemental impurities in marketed products. Recommendations for implementation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T17:10:00Z","last_updated_date":"2015-03-27T17:10:00Z","reference_number":"EMA/CHMP/QWP/109127/2015","document_url":"https://www.ema.europa.eu/en/documents/other/elemental-impurities-marketed-products-recommendations-implementation_en.pdf"},
    {"id":"20409","name":"Outcome of written procedures finalised during the period from 9 May 2015 to 1 September 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"EMA/MB/480836/2015","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-9-may-2015-1-september-2015_en.pdf"},
    {"id":"20421","name":"Confidentiality arrangements concluded between the European Union (European Commission and European Medicines Agency) and the United States Food and Drug Administration / Department of Health and Human Services - Impleme...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-05-22T02:09:21Z","last_updated_date":"2008-05-22T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/confidentiality-arrangements-concluded-between-european-union-european-commission-and-european-medicines-agency-and-united-states-food-and-drug-administration-department-health-and-human-services_en.pdf-1"},
    {"id":"20425","name":"Joint opinion on antimicrobial resistance focused on zoonotic infections","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-11-16T00:09:21Z","last_updated_date":"2009-11-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/joint-opinion-antimicrobial-resistance-focused-zoonotic-infections_en.pdf"},
    {"id":"20440","name":"Outcome of written procedures finalised during the period from 25 November 2011 to 29 February 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"EMA/MB/2671/2012","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-25-november-2011-29-february-2012_en.pdf"},
    {"id":"20485","name":"Overview of comments received on setting specifications for related impurities in antibiotics","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-13T13:00:00Z","last_updated_date":"2012-07-13T13:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/310350/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-setting-specifications-related-impurities-antibiotics_en.pdf"},
    {"id":"20494","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): Module IX Addendum I – Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/647795/2017","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal-detection-spontaneous-reports-suspected-adverse-reactions_en.pdf"},
    {"id":"20498","name":"Opinions on safety variations / periodic safety update reports adopted at the CHMP meeting of 16-19 December 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/731012/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-16-19-december-2013_en.pdf"},
    {"id":"20552","name":"Questions and answers relating to open procedure – European Medicines Agency 2012-37-ED Online Strategy and Interface Design","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-11T19:30:00Z","last_updated_date":"2013-07-11T19:30:00Z","reference_number":"EMA/352562/2013","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-procedure-european-medicines-agency-2012-37-ed-online-strategy-and-interface-design_en.pdf-0"},
    {"id":"20558","name":"Overview of comments received on guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome (CPMP/EWP/785/97 Rev. 1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-25T14:10:00Z","last_updated_date":"2014-09-25T14:10:00Z","reference_number":"EMA/CHMP/266108/2014","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-evaluation-medicinal-products-treatment-irritable-bowel-syndrome-cpmpewp78597-rev-1_en.pdf"},
    {"id":"20564","name":"Start of Community reviews - CHMP meeting of 17-20 February 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T13:00:00Z","last_updated_date":"2014-02-21T13:00:00Z","reference_number":"EMA/95295/2014","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-17-20-february-2014_en.pdf"},
    {"id":"20578","name":"Output of EMA policy on access the documents related to medicinal products for human and veterinary use (revision draft)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-02-17T14:30:00Z","last_updated_date":"2017-02-17T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/output-ema-policy-access-documents-related-medicinal-products-human-and-veterinary-use-revision-draft_en.pdf"},
    {"id":"20581","name":"EC - Switzerland MRA Sectoral Annex on GMP medicinal products GMP inspection and batch certification - Update on the operation of the Annex with respect to active pharmaceutical ingredients: Joint Common Statement - \n\nFi...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/INS/MRA/622138/2008","document_url":"https://www.ema.europa.eu/en/documents/other/ec-switzerland-mra-sectoral-annex-gmp-medicinal-products-gmp-inspection-and-batch-certification-update-operation-annex-respect-active-pharmaceutical-ingredients-joint-common-statement-fi_en.pdf"},
    {"id":"20584","name":"Policy 4: Health and safety","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2012-09-04T15:49:00Z","reference_number":"EMA/65832/2011","document_url":"https://www.ema.europa.eu/en/documents/other/policy-4-health-and-safety_en.pdf"},
    {"id":"20600","name":"Draft policy 70: Publication and access to clinical-trial data","type":"other","status":"Draft: consultation closed","consultation_date":"2013-06-24 - 2013-09-30","first_published_date":"2013-06-24T18:00:00Z","last_updated_date":"2013-06-24T18:00:00Z","reference_number":"EMA/240810/2013","document_url":"https://www.ema.europa.eu/en/documents/other/draft-policy-70-publication-and-access-clinical-trial-data_en.pdf"},
    {"id":"20666","name":"Overview of comments received on 'Guideline on statistical principles for clinical trials for veterinary medicinal products (pharmaceuticals)'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-23T10:44:00Z","last_updated_date":"2012-01-23T10:44:00Z","reference_number":"EMA/CVMP/EWP/249785/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-statistical-principles-clinical-trials-veterinary-medicinal-products-pharmaceuticals_en.pdf"},
    {"id":"20678","name":"CTAG1: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on protecting patient confidentiality - Discussion Document","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag1-advice-european-medicines-agency-clinical-trial-advisory-group-protecting-patient-confidentiality-discussion-document_en.pdf"},
    {"id":"20692","name":"Briefing Document to the Clinical Trial Readiness in Spinal Muscular Atrophy (SMA) SMA Europe, TREAT-NMD and European Medicines Agency meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/briefing-document-clinical-trial-readiness-spinal-muscular-atrophy-sma-sma-europe-treat-nmd-and-european-medicines-agency-meeting_en.pdf"},
    {"id":"20697","name":"List of participants - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Group (HCPWG) joint meeting - February 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:00:00Z","last_updated_date":"2013-05-24T18:00:00Z","reference_number":"EMA/50881/2013","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-group-hcpwg-joint-meeting-february-2013_en.pdf"}    {"id":"20791","name":"Summary of transfer of appropriations in the budget 2015 - Management Board meeting: 1-2 October 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"EMA/MB/567233/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2015-management-board-meeting-1-2-october-2015_en.pdf"},
    {"id":"20831","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Ranibizumab for treatment of retinopathy of prematurity","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T11:30:00Z","last_updated_date":"2014-11-25T12:30:00Z","reference_number":"EMA/511523/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-ranibizumab-treatment-retinopathy-prematurity_en.pdf"},
    {"id":"20839","name":"Summary of the evaluation of the proposed paediatric investigation plan: Chimeric anti-disialoganglioside (GD2) monoclonal antibody (ch14.18/CHO) (APN311)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-19T02:00:00Z","last_updated_date":"2015-10-19T02:00:00Z","reference_number":"EMA/179045/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-chimeric-anti-disialoganglioside-gd2-monoclonal-antibody-ch1418cho-apn311_en.pdf"},
    {"id":"20841","name":"Introduction to the draft budget 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/MB/784261/2010","document_url":"https://www.ema.europa.eu/en/documents/other/introduction-draft-budget-2011_en.pdf"},
    {"id":"20845","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: Hemoblast","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-07-03T13:15:00Z","last_updated_date":"2015-07-03T13:15:00Z","reference_number":"EMA/66720/2015","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-hemoblast_en.pdf"},
    {"id":"20894","name":"Withdrawal letter : Opatanol","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-02-14T01:00:00Z","last_updated_date":"2006-02-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-opatanol_en.pdf"},
    {"id":"20899","name":"Opinions on safety variations adopted at the CHMP meeting of 18-21 March 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T14:20:00Z","last_updated_date":"2013-04-02T14:20:00Z","reference_number":"EMA/CHMP/127861/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-18-21-march-2013_en.pdf"},
    {"id":"20900","name":"Technical specifications for open invitation to tender no. EMEA/2008/40/ES, services to support EMEA’s on-line communications activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-03-05T01:00:00Z","last_updated_date":"2008-03-05T01:00:00Z","reference_number":"EMEA/3419/04/5736","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-no-emea200840es-services-support-emeas-line-communications-activities_en.pdf"},
    {"id":"20914","name":"Financial compensation for Member States’ participation in the linguistic checking of product related information","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-12-22T15:00:00Z","last_updated_date":"2014-12-22T15:00:00Z","reference_number":"EMA/MB/618942/2014","document_url":"https://www.ema.europa.eu/en/documents/other/financial-compensation-member-states-participation-linguistic-checking-product-related-information_en.pdf"},
    {"id":"20919","name":"Overview of comments received on reflection paper on stem cell-based medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-02-03T01:00:00Z","last_updated_date":"2011-02-03T01:00:00Z","reference_number":"EMA/CAT/55107/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-stem-cell-based-medicinal-products_en.pdf"},
    {"id":"20943","name":"Best practice guide for staff leaving the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-14T14:15:00Z","last_updated_date":"2015-08-21T12:00:00Z","reference_number":"EMA/70197/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/best-practice-guide-staff-leaving-european-medicines-agency_en.pdf"},
    {"id":"20944","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-30T11:10:03Z","last_updated_date":"2013-03-27T13:20:00Z","reference_number":"EMA/MB/112878/2013","document_url":"https://www.ema.europa.eu/en/documents/other/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures_en.pdf-1"},
    {"id":"20951","name":"More information on Human & Veterinary Medicinal Products' Regulation - Turkey's Road to EU Membership","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-22T02:09:21Z","last_updated_date":"2007-10-22T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/more-information-human-veterinary-medicinal-products-regulation-turkeys-road-eu-membership_en.pdf"},
    {"id":"20953","name":"EudraVigilance - Key milestones and summary of associated EudraVigilance auditable requirements project communications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-26T01:00:00Z","last_updated_date":"2017-06-26T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-key-milestones-and-summary-associated-eudravigilance-auditable-requirements-project-communications_en.pdf"},
    {"id":"20985","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting 17-20 March 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T17:00:00Z","last_updated_date":"2014-03-24T17:00:00Z","reference_number":"EMA/122464/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-17-20-march-2014_en.pdf"},
    {"id":"21024","name":"Khaled El Emam (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/khaled-el-emam-cv_en.pdf"},
    {"id":"21053","name":"Declaration of research interests (addendum) - Saskia de Wildt","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-saskia-de-wildt_en.pdf"},
    {"id":"21060","name":"FP7 and off patent medicines developed for children - List of Participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:09:21Z","last_updated_date":"2007-06-06T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/fp7-and-patent-medicines-developed-children-list-participants_en.pdf"},
    {"id":"21072","name":"Interested parties to the HMPC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-11-26T01:00:00Z","last_updated_date":"2022-11-30T13:30:00Z","reference_number":"EMA/HMPC/14070/2013","document_url":"https://www.ema.europa.eu/en/documents/other/interested-parties-hmpc_en.pdf"},
    {"id":"21073","name":"Important changes to the Controlled Vocabulary lists: eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Pharmaceutical Dose Forms and Routes of Administration","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-07T18:10:00Z","last_updated_date":"2013-11-07T18:10:00Z","reference_number":"EMA/650540/2013","document_url":"https://www.ema.europa.eu/en/documents/other/important-changes-controlled-vocabulary-lists-extended-eudravigilance-medicinal-product-dictionary-xevmpd-pharmaceutical-dose-forms-and-routes-administration_en.pdf"},
    {"id":"21078","name":"Medication errors - Follow-up actions from workshop: Implementation plan 2014-2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-16T13:30:00Z","last_updated_date":"2014-04-16T13:30:00Z","reference_number":"EMA/20791/2014","document_url":"https://www.ema.europa.eu/en/documents/other/medication-errors-follow-actions-workshop-implementation-plan-2014-2015_en.pdf"},
    {"id":"21088","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: EuroNeoNet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817558/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-euroneonet_en.pdf"},
    {"id":"21091","name":"Declaration of interests: Luc Vanheel","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-18T01:00:00Z","last_updated_date":"2014-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-luc-vanheel_en.pdf"},
    {"id":"21114","name":"Compilation of general quality questions addressed by the HMPWP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-06-11T02:00:00Z","last_updated_date":"2004-06-11T02:00:00Z","reference_number":"EMEA/18123/00/rev5","document_url":"https://www.ema.europa.eu/en/documents/other/compilation-general-quality-questions-addressed-hmpwp_en.pdf"},
    {"id":"21130","name":"EMEA workshop - Announcement - Medicines for bees - What the EMEA can do to increase availability","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-10-16T02:09:21Z","last_updated_date":"2009-10-16T02:09:21Z","reference_number":"EMEA/627827/2009","document_url":"https://www.ema.europa.eu/en/documents/other/emea-workshop-announcement-medicines-bees-what-emea-can-do-increase-availability_en.pdf"},
    {"id":"21181","name":"Overview of comments received on 'reflection paper on classification of advanced-therapy medicinal products' (EMA/600280/2010)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-17T17:16:00Z","last_updated_date":"2012-12-17T17:16:00Z","reference_number":"EMA/CAT/658287/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-classification-advanced-therapy-medicinal-products-ema6002802010_en.pdf"},
    {"id":"21203","name":"Regulatory questions and answers on herbal medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-22T01:00:00Z","last_updated_date":"2021-08-02T17:00:00Z","reference_number":"EMA/HMPC/345132/2010 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/regulatory-questions-and-answers-herbal-medicinal-products_en.pdf"},
    {"id":"21222","name":"Focetria: Summary of product characteristics","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-05T01:00:00Z","last_updated_date":"2010-03-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/focetria-summary-product-characteristics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/focetria-summary-product-characteristics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/focetria-summary-product-characteristics_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/focetria-summary-product-characteristics_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/focetria-summary-product-characteristics_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/focetria-summary-product-characteristics_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/focetria-summary-product-characteristics_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/focetria-summary-product-characteristics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/focetria-summary-product-characteristics_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/focetria-summary-product-characteristics_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/focetria-summary-product-characteristics_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/focetria-summary-product-characteristics_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/focetria-summary-product-characteristics_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/focetria-summary-product-characteristics_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/focetria-summary-product-characteristics_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/focetria-summary-product-characteristics_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/focetria-summary-product-characteristics_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/focetria-summary-product-characteristics_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/focetria-summary-product-characteristics_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/focetria-summary-product-characteristics_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/focetria-summary-product-characteristics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/focetria-summary-product-characteristics_sv.pdf"}},
    {"id":"21230","name":"Nicola Orlandi (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/nicola-orlandi-doi_en.pdf"},
    {"id":"21250","name":"Regulation (EU) No 658/2014 of the European Parliament and of the Council of 15 may 2014 on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products f...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-25T17:35:00Z","last_updated_date":"2014-07-25T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/regulation-eu-no-6582014-european-parliament-and-council-15-may-2014-fees-payable-european-medicines-agency-conduct-pharmacovigilance-activities-respect-medicinal-products-f_en.pdf"},
    {"id":"21251","name":"Guidelines on good pharmacovigilance practices: Introductory cover note, last updated with finalisation of module XV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T00:00:00Z","last_updated_date":"2013-01-24T00:00:00Z","reference_number":"EMA/34842/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-introductory-cover-note-last-updated-finalisation-module-xv_en.pdf"},
    {"id":"21259","name":"Overview of comments received on draft revised guideline on the SPC for antimicrobial products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-11-12T00:09:21Z","last_updated_date":"2007-11-12T00:09:21Z","reference_number":"EMEA/CVMP/SAGAM/420018/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-revised-guideline-spc-antimicrobial-products_en.pdf"},
    {"id":"21261","name":"Summary of the evaluation of the proposed paediatric investigation plan: Apremilast for treatment of Behcet disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/609533/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-apremilast-treatment-behcet-disease_en.pdf"},
    {"id":"21262","name":"Surgiflo haemostatic matrix kit - Ferrosan - Procedural steps and scientific information after initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2024-07-30T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/surgiflo-haemostatic-matrix-kit-ferrosan-procedural-steps-scientific-information-after-initial-consultation_en.pdf"},
    {"id":"21274","name":"Comments received from public consultation on good\n\npharmacovigilance practices: Good pharmacovigilance practices module VI – Management and reporting of adverse reactions to medicinal products (Rev 1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-15T13:00:00Z","last_updated_date":"2014-09-15T13:00:00Z","reference_number":"EMA/540396/2014","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-good-pharmacovigilance-practices-module-vi-management-and-reporting-adverse-reactions-medicinal-products-rev-1_en.pdf"},
    {"id":"21284","name":"EU paediatric working groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-21T02:09:21Z","last_updated_date":"2009-04-21T02:09:21Z","reference_number":"EMEA/248833/2009","document_url":"https://www.ema.europa.eu/en/documents/other/eu-paediatric-working-groups_en.pdf"},
    {"id":"21299","name":"List of participants - Fourth stakeholders forum on the implementation of the new pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-03-05T13:00:00Z","reference_number":"EMA/100161/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-fourth-stakeholders-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"21305","name":"European Medicines Agency process for engaging in externally funded regulatory sciences and process improvement research activities for public and animal health","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-15T18:25:00Z","last_updated_date":"2019-03-07T14:42:00Z","reference_number":"EMA/158095/2019","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-process-engaging-externally-funded-regulatory-sciences-and-process-improvement-research-activities-public-and-animal-health_en.pdf"},
    {"id":"21342","name":"CTAG2: Clinical Trial Advisory Group on clinical-trial-data formats - Membership overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag2-clinical-trial-advisory-group-clinical-trial-data-formats-membership-overview_en.pdf"},
    {"id":"21366","name":"Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - Search strategies for 50 top chemical substance groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-30T14:00:00Z","last_updated_date":"2015-06-30T14:00:00Z","reference_number":"EMA/403865/2015","document_url":"https://www.ema.europa.eu/en/documents/other/monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency-search-strategies-50-top-chemical-substance-groups_en.pdf"},
    {"id":"21390","name":"Mandate, objectives and rules of procedure for the Summary of Product Characteristics (SmPC) Advisory Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-08T01:00:00Z","last_updated_date":"2013-01-08T01:00:00Z","reference_number":"EMA/125968/2009","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-summary-product-characteristics-smpc-advisory-group_en.pdf"},
    {"id":"21391","name":"Withdrawal  letter: Firazyr (icatibant)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/95900/2014 ","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-firazyr-icatibant_en.pdf"},
    {"id":"21401","name":"Public summary of the evaluation of the proposed paediatric investigation plan: N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine for treatment of anaemia due to chronic disorders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T12:10:00Z","last_updated_date":"2014-10-21T12:10:00Z","reference_number":"EMA/317118/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-n-13-dicyclohexyl-6-hydroxy-24-dioxo-1234-tetrahydro-5-pyrimidinylcarbonylglycine-treatment-anaemia-due-chronic-disorders_en.pdf"},
    {"id":"21429","name":"Terms of reference 2016 - 2017: ESVAC species Expert Advisory Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-30T17:00:00Z","last_updated_date":"2017-05-30T17:00:00Z","reference_number":"EMA/196621/2015","document_url":"https://www.ema.europa.eu/en/documents/other/terms-reference-2016-2017-esvac-species-expert-advisory-group_en.pdf"},
    {"id":"21437","name":"CTAG4: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on good analysis practice - First draft with comments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag4-advice-european-medicines-agency-clinical-trial-advisory-group-good-analysis-practice-first-draft-comments_en.pdf"},
    {"id":"21440","name":"Overview of comments received on draft guideline on the evaluation of medicinal products in the treatment of primary osteoporosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-11-16T01:00:00Z","last_updated_date":"2006-11-16T01:00:00Z","reference_number":"EMEA/CHMP/EWP/433354/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-evaluation-medicinal-products-treatment-primary-osteoporosis_en.pdf"},
    {"id":"21445","name":"Declaration of interests: Henri Meyer","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-henri-meyer_en.pdf"},
    {"id":"21449","name":"Overview of comments received on 'Committee for Medicinal Products for Human Use position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-28T02:00:00Z","last_updated_date":"2011-06-28T02:00:00Z","reference_number":"EMA/CHMP/BWP/782508/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-committee-medicinal-products-human-use-position-statement-creutzfeldt-jakob-disease-and-plasma-derived-and-urine-derived-medicinal-products_en.pdf"},
    {"id":"21450","name":"Key milestones of European Medicines Agency interactions with patients and consumers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-18T10:00:00Z","last_updated_date":"2015-03-18T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/key-milestones-european-medicines-agency-interactions-patients-and-consumers_en.pdf"},
    {"id":"21454","name":"EudraVigilance Operational Plan - milestones 2018 to 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-06-08T19:00:00Z","last_updated_date":"2018-06-08T19:00:00Z","reference_number":"EMA/100194/2018","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-operational-plan-milestones-2018-2020_en.pdf"},
    {"id":"21464","name":"Overview of comments received on draft guideline on pharmaceutical fixed combination products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-12-18T01:00:00Z","last_updated_date":"2006-12-18T01:00:00Z","reference_number":"EMEA/CVMP/463526/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-pharmaceutical-fixed-combination-products_en.pdf"},
    {"id":"21465","name":"Announcement of European Medicines Agency priorities for adverse drug reaction research","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-08-04T02:00:00Z","last_updated_date":"2009-08-04T02:00:00Z","reference_number":"EMEA/497624/2009","document_url":"https://www.ema.europa.eu/en/documents/other/announcement-european-medicines-agency-priorities-adverse-drug-reaction-research_en.pdf"},
    {"id":"21473","name":"Response to the European Medicines Agency list of issues - In vitro hollow-fibre-system model of tuberculosis (HFS-TB)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-18T15:00:00Z","last_updated_date":"2014-11-18T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/response-european-medicines-agency-list-issues-vitro-hollow-fibre-system-model-tuberculosis-hfs-tb_en.pdf"},
    {"id":"21491","name":"Transfer of appropriations to allow for implementation of simplified information- and communication-technology budget structure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-18T19:00:00Z","last_updated_date":"2013-06-18T19:00:00Z","reference_number":"EMA/MB/273259/2013","document_url":"https://www.ema.europa.eu/en/documents/other/transfer-appropriations-allow-implementation-simplified-information-and-communication-technology-budget-structure_en.pdf"},
    {"id":"21500","name":"Overview of comments received on draft guideline on clinical investigation of medicinal products for the treatment of migraine","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"EMEA/CHMP/EWP/21477/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-migraine_en.pdf"},
    {"id":"21503","name":"List of participants of the European Medicines Agency Human Scientific Committees’ Working Party with Patients’ and Consumers’ organisations (PCWP) meeting with all eligible organisations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"EMA/702226/2014","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations_en.pdf"},
    {"id":"21510","name":"Comments received from public consultation on good pharmacovigilance practices (GVP) - GVP Module VIII Addendum I – Requirements for transmission of information on non-interventional post-authorisation safety studies (Re...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-08-08T17:00:00Z","last_updated_date":"2016-08-08T17:00:00Z","reference_number":"EMA/710507/2015","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-viii-addendum-i-requirements-transmission-information-non-interventional-post-authorisation-safety-studies-re_en.pdf"},
    {"id":"21511","name":"Decision determining the start date of the term of office of the members of the Management Board appointed by Council Decision No 2013/33/EU","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/MB/82143/2013","document_url":"https://www.ema.europa.eu/en/documents/other/decision-determining-start-date-term-office-members-management-board-appointed-council-decision-no-201333eu_en.pdf"},
    {"id":"21529","name":"Timetable: Post-authorisation measure (PAM) Paediatric art. 46 submission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-02T16:15:00Z","last_updated_date":"2025-09-24T12:06:00Z","reference_number":"EMA/403143/2015 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-post-authorisation-measure-pam-paediatric-art-46-submission_en.xlsx"},
    {"id":"21532","name":"Substance, product, organisation, referentials (SPOR) - Application program interface (API) schema","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-15T19:00:00Z","last_updated_date":"2017-03-15T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/substance-product-organisation-referentials-spor-application-program-interface-api-schema_en.zip"},
    {"id":"21546","name":"Attachment 2 for change of scientific opinion holder","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-05T17:20:00Z","last_updated_date":"2014-08-05T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/attachment-2-change-scientific-opinion-holder_en.doc"},
    {"id":"21553","name":"CTAG1: Clinical Trial Advisory Group on protecting patient confidentiality - Membership overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag1-clinical-trial-advisory-group-protecting-patient-confidentiality-membership-overview_en.pdf"},
    {"id":"21560","name":"Open invitation to tender, EMEA/2006/32/DIR, External members of EMEA's audit advisory committee","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-06-28T02:00:00Z","last_updated_date":"2006-06-28T02:00:00Z","reference_number":"EMEA/171075/2006","document_url":"https://www.ema.europa.eu/en/documents/other/open-invitation-tender-emea200632dir-external-members-emeas-audit-advisory-committee_en.pdf"},
    {"id":"21561","name":"Summary of the evaluation of the proposed paediatric investigation plan: Clonidine for treatment of painful diabetic neuropathy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-19T02:00:00Z","last_updated_date":"2015-10-19T02:00:00Z","reference_number":"EMA/629293/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-clonidine-treatment-painful-diabetic-neuropathy_en.pdf"},
    {"id":"21564","name":"List of participants - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - Worksho...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"EMA/348114/2014","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-worksho_en.pdf"},
    {"id":"21570","name":"Summary of the evaluation of the proposed paediatric investigation plan: Trifarotene for the treatment of acne","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/384282/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-trifarotene-treatment-acne_en.pdf"},
    {"id":"21587","name":"Medicines under additional monitoring","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-25T12:00:00Z","last_updated_date":"2013-10-24T11:30:00Z","reference_number":"EMA/244682/2013","document_url":"https://www.ema.europa.eu/en/documents/other/medicines-under-additional-monitoring_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/medicines-under-additional-monitoring_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/medicines-under-additional-monitoring_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/medicines-under-additional-monitoring_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/medicines-under-additional-monitoring_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/medicines-under-additional-monitoring_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/medicines-under-additional-monitoring_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/medicines-under-additional-monitoring_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/medicines-under-additional-monitoring_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/medicines-under-additional-monitoring_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/medicines-under-additional-monitoring_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/medicines-under-additional-monitoring_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/medicines-under-additional-monitoring_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/medicines-under-additional-monitoring_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/medicines-under-additional-monitoring_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/medicines-under-additional-monitoring_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/medicines-under-additional-monitoring_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/medicines-under-additional-monitoring_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/medicines-under-additional-monitoring_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/medicines-under-additional-monitoring_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/medicines-under-additional-monitoring_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/medicines-under-additional-monitoring_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/medicines-under-additional-monitoring_sv.pdf"}},
    {"id":"21616","name":"Overview of comments received on 'guideline on pharmaceutical development of medicines for paediatric use' (EMA/CHMP/QWP/180157/2011)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-04T12:21:00Z","last_updated_date":"2013-01-04T12:21:00Z","reference_number":"EMA/805826/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-pharmaceutical-development-medicines-paediatric-use-emachmpqwp1801572011_en.pdf"},
    {"id":"21621","name":"Extension of arrangement for shared non-public information regarding influenza A (H1N1) pandemic between the European Medicines Agency and the Swiss Agency for Therapeutic Products, Swissmedic","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-03T17:35:10Z","last_updated_date":"2012-02-03T17:35:10Z","reference_number":"EMA/66651/2012","document_url":"https://www.ema.europa.eu/en/documents/other/extension-arrangement-shared-non-public-information-regarding-influenza-h1n1-pandemic-between-european-medicines-agency-and-swiss-agency-therapeutic-products-swissmedic_en.pdf-0"},
    {"id":"21630","name":"Overview of comments received on ' Guideline on the clinical evaluation of antifungal agents for the treatment and prophylaxis of invasive fungal disease'\n\n(CHMP/EWP/1343/01 Rev.1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-30T02:00:00Z","last_updated_date":"2010-04-30T02:00:00Z","reference_number":"EMA/186797/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-evaluation-antifungal-agents-treatment-and-prophylaxis-invasive-fungal-disease-chmpewp134301-rev1_en.pdf"},
    {"id":"21643","name":"CTAG3: Advice to the European Medicines Agency on rules of engagement for accessing clinical-trial data - Final advice 4 April 2013 version 9.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-advice-european-medicines-agency-rules-engagement-accessing-clinical-trial-data-final-advice-4-april-2013-version-90_en.pdf"},
    {"id":"21645","name":"European Union influenza pandemic process map","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-08-21T02:09:21Z","last_updated_date":"2006-08-21T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-influenza-pandemic-process-map_en.pdf"},
    {"id":"21655","name":"P/63/2010: EMA decision of 20 December 2010 on a class waiver on condition(s)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-11-03T00:09:21Z","last_updated_date":"2011-01-11T00:09:21Z","reference_number":"EMA/820860/2010","document_url":"https://www.ema.europa.eu/en/documents/other/p632010-ema-decision-20-december-2010-class-waiver-conditions_en.pdf"},
    {"id":"21678","name":"Joint audit programme for EEA GMP inspectorates JAP: Audit notification template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-19T02:00:00Z","last_updated_date":"2022-12-09T15:00:00Z","reference_number":"EMA/INS/931781/2022 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/joint-audit-programme-eea-gmp-inspectorates-jap-audit-notification-template_en.pdf"},
    {"id":"21699","name":"Letter of invitation to tender - Procurement procedure EMA-2012-09-IF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-04-04T14:30:00Z","reference_number":"EMA/954451/2011","document_url":"https://www.ema.europa.eu/en/documents/other/letter-invitation-tender-procurement-procedure-ema-2012-09-if_en.pdf"},
    {"id":"21725","name":"Defining the strategic vision for the EMA ‘Article 58’ process - Final read-out","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-26T17:30:00Z","last_updated_date":"2016-04-26T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/defining-strategic-vision-ema-article-58-process-final-read-out_en.pdf"},
    {"id":"21752","name":"The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future: Part I: The European Medicines Agency Strategy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-03-07T01:00:00Z","last_updated_date":"2005-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-road-map-2010-preparing-ground-future-part-i-european-medicines-agency-strategy_en.pdf"},
    {"id":"21773","name":"Outcome of SME office survey on the implementation of the SME regulation - Commission Regulation (EC) No 2049/2005","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-05-11T12:30:00Z","last_updated_date":"2016-05-11T12:30:00Z","reference_number":"EMA/242286/2016","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-sme-office-survey-implementation-sme-regulation-commission-regulation-ec-no-20492005_en.pdf"},
    {"id":"21777","name":"Overview of comments received on 'qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for positron-emission-tomography amyloid imaging (positive / negative) as a biomarker for enrichment, for us...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-04T19:00:00Z","last_updated_date":"2012-04-04T19:00:00Z","reference_number":"EMA/991202/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-qualification-opinion-alzheimers-disease-novel-methodologies-biomarkers-positron-emission-tomography-amyloid-imaging-positive-negative-biomarker-enrichment-us_en.pdf"},
    {"id":"21783","name":"Request for CHMP qualification opinion on efficient statistical methodology for model-based design and analysis of phase-II dose-finding studies under model uncertainty","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-15T19:00:00Z","last_updated_date":"2013-10-15T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-chmp-qualification-opinion-efficient-statistical-methodology-model-based-design-and-analysis-phase-ii-dose-finding-studies-under-model-uncertainty_en.pdf"},
    {"id":"21801","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 21-24 July 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-29T18:15:00Z","last_updated_date":"2014-08-01T18:30:00Z","reference_number":"EMA/125405/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-21-24-july-2014_en.pdf"},
    {"id":"21832","name":"Timetable: Marketing authorisation renewal application","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-28T18:00:00Z","last_updated_date":"2026-05-28T15:20:00Z","reference_number":"EMA/461220/2015 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-marketing-authorisation-renewal-application_en.xlsx"},
    {"id":"21836","name":"Data protection notice for legal entity and bank account validation regarding payments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-06-19T02:00:00Z","last_updated_date":"2026-06-08T14:00:00Z","reference_number":"EMA/445121/2019","document_url":"https://www.ema.europa.eu/en/documents/other/data-protection-notice-legal-entity-bank-account-validation-regarding-payments_en.pdf"},
    {"id":"21875","name":"Abbreviations used in HMPC agendas and minutes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T15:45:00Z","last_updated_date":"2016-04-05T12:07:00Z","reference_number":"EMA/HMPC/441838/2013","document_url":"https://www.ema.europa.eu/en/documents/other/abbreviations-used-hmpc-agendas-and-minutes_en.pdf"},
    {"id":"21877","name":"Start of Community reviews - CHMP meeting 18-21 February 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/110776/2013","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-18-21-february-2013_en.pdf"},
    {"id":"21919","name":"European Commision - Canada mutual recognition agreement: Sectoral annex on good manufacturing practices - Ninth joint sectoral group meeting update on the operation of the sectoral annex","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-10T02:00:00Z","last_updated_date":"2007-10-10T02:00:00Z","reference_number":"EMEA/INS/MRA/470284/2007","document_url":"https://www.ema.europa.eu/en/documents/other/european-commision-canada-mutual-recognition-agreement-sectoral-annex-good-manufacturing-practices-ninth-joint-sectoral-group-meeting-update-operation-sectoral-annex_en.pdf"},
    {"id":"21953","name":"CAT meeting dates 2015, 2016, 2017 and 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-06T13:00:00Z","last_updated_date":"2015-01-06T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cat-meeting-dates-2015-2016-2017-and-2018_en.pdf"},
    {"id":"21955","name":"Revised priority list for studies on off-patent paediatric medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-09-11T02:00:00Z","last_updated_date":"2013-08-12T18:00:00Z","reference_number":"EMA/98717/2012 Rev. 2012","document_url":"https://www.ema.europa.eu/en/documents/other/revised-priority-list-studies-patent-paediatric-medicinal-products_en.pdf"},
    {"id":"21970","name":"Policy 43: European Medicines Agency policy on access to documents","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-11-30T01:00:00Z","last_updated_date":"2018-11-23T13:00:00Z","reference_number":"EMA/729522/2016","document_url":"https://www.ema.europa.eu/en/documents/other/policy-43-european-medicines-agency-policy-access-documents_en.pdf"},
    {"id":"21974","name":"Technical specification - Annex 5 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"EMA/201143/2012","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-5-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"21991","name":"Financial compensation and workload estimation of the revised EMA organisation of translations of product related information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/MB/711738/2015","document_url":"https://www.ema.europa.eu/en/documents/other/financial-compensation-and-workload-estimation-revised-ema-organisation-translations-product-related-information_en.pdf"},
    {"id":"21994","name":"Opinions on safety variations/periodic safety update reports adopted during the CHMP meeting 23-26 June 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T16:30:00Z","last_updated_date":"2014-07-01T16:30:00Z","reference_number":"EMA/125340/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variationsperiodic-safety-update-reports-adopted-during-chmp-meeting-23-26-june-2014_en.pdf"},
    {"id":"21998","name":"Members of the Coordinating group of European network of paediatric research at the European Medicines Agency (Enpr-EMA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2026-02-10T12:45:00Z","reference_number":"EMA/257906/2011 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/members-coordinating-group-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"22002","name":"Overview of comments received on guideline on environmental impact assessment for veterinary medicinal products in support of VICH guidelines GL6 and GL 38 - Doc. ref. EMEA/CVMP/ERA/418282/2005-REV.1 post publication","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-17T01:00:00Z","last_updated_date":"2008-11-17T01:00:00Z","reference_number":"EMEA/CVMP/ERA/571947/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-environmental-impact-assessment-veterinary-medicinal-products-support-vich-guidelines-gl6-and-gl-38-doc-ref-emeacvmpera4182822005-rev1-post-publication_en.pdf"},
    {"id":"22023","name":"List of participants - Patients and Consumers Working Party (PCWP) meeting with all EMA eligible patient/consumer organisations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T16:26:00Z","last_updated_date":"2017-12-11T16:26:00Z","reference_number":"EMA/658658/2017","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-patients-and-consumers-working-party-pcwp-meeting-all-ema-eligible-patientconsumer-organisations_en.pdf"},
    {"id":"22053","name":"Summary on compassionate use for Sofosbuvir Gilead","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-03T17:45:00Z","last_updated_date":"2020-10-26T11:22:00Z","reference_number":"EMA/697409/2013","document_url":"https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-sofosbuvir-gilead_en.pdf"},
    {"id":"22056","name":"Decision on amending budget No 1-2015","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"EMA/MB/50215/2015","document_url":"https://www.ema.europa.eu/en/documents/other/decision-amending-budget-no-1-2015_en.pdf"},
    {"id":"22069","name":"Overview of designated orphan medicines that have been the subject of a centralised application for marketing authorisation, CHMP meeting 18-22 September 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/770530/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-designated-orphan-medicines-have-been-subject-centralised-application-marketing-authorisation-chmp-meeting-18-22-september-2011_en.pdf"},
    {"id":"22147","name":"CTAG3: Advice to the European Medicines Agency on rules of engagement for accessing clinical-trial data - Draft 22 March 2013 version 7.1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-advice-european-medicines-agency-rules-engagement-accessing-clinical-trial-data-draft-22-march-2013-version-71_en.pdf"},
    {"id":"22170","name":"Public hearing on quinolones and fluoroquinolones - Summary of safety concerns and list of questions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-04-09T14:00:00Z","last_updated_date":"2018-04-09T14:00:00Z","reference_number":"EMA/166405/2018","document_url":"https://www.ema.europa.eu/en/documents/other/public-hearing-quinolones-and-fluoroquinolones-summary-safety-concerns-and-list-questions_en.pdf"}    {"id":"22178","name":"Competact: Product Information as approved by the CHMP on 20 october 2011, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/competact-product-information-approved-chmp-20-october-2011-pending-endorsement-european-commission_en.pdf"},
    {"id":"22187","name":"Recognition criteria for self assessment - Enpr-EMA: Swedish Peadiatric Society (BLF)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2011-01-07T00:31:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-swedish-peadiatric-society-blf_en.pdf"},
    {"id":"22202","name":"An action plan to improve the perception and use of the Article 58 procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/MB/762330/2015-Rev 1","document_url":"https://www.ema.europa.eu/en/documents/other/action-plan-improve-perception-and-use-article-58-procedure_en.pdf"},
    {"id":"22211","name":"Mandate of the Ad Hoc Pharmacovigilance Inspectors Working Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/MB/575748/2009","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-ad-hoc-pharmacovigilance-inspectors-working-group_en.pdf"},
    {"id":"22212","name":"Medical literature monitoring tracking sheet: individual case safety reports (ICSRs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-08T11:00:00Z","last_updated_date":"2017-11-08T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medical-literature-monitoring-tracking-sheet-individual-case-safety-reports-icsrs_en.xlsx"},
    {"id":"22222","name":"Pre-qualification questionnaire for a restricted tender procedure organised by the European Medicines Agency - Provision of security consumables – EMA/2013/21/IS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T12:00:00Z","last_updated_date":"2013-10-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-restricted-tender-procedure-organised-european-medicines-agency-provision-security-consumables-ema201321is_en.doc"},
    {"id":"22226","name":"Withdrawal letter : Zometa","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-11-15T01:00:00Z","last_updated_date":"2007-11-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-zometa_en.pdf"},
    {"id":"22238","name":"Summary of transfers of appropriations in the budget 2010 - Management Board meeting: 7 October 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/528844/2010","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2010-management-board-meeting-7-october-2010_en.pdf"},
    {"id":"22277","name":"Resource requirements of the CVMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-06-11T02:09:21Z","last_updated_date":"2009-06-11T02:09:21Z","reference_number":"EMEA/MB/301036/2009","document_url":"https://www.ema.europa.eu/en/documents/other/resource-requirements-cvmp_en.pdf"},
    {"id":"22289","name":"Outcome of written procedures finalised during the period from 1 March 2012 to 17 May 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-06-14T16:30:00Z","last_updated_date":"2012-06-14T16:30:00Z","reference_number":"EMA/MB/326836/2012","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-1-march-2012-17-may-2012_en.pdf"},
    {"id":"22297","name":"Avastin - PI","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-16T01:00:00Z","last_updated_date":"2010-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/avastin-pi_en.pdf"},
    {"id":"22325","name":"Summary of transfer of appropriations in the budget 2010 - Management Board meeting: 16 December 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/MB/694689/2010","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2010-management-board-meeting-16-december-2010_en.pdf"},
    {"id":"22333","name":"Data submission of authorised medicines in the European Union: Outlines on Article 57(2) of Regulation (EC) No 726/2004","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-17T12:00:00Z","last_updated_date":"2015-02-23T13:15:00Z","reference_number":"EMA/471367/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/data-submission-authorised-medicines-european-union-outlines-article-572-regulation-ec-no-7262004_en.pdf"},
    {"id":"22354","name":"List of active substances involved in the pilot on signal detection in EudraVigilance by marketing authorisation holders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T17:00:00Z","last_updated_date":"2021-09-16T09:50:00Z","reference_number":"EMA/701527/2017 Corr. 7","document_url":"https://www.ema.europa.eu/en/documents/other/list-active-substances-involved-pilot-signal-detection-eudravigilance-marketing-authorisation-holders_en.xls"},
    {"id":"22396","name":"Invirase amended PI for publication","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-21T02:00:00Z","last_updated_date":"2010-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/invirase-amended-pi-publication_en.pdf"},
    {"id":"22399","name":"Public summary of the evaluation of the proposed product-specific waiver: Pacritinib for treatment of post-polycythaemia vera myelofibrosis and treatment of post-essential thrombocythaemia myelofibrosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T13:00:00Z","last_updated_date":"2014-10-21T13:00:00Z","reference_number":"EMA/515156/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-pacritinib-treatment-post-polycythaemia-vera-myelofibrosis-and-treatment-post-essential-thrombocythaemia-myelofibrosis_en.pdf"},
    {"id":"22409","name":"Letter of invitation to tender - EMA/2012/03/HR","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-24T09:50:00Z","last_updated_date":"2012-01-24T09:50:00Z","reference_number":"EMA/925173/2011","document_url":"https://www.ema.europa.eu/en/documents/other/letter-invitation-tender-ema201203hr_en.pdf"},
    {"id":"22425","name":"Name Review Group form - questions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T12:10:00Z","last_updated_date":"2025-12-18T12:10:00Z","reference_number":"EMA/741768/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/name-review-group-form-questions-answers_en.pdf"},
    {"id":"22439","name":"Macugen: Withdrawal letter","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/macugen-withdrawal-letter_en.pdf"},
    {"id":"22452","name":"Start of Community reviews: CHMP meeting of 10-13 December 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T13:00:00Z","last_updated_date":"2012-12-14T13:00:00Z","reference_number":"EMA/792982/2012","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-10-13-december-2012_en.pdf"},
    {"id":"22467","name":"Withdrawal letter: Exelon and Prometax","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"EMA/226251/2012","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-exelon-and-prometax_en.pdf"},
    {"id":"22491","name":"Download EPS - Species pictograms - Cattle","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-cattle_en.zip"},
    {"id":"22507","name":"Summary of the evaluation of the proposed paediatric investigation plan: Letermovir for the prevention of cytomegalovirus infection","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-19T02:00:00Z","last_updated_date":"2015-10-19T02:00:00Z","reference_number":"EMA/209609/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-letermovir-prevention-cytomegalovirus-infection_en.pdf"},
    {"id":"22510","name":"Mandate, objectives and rules of procedure for the Name Review Group (NRG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T18:30:00Z","last_updated_date":"2019-10-22T11:00:00Z","reference_number":"EMA/411943/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-name-review-group-nrg_en.pdf"},
    {"id":"22524","name":"Performance of the Agency’s scientific procedures: Survey 2009 for medicinal products for human use - Management Board meeting 18 March 2010","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/MB/78873/2010","document_url":"https://www.ema.europa.eu/en/documents/other/performance-agencys-scientific-procedures-survey-2009-medicinal-products-human-use-management-board-meeting-18-march-2010_en.pdf"},
    {"id":"22548","name":"European Medicines Agency budget for 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T13:05:00Z","last_updated_date":"2012-03-12T11:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-budget-2012_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/european-medicines-agency-budget-2012_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/european-medicines-agency-budget-2012_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/european-medicines-agency-budget-2012_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/european-medicines-agency-budget-2012_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/european-medicines-agency-budget-2012_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/european-medicines-agency-budget-2012_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/european-medicines-agency-budget-2012_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/european-medicines-agency-budget-2012_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/european-medicines-agency-budget-2012_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/european-medicines-agency-budget-2012_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/european-medicines-agency-budget-2012_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/european-medicines-agency-budget-2012_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/european-medicines-agency-budget-2012_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/european-medicines-agency-budget-2012_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/european-medicines-agency-budget-2012_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/european-medicines-agency-budget-2012_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/european-medicines-agency-budget-2012_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/european-medicines-agency-budget-2012_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/european-medicines-agency-budget-2012_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/european-medicines-agency-budget-2012_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/european-medicines-agency-budget-2012_sv.pdf"}},
    {"id":"22569","name":"Explanatory note on pharmacovigilance fees payable to EMA (as of 4 October 2023)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T15:00:00Z","last_updated_date":"2023-10-04T10:23:00Z","reference_number":"European Medicines Agency","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-note-pharmacovigilance-fees-payable-ema-4-october-2023_en.pdf"},
    {"id":"22576","name":"Good manufacturing practice: An analysis of regulatory inspection findings in the centralised procedure in 2006 and plasma-master-file procedure during 2004-2006 period","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-04-08T02:00:00Z","last_updated_date":"2008-04-08T02:00:00Z","reference_number":"EMEA/INS/GMP/594072/2007","document_url":"https://www.ema.europa.eu/en/documents/other/good-manufacturing-practice-analysis-regulatory-inspection-findings-centralised-procedure-2006-and-plasma-master-file-procedure-during-2004-2006-period_en.pdf"},
    {"id":"22577","name":"CPMP List of herbal drugs with serious risks","type":"other","status":"unknown","consultation_date":"","first_published_date":"1992-10-26T01:00:00Z","last_updated_date":"1992-10-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cpmp-list-herbal-drugs-serious-risks_en.pdf"},
    {"id":"22612","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with launch of public consultation of module VII revision 1, final module X and revision of module VIII, new annexes and final G...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-25T12:00:00Z","last_updated_date":"2013-04-25T12:00:00Z","reference_number":"EMA/237383/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-launch-public-consultation-module-vii-revision-1-final-module-x-and-revision-module-viii-new-annexes-and-final-g_en.pdf"},
    {"id":"22642","name":"Doribax: Product information as approved by the CHMP on 21 June 2012, pending endorsement by the European Commission","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T12:00:00Z","last_updated_date":"2014-10-17T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/doribax-product-information-approved-chmp-21-june-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"22669","name":"Working party on Herbal Medicinal Products: Final proposal for a core data Thymi Herba","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-03-03T01:00:00Z","last_updated_date":"2004-03-03T01:00:00Z","reference_number":"EMEA/HMPWP/343/03","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-thymi-herba_en.pdf"},
    {"id":"22688","name":"European Medicines Agency 2011 priorities for drug safety research: Epoetins and tumour progression, shortened survival, mortality and thromboembolic events","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-07-08T02:00:00Z","last_updated_date":"2010-07-08T02:00:00Z","reference_number":"EMA/425285/2010","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-2011-priorities-drug-safety-research-epoetins-and-tumour-progression-shortened-survival-mortality-and-thromboembolic-events_en.pdf"},
    {"id":"22691","name":"Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations I: Vaccines for prophylaxis against infectious diseases (with tracked changes)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-12T11:00:00Z","last_updated_date":"2013-12-12T11:00:00Z","reference_number":"EMA/488220/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-i-vaccines-prophylaxis-against-infectious-diseases-tracked-changes_en.pdf"},
    {"id":"22710","name":"Submission deadlines for paediatric applications 2024-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-25T11:06:00Z","last_updated_date":"2024-01-25T11:06:00Z","reference_number":"EMA/21598/2024","document_url":"https://www.ema.europa.eu/en/documents/other/submission-deadlines-paediatric-applications-2024-2026_en.pdf"},
    {"id":"22713","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) M3 (R2) questions and answers - Step 5","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-07-25T02:00:00Z","last_updated_date":"2012-05-25T15:45:00Z","reference_number":"EMA/CHMP/ICH/507008/2011","document_url":"https://www.ema.europa.eu/en/documents/other/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-m3-r2-questions-and-answers-step-5_en.pdf"},
    {"id":"22714","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 16-19 September 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-26T17:35:00Z","last_updated_date":"2013-09-26T17:35:00Z","reference_number":"EMA/568771/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-16-19-september-2013_en.pdf"},
    {"id":"22724","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Mother Infant Child Youth Research Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817621/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-mother-infant-child-youth-research-network_en.pdf"},
    {"id":"22731","name":"Reflection paper on medicinal-product supply shortages caused by manufacturing / good-manufacturing-practice compliance problems","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-23T16:35:00Z","last_updated_date":"2012-11-23T16:35:00Z","reference_number":"EMA/590745/2012","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-medicinal-product-supply-shortages-caused-manufacturing-good-manufacturing-practice-compliance-problems_en.pdf"},
    {"id":"22763","name":"Annex I: Catalogue-2016 donation of IT assets","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-29T12:45:00Z","last_updated_date":"2016-07-29T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-i-catalogue-2016-donation-it-assets_en.xlsx"},
    {"id":"22770","name":"Tyverb: Withdrawal letter","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-16T01:00:00Z","last_updated_date":"2012-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/tyverb-withdrawal-letter_en.pdf"},
    {"id":"22788","name":"Procedural announcements - CHMP meeting 16-19 January 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-23T17:35:00Z","last_updated_date":"2012-01-23T17:35:00Z","reference_number":"EMA/CHMP/8910/2012","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-announcements-chmp-meeting-16-19-january-2012_en.pdf"},
    {"id":"22801","name":"List of meetings, workshops and training activities planned by the European Medicines Agency for human and veterinary medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-08-17T02:00:00Z","last_updated_date":"2009-08-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-meetings-workshops-and-training-activities-planned-european-medicines-agency-human-and-veterinary-medicines_en.pdf"},
    {"id":"22810","name":"Letter of withdrawal of application for the GlaxoSmithKline Biologicals S.A. Globorix vaccine (DTPw-HBV/Hib-MenAC, powder and suspension for suspension for injection) - EMEA/H/W/848","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-17T02:09:00Z","last_updated_date":"2007-10-17T02:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-withdrawal-application-glaxosmithkline-biologicals-sa-globorix-vaccine-dtpw-hbvhib-menac-powder-and-suspension-suspension-injection-emeahw848_en.pdf"},
    {"id":"22835","name":"Questions and answers relating to tender – EMA-2012-09-IF External service providers for enterprise infrastructure support: provision of resources for Oracle database and middleware product management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-14T13:00:00Z","last_updated_date":"2012-04-12T15:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-tender-ema-2012-09-if-external-service-providers-enterprise-infrastructure-support-provision-resources-oracle-database-and-middleware-product-management_en.pdf"},
    {"id":"22848","name":"Organisation chart: Information Management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-16T12:00:00Z","last_updated_date":"2025-08-01T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-chart-information-management_en.pdf"},
    {"id":"22866","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic mesenchymal stem cells suspended in cell supernatant","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-03-21T14:30:00Z","last_updated_date":"2018-03-21T14:30:00Z","reference_number":"EMA/105846/2018","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-mesenchymal-stem-cells-suspended-cell-supernatant_en.pdf"},
    {"id":"22869","name":"Participant list - Workshop on access to clinical-trial data and transparency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-05T17:00:00Z","last_updated_date":"2012-12-05T17:00:00Z","reference_number":"EMA/768613/2012","document_url":"https://www.ema.europa.eu/en/documents/other/participant-list-workshop-access-clinical-trial-data-and-transparency_en.pdf"},
    {"id":"22875","name":"List of participants of the European Medicines Agency Human Scientific Committee’s Working Party with Healthcare Professionals’ Organisations (HCPWP) meeting - 4 June 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-01T02:00:00Z","last_updated_date":"2015-09-01T02:00:00Z","reference_number":"EMA/246492/2015","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-meeting-4-june-2015_en.pdf"},
    {"id":"22884","name":"Biologics Working Party Ad-hoc Influenza Working Group: Amended European Union recommendations for the seasonal-influenza-vaccine composition for the season 2015 / 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T15:12:00Z","last_updated_date":"2015-05-27T17:30:00Z","reference_number":"EMA/CHMP/BWP/169555/2015","document_url":"https://www.ema.europa.eu/en/documents/other/biologics-working-party-ad-hoc-influenza-working-group-amended-european-union-recommendations-seasonal-influenza-vaccine-composition-season-2015-2016_en.pdf"},
    {"id":"22887","name":"PDCO dates for 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-26T01:00:00Z","last_updated_date":"2011-04-20T02:00:00Z","reference_number":"EMA/PDCO/70198/2010","document_url":"https://www.ema.europa.eu/en/documents/other/pdco-dates-2012_en.pdf"},
    {"id":"22889","name":"Frank W. Rockhold  (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-09-05T18:01:00Z","last_updated_date":"2017-09-05T18:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/frank-w-rockhold-doi_en.pdf"},
    {"id":"22890","name":"Declaration of interest: Sebastian Asprella","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2017-08-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-sebastian-asprella_en.pdf"},
    {"id":"22901","name":"Floseal haemostatic matrix (Floseal VH S/D) - Procedural steps and scientific information after initial consultation (archive)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2025-05-26T16:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/floseal-haemostatic-matrix-floseal-vh-s-d-procedural-steps-scientific-information-after-initial-consultation-archive_en.pdf"},
    {"id":"22902","name":"Committee for Orphan Medicinal Products (COMP) meetings 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-19T19:00:00Z","last_updated_date":"2015-10-01T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/committee-orphan-medicinal-products-comp-meetings-2016_en.pdf"},
    {"id":"22915","name":"Advanced therapy medicinal products: Full applications (first phase)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advanced-therapy-medicinal-products-full-applications-first-phase_en.pdf"},
    {"id":"22939","name":"Declaration of interest: Tà¢nia Teixeira","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-26T02:00:00Z","last_updated_date":"2016-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-tacnia-teixeira_en.pdf"},
    {"id":"22943","name":"Welcome speech - Sylvie Benefice, EMEA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T00:09:00Z","last_updated_date":"2008-11-05T00:09:00Z","reference_number":"EMEA/589654/2008","document_url":"https://www.ema.europa.eu/en/documents/other/welcome-speech-sylvie-benefice-emea_en.pdf"},
    {"id":"22983","name":"Organisational matters - CHMP meeting 22-25 July 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T17:00:00Z","last_updated_date":"2013-08-21T17:00:00Z","reference_number":"EMA/CHMP/241123/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-22-25-july-2013_en.pdf"},
    {"id":"23030","name":"High level business consultancy EMA/2013/23/FI - Technical specifications - Annex IV draft framework contract","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications-annex-iv-draft-framework-contract_en.pdf"},
    {"id":"23037","name":"Multinational assessment team concept - The next phase - Extending the concept to the post-authorisation 2nd phase","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-17T13:30:00Z","last_updated_date":"2023-04-14T15:21:00Z","reference_number":"EMA/619544/2016 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/multinational-assessment-team-concept-next-phase-extending-concept-post-authorisation-2nd-phase_en.pdf"},
    {"id":"23078","name":"List of participants of the EMA Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting with all eligible organisations (30 November 2016)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"EMA/697653/2016","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations-30-november-2016_en.pdf"},
    {"id":"23093","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: National Institute for Health Research Medicines for Children Research Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-national-institute-health-research-medicines-children-research-network_en.pdf"},
    {"id":"23104","name":"Public statement on Nuedexta: Withdrawal of the marketing authorisation in the European Union","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T10:00:00Z","last_updated_date":"2016-03-11T10:00:00Z","reference_number":"EMA/186479/2016","document_url":"https://www.ema.europa.eu/en/documents/other/public-statement-nuedexta-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"23114","name":"Organisational matters - CHMP meeting 22-25 April 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-02T14:15:00Z","last_updated_date":"2013-05-02T14:15:00Z","reference_number":"EMA/CHMP/184565/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-22-25-april-2013_en.pdf"},
    {"id":"23116","name":"When healthcare professionals came to the (working) party - Forewords by co-chairs of the working parties","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-21T01:00:00Z","last_updated_date":"2016-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/when-healthcare-professionals-came-working-party-forewords-co-chairs-working-parties_en.pdf"},
    {"id":"23171","name":"Mandate, objectives and rules of procedure for the temporary working parties and drafting groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-08-04T02:00:00Z","last_updated_date":"2010-08-04T02:00:00Z","reference_number":"EMA/CHMP/319651/2010","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-temporary-working-parties-and-drafting-groups_en.pdf"},
    {"id":"23207","name":"Type II variations (90-day procedure)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-25T01:09:21Z","last_updated_date":"2009-12-03T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/type-ii-variations-90-day-procedure_en.pdf"},
    {"id":"23228","name":"Letter of support for eye tracking to be used to stratify populations of people with autism spectrum disorder (ASD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T12:00:00Z","last_updated_date":"2015-12-09T12:00:00Z","reference_number":"EMA/794527/2015","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-eye-tracking-be-used-stratify-populations-people-autism-spectrum-disorder-asd_en.pdf"},
    {"id":"23238","name":"Outcome of written procedures finalised during the period from 22 November 2012 to 27 February 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/MB/67488/2013","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-22-november-2012-27-february-2013_en.pdf"},
    {"id":"23241","name":"Recommendation on the evaluation of the benefit-risk balance of veterinary medicinal products","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/CVMP/248499/2007","document_url":"https://www.ema.europa.eu/en/documents/other/recommendation-evaluation-benefit-risk-balance-veterinary-medicinal-products_en.pdf"},
    {"id":"23244","name":"Performance of the Agency’s scientific procedures: 2011 report for medicinal products for human use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"EMA/MB/157253/2012","document_url":"https://www.ema.europa.eu/en/documents/other/performance-agencys-scientific-procedures-2011-report-medicinal-products-human-use_en.pdf"},
    {"id":"23255","name":"Table of European Paediatric Research Nurse Networks and Groups provided by the Enpr-EMA Research Nurse Training Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-04T16:30:00Z","last_updated_date":"2018-07-10T16:30:00Z","reference_number":"EMA/284404/2018 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/table-european-paediatric-research-nurse-networks-and-groups-provided-enpr-ema-research-nurse-training-group_en.pdf"},
    {"id":"23259","name":"European Medicines Agency / Committee for Medicinal Products for Human Use Working Group with Healthcare Professionals' Organisations (HCP WG) - Final recommendations and proposals for action","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-02-06T00:09:21Z","last_updated_date":"2009-02-06T00:09:21Z","reference_number":"EMEA/185036/2008","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-committee-medicinal-products-human-use-working-group-healthcare-professionals-organisations-hcp-wg-final-recommendations-and-proposals-action_en.pdf"},
    {"id":"23260","name":"Overview of comments received on 'Reflection paper on the use of starting materials and intermediates collected from different sources in the manufacturing of non-recombinant biological medicinal products'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T12:55:00Z","last_updated_date":"2013-07-12T12:55:00Z","reference_number":"EMA/CHMP/BWP/661511/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-use-starting-materials-and-intermediates-collected-different-sources-manufacturing-non-recombinant-biological-medicinal-products_en.pdf"},
    {"id":"23318","name":"Revised framework for interaction between the European Medicines Agency and healthcare professionals and their organisations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T17:30:00Z","last_updated_date":"2016-12-19T17:30:00Z","reference_number":"EMA/89918/2016","document_url":"https://www.ema.europa.eu/en/documents/other/revised-framework-interaction-between-european-medicines-agency-and-healthcare-professionals-and-their-organisations_en.pdf"},
    {"id":"23324","name":"Summary of the evaluation of the proposed product-specific waiver: Amlodipine / perindopril (erbumine) for treatment of hypertension and for treatment of stable coronary artery disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/712433/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-product-specific-waiver-amlodipine-perindopril-erbumine-treatment-hypertension-and-treatment-stable-coronary-artery-disease_en.pdf"},
    {"id":"23359","name":"Mandate, objectives and rules of procedure for the GCP Inspectors Working Group (GCP IWG)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2007-07-27T02:00:00Z","last_updated_date":"2013-11-27T16:10:00Z","reference_number":"EMA/INS/GCP/285522/2013","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-gcp-inspectors-working-group-gcp-iwg_en.pdf"},
    {"id":"23389","name":"Bisphosphonates - Article 31 - changes to product information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/bisphosphonates-article-31-changes-product-information_en.pdf"},
    {"id":"23392","name":"Public summary of the evaluation of a proposed paediatric investigation plan: (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido [1,2-d]pyrazine-8-carb...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T12:15:00Z","last_updated_date":"2014-12-11T12:15:00Z","reference_number":"EMA/719697/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-3s11ar-n-24-difluorophenylmethyl-6-hydroxy-3-methyl-57-dioxo-23571111a-hexahydro13oxazolo32-apyrido-12-dpyrazine-8-carb_en.pdf"},
    {"id":"23405","name":"Annex 6 EMA ICT standards - Procurement Procedure EMA/2012/09/IF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"EMA/399527/2011","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-ema-ict-standards-procurement-procedure-ema201209if_en.pdf"},
    {"id":"23425","name":"Overview of the training on electronic submission of information on medicines - new pharmacovigilance legislation (Art. 57, paragraph 2,\n\n2nd sub-paragraph, Regulation (EC) No. 726/2004): 20-21 March, Madrid, Spain","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-training-electronic-submission-information-medicines-new-pharmacovigilance-legislation-art-57-paragraph-2-2nd-sub-paragraph-regulation-ec-no-7262004-20-21-march-madrid-spain_en.pdf"},
    {"id":"23426","name":"Summary of the EMA public hearing on valproate in pregnancy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-04T19:20:00Z","last_updated_date":"2017-10-04T19:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/summary-ema-public-hearing-valproate-pregnancy_en.pdf"},
    {"id":"23439","name":"Overview of comments received on draft guideline on quality of herbal medicinal products/traditional herbal medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-06-09T02:00:00Z","last_updated_date":"2006-06-09T02:00:00Z","reference_number":"EMEA/CHMP/CVMP/QWP/40683/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-quality-herbal-medicinal-productstraditional-herbal-medicinal-products_en.pdf"},
    {"id":"23464","name":"Pre-qualification questionnaire (“PQQ”) for a restricted tender procedure on DSE Assessments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-dse-assessments_en.docx"},
    {"id":"23486","name":"European Medicines Agency: Clarification Questions - 6 October 2006","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-10-06T02:00:00Z","last_updated_date":"2006-10-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-clarification-questions-6-october-2006_en.pdf"},
    {"id":"23498","name":"Committee for medicinal products for veterinary use -\n\nEMEA public bulletin 2008 on veterinary pharmacovigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T01:00:00Z","last_updated_date":"2009-02-24T01:00:00Z","reference_number":"EMEA/CVMP/PhVWP/253196/2008","document_url":"https://www.ema.europa.eu/en/documents/other/committee-medicinal-products-veterinary-use-emea-public-bulletin-2008-veterinary-pharmacovigilance_en.pdf"},
    {"id":"23528","name":"Guideline on good pharmacovigilance practices: Introductory cover note, last updated with revision 1 of module V on risk management system and subsequent revision 3 of the definitions annex and revision 1 of module XVI o...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T11:30:00Z","last_updated_date":"2014-04-25T11:30:00Z","reference_number":"EMA/213031/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guideline-good-pharmacovigilance-practices-introductory-cover-note-last-updated-revision-1-module-v-risk-management-system-and-subsequent-revision-3-definitions-annex-and-revision-1-module-xvi-o_en.pdf"},
    {"id":"23531","name":"Questions and Answers on the tailored scientific advice to support step-by-step development of new biosimilars","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T16:12:00Z","last_updated_date":"2024-06-10T12:30:00Z","reference_number":"EMA/263753/2024","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-tailored-scientific-advice-support-step-step-development-new-biosimilars_en.pdf"},
    {"id":"23536","name":"Article 58 Strategic Review – Summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-26T17:30:00Z","last_updated_date":"2016-04-26T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/article-58-strategic-review-summary_en.pdf"},
    {"id":"23550","name":"EMEA Information and Communication Technology Standards - Version 15.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-06-19T02:00:00Z","last_updated_date":"2008-06-19T02:00:00Z","reference_number":"EMEA/289231/2008","document_url":"https://www.ema.europa.eu/en/documents/other/emea-information-and-communication-technology-standards-version-150_en.pdf"},
    {"id":"23553","name":"Scientific advice and protocol assistance - Adopted during the CHMP meeting 22-25 September 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T14:00:00Z","last_updated_date":"2014-09-26T14:00:00Z","reference_number":"EMA/CHMP/SAWP/591118/2014","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-22-25-september-2014_en.pdf"},
    {"id":"23569","name":"Declaration of interests: Michael Lenihan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:00Z","last_updated_date":"2025-08-01T17:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-michael-lenihan_en.pdf"},
    {"id":"23576","name":"Questions and answers relating to tender EMA-2012-13-ICT: External service providers for software applications: provision of resources for online analytical processing systems","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-10T15:15:00Z","last_updated_date":"2013-02-19T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-tender-ema-2012-13-ict-external-service-providers-software-applications-provision-resources-online-analytical-processing-systems_en.pdf"},
    {"id":"23584","name":"Guidelines and concept papers adopted at the CHMP meeting of 20-23 January 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-01-30T11:30:00Z","last_updated_date":"2014-01-30T11:30:00Z","reference_number":"EMA/11080/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-chmp-meeting-20-23-january-2014_en.pdf"},
    {"id":"23606","name":"Overview of comments received on draft guideline on conduct of pharmacovigilance for medicines used by the paediatric population","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-06-27T02:00:00Z","last_updated_date":"2007-06-27T02:00:00Z","reference_number":"EMEA/CHMP/PhVWP/228720/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-conduct-pharmacovigilance-medicines-used-paediatric-population_en.pdf"},
    {"id":"23617","name":"Good manufacturing practice: An analysis of regulatory inspection findings in the centralised procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-01-18T01:00:00Z","last_updated_date":"2007-01-18T01:00:00Z","reference_number":"EMEA/INS/GMP/23022/2007","document_url":"https://www.ema.europa.eu/en/documents/other/good-manufacturing-practice-analysis-regulatory-inspection-findings-centralised-procedure_en.pdf"},
    {"id":"23638","name":"ENCePP - 10 years of collaboration to strengthen the monitoring of benefits and risks of medicines in Europe","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-24T01:00:00Z","last_updated_date":"2017-11-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/encepp-10-years-collaboration-strengthen-monitoring-benefits-and-risks-medicines-europe_en.pdf"},
    {"id":"23639","name":"Co-operation between the Pharmaceutical Inspection Co-operation Scheme and the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-02-11T01:00:00Z","last_updated_date":"2011-02-11T01:00:00Z","reference_number":"EMA/714147/2010","document_url":"https://www.ema.europa.eu/en/documents/other/co-operation-between-pharmaceutical-inspection-co-operation-scheme-and-european-medicines-agency_en.pdf"},
    {"id":"23646","name":"Timetable: Initial (full) marketing authorisation application assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-22T12:10:00Z","last_updated_date":"2026-03-27T17:13:00Z","reference_number":"EMA/119185/2015 Rev.15","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-initial-full-marketing-authorisation-application-assessment_en.xlsx"}    {"id":"23655","name":"World Health organization's (WHO) confirmation letter on the working arrangement to exchange non-public information on medical products between the European Commission's Directorate General for Health and Food Safety (DG...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T12:00:00Z","last_updated_date":"2015-09-22T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/world-health-organizations-who-confirmation-letter-working-arrangement-exchange-non-public-information-medical-products-between-european-commissions-directorate-general-health-and-food-safety-dg_en.pdf"},
    {"id":"23667","name":"Timetable: Post-authorisation safety study (PASS) protocols and final results","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-02T16:15:00Z","last_updated_date":"2025-09-23T15:29:29Z","reference_number":"EMA/404060/2015 Rev. 7","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-post-authorisation-safety-study-pass-protocols-final-results_en.xlsx"},
    {"id":"23684","name":"Introductory cover note to the list of European Union reference dates and frequency of submission of periodic safety update reports","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-01T14:45:00Z","last_updated_date":"2026-03-20T10:30:00Z","reference_number":"EMA/606369/2012 Rev.17","document_url":"https://www.ema.europa.eu/en/documents/other/introductory-cover-note-list-european-union-reference-dates-frequency-submission-periodic-safety-update-reports_en.pdf"},
    {"id":"23696","name":"Guidelines and concept papers adopted during the Committee for Medicinal Products for Human Use meeting 17-20 October 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-21T14:01:00Z","last_updated_date":"2011-10-21T14:01:00Z","reference_number":"EMA/827727/2011","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-committee-medicinal-products-human-use-meeting-17-20-october-2011_en.pdf"},
    {"id":"23706","name":"SMEs: a major source of innovation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-25T01:00:00Z","last_updated_date":"2013-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/smes-major-source-innovation_en.pdf"},
    {"id":"23707","name":"Declaration of interests: Olivier Simoen","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:19Z","last_updated_date":"2012-08-03T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-olivier-simoen_en.pdf"},
    {"id":"23726","name":"Withdrawal letter : Zubrin – oral suspension","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-10-03T02:00:00Z","last_updated_date":"2008-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-zubrin-oral-suspension_en.pdf"},
    {"id":"23733","name":"List of pharmaceutical dosage forms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2016-06-17T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-pharmaceutical-dosage-forms_en.xls"},
    {"id":"23758","name":"(Superseded) European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) data collection protocol","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-20T02:00:00Z","last_updated_date":"2013-04-18T11:15:00Z","reference_number":"EMA/85298/2012","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-european-surveillance-veterinary-antimicrobial-consumption-esvac-data-collection-protocol_en.pdf"},
    {"id":"23772","name":"Procedural announcements: Committee for Medicinal Products for Human Use meeting 17-20 October 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-24T13:36:00Z","last_updated_date":"2011-10-24T13:36:00Z","reference_number":"EMA/CHMP/832563/2011","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-announcements-committee-medicinal-products-human-use-meeting-17-20-october-2011_en.pdf"},
    {"id":"23785","name":"Overview of comments received on the draft recommendation on the evaluation of the benefit-risk balance of veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/CVMP/66531/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-recommendation-evaluation-benefit-risk-balance-veterinary-medicinal-products_en.pdf"},
    {"id":"23787","name":"Key milestones of EMA interactions with patients and consumers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T01:00:00Z","last_updated_date":"2017-08-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/key-milestones-ema-interactions-patients-and-consumers_en.pdf"},
    {"id":"23789","name":"Withdrawal letter: Draxxin","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-04T02:00:00Z","last_updated_date":"2012-07-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-draxxin_en.pdf"},
    {"id":"23824","name":"Guidance note for reimbursement of delegates entitled to the double daily allowance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-05T14:25:00Z","last_updated_date":"2014-02-05T14:25:00Z","reference_number":"EMA/160130/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-note-reimbursement-delegates-entitled-double-daily-allowance_en.pdf"},
    {"id":"23825","name":"Overview of comments received on revised ‘Guideline on user safety for pharmaceutical veterinary medicinal products’ (EMEA/CVMP/543/03-Rev.1-CONSULTATION)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/CVMP/SWP/662388/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-revised-guideline-user-safety-pharmaceutical-veterinary-medicinal-products-emeacvmp54303-rev1-consultation_en.pdf"},
    {"id":"23834","name":"Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man (CHMP/EWP/205/95 REV. 3), methodological considerations for using Progression-Free Survival (PFS) as primary endpoint in confirmatory ...","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/CHMP/EWP/27994/2008","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-1-guideline-evaluation-anticancer-medicinal-products-man-chmpewp20595-rev-3-methodological-considerations-using-progression-free-survival-pfs-primary-endpoint-confirmatory_en.pdf"},
    {"id":"23841","name":"Summary of the evaluation of the proposed paediatric investigation plan: (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-19T02:00:00Z","last_updated_date":"2015-10-19T02:00:00Z","reference_number":"EMA/628991/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-4r5r-1-4-4-33-dibutyl-7-dimethylamino-2345-tetrahydro-4-hydroxy-11-dioxido-1-benzothiepin-5-ylphenoxymethylphenylmethyl-4-aza-1_en.pdf"},
    {"id":"23858","name":"Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - Launch phase closure report","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-16T02:00:00Z","last_updated_date":"2015-10-16T02:00:00Z","reference_number":"EMA/576801/2015","document_url":"https://www.ema.europa.eu/en/documents/other/monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency-launch-phase-closure-report_en.pdf"},
    {"id":"23865","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting 14-17 January 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-25T15:56:00Z","last_updated_date":"2013-01-25T15:56:00Z","reference_number":"EMA/28121/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-14-17-january-2013_en.pdf"},
    {"id":"23877","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP module III – Pharmacovigilance inspections","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-13T17:00:00Z","last_updated_date":"2012-12-13T17:00:00Z","reference_number":"EMA/806339/2012","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-iii-pharmacovigilance-inspections_en.pdf"},
    {"id":"23907","name":"Marketing authorisation renewal application - ATMP: Initial 90-day assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T16:00:00Z","last_updated_date":"2023-10-18T18:30:00Z","reference_number":"EMA/825017/2015","document_url":"https://www.ema.europa.eu/en/documents/other/marketing-authorisation-renewal-application-atmp-initial-90-day-assessment_en.xlsx"},
    {"id":"23954","name":"Relevant sources for orphan disease prevalence data","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-24T19:00:48Z","last_updated_date":"2014-12-18T11:20:00Z","reference_number":"EMA/452415/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/relevant-sources-orphan-disease-prevalence-data_en.pdf"},
    {"id":"23972","name":"Declaration of interests: Ana Hidalgo-Simon","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2022-06-13T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-ana-hidalgo-simon_en.pdf"},
    {"id":"24011","name":"Overview of comments received on 'Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure' (EMA/CHMP/BWP/99698/2007)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-01T01:00:00Z","last_updated_date":"2010-12-01T01:00:00Z","reference_number":"EMA/CHMP/BWP/551725/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-procedural-advice-submission-variations-annual-update-human-influenza-inactivated-vaccines-applications-centralised-procedure-emachmpbwp996982007_en.pdf"},
    {"id":"24030","name":"List of participants - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Group (HCPWG) joint meeting: September 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-26T17:00:00Z","last_updated_date":"2012-11-26T17:00:00Z","reference_number":"EMA/604608/2012","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-group-hcpwg-joint-meeting-september-2012_en.pdf"},
    {"id":"24045","name":"CooperSurgical Inc ART Media - Procedural steps and scientific information after initial consultation (archive)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2025-07-24T10:34:00Z","reference_number":"Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/coopersurgical-inc-art-media-procedural-steps-scientific-information-after-initial-consultation-archive_en.pdf"},
    {"id":"24060","name":"Declaration of interests: Sandra Vanlievendael","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-20T12:04:00Z","last_updated_date":"2025-08-01T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-sandra-vanlievendael_en.pdf"},
    {"id":"24123","name":"Draft inventory of paediatric therapeutic needs: Paediatric oncology","type":"other","status":"Draft: consultation closed","consultation_date":"2014-10-07 - 2014-11-30","first_published_date":"2014-10-08T16:05:00Z","last_updated_date":"2014-10-08T16:05:00Z","reference_number":"EMA/PDCO/381728/2014","document_url":"https://www.ema.europa.eu/en/documents/other/draft-inventory-paediatric-therapeutic-needs-paediatric-oncology_en.pdf"},
    {"id":"24126","name":"Introduction to the EU telematics programme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/147558/2010","document_url":"https://www.ema.europa.eu/en/documents/other/introduction-eu-telematics-programme_en.pdf"},
    {"id":"24138","name":"Third Workshop on European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/830477/2010","document_url":"https://www.ema.europa.eu/en/documents/other/third-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"24149","name":"The European Medicines Agency's participation in Innovative Medicines Initiative (IMI) Research projects","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-09-23T02:09:21Z","last_updated_date":"2009-09-23T02:09:21Z","reference_number":"EMEA/585460/2009","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-participation-innovative-medicines-initiative-imi-research-projects_en.pdf"},
    {"id":"24239","name":"Questions and answers on the risk management plan (RMP) summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-06T13:25:00Z","last_updated_date":"2017-03-30T17:00:00Z","reference_number":"EMA/156738/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-risk-management-plan-rmp-summary_en.pdf"},
    {"id":"24252","name":"Reflection paper on antimicrobial resistance surveillance as post-marketing authorisation commitment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-10-21T02:00:00Z","last_updated_date":"2008-10-21T02:00:00Z","reference_number":"EMEA/CVMP/SAGAM/428938/2007","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-antimicrobial-resistance-surveillance-post-marketing-authorisation-commitment_en.pdf"},
    {"id":"24291","name":"Overview of comments received on paediatric addendum to CHMP guidance on clinical investigation of medicinal products in the treatment of lipid disorders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-06T17:00:00Z","last_updated_date":"2012-11-06T17:00:00Z","reference_number":"EMA/CHMP/638198/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-paediatric-addendum-chmp-guidance-clinical-investigation-medicinal-products-treatment-lipid-disorders_en.pdf"},
    {"id":"24312","name":"Communication on reporting of suspected adverse reactions occurring in the European Union by competent authorities in Member States to the World Health Organization","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-27T13:21:00Z","last_updated_date":"2013-09-27T13:21:00Z","reference_number":"EMA/573249/2013","document_url":"https://www.ema.europa.eu/en/documents/other/communication-reporting-suspected-adverse-reactions-occurring-european-union-competent-authorities-member-states-world-health-organization_en.pdf"},
    {"id":"24318","name":"Proposal for European Medicines Agency’s involvement in the 9th IMI Call “WEBAE - leveraging emerging technology for pharmacovigilance”","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T02:00:00Z","last_updated_date":"2013-09-25T02:00:00Z","reference_number":"EMA/564336/2013","document_url":"https://www.ema.europa.eu/en/documents/other/proposal-european-medicines-agencys-involvement-9th-imi-call-webae-leveraging-emerging-technology-pharmacovigilance_en.pdf"},
    {"id":"24398","name":"Mandate of the Management Board task force on the ‘Scientific qualifications of committee members’","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-03-05T00:09:21Z","last_updated_date":"2009-03-05T00:09:21Z","reference_number":"EMEA/MB/673201/2008Adopted","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-management-board-task-force-scientific-qualifications-committee-members_en.pdf"},
    {"id":"24445","name":"Mandate, objectives and rules of procedure for the CVMP Ad Hoc Group on Veterinary Novel Therapies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-16T15:00:02Z","last_updated_date":"2016-12-19T17:30:00Z","reference_number":"EMA/CVMP/ADVENT/630299/2014 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cvmp-ad-hoc-group-veterinary-novel-therapies_en.pdf"},
    {"id":"24447","name":"The new EudraVigilance system – Public communications plan for European Medicines Agency and National Competent Authorities in the European Economic Area: overview of the planned public communication milestones","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-07T13:00:00Z","last_updated_date":"2017-11-22T10:30:00Z","reference_number":"EMA/413091/2017","document_url":"https://www.ema.europa.eu/en/documents/other/new-eudravigilance-system-public-communications-plan-european-medicines-agency-and-national-competent-authorities-european-economic-area-overview-planned-public-communication-milestones_en.pdf"},
    {"id":"24498","name":"Opinions on safety variations / periodic safety update reports adopted at the CHMP meeting of 17-20 February 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-02-25T12:25:00Z","last_updated_date":"2014-02-25T12:25:00Z","reference_number":"EMA/54975/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-17-20-february-2014_en.pdf"},
    {"id":"24508","name":"Marketing authorisation holders invited to register EudraVigilance Data Analysis System (EVDAS) users - timeslots to register","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T17:30:00Z","last_updated_date":"2017-06-26T14:00:00Z","reference_number":"EMA/265057/2017","document_url":"https://www.ema.europa.eu/en/documents/other/marketing-authorisation-holders-invited-register-eudravigilance-data-analysis-system-evdas-users-timeslots-register_en.pdf"},
    {"id":"24513","name":"European Risk Management Strategy (ERMS) Facilitation Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-12-16T01:00:00Z","last_updated_date":"2005-12-16T01:00:00Z","reference_number":"EMEA/424988/2005","document_url":"https://www.ema.europa.eu/en/documents/other/european-risk-management-strategy-erms-facilitation-group_en.pdf"},
    {"id":"24531","name":"List of participants of the ninth stakeholder forum on the pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"EMA/605252/2015","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ninth-stakeholder-forum-pharmacovigilance-legislation_en.pdf"},
    {"id":"24587","name":"Withdrawal letter : Glivec","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-10-18T02:00:00Z","last_updated_date":"2006-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-glivec_en.pdf"},
    {"id":"24590","name":"Overview of comments received on 'Concept paper on extrapolation of efficacy and safety in medicine development'","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T15:47:00Z","last_updated_date":"2013-04-23T15:47:00Z","reference_number":"EMA/184035/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-concept-paper-extrapolation-efficacy-and-safety-medicine-development_en.pdf"},
    {"id":"24602","name":"Overview of comments received on Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T16:55:00Z","last_updated_date":"2014-02-21T16:55:00Z","reference_number":"EMA/INS/GCP/100058/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-use-interactive-response-technologies-interactive-voice-web-response-systems-clinical-trials_en.pdf"},
    {"id":"24631","name":"Abbreviations used in EMA scientific committees and Coordination Group for Mutual Recognition and Decentralised Procedures (CMD) documents, and in relation to EMA’s regulatory activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-05T13:59:00Z","last_updated_date":"2025-12-03T16:36:00Z","reference_number":"EMA/899164/2022 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/abbreviations-used-ema-scientific-committees-coordination-group-mutual-recognition-decentralised-procedures-cmd-documents-relation-emas-regulatory-activities_en.pdf"},
    {"id":"24648","name":"Eudravigilance registration user management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2017-10-23T16:15:00Z","reference_number":"EMA/404288/2016","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-registration-user-management_en.pdf"},
    {"id":"24688","name":"Overview of comments received on draft guideline on the development of new medicinal products for the treatment of ulcerative colitis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/468539/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-development-new-medicinal-products-treatment-ulcerative-colitis_en.pdf"},
    {"id":"24697","name":"Chapter 3: XEVPRM technical specifications, user guidance and practical examples of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-01T21:19:00Z","last_updated_date":"2012-03-05T12:00:00Z","reference_number":"EMA/721644/2011","document_url":"https://www.ema.europa.eu/en/documents/other/chapter-3-xevprm-technical-specifications-user-guidance-and-practical-examples-detailed-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-ema_en.pdf"},
    {"id":"24699","name":"Overview of patient involvement along the medicines lifecycle at European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-18T10:00:00Z","last_updated_date":"2015-03-18T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-patient-involvement-along-medicines-lifecycle-european-medicines-agency_en.pdf"},
    {"id":"24705","name":"Organisational matters - CHMP meeting 24-27 June 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-08T02:00:00Z","last_updated_date":"2013-07-09T19:30:00Z","reference_number":"EMA/CHMP/240802/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-24-27-june-2013_en.pdf"},
    {"id":"24712","name":"Overview of external comments received, and European Medicines Agency / Committee for Medicinal Products for Human Use feedback / action on each comment on guideline on the processing of renewals in the centralised proced...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-10-24T02:00:00Z","last_updated_date":"2005-10-24T02:00:00Z","reference_number":"EMEA/CHMP/2990/00 rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/overview-external-comments-received-and-european-medicines-agency-committee-medicinal-products-human-use-feedback-action-each-comment-guideline-processing-renewals-centralised-proced_en.pdf"},
    {"id":"24741","name":"Mandate, objectives and rules of procedure for the Inter-Committee Scientific Advisory Group (SAG) for Oncology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T16:50:00Z","last_updated_date":"2014-11-24T16:50:00Z","reference_number":"EMA/742599/2012","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-inter-committee-scientific-advisory-group-sag-oncology_en.pdf"},
    {"id":"24753","name":"Technical specifications for open invitation to tender - EMA/2012/03/HR for provision of services for 360 performance evaluation of EMA management\n\nstaff","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-24T09:50:00Z","last_updated_date":"2012-01-24T09:50:00Z","reference_number":"EMA/901316/2011","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-ema201203hr-provision-services-360-performance-evaluation-ema-management-staff_en.pdf"},
    {"id":"24770","name":"CTAG5: Clinical Trial Advisory Group on legal aspects - Membership overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag5-clinical-trial-advisory-group-legal-aspects-membership-overview_en.pdf"},
    {"id":"24771","name":"Paediatric Committee (PDCO) dates for 2008","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-08-27T02:00:00Z","last_updated_date":"2008-08-27T02:00:00Z","reference_number":"EMEA/PDCO/266711/2007-rev 3","document_url":"https://www.ema.europa.eu/en/documents/other/paediatric-committee-pdco-dates-2008_en.pdf"},
    {"id":"24773","name":"Joint meeting organised by EORTC, US NCI, EMA, and AACR on Innovation and Biomarkers in Cancer Drug Development, 3-4 December 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-28T02:00:00Z","last_updated_date":"2015-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/joint-meeting-organised-eortc-us-nci-ema-and-aacr-innovation-and-biomarkers-cancer-drug-development-3-4-december-2015_en.pdf"},
    {"id":"24778","name":"Overview of comments received on draft guideline on the development of medicinal products for the treatment of post-traumatic stress disorder (PTSD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/403001/2008 Corr*","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-development-medicinal-products-treatment-post-traumatic-stress-disorder-ptsd_en.pdf"},
    {"id":"24779","name":"Timetable: Post-authorisation measure (PAM) assessed by CAT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T12:40:00Z","last_updated_date":"2025-09-24T12:15:00Z","reference_number":"EMA/267768/2016 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-post-authorisation-measure-pam-assessed-cat_en.xlsx"},
    {"id":"24793","name":"Start of community reviews, CHMP meeting of 14-17 November 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-11-18T13:02:00Z","last_updated_date":"2011-11-18T13:02:00Z","reference_number":"EMA/891722/2011","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-14-17-november-2011_en.pdf"},
    {"id":"24816","name":"Questions and Answers relating to PQQ – EMEA-2008-39-IT-PM","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-05-09T02:00:00Z","last_updated_date":"2008-05-09T02:00:00Z","reference_number":"EMEA-2008-39-IT-PM","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-pqq-emea-2008-39-it-pm_en.pdf"},
    {"id":"24836","name":"Annex I: Catalogue of assets for donation - Donation of EMA assets no. EMA/2014/28/IS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-08-22T16:05:00Z","reference_number":"Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/annex-i-catalogue-assets-donation-donation-ema-assets-no-ema201428is_en.xls"},
    {"id":"24838","name":"Overview of comments received on draft reflection paper on pharmacogenomic samples, testing and data handling","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-04-02T02:00:00Z","last_updated_date":"2007-04-02T02:00:00Z","reference_number":"EMEA/CHMP/536201/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-reflection-paper-pharmacogenomic-samples-testing-and-data-handling_en.pdf"},
    {"id":"24849","name":"Overview of comments received on list of paediatric needs - Oncology I (cytotoxic therapy)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-01T02:00:00Z","last_updated_date":"2006-09-01T02:00:00Z","reference_number":"EMEA/384188/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-list-paediatric-needs-oncology-i-cytotoxic-therapy_en.pdf"},
    {"id":"24859","name":"Public summary of the evaluation of a proposed product-specific waiver: Human papillomavirus type 18 L1 protein / human papillomavirus type 16 L1 protein for prevention of infection by human papillomavirus","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/140074/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-human-papillomavirus-type-18-l1-protein-human-papillomavirus-type-16-l1-protein-prevention-infection-human-papillomavirus_en.pdf"},
    {"id":"24868","name":"Biologics Working Party Ad-hoc Influenza Working Group: European Union recommendations for the seasonal influenza vaccine composition for the season 2016/2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T12:30:00Z","last_updated_date":"2016-04-04T12:30:00Z","reference_number":"EMA/CHMP/BWP/165983/2016","document_url":"https://www.ema.europa.eu/en/documents/other/biologics-working-party-ad-hoc-influenza-working-group-european-union-recommendations-seasonal-influenza-vaccine-composition-season-20162017_en.pdf"},
    {"id":"24875","name":"Data quality control methodology for data submitted under Article 57(2) of Regulation (EC) No.726/2004","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T15:50:00Z","last_updated_date":"2018-04-10T17:00:00Z","reference_number":"EMA/227883/2014","document_url":"https://www.ema.europa.eu/en/documents/other/data-quality-control-methodology-data-submitted-under-article-572-regulation-ec-no7262004_en.pdf"},
    {"id":"24886","name":"Annex 5 Draft Service Level Agreement - Procurement Procedure EMA/2012/09/IF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"EMA/687454/2011","document_url":"https://www.ema.europa.eu/en/documents/other/annex-5-draft-service-level-agreement-procurement-procedure-ema201209if_en.pdf"},
    {"id":"24908","name":"Overview of comments received on 'guideline on the\n\nevaluation of drugs for the treatment of gastro-oesophageal\n\nreflux disease'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-14T01:00:00Z","last_updated_date":"2011-03-14T01:00:00Z","reference_number":"EMA/131448/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-evaluation-drugs-treatment-gastro-oesophageal-reflux-disease_en.pdf"},
    {"id":"24935","name":"Declaration of interests: Thorsten Olski","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T02:00:00Z","last_updated_date":"2019-10-25T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-thorsten-olski_en.pdf"},
    {"id":"24942","name":"European Commission - Canada mutual recognition agreement (MRA): Sectoral annex on good manufacturing practices - Common statement regarding the scope of the MRA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-03-17T01:00:00Z","last_updated_date":"2008-03-17T01:00:00Z","reference_number":"EMEA/INS/MRA/130275/2008","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-canada-mutual-recognition-agreement-mra-sectoral-annex-good-manufacturing-practices-common-statement-regarding-scope-mra_en.pdf"},
    {"id":"24966","name":"European Medicines Agency and Member States joint implementation checklist","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-20T01:31:00Z","last_updated_date":"2012-06-25T19:04:00Z","reference_number":"EMA/778475/2010","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-and-member-states-joint-implementation-checklist_en.pdf"},
    {"id":"24991","name":"Qsiva : EPAR - Scientific conclusions and grounds for refusal of the marketing authorisation for Qsiva","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-13T02:00:00Z","last_updated_date":"2013-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/qsiva-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-qsiva_sv.pdf"}},
    {"id":"24998","name":"Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for Sofosbuvir Gilead available for compassionate use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-03T17:45:00Z","last_updated_date":"2020-10-26T11:22:00Z","reference_number":"EMA/697129/2013","document_url":"https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distribution-and-patients-targeted-and-conditions-safety-monitoring-addressed-member-states-sofosbuvir-gilead-available-compassionate-use_en.pdf"},
    {"id":"25023","name":"Summary on compassionate use for Ledipasvir/Sofosbuvir","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-02T13:00:00Z","last_updated_date":"2020-10-26T10:06:00Z","reference_number":"EMA/181960/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-ledipasvirsofosbuvir_en.pdf"},
    {"id":"25042","name":"Dates of forthcoming SEED early dialogue meetings and deadlines for briefing book submissions in 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-03T13:04:00Z","last_updated_date":"2014-01-03T13:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/dates-forthcoming-seed-early-dialogue-meetings-and-deadlines-briefing-book-submissions-2014_en.pdf"},
    {"id":"25045","name":"EudraVigilance Report 2012 – Veterinary medicinal products - Revision 1","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/MB/732279/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-report-2012-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"25056","name":"An open letter to the Editor of the British Medical Journal","type":"other","status":"unknown","consultation_date":"","first_published_date":"1998-10-02T02:00:00Z","last_updated_date":"1998-10-02T02:00:00Z","reference_number":"EMEA-D-MH-34849-1998","document_url":"https://www.ema.europa.eu/en/documents/other/open-letter-editor-british-medical-journal_en.pdf"},
    {"id":"25078","name":"Working party on Herbal Medicinal Products: Final proposal for a core data for Peppermint leaf","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-12-17T01:00:00Z","last_updated_date":"2003-12-17T01:00:00Z","reference_number":"EMEA/HMPWP/1418/02","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-peppermint-leaf_en.pdf"},
    {"id":"25106","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Potassium citrate monohydrated / potassium hydrogen carbonate for treatment of cystinuria","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-25T12:30:00Z","last_updated_date":"2014-11-25T12:30:00Z","reference_number":"EMA/466435/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-potassium-citrate-monohydrated-potassium-hydrogen-carbonate-treatment-cystinuria_en.pdf"},
    {"id":"25126","name":"Overview of comments received on guideline on plasma-derived medicinal products EMA/CHMP/BWP/706271/2010 (formerly CPMP/BWP/269/95 rev. 3)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T12:01:00Z","last_updated_date":"2011-10-28T12:01:00Z","reference_number":"EMA/360578/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-plasma-derived-medicinal-products-emachmpbwp7062712010-formerly-cpmpbwp26995-rev-3_en.pdf"},
    {"id":"25144","name":"N-Acetyl-L-Cysteine, L-Alanine, L-Alanyl-L-Glutamine, L-Arginine, Glycine, Glycyl-L-Tyrosine, L-Histidine, L-Isoleucine, L-Leucine, L-Lysine acetate, LMethionine, L-Phenylalanine, L-Proline, L-Serine, Taurine, L-Threonin...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-22T18:15:00Z","last_updated_date":"2015-04-22T18:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/n-acetyl-l-cysteine-l-alanine-l-alanyl-l-glutamine-l-arginine-glycine-glycyl-l-tyrosine-l-histidine-l-isoleucine-l-leucine-l-lysine-acetate-lmethionine-l-phenylalanine-l-proline-l-serine-taurine-l_en.pdf"},
    {"id":"25172","name":"Highlights from the 6th EMA Industry platform meeting on the operation of EU pharmacovigilance legislation – 18 December 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"EMA/858235/2015","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-6th-ema-industry-platform-meeting-operation-eu-pharmacovigilance-legislation-18-december-2015_en.pdf"},
    {"id":"25252","name":"European Medicines Agency 2011 priorities for drug safety research: Insulin / insulin analogues and cancer","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-07-08T02:00:00Z","last_updated_date":"2010-07-08T02:00:00Z","reference_number":"EMA/425284/2010","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-2011-priorities-drug-safety-research-insulin-insulin-analogues-and-cancer_en.pdf"},
    {"id":"25295","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP module VII – Periodic safety update report","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:18:21Z","last_updated_date":"2012-06-25T19:18:21Z","reference_number":"EMA/428915/2012","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-vii-periodic-safety-update-report_en.pdf"},
    {"id":"25302","name":"List of participants - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting: Informat...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-04T13:00:00Z","last_updated_date":"2015-06-04T13:00:00Z","reference_number":"EMA/10472/2015","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf-0"},
    {"id":"25312","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP module I – Pharmacovigilance systems and their quality systems","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:18:16Z","last_updated_date":"2012-06-25T19:18:16Z","reference_number":"EMA/428811/2012","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-i-pharmacovigilance-systems-and-their-quality-systems_en.pdf"},
    {"id":"25318","name":"Opinions on safety variations adopted at the CHMP meeting of 14-17 November 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-11-18T13:02:00Z","last_updated_date":"2011-11-18T13:02:00Z","reference_number":"EMA/CHMP/877161/2011","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-14-17-november-2011_en.pdf"},
    {"id":"25334","name":"Pre-Qualification Questionnaire (PQQ) for a restricted tender procedure organised by European Medicines Agency (EMEA) supply and installation of audio-visual, video-conference, interpretation, ancillary equipment and con...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:21Z","last_updated_date":"2008-11-25T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency-emea-supply-and-installation-audio-visual-video-conference-interpretation-ancillary-equipment-and_en.doc"},
    {"id":"25336","name":"Letter of appointment of Guido Rasi","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-appointment-guido-rasi_en.pdf"},
    {"id":"25352","name":"Report of the expert meeting on paediatric development of fixed-dose combinations (FDCs) for the treatment of human immunodeficiency virus (HIV) infection","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-02T19:10:00Z","last_updated_date":"2016-02-02T19:10:00Z","reference_number":"EMA/766040/2015","document_url":"https://www.ema.europa.eu/en/documents/other/report-expert-meeting-paediatric-development-fixed-dose-combinations-fdcs-treatment-human-immunodeficiency-virus-hiv-infection_en.pdf"},
    {"id":"25366","name":"Launch of the European Network of Paediatric Research at the European Medicines Agency: List of registered participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-05-06T17:13:02Z","last_updated_date":"2011-05-06T17:13:02Z","reference_number":"EMA/353439/2011","document_url":"https://www.ema.europa.eu/en/documents/other/launch-european-network-paediatric-research-european-medicines-agency-list-registered-participants_en.pdf"},
    {"id":"25378","name":"Opinions on consultation procedures on ancillary medicinal substances in medical devices adopted at the CHMP meeting of 16-19 January 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-20T13:00:00Z","last_updated_date":"2012-01-20T13:00:00Z","reference_number":"EMA/CHMP/54867/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-consultation-procedures-ancillary-medicinal-substances-medical-devices-adopted-chmp-meeting-16-19-january-2012_en.pdf"},
    {"id":"25386","name":"Declaration of interests: Constantinos Ziogas","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T16:25:00Z","last_updated_date":"2025-08-01T12:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-constantinos-ziogas_en.pdf"},
    {"id":"25388","name":"Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-02T11:55:00Z","last_updated_date":"2012-10-02T11:55:00Z","reference_number":"EMA/623947/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-format-and-content-protocol-non-interventional-post-authorisation-safety-studies_en.pdf"},
    {"id":"25395","name":"Amending Budget 01-2011 for changes to entry grades for eleven posts and subsequent amendment to the establishment plan of the European Medicines Agency for five posts","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/MB/373047/2011","document_url":"https://www.ema.europa.eu/en/documents/other/amending-budget-01-2011-changes-entry-grades-eleven-posts-and-subsequent-amendment-establishment-plan-european-medicines-agency-five-posts_en.pdf"},
    {"id":"25420","name":"Inventory of paediatric therapeutic needs: gastroenterology","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-10-28T17:20:00Z","last_updated_date":"2015-10-28T17:20:00Z","reference_number":"EMA/PDCO/552359/2015","document_url":"https://www.ema.europa.eu/en/documents/other/inventory-paediatric-therapeutic-needs-gastroenterology_en.pdf"},
    {"id":"25425","name":"Withdrawal letter: Pioglitazone ratiopharm","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T13:00:00Z","last_updated_date":"2012-04-30T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-pioglitazone-ratiopharm_en.pdf"},
    {"id":"25453","name":"Working party on Herbal Medicinal Products: Draft proposal for a core-data for Nettle root","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2003-07-09T02:00:00Z","last_updated_date":"2003-07-09T02:00:00Z","reference_number":"EMEA/HMPWP/342/03","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-draft-proposal-core-data-nettle-root_en.pdf"}    {"id":"25468","name":"Withdrawal letter: Tysabri","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-tysabri_en.pdf"},
    {"id":"25475","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Cholera vaccine, live attenuated, oral (strain CVD 103-HgR) for prevention of disease caused by V. cholerae serogroup O1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T12:15:00Z","last_updated_date":"2014-12-11T12:15:00Z","reference_number":"EMA/507469/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-cholera-vaccine-live-attenuated-oral-strain-cvd-103-hgr-prevention-disease-caused-v-cholerae-serogroup-o1_en.pdf"},
    {"id":"25476","name":"European Medicines Agency policy on access to EudraVigilance data for medicinal products for human use - Revision 3","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2016-12-19T17:30:00Z","last_updated_date":"2016-12-19T17:30:00Z","reference_number":"EMA/759287/2009 Revision 3","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-policy-access-eudravigilance-data-medicinal-products-human-use-revision-3_en.pdf"},
    {"id":"25480","name":"Withdrawal letter: Effentora","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-effentora_en.pdf"},
    {"id":"25481","name":"Update on a pilot project to collaborate on international good-manufacturing-practice-inspection activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-01-08T01:00:00Z","last_updated_date":"2009-01-08T01:00:00Z","reference_number":"EMEA/INS/GMP/430438/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/update-pilot-project-collaborate-international-good-manufacturing-practice-inspection-activities_en.pdf"},
    {"id":"25510","name":"Overview of comments received on draft guideline on clinical medicinal products intended for the treatment of neuropathic pain","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"EMEA/CHMP/EWP/21568/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-medicinal-products-intended-treatment-neuropathic-pain_en.pdf"},
    {"id":"25524","name":"Declaration of interests: Corinne de Vries","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-08T02:00:00Z","last_updated_date":"2024-07-26T17:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-corinne-de-vries_en.pdf"},
    {"id":"25546","name":"Organisational matters - CHMP meeting 13-16 Febury 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T12:25:00Z","last_updated_date":"2012-02-22T12:25:00Z","reference_number":"EMA/CHMP/86234/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-13-16-febury-2012_en.pdf"},
    {"id":"25585","name":"Overview of comments received on list of paediatric needs – Cardiovascular products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-10-10T02:00:00Z","last_updated_date":"2006-10-10T02:00:00Z","reference_number":"EMEA/404310/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-list-paediatric-needs-cardiovascular-products_en.pdf"},
    {"id":"25601","name":"Biologics Working Party Ad-hoc Influenza Working Group: European Union recommendations for the seasonal-influenza-vaccine composition for the season 2014 / 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T13:00:04Z","last_updated_date":"2014-03-21T13:00:04Z","reference_number":"EMA/CHMP/BWP/109993/2014","document_url":"https://www.ema.europa.eu/en/documents/other/biologics-working-party-ad-hoc-influenza-working-group-european-union-recommendations-seasonal-influenza-vaccine-composition-season-2014-2015_en.pdf"},
    {"id":"25603","name":"Using Referential and Organisation data in the electronic application form (eAF)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T10:45:00Z","last_updated_date":"2018-07-05T13:45:00Z","reference_number":"EMA/819524/2017 Version 2","document_url":"https://www.ema.europa.eu/en/documents/other/using-referential-and-organisation-data-electronic-application-form-eaf_en.pdf"},
    {"id":"25624","name":"Declaration of interests: Evdokia Korakianiti","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T12:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-evdokia-korakianiti_en.pdf"},
    {"id":"25630","name":"Cover note - Interaction between the European Medicines Agency and healthcare professionals: Framework and criteria","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T11:30:00Z","last_updated_date":"2011-12-20T11:30:00Z","reference_number":"EMA/903626/2011","document_url":"https://www.ema.europa.eu/en/documents/other/cover-note-interaction-between-european-medicines-agency-and-healthcare-professionals-framework-and-criteria_en.pdf"},
    {"id":"25658","name":"Timetable: Type II variation and worksharing application monthly assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T14:00:00Z","last_updated_date":"2026-06-17T16:30:00Z","reference_number":"EMA/577385/2016 Rev.13","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-type-ii-variation-worksharing-application-monthly-assessment_en.xlsx"},
    {"id":"25685","name":"The European Medicines Agency transparency policy draft for public consultation","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-06-19T02:00:00Z","last_updated_date":"2009-06-19T02:00:00Z","reference_number":"EMEA/232037/2009 - rev*","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-transparency-policy-draft-public-consultation_en.pdf"},
    {"id":"25722","name":"Declaration of interests: Edit Weidlich","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2020-06-30T10:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-edit-weidlich_en.pdf"},
    {"id":"25725","name":"Comments on JECFA/Codex Alimentarius Statistical methods for the estimation of MRLs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-12-09T00:09:21Z","last_updated_date":"2005-12-09T00:09:21Z","reference_number":"EMEA/CVMP/SWP/367651/2005","document_url":"https://www.ema.europa.eu/en/documents/other/comments-jecfacodex-alimentarius-statistical-methods-estimation-mrls_en.pdf"},
    {"id":"25727","name":"European Union BFC conversion v.2.8","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-27T01:00:00Z","last_updated_date":"2018-03-09T16:30:00Z","reference_number":"V. 2.8","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-bfc-conversion-v28_en.zip"},
    {"id":"25736","name":"Committee for medicinal products for veterinary use -\n\nEMEA public bulletin 2006 on veterinary pharmacovigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-02-19T01:00:00Z","last_updated_date":"2007-02-19T01:00:00Z","reference_number":"EMEA/CVMP/PhVWP/73213/2006","document_url":"https://www.ema.europa.eu/en/documents/other/committee-medicinal-products-veterinary-use-emea-public-bulletin-2006-veterinary-pharmacovigilance_en.pdf"},
    {"id":"25773","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: German Neonatal Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817619/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-german-neonatal-network_en.pdf"},
    {"id":"25774","name":"European Union E2B (R3) code lists","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-27T01:00:00Z","last_updated_date":"2022-06-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-e2b-r3-code-lists_en.zip"},
    {"id":"25789","name":"Information security when using the EudraVigilance system: Best practice guide for management of authorised access to EudraVigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-04-19T12:00:00Z","last_updated_date":"2017-04-19T12:00:00Z","reference_number":"EMA/216598/2017","document_url":"https://www.ema.europa.eu/en/documents/other/information-security-when-using-eudravigilance-system-best-practice-guide-management-authorised-access-eudravigilance_en.pdf"},
    {"id":"25802","name":"List of participants of the EMA Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting with all eligible organisations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-all-eligible-organisations_en.pdf"},
    {"id":"25826","name":"Health Canada and European Medicines Agency: update on activities in 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-23T11:16:00Z","last_updated_date":"2014-12-23T11:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/health-canada-and-european-medicines-agency-update-activities-2014_en.pdf"},
    {"id":"25877","name":"Financial compensation for Member States’ participation in the linguistic checking of product related information: Fixed flat hourly cost for 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T11:30:00Z","last_updated_date":"2011-12-20T11:30:00Z","reference_number":"EMA/MB/880875/2011","document_url":"https://www.ema.europa.eu/en/documents/other/financial-compensation-member-states-participation-linguistic-checking-product-related-information-fixed-flat-hourly-cost-2012_en.pdf"},
    {"id":"25888","name":"Adaptive pathways workshop briefing book: readers’ guidance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T16:00:00Z","last_updated_date":"2016-11-18T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/adaptive-pathways-workshop-briefing-book-readers-guidance_en.pdf"},
    {"id":"25902","name":"Working party on Herbal Medicinal Products: points to consider on the biopharmaceutical characterisation of Herbal Medicinal Products","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2003-07-09T02:00:00Z","last_updated_date":"2003-07-09T02:00:00Z","reference_number":"EMEA/HMPWP/344/03","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-points-consider-biopharmaceutical-characterisation-herbal-medicinal-products_en.pdf"},
    {"id":"25932","name":"Cover note on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) substance controlled vocabulary following the quality control exercise","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-05T11:30:00Z","last_updated_date":"2018-04-12T02:00:00Z","reference_number":"EMA/93253/2014","document_url":"https://www.ema.europa.eu/en/documents/other/cover-note-extended-eudravigilance-medicinal-product-dictionary-xevmpd-substance-controlled-vocabulary-following-quality-control-exercise_en.pdf"},
    {"id":"25959","name":"Withdrawal letter : NutropinAq","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T01:00:00Z","last_updated_date":"2008-01-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-nutropinaq_en.pdf"},
    {"id":"25987","name":"Pre-Qualification Questionnaire (PQQ) for a restricted tender procedure organised by European Medicines Agency (EMEA) electronic databases (Lots 1-11) EMEA/2008/60/DM&P","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency-emea-electronic-databases-lots-1-11-emea200860dmp_en.doc"},
    {"id":"26007","name":"Call for expressions of interest, from terminology maintenance organisations, software vendors, service providers and developers of medicinal product dictionaries/databases, for membership in a Task Force for the impleme...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-20T12:00:00Z","last_updated_date":"2015-02-20T12:00:00Z","reference_number":"EMA/60018/2015","document_url":"https://www.ema.europa.eu/en/documents/other/call-expressions-interest-terminology-maintenance-organisations-software-vendors-service-providers-and-developers-medicinal-product-dictionariesdatabases-membership-task-force-impleme_en.pdf"},
    {"id":"26069","name":"The role of members representing patients' and healthcare professionals' organisations on EMA scientific committees","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T10:33:00Z","last_updated_date":"2024-11-27T11:45:00Z","reference_number":"EMA/351699/2018 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/role-members-representing-patients-healthcare-professionals-organisations-ema-scientific-committees_en.pdf"},
    {"id":"26070","name":"Draft template for the qualified person’s declaration concerning good-manufacturing-practice compliance of the active substance used as starting material and verification of its supply chain 'the QP declaration template'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-20T16:30:00Z","last_updated_date":"2014-08-20T16:30:00Z","reference_number":"EMA/337252/2014","document_url":"https://www.ema.europa.eu/en/documents/other/draft-template-qualified-persons-declaration-concerning-good-manufacturing-practice-compliance-active-substance-used-starting-material-and-verification-its-supply-chain-qp-declaration-template_en.pdf"},
    {"id":"26075","name":"Tandemact: Product Information as approved by the CHMP on 20 october 2011, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/tandemact-product-information-approved-chmp-20-october-2011-pending-endorsement-european-commission_en.pdf"},
    {"id":"26078","name":"Recording by marketing authorisation holders of information on suspected adverse reactions held in EudraVigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T13:10:00Z","last_updated_date":"2018-07-19T13:10:00Z","reference_number":"EMA/396720/2018","document_url":"https://www.ema.europa.eu/en/documents/other/recording-marketing-authorisation-holders-information-suspected-adverse-reactions-held-eudravigilance_en.pdf"},
    {"id":"26081","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP module XV – Safety communication","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T18:00:00Z","last_updated_date":"2013-01-24T18:00:00Z","reference_number":"EMA/35763/2013","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-xv-safety-communication_en.pdf"},
    {"id":"26087","name":"EMA response to a letter from a group of scientists clarifying the concept of adaptive pathways","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-16T18:30:00Z","last_updated_date":"2016-06-16T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-response-letter-group-scientists-clarifying-concept-adaptive-pathways_en.pdf"},
    {"id":"26112","name":"Mandate for process-analytical-technology team","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-12-08T01:00:00Z","last_updated_date":"2006-12-08T01:00:00Z","reference_number":"EMEA/48327/2006","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-process-analytical-technology-team_en.pdf"},
    {"id":"26149","name":"CTAG3: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on rules of engagement - Draft advice version 5.0 – With amendments following comments on 1.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-advice-european-medicines-agency-clinical-trial-advisory-group-rules-engagement-draft-advice-version-50-amendments-following-comments-10_en.pdf"},
    {"id":"26158","name":"Pre-Qualification Questionnaire (PQQ) for a restricted tender procedure organised by European Medicines Agency (EMEA) EMEA/2008/90/ISERV Maintenance of Audiovisual (AV) equipment and provision of on-site AV technical sup...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:21Z","last_updated_date":"2008-11-25T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency-emea-emea200890iserv-maintenance-audiovisual-av-equipment-and-provision-site-av-technical-sup_en.doc"},
    {"id":"26163","name":"Financial compensation and workload estimation of the revised EMA organisation of translations of product related informationIII","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T17:00:00Z","last_updated_date":"2017-12-15T17:00:00Z","reference_number":"EMA/MB/731638/2017","document_url":"https://www.ema.europa.eu/en/documents/other/financial-compensation-and-workload-estimation-revised-ema-organisation-translations-product-related-informationiii_en.pdf"},
    {"id":"26170","name":"Overview of comments on ‘Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals’ (EMEA/CVMP/IWP/439467/2007-CONSULTATION)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/614258/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-reflection-paper-demonstration-possible-impact-maternally-derived-antibodies-vaccine-efficacy-young-animals-emeacvmpiwp4394672007-consultation_en.pdf"},
    {"id":"26191","name":"Report on the Expert Group Meeting of Paediatric Heart Failure, London 29 November 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-19T02:00:00Z","last_updated_date":"2011-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/report-expert-group-meeting-paediatric-heart-failure-london-29-november-2010_en.pdf"},
    {"id":"26194","name":"HMPC and MLWP meeting dates in 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-01-22T01:00:00Z","last_updated_date":"2010-01-22T01:00:00Z","reference_number":"EMA/HMPC/6203/2010","document_url":"https://www.ema.europa.eu/en/documents/other/hmpc-and-mlwp-meeting-dates-2010_en.pdf"},
    {"id":"26225","name":"Press release: EMEA sets out its road map to 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-04-15T02:00:00Z","last_updated_date":"2004-04-15T02:00:00Z","reference_number":"EMEA/D/9362/04/Final ","document_url":"https://www.ema.europa.eu/en/documents/other/press-release-emea-sets-out-its-road-map-2010_en.pdf"},
    {"id":"26228","name":"Introduction to ISO Identification of Medicinal Products, SPOR programme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-01T11:05:00Z","last_updated_date":"2016-12-01T11:05:00Z","reference_number":"EMA/732656/2015","document_url":"https://www.ema.europa.eu/en/documents/other/introduction-iso-identification-medicinal-products-spor-programme_en.pdf"},
    {"id":"26246","name":"Outcome of public consultation on 'Questions and answers on implementation of risk-based prevention of cross contamination in production 'and ‘Guideline on setting health based exposure limits for use in risk identificat...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-08-02T16:00:00Z","last_updated_date":"2018-08-02T16:00:00Z","reference_number":"EMA/288493/2018","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-public-consultation-questions-and-answers-implementation-risk-based-prevention-cross-contamination-production-and-guideline-setting-health-based-exposure-limits-use-risk-identificat_en.pdf"},
    {"id":"26253","name":"Public summary of the evaluation of the proposed paediatric investigation plan: (S)-Pyrrolidine-2-carboxylic acid compound with (2S,3R,4R,5S,6R)-2-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydrox...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T12:45:00Z","last_updated_date":"2014-10-21T12:45:00Z","reference_number":"EMA/511927/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-s-pyrrolidine-2-carboxylic-acid-compound-2s3r4r5s6r-2-3-23-dihydrobenzob14dioxin-6-ylmethyl-4-ethylphenyl-6-hydrox_en.pdf"},
    {"id":"26269","name":"Management Board meeting dates 2017-2018","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2016-06-21T18:00:00Z","last_updated_date":"2016-06-21T18:00:00Z","reference_number":"EMA/MB/245471/2016","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2017-2018_en.pdf"},
    {"id":"26277","name":"Policy 26: Records management and archives policy","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2025-04-15T12:05:00Z","reference_number":"EMA/16533/2024","document_url":"https://www.ema.europa.eu/en/documents/other/policy-26-records-management-archives-policy_en.pdf"},
    {"id":"26288","name":"EMA’s individual stakeholder database: patients, consumers, healthcare professionals and academia - Frequently asked questions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T16:00:00Z","last_updated_date":"2023-07-17T16:54:00Z","reference_number":"EMA/441045/2016 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/emas-individual-stakeholder-database-patients-consumers-healthcare-professionals-academia-frequently-asked-questions_en.pdf"},
    {"id":"26297","name":"High level business consultancy EMA/2013/23/FI - Technical specifications - Annex VII project reference form","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications-annex-vii-project-reference-form_en.doc"},
    {"id":"26313","name":"Overview of comments received on draft guideline on the investigation of medicinal products in the term and preterm neonates (EMEA/267484/2007) - First version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/522641/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-investigation-medicinal-products-term-and-preterm-neonates-emea2674842007-first-version_en.pdf"},
    {"id":"26321","name":"Quality Working Party questions and answers on API mix","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-21T12:25:00Z","last_updated_date":"2016-04-21T12:25:00Z","reference_number":"EMA/CHMP/CVMP/QWP/152772/2016","document_url":"https://www.ema.europa.eu/en/documents/other/quality-working-party-questions-and-answers-api-mix_en.pdf"},
    {"id":"26326","name":"Inventory of paediatric medicines - Cardiovascular therapeutic area","type":"other","status":"Adopted","consultation_date":"2012-08-30 - 2012-10-30","first_published_date":"2013-04-25T15:10:00Z","last_updated_date":"2013-04-25T15:10:00Z","reference_number":"EMA/PDCO/246339/2013","document_url":"https://www.ema.europa.eu/en/documents/other/inventory-paediatric-medicines-cardiovascular-therapeutic-area_en.pdf"},
    {"id":"26351","name":"Outcome of Management Board written procedures during the period from 17 May 2011 to 14 September 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/MB/714970/2011","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-management-board-written-procedures-during-period-17-may-2011-14-september-2011_en.pdf"},
    {"id":"26378","name":"Public summary of the evaluation of a proposed product-specific\n\nwaiver: Amlodipine (besylate) / valsartan for treatment of hypertension","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-17T12:30:00Z","last_updated_date":"2015-02-17T12:30:00Z","reference_number":"EMA/728343/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-amlodipine-besylate-valsartan-treatment-hypertension_en.pdf"},
    {"id":"26399","name":"Questions and answers on the review of Invirase (saquinavir)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-21T02:00:00Z","last_updated_date":"2010-10-21T02:00:00Z","reference_number":"EMEA/H/C/113/A-20/0088","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-review-invirase-saquinavir_en.pdf"},
    {"id":"26406","name":"Defined daily doses for animals (DDDvet) and defined course doses for animals (DCDvet) - European Surveillance of Veterinary Antimicrobial Consumption (ESVAC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T16:00:00Z","last_updated_date":"2016-04-28T16:00:00Z","reference_number":"EMA/223665/2016","document_url":"https://www.ema.europa.eu/en/documents/other/defined-daily-doses-animals-dddvet-and-defined-course-doses-animals-dcdvet-european-surveillance-veterinary-antimicrobial-consumption-esvac_en.xls"},
    {"id":"26407","name":"Decision on amending budget No 1-2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-06T17:00:00Z","last_updated_date":"2017-10-06T17:00:00Z","reference_number":"EMA/MB/163175/2017","document_url":"https://www.ema.europa.eu/en/documents/other/decision-amending-budget-no-1-2017_en.pdf"},
    {"id":"26413","name":"EU Medicines Agencies Network Strategy to 2020 : Comments received from public consultation - List of stakeholders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/464136/2015","document_url":"https://www.ema.europa.eu/en/documents/other/eu-medicines-agencies-network-strategy-2020-comments-received-public-consultation-list-stakeholders_en.pdf"},
    {"id":"26456","name":"On-boarding of users to Substance, Product, Organisation and Referentials (SPOR) data services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-07-06T12:00:00Z","last_updated_date":"2025-11-05T15:00:00Z","reference_number":"EMA/307181/2017 Version 6","document_url":"https://www.ema.europa.eu/en/documents/other/boarding-users-substance-product-organisation-referentials-spor-data-services_en.pdf"},
    {"id":"26496","name":"Letter of support for reading speed and functional reading independence (FRI) index in geographic atrophy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-28T18:25:00Z","last_updated_date":"2016-01-28T18:25:00Z","reference_number":"EMA/14494/2016","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-reading-speed-and-functional-reading-independence-fri-index-geographic-atrophy_en.pdf"},
    {"id":"26502","name":"Annex II: Expression of interest form","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-29T12:45:00Z","last_updated_date":"2016-07-29T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-ii-expression-interest-form_en.doc"},
    {"id":"26530","name":"Overview of comments received on draft guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-30T02:00:00Z","last_updated_date":"2008-07-30T02:00:00Z","reference_number":"EMEA/402021/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-parkinsons-disease_en.pdf"},
    {"id":"26541","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 10-13 December 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-19T13:00:00Z","last_updated_date":"2012-12-19T13:00:00Z","reference_number":"EMA/CHMP/732295/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-10-13-december-2012_en.pdf"},
    {"id":"26565","name":"Composition of the Advisory Committee on Procurements and Contracts (ACPC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/576425/2012","document_url":"https://www.ema.europa.eu/en/documents/other/composition-advisory-committee-procurements-and-contracts-acpc_en.pdf"},
    {"id":"26576","name":"Overview of comments received on 'guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia' - Revision 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-23T11:45:00Z","last_updated_date":"2013-01-23T11:45:00Z","reference_number":"EMA/CHMP/57220/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-investigation-medicinal-products-including-depot-preparations-treatment-schizophrenia-revision-1_en.pdf"},
    {"id":"26588","name":"Declaration of interests: Vincenzo Salvatore","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:07Z","last_updated_date":"2012-02-29T10:07:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-vincenzo-salvatore_en.pdf"},
    {"id":"26591","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Daclatasvir (dihydrochloride) / asunaprevir / (1ar,12bs)-8-Cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-(((1R,5S)-3-methyl-3,8-diazabicycl...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T12:15:00Z","last_updated_date":"2014-10-21T12:15:00Z","reference_number":"EMA/PDCO/300434/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-daclatasvir-dihydrochloride-asunaprevir-1ar12bs-8-cyclohexyl-n-dimethylsulfamoyl-11-methoxy-1a-1r5s-3-methyl-38-diazabicycl_en.pdf"},
    {"id":"26612","name":"Innovative drug development approaches \n\nFinal report from the EMEA/CHMP-think-tank group on innovative drug development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-03-22T01:00:00Z","last_updated_date":"2007-03-22T01:00:00Z","reference_number":"EMEA/127318/2007","document_url":"https://www.ema.europa.eu/en/documents/other/innovative-drug-development-approaches-final-report-emeachmp-think-tank-group-innovative-drug-development_en.pdf"},
    {"id":"26622","name":"Reinstatement of the Accounting Officer of the European Medicines Agency","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/MB/729369/2011","document_url":"https://www.ema.europa.eu/en/documents/other/reinstatement-accounting-officer-european-medicines-agency_en.pdf"},
    {"id":"26645","name":"Joint audit programme for EEA GMP inspectorates: Procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-19T02:00:00Z","last_updated_date":"2021-08-02T16:26:00Z","reference_number":"EMA/694531/2017 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/joint-audit-programme-eea-gmp-inspectorates-procedure_en.pdf"},
    {"id":"26668","name":"Overview of comments received on guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-29T16:00:00Z","last_updated_date":"2013-07-29T16:00:00Z","reference_number":"EMA/CVMP/IWP/441123/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-requirements-combined-vaccines-and-associations-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"26712","name":"High level business consultancy EMA/2013/23/FI - Technical specifications - Annex X framework contract execution template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications-annex-x-framework-contract-execution-template_en.pdf"},
    {"id":"26716","name":"Withdrawal letter: Zolvix","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T01:00:00Z","last_updated_date":"2013-01-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-zolvix_en.pdf"},
    {"id":"26727","name":"Pandemrix: Package leaflet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-15T01:00:00Z","last_updated_date":"2010-02-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pandemrix-package-leaflet_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/pandemrix-package-leaflet_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/pandemrix-package-leaflet_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/pandemrix-package-leaflet_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/pandemrix-package-leaflet_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/pandemrix-package-leaflet_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/pandemrix-package-leaflet_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/pandemrix-package-leaflet_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/pandemrix-package-leaflet_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/pandemrix-package-leaflet_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/pandemrix-package-leaflet_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/pandemrix-package-leaflet_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/pandemrix-package-leaflet_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/pandemrix-package-leaflet_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/pandemrix-package-leaflet_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/pandemrix-package-leaflet_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/pandemrix-package-leaflet_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/pandemrix-package-leaflet_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/pandemrix-package-leaflet_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/pandemrix-package-leaflet_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/pandemrix-package-leaflet_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/pandemrix-package-leaflet_sv.pdf"}},
    {"id":"26769","name":"EudraVigilance Access Policy - Confidentiality undertaking for marketing authorisation holders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-20T02:00:00Z","last_updated_date":"2016-06-20T02:00:00Z","reference_number":"EMA/337295/2016","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-access-policy-confidentiality-undertaking-marketing-authorisation-holders_en.pdf"},
    {"id":"26832","name":"Revised implementing rules to the Fee Regulation as of 1 April 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/MB/112878/2013","document_url":"https://www.ema.europa.eu/en/documents/other/revised-implementing-rules-fee-regulation-1-april-2013_en.pdf"},
    {"id":"26839","name":"List of participants of the European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf-1"},
    {"id":"26856","name":"Speaker profiles - Best expertise vs conflicts of interests: Striking the right balance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-06T11:00:00Z","last_updated_date":"2013-09-06T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speaker-profiles-best-expertise-vs-conflicts-interests-striking-right-balance_en.pdf"},
    {"id":"26859","name":"Jean-Marc Ferran (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/jean-marc-ferran-cv_en.pdf"},
    {"id":"26953","name":"Mutual recognition agreements between the European Union and the respective parties Australia, Canada, New Zealand and Switzerland - Guide to the mutual recognition agreements in operation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-05-05T02:00:00Z","last_updated_date":"2003-05-05T02:00:00Z","reference_number":"EMEA/MRA/22/03 final","document_url":"https://www.ema.europa.eu/en/documents/other/mutual-recognition-agreements-between-european-union-and-respective-parties-australia-canada-new-zealand-and-switzerland-guide-mutual-recognition-agreements-operation_en.pdf"},
    {"id":"26972","name":"European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) web based sales and and animal population data collection protocol","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-19T11:15:00Z","last_updated_date":"2023-10-05T17:45:00Z","reference_number":"EMA/210691/2015 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/other/european-surveillance-veterinary-antimicrobial-consumption-esvac-web-based-sales-and-and-animal-population-data-collection-protocol_en.pdf"},
    {"id":"26977","name":"Extension of confidentiality arrangement: Letter from Ministry of Health, Labour and Welfare and Pharmaceuticals and Medical Devices Agency to European Commission and European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-14T16:27:15Z","last_updated_date":"2012-02-14T16:27:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/extension-confidentiality-arrangement-letter-ministry-health-labour-welfare-pharmaceuticals-medical-devices-agency-european-commission-european-medicines-agency_en.pdf"},
    {"id":"26990","name":"Download EPS - Species pictograms - Goat","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-goat_en.zip"},
    {"id":"27017","name":"Outcome of written procedures finalised during the period from 22 February 2014 to 12 May 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-19T14:30:00Z","last_updated_date":"2014-06-19T14:30:00Z","reference_number":"EMA/MB/190422/2014 Noted","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-22-february-2014-12-may-2014_en.pdf"},
    {"id":"27023","name":"Attachment 1 for change of scientific opinion holder","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-05T17:20:00Z","last_updated_date":"2014-08-05T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/attachment-1-change-scientific-opinion-holder_en.doc"},
    {"id":"27029","name":"PRAC signal recommendations requesting an update of the product information – September 2012 to July 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-11-28T12:30:00Z","last_updated_date":"2014-01-21T17:29:00Z","reference_number":"EMA/PRAC/720475/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/prac-signal-recommendations-requesting-update-product-information-september-2012-july-2013_en.pdf"},
    {"id":"27067","name":"Appointment as Accounting Officer of the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/MB/354158/2010","document_url":"https://www.ema.europa.eu/en/documents/other/appointment-accounting-officer-european-medicines-agency_en.pdf"},
    {"id":"27069","name":"Overview of comments received on draft guideline 'clinical trials in small populations'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-07-27T02:00:00Z","last_updated_date":"2006-07-27T02:00:00Z","reference_number":"EMEA/CHMP/EWP/281490/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-trials-small-populations_en.pdf"},
    {"id":"27114","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures - Revised implementing rules to the Fee Regulation as of 1 August 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-29T18:00:00Z","last_updated_date":"2015-07-29T18:00:00Z","reference_number":"EMA/MB/290812/2015","document_url":"https://www.ema.europa.eu/en/documents/other/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures-revised-implementing-rules-fee-regulation-1-august-2015_en.pdf"},
    {"id":"27123","name":"Start of community reviews adopted during the CHMP meeting of 13-16  February 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T13:00:00Z","last_updated_date":"2012-02-17T13:00:00Z","reference_number":"EMA/108019/2012","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-adopted-during-chmp-meeting-13-16-february-2012_en.pdf"},
    {"id":"27154","name":"List of participants - Workshop on biosimilars","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"EMA/681299/2013","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-workshop-biosimilars_en.pdf"},
    {"id":"27156","name":"European Medicines Agency first response to European Ombudsman regarding pre-submission activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-09-20T16:26:00Z","last_updated_date":"2017-09-20T16:26:00Z","reference_number":"EMA/566402/2017","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-first-response-european-ombudsman-regarding-pre-submission-activities_en.pdf"},
    {"id":"27185","name":"Overview of comments received on draft guideline on potency labelling for insulin analogue containing products with particular reference to the use of international units or units","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-08-07T02:00:00Z","last_updated_date":"2006-08-07T02:00:00Z","reference_number":"EMEA/274509/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-potency-labelling-insulin-analogue-containing-products-particular-reference-use-international-units-or-units_en.pdf"},
    {"id":"27229","name":"European Medicines Agency policy on changes in scope of paediatric-investigation-plan decisions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-27T19:05:00Z","last_updated_date":"2023-02-22T13:25:00Z","reference_number":"EMA/472551/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-policy-changes-scope-paediatric-investigation-plan-decisions_en.pdf"},
    {"id":"27235","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted during the CHMP meeting 17-20 September 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-25T17:51:00Z","last_updated_date":"2012-09-25T17:51:00Z","reference_number":"EMA/CHMP/539768/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-during-chmp-meeting-17-20-september-2012_en.pdf"},
    {"id":"27239","name":"Introduction of a 'regulatory contact point' for marketing authorisation holders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2018-07-26T11:00:00Z","reference_number":"EMA/398931/2016","document_url":"https://www.ema.europa.eu/en/documents/other/introduction-regulatory-contact-point-marketing-authorisation-holders_en.pdf"},
    {"id":"27292","name":"Overview of comments received on draft guideline efficacy and target animal safety data requirements for veterinary medicinal products intended for minor uses or minor species","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-07-20T02:00:00Z","last_updated_date":"2006-07-20T02:00:00Z","reference_number":"EMEA/CVMP/EWP/43872/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-efficacy-and-target-animal-safety-data-requirements-veterinary-medicinal-products-intended-minor-uses-or-minor-species_en.pdf"}    {"id":"27322","name":"Abbreviation of names of days on calendarised blisters","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-04T13:30:00Z","last_updated_date":"2025-11-04T12:20:00Z","reference_number":"EMA/188814/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/abbreviation-names-days-calendarised-blisters_en.pdf"},
    {"id":"27329","name":"Overview of comments received on draft guideline on fixed combinations - Revision 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"EMEA/CHMP/EWP/533066/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-fixed-combinations-revision-1_en.pdf"},
    {"id":"27338","name":"Abstract - Expert workshop on process validation for the manufacture of biotechnology-derived active substances","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T17:00:01Z","last_updated_date":"2013-01-21T17:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/abstract-expert-workshop-process-validation-manufacture-biotechnology-derived-active-substances_en.pdf"},
    {"id":"27362","name":"Rafal Swierzewski (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/rafal-swierzewski-cv_en.pdf"},
    {"id":"27399","name":"Opinions on safety variations adopted during the July 2012 CHMP meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-25T14:10:00Z","last_updated_date":"2012-07-25T14:10:00Z","reference_number":"EMA/CHMP/410524/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-during-july-2012-chmp-meeting_en.pdf"},
    {"id":"27433","name":"EMEA 2010 Priorities for Drug Safety Research: Long-term effects in children and in young adults of methylphenidate in the treatment of attention deficit hyperactivity disorder (ADHD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-08-04T02:00:00Z","last_updated_date":"2009-08-04T02:00:00Z","reference_number":"EMEA/493726/2009","document_url":"https://www.ema.europa.eu/en/documents/other/emea-2010-priorities-drug-safety-research-long-term-effects-children-and-young-adults-methylphenidate-treatment-attention-deficit-hyperactivity-disorder-adhd_en.pdf"},
    {"id":"27449","name":"Outcome of written procedures during the period 22 February 2018 to 21 May 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-06-11T17:00:00Z","last_updated_date":"2018-06-11T17:00:00Z","reference_number":"EMA/MB/173925/2018","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-during-period-22-february-2018-21-may-2018_en.pdf"},
    {"id":"27463","name":"Decision of the European Agency for the Evaluation of Medicinal Products of 1 June 1999 concerning the terms and conditions for internal investigations into the prevention of fraud, corruption and any illegal activity de...","type":"other","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/1500/99/EN","document_url":"https://www.ema.europa.eu/en/documents/other/decision-european-agency-evaluation-medicinal-products-1-june-1999-concerning-terms-and-conditions-internal-investigations-prevention-fraud-corruption-and-any-illegal-activity-de_en.pdf"},
    {"id":"27467","name":"CTAG5: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on legal aspects - Draft advice with comments and amendments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag5-advice-european-medicines-agency-clinical-trial-advisory-group-legal-aspects-draft-advice-comments-and-amendments_en.pdf"},
    {"id":"27489","name":"Questions and answers relating to open tender EMA/2011/48/HR for provision of training courses for European Medicines Agency staff (lot 1-6)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-13T09:36:00Z","last_updated_date":"2012-02-20T16:57:00Z","reference_number":"EMA/994147/2011","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-tender-ema201148hr-provision-training-courses-european-medicines-agency-staff-lot-1-6_en.pdf"},
    {"id":"27495","name":"Overview of comments received on 'guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells - First version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-16T02:00:00Z","last_updated_date":"2012-07-16T02:00:00Z","reference_number":"EMA/CAT/GTWP/155212/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-quality-non-clinical-and-clinical-aspects-medicinal-products-containing-genetically-modified-cells-first-version_en.pdf"},
    {"id":"27499","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 19-22 May 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/124023/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-19-22-may-2014_en.pdf"},
    {"id":"27500","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: Steen solution","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-08T14:00:00Z","last_updated_date":"2012-08-08T14:00:00Z","reference_number":"EMEA/CHMP/329441/2005","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-steen-solution_en.pdf"},
    {"id":"27509","name":"Amendments to be included in the relevant sections of the summary of product characteristics of Nimesulide containing medicinal products (systemic formulations)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-09-21T02:09:21Z","last_updated_date":"2007-09-21T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/amendments-be-included-relevant-sections-summary-product-characteristics-nimesulide-containing-medicinal-products-systemic-formulations_en.pdf"},
    {"id":"27510","name":"Overview of comments received on the draft guideline on the development of medicinal products for the treatment of smoking (EMEA/CHMP/EWP/369963/05)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-11-11T01:00:00Z","last_updated_date":"2010-03-25T01:00:00Z","reference_number":"EMEA/432157/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-development-medicinal-products-treatment-smoking-emeachmpewp36996305_en.pdf"},
    {"id":"27521","name":"Draft reflection paper on the necessity of initiatives to stimulate the conduct of clinical studies with herbal medicinal products in the paediatric population","type":"other","status":"Draft: consultation closed","consultation_date":"2011-01-18 - 2011-04-15","first_published_date":"2011-01-19T01:31:00Z","last_updated_date":"2011-01-19T01:31:00Z","reference_number":"EMA/HMPC/833398/2009","document_url":"https://www.ema.europa.eu/en/documents/other/draft-reflection-paper-necessity-initiatives-stimulate-conduct-clinical-studies-herbal-medicinal-products-paediatric-population_en.pdf"},
    {"id":"27552","name":"Outcome of written procedures finalised during the period from  20 February 2016 to 11 May 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-21T18:00:00Z","last_updated_date":"2016-06-21T18:00:00Z","reference_number":"EMA/MB/241599/2016","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-20-february-2016-11-may-2016_en.pdf"},
    {"id":"27556","name":"Incident management plan for medicines for veterinary use","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2004-02-11T01:00:00Z","last_updated_date":"2022-11-18T12:41:00Z","reference_number":"EMEA/711053/2010 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/incident-management-plan-medicines-veterinary-use_en.pdf"},
    {"id":"27609","name":"Request for a joint ECDC, EFSA and EMA scientific opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food producing animals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-01T16:30:00Z","last_updated_date":"2016-12-01T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-joint-ecdc-efsa-and-ema-scientific-opinion-list-outcome-indicators-regards-surveillance-antimicrobial-resistance-and-antimicrobial-consumption-humans-and-food-producing-animals_en.pdf"},
    {"id":"27616","name":"Questions and answers relating to call for expressions of interest for drug safety studies - EMA/2012/08/CN","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T13:45:00Z","last_updated_date":"2012-05-29T15:29:00Z","reference_number":"EMA/290247/2012","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-call-expressions-interest-drug-safety-studies-ema201208cn_en.pdf"},
    {"id":"27628","name":"Programme - Focus groups: a model for a fruitful interaction between the Committee for Advanced Therapies and its stakeholders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-11T18:00:00Z","last_updated_date":"2012-01-11T18:00:00Z","reference_number":"EMA/CAT/27660/2012","document_url":"https://www.ema.europa.eu/en/documents/other/programme-focus-groups-model-fruitful-interaction-between-committee-advanced-therapies-and-its-stakeholders_en.pdf"},
    {"id":"27634","name":"Opinions on annual reassessments, 5-year renewals - Adopted at the CHMP meeting of 12-15 December 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-01-04T14:15:12Z","last_updated_date":"2012-01-04T14:15:12Z","reference_number":"EMA/CHMP/941887/2011","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-reassessments-5-year-renewals-adopted-chmp-meeting-12-15-december-2011_en.pdf"},
    {"id":"27643","name":"Information Technology Directors Group - Terms of reference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-08-23T14:55:00Z","last_updated_date":"2013-12-12T10:40:00Z","reference_number":"EMA/246934/2013","document_url":"https://www.ema.europa.eu/en/documents/other/information-technology-directors-group-terms-reference_en.pdf"},
    {"id":"27647","name":"Outcome of written procedures during the period 13 September 2017 to 20 November 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T17:00:00Z","last_updated_date":"2017-12-15T17:00:00Z","reference_number":"EMA/MB/771195/2017","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-during-period-13-september-2017-20-november-2017_en.pdf"},
    {"id":"27667","name":"Highlights from the 5th EMA Industry platform meeting on the operation of EU pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"EMA/609257/2015","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-5th-ema-industry-platform-meeting-operation-eu-pharmacovigilance-legislation_en.pdf"},
    {"id":"27670","name":"Financial compensation for Member States’ participation in the linguistic checking of product related information","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/MB/742965/2012","document_url":"https://www.ema.europa.eu/en/documents/other/financial-compensation-member-states-participation-linguistic-checking-product-related-information_en.pdf-0"},
    {"id":"27674","name":"Supply and maintenance of plants and containers EMA/2013/12/IS –  Pre-qualification questionnaire for a restricted tender procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/supply-and-maintenance-plants-and-containers-ema201312is-pre-qualification-questionnaire-restricted-tender-procedure_en.doc"},
    {"id":"27712","name":"Declaration of interests: Paola Samassa","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T17:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-paola-samassa_en.pdf"},
    {"id":"27734","name":"Overview of Staff Regulation implementing rules signed by the MB Chair during the period from 13 February 2015 to 2 October 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/MB/737283/2015","document_url":"https://www.ema.europa.eu/en/documents/other/overview-staff-regulation-implementing-rules-signed-mb-chair-during-period-13-february-2015-2-october-2015_en.pdf"},
    {"id":"27736","name":"Frank W. Rockhold (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/frank-w-rockhold-cv_en.pdf"},
    {"id":"27799","name":"European database of suspected adverse drug reaction reports’ website (www.adrreports.eu): release notes v.1.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T18:30:00Z","last_updated_date":"2017-12-19T18:30:00Z","reference_number":"EMA/833629/2017","document_url":"https://www.ema.europa.eu/en/documents/other/european-database-suspected-adverse-drug-reaction-reports-website-wwwadrreportseu-release-notes-v10_en.pdf"},
    {"id":"27824","name":"Understanding the terminology used in pharmacogenetics","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-07-29T02:09:21Z","last_updated_date":"2004-07-29T02:09:21Z","reference_number":"EMEA/3842/04/Final","document_url":"https://www.ema.europa.eu/en/documents/other/understanding-terminology-used-pharmacogenetics_en.pdf"},
    {"id":"27825","name":"Policy on transparency and the handling of potential conflicts of interests of members of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and working groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-24T18:48:00Z","last_updated_date":"2016-03-14T17:00:00Z","reference_number":"EMA/421449/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/policy-transparency-and-handling-potential-conflicts-interests-members-european-network-paediatric-research-european-medicines-agency-enpr-ema-coordinating-group-and-working-groups_en.pdf"},
    {"id":"27833","name":"Communication by the European Medicines Agency on supply shortages of medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T00:00:00Z","last_updated_date":"2015-10-29T12:30:00Z","reference_number":"EMA/531390/2012","document_url":"https://www.ema.europa.eu/en/documents/other/communication-european-medicines-agency-supply-shortages-medicinal-products_en.pdf"},
    {"id":"27837","name":"List of participants - Third stakeholders forum on the implementation of the new pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"EMA/822577/2011","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-third-stakeholders-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"27857","name":"Overview of comments received on the draft public statement on the use of herbal medicinal products containing thujone","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-20T13:00:00Z","last_updated_date":"2012-06-29T14:12:00Z","reference_number":"EMA/HMPC/85696/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-public-statement-use-herbal-medicinal-products-containing-thujone_en.pdf"},
    {"id":"27876","name":"Type IB variations requiring linguistic review","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-21T02:00:00Z","last_updated_date":"2011-07-08T02:00:00Z","reference_number":"EMA/791081/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/type-ib-variations-requiring-linguistic-review_en.pdf"},
    {"id":"27888","name":"Overview of comments received on draft guideline on epidemiological data on blood transmissible infections","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-12T02:00:00Z","last_updated_date":"2010-10-12T02:00:00Z","reference_number":"EMA/CHMP/BWP/711072/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-epidemiological-data-blood-transmissible-infections_en.pdf"},
    {"id":"27916","name":"Overview of comments received on draft guideline on clinical evaluation of medicinal products used in weight control - weight control in children","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/402888/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-evaluation-medicinal-products-used-weight-control-weight-control-children_en.pdf"},
    {"id":"27930","name":"Overview of comments received on 'Guideline on the declaration of the quantitative composition / potency labelling of biological medicinal products that contain modified proteins as active substance’","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T17:55:00Z","last_updated_date":"2014-03-21T17:55:00Z","reference_number":"EMA/CHMP/BWP/692937/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-declaration-quantitative-composition-potency-labelling-biological-medicinal-products-contain-modified-proteins-active-substance_en.pdf"},
    {"id":"27931","name":"Annex D Draft Framework Services Contract Lots 1 5","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-01T02:00:00Z","last_updated_date":"2008-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-d-draft-framework-services-contract-lots-1-5_en.pdf"},
    {"id":"27939","name":"Participants list - European Medicines Agency-EuropaBio information day","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/participants-list-european-medicines-agency-europabio-information-day_en.pdf"},
    {"id":"27944","name":"Adopted terms of reference (ToR) of the Telematics Change Management Board (CMB) and its key user groups","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2017-10-30T10:39:00Z","last_updated_date":"2017-10-30T10:39:00Z","reference_number":"EMA/620721/2017","document_url":"https://www.ema.europa.eu/en/documents/other/adopted-terms-reference-tor-telematics-change-management-board-cmb-and-its-key-user-groups_en.pdf"},
    {"id":"27948","name":"Annex VI - Draft framework service contract for outsourcing - EMA/2012/21/IS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-12T09:50:00Z","last_updated_date":"2012-11-12T09:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-vi-draft-framework-service-contract-outsourcing-ema201221is_en.pdf"},
    {"id":"27952","name":"CTAG2: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on clinical-trial-data formats – Initial text","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag2-advice-european-medicines-agency-clinical-trial-advisory-group-clinical-trial-data-formats-initial-text_en.pdf"},
    {"id":"27957","name":"Declaration of research interests (addendum) - David Coghill","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-david-coghill_en.pdf"},
    {"id":"27993","name":"CTAG2: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on clinical-trial-data formats - Final advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag2-advice-european-medicines-agency-clinical-trial-advisory-group-clinical-trial-data-formats-final-advice_en.pdf"},
    {"id":"28038","name":"Start of community reviews - CHMP meeting of 21-24 October 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T15:00:00Z","last_updated_date":"2013-10-25T15:00:00Z","reference_number":"EMA/647670/2013","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-21-24-october-2013_en.pdf"},
    {"id":"28068","name":"Principles for ensuring the confidentiality of data supplied to the European Surveillance of Veterinary Antimicrobial Agent Consumption (ESVAC) project","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-24T01:00:00Z","last_updated_date":"2016-08-10T18:50:00Z","reference_number":"EMA/327935/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/principles-ensuring-confidentiality-data-supplied-european-surveillance-veterinary-antimicrobial-agent-consumption-esvac-project_en.pdf"},
    {"id":"28089","name":"Declaration of interests: Achilleas Voutsas","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T11:23:38Z","last_updated_date":"2016-09-08T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-achilleas-voutsas_en.pdf"},
    {"id":"28094","name":"Diplomatic notes exchanged on completion of the preparatory work 28 April 2004: Japan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-04-28T02:00:00Z","last_updated_date":"2004-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/diplomatic-notes-exchanged-completion-preparatory-work-28-april-2004-japan_en.pdf"},
    {"id":"28096","name":"Pathogen specific database: Covernote","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-covernote_en.pdf"},
    {"id":"28100","name":"Opinions on safety variations adopted at the CHMP meeting 27-30 May 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T13:00:00Z","last_updated_date":"2013-06-07T13:00:00Z","reference_number":"EMA/CHMP/184573/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-27-30-may-2013_en.pdf"},
    {"id":"28113","name":"Organisational matters, CHMP meeting 12-15 December 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-16T16:15:00Z","last_updated_date":"2011-12-16T16:15:00Z","reference_number":"EMA/CHMP/941889/2011","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-12-15-december-2011_en.pdf"},
    {"id":"28119","name":"European Medicines Agency 2011 priorities for drug safety research: Gadolinium-containing contrast agents and nephrogenic systemic fibrosis: long-term consequences of retention in human skin and bone","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-07-08T02:00:00Z","last_updated_date":"2010-07-26T02:00:00Z","reference_number":"EMA/425304/2010","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-2011-priorities-drug-safety-research-gadolinium-containing-contrast-agents-and-nephrogenic-systemic-fibrosis-long-term-consequences-retention-human-skin-and-bone_en.pdf"},
    {"id":"28125","name":"Declaration of interests: Marco Cavaleri","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T13:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-marco-cavaleri_en.pdf"},
    {"id":"28170","name":"Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - Start-up plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-30T14:00:00Z","last_updated_date":"2015-06-30T14:00:00Z","reference_number":"EMA/402154/2015","document_url":"https://www.ema.europa.eu/en/documents/other/monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency-start-plan_en.pdf"},
    {"id":"28179","name":"PRAC work plan 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-04-04T16:24:00Z","last_updated_date":"2017-04-04T16:24:00Z","reference_number":"EMA/PRAC/213230/2017","document_url":"https://www.ema.europa.eu/en/documents/other/prac-work-plan-2017_en.pdf"},
    {"id":"28189","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Grazoprevir for the treatment of chronic hepatitis C","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/724299/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-grazoprevir-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"28198","name":"Start of community reviews - CHMP meeting of 12-15 December 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-16T13:00:00Z","last_updated_date":"2011-12-16T13:00:00Z","reference_number":"EMA/968891/2011","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-12-15-december-2011_en.pdf"},
    {"id":"28213","name":"Invitation for expressions of interest - European Medicines Agency workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T16:40:00Z","last_updated_date":"2013-06-20T16:40:00Z","reference_number":"EMA/346872/2013","document_url":"https://www.ema.europa.eu/en/documents/other/invitation-expressions-interest-european-medicines-agency-workshop-clinical-investigation-new-medicines-treatment-multiple-sclerosis_en.pdf"},
    {"id":"28241","name":"Overview of comments received on the guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus (CPMP/EWP/1080/00 Rev. 1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-31T15:35:00Z","last_updated_date":"2012-07-31T15:35:00Z","reference_number":"EMA/444348/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-diabetes-mellitus-cpmpewp108000-rev-1_en.pdf"},
    {"id":"28299","name":"Task Force for the implementation of International Standards on Identification of Medicinal Products in the EU (i.e. EU IDMP/SPOR Task Force)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-09-20T13:39:00Z","last_updated_date":"2016-09-20T13:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/task-force-implementation-international-standards-identification-medicinal-products-eu-ie-eu-idmpspor-task-force_en.pdf"},
    {"id":"28308","name":"Workshop on medicines in bees - Break-out session briefing document","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-medicines-bees-break-out-session-briefing-document_en.pdf"},
    {"id":"28319","name":"Summary of the evaluation of the proposed paediatric investigation plan: Ertugliflozin for treatment of type-2 diabetes mellitus","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/663985/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-ertugliflozin-treatment-type-2-diabetes-mellitus_en.pdf"},
    {"id":"28325","name":"Medicines regulators to work together internationally to find innovative solutions to facilitate evaluation of and access to potential new medicines to counter Ebola outbreaks","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-04T16:25:00Z","last_updated_date":"2014-09-04T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicines-regulators-work-together-internationally-find-innovative-solutions-facilitate-evaluation-and-access-potential-new-medicines-counter-ebola-outbreaks_en.pdf"},
    {"id":"28356","name":"Telematics Enterprise Architecture Board: terms of reference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-17T11:00:00Z","last_updated_date":"2016-11-18T17:50:00Z","reference_number":"EMA/246932/2013","document_url":"https://www.ema.europa.eu/en/documents/other/telematics-enterprise-architecture-board-terms-reference_en.pdf"},
    {"id":"28358","name":"Highlights of the European Medicines Agency-Industry Stakeholders Platform second meeting on paediatric medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T13:33:00Z","last_updated_date":"2016-06-28T13:33:00Z","reference_number":"EMA/272465/2016","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-european-medicines-agency-industry-stakeholders-platform-second-meeting-paediatric-medicines_en.pdf"},
    {"id":"28363","name":"Details of the German and Italian national registries","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"EMA/674603/2017","document_url":"https://www.ema.europa.eu/en/documents/other/details-german-and-italian-national-registries_en.pdf"},
    {"id":"28400","name":"Assessment of the paediatric needs - Immunology","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-09-01T02:00:00Z","last_updated_date":"2006-09-01T02:00:00Z","reference_number":"EMEA/381922/2006","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-immunology_en.pdf"},
    {"id":"28401","name":"Renewal of confidentiality arrangement: Main letter from Ministry of Health, Labour and Welfare and Pharmaceuticals and Medical Devices Agency to European Commission and European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-07T14:00:00Z","last_updated_date":"2013-03-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/renewal-confidentiality-arrangement-main-letter-ministry-health-labour-welfare-pharmaceuticals-medical-devices-agency-european-commission-european-medicines-agency_en.pdf"},
    {"id":"28429","name":"Invitation - Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) workshop on advanced-therapy medicinal products: How to bring cell-based medicinal products...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-19T02:00:00Z","last_updated_date":"2014-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/invitation-committee-advanced-therapies-cat-and-german-society-transfusion-medicine-and-immunohaematology-dgti-workshop-advanced-therapy-medicinal-products-how-bring-cell-based-medicinal-products_en.pdf"},
    {"id":"28439","name":"Overview of comments received on 'Reflection paper on quality, non-clinical and clinical issues related to the development of recombinant adeno-associated viral vectors'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-07-08T02:00:00Z","last_updated_date":"2010-07-08T02:00:00Z","reference_number":"EMA/CHMP/GTWP/629733/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-quality-non-clinical-and-clinical-issues-related-development-recombinant-adeno-associated-viral-vectors_en.pdf"},
    {"id":"28444","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Italian Neonatal Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-05-17T02:00:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/153645/2011","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-italian-neonatal-network_en.pdf"},
    {"id":"28462","name":"Declaration of interests: Agneta Brandt","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-05T15:00:00Z","last_updated_date":"2017-08-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-agneta-brandt_en.pdf"},
    {"id":"28483","name":"Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-15T15:36:00Z","last_updated_date":"2017-05-15T15:36:00Z","reference_number":"EMA/180341/2017","document_url":"https://www.ema.europa.eu/en/documents/other/patient-registry-initiative-strategy-and-mandate-cross-committee-task-force_en.pdf"},
    {"id":"28490","name":"PCWP (2006-2016) - The original PCWP members describe the highlights and challenges of the last 10 years","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-21T01:00:00Z","last_updated_date":"2016-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pcwp-2006-2016-original-pcwp-members-describe-highlights-and-challenges-last-10-years_en.pdf"},
    {"id":"28497","name":"Guidelines and concept papers adopted during the CHMP meeting 16-19 January 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-23T17:35:00Z","last_updated_date":"2012-01-23T17:35:00Z","reference_number":"EMA/CHMP/8908/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-16-19-january-2012_en.pdf"},
    {"id":"28500","name":"EU regulatory network reflection paper on the availability of authorised medicinal products for human and veterinary use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-08-29T14:00:00Z","last_updated_date":"2018-08-29T14:00:00Z","reference_number":"EMA/565780/2018","document_url":"https://www.ema.europa.eu/en/documents/other/eu-regulatory-network-reflection-paper-availability-authorised-medicinal-products-human-and-veterinary-use_en.pdf"},
    {"id":"28501","name":"Ad hoc working party on Herbal Medicinal Products:  Final comments for revision of the notice to applicants volume 2B part II: concerning chemical, pharmaceutical and biological documentation for vegetable medicinal prod...","type":"other","status":"unknown","consultation_date":"","first_published_date":"1999-01-28T01:00:00Z","last_updated_date":"1999-01-28T01:00:00Z","reference_number":"EMEA/HMPWP/8/99","document_url":"https://www.ema.europa.eu/en/documents/other/ad-hoc-working-party-herbal-medicinal-products-final-comments-revision-notice-applicants-volume-2b-part-ii-concerning-chemical-pharmaceutical-and-biological-documentation-vegetable-medicinal-prod_en.pdf"},
    {"id":"28503","name":"EMEA 2010 Priorities for Drug Safety Research: Long-term adverse skeletal effects of bisphosphonates","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-08-04T02:00:00Z","last_updated_date":"2009-08-04T02:00:00Z","reference_number":"EMEA/493711/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/emea-2010-priorities-drug-safety-research-long-term-adverse-skeletal-effects-bisphosphonates_en.pdf"},
    {"id":"28511","name":"Recommendations from the Joint EMA/HMA Steering Group on veterinary vaccine availability to CVMP based on the outcome of the Focus Group meeting with invited stakeholders on field efficacy trials in the context of an EU ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T13:30:00Z","last_updated_date":"2017-11-16T13:30:00Z","reference_number":"EMA/548726/2017","document_url":"https://www.ema.europa.eu/en/documents/other/recommendations-joint-emahma-steering-group-veterinary-vaccine-availability-cvmp-based-outcome-focus-group-meeting-invited-stakeholders-field-efficacy-trials-context-eu_en.pdf"},
    {"id":"28537","name":"When patients and consumers join forces","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-21T01:00:00Z","last_updated_date":"2016-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/when-patients-and-consumers-join-forces_en.pdf"},
    {"id":"28541","name":"Online strategy and interface design EMA/2012/37/ED - Letter of invitation to tender","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"EMA/668077/2012","document_url":"https://www.ema.europa.eu/en/documents/other/online-strategy-and-interface-design-ema201237ed-letter-invitation-tender_en.pdf"},
    {"id":"28555","name":"Sponsoring of Patients’ Organisations by pharmaceutical industry – proposed actions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/531926/2010","document_url":"https://www.ema.europa.eu/en/documents/other/sponsoring-patients-organisations-pharmaceutical-industry-proposed-actions_en.pdf"},
    {"id":"28557","name":"Work plan for Good Clinical Practice inspectors Working Group (GCP IWG) for 2008","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-08-12T02:00:00Z","last_updated_date":"2008-08-12T02:00:00Z","reference_number":"EMEA/INS/GCP/546619/2007","document_url":"https://www.ema.europa.eu/en/documents/other/work-plan-good-clinical-practice-inspectors-working-group-gcp-iwg-2008_en.pdf"},
    {"id":"28577","name":"Online strategy and interface design EMA/2012/37/ED – Technical specification annex I - Costing sheet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T02:00:00Z","last_updated_date":"2013-06-07T02:00:00Z","reference_number":"EMA/150442/2013","document_url":"https://www.ema.europa.eu/en/documents/other/online-strategy-and-interface-design-ema201237ed-technical-specification-annex-i-costing-sheet_en.xls"},
    {"id":"28632","name":"Download EPS - Species pictograms - Horse","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-horse_en.zip"},
    {"id":"28640","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Pediatric Rheumatology International Trials Organisation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-pediatric-rheumatology-international-trials-organisation_en.pdf"},
    {"id":"28649","name":"Questions and answers relating to restricted tender procedure – EMA/2013/21/IS Provision of Security Consumables","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T12:35:00Z","last_updated_date":"2013-11-05T09:16:00Z","reference_number":"EMA/614964/2013","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-restricted-tender-procedure-ema201321is-provision-security-consumables_en.pdf"},
    {"id":"28700","name":"Presentation for discussion meeting on efficient statistical methodology for model-based design and analysis of phase-II dose-finding studies under model uncertainty","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-15T19:00:00Z","last_updated_date":"2013-10-15T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/presentation-discussion-meeting-efficient-statistical-methodology-model-based-design-and-analysis-phase-ii-dose-finding-studies-under-model-uncertainty_en.pdf"},
    {"id":"28709","name":"EMA-EUnetHTA work plan 2017-2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T15:30:00Z","last_updated_date":"2020-05-05T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-eunethta-work-plan-2017-2021_en.pdf"},
    {"id":"28721","name":"The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future: Part II: The European Medicines Agency Road Map Implementation Plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-03-07T01:00:00Z","last_updated_date":"2005-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-road-map-2010-preparing-ground-future-part-ii-european-medicines-agency-road-map-implementation-plan_en.pdf"},
    {"id":"28723","name":"Benefit-risk methodology project: Comments received from Dr William Holden on the work package 2 report","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-09T17:04:06Z","last_updated_date":"2011-06-09T17:04:06Z","reference_number":"EMA/314182/2011","document_url":"https://www.ema.europa.eu/en/documents/other/benefit-risk-methodology-project-comments-received-dr-william-holden-work-package-2-report_en.pdf"},
    {"id":"28725","name":"Transition plan from  Article 57 and XEVMPD data submission to SPOR","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-01T11:05:00Z","last_updated_date":"2016-12-01T11:05:00Z","reference_number":"EMA/492403/2016","document_url":"https://www.ema.europa.eu/en/documents/other/transition-plan-article-57-and-xevmpd-data-submission-spor_en.pdf"},
    {"id":"28733","name":"Announcement of European Medicines Agency priorities for adverse drug reaction research – Fifth call, Seventh Framework Programme","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-07-08T02:00:00Z","last_updated_date":"2010-07-26T02:00:00Z","reference_number":"EMA/425371/2010","document_url":"https://www.ema.europa.eu/en/documents/other/announcement-european-medicines-agency-priorities-adverse-drug-reaction-research-fifth-call-seventh-framework-programme_en.pdf"},
    {"id":"28741","name":"Explanatory note - Letter of representation for referral procedure under Article 31 of Directive 2001/83/EC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-05T17:00:00Z","last_updated_date":"2019-09-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-note-letter-representation-referral-procedure-under-article-31-directive-200183ec_en.docx"},
    {"id":"28757","name":"Overview of comments received on guideline on the demonstration of palatability of veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-23T14:00:00Z","last_updated_date":"2014-07-23T14:00:00Z","reference_number":"EMA/CVMP/EWP/391535/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-demonstration-palatability-veterinary-medicinal-products_en.pdf"},
    {"id":"28809","name":"Outcome of written procedures finalised during the period from 7 September 2016 to 16 November 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T17:30:00Z","last_updated_date":"2016-12-19T17:30:00Z","reference_number":"EMA/MB/716724/2016","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-7-september-2016-16-november-2016_en.pdf"},
    {"id":"28812","name":"Technical Specifications - Annex VII-B Herbal substances: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-vii-b-herbal-substances-procurement-procedure-ema201401ph_en.pdf"}    {"id":"28820","name":"Declaration of interests: Sheila Kennedy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:42Z","last_updated_date":"2015-10-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-sheila-kennedy_en.pdf"},
    {"id":"28828","name":"Applications in the Centralised Procedure 1995 to July 1999\n\n- an analysis of outcomes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2000-03-15T00:00:00Z","last_updated_date":"2000-03-15T00:00:00Z","reference_number":"CPMP/602/00","document_url":"https://www.ema.europa.eu/en/documents/other/applications-centralised-procedure-1995-july-1999-analysis-outcomes_en.pdf"},
    {"id":"28846","name":"Summary of questions discussed and answers provided on VeDDRA coding at the workshop held on 27 November 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-11T18:20:00Z","last_updated_date":"2014-02-11T18:20:00Z","reference_number":"EMA/804163/2013","document_url":"https://www.ema.europa.eu/en/documents/other/summary-questions-discussed-and-answers-provided-veddra-coding-workshop-held-27-november-2013_en.pdf"},
    {"id":"28851","name":"Re-allocation of eXtended Medicinal Product Dictionary (XEVMPD) Organisation entities ownership to the marketing authorisation holders (MAHs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-13T14:02:00Z","last_updated_date":"2014-02-13T14:02:00Z","reference_number":"EMA/74525/2014","document_url":"https://www.ema.europa.eu/en/documents/other/re-allocation-extended-medicinal-product-dictionary-xevmpd-organisation-entities-ownership-marketing-authorisation-holders-mahs_en.pdf"},
    {"id":"28858","name":"Questions and answers relating to open tender procedure – EMA/2014/01/PH Monitoring of scientific and medical literature and the entry of relevant information into EudraVigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-04T15:40:00Z","last_updated_date":"2014-05-08T11:10:00Z","reference_number":"EMA/158242/2014 version 13","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-tender-procedure-ema201401ph-monitoring-scientific-and-medical-literature-and-entry-relevant-information-eudravigilance_en.pdf"},
    {"id":"28868","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2008","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/INS/PhV/63112/2008","document_url":"https://www.ema.europa.eu/en/documents/other/work-plan-pharmacovigilance-inspectors-working-group-2008_en.pdf"},
    {"id":"28870","name":"Dossier submitted for qualification opinion - In vitro hollow-fibre-system model of tuberculosis (HFS-TB)","type":"other","status":"unknown","consultation_date":"2014-11-18 - 2015-01-09","first_published_date":"2014-11-18T16:00:00Z","last_updated_date":"2014-11-18T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/dossier-submitted-qualification-opinion-vitro-hollow-fibre-system-model-tuberculosis-hfs-tb_en.pdf"},
    {"id":"28887","name":"Online strategy and interface design EMA/2012/37/ED - Technical specification annex II - Exclusion criteria","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"EMA/150442/2013","document_url":"https://www.ema.europa.eu/en/documents/other/online-strategy-and-interface-design-ema201237ed-technical-specification-annex-ii-exclusion-criteria_en.doc"},
    {"id":"28911","name":"Decision determining the start date of the term of office of the members of\n\nthe Management Board appointed by Council Decision No 2009/75/EC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-03-05T00:09:21Z","last_updated_date":"2009-03-05T00:09:21Z","reference_number":"EMEA/MB/87076/2009Adopted","document_url":"https://www.ema.europa.eu/en/documents/other/decision-determining-start-date-term-office-members-management-board-appointed-council-decision-no-200975ec_en.pdf"},
    {"id":"28928","name":"Overview of comments on reflection paper on adaptogenic concept (EMEA/HMPC/598048/2007)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-05-08T02:00:00Z","last_updated_date":"2008-05-08T02:00:00Z","reference_number":"EMEA/HMPC/598048/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-reflection-paper-adaptogenic-concept-emeahmpc5980482007_en.pdf"},
    {"id":"28949","name":"Outcome of the public consultation on the Reflection paper on PRIME","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2016-03-07T12:00:00Z","reference_number":"EMA/132593/2016","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-public-consultation-reflection-paper-prime_en.pdf"},
    {"id":"28956","name":"Annual list of contractors 2016 - contract values: €15,000 to €134,999","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-28T17:00:00Z","last_updated_date":"2017-06-28T17:00:00Z","reference_number":"EMA/369495/2017","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contractors-2016-contract-values-eu15000-eu134999_en.pdf"},
    {"id":"28963","name":"Kristian Svendsen  (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/kristian-svendsen-doi_en.pdf"},
    {"id":"28982","name":"Event flier: European Medicines Agency scientific debate","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-08-09T02:00:00Z","last_updated_date":"2010-08-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/event-flier-european-medicines-agency-scientific-debate_en.pdf"},
    {"id":"29009","name":"Declaration of interests: Marie-Agnes Heine","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2024-07-26T17:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-marie-agnes-heine_en.pdf"},
    {"id":"29017","name":"Annua Report 2014 - Human medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-30T02:00:00Z","last_updated_date":"2015-04-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annua-report-2014-human-medicines_en.pdf"},
    {"id":"29052","name":"Overview of comments received on draft guideline on the acceptability of names for veterinary medicinal products processed through the centralised procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-01-21T01:00:00Z","last_updated_date":"2008-01-21T01:00:00Z","reference_number":"EMEA/CVMP/532811/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-acceptability-names-veterinary-medicinal-products-processed-through-centralised-procedure_en.pdf"},
    {"id":"29061","name":"List of participants - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-02T17:00:00Z","last_updated_date":"2013-07-02T17:00:00Z","reference_number":"EMA/263314/2013","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting_en.pdf-0"},
    {"id":"29070","name":"European medicines regulatory network incident management plan for medicines for human use ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-13T18:11:58Z","last_updated_date":"2025-11-13T11:10:00Z","reference_number":"EMA/351583/2012 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-regulatory-network-incident-management-plan-medicines-human-use_en.pdf"},
    {"id":"29084","name":"Changes to some business rules of the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD): Submission of substance information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-07T18:10:00Z","last_updated_date":"2019-11-04T12:31:00Z","reference_number":"EMA/254278/2014 Rev.3.1","document_url":"https://www.ema.europa.eu/en/documents/other/changes-some-business-rules-extended-eudravigilance-medicinal-product-dictionary-xevmpd-submission-substance-information_en.pdf"},
    {"id":"29092","name":"Draft programme - Paediatric strategy forum for medicinal product development for mature B cell malignancies in children","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-01T17:53:00Z","last_updated_date":"2017-11-14T17:27:00Z","reference_number":"EMA/341363/2017","document_url":"https://www.ema.europa.eu/en/documents/other/draft-programme-paediatric-strategy-forum-medicinal-product-development-mature-b-cell-malignancies-children_en.pdf"},
    {"id":"29097","name":"Opinions on safety variations / periodic safety update reports adopted at the CHMP meeting of 21-24 July 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-29T18:15:00Z","last_updated_date":"2014-07-29T18:15:00Z","reference_number":"EMA/125407/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-21-24-july-2014_en.pdf"},
    {"id":"29119","name":"Technical specifications for open invitation to tender no. EMEA/2007/53/P&B, the provision of insurance broking services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-12-01T01:00:00Z","last_updated_date":"2007-12-01T01:00:00Z","reference_number":"EMEA/562467/2007","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-no-emea200753pb-provision-insurance-broking-services_en.pdf"},
    {"id":"29121","name":"Summary of transfer of appropriations in the budget 2013 - Management Board meeting: 19-20 March 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-25T13:30:00Z","last_updated_date":"2014-03-25T13:30:00Z","reference_number":"EMA/MB/85740/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2013-management-board-meeting-19-20-march-2014_en.pdf"},
    {"id":"29131","name":"Overview of comments received on draft guideline on the clinical investigation of human Anti-D immunoglobulin for intravenous and/or intramuscular use CPMP/BPWG/575/99 REV. 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-13T02:00:00Z","last_updated_date":"2007-07-13T02:00:00Z","reference_number":"EMEA/CHMP/BPWP/72096/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-human-anti-d-immunoglobulin-intravenous-andor-intramuscular-use-cpmpbpwg57599-rev-1_en.pdf"},
    {"id":"29133","name":"Mandate, objectives and rules of procedure for the CHMP Geriatric Expert Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-07T13:46:00Z","last_updated_date":"2013-06-13T15:00:00Z","reference_number":"EMA/281009/2013","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-chmp-geriatric-expert-group_en.pdf"},
    {"id":"29202","name":"Start of Community reviews - CHMP meeting of 17-20 September 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-21T14:01:00Z","last_updated_date":"2012-09-21T14:01:00Z","reference_number":"EMA/604579/2012","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-17-20-september-2012_en.pdf"},
    {"id":"29228","name":"Organisation chart: Administration and Corporate Management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-16T12:00:00Z","last_updated_date":"2025-09-01T09:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-chart-administration-corporate-management_en.pdf"},
    {"id":"29240","name":"Timetable: Annual reassessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T16:00:00Z","last_updated_date":"2026-05-27T15:10:00Z","reference_number":"EMA/823130/2015 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-annual-reassessment_en.xlsx"},
    {"id":"29256","name":"Summary of transfer of appropriations in the budget 2016 - Management Board meeting: 16 June 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-21T18:00:00Z","last_updated_date":"2016-06-21T18:00:00Z","reference_number":"EMA/MB/294536/2016","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2016-management-board-meeting-16-june-2016_en.pdf"},
    {"id":"29257","name":"Overview of comments received on draft guideline on dossier requirements for anticancer medicinal products for dogs and cats (EMEA/CVMP/28510/2008-consultation)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/CVMP/512902/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-dossier-requirements-anticancer-medicinal-products-dogs-and-cats-emeacvmp285102008-consultation_en.pdf"},
    {"id":"29261","name":"Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004 - On the risk to vultures and other necrophagous bird populations in the European Union in conne...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T18:30:00Z","last_updated_date":"2014-12-12T18:30:00Z","reference_number":"EMA/CVMP/761582/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinion-committee-medicinal-products-veterinary-use-pursuant-article-303-regulation-ec-no-7262004-risk-vultures-and-other-necrophagous-bird-populations-european-union-conne_en.pdf"},
    {"id":"29267","name":"Invitation for expression of interest - European Medicines Agency workshop on the investigation of subgroups in confirmatory clinical trials","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T10:43:00Z","last_updated_date":"2014-05-08T10:43:00Z","reference_number":"EMA/257188/2013","document_url":"https://www.ema.europa.eu/en/documents/other/invitation-expression-interest-european-medicines-agency-workshop-investigation-subgroups-confirmatory-clinical-trials_en.pdf"},
    {"id":"29306","name":"Overview of comments received on draft guideline on virus safety evaluation of biotechnological investigational medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-09-17T02:00:00Z","last_updated_date":"2008-09-17T02:00:00Z","reference_number":"EMEA/CHMP/BWP/67410/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-virus-safety-evaluation-biotechnological-investigational-medicinal-products_en.pdf"},
    {"id":"29326","name":"Outcome of written procedures during the period 12 May 2017 to 12 September 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-06T17:00:00Z","last_updated_date":"2017-10-06T17:00:00Z","reference_number":"EMA/MB/574504/2017","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-during-period-12-may-2017-12-september-2017_en.pdf"},
    {"id":"29329","name":"Guidelines and concept papers adopted during the July 2012 CHMP meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-25T14:10:00Z","last_updated_date":"2012-07-25T14:10:00Z","reference_number":"EMA/CHMP/410522/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-july-2012-chmp-meeting_en.pdf"},
    {"id":"29339","name":"Tools available to micro-, small- and medium-sized enterprises (SMEs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T19:00:00Z","last_updated_date":"2014-03-27T13:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/tools-available-micro-small-and-medium-sized-enterprises-smes_en.pdf"},
    {"id":"29345","name":"Criteria to be fulfilled by industry stakeholder organisations involved in European Medicines Agency activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T16:00:00Z","last_updated_date":"2016-06-17T16:00:00Z","reference_number":"EMA/323235/2016","document_url":"https://www.ema.europa.eu/en/documents/other/criteria-be-fulfilled-industry-stakeholder-organisations-involved-european-medicines-agency-activities_en.pdf"},
    {"id":"29350","name":"Additional monitoring - high resolution images","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-26T02:00:00Z","last_updated_date":"2013-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/additional-monitoring-high-resolution-images_en.zip"},
    {"id":"29365","name":"List of participants – RD-ACTION, European Medicines Agency, and European Commission-DG SANTE workshop: how European Reference Networks can add value to clinical research","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T18:45:00Z","last_updated_date":"2018-06-19T18:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-rd-action-european-medicines-agency-and-european-commission-dg-sante-workshop-how-european-reference-networks-can-add-value-clinical-research_en.pdf"},
    {"id":"29367","name":"Declaration of interests: Stefano Marino","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T11:55:00Z","last_updated_date":"2022-07-01T14:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-stefano-marino_en.pdf"},
    {"id":"29369","name":"Timetable: Non-safety referrals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-13T11:01:00Z","last_updated_date":"2026-06-04T17:40:00Z","reference_number":"EMA/397813/2025","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-non-safety-referrals_en.pdf"},
    {"id":"29378","name":"Financial compensation for Member States’ participation in the linguistic checking of translations of product information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T11:30:00Z","last_updated_date":"2013-12-17T11:30:00Z","reference_number":"EMA/MB/673504/2013 Endorsed","document_url":"https://www.ema.europa.eu/en/documents/other/financial-compensation-member-states-participation-linguistic-checking-translations-product-information_en.pdf"},
    {"id":"29394","name":"Renewal of confidentiality agreement: Confirmation letter from Health Canada to the European Medicines Agency and the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-15T16:30:00Z","last_updated_date":"2013-03-15T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/renewal-confidentiality-agreement-confirmation-letter-health-canada-european-medicines-agency-and-european-commission_en.pdf"},
    {"id":"29405","name":"Medicines granted a Community marketing authorisation under the centralised procedure since the October CHMP meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-02T11:00:00Z","last_updated_date":"2011-12-02T11:00:00Z","reference_number":"EMA/914235/2011","document_url":"https://www.ema.europa.eu/en/documents/other/medicines-granted-community-marketing-authorisation-under-centralised-procedure-october-chmp-meeting_en.pdf"},
    {"id":"29418","name":"List of participants - Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T12:00:00Z","last_updated_date":"2016-01-07T12:00:00Z","reference_number":"EMA/772047/2015","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-workshop-role-pharmacokinetic-and-pharmacodynamic-measurements-use-direct-oral-anticoagulants_en.pdf"},
    {"id":"29420","name":"EMEA meeting with interested parties and research centres on ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance) - List of Participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T01:00:00Z","last_updated_date":"2007-12-14T01:00:00Z","reference_number":"EMEA/598470/2007","document_url":"https://www.ema.europa.eu/en/documents/other/emea-meeting-interested-parties-and-research-centres-encepp-european-network-centres-pharmacoepidemiology-and-pharmacovigilance-list-participants_en.pdf"},
    {"id":"29454","name":"Technical Specifications – Annex IV Draft contract: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-iv-draft-contract-procurement-procedure-ema201401ph_en.pdf"},
    {"id":"29474","name":"Overview of comments received on the guideline on the replacement of rabbit pyrogen testing by an alternative test for plasma derived medicinal products (EMEA/CHMP/BWP/452081/2007)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/BWP/513210/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-replacement-rabbit-pyrogen-testing-alternative-test-plasma-derived-medicinal-products-emeachmpbwp4520812007_en.pdf"},
    {"id":"29482","name":"Victrelis: Product information as approved by the CHMP on 16 February 2012, pending endosement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T16:58:44Z","last_updated_date":"2012-02-16T16:58:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/victrelis-product-information-approved-chmp-16-february-2012-pending-endosement-european-commission_en.pdf"},
    {"id":"29504","name":"Policy 29: Representing the Agency at external events or in professional bodies","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-07-21T02:00:00Z","last_updated_date":"2025-01-20T14:27:00Z","reference_number":"EMA/550476/2024","document_url":"https://www.ema.europa.eu/en/documents/other/policy-29-representing-agency-external-events-or-professional-bodies_en.pdf"},
    {"id":"29519","name":"Recognition criteria for self assessment - Enpr-EMA: United Kingdom Paediatric Vaccines\n\nGroup","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2011-01-07T00:31:00Z","reference_number":"EMA/817614/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-united-kingdom-paediatric-vaccines-group_en.pdf"},
    {"id":"29542","name":"CTAG3: Advice to the European Medicines Agency on rules of engagement for accessing clinical-trial data - Draft 5 March 2013 version 6.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-advice-european-medicines-agency-rules-engagement-accessing-clinical-trial-data-draft-5-march-2013-version-60_en.pdf"},
    {"id":"29571","name":"Recognition criteria for self assessment - Enpr-EMA: EBMT PD WP – European Group for Blood and Marrow Transplantation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2011-05-18T01:31:00Z","reference_number":"EMA/832279/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-ebmt-pd-wp-european-group-blood-and-marrow-transplantation_en.pdf"},
    {"id":"29574","name":"Report on EMEA workshop on homeopathic medicinal products - List of participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-05-23T02:09:21Z","last_updated_date":"2007-05-23T02:09:21Z","reference_number":"EMEA/409134/2006","document_url":"https://www.ema.europa.eu/en/documents/other/report-emea-workshop-homeopathic-medicinal-products-list-participants_en.pdf"},
    {"id":"29593","name":"List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (PSURs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-01T14:08:00Z","last_updated_date":"2026-05-27T08:53:00Z","reference_number":"EMA/630645/2012 Rev. 160","document_url":"https://www.ema.europa.eu/en/documents/other/list-european-union-reference-dates-eurd-frequency-submission-periodic-safety-update-reports-psurs_en.xlsx"},
    {"id":"29601","name":"Inventory of paediatric therapeutic needs - Ophthalmology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-12T12:00:00Z","last_updated_date":"2014-09-12T12:00:00Z","reference_number":"EMA/PDCO/500455/2014","document_url":"https://www.ema.europa.eu/en/documents/other/inventory-paediatric-therapeutic-needs-ophthalmology_en.pdf"},
    {"id":"29604","name":"CTAG3: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on rules of engagement - Draft advice version 5.0 – Clean version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-advice-european-medicines-agency-clinical-trial-advisory-group-rules-engagement-draft-advice-version-50-clean-version_en.pdf"},
    {"id":"29607","name":"Pathogen-specific database: Plague","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-plague_en.pdf"},
    {"id":"29613","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Molidustat for the treatment of anaemia due to chronic disorders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T12:15:00Z","last_updated_date":"2014-12-11T12:15:00Z","reference_number":"EMA/418357/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-molidustat-treatment-anaemia-due-chronic-disorders_en.pdf"},
    {"id":"29622","name":"Swiss PedNet - European Network of Paediatric Research at the European Medicines Agency recognition criteria for self-assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-21T16:40:00Z","last_updated_date":"2013-03-21T16:40:00Z","reference_number":"EMA/25452/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/swiss-pednet-european-network-paediatric-research-european-medicines-agency-recognition-criteria-self-assessment_en.pdf"},
    {"id":"29630","name":"Overview of comments received on the guideline on the clinical investigation of medicinal products for the treatment of urinary incontinence","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T13:15:00Z","last_updated_date":"2013-07-19T13:15:00Z","reference_number":"EMA/CHMP/107622/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-urinary-incontinence_en.pdf"},
    {"id":"29648","name":"Organisation chart: Stakeholders and Communication","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-16T12:00:00Z","last_updated_date":"2026-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-chart-stakeholders-communication_en.pdf"},
    {"id":"29652","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) concentration types","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:01Z","last_updated_date":"2014-01-17T18:15:00Z","reference_number":"EMA/136154/2012 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-concentration-types_en.xls"},
    {"id":"29663","name":"Timetable: Type IB variation requiring linguistic review","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-08T02:00:00Z","last_updated_date":"2025-05-23T14:42:00Z","reference_number":"EMA/99646/2015 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-type-ib-variation-requiring-linguistic-review_en.xlsx"},
    {"id":"29673","name":"Appointment of an Acting Executive Director, Management Board meeting 7 October 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-11-04T01:00:00Z","last_updated_date":"2010-11-04T01:00:00Z","reference_number":"EMA/MB/578243/2010","document_url":"https://www.ema.europa.eu/en/documents/other/appointment-acting-executive-director-management-board-meeting-7-october-2010_en.pdf"},
    {"id":"29748","name":"Question and answer on the CVMP guideline on the summary of product characteristics for antimicrobial products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-20T02:00:00Z","last_updated_date":"2016-02-26T15:10:00Z","reference_number":"EMA/CVMP/414812/2011 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/question-and-answer-cvmp-guideline-summary-product-characteristics-antimicrobial-products_en.pdf"},
    {"id":"29754","name":"Public bulletin: Veterinary pharmacovigilance 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T15:30:00Z","last_updated_date":"2016-02-26T15:30:00Z","reference_number":"EMA/CVMP/448211/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-bulletin-veterinary-pharmacovigilance-2015_en.pdf"},
    {"id":"29760","name":"Product eligibility for adaptive pathways","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-11-09T01:00:00Z","last_updated_date":"2016-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/product-eligibility-adaptive-pathways_en.pdf"},
    {"id":"29798","name":"Declaration of research interests (addendum) - Nicolino Ruperto","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-nicolino-ruperto_en.pdf"},
    {"id":"29802","name":"COOK IVF cell culture media - Procedural steps and scientific information after initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2021-03-04T13:56:00Z","reference_number":"EMA/80490/2021 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/cook-ivf-cell-culture-media-procedural-steps-and-scientific-information-after-initial-consultation_en.pdf"},
    {"id":"29830","name":"Questions and answers on production of water for injections by non-distillation methods – reverse osmosis and biofilms and control strategies - Final","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-02T13:20:00Z","last_updated_date":"2017-08-02T13:20:00Z","reference_number":"EMA/INS/GMP/443117/2017","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-production-water-injections-non-distillation-methods-reverse-osmosis-and-biofilms-and-control-strategies-final_en.pdf-0"},
    {"id":"29840","name":"Letter of invitation to tender - EMA/2012/18/HR Procurement procedure for medical services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/453462/2012","document_url":"https://www.ema.europa.eu/en/documents/other/letter-invitation-tender-ema201218hr-procurement-procedure-medical-services_en.pdf"},
    {"id":"29881","name":"Registration form: EMA-EFPIA Info day 2011 - 23 May 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-30T01:31:00Z","last_updated_date":"2011-03-30T01:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/registration-form-ema-efpia-info-day-2011-23-may-2011_en.pdf"},
    {"id":"29901","name":"Innovation task force dates for submission of requests for briefing meetings & regulatory advice on the eligibility to EMEA procedures as medicinal products 2009","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-06-03T02:00:00Z","last_updated_date":"2009-06-03T02:00:00Z","reference_number":"EMEA/68722/2008","document_url":"https://www.ema.europa.eu/en/documents/other/innovation-task-force-dates-submission-requests-briefing-meetings-regulatory-advice-eligibility-emea-procedures-medicinal-products-2009_en.pdf"},
    {"id":"29925","name":"European Medicines Agency (EMA) stakeholder relations management framework","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T16:00:00Z","last_updated_date":"2026-02-26T16:00:00Z","reference_number":"EMA/48651/2016","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-ema-stakeholder-relations-management-framework_en.pdf"},
    {"id":"29944","name":"Overview of the EudraVigilance training on electronic reporting of ICSRs in the EEA: 19-21 May 2014, London, UK","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-05-07T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-eudravigilance-training-electronic-reporting-icsrs-eea-19-21-may-2014-london-uk_en.pdf"},
    {"id":"29954","name":"Chapter 3.I: Technical specifications of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2024-01-18T09:00:00Z","reference_number":"EMA/101344/2012","document_url":"https://www.ema.europa.eu/en/documents/other/chapter-3i-technical-specifications-detailed-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-ema_en.pdf"},
    {"id":"29976","name":"Declaration of interests: Beatrice Fayl","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:45Z","last_updated_date":"2012-08-02T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-beatrice-fayl_en.pdf"},
    {"id":"29982","name":"Declaration of research interests (addendum) - Mark Turner","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-mark-turner_en.pdf"},
    {"id":"30016","name":"Organisational matters - CHMP meeting 27-30 May 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T13:00:00Z","last_updated_date":"2013-06-07T13:00:00Z","reference_number":"EMA/CHMP/184574/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-27-30-may-2013_en.pdf"},
    {"id":"30032","name":"Organisation chart of the European Medicines Agency, as of 1 September","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-29T02:00:00Z","last_updated_date":"2016-07-29T02:00:00Z","reference_number":"1 September 2016","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-chart-european-medicines-agency-1-september_en.pdf"},
    {"id":"30033","name":"European Medicines Agency letter to European Ombudsman regarding proactive publication of and access to clinical trial data","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-22T19:35:00Z","last_updated_date":"2014-05-22T19:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-letter-european-ombudsman-regarding-proactive-publication-and-access-clinical-trial-data_en.pdf"},
    {"id":"30046","name":"Inventory of paediatric therapeutic needs - Gastroenterology","type":"other","status":"Draft: consultation closed","consultation_date":"2015-05-08 - 2015-07-06","first_published_date":"2015-05-11T18:05:00Z","last_updated_date":"2015-06-01T18:05:00Z","reference_number":"EMA/PDCO/43828/2015 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/other/inventory-paediatric-therapeutic-needs-gastroenterology_en.pdf-0"},
    {"id":"30053","name":"G Rassi downloadable ZIP File","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-28T02:00:00Z","last_updated_date":"2011-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/g-rassi-downloadable-zip-file_en.zip"},
    {"id":"30061","name":"Focetria: Product information as recommended by the CHMP on 22 April 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2010-04-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/focetria-product-information-recommended-chmp-22-april-2010_en.pdf"},
    {"id":"30083","name":"United States Food and Drug Administration - European Medicines Agency: Good-clinical-practice initiative: Frequently asked questions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-08T02:00:00Z","last_updated_date":"2010-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/united-states-food-and-drug-administration-european-medicines-agency-good-clinical-practice-initiative-frequently-asked-questions-and-answers_en.pdf"},
    {"id":"30109","name":"Annex B3 - Candidate host Member States’ offers to relocate the European Medicines Agency - EMA comments on other criteria essential to ensure that EMA remains operational to guarantee business continuity (applied method...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T20:15:00Z","last_updated_date":"2017-10-03T20:15:00Z","reference_number":"EMA/606600/2017","document_url":"https://www.ema.europa.eu/en/documents/other/annex-b3-candidate-host-member-states-offers-relocate-european-medicines-agency-ema-comments-other-criteria-essential-ensure-ema-remains-operational-guarantee-business-continuity-applied-method_en.pdf"},
    {"id":"30123","name":"CVMP opinions and evaluations started for medicines for veterinary use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-20T01:00:00Z","last_updated_date":"2014-01-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cvmp-opinions-and-evaluations-started-medicines-veterinary-use_en.pdf"},
    {"id":"30148","name":"CHMP highlights - October 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-highlights-october-2015_en.pdf"},
    {"id":"30152","name":"Glubrava: Product Information as approved by the CHMP on 20 october 2011, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/glubrava-product-information-approved-chmp-20-october-2011-pending-endorsement-european-commission_en.pdf"},
    {"id":"30157","name":"Scientific advice and protocol assistance - Adopted during the CHMP meeting 16-19 July 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T14:00:00Z","last_updated_date":"2012-07-20T14:00:00Z","reference_number":"EMA/487646/2012","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-16-19-july-2012_en.pdf"},
    {"id":"30160","name":"Declaration of interests: Monika Benstetter","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-27T01:00:00Z","last_updated_date":"2025-08-01T11:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-monika-benstetter_en.pdf"},
    {"id":"30184","name":"EMA tracking tool: relocation to Amsterdam - Main milestones","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-03-05T11:00:00Z","last_updated_date":"2020-04-30T17:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-tracking-tool-relocation-amsterdam-main-milestones_en.pdf"},
    {"id":"30198","name":"Joint EMA/HMA Veterinary Vaccine Availability Action Plan - Analysis of industry recommendations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-06T17:43:00Z","last_updated_date":"2017-06-06T17:43:00Z","reference_number":"EMA/239617/2016","document_url":"https://www.ema.europa.eu/en/documents/other/joint-emahma-veterinary-vaccine-availability-action-plan-analysis-industry-recommendations_en.pdf"},
    {"id":"30207","name":"Overview of comments received on draft guideline on active substance master file procedure - Revision 3","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-13T13:00:00Z","last_updated_date":"2012-07-13T13:00:00Z","reference_number":"EMA/314313/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-active-substance-master-file-procedure-revision-3_en.pdf"},
    {"id":"30230","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting 21-24 October 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T17:30:00Z","last_updated_date":"2013-10-29T17:30:00Z","reference_number":"EMA/653489/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-21-24-october-2013_en.pdf"},
    {"id":"30237","name":"CVMP opinion trends - first half of 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-16T11:30:00Z","last_updated_date":"2014-07-16T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cvmp-opinion-trends-first-half-2014_en.pdf"},
    {"id":"30272","name":"EMEA 2010 Priorities for Drug Safety Research: Medicine Use in Pregnancy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-08-04T02:00:00Z","last_updated_date":"2009-08-04T02:00:00Z","reference_number":"EMEA/493724/2009","document_url":"https://www.ema.europa.eu/en/documents/other/emea-2010-priorities-drug-safety-research-medicine-use-pregnancy_en.pdf"},
    {"id":"30277","name":"Current status of public consultation on new transparency initiatives","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2000-04-10T02:00:00Z","last_updated_date":"2000-04-10T02:00:00Z","reference_number":"EMEA/D/10983/00","document_url":"https://www.ema.europa.eu/en/documents/other/current-status-public-consultation-new-transparency-initiatives_en.pdf"}    {"id":"30300","name":"Electronic submission of Article 57(2) data: questions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2025-04-10T09:36:00Z","reference_number":"EMA/159776/2013 Version 1.14","document_url":"https://www.ema.europa.eu/en/documents/other/electronic-submission-article-572-data-questions-answers_en.pdf"},
    {"id":"30303","name":"High level business consultancy EMA/2013/23/FI - Technical specifications - Annex VI tenderer information form","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications-annex-vi-tenderer-information-form_en.doc"},
    {"id":"30309","name":"Inventory of paediatric therapeutic needs - Nephro-urology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-12T12:00:00Z","last_updated_date":"2014-09-12T12:00:00Z","reference_number":"EMA/PDCO/358806/2013","document_url":"https://www.ema.europa.eu/en/documents/other/inventory-paediatric-therapeutic-needs-nephro-urology_en.pdf"},
    {"id":"30315","name":"Working Arrangement between DG SANTE/EMA and PIC/S for the exchange of non-public information on medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-11T17:30:00Z","last_updated_date":"2022-09-02T17:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/working-arrangement-between-dg-santeema-and-pics-exchange-non-public-information-medicinal-products_en.pdf"},
    {"id":"30327","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP module VI – Management and reporting of adverse reactions to medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:18:22Z","last_updated_date":"2012-06-25T19:18:22Z","reference_number":"EMA/428850/2012","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-vi-management-and-reporting-adverse-reactions-medicinal-products_en.pdf"},
    {"id":"30331","name":"List of participants of the European Medicines Agency Human Scientific Committee’s Working Party with Healthcare Professionals’ Organisations (HCPWP) meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-08-22T02:00:00Z","last_updated_date":"2016-08-22T02:00:00Z","reference_number":"EMA/386903/2016","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-meeting_en.pdf"},
    {"id":"30402","name":"Mandate, objectives and rules of procedure for the CHMP Safety Working Party","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-06-01T02:09:00Z","last_updated_date":"2019-02-01T18:09:00Z","reference_number":"EMEA/CHMP/SWP/142030/2004","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-chmp-safety-working-party_en.pdf"},
    {"id":"30407","name":"European Medicines Agency's data protection notice for the processing of personal data in the context of public procurement procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-01-30T15:13:00Z","last_updated_date":"2022-09-20T11:35:00Z","reference_number":"EMA/13742/2019 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-processing-personal-data-context-public-procurement-procedures_en.pdf"},
    {"id":"30420","name":"Guidelines on good pharmacovigilance practices: Introductory cover note, last updated with final definition annex revision 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-08T10:00:00Z","last_updated_date":"2014-01-08T10:00:00Z","reference_number":"EMA/781168/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-introductory-cover-note-last-updated-final-definition-annex-revision-2_en.pdf"},
    {"id":"30443","name":"Working party on Herbal Medicinal Products: Final proposal for a core data for  Isphagula seed","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-03-27T01:00:00Z","last_updated_date":"2003-03-27T01:00:00Z","reference_number":"EMEA/HMPWP/14/00","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-isphagula-seed_en.pdf"},
    {"id":"30447","name":"Opinion of the CVMP pursuant to Article 30(3) of Regulation (EC) No 726/2004 of the European Parliament and of the Council on dapsone as an impurity in veterinary medicinal products containing sulphamethoxazole or other ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-02-04T01:00:00Z","last_updated_date":"2013-02-04T01:00:00Z","reference_number":"EMA/CVMP/392253/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinion-cvmp-pursuant-article-303-regulation-ec-no-726-2004-european-parliament-council-dapsone-impurity-veterinary-medicinal-products-containing-sulphamethoxazole-or-other_en.pdf"},
    {"id":"30474","name":"EMA working group on committees’ operational preparedness for human medicines","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2017-06-16T15:00:00Z","last_updated_date":"2017-06-16T15:00:00Z","reference_number":"EMA/300951/2017","document_url":"https://www.ema.europa.eu/en/documents/other/ema-working-group-committees-operational-preparedness-human-medicines_en.pdf"},
    {"id":"30502","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Diclofenac sodium/thiocolchicoside for treatment of musculoskeletal and connective tissue pain","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T12:15:00Z","last_updated_date":"2014-12-12T12:15:00Z","reference_number":"EMA/757055/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-diclofenac-sodiumthiocolchicoside-treatment-musculoskeletal-and-connective-tissue-pain_en.pdf"},
    {"id":"30529","name":"Declaration of interests: Kornelia Grein","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:11Z","last_updated_date":"2015-09-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-kornelia-grein_en.pdf"},
    {"id":"30548","name":"Workshop on immunogenicity assessment of biotechnology-derived therapeutic proteins - Workshop summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-04T14:20:00Z","last_updated_date":"2016-07-04T14:20:00Z","reference_number":"EMA/252133/2016","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-workshop-summary_en.pdf"},
    {"id":"30567","name":"Announcement of the European Medicines Agency Management Board: confirmation of functionality of the PSUR repository","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-12T16:00:00Z","last_updated_date":"2015-06-12T16:00:00Z","reference_number":"EMA/MB/303824/2015","document_url":"https://www.ema.europa.eu/en/documents/other/announcement-european-medicines-agency-management-board-confirmation-functionality-psur-repository_en.pdf"},
    {"id":"30576","name":"Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004 on the potential risk for the consumer resulting from the use of diethanolamine as an excipient ...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-25T12:27:00Z","last_updated_date":"2018-07-25T12:27:00Z","reference_number":"EMA/CVMP/473059/2018","document_url":"https://www.ema.europa.eu/en/documents/other/opinion-committee-medicinal-products-veterinary-use-pursuant-article-303-regulation-ec-no-7262004-potential-risk-consumer-resulting-use-diethanolamine-excipient_en.pdf"},
    {"id":"30577","name":"Highlights from the fourth industry stakeholder platform - operation of European Union pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-14T15:00:00Z","last_updated_date":"2015-07-14T15:00:00Z","reference_number":"EMA/400212/2015","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-fourth-industry-stakeholder-platform-operation-european-union-pharmacovigilance-legislation_en.pdf"},
    {"id":"30607","name":"Report from the EMA-FDA QbD pilot program","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-04-19T18:00:00Z","last_updated_date":"2017-04-19T18:00:00Z","reference_number":"EMA/213746/2017","document_url":"https://www.ema.europa.eu/en/documents/other/report-ema-fda-qbd-pilot-program_en.pdf"},
    {"id":"30610","name":"Conventional medicinal products: Responses to list of questions / Supplementary Request of information / List of outstanding issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-25T01:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/conventional-medicinal-products-responses-list-questions-supplementary-request-information-list-outstanding-issues_en.pdf"},
    {"id":"30624","name":"Public summary of the evaluation of a proposed product-specific\n\nwaiver: Calcium (carbonate) / cholecalciferol (in combination with ibandronic acid) for combination treatment of osteoporosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T12:30:00Z","last_updated_date":"2015-02-23T12:30:00Z","reference_number":"EMA/69568/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-calcium-carbonate-cholecalciferol-combination-ibandronic-acid-combination-treatment-osteoporosis_en.pdf"},
    {"id":"30633","name":"Restructuring of activities at the EMEA","type":"other","status":"unknown","consultation_date":"","first_published_date":"1999-12-20T00:00:00Z","last_updated_date":"1999-12-20T00:00:00Z","reference_number":"EMEA/D/39556/99","document_url":"https://www.ema.europa.eu/en/documents/other/restructuring-activities-emea_en.pdf"},
    {"id":"30657","name":"Overview of comments received on draft guideline on data requirements for IVMPS intended for minor use or minor species/limited markets - Revision 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-12T02:00:00Z","last_updated_date":"2007-07-12T02:00:00Z","reference_number":"EMEA/CVMP/IWP/279839/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-data-requirements-ivmps-intended-minor-use-or-minor-specieslimited-markets-revision-2_en.pdf"},
    {"id":"30679","name":"Information for women using oral contraceptives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2001-09-28T02:00:00Z","last_updated_date":"2001-09-28T02:00:00Z","reference_number":"EMEA/CPMP/2259/01/en/Final","document_url":"https://www.ema.europa.eu/en/documents/other/information-women-using-oral-contraceptives_en.pdf"},
    {"id":"30733","name":"Technical Specifications - Annex VII-A Substances and related substance groups: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-vii-substances-and-related-substance-groups-procurement-procedure-ema201401ph_en.pdf"},
    {"id":"30751","name":"Pharmacovigilance fees: questions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T14:00:00Z","last_updated_date":"2021-01-06T10:55:00Z","reference_number":"EMA/175299/2015 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/pharmacovigilance-fees-questions-and-answers_en.pdf"},
    {"id":"30788","name":"Overview of Comments received on Public Statement on the allergenic potency of herbal medicinal products containing soya or peanut protein","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-01-12T01:00:00Z","last_updated_date":"2006-01-12T01:00:00Z","reference_number":"EMEA/381405/2005","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-public-statement-allergenic-potency-herbal-medicinal-products-containing-soya-or-peanut-protein_en.pdf"},
    {"id":"30810","name":"Year 2005-2006 - Module on drug evaluation in children - Objectives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-09-19T02:09:21Z","last_updated_date":"2005-09-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/year-2005-2006-module-drug-evaluation-children-objectives_en.pdf"},
    {"id":"30821","name":"Policy on the determination of the condition(s) for a paediatric investigation plan (PIP) / waiver (scope of the PIP / waiver)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-25T18:13:00Z","last_updated_date":"2024-01-17T13:48:00Z","reference_number":"EMA/272931/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/policy-determination-conditions-paediatric-investigation-plan-pip-waiver-scope-pip-waiver_en.pdf"},
    {"id":"30830","name":"List of participants - Joint Biologics Working Party / Quality Working Party workshop with stakeholders in relation to prior knowledge and its use in regulatory applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-joint-biologics-working-party-quality-working-party-workshop-stakeholders-relation-prior-knowledge-and-its-use-regulatory-applications_en.pdf"},
    {"id":"30835","name":"European Union backwards forwards conversion element mapping spreadsheet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-27T01:00:00Z","last_updated_date":"2015-10-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-backwards-forwards-conversion-element-mapping-spreadsheet_en.xlsx"},
    {"id":"30838","name":"List of participants - First stakeholder forum on the implementation of the new pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-19T02:00:00Z","last_updated_date":"2011-04-19T02:00:00Z","reference_number":"EMA/278009/2011","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-first-stakeholder-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"30849","name":"Humenza: Package leaflet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-26T01:00:00Z","last_updated_date":"2010-02-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/humenza-package-leaflet_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/humenza-package-leaflet_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/humenza-package-leaflet_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/humenza-package-leaflet_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/humenza-package-leaflet_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/humenza-package-leaflet_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/humenza-package-leaflet_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/humenza-package-leaflet_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/humenza-package-leaflet_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/humenza-package-leaflet_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/humenza-package-leaflet_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/humenza-package-leaflet_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/humenza-package-leaflet_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/humenza-package-leaflet_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/humenza-package-leaflet_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/humenza-package-leaflet_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/humenza-package-leaflet_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/humenza-package-leaflet_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/humenza-package-leaflet_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/humenza-package-leaflet_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/humenza-package-leaflet_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/humenza-package-leaflet_sv.pdf"}},
    {"id":"30861","name":"Issues identified by stakeholders at the workshop - Multi-stakeholder advanced therapy medicinal products (ATMPs) expert meeting: exploring solutions to foster ATMPs’ development and patient access in Europe","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-02-06T11:00:00Z","last_updated_date":"2017-02-06T11:00:00Z","reference_number":"EMA/48099/2017","document_url":"https://www.ema.europa.eu/en/documents/other/issues-identified-stakeholders-workshop-multi-stakeholder-advanced-therapy-medicinal-products-atmps-expert-meeting-exploring-solutions-foster-atmps-development-and-patient-access-europe_en.pdf"},
    {"id":"30880","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) - Medicinal product types","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T18:00:00Z","last_updated_date":"2014-07-09T17:15:00Z","reference_number":"EMA/59709/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-medicinal-product-types_en.xls"},
    {"id":"30889","name":"Overview of comments received on list on paediatric needs on rheumatology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-06-02T02:00:00Z","last_updated_date":"2006-06-02T02:00:00Z","reference_number":"EMEA/207562/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-list-paediatric-needs-rheumatology_en.pdf"},
    {"id":"30894","name":"Technical specification - Annex 12a - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-12a-external-service-providers-software-applications-ema201213ict_en.doc"},
    {"id":"30897","name":"Organisational matters: CHMP meeting of 16-19 December 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/731020/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-16-19-december-2013_en.pdf"},
    {"id":"30924","name":"Glustin: Product Information as approved by the CHMP on 20 october 2011, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/glustin-product-information-approved-chmp-20-october-2011-pending-endorsement-european-commission_en.pdf"},
    {"id":"30929","name":"Download EPS - Species pictograms - Fish","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-fish_en.zip"},
    {"id":"30954","name":"List of participants - EMA workshop on the collaboration with general practitioners/family physicians","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T02:00:00Z","last_updated_date":"2016-04-28T02:00:00Z","reference_number":"EMA/202390/2016","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-workshop-collaboration-general-practitionersfamily-physicians_en.pdf"},
    {"id":"30965","name":"Declaration of interests - Christina Peters","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-christina-peters_en.pdf"},
    {"id":"31008","name":"European Medicines Agency 2011 priorities for drug safety research: Anti-diabetic drugs: cardio/cerebrovascular adverse effect and pancreatitis / pancreatic cancer","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-07-08T02:00:00Z","last_updated_date":"2010-07-08T02:00:00Z","reference_number":"EMA/425259/2010","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-2011-priorities-drug-safety-research-anti-diabetic-drugs-cardiocerebrovascular-adverse-effect-and-pancreatitis-pancreatic-cancer_en.pdf"},
    {"id":"31034","name":"Declaration of interests: Christoph Buchhierl","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2019-10-25T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-christoph-buchhierl_en.pdf"},
    {"id":"31108","name":"Background and summary of outcome of first workshop on EnprEMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/background-and-summary-outcome-first-workshop-enprema_en.pdf"},
    {"id":"31110","name":"Pre-notification check for type IA variations: ensuring the quality of veterinary type IA variation submissions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T16:00:00Z","last_updated_date":"2021-05-18T13:06:00Z","reference_number":"EMA/764767/2014 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/pre-notification-check-type-ia-variations-ensuring-quality-veterinary-type-ia-variation-submissions_en.pdf"},
    {"id":"31116","name":"Declaration of interests: Fia Westerholm","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-17T16:52:00Z","last_updated_date":"2017-08-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-fia-westerholm_en.pdf"},
    {"id":"31120","name":"Letter from Health Canada","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-health-canada_en.pdf"},
    {"id":"31129","name":"Management Board liaison process for PRAC composition","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-03-26T14:10:00Z","last_updated_date":"2015-03-26T14:10:00Z","reference_number":"EMA/MB/40714/2015","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-liaison-process-prac-composition_en.pdf"},
    {"id":"31138","name":"Committee on Herbal Medicinal Products (HMPC) 10th anniversary - Herbal medicines 2004-2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-13T01:00:00Z","last_updated_date":"2014-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/committee-herbal-medicinal-products-hmpc-10th-anniversary-herbal-medicines-2004-2014_en.pdf"},
    {"id":"31142","name":"Working party on Herbal Medicinal Products: Final proposal for a core data for Nettle leaf","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-07-09T02:00:00Z","last_updated_date":"2003-07-09T02:00:00Z","reference_number":"EMEA/HMPWP/1416/02/Rev1","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-nettle-leaf_en.pdf"},
    {"id":"31149","name":"Adaptive Pathways Workshop - List of participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T13:48:00Z","last_updated_date":"2016-12-21T13:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/adaptive-pathways-workshop-list-participants_en.pdf"},
    {"id":"31155","name":"Declaration of interests: Ralph Bax","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T13:00:00Z","last_updated_date":"2025-08-01T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-ralph-bax_en.pdf"},
    {"id":"31176","name":"Invitation for expressions of interest - Transatlantic workshop: drug-related progressive multifocal leukoencephalopathy (PML)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-02-05T00:31:00Z","last_updated_date":"2011-02-05T00:31:00Z","reference_number":"EMA/97508/2011","document_url":"https://www.ema.europa.eu/en/documents/other/invitation-expressions-interest-transatlantic-workshop-drug-related-progressive-multifocal-leukoencephalopathy-pml_en.pdf"},
    {"id":"31180","name":"Summary of the evaluation of the proposed paediatric investigation plan: Rosuvastatin / acetylsalicylic acid for treatment of cardiovascular disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/688642/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-evaluation-proposed-paediatric-investigation-plan-rosuvastatin-acetylsalicylic-acid-treatment-cardiovascular-disease_en.pdf"},
    {"id":"31202","name":"Pilot phase to involve patients in benefit / risk discussions at CHMP meetings","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T12:00:00Z","last_updated_date":"2014-10-24T14:00:00Z","reference_number":"EMA/372554/2014 Rev1","document_url":"https://www.ema.europa.eu/en/documents/other/pilot-phase-involve-patients-benefit-risk-discussions-chmp-meetings_en.pdf"},
    {"id":"31211","name":"Outcome of written procedures finalised during the period from 3 November 2015 to 19 February 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-03-21T17:00:00Z","last_updated_date":"2016-03-21T17:00:00Z","reference_number":"EMA/MB/1904/2016","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-3-november-2015-19-february-2016_en.pdf"},
    {"id":"31213","name":"Overview of comments received on the draft revised guideline on stability testing: Stability testing of existing active substances and related finished products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-08-05T02:00:00Z","last_updated_date":"2008-08-05T02:00:00Z","reference_number":"EMEA/CVMP/QWP/360143/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-revised-guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products_en.pdf"},
    {"id":"31223","name":"Declaration of interests: Francesco Pignatti","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2023-06-12T17:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-francesco-pignatti_en.pdf"},
    {"id":"31273","name":"Anti-fraud strategy: November 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-22T15:00:00Z","last_updated_date":"2015-12-02T18:35:00Z","reference_number":"EMA/591051/2014 Corr","document_url":"https://www.ema.europa.eu/en/documents/other/anti-fraud-strategy-november-2014_en.pdf"},
    {"id":"31295","name":"European Commission-Japan mutual recognition agreement: Sectoral annex on good manufacturing practice for medicinal products - Diplomatic notes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-04-28T02:00:00Z","last_updated_date":"2004-04-28T02:00:00Z","reference_number":"EMEA/MRA/JP/8/04","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-japan-mutual-recognition-agreement-sectoral-annex-good-manufacturing-practice-medicinal-products-diplomatic-notes_en.pdf"},
    {"id":"31317","name":"Mission statement of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-24T18:48:00Z","last_updated_date":"2012-02-24T18:48:00Z","reference_number":"EMA/807680/2011","document_url":"https://www.ema.europa.eu/en/documents/other/mission-statement-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"31343","name":"Recognition criteria for self-assessment (EnprEMA): Presentation of comments received during public consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enprema-presentation-comments-received-during-public-consultation_en.pdf"},
    {"id":"31351","name":"Technical specifications - EMA/2012/18/HR Procurement procedure for medical services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/224561/2012","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-ema201218hr-procurement-procedure-medical-services_en.pdf"},
    {"id":"31354","name":"EudraVigilance support guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-05-10T16:50:00Z","last_updated_date":"2026-02-24T16:49:00Z","reference_number":"EMA/434681/2023","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance_support_page_detailed_guidance_en.pdf"},
    {"id":"31370","name":"Timetable: Type II variation and worksharing application assessment - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T16:16:00Z","last_updated_date":"2026-06-17T16:30:00Z","reference_number":"EMA/727192/2017 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-type-ii-variation-worksharing-application-assessment-atmp_en.xlsx"},
    {"id":"31381","name":"Mandate, objectives and rules of procedure for the CHMP Efficacy Working Party (EWP)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2004-11-18T00:09:21Z","last_updated_date":"2004-11-18T00:09:21Z","reference_number":"EMEA/CHMP/EWP/139722/2004","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-chmp-efficacy-working-party-ewp_en.pdf"},
    {"id":"31409","name":"Organisational matters - Adopted during the CHMP meeting 18-21 June 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T11:33:00Z","last_updated_date":"2012-06-25T11:33:00Z","reference_number":"EMA/CHMP/410508/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-adopted-during-chmp-meeting-18-21-june-2012_en.pdf"},
    {"id":"31434","name":"Workshop – Future of telematics in pharmaceuticals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2001-05-17T02:09:21Z","last_updated_date":"2001-05-17T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-future-telematics-pharmaceuticals_en.pdf"},
    {"id":"31439","name":"Call for comments on the Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) standard list ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-02-18T01:00:00Z","last_updated_date":"2025-10-13T11:42:00Z","reference_number":"EMA/123352/2004 Rev. 16","document_url":"https://www.ema.europa.eu/en/documents/other/call-comments-veterinary-dictionary-drug-regulatory-activities-veddra-standard-list_en.pdf"},
    {"id":"31461","name":"Overview of comments received on 'qualification opinion of novel methodologies in the predementia stage of Alzheimer’s disease: cerebrospinal-fluid-related biomarkers for drugs affecting amyloid burden'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-05-16T02:00:00Z","last_updated_date":"2011-05-16T02:00:00Z","reference_number":"EMA/252172/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-qualification-opinion-novel-methodologies-predementia-stage-alzheimers-disease-cerebrospinal-fluid-related-biomarkers-drugs-affecting-amyloid-burden_en.pdf"},
    {"id":"31477","name":"Letter from Swissmedic: Arrangement for shared non-public information regarding influenza A (H1N1) pandemic","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-15T01:00:00Z","last_updated_date":"2010-02-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-swissmedic-arrangement-shared-non-public-information-regarding-influenza-h1n1-pandemic_en.pdf"},
    {"id":"31478","name":"Chapter 4: Structured Substance Information (currently not applicable) of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-01T21:19:00Z","last_updated_date":"2012-03-05T12:00:00Z","reference_number":"EMA/721630/2011","document_url":"https://www.ema.europa.eu/en/documents/other/chapter-4-structured-substance-information-currently-not-applicable-detailed-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-ema_en.pdf"},
    {"id":"31479","name":"Online strategy and interface design EMA/2012/37/ED - Technical specification annex IV - Summary checklist","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T12:00:00Z","last_updated_date":"2013-06-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/online-strategy-and-interface-design-ema201237ed-technical-specification-annex-iv-summary-checklist_en.pdf"},
    {"id":"31508","name":"Withdrawn-product notification: questions and answers - MAH notification time","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-11T02:00:00Z","last_updated_date":"2014-08-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawn-product-notification-questions-and-answers-mah-notification-time_en.pdf"},
    {"id":"31519","name":"European Medicines Agency’s privacy statement public and targeted consultations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-02-14T14:00:00Z","last_updated_date":"2020-02-14T14:00:00Z","reference_number":"EMA/472380/2019","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-public-and-targeted-consultations_en.pdf"},
    {"id":"31561","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) legal basis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T18:00:00Z","last_updated_date":"2021-09-14T09:15:00Z","reference_number":"EMA/59699/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-legal-basis_en.xlsx"},
    {"id":"31579","name":"Annex F: Confidentiality undertaking contractors","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-01T02:00:00Z","last_updated_date":"2008-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-f-confidentiality-undertaking-contractors_en.pdf"},
    {"id":"31586","name":"Pediatric Cluster Terms of Reference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-06-18T02:09:00Z","last_updated_date":"2024-12-03T16:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pediatric-cluster-terms-reference_en.pdf"},
    {"id":"31587","name":"Declaration of interests: Daniela Luehrs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-daniela-luehrs_en.pdf"},
    {"id":"31602","name":"Working party on Herbal Medicinal Products: Final proposal for a core data for Primula Radix","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-03-03T01:00:00Z","last_updated_date":"2004-03-03T01:00:00Z","reference_number":"EMEA/HMPWP/243/03","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-primula-radix_en.pdf"},
    {"id":"31613","name":"Assessment of patient, consumer and healthcare professional organisations’ compliance with EMA eligibility criteria","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-06-11T18:30:00Z","last_updated_date":"2022-10-07T14:30:00Z","reference_number":"EMA/698917/2017","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-patient-consumer-and-healthcare-professional-organisations-compliance-ema-eligibility-criteria_en.pdf"},
    {"id":"31623","name":"Organisation chart of the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-12-08T00:09:00Z","last_updated_date":"2024-04-26T15:28:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-chart-european-medicines-agency_en.pdf"},
    {"id":"31633","name":"Procedural Announcement - Temporary derogations to certain eligibility criteria for whole blood and blood components donors in the context of a risk of shortage caused by the Influenza A(H1N1) pandemic","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-01-18T01:00:00Z","last_updated_date":"2010-01-18T01:00:00Z","reference_number":"EMA/715726/2009","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-announcement-temporary-derogations-certain-eligibility-criteria-whole-blood-and-blood-components-donors-context-risk-shortage-caused-influenza-ah1n1-pandemic_en.pdf"},
    {"id":"31636","name":"Lee Parker (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/lee-parker-cv_en.pdf"},
    {"id":"31643","name":"Declaration of interests: Tiago Freitas","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T15:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-tiago-freitas_en.pdf"},
    {"id":"31649","name":"Letter from the European Medicines Agency: Arrangement for shared non-public information regarding influenza A (H1N1) pandemic with Swissmedic","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-15T01:00:00Z","last_updated_date":"2010-02-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-european-medicines-agency-arrangement-shared-non-public-information-regarding-influenza-h1n1-pandemic-swissmedic_en.pdf"},
    {"id":"31657","name":"Article 57 project","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-19T01:00:00Z","last_updated_date":"2015-03-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/article-57-project_en.pdf"},
    {"id":"31668","name":"Recognition criteria for self assessment - Enpr-EMA: PENTA: Paediatric European Network for the Treatment of AIDS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817622/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-penta-paediatric-european-network-treatment-aids_en.pdf"},
    {"id":"31682","name":"Workshop on Medicines for the Treatment of Pain in children - List of participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-06-22T02:09:21Z","last_updated_date":"2005-06-22T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-medicines-treatment-pain-children-list-participants_en.pdf"},
    {"id":"31685","name":"List of participants - Workshop on measuring the impact of pharmacovigilance activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"EMA/757893/2016","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-workshop-measuring-impact-pharmacovigilance-activities_en.pdf"},
    {"id":"31696","name":"Overview of comments received on the draft guideline on medicinal products for the treatment of insomnia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-02T01:00:00Z","last_updated_date":"2011-03-02T01:00:00Z","reference_number":"EMA/607700/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-medicinal-products-treatment-insomnia_en.pdf"},
    {"id":"31737","name":"Mandate, objectives and rules of procedure for the CVMP Antimicrobials Working Party (AWP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-14T18:15:00Z","last_updated_date":"2018-12-19T10:00:00Z","reference_number":"EMA/CVMP/AWP/749774/2012 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cvmp-antimicrobials-working-party-awp_en.pdf"},
    {"id":"31773","name":"Questions and answers for the guidance on collection and\n\nprovision of national data on antimicrobial use by animal\n\nspecies/categories (EMA/489035/2016-Rev.1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T17:30:00Z","last_updated_date":"2018-02-23T15:07:00Z","reference_number":"EMA/716249/2016-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-guidance-collection-and-provision-national-data-antimicrobial-use-animal-speciescategories-ema4890352016-rev1_en.pdf"},
    {"id":"31776","name":"Key elements for the summaries of product characteristics of non-selective NSAIDs adopted by the CHMP during its meeting in October 2005","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2005-10-17T02:09:21Z","last_updated_date":"2005-10-17T02:09:21Z","reference_number":"EMEA/CHMP/343456/2005","document_url":"https://www.ema.europa.eu/en/documents/other/key-elements-summaries-product-characteristics-non-selective-nsaids-adopted-chmp-during-its-meeting-october-2005_en.pdf"},
    {"id":"31790","name":"Summary of changes in the EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) production environment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-07T18:10:00Z","last_updated_date":"2013-11-07T18:10:00Z","reference_number":"EMA/575783/2013","document_url":"https://www.ema.europa.eu/en/documents/other/summary-changes-eudravigilance-extended-medicinal-product-dictionary-xevmpd-production-environment_en.pdf"},
    {"id":"31804","name":"European Medicines Agency 2013 priorities for drug safety research: DNA collection and studies on the genetic causes of adverse drug reactions: angiotensin-converting-enzyme-inhibitor-related angioedema and statin-induce...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-22T18:13:30Z","last_updated_date":"2012-05-22T18:13:30Z","reference_number":"EMA/281421/2012","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-2013-priorities-drug-safety-research-dna-collection-and-studies-genetic-causes-adverse-drug-reactions-angiotensin-converting-enzyme-inhibitor-related-angioedema-and-statin_en.pdf"},
    {"id":"31843","name":"Timetable: Informed consent and multiple application","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-28T18:00:00Z","last_updated_date":"2026-05-13T15:30:00Z","reference_number":"EMA/488671/2015 Rev.9","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-informed-consent-multiple-application_en.xlsx"},
    {"id":"31857","name":"EMA Technical Anonymisation Group (TAG) - Terms of reference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T15:15:00Z","last_updated_date":"2017-10-31T15:15:00Z","reference_number":"EMA/708101/2017","document_url":"https://www.ema.europa.eu/en/documents/other/ema-technical-anonymisation-group-tag-terms-reference_en.pdf"},
    {"id":"31865","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) substances","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T01:00:00Z","last_updated_date":"2023-01-23T08:48:00Z","reference_number":"EMA/136148/2012 Rev. 64","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-substances_en.xlsx"}    {"id":"31870","name":"Information package for certificates of medicinal products issued by the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-11T02:00:00Z","last_updated_date":"2025-01-06T08:54:00Z","reference_number":"EMA/119843/2013 Rev.18","document_url":"https://www.ema.europa.eu/en/documents/other/information-package-certificates-medicinal-products-issued-european-medicines-agency_en.pdf"},
    {"id":"31894","name":"European Medicines Agency strategy paper: Acceptance of clinical trials conducted in third  countries, for evaluation in marketing-authorisation applications","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-12-05T00:09:21Z","last_updated_date":"2008-12-05T00:09:21Z","reference_number":"EMEA/228067/2008","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-strategy-paper-acceptance-clinical-trials-conducted-third-countries-evaluation-marketing-authorisation-applications_en.pdf"},
    {"id":"31900","name":"Working party on Herbal Medicinal Products: Draft proposal for a core data for Melissa leaf","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2000-03-31T02:00:00Z","last_updated_date":"2000-03-31T02:00:00Z","reference_number":"EMEA/HMPWP/19/00","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-draft-proposal-core-data-melissa-leaf_en.pdf"},
    {"id":"31904","name":"European Medicines Agency-Food and Drug Administration pilot programme for parallel assessment of quality-by-design applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-16T01:00:00Z","last_updated_date":"2011-03-16T01:00:00Z","reference_number":"EMA/172347/2011","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-food-and-drug-administration-pilot-programme-parallel-assessment-quality-design-applications_en.pdf"},
    {"id":"31905","name":"European Union Medicines Agencies Network Strategy to 2020 - Working together to improve health","type":"other","status":"Draft: consultation closed","consultation_date":"2015-03-31 - 2015-06-30","first_published_date":"2015-03-31T15:00:00Z","last_updated_date":"2015-03-31T15:00:00Z","reference_number":"EMA/MB/151414/2015","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-medicines-agencies-network-strategy-2020-working-together-improve-health_en.pdf"},
    {"id":"31909","name":"Start of Community reviews - CHMP meeting of 15-18 October 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:29:00Z","last_updated_date":"2012-10-19T14:29:00Z","reference_number":"EMA/667865/2012","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-15-18-october-2012_en.pdf"},
    {"id":"31958","name":"Declaration of interest: Richard Vesely","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-26T02:00:00Z","last_updated_date":"2019-10-25T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-richard-vesely_en.pdf"},
    {"id":"31968","name":"Chapter 2: Electronic submission of information on medicinal products by MAH of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-01T21:19:00Z","last_updated_date":"2018-08-07T13:00:00Z","reference_number":"EMA/717179/2011","document_url":"https://www.ema.europa.eu/en/documents/other/chapter-2-electronic-submission-information-medicinal-products-mah-detailed-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-ema_en.pdf"},
    {"id":"32001","name":"Draft Service Level Agreement","type":"other","status":"Draft","consultation_date":"","first_published_date":"2008-06-19T02:00:00Z","last_updated_date":"2008-06-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/draft-service-level-agreement_en.pdf"},
    {"id":"32027","name":"Overview of comments received on the draft of the procedural advice on the submission of variations for annual update of human-influenza-inactivated-vaccine applications in the centralised procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T11:10:00Z","last_updated_date":"2013-04-30T11:10:00Z","reference_number":"EMA/239916/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-procedural-advice-submission-variations-annual-update-human-influenza-inactivated-vaccine-applications-centralised-procedure_en.pdf"},
    {"id":"32039","name":"Declaration of interests: Alberto Ganan Jimenez","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-10T01:00:00Z","last_updated_date":"2024-07-26T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-alberto-ganan-jimenez_en.pdf"},
    {"id":"32044","name":"Technical specification - Annex 7 Lot 1 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-7-lot-1-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"32058","name":"Summary of changes to the ‘External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use’ - Version 1.3","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-09-22T15:00:00Z","last_updated_date":"2017-09-22T15:00:00Z","reference_number":"EMA/456715/2017","document_url":"https://www.ema.europa.eu/en/documents/other/summary-changes-external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-version-13_en.pdf"},
    {"id":"32090","name":"Questions and answers on the withdrawal of the CPMP Note for guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP/SWP/465)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/SWP/242917/2016","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-withdrawal-cpmp-note-guidance-preclinical-pharmacological-and-toxicological-testing-vaccines-cpmpswp465_en.pdf"},
    {"id":"32120","name":"Organisational matters - CHMP meeting of 18-21 March 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T14:20:00Z","last_updated_date":"2013-04-02T14:20:00Z","reference_number":"EMA/CHMP/127956/2013","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-18-21-march-2013_en.pdf"},
    {"id":"32129","name":"Questions and answers relating to the Open Tender procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-05-16T02:00:00Z","last_updated_date":"2008-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-tender-procedure_en.pdf"},
    {"id":"32138","name":"Medicines granted a Community marketing authorisation under the centralised procedure from 01 January to 31 January 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T13:00:00Z","last_updated_date":"2012-02-17T13:00:00Z","reference_number":"EMA/124722/2012","document_url":"https://www.ema.europa.eu/en/documents/other/medicines-granted-community-marketing-authorisation-under-centralised-procedure-01-january-31-january-2012_en.pdf"},
    {"id":"32140","name":"Public bulletin: Veterinary pharmacovigilance 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T12:55:00Z","last_updated_date":"2014-03-28T12:55:00Z","reference_number":"EMA/CVMP/781698/2013","document_url":"https://www.ema.europa.eu/en/documents/other/public-bulletin-veterinary-pharmacovigilance-2013_en.pdf"},
    {"id":"32186","name":"Addendum no. 1 to the cooperation between the Pharmaceutical Inspection Cooperation Scheme and the European Medicines Agency of 28 December 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-11T17:30:00Z","last_updated_date":"2012-07-11T17:30:00Z","reference_number":"EMA/352642/2012","document_url":"https://www.ema.europa.eu/en/documents/other/addendum-no-1-cooperation-between-pharmaceutical-inspection-cooperation-scheme-and-european-medicines-agency-28-december-2010_en.pdf"},
    {"id":"32189","name":"Withdrawal letter : Kexxtone","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-22T02:00:00Z","last_updated_date":"2009-04-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-kexxtone_en.pdf"},
    {"id":"32195","name":"Programme to rationalise international good-manufacturing-practice inspections of active-pharmaceutical-ingredient / active-substance manufacturers: Terms of reference and procedures for participating authorities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-06T19:08:00Z","last_updated_date":"2018-12-20T14:00:00Z","reference_number":"EMA/INS/GMP/129953/2012","document_url":"https://www.ema.europa.eu/en/documents/other/programme-rationalise-international-good-manufacturing-practice-inspections-active-pharmaceutical-ingredient-active-substance-manufacturers-terms-reference-and-procedures-participating-authorities_en.pdf"},
    {"id":"32231","name":"Questions and answers relating to restricted tender procedure EMA/2012/19/IS: Provision of security consultancy services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-29T16:46:00Z","last_updated_date":"2012-11-05T11:54:00Z","reference_number":"EMA/668067/2012","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-restricted-tender-procedure-ema201219is-provision-security-consultancy-services_en.pdf"},
    {"id":"32235","name":"Development support and regulatory tools for early access to medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2016-03-07T12:00:00Z","reference_number":"EMA/531801/2015","document_url":"https://www.ema.europa.eu/en/documents/other/development-support-and-regulatory-tools-early-access-medicines_en.pdf"},
    {"id":"32246","name":"Revised criteria to be fulfilled by patients’ and consumers’ organisations involved in EMA activities","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:02Z","last_updated_date":"2011-10-07T16:00:02Z","reference_number":"EMA/MB/24913/2005 rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/revised-criteria-be-fulfilled-patients-and-consumers-organisations-involved-ema-activities_en.pdf"},
    {"id":"32270","name":"CTAG4: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on good analysis practice - Discussion document","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag4-advice-european-medicines-agency-clinical-trial-advisory-group-good-analysis-practice-discussion-document_en.pdf"},
    {"id":"32295","name":"CTAG3: Advice to the European Medicines Agency on rules of engagement for accessing clinical-trial data - Draft 4 April 2013 version 8.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-advice-european-medicines-agency-rules-engagement-accessing-clinical-trial-data-draft-4-april-2013-version-80_en.pdf"},
    {"id":"32299","name":"Engagement framework: European Medicines Agency and patients, consumers and their organisations","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-02-14T01:00:00Z","last_updated_date":"2022-02-07T16:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/engagement-framework-european-medicines-agency-and-patients-consumers-and-their-organisations_en.pdf"},
    {"id":"32318","name":"Start of community reviews - CHMP meeting of 16-19 December 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/792747/2013","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-16-19-december-2013_en.pdf"},
    {"id":"32320","name":"Summary of transfer of appropriations in the budget 2012 - Management Board meeting: 4 October 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/MB/582825/2012","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2012-management-board-meeting-4-october-2012_en.pdf"},
    {"id":"32321","name":"Sarah Nevitt (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sarah-nevitt-doi_en.pdf"},
    {"id":"32347","name":"Referrals triggered by Member States or the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-24T02:09:21Z","last_updated_date":"2007-10-24T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/referrals-triggered-member-states-or-european-commission_en.pdf"},
    {"id":"32354","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: Irvine Scientific Reproductive Media","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-08T14:00:00Z","last_updated_date":"2012-08-08T14:00:00Z","reference_number":"EMEA/CHMP/52056/2008","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-irvine-scientific-reproductive-media_en.pdf"},
    {"id":"32362","name":"Questions and answers EMA/PDCO review of the list of granted Class Waivers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-23T13:00:00Z","last_updated_date":"2015-07-23T13:00:00Z","reference_number":"EMA/484023/2015","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-emapdco-review-list-granted-class-waivers_en.pdf"},
    {"id":"32376","name":"Joint audit programme for EEA GMP inspectorates: Audit plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-19T02:00:00Z","last_updated_date":"2019-02-22T02:00:00Z","reference_number":"EMA/544128/2018 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/joint-audit-programme-eea-gmp-inspectorates-audit-plan_en.docx"},
    {"id":"32377","name":"Celvapan: Labelling","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-29T02:00:00Z","last_updated_date":"2010-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/celvapan-labelling_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/celvapan-labelling_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/celvapan-labelling_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/celvapan-labelling_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/celvapan-labelling_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/celvapan-labelling_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/celvapan-labelling_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/celvapan-labelling_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/celvapan-labelling_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/celvapan-labelling_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/celvapan-labelling_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/celvapan-labelling_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/celvapan-labelling_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/celvapan-labelling_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/celvapan-labelling_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/celvapan-labelling_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/celvapan-labelling_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/celvapan-labelling_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/celvapan-labelling_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/celvapan-labelling_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/celvapan-labelling_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/celvapan-labelling_sv.pdf"}},
    {"id":"32381","name":"Pre-Qualification Questionnaire (PQQ) for a restricted tender procedure organised by European Medicines Agency (EMEA) corporate travel services EMEA/2008/98/MM&C","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:21Z","last_updated_date":"2008-11-25T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency-emea-corporate-travel-services-emea200898mmc_en.doc"},
    {"id":"32396","name":"HMA/EMA Joint Big Data Task Force","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-23T11:20:00Z","last_updated_date":"2017-03-23T11:20:00Z","reference_number":"EMA/189364/2017","document_url":"https://www.ema.europa.eu/en/documents/other/hmaema-joint-big-data-task-force_en.pdf"},
    {"id":"32415","name":"EudraVigilance stakeholder change management plan: integration with the identity and access management (IAM2) project deliverables","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-03T19:00:00Z","last_updated_date":"2018-07-03T19:00:00Z","reference_number":"EMA/349760/2018","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-stakeholder-change-management-plan-integration-identity-and-access-management-iam2-project-deliverables_en.pdf"},
    {"id":"32425","name":"Divergent position on a CVMP opinion on a type II variation to the terms of the marketing authorisation for DRAXXIN (EMEA/V/C/000077/II/0031)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/divergent-position-cvmp-opinion-type-ii-variation-terms-marketing-authorisation-draxxin-emeavc000077ii0031_en.pdf"},
    {"id":"32437","name":"Timetable: Extension application","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-22T11:57:00Z","last_updated_date":"2026-05-13T15:10:00Z","reference_number":"EMA/412809/2015 Rev. 13","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-extension-application_en.xlsx"},
    {"id":"32438","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Medicines for Children Research Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/823843/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-medicines-children-research-network_en.pdf"},
    {"id":"32440","name":"Letter of support for intermediate age related macular degeneration (AMD) biomarker and novel clinical endpoint development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-02-21T13:10:00Z","last_updated_date":"2018-02-21T13:10:00Z","reference_number":"EMA/72511/2018","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-intermediate-age-related-macular-degeneration-amd-biomarker-and-novel-clinical-endpoint-development_en.pdf"},
    {"id":"32442","name":"Data quality control methodology for data submitted under Article 57(2) of Regulation (EC) No.726/2004","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T15:50:00Z","last_updated_date":"2014-06-16T14:00:00Z","reference_number":"EMA/227883/2014","document_url":"https://www.ema.europa.eu/en/documents/other/data-quality-control-methodology-data-submitted-under-article-572-regulation-ec-no7262004_en.doc"},
    {"id":"32450","name":"List of participants - Fifth stakeholder forum on the implementation of the new pharmacovigilance legislation, 25 May 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"EMA/289380/2012","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-fifth-stakeholder-forum-implementation-new-pharmacovigilance-legislation-25-may-2012_en.pdf"},
    {"id":"32452","name":"The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future: Executive Summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-03-04T01:00:00Z","last_updated_date":"2005-03-04T01:00:00Z","reference_number":"EMEA/H/34163/03/Final","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-road-map-2010-preparing-ground-future-executive-summary_en.pdf"},
    {"id":"32454","name":"Call for expression of interest: Access to eXtended Medicinal Product Dictionary (XEVMPD) test environment (XCOMP) for software vendors","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-21T17:20:00Z","last_updated_date":"2014-05-21T17:20:00Z","reference_number":"EMA/220372/2014","document_url":"https://www.ema.europa.eu/en/documents/other/call-expression-interest-access-extended-medicinal-product-dictionary-xevmpd-test-environment-xcomp-software-vendors_en.pdf"},
    {"id":"32456","name":"Mandate of the Coordinating Group of the European network of paediatric research at the European Medicines Agency (Enpr-EMA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-24T18:48:00Z","last_updated_date":"2020-10-23T16:35:00Z","reference_number":"EMA/149503/2020","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-coordinating-group-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"32497","name":"EU Medicines Agencies Network Strategy to 2020: Summary report of the meeting with Industry Stakeholders Associations for human medicines 23 June 2015: Annex 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/441188/2015","document_url":"https://www.ema.europa.eu/en/documents/other/eu-medicines-agencies-network-strategy-2020-summary-report-meeting-industry-stakeholders-associations-human-medicines-23-june-2015-annex-2_en.pdf"},
    {"id":"32535","name":"Focetria: Labelling","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-05T01:00:00Z","last_updated_date":"2010-03-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/focetria-labelling_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/focetria-labelling_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/focetria-labelling_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/focetria-labelling_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/focetria-labelling_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/focetria-labelling_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/focetria-labelling_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/focetria-labelling_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/focetria-labelling_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/focetria-labelling_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/focetria-labelling_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/focetria-labelling_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/focetria-labelling_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/focetria-labelling_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/focetria-labelling_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/focetria-labelling_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/focetria-labelling_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/focetria-labelling_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/focetria-labelling_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/focetria-labelling_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/focetria-labelling_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/focetria-labelling_sv.pdf"}},
    {"id":"32584","name":"Overview of comments received on 'Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance (revision 1)'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-03T14:30:00Z","last_updated_date":"2014-06-03T14:30:00Z","reference_number":"EMA/559452/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-revision-1_en.pdf"},
    {"id":"32587","name":"Conclusions of the Paediatric Epilepsy Experts Group Meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-06T02:00:00Z","last_updated_date":"2010-05-06T02:00:00Z","reference_number":"EMA/153272/2010","document_url":"https://www.ema.europa.eu/en/documents/other/conclusions-paediatric-epilepsy-experts-group-meeting_en.pdf"},
    {"id":"32596","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: FertiPro N.V. HSA-containing ART media","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-08T14:00:00Z","last_updated_date":"2012-08-08T14:00:00Z","reference_number":"EMA/CHMP/66296/2012","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-fertipro-nv-hsa-containing-art-media_en.pdf"},
    {"id":"32597","name":"Summary of the provisional CPMP report: medicinal products for human use affected by commission decision (97/534/ec)","type":"other","status":"unknown","consultation_date":"","first_published_date":"1997-10-27T00:00:00Z","last_updated_date":"1997-10-27T00:00:00Z","reference_number":"CPMP/961/97","document_url":"https://www.ema.europa.eu/en/documents/other/summary-provisional-cpmp-report-medicinal-products-human-use-affected-commission-decision-97534ec_en.pdf"},
    {"id":"32600","name":"Committee for Medicinal Products for Human Use (CHMP) opinions - 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-20T01:00:00Z","last_updated_date":"2014-01-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/committee-medicinal-products-human-use-chmp-opinions-2013_en.pdf"},
    {"id":"32602","name":"Declaration of interests: Nigel Gomeze","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:03Z","last_updated_date":"2017-08-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-nigel-gomeze_en.pdf"},
    {"id":"32605","name":"Small and medium-sized enterprise (SME) Office annual report 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-31T17:00:00Z","last_updated_date":"2017-05-31T17:00:00Z","reference_number":"EMA/790421/2016","document_url":"https://www.ema.europa.eu/en/documents/other/small-and-medium-sized-enterprise-sme-office-annual-report-2016_en.pdf"},
    {"id":"32609","name":"Question and answer document on the possibility to extrapolate pre-inactivation titres as part of validation of an inactivation process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-06-22T02:00:00Z","last_updated_date":"2009-06-22T02:00:00Z","reference_number":"EMEA/CVMP/340494/2009","document_url":"https://www.ema.europa.eu/en/documents/other/question-and-answer-document-possibility-extrapolate-pre-inactivation-titres-part-validation-inactivation-process_en.pdf"},
    {"id":"32620","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: IVF Media G5","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-08T14:00:00Z","last_updated_date":"2012-08-08T14:00:00Z","reference_number":"EMEA/CHMP/212141/2006","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-ivf-media-g5_en.pdf"},
    {"id":"32639","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: European Society for Developmental Perinatal and Paediatric Pharmacology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-21T12:00:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/203955/2012","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-european-society-developmental-perinatal-and-paediatric-pharmacology_en.pdf"},
    {"id":"32643","name":"Output of the European Medicines Agency policy on access to documents non-related to medicinal products for human and veterinary use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-02-17T14:30:00Z","last_updated_date":"2018-11-23T13:00:00Z","reference_number":"EMA/183710/2016","document_url":"https://www.ema.europa.eu/en/documents/other/output-european-medicines-agency-policy-access-documents-non-related-medicinal-products-human-and-veterinary-use_en.pdf"},
    {"id":"32659","name":"Revised framework for interaction between the European Medicines Agency and healthcare professionals Revised framework of interaction between EMA and healthcare professionals - Annex II - EMA activities where healthcare professionals are involved","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T13:00:00Z","last_updated_date":"2017-02-03T13:00:00Z","reference_number":"EMA/677917/2016","document_url":"https://www.ema.europa.eu/en/documents/other/revised-framework-interaction-between-european-medicines-agency-and-healthcare-professionals-revised-framework-interaction-between-ema-and-healthcare-professionals-annex-ii-ema-activities-where_en.pdf"},
    {"id":"32688","name":"Public summary of the evaluation of a proposed product-specific waiver: \n\nCandesartan (cilexetil)/amlodipine (besilate) for treatment of essential hypertension","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/89429/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-candesartan-cilexetilamlodipine-besilate-treatment-essential-hypertension_en.pdf"},
    {"id":"32717","name":"Zometa: Withdrawal letter","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/zometa-withdrawal-letter_en.pdf"},
    {"id":"32752","name":"Annex B - Response questionnaire","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-10-12T02:00:00Z","last_updated_date":"2009-10-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-b-response-questionnaire_en.xls"},
    {"id":"32772","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) Anatomical Therapeutic Chemical (ATC) code addition","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:01Z","last_updated_date":"2014-01-17T18:15:00Z","reference_number":"EMA/136151/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-anatomical-therapeutic-chemical-atc-code-addition_en.xls"},
    {"id":"32795","name":"Guidelines and concept papers adopted at the CHMP meeting 17-20 March 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T17:00:00Z","last_updated_date":"2014-03-24T17:00:00Z","reference_number":"EMA/CHMP/122481/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-chmp-meeting-17-20-march-2014_en.pdf"},
    {"id":"32810","name":"Invitation for expressions of interest - Targeted consultation on the guideline for development of new medicinal products for the treatment of rheumatoid arthritis (RA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-05-03T02:00:00Z","last_updated_date":"2016-05-03T02:00:00Z","reference_number":"EMA/251809/2016","document_url":"https://www.ema.europa.eu/en/documents/other/invitation-expressions-interest-targeted-consultation-guideline-development-new-medicinal-products-treatment-rheumatoid-arthritis-ra_en.pdf"},
    {"id":"32818","name":"Outcome of written procedures finalised during the period from 14 February 2017 to 11 May 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-16T15:30:00Z","last_updated_date":"2017-06-16T15:30:00Z","reference_number":"EMA/MB/109400/2017","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-14-february-2017-11-may-2017_en.pdf"},
    {"id":"32837","name":"Overview of comments received on 'guideline on requirements for the production and control of immunological veterinary medicinal products' - First version","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-06-21T11:45:00Z","last_updated_date":"2012-06-21T11:45:00Z","reference_number":"EMA/CVMP/IWP/913310/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-requirements-production-and-control-immunological-veterinary-medicinal-products-first-version_en.pdf"},
    {"id":"32839","name":"Call for scientific data for the update of advice on the impact on public health and animal health of the use of antibiotics in animals (colistin) following the recent discovery of the first mobile colistin resistance gene (mcr-1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-29T16:00:00Z","last_updated_date":"2016-02-29T16:00:00Z","reference_number":"EMA/103285/2016","document_url":"https://www.ema.europa.eu/en/documents/other/call-scientific-data-update-advice-impact-public-health-and-animal-health-use-antibiotics-animals-colistin-following-recent-discovery-first-mobile-colistin-resistance-gene-mcr-1_en.pdf"},
    {"id":"32844","name":"PRAC – first experience","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/598943/201212","document_url":"https://www.ema.europa.eu/en/documents/other/prac-first-experience_en.pdf"},
    {"id":"32857","name":"Declaration of interests: Mihaela Savastre","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-04T01:00:00Z","last_updated_date":"2016-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-mihaela-savastre_en.pdf"},
    {"id":"32872","name":"Overview of comments received on 'appendix IV of the guideline on the investigation on bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1): Presentation of biopharmaceutical and bioanalytical data in module 2.7.1 (EMA/CHMP/60095...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-11-18T16:51:00Z","last_updated_date":"2011-11-18T16:51:00Z","reference_number":"EMA/CHMP/643484/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-appendix-iv-guideline-investigation-bioequivalence-cpmpewpqwp140198-rev1-presentation-biopharmaceutical-and-bioanalytical-data-module-271-emachmp60095_en.pdf"},
    {"id":"32890","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: Floseal haemostatic matrix (Floseal VH S/D)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-08T14:00:00Z","last_updated_date":"2012-08-08T14:00:00Z","reference_number":"EMEA/CHMP/91490/2009","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-floseal-haemostatic-matrix-floseal-vh-s-d_en.pdf"},
    {"id":"32920","name":"Revlimid: Product information as approved by the CHMP on 22 September 2011, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/revlimid-product-information-approved-chmp-22-september-2011-pending-endorsement-european-commission_en.pdf"},
    {"id":"32928","name":"Letter of support for Patient Data Platform for capturing patient-reported outcome measures for Dravet syndrome","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-05-19T14:30:00Z","last_updated_date":"2016-05-19T14:30:00Z","reference_number":"EMA/327846/2016","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-patient-data-platform-capturing-patient-reported-outcome-measures-dravet-syndrome_en.pdf"},
    {"id":"32930","name":"Withdrawal letter: Qutenza","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-16T02:00:00Z","last_updated_date":"2012-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-qutenza_en.pdf"},
    {"id":"32936","name":"Technical specification - Annex 11 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-11-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"32948","name":"Points to consider for the overall assessment of a supply shortage of a medicinal product due to GMP Non-compliance /quality defects","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T00:00:00Z","last_updated_date":"2018-04-20T17:00:00Z","reference_number":"EMA/352178/2013","document_url":"https://www.ema.europa.eu/en/documents/other/points-consider-overall-assessment-supply-shortage-medicinal-product-due-gmp-non-compliance-quality-defects_en.pdf"},
    {"id":"32955","name":"Recognition criteria for self assessment - Enpr-EMA: EUNETHYDIS (the European Network for Hyperkinetic Disorders)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2011-01-07T00:31:00Z","reference_number":"EMA/632559/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-eunethydis-european-network-hyperkinetic-disorders_en.pdf"},
    {"id":"33000","name":"Summary of transfer of appropriations in the budget 2011 - Management Board meeting: 9 June 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/MB/371536/2011","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2011-management-board-meeting-9-june-2011_en.pdf"},
    {"id":"33017","name":"Sampling and testing of centrally authorised products: Development of risk based approach for the selection of products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-01-10T01:00:00Z","last_updated_date":"2008-01-10T01:00:00Z","reference_number":"EMEA/INS/S&T/120857/2008","document_url":"https://www.ema.europa.eu/en/documents/other/sampling-and-testing-centrally-authorised-products-development-risk-based-approach-selection-products_en.pdf"},
    {"id":"33026","name":"Arepanrix: Package leaflet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-29T02:00:00Z","last_updated_date":"2010-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/arepanrix-package-leaflet_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/arepanrix-package-leaflet_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/arepanrix-package-leaflet_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/arepanrix-package-leaflet_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/arepanrix-package-leaflet_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/arepanrix-package-leaflet_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/arepanrix-package-leaflet_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/arepanrix-package-leaflet_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/arepanrix-package-leaflet_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/arepanrix-package-leaflet_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/arepanrix-package-leaflet_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/arepanrix-package-leaflet_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/arepanrix-package-leaflet_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/arepanrix-package-leaflet_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/arepanrix-package-leaflet_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/arepanrix-package-leaflet_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/arepanrix-package-leaflet_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/arepanrix-package-leaflet_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/arepanrix-package-leaflet_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/arepanrix-package-leaflet_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/arepanrix-package-leaflet_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/arepanrix-package-leaflet_sv.pdf"}},
    {"id":"33042","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Belimumab for treatment of systemic lupus erythematosus","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T12:15:00Z","last_updated_date":"2014-12-11T12:15:00Z","reference_number":"EMA/714847/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-belimumab-treatment-systemic-lupus-erythematosus_en.pdf"},
    {"id":"33044","name":"Choice of timetable for type II variations and worksharing applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-02-28T14:52:00Z","last_updated_date":"2020-01-22T18:15:00Z","reference_number":"EMA/103586/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/choice-timetable-type-ii-variations-and-worksharing-applications_en.pdf"},
    {"id":"33060","name":"Call for expression of interest to the attention of healthcare product (pharmaceuticals or medical devices) developers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-06T11:08:00Z","last_updated_date":"2013-12-06T11:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/call-expression-interest-attention-healthcare-product-pharmaceuticals-or-medical-devices-developers_en.pdf"},
    {"id":"33063","name":"Policy 54: Personal electrical equipment","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T11:38:00Z","last_updated_date":"2021-07-01T11:38:00Z","reference_number":"EMA/256085/2009","document_url":"https://www.ema.europa.eu/en/documents/other/policy-54-personal-electrical-equipment_en.pdf"},
    {"id":"33084","name":"Pandemrix: Product information as recommended by the CHMP on 22 April 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2010-04-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pandemrix-product-information-recommended-chmp-22-april-2010_en.pdf"},
    {"id":"33106","name":"Important information for Tenderers intending to bid for Lots 1 and 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-16T02:00:00Z","last_updated_date":"2008-07-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/important-information-tenderers-intending-bid-lots-1-and-2_en.pdf"},
    {"id":"33119","name":"Withdrawal letter : Abilify","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-01-05T01:00:00Z","last_updated_date":"2010-01-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-abilify_en.pdf"},
    {"id":"33144","name":"Annex 8 Standard Timesheet - Procurement Procedure EMA/2012/09/IF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-8-standard-timesheet-procurement-procedure-ema201209if_en.pdf"},
    {"id":"33234","name":"Timetable: Safety referral (Article-20 and Article-31 pharmacovigilance)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-13T11:02:00Z","last_updated_date":"2026-06-04T17:45:00Z","reference_number":"EMA/397814/2025","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-safety-referral-article-20-article-31-pharmacovigilance_en.pdf"},
    {"id":"33237","name":"Pre-Qualification Questionnaire (PQQ) for a restricted tender procedure organised by European Medicines Agency (EMEA) cashless payment system EMEA/2008/63/ISERV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:21Z","last_updated_date":"2008-11-25T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency-emea-cashless-payment-system-emea200863iserv_en.doc"},
    {"id":"33252","name":"Overview of comments received on draft guideline on quality of combination herbal medicinal products/traditional herbal medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-06-23T02:00:00Z","last_updated_date":"2008-06-23T02:00:00Z","reference_number":"EMEA/HMPC/559281/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-quality-combination-herbal-medicinal-productstraditional-herbal-medicinal-products_en.pdf"},
    {"id":"33256","name":"Summary of transfer of appropriations in the budget 2015 - Management Board meeting: 11 June 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T12:00:00Z","last_updated_date":"2015-06-16T12:00:00Z","reference_number":"EMA/MB/279870/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2015-management-board-meeting-11-june-2015_en.pdf"},
    {"id":"33277","name":"Scientific advice and protocol assistance - Adopted during the CHMP meeting 12–15 November 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T12:59:00Z","last_updated_date":"2012-11-16T12:59:00Z","reference_number":"EMA/CHMP/SAWP/732749/2012","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-12-15-november-2012_en.pdf"},
    {"id":"33301","name":"2006 EU-Swiss GMP China Training Workshop - Announcement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-07-05T02:09:21Z","last_updated_date":"2006-07-05T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/2006-eu-swiss-gmp-china-training-workshop-announcement_en.pdf"},
    {"id":"33302","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: National Center for Child Health and Development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817559/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-national-center-child-health-and-development_en.pdf"},
    {"id":"33306","name":"Declaration of interests: Patrick Costello","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T02:00:00Z","last_updated_date":"2018-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-patrick-costello_en.pdf"},
    {"id":"33311","name":"Required registration documents for EudraVigilance XCOMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T12:00:00Z","last_updated_date":"2019-10-31T12:00:00Z","reference_number":"EMA/503894/2018","document_url":"https://www.ema.europa.eu/en/documents/other/required-registration-documents-eudravigilance-xcomp_en.pdf"}    {"id":"33322","name":"Guidelines and concept papers adopted during the CHMP meeting 27-30 May 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T13:00:00Z","last_updated_date":"2013-06-07T13:00:00Z","reference_number":"EMA/CHMP/184571/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-27-30-may-2013_en.pdf"},
    {"id":"33326","name":"Framework for interaction between the European Medicines Agency and healthcare professionals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T11:56:00Z","last_updated_date":"2011-12-19T11:56:00Z","reference_number":"EMA/688885/2010","document_url":"https://www.ema.europa.eu/en/documents/other/framework-interaction-between-european-medicines-agency-and-healthcare-professionals_en.pdf"},
    {"id":"33328","name":"Comments from the public consultation on the revised priority list of off-patent medicines for children 2013/14","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-08-12T18:00:00Z","last_updated_date":"2013-08-12T18:00:00Z","reference_number":"EMA/443893/2013","document_url":"https://www.ema.europa.eu/en/documents/other/comments-public-consultation-revised-priority-list-patent-medicines-children-201314_en.pdf"},
    {"id":"33336","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous dendritic cells, pulsed with allogeneic tumour cell lysate","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-03-21T14:30:00Z","last_updated_date":"2018-03-21T14:30:00Z","reference_number":"EMA/105911/2018","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-dendritic-cells-pulsed-allogeneic-tumour-cell-lysate_en.pdf"},
    {"id":"33348","name":"Annex A1 - Summary of EMA technical comments on the technical requirements with respect to the candidate host Member States’ offers to relocate EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T20:15:00Z","last_updated_date":"2017-10-03T20:15:00Z","reference_number":"EMA/570623/2017","document_url":"https://www.ema.europa.eu/en/documents/other/annex-a1-summary-ema-technical-comments-technical-requirements-respect-candidate-host-member-states-offers-relocate-ema_en.pdf"},
    {"id":"33360","name":"Annual list of contractors 2017 - contract values: €15,000 - €134,999","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-06-28T18:30:00Z","last_updated_date":"2018-06-28T18:30:00Z","reference_number":"EMA/404660/2018","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contractors-2017-contract-values-eu15000-eu134999_en.pdf"},
    {"id":"33369","name":"Closing speech - Sylvie Benefice, EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T00:09:00Z","last_updated_date":"2008-11-05T00:09:00Z","reference_number":"EMEA/616285/2008","document_url":"https://www.ema.europa.eu/en/documents/other/closing-speech-sylvie-benefice-ema_en.pdf"},
    {"id":"33377","name":"Process description for managing duplicates in the context of the medical literature monitoring (MLM) service","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-12T02:00:00Z","last_updated_date":"2015-06-12T02:00:00Z","reference_number":"EMA/262834/2015","document_url":"https://www.ema.europa.eu/en/documents/other/process-description-managing-duplicates-context-medical-literature-monitoring-mlm-service_en.pdf"},
    {"id":"33383","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Olipudase alfa for treatment of Niemann-Pick disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T17:30:00Z","last_updated_date":"2015-05-19T17:30:00Z","reference_number":"EMA/216670/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-olipudase-alfa-treatment-niemann-pick-disease_en.pdf"},
    {"id":"33386","name":"Preparation for written procedure on adoption of the Agency’s policy on protecting the dignity of the person and preventing any form of psychological or sexual harassment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/575364/2010","document_url":"https://www.ema.europa.eu/en/documents/other/preparation-written-procedure-adoption-agencys-policy-protecting-dignity-person-and-preventing-any-form-psychological-or-sexual-harassment_en.pdf"},
    {"id":"33392","name":"Work plan for the Pharmacogenomics Working Party (PGWP) 2009","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-09-25T02:09:21Z","last_updated_date":"2008-09-25T02:09:21Z","reference_number":"EMEA/324640/2008","document_url":"https://www.ema.europa.eu/en/documents/other/work-plan-pharmacogenomics-working-party-pgwp-2009_en.pdf"},
    {"id":"33404","name":"Consultation procedure - Public consultation regarding the request to the European Medicines Agency from the European Commission for scientific advice on the impact on public health and animal health of the use of antibi...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T16:15:00Z","last_updated_date":"2014-05-06T19:00:00Z","reference_number":"EMA/776691/2013 Rev1","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-procedure-public-consultation-regarding-request-european-medicines-agency-european-commission-scientific-advice-impact-public-health-and-animal-health-use-antibi_en.pdf"},
    {"id":"33425","name":"Competence requirements and training needs for quality assessors","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-06T01:00:00Z","last_updated_date":"2012-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/competence-requirements-and-training-needs-quality-assessors_en.pdf"},
    {"id":"33441","name":"CVMP analysis of the functioning of current veterinary legislation and proposals for its evolution and comments on the Commission paper","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-07-19T02:00:00Z","last_updated_date":"2010-07-19T02:00:00Z","reference_number":"EMA/CVMP/463298/2010","document_url":"https://www.ema.europa.eu/en/documents/other/cvmp-analysis-functioning-current-veterinary-legislation-and-proposals-its-evolution-and-comments-commission-paper_en.pdf"},
    {"id":"33443","name":"Cathal Gallagher (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cathal-gallagher-cv_en.pdf"},
    {"id":"33455","name":"Sample eligibility form - Healthcare professionals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-10T13:47:00Z","last_updated_date":"2018-07-10T13:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sample-eligibility-form-healthcare-professionals_en.pdf"},
    {"id":"33457","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Perindopril / amlodipine for treatment of hypertension","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T17:30:00Z","last_updated_date":"2015-05-19T17:30:00Z","reference_number":"EMA/51623/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-perindopril-amlodipine-treatment-hypertension_en.pdf"},
    {"id":"33470","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 24-27 June 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-08T02:00:00Z","last_updated_date":"2013-07-09T19:30:00Z","reference_number":"EMA/CHMP/240799/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-24-27-june-2013_en.pdf"},
    {"id":"33496","name":"Scientific advice and protocol assistance - Adopted during the CHMP meeting 18-21 June 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T14:00:00Z","last_updated_date":"2012-06-22T14:00:00Z","reference_number":"EMA/CHMP/SAWP/420418/2012","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-advice-and-protocol-assistance-adopted-during-chmp-meeting-18-21-june-2012_en.pdf"},
    {"id":"33506","name":"Committee for Medicinal Products for Veterinary Use (CVMP) positive opinions in 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T15:00:00Z","last_updated_date":"2015-01-27T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/committee-medicinal-products-veterinary-use-cvmp-positive-opinions-2014_en.pdf"},
    {"id":"33515","name":"Questions and answers: implementation of CVMP guideline on environmental impact assessment for veterinary medicinal products in support of the VICH guidelines GL6 (Phase I) and GL38 (Phase II)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2022-05-20T08:51:00Z","reference_number":"EMEA/CVMP/ERA/172074/2008 Rev.7","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-implementation-cvmp-guideline-environmental-impact-assessment-veterinary-medicinal-products-support-vich-guidelines-gl6-phase-i-and-gl38-phase-ii_en.pdf"},
    {"id":"33526","name":"Mandate, objectives and composition of the Patients and Consumers Working Party (PCWP)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-09-07T02:09:00Z","last_updated_date":"2025-04-02T10:14:00Z","reference_number":"EMA/563123/2018 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-composition-patients-consumers-working-party-pcwp_en.pdf"},
    {"id":"33528","name":"Overview of comments received on 'Guideline on the use of bovine serum in the manufacture of human biological medicinal products'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-04T11:10:00Z","last_updated_date":"2013-06-04T11:10:00Z","reference_number":"EMA/CHMP/BWP/596/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-use-bovine-serum-manufacture-human-biological-medicinal-products_en.pdf"},
    {"id":"33540","name":"List of participants - Eighth stakeholders forum on the implementation of the new pharmacovigilance legislation: Building on two years of operation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"EMA/533762/2014","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-eighth-stakeholders-forum-implementation-new-pharmacovigilance-legislation-building-two-years-operation_en.pdf"},
    {"id":"33546","name":"Guidelines and concept papers adopted during the CHMP meeting 16-19 September 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-26T17:35:00Z","last_updated_date":"2013-09-26T17:35:00Z","reference_number":"EMA/568760/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-16-19-september-2013_en.pdf"},
    {"id":"33552","name":"Mandate and objectives for the European Medicines Agency Working Party on Quality Review of Documents (QRD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-09T11:10:00Z","last_updated_date":"2014-07-09T11:10:00Z","reference_number":"EMA/403106/2014","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-and-objectives-european-medicines-agency-working-party-quality-review-documents-qrd_en.pdf"},
    {"id":"33602","name":"Letter of support for Predictive Safety Testing Consortium translational drug-induced kidney injury biomarkers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-07T16:56:00Z","last_updated_date":"2014-11-07T16:56:00Z","reference_number":"EMA/651243/2014","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-predictive-safety-testing-consortium-translational-drug-induced-kidney-injury-biomarkers_en.pdf"},
    {"id":"33651","name":"Opinions on annual re-assessments, 5-year renewals - Adopted at the CHMP meeting of 16-19 April 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-25T14:35:00Z","last_updated_date":"2012-04-25T14:35:00Z","reference_number":"EMA/CHMP/213034/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-5-year-renewals-adopted-chmp-meeting-16-19-april-2012_en.pdf"},
    {"id":"33654","name":"Overall high level plan for SPOR","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-11-09T01:00:00Z","last_updated_date":"2016-03-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overall-high-level-plan-spor_en.pdf"},
    {"id":"33661","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) routes of administration","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2022-11-18T08:25:00Z","reference_number":"EMA/136146/2012 Rev.22","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-routes-administration_en.xls"},
    {"id":"33671","name":"Overview of interactions between the European Medicines Agency (EMA) and Food and Drug Administration (FDA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-interactions-between-european-medicines-agency-ema-and-food-and-drug-administration-fda_en.pdf"},
    {"id":"33698","name":"Overview of comments received on draft guideline on psoriatic arthritis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-12-14T01:00:00Z","last_updated_date":"2006-12-14T01:00:00Z","reference_number":"EMEA/CHMP/EWP/487962/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-psoriatic-arthritis_en.pdf"},
    {"id":"33700","name":"Organisational matters - CHMP meeting 15-18 October 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T14:29:00Z","last_updated_date":"2012-10-19T14:29:00Z","reference_number":"EMA/CHMP/539795/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-15-18-october-2012_en.pdf"},
    {"id":"33705","name":"List of participants of the European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting February 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T13:40:00Z","last_updated_date":"2014-04-28T13:40:00Z","reference_number":"EMA/71668/2014","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-february-2014_en.pdf"},
    {"id":"33719","name":"Pathogen specific database: Brucellosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-brucellosis_en.pdf"},
    {"id":"33727","name":"Note on the removal of the target animal batch safety test (TABST) from European Pharmacopoeia monographs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-18T18:40:00Z","last_updated_date":"2015-05-18T18:40:00Z","reference_number":"EMA/CVMP/IWP/107173/2015","document_url":"https://www.ema.europa.eu/en/documents/other/note-removal-target-animal-batch-safety-test-tabst-european-pharmacopoeia-monographs_en.pdf"},
    {"id":"33755","name":"Declaration of interests: Bruno Pistori","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2020-09-03T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-bruno-pistori_en.pdf"},
    {"id":"33773","name":"Questions and answers relating to open tender EMA/2012/03/HR for provision of services for 360 performance evaluation of European Medicines Agency management staff","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T16:10:00Z","last_updated_date":"2012-02-16T18:15:00Z","reference_number":"EMA/85809/2012","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-tender-ema201203hr-provision-services-360-performance-evaluation-european-medicines-agency-management-staff_en.pdf"},
    {"id":"33783","name":"Letter of support for drug-induced renal tubular injury biomarker(s)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-12T16:10:00Z","last_updated_date":"2017-01-12T16:10:00Z","reference_number":"EMA/715025/2016","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-drug-induced-renal-tubular-injury-biomarkers_en.pdf"},
    {"id":"33796","name":"Online strategy and interface design EMA/2012/37/ED – Technical specification annex III - Response questionnaire","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T02:00:00Z","last_updated_date":"2013-07-05T17:15:00Z","reference_number":"EMA/117115/2013","document_url":"https://www.ema.europa.eu/en/documents/other/online-strategy-and-interface-design-ema201237ed-technical-specification-annex-iii-response-questionnaire_en.xls"},
    {"id":"33819","name":"Draft inventory of paediatric medicines - Infectious diseases","type":"other","status":"Draft: consultation closed","consultation_date":"2013-05-15 - 2013-07-26","first_published_date":"2013-05-15T20:20:00Z","last_updated_date":"2013-06-18T16:00:00Z","reference_number":"EMA/PDCO/287222/2012","document_url":"https://www.ema.europa.eu/en/documents/other/draft-inventory-paediatric-medicines-infectious-diseases_en.pdf"},
    {"id":"33851","name":"Overview of comments received on draft guideline on Core SmPC for human plasma fibrinogen products (EMEA/CHMP/BPWP/122007/2005)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-02-19T01:00:00Z","last_updated_date":"2007-02-19T01:00:00Z","reference_number":"EMEA/CHMP/BPWP/399089/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-core-smpc-human-plasma-fibrinogen-products-emeachmpbpwp1220072005_en.pdf"},
    {"id":"33856","name":"Ad hoc working party on Herbal Medicinal Products:  Final comments for revision of the notice to applicants volume 2B Part IC1 'Tabular formats specific to Herbal Medicinal Products'","type":"other","status":"unknown","consultation_date":"","first_published_date":"1999-01-28T01:00:00Z","last_updated_date":"1999-01-28T01:00:00Z","reference_number":"EMEA/HMPWP/16/99","document_url":"https://www.ema.europa.eu/en/documents/other/ad-hoc-working-party-herbal-medicinal-products-final-comments-revision-notice-applicants-volume-2b-part-ic1-tabular-formats-specific-herbal-medicinal-products_en.pdf"},
    {"id":"33868","name":"Revised procedure for the appointment of the Executive Director - Extraordinary Management Board meeting 5 May 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-06-16T02:00:00Z","last_updated_date":"2011-06-16T02:00:00Z","reference_number":"EMA/MB/400828/2009","document_url":"https://www.ema.europa.eu/en/documents/other/revised-procedure-appointment-executive-director-extraordinary-management-board-meeting-5-may-2011_en.pdf"},
    {"id":"33945","name":"PDCO meetings in 2023, 2024, 2025 and 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-13T10:13:00Z","last_updated_date":"2023-03-13T10:13:00Z","reference_number":"EMA/109170/2023","document_url":"https://www.ema.europa.eu/en/documents/other/pdco-meetings-2023-2024-2025-and-2026_en.pdf"},
    {"id":"33952","name":"Antimicrobial resistance - Combating a serious threat to public and animal health","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-11-18T12:30:00Z","last_updated_date":"2015-11-18T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/antimicrobial-resistance-combating-serious-threat-public-and-animal-health_en.pdf"},
    {"id":"33961","name":"Discussion meeting for MCP-Mod qualification opinion request - Annex 3","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-10T10:20:00Z","last_updated_date":"2014-02-10T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/discussion-meeting-mcp-mod-qualification-opinion-request-annex-3_en.pdf"},
    {"id":"33963","name":"Declaration of interests: Mario Benetti","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-09-21T02:00:00Z","last_updated_date":"2025-08-01T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-mario-benetti_en.pdf"},
    {"id":"33989","name":"Orphan medicinal products - Key figures in 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/orphan-medicinal-products-key-figures-2013_en.pdf"},
    {"id":"34026","name":"Organisation chart: Veterinary Medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-16T12:00:00Z","last_updated_date":"2025-08-18T13:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-chart-veterinary-medicines_en.pdf"},
    {"id":"34055","name":"Keppra: Product Information as approved by the CHMP on 13 October 2016, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/keppra-product-information-approved-chmp-13-october-2016-pending-endorsement-european-commission_en.pdf"},
    {"id":"34069","name":"Successes of the Paediatric Regulation after five years","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-06T11:19:00Z","last_updated_date":"2013-06-06T11:19:00Z","reference_number":"EMA/250577/2013","document_url":"https://www.ema.europa.eu/en/documents/other/successes-paediatric-regulation-after-five-years_en.pdf"},
    {"id":"34070","name":"Participants list - IPA introductory meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/participants-list-ipa-introductory-meeting_en.pdf"},
    {"id":"34083","name":"Dactylis glomarata (8%), Lolium perenne (8%), Phleum pratense (8%), Poa pratensis (8%), Anthoxhantum odoratum (8%), Secale cereale (10%), Betula pendula (16,7%), Corylus avellana (16,6%) and Alnus glutinosa (16,6%) - Not...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/dactylis-glomarata-8-lolium-perenne-8-phleum-pratense-8-poa-pratensis-8-anthoxhantum-odoratum-8-secale-cereale-10-betula-pendula-167-corylus-avellana-166-and-alnus-glutinosa-166-not_en.pdf"},
    {"id":"34087","name":"Technical specifications for open invitation to tender no. EMEA/2006/35/ACC, banking services for European Medicines Agency (EMEA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-08-29T02:00:00Z","last_updated_date":"2006-08-29T02:00:00Z","reference_number":"EMEA/3419/04/5736","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-no-emea200635acc-banking-services-european-medicines-agency-emea_en.pdf"},
    {"id":"34101","name":"List of participants - Workshop on draft reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-workshop-draft-reflection-paper-statistical-methodology-comparative-assessment-quality-attributes-drug-development_en.pdf"},
    {"id":"34116","name":"List of participants - Healthcare Professionals Working Group (HCPWG) meeting 27 Feb 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/50873/2013","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-healthcare-professionals-working-group-hcpwg-meeting-27-feb-2013_en.pdf"},
    {"id":"34117","name":"Outcome of written procedures finalised during the period from 20 September 2012 to 21 November 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/MB/729025/2012","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-20-september-2012-21-november-2012_en.pdf"},
    {"id":"34120","name":"Mandate, objectives and rules of procedure for the CVMP Scientific Advice Working Party (SAWP-V)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2007-09-18T02:09:21Z","last_updated_date":"2018-06-04T14:00:00Z","reference_number":"EMA/CVMP/SAWP/676117/2010 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cvmp-scientific-advice-working-party-sawp-v_en.pdf"},
    {"id":"34131","name":"On consultation on changes in the membership of the CHMP and CVMP scientific committees","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/MB/715154/2009","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-changes-membership-chmp-and-cvmp-scientific-committees_en.pdf"},
    {"id":"34134","name":"Overview of comments received on 'Core SmPC and package leaflet for technetium (99mTc) sestamibi","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T15:15:00Z","last_updated_date":"2013-12-17T15:15:00Z","reference_number":"EMA/528960/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-core-smpc-and-package-leaflet-technetium-99mtc-sestamibi_en.pdf"},
    {"id":"34136","name":"Declaration of interests: Olivier Duquesne","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-20T14:31:00Z","last_updated_date":"2025-08-01T11:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-olivier-duquesne_en.pdf"},
    {"id":"34145","name":"European Medicines Agency Modelling and Simulation Working Group plan 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-02T14:30:00Z","last_updated_date":"2014-06-02T14:30:00Z","reference_number":"EMA/303847/2014","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-modelling-and-simulation-working-group-plan-2014_en.pdf"},
    {"id":"34147","name":"Pre-notification check for type IA/IAIN variations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-18T14:57:33Z","last_updated_date":"2017-06-30T16:00:00Z","reference_number":"EMA/746161/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/pre-notification-check-type-iaiain-variations_en.pdf"},
    {"id":"34158","name":"Guidelines and concept papers adopted during the CHMP meeting 12-15 November 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-22T10:15:00Z","last_updated_date":"2012-11-22T10:15:00Z","reference_number":"EMA/CHMP/732276/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-12-15-november-2012_en.pdf"},
    {"id":"34174","name":"Overview of comments for the guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-12-02T00:09:21Z","last_updated_date":"2009-12-02T00:09:21Z","reference_number":"EMEA/CHMP/EWP/582423/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-guideline-clinical-investigations-medicinal-products-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"34176","name":"Start of community reviews adopted during the CHMP meeting of 16-19 January 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T13:00:00Z","last_updated_date":"2012-01-20T13:00:00Z","reference_number":"EMA/43544/2012","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-adopted-during-chmp-meeting-16-19-january-2012_en.pdf"},
    {"id":"34195","name":"Letter from Thomas Là¶nngren 10-02-2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-21T01:00:00Z","last_updated_date":"2011-03-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-thomas-lapnngren-10-02-2011_en.pdf"},
    {"id":"34211","name":"Response to public comments received on the ‘Inventory of paediatric therapeutic needs – Respiratory’","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T14:08:00Z","last_updated_date":"2016-10-07T14:08:00Z","reference_number":"EMA/528945/2016","document_url":"https://www.ema.europa.eu/en/documents/other/response-public-comments-received-inventory-paediatric-therapeutic-needs-respiratory_en.pdf"},
    {"id":"34245","name":"Decision tree on escalation from national to European level","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T00:00:00Z","last_updated_date":"2013-01-29T00:00:00Z","reference_number":"EMA/314722/2013","document_url":"https://www.ema.europa.eu/en/documents/other/decision-tree-escalation-national-european-level_en.pdf"},
    {"id":"34283","name":"Declaration of interests - Wolfgang Gopel","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-wolfgang-gopel_en.pdf"},
    {"id":"34289","name":"Quixil: Product information as approved by the CHMP on 15 November 2012, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-23T12:54:00Z","last_updated_date":"2012-11-23T12:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/quixil-product-information-approved-chmp-15-november-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"34300","name":"Call for expressions of interest, from software vendors, service providers and pharmacovigilance system implementers, to attend a workshop on 4 March 2016 on the implementation of international ICSR standard (ICH E2B(R3)...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-13T17:00:00Z","last_updated_date":"2016-01-13T17:00:00Z","reference_number":"EMA/847935/2015","document_url":"https://www.ema.europa.eu/en/documents/other/call-expressions-interest-software-vendors-service-providers-and-pharmacovigilance-system-implementers-attend-workshop-4-march-2016-implementation-international-icsr-standard-ich-e2br3_en.pdf"},
    {"id":"34311","name":"European Medicines Agency master data management roadmap","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T16:00:00Z","last_updated_date":"2015-04-29T16:00:00Z","reference_number":"EMA/730453/2014","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-master-data-management-roadmap_en.pdf"},
    {"id":"34313","name":"Questions and answers on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), bluetongue (BT) and foot-and-mouth disease (FMD) - First version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-09-18T14:36:00Z","last_updated_date":"2017-09-18T14:36:00Z","reference_number":"EMA/CVMP/IWP/466888/2017","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-data-requirements-multi-strain-dossiers-inactivated-vaccines-against-avian-influenza-ai-bluetongue-bt-and-foot-and-mouth-disease-fmd-first-version_en.pdf"},
    {"id":"34358","name":"European Medicines Agency mid-year report 2011 from the Acting Executive Director (January - June 2011)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/MB/653974/2011","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-mid-year-report-2011-acting-executive-director-january-june-2011_en.pdf"},
    {"id":"34368","name":"Summary of transfer of appropriations in the budget 2014 - Management Board meeting: 2 October 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-08T15:00:00Z","last_updated_date":"2014-10-08T15:00:00Z","reference_number":"EMA/MB/525840/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2014-management-board-meeting-2-october-2014_en.pdf"},
    {"id":"34376","name":"Scientific advice and protocol assistance - CHMP meeting of 17-20 September 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-21T14:01:00Z","last_updated_date":"2012-09-21T14:01:00Z","reference_number":"EMA/CHMP/SAWP/610283/2012","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-advice-and-protocol-assistance-chmp-meeting-17-20-september-2012_en.pdf"},
    {"id":"34378","name":"Mandate, objectives and rules of procedure for the Scientific Advisory Groups (SAGs) and ad-hoc experts groups","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-06-03T02:00:00Z","last_updated_date":"2010-06-03T13:17:00Z","reference_number":"EMA/117014/2010 ","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-scientific-advisory-groups-sags-and-ad-hoc-experts-groups_en.pdf"},
    {"id":"34381","name":"Outcome of Management Board written procedures during the period from 15 September 2011 to 30 November 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T11:30:00Z","last_updated_date":"2011-12-20T11:30:00Z","reference_number":"EMA/MB/868582/2011","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-management-board-written-procedures-during-period-15-september-2011-30-november-2011_en.pdf"},
    {"id":"34398","name":"Important notice to tenderers - EMA-2012-09-IF external service providers for enterprise infrastructure support","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-30T15:06:00Z","last_updated_date":"2012-03-30T15:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/important-notice-tenderers-ema-2012-09-if-external-service-providers-enterprise-infrastructure-support_en.pdf"},
    {"id":"34402","name":"Revision of section 6 of the 'Functional specifications for the European Union (EU) portal and EU database to be audited - EMA/42176/2014' setting out features to support making information public","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T11:00:00Z","last_updated_date":"2015-04-16T11:00:00Z","reference_number":"EMA/129363/2015","document_url":"https://www.ema.europa.eu/en/documents/other/revision-section-6-functional-specifications-european-union-eu-portal-and-eu-database-be-audited-ema421762014-setting-out-features-support-making-information-public_en.pdf"},
    {"id":"34422","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Nanobody directed towards the fusion protein of human respiratory syncytial virus (ALX-0171) for treatment of lower respiratory tract diseas...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-25T12:30:00Z","last_updated_date":"2014-11-25T12:30:00Z","reference_number":"EMA/691347/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-nanobody-directed-towards-fusion-protein-human-respiratory-syncytial-virus-alx-0171-treatment-lower-respiratory-tract-diseas_en.pdf"},
    {"id":"34426","name":"Highlights from the EMA Industry Platform meeting on the Operation of EU pharmacovigilance legislation – 13 March 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T13:56:00Z","last_updated_date":"2015-05-04T13:56:00Z","reference_number":"EMA/230906/2015","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-ema-industry-platform-meeting-operation-eu-pharmacovigilance-legislation-13-march-2015_en.pdf"},
    {"id":"34427","name":"Heads of Medicines Agencies / European Medicines Agency guidance document on the identification of commercially confidential information and personal data within the structure of the marketing-authorisation application: ...","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-03-27T12:00:00Z","last_updated_date":"2024-12-18T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/heads-medicines-agencies-european-medicines-agency-guidance-document-identification-commercially-confidential-information-personal-data-within-structure-marketing-authorisation-application_en.pdf"},
    {"id":"34442","name":"Summary of transfers of appropriations in the budget 2009 - Management Board meeting: 11 June 2009","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-06-11T02:09:21Z","last_updated_date":"2009-06-11T02:09:21Z","reference_number":"EMEA/MB/90876/2009","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2009-management-board-meeting-11-june-2009_en.pdf"},
    {"id":"34445","name":"Frequently asked questions on phenylbutazone in horsemeat","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T12:00:00Z","last_updated_date":"2013-04-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/frequently-asked-questions-phenylbutazone-horsemeat_en.pdf"},
    {"id":"34467","name":"newList of participants of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"EMA/407107/2015","document_url":"https://www.ema.europa.eu/en/documents/other/newlist-participants-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf"},
    {"id":"34473","name":"PRAC meeting dates 2016, 2017 and 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-24T01:00:00Z","last_updated_date":"2017-11-07T17:00:00Z","reference_number":"EMA/PRAC/105364/2013 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/other/prac-meeting-dates-2016-2017-and-2018_en.pdf"},
    {"id":"34490","name":"Announcement - 2012 European Medicines Agency/International Federation for Animal Health Europe info day","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T12:55:00Z","last_updated_date":"2011-12-19T12:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/announcement-2012-european-medicines-agencyinternational-federation-animal-health-europe-info-day_en.pdf"},
    {"id":"34498","name":"Overview of comments received on draft scientific guideline on the minimum quality and non-clinical data for certification of advanced therapy medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-11-10T01:00:00Z","last_updated_date":"2010-11-10T01:00:00Z","reference_number":"EMA/CAT/45852/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-scientific-guideline-minimum-quality-and-non-clinical-data-certification-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"34515","name":"Declaration of interests: Anabela Luis de Lima Marcal","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2019-10-25T10:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-anabela-luis-de-lima-marcal_en.pdf"},
    {"id":"34542","name":"Strategy for regulatory and scientific training within the European Regulatory Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-06T01:00:00Z","last_updated_date":"2012-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/strategy-regulatory-and-scientific-training-within-european-regulatory-network_en.pdf"},
    {"id":"34548","name":"European Medicines Agency 2013 priorities for drug safety research: Long-term safety effects of antipsychotics in patients with dementia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-22T18:13:29Z","last_updated_date":"2012-05-22T18:13:29Z","reference_number":"EMA/281408/2012","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-2013-priorities-drug-safety-research-long-term-safety-effects-antipsychotics-patients-dementia_en.pdf"},
    {"id":"34559","name":"Opinions on annual re-assessments and five-year renewals adopted at the Committee for Medicinal Products for Human Use meeting of 17-20 October 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-25T13:45:00Z","last_updated_date":"2011-10-25T13:45:00Z","reference_number":"EMA/CHMP/832561/2011","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-and-five-year-renewals-adopted-committee-medicinal-products-human-use-meeting-17-20-october-2011_en.pdf"},
    {"id":"34573","name":"Summary - Meeting on redacting commercially confidential information (CCI) in clinical reports and anonymising clinical reports for the purpose of publication","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"EMA/457830/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-meeting-redacting-commercially-confidential-information-cci-clinical-reports-and-anonymising-clinical-reports-purpose-publication_en.pdf"},
    {"id":"34592","name":"Focetria: Package leaflet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-05T01:00:00Z","last_updated_date":"2010-03-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/focetria-package-leaflet_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/focetria-package-leaflet_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/focetria-package-leaflet_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/focetria-package-leaflet_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/focetria-package-leaflet_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/focetria-package-leaflet_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/focetria-package-leaflet_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/focetria-package-leaflet_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/focetria-package-leaflet_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/focetria-package-leaflet_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/focetria-package-leaflet_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/focetria-package-leaflet_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/focetria-package-leaflet_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/focetria-package-leaflet_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/focetria-package-leaflet_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/focetria-package-leaflet_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/focetria-package-leaflet_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/focetria-package-leaflet_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/focetria-package-leaflet_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/focetria-package-leaflet_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/focetria-package-leaflet_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/focetria-package-leaflet_sv.pdf"}},
    {"id":"34597","name":"PKDOC response to the European Medicines Agency third list of issues - Total kidney volume as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-22T11:00:00Z","last_updated_date":"2015-07-22T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pkdoc-response-european-medicines-agency-third-list-issues-total-kidney-volume-prognostic-biomarker-use-clinical-trials-evaluating-patients-autosomal-dominant-polycystic-kidney-disease-adpkd_en.pdf"},
    {"id":"34603","name":"Delegation of non-substantial amendments to the Work Programme to the authorising officer","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/MB/768568/2015","document_url":"https://www.ema.europa.eu/en/documents/other/delegation-non-substantial-amendments-work-programme-authorising-officer_en.pdf"},
    {"id":"34621","name":"Monitoring medical literature EVWEB literature test cases XML format","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-30T14:00:00Z","last_updated_date":"2015-06-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/monitoring-medical-literature-evweb-literature-test-cases-xml-format_en.zip"}    {"id":"34624","name":"Inventory of herbal substances for assessment","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-10-25T02:00:00Z","last_updated_date":"2021-07-05T13:17:00Z","reference_number":"EMA/HMPC/494079/2007","document_url":"https://www.ema.europa.eu/en/documents/other/inventory-herbal-substances-assessment_en.pdf"},
    {"id":"34642","name":"Policy 1: Quality Management Policy","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-03-10T01:00:00Z","last_updated_date":"2024-07-01T01:00:00Z","reference_number":"EMA/228979/2024","document_url":"https://www.ema.europa.eu/en/documents/other/policy-1-quality-management-policy_en.pdf"},
    {"id":"34695","name":"Outcome of written procedures finalised during the period from 17 November 2016 to 16 February 2017","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T17:00:00Z","last_updated_date":"2017-03-17T17:00:00Z","reference_number":"EMA/MB/27995/2017","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-17-november-2016-16-february-2017_en.pdf"},
    {"id":"34710","name":"Overview of comments received on guideline on the use of porcine trypsin used in the manufacture of human biological medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-04T14:00:00Z","last_updated_date":"2014-03-04T14:00:00Z","reference_number":"EMA/CHMP/BWP/574033/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-use-porcine-trypsin-used-manufacture-human-biological-medicinal-products_en.pdf"},
    {"id":"34725","name":"Pharmacovigilance and Risk Assessment Committee (PRAC): Consultation procedure on final composition and replacement of members/alternates","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"EMA/MB/139702/2012","document_url":"https://www.ema.europa.eu/en/documents/other/pharmacovigilance-and-risk-assessment-committee-prac-consultation-procedure-final-composition-and-replacement-membersalternates_en.pdf"},
    {"id":"34732","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 16-19 July 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-07-27T11:40:00Z","last_updated_date":"2012-07-27T11:40:00Z","reference_number":"EMA/CHMP/410523/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-16-19-july-2012_en.pdf"},
    {"id":"34740","name":"Overview of comments on qualification opinion ILSI / HESI submission of novel renal biomarkers for toxicity","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-11-26T01:00:00Z","last_updated_date":"2010-11-26T01:00:00Z","reference_number":"EMA/CHMP/SAWP/627644/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-qualification-opinion-ilsi-hesi-submission-novel-renal-biomarkers-toxicity_en.pdf"},
    {"id":"34747","name":"HMPC: overview of assessment work - priority list","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-10-26T00:09:00Z","last_updated_date":"2026-05-13T12:00:00Z","reference_number":"EMA/HMPC/561868/2021","document_url":"https://www.ema.europa.eu/en/documents/other/hmpc-overview-assessment-work-priority-list_en.pdf"},
    {"id":"34828","name":"Registration request for the workshop on extrapolation of efficacy and safety in medicine development across age groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-14T17:50:00Z","last_updated_date":"2016-03-01T17:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/registration-request-workshop-extrapolation-efficacy-and-safety-medicine-development-across-age-groups_en.pdf"},
    {"id":"34831","name":"Overview of comments received on 'Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)' (EMEA/CHMP/EWP/431734/2008)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-08-05T02:00:00Z","last_updated_date":"2010-08-05T02:00:00Z","reference_number":"EMEA/CHMP/EWP/431734/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-attention-deficit-hyperactivity-disorder-adhd-emeachmpewp4317342008_en.pdf"},
    {"id":"34843","name":"Start of community reviews - CHMP meeting of 18-21 March 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-22T01:00:00Z","last_updated_date":"2013-03-22T01:00:00Z","reference_number":"EMA/177209/2013","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-18-21-march-2013_en.pdf"},
    {"id":"34848","name":"Overview of comments received on 'Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines' (EMA/CVMP/IWP/314550/2010)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-11-29T16:00:00Z","last_updated_date":"2011-11-29T16:00:00Z","reference_number":"EMA/CVMP/IWP/897330/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-design-studies-evaluate-safety-and-efficacy-fish-vaccines-emacvmpiwp3145502010_en.pdf"},
    {"id":"34856","name":"Recognition criteria for self assessment - Enpr-EMA: European Society of Paediatric Gastroenterology Heptology and Nutrition ((ESPGHAN)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-european-society-paediatric-gastroenterology-heptology-and-nutrition-espghan_en.pdf"},
    {"id":"34907","name":"Report on the Activities of the Working Group on Quality Review of Documents in 1998","type":"other","status":"unknown","consultation_date":"","first_published_date":"1998-12-19T00:00:00Z","last_updated_date":"1998-12-19T00:00:00Z","reference_number":"EMEA/T/SMF/38060/98","document_url":"https://www.ema.europa.eu/en/documents/other/report-activities-working-group-quality-review-documents-1998_en.pdf"},
    {"id":"34911","name":"Irvine Scientific Reproductive Media - Procedural steps and scientific information after initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2024-11-12T13:57:00Z","reference_number":"EMA/529198/2024 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/irvine-scientific-reproductive-media-procedural-steps-scientific-information-after-initial-consultation_en.pdf"},
    {"id":"34917","name":"Overview of comments received on draft guideline on the procedure to be followed when a batch is suspectedtobe contaminated with Bovine Viral Diarrhoea (BVD) virus","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-03-17T01:00:00Z","last_updated_date":"2008-03-17T01:00:00Z","reference_number":"EMEA/123421/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-procedure-be-followed-when-batch-suspectedtobe-contaminated-bovine-viral-diarrhoea-bvd-virus_en.pdf"},
    {"id":"34938","name":"Overview of comments received on 'Questions and answers on the ‘Note for guidance of photosafety testing’'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-04-11T02:00:00Z","last_updated_date":"2011-04-11T02:00:00Z","reference_number":"EMA/CHMP/SWP/170012/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-questions-and-answers-note-guidance-photosafety-testing_en.pdf"},
    {"id":"34944","name":"Overview of comments received on draft guideline on real-time release testing (formerly guideline on parametric release)","type":"other","status":"unknown","consultation_date":"2012-03-15 - 2012-10-31","first_published_date":"2012-04-13T15:50:00Z","last_updated_date":"2012-04-13T15:50:00Z","reference_number":"EMA/CHMP/QWP/142288/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-real-time-release-testing-formerly-guideline-parametric-release_en.pdf"},
    {"id":"34986","name":"Overview of comments received on draft guideline on clinical investigation of immunosupressants for solid organ transplantation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-16T02:00:00Z","last_updated_date":"2008-07-16T02:00:00Z","reference_number":"EMEA/377225/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-immunosupressants-solid-organ-transplantation_en.pdf"},
    {"id":"35011","name":"Technical specification - Annex 12b - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-12b-external-service-providers-software-applications-ema201213ict_en.xls"},
    {"id":"35020","name":"PRAC meetings in 2019, 2020, 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-02-26T14:00:00Z","last_updated_date":"2019-12-03T17:10:00Z","reference_number":"EMA/PRAC/92423/2018 Corr.4","document_url":"https://www.ema.europa.eu/en/documents/other/prac-meetings-2019-2020-2021_en.pdf"},
    {"id":"35039","name":"Overview of comments received on 'CHMP/CAT position statement on Creutzfeldt-Jakob disease and advanced-therapy medicinal products'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-28T02:00:00Z","last_updated_date":"2011-06-28T02:00:00Z","reference_number":"EMA/CHMP/BWP/782739/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-chmpcat-position-statement-creutzfeldt-jakob-disease-and-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"35058","name":"CHMP meeting dates 2016, 2017 and 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-09T01:00:00Z","last_updated_date":"2016-02-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-meeting-dates-2016-2017-and-2018_en.pdf"},
    {"id":"35059","name":"Mandate, objectives and rules of procedure for the Excipients Drafting Group","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2016-03-16T01:00:00Z","last_updated_date":"2016-03-16T01:00:00Z","reference_number":"EMA/CHMP/74184/2015","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-excipients-drafting-group_en.pdf"},
    {"id":"35061","name":"Welcome speech - Sinisa Tomic, ALMP, Croatia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-12-09T00:09:00Z","last_updated_date":"2008-12-09T00:09:00Z","reference_number":"EMEA/662143/2008","document_url":"https://www.ema.europa.eu/en/documents/other/welcome-speech-sinisa-tomic-almp-croatia_en.pdf"},
    {"id":"35066","name":"European Commission - Canada mutual recognition agreement: Sectoral annex on good manufacturing products -  Seventh joint sectoral group meeting, first year of operation of the sectoral annex","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-07-15T02:00:00Z","last_updated_date":"2004-07-15T02:00:00Z","reference_number":"EMEA/INS/MRA/CA/04/04","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-canada-mutual-recognition-agreement-sectoral-annex-good-manufacturing-products-seventh-joint-sectoral-group-meeting-first-year-operation-sectoral-annex_en.pdf"},
    {"id":"35073","name":"European Medicines Agency amends minor-use-minor-species / limited-market policy","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-06-18T18:40:00Z","last_updated_date":"2013-06-18T18:40:00Z","reference_number":"EMA/327514/2013","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-amends-minor-use-minor-species-limited-market-policy_en.pdf"},
    {"id":"35088","name":"Workshop on stem cell-based therapies: Invitation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-16T01:09:21Z","last_updated_date":"2010-02-16T01:09:21Z","reference_number":"EMA/CHMP/CPWP/51422/2010","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-stem-cell-based-therapies-invitation_en.pdf"},
    {"id":"35096","name":"Joint audit programme for EEA GMP inspectorates: Confidentiality agreement for audits","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-18T02:00:00Z","last_updated_date":"2019-02-22T02:00:00Z","reference_number":"EMA/167084/2018 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/joint-audit-programme-eea-gmp-inspectorates-confidentiality-agreement-audits_en.docx"},
    {"id":"35119","name":"Joint audit programme for European Economic Area GMP inspectorates: Audit report template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-08-08T02:00:00Z","last_updated_date":"2022-01-24T15:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/joint-audit-programme-european-economic-area-gmp-inspectorates-audit-report-template_en.docx"},
    {"id":"35120","name":"Medicines granted a Community marketing authorisation under the centralised procedure since the Committee for Medicinal Products for Human Use meeting 18-21 July 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T15:45:00Z","last_updated_date":"2011-10-06T15:45:00Z","reference_number":"EMA/788369/2011","document_url":"https://www.ema.europa.eu/en/documents/other/medicines-granted-community-marketing-authorisation-under-centralised-procedure-committee-medicinal-products-human-use-meeting-18-21-july-2011_en.pdf"},
    {"id":"35148","name":"Guido Rasi - high resolution photo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-01T02:00:00Z","last_updated_date":"2015-10-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/guido-rasi-high-resolution-photo_en.zip"},
    {"id":"35158","name":"Guidelines and concept papers adopted during the CHMP meeting 24-27 June 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-08T02:00:00Z","last_updated_date":"2013-07-09T19:30:00Z","reference_number":"EMA/CHMP/240800/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-24-27-june-2013_en.pdf"},
    {"id":"35166","name":"Overview of comments received on draft guideline on the need for non-clinical testing in juvenile animals of human pharmaceuticals for paediatric indications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-05-26T02:00:00Z","last_updated_date":"2009-05-26T02:00:00Z","reference_number":"EMEA/425007/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-need-non-clinical-testing-juvenile-animals-human-pharmaceuticals-paediatric-indications_en.pdf"},
    {"id":"35180","name":"Discussion paper on antimicrobial resistance","type":"other","status":"unknown","consultation_date":"","first_published_date":"1999-03-25T00:09:21Z","last_updated_date":"1999-03-25T00:09:21Z","reference_number":"EMEA/9880/99,Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/discussion-paper-antimicrobial-resistance_en.pdf"},
    {"id":"35188","name":"Risk indicators for Shortages (Manufacturing and Quality)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T00:00:00Z","last_updated_date":"2013-01-29T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/risk-indicators-shortages-manufacturing-and-quality_en.pdf"},
    {"id":"35234","name":"Start of Community reviews","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T13:00:00Z","last_updated_date":"2013-11-22T13:00:00Z","reference_number":"EMA/711468/2013","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews_en.pdf"},
    {"id":"35245","name":"Frequently asked questions on SmPC paediatric information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-08T01:00:00Z","last_updated_date":"2019-05-20T11:00:00Z","reference_number":"EMA/551202/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/frequently-asked-questions-smpc-paediatric-information_en.pdf"},
    {"id":"35270","name":"Mandate, objectives and rules of procedure of the Scientific Advice Working Party (SAWP)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-08-26T02:09:00Z","last_updated_date":"2025-04-22T17:00:00Z","reference_number":"EMEA/CHMP/SAWP/69686/04 Rev.19","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-scientific-advice-working-party-sawp_en.pdf"},
    {"id":"35283","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: A European Paediatric Oncology Off-Patent Medicines Consortium","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817615/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-european-paediatric-oncology-patent-medicines-consortium_en.pdf"},
    {"id":"35291","name":"PDCO dates for 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-05-20T02:00:00Z","last_updated_date":"2009-05-20T02:00:00Z","reference_number":"EMEA/PDCO/499023/2008-rev 1","document_url":"https://www.ema.europa.eu/en/documents/other/pdco-dates-2011_en.pdf"},
    {"id":"35295","name":"Committee for Medicinal Products for Veterinary Use and Committee for Medicinal Products for Human Use: Presence of the antibiotic resistance marker gene nptII in genetically modified plants for food and feed uses","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-02-22T00:09:21Z","last_updated_date":"2007-02-22T00:09:21Z","reference_number":"EMEA/CVMP/56937/2007- Final","document_url":"https://www.ema.europa.eu/en/documents/other/committee-medicinal-products-veterinary-use-and-committee-medicinal-products-human-use-presence-antibiotic-resistance-marker-gene-nptii-genetically-modified-plants-food-and-feed-uses_en.pdf"},
    {"id":"35309","name":"Ad hoc working group on Herbal Medicinal Products: Final proposal for a core data for Valerianae Radix","type":"other","status":"unknown","consultation_date":"","first_published_date":"1998-09-17T02:00:00Z","last_updated_date":"1998-09-17T02:00:00Z","reference_number":"EMEA/HMPWP/14/99","document_url":"https://www.ema.europa.eu/en/documents/other/ad-hoc-working-group-herbal-medicinal-products-final-proposal-core-data-valerianae-radix_en.pdf"},
    {"id":"35332","name":"Overview of comments received on list of paediatric needs - Epilepsy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/377231/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-list-paediatric-needs-epilepsy_en.pdf"},
    {"id":"35348","name":"Opinions on annual re-assessments, 5-year renewals - Adopted at the CHMP meeting of 12-15 March 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-21T12:00:00Z","last_updated_date":"2012-03-21T12:00:00Z","reference_number":"EMA/CHMP/162993/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-5-year-renewals-adopted-chmp-meeting-12-15-march-2012_en.pdf"},
    {"id":"35349","name":"Declaration of interests: Anne-Sophie Henry-Eude","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-16T12:00:00Z","last_updated_date":"2025-08-01T11:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-anne-sophie-henry-eude_en.pdf"},
    {"id":"35373","name":"Chapter 15: Medicinal products GMP Inspection and Batch certification - Scope and coverage","type":"other","status":"unknown","consultation_date":"","first_published_date":"2000-06-13T02:09:21Z","last_updated_date":"2000-06-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chapter-15-medicinal-products-gmp-inspection-and-batch-certification-scope-and-coverage_en.pdf"},
    {"id":"35382","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: CooperSurgical Inc ART Media","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-08T14:00:00Z","last_updated_date":"2012-08-08T14:00:00Z","reference_number":"EMA/850703/2011","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-coopersurgical-inc-art-media_en.pdf"},
    {"id":"35393","name":"Declaration of interests - Greth Veal","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-greth-veal_en.pdf"},
    {"id":"35407","name":"Download EPS - Species pictograms - Cat","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-cat_en.zip"},
    {"id":"35434","name":"Pre-Qualification Questionnaire (PQQ) for a restricted tender procedure organised by European Medicines Agency (EMEA) Supply of telecommunications equipment and consumables EMEA/2008/47/ISERV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:21Z","last_updated_date":"2008-11-25T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency-emea-supply-telecommunications-equipment-and-consumables-emea200847iserv_en.doc"},
    {"id":"35435","name":"ICMRA - Mapping of the bilateral arrangements between the ICMRA members","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-09T13:20:00Z","last_updated_date":"2017-01-09T13:20:00Z","reference_number":"EMA/562410/2016","document_url":"https://www.ema.europa.eu/en/documents/other/icmra-mapping-bilateral-arrangements-between-icmra-members_en.pdf"},
    {"id":"35458","name":"17-03-2011 Decision of the Management Board under Article 16 of the Staff Regulations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-21T01:00:00Z","last_updated_date":"2011-03-21T01:00:00Z","reference_number":"EMA/MB/218686/2011","document_url":"https://www.ema.europa.eu/en/documents/other/17-03-2011-decision-management-board-under-article-16-staff-regulations_en.pdf"},
    {"id":"35468","name":"Declaration of interests: Brendan Cuddy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-09T02:00:00Z","last_updated_date":"2019-10-25T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-brendan-cuddy_en.pdf"},
    {"id":"35480","name":"Pre-qualification questionnaire (“PQQ”) for a restricted tender procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure_en.doc"},
    {"id":"35487","name":"Selection of members of the Technical Anonymisation Group (TAG) - Public declaration of interests","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-03-22T16:00:00Z","last_updated_date":"2017-03-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/selection-members-technical-anonymisation-group-tag-public-declaration-interests_en.pdf"},
    {"id":"35519","name":"Guidelines on good pharmacovigilance practices: Introductory cover note to the public consultation of the first seven modules","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T14:20:00Z","last_updated_date":"2012-02-22T14:20:00Z","reference_number":"EMA/55612/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-introductory-cover-note-public-consultation-first-seven-modules_en.pdf"},
    {"id":"35520","name":"List of participants - Patients’ and Consumers’ Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint meeting - June 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"EMA/302216/2013","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-meeting-june-2013_en.pdf"},
    {"id":"35563","name":"List of participants - Training session for patients and consumers involved in European Medicines Agency activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T16:00:00Z","last_updated_date":"2014-02-03T16:00:00Z","reference_number":"EMA/625323/2013","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-training-session-patients-and-consumers-involved-european-medicines-agency-activities_en.pdf"},
    {"id":"35611","name":"Start of Community reviews - CHMP meeting of 16-19 July 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T17:00:00Z","last_updated_date":"2012-07-20T17:00:00Z","reference_number":"EMA/483585/2012","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-16-19-july-2012_en.pdf"},
    {"id":"35626","name":"Procedural advice for post-orphan medicinal product designation activities: Guidance for sponsors","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T11:20:00Z","last_updated_date":"2025-01-30T11:54:00Z","reference_number":"EMA/469917/2018 Rev.16","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-advice-post-orphan-medicinal-product-designation-activities-guidance-sponsors_en.pdf"},
    {"id":"35630","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) authorisation procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2021-09-14T09:15:00Z","reference_number":"EMA/136152/2012 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-authorisation-procedures_en.xls"},
    {"id":"35691","name":"Reply to the administrative arrangements to exchange non-public information on medicinal products between DG SANTE-European Medicines Agency and Swiss Federal Department of Home Affairs-Swissmedic","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-22T13:30:00Z","last_updated_date":"2015-07-22T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/reply-administrative-arrangements-exchange-non-public-information-medicinal-products-between-dg-sante-european-medicines-agency-and-swiss-federal-department-home-affairs-swissmedic_en.pdf"},
    {"id":"35709","name":"Answers from the CHMP Scientific Advisory Group for Oncology for revision of the anticancer guideline","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T11:00:00Z","last_updated_date":"2013-01-11T11:00:00Z","reference_number":"EMA/768937/2012","document_url":"https://www.ema.europa.eu/en/documents/other/answers-chmp-scientific-advisory-group-oncology-revision-anticancer-guideline_en.pdf"},
    {"id":"35712","name":"The European Medicines Agency code of good administrative behaviour","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-09-30T11:15:00Z","last_updated_date":"2013-09-30T11:15:00Z","reference_number":"EMA/264257/2013","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-code-good-administrative-behaviour_en.pdf"},
    {"id":"35732","name":"Questions and answers relating to banking service EMA/2012/01/FI-AC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-13T11:59:00Z","last_updated_date":"2012-07-27T12:14:00Z","reference_number":"EMA/470239/2012","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-banking-service-ema201201fi-ac_en.pdf"},
    {"id":"35733","name":"Mandate for joint opinion","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-28T16:00:00Z","last_updated_date":"2015-04-28T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-joint-opinion_en.pdf"},
    {"id":"35739","name":"Humenza: Summary of product characteristics","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-26T01:00:00Z","last_updated_date":"2010-02-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/humenza-summary-product-characteristics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/humenza-summary-product-characteristics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/humenza-summary-product-characteristics_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/humenza-summary-product-characteristics_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/humenza-summary-product-characteristics_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/humenza-summary-product-characteristics_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/humenza-summary-product-characteristics_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/humenza-summary-product-characteristics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/humenza-summary-product-characteristics_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/humenza-summary-product-characteristics_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/humenza-summary-product-characteristics_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/humenza-summary-product-characteristics_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/humenza-summary-product-characteristics_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/humenza-summary-product-characteristics_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/humenza-summary-product-characteristics_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/humenza-summary-product-characteristics_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/humenza-summary-product-characteristics_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/humenza-summary-product-characteristics_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/humenza-summary-product-characteristics_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/humenza-summary-product-characteristics_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/humenza-summary-product-characteristics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/humenza-summary-product-characteristics_sv.pdf"}},
    {"id":"35744","name":"Download EPS - Species pictograms - Duck","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-duck_en.zip"},
    {"id":"35749","name":"Declaration of interests - Saskia de Wildt","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-saskia-de-wildt_en.pdf"},
    {"id":"35761","name":"Medicines granted a Community marketing authorisation under the centralised procedure since the Committee for Medicinal Products for Human Use meeting 19-22 September 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-21T16:50:00Z","last_updated_date":"2011-10-21T16:50:00Z","reference_number":"EMA/852421/2011","document_url":"https://www.ema.europa.eu/en/documents/other/medicines-granted-community-marketing-authorisation-under-centralised-procedure-committee-medicinal-products-human-use-meeting-19-22-september-2011_en.pdf"},
    {"id":"35764","name":"Withdrawal letter: Eviplera","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-eviplera_en.pdf"},
    {"id":"35770","name":"CHMP opinions for medicines for human use - Positive opinions in 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-09T01:00:00Z","last_updated_date":"2015-02-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-opinions-medicines-human-use-positive-opinions-2014_en.pdf"},
    {"id":"35773","name":"CTAG3: Advice to the European Medicines Agency on rules of engagement for accessing clinical-trial data - Draft 22 March 2013 version 7.2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-advice-european-medicines-agency-rules-engagement-accessing-clinical-trial-data-draft-22-march-2013-version-72_en.pdf"},
    {"id":"35811","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 18-21 June 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-06-27T14:00:00Z","last_updated_date":"2012-06-27T14:00:00Z","reference_number":"EMA/CHMP/410510/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-18-21-june-2012_en.pdf"},
    {"id":"35816","name":"Dear Health Care Professional Letter on 3rd Generation Cocs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2001-09-28T02:00:00Z","last_updated_date":"2001-09-28T02:00:00Z","reference_number":"EMEA/CPMP/2225/01/en/Final","document_url":"https://www.ema.europa.eu/en/documents/other/dear-health-care-professional-letter-3rd-generation-cocs_en.pdf"},
    {"id":"35840","name":"Reflection paper on the use of fluoroquinolones in food-producing animals in the European Union: development of resistance and impact on human and animal health","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-01-18T01:00:00Z","last_updated_date":"2006-01-18T01:00:00Z","reference_number":"EMEA/CVMP/SAGAM/184651/2005-CONS","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-use-fluoroquinolones-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"35845","name":"Gems Medium Suite - Procedural steps and scientific information after initial consultation (archive)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2025-08-04T13:57:00Z","reference_number":"EMA/83725/2021 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/gems-medium-suite-procedural-steps-scientific-information-after-initial-consultation-archive_en.pdf"},
    {"id":"35862","name":"Declaration of interests: Amanda Johannson","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:55Z","last_updated_date":"2015-09-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-amanda-johannson_en.pdf"},
    {"id":"35871","name":"European Medicines Agency pharmacovigilance system manual","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-29T18:40:00Z","last_updated_date":"2021-03-16T10:27:00Z","reference_number":"EMA/623550/2013 Version 1.3","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-pharmacovigilance-system-manual_en.pdf"},
    {"id":"35900","name":"Declaration of interests: Georgy Genov","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2025-08-01T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-georgy-genov_en.pdf"},
    {"id":"35902","name":"Updated overview of applications under the simplified registration procedure (cut-off date 30 June 2007)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-08-15T02:00:00Z","last_updated_date":"2007-08-15T02:00:00Z","reference_number":"EMEA/HMPC/148505/2007","document_url":"https://www.ema.europa.eu/en/documents/other/updated-overview-applications-under-simplified-registration-procedure-cut-date-30-june-2007_en.pdf"},
    {"id":"35912","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting 17-20 February 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-02-25T12:25:00Z","last_updated_date":"2014-04-22T16:20:00Z","reference_number":"EMA/54974/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-17-20-february-2014_en.pdf"},
    {"id":"35995","name":"A Review of the Medicines Legislation by the EMEA and National Competent Authorities - Joint EMEA/TO PRA meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-12-03T01:00:00Z","last_updated_date":"2007-12-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/review-medicines-legislation-emea-and-national-competent-authorities-joint-emeato-pra-meeting_en.pdf"},
    {"id":"36011","name":"One-year conditional renewals (60-day procedure)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-25T01:09:21Z","last_updated_date":"2007-10-25T01:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/one-year-conditional-renewals-60-day-procedure_en.pdf"},
    {"id":"36018","name":"Technical specification - Annex 3 Lot 1 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-3-lot-1-external-service-providers-software-applications-ema201213ict_en.xls"},
    {"id":"36075","name":"Outcome of written procedures finalised during the period from 13 May 2014 to 1 September 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-08T15:00:00Z","last_updated_date":"2014-10-08T15:00:00Z","reference_number":"EMA/MB/406461/2014","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-13-may-2014-1-september-2014_en.pdf"},
    {"id":"36077","name":"Withdrawal letter : Draxxin","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-01-17T01:00:00Z","last_updated_date":"2007-01-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-draxxin_en.pdf-0"},
    {"id":"36106","name":"Closing report on assessment of a supply shortage of a medicinal product due to manufacturing and quality problems.","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T00:00:00Z","last_updated_date":"2013-01-29T00:00:00Z","reference_number":"EMA/443443/2013","document_url":"https://www.ema.europa.eu/en/documents/other/closing-report-assessment-supply-shortage-medicinal-product-due-manufacturing-and-quality-problems_en.pdf"},
    {"id":"36107","name":"Bradley Malin (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/bradley-malin-doi_en.pdf"},
    {"id":"36117","name":"Overview of comments received on the guideline on the approach to establish a pharmacological acceptable daily intake","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-19T11:30:00Z","last_updated_date":"2012-11-19T11:30:00Z","reference_number":"EMA/CVMP/SWP/634672/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-approach-establish-pharmacological-acceptable-daily-intake_en.pdf"},
    {"id":"36145","name":"Overview of comments received on draft guideline on similar biological medicinal products containing low-molecular-weight-herapins","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2009-11-18T00:09:21Z","reference_number":"EMEA/582443/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-similar-biological-medicinal-products-containing-low-molecular-weight-herapins_en.pdf"},
    {"id":"36148","name":"Opinions on safety variations adopted during the CHMP meeting 18-21 February 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-02-28T13:45:00Z","last_updated_date":"2013-02-28T13:45:00Z","reference_number":"EMA/CHMP/109950/2013","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-during-chmp-meeting-18-21-february-2013_en.pdf"},
    {"id":"36157","name":"Questions and answers on signal management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-04T14:00:00Z","last_updated_date":"2026-01-20T10:54:00Z","reference_number":"EMA/261758/2013 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-signal-management_en.pdf"},
    {"id":"36201","name":"Letter of support for drug-induced vascular injury (DIVI) biomarker","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-09T15:15:00Z","last_updated_date":"2017-11-09T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-drug-induced-vascular-injury-divi-biomarker_en.pdf"},
    {"id":"36245","name":"Participants list – 6th industry stakeholder platform - operation of EU pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"EMA/48691/2016","document_url":"https://www.ema.europa.eu/en/documents/other/participants-list-6th-industry-stakeholder-platform-operation-eu-pharmacovigilance-legislation_en.pdf"},
    {"id":"36248","name":"Technical specifications for open invitation to tender\n\nprocurement procedure EMA/2013/17/IS Relocation services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-03T11:20:00Z","last_updated_date":"2014-01-03T11:20:00Z","reference_number":"EMA/382193/2013","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-procurement-procedure-ema201317is-relocation-services_en.pdf"},
    {"id":"36270","name":"Organisational matters - CHMP meeting 12-15 November 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-22T10:15:00Z","last_updated_date":"2012-11-22T10:15:00Z","reference_number":"EMA/CHMP/732274/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-12-15-november-2012_en.pdf"},
    {"id":"36276","name":"Letter to the International Federation for Animal Health Europe regarding its request for fee waivers for centralised applications of inactivated bluetongue vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-03-04T00:09:21Z","last_updated_date":"2008-03-04T00:09:21Z","reference_number":"EMEA/111981/2008","document_url":"https://www.ema.europa.eu/en/documents/other/letter-international-federation-animal-health-europe-regarding-its-request-fee-waivers-centralised-applications-inactivated-bluetongue-vaccines_en.pdf"},
    {"id":"36295","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): GVP module V – Risk management systems","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:18:13Z","last_updated_date":"2012-06-25T19:18:13Z","reference_number":"EMA/428848/2012","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-v-risk-management-systems_en.pdf"}    {"id":"36320","name":"Questions and answers on quality of herbal medicinal products / traditional herbal medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-11-10T01:00:00Z","last_updated_date":"2015-04-07T14:10:00Z","reference_number":"EMA/HMPC/41500/2010 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-quality-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"36337","name":"Overview of comments received on 'Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and package leaflets for plasma-derived medicinal products' (EMA/CHMP/BWP/360642/2010 rev. ...","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-14T13:05:00Z","last_updated_date":"2011-12-14T13:05:00Z","reference_number":"EMA/CHMP/BWP/552050/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-warning-transmissible-agents-summary-product-characteristics-smpcs-and-package-leaflets-plasma-derived-medicinal-products-emachmpbwp3606422010-rev_en.pdf"},
    {"id":"36347","name":"Annex A3 - EMA technical comments on the technical requirements with respect to the candidate host Member States’ offers to relocate the European Medicines Agency (applied methodology)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T20:15:00Z","last_updated_date":"2017-10-03T20:15:00Z","reference_number":"EMA/399439/2017","document_url":"https://www.ema.europa.eu/en/documents/other/annex-a3-ema-technical-comments-technical-requirements-respect-candidate-host-member-states-offers-relocate-european-medicines-agency-applied-methodology_en.pdf"},
    {"id":"36368","name":"Analysis and assessment of the 2011 annual activity report of the Executive Director","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-06-14T16:30:00Z","last_updated_date":"2012-06-14T16:30:00Z","reference_number":"EMA/MB/326427/2012","document_url":"https://www.ema.europa.eu/en/documents/other/analysis-and-assessment-2011-annual-activity-report-executive-director_en.pdf"},
    {"id":"36373","name":"Declaration of interests - Dirk Mentzer","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-dirk-mentzer_en.pdf"},
    {"id":"36383","name":"Overview of comments received on guideline on the use of Near Infrared Spectroscopy (NIRS) by the pharmaceutical industry and the data requirements for new submissions and variations draft revision 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-05T16:00:00Z","last_updated_date":"2014-06-05T16:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/63698/2014","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-use-near-infrared-spectroscopy-nirs-pharmaceutical-industry-and-data-requirements-new-submissions-and-variations-draft-revision-2_en.pdf"},
    {"id":"36409","name":"Rasilez - Product information as approved by the CHMP on 16 February 2012, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T12:00:00Z","last_updated_date":"2012-02-17T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/rasilez-product-information-approved-chmp-16-february-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"36417","name":"Overview of comments received on draft guideline on clinical investigation of medicinal products in prevention and treatment of Acute Respiratory Distress Syndrome","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"CHMP/EWP/358390/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-prevention-and-treatment-acute-respiratory-distress-syndrome_en.pdf"},
    {"id":"36424","name":"2011 EudraVigilance Human annual report - Explanatory note","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-19T11:29:00Z","last_updated_date":"2013-06-19T11:29:00Z","reference_number":"EMA/476834/2012","document_url":"https://www.ema.europa.eu/en/documents/other/2011-eudravigilance-human-annual-report-explanatory-note_en.pdf"},
    {"id":"36436","name":"Workshop summary - Adaptive Design Laboratory workshop","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-04-21T02:00:00Z","last_updated_date":"2016-04-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-summary-adaptive-design-laboratory-workshop_en.pdf"},
    {"id":"36446","name":"Ad hoc working group on Herbal Medicinal Products: Note for guidance on fixed combinations of Herbal Medicinal Products with long-term marketing experience - Guidance to facilitate mutual recognition and Uue of bibliogra...","type":"other","status":"unknown","consultation_date":"","first_published_date":"1999-01-28T01:00:00Z","last_updated_date":"1999-01-28T01:00:00Z","reference_number":"EMEA/HMPWP/15/99","document_url":"https://www.ema.europa.eu/en/documents/other/ad-hoc-working-group-herbal-medicinal-products-note-guidance-fixed-combinations-herbal-medicinal-products-long-term-marketing-experience-guidance-facilitate-mutual-recognition-and-uue-bibliogra_en.pdf"},
    {"id":"36455","name":"Outcome of written procedures finalised during the period from 2 September 2015 to 2 November 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/MB/653272/2015","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-2-september-2015-2-november-2015_en.pdf"},
    {"id":"36467","name":"Guiding principles for international pharmacovigilance cluster","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-14T16:00:00Z","last_updated_date":"2015-07-14T16:00:00Z","reference_number":"EMA/443343/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guiding-principles-international-pharmacovigilance-cluster_en.pdf"},
    {"id":"36485","name":"Overview of comments received on guideline on the conduct of bioequivalence studies for veterinary medicinal products' (EMEA/CVMP/016/00-Rev.2-CONSULTATION) - Revision 2","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-04-20T02:00:00Z","last_updated_date":"2011-04-20T02:00:00Z","reference_number":"EMA/CVMP/676396/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-emeacvmp01600-rev2-consultation-revision-2_en.pdf"},
    {"id":"36486","name":"Letter of support for micro-aneurysm formation rate (MAFR) biomarker","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T12:00:00Z","last_updated_date":"2015-01-21T12:00:00Z","reference_number":"EMA/775397/2014","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-micro-aneurysm-formation-rate-mafr-biomarker_en.pdf"},
    {"id":"36499","name":"Withdrawal letter : DepoCyte","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-06-28T02:00:00Z","last_updated_date":"2006-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-depocyte_en.pdf"},
    {"id":"36506","name":"Management Board meeting dates 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/MB/518171/2009Adopted","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2010_en.pdf"},
    {"id":"36509","name":"Announcement for the NRG position paper re-use of invented names of medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/51157/2011","document_url":"https://www.ema.europa.eu/en/documents/other/announcement-nrg-position-paper-re-use-invented-names-medicinal-products_en.pdf"},
    {"id":"36529","name":"Recognition criteria for self assessment - Enpr-EMA: Innovative Therapies for Children with Cancer (ITCC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/241053/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-enpr-ema-innovative-therapies-children-cancer-itcc_en.pdf"},
    {"id":"36532","name":"Medical literature monitoring tracking sheet: search results","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-08T11:00:00Z","last_updated_date":"2017-11-22T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medical-literature-monitoring-tracking-sheet-search-results_en.xlsx"},
    {"id":"36562","name":"EMA public workshop on extrapolation of efficacy and safety in medicine development - Outcome of a multi-stakeholder meeting with experts and regulators","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-18T18:58:00Z","last_updated_date":"2016-10-18T18:58:00Z","reference_number":"EMA/478467/2016","document_url":"https://www.ema.europa.eu/en/documents/other/ema-public-workshop-extrapolation-efficacy-and-safety-medicine-development-outcome-multi-stakeholder-meeting-experts-and-regulators_en.pdf"},
    {"id":"36582","name":"Biologics Working Party Ad-hoc Influenza Working Group: Amended European Union recommendations for the seasonal-influenza-vaccine composition for the season 2013 / 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T12:56:09Z","last_updated_date":"2013-04-02T11:10:00Z","reference_number":"EMA/CHMP/BWP/116620/2013","document_url":"https://www.ema.europa.eu/en/documents/other/biologics-working-party-ad-hoc-influenza-working-group-amended-european-union-recommendations-seasonal-influenza-vaccine-composition-season-2013-2014_en.pdf"},
    {"id":"36601","name":"Overview of comments received on draft guideline on the investigation of bioequivalence CPMP/EWP/QWP/1401/98 Rev. 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-02-10T01:00:00Z","last_updated_date":"2010-02-10T01:00:00Z","reference_number":"EMA/CHMP/EWP/26817/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-investigation-bioequivalence-cpmpewpqwp140198-rev-1_en.pdf"},
    {"id":"36631","name":"Example of Bank Statement header","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-12-21T00:09:21Z","last_updated_date":"2006-12-21T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-bank-statement-header_en.pdf"},
    {"id":"36662","name":"Task force for the implementation of International Standards on Identification of medicinal products in the EU (i.e. EU ISO IDMP task force)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-09-03T14:00:00Z","last_updated_date":"2016-09-20T14:00:00Z","reference_number":"EMA/111947/2015","document_url":"https://www.ema.europa.eu/en/documents/other/task-force-implementation-international-standards-identification-medicinal-products-eu-ie-eu-iso-idmp-task-force_en.pdf"},
    {"id":"36683","name":"Declaration of interests - Alan Boddy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-alan-boddy_en.pdf"},
    {"id":"36695","name":"Overview of comments received on 'Reflection paper on testing strategy and risk assessment for plants - draft' (EMA/CVMP/ERA/147844/2011)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-20T15:15:00Z","last_updated_date":"2011-12-20T15:15:00Z","reference_number":"EMA/CVMP/ERA/521952/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-testing-strategy-and-risk-assessment-plants-draft-emacvmpera1478442011_en.pdf"},
    {"id":"36738","name":"Addendum 1 on pandemic influenza A(H1N1)v vaccines authorised via the core dossier procedure: Explanatory note on scientific considerations regarding the dosage and co-administration with seasonal vaccines recommendation...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-12-15T00:09:21Z","last_updated_date":"2009-12-15T00:09:21Z","reference_number":"EMA/693699/2009","document_url":"https://www.ema.europa.eu/en/documents/other/addendum-1-pandemic-influenza-ah1n1v-vaccines-authorised-core-dossier-procedure-explanatory-note-scientific-considerations-regarding-dosage-and-co-administration-seasonal-vaccines-recommendation_en.pdf"},
    {"id":"36769","name":"Declaration of interests: Oscar Diez","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:20Z","last_updated_date":"2012-10-10T18:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-oscar-diez_en.pdf"},
    {"id":"36791","name":"Organisation Management Services (OMS) operating model","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-01T11:05:00Z","last_updated_date":"2019-05-06T17:50:00Z","reference_number":"EMA/459105/2016 Version 6","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-management-services-oms-operating-model_en.pdf"},
    {"id":"36792","name":"Summary of transfers of appropriations in the budget 2009 - Management Board meeting: 1 October 2009","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/MB/320040/2009","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2009-management-board-meeting-1-october-2009_en.pdf"},
    {"id":"36795","name":"EudraVigilance eXtended medicinal product dictionary acknowledgement codes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-08T17:45:00Z","last_updated_date":"2019-07-25T11:27:00Z","reference_number":"EMA/792575/2014","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-acknowledgement-codes_en.xls"},
    {"id":"36797","name":"Request for an update of the advice on the impact on public health and animal health of the use of antibiotics in animals (categorisation of antimicrobials and early hazard characterisation)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-07-26T13:30:00Z","last_updated_date":"2017-07-26T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-update-advice-impact-public-health-animal-health-use-antibiotics-animals-categorisation-antimicrobials-early-hazard-characterisation_en.pdf"},
    {"id":"36810","name":"National contact points for standalone signal notifications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T11:55:00Z","last_updated_date":"2021-08-03T14:00:00Z","reference_number":"EMA/777916/2017 Corr. 2","document_url":"https://www.ema.europa.eu/en/documents/other/national-contact-points-standalone-signal-notifications_en.xlsx"},
    {"id":"36834","name":"ICH guideline M8 on eCTD – questions and answers - Step 5","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T18:30:00Z","last_updated_date":"2014-01-31T18:30:00Z","reference_number":"EMA/CHMP/ICH/820/2003","document_url":"https://www.ema.europa.eu/en/documents/other/ich-guideline-m8-ectd-questions-and-answers-step-5_en.pdf"},
    {"id":"36842","name":"Withdrawal letter : Zavesca","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-02-19T01:00:00Z","last_updated_date":"2008-02-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-zavesca_en.pdf"},
    {"id":"36843","name":"SPOR data management services high level changes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-01T11:05:00Z","last_updated_date":"2017-12-01T17:18:00Z","reference_number":"EMA/551661/2016 version 3","document_url":"https://www.ema.europa.eu/en/documents/other/spor-data-management-services-high-level-changes_en.pdf"},
    {"id":"36859","name":"Budget and establishment plan 2010 and Staff policy plan","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/MB/628139/2009/Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/budget-and-establishment-plan-2010-and-staff-policy-plan_en.pdf"},
    {"id":"36873","name":"Conclusions from EMA paediatric gastroenterology and rheumatology expert group meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-22T01:00:00Z","last_updated_date":"2011-03-22T01:00:00Z","reference_number":"EMA/82302/2011","document_url":"https://www.ema.europa.eu/en/documents/other/conclusions-ema-paediatric-gastroenterology-and-rheumatology-expert-group-meeting_en.pdf"},
    {"id":"36886","name":"Policy 78: EMA environmental policy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-12T18:00:00Z","last_updated_date":"2024-05-15T16:19:00Z","reference_number":"EMA/83225/2024","document_url":"https://www.ema.europa.eu/en/documents/other/policy-78-ema-environmental-policy_en.pdf"},
    {"id":"36902","name":"Memorandum of understanding on working arrangements between the European Medicines Agency (EMA) and the European Chemicals Agency (ECHA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-14T17:00:00Z","last_updated_date":"2014-05-14T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/memorandum-understanding-working-arrangements-between-european-medicines-agency-ema-and-european-chemicals-agency-echa_en.pdf"},
    {"id":"36916","name":"Participants list from the 5th industry stakeholder platform - Operation of EU pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"EMA/47443/2016","document_url":"https://www.ema.europa.eu/en/documents/other/participants-list-5th-industry-stakeholder-platform-operation-eu-pharmacovigilance-legislation_en.pdf"},
    {"id":"36942","name":"Committee for Orphan Medicinal Products (COMP) meetings 2013-2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-26T17:30:00Z","last_updated_date":"2015-02-18T11:10:00Z","reference_number":"EMA/COMP/478907/2009 Corr","document_url":"https://www.ema.europa.eu/en/documents/other/committee-orphan-medicinal-products-comp-meetings-2013-2015_en.pdf"},
    {"id":"36952","name":"Sampling and testing of centrally authorised products: Objectives and description of the programme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-01-06T01:00:00Z","last_updated_date":"2005-01-06T01:00:00Z","reference_number":"EMEA/INS/S&T/5291/2005","document_url":"https://www.ema.europa.eu/en/documents/other/sampling-and-testing-centrally-authorised-products-objectives-and-description-programme_en.pdf"},
    {"id":"37008","name":"Declaration of interests: Anthony Humphreys","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:07:00Z","last_updated_date":"2023-05-30T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-anthony-humphreys_en.pdf"},
    {"id":"37025","name":"Template to request access to EMA ICT facilities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-13T02:00:00Z","last_updated_date":"2012-07-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/template-request-access-ema-ict-facilities_en.pdf"},
    {"id":"37042","name":"Questions and answers on level of detail in the regulatory submissions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-19T17:00:00Z","last_updated_date":"2014-12-19T17:00:00Z","reference_number":"EMA/59240/2014","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-level-detail-regulatory-submissions_en.pdf"},
    {"id":"37047","name":"Invitation for expressions of interest - European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T17:52:00Z","last_updated_date":"2018-09-13T17:52:00Z","reference_number":"EMA/457607/2018","document_url":"https://www.ema.europa.eu/en/documents/other/invitation-expressions-interest-european-medicines-agency-stakeholder-interaction-development-medicinal-products-chronic-non-infectious-liver-diseases-pbc-psc-nash_en.pdf"},
    {"id":"37067","name":"Overview of comments on 'Draft guideline on core summary of product characteristics and package leaflet for radiopharmaceuticals'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-10-03T11:36:00Z","last_updated_date":"2011-10-03T11:36:00Z","reference_number":"EMA/358709/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-draft-guideline-core-summary-product-characteristics-and-package-leaflet-radiopharmaceuticals_en.pdf"},
    {"id":"37097","name":"EMEA workshop on the requirements and provision of analytical methods for drug residue control in animal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2000-02-15T01:00:00Z","last_updated_date":"2000-02-15T01:00:00Z","reference_number":"EMEA/V/3362/00","document_url":"https://www.ema.europa.eu/en/documents/other/emea-workshop-requirements-and-provision-analytical-methods-drug-residue-control-animal-products_en.pdf"},
    {"id":"37106","name":"Overview of comments received on the draft guideline on the development of medicinal products for the treatment of alcohol dependence (CHMP/EWP/20097/08)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMA/626274/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-development-medicinal-products-treatment-alcohol-dependence-chmpewp2009708_en.pdf"},
    {"id":"37114","name":"Extension of confidentiality arrangement: Letter from European Commission and European Medicines Agency to Ministry of Health, Labour and Welfare and Pharmaceuticals and Medical Devices Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-14T16:27:15Z","last_updated_date":"2012-02-14T16:27:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/extension-confidentiality-arrangement-letter-european-commission-european-medicines-agency-ministry-health-labour-welfare-pharmaceuticals-medical-devices-agency_en.pdf"},
    {"id":"37125","name":"List of official languages per country","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-04T13:30:00Z","last_updated_date":"2026-03-25T11:40:00Z","reference_number":"EMA/315185/2010 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/list-official-languages-country_en.pdf"},
    {"id":"37135","name":"International Generic Drug Regulators Programme information sharing pilot","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-01-19T15:00:00Z","last_updated_date":"2015-01-19T15:00:00Z","reference_number":"EMA/789664/2014","document_url":"https://www.ema.europa.eu/en/documents/other/international-generic-drug-regulators-programme-information-sharing-pilot_en.pdf"},
    {"id":"37145","name":"Overview of comments received on reflection paper on antimicrobial resistance surveillance as postmarketing authorisation commitment (EMEA/CVMP/SAGAM/428938/2007)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-10-21T02:00:00Z","last_updated_date":"2008-10-21T02:00:00Z","reference_number":"MEA/CVMP/SAGAM/341254/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-antimicrobial-resistance-surveillance-postmarketing-authorisation-commitment-emeacvmpsagam4289382007_en.pdf"},
    {"id":"37176","name":"Summary of transfer of appropriations in the budget 2011 - Management Board meeting: 6 October 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:00Z","last_updated_date":"2011-10-07T16:00:00Z","reference_number":"EMA/MB/730141/2011","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2011-management-board-meeting-6-october-2011_en.pdf"},
    {"id":"37204","name":"Involvement of patients in scientific advice procedures at the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-08-23T02:00:00Z","last_updated_date":"2021-10-19T16:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/involvement-patients-scientific-advice-procedures-european-medicines-agency_en.pdf"},
    {"id":"37205","name":"Draft questions and answers - ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological entities)","type":"other","status":"Draft: consultation closed","consultation_date":"2016-12-15 - 2017-03-15","first_published_date":"2016-12-15T14:22:00Z","last_updated_date":"2016-12-15T14:22:00Z","reference_number":"EMA/CHMP/ICH/809509/2016","document_url":"https://www.ema.europa.eu/en/documents/other/draft-questions-and-answers-ich-guideline-q11-development-and-manufacture-drug-substances-chemical-entities-and-biotechnological-biological-entities_en.pdf"},
    {"id":"37211","name":"Declaration of interests: Stefan Blixen-Finecke","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-09-12T02:00:00Z","last_updated_date":"2019-10-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-stefan-blixen-finecke_en.pdf"},
    {"id":"37225","name":"Overview of comments received on draft guideline on radiopharmaceuticals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-26T01:00:00Z","last_updated_date":"2008-11-26T01:00:00Z","reference_number":"EMEA/CHMP/CVMP/QWP/567962/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-radiopharmaceuticals_en.pdf"},
    {"id":"37239","name":"Overview of comments received on draft guideline on selection of test materials for genotoxicity testing for Traditional Herbal Medicinal Products/Herbal Medicinal Products","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-01-18T01:00:00Z","last_updated_date":"2010-01-18T01:00:00Z","reference_number":"EMEA/HMPC/651266/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-selection-test-materials-genotoxicity-testing-traditional-herbal-medicinal-productsherbal-medicinal-products_en.pdf"},
    {"id":"37250","name":"Survey 2008 on the performance of EMEA scientific procedures for\n\nmedicinal products for human use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-03-05T00:00:00Z","last_updated_date":"2009-03-05T00:00:00Z","reference_number":"EMEA/MB/30754/2009","document_url":"https://www.ema.europa.eu/en/documents/other/survey-2008-performance-emea-scientific-procedures-medicinal-products-human-use_en.pdf"},
    {"id":"37257","name":"Comments received from public consultation on good pharmacovigilance practices: GVP module XVI - Risk minimisation measures - Selection of tools and effectiveness indicators","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T10:30:00Z","last_updated_date":"2014-02-28T10:30:00Z","reference_number":"EMA/72273/2014","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-selection-tools-and-effectiveness-indicators_en.pdf"},
    {"id":"37274","name":"Guidelines and concept papers adopted during the CHMP meeting 18-21 February 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-02-28T13:45:00Z","last_updated_date":"2013-02-28T13:45:00Z","reference_number":"EMA/CHMP/109941/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-18-21-february-2013_en.pdf"},
    {"id":"37281","name":"Summary of transfer of appropriations in the budget 2013 - Management Board meeting: 11-12 December 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T11:30:00Z","last_updated_date":"2013-12-17T11:30:00Z","reference_number":"EMA/MB/703501/2013 Noted","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2013-management-board-meeting-11-12-december-2013_en.pdf"},
    {"id":"37310","name":"Overview of comments on draft reflection paper on level of purification of extracts to be considered as herbal preparations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/435996/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-draft-reflection-paper-level-purification-extracts-be-considered-herbal-preparations_en.pdf"},
    {"id":"37315","name":"Measures for Article 57 data quality assurance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-15T16:45:00Z","last_updated_date":"2015-10-15T16:45:00Z","reference_number":"EMA/465609/2015","document_url":"https://www.ema.europa.eu/en/documents/other/measures-article-57-data-quality-assurance_en.pdf"},
    {"id":"37338","name":"Public consultation on EMEA transparency initiatives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-08-13T02:00:00Z","last_updated_date":"2003-08-13T02:00:00Z","reference_number":"EMEA/D/21621/03/Consultation","document_url":"https://www.ema.europa.eu/en/documents/other/public-consultation-emea-transparency-initiatives_en.pdf"},
    {"id":"37364","name":"Overview of comments received on 'reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical samples'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T15:45:00Z","last_updated_date":"2012-02-17T15:45:00Z","reference_number":"EMA/INS/GCP/219642/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-guidance-laboratories-perform-analysis-or-evaluation-clinical-samples_en.pdf"},
    {"id":"37393","name":"Overview of comments received on 'guideline on similar biological medicinal products containing monoclonal antibodies' (EMA/CHMP/BMWP/403543/2010)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:42Z","last_updated_date":"2012-06-15T17:10:42Z","reference_number":"EMA/205886/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-emachmpbmwp4035432010_en.pdf"},
    {"id":"37399","name":"Summary on compassionate use for IV Zanamivir (Rev. 1)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-03-21T01:00:00Z","last_updated_date":"2011-07-12T02:00:00Z","reference_number":"EMA/CHMP/40488/2010","document_url":"https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-iv-zanamivir-rev-1_en.pdf"},
    {"id":"37424","name":"Medication-errors workshop - List of participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-13T12:30:00Z","last_updated_date":"2013-05-13T12:30:00Z","reference_number":"EMA/109271/2013","document_url":"https://www.ema.europa.eu/en/documents/other/medication-errors-workshop-list-participants_en.pdf"},
    {"id":"37447","name":"Overview of comments received on draft guideline on the development of new medicinal products for the treatment of Crohn's disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/492092/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-development-new-medicinal-products-treatment-crohns-disease_en.pdf"},
    {"id":"37468","name":"Letter from European Medicines Agency to Gerard Bapt regarding Dr Xavier Kurz","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-13T03:00:00Z","last_updated_date":"2011-07-13T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-european-medicines-agency-gerard-bapt-regarding-dr-xavier-kurz_en.pdf"},
    {"id":"37507","name":"Letter from Japan to the European Union","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-japan-european-union_en.pdf"},
    {"id":"37518","name":"Change to list of species and breeds for 2009","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-10-16T02:00:00Z","last_updated_date":"2009-10-16T02:00:00Z","reference_number":"EMEA/CVMP/PhVWP/283195/2009","document_url":"https://www.ema.europa.eu/en/documents/other/change-list-species-and-breeds-2009_en.xls"},
    {"id":"37551","name":"Pathogen specific database: Viral haemorrahagic fever","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-viral-haemorrahagic-fever_en.pdf"},
    {"id":"37558","name":"Public summary of the evaluation of the proposed paediatric investigation plan: dupilumab for the treatment of atopic dermatitis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-31T17:45:00Z","last_updated_date":"2014-07-31T17:45:00Z","reference_number":"EMA/436644/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-dupilumab-treatment-atopic-dermatitis_en.pdf"},
    {"id":"37610","name":"Speakers’ abstracts for their presentations - PCWP and HCPWP joint meeting - Workshop on social media","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"EMA/583182/2016","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-abstracts-their-presentations-pcwp-and-hcpwp-joint-meeting-workshop-social-media_en.pdf"},
    {"id":"37635","name":"First EMEA Workshop on European Paediatric Network - Announcement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-12-10T00:09:21Z","last_updated_date":"2008-12-10T00:09:21Z","reference_number":"EMEA/643421/2008","document_url":"https://www.ema.europa.eu/en/documents/other/first-emea-workshop-european-paediatric-network-announcement_en.pdf"},
    {"id":"37638","name":"Pathogen-specific database: Other bacterial infections","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-other-bacterial-infections_en.pdf"},
    {"id":"37640","name":"European Medicines Agency Decision of 13 April 2009 on the review of a class waiver on condition(s) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-13T02:00:00Z","last_updated_date":"2009-04-13T02:00:00Z","reference_number":"EMEA/225021/2009 P/65/2009","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-decision-13-april-2009-review-class-waiver-conditions-accordance-regulation-ec-no-19012006-european-parliament-and-council-amended_en.pdf"},
    {"id":"37649","name":"Policy 51: Stress at work","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-03-21T01:00:00Z","last_updated_date":"2021-12-08T12:30:00Z","reference_number":"EMA/458250/2009 Version 1.1","document_url":"https://www.ema.europa.eu/en/documents/other/policy-51-stress-work_en.pdf"},
    {"id":"37661","name":"Overview of comments received on ‘Guideline on data requirements to support in-use stability claims for veterinary vaccines’ (EMEA/CVMP/IWP/250147/2008-CONSULTATION)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/81346/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-data-requirements-support-use-stability-claims-veterinary-vaccines-emeacvmpiwp2501472008-consultation_en.pdf"},
    {"id":"37677","name":"Comments received from public consultation on good pharmacovigilance practices (GVP) - GVP Module VIII – Post-authorisation safety studies (Rev. 2) (EMA/813938/2011)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-08-08T17:00:00Z","last_updated_date":"2016-08-08T17:00:00Z","reference_number":"EMA/710492/2015","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-viii-post-authorisation-safety-studies-rev-2-ema8139382011_en.pdf"},
    {"id":"37678","name":"Technical specification - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-01-03T10:00:00Z","reference_number":"EMA/180834/2012","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-external-service-providers-software-applications-ema201213ict_en.pdf"},
    {"id":"37697","name":"Expression of interest for software development companies: Creating electronic drug information for prescribing in the European Union","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T19:10:40Z","last_updated_date":"2011-07-27T19:10:40Z","reference_number":"EMA/425283/2011","document_url":"https://www.ema.europa.eu/en/documents/other/expression-interest-software-development-companies-creating-electronic-drug-information-prescribing-european-union_en.pdf"},
    {"id":"37711","name":"Ad hoc working party on Herbal Medicinal Products: Final comments for revision of good manufacturing practice (GMP) provisions","type":"other","status":"unknown","consultation_date":"","first_published_date":"1998-09-17T02:00:00Z","last_updated_date":"1998-09-17T02:00:00Z","reference_number":"EMEA/HMPWG/7/99","document_url":"https://www.ema.europa.eu/en/documents/other/ad-hoc-working-party-herbal-medicinal-products-final-comments-revision-good-manufacturing-practice-gmp-provisions_en.pdf"},
    {"id":"37738","name":"European Medicines Agency 2013 priorities for drug safety research: Long-term adverse skeletal effects of bisphosphonates","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-22T18:13:28Z","last_updated_date":"2012-05-22T18:13:28Z","reference_number":"EMA/281412/2012","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-2013-priorities-drug-safety-research-long-term-adverse-skeletal-effects-bisphosphonates_en.pdf"},
    {"id":"37746","name":"Overview of comments received on 'Answers to the request for scientific advice on the impact on public health and animal health of the use of antibiotics in animals'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-08-01T14:00:00Z","last_updated_date":"2014-12-19T15:00:00Z","reference_number":"EMA/598105/2014","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-answers-request-scientific-advice-impact-public-health-and-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"37758","name":"Start of Community reviews - CHMP meeting of 27-30 May 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-30T12:00:02Z","last_updated_date":"2013-05-30T12:00:02Z","reference_number":"EMA/219461/2013","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-27-30-may-2013_en.pdf"},
    {"id":"37772","name":"Working party on Herbal Medicinal Products: Final proposal for a core data for  Calendulae flower","type":"other","status":"unknown","consultation_date":"","first_published_date":"2003-03-27T01:00:00Z","last_updated_date":"2003-03-27T01:00:00Z","reference_number":"EMEA/HMPWP/17/00","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-calendulae-flower_en.pdf"},
    {"id":"37792","name":"Communication on medicines — now and tomorrow","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"EMA/194543/2016","document_url":"https://www.ema.europa.eu/en/documents/other/communication-medicines-now-and-tomorrow_en.pdf"},
    {"id":"37824","name":"Public summary of the evaluation of the proposed product-specific waiver: Ranibizumab for treatment of choroidal neovascularisation and treatment of macular oedema","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T11:30:00Z","last_updated_date":"2014-10-21T11:30:00Z","reference_number":"EMA/511515/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-ranibizumab-treatment-choroidal-neovascularisation-and-treatment-macular-oedema_en.pdf"},
    {"id":"37836","name":"Withdrawal letter: Tasigna","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-tasigna_en.pdf"},
    {"id":"37842","name":"Overview of comments on the qualification opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of Phase II dose finding studies under model uncertainty'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-10T10:20:00Z","last_updated_date":"2014-02-10T10:20:00Z","reference_number":"EMA/617236/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-qualification-opinion-mcp-mod-efficient-statistical-methodology-model-based-design-and-analysis-phase-ii-dose-finding-studies-under-model-uncertainty_en.pdf"},
    {"id":"37846","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): Annex II – Templates: Communication Plan for Direct Healthcare Professional Communication (CP DHPC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/647372/2017","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-annex-ii-templates-communication-plan-direct-healthcare-professional-communication-cp-dhpc_en.pdf"},
    {"id":"37855","name":"European Commission request for advice on the impact on public health and animal health of the use of antibiotics in animals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-16T12:22:05Z","last_updated_date":"2013-04-16T12:22:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-request-advice-impact-public-health-and-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"37864","name":"Assessment of the paediatric needs - Chemotherapy products (part I)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-09-01T02:00:00Z","last_updated_date":"2006-09-01T02:00:00Z","reference_number":"EMEA/384641/2006","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-chemotherapy-products-part-i_en.pdf"},
    {"id":"37878","name":"Overview of comments received on draft guideline on the scientific requirements for the environmental risk assessment of gene therapy medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/CHMP/GTWP/564874/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-scientific-requirements-environmental-risk-assessment-gene-therapy-medicinal-products_en.pdf"}    {"id":"37883","name":"Summary of transfer of appropriations in the budget 2010  - Management Board meeting 17 March 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2011-03-29T02:00:00Z","reference_number":"EMA/MB/111120/2011","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2010-management-board-meeting-17-march-2011_en.pdf"},
    {"id":"37891","name":"Case studies - Harmonising the approach to VeDDRA coding workshop - 27 November 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-11T18:20:00Z","last_updated_date":"2014-02-11T18:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/case-studies-harmonising-approach-veddra-coding-workshop-27-november-2013_en.pdf"},
    {"id":"37926","name":"Overview of comments received on draft guideline on user safety for pharmaceutical veterinary medicinal products (EMEA/CVMP/543/03-CONSULTATION)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-04-14T02:00:00Z","last_updated_date":"2005-04-14T02:00:00Z","reference_number":"EMEA/CVMP/41180/2005-FINAL","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-user-safety-pharmaceutical-veterinary-medicinal-products-emeacvmp54303-consultation_en.pdf"},
    {"id":"37958","name":"Public summary of the evaluation of the proposed paediatric investigation plan: \n\nDupilumab for treatment of asthma","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-19T02:00:00Z","last_updated_date":"2015-10-19T02:00:00Z","reference_number":"EMA/629439/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-dupilumab-treatment-asthma_en.pdf-0"},
    {"id":"37965","name":"Timetable for generics applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-12-20T01:00:00Z","last_updated_date":"2005-12-20T01:00:00Z","reference_number":"EMEA/327896/2005","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-generics-applications_en.pdf"},
    {"id":"37978","name":"Opinions on safety variations/periodic safety update reports adopted at the CHMP meeting 22-25 April 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-29T17:40:00Z","last_updated_date":"2014-04-29T17:40:00Z","reference_number":"EMA/124016/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variationsperiodic-safety-update-reports-adopted-chmp-meeting-22-25-april-2014_en.pdf"},
    {"id":"37982","name":"Work plan for Good Clinical Practice Inspectors Working Group (GCP IWG) for 2009","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-03-18T01:00:00Z","last_updated_date":"2009-03-18T01:00:00Z","reference_number":"EMEA/INS/GCP/449289/2008","document_url":"https://www.ema.europa.eu/en/documents/other/work-plan-good-clinical-practice-inspectors-working-group-gcp-iwg-2009_en.pdf"},
    {"id":"37983","name":"Letter of support for measures of executive function and basic emotions to be used to stratify populations of people with autism spectrum disorder (ASD) and predict clinical outcome","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T12:00:00Z","last_updated_date":"2015-12-09T12:00:00Z","reference_number":"EMA/794534/2015","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-measures-executive-function-and-basic-emotions-be-used-stratify-populations-people-autism-spectrum-disorder-asd-and-predict-clinical-outcome_en.pdf"},
    {"id":"38002","name":"Public summary of the evaluation of the proposed product-specific waiver: aflibercept for the treatment of branch retinal vein occlusion and for the treatment of choroidal neovascularisation secondary to pathologic myopi...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-31T17:45:00Z","last_updated_date":"2014-07-31T17:45:00Z","reference_number":"EMA/448345/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-aflibercept-treatment-branch-retinal-vein-occlusion-and-treatment-choroidal-neovascularisation-secondary-pathologic-myopi_en.pdf"},
    {"id":"38010","name":"Open invitation to tender, EMEA/2008/62/P&B, Provision of language training for EMEA staff","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-05-03T02:00:00Z","last_updated_date":"2008-05-03T02:00:00Z","reference_number":"EMEA/206208/2008-4542","document_url":"https://www.ema.europa.eu/en/documents/other/open-invitation-tender-emea200862pb-provision-language-training-emea-staff_en.pdf"},
    {"id":"38070","name":"Implementation plan for the introduction of the safety features on the packaging of centrally authorised medicinal products for human use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-09T15:00:00Z","last_updated_date":"2017-07-05T13:40:00Z","reference_number":"EMA/785582/2014 rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/implementation-plan-introduction-safety-features-packaging-centrally-authorised-medicinal-products-human-use_en.pdf"},
    {"id":"38099","name":"Assessment of the paediatric needs - Nephrology","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-12-01T01:00:00Z","last_updated_date":"2006-12-01T01:00:00Z","reference_number":"EMEA/13306/2007","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-nephrology_en.pdf"},
    {"id":"38115","name":"European Medicines Agency action plan related to the European Commission’s recommendations on product information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T12:00:00Z","last_updated_date":"2017-11-15T12:00:00Z","reference_number":"EMA/680018/2017","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-action-plan-related-european-commissions-recommendations-product-information_en.pdf"},
    {"id":"38118","name":"CTAG5: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on legal aspects - Draft advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag5-advice-european-medicines-agency-clinical-trial-advisory-group-legal-aspects-draft-advice_en.pdf"},
    {"id":"38130","name":"Letter from Thomas Là¶nngren 28-12-2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-21T01:00:00Z","last_updated_date":"2011-03-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-thomas-lapnngren-28-12-2010_en.pdf"},
    {"id":"38157","name":"Sample eligibility form - Patients and consumers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-10T13:47:00Z","last_updated_date":"2018-07-10T13:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sample-eligibility-form-patients-and-consumers_en.pdf"},
    {"id":"38166","name":"CTAG4: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on good analysis practice - Final advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag4-advice-european-medicines-agency-clinical-trial-advisory-group-good-analysis-practice-final-advice_en.pdf"},
    {"id":"38190","name":"Declaration of interests - Kaarlo Hoppu","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-kaarlo-hoppu_en.pdf"},
    {"id":"38196","name":"Organisational matters - CHMP May 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/CHMP/273712/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-may-2012_en.pdf"},
    {"id":"38201","name":"Announcement of European Medicines Agency priorities for adverse drug reaction research – Seventh call, Seventh Framework Programme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-22T18:13:27Z","last_updated_date":"2012-05-22T18:13:27Z","reference_number":"EMA/281471/2012","document_url":"https://www.ema.europa.eu/en/documents/other/announcement-european-medicines-agency-priorities-adverse-drug-reaction-research-seventh-call-seventh-framework-programme_en.pdf"},
    {"id":"38214","name":"Overview of comments received on 'Reflection paper on In-Vitro cultured chondrocyte containing products for cartilage repair of the knee’ (EMA/CAT/568181/2009)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-06-04T02:00:00Z","last_updated_date":"2010-06-04T02:00:00Z","reference_number":"EMA/CAT/65294/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-vitro-cultured-chondrocyte-containing-products-cartilage-repair-knee-emacat5681812009_en.pdf"},
    {"id":"38235","name":"Medicines granted a Community marketing authorisation under the centralised procedure since the November CHMP meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-05T01:00:00Z","last_updated_date":"2012-01-05T01:00:00Z","reference_number":"EMA/986798/2011","document_url":"https://www.ema.europa.eu/en/documents/other/medicines-granted-community-marketing-authorisation-under-centralised-procedure-november-chmp-meeting_en.pdf"},
    {"id":"38247","name":"Cover note on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) substance controlled vocabulary following the quality control exercise","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-05T15:10:00Z","last_updated_date":"2018-04-10T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cover-note-extended-eudravigilance-medicinal-product-dictionary-xevmpd-substance-controlled-vocabulary-following-quality-control-exercise_en.doc"},
    {"id":"38250","name":"Instructions for Visual Inspection: Herceptin Vials 150 mg","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-11-22T00:09:21Z","last_updated_date":"2006-11-22T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/instructions-visual-inspection-herceptin-vials-150-mg_en.pdf"},
    {"id":"38258","name":"Workshop on medicines for bees - Report","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/28057/2010","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-medicines-bees-report_en.pdf"},
    {"id":"38260","name":"Declaration of research interests (addendum) - Paolo Rossi","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-paolo-rossi_en.pdf"},
    {"id":"38267","name":"Overview of comments on 'draft guideline on core summary of product characteristics and package leaflet for fludeoxyglucose (18F)'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-14T13:25:00Z","last_updated_date":"2012-08-14T13:25:00Z","reference_number":"EMA/CHMP/448578/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-draft-guideline-core-summary-product-characteristics-and-package-leaflet-fludeoxyglucose-18f_en.pdf"},
    {"id":"38276","name":"Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for Daclatasvir available for compassionate use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T10:40:00Z","last_updated_date":"2020-10-26T11:00:00Z","reference_number":"EMA/24463/2014","document_url":"https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distribution-and-patients-targeted-and-conditions-safety-monitoring-addressed-member-states-daclatasvir-available-compassionate-use_en.pdf"},
    {"id":"38299","name":"1st EMEA/CPMP Workshop for Patients’ Organisations – Participants List","type":"other","status":"unknown","consultation_date":"","first_published_date":"2002-06-06T02:00:00Z","last_updated_date":"2002-06-06T02:00:00Z","reference_number":"EMEA/13971/02","document_url":"https://www.ema.europa.eu/en/documents/other/1st-emeacpmp-workshop-patients-organisations-participants-list_en.pdf"},
    {"id":"38308","name":"Technical specifications for open invitation to tender no. EMEA/2006/32/DIR, external member(s) of EMEA’s audit advisory committee","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-06-28T02:09:21Z","last_updated_date":"2006-06-28T02:09:21Z","reference_number":"EMEA/171058/2006","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-no-emea200632dir-external-members-emeas-audit-advisory-committee_en.pdf"},
    {"id":"38347","name":"Working party on Herbal Medicinal Products: Final proposal for a core data for Salicis Cortex","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-03-03T01:00:00Z","last_updated_date":"2004-03-03T01:00:00Z","reference_number":"EMEA/HMPWP/341/03","document_url":"https://www.ema.europa.eu/en/documents/other/working-party-herbal-medicinal-products-final-proposal-core-data-salicis-cortex_en.pdf"},
    {"id":"38353","name":"Consensus points - Workshop on haemophilia registries","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T18:00:00Z","last_updated_date":"2015-08-03T18:00:00Z","reference_number":"EMA/CHMP/BPWP/380896/2015","document_url":"https://www.ema.europa.eu/en/documents/other/consensus-points-workshop-haemophilia-registries_en.pdf"},
    {"id":"38357","name":"European Medicines Agency workshop on multiplicity issues in clinical trials - Invitation for expressions of interest","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-21T02:00:00Z","last_updated_date":"2012-06-21T02:00:00Z","reference_number":"EMA/308884/2012","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-workshop-multiplicity-issues-clinical-trials-invitation-expressions-interest_en.pdf"},
    {"id":"38360","name":"Summary of transfer of appropriations in the budget 2014: December 2014 - Management Board meeting: 18 December 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-22T15:00:00Z","last_updated_date":"2014-12-22T15:00:00Z","reference_number":"EMA/MB/694819/2014","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2014-december-2014-management-board-meeting-18-december-2014_en.pdf"},
    {"id":"38398","name":"Draft inventory of paediatric medicines - Cardiovascular therapeutic area","type":"other","status":"Draft: consultation closed","consultation_date":"2012-08-30 - 2012-10-30","first_published_date":"2012-08-30T21:38:25Z","last_updated_date":"2012-08-30T21:38:25Z","reference_number":"EMA/550070/2012","document_url":"https://www.ema.europa.eu/en/documents/other/draft-inventory-paediatric-medicines-cardiovascular-therapeutic-area_en.pdf"},
    {"id":"38408","name":"Outcome of the workshop - Joint European Medicines Agency / European Directorate for the Quality of Medicines and Healthcare workshop on characterisation of new clotting factor concentrates (factor VIII and factor IX) wi...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-01-24T16:30:00Z","last_updated_date":"2014-01-24T16:30:00Z","reference_number":"EMA/789960/2013","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-workshop-joint-european-medicines-agency-european-directorate-quality-medicines-and-healthcare-workshop-characterisation-new-clotting-factor-concentrates-factor-viii-and-factor-ix-wi_en.pdf"},
    {"id":"38418","name":"Publication of results-related information on paediatric studies submitted under Article 45 of the Regulation (EC) No 1901/2006 (‘Paediatric Regulation’)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-04T02:00:00Z","last_updated_date":"2015-02-19T17:15:00Z","reference_number":"EMA/428617/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/publication-results-related-information-paediatric-studies-submitted-under-article-45-regulation-ec-no-19012006-paediatric-regulation_en.pdf"},
    {"id":"38458","name":"Outcome of public consultation on new EMEA transparency","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2000-06-09T02:00:00Z","last_updated_date":"2000-06-09T02:00:00Z","reference_number":"EMEA/D/16906/00","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-public-consultation-new-emea-transparency_en.pdf"},
    {"id":"38470","name":"Overview of comments received on guideline on requirements for an authorisation under exceptional circumstances for vaccines for use in birds against avian influenza EMEA/CVMP/IWP/222624/2006","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-05-02T02:00:00Z","last_updated_date":"2007-05-02T02:00:00Z","reference_number":"EMEA/146160/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-requirements-authorisation-under-exceptional-circumstances-vaccines-use-birds-against-avian-influenza-emeacvmpiwp2226242006_en.pdf"},
    {"id":"38478","name":"Pharmacovigilance Risk Assessment Committee (PRAC) criteria to prioritise impact research (Rev.1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T18:13:00Z","last_updated_date":"2024-09-17T13:54:00Z","reference_number":"EMA/153279/2016 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/pharmacovigilance-risk-assessment-committee-prac-criteria-prioritise-impact-research-rev1_en.pdf"},
    {"id":"38484","name":"Policy 72: European Medicines Agency policy on handling of information from external sources disclosing alleged improprieties concerning EMA activities related to the authorisation, supervision and maintenance of human a...","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2017-04-10T12:00:00Z","last_updated_date":"2022-04-20T10:00:00Z","reference_number":"EMA/283205/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/policy-72-european-medicines-agency-policy-handling-information-external-sources-disclosing-alleged-improprieties-concerning-ema-activities-related-authorisation-supervision-and-maintenance-human_en.pdf"},
    {"id":"38491","name":"Key milestones of EMA interactions with healthcare professionals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T01:00:00Z","last_updated_date":"2017-08-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/key-milestones-ema-interactions-healthcare-professionals_en.pdf"},
    {"id":"38502","name":"ICMRA - Mapping of crisis management initiatives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-09T13:20:00Z","last_updated_date":"2017-01-09T13:20:00Z","reference_number":"EMA/580633/2015","document_url":"https://www.ema.europa.eu/en/documents/other/icmra-mapping-crisis-management-initiatives_en.pdf"},
    {"id":"38507","name":"Organisational matters - CHMP meeting of 17-20 September 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-09-24T10:44:00Z","last_updated_date":"2012-09-24T10:44:00Z","reference_number":"EMA/CHMP/539765/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-17-20-september-2012_en.pdf"},
    {"id":"38518","name":"High level business consultancy EMA/2013/23/FI - Letter of invitation to tender","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"EMA/553009/2013","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-letter-invitation-tender_en.pdf"},
    {"id":"38557","name":"Public hearing on Valproate - Summary of safety concerns and list of questions for the public hearing on Valproate","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-07-11T14:00:00Z","last_updated_date":"2017-07-11T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/public-hearing-valproate-summary-safety-concerns-and-list-questions-public-hearing-valproate_en.pdf"},
    {"id":"38559","name":"List of participants - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting: Workshop...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"EMA/71682/2014","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf-2"},
    {"id":"38593","name":"European Commission - Canada mutual recognition agreement: Sectoral annex on good manufacturing practices - Eighth joint sectoral group meeting update on the operation of the sectoral annex","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-06-07T02:00:00Z","last_updated_date":"2004-06-07T02:00:00Z","reference_number":"EMEA/INS/MRA/214440/2006","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-canada-mutual-recognition-agreement-sectoral-annex-good-manufacturing-practices-eighth-joint-sectoral-group-meeting-update-operation-sectoral-annex_en.pdf"},
    {"id":"38596","name":"Public summary of the evaluation of a proposed product-specific\n\nwaiver: Ibandronic acid (in combination with calcium (carbonate) / cholecalciferol) for combination treatment of osteoporosis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/69490/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-ibandronic-acid-combination-calcium-carbonate-cholecalciferol-combination-treatment-osteoporosis_en.pdf"},
    {"id":"38604","name":"Download EPS - Species pictograms - Rabbit","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-rabbit_en.zip"},
    {"id":"38618","name":"Pre-qualification questionnaire (PQQ) for a restricted tender procedure organised by the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T11:30:00Z","last_updated_date":"2013-03-20T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency_en.doc"},
    {"id":"38622","name":"Celvapan: Package leaflet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-29T02:00:00Z","last_updated_date":"2010-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/celvapan-package-leaflet_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/celvapan-package-leaflet_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/celvapan-package-leaflet_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/celvapan-package-leaflet_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/celvapan-package-leaflet_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/celvapan-package-leaflet_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/celvapan-package-leaflet_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/celvapan-package-leaflet_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/celvapan-package-leaflet_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/celvapan-package-leaflet_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/celvapan-package-leaflet_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/celvapan-package-leaflet_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/celvapan-package-leaflet_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/celvapan-package-leaflet_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/celvapan-package-leaflet_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/celvapan-package-leaflet_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/celvapan-package-leaflet_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/celvapan-package-leaflet_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/celvapan-package-leaflet_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/celvapan-package-leaflet_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/celvapan-package-leaflet_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/celvapan-package-leaflet_sv.pdf"}},
    {"id":"38647","name":"Declaration of interests: Tomasz Jablonski","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-06-20T12:04:00Z","last_updated_date":"2025-08-01T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-tomasz-jablonski_en.pdf"},
    {"id":"38650","name":"Workshop on draft guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-04-03T02:09:21Z","last_updated_date":"2007-04-03T02:09:21Z","reference_number":"EMEA/213289/2006","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-draft-guideline-requirements-first-man-clinical-trials-potential-high-risk-medicinal-products_en.pdf"},
    {"id":"38694","name":"Tabular overview of updated / new procedural guidance documents in line with the new pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-26T01:00:00Z","last_updated_date":"2013-03-26T01:00:00Z","reference_number":"EMA/199715/2013","document_url":"https://www.ema.europa.eu/en/documents/other/tabular-overview-updated-new-procedural-guidance-documents-line-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"38702","name":"Reflection paper on advice to applicants/sponsors/CROS of bioequivalence studies","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-09-19T02:00:00Z","last_updated_date":"2008-09-19T02:00:00Z","reference_number":"EMEA/INS/GCP/468975/2007","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-advice-applicantssponsorscros-bioequivalence-studies_en.pdf"},
    {"id":"38711","name":"European Union Telematics Management Board - Terms of reference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-08-23T14:55:00Z","last_updated_date":"2018-03-07T18:00:00Z","reference_number":"EMA/88659/2018","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-telematics-management-board-terms-reference_en.pdf"},
    {"id":"38729","name":"Analysis and assessment of the Executive Director's annual activity report 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-06-18T19:00:00Z","last_updated_date":"2013-06-18T19:00:00Z","reference_number":"EMA/MB/302752/2013","document_url":"https://www.ema.europa.eu/en/documents/other/analysis-and-assessment-executive-directors-annual-activity-report-2012_en.pdf"},
    {"id":"38766","name":"Draft inventory of paediatric therapeutic needs - Neurology","type":"other","status":"Draft: consultation closed","consultation_date":"2014-05-09 - 2014-07-09","first_published_date":"2014-05-08T13:30:00Z","last_updated_date":"2014-05-08T13:30:00Z","reference_number":"EMA/562919/2013","document_url":"https://www.ema.europa.eu/en/documents/other/draft-inventory-paediatric-therapeutic-needs-neurology_en.pdf"},
    {"id":"38777","name":"Validation checklist for initial marketing authorisation applications – pharmaceuticals (applicable to submissions under Regulation (EU) 2019/6)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-30T12:00:00Z","last_updated_date":"2026-04-20T09:00:00Z","reference_number":"EMA/377885/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/validation-checklist-initial-marketing-authorisation-applications-pharmaceuticals-applicable-submissions-under-regulation-eu-2019-6_en.pdf"},
    {"id":"38787","name":"Geriatric medicines strategy","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-02-23T11:23:02Z","last_updated_date":"2011-02-23T11:23:02Z","reference_number":"EMA/CHMP/137793/2011","document_url":"https://www.ema.europa.eu/en/documents/other/geriatric-medicines-strategy_en.pdf"},
    {"id":"38803","name":"Organisational matters - CHMP meeting 19-22 May 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/124025/2014","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-19-22-may-2014_en.pdf"},
    {"id":"38806","name":"The ATCvet classification system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-20T02:00:00Z","last_updated_date":"2011-03-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/atcvet-classification-system_en.pdf"},
    {"id":"38820","name":"Administrative arrangements to exchange non-public information on medicinal products between DG SANTE-European Medicines Agency and Swiss Federal Department of Home Affairs-Swissmedic","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-22T13:30:00Z","last_updated_date":"2015-07-22T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/administrative-arrangements-exchange-non-public-information-medicinal-products-between-dg-sante-european-medicines-agency-and-swiss-federal-department-home-affairs-swissmedic_en.pdf"},
    {"id":"38846","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting 12-15 November 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-22T10:15:00Z","last_updated_date":"2012-11-22T10:15:00Z","reference_number":"EMA/CHMP/732278/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-12-15-november-2012_en.pdf"},
    {"id":"38906","name":"Terms of reference of the Management Board Telematics Committee","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T11:30:00Z","last_updated_date":"2011-12-20T11:30:00Z","reference_number":"EMA/907384/2011","document_url":"https://www.ema.europa.eu/en/documents/other/terms-reference-management-board-telematics-committee_en.pdf-0"},
    {"id":"38916","name":"Withdrawal letter: Simponi","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-simponi_en.pdf"},
    {"id":"38922","name":"Management Board meeting dates 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-06-18T19:00:00Z","last_updated_date":"2013-06-18T19:00:00Z","reference_number":"EMA/MB/290754/2013","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2014_en.pdf"},
    {"id":"38923","name":"Mutual recognition agreements: Sectoral Annex on Good Manufacturing Practices - Internationally Harmonised Requirements for Batch Certification","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-05-01T02:00:00Z","last_updated_date":"2004-05-01T02:00:00Z","reference_number":"EMEA/MRA/23/01 Rev 4","document_url":"https://www.ema.europa.eu/en/documents/other/mutual-recognition-agreements-sectoral-annex-good-manufacturing-practices-internationally-harmonised-requirements-batch-certification_en.doc"},
    {"id":"38924","name":"FertiPro N.V. HSA-containing ART media - Procedural steps and scientific information after initial consultation (archive)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2025-04-24T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/fertipro-nv-hsa-containing-art-media-procedural-steps-scientific-information-after-initial-consultation-archive_en.pdf"},
    {"id":"38933","name":"Declaration of interests: Ana Rodriguez Sanchez Beato","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:00Z","last_updated_date":"2019-10-25T10:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-ana-rodriguez-sanchez-beato_en.pdf"},
    {"id":"38941","name":"Public summary of the evaluation of the proposed product-specific waiver: Human recombinant follicle-stimulating hormone (FE 999049) for treatment of female infertility and treatment of hypogonadotrophic hypogonadism","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T12:00:00Z","last_updated_date":"2014-10-21T12:00:00Z","reference_number":"EMA/503612/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-human-recombinant-follicle-stimulating-hormone-fe-999049-treatment-female-infertility-and-treatment-hypogonadotrophic-hypogonadism_en.pdf"},
    {"id":"38985","name":"Timetable: Multiple applications starting at day 121 of the related ongoing full marketing-authorisation application","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-08T02:00:00Z","last_updated_date":"2015-07-28T18:00:00Z","reference_number":"EMA/518452/2011 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-multiple-applications-starting-day-121-related-ongoing-full-marketing-authorisation-application_en.pdf"},
    {"id":"38989","name":"2006 EU-Swiss GMP China Training Workshop - More information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-07-31T02:09:21Z","last_updated_date":"2006-07-31T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/2006-eu-swiss-gmp-china-training-workshop-more-information_en.pdf"},
    {"id":"38990","name":"Biologics Working Party Ad-hoc Influenza Working Group: European Union recommendations for the seasonal-influenza-vaccine composition for the season 2011 / 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-03-17T17:29:29Z","last_updated_date":"2011-03-17T17:29:29Z","reference_number":"EMA/CHMP/BWP/156215/2011","document_url":"https://www.ema.europa.eu/en/documents/other/biologics-working-party-ad-hoc-influenza-working-group-european-union-recommendations-seasonal-influenza-vaccine-composition-season-2011-2012_en.pdf"},
    {"id":"38997","name":"Vpriv - Recommendation for maintenance of orphan designation at the time of marketing authorisation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-09-10T02:00:00Z","last_updated_date":"2010-09-10T02:00:00Z","reference_number":"EMA/COMP/433831/2010","document_url":"https://www.ema.europa.eu/en/documents/other/vpriv-recommendation-maintenance-orphan-designation-time-marketing-authorisation_en.pdf"},
    {"id":"38999","name":"Declaration of interests: John Forte","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2016-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-john-forte_en.pdf"},
    {"id":"39013","name":"Cover note -  Management Board rules of procedure","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T11:30:00Z","last_updated_date":"2011-12-20T11:30:00Z","reference_number":"EMA/MB/115339/2004","document_url":"https://www.ema.europa.eu/en/documents/other/cover-note-management-board-rules-procedure_en.pdf"},
    {"id":"39021","name":"Appendix - Briefing Document to the Clinical Trial Readiness in Spinal Muscular Atrophy (SMA) SMA Europe, TREAT-NMD and European Medicines Agency meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-briefing-document-clinical-trial-readiness-spinal-muscular-atrophy-sma-sma-europe-treat-nmd-and-european-medicines-agency-meeting_en.pdf"},
    {"id":"39039","name":"Speakers’ biographies - European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting: Informa...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-04T13:00:00Z","last_updated_date":"2015-06-04T13:00:00Z","reference_number":"EMA/132694/2015","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-european-medicines-agency-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf"},
    {"id":"39052","name":"Meetings, virtual meetings and alternative ways of communicating","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/MB/399835/2011","document_url":"https://www.ema.europa.eu/en/documents/other/meetings-virtual-meetings-and-alternative-ways-communicating_en.pdf"},
    {"id":"39088","name":"Celvapan: Product information as recommended by the CHMP on 22 April 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2010-04-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/celvapan-product-information-recommended-chmp-22-april-2010_en.pdf"},
    {"id":"39095","name":"Declaration of research interests (addendum) - Kaarlo Hoppu","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T11:00:00Z","last_updated_date":"2012-11-21T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-research-interests-addendum-kaarlo-hoppu_en.pdf"},
    {"id":"39112","name":"Overview of implementing rules of the Staff Regulations signed by the Management Board chair during the period from 7 October 2011 to 29 February 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"EMA/MB/137391/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-implementing-rules-staff-regulations-signed-management-board-chair-during-period-7-october-2011-29-february-2012_en.pdf"},
    {"id":"39130","name":"Decision on amending budget No 1-2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-03-30T16:16:00Z","last_updated_date":"2012-03-30T16:16:00Z","reference_number":"EMA/MB/155755/2012","document_url":"https://www.ema.europa.eu/en/documents/other/decision-amending-budget-no-1-2012_en.pdf"},
    {"id":"39136","name":"Response to general report on experience acquired as a result of the application of the paediatric regulation of 19 September 2012 submitted for public consultation by the European Commission on ‘experience acquired’ and...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-20T13:13:00Z","last_updated_date":"2012-12-20T13:13:00Z","reference_number":"EMA/746795/2012","document_url":"https://www.ema.europa.eu/en/documents/other/response-general-report-experience-acquired-result-application-paediatric-regulation-19-september-2012-submitted-public-consultation-european-commission-experience-acquired-and_en.pdf"},
    {"id":"39165","name":"Overview of comments received on reflection paper on immune-tolerance induction in haemophilia-A patients with inhibitors","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-26T13:10:00Z","last_updated_date":"2013-03-26T13:10:00Z","reference_number":"EMA/CHMP/BPWP/734487/2012","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-reflection-paper-immune-tolerance-induction-haemophilia-patients-inhibitors_en.pdf"},
    {"id":"39203","name":"Overview of comments received on the guideline on process validation for finished products - information and data to be provided in regulatory submissions - Revision 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T17:20:00Z","last_updated_date":"2014-02-28T17:20:00Z","reference_number":"EMA/659397/2013","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-process-validation-finished-products-information-and-data-be-provided-regulatory-submissions-revision-1_en.pdf"},
    {"id":"39210","name":"Declaration of interests: Michael Berntgen","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:00Z","last_updated_date":"2025-08-01T17:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-michael-berntgen_en.pdf"},
    {"id":"39218","name":"Mandate of the ENCePP Implementation Advisory Group (ENCIAG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-04-11T02:00:00Z","last_updated_date":"2008-04-11T02:00:00Z","reference_number":"EMEA/191017/2008","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-encepp-implementation-advisory-group-enciag_en.pdf"},
    {"id":"39233","name":"Summary of transfer of appropriations in the budget 2014 and 2015 - Management Board meeting: 19 March 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-26T14:10:00Z","last_updated_date":"2015-03-26T14:10:00Z","reference_number":"EMA/MB/67143/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2014-and-2015-management-board-meeting-19-march-2015_en.pdf"},
    {"id":"39280","name":"Rules for reimbursement of expenses for delegates attending meetings with effect from 16 June 2022","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T17:00:00Z","last_updated_date":"2023-02-13T15:05:00Z","reference_number":"EMA/MB/279597/2018, rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/rules-reimbursement-expenses-delegates-attending-meetings-effect-16-june-2022_en.pdf"},
    {"id":"39290","name":"Technical specifications for open invitation to tender - Procurement Procedure EMA/2012/09/IF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"EMA/685025/2011","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-open-invitation-tender-procurement-procedure-ema201209if_en.pdf"},
    {"id":"39291","name":"Declaration of interests: Thomas Girard","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T02:00:00Z","last_updated_date":"2025-08-01T15:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-thomas-girard_en.pdf"},
    {"id":"39295","name":"Guidelines and concept papers adopted during the CHMP meeting 19-22 May 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/124022/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-19-22-may-2014_en.pdf-0"},
    {"id":"39306","name":"Annex I - Privacy statement for bank account validation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2009-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-i-privacy-statement-bank-account-validation_en.pdf"},
    {"id":"39321","name":"Clinical trials submitted in marketing-authorisation applications to the European Medicines Agency: Overview of patient recruitment and the geographical location of investigator sites","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-09-23T02:09:21Z","last_updated_date":"2013-04-09T18:50:00Z","reference_number":"EMA/INS/GCP/676319/2012","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trials-submitted-marketing-authorisation-applications-european-medicines-agency-overview-patient-recruitment-and-geographical-location-investigator-sites_en.pdf"},
    {"id":"39328","name":"Overview of comments received on draft guideline on the assessment of genotoxic constituents in herbal substances/ preparations (EMEA/HMPC/107079/2007)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-05-21T02:00:00Z","last_updated_date":"2008-05-21T02:00:00Z","reference_number":"EMEA/HMPC/232888/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-assessment-genotoxic-constituents-herbal-substances-preparations-emeahmpc1070792007_en.pdf"},
    {"id":"39331","name":"Committee on Herbal Medicinal Products and Working Party on Community Monographs and Community List meeting dates in 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-04-07T02:00:00Z","last_updated_date":"2011-04-19T02:00:00Z","reference_number":"EMA/203076/2010","document_url":"https://www.ema.europa.eu/en/documents/other/committee-herbal-medicinal-products-and-working-party-community-monographs-and-community-list-meeting-dates-2011_en.pdf"},
    {"id":"39341","name":"Withdrawal letter: Velcade (bortezomib)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-07-31T17:15:00Z","last_updated_date":"2012-07-31T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-velcade-bortezomib_en.pdf"}    {"id":"39345","name":"IVF Media G5 - Procedural steps and scientific information after initial consultation (archive)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2025-06-04T15:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ivf-media-g5-procedural-steps-scientific-information-after-initial-consultation-archive_en.pdf"},
    {"id":"39350","name":"Pilot project on adaptive licensing","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-19T17:00:00Z","last_updated_date":"2014-03-19T17:00:00Z","reference_number":"EMA/254350/2012","document_url":"https://www.ema.europa.eu/en/documents/other/pilot-project-adaptive-licensing_en.pdf"},
    {"id":"39355","name":"Recognition criteria for self-assessment - European Network of Paediatric Research at the European Medicines Agency: Finnish Investigators Network for Pediatric Medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T00:31:00Z","last_updated_date":"2012-05-21T12:00:00Z","reference_number":"EMA/817618/2010","document_url":"https://www.ema.europa.eu/en/documents/other/recognition-criteria-self-assessment-european-network-paediatric-research-european-medicines-agency-finnish-investigators-network-pediatric-medicines_en.pdf"},
    {"id":"39367","name":"Report on the meeting of the Paediatric Human Immunodeficiency Virus (HIV) Expert Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-06T02:00:00Z","last_updated_date":"2010-05-06T02:00:00Z","reference_number":"EMA/339929/2009","document_url":"https://www.ema.europa.eu/en/documents/other/report-meeting-paediatric-human-immunodeficiency-virus-hiv-expert-group_en.pdf"},
    {"id":"39370","name":"Annex B2 - Other criteria essential to ensure that EMA remains operational to guarantee business continuity - EMA contributions (detailed tables)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T20:15:00Z","last_updated_date":"2017-10-03T20:15:00Z","reference_number":"EMA/606203/2017","document_url":"https://www.ema.europa.eu/en/documents/other/annex-b2-other-criteria-essential-ensure-ema-remains-operational-guarantee-business-continuity-ema-contributions-detailed-tables_en.pdf"},
    {"id":"39380","name":"European Commission-Japan mutual recognition agreement - Sectoral annex on good manufacturing practice for medicinal products: Third sub-committee meeting, 18 and 19 February 2004","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-02-19T01:00:00Z","last_updated_date":"2004-02-19T01:00:00Z","reference_number":"EMEA/INS/MRA/JP/7/04","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-japan-mutual-recognition-agreement-sectoral-annex-good-manufacturing-practice-medicinal-products-third-sub-committee-meeting-18-and-19-february-2004_en.pdf"},
    {"id":"39394","name":"Steen solution - Procedural steps and scientific information after initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T18:00:00Z","last_updated_date":"2021-03-04T13:58:00Z","reference_number":"EMA/CHMP/105561/2021Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/steen-solution-procedural-steps-and-scientific-information-after-initial-consultation_en.pdf"},
    {"id":"39398","name":"HCP WG meeting dates for 2009","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-10-30T01:00:00Z","last_updated_date":"2008-10-30T01:00:00Z","reference_number":"EMEA/58684/2008","document_url":"https://www.ema.europa.eu/en/documents/other/hcp-wg-meeting-dates-2009_en.pdf"},
    {"id":"39417","name":"CTAG5: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on legal aspects - Comments to draft final advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag5-advice-european-medicines-agency-clinical-trial-advisory-group-legal-aspects-comments-draft-final-advice_en.pdf"},
    {"id":"39429","name":"Timetable: Safety referral (Article 107i, urgent Union procedure)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-13T11:03:00Z","last_updated_date":"2026-06-04T17:45:00Z","reference_number":"EMA/397812/2025","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-safety-referral-article-107i-urgent-union-procedure_en.pdf"},
    {"id":"39469","name":"Questions and answers relating to open tender – EMA/2012/21/IS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-12-12T10:07:00Z","reference_number":"EMA/748793/2012","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-relating-open-tender-ema201221is_en.pdf"},
    {"id":"39471","name":"Overview of comments received on guideline on quality data requirements for veterinary medicinal products intended for minor uses or minor species","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-07-20T02:00:00Z","last_updated_date":"2006-07-20T02:00:00Z","reference_number":"EMEA/CVMP/QWP/50314/2006","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-quality-data-requirements-veterinary-medicinal-products-intended-minor-uses-or-minor-species_en.pdf"},
    {"id":"39479","name":"Response to the questions raised by the qualification team - CHMP qualification opinion on efficient statistical methodology for model-based design and analysis of phase-II dose-finding studies under model uncertainty","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-15T19:00:00Z","last_updated_date":"2013-10-15T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/response-questions-raised-qualification-team-chmp-qualification-opinion-efficient-statistical-methodology-model-based-design-and-analysis-phase-ii-dose-finding-studies-under-model-uncertainty_en.pdf"},
    {"id":"39505","name":"Structure for the operation of the EnprEMA elaborated working group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/structure-operation-enprema-elaborated-working-group_en.pdf"},
    {"id":"39506","name":"Overview of comments received on the Core SPC for human Anti-D immunoglobulin for intravenous use CPMP/BPWP/319619/2005","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-13T02:00:00Z","last_updated_date":"2007-07-13T02:00:00Z","reference_number":"EMEA/CHMP/BPWP/74960/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-core-spc-human-anti-d-immunoglobulin-intravenous-use-cpmpbpwp3196192005_en.pdf"},
    {"id":"39518","name":"Reflection paper on medicinal-product supply shortages caused by manufacturing / good-manufacturing-practice compliance problems - Implementation plan 2012-2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-23T16:35:00Z","last_updated_date":"2012-11-23T16:35:00Z","reference_number":"EMA/708575/2012","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-medicinal-product-supply-shortages-caused-manufacturing-good-manufacturing-practice-compliance-problems-implementation-plan-2012-2015_en.pdf"},
    {"id":"39523","name":"Policy 9: Appropriate coordination between the Agency's scientific committees","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2008-10-31T01:00:00Z","last_updated_date":"2008-10-31T01:00:00Z","reference_number":"EMEA/124704/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/policy-9-appropriate-coordination-between-agencys-scientific-committees_en.pdf"},
    {"id":"39534","name":"Pathogen-specific database: Annex: Biological agents for which currently no specific treatment can be recommended","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-05T01:00:00Z","last_updated_date":"2008-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pathogen-specific-database-annex-biological-agents-which-currently-no-specific-treatment-can-be-recommended_en.pdf"},
    {"id":"39542","name":"Overview of current initiatives at European Union level to assist micro, small and medium-sized enterprises with financing","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-21T17:38:22Z","last_updated_date":"2015-02-04T15:30:00Z","reference_number":"EMA/986534/2011","document_url":"https://www.ema.europa.eu/en/documents/other/overview-current-initiatives-european-union-level-assist-micro-small-and-medium-sized-enterprises-financing_en.pdf"},
    {"id":"39578","name":"Calendar of 2011 dates for the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-06-10T02:00:00Z","last_updated_date":"2011-04-20T02:00:00Z","reference_number":"EMA/367532/2010","document_url":"https://www.ema.europa.eu/en/documents/other/calendar-2011-dates-european-medicines-agency_en.pdf"},
    {"id":"39580","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) units of measurement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2019-01-21T13:22:00Z","reference_number":"EMA/136149/2012 Rev. 12","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-units-measurement_en.xls"},
    {"id":"39581","name":"European Medicines Agency Brexit Preparedness Business Continuity Plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-16T18:21:00Z","last_updated_date":"2017-10-16T18:21:00Z","reference_number":"EMA/196585/2017","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-brexit-preparedness-business-continuity-plan_en.pdf"},
    {"id":"39584","name":"Minor use or minor species (MUMS)/limited market scheme for veterinary medicinal products - 3rd annual report (2012)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/MB/114227/2013","document_url":"https://www.ema.europa.eu/en/documents/other/minor-use-or-minor-species-mumslimited-market-scheme-veterinary-medicinal-products-3rd-annual-report-2012_en.pdf"},
    {"id":"39598","name":"Work plan for the CHMP Excipients Drafting Group (ExcpDG) for the revision of the EC guideline ‘Excipients in the labelling and package leaflet of medicinal products for human use’ for 2018","type":"other","status":"Draft","consultation_date":"","first_published_date":"2018-01-29T01:00:00Z","last_updated_date":"2018-01-29T14:50:00Z","reference_number":"EMA/CHMP/672198/2017","document_url":"https://www.ema.europa.eu/en/documents/other/work-plan-chmp-excipients-drafting-group-excpdg-revision-ec-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-2018_en.pdf"},
    {"id":"39599","name":"Letter of invitation to tender: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"EMA/48364/2014","document_url":"https://www.ema.europa.eu/en/documents/other/letter-invitation-tender-procurement-procedure-ema201401ph_en.pdf"},
    {"id":"39601","name":"Pre-Qualification Questionnaire (PQQ) for a restricted tender procedure organised by European Medicines Agency (EMEA) security consultant EMEA/2008/53/ISERV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pre-qualification-questionnaire-pqq-restricted-tender-procedure-organised-european-medicines-agency-emea-security-consultant-emea200853iserv_en.doc"},
    {"id":"39622","name":"CAT meeting dates 2016, 2017 and 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-05-13T16:15:00Z","last_updated_date":"2016-05-13T16:15:00Z","reference_number":"EMA/CAT/190634/2014","document_url":"https://www.ema.europa.eu/en/documents/other/cat-meeting-dates-2016-2017-and-2018_en.pdf"},
    {"id":"39625","name":"Overview of comments received on ‘Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), bluetongue (BT) and foot and mouth disease (FMD)’ - First version","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/33491/2010","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-data-requirements-multi-strain-dossiers-inactivated-vaccines-against-avian-influenza-ai-bluetongue-bt-and-foot-and-mouth-disease-fmd-first-version_en.pdf"},
    {"id":"39632","name":"Question and answer document on the European database of adverse drug reaction reports website","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-05-31T13:00:00Z","last_updated_date":"2012-05-31T13:00:00Z","reference_number":"EMA/259836/2012","document_url":"https://www.ema.europa.eu/en/documents/other/question-and-answer-document-european-database-adverse-drug-reaction-reports-website_en.pdf"},
    {"id":"39656","name":"Organisational matters - CHMP meeting 10-13 December 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-19T13:00:01Z","last_updated_date":"2012-12-19T13:00:01Z","reference_number":"EMA/CHMP/732293/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-10-13-december-2012_en.pdf"},
    {"id":"39662","name":"Recruitment at the European Medicines Agency - Exemption for nationals of the accession country (Croatia)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-12-10T11:05:00Z","last_updated_date":"2012-12-10T11:05:00Z","reference_number":"EMA/492315/2012","document_url":"https://www.ema.europa.eu/en/documents/other/recruitment-european-medicines-agency-exemption-nationals-accession-country-croatia_en.pdf"},
    {"id":"39732","name":"Open invitation to tender, EMEA/2008/40/ES, Services to support EMEA's online communications activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-03-05T01:00:00Z","last_updated_date":"2008-03-05T01:00:00Z","reference_number":"EMEA/3525/04/5736","document_url":"https://www.ema.europa.eu/en/documents/other/open-invitation-tender-emea200840es-services-support-emeas-online-communications-activities_en.pdf"},
    {"id":"39744","name":"Community project on the practical implementation of the new obligations for manufacturing-authorisation holders (Article 46f/50f of Directive 2001/83(2)/EC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-14T02:00:00Z","last_updated_date":"2008-07-14T02:00:00Z","reference_number":"EMEA/INS/GMP/361819/2008","document_url":"https://www.ema.europa.eu/en/documents/other/community-project-practical-implementation-new-obligations-manufacturing-authorisation-holders-article-46f50f-directive-2001832ec_en.pdf"},
    {"id":"39769","name":"Explanatory note on fees payable to the European Medicines Agency","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-03-30T11:10:03Z","last_updated_date":"2013-03-27T13:20:00Z","reference_number":"EMA/21385/2013","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-note-fees-payable-european-medicines-agency_en.pdf-1"},
    {"id":"39773","name":"European Commission request for joint opinion","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-28T16:00:00Z","last_updated_date":"2015-04-28T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-request-joint-opinion_en.pdf"},
    {"id":"39790","name":"PCWP/HCPWP Session on communication and information on medicines 8 March 2016 - Speakers’ biographies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"EMA/52928/2016","document_url":"https://www.ema.europa.eu/en/documents/other/pcwphcpwp-session-communication-and-information-medicines-8-march-2016-speakers-biographies_en.pdf"},
    {"id":"39812","name":"List of eligible industry stakeholder organisations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-16T17:30:00Z","last_updated_date":"2026-06-10T14:27:00Z","reference_number":"EMA/26652/2017","document_url":"https://www.ema.europa.eu/en/documents/other/list-eligible-industry-stakeholder-organisations_en.pdf"},
    {"id":"39825","name":"CTAG4: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on good analysis practice - Second draft and comments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag4-advice-european-medicines-agency-clinical-trial-advisory-group-good-analysis-practice-second-draft-and-comments_en.pdf"},
    {"id":"39858","name":"European Medicines Agency practical guidance on the application form for centralised type IA and IB variations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-18T16:30:00Z","last_updated_date":"2023-06-14T11:38:00Z","reference_number":"EMA/233564/2014 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-practical-guidance-application-form-centralised-type-ia-and-ib-variations_en.pdf"},
    {"id":"39890","name":"Open Invitation to Tender, EMEA/2006/35/ACC, Banking services for EMEA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-08-29T02:00:00Z","last_updated_date":"2006-08-29T02:00:00Z","reference_number":"EMEA/3525/04/5736","document_url":"https://www.ema.europa.eu/en/documents/other/open-invitation-tender-emea200635acc-banking-services-emea_en.pdf"},
    {"id":"39921","name":"Opinions on safety variations / periodic safety update reports adopted at the CHMP meeting 17-20 March 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-03-24T17:00:00Z","last_updated_date":"2014-03-24T17:00:00Z","reference_number":"EMA/CHMP/123245/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-periodic-safety-update-reports-adopted-chmp-meeting-17-20-march-2014_en.pdf"},
    {"id":"39978","name":"Chapter 5: eXtended EudraVigilance Product Report Acknowledgement Message - Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-01T21:19:00Z","last_updated_date":"2025-01-10T09:35:00Z","reference_number":"EMA/718844/2011 Version 3.5","document_url":"https://www.ema.europa.eu/en/documents/other/chapter-5-extended-eudravigilance-product-report-acknowledgement-message-detailed-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-ema_en.pdf"},
    {"id":"39994","name":"Overview of comments received on draft revised guideline on requirements and controls of bovine serum used in the production of immunological veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-07-13T02:00:00Z","last_updated_date":"2005-07-13T02:00:00Z","reference_number":"EMEA/CVMP/IWP/214680/2005","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-revised-guideline-requirements-and-controls-bovine-serum-used-production-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"40012","name":"New EMEA transparency policy measures","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2003-10-31T01:00:00Z","last_updated_date":"2003-10-31T01:00:00Z","reference_number":"EMEA/MB/52/03/Rev 1/Final","document_url":"https://www.ema.europa.eu/en/documents/other/new-emea-transparency-policy-measures_en.pdf"},
    {"id":"40050","name":"Opinions on safety variations adopted at the CHMP meeting of 16-19 April 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-04-23T02:00:00Z","last_updated_date":"2012-04-23T02:00:00Z","reference_number":"EMA/CHMP/213035/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-chmp-meeting-16-19-april-2012_en.pdf"},
    {"id":"40070","name":"Committee for medicinal products for veterinary use -\n\nEMEA public bulletin 2003 on veterinary pharmacovigilance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2005-03-19T01:00:00Z","last_updated_date":"2005-03-19T01:00:00Z","reference_number":"EMEA/CVMP/359/074","document_url":"https://www.ema.europa.eu/en/documents/other/committee-medicinal-products-veterinary-use-emea-public-bulletin-2003-veterinary-pharmacovigilance_en.pdf"},
    {"id":"40075","name":"Assessment of the paediatric needs - Gastroenterology","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2007-10-01T02:00:00Z","last_updated_date":"2007-10-01T02:00:00Z","reference_number":"EMEA/527934/2007","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-paediatric-needs-gastroenterology_en.pdf"},
    {"id":"40076","name":"Decision on amending budget No 1-2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-03-25T13:30:00Z","last_updated_date":"2014-03-25T13:30:00Z","reference_number":"EMA/MB/45191/2014","document_url":"https://www.ema.europa.eu/en/documents/other/decision-amending-budget-no-1-2014_en.pdf"},
    {"id":"40093","name":"Summary of transfer of appropriations in the budget 2013 - Management Board meeting: 3 October 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-10-08T14:20:00Z","last_updated_date":"2013-10-08T14:20:00Z","reference_number":"EMA/MB/537811/2013","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2013-management-board-meeting-3-october-2013_en.pdf"},
    {"id":"40101","name":"Statement of the Committee for Medicinal Products for Veterinary Use position on the ethical use of animals in the testing, development and manufacture of veterinary medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T15:55:00Z","last_updated_date":"2017-12-19T15:55:00Z","reference_number":"EMA/CVMP/3Rs/506841/2017","document_url":"https://www.ema.europa.eu/en/documents/other/statement-committee-medicinal-products-veterinary-use-position-ethical-use-animals-testing-development-and-manufacture-veterinary-medicines_en.pdf"},
    {"id":"40119","name":"Procedural announcements - CHMP meeting 12-15 March 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-20T15:00:00Z","last_updated_date":"2012-03-20T15:00:00Z","reference_number":"EMA/CHMP/162994/2012","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-announcements-chmp-meeting-12-15-march-2012_en.pdf"},
    {"id":"40133","name":"The joint European Union Telematics governance model","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-08-23T14:55:00Z","last_updated_date":"2017-11-13T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/joint-european-union-telematics-governance-model_en.pdf"},
    {"id":"40134","name":"Memorandum of understanding on working arrangements between the European Medicines Agency and the European Food Safety Authority","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-01-27T18:01:40Z","last_updated_date":"2012-01-27T18:01:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/memorandum-understanding-working-arrangements-between-european-medicines-agency-and-european-food-safety-authority_en.pdf"},
    {"id":"40146","name":"Declaration of interests: Timothy Buxton","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-08-03T13:30:00Z","last_updated_date":"2020-09-03T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-timothy-buxton_en.pdf"},
    {"id":"40154","name":"Overview of comments on guideline on clinical trials with haemopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy (CPMP/EWP/555/95 Rev 1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-03-22T00:09:21Z","last_updated_date":"2007-03-22T00:09:21Z","reference_number":"EMEA/CHMP/EWP/506296/2007","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-guideline-clinical-trials-haemopoietic-growth-factors-prophylaxis-infection-following-myelosuppressive-or-myeloablative-therapy-cpmpewp55595-rev-1_en.pdf"},
    {"id":"40172","name":"A risk management strategic plan for controlling antimicrobial resistance through the authorisation of veterinary medicines: recommendations consequent to the report and quantitative risk assessment of the CVMP (July 199...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2000-01-12T01:00:00Z","last_updated_date":"2000-01-12T01:00:00Z","reference_number":"EMEA/CVMP/818/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/other/risk-management-strategic-plan-controlling-antimicrobial-resistance-through-authorisation-veterinary-medicines-recommendations-consequent-report-and-quantitative-risk-assessment-cvmp-july-199_en.pdf"},
    {"id":"40180","name":"Guidelines on good pharmacovigilance practices: Introductory cover note, last updated with revision 1 of module III on pharmacovigilance inspections and of module VI on the management and reporting of adverse reactions r...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-15T13:00:00Z","last_updated_date":"2014-09-15T13:00:00Z","reference_number":"EMA/475236/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-introductory-cover-note-last-updated-revision-1-module-iii-pharmacovigilance-inspections-and-module-vi-management-and-reporting-adverse-reactions-r_en.pdf"},
    {"id":"40208","name":"Classification and analysis of the good clinical practice (GCP) inspection findings of GCP inspections conducted at the request of CHMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T16:10:00Z","last_updated_date":"2014-12-08T16:10:00Z","reference_number":"INS/GCP/46309/2012","document_url":"https://www.ema.europa.eu/en/documents/other/classification-and-analysis-good-clinical-practice-gcp-inspection-findings-gcp-inspections-conducted-request-chmp_en.pdf"},
    {"id":"40211","name":"MLM substance and herbal substance groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-05-12T14:30:00Z","last_updated_date":"2015-05-12T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/mlm-substance-and-herbal-substance-groups_en.xlsx"},
    {"id":"40252","name":"Legal notice on the implementation of Article 57(2), second subparagraph of Regulation (EC) No. 726/2004","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-01T19:40:05Z","last_updated_date":"2016-02-11T12:10:00Z","reference_number":"EMA/505633/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/legal-notice-implementation-article-572-second-subparagraph-regulation-ec-no-7262004_en.pdf"},
    {"id":"40264","name":"Cover note - Minor use minor species policy: Annual report 2011","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-10-07T16:00:03Z","last_updated_date":"2011-10-07T16:00:03Z","reference_number":"EMA/MB/743894/2011","document_url":"https://www.ema.europa.eu/en/documents/other/cover-note-minor-use-minor-species-policy-annual-report-2011_en.pdf"},
    {"id":"40294","name":"Invitation to tender - Supply, installation and maintenance of audiovisual\n\nequipment and consumables including on-site technical support - EMA/2012/21/IS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-12T09:50:00Z","last_updated_date":"2012-11-12T09:50:00Z","reference_number":"EMA/641950/2012","document_url":"https://www.ema.europa.eu/en/documents/other/invitation-tender-supply-installation-and-maintenance-audiovisual-equipment-and-consumables-including-site-technical-support-ema201221is_en.pdf"},
    {"id":"40296","name":"Decision on implementing rules for the staff regulations of officials of the\n\nEuropean Communities and conditions of employment of other servants of\n\nthe European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-06-11T02:09:21Z","last_updated_date":"2009-06-11T02:09:21Z","reference_number":"EMEA/MB/694348/2008Adopted","document_url":"https://www.ema.europa.eu/en/documents/other/decision-implementing-rules-staff-regulations-officials-european-communities-and-conditions-employment-other-servants-european-medicines-agency_en.pdf"},
    {"id":"40307","name":"Type II variations (30-day procedure)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-10-25T01:09:21Z","last_updated_date":"2009-12-03T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/type-ii-variations-30-day-procedure_en.pdf"},
    {"id":"40325","name":"Declaration of interests: Juan Garcia Burgos","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T10:06:00Z","last_updated_date":"2025-08-01T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-juan-garcia-burgos_en.pdf"},
    {"id":"40327","name":"Overview of Comments received on Public Statement on Chamomilla containing herbal medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-03-08T01:00:00Z","last_updated_date":"2006-03-08T01:00:00Z","reference_number":"EMEA/379986/2005","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-public-statement-chamomilla-containing-herbal-medicinal-products_en.pdf"},
    {"id":"40371","name":"List of participants - Science, Medicines, Health: Patients at the heart of future innovation conference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-20T01:00:00Z","last_updated_date":"2015-03-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-science-medicines-health-patients-heart-future-innovation-conference_en.pdf"},
    {"id":"40437","name":"List of participants - Transatlantic workshop: Drug-related Progressive Multifocal Leukoencephalopathy (PML)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"EMA/582655/2011","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-transatlantic-workshop-drug-related-progressive-multifocal-leukoencephalopathy-pml_en.pdf"},
    {"id":"40439","name":"Annual list of contract modifications 2017","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-06-28T18:30:00Z","last_updated_date":"2018-06-28T18:30:00Z","reference_number":"EMA/406270/2017","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contract-modifications-2017_en.pdf"},
    {"id":"40474","name":"Reflection paper on the use of fluoroquinolones in food-producing animals - precautions for use in the summary of product characteristics regarding prudent-use guidance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2006-11-08T01:00:00Z","last_updated_date":"2006-11-08T01:00:00Z","reference_number":"EMEA/CVMP/416168/2006-FINAL","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-use-fluoroquinolones-food-producing-animals-precautions-use-summary-product-characteristics-regarding-prudent-use-guidance_en.pdf"},
    {"id":"40483","name":"Decision on amending budget No 1-2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:30:00Z","last_updated_date":"2016-10-07T17:30:00Z","reference_number":"EMA/MB/572210/2015","document_url":"https://www.ema.europa.eu/en/documents/other/decision-amending-budget-no-1-2016_en.pdf"},
    {"id":"40487","name":"Technical Specifications - Annex II Exclusion criteria declaration: Procurement procedure EMA/2014/01/PH","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T01:00:00Z","last_updated_date":"2014-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specifications-annex-ii-exclusion-criteria-declaration-procurement-procedure-ema201401ph_en.pdf"},
    {"id":"40505","name":"Guidelines and concept papers adopted during the CHMP meeting 18-21 March 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T14:20:00Z","last_updated_date":"2013-04-02T14:20:00Z","reference_number":"EMA/CHMP/122529/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-18-21-march-2013_en.pdf"},
    {"id":"40510","name":"EMA response to Nordic Cochrane letter on EMA response to Nordic Cochrane letter on human papillomavirus (HPV) vaccines - Maladministration","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T13:30:00Z","last_updated_date":"2016-07-22T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-response-nordic-cochrane-letter-ema-response-nordic-cochrane-letter-human-papillomavirus-hpv-vaccines-maladministration_en.pdf"},
    {"id":"40546","name":"Guidelines and concept papers adopted during the CHMP meeting 21-24 July 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-29T18:15:00Z","last_updated_date":"2014-07-29T18:15:00Z","reference_number":"EMA/125393/2014","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-21-24-july-2014_en.pdf"},
    {"id":"40561","name":"Overview of comments received on draft guideline on quality aspects of single-dose veterinary spot-on products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-02-11T01:00:00Z","last_updated_date":"2009-02-11T01:00:00Z","reference_number":"EMEA/CVMP/QWP/25621/2009","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-quality-aspects-single-dose-veterinary-spot-products_en.pdf"},
    {"id":"40569","name":"Second ENCePP meeting with Centres at the EMEA (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance) - List of Participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-04-22T02:00:00Z","last_updated_date":"2008-04-22T02:00:00Z","reference_number":"EMEA/214880/2008","document_url":"https://www.ema.europa.eu/en/documents/other/second-encepp-meeting-centres-emea-european-network-centres-pharmacoepidemiology-and-pharmacovigilance-list-participants_en.pdf"},
    {"id":"40571","name":"European Medicines Agency policy on access to EudraVigilance data for medicinal products for human use - Revision 2","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/759287/2009 Revision 2","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-policy-access-eudravigilance-data-medicinal-products-human-use-revision-2_en.pdf"},
    {"id":"40576","name":"Opinions on safety variations adopted during the CHMP meeting 15-18 October 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T14:29:00Z","last_updated_date":"2012-10-19T14:29:00Z","reference_number":"EMA/CHMP/539796/2012","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-safety-variations-adopted-during-chmp-meeting-15-18-october-2012_en.pdf"},
    {"id":"40607","name":"Proposed structure for the operation of the network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-04-21T02:09:21Z","last_updated_date":"2009-04-21T02:09:21Z","reference_number":"EMEA/94208/2009","document_url":"https://www.ema.europa.eu/en/documents/other/proposed-structure-operation-network_en.pdf"},
    {"id":"40620","name":"Organisation chart: Advisory functions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-16T12:00:00Z","last_updated_date":"2025-10-01T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-chart-advisory-functions_en.pdf"},
    {"id":"40649","name":"Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to Member States for IV Tamiflu available for compassionate use","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-01-21T00:09:21Z","last_updated_date":"2013-08-30T17:52:00Z","reference_number":"EMA/CHMP/781264/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distribution-and-patients-targeted-and-conditions-safety-monitoring-addressed-member-states-iv-tamiflu-available-compassionate-use_en.pdf"},
    {"id":"40654","name":"Framework for interaction between the European Medicines Agency and industry stakeholders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"EMA/591272/2014","document_url":"https://www.ema.europa.eu/en/documents/other/framework-interaction-between-european-medicines-agency-and-industry-stakeholders_en.pdf"},
    {"id":"40660","name":"Organisation chart: Deputy Executive Director support services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-09-01T02:00:00Z","last_updated_date":"2019-12-19T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-chart-deputy-executive-director-support-services_en.pdf"},
    {"id":"40667","name":"Declaration of interests: Frank Petavy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-09-30T02:00:00Z","last_updated_date":"2024-07-26T12:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-frank-petavy_en.pdf"},
    {"id":"40690","name":"An alternative approach to drug development in children with Gaucher disease: a collaborative proposal from the European Medicines Agency and the Food and Drug Administration","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-11-28T01:00:00Z","last_updated_date":"2012-11-28T01:00:00Z","reference_number":"EMA/754506/2012","document_url":"https://www.ema.europa.eu/en/documents/other/alternative-approach-drug-development-children-gaucher-disease-collaborative-proposal-european-medicines-agency-and-food-and-drug-administration_en.pdf"},
    {"id":"40703","name":"Initiative for patient registries - Strategy and pilot phase","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-12T02:00:00Z","last_updated_date":"2015-10-12T02:00:00Z","reference_number":"EMA/176050/2014","document_url":"https://www.ema.europa.eu/en/documents/other/initiative-patient-registries-strategy-and-pilot-phase_en.pdf"},
    {"id":"40725","name":"Workshop outcome and recommendations - Current use and future needs of radiopharmaceuticals labelled with radionuclides produced in reactors and possible alternatives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-06-16T02:00:00Z","last_updated_date":"2010-06-16T02:00:00Z","reference_number":"EMA/150127/2010","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-outcome-and-recommendations-current-use-and-future-needs-radiopharmaceuticals-labelled-radionuclides-produced-reactors-and-possible-alternatives_en.pdf"},
    {"id":"40754","name":"CVMP draft strategy on antimicrobials 2011-2015","type":"other","status":"Draft: consultation closed","consultation_date":"2011-01-10 - 2011-03-31","first_published_date":"2011-01-11T01:31:00Z","last_updated_date":"2011-01-11T01:31:00Z","reference_number":"EMA/CVMP/287420/2010","document_url":"https://www.ema.europa.eu/en/documents/other/cvmp-draft-strategy-antimicrobials-2011-2015_en.pdf"},
    {"id":"40766","name":"Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for IV Zanamivir available for compassionate use (Rev. 3)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2015-10-23T16:14:00Z","reference_number":"EMA/110920/2010 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distribution-and-patients-targeted-and-conditions-safety-monitoring-addressed-member-states-iv-zanamivir-available-compassionate-use-rev-3_en.pdf"},
    {"id":"40803","name":"Inventory of paediatric therapeutic needs - Respiratory","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2016-10-07T14:08:00Z","last_updated_date":"2016-10-07T14:08:00Z","reference_number":"EMA/PDCO/528943/2016","document_url":"https://www.ema.europa.eu/en/documents/other/inventory-paediatric-therapeutic-needs-respiratory_en.pdf"},
    {"id":"40842","name":"Kynamro : EPAR - Scientific conclusions and grounds for refusal of the marketing authorisation for Kynamro","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-06-17T02:00:00Z","last_updated_date":"2013-06-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_fr.pdf","it":"https://www.ema.europa.eu/it/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_lv.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/kynamro-epar-scientific-conclusions-and-grounds-refusal-marketing-authorisation-kynamro_sv.pdf"}},
    {"id":"40852","name":"Guidelines and concept papers adopted during the CHMP meeting 22-25 July 2013","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-08-21T17:00:00Z","last_updated_date":"2013-08-21T17:00:00Z","reference_number":"EMA/CHMP/241120/2013","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-and-concept-papers-adopted-during-chmp-meeting-22-25-july-2013_en.pdf"},
    {"id":"40857","name":"Member states contact points for review of national versions of the content of mobile scanning and other technologies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T12:00:00Z","last_updated_date":"2026-06-05T14:30:00Z","reference_number":"EMA/358267/2015 Rev.15","document_url":"https://www.ema.europa.eu/en/documents/other/member-states-contact-points-review-national-versions-content-mobile-scanning-other-technologies_en.pdf"},
    {"id":"40865","name":"Survey 2006 on the performance of EMEA scientific procedures for medicinal products for human use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-03-21T00:09:21Z","last_updated_date":"2007-03-21T00:09:21Z","reference_number":"EMEA/489472/2006","document_url":"https://www.ema.europa.eu/en/documents/other/survey-2006-performance-emea-scientific-procedures-medicinal-products-human-use_en.pdf"},
    {"id":"40869","name":"Overview of comments received on draft guideline for the quality of biological active substances produced by stable transgene expression in higher plants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/BWP/125862/2008","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-quality-biological-active-substances-produced-stable-transgene-expression-higher-plants_en.pdf"},
    {"id":"40875","name":"Good manufacturing practice for advanced-therapy medicinal products: Status","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-07-14T02:00:00Z","last_updated_date":"2008-07-14T02:00:00Z","reference_number":"EMEA/INS/GMP/372447/2008","document_url":"https://www.ema.europa.eu/en/documents/other/good-manufacturing-practice-advanced-therapy-medicinal-products-status_en.pdf"},
    {"id":"40900","name":"CHMP opinion trends - first half of 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-09T11:30:00Z","last_updated_date":"2014-07-09T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-opinion-trends-first-half-2014_en.pdf"},
    {"id":"40903","name":"Technical specification - Annex H: Financial identification form - EMA/2011/07/IF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-08-01T02:00:00Z","last_updated_date":"2011-08-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-h-financial-identification-form-ema201107if_en.xls"},
    {"id":"40947","name":"Participants list - Third industry stakeholder platform on the operation of European Union pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"EMA/177559/2015","document_url":"https://www.ema.europa.eu/en/documents/other/participants-list-third-industry-stakeholder-platform-operation-european-union-pharmacovigilance-legislation_en.pdf"}    {"id":"40972","name":"Declaration of interests: Christopher Gadd","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-04T01:00:00Z","last_updated_date":"2025-08-01T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-christopher-gadd_en.pdf"},
    {"id":"40980","name":"Announcement - Annual workshop on the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T15:45:00Z","last_updated_date":"2011-12-19T15:45:00Z","reference_number":"EMA/971491/2011","document_url":"https://www.ema.europa.eu/en/documents/other/announcement-annual-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"40983","name":"CellCept: Product Information as approved by the CHMP on 22 October 2015, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cellcept-product-information-approved-chmp-22-october-2015-pending-endorsement-european-commission_en.pdf"},
    {"id":"40987","name":"Declaration of interests: Ivo Claassen","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T02:00:00Z","last_updated_date":"2025-08-01T12:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-ivo-claassen_en.pdf"},
    {"id":"40994","name":"Overview of comments on 'Reflection paper on clinical aspects related to tissue engineered products'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T16:30:00Z","last_updated_date":"2014-12-11T16:30:00Z","reference_number":"EMA/CAT/20938/2014","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-reflection-paper-clinical-aspects-related-tissue-engineered-products_en.pdf"},
    {"id":"41005","name":"CTAG1: Advice to the European Medicines Agency from the Clinical Trial Advisory Group on protecting patient confidentiality - Revised after second teleconference with comments","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag1-advice-european-medicines-agency-clinical-trial-advisory-group-protecting-patient-confidentiality-revised-after-second-teleconference-comments_en.pdf"},
    {"id":"41007","name":"Start of Community reviews - CHMP meeting of 16-19 September 2013","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-20T14:00:05Z","last_updated_date":"2013-09-20T14:00:05Z","reference_number":"EMA/565898/2013","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-16-19-september-2013_en.pdf"},
    {"id":"41021","name":"CTAG3: Clinical Trial Advisory Group on rules of engagement - Membership overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T16:30:00Z","last_updated_date":"2013-04-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctag3-clinical-trial-advisory-group-rules-engagement-membership-overview_en.pdf"},
    {"id":"41047","name":"Exubera inhalation powder, pre-dispensed (2 and 3 mg): Notice of intension to cease marketing of product - Letter","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-11-19T00:09:21Z","last_updated_date":"2007-11-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/exubera-inhalation-powder-pre-dispensed-2-and-3-mg-notice-intension-cease-marketing-product-letter_en.pdf"},
    {"id":"41090","name":"Start of community reviews - CHMP meeting of 19-22 May 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/308394/2014","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-19-22-may-2014_en.pdf"},
    {"id":"41113","name":"Decision on the granting of a fee reduction","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-04-02T02:09:21Z","last_updated_date":"2008-04-02T02:09:21Z","reference_number":"EMEA/54433/2008","document_url":"https://www.ema.europa.eu/en/documents/other/decision-granting-fee-reduction_en.pdf"},
    {"id":"41115","name":"Organisational matters, CHMP meeting 19-22 September 2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/764331/2011","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-19-22-september-2011_en.pdf"},
    {"id":"41131","name":"Management Board consultation procedure for CHMP and\n\nCVMP nominations - Management Board meeting 18 March 2010","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/MB/281553/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-consultation-procedure-chmp-and-cvmp-nominations-management-board-meeting-18-march-2010_en.pdf"},
    {"id":"41132","name":"Withdrawal letter: Votrient","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-votrient_en.pdf"},
    {"id":"41141","name":"Guido Rasi - Biography","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-10-01T02:00:00Z","last_updated_date":"2015-11-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/guido-rasi-biography_en.pdf"},
    {"id":"41156","name":"Organisational matters - CHMP meeting 21-24 July 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-07-29T18:15:00Z","last_updated_date":"2014-07-29T18:15:00Z","reference_number":"EMA/125409/2014","document_url":"https://www.ema.europa.eu/en/documents/other/organisational-matters-chmp-meeting-21-24-july-2014_en.pdf"},
    {"id":"41173","name":"EudraVigilance registration system: Introduction of new functionalities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2016-06-17T17:00:00Z","reference_number":"EMA/410776/2016","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-registration-system-introduction-new-functionalities_en.pdf"},
    {"id":"41184","name":"Policy 58: European Medicines Agency policy on the handling of competing interests of Management Board members","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2006-01-04T10:13:00Z","last_updated_date":"2025-05-01T11:28:00Z","reference_number":"EMA/MB/89817/2024","document_url":"https://www.ema.europa.eu/en/documents/other/policy-58-european-medicines-agency-policy-handling-competing-interests-management-board-members_en.pdf"},
    {"id":"41187","name":"EudraVigilance Information Day, 19 October 2010 - Agenda and registration form","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-10-01T02:00:00Z","last_updated_date":"2010-10-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-information-day-19-october-2010-agenda-and-registration-form_en.pdf"},
    {"id":"41188","name":"Dossier requirements of members of the CHMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-06-01T02:00:00Z","last_updated_date":"2012-12-17T17:15:05Z","reference_number":"EMA/262123/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/dossier-requirements-members-chmp_en.pdf"},
    {"id":"41191","name":"Jean-Marc Ferran (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/jean-marc-ferran-doi_en.pdf"},
    {"id":"41199","name":"Authorisation for the Acting Executive Director to sign a lease and associated documents for the new EMA headquarters office","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/MB/424329/2011","document_url":"https://www.ema.europa.eu/en/documents/other/authorisation-acting-executive-director-sign-lease-and-associated-documents-new-ema-headquarters-office_en.pdf"},
    {"id":"41224","name":"Letter from Pat O'Mahony 11-01-2011","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-03-21T01:00:00Z","last_updated_date":"2011-03-21T01:00:00Z","reference_number":"EMA/7743/2011","document_url":"https://www.ema.europa.eu/en/documents/other/letter-pat-omahony-11-01-2011_en.pdf"},
    {"id":"41233","name":"List of participants of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting (20 September 2016)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"EMA/464532/2016","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting-20-september-2016_en.pdf"},
    {"id":"41236","name":"Mandate, objectives and rules of procedure for the CVMP Immunologicals Working Party (IWP)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-10-19T02:09:00Z","last_updated_date":"2020-06-29T16:55:00Z","reference_number":"EMEA/CVMP/IWP/208689/2004 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cvmp-immunologicals-working-party-iwp_en.pdf"},
    {"id":"41264","name":"European Medicines Agency - Ebola timeline","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2016-03-14T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-ebola-timeline_en.pdf"},
    {"id":"41270","name":"List of European Union (EU) reference dates and frequency of submission of periodic safety update reports - Introductory cover note to the public consultation of the EU reference date list","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-04-04T18:30:00Z","last_updated_date":"2012-04-04T18:30:00Z","reference_number":"EMA/162926/2012","document_url":"https://www.ema.europa.eu/en/documents/other/list-european-union-eu-reference-dates-and-frequency-submission-periodic-safety-update-reports-introductory-cover-note-public-consultation-eu-reference-date-list_en.pdf"},
    {"id":"41278","name":"Organisation of Management Board meetings","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-06-14T16:30:00Z","last_updated_date":"2012-06-14T16:30:00Z","reference_number":"EMA/MB/251300/2012","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-management-board-meetings_en.pdf"},
    {"id":"41306","name":"Implementation of the framework for interaction between the European Medicines Agency and healthcare professionals - Progress report 2012","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/implementation-framework-interaction-between-european-medicines-agency-and-healthcare-professionals-progress-report-2012_en.pdf"},
    {"id":"41317","name":"Summary of transfer of appropriations in the budget 2012 - Management Board meeting: 13 December 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/MB/724367/2012","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2012-management-board-meeting-13-december-2012_en.pdf"},
    {"id":"41323","name":"Technical specification - Annex 14 - External service providers for software applications EMA/2012/13/ICT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T10:00:00Z","last_updated_date":"2013-02-15T16:30:00Z","reference_number":"EMA/747973/2012","document_url":"https://www.ema.europa.eu/en/documents/other/technical-specification-annex-14-external-service-providers-software-applications-ema201213ict_en.xls"},
    {"id":"41334","name":"European Medicines Agency substance names best practice: Procedure and principles to handle substance name in the substance management system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T14:00:00Z","last_updated_date":"2018-04-10T17:00:00Z","reference_number":"EMA/40951/2014","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-substance-names-best-practice-procedure-and-principles-handle-substance-name-substance-management-system_en.pdf"},
    {"id":"41343","name":"Workshop: In vitro Cytokine release assays; To predict Cytokine release syndrome: The current state-of-the-science - Announcement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-07-14T02:09:21Z","last_updated_date":"2009-07-14T02:09:21Z","reference_number":"EMEA/367714/2009","document_url":"https://www.ema.europa.eu/en/documents/other/workshop-vitro-cytokine-release-assays-predict-cytokine-release-syndrome-current-state-science-announcement_en.pdf"},
    {"id":"41356","name":"Inclusion and exclusion criteria for the important medical events list (MedDRA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-08-19T16:58:00Z","last_updated_date":"2021-03-24T16:40:00Z","reference_number":"EMA/126913/2021","document_url":"https://www.ema.europa.eu/en/documents/other/inclusion-and-exclusion-criteria-important-medical-events-list-meddra_en.pdf"},
    {"id":"41360","name":"Launch of the new EudraVigilance system: questions and answers from stakeholders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-07-07T17:00:00Z","last_updated_date":"2018-12-04T17:30:00Z","reference_number":"EMA/132042/2018 Version 1.7","document_url":"https://www.ema.europa.eu/en/documents/other/launch-new-eudravigilance-system-questions-and-answers-stakeholders_en.pdf"},
    {"id":"41375","name":"Summary - Workshop on immunogenicity assessment of biotechnology-derived therapeutic proteins with interested parties","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"EMA/49653/2016","document_url":"https://www.ema.europa.eu/en/documents/other/summary-workshop-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-interested-parties_en.pdf"},
    {"id":"41410","name":"PRAC rules of procedure","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2013-03-05T13:00:00Z","last_updated_date":"2021-10-15T14:40:00Z","reference_number":"EMA/PRAC/567515/2012 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/prac-rules-procedure_en.pdf"},
    {"id":"41418","name":"Gilenya : Product Information as approved by the CHMP on 17 December 2015, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/gilenya-product-information-approved-chmp-17-december-2015-pending-endorsement-european-commission_en.pdf"},
    {"id":"41421","name":"Declaration of interests: Nerimantas Steikunas","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-16T12:00:00Z","last_updated_date":"2025-08-01T17:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-nerimantas-steikunas_en.pdf"},
    {"id":"41447","name":"Christine Fletcher (DoI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/christine-fletcher-doi_en.pdf"},
    {"id":"41454","name":"EMA response to Nordic Cochrane letter on human papillomavirus (HPV) vaccines - Conflict of interest issues of Executive Director","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T13:30:00Z","last_updated_date":"2016-07-22T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-response-nordic-cochrane-letter-human-papillomavirus-hpv-vaccines-conflict-interest-issues-executive-director_en.pdf"},
    {"id":"41472","name":"Annex III: Draft donation agreement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-29T12:45:00Z","last_updated_date":"2016-07-29T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-iii-draft-donation-agreement_en.pdf"},
    {"id":"41480","name":"Declaration of interests: Federica Castellani","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T02:00:00Z","last_updated_date":"2018-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-federica-castellani_en.pdf"},
    {"id":"41482","name":"Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures adopted at the CHMP meeting of 20-23 January 2014","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2014-01-30T11:30:00Z","last_updated_date":"2014-01-30T11:30:00Z","reference_number":"EMA/11105/2014","document_url":"https://www.ema.europa.eu/en/documents/other/opinions-annual-re-assessments-renewals-marketing-authorisations-and-accelerated-assessment-procedures-adopted-chmp-meeting-20-23-january-2014_en.pdf"},
    {"id":"41507","name":"Summary of transfers of appropriations in the budget 2010 - Management Board meeting: 10 June 2010","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/MB/298753/2010","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2010-management-board-meeting-10-june-2010_en.pdf"},
    {"id":"41526","name":"List of participants - 10th anniversary of European Medicines Agency’s Patients' and Consumers' Working Party (PCWP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-10th-anniversary-european-medicines-agencys-patients-and-consumers-working-party-pcwp_en.pdf"},
    {"id":"41548","name":"High level business consultancy EMA/2013/23/FI - Technical specifications - Annex VIII award criteria questionnaire","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/high-level-business-consultancy-ema201323fi-technical-specifications-annex-viii-award-criteria-questionnaire_en.doc"},
    {"id":"41553","name":"Withdrawal letter for Naxcel: Extension (new target species)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-06-23T02:00:00Z","last_updated_date":"2010-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-naxcel-extension-new-target-species_en.pdf"},
    {"id":"41585","name":"List of participants: Towards EU accession: Serbia’s regulatory challenges expectations and opportunities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/781955/2010","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-towards-eu-accession-serbias-regulatory-challenges-expectations-and-opportunities_en.pdf"},
    {"id":"41587","name":"Public summary of the evaluation of a proposed product-specific\n\nwaiver: Calcium (carbonate) / cholecalciferol (in combination with zoledronic acid (monohydrate)) for prevention of skeletal related events in patients wit...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T12:30:00Z","last_updated_date":"2015-02-23T12:30:00Z","reference_number":"EMA/69421/2015","document_url":"https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-product-specific-waiver-calcium-carbonate-cholecalciferol-combination-zoledronic-acid-monohydrate-prevention-skeletal-related-events-patients-wit_en.pdf"},
    {"id":"41592","name":"Start of community reviews - CHMP meeting of 23-26 June 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/388940/2014","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-23-26-june-2014_en.pdf"},
    {"id":"41598","name":"Draft policy/0043: European Medicines Agency policy on access to documents","type":"other","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2017-02-17T14:30:00Z","last_updated_date":"2017-02-17T14:30:00Z","reference_number":"EMA/729522/2016","document_url":"https://www.ema.europa.eu/en/documents/other/draft-policy0043-european-medicines-agency-policy-access-documents_en.pdf"},
    {"id":"41612","name":"Start of Community reviews - CHMP meeting of 22-25 September 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T14:00:00Z","last_updated_date":"2014-09-26T14:00:00Z","reference_number":"EMA/388940/2014","document_url":"https://www.ema.europa.eu/en/documents/other/start-community-reviews-chmp-meeting-22-25-september-2014_en.pdf"},
    {"id":"41617","name":"Declaration of interest: Iordanis Gravanis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-06-26T02:00:00Z","last_updated_date":"2025-08-01T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-iordanis-gravanis_en.pdf"},
    {"id":"41618","name":"Timetable: Post-authorisation measure (PAM) assessed by CHMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-02T16:15:00Z","last_updated_date":"2025-09-24T11:52:00Z","reference_number":"EMA/403033/2015 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-post-authorisation-measure-pam-assessed-chmp_en.xlsx"},
    {"id":"41631","name":"Report on the survey of all paediatric uses of medicinal\n\nproducts in Europe: Executive summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2011-01-21T00:31:00Z","last_updated_date":"2011-01-21T00:31:00Z","reference_number":"EMA/761434/2010","document_url":"https://www.ema.europa.eu/en/documents/other/report-survey-all-paediatric-uses-medicinal-products-europe-executive-summary_en.pdf"},
    {"id":"41668","name":"Annex C - Response questionnaire - Lot 6","type":"other","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-c-response-questionnaire-lot-6_en.xls"},
    {"id":"41690","name":"Summary of transfer of appropriations in the budget 2015 and 2016 - Management Board meeting: 17 March 2016","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-03-21T17:00:00Z","last_updated_date":"2016-03-21T17:00:00Z","reference_number":"EMA/MB/89899/2016","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2015-and-2016-management-board-meeting-17-march-2016_en.pdf"},
    {"id":"41694","name":"Individual case safety reports (ICSR) export managerliterature test cases XML format","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-06-30T14:00:00Z","last_updated_date":"2015-06-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/individual-case-safety-reports-icsr-export-managerliterature-test-cases-xml-format_en.zip"},
    {"id":"41710","name":"Revised provisional priority list for studies on off-patent paediatric medicinal products","type":"other","status":"Draft: consultation closed","consultation_date":"2013-06-06 - 2013-07-05","first_published_date":"2013-06-05T21:00:00Z","last_updated_date":"2013-06-05T21:00:00Z","reference_number":"EMA/98717/2012 Rev.2013/14","document_url":"https://www.ema.europa.eu/en/documents/other/revised-provisional-priority-list-studies-patent-paediatric-medicinal-products_en.pdf"},
    {"id":"41745","name":"Appendix to the European Medicines Agency Code of Conduct","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-21T18:00:00Z","last_updated_date":"2016-06-21T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-european-medicines-agency-code-conduct_en.pdf"},
    {"id":"41752","name":"Summary - Consultation meeting with stakeholders - Request from EC for advice on the impact on public and animal health of the use of antibiotics in animals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/summary-consultation-meeting-stakeholders-request-ec-advice-impact-public-and-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"41764","name":"User manual E-RS (EXACT-respiratory symptoms): Applicant submission version 3.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-13T12:40:00Z","last_updated_date":"2015-04-13T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/user-manual-e-rs-exact-respiratory-symptoms-applicant-submission-version-30_en.pdf"},
    {"id":"41768","name":"Biologics Working Party (BWP) ad-hoc influenza working group: Amended European Union recommendations for the seasonal influenza vaccine composition for the season 2018/2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-03-26T12:50:00Z","last_updated_date":"2018-04-30T17:18:00Z","reference_number":"EMA/CHMP/BWP/209019/2018","document_url":"https://www.ema.europa.eu/en/documents/other/biologics-working-party-bwp-ad-hoc-influenza-working-group-amended-european-union-recommendations-seasonal-influenza-vaccine-composition-season-20182019_en.pdf"},
    {"id":"41788","name":"List of participants - Patients’ and Consumers’ Working Party and Healthcare Professionals Working Party joint meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-11T10:30:00Z","last_updated_date":"2013-12-11T10:30:00Z","reference_number":"EMA/489113/2013","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-patients-and-consumers-working-party-and-healthcare-professionals-working-party-joint-meeting_en.pdf"},
    {"id":"41806","name":"Training overview for patients and consumers involved in European Medicines Agency activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-11-13T17:35:00Z","last_updated_date":"2014-11-14T15:00:00Z","reference_number":"EMA/664931/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/training-overview-patients-and-consumers-involved-european-medicines-agency-activities_en.pdf"},
    {"id":"41807","name":"Table of the amounts in euro of basic monthly salaries for temporary agents for each grade and step","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T11:00:00Z","last_updated_date":"2019-03-08T11:30:00Z","reference_number":"EMA/94997/2018","document_url":"https://www.ema.europa.eu/en/documents/other/table-amounts-euro-basic-monthly-salaries-temporary-agents-each-grade-and-step_en.pdf"},
    {"id":"41818","name":"Overview of the EudraVigilance training on electronic reporting of individual case safety reports in the European Economic Area: 18-20 June 2014, London, UK","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-05-15T02:00:00Z","last_updated_date":"2014-05-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-eudravigilance-training-electronic-reporting-individual-case-safety-reports-european-economic-area-18-20-june-2014-london-uk_en.pdf"},
    {"id":"41836","name":"Member States involved in the European Medicines Agency-European Union Member states-Food and Drug Administration initiative on inspections for generic applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2013-12-18T15:15:00Z","last_updated_date":"2023-04-18T14:45:00Z","reference_number":"EMA/INS/GCP/572935/2013 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/member-states-involved-european-medicines-agency-european-union-member-states-food-and-drug-administration-initiative-inspections-generic-applications_en.pdf"},
    {"id":"41851","name":"Questions and answers on describing adverse events in the product information (summary of product characteristics (SPC) and package leaflet (PL)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-25T14:15:00Z","last_updated_date":"2023-12-15T15:00:00Z","reference_number":"EMA/CVMP/150343/2016-Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-describing-adverse-events-product-information-summary-product-characteristics-spc-and-package-leaflet-pl_en.pdf"},
    {"id":"41857","name":"Open clinical data - stakeholder quotes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T17:00:00Z","last_updated_date":"2016-10-25T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/open-clinical-data-stakeholder-quotes_en.pdf"},
    {"id":"41872","name":"Summary of transfer of appropriations in the budget 2015 - Management Board meeting: 16-17 December 2015","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/MB/776950/2015","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfer-appropriations-budget-2015-management-board-meeting-16-17-december-2015_en.pdf"},
    {"id":"41877","name":"Answers to the requests for scientific advice on the impact on public health and animal health of the use of antibiotics in animals","type":"other","status":"Adopted","consultation_date":"2014-08-01 - 2014-09-30","first_published_date":"2014-08-01T16:00:00Z","last_updated_date":"2014-12-19T16:00:00Z","reference_number":"EMA/381884/2014","document_url":"https://www.ema.europa.eu/en/documents/other/answers-requests-scientific-advice-impact-public-health-and-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"41889","name":"Semler - Marketing authorisations which are recommended for maintenance and marketing authorisation applications for which bioequivalence vis-à -vis the EU reference medicinal product has been established as adopted by t...","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/499815/2016","document_url":"https://www.ema.europa.eu/en/documents/other/semler-marketing-authorisations-which-are-recommended-maintenance-and-marketing-authorisation-applications-which-bioequivalence-vis-vis-eu-reference-medicinal-product-has-been-established-adopted-t_en.pdf"},
    {"id":"41927","name":"Public bulletin: Veterinary pharmacovigilance 2014","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-03T10:15:00Z","last_updated_date":"2015-03-03T10:15:00Z","reference_number":"EMA/CVMP/793263/2014","document_url":"https://www.ema.europa.eu/en/documents/other/public-bulletin-veterinary-pharmacovigilance-2014_en.pdf"},
    {"id":"41955","name":"ESVAC sales Expert Advisory Group: Terms of reference 2021-2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-05-30T17:00:00Z","last_updated_date":"2021-03-10T17:44:00Z","reference_number":"EMA/235015/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/esvac-sales-expert-advisory-group-terms-reference-2021-2022_en.pdf"},
    {"id":"41961","name":"Timetable: Periodic safety update report (PSUR) and PSUR single assessment (PSUSA) - Advanced therapy medicinal products (ATMPs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-04-30T16:00:00Z","last_updated_date":"2025-09-23T14:33:00Z","reference_number":"EMA/251635/2015 Rev. 8","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-periodic-safety-update-report-psur-psur-single-assessment-psusa-advanced-therapy-medicinal-products-atmps_en.xlsx"},
    {"id":"41972","name":"Sarah Nevitt (CV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T17:01:00Z","last_updated_date":"2017-10-31T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sarah-nevitt-cv_en.pdf"},
    {"id":"42010","name":"Management Board meeting dates 2017 – 2019","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2017-06-16T15:30:00Z","last_updated_date":"2017-06-16T15:30:00Z","reference_number":"EMA/MB/312375/2017","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2017-2019_en.pdf"},
    {"id":"42042","name":"How to forward incoming calls from your EMA Phone","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-09-24T14:01:00Z","last_updated_date":"2018-09-24T14:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/how-forward-incoming-calls-your-ema-phone_en.docx"},
    {"id":"42212","name":"List of participants: 12th stakeholder forum on the pharmacovigilance legislation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-10-05T18:19:00Z","last_updated_date":"2018-10-05T18:19:00Z","reference_number":"EMA/505196/2018","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-12th-stakeholder-forum-pharmacovigilance-legislation_en.pdf"},
    {"id":"42213","name":"Presentation - Pharmacovigilance in 2018 (P. Arlett)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-10-05T18:34:00Z","last_updated_date":"2018-10-05T18:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/presentation-pharmacovigilance-2018-p-arlett_en.pdf"},
    {"id":"42242","name":"EMA Brexit Preparedness Business Continuity Plan – Phase 3 implementation plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-10-09T15:13:00Z","last_updated_date":"2018-10-09T15:13:00Z","reference_number":"EMA/701082/2018","document_url":"https://www.ema.europa.eu/en/documents/other/ema-brexit-preparedness-business-continuity-plan-phase-3-implementation-plan_en.pdf"},
    {"id":"42243","name":"Cut-off dates for UK Rapporteurship appointments for pre and post authorisation procedures for centrally authorised products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-10-09T15:52:00Z","last_updated_date":"2018-10-09T15:52:00Z","reference_number":"EMA/637235/2018","document_url":"https://www.ema.europa.eu/en/documents/other/cut-dates-uk-rapporteurship-appointments-pre-and-post-authorisation-procedures-centrally-authorised-products_en.pdf"},
    {"id":"42365","name":"Outcome of written procedures during the period 22 May 2018 to 10 September 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-10-18T14:56:00Z","last_updated_date":"2018-10-18T14:56:00Z","reference_number":"EMA/MB/540105/2018","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-during-period-22-may-2018-10-september-2018_en.pdf"},
    {"id":"42367","name":"Update on the pilot of signal detection in EudraVigilance by marketing authorisation holders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-10-18T14:59:00Z","last_updated_date":"2018-10-18T14:59:00Z","reference_number":"EMA/MB/493254/2018","document_url":"https://www.ema.europa.eu/en/documents/other/update-pilot-signal-detection-eudravigilance-marketing-authorisation-holders_en.pdf"},
    {"id":"42418","name":"Handling times for requests for EMA certificates through standard procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-10-23T12:13:00Z","last_updated_date":"2021-05-05T17:00:00Z","reference_number":"EMA/579807/2018 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/handling-times-requests-ema-certificates-through-standard-procedure_en.pdf"},
    {"id":"42511","name":"Letter of support for Model-based CT enrichment tool for CTs in aMCI","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T17:30:00Z","last_updated_date":"2018-10-30T17:30:00Z","reference_number":"EMA/693969/2018","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-model-based-ct-enrichment-tool-cts-amci_en.pdf"},
    {"id":"42550","name":"Ex ante publicity of a negotiated procedure - EMA/2018/40/FI – Bank accounts and online banking services for making and receiving payments in EUR mainly within the SEPA area","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T14:57:00Z","last_updated_date":"2018-11-06T14:57:00Z","reference_number":"EMA/721884/2018","document_url":"https://www.ema.europa.eu/en/documents/other/ex-ante-publicity-negotiated-procedure-ema201840fi-bank-accounts-and-online-banking-services-making-and-receiving-payments-eur-mainly-within-sepa-area_en.pdf"},
    {"id":"42564","name":"Comments received from public consultation on good pharmacovigilance practices (GVP): Product- or Population-Specific Considerations IV: Paediatric population","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-07T11:18:00Z","last_updated_date":"2018-11-07T11:18:00Z","reference_number":"EMA/703506/2018","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-iv-paediatric-population_en.pdf"},
    {"id":"42587","name":"List of participants - Multistakeholder workshop to launch consultation on European Medicines Agency (EMA) human regulatory science to 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T15:36:00Z","last_updated_date":"2018-11-08T15:36:00Z","reference_number":"EMA/780447/2018","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-multistakeholder-workshop-launch-consultation-european-medicines-agency-ema-human-regulatory-science-2025_en.pdf"},
    {"id":"42588","name":"Reference material - - Multistakeholder workshop to launch consultation on European Medicines Agency (EMA) human regulatory science to 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T15:39:00Z","last_updated_date":"2018-11-08T15:39:00Z","reference_number":"EMA/723198/2018","document_url":"https://www.ema.europa.eu/en/documents/other/reference-material-multistakeholder-workshop-launch-consultation-european-medicines-agency-ema-human-regulatory-science-2025_en.pdf"},
    {"id":"42598","name":"List of participants  - European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T16:47:00Z","last_updated_date":"2018-11-08T16:47:00Z","reference_number":"EMA/373497/2018","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp_en.pdf"},
    {"id":"42604","name":"Citrix user guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T11:20:00Z","last_updated_date":"2018-11-09T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/citrix-user-guide_en.pdf"},
    {"id":"42611","name":"Summary of changes to the ‘External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use’ - Version 1.4","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2018-11-09T12:56:00Z","last_updated_date":"2018-11-09T12:56:00Z","reference_number":"EMA/482146/2018","document_url":"https://www.ema.europa.eu/en/documents/other/summary-changes-external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-version-14_en.pdf"},
    {"id":"42621","name":"List of participants of the European Medicines Agency Human Scientific Committee’s Working Party with Healthcare Professionals’ Organisations (HCPWP) meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:00:00Z","last_updated_date":"2018-11-09T18:00:00Z","reference_number":"EMA/368105/2018","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-meeting_en.pdf-0"},
    {"id":"42632","name":"List of participants of the EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:00:00Z","last_updated_date":"2018-11-09T18:00:00Z","reference_number":"EMA/373499/2018","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisations-hcpwp-joint-meeting_en.pdf-0"},
    {"id":"42784","name":"List of participants - Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:57:00Z","last_updated_date":"2018-11-23T18:57:00Z","reference_number":"EMA/725241/2018","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-multi-stakeholder-workshop-hmaema-task-force-availability-authorised-medicines_en.pdf"},
    {"id":"42892","name":"Questions and answers on the revision of the guidelines on clinical investigation of recombinant and human plasma-derived factor VIII products (EMA/CHMP/BPWP/144533/2009 Rev. 2) and FIX products (EMA/CHMP/BPWP/144552/2009 Rev. 2)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-30T12:50:00Z","last_updated_date":"2018-11-30T12:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-revision-guidelines-clinical-investigation-recombinant-and-human-plasma-derived-factor-viii-products-emachmpbpwp1445332009-rev-2-and-fix-products-emachmpbpwp1445522009-rev-2_en.pdf"},
    {"id":"42897","name":"CVMP assessment report regarding the request for an opinion under Article 30(3) of Regulation (EC) No. 726/2004","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-30T17:34:00Z","last_updated_date":"2018-11-30T17:34:00Z","reference_number":"EMA/CVMP/766265/2018","document_url":"https://www.ema.europa.eu/en/documents/other/cvmp-assessment-report-regarding-request-opinion-under-article-303-regulation-ec-no-7262004_en.pdf"}    {"id":"42898","name":"Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-11-30T17:37:00Z","last_updated_date":"2018-11-30T17:37:00Z","reference_number":"EMA/CVMP/727329/2018","document_url":"https://www.ema.europa.eu/en/documents/other/opinion-committee-medicinal-products-veterinary-use-pursuant-article-303-regulation-ec-no-7262004_en.pdf"},
    {"id":"42972","name":"Download EPS - Species pictograms - Camel","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-10T13:52:00Z","last_updated_date":"2018-12-10T13:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-camel_en.zip"},
    {"id":"42973","name":"Download EPS - Species pictograms - Fox","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-10T13:54:00Z","last_updated_date":"2018-12-10T13:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-fox_en.zip"},
    {"id":"42974","name":"Download EPS - Species pictograms - Pigeon","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-10T13:56:00Z","last_updated_date":"2018-12-10T13:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-pigeon_en.zip"},
    {"id":"42976","name":"Enpr-EMA Working group on public-private partnership: Network consultation recommendation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-10T14:56:00Z","last_updated_date":"2018-12-10T14:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/enpr-ema-working-group-public-private-partnership-network-consultation-recommendation_en.pdf"},
    {"id":"42979","name":"2018 Season’s greetings from EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-10T18:15:00Z","last_updated_date":"2018-12-10T18:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/2018-seasons-greetings-ema_en.pdf"},
    {"id":"43094","name":"Financial compensation and workload estimation of the EMA organisation of translations of product related information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:07:00Z","last_updated_date":"2018-12-14T16:07:00Z","reference_number":"EMA/MB/781386/2018","document_url":"https://www.ema.europa.eu/en/documents/other/financial-compensation-and-workload-estimation-ema-organisation-translations-product-related-information_en.pdf"},
    {"id":"43095","name":"Outcome of written procedures during the period 11 September 2018 to 23 November 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:18:00Z","last_updated_date":"2018-12-14T16:18:00Z","reference_number":"EMA/MB/810142/2018","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-during-period-11-september-2018-23-november-2018_en.pdf"},
    {"id":"43101","name":"Health threat plan map - Annex to EMA plan for emerging health threats","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-17T14:25:00Z","last_updated_date":"2018-12-17T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/health-threat-plan-map-annex-ema-plan-emerging-health-threats_en.pdf"},
    {"id":"43142","name":"Questions and answers on quality of herbal medicinal products/traditional herbal medicinal products - Revision 6","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T17:09:00Z","last_updated_date":"2018-12-18T17:09:00Z","reference_number":"EMA/HMPC/41500/2010 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-quality-herbal-medicinal-productstraditional-herbal-medicinal-products-revision-6_en.pdf"},
    {"id":"43143","name":"Committee for Advanced Therapies (CAT): work plan 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-08T16:31:00Z","last_updated_date":"2023-03-08T16:31:00Z","reference_number":"EMA/CAT/910738/2022","document_url":"https://www.ema.europa.eu/en/documents/other/committee-advanced-therapies-cat-work-plan-2023_en.pdf"},
    {"id":"43174","name":"List of participants - European Medicines Agency (EMA) / Heads of Medicines Agencies (HMA) / European Commission (EC) workshop on electronic product information (ePI)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:20:00Z","last_updated_date":"2018-12-19T18:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-ema-heads-medicines-agencies-hma-european-commission-ec-workshop-electronic-product-information-epi_en.pdf"},
    {"id":"43231","name":"List of participants - EU-Innovation network workshop with academia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-eu-innovation-network-workshop-academia_en.pdf"},
    {"id":"43260","name":"Manufacturer organisations in the OMS dictionary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T10:00:00Z","last_updated_date":"2019-01-11T10:00:00Z","reference_number":"EMA/465039/2018","document_url":"https://www.ema.europa.eu/en/documents/other/manufacturer-organisations-oms-dictionary_en.pdf"},
    {"id":"43266","name":"Questions and answers on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), Bluetongue (BT) and Foot-and-Mouth disease (FMD) - Revision 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-01-09T17:00:00Z","last_updated_date":"2019-01-09T17:00:00Z","reference_number":"EMA/CVMP/IWP/466888/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-data-requirements-multi-strain-dossiers-inactivated-vaccines-against-avian-influenza-ai-bluetongue-bt-and-foot-and-mouth-disease-fmd-revision-1_en.pdf"},
    {"id":"43353","name":"Extension of reserve lists for external selection procedures: Contract Agent reserve list","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-01-14T16:32:00Z","last_updated_date":"2023-01-23T11:00:00Z","reference_number":"EMA/34904/2023","document_url":"https://www.ema.europa.eu/en/documents/other/extension-reserve-lists-external-selection-procedures-contract-agent-reserve-list_en.pdf"},
    {"id":"43354","name":"Extension of reserve lists for external selection procedures: Temporary Agent reserve lists","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-01-14T16:33:00Z","last_updated_date":"2023-06-19T14:34:00Z","reference_number":"EMA/34905/2023","document_url":"https://www.ema.europa.eu/en/documents/other/extension-reserve-lists-external-selection-procedures-temporary-agent-reserve-lists_en.pdf"},
    {"id":"43629","name":"Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Categorisation of antimicrobials","type":"other","status":"Draft: consultation closed","consultation_date":"2019-02-05 - 2019-04-30","first_published_date":"2019-02-05T15:03:00Z","last_updated_date":"2019-02-05T15:03:00Z","reference_number":"EMA/CVMP/CHMP/682198/2017","document_url":"https://www.ema.europa.eu/en/documents/other/answer-request-european-commission-updating-scientific-advice-impact-public-health-and-animal-health-use-antibiotics-animals-categorisation-antimicrobials_en.pdf"},
    {"id":"43656","name":"HMA/EMA Joint Task Force on big data – Survey for national competent authorities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T11:00:00Z","last_updated_date":"2019-02-15T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/hmaema-joint-task-force-big-data-survey-national-competent-authorities_en.pdf"},
    {"id":"43657","name":"HMA/EMA Joint Task Force on big data – Survey for pharmaceutical industry","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T11:00:00Z","last_updated_date":"2019-02-15T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/hmaema-joint-task-force-big-data-survey-pharmaceutical-industry_en.pdf"},
    {"id":"43658","name":"HMA/EMA Joint Task Force on big data – Surveys results","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T11:00:00Z","last_updated_date":"2019-02-15T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/hmaema-joint-task-force-big-data-surveys-results_en.pdf"},
    {"id":"43945","name":"From laboratory to patient: the journey of a centrally authorised medicine","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-03-04T14:00:00Z","last_updated_date":"2024-07-31T17:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/laboratory-patient-journey-centrally-authorised-medicine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/laboratory-patient-journey-centrally-authorised-medicine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/laboratory-patient-journey-centrally-authorised-medicine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/laboratory-patient-journey-centrally-authorised-medicine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/laboratory-patient-journey-centrally-authorised-medicine_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/laboratory-patient-journey-centrally-authorised-medicine_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/laboratory-patient-journey-centrally-authorised-medicine_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/laboratory-patient-journey-centrally-authorised-medicine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/laboratory-patient-journey-centrally-authorised-medicine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/laboratory-patient-journey-centrally-authorised-medicine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/laboratory-patient-journey-centrally-authorised-medicine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/laboratory-patient-journey-centrally-authorised-medicine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/laboratory-patient-journey-centrally-authorised-medicine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/laboratory-patient-journey-centrally-authorised-medicine_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/laboratory-patient-journey-centrally-authorised-medicine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/laboratory-patient-journey-centrally-authorised-medicine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/laboratory-patient-journey-centrally-authorised-medicine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/laboratory-patient-journey-centrally-authorised-medicine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/laboratory-patient-journey-centrally-authorised-medicine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/laboratory-patient-journey-centrally-authorised-medicine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/laboratory-patient-journey-centrally-authorised-medicine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/laboratory-patient-journey-centrally-authorised-medicine_sv.pdf"}},
    {"id":"44086","name":"European authorities working to avoid shortages of medicines due to Brexit – Questions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-03-26T12:00:00Z","last_updated_date":"2020-02-04T14:30:00Z","reference_number":"EMA/48159/2020 Rev 4","document_url":"https://www.ema.europa.eu/en/documents/other/european-authorities-working-avoid-shortages-medicines-due-brexit-questions-and-answers_en.pdf"},
    {"id":"44095","name":"Decision on amending budget No 1-2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-03-22T16:20:00Z","last_updated_date":"2019-03-22T16:20:00Z","reference_number":"EMA/MB/171445/20199","document_url":"https://www.ema.europa.eu/en/documents/other/decision-amending-budget-no-1-2019_en.pdf"},
    {"id":"44096","name":"Outcome of written procedures finalised during the period from 24 November 2018 to 22 February 2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-03-22T16:31:00Z","last_updated_date":"2019-03-22T16:31:00Z","reference_number":"EMA/MB/112294/2019","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-24-november-2018-22-february-2019_en.pdf"},
    {"id":"44195","name":"Acceptance of working arrangement between EMA-EC and EDQM","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-04-09T11:26:00Z","last_updated_date":"2019-04-09T11:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/acceptance-working-arrangement-between-ema-ec-and-edqm_en.pdf"},
    {"id":"44212","name":"EudraVigilance Access Policy - Confidentiality undertaking for academia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-04-11T09:21:00Z","last_updated_date":"2019-04-11T09:21:00Z","reference_number":"EMA/337294/2016","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-access-policy-confidentiality-undertaking-academia_en.pdf"},
    {"id":"44256","name":"Letter of support for the development of Patient-Reported Outcomes tools for use as an endpoint in Inflammatory Bowel Disease (IBD) clinical trials","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T16:10:00Z","last_updated_date":"2019-04-12T16:10:00Z","reference_number":"EMA/262838/2018","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-development-patient-reported-outcomes-tools-use-endpoint-inflammatory-bowel-disease-ibd-clinical-trials_en.pdf"},
    {"id":"44287","name":"Retraction of the “Letter of support for drug -induced liver  injury (DILI) biomarker” (EMA/423870/2016)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-04-17T11:18:00Z","last_updated_date":"2019-04-17T11:18:00Z","reference_number":"EMA/188045/20199","document_url":"https://www.ema.europa.eu/en/documents/other/retraction-letter-support-drug-induced-liver-injury-dili-biomarker-ema4238702016_en.pdf"},
    {"id":"44395","name":"Tyverb - amended product information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-04-30T09:17:00Z","last_updated_date":"2019-04-30T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/tyverb-amended-product-information_en.pdf"},
    {"id":"44721","name":"Financial Regulation applicable to the budget of the European Medicines Agency from 1 July 2019","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2019-06-17T15:05:00Z","last_updated_date":"2019-12-20T16:07:00Z","reference_number":"EMA/MB/911312/2019","document_url":"https://www.ema.europa.eu/en/documents/other/financial-regulation-applicable-budget-european-medicines-agency-1-july-2019_en.pdf"},
    {"id":"44722","name":"Management Board meeting dates 2020-2021","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2019-06-17T15:12:00Z","last_updated_date":"2019-06-17T15:12:00Z","reference_number":"EMA/MB/198583/2019","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2020-2021_en.pdf"},
    {"id":"44723","name":"Outcome of written procedures finalised during the period from 23 February 2019 to 16 May 2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-17T15:14:00Z","last_updated_date":"2019-06-17T15:14:00Z","reference_number":"EMA/MB/270926/2019","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-23-february-2019-16-may-2019_en.pdf"},
    {"id":"44732","name":"Qualification opinion - Treatment effect measures when using recurrent event endpoints - Applicant's submission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T10:02:00Z","last_updated_date":"2019-06-19T10:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-treatment-effect-measures-when-using-recurrent-event-endpoints-applicants-submission_en.pdf"},
    {"id":"44733","name":"Qualification opinion - Treatment effect measures when using recurrent event endpoints - Applicant's responses to first list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T10:03:00Z","last_updated_date":"2019-06-19T10:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-treatment-effect-measures-when-using-recurrent-event-endpoints-applicants-responses-first-list-issues_en.pdf"},
    {"id":"44744","name":"Draft qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses","type":"other","status":"Draft: consultation closed","consultation_date":"2019-06-19 - 2019-10-09","first_published_date":"2019-06-19T12:26:00Z","last_updated_date":"2019-06-19T12:26:00Z","reference_number":"EMA/CHMP/SAWP/291384/2019","document_url":"https://www.ema.europa.eu/en/documents/other/draft-qualification-opinion-clinically-interpretable-treatment-effect-measures-based-recurrent-event-endpoints-allow-efficient-statistical-analyses_en.pdf"},
    {"id":"44745","name":"Qualification opinion - Treatment effect measures when using recurrent event endpoints - First list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T09:57:00Z","last_updated_date":"2019-06-19T09:57:00Z","reference_number":"EMA/CHMP/SAWP/179482/2018","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-treatment-effect-measures-when-using-recurrent-event-endpoints-first-list-issues_en.pdf"},
    {"id":"44746","name":"Qualification opinion - Treatment effect measures when using recurrent event endpoints - Second list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T10:09:00Z","last_updated_date":"2019-06-19T10:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-treatment-effect-measures-when-using-recurrent-event-endpoints-second-list-issues_en.pdf"},
    {"id":"44747","name":"Qualification opinion - Treatment effect measures when using recurrent event endpoints - Applicant's responses to second list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T10:11:00Z","last_updated_date":"2019-06-19T10:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-treatment-effect-measures-when-using-recurrent-event-endpoints-applicants-responses-second-list-issues_en.pdf"},
    {"id":"44748","name":"Qualification opinion - Treatment effect measures when using recurrent event endpoints - Third list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T10:14:00Z","last_updated_date":"2019-06-19T10:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-treatment-effect-measures-when-using-recurrent-event-endpoints-third-list-issues_en.pdf"},
    {"id":"44749","name":"Qualification opinion - Treatment effect measures when using recurrent event endpoints - Applicant's responses to third list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T10:17:00Z","last_updated_date":"2019-06-19T10:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-treatment-effect-measures-when-using-recurrent-event-endpoints-applicants-responses-third-list-issues_en.pdf"},
    {"id":"44750","name":"Qualification opinion - Treatment effect measures when using recurrent event endpoints - Fourth list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T10:19:00Z","last_updated_date":"2019-06-19T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-treatment-effect-measures-when-using-recurrent-event-endpoints-fourth-list-issues_en.pdf"},
    {"id":"44751","name":"Qualification opinion - Treatment effect measures when using recurrent event endpoints - Applicant's responses to fourth list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T10:22:00Z","last_updated_date":"2019-06-19T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-treatment-effect-measures-when-using-recurrent-event-endpoints-applicants-responses-fourth-list-issues_en.pdf"},
    {"id":"44779","name":"Questions and answers on the use of out-of-specification batches of authorised cell and tissue-based advanced therapy medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-25T09:31:00Z","last_updated_date":"2026-03-03T17:41:00Z","reference_number":"EMA/CAT/224381/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-use-out-specification-batches-authorised-cell-tissue-based-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"44885","name":"Temporary interim limits for NMBA, DIPNA and EIPNA impurities in sartan blood pressure medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-25T16:28:00Z","last_updated_date":"2019-08-20T16:31:00Z","reference_number":"EMA/351053/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/temporary-interim-limits-nmba-dipna-and-eipna-impurities-sartan-blood-pressure-medicines_en.pdf"},
    {"id":"44950","name":"Annual list of contract modifications 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T14:27:00Z","last_updated_date":"2019-06-28T14:27:00Z","reference_number":"EMA/365932/2019","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contract-modifications-2018_en.pdf"},
    {"id":"44951","name":"Annual list of contractors 2018 - contract values Euro 15,000 - 134.999","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T14:29:00Z","last_updated_date":"2019-06-28T14:29:00Z","reference_number":"EMA/365478/2019","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contractors-2018-contract-values-euro-15000-134999_en.pdf"},
    {"id":"44952","name":"Annual list of specific contracts based on framework contracts – 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T14:33:00Z","last_updated_date":"2019-06-28T14:33:00Z","reference_number":"EMA/365479/2019","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-specific-contracts-based-framework-contracts-2018_en.pdf"},
    {"id":"44971","name":"Joint letter by the European Commission, EMA and HMA to stakeholders regarding the requirements to provide results for authorised clinical trials in EudraCT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T14:06:00Z","last_updated_date":"2019-07-03T14:06:00Z","reference_number":"Ref. Ares(2019)3933941 -20/06l2019","document_url":"https://www.ema.europa.eu/en/documents/other/joint-letter-european-commission-ema-and-hma-stakeholders-regarding-requirements-provide-results-authorised-clinical-trials-eudract_en.pdf"},
    {"id":"45009","name":"List of signals discussed at PRAC since September 2012","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2019-07-08T10:38:00Z","last_updated_date":"2026-06-22T16:03:00Z","reference_number":"EMA/PRAC/530804/2013","document_url":"https://www.ema.europa.eu/en/documents/other/list-signals-discussed-prac-september-2012_en.xlsx"},
    {"id":"45083","name":"Statistical method of equivalence studies -  Annex III","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-07-18T13:28:00Z","last_updated_date":"2019-07-18T13:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/statistical-method-equivalence-studies-annex-iii_en.pdf"},
    {"id":"45136","name":"Gilenya: Product Information as approved by the CHMP on 25 July 2019, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/gilenya-product-information-approved-chmp-25-july-2019-pending-endorsement-european-commission_en.pdf"},
    {"id":"45296","name":"Questions and answers on the exemption from batch controls carried out on ATMPs imported into the European Union from a third country","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-08-21T16:08:00Z","last_updated_date":"2019-08-21T16:08:00Z","reference_number":"EMA/354272/2019","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-exemption-batch-controls-carried-out-atmps-imported-european-union-third-country_en.pdf"},
    {"id":"45315","name":"European Medicines Agency policy on access to EudraVigilance data for medicinal products for human use - Revision 4","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-08-23T11:00:00Z","last_updated_date":"2019-08-23T11:00:00Z","reference_number":"EMA/759287/2009 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-policy-access-eudravigilance-data-medicinal-products-human-use-revision-4_en.pdf"},
    {"id":"45431","name":"Preparedness of medicines’ clinical trials in paediatrics: Recommendations by the Enpr-EMA working group on trial preparedness","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-09-12T16:29:00Z","last_updated_date":"2020-08-31T10:01:00Z","reference_number":"EMA/56009/2019","document_url":"https://www.ema.europa.eu/en/documents/other/preparedness-medicines-clinical-trials-paediatrics-recommendations-enpr-ema-working-group-trial-preparedness_en.pdf"},
    {"id":"45505","name":"Letter of support for Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-09-23T11:29:00Z","last_updated_date":"2019-09-23T11:29:00Z","reference_number":"EMA/274960/2019","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-magnetic-resonance-imaging-proton-density-fat-fraction-mri-pdff_en.pdf"},
    {"id":"45506","name":"Letter of support for Corrected T1 (cT1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-09-23T11:31:00Z","last_updated_date":"2019-09-23T11:31:00Z","reference_number":"EMA/274962/2019","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-corrected-t1-ct1_en.pdf"},
    {"id":"45582","name":"Charter of tasks and responsibilities of the Executive Director as authorising officer","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2019-10-07T17:39:00Z","last_updated_date":"2019-10-07T17:39:00Z","reference_number":"EMA/MB/414689/2019","document_url":"https://www.ema.europa.eu/en/documents/other/charter-tasks-and-responsibilities-executive-director-authorising-officer_en.pdf"},
    {"id":"45583","name":"Charter of tasks and responsibilities of the accounting officer","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2019-10-07T17:55:00Z","last_updated_date":"2019-10-07T17:55:00Z","reference_number":"EMA/MB/414778/2019","document_url":"https://www.ema.europa.eu/en/documents/other/charter-tasks-and-responsibilities-accounting-officer_en.pdf"},
    {"id":"45584","name":"Outcome of written procedures finalised during the period from 17 May 2019 to 16 September 2019","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2019-10-07T17:58:00Z","last_updated_date":"2019-10-07T17:58:00Z","reference_number":"EMA/MB/498499/2019","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-17-may-2019-16-september-2019_en.pdf"},
    {"id":"45585","name":"Summary of transfers of appropriations in budget 2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-07T18:02:00Z","last_updated_date":"2019-10-07T18:02:00Z","reference_number":"EMA/MB/447289/2019","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2019_en.pdf"},
    {"id":"45602","name":"List of participants - European Medicines Agency (EMA) Patients' and Consumers' Working Party meeting (PCWP) - September 2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:19:00Z","last_updated_date":"2019-10-09T09:19:00Z","reference_number":"EMA/377520/2019","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-ema-patients-and-consumers-working-party-meeting-pcwp-september-2019_en.pdf"},
    {"id":"45604","name":"List of participants - European Medicines Agency (EMA) Healthcare Professionals' Working Party (HCPWP) meeting - September 2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:28:00Z","last_updated_date":"2019-10-09T09:28:00Z","reference_number":"EMA/377520/2019","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-ema-healthcare-professionals-working-party-hcpwp-meeting-september-2019_en.pdf"},
    {"id":"45606","name":"List of participants - European Medicines Agency (EMA) Joint Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) meeting - September 2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:38:00Z","last_updated_date":"2019-10-09T09:38:00Z","reference_number":"EMA/376430/2019","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-european-medicines-agency-ema-joint-patients-and-consumers-pcwp-and-healthcare-professionals-hcpwp-meeting-september-2019_en.pdf"},
    {"id":"45789","name":"Declaration of interests: Anthony Courtial","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T10:12:00Z","last_updated_date":"2021-06-21T12:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-anthony-courtial_en.pdf"},
    {"id":"45790","name":"Declaration of interests: Barbara Freischem","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T10:15:00Z","last_updated_date":"2022-06-30T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-barbara-freischem_en.pdf"},
    {"id":"45791","name":"Declaration of interests: Christine Bugge","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T10:20:00Z","last_updated_date":"2020-06-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-christine-bugge_en.pdf"},
    {"id":"45792","name":"Declaration of interests: Patricia Isabel Teixeira Chicharo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T11:05:00Z","last_updated_date":"2025-08-01T10:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-patricia-isabel-teixeira-chicharo_en.pdf"},
    {"id":"45793","name":"Declaration of interests: Jean-Michel Becar","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T11:13:00Z","last_updated_date":"2025-08-01T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-jean-michel-becar_en.pdf"},
    {"id":"45794","name":"Declaration of interests: Jean-Michel Mastio","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T11:15:00Z","last_updated_date":"2025-08-01T12:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-jean-michel-mastio_en.pdf"},
    {"id":"45795","name":"Declaration of interests: Jos Olaerts","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T11:20:00Z","last_updated_date":"2024-07-26T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-jos-olaerts_en.pdf"},
    {"id":"45796","name":"Declaration of interests: Monika Irena Hankiewicz-Klopotek","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T11:28:00Z","last_updated_date":"2025-08-01T11:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-monika-irena-hankiewicz-klopotek_en.pdf"},
    {"id":"45797","name":"Declaration of interests: Marek Tomasz Lehmann","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T11:31:00Z","last_updated_date":"2022-06-30T17:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-marek-tomasz-lehmann_en.pdf"},
    {"id":"45798","name":"Declaration of interests: Morgane Colin De Verdiere","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T11:46:00Z","last_updated_date":"2025-08-01T11:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-morgane-colin-de-verdiere_en.pdf"},
    {"id":"45799","name":"Declaration of interests: Maria Noemi Garcia del Blanco","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T11:53:00Z","last_updated_date":"2025-08-01T11:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-maria-noemi-garcia-del-blanco_en.pdf"},
    {"id":"45800","name":"Declaration of interests: Pavel Balabanov","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T11:59:00Z","last_updated_date":"2025-08-01T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-pavel-balabanov_en.pdf"},
    {"id":"45801","name":"Declaration of interests: Simona Iozu","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T12:08:00Z","last_updated_date":"2025-08-01T12:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-simona-iozu_en.pdf"},
    {"id":"45812","name":"PRAC recommendations on signals for update of the product information adopted at the PRAC meeting of 30 September-3 October 2019","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2019-10-28T13:33:00Z","last_updated_date":"2019-10-28T13:33:00Z","reference_number":"EMA/PRAC/532016/2019","document_url":"https://www.ema.europa.eu/en/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/prac-recommendations-signals-update-product-information-adopted-prac-meeting-30-september-3-october-2019_no.pdf"}},
    {"id":"45855","name":"EMA Regulatory Science to 2025 - responses to the online questionnaire","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T10:07:00Z","last_updated_date":"2019-10-31T10:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-regulatory-science-2025-responses-online-questionnaire_en.zip"},
    {"id":"46066","name":"Declaration of interests: Svetoslava Radomirova Naydenova","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-11-19T17:29:00Z","last_updated_date":"2025-08-01T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-svetoslava-radomirova-naydenova_en.pdf"},
    {"id":"46132","name":"European Medicines Agency second response to European Ombudsman regarding pre-submission activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:00:00Z","last_updated_date":"2019-11-26T10:00:00Z","reference_number":"EMA/627113/2019","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-second-response-european-ombudsman-regarding-pre-submission-activities_en.pdf"},
    {"id":"46133","name":"List of participants  - Annual Patients and Consumers Working Party (PCWP) and Healthcare Professionals Working Party (HCPWP) meeting with all eligible organisations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T09:57:00Z","last_updated_date":"2019-11-26T09:57:00Z","reference_number":"EMA/561005/2019","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-annual-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-meeting-all-eligible-organisations_en.pdf"},
    {"id":"46250","name":"Orientation guide for industry - EMA building","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-12-06T09:58:00Z","last_updated_date":"2025-06-16T16:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/orientation-guide-industry-ema-building_en.pdf"},
    {"id":"46251","name":"Orientation guide for delegates - EMA building","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-12-06T10:05:00Z","last_updated_date":"2026-04-24T14:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/orientation-guide-delegates-ema-building_en.pdf"},
    {"id":"46253","name":"Expected publication dates of PRAC recommendations on safety signals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-12-06T13:58:00Z","last_updated_date":"2025-11-26T09:45:00Z","reference_number":"EMA/632790/2019 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/other/expected-publication-dates-prac-recommendations-safety-signals_en.pdf"},
    {"id":"46257","name":"European Medicines Agency’s privacy statement concerning requests for information or access to documents via 'Send a question' form or phone call","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:42:53Z","last_updated_date":"2024-10-28T17:42:53Z","reference_number":"EMA/415481/2019 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-concerning-requests-information-or-access-documents-send-question-form-or-phone-call_en.pdf"},
    {"id":"46280","name":"Open call for data on use of antimicrobials in animals","type":"other","status":"Draft: consultation closed","consultation_date":"2019-12-10 - 2020-03-06","first_published_date":"2019-12-10T15:17:00Z","last_updated_date":"2019-12-10T15:17:00Z","reference_number":"EMA/536558/2019","document_url":"https://www.ema.europa.eu/en/documents/other/open-call-data-use-antimicrobials-animals_en.pdf"},
    {"id":"46316","name":"Questions and answers on comparability considerations for advanced therapy medicinal products (ATMP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-12-13T11:00:00Z","last_updated_date":"2019-12-13T11:00:00Z","reference_number":"EMA/CAT/499821/2019","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-comparability-considerations-advanced-therapy-medicinal-products-atmp_en.pdf"},
    {"id":"46327","name":"Pilot programme for international cooperation in GMP inspection of manufacturers of sterile medicinal products for human use - Terms of reference for participating authorities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-12-17T15:00:00Z","last_updated_date":"2019-12-17T15:00:00Z","reference_number":"EMA/INS/GMP/644249/2019","document_url":"https://www.ema.europa.eu/en/documents/other/pilot-programme-international-cooperation-gmp-inspection-manufacturers-sterile-medicinal-products-human-use-terms-reference-participating-authorities_en.pdf"},
    {"id":"46353","name":"European Medicines Agency’s privacy statement on the processing of personal data in the context of administrative inquiries and disciplinary proceedings","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-12-19T17:12:00Z","last_updated_date":"2019-12-19T17:12:00Z","reference_number":"EMA/868447/2018","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-processing-personal-data-context-administrative-inquiries-disciplinary-proceedings_en.pdf"},
    {"id":"46379","name":"Outcome of written procedures finalised during the period from 17 September 2019 to 22 November 2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-12-20T16:14:00Z","last_updated_date":"2019-12-20T16:14:00Z","reference_number":"EMA/MB/638477/2019","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-17-september-2019-22-november-2019_en.pdf"},
    {"id":"46406","name":"European Medicines Agency’s data protection notice regarding the Experts Management Tool and the handling of competing interests","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-10T11:11:00Z","last_updated_date":"2024-12-06T14:25:00Z","reference_number":"EMA/283094/2023 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-regarding-experts-management-tool-handling-competing-interests_en.pdf"},
    {"id":"46423","name":"HMA-EMA Joint Big Data Taskforce Phase II report: Annex VII - Resources","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T10:30:00Z","last_updated_date":"2020-01-20T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/hma-ema-joint-big-data-taskforce-phase-ii-report-annex-vii-resources_en.xlsx"},
    {"id":"46430","name":"Announcement of the EMA Management Board - Confirmation of the mandatory use of the ISO Individual Case Report standard based on ICH E2B(R3) modalities and related ISO standard terminology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-15T12:30:00Z","last_updated_date":"2020-01-15T12:30:00Z","reference_number":"EMA/561671/2019","document_url":"https://www.ema.europa.eu/en/documents/other/announcement-ema-management-board-confirmation-mandatory-use-iso-individual-case-report-standard-based-ich-e2br3-modalities-and-related-iso-standard-terminology_en.pdf"},
    {"id":"46454","name":"Priority recommendations of the HMA-EMA joint Big Data Task Force","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T10:30:00Z","last_updated_date":"2020-01-20T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/priority-recommendations-hma-ema-joint-big-data-task-force_en.pdf"},
    {"id":"46455","name":"HMA-EMA Joint Big Data Taskforce Phase II report: Evolving data-driven regulation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T10:30:00Z","last_updated_date":"2020-01-20T10:30:00Z","reference_number":"EMA/520966/2019","document_url":"https://www.ema.europa.eu/en/documents/other/hma-ema-joint-big-data-taskforce-phase-ii-report-evolving-data-driven-regulation_en.pdf"},
    {"id":"46460","name":"Detailed guide regarding the EudraVigilance data management activities by the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T12:25:00Z","last_updated_date":"2020-11-09T17:20:00Z","reference_number":"EMA/533039/2019 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/detailed-guide-regarding-eudravigilance-data-management-activities-european-medicines-agency_en.pdf"},
    {"id":"46468","name":"European Medicines Agency’s privacy statement for Small and Medium Enterprises (SME) Office activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-21T12:15:00Z","last_updated_date":"2021-08-09T16:48:00Z","reference_number":"EMA/420340/2019 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-small-medium-enterprises-sme-office-activities_en.pdf"},
    {"id":"46469","name":"European Medicines Agency’s privacy statement for the EMA individual experts’ stakeholder database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-21T13:25:00Z","last_updated_date":"2020-01-21T13:25:00Z","reference_number":"EMA/351266/2019","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-ema-individual-experts-stakeholder-database_en.pdf"},
    {"id":"46470","name":"European Medicines Agency’s privacy statement concerning public hearings at the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-21T13:25:00Z","last_updated_date":"2020-01-21T13:25:00Z","reference_number":"EMA/349369/2019","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-concerning-public-hearings-european-medicines-agency_en.pdf"}    {"id":"46497","name":"European Medicines Agency’s data protection notice for the EMA Account Management system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:43:08Z","last_updated_date":"2026-06-11T14:00:00Z","reference_number":"EMA/112375/2026","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-ema-account-management-system_en.pdf"},
    {"id":"46518","name":"European Medicines Agency's 25th anniversary - Timeline","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T09:43:00Z","last_updated_date":"2020-01-24T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-25th-anniversary-timeline_en.pdf"},
    {"id":"46524","name":"Record of data processing activity relating to personal files","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2024-03-14T13:35:00Z","reference_number":"EMA/186487/2019 Version 3","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-personal-files_en.pdf"},
    {"id":"46525","name":"Record of data processing activity relating to staff absences ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2021-11-24T13:36:00Z","reference_number":"EMA/405230/2019 Version 2","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-staff-absences_en.pdf"},
    {"id":"46526","name":"Record of data processing activity in the context of selection and recruitment procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T15:30:00Z","last_updated_date":"2025-07-29T13:37:00Z","reference_number":"EMA/208341/2019 Version 4","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-context-selection-recruitment-procedures_en.pdf"},
    {"id":"46527","name":"Record of data processing activity relating to trainings","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-05-13T16:45:00Z","reference_number":"EMA/430522/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-trainings_en.pdf"},
    {"id":"46528","name":"Record of data processing activity relating to the Non-EU Social security scheme ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/564581/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-non-eu-social-security-scheme_en.pdf"},
    {"id":"46529","name":"Record of data processing activity relating to requests for access to documents ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-05-26T17:08:00Z","reference_number":"EMA/383048/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-requests-access-documents_en.pdf"},
    {"id":"46530","name":"Record of data processing activity relating to missions ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/429999/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-missions_en.pdf"},
    {"id":"46531","name":"Record of data processing activity relating to SAP Finance ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/564966/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-sap-finance_en.pdf"},
    {"id":"46532","name":"Record of data processing activity relating to first aid records","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-01-24T14:22:00Z","reference_number":"EMA/513791/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-first-aid-records_en.pdf"},
    {"id":"46533","name":"Record of data processing activity relating to working time records ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/438287/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-working-time-records_en.pdf"},
    {"id":"46534","name":"Record of data processing activity regarding visitor management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2024-01-09T11:46:00Z","reference_number":"EMA/416765/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-regarding-visitor-management_en.pdf"},
    {"id":"46535","name":"Record of data processing activity relating to pension data","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/474824/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-pension-data_en.pdf"},
    {"id":"46536","name":"Record of data processing activity relating to the filemaker security database for staff vehicles/bicycles and lost/found property","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2024-01-09T11:47:00Z","reference_number":"EMA/417023/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-filemaker-security-database-staff-vehicles-bicycles-lost-found-property_en.pdf"},
    {"id":"46537","name":"Record of data processing activity relating to Security Access Control System","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2026-03-09T16:30:00Z","reference_number":"EMA/36991/2021","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-security-access-control-system_en.pdf"},
    {"id":"46538","name":"Record of data processing activity relating to managed print services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2021-09-27T08:58:00Z","reference_number":"EMA/518496/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-managed-print-services_en.pdf"},
    {"id":"46539","name":"Records of data processing activity relating to the switchboard recording system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2022-06-24T11:30:00Z","reference_number":"EMA/535220/2021","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-relating-switchboard-recording-system_en.pdf"},
    {"id":"46540","name":"Record of data processing activity regarding EMA Account Management System","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-09-16T14:43:00Z","reference_number":"EMA/676166/2019 Version 2","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-regarding-ema-account-management-system_en.pdf"},
    {"id":"46541","name":"Record of data processing activity for reporting fraud and irregularities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-01-24T14:22:00Z","reference_number":"EMA/671394/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-reporting-fraud-irregularities_en.pdf-0"},
    {"id":"46542","name":"Record of data processing activity relating to legal entity and bank account validation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2026-06-04T15:40:00Z","reference_number":"EMA/472281/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-legal-entity-bank-account-validation_en.pdf"},
    {"id":"46543","name":"Record of data processing activity relating to special education allowance ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/571888/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-special-education-allowance_en.pdf"},
    {"id":"46544","name":"Record of data processing activity for EudraVigilance ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2026-03-10T15:49:00Z","reference_number":"EMA/336722/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-eudravigilance_en.pdf"},
    {"id":"46545","name":"Record of data processing activity for the Experts Management Tool and the handling of competing interests","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2024-12-03T11:11:00Z","reference_number":"EMA/283093/2023","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-experts-management-tool-handling-competing-interests_en.pdf"},
    {"id":"46546","name":"Record of data processing activity relating to honours and decorations ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/573861/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-honours-decorations_en.pdf"},
    {"id":"46547","name":"Record of data processing activity relating to contracts database ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/572058/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-contracts-database_en.pdf"},
    {"id":"46548","name":"Record of data processing activity relating to emergency contact details ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/414540/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-emergency-contact-details_en.pdf"},
    {"id":"46549","name":"Record of data processing activity for handling of reports of alleged improprieties from external sources ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-01-24T14:22:00Z","reference_number":"EMA/436421/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-handling-reports-alleged-improprieties-external-sources_en.pdf"},
    {"id":"46550","name":"Record of data processing activity for administrative inquiries and disciplinary proceedings ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/435083/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-administrative-inquiries-disciplinary-proceedings_en.pdf"},
    {"id":"46551","name":"Records of data processing activity relating to the European Pharmacovigilance Issues Tracking Tool","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-01-24T14:22:00Z","reference_number":"EMA/478558/2019","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-relating-european-pharmacovigilance-issues-tracking-tool_en.pdf"},
    {"id":"46552","name":"Record of data processing activity regarding confidential counsellors and informal procedure ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/437258/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-regarding-confidential-counsellors-informal-procedure_en.pdf"},
    {"id":"46553","name":"Record of data processing activity relating to public hearings","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-01-24T14:22:00Z","reference_number":"EMA/464248/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-public-hearings_en.pdf"},
    {"id":"46554","name":"Record of data processing activity for pre-employment medical examination","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2023-12-12T16:00:00Z","reference_number":"EMA/684623/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-pre-employment-medical-examination_en.pdf"},
    {"id":"46555","name":"Record of data processing activity for individual experts stakeholder database ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-01-24T14:22:00Z","reference_number":"EMA/637643/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-individual-experts-stakeholder-database_en.pdf"},
    {"id":"46556","name":"Record of data processing activity regarding annual medical examination","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2023-12-13T11:54:00Z","reference_number":"EMA/525036/2023","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-regarding-annual-medical-examination_en.pdf"},
    {"id":"46557","name":"Record of data processing activity for organisation of meetings and events","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-01-24T14:22:00Z","reference_number":"EMA/460875/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-organisation-meetings-events_en.pdf"},
    {"id":"46558","name":"Record of data processing activity regarding consultation with the in-house medical advisor / occupational health physician","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/684927/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-regarding-consultation-house-medical-advisor-occupational-health-physician_en.pdf"},
    {"id":"46559","name":"Record of data-processing activity for public and targeted consultations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-01-24T14:22:00Z","reference_number":"EMA/621816/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-public-targeted-consultations_en.pdf"},
    {"id":"46560","name":"Records of data processing activity regarding absences due to illness or accident ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/686449/2019","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regarding-absences-due-illness-or-accident_en.pdf"},
    {"id":"46561","name":"Record of data processing activity regarding Enpr-EMA network database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-08-20T11:00:00Z","reference_number":"EMA/477283/2019 Version 2","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-regarding-enpr-ema-network-database_en.pdf"},
    {"id":"46562","name":"Record of data processing activity for the Small and Medium Enterprises Office (SME office) activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-05-25T16:56:00Z","reference_number":"EMA/420350/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-small-and-medium-enterprises-office-sme-office-activities_en.pdf"},
    {"id":"46563","name":"Record of data processing activity relating to requests for information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-05-26T17:07:00Z","reference_number":"EMA/383047/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-requests-information_en.pdf"},
    {"id":"46564","name":"Record of data processing activity for usability testing exercises","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:22:00Z","last_updated_date":"2020-01-24T14:22:00Z","reference_number":"EMA/589513/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-usability-testing-exercises_en.pdf"},
    {"id":"46565","name":"Record of data processing activity regarding performance management ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/408560/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-regarding-performance-management_en.pdf"},
    {"id":"46566","name":"Record of data processing activity regarding EMA Service Desk Portal","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-01-24T14:20:00Z","reference_number":"EMA/672819/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-regarding-ema-service-desk-portal_en.pdf"},
    {"id":"46567","name":"Record of data processing activity regarding European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Resource Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-08-11T16:17:00Z","reference_number":"EMA/463506/2019","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-regarding-european-network-centres-pharmacoepidemiology-pharmacovigilance-encepp-resource-database_en.pdf"},
    {"id":"46568","name":"Records of data processing activity regarding the European Union electronic Register of Post-Authorisation Studies (EU PAS Register) ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T14:20:00Z","last_updated_date":"2020-08-11T16:18:00Z","reference_number":"EMA/463507/2019","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regarding-european-union-electronic-register-post-authorisation-studies-eu-pas-register_en.pdf"},
    {"id":"46586","name":"Electronic product information for human medicines in the European Union - Contributions received following public consultation (partially anonymised)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-29T15:00:00Z","last_updated_date":"2020-01-29T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/electronic-product-information-human-medicines-european-union-contributions-received-following-public-consultation-partially-anonymised_en.pdf"},
    {"id":"46587","name":"Electronic product information for human medicines in the European Union - Categorised comments received following public consultation (partially anonymised)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-29T15:00:00Z","last_updated_date":"2020-01-29T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/electronic-product-information-human-medicines-european-union-categorised-comments-received-following-public-consultation-partially-anonymised_en.xls"},
    {"id":"46589","name":"Divergent position on the 'Categorisation of antibiotics in the European Union - Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-28T13:00:00Z","last_updated_date":"2020-01-28T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/divergent-position-categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific-advice-impact-public-health-and-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"46600","name":"Declaration of interests: Beyhan Mustafov","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-28T14:00:00Z","last_updated_date":"2022-06-30T12:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-beyhan-mustafov_en.pdf"},
    {"id":"46608","name":"Extended Telematics strategy and implementation roadmap 2019-2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-01-29T11:38:00Z","last_updated_date":"2020-01-29T11:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/extended-telematics-strategy-and-implementation-roadmap-2019-2020_en.pdf"},
    {"id":"46686","name":"European Medicines Agency's privacy statement for the organisation of meetings and events","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/75470/2019","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-organisation-meetings-events_en.pdf"},
    {"id":"46705","name":"ICH M9 on biopharmaceutics classification system based biowaivers - Step 5 - Questions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-02-11T14:11:00Z","last_updated_date":"2020-02-11T14:11:00Z","reference_number":"EMA/CHMP/ICH/10044/2020 ","document_url":"https://www.ema.europa.eu/en/documents/other/ich-m9-biopharmaceutics-classification-system-based-biowaivers-step-5-questions-and-answers_en.pdf"},
    {"id":"46742","name":"Public statement on the use of herbal medicinal products containing estragole - Revision 1","type":"other","status":"Draft: consultation closed","consultation_date":"2020-02-15 - 2020-05-15","first_published_date":"2020-02-14T13:20:00Z","last_updated_date":"2023-06-09T15:43:00Z","reference_number":"EMA/HMPC/137212/2005 Rev. 1 Corr.","document_url":"https://www.ema.europa.eu/en/documents/other/public-statement-use-herbal-medicinal-products-containing-estragole-revision-1_en.pdf"},
    {"id":"46802","name":"European Medicines Agency’s data protection notice for the pre-employment medical examination","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-02-19T14:09:00Z","last_updated_date":"2023-12-13T15:05:00Z","reference_number":"EMA/525037/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-pre-employment-medical-examination_en.pdf"},
    {"id":"46910","name":"Organisation chart: Human Medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-02T12:00:00Z","last_updated_date":"2026-02-12T09:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-chart-human-medicines_en.pdf"},
    {"id":"46911","name":"Organisation chart: Task Forces","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-02T12:00:00Z","last_updated_date":"2026-01-05T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-chart-task-forces_en.pdf"},
    {"id":"46922","name":"Qualification opinion on Multiple sclerosis clinical outcome assessment (MSCOA)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2020-03-02T13:39:00Z","last_updated_date":"2020-03-02T13:39:00Z","reference_number":"EMA/CHMP/SAWP/74371/2020","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-multiple-sclerosis-clinical-outcome-assessment-mscoa_en.pdf"},
    {"id":"46923","name":"Overview of comments received on 'Draft qualification opinion on Multiple Sclerosis Clinical Outcome Assessment (MSCOA) qualification opinion'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-02T13:41:00Z","last_updated_date":"2020-03-02T13:41:00Z","reference_number":"EMA/550514/2019","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-qualification-opinion-multiple-sclerosis-clinical-outcome-assessment-mscoa-qualification-opinion_en.pdf"},
    {"id":"46924","name":"Declaration of interests: Hilmar Hamann","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-02T13:51:00Z","last_updated_date":"2025-08-01T12:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-hilmar-hamann_en.pdf"},
    {"id":"46932","name":"Note on EU implementation of ICH Q12 (guideline on technical and regulatory considerations for pharmaceutical product lifecycle management)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-04T09:30:00Z","last_updated_date":"2020-03-04T09:30:00Z","reference_number":"EMA/CHMP/ICH/78332/2020","document_url":"https://www.ema.europa.eu/en/documents/other/note-eu-implementation-ich-q12-guideline-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management_en.pdf"},
    {"id":"46942","name":"Orientation guide for patient representatives and healthcare professionals - EMA building","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-04T16:21:00Z","last_updated_date":"2026-04-24T14:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/orientation-guide-patient-representatives-healthcare-professionals-ema-building_en.pdf"},
    {"id":"47009","name":"Records of data processing activity for managing the loaning of Information Centre material","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T09:10:00Z","last_updated_date":"2020-03-13T09:10:00Z","reference_number":"EMA/460871/2019","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-managing-loaning-information-centre-material_en.pdf"},
    {"id":"47011","name":"European Medicines Agency’s privacy statement for the Information Centre","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/634004/2019","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-information-centre_en.pdf"},
    {"id":"47038","name":"EudraVigilance XCOMP stakeholder communication – 18 March 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T14:09:00Z","last_updated_date":"2020-03-27T14:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-xcomp-stakeholder-communication-18-march-2020_en.pdf"},
    {"id":"47050","name":"A call to pool EU research resources into large-scale, multi-centre, multi-arm clinical trials against COVID-19","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-19T10:41:00Z","last_updated_date":"2020-03-19T10:41:00Z","reference_number":"EMA/136815/2020","document_url":"https://www.ema.europa.eu/en/documents/other/call-pool-eu-research-resources-large-scale-multi-centre-multi-arm-clinical-trials-against-covid-19_en.pdf"},
    {"id":"47088","name":"Outcome of written procedures finalised during the period from 23 November 2019 to 20 February 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-20T16:28:00Z","last_updated_date":"2020-03-20T16:28:00Z","reference_number":"EMA/MB/91576/2020","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-23-november-2019-20-february-2020_en.pdf"},
    {"id":"47117","name":"EudraVigilance Operational Plan - Milestones 2020 to 2022","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T12:59:00Z","last_updated_date":"2020-03-25T12:59:00Z","reference_number":"EMA/509378/2019","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-operational-plan-milestones-2020-2022_en.pdf"},
    {"id":"47223","name":"Letter of support for Islet autoantibodies as enrichment biomarkers for type 1 diabetes prevention studies, through a quantitative disease progression model","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-03-30T17:22:00Z","last_updated_date":"2020-03-30T17:22:00Z","reference_number":"EMA/625951/2019","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-islet-autoantibodies-enrichment-biomarkers-type-1-diabetes-prevention-studies-through-quantitative-disease-progression-model_en.pdf"},
    {"id":"47277","name":"Safety Working Party (SWP) / Non-clinical Working Party (NcWP) recommendations on the duration of contraception following the end of treatment with a genotoxic drug","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-04-01T14:59:00Z","last_updated_date":"2023-04-24T10:16:00Z","reference_number":"EMA/CHMP/SWP/74077/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/safety-working-party-swp-non-clinical-working-party-ncwp-recommendations-duration-contraception-following-end-treatment-genotoxic-drug_en.pdf"},
    {"id":"47325","name":"Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for Remdesivir Gilead available for compassionate use","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T14:03:00Z","last_updated_date":"2020-07-31T11:00:00Z","reference_number":"EMA/178636/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distribution-and-patients-targeted-and-conditions-safety-monitoring-addressed-member-states-remdesivir-gilead-available-compassionate-use_en.pdf"},
    {"id":"47326","name":"Summary on compassionate use for Remdesivir Gilead","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T14:08:00Z","last_updated_date":"2020-07-31T11:05:00Z","reference_number":"EMA/178637/2020 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf"},
    {"id":"47396","name":"Superseded - Mandate, objectives and rules of procedure of the COVID-19 EMA pandemic Task Force (COVID-ETF)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-04-09T12:30:00Z","last_updated_date":"2021-07-08T11:52:00Z","reference_number":"EMA/166423/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-mandate-objectives-and-rules-procedure-covid-19-ema-pandemic-task-force-covid-etf_en.pdf"},
    {"id":"47404","name":"Qualification opinion of clinically interpretable treatment effect measures based on recurrent event endpoints that allow for efficient statistical analyses","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2020-04-14T15:35:00Z","last_updated_date":"2020-04-14T15:35:00Z","reference_number":"EMA/CHMP/SAWP/120610/2020","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-clinically-interpretable-treatment-effect-measures-based-recurrent-event-endpoints-allow-efficient-statistical-analyses_en.pdf"},
    {"id":"47413","name":"EMA stakeholder workshop: advancing animal health through multi-stakeholder dialogue","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-04-16T11:05:00Z","last_updated_date":"2020-04-16T11:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-stakeholder-workshop-advancing-animal-health-through-multi-stakeholder-dialogue_en.pdf"},
    {"id":"47559","name":"EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines [OBSOLETE]","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-04T16:08:00Z","last_updated_date":"2023-07-26T10:24:00Z","reference_number":"EMA/213341/2020 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/ema-initiatives-acceleration-development-support-and-evaluation-procedures-covid-19-treatments-and-vaccines-obsolete_en.pdf"},
    {"id":"47590","name":"SCOPE training: An active approach to comparisons of Adverse Drug Reaction Reports from patients and healthcare professionals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-active-approach-comparisons-adverse-drug-reaction-reports-patients-and-healthcare-professionals_en.pdf"},
    {"id":"47591","name":"SCOPE training: Identification, management and raising awareness of ADR reports for drugs subject to additional monitoring","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-identification-management-and-raising-awareness-adr-reports-drugs-subject-additional-monitoring_en.pdf"},
    {"id":"47592","name":"SCOPE training: Raising and measuring awareness levels for ADR reporting systems through campaigns and regional monitoring centres","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-raising-and-measuring-awareness-levels-adr-reporting-systems-through-campaigns-and-regional-monitoring-centres_en.zip"},
    {"id":"47593","name":"SCOPE training: Collaboration with patient organisations to promote and support patient ADR reporting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-collaboration-patient-organisations-promote-and-support-patient-adr-reporting_en.pdf"},
    {"id":"47594","name":"SCOPE training: Competency recommendations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-competency-recommendations_en.pdf"},
    {"id":"47595","name":"SCOPE training: Compliance and performance: Management and indicators","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-compliance-and-performance-management-and-indicators_en.pdf"},
    {"id":"47596","name":"SCOPE training: Document and records management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-document-and-records-management_en.pdf"},
    {"id":"47597","name":"SCOPE training: Duplicate detection: Best practice guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-duplicate-detection-best-practice-guide_en.pdf"},
    {"id":"47598","name":"SCOPE training: Exchange of information between PV assessors and PV inspectors: Best Practice Guidance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-exchange-information-between-pv-assessors-and-pv-inspectors-best-practice-guidance_en.pdf"},
    {"id":"47599","name":"SCOPE training: Feedback to patient ADR reports","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-feedback-patient-adr-reports_en.pdf"},
    {"id":"47600","name":"SCOPE training: Handling telephone calls from the public","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-handling-telephone-calls-public_en.pdf"},
    {"id":"47601","name":"SCOPE training: Identification of available data sources outside spontaneous reports: Recommendations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-identification-available-data-sources-outside-spontaneous-reports-recommendations_en.pdf"},
    {"id":"47602","name":"SCOPE training: Survey report: Interaction with Pharmacovigilance Inspectors","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-survey-report-interaction-pharmacovigilance-inspectors_en.pdf"},
    {"id":"47603","name":"SCOPE training: Risk communication: Introduction","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-risk-communication-introduction_en.pdf"},
    {"id":"47604","name":"SCOPE training: IT systems for ADR reporting: Best Practice Guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-it-systems-adr-reporting-best-practice-guide_en.pdf"},
    {"id":"47605","name":"SCOPE training: National strategy for implementation of recommendations on risk communication: Key actions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-national-strategy-implementation-recommendations-risk-communication-key-actions_en.pdf"},
    {"id":"47606","name":"SCOPE training: Medication errors","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-medication-errors_en.pdf"},
    {"id":"47607","name":"SCOPE training: Paper ADR reporting forms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-paper-adr-reporting-forms_en.pdf"},
    {"id":"47608","name":"SCOPE training: PASS recommendations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-pass-recommendations_en.pdf"},
    {"id":"47609","name":"SCOPE training: Practical guide on PASS assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-practical-guide-pass-assessment_en.pdf"},
    {"id":"47610","name":"SCOPE training: Practical guide on PSUR / PSUSA assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-practical-guide-psur-psusa-assessment_en.pdf"},
    {"id":"47611","name":"SCOPE training: Practical guide on risk management plan assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-practical-guide-risk-management-plan-assessment_en.pdf"},
    {"id":"47612","name":"SCOPE training: Practical guide on safety-related referrals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-practical-guide-safety-related-referrals_en.pdf"}    {"id":"47613","name":"SCOPE training: PSUR/PSUSA and Referral Recommendations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-psurpsusa-and-referral-recommendations_en.pdf"},
    {"id":"47614","name":"SCOPE training: Pharmacovigilance Quality Manual Template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-pharmacovigilance-quality-manual-template_en.zip"},
    {"id":"47615","name":"SCOPE training: Quality planning and quality objectives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-quality-planning-and-quality-objectives_en.zip"},
    {"id":"47616","name":"SCOPE training: Quality standards of pharmacovigilance assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-quality-standards-pharmacovigilance-assessment_en.pdf"},
    {"id":"47617","name":"SCOPE training: Survey report: Understanding National Quality Systems","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-survey-report-understanding-national-quality-systems_en.pdf"},
    {"id":"47618","name":"SCOPE training: Raising awareness of National Adverse Drug Reaction Reporting Systems: Case Studies by Country","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-raising-awareness-national-adverse-drug-reaction-reporting-systems-case-studies-country_en.zip"},
    {"id":"47619","name":"SCOPE training: Resource management best practice guidance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-resource-management-best-practice-guidance_en.zip"},
    {"id":"47620","name":"SCOPE training: Survey report: Resource management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-survey-report-resource-management_en.pdf"},
    {"id":"47621","name":"SCOPE training: Risk communication on medicines: Report from the workshop","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-risk-communication-medicines-report-workshop_en.pdf"},
    {"id":"47622","name":"SCOPE training: Risk communication on medicines: Proposals for improvement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-risk-communication-medicines-proposals-improvement_en.zip"},
    {"id":"47623","name":"SCOPE training: Risk management plan recommendations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-risk-management-plan-recommendations_en.pdf"},
    {"id":"47624","name":"SCOPE training: Signal management: Best practice guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-signal-management-best-practice-guide_en.pdf"},
    {"id":"47625","name":"SCOPE training: Stakeholder feedback and customer satisfaction: Guidance and good practice examples","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-stakeholder-feedback-and-customer-satisfaction-guidance-and-good-practice-examples_en.pdf"},
    {"id":"47626","name":"SCOPE training: Quality management systems: Stakeholder feedback and customer satisfaction","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-quality-management-systems-stakeholder-feedback-and-customer-satisfaction_en.pdf"},
    {"id":"47627","name":"SCOPE training: Increasing awareness of national Adverse Drug Reaction Reporting Systems: Best practice guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-increasing-awareness-national-adverse-drug-reaction-reporting-systems-best-practice-guide_en.zip"},
    {"id":"47628","name":"SCOPE training: Tools for measuring and improving the quality of reports in national Adverse Drug Reactions databases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-tools-measuring-and-improving-quality-reports-national-adverse-drug-reactions-databases_en.pdf"},
    {"id":"47629","name":"SCOPE training: Web-based safety information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-07T16:49:00Z","last_updated_date":"2020-05-07T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/scope-training-web-based-safety-information_en.zip"},
    {"id":"47771","name":"Questions and answers: Qualification of digital technology-based methodologies to support approval of medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-27T18:07:00Z","last_updated_date":"2020-06-04T15:42:00Z","reference_number":"EMA/219860/2020","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-qualification-digital-technology-based-methodologies-support-approval-medicinal-products_en.pdf"},
    {"id":"47785","name":"European Medicines Regulatory Network COVID-19 Business Continuity Plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-28T11:00:00Z","last_updated_date":"2020-09-18T11:14:00Z","reference_number":"EMA/199630/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-regulatory-network-covid-19-business-continuity-plan_en.pdf"},
    {"id":"47802","name":"IV Zanamivir compassionate-use programme - Closure of programme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/iv-zanamivir-compassionate-use-programme-closure-programme_en.pdf"},
    {"id":"47824","name":"List of references of observational studies of chloroquine and hydroxychloroquine in COVID-19 patients","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T14:00:00Z","last_updated_date":"2020-06-05T16:13:00Z","reference_number":"EMA/295370/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/list-references-observational-studies-chloroquine-and-hydroxychloroquine-covid-19-patients_en.pdf"},
    {"id":"47825","name":"European Medicines Agency response to IQWIG on transparency of COVID-19 related activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T14:15:00Z","last_updated_date":"2020-05-29T14:15:00Z","reference_number":"EMA/280976/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-response-iqwig-transparency-covid-19-related-activities_en.pdf"},
    {"id":"47837","name":"FDA / EMA common commentary on submitting an initial paediatric study plan (iPSP) and paediatric investigation plan (PIP) for the prevention and treatment of COVID-19","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-02T18:25:00Z","last_updated_date":"2020-06-02T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/fda-ema-common-commentary-submitting-initial-paediatric-study-plan-ipsp-and-paediatric-investigation-plan-pip-prevention-and-treatment-covid-19_en.pdf"},
    {"id":"47892","name":"Working arrangement between EMA, Directorate-General Health and Food Safety (DG SANTE) and Department of Health Canada (Health Canada)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-16T11:00:00Z","last_updated_date":"2020-06-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/working-arrangement-between-ema-directorate-general-health-and-food-safety-dg-sante-and-department-health-canada-health-canada_en.pdf"},
    {"id":"47923","name":"Medical literature monitoring: substance groups 1-309 and herbal substance groups 1-100 valid from 1 June 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-10T11:20:00Z","last_updated_date":"2020-06-10T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medical-literature-monitoring-substance-groups-1-309-and-herbal-substance-groups-1-100-valid-1-june-2020_en.xlsx"},
    {"id":"47998","name":"European Medicines Agency’s privacy statement for electronic newsletters","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/288337/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-electronic-newsletters_en.pdf"},
    {"id":"48013","name":"Outcome of written procedures finalised during the period from 21 February 2020 to 26 May 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-16T09:40:00Z","last_updated_date":"2020-06-16T09:40:00Z","reference_number":"EMA/MB/283295/2020","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-21-february-2020-26-may-2020_en.pdf"},
    {"id":"48059","name":"European Medicines Agency’s privacy statement for managed print services","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/175429/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-managed-print-services_en.pdf"},
    {"id":"48067","name":"Policy 44: European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2004-10-07T10:08:00Z","last_updated_date":"2025-05-01T11:10:00Z","reference_number":"EMA/54457/2024","document_url":"https://www.ema.europa.eu/en/documents/other/policy-44-european-medicines-agency-policy-handling-competing-interests-scientific-committees-members-experts_en.pdf"},
    {"id":"48103","name":"Veklury - Product Information as approved by the CHMP on 25 June 2020, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-25T14:00:00Z","last_updated_date":"2020-06-25T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veklury-product-information-approved-chmp-25-june-2020-pending-endorsement-european-commission_en.pdf"},
    {"id":"48116","name":"European Medicines Agency’s data protection notice for validation of proof of establishment when natural persons apply for orphan designation or a transfer of an orphan designation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-24T17:26:00Z","last_updated_date":"2022-11-23T12:20:00Z","reference_number":"EMA/285766/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-validation-proof-establishment-when-natural-persons-apply-orphan-designation-or-transfer-orphan-designation_en.pdf"},
    {"id":"48121","name":"Appointment of EMA Executive Director - The process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-25T11:43:00Z","last_updated_date":"2020-07-15T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/appointment-ema-executive-director-process_en.pdf"},
    {"id":"48169","name":"Questions and answers on management of extraneous agents in immunological veterinary medicinal products (IVMPs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T13:59:00Z","last_updated_date":"2020-06-26T13:59:00Z","reference_number":"EMA/CVMP/IWP/669993/2019","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-management-extraneous-agents-immunological-veterinary-medicinal-products-ivmps_en.pdf"},
    {"id":"48171","name":"Draft responses to stakeholder comments on the Points to consider on the impact of COVID-19 on methodological aspects of ongoing clinical trials","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-29T13:56:00Z","last_updated_date":"2020-06-29T13:56:00Z","reference_number":"EMA/318376/2020","document_url":"https://www.ema.europa.eu/en/documents/other/draft-responses-stakeholder-comments-points-consider-impact-covid-19-methodological-aspects-ongoing-clinical-trials_en.pdf"},
    {"id":"48176","name":"Management Board meeting dates 2021-2022","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T16:28:00Z","last_updated_date":"2020-06-26T16:28:00Z","reference_number":"EMA/MB/155721/2020","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2021-2022_en.pdf"},
    {"id":"48189","name":"Annual list of contract modifications 2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-30T15:04:00Z","last_updated_date":"2020-06-30T15:04:00Z","reference_number":"EMA/145937/2019","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contract-modifications-2019_en.pdf"},
    {"id":"48190","name":"Annual list of contractors 2019 - contract values Euro 15,000 - 143,999","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-30T15:04:00Z","last_updated_date":"2020-06-30T15:04:00Z","reference_number":"EMA/352493/2020","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contractors-2019-contract-values-euro-15000-143999_en.pdf"},
    {"id":"48191","name":"Annual list of specific contracts based on framework contracts - 2019","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-30T15:04:00Z","last_updated_date":"2020-06-30T15:04:00Z","reference_number":"EMA/352492/2020","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-specific-contracts-based-framework-contracts-2019_en.pdf"},
    {"id":"48192","name":"Declaration of interests: Veronika Jekerle","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-30T16:17:00Z","last_updated_date":"2025-08-01T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-veronika-jekerle_en.pdf"},
    {"id":"48292","name":"Records of data processing activity in internal audit and consultancy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-07-13T14:05:00Z","last_updated_date":"2020-07-13T14:05:00Z","reference_number":"EMA/292019/2020","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-internal-audit-consultancy_en.pdf"},
    {"id":"48305","name":"Record of data processing for validation of proof of establishment when natural persons apply for orphan designation or a transfer of an orphan designation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-07-14T15:57:00Z","last_updated_date":"2020-07-14T15:57:00Z","reference_number":"EMA/331101/2020","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-validation-proof-establishment-when-natural-persons-apply-orphan-designation-or-transfer-orphan-designation_en.pdf"},
    {"id":"48323","name":"Extended EU Telematics strategy and implementation roadmap 2020-2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-07-17T12:10:00Z","last_updated_date":"2020-07-17T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/extended-eu-telematics-strategy-and-implementation-roadmap-2020-2021_en.pdf"},
    {"id":"48400","name":"Questions and Answers on stem cell-based products for veterinary use: specific question on target animal safety addressed by CVMP/ADVENT","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T11:19:00Z","last_updated_date":"2020-07-24T11:19:00Z","reference_number":"EMA/CVMP/ADVENT/791717/2016","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-stem-cell-based-products-veterinary-use-specific-question-target-animal-safety-addressed-cvmpadvent_en.pdf"},
    {"id":"48500","name":"Designation of orphan conditions in Europe: regulatory observations and considerations after implementation of regulation 141/2000","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-07-30T12:41:00Z","last_updated_date":"2020-07-30T12:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/designation-orphan-conditions-europe-regulatory-observations-and-considerations-after-implementation-regulation-1412000_en.pdf"},
    {"id":"48579","name":"European Medicines Agency’s data protection notice for EudraVigilance Human (EV)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-08-11T11:35:00Z","last_updated_date":"2026-02-05T10:35:00Z","reference_number":"EMA/381993/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-human-ev_no.pdf"}},
    {"id":"48687","name":"Quick interactive guide to IRIS registration process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-08-25T10:46:00Z","last_updated_date":"2021-03-10T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/quick-interactive-guide-iris-registration-process_en.pdf"},
    {"id":"48750","name":"Declaration of interests: Chiara Bortoluzzi","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-09-03T16:25:00Z","last_updated_date":"2024-07-26T17:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-chiara-bortoluzzi_en.pdf"},
    {"id":"48751","name":"Declaration of interests: David Bosque Villaverde","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-09-03T10:07:00Z","last_updated_date":"2025-08-01T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-david-bosque-villaverde_en.pdf"},
    {"id":"48752","name":"Declaration of interests: Piero Bortolotti","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-09-03T10:07:00Z","last_updated_date":"2025-08-01T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-piero-bortolotti_en.pdf"},
    {"id":"48753","name":"Declaration of interests: Pieter Vankeerberghen","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-09-03T12:00:00Z","last_updated_date":"2025-08-01T17:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-pieter-vankeerberghen_en.pdf"},
    {"id":"48754","name":"Declaration of interests: Pauline Mattart","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-09-03T12:00:00Z","last_updated_date":"2021-06-16T13:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-pauline-mattart_en.pdf"},
    {"id":"48755","name":"Declaration of interests: Spyridon Drosos","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-09-03T12:00:00Z","last_updated_date":"2024-07-26T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-spyridon-drosos_en.pdf"},
    {"id":"48779","name":"Mandate: HMA-EMA joint Big Data Steering Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-09-14T10:40:00Z","last_updated_date":"2023-06-14T10:00:00Z","reference_number":"EMA/96120/2023","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-hma-ema-joint-big-data-steering-group_en.pdf"},
    {"id":"48780","name":"Membership list: HMA-EMA joint Big Data Steering Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T10:40:00Z","last_updated_date":"2024-09-10T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/membership-list-hma-ema-joint-big-data-steering-group_en.pdf"},
    {"id":"48792","name":"European Medicines Agency’s privacy statement for the use of Microsoft Teams and SharePoint Online pilot users (obsolete)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:42:37Z","last_updated_date":"2024-10-28T17:42:37Z","reference_number":"EMA/330262/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-use-microsoft-teams-sharepoint-online-pilot-users-obsolete_en.pdf"},
    {"id":"48793","name":"Records of data processing activity for the use of Microsoft Applications: OneDrive, Outlook 365, Teams and SharePoint","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T12:27:00Z","last_updated_date":"2026-04-28T15:20:00Z","reference_number":"EMA/188186/2023 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-use-microsoft-applications-onedrive-outlook-365-teams-sharepoint_en.pdf"},
    {"id":"48941","name":"Reply to the European Ombudsman’s letter concerning transparency and independence of the work of the European Medicines Agency in supporting the development and evaluation of COVID-19 medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-05T12:00:00Z","last_updated_date":"2020-10-05T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/reply-european-ombudsmans-letter-concerning-transparency-and-independence-work-european-medicines-agency-supporting-development-and-evaluation-covid-19-medicines_en.pdf"},
    {"id":"49047","name":"Production API and registration process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T10:20:00Z","last_updated_date":"2020-10-21T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/production-api-and-registration-process_en.pdf"},
    {"id":"49048","name":"SPOR API v2 specification","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T10:20:00Z","last_updated_date":"2020-10-21T10:20:00Z","reference_number":"EMA/567640/2018","document_url":"https://www.ema.europa.eu/en/documents/other/spor-api-v2-specification_en.pdf"},
    {"id":"49052","name":"Examples of bundles for create product functionality","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T10:20:00Z","last_updated_date":"2020-10-21T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/examples-bundles-create-product-functionality_en.zip"},
    {"id":"49056","name":"UPD Production Release Notes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T10:20:00Z","last_updated_date":"2020-10-21T10:20:00Z","reference_number":"EMA/556635/2020","document_url":"https://www.ema.europa.eu/en/documents/other/upd-production-release-notes_en.pdf"},
    {"id":"49098","name":"European Medicines Agency’s privacy statement for the Regulatory Science Strategy interviews","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:16:00Z","last_updated_date":"2020-10-21T16:16:00Z","reference_number":"EMA/317034/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-regulatory-science-strategy-interviews_en.pdf"},
    {"id":"49099","name":"European Medicines Agency’s privacy statement for the EU Innovation Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:18:00Z","last_updated_date":"2020-10-21T16:18:00Z","reference_number":"EMA/317033/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-eu-innovation-network_en.pdf"},
    {"id":"49100","name":"Records of data processing activity regarding EU Innovation Network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:31:00Z","last_updated_date":"2020-10-21T16:31:00Z","reference_number":"EMA/682463/2019","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regarding-eu-innovation-network_en.pdf"},
    {"id":"49101","name":"Records of data processing activity Regulatory Science Strategy interviews ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T17:26:00Z","last_updated_date":"2020-10-21T17:26:00Z","reference_number":"EMA/682461/2019","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regulatory-science-strategy-interviews_en.pdf"},
    {"id":"49129","name":"Decision on Amending Budget No 1-2020","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2020-10-26T16:04:00Z","last_updated_date":"2020-10-26T16:04:00Z","reference_number":"EMA/MB/460018/2020","document_url":"https://www.ema.europa.eu/en/documents/other/decision-amending-budget-no-1-2020_en.pdf"},
    {"id":"49141","name":"Lessons learnt from presence of N-nitrosamine impurities in sartan medicines - Implementation plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-28T13:20:00Z","last_updated_date":"2020-10-28T13:20:00Z","reference_number":"EMA/503522/2020","document_url":"https://www.ema.europa.eu/en/documents/other/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines-implementation-plan_en.pdf"},
    {"id":"49163","name":"Reply to open letter concerning the transparency and evaluation of vaccines for COVID-19","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-10-30T14:00:00Z","last_updated_date":"2020-10-30T14:00:00Z","reference_number":"EMA/565800/2020","document_url":"https://www.ema.europa.eu/en/documents/other/reply-open-letter-concerning-transparency-and-evaluation-vaccines-covid-19_en.pdf"},
    {"id":"49173","name":"Declaration of interests: Karl Hamilton","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-04T12:00:00Z","last_updated_date":"2022-06-30T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-karl-hamilton_en.pdf"},
    {"id":"49197","name":"Veterinary Scientific Advice procedure - submission deadlines 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-09T09:53:00Z","last_updated_date":"2020-11-09T09:53:00Z","reference_number":"EMA/564964/2020","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-scientific-advice-procedure-submission-deadlines-2021_en.pdf"},
    {"id":"49207","name":"Letter of support for Mobilise-D digital mobility outcomes as monitoring biomarkers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-11T11:00:00Z","last_updated_date":"2020-11-11T11:00:00Z","reference_number":"EMA/234828/2020","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-mobilise-d-digital-mobility-outcomes-monitoring-biomarkers_en.pdf"},
    {"id":"49252","name":"Pharmacovigilance plan of the EU Regulatory Network for COVID-19 vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T14:30:00Z","last_updated_date":"2020-11-13T14:30:00Z","reference_number":"EMA/333964/2020","document_url":"https://www.ema.europa.eu/en/documents/other/pharmacovigilance-plan-eu-regulatory-network-covid-19-vaccines_en.pdf"},
    {"id":"49253","name":"Consideration on core requirements for RMPs of COVID-19 vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T14:30:00Z","last_updated_date":"2025-12-04T16:27:00Z","reference_number":"EMA/PRAC/709308/2022","document_url":"https://www.ema.europa.eu/en/documents/other/consideration-core-requirements-rmps-covid-19-vaccines_en.pdf"},
    {"id":"49254","name":"Letter from the chairs of EMA's Management Board to Guido Rasi at the end of his term as EMA's Executive Director","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T14:49:00Z","last_updated_date":"2020-11-13T14:49:00Z","reference_number":"EMA/561503/2020","document_url":"https://www.ema.europa.eu/en/documents/other/letter-chairs-emas-management-board-guido-rasi-end-his-term-emas-executive-director_en.pdf"},
    {"id":"49258","name":"Draft appendix 3 to the guideline on the clinical evaluation of anticancer medicinal products - Summary of Product Characteristics for an Anticancer medicinal product – mock-up of 4.8","type":"other","status":"Draft: consultation closed","consultation_date":"2020-11-13 - 2021-02-15","first_published_date":"2020-11-16T09:57:00Z","last_updated_date":"2020-11-16T09:57:00Z","reference_number":"EMA/593364/2020 ","document_url":"https://www.ema.europa.eu/en/documents/other/draft-appendix-3-guideline-clinical-evaluation-anticancer-medicinal-products-summary-product-characteristics-anticancer-medicinal-product-mock-48_en.pdf"},
    {"id":"49270","name":"Declaration of interests: Emer Cooke","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-18T15:00:00Z","last_updated_date":"2026-05-21T11:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-emer-cooke_en.pdf"},
    {"id":"49271","name":"Declaration of interests: Angela-Christina Schmidt","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-16T13:36:00Z","last_updated_date":"2025-08-01T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-angela-christina-schmidt_en.pdf"},
    {"id":"49279","name":"EMA considerations on COVID-19 vaccine approval","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2020-11-19T12:00:00Z","last_updated_date":"2020-11-19T12:00:00Z","reference_number":"EMA/592928/2020","document_url":"https://www.ema.europa.eu/en/documents/other/ema-considerations-covid-19-vaccine-approval_en.pdf"},
    {"id":"49295","name":"Letter of support for N170 ERP as a prognostic biomarker for adaptive social functioning and its potential to stratify study populations in people with Autism spectrum disorders (ASD) without intellectual disability","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-20T09:25:00Z","last_updated_date":"2020-11-20T09:25:00Z","reference_number":"EMA/508140/2020","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-n170-erp-prognostic-biomarker-adaptive-social-functioning-and-its-potential-stratify-study-populations-people-autism-spectrum-disorders-asd-without-intellectual-disability_en.pdf"},
    {"id":"49296","name":"Letter of support for the VABS-II Adaptive Behavior Composite (VABS-II-ABC) score as measure of adaptive social functioning in people with Autism Spectrum Disorders (ASD) without intellectual disability","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-20T09:28:00Z","last_updated_date":"2020-11-20T09:28:00Z","reference_number":"EMA/548136/2020","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-vabs-ii-adaptive-behavior-composite-vabs-ii-abc-score-measure-adaptive-social-functioning-people-autism-spectrum-disorders-asd-without-intellectual-disability_en.pdf"},
    {"id":"49350","name":"European Medicines Agency's privacy statement for media professionals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/416293/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-media-professionals_en.pdf"},
    {"id":"49351","name":"Records of data processing activity for contact details of journalist and other media professionals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-24T17:48:00Z","last_updated_date":"2020-11-24T17:48:00Z","reference_number":"EMA/416292/2020","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-contact-details-journalist-other-media-professionals_en.pdf"},
    {"id":"49396","name":"Questions and answers on labelling flexibilities for COVID-19 vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-27T17:00:00Z","last_updated_date":"2024-01-30T16:59:00Z","reference_number":"EMA/726359/2022","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-labelling-flexibilities-covid-19-vaccines_en.pdf"},
    {"id":"49423","name":"Questions and answers to stakeholders on the implementation of the protocol on Ireland / Northern Ireland","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-11-27T08:23:00Z","last_updated_date":"2021-03-09T10:05:00Z","reference_number":"EMA/520875/2020 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-stakeholders-implementation-protocol-ireland-northern-ireland_en.pdf"},
    {"id":"49430","name":"EMA speaking points for update on COVID-19 vaccines: Informal videoconference of the Ministers of Health on 2 December 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-03T12:33:00Z","last_updated_date":"2020-12-03T12:33:00Z","reference_number":"EMA/651334/2020","document_url":"https://www.ema.europa.eu/en/documents/other/ema-speaking-points-update-covid-19-vaccines-informal-videoconference-ministers-health-2-december-2020_en.pdf"},
    {"id":"49465","name":"Letter from EMA on conditions for making available reports of suspected adverse reactions by EMA to WHO/UMC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-08T12:00:00Z","last_updated_date":"2020-12-08T12:00:00Z","reference_number":"EMA/308793/2020","document_url":"https://www.ema.europa.eu/en/documents/other/letter-ema-conditions-making-available-reports-suspected-adverse-reactions-ema-whoumc_en.pdf"},
    {"id":"49466","name":"Response from WHO to letter from EMA on conditions for making available reports of suspected adverse reactions by EMA to WHO/UMC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-08T12:00:00Z","last_updated_date":"2020-12-08T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/response-who-letter-ema-conditions-making-available-reports-suspected-adverse-reactions-ema-whoumc_en.pdf"},
    {"id":"49467","name":"Response from UMC to letter from EMA on conditions for making available reports of suspected adverse reactions by EMA to WHO/UMC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-08T12:00:00Z","last_updated_date":"2020-12-08T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/response-umc-letter-ema-conditions-making-available-reports-suspected-adverse-reactions-ema-whoumc_en.pdf"},
    {"id":"49485","name":"Privacy statement concerning European Medicines Agency’s public stakeholder meetings on COVID-19 vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-09T10:45:00Z","last_updated_date":"2020-12-09T10:45:00Z","reference_number":"EMA/669919/2020","document_url":"https://www.ema.europa.eu/en/documents/other/privacy-statement-concerning-european-medicines-agencys-public-stakeholder-meetings-covid-19-vaccines_en.pdf"},
    {"id":"49549","name":"List of participants of the EMA Roundtable with Stakeholders on the 15-year anniversary of the SME regulation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T10:19:00Z","last_updated_date":"2020-12-15T10:19:00Z","reference_number":"EMA/669499/2020","document_url":"https://www.ema.europa.eu/en/documents/other/list-participants-ema-roundtable-stakeholders-15-year-anniversary-sme-regulation_en.pdf"},
    {"id":"49550","name":"Outcome of SME office survey on the implementation of the SME regulation - Commission Regulation (EC) No 2049/2005","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T12:00:00Z","last_updated_date":"2020-12-15T12:00:00Z","reference_number":"EMA/277477/2020","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-sme-office-survey-implementation-sme-regulation-commission-regulation-ec-no-20492005_en.pdf-0"},
    {"id":"49605","name":"European Medicines Agency privacy statement for the publication of post-employment decisions regarding senior staff (Article 16 of Staff Regulations)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T13:45:00Z","last_updated_date":"2020-12-18T13:45:00Z","reference_number":"EMA/641439/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-privacy-statement-publication-post-employment-decisions-regarding-senior-staff-article-16-staff-regulations_en.pdf"},
    {"id":"49608","name":"Record of data processing activity for the publication of post-employment decisions regarding senior staff (Article 16 of Staff Regulations)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T13:45:00Z","last_updated_date":"2020-12-18T13:45:00Z","reference_number":"EMA/641437/2020","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-publication-post-employment-decisions-regarding-senior-staff-article-16-staff-regulations_en.pdf"},
    {"id":"49609","name":"Prof. Guido Rasi - Assessment outcome of occupational activities after leaving the service (April 2021)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T14:24:00Z","last_updated_date":"2021-04-30T14:24:00Z","reference_number":"EMA/241188/2021","document_url":"https://www.ema.europa.eu/en/documents/other/prof-guido-rasi-assessment-outcome-occupational-activities-after-leaving-service-april-2021_en.pdf"},
    {"id":"49656","name":"Financial compensation and workload estimation of the EMA organisation of translations of product related information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T09:40:00Z","last_updated_date":"2020-12-21T09:40:00Z","reference_number":"EMA/MB/623265/2020","document_url":"https://www.ema.europa.eu/en/documents/other/financial-compensation-and-workload-estimation-ema-organisation-translations-product-related-information_en.pdf-0"},
    {"id":"49657","name":"Outcome of written procedures finalised during the period from 16 September 2020 to 26 November 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T09:41:00Z","last_updated_date":"2020-12-21T09:41:00Z","reference_number":"EMA/MB/640539/2020","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-16-september-2020-26-november-2020_en.pdf"},
    {"id":"49658","name":"Summary of transfers of appropriations in budget 2020 - Management Board meeting of 16-17 December 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T09:41:00Z","last_updated_date":"2020-12-21T09:41:00Z","reference_number":"EMA/MB/585327/2020","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2020-management-board-meeting-16-17-december-2020_en.pdf"},
    {"id":"49662","name":"EMA’s API general terms and conditions of use - Terms of use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T11:31:00Z","last_updated_date":"2026-06-03T12:00:00Z","reference_number":"EMA/187718/2018","document_url":"https://www.ema.europa.eu/en/documents/other/emas-api-general-terms-conditions-use-terms-use_en.pdf"},
    {"id":"49692","name":"Essential maintenance on 31/12/2020 and 01/01/2021 - Affected systems","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-23T13:45:00Z","last_updated_date":"2020-12-23T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/essential-maintenance-31122020-and-01012021-affected-systems_en.pdf"},
    {"id":"49728","name":"All applications received to speak (interventions from the application form) - EMA public stakeholder meeting on COVID-19","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-06T11:04:00Z","last_updated_date":"2023-07-13T17:19:00Z","reference_number":"EMA/628119/2020 Corr.","document_url":"https://www.ema.europa.eu/en/documents/other/all-applications-received-speak-interventions-application-form-ema-public-stakeholder-meeting-covid-19_en.pdf"}    {"id":"49758","name":"Comirnaty - Product Information as approved by the CHMP on 8 January 2021, pending endorsement by the European Commission","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-08T12:00:00Z","last_updated_date":"2021-01-08T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-product-information-approved-chmp-8-january-2021-pending-endorsement-european-commission_en.pdf"},
    {"id":"49787","name":"List of attendees - EMA public stakeholder meeting on the approval and roll-out of COVID-19 vaccines in the EU","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-12T17:36:00Z","last_updated_date":"2021-01-12T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-attendees-ema-public-stakeholder-meeting-approval-and-roll-out-covid-19-vaccines-eu_en.pdf"},
    {"id":"49809","name":"PRAC statistics: January 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-15T12:00:00Z","last_updated_date":"2021-01-18T09:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/prac-statistics-january-2021_en.pdf"},
    {"id":"49819","name":"Declaration of interests: Roelof Otterspeer","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T14:00:00Z","last_updated_date":"2025-08-01T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-roelof-otterspeer_en.pdf"},
    {"id":"49833","name":"Declaration of interests: Stephen Donnelly","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T17:30:00Z","last_updated_date":"2025-08-01T12:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-stephen-donnelly_en.pdf"},
    {"id":"49834","name":"Declaration of interests: Taavi Pehme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T17:30:00Z","last_updated_date":"2024-07-26T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-taavi-pehme_en.pdf"},
    {"id":"49835","name":"Declaration of interests: Christoph Pillichshammer","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-19T14:00:00Z","last_updated_date":"2023-05-30T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-christoph-pillichshammer_en.pdf"},
    {"id":"49910","name":"Assent / Informed consent guidance for paediatric clinical trials with medicinal products in Europe","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-26T15:50:00Z","last_updated_date":"2021-01-26T15:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/assent-informed-consent-guidance-paediatric-clinical-trials-medicinal-products-europe_en.pdf"},
    {"id":"49914","name":"Presentation - Team NB's perspective on life cycle management under Article 117 / MDR (Petra van Leeuwen, Colm O’Rourke)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T17:27:00Z","last_updated_date":"2021-01-22T17:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/presentation-team-nbs-perspective-life-cycle-management-under-article-117-mdr-petra-van-leeuwen-colm-orourke_en.pdf"},
    {"id":"49930","name":"European Medicines Agency’s privacy statement for user research for the design of the Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-25T12:11:00Z","last_updated_date":"2021-01-25T12:11:00Z","reference_number":"EMA/11841/2021 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-user-research-design-union-product-database_en.pdf"},
    {"id":"49931","name":"Records of data processing activity for user research for the design of the Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-01-25T12:11:00Z","last_updated_date":"2021-01-25T12:11:00Z","reference_number":"EMA/549249/2020","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-user-research-design-union-product-database_en.pdf"},
    {"id":"49942","name":"Policy 82: Union Product Database (UPD) Access Policy - Veterinary Medicinal Products","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2021-01-27T14:46:00Z","last_updated_date":"2026-04-01T16:30:00Z","reference_number":"EMA/354254/2025","document_url":"https://www.ema.europa.eu/en/documents/other/policy-82-union-product-database-upd-access-policy-veterinary-medicinal-products_en.pdf"},
    {"id":"50007","name":"Joining a WebEx meeting as a logged-in user: Instructions for EU Regulatory Network Users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-01T10:16:00Z","last_updated_date":"2021-08-02T17:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/joining-webex-meeting-logged-user-instructions-eu-regulatory-network-users_en.pdf"},
    {"id":"50020","name":"Clinical Trials Information System (CTIS) training - Information update on progress","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-01T14:28:00Z","last_updated_date":"2021-02-01T14:28:00Z","reference_number":"EMA/44466/2021","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trials-information-system-ctis-training-information-update-progress_en.pdf"},
    {"id":"50028","name":"Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-02T12:04:00Z","last_updated_date":"2026-05-13T15:30:00Z","reference_number":"EMA/51610/2021 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-initial-full-marketing-authorisation-application-accelerated-assessment-timetables-advanced-therapy-medicinal-product-atmp_en.xlsx"},
    {"id":"50058","name":"Questions and answers on the pilot project 'OPEN'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-04T12:00:00Z","last_updated_date":"2021-02-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-pilot-project-open_en.pdf"},
    {"id":"50067","name":"Timetable: Accelerated assessment request for initial marketing authorisations - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-04T16:41:00Z","last_updated_date":"2026-05-13T15:00:00Z","reference_number":"EMA/69089/2021 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-accelerated-assessment-request-initial-marketing-authorisations-atmp_en.xlsx"},
    {"id":"50068","name":"Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-04T16:41:00Z","last_updated_date":"2024-04-18T10:13:00Z","reference_number":"EMA/51610/2021 - Rev 3","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-initial-full-marketing-authorisation-application-accelerated-assessment-timetables-advanced-therapy-medicinal-product-atmp_en.xlsx-0"},
    {"id":"50073","name":"Questions and answers on GMP requirements applicable to the early manufacturing steps for comminuted plants and herbal extracts used as active substances","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-05T15:25:00Z","last_updated_date":"2021-02-05T15:25:00Z","reference_number":"EMA/INS/GMP/48514/2021","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-gmp-requirements-applicable-early-manufacturing-steps-comminuted-plants-and-herbal-extracts-used-active-substances_en.pdf"},
    {"id":"50078","name":"FAQs: Introduction to the Clinical Trials Regulation (EU) No 536/2014 - CTIS Training Programme - Module 01","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2025-02-18T11:45:00Z","reference_number":"Version 1.3 – February 2025","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-introduction-clinical-trials-regulation-eu-no-536-2014-ctis-training-programme-module-01_en.pdf"},
    {"id":"50079","name":"FAQs: Overview of CTIS workspaces and common system functionalities - CTIS Training Programme - Module 02","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2022-03-02T15:50:00Z","reference_number":"Version 1.2 January 2022","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-overview-ctis-workspaces-and-common-system-functionalities-ctis-training-programme-module-02_en.pdf"},
    {"id":"50081","name":"FAQs: Support with workload management by workspace - CTIS Training Programme - Module 04","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2026-06-26T13:50:00Z","reference_number":"Version 1.4","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-support-workload-management-workspace-ctis-training-programme-module-04_en.pdf"},
    {"id":"50083","name":"FAQs: How to evaluate a CT application - CTIS Training Programme - Module 06","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2022-10-05T08:46:00Z","reference_number":"Version 1.4 - September 2022","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-how-evaluate-ct-application-ctis-training-programme-module-06_en.pdf"},
    {"id":"50084","name":"FAQs: Management roles and permissions - CTIS Training Programme - Module 07","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2022-11-08T15:20:00Z","reference_number":"Version 1.3– October 2022","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-management-roles-and-permissions-ctis-training-programme-module-07_en.pdf"},
    {"id":"50085","name":"FAQs: How to evaluate an Initial Clinical Trial Application: Assessment and Decision - CTIS Training Programme - Module 08","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2022-05-17T11:00:00Z","reference_number":"Version 1.5 - May 2022","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-how-evaluate-initial-clinical-trial-application-assessment-and-decision-ctis-training-programme-module-08_en.pdf"},
    {"id":"50088","name":"Instructor's guide: Introduction to the Clinical Trials Regulation (EU) No 536/2014 - CTIS Training Programme - Module 01","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2022-03-08T11:35:00Z","reference_number":"Version 1.3 February 2022","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-introduction-clinical-trials-regulation-eu-no-5362014-ctis-training-programme-module-01_en.pdf"},
    {"id":"50089","name":"Instructor's guide: Overview of CTIS workspaces and common system functionalities - CTIS Training Programme - Module 02","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2022-03-02T15:54:00Z","reference_number":"Version  1.2 - January 2022","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-overview-ctis-workspaces-and-common-system-functionalities-ctis-training-programme-module-02_en.pdf"},
    {"id":"50091","name":"Instructor's guide: Support with workload management by workspace - CTIS Training Programme - Module 04","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2021-11-15T09:20:00Z","reference_number":"Version 1.2 September 2021","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-support-workload-management-workspace-ctis-training-programme-module-04_en.pdf"},
    {"id":"50093","name":"Instructor's guide: How to evaluate a CT application - CTIS Training Programme - Module 06","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2022-01-21T11:09:00Z","reference_number":"Version  1.2 - January 2022","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-how-evaluate-ct-application-ctis-training-programme-module-06_en.pdf"},
    {"id":"50094","name":"Instructor's guide: Management roles and permissions - CTIS Training Programme - Module 07","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2022-03-15T09:17:00Z","reference_number":"Version 1.2. February 2022","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-management-roles-and-permissions-ctis-training-programme-module-07_en.pdf"},
    {"id":"50095","name":"Instructor's guide: How to evaluate an Initial Clinical Trial Application: Assessment and Decision - CTIS Training Programme - Module 08","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2022-01-19T17:14:00Z","reference_number":"Version 1.2 - September 2021","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-how-evaluate-initial-clinical-trial-application-assessment-and-decision-ctis-training-programme-module-08_en.pdf"},
    {"id":"50098","name":"Quick guide: Overview of CTIS workspaces and common system functionalities - CTIS Training Programme - Module 02","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-09T11:31:00Z","last_updated_date":"2022-03-02T15:43:00Z","reference_number":"Version 1.2 - January 2022","document_url":"https://www.ema.europa.eu/en/documents/other/quick-guide-overview-ctis-workspaces-and-common-system-functionalities-ctis-training-programme-module-02_en.pdf"},
    {"id":"50100","name":"Infographic: The Clinical Trials Regulation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-08T16:01:00Z","last_updated_date":"2022-03-08T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/infographic-clinical-trials-regulation_en.pdf"},
    {"id":"50183","name":"Audit checklist - Interpretation guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-16T12:16:00Z","last_updated_date":"2021-02-16T12:16:00Z","reference_number":"EMA/92823/2021","document_url":"https://www.ema.europa.eu/en/documents/other/audit-checklist-interpretation-guide_en.pdf"},
    {"id":"50232","name":"Speaker bios - SME and Academia Clinical Trials Information System (CTIS) two-part training webinar","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-18T14:51:00Z","last_updated_date":"2021-03-03T16:10:00Z","reference_number":"EMA/102023/2021","document_url":"https://www.ema.europa.eu/en/documents/other/speaker-bios-sme-and-academia-clinical-trials-information-system-ctis-two-part-training-webinar_en.pdf"},
    {"id":"50233","name":"Product Management Service (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 8 Annex I: Complete representation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-22T10:50:00Z","last_updated_date":"2022-07-27T15:58:00Z","reference_number":"EMA/372009/2020 Version 2.1.1","document_url":"https://www.ema.europa.eu/en/documents/other/product-management-service-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-8-annex-i-complete-representation_en.pdf"},
    {"id":"50242","name":"Pilot phase for CHMP early contact with patient / consumer organisations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-19T10:07:00Z","last_updated_date":"2021-02-19T10:07:00Z","reference_number":"EMA/97615/20212021","document_url":"https://www.ema.europa.eu/en/documents/other/pilot-phase-chmp-early-contact-patient-consumer-organisations_en.pdf"},
    {"id":"50254","name":"Records of data processing activity for workstation ergonomics in the context of Health & Safety of staff and contractors","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-02-22T14:30:00Z","last_updated_date":"2025-11-13T09:02:00Z","reference_number":"EMA/47432/2021","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-workstation-ergonomics-context-health-safety-staff-contractors_en.pdf"},
    {"id":"50370","name":"LifeGlobal Media - Procedural steps and scientific information after initial consultation (archive)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-08T12:43:00Z","last_updated_date":"2025-07-24T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/lifeglobal-media-procedural-steps-scientific-information-after-initial-consultation-archive_en.pdf"},
    {"id":"50397","name":"Clinical Trials Information System (CTIS) common features - CTIS Training Programme - Module 02","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T09:31:00Z","last_updated_date":"2024-06-18T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trials-information-system-ctis-common-features-ctis-training-programme-module-02_en.pdf"},
    {"id":"50443","name":"Pilot project ‘Market Launch Intentions of Centrally Authorised Products’ - practical questions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:00:00Z","last_updated_date":"2021-03-05T14:00:00Z","reference_number":"EMA/90075/2021","document_url":"https://www.ema.europa.eu/en/documents/other/pilot-project-market-launch-intentions-centrally-authorised-products-practical-questions-and-answers_en.pdf"},
    {"id":"50502","name":"Answers to knowledge check from the post-event survey - SME and Academia Clinical Trials Information System (CTIS) two-part training webinar","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:30:00Z","last_updated_date":"2021-03-10T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/answers-knowledge-check-post-event-survey-sme-and-academia-clinical-trials-information-system-ctis-two-part-training-webinar_en.pdf"},
    {"id":"50503","name":"Quick guide - Introduction: How to evaluate an Initial Clinical Trial Application: Assessment and Decision - CTIS Training Programme - Module 08","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:37:00Z","last_updated_date":"2022-06-03T15:30:00Z","reference_number":"Version 1.3 – May 2022","document_url":"https://www.ema.europa.eu/en/documents/other/quick-guide-introduction-how-evaluate-initial-clinical-trial-application-assessment-and-decision-ctis-training-programme-module-08_en.pdf"},
    {"id":"50504","name":"Quick guide - Decision: How to evaluate an Initial Clinical Trial Application: Assessment and Decision - CTIS Training Programme - Module 08","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:37:00Z","last_updated_date":"2022-06-03T15:30:00Z","reference_number":"Version 1.5 May 2022","document_url":"https://www.ema.europa.eu/en/documents/other/quick-guide-decision-how-evaluate-initial-clinical-trial-application-assessment-and-decision-ctis-training-programme-module-08_en.pdf"},
    {"id":"50505","name":"Quick guide - Part I : How to evaluate a clinical trial application: assessment and decision - CTIS Training Programme - Module 08","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:37:00Z","last_updated_date":"2022-10-24T15:30:00Z","reference_number":"Version 1.4 – September 2022","document_url":"https://www.ema.europa.eu/en/documents/other/quick-guide-part-i-how-evaluate-clinical-trial-application-assessment-and-decision-ctis-training-programme-module-08_en.pdf"},
    {"id":"50506","name":"Quick guide - Part II : How to evaluate a clinical trial application: assessment and decision - CTIS Training Programme - Module 08","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:37:00Z","last_updated_date":"2022-10-24T15:30:00Z","reference_number":"Version 1.4 – September 2022","document_url":"https://www.ema.europa.eu/en/documents/other/quick-guide-part-ii-how-evaluate-clinical-trial-application-assessment-and-decision-ctis-training-programme-module-08_en.pdf"},
    {"id":"50536","name":"Answers to knowledge check in the post event survey - SME and Academia Clinical Trials Information System (CTIS) two-part training webinar","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T12:35:00Z","last_updated_date":"2021-03-12T12:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/answers-knowledge-check-post-event-survey-sme-and-academia-clinical-trials-information-system-ctis-two-part-training-webinar_en.pdf-0"},
    {"id":"50542","name":"European Medicines Agency's anti-fraud strategy - revised March 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T14:54:00Z","last_updated_date":"2021-03-12T14:54:00Z","reference_number":"EMA/128273/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-anti-fraud-strategy-revised-march-2021_en.pdf"},
    {"id":"50560","name":"Labelling flexibilities for COVID-19 therapeutics","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-15T16:04:00Z","last_updated_date":"2024-01-30T17:01:00Z","reference_number":"EMA/35618/2021","document_url":"https://www.ema.europa.eu/en/documents/other/labelling-flexibilities-covid-19-therapeutics_en.pdf"},
    {"id":"50631","name":"Substance, Product, Organisation, Referentials (SPOR) API v2 Specification (01.02)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T17:35:00Z","last_updated_date":"2021-03-17T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/substance-product-organisation-referentials-spor-api-v2-specification-0102_en.pdf"},
    {"id":"50632","name":"UPD Production release notes for version 01.02 March 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T17:35:00Z","last_updated_date":"2021-03-17T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/upd-production-release-notes-version-0102-march-2021_en.pdf"},
    {"id":"50633","name":"UPD example files (01.02)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T17:35:00Z","last_updated_date":"2021-03-17T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/upd-example-files-0102_en.zip"},
    {"id":"50634","name":"UPD use cases (01.02)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T17:35:00Z","last_updated_date":"2021-03-17T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/upd-use-cases-0102_en.zip"},
    {"id":"50654","name":"EMA medical terms simplifier","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-19T12:10:00Z","last_updated_date":"2022-05-25T09:37:00Z","reference_number":"EMA/329258/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/ema-medical-terms-simplifier_en.pdf"},
    {"id":"50693","name":"Speakers - European Medicines Agency / AnimalhealthEurope veterinary medicines info day 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-24T16:14:00Z","last_updated_date":"2021-03-24T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-european-medicines-agency-animalhealtheurope-veterinary-medicines-info-day-2021_en.pdf"},
    {"id":"50725","name":"Reply to open letter concerning vaccines for COVID-19","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-26T09:33:00Z","last_updated_date":"2021-03-26T09:33:00Z","reference_number":"EMA/140520/2021","document_url":"https://www.ema.europa.eu/en/documents/other/reply-open-letter-concerning-vaccines-covid-19_en.pdf"},
    {"id":"50730","name":"Committee for Orphan Medicinal Products (COMP) meetings 2022, 2023 and 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-26T14:10:00Z","last_updated_date":"2021-03-26T14:10:00Z","reference_number":"EMA/COMP/182675/2021","document_url":"https://www.ema.europa.eu/en/documents/other/committee-orphan-medicinal-products-comp-meetings-2022-2023-and-2024_en.pdf"},
    {"id":"50742","name":"Declaration of interests: Pierre Pradal","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-03-30T14:30:00Z","last_updated_date":"2022-06-30T17:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-pierre-pradal_en.pdf"},
    {"id":"50772","name":"Records of data processing activity for the handling the contribution towards commuting costs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-04-07T12:26:00Z","last_updated_date":"2026-03-04T12:26:00Z","reference_number":"EMA/2681/2021","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-handling-contribution-towards-commuting-costs_en.pdf"},
    {"id":"50794","name":"Highlights from the Nitrosamine Implementation Oversight Group (NIOG) - industry stakeholders meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-04-12T15:48:00Z","last_updated_date":"2021-04-12T15:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-nitrosamine-implementation-oversight-group-niog-industry-stakeholders-meeting_en.pdf"},
    {"id":"50796","name":"(Superseded) European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) web-based sales and animal population data collection protocol (2019)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T11:36:00Z","last_updated_date":"2019-07-16T12:36:00Z","reference_number":"EMA/210691/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-european-surveillance-veterinary-antimicrobial-consumption-esvac-web-based-sales-and-animal-population-data-collection-protocol-2019_en.pdf"},
    {"id":"50798","name":"(Superseded) European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) web-based sales and animal population data collection protocol (2020)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2019-07-16T11:39:00Z","last_updated_date":"2020-06-19T12:01:00Z","reference_number":"EMA/210691/2015 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-european-surveillance-veterinary-antimicrobial-consumption-esvac-web-based-sales-and-animal-population-data-collection-protocol-2020_en.pdf"},
    {"id":"50802","name":"(Superseded) European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) web-based data collection form (2016)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T12:28:00Z","last_updated_date":"2016-06-20T12:37:00Z","reference_number":"EMA/377366/2016 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-european-surveillance-veterinary-antimicrobial-consumption-esvac-web-based-data-collection-form-2016_en.xlsx"},
    {"id":"50803","name":"(Superseded) European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) web-based data collection form (2020)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-06-20T12:30:00Z","last_updated_date":"2020-06-12T12:57:00Z","reference_number":"EMA/307386/2020 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-european-surveillance-veterinary-antimicrobial-consumption-esvac-web-based-data-collection-form-2020_en.xlsx"},
    {"id":"50852","name":"Common Commentary - EMA/FDA: Common issues requested for discussion by the respective agency (EMA/PDCO and FDA) concerning paediatric oncology development plans (Paediatric Investigation Plans [PIPs] and initial Pediatric Study Plans [iPSPs])","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-04-15T10:57:00Z","last_updated_date":"2021-04-15T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/common-commentary-emafda-common-issues-requested-discussion-respective-agency-emapdco-and-fda-concerning-paediatric-oncology-development-plans-paediatric-investigation-plans-pips-and-initial-pediatric_en.pdf"},
    {"id":"50975","name":"Questions and answers on the principles of GMP for the manufacturing of starting materials of biological origin used to transfer genetic material for the manufacturing of ATMPs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-04-23T17:28:00Z","last_updated_date":"2021-04-23T17:28:00Z","reference_number":"EMA/246400/2021","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-principles-gmp-manufacturing-starting-materials-biological-origin-used-transfer-genetic-material-manufacturing-atmps_en.pdf"},
    {"id":"51003","name":"Academia collaboration matrix action plan 2021-2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T15:10:00Z","last_updated_date":"2021-04-30T15:10:00Z","reference_number":"EMA/159144/2021","document_url":"https://www.ema.europa.eu/en/documents/other/academia-collaboration-matrix-action-plan-2021-2023_en.pdf"},
    {"id":"51025","name":"Prof. Guido Rasi - Assessment outcome of occupational activities after leaving the service (December 2020)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T13:45:00Z","last_updated_date":"2020-12-18T13:45:00Z","reference_number":"EMA/676912/2020","document_url":"https://www.ema.europa.eu/en/documents/other/prof-guido-rasi-assessment-outcome-occupational-activities-after-leaving-service-december-2020_en.pdf"},
    {"id":"51096","name":"Working arrangement between EMA, Directorate-General Health and Food Safety (DG SANTE) and the Brazilian Health Regulatory Agency (ANVISA) for the exchange of non-public information on medical/medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-06T14:07:00Z","last_updated_date":"2021-05-06T14:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/working-arrangement-between-ema-directorate-general-health-and-food-safety-dg-sante-and-brazilian-health-regulatory-agency-anvisa-exchange-non-public-information-medicalmedicinal-products_en.pdf"},
    {"id":"51186","name":"FAQs: Supervise a CT: corrective measures - CTIS training programme - Module 14","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-19T14:47:00Z","last_updated_date":"2022-01-20T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-supervise-ct-corrective-measures-ctis-training-programme-module-14_en.pdf"},
    {"id":"51188","name":"Instructor’s guide: Supervise a CT: corrective measures - CTIS training programme - Module 14","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-19T14:50:00Z","last_updated_date":"2022-01-20T15:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-supervise-ct-corrective-measures-ctis-training-programme-module-14_en.pdf"},
    {"id":"51190","name":"Step-by-step guide: Supervise a CT: corrective measures - CTIS training programme - Module 14","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-19T14:52:00Z","last_updated_date":"2022-01-20T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-supervise-ct-corrective-measures-ctis-training-programme-module-14_en.pdf"},
    {"id":"51195","name":"CTIS training - List of acronyms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-20T14:36:00Z","last_updated_date":"2021-05-20T14:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctis-training-list-acronyms_en.pdf"},
    {"id":"51285","name":"Reply to open letter to ‘Doctors for COVID ethics’ concerning COVID-19 vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-27T15:22:00Z","last_updated_date":"2021-05-27T15:22:00Z","reference_number":"EMA/292405/2021","document_url":"https://www.ema.europa.eu/en/documents/other/reply-open-letter-doctors-covid-ethics-concerning-covid-19-vaccines_en.pdf"},
    {"id":"51288","name":"Records of data processing activity regarding Small and Medium Enterprises (SME) status applications submitted by natural persons","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-27T16:22:00Z","last_updated_date":"2021-05-27T16:22:00Z","reference_number":"EMA/49053/2021","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regarding-small-medium-enterprises-sme-status-applications-submitted-natural-persons_en.pdf"},
    {"id":"51291","name":"European Medicines Agency's privacy statement for SME status applications submitted by natural persons","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-28T12:15:00Z","last_updated_date":"2021-05-28T12:15:00Z","reference_number":"EMA/550671/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-sme-status-applications-submitted-natural-persons_en.pdf"},
    {"id":"51292","name":"From collection to connection – the EMA veterinary data strategy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-28T14:25:00Z","last_updated_date":"2021-05-28T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/collection-connection-ema-veterinary-data-strategy_en.pdf"},
    {"id":"51322","name":"HMPC meetings in 2022, 2023 and 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-01T10:21:00Z","last_updated_date":"2021-06-01T10:21:00Z","reference_number":"EMA/HMPC/559729/2020","document_url":"https://www.ema.europa.eu/en/documents/other/hmpc-meetings-2022-2023-and-2024_en.pdf"},
    {"id":"51323","name":"DARWIN EU Advisory Board: Mandate","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-04T10:22:00Z","last_updated_date":"2023-07-27T16:27:00Z","reference_number":"EMA/272563/2023","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-advisory-board-mandate_en.pdf"},
    {"id":"51356","name":"Reflection paper on forecasting demand for medicinal products in the EU/EEA","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2021-06-03T16:22:00Z","last_updated_date":"2021-06-03T16:22:00Z","reference_number":"EMA/162549/2021","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-forecasting-demand-medicinal-products-eueea_en.pdf"},
    {"id":"51363","name":"Annex 1 -  Field level specification","type":"other","status":"Draft","consultation_date":"","first_published_date":"2021-06-04T14:31:00Z","last_updated_date":"2021-11-23T15:47:00Z","reference_number":"Version 2.7","document_url":"https://www.ema.europa.eu/en/documents/other/annex-1-field-level-specification_en.pdf"},
    {"id":"51364","name":"Annex 2 - EVVET3 Business rules","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-04T14:14:00Z","last_updated_date":"2022-06-01T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-2-evvet3-business-rules_en.xls"},
    {"id":"51365","name":"Annex 1 - XML file examples","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-04T14:31:00Z","last_updated_date":"2021-11-23T15:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-1-xml-file-examples_en.zip"},
    {"id":"51385","name":"Frequently asked questions about parallel distribution","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-09T15:59:00Z","last_updated_date":"2025-10-15T09:08:00Z","reference_number":"EMA/303963/2025 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/other/frequently-asked-questions-about-parallel-distribution_en.pdf"},
    {"id":"51416","name":"Letter of support for Mobilise-D digital mobility outcomes as monitoring biomarkers - Follow-up","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T11:33:00Z","last_updated_date":"2021-06-11T11:33:00Z","reference_number":"EMA/CHMP/SAWP/277641/2021","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-mobilise-d-digital-mobility-outcomes-monitoring-biomarkers-follow_en.pdf"},
    {"id":"51433","name":"Declaration of interests: Patricia Almeida","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-14T17:45:00Z","last_updated_date":"2021-06-14T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-patricia-almeida_en.pdf"},
    {"id":"51438","name":"European Medicines Agency’s privacy statement for the usability testing of the restricted area of the Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-15T14:24:00Z","last_updated_date":"2021-06-15T14:24:00Z","reference_number":"EMA/309427/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-usability-testing-restricted-area-union-product-database_en.pdf"},
    {"id":"51439","name":"Records of data processing activity for user research for the design of the restricted area of the Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-15T14:27:00Z","last_updated_date":"2021-06-15T14:27:00Z","reference_number":"EMA/169242/2021","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-user-research-design-restricted-area-union-product-database_en.pdf"},
    {"id":"51496","name":"Management Board meeting dates 2022-2023","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T16:38:00Z","last_updated_date":"2021-06-18T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2022-2023_en.pdf"},
    {"id":"51516","name":"PRAC meetings in 2022, 2023 and 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-21T15:22:00Z","last_updated_date":"2023-02-24T14:24:00Z","reference_number":"EMA/PRAC/349103/2021 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/other/prac-meetings-2022-2023-and-2024_en.pdf"},
    {"id":"51560","name":"Guide to CTIS training material catalogue","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-23T15:25:00Z","last_updated_date":"2025-07-09T17:58:00Z","reference_number":"Version 2 – July 2025","document_url":"https://www.ema.europa.eu/en/documents/other/guide-ctis-training-material-catalogue_en.pdf"},
    {"id":"51561","name":"Step-by-step guide (high level CTIS administrator): Management of roles and permissions - CTIS training programme - Module 07","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-23T15:25:00Z","last_updated_date":"2022-11-08T15:20:00Z","reference_number":"Version 1.3 October 2022","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-high-level-ctis-administrator-management-roles-and-permissions-ctis-training-programme-module-07_en.pdf"},
    {"id":"51564","name":"CAT meetings in 2022, 2023 and 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-23T16:21:00Z","last_updated_date":"2021-06-23T16:21:00Z","reference_number":"EMA/CAT/354666/2021","document_url":"https://www.ema.europa.eu/en/documents/other/cat-meetings-2022-2023-and-2024_en.pdf"},
    {"id":"51595","name":"Strengthening Training of Academia in Regulatory Science (STARS) overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-24T17:02:00Z","last_updated_date":"2021-06-24T17:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/strengthening-training-academia-regulatory-science-stars-overview_en.pdf"},
    {"id":"51596","name":"Simultaneous National Scientific Advice pilot project","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-24T17:01:00Z","last_updated_date":"2021-06-24T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/simultaneous-national-scientific-advice-pilot-project_en.pdf"},
    {"id":"51694","name":"Annual list of contractors 2020 - contract values Euro 15,000 - 139,000","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-30T16:46:00Z","last_updated_date":"2021-06-30T16:46:00Z","reference_number":"EMA/352493/2020","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contractors-2020-contract-values-euro-15000-139000_en.pdf"},
    {"id":"51695","name":"Annual list of specific contracts based on framework contracts - 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-30T16:47:00Z","last_updated_date":"2021-06-30T16:47:00Z","reference_number":"EMA/352492/2020","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-specific-contracts-based-framework-contracts-2020_en.pdf"},
    {"id":"51696","name":"Annual list of contract modifications 2020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-06-30T16:48:00Z","last_updated_date":"2021-06-30T16:48:00Z","reference_number":"EMA/226414/2020","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contract-modifications-2020_en.pdf"},
    {"id":"51821","name":"Quick guide: How to search, view and download a Clinical Trial and a Clinical Trial Application (authority)  - CTIS Training Programme - Module 15","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T09:45:00Z","last_updated_date":"2022-01-20T16:23:00Z","reference_number":"Version 1.2 - October 2021","document_url":"https://www.ema.europa.eu/en/documents/other/quick-guide-how-search-view-and-download-clinical-trial-and-clinical-trial-application-authority-ctis-training-programme-module-15_en.pdf"},
    {"id":"51822","name":"FAQs: How to search, view and download a Clinical Trial and a Clinical Trial Application (authority) - CTIS Training Programme - Module 15","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T09:45:00Z","last_updated_date":"2022-01-20T15:46:00Z","reference_number":"Version 1.2 - December 2021","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-how-search-view-and-download-clinical-trial-and-clinical-trial-application-authority-ctis-training-programme-module-15_en.pdf"}    {"id":"51823","name":"Instructor's guide: How to search, view and download a Clinical Trial and a Clinical Trial Application (authority) - CTIS Training Programme - Module 15","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T09:45:00Z","last_updated_date":"2022-01-20T15:44:00Z","reference_number":"Version 1.2 - October 2021","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-how-search-view-and-download-clinical-trial-and-clinical-trial-application-authority-ctis-training-programme-module-15_en.pdf"},
    {"id":"51824","name":"Step-by-step guide: How to search, view and download a Clinical Trial and a Clinical Trial Application (authority) - CTIS Training Programme - Module 15","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T09:45:00Z","last_updated_date":"2022-01-20T15:40:00Z","reference_number":"Version 1.1 - December 2021","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-how-search-view-and-download-clinical-trial-and-clinical-trial-application-authority-ctis-training-programme-module-15_en.pdf"},
    {"id":"51854","name":"Instructor's guide: Supervise a Clinical Trial and a Clinical Trial: Inspection records - CTIS Training Programme - Module 16","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T15:24:00Z","last_updated_date":"2021-07-06T15:24:00Z","reference_number":"Version 1.1 - June 2021","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-supervise-clinical-trial-and-clinical-trial-inspection-records-ctis-training-programme-module-16_en.pdf"},
    {"id":"51856","name":"FAQs: Supervise a Clinical Trial : Inspection records - CTIS Training Programme - Module 16","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T15:24:00Z","last_updated_date":"2026-05-04T17:43:00Z","reference_number":"Version 1.3 - April 2026","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-supervise-clinical-trial-inspection-records-ctis-training-programme-module-16_en.pdf"},
    {"id":"51857","name":"Step-by-step guide: Supervise a Clinical Trial and a Clinical Trial: Inspection records - CTIS Training Programme - Module 16","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T15:24:00Z","last_updated_date":"2021-07-06T15:24:00Z","reference_number":"Version 1.1 - June 2021","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-supervise-clinical-trial-and-clinical-trial-inspection-records-ctis-training-programme-module-16_en.pdf"},
    {"id":"51859","name":"Process puzzle exercise : Supervise a Clinical Trial and a Clinical Trial: Inspection records - CTIS Training Programme - Module 16","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T15:24:00Z","last_updated_date":"2021-07-06T15:24:00Z","reference_number":"Version 1.1 - June 2021","document_url":"https://www.ema.europa.eu/en/documents/other/process-puzzle-exercise-supervise-clinical-trial-and-clinical-trial-inspection-records-ctis-training-programme-module-16_en.pptx"},
    {"id":"51887","name":"Speakers - Clinical Trials Information System (CTIS) webinar: How sponsor organisations can prepare for CTIS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-08T17:37:00Z","last_updated_date":"2021-07-27T17:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-clinical-trials-information-system-ctis-webinar-how-sponsor-organisations-can-prepare-ctis_en.pdf"},
    {"id":"51888","name":"FAQs: Supervise a Clinical Trial: Ad Hoc Assessment - CTIS Training Programme - Module 17","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T08:00:00Z","last_updated_date":"2024-08-14T17:53:00Z","reference_number":"Version 1.3 – August 2024","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-supervise-clinical-trial-ad-hoc-assessment-ctis-training-programme-module-17_en.pdf"},
    {"id":"51889","name":"Step-by-step guide: Supervise a Clinical Trial: Ad Hoc Assessment - CTIS Training Programme - Module 17","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T08:00:00Z","last_updated_date":"2024-08-14T17:50:00Z","reference_number":"Version 1.3 – August 2024","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-supervise-clinical-trial-ad-hoc-assessment-ctis-training-programme-module-17_en.pdf"},
    {"id":"51890","name":"Instructor's guide: Supervise a Clinical Trial: Ad Hoc Assessment - CTIS Training Programme - Module 17","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T08:00:00Z","last_updated_date":"2024-08-14T17:52:00Z","reference_number":"Version 1.3 – August 2024","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-supervise-clinical-trial-ad-hoc-assessment-ctis-training-programme-module-17_en.pdf"},
    {"id":"51913","name":"Key conclusions - Veterinary Big Data Stakeholder Forum","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-12T16:24:00Z","last_updated_date":"2021-07-12T16:24:00Z","reference_number":"EMA/379313/2021","document_url":"https://www.ema.europa.eu/en/documents/other/key-conclusions-veterinary-big-data-stakeholder-forum_en.pdf"},
    {"id":"51933","name":"European Medicines Agency’s privacy statement for the Industry Single Point of Contact (i-SPOC) system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-15T09:44:00Z","last_updated_date":"2021-07-15T09:44:00Z","reference_number":"EMA/222043/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-industry-single-point-contact-i-spoc-system_en.pdf"},
    {"id":"51934","name":"Records of data processing activity Industry Single Point of Contact (i-SPOC) reporting system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-15T09:53:00Z","last_updated_date":"2021-07-15T09:53:00Z","reference_number":"EMA/247394/2020","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-industry-single-point-contact-i-spoc-reporting-system_en.pdf"},
    {"id":"51975","name":"CHMP SWP opinion on diethanolamine and coconut oil diethanolamine condensate as excipients","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-20T16:46:00Z","last_updated_date":"2021-07-20T16:46:00Z","reference_number":"EMA/275956/2021","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-swp-opinion-diethanolamine-and-coconut-oil-diethanolamine-condensate-excipients_en.pdf"},
    {"id":"52097","name":"Implementation of comments received on 'Draft reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development'","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-27T11:12:00Z","last_updated_date":"2021-07-27T11:12:00Z","reference_number":"EMA/CHMP/310801/2021","document_url":"https://www.ema.europa.eu/en/documents/other/implementation-comments-received-draft-reflection-paper-statistical-methodology-comparative-assessment-quality-attributes-drug-development_en.pdf"},
    {"id":"52109","name":"UPD production release notes for version 01.03 July 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-28T09:42:00Z","last_updated_date":"2021-07-28T09:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/upd-production-release-notes-version-0103-july-2021-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"52110","name":"Production API and registration process - production release version 01.03 July 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-28T09:42:00Z","last_updated_date":"2021-07-28T17:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/production-api-and-registration-process-production-release-version-0103-july-2021-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"52111","name":"Example files - production release version 01.03 July 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-28T09:42:00Z","last_updated_date":"2021-07-28T09:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-0103-july-2021-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"52142","name":"Clinical Trial Information System (CTIS) - Sponsor handbook","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-29T10:40:00Z","last_updated_date":"2026-06-26T13:48:00Z","reference_number":"EMA/186412/2021 v. 6.3","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-sponsor-handbook_en.pdf"},
    {"id":"52154","name":"UAT registration process for API manager - production release version 01.03 July 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T09:21:00Z","last_updated_date":"2021-07-30T09:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/uat-registration-process-api-manager-production-release-version-0103-july-2021-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"52169","name":"Record of data processing activity for video-surveillance (CCTV) system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-08-02T16:49:00Z","last_updated_date":"2025-04-16T11:45:00Z","reference_number":"EMA/351947/2021","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-video-surveillance-cctv-system_en.pdf"},
    {"id":"52170","name":"European Medicines Agency’s Data Protection Notice for the operation of video-surveillance (CCTV) system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-08-02T16:51:00Z","last_updated_date":"2025-04-16T11:52:00Z","reference_number":"EMA/150897/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-operation-video-surveillance-cctv-system_en.pdf"},
    {"id":"52184","name":"Records of data processing activity for the Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-08-03T17:18:00Z","last_updated_date":"2026-04-01T16:30:00Z","reference_number":"EMA/318484/2021 – ver.3","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-union-product-database_en.pdf"},
    {"id":"52185","name":"European Medicines Agency’s data protection notice for the Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-08-03T17:19:00Z","last_updated_date":"2026-04-01T15:46:00Z","reference_number":"EMA/686248/2020 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-union-product-database_en.pdf"},
    {"id":"52227","name":"Records of data processing activity for personal data of staff or external experts processed in a procurement procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-08-17T09:42:00Z","last_updated_date":"2021-08-17T09:42:00Z","reference_number":"EMA/486119/2020","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-personal-data-staff-or-external-experts-processed-procurement-procedure_en.pdf"},
    {"id":"52261","name":"Mr Noel Wathion - Assessment outcome of occupational activities after leaving the service","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-08-24T15:57:00Z","last_updated_date":"2021-08-24T15:57:00Z","reference_number":"EMA/463295/2021","document_url":"https://www.ema.europa.eu/en/documents/other/mr-noel-wathion-assessment-outcome-occupational-activities-after-leaving-service_en.pdf"},
    {"id":"52337","name":"CVMP meeting dates 2022, 2023 and 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-03T15:43:00Z","last_updated_date":"2021-09-03T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cvmp-meeting-dates-2022-2023-and-2024_en.pdf"},
    {"id":"52350","name":"UPD production release notes for version 1.4.1-0 September 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-06T16:38:00Z","last_updated_date":"2021-09-06T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/upd-production-release-notes-version-141-0-september-2021-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"52386","name":"Summary report - Technical workshop on real-world metadata for regulatory purposes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-09T09:14:00Z","last_updated_date":"2021-09-09T09:14:00Z","reference_number":"EMA/139729/2021","document_url":"https://www.ema.europa.eu/en/documents/other/summary-report-technical-workshop-real-world-metadata-regulatory-purposes_en.pdf"},
    {"id":"52436","name":"New legal basis and authorisation procedure values available in the Article 57 database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-14T09:16:00Z","last_updated_date":"2021-09-14T09:16:00Z","reference_number":"EMA/501910/2021","document_url":"https://www.ema.europa.eu/en/documents/other/new-legal-basis-and-authorisation-procedure-values-available-article-57-database_en.pdf"},
    {"id":"52448","name":"Mandate, objectives and rules of procedure for the CVMP Veterinary Novel Therapies & Technologies Working Party (NTWP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-15T16:20:00Z","last_updated_date":"2021-09-15T16:20:00Z","reference_number":"EMA/CVMP/NTWP/706123/2020","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cvmp-veterinary-novel-therapies-technologies-working-party-ntwp_en.pdf"},
    {"id":"52460","name":"DARWIN EU Advisory Board: Membership","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T14:55:00Z","last_updated_date":"2026-03-11T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-advisory-board-membership_en.pdf"},
    {"id":"52584","name":"Online travel booking tool Cytric - FAQs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-23T15:47:00Z","last_updated_date":"2021-09-23T15:47:00Z","reference_number":"EMA/529224/2021","document_url":"https://www.ema.europa.eu/en/documents/other/online-travel-booking-tool-cytric-faqs_en.pdf"},
    {"id":"52615","name":"European Medicines Agency’s data protection notice for recording of telephone calls to the EMA official telephone number received at the EMA switchboard","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/542660/2020","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-recording-telephone-calls-ema-official-telephone-number-received-ema-switchboard_en.pdf"},
    {"id":"52653","name":"European Medicines Agency’s privacy statement for the clinical data publication website","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-28T15:56:00Z","last_updated_date":"2021-09-28T15:56:00Z","reference_number":"EMA/88784/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-clinical-data-publication-website_en.pdf"},
    {"id":"52664","name":"Standard term lists mapping from Data Elements Guideline (DEG) standard to VICH standard","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-30T17:30:00Z","last_updated_date":"2022-06-13T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/standard-term-lists-mapping-data-elements-guideline-deg-standard-vich-standard_en.xls"},
    {"id":"52665","name":"Field-by-field mapping from Data Elements Guideline (DEG) standard to VICH standard","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-30T17:31:00Z","last_updated_date":"2021-09-30T17:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/field-field-mapping-data-elements-guideline-deg-standard-vich-standard_en.xlsx"},
    {"id":"52685","name":"Policy 46: European Medicines Agency policy on video surveillance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-18T15:31:00Z","last_updated_date":"2025-11-03T16:04:00Z","reference_number":"EMA/181117/2025","document_url":"https://www.ema.europa.eu/en/documents/other/policy-46-european-medicines-agency-policy-video-surveillance_en.pdf"},
    {"id":"52687","name":"Clinical Trial Information System (CTIS) - Member state user personas","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-09-30T17:19:00Z","last_updated_date":"2021-09-30T17:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-member-state-user-personas_en.pdf"},
    {"id":"52691","name":"Declaration of interests: Monica Dias","type":"other","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T02:00:00Z","last_updated_date":"2025-08-01T13:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-monica-dias_en.pdf"},
    {"id":"52705","name":"UPD production release notes for version 1.4.2.0 October 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T16:00:00Z","last_updated_date":"2021-10-01T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/upd-production-release-notes-version-1420-october-2021-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"52715","name":"Procedural advice for requests for the classification of variations not already listed in Commission Implementing Regulation (EU) 2021/17 or EMA/CMDv guidance on the details of the classification of variations requiring assessment according to Article 62","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-04T15:20:00Z","last_updated_date":"2024-02-28T13:50:00Z","reference_number":"EMA/CMDv/144284/2021 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-advice-requests-classification-variations-not-already-listed-commission-implementing-regulation-eu-2021-17-or-ema-cmdv-guidance-details-classification-variations-requiring-assessment_en.pdf"},
    {"id":"52723","name":"Example files - production release version 01.04.02 October 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-05T11:16:00Z","last_updated_date":"2021-10-06T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-010402-october-2021-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"52735","name":"Annex I - Use of titanium dioxide as excipient in human medicines - Industry feedback to QWP Experts / EMA questions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-08T12:00:00Z","last_updated_date":"2021-10-08T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-i-use-titanium-dioxide-excipient-human-medicines-industry-feedback-qwp-experts-ema-questions_en.pdf"},
    {"id":"52736","name":"Annex II - Use of titanium dioxide as excipient in veterinary medicines - Industry feedback to QWP Experts / EMA questions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-08T12:00:00Z","last_updated_date":"2021-10-08T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-ii-use-titanium-dioxide-excipient-veterinary-medicines-industry-feedback-qwp-experts-ema-questions_en.pdf"},
    {"id":"52770","name":"Consultation procedure Public Assessment Report (CPAR) - Vitrolife IVF media","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-07T15:32:00Z","last_updated_date":"2021-10-07T15:32:00Z","reference_number":"EMA/CHMP/499319/2021","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-procedure-public-assessment-report-cpar-vitrolife-ivf-media_en.pdf"},
    {"id":"52771","name":"Vitrolife IVF media - Procedural steps and scientific information after initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-07T15:43:00Z","last_updated_date":"2025-03-05T13:00:00Z","reference_number":"EMA/CHMP/81378/20255 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/vitrolife-ivf-media-procedural-steps-scientific-information-after-initial-consultation_en.pdf"},
    {"id":"52782","name":"European Union Clinical Trials Information System CTIS: Go-live planning - Summary of key areas in preparation of the operation of CTIS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-08T15:00:00Z","last_updated_date":"2021-10-08T15:00:00Z","reference_number":"EMA/MB/473854/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-clinical-trials-information-system-ctis-go-live-planning-summary-key-areas-preparation-operation-ctis_en.pdf"},
    {"id":"52795","name":"Step-by-step guide : Assess an annual safety report - CTIS Training Programme - Module 20","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-11T15:30:00Z","last_updated_date":"2021-10-11T15:30:00Z","reference_number":"Version 1.1 - September 2021","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-assess-annual-safety-report-ctis-training-programme-module-20_en.pdf"},
    {"id":"52796","name":"Instructor's guide: Assess an annual safety report - CTIS Training Programme - Module 20","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-11T15:30:00Z","last_updated_date":"2021-10-11T15:30:00Z","reference_number":"Version 1.1 - September 2021","document_url":"https://www.ema.europa.eu/en/documents/other/instructors-guide-assess-annual-safety-report-ctis-training-programme-module-20_en.pdf"},
    {"id":"52797","name":"FAQs: Assess an annual safety report - CTIS Training Programme - Module 20","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-11T15:30:00Z","last_updated_date":"2021-10-11T15:30:00Z","reference_number":"Version 1.1 - September 2021","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-assess-annual-safety-report-ctis-training-programme-module-20_en.pdf"},
    {"id":"52798","name":"Crossword puzzle: How to assess an annual safety report - CTIS Training Programme - Module 20","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-11T15:30:00Z","last_updated_date":"2021-10-11T15:30:00Z","reference_number":"Version 1.0 - September 2021","document_url":"https://www.ema.europa.eu/en/documents/other/crossword-puzzle-how-assess-annual-safety-report-ctis-training-programme-module-20_en.pdf"},
    {"id":"52800","name":"Summary of transfers of appropriations in budget 2021 - Management Board meeting of 7 October 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-11T15:34:00Z","last_updated_date":"2021-10-11T15:34:00Z","reference_number":"EMA/MB/457657/2021","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2021-management-board-meeting-7-october-2021_en.pdf"},
    {"id":"52802","name":"Decision of the Management Board on amending budget No. 01, amending appropriations in budget 2021","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2021-10-11T15:36:00Z","last_updated_date":"2021-10-11T15:36:00Z","reference_number":"EMA/MB/458302/2021","document_url":"https://www.ema.europa.eu/en/documents/other/decision-management-board-amending-budget-no-01-amending-appropriations-budget-2021_en.pdf"},
    {"id":"52804","name":"Letter of support for International Niemann-Pick Disease Registry (INPDR)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-12T10:13:00Z","last_updated_date":"2021-10-12T10:13:00Z","reference_number":"EMA/206704/2021","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-international-niemann-pick-disease-registry-inpdr_en.pdf"},
    {"id":"52840","name":"Records of data processing activity for Clinical data publication website","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-14T13:51:00Z","last_updated_date":"2021-10-14T13:51:00Z","reference_number":"EMA/577572/2021","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-clinical-data-publication-website_en.pdf"},
    {"id":"52881","name":"Release notes - production release version 01.04.03 October 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-18T14:45:00Z","last_updated_date":"2021-10-18T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-010403-october-2021-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"52886","name":"Letter of support for Master Protocol for Type 1 diabetes prevention studies in INNODIA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-20T15:11:00Z","last_updated_date":"2021-10-20T15:11:00Z","reference_number":"EMADOC-1700519818-703684","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-master-protocol-type-1-diabetes-prevention-studies-innodia_en.pdf"},
    {"id":"52887","name":"Guidance on the electronic submission of information on investigational medicinal products for human use in the Extended EudraVigilance medicinal product dictionary (XEVMPD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-20T15:30:00Z","last_updated_date":"2026-04-20T17:45:00Z","reference_number":"EMA/186412/2021 v. 1.5","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-electronic-submission-information-investigational-medicinal-products-human-use-extended-eudravigilance-medicinal-product-dictionary-xevmpd_en.pdf"},
    {"id":"52888","name":"Electronic submission of investigational medicinal product (IMP) data to the Extended EudraVigilance medicinal product dictionary (XEVMPD) - Frequently asked questions and answers (FAQs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-20T15:32:00Z","last_updated_date":"2021-10-20T15:32:00Z","reference_number":"EMA/157035/2021","document_url":"https://www.ema.europa.eu/en/documents/other/electronic-submission-investigational-medicinal-product-imp-data-extended-eudravigilance-medicinal-product-dictionary-xevmpd-frequently-asked-questions-and-answers-faqs_en.pdf"},
    {"id":"52926","name":"Agnes Saint-Raymond - Assessment outcome of occupational activities after leaving the service (Sept 2021)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-27T17:32:00Z","last_updated_date":"2021-10-27T17:32:00Z","reference_number":"EMA/540433/2021","document_url":"https://www.ema.europa.eu/en/documents/other/agnes-saint-raymond-assessment-outcome-occupational-activities-after-leaving-service-sept-2021_en.pdf"},
    {"id":"52927","name":"Mr Noel Wathion - Assessment outcome of occupational activities after leaving the service (Oct 2021)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-27T17:48:00Z","last_updated_date":"2021-10-27T17:48:00Z","reference_number":"EMA/612369/2021","document_url":"https://www.ema.europa.eu/en/documents/other/mr-noel-wathion-assessment-outcome-occupational-activities-after-leaving-service-oct-2021_en.pdf"},
    {"id":"52928","name":"Question and Answers on repurposing pilot project on proposal for framework to support not-for-profit organisations and academia in repurposing authorised medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-28T12:45:00Z","last_updated_date":"2022-02-04T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/question-and-answers-repurposing-pilot-project-proposal-framework-support-not-profit-organisations-and-academia-repurposing-authorised-medicines_en.pdf"},
    {"id":"52962","name":"Declaration of interests: Aleksandra Dacic-Pilcevic","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T15:03:00Z","last_updated_date":"2025-08-01T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-aleksandra-dacic-pilcevic_en.pdf"},
    {"id":"52963","name":"Declaration of interests: Sokratis Kartelias","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-30T17:14:00Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-sokratis-kartelias_en.pdf"},
    {"id":"52965","name":"Release notes - production release version 01.04.04 November 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T17:45:00Z","last_updated_date":"2021-10-29T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-010404-november-2021-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"52966","name":"Example files - production release version 01.04.04 November 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T17:45:00Z","last_updated_date":"2021-10-29T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-010404-november-2021-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"52984","name":"Islet Autoantibodies (AAs) - Briefing document","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-03T17:08:00Z","last_updated_date":"2021-11-03T17:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/islet-autoantibodies-aas-briefing-document_en.pdf"},
    {"id":"52985","name":"Islet Autoantibodies (AAs) - Written response to the list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-03T17:09:00Z","last_updated_date":"2021-11-03T17:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/islet-autoantibodies-aas-written-response-list-issues_en.pdf"},
    {"id":"52986","name":"Islet Autoantibodies (AAs) - Appendix H","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-03T17:12:00Z","last_updated_date":"2021-11-03T17:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/islet-autoantibodies-aas-appendix-h_en.pdf"},
    {"id":"53006","name":"Veterinary Scientific Advice procedure – timelines 2026 - information for applicants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-05T15:41:00Z","last_updated_date":"2025-12-04T10:45:00Z","reference_number":"EMA/CVMP/SAWP/357647/2025","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-scientific-advice-procedure-timelines-2026-information-applicants_en.pdf"},
    {"id":"53045","name":"Scientific recommendations on classification of advanced therapy medicinal products (April 2019 - December 2020)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-10T09:16:00Z","last_updated_date":"2021-11-10T09:16:00Z","reference_number":"EMA/321214/2021","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-recommendations-classification-advanced-therapy-medicinal-products-april-2019-december-2020_en.xlsx"},
    {"id":"53081","name":"Notification on arrangements for requesting EMA certificates through urgent and standard procedure for December 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-14T09:53:00Z","last_updated_date":"2024-11-11T11:52:00Z","reference_number":"EMA/511024/2024","document_url":"https://www.ema.europa.eu/en/documents/other/notification-arrangements-requesting-ema-certificates-through-urgent-standard-procedure-december-2024_en.pdf"},
    {"id":"53113","name":"Step-by-step guide : Support with workload management in the sponsor workspace - CTIS Training Programme - Module 04","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-15T09:08:00Z","last_updated_date":"2021-11-15T09:08:00Z","reference_number":"Version 1.0 - September 2021","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-support-workload-management-sponsor-workspace-ctis-training-programme-module-04_en.pdf"},
    {"id":"53114","name":"Step-by-step guide : Support with workload management in the authority workspace - CTIS Training Programme - Module 04","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-15T09:08:00Z","last_updated_date":"2026-06-26T13:51:00Z","reference_number":"Version 1.1","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-support-workload-management-authority-workspace-ctis-training-programme-module-04_en.pdf"},
    {"id":"53134","name":"Questions and answers from the webinar for industry on integration of EudraGMDP and OMS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-16T09:41:00Z","last_updated_date":"2021-11-16T09:41:00Z","reference_number":"EMA/587537/2021","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-webinar-industry-integration-eudragmdp-and-oms_en.pdf"},
    {"id":"53190","name":"Declaration of interests: Valentina Stamouli","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T17:45:00Z","last_updated_date":"2021-11-19T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-valentina-stamouli_en.pdf"},
    {"id":"53191","name":"Declaration of interests: Francesca Day","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T17:45:00Z","last_updated_date":"2025-08-01T12:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-francesca-day_en.pdf"},
    {"id":"53194","name":"List of Q&As received during the webinar training on 10 November 2021: VGVP module on collection and recording of suspected adverse events for veterinary medicinal products & EVV system functionalities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-22T09:36:00Z","last_updated_date":"2021-11-22T09:36:00Z","reference_number":"EMA/679405/2021","document_url":"https://www.ema.europa.eu/en/documents/other/list-qas-received-during-webinar-training-10-november-2021-vgvp-module-collection-and-recording-suspected-adverse-events-veterinary-medicinal-products-evv-system-functionalities_en.pdf"},
    {"id":"53201","name":"Questions and answers on generic medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2007-07-09T15:51:00Z","last_updated_date":"2012-12-07T11:52:00Z","reference_number":"EMA/393905/2006 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/questions-and-answers-generic-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/questions-and-answers-generic-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/questions-and-answers-generic-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/questions-and-answers-generic-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/questions-and-answers-generic-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/questions-and-answers-generic-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf"}},
    {"id":"53246","name":"VICH schema","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T15:57:00Z","last_updated_date":"2021-11-23T15:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/vich-schema_en.zip"},
    {"id":"53273","name":"Speakers - European Medicines Agency veterinary medicines info day","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T15:23:00Z","last_updated_date":"2021-11-25T15:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-european-medicines-agency-veterinary-medicines-info-day_en.pdf"},
    {"id":"53320","name":"Guide on advanced therapy medicinal products - Quality checklist","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T14:52:00Z","last_updated_date":"2021-11-29T14:52:00Z","reference_number":"Version 1.0","document_url":"https://www.ema.europa.eu/en/documents/other/guide-advanced-therapy-medicinal-products-quality-checklist_en.pdf"},
    {"id":"53321","name":"Guide on advanced therapy medicinal products - Non-clinical development checklist","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T14:55:00Z","last_updated_date":"2021-11-29T14:55:00Z","reference_number":"Version 1.0","document_url":"https://www.ema.europa.eu/en/documents/other/guide-advanced-therapy-medicinal-products-non-clinical-development-checklist_en.pdf"},
    {"id":"53322","name":"Guide on advanced therapy medicinal products - Clinical development checklist","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T14:57:00Z","last_updated_date":"2021-11-29T14:57:00Z","reference_number":"Version 1.0 ","document_url":"https://www.ema.europa.eu/en/documents/other/guide-advanced-therapy-medicinal-products-clinical-development-checklist_en.pdf"},
    {"id":"53326","name":"Guide on advanced therapy medicinal products - Quality flowchart","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T15:49:00Z","last_updated_date":"2021-11-29T15:49:00Z","reference_number":"Version 1.0","document_url":"https://www.ema.europa.eu/en/documents/other/guide-advanced-therapy-medicinal-products-quality-flowchart_en.pdf"},
    {"id":"53327","name":"Guide on advanced therapy medicinal products - Non-clinical development flowchart","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T16:00:00Z","last_updated_date":"2021-11-29T16:00:00Z","reference_number":"Version 1.0","document_url":"https://www.ema.europa.eu/en/documents/other/guide-advanced-therapy-medicinal-products-non-clinical-development-flowchart_en.pdf"},
    {"id":"53328","name":"Guide on advanced therapy medicinal products - Clinical development flowchart","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T16:02:00Z","last_updated_date":"2021-11-29T16:02:00Z","reference_number":"Version 1.0","document_url":"https://www.ema.europa.eu/en/documents/other/guide-advanced-therapy-medicinal-products-clinical-development-flowchart_en.pdf"},
    {"id":"53330","name":"Union Product Database (UPD) - questions and answers for industry users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T17:04:00Z","last_updated_date":"2025-10-20T17:02:00Z","reference_number":"EMA/708407/2021","document_url":"https://www.ema.europa.eu/en/documents/other/union-product-database-upd-questions-answers-industry-users_en.pdf"},
    {"id":"53397","name":"EMA reply to a letter from Members of the European Parliament, Ms M. Rivasi, Mr P. Pedicini and Ms T. Metz concerning COVID-19 vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-07T16:00:00Z","last_updated_date":"2021-12-07T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-reply-letter-members-european-parliament-ms-m-rivasi-mr-p-pedicini-and-ms-t-metz-concerning-covid-19-vaccines_en.pdf","translations":{"fr":"https://www.ema.europa.eu/fr/documents/other/ema-reply-letter-members-european-parliament-ms-m-rivasi-mr-p-pedicini-and-ms-t-metz-concerning-covid-19-vaccines_fr.pdf"}},
    {"id":"53454","name":"European Medicines Regulatory Network Data Standardisation Strategy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-17T17:58:00Z","last_updated_date":"2021-12-17T17:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-regulatory-network-data-standardisation-strategy_en.pdf"},
    {"id":"53480","name":"Regulatory Science - Research needs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-15T11:47:00Z","last_updated_date":"2021-12-15T11:47:00Z","reference_number":"EMA/705364/2021","document_url":"https://www.ema.europa.eu/en/documents/other/regulatory-science-research-needs_en.pdf"},
    {"id":"53507","name":"FAQs: Introduction to CTIS for public users - CTIS Training Programme - Module 22","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T17:26:00Z","last_updated_date":"2021-12-14T17:26:00Z","reference_number":"Version 1.1 - December 2021","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-introduction-ctis-public-users-ctis-training-programme-module-22_en.pdf"},
    {"id":"53508","name":"Quick guide: Introduction to CTIS for public users - CTIS Training Programme - Module 22","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T17:26:00Z","last_updated_date":"2021-12-14T17:26:00Z","reference_number":"Version 1.1 - December 2021","document_url":"https://www.ema.europa.eu/en/documents/other/quick-guide-introduction-ctis-public-users-ctis-training-programme-module-22_en.pdf"},
    {"id":"53511","name":"Step-by-step guide : Union Controls in CTIS - CTIS Training Programme - Module 21","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T17:42:00Z","last_updated_date":"2021-12-14T17:42:00Z","reference_number":"Version 1.1 - December 2021","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-union-controls-ctis-ctis-training-programme-module-21_en.pdf"},
    {"id":"53512","name":"FAQs : Union Controls in CTIS - CTIS Training Programme - Module 21","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T17:42:00Z","last_updated_date":"2021-12-14T17:42:00Z","reference_number":"Version 1.1 - December 2021","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-union-controls-ctis-ctis-training-programme-module-21_en.pdf"},
    {"id":"53513","name":"Release notes - production release version 1.5.1-0 December 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-13T17:40:00Z","last_updated_date":"2021-12-13T17:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-151-0-december-2021-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"53514","name":"Example files - production release version 1.5.1-0 December 2021 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T17:40:00Z","last_updated_date":"2021-12-14T17:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-151-0-december-2021-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"53525","name":"EMA framework of interaction with healthcare professionals: 10 years of implementation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-15T13:23:00Z","last_updated_date":"2021-12-15T13:23:00Z","reference_number":"EMA/698996/2021","document_url":"https://www.ema.europa.eu/en/documents/other/ema-framework-interaction-healthcare-professionals-10-years-implementation_en.pdf"},
    {"id":"53548","name":"EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 7: Submission of other post-authorisation data","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-16T12:16:00Z","last_updated_date":"2026-06-17T16:43:00Z","reference_number":"EMA/772580/2022","document_url":"https://www.ema.europa.eu/en/documents/other/eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-chapter-7-submission-other-post-authorisation-data_en.pdf"}    {"id":"53580","name":"Questions and answers - Practical arrangements on the companion diagnostics consultation procedure to the European Medicines Agency by notified bodies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-20T10:27:00Z","last_updated_date":"2026-05-18T16:35:37Z","reference_number":"EMA/619893/2022 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-practical-arrangements-companion-diagnostics-consultation-procedure-european-medicines-agency-notified-bodies_en.pdf"},
    {"id":"53587","name":"Highlights from the second meeting of the Nitrosamine Implementation Oversight Group (NIOG) and pharmaceutical Industry","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-17T14:16:00Z","last_updated_date":"2021-12-17T14:16:00Z","reference_number":"EMA/711797/2021","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-second-meeting-nitrosamine-implementation-oversight-group-niog-and-pharmaceutical-industry_en.pdf"},
    {"id":"53602","name":"Summary of transfers of appropriations in budget 2021 - Management Board meeting of 15-16 December 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-20T10:48:00Z","last_updated_date":"2021-12-20T10:48:00Z","reference_number":"EMA/MB/613491/2021","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budget-2021-management-board-meeting-15-16-december-2021_en.pdf"},
    {"id":"53612","name":"Note on European Medicines Agency’s involvement in HORIZON-HLTH-2022-TOOL-11-02: New methods for the effective use of real-world data and/or synthetic data in regulatory decision-making and/or in health technology assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-21T12:06:00Z","last_updated_date":"2021-12-21T12:06:00Z","reference_number":"EMA/647111/2021","document_url":"https://www.ema.europa.eu/en/documents/other/note-european-medicines-agencys-involvement-horizon-hlth-2022-tool-11-02-new-methods-effective-use-real-world-data-andor-synthetic-data-regulatory-decision-making-andor-health-technology-assessment_en.pdf"},
    {"id":"53619","name":"One year since the first COVID-19 vaccine approval in the EU","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-12-22T16:35:00Z","last_updated_date":"2021-12-22T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/one-year-first-covid-19-vaccine-approval-eu_en.pdf"},
    {"id":"53671","name":"Joint Controllership Arrangement with regard to the Clinical Trials Information System (CTIS)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T15:43:00Z","last_updated_date":"2026-03-13T16:13:00Z","reference_number":"EMA/541334/2021","document_url":"https://www.ema.europa.eu/en/documents/other/joint-controllership-arrangement-regard-clinical-trials-information-system-ctis_en.pdf"},
    {"id":"53672","name":"European Medicines Agency's data protection notice regarding personal data processing in the Clinical Trials Information System (CTIS)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T16:21:00Z","last_updated_date":"2026-03-13T16:12:45Z","reference_number":"EMA/587422/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-regarding-personal-data-processing-clinical-trials-information-system-ctis_en.pdf"},
    {"id":"53698","name":"Union Product Database (UPD) registration guide for UI and API users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-12T11:06:00Z","last_updated_date":"2026-06-05T14:20:00Z","reference_number":"EMA/362250/2023","document_url":"https://www.ema.europa.eu/en/documents/other/upd-registration-guide-ui-api-users_en.pdf"},
    {"id":"53711","name":"Release notes - production release version 1.5.2-0 January 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-13T17:34:00Z","last_updated_date":"2022-01-13T17:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-152-0-january-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"53712","name":"Example files - production release version 1.5.2-0 January 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-13T17:35:00Z","last_updated_date":"2022-01-13T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-152-0-january-2022-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"53845","name":"Step-by-step guide: How to evaluate an Additional MSC clinical trial application - CTIS Training Programme - Module 8","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-20T10:49:00Z","last_updated_date":"2022-01-20T10:49:00Z","reference_number":"Version 1.0 - October 2021","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-how-evaluate-additional-msc-clinical-trial-application-ctis-training-programme-module-8_en.pdf"},
    {"id":"53846","name":"Step-by-step guide: How to evaluate a substantial modification clinical trial application - CTIS Training Programme - Module 8","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-22T15:49:00Z","last_updated_date":"2022-03-22T15:49:00Z","reference_number":"Version 1.1 - March 2022","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-how-evaluate-substantial-modification-clinical-trial-application-ctis-training-programme-module-8_en.pdf"},
    {"id":"53852","name":"Letter of Support for performing registry-based post authorisation safety studies (PASS) in Multiple Sclerosis (MS) using data of the Big MS Data Network (BMSD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-20T12:16:00Z","last_updated_date":"2022-01-20T12:16:00Z","reference_number":"EMADOC-1700519818-759902","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-performing-registry-based-post-authorisation-safety-studies-pass-multiple-sclerosis-ms-using-data-big-ms-data-network-bmsd_en.pdf"},
    {"id":"53869","name":"Step-by-step guide: How to evaluate a CT application - CTIS Training Programme - Module 06","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T11:31:00Z","last_updated_date":"2025-11-25T11:01:34Z","reference_number":"Version 1.2 - November 2025","document_url":"https://www.ema.europa.eu/en/documents/other/step-step-guide-how-evaluate-ct-application-ctis-training-programme-module-06_en.pdf"},
    {"id":"53874","name":"Timetable: Companion diagnostic initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T13:43:00Z","last_updated_date":"2025-10-03T16:49:00Z","reference_number":"EMA/3932/2022 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-companion-diagnostic-initial-consultation_en.xlsx"},
    {"id":"53875","name":"Timetable: Companion diagnostic initial consultation - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T13:45:00Z","last_updated_date":"2025-10-03T15:47:00Z","reference_number":"EMA/3933/2022 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-companion-diagnostic-initial-consultation-atmp_en.xlsx"},
    {"id":"53907","name":"Release notes - production release version 1.5.3-4 January 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-25T16:47:00Z","last_updated_date":"2022-01-25T16:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-153-4-january-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"53908","name":"Example files - production release version 1.5.3-4 January 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-25T16:49:00Z","last_updated_date":"2022-01-25T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-153-4-january-2022-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"53939","name":"EVVET – Data warehouse user manual","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:02:00Z","last_updated_date":"2025-05-16T14:20:00Z","reference_number":"EMA/53385/2022 Version 3.0","document_url":"https://www.ema.europa.eu/en/documents/other/evvet-data-warehouse-user-manual_en.pdf"},
    {"id":"53942","name":"EudraVigilance veterinary - Registration manual","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:25:00Z","last_updated_date":"2024-01-11T08:45:00Z","reference_number":"Revision 5","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-veterinary-registration-manual_en.pdf"},
    {"id":"53943","name":"EVVET - Procedures to be followed in case of prolonged system failure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:31:00Z","last_updated_date":"2022-01-28T10:31:00Z","reference_number":"EMA/131441/2010","document_url":"https://www.ema.europa.eu/en/documents/other/evvet-procedures-be-followed-case-prolonged-system-failure_en.pdf"},
    {"id":"53944","name":"EVVET - EVWEB user manual","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:34:00Z","last_updated_date":"2023-12-11T14:45:00Z","reference_number":"Version 1.8","document_url":"https://www.ema.europa.eu/en/documents/other/evvet-evweb-user-manual_en.pdf"},
    {"id":"53956","name":"Procedural note for interim measures regarding notification of pharmacovigilance alerts by marketing authorisation holders under Regulation (EU) 2019/6","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-27T15:27:00Z","last_updated_date":"2022-01-27T15:27:00Z","reference_number":"EMA/CVMP/PhVWP/751940/2021","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-note-interim-measures-regarding-notification-pharmacovigilance-alerts-marketing-authorisation-holders-under-regulation-eu-20196_en.pdf"},
    {"id":"53957","name":"Annex to interim measures regarding notification of pharmacovigilance alerts by marketing authorisation holders under Regulation (EU) 2019/6: contact points","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-27T15:27:00Z","last_updated_date":"2025-01-06T13:44:00Z","reference_number":"EMA/586463/2021 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/other/annex-interim-measures-regarding-notification-pharmacovigilance-alerts-marketing-authorisation-holders-under-regulation-eu-2019-6-contact-points_en.pdf"},
    {"id":"53971","name":"Joint Controllership Arrangement with regard to the Union product database (UPD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T09:00:00Z","last_updated_date":"2026-04-01T16:30:00Z","reference_number":"EMA/366104/2021 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/joint-controllership-arrangement-regard-union-product-database-upd_en.pdf"},
    {"id":"53975","name":"Information on all EU veterinary medicines in one place - Infocards","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T19:58:00Z","last_updated_date":"2022-01-28T19:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/information-all-eu-veterinary-medicines-one-place-infocards_en.pdf"},
    {"id":"54023","name":"Sponsors' guide: Transition of trials from EudraCT to CTIS - CTIS Training Programme - Module 23","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T16:10:00Z","last_updated_date":"2024-08-14T17:56:00Z","reference_number":"Version 1.5 - August 2024","document_url":"https://www.ema.europa.eu/en/documents/other/sponsors-guide-transition-trials-eudract-ctis-ctis-training-programme-module-23_en.pdf"},
    {"id":"54024","name":"Member states' guide: Transition of trials from EudraCT to CTIS - CTIS Training Programme - Module 23","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T16:10:00Z","last_updated_date":"2023-01-26T10:09:00Z","reference_number":"Version 1.2 - August 2022","document_url":"https://www.ema.europa.eu/en/documents/other/member-states-guide-transition-trials-eudract-ctis-ctis-training-programme-module-23_en.pdf"},
    {"id":"54025","name":"FAQs: Transition of trials from EudraCT to CTIS - CTIS Training Programme - Module 23","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T16:10:00Z","last_updated_date":"2024-08-14T17:55:00Z","reference_number":"Version 1.4 – August 2024","document_url":"https://www.ema.europa.eu/en/documents/other/faqs-transition-trials-eudract-ctis-ctis-training-programme-module-23_en.pdf"},
    {"id":"54028","name":"Questions and Answers on the Joint Controllership Arrangement and data protection matters related to the use of the Clinical Trials Information System","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T09:00:00Z","last_updated_date":"2026-03-13T16:12:00Z","reference_number":"EMA/616933/2021","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-joint-controllership-arrangement-data-protection-matters-related-use-clinical-trials-information-system_en.pdf"},
    {"id":"54029","name":"Clinical trials information system - Key information for sponsors on CTIS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T09:00:00Z","last_updated_date":"2022-05-17T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trials-information-system-key-information-sponsors-ctis_en.pdf"},
    {"id":"54050","name":"Roles and permissions matrix summary - Authority workspace - CTIS Training Programme - Module 07","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T11:04:00Z","last_updated_date":"2024-06-18T16:00:00Z","reference_number":"Version 2.24 – June 2024","document_url":"https://www.ema.europa.eu/en/documents/other/roles-permissions-matrix-summary-authority-workspace-ctis-training-programme-module-07_en.pdf"},
    {"id":"54051","name":"Member states business processes and roles - CTIS Training Programme - Module 07","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T11:04:00Z","last_updated_date":"2022-04-04T15:33:00Z","reference_number":"Version n 1.68 – March 2022","document_url":"https://www.ema.europa.eu/en/documents/other/member-states-business-processes-and-roles-ctis-training-programme-module-07_en.pdf"},
    {"id":"54052","name":"Roles and permissions matrix summary - Sponsors workspace - CTIS Training Programme - Module 07","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T11:04:00Z","last_updated_date":"2022-11-08T15:20:00Z","reference_number":"Version  2.29 – October 2022","document_url":"https://www.ema.europa.eu/en/documents/other/roles-and-permissions-matrix-summary-sponsors-workspace-ctis-training-programme-module-07_en.pdf"},
    {"id":"54053","name":"Sponsors business processes and roles - CTIS Training Programme - Module 07","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T11:04:00Z","last_updated_date":"2022-04-04T15:29:00Z","reference_number":"Version 1.45 – March 2022","document_url":"https://www.ema.europa.eu/en/documents/other/sponsors-business-processes-and-roles-ctis-training-programme-module-07_en.pdf"},
    {"id":"54054","name":"Notices and alerts per role - CTIS Training Programme - Module 07","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T11:04:00Z","last_updated_date":"2026-04-07T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/notices-alerts-role-ctis-training-programme-module-07_en.xlsx"},
    {"id":"54061","name":"Mandatory use of ISO ICSR/ICH E2B(R3) and EDQM terminology for Dosage Forms (DF) and Routes of  Administration (RoA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T15:18:00Z","last_updated_date":"2022-05-20T11:48:00Z","reference_number":"EMA/580321/2021 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/mandatory-use-iso-icsrich-e2br3-and-edqm-terminology-dosage-forms-df-and-routes-administration-roa_en.pdf"},
    {"id":"54062","name":"EudraVigilance: Obtaining EDQM terms from SPOR","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T15:20:00Z","last_updated_date":"2022-02-03T15:20:00Z","reference_number":"EMA/580322/2021","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-obtaining-edqm-terms-spor_en.pdf"},
    {"id":"54084","name":"Network ICT Advisory Committee (NICTAC) - Membership and role","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T12:55:00Z","last_updated_date":"2022-02-08T12:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/network-ict-advisory-committee-nictac-membership-and-role_en.pdf"},
    {"id":"54085","name":"Network Portfolio Advisory Group (NPAG) - Membership and role","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T12:56:00Z","last_updated_date":"2022-02-08T12:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/network-portfolio-advisory-group-npag-membership-and-role_en.pdf"},
    {"id":"54086","name":"Network ICT Advisory Committee (NICTAC) - Updated Terms of reference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T12:55:00Z","last_updated_date":"2023-06-29T09:24:00Z","reference_number":"EMA/261670/2023","document_url":"https://www.ema.europa.eu/en/documents/other/network-ict-advisory-committee-nictac-updated-terms-reference_en.pdf"},
    {"id":"54087","name":"Network Portfolio Advisory Group (NPAG) - Terms of reference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T12:56:00Z","last_updated_date":"2022-02-08T12:56:00Z","reference_number":"EMA/535331/2021","document_url":"https://www.ema.europa.eu/en/documents/other/network-portfolio-advisory-group-npag-terms-reference_en.pdf"},
    {"id":"54088","name":"EMA Agile governance model","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T12:56:00Z","last_updated_date":"2025-04-30T13:32:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-agile-governance-model_en.pdf"},
    {"id":"54089","name":"Nominations to the Network Portfolio Advisory Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T12:56:00Z","last_updated_date":"2026-01-07T17:03:00Z","reference_number":"EMA/593340/2021 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/other/nominations-network-portfolio-advisory-group_en.pdf"},
    {"id":"54094","name":"Appendix to the European Medicines Agency code of conduct","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-07T13:42:00Z","last_updated_date":"2022-02-07T13:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-european-medicines-agency-code-conduct_en.pdf-0"},
    {"id":"54098","name":"Network ICT Advisory Committee (NICTAC) - List of nominated members","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T12:56:00Z","last_updated_date":"2024-11-04T14:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/network-ict-advisory-committee-nictac-list-nominated-members_en.pdf"},
    {"id":"54111","name":"ATMPs submissions (Ana Hidalgo-Simon)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T17:41:00Z","last_updated_date":"2022-02-08T17:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/atmps-submissions-ana-hidalgo-simon_en.pdf"},
    {"id":"54130","name":"Speaker bios - Demonstration on Clinical Trial Information System (CTIS)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-10T16:08:00Z","last_updated_date":"2022-02-10T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speaker-bios-demonstration-clinical-trial-information-system-ctis_en.pdf"},
    {"id":"54226","name":"European Medicines Agency budget for 2022","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-02-18T16:59:00Z","last_updated_date":"2022-08-12T09:16:00Z","reference_number":"EMA/MB/678773/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-budget-2022_en.pdf"},
    {"id":"54249","name":"Release notes - production release version 1.5.4 February 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-22T17:13:00Z","last_updated_date":"2022-02-22T17:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-154-february-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"54250","name":"Letter of support for intermediate Age-Related Macular Degeneration (AMD) biomarker and novel clinical endpoint development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-22T17:14:00Z","last_updated_date":"2022-02-22T17:14:00Z","reference_number":"EMADOC-1700519818-776978","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-intermediate-age-related-macular-degeneration-amd-biomarker-and-novel-clinical-endpoint-development_en.pdf-0"},
    {"id":"54261","name":"Enroll-HD Registry for Huntington's Disease - Briefing Package - 1 of 2 - questions and answers and context of use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T11:36:00Z","last_updated_date":"2022-02-23T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/enroll-hd-registry-huntingtons-disease-briefing-package-1-2-questions-and-answers-and-context-use_en.pdf"},
    {"id":"54262","name":"Enroll-HD Registry for Huntington's Disease - Briefing package - 2 of 2 - Supplement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T11:37:00Z","last_updated_date":"2022-02-23T11:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/enroll-hd-registry-huntingtons-disease-briefing-package-2-2-supplement_en.pdf"},
    {"id":"54263","name":"Qualification Advice List of Issues: Enroll-HD Response","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T11:39:00Z","last_updated_date":"2022-02-23T11:39:00Z","reference_number":"EMA/SA/0000056662","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-advice-list-issues-enroll-hd-response_en.pdf"},
    {"id":"54274","name":"European Medicines Agency's data protection notice concerning the Multistakeholder Workshop on EMA  extended mandate on 1 April 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-24T11:57:00Z","last_updated_date":"2022-02-24T11:57:00Z","reference_number":"EMA/112793/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-concerning-multistakeholder-workshop-ema-extended-mandate-1-april-2022_en.pdf"},
    {"id":"54308","name":"Quick guide - Fill in the blanks exercise: Overview of CTIS workspaces and common system functionalities - CTIS Training Programme - Module 02","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-01T13:50:00Z","last_updated_date":"2022-03-01T13:50:00Z","reference_number":"Version 1.2. January 2022","document_url":"https://www.ema.europa.eu/en/documents/other/quick-guide-fill-blanks-exercise-overview-ctis-workspaces-and-common-system-functionalities-ctis-training-programme-module-02_en.pdf"},
    {"id":"54324","name":"Agnes Saint-Raymond - Assessment outcome of occupational activities after leaving the service (February 2022)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-01T16:51:00Z","last_updated_date":"2022-03-01T16:51:00Z","reference_number":"EMA/99418/2022","document_url":"https://www.ema.europa.eu/en/documents/other/agnes-saint-raymond-assessment-outcome-occupational-activities-after-leaving-service-february-2022_en.pdf"},
    {"id":"54366","name":"Variation fast healthcare interoperability resources (FHIR) mapping & examples","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-07T17:00:00Z","last_updated_date":"2022-05-31T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/variation-fast-healthcare-interoperability-resources-fhir-mapping-examples_en.zip"},
    {"id":"54407","name":"Letter of support for Minimal Disease Activity Score (MDA) as primary outcome instrument for clinical studies in psoriatic arthritis (PsA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-09T16:21:00Z","last_updated_date":"2022-03-09T16:21:00Z","reference_number":"EMADOC-1700519818-782278","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-minimal-disease-activity-score-mda-primary-outcome-instrument-clinical-studies-psoriatic-arthritis-psa_en.pdf"},
    {"id":"54409","name":"European Medicines Agency’s data protection notice for the processing of the contact points of scientific committees (CXMP) members/alternates’ for internal use by the same committees","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-10T10:45:00Z","last_updated_date":"2022-03-10T10:45:00Z","reference_number":"EMA/67519/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-processing-contact-points-scientific-committees-cxmp-members-alternates-internal-use-same-committees_en.pdf"},
    {"id":"54419","name":"Records of data processing activity for the processing of the contact points of scientific committees (CXMP) members/alternates’ for internal use by the same committees","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-11T09:48:00Z","last_updated_date":"2022-03-11T09:48:00Z","reference_number":"EMA/123714/2022","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-processing-contact-points-scientific-committees-cxmp-members-alternates-internal-use-same-committees_en.pdf"},
    {"id":"54468","name":"testing","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-15T12:20:00Z","last_updated_date":"2022-03-15T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/testing_en.zip"},
    {"id":"54512","name":"Letter of support for Sjögren’s Tool for Assessing  Response (STAR)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-17T15:19:00Z","last_updated_date":"2022-03-17T15:19:00Z","reference_number":"EMADOC-1700519818-746443 ","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-sjogrens-tool-assessing-response-star_en.pdf"},
    {"id":"54513","name":"Letter of support for Sjögren’s Tool for Assessing Response (STAR)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-17T15:19:00Z","last_updated_date":"2022-03-17T15:19:00Z","reference_number":"EMADOC-1700519818-746443 ","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-sjogrens-tool-assessing-response-star_en.pdf-0"},
    {"id":"54522","name":"Superseded - Composition of the Emergency Task Force (ETF) for the therapeutic response to the COVID-19 pandemic","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-18T16:39:00Z","last_updated_date":"2022-11-08T10:09:00Z","reference_number":"EMA/555794/2021","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-composition-emergency-task-force-etf-therapeutic-response-covid-19-pandemic_en.pdf"},
    {"id":"54529","name":"Release notes - production release version 1.6.1 March 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-21T14:24:00Z","last_updated_date":"2022-03-21T14:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-161-march-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"54536","name":"Draft qualification opinion for prognostic covariate adjustment (PROCOVA™)","type":"other","status":"Draft: consultation closed","consultation_date":"2022-03-22 - 2022-05-02","first_published_date":"2022-03-22T16:30:00Z","last_updated_date":"2022-03-22T16:30:00Z","reference_number":"Case No.: EMA/SA/0000059571","document_url":"https://www.ema.europa.eu/en/documents/other/draft-qualification-opinion-prognostic-covariate-adjustment-procovatm_en.pdf"},
    {"id":"54537","name":"Briefing book","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-22T13:43:00Z","last_updated_date":"2022-03-22T13:43:00Z","reference_number":"Version 2.0","document_url":"https://www.ema.europa.eu/en/documents/other/briefing-book_en.pdf"},
    {"id":"54538","name":"PROCOVA™ handbook","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-22T13:52:00Z","last_updated_date":"2022-03-22T13:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/procovatm-handbook_en.pdf"},
    {"id":"54539","name":"Response to list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-22T13:58:00Z","last_updated_date":"2022-03-22T13:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/response-list-issues_en.pdf"},
    {"id":"54542","name":"Response to 2nd list of issues","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-22T14:15:00Z","last_updated_date":"2022-03-22T14:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/response-2nd-list-issues_en.pdf"},
    {"id":"54548","name":"European Medicines Agency's data protection notice concerning the VMP-Reg stakeholders meetings","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/173739/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-concerning-vmp-reg-stakeholders-meetings_en.pdf"},
    {"id":"54554","name":"European Medicines Agency’s Privacy Statement for the provision of hotel and travel services through the Agency’s online booking tool","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-24T15:32:00Z","last_updated_date":"2022-03-24T15:32:00Z","reference_number":"EMA/179740/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-provision-hotel-and-travel-services-through-agencys-online-booking-tool_en.pdf"},
    {"id":"54580","name":"Applying for an Innovation Task Force Briefing Meeting (ITF BM) - Step-by-step guide and FAQ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T10:24:00Z","last_updated_date":"2022-03-25T10:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/applying-innovation-task-force-briefing-meeting-itf-bm-step-step-guide-and-faq_en.pdf"},
    {"id":"54609","name":"Online verification system for electronic certificates issued by European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-29T12:18:00Z","last_updated_date":"2023-01-16T14:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/online-verification-system-electronic-certificates-issued-european-medicines-agency_en.pdf"},
    {"id":"54612","name":"Launch of EMA’s Cancer Medicines Forum with Academia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-31T15:06:00Z","last_updated_date":"2022-03-31T15:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/launch-emas-cancer-medicines-forum-academia_en.pdf"},
    {"id":"54648","name":"Explanatory note on general fees payable to the European Medicines Agency as of 01 April 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-01T13:43:00Z","last_updated_date":"2022-04-01T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-note-general-fees-payable-european-medicines-agency-01-april-2022_en.pdf"},
    {"id":"54650","name":"European Medicines Agency's data protection notice concerning the Annual ESVAC Network meeting on 3 May 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/193804/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-concerning-annual-esvac-network-meeting-3-may-2022_en.pdf"},
    {"id":"54681","name":"Letter of support for the Global Platform Study of Novel Medicines in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL platform)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-05T16:15:00Z","last_updated_date":"2022-04-05T16:15:00Z","reference_number":"EMADOC-1700519818-746444","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-global-platform-study-novel-medicines-paediatric-and-adolescent-relapsed-and-refractory-b-cell-non-hodgkin-lymphoma-glo-bnhl-platform_en.pdf"},
    {"id":"54682","name":"Release notes - production release version 1.6.2 April 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-05T16:35:00Z","last_updated_date":"2022-04-05T16:35:00Z","reference_number":"version 1.6.2 - April 2022","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-162-april-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"54683","name":"Example files - production release version 1.6.2 April 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-05T16:35:00Z","last_updated_date":"2022-04-05T16:35:00Z","reference_number":"Version 1.6.2 - April 2022","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-162-april-2022-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"54684","name":"Speakers' biographies - Clinical Trials Information System (CTIS) bitesize talk: Requests for information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-05T17:03:00Z","last_updated_date":"2022-04-26T14:02:00Z","reference_number":"EMA/202248/2022","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-clinical-trials-information-system-ctis-bitesize-talk-requests-information_en.pdf"},
    {"id":"54692","name":"Speakers' biographies - Clinical Trials Information System (CTIS) bitesize talk: Initial clinical trial application","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-07T16:35:00Z","last_updated_date":"2022-04-07T16:35:00Z","reference_number":"EMA/173434/2022","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-clinical-trials-information-system-ctis-bitesize-talk-initial-clinical-trial-application_en.pdf"},
    {"id":"54711","name":"Draft guidance document on how to approach the protection of personal data and commercially confidential information in documents uploaded and published in the Clinical Trial Information System (CTIS)","type":"other","status":"Draft: consultation closed","consultation_date":"2022-04-08 - 2022-09-08","first_published_date":"2022-04-08T18:17:00Z","last_updated_date":"2022-04-08T18:17:00Z","reference_number":"EMA/212507/2021","document_url":"https://www.ema.europa.eu/en/documents/other/draft-guidance-document-how-approach-protection-personal-data-and-commercially-confidential-information-documents-uploaded-and-published-clinical-trial-information-system-ctis_en.pdf"},
    {"id":"54727","name":"European Medicines Agency data protection notice concerning the Veterinary Info Day meeting on 12-13 May 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T17:25:00Z","last_updated_date":"2022-04-11T17:25:00Z","reference_number":"EMA/194250/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-data-protection-notice-concerning-veterinary-info-day-meeting-12-13-may-2022_en.pdf"},
    {"id":"54754","name":"Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU, Expert Opinion on Drug Safety","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-13T15:39:00Z","last_updated_date":"2022-04-13T15:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/regulatory-experience-handling-risk-management-plans-rmps-medicinal-products-eu-expert-opinion-drug-safety_en.pdf"},
    {"id":"54756","name":"Compilation of terms and definitions for Cannabis-derived medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-13T15:27:00Z","last_updated_date":"2022-04-13T15:27:00Z","reference_number":"EMA/HMPC/161753/2020","document_url":"https://www.ema.europa.eu/en/documents/other/compilation-terms-and-definitions-cannabis-derived-medicinal-products_en.pdf"},
    {"id":"54767","name":"Summary of transfers of appropriations in budgets 2021 and 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-20T13:04:00Z","last_updated_date":"2022-04-20T13:04:00Z","reference_number":"EMA/MB/58837/2022","document_url":"https://www.ema.europa.eu/en/documents/other/summary-transfers-appropriations-budgets-2021-and-2022_en.pdf"},
    {"id":"54768","name":"Outcome of written procedures finalised during the period from 25 November 2021 to 18 February 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-04-20T13:05:00Z","last_updated_date":"2022-04-20T13:05:00Z","reference_number":"EMA/MB/149565/2022","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-25-november-2021-18-february-2022_en.pdf"},
    {"id":"54862","name":"Executive Steering Group on Shortages and Safety of Medicinal Products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-11T10:52:00Z","last_updated_date":"2022-05-11T10:52:00Z","reference_number":"EMA/41493/2022 ","document_url":"https://www.ema.europa.eu/en/documents/other/executive-steering-group-shortages-and-safety-medicinal-products_en.pdf"},
    {"id":"54868","name":"Release notes - production release version 1.6.3 May 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-02T12:40:00Z","last_updated_date":"2022-05-02T12:40:00Z","reference_number":"version 1.6.3 - May 2022","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-163-may-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"54869","name":"Example files - production release version 1.6.3 May 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-02T12:39:00Z","last_updated_date":"2022-05-02T12:39:00Z","reference_number":"Version 1.6.3 - May 2022","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-163-may-2022-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"54911","name":"Superseded - Rules of procedure of the Emergency Task Force (ETF)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-05-06T17:00:00Z","last_updated_date":"2025-04-11T10:49:00Z","reference_number":"EMA/336551/2021","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-rules-procedure-emergency-task-force-etf_en.pdf"},
    {"id":"54930","name":"List of speakers, co-chairs and panellists - European Medicines Agency veterinary medicines info day 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-11T09:54:00Z","last_updated_date":"2022-05-11T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-speakers-co-chairs-and-panellists-european-medicines-agency-veterinary-medicines-info-day-2022_en.pdf"},
    {"id":"54937","name":"Speakers' biographies - Clinical Trials Information System (CTIS) bitesize talk: Modifications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-11T12:31:00Z","last_updated_date":"2022-07-27T17:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-clinical-trials-information-system-ctis-bitesize-talk-modifications_en.pdf"},
    {"id":"54943","name":"Methodology for the establishment of lists of “main therapeutic groups” in crisis preparedness and of the lists of “critical medicines” in the context of a major event and/or public health emergency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-11T17:18:00Z","last_updated_date":"2022-05-11T17:18:00Z","reference_number":"EMA/45332/2022","document_url":"https://www.ema.europa.eu/en/documents/other/methodology-establishment-lists-main-therapeutic-groups-crisis-preparedness-and-lists-critical-medicines-context-major-event-andor-public-health-emergency_en.pdf"},
    {"id":"54980","name":"How to access an EMA Microsoft Team as guest user","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-17T17:05:00Z","last_updated_date":"2022-11-30T16:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/how-access-ema-microsoft-team-guest-user_en.pdf"},
    {"id":"54982","name":"Speakers' biographies -  Clinical Trials Information System (CTIS) bitesize talk: Transitional trials and additional Member State concerned (MSC) application","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-18T11:18:00Z","last_updated_date":"2022-05-18T11:18:00Z","reference_number":"EMA/284871/2022","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-clinical-trials-information-system-ctis-bitesize-talk-transitional-trials-and-additional-member-state-concerned-msc-application_en.pdf"},
    {"id":"55007","name":"Revised policy: EMA's handling of information from external reporting persons about alleged breaches related to the authorisation, supervision and maintenance of human and veterinary medicinal products or other EMA activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-19T11:31:00Z","last_updated_date":"2022-05-19T11:31:00Z","reference_number":"Policy/0072","document_url":"https://www.ema.europa.eu/en/documents/other/revised-policy-emas-handling-information-external-reporting-persons-about-alleged-breaches-related-authorisation-supervision-and-maintenance-human-and-veterinary-medicinal-products-or-other-ema_en.pdf"},
    {"id":"55089","name":"Appendix 3 to the guideline on the clinical evaluation of anticancer medicinal products - Summary of Product Characteristics for an Anticancer medicinal product – mock-up of 4.8","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-05-24T17:26:00Z","last_updated_date":"2022-05-24T17:26:00Z","reference_number":"EMA/631612/2021","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-3-guideline-clinical-evaluation-anticancer-medicinal-products-summary-product-characteristics-anticancer-medicinal-product-mock-48_en.pdf"}    {"id":"55090","name":"Release notes - production release version 1.6.4 May 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-24T17:34:00Z","last_updated_date":"2022-06-01T11:30:00Z","reference_number":"version 1.6.4 - May 2022","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-164-may-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"55091","name":"Example files - production release version 1.6.4 May 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-24T17:35:00Z","last_updated_date":"2022-05-24T17:35:00Z","reference_number":"Version 1.6.4 - May 2022","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-164-may-2022-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"55097","name":"Highlights from the third meeting of the Nitrosamine Implementation Oversight Group (NIOG) and pharmaceutical Industry","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-25T14:16:00Z","last_updated_date":"2022-05-25T14:16:00Z","reference_number":"EMA/171423/2022","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-third-meeting-nitrosamine-implementation-oversight-group-niog-and-pharmaceutical-industry_en.pdf"},
    {"id":"55100","name":"Digital application dataset integration (DADI) human variations form timeline","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-25T13:11:00Z","last_updated_date":"2022-05-25T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/digital-application-dataset-integration-dadi-human-variations-form-timeline_en.pdf"},
    {"id":"55101","name":"Antimicrobial use data reporting per animal categories (numerator) - Manual for reporting the data to EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-25T13:16:00Z","last_updated_date":"2022-05-25T13:16:00Z","reference_number":"EMA/757638/2021","document_url":"https://www.ema.europa.eu/en/documents/other/antimicrobial-use-data-reporting-animal-categories-numerator-manual-reporting-data-ema_en.pdf"},
    {"id":"55106","name":"Role descritpion: Communication officer - FGIV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-30T09:55:00Z","last_updated_date":"2022-05-30T09:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/role-descritpion-communication-officer-fgiv_en.pdf"},
    {"id":"55134","name":"Records of data processing activity for planned presence in EMA's office building","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-07T10:08:00Z","last_updated_date":"2022-06-07T10:08:00Z","reference_number":"EMA/569172/2022","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-planned-presence-emas-office-building_en.pdf"},
    {"id":"55146","name":"List of critical medicines for COVID-19 public health emergency (PHE) under Regulation (EU) 2022/123 (obsolete)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-08T12:55:00Z","last_updated_date":"2023-05-17T09:11:00Z","reference_number":"EMA/285556/2022 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/list-critical-medicines-covid-19-public-health-emergency-phe-under-regulation-eu-2022123-obsolete_en.pdf"},
    {"id":"55151","name":"European Medicines Agency’s data protection notice use of personal data as part of the emergency mass notification system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:42:18Z","last_updated_date":"2024-10-28T17:42:18Z","reference_number":"EMA/519784/2019","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-use-personal-data-part-emergency-mass-notification-system_en.pdf"},
    {"id":"55153","name":"List of metadata for the HMA-EMA Catalogues of real-world data sources and studies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-10T12:23:00Z","last_updated_date":"2025-06-12T11:09:00Z","reference_number":"EMA/563896/2022","document_url":"https://www.ema.europa.eu/en/documents/other/list-metadata-hma-ema-catalogues-real-world-data-sources-studies_en.pdf"},
    {"id":"55174","name":"Speakers' biographies - Clinical Trials Information System (CTIS) bitesize talk: Deferral rules and Public website","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-10T12:31:00Z","last_updated_date":"2022-07-28T09:42:00Z","reference_number":"EMA/318194/2022","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-clinical-trials-information-system-ctis-bitesize-talk-deferral-rules-and-public-website_en.pdf"},
    {"id":"55210","name":"European veterinary big data strategy 2022-2027","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T16:48:00Z","last_updated_date":"2022-06-13T16:48:00Z","reference_number":"EMA/648865/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-veterinary-big-data-strategy-2022-2027_en.pdf"},
    {"id":"55252","name":"Validation checklist for initial marketing authorisation applications - biologicals other than immunologicals (applicable to submissions under Regulation (EU) 2019/6)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-15T17:33:00Z","last_updated_date":"2026-04-20T09:00:00Z","reference_number":"EMA/819958/2022-Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/validation-checklist-initial-marketing-authorisation-applications-biologicals-other-immunologicals-applicable-submissions-under-regulation-eu-2019-6_en.pdf"},
    {"id":"55282","name":"Medicine Shortages Single Point of Contact (SPOC) Working Party - Mandate, objectives and rules of procedure","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-17T13:25:00Z","last_updated_date":"2023-04-03T13:40:00Z","reference_number":"EMA/26157/2022","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortages-single-point-contact-spoc-working-party-mandate-objectives-and-rules-procedure_en.pdf"},
    {"id":"55285","name":"Management Board meeting dates 2023-2024","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-06-17T17:00:00Z","last_updated_date":"2022-06-17T17:00:00Z","reference_number":"EMA/MB/94597/2022","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2023-2024_en.pdf"},
    {"id":"55286","name":"Outcome of written procedures finalised during the period from 19 February 2022 to 8 June 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-17T17:00:00Z","last_updated_date":"2022-06-17T17:00:00Z","reference_number":"EMA/MB/180164/2022","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-19-february-2022-8-june-2022_en.pdf"},
    {"id":"55288","name":"European Medicines Agency’s data protection notice concerning the processing of patient and product traceability data for Zynteglo following the withdrawal of the marketing authorisation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-20T09:41:00Z","last_updated_date":"2022-06-20T09:41:00Z","reference_number":"EMA/198331/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-concerning-processing-patient-product-traceability-data-zynteglo-following-withdrawal-marketing-authorisation_en.pdf"},
    {"id":"55319","name":"Release notes - production release version 1.6.5 June 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-22T11:29:00Z","last_updated_date":"2022-06-27T11:15:00Z","reference_number":"Version 1.6.5","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-165-june-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"55368","name":"Record of data processing activity regarding hotel and travel bookings","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T14:18:00Z","last_updated_date":"2022-06-24T14:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-regarding-hotel-travel-bookings_en.pdf"},
    {"id":"55369","name":"Records of data processing activity for testimonials for career page","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T14:20:00Z","last_updated_date":"2022-06-24T14:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-testimonials-career-page_en.pdf"},
    {"id":"55370","name":"Records of data processing activity of personal data in the context of public procurement procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T14:23:00Z","last_updated_date":"2022-09-20T11:36:00Z","reference_number":"EMA/573064/2022","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-personal-data-context-public-procurement-procedures_en.pdf"},
    {"id":"55371","name":"European Medicines Agency’s data protection on notice for certificates of medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:06:00Z","last_updated_date":"2022-06-24T15:06:00Z","reference_number":"EMA/134763/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-certificates-medicinal-products_en.pdf"},
    {"id":"55384","name":"Example files - production release version 1.6.5 June 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-27T11:16:00Z","last_updated_date":"2022-06-27T11:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-165-june-2022-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"55395","name":"Records of data processing activity for the certification of medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-28T15:03:00Z","last_updated_date":"2022-06-28T15:03:00Z","reference_number":"EMA/185307/2022","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-certification-medicinal-products_en.pdf"},
    {"id":"55409","name":"Annual list of specific contracts based on framework contracts - 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-30T08:36:00Z","last_updated_date":"2022-06-30T08:36:00Z","reference_number":"EMA/595881/2022","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-specific-contracts-based-framework-contracts-2021_en.pdf"},
    {"id":"55410","name":"Annual list of contractors 2021 - contract values Euro 15,000 - 139,000","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-30T08:37:00Z","last_updated_date":"2022-06-30T08:37:00Z","reference_number":"EMA/595880/2022","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contractors-2021-contract-values-euro-15000-139000_en.pdf"},
    {"id":"55411","name":"Annual list of contract modifications 2021","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-30T08:38:00Z","last_updated_date":"2022-06-30T08:38:00Z","reference_number":"EMA/55390/2021","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contract-modifications-2021_en.pdf"},
    {"id":"55421","name":"Declaration of interests: Etstratia Vatzaki","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-30T14:36:00Z","last_updated_date":"2023-06-14T10:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-etstratia-vatzaki_en.pdf"},
    {"id":"55424","name":"Declaration of interests: Jana Schalansky","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-06-30T15:57:00Z","last_updated_date":"2025-08-01T12:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-jana-schalansky_en.pdf"},
    {"id":"55435","name":"Declaration of interests: Silvy da Rocha Dias","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-01T13:52:00Z","last_updated_date":"2025-08-01T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-silvy-da-rocha-dias_en.pdf"},
    {"id":"55437","name":"Declaration of interests: Steffen Thirstrup","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-01T00:02:00Z","last_updated_date":"2024-07-26T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-steffen-thirstrup_en.pdf"},
    {"id":"55501","name":"Questions and answers - Webinar on submissions of parallel distribution notifications for centrally authorised products (CAPs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-08T11:04:00Z","last_updated_date":"2022-07-08T11:04:00Z","reference_number":"EMA/594607/2022","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-webinar-submissions-parallel-distribution-notifications-centrally-authorised-products-caps_en.pdf"},
    {"id":"55502","name":"List of the main therapeutic groups (MTGs) in crisis preparedness","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-08T14:30:00Z","last_updated_date":"2022-07-08T14:30:00Z","reference_number":"EMA/243660/2022","document_url":"https://www.ema.europa.eu/en/documents/other/list-main-therapeutic-groups-mtgs-crisis-preparedness_en.pdf"},
    {"id":"55507","name":"Agnes Saint-Raymond - Assessment outcome of occupational activities after leaving the service (June 2022)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-08T14:44:00Z","last_updated_date":"2022-07-08T14:44:00Z","reference_number":"EMA/609895/2022","document_url":"https://www.ema.europa.eu/en/documents/other/agnes-saint-raymond-assessment-outcome-occupational-activities-after-leaving-service-june-2022_en.pdf"},
    {"id":"55511","name":"Information about the clinical study data proof-of-concept pilot for industry","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-12T12:00:00Z","last_updated_date":"2024-10-18T14:08:00Z","reference_number":"EMA/174598/2022","document_url":"https://www.ema.europa.eu/en/documents/other/information-about-clinical-study-data-proof-concept-pilot-industry_en.pdf"},
    {"id":"55514","name":"Declaration of interests: Peter Twomey","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-12T09:58:00Z","last_updated_date":"2024-07-26T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-peter-twomey_en.pdf"},
    {"id":"55535","name":"Joint controllership arrangement with regard to EudraVigilance Human (EV)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-07-13T16:11:00Z","last_updated_date":"2026-01-23T17:15:00Z","reference_number":"EMA/137320/2022 Revision 1","document_url":"https://www.ema.europa.eu/en/documents/other/joint-controllership-arrangement-regard-eudravigilance-human-ev_en.pdf"},
    {"id":"55557","name":"Good practice guidance for patient and healthcare professional organisations on the prevention of shortages of medicines for human use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-15T09:18:00Z","last_updated_date":"2022-07-15T09:18:00Z","reference_number":"EMA/397143/2020","document_url":"https://www.ema.europa.eu/en/documents/other/good-practice-guidance-patient-and-healthcare-professional-organisations-prevention-shortages-medicines-human-use_en.pdf"},
    {"id":"55562","name":"Questions and answers - Digital application dataset integration (DADI) and Product Management Service (PMS) webinar - Variations form for human medicinal products - What will happen at go-live","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-15T14:52:00Z","last_updated_date":"2022-07-15T14:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-digital-application-dataset-integration-dadi-and-product-management-service-pms-webinar-variations-form-human-medicinal-products-what-will-happen-go-live_en.pdf"},
    {"id":"55586","name":"Name Review Group (NRG) plenary meeting dates: 2025-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-21T10:18:00Z","last_updated_date":"2025-08-12T15:30:00Z","reference_number":"EMA/223673/2025","document_url":"https://www.ema.europa.eu/en/documents/other/name-review-group-nrg-plenary-meeting-dates-2025-2026_en.pdf"},
    {"id":"55684","name":"Agnes Saint-Raymond - Assessment outcome of occupational activities after leaving the service (July 2022)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-25T17:29:00Z","last_updated_date":"2022-07-25T17:29:00Z","reference_number":"EMA/646562/2022","document_url":"https://www.ema.europa.eu/en/documents/other/agnes-saint-raymond-assessment-outcome-occupational-activities-after-leaving-service-july-2022_en.pdf"},
    {"id":"55701","name":"Products Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 7 Annex I: rules between SIAMED and PMS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-07-27T16:06:00Z","last_updated_date":"2022-07-27T16:06:00Z","reference_number":"EMA/622366/2022","document_url":"https://www.ema.europa.eu/en/documents/other/products-management-services-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-7-annex-i-rules-between-siamed-and-pms_en.pdf"},
    {"id":"55737","name":"Explanatory note on general fees payable to the European Medicines Agency as of 01 August 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-08-01T09:45:00Z","last_updated_date":"2022-08-01T09:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-note-general-fees-payable-european-medicines-agency-01-august-2022_en.pdf"},
    {"id":"55745","name":"Declaration of interests: Davide Prandi","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-08-01T14:11:00Z","last_updated_date":"2022-08-01T14:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-davide-prandi_en.pdf"},
    {"id":"55756","name":"Questions and answers - Digital application dataset integration (DADI) Q&A webinar - variations form for human medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-08-02T09:38:00Z","last_updated_date":"2022-08-02T09:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-digital-application-dataset-integration-dadi-qa-webinar-variations-form-human-medicinal-products_en.pdf"},
    {"id":"55806","name":"Record of data processing activity EMA IT Security Operations Centre (SOC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-08-09T15:23:00Z","last_updated_date":"2022-08-09T15:23:00Z","reference_number":"EMA/684879/2022","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-ema-it-security-operations-centre-soc_en.pdf"},
    {"id":"55813","name":"Declaration of interests: Stylianos Dolopikos","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-08-10T00:15:00Z","last_updated_date":"2025-08-01T15:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-stylianos-dolopikos_en.pdf"},
    {"id":"55848","name":"Considerations on posology for the use of the vaccine Jynneos/ Imvanex (MVA-BN) against monkeypox","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-08-19T15:32:00Z","last_updated_date":"2022-08-19T15:32:00Z","reference_number":"EMA/700120/2022","document_url":"https://www.ema.europa.eu/en/documents/other/considerations-posology-use-vaccine-jynneos-imvanex-mva-bn-against-monkeypox_en.pdf"},
    {"id":"55853","name":"List of critical medicines for Monkeypox public health emergency (PHE) under Regulation (EU) 2022/123 (obsolete)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-08-22T12:37:00Z","last_updated_date":"2023-05-17T09:14:00Z","reference_number":"EMA/662490/2022","document_url":"https://www.ema.europa.eu/en/documents/other/list-critical-medicines-monkeypox-public-health-emergency-phe-under-regulation-eu-2022123-obsolete_en.pdf"},
    {"id":"55883","name":"ACT EU multi-annual workplan 2022-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-08-30T12:01:00Z","last_updated_date":"2022-09-02T17:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/act-eu-multi-annual-workplan-2022-2026_en.pdf"},
    {"id":"55932","name":"Superseded - Composition of the Emergency Task Force (ETF) for the therapeutic response to the COVID-19 and Monkeypox Public Health Emergencies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-09-01T15:39:00Z","last_updated_date":"2023-07-27T10:11:00Z","reference_number":"EMA/687738/2022","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-composition-emergency-task-force-etf-therapeutic-response-covid-19-and-monkeypox-public-health-emergencies_en.pdf"},
    {"id":"56012","name":"Speakers' biographies - Clinical Trials Information System (CTIS) bitesize talk: Notifications - Part 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-09-07T12:47:00Z","last_updated_date":"2022-09-07T12:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-clinical-trials-information-system-ctis-bitesize-talk-notifications-part-1_en.pdf"},
    {"id":"56021","name":"European Medicine Agency's data protection notice for the Interactive Regulatory Information System (IRIS)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:41:58Z","last_updated_date":"2025-11-03T10:47:00Z","reference_number":"EMA/338056/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicine-agencys-data-protection-notice-interactive-regulatory-information-system-iris_en.pdf"},
    {"id":"56024","name":"Record of data processing activity for Interactive Regulatory Information System (IRIS)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-09-08T08:54:00Z","last_updated_date":"2023-07-20T12:29:00Z","reference_number":"EMA/338096/2023","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-interactive-regulatory-information-system-iris_en.pdf"},
    {"id":"56071","name":"Release notes - production release version 1.6.8 September 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:07:00Z","last_updated_date":"2022-09-12T16:07:00Z","reference_number":"Version 1.6.8","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-168-september-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"56072","name":"Example files - production release version 1.6.8 September 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:08:00Z","last_updated_date":"2022-09-12T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-168-september-2022-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"56074","name":"Appendix - European Union list of fragrance allergens requiring labelling on cosmetic and detergent products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:29:00Z","last_updated_date":"2022-09-12T16:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/appendix-european-union-list-fragrance-allergens-requiring-labelling-cosmetic-and-detergent-products_no.pdf"}},
    {"id":"56124","name":"Decision of the Management Board on amending budget No. 01, amending appropriations in budget 2022","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T09:59:00Z","last_updated_date":"2022-09-16T09:59:00Z","reference_number":"EMA/93616/2022","document_url":"https://www.ema.europa.eu/en/documents/other/decision-management-board-amending-budget-no-01-amending-appropriations-budget-2022_en.pdf"},
    {"id":"56177","name":"Agenda - EMA risk management information day 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-05T16:06:00Z","last_updated_date":"2024-11-05T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/agenda-ema-risk-management-information-day-2024_en.pdf"},
    {"id":"56180","name":"Terms of reference of the HMA/EMA task force on availability of authorised medicines for human and veterinary use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-09-26T09:04:00Z","last_updated_date":"2022-10-10T09:26:00Z","reference_number":"EMA/857232/2016 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/terms-reference-hmaema-task-force-availability-authorised-medicines-human-and-veterinary-use_en.pdf"},
    {"id":"56193","name":"Article 57 product data","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-07-30T09:49:00Z","last_updated_date":"2026-05-12T13:12:00Z","reference_number":"EMA/518502/2018 Rev. 86","document_url":"https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx"},
    {"id":"56270","name":"Highlights from the eighth meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-09-30T16:47:00Z","last_updated_date":"2022-09-30T16:47:00Z","reference_number":"EMA/735626/2022","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-eighth-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf"},
    {"id":"56350","name":"Composition of the HMA/EMA task force on availability of authorised medicines for human and veterinary use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-10T09:16:00Z","last_updated_date":"2022-10-26T11:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/composition-hmaema-task-force-availability-authorised-medicines-human-and-veterinary-use_en.pdf"},
    {"id":"56353","name":"Release notes - production release version 1.6.10 October 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-10T11:19:00Z","last_updated_date":"2022-10-10T11:19:00Z","reference_number":"Version 1.6.10","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1610-october-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"56355","name":"Highlights of the fifth EMA - Medicines for Europe bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-10T11:28:00Z","last_updated_date":"2022-10-10T11:28:00Z","reference_number":"EMA/775191/2021","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-fifth-ema-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"56362","name":"Questions and answers - IRIS for Good Pharmacovigilance practice (GVP) inspections training session for industry users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-11T17:07:00Z","last_updated_date":"2022-10-11T17:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-iris-good-pharmacovigilance-practice-gvp-inspections-training-session-industry-users_en.pdf"},
    {"id":"56364","name":"Questions and answers - DADI PDF electronic application forms (eAF) training webinars (26 July 2022 and 2 September 2022)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-12T17:02:00Z","last_updated_date":"2022-10-12T17:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-dadi-pdf-electronic-application-forms-eaf-training-webinars-26-july-2022-and-2-september-2022_en.pdf"},
    {"id":"56377","name":"Outcome of written procedures finalised during the period from 08 June 2022 to 29 September 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-12T18:03:00Z","last_updated_date":"2022-10-12T18:03:00Z","reference_number":"EMA/MB/792353/2022","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-08-june-2022-29-september-2022_en.pdf"},
    {"id":"56424","name":"Executive summary - Patient experience data in EU medicines development and regulatory decision-making workshop","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-17T12:03:00Z","last_updated_date":"2022-10-17T12:03:00Z","reference_number":"EMA/354012/2020","document_url":"https://www.ema.europa.eu/en/documents/other/executive-summary-patient-experience-data-eu-medicines-development-and-regulatory-decision-making-workshop_en.pdf"},
    {"id":"56471","name":"Questions and Answers about the raw data proof-of-concept pilot for industry","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-25T14:04:00Z","last_updated_date":"2022-10-25T14:04:00Z","reference_number":"EMA/658116/2022","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-about-raw-data-proof-concept-pilot-industry_en.docx"},
    {"id":"56472","name":"Pilot participation letter","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-25T14:34:00Z","last_updated_date":"2022-10-25T14:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pilot-participation-letter_en.pdf"},
    {"id":"56473","name":"Pilot participation letter","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-25T14:37:00Z","last_updated_date":"2022-10-25T14:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pilot-participation-letter_en.docx"},
    {"id":"56474","name":"Raw data submission cover letter template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-25T16:14:00Z","last_updated_date":"2022-10-25T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/raw-data-submission-cover-letter-template_en.docx"},
    {"id":"56477","name":"Amendment to the Decision of the Management Board On the EMA policy on protecting the dignity of the person and preventing psychological harassment and sexual harassment","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-10-26T10:50:00Z","last_updated_date":"2022-10-26T10:50:00Z","reference_number":"EMA/MB/259770/2022","document_url":"https://www.ema.europa.eu/en/documents/other/amendment-decision-management-board-ema-policy-protecting-dignity-person-and-preventing-psychological-harassment-and-sexual-harassment_en.pdf"},
    {"id":"56478","name":"Decision of the Management Board On application by analogy of Commission Decision C(2022) 1715 final of 24 March 2022 on home leave for officials, temporary staff and contract staff serving in a third country and repealing Commission Decision C(2013) 9035","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-10-26T10:52:00Z","last_updated_date":"2022-10-26T10:52:00Z","reference_number":"EMA/MB/574554/2022","document_url":"https://www.ema.europa.eu/en/documents/other/decision-management-board-application-analogy-commission-decision-c2022-1715-final-24-march-2022-home-leave-officials-temporary-staff-and-contract-staff-serving-third-country-and-repealing-commission_en.pdf"},
    {"id":"56488","name":"Questions and answers about the clinical study data proof-of-concept pilot for industry","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T13:00:00Z","last_updated_date":"2026-01-21T09:30:00Z","reference_number":"EMA/658116/2022","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-about-clinical-study-data-proof-concept-pilot-industry_en.pdf"},
    {"id":"56489","name":"Pilot participation letter: Clinical study data proof-of-concept","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T13:00:00Z","last_updated_date":"2025-07-07T14:01:00Z","reference_number":"EMA/659352/2022 ","document_url":"https://www.ema.europa.eu/en/documents/other/pilot-participation-letter-clinical-study-data-proof-concept_en.pdf"},
    {"id":"56490","name":"Data submission cover letter template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T13:00:00Z","last_updated_date":"2024-10-18T13:47:00Z","reference_number":"EMA/658203/2022","document_url":"https://www.ema.europa.eu/en/documents/other/data-submission-cover-letter-template_en.pdf"},
    {"id":"56491","name":"European Medicines Agency’s data protection notice for the clinical study data proof-of-concept pilot","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T13:00:00Z","last_updated_date":"2024-10-18T14:12:00Z","reference_number":"EMA/716436/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-clinical-study-data-proof-concept-pilot_en.pdf"},
    {"id":"56492","name":"Records of data processing activity for the clinical study data proof-of-concept pilot","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T13:58:00Z","last_updated_date":"2024-10-18T14:05:00Z","reference_number":"EMA/716437/2022","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-clinical-study-data-proof-concept-pilot_en.pdf"},
    {"id":"56504","name":"Decision of the European Medicines Agency on rules relating to Articles 11, 11a and 13 of the Staff Regulations concerning the handling of declared interests of staff members of the European Medicines Agency and candidates before recruitment","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2020-10-05T15:50:00Z","last_updated_date":"2025-03-26T09:04:00Z","reference_number":"EMA/259494/2016, Rev.7","document_url":"https://www.ema.europa.eu/en/documents/other/decision-european-medicines-agency-rules-relating-articles-11-11a-13-staff-regulations-concerning-handling-declared-interests-staff-members-european-medicines-agency-candidates-recruitment_en.pdf"},
    {"id":"56506","name":"Meeting highlights from the Second European Medicines Agency-Nuclear Medicines Europe bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T16:24:00Z","last_updated_date":"2022-10-28T16:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/meeting-highlights-second-european-medicines-agency-nuclear-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"56517","name":"Consolidated 3-year work plan for the Non-clinical domain including the priorities for 2023","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-11-03T10:08:00Z","last_updated_date":"2023-02-08T15:15:00Z","reference_number":"EMA/CHMP/14829/2023","document_url":"https://www.ema.europa.eu/en/documents/other/consolidated-3-year-work-plan-non-clinical-domain-including-priorities-2023_en.pdf"},
    {"id":"56602","name":"Declaration of interests: Paul Damien Lynn","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-14T11:07:00Z","last_updated_date":"2023-06-14T11:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-paul-damien-lynn_en.pdf"},
    {"id":"56603","name":"Declaration of interests: Caroline Pothet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-14T11:07:00Z","last_updated_date":"2025-08-01T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-caroline-pothet_en.pdf"},
    {"id":"56604","name":"Declaration of interests: Virginia Rojo Guerra","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-14T16:21:00Z","last_updated_date":"2025-08-01T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-virginia-rojo-guerra_en.pdf"},
    {"id":"56605","name":"Release notes - production release version 1.6.12 November 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-14T11:37:00Z","last_updated_date":"2022-11-17T09:10:00Z","reference_number":"Version 1.6.12","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1612-november-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"56606","name":"Example files - production release version 1.6.12 November 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-14T11:39:00Z","last_updated_date":"2022-11-14T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-1612-november-2022-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"56611","name":"System Demo 2022 Q1 Q&A","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-14T14:03:00Z","last_updated_date":"2022-11-14T14:03:00Z","reference_number":"EMA/871728/2022","document_url":"https://www.ema.europa.eu/en/documents/other/system-demo-2022-q1-qa_en.pdf"},
    {"id":"56612","name":"System Demo 2022 Q2 Q&A","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-14T14:03:00Z","last_updated_date":"2022-11-14T14:03:00Z","reference_number":"EMA/871758/2022","document_url":"https://www.ema.europa.eu/en/documents/other/system-demo-2022-q2-qa_en.pdf"},
    {"id":"56613","name":"Questions and answers - Quarterly system demo - Q3 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-14T14:03:00Z","last_updated_date":"2022-11-14T14:03:00Z","reference_number":"EMA/871797/2022","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-quarterly-system-demo-q3-2022_en.pdf"},
    {"id":"56622","name":"DARWIN EU data partners onboarded in Year I, II, III and IV","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-23T14:00:00Z","last_updated_date":"2026-06-17T15:46:00Z","reference_number":"EMA/856996/2022","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-data-partners-onboarded-year-i-ii-iii-iv_en.pdf"},
    {"id":"56706","name":"Provisional mandate, objectives and rules of procedure for the Quality Innovation Group (QIG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T10:36:00Z","last_updated_date":"2022-11-18T10:36:00Z","reference_number":"EMA/619783/2022","document_url":"https://www.ema.europa.eu/en/documents/other/provisional-mandate-objectives-and-rules-procedure-quality-innovation-group-qig_en.pdf"},
    {"id":"56750","name":"Science advice on medicines for Human use in the EU medicines regulatory network","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-22T16:40:00Z","last_updated_date":"2022-12-15T17:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/science-advice-medicines-human-use-eu-medicines-regulatory-network_en.pdf"},
    {"id":"56752","name":"Speaker bios - Clinical Trials Information System (CTIS) bitesize talk: Notifications - Part 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-23T16:08:00Z","last_updated_date":"2022-11-23T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speaker-bios-clinical-trials-information-system-ctis-bitesize-talk-notifications-part-2_en.pdf"},
    {"id":"56813","name":"Records of data processing activity regarding the processing of personal data in the Clinical Trials Information System (CTIS)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T11:22:00Z","last_updated_date":"2025-02-14T14:26:58Z","reference_number":"EMA/704295/2022","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regarding-processing-personal-data-clinical-trials-information-system-ctis_en.pdf"},
    {"id":"56814","name":"Launch of phase 2 of the Simultaneous National Scientific Advice pilot","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T11:50:00Z","last_updated_date":"2022-11-28T11:50:00Z","reference_number":"EMA/903809/2022","document_url":"https://www.ema.europa.eu/en/documents/other/launch-phase-2-simultaneous-national-scientific-advice-pilot_en.pdf"},
    {"id":"56830","name":"Letter of support for Neurofilament light in childhood neurological diseases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-29T16:36:00Z","last_updated_date":"2022-11-29T16:36:00Z","reference_number":"EMADOC-1700519818-959805","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-neurofilament-light-childhood-neurological-diseases_en.pdf"},
    {"id":"56831","name":"Letter of support for a Model-based Clinical Trial Simulation Platform to Optimize Design of Efficacy Evaluation Studies in Parkinson’s Disease","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-29T16:36:00Z","last_updated_date":"2022-11-29T16:36:00Z","reference_number":"EMADOC-1700519818-955717","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-model-based-clinical-trial-simulation-platform-optimize-design-efficacy-evaluation-studies-parkinsons-disease_en.pdf"},
    {"id":"56855","name":"Minimum inhibitory concentration (MIC) breakpoints","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-01T18:02:00Z","last_updated_date":"2025-04-14T17:04:00Z","reference_number":"EMA/916812/2022","document_url":"https://www.ema.europa.eu/en/documents/other/minimum-inhibitory-concentration-mic-breakpoints_en.xlsx"}    {"id":"56879","name":"Release notes - production release version 1.6.13 December 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-05T16:53:00Z","last_updated_date":"2022-12-19T17:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1613-december-2022-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"56887","name":"Questions and answers - Human Variations eAF go-live Q&A session (8 November 2022)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-06T13:19:00Z","last_updated_date":"2022-12-06T13:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-human-variations-eaf-go-live-qa-session-8-november-2022_en.pdf"},
    {"id":"56888","name":"Questions and answers - Human Variations eAF go-live Q&A session (27 October 2022)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-06T13:21:00Z","last_updated_date":"2022-12-06T13:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-human-variations-eaf-go-live-qa-session-27-october-2022_en.pdf"},
    {"id":"56890","name":"ETF statement on the use of the EMA approved bivalent original / Omicron BA.4-5 mRNA vaccines for primary series","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-06T16:22:00Z","last_updated_date":"2022-12-06T16:22:00Z","reference_number":"EMA/922920/2022","document_url":"https://www.ema.europa.eu/en/documents/other/etf-statement-use-ema-approved-bivalent-original-omicron-ba4-5-mrna-vaccines-primary-series_en.pdf"},
    {"id":"56905","name":"Timetable: Companion diagnostic follow-up consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-08T08:50:00Z","last_updated_date":"2025-10-03T16:52:00Z","reference_number":"EMA/3932/2022 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-companion-diagnostic-follow-consultation_en.xlsx"},
    {"id":"56906","name":"Timetable: Companion diagnostic follow-up consultation - ATMP","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-08T08:52:00Z","last_updated_date":"2025-10-03T16:51:00Z","reference_number":"EMA/3933/2022 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/timetable-companion-diagnostic-follow-consultation-atmp_en.xlsx"},
    {"id":"56913","name":"Possible use of the medicinal product TPOXX for the treatment of monkeypox","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-08T17:15:00Z","last_updated_date":"2022-12-08T17:15:00Z","reference_number":"EMA/904994/2022","document_url":"https://www.ema.europa.eu/en/documents/other/possible-use-medicinal-product-tpoxx-treatment-monkeypox_en.pdf"},
    {"id":"56919","name":"Letter of support for TREAT-NMD Core Dataset for Spinal Muscular Atrophy (SMA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-08T17:55:00Z","last_updated_date":"2022-12-08T17:55:00Z","reference_number":"EMADOC-1700519818-958775","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-treat-nmd-core-dataset-spinal-muscular-atrophy-sma_en.pdf"},
    {"id":"56976","name":"Programme and registration form - eXtended EudraVigilance Medicinal Product Dictionary training courses - February, May and July 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T13:15:00Z","last_updated_date":"2022-12-15T13:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/programme-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-training-courses-february-may-and-july-2023_en.pdf"},
    {"id":"56978","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary live virtual training course for sponsors - February, May 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T14:23:00Z","last_updated_date":"2022-12-15T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/programme-extended-eudravigilance-medicinal-product-dictionary-live-virtual-training-course-sponsors-february-may-2023_en.pdf"},
    {"id":"56979","name":"Declaration of interests: Emily Drury","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T14:27:00Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-emily-drury_en.pdf"},
    {"id":"56990","name":"European Medicines Agency’s data protection notice for the operation of the Security Access Control System","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:41:41Z","last_updated_date":"2026-02-24T11:00:00Z","reference_number":"EMA/225532/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-operation-security-access-control-system_en.pdf"},
    {"id":"57024","name":"Vaccine Working Party (VWP) work plan 2022-2024","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2022-12-15T08:30:00Z","last_updated_date":"2024-02-14T16:46:00Z","reference_number":"EMA/531728/2023","document_url":"https://www.ema.europa.eu/en/documents/other/vaccine-working-party-vwp-work-plan-2022-2024_en.pdf"},
    {"id":"57092","name":"Recommended due dates for submission of annual statements for centrally and non-centrally authorised products (CAPs and non-CAPs) to end 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-07T11:07:00Z","last_updated_date":"2023-02-07T11:07:00Z","reference_number":"EMA/58848/2023","document_url":"https://www.ema.europa.eu/en/documents/other/recommended-due-dates-submission-annual-statements-centrally-and-non-centrally-authorised-products-caps-and-non-caps-end-2023_en.xlsx"},
    {"id":"57095","name":"Letter of Support of model-based clinical trial simulation platform (CTSP) for Duchenne Muscular Dystrophy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T15:36:00Z","last_updated_date":"2022-12-16T15:36:00Z","reference_number":"EMADOC-1700519818-955047","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-model-based-clinical-trial-simulation-platform-ctsp-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"57103","name":"Speakers' biographies - Clinical Trials Information System (CTIS) bitesize talk: Annual safety report (ASR)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-20T15:29:00Z","last_updated_date":"2022-12-20T15:29:00Z","reference_number":"EMA/587142/2022","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biographies-clinical-trials-information-system-ctis-bitesize-talk-annual-safety-report-asr_en.pdf"},
    {"id":"57110","name":"Highlights from the ninth meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-21T14:47:00Z","last_updated_date":"2022-12-21T14:47:00Z","reference_number":"EMA/INS/GMP/907821/2022","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-ninth-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf"},
    {"id":"57145","name":"European Medicines Agency's data protection notice concerning the Veterinary Info Day meeting on 16-17 February 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T15:20:00Z","last_updated_date":"2022-12-22T15:20:00Z","reference_number":"EMA/931102/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-concerning-veterinary-info-day-meeting-16-17-february-2023_en.pdf"},
    {"id":"57148","name":"Questions and answers - Quarterly system demo - Q4 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T16:38:00Z","last_updated_date":"2022-12-22T16:38:00Z","reference_number":"EMA/955937/2022 ","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-quarterly-system-demo-q4-2022_en.pdf"},
    {"id":"57163","name":"Outcome of written procedures finalised during the period from 30 September 2022 to 5 December 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-05T10:40:00Z","last_updated_date":"2023-01-05T10:40:00Z","reference_number":"EMA/MB/794683/2022","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-30-september-2022-5-december-2022_en.pdf"},
    {"id":"57174","name":"European Medicines Agency budget for 2023","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-01-09T08:50:00Z","last_updated_date":"2023-01-09T08:50:00Z","reference_number":"EMA/MB/914861/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-budget-2023_en.pdf"},
    {"id":"57297","name":"Implementation of the new WHO certificate template – compilation of changes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-16T15:22:00Z","last_updated_date":"2023-01-16T15:22:00Z","reference_number":"EMA/12375/2023","document_url":"https://www.ema.europa.eu/en/documents/other/implementation-new-who-certificate-template-compilation-changes_en.pdf"},
    {"id":"57303","name":"Policy 44: European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts - As adopted by EMA Management Board on 14-15 December 2022","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-01-04T11:12:00Z","last_updated_date":"2023-01-04T11:12:00Z","reference_number":"EMA/MB/89351/2020 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/policy-44-european-medicines-agency-policy-handling-competing-interests-scientific-committees-members-and-experts-adopted-ema-management-board-14-15-december-2022_en.pdf"},
    {"id":"57304","name":"Policy 58: European Medicines Agency policy on the handling of competing interests of Management Board members - As adopted by EMA Management Board on 14-15 December 2022","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-01-04T10:13:00Z","last_updated_date":"2023-01-04T10:13:00Z","reference_number":"EMA/MB/89374/2020 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/policy-58-european-medicines-agency-policy-handling-competing-interests-management-board-members-adopted-ema-management-board-14-15-december-2022_en.pdf"},
    {"id":"57305","name":"European Medicines Agency breach of trust procedure for competing interests of and disclosure of confidential information by scientific committees’ members and experts - As adopted by EMA Management Board on 14-15 December 2022","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-01-04T21:01:00Z","last_updated_date":"2023-01-04T21:01:00Z","reference_number":"EMA/154320/2012 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-breach-trust-procedure-competing-interests-and-disclosure-confidential-information-scientific-committees-members-and-experts-adopted-ema-management-board-14-15-december-2022_en.pdf"},
    {"id":"57306","name":"Breach of trust procedure for competing interests and disclosure of confidential information by members of the European Medicines Agency’s Management Board","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-01-04T17:00:00Z","last_updated_date":"2025-12-18T18:08:42Z","reference_number":"EMA/MB/309079/2012 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/breach-trust-procedure-competing-interests-disclosure-confidential-information-members-european-medicines-agencys-management-board_en.pdf"},
    {"id":"57337","name":"EMA transparency measures for medicines addressing public health emergencies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-20T09:00:00Z","last_updated_date":"2023-01-20T09:00:00Z","reference_number":"EMA/244151/2020","document_url":"https://www.ema.europa.eu/en/documents/other/ema-transparency-measures-medicines-addressing-public-health-emergencies_en.pdf"},
    {"id":"57358","name":"Records of data processing activity for the Network Portfolio website","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-23T11:17:00Z","last_updated_date":"2023-01-23T11:17:00Z","reference_number":"EMA/945990/2022","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-network-portfolio-website_en.pdf"},
    {"id":"57374","name":"EVVet3 EVWeb Production - Release notes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T12:04:00Z","last_updated_date":"2026-01-26T11:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/evvet3-evweb-production-release-notes_en.pdf"},
    {"id":"57375","name":"Records of data processing activity for training using virtual reality EMA/75747/2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-24T14:49:00Z","last_updated_date":"2023-01-24T14:49:00Z","reference_number":"EMA/112992/2022","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-training-using-virtual-reality-ema-75747-2022_en.pdf"},
    {"id":"57377","name":"European Medicines Agency’s data protection notice for the procedure for handling and reporting internally potential fraud and irregularities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-25T10:40:00Z","last_updated_date":"2023-01-25T10:40:00Z","reference_number":"EMA/905403/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-procedure-handling-reporting-internally-potential-fraud-irregularities_en.pdf"},
    {"id":"57378","name":"Record of data processing activity for reporting fraud and irregularities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-25T11:08:00Z","last_updated_date":"2023-01-25T11:08:00Z","reference_number":"EMA/905306/2022","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-reporting-fraud-irregularities_en.pdf"},
    {"id":"57383","name":"Statement on the amended policy on orphan designations for inherited retinal dystrophies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-25T12:09:00Z","last_updated_date":"2023-01-25T12:09:00Z","reference_number":"EMADOC-628903358-34665","document_url":"https://www.ema.europa.eu/en/documents/other/statement-amended-policy-orphan-designations-inherited-retinal-dystrophies_en.pdf"},
    {"id":"57390","name":"Questions and answers on EMA pilot offering enhanced support to academic and non- profit developers of Advanced Therapy Medicinal Products (ATMPs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-26T10:25:00Z","last_updated_date":"2024-02-08T15:30:00Z","reference_number":"EMA/797476/2022/Rev1","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-ema-pilot-offering-enhanced-support-academic-non-profit-developers-advanced-therapy-medicinal-products-atmps_en.pdf"},
    {"id":"57405","name":"Letter of Support for Braintale platforms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-26T14:38:00Z","last_updated_date":"2023-01-26T14:38:00Z","reference_number":"EMADOC-1700519818-982447","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-braintale-platforms_en.pdf"},
    {"id":"57436","name":"Question and answer document on the Guideline on assessment and control of DNA reactive (mutagenic) impurities in veterinary medicinal products (EMA/CVMP/SWP/377245/2016)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T12:15:00Z","last_updated_date":"2023-01-27T12:15:00Z","reference_number":"EMA/CVMP/SWP/32272/2022","document_url":"https://www.ema.europa.eu/en/documents/other/question-and-answer-document-guideline-assessment-and-control-dna-reactive-mutagenic-impurities-veterinary-medicinal-products-emacvmpswp3772452016_en.pdf"},
    {"id":"57438","name":"Q&A on the Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T14:20:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/93740/2023 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/qa-statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf"},
    {"id":"57440","name":"CTTM03 - Step-by-step guide (Create organisations locally in CTIS)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T16:44:00Z","last_updated_date":"2023-01-27T16:44:00Z","reference_number":"Version 1 – January 2023","document_url":"https://www.ema.europa.eu/en/documents/other/cttm03-step-step-guide-create-organisations-locally-ctis_en.pdf"},
    {"id":"57475","name":"Release notes - production release version 1.6.216 January 2023 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T12:57:00Z","last_updated_date":"2023-02-21T15:31:00Z","reference_number":"Version 2","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-16216-january-2023-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"57476","name":"Examples files for API","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T12:59:00Z","last_updated_date":"2023-01-31T12:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/examples-files-api_en.zip"},
    {"id":"57484","name":"CTIS - Readiness for Mandatory use of the CTR from 31 January 2023 - Presentation deck","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T14:26:00Z","last_updated_date":"2023-01-31T14:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ctis-readiness-mandatory-use-ctr-31-january-2023-presentation-deck_en.pdf"},
    {"id":"57485","name":"Speaker Bios","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T14:31:00Z","last_updated_date":"2023-01-31T14:31:00Z","reference_number":"EMA/33990/2023","document_url":"https://www.ema.europa.eu/en/documents/other/speaker-bios_en.pdf"},
    {"id":"57493","name":"Application of EMA’s transparency principles to the clinical study data proof-of-concept pilot","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-01T15:41:00Z","last_updated_date":"2024-10-18T14:16:00Z","reference_number":"EMA/949891/2022","document_url":"https://www.ema.europa.eu/en/documents/other/application-emas-transparency-principles-clinical-study-data-proof-concept-pilot_en.pdf"},
    {"id":"57498","name":"Clinical Trials Information System - Risk mitigation plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-07T11:10:00Z","last_updated_date":"2023-02-07T11:10:00Z","reference_number":"EMA/956806/2022","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trials-information-system-risk-mitigation-plan_en.pdf"},
    {"id":"57513","name":"Scientific recommendations on classification of advanced therapy medicinal products (January 2021 – December 2022)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-03T11:33:00Z","last_updated_date":"2023-02-03T11:33:00Z","reference_number":"EMA/140033/2021","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-recommendations-classification-advanced-therapy-medicinal-products-january-2021-december-2022_en.xlsx"},
    {"id":"57516","name":"Priority Action 10: Training strategy - Accelerating Clinical Trials in the European Union (ACT EU)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-03T13:00:00Z","last_updated_date":"2023-02-03T13:00:00Z","reference_number":"EMA/42033/2023","document_url":"https://www.ema.europa.eu/en/documents/other/priority-action-10-training-strategy-accelerating-clinical-trials-european-union-act-eu_en.pdf"},
    {"id":"57545","name":"Highlights from the fourth meeting of the Nitrosamine Implementation Oversight Group (NIOG) and pharmaceutical Industry","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-07T14:16:00Z","last_updated_date":"2023-02-07T14:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-fourth-meeting-nitrosamine-implementation-oversight-group-niog-and-pharmaceutical-industry_en.pdf"},
    {"id":"57567","name":"Speakers’ biography","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T11:37:00Z","last_updated_date":"2023-02-08T11:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speakers-biography_en.pdf"},
    {"id":"57581","name":"EMA health threats plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-12-17T10:13:00Z","last_updated_date":"2025-11-18T13:28:00Z","reference_number":"EMA/864626/2022 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/ema-health-threats-plan_en.pdf"},
    {"id":"57583","name":"Note on European Medicines Agency’s involvement in HORIZON-HLTH-2023-TOOL-05-09: Developing a Data Quality and Utility Label for the European Health Data Space","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-09T11:41:00Z","last_updated_date":"2023-02-09T11:41:00Z","reference_number":"EMA/53514/2023","document_url":"https://www.ema.europa.eu/en/documents/other/note-european-medicines-agencys-involvement-horizon-hlth-2023-tool-05-09-developing-data-quality-and-utility-label-european-health-data-space_en.pdf"},
    {"id":"57586","name":"Questions and answers by the Query Management Working Group on CTIS and the CTR","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T08:00:00Z","last_updated_date":"2023-02-15T16:09:00Z","reference_number":"EMA/618888/2022","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-query-management-working-group-ctis-ctr_en.pdf"},
    {"id":"57697","name":"Considerations for research / project teams seeking competent authority participation in externally funded regulatory science and public health research projects related to medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-20T10:15:00Z","last_updated_date":"2023-02-20T10:15:00Z","reference_number":"EMA/38599/2023","document_url":"https://www.ema.europa.eu/en/documents/other/considerations-research-project-teams-seeking-competent-authority-participation-externally-funded-regulatory-science-and-public-health-research-projects-related-medicinal-products_en.pdf"},
    {"id":"57716","name":"Policy 84: Multilingualism on the EMA website and in external communications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-17T16:45:00Z","last_updated_date":"2026-06-02T14:20:00Z","reference_number":"EMA/60848/2026","document_url":"https://www.ema.europa.eu/en/documents/other/policy-84-multilingualism-ema-website-external-communications_en.pdf"},
    {"id":"57765","name":"Committee for Orphan Medicinal Products (COMP) meetings 2023, 2024, 2025 and 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-21T16:56:00Z","last_updated_date":"2023-02-21T16:56:00Z","reference_number":"EMA/COMP/79977/2023","document_url":"https://www.ema.europa.eu/en/documents/other/committee-orphan-medicinal-products-comp-meetings-2023-2024-2025-and-2026_en.pdf"},
    {"id":"57772","name":"CAT meetings in 2025 and 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-22T09:12:00Z","last_updated_date":"2023-02-22T09:12:00Z","reference_number":"EMA/CAT/78070/2023","document_url":"https://www.ema.europa.eu/en/documents/other/cat-meetings-2025-and-2026_en.pdf"},
    {"id":"57796","name":"CVMP meeting dates 2025 and 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-23T11:50:00Z","last_updated_date":"2023-02-23T11:50:00Z","reference_number":"EMA/60458/2023","document_url":"https://www.ema.europa.eu/en/documents/other/cvmp-meeting-dates-2025-and-2026_en.pdf"},
    {"id":"57799","name":"Mandate, objectives and rules of procedure for the Oncology European Specialised Expert Communities (ESEC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-23T14:23:00Z","last_updated_date":"2023-02-23T14:23:00Z","reference_number":"EMA/CHMP/58471/2022","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-oncology-european-specialised-expert-communities-esec_en.pdf"},
    {"id":"57814","name":"Question and Answer information session on the pilot for expert panels’ scientific advice to manufacturers of high-risk medical devices","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-02-24T10:45:00Z","last_updated_date":"2023-02-24T10:45:00Z","reference_number":"EMA/81171/2023","document_url":"https://www.ema.europa.eu/en/documents/other/question-answer-information-session-pilot-expert-panels-scientific-advice-manufacturers-high-risk-medical-devices_en.pdf"},
    {"id":"57855","name":"Responses to list of issues - Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-01T17:21:00Z","last_updated_date":"2023-03-01T17:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/responses-list-issues-stride-velocity-95th-centile-primary-endpoint-studies-ambulatory-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"57937","name":"CHMP meeting dates 2023, 2024, 2025 and 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T15:40:00Z","last_updated_date":"2023-03-07T15:40:00Z","reference_number":"EMA/73125/2023","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-meeting-dates-2023-2024-2025-and-2026_en.pdf"},
    {"id":"57963","name":"EMA reply to a letter from Members of the European Parliament, Mr Agius Saliba, Ms Ries, Mr Duda, Mr Biedroń, Ms Cerdas and Ms Metz concerning psychedelic-assisted therapies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T13:42:00Z","last_updated_date":"2023-03-09T13:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-reply-letter-members-european-parliament-mr-agius-saliba-ms-ries-mr-duda-mr-biedron-ms-cerdas-and-ms-metz-concerning-psychedelic-assisted-therapies_en.pdf"},
    {"id":"57986","name":"European Medicines Agency’s data protection notice for the European Union (EU) Metadata Catalogue","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:41:22Z","last_updated_date":"2024-10-28T17:41:22Z","reference_number":"EMA/114219/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-european-union-eu-metadata-catalogue_en.pdf"},
    {"id":"58001","name":"Clusters of Excellence Discussion Paper","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-13T11:54:00Z","last_updated_date":"2023-03-13T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/clusters-excellence-discussion-paper_en.pdf"},
    {"id":"58002","name":"Records of data processing activity regarding the European Union (EU) Metadata Catalogue","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-13T11:56:00Z","last_updated_date":"2023-03-13T11:56:00Z","reference_number":"EMA/110797/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regarding-european-union-eu-metadata-catalogue_en.pdf"},
    {"id":"58014","name":"Release notes - production release version 1.6.20 March 2023 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-13T17:33:00Z","last_updated_date":"2023-03-13T17:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1620-march-2023-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"58016","name":"Annex to the evaluation guide for good-manufacturing-practice regulatory compliance programme: Audit checklist","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-14T08:45:00Z","last_updated_date":"2023-03-14T08:45:00Z","reference_number":"EMA/INS/GMP/119414/2023","document_url":"https://www.ema.europa.eu/en/documents/other/annex-evaluation-guide-good-manufacturing-practice-regulatory-compliance-programme-audit-checklist_en.pdf"},
    {"id":"58018","name":"Annex to the working arrangement between the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-14T09:17:00Z","last_updated_date":"2023-03-14T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-working-arrangement-between-european-medicines-agency-ema-and-european-centre-disease-prevention-and-control-ecdc_en.pdf"},
    {"id":"58028","name":"Records of data processing activity for the EMA intranet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-15T15:53:00Z","last_updated_date":"2023-03-15T15:53:00Z","reference_number":"EMA/789752/2022","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-ema-intranet_en.pdf"},
    {"id":"58069","name":"Outcome of written procedures finalised during the period from 6 December 2022 to 8 March 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-20T13:41:00Z","last_updated_date":"2023-03-20T13:41:00Z","reference_number":"EMA/MB/948919/2022","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-6-december-2022-8-march-2023_en.pdf"},
    {"id":"58075","name":"Records of data processing activity for the use of Microsoft Edge","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-20T16:14:00Z","last_updated_date":"2023-03-20T16:14:00Z","reference_number":"EMA/123800/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-use-microsoft-edge_en.pdf"},
    {"id":"58076","name":"Records of data processing activity for the use of Microsoft Intune","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-20T16:15:00Z","last_updated_date":"2023-03-20T16:15:00Z","reference_number":"EMA/124005/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-use-microsoft-intune_en.pdf"},
    {"id":"58077","name":"European Medicines Agency's data protection notice for Microsoft Edge","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:40:48Z","last_updated_date":"2024-10-28T17:40:48Z","reference_number":"EMA/123801/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-microsoft-edge_en.pdf"},
    {"id":"58078","name":"European Medicines Agency's data protection notice for use of Microsoft Intune for personal and corporate-owned devices","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:41:06Z","last_updated_date":"2024-10-28T17:41:06Z","reference_number":"EMA/124004/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-use-microsoft-intune-personal-corporate-owned-devices_en.pdf"},
    {"id":"58102","name":"Questions and answers - EIC / EMA Info Day: Regulatory support for the development of innovative medicines and technologies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-21T16:43:00Z","last_updated_date":"2023-03-23T16:56:00Z","reference_number":"EMA/104804/2023","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-eic-ema-info-day-regulatory-support-development-innovative-medicines-and-technologies_en.pdf"},
    {"id":"58124","name":"Rules for reimbursement of expenses for delegates attending meetings with effect from 17 March 2023","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T15:36:00Z","last_updated_date":"2025-09-03T17:30:00Z","reference_number":"EMA/MB/279597/2018 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/other/rules-reimbursement-expenses-delegates-attending-meetings-effect-17-march-2023_en.pdf"},
    {"id":"58153","name":"HMPC meetings in 2025 and 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T11:55:00Z","last_updated_date":"2026-05-13T12:30:00Z","reference_number":"EMA/HMPC/138815/2023","document_url":"https://www.ema.europa.eu/en/documents/other/hmpc-meetings-2025-2026_en.pdf"},
    {"id":"58159","name":"Agnes Saint-Raymond - Assessment outcome of occupational activities after leaving the service (March 2023)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T15:00:00Z","last_updated_date":"2023-03-24T15:00:00Z","reference_number":"EMA/133985/2023","document_url":"https://www.ema.europa.eu/en/documents/other/agnes-saint-raymond-assessment-outcome-occupational-activities-after-leaving-service-march-2023_en.pdf"},
    {"id":"58173","name":"Records of data processing activity relating to staff engagement surveys","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-27T16:41:00Z","last_updated_date":"2023-03-27T16:41:00Z","reference_number":"EMA/599777/2020","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-relating-staff-engagement-surveys_en.pdf"},
    {"id":"58212","name":"Records of data processing for Data Analysis and Real World Interrogation Network (DARWIN EU®)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T10:47:00Z","last_updated_date":"2023-03-30T10:47:00Z","reference_number":"EMA/51069/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-data-analysis-real-world-interrogation-network-darwin-eur_en.pdf"},
    {"id":"58225","name":"Questions and answers - Quarterly system demo - Q1 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T13:34:00Z","last_updated_date":"2023-03-30T13:34:00Z","reference_number":"EMA/149104/2023","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-quarterly-system-demo-q1-2023_en.pdf"},
    {"id":"58248","name":"Explanatory note on general fees payable to the European Medicines Agency as of 1 April 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T15:22:00Z","last_updated_date":"2023-03-31T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-note-general-fees-payable-european-medicines-agency-1-april-2023_en.pdf"},
    {"id":"58256","name":"European Medicines Agency guidance to support the preparation of the PRIME kick-off meeting and submission readiness meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T15:55:00Z","last_updated_date":"2023-03-31T15:55:00Z","reference_number":"EMA/150060/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-guidance-support-preparation-prime-kick-meeting-and-submission-readiness-meeting_en.pdf"},
    {"id":"58270","name":"Letter of support for the development of the PAH-SYMPACT Instrument for use in Pulmonary Hypertension clinical trials","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-04-03T11:37:00Z","last_updated_date":"2023-04-03T11:37:00Z","reference_number":"EMADOC-1700519818-1054252","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-development-pah-sympact-instrument-use-pulmonary-hypertension-clinical-trials_en.pdf"},
    {"id":"58292","name":"EMA GCP IWG points to consider regarding the management of ongoing clinical trials impacted by political conflicts, natural disasters or other major disruptions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-04-05T14:01:00Z","last_updated_date":"2023-04-05T14:01:00Z","reference_number":"EMA/INS/GCP/622198/2022","document_url":"https://www.ema.europa.eu/en/documents/other/ema-gcp-iwg-points-consider-regarding-management-ongoing-clinical-trials-impacted-political-conflicts-natural-disasters-or-other-major-disruptions_en.pdf"},
    {"id":"58407","name":"Release notes - production release version 1.6.22 April 2023 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-04-18T13:59:00Z","last_updated_date":"2023-04-20T14:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1622-april-2023-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"58469","name":"European Union Member State Public Holidays Recorded in CTIS (year: 2023)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-04-20T09:44:00Z","last_updated_date":"2023-04-20T09:44:00Z","reference_number":"EMA/176184/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-member-state-public-holidays-recorded-ctis-year-2023_en.pdf"},
    {"id":"58496","name":"EMA reply in follow up to the COVI exchange of views on 27 March 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T10:17:00Z","last_updated_date":"2023-04-24T10:17:00Z","reference_number":"EMA/150586/2023","document_url":"https://www.ema.europa.eu/en/documents/other/ema-reply-follow-covi-exchange-views-27-march-2023_en.pdf"},
    {"id":"58561","name":"Guidance document on how to approach the protection of personal data and commercially confidential information while using the Clinical Trials Information System (CTIS) version 1.1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-03T15:00:00Z","last_updated_date":"2023-07-12T13:05:00Z","reference_number":"EMA/212507/2021","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-document-how-approach-protection-personal-data-commercially-confidential-information-while-using-clinical-trials-information-system-ctis-version-11_en.pdf"},
    {"id":"58564","name":"Provisional mandate, objectives and rules of procedure for the Nitrosamines Safety Operational Experts Group (NS OEG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-03T09:56:00Z","last_updated_date":"2023-05-03T09:56:00Z","reference_number":"EMA/425517/2022","document_url":"https://www.ema.europa.eu/en/documents/other/provisional-mandate-objectives-and-rules-procedure-nitrosamines-safety-operational-experts-group-ns-oeg_en.pdf"},
    {"id":"58567","name":"Letter of Support for an Acceptability Score Test in relative acceptability testing for oral medicines in children under 12 years of age","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-03T10:30:00Z","last_updated_date":"2023-05-03T10:30:00Z","reference_number":"EMADOC-1700519818-1066960","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-acceptability-score-test-relative-acceptability-testing-oral-medicines-children-under-12-years-age_en.pdf"},
    {"id":"58570","name":"European Medicines Agency’s data protection notice for the EMA Help Desk","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/123948/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-ema-help-desk_en.pdf"},
    {"id":"58571","name":"Records of data processing activity for ServiceNow","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-03T11:25:00Z","last_updated_date":"2023-05-03T11:25:00Z","reference_number":"EMA/123947/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-servicenow_en.pdf"},
    {"id":"58577","name":"Rules of procedure of the Executive Steering Group on Shortages of Medical Devices","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-03T16:14:00Z","last_updated_date":"2023-05-03T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/rules-procedure-executive-steering-group-shortages-medical-devices_en.pdf"},
    {"id":"58633","name":"Letter of Support for the statistical adjustment on deep learning prognosis covariates obtained from histological slides","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-11T14:52:00Z","last_updated_date":"2023-05-11T14:52:00Z","reference_number":"EMADOC-1700519818-1064889","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-statistical-adjustment-deep-learning-prognosis-covariates-obtained-histological-slides_en.pdf"},
    {"id":"58656","name":"Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T12:30:00Z","last_updated_date":"2023-05-12T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/real-world-evidence-perspectives-european-society-cardiology-cardiovascular-round-table-contribution-european-medicines-agency_en.pdf"},
    {"id":"58668","name":"Highlights - Fourth Industry Standing Group (ISG) meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:16:00Z","last_updated_date":"2023-05-12T16:16:00Z","reference_number":"EMA/44728/2023","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-fourth-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"58674","name":"COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose - European Centre for Disease Prevention and Control (ECDC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:39:00Z","last_updated_date":"2023-05-12T16:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/covid-19-vaccine-effectiveness-adolescents-aged-12-17-years-and-interim-public-health-considerations-administration-booster-dose-european-centre-disease-prevention-and-control-ecdc_en.pdf"},
    {"id":"58725","name":"Records of data processing activity for MS Suite","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T10:59:00Z","last_updated_date":"2023-05-22T10:59:00Z","reference_number":"EMA/188186/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-ms-suite_en.pdf"},
    {"id":"58726","name":"Records of data processing activity for MS Suite","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T10:59:00Z","last_updated_date":"2023-05-22T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-ms-suite_en.pdf-0"},
    {"id":"58727","name":"European Medicines Agency’s Data Protection Notice for the use of Microsoft Applications: OneDrive, Outlook 365, Teams and SharePoint","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:40:29Z","last_updated_date":"2026-04-28T15:16:00Z","reference_number":"EMA/188185/2023 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-use-microsoft-applications-onedrive-outlook-365-teams-sharepoint_en.pdf"}    {"id":"58779","name":"Scientific recommendations on classification of advanced therapy medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-25T12:36:00Z","last_updated_date":"2025-11-25T11:17:00Z","reference_number":"EMA/140033/2021","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-recommendations-classification-advanced-therapy-medicinal-products_en.xlsx"},
    {"id":"58780","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) live virtual training courses for sponsors - October and November 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-25T13:14:00Z","last_updated_date":"2023-07-12T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/programme-extended-eudravigilance-medicinal-product-dictionary-xevmpd-live-virtual-training-courses-sponsors-october-and-november-2023_en.pdf"},
    {"id":"58781","name":"Programme - eXtended EudraVigilance Medicinal Product Dictionary training courses - September, October and November 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-25T13:24:00Z","last_updated_date":"2023-07-12T14:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/programme-extended-eudravigilance-medicinal-product-dictionary-training-courses-september-october-and-november-2023_en.pdf"},
    {"id":"58811","name":"Agenda and registration form - Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Virtual hands-on training course using the EudraVigilance system (September-December 2023)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-30T13:07:00Z","last_updated_date":"2023-05-30T13:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/agenda-and-registration-form-mandatory-use-isoich-e2br3-individual-case-safety-reporting-eu-virtual-hands-training-course-using-eudravigilance-system-september-december-2023_en.pdf"},
    {"id":"58816","name":"Mandate, objectives and rules of procedure for the European Sales and Use of Antimicrobials for veterinary medicine Working Group (ESUAvet WG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-31T09:31:00Z","last_updated_date":"2023-05-31T09:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-european-sales-and-use-antimicrobials-veterinary-medicine-working-group-esuavet-wg_en.pdf"},
    {"id":"58817","name":"Mandate, objectives and rules of procedure for the European Sales and Use of Antimicrobials for veterinary medicine Working Group (ESUAvet WG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-05-31T09:31:00Z","last_updated_date":"2023-05-31T09:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-european-sales-and-use-antimicrobials-veterinary-medicine-working-group-esuavet-wg_en.pdf-0"},
    {"id":"58841","name":"Mandate, objectives and rules of procedure for the European Sales and Use of Antimicrobials for veterinary medicine Working Group (ESUAvet WG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-01T07:27:00Z","last_updated_date":"2023-06-01T07:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-european-sales-and-use-antimicrobials-veterinary-medicine-working-group-esuavet-wg_en.pdf-1"},
    {"id":"58851","name":"Contacts at the European Medicines Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-02T09:46:00Z","last_updated_date":"2023-06-02T09:46:00Z","reference_number":"EMA/147114/2023","document_url":"https://www.ema.europa.eu/en/documents/other/contacts-european-medicines-agency_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/contacts-european-medicines-agency_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/contacts-european-medicines-agency_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/contacts-european-medicines-agency_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/contacts-european-medicines-agency_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/contacts-european-medicines-agency_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/contacts-european-medicines-agency_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/contacts-european-medicines-agency_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/contacts-european-medicines-agency_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/other/contacts-european-medicines-agency_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/contacts-european-medicines-agency_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/contacts-european-medicines-agency_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/contacts-european-medicines-agency_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/contacts-european-medicines-agency_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/contacts-european-medicines-agency_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/contacts-european-medicines-agency_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/contacts-european-medicines-agency_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/contacts-european-medicines-agency_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/contacts-european-medicines-agency_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/contacts-european-medicines-agency_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/contacts-european-medicines-agency_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/contacts-european-medicines-agency_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/contacts-european-medicines-agency_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/contacts-european-medicines-agency_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/contacts-european-medicines-agency_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/contacts-european-medicines-agency_no.pdf"}},
    {"id":"58856","name":"Declaration of interests: Veronique Le Ber","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-02T10:19:00Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-veronique-le-ber_en.pdf"},
    {"id":"58878","name":"Release notes - production release version 1.6.25 June 2023 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-06T08:40:00Z","last_updated_date":"2023-06-06T08:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1625-june-2023-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"58879","name":"ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-06T11:45:00Z","last_updated_date":"2023-06-06T11:45:00Z","reference_number":"EMA/257222/2023","document_url":"https://www.ema.europa.eu/en/documents/other/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants_en.pdf"},
    {"id":"58880","name":"EMA and ECDC statement on updating COVID-19 vaccines to target new SARS-CoV-2 virus variants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-06T12:18:00Z","last_updated_date":"2023-06-06T12:18:00Z","reference_number":"EMA/253989/2023","document_url":"https://www.ema.europa.eu/en/documents/other/ema-and-ecdc-statement-updating-covid-19-vaccines-target-new-sars-cov-2-virus-variants_en.pdf"},
    {"id":"58909","name":"Management Board meeting dates 2024-2025","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-06-09T13:59:00Z","last_updated_date":"2023-06-09T13:59:00Z","reference_number":"EMA/MB/38032/2023","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2024-2025_en.pdf"},
    {"id":"58917","name":"Outcome of written procedure finalised during the period from 9 March to 2 June 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-12T11:34:00Z","last_updated_date":"2023-06-12T11:34:00Z","reference_number":"EMA/MB/106869/2023","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedure-finalised-during-period-9-march-2-june-2023_en.pdf"},
    {"id":"58919","name":"Letter of Support for TUMMY-UC – a Patient- and Observer-Reported Outcome for Paediatric Ulcerative Colitis (UC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-12T11:47:00Z","last_updated_date":"2023-06-12T11:47:00Z","reference_number":"EMADOC-1700519818-1033762","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-tummy-uc-patient-and-observer-reported-outcome-paediatric-ulcerative-colitis-uc_en.pdf"},
    {"id":"58949","name":"Registration form and agenda - EMA EudraVigilance and Signal Management Information Day","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-15T10:20:00Z","last_updated_date":"2023-11-21T17:03:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/registration-form-and-agenda-ema-eudravigilance-and-signal-management-information-day_en.pdf"},
    {"id":"58966","name":"Questions and Answers - Union Product Database (UPD) - Volume of Sales webinar for UPD industry users held on 24 April 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-15T16:56:00Z","last_updated_date":"2023-06-15T16:56:00Z","reference_number":"EMA/273124/2023","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-union-product-database-upd-volume-sales-webinar-upd-industry-users-held-24-april-2023_en.pdf"},
    {"id":"58968","name":"Declaration of interests: Franck Diafouka","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-16T09:52:00Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-franck-diafouka_en.pdf"},
    {"id":"58978","name":"Declaration of interests: Mireia Castillon","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-16T11:44:00Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-mireia-castillon_en.pdf"},
    {"id":"58985","name":"Mandate, objectives and rules of procedure for the Haematology European Specialised Expert Communities (ESEC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T11:05:00Z","last_updated_date":"2023-06-19T11:05:00Z","reference_number":"EMA/CHMP/BPWP/90503/2023","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-haematology-european-specialised-expert-communities-esec_en.pdf"},
    {"id":"59028","name":"Annex 1: List of EMA RWD study requests from 1 September 2021 to 7 February 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-22T09:28:00Z","last_updated_date":"2023-06-22T09:28:00Z","reference_number":"EMA/286356/2023","document_url":"https://www.ema.europa.eu/en/documents/other/annex-1-list-ema-rwd-study-requests-1-september-2021-7-february-2023_en.xlsx"},
    {"id":"59069","name":"Questions and answers on the guideline on the SPC for VMPs containing antimicrobial substances – antibiotic clinical breakpoints that may be included in section 4.2 of the SPC for generic VMPs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T11:14:00Z","last_updated_date":"2023-07-19T17:37:00Z","reference_number":"EMA/CVMP/AWP/933465/2022 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-guideline-spc-vmps-containing-antimicrobial-substances-antibiotic-clinical-breakpoints-may-be-included-section-42-spc-generic-vmps_en.pdf"},
    {"id":"59123","name":"EU veterinary big data workplan to 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T11:41:00Z","last_updated_date":"2023-09-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eu-veterinary-big-data-workplan-2025_en.pdf"},
    {"id":"59137","name":"Records of data processing activity for the user test of the Critical Medical Device Shortages (CMDS) system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T11:33:00Z","last_updated_date":"2023-06-29T11:33:00Z","reference_number":"EMA/217863/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-user-test-critical-medical-device-shortages-cmds-system_en.pdf"},
    {"id":"59138","name":"Questions and answers - Quarterly system demo - Q2 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T11:44:00Z","last_updated_date":"2023-06-29T11:44:00Z","reference_number":"EMA/292141/2023","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-quarterly-system-demo-q2-2023_en.pdf"},
    {"id":"59153","name":"European Medicines Agency’s data protection notice For the electronic EMA newsletters published via Newsroom","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/301502/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-electronic-ema-newsletters-published-newsroom_en.pdf"},
    {"id":"59155","name":"Records of data processing activity for the electronic EMA newsletters published via Newsroom","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T09:38:00Z","last_updated_date":"2023-06-30T09:38:00Z","reference_number":"EMA/301503/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-electronic-ema-newsletters-published-newsroom_en.pdf"},
    {"id":"59156","name":"European Medicines Agency data protection notice concerning the 3rd Veterinary Stakeholder Forum on 23 November 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T13:59:00Z","last_updated_date":"2023-06-30T13:59:00Z","reference_number":"EMA/295350/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-data-protection-notice-concerning-3rd-veterinary-stakeholder-forum-23-november-2023_en.pdf"},
    {"id":"59157","name":"European Medicines Agency data protection notice concerning the EMA Veterinary Awareness Day event on 12-13 September 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:01:00Z","last_updated_date":"2023-06-30T14:01:00Z","reference_number":"EMA/295351/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-data-protection-notice-concerning-ema-veterinary-awareness-day-event-12-13-september-2023_en.pdf"},
    {"id":"59178","name":"Declaration of interests: Patrice Verpillat","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:39:00Z","last_updated_date":"2025-08-01T17:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-patrice-verpillat_en.pdf"},
    {"id":"59192","name":"Questions and Answers on the 'OPEN' Framework","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T15:04:00Z","last_updated_date":"2026-01-20T23:46:00Z","reference_number":"EMA/55338/2023","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-open-framework_en.pdf"},
    {"id":"59220","name":"Records of data processing activity for WebEx","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-07-04T16:35:00Z","last_updated_date":"2023-07-04T16:35:00Z","reference_number":"EMA/304030/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-webex_en.pdf"},
    {"id":"59221","name":"European Medicines Agency’s data protection notice for the Cisco Webex meetings and Webex events participants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2024-10-28T17:21:10Z","reference_number":"EMA/304030/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-cisco-webex-meetings-webex-events-participants_en.pdf"},
    {"id":"59268","name":"Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T15:23:00Z","last_updated_date":"2023-07-05T15:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-dictionary-drug-regulatory-activities-veddra-template_en.xlsx"},
    {"id":"59269","name":"Combined VeDDRA list of clinical terms for reporting suspected adverse events in animals and humans to veterinary medicinal products","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-07-05T15:34:00Z","last_updated_date":"2025-08-12T16:20:00Z","reference_number":"EMA/148106/2025","document_url":"https://www.ema.europa.eu/en/documents/other/combined-veddra-list-clinical-terms-reporting-suspected-adverse-events-animals-humans-veterinary-medicinal-products_en.xlsx"},
    {"id":"59293","name":"Release notes - production release version 1.6.28 July 2023 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-07-07T11:19:00Z","last_updated_date":"2023-07-07T11:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1628-july-2023-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"59304","name":"Appendix 1: Acceptable intakes established for N-nitrosamines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-07-07T15:33:00Z","last_updated_date":"2026-06-24T13:01:00Z","reference_number":"EMA/42261/2025 Rev.13","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-1-acceptable-intakes-established-n-nitrosamines_en.xlsx"},
    {"id":"59315","name":"European Medicines Agency Guidance for applicants seeking access to PRIME scheme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2024-10-10T16:00:00Z","reference_number":"EMA/7872/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-guidance-applicants-seeking-access-prime-scheme_en.pdf"},
    {"id":"59316","name":"European Medicines Agency Guidance for applicants seeking access to PRIME scheme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-07-10T18:10:00Z","last_updated_date":"2023-07-10T18:10:00Z","reference_number":"EMA/191104/2015","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-guidance-applicants-seeking-access-prime-scheme_en.pdf-0"},
    {"id":"59343","name":"Anniversary messages from HCPWP members","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T17:54:00Z","last_updated_date":"2023-07-12T17:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/anniversary-messages-hcpwp-members_en.pdf"},
    {"id":"59350","name":"Methodology for the establishment of the “public health emergency critical medical devices list”","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-07-13T16:13:00Z","last_updated_date":"2023-07-13T16:13:00Z","reference_number":"EMA/54552/2023","document_url":"https://www.ema.europa.eu/en/documents/other/methodology-establishment-public-health-emergency-critical-medical-devices-list_en.pdf"},
    {"id":"59352","name":"Highlights of EMA-AESGP Bilateral meeting of 18th April 2023 meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-07-13T17:36:00Z","last_updated_date":"2023-07-13T17:36:00Z","reference_number":"EMA/175887/2023","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-ema-aesgp-bilateral-meeting-18th-april-2023-meeting_en.pdf"},
    {"id":"59362","name":"Recommendations of the Executive Steering Group on Shortages and Safety of Medicinal Products on the availability of a subset of antibiotics","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-07-17T10:12:00Z","last_updated_date":"2023-07-17T10:12:00Z","reference_number":"EMA/312229/2023","document_url":"https://www.ema.europa.eu/en/documents/other/recommendations-executive-steering-group-shortages-and-safety-medicinal-products-availability-subset-antibiotics_en.pdf"},
    {"id":"59472","name":"Release notes - production release version 1.6.30 July 2023 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-07-24T14:18:00Z","last_updated_date":"2023-08-10T10:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1630-july-2023-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"59504","name":"Superseded - Composition of the Emergency Task Force (ETF) for preparedness","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-07-27T10:10:00Z","last_updated_date":"2025-08-07T16:26:00Z","reference_number":"EMA/35247/2025","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-composition-emergency-task-force-etf-preparedness_en.pdf"},
    {"id":"59513","name":"List of medicines currently in PRIME scheme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2016-10-17T17:41:00Z","last_updated_date":"2026-06-09T17:15:00Z","reference_number":"EMA/521657/2016","document_url":"https://www.ema.europa.eu/en/documents/other/list-medicines-currently-prime-scheme_en.xlsx"},
    {"id":"59554","name":"Declaration of interests: Karen Quigley","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-04T14:12:00Z","last_updated_date":"2025-08-01T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-karen-quigley_en.pdf"},
    {"id":"59558","name":"PRAC meetings in 2025 and 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-07T13:11:00Z","last_updated_date":"2023-08-07T13:11:00Z","reference_number":"EMA/PRAC/340824/2023","document_url":"https://www.ema.europa.eu/en/documents/other/prac-meetings-2025-and-2026_en.pdf"},
    {"id":"59559","name":"Declaration of interests : Elias Pean","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-07T15:31:00Z","last_updated_date":"2025-08-01T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-elias-pean_en.pdf"},
    {"id":"59561","name":"Mandate, objective and rules of procedure for the Non-Clinical and New Approach Methodologies European Specialised Expert Community","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-09T17:35:00Z","last_updated_date":"2023-08-09T17:35:00Z","reference_number":"EMA/CHMP/127687/2023","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objective-and-rules-procedure-non-clinical-and-new-approach-methodologies-european-specialised-expert-community_en.pdf"},
    {"id":"59582","name":"EMA's response to the COVID-19 pandemic: Putting people's health first","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-10T13:56:00Z","last_updated_date":"2023-08-10T13:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/emas-response-covid-19-pandemic-putting-peoples-health-first_en.pdf"},
    {"id":"59587","name":"Mandate, objectives and rules of procedure for the Medical Device Shortages SPOC Working Party","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-17T11:58:00Z","last_updated_date":"2023-08-17T11:58:00Z","reference_number":"EMA/5107/20233","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-medical-device-shortages-spoc-working-party_en.pdf"},
    {"id":"59605","name":"European Medicines Agency’s data protection notice for publication of contact details of industry representatives in Agile teams","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-17T14:07:00Z","last_updated_date":"2023-08-17T14:07:00Z","reference_number":"EMA/282298/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-publication-contact-details-industry-representatives-agile-teams_en.pdf"},
    {"id":"59607","name":"Records of data processing activity for the publication of contact details of industry representatives in Agile teams","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-18T11:28:00Z","last_updated_date":"2026-06-25T14:50:00Z","reference_number":"EMA/76076/2026","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-publication-contact-details-industry-representatives-agile-teams_en.pdf"},
    {"id":"59616","name":"National Innovation Offices Contacts","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-08T12:35:00Z","last_updated_date":"2026-03-09T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/national-innovation-offices-contacts_en.pdf"},
    {"id":"59617","name":"EU-Innovation Network Workplan 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-08T12:30:00Z","last_updated_date":"2023-09-08T12:30:00Z","reference_number":"EMA/120370/2023","document_url":"https://www.ema.europa.eu/en/documents/other/eu-innovation-network-workplan-2023_en.pdf"},
    {"id":"59680","name":"Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-26T09:07:29Z","last_updated_date":"2023-09-26T09:07:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-rules-procedure-cvmp-ad-hoc-expert-group-veterinary-novel-therapies-advent_en.pdf"},
    {"id":"59681","name":"Work plan for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT) 2018","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-26T09:10:12Z","last_updated_date":"2023-09-26T09:10:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/work-plan-cvmp-ad-hoc-expert-group-veterinary-novel-therapies-advent-2018_en.pdf"},
    {"id":"59690","name":"Vaccine Monitoring Platform (VMP) research agenda","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T18:36:44Z","last_updated_date":"2023-09-27T18:36:44Z","reference_number":"EMA/430310/2023","document_url":"https://www.ema.europa.eu/en/documents/other/vaccine-monitoring-platform-vmp-research-agenda_en.pdf"},
    {"id":"59691","name":"Executive Steering Group on Shortages and Safety of Medicinal Products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-28T14:59:37Z","last_updated_date":"2023-09-28T14:59:37Z","reference_number":"EMA/41493/2022 ","document_url":"https://www.ema.europa.eu/en/documents/other/executive-steering-group-shortages-and-safety-medicinal-products_en.pdf-0"},
    {"id":"59829","name":"Mandate, objectives and composition of Industry Standing Group (ISG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-04T16:00:08Z","last_updated_date":"2024-07-10T16:10:00Z","reference_number":"EMA/52789/2022","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-composition-industry-standing-group-isg_en.pdf"},
    {"id":"59875","name":"European Medicines Agency’s data protection notice for the user test of the Critical Medical Device Shortages (CMDS) system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-31T15:37:00Z","last_updated_date":"2023-08-31T15:37:00Z","reference_number":"EMA/335709/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-user-test-critical-medical-device-shortages-cmds-system_en.pdf"},
    {"id":"59888","name":"Records of data processing activity for the user test of the Critical Medical Device Shortages (CMDS) system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-04T09:12:00Z","last_updated_date":"2023-09-04T09:12:00Z","reference_number":"EMA/335710/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-user-test-critical-medical-device-shortages-cmds-system_en.pdf-0"},
    {"id":"59905","name":"Briefing document - GFR slope as a Surrogate Endpoint in RCT for CKD","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-06T11:57:00Z","last_updated_date":"2023-09-06T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/briefing-document-gfr-slope-surrogate-endpoint-rct-ckd_en.pdf"},
    {"id":"59906","name":"Responses to list of issues - GFR slope as a Surrogate Endpoint in RCT for CKD","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-06T12:07:00Z","last_updated_date":"2023-09-28T09:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/responses-list-issues-gfr-slope-surrogate-endpoint-rct-ckd_en.pdf"},
    {"id":"59912","name":"Declaration of interests: Falk Ehmann","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-07T10:07:00Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-falk-ehmann_en.pdf"},
    {"id":"59913","name":"Declaration of interests: Ralf Herold","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-07T10:07:00Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-ralf-herold_en.pdf"},
    {"id":"59935","name":"Highlights of the fifth EMA-EuropaBio Bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-12T11:43:00Z","last_updated_date":"2023-09-12T11:43:00Z","reference_number":"EMA/314519/2023","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-fifth-ema-europabio-bilateral-meeting_en.pdf"},
    {"id":"59936","name":"Highlights - Fifth Industry Standing Group (ISG) meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-12T12:01:00Z","last_updated_date":"2023-09-12T12:01:00Z","reference_number":"EMA/294473/2023","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-fifth-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"59938","name":"20 years of EU / US collaboration on medicines regulation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-12T16:36:00Z","last_updated_date":"2023-09-12T16:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/20-years-eu-us-collaboration-medicines-regulation_en.pdf"},
    {"id":"59969","name":"Network Portfolio Roadmap","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T16:00:00Z","last_updated_date":"2026-05-26T09:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/network-portfolio-roadmap_en.pdf"},
    {"id":"59970","name":"Guidance on the interpretation of document - Confidentiality undertaking for network product owner and subject matter experts (SMEs) in European Medicines Agency’s agile way-of-working (EMA/250671/2022)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T16:00:00Z","last_updated_date":"2023-09-15T16:00:00Z","reference_number":"EMA/28183/2023","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-interpretation-document-confidentiality-undertaking-network-product-owner-and-subject-matter-experts-smes-european-medicines-agencys-agile-way-working-ema-250671-2022_en.pdf"},
    {"id":"59971","name":"Confidentiality undertaking for network product owner and subject matter experts (SMEs) in European Medicines Agency’s agile way-of-working","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T16:00:00Z","last_updated_date":"2023-09-15T16:00:00Z","reference_number":"EMA/250671/2022","document_url":"https://www.ema.europa.eu/en/documents/other/confidentiality-undertaking-network-product-owner-and-subject-matter-experts-smes-european-medicines-agencys-agile-way-working_en.pdf"},
    {"id":"59972","name":"Network product owner and subject matter experts in EMA Agile way-of-working - Terms of Reference (ToR)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T16:00:00Z","last_updated_date":"2023-09-15T16:00:00Z","reference_number":"EMA/198482/2022","document_url":"https://www.ema.europa.eu/en/documents/other/network-product-owner-and-subject-matter-experts-ema-agile-way-working-terms-reference-tor_en.pdf"},
    {"id":"59973","name":"List of industry subject matter experts and list of planned calls for industry subject matter experts","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T15:10:00Z","last_updated_date":"2026-05-07T10:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-industry-subject-matter-experts-list-planned-calls-industry-subject-matter-experts_en.pdf"},
    {"id":"60003","name":"Withdrawal letter: Iclusig (II-64)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T08:48:00Z","last_updated_date":"2023-09-15T08:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawal-letter-iclusig-ii-64_en.pdf"},
    {"id":"60054","name":"Release notes - production release version 1.6.34 September 2023 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T16:35:00Z","last_updated_date":"2023-10-06T17:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1634-september-2023-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"60153","name":"Vaccine Monitoring Platform (VMP) research agenda","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-26T09:55:00Z","last_updated_date":"2023-09-26T09:55:00Z","reference_number":"EMA/430310/2023","document_url":"https://www.ema.europa.eu/en/documents/other/vaccine-monitoring-platform-vmp-research-agenda_en.pdf-0"},
    {"id":"60154","name":"Questions and answers - Q3 2023 System Demo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-26T12:18:00Z","last_updated_date":"2023-09-26T12:18:00Z","reference_number":"EMA/429086/2023","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-q3-2023-system-demo_en.pdf"},
    {"id":"60155","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: Origio A.R.T. Media","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-26T12:48:00Z","last_updated_date":"2023-09-26T12:48:00Z","reference_number":"EMA/421977/2023","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-origio-art-media_en.pdf"},
    {"id":"60226","name":"European Medicines Agency guidance to support the preparation of PRIME meetings","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-02T15:40:00Z","last_updated_date":"2023-10-02T15:40:00Z","reference_number":"EMA/7874/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-guidance-support-preparation-prime-meetings_en.pdf"},
    {"id":"60243","name":"Declaration of interests: Zoltan Kunsagi","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-03T15:53:00Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-zoltan-kunsagi_en.pdf"},
    {"id":"60251","name":"Mandate, objectives and composition of Industry Standing Group (ISG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-04T15:55:00Z","last_updated_date":"2023-10-04T15:55:00Z","reference_number":"EMA/52789/2022","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-and-composition-industry-standing-group-isg_en.pdf-0"},
    {"id":"60273","name":"Records of data processing activity relating to the reasonable accommodation request process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-05T15:47:00Z","last_updated_date":"2023-10-05T15:47:00Z","reference_number":"EMA/391331/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-relating-reasonable-accommodation-request-process_en.pdf"},
    {"id":"60284","name":"Revised CTIS Transparency Rules","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-06T13:16:00Z","last_updated_date":"2023-10-06T13:16:00Z","reference_number":"EMA/263067/2023","document_url":"https://www.ema.europa.eu/en/documents/other/revised-ctis-transparency-rules_en.pdf"},
    {"id":"60291","name":"Example - production release version 1.6.34 September 2023 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-06T16:57:00Z","last_updated_date":"2023-10-06T16:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-production-release-version-1634-september-2023-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"60363","name":"Use of EDQM terminologies for Dose Forms and Routes of Administration for Individual  Case Safety Reports in E2B(R3) message ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-11T11:36:00Z","last_updated_date":"2024-01-16T15:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/use-edqm-terminologies-dose-forms-and-routes-administration-individual-case-safety-reports-e2br3-message_en.pdf"},
    {"id":"60415","name":"Speaker biographies - Clinical Trials Information System (CTIS): Information day (17/10/2023)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T11:19:00Z","last_updated_date":"2023-10-13T11:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/speaker-biographies-clinical-trials-information-system-ctis-information-day-17-10-2023_en.pdf"},
    {"id":"60466","name":"MSSG Toolkit on recommendations on tackling shortages of medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-24T15:38:00Z","last_updated_date":"2023-10-24T15:38:00Z","reference_number":"EMA/899955/2022","document_url":"https://www.ema.europa.eu/en/documents/other/mssg-toolkit-recommendations-tackling-shortages-medicinal-products_en.pdf"},
    {"id":"60467","name":"MSSG Voluntary Solidarity Mechanism","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-24T15:39:00Z","last_updated_date":"2025-11-07T15:54:22Z","reference_number":"EMA/323316/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/mssg-voluntary-solidarity-mechanism_en.pdf"},
    {"id":"60481","name":"Outcome of written procedures finalised during the period from 3 June to 26 September 2023","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-10-24T17:51:00Z","last_updated_date":"2023-10-24T17:51:00Z","reference_number":"EMA/MB/336972/2023","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-3-june-26-september-2023_en.pdf"},
    {"id":"60502","name":"Records of data processing activity for handling of requests submitted under Article 24 of the Staff Regulations (\"SR\") and Article 90(1) SR and of complaints submitted under Article 90(2) SR","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-27T11:03:00Z","last_updated_date":"2023-10-27T11:03:00Z","reference_number":"EMA/424093/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-handling-requests-submitted-under-article-24-staff-regulations-sr-article-901-sr-complaints-submitted-under-article-902-sr_en.pdf"},
    {"id":"60532","name":"EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) units of presentation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T12:00:00Z","last_updated_date":"2015-02-17T10:50:00Z","reference_number":"EMA/136150/2012 Rev. 7","document_url":"https://www.ema.europa.eu/en/documents/other/eudravigilance-extended-medicinal-product-dictionary-xevmpd-units-presentation_en.xls"},
    {"id":"60579","name":"Meet and Talk guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-09-27T12:12:00Z","last_updated_date":"2018-09-27T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/meet-and-talk-guide_en.pdf"},
    {"id":"60580","name":"Outlook Web Access User Manual","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-09-27T13:25:00Z","last_updated_date":"2018-09-27T13:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/outlook-web-access-user-manual_en.pdf"},
    {"id":"60581","name":"Citrix remote access user manual","type":"other","status":"unknown","consultation_date":"","first_published_date":"2017-09-27T13:58:00Z","last_updated_date":"2017-09-27T13:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/citrix-remote-access-user-manual_en.doc"},
    {"id":"60582","name":"European Medicines Agency rapid response to the British Medical Journal on Pandemrix","type":"other","status":"unknown","consultation_date":"","first_published_date":"2018-09-26T16:38:00Z","last_updated_date":"2018-09-26T16:38:00Z","reference_number":"EMA/659264/2018","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-rapid-response-british-medical-journal-pandemrix_en.pdf"},
    {"id":"60613","name":"Emer Cooke - High resolution photo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2020-06-25T13:25:00Z","last_updated_date":"2020-06-25T13:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/emer-cooke-high-resolution-photo_en.zip"},
    {"id":"60633","name":"Download EPS - Species pictograms - Elephant","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-28T01:00:00Z","last_updated_date":"2021-05-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-elephant_en.zip"},
    {"id":"60635","name":"Download EPS - Species pictograms - Guinea pig","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-28T01:00:00Z","last_updated_date":"2021-05-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-guinea-pig_en.zip"}    {"id":"60636","name":"Download EPS - Species pictograms - Parrot","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-28T01:00:00Z","last_updated_date":"2021-05-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-parrot_en.zip"},
    {"id":"60638","name":"Download EPS - Species pictograms - Snake","type":"other","status":"unknown","consultation_date":"","first_published_date":"2021-05-28T01:00:00Z","last_updated_date":"2021-05-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/download-eps-species-pictograms-snake_en.zip"},
    {"id":"60666","name":"Example files - production release version 1.5.4 February 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T09:47:00Z","last_updated_date":"2022-02-23T09:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-154-february-2022-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"60669","name":"Example files - production release version 1.6.1 March 2022 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-03-21T14:25:00Z","last_updated_date":"2022-03-21T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-files-production-release-version-161-march-2022-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"60673","name":"European Medicines Agency Cloud Strategy: Accelerating innovation and digitalisation for better public and animal health outcomes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-05-24T13:43:00Z","last_updated_date":"2022-05-24T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-cloud-strategy-accelerating-innovation-and-digitalisation-better-public-and-animal-health-outcomes_en.pdf"},
    {"id":"60737","name":"Test cases (1a-10) RTFs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-08-23T14:58:00Z","last_updated_date":"2025-05-23T15:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/test-cases-1a-10-rtfs_en.zip"},
    {"id":"60738","name":"Working arrangements between the European Health Emergency Preparedness and Response Authority (HERA) and the European Medicines Agency (EMA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T11:30:00Z","last_updated_date":"2023-09-01T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/working-arrangements-between-european-health-emergency-preparedness-and-response-authority-hera-and-european-medicines-agency-ema_en.pdf"},
    {"id":"60739","name":"Highlights from the 10th meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-05T11:52:00Z","last_updated_date":"2023-09-05T11:52:00Z","reference_number":"EMA/INS/GMP/190573/2023","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-10th-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf"},
    {"id":"60742","name":"Highlights from the 11th meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-09-05T11:56:00Z","last_updated_date":"2023-09-05T11:56:00Z","reference_number":"EMA/353244/2023","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-11th-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf"},
    {"id":"60773","name":"Assessment outcome of occupational activities after leaving the service F Sweeney 19.10.23","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-26T09:04:00Z","last_updated_date":"2023-10-26T09:04:00Z","reference_number":"EMA/480774/2023","document_url":"https://www.ema.europa.eu/en/documents/other/assessment-outcome-occupational-activities-after-leaving-service-f-sweeney-191023_en.pdf"},
    {"id":"60774","name":"Question and answers - Union Product Database - Product grouping and third country product names Webinar for Industry users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-27T10:35:00Z","last_updated_date":"2023-11-03T15:00:00Z","reference_number":"EMA/483124/2023","document_url":"https://www.ema.europa.eu/en/documents/other/question-and-answers-union-product-database-product-grouping-and-third-country-product-names-webinar-industry-users_en.pdf"},
    {"id":"60783","name":"Consultation on an ancillary medicinal substance incorporated in a medical device : Kitazato ART media","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-11-07T11:56:00Z","last_updated_date":"2023-11-07T11:56:00Z","reference_number":"EMA/346099/2023","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-kitazato-art-media_en.pdf"},
    {"id":"60806","name":"Origio A.R.T. Media - Procedural steps and scientific information after initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-11-09T09:32:00Z","last_updated_date":"2023-11-09T09:32:00Z","reference_number":"EMA/502063/2023","document_url":"https://www.ema.europa.eu/en/documents/other/origio-art-media-procedural-steps-and-scientific-information-after-initial-consultation_en.pdf"},
    {"id":"60808","name":"Appendix 2 : Carcinogenic Potency Categorisation Approach for N-nitrosamines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-11-09T11:54:00Z","last_updated_date":"2023-11-09T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-2-carcinogenic-potency-categorisation-approach-n-nitrosamines_en.pdf"},
    {"id":"60809","name":"Appendix 3 : Enhanced Ames Test Conditions for N-nitrosamines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-11-09T11:58:00Z","last_updated_date":"2024-03-26T12:22:00Z","reference_number":"EMA/120337/2024","document_url":"https://www.ema.europa.eu/en/documents/other/appendix-3-enhanced-ames-test-conditions-n-nitrosamines_en.pdf"},
    {"id":"60813","name":"Question and answers on the use of X-ray sterilisation processes for Single Use Systems (SUS) used in pharmaceutical manufacturing","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-11-09T13:02:00Z","last_updated_date":"2023-11-09T15:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/question-answers-use-x-ray-sterilisation-processes-single-use-systems-sus-used-pharmaceutical-manufacturing_en.pdf"},
    {"id":"60870","name":"Start of Union reviews adopted during the CHMP meeting of  6-9 November 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T16:56:00Z","last_updated_date":"2023-11-10T16:56:00Z","reference_number":"EMA/493380/2023","document_url":"https://www.ema.europa.eu/en/documents/other/start-union-reviews-adopted-during-chmp-meeting-6-9-november-2023_en.pdf"},
    {"id":"60963","name":"Reply to Members of the European Parliament regarding mRNA COVID-19 vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-11-23T14:30:50Z","last_updated_date":"2023-11-23T14:30:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/reply-members-european-parliament-regarding-mrna-covid-19-vaccines_en.pdf"},
    {"id":"61035","name":"Heading and text to be inserted in Section 5.1 of the SmPC","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T11:00:00Z","last_updated_date":"2025-02-21T11:50:00Z","reference_number":"EMA/457563/2023","document_url":"https://www.ema.europa.eu/en/documents/other/heading-text-be-inserted-section-51-smpc_en.docx"},
    {"id":"61087","name":"CHMP early contact with patient and healthcare professional organisations: process and FAQs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T16:12:20Z","last_updated_date":"2024-10-08T15:10:00Z","reference_number":"EMA/188551/2023 rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-early-contact-patient-healthcare-professional-organisations-process-faqs_en.pdf"},
    {"id":"61105","name":"Veterinary Union Pharmacovigilance Database - Best Practice Guide ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-11-30T19:06:12Z","last_updated_date":"2025-12-04T14:30:00Z","reference_number":"EMA/371192/2021 Rev.13","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-union-pharmacovigilance-database-best-practice-guide_en.pdf"},
    {"id":"61148","name":"Austria - Sales trends (mg/PCU) of antibiotic VMPs for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T15:13:56Z","last_updated_date":"2023-12-01T15:13:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/austria-sales-trends-mg-pcu-antibiotic-vmps-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61161","name":"Finland - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T16:33:29Z","last_updated_date":"2023-12-01T16:33:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/finland-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61187","name":"Belgium - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T14:45:55Z","last_updated_date":"2023-12-04T14:45:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/belgium-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61189","name":"Bulgaria - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T14:47:53Z","last_updated_date":"2023-12-04T14:47:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/bulgaria-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61190","name":"Croatia - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022​","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T14:50:10Z","last_updated_date":"2023-12-04T14:50:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/croatia-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61191","name":"Cyprus - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T14:54:08Z","last_updated_date":"2023-12-04T14:54:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cyprus-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61193","name":"​Czechia - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T14:58:21Z","last_updated_date":"2023-12-04T14:58:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/czechia-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61194","name":"Denmark - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:00:32Z","last_updated_date":"2023-12-04T15:00:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/denmark-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61195","name":"​Estonia - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:04:03Z","last_updated_date":"2023-12-04T15:04:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/estonia-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61196","name":"​Finland - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:07:26Z","last_updated_date":"2023-12-04T15:07:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/finland-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf-0"},
    {"id":"61197","name":"France - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:12:36Z","last_updated_date":"2023-12-04T15:12:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/france-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61198","name":"Germany - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:14:42Z","last_updated_date":"2023-12-04T15:14:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/germany-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61199","name":"Greece - Sales trends (mg/PCU) of antibiotic VMPs for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:19:53Z","last_updated_date":"2023-12-04T15:19:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/greece-sales-trends-mg-pcu-antibiotic-vmps-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61200","name":"Hungary - Sales trends (mg/PCU) of antibiotic VMPs for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:22:39Z","last_updated_date":"2023-12-04T15:22:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/hungary-sales-trends-mg-pcu-antibiotic-vmps-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61201","name":"Iceland - Sales trends (mg/PCU) of antibiotic VMPs for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:24:21Z","last_updated_date":"2023-12-04T15:24:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/iceland-sales-trends-mg-pcu-antibiotic-vmps-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61202","name":"Ireland - Sales trends (mg/PCU) of antibiotic VMPs for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:26:35Z","last_updated_date":"2023-12-04T15:26:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ireland-sales-trends-mg-pcu-antibiotic-vmps-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61203","name":"Italy - Sales trends (mg/PCU) of antibiotic VMPs for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:28:09Z","last_updated_date":"2023-12-04T15:28:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/italy-sales-trends-mg-pcu-antibiotic-vmps-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61204","name":"Latvia - Sales trends (mg/PCU) of antibiotic VMPs for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:29:30Z","last_updated_date":"2023-12-04T15:29:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/latvia-sales-trends-mg-pcu-antibiotic-vmps-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61205","name":"Lithuania - Sales trends (mg/PCU) of antibiotic VMPs for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:31:06Z","last_updated_date":"2023-12-04T15:31:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/lithuania-sales-trends-mg-pcu-antibiotic-vmps-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61206","name":"Luxembourg - Sales trends (mg/PCU) of antibiotic VMPs for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:32:35Z","last_updated_date":"2023-12-04T15:32:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/luxembourg-sales-trends-mg-pcu-antibiotic-vmps-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61207","name":"Malta - Sales trends (mg/PCU) of antibiotic VMPs for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:34:58Z","last_updated_date":"2023-12-04T15:34:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/malta-sales-trends-mg-pcu-antibiotic-vmps-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61208","name":"Netherlands - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:38:36Z","last_updated_date":"2023-12-04T15:38:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/netherlands-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61209","name":"Norway - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:40:35Z","last_updated_date":"2023-12-04T15:40:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/norway-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61210","name":"Poland - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:42:11Z","last_updated_date":"2023-12-04T15:42:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/poland-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61211","name":"Portugal - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:43:36Z","last_updated_date":"2023-12-04T15:43:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/portugal-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61212","name":"Romania - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:55:27Z","last_updated_date":"2023-12-04T15:55:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/romania-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61213","name":"Slovakia - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:57:03Z","last_updated_date":"2023-12-04T15:57:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/slovakia-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61214","name":"Slovenia - ​Portugal - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T15:59:48Z","last_updated_date":"2023-12-04T15:59:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/slovenia-portugal-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61215","name":"Spain - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T16:02:37Z","last_updated_date":"2023-12-04T16:02:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spain-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61216","name":"Sweden - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T16:04:23Z","last_updated_date":"2023-12-04T16:04:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sweden-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61217","name":"​Switzerland - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T16:10:14Z","last_updated_date":"2023-12-04T16:10:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/switzerland-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61218","name":"United Kingdom - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2022","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T16:12:14Z","last_updated_date":"2023-12-04T16:12:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/united-kingdom-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2022_en.pdf"},
    {"id":"61229","name":"Periodic safety update report single assessments (PSUSAs) - Download table of 4 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T09:06:47Z","last_updated_date":"2023-12-05T09:06:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/periodic-safety-update-report-single-assessments-psusas-download-table-4-december-2023_en.xlsx"},
    {"id":"61230","name":"European public assessment reports (EPARs) for human and veterinary medicines - Download table of 4 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T09:13:05Z","last_updated_date":"2023-12-05T09:13:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-public-assessment-reports-epars-human-and-veterinary-medicines-download-table-4-december-2023_en.xlsx"},
    {"id":"61233","name":"Withdrawn applications for human and veterinary medicines - Download table of 4 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T09:19:03Z","last_updated_date":"2023-12-05T09:19:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/withdrawn-applications-human-and-veterinary-medicines-download-table-4-december-2023_en.xlsx"},
    {"id":"61234","name":"Paediatric investigation plans - Download table of 4 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T09:23:36Z","last_updated_date":"2023-12-05T09:23:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/paediatric-investigation-plans-download-table-4-december-2023_en.xlsx"},
    {"id":"61235","name":"Rare disease (orphan) designations - Download table of 4 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T09:25:58Z","last_updated_date":"2023-12-05T09:25:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/rare-disease-orphan-designations-download-table-4-december-2023_en.xlsx"},
    {"id":"61236","name":"Referrals for human and veterinary medicines - Download table of 4 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T09:28:25Z","last_updated_date":"2023-12-05T09:28:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/referrals-human-and-veterinary-medicines-download-table-4-december-2023_en.xlsx"},
    {"id":"61237","name":"Medicine shortages - Download table of 4 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T09:31:08Z","last_updated_date":"2023-12-05T09:31:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortages-download-table-4-december-2023_en.xlsx"},
    {"id":"61238","name":"Herbal medicines - Download table of 4 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T09:33:22Z","last_updated_date":"2023-12-05T09:33:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/herbal-medicines-download-table-4-december-2023_en.xlsx"},
    {"id":"61239","name":"Medicines for use outside the European Union - Download table of 4 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T09:35:08Z","last_updated_date":"2023-12-05T09:35:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicines-use-outside-european-union-download-table-4-december-2023_en.xlsx"},
    {"id":"61258","name":"Recommended due dates for submitting  annual statements for centrally and non-centrally authorised products (CAPs and non-CAPs) and homeopathic medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T16:24:36Z","last_updated_date":"2026-06-05T10:00:00Z","reference_number":"EMA/546918/2023-Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/recommended-due-dates-submitting-annual-statements-centrally-non-centrally-authorised-products-caps-non-caps-homeopathic-medicinal-products_en.xlsx"},
    {"id":"61271","name":"Frequently asked questions on medicinal products development and assessment involving companion diagnostic (CDx)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T14:08:10Z","last_updated_date":"2023-12-06T14:08:10Z","reference_number":"EMA/CHMP/821321/2022","document_url":"https://www.ema.europa.eu/en/documents/other/frequently-asked-questions-medicinal-products-development-and-assessment-involving-companion-diagnostic-cdx_en.pdf"},
    {"id":"61288","name":"Info cards antimicrobial resistance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T17:25:12Z","last_updated_date":"2022-11-11T17:25:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/info-cards-antimicrobial-resistance_en.pdf"},
    {"id":"61327","name":"Release notes - production release version 1.6.37 October 2023 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-10-30T12:00:00Z","last_updated_date":"2023-10-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1637-october-2023-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"61338","name":"SMS guidance for external users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-08T14:29:49Z","last_updated_date":"2026-03-10T10:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sms-guidance-external-users_en.pdf"},
    {"id":"61340","name":"Release notes - production release version 1.6.40 December 2023 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-08T15:13:10Z","last_updated_date":"2023-12-08T15:13:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1640-december-2023-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"61355","name":"EMA–FDA joint Q&As on Quality and GMP aspects of  PRIME/Breakthrough therapy applications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T14:00:00Z","last_updated_date":"2023-12-19T14:00:00Z","reference_number":"EMA/CHMP/531552/2023","document_url":"https://www.ema.europa.eu/en/documents/other/ema-fda-joint-qas-quality-and-gmp-aspects-prime-breakthrough-therapy-applications_en.pdf"},
    {"id":"61366","name":"Union list of critical medicines - version 1","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T11:40:00Z","last_updated_date":"2023-12-12T11:40:00Z","reference_number":"EMA/528805/2023","document_url":"https://www.ema.europa.eu/en/documents/other/union-list-critical-medicines-version-1_en.xlsx"},
    {"id":"61367","name":"Methodology to identify critical medicines for the “Union  List of critical medicines”","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T11:42:33Z","last_updated_date":"2023-12-12T11:42:33Z","reference_number":"EMA/432940/2023","document_url":"https://www.ema.europa.eu/en/documents/other/methodology-identify-critical-medicines-union-list-critical-medicines_en.pdf"},
    {"id":"61368","name":"Questions and answers on the Union list of critical medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T11:44:18Z","last_updated_date":"2023-12-12T11:44:18Z","reference_number":"EMA/438798/2023","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-union-list-critical-medicines_en.pdf"},
    {"id":"61369","name":"Questions and answers on the Union list of critical medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T11:51:24Z","last_updated_date":"2025-12-12T11:08:00Z","reference_number":"EMA/363146/2025","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-union-list-critical-medicines_en.pdf"},
    {"id":"61417","name":"Questions and answers on implementation of Ph.Eur. Medicinal Product Monographs (MPM)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T12:00:00Z","last_updated_date":"2026-05-05T16:02:00Z","reference_number":"EMA/CHMP/QWP/505156/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-implementation-pheur-medicinal-product-monographs-mpm_en.pdf"},
    {"id":"61443","name":"Overview of comments received on draft ‘Guideline on the  acceptability of names for human medicinal products  processed through the centralised procedure’","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T14:23:29Z","last_updated_date":"2023-12-15T14:23:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-acceptability-names-human-medicinal-products-processed-through-centralised-procedure_en.pdf"},
    {"id":"61490","name":"Questions and Answers - Union Product Database - Product grouping and third country product names Webinar for Industry users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-18T17:28:17Z","last_updated_date":"2023-12-18T17:28:17Z","reference_number":"EMA/483124/2023","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-union-product-database-product-grouping-and-third-country-product-names-webinar-industry-users_en.pdf"},
    {"id":"61494","name":"Advice on implementing measures under Article 93(2) of Reg (EU) 2019/6 of the European Parliament and of the Council on Veterinary Medicinal Products, as regards the GMP for veterinary medicinal products and active substances used as starting materials","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T11:00:00Z","last_updated_date":"2023-12-19T11:00:00Z","reference_number":"EMA/INS/GMP/533512/2023","document_url":"https://www.ema.europa.eu/en/documents/other/advice-implementing-measures-under-article-932-reg-eu-2019-6-european-parliament-council-veterinary-medicinal-products-regards-gmp-veterinary-medicinal-products-active-substances-used-starting_en.pdf"},
    {"id":"61501","name":"Inclusion/exclusion criteria for the Important Medical Events (IME) list","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T15:00:49Z","last_updated_date":"2025-09-23T15:57:26Z","reference_number":"EMA/126913/2021","document_url":"https://www.ema.europa.eu/en/documents/other/inclusion-exclusion-criteria-important-medical-events-ime-list_en.pdf"},
    {"id":"61550","name":"Letter of support for a composite endpoint method for acceptability evaluation of oral drug formulations in the paediatric population","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T16:36:47Z","last_updated_date":"2023-12-20T16:36:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-composite-endpoint-method-acceptability-evaluation-oral-drug-formulations-paediatric-population_en.pdf"},
    {"id":"61558","name":"Qualification Opinion for GFR slope as a Validated Surrogate Endpoint for RCT in CKD","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T11:13:30Z","last_updated_date":"2023-12-21T11:13:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf"},
    {"id":"61559","name":"Overview of comments on draft Qualification opinion for  GFR slope as a Validated Surrogate Endpoint for RCT in  CKD","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T11:16:13Z","last_updated_date":"2023-12-21T11:16:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-draft-qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf"},
    {"id":"61564","name":"Highlights from the 18th EMA Industry Platform meeting  on the operation of EU pharmacovigilance legislation – 22  November 2023 ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T13:01:07Z","last_updated_date":"2023-12-21T13:01:07Z","reference_number":"EMA/532475/2023","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-18th-ema-industry-platform-meeting-operation-eu-pharmacovigilance-legislation-22-november-2023_en.pdf"},
    {"id":"61565","name":"Highlights of the seventh Industry Standing Group (ISG) meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T12:47:38Z","last_updated_date":"2023-12-21T12:47:38Z","reference_number":"EMA/513682/2023","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-seventh-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"61600","name":"Follow-up reply to Members of the European Parliament regarding mRNA COVID-19 vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T14:08:20Z","last_updated_date":"2023-12-22T14:08:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/follow-reply-members-european-parliament-regarding-mrna-covid-19-vaccines_en.pdf"},
    {"id":"61621","name":"Questions and answers - Q4 2023 System Demo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T18:02:48Z","last_updated_date":"2023-12-22T18:02:48Z","reference_number":"EMA/582819/2023","document_url":"https://www.ema.europa.eu/en/documents/other/questions-and-answers-q4-2023-system-demo_en.pdf"},
    {"id":"61631","name":"Questions and answers to stakeholders on the implications of Regulation (EU) 2023/1182 for centrally authorised medicinal products for human use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T16:18:36Z","last_updated_date":"2025-01-21T13:53:55Z","reference_number":"EMA/581345/2023 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-stakeholders-implications-regulation-eu-2023-1182-centrally-authorised-medicinal-products-human-use_en.pdf"},
    {"id":"61637","name":"Product Lifecycle Management Value Stream Deep-Dive Webinar (30 November 2023) – Questions & Answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T10:12:24Z","last_updated_date":"2024-01-05T10:12:24Z","reference_number":"EMA/821/2024","document_url":"https://www.ema.europa.eu/en/documents/other/product-lifecycle-management-value-stream-deep-dive-webinar-30-november-2023-questions-answers_en.pdf"},
    {"id":"61656","name":"European Medicines Agency budget for 2024","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2024-01-08T12:47:01Z","last_updated_date":"2024-01-08T12:47:01Z","reference_number":"EMA/533652/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-budget-2024_en.pdf"},
    {"id":"61658","name":"Outcome of written procedures finalised during the period from 27 September to 06 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-08T13:44:31Z","last_updated_date":"2024-01-08T13:44:31Z","reference_number":"EMA/MB/432308/2023","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-27-september-06-december-2023_en.pdf"},
    {"id":"61665","name":"Decision of the Management Board Amending budget No. 01, amending appropriations in budget 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-08T16:37:53Z","last_updated_date":"2024-01-08T16:37:53Z","reference_number":"EMA/575753/2023","document_url":"https://www.ema.europa.eu/en/documents/other/decision-management-board-amending-budget-no-01-amending-appropriations-budget-2023_en.pdf"},
    {"id":"61667","name":"European Medicines Agency’s privacy statement for the visitor management application","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-09T13:04:23Z","last_updated_date":"2024-01-09T13:04:23Z","reference_number":"EMA/233274/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-privacy-statement-visitor-management-application_en.pdf"},
    {"id":"61668","name":"European Medicines Agency’s data protection notice for parking access and record of lost and found items (Filemaker internal security database)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-09T13:08:10Z","last_updated_date":"2024-01-09T13:08:10Z","reference_number":"EMA/232805/2021","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-parking-access-record-lost-found-items-filemaker-internal-security-database_en.pdf"},
    {"id":"61671","name":"Presentation - An agency of the European Union Portfolio & Technology Meetings (E. Tognana, EMA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-09T13:21:40Z","last_updated_date":"2024-01-09T13:21:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/presentation-agency-european-union-portfolio-technology-meetings-e-tognana-ema_en.pdf"},
    {"id":"61712","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2024-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-10T17:23:05Z","last_updated_date":"2024-01-10T17:23:05Z","reference_number":"EMA/409642/2023 ","document_url":"https://www.ema.europa.eu/en/documents/other/work-plan-pharmacovigilance-inspectors-working-group-2024-2026_en.pdf"},
    {"id":"61713","name":"Union procedure on the coordination of veterinary pharmacovigilance inspections","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-10T17:39:37Z","last_updated_date":"2024-10-16T14:00:00Z","reference_number":"EMA/INS/PhV/716593/2021 Rev 01","document_url":"https://www.ema.europa.eu/en/documents/other/union-procedure-coordination-veterinary-pharmacovigilance-inspections_en.pdf"},
    {"id":"61738","name":"Letter of Support for PRE score","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T15:08:26Z","last_updated_date":"2024-01-11T15:08:26Z","reference_number":"EMADOC-1700519818-1207253","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-pre-score_en.pdf"},
    {"id":"61772","name":"Human medicines highlights 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-16T11:00:25Z","last_updated_date":"2024-01-16T11:00:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/human-medicines-highlights-2023_en.pdf"},
    {"id":"61816","name":"Regulatory Procedure Management (RPM) for the Product Lifecycle Management (PLM) - Frequently asked questions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-19T16:38:54Z","last_updated_date":"2025-09-10T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/regulatory-procedure-management-rpm-product-lifecycle-management-plm-frequently-asked-questions_en.pdf"},
    {"id":"61819","name":"What is the meaning of the terms \"unresolved\" and \"outstanding\" in Article 8(3), Article 22(2)(e)(vi) and Article 22(3)(d)(ii) of the Commission Implementing Regulation (EU) 2021/1281","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T11:56:25Z","last_updated_date":"2024-01-22T11:56:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/what-meaning-terms-unresolved-and-outstanding-article-83-article-222evi-and-article-223dii-commission-implementing-regulation-eu-2021-1281_en.pdf"},
    {"id":"61843","name":"Annex - National provisions for SMEs applicable to the pharmaceutical sector","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-23T14:34:00Z","last_updated_date":"2025-05-15T13:10:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-national-provisions-smes-applicable-pharmaceutical-sector_en.pdf"}    {"id":"61847","name":"How Competent Authorities should update packages in UPD without changing the package identifier","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-23T15:37:26Z","last_updated_date":"2024-02-08T10:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/how-competent-authorities-should-update-packages-upd-without-changing-package-identifier_en.pdf"},
    {"id":"61853","name":"Release notes - production release version 1.6.42 January 2024 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-23T18:34:37Z","last_updated_date":"2024-02-12T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1642-january-2024-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"61854","name":"Example - production release version 1.6.42 January 2024 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-23T18:53:13Z","last_updated_date":"2024-01-23T18:53:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-production-release-version-1642-january-2024-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"61873","name":"Veterinary medicines highlights 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-24T15:00:40Z","last_updated_date":"2024-01-24T15:00:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-medicines-highlights-2023_en.pdf"},
    {"id":"61920","name":"Decision of the Management Board amending budget No. 01, amending appropriations in budget 2024","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2024-01-26T15:07:36Z","last_updated_date":"2024-01-26T15:07:36Z","reference_number":"EMA/MB/572599/2023","document_url":"https://www.ema.europa.eu/en/documents/other/decision-management-board-amending-budget-no-01-amending-appropriations-budget-2024_en.pdf"},
    {"id":"61926","name":"Recommendation on the Assessment of the quality of medicinal products containing existing/ known active substances - superseded","type":"other","status":"unknown","consultation_date":"","first_published_date":"2009-02-10T16:37:21Z","last_updated_date":"2024-01-26T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/recommendation-assessment-quality-medicinal-products-containing-existing-known-active-substances-superseded_en.pdf"},
    {"id":"61927","name":"Antimicrobial Sales and Use (ASU) technical implementation protocol","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-29T13:48:00Z","last_updated_date":"2024-01-29T13:48:00Z","reference_number":"EMA/27838/2024","document_url":"https://www.ema.europa.eu/en/documents/other/antimicrobial-sales-and-use-asu-technical-implementation-protocol_en.pdf"},
    {"id":"61928","name":"Antimicrobial Sales and Use (ASU) Power BI application user guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-29T12:25:00Z","last_updated_date":"2026-03-17T09:51:00Z","reference_number":"EMA/392049/2025","document_url":"https://www.ema.europa.eu/en/documents/other/antimicrobial-sales-use-asu-power-bi-application-user-guide_en.pdf"},
    {"id":"61929","name":"Antimicrobial Sales and Use (ASU) platform user guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-29T11:15:00Z","last_updated_date":"2026-03-17T09:48:00Z","reference_number":"EMA/392051/2025","document_url":"https://www.ema.europa.eu/en/documents/other/antimicrobial-sales-use-asu-platform-user-guide_en.pdf"},
    {"id":"61936","name":"Highlights from the 6th meeting of the Nitrosamine Implementation Oversight Group (NIOG) industry partners (IP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-29T14:18:34Z","last_updated_date":"2024-01-29T14:18:34Z","reference_number":"EMA/INS/GMP/30231/2024","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-6th-meeting-nitrosamine-implementation-oversight-group-niog-industry-partners-ip_en.pdf"},
    {"id":"61940","name":"Highlights from the 12th meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-29T14:58:21Z","last_updated_date":"2024-01-29T14:58:21Z","reference_number":"EMA/INS/GMP/30230/2024","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-12th-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf"},
    {"id":"61942","name":"European Medicines Agency's data protection notice for the Security Operation Centre (SOC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:40:03Z","last_updated_date":"2024-10-28T17:40:03Z","reference_number":"EMA/684090/2022","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-security-operation-centre-soc_en.pdf"},
    {"id":"61956","name":"Data access to medicinal products for human use - Chapter 5","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-30T17:33:30Z","last_updated_date":"2026-01-20T14:22:00Z","reference_number":"EMA/8954/2024","document_url":"https://www.ema.europa.eu/en/documents/other/data-access-medicinal-products-human-use-chapter-5_en.pdf"},
    {"id":"61957","name":"Data access to medicinal products for human use - Chapter 5 Annex A: Product data elements accessible by stakeholder group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-30T17:39:45Z","last_updated_date":"2026-02-19T13:37:00Z","reference_number":"EMA/8806/2024","document_url":"https://www.ema.europa.eu/en/documents/other/data-access-medicinal-products-human-use-chapter-5-annex-product-data-elements-accessible-stakeholder-group_en.xlsx"},
    {"id":"61958","name":"Process for submitting existing data on medicinal products authorised for human use – SIAMED II & XEVMPD to PMS deltas - Chapter 9","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-30T17:43:01Z","last_updated_date":"2026-04-21T10:20:00Z","reference_number":"EMA/8748/2024","document_url":"https://www.ema.europa.eu/en/documents/other/process-submitting-existing-data-medicinal-products-authorised-human-use-siamed-ii-xevmpd-pms-deltas-chapter-9_en.pdf"},
    {"id":"61959","name":"Highlights - Second bilateral meeting between European Medicines Agency and Vaccines Europe","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-01-31T10:23:39Z","last_updated_date":"2024-01-31T10:23:39Z","reference_number":"EMA/513733/2023","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-second-bilateral-meeting-between-european-medicines-agency-vaccines-europe_en.pdf"},
    {"id":"61971","name":"Concept paper for the development of a reflection paper on a tailored clinical approach in biosimilar development","type":"other","status":"Draft: consultation closed","consultation_date":"2024-02-01 - 2024-04-30","first_published_date":"2024-02-01T11:35:43Z","last_updated_date":"2024-02-01T11:35:43Z","reference_number":"EMA/CHMP/BMWP/35061/2024","document_url":"https://www.ema.europa.eu/en/documents/other/concept-paper-development-reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf"},
    {"id":"61977","name":"European Medicines Agency’s data protection notice for grant procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-01T15:55:00Z","last_updated_date":"2024-02-01T15:55:00Z","reference_number":"EMA/568334/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-grant-procedures_en.pdf"},
    {"id":"61979","name":"Questions and answers on quality of herbal medicinal products/traditional herbal medicinal products - Revision 7","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-01T15:57:01Z","last_updated_date":"2024-02-01T15:57:01Z","reference_number":"EMA/HMPC/41500/2010 Rev.7","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-quality-herbal-medicinal-products-traditional-herbal-medicinal-products-revision-7_en.pdf"},
    {"id":"61982","name":"Shoulder prostheses - Notified body 0459 - 25/08/2022 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/shoulder-prostheses-notified-body-0459-25-08-2022-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"61984","name":"EU-Innovation Network Workplan 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-02T11:02:49Z","last_updated_date":"2025-02-19T16:00:00Z","reference_number":"EMA/495495/2024","document_url":"https://www.ema.europa.eu/en/documents/other/eu-innovation-network-workplan-2025_en.pdf"},
    {"id":"61985","name":"Working instructions for Notified Bodies on the application of Article 54 of Regulation (EU) 2017/745 on medical devices and Article 48 of Regulation (EU) 2017/746 on in vitro diagnostic medical devices","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-02T11:31:58Z","last_updated_date":"2024-02-02T11:31:58Z","reference_number":"EMA/416077/2023","document_url":"https://www.ema.europa.eu/en/documents/other/working-instructions-notified-bodies-application-article-54-regulation-eu-2017-745-medical-devices-article-48-regulation-eu-2017-746-vitro-diagnostic-medical-devices_en.pdf"},
    {"id":"61989","name":"Letter of support for Universal Immune System Simulator – Tuberculosis disease model (UISS-TB-DR)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-02T16:42:24Z","last_updated_date":"2024-02-02T16:42:24Z","reference_number":"EMADOC-1700519818-1207681","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-universal-immune-system-simulator-tuberculosis-disease-model-uiss-tb-dr_en.pdf"},
    {"id":"61990","name":"European Medicines Agency’s data protection notice for the Antimicrobials Sales and Use platform","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-02T16:43:39Z","last_updated_date":"2024-02-02T16:43:39Z","reference_number":"EMA/104751/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-antimicrobials-sales-use-platform_en.pdf"},
    {"id":"61991","name":"Records of data processing activity for the Antimicrobials Sales and Use (ASU) platform","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-02T16:46:03Z","last_updated_date":"2024-02-02T16:46:03Z","reference_number":"EMA/104752/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-antimicrobials-sales-use-asu-platform_en.pdf"},
    {"id":"61992","name":"Highlights – EMA-IPFA-PPTA first bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-05T10:52:41Z","last_updated_date":"2024-02-05T10:52:41Z","reference_number":"EMA/565009/2023","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-ema-ipfa-ppta-first-bilateral-meeting_en.pdf"},
    {"id":"61998","name":"Highlights – Sixth EMA-Medicines for Europe bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-05T14:03:40Z","last_updated_date":"2024-02-05T14:03:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-sixth-ema-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"62003","name":"PRAC recommendations on signals adopted at the 8-11 January 2024 PRAC meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-05T16:05:33Z","last_updated_date":"2024-02-05T16:05:33Z","reference_number":"EMA/PRAC/2748/2024","document_url":"https://www.ema.europa.eu/en/documents/other/prac-recommendations-signals-adopted-8-11-january-2024-prac-meeting_en.pdf"},
    {"id":"62006","name":"Decision of the Executive Director on fee incentives for scientific advice, marketing authorisation applications and pre-authorisation inspections in the ATMP support pilot for academia - No longer applicable","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-08T15:30:00Z","last_updated_date":"2024-02-08T15:30:00Z","reference_number":"EMA/CAT/317778/2023","document_url":"https://www.ema.europa.eu/en/documents/other/decision-executive-director-fee-incentives-scientific-advice-marketing-authorisation-applications-pre-authorisation-inspections-atmp-support-pilot-academia-no-longer-applicable_en.pdf"},
    {"id":"62028","name":"Mandate, objectives, and rules of procedure for the European Specialised Expert Community (ESEC) for Methodology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:36:27Z","last_updated_date":"2024-12-13T15:16:00Z","reference_number":"EMA/125839/2023","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-european-specialised-expert-community-esec-methodology_en.pdf"},
    {"id":"62071","name":"Committee on Herbal Medicinal Products (HMPC): Work Plan 2024","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2024-02-12T12:41:56Z","last_updated_date":"2024-02-12T12:41:56Z","reference_number":"EMA/HMPC/512506/2023","document_url":"https://www.ema.europa.eu/en/documents/other/committee-herbal-medicinal-products-hmpc-work-plan-2024_en.pdf"},
    {"id":"62074","name":"Hip prostheses - Notified body 2797 - 22/10/2021 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/hip-prostheses-notified-body-2797-22-10-2021-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"62077","name":"Implantable cardiac devices (various) - Notified body 0123 - 11/11/2023 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/implantable-cardiac-devices-various-notified-body-0123-11-11-2023-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"62078","name":"Vascular and cardiac endoprostheses - Notified body 0344 - 05/07/2022 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/vascular-cardiac-endoprostheses-notified-body-0344-05-07-2022-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"62079","name":"Surgical meshes - Notified body 2797 - 06/10/2022 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/surgical-meshes-notified-body-2797-06-10-2022-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"62080","name":"Structures filling, replacement and reconstruction devices - Notified body 0483 - 15/06/2021 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/structures-filling-replacement-reconstruction-devices-notified-body-0483-15-06-2021-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"62081","name":"Cerebral implantable neurostimulators - Notified body 0344 - 01/08/2022 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cerebral-implantable-neurostimulators-notified-body-0344-01-08-2022-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"62082","name":"Cardiac valves - Notified body 0344 - 27/06/2022 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cardiac-valves-notified-body-0344-27-06-2022-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"62083","name":"\tCardiac valves - Notified body 0344 - 23/05/2022 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cardiac-valves-notified-body-0344-23-05-2022-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"62084","name":"\tCardiac valves - Notified body 0344 - 07/12/2021 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cardiac-valves-notified-body-0344-07-12-2021-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"62086","name":"Advice on the influenza virus on request from the Medical Device Coordination Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advice-influenza-virus-request-medical-device-coordination-group_en.pdf"},
    {"id":"62087","name":"IgG antibodies to Epstein-Barr Virus (EBV) Viral Capsid Antigen (VCA) - Notified body 0123 - 16/02/2022 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/igg-antibodies-epstein-barr-virus-ebv-viral-capsid-antigen-vca-notified-body-0123-16-02-2022-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62105","name":"Glycoprotein (GP) gene and/or nucleoprotein - Notified body 2797 - 05/09/2022 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/glycoprotein-gp-gene-or-nucleoprotein-notified-body-2797-05-09-2022-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62106","name":"Antibodies to Treponema pallidum - Notified body 0123 - 03/02/2022 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-17T16:20:00Z","last_updated_date":"2024-02-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/antibodies-treponema-pallidum-notified-body-0123-03-02-2022-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62107","name":"Determination of IgG antibodies to SARSCoV-2 - Notified body 0123 - 04/02/2022 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/determination-igg-antibodies-sarscov-2-notified-body-0123-04-02-2022-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62108","name":"Determination of IgM antibodies to SARS-CoV-2 - Notified body 0123 - 03/02/2022 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T14:20:00Z","last_updated_date":"2024-10-17T14:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/determination-igm-antibodies-sars-cov-2-notified-body-0123-03-02-2022-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62109","name":"Antibodies to Trypanosoma cruzi - Notified body 0123 - 26/01/2022 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/antibodies-trypanosoma-cruzi-notified-body-0123-26-01-2022-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62110","name":"SARS-CoV-2 RdRp, E and N genes - Notified body 2797 - 20/01/2022 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sars-cov-2-rdrp-e-n-genes-notified-body-2797-20-01-2022-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62116","name":"IgG and IgM antibodies Treponema pallidum - Notified body 2797 - 12/01/2022 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/igg-igm-antibodies-treponema-pallidum-notified-body-2797-12-01-2022-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62117","name":"SARS-CoV-2 ORF1 a/b non-structural region and nucleocapsid protein gene & Influenza A matrix gene & Influenza B non-structural protein gene - Notified body 2797 - 10/01/2022 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sars-cov-2-orf1-b-non-structural-region-nucleocapsid-protein-gene-influenza-matrix-gene-influenza-b-non-structural-protein-gene-notified-body-2797-10-01-2022-view-context-performance-evaluation_en.pdf"},
    {"id":"62118","name":"Antibodies (including IgG) to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) - Notified body 0123 - 14/12/2021 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/antibodies-including-igg-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-notified-body-0123-14-12-2021-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62119","name":"Chikungunya virus (CHIKV) RNA and dengue virus (DENV) RNA - Notified body 2797 - 10/12/2021 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chikungunya-virus-chikv-rna-dengue-virus-denv-rna-notified-body-2797-10-12-2021-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62120","name":"Zika Virus RNA - Notified body 2797 - 09/12/2021 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/zika-virus-rna-notified-body-2797-09-12-2021-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62121","name":"Babesia (B. microti, B, duncani, B. divergens, and B. venatorum) DNA and RNA - Notified body 2797 - 19/11/2021 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T17:20:00Z","last_updated_date":"2024-10-17T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/babesia-b-microti-b-duncani-b-divergens-b-venatorum-dna-rna-notified-body-2797-19-11-2021-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62122","name":"West Nile Virus (WNV) RNA - Notified body 2797 - 12/11/2021 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/west-nile-virus-wnv-rna-notified-body-2797-12-11-2021-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62123","name":"Hepatitis E virus (HEV) - Notified body 2797 - 08/11/2021 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/hepatitis-e-virus-hev-notified-body-2797-08-11-2021-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62124","name":"Parvovirus B19 genotypes 1, 2, and 3 DNA & Hepatitis A virus (HAV) genotypes I, II, and III RNA - Notified body 2797 - 22/11/2021 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/parvovirus-b19-genotypes-1-2-3-dna-hepatitis-virus-hav-genotypes-i-ii-iii-rna-notified-body-2797-22-11-2021-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"62138","name":"3-year work plan for the Biologics Working Party (BWP) 2024-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T15:55:43Z","last_updated_date":"2024-02-14T15:55:43Z","reference_number":"EMA/3681/2024","document_url":"https://www.ema.europa.eu/en/documents/other/3-year-work-plan-biologics-working-party-bwp-2024-2026_en.pdf"},
    {"id":"62139","name":"3-year work plan for Biosimilar Medicinal Products Working Party (BMWP) 2024-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:02:39Z","last_updated_date":"2024-02-14T16:02:39Z","reference_number":"EMA/8649/2024","document_url":"https://www.ema.europa.eu/en/documents/other/3-year-work-plan-biosimilar-medicinal-products-working-party-bmwp-2024-2026_en.pdf"},
    {"id":"62143","name":"3-year work plan for the joint CHMP/CVMP Quality Working Party 2024-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:23:52Z","last_updated_date":"2024-02-14T16:23:52Z","reference_number":"EMA/54514/2023","document_url":"https://www.ema.europa.eu/en/documents/other/3-year-work-plan-joint-chmp-cvmp-quality-working-party-2024-2026_en.pdf"},
    {"id":"62147","name":"Consolidated 3-year work plan for the Rheumatology and Immunology Working Party (RIWP) 2024-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:42:20Z","last_updated_date":"2024-02-14T16:42:20Z","reference_number":"EMA/531728/2023","document_url":"https://www.ema.europa.eu/en/documents/other/consolidated-3-year-work-plan-rheumatology-immunology-working-party-riwp-2024-2026_en.pdf"},
    {"id":"62153","name":"Non-clinical domain work plan: Priorities for 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T17:19:07Z","last_updated_date":"2024-02-14T17:19:07Z","reference_number":"EMA/576362/2023","document_url":"https://www.ema.europa.eu/en/documents/other/non-clinical-domain-work-plan-priorities-2024_en.pdf"},
    {"id":"62154","name":"Oncology Working Party (ONCWP) work plan: Priorities for 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T17:22:24Z","last_updated_date":"2024-02-14T17:22:24Z","reference_number":"EMA/547793/2023","document_url":"https://www.ema.europa.eu/en/documents/other/oncology-working-party-oncwp-work-plan-priorities-2024_en.pdf"},
    {"id":"62173","name":"Committee for Advanced Therapies (CAT): Work Plan 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T12:08:16Z","last_updated_date":"2024-02-15T12:08:16Z","reference_number":"EMA/CAT/447703/2023","document_url":"https://www.ema.europa.eu/en/documents/other/committee-advanced-therapies-cat-work-plan-2024_en.pdf"},
    {"id":"62184","name":"Presentation - We need a sandbox (J. Isla, Dravet Syndrome European Federation, COMP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T13:52:37Z","last_updated_date":"2024-02-15T13:52:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/presentation-we-need-sandbox-j-isla-dravet-syndrome-european-federation-comp_en.pdf"},
    {"id":"62186","name":"Presentation - Clinical trial data: present & future (H. Gardarsdottir, Utrecht University)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T13:56:30Z","last_updated_date":"2024-02-15T13:56:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/presentation-clinical-trial-data-present-future-h-gardarsdottir-utrecht-university_en.pdf"},
    {"id":"62198","name":"European Medicines Agency’s data protection notice for the HMA-EMA Catalogue of real-world data studies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T16:55:38Z","last_updated_date":"2024-07-02T12:22:00Z","reference_number":"EMA/60093/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-hma-ema-catalogue-real-world-data-studies_en.pdf"},
    {"id":"62199","name":"European Medicines Agency's data protection notice for the HMA-EMA Catalogue of real-world data sources (and networks and institutions)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T16:57:04Z","last_updated_date":"2024-07-02T13:43:00Z","reference_number":"EMA/110797/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-hma-ema-catalogue-real-world-data-sources-networks-institutions_en.pdf"},
    {"id":"62200","name":"Records of data processing activity regarding the HMA- EMA Catalogue of real-world data studies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T17:00:09Z","last_updated_date":"2024-02-15T17:00:09Z","reference_number":"EMA/60092/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regarding-hma-ema-catalogue-real-world-data-studies_en.pdf"},
    {"id":"62201","name":"Records of data processing activity for the HMA-EMA Catalogue of real-world data sources (and networks and institutions)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T17:02:15Z","last_updated_date":"2024-02-15T17:02:15Z","reference_number":"EMA/110797/2023","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-hma-ema-catalogue-real-world-data-sources-networks-institutions_en.pdf"},
    {"id":"62212","name":"Letter of support for Measurable Residual Disease (MRD) as a Surrogate Efficacy Endpoint in Clinical Studies with Acute Myeloid Leukemia","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-19T15:16:24Z","last_updated_date":"2024-02-19T15:16:24Z","reference_number":"EMADOC-1700519818-1285629","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-measurable-residual-disease-mrd-surrogate-efficacy-endpoint-clinical-studies-acute-myeloid-leukemia_en.pdf"},
    {"id":"62227","name":"ETF statement on use of recently updated COVID-19 vaccines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T10:09:11Z","last_updated_date":"2024-02-21T10:09:11Z","reference_number":"EMA/46094/2024","document_url":"https://www.ema.europa.eu/en/documents/other/etf-statement-use-recently-updated-covid-19-vaccines_en.pdf"},
    {"id":"62247","name":"Valproate : List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0043","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T17:28:14Z","last_updated_date":"2024-02-21T17:28:14Z","reference_number":"EMA/581954/2023","document_url":"https://www.ema.europa.eu/en/documents/other/valproate-list-nationally-authorised-medicinal-products-emea-h-n-psr-j-0043_en.pdf"},
    {"id":"62248","name":"Valproate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/J/0043","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T17:35:01Z","last_updated_date":"2024-02-21T17:35:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/valproate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0043_no.pdf"}},
    {"id":"62249","name":"Valproate : PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0043","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T17:36:59Z","last_updated_date":"2024-07-24T11:31:00Z","reference_number":"EMA/334781/2024","document_url":"https://www.ema.europa.eu/en/documents/other/valproate-prac-non-interventional-imposed-pass-final-study-report-assessment-report-emea-h-n-psr-j-0043_en.pdf"},
    {"id":"62286","name":"Declaration of interests: Kristina Paterson","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T15:19:13Z","last_updated_date":"2025-08-01T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-kristina-paterson_en.pdf"},
    {"id":"62341","name":"Submission of comments on draft qualification opinion ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T14:30:49Z","last_updated_date":"2024-02-28T14:30:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/submission-comments-draft-qualification-opinion_en.docx"},
    {"id":"62342","name":" ICH E2D(R1) Public consultation explanatory note","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T14:38:37Z","last_updated_date":"2024-02-28T14:38:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ich-e2dr1-public-consultation-explanatory-note_en.pdf"},
    {"id":"62352","name":"Methodology European Specialised Expert Community (ESEC): Members","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T10:20:00Z","last_updated_date":"2025-12-11T12:25:00Z","reference_number":"EMA/389254/2025","document_url":"https://www.ema.europa.eu/en/documents/other/methodology-european-specialised-expert-community-esec-members_en.pdf"},
    {"id":"62378","name":"Final programming document 2024-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:46:27Z","last_updated_date":"2024-02-29T16:46:27Z","reference_number":"EMA/426707/2023","document_url":"https://www.ema.europa.eu/en/documents/other/final-programming-document-2024-2026_en.pdf"},
    {"id":"62389","name":"European Medicines Agency’s data protection notice for the exploration of the DEEP platform","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:39:50Z","last_updated_date":"2024-10-28T17:39:50Z","reference_number":"EMA/5888197/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-exploration-deep-platform_en.pdf"},
    {"id":"62392","name":"Records of data processing activity for the exploration of the DEEP platform","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T11:22:05Z","last_updated_date":"2024-03-01T11:22:05Z","reference_number":"EMA/588198/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-exploration-deep-platform_en.pdf"},
    {"id":"62406","name":"Declaration of Interests: Emmanuel Cormier","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T16:05:35Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-emmanuel-cormier_en.pdf"},
    {"id":"62408","name":"Declaration of Interests: Jordi Torren Edo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T16:17:26Z","last_updated_date":"2025-01-07T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-jordi-torren-edo_en.pdf"},
    {"id":"62443","name":"Valproate guide for healthcare professionals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-05T16:40:41Z","last_updated_date":"2024-03-05T16:40:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/valproate-guide-healthcare-professionals_en.pdf"},
    {"id":"62444","name":"Valproate guide for male patients","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-05T16:43:51Z","last_updated_date":"2024-03-05T16:43:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/valproate-guide-male-patients_en.pdf"},
    {"id":"62446","name":"PRAC recommendations on signals adopted at the 5-8 February 2024 PRAC meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-06T11:49:26Z","last_updated_date":"2024-03-06T11:49:26Z","reference_number":"EMA/PRAC/54558/2024","document_url":"https://www.ema.europa.eu/en/documents/other/prac-recommendations-signals-adopted-5-8-february-2024-prac-meeting_en.pdf"},
    {"id":"62452","name":"Darwin EU: Making health data count","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-06T15:03:00Z","last_updated_date":"2026-06-17T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-making-health-data-count_en.pdf"},
    {"id":"62458","name":"Draft Qualification opinion for Centiloid measure of Amyloid PET to quantify brain amyloid deposition","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T09:27:12Z","last_updated_date":"2024-03-07T09:27:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/draft-qualification-opinion-centiloid-measure-amyloid-pet-quantify-brain-amyloid-deposition_en.pdf"},
    {"id":"62459","name":"Summary CL- Additional Analyses presented at Discussion Meeting for Centiloid measure of Amyloid PET to quantify brain amyloid deposition","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T09:29:06Z","last_updated_date":"2024-03-07T09:29:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/summary-cl-additional-analyses-presented-discussion-meeting-centiloid-measure-amyloid-pet-quantify-brain-amyloid-deposition_en.pdf"},
    {"id":"62460","name":"Final briefing book submitted for qualification opinion on Centiloid measure of Amyloid PET to quantify brain amyloid deposition","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T09:30:45Z","last_updated_date":"2024-03-07T09:30:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/final-briefing-book-submitted-qualification-opinion-centiloid-measure-amyloid-pet-quantify-brain-amyloid-deposition_en.pdf"},
    {"id":"62475","name":"Vaccine Monitoring Platform: List of EMA-funded studies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T15:40:32Z","last_updated_date":"2026-02-18T08:32:43Z","reference_number":"EXT/261018/2025","document_url":"https://www.ema.europa.eu/en/documents/other/vaccine-monitoring-platform-list-ema-funded-studies_en.pdf"},
    {"id":"62478","name":"Annex II to Regulation (EU) 2019/6 on veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:11:31Z","last_updated_date":"2024-03-07T17:11:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-ii-regulation-eu-2019-6-veterinary-medicinal-products_en.pdf"},
    {"id":"62479","name":"List of variations not requiring assessment ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:13:39Z","last_updated_date":"2024-03-07T17:13:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-variations-not-requiring-assessment_en.pdf"},
    {"id":"62480","name":"Request for recommendations on the Union Product Database and the technical and functional analysis necessary for its establishment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:16:39Z","last_updated_date":"2024-03-07T17:16:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-recommendations-union-product-database-technical-functional-analysis-necessary-its-establishment_en.pdf"},
    {"id":"62481","name":"Request for scientific recommendation on specific requirements for the collection of data on antimicrobial medicines used in animals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:20:02Z","last_updated_date":"2024-03-07T17:20:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-scientific-recommendation-specific-requirements-collection-data-antimicrobial-medicines-used-animals_en.pdf"},
    {"id":"62482","name":"Request for recommendations on the format for the collection of data on antimicrobial medicinal products used in animals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:21:23Z","last_updated_date":"2024-03-07T17:21:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-recommendations-format-collection-data-antimicrobial-medicinal-products-used-animals_en.pdf"},
    {"id":"62483","name":"Request for recommendations on the establishment of the criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:23:02Z","last_updated_date":"2024-03-07T17:23:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-recommendations-establishment-criteria-designation-antimicrobials-be-reserved-treatment-certain-infections-humans-order-preserve-efficacy-those-antimicrobials_en.pdf"},
    {"id":"62484","name":"Request for scientific recommendations on the content of list of antimicrobials to be reserved for human medicine","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:24:35Z","last_updated_date":"2024-03-07T17:24:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-scientific-recommendations-content-list-antimicrobials-be-reserved-human-medicine_en.pdf"},
    {"id":"62485","name":"Implementing measures under Article 107(6) of Regulation (EU) 2019/6 on veterinary medicinal products, regarding the establishment of a list of antimicrobials, which shall not be used in accordance with Articles 112, 113 and 114 [...]","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:26:13Z","last_updated_date":"2024-03-07T17:26:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/implementing-measures-under-article-1076-regulation-eu-2019-6-veterinary-medicinal-products-regarding-establishment-list-antimicrobials-which-shall-not-be-used-accordance-articles-112-113-114_en.pdf"}    {"id":"62486","name":"Request for recommendations on implementing measures on veterinary medicinal products regarding good pharmacovigilance practice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:29:03Z","last_updated_date":"2024-03-07T17:29:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-recommendations-implementing-measures-veterinary-medicinal-products-regarding-good-pharmacovigilance-practice_en.pdf"},
    {"id":"62487","name":"Request for scientific recommendations on the format and content of the pharmacovigilance system master file and its summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:30:49Z","last_updated_date":"2024-03-07T17:30:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-scientific-recommendations-format-content-pharmacovigilance-system-master-file-its-summary_en.pdf"},
    {"id":"62488","name":"Request for scientific recommendations on measures on good distribution practice for veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:32:07Z","last_updated_date":"2024-03-07T17:32:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-scientific-recommendations-measures-good-distribution-practice-veterinary-medicinal-products_en.pdf"},
    {"id":"62489","name":"Request for recommendations on good distribution practice for active substances used as starting material in veterinary medicines (Article 95 (8))","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:33:25Z","last_updated_date":"2024-03-07T17:33:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-recommendations-good-distribution-practice-active-substances-used-starting-material-veterinary-medicines-article-95-8_en.pdf"},
    {"id":"62490","name":"Request for recommendations on the rules on appropriate measures to ensure the effective and safe use of veterinary medicines authorised and prescribed for oral administration via routes other than medicated feed","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T17:35:50Z","last_updated_date":"2024-03-07T17:35:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-recommendations-rules-appropriate-measures-ensure-effective-safe-use-veterinary-medicines-authorised-prescribed-oral-administration-routes-other-medicated-feed_en.pdf"},
    {"id":"62494","name":"Note on the HORIZON-JU-IHI-2024-06-two-stage funding call: Development of evidence based practical guidance for sponsors on the use of real-world data / real-world evidence","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T11:13:07Z","last_updated_date":"2024-03-08T11:13:07Z","reference_number":"EMA/65720/2024","document_url":"https://www.ema.europa.eu/en/documents/other/note-horizon-ju-ihi-2024-06-two-stage-funding-call-development-evidence-based-practical-guidance-sponsors-use-real-world-data-real-world-evidence_en.pdf"},
    {"id":"62583","name":"Chlormadinone acetate (CMA), ethinylestradiol (EE) : List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0042","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T09:10:43Z","last_updated_date":"2024-03-13T09:10:43Z","reference_number":"EMA/111641/2024","document_url":"https://www.ema.europa.eu/en/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-list-nationally-authorised-medicinal-products-emea-h-n-psr-j-0042_en.pdf"},
    {"id":"62584","name":"Chlormadinone acetate (CMA), ethinylestradiol (EE) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/J/0042","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T09:13:21Z","last_updated_date":"2024-05-02T14:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/chlormadinone-acetate-cma-ethinylestradiol-ee-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-emea-h-n-psr-j-0042_no.pdf"}},
    {"id":"62587","name":"Innovation Task Force (ITF) briefing meeting - Briefing document template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T14:10:05Z","last_updated_date":"2026-03-20T13:00:00Z","reference_number":"EMA/76018/2021","document_url":"https://www.ema.europa.eu/en/documents/other/innovation-task-force-itf-briefing-meeting-briefing-document-template_en.docx"},
    {"id":"62600","name":"Innovation Task Force (ITF) briefing meeting - Instructions on how to apply","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T14:16:20Z","last_updated_date":"2024-03-13T14:16:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/innovation-task-force-itf-briefing-meeting-instructions-how-apply_en.pdf"},
    {"id":"62627","name":"Release notes - production release version 1.71.2413d March 2024 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-18T11:31:50Z","last_updated_date":"2024-03-18T11:31:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-1712413d-march-2024-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"62643","name":"MedDRA important medical event terms list - version 29.0","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-26T08:56:02Z","last_updated_date":"2026-03-20T15:02:00Z","reference_number":"EMA/67785/2026","document_url":"https://www.ema.europa.eu/en/documents/other/meddra-important-medical-event-terms-list-version-29-0_en.xlsx"},
    {"id":"62711","name":"Scientific Explorer - Frequently Asked Questions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T14:00:00Z","last_updated_date":"2026-03-03T11:54:00Z","reference_number":"EMA/48978/2026","document_url":"https://www.ema.europa.eu/en/documents/other/scientific-explorer-frequently-asked-questions_en.pdf"},
    {"id":"62730","name":"Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency – IPA and AMED","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-25T16:40:30Z","last_updated_date":"2024-03-25T16:40:30Z","reference_number":"EMA/698804/2015 Revision 2*","document_url":"https://www.ema.europa.eu/en/documents/other/monitoring-medical-literature-entry-relevant-information-eudravigilance-database-european-medicines-agency-ipa-amed_en.pdf"},
    {"id":"62733","name":"Replacement of quadrivalent seasonal influenza vaccines with trivalent vaccines in the EU","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T12:00:00Z","last_updated_date":"2024-03-26T12:00:00Z","reference_number":"EMA/123036/2024","document_url":"https://www.ema.europa.eu/en/documents/other/replacement-quadrivalent-seasonal-influenza-vaccines-trivalent-vaccines-eu_en.pdf"},
    {"id":"62747","name":"Outcome of written procedures finalised during the period from 07 December 2023 to 11 March 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T14:26:43Z","last_updated_date":"2024-03-26T14:26:43Z","reference_number":"EMA/MB/585245/2023 Noted","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-07-december-2023-11-march-2024_en.pdf"},
    {"id":"62757","name":"Explanatory note on general fees payable to the European Medicines Agency as of 1 April 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-27T11:59:15Z","last_updated_date":"2024-04-11T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/explanatory-note-general-fees-payable-european-medicines-agency-1-april-2024_en.pdf"},
    {"id":"62759","name":"European Medicines Agency’s data protection notice for Scientific Explorer","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:39:32Z","last_updated_date":"2026-03-04T12:30:00Z","reference_number":"EMA/119597/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-scientific-explorer_en.pdf"},
    {"id":"62760","name":"Records of data processing activity for Scientific Explorer","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-27T15:20:49Z","last_updated_date":"2024-03-27T15:20:49Z","reference_number":"EMA/119622/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-scientific-explorer_en.pdf"},
    {"id":"62763","name":"Questions and answers - Q1 2024 System Demo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-03-27T18:01:03Z","last_updated_date":"2024-04-04T14:33:00Z","reference_number":"EMA/131035/2024","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-q1-2024-system-demo_en.pdf"},
    {"id":"62771","name":"PRAC recommendations on signals adopted at the 4-7 March 2024 PRAC meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-02T11:13:41Z","last_updated_date":"2024-04-02T11:13:41Z","reference_number":"EMA/PRAC/77162/2024","document_url":"https://www.ema.europa.eu/en/documents/other/prac-recommendations-signals-adopted-4-7-march-2024-prac-meeting_en.pdf"},
    {"id":"62782","name":"European Medicines Agency's data protection notice for the handling of data subjects’ requests","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:21:10Z","last_updated_date":"2026-03-24T10:49:00Z","reference_number":"EMA/116897/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-handling-data-subjects-requests_en.pdf"},
    {"id":"62783","name":"Records of data processing activity for the handling of data subjects’ requests","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-02T17:19:24Z","last_updated_date":"2026-03-24T10:50:00Z","reference_number":"EMA/116896/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-handling-data-subjects-requests_en.pdf"},
    {"id":"62791","name":"Transferring a veterinary marketing authorisation (MA) - Choosing the implementation date","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-03T14:04:41Z","last_updated_date":"2026-03-05T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/transferring-veterinary-marketing-authorisation-ma-choosing-implementation-date_en.pdf"},
    {"id":"62813","name":"Technical Webinar: Regulatory Procedure Management for PLM in  IRIS for Network Users (27 February 2024) – Questions & Answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T14:01:50Z","last_updated_date":"2024-04-04T14:01:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/technical-webinar-regulatory-procedure-management-plm-iris-network-users-27-february-2024-questions-answers_en.pdf"},
    {"id":"62822","name":"Antimicrobial Sales and Use (ASU) Platform: Release notes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T15:30:18Z","last_updated_date":"2026-05-11T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/antimicrobial-sales-use-asu-platform-release-notes_en.pdf"},
    {"id":"62870","name":"Decision of the Management Board amending budget No. 02, amending appropriations in budget 2024","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2024-04-09T11:46:55Z","last_updated_date":"2024-04-09T11:46:55Z","reference_number":"EMA/MB/101159/2024","document_url":"https://www.ema.europa.eu/en/documents/other/decision-management-board-amending-budget-no-02-amending-appropriations-budget-2024_en.pdf"},
    {"id":"62879","name":"Q&A Document - Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-09T15:28:43Z","last_updated_date":"2024-04-09T15:28:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qa-document-update-webinar-regulatory-procedure-management-product-lifecycle-management-iris_en.pdf"},
    {"id":"62925","name":"Draft revised Heads of Medicines Agency / European Medicines Agency guidance document on the identification of personal data and commercially confidential information within the structure of the marketing authorisation application dossier","type":"other","status":"Draft: consultation closed","consultation_date":"2024-04-12 - 2024-06-28","first_published_date":"2024-04-12T09:28:07Z","last_updated_date":"2024-04-12T09:28:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/draft-revised-heads-medicines-agency-european-medicines-agency-guidance-document-identification-personal-data-commercially-confidential-information-within-structure-marketing-authorisation-application_en.pdf"},
    {"id":"62939","name":"Guide on real-world evidence provided by EMA: support for regulatory decision-making","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T14:24:18Z","last_updated_date":"2024-04-12T14:24:18Z","reference_number":"EMA/152628/2024","document_url":"https://www.ema.europa.eu/en/documents/other/guide-real-world-evidence-provided-ema-support-regulatory-decision-making_en.pdf"},
    {"id":"62979","name":"Q & A Orphan Medicines Development – ask the European Regulator","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T15:35:23Z","last_updated_date":"2024-04-16T15:35:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/q-orphan-medicines-development-ask-european-regulator_en.pdf"},
    {"id":"62992","name":"All languages - Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668) - Revision 4","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2024-04-17T10:40:00Z","last_updated_date":"2024-04-17T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/all-languages-annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-4_en.xlsx"},
    {"id":"62999","name":"Remote RP activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-18T10:54:52Z","last_updated_date":"2024-05-22T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/remote-rp-activities_en.pdf"},
    {"id":"63043","name":"MSSG recommendations to strengthen supply chains of critical medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-23T13:27:00Z","last_updated_date":"2024-04-23T13:27:00Z","reference_number":"EMA/44164/2024","document_url":"https://www.ema.europa.eu/en/documents/other/mssg-recommendations-strengthen-supply-chains-critical-medicinal-products_en.pdf"},
    {"id":"63058","name":"Release notes -  production release version 1.7.2417 April 2024 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-24T18:04:00Z","last_updated_date":"2024-04-24T18:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172417-april-2024-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"63060","name":"Declaration of interests: Gaëtan Guyodo","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-25T09:10:33Z","last_updated_date":"2025-08-01T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-gaetan-guyodo_en.pdf"},
    {"id":"63064","name":"Factsheet: using facts and science when making decisions about vaccination","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-25T14:48:29Z","last_updated_date":"2024-04-25T14:48:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/factsheet-using-facts-science-when-making-decisions-about-vaccination_en.pdf"},
    {"id":"63087","name":"Working arrangement between the Ministry of Food and Drug Safety of the Republic of Korea and the Directorate-General for Health and Food Safety of the European Commission and EMA for the Exchange of Non-Public Information on Medicinal Products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-26T14:15:00Z","last_updated_date":"2024-04-26T14:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/working-arrangement-between-ministry-food-drug-safety-republic-korea-directorate-general-health-food-safety-european-commission-ema-exchange-non-public-information-medicinal-products_en.pdf"},
    {"id":"63094","name":"Manual for Member States for establishing a data quality management plan for the collection of antimicrobial sales and use data under Regulation (EU) 2019-6 and its delegated and implementing regulations","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-26T15:16:21Z","last_updated_date":"2024-04-26T15:16:21Z","reference_number":"EMA/CVMP/ESUAVET/570091/2023","document_url":"https://www.ema.europa.eu/en/documents/other/manual-member-states-establishing-data-quality-management-plan-collection-antimicrobial-sales-use-data-under-regulation-eu-2019-6-its-delegated-implementing-regulations_en.pdf"},
    {"id":"63108","name":"EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024-2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-30T12:00:00Z","last_updated_date":"2024-04-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-recommendation-update-antigenic-composition-authorised-covid-19-vaccines-2024-2025_en.pdf"},
    {"id":"63109","name":"EMA recommendation to update the antigenic composition  of authorised COVID-19 vaccines for 2024-2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-30T11:46:00Z","last_updated_date":"2024-04-30T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-recommendation-update-antigenic-composition-authorised-covid-19-vaccines-2024-2025_en.pdf-0"},
    {"id":"63118","name":"CAT meetings in 2025 and 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-04-30T17:09:24Z","last_updated_date":"2024-04-30T17:09:24Z","reference_number":"EMA/CAT/78070/2023","document_url":"https://www.ema.europa.eu/en/documents/other/cat-meetings-2025-2026_en.pdf"},
    {"id":"63140","name":"Stefano Marino – Outcome of assessment of declared occupational activities after leaving the service (January 2024)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-02T13:55:46Z","last_updated_date":"2024-05-02T13:55:46Z","reference_number":"EMA/165849/2024","document_url":"https://www.ema.europa.eu/en/documents/other/stefano-marino-outcome-assessment-declared-occupational-activities-after-leaving-service-january-2024_en.pdf"},
    {"id":"63158","name":"Highlights - Third European Medicines Agency and Affordable Medicines Europe bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-03T10:00:00Z","last_updated_date":"2024-05-03T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-third-european-medicines-agency-affordable-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"63165","name":"PRAC recommendations on signals adopted at the 8-11 April 2024 PRAC meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-06T09:36:49Z","last_updated_date":"2024-05-06T09:36:49Z","reference_number":"EMA/PRAC/147679/2024","document_url":"https://www.ema.europa.eu/en/documents/other/prac-recommendations-signals-adopted-8-11-april-2024-prac-meeting_en.pdf"},
    {"id":"63175","name":"European Medicines Agency’s data protection notice for the audiovisual tool for checking presence in meeting rooms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-06T16:47:54Z","last_updated_date":"2024-05-06T16:47:54Z","reference_number":"EMA/177150/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-audiovisual-tool-checking-presence-meeting-rooms_en.pdf"},
    {"id":"63176","name":"Records of data processing activity for audiovisual tool for checking presence in meeting rooms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-06T16:54:16Z","last_updated_date":"2024-05-06T16:54:16Z","reference_number":"EMA/177151/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-audiovisual-tool-checking-presence-meeting-rooms_en.pdf"},
    {"id":"63219","name":"European Medicines Agency's data protection notice on the study of the “Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV- during the Omicron period”","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T11:18:28Z","last_updated_date":"2024-05-16T11:18:28Z","reference_number":"EMA/221505/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-study-natural-history-coagulopathy-covid-19-patients-persons-vaccinated-against-sars-cov-during-omicron-period_en.pdf","translations":{"fr":"https://www.ema.europa.eu/fr/documents/other/european-medicines-agencys-data-protection-notice-study-natural-history-coagulopathy-covid-19-patients-persons-vaccinated-against-sars-cov-during-omicron-period_fr.pdf"}},
    {"id":"63228","name":"Records of data processing activity for study of the “Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV- during the Omicron period”","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T11:47:07Z","last_updated_date":"2024-05-16T11:47:07Z","reference_number":"EMA/228382/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-study-natural-history-coagulopathy-covid-19-patients-persons-vaccinated-against-sars-cov-during-omicron-period_en.pdf"},
    {"id":"63231","name":"Question & Answers - Technical Webinar: Information and Q&A session on updated CAPs in web-based eAF","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T11:53:25Z","last_updated_date":"2024-05-16T11:53:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/question-answers-technical-webinar-information-qa-session-updated-caps-web-based-eaf_en.pdf"},
    {"id":"63249","name":"Questions and answers relating to Grant Procedure no. EMA/GRANT/2024/02/IA - Medicines regulatory systems strengthening in Sub-Saharan Africa","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-17T11:25:00Z","last_updated_date":"2024-08-26T14:25:00Z","reference_number":"EMA/228100/2024","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-relating-grant-procedure-no-ema-grant-2024-02-ia-medicines-regulatory-systems-strengthening-sub-saharan-africa_en.pdf"},
    {"id":"63263","name":"Valproate - Paternal exposure to valproate (Final report)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-17T14:48:00Z","last_updated_date":"2024-05-17T14:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/valproate-paternal-exposure-valproate-final-report_en.pdf"},
    {"id":"63264","name":"Valproate - Paternal exposure to valproate (Corrigendum to the final report))","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-17T14:51:00Z","last_updated_date":"2024-05-17T14:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/valproate-paternal-exposure-valproate-corrigendum-final-report_en.pdf"},
    {"id":"63265","name":"Valproate - Paternal exposure to valproate (Addendum)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-17T14:53:00Z","last_updated_date":"2024-05-17T14:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/valproate-paternal-exposure-valproate-addendum_en.pdf"},
    {"id":"63320","name":"Anonymisation report form instructions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-24T14:51:57Z","last_updated_date":"2024-05-24T14:51:57Z","reference_number":"EMA/482639/2023","document_url":"https://www.ema.europa.eu/en/documents/other/anonymisation-report-form-instructions_en.pdf"},
    {"id":"63322","name":"European Medicines Agency’s Data Protection Notice For the Risk Management Plans Publication Process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-24T15:37:00Z","last_updated_date":"2024-05-24T15:37:00Z","reference_number":"EMA/219344/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-risk-management-plans-publication-process_en.pdf"},
    {"id":"63323","name":"Record of data processing activity for Risk Management Plans Publication Process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-24T15:50:00Z","last_updated_date":"2024-05-24T15:50:00Z","reference_number":"EMA/219343/2024","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-risk-management-plans-publication-process_en.pdf"},
    {"id":"63327","name":"Declaration of interests: Marko Banjanin","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-05-27T13:59:04Z","last_updated_date":"2025-08-01T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-marko-banjanin_en.pdf"},
    {"id":"63459","name":"Guidance for applicants on Simultaneous National Scientific Advice (SNSA) – phase 2 pilot – Optimized process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-03T17:00:00Z","last_updated_date":"2024-06-03T17:00:00Z","reference_number":"EMA/251446/2024","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-applicants-simultaneous-national-scientific-advice-snsa-phase-2-pilot-optimized-process_en.pdf"},
    {"id":"63460","name":"SNSA procedural flowchart","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-03T17:00:00Z","last_updated_date":"2024-06-03T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/snsa-procedural-flowchart_en.pdf"},
    {"id":"63461","name":"Guidance for applicants on Simultaneous National Scientific Advice (SNSA) Briefing book format and content","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-03T17:00:00Z","last_updated_date":"2024-06-03T17:00:00Z","reference_number":"EMA/896929/2022","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-applicants-simultaneous-national-scientific-advice-snsa-briefing-book-format-content_en.pdf"},
    {"id":"63462","name":"Overview of NCAs participating in the voluntary Simultaneous National Scientific Advice (SNSA) project","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-03T17:00:00Z","last_updated_date":"2025-04-11T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-ncas-participating-voluntary-simultaneous-national-scientific-advice-snsa-project_en.pdf"},
    {"id":"63497","name":"Research projects conducted under the remit of the PRAC impact strategy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T10:52:00Z","last_updated_date":"2024-06-06T10:52:00Z","reference_number":"EMA/219485/2024","document_url":"https://www.ema.europa.eu/en/documents/other/research-projects-conducted-under-remit-prac-impact-strategy_en.pdf"},
    {"id":"63501","name":"Questions and Answers - Product Management Service (PMS) Product UI training (access & navigation)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T09:47:17Z","last_updated_date":"2024-06-06T09:47:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-product-management-service-pms-product-ui-training-access-navigation_en.pdf"},
    {"id":"63539","name":"Change management activities delivery plan - HMA-EMA joint Big Data Steering Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-07T15:34:50Z","last_updated_date":"2026-06-11T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/change-management-activities-delivery-plan-hma-ema-joint-big-data-steering-group_en.pdf"},
    {"id":"63548","name":"Declaration of interests: Alexander Jacobs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-10T14:42:13Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-alexander-jacobs_en.pdf"},
    {"id":"63569","name":"European Shortages Monitoring Platform (ESMP) Informational brief","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-11T13:48:32Z","last_updated_date":"2025-12-16T16:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-informational-brief_en.pdf"},
    {"id":"63572","name":"Executive summary for proposed amendments to the European Commission guidelines on variations categories and procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-13T09:43:00Z","last_updated_date":"2024-06-13T09:43:00Z","reference_number":"EMA/269251/2024","document_url":"https://www.ema.europa.eu/en/documents/other/executive-summary-proposed-amendments-european-commission-guidelines-variations-categories-procedures_en.pdf"},
    {"id":"63573","name":"European Commission guidelines on variations categories and procedures: Proposal for stakeholder consultation - in tracked changes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-13T09:44:00Z","last_updated_date":"2024-06-13T09:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-guidelines-variations-categories-procedures-proposal-stakeholder-consultation-tracked-changes_en.pdf"},
    {"id":"63574","name":"European Commission guidelines on variations categories and procedures: Proposal for stakeholder consultation - clean version","type":"other","status":"Draft: consultation closed","consultation_date":"2024-06-13 - 2024-08-23","first_published_date":"2024-06-13T09:43:00Z","last_updated_date":"2024-06-13T09:43:00Z","reference_number":"EMA/269287/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-commission-guidelines-variations-categories-procedures-proposal-stakeholder-consultation-clean-version_en.pdf"},
    {"id":"63592","name":"Release notes - production release version 1.7.2424 June 2024 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-13T09:28:57Z","last_updated_date":"2024-06-13T09:28:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172424-june-2024-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"63645","name":"SME Info Day Programme, 18 October 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-17T12:00:00Z","last_updated_date":"2024-10-25T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/sme-info-day-programme-18-october-2024_en.pdf"},
    {"id":"63653","name":"Medicine shortage prevention plan - template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T13:57:00Z","last_updated_date":"2024-12-04T11:34:00Z","reference_number":"EMA/549304/2023","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-prevention-plan-template_en.pdf"},
    {"id":"63654","name":"Medicine shortage mitigation plan - template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T13:58:00Z","last_updated_date":"2024-12-04T11:35:00Z","reference_number":"EMA/549303/2023","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-mitigation-plan-template_en.pdf"},
    {"id":"63667","name":"Hearing the Association of the European Self-Medication Industry (AESGP) during the November 2023 Working Party meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T13:52:54Z","last_updated_date":"2024-06-18T13:52:54Z","reference_number":"EMA/HMPC/996/2024","document_url":"https://www.ema.europa.eu/en/documents/other/hearing-association-european-self-medication-industry-aesgp-during-november-2023-working-party-meeting_en.pdf"},
    {"id":"63713","name":"Dates of 2025 Scientific Advice Working Party - Human (SAWP-H) meetings and submission deadlines for scientific advice, protocol assistance, qualification of novel methodologies and HTACG/EMA parallel Joint Scientific Consultation (JSC) requests","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T12:37:00Z","last_updated_date":"2025-11-18T09:50:00Z","reference_number":"EMA/81764/2023 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/other/dates-2025-scientific-advice-working-party-human-sawp-h-meetings-submission-deadlines-scientific-advice-protocol-assistance-qualification-novel-methodologies-htacg-ema-parallel-joint-scientific_en.pdf"},
    {"id":"63715","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures - Revised implementing rules to the Fee Regulation as of 1 April 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T13:00:00Z","last_updated_date":"2024-06-21T13:00:00Z","reference_number":"EMA/MB/182939/2023","document_url":"https://www.ema.europa.eu/en/documents/other/rules-implementation-council-regulation-ec-no-297-95-fees-payable-european-medicines-agency-other-measures-revised-implementing-rules-fee-regulation-1-april-2024_en.pdf"},
    {"id":"63722","name":"Presentation - New Fee Regulation: webinar for veterinary Marketing Authorisation Holders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T17:54:56Z","last_updated_date":"2024-06-21T17:54:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/presentation-new-fee-regulation-webinar-veterinary-marketing-authorisation-holders_en.pdf"},
    {"id":"63728","name":"Qualification opinion for Centiloid measure of Amyloid PET to quantify brain amyloid deposition","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2024-06-25T09:42:24Z","last_updated_date":"2024-06-25T09:42:24Z","reference_number":"EMADOC-1700519818-1200791","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-centiloid-measure-amyloid-pet-quantify-brain-amyloid-deposition_en.pdf"},
    {"id":"63738","name":"Annual list of contracts 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-25T10:54:00Z","last_updated_date":"2024-06-25T10:54:00Z","reference_number":"EMA/50768/2023","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contracts-2023_en.pdf"},
    {"id":"63739","name":"Outcome of written procedures finalised during the period from 12 March to 03 June 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-25T11:12:00Z","last_updated_date":"2024-06-25T11:12:00Z","reference_number":"EMA/MB/131031/2024 Noted","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-12-march-03-june-2024_en.pdf"},
    {"id":"63740","name":"Management Board meeting dates 2025-2026","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2024-06-25T11:17:00Z","last_updated_date":"2024-06-25T11:17:00Z","reference_number":"EMA/MB/248390/2024","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2025-2026_en.pdf"},
    {"id":"63742","name":"EMA and FDA-CVM parallel scientific advice timetable","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-26T13:50:00Z","last_updated_date":"2024-06-26T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-fda-cvm-parallel-scientific-advice-timetable_en.pdf"},
    {"id":"63743","name":"General principles EMA-FDA parallel scientific advice (animal drug products)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-26T13:50:00Z","last_updated_date":"2024-06-26T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/general-principles-ema-fda-parallel-scientific-advice-animal-drug-products_en.pdf"},
    {"id":"63746","name":"Decision of the Management Board amending budget No. 03, amending appropriations in budget 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-25T13:32:00Z","last_updated_date":"2024-06-25T13:32:00Z","reference_number":"EMA/MB/229817/2024","document_url":"https://www.ema.europa.eu/en/documents/other/decision-management-board-amending-budget-no-03-amending-appropriations-budget-2024_en.pdf"},
    {"id":"63751","name":"MSSG recommendations on shortage of Glucagon-Like Peptide-1 (GLP-1) receptor agonists","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-26T15:30:00Z","last_updated_date":"2024-06-26T15:30:00Z","reference_number":"EMA/143883/2024","document_url":"https://www.ema.europa.eu/en/documents/other/mssg-recommendations-shortage-glucagon-peptide-1-glp-1-receptor-agonists_en.pdf"},
    {"id":"63790","name":"Questions and answers on classification of veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T11:30:00Z","last_updated_date":"2024-06-28T11:30:00Z","reference_number":"EMA/CVMP/93401/2024","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-classification-veterinary-medicinal-products_en.pdf"},
    {"id":"63812","name":"Q&A - Quarterly System Demo Q2 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T11:11:01Z","last_updated_date":"2024-07-18T14:01:00Z","reference_number":"EMA/280347/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/other/qa-quarterly-system-demo-q2-2024_en.pdf"},
    {"id":"63829","name":"ICH reflection paper on pursuing opportunities for harmonisation in using real-world data to generate real-world evidence","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T10:00:00Z","last_updated_date":"2024-07-03T10:00:00Z","reference_number":"EMA/CHMP/ICH/295401/2023","document_url":"https://www.ema.europa.eu/en/documents/other/ich-reflection-paper-pursuing-opportunities-harmonisation-using-real-world-data-generate-real-world-evidence_en.pdf"},
    {"id":"63838","name":"Release notes - production release version 1.7.2424-1 July 2024 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-02T09:38:40Z","last_updated_date":"2024-07-02T09:38:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172424-1-july-2024-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"63845","name":"Guidance for competent authorities super users on how to configure email addresses for UPD notifications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-02T12:18:24Z","last_updated_date":"2024-07-02T12:18:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-competent-authorities-super-users-how-configure-email-addresses-upd-notifications_en.pdf"},
    {"id":"63846","name":"Guidance for marketing authorisation holders super users how to configure email addresses for UPD notifications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-02T12:23:31Z","last_updated_date":"2024-07-02T12:23:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-marketing-authorisation-holders-super-users-how-configure-email-addresses-upd-notifications_en.pdf"},
    {"id":"63868","name":"Fee regulation working arrangements","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T10:41:00Z","last_updated_date":"2026-06-24T11:00:00Z","reference_number":"EMA/MB/183645/2024 Revision 3","document_url":"https://www.ema.europa.eu/en/documents/other/fee-regulation-working-arrangements_en.pdf"},
    {"id":"63874","name":"Mandate, objectives and rules of procedure for the  European Specialised Expert Community (ESEC)- Cardiovascular Diseases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-04T14:32:00Z","last_updated_date":"2024-07-04T14:32:00Z","reference_number":"EMA/913729/2022","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-european-specialised-expert-community-esec-cardiovascular-diseases_en.pdf"},
    {"id":"63999","name":"European Medicines Agency’s data protection notice for regulatory science and innovation task force (TRS) activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T16:38:00Z","last_updated_date":"2024-07-10T16:38:00Z","reference_number":"EMA/79065/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-regulatory-science-innovation-task-force-trs-activities_en.pdf"},
    {"id":"64001","name":"Records of data processing activity for regulatory science and innovation task force (TRS) activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T17:00:00Z","last_updated_date":"2024-07-10T17:00:00Z","reference_number":"EMA/79066/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regulatory-science-innovation-task-force-trs-activities_en.pdf"},
    {"id":"64070","name":"PRAC statistics: July 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T11:43:00Z","last_updated_date":"2024-07-12T11:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/prac-statistics-july-2024_en.pdf"},
    {"id":"64221","name":"EMA confirms its recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024-2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T13:50:00Z","last_updated_date":"2024-07-19T13:50:00Z","reference_number":"EMA/338472/2024","document_url":"https://www.ema.europa.eu/en/documents/other/ema-confirms-its-recommendation-update-antigenic-composition-authorised-covid-19-vaccines-2024-2025_en.pdf"},
    {"id":"64329","name":"Annex 1: List of EMA RWD study requests from 8 February 2023 to 7 February 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T10:55:00Z","last_updated_date":"2024-08-01T10:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-1-list-ema-rwd-study-requests-8-february-2023-7-february-2024_en.xlsx"},
    {"id":"64330","name":"Extended Annex 2 - Portfolio of use cases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-31T11:07:00Z","last_updated_date":"2024-07-31T11:07:00Z","reference_number":"EMA/345274/2024","document_url":"https://www.ema.europa.eu/en/documents/other/extended-annex-2-portfolio-use-cases_en.pdf"}    {"id":"64345","name":"Questions and answers on standard animal weights for estimating worst-case consumer exposure scenarios","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-26T13:51:40Z","last_updated_date":"2024-07-26T13:51:40Z","reference_number":"EMA/250170/2024","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-standard-animal-weights-estimating-worst-case-consumer-exposure-scenarios_en.pdf"},
    {"id":"64347","name":"Records of data processing activity for digital business cards (QR code)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-26T14:45:26Z","last_updated_date":"2024-07-26T14:45:26Z","reference_number":"EMA/89805/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-digital-business-cards-qr-code_en.pdf"},
    {"id":"64350","name":"Declaration of interests: Ana Zanoletty Perez","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-26T17:24:04Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-ana-zanoletty-perez_en.pdf"},
    {"id":"64351","name":"Declaration of interests: Hannes Kulovits","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-26T17:31:13Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-hannes-kulovits_en.pdf"},
    {"id":"64352","name":"Declaration of interests : Patrycja Gdynia-Kijewska","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-26T17:38:39Z","last_updated_date":"2024-07-26T17:38:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-patrycja-gdynia-kijewska_en.pdf"},
    {"id":"64374","name":"European Shortages Monitoring Platform (ESMP) essentials: Industry and network reporting requirements","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-31T16:55:00Z","last_updated_date":"2025-05-13T15:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-essentials-industry-network-reporting-requirements_en.pdf"},
    {"id":"64375","name":"Frequently asked questions on the European Shortages Monitoring Platform (ESMP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-31T16:55:00Z","last_updated_date":"2026-02-02T17:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/frequently-asked-questions-european-shortages-monitoring-platform-esmp_en.pdf"},
    {"id":"64376","name":"European Shortages Monitoring Platform (ESMP): Implementation guide for marketing authorisation holders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-31T16:55:00Z","last_updated_date":"2026-04-28T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-implementation-guide-marketing-authorisation-holders_en.pdf"},
    {"id":"64377","name":"European Shortages Monitoring Platform (ESMP): Implementation guide for national competent authorities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-31T16:55:00Z","last_updated_date":"2026-04-28T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-implementation-guide-national-competent-authorities_en.pdf"},
    {"id":"64378","name":"European Shortages Monitoring Platform (ESMP): Stakeholder engagement plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-31T16:55:00Z","last_updated_date":"2024-12-10T15:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-stakeholder-engagement-plan_en.pdf"},
    {"id":"64392","name":"Mandate, objectives and rules of procedure for the Environmental Risk Assessment European Specialised Expert Community","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2024-07-30T09:56:27Z","last_updated_date":"2024-07-30T09:56:27Z","reference_number":"EMA/86916/2024","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-environmental-risk-assessment-european-specialised-expert-community_en.pdf"},
    {"id":"64406","name":"Release notes - production release version 1.7.2427- 30 July 2024 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-07-30T15:52:10Z","last_updated_date":"2024-07-30T15:52:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172427-30-july-2024-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"64484","name":"Questions and answers (Q&A) from the European Shortages Monitoring Platform (ESMP) essentials and industry reporting requirements webinar","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-02T11:53:44Z","last_updated_date":"2024-08-02T11:53:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-qa-european-shortages-monitoring-platform-esmp-essentials-industry-reporting-requirements-webinar_en.pdf"},
    {"id":"64492","name":"ICH M13A Guideline on bioequivalence for immediate-release solid oral dosage forms - Questions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-02T12:45:55Z","last_updated_date":"2024-08-02T12:45:55Z","reference_number":"EMA/CHMP/ICH/325575/2024","document_url":"https://www.ema.europa.eu/en/documents/other/ich-m13a-guideline-bioequivalence-immediate-release-solid-oral-dosage-forms-questions-answers_en.pdf"},
    {"id":"64502","name":"Union list of critical medicines: eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) / Product Management System (PMS) entries (outdated)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-05T16:55:00Z","last_updated_date":"2025-02-14T15:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/union-list-critical-medicines-extended-eudravigilance-medicinal-product-dictionary-xevmpd-product-management-system-pms-entries-outdated_en.xlsx"},
    {"id":"64507","name":"Comments received from public consultation on good pharmacovigilance practices: GVP module XVI - Risk minimisation measures (Rev. 3)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-05T12:10:00Z","last_updated_date":"2024-08-05T12:10:00Z","reference_number":"EMA/341696/2024","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-rev-3_en.pdf"},
    {"id":"64508","name":"Guideline on good pharmacovigilance practices: Module XVI– Risk minimisation measures - Selection of tools and effectiveness indicators with tracked changes (Rev.3)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-05T12:15:00Z","last_updated_date":"2024-08-05T12:15:00Z","reference_number":"EMA/204715/2012","document_url":"https://www.ema.europa.eu/en/documents/other/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools-effectiveness-indicators-tracked-changes-rev3_en.pdf"},
    {"id":"64509","name":"Guideline on good pharmacovigilance practices (GVP): Module XVI Addendum II –Methods for evaluating effectiveness of risk minimisation measures with tracked changes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-05T12:15:00Z","last_updated_date":"2024-08-05T12:15:00Z","reference_number":"EMA/419982/2019","document_url":"https://www.ema.europa.eu/en/documents/other/guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-ii-methods-evaluating-effectiveness-risk-minimisation-measures-tracked-changes_en.pdf"},
    {"id":"64512","name":"Comments received from public consultation on good pharmacovigilance practices: GVP Module XVI Addendum II - Methods for effectiveness evaluation of risk minimisation measures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-05T12:10:00Z","last_updated_date":"2024-08-05T12:10:00Z","reference_number":"EMA/341741/2024","document_url":"https://www.ema.europa.eu/en/documents/other/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-module-xvi-addendum-ii-methods-effectiveness-evaluation-risk-minimisation-measures_en.pdf"},
    {"id":"64546","name":"Product Management Service (PMS) – Frequently Asked Questions (FAQs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-08T17:51:08Z","last_updated_date":"2026-04-23T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/product-management-service-pms-frequently-asked-questions-faqs_en.pdf"},
    {"id":"64644","name":"Release notes - production release version 1.7.2427-2 -28 August 2024 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-28T09:26:08Z","last_updated_date":"2024-08-28T09:26:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172427-2-28-august-2024-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"64646","name":"General conditions of purchase orders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-08-28T14:02:04Z","last_updated_date":"2024-08-28T14:02:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/general-conditions-purchase-orders_en.pdf"},
    {"id":"64696","name":"Future-proofing Qualification of Novel Methodologies (QoNM) - Action plan","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-04T14:43:28Z","last_updated_date":"2024-09-04T14:43:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/future-proofing-qualification-novel-methodologies-qonm-action-plan_en.pdf"},
    {"id":"64697","name":"Guiding principles on the use of large language models in regulatory science and for medicines regulatory activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-05T14:52:30Z","last_updated_date":"2024-09-05T14:52:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/guiding-principles-use-large-language-models-regulatory-science-medicines-regulatory-activities_en.pdf"},
    {"id":"64698","name":"Factsheet - four principles for safe and responsible use of large language models","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-05T14:52:00Z","last_updated_date":"2024-09-05T14:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/factsheet-four-principles-safe-responsible-use-large-language-models_en.pdf"},
    {"id":"64738","name":"PRAC statistics: September 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T12:40:40Z","last_updated_date":"2024-09-06T12:40:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/prac-statistics-september-2024_en.pdf"},
    {"id":"64766","name":"Questions and answers - Info session on web-based electronic Application Form (eAF) add package","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T16:27:20Z","last_updated_date":"2024-09-09T16:27:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-info-session-web-based-electronic-application-form-eaf-add-package_en.pdf"},
    {"id":"64812","name":"European Medicines Agency’s data protection notice for the Referentials Management System (RMS) activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-12T13:53:00Z","last_updated_date":"2024-09-12T13:53:00Z","reference_number":"EMA/315609/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-referentials-management-system-rms-activities_en.pdf"},
    {"id":"64873","name":"Guidance for competent authorities on how to highlight VNRAs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T16:30:00Z","last_updated_date":"2024-09-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-competent-authorities-how-highlight-vnras_en.pdf"},
    {"id":"64875","name":"Joint Committee Opinion 27/2020 on criteria and restrictions for senior staff applying for occupational activities within two years after leaving the Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T16:45:26Z","last_updated_date":"2024-09-16T16:45:26Z","reference_number":"EMA/504095/2020","document_url":"https://www.ema.europa.eu/en/documents/other/joint-committee-opinion-27-2020-criteria-restrictions-senior-staff-applying-occupational-activities-within-two-years-after-leaving-agency_en.pdf"},
    {"id":"64876","name":"Decision of the Executive Director on transparency measures for senior staff leaving the Agency","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T16:47:05Z","last_updated_date":"2024-09-16T16:47:05Z","reference_number":"EMA/394879/2024","document_url":"https://www.ema.europa.eu/en/documents/other/decision-executive-director-transparency-measures-senior-staff-leaving-agency_en.pdf"},
    {"id":"64877","name":"Questions and answers on labelling requirements for centrally authorised metered dose inhalers containing fluorinated greenhouse gases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T10:51:00Z","last_updated_date":"2024-09-19T10:51:00Z","reference_number":"EMA/333735/2024","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-labelling-requirements-centrally-authorised-metered-dose-inhalers-containing-fluorinated-greenhouse-gases_en.pdf"},
    {"id":"64878","name":"QRD statements for metered dose inhalers containing fluorinated greenhouse gases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T10:52:00Z","last_updated_date":"2025-03-19T11:00:00Z","reference_number":"EMA/430888/2024 Corr.5","document_url":"https://www.ema.europa.eu/en/documents/other/qrd-statements-metered-dose-inhalers-containing-fluorinated-greenhouse-gases_en.pdf"},
    {"id":"64944","name":"Clinical trial information system (CTIS) public portal summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T17:32:07Z","last_updated_date":"2024-09-19T17:32:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-public-portal-summary_en.pdf"},
    {"id":"64945","name":"Clinical trial information system (CTIS) public portal full trial information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T17:35:17Z","last_updated_date":"2025-01-29T14:57:00Z","reference_number":"EMA/441147/202424","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-public-portal-full-trial-information_en.pdf"},
    {"id":"64946","name":"Clinical trial information system (CTIS) public portal trial documents","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T17:38:57Z","last_updated_date":"2025-01-29T15:06:18Z","reference_number":"EMA/441150/2024","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-public-portal-trial-documents_en.pdf"},
    {"id":"64947","name":"Clinical trial information system (CTIS) public portal trial results","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T17:42:50Z","last_updated_date":"2024-12-10T14:56:00Z","reference_number":"EMA/441151/2024","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-public-portal-trial-results_en.pdf"},
    {"id":"64948","name":"Clinical trial information system (CTIS) public portal locations and contact points","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T17:44:06Z","last_updated_date":"2024-09-19T17:44:06Z","reference_number":"EMA/441148/2024","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-trial-information-system-ctis-public-portal-locations-contact-points_en.pdf"},
    {"id":"64953","name":"Questions and answers - Quarterly System Demo - Q3 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T09:32:05Z","last_updated_date":"2024-10-16T10:46:00Z","reference_number":"EMA/438319/2024 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-quarterly-system-demo-q3-2024_en.pdf"},
    {"id":"65172","name":"Mandate of joint HMA-EMA Network Data Steering Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T15:02:55Z","last_updated_date":"2024-10-04T15:02:55Z","reference_number":"EMA/419729/2024","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-joint-hma-ema-network-data-steering-group_en.pdf"},
    {"id":"65200","name":"Outcome of written procedures finalised during the period from 04 June 2024 to 25 September 2024","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2024-10-07T09:43:41Z","last_updated_date":"2024-10-07T09:43:41Z","reference_number":"EMA/MB/292679/2024","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-04-june-2024-25-september-2024_en.pdf"},
    {"id":"65225","name":"Question & Answers: EMA Account Management, what’s new?","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T16:38:15Z","last_updated_date":"2024-10-07T16:38:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/question-answers-ema-account-management-whats-new_en.pdf"},
    {"id":"65233","name":"Release notes - production release version 1.7.2434 - 8 October 2024 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-08T11:33:18Z","last_updated_date":"2024-10-08T11:33:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172434-8-october-2024-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"65242","name":"Seizing opportunities in a changing medicines landscape: The European medicines agencies network strategy 2028 (draft)","type":"other","status":"Draft: consultation closed","consultation_date":"2024-10-09 - 2024-11-30","first_published_date":"2024-10-09T13:56:00Z","last_updated_date":"2024-10-09T13:56:00Z","reference_number":"EMA/376542/2024","document_url":"https://www.ema.europa.eu/en/documents/other/seizing-opportunities-changing-medicines-landscape-european-medicines-agencies-network-strategy-2028-draft_en.pdf"},
    {"id":"65243","name":"Towards the European medicines agencies network strategy 2028: Reflection paper","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-09T13:57:00Z","last_updated_date":"2024-10-09T13:57:00Z","reference_number":"EMA/297150/2024","document_url":"https://www.ema.europa.eu/en/documents/other/towards-european-medicines-agencies-network-strategy-2028-reflection-paper_en.pdf"},
    {"id":"65246","name":"EMA policy on handling of competing interests of scientific committee members and experts: Draft for public consultation","type":"other","status":"Draft: consultation closed","consultation_date":"2024-10-10 - 2024-11-10","first_published_date":"2024-10-10T13:56:00Z","last_updated_date":"2024-10-10T13:56:00Z","reference_number":"EMA/54457/2024","document_url":"https://www.ema.europa.eu/en/documents/other/ema-policy-handling-competing-interests-scientific-committee-members-experts-draft-public-consultation_en.pdf"},
    {"id":"65259","name":"European Union Member State Public Holidays Recorded in CTIS (year: 2025)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-09T16:03:03Z","last_updated_date":"2024-10-09T16:03:03Z","reference_number":"EMA/416959/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-member-state-public-holidays-recorded-ctis-year-2025_en.pdf"},
    {"id":"65288","name":"Product Lifecycle Management Portal – Human Variations eAF - Guide to navigation - October 2024 update","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-14T14:23:00Z","last_updated_date":"2024-10-14T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/product-lifecycle-management-portal-human-variations-eaf-guide-navigation-october-2024-update_en.pdf"},
    {"id":"65328","name":"Anti-HEV IgG - Notified body 0459 - 19/10/2023 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/anti-hev-igg-notified-body-0459-19-10-2023-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"65329","name":"Anti-HEV IgM - Notified body 0459 - 19/10/2023 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/anti-hev-igm-notified-body-0459-19-10-2023-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"65330","name":"Plasmodium DNA and RNA - Notified body 2797 - 18/02/2024 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/plasmodium-dna-rna-notified-body-2797-18-02-2024-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"65331","name":"Fetal RHD status - Notified body 2962 - 24/4/2024 - View in the context of the performance evaluation consultation procedure (PECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/fetal-rhd-status-notified-body-2962-24-4-2024-view-context-performance-evaluation-consultation-procedure-pecp_en.pdf"},
    {"id":"65332","name":"Advice on indirect antiglobulin tests on request from the Medical Device Coordination Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advice-indirect-antiglobulin-tests-request-medical-device-coordination-group_en.pdf"},
    {"id":"65333","name":"Advice on SARS-CoV-2 neutralising antibodies on request from the Medical Device Coordination Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advice-sars-cov-2-neutralising-antibodies-request-medical-device-coordination-group_en.pdf"},
    {"id":"65334","name":"Advice on mpox virus on request from the Medical Device Coordination Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T16:20:00Z","last_updated_date":"2024-10-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advice-mpox-virus-request-medical-device-coordination-group_en.pdf"},
    {"id":"65349","name":"Overview of comments received on Guideline on safety and efficacy data requirements for applications immunological veterinary medicinal products intended for limited markets but not eligible for authorisation under Article 23 of Regulation (EU) 2019/6 (EM","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T14:45:00Z","last_updated_date":"2024-10-18T14:45:00Z","reference_number":"EMA/CVMP/IWP/53315/2024","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-safety-efficacy-data-requirements-applications-immunological-veterinary-medicinal-products-intended-limited-markets-not-eligible-authorisation-under-article-23_en.pdf"},
    {"id":"65353","name":"Overview of comments received on 'Guideline on efficacy and target animal safety data requirements for applications for non-immunological veterinary medicinal products intended for limited markets but not eligible for authorisation under Article 23 of Reg","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T15:20:00Z","last_updated_date":"2024-10-18T15:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-efficacy-target-animal-safety-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-not-eligible-authorisation_en.pdf"},
    {"id":"65354","name":"Overview of comments received on 'Guideline on quality data requirements for applications for veterinary medicinal products other than biologicals intended for limited markets' (EMA/CVMP/QWP/47285/2022)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T15:40:00Z","last_updated_date":"2024-10-18T15:40:00Z","reference_number":"EMA/CVMP/QWP/50888/2024","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-quality-data-requirements-applications-veterinary-medicinal-products-other-biologicals-intended-limited-markets-ema-cvmp-qwp-47285-2022_en.pdf"},
    {"id":"65355","name":"Overview of comments received on Guideline on quality data requirements for applications for biological veterinary medicinal products intended for limited markets (EMA/CVMP/IWP/228730/2022)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T16:10:00Z","last_updated_date":"2024-10-18T16:10:00Z","reference_number":"EMA/CVMP/IWP/53990/2024","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-quality-data-requirements-applications-biological-veterinary-medicinal-products-intended-limited-markets-ema-cvmp-iwp-228730-2022_en.pdf"},
    {"id":"65432","name":"Release notes - production release version 1.7.2434-12 - 24 October 2024 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T16:00:00Z","last_updated_date":"2024-11-22T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172434-12-24-october-2024-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"65454","name":"Advice on the use of paclitaxel-coated devices in peripheral artery disease and potential association with higher mortality, on request from the Medical Device Coordination Group - 5 August 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T11:44:07Z","last_updated_date":"2024-10-28T11:44:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advice-use-paclitaxel-coated-devices-peripheral-artery-disease-potential-association-higher-mortality-request-medical-device-coordination-group-5-august-2024_en.pdf"},
    {"id":"65585","name":"Highlights – sixth EMA/EuropaBio bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-11T11:54:12Z","last_updated_date":"2024-11-11T11:54:12Z","reference_number":"EMA/456159/2024","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-sixth-ema-europabio-bilateral-meeting_en.pdf"},
    {"id":"65604","name":"ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of age","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-13T10:00:00Z","last_updated_date":"2024-11-13T10:00:00Z","reference_number":"EMA/528419/2024","document_url":"https://www.ema.europa.eu/en/documents/other/etf-statement-use-imvanex-prevention-mpox-children-below-12-years-age_en.pdf"},
    {"id":"65615","name":"Question & answer on the need for bioequivalence studies with acid reducing agents (ARAs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-13T16:02:59Z","last_updated_date":"2024-11-13T16:02:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/question-answer-need-bioequivalence-studies-acid-reducing-agents-aras_en.pdf"},
    {"id":"65652","name":"Draft European Medicines Agencies Network Data Strategy - Increasing the value of data for the benefit of public and animal health","type":"other","status":"Draft: consultation closed","consultation_date":"2024-11-15 - 2024-12-31","first_published_date":"2024-11-15T13:06:00Z","last_updated_date":"2024-11-15T13:06:00Z","reference_number":"EMA/458778/2024","document_url":"https://www.ema.europa.eu/en/documents/other/draft-european-medicines-agencies-network-data-strategy-increasing-value-data-benefit-public-animal-health_en.pdf"},
    {"id":"65662","name":"Social Media Data for Real World Evidence in Regulatory Decision Making","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T10:12:07Z","last_updated_date":"2024-11-20T13:40:00Z","reference_number":"EMA/348808/2024","document_url":"https://www.ema.europa.eu/en/documents/other/social-media-data-real-world-evidence-regulatory-decision-making_en.pdf"},
    {"id":"65673","name":"Draft concept paper on the European Platform for Regulatory Science Research","type":"other","status":"Draft: consultation closed","consultation_date":"2024-11-14 - 2024-12-18","first_published_date":"2024-11-15T16:49:00Z","last_updated_date":"2024-11-20T15:10:00Z","reference_number":"EMA/530334/2024","document_url":"https://www.ema.europa.eu/en/documents/other/draft-concept-paper-european-platform-regulatory-science-research_en.pdf"},
    {"id":"65674","name":"Draft Regulatory Science Research Needs - 2024 update","type":"other","status":"Draft: consultation closed","consultation_date":"2024-11-13 - 2024-12-18","first_published_date":"2024-11-15T16:46:09Z","last_updated_date":"2024-11-20T15:10:00Z","reference_number":"EMA/510633/2024","document_url":"https://www.ema.europa.eu/en/documents/other/draft-regulatory-science-research-needs-2024-update_en.pdf"},
    {"id":"65675","name":"Overview of comments received on Guideline on the evaluation of the benefit-risk balance of veterinary medicinal products (EMA/CVMP/307496/2024 – Rev.1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T13:45:17Z","last_updated_date":"2024-11-15T13:45:17Z","reference_number":"EMA/CVMP/307496/2024","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-evaluation-benefit-risk-balance-veterinary-medicinal-products-ema-cvmp-307496-2024-rev1_en.pdf"},
    {"id":"65676","name":"Declaration of interests: Francisco Penaranda Fernandez","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T14:38:50Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-francisco-penaranda-fernandez_en.pdf"},
    {"id":"65682","name":"Antimicrobial resistance: A call to action against the silent pandemic","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-18T13:14:00Z","last_updated_date":"2024-11-18T13:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/antimicrobial-resistance-call-action-against-silent-pandemic_en.pdf"},
    {"id":"65699","name":"Q&A from CTIS Bitesize Talk on Alternate IMPD-Q and new guidance AxMP (24/04/2024)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-18T15:21:41Z","last_updated_date":"2024-11-18T15:21:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qa-ctis-bitesize-talk-alternate-impd-q-new-guidance-axmp-24-04-2024_en.pdf"},
    {"id":"65707","name":"European Shortages Monitoring Platform (ESMP) User guide for marketing authorisation holders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-19T17:49:00Z","last_updated_date":"2026-04-28T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-user-guide-marketing-authorisation-holders_en.pdf"},
    {"id":"65821","name":"Business process description for committee management ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:07:00Z","last_updated_date":"2025-04-22T16:07:00Z","reference_number":"EMA/228156/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-committee-management_en.pdf"},
    {"id":"65846","name":"Questions and answers on the information session on the pilot for expert panels' advice for orphan medical devices","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T16:09:50Z","last_updated_date":"2024-11-27T16:09:50Z","reference_number":"EMA/524472/2024","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-information-session-pilot-expert-panels-advice-orphan-medical-devices_en.pdf"},
    {"id":"65858","name":"European Shortages Monitoring Platform (ESMP) release notes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-11-28T00:00:00Z","last_updated_date":"2025-01-29T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-release-notes_en.pdf"},
    {"id":"65880","name":"Draft of Data Quality Framework for EU medicines regulation application to real-world data","type":"other","status":"Draft: consultation closed","consultation_date":"2024-11-29 - 2025-02-28","first_published_date":"2024-11-29T14:47:00Z","last_updated_date":"2024-11-29T14:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/draft-data-quality-framework-eu-medicines-regulation-application-real-world-data_en.pdf"},
    {"id":"65894","name":"How to pay fees and charges levied by EMA: Guidance to marketing authorisation holders and applicants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-04T13:57:00Z","last_updated_date":"2024-12-04T13:57:00Z","reference_number":"EMA/535202/2024","document_url":"https://www.ema.europa.eu/en/documents/other/how-pay-fees-charges-levied-ema-guidance-marketing-authorisation-holders-applicants_en.pdf"},
    {"id":"65942","name":"Draft qualification opinion for artificial intelligence-based measurement of non-alcoholic steatohepatitis  histology in liver biopsies to determine disease activity in NASH/MASH clinical trials","type":"other","status":"Draft: consultation closed","consultation_date":"2024-12-06 - 2025-01-24","first_published_date":"2024-12-06T12:00:00Z","last_updated_date":"2024-12-06T12:00:00Z","reference_number":"EMADOC-1700519818-1761332","document_url":"https://www.ema.europa.eu/en/documents/other/draft-qualification-opinion-artificial-intelligence-based-measurement-non-alcoholic-steatohepatitis-histology-liver-biopsies-determine-disease-activity-nash-mash-clinical-trials_en.pdf"},
    {"id":"65944","name":"User manual: AIM-NASH algorithm for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-06T12:00:00Z","last_updated_date":"2024-12-06T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/user-manual-aim-nash-algorithm-artificial-intelligence-based-measurement-non-alcoholic-steatohepatitis-histology_en.pdf"},
    {"id":"65946","name":"Briefing book: AI-based histologic measurement of NASH (AIM-NASH)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-06T12:00:00Z","last_updated_date":"2024-12-06T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/briefing-book-ai-based-histologic-measurement-nash-aim-nash_en.pdf"},
    {"id":"65947","name":"Written responses to first list of Issues for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology (AIM-NASH) tool","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-06T12:00:00Z","last_updated_date":"2024-12-06T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/written-responses-first-list-issues-artificial-intelligence-based-measurement-non-alcoholic-steatohepatitis-histology-aim-nash-tool_en.pdf"},
    {"id":"65948","name":"Written responses to second list of Issues for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology (AIM-NASH) tool","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-06T12:00:00Z","last_updated_date":"2024-12-06T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/written-responses-second-list-issues-artificial-intelligence-based-measurement-non-alcoholic-steatohepatitis-histology-aim-nash-tool_en.pdf"},
    {"id":"65952","name":"Guidance for industry on implementing shortage prevention plans (SPP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T13:47:00Z","last_updated_date":"2024-12-09T13:47:00Z","reference_number":"EMA/65984/2024","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-industry-implementing-shortage-prevention-plans-spp_en.pdf"},
    {"id":"65953","name":"Guidance for industry on implementing shortage mitigation plans (SMP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T13:49:00Z","last_updated_date":"2024-12-09T13:49:00Z","reference_number":"EMA/183138/2024","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-industry-implementing-shortage-mitigation-plans-smp_en.pdf"},
    {"id":"65956","name":"Data protection notice for the Experts Management Tool and the handling of competing interests","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T10:22:26Z","last_updated_date":"2024-12-05T10:22:26Z","reference_number":"MA/283094/2023 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/data-protection-notice-experts-management-tool-handling-competing-interests_en.pdf"},
    {"id":"66003","name":"Release notes - production release version 1.7.2443 - 5 December 2024 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T17:13:21Z","last_updated_date":"2024-12-05T17:13:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172443-5-december-2024-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"66004","name":"Example - production release version 1.7.2443 December 2024 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T17:20:06Z","last_updated_date":"2024-12-05T17:20:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/example-production-release-version-172443-december-2024-veterinary-medicinal-products-regulation-union-product-database_en.zip"},
    {"id":"66010","name":"Medicine shortage communication (MSC) template","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T13:44:00Z","last_updated_date":"2024-12-09T13:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-template_en.doc"},
    {"id":"66019","name":"Notification in preparation for the New fee regulation and new prepayment system for certificates of medicinal products, with implementation from January 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T14:10:33Z","last_updated_date":"2024-12-09T14:10:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/notification-preparation-new-fee-regulation-new-prepayment-system-certificates-medicinal-products-implementation-january-2025_en.pdf"},
    {"id":"66020","name":"Letter of Support for intermediate Age-Related Macular Degeneration (AMD) biomarker and novel clinical endpoint development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T14:19:18Z","last_updated_date":"2024-12-09T14:19:18Z","reference_number":"EMADOC-1700519818-1790091","document_url":"https://www.ema.europa.eu/en/documents/other/letter-support-intermediate-age-related-macular-degeneration-amd-biomarker-novel-clinical-endpoint-development_en.pdf"},
    {"id":"66033","name":"Records of data processing activity related to user visits on the EMA website","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T16:11:15Z","last_updated_date":"2024-12-09T16:11:15Z","reference_number":"EMA/559567/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-related-user-visits-ema-website_en.pdf"},
    {"id":"66035","name":"ETF statement on the loss of activity of anti-spike protein monoclonal antibodies due to emerging SARS-CoV-2 variants: December 2024 update","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-13T12:27:00Z","last_updated_date":"2024-12-13T12:27:00Z","reference_number":"EMA/571903/2024","document_url":"https://www.ema.europa.eu/en/documents/other/etf-statement-loss-activity-anti-spike-protein-monoclonal-antibodies-due-emerging-sars-cov-2-variants-december-2024-update_en.pdf"},
    {"id":"66071","name":"Union list of critical medicines - version 2.1 (revision 1)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T11:05:00Z","last_updated_date":"2026-01-19T12:48:00Z","reference_number":"EMA/361872/2025","document_url":"https://www.ema.europa.eu/en/documents/other/union-list-critical-medicines-en.xlsx"},
    {"id":"66125","name":"Instructions on how to submit a request for certificates of medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-13T16:27:57Z","last_updated_date":"2025-08-12T14:50:00Z","reference_number":"EMA/553972/2024","document_url":"https://www.ema.europa.eu/en/documents/other/instructions-how-submit-request-certificates-medicinal-products_en.pdf"},
    {"id":"66135","name":"Declaration of interest: Olivier Simoen","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:24:54Z","last_updated_date":"2024-12-16T11:24:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-olivier-simoen_en.pdf"},
    {"id":"66167","name":"Process for the electronic submission of medicinal product information - Chapter 3","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-17T13:00:29Z","last_updated_date":"2026-06-16T11:48:00Z","reference_number":"EMA/795140/2018","document_url":"https://www.ema.europa.eu/en/documents/other/process-electronic-submission-medicinal-product-information-chapter-3_en.pdf"},
    {"id":"66175","name":"Questions and Answers - Quarterly System Demo Q4 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2024-12-17T16:54:04Z","last_updated_date":"2024-12-17T16:54:04Z","reference_number":"EMA/559843/2024","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-quarterly-system-demo-q4-2024_en.pdf"},
    {"id":"66254","name":"Training module EV-M8 - Considerations on the international transfer of personal (health) data in ICSRs -SUSARs originating in the EU ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-07T14:13:20Z","last_updated_date":"2026-02-02T17:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/training-module-ev-m8-considerations-international-transfer-personal-health-data-icsrs-susars-originating-eu_en.pdf"},
    {"id":"66256","name":"Decision of the Management Board amending budget No. 04, amending appropriations in budget 2024","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-01-07T14:26:20Z","last_updated_date":"2025-01-07T14:26:20Z","reference_number":"EMA/MB/540345/2024","document_url":"https://www.ema.europa.eu/en/documents/other/decision-management-board-amending-budget-no-04-amending-appropriations-budget-2024_en.pdf"}    {"id":"66257","name":"European Medicines Agency budget for 2025","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-01-07T14:30:55Z","last_updated_date":"2025-01-07T14:30:55Z","reference_number":"EMA/538371/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-budget-2025_en.pdf"},
    {"id":"66264","name":"Terms of Reference (ToR) for the International Medicines Regulators’ Working Group on 3Rs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-08T08:23:39Z","last_updated_date":"2025-01-08T08:23:39Z","reference_number":"EMA/27380/2024","document_url":"https://www.ema.europa.eu/en/documents/other/terms-reference-tor-international-medicines-regulators-working-group-3rs_en.pdf"},
    {"id":"66270","name":"European Medicines Agency’s data protection notice for the processing of personal data contained in the Agency’s historical records selected for permanent preservation and opening to the public","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-09T10:17:53Z","last_updated_date":"2025-01-09T10:17:53Z","reference_number":"EMA/559852/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-processing-personal-data-contained-agencys-historical-records-selected-permanent-preservation-opening-public_en.pdf"},
    {"id":"66271","name":"Records of data processing activity for of the EMA's historical archives and opening to the public","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-09T10:19:10Z","last_updated_date":"2025-01-09T10:19:10Z","reference_number":"EMA/559854/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-emas-historical-archives-opening-public_en.pdf"},
    {"id":"66273","name":"Meeting highlights - EMA-IPFA and PPTA Global bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-09T13:20:29Z","last_updated_date":"2025-01-09T13:20:29Z","reference_number":"EMA/528442/2024","document_url":"https://www.ema.europa.eu/en/documents/other/meeting-highlights-ema-ipfa-ppta-global-bilateral-meeting_en.pdf"},
    {"id":"66288","name":"Outcome of written procedures finalised during the period from 26 September 04 December 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-10T14:46:42Z","last_updated_date":"2025-01-10T14:46:42Z","reference_number":"EMA/MB/454481/2024","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-26-september-04-december-2024_en.pdf"},
    {"id":"66305","name":"Policy 58: European Medicines Agency policy on the handling of competing interests of Management Board members","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-01-14T14:02:00Z","last_updated_date":"2025-01-14T14:02:00Z","reference_number":"EMA/MB/89817/2024","document_url":"https://www.ema.europa.eu/en/documents/other/policy-58-european-medicines-agency-policy-handling-competing-interests-management-board-members_en.pdf-0"},
    {"id":"66310","name":"Policy 58: European Medicines Agency policy on the handling of competing interests of Management Board members -  As adopted by EMA Management Board on 11-12 December 2024","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-01-14T15:03:18Z","last_updated_date":"2025-01-14T15:03:18Z","reference_number":"EMA/MB/89817/2024","document_url":"https://www.ema.europa.eu/en/documents/other/policy-58-european-medicines-agency-policy-handling-competing-interests-management-board-members-adopted-ema-management-board-11-12-december-2024_en.pdf"},
    {"id":"66311","name":"Policy 44: European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts - As adopted by EMA Management Board on 11-12 December 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-14T15:07:18Z","last_updated_date":"2025-01-14T15:07:18Z","reference_number":"EMA/54457/2024","document_url":"https://www.ema.europa.eu/en/documents/other/policy-44-european-medicines-agency-policy-handling-competing-interests-scientific-committees-members-experts-adopted-ema-management-board-11-12-december-2024_en.pdf"},
    {"id":"66313","name":"Highlights - Third bilateral meeting between European Medicines Agency and Vaccines Europe","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-15T11:20:00Z","last_updated_date":"2025-01-15T11:20:00Z","reference_number":"EMA/539768/2024","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-third-bilateral-meeting-between-european-medicines-agency-vaccines-europe_en.pdf"},
    {"id":"66341","name":"Policy 83: Visiting and collaborating experts involved in the activities of the European Medicines Agency","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-01-17T10:27:28Z","last_updated_date":"2025-01-23T16:20:00Z","reference_number":"EMA/55453/2022","document_url":"https://www.ema.europa.eu/en/documents/other/policy-83-visiting-collaborating-experts-involved-activities-european-medicines-agency_en.pdf"},
    {"id":"66375","name":"Policy 15: Policy on publications by EMA staff and EMA scientific committee members on EMA’s work","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-01-20T14:14:44Z","last_updated_date":"2025-01-20T14:14:44Z","reference_number":"EMA/33844/2022","document_url":"https://www.ema.europa.eu/en/documents/other/policy-15-policy-publications-ema-staff-ema-scientific-committee-members-emas-work_en.pdf"},
    {"id":"66423","name":"European Medicines Agency’s data protection notice for meeting registration forms via EUSurvey","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-23T08:52:45Z","last_updated_date":"2025-01-23T08:52:45Z","reference_number":"EMA/27016/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-meeting-registration-forms-eusurvey_en.pdf"},
    {"id":"66432","name":"European Medicines Agency’s data protection notice for conducting surveys via EUSurvey","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-23T12:43:58Z","last_updated_date":"2025-01-23T12:43:58Z","reference_number":"EMA/30411/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-conducting-surveys-eusurvey_en.pdf"},
    {"id":"66447","name":"Product Management Service (PMS) roadmap","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-24T13:27:43Z","last_updated_date":"2025-12-08T11:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/product-management-service-pms-roadmap_en.pdf"},
    {"id":"66457","name":"Consultation on an ancillary medicinal substance incorporated in a medical device: VitaVitro Vitrification Kit, VitaVitro Warming Kit","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-24T16:28:27Z","last_updated_date":"2025-01-24T16:28:27Z","reference_number":"EMA/22987/2025","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-vitavitro-vitrification-kit-vitavitro-warming-kit_en.pdf"},
    {"id":"66502","name":"European Shortages Monitoring Platform (ESMP) User guide for national competent authorities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-29T11:42:00Z","last_updated_date":"2026-04-29T13:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-user-guide-national-competent-authorities_en.pdf"},
    {"id":"66533","name":"Advice related to classification of SARS-CoV-2 devices on request from the Medical Device Coordination Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-30T15:52:45Z","last_updated_date":"2025-01-30T15:52:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advice-related-classification-sars-cov-2-devices-request-medical-device-coordination-group_en.pdf"},
    {"id":"66537","name":"Release notes - production release version 1.7.2443-15 - 30 January 2025 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-30T16:42:20Z","last_updated_date":"2025-01-30T16:42:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172443-15-30-january-2025-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"66555","name":"Questions and answers: Union Product Database (UPD) - Volume of Sales webinar for UPD industry users held on 5 December 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T13:57:32Z","last_updated_date":"2025-01-31T13:57:32Z","reference_number":"EMA/40218/2025","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-union-product-database-upd-volume-sales-webinar-upd-industry-users-held-5-december-2024_en.pdf"},
    {"id":"66559","name":"Q&A document - Questions and answers clinic on post-authorisation procedure management in IRIS - 17 January 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T14:09:02Z","last_updated_date":"2025-02-06T16:23:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qa-document-questions-answers-clinic-post-authorisation-procedure-management-iris-17-january-2025_en.xlsx"},
    {"id":"66574","name":"Q&A - Product Management Service (PMS) webinar on Product User Interface (PUI) edit functionalities for industry users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-03T14:54:56Z","last_updated_date":"2025-02-03T14:54:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qa-product-management-service-pms-webinar-product-user-interface-pui-edit-functionalities-industry-users_en.xlsx"},
    {"id":"66581","name":"3-year work plan for the Biologics Working Party (BWP) 2026-2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T11:36:16Z","last_updated_date":"2025-12-09T11:36:16Z","reference_number":"EMADOC-628903358-21653","document_url":"https://www.ema.europa.eu/en/documents/other/3-year-work-plan-biologics-working-party-bwp-2026-2028_en.pdf"},
    {"id":"66582","name":"3-year rolling work plan for the Biosimilar Medicinal Products Working Party 2026-2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T11:41:41Z","last_updated_date":"2025-12-09T11:41:41Z","reference_number":"EMA/CHMP/BMWP/156161/2025","document_url":"https://www.ema.europa.eu/en/documents/other/3-year-rolling-work-plan-biosimilar-medicinal-products-working-party-2026-2028_en.pdf"},
    {"id":"66583","name":"Consolidated 3-year rolling work plan for the CNS Working Party 2025-2027","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-04T11:49:17Z","last_updated_date":"2025-02-04T11:49:17Z","reference_number":"EMA/CHMP/323166/2024","document_url":"https://www.ema.europa.eu/en/documents/other/consolidated-3-year-rolling-work-plan-cns-working-party-2025-2027_en.pdf"},
    {"id":"66585","name":"Consolidated 3-year rolling work plan for the Cardiovascular Working Party (CVSWP) 2025-2027","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-04T11:52:46Z","last_updated_date":"2025-02-04T11:52:46Z","reference_number":"EMA/248684/2024","document_url":"https://www.ema.europa.eu/en/documents/other/consolidated-3-year-rolling-work-plan-cardiovascular-working-party-cvswp-2025-2027_en.pdf"},
    {"id":"66586","name":"Consolidated 3-year rolling work plan for the Haematology Working Party (HAEMWP) 2025-2027","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-02-04T11:59:15Z","last_updated_date":"2025-02-04T11:59:15Z","reference_number":"EMA/CHMP/BPWP/320406/2024","document_url":"https://www.ema.europa.eu/en/documents/other/consolidated-3-year-rolling-work-plan-haematology-working-party-haemwp-2025-2027_en.pdf"},
    {"id":"66587","name":"Consolidated 3-year rolling work plan for the Non-clinical domain 2026-2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T12:06:06Z","last_updated_date":"2026-01-21T16:15:00Z","reference_number":"EMA/372540/2025","document_url":"https://www.ema.europa.eu/en/documents/other/consolidated-3-year-rolling-work-plan-non-clinical-domain-2026-2028_en.pdf"},
    {"id":"66588","name":"3-year work plan for the joint CHMP/CVMP Quality Working Party 2026-2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T12:13:30Z","last_updated_date":"2025-12-09T12:13:30Z","reference_number":"EMA/160693/2025","document_url":"https://www.ema.europa.eu/en/documents/other/3-year-work-plan-joint-chmp-cvmp-quality-working-party-2026-2028_en.pdf"},
    {"id":"66591","name":"3-year rolling work plan for the Rheumatology and Immunology Working Party (RIWP) 2025-2027","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-02-04T13:07:13Z","last_updated_date":"2025-02-04T13:07:13Z","reference_number":"EMA/595391/2024","document_url":"https://www.ema.europa.eu/en/documents/other/3-year-rolling-work-plan-rheumatology-immunology-working-party-riwp-2025-2027_en.pdf"},
    {"id":"66592","name":"Consolidated 3-year rolling work plan for the Vaccine Working Party (VWP) 2025-2027","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-02-04T13:11:11Z","last_updated_date":"2025-02-04T13:11:11Z","reference_number":"EMA/CHMP/VWP/14129/2025","document_url":"https://www.ema.europa.eu/en/documents/other/consolidated-3-year-rolling-work-plan-vaccine-working-party-vwp-2025-2027_en.pdf"},
    {"id":"66593","name":"Consolidated 3-year rolling work plan for the Methodology Working Party 2026-2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T13:16:25Z","last_updated_date":"2026-01-21T16:15:00Z","reference_number":"EMA/370294/2025","document_url":"https://www.ema.europa.eu/en/documents/other/consolidated-3-year-rolling-work-plan-methodology-working-party-2026-2028_en.pdf"},
    {"id":"66610","name":"EMA human resources strategy: Priorities 2023-2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-06T18:05:00Z","last_updated_date":"2025-02-06T18:05:00Z","reference_number":"EMA/405736/2023","document_url":"https://www.ema.europa.eu/en/documents/other/ema-human-resources-strategy-priorities-2023-2025_en.pdf"},
    {"id":"66641","name":"Guide to manufacturers on the procedure for requesting advice from expert panels on clinical investigations and / or clinical development strategies for high-risk medical devices","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T12:01:06Z","last_updated_date":"2025-02-10T12:01:06Z","reference_number":"EMA/23357/2025","document_url":"https://www.ema.europa.eu/en/documents/other/guide-manufacturers-procedure-requesting-advice-expert-panels-clinical-investigations-or-clinical-development-strategies-high-risk-medical-devices_en.pdf"},
    {"id":"66642","name":"Request for advice on the clinical development strategy and / or clinical investigations according to Article 61(2) of Regulation (EU) 2017/745 on <device name> from the medical device expert panels","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T12:03:09Z","last_updated_date":"2025-02-10T12:03:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/request-advice-clinical-development-strategy-or-clinical-investigations-according-article-612-regulation-eu-2017-745-medical-device-expert-panels_en.pdf"},
    {"id":"66643","name":"Advice to medical device manufacturers - 2025 Timetable","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T12:04:42Z","last_updated_date":"2025-02-10T12:04:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advice-medical-device-manufacturers-2025-timetable_en.pdf"},
    {"id":"66700","name":"EMAS - certificate of registration","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-17T14:00:00Z","last_updated_date":"2025-02-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/emas-certificate-registration_en.pdf","translations":{"nl":"https://www.ema.europa.eu/nl/documents/other/emas-certificate-registration_nl.pdf"}},
    {"id":"66701","name":"Environmental statement 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-17T14:00:00Z","last_updated_date":"2025-02-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/environmental-statement-2023_en.pdf"},
    {"id":"66759","name":"Simultaneous National Scientific Advice (SNSA) - Continuation and further development during 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T16:48:20Z","last_updated_date":"2025-02-19T10:43:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/simultaneous-national-scientific-advice-snsa-continuation-further-development-during-2025_en.pdf"},
    {"id":"66827","name":"Surgical meshes - Notified body 2797 - 10/06/2024 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-17T15:42:09Z","last_updated_date":"2025-02-17T15:42:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/surgical-meshes-notified-body-2797-10-06-2024-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"66831","name":"Hearing the Association of the European Self-Medication Industry (AESGP) during the September 2024 Working Party meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-17T17:44:37Z","last_updated_date":"2025-02-17T17:44:37Z","reference_number":"EMA/HMPC/448628/2024","document_url":"https://www.ema.europa.eu/en/documents/other/hearing-association-european-self-medication-industry-aesgp-during-september-2024-working-party-meeting_en.pdf"},
    {"id":"66839","name":"European Medicines Agency’s data protection notice regarding personal data processing in the Clinical Trials Information System (CTIS)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-02-18T09:44:39Z","last_updated_date":"2025-02-18T09:44:39Z","reference_number":"EMA/587422/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-regarding-personal-data-processing-clinical-trials-information-system-ctis_en.pdf-0"},
    {"id":"67111","name":"Release notes - production release version 1.7.2513 - 4 March 2025 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-05T11:45:26Z","last_updated_date":"2025-03-05T11:45:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172513-4-march-2025-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"67159","name":"European Shortages Monitoring Platform (ESMP) Application Programming Interface (API) specifications","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-10T11:46:27Z","last_updated_date":"2025-03-10T11:46:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-application-programming-interface-api-specifications_en.pdf"},
    {"id":"67160","name":"European Shortages Monitoring Platform (ESMP) open Application Programming Interface (API) specifications for the ESMP API for national competent authorities (NCAs) (JSON) (YAML)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-10T11:51:20Z","last_updated_date":"2025-03-10T11:51:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-open-application-programming-interface-api-specifications-esmp-api-national-competent-authorities-ncas-json-yaml_en.zip"},
    {"id":"67161","name":"European Shortages Monitoring Platform (ESMP) data access policy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-10T11:42:31Z","last_updated_date":"2025-03-10T11:42:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-data-access-policy_en.pdf"},
    {"id":"67162","name":"European Shortages Monitoring Platform (ESMP) data access policy - Annex A: Data elements accessible by ESMP access level","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-10T11:43:30Z","last_updated_date":"2025-03-10T11:43:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-data-access-policy-annex-data-elements-accessible-esmp-access-level_en.xlsx"},
    {"id":"67181","name":"Records of data processing activity for the European shortages monitoring platform (ESMP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T13:10:39Z","last_updated_date":"2025-03-11T13:10:39Z","reference_number":"EMA/88328/2025","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-european-shortages-monitoring-platform-esmp_en.pdf"},
    {"id":"67182","name":"European Medicines Agency’s data protection notice for the European shortages monitoring platform (ESMP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T13:17:19Z","last_updated_date":"2025-03-11T13:17:19Z","reference_number":"EMA/88329/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-european-shortages-monitoring-platform-esmp_en.pdf"},
    {"id":"67216","name":"Release notes - production release version 1.7.2514 - 12 March 2025 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-12T08:16:57Z","last_updated_date":"2025-03-13T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172514-12-march-2025-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"67217","name":"European Medicines Agency's data protection notice on the use of SNDS data for the performance of DARWIN EU® studies on incidence and prevalence of pathologies and use of drugs in the French population","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-12T10:16:38Z","last_updated_date":"2025-03-12T10:16:38Z","reference_number":"EMA/89626/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-use-snds-data-performance-darwin-eur-studies-incidence-prevalence-pathologies-use-drugs-french-population_en.pdf","translations":{"fr":"https://www.ema.europa.eu/fr/documents/other/data-protection-notice-use-snds-data-performance-darwin-eur-studies-incidence-prevalence-pathologies-use-drugs-french-population_fr.pdf"}},
    {"id":"67223","name":"Questions and answers - Regulation (EU) 2024/568: Questions and answers clinic for the Veterinary Industry stakeholders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-12T11:02:18Z","last_updated_date":"2025-03-12T11:02:18Z","reference_number":"EMA/90567/2025","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-regulation-eu-2024-568-questions-answers-clinic-veterinary-industry-stakeholders_en.pdf"},
    {"id":"67224","name":"Questions and answers - Regulation (EU) 2024/568: Questions and answers clinic for the Human Industry stakeholders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-12T11:05:08Z","last_updated_date":"2025-03-12T11:05:08Z","reference_number":"EMA/90568/2025","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-regulation-eu-2024-568-questions-answers-clinic-human-industry-stakeholders_en.pdf"},
    {"id":"67251","name":"Drug-Eluting stent (DES) - Notified Body 2265 - 10/01/2025 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP) ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T14:25:40Z","last_updated_date":"2025-03-13T14:25:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/drug-eluting-stent-des-notified-body-2265-10-01-2025-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"67252","name":"List of clinical evaluation consultation procedure (CECP) opinions issued for medical devices awaiting finalisation of conformity assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T14:33:35Z","last_updated_date":"2026-04-28T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-clinical-evaluation-consultation-procedure-cecp-opinions-issued-medical-devices-awaiting-finalisation-conformity-assessment_en.pdf"},
    {"id":"67256","name":"Call for expression of interest to participate in the EMA multi-stakeholder workshop on reporting and qualification of mechanistic models for regulatory assessment October 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-25T15:17:20Z","last_updated_date":"2025-04-01T15:47:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/call-expression-interest-participate-ema-multi-stakeholder-workshop-reporting-qualification-mechanistic-models-regulatory-assessment-october-2025_en.pdf"},
    {"id":"67290","name":"PhV non-compliance notification contact points at National Competent Authority (NCA) level","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-14T15:44:17Z","last_updated_date":"2026-02-10T15:20:00Z","reference_number":"EMA/92435/2025","document_url":"https://www.ema.europa.eu/en/documents/other/phv-non-compliance-notification-contact-points-national-competent-authority-nca-level_en.xlsx"},
    {"id":"67320","name":"Seizing opportunities in a changing medicines landscape: The European medicines agencies network strategy 2028 (final)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-18T11:59:00Z","last_updated_date":"2025-03-18T11:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/seizing-opportunities-changing-medicines-landscape-european-medicines-agencies-network-strategy-2028-final_en.pdf"},
    {"id":"67321","name":"Analysis and summaries of public consultation results: The European medicines agencies network strategy to 2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-18T11:59:00Z","last_updated_date":"2025-03-18T11:59:00Z","reference_number":"EMA/98153/2025","document_url":"https://www.ema.europa.eu/en/documents/other/analysis-summaries-public-consultation-results-european-medicines-agencies-network-strategy-2028_en.pdf"},
    {"id":"67330","name":"Questions and answers - MAH & Software Developers to explore PMS API Machine-to-Machine Connection","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-18T13:55:05Z","last_updated_date":"2025-03-18T13:55:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-mah-software-developers-explore-pms-api-machine-machine-connection_en.xlsx"},
    {"id":"67332","name":"Qualification opinion for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology in liver biopsies to determine disease activity in NASH/MASH clinical trials","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-03-20T12:00:00Z","last_updated_date":"2025-04-22T15:03:59Z","reference_number":"EMADOC-1700519818-1761332 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-artificial-intelligence-based-measurement-non-alcoholic-steatohepatitis-histology-liver-biopsies-determine-disease-activity-nash-mash-clinical-trials_en.pdf"},
    {"id":"67359","name":"Certificates Processing System: Demo and Q&A session for Industry stakeholders (H+V)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-19T17:16:31Z","last_updated_date":"2025-03-19T17:16:31Z","reference_number":"EMA/100624/2025","document_url":"https://www.ema.europa.eu/en/documents/other/certificates-processing-system-demo-qa-session-industry-stakeholders-hv_en.pdf"},
    {"id":"67361","name":"Instructions on how to apply for a portfolio & technology meeting (PTM)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-20T09:39:47Z","last_updated_date":"2025-06-20T08:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/instructions-how-apply-portfolio-technology-meeting-ptm_en.pdf"},
    {"id":"67377","name":"Release notes - production release version 1.7.2514-3 - 21 March 2025 - Veterinary Medical Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T11:19:02Z","last_updated_date":"2025-03-21T11:19:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172514-3-21-march-2025-veterinary-medical-products-regulation-union-product-database_en.pdf"},
    {"id":"67490","name":"Guidance for rapporteurs and members of drafting groups of documents developed by the GMP/GDP Inspectors Working Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-27T13:16:56Z","last_updated_date":"2026-01-16T15:07:00Z","reference_number":"EMA/INS/GMP/79525/2025","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-rapporteurs-members-drafting-groups-documents-developed-gmp-gdp-inspectors-working-group_en.pdf"},
    {"id":"67492","name":"European Shortages Monitoring Platform (ESMP) open Application Programming Interface (API) specifications for the ESMP API for marketing authorisation holders (MAHs) (JSON) (YAML)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-27T13:33:34Z","last_updated_date":"2025-03-27T13:33:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-open-application-programming-interface-api-specifications-esmp-api-marketing-authorisation-holders-mahs-json-yaml_en.zip"},
    {"id":"67494","name":"European shortages monitoring platform (ESMP) API - Instructions to request access for national competent authorities (NCAs) and marketing authorisation holders (MAHs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-27T13:35:47Z","last_updated_date":"2025-03-27T13:35:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/european-shortages-monitoring-platform-esmp-api-instructions-request-access-national-competent-authorities-ncas-marketing-authorisation-holders-mahs_en.pdf"},
    {"id":"67496","name":"Fields and business rules for the European Shortages Monitoring Platform (ESMP) API datasets","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-27T16:02:10Z","last_updated_date":"2025-03-27T16:02:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/fields-business-rules-european-shortages-monitoring-platform-esmp-api-datasets_en.xlsx"},
    {"id":"67508","name":"Draft Reflection paper on linking to electronic product information (ePI) from EU medicine packages","type":"other","status":"Draft: consultation closed","consultation_date":"2025-03-31 - 2025-06-30","first_published_date":"2025-03-31T16:10:05Z","last_updated_date":"2025-03-31T16:10:05Z","reference_number":"EMA/95076/2025","document_url":"https://www.ema.europa.eu/en/documents/other/draft-reflection-paper-linking-electronic-product-information-epi-eu-medicine-packages_en.pdf"},
    {"id":"67516","name":"Questions and answers - Quarterly System Demo Q1 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T09:37:10Z","last_updated_date":"2025-03-28T09:37:10Z","reference_number":"EMA/103560/2025","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-quarterly-system-demo-q1-2025_en.pdf"},
    {"id":"67517","name":"Policy 85: Identity and Access Management to EMA IT Systems","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-03-28T09:43:19Z","last_updated_date":"2025-03-28T09:43:19Z","reference_number":"EMA/553746/2024","document_url":"https://www.ema.europa.eu/en/documents/other/policy-85-identity-access-management-ema-it-systems_en.pdf"},
    {"id":"67559","name":"Reflection paper on a tailored clinical approach in biosimilar development","type":"other","status":"Draft: consultation closed","consultation_date":"2025-04-01 - 2025-09-30","first_published_date":"2025-04-01T14:57:00Z","last_updated_date":"2025-04-01T14:57:00Z","reference_number":"EMA/CHMP/BMWP/60916/2025","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf"},
    {"id":"67588","name":"Journey towards a roadmap for regulatory guidance on real-world evidence","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-03T14:37:00Z","last_updated_date":"2025-04-03T14:37:00Z","reference_number":"EMA/100019/2025","document_url":"https://www.ema.europa.eu/en/documents/other/journey-towards-roadmap-regulatory-guidance-real-world-evidence_en.pdf"},
    {"id":"67590","name":"Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence for regulatory purposes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-03T14:38:00Z","last_updated_date":"2025-06-17T14:25:00Z","reference_number":"EMA/99865/2025","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-regulatory-purposes_en.pdf"},
    {"id":"67591","name":"Outcome of written procedures finalised during the period from 5 December 2024 to 3 March 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-01T17:52:39Z","last_updated_date":"2025-04-01T17:52:39Z","reference_number":"EMA/MB/587514/2024","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-5-december-2024-3-march-2025_en.pdf"},
    {"id":"67599","name":"Joint HTAb-regulatory perspectives on understanding evidence challenges, managing uncertainties and exploring potential solutions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-02T14:00:00Z","last_updated_date":"2025-04-02T14:00:00Z","reference_number":"EMA/115125/2025","document_url":"https://www.ema.europa.eu/en/documents/other/joint-htab-regulatory-perspectives-understanding-evidence-challenges-managing-uncertainties-exploring-potential-solutions_en.pdf"},
    {"id":"67606","name":"Declaration of interest: Camelia Mihaescu","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-03T09:40:45Z","last_updated_date":"2025-08-01T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-camelia-mihaescu_en.pdf"},
    {"id":"67608","name":"Background to the addendum to the scientific advice under Article 115(5) of Regulation (EU) 2019/6 on veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-03T10:22:48Z","last_updated_date":"2025-04-03T10:22:48Z","reference_number":"EMA/112916/2025","document_url":"https://www.ema.europa.eu/en/documents/other/background-addendum-scientific-advice-under-article-1155-regulation-eu-2019-6-veterinary-medicinal-products_en.pdf"},
    {"id":"67609","name":"Addendum to the scientific advice under Article 115(5) of Regulation (EU) 2019/6 on veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-03T10:24:56Z","last_updated_date":"2025-04-03T10:24:56Z","reference_number":"EMA/CVMP/35961/2025","document_url":"https://www.ema.europa.eu/en/documents/other/addendum-scientific-advice-under-article-1155-regulation-eu-2019-6-veterinary-medicinal-products_en.pdf"},
    {"id":"67642","name":"Project for dosage review and adjustment of selected antibiotic veterinary medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T15:04:50Z","last_updated_date":"2025-04-04T15:04:50Z","reference_number":"EMA/CVMP/99332/2025","document_url":"https://www.ema.europa.eu/en/documents/other/project-dosage-review-adjustment-selected-antibiotic-veterinary-medicines_en.pdf"},
    {"id":"67650","name":"HMA-EMA Network Data Steering Group: membership list","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T16:41:42Z","last_updated_date":"2026-06-26T14:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/hma-ema-network-data-steering-group-membership-list_en.pdf"},
    {"id":"67666","name":"Medicine shortage communication (MSC): Mimpara (cinacalcet)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-07T15:29:07Z","last_updated_date":"2025-04-07T15:29:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-mimpara-cinacalcet_en.pdf"},
    {"id":"67669","name":"CHMP meeting dates 2027 and 2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-07T16:02:25Z","last_updated_date":"2025-04-07T16:02:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/chmp-meeting-dates-2027-2028_en.pdf"},
    {"id":"67676","name":"CAT meetings in 2027 and 2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-08T09:54:25Z","last_updated_date":"2025-04-08T09:54:25Z","reference_number":"EMA/CAT/72042/2025","document_url":"https://www.ema.europa.eu/en/documents/other/cat-meetings-2027-2028_en.pdf"},
    {"id":"67687","name":"Veterinary medicines safety day: Social media infocards","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-08T12:14:01Z","last_updated_date":"2025-04-08T12:14:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-medicines-safety-day-social-media-infocards_en.pdf"},
    {"id":"67690","name":"Veterinary medicines safety day: Adverse event reporting in the EU - presentation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-08T12:16:33Z","last_updated_date":"2025-04-08T12:16:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-medicines-safety-day-adverse-event-reporting-eu-presentation_en.pdf"},
    {"id":"67691","name":"Veterinary medicines safety day: How to report adverse events - simple guide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-08T12:17:40Z","last_updated_date":"2025-04-08T12:17:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-medicines-safety-day-how-report-adverse-events-simple-guide_en.pdf"},
    {"id":"67704","name":"Outcome of public consultation on the Good practice guide for the use of the HMA-EMA Catalogues of real-world data sources and studies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-08T16:27:21Z","last_updated_date":"2025-04-08T16:27:21Z","reference_number":"EMA/124430/2025","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-public-consultation-good-practice-guide-use-hma-ema-catalogues-real-world-data-sources-studies_en.pdf"},
    {"id":"67706","name":"Certificates processing system: 2nd Demo & Q&A session for Industry stakeholders (H+V)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-09T09:55:34Z","last_updated_date":"2025-04-09T09:55:34Z","reference_number":"EMA/125227/2025","document_url":"https://www.ema.europa.eu/en/documents/other/certificates-processing-system-2nd-demo-qa-session-industry-stakeholders-hv_en.pdf"},
    {"id":"67738","name":"PDCO meetings in 2027 and 2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-10T15:46:56Z","last_updated_date":"2025-04-10T15:46:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pdco-meetings-2027-2028_en.pdf"},
    {"id":"67742","name":"HMPC meetings in 2027 and 2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-10T17:25:20Z","last_updated_date":"2025-04-10T17:25:20Z","reference_number":"EMA/HMPC/125139/2025","document_url":"https://www.ema.europa.eu/en/documents/other/hmpc-meetings-2027-2028_en.pdf"},
    {"id":"67744","name":"Rules of procedure of the Emergency Task Force (ETF)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-11T10:52:00Z","last_updated_date":"2025-04-11T10:52:00Z","reference_number":"EMA/36439/2025","document_url":"https://www.ema.europa.eu/en/documents/other/rules-procedure-emergency-task-force-etf_en.pdf"},
    {"id":"67746","name":"Superseded - Composition of the Emergency Task Force (ETF) for preparedness","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-07T16:28:00Z","last_updated_date":"2026-01-05T11:11:11Z","reference_number":"EMA/206184/2025","document_url":"https://www.ema.europa.eu/en/documents/other/superseded-composition-emergency-task-force-etf-preparedness_en.pdf-0"},
    {"id":"67764","name":"Questions and answers - Practical arrangements on the companion diagnostics consultation procedure to the European Medicines Agency by notified bodies - tracked changes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-11T15:48:36Z","last_updated_date":"2026-05-18T16:34:00Z","reference_number":"EMA/619893/2022 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-practical-arrangements-companion-diagnostics-consultation-procedure-european-medicines-agency-notified-bodies-tracked-changes_en.pdf"},
    {"id":"67766","name":"Questions and answers on how should third party audit(s) be reflected in part C of the QP declaration","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-11T15:51:57Z","last_updated_date":"2025-04-11T15:51:57Z","reference_number":"EMA/129980/2025","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-how-should-third-party-audits-be-reflected-part-c-qp-declaration_en.pdf"},
    {"id":"67773","name":"Recommendations of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) to address vulnerabilities in the supply chain of radiopharmaceuticals","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T12:07:00Z","last_updated_date":"2025-04-14T12:07:00Z","reference_number":"EMA/95894/2025","document_url":"https://www.ema.europa.eu/en/documents/other/recommendations-executive-steering-group-shortages-safety-medicinal-products-mssg-address-vulnerabilities-supply-chain-radiopharmaceuticals_en.pdf"},
    {"id":"67791","name":"Key information section in package leaflet of centrally authorised medicinal products: Public consultation","type":"other","status":"Draft: consultation closed","consultation_date":"2025-04-14 - 2025-05-31","first_published_date":"2025-04-14T15:37:00Z","last_updated_date":"2025-04-14T15:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/key-information-section-package-leaflet-centrally-authorised-medicinal-products-public-consultation_en.pdf"},
    {"id":"67850","name":"Questions and answers - European Shortages Monitoring Platform (ESMP) workshop on application programming interface (API) for marketing authorisation holders (MAHs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-15T13:51:15Z","last_updated_date":"2025-04-15T13:51:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-european-shortages-monitoring-platform-esmp-workshop-application-programming-interface-api-marketing-authorisation-holders-mahs_en.pdf"},
    {"id":"67858","name":"Pool of patient and consumer experts: list for 2024-2029","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-15T16:00:00Z","last_updated_date":"2025-10-14T15:00:01Z","reference_number":"EMA/112409/2025","document_url":"https://www.ema.europa.eu/en/documents/other/pool-patient-consumer-experts-list-2024-2029_en.pdf"},
    {"id":"67860","name":"Pool of healthcare professional experts: list for 2024-2029","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-15T16:02:00Z","last_updated_date":"2025-10-14T15:00:00Z","reference_number":"EMA/112303/2025","document_url":"https://www.ema.europa.eu/en/documents/other/pool-healthcare-professional-experts-list-2024-2029_en.pdf"}    {"id":"67900","name":"Business process description for expert management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:07:54Z","last_updated_date":"2025-04-30T11:35:00Z","reference_number":"EMA/182440/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-expert-management_en.pdf"},
    {"id":"67901","name":"Business process description for regulatory and scientific guidelines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:08:53Z","last_updated_date":"2025-04-22T16:08:53Z","reference_number":"EMA/222507/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-regulatory-scientific-guidelines_en.pdf"},
    {"id":"67902","name":"Business process description for marketing authorisation and other related processes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:10:08Z","last_updated_date":"2025-04-22T16:10:08Z","reference_number":"EMA/272204/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-marketing-authorisation-other-related-processes_en.pdf"},
    {"id":"67903","name":"Business process description for PSUSA and other related post-authorisation processes ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:11:01Z","last_updated_date":"2025-04-22T16:11:01Z","reference_number":"EMA/336410/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-psusa-other-related-post-authorisation-processes_en.pdf"},
    {"id":"67904","name":"Business process description for scientific meeting management ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:11:52Z","last_updated_date":"2025-04-30T11:40:00Z","reference_number":"EMA/156497/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-scientific-meeting-management_en.pdf"},
    {"id":"67905","name":"Business process description for orphan status management ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:12:37Z","last_updated_date":"2025-04-22T16:12:37Z","reference_number":"EMA/367793/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-orphan-status-management_en.pdf"},
    {"id":"67906","name":"Business process description for paediatric medicines development ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:13:30Z","last_updated_date":"2025-04-22T16:13:30Z","reference_number":"EMA/233986/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-paediatric-medicines-development_en.pdf"},
    {"id":"67907","name":"Business process description for pharmacovigilance ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:14:15Z","last_updated_date":"2025-10-29T09:45:00Z","reference_number":"EMA/182390/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-pharmacovigilance_en.pdf"},
    {"id":"67908","name":"Business process description for medical devices ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:15:06Z","last_updated_date":"2025-04-22T16:15:06Z","reference_number":"EMA/182497/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-medical-devices_en.pdf"},
    {"id":"67909","name":"Business process description for parallel distribution ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:15:53Z","last_updated_date":"2025-04-22T16:15:53Z","reference_number":"EMA/184143/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-parallel-distribution_en.pdf"},
    {"id":"67910","name":"Business process description for certificates of medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:16:50Z","last_updated_date":"2025-04-22T16:16:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-certificates-medicinal-products_en.pdf"},
    {"id":"67911","name":"Business process description for quality defect and non-compliance management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:17:40Z","last_updated_date":"2025-04-22T16:17:40Z","reference_number":"EMA/222433/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-quality-defect-non-compliance-management_en.pdf"},
    {"id":"67912","name":"Business process description for referral procedures ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:18:27Z","last_updated_date":"2025-04-22T16:18:27Z","reference_number":"EMA/289031/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-referral-procedures_en.pdf"},
    {"id":"67913","name":"Business process description for sampling and testing of CAPs ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:19:18Z","last_updated_date":"2025-04-22T16:19:18Z","reference_number":"EMA/268846/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-sampling-testing-caps_en.pdf"},
    {"id":"67914","name":"Business process description for scientific advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:20:13Z","last_updated_date":"2025-04-22T16:20:13Z","reference_number":"EMA/367662/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-scientific-advice_en.pdf"},
    {"id":"67915","name":"Business process description for translations ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:21:07Z","last_updated_date":"2025-04-22T16:21:07Z","reference_number":"EMA/224726/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-translations_en.pdf"},
    {"id":"67916","name":"Business process description for inspection coordination","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:21:57Z","last_updated_date":"2025-04-22T16:21:57Z","reference_number":"EMA/68213/2024","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-inspection-coordination_en.pdf"},
    {"id":"67918","name":"Business process description for variations and other related post-authorisation processes ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-22T16:22:44Z","last_updated_date":"2025-04-22T16:22:44Z","reference_number":"EMA/185012/2023","document_url":"https://www.ema.europa.eu/en/documents/other/business-process-description-variations-other-related-post-authorisation-processes_en.pdf"},
    {"id":"67951","name":"FertiPro N.V. HSA-containing ART media - Procedural steps and scientific information after initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-24T12:30:05Z","last_updated_date":"2025-04-24T12:30:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/fertipro-nv-hsa-containing-art-media-procedural-steps-scientific-information-after-initial-consultation_en.pdf"},
    {"id":"67970","name":"Committee for Orphan Medicinal Products (COMP) meetings 2025, 2026, 2027 and 2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-25T10:44:07Z","last_updated_date":"2025-04-25T10:44:07Z","reference_number":"EMA/COMP/125495/2025","document_url":"https://www.ema.europa.eu/en/documents/other/committee-orphan-medicinal-products-comp-meetings-2025-2026-2027-2028_en.pdf"},
    {"id":"68007","name":"Overview of comments received on guideline on clinical investigation of medicinal products in the treatment of epileptic disorders (CHMP/EWP/566/98 Rev.3)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-28T13:32:39Z","last_updated_date":"2025-04-28T13:32:39Z","reference_number":"EMA/117925/2025","document_url":"https://www.ema.europa.eu/en/documents/other/overview-comments-received-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-chmp-ewp-566-98-rev3_en.pdf"},
    {"id":"68019","name":"CTIS Simplification Task Force: topics for analysis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-29T16:04:59Z","last_updated_date":"2025-12-12T16:40:46Z","reference_number":"EMA/121136/2025","document_url":"https://www.ema.europa.eu/en/documents/other/ctis-simplification-task-force-topics-analysis_en.pdf"},
    {"id":"68031","name":"CVMP meeting dates 2027 and 2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-04-29T16:38:00Z","last_updated_date":"2025-04-29T16:38:00Z","reference_number":"EMA/139949/2025","document_url":"https://www.ema.europa.eu/en/documents/other/cvmp-meeting-dates-2027-2028_en.pdf"},
    {"id":"68052","name":"Records of data processing activity relating to EU NTC learning management system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-02T11:19:08Z","last_updated_date":"2025-09-01T15:27:35Z","reference_number":"EMA/184134/2025","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-relating-eu-ntc-learning-management-system_en.pdf"},
    {"id":"68053","name":"European Medicines Agency’s data protection notice for the EU NTC learning management system","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-02T11:40:00Z","last_updated_date":"2025-09-01T15:26:17Z","reference_number":"EMA/184133/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-eu-ntc-learning-management-system_en.pdf"},
    {"id":"68067","name":"EMA Gender equality plan 2025 - 2030","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T17:42:00Z","last_updated_date":"2025-05-08T17:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ema-gender-equality-plan-2025-2030_en.pdf"},
    {"id":"68070","name":"European Medicines Agency’s data protection notice for Product Management System (PMS) activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-02T15:52:52Z","last_updated_date":"2025-05-02T15:52:52Z","reference_number":"EMA/109929/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-product-management-system-pms-activities_en.pdf"},
    {"id":"68071","name":"European Medicines Agency’s data protection notice for Extended EudraVigilance Medicinal Production Dictionary (XEVMPD) processing activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-02T15:56:12Z","last_updated_date":"2025-05-02T15:56:12Z","reference_number":"EMA/109932/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-extended-eudravigilance-medicinal-production-dictionary-xevmpd-processing-activities_en.pdf"},
    {"id":"68076","name":"PRAC-ETF considerations on the use of Ixchiq live  attenuated virus vaccine against chikungunya","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-02T18:14:45Z","last_updated_date":"2025-05-02T18:14:45Z","reference_number":"EMA/151849/2025","document_url":"https://www.ema.europa.eu/en/documents/other/prac-etf-considerations-use-ixchiq-live-attenuated-virus-vaccine-against-chikungunya_en.pdf"},
    {"id":"68086","name":"European Medicines Agency policy on access to EudraVigilance data for medicinal products for human use - Revision 5","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-05T14:17:19Z","last_updated_date":"2025-05-05T14:17:19Z","reference_number":"EMA/759287/2009 Revision 5","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-policy-access-eudravigilance-data-medicinal-products-human-use_en.pdf"},
    {"id":"68099","name":"Network Data Steering Group workplan 2025-2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-07T14:44:00Z","last_updated_date":"2025-07-22T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/network-data-steering-group-workplan-2025-2028_en.pdf"},
    {"id":"68163","name":"Certificates Processing System: third demo and Q&A session for industry stakeholders (H+V)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T11:13:00Z","last_updated_date":"2025-05-08T11:13:00Z","reference_number":"EMA/156481/2025","document_url":"https://www.ema.europa.eu/en/documents/other/certificates-processing-system-third-demo-qa-session-industry-stakeholders-hv_en.pdf"},
    {"id":"68170","name":"PRAC statistics: May 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T14:15:44Z","last_updated_date":"2025-05-08T14:15:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/prac-statistics-may-2025_en.pdf"},
    {"id":"68172","name":"Draft qualification opinion for Simcyp Simulator","type":"other","status":"Draft: consultation closed","consultation_date":"2025-05-08 - 2025-06-19","first_published_date":"2025-05-08T16:43:41Z","last_updated_date":"2025-05-08T16:43:41Z","reference_number":"EMADOC-1700519818-2006369","document_url":"https://www.ema.europa.eu/en/documents/other/draft-qualification-opinion-simcyp-simulator_en.pdf"},
    {"id":"68173","name":"Annex 1 - Bayesian Analysis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:02:46Z","last_updated_date":"2025-05-08T15:02:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-1-bayesian-analysis_en.pdf"},
    {"id":"68174","name":"Annex 2 - Description of Systems models and related parameters for the full and minimal PBPK models","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:05:09Z","last_updated_date":"2025-05-08T15:05:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-2-description-systems-models-related-parameters-full-minimal-pbpk-models_en.pdf"},
    {"id":"68175","name":"Annex 3 - Simcyp Compound Summaries - Cimetidine","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:06:15Z","last_updated_date":"2025-05-08T15:06:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-3-simcyp-compound-summaries-cimetidine_en.pdf"},
    {"id":"68176","name":"Annex 3 - Simcyp Compound Summaries – Fluvoxamine","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:07:21Z","last_updated_date":"2025-05-08T15:07:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-3-simcyp-compound-summaries-fluvoxamine_en.pdf"},
    {"id":"68177","name":"Annex 3 - Simcyp Compound Summaries - Midazolam","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:07:53Z","last_updated_date":"2025-05-08T15:07:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-3-simcyp-compound-summaries-midazolam_en.pdf"},
    {"id":"68178","name":"Annex 4 - Evolution of DDI qualification matrix and substrates inhibitors","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:09:46Z","last_updated_date":"2025-05-08T15:09:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-4-evolution-ddi-qualification-matrix-substrates-inhibitors_en.pdf"},
    {"id":"68179","name":"Annex 5 - DDI Qualification Matrix","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:10:39Z","last_updated_date":"2025-05-08T15:10:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-5-ddi-qualification-matrix_en.pdf"},
    {"id":"68180","name":"Annex 6 - Substrate-Inhibitor Matrix for CYP competitive and mechanism-based inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP3A4/5","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:12:42Z","last_updated_date":"2025-05-08T15:12:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-substrate-inhibitor-matrix-cyp-competitive-mechanism-based-inhibition-cyp1a2-cyp2c8-cyp2c9-cyp2c19-cyp3a4-5_en.pdf"},
    {"id":"68181","name":"Annex 6 - Briefing document - Qualification of the effects of invetsigational drugs as victims or perpetrators of CYP=mediated drug interactions involving inhibition in the Simcyp Simulator","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:13:35Z","last_updated_date":"2025-05-08T15:13:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-briefing-document-qualification-effects-invetsigational-drugs-victims-or-perpetrators-cypmediated-drug-interactions-involving-inhibition-simcyp-simulator_en.pdf"},
    {"id":"68182","name":"Annex 6 - SAWP discussion meeting 15 January 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:15:19Z","last_updated_date":"2025-05-08T15:15:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-sawp-discussion-meeting-15-january-2025_en.pdf"},
    {"id":"68183","name":"Annex 6 - SAWP discussion meeting 10 July 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:16:14Z","last_updated_date":"2025-05-08T15:16:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-sawp-discussion-meeting-10-july-2024_en.pdf"},
    {"id":"68184","name":"Annex 6 - SAWP discussion meeting 6 March 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:16:53Z","last_updated_date":"2025-05-08T15:16:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-sawp-discussion-meeting-6-march-2024_en.pdf"},
    {"id":"68185","name":"Annex 6 - Preparation meeting 21 February 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:17:47Z","last_updated_date":"2025-05-08T15:17:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-preparation-meeting-21-february-2023_en.pdf"},
    {"id":"68186","name":"Annex 6 - Response to EMA 18 March 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:18:51Z","last_updated_date":"2025-05-08T15:18:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-response-ema-18-march-2025_en.pdf"},
    {"id":"68187","name":"Annex 6 - Response to EMA 16 December 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:19:59Z","last_updated_date":"2025-05-08T15:19:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-response-ema-16-december-2024_en.pdf"},
    {"id":"68188","name":"Annex 6 - Response to EMA 19 February 2025 (items 1 and 5)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:20:34Z","last_updated_date":"2025-05-08T15:20:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-response-ema-19-february-2025-items-1-5_en.pdf"},
    {"id":"68189","name":"Annex 6 - Response to EMA 9 April 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:21:05Z","last_updated_date":"2025-05-08T15:21:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-response-ema-9-april-2025_en.pdf"},
    {"id":"68190","name":"Annex 6 - Response to EMA 19 February 2025 (items 2-4)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:22:16Z","last_updated_date":"2025-05-08T15:22:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-response-ema-19-february-2025-items-2-4_en.pdf"},
    {"id":"68191","name":"Annex 6 - CYPDDI document","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:23:43Z","last_updated_date":"2025-05-08T15:23:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-cypddi-document_en.pdf"},
    {"id":"68192","name":"Annex 6 - Additional supporting documentation – System parameters and compound files","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:24:24Z","last_updated_date":"2025-05-08T15:24:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-additional-supporting-documentation-system-parameters-compound-files_en.pdf"},
    {"id":"68193","name":"Annex 6 - Fluvoxamine summary March 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:26:23Z","last_updated_date":"2025-05-08T15:26:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-fluvoxamine-summary-march-2025_en.pdf"},
    {"id":"68194","name":"Annex 6 - Response to EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:27:43Z","last_updated_date":"2025-05-08T15:27:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-response-ema_en.pdf"},
    {"id":"68196","name":"Annex 6 - Response to EMA 21 December 2023","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:33:34Z","last_updated_date":"2025-05-08T15:33:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-response-ema-21-december-2023_en.pdf"},
    {"id":"68197","name":"Annex 6 - Response to EMA 26 June 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:34:12Z","last_updated_date":"2025-05-08T15:34:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-response-ema-26-june-2024_en.pdf"},
    {"id":"68198","name":"Annex 6 - DDI qualification matrix","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:34:50Z","last_updated_date":"2025-05-08T15:34:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-ddi-qualification-matrix_en.pdf"},
    {"id":"68199","name":"Annex 6 - V19R1 vs V20R1 version comparison","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:36:15Z","last_updated_date":"2025-05-08T15:36:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-v19r1-vs-v20r1-version-comparison_en.pdf"},
    {"id":"68200","name":"Annex 6 - V20R1 vs V21R1 version comparison","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:36:59Z","last_updated_date":"2025-05-08T15:36:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-v20r1-vs-v21r1-version-comparison_en.pdf"},
    {"id":"68201","name":"Annex 6 - V21R1 vs V22R1 version comparison","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:37:32Z","last_updated_date":"2025-05-08T15:37:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-v21r1-vs-v22r1-version-comparison_en.pdf"},
    {"id":"68202","name":"Annex 6 - V22R1 vs V23R2 version comparison","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T15:38:03Z","last_updated_date":"2025-05-08T15:38:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-6-v22r1-vs-v23r2-version-comparison_en.pdf"},
    {"id":"68219","name":"Medicine shortage communication (MSC): Fiasp PumpCart and NovoRapid PumpCart","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T12:35:00Z","last_updated_date":"2025-05-12T12:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-fiasp-pumpcart-novorapid-pumpcart_en.pdf"},
    {"id":"68307","name":"PRAC meetings in 2027 and 2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-15T15:15:00Z","last_updated_date":"2025-05-15T15:15:00Z","reference_number":"EMA/PRAC/126713/2025","document_url":"https://www.ema.europa.eu/en/documents/other/prac-meetings-2027-2028_en.pdf"},
    {"id":"68318","name":"Declaration of interests: Georgia Gavriilidou","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-16T11:58:58Z","last_updated_date":"2026-01-22T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-georgia-gavriilidou_en.pdf"},
    {"id":"68319","name":"EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2025-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-16T13:35:00Z","last_updated_date":"2025-05-16T13:35:00Z","reference_number":"EMA/166854/2025","document_url":"https://www.ema.europa.eu/en/documents/other/ema-recommendation-update-antigenic-composition-authorised-covid-19-vaccines-2025-2026_en.pdf"},
    {"id":"68349","name":"Records of data processing activity for the Organisation Management System (OMS) activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-19T15:27:17Z","last_updated_date":"2025-05-19T15:27:17Z","reference_number":"EMA/593972/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-organisation-management-system-oms-activities_en.pdf"},
    {"id":"68350","name":"European Medicines Agency’s Data Protection Notice for the Organisation Management System (OMS) activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-19T15:34:40Z","last_updated_date":"2025-05-19T15:34:40Z","reference_number":"EMA/565742/2023","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-organisation-management-system-oms-activities_en.pdf"},
    {"id":"68401","name":"Decision of the European Medicines Agency on laying down guidelines on whistleblowing","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T10:25:41Z","last_updated_date":"2025-05-23T10:25:41Z","reference_number":"EMA/MB/232598/2018","document_url":"https://www.ema.europa.eu/en/documents/other/decision-european-medicines-agency-laying-down-guidelines-whistleblowing_en.pdf"},
    {"id":"68424","name":"Decision of the Management Board on the EMA policy on protecting the dignity of the person and preventing psychological harassment and sexual harassment","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T15:05:40Z","last_updated_date":"2025-05-23T15:05:40Z","reference_number":"EMA/MB/854173/2016","document_url":"https://www.ema.europa.eu/en/documents/other/decision-management-board-ema-policy-protecting-dignity-person-preventing-psychological-harassment-sexual-harassment_en.pdf"},
    {"id":"68457","name":"Floseal haemostatic matrix (Floseal VH S/D) - Procedural steps and scientific information after initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-05-26T16:19:31Z","last_updated_date":"2026-04-10T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/floseal-haemostatic-matrix-floseal-vh-s-d-procedural-steps-scientific-information-after-initial-consultation_en.pdf"},
    {"id":"68491","name":"ICH E21 Guideline on inclusion of pregnant and breastfeeding individuals in clinical trials","type":"other","status":"Draft: consultation closed","consultation_date":"2025-06-04 - 2025-09-15","first_published_date":"2025-06-04T10:00:00Z","last_updated_date":"2025-06-04T10:00:00Z","reference_number":"EMA/CHMP/ICH/149462/2025","document_url":"https://www.ema.europa.eu/en/documents/other/ich-e21-guideline-inclusion-pregnant-breastfeeding-individuals-clinical-trials_en.pdf"},
    {"id":"68520","name":"Declaration of interests: Helen Kerr","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-02T11:32:07Z","last_updated_date":"2025-08-01T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-helen-kerr_en.pdf"},
    {"id":"68546","name":"EMA/PDCO summary report on the review of the list of granted Class Waivers 2 June 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T14:34:16Z","last_updated_date":"2025-06-03T14:34:16Z","reference_number":"EMADOC-1700519818-2008871","document_url":"https://www.ema.europa.eu/en/documents/other/ema-pdco-summary-report-review-list-granted-class-waivers-2-june-2025_en.pdf"},
    {"id":"68548","name":"European Medicines Agency decision CW/0001/2025 of 2 June 2025 on class waivers in accordance with Regulation EC No 1901-2006 of the European Parliament and of the Council","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T14:37:19Z","last_updated_date":"2025-06-03T14:37:19Z","reference_number":"EMADOC-1700519818-2155553","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-decision-cw-0001-2025-2-june-2025-class-waivers-accordance-regulation-ec-no-1901-2006-european-parliament-council_en.pdf"},
    {"id":"68582","name":"Understanding the first report of sales and use of antimicrobials in animals - Info session for veterinary practitioners","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-05T11:46:24Z","last_updated_date":"2025-06-05T11:46:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/understanding-first-report-sales-use-antimicrobials-animals-info-session-veterinary-practitioners_en.pdf"},
    {"id":"68587","name":"Highlights - Second EMA / Alliance for Regenerative Medicine bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-05T15:48:53Z","last_updated_date":"2025-06-05T15:48:53Z","reference_number":"EMA/158016/2025","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-second-ema-alliance-regenerative-medicine-bilateral-meeting_en.pdf"},
    {"id":"68761","name":"European Medicines Agency's anti-fraud strategy - revised June 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-17T12:14:00Z","last_updated_date":"2025-06-17T12:14:00Z","reference_number":"EMA/165696/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-anti-fraud-strategy-revised-june-2025_en.pdf"},
    {"id":"68764","name":"Release notes - production release version 1.7.2523 - 16 June 2025 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-16T09:08:14Z","last_updated_date":"2025-06-16T09:08:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172523-16-june-2025-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"68767","name":"Questions and answers about the SEND proof-of-concept for industry:  Scope, terms of participation and data submission process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-16T13:40:00Z","last_updated_date":"2025-06-16T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-about-send-proof-concept-industry-scope-terms-participation-data-submission-process_en.pdf"},
    {"id":"68824","name":"Union Product Database (UPD) - Quick guide for UPD notifications via the user interface and via email ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-19T09:25:36Z","last_updated_date":"2025-10-08T15:13:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/union-product-database-upd-quick-guide-upd-notifications-user-interface-email_en.pdf"},
    {"id":"68836","name":"Outcome of written procedures finalised during the period from 4 March 2025 to 28 May 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-19T13:41:25Z","last_updated_date":"2025-06-19T13:41:25Z","reference_number":"EMA/MB/114131/2025","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-4-march-2025-28-may-2025_en.pdf"},
    {"id":"68848","name":"Management Board meeting dates 2026-2027","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T08:43:03Z","last_updated_date":"2025-06-20T08:43:03Z","reference_number":"EMA/MB/164895/2025","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2026-2027_en.pdf"},
    {"id":"68939","name":"Event report - Advancing regulatory science research","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-24T16:16:09Z","last_updated_date":"2025-06-24T16:16:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/event-report-advancing-regulatory-science-research_en.pdf"},
    {"id":"68996","name":"Spikevax : Module 4.2.2.3 distribution","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T18:07:44Z","last_updated_date":"2025-06-30T18:07:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-module-4223-distribution_en.zip"},
    {"id":"68997","name":"Comirnaty : 4.2.3.2 repeat-dose toxicity","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T18:23:22Z","last_updated_date":"2025-06-30T18:23:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-4232-repeat-dose-toxicity_en.zip"},
    {"id":"68998","name":"Comirnaty : 2.6. non-clinical summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T18:22:11Z","last_updated_date":"2025-11-28T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-26-non-clinical-summary_en.zip"},
    {"id":"69002","name":"Mechanical ventilator - Notified body 2696 - 10/01/2025 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-27T10:50:53Z","last_updated_date":"2025-06-27T10:50:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/mechanical-ventilator-notified-body-2696-10-01-2025-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"69004","name":"Infosheet: EMA review of real-world data studies from September 2021 to February 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T14:06:09Z","last_updated_date":"2025-06-30T14:06:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/infosheet-ema-review-real-world-data-studies-september-2021-february-2025_en.pdf"},
    {"id":"69023","name":"Comirnaty : 4.2.3.5.1 fertility and early embryonic development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T16:06:26Z","last_updated_date":"2025-06-30T16:06:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-42351-fertility-early-embryonic-development_en.zip"},
    {"id":"69030","name":"Questions and answers - System demo Q2 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T09:57:00Z","last_updated_date":"2025-06-30T09:57:00Z","reference_number":"EMA/215795/2025","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-system-demo-q2-2025_en.pdf"},
    {"id":"69035","name":"Annual list of contracts 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T10:36:46Z","last_updated_date":"2025-06-30T10:36:46Z","reference_number":"EMA/34081/2024","document_url":"https://www.ema.europa.eu/en/documents/other/annual-list-contracts-2024_en.pdf"},
    {"id":"69037","name":"Spikevax : Module 4.2.3.2 repeat-dose toxicity (in order by species, by route, by duration; including supportive toxicokinetics evaluations)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T11:10:18Z","last_updated_date":"2025-06-30T11:10:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-module-4232-repeat-dose-toxicity-order-species-route-duration-including-supportive-toxicokinetics-evaluations_en.zip"},
    {"id":"69038","name":"Spikevax : Module 4.2.3.3.1 in vitro","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T11:11:51Z","last_updated_date":"2025-06-30T11:11:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-module-42331-vitro_en.zip"},
    {"id":"69039","name":"Spikevax : Module 4.2.3.3.2 in vivo (including supportive toxicokinetics evaluations)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T11:12:49Z","last_updated_date":"2025-06-30T11:12:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-module-42332-vivo-including-supportive-toxicokinetics-evaluations_en.zip"},
    {"id":"69040","name":"Spikevax : Module 4.2.3.7.2 immunotoxicity","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T11:13:56Z","last_updated_date":"2025-06-30T11:13:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-module-42372-immunotoxicity_en.zip"},
    {"id":"69065","name":"Medicinal Product master data for better regulation and better health - Network Data Steering Group (NDSG) recommendations for human Product Master Data implementation and data management","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-07-01T12:02:01Z","last_updated_date":"2025-07-01T12:02:01Z","reference_number":"EMA/135628/2025","document_url":"https://www.ema.europa.eu/en/documents/other/medicinal-product-master-data-better-regulation-better-health-network-data-steering-group-ndsg-recommendations-human-product-master-data-implementation-data-management_en.pdf"},
    {"id":"69099","name":"Recommendations of the Executive Steering Group on Shortages and Safety of Medicinal Products to address anti-D immunoglobulin supply chain vulnerabilities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-04T13:49:49Z","last_updated_date":"2025-07-04T13:49:49Z","reference_number":"EMA/135603/2025","document_url":"https://www.ema.europa.eu/en/documents/other/recommendations-executive-steering-group-shortages-safety-medicinal-products-address-anti-d-immunoglobulin-supply-chain-vulnerabilities_en.pdf"},
    {"id":"69168","name":"Dates of 2026 Scientific Advice Working Party - Human (SAWP-H) meetings and submission deadlines for scientific advice, protocol assistance, qualification of novel methodologies and HTACG/EMA parallel Joint Scientific Consultation (JSC) requests","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-08T15:00:36Z","last_updated_date":"2026-01-13T15:00:00Z","reference_number":"EMA/81856/2023 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/dates-2026-scientific-advice-working-party-human-sawp-h-meetings-submission-deadlines-scientific-advice-protocol-assistance-qualification-novel-methodologies-htacg-ema-parallel-joint-scientific_en.pdf"}    {"id":"69251","name":"Q&A extract - SPOR and XEVMPD status update webinar 9 April 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-11T15:06:42Z","last_updated_date":"2025-07-11T15:06:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qa-extract-spor-xevmpd-status-update-webinar-9-april-2025_en.pdf"},
    {"id":"69303","name":"List of EU Medicines Regulatory Agency Organisation with single and multiple LOC IDs for Product Management Services (PMS) data enrichment - Chapter 2 Annex III","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T16:49:45Z","last_updated_date":"2025-07-31T16:52:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/list-eu-medicines-regulatory-agency-organisation-single-multiple-loc-ids-product-management-services-pms-data-enrichment-chapter-2-annex-iii_en.pdf"},
    {"id":"69338","name":"Comirnaty : 3.2.S.2.6 manufacturing process development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-17T10:45:36Z","last_updated_date":"2025-07-17T10:45:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-32s26-manufacturing-process-development_en.zip"},
    {"id":"69339","name":"Comirnaty : 3.2.S.2.4 controls of critical steps and intermediates","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-17T10:47:37Z","last_updated_date":"2025-07-17T10:47:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-32s24-controls-critical-steps-intermediates_en.zip"},
    {"id":"69340","name":"Comirnaty : 3.2.S.2.3 control of materials","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-17T10:48:49Z","last_updated_date":"2025-07-25T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-32s23-control-materials_en.zip"},
    {"id":"69341","name":"Comirnaty : 3.2.S.2.2 description of manufacturing process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-17T10:50:22Z","last_updated_date":"2025-07-25T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-32s22-description-manufacturing-process_en.zip"},
    {"id":"69382","name":"Regulatory Science - Research needs - 2025 update","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T14:54:09Z","last_updated_date":"2025-07-18T14:54:09Z","reference_number":"EMA/510633/2024","document_url":"https://www.ema.europa.eu/en/documents/other/regulatory-science-research-needs-2025-update_en.pdf"},
    {"id":"69391","name":"PMS data matrix - Cross-platforms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T16:00:19Z","last_updated_date":"2025-07-18T16:00:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/pms-data-matrix-cross-platforms_en.xlsx"},
    {"id":"69465","name":"Origio - Procedural steps and scientific information after initial consultation ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-24T19:19:31Z","last_updated_date":"2025-07-24T19:19:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/origio-procedural-steps-scientific-information-after-initial-consultation_en.pdf"},
    {"id":"69467","name":"Origio - Procedural steps and scientific information after initial consultation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-24T19:23:02Z","last_updated_date":"2025-07-24T19:23:02Z","reference_number":"Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/other/origio-procedural-steps-scientific-information-after-initial-consultation_en.pdf-0"},
    {"id":"69495","name":"Questions and answers on Implementing Regulation (EU) 2025/1466: Amendment of Regulation (EU) No 520/2012 and Conclusion of the Signal Detection in EudraVigilance Pilot by marketing authorisation holders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T14:04:13Z","last_updated_date":"2026-01-28T16:08:00Z","reference_number":"EMA/243145/2025 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-implementing-regulation-eu-2025-1466-amendment-regulation-eu-no-520-2012-conclusion-signal-detection-eudravigilance-pilot-marketing-authorisation-holders_en.pdf"},
    {"id":"69496","name":"European Union Member State Public Holidays Recorded in CTIS (year: 2026)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T14:14:41Z","last_updated_date":"2025-07-25T14:14:41Z","reference_number":"EMA/240605/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-union-member-state-public-holidays-recorded-ctis-year-2026_en.pdf"},
    {"id":"69497","name":"Comirnaty : 2.3.P drug product","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T14:18:34Z","last_updated_date":"2025-11-19T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-23p-drug-product_en.zip"},
    {"id":"69499","name":"Comirnaty : 2.3.S drug substance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T14:22:59Z","last_updated_date":"2026-05-28T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-23s-drug-substance_en.zip"},
    {"id":"69544","name":"Questions & Answers extract - SPOR and XEVMPD status update webinar 9 July 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T14:45:31Z","last_updated_date":"2025-07-28T14:45:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-extract-spor-xevmpd-status-update-webinar-9-july-2025_en.pdf"},
    {"id":"69605","name":"Qualification opinion for Simcyp Simulator","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-08-01T08:59:38Z","last_updated_date":"2025-08-01T08:59:38Z","reference_number":"EMADOC-1700519818-2006369","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-simcyp-simulator_en.pdf"},
    {"id":"69607","name":"Declaration of interests: Andres Ganan Jimenez","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-01T10:31:36Z","last_updated_date":"2025-08-01T10:31:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-andres-ganan-jimenez_en.pdf"},
    {"id":"69627","name":"Declaration of interests: Nektaria Varela","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-01T15:19:44Z","last_updated_date":"2025-08-01T15:19:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-nektaria-varela_en.pdf"},
    {"id":"69631","name":"Declaration of interests: Nicholas Perombelon","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-01T15:24:38Z","last_updated_date":"2025-08-01T15:24:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-nicholas-perombelon_en.pdf"},
    {"id":"69632","name":"Declaration of interests: Stefanie Prilla","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-01T15:58:39Z","last_updated_date":"2025-12-02T10:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-stefanie-prilla_en.pdf"},
    {"id":"69656","name":"Declaration of interest form: Public call for Scientific Advisory Group on Immune and Inflammatory Diseases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-05T11:17:00Z","last_updated_date":"2025-08-05T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interest-form-public-call-scientific-advisory-group-immune-inflammatory-diseases_en.pdf"},
    {"id":"69657","name":"Public call for expression of interest for experts to become members of the European Medicines Agency's Scientific Advisory Group on Immune and Inflammatory Diseases","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-05T11:16:00Z","last_updated_date":"2025-09-15T15:23:00Z","reference_number":"EMA/217895/2025","document_url":"https://www.ema.europa.eu/en/documents/other/public-call-expression-interest-experts-become-members-european-medicines-agencys-scientific-advisory-group-immune-inflammatory-diseases_en.pdf"},
    {"id":"69668","name":"Annex I - Use of titanium dioxide as excipient in human and veterinary medicines and identification of alternatives - Industry feedback to QWP experts / EMA questions - Final report February 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-06T14:00:00Z","last_updated_date":"2025-08-06T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-i-use-titanium-dioxide-excipient-human-veterinary-medicines-identification-alternatives-industry-feedback-qwp-experts-ema-questions-final-report-february-2024_en.pdf"},
    {"id":"69682","name":"Medicine shortage communication (MSC): Zypadhera (olanzapine pamoate monohydrate <210 mg / 300 mg / 405 mg> powder and solvent for prolonged release suspension for injection)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-07T11:12:40Z","last_updated_date":"2025-08-07T11:12:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-zypadhera-olanzapine-pamoate-monohydrate-powder-solvent-prolonged-release-suspension-injection_en.pdf"},
    {"id":"69697","name":"Highlights 8th EMA-EFPIA bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T14:16:57Z","last_updated_date":"2025-08-12T14:16:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-8th-ema-efpia-bilateral-meeting_en.pdf"},
    {"id":"69701","name":"Comirnaty : residual DNA characterization report ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T15:20:26Z","last_updated_date":"2025-08-12T15:20:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-residual-dna-characterization-report_en.pdf"},
    {"id":"69702","name":"Comirnaty: response to EMA request for supplementary information","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T15:26:42Z","last_updated_date":"2025-08-12T15:26:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-response-ema-request-supplementary-information_en.pdf"},
    {"id":"69704","name":"Spikevax : m32S25 process validation and/or evaluation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T15:54:40Z","last_updated_date":"2025-08-12T15:54:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-m32s25-process-validation-or-evaluation_en.pdf"},
    {"id":"69705","name":"Spikevax : m32S42 analytical procedures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T15:59:12Z","last_updated_date":"2025-08-12T15:59:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-m32s42-analytical-procedures_en.pdf"},
    {"id":"69706","name":"Spikevax : m32S42 analytical procedures lonza visp","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T16:00:46Z","last_updated_date":"2025-08-12T16:00:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-m32s42-analytical-procedures-lonza-visp_en.pdf"},
    {"id":"69707","name":"Spikevax : m32S42 analytical procedures sop 1020","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T16:02:30Z","last_updated_date":"2025-08-12T16:02:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-m32s42-analytical-procedures-sop-1020_en.pdf"},
    {"id":"69708","name":"Spikevax : m32S43 validation of analytical procedures lonza_visp","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T16:04:38Z","last_updated_date":"2025-08-12T16:04:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-m32s43-validation-analytical-procedures-lonza_visp_en.pdf"},
    {"id":"69709","name":"Spikevax : m32S44 batch analyses ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T16:06:17Z","last_updated_date":"2025-08-12T16:06:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-m32s44-batch-analyses_en.pdf"},
    {"id":"69710","name":"Spikevax : m32S44 batch analyses CX-024414","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T16:07:27Z","last_updated_date":"2025-08-12T16:07:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-m32s44-batch-analyses-cx-024414_en.pdf"},
    {"id":"69720","name":"Highlights- 4th EMA- affordable medicines Europe bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-13T09:12:14Z","last_updated_date":"2025-08-13T09:12:14Z","reference_number":"EMA/158016/2025","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-4th-ema-affordable-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"69734","name":"Records of data processing activity for Microsoft (MS) Copilot 365 - EMA pilot phase","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-14T09:47:45Z","last_updated_date":"2025-08-14T09:47:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-microsoft-ms-copilot-365-ema-pilot-phase_en.pdf"},
    {"id":"69742","name":"European Medicines Agency’s data protection notice for mail management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-14T14:56:36Z","last_updated_date":"2025-08-14T14:56:36Z","reference_number":"EMA/EXT/269377/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-mail-management_en.pdf"},
    {"id":"69759","name":"Records of data processing activity for mail management","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-19T11:22:38Z","last_updated_date":"2025-08-19T11:22:38Z","reference_number":"EMA/EXT/269433/2025","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-mail-management_en.pdf"},
    {"id":"69762","name":"Records of data processing activity for EMA Authentication Services and Microsoft Entra ID","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-19T13:11:37Z","last_updated_date":"2025-08-19T13:11:37Z","reference_number":"EMA/124628/2025","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-ema-authentication-services-microsoft-entra-id_en.pdf"},
    {"id":"69763","name":"European Medicines Agency’s data protection notice for the use of EMA Authentication Services and Microsoft Entra ID","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-19T13:14:37Z","last_updated_date":"2025-08-19T13:14:37Z","reference_number":"EMA/124625/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-use-ema-authentication-services-microsoft-entra-id_en.pdf"},
    {"id":"69780","name":"Spikevax : 3.2.P Drug product","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-20T09:10:19Z","last_updated_date":"2025-08-20T09:10:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-32p-drug-product_en.zip"},
    {"id":"69781","name":"Comirnaty : 3.2.P drug product","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-20T10:25:15Z","last_updated_date":"2025-12-19T11:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-32p-drug-product_en.zip"},
    {"id":"69833","name":"Flyer - Webinar 1 on new approach methodologies (NAMs) in ecotoxicology: State of the science for bioaccumulation (an integrated, weight of evidence approach)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-21T15:46:40Z","last_updated_date":"2025-08-21T15:46:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/flyer-webinar-1-new-approach-methodologies-nams-ecotoxicology-state-science-bioaccumulation-integrated-weight-evidence-approach_en.pptx"},
    {"id":"69862","name":"Comirnaty : 3.2.A appendices","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-27T09:03:36Z","last_updated_date":"2025-08-27T09:03:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-32a-appendices_en.zip"},
    {"id":"69890","name":"Infosheet: European Medicines Agency - World Health Organization collaboration and partnership","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-01T14:51:00Z","last_updated_date":"2025-09-01T14:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/infosheet-european-medicines-agency-world-health-organization-collaboration-partnership_en.pdf"},
    {"id":"69910","name":"Verification application form","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-03T14:00:00Z","last_updated_date":"2025-09-03T14:00:00Z","reference_number":"EMA/557970/2024","document_url":"https://www.ema.europa.eu/en/documents/other/verification-application-form_en.docx"},
    {"id":"69911","name":"European Medicines Agency’s data protection notice for Microsoft (MS) Copilot 365 - EMA pilot phase","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-08-29T16:08:59Z","last_updated_date":"2025-08-29T16:08:59Z","reference_number":"EMA/216030/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-microsoft-ms-copilot-365-ema-pilot-phase_en.pdf"},
    {"id":"69922","name":"Comirnaty : 3.2.S Drug substance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-02T09:31:43Z","last_updated_date":"2025-12-19T11:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-32s-drug-substance_en.zip"},
    {"id":"69926","name":"Decision of the Executive Director on rules governing the secondment of national experts to the EMA (from 1 October 2025)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-02T14:15:10Z","last_updated_date":"2025-09-02T14:15:10Z","reference_number":"EMA/85885/2025","document_url":"https://www.ema.europa.eu/en/documents/other/decision-executive-director-rules-governing-secondment-national-experts-ema-1-october-2025_en.pdf"},
    {"id":"69947","name":"Mandate, objectives and rules of procedure for the CHMP Companion diagnostics expert group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-03T16:21:46Z","last_updated_date":"2025-09-03T16:21:46Z","reference_number":"EMA/115804/2025","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-chmp-companion-diagnostics-expert-group_en.pdf"},
    {"id":"69966","name":"Involvement of patients in Scientific Advisory Group and Ad Hoc Expert meetings at EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2015-03-26T14:33:36Z","last_updated_date":"2021-10-19T14:34:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/involvement-patients-scientific-advisory-group-ad-hoc-expert-meetings-ema_en.pdf"},
    {"id":"69968","name":"Reflection paper on the further involvement of patients and consumers in the Agency’s activities","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T15:00:08Z","last_updated_date":"2009-12-17T15:01:32Z","reference_number":"EMA/MB/753771/2009","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-further-involvement-patients-consumers-agencys-activities_en.pdf"},
    {"id":"69969","name":"European Medicines Agency/Committee for Proprietary Medicinal Products Working Group with Patients' Organisations - Outcome of discussions: Recommendations and proposals for action","type":"other","status":"unknown","consultation_date":"","first_published_date":"2004-04-20T15:04:25Z","last_updated_date":"2004-04-20T15:05:14Z","reference_number":"EMEA/CPMP/5819/04","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-committee-proprietary-medicinal-products-working-group-patients-organisations-outcome-discussions-recommendations-proposals-action_en.pdf"},
    {"id":"69976","name":"Medicine shortage communication (MSC): Victoza 6 mg/mL solution for injection in pre-filled pen (liraglutide)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T15:26:28Z","last_updated_date":"2025-09-05T15:26:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-victoza-6-mg-ml-solution-injection-pre-filled-pen-liraglutide_en.pdf"},
    {"id":"70013","name":"Release notes - production release version 1.7.2534 - 9 September 2025 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-09T10:28:27Z","last_updated_date":"2025-09-09T10:28:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172534-9-september-2025-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"70041","name":"Regulatory Procedure Management (RPM) for the Product Lifecycle Management (PLM) - Frequently asked questions - tracked changes","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-10T11:26:04Z","last_updated_date":"2025-09-10T11:26:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/regulatory-procedure-management-rpm-product-lifecycle-management-plm-frequently-asked-questions-tracked-changes_en.pdf"},
    {"id":"70082","name":"Training session on human variations web-based electronic application form (eAF) for non-CAPs","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-15T14:51:56Z","last_updated_date":"2025-09-15T14:51:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/training-session-human-variations-web-based-electronic-application-form-eaf-non-caps_en.pdf"},
    {"id":"70135","name":"Overview of Network Data Steering Group (NDSG) change management activities 2025-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-18T10:01:13Z","last_updated_date":"2026-06-24T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/overview-network-data-steering-group-ndsg-change-management-activities-2025-2026_en.pdf"},
    {"id":"70144","name":"Management Board meeting dates 2026-2027","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2025-09-18T12:28:03Z","last_updated_date":"2025-09-18T12:28:03Z","reference_number":"EMA/MB/164895/2025","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2026-2027_en.pdf-0"},
    {"id":"70155","name":"Medicine shortage communication (MSC): Visudyne (verteporfin, powder for solution for injection, 15 mg)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-18T16:00:26Z","last_updated_date":"2025-09-18T16:00:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-visudyne-verteporfin-powder-solution-injection-15-mg_en.pdf"},
    {"id":"70198","name":"Mandate, objectives, and rules of procedure for working parties under the quality, non-clinical, methodology, clinical and veterinary domains","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-22T10:22:20Z","last_updated_date":"2025-09-22T10:22:20Z","reference_number":"EMA/299541/2025","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-working-parties-under-quality-non-clinical-methodology-clinical-veterinary-domains_en.pdf"},
    {"id":"70237","name":"Q&A - System Demo Q3 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-23T17:04:35Z","last_updated_date":"2025-09-23T17:04:35Z","reference_number":"EMA/305939/2025","document_url":"https://www.ema.europa.eu/en/documents/other/qa-system-demo-q3-2025_en.pdf"},
    {"id":"70241","name":"Mandate and objectives for the Working Group of the MSSG on the European Shortages Monitoring Platform (ESMP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-24T11:14:59Z","last_updated_date":"2025-09-24T11:14:59Z","reference_number":"EMA/864607/2022","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-working-group-mssg-european-shortages-monitoring-platform-esmp_en.pdf"},
    {"id":"70242","name":"Mandate and objectives for the Working Group of the MSSG on the Voluntary Solidarity Mechanism and Policy","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-24T11:14:40Z","last_updated_date":"2025-09-24T11:14:40Z","reference_number":"EMA/304978/2023","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-working-group-mssg-voluntary-solidarity-mechanism-policy_en.pdf"},
    {"id":"70243","name":"Mandate and objectives for the Working Group of the MSSG on the Vulnerability Analysis Methodology","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-24T11:13:08Z","last_updated_date":"2025-09-24T11:13:08Z","reference_number":"EMA/110174/2025","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-working-group-mssg-vulnerability-analysis-methodology_en.pdf"},
    {"id":"70254","name":"Procedural advice on publication of information on withdrawals of marketing authorisation and variation applications for veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-09-24T15:11:25Z","last_updated_date":"2025-09-24T15:11:25Z","reference_number":"EMA/562284/2024","document_url":"https://www.ema.europa.eu/en/documents/other/procedural-advice-publication-information-withdrawals-marketing-authorisation-variation-applications-veterinary-medicinal-products_en.pdf"},
    {"id":"70405","name":"European Medicines Agencies Network Data Strategy - Increasing the value of data for the benefit of public and animal health","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T14:30:00Z","last_updated_date":"2025-10-03T14:30:00Z","reference_number":"EMA/128369/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencies-network-data-strategy-increasing-value-data-benefit-public-animal-health_en.pdf"},
    {"id":"70506","name":"European Medicines Agency’s data protection notice for the TRIP digital workstation for horizon scanning and regulatory science","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-09T13:20:46Z","last_updated_date":"2025-10-09T13:20:46Z","reference_number":"EMA/321117/2015","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-trip-digital-workstation-horizon-scanning-regulatory-science_en.pdf"},
    {"id":"70507","name":"Records of data processing activity for the TRIP digital workstation for horizon scanning and regulatory science","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-09T13:25:52Z","last_updated_date":"2025-10-09T13:25:52Z","reference_number":"EMA/321118/2025","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-trip-digital-workstation-horizon-scanning-regulatory-science_en.pdf"},
    {"id":"70514","name":"Comirnaty : 2.4 non-clinical overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-09T15:59:12Z","last_updated_date":"2025-10-09T15:59:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/comirnaty-24-non-clinical-overview_en.zip"},
    {"id":"70516","name":"Spikevax : Module 2.4 non-clinical overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-09T16:03:52Z","last_updated_date":"2025-10-09T16:03:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-module-24-non-clinical-overview_en.zip"},
    {"id":"70539","name":"Outcome of written procedures finalised during the period from 29 June to 22 September 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-14T10:37:57Z","last_updated_date":"2025-10-16T12:00:00Z","reference_number":"EMA/MB/206039/2025","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-29-june-22-september-2025_en.pdf"},
    {"id":"70596","name":"Work plan for the ADRA temporary Working Party (tWP) 2025-2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-16T13:11:48Z","last_updated_date":"2025-10-16T13:11:48Z","reference_number":"EMA/CVMP/314118/2025","document_url":"https://www.ema.europa.eu/en/documents/other/work-plan-adra-temporary-working-party-twp-2025-2026_en.pdf"},
    {"id":"70597","name":"Mandate, objectives and rules of procedure for the CVMP temporary Working Party (tWP) on the ADRA project","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-16T13:17:06Z","last_updated_date":"2025-10-16T13:17:06Z","reference_number":"EMA/CVMP/182608/2025","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-cvmp-temporary-working-party-twp-adra-project_en.pdf"},
    {"id":"70600","name":"Product Management Service (PMS) User Acceptance Testing (UAT) Application Programming Interface (API) registration process for industry - Chapter 1, Annex A","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-16T13:52:48Z","last_updated_date":"2026-06-12T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/product-management-service-pms-user-acceptance-testing-uat-application-programming-interface-api-registration-process-industry-chapter-1_en.pdf"},
    {"id":"70761","name":"Highlights - European Medicine Agency (EMA) and European Association for the Study of Diabetes (EASD) bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-22T15:08:35Z","last_updated_date":"2025-11-14T10:37:00Z","reference_number":"EMA/322020/2025","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-european-medicine-agency-ema-european-association-study-diabetes-easd-bilateral-meeting_en.pdf"},
    {"id":"70800","name":"Draft qualification opinion for molecule-independent device bridging approach (MIDBA)","type":"other","status":"Draft: consultation closed","consultation_date":"2025-10-24 - 2025-12-19","first_published_date":"2025-10-24T09:56:41Z","last_updated_date":"2025-10-24T09:56:41Z","reference_number":"EMADOC-1700519818-2552151","document_url":"https://www.ema.europa.eu/en/documents/other/draft-qualification-opinion-molecule-independent-device-bridging-approach-midba_en.pdf"},
    {"id":"70801","name":"Annex I - Briefing document - molecule-independent device bridging approach (MIDBA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T10:00:21Z","last_updated_date":"2025-10-24T10:00:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-i-briefing-document-molecule-independent-device-bridging-approach-midba_en.pdf"},
    {"id":"70802","name":"Annex II - Initial Qualification Opinion List of Issues - molecule-independent device bridging approach (MIDBA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T10:00:05Z","last_updated_date":"2025-10-24T10:00:05Z","reference_number":"EMADOC-360526170-2157788","document_url":"https://www.ema.europa.eu/en/documents/other/annex-ii-initial-qualification-opinion-list-issues-molecule-independent-device-bridging-approach-midba_en.pdf"},
    {"id":"70803","name":"Annex III - Written responses to list of issues - molecule-independent device bridging approach (MIDBA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T10:00:06Z","last_updated_date":"2025-10-24T10:00:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-iii-written-responses-list-issues-molecule-independent-device-bridging-approach-midba_en.pdf"},
    {"id":"70804","name":"Annex IV - Discussion meeting with applicant - molecule-independent device bridging approach (MIDBA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T10:04:09Z","last_updated_date":"2025-10-24T10:04:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-iv-discussion-meeting-applicant-molecule-independent-device-bridging-approach-midba_en.pdf"},
    {"id":"70970","name":"Medicine shortage communication (MSC): Insulin (human insulin) (various short-, rapid-, intermediate-, mixed- and long-acting forms) 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T16:01:23Z","last_updated_date":"2025-10-31T16:01:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-insulin-human-insulin-various-short-rapid-intermediate-mixed-long-acting-forms-2025_en.pdf"},
    {"id":"70972","name":"Records of data processing activity for Early Notification System (ENS)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-03T10:50:46Z","last_updated_date":"2025-11-03T10:50:46Z","reference_number":"EMA/903983/2019","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-early-notification-system-ens_en.pdf"},
    {"id":"70978","name":"Consultation on an ancillary medicinal substance incorporated in a medical device - XVIVO Heart Solution","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-03T14:56:31Z","last_updated_date":"2025-11-03T14:56:31Z","reference_number":"EMA/170310/2025","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-xvivo-heart-solution_en.pdf"},
    {"id":"70984","name":"Advice to medical device manufacturers - 2026 Timetable","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-03T17:45:39Z","last_updated_date":"2025-11-03T17:45:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advice-medical-device-manufacturers-2026-timetable_en.pdf"},
    {"id":"71028","name":"From laboratory to patients: How the safety of medicines is ensured in the European Union","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-06T12:00:00Z","last_updated_date":"2025-12-11T12:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/laboratory-patients-how-safety-medicines-ensured-european-union_en.pdf"},
    {"id":"71049","name":"Release notes - production release version 1.7.2541 - 7 November 2025 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-07T13:34:46Z","last_updated_date":"2025-11-07T13:34:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172541-7-november-2025-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"71096","name":"Medicine shortage communication (MSC) : Beriglobin (human normal immunoglobulin), 2 mL and 5 mL solution for injection in pre-filled syringe: supply shortage and cessation of marketing (discontinuation)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-11T12:33:00Z","last_updated_date":"2025-11-11T12:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-beriglobin-human-normal-immunoglobulin-2-ml-5-ml-solution-injection-pre-filled-syringe-supply-shortage-cessation-marketing-discontinuation_en.pdf"},
    {"id":"71100","name":"Highlights – Fourth EMA-Vaccines Europe bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-12T10:35:51Z","last_updated_date":"2025-11-12T10:35:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-fourth-ema-vaccines-europe-bilateral-meeting_en.pdf"},
    {"id":"71132","name":"Records of data processing activity for internal publication of appointments, transfers and departures","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T14:42:34Z","last_updated_date":"2025-11-13T14:42:34Z","reference_number":"EMA/357549/2025","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-internal-publication-appointments-transfers-departures_en.pdf"},
    {"id":"71166","name":"Medicine shortage communication (MSC) : Bronchitol, 40 mg inhalation powder, hard capsules: ongoing shortage","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-14T10:37:09Z","last_updated_date":"2025-11-14T10:37:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-bronchitol-40-mg-inhalation-powder-hard-capsules-ongoing-shortage_en.pdf"},
    {"id":"71190","name":"Guidance for applicants: the ETF scientific advice that facilitates clinical trial authorisations (SA-CTA)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-17T13:52:00Z","last_updated_date":"2025-11-17T13:52:00Z","reference_number":"EMA/47386/2025","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-applicants-etf-scientific-advice-facilitates-clinical-trial-authorisations-sa-cta_en.pdf"},
    {"id":"71221","name":"EMA health threats plan - Annex 1: Acceleration of regulatory procedures during public health emergencies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-18T13:33:00Z","last_updated_date":"2025-11-18T13:33:00Z","reference_number":"EMA/360547/2025","document_url":"https://www.ema.europa.eu/en/documents/other/ema-health-threats-plan-annex-1-acceleration-regulatory-procedures-during-public-health-emergencies_en.pdf"},
    {"id":"71246","name":"Notification on arrangements for requesting EMA certificates through urgent and standard procedure for December 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-19T11:49:58Z","last_updated_date":"2025-11-19T11:49:58Z","reference_number":"EMA/351581/2025","document_url":"https://www.ema.europa.eu/en/documents/other/notification-arrangements-requesting-ema-certificates-through-urgent-standard-procedure-december-2025_en.pdf"},
    {"id":"71277","name":"Regulatory Procedure Management in IRIS roadmap","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-21T11:06:31Z","last_updated_date":"2026-06-16T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/regulatory-procedure-management-iris-roadmap_en.pdf"},
    {"id":"71286","name":"Guiding principles of good AI practice in drug development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-14T15:56:00Z","last_updated_date":"2026-01-14T15:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/guiding-principles-good-ai-practice-drug-development_en.pdf"},
    {"id":"71326","name":"European Medicines Agency’s data protection notice for PMS user acceptance stakeholder involvement","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T10:43:24Z","last_updated_date":"2025-11-25T10:43:24Z","reference_number":"EMA/57555/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-pms-user-acceptance-stakeholder-involvement_en.pdf"},
    {"id":"71388","name":"Mandate of the HMA-EMA group focused on AI with industry stakeholders","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T11:26:46Z","last_updated_date":"2025-11-28T11:26:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-hma-ema-group-focused-ai-industry-stakeholders_en.pdf"},
    {"id":"71405","name":"Spikevax : Module 2.6 non-clinical summary","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T15:28:34Z","last_updated_date":"2025-11-28T15:28:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-module-26-non-clinical-summary_en.zip"},
    {"id":"71447","name":"Union Product Database (UPD) - Questions & answers: Network use","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-02T10:32:11Z","last_updated_date":"2025-12-02T10:32:11Z","reference_number":"EMA/379949/2025","document_url":"https://www.ema.europa.eu/en/documents/other/union-product-database-upd-questions-answers-network-use_en.pdf"}    {"id":"71458","name":"SPOR & XEVMPD status update webinar – Questions and Answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-02T16:33:44Z","last_updated_date":"2025-12-02T16:33:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spor-xevmpd-status-update-webinar-questions-answers_en.pdf"},
    {"id":"71469","name":"Keeping medicines safe: Reporting side effects can make medicines safer for everyone","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-03T12:00:00Z","last_updated_date":"2025-12-03T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/keeping-medicines-safe-reporting-side-effects-can-make-medicines-safer-everyone_en.pdf"},
    {"id":"71471","name":"Keeping medicines safe: What actions can EMA take?","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-03T12:00:00Z","last_updated_date":"2025-12-03T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/keeping-medicines-safe-what-actions-can-ema-take_en.pdf"},
    {"id":"71474","name":"EMA decision on adoption by analogy of Commission decision C (2025) 2495","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-03T13:54:42Z","last_updated_date":"2025-12-03T13:54:42Z","reference_number":"EMA/MB/283584/2025","document_url":"https://www.ema.europa.eu/en/documents/other/ema-decision-adoption-analogy-commission-decision-c-2025-2495_en.pdf"},
    {"id":"71476","name":"Compliance notifications explanation and Q&A","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-03T15:00:00Z","last_updated_date":"2025-12-03T15:00:00Z","reference_number":"EMA/362031/2025","document_url":"https://www.ema.europa.eu/en/documents/other/compliance-notifications-explanation-qa_en.pdf"},
    {"id":"71477","name":"Guidelines for real-time co-authoring in SharePoint online","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-03T15:06:58Z","last_updated_date":"2025-12-03T15:06:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/guidelines-real-time-co-authoring-sharepoint-online_en.pdf"},
    {"id":"71496","name":"Declaration of interests: Anna-Sofia Joro","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-04T10:32:17Z","last_updated_date":"2025-12-04T10:32:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-anna-sofia-joro_en.pdf"},
    {"id":"71512","name":"Consultation on an ancillary medicinal substance incorporated in a medical device - Gynemed GmbH & Co. KG HSA-containing ART media","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-04T16:40:00Z","last_updated_date":"2025-12-04T16:40:00Z","reference_number":"EMA/CHMP/258625/2025","document_url":"https://www.ema.europa.eu/en/documents/other/consultation-ancillary-medicinal-substance-incorporated-medical-device-gynemed-gmbh-co-kg-hsa-containing-art-media_en.pdf"},
    {"id":"71561","name":"Call for user acceptance testers for the read functionality in the Public Product Management Service (PMS) Application Programming Interface (API)","type":"other","status":"Draft: consultation closed","consultation_date":"2025-12-08 - 2026-01-12","first_published_date":"2025-12-08T09:32:29Z","last_updated_date":"2025-12-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/call-user-acceptance-testers-read-functionality-public-product-management-service-pms-application-programming-interface-api_en.pdf"},
    {"id":"71586","name":"Release notes - production release version 1.7.2544 - 5 December 2025 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-08T13:30:37Z","last_updated_date":"2025-12-08T13:30:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172544-5-december-2025-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"71595","name":"Medicine shortage communication (MSC): Insulin lispro Sanofi (insulin lispro 100 units/ml solution for injection in cartridge and pre-filled pen)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-08T16:50:51Z","last_updated_date":"2025-12-08T16:50:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-insulin-lispro-sanofi-insulin-lispro-100-units-ml-solution-injection-cartridge-pre-filled-pen_en.pdf"},
    {"id":"71623","name":"Combination Products Operational Group (COMBO) - Terms of reference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T15:01:06Z","last_updated_date":"2025-12-09T15:01:06Z","reference_number":"EMA/219064/2025","document_url":"https://www.ema.europa.eu/en/documents/other/combination-products-operational-group-combo-terms-reference_en.pdf"},
    {"id":"71631","name":"Mandate, objectives and rules of procedure for the Cancer Medicines Forum","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T16:15:59Z","last_updated_date":"2025-12-09T16:15:59Z","reference_number":"EMA/CHMP/58471/2024","document_url":"https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-cancer-medicines-forum_en.pdf"},
    {"id":"71677","name":"User manual for the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) user interface (XEVMPDweb)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-11T16:31:57Z","last_updated_date":"2026-02-11T16:31:57Z","reference_number":"EMA/389113/2025","document_url":"https://www.ema.europa.eu/en/documents/other/user-manual-extended-eudravigilance-medicinal-product-dictionary-xevmpd-user-interface-xevmpdweb_en.pdf"},
    {"id":"71743","name":"Biomarkers in oncology indications approved in the EU: key facts","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T16:30:00Z","last_updated_date":"2025-12-12T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/biomarkers-oncology-indications-approved-eu-key-facts_en.pdf"},
    {"id":"71748","name":"Factsheet - Industry reporting via the European Shortages Monitoring Platform (ESMP) during a crisis or MSSG-led preparedness action","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-16T19:57:07Z","last_updated_date":"2025-12-16T19:57:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/factsheet-industry-reporting-european-shortages-monitoring-platform-esmp-during-crisis-or-mssg-led-preparedness-action_en.pdf"},
    {"id":"71749","name":"Factsheet - Network reporting via the European Shortages Monitoring Platform (ESMP) during a crisis","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-16T15:58:00Z","last_updated_date":"2025-12-16T15:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/factsheet-network-reporting-european-shortages-monitoring-platform-esmp-during-crisis_en.pdf"},
    {"id":"71750","name":"Factsheet - Network reporting via the European Shortages Monitoring Platform (ESMP) during an MSSG-led preparedness action","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-16T15:57:00Z","last_updated_date":"2025-12-16T15:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/factsheet-network-reporting-european-shortages-monitoring-platform-esmp-during-mssg-led-preparedness-action_en.pdf"},
    {"id":"71751","name":"Factsheet - Industry reporting via the European Shortages Monitoring Platform (ESMP) in normal circumstances","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-16T15:54:00Z","last_updated_date":"2025-12-16T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/factsheet-industry-reporting-european-shortages-monitoring-platform-esmp-normal-circumstances_en.pdf"},
    {"id":"71788","name":"eCTD v4.0 and EURSnext roadmap","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-16T15:46:04Z","last_updated_date":"2025-12-16T15:46:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ectd-v40-eursnext-roadmap_en.pdf"},
    {"id":"71824","name":"Q&A - System Demo Q4 2025","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-17T16:11:23Z","last_updated_date":"2025-12-17T16:11:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/qa-system-demo-q4-2025_en.pdf"},
    {"id":"71825","name":"Shortage Prevention Plan (SPP) and Shortage Mitigation Plan (SMP) pilot report","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-17T16:19:26Z","last_updated_date":"2025-12-17T16:19:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/shortage-prevention-plan-spp-shortage-mitigation-plan-smp-pilot-report_en.pdf"},
    {"id":"71852","name":"Summary of bilateral meeting: European Medicines Agency and the European Consumer Organisation (BEUC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2025-12-18T15:16:51Z","last_updated_date":"2025-12-18T15:16:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/summary-bilateral-meeting-european-medicines-agency-european-consumer-organisation-beuc_en.pdf"},
    {"id":"71911","name":"Composition of the Emergency Task Force (ETF) for preparedness","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2026-01-05T09:43:09Z","last_updated_date":"2026-01-05T09:43:09Z","reference_number":"EMA/206184/2025 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/other/composition-emergency-task-force-etf-preparedness_en.pdf"},
    {"id":"71926","name":"Flyer - Webinar 2 on new approach methodologies (NAMs) in ecotoxicology: Gill cell line assay for acute fish toxicity prediction","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-05T15:35:04Z","last_updated_date":"2026-01-07T10:50:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/flyer-webinar-2-new-approach-methodologies-nams-ecotoxicology-gill-cell-line-assay-acute-fish-toxicity-prediction_en.pdf"},
    {"id":"71986","name":"Topics - PCWP and HCPWP joint meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-08T10:54:28Z","last_updated_date":"2026-01-08T10:54:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/topics-pcwp-hcpwp-joint-meeting_en.pdf"},
    {"id":"71998","name":"European Medicines Agency budget for 2026","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2026-01-08T16:40:56Z","last_updated_date":"2026-01-08T16:40:56Z","reference_number":"EMA/354245/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agency-budget-2026_en.pdf"},
    {"id":"72059","name":"3-year rolling work plan for the Quality Innovation Group (QIG) 2026-2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T13:16:00Z","last_updated_date":"2026-01-15T13:16:00Z","reference_number":"EMA/326306/2025","document_url":"https://www.ema.europa.eu/en/documents/other/3-year-rolling-work-plan-quality-innovation-group-qig-2026-2028_en.pdf"},
    {"id":"72060","name":"Declaration of interests:  Jacobus van Wyk","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T13:32:24Z","last_updated_date":"2026-01-15T13:32:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-jacobus-van-wyk_en.pdf"},
    {"id":"72101","name":"PRAC statistics: January 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T10:53:08Z","last_updated_date":"2026-01-16T10:53:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/prac-statistics-january-2026_en.pdf"},
    {"id":"72120","name":"eCTD v4.0 implementation milestones - Industry","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-19T10:37:46Z","last_updated_date":"2026-01-19T10:37:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ectd-v40-implementation-milestones-industry_en.pdf"},
    {"id":"72130","name":"Methodology for the annual review of the Union list of critical medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-19T12:47:04Z","last_updated_date":"2026-01-19T12:47:04Z","reference_number":"EMA/376463/2025","document_url":"https://www.ema.europa.eu/en/documents/other/methodology-annual-review-union-list-critical-medicines_en.pdf"},
    {"id":"72247","name":"European Medicines Agency’s data protection notice for the EudraVigilance Signal and Safety Analytics (EV SSA) platform","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-26T11:40:18Z","last_updated_date":"2026-03-10T11:15:00Z","reference_number":"EMA/228281/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/european-medicines-agencys-data-protection-notice-eudravigilance-signal-safety-analytics-ev-ssa-platform_no.pdf"}},
    {"id":"72264","name":"Environmental Statement 2024","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-26T17:44:00Z","last_updated_date":"2026-01-26T17:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/environmental-statement-2024_en.pdf"},
    {"id":"72334","name":"Breach of trust procedure for competing interests and disclosure of confidential information by members of the European Medicines Agency’s Management Board - as adopted in December 2025","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2023-01-04T15:45:56Z","last_updated_date":"2025-12-18T15:49:00Z","reference_number":"EMA/MB/309079/2012 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/other/breach-trust-procedure-competing-interests-disclosure-confidential-information-members-european-medicines-agencys-management-board-adopted-december-2025_en.pdf"},
    {"id":"72387","name":"Spikevax : Module 2.3.S drug substance","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T14:38:06Z","last_updated_date":"2026-05-28T15:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/spikevax-module-23-quality-overall-summary_en.zip"},
    {"id":"72417","name":"Appendices to guideline on epidemiological data on blood transmissible infections - Revision 2","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-04T16:26:28Z","last_updated_date":"2026-02-04T16:26:28Z","reference_number":"EMA/735037/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/other/appendices-guideline-epidemiological-data-blood-transmissible-infections-revision-2_en.doc"},
    {"id":"72442","name":"Highlights – seventh EMA-EuropaBio bilateral meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-06T11:09:51Z","last_updated_date":"2026-02-06T11:09:51Z","reference_number":"EMA/5433/2026","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-seventh-ema-europabio-bilateral-meeting_en.pdf"},
    {"id":"72443","name":"Drug Shortages Global Regulatory Working Group: Group statement published on behalf of the Working Group by EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-06T00:00:00Z","last_updated_date":"2026-02-06T00:00:00Z","reference_number":"EMA/559618/2024","document_url":"https://www.ema.europa.eu/en/documents/other/drug-shortages-global-regulatory-working-group-group-statement-published-behalf-working-group-ema_en.pdf"},
    {"id":"72523","name":"Questions and answers - SPOR and XEVMPD status update webinar - Q1 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T10:15:24Z","last_updated_date":"2026-02-12T10:15:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-spor-xevmpd-status-update-webinar-q1-2026_en.pdf"},
    {"id":"72524","name":"Network Portfolio Objectives","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T10:47:59Z","last_updated_date":"2026-02-12T10:47:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/network-portfolio-objectives_en.pdf"},
    {"id":"72547","name":"PRAC statistics: February 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-13T10:59:00Z","last_updated_date":"2026-02-13T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/prac-statistics-february-2026_en.pdf"},
    {"id":"72549","name":"Medicine shortage communication (MSC): Natpar (parathyroid hormone) (25, 50, 75 and 100 micrograms/dose powder and solvent for solution for injection)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-13T11:41:24Z","last_updated_date":"2026-02-13T11:41:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-natpar-parathyroid-hormone-25-50-75-100-micrograms-dose-powder-solvent-solution-injection_en.pdf"},
    {"id":"72648","name":"Declaration of interests: Stefano Ponzano","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-23T15:51:20Z","last_updated_date":"2026-02-23T15:51:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-stefano-ponzano_en.pdf"},
    {"id":"72680","name":"Electronic reporting to EudraVigilance - List of reference documents","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-24T17:22:41Z","last_updated_date":"2026-02-24T17:22:41Z","reference_number":"EMA/274082/2025","document_url":"https://www.ema.europa.eu/en/documents/other/electronic-reporting-eudravigilance-list-reference-documents_en.pdf"},
    {"id":"72748","name":"EU-Innovation Network Workplan 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-27T12:39:28Z","last_updated_date":"2026-02-27T12:39:28Z","reference_number":"EMA/46752/2026","document_url":"https://www.ema.europa.eu/en/documents/other/eu-innovation-network-workplan-2026_en.pdf"},
    {"id":"72755","name":"European Medicines Agency’s data protection notice for personal data relating to temporary agency workers (‘interims’)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-02-27T15:16:46Z","last_updated_date":"2026-03-03T10:15:00Z","reference_number":"EMA/48615/2026","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-personal-data-relating-temporary-agency-workers-interims_en.pdf"},
    {"id":"72780","name":"Darwin EU study: Background incidence rates of selected vaccine adverse events of special in Europe","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:09:00Z","last_updated_date":"2026-03-04T10:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-study-background-incidence-rates-selected-vaccine-adverse-events-special-europe_en.pdf"},
    {"id":"72781","name":"Darwin EU study: Co-prescribing medicines in pulmonary arterial hypertension","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:18:00Z","last_updated_date":"2026-03-04T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-study-co-prescribing-medicines-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"72782","name":"Darwin EU study: Clozapine and the incidence of severe neutropenia over time","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:17:00Z","last_updated_date":"2026-03-04T10:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-study-clozapine-incidence-severe-neutropenia-over-time_en.pdf"},
    {"id":"72783","name":"Darwin EU study: How medicines are used to treat adults and children with lupus","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:17:00Z","last_updated_date":"2026-03-04T10:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-study-how-medicines-are-used-treat-adults-children-lupus_en.pdf"},
    {"id":"72784","name":"Darwin EU study: Overall survival in patients with non-small cell lung cancer treated with selected immunotherapies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:16:00Z","last_updated_date":"2026-03-04T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-study-overall-survival-patients-non-small-cell-lung-cancer-treated-selected-immunotherapies_en.pdf"},
    {"id":"72785","name":"Darwin EU study: Treatment patterns and user characteristics for novel migraine medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:16:00Z","last_updated_date":"2026-03-04T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-study-treatment-patterns-user-characteristics-novel-migraine-medicines_en.pdf"},
    {"id":"72786","name":"Darwin EU study: Is there a link between blood clots and common painkillers in women who use hormonal birth control","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:15:00Z","last_updated_date":"2026-03-04T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-study-there-link-between-blood-clots-common-painkillers-women-who-use-hormonal-birth-control_en.pdf"},
    {"id":"72787","name":"Darwin EU: Is there a risk of suicidality after taking the antibiotic doxycycline","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:15:00Z","last_updated_date":"2026-03-04T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-there-risk-suicidality-after-taking-antibiotic-doxycycline_en.pdf"},
    {"id":"72788","name":"Darwin EU: How often respiratory syncytial virus (RSV) affects different age groups in Europe","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:14:00Z","last_updated_date":"2026-03-04T10:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-how-often-respiratory-syncytial-virus-rsv-affects-different-age-groups-europe_en.pdf"},
    {"id":"72789","name":"Darwin EU study: Use of higher-risk antibiotics from the WHO Watch list, including azithromycin","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:13:00Z","last_updated_date":"2026-03-04T10:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/darwin-eu-study-use-higher-risk-antibiotics-who-watch-list-including-azithromycin_en.pdf"},
    {"id":"72883","name":"Organisation Management Service (OMS) in processes and systems","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T09:25:55Z","last_updated_date":"2026-03-09T09:25:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-management-service-oms-processes-systems_en.pdf"},
    {"id":"72906","name":"Network Data Steering Group workplan 2026-2028: Data and artificial intelligence in medicines regulation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T17:33:14Z","last_updated_date":"2026-03-09T17:33:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/network-data-steering-group-workplan-2026-2028-data-artificial-intelligence-medicines-regulation_en.pdf"},
    {"id":"72910","name":"Methodology to identify vulnerabilities in supply chains of critical medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-10T10:27:52Z","last_updated_date":"2026-03-10T10:27:52Z","reference_number":"EMA/344341/2025","document_url":"https://www.ema.europa.eu/en/documents/other/methodology-identify-vulnerabilities-supply-chains-critical-medicines_en.pdf"},
    {"id":"72931","name":"Structures filling, replacement and reconstruction devices - Notified body 1434 - 07/04/2025 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-10T15:25:17Z","last_updated_date":"2026-03-10T15:25:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/structures-filling-replacement-reconstruction-devices-notified-body-1434-07-04-2025-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"72997","name":"European Medicines Agency’s data protection notice for women leadership development and mentoring activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-13T10:08:20Z","last_updated_date":"2026-03-13T10:08:20Z","reference_number":"EMA/59131/2026","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-women-leadership-development-mentoring-activities_en.pdf"},
    {"id":"72998","name":"Records of data processing activity relating to temporary agency workers (interims)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-13T10:12:08Z","last_updated_date":"2026-03-13T10:12:08Z","reference_number":"EMA/48970/2026","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-relating-temporary-agency-workers-interims_en.pdf"},
    {"id":"73000","name":"EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 5: Example payloads for API","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-13T10:37:50Z","last_updated_date":"2026-03-13T10:37:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-chapter-5-example-payloads-api_en.zip"},
    {"id":"73005","name":"Appointment of the Executive Director - The process","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-13T14:40:00Z","last_updated_date":"2026-03-13T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/appointment-executive-director-process_en.pdf"},
    {"id":"73016","name":"Release notes - production release version 1.7.2615 March 2026 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-16T08:04:12Z","last_updated_date":"2026-03-16T08:04:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172615-march-2026-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"73048","name":"Records of data processing activity for women leadership development and mentoring activities","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T09:39:47Z","last_updated_date":"2026-03-17T09:39:47Z","reference_number":"EMA/59133/2026","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-women-leadership-development-mentoring-activities_en.pdf"},
    {"id":"73064","name":"Declaration of interests: Susan Carroll","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T13:38:39Z","last_updated_date":"2026-03-17T13:38:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/declaration-interests-susan-carroll_en.pdf"},
    {"id":"73122","name":"Electronic product information (ePI) roadmap","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-20T09:56:00Z","last_updated_date":"2026-03-20T09:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/electronic-product-information-epi-roadmap_en.pdf"},
    {"id":"73126","name":"Qualification opinion for Molecule-independent device bridging approach (MIDBA)","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2026-03-20T10:13:35Z","last_updated_date":"2026-03-20T10:13:35Z","reference_number":"EMADOC-1700519818-2552151","document_url":"https://www.ema.europa.eu/en/documents/other/qualification-opinion-molecule-independent-device-bridging-approach-midba_en.pdf"},
    {"id":"73130","name":"Submission deadlines for paediatric applications 2026-2028","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-20T11:40:57Z","last_updated_date":"2026-03-20T11:40:57Z","reference_number":"EMA/36889/2026","document_url":"https://www.ema.europa.eu/en/documents/other/submission-deadlines-paediatric-applications-2026-2028_en.pdf"},
    {"id":"73142","name":"Recommendations of the Executive Steering Group on the Shortages and Safety of Medicinal Products on shortages of intravenous ifosfamide and cyclophosphamide","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T12:02:00Z","last_updated_date":"2026-03-24T12:02:00Z","reference_number":"EMA/62884/2026","document_url":"https://www.ema.europa.eu/en/documents/other/recommendations-executive-steering-group-shortages-safety-medicinal-products-shortages-intravenous-ifosfamide-cyclophosphamide_en.pdf"},
    {"id":"73143","name":"Outcome of written procedures finalised during the period from 4 December 2025 to 3 March 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-23T10:43:00Z","last_updated_date":"2026-03-23T10:43:00Z","reference_number":"EMA/MB/316806/2025","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-4-december-2025-3-march-2026_en.pdf"},
    {"id":"73148","name":"3-year work plan for the Inspectors Working Group","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-23T16:47:52Z","last_updated_date":"2026-03-23T16:47:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/3-year-work-plan-inspectors-working-group_en.pdf"},
    {"id":"73150","name":"Medicine Shortage Communication (MSC): Insulin (human insulin) (various short-, rapid-, intermediate-, mixed- and long-acting forms) 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-23T17:50:55Z","last_updated_date":"2026-03-23T17:50:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-insulin-human-insulin-various-short-rapid-intermediate-mixed-long-acting-forms-2026_en.pdf"},
    {"id":"73154","name":"Questions and answers on the implementation of 3DP technology (Additive Manufacturing Technology) for solid oral dosage forms","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T10:53:08Z","last_updated_date":"2026-03-24T10:53:08Z","reference_number":"EMA/CHMP/CVMP/QIG/GMP/QWP/55150/2026","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-implementation-3dp-technology-additive-manufacturing-technology-solid-oral-dosage-forms_en.pdf"},
    {"id":"73156","name":"Reflection paper on a tailored clinical approach in biosimilar development","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T14:00:00Z","last_updated_date":"2026-03-27T14:00:00Z","reference_number":"EMA/CHMP/BMWP/60916/2025","document_url":"https://www.ema.europa.eu/en/documents/other/reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf-0"},
    {"id":"73158","name":"Outcome of the Public Consultation – Reflection Paper on a Tailored Clinical Approach in Biosimilar Development","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T14:00:00Z","last_updated_date":"2026-03-27T14:00:00Z","reference_number":"EMA/CHMP/BMWP/60936/2026","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-public-consultation-reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf"},
    {"id":"73161","name":"Cardiac valves - Notified Body 0344 - 07/12/2021 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T11:46:07Z","last_updated_date":"2026-03-24T11:46:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/cardiac-valves-notified-body-0344-07-12-2021-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf-0"},
    {"id":"73162","name":"Medicine Shortage Communication (MSC): Holoxan / Tronoxal / Mitoxana (ifosfamide), 500 mg, 1 g and 2 g powder for solution for injection","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T12:02:00Z","last_updated_date":"2026-03-24T12:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-holoxan-tronoxal-mitoxana-ifosfamide-500-mg-1-g-2-g-powder-solution-injection_en.pdf"},
    {"id":"73163","name":" Medicine Shortage Communication (MSC): Endoxan / Sendoxan / Genoxal (cyclophosphamide), 100 mg, 200 mg, 500 mg, 1 g and 2 g, powder for solution for injection or infusion","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T12:02:00Z","last_updated_date":"2026-03-24T12:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/medicine-shortage-communication-msc-endoxan-sendoxan-genoxal-cyclophosphamide-100-mg-200-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_en.pdf"},
    {"id":"73179","name":"Bioabsorbable orthopaedic screws - Notified body 0344 - 14/05/2024 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T16:27:05Z","last_updated_date":"2026-03-24T16:27:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/bioabsorbable-orthopaedic-screws-notified-body-0344-14-05-2024-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"73204","name":"Decision of the Executive Director on the access to financial and administrative incentives for micro, small and medium-sized enterprises","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T15:09:00Z","last_updated_date":"2026-03-25T15:09:00Z","reference_number":"EMA/37378/2026","document_url":"https://www.ema.europa.eu/en/documents/other/decision-executive-director-access-financial-administrative-incentives-micro-small-medium-sized-enterprises_en.pdf"},
    {"id":"73207","name":"Revised rules for reimbursement of expenses for delegates attending meetings ","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2026-03-25T15:40:07Z","last_updated_date":"2026-03-25T15:40:07Z","reference_number":"EMA/MB/279597/2018 Rev. 6 ","document_url":"https://www.ema.europa.eu/en/documents/other/revised-rules-reimbursement-expenses-delegates-attending-meetings_en.pdf"},
    {"id":"73209","name":"Records of data processing activity on processing of personal data pertaining to staff absence","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T16:11:46Z","last_updated_date":"2026-03-25T16:11:46Z","reference_number":"EMA/72806/2026","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-processing-personal-data-pertaining-staff-absence_en.pdf"},
    {"id":"73210","name":"Vaccine Essentials: Meningococcal group B vaccines - facts and figures overview","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-26T13:22:00Z","last_updated_date":"2026-03-26T13:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/vaccine-essentials-meningococcal-group-b-vaccines-facts-figures-overview_en.pdf"},
    {"id":"73233","name":"Management Board meeting dates 2026-2027-2028","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T09:55:06Z","last_updated_date":"2026-03-27T09:55:06Z","reference_number":"EMA/MB/44754/2026","document_url":"https://www.ema.europa.eu/en/documents/other/management-board-meeting-dates-2026-2027-2028_en.pdf"},
    {"id":"73247","name":"Data Quality Framework for EU medicines regulation: application to Real-World Data","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T14:25:44Z","last_updated_date":"2026-03-27T14:25:44Z","reference_number":"EMA/503781/2024","document_url":"https://www.ema.europa.eu/en/documents/other/data-quality-framework-eu-medicines-regulation-application-real-world-data_en.pdf"},
    {"id":"73255","name":"Questions and answers - Quarterly System Demo - Q1 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T17:15:59Z","last_updated_date":"2026-03-27T17:15:59Z","reference_number":"EMA/68115/2026","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-quarterly-system-demo-q1-2026_en.pdf"},
    {"id":"73258","name":"Veterinary medicine safety day: How to check veterinary medicines are working","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-08T09:52:00Z","last_updated_date":"2026-04-08T09:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-medicine-safety-day-how-check-veterinary-medicines-are-working_en.pdf"},
    {"id":"73260","name":"Veterinary medicine safety day: Why read veterinary medicines package leaflet","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-08T09:51:00Z","last_updated_date":"2026-04-08T09:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-medicine-safety-day-why-read-veterinary-medicines-package-leaflet_en.pdf"},
    {"id":"73262","name":"Veterinary medicine safety day: How to dispose of unused veterinary medicines","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-08T09:50:00Z","last_updated_date":"2026-04-08T09:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-medicine-safety-day-how-dispose-unused-veterinary-medicines_en.pdf"},
    {"id":"73272","name":"Draft Qualification opinion for Virtual Control Groups (VCG) to replace Concurrent Control Groups (CCG) in rat non-GLP Dose-Range Finding (DRF) studies","type":"other","status":"Draft: consultation closed","consultation_date":"2026-03-31 - 2026-05-12","first_published_date":"2026-03-31T14:00:22Z","last_updated_date":"2026-03-31T14:00:22Z","reference_number":"EMADOC-1700519818-3025927","document_url":"https://www.ema.europa.eu/en/documents/other/draft-qualification-opinion-virtual-control-groups-vcg-replace-concurrent-control-groups-ccg-rat-non-glp-dose-range-finding-drf-studies_en.pdf"},
    {"id":"73273","name":"Annex 1 - Standard Operating Procedure for the Implementation of Virtual Control Groups in Preclinical Studies","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-31T11:32:48Z","last_updated_date":"2026-03-31T11:32:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-1-standard-operating-procedure-implementation-virtual-control-groups-preclinical-studies_en.pdf"},
    {"id":"73274","name":"Annex 3 - CHMP Scientific Advice - Summary Qualification Document","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-31T14:00:00Z","last_updated_date":"2026-03-31T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/annex-3-chmp-scientific-advice-summary-qualification-document_en.pdf"},
    {"id":"73275","name":"Annex 4 - Initial Qualification Procedure List of Issues and Replies - Virtual Control Groups","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-03-31T14:00:00Z","last_updated_date":"2026-03-31T14:00:00Z","reference_number":"EMADOC-1700519818-2810632","document_url":"https://www.ema.europa.eu/en/documents/other/annex-4-initial-qualification-procedure-list-issues-replies-virtual-control-groups_en.pdf"},
    {"id":"73282","name":"Orphan medical devices regular process: Guide for applicants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T15:19:00Z","last_updated_date":"2026-04-01T15:19:00Z","reference_number":"EMA/77963/2026","document_url":"https://www.ema.europa.eu/en/documents/other/orphan-medical-devices-regular-process-guide-applicants_en.pdf"},
    {"id":"73283","name":"Orphan status request: Template for applicants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T15:16:00Z","last_updated_date":"2026-04-01T15:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/orphan-status-request-template-applicants_en.pdf"},
    {"id":"73284","name":"Orphan medical devices regular process: 2026 timetable","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T15:18:00Z","last_updated_date":"2026-04-01T15:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/orphan-medical-devices-regular-process-2026-timetable_en.pdf"},
    {"id":"73285","name":"Clinical advice request: Template for applicants","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T15:17:00Z","last_updated_date":"2026-04-01T15:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-advice-request-template-applicants_en.pdf"}    {"id":"73289","name":"Implantable cardiac devices (various) - Notified body 2797 - 15/07/2025 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T09:14:58Z","last_updated_date":"2026-04-01T09:14:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/implantable-cardiac-devices-various-notified-body-2797-15-07-2025-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"73297","name":"Overview of (invented) names reviewed in February 2026 by the Name Review Group (NRG) adopted at the CHMP meeting of 24 March 2026","type":"other","status":"Adopted","consultation_date":"","first_published_date":"2026-04-01T15:42:46Z","last_updated_date":"2026-04-01T15:42:46Z","reference_number":"EMA/52722/2026","document_url":"https://www.ema.europa.eu/en/documents/other/overview-invented-names-reviewed-february-2026-name-review-group-nrg-adopted-chmp-meeting-24-march-2026_en.pdf"},
    {"id":"73298","name":"Start of procedure: Extension of marketing authorisation (27 February 2026 - 26 March 2026)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T15:48:05Z","last_updated_date":"2026-04-01T15:48:05Z","reference_number":"EMA/76189/2026","document_url":"https://www.ema.europa.eu/en/documents/other/start-procedure-extension-marketing-authorisation-27-february-2026-26-march-2026_en.xlsx"},
    {"id":"73299","name":"Union product database (UPD) access policy - Veterinary medicinal products","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T15:56:40Z","last_updated_date":"2026-04-01T15:56:40Z","reference_number":"EMA/354254/2025 – Noted and adopted","document_url":"https://www.ema.europa.eu/en/documents/other/union-product-database-upd-access-policy-veterinary-medicinal-products_en.pdf"},
    {"id":"73300","name":"Joint controllership arrangement with regard to the Union product database (UPD)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T16:08:34Z","last_updated_date":"2026-04-01T16:08:34Z","reference_number":"EMA/366104/2021, rev.2 – 'Noted and endorsed","document_url":"https://www.ema.europa.eu/en/documents/other/joint-controllership-arrangement-regard-union-product-database-upd_en.pdf-0"},
    {"id":"73302","name":"European Medicines Agency’s data protection notice for the exchange of information during the Critical Medicines Vulnerability Assessment exercise","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T16:25:43Z","last_updated_date":"2026-04-01T16:25:43Z","reference_number":"EMA/78505/2026","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-exchange-information-during-critical-medicines-vulnerability-assessment-exercise_en.pdf"},
    {"id":"73317","name":"eAF – Q&A Clinic - 09 March 2026 - slides","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T10:32:38Z","last_updated_date":"2026-04-07T10:32:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/eaf-qa-clinic-09-march-2026-slides_en.pdf"},
    {"id":"73323","name":"European Medicines Agency's data protection notice for the implementation of the Instrument for Pre-accession Assistance (IPA) programme","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T13:36:47Z","last_updated_date":"2026-04-07T13:36:47Z","reference_number":"EMA/368013/2025","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-implementation-instrument-pre-accession-assistance-ipa-programme_en.pdf"},
    {"id":"73343","name":"Veterinary medicine safety day 2026: Expert presentation","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-08T09:52:00Z","last_updated_date":"2026-04-08T09:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-medicine-safety-day-2026-expert-presentation_en.pdf"},
    {"id":"73344","name":"Veterinary medicine safety day 2026: Campaign poster","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-08T09:53:00Z","last_updated_date":"2026-04-08T09:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-medicine-safety-day-2026-campaign-poster_en.pdf"},
    {"id":"73345","name":"Veterinary medicine safety day 2026: Image carousel","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-08T09:54:00Z","last_updated_date":"2026-04-08T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/veterinary-medicine-safety-day-2026-image-carousel_en.pdf"},
    {"id":"73423","name":"Records of data processing activity for the EudraVigilance Signal and Safety Analytics (EV SSA) platform ","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-13T10:00:19Z","last_updated_date":"2026-04-13T10:00:19Z","reference_number":"EMA/83326/2024","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-eudravigilance-signal-safety-analytics-ev-ssa-platform_en.pdf"},
    {"id":"73429","name":"Records of data processing activity for critical medicines vulnerability assessment","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-13T17:37:36Z","last_updated_date":"2026-04-13T17:37:36Z","reference_number":"EMA/77651/2026","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-critical-medicines-vulnerability-assessment_en.pdf"},
    {"id":"73507","name":"Clinical Data Publication (CDP) - Questions and Answers (Q&As) on the European Medicines Agency policy on the publication of clinical data for medicinal products for human use (Policy 0070) work-share initiative with Health Canada (HC)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-21T16:17:55Z","last_updated_date":"2026-04-21T16:17:55Z","reference_number":"EMA/382200/2025","document_url":"https://www.ema.europa.eu/en/documents/other/clinical-data-publication-cdp-questions-answers-qas-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-policy-0070-work-share-initiative-health-canada-hc_en.pdf"},
    {"id":"73526","name":"Breakthrough status request: Template for applicants for breakthrough medical devices pilot","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-24T10:57:00Z","last_updated_date":"2026-04-28T11:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/breakthrough-status-request-template-applicants-breakthrough-medical-devices-pilot_en.docx"},
    {"id":"73527","name":"Advice request: Template for applicants for breakthrough medical devices pilot","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-24T10:55:00Z","last_updated_date":"2026-04-28T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/advice-request-template-applicants-breakthrough-medical-devices-pilot_en.docx"},
    {"id":"73528","name":"Organisation Management Service (OMS) in processes and systems","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-23T09:38:41Z","last_updated_date":"2026-04-23T09:38:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/organisation-management-service-oms-processes-systems_en.pdf-0"},
    {"id":"73576","name":"Highlights - 16th Industry Standing Group meeting","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-28T10:49:15Z","last_updated_date":"2026-04-28T10:49:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/highlights-16th-industry-standing-group-meeting_en.pdf"},
    {"id":"73582","name":"Vaccine confidence advisory group: Terms of reference","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-04-29T11:58:00Z","last_updated_date":"2026-04-29T11:58:00Z","reference_number":"EMA/60245/2026","document_url":"https://www.ema.europa.eu/en/documents/other/vaccine-confidence-advisory-group-terms-reference_en.pdf"},
    {"id":"73627","name":"European Medicines Agency’s data protection notice for the management of traineeships at EMA","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-05T16:21:56Z","last_updated_date":"2026-05-05T16:21:56Z","reference_number":"EMA/355081/2024","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-management-traineeships-ema_en.pdf"},
    {"id":"73639","name":"European Medicines Agency's data protection notice for Modelling and Simulation Pilot - Use of clinical study data for scientific advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-07T10:17:25Z","last_updated_date":"2026-05-07T10:17:25Z","reference_number":"EMA/76223/2026","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-modelling-simulation-pilot-use-clinical-study-data-scientific-advice_en.pdf"},
    {"id":"73640","name":"Record of data processing activity for Modelling and Simulation Pilot - Use of clinical study data for scientific advice","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-07T10:19:46Z","last_updated_date":"2026-05-07T10:19:46Z","reference_number":"EMA/108052/2026","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-modelling-simulation-pilot-use-clinical-study-data-scientific-advice_en.pdf"},
    {"id":"73652","name":"Final minutes and answers from the Scientific Scientific Advisory Group (SAG) on Cardiovascular Issues meeting on TZIELD","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T09:45:03Z","last_updated_date":"2026-05-08T09:45:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/final-minutes-answers-scientific-scientific-advisory-group-sag-cardiovascular-issues-meeting-tzield_en.pdf"},
    {"id":"73704","name":"Applications for new human medicines under evaluation: May 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-11T14:03:43Z","last_updated_date":"2026-05-11T14:03:43Z","reference_number":"EMA/106089/2026","document_url":"https://www.ema.europa.eu/en/documents/other/applications-new-human-medicines-under-evaluation-may-2026_en.xlsx"},
    {"id":"73725","name":"EMA workshop on the Vulnerability Assessment with marketing authorisation holders responsible for a subset of critical medicines on the Union list - Questions and answers","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-12T12:59:23Z","last_updated_date":"2026-05-12T12:59:23Z","reference_number":"EMA/112705/2026","document_url":"https://www.ema.europa.eu/en/documents/other/ema-workshop-vulnerability-assessment-marketing-authorisation-holders-responsible-subset-critical-medicines-union-list-questions-answers_en.pdf"},
    {"id":"73816","name":"EC request to EMA for guidance on scientific issues in relation to Articles 107(6) and 114(3) of Regulation (EU) 2019/6","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T15:00:00Z","last_updated_date":"2026-05-22T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ec-request-ema-guidance-scientific-issues-relation-articles-1076-1143-regulation-eu-2019-6_en.pdf"},
    {"id":"73817","name":"Guidance under Article 141(1)(f) of Regulation (EU) 2019/6 on veterinary medicinal products in relation to Articles 107(6) and 114(3)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T15:00:00Z","last_updated_date":"2026-05-22T15:00:00Z","reference_number":"EMA/CVMP/724/2026","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-under-article-1411f-regulation-eu-2019-6-veterinary-medicinal-products-relation-articles-1076-1143_en.pdf"},
    {"id":"73818","name":"Questions for CVMP in relation to EMA’s recommendations under Article 107(6) and Article 114(3)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T15:00:00Z","last_updated_date":"2026-05-22T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-cvmp-relation-emas-recommendations-under-article-1076-article-1143_en.pdf"},
    {"id":"73819","name":"Guidance under Article 141(1)(f) of Regulation (EU) 2019/6 on veterinary medicinal products with regards five substances not included in Commission Implementing Regulation (EU) 2025/901","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T15:00:00Z","last_updated_date":"2026-05-22T15:00:00Z","reference_number":"EMA/CVMP/382370/2025","document_url":"https://www.ema.europa.eu/en/documents/other/guidance-under-article-1411f-regulation-eu-2019-6-veterinary-medicinal-products-regards-five-substances-not-included-commission-implementing-regulation-eu-2025-901_en.pdf"},
    {"id":"73820","name":"EC letter to EMA - Request pursuant to Article 141(1)(f) of Regulation (EU) 2019/6","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T15:00:00Z","last_updated_date":"2026-05-22T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/ec-letter-ema-request-pursuant-article-1411f-regulation-eu-2019-6_en.pdf"},
    {"id":"73821","name":"Questions to EMA on midazolam","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T15:00:00Z","last_updated_date":"2026-05-22T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-ema-midazolam_en.pdf"},
    {"id":"73907","name":"EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-05-29T13:34:00Z","last_updated_date":"2026-05-29T13:34:00Z","reference_number":"EMA/127531/2026","document_url":"https://www.ema.europa.eu/en/documents/other/ema-recommendation-update-antigenic-composition-authorised-covid-19-vaccines-2026-2027_en.pdf"},
    {"id":"73948","name":"Meeting summary - Medicine shortages SPOC working party meeting 15 April 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T10:49:10Z","last_updated_date":"2026-06-03T10:49:10Z","reference_number":"EMA/119443 /2026","document_url":"https://www.ema.europa.eu/en/documents/other/meeting-summary-medicine-shortages-spoc-working-party-meeting-15-april-2026_en.pdf"},
    {"id":"74003","name":"Applications for new human medicines under evaluation: June 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-08T15:10:06Z","last_updated_date":"2026-06-08T15:10:06Z","reference_number":"EMA/129119/2026","document_url":"https://www.ema.europa.eu/en/documents/other/applications-new-human-medicines-under-evaluation-june-2026_en.xlsx"},
    {"id":"74013","name":"Records of data processing activity regarding EMA Account Management System (public)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T14:27:43Z","last_updated_date":"2026-06-09T14:27:43Z","reference_number":"EMA/112376/2026","document_url":"https://www.ema.europa.eu/en/documents/other/records-data-processing-activity-regarding-ema-account-management-system-public_en.pdf"},
    {"id":"74034","name":"Vaccine confidence advisory group: summary of discussion 29 April 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-10T09:03:18Z","last_updated_date":"2026-06-10T09:03:18Z","reference_number":"EMA/106394/2026","document_url":"https://www.ema.europa.eu/en/documents/other/vaccine-confidence-advisory-group-summary-discussion-29-april-2026_en.pdf"},
    {"id":"74047","name":"Shoulder prostheses - Notified body 2797 – 09/11/2024 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-10T14:15:16Z","last_updated_date":"2026-06-10T14:15:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/shoulder-prostheses-notified-body-2797-09-11-2024-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"},
    {"id":"74048","name":"Shoulder prostheses - Notified body 2797 – Notified body justification for divergent view","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-10T14:16:14Z","last_updated_date":"2026-06-10T14:16:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/shoulder-prostheses-notified-body-2797-notified-body-justification-divergent-view_en.pdf"},
    {"id":"74076","name":"Product Management Service (PMS) public API - Frequently asked questions (FAQs)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-12T11:10:54Z","last_updated_date":"2026-06-12T11:10:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/product-management-service-pms-public-api-frequently-asked-questions-faqs_en.pdf"},
    {"id":"74085","name":"Product Management Service (PMS) - Implementation of International Organization for Standardization (ISO) standards for Identification of Medicinal Products (IDMP) in Europe: Registration requirements to public PMS API (beta release) - Chapter 1, Annex B","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-12T14:48:32Z","last_updated_date":"2026-06-12T14:48:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/product-management-service-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-registration-requirements-public-pms-api-beta_en.pdf"},
    {"id":"74088","name":"Products Management Services (PMS) public API - Terms and conditions","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-12T15:54:04Z","last_updated_date":"2026-06-12T15:54:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/products-management-services-pms-public-api-terms-conditions_en.pdf"},
    {"id":"74097","name":"Dates of 2027 SAWP meetings and submission deadlines Scientific advice, protocol assistance, qualification of biomarkers and parallel HTACG/EMA Joint Scientific Consultation requests","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-15T12:55:23Z","last_updated_date":"2026-06-15T12:55:23Z","reference_number":"EMA/62816/2026","document_url":"https://www.ema.europa.eu/en/documents/other/dates-2027-sawp-meetings-submission-deadlines-scientific-advice-protocol-assistance-qualification-biomarkers-parallel-htacg-ema-joint-scientific-consultation-requests_en.pdf"},
    {"id":"74140","name":"Record of data processing activity relating to the psychosocial risk survey (public)","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-17T14:57:42Z","last_updated_date":"2026-06-17T14:57:42Z","reference_number":"EMA/138729/2026","document_url":"https://www.ema.europa.eu/en/documents/other/record-data-processing-activity-relating-psychosocial-risk-survey-public_en.pdf"},
    {"id":"74153","name":"IRIS transition plan - EMA users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-18T17:26:51Z","last_updated_date":"2026-06-18T17:26:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/iris-transition-plan-ema-users_en.pdf"},
    {"id":"74154","name":"IRIS transition plan - Industry users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-18T17:29:24Z","last_updated_date":"2026-06-18T17:29:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/iris-transition-plan-industry-users_en.pdf"},
    {"id":"74155","name":" IRIS transition plan - Network users","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-18T17:30:53Z","last_updated_date":"2026-06-18T17:30:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/iris-transition-plan-network-users_en.pdf"},
    {"id":"74249","name":"Questions and answers - Breakthrough medical devices pilot information session","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-24T14:24:06Z","last_updated_date":"2026-06-24T14:24:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/questions-answers-breakthrough-medical-devices-pilot-information-session_en.pdf"},
    {"id":"74252","name":"Outcome of written procedures finalised during the period from 04 March 2026 to 03 June 2026","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-24T17:17:21Z","last_updated_date":"2026-06-24T17:17:21Z","reference_number":"EMA/MB/68666/2026","document_url":"https://www.ema.europa.eu/en/documents/other/outcome-written-procedures-finalised-during-period-04-march-2026-03-june-2026_en.pdf"},
    {"id":"74276","name":"Role description: Regulatory and digital development officer","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T13:23:50Z","last_updated_date":"2026-06-25T13:23:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/role-description-regulatory-digital-development-officer_en.pdf"},
    {"id":"74293","name":"European Medicines Agency’s data protection notice for sharing contact details of network representatives in Agile teams via the restricted Network Portfolio website","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T15:25:23Z","last_updated_date":"2026-06-25T15:25:23Z","reference_number":"EMA/76073/2026","document_url":"https://www.ema.europa.eu/en/documents/other/european-medicines-agencys-data-protection-notice-sharing-contact-details-network-representatives-agile-teams-restricted-network-portfolio-website_en.pdf"},
    {"id":"74326","name":"Release notes - production release version 1.7.2625 - 26 June 2026 - Veterinary Medicinal Products Regulation: Union Product Database","type":"other","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T13:16:13Z","last_updated_date":"2026-06-26T13:16:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/other/release-notes-production-release-version-172625-26-june-2026-veterinary-medicinal-products-regulation-union-product-database_en.pdf"},
    {"id":"2426","name":"P/48/2009: European Medicines Agency decision of 24 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for tapentadol hydrochloride (EMEA-000325-PIP01-08) in accordance with ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/157910/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-48-2009-european-medicines-agency-decision-24-march-2009-agreement-paediatric-investigation-plan-granting-deferral-tapentadol-hydrochloride-emea-000325-pip01-08-accordance_en.pdf"},
    {"id":"2432","name":"P/143/2010: EMA decision of 30 July 2010 on the refusal of a modification of an agreed paediatric investigation plan for tapentadol hydrochloride (EMEA-000495-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"EMA/469405/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-143-2010-ema-decision-30-july-2010-refusal-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-emea-000495-pip01-08-m02_en.pdf"},
    {"id":"2444","name":"P/128/2010:  European Medicines Agency decision of 28 July 2010 on the agreement of a paediatric investigation plan and on the granting of a waiver for bosentan monohydrate (Tracleer) (EMEA-000425-PIP02-10) in accordance...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/463926/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-128-2010-european-medicines-agency-decision-28-july-2010-agreement-paediatric-investigation-plan-granting-waiver-bosentan-monohydrate-tracleer-emea-000425-pip02-10-accordance_en.pdf"},
    {"id":"2451","name":"P/104/2010: European Medicines Agency decision of 14 June 2010 for waiver for pneumococcal polysaccharide serotype 1/serotype 4/serotype 5/serotype  6B/serotype 7F/serotype 9V/serotype 14/serotype 23F conjugated to prote...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/363927/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-104-2010-european-medicines-agency-decision-14-june-2010-waiver-pneumococcal-polysaccharide-serotype-1-serotype-4-serotype-5-serotype-6b-serotype-7f-serotype-9v-serotype-14-serotype-23f-conjugated_en.pdf"},
    {"id":"2468","name":"P/0017/2013: EMA decision of 18 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for rituximab (MabThera), (EMEA-000308-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T18:30:00Z","last_updated_date":"2013-04-03T18:30:00Z","reference_number":"EMA/821178/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2013-ema-decision-18-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-rituximab-mabthera-emea-000308-pip01-08-m02_en.pdf"},
    {"id":"2486","name":"P/0317/2013: EMA decision of 19 December 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for estetrol / levonorgestrel (EMEA-001513-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-05T00:00:00Z","last_updated_date":"2014-02-05T00:00:00Z","reference_number":"EMA/725501/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2013-ema-decision-19-december-2013-agreement-paediatric-investigation-plan-granting-waiver-estetrol-levonorgestrel-emea-001513-pip01-13_en.pdf"},
    {"id":"2497","name":"P/0154/2014: EMA decision of 13 June 2014 on the granting of a product specific waiver for amlodipine besilate / ramipril (EMEA-001607-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T00:00:00Z","last_updated_date":"2014-07-22T00:00:00Z","reference_number":"EMA/268742/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2014-ema-decision-13-june-2014-granting-product-specific-waiver-amlodipine-besilate-ramipril-emea-001607-pip01-13_en.pdf"},
    {"id":"2498","name":"P/0217/2012: EMA decision of 28 September 2012 on the granting of a product specific waiver for icosapent ethyl (EMEA-001300-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T18:45:00Z","last_updated_date":"2012-10-17T18:45:00Z","reference_number":"EMA/495588/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2012-ema-decision-28-september-2012-granting-product-specific-waiver-icosapent-ethyl-emea-001300-pip01-12_en.pdf"},
    {"id":"2501","name":"P/69/2011: EMA decision of 15 March 2011 on the acceptance of a modification of an agreed Paediatric Investigation Plan for Saxagliptin (EMEA-000200-PIP01-08-M02) in accordance with Regulation (EC) No 1901/2006 of the Eu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2011-04-07T02:00:00Z","reference_number":"EMA/193657/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-69-2011-ema-decision-15-march-2011-acceptance-modification-agreed-paediatric-investigation-plan-saxagliptin-emea-000200-pip01-08-m02-accordance-regulation-ec-no-1901-2006-eu_en.pdf"},
    {"id":"2516","name":"P/0117/2013: EMA decision of 26 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for fingolimod (hydrochloride) (Gilenya), (EMEA-000087-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/250547/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2013-ema-decision-26-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-fingolimod-hydrochloride-gilenya-emea-000087-pip01-07-m03_en.pdf"},
    {"id":"2521","name":"P/0048/2013: EMA decision of 1 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for N-{4-chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/120296/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2013-ema-decision-1-march-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-n-4-chloro-2-1-oxido-4-pyridinylcarbonylphenyl-4_en.pdf"},
    {"id":"2532","name":"P/123/2011: EMA decision of 7 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant fusion protein consisting of human coagulation factor IX attached to the Fc do...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/422220/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-123-2011-ema-decision-7-june-2011-agreement-paediatric-investigation-plan-granting-deferral-recombinant-fusion-protein-consisting-human-coagulation-factor-ix-attached-fc-do_en.pdf"},
    {"id":"2539","name":"P/32/2009: European Medicines Agency decision of 23 February 2009 on the granting of a product specific waiver for aliskiren hemifumarate / hydrochlorothiazide (EMEA-000344-PIP01-08 ) in accordance with Regulation (EC) N...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/1025579/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-32-2009-european-medicines-agency-decision-23-february-2009-granting-product-specific-waiver-aliskiren-hemifumarate-hydrochlorothiazide-emea-000344-pip01-08-accordance-regulation-ec-n_en.pdf"},
    {"id":"2606","name":"P/306/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human normal immunoglobulin / recombinant human hyalu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/757737/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-306-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-normal-immunoglobulin-recombinant-human-hyalu_en.pdf"},
    {"id":"2622","name":"P/0312/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for grazoprevir (EMEA-001602-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/760982/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-grazoprevir-emea-001602-pip01-13-m01_en.pdf"},
    {"id":"2629","name":"P/0172/2017: EMA decision of 31 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for cysteamine\n\n(hydrochloride) (Cystadrops), (EMEA-000322-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-29T02:00:00Z","last_updated_date":"2017-09-29T02:00:00Z","reference_number":"EMA/462362/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2017-ema-decision-31-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-cysteamine-hydrochloride-cystadrops-emea-000322-pip01-08-m05_en.pdf"},
    {"id":"2650","name":"P/253/2010:  EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aluminium hydroxide adsorbed, depigmented glutaralde...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/670701/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-253-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaralde_en.pdf"},
    {"id":"2669","name":"P/203/2009: European Medicines Agency decision of 15 October 2009 on the granting of a product specific waiver for dirucotide acetate (EMEA-000565-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/644613/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-203-2009-european-medicines-agency-decision-15-october-2009-granting-product-specific-waiver-dirucotide-acetate-emea-000565-pip01-09-accordance-regulation-ec-no-1901-2006-european_en.pdf"},
    {"id":"2684","name":"P/0255/2013: EMA decision of 29 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for pegloticase (Krystexxa) (EMEA-000293-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/589182/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2013-ema-decision-29-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-pegloticase-krystexxa-emea-000293-pip02-10-m01_en.pdf"},
    {"id":"2688","name":"P/0061/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for pazopanib (Votrient) (EMEA-000601-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/138317/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-pazopanib-votrient-emea-000601-pip01-09-m03_en.pdf"},
    {"id":"2693","name":"P/0276/2017: EMA decision of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen /\n\nhuman thrombin (Raplixa), (EMEA-001340-PIP01-12-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T01:00:00Z","last_updated_date":"2018-02-15T01:00:00Z","reference_number":"EMA/627576/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2017-ema-decision-4-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-raplixa-emea-001340-pip01-12-m03_en.pdf"},
    {"id":"2694","name":"P/0248/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ex-vivo expanded human autologous epithelium containing stem cells (Holoclar), (EMEA-001082-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/624830/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-ex-vivo-expanded-human-autologous-epithelium-containing-stem-cells-holoclar-emea-001082_en.pdf"},
    {"id":"2702","name":"P/0173/2013: EMA decision of 30 July 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 3-[[4-[(1S)-1-[4-(4-tert-butylphenyl)-3,5-dimethyl-pheno...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/375056/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2013-ema-decision-30-july-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-3-4-1s-1-4-4-tert-butylphenyl-35-dimethyl-pheno_en.pdf"},
    {"id":"2703","name":"P/0116/2012: EMA decisionof 2 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-06T18:00:00Z","last_updated_date":"2012-08-06T18:00:00Z","reference_number":"EMA/405297/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2012-ema-decisionof-2-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-yervoy-emea-000117-pip02-10-m02_en.pdf"},
    {"id":"2716","name":"P/59/2010: European Medicines Agency decision of 29 March 2010\n\non the granting of a product specific waiver for esomeprazole magnesium/acetylsalisylic acid (EMEA-000682-PIP01-09) in accordance with Regulation (EC) No 19...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/202139/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-59-2010-european-medicines-agency-decision-29-march-2010-granting-product-specific-waiver-esomeprazole-magnesium-acetylsalisylic-acid-emea-000682-pip01-09-accordance-regulation-ec-no-19_en.pdf"},
    {"id":"2719","name":"P/0088/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for purified antigen fractions of inactivated split virion Influenza A/Indonesi...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/205462/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-purified-antigen-fractions-inactivated-split-virion-influenza-indonesi_en.pdf"},
    {"id":"2726","name":"P/261/2011: EMA decision of 28 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for doripenem (monohydrate) (Doribax), (EMEA-000015-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T16:00:00Z","last_updated_date":"2011-11-30T16:00:00Z","reference_number":"EMA/830158/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-261-2011-ema-decision-28-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-doripenem-monohydrate-doribax-emea-000015-pip01-07-m03_en.pdf"},
    {"id":"2746","name":"P/0003/2018: EMA decision of 4 January 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for glutamine (levoglutamide) (EMEA-001996-PIP02-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T02:00:00Z","last_updated_date":"2018-04-17T02:00:00Z","reference_number":"EMA/501874/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2018-ema-decision-4-january-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-glutamine-levoglutamide-emea-001996-pip02-16_en.pdf"},
    {"id":"2748","name":"P/0240/2016: EMA decision of 9 September 2016 on the granting of a product specific waiver for (S)-lactic acid, (EMEA-001953-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/580058/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2016-ema-decision-9-september-2016-granting-product-specific-waiver-s-lactic-acid-emea-001953-pip01-16_en.pdf"},
    {"id":"2758","name":"P/0163/2014: EMA decision of 16 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/329347/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2014-ema-decision-16-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-linagliptin-trajenta-emea-000498-pip01-08-m03_en.pdf"},
    {"id":"2775","name":"P/0126/2017: EMA decision of 5 May 2017 on the granting of a product-specific waiver for erdafitinib (EMEA-002042-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/224407/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2017-ema-decision-5-may-2017-granting-product-specific-waiver-erdafitinib-emea-002042-pip01-16_en.pdf"},
    {"id":"2793","name":"P/0291/2017: EMA decision of 4 October 2017 on the granting of a product specific waiver for amlodipine (besylate) / candesartan (cilexetil) /\n\nhydrochlorothiazide (EMEA-002174-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/574573/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2017-ema-decision-4-october-2017-granting-product-specific-waiver-amlodipine-besylate-candesartan-cilexetil-hydrochlorothiazide-emea-002174-pip01-17_en.pdf"},
    {"id":"2795","name":"P/0296/2015: EMA decision of 4 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for vosaroxin (EMEA-001450-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/785820/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2015-ema-decision-4-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-vosaroxin-emea-001450-pip01-13-m01_en.pdf"},
    {"id":"2820","name":"P/0012/2012: EMA decision of 24 January 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for recombinant\n\ndimer of 6 kD early secretory antigenic target / recombinant 10 kD culture...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/968339/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2012-ema-decision-24-january-2012-agreement-paediatric-investigation-plan-granting-waiver-recombinant-dimer-6-kd-early-secretory-antigenic-target-recombinant-10-kd-culture_en.pdf"},
    {"id":"2836","name":"P/56/2009: European Medicines Agency decision of 24 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for tapentadol hydrochloride (EMEA-000486-PIP01-08) in accordance with ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/161794/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-56-2009-european-medicines-agency-decision-24-march-2009-agreement-paediatric-investigation-plan-granting-deferral-tapentadol-hydrochloride-emea-000486-pip01-08-accordance_en.pdf"},
    {"id":"2837","name":"P/201/2011: EMA decision of 30 August 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for cilengitide\n\n(EMEA-000550-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/647363/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-201-2011-ema-decision-30-august-2011-agreement-paediatric-investigation-plan-granting-deferral-cilengitide-emea-000550-pip02-10_en.pdf"},
    {"id":"2874","name":"P/122/2009: European Medicines Agency decision of 15 June 2009 on the refusal of a product specific waiver for human autologous mesenchymal adult stem cells extracted from adipose tissue (EMEA-000519-PIP01-08) in accorda...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/347809/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-122-2009-european-medicines-agency-decision-15-june-2009-refusal-product-specific-waiver-human-autologous-mesenchymal-adult-stem-cells-extracted-adipose-tissue-emea-000519-pip01-08-accorda_en.pdf"},
    {"id":"2884","name":"P/0210/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for vemurafenib (Zelboraf), (EMEA-000978-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/513271/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-vemurafenib-zelboraf-emea-000978-pip01-10-m01_en.pdf"},
    {"id":"2891","name":"P/0155/2012: EMA decision of 24 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor (EMEA-\n\n000335-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/472129/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2012-ema-decision-24-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-emea-000335-pip01-08-m06_en.pdf"},
    {"id":"2897","name":"P/77/2011: EMA decision of 5 April 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ciclosporin (EMEA-000988-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-13T02:00:00Z","last_updated_date":"2011-05-13T02:00:00Z","reference_number":"EMA/242217/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-77-2011-ema-decision-5-april-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ciclosporin-emea-000988-pip01-10_en.pdf"},
    {"id":"2903","name":"P/262/2011: EMA decision of 28 October 2011 on the granting of a product specific waiver for temsirolimus (Torisel) (EMEA-000026-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T01:00:00Z","last_updated_date":"2011-11-29T01:00:00Z","reference_number":"EMA/846762/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-262-2011-ema-decision-28-october-2011-granting-product-specific-waiver-temsirolimus-torisel-emea-000026-pip02-11_en.pdf"},
    {"id":"2930","name":"P/0182/2013: EMA decision of 31 July on the acceptance of a modification of an agreed paediatric investigation plan for laquinimod (sodium) (EMEA-000972-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/376351/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2013-ema-decision-31-july-acceptance-modification-agreed-paediatric-investigation-plan-laquinimod-sodium-emea-000972-pip01-10-m03_en.pdf"},
    {"id":"2957","name":"P/167/2010: European Medicines Agency decision of 3 September 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human glutamic acid...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/477712/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-167-2010-european-medicines-agency-decision-3-september-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-glutamic-acid_en.pdf"},
    {"id":"2997","name":"P/0024/2014: EMA decision of 22 January 2014 on the granting of a product-specific waiver for caffeine / ibuprofen (EMEA-001537-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/12526/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2014-ema-decision-22-january-2014-granting-product-specific-waiver-caffeine-ibuprofen-emea-001537-pip01-13_en.pdf"},
    {"id":"3007","name":"P/0114/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for alogliptin (Vipidia), (EMEA-000496-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/284179/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0114-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-alogliptin-vipidia-emea-000496-pip01-08-m04_en.pdf"},
    {"id":"3010","name":"P/0034/2012: EMA decision of 3 February 2012 on the acceptance of a modification of an agreed paediatric investigation plan for inactivated type 1 poliovirus (Mahoney) / purified fimbriae types 2 and 3 (EMEA-000394-PIP01...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T14:30:00Z","last_updated_date":"2012-03-15T14:30:00Z","reference_number":"EMA/8478/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2012-ema-decision-3-february-2012-acceptance-modification-agreed-paediatric-investigation-plan-inactivated-type-1-poliovirus-mahoney-purified-fimbriae-types-2-3-emea-000394-pip01_en.pdf"},
    {"id":"3012","name":"P/0120/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for andexanet alfa,\n\n(EMEA-001902-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/194606/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-andexanet-alfa-emea-001902-pip01-15-m02_en.pdf"},
    {"id":"3022","name":"P/303/2011: EMA decision of 21 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for macitentan (EMEA-001032-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/982770/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-303-2011-ema-decision-21-december-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-macitentan-emea-001032-pip01-10_en.pdf"},
    {"id":"3033","name":"P/0219/2014: EMA decision of 3 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for enalapril (maleate) (EMEA-001241-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/468294/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2014-ema-decision-3-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-enalapril-maleate-emea-001241-pip02-13-m01_en.pdf"}    {"id":"3047","name":"P/0119/2012: EMA decision of 2 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for azithromycin (monohydrate), (EMEA-001145-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-09T14:00:00Z","last_updated_date":"2012-08-09T14:00:00Z","reference_number":"EMA/405266/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2012-ema-decision-2-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-azithromycin-monohydrate-emea-001145-pip01-10_en.pdf"},
    {"id":"3062","name":"P/0040/2014: EMA decision of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (EMEA-001119-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/797044/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2014-ema-decision-5-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-emea-001119-pip02-12-m01_en.pdf"},
    {"id":"3071","name":"P/0037/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir alafenamide (as fumarate) (Vemlidy) (EMEA-001584-PIP01-13-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T18:50:00Z","last_updated_date":"2018-04-27T18:50:00Z","reference_number":"EMA/848792/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-alafenamide-fumarate-vemlidy-emea-001584-pip01-13-m03_en.pdf"},
    {"id":"3074","name":"P/0279/2012: EMA decision of 21 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for lebrikizumab (EMEA-001053-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/717305/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2012-ema-decision-21-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-lebrikizumab-emea-001053-pip01-10-m01_en.pdf"},
    {"id":"3079","name":"P/0181/2016: EMA decision of of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for eltrombopag\n\n(Revolade), (EMEA-000170-PIP03-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:05:00Z","last_updated_date":"2016-09-22T16:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-eltrombopag-revolade-emea-000170-pip03-13-m01_en.pdf"},
    {"id":"3103","name":"P/0078/2013: European medicines agency decision of 27 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (EMEA-000332-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/101626/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2013-european-medicines-agency-decision-27-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-emea-000332-pip01-08-m06_en.pdf"},
    {"id":"3115","name":"P/331/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for aqueous allergen extract of grass pollen (EMEA-00096...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/815095/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-331-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aqueous-allergen-extract-grass-pollen-emea-00096_en.pdf"},
    {"id":"3118","name":"P/0027/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for patiromer calcium\n\n(EMEA-001720-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/34939/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-patiromer-calcium-emea-001720-pip01-14-m01_en.pdf"},
    {"id":"3144","name":"P/0241/2013: EMA decision of 24 September 2013 on the granting of a product specific waiver for ramipril / amlodipine (besilate) (EMEA-001471-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/496894/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2013-ema-decision-24-september-2013-granting-product-specific-waiver-ramipril-amlodipine-besilate-emea-001471-pip01-13_en.pdf"},
    {"id":"3164","name":"P/26/2011: EMA decision of 26 January 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for meropenem (EMEA-000898-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/30340/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-26-2011-ema-decision-26-january-2011-agreement-paediatric-investigation-plan-granting-waiver-meropenem-emea-000898-pip01-10-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"3210","name":"P/0292/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin\n\n(Forxiga), (EMEA-000694-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/693020/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-forxiga-emea-000694-pip01-09-m03_en.pdf"},
    {"id":"3219","name":"P/128/2011: EMA decision of 8 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for ipilimumab (EMEA-000117-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-13T02:00:00Z","last_updated_date":"2011-07-13T02:00:00Z","reference_number":"EMA/426558/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-128-2011-ema-decision-8-june-2011-agreement-paediatric-investigation-plan-granting-deferral-ipilimumab-emea-000117-pip02-10_en.pdf"},
    {"id":"3224","name":"P/0217/2017: EMA decision of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tocilizumab (RoActemra), (EMEA-000309-PIP04-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/458626/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2017-ema-decision-9-august-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tocilizumab-roactemra-emea-000309-pip04-17_en.pdf"},
    {"id":"3232","name":"P/0260/2015: EMA decision of 30 October 2015 on the granting of a product specific waiver for mogamulizumab (EMEA-001816-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-22T13:00:00Z","last_updated_date":"2015-12-22T13:00:00Z","reference_number":"EMA/624282/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2015-ema-decision-30-october-2015-granting-product-specific-waiver-mogamulizumab-emea-001816-pip01-15_en.pdf"},
    {"id":"3256","name":"P/0077/2016: EMA decision of 18 March 2016 on the granting of a product specific waiver for biotin (EMEA-001712-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/131679/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2016-ema-decision-18-march-2016-granting-product-specific-waiver-biotin-emea-001712-pip02-15_en.pdf"},
    {"id":"3269","name":"P/0316/2013: EMA decision of 19 December 2013 on the granting of a product specific waiver for acetylsalicylic acid / omeprazole (EMEA-001473-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-05T01:00:00Z","last_updated_date":"2014-02-05T01:00:00Z","reference_number":"EMA/693817/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2013-ema-decision-19-december-2013-granting-product-specific-waiver-acetylsalicylic-acid-omeprazole-emea-001473-pip01-13_en.pdf"},
    {"id":"3321","name":"P/0075/2015: EMA decision of 1 April 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for a derivative of 2-methyl-6-(5-methyl-3-phenyl-isoxazol-4...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-07T02:00:00Z","last_updated_date":"2015-05-07T02:00:00Z","reference_number":"EMA/160752/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2015-ema-decision-1-april-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-derivative-2-methyl-6-5-methyl-3-phenyl-isoxazol-4_en.pdf"},
    {"id":"3325","name":"P/0053/2015: EMA decision of 6 March 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for olipudase alfa (EMEA-001600-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-24T01:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/111412/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2015-ema-decision-6-march-2015-agreement-paediatric-investigation-plan-granting-deferral-olipudase-alfa-emea-001600-pip01-13_en.pdf"},
    {"id":"3331","name":"P/0215/2014: EMA decision of 3 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for insulin degludec / insulin aspart (Ryzodeg) (EMEA-000479-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/454352/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2014-ema-decision-3-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-insulin-degludec-insulin-aspart-ryzodeg-emea-000479-pip01-08-m02_en.pdf"},
    {"id":"3339","name":"P/0078/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for gemtuzumab linked to ozogamicin (EMEA-001733-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/131580/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-gemtuzumab-linked-ozogamicin-emea-001733-pip02-15_en.pdf"},
    {"id":"3342","name":"P/57/2011: EMA decision of 4 March 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for human coagulation factor X (EMEA-000971-PIP01-10) in accordance with Regulation (EC) No 19...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/78582/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-57-2011-ema-decision-4-march-2011-agreement-paediatric-investigation-plan-granting-deferral-human-coagulation-factor-x-emea-000971-pip01-10-accordance-regulation-ec-no-19_en.pdf"},
    {"id":"3344","name":"P/217/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for birch pollen extract, (EMEA-0008...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/629233/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-217-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-birch-pollen-extract-emea-0008_en.pdf"},
    {"id":"3366","name":"P/0221/2015: EMA decision of 2 October 2015 on the agreement of a paediatric investigation plan and on the granting of a waiver for adenovirus associated viral vector serotype 2 containing the human RPE65 gene (EMEA-0016...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-19T01:00:00Z","last_updated_date":"2015-11-19T01:00:00Z","reference_number":"EMA/603716/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2015-ema-decision-2-october-2015-agreement-paediatric-investigation-plan-granting-waiver-adenovirus-associated-viral-vector-serotype-2-containing-human-rpe65-gene-emea-0016_en.pdf"},
    {"id":"3372","name":"P/0197/2016: EMA decision of of 18 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for corifollitropin alfa\n\n(Elonva), (EMEA-000306-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:05:00Z","last_updated_date":"2016-09-22T16:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2016-ema-decision-18-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-corifollitropin-alfa-elonva-emea-000306-pip01-08-m03_en.pdf"},
    {"id":"3394","name":"P/33/2011: EMA decision of the 28 January on the agreement of a PIP and on the granting of a deferral and a waiver for (2S,3R,4R,5S,6R)-2-(4-Chloro-3-{3-[(S)-(tetrahydrofuran-3-yl)oxy]benzyl}-phenyl)-6-hydroxymethyltetra...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"EMA/35774/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-33-2011-ema-decision-28-january-agreement-pip-granting-deferral-waiver-2s3r4r5s6r-2-4-chloro-3-3-s-tetrahydrofuran-3-yloxybenzyl-phenyl-6-hydroxymethyltetra_en.pdf"},
    {"id":"3397","name":"P/0065/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline (fumarate) (Sirturo), (EMEA-000912-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/160743/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-bedaquiline-fumarate-sirturo-emea-000912-pip01-10-m02_en.pdf"},
    {"id":"3426","name":"P/0124/2013: EMA decision of 28 May 2013 on the acceptance of a modification of an agreed paediatric investigation plan for aztreonam (Cayston), (EMEA-000827-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-21T13:30:00Z","last_updated_date":"2013-06-21T13:30:00Z","reference_number":"EMA/248608/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2013-ema-decision-28-may-2013-acceptance-modification-agreed-paediatric-investigation-plan-aztreonam-cayston-emea-000827-pip01-09-m02_en.pdf"},
    {"id":"3438","name":"P/0029/2015: EMA decision of 30 January 2015 on the granting of a product specific waiver for lutetium [177 Lu] (chloride) (EMEA-001674-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/792665/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2015-ema-decision-30-january-2015-granting-product-specific-waiver-lutetium-177-lu-chloride-emea-001674-pip01-14_en.pdf"},
    {"id":"3475","name":"P/0026/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for humanised anti-IL-6 receptor (IL-6R) monoclonal antibody (EMEA-001625-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/22662/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-humanised-anti-il-6-receptor-il-6r-monoclonal-antibody-emea-001625-pip01-14-m01_en.pdf"},
    {"id":"3485","name":"P/0069/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / abacavir / lamivudine (Triumeq), (EMEA-001219-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/155305/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-abacavir-lamivudine-triumeq-emea-001219-pip01-11-m01_en.pdf"},
    {"id":"3486","name":"P/0168/2017: EMA decision of 3 July 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for omadacycline (EMEA-000560-PIP03-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/354131/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2017-ema-decision-3-july-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-omadacycline-emea-000560-pip03-15_en.pdf"},
    {"id":"3514","name":"P/0029/2012: EMA decision of 30 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for semuloparin sodium\n\n(EMEA-000562-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/931898/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2012-ema-decision-30-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-semuloparin-sodium-emea-000562-pip01-09-m01_en.pdf"},
    {"id":"3521","name":"P/0112/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor (Kalydeco) (EMEA-000335-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/355412/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-kalydeco-emea-000335-pip01-08-m10_en.pdf"},
    {"id":"3529","name":"P/13/2010 EMA decision of 22 January 2010 on the acceptance of a modification of an agreed Paediatric Investigation Plan for Human Papillomavirus type 6 L1 protein/Human Papillomavirus type 11 L1 protein/Hum...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/37131/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-13-2010-ema-decision-22-january-2010-acceptance-modification-agreed-paediatric-investigation-plan-human-papillomavirus-type-6-l1-protein-human-papillomavirus-type-11-l1-protein-hum_en.pdf"},
    {"id":"3552","name":"P/0087/2018: EMA decision of 16 March 2018 on the granting of a product specific waiver for Entinostat Polymorph B (EMEA-002272-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/75586/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2018-ema-decision-16-march-2018-granting-product-specific-waiver-entinostat-polymorph-b-emea-002272-pip01-17_en.pdf"},
    {"id":"3563","name":"P/0223/2015: EMA decision of 2 October 2015 on the granting of a product specific waiver for hydromorphone (hydrochloride) / naloxone (hydrochloride) (EMEA-001762-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-19T01:00:00Z","last_updated_date":"2015-11-19T01:00:00Z","reference_number":"EMA/603271/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2015-ema-decision-2-october-2015-granting-product-specific-waiver-hydromorphone-hydrochloride-naloxone-hydrochloride-emea-001762-pip01-15_en.pdf"},
    {"id":"3564","name":"P/0380/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for human normal\n\nimmunoglobulin (EMEA-001853-PIP01-15-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T16:03:00Z","last_updated_date":"2018-03-02T16:03:00Z","reference_number":"EMA/759103/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0380-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-001853-pip01-15-m01_en.pdf"},
    {"id":"3566","name":"P/203/2010: European Medicines Agency decision of 27 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dermatophagoides pteronyssinus a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/642983/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-203-2010-european-medicines-agency-decision-27-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dermatophagoides-pteronyssinus_en.pdf"},
    {"id":"3571","name":"P/202/2010: European Medicines Agency decision of 27 October 2010 on the acceptance of a modification of an agreed paediatric investigation plan for propranolol hydrochloride, (EMEA-000511-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-24T01:00:00Z","last_updated_date":"2010-11-24T01:00:00Z","reference_number":"EMA/650134/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-202-2010-european-medicines-agency-decision-27-october-2010-acceptance-modification-agreed-paediatric-investigation-plan-propranolol-hydrochloride-emea-000511-pip01-08-m02_en.pdf"},
    {"id":"3573","name":"P/0178/2012: EMA decision of 20 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for catridecacog (EMEA-\n\n000185-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/477706/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2012-ema-decision-20-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-catridecacog-emea-000185-pip01-08-m04_en.pdf"},
    {"id":"3576","name":"P/0359/2016: EMA decision of 21 December 2016\n\non the acceptance of a modification of an agreed paediatric investigation plan for estetrol/drospirenone (EMEA-001332-PIP01-12-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T12:18:00Z","last_updated_date":"2017-02-03T12:18:00Z","reference_number":"EMA/757965/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0359-2016-ema-decision-21-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-estetrol-drospirenone-emea-001332-pip01-12-m02_en.pdf"},
    {"id":"3593","name":"P/0059/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for saxagliptin (Onglyza) (EMEA-000200-PIP01-08-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/107875/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-saxagliptin-onglyza-emea-000200-pip01-08-m06_en.pdf"},
    {"id":"3609","name":"P/0271/2012: EMA decision of 20 November 2012 on the granting of a product-specific waiver for ezetimibe / rosuvastatin (EMEA-001344-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/646972/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2012-ema-decision-20-november-2012-granting-product-specific-waiver-ezetimibe-rosuvastatin-emea-001344-pip01-12_en.pdf"},
    {"id":"3613","name":"P/0296/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for sodium zirconium\n\ncyclosilicate (EMEA-001539-PIP01-13-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-20T16:17:00Z","last_updated_date":"2017-01-20T16:17:00Z","reference_number":"EMA/666520/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-sodium-zirconium-cyclosilicate-emea-001539-pip01-13-m01_en.pdf"},
    {"id":"3635","name":"P/0255/2014: EMA decision of 30 September 2014 on the agreement of a paediatric investigation plan and on the granting of a waiver for ibuprofen (sodium dihydrate), (EMEA-001599-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/519929/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2014-ema-decision-30-september-2014-agreement-paediatric-investigation-plan-granting-waiver-ibuprofen-sodium-dihydrate-emea-001599-pip01-13_en.pdf"},
    {"id":"3637","name":"P/0177/2017: EMA decision of 3 July 2017 on the granting of a product specific waiver for olmesartan medoxomil/amlodipine (besilate)/hydrochlorothiazide (EMEA-002104-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/382336/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2017-ema-decision-3-july-2017-granting-product-specific-waiver-olmesartan-medoxomil-amlodipine-besilate-hydrochlorothiazide-emea-002104-pip01-16_en.pdf"},
    {"id":"3645","name":"P/140/2009: European Medicines Agency decision of 15 July 2009 on the refusal of a Paediatric Investigation Plan and on the refusal of a deferral and on the granting of a waiver for estradiol valerate / dienogest (Qlaira...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/387209/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-140-2009-european-medicines-agency-decision-15-july-2009-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-estradiol-valerate-dienogest-qlaira_en.pdf"},
    {"id":"3650","name":"P/307/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for modified allergen extract of grass and mugwort polle...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/683319/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-307-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-grass-mugwort-polle_en.pdf"},
    {"id":"3655","name":"P/0260/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dabrafenib (mesilate) (Tafinlar), (EMEA-001147-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-25T17:00:00Z","last_updated_date":"2017-10-25T17:00:00Z","reference_number":"EMA/501662/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-dabrafenib-mesilate-tafinlar-emea-001147-pip01-11-m05_en.pdf"},
    {"id":"3684","name":"P/0302/2016: EMA decision of 4 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for birch pollen extract (Betula verrucosa) (EMEA-001879-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-10T01:00:00Z","last_updated_date":"2017-01-10T01:00:00Z","reference_number":"EMA/669787/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2016-ema-decision-4-november-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-birch-pollen-extract-betula-verrucosa-emea-001879_en.pdf"},
    {"id":"3685","name":"P/0249/2012: EMA decision of 23 October 2012 on the granting of a product-specific waiver for etarfolatide (EMEA-001322-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/587270/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2012-ema-decision-23-october-2012-granting-product-specific-waiver-etarfolatide-emea-001322-pip01-12_en.pdf"},
    {"id":"3694","name":"P/0197/2014: EMA decision of 8 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta, Bydureon), (EMEA-000689-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/409211/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2014-ema-decision-8-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-exenatide-byetta-bydureon-emea-000689-pip01-09-m05_en.pdf"},
    {"id":"3708","name":"P/0154/2015: EMA decision of 10 July 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for humanised anti-IL-6 receptor (IL-6R) monoclonal antibody...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-25T02:00:00Z","last_updated_date":"2015-08-25T02:00:00Z","reference_number":"EMA/382979/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2015-ema-decision-10-july-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-humanised-anti-il-6-receptor-il-6r-monoclonal-antibody_en.pdf"},
    {"id":"3710","name":"P/0288/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron\n\n(Betmiga), (EMEA-000597-PIP03-15-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T10:48:00Z","last_updated_date":"2017-01-23T10:48:00Z","reference_number":"EMA/666528/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip03-15-m02_en.pdf"},
    {"id":"3725","name":"P/0187/2013: EMA decision of 8 August 2013 on the acceptance of a modification of an agreed paediatric investigation plan for levofloxacin (hemihydrate) (EMEA-001211-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-09T18:00:00Z","last_updated_date":"2013-09-09T18:00:00Z","reference_number":"EMA/473134/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2013-ema-decision-8-august-2013-acceptance-modification-agreed-paediatric-investigation-plan-levofloxacin-hemihydrate-emea-001211-pip01-11-m01_en.pdf"},
    {"id":"3733","name":"P/0251/2012: EMA decision of 24 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for peginesatide (EMEA-000646-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/666263/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2012-ema-decision-24-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-peginesatide-emea-000646-pip01-09-m01_en.pdf"},
    {"id":"3762","name":"P/0251/2014: EMA decision of 30 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for sirukumab (EMEA-001043-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/519902/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2014-ema-decision-30-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-sirukumab-emea-001043-pip01-10-m01_en.pdf"},
    {"id":"3763","name":"P/0334/2017: EMA decision of 31 October 2017 on the granting of a product specific waiver for bempedoic acid / ezetimibe (EMEA-002200-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/666309/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2017-ema-decision-31-october-2017-granting-product-specific-waiver-bempedoic-acid-ezetimibe-emea-002200-pip01-17_en.pdf"},
    {"id":"3764","name":"P/0218/2016: EMA decision of 15 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for elobixibat (EMEA-\n\n001484-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/501683/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2016-ema-decision-15-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-elobixibat-emea-001484-pip01-13-m01_en.pdf"},
    {"id":"3767","name":"P/225/2010: European Medicines Agency decision of 29 October 2010 on the granting of a product specific waiver for 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl] amino]phenyl]amin...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/644826/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-225-2010-european-medicines-agency-decision-29-october-2010-granting-product-specific-waiver-1h-indole-6-carboxylic-acid-23-dihydro-3-4-methyl4-methyl-1-piperazinylacetyl-aminophenylamin_en.pdf"},
    {"id":"3768","name":"P/0232/2012: EMA decision of 5 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for pitavastatin (calcium) (Vezepra and associated names), (EMEA-000301-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T01:00:00Z","last_updated_date":"2012-11-23T01:00:00Z","reference_number":"EMA/626080/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2012-ema-decision-5-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-pitavastatin-calcium-vezepra-associated-names-emea-000301-pip01-08-m03_en.pdf"},
    {"id":"3781","name":"P/0015/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for terbinafine\n\n(hydrochloride) (EMEA-001259-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/38340/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-terbinafine-hydrochloride-emea-001259-pip02-13-m01_en.pdf"},
    {"id":"3806","name":"P/0076/2013: EMA decision of 26 March 2013 on the granting of a product-specific waiver for lutetium [177 Lu] (EMEA-001381-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/85722/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2013-ema-decision-26-march-2013-granting-product-specific-waiver-lutetium-177-lu-emea-001381-pip01-12_en.pdf"},
    {"id":"3807","name":"P/0144/2014: EMA decision of 13 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human monoclonal antibody to human interleukin-17A of the IgG1/kappa-class (AIN457)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/280412/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2014-ema-decision-13-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-monoclonal-antibody-human-interleukin-17a-igg1-kappa-class-ain457_en.pdf"},
    {"id":"3829","name":"P/129/2008: European Medicines Agency decision of  23 December 2008 on the application for product specific waiver for pirfenidone EMEA-000357-PIP01-08 in accordance with Regulation (EC) No 1901/2006 of the European Parl...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/664303/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-129-2008-european-medicines-agency-decision-23-december-2008-application-product-specific-waiver-pirfenidone-emea-000357-pip01-08-accordance-regulation-ec-no-1901-2006-european-parl_en.pdf"},
    {"id":"3846","name":"P/298/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pollen from dactylis glomerata, festuca pratensis, l...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/683426/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-298-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-dactylis-glomerata-festuca-pratensis-l_en.pdf"},
    {"id":"3855","name":"P/65/2008: European medicines agency decision of 15 August 2008 on the application for agreement of a Paediatric Investigation Plan for balaglitazone\n\n(EMEA-000106-PIP01-07), in accordance with Regulation (EC) No 1901/20...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/429922/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-65-2008-european-medicines-agency-decision-15-august-2008-application-agreement-paediatric-investigation-plan-balaglitazone-emea-000106-pip01-07-accordance-regulation-ec-no-1901-20_en.pdf"},
    {"id":"3868","name":"P/0021/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for nonacog gamma (Rixubis), (EMEA-001139-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/8664240/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-nonacog-gamma-rixubis-emea-001139-pip01-11-m02_en.pdf"},
    {"id":"3882","name":"P/0103/2014: EMA decision of 2 May 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for N-{2-(2,3-Difluorobenzylthio)-6-[(2R,3S)-3,4-dihydroxybut-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/232202/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2014-ema-decision-2-may-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-n-2-23-difluorobenzylthio-6-2r3s-34-dihydroxybut_en.pdf"},
    {"id":"3906","name":"P/153/2010: EMA decision of 27 August 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for rufinamide (Inovelon) (EMEA-000709-PIP01-09))","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/524353/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-153-2010-ema-decision-27-august-2010-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-rufinamide-inovelon-emea-000709-pip01-09_en.pdf"},
    {"id":"3907","name":"P/0132/2012: EMA decision of 4 July 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for tafluprost (Taflotan and associated names), (EMEA-001187-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-09T14:00:00Z","last_updated_date":"2012-08-09T14:00:00Z","reference_number":"EMA/414428/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2012-ema-decision-4-july-2012-agreement-paediatric-investigation-plan-granting-waiver-tafluprost-taflotan-associated-names-emea-001187-pip01-11_en.pdf"},
    {"id":"3924","name":"P/0095/2014: EMA decision of 7 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names and Tapen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/186577/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2014-ema-decision-7-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapen_en.pdf"},
    {"id":"3943","name":"P/0297/2017: EMA decision of 4 October 2017 on the granting of a product specific waiver for ibrutinib (Imbruvica) (EMEA-001397-PIP06-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T13:11:00Z","last_updated_date":"2018-02-12T13:11:00Z","reference_number":"EMA/635149/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2017-ema-decision-4-october-2017-granting-product-specific-waiver-ibrutinib-imbruvica-emea-001397-pip06-17_en.pdf"},
    {"id":"3956","name":"P/0236/2017: EMA decision of 9 August 2017 on the granting of a product specific waiver for recombinant humanized anti-alpha-synuclein IgG1\n\nmonoclonal antibody (EMEA-002137-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/434819/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2017-ema-decision-9-august-2017-granting-product-specific-waiver-recombinant-humanized-anti-alpha-synuclein-igg1-monoclonal-antibody-emea-002137-pip01-17_en.pdf"},
    {"id":"3976","name":"P/0170/2014: EMA decision of 9 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin, Januvia (EMEA-000470-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/392170/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2014-ema-decision-9-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-januvia-emea-000470-pip01-08-m08_en.pdf"},
    {"id":"3977","name":"P/276/2011: EMA decision of 25 November 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human normal immunoglobulin (EMEA-001110-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T12:15:00Z","last_updated_date":"2011-12-21T12:15:00Z","reference_number":"EMA/908420/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-276-2011-ema-decision-25-november-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-normal-immunoglobulin-emea-001110-pip01-10_en.pdf"},
    {"id":"3993","name":"P/34/2010: European Medicines Agency decision of 19 March 2010\n\non the acceptance of a modification of an agreed Paediatric Investigation Plan for rabeprazole (sodium) (Pariet and associated names) (EMEA-000055-PIP01-07-...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/168181/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-34-2010-european-medicines-agency-decision-19-march-2010-acceptance-modification-agreed-paediatric-investigation-plan-rabeprazole-sodium-pariet-associated-names-emea-000055-pip01-07_en.pdf"},
    {"id":"4001","name":"P/0199/2014: EMA decision of 8 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for deferasirox (Exjade), (EMEA-001103-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/439456/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2014-ema-decision-8-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-deferasirox-exjade-emea-001103-pip01-10-m01_en.pdf"},
    {"id":"4007","name":"P/0090/2013: EMA decision of 29 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for bosentan (Tracleer) (EMEA-000425-PIP02-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/203780/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2013-ema-decision-29-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-bosentan-tracleer-emea-000425-pip02-10-m04_en.pdf"},
    {"id":"4014","name":"P/0373/2017: EMA decision of 1 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for synthetic\n\ndouble-stranded siRNA oligonucleotide directed against hydroxyacid oxidase...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-05T15:26:00Z","last_updated_date":"2018-03-05T15:26:00Z","reference_number":"EMA/710110/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0373-2017-ema-decision-1-december-2017-agreement-paediatric-investigation-plan-granting-deferral-synthetic-double-stranded-sirna-oligonucleotide-directed-against-hydroxyacid-oxidase_en.pdf"},
    {"id":"4031","name":"P/0123/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for tasimelteon (EMEA-001531-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/284185/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-tasimelteon-emea-001531-pip01-13-m01_en.pdf"},
    {"id":"4035","name":"P/22/2008: European medicines agency decision of 16 May 2008 on the application for agreement of a Paediatric Investigation Plan for Docetaxel, Taxotere (EMEA-000029-PIP01-07) in accordance with Regulation (EC) No 1901/2...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-06-04T02:00:00Z","last_updated_date":"2008-06-04T02:00:00Z","reference_number":"EMEA/244977/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-22-2008-european-medicines-agency-decision-16-may-2008-application-agreement-paediatric-investigation-plan-docetaxel-taxotere-emea-000029-pip01-07-accordance-regulation-ec-no-1901-2_en.pdf"},
    {"id":"4049","name":"P/41/2012: EMA decision of 28 February 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for eliglustat (tartrate) (EMEA-000461-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/129490/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-41-2012-ema-decision-28-february-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eliglustat-tartrate-emea-000461-pip02-11_en.pdf"},
    {"id":"4066","name":"P/0269/2020 : EMA decision of 17 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for alemtuzumab (Lemtrada) (EMEA-001072-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-24T14:00:00Z","last_updated_date":"2021-06-24T14:00:00Z","reference_number":"EMA/366649/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2020-ema-decision-17-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-alemtuzumab-lemtrada-emea-001072-pip01-10-m04_en.pdf"},
    {"id":"4073","name":"P/49/2011: EMA decision of 4 March 2011 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (EMEA-000332-PIP01-08-M03), in accordance with Regulation (EC) No 1901/2006 of the E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-24T01:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/156014/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-49-2011-ema-decision-4-march-2011-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-emea-000332-pip01-08-m03-accordance-regulation-ec-no-1901-2006-e_en.pdf"},
    {"id":"4081","name":"P/158/2010: European Medicines Agency decision of 6 September 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral for ceftaroline fosamil, (EMEA-000769-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/559070/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-158-2010-european-medicines-agency-decision-6-september-2010-agreement-paediatric-investigation-plan-granting-deferral-ceftaroline-fosamil-emea-000769-pip01-09_en.pdf"},
    {"id":"4100","name":"P/0002/2015: EMA decision of 15 January 2015 of 15 January 2015\n\non the acceptance of a modification of an agreed paediatric investigation plan for daclatasvir (dihydrochloride) / asunaprevir / (1aR,12bS)-8-Cyclohexyl-N-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-17T01:00:00Z","last_updated_date":"2015-02-17T01:00:00Z","reference_number":"EMA/779625/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2015-ema-decision-15-january-2015-15-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-daclatasvir-dihydrochloride-asunaprevir-1ar12bs-8-cyclohexyl-n_en.pdf"},
    {"id":"4111","name":"P/228/2011: EMA decision of 28 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for split Influenza virus,\n\ninactivated, containing antigen: A/California/7/2009 (H1N1)v like s...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/698108/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-228-2011-ema-decision-28-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigen-california-7-2009-h1n1v-s_en.pdf"},
    {"id":"4129","name":"P/34/2011: EMA decision of 28 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for house dust mites allergen extract from Dermatophagoide...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/58433/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-34-2011-ema-decision-28-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-house-dust-mites-allergen-extract-dermatophagoide_en.pdf"},
    {"id":"4142","name":"P/0025/2015: EMA decision of 30 January 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for finerenone (EMEA-001623-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/792653/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2015-ema-decision-30-january-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-finerenone-emea-001623-pip01-14_en.pdf"},
    {"id":"4146","name":"P/260/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for Dermatophagoides pteronyssinus allergen extract, (EM...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/716651/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-260-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dermatophagoides-pteronyssinus-allergen-extract-em_en.pdf"},
    {"id":"4157","name":"P/34/2009: European Medicines Agency decision of 24 February 2009 on the granting of a product-specific waiver for pemetrexed disodium (Alimta) (EMEA-000126-PIP01-07) in accordance with Regulation (EC) No 1901/2006 of th...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/90603/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-34-2009-european-medicines-agency-decision-24-february-2009-granting-product-specific-waiver-pemetrexed-disodium-alimta-emea-000126-pip01-07-accordance-regulation-ec-no-1901-2006-th_en.pdf"},
    {"id":"4166","name":"P/0022/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dabrafenib (Tafinlar), (EMEA-001147-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/23029/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-dabrafenib-tafinlar-emea-001147-pip01-11-m03_en.pdf"},
    {"id":"4177","name":"P/0175/2014: EMA decision of 11 July 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obeticholic acid (6 alpha-ethylchenodeoxycholic acid), (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-31T12:00:00Z","last_updated_date":"2014-07-31T12:00:00Z","reference_number":"EMA/344720/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2014-ema-decision-11-july-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-obeticholic-acid-6-alpha-ethylchenodeoxycholic-acid_en.pdf"},
    {"id":"4191","name":"P/207/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for everolimus (Certican, Afinitor a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/656487/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-207-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-everolimus-certican-afinitor_en.pdf"},
    {"id":"4195","name":"P/105/2008: European Medicines Agency decision of 28 November 2008 on the application for agreement of a Paediatric Investigation Plan for liraglutide EMEA-000128-PIP01-07 in accordance with Regulation (EC) No 1901/2006 ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/625240/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-105-2008-european-medicines-agency-decision-28-november-2008-application-agreement-paediatric-investigation-plan-liraglutide-emea-000128-pip01-07-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"4200","name":"P/0206/2014: EMA decision of 8 August 2014 on the agreement of a paediatric investigation plan for captopril (EMEA-001544-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/392193/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2014-ema-decision-8-august-2014-agreement-paediatric-investigation-plan-captopril-emea-001544-pip01-13_en.pdf"},
    {"id":"4204","name":"P/100/2011: EMA decision of 11 April 2011 on the acceptance of a modification of an agreed paediatric investigation plan for cinacalcet hydrochloride (Mimpara), (EMEA-000078-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/289139/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-100-2011-ema-decision-11-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-cinacalcet-hydrochloride-mimpara-emea-000078-pip01-07-m02_en.pdf"},
    {"id":"4236","name":"P/0164/2014: EMA decision of 25 June 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for expanded autologous bone marrow-derived osteoblastic cel...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-31T12:00:00Z","last_updated_date":"2014-07-31T12:00:00Z","reference_number":"EMA/268706/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2014-ema-decision-25-june-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-expanded-autologous-bone-marrow-derived-osteoblastic-cel_en.pdf"},
    {"id":"4241","name":"P/251/2011: EMA decision of 25 October 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant\n\nfusion protein linking human coagulation factor IX with human albumin (EM...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T01:00:00Z","last_updated_date":"2011-11-29T01:00:00Z","reference_number":"EMA/693940/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-251-2011-ema-decision-25-october-2011-agreement-paediatric-investigation-plan-granting-deferral-recombinant-fusion-protein-linking-human-coagulation-factor-ix-human-albumin-em_en.pdf"}    {"id":"4245","name":"P/0059/2012: EMA decision of 26 March 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for rubidium (82Rb) chloride (EMEA-000882-PIP03-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"EMA/108383/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2012-ema-decision-26-march-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rubidium-82rb-chloride-emea-000882-pip03-11_en.pdf"},
    {"id":"4277","name":"P/41/2011: EMA decision of 7 February 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mipomersen (sodium) (EMEA-000928-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2011-03-08T01:00:00Z","reference_number":"EMA/85088/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-41-2011-ema-decision-7-february-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mipomersen-sodium-emea-000928-pip01-10_en.pdf"},
    {"id":"4296","name":"P/0051/2014: European Medicines Agency decision of 7 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for citric acid (as citric acid anhydr...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/45733/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2014-european-medicines-agency-decision-7-march-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-citric-acid-citric-acid-anhydr_en.pdf"},
    {"id":"4297","name":"P/195/2009: European Medicines Agency decision of 7 October 2009 on the granting of a product specific waiver for pegaptanib sodium, Macugen (EMEA-000611-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/604653/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-195-2009-european-medicines-agency-decision-7-october-2009-granting-product-specific-waiver-pegaptanib-sodium-macugen-emea-000611-pip01-09-accordance-regulation-ec-no-1901-2006-e_en.pdf"},
    {"id":"4305","name":"P/0275/2016: EMA decision of 7 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for peanut flour\n\n(EMEA-001734-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/632101/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2016-ema-decision-7-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-peanut-flour-emea-001734-pip01-14-m01_en.pdf"},
    {"id":"4308","name":"P/0242/2014: EMA decision of 29 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for alogliptin (Vipidia), (EMEA-000496-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/527086/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2014-ema-decision-29-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-alogliptin-vipidia-emea-000496-pip01-08-m03_en.pdf"},
    {"id":"4313","name":"P/0098/2013: EMA decision of 29 April 2013 on the granting of a product-specific waiver for chlormethine (EMEA-001392-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/201938/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2013-ema-decision-29-april-2013-granting-product-specific-waiver-chlormethine-emea-001392-pip01-12_en.pdf"},
    {"id":"4316","name":"P/0190/2016: EMA decision of of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for regorafenib\n\n(Stivarga), (EMEA-001178-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:14:00Z","last_updated_date":"2016-09-22T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-regorafenib-stivarga-emea-001178-pip01-11-m02_en.pdf"},
    {"id":"4321","name":"P/0036/2013: EMA decision of 27 February 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for darunavir / cobicistat (EMEA-001280-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/24564/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2013-ema-decision-27-february-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-darunavir-cobicistat-emea-001280-pip01-12_en.pdf"},
    {"id":"4330","name":"P/0304/2016: EMA decision of 4 November 2016 on the granting of a product specific waiver for perindopril / amlodipine (EMEA-001968-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-10T01:00:00Z","last_updated_date":"2017-01-10T01:00:00Z","reference_number":"EMA/639658/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2016-ema-decision-4-november-2016-granting-product-specific-waiver-perindopril-amlodipine-emea-001968-pip01-16_en.pdf"},
    {"id":"4357","name":"P/0086/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Victoza, Saxenda) (EMEA-000128-PIP02-09-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/281883/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-victoza-saxenda-emea-000128-pip02-09-m01_en.pdf"},
    {"id":"4358","name":"P/4/2010: European Medicines Agency decision of 25 January 2010on the granting of a product specific waiver for Larvae of Lucilia sericata (EMEA-000714-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/6638/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-4-2010-european-medicines-agency-decision-25-january-2010on-granting-product-specific-waiver-larvae-lucilia-sericata-emea-000714-pip01-09-accordance-regulation-ec-no-1901-2006-e_en.pdf"},
    {"id":"4368","name":"P/168/2011: EMA decision of 8 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for aprepitant (Emend),\n\n(EMEA-000144-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/387100/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-168-2011-ema-decision-8-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-aprepitant-emend-emea-000144-pip01-07-m02_en.pdf"},
    {"id":"4388","name":"P/0317/2014: EMA decision of 11 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for vedolizumab (Entyvio) (EMEA-000645-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-22T01:00:00Z","reference_number":"EMA/719224/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2014-ema-decision-11-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-vedolizumab-entyvio-emea-000645-pip01-09-m02_en.pdf"},
    {"id":"4415","name":"P/0159/2012: EMA decision of 25 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for nonacog alfa, (EMEA-001139-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/443546/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2012-ema-decision-25-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-nonacog-alfa-emea-001139-pip01-11-m01_en.pdf"},
    {"id":"4417","name":"P/0342/2014: EMA decision of 12 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for drisapersen (EMEA-000746-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-22T01:00:00Z","reference_number":"EMA/737996/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0342-2014-ema-decision-12-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-drisapersen-emea-000746-pip01-09-m03_en.pdf"},
    {"id":"4437","name":"P/0239/2012: EMA decision of 22 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for cobicistat (EMEA-000969-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/636901/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2012-ema-decision-22-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-cobicistat-emea-000969-pip01-10-m01_en.pdf"},
    {"id":"4456","name":"P/0149/2013: EMA decision of 3 July 2013 on the granting of a product-specific waiver for ibrutinib (EMEA-001397-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-13T17:30:00Z","last_updated_date":"2013-08-13T17:30:00Z","reference_number":"EMA/311887/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2013-ema-decision-3-july-2013-granting-product-specific-waiver-ibrutinib-emea-001397-pip01-12_en.pdf"},
    {"id":"4462","name":"P/0183/2014: EMA decision of 24 July 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (S)-Pyrrolidine-2-carboxylic acid compound (EMEA-001527-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/415156/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2014-ema-decision-24-july-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-s-pyrrolidine-2-carboxylic-acid-compound-emea-001527_en.pdf"},
    {"id":"4487","name":"P/0280/2012: EMA decision of 21 November on the agreement of a paediatric investigation plan and on the granting of a deferral for tazobactam /\n\nceftolozane (EMEA-001142-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-07T01:00:00Z","last_updated_date":"2013-01-07T01:00:00Z","reference_number":"EMA/710289/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2012-ema-decision-21-november-agreement-paediatric-investigation-plan-granting-deferral-tazobactam-ceftolozane-emea-001142-pip01-11_en.pdf"},
    {"id":"4533","name":"P/0136/2014: EMA decision of 11 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for fibrinogen (human plasma-derived), (EMEA-000457-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/319531/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2014-ema-decision-11-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-fibrinogen-human-plasma-derived-emea-000457-pip02-10-m02_en.pdf"},
    {"id":"4543","name":"P/0329/2017: EMA decision of 30 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for ligelizumab (EMEA-001811-PIP02-15)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T10:22:00Z","last_updated_date":"2018-02-13T10:22:00Z","reference_number":"EMA/654970/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0329-2017-ema-decision-30-october-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ligelizumab-emea-001811-pip02-15_en.pdf"},
    {"id":"4556","name":"P/0020/2015: EMA decision of 30 January 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for roxadustat (EMEA-001557-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/792661/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2015-ema-decision-30-january-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-roxadustat-emea-001557-pip01-13_en.pdf"},
    {"id":"4560","name":"P/0262/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil\n\nfumarate) (Viread), (EMEA-000533-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-25T17:00:00Z","last_updated_date":"2017-10-25T17:00:00Z","reference_number":"EMA/552300/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-fumarate-viread-emea-000533-pip01-08-m07_en.pdf"},
    {"id":"4562","name":"P/0197/2013: EMA decision of 2 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for eslicarbazepine (acetate) (Zebinix), (EMEA-000696-PIP02-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/483644/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2013-ema-decision-2-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-eslicarbazepine-acetate-zebinix-emea-000696-pip02-10-m04_en.pdf"},
    {"id":"4608","name":"P/0343/2016: EMA decision of 2 December 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant\n\nFusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP; C...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/758347/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0343-2016-ema-decision-2-december-2016-agreement-paediatric-investigation-plan-granting-deferral-recombinant-fusion-protein-linking-coagulation-factor-viia-albumin-rviia-fp-c_en.pdf"},
    {"id":"4616","name":"P/0242/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tilmanocept\n\n(Lymphoseek), (EMEA-001255-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T17:00:00Z","last_updated_date":"2017-10-26T17:00:00Z","reference_number":"EMA/507355/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-tilmanocept-lymphoseek-emea-001255-pip01-11-m02_en.pdf"},
    {"id":"4643","name":"P/0022/2015: EMA decision of 30 January 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for grazoprevir (EMEA-001602-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/779740/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2015-ema-decision-30-january-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-grazoprevir-emea-001602-pip01-13_en.pdf"},
    {"id":"4649","name":"P/311/2011: EMA decision of 22 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for maraviroc (Celsentri), (EMEA-000020-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/931177/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-311-2011-ema-decision-22-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-maraviroc-celsentri-emea-000020-pip01-07-m02_en.pdf"},
    {"id":"4660","name":"P/0144/2012: EMA decision of 23 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for lopinavir / ritonavir (Kaletra) (EMEA-001005-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/451374/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2012-ema-decision-23-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-lopinavir-ritonavir-kaletra-emea-001005-pip01-10-m01_en.pdf"},
    {"id":"4668","name":"P/0265/2016: EMA decision of 5 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for human recombinant\n\nIgG1 monoclonal antibody targeting fibroblast growth factor 23 (KRN23) (EM...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/576578/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2016-ema-decision-5-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-human-recombinant-igg1-monoclonal-antibody-targeting-fibroblast-growth-factor-23-krn23-em_en.pdf"},
    {"id":"4672","name":"P/0018/2013: EMA decision of 31 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil fumarate) (Viread), (EMEA-000533-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-08T12:00:00Z","last_updated_date":"2013-04-08T12:00:00Z","reference_number":"EMA/24109/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2013-ema-decision-31-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-fumarate-viread-emea-000533-pip01-08-m04_en.pdf"},
    {"id":"4678","name":"P/55/2011: EMA decision of 4 March 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for (1R,2S)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta phenyl-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/155252/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-55-2011-ema-decision-4-march-2011-agreement-paediatric-investigation-plan-granting-deferral-1r2s-6-bromo-alpha-2-dimethylaminoethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl_en.pdf"},
    {"id":"4684","name":"P/6/2008: European medicines agency decision of 1 February 2008 on the application for product specific waiver for Panobinostat as panobinostat lactate salt EMEA-000097-PIP01-07 in accordance with Regulation (EC) No 1901...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-01-15T01:00:00Z","last_updated_date":"2008-01-15T01:00:00Z","reference_number":"EMEA/43569/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-6-2008-european-medicines-agency-decision-1-february-2008-application-product-specific-waiver-panobinostat-panobinostat-lactate-salt-emea-000097-pip01-07-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"4692","name":"P/0162/2014: EMA decision of 13 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira), (EMEA-000366-PIP02-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/340720/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2014-ema-decision-13-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip02-09-m03_en.pdf"},
    {"id":"4705","name":"P/0363/2016: EMA decision of 21 December 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for\n\ndipalmitoylphosphatidylcholine / 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol so...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/788583/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0363-2016-ema-decision-21-december-2016-agreement-paediatric-investigation-plan-granting-waiver-dipalmitoylphosphatidylcholine-1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol-so_en.pdf"},
    {"id":"4710","name":"P/0054/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for encorafenib (EMEA-001588-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/133091/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-deferral-encorafenib-emea-001588-pip01-13_en.pdf"},
    {"id":"4725","name":"P/81/2011: EMA decision of 6 April 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ivabradine\n\nhydrochloride (Procoralan) (EMEA-000628-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/220941/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-81-2011-ema-decision-6-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-ivabradine-hydrochloride-procoralan-emea-000628-pip01-09-m01_en.pdf"},
    {"id":"4735","name":"P/0037/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir alafenamide (as fumarate) (Vemlidy), (EMEA-001584-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"EMA/848792/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-alafenamide-fumarate-vemlidy-emea-001584-pip01-13-m03_en.pdf-0"},
    {"id":"4767","name":"P/209/2009: European Medicines Agency decision of 30 October 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for esomeprazole sodium, esomeprazole magnesium trihydrate (Nexium and asso...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/688217/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-209-2009-european-medicines-agency-decision-30-october-2009-acceptance-modification-agreed-paediatric-investigation-plan-esomeprazole-sodium-esomeprazole-magnesium-trihydrate-nexium-asso_en.pdf"},
    {"id":"4777","name":"P/271/2011: EMA decision of 28 October 2011 on the granting of a product specific waiver for (2S,3R,4R,5S,6R)-2-(4-chloro-3-{3-[(S)-(tetrahydrofuran-3-yl)oxy]-benzyl}-phenyl)-6-hydroxymethyltetrahydro-pyran-3,4,5-triol /...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T01:00:00Z","last_updated_date":"2011-11-29T01:00:00Z","reference_number":"EMA/774939/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-271-2011-ema-decision-28-october-2011-granting-product-specific-waiver-2s3r4r5s6r-2-4-chloro-3-3-s-tetrahydrofuran-3-yloxy-benzyl-phenyl-6-hydroxymethyltetrahydro-pyran-345-triol_en.pdf"},
    {"id":"4786","name":"P/0181/2013: EMA decision of 31 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (Colobreathe), (EMEA-000176-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/419466/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2013-ema-decision-31-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-colistimethate-sodium-colobreathe-emea-000176-pip01-07-m04_en.pdf"},
    {"id":"4792","name":"P/0063/2014: EMA decision of 7 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for fidaxomicin (Dificlir) (EMEA-000636-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/121846/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2014-ema-decision-7-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-fidaxomicin-dificlir-emea-000636-pip01-09-m02_en.pdf"},
    {"id":"4804","name":"P/0096/2014: EMA decision of 7 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names and Tapen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/186585/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2014-ema-decision-7-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapen_en.pdf"},
    {"id":"4807","name":"P/118/2008: European Medicines Agency decision of 1 December 2008 on the application for product specific waiver ibuprofen, diphenhydramine hydrochloride (EMEA-000220-PIP01-08) in accordance with Regulation (EC) No 1901/...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/623766/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-118-2008-european-medicines-agency-decision-1-december-2008-application-product-specific-waiver-ibuprofen-diphenhydramine-hydrochloride-emea-000220-pip01-08-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"4811","name":"P/321/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of birch pollen (EMEA-00094...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/697309/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-321-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-birch-pollen-emea-00094_en.pdf"},
    {"id":"4834","name":"P/46/2010: European Medicines Agency decision of 31 March 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Insulin degludec / Insulin aspart (...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/190440/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-46-2010-european-medicines-agency-decision-31-march-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-insulin-degludec-insulin-aspart_en.pdf"},
    {"id":"4863","name":"P/0093/2016: EMA decision of 23 March 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for octenidine (dihydrochloride) (EMEA-001514-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/199478/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2016-ema-decision-23-march-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-octenidine-dihydrochloride-emea-001514-pip01-13_en.pdf"},
    {"id":"4867","name":"P/0334/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (EMEA-\n\n001441-PIP01-13-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T13:11:00Z","last_updated_date":"2017-02-03T13:11:00Z","reference_number":"EMA/756858/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-semaglutide-emea-001441-pip01-13-m01_en.pdf"},
    {"id":"4895","name":"P/0057/2014: European Medicines Agency decision of 6 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for herpes simplex 1 virus thymidine kinase and truncated low affinity...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/111582/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2014-european-medicines-agency-decision-6-march-2014-agreement-paediatric-investigation-plan-granting-deferral-herpes-simplex-1-virus-thymidine-kinase-truncated-low-affinity_en.pdf"},
    {"id":"4919","name":"P/0004/2015: EMA decision of 30 January 2015 on the granting of a product specific waiver for everolimus (Certican and associated names), (EMEA-000019-PIP11-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/792666/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2015-ema-decision-30-january-2015-granting-product-specific-waiver-everolimus-certican-associated-names-emea-000019-pip11-14_en.pdf"},
    {"id":"4931","name":"P/0100/2012: EMA decision of 30 May 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for anti-BAFF monoclonal antibody (LY2127399) (EMEA-000802-P...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T18:00:00Z","last_updated_date":"2012-06-25T18:00:00Z","reference_number":"EMA/304286/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2012-ema-decision-30-may-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-baff-monoclonal-antibody-ly2127399-emea-000802-p_en.pdf"},
    {"id":"4939","name":"P/0012/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for melatonin (Circadin), (EMEA-000440-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/794178/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-melatonin-circadin-emea-000440-pip02-11-m02_en.pdf"},
    {"id":"4942","name":"P/17/2009: European Medicines Agency decision of 27 January 2009 on the granting of a product-specific waiver for raltitrexed (Tomudex), EMEA-000400-PIP01-08, in accordance with Regulation (EC) No 1901/2006 of the Europe...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/29859/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-17-2009-european-medicines-agency-decision-27-january-2009-granting-product-specific-waiver-raltitrexed-tomudex-emea-000400-pip01-08-accordance-regulation-ec-no-1901-2006-europe_en.pdf"},
    {"id":"4944","name":"P/0013/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (EMEA-000576-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/43932/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-emea-000576-pip01-09-m05_en.pdf"},
    {"id":"4950","name":"P/0282/2014: EMA decision of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (EMEA-001119-PIP02-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-10T01:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"EMA/605276/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2014-ema-decision-28-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-emea-001119-pip02-12-m02_en.pdf"},
    {"id":"4952","name":"P/0006/2018: EMA decision of 19 January 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for gilteritinib (as fumarate) (EMEA-002064-PIP01-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T02:00:00Z","last_updated_date":"2018-04-17T02:00:00Z","reference_number":"EMA/850789/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2018-ema-decision-19-january-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-gilteritinib-fumarate-emea-002064-pip01-16_en.pdf"},
    {"id":"4974","name":"P/0033/2014: European Medicines Agency decision of 4 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for treosulfan (EMEA-000883-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-03-20T01:00:00Z","last_updated_date":"2014-03-20T01:00:00Z","reference_number":"EMA/53188/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2014-european-medicines-agency-decision-4-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-treosulfan-emea-000883-pip01-10-m02_en.pdf"},
    {"id":"4985","name":"P/231/2011: EMA decision of 20 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for coagulation factor IX (recombinant) (EMEA-000661-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/759480/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-231-2011-ema-decision-20-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-coagulation-factor-ix-recombinant-emea-000661-pip01-09-m04_en.pdf"},
    {"id":"5002","name":"P/92/2010: European medicines agency decision of 2 June 2010\n\non the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (EMEA-000117-PIP01-07-M01) in accordance with Regulation (EC) No...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-07T00:00:00Z","last_updated_date":"2010-07-28T01:00:00Z","reference_number":"EMA/337445/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-92-2010-european-medicines-agency-decision-2-june-2010-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-emea-000117-pip01-07-m01-accordance-regulation-ec-no_en.pdf"},
    {"id":"5030","name":"P/109/2008: European Medicines Agency decision of 1 December 2008 on the application for agreement of a Paediatric Investigation Plan for maraviroc (CELSENTRI), EMEA-000020-PIP01-07, in accordance with Regulation (EC) No...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/624645/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-109-2008-european-medicines-agency-decision-1-december-2008-application-agreement-paediatric-investigation-plan-maraviroc-celsentri-emea-000020-pip01-07-accordance-regulation-ec-no_en.pdf"},
    {"id":"5038","name":"P/0029/2016: EMA decision of 29 January 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for eteplirsen (EMEA-001722-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/866546/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2016-ema-decision-29-january-2016-agreement-paediatric-investigation-plan-granting-deferral-eteplirsen-emea-001722-pip01-14_en.pdf"},
    {"id":"5043","name":"P/0097/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human\n\nN-acetylglucosaminidase (rhNAGLU) (EMEA-001653-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/178290/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-n-acetylglucosaminidase-rhnaglu-emea-001653-pip01-14-m02_en.pdf"},
    {"id":"5044","name":"P/0243/2016: EMA decision of 9 September 2016 on the granting of a product specific waiver for macitentan / tadalafil (EMEA-001961-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/576566/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2016-ema-decision-9-september-2016-granting-product-specific-waiver-macitentan-tadalafil-emea-001961-pip01-16_en.pdf"},
    {"id":"5065","name":"P/0234/2012: EMA decision of 12 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus type A, H1N1 / influenza virus type A, H3N2 / influenza virus type B, Yamaga...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/641295/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2012-ema-decision-12-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-type-h1n1-influenza-virus-type-h3n2-influenza-virus-type-b-yamaga_en.pdf"},
    {"id":"5083","name":"P/0284/2014: EMA decision of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for turoctocog alfa pego (EMEA-001174-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-10T01:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"EMA/590080/2014 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2014-ema-decision-28-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-turoctocog-alfa-pego-emea-001174-pip02-12-m01_en.pdf"},
    {"id":"5096","name":"P/292/2011: EMA decision of 2 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for afamelanotide (EMEA-000737-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/927100/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-292-2011-ema-decision-2-december-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-afamelanotide-emea-000737-pip02-11_en.pdf"},
    {"id":"5148","name":"P/0199/2013: EMA decision of 2 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for L-cysteinyl-L-prolyl-L-alanyl-L-valyl-L-lysyl-L-arginyl-L-aspartyl-L-valyl-L-aspartyl-L-leu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/483678/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2013-ema-decision-2-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-l-cysteinyl-l-prolyl-l-alanyl-l-valyl-l-lysyl-l-arginyl-l-aspartyl-l-valyl-l-aspartyl-l-leu_en.pdf"},
    {"id":"5151","name":"P/0014/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for blinatumomab (EMEA-000574-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/23025/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-blinatumomab-emea-000574-pip02-12-m01_en.pdf"},
    {"id":"5152","name":"P/0351/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for teduglutide\n\n(Revestive), (EMEA-000482-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/709764/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0351-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-teduglutide-revestive-emea-000482-pip01-08-m04_en.pdf"},
    {"id":"5155","name":"P/0086/2014: EMA decision of 4 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for laquinimod (sodium) (EMEA-000972-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-15T02:00:00Z","last_updated_date":"2014-05-15T02:00:00Z","reference_number":"EMA/123754/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2014-ema-decision-4-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-laquinimod-sodium-emea-000972-pip01-10-m04_en.pdf"},
    {"id":"5159","name":"P/0027/2018: EMA decision of 5 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for midostaurin (Rydapt), (EMEA-000780-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/33814/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2018-ema-decision-5-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-midostaurin-rydapt-emea-000780-pip01-09-m04_en.pdf"},
    {"id":"5173","name":"P/0024/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for trametinib (Mekinist), (EMEA-001177-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/1364/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-trametinib-mekinist-emea-001177-pip01-11-m02_en.pdf"},
    {"id":"5176","name":"P/233/2009: European Medicines Agency decision of 27 November 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for asenapine maleate (EMEA-000228-PIP01-08-M01) in accordance with Regula...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:00:00Z","last_updated_date":"2009-12-23T00:00:00Z","reference_number":"EMEA/695125/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-233-2009-european-medicines-agency-decision-27-november-2009-acceptance-modification-agreed-paediatric-investigation-plan-asenapine-maleate-emea-000228-pip01-08-m01-accordance-regula_en.pdf"},
    {"id":"5213","name":"P/0078/2014: EMA decision of 2 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for trametinib (dimethyl sulfoxide) (EMEA-001177-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-15T02:00:00Z","last_updated_date":"2014-05-15T02:00:00Z","reference_number":"EMA/121752/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2014-ema-decision-2-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-trametinib-dimethyl-sulfoxide-emea-001177-pip01-11-m01_en.pdf"},
    {"id":"5226","name":"P/0134/2017: EMA decision of 7 June 2017 on the refusal of a paediatric investigation plan and on the granting of a waiver for polihexanide\n\n(PHMB) (EMEA-002053-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/307704/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2017-ema-decision-7-june-2017-refusal-paediatric-investigation-plan-granting-waiver-polihexanide-phmb-emea-002053-pip01-16_en.pdf"},
    {"id":"5260","name":"P/0348/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sarilumab (Kevzara)\n\n(EMEA-001045-PIP01-10-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T11:48:00Z","last_updated_date":"2018-03-02T11:48:00Z","reference_number":"EMA/704026/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0348-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-sarilumab-kevzara-emea-001045-pip01-10-m01_en.pdf"},
    {"id":"5268","name":"P/312/2011: EMA decision of 22 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for eltrombopag\n\n(Revolade), (EMEA-000170-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/982073/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-312-2011-ema-decision-22-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-eltrombopag-revolade-emea-000170-pip02-10-m01_en.pdf"},
    {"id":"5274","name":"P/0192/2012: EMA decision of 24 August 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for N-[6-(cis-2,6-Dimethylmorpholin-4-yl)pyridine-3-yl]-2...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T11:45:00Z","last_updated_date":"2012-09-18T11:45:00Z","reference_number":"EMA/540970/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2012-ema-decision-24-august-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-n-6-cis-26-dimethylmorpholin-4-ylpyridine-3-yl-2_en.pdf"},
    {"id":"5299","name":"P/0080/2015: EMA decision of 10 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for belatacept (Nulojix), (EMEA-000157-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-19T02:00:00Z","last_updated_date":"2015-05-19T02:00:00Z","reference_number":"EMA/212021/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2015-ema-decision-10-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-belatacept-nulojix-emea-000157-pip01-07-m02_en.pdf"},
    {"id":"5319","name":"P/0058/2014: European Medicines Agency decision of 6 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-human interleukin 23 p19 huma...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/112332/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2014-european-medicines-agency-decision-6-march-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-human-interleukin-23-p19-huma_en.pdf"},
    {"id":"5326","name":"P/245/2009: European Medicines Agency Decision of 27 November 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for velaglucerase alfa (EMEA-000556...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:09:21Z","last_updated_date":"2009-12-23T00:09:21Z","reference_number":"EMEA/755592/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-245-2009-european-medicines-agency-decision-27-november-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-velaglucerase-alfa-emea-000556_en.pdf"},
    {"id":"5329","name":"P/207/2009: European Medicines Agency decision of 30 October 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for eltrombopag (EMEA-000170-PIP01-07-M02) in accordance with Regulation (E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/614741/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-207-2009-european-medicines-agency-decision-30-october-2009-acceptance-modification-agreed-paediatric-investigation-plan-eltrombopag-emea-000170-pip01-07-m02-accordance-regulation-e_en.pdf"},
    {"id":"5330","name":"P/0080/2014: EMA decision of 2 April 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti proprotein convertase subtilisin kexin type 9 human...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2014-05-13T02:00:00Z","reference_number":"EMA/52874/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2014-ema-decision-2-april-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-proprotein-convertase-subtilisin-kexin-type-9-human_en.pdf"},
    {"id":"5346","name":"P/0096/2015: EMA decision of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for simtuzumab (EMEA-001511-PIP02-13 )","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/281873/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2015-ema-decision-8-may-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-simtuzumab-emea-001511-pip02-13_en.pdf"},
    {"id":"5366","name":"P/177/2011: EMA decision of 26 August 2011 on the granting of a product specific waiver for vildagliptin (Galvus), (EMEA-000700-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/691227/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-177-2011-ema-decision-26-august-2011-granting-product-specific-waiver-vildagliptin-galvus-emea-000700-pip02-10_en.pdf"},
    {"id":"5419","name":"P/0287/2014: EMA decision of 28 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sotagliflozin (EMEA-001517-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-04T01:00:00Z","last_updated_date":"2014-12-04T01:00:00Z","reference_number":"EMA/605313/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2014-ema-decision-28-october-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sotagliflozin-emea-001517-pip01-13_en.pdf"},
    {"id":"5448","name":"P/0229/2014: EMA decision of 5 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tadalafil (Adcirca, Cialis) (EMEA-000452-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/454815/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2014-ema-decision-5-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-tadalafil-adcirca-cialis-emea-000452-pip02-10-m02_en.pdf"},
    {"id":"5457","name":"P/0087/2016: EMA decision of 18 March 2016 on the granting of a product specific waiver for testosterone (EMEA-001873-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/136748/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2016-ema-decision-18-march-2016-granting-product-specific-waiver-testosterone-emea-001873-pip01-15_en.pdf"},
    {"id":"5480","name":"P110/2008: EUROPEAN MEDICINES AGENCY DECISION of 1 December 2008 on application for agreement of Paediatric Investigation Plan for TGp1PTH1-34 L-Asparaginyl-L-glutaminyl-L-glutamyl-L-glutaminyl-L-valy1-L-seryl-L-prolyl-L...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/620766/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p110-2008-european-medicines-agency-decision-1-december-2008-application-agreement-paediatric-investigation-plan-tgp1pth1-34-l-asparaginyl-l-glutaminyl-l-glutamyl-l-glutaminyl-l-valy1-l-seryl-l-prolyl_en.pdf"},
    {"id":"5490","name":"P/0045/2014: European Medicines Agency decision of 7 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ustekinumab (Stelara) (EMEA-000311...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/58229/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2014-european-medicines-agency-decision-7-march-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ustekinumab-stelara-emea-000311_en.pdf"},
    {"id":"5524","name":"P/0174/2017: EMA decision of 3 July 2017 on the granting of a product-specific waiver for miridesap (EMEA-002111-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/354128/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2017-ema-decision-3-july-2017-granting-product-specific-waiver-miridesap-emea-002111-pip01-17_en.pdf"},
    {"id":"5548","name":"P/0241/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for darbepoetin alfa (Aranesp), (EMEA-000329-PIP02-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/617366/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-darbepoetin-alfa-aranesp-emea-000329-pip02-09-m04_en.pdf"},
    {"id":"5561","name":"P/0018/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA-001214-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/779670/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-benralizumab-emea-001214-pip01-11-m02_en.pdf"},
    {"id":"5569","name":"P/0296/2017: EMA decision of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz)\n\n(EMEA-000576-PIP01-09-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-14T16:17:00Z","last_updated_date":"2018-02-14T16:17:00Z","reference_number":"EMA/632917/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2017-ema-decision-4-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip01-09-m07_en.pdf"},
    {"id":"5570","name":"P/125/2009: European Medicines Agency decision of 26 June 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for valsartan (Diovan), (EMEA-000005-PIP01-07-M01) in accordance with Regulati...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/386713/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-125-2009-european-medicines-agency-decision-26-june-2009-acceptance-modification-agreed-paediatric-investigation-plan-valsartan-diovan-emea-000005-pip01-07-m01-accordance-regulati_en.pdf"},
    {"id":"5580","name":"P/0006/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for concentrate of proteolytic enzymes in bromelain (NexoBrid), (EMEA-000142-PIP02-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/61782/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-concentrate-proteolytic-enzymes-bromelain-nexobrid-emea-000142-pip02-09-m05_en.pdf"},
    {"id":"5589","name":"P/0070/2012: EMA decision of 4 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for sildenafil citrate\n\n(Revatio), (EMEA-000671-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-27T13:00:00Z","last_updated_date":"2012-04-27T13:00:00Z","reference_number":"EMA/222891/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2012-ema-decision-4-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-sildenafil-citrate-revatio-emea-000671-pip01-09-m02_en.pdf"},
    {"id":"5606","name":"P/0256/2012: EMA decision of 26 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for aripiprazole (Abilify), (EMEA-000235-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2013-03-21T13:00:00Z","reference_number":"EMA/646932/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2012-ema-decision-26-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-aripiprazole-abilify-emea-000235-pip02-10-m02_en.pdf"},
    {"id":"5621","name":"P/0003/2017: EMA decision of 12 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy),\n\n(EMEA-000117-PIP02-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/7963/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2017-ema-decision-12-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-yervoy-emea-000117-pip02-10-m07_en.pdf"}    {"id":"5674","name":"P/171/2009: European Medicines Agency decision of 28 August 2009 on the granting of a product specific waiver for sitagliptin phosphate monohydrate / simvastatin (EMEA-000537-PIP01-09) in accordance with Regulation (EC) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/531541/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-171-2009-european-medicines-agency-decision-28-august-2009-granting-product-specific-waiver-sitagliptin-phosphate-monohydrate-simvastatin-emea-000537-pip01-09-accordance-regulation-ec_en.pdf"},
    {"id":"5696","name":"P/54/2011: EMA decision of 4 March 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for 2'-O-methyluridylyl-( 3'→5' O,O-phosphorothioyl)-2'-O-methyl-cytidylyl-(3'→5' O,O-phos...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/155211/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-54-2011-ema-decision-4-march-2011-agreement-paediatric-investigation-plan-granting-deferral-2-o-methyluridylyl-3a5-oo-phosphorothioyl-2-o-methyl-cytidylyl-3a5-oo-phos_en.pdf"},
    {"id":"5702","name":"P/240/2011: EMA decision of 30 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for dextromethorphan (hydrobromide) / quinidine sulfate...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/706711/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-240-2011-ema-decision-30-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dextromethorphan-hydrobromide-quinidine-sulfate_en.pdf"},
    {"id":"5709","name":"P/0094/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira), (EMEA-000366-PIP05-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/195513/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip05-12-m01_en.pdf"},
    {"id":"5736","name":"P/0111/2014: EMA decision of 5 May 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fentanyl (hydrochloride) (EMEA-001509-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/169011/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2014-ema-decision-5-may-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fentanyl-hydrochloride-emea-001509-pip01-13_en.pdf"},
    {"id":"5740","name":"P/325/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of grass pollen (EMEA-00095...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769513/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-325-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-grass-pollen-emea-00095_en.pdf"},
    {"id":"5741","name":"P/0281/2014: EMA decision of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for delamanid (Deltyba), (EMEA-001113-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-10T01:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"EMA/587559/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2014-ema-decision-28-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-delamanid-deltyba-emea-001113-pip01-10-m03_en.pdf"},
    {"id":"5780","name":"P/0320/2016: EMA decision of 21 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for methoxyflurane\n\n(Penthrox), (EMEA-000334-PIP01-08-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T11:23:00Z","last_updated_date":"2017-01-30T11:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2016-ema-decision-21-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-methoxyflurane-penthrox-emea-000334-pip01-08-m05_en.pdf"},
    {"id":"5786","name":"P/0044/2018: EMA decision of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strain...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"EMA/83813/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2018-ema-decision-16-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-following-strain_en.pdf"},
    {"id":"5808","name":"P/211/2010: European Medicines Agency decision of 29 October 2010 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (H5N1) / influenza virus surface antig...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-24T01:00:00Z","last_updated_date":"2010-11-24T01:00:00Z","reference_number":"EMA/615237/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-211-2010-european-medicines-agency-decision-29-october-2010-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-h5n1-influenza-virus-surface-antig_en.pdf"},
    {"id":"5837","name":"P/0320/2015: EMA decision of 21 December 2015 on the granting of a product-specific waiver for inactivated poliovirus type 1 (Brunhilde), inactivated poliovirus type 2 (MEF-1),inactivated poliovirus type 3 (Saukett) (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/792006/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2015-ema-decision-21-december-2015-granting-product-specific-waiver-inactivated-poliovirus-type-1-brunhilde-inactivated-poliovirus-type-2-mef-1inactivated-poliovirus-type-3-saukett-eme_en.pdf"},
    {"id":"5839","name":"P/0228/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant varicella zoster virus (VZV) glycoprotein E (EMEA-001426-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/430894/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-varicella-zoster-virus-vzv-glycoprotein-e-emea-001426-pip01-13-m01_en.pdf"},
    {"id":"5841","name":"P/0101/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for ivabradine (hydrochloride) (Corlentor) (EMEA-000627-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/201371/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2013-ema-decision-30-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-ivabradine-hydrochloride-corlentor-emea-000627-pip01-09-m04_en.pdf"},
    {"id":"5884","name":"P/0129/2017: EMA decision of 5 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Split influenza virus, inactivated containing antigens equivalent to the B-like strain (B/Yamagat...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/279562/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2017-ema-decision-5-may-2017-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigens-equivalent-b-strain-b-yamagat_en.pdf"},
    {"id":"5901","name":"P/155/2010: European Medicines Agency decision of 3 September 2010 on the granting of a product specific waiver for bazedoxifene / conjugated estrogens, (EMEA-000998-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/477259/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-155-2010-european-medicines-agency-decision-3-september-2010-granting-product-specific-waiver-bazedoxifene-conjugated-estrogens-emea-000998-pip01-10_en.pdf"},
    {"id":"5914","name":"P/0288/2014: EMA decision of 12 December 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (R)-7-Chloro-benzo[b]thiophene-2-carboxylic acid (1-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-22T01:00:00Z","reference_number":"EMA/591053/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2014-ema-decision-12-december-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-r-7-chloro-benzobthiophene-2-carboxylic-acid-1_en.pdf"},
    {"id":"5919","name":"P/0287/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for autologous CD4+ and CD8+ T cells expressing a CD19-sp...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/626321/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-cd4-cd8-t-cells-expressing-cd19-sp_en.pdf"},
    {"id":"5926","name":"P/0252/2016: EMA decision of 26 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linaclotide\n\n(Constella), (EMEA-000927-PIP01-10-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/557955/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2016-ema-decision-26-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-linaclotide-constella-emea-000927-pip01-10-m03_en.pdf"},
    {"id":"5939","name":"P/0165/2016: EMA decision of 15 June 2016 on the granting of a product specific waiver for imetelstat (EMEA-001910-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/380499/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2016-ema-decision-15-june-2016-granting-product-specific-waiver-imetelstat-emea-001910-pip01-15_en.pdf"},
    {"id":"5943","name":"P/0196/2013: EMA decision of 2 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for human-papillomavirus-type-6 L1 protein / human-papillomavirus-type-11 L1 protein / human-pa...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/456116/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2013-ema-decision-2-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-human-papillomavirus-type-6-l1-protein-human-papillomavirus-type-11-l1-protein-human-pa_en.pdf"},
    {"id":"5946","name":"P/271/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allergens of birch pollen (betula alba / pendula / ve...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-10T01:00:00Z","last_updated_date":"2011-01-10T01:00:00Z","reference_number":"EMA/683356/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-271-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergens-birch-pollen-betula-alba-pendula-ve_en.pdf"},
    {"id":"5948","name":"P/0270/2017: EMA decision of 22 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for autologous T cells transduced with lentiviral vector containing a chimeric antigen recepto...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T17:00:00Z","last_updated_date":"2017-10-26T17:00:00Z","reference_number":"EMA/615104/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2017-ema-decision-22-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-autologous-t-cells-transduced-lentiviral-vector-containing-chimeric-antigen-recepto_en.pdf"},
    {"id":"5959","name":"P/0238/2012: EMA decision of 22 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ciclosporin (EMEA-\n\n000575-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/587077/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2012-ema-decision-22-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-ciclosporin-emea-000575-pip01-09-m02_en.pdf"},
    {"id":"5962","name":"P/0199/2015: EMA decision of 4 September 2015 on the granting of a product-specific waiver for torasemide / lisinopril (EMEA-001759-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/570750/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2015-ema-decision-4-september-2015-granting-product-specific-waiver-torasemide-lisinopril-emea-001759-pip01-15_en.pdf"},
    {"id":"5993","name":"P/0047/2014: European Medicines Agency decision of 11 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human normal immunoglobulin (EMEA...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/58370/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2014-european-medicines-agency-decision-11-march-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-normal-immunoglobulin-emea_en.pdf"},
    {"id":"5994","name":"P/0258/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen (EMEA-001208-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T17:00:00Z","last_updated_date":"2017-10-26T17:00:00Z","reference_number":"EMA/493103/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-emea-001208-pip01-11-m03_en.pdf"},
    {"id":"6006","name":"P/0218/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Victoza),\n\n(EMEA-000128-PIP01-07-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-29T02:00:00Z","last_updated_date":"2017-09-29T02:00:00Z","reference_number":"EMA/459439/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-victoza-emea-000128-pip01-07-m08_en.pdf"},
    {"id":"6031","name":"P/0216/2012: EMA decision of 28 September 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for pegylated B-domain-deleted sequence-modified recombinant human factor VIII, (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T18:45:00Z","last_updated_date":"2012-10-17T18:45:00Z","reference_number":"EMA/494657/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2012-ema-decision-28-september-2012-agreement-paediatric-investigation-plan-granting-deferral-pegylated-b-domain-deleted-sequence-modified-recombinant-human-factor-viii-emea-0_en.pdf"},
    {"id":"6034","name":"P/71/2010: European Medicines Agency decision of 5 May 2010 on the acceptance of a modification of an agreed paediatric investigation plan for tocilizumab (RoActemra) (EMEA-000309-PIP01-08-M02) in accordance with Regulat...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/267488/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-71-2010-european-medicines-agency-decision-5-may-2010-acceptance-modification-agreed-paediatric-investigation-plan-tocilizumab-roactemra-emea-000309-pip01-08-m02-accordance-regulat_en.pdf"},
    {"id":"6036","name":"P/0051/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for saxagliptin\n\n(Onglyza), (EMEA-000200-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/137071/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-saxagliptin-onglyza-emea-000200-pip01-08-m07_en.pdf"},
    {"id":"6115","name":"P/0353/2016: EMA decision of 9 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for talimogene laherparepvec (Imlygic), (EMEA-001251-PIP01-11-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T12:18:00Z","last_updated_date":"2017-02-03T12:18:00Z","reference_number":"EMA/790396/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0353-2016-ema-decision-9-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-talimogene-laherparepvec-imlygic-emea-001251-pip01-11-m02_en.pdf"},
    {"id":"6126","name":"P/0234/2014: EMA decision of 29 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab (EMEA-000069-PIP02-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/520186/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2014-ema-decision-29-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-emea-000069-pip02-10-m04_en.pdf"},
    {"id":"6144","name":"P/0240/2014: EMA decision of 26 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for glycopyrronium (bromide) (EMEA-001366-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-10-09T02:00:00Z","last_updated_date":"2014-10-09T02:00:00Z","reference_number":"EMA/573797/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2014-ema-decision-26-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-glycopyrronium-bromide-emea-001366-pip01-12-m02_en.pdf"},
    {"id":"6145","name":"P/256/09: EMA decision of 22 December 2009 on the granting of a product specific waiver for Nitric oxide (INOmax) (EMEA-000612-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the Europ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMA/821254/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-256-09-ema-decision-22-december-2009-granting-product-specific-waiver-nitric-oxide-inomax-emea-000612-pip01-09-accordance-regulation-ec-no-1901-2006-europ_en.pdf"},
    {"id":"6152","name":"P/0164/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone furoate / vilanterol (Relvar Ellipta and associated names), (EMEA-000431-PIP01-08-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/473687/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-vilanterol-relvar-ellipta-associated-names-emea-000431-pip01-08_en.pdf"},
    {"id":"6175","name":"P/0164/2013: EMA decision of 29 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for C1 inhibitor (Cinryze) (EMEA-000568-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/393013/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2013-ema-decision-29-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-c1-inhibitor-cinryze-emea-000568-pip01-09-m05_en.pdf"},
    {"id":"6192","name":"P/0288/2012: EMA decision of 26 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for serelaxin (EMEA-001168-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/737430/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2012-ema-decision-26-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-serelaxin-emea-001168-pip01-11-m01_en.pdf"},
    {"id":"6198","name":"P/0064/2012: EMA decision of 28 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for (3R,4R)-4-methyl-3-\n\n(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T17:42:00Z","last_updated_date":"2012-04-20T17:42:00Z","reference_number":"EMA/183907/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2012-ema-decision-28-march-2012-acceptance-modification-agreed-paediatric-investigation-plan-3r4r-4-methyl-3-methyl-7h-pyrrolo23-dpyrimidin-4-ylamino-i2-oxo-1-piperidinepropanen_en.pdf"},
    {"id":"6211","name":"P/299/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for Pollen from Dactylis glomarata, Lolium perenne, Phle...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/778321/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-299-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-dactylis-glomarata-lolium-perenne-phle_en.pdf"},
    {"id":"6228","name":"P/0185/2016: EMA decision of of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris)\n\n(EMEA-000876-PIP05-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:12:00Z","last_updated_date":"2016-09-22T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip05-15-m01_en.pdf"},
    {"id":"6232","name":"P/0287/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for cysteamine hydrochloride (EMEA-000322-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/708150/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-cysteamine-hydrochloride-emea-000322-pip01-08-m03_en.pdf"},
    {"id":"6243","name":"P/0285/2014: EMA decision of 28 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for 4-((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-ne...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-04T01:00:00Z","last_updated_date":"2014-12-04T01:00:00Z","reference_number":"EMA/605314/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2014-ema-decision-28-october-2014-agreement-paediatric-investigation-plan-granting-deferral-4-2r3s4r5s-3-3-chloro-2-fluorophenyl-4-4-chloro-2-fluorophenyl-4-cyano-5-ne_en.pdf"},
    {"id":"6244","name":"P/0054/2013: European medicines agency decision of 25 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab (EMEA-000069-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/101962/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2013-european-medicines-agency-decision-25-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-emea-000069-pip02-10-m01_en.pdf"},
    {"id":"6255","name":"P/0143/2014: EMA decision of 13 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ocrelizumab (EMEA-000310-PIP03-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/268693/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2014-ema-decision-13-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-ocrelizumab-emea-000310-pip03-10-m01_en.pdf"},
    {"id":"6263","name":"P/0117/2016: EMA decision of 22 April 2016 on the granting of a product specific waiver for levodopa (EMEA-001874-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/269231/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2016-ema-decision-22-april-2016-granting-product-specific-waiver-levodopa-emea-001874-pip01-15_en.pdf"},
    {"id":"6267","name":"P/0075/2014: EMA decision of 2 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-000775-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/52893/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2014-ema-decision-2-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000775-pip01-09-m01_en.pdf"},
    {"id":"6279","name":"P/0308/2014: EMA decision of 24 November 2014 on the granting of a product specific waiver for macrogol 3350 (EMEA-001668-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/642067/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2014-ema-decision-24-november-2014-granting-product-specific-waiver-macrogol-3350-emea-001668-pip01-14_en.pdf"},
    {"id":"6292","name":"P/309/2011: EMA decision of 20 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for (1-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohe...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/878740/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-309-2011-ema-decision-20-december-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-1-3-chloro-5-4-4-chloro-2-thienyl-5-4-cyclohe_en.pdf"},
    {"id":"6318","name":"P/0113/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-000454-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/355377/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000454-pip01-08-m06_en.pdf"},
    {"id":"6323","name":"P/0181/2015: EMA decision on the granting of a product-specific waiver: DNA, d(P-thio)([2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rC-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-24T02:00:00Z","last_updated_date":"2015-09-24T02:00:00Z","reference_number":"EMA/473568/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2015-ema-decision-granting-product-specific-waiver-dna-dp-thio2-0-2-methoxyethylm5ru-2-0-2-methoxyethylm5rc-2-0-2-methoxyethylm5ru-2-0-2-methoxyethylm5ru-2-0-2-methoxyethyl_en.pdf"},
    {"id":"6330","name":"P/0148/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride)(Palexia and associated names, Yantil and associated names, Tapentadol...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/305255/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloridepalexia-associated-names-yantil-associated-names-tapentadol_en.pdf"},
    {"id":"6393","name":"P/0310/2012: EMA decision of 21 December 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human dermal fibroblasts cultured on bioresorbable p...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T14:00:00Z","last_updated_date":"2013-02-08T14:00:00Z","reference_number":"EMA/810422/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0310-2012-ema-decision-21-december-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-dermal-fibroblasts-cultured-bioresorbable-p_en.pdf"},
    {"id":"6408","name":"P/0270/2013: EMA decision of 30 October 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for eptacog alfa (activated) (EMEA-001382-PIP01-12)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/585994/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2013-ema-decision-30-october-2013-agreement-paediatric-investigation-plan-granting-waiver-eptacog-alfa-activated-emea-001382-pip01-12_en.pdf"},
    {"id":"6411","name":"P/0225/2012: EMA decision of 3 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for retigabine (Trobalt), (EMEA-000116-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T01:00:00Z","last_updated_date":"2012-11-23T01:00:00Z","reference_number":"EMA/610846/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2012-ema-decision-3-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-retigabine-trobalt-emea-000116-pip01-07-m05_en.pdf"},
    {"id":"6413","name":"P/0235/2014: EMA decision of 8 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for brodalumab (EMEA-001089-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-10-09T02:00:00Z","last_updated_date":"2014-10-09T02:00:00Z","reference_number":"EMA/519145/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2014-ema-decision-8-september-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-brodalumab-emea-001089-pip02-13_en.pdf"},
    {"id":"6422","name":"P/0285/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for entospletinib (EMEA-002058-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/574574/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-entospletinib-emea-002058-pip01-16_en.pdf"},
    {"id":"6423","name":"P/0043/2013: European medicines agency decision of 1 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for boceprevir (Victrelis), (EMEA-000583-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/68060/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2013-european-medicines-agency-decision-1-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-boceprevir-victrelis-emea-000583-pip01-09-m05_en.pdf"},
    {"id":"6435","name":"P/0116/2016: EMA decision of 22 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for rufinamide (Inovelon), (EMEA-000709-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/249393/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2016-ema-decision-22-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-rufinamide-inovelon-emea-000709-pip01-09-m05_en.pdf"},
    {"id":"6453","name":"P/0269/2013: EMA decision of 30 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for lurasidone (hydrochloride) (EMEA-001230-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/588810/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2013-ema-decision-30-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-lurasidone-hydrochloride-emea-001230-pip01-11-m01_en.pdf"},
    {"id":"6488","name":"P/265/2009: European Medicines Agency decision of 23 December 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for moxifloxacin hydrochloride (Actira and associated names: Proflox) (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2010-01-25T01:00:00Z","reference_number":"EMEA/289563/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-265-2009-european-medicines-agency-decision-23-december-2009-acceptance-modification-agreed-paediatric-investigation-plan-moxifloxacin-hydrochloride-actira-associated-names-proflox-eme_en.pdf"},
    {"id":"6495","name":"P/0232/2017: EMA decision of 11 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for brentuximab vedotin (Adcetris), (EMEA-000980-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/460036/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2017-ema-decision-11-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-brentuximab-vedotin-adcetris-emea-000980-pip01-10-m05_en.pdf"},
    {"id":"6508","name":"P/0350/2017: EMA decision of 1 December 2017 on the refusal of a modification of an agreed paediatric investigation plan for mirabegron\n\n(Betmiga), (EMEA-000597-PIP02-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/724286/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0350-2017-ema-decision-1-december-2017-refusal-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip02-10-m06_en.pdf"},
    {"id":"6512","name":"P/0036/2012: EMA decision of 13 February 2012 on the acceptance of a modification of an agreed paediatric investigation plan for pixantrone (EMEA-\n\n000713-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T14:30:00Z","last_updated_date":"2012-03-15T14:30:00Z","reference_number":"EMA/94189/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2012-ema-decision-13-february-2012-acceptance-modification-agreed-paediatric-investigation-plan-pixantrone-emea-000713-pip02-10-m01_en.pdf"},
    {"id":"6521","name":"P/213/2009: European Medicines Agency decision of 30 October 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for sitagliptin (phosphate monohydrate) (Tesavel) (EMEA-000472-PIP01-08-M01...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/691459/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-213-2009-european-medicines-agency-decision-30-october-2009-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-phosphate-monohydrate-tesavel-emea-000472-pip01-08-m01_en.pdf"},
    {"id":"6535","name":"P/31/2011: EMA decision of the 28 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for amikacin (sulfate) (EMEA-000525-PIP01-08) in accor...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"EMA/34144/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-31-2011-ema-decision-28-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-amikacin-sulfate-emea-000525-pip01-08-accor_en.pdf"},
    {"id":"6541","name":"P/285/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for Dermatophagoides farinae extract 100 % (EMEA-000834-P...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/767538/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-285-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dermatophagoides-farinae-extract-100-emea-000834-p_en.pdf"},
    {"id":"6553","name":"P/203/2011: EMA decision of 31 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for telbivudine (Sebivo),\n\n(EMEA-000065-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/505512/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-203-2011-ema-decision-31-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-telbivudine-sebivo-emea-000065-pip01-07-m02_en.pdf"},
    {"id":"6597","name":"P/224/2011: EMA decision of 27 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta)\n\n(EMEA-000689-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/686495/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-224-2011-ema-decision-27-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-exenatide-byetta-emea-000689-pip01-09-m03_en.pdf"},
    {"id":"6619","name":"P/0295/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen /\n\nhuman thrombin (Raplixa), (EMEA-001340-PIP01-12-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-20T16:17:00Z","last_updated_date":"2017-01-20T16:17:00Z","reference_number":"EMA/666531/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-raplixa-emea-001340-pip01-12-m02_en.pdf"},
    {"id":"6632","name":"P/106/2011: EMA decision of 4 May 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for ataluren (EMEA-000115-PIP02-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-09T02:00:00Z","last_updated_date":"2011-06-09T02:00:00Z","reference_number":"EMA/299522/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-106-2011-ema-decision-4-may-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ataluren-emea-000115-pip02-09_en.pdf"},
    {"id":"6678","name":"P/0132/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dimethyl fumarate (Tecfidera), (EMEA-000832-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/287340/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-dimethyl-fumarate-tecfidera-emea-000832-pip01-10-m03_en.pdf"},
    {"id":"6709","name":"P/0095/2017: EMA decision of 11 April 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for rVSVΔG-ZEBOV-GP (EMEA-001786-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/196323/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2017-ema-decision-11-april-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rvsvig-zebov-gp-emea-001786-pip01-15_en.pdf"},
    {"id":"6710","name":"P/0027/2012: EMA decision of 27 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for laquinimod (sodium)\n\n(EMEA-000972-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/57911/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2012-ema-decision-27-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-laquinimod-sodium-emea-000972-pip01-10-m01_en.pdf"},
    {"id":"6727","name":"P/0241/2012: EMA decision of 22 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for delamanid (EMEA-001113-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/636914/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2012-ema-decision-22-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-delamanid-emea-001113-pip01-10-m01_en.pdf"},
    {"id":"6732","name":"P/0023/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for albiglutide (Eperzan), (EMEA-001175-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/1363/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-albiglutide-eperzan-emea-001175-pip01-11-m03_en.pdf"},
    {"id":"6745","name":"P/0047/2016: EMA decision of 3 March 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rolapitant (EMEA-001768-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/131427/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2016-ema-decision-3-march-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rolapitant-emea-001768-pip02-15_en.pdf"},
    {"id":"6753","name":"P/0212/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for zanamivir (Relenza),\n\n(EMEA-001318-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/430892/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-zanamivir-relenza-emea-001318-pip01-12-m02_en.pdf"},
    {"id":"6758","name":"P/0259/2015: EMA decision of 30 October 2015\n\non the granting of a product specific waiver for L-Cysteine, L-leucyl-L-α-glutamyl-L-α-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-Î...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-22T13:00:00Z","last_updated_date":"2015-12-22T13:00:00Z","reference_number":"EMA/627030/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2015-ema-decision-30-october-2015-granting-product-specific-waiver-l-cysteine-l-leucyl-l-i-glutamyl-l-i-glutamyl-l-lysyl-l-lysylglycyl-l-asparaginyl-l-tyrosyl-l-valyl-l-valyl-l-threonyl-l-i_en.pdf"},
    {"id":"6760","name":"P/0116/2013: EMA decision of 26 April 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for paclitaxel (Abraxane), (EMEA-001308-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/245670/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2013-ema-decision-26-april-2013-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-paclitaxel-abraxane-emea-001308-pip01-12_en.pdf"},
    {"id":"6762","name":"P/0345/2016: EMA decision of 2 December 2016 on the granting of a product specific waiver for teprotumumab (EMEA-001973-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/741998/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0345-2016-ema-decision-2-december-2016-granting-product-specific-waiver-teprotumumab-emea-001973-pip01-16_en.pdf"},
    {"id":"6772","name":"P/0262/2013: EMA decision of 30 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Bi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/597267/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2013-ema-decision-30-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-bi_en.pdf"},
    {"id":"6783","name":"P/0159/2015: EMA decision of 13 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for meropenem (EMEA-000898-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/364926/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2015-ema-decision-13-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-meropenem-emea-000898-pip01-10-m01_en.pdf"},
    {"id":"6784","name":"P/179/2011: EMA decision of 1 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for anagrelide (Xagrid),\n\n(EMEA-000720-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/500865/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-179-2011-ema-decision-1-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-anagrelide-xagrid-emea-000720-pip01-09-m01_en.pdf"},
    {"id":"6785","name":"P/0302/2013: EMA decision of of 29 November 2013 on the granting of a product-specific waiver for lanreotide (acetate) (Somatuline LA and associated names) (EMEA-001503-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-17T12:00:00Z","last_updated_date":"2014-01-17T12:00:00Z","reference_number":"EMEA-001503-PIP01-13","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2013-ema-decision-29-november-2013-granting-product-specific-waiver-lanreotide-acetate-somatuline-la-associated-names-emea-001503-pip01-13_en.pdf"},
    {"id":"6799","name":"P/221/2009: European Medicines Agency Decision of 3 November 2009 on the granting of a product specific waiver for soluble yeast beta-1,3/1,6-glucan EMEA-000633-PIP01-09) in accordance with Regulation (EC) No 1901/2006 o...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:09:21Z","last_updated_date":"2009-12-23T00:09:21Z","reference_number":"EMEA/687790/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-221-2009-european-medicines-agency-decision-3-november-2009-granting-product-specific-waiver-soluble-yeast-beta-13-16-glucan-emea-000633-pip01-09-accordance-regulation-ec-no-1901-2006-o_en.pdf"},
    {"id":"6839","name":"P/0027/2015: EMA decision of 30 January 2015 on the agreement of a paediatric investigation plan for recombinant human heparan N-sulfatase (rhHNS) (EMEA-001634-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/794400/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2015-ema-decision-30-january-2015-agreement-paediatric-investigation-plan-recombinant-human-heparan-n-sulfatase-rhhns-emea-001634-pip01-14_en.pdf"},
    {"id":"6855","name":"P/0198/2015: EMA decision of 4 September 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ozanimod (EMEA-001710-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/568910/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2015-ema-decision-4-september-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ozanimod-emea-001710-pip02-14_en.pdf"},
    {"id":"6857","name":"P/0323/2014: EMA decision of 19 December 2014 on the granting of a product specific waiver for amlodipine / ramipril (EMEA-001685-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/755900/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2014-ema-decision-19-december-2014-granting-product-specific-waiver-amlodipine-ramipril-emea-001685-pip01-14_en.pdf"},
    {"id":"6875","name":"P/0354/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for telavancin\n\n(hydrochloride) (Vibativ), (EMEA-000239-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/763133/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0354-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-telavancin-hydrochloride-vibativ-emea-000239-pip01-08-m03_en.pdf"},
    {"id":"6877","name":"P/0118/2012: EMA decision of 2 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tadalafil (Adcirca, Cialis) (EMEA-000452-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-06T18:00:00Z","last_updated_date":"2012-08-06T18:00:00Z","reference_number":"EMA/405309/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2012-ema-decision-2-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-tadalafil-adcirca-cialis-emea-000452-pip02-10-m01_en.pdf"},
    {"id":"6886","name":"P/0322/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate)\n\n(Lixiana) (EMEA-000788-PIP02-11-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-14T16:17:00Z","last_updated_date":"2018-02-14T16:17:00Z","reference_number":"EMA/666037/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0322-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-lixiana-emea-000788-pip02-11-m06_en.pdf"},
    {"id":"6889","name":"P/0044/2013: EMA decision of 1 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for volasertib (EMEA-000674-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/118204/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2013-ema-decision-1-march-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-volasertib-emea-000674-pip02-11_en.pdf"},
    {"id":"6911","name":"P/0010/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon alfa-2a (Pegasys), (EMEA-000298-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/23022/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-peginterferon-alfa-2a-pegasys-emea-000298-pip01-08-m05_en.pdf"},
    {"id":"6922","name":"P/0269/2016: EMA decision of 7 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for delamanid (Deltyba),\n\n(EMEA-001113-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/632684/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2016-ema-decision-7-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-delamanid-deltyba-emea-001113-pip01-10-m05_en.pdf"},
    {"id":"6946","name":"P/13/2009: European Medicines Agency decision of 27 January 2009 on the granting of a product specific waiver for telmisartan and amlodipine besylate (EMEA-000377-PIP01-08) in accordance with Regulation (EC) No 1901/2006...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/26624/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-13-2009-european-medicines-agency-decision-27-january-2009-granting-product-specific-waiver-telmisartan-amlodipine-besylate-emea-000377-pip01-08-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"6953","name":"P/0059/2013: European medicines agency decision of 26 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Afinitor, Certican and associated names), (EMEA-000019-PIP06...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/85730/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2013-european-medicines-agency-decision-26-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-afinitor-certican-associated-names-emea-000019-pip06_en.pdf"},
    {"id":"6965","name":"P/0029/2013: EMA decision of 26 February 2013 on the granting of a product specific waiver for strontium succinate / Vitamin D3, (EMEA-001131-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/65773/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2013-ema-decision-26-february-2013-granting-product-specific-waiver-strontium-succinate-vitamin-d3-emea-001131-pip02-12_en.pdf"},
    {"id":"6980","name":"P/300/2010: EMA decision of 22 December 2010 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for Pollen from Dactylis glomarata (16%), Lolium perenne (16%), Phleum pratense (16...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/778360/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-300-2010-ema-decision-22-december-2010-agreement-pip-granting-deferral-granting-waiver-pollen-dactylis-glomarata-16-lolium-perenne-16-phleum-pratense-16_en.pdf"},
    {"id":"7020","name":"P/0281/2017: EMA decision of 4 October 2017 on the granting of a product specific waiver for netarsudil / latanoprost (EMEA-002175-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/626326/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2017-ema-decision-4-october-2017-granting-product-specific-waiver-netarsudil-latanoprost-emea-002175-pip01-17_en.pdf"},
    {"id":"7028","name":"P/0190/2014: EMA decision of 6 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ Cells Transduced ex-vivo with Retroviral Vector (GIADAl) Containing Human Ade...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/391460/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2014-ema-decision-6-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-cells-transduced-ex-vivo-retroviral-vector-giadal-containing-human-ade_en.pdf"}    {"id":"7034","name":"P/0123/2014: EMA decision of 8 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation Factor VIII / von Willebrand Factor (Voncento), (EMEA-000312-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-11T16:00:00Z","last_updated_date":"2014-06-11T16:00:00Z","reference_number":"EMA/182183/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2014-ema-decision-8-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-human-coagulation-factor-viii-von-willebrand-factor-voncento-emea-000312-pip01-08-m06_en.pdf"},
    {"id":"7042","name":"P/0064/2014: European Medicines Agency decision of 7 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nivolumab (EMEA-001407-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/103630/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2014-european-medicines-agency-decision-7-march-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-nivolumab-emea-001407-pip01-12_en.pdf"},
    {"id":"7066","name":"P/0053/2012: EMA decision of 23 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for lisdexamfetamine\n\n(dimesylate) (EMEA-000553-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T17:42:00Z","last_updated_date":"2012-04-20T17:42:00Z","reference_number":"EMA/195952/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2012-ema-decision-23-march-2012-acceptance-modification-agreed-paediatric-investigation-plan-lisdexamfetamine-dimesylate-emea-000553-pip01-09-m03_en.pdf"},
    {"id":"7083","name":"P/0284/2013: EMA decision of 8 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tapen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-12-06T01:00:00Z","last_updated_date":"2013-12-06T01:00:00Z","reference_number":"EMA/648110/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2013-ema-decision-8-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapen_en.pdf"},
    {"id":"7095","name":"P/0203/2016: EMA decision of 22 July 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for quizartinib (EMEA-001821-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T02:00:00Z","last_updated_date":"2016-09-22T02:00:00Z","reference_number":"EMA/507354/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2016-ema-decision-22-july-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-quizartinib-emea-001821-pip01-15_en.pdf"},
    {"id":"7103","name":"P/119/2010: European Medicines Agency decision of 9 July 2010\n\non the acceptance of a modification of an agreed paediatric investigation plan for telbivudine (Sebivo) (EMEA-000065-PIP01-07-M01) in accordance with Regulat...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/349760/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-119-2010-european-medicines-agency-decision-9-july-2010-acceptance-modification-agreed-paediatric-investigation-plan-telbivudine-sebivo-emea-000065-pip01-07-m01-accordance-regulat_en.pdf"},
    {"id":"7111","name":"P/0399/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen /\n\nhuman thrombin (Evicel, Evarrest) (EMEA-001149-PIP01-11-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T11:48:00Z","last_updated_date":"2018-03-02T11:48:00Z","reference_number":"EMA/759119/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0399-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-evicel-evarrest-emea-001149-pip01-11-m04_en.pdf"},
    {"id":"7123","name":"P/0367/2017: EMA decision of 1 December 2017 on the refusal of a product specific waiver for human neutrophil elastase inhibitor (CHF6333)\n\n(EMEA-002196-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T14:03:00Z","last_updated_date":"2018-03-07T14:03:00Z","reference_number":"EMA/723579/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0367-2017-ema-decision-1-december-2017-refusal-product-specific-waiver-human-neutrophil-elastase-inhibitor-chf6333-emea-002196-pip01-17_en.pdf"},
    {"id":"7130","name":"P/0153/2014: EMA decision of 13 June 2014 on the granting of a product-specific waiver for lesinurad (EMEA-001597-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/268797/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2014-ema-decision-13-june-2014-granting-product-specific-waiver-lesinurad-emea-001597-pip01-13_en.pdf"},
    {"id":"7141","name":"P/0123/2016: EMA decision of 12 May 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for darunavir / cobicistat / emtricitabine / tenofovir alafen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/287464/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2016-ema-decision-12-may-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-darunavir-cobicistat-emtricitabine-tenofovir-alafen_en.pdf"},
    {"id":"7148","name":"P/0068/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine (Valdoxan, Thymanax) (EMEA-001181-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/160746/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-agomelatine-valdoxan-thymanax-emea-001181-pip01-11-m02_en.pdf"},
    {"id":"7150","name":"P/138/2009: European Medicines Agency decision of 15 July 2009 on the granting of a product specific waiver for omacetaxine mepesuccinate (EMEA-000484-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the Euro...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/416511/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-138-2009-european-medicines-agency-decision-15-july-2009-granting-product-specific-waiver-omacetaxine-mepesuccinate-emea-000484-pip01-08-accordance-regulation-ec-no-1901-2006-euro_en.pdf"},
    {"id":"7170","name":"P/0132/2015: EMA decision of 12 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (Translarna), (EMEA-000115-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-07T02:00:00Z","last_updated_date":"2015-07-07T02:00:00Z","reference_number":"EMA/364986/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2015-ema-decision-12-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-translarna-emea-000115-pip01-07-m05_en.pdf"},
    {"id":"7177","name":"P/0265/2013: EMA decision of 30 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for Guanfacine (hydrochloride) (EMEA-000745-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/85737/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2013-ema-decision-30-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-guanfacine-hydrochloride-emea-000745-pip01-09-m03_en.pdf"},
    {"id":"7183","name":"P/0163/2012: EMA decision of 23 July 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for misoprostol (EMEA-001159-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T13:00:00Z","last_updated_date":"2012-08-23T13:00:00Z","reference_number":"EMA/475432/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2012-ema-decision-23-july-2012-agreement-paediatric-investigation-plan-granting-waiver-misoprostol-emea-001159-pip02-12_en.pdf"},
    {"id":"7185","name":"P/0237/2017: EMA decision of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous T cells transduced with retroviral vector en...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/491411/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2017-ema-decision-9-august-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-t-cells-transduced-retroviral-vector-en_en.pdf"},
    {"id":"7196","name":"P/0269/2014: EMA decision of 27 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant fusion protein linking human coagulation factor IX with human albumin (EMEA-0011...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-09T01:00:00Z","last_updated_date":"2014-12-09T01:00:00Z","reference_number":"EMA/591163/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2014-ema-decision-27-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-fusion-protein-linking-human-coagulation-factor-ix-human-albumin-emea-0011_en.pdf"},
    {"id":"7203","name":"P/0057/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus\n\nsurface antigens - A/turkey/Turkey/1/05 (H5N1) (Aflunov and associated names)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/104668/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-turkey-turkey-1-05-h5n1-aflunov-associated-names_en.pdf"},
    {"id":"7206","name":"P/84/2008: European medicines agency decision of of 14 October 2008 \n\non the application for agreement of a Paediatric Investigation Plan for valsartan (Diovan) (EMEA-000005-PIP01-07) in accordance with Regulation (EC) N...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-11-24T00:00:00Z","last_updated_date":"2008-11-24T00:00:00Z","reference_number":"EMEA/522876/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-84-2008-european-medicines-agency-decision-14-october-2008-application-agreement-paediatric-investigation-plan-valsartan-diovan-emea-000005-pip01-07-accordance-regulation-ec-n_en.pdf"},
    {"id":"7225","name":"P/0112/2014: EMA decision of 5 May 2014 on the agreement of a paediatric investigation plan and on the refusal of a waiver for enalapril (maleate) (EMEA-001516-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/235549/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2014-ema-decision-5-may-2014-agreement-paediatric-investigation-plan-refusal-waiver-enalapril-maleate-emea-001516-pip01-13_en.pdf"},
    {"id":"7231","name":"P/0013/2018: EMA decision of 26 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ceftaroline fosamil\n\n(Zinforo) (EMEA-000769-PIP01-09-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T11:41:00Z","last_updated_date":"2018-04-18T11:41:00Z","reference_number":"EMA/28040/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2018-ema-decision-26-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-ceftaroline-fosamil-zinforo-emea-000769-pip01-09-m07_en.pdf"},
    {"id":"7235","name":"P/48/2012: EMA decision of 29 February 2012 on the agreement of a paediatric investigation plan for recombinant human A disintegrin and metalloprotease with thrombospind type-1 motifs 13 (EMEA-001160-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/PDCO/54526/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-48-2012-ema-decision-29-february-2012-agreement-paediatric-investigation-plan-recombinant-human-disintegrin-metalloprotease-thrombospind-type-1-motifs-13-emea-001160-pip01-11_en.pdf"},
    {"id":"7237","name":"P/0245/2013: EMA decision of 4 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for dalbavancin (EMEA-000016-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/588205/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2013-ema-decision-4-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-dalbavancin-emea-000016-pip01-07-m02_en.pdf"},
    {"id":"7254","name":"P/0204/2013: EMA decision of 3 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for modified grass-pollen extract (EMEA-000284-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/476174/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2013-ema-decision-3-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-modified-grass-pollen-extract-emea-000284-pip01-08-m04_en.pdf"},
    {"id":"7258","name":"P/63/2009: European Medicines Agency decision of 27 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for sitagliptin phosphate monohydrate (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/174961/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-63-2009-european-medicines-agency-decision-27-march-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sitagliptin-phosphate-monohydrate_en.pdf"},
    {"id":"7281","name":"P/0230/2015: EMA decision of 22 October 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for vaborbactam (in combination with meropenem trihydrate) (EMEA-001740-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-22T13:00:00Z","last_updated_date":"2015-12-22T13:00:00Z","reference_number":"EMA/624852/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2015-ema-decision-22-october-2015-agreement-paediatric-investigation-plan-granting-deferral-vaborbactam-combination-meropenem-trihydrate-emea-001740-pip01-14_en.pdf"},
    {"id":"7283","name":"P/0021/2012: EMA decision of 27 January 2012 on the agreement of a paediatric investigation plan for cyclophosphamide (EMEA-000530-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/985495/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2012-ema-decision-27-january-2012-agreement-paediatric-investigation-plan-cyclophosphamide-emea-000530-pip02-11_en.pdf"},
    {"id":"7287","name":"P/73/2009: European Medicines Agency decision of 20 April 2009 on the agreement of a Paediatric Investigation Plan for mercaptopurine monohydrate (EMEA-000350-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-06-10T02:00:00Z","last_updated_date":"2009-06-10T02:00:00Z","reference_number":"EMEA/233188/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-73-2009-european-medicines-agency-decision-20-april-2009-agreement-paediatric-investigation-plan-mercaptopurine-monohydrate-emea-000350-pip01-08-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"7291","name":"P/308/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of birch, alder and hazel p...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/769331/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-308-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-birch-alder-hazel-p_en.pdf"},
    {"id":"7308","name":"P/254/2011: EMA decision of 26 October 2011 on the granting of a product specific waiver for pancreas powder (EMEA-000287-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T01:00:00Z","last_updated_date":"2011-11-29T01:00:00Z","reference_number":"EMA/776844/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-254-2011-ema-decision-26-october-2011-granting-product-specific-waiver-pancreas-powder-emea-000287-pip02-10_en.pdf"},
    {"id":"7324","name":"P/175/2010: European Medicines Agency decision of 20 September 2010 on the granting of a product specific waiver for (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrilephosphate (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/547271/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-175-2010-european-medicines-agency-decision-20-september-2010-granting-product-specific-waiver-r-34-7h-pyrrolo23-dpyrimidin-4-yl-1h-pyrazol-1-yl-3-cyclopentylpropanenitrilephosphate-emea-0_en.pdf"},
    {"id":"7344","name":"P/0149/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for human recombinant IgG1 monoclonal antibody targeting fibroblast growth factor 23 (KRN23) (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/305257/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-human-recombinant-igg1-monoclonal-antibody-targeting-fibroblast-growth-factor-23-krn23-emea-0_en.pdf"},
    {"id":"7395","name":"P/0188/2014: EMA decision of 6 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation factor X (EMEA-000971-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/447727/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2014-ema-decision-6-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-human-coagulation-factor-x-emea-000971-pip01-10-m02_en.pdf"},
    {"id":"7431","name":"P/272/2010: EMA decision of 29 November 2010 on the acceptance of a modification of an agreed paediatric investigation plan for eritoran (EMEA-\n\n000509-PIP02-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-10T01:00:00Z","last_updated_date":"2011-01-10T01:00:00Z","reference_number":"EMA/757016/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-272-2010-ema-decision-29-november-2010-acceptance-modification-agreed-paediatric-investigation-plan-eritoran-emea-000509-pip02-09-m02_en.pdf"},
    {"id":"7454","name":"P/194/2011: EMA decision of 3 August 2011 on the granting of a product specific waiver for recombinant salmon calcitonin (EMEA-000092-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/593331/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-194-2011-ema-decision-3-august-2011-granting-product-specific-waiver-recombinant-salmon-calcitonin-emea-000092-pip02-11_en.pdf"},
    {"id":"7458","name":"P/0093/2015: EMA decision of 8 May 2015 on the refusal of a paediatric investigation plan and on the granting of a waiver for masitinib (mesylate) (EMEA-001266-PIP02-14)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/215125/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2015-ema-decision-8-may-2015-refusal-paediatric-investigation-plan-granting-waiver-masitinib-mesylate-emea-001266-pip02-14_en.pdf"},
    {"id":"7464","name":"P/0162/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP02-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/446651/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-yervoy-emea-000117-pip02-10-m06_en.pdf"},
    {"id":"7478","name":"P/95/2011: EMA decision of 4 April 2011 on the granting of a product specific waiver for ezetimibe/simvastatin (Inegy and associated names)\n\n(EMEA-000006-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"EMA/247674/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-95-2011-ema-decision-4-april-2011-granting-product-specific-waiver-ezetimibe-simvastatin-inegy-associated-names-emea-000006-pip02-10_en.pdf"},
    {"id":"7502","name":"P/0160/2012: EMA decision of 25 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]quino...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T18:30:00Z","last_updated_date":"2012-10-08T11:50:00Z","reference_number":"EMA/458409/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2012-ema-decision-25-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-7-4-4-benzobthiophen-4-ylpiperazin-1-ylbutoxyquino_en.pdf"},
    {"id":"7514","name":"P/0279/2014: EMA decision of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for Neisseria meningitidis serogroup B recombinant lipoprotein (rLP2086; subfamily A; Escherichi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-09T01:00:00Z","last_updated_date":"2014-12-09T01:00:00Z","reference_number":"EMA/590270/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2014-ema-decision-28-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-b-recombinant-lipoprotein-rlp2086-subfamily-escherichi_en.pdf"},
    {"id":"7521","name":"P/0135/2012: EMA decision of 20 July 2012 on the granting of a product specific waiver for ezetimibe (Ezetrol and associated names) (EMEA-\n\n000007-PIP04-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T17:15:00Z","last_updated_date":"2012-08-22T17:15:00Z","reference_number":"EMA/452159/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2012-ema-decision-20-july-2012-granting-product-specific-waiver-ezetimibe-ezetrol-associated-names-emea-000007-pip04-12_en.pdf"},
    {"id":"7533","name":"P/156/2011: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for retigabine (EMEA-\n\n000116-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/513798/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-156-2011-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-retigabine-emea-000116-pip01-07-m04_en.pdf"},
    {"id":"7556","name":"P/0196/2012: EMA decision of 24 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for fibrinogen (human\n\nplasma-derived), (EMEA-000457-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/533974/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2012-ema-decision-24-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-fibrinogen-human-plasma-derived-emea-000457-pip02-10-m01_en.pdf"},
    {"id":"7561","name":"P/121/2009: European Medicines Agency decision of 15 June 2009 on the refusal of a Paediatric Investigation Plan and on the granting of a waiver for dienogest / ethinylestradiol (as betadex clathrate) / L-5-methyltetrahy...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351771/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-121-2009-european-medicines-agency-decision-15-june-2009-refusal-paediatric-investigation-plan-granting-waiver-dienogest-ethinylestradiol-betadex-clathrate-l-5-methyltetrahy_en.pdf"},
    {"id":"7563","name":"P/0115/2014: EMA decision of 6 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for methyl aminolevulinate hydrochloride (EMEA-000698-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-11T19:00:00Z","last_updated_date":"2014-06-11T19:00:00Z","reference_number":"EMA/196390/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2014-ema-decision-6-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-methyl-aminolevulinate-hydrochloride-emea-000698-pip02-10-m01_en.pdf"},
    {"id":"7569","name":"P/0210/2014: EMA decision of 12 August 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for silicic acid, sodium zirconium (4+) salt (3:2:1) hydrate (EMEA-001539-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/391489/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2014-ema-decision-12-august-2014-agreement-paediatric-investigation-plan-granting-deferral-silicic-acid-sodium-zirconium-4-salt-321-hydrate-emea-001539-pip01-13_en.pdf"},
    {"id":"7579","name":"P/0292/2012: EMA decision of 18 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara) (EMEA-000311-PIP03-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/792254/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2012-ema-decision-18-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip03-11-m01_en.pdf"},
    {"id":"7588","name":"P/0231/2017: EMA decision of 11 August 2017 on the refusal of a modification of an agreed paediatric investigation plan for chlorhexidine gluconate /\n\nisopropyl alcohol (EMEA-000989-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/460041/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2017-ema-decision-11-august-2017-refusal-modification-agreed-paediatric-investigation-plan-chlorhexidine-gluconate-isopropyl-alcohol-emea-000989-pip01-10-m02_en.pdf"},
    {"id":"7591","name":"P/0315/2014: EMA decision of 5 December 2014 on the granting of a product specific waiver for amlodipine (besylate) / valsartan (Exforge), (EMEA-001680-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-22T01:00:00Z","reference_number":"EMA/668036/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0315-2014-ema-decision-5-december-2014-granting-product-specific-waiver-amlodipine-besylate-valsartan-exforge-emea-001680-pip01-14_en.pdf"},
    {"id":"7593","name":"P/242/2010: EMA decision of 16 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pixantrone (000713-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/703753/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-242-2010-ema-decision-16-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pixantrone-000713-pip02-10_en.pdf"},
    {"id":"7608","name":"P/0008/2012: EMA decision of 24 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for telaprevir (Incivo),\n\n(EMEA-000196-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-03-14T16:45:00Z","reference_number":"EMA/973114/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2012-ema-decision-24-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-telaprevir-incivo-emea-000196-pip01-08-m01_en.pdf"},
    {"id":"7650","name":"P/165/2009: European Medicines Agency decision of 14 August 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for human normal immunoglobulin (Gamm...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/493745/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-165-2009-european-medicines-agency-decision-14-august-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-normal-immunoglobulin-gamm_en.pdf"},
    {"id":"7659","name":"P/0110/2016: EMA decision of 15 April 2016 on the granting of a product specific waiver for Gallium [68Ga] (EMEA-001842-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/188353/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2016-ema-decision-15-april-2016-granting-product-specific-waiver-gallium-68ga-emea-001842-pip02-15_en.pdf"},
    {"id":"7660","name":"P/0385/2017: EMA decision of 19 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for cemiplimab\n\n(EMEA-002007-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/797357/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0385-2017-ema-decision-19-december-2017-agreement-paediatric-investigation-plan-granting-deferral-cemiplimab-emea-002007-pip02-17_en.pdf"},
    {"id":"7663","name":"P/81/2010: European Medicines Agency decision of 7 May 2010\n\non the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for taspoglutide (EMEA-000665-PIP01-09) i...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/265569/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-81-2010-european-medicines-agency-decision-7-may-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-taspoglutide-emea-000665-pip01-09-i_en.pdf"},
    {"id":"7688","name":"P/0117/2014: EMA decision of 6 May 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for febuxostat (Adenuric) (EMEA-001417-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-05T02:00:00Z","last_updated_date":"2014-06-05T02:00:00Z","reference_number":"EMA/195549/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2014-ema-decision-6-may-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-febuxostat-adenuric-emea-001417-pip01-12_en.pdf"},
    {"id":"7689","name":"P/0017/2018: EMA decision of 30 January 2018 on the agreement of a paediatric investigation plan and on the granting of a waiver for dienogest /\n\nethinyl estradiol (EMEA-002229-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T02:00:00Z","last_updated_date":"2018-04-17T02:00:00Z","reference_number":"EMA/28002/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2018-ema-decision-30-january-2018-agreement-paediatric-investigation-plan-granting-waiver-dienogest-ethinyl-estradiol-emea-002229-pip01-17_en.pdf"},
    {"id":"7695","name":"P/0116/2017: EMA decision of 28 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for doravirine /\n\nlamivudine / tenofovir disoproxil (fumarate) (EMEA-001695-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/251175/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2017-ema-decision-28-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-doravirine-lamivudine-tenofovir-disoproxil-fumarate-emea-001695-pip01-14-m01_en.pdf"},
    {"id":"7696","name":"P/0127/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tadalafil (Adcirca, Cialis), (EMEA-000452-PIP02-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/265075/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-tadalafil-adcirca-cialis-emea-000452-pip02-10-m04_en.pdf"},
    {"id":"7699","name":"P/10/2011:  EMA decision of 3 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pollen from betula pendula, (EMEA-000853-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/683406/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-10-2011-ema-decision-3-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-betula-pendula-emea-000853-pip01-10_en.pdf"},
    {"id":"7727","name":"P/0089/2012: EMA decision of 29 May 2012 on the granting of a product specific waiver for bimatoprost (Lumigan), (EMEA-000917-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T18:00:00Z","last_updated_date":"2012-06-25T18:00:00Z","reference_number":"EMA/329833/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2012-ema-decision-29-may-2012-granting-product-specific-waiver-bimatoprost-lumigan-emea-000917-pip02-11_en.pdf"},
    {"id":"7749","name":"P/114/2009: EMEA decision of 15 June 2009 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351836/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-114-2009-emea-decision-15-june-2009-agreement-pip-granting-deferral-granting-waiver-1h-purine-26-dione-8-3r-3-amino-1-piperidinyl-7-2-butyn-1-yl-37-dihydro-3_en.pdf"},
    {"id":"7754","name":"P/0061/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tafluprost\n\n(Taflotan and associated names), (EMEA-001187-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/130759/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-tafluprost-taflotan-associated-names-emea-001187-pip01-11-m04_en.pdf"},
    {"id":"7756","name":"P/151/2010: EMA decision of 16 August 2010 on the acceptance of a modification of an agreed paediatric investigation plan for zoledronic acid (Aclasta) (EMEA-000057-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-07T02:00:00Z","last_updated_date":"2010-10-07T02:00:00Z","reference_number":"EMA/500538/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-151-2010-ema-decision-16-august-2010-acceptance-modification-agreed-paediatric-investigation-plan-zoledronic-acid-aclasta-emea-000057-pip01-07-m02_en.pdf"},
    {"id":"7763","name":"P/0183/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat) (EMEA-000402-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/533642/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip02-11-m02_en.pdf"},
    {"id":"7774","name":"P/0235/2013: EMA decision of 24 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis), (EMEA-000183-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/496858/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2013-ema-decision-24-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip02-12-m01_en.pdf"},
    {"id":"7781","name":"P/0253/2015: EMA decision of 30 October 2015 on the granting of a product-specific waiver for gevokizumab (EMEA-001487-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/627024/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2015-ema-decision-30-october-2015-granting-product-specific-waiver-gevokizumab-emea-001487-pip02-15_en.pdf"},
    {"id":"7782","name":"P/111/2010: European Medicines Agency decision of 6 July 2010\n\non the refusal of a paediatric investigation plan and on the granting of a waiver for tulobuterol (EMEA-000763-PIP01-09) in accordance with Regulation (EC) N...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/409589/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-111-2010-european-medicines-agency-decision-6-july-2010-refusal-paediatric-investigation-plan-granting-waiver-tulobuterol-emea-000763-pip01-09-accordance-regulation-ec-n_en.pdf"},
    {"id":"7785","name":"P/0123/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for nusinersen (Spinraza), (EMEA-001448-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T02:00:00Z","last_updated_date":"2018-07-25T02:00:00Z","reference_number":"EMA/194906/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-nusinersen-spinraza-emea-001448-pip01-13-m03_en.pdf"},
    {"id":"7793","name":"P/0251/2013: EMA decision of 29 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Afinitor, Certican and associated names), (EMEA-000019-PIP06-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/598169/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2013-ema-decision-29-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-afinitor-certican-associated-names-emea-000019-pip06-09-m04_en.pdf"},
    {"id":"7809","name":"P/0216/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for tafluprost (Taflotan and associated names) (EMEA-001187-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/591158/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-tafluprost-taflotan-associated-names-emea-001187-pip01-11-m02_en.pdf"},
    {"id":"7821","name":"P/67/2009: European Medicines Agency decision of 20 April 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for Dihydroartemisinin / Piperaquine ph...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-06-10T02:00:00Z","last_updated_date":"2009-06-10T02:00:00Z","reference_number":"EMEA/23353/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-67-2009-european-medicines-agency-decision-20-april-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dihydroartemisinin-piperaquine-ph_en.pdf"},
    {"id":"7825","name":"P/0194/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for rivaroxaban (Xarelto), (EMEA-000430-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/310510/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-rivaroxaban-xarelto-emea-000430-pip01-08-m10_en.pdf"},
    {"id":"7834","name":"P/0008/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for aprepitant (Emend) (EMEA-000144-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-19T01:00:00Z","last_updated_date":"2014-02-19T01:00:00Z","reference_number":"EMA/10425/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-aprepitant-emend-emea-000144-pip01-07-m05_en.pdf"},
    {"id":"7836","name":"P/0108/2016: EMA decision of 15 April 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for humanised monoclonal antibody against myostatin (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/203699/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2016-ema-decision-15-april-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-humanised-monoclonal-antibody-against-myostatin-emea-0_en.pdf"},
    {"id":"7842","name":"P/0099/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (EMEA-000782-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/199534/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-emea-000782-pip01-09-m03_en.pdf"},
    {"id":"7850","name":"P/75/2011: EMA decision of 5 April 2011 on the acceptance of a modification of an agreed paediatric investigation plan for anidulafungin\n\n(Ecalta), (EMEA-000469-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/244166/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-75-2011-ema-decision-5-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-anidulafungin-ecalta-emea-000469-pip01-08-m02_en.pdf"},
    {"id":"7927","name":"P/0016/2017: EMA decision of 31 January 2017 on the refusal of a modification of an agreed paediatric investigation plan for bumetanide, (EMEA-001303-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/12333/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2017-ema-decision-31-january-2017-refusal-modification-agreed-paediatric-investigation-plan-bumetanide-emea-001303-pip01-12-m01_en.pdf"},
    {"id":"7928","name":"P/3/2011:  EMA decision of 3 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tazarotene (EMEA-000510-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/757746/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-3-2011-ema-decision-3-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tazarotene-emea-000510-pip02-10_en.pdf"},
    {"id":"7939","name":"P/0255/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for grazoprevir / elbasvir (Zepatier), (EMEA-001604-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T17:00:00Z","last_updated_date":"2017-10-26T17:00:00Z","reference_number":"EMA/501661/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-grazoprevir-elbasvir-zepatier-emea-001604-pip01-13-m03_en.pdf"},
    {"id":"7962","name":"P/257/2010:  EMA decision of 26 November 2010 on the agreement of a PIP and on the granting of a deferral and a waiver for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extracts of Phleum...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/710437/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-257-2010-ema-decision-26-november-2010-agreement-pip-granting-deferral-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergen-extracts-phleum_en.pdf"},
    {"id":"7972","name":"P/77/2010: European Medicines Agency decision of 7 May 2010 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-000167-PIP01-07-M01) in accordance with Reg...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/261382/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-77-2010-european-medicines-agency-decision-7-may-2010-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000167-pip01-07-m01-accordance-reg_en.pdf"},
    {"id":"7973","name":"P/0085/2014: EMA decision of 4 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-000454-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/103190/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2014-ema-decision-4-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000454-pip01-08-m04_en.pdf"},
    {"id":"7990","name":"P/101/2008: European Medicines Agency decision of 3 November 2008 on the application for product specific waiver for influenza virus type A, H3N2, influenza virus type A, H1N1, influenza virus type B (EMEA-000249-PIP01-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-07T01:00:00Z","last_updated_date":"2009-01-07T01:00:00Z","reference_number":"EMEA/572430/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-101-2008-european-medicines-agency-decision-3-november-2008-application-product-specific-waiver-influenza-virus-type-h3n2-influenza-virus-type-h1n1-influenza-virus-type-b-emea-000249-pip01-0_en.pdf"},
    {"id":"8004","name":"P/0268/2017: EMA decision of 7 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for avacopan\n\n(EMEA-002023-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T17:00:00Z","last_updated_date":"2017-10-26T17:00:00Z","reference_number":"EMA/541695/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2017-ema-decision-7-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-avacopan-emea-002023-pip01-16-m01_en.pdf"},
    {"id":"8008","name":"P/58/2009: European Medicines Agency decision of 27 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for tobramycin (EMEA-000184-PIP01-08) i...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/155979/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-58-2009-european-medicines-agency-decision-27-march-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tobramycin-emea-000184-pip01-08-i_en.pdf"},
    {"id":"8024","name":"P/0028/2012: EMA decision of 27 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for imatinib mesilate\n\n(Glivec) (EMEA-000463-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/36974/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2012-ema-decision-27-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-imatinib-mesilate-glivec-emea-000463-pip01-08-m03_en.pdf"},
    {"id":"8047","name":"P/0072/2017: EMA decision of 17 March 2017 on the granting of a product specific waiver for 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-\n\nisopropyl-4H-1,2,4-triazol-3-yl)pyridi-2-yl)-4-methylbenzamide (EMEA-00186...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/137095/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2017-ema-decision-17-march-2017-granting-product-specific-waiver-5-4-cyclopropyl-1h-imidazol-1-yl-2-fluoro-n-6-4-isopropyl-4h-124-triazol-3-ylpyridi-2-yl-4-methylbenzamide-emea-00186_en.pdf"},
    {"id":"8052","name":"P/0289/2015: EMA decision of 27 November 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 4-Amino-2-butoxy-8-[3-(pyrrolidin-1-ylmethyl)benzyl]...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/689628/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2015-ema-decision-27-november-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-4-amino-2-butoxy-8-3-pyrrolidin-1-ylmethylbenzyl_en.pdf"},
    {"id":"8059","name":"P/0183/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lonoctocog alfa (Afstyla), (EMEA-001215-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/358069/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-lonoctocog-alfa-afstyla-emea-001215-pip01-11-m05_en.pdf"},
    {"id":"8083","name":"P/0213/2012: EMA decision of 28 September 2012 on the granting of a product specific waiver for lapatinib (ditosylate monohydrate) (Tyverb), (EMEA-000404-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T18:45:00Z","last_updated_date":"2012-10-17T18:45:00Z","reference_number":"EMA/492880/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2012-ema-decision-28-september-2012-granting-product-specific-waiver-lapatinib-ditosylate-monohydrate-tyverb-emea-000404-pip02-12_en.pdf"},
    {"id":"8090","name":"P/0145/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for loxapine (EMEA-001115-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/367143/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-loxapine-emea-001115-pip01-10-m03_en.pdf"},
    {"id":"8103","name":"P/0071/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for naltrexone (hydrochloride) / bupropion (hydrochloride) (Mysimba), (EMEA-001373-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/104834/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-naltrexone-hydrochloride-bupropion-hydrochloride-mysimba-emea-001373-pip01-12-m01_en.pdf"},
    {"id":"8122","name":"P/0204/2016: EMA decision of 1 August 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pembrolizumab (Keytruda), (EMEA-001474-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/508723/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2016-ema-decision-1-august-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pembrolizumab-keytruda-emea-001474-pip02-16_en.pdf"},
    {"id":"8153","name":"P/190/2011: EMA decision of 2 August 2011 on the granting of a product specific waiver for amlodipine (besilate) / valsartan (EMEA-001138-PIP02-\n\n11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/500415/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-190-2011-ema-decision-2-august-2011-granting-product-specific-waiver-amlodipine-besilate-valsartan-emea-001138-pip02-11_en.pdf"},
    {"id":"8160","name":"P/0038/2017: European Medicines Agency decision of 30 January 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for ambrisentan / tadalafil (EMEA-0020...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/2910/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2017-european-medicines-agency-decision-30-january-2017-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-ambrisentan-tadalafil-emea-0020_en.pdf"},
    {"id":"8165","name":"P/49/2009: European Medicines Agency decision of 24 March 2009 on the refusal of a product specific waiver for melatonin (Circadin) (EMEA-000440-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European P...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/156983/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-49-2009-european-medicines-agency-decision-24-march-2009-refusal-product-specific-waiver-melatonin-circadin-emea-000440-pip01-08-accordance-regulation-ec-no-1901-2006-european-p_en.pdf"},
    {"id":"8184","name":"P/0233/2017: EMA decision of 11 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for romiplostim (Nplate), (EMEA-000653-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/460032/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2017-ema-decision-11-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-romiplostim-nplate-emea-000653-pip01-09-m05_en.pdf"},
    {"id":"8195","name":"P/0042/2013: European medicines agency decision of 1 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for cilengitide (EMEA-000550-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/117801/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2013-european-medicines-agency-decision-1-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-cilengitide-emea-000550-pip02-10-m01_en.pdf"},
    {"id":"8213","name":"P/0181/2012: EMA decision of 20 August 2012 on the granting of a product specific waiver for rosuvastatin / ezetimibe (EMEA-001278-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/480335/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2012-ema-decision-20-august-2012-granting-product-specific-waiver-rosuvastatin-ezetimibe-emea-001278-pip01-12_en.pdf"}    {"id":"8219","name":"P/0114/2017: EMA decision of 11 April 2017 on the granting of a product specific waiver for tobramycin (TOBI Podhaler) (EMEA-000184-PIP03-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/199884/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0114-2017-ema-decision-11-april-2017-granting-product-specific-waiver-tobramycin-tobi-podhaler-emea-000184-pip03-16_en.pdf"},
    {"id":"8229","name":"P/0303/2014: EMA decision of 24 November 2014 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant fusion protein consisting of human coagulation factor IX attached to the Fc dom...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/640510/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2014-ema-decision-24-november-2014-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-fusion-protein-consisting-human-coagulation-factor-ix-attached-fc-dom_en.pdf"},
    {"id":"8230","name":"P/0173/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (Colobreathe), (EMEA-000176-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/357972/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-colistimethate-sodium-colobreathe-emea-000176-pip01-07-m05_en.pdf"},
    {"id":"8233","name":"P/136/2010:  European Medicines Agency decision of 28 July 2010 on the granting of a product specific waiver for amlodipine/ramipril (EMEA-000887-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/464681/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-136-2010-european-medicines-agency-decision-28-july-2010-granting-product-specific-waiver-amlodipine-ramipril-emea-000887-pip01-10-accordance-regulation-ec-no-1901-2006-european_en.pdf"},
    {"id":"8239","name":"P/214/2010: European Medicines Agency decision of 29 October 2010 on the granting of a product specific waiver for dronabinol (EMEA-000643-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/655072/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-214-2010-european-medicines-agency-decision-29-october-2010-granting-product-specific-waiver-dronabinol-emea-000643-pip01-09_en.pdf"},
    {"id":"8244","name":"P/0128/2015: EMA decision of 5 June 2015 on the refusal of a product-specific waiver for levomilnacipran (EMEA-001724-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/355186/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2015-ema-decision-5-june-2015-refusal-product-specific-waiver-levomilnacipran-emea-001724-pip01-14_en.pdf"},
    {"id":"8260","name":"P/322/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for cysteamine hydrochloride (EMEA-000322-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/790256/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-322-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-cysteamine-hydrochloride-emea-000322-pip01-08-m04_en.pdf"},
    {"id":"8264","name":"P/333/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for aqueous allergen extract of grass and cereal pollen ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/815111/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-333-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aqueous-allergen-extract-grass-cereal-pollen_en.pdf"},
    {"id":"8277","name":"P/0083/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tralokinumab (EMEA-001900-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/75601/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tralokinumab-emea-001900-pip02-17_en.pdf"},
    {"id":"8286","name":"P/0004/2016: EMA decision of 22 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for conestat alfa (Ruconest), (EMEA-000367-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/864426/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2016-ema-decision-22-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-conestat-alfa-ruconest-emea-000367-pip01-08-m05_en.pdf"},
    {"id":"8295","name":"P/0178/2013: EMA decision of 30 July 2013 on the granting of a product-specific waiver for pegylated proline-interferon alpha-2b (EMEA-001433-\n\nPIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/367827/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2013-ema-decision-30-july-2013-granting-product-specific-waiver-pegylated-proline-interferon-alpha-2b-emea-001433-pip01-13_en.pdf"},
    {"id":"8304","name":"P/293/2011: EMA decision of 8 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for nonacog alfa\n\n(recombinant coagulation factor IX) (EMEA-001139-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/878747/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-293-2011-ema-decision-8-december-2011-agreement-paediatric-investigation-plan-granting-deferral-nonacog-alfa-recombinant-coagulation-factor-ix-emea-001139-pip01-11_en.pdf"},
    {"id":"8305","name":"P/0050/2018: EMA decision of 22 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for nivolumab (Opdivo),\n\n(EMEA-001407-PIP02-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/101775/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2018-ema-decision-22-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-nivolumab-opdivo-emea-001407-pip02-15-m02_en.pdf"},
    {"id":"8306","name":"P/106/2008: European Medicines Agency decision of 28 November 2008 on the application for product specific waiver for perflubutane EMEA-000194-PIP01-08 in accordance with Regulation (EC) No 1901/2006 of the European Parl...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/625241/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-106-2008-european-medicines-agency-decision-28-november-2008-application-product-specific-waiver-perflubutane-emea-000194-pip01-08-accordance-regulation-ec-no-1901-2006-european-parl_en.pdf"},
    {"id":"8307","name":"P/0201/2013: EMA decision of 2 September 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for retosiban (EMEA-001359-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"EMA/482792/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2013-ema-decision-2-september-2013-agreement-paediatric-investigation-plan-granting-waiver-retosiban-emea-001359-pip01-12_en.pdf"},
    {"id":"8309","name":"P/253/2009: EMA decision of 22 December 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for aliskiren (Rasilez) (EMEA-0003...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMA/812054/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-253-2009-ema-decision-22-december-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aliskiren-rasilez-emea-0003_en.pdf"},
    {"id":"8364","name":"P/0253/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat / emtricitabine / tenofovir alafenamide (EMEA-001825-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T17:00:00Z","last_updated_date":"2017-10-26T17:00:00Z","reference_number":"EMA/493101/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-emea-001825-pip01-15-m01_en.pdf"},
    {"id":"8380","name":"P/8/2011:  EMA decision of 3 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pollen from pollen from alnus glutinosa, betula verrucos...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/753493/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-8-2011-ema-decision-3-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-pollen-alnus-glutinosa-betula-verrucos_en.pdf"},
    {"id":"8431","name":"P/0031/2017: European Medicines Agency decision of 30 January 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for volanesorsen (EMEA-001915-PIP01...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/2917/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2017-european-medicines-agency-decision-30-january-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-volanesorsen-emea-001915-pip01_en.pdf"},
    {"id":"8437","name":"P/0063/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir /\n\nledipasvir (Harvoni), (EMEA-001411-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/114829/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-sofosbuvir-ledipasvir-harvoni-emea-001411-pip01-12-m04_en.pdf"},
    {"id":"8448","name":"P/0136/2017: EMA decision of 7 June 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cannabidiol (CBD) (EMEA-001964-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/312728/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2017-ema-decision-7-june-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cannabidiol-cbd-emea-001964-pip01-16_en.pdf"},
    {"id":"8458","name":"P/95/2010: EMA decision of 2 June 2010on the acceptance of a modification of an agreed paediatric investigation plan for rivaroxaban (Xarelto) (EMEA-000430-PIP01-08-M01) in accordance with Regula...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-07-28T01:09:00Z","reference_number":"EMA/309268/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-95-2010-ema-decision-2-june-2010on-acceptance-modification-agreed-paediatric-investigation-plan-rivaroxaban-xarelto-emea-000430-pip01-08-m01-accordance-regula_en.pdf"},
    {"id":"8484","name":"P/188/2011: EMA decision of 2 August 2011 on the granting of a product specific waiver for strontium (ranelate) / colecalciferol (EMEA-001131-\n\nPIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/503744/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-188-2011-ema-decision-2-august-2011-granting-product-specific-waiver-strontium-ranelate-colecalciferol-emea-001131-pip01-11_en.pdf"},
    {"id":"8524","name":"P/256/2011: EMA decision of 26 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ceftaroline fosamil (EMEA-000769-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T17:00:00Z","last_updated_date":"2011-11-30T17:00:00Z","reference_number":"EMA/829145/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-256-2011-ema-decision-26-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-ceftaroline-fosamil-emea-000769-pip01-09-m01_en.pdf"},
    {"id":"8533","name":"P/0103/2018: EMA decision of 19 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for plazomicin (sulfate) (EMEA-001639-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/156109/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2018-ema-decision-19-march-2018-agreement-paediatric-investigation-plan-granting-deferral-plazomicin-sulfate-emea-001639-pip02-17_en.pdf"},
    {"id":"8540","name":"P/0052/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ceftazidime / avibactam (EMEA-001313-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-25T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/133540/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2015-ema-decision-6-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-emea-001313-pip01-12-m03_en.pdf"},
    {"id":"8545","name":"P/0275/2017: EMA decision of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for roxadustat (EMEA-\n\n001557-PIP01-13-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/565803/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2017-ema-decision-4-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-roxadustat-emea-001557-pip01-13-m01_en.pdf"},
    {"id":"8565","name":"P/0191/2013: EMA decision of 9 August 2013 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga) (EMEA-000597-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-10T12:20:00Z","last_updated_date":"2013-09-10T12:20:00Z","reference_number":"EMA/476084/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2013-ema-decision-9-august-2013-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip02-10-m01_en.pdf"},
    {"id":"8599","name":"P/0275/2012: EMA decision of of 21 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for human normal\n\nimmunoglobulin (EMEA-000454-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/727269/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2012-ema-decision-21-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000454-pip01-08-m02_en.pdf"},
    {"id":"8643","name":"P/154/2010: EMA decision of 17 March 2010 on the acceptance of a modification of an agreed paediatric investigation plan for boceprevir\n\n(EMEA-000583-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-07T02:00:00Z","last_updated_date":"2010-10-07T02:00:00Z","reference_number":"EMA/525486/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-154-2010-ema-decision-17-march-2010-acceptance-modification-agreed-paediatric-investigation-plan-boceprevir-emea-000583-pip01-09-m01_en.pdf"},
    {"id":"8657","name":"P/0045/2018: EMA decision of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor (Kalydeco) (EMEA-000335-PIP01-08-M12)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T13:35:00Z","last_updated_date":"2018-04-17T13:35:00Z","reference_number":"EMA/85241/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2018-ema-decision-16-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-kalydeco-emea-000335-pip01-08-m12_en.pdf"},
    {"id":"8660","name":"P/0273/2016: EMA decision of 5 October 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for recombinant, CHO cell expressed, fully human IgG1, ka...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/592953/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2016-ema-decision-5-october-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-cho-cell-expressed-fully-human-igg1-ka_en.pdf"},
    {"id":"8714","name":"P/216/2009: European Medicines Agency decision of 30 October 2009 on the refusal of a product specific waiver for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerized allergic extract of birch pollen (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/679780/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-216-2009-european-medicines-agency-decision-30-october-2009-refusal-product-specific-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerized-allergic-extract-birch-pollen-eme_en.pdf"},
    {"id":"8727","name":"P/0112/2016: EMA decision of 15 April 2016 on the granting of a product specific waiver for Atorvastatin / Perindopril (arginine) (EMEA-001876-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/199336/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2016-ema-decision-15-april-2016-granting-product-specific-waiver-atorvastatin-perindopril-arginine-emea-001876-pip01-15_en.pdf"},
    {"id":"8741","name":"P/54/2010: European Medicines Agency decision of 7 April 2010 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for semuloparin sodium (EMEA-000562-PIP0...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/118884/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-54-2010-european-medicines-agency-decision-7-april-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-semuloparin-sodium-emea-000562-pip0_en.pdf"},
    {"id":"8764","name":"P/0146/2014: EMA decision of 13 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine (Valdoxan, Thymanax), (EMEA-001181-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-28T02:00:00Z","last_updated_date":"2014-07-28T02:00:00Z","reference_number":"EMA/319518/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2014-ema-decision-13-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-agomelatine-valdoxan-thymanax-emea-001181-pip01-11-m01_en.pdf"},
    {"id":"8778","name":"P/0262/2015: EMA decision of 30 October 2015 on the granting of a product specific waiver for 18F-fluoroestradiol (EMEA-001817-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-22T13:00:00Z","last_updated_date":"2015-12-22T13:00:00Z","reference_number":"EMA/627027/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2015-ema-decision-30-october-2015-granting-product-specific-waiver-18f-fluoroestradiol-emea-001817-pip01-15_en.pdf"},
    {"id":"8801","name":"P/173/2011: EMA decision of 8 July 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant\n\nfusion protein consisting of Human Coagulation Factor VIII attached to the Fc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/491168/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-173-2011-ema-decision-8-july-2011-agreement-paediatric-investigation-plan-granting-deferral-recombinant-fusion-protein-consisting-human-coagulation-factor-viii-attached-fc_en.pdf"},
    {"id":"8804","name":"P/0112/2013: EMA decision of 30 April 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant human lysosomal acid lipase (EMEA-001331-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/203353/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2013-ema-decision-30-april-2013-agreement-paediatric-investigation-plan-granting-deferral-recombinant-human-lysosomal-acid-lipase-emea-001331-pip01-12_en.pdf"},
    {"id":"8814","name":"P/246/2009: European medicines agency decision of 27 November 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for Dabigatran etexilate mesilate (Pradaxa) (EMEA-000081-PIP01-07-M01) in ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:00:00Z","last_updated_date":"2009-12-23T00:00:00Z","reference_number":"EMEA/757789/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-246-2009-european-medicines-agency-decision-27-november-2009-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-mesilate-pradaxa-emea-000081-pip01-07-m01_en.pdf"},
    {"id":"8816","name":"P/0317/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for methoxy\n\npolyethylene glycol - epoetin beta (Mircera) (EMEA-000172-PIP01-07-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T16:26:00Z","last_updated_date":"2018-02-13T16:26:00Z","reference_number":"EMA/662067/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-methoxy-polyethylene-glycol-epoetin-beta-mircera-emea-000172-pip01-07-m03_en.pdf"},
    {"id":"8850","name":"P/0058/2013: European medicines agency decision of 26 March 2013 on the refusal of a modification of an agreed paediatric investigation plan for everolimus (Votubia), (EMEA-000019-PIP02-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/111742/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2013-european-medicines-agency-decision-26-march-2013-refusal-modification-agreed-paediatric-investigation-plan-everolimus-votubia-emea-000019-pip02-07-m04_en.pdf"},
    {"id":"8860","name":"P/0334/2014: EMA decision of 22 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen (EMEA-001208-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T01:00:00Z","last_updated_date":"2015-02-23T01:00:00Z","reference_number":"EMA/711021/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2014-ema-decision-22-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-emea-001208-pip01-11-m01_en.pdf"},
    {"id":"8884","name":"P/270/2011: EMA decision of 28 October 2011 on the granting of a product specific waiver for clopidogrel (bisulphate) / acetylsalicylic acid (EMEA-\n\n001163-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T01:00:00Z","last_updated_date":"2011-11-29T01:00:00Z","reference_number":"EMA/849727/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-270-2011-ema-decision-28-october-2011-granting-product-specific-waiver-clopidogrel-bisulphate-acetylsalicylic-acid-emea-001163-pip01-11_en.pdf"},
    {"id":"8896","name":"P/260/2011: EMA decision of 28 October 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for secretin (EMEA-001069-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T01:00:00Z","last_updated_date":"2011-11-29T01:00:00Z","reference_number":"EMA/776844/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-260-2011-ema-decision-28-october-2011-agreement-paediatric-investigation-plan-granting-deferral-secretin-emea-001069-pip01-10_en.pdf"},
    {"id":"8916","name":"P/0043/2014: European Medicines Agency decision of 26 February 2014\n\non the acceptance of a modification of an agreed paediatric investigation plan for rupadatine fumarate (Rupafin and associated names) (EMEA-000582-PIP0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-03-20T01:00:00Z","last_updated_date":"2014-03-20T01:00:00Z","reference_number":"EMA/87776/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2014-european-medicines-agency-decision-26-february-2014-acceptance-modification-agreed-paediatric-investigation-plan-rupadatine-fumarate-rupafin-associated-names-emea-000582-pip0_en.pdf"},
    {"id":"8927","name":"P/133/2009: European Medicines Agency decision of 15 July 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for insulin glargine (Lantus) (EMEA-000387-PIP01-08) in accordance with R...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/387927/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-133-2009-european-medicines-agency-decision-15-july-2009-agreement-paediatric-investigation-plan-granting-waiver-insulin-glargine-lantus-emea-000387-pip01-08-accordance-r_en.pdf"},
    {"id":"8994","name":"P/0238/2014: EMA decision of 19 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tap...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-10-09T02:00:00Z","last_updated_date":"2014-10-09T02:00:00Z","reference_number":"EMA/555779/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2014-ema-decision-19-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tap_en.pdf"},
    {"id":"9007","name":"P/0233/2016: EMA decision of 9 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz),\n\n(EMEA-001050-PIP01-10-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/576562/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2016-ema-decision-9-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-ixekizumab-taltz-emea-001050-pip01-10-m02_en.pdf"},
    {"id":"9051","name":"P/0102/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ferric maltol\n\n(Feraccru), (EMEA-001195-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/202479/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-ferric-maltol-feraccru-emea-001195-pip01-11-m02_en.pdf"},
    {"id":"9053","name":"P/09/2009: European Medicines Agency decision of 27 January 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for ceftobiprole medocaril sodium (EMEA-000205-PIP01-08) in accordanc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/23291/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-09-2009-european-medicines-agency-decision-27-january-2009-agreement-paediatric-investigation-plan-granting-deferral-ceftobiprole-medocaril-sodium-emea-000205-pip01-08-accordanc_en.pdf"},
    {"id":"9055","name":"P/0134/2012: EMA decision of 6 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for rivaroxaban (Xarelto) (EMEA-000430-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-06T18:00:00Z","last_updated_date":"2012-08-06T18:00:00Z","reference_number":"EMA/430103/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2012-ema-decision-6-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-rivaroxaban-xarelto-emea-000430-pip01-08-m03_en.pdf"},
    {"id":"9068","name":"P/0149/2012: EMA decision of 24 July 2012 on the refusal of a product specific waiver for tivantinib (EMEA-001284-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T18:30:00Z","last_updated_date":"2012-08-22T18:30:00Z","reference_number":"EMA/470735/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2012-ema-decision-24-july-2012-refusal-product-specific-waiver-tivantinib-emea-001284-pip01-12_en.pdf"},
    {"id":"9078","name":"P/0265/2014: EMA decision of 10 October 2014 on the refusal of a modification of an agreed paediatric investigation plan for dihydroartemisinin / piperaquine phosphate anhydride (EMEA-000153-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/590274/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2014-ema-decision-10-october-2014-refusal-modification-agreed-paediatric-investigation-plan-dihydroartemisinin-piperaquine-phosphate-anhydride-emea-000153-pip01-07-m02_en.pdf"},
    {"id":"9081","name":"P/0083/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for vigabatrin (EMEA-\n\n000717-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/128919/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-vigabatrin-emea-000717-pip02-13-m02_en.pdf"},
    {"id":"9086","name":"P/0083/2012: EMA decision of 16 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for belatacept (Nulojix) (EMEA-000157-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/304247/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2012-ema-decision-16-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-belatacept-nulojix-emea-000157-pip01-07-m01_en.pdf"},
    {"id":"9093","name":"P/0120/2017: EMA decision of 5 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol hydrochloride) (Palexia and associated names, Yantil and associated names, Tapentadol ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/244179/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2017-ema-decision-5-may-2017-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapentadol_en.pdf"},
    {"id":"9128","name":"P/0002/2012: EMA decision of 23 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract from ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/972929/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2012-ema-decision-23-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergen-extract_en.pdf"},
    {"id":"9133","name":"P/0336/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for eravacycline\n\n(EMEA-001555-PIP01-13-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T13:11:00Z","last_updated_date":"2017-02-03T13:11:00Z","reference_number":"EMA/765277/2016 corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-eravacycline-emea-001555-pip01-13-m02_en.pdf"},
    {"id":"9151","name":"P/0046/2013: EMA decision of 1 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obinutuzumab (EMEA-001207-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/119910/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2013-ema-decision-1-march-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-obinutuzumab-emea-001207-pip01-11_en.pdf"},
    {"id":"9152","name":"P/0030/2017: European Medicines Agency decision of 31 January 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for 2-hydroxypropyl-àŸ-cyclodextrin (EMEA-001866-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/12304/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2017-european-medicines-agency-decision-31-january-2017-agreement-paediatric-investigation-plan-granting-deferral-2-hydroxypropyl-ay-cyclodextrin-emea-001866-pip01-15_en.pdf"},
    {"id":"9166","name":"P/0369/2017: EMA decision of 1 December 2017 on the granting of a product specific waiver for opicinumab (EMEA-002194-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-05T15:26:00Z","last_updated_date":"2018-03-05T15:26:00Z","reference_number":"EMA/709975/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0369-2017-ema-decision-1-december-2017-granting-product-specific-waiver-opicinumab-emea-002194-pip01-17_en.pdf"},
    {"id":"9175","name":"P/26/2010: European Medicines Agency decision of of 3 March 2010 on the acceptance of a modification of an agreed Paediatric Investigation Plan for nevirapine (Viramune) (EMEA-000391-PIP01-08-M01) in accordance with Regu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMA/116975/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-26-2010-european-medicines-agency-decision-3-march-2010-acceptance-modification-agreed-paediatric-investigation-plan-nevirapine-viramune-emea-000391-pip01-08-m01-accordance-regu_en.pdf"},
    {"id":"9178","name":"P/0015/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for regadenoson\n\n(Rapiscan) (EMEA-000410-PIP01-08-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T15:28:00Z","last_updated_date":"2018-04-17T15:28:00Z","reference_number":"EMA/792962/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-regadenoson-rapiscan-emea-000410-pip01-08-m02_en.pdf"},
    {"id":"9182","name":"P/0172/2016: EMA decision of 17 June 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Influenza virus surface antigens of strain A (H3N2) / st...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/337108/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2016-ema-decision-17-june-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-influenza-virus-surface-antigens-strain-h3n2-st_en.pdf"},
    {"id":"9199","name":"P/0006/2012: EMA decision of 24 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Afinitor), (Certican and associated names), (EMEA-000019-PIP06-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/25160/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2012-ema-decision-24-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-afinitor-certican-associated-names-emea-000019-pip06-09-m02_en.pdf"},
    {"id":"9211","name":"P/0301/2017: EMA decision of 6 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dabigatran etexilate\n\nmesilate (Pradaxa) (EMEA-000081-PIP01-07-M10)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T16:26:00Z","last_updated_date":"2018-02-13T16:26:00Z","reference_number":"EMA/644227/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2017-ema-decision-6-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-mesilate-pradaxa-emea-000081-pip01-07-m10_en.pdf"},
    {"id":"9236","name":"P/147/2010:  European Medicines Agency decision of 30 July 2010 on the granting of a product specific waiver for tafamidis meglumine (EMEA-000884-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/425477/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-147-2010-european-medicines-agency-decision-30-july-2010-granting-product-specific-waiver-tafamidis-meglumine-emea-000884-pip01-10-accordance-regulation-ec-no-1901-2006-european_en.pdf"},
    {"id":"9244","name":"P/0288/2017: EMA decision of 4 October 2017 on the granting of a product specific waiver for benralizumab (EMEA-001214-PIP02-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T13:11:00Z","last_updated_date":"2018-02-12T13:11:00Z","reference_number":"EMA/541691/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2017-ema-decision-4-october-2017-granting-product-specific-waiver-benralizumab-emea-001214-pip02-17_en.pdf"},
    {"id":"9245","name":"P/0148/2016: EMA decision of 14 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for melatonin (Circadin)\n\n(EMEA-000440-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/380534/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2016-ema-decision-14-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-melatonin-circadin-emea-000440-pip02-11-m04_en.pdf"},
    {"id":"9255","name":"P/0073/2017: EMA decision of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for 8-chloro-5-methyl-1-[trans-4-(pyridin-2-yloxy)cyclohex...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/137097/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2017-ema-decision-17-march-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-8-chloro-5-methyl-1-trans-4-pyridin-2-yloxycyclohex_en.pdf"},
    {"id":"9260","name":"P/139/2011: EMA decision of 1 June 2011 on the acceptance of a modification of an agreed paediatric investigation plan for mipomersen (sodium) (EMEA-000928-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-13T02:00:00Z","last_updated_date":"2011-07-13T02:00:00Z","reference_number":"EMA/425115/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-139-2011-ema-decision-1-june-2011-acceptance-modification-agreed-paediatric-investigation-plan-mipomersen-sodium-emea-000928-pip01-10-m01_en.pdf"},
    {"id":"9266","name":"P/0218/2012: EMA decision of 28 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol\n\n(hydrochloride) (Palexia, Yantil), (EMEA-000018-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T17:00:00Z","last_updated_date":"2012-10-17T17:00:00Z","reference_number":"EMA/598557/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2012-ema-decision-28-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-yantil-emea-000018-pip01-07-m04_en.pdf"},
    {"id":"9269","name":"P/0232/2015: EMA decision of 27 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine / rilpivirine (hydrochloride) / tenofovir (disoproxil fumarate), (Eviplera), (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/619851/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2015-ema-decision-27-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-emtricitabine-rilpivirine-hydrochloride-tenofovir-disoproxil-fumarate-eviplera_en.pdf"},
    {"id":"9270","name":"P/0033/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for house dust mites allergen extracts (EMEA-000319-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-25T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/49374/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2015-ema-decision-6-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-house-dust-mites-allergen-extracts-emea-000319-pip01-08-m03_en.pdf"},
    {"id":"9290","name":"P/0021/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-001797-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"EMA/850458/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-001797-pip01-15-m01_en.pdf"},
    {"id":"9306","name":"P/0172/2014: EMA decision of 11 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for insulin detemir (Levemir), (EMEA-000412-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/314402/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2014-ema-decision-11-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-insulin-detemir-levemir-emea-000412-pip01-08-m01_en.pdf"},
    {"id":"9310","name":"P/0092/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tapenta...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/188340/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapenta_en.pdf"},
    {"id":"9341","name":"P/0191/2014: EMA decision of 6 August 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrah...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/447544/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2014-ema-decision-6-august-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-n-13-dicyclohexyl-6-hydroxy-24-dioxo-1234-tetrah_en.pdf"},
    {"id":"9348","name":"P/0233/2012: EMA decision of 5 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for pitavastatin (calcium) (Pitavastatin and associated names), (EMEA-000302-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/626087/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2012-ema-decision-5-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-pitavastatin-calcium-pitavastatin-associated-names-emea-000302-pip01-08-m03_en.pdf"},
    {"id":"9357","name":"P/0319/2015: EMA decision of 21 December 2015 on the granting of a product-specific waiver for recombinant human monoclonal IgG1 antibody directed against Programmed Death Ligand-1 (anti-PD-L1) (MSB0010718C) (EMEA-001849...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/791990/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0319-2015-ema-decision-21-december-2015-granting-product-specific-waiver-recombinant-human-monoclonal-igg1-antibody-directed-against-programmed-death-ligand-1-anti-pd-l1-msb0010718c-emea-001849_en.pdf"},
    {"id":"9371","name":"P/0124/2015: EMA decision of 5 June 2015 on the agreement of a paediatric investigation plan and on the granting of a waiver for misoprostol (EMEA-001601-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-03T02:00:00Z","last_updated_date":"2015-07-03T02:00:00Z","reference_number":"EMA/300766/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2015-ema-decision-5-june-2015-agreement-paediatric-investigation-plan-granting-waiver-misoprostol-emea-001601-pip01-13_en.pdf"},
    {"id":"9373","name":"P/159/2010: EMA decision of 27 August 2010 on the agreement of a paediatric investigation plan and on the granting of a product specific waiver for telmisartan / hydrochlorothiazide (MicardisPlus)\n\n(EMEA-000885-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/477373/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-159-2010-ema-decision-27-august-2010-agreement-paediatric-investigation-plan-granting-product-specific-waiver-telmisartan-hydrochlorothiazide-micardisplus-emea-000885-pip01-10_en.pdf"},
    {"id":"9375","name":"P/0212/2013: EMA decision of 3 September 2013 on the granting of a product-specific waiver for risedronate sodium / colecalciferol (EMEA-001421-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/483102/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2013-ema-decision-3-september-2013-granting-product-specific-waiver-risedronate-sodium-colecalciferol-emea-001421-pip01-12_en.pdf"},
    {"id":"9418","name":"P/255/2011: EMA decision of 26 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for 2'-O-methyl-uridylyl-(3'→5' O,O-phosphorothioyl)-2'-O-methyl-cytidylyl-..(EMEA-000746-PIP01...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T17:00:00Z","last_updated_date":"2011-11-30T17:00:00Z","reference_number":"EMA/764016/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-255-2011-ema-decision-26-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-2-o-methyl-uridylyl-3a5-oo-phosphorothioyl-2-o-methyl-cytidylyl-emea-000746-pip01_en.pdf"},
    {"id":"9450","name":"P/56/2011: EMA decision of 4 March 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bimatoprost (LUMIGAN 0.1 mg/ml eye drops, solution, LUMIGA...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/78091/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-56-2011-ema-decision-4-march-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bimatoprost-lumigan-01-mg-ml-eye-drops-solution-lumiga_en.pdf"},
    {"id":"9452","name":"P/0042/2014: EMA decision of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for darbepoetin alfa (Aranesp), (EMEA-000329-PIP02-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/52905/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2014-ema-decision-5-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-darbepoetin-alfa-aranesp-emea-000329-pip02-09-m03_en.pdf"},
    {"id":"9468","name":"P/232/2010:  EMA decision of 23 November 2010 on the refusal of a product specific waiver for 4-hydroxy-n-(2-hydroxyethyl)-butyramide (EMEA-\n\n000764-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/663284/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-232-2010-ema-decision-23-november-2010-refusal-product-specific-waiver-4-hydroxy-n-2-hydroxyethyl-butyramide-emea-000764-pip01-09_en.pdf"},
    {"id":"9471","name":"P/0225/2017: EMA decision of 11 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for allantoin (EMEA-\n\n001590-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/460043/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2017-ema-decision-11-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-allantoin-emea-001590-pip01-13-m04_en.pdf"},
    {"id":"9491","name":"P/0034/2015: EMA decision of 6 March 2015on the acceptance of a modification of an agreed paediatric investigation plan for insulin degludec / insulin aspart (Ryzodeg), (EMEA-000479-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-25T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/86543/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2015-ema-decision-6-march-2015on-acceptance-modification-agreed-paediatric-investigation-plan-insulin-degludec-insulin-aspart-ryzodeg-emea-000479-pip01-08-m03_en.pdf"},
    {"id":"9499","name":"P/0276/2012: EMA decision of of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for simeprevir (EMEA-000625-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/10917/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2012-ema-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-simeprevir-emea-000625-pip01-09-m02_en.pdf"},
    {"id":"9501","name":"P/0285/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for febuxostat (Adenuric), (EMEA-001417-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/690898/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-febuxostat-adenuric-emea-001417-pip01-12-m01_en.pdf"},
    {"id":"9512","name":"P/0015/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for siponimod (hemifumarate) (EMEA-000716-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-03-25T01:00:00Z","reference_number":"EMA/784023/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-siponimod-hemifumarate-emea-000716-pip01-09-m01_en.pdf"},
    {"id":"9516","name":"P/2/2010: EMA decision on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the refusal of a waiver for (1R,2R,4S)-4-{(2R)-2- [(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-(...)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/27223/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-2-2010-ema-decision-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-1r2r4s-4-2r-2-3s6r7e9r10r12r14s15e17e19e21s23s26r27r34as-927-dihydroxy-1021_en.pdf"},
    {"id":"9541","name":"P/67/2011: EMA decision of 11 March 2011 on the acceptance of a modification of an agreed paediatric investigation plan for antigen of prepandemic strain A/Vietnam/1203/2004 propagated in vero cells (EMEA-000156-PIP01-07...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/412014/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-67-2011-ema-decision-11-march-2011-acceptance-modification-agreed-paediatric-investigation-plan-antigen-prepandemic-strain-vietnam-1203-2004-propagated-vero-cells-emea-000156-pip01-07_en.pdf"},
    {"id":"9558","name":"P/256/2010:  EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aluminium hydroxide adsorbed, depigmented glutaralde...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/710434/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-256-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaralde_en.pdf"},
    {"id":"9574","name":"P/0303/2016: EMA decision of 4 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for influenza virus surface antigens (haemagglutinin and ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-10T01:00:00Z","last_updated_date":"2017-01-10T01:00:00Z","reference_number":"EMA/501874/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2016-ema-decision-4-november-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-influenza-virus-surface-antigens-haemagglutinin_en.pdf"},
    {"id":"9580","name":"P/0247/2017: EMA decision of 4 September 2017 on the granting of a product-specific waiver for litoxetine (benzoate) (EMEA-002151-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/497295/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2017-ema-decision-4-september-2017-granting-product-specific-waiver-litoxetine-benzoate-emea-002151-pip01-17_en.pdf"},
    {"id":"9584","name":"P/0154/2013: EMA decision of 5 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for selexipag (EMEA-000997-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-08T18:00:00Z","last_updated_date":"2013-08-08T18:00:00Z","reference_number":"EMA/392509/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2013-ema-decision-5-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-selexipag-emea-000997-pip01-10-m01_en.pdf"},
    {"id":"9593","name":"P/0183/2012: EMA decision of 21 August 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for naloxegol (EMEA-001146-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T02:00:00Z","last_updated_date":"2012-09-18T02:00:00Z","reference_number":"EMA/472485/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2012-ema-decision-21-august-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-naloxegol-emea-001146-pip01-11_en.pdf"}    {"id":"9612","name":"P/31/2008: European medicines agency decision of 19 June 2008 on the application for agreement of a Paediatric Investigation Plan for dalbavancin, EMEA- 000016-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/306721/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-31-2008-european-medicines-agency-decision-19-june-2008-application-agreement-paediatric-investigation-plan-dalbavancin-emea-000016-pip01-07-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"9622","name":"P/0253/2016: EMA decision of 9 September 2016 on the refusal of a paediatric investigation plan and on the refusal of a deferral for angiotensin II\n\n(LJPC-501) (EMEA-001912-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/557943/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2016-ema-decision-9-september-2016-refusal-paediatric-investigation-plan-refusal-deferral-angiotensin-ii-ljpc-501-emea-001912-pip01-15_en.pdf"},
    {"id":"9634","name":"P/0018/2017: EMA decision of 30 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for idelalisib (Zydelig),\n\n(EMEA-001350-PIP02-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/2921/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2017-ema-decision-30-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-idelalisib-zydelig-emea-001350-pip02-13-m03_en.pdf"},
    {"id":"9645","name":"P/0091/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for regorafenib\n\n(Stivarga), (EMEA-001178-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/181812/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-regorafenib-stivarga-emea-001178-pip01-11-m03_en.pdf"},
    {"id":"9647","name":"P/0080/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for exenatide (EMEA-001755-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/139205/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-exenatide-emea-001755-pip01-15_en.pdf"},
    {"id":"9656","name":"P/0253/2014: EMA decision of 29 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for expanded human allogeneic mesenchymal adult stem ce...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/528122/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2014-ema-decision-29-september-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-expanded-human-allogeneic-mesenchymal-adult-stem-ce_en.pdf"},
    {"id":"9680","name":"P/0105/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline (fumarate), (EMEA-000912-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/183759/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2013-ema-decision-30-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-bedaquiline-fumarate-emea-000912-pip01-10-m01_en.pdf"},
    {"id":"9706","name":"P/0002/2017: EMA decision of 12 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for belatacept (Nulojix),\n\n(EMEA-000157-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/5126/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2017-ema-decision-12-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-belatacept-nulojix-emea-000157-pip01-07-m03_en.pdf"},
    {"id":"9716","name":"P/198/2011: EMA decision of 30 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ulipristal acetate\n\n(EllaOne), (EMEA-000305-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/642354/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-198-2011-ema-decision-30-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-ulipristal-acetate-ellaone-emea-000305-pip01-08-m02_en.pdf"},
    {"id":"9735","name":"P/0148/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for etrolizumab (EMEA-001434-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/398302/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-etrolizumab-emea-001434-pip01-13-m01_en.pdf"},
    {"id":"9739","name":"P/91/2010: European Medicines Agency decision of 1 June 2010 on the  granting of a product specific waiver for fluocinolone acetonide (EMEA-000801-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-26T02:00:00Z","last_updated_date":"2010-07-26T02:00:00Z","reference_number":"EMA//337503/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-91-2010-european-medicines-agency-decision-1-june-2010-granting-product-specific-waiver-fluocinolone-acetonide-emea-000801-pip01-09-accordance-regulation-ec-no-1901-2006-european_en.pdf"},
    {"id":"9747","name":"P/0117/2012: EMA decision of 2 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for melatonin (Circadin), (EMEA-000440-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-08T16:45:00Z","last_updated_date":"2012-08-08T16:45:00Z","reference_number":"EMA/405270/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2012-ema-decision-2-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-melatonin-circadin-emea-000440-pip02-11_en.pdf"},
    {"id":"9749","name":"P/0120/2013: EMA decision of 3 May 2013 on the granting of a product-specific waiver for Clostridium botulinum toxin type A, purified neurotoxin (EMEA-001396-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-24T13:30:00Z","last_updated_date":"2013-06-24T13:30:00Z","reference_number":"EMA/202092/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2013-ema-decision-3-may-2013-granting-product-specific-waiver-clostridium-botulinum-toxin-type-purified-neurotoxin-emea-001396-pip01-12_en.pdf"},
    {"id":"9754","name":"P/0095/2018: EMA decision of 16 March 2018 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of\n\na waiver for non-pathogenic bacterial lysate of Escherichia coli and E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/102420/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2018-ema-decision-16-march-2018-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-non-pathogenic-bacterial-lysate-escherichia-coli-e_en.pdf"},
    {"id":"9772","name":"P/0210/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sotagliflozin (EMEA-\n\n001517-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/430899/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-sotagliflozin-emea-001517-pip01-13-m01_en.pdf"},
    {"id":"9778","name":"P/0171/2014: EMA decision of 9 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant dimer of 6 kD early secretory antigenic target / recombinant 10 kD culture filtrate ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/349668/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2014-ema-decision-9-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-dimer-6-kd-early-secretory-antigenic-target-recombinant-10-kd-culture-filtrate_en.pdf"},
    {"id":"9802","name":"P/0312/2017: EMA decision of 30 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (EMEA-\n\n001418-PIP01-13-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T01:00:00Z","last_updated_date":"2018-02-15T01:00:00Z","reference_number":"EMA/654883/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2017-ema-decision-30-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-cabotegravir-emea-001418-pip01-13-m01_en.pdf"},
    {"id":"9810","name":"P/117/2008: European Medicines Agency decision of 1 December 2008 on the application for agreement of a Paediatric Investigation Plan for sitagliptin phosphate monohydrate, metformin hydrochloride (Efficib)\n\nEMEA-000213-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/625237/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-117-2008-european-medicines-agency-decision-1-december-2008-application-agreement-paediatric-investigation-plan-sitagliptin-phosphate-monohydrate-metformin-hydrochloride-efficib-emea-000213_en.pdf"},
    {"id":"9839","name":"P/273/2011: EMA decision of 28 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for etravirine\n\n(Intelence), (EMEA-000222-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T16:00:00Z","last_updated_date":"2011-11-30T16:00:00Z","reference_number":"EMA/828307/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-273-2011-ema-decision-28-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-etravirine-intelence-emea-000222-pip01-08-m05_en.pdf"},
    {"id":"9849","name":"P/0120/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for epratuzumab (EMEA-001295-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/329539/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-epratuzumab-emea-001295-pip01-12-m01_en.pdf"},
    {"id":"9869","name":"P/0306/2012: EMA decision of 21 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/792272/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2012-ema-decision-21-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip02-11-m01_en.pdf"},
    {"id":"9873","name":"P/213/2011: EMA decision of 2 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for eslicarbazepine (acetate) (Zebinix, Exalief) (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/644037/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-213-2011-ema-decision-2-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eslicarbazepine-acetate-zebinix-exalief-emea-0_en.pdf"},
    {"id":"9884","name":"P/0153/2017: EMA decision of 2 June 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for lacosamide\n\n(Vimpat), (EMEA-000402-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/341255/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2017-ema-decision-2-june-2017-agreement-paediatric-investigation-plan-granting-deferral-lacosamide-vimpat-emea-000402-pip03-17_en.pdf"},
    {"id":"9892","name":"P/313/2011: EMA decision of 22 December 2011 on the granting of a product specific waiver for anti-sclerostin human monoclonal antibody (AMG785)\n\n(EMEA-001075-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/983445/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-313-2011-ema-decision-22-december-2011-granting-product-specific-waiver-anti-sclerostin-human-monoclonal-antibody-amg785-emea-001075-pip01-10_en.pdf"},
    {"id":"9902","name":"P/0152/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for telbivudine (Sebivo), (EMEA-000065-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2021-01-14T02:00:00Z","reference_number":"EMA/305258/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-telbivudine-sebivo-emea-000065-pip01-07-m05_en.pdf"},
    {"id":"9931","name":"P/0118/2014: EMA decision of 6 May 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for lumacaftor / ivacaftor (EMEA-001582-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/182155/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2014-ema-decision-6-may-2014-agreement-paediatric-investigation-plan-granting-deferral-lumacaftor-ivacaftor-emea-001582-pip01-13_en.pdf"},
    {"id":"9936","name":"P/0075/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anifrolumab (EMEA-001435-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/91887/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anifrolumab-emea-001435-pip02-16_en.pdf"},
    {"id":"9938","name":"P/0182/2012: EMA decision of 21 August 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pegylated human interferon beta-1a (EMEA-001129-PIP01...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T02:00:00Z","last_updated_date":"2012-09-18T02:00:00Z","reference_number":"EMA/532704/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2012-ema-decision-21-august-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pegylated-human-interferon-beta-1a-emea-001129-pip01_en.pdf"},
    {"id":"9958","name":"P/0168/2012: EMA decision of 26 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for MAGE-A3 recombinant protein (EMEA-001099-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T16:00:00Z","last_updated_date":"2012-08-23T16:00:00Z","reference_number":"EMA/481527/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2012-ema-decision-26-july-2012-agreement-paediatric-investigation-plan-granting-deferral-mage-a3-recombinant-protein-emea-001099-pip02-11_en.pdf"},
    {"id":"9969","name":"P/146/2011: EMA decision of 9 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chemically modified house dust mites allergen extract","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/417760/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-146-2011-ema-decision-9-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chemically-modified-house-dust-mites-allergen-extract_en.pdf"},
    {"id":"9972","name":"P/0116/2014: EMA decision of 6 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for poly(oxy-1,2-ethanediyl),alpha-hydro-omega-methoxy-133 ester with granulocyte colony-stimulating ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-12T16:00:00Z","last_updated_date":"2014-06-12T16:00:00Z","reference_number":"EMA/195554/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2014-ema-decision-6-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-polyoxy-12-ethanediylalpha-hydro-omega-methoxy-133-ester-granulocyte-colony-stimulating_en.pdf"},
    {"id":"10003","name":"P/193/2011: EMA decision of 3 August 2011 on the granting of a product specific waiver for florbetaben (EMEA-001090-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/500224/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-193-2011-ema-decision-3-august-2011-granting-product-specific-waiver-florbetaben-emea-001090-pip01-11_en.pdf"},
    {"id":"10007","name":"P/0052/2018: EMA decision of 22 February 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for brivaracetam (Briviact), (EMEA-000332-PIP02-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/102423/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2018-ema-decision-22-february-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-brivaracetam-briviact-emea-000332-pip02-17_en.pdf"},
    {"id":"10022","name":"P/0155/2013: EMA decision of 5 July 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for evacetrapib (EMEA-001180-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-09T16:30:00Z","last_updated_date":"2013-08-09T16:30:00Z","reference_number":"EMA/332288/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2013-ema-decision-5-july-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-evacetrapib-emea-001180-pip01-11_en.pdf"},
    {"id":"10028","name":"P/0036/2014: EMA decision of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (EMEA-000576-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/43442/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2014-ema-decision-5-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-emea-000576-pip02-11-m02_en.pdf"},
    {"id":"10046","name":"P/90/2011: EMA decision of 8 April 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant\n\nhuman N-acetylgalactosamine-6-sulfatase (EMEA-000973-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/247811/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-90-2011-ema-decision-8-april-2011-agreement-paediatric-investigation-plan-granting-deferral-recombinant-human-n-acetylgalactosamine-6-sulfatase-emea-000973-pip01-10_en.pdf"},
    {"id":"10069","name":"P/0269/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga), (EMEA-000597-PIP03-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/690906/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip03-15-m01_en.pdf"},
    {"id":"10070","name":"P/117/2009: European Medicines Agency decision of 16 June 2009 on the granting of a product specific waiver for Recombinant human anti-Rhesus D monoclonal antibody (LFB-R593) (EMEA-000512-PIP01-08) in accordance with Reg...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351778/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-117-2009-european-medicines-agency-decision-16-june-2009-granting-product-specific-waiver-recombinant-human-anti-rhesus-d-monoclonal-antibody-lfb-r593-emea-000512-pip01-08-accordance-reg_en.pdf"},
    {"id":"10082","name":"P/0069/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ferric maltol (EMEA-001195-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/107887/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-ferric-maltol-emea-001195-pip01-11-m01_en.pdf"},
    {"id":"10095","name":"P/0035/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz) (EMEA-000576-PIP01-09-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T11:41:00Z","last_updated_date":"2018-04-18T11:41:00Z","reference_number":"EMA/848770/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip01-09-m08_en.pdf"},
    {"id":"10105","name":"P/0179/2016: EMA decision of of 8 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for levamisole\n\n(hydrochloride) (EMEA-001885-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:21:00Z","last_updated_date":"2016-09-22T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2016-ema-decision-8-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-levamisole-hydrochloride-emea-001885-pip01-15-m01_en.pdf"},
    {"id":"10107","name":"P/0103/2017: EMA decision of 11 April 2017 on the granting of a product specific waiver for candesartan / amlodipine (EMEA-002090-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/166786/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2017-ema-decision-11-april-2017-granting-product-specific-waiver-candesartan-amlodipine-emea-002090-pip01-16_en.pdf"},
    {"id":"10108","name":"P/0313/2012: EMA decision of 21 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for fidaxomicin (Dificlir), (EMEA-000636-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/779382/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2012-ema-decision-21-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-fidaxomicin-dificlir-emea-000636-pip01-09-m01_en.pdf"},
    {"id":"10113","name":"P/0037/2017: European Medicines Agency decision of 31 January 2017 on the granting of a product specific waiver for hydrochlorothiazide / amlodipine (besylate) / candesartan (cilexetil) (EMEA-002024-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/36030/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2017-european-medicines-agency-decision-31-january-2017-granting-product-specific-waiver-hydrochlorothiazide-amlodipine-besylate-candesartan-cilexetil-emea-002024-pip01-16_en.pdf"},
    {"id":"10118","name":"P/294/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pollen from Dactylis glomerata, Lolium perenne, Phleu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/768169/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-294-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-dactylis-glomerata-lolium-perenne-phleu_en.pdf"},
    {"id":"10158","name":"P/0105/2014: EMA decision of 5 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Afinitor, Certican and associated names) (EMEA-000019-PIP06-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-11T16:00:00Z","last_updated_date":"2014-06-11T16:00:00Z","reference_number":"EMA/169119/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2014-ema-decision-5-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-afinitor-certican-associated-names-emea-000019-pip06-09-m05_en.pdf"},
    {"id":"10167","name":"P/109/2011: EMA decision of 6 May 2011 on the acceptance of a modification of an agreed paediatric investigation plan for tazarotene (EMEA-\n\n000510-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-07T02:00:00Z","last_updated_date":"2011-06-07T02:00:00Z","reference_number":"EMA/252776/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-109-2011-ema-decision-6-may-2011-acceptance-modification-agreed-paediatric-investigation-plan-tazarotene-emea-000510-pip02-10-m01_en.pdf"},
    {"id":"10176","name":"P/0091/2018: EMA decision of 16 March 2018 on the granting of a product- specific waiver for T-cell bispecific antibody targeting carcinoembryonic\n\nantigen expressed on tumor cells and CD3 epsilon chain present on T-cell...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/91876/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2018-ema-decision-16-march-2018-granting-product-specific-waiver-t-cell-bispecific-antibody-targeting-carcinoembryonic-antigen-expressed-tumor-cells-cd3-epsilon-chain-present-t-cell_en.pdf"},
    {"id":"10184","name":"P/233/2011: EMA decision of 26 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aciclovir (EMEA-001066-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/764286/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-233-2011-ema-decision-26-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aciclovir-emea-001066-pip02-11_en.pdf"},
    {"id":"10191","name":"P/0250/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for gabapentin (EMEA-001310-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/624845/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-gabapentin-emea-001310-pip01-12-m02_en.pdf"},
    {"id":"10203","name":"P/269/2011: EMA decision of 28 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ombrabulin (EMEA-\n\n000800-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T17:00:00Z","last_updated_date":"2011-11-30T17:00:00Z","reference_number":"EMA/847881/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-269-2011-ema-decision-28-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-ombrabulin-emea-000800-pip01-09-m01_en.pdf"},
    {"id":"10224","name":"P/0221/2017: EMA decision of 11 August 2017 on the granting of a product specific waiver for 5, 7-dihydroxy-2-[3-hydroxy-4-methoxy-2-(2-methyl-\n\n2-propenyl) phenyl]-6, 8-bis (2-methyl-2-propenyl)-4H-chromen-4-one (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/460050/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2017-ema-decision-11-august-2017-granting-product-specific-waiver-5-7-dihydroxy-2-3-hydroxy-4-methoxy-2-2-methyl-2-propenyl-phenyl-6-8-bis-2-methyl-2-propenyl-4h-chromen-4-one-emea-0_en.pdf"},
    {"id":"10234","name":"P/0233/2015: EMA decision of 27 October 2015 on the granting of a product-specific waiver for nintedanib (Ofev) (EMEA-001006-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/619831/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2015-ema-decision-27-october-2015-granting-product-specific-waiver-nintedanib-ofev-emea-001006-pip02-15_en.pdf"},
    {"id":"10252","name":"P/0176/2015: EMA decision of 7 August 2015 on the agreement of a paediatric investigation plan for enalapril (maleate), (EMEA-001706-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"EMA/43439/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2015-ema-decision-7-august-2015-agreement-paediatric-investigation-plan-enalapril-maleate-emea-001706-pip01-14_en.pdf"},
    {"id":"10257","name":"P/63/2008: European medicines agency decision of 15 August 2008 on the application for agreement of a Paediatric Investigation Plan for ribavirin, Rebetol (EMEA-000070-PIP01-07) in accordance with Regulation (EC) No 1901...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/424601/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-63-2008-european-medicines-agency-decision-15-august-2008-application-agreement-paediatric-investigation-plan-ribavirin-rebetol-emea-000070-pip01-07-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"10279","name":"P/0021/2017: EMA decision of 3 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-\n\n001501-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-18T02:00:00Z","last_updated_date":"2017-04-18T02:00:00Z","reference_number":"EMA/38339/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2017-ema-decision-3-february-2017-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-emea-001501-pip02-13-m02_en.pdf"},
    {"id":"10283","name":"P/0298/2014: EMA decision of 24 November 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for cannabidiol / delta-9-tetrahydrocannabinol (Sativex), (EMEA-000181-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/641622/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2014-ema-decision-24-november-2014-agreement-paediatric-investigation-plan-granting-deferral-cannabidiol-delta-9-tetrahydrocannabinol-sativex-emea-000181-pip02-13_en.pdf"},
    {"id":"10313","name":"P/0076/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fluticasone furoate / umeclidinium bromide / vilanterol...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/75596/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fluticasone-furoate-umeclidinium-bromide-vilanterol_en.pdf"},
    {"id":"10324","name":"P/0330/2017: EMA decision of 31 October 2017 on the agreement of a paediatric investigation plan and on the granting of a waiver for lactobacillus\n\nreuteri (IBP-9414) (EMEA-001895-PIP01-15)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T10:22:00Z","last_updated_date":"2018-02-13T10:22:00Z","reference_number":"EMA/666659/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0330-2017-ema-decision-31-october-2017-agreement-paediatric-investigation-plan-granting-waiver-lactobacillus-reuteri-ibp-9414-emea-001895-pip01-15_en.pdf"},
    {"id":"10332","name":"P/33/2010: European Medicines Agency decision of of 17 March 2010 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the refusal of a waiver for Sildenafil citrate (Revatio) (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-04-20T01:09:21Z","last_updated_date":"2010-04-20T01:09:21Z","reference_number":"EMA/159661/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-33-2010-european-medicines-agency-decision-17-march-2010-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-sildenafil-citrate-revatio-eme_en.pdf"},
    {"id":"10339","name":"P/0276/2013: EMA decision of 30 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for nitisinone (Orfadin), (EMEA-000784-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/592153/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2013-ema-decision-30-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-nitisinone-orfadin-emea-000784-pip02-11-m01_en.pdf"},
    {"id":"10353","name":"P/0343/2017: EMA decision of 23 November 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for risankizumab (EMEA-001776-PIP02-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T17:30:00Z","last_updated_date":"2018-02-12T17:30:00Z","reference_number":"EMA/752307/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0343-2017-ema-decision-23-november-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-risankizumab-emea-001776-pip02-17_en.pdf"},
    {"id":"10356","name":"P/86/2010: European Medicines Agency decision of 1 June 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for cediranib maleate (EMEA-000477-PIP01-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/330478/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-86-2010-european-medicines-agency-decision-1-june-2010-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-cediranib-maleate-emea-000477-pip01-0_en.pdf"},
    {"id":"10367","name":"P/283/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allergen extract of equal parts of betula verrucosa, ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/754107/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-283-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extract-equal-parts-betula-verrucosa_en.pdf"},
    {"id":"10375","name":"P/0293/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for potassium\n\n(chloride) / magnesium (sulphate heptahydrate) / procaine (hydrochloride) / xylit...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-19T11:00:00Z","last_updated_date":"2017-01-19T11:00:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-potassium-chloride-magnesium-sulphate-heptahydrate-procaine-hydrochloride-xylit_en.pdf"},
    {"id":"10391","name":"P/0364/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for palovarotene\n\n(EMEA-001662-PIP01-14-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T13:05:00Z","last_updated_date":"2018-03-02T13:05:00Z","reference_number":"EMA/724437/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0364-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-palovarotene-emea-001662-pip01-14-m01_en.pdf"},
    {"id":"10432","name":"P/0298/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for travoprost (Travatan)\n\n(EMEA-001271-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/647635/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-travoprost-travatan-emea-001271-pip01-12-m01_en.pdf"},
    {"id":"10441","name":"P/107/2010: European Medicines Agency decision of 28 June 2010\n\non the acceptance of a modification of an agreed paediatric investigation plan for dabigatran etexilate mesilate (Pradaxa)( EMEA-000081-PIP01-07-M02) in acc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/398370/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-107-2010-european-medicines-agency-decision-28-june-2010-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-mesilate-pradaxa-emea-000081-pip01-07-m02-acc_en.pdf"},
    {"id":"10446","name":"P/0067/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocoutur...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/147276/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-clostridium-botulinum-neurotoxin-type-150-kd-free-complexing-proteins-xeomin-bocoutur_en.pdf"},
    {"id":"10449","name":"P/102/2011: EMA decision of 3 May 2011 on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Victoza)\n\n(EMEA-000128-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-07T02:00:00Z","last_updated_date":"2011-06-07T02:00:00Z","reference_number":"EMA/247793/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-102-2011-ema-decision-3-may-2011-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-victoza-emea-000128-pip01-07-m03_en.pdf"},
    {"id":"10454","name":"P/0095/2013: EMA decision of 29 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for atomoxetine (hydrochloride) (Strattera), (EMEA-001167-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/206942/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2013-ema-decision-29-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-atomoxetine-hydrochloride-strattera-emea-001167-pip02-11-m01_en.pdf"},
    {"id":"10476","name":"P/0217/2016: EMA decision of 12 August 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for semaglutide (EMEA-001441-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/441093/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2016-ema-decision-12-august-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-semaglutide-emea-001441-pip02-15_en.pdf"},
    {"id":"10505","name":"P/26/2009: European Medicines Agency decision of 23 February 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for methoxy polyethylene glycol - epoetin beta, MIRCERA (EMEA-000172-P...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/99507/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-26-2009-european-medicines-agency-decision-23-february-2009-agreement-paediatric-investigation-plan-granting-waiver-methoxy-polyethylene-glycol-epoetin-beta-mircera-emea-000172-p_en.pdf"},
    {"id":"10519","name":"P/170/2010: European Medicines Agency decision of 3 September 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bosutinib, (EMEA-000727-PIP01-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/478080/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-170-2010-european-medicines-agency-decision-3-september-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bosutinib-emea-000727-pip01-0_en.pdf"},
    {"id":"10566","name":"P/80/2011: EMA decision of 6 April 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ivabradine hydrochloride (Corlentor) (EMEA-000627-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/213008/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-80-2011-ema-decision-6-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-ivabradine-hydrochloride-corlentor-emea-000627-pip01-09-m01_en.pdf"},
    {"id":"10574","name":"P/0047/2015: EMA decision of 6 March 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efinaconazole (EMEA-001627-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-24T01:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/86511/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2015-ema-decision-6-march-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-efinaconazole-emea-001627-pip01-14_en.pdf"},
    {"id":"10593","name":"P/0305/2014: EMA decision of 24 November 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for naloxone (hydrochloride) (EMEA-001567-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/643802/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2014-ema-decision-24-november-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-naloxone-hydrochloride-emea-001567-pip01-13_en.pdf"},
    {"id":"10605","name":"P/5/2008: European medicines agency decision of 1 February 2008 on the application for product specific waiver for Indacaterol maleate, Glycopyrronium bromide EMEA-000059-PIP01-07 in accordance with Regulation (EC) No 19...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-01-15T01:00:00Z","last_updated_date":"2008-01-15T01:00:00Z","reference_number":"EMEA/43543/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-5-2008-european-medicines-agency-decision-1-february-2008-application-product-specific-waiver-indacaterol-maleate-glycopyrronium-bromide-emea-000059-pip01-07-accordance-regulation-ec-no-19_en.pdf"},
    {"id":"10629","name":"P/0219/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for naloxone (EMEA-001567-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/578879/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-naloxone-emea-001567-pip01-13-m01_en.pdf"},
    {"id":"10644","name":"P/0271/2014: EMA decision of 27 October 2014 on the granting of a product-specific waiver for ibrutinib (EMEA-001397-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-04T01:00:00Z","last_updated_date":"2014-12-04T01:00:00Z","reference_number":"EMA/639585/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2014-ema-decision-27-october-2014-granting-product-specific-waiver-ibrutinib-emea-001397-pip02-13_en.pdf"},
    {"id":"10667","name":"P/0313/2017: EMA decision of 30 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for febuxostat\n\n(Adenuric), (EMEA-001417-PIP01-12-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T01:00:00Z","last_updated_date":"2018-02-15T01:00:00Z","reference_number":"EMA/654877/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2017-ema-decision-30-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-febuxostat-adenuric-emea-001417-pip01-12-m03_en.pdf"},
    {"id":"10671","name":"P/0282/2013: EMA decision of 8 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tapen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-12-06T01:00:00Z","last_updated_date":"2013-12-06T01:00:00Z","reference_number":"EMA/670636/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2013-ema-decision-8-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapen_en.pdf"},
    {"id":"10676","name":"P/290/2010: EMA decision of of 22 December 2010 on the acceptance of a modification of an agreed paediatric investigation plan for entecavir (Baraclude), (EMEA-000339-PIP02-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/789203/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-290-2010-ema-decision-22-december-2010-acceptance-modification-agreed-paediatric-investigation-plan-entecavir-baraclude-emea-000339-pip02-09-m01_en.pdf"},
    {"id":"10679","name":"P/0306/2016: EMA decision of 4 November 2016 on the granting of a product specific waiver for amlodipine / atorvastatin (EMEA-002005-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-10T01:00:00Z","last_updated_date":"2017-01-10T01:00:00Z","reference_number":"EMA/669062/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2016-ema-decision-4-november-2016-granting-product-specific-waiver-amlodipine-atorvastatin-emea-002005-pip01-16_en.pdf"},
    {"id":"10705","name":"P/0104/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for indacaterol (acetate) / mometasone (furoate) (EMEA-001217-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/199532/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-indacaterol-acetate-mometasone-furoate-emea-001217-pip01-11-m02_en.pdf"},
    {"id":"10706","name":"P/0197/2012: EMA decision of 24 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for human normal\n\nimmunoglobulin (000558-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/502094/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2012-ema-decision-24-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-000558-pip01-09-m01_en.pdf"},
    {"id":"10708","name":"P/0391/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide\n\nadsorbed, depigmented glutaraldehyde polymerised, allergic extract of ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/792972/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0391-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergic-extract_en.pdf"},
    {"id":"10717","name":"P/0102/2015: European medicines agency decision of 11 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine Bilaxten and associated names (EMEA-000347-PIP01-08-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/281890/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2015-european-medicines-agency-decision-11-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-associated-names-emea-000347-pip01-08-m05_en.pdf"},
    {"id":"10719","name":"P/0019/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for albiglutide (EMEA-001175-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/738893/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-albiglutide-emea-001175-pip01-11-m01_en.pdf"},
    {"id":"10724","name":"P/39/2011: EMA decision of 4 February 2011 on the acceptance of a modification of an agreed paediatric investigation plan for azilsartan medoxomil (EMEA-000237-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T01:00:00Z","last_updated_date":"2011-03-09T00:00:00Z","reference_number":"EMA/67881/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-39-2011-ema-decision-4-february-2011-acceptance-modification-agreed-paediatric-investigation-plan-azilsartan-medoxomil-emea-000237-pip01-08-m03_en.pdf"},
    {"id":"10726","name":"P/29/2010: European Medicines Agency decision of 8 March 2010 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for rupatadine fumarate (Rupafin and ass...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMA/123304/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-29-2010-european-medicines-agency-decision-8-march-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rupatadine-fumarate-rupafin-ass_en.pdf"},
    {"id":"10735","name":"P/0031/2016: EMA decision of 29 January 2016 on the granting of a product specific waiver for revusiran (EMEA-001836-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/13230/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2016-ema-decision-29-january-2016-granting-product-specific-waiver-revusiran-emea-001836-pip01-15_en.pdf"},
    {"id":"10736","name":"P/28/2008: European medicines agency decision of 23 May 2008 on the application for agreement of a Paediatric Investigation Plan for adenovirus-mediated Herpes simplex virus-thymidine kinase gene (EMEA-000140-PIP01-07) i...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-17T02:00:00Z","last_updated_date":"2008-07-17T02:00:00Z","reference_number":"EMEA/259189/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-28-2008-european-medicines-agency-decision-23-may-2008-application-agreement-paediatric-investigation-plan-adenovirus-mediated-herpes-simplex-virus-thymidine-kinase-gene-emea-000140-pip01-07-i_en.pdf"},
    {"id":"10763","name":"P/177/2010: European Medicines Agency decision of 21 September 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for artemether / lumefantrine (Ria...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/572669/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-177-2010-european-medicines-agency-decision-21-september-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-artemether-lumefantrine-ria_en.pdf"},
    {"id":"10767","name":"P/107/2012: EMA decision of 8 June 2012 on the acceptance of a modification of an agreed paediatric investigation plan for modified grass pollen extract (EMEA-000284-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-23T17:00:00Z","last_updated_date":"2012-07-23T17:00:00Z","reference_number":"EMA/332274/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-107-2012-ema-decision-8-june-2012-acceptance-modification-agreed-paediatric-investigation-plan-modified-grass-pollen-extract-emea-000284-pip01-08-m03_en.pdf"},
    {"id":"10771","name":"P/0179/2015: EMA decision of 7 August 2015 on the granting of a product-specific waiver for (S)-1-{5-Phenyl-4-[(pyridin-2-ylmethyl)-amino]-thieno[2,3-d]pyrimidin-2-yl}-piperidine-3-carboxylic acid (2-hydroxy-ethyl)-amide...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"EMA/434216/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2015-ema-decision-7-august-2015-granting-product-specific-waiver-s-1-5-phenyl-4-pyridin-2-ylmethyl-amino-thieno23-dpyrimidin-2-yl-piperidine-3-carboxylic-acid-2-hydroxy-ethyl-amide_en.pdf"},
    {"id":"10788","name":"P/0162/2017: EMA decision of 30 June 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for empagliflozin (Jardiance), (EMEA-000828-PIP04-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/398408/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2017-ema-decision-30-june-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-empagliflozin-jardiance-emea-000828-pip04-16_en.pdf"},
    {"id":"10795","name":"P/0108/2015: EMA decision of 1 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sunitinib (Sutent), (EMEA-000342-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/321148/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2015-ema-decision-1-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-sunitinib-sutent-emea-000342-pip01-08-m04_en.pdf"},
    {"id":"10804","name":"P/216/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 12 Grass Pollen Extract and Cult...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/615516/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-216-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-12-grass-pollen-extract-cult_en.pdf"},
    {"id":"10821","name":"P/0139/2014: EMA decision of 11 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for PEGylated recombinant factor VIII (EMEA-001296-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-28T02:00:00Z","last_updated_date":"2014-07-28T02:00:00Z","reference_number":"EMA/268980/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2014-ema-decision-11-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-pegylated-recombinant-factor-viii-emea-001296-pip01-12-m01_en.pdf"}    {"id":"10838","name":"P/0230/2016: EMA decision of 9 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for fingolimod\n\n(hydrochloride) (Gilenya), (EMEA-000087-PIP01-07-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/576559/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2016-ema-decision-9-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-fingolimod-hydrochloride-gilenya-emea-000087-pip01-07-m04_en.pdf"},
    {"id":"10840","name":"P/0273/2013: EMA decision of 30 October 2013 on the granting of a product specific waiver for ezetimibe / atorvastatin (EMEA-001477-PIP01-13)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/587980/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2013-ema-decision-30-october-2013-granting-product-specific-waiver-ezetimibe-atorvastatin-emea-001477-pip01-13_en.pdf"},
    {"id":"10867","name":"P/0398/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ibrutinib (Imbruvica) (EMEA-001397-PIP03-14-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T11:48:00Z","last_updated_date":"2018-03-02T11:48:00Z","reference_number":"EMA/797361/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0398-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-ibrutinib-imbruvica-emea-001397-pip03-14-m03_en.pdf"},
    {"id":"10869","name":"P/0066/2014: European Medicines Agency decision of 10 March 2014 on the granting of a product specific waiver for amlodipine (besylate) / ramipril (EMEA-001560-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/55126/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2014-european-medicines-agency-decision-10-march-2014-granting-product-specific-waiver-amlodipine-besylate-ramipril-emea-001560-pip01-13_en.pdf"},
    {"id":"10873","name":"P/0354/2016: EMA decision of 21 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for sacubitril / valsartan (Entresto), (EMEA-000316-PIP02-11-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T09:55:00Z","last_updated_date":"2017-01-30T09:55:00Z","reference_number":"EMA/788570/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0354-2016-ema-decision-21-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-sacubitril-valsartan-entresto-emea-000316-pip02-11-m03_en.pdf"},
    {"id":"10875","name":"P/0211/2014: EMA decision of of 22 August 2014 on the granting of a product specific waiver for rosuvastatin / valsartan (EMEA-001632-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/467371/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2014-ema-decision-22-august-2014-granting-product-specific-waiver-rosuvastatin-valsartan-emea-001632-pip01-14_en.pdf"},
    {"id":"10877","name":"P/187/2011: EMA decision of 29 July 2011 on the granting of a product specific waiver for perindopril (erbumine) / amlodipine (besylate) (EMEA-\n\n001141-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/500622/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-187-2011-ema-decision-29-july-2011-granting-product-specific-waiver-perindopril-erbumine-amlodipine-besylate-emea-001141-pip01-11_en.pdf"},
    {"id":"10880","name":"P/130/2009: European Medicines Agency decision of 14 July 2009 on the refusal of a Paediatric Investigation Plan and on the granting of a waiver for drospirenone / ethinylestradiol, betadex clathrate / L-5-methyltetrahyd...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/420939/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-130-2009-european-medicines-agency-decision-14-july-2009-refusal-paediatric-investigation-plan-granting-waiver-drospirenone-ethinylestradiol-betadex-clathrate-l-5-methyltetrahyd_en.pdf"},
    {"id":"10913","name":"P/314/2011: EMA decision of 22 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for solifenacin succinate (Vesicare and associated names) (EMEA-000573-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/984967/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-314-2011-ema-decision-22-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-solifenacin-succinate-vesicare-associated-names-emea-000573-pip01-09-m01_en.pdf"},
    {"id":"10919","name":"P/0177/2012: EMA decision of 17 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for beclometasone\n\ndipropionate / formoterol fumarate dihydrate (Foster and associated names, Kan...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/502097/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2012-ema-decision-17-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-beclometasone-dipropionate-formoterol-fumarate-dihydrate-foster-associated-names-kan_en.pdf"},
    {"id":"10921","name":"P/0203/2017: EMA decision of 9 August 2017 on the granting of a product specific waiver for diclofenac (sodium) (Pennsaid), (EMEA-002132-PIP01-\n\n17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/460841/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2017-ema-decision-9-august-2017-granting-product-specific-waiver-diclofenac-sodium-pennsaid-emea-002132-pip01-17_en.pdf"},
    {"id":"10930","name":"P/149/2010:  European Medicines Agency decision of 30 July 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chloroprocaine hydrochloride, (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/469130/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-149-2010-european-medicines-agency-decision-30-july-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chloroprocaine-hydrochloride-eme_en.pdf"},
    {"id":"10943","name":"P/0005/2017: European Medicines Agency decision of 16 January 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for abatacept (Orencia), (EMEA-0001...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/13161/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2017-european-medicines-agency-decision-16-january-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-abatacept-orencia-emea-0001_en.pdf"},
    {"id":"10945","name":"P/0046/2016: EMA decision of 26 February 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for eculizumab (Soliris) (EMEA-000876-PIP05-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/133082/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2016-ema-decision-26-february-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eculizumab-soliris-emea-000876-pip05-15_en.pdf"},
    {"id":"10953","name":"P/15/2011: EMA  decision of 21 January 2011 on the application for agreement of a Paediatric Investigation Plan for ezetimibe, EZETROL and associated names, EMEA-000007-PIP01-07-M01 in accordance with Regulation (EC) No ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-08T02:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/27910/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-15-2011-ema-decision-21-january-2011-application-agreement-paediatric-investigation-plan-ezetimibe-ezetrol-associated-names-emea-000007-pip01-07-m01-accordance-regulation-ec-no_en.pdf"},
    {"id":"11005","name":"P/0010/2013: EMA decision of 22 January 2013 on the granting of a product-specific waiver for amlodipine (besylate) / atorvastatin (calcium), (EMEA-001353-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T14:30:00Z","last_updated_date":"2013-04-03T14:30:00Z","reference_number":"EMA/779486/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2013-ema-decision-22-january-2013-granting-product-specific-waiver-amlodipine-besylate-atorvastatin-calcium-emea-001353-pip01-12_en.pdf"},
    {"id":"11036","name":"P/0058/2015: EMA decision of 1 April 2015 on the agreement of a paediatric investigation plan and on the granting of a waiver for canakinumab (EMEA-000060-PIP05-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-07T02:00:00Z","last_updated_date":"2015-05-07T02:00:00Z","reference_number":"EMA/153862/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2015-ema-decision-1-april-2015-agreement-paediatric-investigation-plan-granting-waiver-canakinumab-emea-000060-pip05-14_en.pdf"},
    {"id":"11049","name":"P/0058/2012: EMA decision of 26 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for eslicarbazepine\n\n(acetate) (Zebinix, Exalief), (EMEA-000696-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T17:42:00Z","last_updated_date":"2012-04-20T17:42:00Z","reference_number":"EMA/196227/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2012-ema-decision-26-march-2012-acceptance-modification-agreed-paediatric-investigation-plan-eslicarbazepine-acetate-zebinix-exalief-emea-000696-pip02-10-m01_en.pdf"},
    {"id":"11061","name":"P/0237/2012: EMA decision of 22 October 2012 on the agreement of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for human heterologous liver cells (EMEA-000067-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/587322/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2012-ema-decision-22-october-2012-agreement-paediatric-investigation-plan-refusal-deferral-granting-waiver-human-heterologous-liver-cells-emea-000067-pip02-11_en.pdf"},
    {"id":"11083","name":"P/0231/2016: EMA decision of 9 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dihydroartemisinin /\n\npiperaquine phosphate anhydride (Eurartesim), (EMEA-000153-PIP01-07-M...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/557959/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2016-ema-decision-9-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-dihydroartemisinin-piperaquine-phosphate-anhydride-eurartesim-emea-000153-pip01-07-m_en.pdf"},
    {"id":"11092","name":"P/0101/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for evolocumab\n\n(Repatha), (EMEA-001268-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/202483/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-evolocumab-repatha-emea-001268-pip01-12-m04_en.pdf"},
    {"id":"11096","name":"P/0335/2014: EMA decision of 22 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant single chain coagulation factor VIII (EMEA-001215-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T01:00:00Z","last_updated_date":"2015-02-23T01:00:00Z","reference_number":"EMA/713540/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0335-2014-ema-decision-22-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-single-chain-coagulation-factor-viii-emea-001215-pip01-11-m02_en.pdf"},
    {"id":"11112","name":"P/213/2010: European Medicines Agency decision of 29 October 2010 on the granting of a product specific waiver for fampridine (EMEA-000614-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T00:09:21Z","last_updated_date":"2010-11-25T00:09:21Z","reference_number":"EMA/655503/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-213-2010-european-medicines-agency-decision-29-october-2010-granting-product-specific-waiver-fampridine-emea-000614-pip01-10-m01_en.pdf"},
    {"id":"11124","name":"P/51/2009: European Medicines Agency decision of 24 March 2009 on the granting of a product specific waiver for bisoprolol fumarate / acetylsalicylic acid (EMEA-000446-PIP01-08) in accordance with Regulation (EC) No 1901...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/167147/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-51-2009-european-medicines-agency-decision-24-march-2009-granting-product-specific-waiver-bisoprolol-fumarate-acetylsalicylic-acid-emea-000446-pip01-08-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"11136","name":"P/0226/2016: EMA decision of 12 August 2016 on the granting of a product specific waiver for ramipril / amlodipine / hydrochlorothiazide (EMEA-\n\n001942-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/472133/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2016-ema-decision-12-august-2016-granting-product-specific-waiver-ramipril-amlodipine-hydrochlorothiazide-emea-001942-pip01-16_en.pdf"},
    {"id":"11158","name":"P/0147/2012: EMA decision of 24 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract from the...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/471477/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2012-ema-decision-24-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergen-extract_en.pdf"},
    {"id":"11166","name":"P/0305/2015: EMA decision of 21 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for lorcaserin (EMEA-001098-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/759834/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2015-ema-decision-21-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-lorcaserin-emea-001098-pip01-10-m01_en.pdf"},
    {"id":"11192","name":"P/12/2011:  EMA decision of 3 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pollen from alnus glutinosa (33%), betula verrucosa (33...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/753903/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-12-2011-ema-decision-3-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-alnus-glutinosa-33-betula-verrucosa-33_en.pdf"},
    {"id":"11198","name":"P/279/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allergen extract of a mixture of 50% dermatophagoides...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/683368/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-279-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extract-mixture-50-dermatophagoides_en.pdf"},
    {"id":"11203","name":"P/113/2011: EMA decision of 27 April 2011 on the granting of a product specific waiver for rivastigmine (Exelon and Prometax) (EMEA-001084-\n\nPIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"EMA/320397/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-113-2011-ema-decision-27-april-2011-granting-product-specific-waiver-rivastigmine-exelon-prometax-emea-001084-pip02-11_en.pdf"},
    {"id":"11206","name":"P/47/2009: European Medicines Agency decision of 24 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for cysteamine hydrochloride (EMEA-0003...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/158143/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-47-2009-european-medicines-agency-decision-24-march-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cysteamine-hydrochloride-emea-0003_en.pdf"},
    {"id":"11240","name":"P/0098/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for fidaxomicin (Dificlir)\n\n(EMEA-000636-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/199518/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-fidaxomicin-dificlir-emea-000636-pip01-09-m04_en.pdf"},
    {"id":"11257","name":"P/0056/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tapentad...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/155881/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapentad_en.pdf"},
    {"id":"11261","name":"P/37/2010: European Medicines Agency decision of 31 March 2010 on the acceptance of a modification of an agreed Paediatric Investigation Plan for brivaracetam (EMEA-000332-PIP01-08-M01) in accordance with Regulation (EC)...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/171189/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-37-2010-european-medicines-agency-decision-31-march-2010-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-emea-000332-pip01-08-m01-accordance-regulation-ec_en.pdf"},
    {"id":"11286","name":"P/0252/2015: EMA decision of 30 October 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ibrutinib, (Imbruvica) (EMEA-001397-PIP03-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/627047/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2015-ema-decision-30-october-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ibrutinib-imbruvica-emea-001397-pip03-14_en.pdf"},
    {"id":"11301","name":"P/22/2011: EMA decision of 25 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for grass pollen allergen extract from Dactylis glomerata ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/25657/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-22-2011-ema-decision-25-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-grass-pollen-allergen-extract-dactylis-glomerata_en.pdf"},
    {"id":"11325","name":"P/14/2009: European Medicines Agency decision of 27 January 2009 on the granting of a product specific waiver for amlodipine besylate, valsartan, hydrochlorothiazide, (Copalia HCT), (EMEA-000397-PIP01-08) in accordance w...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/24151/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-14-2009-european-medicines-agency-decision-27-january-2009-granting-product-specific-waiver-amlodipine-besylate-valsartan-hydrochlorothiazide-copalia-hct-emea-000397-pip01-08-accordance-w_en.pdf"},
    {"id":"11338","name":"P/0001/2015: EMA decision of 7 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-17T01:00:00Z","last_updated_date":"2015-02-17T01:00:00Z","reference_number":"EMA/776083/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2015-ema-decision-7-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-linagliptin-trajenta-emea-000498-pip01-08-m04_en.pdf"},
    {"id":"11339","name":"P/0018/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for sonidegib (Odomzo) (EMEA-000880-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/3207/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-sonidegib-odomzo-emea-000880-pip02-11-m03_en.pdf"},
    {"id":"11343","name":"P/0224/2017: EMA decision of 11 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for bivalent anti-human\n\nmyostatin adnectin recombinant human IgG1-Fc fusion protein (BMS-986089)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/460045/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2017-ema-decision-11-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-bivalent-anti-human-myostatin-adnectin-recombinant-human-igg1-fc-fusion-protein-bms-986089_en.pdf"},
    {"id":"11345","name":"P/0249/2016: EMA decision of 9 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for sapropterin\n\ndihydrochloride (Kuvan), (EMEA-001476-PIP01-13-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/585771/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2016-ema-decision-9-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-sapropterin-dihydrochloride-kuvan-emea-001476-pip01-13-m01_en.pdf"},
    {"id":"11355","name":"P/214/2011: EMA decision of 2 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for sodium sulphate / potassium sulphate / magnesium sul...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/696054/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-214-2011-ema-decision-2-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sodium-sulphate-potassium-sulphate-magnesium-sul_en.pdf"},
    {"id":"11367","name":"P/0260/2012: EMA decision of 19 November 2012 on the granting of a product-specific waiver for alpha1-proteinase inhibitor (EMEA-001312-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"EMA/680100/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2012-ema-decision-19-november-2012-granting-product-specific-waiver-alpha1-proteinase-inhibitor-emea-001312-pip01-12_en.pdf"},
    {"id":"11368","name":"P/0183/2013: EMA decision of 31 July 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ferric citrate (EMEA-001213-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/393022/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2013-ema-decision-31-july-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ferric-citrate-emea-001213-pip02-12_en.pdf"},
    {"id":"11383","name":"P/0264/2014: EMA decision of 3 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for fidaxomicin (Dificlir), (EMEA-000636-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/591650/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2014-ema-decision-3-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-fidaxomicin-dificlir-emea-000636-pip01-09-m03_en.pdf"},
    {"id":"11388","name":"P/44/2007: European medicines agency decision of 23 June 2008 on the application for agreement of a Paediatric Investigation Plan for Nicotinic acid and laropiprant (EMEA-000063-PIP01-07) in accordance with Regulation (E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/315476/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-44-2007-european-medicines-agency-decision-23-june-2008-application-agreement-paediatric-investigation-plan-nicotinic-acid-laropiprant-emea-000063-pip01-07-accordance-regulation-e_en.pdf"},
    {"id":"11414","name":"P/221/2011: EMA decision of 26 September 2011 on the granting of a product specific waiver for dapagliflozin / metformin hydrochloride (EMEA-001151-\n\nPIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/679347/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-221-2011-ema-decision-26-september-2011-granting-product-specific-waiver-dapagliflozin-metformin-hydrochloride-emea-001151-pip01-11_en.pdf"},
    {"id":"11415","name":"P/0365/2016: EMA decision of 21 December 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for galcanezumab (EMEA-001860-PIP04-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-07-20T13:52:00Z","reference_number":"EMA/788580/2016 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0365-2016-ema-decision-21-december-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-galcanezumab-emea-001860-pip04-16_en.pdf"},
    {"id":"11422","name":"P/0226/2015: EMA decision of 2 October 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for begelomab (EMEA-001744-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-19T01:00:00Z","last_updated_date":"2015-11-19T01:00:00Z","reference_number":"EMA/627044/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2015-ema-decision-2-october-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-begelomab-emea-001744-pip01-14_en.pdf"},
    {"id":"11459","name":"P/0195/2015: EMA decision of 4 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (EMEA-001460-PIP01-13-M01...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/532368/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2015-ema-decision-4-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-emea-001460-pip01-13-m01_en.pdf"},
    {"id":"11478","name":"P/258/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mixture of Birch, Hazel and Alder allergen extracts (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/710506/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-258-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mixture-birch-hazel-alder-allergen-extracts_en.pdf"},
    {"id":"11480","name":"P/0080/2012: EMA decision of 27 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for boceprevir (Victrelis), (EMEA-000583-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/229260/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2012-ema-decision-27-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-boceprevir-victrelis-emea-000583-pip01-09-m04_en.pdf"},
    {"id":"11507","name":"P/0201/2014: EMA decision of 8 August 2014 on the granting of a product specific waiver for rosuvastatin / acetylsalicylic acid (EMEA-001269-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/439158/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2014-ema-decision-8-august-2014-granting-product-specific-waiver-rosuvastatin-acetylsalicylic-acid-emea-001269-pip02-14_en.pdf"},
    {"id":"11510","name":"P/110/2012: EMA decision of 18 June 2012 on the refusal of a paediatric investigation plan and on the granting of a waiver for bivalirudin\n\n(Angiox), (EMEA-001065-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-19T17:00:00Z","last_updated_date":"2012-07-19T17:00:00Z","reference_number":"EMA/332323/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-110-2012-ema-decision-18-june-2012-refusal-paediatric-investigation-plan-granting-waiver-bivalirudin-angiox-emea-001065-pip01-10_en.pdf"},
    {"id":"11520","name":"P/0113/2013: EMA decision of 30 April 2013 on the granting of a product-specific waiver for amlodipine (besilate) / losartan (potassium) (EMEA-001390-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/203291/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2013-ema-decision-30-april-2013-granting-product-specific-waiver-amlodipine-besilate-losartan-potassium-emea-001390-pip01-12_en.pdf"},
    {"id":"11527","name":"P/0309/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for tilmanocept (Lymphoseek), (EMEA-001255-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/773337/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0309-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-tilmanocept-lymphoseek-emea-001255-pip01-11-m01_en.pdf"},
    {"id":"11545","name":"P/160/2011: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for house dust mites\n\nallergen extracts (EMEA-000319-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/398971/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-160-2011-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-house-dust-mites-allergen-extracts-emea-000319-pip01-08-m02_en.pdf"},
    {"id":"11548","name":"P/0207/2013: EMA decision of 3 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant fusion protein consisting of human coagulation factor VIII attached to the Fc d...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/476176/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2013-ema-decision-3-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-fusion-protein-consisting-human-coagulation-factor-viii-attached-fc-d_en.pdf"},
    {"id":"11551","name":"P/0155/2017: EMA decision of 2 June 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for mexiletine\n\n(hydrochloride), (EMEA-002012-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/354124/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2017-ema-decision-2-june-2017-agreement-paediatric-investigation-plan-granting-deferral-mexiletine-hydrochloride-emea-002012-pip01-16_en.pdf"},
    {"id":"11563","name":"P/0057/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for indacaterol (acetate) / mometasone (furoate) (EMEA-001217-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/75528/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-indacaterol-acetate-mometasone-furoate-emea-001217-pip01-11-m04_en.pdf"},
    {"id":"11568","name":"P/286/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for Dermatophagoides pteronyssinus extract 100 % (EMEA-00...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/766211/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-286-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dermatophagoides-pteronyssinus-extract-100-emea-00_en.pdf"},
    {"id":"11573","name":"P/309/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of birch and hazel pollen (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/769333/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-309-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-birch-hazel-pollen_en.pdf"},
    {"id":"11619","name":"P/0038/2015: EMA decision of 20 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for obeticholic acid (6 alpha-ethylchenodeoxycholic acid) (EMEA-001304-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/160747/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2015-ema-decision-20-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-obeticholic-acid-6-alpha-ethylchenodeoxycholic-acid-emea-001304-pip02-13-m01_en.pdf"},
    {"id":"11633","name":"P/0004/2013: EMA decision of 21 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for propranolol hydrochloride (EMEA-000511-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T18:30:00Z","last_updated_date":"2013-04-03T18:30:00Z","reference_number":"EMA/795938/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2013-ema-decision-21-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-propranolol-hydrochloride-emea-000511-pip01-08-m04_en.pdf"},
    {"id":"11656","name":"P/217/2011: EMA decision of 1 September 2011 on the agreement of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for prednicarbate / octenidine dihydrochloride, (EMEA-0009...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/698088/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-217-2011-ema-decision-1-september-2011-agreement-paediatric-investigation-plan-refusal-deferral-granting-waiver-prednicarbate-octenidine-dihydrochloride-emea-0009_en.pdf"},
    {"id":"11672","name":"P/0302/2017: EMA decision of 12 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin\n\n(Forxiga) (EMEA-000694-PIP02-14-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-14T16:17:00Z","last_updated_date":"2018-02-14T16:17:00Z","reference_number":"EMA/652550/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2017-ema-decision-12-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-forxiga-emea-000694-pip02-14-m02_en.pdf"},
    {"id":"11679","name":"P/330/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Aqueous allergen extract of birch (EMEA-000959-PIP01-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMEA/778433/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-330-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aqueous-allergen-extract-birch-emea-000959-pip01_en.pdf"},
    {"id":"11699","name":"P/0135/2015: EMA decision of 15 June 2015 on the granting of a product-specific waiver for tocilizumab (RoActemra), (EMEA-000309-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-03T02:00:00Z","last_updated_date":"2015-07-03T02:00:00Z","reference_number":"EMA/368601/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2015-ema-decision-15-june-2015-granting-product-specific-waiver-tocilizumab-roactemra-emea-000309-pip02-14_en.pdf"},
    {"id":"11731","name":"P/0294/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for influenza virus surface antigens (haemagglutinin) of ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/626320/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-influenza-virus-surface-antigens-haemagglutinin_en.pdf"},
    {"id":"11746","name":"P/31/2009: European Medicines Agency decision of 23 February 2009 on the granting of a product specific waiver for aliskiren hemifumarate / hydrochlorothiazide (EMEA-000343-PIP01-08 ) in accordance with Regulation (EC) N...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/101813/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-31-2009-european-medicines-agency-decision-23-february-2009-granting-product-specific-waiver-aliskiren-hemifumarate-hydrochlorothiazide-emea-000343-pip01-08-accordance-regulation-ec-n_en.pdf"},
    {"id":"11747","name":"P/0060/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for cobicistat (Tybost),\n\n(EMEA-000969-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/137076/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-cobicistat-tybost-emea-000969-pip01-10-m04_en.pdf"},
    {"id":"11755","name":"P/0115/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for solifenacin (succinate) (Vesicare and associated names) (EMEA-000573-PIP02-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/355269/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-solifenacin-succinate-vesicare-associated-names-emea-000573-pip02-13-m03_en.pdf"},
    {"id":"11757","name":"P/338/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for modified allergen extract of dermatophagoides farina...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/801198/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-338-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-dermatophagoides-farina_en.pdf"},
    {"id":"11771","name":"P/48/2011: EMA decision of 4 March 2011 on the acceptance of a modification of an agreed paediatric investigation plan for purified antigen fractions of inactivated split virion Influenza A/Indonesia/5/05/ (H5N1), (EMEA-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-06-10T02:00:00Z","last_updated_date":"2011-04-05T12:56:34Z","reference_number":"EMA/78785/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-48-2011-ema-decision-4-march-2011-acceptance-modification-agreed-paediatric-investigation-plan-purified-antigen-fractions-inactivated-split-virion-influenza-indonesia-5-05-h5n1-emea_en.pdf"},
    {"id":"11772","name":"P/0166/2013: EMA decision of 30 July on the acceptance of a modification of an agreed paediatric investigation plan for 2'-O-methyl-uridylyl-\n\n(3'→5' O,O-phosphorothioyl)-2'-O-methyl-cytidyly... (EMEA-000746-PIP01-09-M...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/378889/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2013-ema-decision-30-july-acceptance-modification-agreed-paediatric-investigation-plan-2-o-methyl-uridylyl-3a5-oo-phosphorothioyl-2-o-methyl-cytidyly-emea-000746-pip01-09-m_en.pdf"},
    {"id":"11773","name":"P/0276/2016: EMA decision of 10 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone furoate / vilanterol (Relvar Ellipta and associated names), (EMEA-000431-PIP01-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/632356/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2016-ema-decision-10-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-vilanterol-relvar-ellipta-associated-names-emea-000431-pip01-0_en.pdf"},
    {"id":"11777","name":"P/0267/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for L-asparaginase\n\nencapsulated in erythrocytes (EMEA-000341-PIP02-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-25T17:00:00Z","last_updated_date":"2017-10-25T17:00:00Z","reference_number":"EMA/565799/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-l-asparaginase-encapsulated-erythrocytes-emea-000341-pip02-09-m04_en.pdf"},
    {"id":"11787","name":"P/197/2010: European Medicines Agency decision of 26 October 2010 on the granting of a product specific waiver for lidocaine hydrochloride,  phenylephrine hydrochloride and tropicamide (EMEA-000991-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/651431/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-197-2010-european-medicines-agency-decision-26-october-2010-granting-product-specific-waiver-lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-emea-000991-pip01-10_en.pdf"},
    {"id":"11799","name":"P/0144/2016: EMA decision of 23 May 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for human recombinant IgG1 monoclonal antibody targeting fibroblast growth factor 23 (KRN23) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-18T02:00:00Z","last_updated_date":"2016-07-18T02:00:00Z","reference_number":"EMA/269233/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2016-ema-decision-23-may-2016-agreement-paediatric-investigation-plan-granting-deferral-human-recombinant-igg1-monoclonal-antibody-targeting-fibroblast-growth-factor-23-krn23_en.pdf"},
    {"id":"11802","name":"P/0261/2013: EMA decision of 29 October 2013 on the granting of a product specific waiver for amlodipine / atorvastatin (EMEA-001510-PIP01-13)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/602360/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2013-ema-decision-29-october-2013-granting-product-specific-waiver-amlodipine-atorvastatin-emea-001510-pip01-13_en.pdf"},
    {"id":"11805","name":"P/0033/2016: EMA decision of 29 January 2016 on the granting of a product specific waiver for tiprelestat (EMEA-001851-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/4263/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2016-ema-decision-29-january-2016-granting-product-specific-waiver-tiprelestat-emea-001851-pip01-15_en.pdf"},
    {"id":"11813","name":"P/0184/2017: EMA decision of 30 June 2017 on the granting of a product-specific waiver for econazole (nitrate) / benzydamine (hydrochloride)\n\n(EMEA-002143-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/371181/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2017-ema-decision-30-june-2017-granting-product-specific-waiver-econazole-nitrate-benzydamine-hydrochloride-emea-002143-pip01-17_en.pdf"},
    {"id":"11838","name":"P/0227/2012: EMA decision of 3 October 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for glycopegylated recombinant coagulation factor VIII (EMEA-001174-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/616386/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2012-ema-decision-3-october-2012-agreement-paediatric-investigation-plan-granting-deferral-glycopegylated-recombinant-coagulation-factor-viii-emea-001174-pip02-12_en.pdf"},
    {"id":"11856","name":"P/0035/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for diphtheria toxoid / Tetanus toxoid / Bordetella pertussis antigen: Pertussis toxoid / Bordetell...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-25T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/64952/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2015-ema-decision-6-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-diphtheria-toxoid-tetanus-toxoid-bordetella-pertussis-antigen-pertussis-toxoid-bordetell_en.pdf"},
    {"id":"11858","name":"P/0011/2013: EMA decision of 22 January 2013 on the granting of a product-specific waiver for perindopril / indapamide / amlodipine (EMEA-001358-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T14:30:00Z","last_updated_date":"2013-04-03T14:30:00Z","reference_number":"EMA/779493/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2013-ema-decision-22-january-2013-granting-product-specific-waiver-perindopril-indapamide-amlodipine-emea-001358-pip01-12_en.pdf"},
    {"id":"11879","name":"P/0310/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for pixantrone\n\n(dimaleate) (Pixuvri), (EMEA-000713-PIP02-10-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-19T15:50:00Z","last_updated_date":"2017-01-19T15:50:00Z","reference_number":"EMA/719274/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0310-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-pixantrone-dimaleate-pixuvri-emea-000713-pip02-10-m04_en.pdf"},
    {"id":"11881","name":"P/0267/2013: EMA decision of30 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for ozenoxacin (EMEA-000981-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/588641/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2013-ema-decision-of30-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-ozenoxacin-emea-000981-pip01-10-m03_en.pdf"},
    {"id":"11883","name":"P/0171/2016: EMA decision of 17 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for atrasentan\n\n(hydrochloride) (EMEA-001666-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/385694/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2016-ema-decision-17-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-atrasentan-hydrochloride-emea-001666-pip01-14-m01_en.pdf"},
    {"id":"11887","name":"P/0179/2014: EMA decision of 11 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human lysosomal acid lipase (EMEA-001331-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/391453/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2014-ema-decision-11-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-lysosomal-acid-lipase-emea-001331-pip01-12-m01_en.pdf"},
    {"id":"11894","name":"P/227/2011: EMA decision of 28 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for dihydroartemisinin /\n\npiperaquine phosphate anhydride (EMEA-000153-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/691622/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-227-2011-ema-decision-28-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-dihydroartemisinin-piperaquine-phosphate-anhydride-emea-000153-pip01-07-m01_en.pdf"},
    {"id":"11926","name":"P/79/2010: European Medicines Agency decision of 7 May 2010\n\non the agreement of a paediatric investigation plan and on the granting of a deferral for perampanel (EMEA-000467-PIP01-08) in accordance with Regulation (EC) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/261727/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-79-2010-european-medicines-agency-decision-7-may-2010-agreement-paediatric-investigation-plan-granting-deferral-perampanel-emea-000467-pip01-08-accordance-regulation-ec_en.pdf"},
    {"id":"11979","name":"P/0125/2014: EMA decision of 16 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for entecavir (monohydrate) (Baraclude), (EMEA-000339-PIP02-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-25T02:00:00Z","last_updated_date":"2014-06-25T02:00:00Z","reference_number":"EMA/280408/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2014-ema-decision-16-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-entecavir-monohydrate-baraclude-emea-000339-pip02-09-m03_en.pdf"},
    {"id":"12046","name":"P/0307/2017: EMA decision of 30 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for andexanet alfa\n\n(EMEA-001902-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-20T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"EMA/654890/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2017-ema-decision-30-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-andexanet-alfa-emea-001902-pip01-15-m01_en.pdf"},
    {"id":"12049","name":"P/38/2011: EMA decision on 17 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for N.meningitidis Outer Membrane Vesicles (OMV) from NZ 98/254 strain, N.meningitidis 287-953 pur...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/42919/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-38-2011-ema-decision-17-january-2011-acceptance-modification-agreed-paediatric-investigation-plan-nmeningitidis-outer-membrane-vesicles-omv-nz-98-254-strain-nmeningitidis-287-953-pur_en.pdf"},
    {"id":"12057","name":"P/0293/2012: EMA decision of 18 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for prucalopride (Resolor), (EMEA-000459-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/802543/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2012-ema-decision-18-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-prucalopride-resolor-emea-000459-pip01-08-m02_en.pdf"},
    {"id":"12064","name":"P/0347/2016: EMA decision of 5 December 2016 on the granting of a product specific waiver for synthetic double-stranded siRNA oligonucleotide\n\ndirected against p53 mRNA (QPI-1002) (EMEA-001993-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/760455/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0347-2016-ema-decision-5-december-2016-granting-product-specific-waiver-synthetic-double-stranded-sirna-oligonucleotide-directed-against-p53-mrna-qpi-1002-emea-001993-pip01-16_en.pdf"},
    {"id":"12066","name":"P/2/2008: European medicines agency decision of 1 February 2008 on the application for a product specific waiver for Indacaterol maleate EMEA-000043-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the Europea...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-02-01T00:00:00Z","last_updated_date":"2008-02-01T00:00:00Z","reference_number":"EMEA/43267/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-2-2008-european-medicines-agency-decision-1-february-2008-application-product-specific-waiver-indacaterol-maleate-emea-000043-pip01-07-accordance-regulation-ec-no-1901-2006-europea_en.pdf"},
    {"id":"12072","name":"P/62/2009: European Medicines Agency decision of 27 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for sitagliptin phosphate monohydrate (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/174958/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-62-2009-european-medicines-agency-decision-27-march-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sitagliptin-phosphate-monohydrate_en.pdf"},
    {"id":"12093","name":"P/94/2011: EMA decision of 4 April 2011 on the granting of a product specific waiver for amlodipine (besylate) / atorvastatin (calcium) (EMEA-\n\n001085-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/244984/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-94-2011-ema-decision-4-april-2011-granting-product-specific-waiver-amlodipine-besylate-atorvastatin-calcium-emea-001085-pip01-10_en.pdf"},
    {"id":"12099","name":"P/285/2011: EMA decision of 30 November 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for budesonide (Budiair and associated names) (EMEA-001120-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T12:15:00Z","last_updated_date":"2011-12-21T12:15:00Z","reference_number":"EMA/910691/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-285-2011-ema-decision-30-november-2011-agreement-paediatric-investigation-plan-granting-waiver-budesonide-budiair-associated-names-emea-001120-pip01-10_en.pdf"}    {"id":"12157","name":"P/0174/2013: EMA decision of 30 July 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for alpha\n\ntocotrienol quinone (EMEA-001238-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/393021/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2013-ema-decision-30-july-2013-agreement-paediatric-investigation-plan-granting-deferral-alpha-tocotrienol-quinone-emea-001238-pip01-12_en.pdf"},
    {"id":"12158","name":"P/0236/2012: EMA decision of 22 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for telbivudine (Sebivo), (EMEA-000065-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/636818/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2012-ema-decision-22-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-telbivudine-sebivo-emea-000065-pip01-07-m03_en.pdf"},
    {"id":"12163","name":"P/0258/2012: EMA decision of 31 October 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for regorafenib (EMEA-001178-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/689054/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2012-ema-decision-31-october-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-regorafenib-emea-001178-pip01-11_en.pdf"},
    {"id":"12170","name":"P/0108/2014: EMA decision of 5 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for naloxegol (EMEA-001146-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-12T16:00:00Z","last_updated_date":"2014-06-12T16:00:00Z","reference_number":"EMA/235395/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2014-ema-decision-5-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-naloxegol-emea-001146-pip01-11-m01_en.pdf"},
    {"id":"12183","name":"P/0214/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for lurasidone (hydrochloride) (Latuda) (EMEA-001230-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/520138/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-lurasidone-hydrochloride-latuda-emea-001230-pip01-11-m02_en.pdf"},
    {"id":"12209","name":"P/163/2010: EMA decision of 27 August 2010 on the agreement of a paediatric investigation plan and on the granting of a product specific waiver for amlodipine besylate / valsartan, (EMEA-001000-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/476864/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-163-2010-ema-decision-27-august-2010-agreement-paediatric-investigation-plan-granting-product-specific-waiver-amlodipine-besylate-valsartan-emea-001000-pip01-10_en.pdf"},
    {"id":"12216","name":"P/0055/2014: European Medicines Agency decision of 8 March 2014 on the granting of a product specific waiver for telmisartan / amlodipine (besylate) (EMEA-001552-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/57059/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2014-european-medicines-agency-decision-8-march-2014-granting-product-specific-waiver-telmisartan-amlodipine-besylate-emea-001552-pip01-13_en.pdf"},
    {"id":"12219","name":"P/0298/2016: EMA decision of 4 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for humanised chimeric antibody with a humanised H chain and a chimeric (mouse V-domain, ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-06T01:00:00Z","last_updated_date":"2017-01-06T01:00:00Z","reference_number":"EMA/667315/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2016-ema-decision-4-november-2016-agreement-paediatric-investigation-plan-granting-deferral-humanised-chimeric-antibody-humanised-h-chain-chimeric-mouse-v-domain_en.pdf"},
    {"id":"12223","name":"P/264/2009: European Medicines Agency decision of 23 December 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for moxifloxacin hydrochloride (Actimax and associated names: Proflox) (EM...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:00:00Z","last_updated_date":"2010-01-25T00:00:00Z","reference_number":"EMA/827812/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-264-2009-european-medicines-agency-decision-23-december-2009-acceptance-modification-agreed-paediatric-investigation-plan-moxifloxacin-hydrochloride-actimax-associated-names-proflox-em_en.pdf"},
    {"id":"12231","name":"P/0100/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (EMEA-001050-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/188347/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-ixekizumab-emea-001050-pip01-10-m01_en.pdf"},
    {"id":"12249","name":"P/0308/2016: EMA decision of 4 November 2016 on the granting of a product-specific waiver for candesartan / amlodipine (EMEA-002014-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-10T01:00:00Z","last_updated_date":"2017-01-10T01:00:00Z","reference_number":"EMA/639657/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2016-ema-decision-4-november-2016-granting-product-specific-waiver-candesartan-amlodipine-emea-002014-pip01-16_en.pdf"},
    {"id":"12265","name":"P/0145/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla), (EMEA-000715-PIP03-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/308179/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip03-11-m04_en.pdf"},
    {"id":"12291","name":"P/0125/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Xgeva), (EMEA-000145-PIP01-07-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T02:00:00Z","last_updated_date":"2016-07-27T02:00:00Z","reference_number":"EMA/269205/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-xgeva-emea-000145-pip01-07-m08_en.pdf"},
    {"id":"12348","name":"P/06/2009: European Medicines Agency decision of 27 January 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver casopitant, EMEA-000154-PIP01-07 in a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/31310/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-06-2009-european-medicines-agency-decision-27-january-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-casopitant-emea-000154-pip01-07_en.pdf"},
    {"id":"12366","name":"P/0300/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla) (EMEA-000715-PIP03-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/792939/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip03-11-m03_en.pdf"},
    {"id":"12367","name":"P/0038/2018: EMA decision of 30 January 2018 on the granting of a product specific waiver for recombinant human epidermal growth factor (EMEA-\n\n002258-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/848796/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2018-ema-decision-30-january-2018-granting-product-specific-waiver-recombinant-human-epidermal-growth-factor-emea-002258-pip01-17_en.pdf"},
    {"id":"12380","name":"P/0315/2013: EMA decision of 19 December 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-6-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-05T01:00:00Z","last_updated_date":"2014-02-05T01:00:00Z","reference_number":"EMA/693866/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0315-2013-ema-decision-19-december-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-2r6s12z13as14ar16as-n-cyclopropylsulfonyl-6_en.pdf"},
    {"id":"12381","name":"P/89/09: European medicines agency decision of 18 May 2009 on the refusal of a Paediatric Investigation Plan and on the granting of a waiver for drospirenone / ethinylestradiol, betadex clathrate / L-5 methyltetrahydrofo...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/272661/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-89-09-european-medicines-agency-decision-18-may-2009-refusal-paediatric-investigation-plan-granting-waiver-drospirenone-ethinylestradiol-betadex-clathrate-l-5-methyltetrahydrofo_en.pdf"},
    {"id":"12414","name":"P/0246/2016: EMA decision of 12 September 2016 on the granting of a product specific waiver for allogeneic human neural stem cells genetically modified\n\nto express c-MycERTAM, a c-Myc and modified oestrogen receptor fusi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/557965/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2016-ema-decision-12-september-2016-granting-product-specific-waiver-allogeneic-human-neural-stem-cells-genetically-modified-express-c-mycertam-c-myc-modified-oestrogen-receptor-fusi_en.pdf"},
    {"id":"12462","name":"P/0174/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for Live, attenuated, chimeric dengue virus, serotype 1 / Live, attenuated, chimeric dengue virus,...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/434507/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-live-attenuated-chimeric-dengue-virus-serotype-1-live-attenuated-chimeric-dengue-virus_en.pdf"},
    {"id":"12478","name":"P/175/2011: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for dabigatran etexilate\n\nmesilate (Pradaxa) (EMEA-000081-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/503627/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-175-2011-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-mesilate-pradaxa-emea-000081-pip01-07-m03_en.pdf"},
    {"id":"12490","name":"P/0232/2013: EMA decision of 23 September 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for sapropterin dihydrochloride (Kuvan), (EMEA-001476-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/562037/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2013-ema-decision-23-september-2013-agreement-paediatric-investigation-plan-granting-waiver-sapropterin-dihydrochloride-kuvan-emea-001476-pip01-13_en.pdf"},
    {"id":"12496","name":"P/0223/2013: EMA decision of 23 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for azilsartan medoxomil (Edarbi, Ipreziv), (EMEA-000237-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/492667/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2013-ema-decision-23-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-azilsartan-medoxomil-edarbi-ipreziv-emea-000237-pip01-08-m05_en.pdf"},
    {"id":"12514","name":"P/0239/2014: EMA decision of 22 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for vortioxetine (Brintellix), (EMEA-000455-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-10-09T02:00:00Z","last_updated_date":"2014-10-09T02:00:00Z","reference_number":"EMA/391701/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2014-ema-decision-22-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-vortioxetine-brintellix-emea-000455-pip02-10-m02_en.pdf"},
    {"id":"12518","name":"P/0122/2012: EMA decision of 4 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Victoza) (EMEA-000128-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-06T18:00:00Z","last_updated_date":"2012-08-06T18:00:00Z","reference_number":"EMA/418254/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2012-ema-decision-4-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-victoza-emea-000128-pip01-07-m04_en.pdf"},
    {"id":"12521","name":"P/0167/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla), (EMEA-000715-PIP03-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/507290/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip03-11-m02_en.pdf"},
    {"id":"12527","name":"P/0058/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Prolia, Xgeva), (EMEA-000145-PIP02-12-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/104818/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-prolia-xgeva-emea-000145-pip02-12-m01_en.pdf"},
    {"id":"12532","name":"P/0089/2013: EMA decision of 29 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon alfa-2a (Pegasys) (EMEA-000298-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/206723/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2013-ema-decision-29-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-peginterferon-alfa-2a-pegasys-emea-000298-pip01-08-m03_en.pdf"},
    {"id":"12555","name":"P/0219/2012: EMA decision of 28 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol\n\n(hydrochloride) (Palexia, Yantil), (EMEA-000494-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T17:00:00Z","last_updated_date":"2012-10-17T17:00:00Z","reference_number":"EMA/598561/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2012-ema-decision-28-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-yantil-emea-000494-pip01-08-m04_en.pdf"},
    {"id":"12564","name":"P/0009/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ocrelizumab (EMEA-\n\n000310-PIP03-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/38334/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-ocrelizumab-emea-000310-pip03-10-m02_en.pdf"},
    {"id":"12594","name":"P/0189/2017: EMA decision of 3 July 2017 on the granting of a product-specific waiver for rosuvastatin / amlodipine (EMEA-002130-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/348031/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2017-ema-decision-3-july-2017-granting-product-specific-waiver-rosuvastatin-amlodipine-emea-002130-pip01-17_en.pdf"},
    {"id":"12597","name":"P/0167/2013: EMA decision of 30 July on the acceptance of a modification of an agreed paediatric investigation plan for cobicistat (EMEA-\n\n000969-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/378738/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2013-ema-decision-30-july-acceptance-modification-agreed-paediatric-investigation-plan-cobicistat-emea-000969-pip01-10-m02_en.pdf"},
    {"id":"12608","name":"P/237/2011: EMA decision of 30 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for aliskiren (Rasilez and associated names) (EMEA-000362-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/708577/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-237-2011-ema-decision-30-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-aliskiren-rasilez-associated-names-emea-000362-pip01-08-m01_en.pdf"},
    {"id":"12624","name":"P/0062/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for trenonacog alfa (EMEA-000661-PIP01-09-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/138328/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-trenonacog-alfa-emea-000661-pip01-09-m07_en.pdf"},
    {"id":"12640","name":"P/33/2008: European medicines agency decision of 24 June 2008 on the application for agreement of a Paediatric Investigation Plan for tifacogin EMEA-000027- PIP01-07 in accordance with Regulation (EC) No 1901/2006","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/311526/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-33-2008-european-medicines-agency-decision-24-june-2008-application-agreement-paediatric-investigation-plan-tifacogin-emea-000027-pip01-07-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"12647","name":"P/0400/2017: EMA decision of 19 December 2017 on the refusal of a modification of an agreed paediatric investigation plan for recombinant human\n\nglutamic acid decarboxylase (rhGAD65) (EMEA-000609-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/797359/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0400-2017-ema-decision-19-december-2017-refusal-modification-agreed-paediatric-investigation-plan-recombinant-human-glutamic-acid-decarboxylase-rhgad65-emea-000609-pip01-09-m01_en.pdf"},
    {"id":"12648","name":"P/0221/2014: EMA decision of 3 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/454986/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2014-ema-decision-3-september-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-4-1r2s3s5s7s-5-hydroxy-2-adamantylamino-1h_en.pdf"},
    {"id":"12657","name":"P/0003/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Votubia) (EMEA-000019-PIP02-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-19T01:00:00Z","last_updated_date":"2014-02-19T01:00:00Z","reference_number":"EMA/776286/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-votubia-emea-000019-pip02-07-m05_en.pdf"},
    {"id":"12666","name":"P/0135/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for pitolisant (Wakix), (EMEA-001176-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T02:00:00Z","last_updated_date":"2016-07-27T02:00:00Z","reference_number":"EMA/287396/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-pitolisant-wakix-emea-001176-pip01-11-m02_en.pdf"},
    {"id":"12689","name":"P/0371/2017: EMA decision of 1 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for recombinant humanised IgG4 monoclonal antibody again...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-05T15:26:00Z","last_updated_date":"2018-03-05T15:26:00Z","reference_number":"EMA/723480/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0371-2017-ema-decision-1-december-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-humanised-igg4-monoclonal-antibody-again_en.pdf"},
    {"id":"12690","name":"P/0300/2013: EMA decision of 29 November 2013 on the granting of a product specific waiver for amlodipine (besylate), perindopril (arginine), atorvastatin (calcium trihydrate) (EMEA-001496-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/705684/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2013-ema-decision-29-november-2013-granting-product-specific-waiver-amlodipine-besylate-perindopril-arginine-atorvastatin-calcium-trihydrate-emea-001496-pip01-13_en.pdf"},
    {"id":"12699","name":"P/315/2011: EMA decision of 22 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for atomoxetine (hydrochloride) (Strattera), (EMEA-00116...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/973117/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-315-2011-ema-decision-22-december-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-atomoxetine-hydrochloride-strattera-emea-00116_en.pdf"},
    {"id":"12711","name":"P/0158/2012: EMA decision of 25 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for sildenafil (Revatio), (EMEA-000671-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/478172/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2012-ema-decision-25-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-sildenafil-revatio-emea-000671-pip01-09-m03_en.pdf"},
    {"id":"12714","name":"P/0217/2013: EMA decision of 6 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta, Bydureon) (EMEA-000689-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/476175/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2013-ema-decision-6-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-exenatide-byetta-bydureon-emea-000689-pip01-09-m04_en.pdf"},
    {"id":"12722","name":"P/0018/2012: EMA decision of 25 January 2012 on the granting of a product specific waiver for ezetimibe / atorvastatin (calcium) (EMEA-001204-\n\nPIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/25154/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2012-ema-decision-25-january-2012-granting-product-specific-waiver-ezetimibe-atorvastatin-calcium-emea-001204-pip01-11_en.pdf"},
    {"id":"12738","name":"P/0267/2014: EMA decision of 16 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ambrisentan (Volibris), (EMEA-000434-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/592401/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2014-ema-decision-16-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-ambrisentan-volibris-emea-000434-pip01-08-m03_en.pdf"},
    {"id":"12779","name":"P/324/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira) (EMEA-000366-PIP01-08-M06) in","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/804453/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-324-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip01-08-m06_en.pdf"},
    {"id":"12783","name":"P/0017/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity), (EMEA-000783-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/23027/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-dulaglutide-trulicity-emea-000783-pip01-09-m03_en.pdf"},
    {"id":"12794","name":"P/0201/2017: EMA decision of 14 July 2017 on the granting of a product-specific waiver for pexastimogene devacirepvec (EMEA-002124-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/444489/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2017-ema-decision-14-july-2017-granting-product-specific-waiver-pexastimogene-devacirepvec-emea-002124-pip01-17_en.pdf"},
    {"id":"12812","name":"P/0067/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ombitasvir /\n\nparitaprevir / ritonavir (Viekirax), (EMEA-001440-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/91096/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-ombitasvir-paritaprevir-ritonavir-viekirax-emea-001440-pip01-13-m01_en.pdf"},
    {"id":"12814","name":"P/199/2011: EMA decision of 4 August 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for lopinavir /\n\nritonavir (Kaletra), (EMEA-001005-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/603159/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-199-2011-ema-decision-4-august-2011-agreement-paediatric-investigation-plan-granting-waiver-lopinavir-ritonavir-kaletra-emea-001005-pip01-10_en.pdf"},
    {"id":"12816","name":"P/124/2008: European Medicines Agency decision of 5 December 2008 on the application for agreement of a Paediatric Investigation Plan for everolimus (Certican and associated names) EMEA-000019-PIP02-07 in accordance with...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/626873/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-124-2008-european-medicines-agency-decision-5-december-2008-application-agreement-paediatric-investigation-plan-everolimus-certican-associated-names-emea-000019-pip02-07-accordance_en.pdf"},
    {"id":"12820","name":"P/86/2011: EMA decision of 8 April 2011 on the acceptance of a modification of an agreed paediatric investigation plan for velaglucerase alfa (EMEA-000556-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/259113/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-86-2011-ema-decision-8-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-velaglucerase-alfa-emea-000556-pip01-09-m01_en.pdf"},
    {"id":"12830","name":"P/0277/2012: EMA decision of 21 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for EMEA-000673-PIP01-09-M06","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/723426/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2012-ema-decision-21-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-emea-000673-pip01-09-m06_en.pdf"},
    {"id":"12883","name":"P/0250/2014: EMA decision of 30 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate) (EMEA-000788-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/527089/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2014-ema-decision-30-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-emea-000788-pip02-11-m03_en.pdf"},
    {"id":"12924","name":"P/191/2010: European Medicines Agency decision of 15 October 2010 on the acceptance of a modification of an agreed paediatric investigation plan for cholic acid (EMEA-000651-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-24T01:00:00Z","last_updated_date":"2010-11-24T01:00:00Z","reference_number":"EMA/478331/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-191-2010-european-medicines-agency-decision-15-october-2010-acceptance-modification-agreed-paediatric-investigation-plan-cholic-acid-emea-000651-pip01-09-m01_en.pdf"},
    {"id":"12929","name":"P/0112/2017: EMA decision of 11 April 2017 on the agreement of a paediatric investigation plan and on the granting of a waiver for olodaterol\n\n(hydrochloride) (Striverdi Respimat), (EMEA-001965-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/181827/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2017-ema-decision-11-april-2017-agreement-paediatric-investigation-plan-granting-waiver-olodaterol-hydrochloride-striverdi-respimat-emea-001965-pip01-16_en.pdf"},
    {"id":"12940","name":"P/0193/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-me...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/354121/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-1-22-difluoro-13-benzodioxol-5-yl-n-1-2r-23-dihydroxypropyl-6-fluoro-2-1-hydroxy-2-me_en.pdf"},
    {"id":"12941","name":"P/42/2008: European medicines agency decision of 24 June 2008\n\non the application for product specific waiver for dutasteride, tamsulosin hydrochloride (EMEA-000216-PIP01-08) in accordance with Regulation (EC) No 1901/20...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/313699/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-42-2008-european-medicines-agency-decision-24-june-2008-application-product-specific-waiver-dutasteride-tamsulosin-hydrochloride-emea-000216-pip01-08-accordance-regulation-ec-no-1901-20_en.pdf"},
    {"id":"12943","name":"P/0165/2012: EMA decision of 26 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for asunaprevir (EMEA-001190-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T16:00:00Z","last_updated_date":"2012-08-23T16:00:00Z","reference_number":"EMA/476808/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2012-ema-decision-26-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-asunaprevir-emea-001190-pip01-11_en.pdf"},
    {"id":"12944","name":"P/0158/2014: EMA decision of 18 June 2014 on the granting of a product specific waiver for metronidazole (in combination with amoxicillin + clarithromycin + pantoprazole) (EMEA-001615-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T14:20:00Z","last_updated_date":"2014-07-22T14:20:00Z","reference_number":"EMA/259620/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2014-ema-decision-18-june-2014-granting-product-specific-waiver-metronidazole-combination-amoxicillin-clarithromycin-pantoprazole-emea-001615-pip01-13_en.pdf"},
    {"id":"12956","name":"P/245/2011: EMA decision of 21 October 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for furosemide (EMEA-000982-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-28T17:00:00Z","last_updated_date":"2011-11-28T17:00:00Z","reference_number":"EMA/826074/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-245-2011-ema-decision-21-october-2011-agreement-paediatric-investigation-plan-granting-waiver-furosemide-emea-000982-pip01-10_en.pdf"},
    {"id":"12984","name":"P/0206/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine\n\n(hydrochloride) (EDURANT), (EMEA-000317-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/472137/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-edurant-emea-000317-pip01-08-m09_en.pdf"},
    {"id":"12986","name":"P/0041/2013: EMA decision of 25 February 2013 on the acceptance of a modification of an agreed paediatric investigation plan for beclometasone dipropionate / formoterol fumarate dihydrate (Foster and associated names, Ka...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T02:00:00Z","last_updated_date":"2013-04-23T02:00:00Z","reference_number":"EMA/104506/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2013-ema-decision-25-february-2013-acceptance-modification-agreed-paediatric-investigation-plan-beclometasone-dipropionate-formoterol-fumarate-dihydrate-foster-associated-names-ka_en.pdf"},
    {"id":"13002","name":"P/321/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for lisdexamfetamine (dimesylate) (EMEA-000553-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/775944/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-321-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-lisdexamfetamine-dimesylate-emea-000553-pip01-09-m04_en.pdf"},
    {"id":"13011","name":"P/73/2010: European Medicines Agency decision of 5 May 2010 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-000454-PIP01-08-M01) in accordance with Reg...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/261595/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-73-2010-european-medicines-agency-decision-5-may-2010-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000454-pip01-08-m01-accordance-reg_en.pdf"},
    {"id":"13012","name":"P/0243/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for fidaxomicin (Dificlir), (EMEA-000636-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-25T17:00:00Z","last_updated_date":"2017-10-25T17:00:00Z","reference_number":"EMA/507343/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-fidaxomicin-dificlir-emea-000636-pip01-09-m06_en.pdf"},
    {"id":"13013","name":"P/336/2010: EMA decision of 22 December 2010 on the granting of a product specific waiver for interferon alpha 2b (EMEA-001036-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/683287/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-336-2010-ema-decision-22-december-2010-granting-product-specific-waiver-interferon-alpha-2b-emea-001036-pip01-10_en.pdf"},
    {"id":"13017","name":"P/0086/2017: EMA decision of 20 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (Orkambi), (EMEA-001582-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/155547/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2017-ema-decision-20-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-lumacaftor-ivacaftor-orkambi-emea-001582-pip01-13-m05_en.pdf"},
    {"id":"13032","name":"P/0207/2015: EMA decision of 10 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/561311/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2015-ema-decision-10-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-linagliptin-trajenta-emea-000498-pip01-08-m05_en.pdf"},
    {"id":"13043","name":"P/231/2010:  EMA decision of 23 November 2010 on the agreement of a paediatric investigation plan and on the granting of a waiver for fentanyl citrate, (EMEA-000712-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/656702/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-231-2010-ema-decision-23-november-2010-agreement-paediatric-investigation-plan-granting-waiver-fentanyl-citrate-emea-000712-pip01-09_en.pdf"},
    {"id":"13044","name":"P/0156/2016: EMA decision of 15 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocoutur...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/314185/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2016-ema-decision-15-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-clostridium-botulinum-neurotoxin-type-150-kd-free-complexing-proteins-xeomin-bocoutur_en.pdf"},
    {"id":"13047","name":"P/114/2011: EMA decision of 6 May 2011 on the acceptance of a modification of an agreed paediatric investigation plan for sildenafil citrate\n\n(Revatio), (EMEA-000671-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-07T02:00:00Z","last_updated_date":"2011-06-07T02:00:00Z","reference_number":"EMA/330172/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-114-2011-ema-decision-6-may-2011-acceptance-modification-agreed-paediatric-investigation-plan-sildenafil-citrate-revatio-emea-000671-pip01-09-m01_en.pdf"},
    {"id":"13064","name":"P/119/2009: European Medicines Agency decision of 15 June 2009 on the granting of a product specific waiver for aliskiren hemifumarate / amlodipine besilate (EMEA-000516-PIP01-08) in accordance with Regulation (EC) No 19...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351842/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-119-2009-european-medicines-agency-decision-15-june-2009-granting-product-specific-waiver-aliskiren-hemifumarate-amlodipine-besilate-emea-000516-pip01-08-accordance-regulation-ec-no-19_en.pdf"},
    {"id":"13070","name":"P/82/2009: European medicines agency decision of 24 April 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for regadenoson (EMEA-000410-PIP01-08) in accordance with Regulation (E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2006-06-10T02:00:00Z","last_updated_date":"2006-06-10T02:00:00Z","reference_number":"EMEA/231051/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-82-2009-european-medicines-agency-decision-24-april-2009-agreement-paediatric-investigation-plan-granting-deferral-regadenoson-emea-000410-pip01-08-accordance-regulation-e_en.pdf"},
    {"id":"13083","name":"P/200/2010: European Medicines Agency decision of  27 October 2010 on the acceptance of a modification of an agreed paediatric investigation plan for Sodium-X-5-Hydroxy-X-6,10-dioxo-3,4,5,6,9,9a,10-hexahydro-2H-1-oxa-4a,...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-24T01:00:00Z","last_updated_date":"2010-11-24T01:00:00Z","reference_number":"EMA/650005/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-200-2010-european-medicines-agency-decision-27-october-2010-acceptance-modification-agreed-paediatric-investigation-plan-sodium-x-5-hydroxy-x-610-dioxo-345699a10-hexahydro-2h-1-oxa-4a_en.pdf"},
    {"id":"13094","name":"P/0220/2017: EMA decision of 9 August 2017 on the granting of a product specific waiver for daxibotulinumtoxinA (EMEA-002149-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/436417/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2017-ema-decision-9-august-2017-granting-product-specific-waiver-daxibotulinumtoxina-emea-002149-pip01-17_en.pdf"},
    {"id":"13107","name":"P/94/2008: European medicines agency decision of 3 November 2008\n\non the application for agreement of a Paediatric Investigation Plan for vandetanib, EMEA-000052-PIP01-07 in accordance with Regulation (EC) No 1901/2006 o...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-07T00:00:00Z","last_updated_date":"2009-01-07T00:00:00Z","reference_number":"EMEA/562638/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-94-2008-european-medicines-agency-decision-3-november-2008-application-agreement-paediatric-investigation-plan-vandetanib-emea-000052-pip01-07-accordance-regulation-ec-no-1901-2006-o_en.pdf"},
    {"id":"13163","name":"P/0041/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for albiglutide, (Eperzan) (EMEA-001175-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-25T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/89509/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2015-ema-decision-6-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-albiglutide-eperzan-emea-001175-pip01-11-m02_en.pdf"},
    {"id":"13167","name":"P/185/2011: EMA decision of 4 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia) (EMEA-000495-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/601930/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-185-2011-ema-decision-4-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-emea-000495-pip01-08-m03_en.pdf"},
    {"id":"13182","name":"P/0323/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel(Fycompa), (EMEA-000467-PIP01-08-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T11:23:00Z","last_updated_date":"2017-01-30T11:23:00Z","reference_number":"EMA/741982/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-perampanelfycompa-emea-000467-pip01-08-m08_en.pdf"},
    {"id":"13195","name":"P/0210/2013: EMA decision of 3 September 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for cangrelor (tetrasodium), (EMEA-001348-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"EMA/466068/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2013-ema-decision-3-september-2013-agreement-paediatric-investigation-plan-granting-deferral-cangrelor-tetrasodium-emea-001348-pip01-12_en.pdf"},
    {"id":"13206","name":"P/0195/2013: EMA decision of 2 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy) (EMEA-000117-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/456074/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2013-ema-decision-2-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-yervoy-emea-000117-pip01-07-m05_en.pdf"},
    {"id":"13212","name":"P/0165/2014: EMA decision of 27 June 2014 on the granting of a product specific waiver for aflibercept (Eylea), (EMEA-000236-PIP04-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-31T12:00:00Z","last_updated_date":"2014-07-31T12:00:00Z","reference_number":"EMA/356633/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2014-ema-decision-27-june-2014-granting-product-specific-waiver-aflibercept-eylea-emea-000236-pip04-14_en.pdf"},
    {"id":"13238","name":"P/79/2008: European medicines agency decision of 15 September 2007 on the application for product specific waiver for prilocaine, lidocaine (EMEA-000248-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the Eu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-10-10T02:00:00Z","last_updated_date":"2008-10-10T02:00:00Z","reference_number":"EMEA/471376/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-79-2008-european-medicines-agency-decision-15-september-2007-application-product-specific-waiver-prilocaine-lidocaine-emea-000248-pip01-08-accordance-regulation-ec-no-1901-2006-eu_en.pdf"},
    {"id":"13240","name":"P/0224/2012: EMA decision of 1 October 2012 on the granting of a product specific waiver for azilsartan medoxomil / chlortalidone (EMEA-001294-\n\nPIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/568807/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2012-ema-decision-1-october-2012-granting-product-specific-waiver-azilsartan-medoxomil-chlortalidone-emea-001294-pip01-12_en.pdf"},
    {"id":"13244","name":"P/218/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 12 grass pollen extract, cultiva...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/615624/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-218-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-12-grass-pollen-extract-cultiva_en.pdf"},
    {"id":"13254","name":"P/0178/2017: EMA decision of 3 July 2017 on the granting of a product specific waiver for radium Ra223 dichloride (Xofigoe), (EMEA-001986-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/348033/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2017-ema-decision-3-july-2017-granting-product-specific-waiver-radium-ra223-dichloride-xofigoe-emea-001986-pip01-16_en.pdf"},
    {"id":"13261","name":"P/30/2008: European medicines agency decision of 23 May 2008 on the application for modification of an agreed Paediatric Investigation Plan for Cancidas, caspofungin acetate, EMEA-000010-PIP01-07 MO1 in accordance with R...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-17T02:00:00Z","last_updated_date":"2008-07-17T02:00:00Z","reference_number":"EMEA/259268/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-30-2008-european-medicines-agency-decision-23-may-2008-application-modification-agreed-paediatric-investigation-plan-cancidas-caspofungin-acetate-emea-000010-pip01-07-mo1-accordance-r_en.pdf"},
    {"id":"13276","name":"P/0040/2016: EMA decision of 19 February 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nivolumab (Opdivo), (EMEA-001407-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/103118/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2016-ema-decision-19-february-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-nivolumab-opdivo-emea-001407-pip02-15_en.pdf"},
    {"id":"13277","name":"P/0001/2014: EMA decision of 13 January 2014 on the agreement of a paediatric investigation plan and on the granting of a waiver for raltegravir / lamivudine (EMEA-001442-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-05T01:00:00Z","last_updated_date":"2014-02-05T01:00:00Z","reference_number":"EMA/738904/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2014-ema-decision-13-january-2014-agreement-paediatric-investigation-plan-granting-waiver-raltegravir-lamivudine-emea-001442-pip01-13_en.pdf"},
    {"id":"13287","name":"P/0102/2012: EMA decision of 30 May 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for agomelatine (Valdoxan, Thymanax), (EMEA-001181-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T18:00:00Z","last_updated_date":"2012-06-25T18:00:00Z","reference_number":"EMA/230119/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2012-ema-decision-30-may-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-agomelatine-valdoxan-thymanax-emea-001181-pip01-11_en.pdf"},
    {"id":"13302","name":"P/0030/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for amikacin (sulfate) (EMEA-000525-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/44366/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-amikacin-sulfate-emea-000525-pip01-08-m04_en.pdf"},
    {"id":"13318","name":"P/0196/2016: EMA decision of 15 July 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for emicizumab (EMEA-001839-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T02:00:00Z","last_updated_date":"2016-09-22T02:00:00Z","reference_number":"EMA/387121/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2016-ema-decision-15-july-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-emicizumab-emea-001839-pip01-15_en.pdf"},
    {"id":"13323","name":"P/0187/2017: EMA decision of 3 July 2017 on the granting of a product specific waiver for miridesap (EMEA-002111-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/354129/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2017-ema-decision-3-july-2017-granting-product-specific-waiver-miridesap-emea-002111-pip02-17_en.pdf"},
    {"id":"13328","name":"P/0231/2013: EMA decision of 23 September 2013 on the granting of a product specific waiver for valsartan / atorvastatin (EMEA-001472-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/492660/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2013-ema-decision-23-september-2013-granting-product-specific-waiver-valsartan-atorvastatin-emea-001472-pip01-13_en.pdf"},
    {"id":"13332","name":"P/0260/2016: EMA decision of 5 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+\n\ncells transduced with lentiviral vector containing the human Wiskott Aldric...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/585489/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2016-ema-decision-5-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-cells-transduced-lentiviral-vector-containing-human-wiskott-aldric_en.pdf"},
    {"id":"13341","name":"P/0289/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for riociguat (Adempas),\n\n(EMEA-000718-PIP01-09-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-19T15:52:00Z","last_updated_date":"2017-01-19T15:52:00Z","reference_number":"EMA/639656/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-riociguat-adempas-emea-000718-pip01-09-m06_en.pdf"},
    {"id":"13360","name":"P/310/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of birch pollen (EMEA-00093...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/697312/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-310-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-birch-pollen-emea-00093_en.pdf"},
    {"id":"13362","name":"P/20/2009: European Medicines Agency decision of of 6 February 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for anastrozole, Arimidex and associated names (EMEA-000283-PIP-01-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/64242/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-20-2009-european-medicines-agency-decision-6-february-2009-agreement-paediatric-investigation-plan-granting-waiver-anastrozole-arimidex-associated-names-emea-000283-pip-01-0_en.pdf"}    {"id":"13411","name":"P/0104/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for treosulfan (EMEA-000883-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/202483/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2013-ema-decision-30-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-treosulfan-emea-000883-pip01-10-m01_en.pdf"},
    {"id":"13417","name":"P/0140/2014: EMA decision of 11 June 2014 on the refusal of a paediatric investigation plan and on the granting of a waiver for doxylamine (succinate) / pyridoxine (hydrochloride) (EMEA-001608-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/275220/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2014-ema-decision-11-june-2014-refusal-paediatric-investigation-plan-granting-waiver-doxylamine-succinate-pyridoxine-hydrochloride-emea-001608-pip01-13_en.pdf"},
    {"id":"13430","name":"P/0254/2014: EMA decision of 30 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for solithromycin (EMEA-001581-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/528092/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2014-ema-decision-30-september-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-solithromycin-emea-001581-pip01-13_en.pdf"},
    {"id":"13436","name":"P/323/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (Edurant), (EMEA-000317-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/738887/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-323-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-edurant-emea-000317-pip01-08-m05_en.pdf"},
    {"id":"13442","name":"P/0296/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for delamanid (EMEA-\n\n001113-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/708157/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-delamanid-emea-001113-pip01-10-m02_en.pdf"},
    {"id":"13447","name":"P/0202/2016: EMA decision of of 28 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human\n\nbeta-glucuronidase (rhGUS, UX003) (EMEA-001540-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:17:00Z","last_updated_date":"2016-09-22T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2016-ema-decision-28-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-beta-glucuronidase-rhgus-ux003-emea-001540-pip01-13-m01_en.pdf"},
    {"id":"13464","name":"P/0037/2013: EMA decision of 27 February 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for azithromycin (EMEA-001298-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/75623/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2013-ema-decision-27-february-2013-agreement-paediatric-investigation-plan-granting-waiver-azithromycin-emea-001298-pip01-12_en.pdf"},
    {"id":"13486","name":"P/101/2009: European Medicines Agency decision of 19 May 2009 on the granting of a product specific waiver for cladribine (EMEA-000383-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/290924/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-101-2009-european-medicines-agency-decision-19-may-2009-granting-product-specific-waiver-cladribine-emea-000383-pip01-08-accordance-regulation-ec-no-1901-2006-european-parliament_en.pdf"},
    {"id":"13487","name":"P/178/2011: EMA decision of 26 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for asenapine (maleate)\n\n(Sycrest), (EMEA-000228-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/670593/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-178-2011-ema-decision-26-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-asenapine-maleate-sycrest-emea-000228-pip01-08-m02_en.pdf"},
    {"id":"13494","name":"P/0158/2017: EMA decision of 29 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla),\n\n(EMEA-000715-PIP05-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/394680/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2017-ema-decision-29-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip05-13-m01_en.pdf"},
    {"id":"13495","name":"P/0087/2013: EMA decision of 29 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for ceftobiprole medocaril (sodium) (EMEA-000205-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/206620/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2013-ema-decision-29-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-ceftobiprole-medocaril-sodium-emea-000205-pip01-08-m02_en.pdf"},
    {"id":"13571","name":"P/0087/2017: EMA decision of 24 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for talimogene\n\nlaherparepvec (Imlygic), (EMEA-001251-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/181816/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2017-ema-decision-24-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-talimogene-laherparepvec-imlygic-emea-001251-pip01-11-m03_en.pdf"},
    {"id":"13578","name":"P/315/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of grass pollen (EMEA-00094...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769460/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-315-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-grass-pollen-emea-00094_en.pdf"},
    {"id":"13581","name":"P/235/2011: EMA decision of 30 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for rituximab (Mabthera) (EMEA-000308-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/708063/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-235-2011-ema-decision-30-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-rituximab-mabthera-emea-000308-pip01-08-m01_en.pdf"},
    {"id":"13604","name":"P/103/2011: EMA decision of 3 May 2011 on the acceptance of a modification of an agreed paediatric investigation plan for conestat alfa (Ruconest) (EMEA-000367-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-09T02:00:00Z","last_updated_date":"2011-06-09T02:00:00Z","reference_number":"EMA/247030/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-103-2011-ema-decision-3-may-2011-acceptance-modification-agreed-paediatric-investigation-plan-conestat-alfa-ruconest-emea-000367-pip01-08-m01_en.pdf"},
    {"id":"13626","name":"P/0055/2016: EMA decision of 18 March 2016 on the granting of a product specific waiver for fluoroestradiol (18F) (EMEA-001892-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/90033/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2016-ema-decision-18-march-2016-granting-product-specific-waiver-fluoroestradiol-18f-emea-001892-pip01-15_en.pdf"},
    {"id":"13642","name":"P/0025/2012: EMA decision of 27 January 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for human fibrinogen / human thrombin (Evicel), (EMEA-00...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/987057/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2012-ema-decision-27-january-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-fibrinogen-human-thrombin-evicel-emea-00_en.pdf"},
    {"id":"13650","name":"P/0248/2012: EMA decision of 23 October 2012 on the granting of a product-specific waiver for folic acid (EMEA-001321-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/587247/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2012-ema-decision-23-october-2012-granting-product-specific-waiver-folic-acid-emea-001321-pip01-12_en.pdf"},
    {"id":"13672","name":"P/144/2011: EMA decision of 9 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chemically modified extract of trees pollen from birch and...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/417339/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-144-2011-ema-decision-9-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chemically-modified-extract-trees-pollen-birch_en.pdf"},
    {"id":"13687","name":"P/0131/2016: EMA decision of 20 May 2016on the acceptance of a modification of an agreed paediatric investigation plan for vorapaxar (EMEA-000778-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/269206/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2016-ema-decision-20-may-2016on-acceptance-modification-agreed-paediatric-investigation-plan-vorapaxar-emea-000778-pip02-12-m01_en.pdf"},
    {"id":"13712","name":"P/0261/2016: EMA decision of 5 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for eftrenonacog alfa\n\n(ALPROLIX), (EMEA-000914-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/585499/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2016-ema-decision-5-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-eftrenonacog-alfa-alprolix-emea-000914-pip01-10-m03_en.pdf"},
    {"id":"13716","name":"P/0134/2013: EMA decision of 14 June 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for isavuconazonium (sulfate) (EMEA-001301-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T12:00:00Z","last_updated_date":"2013-07-23T12:00:00Z","reference_number":"EMA/313498/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2013-ema-decision-14-june-2013-agreement-paediatric-investigation-plan-granting-deferral-isavuconazonium-sulfate-emea-001301-pip01-12_en.pdf"},
    {"id":"13729","name":"P/124/2010: European Medicines Agency decision of 28 July 2010 on the acceptance of a modification of an agreed paediatric investigation plan for voclosporin (EMEA-000132-PIP01-07-M02) in accordance with Regulation (EC) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/463403/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-124-2010-european-medicines-agency-decision-28-july-2010-acceptance-modification-agreed-paediatric-investigation-plan-voclosporin-emea-000132-pip01-07-m02-accordance-regulation-ec_en.pdf"},
    {"id":"13766","name":"P/0068/2012: EMA decision of 4 April 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rituximab (MabThera), (EMEA-000308-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-27T13:00:00Z","last_updated_date":"2012-04-27T13:00:00Z","reference_number":"EMA/215413/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2012-ema-decision-4-april-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rituximab-mabthera-emea-000308-pip02-11_en.pdf"},
    {"id":"13769","name":"P/0081/2017: EMA decision of 17 March 2017 on the granting of a product specific waiver for atorvastatin (calcium) / ezetimibe (EMEA-002047-\n\nPIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/104150/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2017-ema-decision-17-march-2017-granting-product-specific-waiver-atorvastatin-calcium-ezetimibe-emea-002047-pip01-16_en.pdf"},
    {"id":"13777","name":"P/0191/2015: EMA decision of 4 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for eliglustat (tartrate) (Cerdelga), (EMEA-000461-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/505296/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2015-ema-decision-4-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-eliglustat-tartrate-cerdelga-emea-000461-pip02-11-m01_en.pdf"},
    {"id":"13792","name":"P/45/2007: European medicines agency decision of 23 June 2008\n\non the application for agreement of a Paediatric Investigation Plan for Nicotinic acid and laropiprant (EMEA-000251-PIP01-08) in accordance with Regulation (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/315694/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-45-2007-european-medicines-agency-decision-23-june-2008-application-agreement-paediatric-investigation-plan-nicotinic-acid-laropiprant-emea-000251-pip01-08-accordance-regulation_en.pdf"},
    {"id":"13794","name":"P/0068/2017: EMA decision of 17 March 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for somapacitan (EMEA-001469-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/104169/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2017-ema-decision-17-march-2017-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-somapacitan-emea-001469-pip01-13_en.pdf"},
    {"id":"13812","name":"P/0122/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for luspatercept (EMEA-\n\n001521-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/141787/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-luspatercept-emea-001521-pip01-13-m02_en.pdf"},
    {"id":"13826","name":"P/170/2011: EMA decision of 8 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for fosaprepitant\n\n(Ivemend), (EMEA-000406-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/387079/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-170-2011-ema-decision-8-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-fosaprepitant-ivemend-emea-000406-pip01-08-m02_en.pdf"},
    {"id":"13841","name":"P/0220/2013: EMA decision of 6 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for valganciclovir (Valcyte and associated names), (EMEA-000726-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/496855/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2013-ema-decision-6-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-valganciclovir-valcyte-associated-names-emea-000726-pip01-09-m02_en.pdf"},
    {"id":"13899","name":"P/0011/2016: EMA decision of 29 January 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for osilodrostat (EMEA-000315-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/2821/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2016-ema-decision-29-january-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-osilodrostat-emea-000315-pip02-15_en.pdf"},
    {"id":"13906","name":"P/0135/2017: EMA decision of 7 June 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for pimodivir (EMEA-001975-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/312727/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2017-ema-decision-7-june-2017-agreement-paediatric-investigation-plan-granting-deferral-pimodivir-emea-001975-pip01-16_en.pdf"},
    {"id":"13930","name":"P/0097/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (RS)-Bacoflen / naltrexone HCl / D-Sorbitol (PXT3003) (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/112469/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rs-bacoflen-naltrexone-hcl-d-sorbitol-pxt3003_en.pdf"},
    {"id":"13937","name":"P/0009/2013: EMA decision of 22 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for atazanavir sulphate (Reyataz), (EMEA-000804-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T18:30:00Z","last_updated_date":"2013-04-03T18:30:00Z","reference_number":"EMA/21189/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2013-ema-decision-22-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-atazanavir-sulphate-reyataz-emea-000804-pip01-09-m01_en.pdf"},
    {"id":"13951","name":"P/137/2009: European Medicines Agency decision of 15 July 2009 on the agreement of a Paediatric Investigation Plan and on the refusal of a deferral and on the granting of a waiver for fosaprepitant dimeglumine (Ivemend) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/416941/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-137-2009-european-medicines-agency-decision-15-july-2009-agreement-paediatric-investigation-plan-refusal-deferral-granting-waiver-fosaprepitant-dimeglumine-ivemend_en.pdf"},
    {"id":"13960","name":"P/0368/2017: EMA decision of 1 December 2017 on the granting of a product specific waiver for vonapanitase (EMEA-002195-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T14:03:00Z","last_updated_date":"2018-03-07T14:03:00Z","reference_number":"EMA/711132/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0368-2017-ema-decision-1-december-2017-granting-product-specific-waiver-vonapanitase-emea-002195-pip01-17_en.pdf"},
    {"id":"13965","name":"P/0158/2016: EMA decision of 15 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for naloxegol (EMEA-001146-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/314193/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2016-ema-decision-15-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-naloxegol-emea-001146-pip01-11-m02_en.pdf"},
    {"id":"14009","name":"P/20/2008: European medicines agency decision of  28 April 2008 on the application for product specific waiver for flibanserin, EMEA-000085-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliam...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-05-16T02:00:00Z","last_updated_date":"2008-05-16T02:00:00Z","reference_number":"EMEA/212132/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-20-2008-european-medicines-agency-decision-28-april-2008-application-product-specific-waiver-flibanserin-emea-000085-pip01-07-accordance-regulation-ec-no-1901-2006-european-parliam_en.pdf"},
    {"id":"14033","name":"P/21/2009: European Medicines Agency decision of 23 February 2009 on the refusal of a Paediatric Investigation Plan and on the refusal of a waiver for candesartan cilexetil (Atacand and associated name), (EMEA-000021-PIP...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/95694/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-21-2009-european-medicines-agency-decision-23-february-2009-refusal-paediatric-investigation-plan-refusal-waiver-candesartan-cilexetil-atacand-associated-name-emea-000021-pip_en.pdf"},
    {"id":"14046","name":"P/165/2011: EMA decision of 4 July 2011 on the granting of a product specific waiver for alogliptin (benzoate) / metformin (hydrochloride)\n\n(EMEA-001128-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/423967/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-165-2011-ema-decision-4-july-2011-granting-product-specific-waiver-alogliptin-benzoate-metformin-hydrochloride-emea-001128-pip01-10_en.pdf"},
    {"id":"14052","name":"P/101/2011: EMA decision of 11 April 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for darbepoetin\n\nalfa (Aranesp) (EMEA-000329-PIP02-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/278715/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-101-2011-ema-decision-11-april-2011-agreement-paediatric-investigation-plan-granting-waiver-darbepoetin-alfa-aranesp-emea-000329-pip02-09_en.pdf"},
    {"id":"14063","name":"P/0062/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for\n\nceftazidime / avibactam (Zavicefta), (EMEA-001313-PIP01-12-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/136639/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-zavicefta-emea-001313-pip01-12-m05_en.pdf"},
    {"id":"14078","name":"P/0136/2013: EMA decision of 14 June 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for phenylephrine hydrochloride / ketorolac trometamol (OMS3...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T12:00:00Z","last_updated_date":"2013-07-23T12:00:00Z","reference_number":"EMA/306111/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2013-ema-decision-14-june-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-phenylephrine-hydrochloride-ketorolac-trometamol-oms3_en.pdf"},
    {"id":"14087","name":"P/0002/2013: EMA decision of 18 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tigecycline (Tygacil), (EMEA-000120-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T18:30:00Z","last_updated_date":"2013-04-03T18:30:00Z","reference_number":"EMA/795743/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2013-ema-decision-18-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-tigecycline-tygacil-emea-000120-pip01-07-m03_en.pdf"},
    {"id":"14094","name":"P/0042/2017: European Medicines Agency decision of 30 January 2017 on the granting of a product specific waiver for (1S, 3S, 4R)-4-[(3aS, 4R, 5S,7aS)-4-(aminomethyl)-7a-methyl-1-methylidene-octahydro-1H-inden-5-yl]-3-(hy...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/2919/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2017-european-medicines-agency-decision-30-january-2017-granting-product-specific-waiver-1s-3s-4r-4-3as-4r-5s7as-4-aminomethyl-7a-methyl-1-methylidene-octahydro-1h-inden-5-yl-3-hy_en.pdf"},
    {"id":"14098","name":"P/62/2008: European medicines agency decision of 14 August 2008\n\non the application for agreement of a Paediatric Investigation Plan for thrombin alfa EMEA-000163-PIP01-07 in accordance with Regulation (EC) No 1901/2006 ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/421270/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-62-2008-european-medicines-agency-decision-14-august-2008-application-agreement-paediatric-investigation-plan-thrombin-alfa-emea-000163-pip01-07-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"14137","name":"P/0016/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin (Jardiance) (EMEA-000828-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/793465/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-jardiance-emea-000828-pip01-09-m03_en.pdf"},
    {"id":"14138","name":"P/0190/2015: EMA decision of 4 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for vortioxetine (Brintellix), (EMEA-000455-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/571186/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2015-ema-decision-4-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-vortioxetine-brintellix-emea-000455-pip02-10-m03_en.pdf"},
    {"id":"14152","name":"P/0025/2013: EMA decision of 26 February 2013 on the acceptance of a modification of an agreed paediatric investigation plan for C1 inhibitor (Cinryze) (EMEA-000568-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T02:00:00Z","last_updated_date":"2013-04-23T02:00:00Z","reference_number":"EMA/89687/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2013-ema-decision-26-february-2013-acceptance-modification-agreed-paediatric-investigation-plan-c1-inhibitor-cinryze-emea-000568-pip01-09-m04_en.pdf"},
    {"id":"14159","name":"P/9/2008: European medicines agency decision of 29 February 2008 on the application for agreement of a Paediatric Investigation Plan for Cozaar and associated names, losartan potassium EMEA-000008-PIP01-07 in accordance ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-03-19T01:00:00Z","last_updated_date":"2008-03-19T01:00:00Z","reference_number":"EMEA/96630/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-9-2008-european-medicines-agency-decision-29-february-2008-application-agreement-paediatric-investigation-plan-cozaar-associated-names-losartan-potassium-emea-000008-pip01-07-accordance_en.pdf"},
    {"id":"14162","name":"P/0207/2014: EMA decision of 8 August 2014 on the agreement of a paediatric investigation plan and on the granting of a waiver for valaciclovir  (hydrochloride) (EMEA-001548-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/433934/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2014-ema-decision-8-august-2014-agreement-paediatric-investigation-plan-granting-waiver-valaciclovir-hydrochloride-emea-001548-pip01-13_en.pdf"},
    {"id":"14204","name":"P/0033/2017: European Medicines Agency decision of 31 January 2017 on the agreement of a paediatric investigation plan and on the granting of a waiver for autologous CD34+ cells transduced with lentiviral vector encoding...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/12300/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2017-european-medicines-agency-decision-31-january-2017-agreement-paediatric-investigation-plan-granting-waiver-autologous-cd34-cells-transduced-lentiviral-vector-encoding_en.pdf"},
    {"id":"14218","name":"P/0181/2017: EMA decision of 30 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for atazanavir / cobicistat (Evotaz), (EMEA-001465-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/370810/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2017-ema-decision-30-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-atazanavir-cobicistat-evotaz-emea-001465-pip01-13-m01_en.pdf"},
    {"id":"14227","name":"P/44/2012: EMA decision of 28 February 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]- ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/131595/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-44-2012-ema-decision-28-february-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-n-3-3-cyclopropyl-5-2-fluoro-4-iodophenylamino_en.pdf"},
    {"id":"14233","name":"P/0227/2016: EMA decision of 26 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide\n\n(Trulicity), (EMEA-000783-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/399460/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2016-ema-decision-26-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-dulaglutide-trulicity-emea-000783-pip01-09-m04_en.pdf"},
    {"id":"14241","name":"P/0154/2017: EMA decision of 2 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat), (EMEA-000402-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/341236/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2017-ema-decision-2-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip02-11-m04_en.pdf"},
    {"id":"14242","name":"P/0023/2013: EMA decision of 25 February 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for eribulin (Halaven), (EMEA-001261-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/51372/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2013-ema-decision-25-february-2013-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-eribulin-halaven-emea-001261-pip01-11_en.pdf"},
    {"id":"14248","name":"P/0344/2014: EMA decision of 22 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (EDURANT) (EMEA-000317-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-20T01:00:00Z","last_updated_date":"2015-02-20T01:00:00Z","reference_number":"EMA/785324/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0344-2014-ema-decision-22-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-edurant-emea-000317-pip01-08-m07_en.pdf"},
    {"id":"14253","name":"P/0031/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tedizolid (phosphate)\n\n(Sivextro), (EMEA-001379-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/848775/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-tedizolid-phosphate-sivextro-emea-001379-pip01-12-m03_en.pdf"},
    {"id":"14275","name":"P/0383/2017: EMA decision of 19 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for carotuximab (EMEA-002138-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-05T15:26:00Z","last_updated_date":"2018-03-05T15:26:00Z","reference_number":"EMA/801177/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0383-2017-ema-decision-19-december-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-carotuximab-emea-002138-pip01-17_en.pdf"},
    {"id":"14300","name":"P/88/2010: European Medicines Agency decision of 1 June 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for beclometasone dipropionate / formoter...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/335695/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-88-2010-european-medicines-agency-decision-1-june-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-beclometasone-dipropionate-formoter_en.pdf"},
    {"id":"14308","name":"P/0223/2014: EMA decision of 5 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for dalbavancin (EMEA-000016-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/464831/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2014-ema-decision-5-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-dalbavancin-emea-000016-pip01-07-m03_en.pdf"},
    {"id":"14315","name":"P/0089/2014: EMA decision of 4 April 2014 on the granting of a product specific waiver for atropine (sulphate) / dimethanesulfonate / avizafone (hydrochloride) (EMEA-001586-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T14:00:00Z","last_updated_date":"2014-05-13T14:00:00Z","reference_number":"EMA/122781/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2014-ema-decision-4-april-2014-granting-product-specific-waiver-atropine-sulphate-dimethanesulfonate-avizafone-hydrochloride-emea-001586-pip01-13_en.pdf"},
    {"id":"14325","name":"P/269/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for insulin detemir (Levemir) (EMEA-000412-PIP01-08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-10T01:00:00Z","last_updated_date":"2011-01-10T01:00:00Z","reference_number":"EMA/735668/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-269-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-insulin-detemir-levemir-emea-000412-pip01-08_en.pdf"},
    {"id":"14341","name":"P/0146/2016: EMA decision of 27 May 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant humanized anti-MMP9 monoclonal antibody IgG4 ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-18T02:00:00Z","last_updated_date":"2016-07-18T02:00:00Z","reference_number":"EMA/337422/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2016-ema-decision-27-may-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-humanized-anti-mmp9-monoclonal-antibody-igg4_en.pdf"},
    {"id":"14358","name":"P/0083/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan for autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/107868/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-autologous-cd34-enriched-cell-fraction-contains-cd34-cells-transduced-lentiviral-vector-encodes_en.pdf"},
    {"id":"14359","name":"P/0305/2017: EMA decision of 30 October 2017 on the granting of a product specific waiver for capmatinib (EMEA-002203-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/654585/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2017-ema-decision-30-october-2017-granting-product-specific-waiver-capmatinib-emea-002203-pip01-17_en.pdf"},
    {"id":"14361","name":"P/0196/2014: EMA decision of 8 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for sildenafil (Revatio), (EMEA-000671-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/390359/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2014-ema-decision-8-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-sildenafil-revatio-emea-000671-pip01-09-m05_en.pdf"},
    {"id":"14382","name":"P/0239/2016: EMA decision of 9 September 2016 on the granting of a product specific waiver for lesinurad / allopurinol, (EMEA-001952-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/580049/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2016-ema-decision-9-september-2016-granting-product-specific-waiver-lesinurad-allopurinol-emea-001952-pip01-16_en.pdf"},
    {"id":"14390","name":"P/0165/2013: EMA decision of 29 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for sildenafil (Revatio), (EMEA-000671-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/393007/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2013-ema-decision-29-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-sildenafil-revatio-emea-000671-pip01-09-m04_en.pdf"},
    {"id":"14403","name":"P/0060/2012: EMA decision of 26 March 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for anti-von Willebrand factor nanobody (ALX-0081) (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"EMA/8483/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2012-ema-decision-26-march-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-von-willebrand-factor-nanobody-alx-0081-emea-0_en.pdf"},
    {"id":"14426","name":"P/0281/2013: EMA decision of 8 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tapen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-12-06T01:00:00Z","last_updated_date":"2013-12-06T01:00:00Z","reference_number":"EMA/670626/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2013-ema-decision-8-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapen_en.pdf"},
    {"id":"14477","name":"P/255/2009: EMA decision of 22 December 2009 on the refusal of a Paediatric Investigation Plan and on the granting of a waiver for Allogeneic ex vivo expanded umbilical cord blood cells (EMA-000554...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMA/811657/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-255-2009-ema-decision-22-december-2009-refusal-paediatric-investigation-plan-granting-waiver-allogeneic-ex-vivo-expanded-umbilical-cord-blood-cells-ema-000554_en.pdf"},
    {"id":"14493","name":"P/0263/2012: EMA decision of of 20 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for methoxy polyethylene glycol-epoetin beta (Mircera), (EMEA-000172-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/646943/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2012-ema-decision-20-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-methoxy-polyethylene-glycol-epoetin-beta-mircera-emea-000172-pip01-07-m01_en.pdf"},
    {"id":"14524","name":"P/93/2008: European medicines agency decision of 22 October 2008\n\non the application for agreement of a Paediatric Investigation Plan for Nalfurafine Hydrochloride, EMEA-000266-PIP01-08 in accordance with Regulation (EC)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-11-24T00:00:00Z","last_updated_date":"2008-11-24T00:00:00Z","reference_number":"EMEA/540588/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-93-2008-european-medicines-agency-decision-22-october-2008-application-agreement-paediatric-investigation-plan-nalfurafine-hydrochloride-emea-000266-pip01-08-accordance-regulation-ec_en.pdf"},
    {"id":"14529","name":"P/0352/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for secukinumab\n\n(Cosentyx) (EMEA-000380-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/724324/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0352-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-secukinumab-cosentyx-emea-000380-pip01-08-m04_en.pdf"},
    {"id":"14537","name":"P/112/2008: European Medicines Agency decision of 1 December 2008 on the application for agreement of a Paediatric Investigation Plan for 3-(1H-indol-3-yl)-4-(2-(4-methyl-1-piperazinyl)-4-quinazolinyl)-1H-pyrrole-2,5-dio...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/624134/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-112-2008-european-medicines-agency-decision-1-december-2008-application-agreement-paediatric-investigation-plan-3-1h-indol-3-yl-4-2-4-methyl-1-piperazinyl-4-quinazolinyl-1h-pyrrole-25-dio_en.pdf"},
    {"id":"14553","name":"P/156/2009: European Medicines Agency decision of 11 August 2009 on the granting of a product specific waiver for Mifepristone / Misoprostol (EMEA-000411-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/492918/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-156-2009-european-medicines-agency-decision-11-august-2009-granting-product-specific-waiver-mifepristone-misoprostol-emea-000411-pip01-08-accordance-regulation-ec-no-1901-2006-e_en.pdf"},
    {"id":"14555","name":"P/247/2010:  EMA decision of 26 November 2010 on the agreement of a PIP and on the granting of a deferral and a waiver for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of equal a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/709901/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-247-2010-ema-decision-26-november-2010-agreement-pip-granting-deferral-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergic-extract-equal_en.pdf"},
    {"id":"14581","name":"P/0152/2012: EMA decision of 25 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for purified antigen fractions of inactivated split virion influenza H5N1 (Prepandrix, Pandemic inf...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/480054/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2012-ema-decision-25-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-purified-antigen-fractions-inactivated-split-virion-influenza-h5n1-prepandrix-pandemic-inf_en.pdf"},
    {"id":"14607","name":"P/0317/2015: EMA decision of 21 December 2015 on the granting of a product-specific waiver for ketoprofen (EMEA-001783-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/807033/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2015-ema-decision-21-december-2015-granting-product-specific-waiver-ketoprofen-emea-001783-pip02-15_en.pdf"},
    {"id":"14618","name":"P/0245/2014: EMA decision of 29 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant soluble fusion protein with a modified ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/527327/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2014-ema-decision-29-september-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-soluble-fusion-protein-modified_en.pdf"},
    {"id":"14659","name":"P/212/2011: EMA decision of 2 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for veliparib (EMEA-000499-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/654593/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-212-2011-ema-decision-2-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-veliparib-emea-000499-pip02-10_en.pdf"},
    {"id":"14662","name":"P/0174/2014: EMA decision of 11 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tafluprost (Taflotan and associated names), (EMEA-001187-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/314400/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2014-ema-decision-11-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-tafluprost-taflotan-associated-names-emea-001187-pip01-11-m01_en.pdf"},
    {"id":"14692","name":"P/0017/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for paclitaxel Abraxane), (EMEA-001308-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/34936/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-paclitaxel-abraxane-emea-001308-pip01-12-m01_en.pdf"},
    {"id":"14702","name":"P/0261/2014: EMA decision of 29 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for solifenacin (succinate) (Vesicare and associated names), (EMEA-000573-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/586420/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2014-ema-decision-29-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-solifenacin-succinate-vesicare-associated-names-emea-000573-pip02-13-m02_en.pdf"},
    {"id":"14704","name":"P/92/2008: European medicines agency decision of 14 October 2008 on the application for agreement of a Paediatric Investigation Plan for peginterferon alfa-2b (ViraferonPeg) (EMEA-000384-PIP01-08) in accordance with Regu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-11-24T00:00:00Z","last_updated_date":"2008-11-24T00:00:00Z","reference_number":"EMEA/527764/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-92-2008-european-medicines-agency-decision-14-october-2008-application-agreement-paediatric-investigation-plan-peginterferon-alfa-2b-viraferonpeg-emea-000384-pip01-08-accordance-regu_en.pdf"},
    {"id":"14708","name":"P/0291/2014: EMA decision of 24 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone furoate / vilanterol (Relvar Ellipta and associated names), (EMEA-000431-PIP01-0...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T01:00:00Z","last_updated_date":"2014-12-05T01:00:00Z","reference_number":"EMA/640503/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2014-ema-decision-24-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-vilanterol-relvar-ellipta-associated-names-emea-000431-pip01-0_en.pdf"},
    {"id":"14714","name":"P/0222/2014: EMA decision of 3 September 2014 on the refusal of a product specific waiver for (R)-2-[3-({Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butanoic acid (EMEA-001573-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/514822/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2014-ema-decision-3-september-2014-refusal-product-specific-waiver-r-2-3-benzoxazol-2-yl3-4-methoxyphenoxypropylaminomethylphenoxybutanoic-acid-emea-001573-pip01-13_en.pdf"},
    {"id":"14716","name":"P/0209/2017: EMA decision of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for influenza virus surface antigens (haemagglutinin and ne...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/458748/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2017-ema-decision-9-august-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-influenza-virus-surface-antigens-haemagglutinin-ne_en.pdf"},
    {"id":"14741","name":"P/55/2009: European Medicines Agency decision of 24 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for tapentadol hydrochloride (EMEA-000485-PIP01-08) in accordance with ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/161790/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-55-2009-european-medicines-agency-decision-24-march-2009-agreement-paediatric-investigation-plan-granting-deferral-tapentadol-hydrochloride-emea-000485-pip01-08-accordance_en.pdf"},
    {"id":"14744","name":"P/0189/2016: EMA decision of of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for caplacizumab (EMEA-\n\n001157-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:13:00Z","last_updated_date":"2016-09-22T16:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-caplacizumab-emea-001157-pip01-11-m01_en.pdf"},
    {"id":"14745","name":"P/0043/2017: European Medicines Agency decision of 31 January 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for varicella-zoster virus (inactiv...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/12299/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2017-european-medicines-agency-decision-31-january-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-varicella-zoster-virus-inactiv_en.pdf"},
    {"id":"14758","name":"P/0338/2017: EMA decision of 10 November 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for crisaborole (EMEA-002065-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/666639/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0338-2017-ema-decision-10-november-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-crisaborole-emea-002065-pip01-16_en.pdf"},
    {"id":"14768","name":"P/0055/2015: EMA decision of 30 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human N-acetylgalactosamine-6-sulfatase (BMN110) Vimizim (elosulfase alfa) (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/195738/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2015-ema-decision-30-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-n-acetylgalactosamine-6-sulfatase-bmn110-vimizim-elosulfase-alfa-emea-0_en.pdf"},
    {"id":"14778","name":"P/252/2009: European Medicines Agency decision of 22 December 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for house dust mites allergen extract (EMEA-000319-PIP01-08-M01) in accord...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:00:00Z","last_updated_date":"2010-01-25T00:00:00Z","reference_number":"EMA/816085/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-252-2009-european-medicines-agency-decision-22-december-2009-acceptance-modification-agreed-paediatric-investigation-plan-house-dust-mites-allergen-extract-emea-000319-pip01-08-m01-accord_en.pdf"},
    {"id":"14784","name":"P/173/2010: European Medicines Agency decision of 17 September 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for romiplostim (Nplate), (EMEA-00...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/558114/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-173-2010-european-medicines-agency-decision-17-september-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-romiplostim-nplate-emea-00_en.pdf"},
    {"id":"14804","name":"P/102/2008: European Medicines Agency decision of 6 November 2008 on the application for product specific waiver for lenalidomide (Revlimid) (EMEA-000371-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-07T01:00:00Z","last_updated_date":"2009-01-07T01:00:00Z","reference_number":"EMEA/575498/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-102-2008-european-medicines-agency-decision-6-november-2008-application-product-specific-waiver-lenalidomide-revlimid-emea-000371-pip01-08-accordance-regulation-ec-no-1901-2006-e_en.pdf"},
    {"id":"14834","name":"P/38/2010: European Medicines Agency decision of 31 March 2010 on the acceptance of a modification of an agreed Paediatric Investigation Plan for ferumoxytol (EMEA-000373-PIP02-09-M01) in accordance with Regulation (EC) ...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/173548/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-38-2010-european-medicines-agency-decision-31-march-2010-acceptance-modification-agreed-paediatric-investigation-plan-ferumoxytol-emea-000373-pip02-09-m01-accordance-regulation-ec_en.pdf"}    {"id":"14852","name":"P/0220/2012: EMA decision of 28 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol\n\n(hydrochloride) (Palexia, Yantil), (EMEA-000495-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T17:00:00Z","last_updated_date":"2012-10-17T17:00:00Z","reference_number":"EMA/598593/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2012-ema-decision-28-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-yantil-emea-000495-pip01-08-m04_en.pdf"},
    {"id":"14854","name":"P/0254/2016: EMA decision of 55 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis),\n\n(EMEA-000183-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/585767/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2016-ema-decision-55-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip01-08-m04_en.pdf"},
    {"id":"14874","name":"P/0327/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for domagrozumab\n\n(EMEA-001763-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-20T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"EMA/666036/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0327-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-domagrozumab-emea-001763-pip01-15-m01_en.pdf"},
    {"id":"14878","name":"P/0127/2014: EMA decision of 22 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (EMEA-000332-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-25T02:00:00Z","last_updated_date":"2014-06-25T02:00:00Z","reference_number":"EMA/289586/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2014-ema-decision-22-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-emea-000332-pip01-08-m08_en.pdf"},
    {"id":"14879","name":"P/0322/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ambrisentan (Volibris), (EMEA-000434-PIP01-08-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T11:23:00Z","last_updated_date":"2017-01-30T11:23:00Z","reference_number":"EMA/757940/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0322-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-ambrisentan-volibris-emea-000434-pip01-08-m04_en.pdf"},
    {"id":"14900","name":"P/21/2011: EMA decision of 25 January 2011 on the acceptance of a modification of an agreed Paediatric Investigation Plan for exenatide (Byetta) (EMEA-000689-PIP01-09-M02) in accordance with Regulation (EC) No 1901/2006 ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-26T00:09:21Z","last_updated_date":"2011-02-25T00:09:21Z","reference_number":"EMA/26216/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-21-2011-ema-decision-25-january-2011-acceptance-modification-agreed-paediatric-investigation-plan-exenatide-byetta-emea-000689-pip01-09-m02-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"14911","name":"P/295/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pollen from betula verrucosa, (EMEA-000846-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/683397/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-295-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-betula-verrucosa-emea-000846-pip01-10_en.pdf"},
    {"id":"14917","name":"P/237/2010:  EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human monoclonal antibody to human Inter...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/703761/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-237-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-monoclonal-antibody-human-inter_en.pdf"},
    {"id":"14931","name":"P/0064/2015: EMA decision of 1 April 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dapagliflozin (Forxiga), (EMEA-000694-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-07T02:00:00Z","last_updated_date":"2015-05-07T02:00:00Z","reference_number":"EMA/153838/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2015-ema-decision-1-april-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dapagliflozin-forxiga-emea-000694-pip02-14_en.pdf"},
    {"id":"14949","name":"P/275/2011: EMA decision of 11 November 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for delamanid\n\n(EMEA-001113-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T12:15:00Z","last_updated_date":"2011-12-21T12:15:00Z","reference_number":"EMA/700668/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-275-2011-ema-decision-11-november-2011-agreement-paediatric-investigation-plan-granting-deferral-delamanid-emea-001113-pip01-10_en.pdf"},
    {"id":"14971","name":"P/0122/2013: EMA decision of 28 May 2013 on the acceptance of a modification of an agreed paediatric investigation plan for concentrate of proteolytic enzymes in bromelain (NexoBrid), (EMEA-000142-PIP02-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-21T13:30:00Z","last_updated_date":"2013-06-21T13:30:00Z","reference_number":"EMA/248970/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2013-ema-decision-28-may-2013-acceptance-modification-agreed-paediatric-investigation-plan-concentrate-proteolytic-enzymes-bromelain-nexobrid-emea-000142-pip02-09-m01_en.pdf"},
    {"id":"14976","name":"P/0346/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for thrombomodulin alfa\n\n(EMEA-001363-PIP01-12-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T11:48:00Z","last_updated_date":"2018-03-02T11:48:00Z","reference_number":"EMA/709640/2017 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0346-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-thrombomodulin-alfa-emea-001363-pip01-12-m01_en.pdf"},
    {"id":"14979","name":"P/0152/2016: EMA decision of 14 June 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for (EMEA-001832-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/347828/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2016-ema-decision-14-june-2016-agreement-paediatric-investigation-plan-granting-deferral-emea-001832-pip01-15_en.pdf"},
    {"id":"14983","name":"P/0277/2013: EMA decision of 24 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for insulin degludec (Tresiba) (EMEA-000456-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/646736/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2013-ema-decision-24-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-insulin-degludec-tresiba-emea-000456-pip01-08-m01_en.pdf"},
    {"id":"14998","name":"P/0072/2013: EMA decision of 26 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for pegylated human recombinant factor VIII (BAX 855) (EMEA-001296-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/506548/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2013-ema-decision-26-march-2013-agreement-paediatric-investigation-plan-granting-deferral-pegylated-human-recombinant-factor-viii-bax-855-emea-001296-pip01-12_en.pdf"},
    {"id":"15061","name":"P/0172/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for clonidine (hydrochloride) (EMEA-001316-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/507523/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-clonidine-hydrochloride-emea-001316-pip01-12-m01_en.pdf"},
    {"id":"15062","name":"P/131/2008: European Medicines Agency decision of 19 December 2008 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for corifollitropin alfa (EMEA-0003...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/679022/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-131-2008-european-medicines-agency-decision-19-december-2008-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-corifollitropin-alfa-emea-0003_en.pdf"},
    {"id":"15063","name":"P/276/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allergen extract of equal parts of lolium perenne, ph...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/754260/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-276-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extract-equal-parts-lolium-perenne-ph_en.pdf"},
    {"id":"15066","name":"P/0065/2012: EMA decision of 28 March 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for nitisinone (Orfadin) (EMEA-000784-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-23T16:00:00Z","last_updated_date":"2012-07-23T16:00:00Z","reference_number":"EMA/202042/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2012-ema-decision-28-march-2012-agreement-paediatric-investigation-plan-granting-deferral-nitisinone-orfadin-emea-000784-pip02-11_en.pdf"},
    {"id":"15073","name":"P/0231/2015: EMA decision of 27 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for chloroprocaine (hydrochloride), (EMEA-000639-PIP02-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/619839/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2015-ema-decision-27-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-chloroprocaine-hydrochloride-emea-000639-pip02-09-m02_en.pdf"},
    {"id":"15085","name":"P/46/2007: European medicines agency decision of 23 June 2008 on the application for agreement of a Paediatric Investigation Plan for Nicotinic acid and laropiprant (EMEA-000252-PIP01-08) in accordance with Regulation (E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/315706/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-46-2007-european-medicines-agency-decision-23-june-2008-application-agreement-paediatric-investigation-plan-nicotinic-acid-laropiprant-emea-000252-pip01-08-accordance-regulation-e_en.pdf"},
    {"id":"15112","name":"P/0032/2015: EMA decision of 16 February 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for emtricitabine / propan-2-yl N-[(S)-({[(2R)-1-(6-amin...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/49377/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2015-ema-decision-16-february-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-emtricitabine-propan-2-yl-n-s-2r-1-6-amin_en.pdf"},
    {"id":"15115","name":"P/8/2008: European medicines agency decision of 1 February 2008 on the application for product specific waiver for Rosiglitazone Maleate EMEA-000074-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the Europea...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-01-15T01:00:00Z","last_updated_date":"2008-01-15T01:00:00Z","reference_number":"EMEA/43606/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-8-2008-european-medicines-agency-decision-1-february-2008-application-product-specific-waiver-rosiglitazone-maleate-emea-000074-pip01-07-accordance-regulation-ec-no-1901-2006-europea_en.pdf"},
    {"id":"15142","name":"P/0343/2014: EMA decision of 22 December 2014 on the refusal of a paediatric investigation plan and on the refusal of a waiver for glycopyrronium bromide (EMEA-001591-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/624773/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0343-2014-ema-decision-22-december-2014-refusal-paediatric-investigation-plan-refusal-waiver-glycopyrronium-bromide-emea-001591-pip01-14_en.pdf"},
    {"id":"15147","name":"P/0225/2015: EMA decision of 2 October 2015 on the granting of a product-specific waiver for alpha connexin C-terminal 1 peptide (ACT1) (EMEA-001790-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-19T01:00:00Z","last_updated_date":"2015-11-19T01:00:00Z","reference_number":"EMA/603243/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2015-ema-decision-2-october-2015-granting-product-specific-waiver-alpha-connexin-c-terminal-1-peptide-act1-emea-001790-pip01-15_en.pdf"},
    {"id":"15155","name":"P/0140/2013: EMA decision of 3 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for zoledronic acid\n\n(Aclasta), (EMEA-000057-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-08T18:00:00Z","last_updated_date":"2013-08-08T18:00:00Z","reference_number":"EMA/331252/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2013-ema-decision-3-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-zoledronic-acid-aclasta-emea-000057-pip01-07-m05_en.pdf"},
    {"id":"15165","name":"P/0076/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for cariprazine (hydrochloride) (EMEA-001652-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/138341/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-cariprazine-hydrochloride-emea-001652-pip01-14-m01_en.pdf"},
    {"id":"15180","name":"P/61/2009: European Medicines Agency decision of 27 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for sitagliptin phosphate monohydrate (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/174941/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-61-2009-european-medicines-agency-decision-27-march-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sitagliptin-phosphate-monohydrate_en.pdf"},
    {"id":"15183","name":"P/0022/2013: EMA decision of 25 February 2013 on the granting of a product specific waiver for strontium (succinate) (Protelos, Osseor), (EMEA-000733-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/51547/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2013-ema-decision-25-february-2013-granting-product-specific-waiver-strontium-succinate-protelos-osseor-emea-000733-pip02-12_en.pdf"},
    {"id":"15184","name":"P/0262/2014: EMA decision of 3 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for eltrombopag (olamine) (Revolade), (EMEA-000170-PIP03-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/508736/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2014-ema-decision-3-october-2014-agreement-paediatric-investigation-plan-granting-deferral-eltrombopag-olamine-revolade-emea-000170-pip03-13_en.pdf"},
    {"id":"15195","name":"P/0086/2012: EMA decision of 25 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ferumoxytol (EMEA-000373-PIP02-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/339708/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2012-ema-decision-25-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-ferumoxytol-emea-000373-pip02-09-m02_en.pdf"},
    {"id":"15208","name":"P/0306/2014: EMA decision of 24 November 2014 on the granting of a product specific waiver for purified adenylate cyclase recombinant protein carrying subfragments of the early protein E7 antigen from human papillomaviru...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/643705/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2014-ema-decision-24-november-2014-granting-product-specific-waiver-purified-adenylate-cyclase-recombinant-protein-carrying-subfragments-early-protein-e7-antigen-human-papillomaviru_en.pdf"},
    {"id":"15245","name":"P/0048/2015: EMA decision of 6 March 2015 on the granting of a product-specific waiver for hydromorphone (hydrochloride) / naloxone (hydrochloride) (EMEA-001699-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-24T01:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/49371/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2015-ema-decision-6-march-2015-granting-product-specific-waiver-hydromorphone-hydrochloride-naloxone-hydrochloride-emea-001699-pip01-14_en.pdf"},
    {"id":"15249","name":"P/80/2008: EMA decision of of 19 September 2008 on the application for product specific waiver for naproxen, esomeprazole magnesium trihydrate, EMEA-000268-PIP01-08","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-10-10T02:00:00Z","last_updated_date":"2008-10-10T02:00:00Z","reference_number":"EMEA/480433/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-80-2008-ema-decision-19-september-2008-application-product-specific-waiver-naproxen-esomeprazole-magnesium-trihydrate-emea-000268-pip01-08_en.pdf"},
    {"id":"15250","name":"P/0090/2012: EMA decision of 29 May 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for ixekizumab (EMEA-001050-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T18:00:00Z","last_updated_date":"2012-06-25T18:00:00Z","reference_number":"EMA/331564/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2012-ema-decision-29-may-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ixekizumab-emea-001050-pip01-10_en.pdf"},
    {"id":"15256","name":"P/0030/2012: EMA decision of 2 February 2012 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine\n\n(hydrochloride) (000317-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T14:30:00Z","last_updated_date":"2012-03-15T14:30:00Z","reference_number":"EMA/54350/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2012-ema-decision-2-february-2012-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-000317-pip01-08-m03_en.pdf"},
    {"id":"15257","name":"P/0226/2013: EMA decision of 23 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for nonacog beta pegol, (EMEA-000731-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-21T01:00:00Z","last_updated_date":"2013-11-21T01:00:00Z","reference_number":"EMA/562274/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2013-ema-decision-23-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-nonacog-beta-pegol-emea-000731-pip01-09-m01_en.pdf"},
    {"id":"15259","name":"P/230/2009: European Medicines Agency Decision of 13 November 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for nomegestrol acetate, 17beta – e...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:09:00Z","last_updated_date":"2009-12-23T00:09:00Z","reference_number":"EMEA/711448/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-230-2009-european-medicines-agency-decision-13-november-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-nomegestrol-acetate-17beta-e_en.pdf"},
    {"id":"15261","name":"P/38/2012: EMA decision of 24 February 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for modified Vaccinia Ankara - Bavarian Nordic virus (smallpox), (EMEA-001161-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/107989/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-38-2012-ema-decision-24-february-2012-agreement-paediatric-investigation-plan-granting-deferral-modified-vaccinia-ankara-bavarian-nordic-virus-smallpox-emea-001161-pip02-11_en.pdf"},
    {"id":"15270","name":"P/205/2010: European Medicines Agency decision of 27 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dermatophagoides pteronyssinus a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/643466/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-205-2010-european-medicines-agency-decision-27-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dermatophagoides-pteronyssinus_en.pdf"},
    {"id":"15301","name":"P/0140/2012: EMA decision of 20 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for potassium (chloride) / magnesium (sulphate heptahydrate) / procaine (hydrochloride) / xy...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T17:15:00Z","last_updated_date":"2012-08-22T17:15:00Z","reference_number":"EMA/458510/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2012-ema-decision-20-july-2012-agreement-paediatric-investigation-plan-granting-deferral-potassium-chloride-magnesium-sulphate-heptahydrate-procaine-hydrochloride-xy_en.pdf"},
    {"id":"15327","name":"P/0189/2014: EMA decision of 6 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant single chain coagulation factor VIII (EMEA-001215-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/447572/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2014-ema-decision-6-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-single-chain-coagulation-factor-viii-emea-001215-pip01-11-m01_en.pdf"},
    {"id":"15344","name":"P/0293/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for enasidenib (EMEA-001798-PIP02-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T10:22:00Z","last_updated_date":"2018-02-13T10:22:00Z","reference_number":"EMA/565652/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-enasidenib-emea-001798-pip02-16_en.pdf"},
    {"id":"15346","name":"P/0217/2014: EMA decision of 3 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for apremilast (EMEA-000715-PIP05-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/468813/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2014-ema-decision-3-september-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-apremilast-emea-000715-pip05-13_en.pdf"},
    {"id":"15352","name":"P/0113/2014: EMA decision of 5 May 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for Live, attenuated, chimeric dengue virus, serotype 1 / Live,...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/169096/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2014-ema-decision-5-may-2014-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-live-attenuated-chimeric-dengue-virus-serotype-1-live_en.pdf"},
    {"id":"15383","name":"P/0242/2012: EMA decision of 22 October 2012 on the granting of a product specific waiver for fostamatinib (EMEA-001196-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/624726/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2012-ema-decision-22-october-2012-granting-product-specific-waiver-fostamatinib-emea-001196-pip01-11_en.pdf"},
    {"id":"15402","name":"P/0107/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for (3aR,4S,7aR)-octahydro-4-hydroxy-4-[(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid methy...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/203225/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2013-ema-decision-30-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-3ar4s7ar-octahydro-4-hydroxy-4-3-methylphenylethynyl-1h-indole-1-carboxylic-acid-methy_en.pdf"},
    {"id":"15418","name":"P/0333/2017: EMA decision of 31 October 2017 on the granting of a product specific waiver for pilocarpine (hydrochloride) / oxymetazoline\n\n(hydrochloride) (EMEA-002181-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/661912/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0333-2017-ema-decision-31-october-2017-granting-product-specific-waiver-pilocarpine-hydrochloride-oxymetazoline-hydrochloride-emea-002181-pip01-17_en.pdf"},
    {"id":"15422","name":"P/0185/2015: EMA decision of 24 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (EMEA-001582-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/551845/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2015-ema-decision-24-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-lumacaftor-ivacaftor-emea-001582-pip01-13-m03_en.pdf"},
    {"id":"15451","name":"P/0144/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for rubidium (82Rb) chloride (Ruby-Fill (82Sr/82Rb Generator)), (EMEA-000882-PIP03-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/293459/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-rubidium-82rb-chloride-ruby-fill-82sr-82rb-generator-emea-000882-pip03-11-m03_en.pdf"},
    {"id":"15457","name":"P/0056/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dermatophagoides\n\npteronyssinus / dermatophagoides farinae allergen extract (acarizax and asso...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/83696/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-dermatophagoides-pteronyssinus-dermatophagoides-farinae-allergen-extract-acarizax-asso_en.pdf"},
    {"id":"15480","name":"P/0020/2018: EMA decision of 30 January 2018 on the refusal of a modification of an agreed paediatric investigation plan for gadolinium, [α3,α6,α9-\n\ntris[3-[(2,3-dihydroxypropyl)amino]-3-oxopropyl]-3,6,9,15-tetraazabi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"EMA/28287/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2018-ema-decision-30-january-2018-refusal-modification-agreed-paediatric-investigation-plan-gadolinium-i-3i-6i-9-tris3-23-dihydroxypropylamino-3-oxopropyl-36915-tetraazabi_en.pdf"},
    {"id":"15481","name":"P/0082/2013: EMA decision of 27 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 1-(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2,5-dihydro-2-fur...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/192018/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2013-ema-decision-27-march-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-1-2r5r-5-ethynyl-5-hydroxymethyl-25-dihydro-2-fur_en.pdf"},
    {"id":"15493","name":"P/0076/2012: EMA decision of 25 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (EMEA-\n\n000916-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/247588/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2012-ema-decision-25-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-lixisenatide-emea-000916-pip01-10-m02_en.pdf"},
    {"id":"15516","name":"P/0276/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for pollen from Alnus glutinosa, Betula verrucosa and Corylus avellana (EMEA-000849-PIP01-10-M0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/766592/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-pollen-alnus-glutinosa-betula-verrucosa-corylus-avellana-emea-000849-pip01-10-m0_en.pdf"},
    {"id":"15528","name":"P/0204/2015: EMA decision of 4 September 2015 on the granting of a product-specific waiver for enclomifene (citrate) (EMEA-001779-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/505398/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2015-ema-decision-4-september-2015-granting-product-specific-waiver-enclomifene-citrate-emea-001779-pip01-15_en.pdf"},
    {"id":"15531","name":"P/0016/2013: EMA decision of 25 January 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for dobutamine (hydrochloride) (EMEA-001262-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T14:30:00Z","last_updated_date":"2013-04-03T14:30:00Z","reference_number":"EMA/22299/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2013-ema-decision-25-january-2013-agreement-paediatric-investigation-plan-granting-waiver-dobutamine-hydrochloride-emea-001262-pip01-12_en.pdf"},
    {"id":"15545","name":"P/0105/2017: EMA decision of 11 April 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for macimorelin (EMEA-001988-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/166791/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2017-ema-decision-11-april-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-macimorelin-emea-001988-pip01-16_en.pdf"},
    {"id":"15556","name":"P/112/2012: EMA decision of 22 June 2012 on the acceptance of a modification of an agreed paediatric investigation plan for voriconazole (Vfend), (EMEA-000191-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-23T17:00:00Z","last_updated_date":"2012-07-23T17:00:00Z","reference_number":"EMA/409344/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-112-2012-ema-decision-22-june-2012-acceptance-modification-agreed-paediatric-investigation-plan-voriconazole-vfend-emea-000191-pip01-08-m04_en.pdf"},
    {"id":"15578","name":"P/201/2010: European Medicines Agency decision of 27 October 2010 on the acceptance of a modification of an agreed paediatric investigation plan for anidulafungin (Ecalta), (EMEA-000469-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-24T01:00:00Z","last_updated_date":"2010-11-24T01:00:00Z","reference_number":"EMA/647157/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-201-2010-european-medicines-agency-decision-27-october-2010-acceptance-modification-agreed-paediatric-investigation-plan-anidulafungin-ecalta-emea-000469-pip01-08-m01_en.pdf"},
    {"id":"15606","name":"P/208/2009: European Medicines Agency decision of 30 October 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for skimmed cow's milk powder (EMEA-000201-PIP01-08-M01) in accordance with...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/615805/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-208-2009-european-medicines-agency-decision-30-october-2009-acceptance-modification-agreed-paediatric-investigation-plan-skimmed-cows-milk-powder-emea-000201-pip01-08-m01-accordance_en.pdf"},
    {"id":"15636","name":"P/0157/2015: EMA decision of 10 July 2015 on the agreement of a paediatric investigation plan and on the granting of a waiver for momelotinib (EMEA-001656-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-25T02:00:00Z","last_updated_date":"2015-08-25T02:00:00Z","reference_number":"EMA/424132/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2015-ema-decision-10-july-2015-agreement-paediatric-investigation-plan-granting-waiver-momelotinib-emea-001656-pip01-14_en.pdf"},
    {"id":"15643","name":"P/300/2011: EMA decision of 20 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for belimumab\n\n(Benlysta), (EMEA-000520-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/925807/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-300-2011-ema-decision-20-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-belimumab-benlysta-emea-000520-pip01-08-m01_en.pdf"},
    {"id":"15656","name":"P/0115/2018: EMA decision of 11 April 2018 on the granting of a product specific waiver for calcium, N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-2-\n\nmethyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycine] manganese complex...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T02:00:00Z","last_updated_date":"2018-07-25T02:00:00Z","reference_number":"EMA/194478/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2018-ema-decision-11-april-2018-granting-product-specific-waiver-calcium-nn-12-ethanediylbisn-3-hydroxy-2-methyl-5-phosphonooxymethyl-4-pyridinylmethylglycine-manganese-complex_en.pdf"},
    {"id":"15665","name":"P/02/2009: European Medicines Agency decision of 27 January 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for recombinant L-asparaginase (EMEA-000013-PIP01-07-M01) in accordance with...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/29650/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-02-2009-european-medicines-agency-decision-27-january-2009-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-l-asparaginase-emea-000013-pip01-07-m01-accordance_en.pdf"},
    {"id":"15682","name":"P/0066/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dasabuvir (sodium\n\nmonohydrate) (Exviera), (EMEA-001439-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/90973/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-dasabuvir-sodium-monohydrate-exviera-emea-001439-pip01-13-m01_en.pdf"},
    {"id":"15689","name":"P/99/2011: EMA decision of 14 April 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aripiprazole (Abilify) (EMEA-000235-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-13T02:00:00Z","last_updated_date":"2011-05-13T02:00:00Z","reference_number":"EMA/247887/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-99-2011-ema-decision-14-april-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aripiprazole-abilify-emea-000235-pip02-10_en.pdf"},
    {"id":"15699","name":"P/0082/2012: EMA decision of 3 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for purified tetanus toxoid / inactivated type 1 poliovirus (Mahoney) / inactivated type 2 poliovirus...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/272836/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2012-ema-decision-3-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-purified-tetanus-toxoid-inactivated-type-1-poliovirus-mahoney-inactivated-type-2-poliovirus_en.pdf"},
    {"id":"15700","name":"P/0194/2015: EMA decision of 4 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for retosiban (EMEA-001359-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/505298/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2015-ema-decision-4-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-retosiban-emea-001359-pip01-12-m02_en.pdf"},
    {"id":"15702","name":"P/108/2009: European Medicines Agency decision of 9 June 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for carisbamate (EMEA-000360-PIP01-08) i...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/348643/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-108-2009-european-medicines-agency-decision-9-june-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-carisbamate-emea-000360-pip01-08-i_en.pdf"},
    {"id":"15710","name":"P/35/2011: EMA decision of 28 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ozenoxacin (EMA-000981-PIP01-10) in accordance with Reg...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/35658/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-35-2011-ema-decision-28-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ozenoxacin-ema-000981-pip01-10-accordance-reg_en.pdf"},
    {"id":"15731","name":"P/0212/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for budesonide (EMEA-\n\n001087-PIP02-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/441052/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-budesonide-emea-001087-pip02-12-m02_en.pdf"},
    {"id":"15749","name":"P/0163/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for etravirine (Intelence), (EMEA-000222-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/473688/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-etravirine-intelence-emea-000222-pip01-08-m08_en.pdf"},
    {"id":"15753","name":"P/0284/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (Translarna), (EMEA-000115-PIP02-09-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T12:37:00Z","last_updated_date":"2017-01-23T12:37:00Z","reference_number":"EMA/704430/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-translarna-emea-000115-pip02-09-m03_en.pdf"},
    {"id":"15760","name":"P/0139/2013: EMA decision of 24 June 2013 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (EMEA-000715-PIP03-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T12:00:00Z","last_updated_date":"2013-07-23T12:00:00Z","reference_number":"EMA/332686/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2013-ema-decision-24-june-2013-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-emea-000715-pip03-11-m01_en.pdf"},
    {"id":"15781","name":"P/0020/2012: EMA decision of 27 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (Brilique, Possia) (EMEA-000480-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/44693/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2012-ema-decision-27-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-ticagrelor-brilique-possia-emea-000480-pip01-08-m03_en.pdf"},
    {"id":"15818","name":"P/0289/2014: EMA decision of 24 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for human fibrinogen / human thrombin (EMEA-001598-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-04T01:00:00Z","last_updated_date":"2014-12-04T01:00:00Z","reference_number":"EMA/637703/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2014-ema-decision-24-october-2014-agreement-paediatric-investigation-plan-granting-deferral-human-fibrinogen-human-thrombin-emea-001598-pip01-13_en.pdf"},
    {"id":"15841","name":"P/0222/2017: EMA decision of 9 August 2017 on the granting of a product-specific waiver for osimertinib (as mesylate) (Tagrisso), (EMEA-002125-\n\nPIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/431229/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2017-ema-decision-9-august-2017-granting-product-specific-waiver-osimertinib-mesylate-tagrisso-emea-002125-pip01-17_en.pdf"},
    {"id":"15847","name":"P/0132/2017: EMA decision of 7 June 2017 on the granting of a product specific waiver for nimodipine (EMEA-002097-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/306123/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2017-ema-decision-7-june-2017-granting-product-specific-waiver-nimodipine-emea-002097-pip01-16_en.pdf"},
    {"id":"15864","name":"P/0031/2014: European Medicines Agency decision of 21 February 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for azacitidine (Vidaza) (EMEA-001...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-03-20T01:00:00Z","last_updated_date":"2014-03-20T01:00:00Z","reference_number":"EMA/50728/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2014-european-medicines-agency-decision-21-february-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-azacitidine-vidaza-emea-001_en.pdf"},
    {"id":"15876","name":"P/0120/2016: EMA decision of 28 April 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for solithromycin (EMEA-001581-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/266752/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2016-ema-decision-28-april-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-solithromycin-emea-001581-pip02-16_en.pdf"},
    {"id":"15880","name":"P/0172/2012: EMA decision of 27 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for human normal\n\nimmunoglobulin (EMEA-000872-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/489362/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2012-ema-decision-27-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000872-pip01-10-m01_en.pdf"},
    {"id":"15882","name":"P/0306/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for delamanid (Deltyba) (EMEA-001113-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/792872/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-delamanid-deltyba-emea-001113-pip01-10-m04_en.pdf"},
    {"id":"15893","name":"P/215/2009: European Medicines Agency decision of 30 October 2009 on the refusal of a Paediatric Investigation Plan and on the refusal of a deferral and on the granting of a waiver for ulipristal acetate (EMEA-000629-PIP...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/687582/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-215-2009-european-medicines-agency-decision-30-october-2009-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-ulipristal-acetate-emea-000629-pip_en.pdf"},
    {"id":"15926","name":"P/0120/2014: EMA decision of 7 May 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pradigastat (EMEA-001333-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-05T02:00:00Z","last_updated_date":"2014-06-05T02:00:00Z","reference_number":"EMA/195548/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2014-ema-decision-7-may-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pradigastat-emea-001333-pip02-13_en.pdf"},
    {"id":"15935","name":"P/0350/2016: EMA decision of 2 December 2016on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the refusal of a\n\nwaiver for antithrombin alfa (Recombinant human antithrombin), (EMEA...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/742001/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0350-2016-ema-decision-2-december-2016on-refusal-paediatric-investigation-plan-refusal-deferral-refusal-waiver-antithrombin-alfa-recombinant-human-antithrombin-emea_en.pdf"},
    {"id":"15939","name":"P/91/2011: EMA decision of 8 April 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for propane-1-\n\nsulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/193393/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-91-2011-ema-decision-8-april-2011-agreement-paediatric-investigation-plan-granting-deferral-propane-1-sulfonic-acid-3-5-4-chlorophenyl-1h-pyrrolo23-bpyridine-3-carbonyl-24_en.pdf"},
    {"id":"15941","name":"P/0118/2017: EMA decision of 5 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for 3-[[5-chloro-1-[3-\n\n(methylsulfonyl)propyl]-1H-indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)-1,3-di...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/244252/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2017-ema-decision-5-may-2017-acceptance-modification-agreed-paediatric-investigation-plan-3-5-chloro-1-3-methylsulfonylpropyl-1h-indol-2-ylmethyl-1-222-trifluoroethyl-13-di_en.pdf"},
    {"id":"15966","name":"P/0355/2016: EMA decision of 21 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ceftaroline fosamil (Zinforo), (EMEA-000769-PIP01-09-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T12:18:00Z","last_updated_date":"2017-02-03T12:18:00Z","reference_number":"EMA/826956/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0355-2016-ema-decision-21-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-ceftaroline-fosamil-zinforo-emea-000769-pip01-09-m06_en.pdf"},
    {"id":"15967","name":"P/0272/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for pollen from Dactylis glomerata, Lolium perenne, Phleum pratense, Festuca pratensis, Secale ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/690865/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-pollen-dactylis-glomerata-lolium-perenne-phleum-pratense-festuca-pratensis-secale_en.pdf"},
    {"id":"15972","name":"P/110/2009: EMEA decision of 16 June 2009 on the agreement of a PIP and on the granting of a waiver for Human Papillomavirus type 6 L1 protein / Human Papillomavirus type 11 L1 protein / Human Papillomavirus type 16 L1 p...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-06-17T02:09:21Z","last_updated_date":"2009-06-17T02:09:21Z","reference_number":"EMEA/351400/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-110-2009-emea-decision-16-june-2009-agreement-pip-granting-waiver-human-papillomavirus-type-6-l1-protein-human-papillomavirus-type-11-l1-protein-human-papillomavirus-type-16-l1-p_en.pdf"},
    {"id":"15979","name":"P/308/2011: EMA decision of 20 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for chimeric monoclonal anti-Shiga toxin (Stx) antibodies ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/954001/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-308-2011-ema-decision-20-december-2011-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-chimeric-monoclonal-anti-shiga-toxin-stx-antibodies_en.pdf"},
    {"id":"15980","name":"P/0152/2013: EMA decision of 5 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation factor VIII / von Willebrand factor (EMEA-000312-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-08T18:00:00Z","last_updated_date":"2013-08-08T18:00:00Z","reference_number":"EMA/339828/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2013-ema-decision-5-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-human-coagulation-factor-viii-von-willebrand-factor-emea-000312-pip01-08-m05_en.pdf"},
    {"id":"16005","name":"P/0263/2015: EMA decision of 30 October 2015 on the refusal of a modification of an agreed paediatric investigation plan for rufinamide (Inovelon) (EMEA-000709-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/702366/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2015-ema-decision-30-october-2015-refusal-modification-agreed-paediatric-investigation-plan-rufinamide-inovelon-emea-000709-pip01-09-m03_en.pdf"},
    {"id":"16013","name":"P/0077/2013: EMA decision of 26 March 2013 on the granting of a product-specific waiver for bisoprolol / amlodipine (EMEA-001385-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/85726/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2013-ema-decision-26-march-2013-granting-product-specific-waiver-bisoprolol-amlodipine-emea-001385-pip01-12_en.pdf"},
    {"id":"16024","name":"P/0049/2012: EMA decision of 1 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone furoate / triphenylacetic acid - 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}h...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-10T02:00:00Z","last_updated_date":"2012-04-10T02:00:00Z","reference_number":"EMA/354564/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2012-ema-decision-1-march-2012-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-triphenylacetic-acid-4-1r-2-6-2-26-dichlorobenzyloxyethoxyh_en.pdf"},
    {"id":"16028","name":"P/0193/2016: EMA decision of of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for 1-(2,2-difluoro-1,3-\n\nbenzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydrox...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:19:00Z","last_updated_date":"2016-09-22T16:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-1-22-difluoro-13-benzodioxol-5-yl-n-1-2r-23-dihydroxypropyl-6-fluoro-2-1-hydrox_en.pdf"},
    {"id":"16037","name":"P/0336/2017: EMA decision of 30 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat)\n\n(EMEA-000402-PIP03-17-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-14T16:17:00Z","last_updated_date":"2018-02-14T16:17:00Z","reference_number":"EMA/706354/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2017-ema-decision-30-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip03-17-m01_en.pdf"},
    {"id":"16056","name":"P/0118/2013: EMA decision of 2 May 2013 on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel), (EMEA-000567-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-21T13:10:00Z","last_updated_date":"2013-06-21T13:10:00Z","reference_number":"EMA/242689/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2013-ema-decision-2-may-2013-acceptance-modification-agreed-paediatric-investigation-plan-dasatinib-sprycel-emea-000567-pip01-09-m04_en.pdf"},
    {"id":"16063","name":"P/254/2010:  EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aluminium hydroxide adsorbed, depigmented glutaralde...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/710352/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-254-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaralde_en.pdf"}    {"id":"16075","name":"P/151/2011: EMA decision of 10 June 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (EMEA-000117-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-13T02:00:00Z","last_updated_date":"2011-07-13T02:00:00Z","reference_number":"EMA/440862/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-151-2011-ema-decision-10-june-2011-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-emea-000117-pip01-07-m02_en.pdf"},
    {"id":"16085","name":"P/0005/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocou...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/864531/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-clostridium-botulinum-neurotoxin-type-150-kd-free-complexing-proteins-xeomin-bocou_en.pdf"},
    {"id":"16089","name":"P/0297/2013: EMA decision of 29 November 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for alirocumab (EMEA-001169-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/647587/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2013-ema-decision-29-november-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-alirocumab-emea-001169-pip01-11_en.pdf"},
    {"id":"16092","name":"P/6/2011:  EMA decision of 3 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for midostaurin, (EMEA-000780-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/716713/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-6-2011-ema-decision-3-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-midostaurin-emea-000780-pip01-09_en.pdf"},
    {"id":"16131","name":"P/0054/2018: EMA decision of 2 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pevonedistat (EMEA-002117-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/91894/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2018-ema-decision-2-march-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pevonedistat-emea-002117-pip01-17_en.pdf"},
    {"id":"16155","name":"P/0131/2012: EMA decision of 4 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ponatinib (EMEA-001186-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-09T14:00:00Z","last_updated_date":"2012-08-09T14:00:00Z","reference_number":"EMA/429450/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2012-ema-decision-4-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ponatinib-emea-001186-pip01-11_en.pdf"},
    {"id":"16177","name":"P/0123/2016: EMA decision of 12 May 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for darunavir / cobicistat / emtricitabine / tenofovir alafen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-18T02:00:00Z","last_updated_date":"2016-07-18T02:00:00Z","reference_number":"EMA/287464/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2016-ema-decision-12-may-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-darunavir-cobicistat-emtricitabine-tenofovir-alafen_en.pdf-0"},
    {"id":"16181","name":"P/0369/2016: EMA decision of 21 December 2016 on the granting of a product specific waiver for botulinum toxin, Type A (EMEA-002038-PIP01-16","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/791416/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0369-2016-ema-decision-21-december-2016-granting-product-specific-waiver-botulinum-toxin-type-emea-002038-pip01-16_en.pdf"},
    {"id":"16199","name":"P/0335/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for fentanyl\n\n(hydrochloride) (IONSYS), (EMEA-001509-PIP01-13-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T13:11:00Z","last_updated_date":"2017-02-03T13:11:00Z","reference_number":"EMA/765281/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0335-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-fentanyl-hydrochloride-ionsys-emea-001509-pip01-13-m01_en.pdf"},
    {"id":"16207","name":"P/0095/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for pitavastatin (calcium) (Livazo and associated names) (EMEA-000054-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/195514/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-pitavastatin-calcium-livazo-associated-names-emea-000054-pip01-07-m04_en.pdf"},
    {"id":"16214","name":"P/111/2012: EMA decision of 29 June 2012 on the acceptance of a modification of an agreed paediatric investigation plan for asenapine (maleate) (Sycrest) (EMEA-000228-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-23T17:00:00Z","last_updated_date":"2012-07-23T17:00:00Z","reference_number":"EMA/332277/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-111-2012-ema-decision-29-june-2012-acceptance-modification-agreed-paediatric-investigation-plan-asenapine-maleate-sycrest-emea-000228-pip01-08-m03_en.pdf"},
    {"id":"16216","name":"P/0121/2013: EMA decision of 3 May 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adalimumab (Humira), (EMEA-000366-PIP04-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-21T14:10:00Z","last_updated_date":"2013-06-21T14:10:00Z","reference_number":"EMA/242511/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2013-ema-decision-3-may-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-adalimumab-humira-emea-000366-pip04-12_en.pdf"},
    {"id":"16217","name":"P/0048/2017: EMA decision of 23 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam\n\n(Briviact), (EMEA-000332-PIP01-08-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-18T02:00:00Z","last_updated_date":"2017-04-18T02:00:00Z","reference_number":"EMA/105851/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2017-ema-decision-23-february-2017-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-emea-000332-pip01-08-m11_en.pdf"},
    {"id":"16219","name":"P/0209/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for pneumococcal\n\npolysaccharide serotype 6B conjugated to protein D ... (EMEA-000673-PIP01-09-M0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/520305/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-pneumococcal-polysaccharide-serotype-6b-conjugated-protein-d-emea-000673-pip01-09-m0_en.pdf"},
    {"id":"16223","name":"P/224/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for eculizumab (Soliris), (EMEA-0008...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/629630/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-224-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eculizumab-soliris-emea-0008_en.pdf"},
    {"id":"16228","name":"P/0153/2013: EMA decision of 5 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for cysteamine hydrochloride (EMEA-000322-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-08T18:00:00Z","last_updated_date":"2013-08-08T18:00:00Z","reference_number":"EMA/339827/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2013-ema-decision-5-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-cysteamine-hydrochloride-emea-000322-pip01-08-m02_en.pdf"},
    {"id":"16269","name":"P/44/2009: European Medicines Agency decision of 23 March 2009 on the refusal of a product specific waiver for dexamethasone (EMEA-000198-PIP02-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliame...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/155675/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-44-2009-european-medicines-agency-decision-23-march-2009-refusal-product-specific-waiver-dexamethasone-emea-000198-pip02-08-accordance-regulation-ec-no-1901-2006-european-parliame_en.pdf"},
    {"id":"16307","name":"P/0089/2017: EMA decision of 6 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for melatonin (Circadin), (EMEA-000440-PIP02-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/208387/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2017-ema-decision-6-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-melatonin-circadin-emea-000440-pip02-11-m05_en.pdf"},
    {"id":"16323","name":"P/0005/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bevacizumab (Avastin), (EMEA-000056-PIP03-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-19T01:00:00Z","last_updated_date":"2014-02-19T01:00:00Z","reference_number":"EMA/738885/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-bevacizumab-avastin-emea-000056-pip03-10-m02_en.pdf"},
    {"id":"16345","name":"P/0140/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for enalapril (maleate) (EMEA-001706-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/312701/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-enalapril-maleate-emea-001706-pip01-14-m01_en.pdf"},
    {"id":"16359","name":"P/0277/2014: EMA decision of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for rufinamide (Inovelon), (EMEA-000709-PIP01-09-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T01:00:00Z","last_updated_date":"2014-12-05T01:00:00Z","reference_number":"EMA/605297/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2014-ema-decision-28-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-rufinamide-inovelon-emea-000709-pip01-09-m02_en.pdf"},
    {"id":"16368","name":"P/37/2008: European medicines agency decision of 24 June 2008\n\non the application for agreement of a Paediatric Investigation Plan for pitavastatin calcium EMEA-000301-PIP01-08 in accordance with Regulation (EC) No 1901/...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-06-24T03:00:00Z","last_updated_date":"2008-06-24T03:00:00Z","reference_number":"EMEA/315967/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-37-2008-european-medicines-agency-decision-24-june-2008-application-agreement-paediatric-investigation-plan-pitavastatin-calcium-emea-000301-pip01-08-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"16371","name":"P/0075/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for naloxone (hydrochloride) (EMEA-001567-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/131048/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-naloxone-hydrochloride-emea-001567-pip01-13-m02_en.pdf"},
    {"id":"16375","name":"P/120/2008: European Medicines Agency decision of 1 December 2008 on the application for product specific waiver for omega-3-acid (85% ethyl esters of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a ratio...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/624450/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-120-2008-european-medicines-agency-decision-1-december-2008-application-product-specific-waiver-omega-3-acid-85-ethyl-esters-eicosapentaenoic-acid-epa-docosahexaenoic-acid-dha-ratio_en.pdf"},
    {"id":"16387","name":"P/0131/2015: EMA decision of 12 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira), (EMEA-000366-PIP02-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-07T02:00:00Z","last_updated_date":"2015-07-07T02:00:00Z","reference_number":"EMA/368695/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2015-ema-decision-12-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip02-09-m04_en.pdf"},
    {"id":"16390","name":"P/12/2009: European Medicines Agency decision of 27 January 2009 on the granting of a product specific waiver for ibuprofen, paracetamol, (EMEA-000313-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the Euro...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/29899/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-12-2009-european-medicines-agency-decision-27-january-2009-granting-product-specific-waiver-ibuprofen-paracetamol-emea-000313-pip01-08-accordance-regulation-ec-no-1901-2006-euro_en.pdf"},
    {"id":"16399","name":"P/150/2010: EMA decision of 6 August 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for tenofovir disoproxil fumarate/emtricitabine/rilpivirine h...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/488816/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-150-2010-ema-decision-6-august-2010-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-tenofovir-disoproxil-fumarate-emtricitabine-rilpivirine-h_en.pdf"},
    {"id":"16401","name":"P/0079/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan for arimoclomol (citrate) (EMEA-001748-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/104860/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-arimoclomol-citrate-emea-001748-pip01-15_en.pdf"},
    {"id":"16402","name":"P/0129/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab (Tremfya), (EMEA-001523-PIP02-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T02:00:00Z","last_updated_date":"2018-07-25T02:00:00Z","reference_number":"EMA/201260/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-guselkumab-tremfya-emea-001523-pip02-14-m02_en.pdf"},
    {"id":"16408","name":"P/0130/2012: EMA decision of 4 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for albiglutide (EMEA-001175-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-09T14:00:00Z","last_updated_date":"2012-08-09T14:00:00Z","reference_number":"EMA/411120/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2012-ema-decision-4-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-albiglutide-emea-001175-pip01-11_en.pdf"},
    {"id":"16422","name":"P/0280/2014: EMA decision of 30 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for fibrinogen / thrombin / aprotinin / calcium chloride (EMEA-001079-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-09T01:00:00Z","last_updated_date":"2014-12-09T01:00:00Z","reference_number":"EMA/587540/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2014-ema-decision-30-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-fibrinogen-thrombin-aprotinin-calcium-chloride-emea-001079-pip01-10-m02_en.pdf"},
    {"id":"16427","name":"P/0279/2016: EMA decision of 7 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for Eteplirsen (EMEA-\n\n001722-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/643929/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2016-ema-decision-7-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-eteplirsen-emea-001722-pip01-14-m01_en.pdf"},
    {"id":"16433","name":"P/0186/2015: EMA decision of 27 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (HyQvia) (EMEA-000872-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/556402/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2015-ema-decision-27-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-hyqvia-emea-000872-pip01-10-m03_en.pdf"},
    {"id":"16441","name":"P/209/2011: EMA decision of 30 August 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for teriflunomide (EMEA-001094-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/643565/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-209-2011-ema-decision-30-august-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-teriflunomide-emea-001094-pip01-10_en.pdf"},
    {"id":"16445","name":"P/0250/2016: EMA decision of 9 September 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for bivalent anti-human myostatin adnectin recombinant ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/585777/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2016-ema-decision-9-september-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bivalent-anti-human-myostatin-adnectin-recombinant_en.pdf"},
    {"id":"16450","name":"P/0261/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lipegfilgrastim\n\n(Lonquex), (EMEA-001019-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-25T17:00:00Z","last_updated_date":"2017-10-25T17:00:00Z","reference_number":"EMA/493094/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-lipegfilgrastim-lonquex-emea-001019-pip01-10-m04_en.pdf"},
    {"id":"16455","name":"P/0259/2014: EMA decision of 1 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for D-argininamide, N-acetyl-D-cysteinyl-D-alanyl-D-arginy...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/514793/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2014-ema-decision-1-october-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-d-argininamide-n-acetyl-d-cysteinyl-d-alanyl-d-arginy_en.pdf"},
    {"id":"16485","name":"P/0080/2017: EMA decision of 17 March 2017 on the refusal of a paediatric investigation plan and on the granting of a waiver for methylphenidate\n\n(hydrochloride) (EMEA-002034-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/137024/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2017-ema-decision-17-march-2017-refusal-paediatric-investigation-plan-granting-waiver-methylphenidate-hydrochloride-emea-002034-pip01-16_en.pdf"},
    {"id":"16487","name":"P/258/2009: EMA decision of 23 December 2009 on the refusal of a Paediatric Investigation Plan and on the refusal of a deferral and on the refusal of a waiver for fentanyl citrate (EMEA-000481-PIP0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMA/749288/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-258-2009-ema-decision-23-december-2009-refusal-paediatric-investigation-plan-refusal-deferral-refusal-waiver-fentanyl-citrate-emea-000481-pip0_en.pdf"},
    {"id":"16491","name":"P/0236/2014: EMA decision of 19 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tap...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-10-09T02:00:00Z","last_updated_date":"2014-10-09T02:00:00Z","reference_number":"EMA/547327/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2014-ema-decision-19-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tap_en.pdf"},
    {"id":"16502","name":"P/0192/2017: EMA decision of 3 July 2017 on the refusal of a modification of an agreed paediatric investigation plan for certolizumab pegol (Cimzia), (EMEA-001071-PIP02-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/348026/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2017-ema-decision-3-july-2017-refusal-modification-agreed-paediatric-investigation-plan-certolizumab-pegol-cimzia-emea-001071-pip02-12-m02_en.pdf"},
    {"id":"16509","name":"P/1/2008: European medicines agency decision of 7 January 2008 on the application for product-specific waiver for Lasofoxifene tartrate EMEA-000039-PIP01-2007 in accordance with Regulation (EC) No 1901/2006 of the Europe...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-01-07T00:00:00Z","last_updated_date":"2008-01-07T00:00:00Z","reference_number":"EMEA/602212/2007","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-1-2008-european-medicines-agency-decision-7-january-2008-application-product-specific-waiver-lasofoxifene-tartrate-emea-000039-pip01-2007-accordance-regulation-ec-no-1901-2006-europe_en.pdf"},
    {"id":"16515","name":"P/142/2009: EMA decision of 30 July 2010 on the refusal of a modification of an agreed paediatric investigation plan for tapentadol hydrochloride (EMEA-000494-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"EMA/469400/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-142-2009-ema-decision-30-july-2010-refusal-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-emea-000494-pip01-08-m02_en.pdf"},
    {"id":"16517","name":"P/89/2010: European Medicines Agency decision of 1 June 2010 on the agreement of a paediatric investigation plan and on the granting of a waiver for solifenacin succinate (Vesicare and associated names) (EMEA-000573-PIP0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/337481/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-89-2010-european-medicines-agency-decision-1-june-2010-agreement-paediatric-investigation-plan-granting-waiver-solifenacin-succinate-vesicare-associated-names-emea-000573-pip0_en.pdf"},
    {"id":"16522","name":"P/64/2011: EMA decision of 10 March 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for abatacept (Orencia) (EMEA-000118-PIP02-10) in accordance ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/170436/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-64-2011-ema-decision-10-march-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-abatacept-orencia-emea-000118-pip02-10-accordance_en.pdf"},
    {"id":"16541","name":"P/215/2010: European Medicines Agency decision of 29 October 2010 on the granting of a product specific waiver for derivative of 4,4'-(1-methylene)-bisbenzonitrile (EMEA-000758-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/629943/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-215-2010-european-medicines-agency-decision-29-october-2010-granting-product-specific-waiver-derivative-44-1-methylene-bisbenzonitrile-emea-000758-pip01-09_en.pdf"},
    {"id":"16549","name":"P/0108/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for canagliflozin (EMEA-001030-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/206799/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2013-ema-decision-30-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-canagliflozin-emea-001030-pip01-10-m01_en.pdf"},
    {"id":"16556","name":"P/0011/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz),\n\n(EMEA-001050-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/28229/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-ixekizumab-taltz-emea-001050-pip01-10-m03_en.pdf"},
    {"id":"16598","name":"P/0001/2013: EMA decision of 11 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for catridecacog (NovoThirteen) (EMEA-000185-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T18:30:00Z","last_updated_date":"2013-04-03T18:30:00Z","reference_number":"EMA/826252/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2013-ema-decision-11-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-catridecacog-novothirteen-emea-000185-pip01-08-m05_en.pdf"},
    {"id":"16606","name":"P/275/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allergen extract of betula verrucosa pollen (EMEA-000...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/683371/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-275-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extract-betula-verrucosa-pollen-emea-000_en.pdf"},
    {"id":"16654","name":"P/0044/2014: EMA decision of 7 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for cinacalcet hydrochloride (Mimpara) (EMEA-000078-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/58492/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2014-ema-decision-7-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-cinacalcet-hydrochloride-mimpara-emea-000078-pip01-07-m04_en.pdf"},
    {"id":"16686","name":"P/218/2011: EMA decision of 26 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for canakinumab (Ilaris)\n\n(EMEA-000060-PIP02-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/554227/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-218-2011-ema-decision-26-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-canakinumab-ilaris-emea-000060-pip02-08-m03_en.pdf"},
    {"id":"16727","name":"P/0370/2016: European Medicines Agency decision of 4 January 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-(human calcitonin gene-rela...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/4029/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0370-2016-european-medicines-agency-decision-4-january-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-human-calcitonin-gene-rela_en.pdf"},
    {"id":"16737","name":"P/0291/2015: EMA decision of 27 November 2015 on the refusal of a paediatric investigation plan and on the granting of a waiver for recombinant human growth hormone fused to hybrid Fc composed of the hinge region and N-t...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/690013/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2015-ema-decision-27-november-2015-refusal-paediatric-investigation-plan-granting-waiver-recombinant-human-growth-hormone-fused-hybrid-fc-composed-hinge-region-n-t_en.pdf"},
    {"id":"16742","name":"P/204/2010: European Medicines Agency decision of 27 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Birch, Hazel and Alder Pollen Ex...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/647417/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-204-2010-european-medicines-agency-decision-27-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-birch-hazel-alder-pollen-ex_en.pdf"},
    {"id":"16743","name":"P/0121/2014: EMA decision of 7 May 2014 on the granting of a product specific waiver for amlodipine / rosuvastatin (EMEA-001578-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/195552/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2014-ema-decision-7-may-2014-granting-product-specific-waiver-amlodipine-rosuvastatin-emea-001578-pip01-13_en.pdf"},
    {"id":"16747","name":"P/304/2011: EMA decision of 20 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for recombinant human granulocyte colony stimulating facto...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/953999/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-304-2011-ema-decision-20-december-2011-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-recombinant-human-granulocyte-colony-stimulating-facto_en.pdf"},
    {"id":"16772","name":"P/0059/2014: European Medicines Agency decision of 7 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-PD1 humanized monoclonal anti...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/52884/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2014-european-medicines-agency-decision-7-march-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-pd1-humanized-monoclonal-anti_en.pdf"},
    {"id":"16775","name":"P/188/2010: European Medicines Agency decision of 24 September 2010 on the granting of a product specific waiver for amlodipine camsylate / losartan potassium (EMEA-000886-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/596152/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-188-2010-european-medicines-agency-decision-24-september-2010-granting-product-specific-waiver-amlodipine-camsylate-losartan-potassium-emea-000886-pip01-10_en.pdf"},
    {"id":"16779","name":"P/0001/2017: EMA decision of 5 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for beclometasone(dipropionate) / formoterol (fumarate dihydrate) (Foster and associated names, K...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/3349/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2017-ema-decision-5-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-beclometasonedipropionate-formoterol-fumarate-dihydrate-foster-associated-names-k_en.pdf"},
    {"id":"16786","name":"P/0215/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dinutuximab\n\n(Unituxin) (EMEA-001285-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/472143/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-dinutuximab-unituxin-emea-001285-pip01-12-m02_en.pdf"},
    {"id":"16796","name":"P/0283/2014: EMA decision of 30 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for landiolol (hydrochloride) (EMEA-001150-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-04T01:00:00Z","last_updated_date":"2014-12-04T01:00:00Z","reference_number":"EMA/592453/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2014-ema-decision-30-october-2014-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-landiolol-hydrochloride-emea-001150-pip02-13_en.pdf"},
    {"id":"16805","name":"P/55/2010: EMA decision of 7.04.10 on the agreement of a PIP and on granting of deferral and on granting of waiver for (2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl)-2-[[2-(4-isopropyl-1,3-thiazol-2-yl)-7-methoxy-8-...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/199538/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-55-2010-ema-decision-70410-agreement-pip-granting-deferral-granting-waiver-2r3ar10z11as12ar14ar-n-cyclopropylsulfonyl-2-2-4-isopropyl-13-thiazol-2-yl-7-methoxy-8_en.pdf"},
    {"id":"16812","name":"P/319/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of birch, alder and hazel p...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769414/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-319-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-birch-alder-hazel-p_en.pdf"},
    {"id":"16819","name":"P/0161/2012: EMA decision of 20 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for pneumococcal polysaccharide serotype 1 – diphtheria CRM197 conjugate, pneumococcal polysacchari...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/474586/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2012-ema-decision-20-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-pneumococcal-polysaccharide-serotype-1-diphtheria-crm197-conjugate-pneumococcal-polysacchari_en.pdf"},
    {"id":"16839","name":"P/0277/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for pollen from betula pendula (33%), corylus avellana (33%) and alnus glutinosa (33%), (EMEA-000852-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/732714/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-pollen-betula-pendula-33-corylus-avellana-33-alnus-glutinosa-33-emea-000852-pip01-10-m01_en.pdf"},
    {"id":"16849","name":"P/0026/2014: EMA decision of 24 January 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for elvitegravir / cobicistat / emtricitabine / tenofovir...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/774466/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2014-ema-decision-24-january-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-elvitegravir-cobicistat-emtricitabine-tenofovir_en.pdf"},
    {"id":"16878","name":"P/322/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for modified allergen extract of grass and birch pollen ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/683348/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-322-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-grass-birch-pollen_en.pdf"},
    {"id":"16892","name":"P/0081/2014: EMA decision of 2 April 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (E)-4-[(5-Phenyl-1,3,4-thiadiazol-2-yl)oxy]-1-azoniatric...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2014-05-13T02:00:00Z","reference_number":"EMA/122563/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2014-ema-decision-2-april-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-e-4-5-phenyl-134-thiadiazol-2-yloxy-1-azoniatric_en.pdf"},
    {"id":"16905","name":"P/157/2009: European Medicines Agency decision of 11 August 2009 on the granting of a product specific waiver for 5-aminolevulinic acid, hydrochloride (EMEA-000521-PIP01-08) in accordance with Regulation (EC) No 1901/200...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/492758/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-157-2009-european-medicines-agency-decision-11-august-2009-granting-product-specific-waiver-5-aminolevulinic-acid-hydrochloride-emea-000521-pip01-08-accordance-regulation-ec-no-1901-200_en.pdf"},
    {"id":"16910","name":"P/0168/2014: EMA decision of 8 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for insulin peglispro (EMEA-001097-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/349913/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2014-ema-decision-8-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-insulin-peglispro-emea-001097-pip01-10-m02_en.pdf"},
    {"id":"16914","name":"P/0076/2015: EMA decision of 1 April 2015 on the agreement of a paediatric investigation plan for anti programmed death-ligand 1 (PD-L1) monoclonal antibody (MPDL3280A) (EMEA-001638-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-07T02:00:00Z","last_updated_date":"2015-05-07T02:00:00Z","reference_number":"EMA/111608/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2015-ema-decision-1-april-2015-agreement-paediatric-investigation-plan-anti-programmed-death-ligand-1-pd-l1-monoclonal-antibody-mpdl3280a-emea-001638-pip01-14_en.pdf"},
    {"id":"16918","name":"P/219/2011: EMA decision of 26 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for mepolizumab (EMEA-000069-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/679385/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-219-2011-ema-decision-26-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mepolizumab-emea-000069-pip02-10_en.pdf"},
    {"id":"16920","name":"P/0141/2013: EMA decision of 3 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for canakinumab (Ilaris) (EMEA-000060-PIP02-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-08T18:00:00Z","last_updated_date":"2013-08-08T18:00:00Z","reference_number":"EMA/331976/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2013-ema-decision-3-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-canakinumab-ilaris-emea-000060-pip02-08-m06_en.pdf"},
    {"id":"16927","name":"P/0009/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for retigabine (Trobalt), (EMEA-000116-PIP01-07-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/23015/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-retigabine-trobalt-emea-000116-pip01-07-m08_en.pdf"},
    {"id":"16933","name":"P/0255/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant parathyroid hormone (EMEA-001526-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/619860/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-parathyroid-hormone-emea-001526-pip01-13-m01_en.pdf"},
    {"id":"16962","name":"P/0065/2014: European Medicines Agency decision of 10 March 2014 on the refusal of a paediatric investigation plan and on the granting of a waiver for recombinant human growth hormone modified by fusion with two hydrophi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/55121/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2014-european-medicines-agency-decision-10-march-2014-refusal-paediatric-investigation-plan-granting-waiver-recombinant-human-growth-hormone-modified-fusion-two-hydrophi_en.pdf"},
    {"id":"16980","name":"P/230/2011: EMA decision of 28 September 2011 on the granting of a product specific waiver for progesterone (EMEA-001109-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/698094/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-230-2011-ema-decision-28-september-2011-granting-product-specific-waiver-progesterone-emea-001109-pip01-10_en.pdf"},
    {"id":"16988","name":"P/74/2011: EMA decision of 5 April 2011 on the acceptance of a modification of an agreed paediatric investigation plan for voriconazole (Vfend),\n\n(EMEA-000191-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"EMA/244232/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-74-2011-ema-decision-5-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-voriconazole-vfend-emea-000191-pip01-08-m02_en.pdf"},
    {"id":"17001","name":"P/0062/2013: European medicines agency decision of 26 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for ambrisentan (Volibris), (EMEA-000434-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/102949/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2013-european-medicines-agency-decision-26-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-ambrisentan-volibris-emea-000434-pip01-08-m01_en.pdf"},
    {"id":"17043","name":"P/0248/2017: EMA decision of 4 September 2017 on the granting of a product specific waiver for human normal immunoglobulin (EMEA-002092-PIP01-\n\n16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/506969/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2017-ema-decision-4-september-2017-granting-product-specific-waiver-human-normal-immunoglobulin-emea-002092-pip01-16_en.pdf"},
    {"id":"17045","name":"P/313/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of grass and rye pollen (60...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769458/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-313-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-grass-rye-pollen-60_en.pdf"},
    {"id":"17049","name":"P/0004/2018: EMA decision of 4 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for L-asparaginase\n\nencapsulated in erythrocytes, (EMEA-000341-PIP02-09-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T15:28:00Z","last_updated_date":"2018-04-17T15:28:00Z","reference_number":"EMA/993/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2018-ema-decision-4-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-l-asparaginase-encapsulated-erythrocytes-emea-000341-pip02-09-m05_en.pdf"},
    {"id":"17088","name":"P/243/2011: EMA decision of 30 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for lorcaserin (EMEA-001098-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/760982/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-243-2011-ema-decision-30-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lorcaserin-emea-001098-pip01-10_en.pdf"},
    {"id":"17097","name":"P/0078/2017: EMA decision of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for T-lymphocytes\n\nenriched leukocyte preparation depleted ex vivo of host host-alloreactiv...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/106106/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2017-ema-decision-17-march-2017-agreement-paediatric-investigation-plan-granting-deferral-t-lymphocytes-enriched-leukocyte-preparation-depleted-ex-vivo-host-host-alloreactiv_en.pdf"},
    {"id":"17102","name":"P/49/2010: European Medicines Agency decision of 6 April 2010 on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for ciclosporin (EMEA-000575-PIP01-09) in accordance with Regulation (EC) ...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/118885/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-49-2010-european-medicines-agency-decision-6-april-2010-agreement-paediatric-investigation-plan-granting-waiver-ciclosporin-emea-000575-pip01-09-accordance-regulation-ec_en.pdf"},
    {"id":"17113","name":"P/0200/2016: EMA decision of of 22 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab\n\n(Humira) (EMEA-000366-PIP05-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:10:00Z","last_updated_date":"2016-09-22T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2016-ema-decision-22-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip05-12-m02_en.pdf"},
    {"id":"17115","name":"P/0185/2017: EMA decision of 30 June 2017 on the granting of a product-specific waiver for rosuvastatin (calcium) / ezetimibe (EMEA-002135-\n\nPIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/371180/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2017-ema-decision-30-june-2017-granting-product-specific-waiver-rosuvastatin-calcium-ezetimibe-emea-002135-pip01-17_en.pdf"},
    {"id":"17134","name":"P/0135/2013: EMA decision of 14 June 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for\n\nisavuconazonium (sulfate) (EMEA-001301-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T12:00:00Z","last_updated_date":"2013-07-23T12:00:00Z","reference_number":"EMA/314990/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2013-ema-decision-14-june-2013-agreement-paediatric-investigation-plan-granting-deferral-isavuconazonium-sulfate-emea-001301-pip02-12_en.pdf"},
    {"id":"17135","name":"P/52/2009: European Medicines Agency decision of 24 March 2009 on the granting of a product specific waiver for bisoprolol fumarate / acetylsalicylic acid (EMEA-000447-PIP01-08) in accordance with Regulation (EC) No 1901...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/167281/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-52-2009-european-medicines-agency-decision-24-march-2009-granting-product-specific-waiver-bisoprolol-fumarate-acetylsalicylic-acid-emea-000447-pip01-08-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"17144","name":"P/0146/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for vedolizumab (Entyvio), (EMEA-000645-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/293460/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-vedolizumab-entyvio-emea-000645-pip01-09-m05_en.pdf"},
    {"id":"17189","name":"P/0224/2016: EMA decision of 12 August 2016 on the granting of a product specific waiver for lusutrombopag (EMEA-001905-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/441060/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2016-ema-decision-12-august-2016-granting-product-specific-waiver-lusutrombopag-emea-001905-pip01-15_en.pdf"},
    {"id":"17191","name":"P/239/2011: EMA decision of 30 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (Brilique, Possia) (EMEA-000480-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/766413/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-239-2011-ema-decision-30-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-ticagrelor-brilique-possia-emea-000480-pip01-08-m02_en.pdf"},
    {"id":"17198","name":"P/262/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mixture of Phleum pratense, Dactylis glomerata, Festu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/670697/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-262-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mixture-phleum-pratense-dactylis-glomerata-festu_en.pdf"},
    {"id":"17208","name":"P/0294/2012: EMA decision of 18 December 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T14:00:00Z","last_updated_date":"2013-02-08T14:00:00Z","reference_number":"EMA/802135/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2012-ema-decision-18-december-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-s-isopropyl-2-s-2r3r4r5r-5-24-dioxo-3_en.pdf"},
    {"id":"17236","name":"P/0316/2016: EMA decision of 2 December 2016\n\non the acceptance of a modification of an agreed paediatric investigation plan for cannabidiol / delta-9-tetrahydrocannabinol (Sativex), (EMEA-000181-PIP01-08-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T09:55:00Z","last_updated_date":"2017-01-30T09:55:00Z","reference_number":"EMA/741977/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-cannabidiol-delta-9-tetrahydrocannabinol-sativex-emea-000181-pip01-08-m03_en.pdf"},
    {"id":"17253","name":"P/0304/2014: EMA decision of 24 November 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inotuzumab ozogamicin (EMEA-001429-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/641736/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2014-ema-decision-24-november-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-inotuzumab-ozogamicin-emea-001429-pip01-13_en.pdf"},
    {"id":"17261","name":"P/0359/2017: EMA decision of 1 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for Neisseria meningitidis serogroup A polysaccharide co...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/710066/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0359-2017-ema-decision-1-december-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-neisseria-meningitidis-serogroup-polysaccharide-co_en.pdf"},
    {"id":"17275","name":"P/0150/2012: EMA decision of 16 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for turoctocog alpha (EMEA-000428-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/472343/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2012-ema-decision-16-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-turoctocog-alpha-emea-000428-pip01-08-m01_en.pdf"},
    {"id":"17277","name":"P/0286/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for retigabine (Trobalt), (EMEA-000116-PIP01-07-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/659500/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-retigabine-trobalt-emea-000116-pip01-07-m07_en.pdf"}    {"id":"17279","name":"P/0071/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for encorafenib\n\n(EMEA-001588-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/75543/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-encorafenib-emea-001588-pip01-13-m01_en.pdf"},
    {"id":"17286","name":"P/0003/2012: EMA decision of 23 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of bi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/972923/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2012-ema-decision-23-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergen-extract-bi_en.pdf"},
    {"id":"17287","name":"P/199/2010: European Medicines Agency decision of 27 October 2010 on the acceptance of a modification of an agreed paediatric investigation plan for motavizumab (EMEA-000352-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-24T01:00:00Z","last_updated_date":"2010-11-24T01:00:00Z","reference_number":"EMA/651476/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-199-2010-european-medicines-agency-decision-27-october-2010-acceptance-modification-agreed-paediatric-investigation-plan-motavizumab-emea-000352-pip01-08-m01_en.pdf"},
    {"id":"17302","name":"P/0012/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (EDURANT) (EMEA-000317-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/4099/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-edurant-emea-000317-pip01-08-m08_en.pdf"},
    {"id":"17312","name":"P/58/2011: EMA decision of 4 March 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for laquinimod (sodium) (EMEA-000972-PIP01-10) in accordance w...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/155689/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-58-2011-ema-decision-4-march-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-laquinimod-sodium-emea-000972-pip01-10-accordance-w_en.pdf"},
    {"id":"17319","name":"P/0326/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin\n\n(Jardiance), (EMEA-000828-PIP01-09-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-31T11:35:00Z","last_updated_date":"2017-01-31T11:35:00Z","reference_number":"EMA/756830/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0326-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-jardiance-emea-000828-pip01-09-m05_en.pdf"},
    {"id":"17336","name":"P/0111/2013: EMA decision of 30 April 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for palivizumab (Synagis) (EMEA-001309-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/203434/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2013-ema-decision-30-april-2013-agreement-paediatric-investigation-plan-granting-waiver-palivizumab-synagis-emea-001309-pip01-12_en.pdf"},
    {"id":"17343","name":"P/0028/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin\n\n(Jardiance) (EMEA-000828-PIP01-09-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T11:41:00Z","last_updated_date":"2018-04-18T11:41:00Z","reference_number":"EMA/792965/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-jardiance-emea-000828-pip01-09-m06_en.pdf"},
    {"id":"17372","name":"P/0312/2014: EMA decision of 26 November 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lomitapide (Lojuxta), (EMEA-001124-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/667883/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2014-ema-decision-26-november-2014-acceptance-modification-agreed-paediatric-investigation-plan-lomitapide-lojuxta-emea-001124-pip01-10-m02_en.pdf"},
    {"id":"17381","name":"P/54/2008: European medicines agency decision of 20 July 2008 on the application for product specific waiver for Glucosamine hydrochloride,\n\nchondroitin sulphate, PIP number EMEA-000171-PIP01-07 in accordance with Regula...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-08T02:00:00Z","last_updated_date":"2008-09-08T02:00:00Z","reference_number":"EMEA/363689/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-54-2008-european-medicines-agency-decision-20-july-2008-application-product-specific-waiver-glucosamine-hydrochloride-chondroitin-sulphate-pip-number-emea-000171-pip01-07-accordance-regula_en.pdf"},
    {"id":"17384","name":"P/0121/2012: EMA decision of 3 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for lumacaftor (EMEA-001173-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-09T14:00:00Z","last_updated_date":"2012-08-09T14:00:00Z","reference_number":"EMA/422871/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2012-ema-decision-3-july-2012-agreement-paediatric-investigation-plan-granting-deferral-lumacaftor-emea-001173-pip01-11_en.pdf"},
    {"id":"17386","name":"P/0150/2016: EMA decision of 14 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for irutinib (Imbruvica)\n\n(EMEA-001397-PIP03-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/380518/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2016-ema-decision-14-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-irutinib-imbruvica-emea-001397-pip03-14-m01_en.pdf"},
    {"id":"17407","name":"P/0038/2016: EMA decision of 19 February 2016 on the acceptance of a modification of an agreed paediatric investigation plan for rufinamide, (Inovelon) (EMEA-000709-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/95670/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2016-ema-decision-19-february-2016-acceptance-modification-agreed-paediatric-investigation-plan-rufinamide-inovelon-emea-000709-pip01-09-m04_en.pdf"},
    {"id":"17429","name":"P/63/2011: EMA decision of 18 February 2011 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab\n\n(Humira) (EMEA-000366-PIP02-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2011-03-08T01:00:00Z","reference_number":"EMA/140284/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-63-2011-ema-decision-18-february-2011-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip02-09-m01_en.pdf"},
    {"id":"17441","name":"P/0143/2016: EMA decision of 20 May 2016 on the granting of a product specific waiver for hydrogen peroxide (EMEA-001884-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-18T02:00:00Z","last_updated_date":"2016-07-18T02:00:00Z","reference_number":"EMA/249420/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2016-ema-decision-20-may-2016-granting-product-specific-waiver-hydrogen-peroxide-emea-001884-pip02-15_en.pdf"},
    {"id":"17444","name":"P/142/2011: EMA decision of 9 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chemically modified house dust mites allergen extract (der...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/417239/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-142-2011-ema-decision-9-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chemically-modified-house-dust-mites-allergen-extract-der_en.pdf"},
    {"id":"17456","name":"P/0282/2012: EMA decision of 23 November 2012 on the granting of a product-specific waiver for icatibant (Firazyr), (EMEA-000408-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-07T01:00:00Z","last_updated_date":"2013-01-07T01:00:00Z","reference_number":"EMA/739090/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2012-ema-decision-23-november-2012-granting-product-specific-waiver-icatibant-firazyr-emea-000408-pip02-12_en.pdf"},
    {"id":"17457","name":"P/0282/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dabigatran etexilate\n\n(Pradaxa), (EMEA-000081-PIP01-07-M09)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T14:44:00Z","last_updated_date":"2017-01-23T14:44:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-pradaxa-emea-000081-pip01-07-m09_en.pdf"},
    {"id":"17486","name":"P/267/2011: EMA decision of 28 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for pitavastatin (calcium) (Vezepra and associated names) (EMEA-000301-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T16:00:00Z","last_updated_date":"2011-11-30T16:00:00Z","reference_number":"EMA/831322/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-267-2011-ema-decision-28-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-pitavastatin-calcium-vezepra-associated-names-emea-000301-pip01-08-m02_en.pdf"},
    {"id":"17490","name":"P/35/2009: European Medicines Agency decision of 24 February 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for sunitinib malate (Sutent) (EMEA-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/94177/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-35-2009-european-medicines-agency-decision-24-february-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sunitinib-malate-sutent-emea_en.pdf"},
    {"id":"17492","name":"P/298/2011: EMA decision of 20 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (phosphate monohydrate) (Januvia), (EMEA-000470-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/943257/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-298-2011-ema-decision-20-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-phosphate-monohydrate-januvia-emea-000470-pip01-08-m05_en.pdf"},
    {"id":"17495","name":"P/162/2010: EMA decision of 27 August 2010 on the agreement of a paediatric investigation plan and on the granting of a product specific waiver for perindopril erbumine / amlodipine besylate (EMEA-\n\n000983-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/476893/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-162-2010-ema-decision-27-august-2010-agreement-paediatric-investigation-plan-granting-product-specific-waiver-perindopril-erbumine-amlodipine-besylate-emea-000983-pip01-10_en.pdf"},
    {"id":"17504","name":"P/0179/2012: EMA decision of 20 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tocilizumab (RoActemra) (EMEA-000309-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/477977/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2012-ema-decision-20-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-tocilizumab-roactemra-emea-000309-pip01-08-m04_en.pdf"},
    {"id":"17516","name":"P/0035/2012: EMA decision of 3 February 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for 2-Iminobiotin\n\n(EMEA-001070-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T14:30:00Z","last_updated_date":"2012-03-15T14:30:00Z","reference_number":"EMA/72070/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2012-ema-decision-3-february-2012-agreement-paediatric-investigation-plan-granting-waiver-2-iminobiotin-emea-001070-pip01-10_en.pdf"},
    {"id":"17522","name":"P/252/2011: EMA decision of 26 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone propionate / formoterol fumarate, (EMEA-000127-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T16:00:00Z","last_updated_date":"2011-11-30T16:00:00Z","reference_number":"EMA/829912/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-252-2011-ema-decision-26-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-propionate-formoterol-fumarate-emea-000127-pip01-07-m02_en.pdf"},
    {"id":"17567","name":"P/166/2009: European Medicines Agency decision of 21 August 2009 on the refusal of a Paediatric Investigation Plan for live bacterium B. thetaiotaomicron (EMEA-000561-PIP01-09) in accordance with Regulation (EC) No 1901/...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/494847/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-166-2009-european-medicines-agency-decision-21-august-2009-refusal-paediatric-investigation-plan-live-bacterium-b-thetaiotaomicron-emea-000561-pip01-09-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"17571","name":"P/0309/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for elvitegravir /\n\nemtricitabine / tenofovir disoproxil (as fumarate) / cobicistat (Stribild), ...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-19T11:00:00Z","last_updated_date":"2017-01-19T11:00:00Z","reference_number":"EMA/713477/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0309-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-elvitegravir-emtricitabine-tenofovir-disoproxil-fumarate-cobicistat-stribild_en.pdf"},
    {"id":"17598","name":"P/112/2011: poly(oxy-1,2-ethanediyl),alpha-hydro-omega-methoxy-133 ester with granulocyte colony-stimulating factor [methionyl,133-[O-[2-(acetylamino]-6-O-[N-[Ncarboxyglycyl) amino]-alpha neuraminosyl]-2-deoxy-alpha-D-ga...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-09T02:00:00Z","last_updated_date":"2011-06-09T02:00:00Z","reference_number":"EMA/334992/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-112-2011-polyoxy-12-ethanediylalpha-hydro-omega-methoxy-133-ester-granulocyte-colony-stimulating-factor-methionyl133-o-2-acetylamino-6-o-n-ncarboxyglycyl-amino-alpha-neuraminosyl-2-deoxy-alpha-d-ga_en.pdf"},
    {"id":"17616","name":"P/208/2011: EMA decision of 2 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for canakinumab (EMEA-\n\n000060-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/644005/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-208-2011-ema-decision-2-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-canakinumab-emea-000060-pip01-07-m03_en.pdf"},
    {"id":"17634","name":"P/0180/2014: EMA decision of 17 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for daclatasvir (EMEA-001191-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/414728/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2014-ema-decision-17-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-daclatasvir-emea-001191-pip01-11-m01_en.pdf"},
    {"id":"17639","name":"P/0063/2013: European medicines agency decision of 26 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for belimumab (Benlysta), (EMEA-000520-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/104070/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2013-european-medicines-agency-decision-26-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-belimumab-benlysta-emea-000520-pip01-08-m02_en.pdf"},
    {"id":"17641","name":"P/0370/2017: EMA decision of 1 December 2017 on the granting of a product specific waiver for tolonium chloride (EMEA-002170-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-05T15:26:00Z","last_updated_date":"2018-03-05T15:26:00Z","reference_number":"EMA/704008/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0370-2017-ema-decision-1-december-2017-granting-product-specific-waiver-tolonium-chloride-emea-002170-pip01-17_en.pdf"},
    {"id":"17659","name":"P/0007/2012: EMA decision of 24 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Xgeva\n\n(previously Amgiva)), (Prolia), (EMEA-000145-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/25162/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2012-ema-decision-24-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-xgeva-previously-amgiva-prolia-emea-000145-pip01-07-m04_en.pdf"},
    {"id":"17662","name":"P/206/2010: European Medicines Agency decision of 27 October 2010 on the granting of a product specific waiver for ingenol mebutate (EMEA-000894-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/649852/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-206-2010-european-medicines-agency-decision-27-october-2010-granting-product-specific-waiver-ingenol-mebutate-emea-000894-pip01-10_en.pdf"},
    {"id":"17684","name":"P/0018/2018: EMA decision of 30 January 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for obiltoxaximab (EMEA-002144-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T02:00:00Z","last_updated_date":"2018-04-17T02:00:00Z","reference_number":"EMA/850790/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2018-ema-decision-30-january-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-obiltoxaximab-emea-002144-pip01-17_en.pdf"},
    {"id":"17704","name":"P/327/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of pollen from Phleum prate...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/697310/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-327-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-pollen-phleum-prate_en.pdf"},
    {"id":"17708","name":"P/0243/2014: EMA decision of 29 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for 7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]quinolin-2(1H)-one (OPC-34712) (EMEA-00...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/508721/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2014-ema-decision-29-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-7-4-4-benzobthiophen-4-ylpiperazin-1-ylbutoxyquinolin-21h-one-opc-34712-emea-00_en.pdf"},
    {"id":"17719","name":"P/135/2009: European Medicines Agency decision of 15 July 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for N-[4-(3-amino-1H-indazol-4 yl)phenyl]-N1-(2-fluoro-5-methylphenyl) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/388509/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-135-2009-european-medicines-agency-decision-15-july-2009-agreement-paediatric-investigation-plan-granting-deferral-n-4-3-amino-1h-indazol-4-ylphenyl-n1-2-fluoro-5-methylphenyl_en.pdf"},
    {"id":"17746","name":"P/0258/2015: EMA decision of 30 October 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (3-((4-Benzoyl-1-piperazinyl)(oxo)acetyl)-4-methoxy-7...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T01:00:00Z","last_updated_date":"2015-12-21T01:00:00Z","reference_number":"EMA/627049/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2015-ema-decision-30-october-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-3-4-benzoyl-1-piperazinyloxoacetyl-4-methoxy-7_en.pdf"},
    {"id":"17754","name":"P/0104/2015: EMA decision of 11 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ibodutant (EMEA-001663-PIP01-14)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/215116/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2015-ema-decision-11-may-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ibodutant-emea-001663-pip01-14_en.pdf"},
    {"id":"17758","name":"P/0012/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for matrix applied\n\ncharacterised autologous cultured chondrocytes (MACI) (EMEA-000979-PIP01-10-...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T11:41:00Z","last_updated_date":"2018-04-18T11:41:00Z","reference_number":"EMA/28037/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-matrix-applied-characterised-autologous-cultured-chondrocytes-maci-emea-000979-pip01-10_en.pdf"},
    {"id":"17769","name":"P/0124/2012: EMA decision of 4 July 2012 on the granting of a product specific waiver for alisporivir, (EMEA-000724-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-09T14:00:00Z","last_updated_date":"2012-08-09T14:00:00Z","reference_number":"EMA/416052/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2012-ema-decision-4-july-2012-granting-product-specific-waiver-alisporivir-emea-000724-pip02-11_en.pdf"},
    {"id":"17770","name":"P/0387/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for bezlotoxumab\n\n(Zinplava) (EMEA-001645-PIP01-14-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T13:05:00Z","last_updated_date":"2018-03-07T13:05:00Z","reference_number":"EMA/792977/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0387-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-bezlotoxumab-zinplava-emea-001645-pip01-14-m02_en.pdf"},
    {"id":"17797","name":"P/0020/2013: EMA decision of 15 February 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tiotropium bromide (monohydrate) (Spiriva Respimat, ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2013-ema-decision-15-february-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tiotropium-bromide-monohydrate-spiriva-respimat_en.pdf"},
    {"id":"17808","name":"P/116/2008: European Medicines Agency decision of 1 December 2008 on the application for agreement of a Paediatric Investigation Plan for sitagliptin phosphate monohydrate, metformin hydrochloride (Velmetia)\n\nEMEA-000212...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/625239/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-116-2008-european-medicines-agency-decision-1-december-2008-application-agreement-paediatric-investigation-plan-sitagliptin-phosphate-monohydrate-metformin-hydrochloride-velmetia-emea-000212_en.pdf"},
    {"id":"17828","name":"P/0332/2014: EMA decision of 22 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for dabrafenib (Tafinlar), (EMEA-001147-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T01:00:00Z","last_updated_date":"2015-02-23T01:00:00Z","reference_number":"EMA/740214/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0332-2014-ema-decision-22-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-dabrafenib-tafinlar-emea-001147-pip01-11-m02_en.pdf"},
    {"id":"17870","name":"P/0320/2014: EMA decision of 19 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for pollen from Phleum pratense (EMEA-000848-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-20T01:00:00Z","last_updated_date":"2015-02-20T01:00:00Z","reference_number":"EMA/719217/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2014-ema-decision-19-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-pollen-phleum-pratense-emea-000848-pip01-10-m01_en.pdf"},
    {"id":"17876","name":"P/0176/2013: EMA decision of 30 July 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for glucarpidase (EMEA-001391-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/375098/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2013-ema-decision-30-july-2013-agreement-paediatric-investigation-plan-granting-waiver-glucarpidase-emea-001391-pip01-12_en.pdf"},
    {"id":"17889","name":"P/0193/2012: EMA decision of 24 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen /\n\nhuman thrombin (Evicel) (EMEA-001149-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/547580/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2012-ema-decision-24-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-evicel-emea-001149-pip01-11-m01_en.pdf"},
    {"id":"17900","name":"P/326/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of hazel pollen (EMEA-00095...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769413/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-326-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-hazel-pollen-emea-00095_en.pdf"},
    {"id":"17913","name":"P/236/2011: EMA decision of 30 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vatreptacog alfa (activated) (EMEA-000328-PIP02-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/766294/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-236-2011-ema-decision-30-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vatreptacog-alfa-activated-emea-000328-pip02-09_en.pdf"},
    {"id":"17943","name":"P/0209/2015: EMA decision of 18 September 2015 on the agreement of a paediatric investigation plan and on the refusal of a deferral for recombinant human tripeptidyl peptidase 1 (rhTPP1) (EMEA-001362-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/600723/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2015-ema-decision-18-september-2015-agreement-paediatric-investigation-plan-refusal-deferral-recombinant-human-tripeptidyl-peptidase-1-rhtpp1-emea-001362-pip01-12-m02_en.pdf"},
    {"id":"17968","name":"P/0062/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for fidaxomicin (Dificlir), (EMEA-000636-PIP01-09-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/107498/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-fidaxomicin-dificlir-emea-000636-pip01-09-m07_en.pdf"},
    {"id":"17969","name":"P/184/2009: European Medicines Agency decision of 7 September 2009 \n\non the agreement of a Paediatric Investigation Plan and on the granting of a waiver for human normal immunoglobulin (EMEA-000558-PIP01-09) in accordanc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/525379/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-184-2009-european-medicines-agency-decision-7-september-2009-agreement-paediatric-investigation-plan-granting-waiver-human-normal-immunoglobulin-emea-000558-pip01-09-accordanc_en.pdf"},
    {"id":"17974","name":"P/0263/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sunitinib (Sutent),\n\n(EMEA-000342-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-25T17:00:00Z","last_updated_date":"2017-10-25T17:00:00Z","reference_number":"EMA/493111/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-sunitinib-sutent-emea-000342-pip01-08-m06_en.pdf"},
    {"id":"18012","name":"P/0084/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for vamorolone\n\n(EMEA-001794-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/88205/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-vamorolone-emea-001794-pip02-16_en.pdf"},
    {"id":"18026","name":"P/0137/2013: EMA decision of 21 June 2013 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira), (EMEA-000366-PIP02-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T12:00:00Z","last_updated_date":"2013-07-23T12:00:00Z","reference_number":"EMA/306479/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2013-ema-decision-21-june-2013-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip02-09-m02_en.pdf"},
    {"id":"18040","name":"P/0314/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ceftazidime /\n\navibactam (Zavicefta), (EMEA-001313-PIP01-12-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T17:23:00Z","last_updated_date":"2018-02-15T17:23:00Z","reference_number":"EMA/679216/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-zavicefta-emea-001313-pip01-12-m06_en.pdf"},
    {"id":"18046","name":"P/0188/2012: EMA decision of 24 August 2012 on the granting of a product specific waiver for amlodipine (besilate) / lisinopril (dihydrate) / rosuvastatin (calcium), (EMEA-001291-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T02:00:00Z","last_updated_date":"2012-09-18T02:00:00Z","reference_number":"EMA/472452/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2012-ema-decision-24-august-2012-granting-product-specific-waiver-amlodipine-besilate-lisinopril-dihydrate-rosuvastatin-calcium-emea-001291-pip01-12_en.pdf"},
    {"id":"18047","name":"P/0290/2017: EMA decision of 31 October 2017 on the granting of a product specific waiver for bisoprolol (fumarate) / perindopril arginine / amlodipine\n\n(EMEA-002173-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/565635/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2017-ema-decision-31-october-2017-granting-product-specific-waiver-bisoprolol-fumarate-perindopril-arginine-amlodipine-emea-002173-pip01-17_en.pdf"},
    {"id":"18056","name":"P/0294/2015: EMA decision of 3 December 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for emtricitabine / tenofovir disoproxil fumarate (Truvad...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/785816/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2015-ema-decision-3-december-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-emtricitabine-tenofovir-disoproxil-fumarate-truvad_en.pdf"},
    {"id":"18059","name":"P/215/2011: EMA decision of 9 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for split influenza virus,\n\ninactivated containing antigen equivalent to A/California/7/2009 (H1...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/698105/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-215-2011-ema-decision-9-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigen-equivalent-california-7-2009-h1_en.pdf"},
    {"id":"18071","name":"P/0068/2013: EMA decision of 26 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anacetrapib (EMEA-001100-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/85749/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2013-ema-decision-26-march-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anacetrapib-emea-001100-pip01-10_en.pdf"},
    {"id":"18102","name":"P/0254/2013: EMA decision of 30 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for purified antigen fractions of inactivated split virion Influenza A/Indonesia/05/2005(H5N1) l...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/595216/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2013-ema-decision-30-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-purified-antigen-fractions-inactivated-split-virion-influenza-indonesia-05-2005h5n1-l_en.pdf"},
    {"id":"18103","name":"P/0040/2017: European Medicines Agency decision of 31 January 2017 on the granting of a product specific waiver for apolipoprotein A-1 (EMEA-002040-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/38346/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2017-european-medicines-agency-decision-31-january-2017-granting-product-specific-waiver-apolipoprotein-1-emea-002040-pip01-16_en.pdf"},
    {"id":"18134","name":"P/0145/2016: EMA decision of 23 May 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for KEOC liquid extract ethanolic 30 per cent (w/w) of Allium...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-18T02:00:00Z","last_updated_date":"2016-07-18T02:00:00Z","reference_number":"EMA/269232/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2016-ema-decision-23-may-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-keoc-liquid-extract-ethanolic-30-cent-w-w-allium_en.pdf"},
    {"id":"18136","name":"P/0141/2012: EMA decision of 23 July 2012 on the granting of a product specific waiver for ezetimibe / simvastatin (Inegy and associated names) (EMEA-000006-PIP03-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T17:15:00Z","last_updated_date":"2012-08-22T17:15:00Z","reference_number":"EMA/436977/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2012-ema-decision-23-july-2012-granting-product-specific-waiver-ezetimibe-simvastatin-inegy-associated-names-emea-000006-pip03-12_en.pdf"},
    {"id":"18145","name":"P/0138/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dalbavancin (Xydalba), (EMEA-000016-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/364959/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-dalbavancin-xydalba-emea-000016-pip01-07-m04_en.pdf"},
    {"id":"18179","name":"P/0043/2018: EMA decision of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for pembrolizumab\n\n(Keytruda), (EMEA-001474-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"EMA/75530/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2018-ema-decision-16-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-pembrolizumab-keytruda-emea-001474-pip01-13-m01_en.pdf"},
    {"id":"18185","name":"P/0065/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for cobimetinib\n\n(Cotellic), (EMEA-001425-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/137082/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-cobimetinib-cotellic-emea-001425-pip01-13-m02_en.pdf"},
    {"id":"18196","name":"P/184/2010: European Medicines Agency decision of 24 September 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for influenza virus surface antige...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/540825/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-184-2010-european-medicines-agency-decision-24-september-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-influenza-virus-surface-antige_en.pdf"},
    {"id":"18217","name":"P/0014/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga), (EMEA-000597-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/792649/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip02-10-m03_en.pdf"},
    {"id":"18268","name":"P/0006/2013: EMA decision of 21 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for ceftaroline fosamil (Zinforo), (EMEA-000769-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T18:30:00Z","last_updated_date":"2013-04-03T18:30:00Z","reference_number":"EMA/18212/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2013-ema-decision-21-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-ceftaroline-fosamil-zinforo-emea-000769-pip01-09-m03_en.pdf"},
    {"id":"18275","name":"P/0161/2015: EMA decision of 9 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin (Forxiga), (EMEA-000694-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-28T02:00:00Z","last_updated_date":"2015-07-28T02:00:00Z","reference_number":"EMA/440468/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2015-ema-decision-9-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-forxiga-emea-000694-pip01-09-m05_en.pdf"},
    {"id":"18325","name":"P/182/2009: European Medicines Agency decision of 7 September 2009 on the granting of a product specific waiver for paracetamol / opium prepared (EMEA-000514-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of t...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/523544/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-182-2009-european-medicines-agency-decision-7-september-2009-granting-product-specific-waiver-paracetamol-opium-prepared-emea-000514-pip01-08-accordance-regulation-ec-no-1901-2006-t_en.pdf"},
    {"id":"18335","name":"P/0223/2016: EMA decision of 12 August 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for 3-[[5-chloro-\n\n1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl]methyl]-1-(2,2,2-trifluoroet...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/501690/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2016-ema-decision-12-august-2016-agreement-paediatric-investigation-plan-granting-deferral-3-5-chloro-1-3-methylsulfonylpropyl-1h-indol-2-ylmethyl-1-222-trifluoroet_en.pdf"},
    {"id":"18414","name":"P/176/2010: European Medicines Agency decision of 20 September 2010 on the granting of a product specific waiver for (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrilephosphate (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/547266/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-176-2010-european-medicines-agency-decision-20-september-2010-granting-product-specific-waiver-r-34-7h-pyrrolo23-dpyrimidin-4-yl-1h-pyrazol-1-yl-3-cyclopentylpropanenitrilephosphate-emea-0_en.pdf"},
    {"id":"18420","name":"P/69/2009: European Medicines Agency decision of 20 April 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for calcipotriol hydrate / hydrocortiso...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-06-10T02:00:00Z","last_updated_date":"2009-06-10T02:00:00Z","reference_number":"EMEA/231675/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-69-2009-european-medicines-agency-decision-20-april-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-calcipotriol-hydrate-hydrocortiso_en.pdf"},
    {"id":"18423","name":"P/0386/2017: EMA decision of 19 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for fremanezumab (EMEA-001877-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/759545/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0386-2017-ema-decision-19-december-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fremanezumab-emea-001877-pip03-17_en.pdf"},
    {"id":"18447","name":"P/325/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for anagrelide (Xagrid) (EMEA-000720-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/776034/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-325-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-anagrelide-xagrid-emea-000720-pip01-09-m02_en.pdf"},
    {"id":"18470","name":"P/0363/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (EMEA-\n\n001741-PIP01-14-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T13:05:00Z","last_updated_date":"2018-03-02T13:05:00Z","reference_number":"EMA/709763/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0363-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-emea-001741-pip01-14-m01_en.pdf"},
    {"id":"18488","name":"P/0318/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for telavancin (hydrochloride) (Vibativ), (EMEA-000239-PIP01-08-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T09:55:00Z","last_updated_date":"2017-01-30T09:55:00Z","reference_number":"EMA/741979/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-telavancin-hydrochloride-vibativ-emea-000239-pip01-08-m02_en.pdf"},
    {"id":"18500","name":"P/0356/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Fc- and CDRmodified\n\nhumanised monoclonal antibody against C5 (EMEA-002077-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/724510/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0356-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-fc-cdrmodified-humanised-monoclonal-antibody-against-c5-emea-002077-pip01-16-m01_en.pdf"},
    {"id":"18506","name":"P/0304/2017: EMA decision of 31 October 2017 on the granting of a product specific waiver for meldonium (dihydrate) (EMEA-002212-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/666635/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2017-ema-decision-31-october-2017-granting-product-specific-waiver-meldonium-dihydrate-emea-002212-pip01-17_en.pdf"},
    {"id":"18527","name":"P/0109/2016: EMA decision of 15 April 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human alpha-galactosidase A (PRX 102) (EMEA...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/203451/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2016-ema-decision-15-april-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-alpha-galactosidase-prx-102-emea_en.pdf"},
    {"id":"18533","name":"P/0180/2016: EMA decision of of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for solithromycin (EMEA-\n\n001581-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:18:00Z","last_updated_date":"2016-09-22T16:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-solithromycin-emea-001581-pip01-13-m03_en.pdf"},
    {"id":"18548","name":"P/0072/2014: EMA decision of 1 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for concentrate of proteolytic enzymes in bromelain (NexoBrid), (EMEA-000142-PIP02-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/113587/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2014-ema-decision-1-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-concentrate-proteolytic-enzymes-bromelain-nexobrid-emea-000142-pip02-09-m03_en.pdf"},
    {"id":"18549","name":"P/137/2011: EMA decision of 10 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium sa...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/425992/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-137-2011-ema-decision-10-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-s-3-oh-desazadesferrithiocin-polyether-magnesium-sa_en.pdf"},
    {"id":"18573","name":"P/0062/2012: EMA decision of 28 March 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for ustekinumab (Stelara), (EMEA-000311-PIP03-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"EMA/182841/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2012-ema-decision-28-march-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ustekinumab-stelara-emea-000311-pip03-11_en.pdf"},
    {"id":"18579","name":"P/186/2011: EMA decision of 2 August 2011 on the granting of a product specific waiver for aflibercept (EMEA-000236-PIP03-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/500870/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-186-2011-ema-decision-2-august-2011-granting-product-specific-waiver-aflibercept-emea-000236-pip03-11_en.pdf"},
    {"id":"18594","name":"P/0037/2016: EMA decision of 12 February 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human antibody against the respiratory s...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/2822/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2016-ema-decision-12-february-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-antibody-against-respiratory-s_en.pdf"},
    {"id":"18597","name":"P/0095/2012: EMA decision of 30 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for clevidipine butyrate (Cleviprex and associated names) (EMEA-000282-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/274427/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2012-ema-decision-30-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-clevidipine-butyrate-cleviprex-associated-names-emea-000282-pip01-08-m01_en.pdf"},
    {"id":"18603","name":"P/43/2012: EMA decision of 28 February 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for elacytarabine (EMEA-001121-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/130187/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-43-2012-ema-decision-28-february-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-elacytarabine-emea-001121-pip01-10_en.pdf"},
    {"id":"18617","name":"P/0064/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for aztreonam (Cayston) (EMEA-000827-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/138297/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-aztreonam-cayston-emea-000827-pip01-09-m04_en.pdf"},
    {"id":"18633","name":"P/252/2010:  EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-BAFF monoclonal antibody (LY2127399), (EMEA-000...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/716619/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-252-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-baff-monoclonal-antibody-ly2127399-emea-000_en.pdf"},
    {"id":"18694","name":"P/143/2011: EMA decision of 9 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chemically modified extract of trees pollen from birch and...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/430651/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-143-2011-ema-decision-9-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chemically-modified-extract-trees-pollen-birch_en.pdf"},
    {"id":"18696","name":"P/0285/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for alipogene tiparvovec (Glybera), (EMEA-000292-PIP01-08-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T11:35:00Z","last_updated_date":"2017-01-23T11:35:00Z","reference_number":"EMA/639652/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-alipogene-tiparvovec-glybera-emea-000292-pip01-08-m03_en.pdf"},
    {"id":"18704","name":"P/128/2009: European Medicines Agency decision of 14 July 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for rituximab (Mabthera) (EMEA-000308-PIP01-08) in accordance with Regula...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/427084/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-128-2009-european-medicines-agency-decision-14-july-2009-agreement-paediatric-investigation-plan-granting-waiver-rituximab-mabthera-emea-000308-pip01-08-accordance-regula_en.pdf"},
    {"id":"18710","name":"P/21/2008: European medicines agency decision of 28 April 2008 on the application for product specific waiver for Roflumilast PIP number EMEA-000113-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the Europea...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-05-16T02:00:00Z","last_updated_date":"2008-05-16T02:00:00Z","reference_number":"EMEA/211804/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-21-2008-european-medicines-agency-decision-28-april-2008-application-product-specific-waiver-roflumilast-pip-number-emea-000113-pip01-07-accordance-regulation-ec-no-1901-2006-europea_en.pdf"},
    {"id":"18714","name":"P/0341/2016: EMA decision of 5 December 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for galcanezumab (EMEA-001860-PIP03-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/757981/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0341-2016-ema-decision-5-december-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-galcanezumab-emea-001860-pip03-16_en.pdf"}    {"id":"18724","name":"P/0402/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for inotuzumab\n\nozogamicin (Besponsa) (EMEA-001429-PIP01-13-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T13:05:00Z","last_updated_date":"2018-03-02T13:05:00Z","reference_number":"EMA/801040/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0402-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-inotuzumab-ozogamicin-besponsa-emea-001429-pip01-13-m02_en.pdf"},
    {"id":"18730","name":"P/0039/2014: EMA decision of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (EMEA-000783-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/797040/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2014-ema-decision-5-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-dulaglutide-emea-000783-pip01-09-m01_en.pdf"},
    {"id":"18737","name":"P/0029/2017: EMA decision of 1 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for 4-amino-1-[5-chloro-2,5-dideoxy-2-fluoro-3-O-(2-methylpropanoyl)-4-[[(2-methylpropanoyl)oxy ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/23023/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2017-ema-decision-1-february-2017-acceptance-modification-agreed-paediatric-investigation-plan-4-amino-1-5-chloro-25-dideoxy-2-fluoro-3-o-2-methylpropanoyl-4-2-methylpropanoyloxy_en.pdf"},
    {"id":"18742","name":"P/0194/2014: EMA decision of 8 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (EDURANT), (EMEA-000317-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/439626/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2014-ema-decision-8-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-edurant-emea-000317-pip01-08-m06_en.pdf"},
    {"id":"18748","name":"P/0230/2013: EMA decision of 23 September 2013 on the granting of a product specific waiver for perindopril (erbumine) / amlodipin (besylate), (EMEA-001467-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/561630/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2013-ema-decision-23-september-2013-granting-product-specific-waiver-perindopril-erbumine-amlodipin-besylate-emea-001467-pip01-13_en.pdf"},
    {"id":"18766","name":"P/0046/2017: EMA decision of 17 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat),\n\n(EMEA-000402-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-18T02:00:00Z","last_updated_date":"2017-04-18T02:00:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2017-ema-decision-17-february-2017-acceptance-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip02-11-m03_en.pdf"},
    {"id":"18771","name":"P/0146/2012: EMA decision of 24 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tobramycin (Tobi Podhaler), (EMEA-000184-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/471216/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2012-ema-decision-24-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-tobramycin-tobi-podhaler-emea-000184-pip01-08-m01_en.pdf"},
    {"id":"18775","name":"P/0094/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for zanamivir (Relenza), (EMEA-001318-PIP01-12-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/281565/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-zanamivir-relenza-emea-001318-pip01-12-m01_en.pdf"},
    {"id":"18777","name":"P/148/2011: EMA decision of 9 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chemically modified extract of grass pollen from Holcus la...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/430667/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-148-2011-ema-decision-9-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chemically-modified-extract-grass-pollen-holcus-la_en.pdf"},
    {"id":"18782","name":"P/0233/2013: EMA decision of 23 September 2013 on the granting of a product specific waiver for metformin / rosuvastatin, (EMEA-001479-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/561761/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2013-ema-decision-23-september-2013-granting-product-specific-waiver-metformin-rosuvastatin-emea-001479-pip01-13_en.pdf"},
    {"id":"18788","name":"P/0202/2014: EMA decision of 8 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for mifepristone (EMEA–001292-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/439791/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2014-ema-decision-8-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-mifepristone-emea-001292-pip01-12-m01_en.pdf"},
    {"id":"18790","name":"P/123/2010: European medicines agency decision of 28 July 2010 on the acceptance of a modification of an agreed paediatric investigation plan for 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid, (EMEA-000115-P...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/472907/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-123-2010-european-medicines-agency-decision-28-july-2010-acceptance-modification-agreed-paediatric-investigation-plan-3-5-2-fluorophenyl-124oxadiazole-3-yl-benzoic-acid-emea-000115-p_en.pdf"},
    {"id":"18792","name":"P/52/2011: EMA decision of 4 March 2011 on the acceptance of a modification of an agreed paediatric investigation plan for decitabine (EMEA-000555-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 of the Euro...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/140366/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-52-2011-ema-decision-4-march-2011-acceptance-modification-agreed-paediatric-investigation-plan-decitabine-emea-000555-pip01-09-m01-accordance-regulation-ec-no-1901-2006-euro_en.pdf"},
    {"id":"18806","name":"P/0307/2014: EMA decision of 24 November 2014 on the granting of a product specific waiver for abaloparatide (EMEA-001667-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/624747/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2014-ema-decision-24-november-2014-granting-product-specific-waiver-abaloparatide-emea-001667-pip01-14_en.pdf"},
    {"id":"18817","name":"P/0141/2014: EMA decision of 28 May 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tasimelteon (EMEA-001531-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-25T02:00:00Z","last_updated_date":"2014-06-25T02:00:00Z","reference_number":"EMA/283015/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2014-ema-decision-28-may-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tasimelteon-emea-001531-pip01-13_en.pdf"},
    {"id":"18862","name":"P/0066/2018: EMA decision of 16 March 2018 on the granting of a product- specific waiver for venglustat (EMEA-001716-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/87971/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2018-ema-decision-16-march-2018-granting-product-specific-waiver-venglustat-emea-001716-pip02-17_en.pdf"},
    {"id":"18863","name":"P/311/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of grass and birch pollen (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/773521/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-311-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-grass-birch-pollen_en.pdf"},
    {"id":"18892","name":"P/14/2011:  EMA decision of 3 January 2011 on the review of a granted waiver for influenza virus type A, H3N2, influenza virus type A, H1N1, influenza virus type B (Fluenz) (EMEA-000249-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/717956/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-14-2011-ema-decision-3-january-2011-review-granted-waiver-influenza-virus-type-h3n2-influenza-virus-type-h1n1-influenza-virus-type-b-fluenz-emea-000249-pip01-10_en.pdf"},
    {"id":"18915","name":"P/0310/2014: EMA decision of 25 November 2014 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin (Forxiga), (EMEA-000694-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/640509/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0310-2014-ema-decision-25-november-2014-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-forxiga-emea-000694-pip01-09-m04_en.pdf"},
    {"id":"18928","name":"P/0188/2015: EMA decision of 4 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for L-asparaginase encapsulated in erythrocytes (EMEA-000341-PIP02-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/571249/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2015-ema-decision-4-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-l-asparaginase-encapsulated-erythrocytes-emea-000341-pip02-09-m02_en.pdf"},
    {"id":"18942","name":"P/0320/2013: EMA decision of 19 December 2013 on the granting of a product specific waiver for amlodipine (besilate) / olmesartan (medoxomil) (EMEA-001538-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-05T01:00:00Z","last_updated_date":"2014-02-05T01:00:00Z","reference_number":"EMA/698367/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2013-ema-decision-19-december-2013-granting-product-specific-waiver-amlodipine-besilate-olmesartan-medoxomil-emea-001538-pip01-13_en.pdf"},
    {"id":"18948","name":"P/0114/2014: EMA decision of 6 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for romiplostim (Nplate) (EMEA-000653-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-11T19:00:00Z","last_updated_date":"2014-06-11T19:00:00Z","reference_number":"EMA/232690/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0114-2014-ema-decision-6-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-romiplostim-nplate-emea-000653-pip01-09-m04_en.pdf"},
    {"id":"18991","name":"P/0191/2017: EMA decision of 30 June 2017 on the granting of a product-specific waiver for abacavir / lamivudine / efavirenz (EMEA-002114-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/398222/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2017-ema-decision-30-june-2017-granting-product-specific-waiver-abacavir-lamivudine-efavirenz-emea-002114-pip01-16_en.pdf"},
    {"id":"19007","name":"P/0091/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tapenta...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/188338/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapenta_en.pdf"},
    {"id":"19012","name":"P/0101/2012: EMA decision of 30 May 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for poly (oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, 28B-est...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T18:00:00Z","last_updated_date":"2012-06-25T18:00:00Z","reference_number":"EMA/304282/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2012-ema-decision-30-may-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-poly-oxy-12-ethanediyl-i-hydro-i0-methoxy-28b-est_en.pdf"},
    {"id":"19013","name":"P/0264/2016: EMA decision of 5 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tedizolid (phosphate) (Sivextro), (EMEA-001379-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/576579/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2016-ema-decision-5-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-tedizolid-phosphate-sivextro-emea-001379-pip01-12-m02_en.pdf"},
    {"id":"19031","name":"P/0049/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for macitentan (Opsumit) (EMEA-001032-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/133062/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-macitentan-opsumit-emea-001032-pip01-10-m02_en.pdf"},
    {"id":"19059","name":"P/0185/2012: EMA decision of 21 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for amikacin (sulfate),\n\n(EMEA-000525-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/533009/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2012-ema-decision-21-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-amikacin-sulfate-emea-000525-pip01-08-m01_en.pdf"},
    {"id":"19093","name":"P/0147/2016: EMA decision of 14 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for darbepoetin alfa\n\n(Aranesp), (EMEA-000329-PIP02-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/347579/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2016-ema-decision-14-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-darbepoetin-alfa-aranesp-emea-000329-pip02-09-m05_en.pdf"},
    {"id":"19106","name":"P/0145/2013: EMA decision of 3 July 2013on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cebranopadol (EMEA-001305-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-09T16:30:00Z","last_updated_date":"2013-08-09T16:30:00Z","reference_number":"EMA/306400/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2013-ema-decision-3-july-2013on-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cebranopadol-emea-001305-pip01-12_en.pdf"},
    {"id":"19117","name":"P/0299/2012: EMA decision of 18 December 2012 on the granting of a product-specific waiver for skeletal-muscle-derived cells (EMEA-001345-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T14:00:00Z","last_updated_date":"2013-02-11T14:00:00Z","reference_number":"EMA/737210/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2012-ema-decision-18-december-2012-granting-product-specific-waiver-skeletal-muscle-derived-cells-emea-001345-pip01-12_en.pdf"},
    {"id":"19152","name":"P/0246/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for volasertib (EMEA-000674-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/701048/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-volasertib-emea-000674-pip02-11-m01_en.pdf"},
    {"id":"19168","name":"P/0186/2012: EMA decision of 21 August 2012 on the granting of a product specific waiver for sitagliptin / atorvastatin (EMEA-001275-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T02:00:00Z","last_updated_date":"2012-09-18T02:00:00Z","reference_number":"EMA/472398/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2012-ema-decision-21-august-2012-granting-product-specific-waiver-sitagliptin-atorvastatin-emea-001275-pip01-12_en.pdf"},
    {"id":"19191","name":"P/0090/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for rivaroxaban (Xarelto), (EMEA-000430-PIP01-08-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/281916/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-rivaroxaban-xarelto-emea-000430-pip01-08-m07_en.pdf"},
    {"id":"19202","name":"P/0088/2013: EMA decision of 29 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for nilotinib (Tasigna), (EMEA-000290-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/201644/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2013-ema-decision-29-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-nilotinib-tasigna-emea-000290-pip01-08-m03_en.pdf"},
    {"id":"19212","name":"P/121/2011: EMA decision of 7 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for human normal immunoglobulin (Gammaplex), (EMEA-000830-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/355119/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-121-2011-ema-decision-7-june-2011-agreement-paediatric-investigation-plan-granting-deferral-human-normal-immunoglobulin-gammaplex-emea-000830-pip02-10_en.pdf"},
    {"id":"19214","name":"P/217/2009: European Medicines Agency decision of 30 October 2009 on the refusal of a product specific waiver for chloroprocaine hydrochloride (EMEA-000639-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/617544/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-217-2009-european-medicines-agency-decision-30-october-2009-refusal-product-specific-waiver-chloroprocaine-hydrochloride-emea-000639-pip01-09-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"19232","name":"P/75/2009: European Medicines Agency decision of 20 April 2009 on the granting of a product specific waiver for pasireotide (EMEA-000464-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliamen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-06-10T02:00:00Z","last_updated_date":"2009-06-10T02:00:00Z","reference_number":"EMEA/218895/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-75-2009-european-medicines-agency-decision-20-april-2009-granting-product-specific-waiver-pasireotide-emea-000464-pip01-08-accordance-regulation-ec-no-1901-2006-european-parliamen_en.pdf"},
    {"id":"19259","name":"P/0119/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD4+ and\n\nCD8+ T cells expressing a CD19-specific chimeric antigen receptor (JCAR01...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/141789/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd4-cd8-t-cells-expressing-cd19-specific-chimeric-antigen-receptor-jcar01_en.pdf"},
    {"id":"19288","name":"P/248/2010:  EMA decision of 26 November 2010\n\non the agreement of a PIP and on the granting of a deferral and a waiver for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of equal ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/709902/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-248-2010-ema-decision-26-november-2010-agreement-pip-granting-deferral-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergic-extract-equal_en.pdf"},
    {"id":"19291","name":"P/0139/2012: EMA decision of 20 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for serelaxin\n\n(EMEA-001168-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T17:15:00Z","last_updated_date":"2012-08-22T17:15:00Z","reference_number":"EMA/452226/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2012-ema-decision-20-july-2012-agreement-paediatric-investigation-plan-granting-deferral-serelaxin-emea-001168-pip01-11_en.pdf"},
    {"id":"19310","name":"P/0213/2013: EMA decision of 3 September 2013 on the refusal of a product-specific waiver for acotiamide (EMEA-001461-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/515460/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2013-ema-decision-3-september-2013-refusal-product-specific-waiver-acotiamide-emea-001461-pip01-13_en.pdf"},
    {"id":"19339","name":"P/0052/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for basmisanil (EMEA-001506-PIP02-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/133060/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-basmisanil-emea-001506-pip02-14-m01_en.pdf"},
    {"id":"19349","name":"P/0093/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for telaprevir (EMEA-\n\n000196-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/181808/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-telaprevir-emea-000196-pip01-08-m04_en.pdf"},
    {"id":"19357","name":"P/0178/2015: EMA decision of 7 August 2015 on the granting of a product-specific waiver for carvedilol / ivabradine (hydrochloride) (EMEA-001743-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"EMA/473695/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2015-ema-decision-7-august-2015-granting-product-specific-waiver-carvedilol-ivabradine-hydrochloride-emea-001743-pip01-14_en.pdf"},
    {"id":"19365","name":"P/0234/2013: EMA decision of 24 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab (EMEA-000069-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/567191/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2013-ema-decision-24-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-emea-000069-pip02-10-m02_en.pdf"},
    {"id":"19369","name":"P/0273/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for pollen from Betula verrucosa (EMEA-000846-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/766485/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-pollen-betula-verrucosa-emea-000846-pip01-10-m01_en.pdf"},
    {"id":"19377","name":"P/116/2010: European Medicines Agency decision of 7 July 2010 on the refusal of a product specific waiver for sodium sulfate/potassium sulfate/magnesium sulfate heptahydrate (EMEA-000816-PIP01-09) in accordance with Regu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/343627/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-116-2010-european-medicines-agency-decision-7-july-2010-refusal-product-specific-waiver-sodium-sulfate-potassium-sulfate-magnesium-sulfate-heptahydrate-emea-000816-pip01-09-accordance-regu_en.pdf"},
    {"id":"19393","name":"P/0241/2016: EMA decision of 9 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for lubiprostone\n\n(Amitiza), (EMEA-000245-PIP01-08-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/536151/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2016-ema-decision-9-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-lubiprostone-amitiza-emea-000245-pip01-08-m03_en.pdf"},
    {"id":"19397","name":"P/0389/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation\n\nfactor X (Coagadex), (EMEA-000971-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/797364/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0389-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-human-coagulation-factor-x-coagadex-emea-000971-pip01-10-m03_en.pdf"},
    {"id":"19399","name":"P/0072/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-001501-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-05-17T12:40:00Z","last_updated_date":"2016-05-17T12:40:00Z","reference_number":"EMA/107921/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-emea-001501-pip01-13-m02_en.pdf"},
    {"id":"19408","name":"P/0063/2012: EMA decision of 28 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for decitabine (EMEA-\n\n000555-PIP01-09-M02","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T17:42:00Z","last_updated_date":"2012-04-20T17:42:00Z","reference_number":"EMA/201836/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2012-ema-decision-28-march-2012-acceptance-modification-agreed-paediatric-investigation-plan-decitabine-emea-000555-pip01-09-m02_en.pdf"},
    {"id":"19427","name":"P/0361/2016: EMA decision of 21 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for allantoin (EMEA-\n\n001590-PIP01-13-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T17:48:00Z","last_updated_date":"2017-02-03T17:48:00Z","reference_number":"EMA/757975/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0361-2016-ema-decision-21-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-allantoin-emea-001590-pip01-13-m03_en.pdf"},
    {"id":"19433","name":"P/0041/2017: European Medicines Agency decision of 31 January 2017 on the granting of a product specific waiver for doxorubicin (hydrochloride) (EMEA-002043-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/38351/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2017-european-medicines-agency-decision-31-january-2017-granting-product-specific-waiver-doxorubicin-hydrochloride-emea-002043-pip01-16_en.pdf"},
    {"id":"19473","name":"P/0206/2015: EMA decision of 7 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for odanacatib (EMEA-001123-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/578832/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2015-ema-decision-7-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-odanacatib-emea-001123-pip01-11-m02_en.pdf"},
    {"id":"19476","name":"P/253/2011: EMA decision of 26 October 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (1R, 4S, 5S, 6S)-4-[[(2s)-2-amino-4-(methylthio)-1-oxo...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T01:00:00Z","last_updated_date":"2011-11-29T01:00:00Z","reference_number":"EMA/777093/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-253-2011-ema-decision-26-october-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-1r-4s-5s-6s-4-2s-2-amino-4-methylthio-1-oxo_en.pdf"},
    {"id":"19490","name":"P/0248/2016: EMA decision of 5 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for cerliponase alfa\n\n(EMEA-001362-PIP01-12-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/580078/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2016-ema-decision-5-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-cerliponase-alfa-emea-001362-pip01-12-m03_en.pdf"},
    {"id":"19504","name":"P/0274/2017: EMA decision of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir alafenamide (as fumarate) (Vemlidy), (EMEA-001584-PIP01-13-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/574570/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2017-ema-decision-4-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-alafenamide-fumarate-vemlidy-emea-001584-pip01-13-m02_en.pdf"},
    {"id":"19517","name":"P/0030/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for birch pollen extract (Betula verrucosa) (EMEA-001879-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"EMA/848794/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-birch-pollen-extract-betula-verrucosa-emea-001879-pip01-15-m01_en.pdf"},
    {"id":"19519","name":"P/0169/2016: EMA decision of 17 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for sodium sulphate /\n\npotassium sulphate / magnesium sulphate heptahydrate (Izinova and associated...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-26T02:00:00Z","last_updated_date":"2016-10-26T02:00:00Z","reference_number":"EMA/385684/2016 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2016-ema-decision-17-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-sodium-sulphate-potassium-sulphate-magnesium-sulphate-heptahydrate-izinova-associated_en.pdf"},
    {"id":"19542","name":"P/0279/2013: EMA decision of 8 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tapen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-12-06T01:00:00Z","last_updated_date":"2013-12-06T01:00:00Z","reference_number":"EMA/648052/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2013-ema-decision-8-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapen_en.pdf"},
    {"id":"19545","name":"P/73/2011: EMA decision of 5 April 2011 on the acceptance of a modification of an agreed Paediatric Investigation Plan for 13 valent pneumococcal polysaccharide conjugate vaccine (EMEA-000036-PIP01-07-\n\nM05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"P/73/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-73-2011-ema-decision-5-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-13-valent-pneumococcal-polysaccharide-conjugate-vaccine-emea-000036-pip01-07-m05_en.pdf"},
    {"id":"19551","name":"P/44/2010: European Medicines Agency decision of 31 March 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Insulin degludec (EMEA-000456-PIP01...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/190278/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-44-2010-european-medicines-agency-decision-31-march-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-insulin-degludec-emea-000456-pip01_en.pdf"},
    {"id":"19569","name":"P/65/2010: European Medicines Agency decision on the granting of a product specific waiver for octocog alfa (Advate) (EMEA-000358-PIP02-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/236895/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-65-2010-european-medicines-agency-decision-granting-product-specific-waiver-octocog-alfa-advate-emea-000358-pip02-09_en.pdf"},
    {"id":"19572","name":"P/0221/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir alafenamide (as fumarate), (EMEA-001584-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/513429/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-alafenamide-fumarate-emea-001584-pip01-13-m01_en.pdf"},
    {"id":"19580","name":"P/204/2011: EMA decision of 26 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for riociguat (EMEA-000718-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/645313/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-204-2011-ema-decision-26-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-riociguat-emea-000718-pip01-09-m01_en.pdf"},
    {"id":"19595","name":"P/0082/2014: EMA decision of 31 March 2014 on the agreement of a paediatric investigation plan for RNA,[2'-O-(2-methoxyethyl)](P-thio)(m5U- m5C-A- m5C-m5U-m5U-m5U- m5C-A-m5U-A-A-m5U-G- m5C-m5U-G-G) (ISIS 396443) (EMEA-00...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2014-05-13T02:00:00Z","reference_number":"EMA/103545/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2014-ema-decision-31-march-2014-agreement-paediatric-investigation-plan-rna2-o-2-methoxyethylp-thiom5u-m5c-m5c-m5u-m5u-m5u-m5c-m5u-m5u-g-m5c-m5u-g-g-isis-396443-emea-00_en.pdf"},
    {"id":"19603","name":"P/0331/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+\n\nhematopoietic stem cells transduced ex vivo with EFS lentiviral vector enc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-20T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"EMA/666039/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0331-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-hematopoietic-stem-cells-transduced-ex-vivo-efs-lentiviral-vector-enc_en.pdf"},
    {"id":"19616","name":"P/178/2010: European Medicines Agency decision of 24 September 2010 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (EMEA-000176-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/582773/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-178-2010-european-medicines-agency-decision-24-september-2010-acceptance-modification-agreed-paediatric-investigation-plan-colistimethate-sodium-emea-000176-pip01-07-m02_en.pdf"},
    {"id":"19666","name":"P/50/2011: EMA decision of 4 March 2011 on the granting of a product specific waiver for lenalidomide (Revlimid) (EMEA 000371-PIP02-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of th...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/157193/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-50-2011-ema-decision-4-march-2011-granting-product-specific-waiver-lenalidomide-revlimid-emea-000371-pip02-09-accordance-regulation-ec-no-1901-2006-european-parliament-th_en.pdf"},
    {"id":"19671","name":"P/0128/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (phosphate monohydrate) (Xelevia) (EMEA-000471-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/295715/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-phosphate-monohydrate-xelevia-emea-000471-pip01-08-m02_en.pdf"},
    {"id":"19677","name":"P/0214/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for vonicog alfa (EMEA-001164-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/591387/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-vonicog-alfa-emea-001164-pip01-11-m01_en.pdf"},
    {"id":"19679","name":"P/0052/2014: EMA decision of 7 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for glycopyrronium (bromide) (EMEA-001366-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/58638/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2014-ema-decision-7-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-glycopyrronium-bromide-emea-001366-pip01-12-m01_en.pdf"},
    {"id":"19697","name":"P/0313/2014: EMA decision of 26 November 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pandemic live attenuated influenza virus (H5N1) (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/667770/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2014-ema-decision-26-november-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pandemic-live-attenuated-influenza-virus-h5n1-eme_en.pdf"},
    {"id":"19707","name":"P/125/2008: European Medicines Agency decision of 5 December 2008 on the application for agreement of a Paediatric Investigation Plan for fingolimod hydrochloride (EMEA-000087-PIP01-07) in accordance with Regulation (EC)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/637148/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-125-2008-european-medicines-agency-decision-5-december-2008-application-agreement-paediatric-investigation-plan-fingolimod-hydrochloride-emea-000087-pip01-07-accordance-regulation-ec_en.pdf"},
    {"id":"19714","name":"P/158/2009: European Medicines Agency decision of 11 August 2009 on the granting of a product specific waiver for desvenlafaxine succinate monohydrate (EMEA-000523-PIP01-08) in accordance with Regulation (EC) No 1901/200...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/495247/200","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-158-2009-european-medicines-agency-decision-11-august-2009-granting-product-specific-waiver-desvenlafaxine-succinate-monohydrate-emea-000523-pip01-08-accordance-regulation-ec-no-1901-200_en.pdf"},
    {"id":"19719","name":"P/0304/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for Neisseria meningitidis serogroup B recombinant lipoprotein (rLP2086; subfamily A; Escherich...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/785818/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-b-recombinant-lipoprotein-rlp2086-subfamily-escherich_en.pdf"},
    {"id":"19730","name":"P/104/2011: EMA decision of 3 May 2011 on the acceptance of a modification of an agreed paediatric investigation plan for lisdexamfetamine\n\ndimesylate (EMEA-000553-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-07T02:00:00Z","last_updated_date":"2011-06-07T02:00:00Z","reference_number":"EMA/343550/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-104-2011-ema-decision-3-may-2011-acceptance-modification-agreed-paediatric-investigation-plan-lisdexamfetamine-dimesylate-emea-000553-pip01-09-m02_en.pdf"},
    {"id":"19731","name":"P/0116/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga), (EMEA-000597-PIP02-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/296253/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip02-10-m04_en.pdf"},
    {"id":"19747","name":"P/280/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allergen extract of corylus avellana pollen (EMEA-000...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/754048/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-280-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extract-corylus-avellana-pollen-emea-000_en.pdf"},
    {"id":"19768","name":"P/0041/2016: EMA decision of 9 February 2016 on the granting of a product specific waiver for humanised IgG4 monoclonal antibody against extracellular tau (BMS-986168) (EMEA-001867-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/103424/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2016-ema-decision-9-february-2016-granting-product-specific-waiver-humanised-igg4-monoclonal-antibody-against-extracellular-tau-bms-986168-emea-001867-pip01-15_en.pdf"},
    {"id":"19769","name":"P/0093/2013: EMA decision of 29 April 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Neisseria meningitidis serogroup B recombinant lipoprot...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/179753/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2013-ema-decision-29-april-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-neisseria-meningitidis-serogroup-b-recombinant-lipoprot_en.pdf"},
    {"id":"19771","name":"P/0128/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ponesimod (EMEA-000798-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T02:00:00Z","last_updated_date":"2018-07-25T02:00:00Z","reference_number":"EMA/151862/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-ponesimod-emea-000798-pip01-09-m01_en.pdf"},
    {"id":"19777","name":"P/0143/2017: EMA decision of 7 June 2017 on the refusal of a modification of an agreed paediatric investigation plan and on the granting of a product-specific waiver for laquinimod (sodium) (EMEA-000972-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/305260/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2017-ema-decision-7-june-2017-refusal-modification-agreed-paediatric-investigation-plan-granting-product-specific-waiver-laquinimod-sodium-emea-000972-pip01-10-m05_en.pdf"},
    {"id":"19790","name":"P/0274/2012: EMA decision of of 21 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for nilotinib (Tasigna)\n\n(EMEA-000290-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/718673/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2012-ema-decision-21-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-nilotinib-tasigna-emea-000290-pip01-08-m02_en.pdf"},
    {"id":"19792","name":"P/0168/2016: EMA decision of 17 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for secukinumab\n\n(Cosentyx), (EMEA-000380-PIP02-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/385682/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2016-ema-decision-17-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-secukinumab-cosentyx-emea-000380-pip02-09-m03_en.pdf"},
    {"id":"19826","name":"P/0162/2012: EMA decision of 23 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for pneumococcal\n\npolysaccharide serotype 1 conjugated to protein D (derived from non-typeable haem...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/473616/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2012-ema-decision-23-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-pneumococcal-polysaccharide-serotype-1-conjugated-protein-d-derived-non-typeable-haem_en.pdf"},
    {"id":"19860","name":"P/0175/2012: EMA decision of 27 July 2012 on the granting of a product specific waiver for tafluprost / timolol (EMEA-001216-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T16:00:00Z","last_updated_date":"2012-08-23T16:00:00Z","reference_number":"EMA/491022/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2012-ema-decision-27-july-2012-granting-product-specific-waiver-tafluprost-timolol-emea-001216-pip01-12_en.pdf"},
    {"id":"19867","name":"P/0108/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir\n\n(phosphate) (Tamiflu), (EMEA-000365-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/163780/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-oseltamivir-phosphate-tamiflu-emea-000365-pip01-08-m08_en.pdf"},
    {"id":"19868","name":"P/146/2010: European Medicines Agency decision of 30 July 2010 on the acceptance of a modification of an agreed paediatric investigation plan for A/California/7/2009 influenza-like virus strain (EMEA-000663-PIP01-09-M03)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/425506/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-146-2010-european-medicines-agency-decision-30-july-2010-acceptance-modification-agreed-paediatric-investigation-plan-california-7-2009-influenza-virus-strain-emea-000663-pip01-09-m03_en.pdf"},
    {"id":"19883","name":"P/0045/2012: EMA decision of 29 February 2012 on the acceptance of a modification of an agreed paediatric investigation plan for sunitinib (Sutent)\n\n(EMEA-000342-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/130075/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2012-ema-decision-29-february-2012-acceptance-modification-agreed-paediatric-investigation-plan-sunitinib-sutent-emea-000342-pip01-08-m02_en.pdf"},
    {"id":"19884","name":"P/0170/2013: EMA decision of 30 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (EMEA-000576-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/376647/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2013-ema-decision-30-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-emea-000576-pip02-11-m01_en.pdf"},
    {"id":"19901","name":"P/43/2010: European Medicines Agency decision of 31 March 2010 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (EMEA-000317-PIP01-08-M01) in accordance with ...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/200228/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-43-2010-european-medicines-agency-decision-31-march-2010-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-emea-000317-pip01-08-m01-accordance_en.pdf"},
    {"id":"19903","name":"P/0172/2013: EMA decision of 30 July on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (Gammaplex), (EMEA-000830-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/419226/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2013-ema-decision-30-july-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-gammaplex-emea-000830-pip02-10-m01_en.pdf"},
    {"id":"19908","name":"P/0295/2014: EMA decision of 30 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (Brilique), (EMEA-000480-PIP01-08-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T01:00:00Z","last_updated_date":"2014-12-05T01:00:00Z","reference_number":"EMA/643855/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2014-ema-decision-30-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-ticagrelor-brilique-emea-000480-pip01-08-m07_en.pdf"},
    {"id":"19914","name":"P/0133/2012: EMA decision of 2 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for abatacept (Orencia), (EMEA-000118-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-06T18:00:00Z","last_updated_date":"2012-08-06T18:00:00Z","reference_number":"EMA/426751/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2012-ema-decision-2-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-abatacept-orencia-emea-000118-pip02-10-m01_en.pdf"},
    {"id":"19917","name":"P/0340/2016: EMA decision of 25 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for peramivir\n\n(EMEA-001856-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-06T01:00:00Z","last_updated_date":"2017-01-06T01:00:00Z","reference_number":"EMA/764433/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0340-2016-ema-decision-25-november-2016-agreement-paediatric-investigation-plan-granting-deferral-peramivir-emea-001856-pip02-16_en.pdf"},
    {"id":"19923","name":"P/0061/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ruxolitinib (phosphate) (Jakavi), (EMEA-000901-PIP04-17...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/125284/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ruxolitinib-phosphate-jakavi-emea-000901-pip04-17_en.pdf"},
    {"id":"19948","name":"P/0208/2015: EMA decision of 11 September 2015 on the acceptance of a modification of an agreed paediatric investigation on the acceptance of a modification of an agreed paediatric investigation plan for PEGylated recomb...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/561412/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2015-ema-decision-11-september-2015-acceptance-modification-agreed-paediatric-investigation-acceptance-modification-agreed-paediatric-investigation-plan-pegylated-recomb_en.pdf"},
    {"id":"19961","name":"P/113/2009: European Medicines Agency decision of 15 June 2009 on the granting of a product specific waiver for triamcinolone acetonide (EMEA-000465-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the Europe...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351933/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-113-2009-european-medicines-agency-decision-15-june-2009-granting-product-specific-waiver-triamcinolone-acetonide-emea-000465-pip01-08-accordance-regulation-ec-no-1901-2006-europe_en.pdf"}    {"id":"19991","name":"P/0236/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for everolimus, (Votubia) (EMEA-000019-PIP08-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/627033/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-votubia-emea-000019-pip08-12-m01_en.pdf"},
    {"id":"20005","name":"P/0068/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for erenumab\n\n(EMEA-001664-PIP02-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/102414/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-erenumab-emea-001664-pip02-15-m02_en.pdf"},
    {"id":"20006","name":"P/307/2011: EMA decision of 20 December 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for deferiprone\n\n(EMEA-001126-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/973213/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-307-2011-ema-decision-20-december-2011-agreement-paediatric-investigation-plan-granting-waiver-deferiprone-emea-001126-pip01-10_en.pdf"},
    {"id":"20029","name":"P/0022/2012: EMA decision of 27 January 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for culture expanded autologous chondrocytes (EMEA-00073...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/994223/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2012-ema-decision-27-january-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-culture-expanded-autologous-chondrocytes-emea-00073_en.pdf"},
    {"id":"20034","name":"P/0134/2014: EMA decision of 10 June 2014 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for anamorelin (hydrochloride) (EMEA-001365-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-18T02:00:00Z","last_updated_date":"2014-07-18T02:00:00Z","reference_number":"EMA/275459/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2014-ema-decision-10-june-2014-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-anamorelin-hydrochloride-emea-001365-pip01-12_en.pdf"},
    {"id":"20053","name":"P/145/2011: EMA decision of 9 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chemically modified house dust mites allergen extract (der...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/417534/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-145-2011-ema-decision-9-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chemically-modified-house-dust-mites-allergen-extract-der_en.pdf"},
    {"id":"20058","name":"P/0240/2013: EMA decision of 24 September 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deleobuvir (EMEA-001389-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/564979/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2013-ema-decision-24-september-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-deleobuvir-emea-001389-pip01-12_en.pdf"},
    {"id":"20065","name":"P/127/2011: EMA decision of 8 June 2011 on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Afinitor) (EMEA-000019-PIP02-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-13T02:00:00Z","last_updated_date":"2011-07-13T02:00:00Z","reference_number":"EMA/396247/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-127-2011-ema-decision-8-june-2011-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-afinitor-emea-000019-pip02-07-m02_en.pdf"},
    {"id":"20076","name":"P/0007/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for dabigatran etexilate (Pradaxa) (EMEA-000081-PIP01-07-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-19T01:00:00Z","last_updated_date":"2014-02-19T01:00:00Z","reference_number":"EMA/10367/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-pradaxa-emea-000081-pip01-07-m06_en.pdf"},
    {"id":"20115","name":"P/123/2008: European Medicines Agency decision of 5 December 2008 on the application for modification of an agreed Paediatric Investigation Plan for clopidogrel (Iscover) EMEA-000050-PIP01-07-M01 in accordance with Regul...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/626714/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-123-2008-european-medicines-agency-decision-5-december-2008-application-modification-agreed-paediatric-investigation-plan-clopidogrel-iscover-emea-000050-pip01-07-m01-accordance-regul_en.pdf"},
    {"id":"20123","name":"P/287/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for Dermatophagoides pteronyssinus and Dermatophagoides f...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/767544/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-287-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dermatophagoides-pteronyssinus-dermatophagoides-f_en.pdf"},
    {"id":"20124","name":"P/0182/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dobutamine (EMEA-001262-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/357906/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-dobutamine-emea-001262-pip01-12-m03_en.pdf"},
    {"id":"20152","name":"P/0107/2014: EMA decision of 5 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for octocog alfa (EMEA-001064-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-12T16:00:00Z","last_updated_date":"2014-06-12T16:00:00Z","reference_number":"EMA/231268/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2014-ema-decision-5-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-octocog-alfa-emea-001064-pip01-10-m02_en.pdf"},
    {"id":"20164","name":"P/0271/2013: EMA decision of 30 October 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for quilizumab (EMEA-001395-PIP01-12)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/586656/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2013-ema-decision-30-october-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-quilizumab-emea-001395-pip01-12_en.pdf"},
    {"id":"20187","name":"P/157/2010: EMA decision of 27 August 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for ivabradine hydrochloride (Procoralan) (EMEA-000628-PIP01...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/477310/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-157-2010-ema-decision-27-august-2010-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-ivabradine-hydrochloride-procoralan-emea-000628-pip01_en.pdf"},
    {"id":"20188","name":"P/0202/2013: EMA decision of 2 September 2013 on the granting of a product-specific waiver for mifepristone (EMEA-001437-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"EMA/483605/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2013-ema-decision-2-september-2013-granting-product-specific-waiver-mifepristone-emea-001437-pip01-13_en.pdf"},
    {"id":"20191","name":"P/0050/2017: EMA decision of 3 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for fingolimod (hydrochloride), (Gilenya) (EMEA-000087-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/120501/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2017-ema-decision-3-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-fingolimod-hydrochloride-gilenya-emea-000087-pip01-07-m05_en.pdf"},
    {"id":"20193","name":"P/0278/2014: EMA decision of 30 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (HyQvia), (EMEA-000872-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-09T01:00:00Z","last_updated_date":"2014-12-09T01:00:00Z","reference_number":"EMA/605279/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2014-ema-decision-30-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-hyqvia-emea-000872-pip01-10-m02_en.pdf"},
    {"id":"20227","name":"P/265/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mixture of Phleum pratense and Secale cereale allerge...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/710529/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-265-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mixture-phleum-pratense-secale-cereale-allerge_en.pdf"},
    {"id":"20265","name":"P/0088/2012: EMA decision of 29 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir (EMEA-000409-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/325187/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2012-ema-decision-29-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-emea-000409-pip01-08-m02_en.pdf"},
    {"id":"20275","name":"P/0103/2015: EMA decision of 11 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous T cells transduced with lentiviral vector cont...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/205922/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2015-ema-decision-11-may-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-t-cells-transduced-lentiviral-vector-cont_en.pdf"},
    {"id":"20278","name":"P/0121/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for palovarotene\n\n(EMEA-001662-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/151869/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-palovarotene-emea-001662-pip01-14-m02_en.pdf"},
    {"id":"20296","name":"P/0160/2017: EMA decision of 30 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+\n\nenriched cell fraction that contains CD34+ cells transduced with lentiviral v...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/397195/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2017-ema-decision-30-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-enriched-cell-fraction-contains-cd34-cells-transduced-lentiviral-v_en.pdf"},
    {"id":"20298","name":"P/0138/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for allantoin (EMEA-001590-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T02:00:00Z","last_updated_date":"2016-07-27T02:00:00Z","reference_number":"EMA/249418/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-allantoin-emea-001590-pip01-13-m02_en.pdf"},
    {"id":"20307","name":"P/53/2008: European medicines agency decision of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium (Sortis and associated names) EMEA-000073-PIP01-07 in accordance ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-08T02:00:00Z","last_updated_date":"2008-09-08T02:00:00Z","reference_number":"EMEA/357907/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-53-2008-european-medicines-agency-decision-20-july-2008-application-agreement-paediatric-investigation-plan-atorvastatin-calcium-sortis-associated-names-emea-000073-pip01-07-accordance_en.pdf"},
    {"id":"20324","name":"P/0025/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for grazoprevir / elbasvir (Zepatier), (EMEA-001604-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/12334/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-grazoprevir-elbasvir-zepatier-emea-001604-pip01-13-m02_en.pdf"},
    {"id":"20344","name":"P/0261/2015: EMA decision of 30 October 2015 on the granting of a product specific waiver for mogamulizumab (EMEA-001816-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-22T13:00:00Z","last_updated_date":"2015-12-22T13:00:00Z","reference_number":"EMA/624577/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2015-ema-decision-30-october-2015-granting-product-specific-waiver-mogamulizumab-emea-001816-pip02-15_en.pdf"},
    {"id":"20353","name":"P/140/2011: EMA decision of 6 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for influenza virus type A, H1N1 / influenza virus type A, H3N...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/384223/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-140-2011-ema-decision-6-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-influenza-virus-type-h1n1-influenza-virus-type-h3n_en.pdf"},
    {"id":"20357","name":"P/0128/2014: EMA decision of 22 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for abatacept (Orencia) (EMEA-000118-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-25T02:00:00Z","last_updated_date":"2014-06-25T02:00:00Z","reference_number":"EMA/252138/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2014-ema-decision-22-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-abatacept-orencia-emea-000118-pip02-10-m02_en.pdf"},
    {"id":"20372","name":"P/0019/2018: EMA decision of 30 January 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for recombinant Clostridium difficile toxoid A / recombi...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T02:00:00Z","last_updated_date":"2018-04-17T02:00:00Z","reference_number":"EMA/31787/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2018-ema-decision-30-january-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-clostridium-difficile-toxoid-recombi_en.pdf"},
    {"id":"20436","name":"P/39/2009: European Medicines Agency decision of 20 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for fluticasone propionate / formoterol...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/153058/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-39-2009-european-medicines-agency-decision-20-march-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fluticasone-propionate-formoterol_en.pdf"},
    {"id":"20446","name":"P/0203/2012: EMA decision of 31 August 2012 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for split influenza virus, inactivated containing antigens equivalent to the B-like ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T14:00:00Z","last_updated_date":"2012-09-18T14:00:00Z","reference_number":"EMA/494888/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2012-ema-decision-31-august-2012-agreement-pip-granting-deferral-granting-waiver-split-influenza-virus-inactivated-containing-antigens-equivalent-b_en.pdf"},
    {"id":"20453","name":"P/4/2011:  EMA decision of 3 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pazopanib (Votrient) (EMEA-000601-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/716868/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-4-2011-ema-decision-3-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pazopanib-votrient-emea-000601-pip01-09_en.pdf"},
    {"id":"20465","name":"P/297/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pollen from dactylis glomerata, festuca pratensis, l...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/683411/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-297-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-dactylis-glomerata-festuca-pratensis-l_en.pdf"},
    {"id":"20476","name":"P/0047/2018: EMA decision of 19 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for alirocumab\n\n(Praluent), (EMEA-001169-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/88692/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2018-ema-decision-19-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-alirocumab-praluent-emea-001169-pip01-11-m04_en.pdf"},
    {"id":"20486","name":"P/0240/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sacubitril / valsartan (LCZ696) (EMEA-000316-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/617360/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-sacubitril-valsartan-lcz696-emea-000316-pip02-11-m02_en.pdf"},
    {"id":"20493","name":"P/0150/2015: EMA decision of 10 July 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sotagliflozin (EMEA-001517-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-25T02:00:00Z","last_updated_date":"2015-08-25T02:00:00Z","reference_number":"EMA/405627/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2015-ema-decision-10-july-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sotagliflozin-emea-001517-pip02-14_en.pdf"},
    {"id":"20501","name":"P/0195/2017: EMA decision of 10 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for damoctocog alfa pegol (EMEA-001229-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/420384/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2017-ema-decision-10-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-damoctocog-alfa-pegol-emea-001229-pip01-11-m03_en.pdf"},
    {"id":"20531","name":"P/0131/2017: EMA decision of 7 June 2017 on the granting of a product specific waiver for buprenorphine (hydrochloride) (EMEA-002099-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/293455/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2017-ema-decision-7-june-2017-granting-product-specific-waiver-buprenorphine-hydrochloride-emea-002099-pip01-16_en.pdf"},
    {"id":"20536","name":"P/198/2009: European Medicines Agency decision of 9 October 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for A/California/7/2009 influenza-lik...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/608559/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-198-2009-european-medicines-agency-decision-9-october-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-california-7-2009-influenza-lik_en.pdf"},
    {"id":"20561","name":"P/160/2010: EMA decision of 27 August 2010 on the agreement of a paediatric investigation plan and on the granting of a waiver for clindamycin phosphate / tretinoin (EMEA-000892-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/530413/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-160-2010-ema-decision-27-august-2010-agreement-paediatric-investigation-plan-granting-waiver-clindamycin-phosphate-tretinoin-emea-000892-pip01-10_en.pdf"},
    {"id":"20562","name":"P/0266/2012: EMA decision of 20 November 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2,6-dihydro-2-(...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/721373/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2012-ema-decision-20-november-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-2r3s5r-2-25-difluorophenyl-5-26-dihydro-2_en.pdf"},
    {"id":"20576","name":"P/0045/2015: EMA decision of 6 March 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N’-bis(2-br...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-23T01:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMA/65014/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2015-ema-decision-6-march-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-1-methyl-2-nitro-1h-imidazole-5-ylmethyl-nn-bis2-br_en.pdf"},
    {"id":"20580","name":"P/0051/2013: European medicines agency decision of 1 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and asso...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/85746/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2013-european-medicines-agency-decision-1-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-asso_en.pdf"},
    {"id":"20609","name":"P/0075/2017: EMA decision of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant\n\nhuman alpha-glucosidase conjugated with synthetic bismannose-6-phosphate-t...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/110877/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2017-ema-decision-17-march-2017-agreement-paediatric-investigation-plan-granting-deferral-recombinant-human-alpha-glucosidase-conjugated-synthetic-bismannose-6-phosphate-t_en.pdf"},
    {"id":"20626","name":"P/0122/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-001501-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/300768/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-emea-001501-pip01-13-m01_en.pdf"},
    {"id":"20632","name":"P/0238/2017: EMA decision of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous T cells transduced with retroviral vector en...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/495998/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2017-ema-decision-9-august-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-t-cells-transduced-retroviral-vector-en_en.pdf"},
    {"id":"20660","name":"P/0061/2014: EMA decision of 7 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for entecavir (Baraclude), (EMEA-000339-PIP02-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/52898/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2014-ema-decision-7-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-entecavir-baraclude-emea-000339-pip02-09-m02_en.pdf"},
    {"id":"20667","name":"P/12/2008: European medicines agency decision of 29 February 2008 on the application for agreement of a Paediatric Investigation Plan for Singulair and associated names, montelukast sodium (EMEA-000012-PIP01-07) in accor...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-03-19T01:00:00Z","last_updated_date":"2008-03-19T01:00:00Z","reference_number":"EMEA/96354/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-12-2008-european-medicines-agency-decision-29-february-2008-application-agreement-paediatric-investigation-plan-singulair-associated-names-montelukast-sodium-emea-000012-pip01-07-accor_en.pdf"},
    {"id":"20683","name":"P/246/2011: EMA decision of 21 October 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for selexipag (EMEA-000997-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-28T17:00:00Z","last_updated_date":"2011-11-28T17:00:00Z","reference_number":"EMA/826104/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-246-2011-ema-decision-21-october-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-selexipag-emea-000997-pip01-10_en.pdf"},
    {"id":"20690","name":"P/299/2011: EMA decision of 20 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for alogliptin benzoate,\n\n(EMEA-000496-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/943611/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-299-2011-ema-decision-20-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-alogliptin-benzoate-emea-000496-pip01-08-m02_en.pdf"},
    {"id":"20704","name":"P/0053/2014: European Medicines Agency decision of 7 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for elobixibat (EMEA-001484-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/50230/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2014-european-medicines-agency-decision-7-march-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-elobixibat-emea-001484-pip01-13_en.pdf"},
    {"id":"20706","name":"P/267/2010: EMA decision of 26 November 2010 on the granting of a product specific waiver for ocriplasmin (EMEA-000986-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/703551/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-267-2010-ema-decision-26-november-2010-granting-product-specific-waiver-ocriplasmin-emea-000986-pip01-10_en.pdf"},
    {"id":"20723","name":"P/0371/2016: EMA decision of 4 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline\n\n(fumarate) (SIRTURO), (EMEA-000912-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/4055/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0371-2016-ema-decision-4-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-bedaquiline-fumarate-sirturo-emea-000912-pip01-10-m03_en.pdf"},
    {"id":"20729","name":"P/0104/2018: EMA decision of 11 April 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obeticholic acid (Ocaliva), (EMEA-001304-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T02:00:00Z","last_updated_date":"2018-07-25T02:00:00Z","reference_number":"EMA/197888/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2018-ema-decision-11-april-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-obeticholic-acid-ocaliva-emea-001304-pip03-17_en.pdf"},
    {"id":"20735","name":"P/0036/2018: EMA decision of 30 January 2018 on the granting of a product specific waiver for tucatinib (EMEA-002242-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/848797/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2018-ema-decision-30-january-2018-granting-product-specific-waiver-tucatinib-emea-002242-pip01-17_en.pdf"},
    {"id":"20753","name":"P/183/2010: European Medicines Agency decision of 24 September 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral for (Glycinamide, L-cysteinyl-L-phenylalanyl-L-isoleucyl-6-oxo-L-l...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/583690/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-183-2010-european-medicines-agency-decision-24-september-2010-agreement-paediatric-investigation-plan-granting-deferral-glycinamide-l-cysteinyl-l-phenylalanyl-l-isoleucyl-6-oxo-l-l_en.pdf"},
    {"id":"20758","name":"P/0179/2013: EMA decision of 30 July 2013 on the granting of a product-specific waiver for clopidogrel (hydrogen sulphate) / acetylsalicylic acid\n\n(EMEA-001463-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/419133/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2013-ema-decision-30-july-2013-granting-product-specific-waiver-clopidogrel-hydrogen-sulphate-acetylsalicylic-acid-emea-001463-pip01-13_en.pdf"},
    {"id":"20760","name":"P/0169/2017: EMA decision of 3 July 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for omadacycline (EMEA-000560-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/354130/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2017-ema-decision-3-july-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-omadacycline-emea-000560-pip02-15_en.pdf"},
    {"id":"20762","name":"P/0265/2012: EMA decision of 20 November 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for levofloxacin (hemihydrate), (EMEA-001211-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/646979/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2012-ema-decision-20-november-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-levofloxacin-hemihydrate-emea-001211-pip01-11_en.pdf"},
    {"id":"20767","name":"P/189/2009: European Medicines Agency decision of 22 September 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for clopidogrel (Clopidogrel Winth...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/PDCO/583267","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-189-2009-european-medicines-agency-decision-22-september-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-clopidogrel-clopidogrel-winth_en.pdf"},
    {"id":"20779","name":"P/0089/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for N. meningitidis serogroup A polysaccharide conjugated to tetanus toxoid / N...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/211923/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-n-meningitidis-serogroup-polysaccharide-conjugated-tetanus-toxoid-n_en.pdf"},
    {"id":"20794","name":"P/0026/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib\n\n(Olumiant), (EMEA-001220-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/850457/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip01-11-m02_en.pdf"},
    {"id":"20809","name":"P/264/2011: EMA decision of 28 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy)\n\n(EMEA-000117-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T16:00:00Z","last_updated_date":"2011-11-30T16:00:00Z","reference_number":"EMA/848187/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-264-2011-ema-decision-28-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-yervoy-emea-000117-pip01-07-m03_en.pdf"},
    {"id":"20825","name":"P/0189/2013: EMA decision of 9 August 2013 on the acceptance of a modification of an agreed paediatric investigation plan for solifenacin (succinate) (Vesicare and associated names) (EMEA-000573-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-10T13:20:00Z","last_updated_date":"2013-09-10T13:20:00Z","reference_number":"EMA/476169/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2013-ema-decision-9-august-2013-acceptance-modification-agreed-paediatric-investigation-plan-solifenacin-succinate-vesicare-associated-names-emea-000573-pip01-09-m04_en.pdf"},
    {"id":"20833","name":"P/0003/2016: EMA decision of 15 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara) (EMEA-000311-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/3164/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2016-ema-decision-15-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip01-08-m04_en.pdf"},
    {"id":"20840","name":"P/0358/2016: EMA decision of 21 December 2016 on the refusal of a product specific waiver for fosnetupitant / palonosetron (Akynzeo), (EMEA-001198-\n\nPIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/791414/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0358-2016-ema-decision-21-december-2016-refusal-product-specific-waiver-fosnetupitant-palonosetron-akynzeo-emea-001198-pip02-16_en.pdf"},
    {"id":"20846","name":"P/332/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aqueous allergen extract of grass and birch pollen (E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/758160/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-332-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aqueous-allergen-extract-grass-birch-pollen-e_en.pdf"},
    {"id":"20880","name":"P/0297/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for nilotinib (Tasigna) (EMEA-000290-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/792883/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-nilotinib-tasigna-emea-000290-pip01-08-m04_en.pdf"},
    {"id":"20886","name":"P/0205/2015: EMA decision of 4 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sucroferric oxyhydroxide (mixture of iron (III)-oxyhydroxide, sucrose, starch) (PA21) (Velp...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/568199/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2015-ema-decision-4-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-sucroferric-oxyhydroxide-mixture-iron-iii-oxyhydroxide-sucrose-starch-pa21-velp_en.pdf"},
    {"id":"20913","name":"P/0331/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dobutamine\n\n(hydrochloride) (EMEA-001262-PIP01-12-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T12:18:00Z","last_updated_date":"2017-02-03T12:18:00Z","reference_number":"EMA/757952/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0331-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-dobutamine-hydrochloride-emea-001262-pip01-12-m02_en.pdf"},
    {"id":"20922","name":"P/126/2011: EMA decision of 7 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for octocog alfa (EMEA-001064-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/421237/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-126-2011-ema-decision-7-june-2011-agreement-paediatric-investigation-plan-granting-deferral-octocog-alfa-emea-001064-pip01-10_en.pdf"},
    {"id":"20969","name":"P/94/2010: European Medicines Agency decision of 2 June 2010 on the agreement of a paediatric investigation plan and on the refusal of a deferral  and on the granting of a waiver for peginterferon alfa-2a (Pegasys) (EMEA...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/330327/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-94-2010-european-medicines-agency-decision-2-june-2010-agreement-paediatric-investigation-plan-refusal-deferral-granting-waiver-peginterferon-alfa-2a-pegasys-emea_en.pdf"},
    {"id":"20971","name":"P/0281/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for lebrikizumab (EMEA-001053-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/688239/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-lebrikizumab-emea-001053-pip01-10-m03_en.pdf"},
    {"id":"20990","name":"P/0120/2012: EMA decision of 3 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for cinacalcet hydrochloride (Mimpara), (EMEA-000078-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-06T18:00:00Z","last_updated_date":"2012-08-06T18:00:00Z","reference_number":"EMA/412355/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2012-ema-decision-3-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-cinacalcet-hydrochloride-mimpara-emea-000078-pip01-07-m03_en.pdf"},
    {"id":"20995","name":"P/0393/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren\n\n(Translarna), (EMEA-000115-PIP01-07-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/797360/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0393-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-translarna-emea-000115-pip01-07-m09_en.pdf"},
    {"id":"21004","name":"P/0006/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for human heterologous liver cells (EMEA-000067-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/1361/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-human-heterologous-liver-cells-emea-000067-pip02-11-m02_en.pdf"},
    {"id":"21007","name":"P/0290/2016: EMA decision of 4 November 2016 on the granting of a product-specific waiver for Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) (EMEA-001140-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-06T01:00:00Z","last_updated_date":"2017-01-06T01:00:00Z","reference_number":"EMA/667230/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2016-ema-decision-4-november-2016-granting-product-specific-waiver-allogeneic-mesenchymal-precursor-cells-rexlemestrocel-l-emea-001140-pip02-15_en.pdf"},
    {"id":"21036","name":"P/0244/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta,\n\nBydureon), (EMEA-000689-PIP01-09-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-25T17:00:00Z","last_updated_date":"2017-10-25T17:00:00Z","reference_number":"EMA/507344/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-exenatide-byetta-bydureon-emea-000689-pip01-09-m07_en.pdf"},
    {"id":"21050","name":"P/0048/2014: EMA decision of 8 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for rubidium (82Rb) chloride (EMEA-000882-PIP03-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/58300/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2014-ema-decision-8-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-rubidium-82rb-chloride-emea-000882-pip03-11-m01_en.pdf"},
    {"id":"21067","name":"P/0101/2016: EMA decision of 15 April 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for certolizumab pegol (Cimzia), (EMEA-001071-PIP03-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/188946/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2016-ema-decision-15-april-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-certolizumab-pegol-cimzia-emea-001071-pip03-14_en.pdf"},
    {"id":"21095","name":"P/0072/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for selumetinib (EMEA-\n\n001585-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/83697/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-selumetinib-emea-001585-pip01-13-m02_en.pdf"},
    {"id":"21145","name":"P/268/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor (EMEA-001173-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/592149/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-268-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-lumacaftor-emea-001173-pip01-11-m01_en.pdf"},
    {"id":"21150","name":"P/0161/2014: EMA decision of 12 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab (EMEA-000069-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/329215/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2014-ema-decision-12-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-emea-000069-pip02-10-m03_en.pdf"},
    {"id":"21153","name":"P/212/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pagibaximab (EMEA-000608-PIP01-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/644824/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-212-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pagibaximab-emea-000608-pip01-0_en.pdf"},
    {"id":"21173","name":"P/0057/2013: European medicines agency decision of 26 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for dalbavancin (EMEA-000016-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/102646/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2013-european-medicines-agency-decision-26-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-dalbavancin-emea-000016-pip01-07-m01_en.pdf"},
    {"id":"21175","name":"P/0242/2013: EMA decision of 24 September 2013 on the granting of a product specific waiver for calcium (citrate) / colecalciferol (EMEA-001480-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/496911/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2013-ema-decision-24-september-2013-granting-product-specific-waiver-calcium-citrate-colecalciferol-emea-001480-pip01-13_en.pdf"},
    {"id":"21183","name":"P/145/2010:  European Medicines Agency decision of 30 July 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vedolizumab (EMEA-000645-PIP01-09)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/469701/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-145-2010-european-medicines-agency-decision-30-july-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vedolizumab-emea-000645-pip01-09_en.pdf"},
    {"id":"21236","name":"P/0059/2018: EMA decision of 16 March 2018 on the granting of a product specific waiver for dapagliflozin / metformin (hydrochloride)\n\n(EMEA-001151-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/75594/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2018-ema-decision-16-march-2018-granting-product-specific-waiver-dapagliflozin-metformin-hydrochloride-emea-001151-pip02-17_en.pdf"},
    {"id":"21242","name":"P/0188/2017: EMA decision of 3 July 2017 on the granting of a product-specific waiver for rosuvastatin / amlodipine (EMEA-002136-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/348030/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2017-ema-decision-3-july-2017-granting-product-specific-waiver-rosuvastatin-amlodipine-emea-002136-pip01-17_en.pdf"},
    {"id":"21252","name":"P/107/2008: European Medicines Agency decision of 28 November 2008 on the application for agreement of a Paediatric Investigation Plan for skimmed cow's milk powder EMEA-000201-PIP01-08 in accordance with Regulation (EC)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/625236/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-107-2008-european-medicines-agency-decision-28-november-2008-application-agreement-paediatric-investigation-plan-skimmed-cows-milk-powder-emea-000201-pip01-08-accordance-regulation-ec_en.pdf"},
    {"id":"21253","name":"P/0088/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for levamisole (hydrochloride) (EMEA-001885-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/136529/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-waiver-levamisole-hydrochloride-emea-001885-pip01-15_en.pdf"},
    {"id":"21267","name":"P/0070/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for vericiguat (EMEA-\n\n001636-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/137083/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-vericiguat-emea-001636-pip01-14-m01_en.pdf"},
    {"id":"21285","name":"P/0352/2016: EMA decision of 2 December 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for betrixaban\n\n(EMEA-001834-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/788682/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0352-2016-ema-decision-2-december-2016-agreement-paediatric-investigation-plan-granting-deferral-betrixaban-emea-001834-pip02-16_en.pdf"},
    {"id":"21291","name":"P/0279/2017: EMA decision of 4 October 2017 on the granting of a product specific waiver for lenalidomide (Revlimid) (EMEA-000371-PIP04-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T13:11:00Z","last_updated_date":"2018-02-12T13:11:00Z","reference_number":"EMA/565633/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2017-ema-decision-4-october-2017-granting-product-specific-waiver-lenalidomide-revlimid-emea-000371-pip04-16_en.pdf"},
    {"id":"21294","name":"P/16/2008: European medicines agency decision of 31 March 2008 on the application for product specific waiver for Naproxcinod (EMEA-000104-PIP01-07) in accordance with Regulation (EC) No 1901/2006 of the European Parliam...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-04-22T02:00:00Z","last_updated_date":"2008-04-22T02:00:00Z","reference_number":"EMEA/157227/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-16-2008-european-medicines-agency-decision-31-march-2008-application-product-specific-waiver-naproxcinod-emea-000104-pip01-07-accordance-regulation-ec-no-1901-2006-european-parliam_en.pdf"},
    {"id":"21319","name":"P/338/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for modified allergen extract of dermatophagoides farina...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/801198/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-338-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-dermatophagoides-farina_en.pdf-0"},
    {"id":"21321","name":"P/0127/2015: EMA decision of 5 June 2015 on the agreement of a paediatric investigation plan for palovarotene (EMEA-001662-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/355150/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2015-ema-decision-5-june-2015-agreement-paediatric-investigation-plan-palovarotene-emea-001662-pip01-14_en.pdf"},
    {"id":"21322","name":"P/0015/2012: EMA decision of 24 January 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for purified tetanus toxoid / inactivated type 1 poliovi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/8126/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2012-ema-decision-24-january-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-purified-tetanus-toxoid-inactivated-type-1-poliovi_en.pdf"},
    {"id":"21333","name":"P/206/2011: EMA decision of 31 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for cholic acid, (EMEA-\n\n000651-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/688412/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-206-2011-ema-decision-31-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-cholic-acid-emea-000651-pip01-09-m02_en.pdf"}    {"id":"21336","name":"P/292/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral for 40K pegylated recombinant blood coagulation factor IX, (EMEA-000731-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/683312/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-292-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-40k-pegylated-recombinant-blood-coagulation-factor-ix-emea-000731-pip01-09_en.pdf"},
    {"id":"21340","name":"P/0280/2017: EMA decision of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for eltrombopag\n\n(Revolade) (EMEA-000170-PIP03-13-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T16:26:00Z","last_updated_date":"2018-02-13T16:26:00Z","reference_number":"EMA/541692/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2017-ema-decision-4-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-eltrombopag-revolade-emea-000170-pip03-13-m03_en.pdf"},
    {"id":"21358","name":"P/0051/2018: EMA decision of 22 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam\n\n(Briviact) (EMEA-000332-PIP01-08-M13)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T13:35:00Z","last_updated_date":"2018-04-17T13:35:00Z","reference_number":"EMA/102425/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2018-ema-decision-22-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-emea-000332-pip01-08-m13_en.pdf"},
    {"id":"21370","name":"P/72/2008: European medicines agency decision of 20 August 2008\n\non the application for agreement of a Paediatric Investigation Plan for nicotinic acid, simvastatin and laropiprant (EMEA-000254-PIP01-08), in accordance w...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/431920/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-72-2008-european-medicines-agency-decision-20-august-2008-application-agreement-paediatric-investigation-plan-nicotinic-acid-simvastatin-laropiprant-emea-000254-pip01-08-accordance-w_en.pdf"},
    {"id":"21379","name":"P/0156/2013: EMA decision of 5 July 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for dry extract from Betulae cortex (EMEA-001299-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-09T16:30:00Z","last_updated_date":"2013-08-09T16:30:00Z","reference_number":"EMA/346350/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2013-ema-decision-5-july-2013-agreement-paediatric-investigation-plan-granting-deferral-dry-extract-betulae-cortex-emea-001299-pip01-12_en.pdf"},
    {"id":"21386","name":"P/0166/2014: EMA decision of 8 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (EMEA-000715-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/392184/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2014-ema-decision-8-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-emea-000715-pip02-11-m01_en.pdf"},
    {"id":"21392","name":"P/0122/2016: EMA decision of 29 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (Translarna), (EMEA-000115-PIP01-07-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/287097/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2016-ema-decision-29-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-translarna-emea-000115-pip01-07-m07_en.pdf"},
    {"id":"21419","name":"P/0094/2012: EMA decision of 30 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for nalfurafine (hydrochloride) (EMEA-000266-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/266429/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2012-ema-decision-30-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-nalfurafine-hydrochloride-emea-000266-pip01-08-m01_en.pdf"},
    {"id":"21421","name":"P/0184/2013: EMA decision of 31 July 2013 on the granting of a product-specific waiver for capsici acris extractum spissum normatum (EMEA-001409-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/418994/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2013-ema-decision-31-july-2013-granting-product-specific-waiver-capsici-acris-extractum-spissum-normatum-emea-001409-pip01-12_en.pdf"},
    {"id":"21431","name":"P/0230/2012: EMA decision of 5 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for pitavastatin (calcium) (Livazo and associated names), (EMEA-000054-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T01:00:00Z","last_updated_date":"2012-11-23T01:00:00Z","reference_number":"EMA/625236/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2012-ema-decision-5-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-pitavastatin-calcium-livazo-associated-names-emea-000054-pip01-07-m03_en.pdf"},
    {"id":"21455","name":"P/222/2011: EMA decision of 27 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for rabeprazole (sodium) (Pariet and associated names), (EMEA-000055-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/703629/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-222-2011-ema-decision-27-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-rabeprazole-sodium-pariet-associated-names-emea-000055-pip01-07-m04_en.pdf"},
    {"id":"21474","name":"P/0009/2012: EMA decision of 24 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for darbepoetin alfa\n\n(Aranesp and associated names) (EMEA-000329-PIP02-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/43583/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2012-ema-decision-24-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-darbepoetin-alfa-aranesp-associated-names-emea-000329-pip02-09-m01_en.pdf"},
    {"id":"21475","name":"P/0027/2016: EMA decision of 29 January 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for abrilumab (EMEA-001671-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/2820/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2016-ema-decision-29-january-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-abrilumab-emea-001671-pip01-14_en.pdf"},
    {"id":"21520","name":"P/0086/2018: EMA decision of 16 March 2018 on the granting of a product- specific waiver for ibuprofen (EMEA-002302-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/102438/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2018-ema-decision-16-march-2018-granting-product-specific-waiver-ibuprofen-emea-002302-pip01-17_en.pdf"},
    {"id":"21554","name":"P/0142/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ciclosporin (EMEA-000575-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/398291/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-ciclosporin-emea-000575-pip01-09-m03_en.pdf"},
    {"id":"21563","name":"P/64/2009: Purified diphtheria toxoid/Purified tetanus toxoid/Five component acellular pertussis [Purified Pertussis Toxoid, Purified Filamentous Haemagglutinin, Purified Fimbriae Types 2 and 3, and Purified Pertactin]/ ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/160106/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-64-2009-purified-diphtheria-toxoid-purified-tetanus-toxoid-five-component-acellular-pertussis-purified-pertussis-toxoid-purified-filamentous-haemagglutinin-purified-fimbriae-types-2-3-purified_en.pdf"},
    {"id":"21571","name":"P/144/2010:  Agency decision of 30 July 2010 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piper...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/469865/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-144-2010-agency-decision-30-july-2010-agreement-pip-granting-deferral-granting-waiver-3r4r-4-methyl-3-methyl-1h-pyrrolo23-dpyrimidin-4-ylamino-i2-oxo-1-piper_en.pdf"},
    {"id":"21589","name":"P/244/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant Bet v1 folding variant (rBet v1-FV), (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/678209/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-244-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-bet-v1-folding-variant-rbet-v1-fv-eme_en.pdf"},
    {"id":"21607","name":"P/0105/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for talimogene laherparepvec (Imlygic), (EMEA-001251-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/188343/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-talimogene-laherparepvec-imlygic-emea-001251-pip01-11-m01_en.pdf"},
    {"id":"21633","name":"P/126/2010: European Medicines Agency decision of 28 July 2010 on the acceptance of a modification of an agreed paediatric investigation plan for modified grass pollen extract, (EMEA-000284-PIP01-08-M01) in accordance wi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/472908/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-126-2010-european-medicines-agency-decision-28-july-2010-acceptance-modification-agreed-paediatric-investigation-plan-modified-grass-pollen-extract-emea-000284-pip01-08-m01-accordance-wi_en.pdf"},
    {"id":"21651","name":"P/125/2011: EMA decision of 7 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for elvitegravir / emtricitabine / tenofovir disoproxil (as fu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/359899/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-125-2011-ema-decision-7-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-elvitegravir-emtricitabine-tenofovir-disoproxil-fu_en.pdf"},
    {"id":"21658","name":"P/0049/2015: EMA decision of 6 March 2015 on the granting of a product-specific waiver for oxycodone (hydrochloride) / naloxone (hydrochloride) (EMEA-001700-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-24T01:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/49368/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2015-ema-decision-6-march-2015-granting-product-specific-waiver-oxycodone-hydrochloride-naloxone-hydrochloride-emea-001700-pip01-14_en.pdf"},
    {"id":"21686","name":"P/0028/2016: EMA decision of 29 January 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 17 beta-estradiol / etonogestrel (EMEA-001718-PIP01-1...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/23043/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2016-ema-decision-29-january-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-17-beta-estradiol-etonogestrel-emea-001718-pip01-1_en.pdf"},
    {"id":"21698","name":"P/0025/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for damoctocog alfa pegol (EMEA-001229-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/1076/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-damoctocog-alfa-pegol-emea-001229-pip01-11-m02_en.pdf"},
    {"id":"21712","name":"P/234/2010: Acceptance of a modification of an agreed PIP for influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains: A/Solomon Islands/3/2006 (H1N1) like strain (A/Sol...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-27T00:00:00Z","last_updated_date":"2010-12-21T00:00:00Z","reference_number":"EMA/672567/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-234-2010-acceptance-modification-agreed-pip-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-inactivated-following-strains-solomon-islands-3-2006-h1n1-strain-sol_en.pdf"},
    {"id":"21715","name":"P/0298/2012: EMA decision of 18 December 2012 on the granting of a product-specific waiver for ivermectin (EMEA-001334-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T14:00:00Z","last_updated_date":"2013-02-11T14:00:00Z","reference_number":"EMA/736952/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2012-ema-decision-18-december-2012-granting-product-specific-waiver-ivermectin-emea-001334-pip01-12_en.pdf"},
    {"id":"21717","name":"P/226/2009: European Medicines Agency Decision of 4 November 2009 on the granting of a product specific waiver for olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide (EMEA-000666-PIP01-09) in accordance wit...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:09:21Z","last_updated_date":"2009-12-23T00:09:21Z","reference_number":"EMEA/693323/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-226-2009-european-medicines-agency-decision-4-november-2009-granting-product-specific-waiver-olmesartan-medoxomil-amlodipine-besilate-hydrochlorothiazide-emea-000666-pip01-09-accordance-wit_en.pdf"},
    {"id":"21733","name":"P/0175/2013: EMA decision of 30 July 2013 on the granting of a product-specific waiver for lopinavir / lamivudine / ritonavir / zidovudine (EMEA-001368-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/367930/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2013-ema-decision-30-july-2013-granting-product-specific-waiver-lopinavir-lamivudine-ritonavir-zidovudine-emea-001368-pip01-12_en.pdf"},
    {"id":"21751","name":"P/0325/2014: EMA decision of 19 December 2014 on the granting of a product specific waiver for calcium (carbonate) / cholecalciferol (in combination with zoledronic acid (monohydrate)) (EMEA-001690-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/759441/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0325-2014-ema-decision-19-december-2014-granting-product-specific-waiver-calcium-carbonate-cholecalciferol-combination-zoledronic-acid-monohydrate-emea-001690-pip01-14_en.pdf"},
    {"id":"21760","name":"P/0215/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for brexpiprazole (EMEA-001185-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/603375/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-brexpiprazole-emea-001185-pip01-11-m02_en.pdf"},
    {"id":"21764","name":"P/251/2009: EMA decision of 18 December 2009 on the granting of a product specific waiver for amlodipine besilate / bisoprolol fumarate (EMEA-000657-PIP01-09) in accordance with Regulation (EC) No ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMA/817473/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-251-2009-ema-decision-18-december-2009-granting-product-specific-waiver-amlodipine-besilate-bisoprolol-fumarate-emea-000657-pip01-09-accordance-regulation-ec-no_en.pdf"},
    {"id":"21774","name":"P/0309/2014: EMA decision of 24 November 2014 on the granting of a product specific waiver for varicella-zoster virus (live, attenuated) (Zostavax) (EMEA-001672-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/624743/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0309-2014-ema-decision-24-november-2014-granting-product-specific-waiver-varicella-zoster-virus-live-attenuated-zostavax-emea-001672-pip01-14_en.pdf"},
    {"id":"21791","name":"P/54/2009: European Medicines Agency decision of 24 March 2009 on the granting of a product specific waiver for bisoprolol fumarate / acetylsalicylic acid (EMEA-000449-PIP01-08) in accordance with Regulation (EC) No 1901...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/167372/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-54-2009-european-medicines-agency-decision-24-march-2009-granting-product-specific-waiver-bisoprolol-fumarate-acetylsalicylic-acid-emea-000449-pip01-08-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"21794","name":"P/0213/2014: EMA decision of 1 September 2014 on the granting of a product specific waiver for perindopril / bisoprolol (EMEA-001497-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/467314/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2014-ema-decision-1-september-2014-granting-product-specific-waiver-perindopril-bisoprolol-emea-001497-pip01-13_en.pdf"},
    {"id":"21809","name":"P/2/2007: European medicines agency decision of 11 December 2007 on the application for a product specific waiver for Everolimus (EMEA-000019-PIP01-07) in accordance with Regulation (EC) No 1901/2006 of the European Parl...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2007-12-20T00:00:00Z","last_updated_date":"2007-12-20T00:00:00Z","reference_number":"EMEA/575610/2007","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-2-2007-european-medicines-agency-decision-11-december-2007-application-product-specific-waiver-everolimus-emea-000019-pip01-07-accordance-regulation-ec-no-1901-2006-european-parl_en.pdf"},
    {"id":"21824","name":"P/0023/2014: EMA decision of 22 January 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for 9-cis-retinyl acetate (EMEA-001453-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/738903/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2014-ema-decision-22-january-2014-agreement-paediatric-investigation-plan-granting-deferral-9-cis-retinyl-acetate-emea-001453-pip01-13_en.pdf"},
    {"id":"21844","name":"P/0259/2016: EMA decision of 5 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for selepressin (EMEA-\n\n000506-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/585444/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2016-ema-decision-5-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-selepressin-emea-000506-pip01-08-m02_en.pdf"},
    {"id":"21865","name":"P/287/2011: EMA decision of 1 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for purified antigen fractions of inactivated split virion...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/912704/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-287-2011-ema-decision-1-december-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-purified-antigen-fractions-inactivated-split-virion_en.pdf"},
    {"id":"21871","name":"P/167/2011: EMA decision of 6 July 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for risperidone\n\n(Risperdal and associated names) (EMEA-001034-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/484972/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-167-2011-ema-decision-6-july-2011-agreement-paediatric-investigation-plan-granting-waiver-risperidone-risperdal-associated-names-emea-001034-pip01-10_en.pdf"},
    {"id":"21883","name":"P/0207/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant Fusion\n\nProtein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689) (E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/466902/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-fusion-protein-linking-coagulation-factor-viia-albumin-rviia-fp-csl689-e_en.pdf"},
    {"id":"21911","name":"P/0224/2014: EMA decision of 5 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for maraviroc (Celsentri), (EMEA-000020-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/469464/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2014-ema-decision-5-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-maraviroc-celsentri-emea-000020-pip01-07-m04_en.pdf"},
    {"id":"21923","name":"P/0100/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for decitabine (Dacogen), (EMEA-000555-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/201519/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2013-ema-decision-30-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-decitabine-dacogen-emea-000555-pip01-09-m03_en.pdf"},
    {"id":"21932","name":"P/0300/2016: EMA decision of 4 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for monoclonal IgG1 anti-influenza A antibody (EMEA-001831-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-06T01:00:00Z","last_updated_date":"2017-01-06T01:00:00Z","reference_number":"EMA/639659/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2016-ema-decision-4-november-2016-agreement-paediatric-investigation-plan-granting-deferral-monoclonal-igg1-anti-influenza-antibody-emea-001831-pip01-15_en.pdf"},
    {"id":"21950","name":"P/0027/2013: EMA decision of 26 February 2013 on the acceptance of a modification of an agreed paediatric investigation plan for dimethyl fumarate, (EMEA-000832-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T02:00:00Z","last_updated_date":"2013-04-23T02:00:00Z","reference_number":"EMA/66153/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2013-ema-decision-26-february-2013-acceptance-modification-agreed-paediatric-investigation-plan-dimethyl-fumarate-emea-000832-pip01-10-m01_en.pdf"},
    {"id":"21972","name":"P/0198/2013: EMA decision of 2 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant fusion protein consisting of human coagulation factor IX attached to the Fc dom...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/483690/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2013-ema-decision-2-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-fusion-protein-consisting-human-coagulation-factor-ix-attached-fc-dom_en.pdf"},
    {"id":"22006","name":"P/0007/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for eltrombopag (Revolade) (EMEA-000170-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/776065/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-eltrombopag-revolade-emea-000170-pip02-10-m02_en.pdf"},
    {"id":"22024","name":"P/0168/2013: EMA decision of 29 July 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant Varicella-zoster-virus (VZV) glycoprotein-E ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/393025/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2013-ema-decision-29-july-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-varicella-zoster-virus-vzv-glycoprotein-e_en.pdf"},
    {"id":"22029","name":"P/0011/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga) (EMEA-000597-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/784278/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip02-10-m02_en.pdf"},
    {"id":"22036","name":"P/0023/2017: EMA decision of 13 February 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for ciprofloxacin (hydrochloride) (EMEA-001563-PIP02-15...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-18T02:00:00Z","last_updated_date":"2017-04-18T02:00:00Z","reference_number":"EMA/36089/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2017-ema-decision-13-february-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ciprofloxacin-hydrochloride-emea-001563-pip02-15_en.pdf"},
    {"id":"22044","name":"P/0257/2015: EMA decision of 30 October 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous CD34+ haematopoietic stem cells transduced...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T01:00:00Z","last_updated_date":"2015-12-21T01:00:00Z","reference_number":"EMA/617562/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2015-ema-decision-30-october-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-cd34-haematopoietic-stem-cells-transduced_en.pdf"},
    {"id":"22049","name":"P/3/2007: European medicines agency decision of 11 December 2007 on the application for a product specific waiver for Atacand Plus and associated names, Candesartan/Hydrochlorothiazide (EMEA-000030-PIP01-07) in accordanc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2007-12-20T00:00:00Z","last_updated_date":"2007-12-20T00:00:00Z","reference_number":"EMEA/575732/2007","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-3-2007-european-medicines-agency-decision-11-december-2007-application-product-specific-waiver-atacand-plus-associated-names-candesartan-hydrochlorothiazide-emea-000030-pip01-07-accordanc_en.pdf"},
    {"id":"22061","name":"P/0156/2015: EMA decision of 10 July 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cariprazine (hydrochloride) (EMEA-001652-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-25T02:00:00Z","last_updated_date":"2015-08-25T02:00:00Z","reference_number":"EMA/398316/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2015-ema-decision-10-july-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cariprazine-hydrochloride-emea-001652-pip01-14_en.pdf"},
    {"id":"22063","name":"P/0194/2012: EMA decision of 24 August 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pitolisant (EMEA-001176-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T13:05:00Z","last_updated_date":"2012-09-18T13:05:00Z","reference_number":"EMA/547633/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2012-ema-decision-24-august-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pitolisant-emea-001176-pip01-11_en.pdf"},
    {"id":"22065","name":"P/0176/2016: EMA decision of 1 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Victoza)\n\n(EMEA-000128-PIP01-07-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-22T01:00:00Z","last_updated_date":"2017-02-22T01:00:00Z","reference_number":"EMA/408672/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2016-ema-decision-1-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-victoza-emea-000128-pip01-07-m07_en.pdf"},
    {"id":"22073","name":"P/0211/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for brentuximab vedotin\n\n(Adcetris), (EMEA-000980-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/472138/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-brentuximab-vedotin-adcetris-emea-000980-pip01-10-m04_en.pdf"},
    {"id":"22079","name":"P/0130/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta, Bydureon), (EMEA-000689-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/264477/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-exenatide-byetta-bydureon-emea-000689-pip01-09-m06_en.pdf"},
    {"id":"22092","name":"P/258/2011: EMA decision of 26 October 2011 on the granting of a product specific waiver for 4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-\n\ntrifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol (CC-930) (EMEA-001...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T01:00:00Z","last_updated_date":"2011-11-29T01:00:00Z","reference_number":"EMA/751564/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-258-2011-ema-decision-26-october-2011-granting-product-specific-waiver-4-9-3s-tetrahydro-3-furanyl-8-246-trifluorophenylamino-9h-purin-2-ylamino-trans-cyclohexanol-cc-930-emea-001_en.pdf"},
    {"id":"22095","name":"P/0083/2013: EMA decision of 26 April 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for ceftazidime / avibactam (EMEA-001313-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/202542/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2013-ema-decision-26-april-2013-agreement-paediatric-investigation-plan-granting-deferral-ceftazidime-avibactam-emea-001313-pip01-12_en.pdf"},
    {"id":"22112","name":"P/0080/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for pridopyrimidione\n\nSMN2 Splicing Modifier (EMEA-002070-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/91848/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-pridopyrimidione-smn2-splicing-modifier-emea-002070-pip01-16-m01_en.pdf"},
    {"id":"22125","name":"P/0092/2013: EMA decision of 29 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for bucelipase alfa (EMEA-000822-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/179906/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2013-ema-decision-29-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-bucelipase-alfa-emea-000822-pip01-09-m01_en.pdf"},
    {"id":"22135","name":"P/71/2011: EMA decision of 4 April 2011 on the granting of a product specific waiver for iloperidone (EMEA-000995-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"EMA/221083/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-71-2011-ema-decision-4-april-2011-granting-product-specific-waiver-iloperidone-emea-000995-pip01-10_en.pdf"},
    {"id":"22137","name":"P/0208/2014: EMA decision of 8 August 2014 on the granting of a product specific waiver for tirasemtiv (EMEA-001594-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/439330/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2014-ema-decision-8-august-2014-granting-product-specific-waiver-tirasemtiv-emea-001594-pip02-13_en.pdf"},
    {"id":"22160","name":"P/0156/2012: EMA decision of 25 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for fosaprepitant (Ivemend), (EMEA-000406-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/478451/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2012-ema-decision-25-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-fosaprepitant-ivemend-emea-000406-pip01-08-m03_en.pdf"},
    {"id":"22161","name":"P/0009/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for clevidipine butyrate (Cleviprex and associated names) (EMEA-000282-PIP...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-19T01:00:00Z","last_updated_date":"2014-02-19T01:00:00Z","reference_number":"EMA/10229/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-clevidipine-butyrate-cleviprex-associated-names-emea-000282-pip_en.pdf"},
    {"id":"22172","name":"P/0050/2013: European medicines agency decision of 1 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and asso...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/85745/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2013-european-medicines-agency-decision-1-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-asso_en.pdf"},
    {"id":"22196","name":"P/0224/2015: EMA decision of 2 October 2015 on the granting of a product specific waiver for botulinum Neurotoxin Type A (EMEA-001788-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-19T01:00:00Z","last_updated_date":"2015-11-19T01:00:00Z","reference_number":"EMA/568184/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2015-ema-decision-2-october-2015-granting-product-specific-waiver-botulinum-neurotoxin-type-emea-001788-pip01-15_en.pdf"},
    {"id":"22216","name":"P/0299/2013: EMA decision of 29 November 2013 on the agreement of a paediatric investigation plan and on granting for sodium benzylpenilloate / benzylpenicilloyl octa- L-lysine (EMEA-001398-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/692933/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2013-ema-decision-29-november-2013-agreement-paediatric-investigation-plan-granting-sodium-benzylpenilloate-benzylpenicilloyl-octa-l-lysine-emea-001398-pip02-13_en.pdf"},
    {"id":"22239","name":"P/40/2012: EMA decision of 24 February 2012 on the granting of a product specific waiver for recombinant porcine factor VIII, B-domain deleted (EMEA-000753-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/8530/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-40-2012-ema-decision-24-february-2012-granting-product-specific-waiver-recombinant-porcine-factor-viii-b-domain-deleted-emea-000753-pip01-11_en.pdf"},
    {"id":"22252","name":"P/0142/2014: EMA decision of 13 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lubiprostone (Amitiza) (EMEA-000245-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/252147/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2014-ema-decision-13-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-lubiprostone-amitiza-emea-000245-pip01-08-m02_en.pdf"},
    {"id":"22255","name":"P/0014/2012: EMA decision of 24 January 2012 on the granting of a product specific waiver for netupitant / palonosetron (EMEA-001198-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/973120/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2012-ema-decision-24-january-2012-granting-product-specific-waiver-netupitant-palonosetron-emea-001198-pip01-11_en.pdf"},
    {"id":"22262","name":"P/0126/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for rivaroxaban (Xarelto) (EMEA-000430-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/293994/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-rivaroxaban-xarelto-emea-000430-pip01-08-m09_en.pdf"},
    {"id":"22272","name":"P/0194/2016: EMA decision of 15 July 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for metreleptin (EMEA-001701-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-19T02:00:00Z","last_updated_date":"2016-09-19T02:00:00Z","reference_number":"EMA/408691/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2016-ema-decision-15-july-2016-agreement-paediatric-investigation-plan-granting-deferral-metreleptin-emea-001701-pip01-14_en.pdf"},
    {"id":"22283","name":"P/0052/2012: EMA decision of 23 March 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for rubidium (82Rb) chloride (EMEA-000488-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"EMA/108295/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2012-ema-decision-23-march-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rubidium-82rb-chloride-emea-000488-pip02-11_en.pdf"},
    {"id":"22287","name":"P/0151/2013: EMA decision of 5 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for voriconazole (Vfend), (EMEA-000191-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-08T18:00:00Z","last_updated_date":"2013-08-08T18:00:00Z","reference_number":"EMA/342140/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2013-ema-decision-5-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-voriconazole-vfend-emea-000191-pip01-08-m05_en.pdf"},
    {"id":"22302","name":"P/0176/2017: EMA decision of 3 July 2017 on the granting of a product specific waiver for dezamizumab (EMEA-002110-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/354123/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2017-ema-decision-3-july-2017-granting-product-specific-waiver-dezamizumab-emea-002110-pip01-17_en.pdf"},
    {"id":"22305","name":"P/0248/2013: EMA decision of 10 October 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sofosbuvir / ledipasvir (EMEA-001411-PIP01-12)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/587280/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2013-ema-decision-10-october-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sofosbuvir-ledipasvir-emea-001411-pip01-12_en.pdf"},
    {"id":"22314","name":"P/227/2010: EMA decision of 28 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral for partially purified bromelain (EMEA-000142-PIP02-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/651486/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-227-2010-ema-decision-28-october-2010-agreement-paediatric-investigation-plan-granting-deferral-partially-purified-bromelain-emea-000142-pip02-09_en.pdf"},
    {"id":"22316","name":"P/210/2011: EMA decision of 2 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis),\n\n(EMEA-000183-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/554940/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-210-2011-ema-decision-2-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip01-08-m01_en.pdf"},
    {"id":"22352","name":"P/0301/2014: EMA decision of 24 November 2014 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (Fycompa), (EMEA-000467-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/651537/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2014-ema-decision-24-november-2014-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-fycompa-emea-000467-pip01-08-m06_en.pdf"},
    {"id":"22355","name":"P/210/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for prucalopride succinate (Resolor)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/615425/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-210-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-prucalopride-succinate-resolor_en.pdf"},
    {"id":"22364","name":"P/0246/2013: EMA decision of 4 October 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for exon 45 specific phosphorothioate oligonucleotide (EMEA-001369-PIP01-12)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/592500/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2013-ema-decision-4-october-2013-agreement-paediatric-investigation-plan-granting-deferral-exon-45-specific-phosphorothioate-oligonucleotide-emea-001369-pip01-12_en.pdf"},
    {"id":"22366","name":"P/264/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for phleum pratense allergen extract (EMEA-000924-PIP01-1...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/670698/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-264-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-phleum-pratense-allergen-extract-emea-000924-pip01-1_en.pdf"},
    {"id":"22367","name":"P/57/2008: European medicines agency decision of 20 July 2008\n\non the application for product specific waiver for Epoetin theta (EMEA-000219-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parli...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-08T02:00:00Z","last_updated_date":"2008-09-08T02:00:00Z","reference_number":"EMEA/357430/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-57-2008-european-medicines-agency-decision-20-july-2008-application-product-specific-waiver-epoetin-theta-emea-000219-pip01-08-accordance-regulation-ec-no-1901-2006-european-parli_en.pdf"},
    {"id":"22368","name":"P/0105/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for evolocumab\n\n(Repatha), (EMEA-001268-PIP01-12-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/194970/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-evolocumab-repatha-emea-001268-pip01-12-m05_en.pdf"},
    {"id":"22373","name":"P/0114/2018: EMA decision of 11 April 2018 on the granting of a product specific waiver for enfortumab vedotin (EMEA-002299-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T02:00:00Z","last_updated_date":"2026-05-06T02:00:00Z","reference_number":"EMA/152182/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0114-2018-ema-decision-11-april-2018-granting-product-specific-waiver-enfortumab-vedotin-emea-002299-pip01-17_en.pdf"},
    {"id":"22376","name":"P/0004/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bevacizumab (Avastin), (EMEA-000056-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-19T01:00:00Z","last_updated_date":"2014-02-19T01:00:00Z","reference_number":"EMA/738884/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-bevacizumab-avastin-emea-000056-pip01-07-m02_en.pdf"},
    {"id":"22377","name":"P/0103/2016: EMA decision of 4 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for coagulation Factor VIIa (Recombinant) (EMEA-001203-PIP02-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/203384/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2016-ema-decision-4-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-coagulation-factor-viia-recombinant-emea-001203-pip02-14-m01_en.pdf"},
    {"id":"22392","name":"P/25/2011: EMA decision of 26 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for briakinumab (EMEA-000552-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 of the...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/30702/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-25-2011-ema-decision-26-january-2011-acceptance-modification-agreed-paediatric-investigation-plan-briakinumab-emea-000552-pip01-09-m01-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"22404","name":"P/281/2011: EMA decision of 28 November 2011 on the granting of a product specific waiver for icosapent (EMEA-001117-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T12:15:00Z","last_updated_date":"2011-12-21T12:15:00Z","reference_number":"EMA/878709/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-281-2011-ema-decision-28-november-2011-granting-product-specific-waiver-icosapent-emea-001117-pip01-10_en.pdf"},
    {"id":"22419","name":"P/0167/2014: EMA decision of 8 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ozenoxacin (EMEA-000981-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/344600/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2014-ema-decision-8-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-ozenoxacin-emea-000981-pip01-10-m04_en.pdf"},
    {"id":"22476","name":"P/0171/2013: EMA decision of 30 July on the acceptance of a modification of an agreed paediatric investigation plan for purified antigen fractions of inactivated split virion Influenza virus type A, H1N1 / Influenza viru...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/376110/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2013-ema-decision-30-july-acceptance-modification-agreed-paediatric-investigation-plan-purified-antigen-fractions-inactivated-split-virion-influenza-virus-type-h1n1-influenza-viru_en.pdf"},
    {"id":"22481","name":"P/120/2009: European Medicines Agency decision of 15 June 2009 on the granting of a product specific waiver for aliskiren hemifumarate / amlodipine besilate (EMEA-000517-PIP01-08) in accordance with Regulation (EC) No 19...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351843/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-120-2009-european-medicines-agency-decision-15-june-2009-granting-product-specific-waiver-aliskiren-hemifumarate-amlodipine-besilate-emea-000517-pip01-08-accordance-regulation-ec-no-19_en.pdf"},
    {"id":"22493","name":"P/137/2010: EMA decision of 30 July 2010 on the refusal of a modification of an agreed paediatric investigation plan for tapentadol hydrochloride (EMEA-000018-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-09-07T02:00:00Z","last_updated_date":"2010-09-07T02:00:00Z","reference_number":"EMA/469385/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-137-2010-ema-decision-30-july-2010-refusal-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-emea-000018-pip01-07-m02_en.pdf"},
    {"id":"22501","name":"P/6/2010: European Medicines Agency decision of 25 January 2010\n\non the granting of a product specific waiver for amlodipine besylate / valsartan / hydrochlorothiazide (EMEA-000744-PIP01-09) in accordance with Regulation...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMEA/35952/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-6-2010-european-medicines-agency-decision-25-january-2010-granting-product-specific-waiver-amlodipine-besylate-valsartan-hydrochlorothiazide-emea-000744-pip01-09-accordance-regulation_en.pdf"},
    {"id":"22533","name":"P/0173/2014: EMA decision of 11 July 2014 on the agreement of a paediatric investigation plan and on the granting of a waiver for vigabatrin (EMEA-000717-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-31T12:00:00Z","last_updated_date":"2014-07-31T12:00:00Z","reference_number":"EMA/354911/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2014-ema-decision-11-july-2014-agreement-paediatric-investigation-plan-granting-waiver-vigabatrin-emea-000717-pip02-13_en.pdf"},
    {"id":"22540","name":"P/87/2009: European medicines agency decision of 18 May 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for rolofylline (EMEA-000275-PIP01-08) in accordance with Regulation (EC)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/288303/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-87-2009-european-medicines-agency-decision-18-may-2009-agreement-paediatric-investigation-plan-granting-deferral-rolofylline-emea-000275-pip01-08-accordance-regulation-ec_en.pdf"},
    {"id":"22561","name":"P/0182/2016: EMA decision of of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam\n\n(Briviact), (EMEA-000332-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:10:00Z","last_updated_date":"2016-09-22T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-emea-000332-pip01-08-m10_en.pdf"},
    {"id":"22568","name":"P/0342/2017: EMA decision of 10 November 2017 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab\n\n(Humira) (EMEA-000366-PIP02-09-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T16:26:00Z","last_updated_date":"2018-02-13T16:26:00Z","reference_number":"EMA/711124/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0342-2017-ema-decision-10-november-2017-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip02-09-m05_en.pdf"},
    {"id":"22572","name":"P/221/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 12 Grass Pollen Extract and Cult...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/629199/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-221-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-12-grass-pollen-extract-cult_en.pdf"},
    {"id":"22579","name":"P/0307/2016: EMA decision of 4 November 2016 on the granting of a product-specific waiver for amlodipine / valsartan / hydrochlorothiazide (EMEA-002006-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-10T01:00:00Z","last_updated_date":"2017-01-10T01:00:00Z","reference_number":"EMA/707931/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2016-ema-decision-4-november-2016-granting-product-specific-waiver-amlodipine-valsartan-hydrochlorothiazide-emea-002006-pip01-16_en.pdf"}    {"id":"22623","name":"P/147/2009: EMEA decision on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for aqueous extract of grass pollen from Dactylis glomerata, Festuca pratensis, Holcus lanatus, Lolium...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/431574/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-147-2009-emea-decision-agreement-pip-granting-deferral-granting-waiver-aqueous-extract-grass-pollen-dactylis-glomerata-festuca-pratensis-holcus-lanatus-lolium_en.pdf"},
    {"id":"22627","name":"P/0085/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP01-07-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/215073/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-yervoy-emea-000117-pip01-07-m07_en.pdf"},
    {"id":"22639","name":"P/0026/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for vancomycin (EMEA-001311-PIP01-12-01-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/3765/2016 corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-vancomycin-emea-001311-pip01-12-01-m01_en.pdf"},
    {"id":"22661","name":"P/13/2011:  EMA decision of 3 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for allergen extracts of dermatophagoides farinae and derma...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/708102/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-13-2011-ema-decision-3-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extracts-dermatophagoides-farinae-derma_en.pdf"},
    {"id":"22663","name":"P/0110/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for methoxyflurane\n\n(Penthrox), (EMEA-000334-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/141782/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-methoxyflurane-penthrox-emea-000334-pip01-08-m07_en.pdf"},
    {"id":"22671","name":"P/0275/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for pollen from Phleum pratense (EMEA-000848-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/690870/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-pollen-phleum-pratense-emea-000848-pip01-10-m02_en.pdf"},
    {"id":"22677","name":"P/0060/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ferumoxytol, (Rienso) (EMEA-000373-PIP02-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/137334/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-ferumoxytol-rienso-emea-000373-pip02-09-m04_en.pdf"},
    {"id":"22695","name":"P/35/2008: European medicines agency decision of 24 June 2008\n\non the application for agreement of a Paediatric Investigation Plan for pitavastatin calcium EMEA-000054-PIP01-07 in accordance with Regulation (EC) No 1901/...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/313267/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-35-2008-european-medicines-agency-decision-24-june-2008-application-agreement-paediatric-investigation-plan-pitavastatin-calcium-emea-000054-pip01-07-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"22737","name":"P/0126/2014: EMA decision of 16 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ceftolozane / tazobactam (EMEA-001142-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-25T02:00:00Z","last_updated_date":"2014-06-25T02:00:00Z","reference_number":"EMA/187330/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2014-ema-decision-16-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-ceftolozane-tazobactam-emea-001142-pip01-11-m01_en.pdf"},
    {"id":"22751","name":"P/9/2011:  EMA decision of 3 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pollen from betula pendula (33%), corylus avellana (33%)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/753333/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-9-2011-ema-decision-3-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-betula-pendula-33-corylus-avellana-33_en.pdf"},
    {"id":"22762","name":"P/90/2010: European Medicines Agency decision of 1 June 2010 on the agreement of a paediatric investigation plan and on the granting of a waiver for bisoctrizole / titanium dioxide (EMEA-000585-PIP01-09) in accordance wi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-26T02:00:00Z","last_updated_date":"2010-07-26T02:00:00Z","reference_number":"EMA/335351/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-90-2010-european-medicines-agency-decision-1-june-2010-agreement-paediatric-investigation-plan-granting-waiver-bisoctrizole-titanium-dioxide-emea-000585-pip01-09-accordance-wi_en.pdf"},
    {"id":"22764","name":"P/0360/2016: EMA decision of 21 December 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for octenidine\n\n(dihydrochloride) (EMEA-001384-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/791551/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0360-2016-ema-decision-21-december-2016-agreement-paediatric-investigation-plan-granting-waiver-octenidine-dihydrochloride-emea-001384-pip01-12_en.pdf"},
    {"id":"22765","name":"P/0032/2013: EMA decision of 26 February 2013 on the granting of a product specific waiver for frovatriptan (succinate monohydrate) / dexketoprofen (trometamol) (EMEA-001317-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/89574/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2013-ema-decision-26-february-2013-granting-product-specific-waiver-frovatriptan-succinate-monohydrate-dexketoprofen-trometamol-emea-001317-pip01-12_en.pdf"},
    {"id":"22771","name":"P/0222/2015: EMA decision of 2 October 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for peanut flour (EMEA-001734-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-19T01:00:00Z","last_updated_date":"2015-11-19T01:00:00Z","reference_number":"EMA/603603/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2015-ema-decision-2-october-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-peanut-flour-emea-001734-pip01-14_en.pdf"},
    {"id":"22777","name":"P/0051/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for binimetinib (EMEA-001454-PIP03-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/133085/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-deferral-binimetinib-emea-001454-pip03-15_en.pdf"},
    {"id":"22783","name":"P/0270/2016: EMA decision of 7 October 2016 on the refusal of a modification of an agreed paediatric investigation plan for human fibrinogen /\n\nhuman thrombin (EMEA-001598-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-25T01:00:00Z","last_updated_date":"2016-11-25T01:00:00Z","reference_number":"EMA/631424/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2016-ema-decision-7-october-2016-refusal-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-emea-001598-pip01-13-m02_en.pdf"},
    {"id":"22800","name":"P/0041/2018: EMA decision of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for posaconazole\n\n(Noxafil) (EMEA-000468-PIP02-12-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T15:28:00Z","last_updated_date":"2018-04-17T15:28:00Z","reference_number":"EMA/77354/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2018-ema-decision-16-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-posaconazole-noxafil-emea-000468-pip02-12-m04_en.pdf"},
    {"id":"22808","name":"P/0198/2012: EMA decision of 24 August 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for apremilast (EMEA-000715-PIP03-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T14:00:00Z","last_updated_date":"2012-09-18T14:00:00Z","reference_number":"EMA/537337/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2012-ema-decision-24-august-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-apremilast-emea-000715-pip03-11_en.pdf"},
    {"id":"22817","name":"P/0034/2018: EMA decision of 30 January 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lucerastat (EMEA-002095-PIP01-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/848802/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2018-ema-decision-30-january-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lucerastat-emea-002095-pip01-16_en.pdf"},
    {"id":"22819","name":"P/0273/2014: EMA decision of 27 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for molidustat (sodium) (EMEA-001546-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-04T01:00:00Z","last_updated_date":"2014-12-04T01:00:00Z","reference_number":"EMA/624619/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2014-ema-decision-27-october-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-molidustat-sodium-emea-001546-pip01-13_en.pdf"},
    {"id":"22830","name":"P/0260/2014: EMA decision of 29 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for solifenacin (succinate) (Vesicare and associated names), (EMEA-000573-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/586421/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2014-ema-decision-29-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-solifenacin-succinate-vesicare-associated-names-emea-000573-pip01-09-m05_en.pdf"},
    {"id":"22855","name":"P/0229/2013: EMA decision of 23 September 2013 on the acceptance of a modification of an agreed PIP for Purified Tetanus Toxoid / Inactivated Type 1, 2 and 3 Poliovirus / Purified Pertussis Toxoid / Haemophilus influenza...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/492665/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2013-ema-decision-23-september-2013-acceptance-modification-agreed-pip-purified-tetanus-toxoid-inactivated-type-1-2-3-poliovirus-purified-pertussis-toxoid-haemophilus-influenza_en.pdf"},
    {"id":"22857","name":"P/72/2010: European Medicines Agency decision of 5 May 2010 on the acceptance of a modification of an agreed paediatric investigation plan for icatibant acetate (Firazyr) (EMEA-000408-PIP01-08-M02) in accordance with Reg...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/249207/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-72-2010-european-medicines-agency-decision-5-may-2010-acceptance-modification-agreed-paediatric-investigation-plan-icatibant-acetate-firazyr-emea-000408-pip01-08-m02-accordance-reg_en.pdf"},
    {"id":"22858","name":"P/0166/2012: EMA decision of 26 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for daclatasvir (EMEA-001191-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T16:00:00Z","last_updated_date":"2012-08-23T16:00:00Z","reference_number":"EMA/476938/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2012-ema-decision-26-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-daclatasvir-emea-001191-pip01-11_en.pdf"},
    {"id":"22871","name":"P/15/2008: European medicines agency decision of 31 March 2008 on the application for product-specific waiver for fosfluridine tidoxil (EMEA-000094-PIP01-07) in accordance with Regulation (EC) No 1901/2006 of the Europea...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-04-22T02:00:00Z","last_updated_date":"2008-04-22T02:00:00Z","reference_number":"EMEA/155447/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-15-2008-european-medicines-agency-decision-31-march-2008-application-product-specific-waiver-fosfluridine-tidoxil-emea-000094-pip01-07-accordance-regulation-ec-no-1901-2006-europea_en.pdf"},
    {"id":"22899","name":"P/0068/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant dimer of 6 kD early secretory antigenic target / recombinant 10 kD culture filtrat...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"P/0068/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-dimer-6-kd-early-secretory-antigenic-target-recombinant-10-kd-culture-filtrat_en.pdf"},
    {"id":"22916","name":"P/0125/2012: EMA decision of of 4 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for bimatoprost (Lumigan 0.1 mg/ml eye drops, solution, Lumigan 0.3 mg/ml eye drops, solution), (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-06T18:00:00Z","last_updated_date":"2012-08-06T18:00:00Z","reference_number":"EMA/435533/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2012-ema-decision-4-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-bimatoprost-lumigan-01-mg-ml-eye-drops-solution-lumigan-03-mg-ml-eye-drops-solution_en.pdf"},
    {"id":"22925","name":"P/0180/2015: EMA decision of 7 August 2015 on the granting of a product-specific waiver for rifamycin (EMEA-001754-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-24T02:00:00Z","last_updated_date":"2015-09-24T02:00:00Z","reference_number":"EMA/508333/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2015-ema-decision-7-august-2015-granting-product-specific-waiver-rifamycin-emea-001754-pip01-15_en.pdf"},
    {"id":"22940","name":"P/239/2010: EMA decision of 05 November 2010 on the acceptance of a modification of an agreed paediatric investigation plan for infliximab (Remicade), (EMEA-000549-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/678121/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-239-2010-ema-decision-05-november-2010-acceptance-modification-agreed-paediatric-investigation-plan-infliximab-remicade-emea-000549-pip01-09-m01_en.pdf"},
    {"id":"22962","name":"P/0084/2012: EMA decision of 21 May 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for liraglutide (Victoza) (EMEA-000128-PIP02-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T18:00:00Z","last_updated_date":"2012-06-25T18:00:00Z","reference_number":"EMA/304164/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2012-ema-decision-21-may-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-liraglutide-victoza-emea-000128-pip02-09_en.pdf"},
    {"id":"22967","name":"P/0188/2016: EMA decision of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant dimer of 6 kD early secretory antigenic target / recombinant 10 kD culture filtrate...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T02:00:00Z","last_updated_date":"2016-09-22T02:00:00Z","reference_number":"EMA/399717/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-dimer-6-kd-early-secretory-antigenic-target-recombinant-10-kd-culture-filtrate_en.pdf"},
    {"id":"22978","name":"P/86/2008:Alanine,arginine,aspartic acid,cysteine/cystine,glutamic acid, glycine, histidine, isoleucine, leucine, lysine monohydrate, methionine, ornithine hydrochloride, phenylalanine, proline, serine, taurine, threonin...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-11-24T00:00:00Z","last_updated_date":"2008-11-24T00:00:00Z","reference_number":"EMEA/526469/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-86-2008alaninearginineaspartic-acidcysteine-cystineglutamic-acid-glycine-histidine-isoleucine-leucine-lysine-monohydrate-methionine-ornithine-hydrochloride-phenylalanine-proline-serine-taurine_en.pdf"},
    {"id":"22980","name":"P/159/2011: EMA decision of 4 July 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for ocrelizumab (EMEA-000310-PIP03-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-08T02:00:00Z","last_updated_date":"2011-08-08T02:00:00Z","reference_number":"EMA/424485/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-159-2011-ema-decision-4-july-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ocrelizumab-emea-000310-pip03-10_en.pdf"},
    {"id":"22986","name":"P/0032/2012: EMA decision of 2 February 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ivabradine\n\n(hydrochloride) (Procoralan), (EMEA-000628-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T14:30:00Z","last_updated_date":"2012-03-15T14:30:00Z","reference_number":"EMA/62972/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2012-ema-decision-2-february-2012-acceptance-modification-agreed-paediatric-investigation-plan-ivabradine-hydrochloride-procoralan-emea-000628-pip01-09-m02_en.pdf"},
    {"id":"22988","name":"P/51/2011: EMA decision of 4 March 2011on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil fumarate) (EMEA-000533 PIP01-08-M01) in accordance with Regulation (EC) No 1...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/78723/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-51-2011-ema-decision-4-march-2011on-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-fumarate-emea-000533-pip01-08-m01-accordance-regulation-ec-no-1_en.pdf"},
    {"id":"22992","name":"P/78/2011: EMA decision of 6 April 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for fibrinogen\n\n(human plasma-derived) (EMEA-000457-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"EMA/248805/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-78-2011-ema-decision-6-april-2011-agreement-paediatric-investigation-plan-granting-deferral-fibrinogen-human-plasma-derived-emea-000457-pip02-10_en.pdf"},
    {"id":"23010","name":"P/0074/2013: EMA decision of 26 March 2013 on the agreement of a paediatric investigation plan for clonidine (Hydrochloride) (EMEA-001316-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/114384/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2013-ema-decision-26-march-2013-agreement-paediatric-investigation-plan-clonidine-hydrochloride-emea-001316-pip01-12_en.pdf"},
    {"id":"23021","name":"P/232/2011: Pneumococcal polysaccharide serotypes 1, 4, 5, 6B, 7F, 9V, 14, 23 F conjugated to protein D (derived from non-typeable haemophilus influenzae) carrier protein; Pneumococcal polysaccharide serotype 18C conjuga...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/763267/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-232-2011-pneumococcal-polysaccharide-serotypes-1-4-5-6b-7f-9v-14-23-f-conjugated-protein-d-derived-non-typeable-haemophilus-influenzae-carrier-protein-pneumococcal-polysaccharide-serotype-18c_en.pdf"},
    {"id":"23072","name":"P/0166/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for aciclovir (Sitavig and associated names), (EMEA-001066-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/348027/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-aciclovir-sitavig-associated-names-emea-001066-pip02-11-m02_en.pdf"},
    {"id":"23084","name":"P/0175/2017: EMA decision of 3 July 2017 on the granting of a product specific waiver for dezamizumab (EMEA-002110-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/354124/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2017-ema-decision-3-july-2017-granting-product-specific-waiver-dezamizumab-emea-002110-pip02-17_en.pdf"},
    {"id":"23122","name":"P/0308/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / abacavir / lamivudine (Triumeq) (EMEA-001219-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/792871/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-abacavir-lamivudine-triumeq-emea-001219-pip01-11-m02_en.pdf"},
    {"id":"23133","name":"P/0137/2017: EMA decision of 7 June 2017 on the agreement of a paediatric investigation plan and on the refusal of a deferral for rimiducid\n\n(EMEA-001870-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/293457/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2017-ema-decision-7-june-2017-agreement-paediatric-investigation-plan-refusal-deferral-rimiducid-emea-001870-pip01-15_en.pdf"},
    {"id":"23138","name":"P/85/2011: EMA decision of 8 April 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for imatinib (mesilate) (Glivec) (EMEA-000463-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/254705/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-85-2011-ema-decision-8-april-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-imatinib-mesilate-glivec-emea-000463-pip02-10_en.pdf"},
    {"id":"23143","name":"P/0199/2012: EMA decision of 24 August 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ex-vivo expanded human autologous epithelium containin...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T14:00:00Z","last_updated_date":"2012-09-18T14:00:00Z","reference_number":"EMA/534631/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2012-ema-decision-24-august-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ex-vivo-expanded-human-autologous-epithelium-containin_en.pdf"},
    {"id":"23158","name":"P/346/2010: EMA decision of 21 December 2010 on the acceptance of a modification of an agreed paediatric investigation plan for paliperidone / paliperidone palmitate (Invega) (EMEA-000014-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T00:00:00Z","last_updated_date":"2011-01-25T00:00:00Z","reference_number":"EMA/830331/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-346-2010-ema-decision-21-december-2010-acceptance-modification-agreed-paediatric-investigation-plan-paliperidone-paliperidone-palmitate-invega-emea-000014-pip01-07-m05_en.pdf"},
    {"id":"23225","name":"P/226/2010: EMA decision of 27 October 2010 on the agreement of a paediatric investigation plan and on the granting of a waiver for atazanavir\n\nsulphate (Reyataz), (EMA-000804-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/649948/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-226-2010-ema-decision-27-october-2010-agreement-paediatric-investigation-plan-granting-waiver-atazanavir-sulphate-reyataz-ema-000804-pip01-09_en.pdf"},
    {"id":"23229","name":"P/230/2010: EMA decision of 23 November 2010 on the acceptance of a modification of an agreed paediatric investigation plan for moxifloxacin\n\nhydrochloride (Avalox and associated names; Octegra and associated names; Acti...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T00:00:00Z","last_updated_date":"2010-12-21T00:00:00Z","reference_number":"EMA/656733/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-230-2010-ema-decision-23-november-2010-acceptance-modification-agreed-paediatric-investigation-plan-moxifloxacin-hydrochloride-avalox-associated-names-octegra-associated-names-acti_en.pdf"},
    {"id":"23274","name":"P/133/2011: EMA decision of 8 June 2011 on the granting of a product specific waiver for Gallium [68 Ga] Chloride / Germanium [68 Ge] Chloride (EMEA-001102-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/418845/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-133-2011-ema-decision-8-june-2011-granting-product-specific-waiver-gallium-68-ga-chloride-germanium-68-ge-chloride-emea-001102-pip01-10_en.pdf"},
    {"id":"23279","name":"P/67/2008: European medicines agency decision of 15 August 2008 on the application for product specific waiver for everolimus (EMEA-00019-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliame...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMEA/424631/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-67-2008-european-medicines-agency-decision-15-august-2008-application-product-specific-waiver-everolimus-emea-00019-pip01-08-accordance-regulation-ec-no-1901-2006-european-parliame_en.pdf"},
    {"id":"23287","name":"P/0198/2016: EMA decision of of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for (3-((4-Benzoyl-1-\n\npiperazinyl)(oxo)acetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:21:00Z","last_updated_date":"2016-09-22T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-3-4-benzoyl-1-piperazinyloxoacetyl-4-methoxy-7-3-methyl-1h-124-triazol-1-yl-1h_en.pdf"},
    {"id":"23321","name":"P/0126/2012: EMA decision of of 4 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for (3aR,4S,7aR)-octahydro-4-hydroxy-4-[(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid meth...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-06T18:00:00Z","last_updated_date":"2012-08-06T18:00:00Z","reference_number":"EMA/411114/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2012-ema-decision-4-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-3ar4s7ar-octahydro-4-hydroxy-4-3-methylphenylethynyl-1h-indole-1-carboxylic-acid-meth_en.pdf"},
    {"id":"23323","name":"P/0284/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for\n\npyridopyrimidione SMN2 splicing modifier (EMEA-002070-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/541730/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-pyridopyrimidione-smn2-splicing-modifier-emea-002070-pip01-16_en.pdf"},
    {"id":"23363","name":"P/0161/2013: EMA decision of 29 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (Fycompa), (EMEA-000467-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/379357/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2013-ema-decision-29-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-fycompa-emea-000467-pip01-08-m03_en.pdf"},
    {"id":"23373","name":"P/8/2010: European Medicines Agency Decision of 29 January 2010\n\non the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for Teplizumab (EMEA-000524-PIP01-08)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/44293/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-8-2010-european-medicines-agency-decision-29-january-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-teplizumab-emea-000524-pip01-08_en.pdf"},
    {"id":"23381","name":"P/0257/2016: EMA decision of 5 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for zuretinol (acetate)\n\n(EMEA-001453-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/585770/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2016-ema-decision-5-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-zuretinol-acetate-emea-001453-pip01-13-m01_en.pdf"},
    {"id":"23395","name":"P/182/2010: EMA decision of 24/9/10 on the acceptance of a modification of an agreed paediatric investigation plan for Diphtheria toxoid/Tetanus toxoid/Bordetella pertussis antigen: Pertussis toxoid/Bordetella pertussis ant...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-30T01:09:00Z","last_updated_date":"2010-10-30T01:09:00Z","reference_number":"EMA/583529/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-182-2010-ema-decision-24-9-10-acceptance-modification-agreed-paediatric-investigation-plan-diphtheria-toxoid-tetanus-toxoid-bordetella-pertussis-antigen-pertussis-toxoid-bordetella-pertussis-ant_en.pdf"},
    {"id":"23396","name":"P/0129/2015: EMA decision of 5 June 2015 on the granting of a product-specific waiver for ranolazine / dronedarone (EMEA-001726-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/347667/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2015-ema-decision-5-june-2015-granting-product-specific-waiver-ranolazine-dronedarone-emea-001726-pip01-14_en.pdf"},
    {"id":"23400","name":"P/0071/2017: EMA decision of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for avelumab\n\n(EMEA-001849-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/91509/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2017-ema-decision-17-march-2017-agreement-paediatric-investigation-plan-granting-deferral-avelumab-emea-001849-pip02-15_en.pdf"},
    {"id":"23410","name":"P/29/2011: EMA decision of 28 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir\n\n(phosphate) (Tamiflu) (EMEA-000365-PIP01-08-M02) in accordance with Regulation (E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"EMA/58239/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-29-2011-ema-decision-28-january-2011-acceptance-modification-agreed-paediatric-investigation-plan-oseltamivir-phosphate-tamiflu-emea-000365-pip01-08-m02-accordance-regulation-e_en.pdf"},
    {"id":"23415","name":"P/0035/2016: EMA decision of 1 February 2016 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for 13C-Methacetin (EMEA-001844-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/23036/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2016-ema-decision-1-february-2016-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-13c-methacetin-emea-001844-pip01-15_en.pdf"},
    {"id":"23437","name":"P/0053/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for anidulafungin\n\n(Ecalta), (EMEA-000469-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/90864/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-anidulafungin-ecalta-emea-000469-pip01-08-m07_en.pdf"},
    {"id":"23438","name":"P/243/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for [(3S)-6-({2',6'-Dimethyl-4'-[3-(methylsulfonyl) propo...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/501874/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-243-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-3s-6-26-dimethyl-4-3-methylsulfonyl-propo_en.pdf"},
    {"id":"23467","name":"P/0031/2015: EMA decision of 12 February 2015 on the acceptance of a modification of an agreed paediatric investigation plan for allantoin (EMEA-001590-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/75713/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2015-ema-decision-12-february-2015-acceptance-modification-agreed-paediatric-investigation-plan-allantoin-emea-001590-pip01-13-m01_en.pdf"},
    {"id":"23478","name":"P/0294/2014: EMA decision of 30 October 2014on the acceptance of a modification of an agreed paediatric investigation plan for MAGE-A3 recombinant protein (EMEA-001099-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-09T01:00:00Z","last_updated_date":"2014-12-09T01:00:00Z","reference_number":"EMA/590079/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2014-ema-decision-30-october-2014on-acceptance-modification-agreed-paediatric-investigation-plan-mage-a3-recombinant-protein-emea-001099-pip02-11-m01_en.pdf"},
    {"id":"23506","name":"P/0134/2015: EMA decision of 15 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for tocilizumab (RoActemra), (EMEA-000309-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-07T02:00:00Z","last_updated_date":"2015-07-07T02:00:00Z","reference_number":"EMA/383650/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2015-ema-decision-15-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-tocilizumab-roactemra-emea-000309-pip01-08-m06_en.pdf"},
    {"id":"23520","name":"P/80/2010: European Medicines Agency decision of 7 May 2010\n\non the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for taspoglutide (EMEA-000649-PIP01-09) i...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/265545/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-80-2010-european-medicines-agency-decision-7-may-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-taspoglutide-emea-000649-pip01-09-i_en.pdf"},
    {"id":"23567","name":"P/0299/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for olaratumab (EMEA-\n\n001760-PIP01-15-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-20T16:17:00Z","last_updated_date":"2017-01-20T16:17:00Z","reference_number":"P/0299/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-olaratumab-emea-001760-pip01-15-m01_en.pdf"},
    {"id":"23570","name":"P/0102/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for alirocumab (EMEA-\n\n001169-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/188342/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-alirocumab-emea-001169-pip01-11-m01_en.pdf"},
    {"id":"23574","name":"P/241/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aluminium hydroxide adsorbed, depigmented glutaraldeh...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/709776/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-241-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaraldeh_en.pdf"},
    {"id":"23580","name":"P/329/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Aqueous allergen extract of birch, alder and hazel po...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/778420/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-329-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aqueous-allergen-extract-birch-alder-hazel-po_en.pdf"},
    {"id":"23582","name":"P/150/2011: EMA decision of 10 June 2011 on the granting of a product specific waiver for progesterone (EMEA-001137-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/387190/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-150-2011-ema-decision-10-june-2011-granting-product-specific-waiver-progesterone-emea-001137-pip01-11_en.pdf"},
    {"id":"23595","name":"P/0318/2014: EMA decision of 19 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Victoza) (EMEA-000128-PIP01-07-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-20T01:00:00Z","last_updated_date":"2015-02-20T01:00:00Z","reference_number":"EMA/761550/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2014-ema-decision-19-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-victoza-emea-000128-pip01-07-m06_en.pdf"},
    {"id":"23599","name":"P/0054/2012: EMA decision of 23 March 2012 on the granting of a product specific waiver for deoxycholic acid (EMEA-001218-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"EMA/107390/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2012-ema-decision-23-march-2012-granting-product-specific-waiver-deoxycholic-acid-emea-001218-pip01-11_en.pdf"},
    {"id":"23602","name":"P/0203/2014: EMA decision of 8 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for cangrelor\n\n(tetrasodium), (EMEA-001348-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/391891/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2014-ema-decision-8-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-cangrelor-tetrasodium-emea-001348-pip01-12-m01_en.pdf"},
    {"id":"23619","name":"P/0234/2016: EMA decision of 9 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for brexpiprazole\n\n(EMEA-001185-PIP01-11-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/579489/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2016-ema-decision-9-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-brexpiprazole-emea-001185-pip01-11-m03_en.pdf"},
    {"id":"23649","name":"P/0153/2015: EMA decision of 10 July 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for calcipotriol (EMEA-001606-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-25T02:00:00Z","last_updated_date":"2015-08-25T02:00:00Z","reference_number":"EMA/382980/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2015-ema-decision-10-july-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-calcipotriol-emea-001606-pip02-14_en.pdf"},
    {"id":"23656","name":"P/82/2011: EMA decision of 6 April 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for azelastine\n\n(hydrochloride) / fluticasone (propionate) (EMEA-000990-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/221225/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-82-2011-ema-decision-6-april-2011-agreement-paediatric-investigation-plan-granting-waiver-azelastine-hydrochloride-fluticasone-propionate-emea-000990-pip02-10_en.pdf"},
    {"id":"23665","name":"P/0010/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for fosaprepitant (Ivemend) (EMEA-000406-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-19T01:00:00Z","last_updated_date":"2014-02-19T01:00:00Z","reference_number":"EMA/10721/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-fosaprepitant-ivemend-emea-000406-pip01-08-m04_en.pdf"},
    {"id":"23673","name":"P/0229/2015: EMA decision of 22 October 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for meropenem trihydrate (in combination with vaborbactam) (EMEA-001731-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-22T13:00:00Z","last_updated_date":"2015-12-22T13:00:00Z","reference_number":"EMA/624853/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2015-ema-decision-22-october-2015-agreement-paediatric-investigation-plan-granting-deferral-meropenem-trihydrate-combination-vaborbactam-emea-001731-pip01-14_en.pdf"},
    {"id":"23679","name":"P/0287/2012: EMA decision of 23 November on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for dolutegravir / abacavir / lamivudine (EMEA-001219-PIP01-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-07T01:00:00Z","last_updated_date":"2013-01-07T01:00:00Z","reference_number":"EMA/572310/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2012-ema-decision-23-november-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dolutegravir-abacavir-lamivudine-emea-001219-pip01_en.pdf"},
    {"id":"23682","name":"P/0248/2014: EMA decision of 30 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for amikacin (sulfate) (EMEA-000525-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/508733/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2014-ema-decision-30-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-amikacin-sulfate-emea-000525-pip01-08-m03_en.pdf"},
    {"id":"23685","name":"P/24/2010: European Medicines Agency decision of 15 March 2010 on the granting of a product specific waiver for strontium ranelate (Osseor) (EMEA-000733-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the Eu...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMA/164722/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-24-2010-european-medicines-agency-decision-15-march-2010-granting-product-specific-waiver-strontium-ranelate-osseor-emea-000733-pip01-09-accordance-regulation-ec-no-1901-2006-eu_en.pdf"},
    {"id":"23722","name":"P/0216/2016: EMA decision of 12 August 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cabotegravir, (EMEA-001418-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/519949/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2016-ema-decision-12-august-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cabotegravir-emea-001418-pip02-15_en.pdf"},
    {"id":"23725","name":"P/0043/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen / human thrombin (EMEA-001340-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-25T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/86529/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2015-ema-decision-6-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-emea-001340-pip01-12-m01_en.pdf"},
    {"id":"23731","name":"P/0003/2015: EMA decision of 16 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir / ledipasvir (EMEA-001411-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-17T01:00:00Z","last_updated_date":"2015-02-17T01:00:00Z","reference_number":"EMA/776076/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2015-ema-decision-16-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-sofosbuvir-ledipasvir-emea-001411-pip01-12-m02_en.pdf"},
    {"id":"23745","name":"P/0052/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for conestat alfa\n\n(Ruconest), (EMEA-000367-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/136542/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-conestat-alfa-ruconest-emea-000367-pip01-08-m06_en.pdf"},
    {"id":"23770","name":"P/0324/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T11:23:00Z","last_updated_date":"2017-01-30T11:23:00Z","reference_number":"EMA/741983/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0324-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-linagliptin-trajenta-emea-000498-pip01-08-m06_en.pdf"},
    {"id":"23790","name":"P/0305/2013: EMA decision of 28 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (EMEA-000332-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/712653/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2013-ema-decision-28-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-emea-000332-pip01-08-m07_en.pdf"},
    {"id":"23804","name":"P/316/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of hazel pollen (EMEA-00094...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769330/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-316-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-hazel-pollen-emea-00094_en.pdf"},
    {"id":"23812","name":"P/286/2011: EMA decision of 30 November 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for alemtuzumab (EMEA-001072-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/910511/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-286-2011-ema-decision-30-november-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-alemtuzumab-emea-001072-pip01-10_en.pdf"},
    {"id":"23815","name":"P/0161/2017: EMA decision of 30 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod (EMEA-001710-PIP02-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/397269/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2017-ema-decision-30-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-ozanimod-emea-001710-pip02-14-m01_en.pdf"},
    {"id":"23820","name":"P/0110/2017: EMA decision of 11 April 2017 on the granting of a product specific waiver for amlodipine / perindopril (EMEA-002091-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/196235/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2017-ema-decision-11-april-2017-granting-product-specific-waiver-amlodipine-perindopril-emea-002091-pip01-16_en.pdf"},
    {"id":"23833","name":"P/0173/2012: EMA decision of 27 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for trivalent, seasonal, recombinant influenza hemagglutinin...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T16:00:00Z","last_updated_date":"2012-08-23T16:00:00Z","reference_number":"EMA/475588/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2012-ema-decision-27-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-trivalent-seasonal-recombinant-influenza-hemagglutinin_en.pdf"},
    {"id":"23849","name":"P/289/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for aqueous allergen extract of dermatophagoides pterony...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/802406/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-289-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aqueous-allergen-extract-dermatophagoides-pterony_en.pdf"},
    {"id":"23880","name":"P/0218/2014: EMA decision of 3 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ferric citrate (EMEA-001213-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/454411/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2014-ema-decision-3-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-ferric-citrate-emea-001213-pip02-12-m01_en.pdf"},
    {"id":"23911","name":"P/57/2010: European Medicines Agency decision of 9 April 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for taliglucerase alfa (EMEA-000648-PIP0...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/208668/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-57-2010-european-medicines-agency-decision-9-april-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-taliglucerase-alfa-emea-000648-pip0_en.pdf"},
    {"id":"23927","name":"P/0067/2014: European Medicines Agency decision of 14 March 2014 on the agreement of a paediatric investigation plan and on the granting of a waiver for allergoid preparation of Phleum pratense pollen extract (EMEA-00141...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/103581/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2014-european-medicines-agency-decision-14-march-2014-agreement-paediatric-investigation-plan-granting-waiver-allergoid-preparation-phleum-pratense-pollen-extract-emea-00141_en.pdf"},
    {"id":"23946","name":"P/9/2010: European Medicines Agency of 29 January 2010 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the\n\ngranting of a waiver for Givinostat (EMEA-000551-PIP01-09) in accor...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/35973/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-9-2010-european-medicines-agency-29-january-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-givinostat-emea-000551-pip01-09-accor_en.pdf"},
    {"id":"23948","name":"P/309/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for golimumab (Simponi), (EMEA-000265-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/698393/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-309-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-golimumab-simponi-emea-000265-pip01-08-m03_en.pdf"},
    {"id":"23960","name":"P/0247/2013: EMA decision of 4 October 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for exon 53 specific phosphorothioate oligonucleotide (EMEA-001374-PIP01-12)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/592589/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2013-ema-decision-4-october-2013-agreement-paediatric-investigation-plan-granting-deferral-exon-53-specific-phosphorothioate-oligonucleotide-emea-001374-pip01-12_en.pdf"}    {"id":"23994","name":"P/0220/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for anti programmed death-ligand 1 (PD-L1) monoclonal antibody (MPDL3280A) (EMEA-001638-PIP01-14-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-24T12:00:00Z","last_updated_date":"2015-11-24T12:00:00Z","reference_number":"EMA/568187/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-anti-programmed-death-ligand-1-pd-l1-monoclonal-antibody-mpdl3280a-emea-001638-pip01-14_en.pdf"},
    {"id":"23996","name":"P/0084/2013: EMA decision of 29 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant L-asparaginase (EMEA-000013-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/187814/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2013-ema-decision-29-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-l-asparaginase-emea-000013-pip01-07-m03_en.pdf"},
    {"id":"24000","name":"P/0110/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis), (EMEA-000183-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/296248/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip01-08-m03_en.pdf"},
    {"id":"24021","name":"P/0337/2017: EMA decision of 30 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sotagliflozin (EMEA-\n\n001517-PIP02-14-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T01:00:00Z","last_updated_date":"2018-02-15T01:00:00Z","reference_number":"EMA/711130/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0337-2017-ema-decision-30-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-sotagliflozin-emea-001517-pip02-14-m02_en.pdf"},
    {"id":"24053","name":"P/0065/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for meropenem (EMEA-000898-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/131047/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-meropenem-emea-000898-pip01-10-m02_en.pdf"},
    {"id":"24058","name":"P/0301/2016: EMA decision of 4 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for immunoglobulin G2, anti-(human α-calcitonin gene-rel...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-09T01:00:00Z","last_updated_date":"2017-01-09T01:00:00Z","reference_number":"EMA/501874/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2016-ema-decision-4-november-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-immunoglobulin-g2-anti-human-i-calcitonin-gene-rel_en.pdf"},
    {"id":"24061","name":"P/0115/2013: EMA decision of 26 April 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for solifenacin (succinate) (Vesicare and associated names), (EMEA-000573-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/247088/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2013-ema-decision-26-april-2013-agreement-paediatric-investigation-plan-granting-waiver-solifenacin-succinate-vesicare-associated-names-emea-000573-pip02-13_en.pdf"},
    {"id":"24064","name":"P/0221/2012: EMA decision of 1 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for chloroprocaine\n\n(hydrochloride) (EMEA-000639-PIP02-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T01:00:00Z","last_updated_date":"2012-11-23T01:00:00Z","reference_number":"EMA/568824/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2012-ema-decision-1-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-chloroprocaine-hydrochloride-emea-000639-pip02-09-m01_en.pdf"},
    {"id":"24065","name":"P/0125/2018: EMA decision of 11 April 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ixazomib (Ninlaro), (EMEA-001410-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-26T02:00:00Z","last_updated_date":"2018-07-26T02:00:00Z","reference_number":"EMA/191160/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2018-ema-decision-11-april-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ixazomib-ninlaro-emea-001410-pip02-17_en.pdf"},
    {"id":"24077","name":"P/0020/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for sirukumab (EMEA-001043-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/866518/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-sirukumab-emea-001043-pip01-10-m02_en.pdf"},
    {"id":"24091","name":"P/5/2010: European Medicines Agency decision of 25 January 2010\n\non the granting of a product specific waiver for atorvastatin (L-lysine salt) / amlodipine besilate (EMEA-000719-PIP01-09) in accordance with Regulation (E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMEA/35952/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-5-2010-european-medicines-agency-decision-25-january-2010-granting-product-specific-waiver-atorvastatin-l-lysine-salt-amlodipine-besilate-emea-000719-pip01-09-accordance-regulation-e_en.pdf"},
    {"id":"24102","name":"P/0015/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for eslicarbazepine (acetate) (Zebinix) (EMEA-000696-PIP02-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/43935/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-eslicarbazepine-acetate-zebinix-emea-000696-pip02-10-m05_en.pdf"},
    {"id":"24105","name":"P/129/2011: EMA decision of 8 June 2011 on the acceptance of a modification of an agreed paediatric investigation plan for etravirine (Intelence) (EMEA-000222-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-13T02:00:00Z","last_updated_date":"2011-07-13T02:00:00Z","reference_number":"EMA/326623/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-129-2011-ema-decision-8-june-2011-acceptance-modification-agreed-paediatric-investigation-plan-etravirine-intelence-emea-000222-pip01-08-m04_en.pdf"},
    {"id":"24113","name":"P/107/2009: European Medicines Agency decision of 19 June 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for esomeprazole sodium, esomeprazole m...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351948/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-107-2009-european-medicines-agency-decision-19-june-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-esomeprazole-sodium-esomeprazole-m_en.pdf"},
    {"id":"24116","name":"P/0347/2017: EMA decision of 1 December 2017 on the refusal of a modification of an agreed paediatric investigation plan for tolvaptan (Samsca and associated names) (EMEA-001231-PIP02-13-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T11:48:00Z","last_updated_date":"2018-03-02T11:48:00Z","reference_number":"EMA/724148/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0347-2017-ema-decision-1-december-2017-refusal-modification-agreed-paediatric-investigation-plan-tolvaptan-samsca-associated-names-emea-001231-pip02-13-m05_en.pdf"},
    {"id":"24130","name":"P/79/2009: European Medicines Agency decision of 24 April 2009 on the agreement of a Paediatric Investigation Plan and on granting of a deferral and on granting of a waiver for purified antigen fractions of inactivated s...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-06-10T02:00:00Z","last_updated_date":"2009-06-10T02:00:00Z","reference_number":"EMEA/227977/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-79-2009-european-medicines-agency-decision-24-april-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-purified-antigen-fractions-inactivated-s_en.pdf"},
    {"id":"24132","name":"P/134/2010:  European Medicines Agency decision of 28 July 2010 on the granting of a product specific waiver for amlodipine besilate/perindopril tert-butylamine (EMEA-000823-PIP01-10) in accordance with Regulation (EC) N...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/465065/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-134-2010-european-medicines-agency-decision-28-july-2010-granting-product-specific-waiver-amlodipine-besilate-perindopril-tert-butylamine-emea-000823-pip01-10-accordance-regulation-ec-n_en.pdf"},
    {"id":"24148","name":"P/0046/2015: EMA decision of 6 March 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for eravacycline (EMEA-001555-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-23T01:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMA/86510/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2015-ema-decision-6-march-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eravacycline-emea-001555-pip01-13_en.pdf"},
    {"id":"24151","name":"P/0029/2018: EMA decision of 30 January 2018 on the refusal of a product specific waiver for fluorocholine (18F), (EMEA-002129-PIP02-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/27426/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2018-ema-decision-30-january-2018-refusal-product-specific-waiver-fluorocholine-18f-emea-002129-pip02-17_en.pdf"},
    {"id":"24161","name":"P/5/2011: EMA decision of 3 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ecallantide (Recombinant Inhibitor of Human Plasma Kallikrein), (EMEA-000688-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/683299/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-5-2011-ema-decision-3-january-2011-acceptance-modification-agreed-paediatric-investigation-plan-ecallantide-recombinant-inhibitor-human-plasma-kallikrein-emea-000688-pip01-09-m01_en.pdf"},
    {"id":"24174","name":"P/0141/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for indacaterol (acetate) / mometasone (furoate) (EMEA-001217-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/312561/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-indacaterol-acetate-mometasone-furoate-emea-001217-pip01-11-m03_en.pdf"},
    {"id":"24176","name":"P/0048/2016: EMA decision of 4 March 2016 on the granting of a product specific waiver for ramipril / amlodipine (EMEA-001871-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/90061/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2016-ema-decision-4-march-2016-granting-product-specific-waiver-ramipril-amlodipine-emea-001871-pip01-15_en.pdf"},
    {"id":"24179","name":"P/248/2011: EMA decision of 25 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (EMEA-000467-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T17:30:00Z","last_updated_date":"2011-11-29T17:30:00Z","reference_number":"EMA/751065/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-248-2011-ema-decision-25-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-emea-000467-pip01-08-m01_en.pdf"},
    {"id":"24188","name":"P/0297/2014: EMA decision of 24 November 2014 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone propionate / formoterol fumarate (Flutiform and associated names) (EMEA-000127-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/624740/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2014-ema-decision-24-november-2014-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-propionate-formoterol-fumarate-flutiform-associated-names-emea-000127_en.pdf"},
    {"id":"24215","name":"P/0259/2012: EMA decision of of 19 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab\n\n(Humira) (EMEA-000366-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/680269/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2012-ema-decision-19-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip01-08-m05_en.pdf"},
    {"id":"24222","name":"P/0305/2016: EMA decision of 4 November 2016 on the granting of a product-specific waiver for ciclosporin, (EMEA-001998-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-10T01:00:00Z","last_updated_date":"2017-01-10T01:00:00Z","reference_number":"EMA/501922/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2016-ema-decision-4-november-2016-granting-product-specific-waiver-ciclosporin-emea-001998-pip01-16_en.pdf"},
    {"id":"24227","name":"P/0039/2013: EMA decision of 27 February 2013 on the granting of a product-specific waiver for valsartan / indapamide (EMEA-001377-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/23964/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2013-ema-decision-27-february-2013-granting-product-specific-waiver-valsartan-indapamide-emea-001377-pip01-12_en.pdf"},
    {"id":"24234","name":"P/0124/2018: EMA decision of 11 April 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fevipiprant (EMEA-001315-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-26T02:00:00Z","last_updated_date":"2018-07-26T02:00:00Z","reference_number":"EMA/141779/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2018-ema-decision-11-april-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fevipiprant-emea-001315-pip02-16_en.pdf"},
    {"id":"24255","name":"P/0072/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for glibenclamide (EMEA-001324-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/137572/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-glibenclamide-emea-001324-pip01-12-m01_en.pdf"},
    {"id":"24256","name":"P/291/2011: EMA decision of 2 December 2011 on the agreement of a paediatric investigation plan for dopamine (hydrochloride) (EMEA-001105-\n\nPIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/922736/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-291-2011-ema-decision-2-december-2011-agreement-paediatric-investigation-plan-dopamine-hydrochloride-emea-001105-pip01-10_en.pdf"},
    {"id":"24265","name":"P/0349/2016: EMA decision of 2 December 2016 on the refusal of a product specific waiver for terguride (hydrogenmaleate) (EMEA-002015-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/757984/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0349-2016-ema-decision-2-december-2016-refusal-product-specific-waiver-terguride-hydrogenmaleate-emea-002015-pip01-16_en.pdf"},
    {"id":"24267","name":"P/0007/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab (EMEA-000069-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/4124/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-emea-000069-pip01-07-m04_en.pdf"},
    {"id":"24286","name":"P/0219/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-\n\n001501-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/513635/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-emea-001501-pip01-13-m03_en.pdf"},
    {"id":"24303","name":"P/7/2011:  EMA decision of 3 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for allergens from Dermatophagoides pteronyssinus and Dermat...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/707916/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-7-2011-ema-decision-3-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergens-dermatophagoides-pteronyssinus-dermat_en.pdf"},
    {"id":"24326","name":"P/0043/2016: EMA decision of 26 February 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names and T...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/133034/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2016-ema-decision-26-february-2016-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-t_en.pdf"},
    {"id":"24331","name":"P/108/2012: EMA decision of 8 June 2012 on the acceptance of a modification of an agreed paediatric investigation plan for canakinumab (Ilaris), (EMEA-000060-PIP02-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-23T17:00:00Z","last_updated_date":"2012-07-23T17:00:00Z","reference_number":"EMA/326702/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-108-2012-ema-decision-8-june-2012-acceptance-modification-agreed-paediatric-investigation-plan-canakinumab-ilaris-emea-000060-pip02-08-m05_en.pdf"},
    {"id":"24332","name":"P/0149/2015: EMA decision of 10 July 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxid...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-25T02:00:00Z","last_updated_date":"2015-08-25T02:00:00Z","reference_number":"EMA/368538/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2015-ema-decision-10-july-2015-agreement-paediatric-investigation-plan-granting-deferral-4r5r-1-4-4-33-dibutyl-7-dimethylamino-2345-tetrahydro-4-hydroxy-11-dioxid_en.pdf"},
    {"id":"24336","name":"P/0148/2013: EMA decision of 3 July 2013 on the granting of a product-specific waiver for ketoprofen / omeprazole (EMEA-001361-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-13T17:30:00Z","last_updated_date":"2013-08-13T17:30:00Z","reference_number":"EMA/316683/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2013-ema-decision-3-july-2013-granting-product-specific-waiver-ketoprofen-omeprazole-emea-001361-pip01-12_en.pdf"},
    {"id":"24340","name":"P/87/2010: European Medicines Agency decision of 1 June 2010 on the agreement of a paediatric investigation plan and on the granting of a waiver for clindamycin (phosphate) / bituminosulphonate (sodium) (EMEA-000532-PIP0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/335299/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-87-2010-european-medicines-agency-decision-1-june-2010-agreement-paediatric-investigation-plan-granting-waiver-clindamycin-phosphate-bituminosulphonate-sodium-emea-000532-pip0_en.pdf"},
    {"id":"24341","name":"P/0283/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for (Z)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-(2-\n\n(sul...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/565682/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-z-n-3-bromo-4-fluorophenyl-n-hydroxy-4-2-sul_en.pdf"},
    {"id":"24356","name":"P/0135/2014: EMA decision of 11 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for raltegravir (Isentress), (EMEA-000279-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/280409/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2014-ema-decision-11-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-raltegravir-isentress-emea-000279-pip01-08-m02_en.pdf"},
    {"id":"24366","name":"P/0076/2017: EMA decision of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for gadolinium,\n\n[α3,α6,α9-tris[3-[(2,3-dihydroxypropyl)amino]-3-oxopropyl]-3,6,9,15-\n\nt...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/106208/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2017-ema-decision-17-march-2017-agreement-paediatric-investigation-plan-granting-deferral-gadolinium-i-3i-6i-9-tris3-23-dihydroxypropylamino-3-oxopropyl-36915-t_en.pdf"},
    {"id":"24372","name":"P/0100/2018: EMA decision of 15 March 2018 on the granting of a product-specific waiver for humanized recombinant IgG4 anti-human tau antibody\n\n(EMEA-002226-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/141125/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2018-ema-decision-15-march-2018-granting-product-specific-waiver-humanized-recombinant-igg4-anti-human-tau-antibody-emea-002226-pip02-17_en.pdf"},
    {"id":"24376","name":"P/0256/2013: EMA decision of 29 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for regadenoson (Rapiscan) (EMEA-000410-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/598291/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2013-ema-decision-29-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-regadenoson-rapiscan-emea-000410-pip01-08-m01_en.pdf"},
    {"id":"24401","name":"P/270/2010: EMA decision of 6 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pralatrexate (EMEA-000619-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-10T01:00:00Z","last_updated_date":"2011-01-10T01:00:00Z","reference_number":"EMA/716808/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-270-2010-ema-decision-6-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pralatrexate-emea-000619-pip02-10_en.pdf"},
    {"id":"24403","name":"P/0291/2016: EMA decision of 4 November 2016 on the granting of a product-specific waiver for sirukumab (EMEA-001043-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-06T01:00:00Z","last_updated_date":"2017-01-06T01:00:00Z","reference_number":"EMA/708027/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2016-ema-decision-4-november-2016-granting-product-specific-waiver-sirukumab-emea-001043-pip02-16_en.pdf"},
    {"id":"24406","name":"P/0203/2015: EMA decision of 4 September 2015 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for azithromycin (EMEA-001777-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/570271/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2015-ema-decision-4-september-2015-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-azithromycin-emea-001777-pip01-15_en.pdf"},
    {"id":"24408","name":"P/0035/2013: EMA decision of 27 February 2013 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide, (EMEA-000916-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T02:00:00Z","last_updated_date":"2013-04-23T02:00:00Z","reference_number":"EMA/66787/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2013-ema-decision-27-february-2013-acceptance-modification-agreed-paediatric-investigation-plan-lixisenatide-emea-000916-pip01-10-m03_en.pdf"},
    {"id":"24444","name":"P/132/2011: EMA decision of 8 June 2011 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (H5N1 or H1N1 strains) (Focetria and associated names, Aflunov a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-13T02:00:00Z","last_updated_date":"2011-07-13T02:00:00Z","reference_number":"EMA/374750/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-132-2011-ema-decision-8-june-2011-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-h5n1-or-h1n1-strains-focetria-associated-names-aflunov_en.pdf"},
    {"id":"24468","name":"P/0066/2012: EMA decision of 28 March 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for anakinra\n\n(Kineret), (EMEA-001212-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"EMA/184118/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2012-ema-decision-28-march-2012-agreement-paediatric-investigation-plan-granting-waiver-anakinra-kineret-emea-001212-pip01-11_en.pdf"},
    {"id":"24470","name":"P/0296/2014: EMA decision of 7 November 2014 on the acceptance of a modification of an agreed paediatric investigation plan for midostaurin (EMEA-000780-PIP01-09-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T01:00:00Z","last_updated_date":"2014-12-05T01:00:00Z","reference_number":"EMA/651535/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2014-ema-decision-7-november-2014-acceptance-modification-agreed-paediatric-investigation-plan-midostaurin-emea-000780-pip01-09-m01_en.pdf"},
    {"id":"24474","name":"P/0049/2013: European medicines agency decision of 1 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and asso...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/85743/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2013-european-medicines-agency-decision-1-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-asso_en.pdf"},
    {"id":"24476","name":"P/83/2008: European medicines agency decision of of 14 October 2008 \n\non the application for agreement of a Paediatric Investigation Plan for valsartan (Diovan) (EMEA-000005-PIP01-07) in accordance with Regulation (EC) N...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-11-24T00:00:00Z","last_updated_date":"2008-11-24T00:00:00Z","reference_number":"EMEA/523615/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-83-2008-european-medicines-agency-decision-14-october-2008-application-agreement-paediatric-investigation-plan-valsartan-diovan-emea-000005-pip01-07-accordance-regulation-ec-n_en.pdf"},
    {"id":"24483","name":"P/0109/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for vedolizumab\n\n(Entyvio), (EMEA-000645-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/197922/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-vedolizumab-entyvio-emea-000645-pip01-09-m06_en.pdf"},
    {"id":"24486","name":"P/0291/2012: EMA decision of 18 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for treprostinil (Remodulin and associated names), (EMEA-000207-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/802680/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2012-ema-decision-18-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-treprostinil-remodulin-associated-names-emea-000207-pip01-08-m03_en.pdf"},
    {"id":"24496","name":"P/0251/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ceftazidime / avibactam (EMEA-001313-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/619847/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-emea-001313-pip01-12-m04_en.pdf"},
    {"id":"24521","name":"P/0270/2014: EMA decision of 27 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for regorafenib (Stivarga), (EMEA-001178-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-10T01:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"EMA/587625/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2014-ema-decision-27-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-regorafenib-stivarga-emea-001178-pip01-11-m01_en.pdf"},
    {"id":"24537","name":"P/0295/2015: EMA decision of 3 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (Gammaplex), (EMEA-000830-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/773326/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2015-ema-decision-3-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-gammaplex-emea-000830-pip02-10-m02_en.pdf"},
    {"id":"24538","name":"P/0310/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for erenumab (EMEA-\n\n001664-PIP02-15-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/666628/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0310-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-erenumab-emea-001664-pip02-15-m01_en.pdf"},
    {"id":"24539","name":"P/0300/2014: EMA decision of 24 November 2014 on the acceptance of a modification of an agreed paediatric investigation plan for L-asparaginase encapsulated in erythrocytes (EMEA-000341-PIP02-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/624771/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2014-ema-decision-24-november-2014-acceptance-modification-agreed-paediatric-investigation-plan-l-asparaginase-encapsulated-erythrocytes-emea-000341-pip02-09-m01_en.pdf"},
    {"id":"24544","name":"P/0125/2017: EMA decision of 5 May 2017 on the granting of a product-specific waiver for ramipril / indapamide (EMEA-002081-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/253504/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2017-ema-decision-5-may-2017-granting-product-specific-waiver-ramipril-indapamide-emea-002081-pip01-16_en.pdf"},
    {"id":"24553","name":"P/0032/2014: European Medicines Agency decision of 3 March 2014 on the granting of a product specific waiver for ertugliflozin / sitagliptin (EMEA-001534-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-03-20T01:00:00Z","last_updated_date":"2014-03-20T01:00:00Z","reference_number":"EMA/42215/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2014-european-medicines-agency-decision-3-march-2014-granting-product-specific-waiver-ertugliflozin-sitagliptin-emea-001534-pip01-13_en.pdf"},
    {"id":"24554","name":"P/296/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pollen from Phleum pratense (EMEA-000848-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/697311/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-296-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-phleum-pratense-emea-000848-pip01-10_en.pdf"},
    {"id":"24564","name":"P/0216/2013: EMA decision of 30 August 2013 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone furoate / triphenylacetic acid - 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/493077/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2013-ema-decision-30-august-2013-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-triphenylacetic-acid-4-1r-2-6-2-26-dichlorobenzyloxyethoxy_en.pdf"},
    {"id":"24565","name":"P/0290/2012: EMA decision of 18 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for cannabidiol / delta-9-tetrahydrocannabinol (Sativex) (EMEA-000181-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/737330/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2012-ema-decision-18-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-cannabidiol-delta-9-tetrahydrocannabinol-sativex-emea-000181-pip01-08-m01_en.pdf"},
    {"id":"24572","name":"P/263/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mixture of Phleum pratense, Dactylis glomerata, Festu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/710530/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-263-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mixture-phleum-pratense-dactylis-glomerata-festu_en.pdf"},
    {"id":"24584","name":"P/0272/2013: EMA decision of 30 October 2013 on the granting of a product specific waiver for (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]p...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/587446/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2013-ema-decision-30-october-2013-granting-product-specific-waiver-4r5r-1-4-4-33-dibutyl-7-dimethylamino-2345-tetrahydro-4-hydroxy-11-dioxido-1-benzothiepin-5-ylphenoxymethylp_en.pdf"},
    {"id":"24665","name":"P/111/2008: European Medicines Agency decision of 1 December 2008 on the application for agreement of a Paediatric Investigation Plan for telbivudine (Sebivo), EMEA-000065-PIP01-07, in accordance with Regulation (EC) No ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/622947/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-111-2008-european-medicines-agency-decision-1-december-2008-application-agreement-paediatric-investigation-plan-telbivudine-sebivo-emea-000065-pip01-07-accordance-regulation-ec-no_en.pdf"},
    {"id":"24669","name":"P/53/2011:  EMA decision of 4 March 2011 on the acceptance of a modification of an agreed paediatric investigation plan for coagulation Factor IX (Recombinant), (EMEA-000661-PIP01-09-M02) in accordance with Regulation (E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/78825/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-53-2011-ema-decision-4-march-2011-acceptance-modification-agreed-paediatric-investigation-plan-coagulation-factor-ix-recombinant-emea-000661-pip01-09-m02-accordance-regulation-e_en.pdf"},
    {"id":"24690","name":"P/0186/2016: EMA decision of 15 July 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for cadazolid\n\n(EMEA-001108-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-19T02:00:00Z","last_updated_date":"2016-09-19T02:00:00Z","reference_number":"EMA/394469/2016 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2016-ema-decision-15-july-2016-agreement-paediatric-investigation-plan-granting-deferral-cadazolid-emea-001108-pip02-15_en.pdf"},
    {"id":"24704","name":"P/0092/2018: EMA decision of 16 March 2018 on the granting of a product specific waiver for dapagliflozin / saxagliptin / metformin (hydrochloride)\n\n(EMEA-002249-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/75592/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2018-ema-decision-16-march-2018-granting-product-specific-waiver-dapagliflozin-saxagliptin-metformin-hydrochloride-emea-002249-pip01-17_en.pdf"},
    {"id":"24708","name":"P/24/2011: EMA decision of 26 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sotrastaurin acetate (EMEA-000093-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/32854/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-24-2011-ema-decision-26-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sotrastaurin-acetate-emea-000093-pip02-10_en.pdf"},
    {"id":"24721","name":"P/0238/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for canakinumab (Ilaris), (EMEA-000060-PIP04-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/617358/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-canakinumab-ilaris-emea-000060-pip04-14-m01_en.pdf"},
    {"id":"24725","name":"P/169/2010: European Medicines Agency decision of 3 September 2010 on the granting of a product specific waiver for vildagliptin / metformin hydrochloride (Eucreas), (EMEA-000703-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/477499/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-169-2010-european-medicines-agency-decision-3-september-2010-granting-product-specific-waiver-vildagliptin-metformin-hydrochloride-eucreas-emea-000703-pip01-09_en.pdf"},
    {"id":"24750","name":"P/0067/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen / human thrombin (Evicel, Evarrest), (EMEA-001149-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/104821/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-evicel-evarrest-emea-001149-pip01-11-m03_en.pdf"},
    {"id":"24754","name":"P/0098/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Xgeva, Prolia), (EMEA-000145-PIP01-07-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/107500/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-xgeva-prolia-emea-000145-pip01-07-m09_en.pdf"},
    {"id":"24764","name":"P/78/2008: European medicines agency decision of 14 September 2008\n\non the application for product specific waiver for bortezomib (Velcade)\n\nEMEA-000233-PIP01-08 in accordance with Regulation (EC) No 1901/2006 of the Eur...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-10-10T02:00:00Z","last_updated_date":"2008-10-10T02:00:00Z","reference_number":"EMEA/466976/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-78-2008-european-medicines-agency-decision-14-september-2008-application-product-specific-waiver-bortezomib-velcade-emea-000233-pip01-08-accordance-regulation-ec-no-1901-2006-eur_en.pdf"},
    {"id":"24767","name":"P/301/2010: EMA decision of 22 December 2010 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for pollen from dactylis glomarata (8%), lolium perenne (8%), phleum pratense (8%),...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/683424/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-301-2010-ema-decision-22-december-2010-agreement-pip-granting-deferral-granting-waiver-pollen-dactylis-glomarata-8-lolium-perenne-8-phleum-pratense-8_en.pdf"},
    {"id":"24768","name":"P/0315/2015: EMA decision of 21 December 2015 on the agreement of a paediatric investigation plan and on the granting of a waiver for ethosuximide (EMEA-001617-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/781916/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0315-2015-ema-decision-21-december-2015-agreement-paediatric-investigation-plan-granting-waiver-ethosuximide-emea-001617-pip01-14_en.pdf"},
    {"id":"24807","name":"P/0047/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab\n\n(NUCALA), (EMEA-000069-PIP02-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/90861/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-nucala-emea-000069-pip02-10-m07_en.pdf"},
    {"id":"24821","name":"P/0118/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for artemether / lumefantrine (Riamet), (EMEA-000777-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/300785/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-artemether-lumefantrine-riamet-emea-000777-pip01-09-m05_en.pdf"},
    {"id":"24839","name":"P/0146/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA-001214-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/398299/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-benralizumab-emea-001214-pip01-11-m03_en.pdf"},
    {"id":"24857","name":"P/278/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allergen extract of alnus glutinosa pollen (EMEA-0009...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/754029/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-278-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extract-alnus-glutinosa-pollen-emea-0009_en.pdf"},
    {"id":"24860","name":"P/0290/2014: EMA decision of 24 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-02T15:45:00Z","last_updated_date":"2017-03-02T15:45:00Z","reference_number":"EMA/642021/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2014-ema-decision-24-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip01-10-m01_en.pdf"},
    {"id":"24862","name":"P/0061/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir (EMEA-000409-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/160739/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-emea-000409-pip01-08-m03_en.pdf"},
    {"id":"24874","name":"P/157/2011: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone\n\npropionate / formoterol fumarate dihydrate (EMEA-000127-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/441528/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-157-2011-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-propionate-formoterol-fumarate-dihydrate-emea-000127-pip01-07-m01_en.pdf"},
    {"id":"24885","name":"P/0094/2017: EMA decision of 11 April 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for bempedoic acid (ETC-1002) (EMEA-001872-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/196292/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2017-ema-decision-11-april-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bempedoic-acid-etc-1002-emea-001872-pip01-15_en.pdf"},
    {"id":"24892","name":"P/0065/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for golimumab (Simponi), (EMEA-000265-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/83632/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-golimumab-simponi-emea-000265-pip02-11-m02_en.pdf"},
    {"id":"24904","name":"P/0079/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for insulin human (NTRA-2112) (EMEA-002116-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/91892/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-insulin-human-ntra-2112-emea-002116-pip01-17_en.pdf"},
    {"id":"24920","name":"P/68/2011: EMA decision of 17/03/2011\n\non the agreement of a paediatric investigation plan and on the granting of a waiver for rotavirus type G1/rotavirus type G2/rotavirus type G3/rotavirus type G4/rotavirus type P1A[8]...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/187222/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-68-2011-ema-decision-17-03-2011-agreement-paediatric-investigation-plan-granting-waiver-rotavirus-type-g1-rotavirus-type-g2-rotavirus-type-g3-rotavirus-type-g4-rotavirus-type-p1a8_en.pdf"},
    {"id":"24927","name":"P/0137/2015: EMA decision of 26 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for teduglutide (Revestive) (EMEA-000482-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-28T02:00:00Z","last_updated_date":"2015-07-28T02:00:00Z","reference_number":"EMA/398283/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2015-ema-decision-26-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-teduglutide-revestive-emea-000482-pip01-08-m02_en.pdf"},
    {"id":"24947","name":"P/0319/2016: EMA decision of 2 December 2016 on the refusal of a modification of an agreed paediatric investigation plan for tapentadol\n\n(hydrochloride) (Palexia and associated names, Yantil and associated names, Tapenta...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T09:55:00Z","last_updated_date":"2017-01-30T09:55:00Z","reference_number":"EMA/758229/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0319-2016-ema-decision-2-december-2016-refusal-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapenta_en.pdf"},
    {"id":"24977","name":"P/118/2011: EMA decision of 23 May 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for autologous oral mucosal epithelial cells, (EMEA-001004-PI...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-09T02:00:00Z","last_updated_date":"2011-06-09T02:00:00Z","reference_number":"EMA/338204/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-118-2011-ema-decision-23-may-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-oral-mucosal-epithelial-cells-emea-001004-pi_en.pdf"},
    {"id":"24985","name":"P/70/2010: European Medicines Agency decision on the granting of a product specific waiver for diamorphine hydrochloride (EMEA-000799-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/236650/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-70-2010-european-medicines-agency-decision-granting-product-specific-waiver-diamorphine-hydrochloride-emea-000799-pip01-09_en.pdf"},
    {"id":"24990","name":"P/211/2011: EMA decision of 2 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (EMEA-000332-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/647403/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-211-2011-ema-decision-2-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-emea-000332-pip01-08-m04_en.pdf"},
    {"id":"25031","name":"P/228/2010: EMA decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for aztreonam (Cayston), (EMEA-000827-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/663186/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-228-2010-ema-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aztreonam-cayston-emea-000827-pip01-09_en.pdf"},
    {"id":"25063","name":"P/0384/2017: EMA decision of 19 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for budesonide / glycopyrronium bromide / formoterol (f...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/793125/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0384-2017-ema-decision-19-december-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-budesonide-glycopyrronium-bromide-formoterol-f_en.pdf"},
    {"id":"25067","name":"P/0326/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for gemtuzumab\n\nozogamicin (EMEA-001733-PIP02-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-20T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"EMA/666027/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0326-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-gemtuzumab-ozogamicin-emea-001733-pip02-15-m01_en.pdf"},
    {"id":"25068","name":"P/0180/2012: EMA decision of 20 August 2012 on the granting of a product specific waiver for autologous tumour-derived immunoglobulin idiotype\n\ncoupled to keyhole limpet haemocyanin (EMEA-001274-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/480264/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2012-ema-decision-20-august-2012-granting-product-specific-waiver-autologous-tumour-derived-immunoglobulin-idiotype-coupled-keyhole-limpet-haemocyanin-emea-001274-pip01-12_en.pdf"},
    {"id":"25098","name":"P/0165/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for teriflunomide (Aubagio), (EMEA-001094-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/354119/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-teriflunomide-aubagio-emea-001094-pip01-10-m04_en.pdf"}    {"id":"25137","name":"P/0096/2013: EMA decision of 29 April 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for surotomycin (EMEA-001226-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/202226/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2013-ema-decision-29-april-2013-agreement-paediatric-investigation-plan-granting-deferral-surotomycin-emea-001226-pip01-11_en.pdf"},
    {"id":"25159","name":"P/0069/2014: European Medicines Agency decision of 17 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for idarucizumab (EMEA-001438-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/43446/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2014-european-medicines-agency-decision-17-march-2014-agreement-paediatric-investigation-plan-granting-deferral-idarucizumab-emea-001438-pip01-13_en.pdf"},
    {"id":"25164","name":"P/0070/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tanezumab (EMEA-001635-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/102436/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tanezumab-emea-001635-pip03-17_en.pdf"},
    {"id":"25171","name":"P/0070/2014: European Medicines Agency decision of 18 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adalimumab (Humira), (EMEA-000366...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/143776/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2014-european-medicines-agency-decision-18-march-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-adalimumab-humira-emea-000366_en.pdf"},
    {"id":"25179","name":"P/240/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aluminium hydroxide adsorbed, depigmented glutaraldeh...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/670699/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-240-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaraldeh_en.pdf"},
    {"id":"25210","name":"P/56/2008: European medicines agency decision of 20 July 2008 on the application for product specific waiver for Epoetin theta (EMEA-000218-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parlia...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-08T02:00:00Z","last_updated_date":"2008-09-08T02:00:00Z","reference_number":"EMEA/357429/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-56-2008-european-medicines-agency-decision-20-july-2008-application-product-specific-waiver-epoetin-theta-emea-000218-pip01-08-accordance-regulation-ec-no-1901-2006-european-parlia_en.pdf"},
    {"id":"25230","name":"P/223/2011: EMA decision of 27 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for fingolimod (hydrochloride) (Gilenya) (EMEA-000087-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/763026/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-223-2011-ema-decision-27-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-fingolimod-hydrochloride-gilenya-emea-000087-pip01-07-m01_en.pdf"},
    {"id":"25231","name":"P/0132/2014: EMA decision of 10 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for pazopanib (Votrient), (EMEA-000601-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-28T02:00:00Z","last_updated_date":"2014-07-28T02:00:00Z","reference_number":"EMA/280414/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2014-ema-decision-10-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-pazopanib-votrient-emea-000601-pip01-09-m02_en.pdf"},
    {"id":"25239","name":"P/0106/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tilmanocept\n\n(Lymphoseek), (EMEA-001255-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/194500/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-tilmanocept-lymphoseek-emea-001255-pip01-11-m03_en.pdf"},
    {"id":"25247","name":"P/312/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of grass and cereal pollen ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769455/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-312-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-grass-cereal-pollen_en.pdf"},
    {"id":"25260","name":"P/0130/2017: EMA decision of 7 June 2017 on the granting of a product-specific waiver for rosuvastatin (calcium) / ezetimibe (EMEA-002118-\n\nPIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/312711/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2017-ema-decision-7-june-2017-granting-product-specific-waiver-rosuvastatin-calcium-ezetimibe-emea-002118-pip01-17_en.pdf"},
    {"id":"25270","name":"P/131/2011: EMA decision of 8 June 2011 on the acceptance of a modification of an agreed paediatric investigation plan for imatinib mesilate (Glivec) (EMEA-000463-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-13T02:00:00Z","last_updated_date":"2011-07-13T02:00:00Z","reference_number":"EMA/398055/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-131-2011-ema-decision-8-june-2011-acceptance-modification-agreed-paediatric-investigation-plan-imatinib-mesilate-glivec-emea-000463-pip01-08-m02_en.pdf"},
    {"id":"25272","name":"P/0189/2015: EMA decision of 4 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten and associated names), (EMEA-000347-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/532369/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2015-ema-decision-4-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-associated-names-emea-000347-pip01-08-m06_en.pdf"},
    {"id":"25273","name":"P/0299/2014: EMA decision of 24 November 2014 on the acceptance of a modification of an agreed paediatric investigation plan for asenapine (maleate) (Sycrest) (EMEA-000228-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/624761/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2014-ema-decision-24-november-2014-acceptance-modification-agreed-paediatric-investigation-plan-asenapine-maleate-sycrest-emea-000228-pip01-08-m04_en.pdf"},
    {"id":"25275","name":"P/38/2009: European Medicines Agency decision of 4 March 2009 on the granting of a product specific waiver for 17-allylamino-17-demethoxygeldanamycin hydroquinone, hydrochloride (EMEA-000435-PIP01-08) in accordance with ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/116062/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-38-2009-european-medicines-agency-decision-4-march-2009-granting-product-specific-waiver-17-allylamino-17-demethoxygeldanamycin-hydroquinone-hydrochloride-emea-000435-pip01-08-accordance_en.pdf"},
    {"id":"25296","name":"P/0303/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for lipegfilgrastim (Lonquex), (EMEA-001019-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/773335/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-lipegfilgrastim-lonquex-emea-001019-pip01-10-m03_en.pdf"},
    {"id":"25307","name":"P/0259/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for trametinib (dimethyl\n\nsulfoxide) (Mekinist), (EMEA-001177-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-25T17:00:00Z","last_updated_date":"2017-10-25T17:00:00Z","reference_number":"EMA/501663/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-trametinib-dimethyl-sulfoxide-mekinist-emea-001177-pip01-11-m04_en.pdf"},
    {"id":"25350","name":"P/0257/2013: EMA decision of 29 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for melatonin (Circadin) (EMEA-000440-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/602055/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2013-ema-decision-29-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-melatonin-circadin-emea-000440-pip02-11-m01_en.pdf"},
    {"id":"25365","name":"P/0147/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for gabapentin (EMEA-001310-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/367765/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-gabapentin-emea-001310-pip01-12-m01_en.pdf"},
    {"id":"25371","name":"P/0200/2015: EMA decision of 4 September 2015 on the granting of a product-specific waiver for hydrochlorothiazide / nebivolol (hydrochloride) (EMEA-001761-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/571076/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2015-ema-decision-4-september-2015-granting-product-specific-waiver-hydrochlorothiazide-nebivolol-hydrochloride-emea-001761-pip01-15_en.pdf"},
    {"id":"25391","name":"P/0085/2013: EMA decision of 29 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for voclosporin (EMEA-000132-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/201721/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2013-ema-decision-29-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-voclosporin-emea-000132-pip01-07-m04_en.pdf"},
    {"id":"25403","name":"P/0039/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for deferasirox, (Exjade) (EMEA-001103-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-25T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/89606/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2015-ema-decision-6-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-deferasirox-exjade-emea-001103-pip01-10-m02_en.pdf"},
    {"id":"25432","name":"P/65/2011: EMA decision of 11 March 2011 on the granting of a product specific waiver for rivastigmine, (EMEA-001084-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/170473/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-65-2011-ema-decision-11-march-2011-granting-product-specific-waiver-rivastigmine-emea-001084-pip01-10-accordance-regulation-ec-no-1901-2006-european-parliament-council_en.pdf"},
    {"id":"25457","name":"P/31/2010: European Medicines Agency decision of 5 March 2010 on the acceptance of a modification of an agreed Paediatric Investigation Plan for dasatinib (Sprycel) (EMEA-000567-PIP01-09-M01) in accordance with Regulatio...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/127181/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-31-2010-european-medicines-agency-decision-5-march-2010-acceptance-modification-agreed-paediatric-investigation-plan-dasatinib-sprycel-emea-000567-pip01-09-m01-accordance-regulatio_en.pdf"},
    {"id":"25485","name":"P/66/2010: European Medicines Agency decision on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for avotermin (EMEA-000634-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/265398/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-66-2010-european-medicines-agency-decision-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-avotermin-emea-000634-pip01-09_en.pdf"},
    {"id":"25487","name":"P/127/2009: European Medicines Agency decision of 14 July 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for Telavancin hydrochloride (EMEA-000239-PIP01-08) in accordance with ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/426945/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-127-2009-european-medicines-agency-decision-14-july-2009-agreement-paediatric-investigation-plan-granting-deferral-telavancin-hydrochloride-emea-000239-pip01-08-accordance_en.pdf"},
    {"id":"25490","name":"P/0177/2015: EMA decision of 7 August 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for recombinant human nerve growth factor (EMEA-001729-PIP01...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"EMA/473457/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2015-ema-decision-7-august-2015-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-recombinant-human-nerve-growth-factor-emea-001729-pip01_en.pdf"},
    {"id":"25506","name":"P/234/2011: EMA decision of 26 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for eltrombopag (EMEA-000170-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/706287/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-234-2011-ema-decision-26-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eltrombopag-emea-000170-pip02-10_en.pdf"},
    {"id":"25516","name":"P/62/2011: EMA decision of 7 March 2011\n\non the agreement of a paediatric investigation plan and on the granting of a waiver for bucelipase alfa (EMEA-000822-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of t...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/158091/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-62-2011-ema-decision-7-march-2011-agreement-paediatric-investigation-plan-granting-waiver-bucelipase-alfa-emea-000822-pip01-09-accordance-regulation-ec-no-1901-2006-t_en.pdf"},
    {"id":"25517","name":"P/0223/2017: EMA decision of 11 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant Fusion\n\nProtein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689) (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/460047/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2017-ema-decision-11-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-fusion-protein-linking-coagulation-factor-viia-albumin-rviia-fp-csl689_en.pdf"},
    {"id":"25519","name":"P/0044/2015: EMA decision of 6 March 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for olesoxime (EMEA-001414-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-23T01:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMA/86502/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2015-ema-decision-6-march-2015-agreement-paediatric-investigation-plan-granting-deferral-olesoxime-emea-001414-pip01-12_en.pdf"},
    {"id":"25528","name":"P/0092/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for posaconazole\n\n(Noxafil), (EMEA-000468-PIP02-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/181811/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-posaconazole-noxafil-emea-000468-pip02-12-m03_en.pdf"},
    {"id":"25531","name":"P/0039/2016: EMA decision of 19 February 2016 on the acceptance of a modification of an agreed paediatric investigation plan for midostaurin (EMEA-000780-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/103092/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2016-ema-decision-19-february-2016-acceptance-modification-agreed-paediatric-investigation-plan-midostaurin-emea-000780-pip01-09-m02_en.pdf"},
    {"id":"25551","name":"P/0281/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab\n\n(Nucala), (EMEA-000069-PIP04-13-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T15:28:00Z","last_updated_date":"2017-01-23T15:28:00Z","reference_number":"EMA/704428/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-nucala-emea-000069-pip04-13-m01_en.pdf"},
    {"id":"25561","name":"P/0265/2015: EMA decision of 6 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for elvitegravir (Vitekta), (EMEA-000968-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/688246/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2015-ema-decision-6-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-elvitegravir-vitekta-emea-000968-pip02-11-m04_en.pdf"},
    {"id":"25591","name":"P/43/2009: European Medicines Agency decision of 23 March 2009 on the refusal of a product specific waiver for dirucotide acetate (EMEA-000433-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Par...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/167848/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-43-2009-european-medicines-agency-decision-23-march-2009-refusal-product-specific-waiver-dirucotide-acetate-emea-000433-pip01-08-accordance-regulation-ec-no-1901-2006-european-par_en.pdf"},
    {"id":"25612","name":"P/163/2011: EMA decision of 4 July 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for chlorhexidine gluconate / isopropyl alcohol (EMEA-000989-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-08T02:00:00Z","last_updated_date":"2011-08-08T02:00:00Z","reference_number":"EMA/384457/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-163-2011-ema-decision-4-july-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chlorhexidine-gluconate-isopropyl-alcohol-emea-000989_en.pdf"},
    {"id":"25614","name":"P/0284/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dermatophagoides pteronyssinus / dermatophagoides farinae (EMEA-001258-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/688234/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-dermatophagoides-pteronyssinus-dermatophagoides-farinae-emea-001258-pip01-11-m01_en.pdf"},
    {"id":"25632","name":"P/0278/2013: EMA decision of 31 October 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for idelalisib (EMEA-001350-PIP02-13)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/650681/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2013-ema-decision-31-october-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-idelalisib-emea-001350-pip02-13_en.pdf"},
    {"id":"25639","name":"P/36/2009: European Medicines Agency decision of 24 February 2009 on the granting of a product-specific waiver for lapatinib ditosylate monohydrate (Tyverb) (EMEA-000404-PIP01-08) in accordance with Regulation (EC) No 19...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/90351/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-36-2009-european-medicines-agency-decision-24-february-2009-granting-product-specific-waiver-lapatinib-ditosylate-monohydrate-tyverb-emea-000404-pip01-08-accordance-regulation-ec-no-19_en.pdf"},
    {"id":"25642","name":"P/0001/2012: EMA decision of 20 January 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for morphine\n\n(hydrochloride), (EMEA-000711-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/968331/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2012-ema-decision-20-january-2012-agreement-paediatric-investigation-plan-granting-waiver-morphine-hydrochloride-emea-000711-pip01-09_en.pdf"},
    {"id":"25657","name":"P/0063/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for belimumab (Benlysta), (EMEA-000520-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/147277/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-belimumab-benlysta-emea-000520-pip02-13-m01_en.pdf"},
    {"id":"25667","name":"P/36/2008: European medicines agency decision of 24 June 2008 on the application for agreement of a Paediatric Investigation Plan for pitavastatin calcium EMEA-000300-PIP01-08 in accordance with Regulation (EC) No 1901/2...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/315958/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-36-2008-european-medicines-agency-decision-24-june-2008-application-agreement-paediatric-investigation-plan-pitavastatin-calcium-emea-000300-pip01-08-accordance-regulation-ec-no-1901-2_en.pdf"},
    {"id":"25693","name":"P/0070/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for evolocumab (Repatha), (EMEA-001268-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/104827/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-evolocumab-repatha-emea-001268-pip01-12-m02_en.pdf"},
    {"id":"25720","name":"P/0283/2013: EMA decision of 8 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tapen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-12-06T01:00:00Z","last_updated_date":"2013-12-06T01:00:00Z","reference_number":"EMA/648087/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2013-ema-decision-8-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapen_en.pdf"},
    {"id":"25738","name":"P/0218/2013: EMA decision of 6 September 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for budesonide (EMEA-001087-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/455765/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2013-ema-decision-6-september-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-budesonide-emea-001087-pip02-12_en.pdf"},
    {"id":"25741","name":"P/0045/2013: EMA decision of 1 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for enzastaurin (hydrochloride) (EMEA-001033-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/118509/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2013-ema-decision-1-march-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-enzastaurin-hydrochloride-emea-001033-pip02-11_en.pdf"},
    {"id":"25756","name":"P/0286/2014: EMA decision of 28 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cholera vaccine, live attenuated, oral (strain CVD 10...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-04T01:00:00Z","last_updated_date":"2014-12-04T01:00:00Z","reference_number":"EMA/587832/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2014-ema-decision-28-october-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cholera-vaccine-live-attenuated-oral-strain-cvd-10_en.pdf"},
    {"id":"25766","name":"P/0271/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for angiotensin II (LJPC-501), (EMEA-001912-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/626322/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-angiotensin-ii-ljpc-501-emea-001912-pip02-16_en.pdf"},
    {"id":"25778","name":"P/98/2011: EMA decision of 8 April 2011 on the granting of a product specific waiver for delafloxacin (EMEA-001080-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"EMA/261657/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-98-2011-ema-decision-8-april-2011-granting-product-specific-waiver-delafloxacin-emea-001080-pip01-10_en.pdf"},
    {"id":"25787","name":"P/0087/2014: EMA decision of 4 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for sucroferric oxyhydroxide (mixture of iron (III)-oxyhydroxide, sucrose, starch) (PA21) (EMEA-001...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-15T02:00:00Z","last_updated_date":"2014-05-15T02:00:00Z","reference_number":"EMA/52891/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2014-ema-decision-4-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-sucroferric-oxyhydroxide-mixture-iron-iii-oxyhydroxide-sucrose-starch-pa21-emea-001_en.pdf"},
    {"id":"25795","name":"P/0228/2012: EMA decision of 1 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for dabigatran etexilate\n\n(Pradaxa) (EMEA-000081-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T01:00:00Z","last_updated_date":"2012-11-23T01:00:00Z","reference_number":"EMA/595801/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2012-ema-decision-1-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-pradaxa-emea-000081-pip01-07-m05_en.pdf"},
    {"id":"25803","name":"P/188/2009: European Medicines Agency decision of 11 September 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for vicriviroc maleate (EMEA-000122-PIP01-07-M01) in accordance with Regu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/525373/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-188-2009-european-medicines-agency-decision-11-september-2009-acceptance-modification-agreed-paediatric-investigation-plan-vicriviroc-maleate-emea-000122-pip01-07-m01-accordance-regu_en.pdf"},
    {"id":"25832","name":"P/0275/2014: EMA decision of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat), (EMEA-000402-PIP02-11-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T01:00:00Z","last_updated_date":"2014-12-05T01:00:00Z","reference_number":"EMA/590275/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2014-ema-decision-28-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip02-11-m01_en.pdf"},
    {"id":"25834","name":"P/343/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for modified allergen extract of dermatophagoides pteron...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/801965/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-343-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-dermatophagoides-pteron_en.pdf"},
    {"id":"25845","name":"P/0318/2013: EMA decision of 19 December 2013 on the granting of a product specific waiver for alpha-1 antitrypsin (EMEA-001525-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-05T01:00:00Z","last_updated_date":"2014-02-05T01:00:00Z","reference_number":"EMA/693820/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2013-ema-decision-19-december-2013-granting-product-specific-waiver-alpha-1-antitrypsin-emea-001525-pip01-13_en.pdf"},
    {"id":"25854","name":"P/0395/2017: EMA decision of 19 December 2017 on the granting of a product specific waiver for sirolimus (EMEA-002213-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T14:03:00Z","last_updated_date":"2018-03-07T14:03:00Z","reference_number":"EMA/771137/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0395-2017-ema-decision-19-december-2017-granting-product-specific-waiver-sirolimus-emea-002213-pip01-17_en.pdf"},
    {"id":"25863","name":"P/130/2010:  European Medicines Agency decision of 28 July 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for synthetic erythropoietin (EPO) rec...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/475515/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-130-2010-european-medicines-agency-decision-28-july-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-synthetic-erythropoietin-epo-rec_en.pdf"},
    {"id":"25904","name":"P/75/2010: European Medicines Agency decision of 5 May 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for levonorgestrel (EMEA-000606-PIP01-09) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/249209/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-75-2010-european-medicines-agency-decision-5-may-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-levonorgestrel-emea-000606-pip01-09_en.pdf"},
    {"id":"25914","name":"P/45/2011: EMA decision of the 3 March 2011 on the granting of a product specific waiver for atorvastatin (L-lysine salt) / amlodipine (besilate) (EMEA-000719-PIP02-10) in accordance with Regulation (EC) No 1901/2006 of ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-05T02:00:00Z","last_updated_date":"2011-04-05T02:00:00Z","reference_number":"EMA/115356/201","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-45-2011-ema-decision-3-march-2011-granting-product-specific-waiver-atorvastatin-l-lysine-salt-amlodipine-besilate-emea-000719-pip02-10-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"25929","name":"P/0232/2014: EMA decision of 5 September 2014 on the granting of a product specific waiver for bromfenac (sodium sesquihydrate) (EMEA-001595-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/469254/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2014-ema-decision-5-september-2014-granting-product-specific-waiver-bromfenac-sodium-sesquihydrate-emea-001595-pip01-13_en.pdf"},
    {"id":"25953","name":"P/0031/2013: EMA decision of 26 February 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for hydrocortisone, (EMEA-001283-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/65467/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2013-ema-decision-26-february-2013-agreement-paediatric-investigation-plan-granting-waiver-hydrocortisone-emea-001283-pip01-12_en.pdf"},
    {"id":"25996","name":"P/0023/2018: EMA decision of 30 January 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydr...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/28678/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2018-ema-decision-30-january-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-14-dihydro-1-2r-2-2-methoxyphenyl-2-tetrahydr_en.pdf"},
    {"id":"26008","name":"P/0025/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/29826/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-n-13-dicyclohexyl-6-hydroxy-24-dioxo-1234-tetrahydro-5-pyrimidinylcarbonylglycine_en.pdf"},
    {"id":"26012","name":"P/0037/2012: EMA decision of 20 February 2012 on the acceptance of a modification of an agreed paediatric investigation plan for romiplostim (Nplate),\n\n(EMEA-000653-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T14:30:00Z","last_updated_date":"2012-03-15T14:30:00Z","reference_number":"EMA/2090/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2012-ema-decision-20-february-2012-acceptance-modification-agreed-paediatric-investigation-plan-romiplostim-nplate-emea-000653-pip01-09-m01_en.pdf"},
    {"id":"26013","name":"P/0252/2013: EMA decision of 29 October 2013 on the modification of an agreed paediatric investigation plan for denosumab (Xgeva (previously Amgiva), Prolia), (EMEA-000145-PIP01-07-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/602409/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2013-ema-decision-29-october-2013-modification-agreed-paediatric-investigation-plan-denosumab-xgeva-previously-amgiva-prolia-emea-000145-pip01-07-m06_en.pdf"},
    {"id":"26025","name":"P/0237/2014: EMA decision of 19 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tap...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-10-09T02:00:00Z","last_updated_date":"2014-10-09T02:00:00Z","reference_number":"EMA/555776/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2014-ema-decision-19-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tap_en.pdf"},
    {"id":"26037","name":"P/0101/2015: EMA decision of 8 May 2015 on the granting of a product specific waiver for L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser (EMEA-001719-PIP01-14)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/211869/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2015-ema-decision-8-may-2015-granting-product-specific-waiver-l-pyr-l-glu-l-gln-l-leu-l-glu-l-arg-l-ala-l-leu-l-asn-l-ser-l-ser-emea-001719-pip01-14_en.pdf"},
    {"id":"26056","name":"P/0130/2015: EMA decision of 10 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for drisapersen (EMEA-000746-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/364928/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2015-ema-decision-10-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-drisapersen-emea-000746-pip01-09-m04_en.pdf"},
    {"id":"26060","name":"P/0056/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga), (EMEA-000597-PIP03-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/128650/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip03-15-m03_en.pdf"},
    {"id":"26063","name":"P/0169/2012: EMA decision of 27 July 2012 on the refusal of a modification of an agreed paediatric investigation plan for zoledronic acid (Aclasta)\n\n(EMEA-000057-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/485855/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2012-ema-decision-27-july-2012-refusal-modification-agreed-paediatric-investigation-plan-zoledronic-acid-aclasta-emea-000057-pip01-07-m04_en.pdf"},
    {"id":"26116","name":"P/0164/2012: EMA decision of 23 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for eculizumab (Soliris), (EMEA-000876-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T13:00:00Z","last_updated_date":"2012-10-08T11:50:00Z","reference_number":"EMA/475332/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2012-ema-decision-23-july-2012-agreement-paediatric-investigation-plan-granting-deferral-eculizumab-soliris-emea-000876-pip02-11_en.pdf"},
    {"id":"26133","name":"P/0011/2012: EMA decision of 24 January 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for lebrikizumab (EMEA-001053-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/32930/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2012-ema-decision-24-january-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lebrikizumab-emea-001053-pip01-10_en.pdf"},
    {"id":"26146","name":"P/0272/2016: EMA decision of 7 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for albiglutide (Eperzan), (EMEA-001175-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/585484/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2016-ema-decision-7-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-albiglutide-eperzan-emea-001175-pip01-11-m04_en.pdf"},
    {"id":"26171","name":"P/0147/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor (Kalydeco), (EMEA-000335-PIP01-08-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/305214/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-kalydeco-emea-000335-pip01-08-m11_en.pdf"},
    {"id":"26173","name":"P/268/2011: EMA decision of 28 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for pitavastatin (calcium) (Pitavastatin and associated names) (EMEA-000302-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T17:00:00Z","last_updated_date":"2011-11-30T17:00:00Z","reference_number":"EMA/831324/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-268-2011-ema-decision-28-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-pitavastatin-calcium-pitavastatin-associated-names-emea-000302-pip01-08-m02_en.pdf"},
    {"id":"26174","name":"P/0274/2014: EMA decision of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation Factor VIII / von Willebrand Factor (Voncento), (EMEA-000312-PIP01-08-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T01:00:00Z","last_updated_date":"2014-12-05T01:00:00Z","reference_number":"EMA/605305/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2014-ema-decision-28-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-human-coagulation-factor-viii-von-willebrand-factor-voncento-emea-000312-pip01-08-m07_en.pdf"},
    {"id":"26181","name":"P/0330/2014: EMA decision of 22 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for pollen from Dactylis glomerata, Lolium perenne, Phleum pratense, Festuca pratensis, Secale ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-20T01:00:00Z","last_updated_date":"2015-02-20T01:00:00Z","reference_number":"EMA/713543/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0330-2014-ema-decision-22-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-pollen-dactylis-glomerata-lolium-perenne-phleum-pratense-festuca-pratensis-secale_en.pdf"},
    {"id":"26187","name":"P/0204/2014: EMA decision of 8 August 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vosaroxin (EMEA-001450-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/392207/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2014-ema-decision-8-august-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vosaroxin-emea-001450-pip01-13_en.pdf"},
    {"id":"26198","name":"P/0008/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for cinacalcet hydrochloride (Mimpara), (EMEA-000078-PIP01-07-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/1359/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-cinacalcet-hydrochloride-mimpara-emea-000078-pip01-07-m07_en.pdf"},
    {"id":"26221","name":"P/220/2009: European Medicines Agency decision of 3 November 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for latanoprost (Xalatan and associated names) (EMEA-000011-PIP01-07-M03) i...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:00:00Z","last_updated_date":"2009-12-23T00:00:00Z","reference_number":"EMEA/688850/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-220-2009-european-medicines-agency-decision-3-november-2009-acceptance-modification-agreed-paediatric-investigation-plan-latanoprost-xalatan-associated-names-emea-000011-pip01-07-m03-i_en.pdf"},
    {"id":"26224","name":"P/0137/2012: EMA decision of 20 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten and associated names), (EMEA-000347-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/452347/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2012-ema-decision-20-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-associated-names-emea-000347-pip01-08-m02_en.pdf"},
    {"id":"26263","name":"P/0206/2012: EMA decision of 17 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir\n\n(phosphate) (Tamiflu), (EMEA-000365-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T17:00:00Z","last_updated_date":"2012-10-17T17:00:00Z","reference_number":"EMA/538918/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2012-ema-decision-17-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-oseltamivir-phosphate-tamiflu-emea-000365-pip01-08-m04_en.pdf"},
    {"id":"26273","name":"P/127/2010: European Medicines Agency decision of 28 July 2010 on the acceptance of a modification of an agreed paediatric investigation plan for N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxa...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/472909/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-127-2010-european-medicines-agency-decision-28-july-2010-acceptance-modification-agreed-paediatric-investigation-plan-n-24-di-tert-butyl-5-hydroxyphenyl-14-dihydro-4-oxoquinoline-3-carboxa_en.pdf"},
    {"id":"26290","name":"P/0208/2013: EMA decision of 3 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for chimaeric anti-disialoganglioside (GD2) monoclonal antibody (NSC764038) (EMEA-001285-PIP01-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/466271/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2013-ema-decision-3-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-chimaeric-anti-disialoganglioside-gd2-monoclonal-antibody-nsc764038-emea-001285-pip01_en.pdf"},
    {"id":"26316","name":"P/0109/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab\n\n(Stelara), (EMEA-000311-PIP03-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/163772/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip03-11-m02_en.pdf"},
    {"id":"26339","name":"P/122/2010: European Medicines Agency decision of 26 July 2010 on the acceptance of a modification of an agreed paediatric investigation plan for lisdexamfetamine dimesylate, (EMA-000553-PIP01-09-M01) in accordance with ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/470611/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-122-2010-european-medicines-agency-decision-26-july-2010-acceptance-modification-agreed-paediatric-investigation-plan-lisdexamfetamine-dimesylate-ema-000553-pip01-09-m01-accordance_en.pdf"},
    {"id":"26342","name":"P/38/2008: European medicines agency decision of 24 June 2008\n\non the application for agreement of a Paediatric Investigation Plan for pitavastatin calcium EMEA-000302-PIP01-08 in accordance with Regulation (EC) No 1901/...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/315969/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-38-2008-european-medicines-agency-decision-24-june-2008-application-agreement-paediatric-investigation-plan-pitavastatin-calcium-emea-000302-pip01-08-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"26382","name":"P/0258/2016: EMA decision of 5 October 2016 on the granting of a product specific waiver for recombinant respiratory syncytial virus vaccine (EMEA-\n\n001966-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/576568/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2016-ema-decision-5-october-2016-granting-product-specific-waiver-recombinant-respiratory-syncytial-virus-vaccine-emea-001966-pip01-16_en.pdf"},
    {"id":"26386","name":"P/272/2011: EMA decision of 28 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for Pneumococcal\n\npolysaccharide serotype 1 conjugated to protein D..(EMEA-000673-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T17:00:00Z","last_updated_date":"2011-11-30T17:00:00Z","reference_number":"EMA/828368/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-272-2011-ema-decision-28-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-pneumococcal-polysaccharide-serotype-1-conjugated-protein-demea-000673-pip01-09-m03_en.pdf"},
    {"id":"26405","name":"P/259/2009: EMA decision of 23 December 2009 on the granting of a product specific waiver for paracetamol / ibuprofen (EMEA-000564-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMA/749493/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-259-2009-ema-decision-23-december-2009-granting-product-specific-waiver-paracetamol-ibuprofen-emea-000564-pip01-09-accordance-regulation-ec-no-1901-2006-e_en.pdf"},
    {"id":"26416","name":"P/0050/2014: European Medicines Agency decision of 7 March 2014 on the agreement of a paediatric investigation plan and on the refusal of a waiver for enalapril (maleate) (EMEA-001241-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/43448/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2014-european-medicines-agency-decision-7-march-2014-agreement-paediatric-investigation-plan-refusal-waiver-enalapril-maleate-emea-001241-pip02-13_en.pdf"},
    {"id":"26443","name":"P/339/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for modified allergen extract of Dermatophagoides pteron...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/800116/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-339-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-dermatophagoides-pteron_en.pdf"},
    {"id":"26446","name":"P/0002/2014: European Medicines Agency decision of 21 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for secukinumab (EMEA-000380-PIP02-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"EMA/738883/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2014-european-medicines-agency-decision-21-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-secukinumab-emea-000380-pip02-09-m01_en.pdf"},
    {"id":"26455","name":"P/189/2010: European Medicines Agency decision of 27 September 2010 on the granting of a product specific waiver for copper [64 Cu] chloride (EMEA-001002-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/583623/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-189-2010-european-medicines-agency-decision-27-september-2010-granting-product-specific-waiver-copper-64-cu-chloride-emea-001002-pip01-10_en.pdf"},
    {"id":"26466","name":"P/37/2011: EMA decision of 24 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for GLP-1 analogue linked to human IgG4 Fc-fragment (LY2189...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/37133/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-37-2011-ema-decision-24-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-glp-1-analogue-linked-human-igg4-fc-fragment-ly2189_en.pdf"},
    {"id":"26471","name":"P/0225/2016: EMA decision of 12 August 2016 on the granting of a product specific waiver for amlodipine / rosuvastatin (EMEA-001935-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/519655/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2016-ema-decision-12-august-2016-granting-product-specific-waiver-amlodipine-rosuvastatin-emea-001935-pip01-16_en.pdf"},
    {"id":"26476","name":"P/0097/2013: EMA decision of 29 April 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for zanamivir (Relenza), (EMEA-001318-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/201171/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2013-ema-decision-29-april-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-zanamivir-relenza-emea-001318-pip01-12_en.pdf"},
    {"id":"26479","name":"P/152/2011: EMA decision of 30 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for a derivative of\n\noctahydro-4-hydroxy-4-[phenylethynyl]-1H-indole-1-carboxylic acid ester ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2011-07-15T02:00:00Z","reference_number":"EMA/493240/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-152-2011-ema-decision-30-june-2011-agreement-paediatric-investigation-plan-granting-deferral-derivative-octahydro-4-hydroxy-4-phenylethynyl-1h-indole-1-carboxylic-acid-ester_en.pdf"},
    {"id":"26506","name":"P/0307/2013: EMA decision of 13 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (Fycompa) (EMEA-000467-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-17T11:00:00Z","last_updated_date":"2014-01-17T11:00:00Z","reference_number":"EMA/698175/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2013-ema-decision-13-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-fycompa-emea-000467-pip01-08-m04_en.pdf"}    {"id":"26510","name":"P/0319/2017: EMA decision of 31 October 2017 on the granting of a product specific waiver for veliparib (EMEA-000499-PIP03-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T13:11:00Z","last_updated_date":"2018-02-12T13:11:00Z","reference_number":"EMA/671458/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0319-2017-ema-decision-31-october-2017-granting-product-specific-waiver-veliparib-emea-000499-pip03-17_en.pdf"},
    {"id":"26529","name":"P/296/2011: EMA decision of 20 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for canakinumab (Ilaris), (EMEA-000060-PIP02-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/958604/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-296-2011-ema-decision-20-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-canakinumab-ilaris-emea-000060-pip02-08-m04_en.pdf"},
    {"id":"26535","name":"P/0208/2012: EMA decision of 27 September 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for certolizumab pegol (Cimzia) (EMEA-001071-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T18:45:00Z","last_updated_date":"2012-10-17T18:45:00Z","reference_number":"EMA/603850/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2012-ema-decision-27-september-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-certolizumab-pegol-cimzia-emea-001071-pip02-12_en.pdf"},
    {"id":"26539","name":"P/0032/2016: EMA decision of 29 January 2016 on the granting of a product specific waiver for pexiganan (acetate) (EMEA-001847-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/864347/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2016-ema-decision-29-january-2016-granting-product-specific-waiver-pexiganan-acetate-emea-001847-pip01-15_en.pdf"},
    {"id":"26555","name":"P/0083/2014: EMA decision of 4 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ceftobiprole medocaril (sodium) (Zevtera and associated names), (EMEA-000205-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/113585/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2014-ema-decision-4-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-ceftobiprole-medocaril-sodium-zevtera-associated-names-emea-000205-pip02-11-m01_en.pdf"},
    {"id":"26579","name":"P/0129/2013: EMA decision of 28 May 2013 on the granting of a product-specific waiver for ivabradine (hydrochloride) / metoprolol (tartrate) (EMEA-001405-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-24T13:30:00Z","last_updated_date":"2013-06-24T13:30:00Z","reference_number":"EMA/250331/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2013-ema-decision-28-may-2013-granting-product-specific-waiver-ivabradine-hydrochloride-metoprolol-tartrate-emea-001405-pip01-12_en.pdf"},
    {"id":"26582","name":"P/0222/2012: EMA decision of 1 October 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for ioforminol (EMEA-001197-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/494333/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2012-ema-decision-1-october-2012-agreement-paediatric-investigation-plan-granting-deferral-ioforminol-emea-001197-pip01-11_en.pdf"},
    {"id":"26627","name":"P/0079/2015: EMA decision of 10 April 2015 on the granting of a product-specific waiver for ezetimibe / atorvastatin (calcium trihydrate) (Atozet and associated names, Kexrolt and associated names, Orvatez and associated...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-19T02:00:00Z","last_updated_date":"2015-05-19T02:00:00Z","reference_number":"EMA/222887/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2015-ema-decision-10-april-2015-granting-product-specific-waiver-ezetimibe-atorvastatin-calcium-trihydrate-atozet-associated-names-kexrolt-associated-names-orvatez-associated_en.pdf"},
    {"id":"26637","name":"P/0036/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for riociguat (Adempas), (EMEA-000718-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-25T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/64978/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2015-ema-decision-6-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-riociguat-adempas-emea-000718-pip01-09-m05_en.pdf"},
    {"id":"26658","name":"P/60/2011: EMA decision of 4 March 2011 on the granting of a product specific waiver for testosterone (EMEA-001026-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/78568/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-60-2011-ema-decision-4-march-2011-granting-product-specific-waiver-testosterone-emea-001026-pip01-10-accordance-regulation-ec-no-1901-2006-european-parliament-council_en.pdf"},
    {"id":"26666","name":"P/0325/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant\n\nparathyroid hormone (Natpar), (EMEA-001526-PIP01-13-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/662328/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0325-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-parathyroid-hormone-natpar-emea-001526-pip01-13-m02_en.pdf"},
    {"id":"26669","name":"P/0093/2012: EMA decision of 30 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for voclosporin (EMEA-000132-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/304302/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2012-ema-decision-30-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-voclosporin-emea-000132-pip01-07-m03_en.pdf"},
    {"id":"26690","name":"P/0313/2016: EMA decision of 21 December 2016 on the agreement of a paediatric investigation plan for complex of povidone and iodine /\n\ndexamethasone (SHP640) (EMEA-001936-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/757980/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2016-ema-decision-21-december-2016-agreement-paediatric-investigation-plan-complex-povidone-iodine-dexamethasone-shp640-emea-001936-pip01-16_en.pdf"},
    {"id":"26692","name":"P/0081/2012: EMA decision of 30 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation factor VIII / von Willebrand Factor (EMEA-000312-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/269507/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2012-ema-decision-30-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-human-coagulation-factor-viii-von-willebrand-factor-emea-000312-pip01-08-m03_en.pdf"},
    {"id":"26812","name":"P/0289/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for N. meningitidis serogroup A / C / W / Y polysaccharide conjugated to tetanus toxoid / N.  (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/693022/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-n-meningitidis-serogroup-c-w-y-polysaccharide-conjugated-tetanus-toxoid-n_en.pdf"},
    {"id":"26828","name":"P/0110/2014: EMA decision of 5 May 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for drospirenone (EMEA-001495-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-05T02:00:00Z","last_updated_date":"2014-06-05T02:00:00Z","reference_number":"EMA/188327/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2014-ema-decision-5-may-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-drospirenone-emea-001495-pip01-13_en.pdf"},
    {"id":"26848","name":"P/225/2011: EMA decision of 27 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (EMEA-\n\n000916-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/686500/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-225-2011-ema-decision-27-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-lixisenatide-emea-000916-pip01-10-m01_en.pdf"},
    {"id":"26866","name":"P/89/2011: EMA decision of 8 April 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for valganciclovir\n\n(Valcyte and associated names), (EMEA-000726-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/193382/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-89-2011-ema-decision-8-april-2011-agreement-paediatric-investigation-plan-granting-waiver-valganciclovir-valcyte-associated-names-emea-000726-pip01-09_en.pdf"},
    {"id":"26878","name":"P/0067/2013: EMA decision of 26 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sarilumab (EMEA-001045-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/113206/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2013-ema-decision-26-march-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sarilumab-emea-001045-pip01-10_en.pdf"},
    {"id":"26880","name":"P/0016/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin (EMEA-000828-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/783837/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-emea-000828-pip01-09-m02_en.pdf"},
    {"id":"26882","name":"P/0267/2016: EMA decision of 5 October 2016 on the granting of a product specific waiver for ibuprofen / paracetamol (EMEA-002002-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/585779/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2016-ema-decision-5-october-2016-granting-product-specific-waiver-ibuprofen-paracetamol-emea-002002-pip01-16_en.pdf"},
    {"id":"26901","name":"P/0117/2017: EMA decision of 5 May 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for 3,6-diamino-\n\n2,5-bis{N-[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl}pyrazine (MB-102) (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/256197/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2017-ema-decision-5-may-2017-agreement-paediatric-investigation-plan-granting-deferral-36-diamino-25-bisn-1r-1-carboxy-2-hydroxyethylcarbamoylpyrazine-mb-102-emea-0_en.pdf"},
    {"id":"26906","name":"P/0087/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for purified antigen fractions of inactivated split virion Influenza A/Vietnam/...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/205459/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-purified-antigen-fractions-inactivated-split-virion-influenza-vietnam_en.pdf"},
    {"id":"26932","name":"P/0019/2012: EMA decision of 27 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for bevacizumab (Avastin), (EMEA-000056-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/984981/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2012-ema-decision-27-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-bevacizumab-avastin-emea-000056-pip01-07-m01_en.pdf"},
    {"id":"26943","name":"P/88/2011: EMA decision of 8 April 2011 on the acceptance of a modification of an agreed paediatric investigation plan for boceprevir (EMEA-000583-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/254196/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-88-2011-ema-decision-8-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-boceprevir-emea-000583-pip01-09-m02_en.pdf"},
    {"id":"26975","name":"P/0160/2013: EMA decision of 8 July 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mifepristone (EMEA-001292-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-09T16:30:00Z","last_updated_date":"2013-08-09T16:30:00Z","reference_number":"EMA/398270/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2013-ema-decision-8-july-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mifepristone-emea-001292-pip01-12_en.pdf"},
    {"id":"27003","name":"P/43/2008: European medicines agency decision of 24 June 2008\n\non the application for product specific waiver for vernakalant hydrochloride\n\n(EMEA-000226-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/313727/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-43-2008-european-medicines-agency-decision-24-june-2008-application-product-specific-waiver-vernakalant-hydrochloride-emea-000226-pip01-08-accordance-regulation-ec-no-1901-2006-e_en.pdf"},
    {"id":"27012","name":"P/133/2010:  European Medicines Agency decision of 28 July 2010 on the refusal of a paediatric investigation plan and on the granting of a waiver for omalizumab, (Xolair) (EMEA-000735-PIP01-09) in accordance with Regulat...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/463568/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-133-2010-european-medicines-agency-decision-28-july-2010-refusal-paediatric-investigation-plan-granting-waiver-omalizumab-xolair-emea-000735-pip01-09-accordance-regulat_en.pdf"},
    {"id":"27019","name":"P/0214/2012: EMA decision of 28 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for human-cell-line\n\nrecombinant human factor VIII (human-cl rhFVIII) / human coagulation fact...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T17:00:00Z","last_updated_date":"2012-10-17T17:00:00Z","reference_number":"EMA/501506/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2012-ema-decision-28-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-human-cell-line-recombinant-human-factor-viii-human-cl-rhfviii-human-coagulation-fact_en.pdf"},
    {"id":"27024","name":"P/47/2010: European Medicines Agency decision of 31 March 2010 on the granting of a product specific waiver for budesonide / salmeterol xinafoate (EMEA-000623-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of ...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/200821/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-47-2010-european-medicines-agency-decision-31-march-2010-granting-product-specific-waiver-budesonide-salmeterol-xinafoate-emea-000623-pip01-09-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"27032","name":"P/0100/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ibrutinib (Imbruvica), (EMEA-001397-PIP03-14-M02) CORR","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/202477/2017 corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-ibrutinib-imbruvica-emea-001397-pip03-14-m02-corr_en.pdf"},
    {"id":"27035","name":"P/0124/2014: EMA decision of 16 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for cobimetinib (EMEA-001425-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-25T02:00:00Z","last_updated_date":"2014-06-25T02:00:00Z","reference_number":"EMA/273992/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2014-ema-decision-16-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-cobimetinib-emea-001425-pip01-13-m01_en.pdf"},
    {"id":"27045","name":"P/155/2009: European Medicines Agency decision of 11 August 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for midazolam hydrochloride (EMEA-000395-PIP01-08 in accordance with Re...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/494800/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-155-2009-european-medicines-agency-decision-11-august-2009-agreement-paediatric-investigation-plan-granting-waiver-midazolam-hydrochloride-emea-000395-pip01-08-accordance-re_en.pdf"},
    {"id":"27055","name":"P/205/2011: EMA decision of 26 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for artemether / lumefantrine (Riamet) (EMEA-000777-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/646448/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-205-2011-ema-decision-26-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-artemether-lumefantrine-riamet-emea-000777-pip01-09-m01_en.pdf"},
    {"id":"27066","name":"P/0127/2012: EMA decision of 4 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for odanacatib (EMEA-001123-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-09T14:00:00Z","last_updated_date":"2012-08-09T14:00:00Z","reference_number":"EMA/416710/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2012-ema-decision-4-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-odanacatib-emea-001123-pip01-11_en.pdf"},
    {"id":"27089","name":"P/0142/2016: EMA decision of 20 May 2016 on the granting of a product specific waiver for diclofenac (sodium) / capsaicin (EMEA-001861-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-18T02:00:00Z","last_updated_date":"2016-07-18T02:00:00Z","reference_number":"EMA/290708/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2016-ema-decision-20-may-2016-granting-product-specific-waiver-diclofenac-sodium-capsaicin-emea-001861-pip01-15_en.pdf"},
    {"id":"27095","name":"P/0099/2012: EMA decision of 30 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ivabradine (hydrochloride) (Procoralan) (EMEA-000628-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/274366/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2012-ema-decision-30-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-ivabradine-hydrochloride-procoralan-emea-000628-pip01-09-m03_en.pdf"},
    {"id":"27105","name":"P/0160/2014: EMA decision of 11 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (Fycompa), (EMEA-000467-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/330921/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2014-ema-decision-11-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-fycompa-emea-000467-pip01-08-m05_en.pdf"},
    {"id":"27107","name":"P/0106/2012: EMA decision of 8 June 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for golimumab (Simponi) (EMEA-000265-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-19T17:00:00Z","last_updated_date":"2012-07-19T17:00:00Z","reference_number":"EMA/354076/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2012-ema-decision-8-june-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-golimumab-simponi-emea-000265-pip02-11_en.pdf"},
    {"id":"27115","name":"P/0272/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for recombinant human monoclonal antibody to GM-CSF (GSK3...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T10:22:00Z","last_updated_date":"2018-02-13T10:22:00Z","reference_number":"EMA/541729/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-monoclonal-antibody-gm-csf-gsk3_en.pdf"},
    {"id":"27138","name":"P/0078/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adeno-associated viral vector serotype rh.10 carrying t...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/88202/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-adeno-associated-viral-vector-serotype-rh10-carrying-t_en.pdf"},
    {"id":"27150","name":"P/0113/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dalbavancin\n\n(Xydalba), (EMEA-000016-PIP01-07-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/190072/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-dalbavancin-xydalba-emea-000016-pip01-07-m06_en.pdf"},
    {"id":"27153","name":"P/0281/2012: EMA decision of 21 November 2012 on the granting of a product-specific waiver for brimonidine tartrate (EMEA-001239-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-07T01:00:00Z","last_updated_date":"2013-01-07T01:00:00Z","reference_number":"EMA/725996/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2012-ema-decision-21-november-2012-granting-product-specific-waiver-brimonidine-tartrate-emea-001239-pip01-11_en.pdf"},
    {"id":"27184","name":"P/0263/2013: EMA decision of 30 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor (Kalydeco), (EMEA-000335-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/592124/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2013-ema-decision-30-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-kalydeco-emea-000335-pip01-08-m08_en.pdf"},
    {"id":"27188","name":"P/0063/2018: EMA decision of 16 March 2018 on the granting of a product- specific waiver for veliparib (EMEA-000499-PIP04-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/105839/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2018-ema-decision-16-march-2018-granting-product-specific-waiver-veliparib-emea-000499-pip04-17_en.pdf"},
    {"id":"27190","name":"P/0099/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for raltegravir (Isentress), (EMEA-000279-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/206647/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2013-ema-decision-30-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-raltegravir-isentress-emea-000279-pip01-08-m01_en.pdf"},
    {"id":"27206","name":"P/0240/2017: EMA decision of 11 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam\n\n(Briviact), (EMEA-000332-PIP01-08-M12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-29T02:00:00Z","last_updated_date":"2017-09-29T02:00:00Z","reference_number":"EMA/506967/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2017-ema-decision-11-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-emea-000332-pip01-08-m12_en.pdf"},
    {"id":"27217","name":"P/0179/2017: EMA decision of 3 July 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for larotrectinib (EMEA-001971-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/382606/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2017-ema-decision-3-july-2017-agreement-paediatric-investigation-plan-granting-deferral-larotrectinib-emea-001971-pip02-16_en.pdf"},
    {"id":"27224","name":"P/0279/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for pollen from Dactylis glomarata, Lolium perenne, Phleum pratense, Poa pratensis, Anthoxhantu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/690862/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-pollen-dactylis-glomarata-lolium-perenne-phleum-pratense-poa-pratensis-anthoxhantu_en.pdf"},
    {"id":"27240","name":"P/0022/2018: EMA decision of 30 January 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for upadacitinib (ABT-494) (EMEA-001741-PIP02-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/29956/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2018-ema-decision-30-january-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-upadacitinib-abt-494-emea-001741-pip02-16_en.pdf"},
    {"id":"27270","name":"P/132/2009: European Medicines Agency decision of 17 July 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for recombinant human C1 inhibitor (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/352210/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-132-2009-european-medicines-agency-decision-17-july-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-c1-inhibitor-eme_en.pdf"},
    {"id":"27344","name":"P/0257/2012: EMA decision of 26 October 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tofacitinib (citrate) (EMEA-000576-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/677853/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2012-ema-decision-26-october-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tofacitinib-citrate-emea-000576-pip02-11_en.pdf"},
    {"id":"27384","name":"P/0014/2018: EMA decision of 30 January 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for chloroprocaine (hydrochloride) (Ampres), (EMEA-000639-PIP03-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T02:00:00Z","last_updated_date":"2018-04-17T02:00:00Z","reference_number":"EMA/850788/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2018-ema-decision-30-january-2018-agreement-paediatric-investigation-plan-granting-deferral-chloroprocaine-hydrochloride-ampres-emea-000639-pip03-16_en.pdf"},
    {"id":"27391","name":"P/0241/2017: EMA decision of 4 September 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for lefamulin\n\n(EMEA-002075-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/507360/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2017-ema-decision-4-september-2017-agreement-paediatric-investigation-plan-granting-deferral-lefamulin-emea-002075-pip01-16_en.pdf"},
    {"id":"27402","name":"P/0084/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for cinacalcet hydrochloride (Mimpara), (EMEA-000078-PIP01-07-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/215072/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-cinacalcet-hydrochloride-mimpara-emea-000078-pip01-07-m06_en.pdf"},
    {"id":"27404","name":"P/70/2008: European medicines agency decision of 20 August 2008\n\non the application for agreement of a Paediatric Investigation Plan for nicotinic acid, simvastatin and laropiprant (EMEA-000064-PIP01-07), in accordance w...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/431839/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-70-2008-european-medicines-agency-decision-20-august-2008-application-agreement-paediatric-investigation-plan-nicotinic-acid-simvastatin-laropiprant-emea-000064-pip01-07-accordance-w_en.pdf"},
    {"id":"27427","name":"P/245/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aluminium hydroxide adsorbed, depigmented glutaraldeh...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/672975/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-245-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaraldeh_en.pdf"},
    {"id":"27432","name":"P/0073/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for guselkumab (EMEA-001523-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/138342/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-guselkumab-emea-001523-pip02-14_en.pdf"},
    {"id":"27444","name":"P/0002/2016: EMA decision of 14 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (Translarna), (EMEA-000115-PIP01-07-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/866032/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2016-ema-decision-14-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-translarna-emea-000115-pip01-07-m06_en.pdf"},
    {"id":"27465","name":"P/0324/2014: EMA decision of 19 December 2014 on the granting of a product specific waiver for zoledronic acid (monohydrate) (in combination with calcium (carbonate) / cholecalciferol) (EMEA-001689-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/759442/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0324-2014-ema-decision-19-december-2014-granting-product-specific-waiver-zoledronic-acid-monohydrate-combination-calcium-carbonate-cholecalciferol-emea-001689-pip01-14_en.pdf"},
    {"id":"27480","name":"P/60/2009: European Medicines Agency decision of 27 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for nilotinib (Tasigna) (EMEA-000290-PI...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/161203/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-60-2009-european-medicines-agency-decision-27-march-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-nilotinib-tasigna-emea-000290-pi_en.pdf"},
    {"id":"27482","name":"P/266/2011: EMA decision of 28 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for pitavastatin (calcium) (Alipza and associated names) (EMEA-000300-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T16:00:00Z","last_updated_date":"2011-11-30T16:00:00Z","reference_number":"EMA/831320/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-266-2011-ema-decision-28-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-pitavastatin-calcium-alipza-associated-names-emea-000300-pip01-08-m02_en.pdf"},
    {"id":"27490","name":"P/0234/2015: EMA decision of 27 October 2015 on the granting of a product-specific waiver for ciclosporin (EMEA-001007-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/619832/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2015-ema-decision-27-october-2015-granting-product-specific-waiver-ciclosporin-emea-001007-pip02-15_en.pdf"},
    {"id":"27491","name":"P/233/2010: EMA decision of 26 November 2010 on the acceptance of a modification of an agreed paediatric investigation plan for clopidogrel (Plavix) (EMEA-000049-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/706562/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-233-2010-ema-decision-26-november-2010-acceptance-modification-agreed-paediatric-investigation-plan-clopidogrel-plavix-emea-000049-pip01-07-m03_en.pdf"},
    {"id":"27506","name":"P/0290/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for human normal\n\nimmunoglobulin (EMEA-000454-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/647795/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000454-pip01-08-m03_en.pdf"},
    {"id":"27518","name":"P/0071/2012: EMA decision of 24 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for doripenem (monohydrate) (Doribax), (EMEA-000015-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/202883/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2012-ema-decision-24-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-doripenem-monohydrate-doribax-emea-000015-pip01-07-m04_en.pdf"},
    {"id":"27550","name":"P/0216/2017: EMA decision of 9 August 2017 on the granting of a product specific waiver for empagliflozin (Jardiance), (EMEA-000828-PIP05-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/431236/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2017-ema-decision-9-august-2017-granting-product-specific-waiver-empagliflozin-jardiance-emea-000828-pip05-17_en.pdf"},
    {"id":"27554","name":"P/130/2011: EMA decision of 8 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine (Lu AA...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/419326/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-130-2011-ema-decision-8-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-1-2-24-dimethyl-phenylsulfanylphenylpiperazine-lu-aa_en.pdf"},
    {"id":"27585","name":"P/0235/2017: EMA decision of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for venetoclax (Venclyxto), (EMEA-002018-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/434825/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2017-ema-decision-9-august-2017-agreement-paediatric-investigation-plan-granting-deferral-venetoclax-venclyxto-emea-002018-pip02-16_en.pdf"},
    {"id":"27598","name":"P/0081/2013: European medicines agency decision of 27 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for retigabine (Trobalt), (EMEA-000116-PIP01-07-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/102701/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2013-european-medicines-agency-decision-27-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-retigabine-trobalt-emea-000116-pip01-07-m06_en.pdf"},
    {"id":"27610","name":"P/0184/2012: EMA decision of 21 August 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for indacaterol (acetate) / mometasone (furoate) (EMEA-001...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T02:00:00Z","last_updated_date":"2012-09-18T02:00:00Z","reference_number":"EMA/472512/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2012-ema-decision-21-august-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-indacaterol-acetate-mometasone-furoate-emea-001_en.pdf"},
    {"id":"27619","name":"P/0331/2014: EMA decision of 22 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for deferiprone (EMEA-001126-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-20T01:00:00Z","last_updated_date":"2015-02-20T01:00:00Z","reference_number":"EMA/761533/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0331-2014-ema-decision-22-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-deferiprone-emea-001126-pip01-10-m01_en.pdf"},
    {"id":"27656","name":"P/0227/2014: EMA decision of 5 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for aliskiren (Rasilez and associated names), (EMEA-000362-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/501292/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2014-ema-decision-5-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-aliskiren-rasilez-associated-names-emea-000362-pip01-08-m04_en.pdf"},
    {"id":"27658","name":"P/0305/2012:EMA decision of 20 December 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for human normal immunoglobulin (LFB-IgSC), (EMEA-001290-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T12:40:00Z","last_updated_date":"2013-02-11T12:40:00Z","reference_number":"EMA/755990/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2012ema-decision-20-december-2012-agreement-paediatric-investigation-plan-granting-waiver-human-normal-immunoglobulin-lfb-igsc-emea-001290-pip01-12_en.pdf"},
    {"id":"27668","name":"P/0188/2013: EMA decision of 8 August 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for naltrexone (hydrochloride) / bupropion (hydrochloride)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-09T17:00:00Z","last_updated_date":"2013-09-09T17:00:00Z","reference_number":"EMA/473174/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2013-ema-decision-8-august-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-naltrexone-hydrochloride-bupropion-hydrochloride_en.pdf"},
    {"id":"27681","name":"P/284/2011: EMA decision of 30 November 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for iron (III)-oxyhydroxide (EMEA-001061-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T12:15:00Z","last_updated_date":"2011-12-21T12:15:00Z","reference_number":"EMA/910410/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-284-2011-ema-decision-30-november-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-iron-iii-oxyhydroxide-emea-001061-pip01-10_en.pdf"},
    {"id":"27692","name":"P/0097/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for boceprevir (Victrelis), (EMEA-000583-PIP01-09-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/203188/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-boceprevir-victrelis-emea-000583-pip01-09-m07_en.pdf"},
    {"id":"27696","name":"P/0013/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Neisseria meningitidis serogroup B recombinant lipoprotein (rLP2086; subfamily A; Escherichi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/34937/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-b-recombinant-lipoprotein-rlp2086-subfamily-escherichi_en.pdf"},
    {"id":"27697","name":"P/0077/2014: EMA decision of 2 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant fusion protein consisting of human coagulation factor VIII attached to the Fc domai...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-15T02:00:00Z","last_updated_date":"2014-05-15T02:00:00Z","reference_number":"EMA/123330/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2014-ema-decision-2-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-fusion-protein-consisting-human-coagulation-factor-viii-attached-fc-domai_en.pdf"},
    {"id":"27698","name":"P/0106/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for potassium citrate monohydrated / potassium hydrogen carbonate (EMEA-001357-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/199537/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-potassium-citrate-monohydrated-potassium-hydrogen-carbonate-emea-001357-pip01-12-m01_en.pdf"},
    {"id":"27702","name":"P/0067/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the huma...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/107503/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-haematopoietic-stem-cells-transduced-lentiviral-vector-encoding-huma_en.pdf"},
    {"id":"27718","name":"P/92/2009: European medicines agency decision of 18 May 2009 on the granting of a product specific waiver for simvastatin / fenofibrate (EMEA-000490-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the Europe...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/280391/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-92-2009-european-medicines-agency-decision-18-may-2009-granting-product-specific-waiver-simvastatin-fenofibrate-emea-000490-pip01-08-accordance-regulation-ec-no-1901-2006-europe_en.pdf"},
    {"id":"27731","name":"P/78/2010: European Medicines Agency decision of 7 May 2010\n\non the granting of a product specific waiver for mometasone furoate (Nasonex and associated names) (EMEA-000351-PIP01-08) in accordance with Regulation (EC) No...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/236423/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-78-2010-european-medicines-agency-decision-7-may-2010-granting-product-specific-waiver-mometasone-furoate-nasonex-associated-names-emea-000351-pip01-08-accordance-regulation-ec-no_en.pdf"},
    {"id":"27759","name":"P/220/2011: EMA decision of 30 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for loxapine (EMEA-001115-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/692206/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-220-2011-ema-decision-30-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-loxapine-emea-001115-pip01-10_en.pdf"},
    {"id":"27764","name":"P/0085/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for rolapitant (Varuby),\n\n(EMEA-001768-PIP02-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/75565/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-rolapitant-varuby-emea-001768-pip02-15-m01_en.pdf"},
    {"id":"27775","name":"P/0187/2016: EMA decision of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for landiolol\n\n(hydrochloride) (EMEA-001150-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T02:00:00Z","last_updated_date":"2016-09-22T02:00:00Z","reference_number":"EMA/408654/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-landiolol-hydrochloride-emea-001150-pip02-13-m01_en.pdf"},
    {"id":"27781","name":"P/0100/2015: EMA decision of 8 May 2015 on the granting of a product specific waiver for reparixin (EMEA-001693-PIP01-14)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/215088/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2015-ema-decision-8-may-2015-granting-product-specific-waiver-reparixin-emea-001693-pip01-14_en.pdf"},
    {"id":"27785","name":"P/0081/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for (2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-(chloromethyl)-4-fluoro-2-((isobuty...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/104855/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-deferral-2r3r4r5r-5-4-amino-2-oxopyrimidin-12h-yl-2-chloromethyl-4-fluoro-2-isobuty_en.pdf"},
    {"id":"27790","name":"P/0028/2014: European Medicines Agency decision of 27 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate) (EMEA-000788-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/36012/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2014-european-medicines-agency-decision-27-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-emea-000788-pip02-11-m02_en.pdf"},
    {"id":"27815","name":"P/0069/2013: EMA decision of 26 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for baricitinib (EMEA-001220-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/113253/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2013-ema-decision-26-march-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-baricitinib-emea-001220-pip01-11_en.pdf"},
    {"id":"27820","name":"P/0301/2012: EMA decision of 20 December 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for faldaprevir (EMEA-000602-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T10:40:00Z","last_updated_date":"2013-02-08T10:40:00Z","reference_number":"EMA/805028/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2012-ema-decision-20-december-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-faldaprevir-emea-000602-pip02-12_en.pdf"},
    {"id":"27823","name":"P/0151/2015: EMA decision of 10 July 2015 on the granting of a product specific waiver for atorvastatin / perindopril / acetylsalicylic acid (EMEA-001547-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-25T02:00:00Z","last_updated_date":"2015-08-25T02:00:00Z","reference_number":"EMA/382964/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2015-ema-decision-10-july-2015-granting-product-specific-waiver-atorvastatin-perindopril-acetylsalicylic-acid-emea-001547-pip01-13_en.pdf"},
    {"id":"27869","name":"P/289/2011: EMA decision of 2 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for zoledronic acid\n\n(Aclasta) (EMEA-000057-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/915429/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-289-2011-ema-decision-2-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-zoledronic-acid-aclasta-emea-000057-pip01-07-m03_en.pdf"},
    {"id":"27870","name":"P/0329/2014: EMA decision of 11 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for nonacog beta pegol (EMEA-000731-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-22T01:00:00Z","reference_number":"EMA/713546/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0329-2014-ema-decision-11-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-nonacog-beta-pegol-emea-000731-pip01-09-m02_en.pdf"},
    {"id":"27883","name":"P/0212/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for canagliflozin (Invokana), (EMEA-001030-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/603314/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-canagliflozin-invokana-emea-001030-pip01-10-m04_en.pdf"},
    {"id":"27920","name":"P/0032/2017: European Medicines Agency decision of 31 January 2017 on the granting of a product specific waiver for mirvetuximab soravtansine (EMEA-001921-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/12265/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2017-european-medicines-agency-decision-31-january-2017-granting-product-specific-waiver-mirvetuximab-soravtansine-emea-001921-pip01-16_en.pdf"},
    {"id":"27928","name":"P/91/2009: European medicines agency decision of 18 May 2009 on the refusal of a product specific waiver for rubidium-82 (EMEA-000488-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/294264/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-91-2009-european-medicines-agency-decision-18-may-2009-refusal-product-specific-waiver-rubidium-82-emea-000488-pip01-08-accordance-regulation-ec-no-1901-2006-european-parliament_en.pdf"},
    {"id":"27929","name":"P/0078/2012: EMA decision of 27 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis),\n\n(EMEA-000183-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/2239/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2012-ema-decision-27-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip01-08-m02_en.pdf"},
    {"id":"27932","name":"P/0316/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Votubia) (EMEA-000019-PIP08-12-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T16:26:00Z","last_updated_date":"2018-02-13T16:26:00Z","reference_number":"EMA/666624/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-votubia-emea-000019-pip08-12-m03_en.pdf"},
    {"id":"27958","name":"P/0264/2017: EMA decision of 4 September 2017 on the granting of a product-specific waiver for daratumumab (Darzalex), (EMEA-002152-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/552272/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2017-ema-decision-4-september-2017-granting-product-specific-waiver-daratumumab-darzalex-emea-002152-pip02-17_en.pdf"}    {"id":"27972","name":"P/0098/2015: EMA decision of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydrox...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/215117/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2015-ema-decision-8-may-2015-agreement-paediatric-investigation-plan-granting-deferral-1-22-difluoro-13-benzodioxol-5-yl-n-1-2r-23-dihydroxypropyl-6-fluoro-2-1-hydrox_en.pdf"},
    {"id":"27974","name":"P/186/2009: Agreement of a PIP, granting of a deferral and a waiver for N. meningitidis serogroup A polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup C polysaccharide conjugated to tetanus toxoid / ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/525904/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-186-2009-agreement-pip-granting-deferral-waiver-n-meningitidis-serogroup-polysaccharide-conjugated-tetanus-toxoid-n-meningitidis-serogroup-c-polysaccharide-conjugated-tetanus-toxoid_en.pdf"},
    {"id":"27999","name":"P/0208/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for anidulafungin\n\n(Ecalta), (EMEA-000469-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/513327/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-anidulafungin-ecalta-emea-000469-pip01-08-m06_en.pdf"},
    {"id":"28008","name":"P/0202/2017: EMA decision of 9 August 2017 on the refusal of a paediatric investigation plan and on the granting of waiver for methacholine chloride\n\n(EMEA-002120-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/460836/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2017-ema-decision-9-august-2017-refusal-paediatric-investigation-plan-granting-waiver-methacholine-chloride-emea-002120-pip01-17_en.pdf"},
    {"id":"28021","name":"P/0033/2012: EMA decision of 3 February 2012 on the acceptance of a modification of an agreed paediatric investigation plan for dabigatran etexilate (Pradaxa) (EMEA-000081-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T14:30:00Z","last_updated_date":"2012-03-15T14:30:00Z","reference_number":"EMA/64914/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2012-ema-decision-3-february-2012-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-pradaxa-emea-000081-pip01-07-m04_en.pdf"},
    {"id":"28034","name":"P/17/2011: EMA decision of 21 January 2011 on the granting of a product specific waiver for perindopril arginine / indapamide / amlodipine besilate(EMEA-001048-PIP01-10) in accordance with Regulation (EC) No 1901/2006...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/800809/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-17-2011-ema-decision-21-january-2011-granting-product-specific-waiver-perindopril-arginine-indapamide-amlodipine-besilateemea-001048-pip01-10-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"28039","name":"P/0047/2013: EMA decision of 1 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for talimogene laherparepvec (EMEA-001251-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/120181/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2013-ema-decision-1-march-2013-agreement-paediatric-investigation-plan-granting-deferral-talimogene-laherparepvec-emea-001251-pip01-11_en.pdf"},
    {"id":"28042","name":"P/0069/2017: EMA decision of 3 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab\n\n(EMEA-001501-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/120432/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2017-ema-decision-3-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-emea-001501-pip01-13-m04_en.pdf"},
    {"id":"28046","name":"P/0014/2013: EMA decision of 23 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for ferumoxytol (Rienso) (EMEA-000373-PIP02-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T18:30:00Z","last_updated_date":"2013-04-03T18:30:00Z","reference_number":"EMA/22310/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2013-ema-decision-23-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-ferumoxytol-rienso-emea-000373-pip02-09-m03_en.pdf"},
    {"id":"28047","name":"P/0254/2015: EMA decision of 30 October 2015 on the granting of a paediatric investigation plan and on the deferral and on the granting of a waiver for simtuzumab (EMEA-001511-PIP03-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T01:00:00Z","last_updated_date":"2015-12-21T01:00:00Z","reference_number":"EMA/627050/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2015-ema-decision-30-october-2015-granting-paediatric-investigation-plan-deferral-granting-waiver-simtuzumab-emea-001511-pip03-14_en.pdf"},
    {"id":"28073","name":"P/306/2011: EMA decision of 20 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for lomitapide (EMEA-001124-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/941395/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-306-2011-ema-decision-20-december-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lomitapide-emea-001124-pip01-10_en.pdf"},
    {"id":"28111","name":"P/194/2010: European medicines agency decision of of 26 October 2010 on the acceptance of a modification of an agreed paediatric investigation plan for tiotropium bromide (monohydrate) (Spiriva Respimat and associated na...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-24T01:00:00Z","last_updated_date":"2010-11-24T01:00:00Z","reference_number":"EMA/646432/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-194-2010-european-medicines-agency-decision-26-october-2010-acceptance-modification-agreed-paediatric-investigation-plan-tiotropium-bromide-monohydrate-spiriva-respimat-associated-na_en.pdf"},
    {"id":"28123","name":"P/0157/2013: EMA decision of 8 July 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mifepristone (EMEA-001292-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-13T17:30:00Z","last_updated_date":"2013-08-13T17:30:00Z","reference_number":"EMA/332108/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2013-ema-decision-8-july-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mifepristone-emea-001292-pip01-12_en.pdf"},
    {"id":"28124","name":"P/0069/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for 1-(2,2-difluoro-1,3-\n\nbenzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/83700/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-1-22-difluoro-13-benzodioxol-5-yl-n-1-2r-23-dihydroxypropyl-6-fluoro-2-1-hydroxy_en.pdf"},
    {"id":"28130","name":"P/84/2010: European Medicines Agency decision of 1 June 2010\n\non the acceptance of a modification of an agreed paediatric investigation plan for golimumab (Simponi) (EMEA-000265-PIP01-08-M01) in accordance with Regulatio...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/330874/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-84-2010-european-medicines-agency-decision-1-june-2010-acceptance-modification-agreed-paediatric-investigation-plan-golimumab-simponi-emea-000265-pip01-08-m01-accordance-regulatio_en.pdf"},
    {"id":"28132","name":"P/263/2011: EMA decision of 28 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for pitavastatin (calcium) (Livazo and associated names) (EMEA-000054-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T16:00:00Z","last_updated_date":"2011-11-30T16:00:00Z","reference_number":"EMA/831326/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-263-2011-ema-decision-28-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-pitavastatin-calcium-livazo-associated-names-emea-000054-pip01-07-m02_en.pdf"},
    {"id":"28159","name":"P/0012/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for simeprevir (EMEA-000625-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/10917/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-simeprevir-emea-000625-pip01-09-m02_en.pdf"},
    {"id":"28171","name":"P/0046/2014: EMA decision of 7 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (EMEA-000498-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/43440/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2014-ema-decision-7-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-linagliptin-emea-000498-pip01-08-m02_en.pdf"},
    {"id":"28174","name":"P/195/201: EMA decision of 29 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-000167-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/553360/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-195-201-ema-decision-29-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000167-pip01-07-m02_en.pdf"},
    {"id":"28202","name":"P/304/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for Pollen from Phleum pratense (EMEA-000867-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/778412/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-304-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-phleum-pratense-emea-000867-pip01-10_en.pdf"},
    {"id":"28205","name":"P/210/2009: European Medicines Agency decision of 30 October 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for methoxyflurane (EMEA-000334-PIP0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/604416/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-210-2009-european-medicines-agency-decision-30-october-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-methoxyflurane-emea-000334-pip0_en.pdf"},
    {"id":"28214","name":"P/318/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of rye pollen (EMEA-000943-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769453/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-318-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-rye-pollen-emea-000943_en.pdf"},
    {"id":"28217","name":"P/305/2011: EMA decision of 20 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human monoclonal antibody against IL-6 (CNTO 136), (E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/792730/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-305-2011-ema-decision-20-december-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-monoclonal-antibody-against-il-6-cnto-136-e_en.pdf"},
    {"id":"28295","name":"P/0091/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for anidulafungin (Ecalta), (EMEA-000469-PIP01-08-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/205463/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-anidulafungin-ecalta-emea-000469-pip01-08-m05_en.pdf"},
    {"id":"28301","name":"P/0155/2014: EMA decision of 16 June 2014 on the refusal of a paediatric investigation plan and on the granting of a waiver and on the granting of a waiver ex officio for freeze-dried culture of Lactobacillus casei subsp...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/252168/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2014-ema-decision-16-june-2014-refusal-paediatric-investigation-plan-granting-waiver-granting-waiver-ex-officio-freeze-dried-culture-lactobacillus-casei-subsp_en.pdf"},
    {"id":"28322","name":"P/96/2008: European medicines agency decision of 3 November 2008\n\non the application for agreement of a Paediatric Investigation Plan for paracetamol (EMEA-000130-PIP01-07) in accordance with Regulation (EC) No 1901/2006...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-07T00:00:00Z","last_updated_date":"2009-01-07T00:00:00Z","reference_number":"EMEA/570616/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-96-2008-european-medicines-agency-decision-3-november-2008-application-agreement-paediatric-investigation-plan-paracetamol-emea-000130-pip01-07-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"28329","name":"P/0286/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for peanut allergen extract (EMEA-001481-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/766272/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-peanut-allergen-extract-emea-001481-pip01-13-m01_en.pdf"},
    {"id":"28353","name":"P/172/2009: European Medicines Agency decision of 28 August 2009 on the granting of a product specific waiver for sitagliptin phosphate monohydrate / simvastatin (EMEA-000538-PIP01-09) in accordance with Regulation (EC) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/531555/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-172-2009-european-medicines-agency-decision-28-august-2009-granting-product-specific-waiver-sitagliptin-phosphate-monohydrate-simvastatin-emea-000538-pip01-09-accordance-regulation-ec_en.pdf"},
    {"id":"28360","name":"P/88/2009: European medicines agency decision of 18 May 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for bilastine (EMEA-000347-PIP01-08) in a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/272633/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-88-2009-european-medicines-agency-decision-18-may-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bilastine-emea-000347-pip01-08_en.pdf"},
    {"id":"28375","name":"P/0034/2016: EMA decision of 29 January 2016 on the granting of a product specific waiver for (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)-carbonyl]-3-pyrrolidinone-O-methyloxime (EMEA-001854-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/2823/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2016-ema-decision-29-january-2016-granting-product-specific-waiver-3z5s-5-hydroxymethyl-1-2-methyl11-biphenyl-4-yl-carbonyl-3-pyrrolidinone-o-methyloxime-emea-001854-pip01-15_en.pdf"},
    {"id":"28427","name":"P/341/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of dermatophagoides farinae...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/802042/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-341-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-dermatophagoides-farinae_en.pdf"},
    {"id":"28449","name":"P/177/2009: European Medicines Agency decision of 7 September 2009\n\non the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for 6,7-dihydro-5H-pyrrolo[1,2-c] ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/516800/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-177-2009-european-medicines-agency-decision-7-september-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-67-dihydro-5h-pyrrolo12-c_en.pdf"},
    {"id":"28460","name":"P/0154/2016: EMA decision of 15 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Saxenda)\n\n(EMEA-000128-PIP02-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/380505/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2016-ema-decision-15-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-saxenda-emea-000128-pip02-09-m02_en.pdf"},
    {"id":"28465","name":"P/0164/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ferric maltol (Feraccru), (EMEA-001195-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/348022/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-ferric-maltol-feraccru-emea-001195-pip01-11-m03_en.pdf"},
    {"id":"28477","name":"P/0198/2017: EMA decision of 14 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (Orkambi), (EMEA-001582-PIP01-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/433402/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2017-ema-decision-14-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-lumacaftor-ivacaftor-orkambi-emea-001582-pip01-13-m06_en.pdf"},
    {"id":"28504","name":"P/0114/2013: EMA decision of 26 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for solifenacin (succinate) (Vesicare and associated names), (EMEA-000573-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/247143/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0114-2013-ema-decision-26-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-solifenacin-succinate-vesicare-associated-names-emea-000573-pip01-09-m03_en.pdf"},
    {"id":"28533","name":"P/236/2009: European Medicines Agency Decision of 27 November 2009 on the granting of a product specific waiver for aliskiren hemifumarate / amlodipine besilate / hydrochlorothiazide (EMEA-000656-PIP01-09) in accordance ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:09:21Z","last_updated_date":"2009-12-23T00:09:21Z","reference_number":"EMEA/748101/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-236-2009-european-medicines-agency-decision-27-november-2009-granting-product-specific-waiver-aliskiren-hemifumarate-amlodipine-besilate-hydrochlorothiazide-emea-000656-pip01-09-accordance_en.pdf"},
    {"id":"28535","name":"P/0102/2014: EMA decision of 2 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for corifollitropin alfa (Elonva) (EMEA-000306-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-11T16:00:00Z","last_updated_date":"2014-06-11T16:00:00Z","reference_number":"EMA/232938/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2014-ema-decision-2-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-corifollitropin-alfa-elonva-emea-000306-pip01-08-m02_en.pdf"},
    {"id":"28548","name":"P/70/2011: EMA decision of 4 April 2011 on the granting of a product specific waiver for amlodipine besilate / perindopril tert-butylamine\n\n(EMEA-000823-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"EMA/212712/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-70-2011-ema-decision-4-april-2011-granting-product-specific-waiver-amlodipine-besilate-perindopril-tert-butylamine-emea-000823-pip02-10_en.pdf"},
    {"id":"28564","name":"P/0226/2017: EMA decision of 11 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sodium zirconium\n\ncyclosilicate (EMEA-001539-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/459236/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2017-ema-decision-11-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-sodium-zirconium-cyclosilicate-emea-001539-pip01-13-m02_en.pdf"},
    {"id":"28588","name":"P/0132/2013: EMA decision of 31 May 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for lacosamide (Vimpat) (EMEA-000402-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-24T13:30:00Z","last_updated_date":"2013-06-24T13:30:00Z","reference_number":"EMA/317063/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2013-ema-decision-31-may-2013-agreement-paediatric-investigation-plan-granting-deferral-lacosamide-vimpat-emea-000402-pip02-11_en.pdf"},
    {"id":"28589","name":"P/0361/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for avelumab (Bavencio)\n\n(EMEA-001849-PIP02-15-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T16:03:00Z","last_updated_date":"2018-03-02T16:03:00Z","reference_number":"EMA/709765/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0361-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-avelumab-bavencio-emea-001849-pip02-15-m01_en.pdf"},
    {"id":"28596","name":"P/0211/2012: EMA decision of 28 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Xgeva (previously Amgiva), Prolia) (EMEA-000145-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T17:00:00Z","last_updated_date":"2012-10-17T17:00:00Z","reference_number":"EMA/611454/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2012-ema-decision-28-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-xgeva-previously-amgiva-prolia-emea-000145-pip01-07-m05_en.pdf"},
    {"id":"28606","name":"P/0103/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for pixantrone (dimaleate) (Pixuvri), (EMEA-000713-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/187577/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2013-ema-decision-30-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-pixantrone-dimaleate-pixuvri-emea-000713-pip02-10-m02_en.pdf"},
    {"id":"28617","name":"P/200/2009: European Medicines Agency decision of 1 October 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for montelukast sodium (Singulair), (EMEA-000012-PIP01-07-M01) in accordance...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/615793/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-200-2009-european-medicines-agency-decision-1-october-2009-acceptance-modification-agreed-paediatric-investigation-plan-montelukast-sodium-singulair-emea-000012-pip01-07-m01-accordance_en.pdf"},
    {"id":"28619","name":"P/0072/2012: EMA decision of 24 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ceftaroline fosamil (EMEA-000769-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/202840/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2012-ema-decision-24-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-ceftaroline-fosamil-emea-000769-pip01-09-m02_en.pdf"},
    {"id":"28631","name":"P/0241/2014: EMA decision of 29 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for dabigatran etexilate (Pradaxa), (EMEA-000081-PIP01-07-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/527083/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2014-ema-decision-29-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-pradaxa-emea-000081-pip01-07-m07_en.pdf"},
    {"id":"28636","name":"P/0046/2018: EMA decision of 16 February 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for upadacitinib (ABT-494) (EMEA-001741-PIP03-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/85849/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2018-ema-decision-16-february-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-upadacitinib-abt-494-emea-001741-pip03-16_en.pdf"},
    {"id":"28652","name":"P/18/2011: EMA decision of 24 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lixisenatide (EMEA-000916-PIP01-10) in accordance with...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/27474/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-18-2011-ema-decision-24-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lixisenatide-emea-000916-pip01-10-accordance_en.pdf"},
    {"id":"28653","name":"P/29/2008: European medicines agency decision of 23 May 2008 on the application for product specific waiver for arzoxifene (EMEA-000179-PIP01-07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-17T02:00:00Z","last_updated_date":"2008-07-17T02:00:00Z","reference_number":"EMEA/259255/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-29-2008-european-medicines-agency-decision-23-may-2008-application-product-specific-waiver-arzoxifene-emea-000179-pip01-07-accordance-regulation-ec-no-1901-2006-european-parliament_en.pdf"},
    {"id":"28660","name":"P/0362/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lumicitabine (EMEA-\n\n001758-PIP01-15-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T13:05:00Z","last_updated_date":"2018-03-02T13:05:00Z","reference_number":"EMA/762994/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0362-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-lumicitabine-emea-001758-pip01-15-m02_en.pdf"},
    {"id":"28680","name":"P/260/2009: EMA decision of 23 December 2009 on the granting of a product specific waiver for tramadol hydrochloride / paracetamol (EMEA-000680-PIP01-09) in accordance with Regulation (EC) No 1901/...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMA/749363/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-260-2009-ema-decision-23-december-2009-granting-product-specific-waiver-tramadol-hydrochloride-paracetamol-emea-000680-pip01-09-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"28682","name":"P/0283/2012: EMA decision of 23 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for bosentan (Tracleer),\n\n(EMEA-000425-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/493954/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2012-ema-decision-23-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-bosentan-tracleer-emea-000425-pip02-10-m03_en.pdf"},
    {"id":"28714","name":"P/0268/2016: EMA decision of 7 October 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for guadecitabine (EMEA-001730-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/632890/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2016-ema-decision-7-october-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-guadecitabine-emea-001730-pip02-15_en.pdf"},
    {"id":"28730","name":"P/310/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for elvitegravir (EMEA-000968-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/693832/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-310-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-elvitegravir-emea-000968-pip02-11-m03_en.pdf"},
    {"id":"28735","name":"P/0013/2013: EMA decision of 23 January 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for apixaban (Eliquis) (EMEA-000183-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T14:30:00Z","last_updated_date":"2013-04-03T14:30:00Z","reference_number":"EMA/28382/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2013-ema-decision-23-january-2013-agreement-paediatric-investigation-plan-granting-deferral-apixaban-eliquis-emea-000183-pip02-12_en.pdf"},
    {"id":"28744","name":"P/0255/2016: EMA decision of 5 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for alogliptin (Vipidia),\n\n(EMEA-000496-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/585768/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2016-ema-decision-5-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-alogliptin-vipidia-emea-000496-pip01-08-m05_en.pdf"},
    {"id":"28750","name":"P/0158/2015: EMA decision of 10 July 2015 on the granting of a product specific waiver for clonidine (EMEA-001746-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-25T02:00:00Z","last_updated_date":"2015-08-25T02:00:00Z","reference_number":"EMA/366856/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2015-ema-decision-10-july-2015-granting-product-specific-waiver-clonidine-emea-001746-pip01-15_en.pdf"},
    {"id":"28758","name":"P/135/2010:  European Medicines Agency decision of 28 July 2010 on the granting of a product specific waiver for levonorgestrel/ethinylestradiol (EMEA-000829-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of t...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/463871/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-135-2010-european-medicines-agency-decision-28-july-2010-granting-product-specific-waiver-levonorgestrel-ethinylestradiol-emea-000829-pip01-09-accordance-regulation-ec-no-1901-2006-t_en.pdf"},
    {"id":"28773","name":"P/0303/2017: EMA decision of 9 November 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the refusal of a\n\nwaiver for 1H-Isoindol-1-one,2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/735836/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2017-ema-decision-9-november-2017-refusal-paediatric-investigation-plan-refusal-deferral-refusal-waiver-1h-isoindol-1-one2-1-2-4-fluorophenyl-2-oxoethyl_en.pdf"},
    {"id":"28790","name":"P/0187/2012: EMA decision of 21 August 2012 on the granting of a product specific waiver for [N-\n\n((2S,3R,3aS,3´R,4a´R,6S,6a´R,6b´S,7aR,12a´S,12b´S,Z)-3,6,11´,12b´-tetramethyl-\n\n2´,3a,3´,4,4´,4a´,5,5´,6,6´,6a´,6b´,7,7a,7...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T02:00:00Z","last_updated_date":"2012-09-18T02:00:00Z","reference_number":"EMA/528778/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2012-ema-decision-21-august-2012-granting-product-specific-waiver-n-2s3r3as3r4ar6s6ar6bs7ar12as12bsz-361112b-tetramethyl-23a3444a55666a6b77a7_en.pdf"},
    {"id":"28800","name":"P/229/2010: EMA decision of 23 November 2010 on the acceptance of a modification of an agreed paediatric investigation plan for rosuvastatin (calcium) (Crestor and associated names) (EMEA-000022-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T00:09:21Z","last_updated_date":"2010-12-21T00:09:21Z","reference_number":"EMA/714398/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-229-2010-ema-decision-23-november-2010-acceptance-modification-agreed-paediatric-investigation-plan-rosuvastatin-calcium-crestor-associated-names-emea-000022-pip01-07-m04_en.pdf"},
    {"id":"28805","name":"P/218/2009: European Medicines Agency decision of 30 October 2009 on the refusal of a product specific waiver for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerized, allergenic extract of birch, alder a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/679781/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-218-2009-european-medicines-agency-decision-30-october-2009-refusal-product-specific-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerized-allergenic-extract-birch-alder_en.pdf"},
    {"id":"28808","name":"P/0278/2012: EMA decision of 21 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for brentuximab vedotin\n\n(EMEA-000980-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/725347/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2012-ema-decision-21-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-brentuximab-vedotin-emea-000980-pip01-10-m01_en.pdf"},
    {"id":"28815","name":"P/0266/2017: EMA decision of 4 September 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous T cells transduced with lentiviral vector...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/496518/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2017-ema-decision-4-september-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-t-cells-transduced-lentiviral-vector_en.pdf"},
    {"id":"28835","name":"P/169/2009: European Medicines Agency decision of 28 August 2009 on the granting of a product specific waiver for sitagliptin phosphate monohydrate / simvastatin (EMEA-000535-PIP01-09) in accordance with Regulation (EC) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/531433/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-169-2009-european-medicines-agency-decision-28-august-2009-granting-product-specific-waiver-sitagliptin-phosphate-monohydrate-simvastatin-emea-000535-pip01-09-accordance-regulation-ec_en.pdf"},
    {"id":"28841","name":"P/0193/2013: EMA decision of 13 August 2013 on the acceptance of a modification of an agreed paediatric investigation plan for rupadatine fumarate (Rupafin and associated names) (EMEA-000582-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-09T18:45:00Z","last_updated_date":"2013-09-09T18:45:00Z","reference_number":"EMA/449238/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2013-ema-decision-13-august-2013-acceptance-modification-agreed-paediatric-investigation-plan-rupadatine-fumarate-rupafin-associated-names-emea-000582-pip01-09-m02_en.pdf"},
    {"id":"28860","name":"P/176/2011: EMA decision of 8 July 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for gadobutrol (Gadovist) (EMEA-000994-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/513777/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-176-2011-ema-decision-8-july-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-gadobutrol-gadovist-emea-000994-pip01-10_en.pdf"},
    {"id":"28866","name":"P/46/2011: EMA decision of 2 March 2011on the granting of a product specific waiver for (E)-4-(2-(6-(2-(2-(2- [18F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl vinyl)-N-methylbenzenamine (EMEA-001060-PIP01-10) in accordance w...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-05T02:00:00Z","last_updated_date":"2011-04-05T02:00:00Z","reference_number":"EMA/72156/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-46-2011-ema-decision-2-march-2011on-granting-product-specific-waiver-e-4-2-6-2-2-2-18ffluoroethoxyethoxyethoxypyridin-3-yl-vinyl-n-methylbenzenamine-emea-001060-pip01-10-accordance-w_en.pdf"},
    {"id":"28874","name":"P/138/2010: European Medicines Agency decision of 30 July 2010 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir (Prezista), (EMEA-000038-PIP01-07-M03) in accordance with Regula...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/463333/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-138-2010-european-medicines-agency-decision-30-july-2010-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-prezista-emea-000038-pip01-07-m03-accordance-regula_en.pdf"},
    {"id":"28876","name":"P/0071/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for evolocumab (EMEA-001268-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/108903/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-evolocumab-emea-001268-pip01-12-m01_en.pdf"},
    {"id":"28917","name":"P/16/2011: EMA decision of 21 January 2011 on the granting of a product specific waiver for nepafenac (Nevanac) (EMEA-000913-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of th...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/800821/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-16-2011-ema-decision-21-january-2011-granting-product-specific-waiver-nepafenac-nevanac-emea-000913-pip01-10-accordance-regulation-ec-no-1901-2006-european-parliament-th_en.pdf"},
    {"id":"28922","name":"P/0001/2016: EMA decision of 8 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for PEGylated recombinant factor VIII (EMEA-001296-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/866072/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2016-ema-decision-8-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-pegylated-recombinant-factor-viii-emea-001296-pip01-12-m03_en.pdf"},
    {"id":"28953","name":"P/32/2011: EMA decision of the 28 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for C1 inhibitor (EMEA-\n\n000568-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"EMA/58038/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-32-2011-ema-decision-28-january-2011-acceptance-modification-agreed-paediatric-investigation-plan-c1-inhibitor-emea-000568-pip01-09-m01-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"28957","name":"P/0012/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate)\n\n(Lixiana), (EMEA-000788-PIP02-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/34675/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-lixiana-emea-000788-pip02-11-m05_en.pdf"},
    {"id":"28958","name":"P/0187/2014: EMA decision of 6 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for riociguat (ADEMPAS), (EMEA-000718-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/409208/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2014-ema-decision-6-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-riociguat-adempas-emea-000718-pip01-09-m04_en.pdf"},
    {"id":"28995","name":"P/72/2011: EMA decision of 4 April 2011 on the granting of a product-specific waiver for [18F]flutemetamol (EMEA-001028-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2012-12-11T18:00:03Z","reference_number":"EMA/206028/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-72-2011-ema-decision-4-april-2011-granting-product-specific-waiver-18fflutemetamol-emea-001028-pip01-10_en.pdf"},
    {"id":"28997","name":"P/0238/2013: EMA decision of 24 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for insulin peglispro, (EMEA-001097-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/566317/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2013-ema-decision-24-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-insulin-peglispro-emea-001097-pip01-10-m01_en.pdf"},
    {"id":"29002","name":"P/04/2009: European Medicines Agency decision of 27 January 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for mometasone furoate, formoterol fumarate dihydrate (EMEA-000025-PIP01-07-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/24357/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-04-2009-european-medicines-agency-decision-27-january-2009-acceptance-modification-agreed-paediatric-investigation-plan-mometasone-furoate-formoterol-fumarate-dihydrate-emea-000025-pip01-07_en.pdf"},
    {"id":"29003","name":"P/0029/2014: European Medicines Agency decision of 13 February 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for clazakizumab (EMEA-001371-PIP0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-03-20T01:00:00Z","last_updated_date":"2014-03-20T01:00:00Z","reference_number":"EMA/58743/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2014-european-medicines-agency-decision-13-february-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-clazakizumab-emea-001371-pip0_en.pdf"},
    {"id":"29036","name":"P/68/2010: European Medicines Agency decision on the granting of a product specific waiver for sorafenib (as tosylate) (Nexavar) (EMEA-000781-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/264450/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-68-2010-european-medicines-agency-decision-granting-product-specific-waiver-sorafenib-tosylate-nexavar-emea-000781-pip01-09_en.pdf"},
    {"id":"29037","name":"P/0039/2012: EMA decision of 24 February 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaflor (EMEA-\n\n000335-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/97657/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2012-ema-decision-24-february-2012-acceptance-modification-agreed-paediatric-investigation-plan-ivacaflor-emea-000335-pip01-08-m05_en.pdf"},
    {"id":"29049","name":"P/235/2010: EMA decision of 26 November 2010 on the acceptance of a modification of an agreed paediatric investigation plan for eptacog alfa pegol (activated) (EMEA-000189-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/720293/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-235-2010-ema-decision-26-november-2010-acceptance-modification-agreed-paediatric-investigation-plan-eptacog-alfa-pegol-activated-emea-000189-pip01-08-m01_en.pdf"},
    {"id":"29051","name":"P/0131/2018: EMA decision of 13 April 2018 on the granting of a product specific waiver for clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins (Xeomin, Bocouture), (EMEA-001039-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-26T02:00:00Z","last_updated_date":"2018-07-26T02:00:00Z","reference_number":"EMA/501922/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2018-ema-decision-13-april-2018-granting-product-specific-waiver-clostridium-botulinum-neurotoxin-type-150-kd-free-complexing-proteins-xeomin-bocouture-emea-001039-pip03-17_en.pdf"},
    {"id":"29080","name":"P/0150/2017: EMA decision of 9 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sirukumab (EMEA-001043-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/318383/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2017-ema-decision-9-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-sirukumab-emea-001043-pip01-10-m03_en.pdf"},
    {"id":"29129","name":"P/219/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 12 grass pollen extract, cultiva...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/627636/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-219-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-12-grass-pollen-extract-cultiva_en.pdf"},
    {"id":"29132","name":"P/0214/2013: EMA decision of 3 September 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for glycerol phenylbutyrate (GPB) (EMEA-000297-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/519775/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2013-ema-decision-3-september-2013-agreement-paediatric-investigation-plan-granting-deferral-glycerol-phenylbutyrate-gpb-emea-000297-pip02-12_en.pdf"},
    {"id":"29139","name":"P/61/2011: EMA decision of 4 March 2011 on the granting of a product specific waiver for Human Papilloma Virus Type 16 E6 071-095 / Human Papilloma Virus Type 16 E7 064-098 / Human Papilloma Virus Type 16 E6 055 080 / Hu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/78577/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-61-2011-ema-decision-4-march-2011-granting-product-specific-waiver-human-papilloma-virus-type-16-e6-071-095-human-papilloma-virus-type-16-e7-064-098-human-papilloma-virus-type-16-e6-055-080-hu_en.pdf"},
    {"id":"29149","name":"P/0130/2013: EMA decision of 28 May 2013 on the granting of a product-specific waiver for valsartan / hydrochlorothiazide + rosuvastatin (EMEA-001408-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-24T13:30:00Z","last_updated_date":"2013-06-24T13:30:00Z","reference_number":"EMA/250243/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2013-ema-decision-28-may-2013-granting-product-specific-waiver-valsartan-hydrochlorothiazide-rosuvastatin-emea-001408-pip01-12_en.pdf"},
    {"id":"29158","name":"P/0140/2016: EMA decision of 20 May 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for doravirine / lamivudine / tenofovir disoproxil fumarate (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-18T02:00:00Z","last_updated_date":"2016-07-18T02:00:00Z","reference_number":"EMA/290656/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2016-ema-decision-20-may-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-doravirine-lamivudine-tenofovir-disoproxil-fumarate_en.pdf"},
    {"id":"29185","name":"P/0226/2014: EMA decision of 5 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for golimumab (Simponi), (EMEA-000265-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/468298/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2014-ema-decision-5-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-golimumab-simponi-emea-000265-pip01-08-m04_en.pdf"},
    {"id":"29190","name":"P/0283/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for\n\nphenyl- and piperidin-containing derivative of amiloride (BI 443651)\n\n(EMEA-002082-PI...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-03-26T02:00:00Z","reference_number":"EMA/565683/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-phenyl-piperidin-containing-derivative-amiloride-bi-443651-emea-002082-pi_en.pdf"},
    {"id":"29214","name":"P/0199/2016: EMA decision of 18 July 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for andexanet alfa\n\n(EMEA-001902-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T02:00:00Z","last_updated_date":"2016-09-22T02:00:00Z","reference_number":"EMA/479450/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2016-ema-decision-18-july-2016-agreement-paediatric-investigation-plan-granting-deferral-andexanet-alfa-emea-001902-pip01-15_en.pdf"},
    {"id":"29272","name":"P/0212/2014: EMA decision of 1 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for cobicistat (Tybost), (EMEA-000969-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/464765/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2014-ema-decision-1-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-cobicistat-tybost-emea-000969-pip01-10-m03_en.pdf"},
    {"id":"29297","name":"P/0118/2016: EMA decision of 22 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (Fycompa), (EMEA-000467-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/249406/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2016-ema-decision-22-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-fycompa-emea-000467-pip01-08-m07_en.pdf"},
    {"id":"29316","name":"P/0178/2014: EMA decision of 7 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir (Sovaldi) (EMEA-001276-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/392133/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2014-ema-decision-7-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-sofosbuvir-sovaldi-emea-001276-pip01-12-m01_en.pdf"},
    {"id":"29319","name":"P/168/2010: European Medicines Agency decision of 3 September 2010 on the granting of a product specific waiver for lixisenatide / insulin glargine,\n\n(EMEA-000915-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/477369/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-168-2010-european-medicines-agency-decision-3-september-2010-granting-product-specific-waiver-lixisenatide-insulin-glargine-emea-000915-pip01-10_en.pdf"},
    {"id":"29353","name":"P/334/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for aqueous allergen extract of grass and rye pollen (EM...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/814935/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-334-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aqueous-allergen-extract-grass-rye-pollen-em_en.pdf"},
    {"id":"29355","name":"P/0076/2014: EMA decision of 2 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bimatoprost (Lumigan and associated names), (EMEA-000917-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/113584/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2014-ema-decision-2-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-bimatoprost-lumigan-associated-names-emea-000917-pip01-10-m03_en.pdf"},
    {"id":"29359","name":"P/0315/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol\n\n(hydrochloride) (Palexia and associated names, Yantil and associated names, Tape...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T17:47:00Z","last_updated_date":"2017-01-27T17:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0315-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tape_en.pdf"}    {"id":"29371","name":"P/0368/2016: EMA decision of 21 December 2016 on the granting of a product specific waiver for netarsudil (EMEA-002037-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/826798/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0368-2016-ema-decision-21-december-2016-granting-product-specific-waiver-netarsudil-emea-002037-pip01-16_en.pdf"},
    {"id":"29387","name":"P/0045/2016: EMA decision of 26 February 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tolvaptan (Samsca and associated names), (EMEA-001231-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/131042/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2016-ema-decision-26-february-2016-acceptance-modification-agreed-paediatric-investigation-plan-tolvaptan-samsca-associated-names-emea-001231-pip02-13-m02_en.pdf"},
    {"id":"29390","name":"P/0101/2018: EMA decision of 15 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for crisaborole (EMEA-002065-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/141028/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2018-ema-decision-15-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-crisaborole-emea-002065-pip01-16-m01_en.pdf"},
    {"id":"29415","name":"P/0348/2016: EMA decision of 2 December 2016 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of\n\na waiver for chlorhexidine gluconate / isopropyl alcohol (EMEA-00201...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/742003/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0348-2016-ema-decision-2-december-2016-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-chlorhexidine-gluconate-isopropyl-alcohol-emea-00201_en.pdf"},
    {"id":"29431","name":"P/0156/2014: EMA decision of 18 June 2014 on the granting of a product specific waiver for amoxicillin (in combination with clarithromycin + metronidazole + pantoprazole), (EMEA-001574-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/252172/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2014-ema-decision-18-june-2014-granting-product-specific-waiver-amoxicillin-combination-clarithromycin-metronidazole-pantoprazole-emea-001574-pip01-13_en.pdf"},
    {"id":"29445","name":"P/0351/2016: EMA decision of 2 December 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pimavanserin (EMEA-001688-PIP03-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/765283/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0351-2016-ema-decision-2-december-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pimavanserin-emea-001688-pip03-16_en.pdf"},
    {"id":"29452","name":"P/40/2011: EMA decision of 3 February 2011 on the granting of a product specific waiver for romidepsin (EMEA-001023-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2011-03-08T01:00:00Z","reference_number":"EMA/65907/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-40-2011-ema-decision-3-february-2011-granting-product-specific-waiver-romidepsin-emea-001023-pip01-10_en.pdf"},
    {"id":"29473","name":"P/0273/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for filgotinib (EMEA-001619-PIP04-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T17:31:00Z","last_updated_date":"2018-02-12T17:31:00Z","reference_number":"EMA/541698/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-filgotinib-emea-001619-pip04-17_en.pdf"},
    {"id":"29485","name":"P/99/2008: European Medicines Agency decision of 3 November 2008 on the application for agreement of a Paediatric Investigation Plan for belatacept (EMEA-000157-PIP01-07) in accordance with Regulation (EC) No 1901/2006 o...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-07T01:00:00Z","last_updated_date":"2009-01-07T01:00:00Z","reference_number":"EMEA/571733/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-99-2008-european-medicines-agency-decision-3-november-2008-application-agreement-paediatric-investigation-plan-belatacept-emea-000157-pip01-07-accordance-regulation-ec-no-1901-2006-o_en.pdf"},
    {"id":"29526","name":"P/155/2011: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for sotrastaurin (acetate)\n\n(EMEA-000093-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/485323/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-155-2011-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-sotrastaurin-acetate-emea-000093-pip01-07-m01_en.pdf"},
    {"id":"29536","name":"P/0302/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate) (Lixiana), (EMEA-000788-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/785817/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-lixiana-emea-000788-pip02-11-m04_en.pdf"},
    {"id":"29537","name":"P/202/2011: EMA decision of 26 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for Modified Grass Pollen Extract (EMEA-000284-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/648927/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-202-2011-ema-decision-26-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-modified-grass-pollen-extract-emea-000284-pip01-08-m02_en.pdf"},
    {"id":"29539","name":"P/0055/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (EMEA-\n\n000576-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/104672/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-emea-000576-pip02-11-m04_en.pdf"},
    {"id":"29544","name":"P/0362/2016: EMA decision of 21 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for finerenone\n\n(EMEA-001623-PIP01-14-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T17:48:00Z","last_updated_date":"2017-02-03T17:48:00Z","reference_number":"EMA/826903/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0362-2016-ema-decision-21-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-finerenone-emea-001623-pip01-14-m01_en.pdf"},
    {"id":"29567","name":"P/0115/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for heterologous Human\n\nAdult Liver-derived Progenitor Cells (HHALPC) (EMEA-001155-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/206203/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-heterologous-human-adult-liver-derived-progenitor-cells-hhalpc-emea-001155-pip01-11-m03_en.pdf"},
    {"id":"29598","name":"P/0308/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for fremanezumab\n\n(EMEA-001877-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-20T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"EMA/666633/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-fremanezumab-emea-001877-pip01-15-m01_en.pdf"},
    {"id":"29600","name":"P/3/2008: European medicines agency decision of 1 February 2008 on the application for product specific waiver for Telmisartan/ramipril (fixed combination) EMEA-000045-PIP01-07 in accordance with Regulation (EC) No 1901/...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-01-15T01:00:00Z","last_updated_date":"2008-01-15T01:00:00Z","reference_number":"EMEA/43360/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-3-2008-european-medicines-agency-decision-1-february-2008-application-product-specific-waiver-telmisartan-ramipril-fixed-combination-emea-000045-pip01-07-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"29606","name":"Meningococcal group A oligosaccharide Conjugated to Corynebacterium diphteriae CRM197 protein, meningococcal group C oligosaccharide Conjugated to Corynebacterium diphteriae CRM197 protein, meningococcal group W-135 olig...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2011-03-08T01:00:00Z","reference_number":"EMA/84850/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/meningococcal-group-oligosaccharide-conjugated-corynebacterium-diphteriae-crm197-protein-meningococcal-group-c-oligosaccharide-conjugated-corynebacterium-diphteriae-crm197-protein-meningococcal-group_en.pdf"},
    {"id":"29636","name":"P/0088/2014: EMA decision of 4 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for loxapine (EMEA-001115-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-15T02:00:00Z","last_updated_date":"2014-05-15T02:00:00Z","reference_number":"EMA/52888/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2014-ema-decision-4-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-loxapine-emea-001115-pip01-10-m02_en.pdf"},
    {"id":"29640","name":"P/0245/2012: EMA decision of 22 October 2012 on the granting of a product specific waiver for amlodipine (besylate) / candesartan (cilexetil) (EMEA-001319-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/636948/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2012-ema-decision-22-october-2012-granting-product-specific-waiver-amlodipine-besylate-candesartan-cilexetil-emea-001319-pip01-12_en.pdf"},
    {"id":"29646","name":"P/0038/2013: EMA decision of 27 February 2013 on the granting of a product-specific waiver for perindopril / indapamide / amlodipine (EMEA-001355-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/23778/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2013-ema-decision-27-february-2013-granting-product-specific-waiver-perindopril-indapamide-amlodipine-emea-001355-pip01-12_en.pdf"},
    {"id":"29694","name":"P/0205/2016: EMA decision of 4 August 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for risankizumab (EMEA-001776-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/512975/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2016-ema-decision-4-august-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-risankizumab-emea-001776-pip01-15_en.pdf"},
    {"id":"29701","name":"P/0092/2014: EMA decision of 7 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP01-07-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/186334/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2014-ema-decision-7-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-yervoy-emea-000117-pip01-07-m06_en.pdf"},
    {"id":"29730","name":"P/0153/2016: EMA decision of 14 June 2016 on the granting of a product specific waiver for ibuprofen / tramadol (EMEA-001887-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/334199/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2016-ema-decision-14-june-2016-granting-product-specific-waiver-ibuprofen-tramadol-emea-001887-pip01-15_en.pdf"},
    {"id":"29753","name":"P/0051/2012: EMA decision of 2 March 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for hepatitis B (rDNA) surface antigen adjuvanted (EMEA-001...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-10T02:00:00Z","last_updated_date":"2012-04-10T02:00:00Z","reference_number":"EMA/108063/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2012-ema-decision-2-march-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-hepatitis-b-rdna-surface-antigen-adjuvanted-emea-001_en.pdf"},
    {"id":"29758","name":"P/0231/2014: EMA decision of 5 September 2014 on the agreement of a paediatric investigation plan and on the granting of a waiver for trifarotene (EMEA-001492-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/468799/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2014-ema-decision-5-september-2014-agreement-paediatric-investigation-plan-granting-waiver-trifarotene-emea-001492-pip01-13_en.pdf"},
    {"id":"29759","name":"P/114/2012: EMA decision of 29 June 2012 on the granting of a product specific waiver for amlodipine (besilate) / valsartan (EMEA-001247-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-19T17:00:00Z","last_updated_date":"2012-07-19T17:00:00Z","reference_number":"EMA/332315/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-114-2012-ema-decision-29-june-2012-granting-product-specific-waiver-amlodipine-besilate-valsartan-emea-001247-pip01-11_en.pdf"},
    {"id":"29763","name":"P/0032/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T11:41:00Z","last_updated_date":"2018-04-18T11:41:00Z","reference_number":"EMA/848761/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-linagliptin-trajenta-emea-000498-pip01-08-m07_en.pdf"},
    {"id":"29781","name":"P/0332/2017: EMA decision of 31 October 2017 on the granting of a product specific waiver for amlodipine / irbesartan / hydrochlorothiazide (EMEA-\n\n002167-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/666337/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0332-2017-ema-decision-31-october-2017-granting-product-specific-waiver-amlodipine-irbesartan-hydrochlorothiazide-emea-002167-pip01-17_en.pdf"},
    {"id":"29803","name":"P/0213/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dopamine (EMEA-001105-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/561416/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-dopamine-emea-001105-pip01-10-m02_en.pdf"},
    {"id":"29817","name":"P/0282/2017: EMA decision of 4 October 2017 on the granting of a product specific waiver for ramucirumab (Cyramza), (EMEA-002074-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/565636/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2017-ema-decision-4-october-2017-granting-product-specific-waiver-ramucirumab-cyramza-emea-002074-pip01-16_en.pdf"},
    {"id":"29818","name":"P/0190/2013: EMA decision of 9 August 2013 on the acceptance of a modification of an agreed paediatric investigation plan for solifenacin (succinate) (Vesicare and associated names) (EMEA-000573-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-10T13:35:00Z","last_updated_date":"2013-09-10T13:35:00Z","reference_number":"EMA/476109/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2013-ema-decision-9-august-2013-acceptance-modification-agreed-paediatric-investigation-plan-solifenacin-succinate-vesicare-associated-names-emea-000573-pip02-13-m01_en.pdf"},
    {"id":"29826","name":"P/223/2010: European Medicines Agency decision of 29 October 2010 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for phentermine / topiramate, (EMEA-000...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/654862/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-223-2010-european-medicines-agency-decision-29-october-2010-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-phentermine-topiramate-emea-000_en.pdf"},
    {"id":"29836","name":"P/11/2009: European Medicines Agency decision of 27 January 2009 on refusal of a Paediatric Investigation Plan and on the refusal of a deferral and on the granting of a waiver for Human Papillomavirus type 16 L1 protein,...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/30247/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-11-2009-european-medicines-agency-decision-27-january-2009-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-human-papillomavirus-type-16-l1-protein_en.pdf"},
    {"id":"29847","name":"P/0142/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for turoctocog alfa pegol (EMEA-001174-PIP02-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/312705/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-turoctocog-alfa-pegol-emea-001174-pip02-12-m02_en.pdf"},
    {"id":"29859","name":"P/0325/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (Bosulif),\n\n(EMEA-000727-PIP01-09-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T11:23:00Z","last_updated_date":"2017-01-30T11:23:00Z","reference_number":"EMA/741983/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0325-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-bosutinib-bosulif-emea-000727-pip01-09-m02_en.pdf"},
    {"id":"29868","name":"P/0121/2015: EMA decision of 5 June 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for peanut allergen extract (EMEA-001481-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-03T02:00:00Z","last_updated_date":"2015-07-03T02:00:00Z","reference_number":"EMA/297899/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2015-ema-decision-5-june-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-peanut-allergen-extract-emea-001481-pip01-13_en.pdf"},
    {"id":"29892","name":"P/0314/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for grazoprevir / elbasvir (EMEA-001604-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/761439/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-grazoprevir-elbasvir-emea-001604-pip01-13-m01_en.pdf"},
    {"id":"29893","name":"P/0240/2012: EMA decision of 22 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human\n\nN-acetylgalactosamine-6-sulfatase (EMEA-000973-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/660447/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2012-ema-decision-22-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-n-acetylgalactosamine-6-sulfatase-emea-000973-pip01-10-m01_en.pdf"},
    {"id":"29897","name":"P/312/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for aciclovir (Sitavig and associated names) (EMEA-001066-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/717745/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-312-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-aciclovir-sitavig-associated-names-emea-001066-pip02-11-m01_en.pdf"},
    {"id":"29912","name":"P/16/2009: European Medicines Agency decision of 27 January 2009 on the granting of a product specific waiver for amlodipine besylate, valsartan, hydrochlorothiazide, (Imprida HCT), (EMEA-000399-PIP01-08) in accordance w...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/24175/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-16-2009-european-medicines-agency-decision-27-january-2009-granting-product-specific-waiver-amlodipine-besylate-valsartan-hydrochlorothiazide-imprida-hct-emea-000399-pip01-08-accordance-w_en.pdf"},
    {"id":"29923","name":"P/0014/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for budesonide (EMEA-\n\n001087-PIP02-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/38337/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-budesonide-emea-001087-pip02-12-m03_en.pdf"},
    {"id":"29950","name":"P/0276/2014: EMA decision of 28 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for belimumab (Benlysta), (EMEA-000520-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-04T01:00:00Z","last_updated_date":"2014-12-04T01:00:00Z","reference_number":"EMA/587684/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2014-ema-decision-28-october-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-belimumab-benlysta-emea-000520-pip02-13_en.pdf"},
    {"id":"29958","name":"P/227/2009: European Medicines Agency Decision of 4 November 2009 on the granting of a product specific waiver for olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide (EMEA-000667-PIP01-09) in accordance wit...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:09:21Z","last_updated_date":"2009-12-23T00:09:21Z","reference_number":"EMEA/693325/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-227-2009-european-medicines-agency-decision-4-november-2009-granting-product-specific-waiver-olmesartan-medoxomil-amlodipine-besilate-hydrochlorothiazide-emea-000667-pip01-09-accordance-wit_en.pdf"},
    {"id":"29971","name":"P/0031/2012: EMA decision of 2 February 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ivabradine\n\n(hydrochloride) (Corlentor), (EMEA-000627-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T14:30:00Z","last_updated_date":"2012-03-15T14:30:00Z","reference_number":"EMA/62804/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2012-ema-decision-2-february-2012-acceptance-modification-agreed-paediatric-investigation-plan-ivabradine-hydrochloride-corlentor-emea-000627-pip01-09-m02_en.pdf"},
    {"id":"29977","name":"P/61/2010: European Medicines Agency decision on the acceptance of a modification of an agreed paediatric investigation plan for nomegestrol acetate / 17 beta - estradiol (EMEA-000250-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/216040/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-61-2010-european-medicines-agency-decision-acceptance-modification-agreed-paediatric-investigation-plan-nomegestrol-acetate-17-beta-estradiol-emea-000250-pip01-08-m02_en.pdf"},
    {"id":"29993","name":"P/0093/2018: EMA decision of 16 March 2018 on the granting of a product specific waiver for candesartan (cilexetil) / amlodipine (besylate) (EMEA-002248-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/100992/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2018-ema-decision-16-march-2018-granting-product-specific-waiver-candesartan-cilexetil-amlodipine-besylate-emea-002248-pip01-17_en.pdf"},
    {"id":"30006","name":"P/226/2011: EMA decision of 27 September 2011 on the refusal of a product specific waiver for antithrombin alfa (ATryn) (EMEA-001154-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/710340/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-226-2011-ema-decision-27-september-2011-refusal-product-specific-waiver-antithrombin-alfa-atryn-emea-001154-pip01-11_en.pdf"},
    {"id":"30024","name":"P/0286/2012: EMA decision of 23 November 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for ponesimod (EMEA-000798-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-07T01:00:00Z","last_updated_date":"2013-01-07T01:00:00Z","reference_number":"EMA/734844/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2012-ema-decision-23-november-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ponesimod-emea-000798-pip01-09_en.pdf"},
    {"id":"30035","name":"P/0273/2012: EMA decision of of 21 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for azilsartan medoxomil (Edarbi, Ipreziv), (EMEA-000237-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/680042/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2012-ema-decision-21-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-azilsartan-medoxomil-edarbi-ipreziv-emea-000237-pip01-08-m04_en.pdf"},
    {"id":"30042","name":"P/0295/2017: EMA decision of 29 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for entolimod (EMEA-\n\n002020-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T17:00:00Z","last_updated_date":"2017-10-26T17:00:00Z","reference_number":"EMA/630131/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2017-ema-decision-29-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-entolimod-emea-002020-pip01-16-m01_en.pdf"},
    {"id":"30059","name":"P/0207/2012: EMA decision of 21 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin (EMEA-000694-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T17:00:00Z","last_updated_date":"2012-10-17T17:00:00Z","reference_number":"EMA/598488/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2012-ema-decision-21-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-emea-000694-pip01-09-m01_en.pdf"},
    {"id":"30066","name":"P/0055/2012: EMA decision of 26 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for rabeprazole (sodium) (Pariet and associated names), (EMEA-000055-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T17:42:00Z","last_updated_date":"2012-04-20T17:42:00Z","reference_number":"EMA/124630/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2012-ema-decision-26-march-2012-acceptance-modification-agreed-paediatric-investigation-plan-rabeprazole-sodium-pariet-associated-names-emea-000055-pip01-07-m05_en.pdf"},
    {"id":"30067","name":"P/105/2010: European Medicines Agency decision of 25 June 2010\n\non the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Afinitor) (EMEA-000019-PIP02-07-M01) in accordance with Regul...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/415023/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-105-2010-european-medicines-agency-decision-25-june-2010-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-afinitor-emea-000019-pip02-07-m01-accordance-regul_en.pdf"},
    {"id":"30070","name":"P/0035/2017: European Medicines Agency decision of 31 January 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vadadustat (EMEA-001944-PIP01-1...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/38355/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2017-european-medicines-agency-decision-31-january-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vadadustat-emea-001944-pip01-1_en.pdf"},
    {"id":"30078","name":"P/0184/2015: EMA decision of 21 August 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for glucagon (EMEA-001657-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-24T02:00:00Z","last_updated_date":"2015-09-24T02:00:00Z","reference_number":"EMA/473658/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2015-ema-decision-21-august-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-glucagon-emea-001657-pip01-14_en.pdf"},
    {"id":"30091","name":"P/136/2009: European Medicines Agency decision of 15 July 2009\n\non the agreement of a Paediatric Investigation Plan and on the granting of a waiver for insulin glargine (Optisulin) (EMEA-000396-PIP01-08) in accordance wi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/387961/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-136-2009-european-medicines-agency-decision-15-july-2009-agreement-paediatric-investigation-plan-granting-waiver-insulin-glargine-optisulin-emea-000396-pip01-08-accordance-wi_en.pdf"},
    {"id":"30095","name":"P/39/2010: EMA decision of 18 March 2010 on the acceptance of a modification of an agreed PIP for Split influenza virus, inactivated containing antigen equivalent to A/California/7/2009 (H1N1)-like strain (A/California/7...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/172533/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-39-2010-ema-decision-18-march-2010-acceptance-modification-agreed-pip-split-influenza-virus-inactivated-containing-antigen-equivalent-california-7-2009-h1n1-strain-california-7_en.pdf"},
    {"id":"30096","name":"P/0262/2016: EMA decision of 5 October 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for copanlisib (EMEA-001757-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/592849/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2016-ema-decision-5-october-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-copanlisib-emea-001757-pip02-15_en.pdf"},
    {"id":"30104","name":"P/0097/2014: EMA decision of 7 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names and Tapen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/186586/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2014-ema-decision-7-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapen_en.pdf"},
    {"id":"30110","name":"P/0040/2013: EMA decision of 27 February 2013 on the granting of a product-specific waiver for amlodipine / losartan (EMEA-001380-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/24016/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2013-ema-decision-27-february-2013-granting-product-specific-waiver-amlodipine-losartan-emea-001380-pip01-12_en.pdf"},
    {"id":"30119","name":"P/0164/2016: EMA decision of 15 June 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for bexagliflozin (EMEA-001841-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/336929/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2016-ema-decision-15-june-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bexagliflozin-emea-001841-pip01-15_en.pdf"},
    {"id":"30130","name":"P/164/2011: EMA decision of 4 July 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for canagliflozin (EMEA-001030-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/487800/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-164-2011-ema-decision-4-july-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-canagliflozin-emea-001030-pip01-10_en.pdf"},
    {"id":"30143","name":"P/0290/2015: EMA decision of 27 November 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for olaratumab (EMEA-001760-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/688273/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2015-ema-decision-27-november-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-olaratumab-emea-001760-pip01-15_en.pdf"},
    {"id":"30156","name":"P/100/2010: European Medicines Agency decision of 11 June 2010\n\non the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dapagliflozin (EMEA-000694-PIP01-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/352334/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-100-2010-european-medicines-agency-decision-11-june-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dapagliflozin-emea-000694-pip01-0_en.pdf"},
    {"id":"30180","name":"P/0012/2013: EMA decision of 23 January 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for everolimus (Votubia) (EMEA-000019-PIP08-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T14:30:00Z","last_updated_date":"2013-04-03T14:30:00Z","reference_number":"EMA/27942/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2013-ema-decision-23-january-2013-agreement-paediatric-investigation-plan-granting-deferral-everolimus-votubia-emea-000019-pip08-12_en.pdf"},
    {"id":"30183","name":"P/0161/2016: EMA decision of 15 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tolvaptan (Samsca\n\nand associated names), (EMEA-001231-PIP02-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/314188/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2016-ema-decision-15-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-tolvaptan-samsca-associated-names-emea-001231-pip02-13-m03_en.pdf"},
    {"id":"30189","name":"P/0169/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for Neisseria meningitidis serogroup B recombinant lipoprotein (rLP2086; subfamily A; Escherichia ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/473608/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-b-recombinant-lipoprotein-rlp2086-subfamily-escherichia_en.pdf"},
    {"id":"30212","name":"P/0228/2016: EMA decision of 12 August 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for cathine (hydrochloride) (EMEA-001909-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/532758/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2016-ema-decision-12-august-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cathine-hydrochloride-emea-001909-pip01-15_en.pdf"},
    {"id":"30224","name":"P/0316/2015: EMA decision of 21 December 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for emtricitabine / tenofovir alafenamide / Sodium (2R,5...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/791470/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2015-ema-decision-21-december-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-emtricitabine-tenofovir-alafenamide-sodium-2r5_en.pdf"},
    {"id":"30226","name":"P/129/2010:  European Medicines Agency decision of 28 July 2010 on the refusal of a paediatric investigation plan and on the granting of a waiver for 4-0-(àŸ-D-galactopiranosyl)-D-xylopyranose (EMEA-000641-PIP01-09) in a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/464155/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-129-2010-european-medicines-agency-decision-28-july-2010-refusal-paediatric-investigation-plan-granting-waiver-4-0-ay-d-galactopiranosyl-d-xylopyranose-emea-000641-pip01-09_en.pdf"},
    {"id":"30236","name":"P/0235/2015: EMA decision of 27 October 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for patiromer calcium (EMEA-001720-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T01:00:00Z","last_updated_date":"2015-12-21T01:00:00Z","reference_number":"EMA/645778/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2015-ema-decision-27-october-2015-agreement-paediatric-investigation-plan-granting-deferral-patiromer-calcium-emea-001720-pip01-14_en.pdf"},
    {"id":"30246","name":"P/132/2010: European Medicines Agency decision of 28 July 2010 on the acceptance of a modification of an agreed paediatric investigation plan for split influenza virus, inactivated, containing antigen: A/California/7/200...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-27T01:09:21Z","last_updated_date":"2010-08-27T01:09:21Z","reference_number":"EMA/425577/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-132-2010-european-medicines-agency-decision-28-july-2010-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigen-california-7-200_en.pdf"},
    {"id":"30262","name":"P/0256/2014: EMA decision of 1 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for migalastat (hydrochloride) (EMEA-001194-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/514341/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2014-ema-decision-1-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-migalastat-hydrochloride-emea-001194-pip01-11-m01_en.pdf"},
    {"id":"30280","name":"P/0378/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lanadelumab (DX-\n\n2930) (EMEA-001864-PIP01-15-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T16:03:00Z","last_updated_date":"2018-03-02T16:03:00Z","reference_number":"EMA/774069/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0378-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-lanadelumab-dx-2930-emea-001864-pip01-15-m01_en.pdf"},
    {"id":"30284","name":"P/91/2008: European medicines agency decision of 14 October 2008 on the application for product specific waiver for chimeric murine-human anti Interleukin 6 monoclonal antibody EMEA-000323-PIP01-08 in accordance with Reg...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-11-24T00:00:00Z","last_updated_date":"2008-11-24T00:00:00Z","reference_number":"EMEA/522198/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-91-2008-european-medicines-agency-decision-14-october-2008-application-product-specific-waiver-chimeric-murine-human-anti-interleukin-6-monoclonal-antibody-emea-000323-pip01-08-accordance-reg_en.pdf"},
    {"id":"30288","name":"P/87/2011: EMA decision of 8 April 2011 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis\n\nvirus, inactivated (attenuated strain SA14-14-2 grown in vero cells) (Ixia...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/278824/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-87-2011-ema-decision-8-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-japanese-encephalitis-virus-inactivated-attenuated-strain-sa14-14-2-grown-vero-cells-ixia_en.pdf"},
    {"id":"30291","name":"P/0280/2013: EMA decision of 8 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tapen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-12-06T01:00:00Z","last_updated_date":"2013-12-06T01:00:00Z","reference_number":"EMA/670446/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2013-ema-decision-8-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapen_en.pdf"},
    {"id":"30297","name":"P/0022/2014: EMA decision of 22 January 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for etrolizumab (EMEA-001434-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/12887/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2014-ema-decision-22-january-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-etrolizumab-emea-001434-pip01-13_en.pdf"},
    {"id":"30310","name":"P/41/2008: European medicines agency decision of 24 June 2008\n\non the application for product specific waiver for elocalcitol (EMEA-000182-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliam...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/313552/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-41-2008-european-medicines-agency-decision-24-june-2008-application-product-specific-waiver-elocalcitol-emea-000182-pip01-08-accordance-regulation-ec-no-1901-2006-european-parliam_en.pdf"},
    {"id":"30311","name":"P/0244/2012: EMA decision of 22 October 2012 on the granting of a product specific waiver for dexketoprofen (trometamol) / tramadol (hydrochloride)\n\n(EMEA-001302-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/660593/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2012-ema-decision-22-october-2012-granting-product-specific-waiver-dexketoprofen-trometamol-tramadol-hydrochloride-emea-001302-pip01-12_en.pdf"},
    {"id":"30317","name":"P/08/2009: European Medicines Agency decision of 27 January 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for apixaban (EMEA-000183-PIP01-08) i...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/32088/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-08-2009-european-medicines-agency-decision-27-january-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-apixaban-emea-000183-pip01-08-i_en.pdf"},
    {"id":"30326","name":"P/0034/2014: EMA decision of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for telaprevir (Incivo), (EMEA-000196-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/54901/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2014-ema-decision-5-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-telaprevir-incivo-emea-000196-pip01-08-m02_en.pdf"},
    {"id":"30367","name":"P/182/2011: EMA decision of 3 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for corifollitropin alfa (Elonva) (EMEA-000306-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/544597/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-182-2011-ema-decision-3-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-corifollitropin-alfa-elonva-emea-000306-pip01-08-m01_en.pdf"},
    {"id":"30384","name":"P/284/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for lanthanum carbonate hydrate (Fosrenol and associated ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/683431/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-284-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lanthanum-carbonate-hydrate-fosrenol-associated_en.pdf"},
    {"id":"30412","name":"P/249/2010:  EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aluminium hydroxide adsorbed, depigmented glutaralde...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/709904/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-249-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaralde_en.pdf"},
    {"id":"30421","name":"P/0306/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for (2S)-2-{[(2R)-\n\n2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahyd...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/679304/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-2s-2-2r-2-33-dibutyl-7-methylthio-11-dioxido-5-phenyl-2345-tetrahyd_en.pdf"},
    {"id":"30425","name":"P/0294/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for autologous cartilage\n\nderived cultured chondrocytes (EMEA-000979-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/693018/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cartilage-derived-cultured-chondrocytes-emea-000979-pip01-10-m01_en.pdf"},
    {"id":"30431","name":"P/0091/2013: EMA decision of 29 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for turoctocog alfa (EMEA-000428-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/180067/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2013-ema-decision-29-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-turoctocog-alfa-emea-000428-pip01-08-m02_en.pdf"},
    {"id":"30448","name":"P/11/2011:  EMA decision of 3 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for allergen extracts of dermatophagoides farinae and derma...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/707984/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-11-2011-ema-decision-3-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extracts-dermatophagoides-farinae-derma_en.pdf"},
    {"id":"30468","name":"P/0396/2017: EMA decision of 19 December 2017 on the agreement of a paediatric investigation plan and on the granting of a waiver for trazodone\n\n(hydrochloride) (Trittico and associated names) (EMEA-002142-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-05T15:26:00Z","last_updated_date":"2018-03-05T15:26:00Z","reference_number":"EMA/793134/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0396-2017-ema-decision-19-december-2017-agreement-paediatric-investigation-plan-granting-waiver-trazodone-hydrochloride-trittico-associated-names-emea-002142-pip01-17_en.pdf"},
    {"id":"30476","name":"P/0278/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for pollen from Betula pendula (EMEA-000853-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/732744/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-pollen-betula-pendula-emea-000853-pip01-10-m01_en.pdf"},
    {"id":"30495","name":"P/0071/2014: EMA decision of 21 March 2014 on the agreement of a paediatric investigation plan and on the refusal of a waiver for cyclic pyranopterin monophosphate (monohydrobromide dihydrate) (EMEA-001491-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2014-05-13T02:00:00Z","reference_number":"EMA/113591/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2014-ema-decision-21-march-2014-agreement-paediatric-investigation-plan-refusal-waiver-cyclic-pyranopterin-monophosphate-monohydrobromide-dihydrate-emea-001491-pip01-13_en.pdf"},
    {"id":"30524","name":"P/32/2008: European medicines agency decision of 24 June 2008 on the application for agreement of a Paediatric Investigation Plan for zoledronic acid (Zometa) EMEA-000024-PIP01-07 in accordance with Regulation (EC) No 19...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/310181/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-32-2008-european-medicines-agency-decision-24-june-2008-application-agreement-paediatric-investigation-plan-zoledronic-acid-zometa-emea-000024-pip01-07-accordance-regulation-ec-no-19_en.pdf"},
    {"id":"30540","name":"P/0024/2013: EMA decision of 26 February 2013 on the acceptance of a modification of an agreed paediatric investigation plan for conestat alfa (Ruconest) (EMEA-000367-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T02:00:00Z","last_updated_date":"2013-04-23T02:00:00Z","reference_number":"EMA/89683/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2013-ema-decision-26-february-2013-acceptance-modification-agreed-paediatric-investigation-plan-conestat-alfa-ruconest-emea-000367-pip01-08-m02_en.pdf"},
    {"id":"30542","name":"P/0019/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for canagliflozin (Invokana), (EMEA-001030-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/864480/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-canagliflozin-invokana-emea-001030-pip01-10-m05_en.pdf"},
    {"id":"30557","name":"P/0246/2012: EMA decision of 22 October 2012 on the granting of a product-specific waiver for perindopril (tosilate) / amlodipine (besilate) (EMEA-001320-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/636961/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2012-ema-decision-22-october-2012-granting-product-specific-waiver-perindopril-tosilate-amlodipine-besilate-emea-001320-pip01-12_en.pdf"},
    {"id":"30569","name":"P/148/2010: EMA decision of 3 August 2010 on the acceptance of a modification of an agreed paediatric investigation plan for pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted), containing antigen e...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-07T02:00:00Z","last_updated_date":"2010-10-07T02:00:00Z","reference_number":"EMA/425529/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-148-2010-ema-decision-3-august-2010-acceptance-modification-agreed-paediatric-investigation-plan-pandemic-influenza-vaccine-h1n1-split-virion-inactivated-adjuvanted-containing-antigen-e_en.pdf"},
    {"id":"30580","name":"P/22/2009: European Medicines Agency decision of 23 February 2009 on the refusal of a Paediatric Investigation Plan and on the refusal of a waiver for candesartan cilexetil (Blopress and associated names), (EMEA-000023-P...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/96351/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-22-2009-european-medicines-agency-decision-23-february-2009-refusal-paediatric-investigation-plan-refusal-waiver-candesartan-cilexetil-blopress-associated-names-emea-000023-p_en.pdf"},
    {"id":"30583","name":"P/0121/2016: EMA decision of 29 April 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sofosbuvir / velpatasvir / a derivative of (2S,3S,4R)-3...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/265338/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2016-ema-decision-29-april-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sofosbuvir-velpatasvir-derivative-2s3s4r-3_en.pdf"}    {"id":"30589","name":"P/0237/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for maraviroc (Celsentri), (EMEA-000020-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/624833/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-maraviroc-celsentri-emea-000020-pip01-07-m05_en.pdf"},
    {"id":"30599","name":"P/0356/2016: EMA decision of 21 December 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for eculizumab (Soliris), (EMEA-000876-PIP03-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/827230/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0356-2016-ema-decision-21-december-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eculizumab-soliris-emea-000876-pip03-14_en.pdf"},
    {"id":"30605","name":"P/117/2010: European Medicines Agency decision of 7 July 2010 on the granting of a product specific waiver for diclofenac sodium / omeprazole\n\n(EMEA-000820-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/343648/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-117-2010-european-medicines-agency-decision-7-july-2010-granting-product-specific-waiver-diclofenac-sodium-omeprazole-emea-000820-pip01-09-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"30606","name":"P/0095/2015: EMA decision of 8 May 2015 on the refusal of a paediatric investigation plan and on the granting of a waiver for masitinib (mesylate) (EMEA-001266-PIP02-14)on the agreement of a paediatric investigation plan...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/205920/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2015-ema-decision-8-may-2015-refusal-paediatric-investigation-plan-granting-waiver-masitinib-mesylate-emea-001266-pip02-14on-agreement-paediatric-investigation-plan_en.pdf"},
    {"id":"30632","name":"P/0339/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for bictegravir /\n\nemtricitabine / tenofovir alafenamide (EMEA-001766-PIP01-15-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T17:48:00Z","last_updated_date":"2017-02-03T17:48:00Z","reference_number":"EMA/741989/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0339-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-bictegravir-emtricitabine-tenofovir-alafenamide-emea-001766-pip01-15-m01_en.pdf"},
    {"id":"30646","name":"P/0030/2013: EMA decision of 26 February 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for proteinase, metallo- (synthetic nociceptin receptor-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/24831/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2013-ema-decision-26-february-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-proteinase-metallo-synthetic-nociceptin-receptor_en.pdf"},
    {"id":"30664","name":"P/229/2011: EMA decision of 28 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ozenoxacin (EMEA-\n\n000981-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/693053/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-229-2011-ema-decision-28-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-ozenoxacin-emea-000981-pip01-10-m01_en.pdf"},
    {"id":"30674","name":"P/50/2009: European Medicines Agency decision of 24 March 2009 on the granting of a product specific waiver for bisoprolol fumarate / acetylsalicylic acid (EMEA-000445-PIP01-08) in accordance with Regulation (EC) No 1901...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/157735/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-50-2009-european-medicines-agency-decision-24-march-2009-granting-product-specific-waiver-bisoprolol-fumarate-acetylsalicylic-acid-emea-000445-pip01-08-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"30698","name":"P/0292/2014: EMA decision of 24 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tigecycline (Tygacil), (EMEA-000120-PIP01-07-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T01:00:00Z","last_updated_date":"2014-12-05T01:00:00Z","reference_number":"EMA/640003/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2014-ema-decision-24-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-tigecycline-tygacil-emea-000120-pip01-07-m05_en.pdf"},
    {"id":"30706","name":"P/0308/2012: EMA decision of 21 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/809648/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2012-ema-decision-21-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-linagliptin-trajenta-emea-000498-pip01-08-m01_en.pdf"},
    {"id":"30717","name":"P/97/2008: European medicines agency decision of 3 November 2008\n\non the application for agreement of a Paediatric Investigation Plan for aprepitant (EMEND), EMEA-000144-PIP01-07 in accordance with Regulation (EC) No 190...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-07T00:00:00Z","last_updated_date":"2009-01-07T00:00:00Z","reference_number":"EMEA/562760/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-97-2008-european-medicines-agency-decision-3-november-2008-application-agreement-paediatric-investigation-plan-aprepitant-emend-emea-000144-pip01-07-accordance-regulation-ec-no-190_en.pdf"},
    {"id":"30719","name":"P/0091/2012: EMA decision of 29 May 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for vonicog alfa (EMEA-001164-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T18:00:00Z","last_updated_date":"2012-06-25T18:00:00Z","reference_number":"EMA/330397/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2012-ema-decision-29-may-2012-agreement-paediatric-investigation-plan-granting-deferral-vonicog-alfa-emea-001164-pip01-11_en.pdf"},
    {"id":"30724","name":"P/200/2011: EMA decision of 5 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel)\n\n(EMEA-000567-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/635452/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-200-2011-ema-decision-5-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-dasatinib-sprycel-emea-000567-pip01-09-m02_en.pdf"},
    {"id":"30734","name":"P/37/2009: European Medicines Agency decision of 23 February 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for clevidipine butyrate (EMEA-000282-PIP01-08) in accordance with R...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/96585/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-37-2009-european-medicines-agency-decision-23-february-2009-agreement-paediatric-investigation-plan-granting-deferral-clevidipine-butyrate-emea-000282-pip01-08-accordance-r_en.pdf"},
    {"id":"30783","name":"P/0227/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sotagliflozin (EMEA-\n\n001517-PIP02-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/430901/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-sotagliflozin-emea-001517-pip02-14-m01_en.pdf"},
    {"id":"30806","name":"P/342/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for modified allergen extract of dermatophagoides pteron...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/801965/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-342-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-dermatophagoides-pteron_en.pdf"},
    {"id":"30857","name":"P/0337/2014: EMA decision of 22 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (EMEA-001582-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T01:00:00Z","last_updated_date":"2015-02-23T01:00:00Z","reference_number":"EMA/719228/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0337-2014-ema-decision-22-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-lumacaftor-ivacaftor-emea-001582-pip01-13-m02_en.pdf"},
    {"id":"30867","name":"P/0394/2017: EMA decision of 19 December 2017 on the granting of a product specific waiver for synthetic double-stranded small interfering RNA (siRNA)\n\noligonucleotide specific to the mRNA of the caspase 2 gene (QPI-1007...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T14:03:00Z","last_updated_date":"2018-03-07T14:03:00Z","reference_number":"EMA/797358/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0394-2017-ema-decision-19-december-2017-granting-product-specific-waiver-synthetic-double-stranded-small-interfering-rna-sirna-oligonucleotide-specific-mrna-caspase-2-gene-qpi-1007_en.pdf"},
    {"id":"30868","name":"P/0244/2014: EMA decision of 29 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for metformin (hydrochloride) (EMEA-001352-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/508731/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2014-ema-decision-29-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-metformin-hydrochloride-emea-001352-pip01-12-m01_en.pdf"},
    {"id":"30875","name":"P/174/2011: EMA decision of 8 July 2011 on the granting of a product specific waiver for pravastatin (sodium) / acetylsalicylic acid (EMEA-\n\n001118-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/522147/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-174-2011-ema-decision-8-july-2011-granting-product-specific-waiver-pravastatin-sodium-acetylsalicylic-acid-emea-001118-pip01-10_en.pdf"},
    {"id":"30881","name":"P/0160/2015: EMA decision of 13 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-001501-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/382954/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2015-ema-decision-13-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-emea-001501-pip02-13-m01_en.pdf"},
    {"id":"30882","name":"P/0253/2012: EMA decision of 30 November 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for spheroids of human autologous matrix-associated chon...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"EMA/751595/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2012-ema-decision-30-november-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-spheroids-human-autologous-matrix-associated-chon_en.pdf"},
    {"id":"30887","name":"P/0209/2012: EMA decision of 27 September 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for ceftobiprole medocaril (sodium) (EMEA-000205-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T18:45:00Z","last_updated_date":"2012-10-17T18:45:00Z","reference_number":"EMA/605416/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2012-ema-decision-27-september-2012-agreement-paediatric-investigation-plan-granting-deferral-ceftobiprole-medocaril-sodium-emea-000205-pip02-11_en.pdf"},
    {"id":"30900","name":"P/0005/2013: EMA decision of 21 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for valganciclovir (Valcyte and associated names), (EMEA-000726-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T18:30:00Z","last_updated_date":"2013-04-03T18:30:00Z","reference_number":"EMA/19909/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2013-ema-decision-21-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-valganciclovir-valcyte-associated-names-emea-000726-pip01-09-m01_en.pdf"},
    {"id":"30909","name":"P/0037/2014: EMA decision of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lanthanum carbonate hydrate (Fosrenol and associated names) (EMEA-000637-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/54828/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2014-ema-decision-5-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-lanthanum-carbonate-hydrate-fosrenol-associated-names-emea-000637-pip02-10-m03_en.pdf"},
    {"id":"30944","name":"P/0042/2015: EMA decision of 6 March 2015 on the agreement of a paediatric investigation plan and on the granting of a waiver for coagulation factor VIIa (recombinant) (EMEA-001203-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-23T01:00:00Z","last_updated_date":"2015-03-23T01:00:00Z","reference_number":"EMA/49380/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2015-ema-decision-6-march-2015-agreement-paediatric-investigation-plan-granting-waiver-coagulation-factor-viia-recombinant-emea-001203-pip02-14_en.pdf"},
    {"id":"30956","name":"P/0056/2014: European Medicines Agency decision of 7 March 2014 on the granting of a product specific waiver for diclofenac sodium / thiocolchicoside (EMEA-001558-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/53679/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2014-european-medicines-agency-decision-7-march-2014-granting-product-specific-waiver-diclofenac-sodium-thiocolchicoside-emea-001558-pip01-13_en.pdf"},
    {"id":"30957","name":"P/36/2010: EMA decision of 18 March 2010 on the acceptance of a modification of an agreed Paediatric Investigation Plan for Split influenza virus, inactivated containing antigen equivalent to A/California/7/2009 (H1N1)-l...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/172584/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-36-2010-ema-decision-18-march-2010-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigen-equivalent-california-7-2009-h1n1-l_en.pdf"},
    {"id":"30958","name":"P/116/2009: European Medicines Agency decision of 16 June 2009\n\non the granting of a product specific waiver for human plasma proteins\n\n(EMEA-000507-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the Europe...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351605/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-116-2009-european-medicines-agency-decision-16-june-2009-granting-product-specific-waiver-human-plasma-proteins-emea-000507-pip01-08-accordance-regulation-ec-no-1901-2006-europe_en.pdf"},
    {"id":"30960","name":"P/122/2011: EMA decision of 7 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for treosulfan (EMEA-000883-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/359711/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-122-2011-ema-decision-7-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-treosulfan-emea-000883-pip01-10_en.pdf"},
    {"id":"30977","name":"P/120/2011: EMA decision of 7 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for ombrabulin\n\n(EMEA-000800-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/426561/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-120-2011-ema-decision-7-june-2011-agreement-paediatric-investigation-plan-granting-deferral-ombrabulin-emea-000800-pip01-09_en.pdf"},
    {"id":"30978","name":"P/0156/2017: EMA decision of 8 June 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fluocinolone acetonide (EMEA-000801-PIP03-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/343374/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2017-ema-decision-8-june-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fluocinolone-acetonide-emea-000801-pip03-16_en.pdf"},
    {"id":"30983","name":"P/0023/2012: EMA decision of 27 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for (S)-3'-(OH)-\n\ndesazadesferrithiocin-polyether, magnesium salt (FBS0701), (EMEA-001057-PIP01-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/985539/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2012-ema-decision-27-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-s-3-oh-desazadesferrithiocin-polyether-magnesium-salt-fbs0701-emea-001057-pip01_en.pdf"},
    {"id":"30994","name":"P/247/2011: EMA decision of 21 October 2011 on the granting of a product specific waiver for (2S,3R,4R,5S,6R)-2-(4-Chloro-3-{3-[(S)-(tetrahydrofuran-3-yl)oxy]-benzyl}-phenyl)-6-hydroxymethyltetrahydro-pyran-3,4,5-triol /...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-28T17:00:00Z","last_updated_date":"2011-11-28T17:00:00Z","reference_number":"EMA/826136/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-247-2011-ema-decision-21-october-2011-granting-product-specific-waiver-2s3r4r5s6r-2-4-chloro-3-3-s-tetrahydrofuran-3-yloxy-benzyl-phenyl-6-hydroxymethyltetrahydro-pyran-345-triol_en.pdf"},
    {"id":"30996","name":"P/0263/2014: EMA decision of 3 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for brentuximab vedotin (Adcetris), (EMEA-000980-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/508722/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2014-ema-decision-3-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-brentuximab-vedotin-adcetris-emea-000980-pip01-10-m02_en.pdf"},
    {"id":"31017","name":"P/244/2011: EMA decision of 7 October 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for L-Cysteinyl-L-prolyl-L-alanyl-L-valyl-L-lysyl-L-arginyl...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-28T17:00:00Z","last_updated_date":"2011-11-28T17:00:00Z","reference_number":"EMA/778474/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-244-2011-ema-decision-7-october-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-l-cysteinyl-l-prolyl-l-alanyl-l-valyl-l-lysyl-l-arginyl_en.pdf"},
    {"id":"31029","name":"P/0053/2013: European medicines agency decision of 20 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for vedolizumab (EMEA-000645-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/112003/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2013-european-medicines-agency-decision-20-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-vedolizumab-emea-000645-pip01-09-m01_en.pdf"},
    {"id":"31031","name":"P/0183/2016: EMA decision of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for belimumab (Benlysta) (EMEA-000520-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/410886/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-belimumab-benlysta-emea-000520-pip01-08-m05_en.pdf"},
    {"id":"31033","name":"P/0105/2015: EMA decision of 29 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity) (EMEA-000783-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-19T02:00:00Z","last_updated_date":"2015-05-19T02:00:00Z","reference_number":"EMA/282053/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2015-ema-decision-29-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-dulaglutide-trulicity-emea-000783-pip01-09-m02_en.pdf"},
    {"id":"31037","name":"P/0060/2014: EMA decision of 7 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor (Kalydeco), (EMEA-000335-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/113589/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2014-ema-decision-7-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-kalydeco-emea-000335-pip01-08-m09_en.pdf"},
    {"id":"31043","name":"P/0143/2013: EMA decision of 3 July 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Clostridium botulinum neurotoxin type A (150 kD), free of...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-09T16:30:00Z","last_updated_date":"2013-08-09T16:30:00Z","reference_number":"EMA/312139/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2013-ema-decision-3-july-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-clostridium-botulinum-neurotoxin-type-150-kd-free_en.pdf"},
    {"id":"31068","name":"P/323/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of grass and cereal pollen ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769510/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-323-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-grass-cereal-pollen_en.pdf"},
    {"id":"31072","name":"P/0286/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for 5-(4-Fluoro-1-benzothiophen-2-yl)-8-methyl-1,9-dihydr...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/565789/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-5-4-fluoro-1-benzothiophen-2-yl-8-methyl-19-dihydr_en.pdf"},
    {"id":"31081","name":"P/98/2008: European Medicines Agency decision of 3 November 2008 on the application for agreement of a Paediatric Investigation Plan for dienogest (EMEA-000147-PIP01-07) in accordance with Regulation (EC) No 1901/2006 of...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-07T01:00:00Z","last_updated_date":"2009-01-07T01:00:00Z","reference_number":"EMEA/572815/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-98-2008-european-medicines-agency-decision-3-november-2008-application-agreement-paediatric-investigation-plan-dienogest-emea-000147-pip01-07-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"31083","name":"P/0064/2013: European medicines agency decision of 26 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for guanfacine (hydrochloride) (EMEA-000745-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/95728/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2013-european-medicines-agency-decision-26-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-guanfacine-hydrochloride-emea-000745-pip01-09-m02_en.pdf"},
    {"id":"31088","name":"P/0042/2016: EMA decision of 26 February 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names and T...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/133069/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2016-ema-decision-26-february-2016-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-t_en.pdf"},
    {"id":"31103","name":"P/23/2010: European Medicines Agency decision of 15 March 2010 on the granting of a product specific waiver for strontium ranelate (Protelos) (EMEA-000732-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the ...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMA/164721/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-23-2010-european-medicines-agency-decision-15-march-2010-granting-product-specific-waiver-strontium-ranelate-protelos-emea-000732-pip01-09-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"31117","name":"P/0206/2013: EMA decision of 3 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for fibrinogen concentrate / thrombin preparation / aprotinin / calcium chloride (EMEA-001079-P...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/456020/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2013-ema-decision-3-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-fibrinogen-concentrate-thrombin-preparation-aprotinin-calcium-chloride-emea-001079-p_en.pdf"},
    {"id":"31141","name":"P/0057/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dabigatran etexilate (Pradaxa) (EMEA-000081-PIP01-07-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/138298/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-pradaxa-emea-000081-pip01-07-m08_en.pdf"},
    {"id":"31161","name":"P/15/2009: European Medicines Agency decision of 27 January 2009 on the granting of a product specific waiver for amlodipine besylate, valsartan, hydrochlorothiazide, (Dafiro HCT), (EMEA-000398-PIP01-08) in accordance wi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/24169/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-15-2009-european-medicines-agency-decision-27-january-2009-granting-product-specific-waiver-amlodipine-besylate-valsartan-hydrochlorothiazide-dafiro-hct-emea-000398-pip01-08-accordance-wi_en.pdf"},
    {"id":"31184","name":"P/0148/2014: EMA decision of 13 June 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for gevokizumab (EMEA-001487-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-18T02:00:00Z","last_updated_date":"2014-07-18T02:00:00Z","reference_number":"EMA/268731/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2014-ema-decision-13-june-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-gevokizumab-emea-001487-pip01-13_en.pdf"},
    {"id":"31187","name":"P/0246/2017: EMA decision of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of\n\na waiver for human normal immunoglobulin (EMEA-002163-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/493695/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2017-ema-decision-4-september-2017-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-human-normal-immunoglobulin-emea-002163-pip01-17_en.pdf"},
    {"id":"31209","name":"P/0341/2017: EMA decision of 16 November 2017 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus\n\nsurface antigens (haemagglutinin and neuraminidase) of strain A (H1N1)/inf...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-20T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"EMA/731087/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0341-2017-ema-decision-16-november-2017-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h1n1-inf_en.pdf"},
    {"id":"31210","name":"P/251/2010:  EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aluminium hydroxide adsorbed, depigmented glutaralde...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/670700/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-251-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaralde_en.pdf"},
    {"id":"31244","name":"P/0357/2017: EMA decision of 1 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allopregnanolone (EMEA-002051-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/704280/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0357-2017-ema-decision-1-december-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allopregnanolone-emea-002051-pip02-16_en.pdf"},
    {"id":"31254","name":"P/220/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 12 grass pollen extract, cultiva...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/627976/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-220-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-12-grass-pollen-extract-cultiva_en.pdf"},
    {"id":"31263","name":"P/0050/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for loxapine (EMEA-001115-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/108652/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-loxapine-emea-001115-pip01-10-m04_en.pdf"},
    {"id":"31265","name":"P/212/2009: European Medicines Agency decision of 30 October 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for sitagliptin (phosphate monohydrate) (Xelevia) (EMEA-000471-PIP01-08-M01...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/691445/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-212-2009-european-medicines-agency-decision-30-october-2009-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-phosphate-monohydrate-xelevia-emea-000471-pip01-08-m01_en.pdf"},
    {"id":"31274","name":"P/0252/2017: EMA decision of 4 September 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for selonsertib (EMEA-001868-PIP03-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/498686/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2017-ema-decision-4-september-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-selonsertib-emea-001868-pip03-16_en.pdf"},
    {"id":"31290","name":"P/0336/2014: EMA decision of 22 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tolvaptan (Samsca) (EMEA-001231-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-20T01:00:00Z","last_updated_date":"2015-02-20T01:00:00Z","reference_number":"EMA/711194/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2014-ema-decision-22-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-tolvaptan-samsca-emea-001231-pip02-13-m01_en.pdf"},
    {"id":"31294","name":"P/27/2011: EMA decision of the 28 January 2011on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rizatriptan benzoate (Maxalt and associated names), ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"EMA/37992/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-27-2011-ema-decision-28-january-2011on-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rizatriptan-benzoate-maxalt-associated-names_en.pdf"},
    {"id":"31297","name":"P/0138/2017: EMA decision of 7 June 2017 on the agreement of a paediatric investigation plan for expanded donor-derived allogenic T cells transduced with the retroviral vector expressing the transgenes for inducible casp...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/293456/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2017-ema-decision-7-june-2017-agreement-paediatric-investigation-plan-expanded-donor-derived-allogenic-t-cells-transduced-retroviral-vector-expressing-transgenes-inducible-casp_en.pdf"},
    {"id":"31315","name":"P/288/2010: EMA decision of 22 December 2010 on on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Victoza) (EMEA-000128-PIP01-07-M02","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/756626/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-288-2010-ema-decision-22-december-2010-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-victoza-emea-000128-pip01-07-m02_en.pdf"},
    {"id":"31332","name":"P/0193/2014: EMA decision of 6 August 2014 on the granting of a product specific waiver for pacritinib (EMEA-001621-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/447502/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2014-ema-decision-6-august-2014-granting-product-specific-waiver-pacritinib-emea-001621-pip01-14_en.pdf"},
    {"id":"31344","name":"P/162/2011: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for (3R,4R)-4- methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitri...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/398978/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-162-2011-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-3r4r-4-methyl-3-methyl-7h-pyrrolo23-dpyrimidin-4-ylamino-i2-oxo-1-piperidinepropanenitri_en.pdf"},
    {"id":"31349","name":"P/118/2010: European Medicines Agency decision of 7 July 2010 on the granting of a product specific waiver for chimeric antibody to mesothelin (MORAB-009) (EMEA-000833-PIP01-10) in accordance with Regulation (EC) No 1901...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/413738/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-118-2010-european-medicines-agency-decision-7-july-2010-granting-product-specific-waiver-chimeric-antibody-mesothelin-morab-009-emea-000833-pip01-10-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"31361","name":"P/66/2011: EMA decision of 11 March 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bevacizumab (Avastin) (EMEA-000056-PIP03-10) in accordanc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/174396/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-66-2011-ema-decision-11-march-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bevacizumab-avastin-emea-000056-pip03-10-accordanc_en.pdf"},
    {"id":"31364","name":"P/0309/2017: EMA decision of 30 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for acalabrutinib (EMEA-001796-PIP03-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T18:00:00Z","last_updated_date":"2018-02-12T18:00:00Z","reference_number":"EMA/654967/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0309-2017-ema-decision-30-october-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-acalabrutinib-emea-001796-pip03-16_en.pdf"},
    {"id":"31377","name":"P/0185/2014: EMA decision of 6 August 2014 on the granting of a product specific waiver for ranibizumab (Lucentis), (EMEA-000527-PIP03-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/416185/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2014-ema-decision-6-august-2014-granting-product-specific-waiver-ranibizumab-lucentis-emea-000527-pip03-13_en.pdf"},
    {"id":"31379","name":"P/0151/2016: EMA decision of 14 June 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for peanut flour (EMEA-001753-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/334522/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2016-ema-decision-14-june-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-peanut-flour-emea-001753-pip02-15_en.pdf"},
    {"id":"31391","name":"P/257/2011: EMA decision of 26 October 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lixivaptan (EMEA-001078-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T01:00:00Z","last_updated_date":"2011-11-29T01:00:00Z","reference_number":"EMA/778788/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-257-2011-ema-decision-26-october-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lixivaptan-emea-001078-pip01-10_en.pdf"},
    {"id":"31412","name":"P/0209/2013: EMA decision of 3 September 2013 on the agreement of a paediatric investigation plan for glibenclamide (EMEA-001324-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"EMA/482989/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2013-ema-decision-3-september-2013-agreement-paediatric-investigation-plan-glibenclamide-emea-001324-pip01-12_en.pdf"},
    {"id":"31413","name":"P/0367/2016: EMA decision of 21 December 2016 on the granting of a product specific waiver for DNA plasmid encoding HPV type 16 consensus E6 and\n\nE7 proteins (pGX3001) / DNA plasmid encoding HPV type 18 consensus E6 and ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/791397/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0367-2016-ema-decision-21-december-2016-granting-product-specific-waiver-dna-plasmid-encoding-hpv-type-16-consensus-e6-e7-proteins-pgx3001-dna-plasmid-encoding-hpv-type-18-consensus-e6_en.pdf"},
    {"id":"31415","name":"P/0170/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for EMEA-001054-PIP01-10-M03","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/508507/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-emea-001054-pip01-10-m03_en.pdf"},
    {"id":"31420","name":"P/0033/2013: EMA decision of 26 February 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for 2,6-bis-{(1-napthalenyl-3,6-disulfonic acid)-oxyacetamido}-2,6-bis-2,6-bis-2,6-bis-(2,...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/65700/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2013-ema-decision-26-february-2013-agreement-paediatric-investigation-plan-granting-waiver-26-bis-1-napthalenyl-36-disulfonic-acid-oxyacetamido-26-bis-26-bis-26-bis-2_en.pdf"},
    {"id":"31421","name":"P/0266/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for tocilizumab (RoActemra) (EMEA-000309-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/766676/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-tocilizumab-roactemra-emea-000309-pip01-08-m07_en.pdf"},
    {"id":"31426","name":"P/0274/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for allergens from Dermatophagoides pteronyssinus and Dermatophagoides farinae (EMEA-000847-PIP...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/690885/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-allergens-dermatophagoides-pteronyssinus-dermatophagoides-farinae-emea-000847-pip_en.pdf"},
    {"id":"31440","name":"P/0130/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for angiotensin II (LJPC-501) (EMEA-001912-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T02:00:00Z","last_updated_date":"2018-07-25T02:00:00Z","reference_number":"EMA/206467/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-angiotensin-ii-ljpc-501-emea-001912-pip02-16-m01_en.pdf"},
    {"id":"31451","name":"P/0208/2017: EMA decision of 9August 2017 on the granting of a product specific waiver for H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH (YGRKKRRQRRRKLSSIESDV), (EMEA-002108-PIP01-1...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/459054/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2017-ema-decision-9august-2017-granting-product-specific-waiver-h-tyr-gly-arg-lys-lys-arg-arg-gln-arg-arg-arg-lys-leu-ser-ser-ile-glu-ser-asp-val-oh-ygrkkrrqrrrklssiesdv-emea-002108-pip01-1_en.pdf"},
    {"id":"31454","name":"Pneumococcal polysaccharide serotypes 1, 4, 5, 6B, 7F, 9V, 14, 23 F conjugated to protein D (derived from non-typeable haemophilus influenzae) carrier protein;\n\nPneumococcal polysaccharide serotype 18C conjugated to teta...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/553987/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/pneumococcal-polysaccharide-serotypes-1-4-5-6b-7f-9v-14-23-f-conjugated-protein-d-derived-non-typeable-haemophilus-influenzae-carrier-protein-pneumococcal-polysaccharide-serotype-18c-conjugated-teta_en.pdf"},
    {"id":"31486","name":"P/0140/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for secukinumab (Cosentyx), (EMEA-000380-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/404947/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-secukinumab-cosentyx-emea-000380-pip01-08-m03_en.pdf"},
    {"id":"31490","name":"P/28/2011: EMA decision of 8 January 2011 on the on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for pegloticase (EMEA-000293-PIP02-10) in accordance w...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"EMA/13274/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-28-2011-ema-decision-8-january-2011-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-pegloticase-emea-000293-pip02-10-accordance-w_en.pdf"},
    {"id":"31494","name":"P/164/2010: EMA decision of 31 August 2010 on the modification of an agreed paediatric investigation plan for mepolizumab (EMEA-000069-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-07T02:00:00Z","last_updated_date":"2010-10-07T02:00:00Z","reference_number":"EMA/535848/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-164-2010-ema-decision-31-august-2010-modification-agreed-paediatric-investigation-plan-mepolizumab-emea-000069-pip01-07-m02_en.pdf"},
    {"id":"31499","name":"P/0107/2015: EMA decision of 13 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for emtricitabine / rilpivirine / tenofovir alafenamide (EMEA...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/284193/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2015-ema-decision-13-may-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-emtricitabine-rilpivirine-tenofovir-alafenamide-emea_en.pdf"},
    {"id":"31527","name":"P/0271/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for vigabatrin (EMEA-000717-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/764505/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-vigabatrin-emea-000717-pip02-13-m01_en.pdf"},
    {"id":"31544","name":"P/141/2010:  European Medicines Agency decision of 30 July 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human monoclonal antib...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/469942/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-141-2010-european-medicines-agency-decision-30-july-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-monoclonal-antib_en.pdf"},
    {"id":"31548","name":"P/0128/2012: EMA decision of 4 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for cabozantinib (EMEA-001143-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-09T14:00:00Z","last_updated_date":"2012-08-09T14:00:00Z","reference_number":"EMA/428959/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2012-ema-decision-4-july-2012-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-cabozantinib-emea-001143-pip01-11_en.pdf"},
    {"id":"31563","name":"P/0256/2015: EMA decision of 30 October 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for fluciclovine (18F) (EMEA-001644-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T01:00:00Z","last_updated_date":"2015-12-21T01:00:00Z","reference_number":"EMA/626777/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2015-ema-decision-30-october-2015-agreement-paediatric-investigation-plan-granting-deferral-fluciclovine-18f-emea-001644-pip02-14_en.pdf"},
    {"id":"31606","name":"P/0163/2016: EMA decision of 15 June 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for imipenem\n\n(monohydrate) / cilastatin (sodium) / relebactam (MK-7655A), (EMEA-001809-PIP0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/337482/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2016-ema-decision-15-june-2016-agreement-paediatric-investigation-plan-granting-deferral-imipenem-monohydrate-cilastatin-sodium-relebactam-mk-7655a-emea-001809-pip0_en.pdf"},
    {"id":"31630","name":"P/0338/2016: EMA decision of 2 December 2016 on the refusal of a paediatric investigation plan and on the refusal of a waiver for derivative of 4Hpyrazolo[\n\n3,4-d]pyrimidin-4-one (EMEA-001742-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/757989/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0338-2016-ema-decision-2-december-2016-refusal-paediatric-investigation-plan-refusal-waiver-derivative-4hpyrazolo-34-dpyrimidin-4-one-emea-001742-pip02-16_en.pdf"},
    {"id":"31667","name":"P/0106/2017: EMA decision of 11 April 2017 on the agreement of a paediatric investigation plan for human fibrinogen concentrate (BT524) (EMEA-\n\n001931-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/166793/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2017-ema-decision-11-april-2017-agreement-paediatric-investigation-plan-human-fibrinogen-concentrate-bt524-emea-001931-pip01-16_en.pdf"},
    {"id":"31669","name":"P/0149/2014: EMA decision of 13 June 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adeno-associated viral vector serotype 9 containing huma...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-18T02:00:00Z","last_updated_date":"2014-07-18T02:00:00Z","reference_number":"EMA/330057/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2014-ema-decision-13-june-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-adeno-associated-viral-vector-serotype-9-containing-huma_en.pdf"},
    {"id":"31675","name":"P/0301/2013: EMA decision of 29 November 2013 on the granting of a product specific waiver for odanacatib / colecalciferol (EMEA-001499-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/659494/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2013-ema-decision-29-november-2013-granting-product-specific-waiver-odanacatib-colecalciferol-emea-001499-pip01-13_en.pdf"},
    {"id":"31681","name":"P/0094/2014: EMA decision of 7 April 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chimeric anti-disialoganglioside (GD2) monoclonal antibo...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/182153/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2014-ema-decision-7-april-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chimeric-anti-disialoganglioside-gd2-monoclonal-antibo_en.pdf"},
    {"id":"31687","name":"P/0268/2014: EMA decision of 27 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tabalumab (EMEA-000802-PIP02-11-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T01:00:00Z","last_updated_date":"2014-12-05T01:00:00Z","reference_number":"EMA/591155/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2014-ema-decision-27-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-tabalumab-emea-000802-pip02-11-m01_en.pdf"},
    {"id":"31703","name":"P/266/2009: European Medicines Agency decision of 23 December 2009\n\non the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for recombinant human monoclonal a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/837966/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-266-2009-european-medicines-agency-decision-23-december-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-monoclonal_en.pdf"},
    {"id":"31726","name":"P/0093/2014: EMA decision of 7 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy) (EMEA-000117-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/186565/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2014-ema-decision-7-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-yervoy-emea-000117-pip02-10-m03_en.pdf"},
    {"id":"31732","name":"P/0177/2013: EMA decision of 30 July 2013 on the refusal of a product-specific waiver for esketamine (EMEA-001428-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/419089/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2013-ema-decision-30-july-2013-refusal-product-specific-waiver-esketamine-emea-001428-pip01-13_en.pdf"},
    {"id":"31743","name":"P/0054/2015: EMA decision of 9 March 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for ceftriaxone / sulbactam (EMEA-001568-PIP03-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-24T01:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/114881/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2015-ema-decision-9-march-2015-agreement-paediatric-investigation-plan-granting-deferral-ceftriaxone-sulbactam-emea-001568-pip03-14_en.pdf"},
    {"id":"31744","name":"P/115/2011: EMA decision of 6 May 2011 on the acceptance of a modification of an agreed paediatric investigation plan for canakinumab,\n\n(EMEA-000060-PIP02-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-07T02:00:00Z","last_updated_date":"2011-06-07T02:00:00Z","reference_number":"EMA/314974/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-115-2011-ema-decision-6-may-2011-acceptance-modification-agreed-paediatric-investigation-plan-canakinumab-emea-000060-pip02-08-m02_en.pdf"}    {"id":"31772","name":"P/0163/2013: EMA decision of 29 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for rivaroxaban\n\n(Xarelto), (EMEA-000430-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/393010/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2013-ema-decision-29-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-rivaroxaban-xarelto-emea-000430-pip01-08-m04_en.pdf"},
    {"id":"31778","name":"P/0195/2014: EMA decision of 8 August 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tofacitinib (EMEA-000576-PIP03-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/392211/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2014-ema-decision-8-august-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tofacitinib-emea-000576-pip03-12_en.pdf"},
    {"id":"31793","name":"P/130/2008: EMA decision of 23 December 2008 on the refusal of a PIP and on the refusal of a deferral and on the granting of a waiver for travoprost/brinzolamide (EMEA-000368-PIP01-08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/669012/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-130-2008-ema-decision-23-december-2008-refusal-pip-refusal-deferral-granting-waiver-travoprost-brinzolamide-emea-000368-pip01-08_en.pdf"},
    {"id":"31795","name":"P/154/2011: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for paliperidone /\n\npaliperidone palmitate (Invega) ( EMEA-000014-PIP01-07-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/417965/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-154-2011-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-paliperidone-paliperidone-palmitate-invega-emea-000014-pip01-07-m06_en.pdf"},
    {"id":"31824","name":"P/0013/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for selepressin (EMEA-000506-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/1366/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-selepressin-emea-000506-pip01-08-m01_en.pdf"},
    {"id":"31834","name":"P/45/2009: European Medicines Agency decision of 24 March 2009 on the agreement of a Paediatric Investigation Plan and on the refusal of a deferral and on the granting of a waiver for glucose monohydrate (EMEA-000221-PIP...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/161418/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-45-2009-european-medicines-agency-decision-24-march-2009-agreement-paediatric-investigation-plan-refusal-deferral-granting-waiver-glucose-monohydrate-emea-000221-pip_en.pdf"},
    {"id":"31836","name":"P/42/2012: EMA decision of 28 February 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, B...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/128416/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-42-2012-ema-decision-28-february-2012-agreement-paediatric-investigation-plan-granting-waiver-clostridium-botulinum-neurotoxin-type-150-kd-free-complexing-proteins-xeomin-b_en.pdf"},
    {"id":"31848","name":"P/114/2008: European Medicines Agency decision of 1 December 2008 on the application for agreement of a Paediatric Investigation Plan for sitagliptin phosphate monohydrate, metformin hydrochloride (Janumet)\n\nEMEA-000165-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/625238/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-114-2008-european-medicines-agency-decision-1-december-2008-application-agreement-paediatric-investigation-plan-sitagliptin-phosphate-monohydrate-metformin-hydrochloride-janumet-emea-000165_en.pdf"},
    {"id":"31853","name":"P/0154/2012: EMA decision of 25 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation factor VIII / von Willebrand factor (EMEA-000312-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/477564/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2012-ema-decision-25-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-human-coagulation-factor-viii-von-willebrand-factor-emea-000312-pip01-08-m04_en.pdf"},
    {"id":"31868","name":"P/0319/2014: EMA decision of 19 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-000454-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-20T01:00:00Z","last_updated_date":"2015-02-20T01:00:00Z","reference_number":"EMA/719221/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0319-2014-ema-decision-19-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000454-pip01-08-m05_en.pdf"},
    {"id":"31873","name":"P/0059/2015: EMA decision of 1 April 2015 on the refusal of a modification of an agreed paediatric investigation plan for treprostinil (Remodulin and associated names) (EMEA-000207-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/111310/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2015-ema-decision-1-april-2015-refusal-modification-agreed-paediatric-investigation-plan-treprostinil-remodulin-associated-names-emea-000207-pip01-08-m05_en.pdf"},
    {"id":"31883","name":"P/0242/2016: EMA decision of 9 September 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for autologous cartilage derived cultured chondrocytes ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/536150/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2016-ema-decision-9-september-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-cartilage-derived-cultured-chondrocytes_en.pdf"},
    {"id":"31895","name":"P/0337/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor ...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T17:48:00Z","last_updated_date":"2017-02-03T17:48:00Z","reference_number":"EMA/756866/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0337-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-autologous-t-cells-transduced-lentiviral-vector-containing-chimeric-antigen-receptor_en.pdf"},
    {"id":"31926","name":"P/20/2010: EMA decision of 19 February 2010 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for expanded human autologous mesenchymal adult stem cells...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMA/63059/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-20-2010-ema-decision-19-february-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-expanded-human-autologous-mesenchymal-adult-stem-cells_en.pdf"},
    {"id":"31931","name":"P/344/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for aqueous allergen extract of dermatophagoides pterony...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/708709/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-344-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aqueous-allergen-extract-dermatophagoides-pterony_en.pdf"},
    {"id":"31932","name":"P/0211/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin (Jardiance), (EMEA-000828-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/578688/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-jardiance-emea-000828-pip01-09-m04_en.pdf"},
    {"id":"31940","name":"P/0228/2014: EMA decision of 5 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for N. meningitidis serogroup A, C, W and Y polysaccharide conjugated to tetanus toxoid / N. to...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/464768/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2014-ema-decision-5-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-n-meningitidis-serogroup-c-w-y-polysaccharide-conjugated-tetanus-toxoid-n_en.pdf"},
    {"id":"31948","name":"P/128/2008: European Medicines Agency decision of 23 December 2008 on the application for product specific waiver for eprotirome (EMEA-000255-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parl...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/671590/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-128-2008-european-medicines-agency-decision-23-december-2008-application-product-specific-waiver-eprotirome-emea-000255-pip01-08-accordance-regulation-ec-no-1901-2006-european-parl_en.pdf"},
    {"id":"31962","name":"P/0328/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for migalastat (hydrochloride) (Galafold), (EMEA-001194-PIP01-11-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T11:35:00Z","last_updated_date":"2017-02-03T11:35:00Z","reference_number":"EMA/741988/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0328-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-migalastat-hydrochloride-galafold-emea-001194-pip01-11-m02_en.pdf"},
    {"id":"31965","name":"P/0126/2013: EMA decision of 28 May 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for benralizumab (EMEA-001214-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-24T13:30:00Z","last_updated_date":"2013-06-24T13:30:00Z","reference_number":"EMA/248952/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2013-ema-decision-28-may-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-benralizumab-emea-001214-pip01-11_en.pdf"},
    {"id":"31992","name":"P/183/201: EMA decision of 4 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia) (EMEA-000018-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/589982/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-183-201-ema-decision-4-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-emea-000018-pip01-07-m03_en.pdf"},
    {"id":"31994","name":"P/0143/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-000775-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/382957/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000775-pip01-09-m02_en.pdf"},
    {"id":"32011","name":"P/0326/2014: EMA decision of 22 December 2014 on the agreement of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for mepolizumab (EMEA-000069-PIP04-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/755906/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0326-2014-ema-decision-22-december-2014-agreement-paediatric-investigation-plan-refusal-deferral-granting-waiver-mepolizumab-emea-000069-pip04-13_en.pdf"},
    {"id":"32031","name":"P/0096/2016: EMA decision of 26 February 2016 on the acceptance of a modification of an agreed paediatric investigation plan for pitavastatin (calcium) (Alipza and associated names) (EMEA-000300-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/195518/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2016-ema-decision-26-february-2016-acceptance-modification-agreed-paediatric-investigation-plan-pitavastatin-calcium-alipza-associated-names-emea-000300-pip01-08-m04_en.pdf"},
    {"id":"32048","name":"P/0178/2016: EMA decision of 8 July 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for eleclazine\n\n(EMEA-001697-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-19T02:00:00Z","last_updated_date":"2016-09-19T02:00:00Z","reference_number":"EMA/408699/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2016-ema-decision-8-july-2016-agreement-paediatric-investigation-plan-granting-deferral-eleclazine-emea-001697-pip02-14_en.pdf"},
    {"id":"32056","name":"P/0087/2012: EMA decision of 25 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for macitentan (EMEA-001032-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/339546/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2012-ema-decision-25-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-macitentan-emea-001032-pip01-10-m01_en.pdf"},
    {"id":"32075","name":"P/0049/2014: European Medicines Agency decision of 7 March 2014 on the granting of a product specific waiver for ocriplasmin (Jetrea) (EMEA-000986-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/43438/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2014-european-medicines-agency-decision-7-march-2014-granting-product-specific-waiver-ocriplasmin-jetrea-emea-000986-pip02-13_en.pdf"},
    {"id":"32080","name":"P/0026/2013: EMA decision of 26 February 2013 on the granting of a product specific waiver for aztreonam (Cayston), (EMEA-000827-PIP03-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/75621/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2013-ema-decision-26-february-2013-granting-product-specific-waiver-aztreonam-cayston-emea-000827-pip03-11_en.pdf"},
    {"id":"32092","name":"P/108/2011: EMA decision of 6 May 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for tadalafil (Adcirca, Cialis), (EMEA-000452-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-09T02:00:00Z","last_updated_date":"2011-06-09T02:00:00Z","reference_number":"EMA/343619/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-108-2011-ema-decision-6-may-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tadalafil-adcirca-cialis-emea-000452-pip02-10_en.pdf"},
    {"id":"32110","name":"P/0166/2016: EMA decision of 15 June 2016 on the granting of a product specific waiver for olmesartan (medoxomil) / rosuvastatin (calcium)\n\n(EMEA-001914-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/314198/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2016-ema-decision-15-june-2016-granting-product-specific-waiver-olmesartan-medoxomil-rosuvastatin-calcium-emea-001914-pip01-15_en.pdf"},
    {"id":"32135","name":"P/0244/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for melatonin (Circadin), (EMEA-000440-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/617371/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-melatonin-circadin-emea-000440-pip02-11-m03_en.pdf"},
    {"id":"32142","name":"P/0283/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA-001214-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/689612/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-benralizumab-emea-001214-pip01-11-m04_en.pdf"},
    {"id":"32145","name":"20/2011: EMA decision of 25 January 2011 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for alogliptin benzoate (EMEA-000496-PIP01-08-M01) in accorda...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/28395/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/20-2011-ema-decision-25-january-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-alogliptin-benzoate-emea-000496-pip01-08-m01-accorda_en.pdf"},
    {"id":"32166","name":"P/0320/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for beclometasone\n\n(dipropionate) / formoterol (fumarate dihydrate) (Foster and associated names...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-14T16:17:00Z","last_updated_date":"2018-02-14T16:17:00Z","reference_number":"EMA/679136/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-beclometasone-dipropionate-formoterol-fumarate-dihydrate-foster-associated-names_en.pdf"},
    {"id":"32225","name":"P/0142/2012: EMA decision of 23 July 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for ethanol (EMEA-000414-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T17:15:00Z","last_updated_date":"2012-08-22T17:15:00Z","reference_number":"EMA/394700/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2012-ema-decision-23-july-2012-agreement-paediatric-investigation-plan-granting-waiver-ethanol-emea-000414-pip02-11_en.pdf"},
    {"id":"32234","name":"P/187/2010: European Medicines Agency decision of 24 September 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human monoclonal a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/585817/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-187-2010-european-medicines-agency-decision-24-september-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-monoclonal_en.pdf"},
    {"id":"32253","name":"P/0159/2014: EMA decision of 18 June 2014 on the granting of a product specific waiver for pantoprazole (in combination with amoxicillin + clarithromycin + metronidazole) (EMEA-001616-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T11:45:00Z","last_updated_date":"2014-07-22T11:45:00Z","reference_number":"EMA/259622/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2014-ema-decision-18-june-2014-granting-product-specific-waiver-pantoprazole-combination-amoxicillin-clarithromycin-metronidazole-emea-001616-pip01-13_en.pdf"},
    {"id":"32256","name":"P/238/2009: European Medicines Agency descion of 1 December 2009on the acceptance of a modification of an agreed Paediatric Investigation Plan for canakinumab (EMEA-000060-PIP02-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-08T01:00:00Z","last_updated_date":"2010-12-08T01:00:00Z","reference_number":"EMEA/760824/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-238-2009-european-medicines-agency-descion-1-december-2009on-acceptance-modification-agreed-paediatric-investigation-plan-canakinumab-emea-000060-pip02-08-m01_en.pdf"},
    {"id":"32268","name":"P/0102/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for quizartinib (EMEA-\n\n001821-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/145135/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-quizartinib-emea-001821-pip01-15-m01_en.pdf"},
    {"id":"32283","name":"P/0171/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen / human thrombin (Evicel, Evarrest), (EMEA-001149-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/434441/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-evicel-evarrest-emea-001149-pip01-11-m02_en.pdf"},
    {"id":"32290","name":"P/0288/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten and associated names) (EMEA-000347-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/708153/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-associated-names-emea-000347-pip01-08-m03_en.pdf"},
    {"id":"32291","name":"P/209/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral for Lasparaginase encapsulated in erythrocytes, (EMEA-000341-PIP02-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/656412/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-209-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-lasparaginase-encapsulated-erythrocytes-emea-000341-pip02-0_en.pdf"},
    {"id":"32300","name":"P/0202/2015: EMA decision of 4 September 2015 on the granting of a product specific waiver for amlodipine / perindopril (tert-butylamine) / rosuvastatin (EMEA-001772-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/568912/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2015-ema-decision-4-september-2015-granting-product-specific-waiver-amlodipine-perindopril-tert-butylamine-rosuvastatin-emea-001772-pip01-15_en.pdf"},
    {"id":"32324","name":"P/0146/2013: EMA decision of 3 July 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for estetrol /\n\ndrospirenone (EMEA-001332-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-09T16:30:00Z","last_updated_date":"2013-08-09T16:30:00Z","reference_number":"EMA/311599/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2013-ema-decision-3-july-2013-agreement-paediatric-investigation-plan-granting-waiver-estetrol-drospirenone-emea-001332-pip01-12_en.pdf"},
    {"id":"32331","name":"P/0123/2013: EMA decision of 28 May 2013 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-21T13:30:00Z","last_updated_date":"2013-06-21T13:30:00Z","reference_number":"EMA/245786/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2013-ema-decision-28-may-2013-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-januvia-emea-000470-pip01-08-m07_en.pdf"},
    {"id":"32339","name":"P/0199/2017: EMA decision of 14 July 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for Fc- and CDRmodified\n\nhumanised monoclonal antibody against C5 (EMEA-002077-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/434826/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2017-ema-decision-14-july-2017-agreement-paediatric-investigation-plan-granting-deferral-fc-cdrmodified-humanised-monoclonal-antibody-against-c5-emea-002077-pip01-16_en.pdf"},
    {"id":"32348","name":"P/0034/2013: EMA decision of 26 February 2013 on the granting of a product-specific waiver for amlodipine (besylate) / atorvastatin (calcium), (EMEA-001364-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T16:00:00Z","last_updated_date":"2013-04-23T16:00:00Z","reference_number":"EMA/23839/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2013-ema-decision-26-february-2013-granting-product-specific-waiver-amlodipine-besylate-atorvastatin-calcium-emea-001364-pip01-12_en.pdf"},
    {"id":"32353","name":"P/339/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for modified allergen extract of Dermatophagoides pteron...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/800116/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-339-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-dermatophagoides-pteron_en.pdf-0"},
    {"id":"32383","name":"P/0295/2012: EMA decision of 18 December 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for chimeric anti-disialoganglioside (GD2) monoclonal antibody (NSC764038) (EMEA-001285-PI...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T14:00:00Z","last_updated_date":"2013-02-08T14:00:00Z","reference_number":"EMA/802482/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2012-ema-decision-18-december-2012-agreement-paediatric-investigation-plan-granting-waiver-chimeric-anti-disialoganglioside-gd2-monoclonal-antibody-nsc764038-emea-001285-pi_en.pdf"},
    {"id":"32384","name":"P/0349/2017: EMA decision of 1 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for ruxolitinib (phosphate) (Jakavi), (EMEA-000901-PIP03...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/723538/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0349-2017-ema-decision-1-december-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ruxolitinib-phosphate-jakavi-emea-000901-pip03_en.pdf"},
    {"id":"32405","name":"P/170/2009: European Medicines Agency decision of 28 August 2009 on the granting of a product specific waiver for sitagliptin phosphate monohydrate / simvastatin (EMEA-000536-PIP01-09) in accordance with Regulation (EC) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/531540/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-170-2009-european-medicines-agency-decision-28-august-2009-granting-product-specific-waiver-sitagliptin-phosphate-monohydrate-simvastatin-emea-000536-pip01-09-accordance-regulation-ec_en.pdf"},
    {"id":"32413","name":"P/0232/2016: EMA decision of 9 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for lanthanum carbonate hydrate (Fosrenol and associated names), (EMEA-000637-PIP02-10-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/579872/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2016-ema-decision-9-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-lanthanum-carbonate-hydrate-fosrenol-associated-names-emea-000637-pip02-10-m05_en.pdf"},
    {"id":"32429","name":"P/0357/2016: EMA decision of 21 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for deferiprone (EMEA-\n\n001126-PIP01-10-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T11:35:00Z","last_updated_date":"2017-02-03T11:35:00Z","reference_number":"EMA/788574/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0357-2016-ema-decision-21-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-deferiprone-emea-001126-pip01-10-m02_en.pdf"},
    {"id":"32434","name":"P/0085/2017: EMA decision of 17 March 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of\n\na waiver for baclofen (EMEA-001549-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/165668/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2017-ema-decision-17-march-2017-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-baclofen-emea-001549-pip02-14_en.pdf"},
    {"id":"32485","name":"P/0207/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for turoctocog alfa\n\n(NovoEight) (EMEA-000428-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/441051/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-turoctocog-alfa-novoeight-emea-000428-pip01-08-m03_en.pdf"},
    {"id":"32491","name":"P/0073/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for retosiban (EMEA-001359-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/156141/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-retosiban-emea-001359-pip01-12-m01_en.pdf"},
    {"id":"32494","name":"P/0133/2014: EMA decision of 10 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ceftazidime / avibactam (EMEA-001313-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-28T02:00:00Z","last_updated_date":"2014-07-28T02:00:00Z","reference_number":"EMA/268696/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2014-ema-decision-10-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-emea-001313-pip01-12-m01_en.pdf"},
    {"id":"32495","name":"P/0196/2017: EMA decision of 14 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis),\n\n(EMEA-000183-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-29T02:00:00Z","last_updated_date":"2017-09-29T02:00:00Z","reference_number":"EMA/430856/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2017-ema-decision-14-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip01-08-m05_en.pdf"},
    {"id":"32511","name":"P/0184/2014: EMA decision of 6 August 2014 on the agreement of a paediatric investigation plan and on the granting of a waiver for tobramycin (TOBI), (EMEA-000184-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/414809/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2014-ema-decision-6-august-2014-agreement-paediatric-investigation-plan-granting-waiver-tobramycin-tobi-emea-000184-pip02-14_en.pdf"},
    {"id":"32537","name":"P/0311/2014: EMA decision of 25 November 2014 on the granting of a product specific waiver for diclofenac sodium / thiocolchicoside (EMEA-001558-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/643639/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0311-2014-ema-decision-25-november-2014-granting-product-specific-waiver-diclofenac-sodium-thiocolchicoside-emea-001558-pip02-14_en.pdf"},
    {"id":"32577","name":"P/0309/2012: EMA decision of 21 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin (EMEA-000828-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/809327/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0309-2012-ema-decision-21-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-emea-000828-pip01-09-m01_en.pdf"},
    {"id":"32578","name":"P/50/2010: European Medicines Agency decision of 7 April 2010 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for recombinant coagulation Factor VIII (N8) (EMEA-000428-PIP01-08) in a...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/118879/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-50-2010-european-medicines-agency-decision-7-april-2010-agreement-paediatric-investigation-plan-granting-deferral-recombinant-coagulation-factor-viii-n8-emea-000428-pip01-08_en.pdf"},
    {"id":"32583","name":"P/297/2011: EMA decision of 20 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for anidulafungin\n\n(Ecalta), (EMEA-000469-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/944542/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-297-2011-ema-decision-20-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-anidulafungin-ecalta-emea-000469-pip01-08-m03_en.pdf"},
    {"id":"32599","name":"P/314/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of grass and rye pollen (50...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769459/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-314-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-grass-rye-pollen-50_en.pdf"},
    {"id":"32601","name":"P/0227/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for lonoctocog alfa (EMEA-001215-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/619901/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-lonoctocog-alfa-emea-001215-pip01-11-m04_en.pdf"},
    {"id":"32616","name":"P/0108/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dopamine\n\n(EMEA-001105-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/151864/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-dopamine-emea-001105-pip01-10-m04_en.pdf"},
    {"id":"32628","name":"P/0379/2017: EMA decision of 19 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for vosoritide\n\n(BMN 111) (EMEA-002033-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/759547/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0379-2017-ema-decision-19-december-2017-agreement-paediatric-investigation-plan-granting-deferral-vosoritide-bmn-111-emea-002033-pip01-16_en.pdf"},
    {"id":"32634","name":"P/0341/2014: EMA decision of 22 December 2014 on the granting of a product specific waiver for calcium (carbonate) / cholecalciferol (in combination with ibandronic acid) (EMEA-001670-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/713537/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0341-2014-ema-decision-22-december-2014-granting-product-specific-waiver-calcium-carbonate-cholecalciferol-combination-ibandronic-acid-emea-001670-pip01-14_en.pdf"},
    {"id":"32642","name":"P/0015/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for vedolizumab (Entyvio), (EMEA-000645-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/1372/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-vedolizumab-entyvio-emea-000645-pip01-09-m03_en.pdf"},
    {"id":"32666","name":"P/0210/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for azilsartan medoxomil (Edarbi), (EMEA-000237-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/568205/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-azilsartan-medoxomil-edarbi-emea-000237-pip01-08-m06_en.pdf"},
    {"id":"32669","name":"P/101/2010: European Medicines Agency decision of 4 June 2010\n\non the acceptance of a modification of an agreed paediatric investigation plan for rabeprazole (sodium) (Pariet and associated names) (EMEA-000055-PIP01-07-M...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/354482/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-101-2010-european-medicines-agency-decision-4-june-2010-acceptance-modification-agreed-paediatric-investigation-plan-rabeprazole-sodium-pariet-associated-names-emea-000055-pip01-07-m_en.pdf"},
    {"id":"32674","name":"P/28/2010: European Medicines Agency decision of 5 March 2010 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for dalcetrapib (EMEA-000580-PIP01-09) i...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMA/129196/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-28-2010-european-medicines-agency-decision-5-march-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dalcetrapib-emea-000580-pip01-09-i_en.pdf"},
    {"id":"32686","name":"P/0231/2012: EMA decision of 5 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for pitavastatin (calcium) (Alipza and associated names), (EMEA-000300-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T01:00:00Z","last_updated_date":"2012-11-23T01:00:00Z","reference_number":"EMA/625279/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2012-ema-decision-5-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-pitavastatin-calcium-alipza-associated-names-emea-000300-pip01-08-m03_en.pdf"},
    {"id":"32691","name":"P/261/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver mixture of Phleum pratense, Dactylis glomerata, Festuca e...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/710663/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-261-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mixture-phleum-pratense-dactylis-glomerata-festuca-e_en.pdf"},
    {"id":"32709","name":"P/0071/2013: EMA decision of 26 March 2013 on the agreement of a paediatric investigation plan and on the refusal of a waiver for autologous CD34+ cells transduced ex-vivo with retroviral Vector (GIADAl) containing human...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/113454/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2013-ema-decision-26-march-2013-agreement-paediatric-investigation-plan-refusal-waiver-autologous-cd34-cells-transduced-ex-vivo-retroviral-vector-giadal-containing-human_en.pdf"},
    {"id":"32721","name":"P/0013/2012: EMA decision of 24 January 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for treprostinil\n\n(diethanolamine) (EMEA-001165-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/13957/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2012-ema-decision-24-january-2012-agreement-paediatric-investigation-plan-granting-deferral-treprostinil-diethanolamine-emea-001165-pip01-11_en.pdf"},
    {"id":"32742","name":"P/0211/2013: EMA decision of 3 September 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for thrombomodulin alfa (EMEA-001363-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/483101/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2013-ema-decision-3-september-2013-agreement-paediatric-investigation-plan-granting-deferral-thrombomodulin-alfa-emea-001363-pip01-12_en.pdf"},
    {"id":"32756","name":"P/0218/2015: EMA decision of 2 October 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for acotiamide (EMEA-001461-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-19T01:00:00Z","last_updated_date":"2015-11-19T01:00:00Z","reference_number":"EMA/561659/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2015-ema-decision-2-october-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-acotiamide-emea-001461-pip02-14_en.pdf"},
    {"id":"32763","name":"P/0077/2017: EMA decision of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a waiver for autologous CD34+ hematopoietic stem cells transduced ex vivo with EFS lentiviral vector e...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/104958/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2017-ema-decision-17-march-2017-agreement-paediatric-investigation-plan-granting-waiver-autologous-cd34-hematopoietic-stem-cells-transduced-ex-vivo-efs-lentiviral-vector-e_en.pdf"},
    {"id":"32765","name":"P/0004/2012: EMA decision of 23 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of bi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/972925/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2012-ema-decision-23-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergen-extract-bi_en.pdf"},
    {"id":"32787","name":"P/0097/2012: EMA decision of 30 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for bosentan (Tracleer) (EMEA-000425-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/331076/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2012-ema-decision-30-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-bosentan-tracleer-emea-000425-pip02-10-m02_en.pdf"},
    {"id":"32798","name":"P/0055/2013: EMA decision of 25 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for etoxybamide (EMEA-000764-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/85747/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2013-ema-decision-25-march-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-etoxybamide-emea-000764-pip02-11_en.pdf"},
    {"id":"32803","name":"P/0174/2012: EMA decision of 27 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for migalastat (hydrochloride) (EMEA-001194-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T16:00:00Z","last_updated_date":"2012-08-23T16:00:00Z","reference_number":"EMA/492342/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2012-ema-decision-27-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-migalastat-hydrochloride-emea-001194-pip01-11_en.pdf"},
    {"id":"32819","name":"P/158/201: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab\n\n(XGEVA, previously Amgiva and Prolia) (EMEA-000145-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/424850/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-158-201-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-xgeva-previously-amgiva-prolia-emea-000145-pip01-07-m03_en.pdf"},
    {"id":"32832","name":"P/110/2011: EMA decision of 6 May 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for linaclotide (EMEA-000927-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-09T02:00:00Z","last_updated_date":"2011-06-09T02:00:00Z","reference_number":"EMA/334962/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-110-2011-ema-decision-6-may-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-linaclotide-emea-000927-pip01-10_en.pdf"},
    {"id":"32860","name":"P/268/2010: EMA decision of 17 November 2010 on review of a granted waiver for duloxetine hydrochloride (Cymbalta/Xeristar/Yentreve/Ariclaim)(EMEA-000420-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2021-06-22T15:05:00Z","reference_number":"EMA/704354/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-268-2010-ema-decision-17-november-2010-review-granted-waiver-duloxetine-hydrochloride-cymbalta-xeristar-yentreve-ariclaimemea-000420-pip01-10_en.pdf"},
    {"id":"32876","name":"P/0141/2016: EMA decision of 20 May 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for anti-respiratory syncytial virus human IgG1κ monoclonal antibody (MEDI8897) (EMEA-001784-P...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-18T02:00:00Z","last_updated_date":"2016-07-18T02:00:00Z","reference_number":"EMA/287537/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2016-ema-decision-20-may-2016-agreement-paediatric-investigation-plan-granting-waiver-anti-respiratory-syncytial-virus-human-igg1io-monoclonal-antibody-medi8897-emea-001784-p_en.pdf"},
    {"id":"32879","name":"P/310/2011: EMA decision of 20 December 2011 on the granting of a product specific waiver for insulin degludec / liraglutide (EMEA-001193-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/944182/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-310-2011-ema-decision-20-december-2011-granting-product-specific-waiver-insulin-degludec-liraglutide-emea-001193-pip01-11_en.pdf"},
    {"id":"32880","name":"P/22/2010: European Medicines Agency decision of 2 March 2010 on the refusal of a product specific waiver for lanthanum carbonate hydrate (Fosrenol and associated names) (EMEA-000637-PIP01-09) in accordance with Regulati...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMA/118075/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-22-2010-european-medicines-agency-decision-2-march-2010-refusal-product-specific-waiver-lanthanum-carbonate-hydrate-fosrenol-associated-names-emea-000637-pip01-09-accordance-regulati_en.pdf"},
    {"id":"32914","name":"P/163/2009: European Medicines Agency decision of 12 August 2009 on the granting of a product specific waiver for patupilone (EMEA-000557-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliame...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/489978/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-163-2009-european-medicines-agency-decision-12-august-2009-granting-product-specific-waiver-patupilone-emea-000557-pip01-09-accordance-regulation-ec-no-1901-2006-european-parliame_en.pdf"},
    {"id":"32931","name":"P/0152/2014: EMA decision of 13 June 2014 on the granting of a product specific waiver for (11beta,17beta)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one (EMEA-001576-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/275214/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2014-ema-decision-13-june-2014-granting-product-specific-waiver-11beta17beta-17-hydroxy-11-4-methylsulfonylphenyl-17-pentafluoroethylestra-49-dien-3-one-emea-001576-pip01-13_en.pdf"},
    {"id":"32940","name":"P/0177/2016: EMA decision of 8 July 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for eleclazine\n\n(EMEA-001697-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-19T02:00:00Z","last_updated_date":"2016-09-19T02:00:00Z","reference_number":"EMA/408698/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2016-ema-decision-8-july-2016-agreement-paediatric-investigation-plan-granting-deferral-eleclazine-emea-001697-pip01-14_en.pdf"},
    {"id":"32965","name":"P/0039/2017: European Medicines Agency decision of 31 January 2017 on the granting of a product specific waiver for (2-Hydroxyethyl)trimethylammonium 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4- methoxyphenyl]-2,4-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/12260/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2017-european-medicines-agency-decision-31-january-2017-granting-product-specific-waiver-2-hydroxyethyltrimethylammonium-3-2-fluoro-5-23-difluoro-6-methoxybenzyloxy-4-methoxyphenyl-24_en.pdf"},
    {"id":"32978","name":"P/0107/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab\n\n(Fasenra), (EMEA-001214-PIP01-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/151867/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-benralizumab-fasenra-emea-001214-pip01-11-m07_en.pdf"},
    {"id":"32991","name":"P/0028/2017: EMA decision of 10 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine /\n\ndolutegravir (EMEA-001750-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-18T02:00:00Z","last_updated_date":"2017-04-18T02:00:00Z","reference_number":"EMA/2926/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2017-ema-decision-10-february-2017-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-dolutegravir-emea-001750-pip01-15-m01_en.pdf"},
    {"id":"32994","name":"P/0007/2013: EMA decision of 21 January 2013 on the granting of a product-specific waiver for morphine / oxycodone (EMEA-001281-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T14:30:00Z","last_updated_date":"2013-04-03T14:30:00Z","reference_number":"EMA/779528/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2013-ema-decision-21-january-2013-granting-product-specific-waiver-morphine-oxycodone-emea-001281-pip01-12_en.pdf"},
    {"id":"33032","name":"P/0219/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for luspatercept (EMEA-\n\n001521-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/430903/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-luspatercept-emea-001521-pip01-13-m01_en.pdf"},
    {"id":"33034","name":"P/0139/2016: EMA decision of 20 May 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for doravirine (EMEA-001676-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-18T02:00:00Z","last_updated_date":"2016-07-18T02:00:00Z","reference_number":"EMA/290659/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2016-ema-decision-20-may-2016-agreement-paediatric-investigation-plan-granting-deferral-doravirine-emea-001676-pip01-14_en.pdf"},
    {"id":"33038","name":"P/174/2010: European Medicines Agency decision of 20 September 2010 on the acceptance of a modification of an agreed paediatric investigation plan for retigabine (EMEA-000116-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/582666/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-174-2010-european-medicines-agency-decision-20-september-2010-acceptance-modification-agreed-paediatric-investigation-plan-retigabine-emea-000116-pip01-07-m03_en.pdf"},
    {"id":"33059","name":"P/282/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allergen extract of secale cereale pollen (EMEA-00091...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/754285/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-282-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extract-secale-cereale-pollen-emea-00091_en.pdf"}    {"id":"33068","name":"P/0366/2017: EMA decision of 1 December 2017 on the granting of a product specific waiver for soluble human T cell receptor (TCR) directed against\n\nthe glycoprotein 100 (gp100) melanoma antigen, linked to the single-chai...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T14:03:00Z","last_updated_date":"2018-03-07T14:03:00Z","reference_number":"EMA/710015/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0366-2017-ema-decision-1-december-2017-granting-product-specific-waiver-soluble-human-t-cell-receptor-tcr-directed-against-glycoprotein-100-gp100-melanoma-antigen-linked-single-chai_en.pdf"},
    {"id":"33074","name":"P/0329/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for autologous\n\nhaematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T11:35:00Z","last_updated_date":"2017-02-03T11:35:00Z","reference_number":"EMA/765280/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0329-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-autologous-haematopoietic-stem-cells-transduced-lentiviral-vector-lenti-d-encoding_en.pdf"},
    {"id":"33075","name":"P/0019/2013: EMA decision of 1 February 2013 on the acceptance of a modification of an agreed paediatric investigation plan for solifenacin (succinate) (Vesicare and associated names), (EMEA-000573-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T02:00:00Z","last_updated_date":"2013-04-23T02:00:00Z","reference_number":"EMA/49423/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2013-ema-decision-1-february-2013-acceptance-modification-agreed-paediatric-investigation-plan-solifenacin-succinate-vesicare-associated-names-emea-000573-pip01-09-m02_en.pdf"},
    {"id":"33083","name":"P/191/2009: Modification of a PIP for alanine, arginine, aspartic acid, cysteine/cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine monohydrate, methionine, ornithine hydrochloride, phenylalanine, pr...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/610520/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-191-2009-modification-pip-alanine-arginine-aspartic-acid-cysteine-cystine-glutamic-acid-glycine-histidine-isoleucine-leucine-lysine-monohydrate-methionine-ornithine-hydrochloride-phenylalanine-pr_en.pdf"},
    {"id":"33085","name":"P/0094/2018: EMA decision of 16 March 2018 on the granting of a product- specific waiver for treprostinil (sodium) (EMEA-002254-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/100876/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2018-ema-decision-16-march-2018-granting-product-specific-waiver-treprostinil-sodium-emea-002254-pip01-17_en.pdf"},
    {"id":"33097","name":"P/0098/2012: EMA decision of 30 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ivabradine (hydrochloride) (Corlentor), (EMEA-000627-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/273382/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2012-ema-decision-30-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-ivabradine-hydrochloride-corlentor-emea-000627-pip01-09-m03_en.pdf"},
    {"id":"33103","name":"P/83/2011: EMA decision of 6 April 2011 on the refusal of a product specific waiver for aciclovir (EMEA-001066-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/249985/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-83-2011-ema-decision-6-april-2011-refusal-product-specific-waiver-aciclovir-emea-001066-pip01-10_en.pdf"},
    {"id":"33128","name":"P/0053/2018: EMA decision of 1 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sodium zirconium\n\ncyclosilicate (EMEA-001539-PIP01-13-M03) (Lokelma was authorised after the De...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/91846/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2018-ema-decision-1-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-sodium-zirconium-cyclosilicate-emea-001539-pip01-13-m03-lokelma-was-authorised-after-de_en.pdf"},
    {"id":"33147","name":"P/0342/2016: EMA decision of 2 December 2016 on the agreement of a paediatric investigation plan for recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689) (EMEA-001886-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/758312/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0342-2016-ema-decision-2-december-2016-agreement-paediatric-investigation-plan-recombinant-fusion-protein-linking-coagulation-factor-viia-albumin-rviia-fp-csl689-emea-001886-pip01-15_en.pdf"},
    {"id":"33192","name":"P/0285/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for vandetanib (Caprelsa), (EMEA-000052-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/659472/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-vandetanib-caprelsa-emea-000052-pip01-07-m03_en.pdf"},
    {"id":"33194","name":"P/196/2010: European Medicines Agency decision of 26 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for riociguat (EMEA-000718-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/651401/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-196-2010-european-medicines-agency-decision-26-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-riociguat-emea-000718-pip01-09_en.pdf"},
    {"id":"33212","name":"P/109/2009: European Medicines Agency decision of 16 June 2009 on the granting of a product specific waiver for clazosentan (EMEA-000369-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliamen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351854/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-109-2009-european-medicines-agency-decision-16-june-2009-granting-product-specific-waiver-clazosentan-emea-000369-pip01-08-accordance-regulation-ec-no-1901-2006-european-parliamen_en.pdf"},
    {"id":"33239","name":"P/0291/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for beclometasone\n\ndipropionate / formoterol fumarate dihydrate (Foster and associated names, K...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/647900/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-beclometasone-dipropionate-formoterol-fumarate-dihydrate-foster-associated-names-k_en.pdf"},
    {"id":"33253","name":"P/141/2011: EMA decision of 6 June 2011 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira), (EMEA-000366-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-13T02:00:00Z","last_updated_date":"2011-07-13T02:00:00Z","reference_number":"EMA/431193/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-141-2011-ema-decision-6-june-2011-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip01-08-m04_en.pdf"},
    {"id":"33267","name":"P/0364/2016: EMA decision of 21 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for KEOC liquid extract\n\nethanolic 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus ...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T17:48:00Z","last_updated_date":"2017-02-03T17:48:00Z","reference_number":"EMA/757977/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0364-2016-ema-decision-21-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-keoc-liquid-extract-ethanolic-30-cent-w-w-allium-cepa-l-fresh-bulb-citrus_en.pdf"},
    {"id":"33299","name":"P/0103/2012: EMA decision of 30 May 2012 on the granting of a product specific waiver for glimepiride / atorvastatin (calcium), (EMEA-001232-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T18:00:00Z","last_updated_date":"2012-06-25T18:00:00Z","reference_number":"EMA/274474/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2012-ema-decision-30-may-2012-granting-product-specific-waiver-glimepiride-atorvastatin-calcium-emea-001232-pip01-11_en.pdf"},
    {"id":"33300","name":"P/0197/2017: EMA decision of 14 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for treosulfan (EMEA-000883-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/433425/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2017-ema-decision-14-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-treosulfan-emea-000883-pip01-10-m04_en.pdf"},
    {"id":"33334","name":"P/0225/2014: EMA decision of 5 September 2014 on the refusal of a modification of an agreed paediatric investigation plan for telaprevir (Incivo), (EMEA-000196-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/501714/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2014-ema-decision-5-september-2014-refusal-modification-agreed-paediatric-investigation-plan-telaprevir-incivo-emea-000196-pip01-08-m03_en.pdf"},
    {"id":"33362","name":"P/293/2010: EMA decision of 22 December 2010 on the granting of a product specific waiver for nalmefene hydrochloride dihydrate (EMEA-000824-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/683265/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-293-2010-ema-decision-22-december-2010-granting-product-specific-waiver-nalmefene-hydrochloride-dihydrate-emea-000824-pip01-09_en.pdf"},
    {"id":"33364","name":"P/73/2008: European medicines agency decision of 14 September 2008\n\non the application for agreement of a Paediatric Investigation Plan for[d2] ezetimibe and simvastatin (fixed combination) (INEGY and associated trade na...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-10-10T02:00:00Z","last_updated_date":"2008-10-10T02:00:00Z","reference_number":"EMEA/467238/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-73-2008-european-medicines-agency-decision-14-september-2008-application-agreement-paediatric-investigation-plan-ford2-ezetimibe-simvastatin-fixed-combination-inegy-associated-trade-na_en.pdf"},
    {"id":"33397","name":"P/79/2011: EMA decision of 6 April 2011 on the granting of a product specific waiver for human normal immunoglobulin (EMEA-000558-PIP02-\n\n10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/248312/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-79-2011-ema-decision-6-april-2011-granting-product-specific-waiver-human-normal-immunoglobulin-emea-000558-pip02-10_en.pdf"},
    {"id":"33408","name":"P/0170/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (Brilique), (EMEA-000480-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/354118/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-ticagrelor-brilique-emea-000480-pip01-08-m10_en.pdf"},
    {"id":"33420","name":"P/0090/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names, Tapenta...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/188336/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapenta_en.pdf"},
    {"id":"33476","name":"P/0017/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation factor X (EMEA-000971-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/10879/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-human-coagulation-factor-x-emea-000971-pip01-10-m01_en.pdf"},
    {"id":"33504","name":"P/0155/2016: EMA decision of 15 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for raltegravir\n\n(Isentress), (EMEA-000279-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/314181/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2016-ema-decision-15-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-raltegravir-isentress-emea-000279-pip01-08-m05_en.pdf"},
    {"id":"33512","name":"P/0018/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lomitapide (Lojuxta) (EMEA-001124-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/10760/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-lomitapide-lojuxta-emea-001124-pip01-10-m01_en.pdf"},
    {"id":"33529","name":"P/0077/2015: EMA decision of 1 April 2015 on the granting of a product-specific waiver for autologous bone marrow-derived cardiopoietic stem cells (EMEA-001694-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-07T02:00:00Z","last_updated_date":"2015-05-07T02:00:00Z","reference_number":"EMA/108893/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2015-ema-decision-1-april-2015-granting-product-specific-waiver-autologous-bone-marrow-derived-cardiopoietic-stem-cells-emea-001694-pip01-14_en.pdf"},
    {"id":"33531","name":"P/0074/2012: EMA decision of 25 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for treprostinil\n\n(Remodulin and associated names), (EMEA-000207-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/255881/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2012-ema-decision-25-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-treprostinil-remodulin-associated-names-emea-000207-pip01-08-m02_en.pdf"},
    {"id":"33550","name":"P/139/2010:  European Medicines Agency decision of 30 July 2010 on the granting of a product specific waiver for dexamethasone (EMEA-000198-PIP04-10) in accordance with Regulation (EC) No 1901/2006 of the European Parlia...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/425487/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-139-2010-european-medicines-agency-decision-30-july-2010-granting-product-specific-waiver-dexamethasone-emea-000198-pip04-10-accordance-regulation-ec-no-1901-2006-european-parlia_en.pdf"},
    {"id":"33603","name":"P/0390/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide\n\nadsorbed, depigmented glutaraldehyde polymerised, allergic extract of ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/792970/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0390-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergic-extract_en.pdf"},
    {"id":"33607","name":"P/0074/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for etelcalcetide (EMEA-001554-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/104835/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-etelcalcetide-emea-001554-pip01-13-m01_en.pdf"},
    {"id":"33608","name":"P/0230/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant fusion\n\nprotein linking human coagulation factor IX with human albumin (Albutrepen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/434833/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-fusion-protein-linking-human-coagulation-factor-ix-human-albumin-albutrepen_en.pdf"},
    {"id":"33637","name":"P/0084/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human normal immunoglobulin (EMEA-001797-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/104853/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-normal-immunoglobulin-emea-001797-pip01-15_en.pdf"},
    {"id":"33639","name":"P/84/2011: EMA decision of 8 April 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for lubiprostone (EMEA-000245-PIP01-08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/258610/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-84-2011-ema-decision-8-april-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lubiprostone-emea-000245-pip01-08_en.pdf"},
    {"id":"33659","name":"P/0235/2016: EMA decision of 9 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for evolocumab\n\n(Repatha) (EMEA-001268-PIP01-12-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/579793/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2016-ema-decision-9-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-evolocumab-repatha-emea-001268-pip01-12-m03_en.pdf"},
    {"id":"33669","name":"P/0259/2013: EMA decision of 29 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for octocog alfa (EMEA-001064-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/601910/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2013-ema-decision-29-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-octocog-alfa-emea-001064-pip01-10-m01_en.pdf"},
    {"id":"33677","name":"P/263/2009: European Medicines Agency decision of 23 December 2009  on the acceptance of a modification of an agreed Paediatric Investigation Plan for moxifloxacin hydrochloride (Octegra and associated names: Proflox)(...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:00:00Z","last_updated_date":"2010-01-25T00:00:00Z","reference_number":"EMA/827807/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-263-2009-european-medicines-agency-decision-23-december-2009-acceptance-modification-agreed-paediatric-investigation-plan-moxifloxacin-hydrochloride-octegra-associated-names-proflox_en.pdf"},
    {"id":"33720","name":"P/0292/2017: EMA decision of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for naloxegol (Moventig) (EMEA-001146-PIP01-11-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T10:19:00Z","last_updated_date":"2018-02-15T10:19:00Z","reference_number":"EMA/626339/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2017-ema-decision-4-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-naloxegol-moventig-emea-001146-pip01-11-m03_en.pdf"},
    {"id":"33725","name":"P/238/2010:  EMA decision of 12 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for teduglutide, (EMEA-000482-PIP01-08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/672693/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-238-2010-ema-decision-12-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-teduglutide-emea-000482-pip01-08_en.pdf"},
    {"id":"33752","name":"P/0086/2016: EMA decision of 18 March 2016 on the granting of a product specific waiver for recombinant human monoclonal antibody against growth differentiation factor 8 (REGN1033) (EMEA-001859-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/107873/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2016-ema-decision-18-march-2016-granting-product-specific-waiver-recombinant-human-monoclonal-antibody-against-growth-differentiation-factor-8-regn1033-emea-001859-pip02-15_en.pdf"},
    {"id":"33765","name":"P/0004/2017: EMA decision of 13 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for nivolumab (Opdivo),\n\n(EMEA-001407-PIP02-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/8040/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2017-ema-decision-13-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-nivolumab-opdivo-emea-001407-pip02-15-m01_en.pdf"},
    {"id":"33769","name":"P/69/2010: European Medicines Agency decision on the granting of a product specific waiver for forodesine hydrochloride (EMEA-000785-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/265315/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-69-2010-european-medicines-agency-decision-granting-product-specific-waiver-forodesine-hydrochloride-emea-000785-pip01-09_en.pdf"},
    {"id":"33776","name":"P/0196/2015: EMA decision of 4 September 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for raxibacumab (EMEA-001569-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/571294/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2015-ema-decision-4-september-2015-agreement-paediatric-investigation-plan-granting-deferral-raxibacumab-emea-001569-pip01-13_en.pdf"},
    {"id":"33778","name":"P/44/2011: EMA decision of 3 March 2011 on the acceptance of a modification of an agreed paediatric investigation plan for telcagepant (EMEA-000274-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the Eur...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-06-10T02:00:00Z","last_updated_date":"2011-04-05T02:00:00Z","reference_number":"EMA/115432/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-44-2011-ema-decision-3-march-2011-acceptance-modification-agreed-paediatric-investigation-plan-telcagepant-emea-000274-pip01-08-m01-accordance-regulation-ec-no-1901-2006-eur_en.pdf"},
    {"id":"33785","name":"P/0293/2013: EMA decision of 29 November 2013 on the refusal of a modification of an agreed paediatric investigation plan for riociguat (EMEA-000718-\n\nPIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/693021/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2013-ema-decision-29-november-2013-refusal-modification-agreed-paediatric-investigation-plan-riociguat-emea-000718-pip01-09-m03_en.pdf"},
    {"id":"33791","name":"P/241/2009: EMA decision of 1 December 2009 on the granting of a product specific waiver for fluorouracil / salicylic acid (EMEA-000650-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMEA/760603/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-241-2009-ema-decision-1-december-2009-granting-product-specific-waiver-fluorouracil-salicylic-acid-emea-000650-pip01-09-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"33800","name":"P/0190/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir / velpatasvir (Epclusa), (EMEA-001646-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/354122/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-sofosbuvir-velpatasvir-epclusa-emea-001646-pip01-14-m01_en.pdf"},
    {"id":"33846","name":"P/0151/2012: EMA decision of 25 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for aprepitant (Emend), (EMEA-000144-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/475860/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2012-ema-decision-25-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-aprepitant-emend-emea-000144-pip01-07-m03_en.pdf"},
    {"id":"33862","name":"P/24/2009: European Medicines Agency decision of 23 February 2009 on the refusal of a Paediatric Investigation Plan and on the granting of a waiver for drospirenone / ethinylestradiol bethadex clathrate, Yaz and associat...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/95882/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-24-2009-european-medicines-agency-decision-23-february-2009-refusal-paediatric-investigation-plan-granting-waiver-drospirenone-ethinylestradiol-bethadex-clathrate-yaz-associat_en.pdf"},
    {"id":"33870","name":"P/0213/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for obeticholic acid\n\n(6 alpha-ethylchenodeoxycholic acid) (Ocaliva), (EMEA-001304-PIP02-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/430844/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-obeticholic-acid-6-alpha-ethylchenodeoxycholic-acid-ocaliva-emea-001304-pip02-13-m03_en.pdf"},
    {"id":"33893","name":"P/0137/2014: EMA decision of 11 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ cells transduced with lentiviral vector containing the human Wiskott Aldrich S...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-28T02:00:00Z","last_updated_date":"2014-07-28T02:00:00Z","reference_number":"EMA/273931/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2014-ema-decision-11-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-cells-transduced-lentiviral-vector-containing-human-wiskott-aldrich-s_en.pdf"},
    {"id":"33910","name":"P/0200/2017: EMA decision of 21 July 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for liposomal combination of cytarabine and daunorubicin (EM...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/431300/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2017-ema-decision-21-july-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-liposomal-combination-cytarabine-daunorubicin-em_en.pdf"},
    {"id":"33916","name":"P/0344/2017: EMA decision of 23 November 2017 on the acceptance of a modification of an agreed paediatric investigation plan for avacopan (EMEA-\n\n002023-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-20T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"EMA/753000/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0344-2017-ema-decision-23-november-2017-acceptance-modification-agreed-paediatric-investigation-plan-avacopan-emea-002023-pip01-16-m02_en.pdf"},
    {"id":"33928","name":"P/0122/2017: EMA decision of 5 May 2017 on the granting of a product specific waiver for small interfering RNA targeting human TRPV1 mRNA\n\n(EMEA-002061-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/260021/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2017-ema-decision-5-may-2017-granting-product-specific-waiver-small-interfering-rna-targeting-human-trpv1-mrna-emea-002061-pip01-16_en.pdf"},
    {"id":"33936","name":"P/0080/2013: EMA decision of 27 March 2013 on the granting of a product-specific waiver for sialic acid (EMEA-001400-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/115012/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2013-ema-decision-27-march-2013-granting-product-specific-waiver-sialic-acid-emea-001400-pip01-12_en.pdf"},
    {"id":"33971","name":"P/0186/2014: EMA decision of 6 August 2014 on the agreement of a paediatric investigation plan and on the granting of a waiver for ranibizumab (Lucentis), (EMEA-000527-PIP04-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/416368/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2014-ema-decision-6-august-2014-agreement-paediatric-investigation-plan-granting-waiver-ranibizumab-lucentis-emea-000527-pip04-13_en.pdf"},
    {"id":"33987","name":"P/0272/2012: EMA decision of of 21 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for fingolimod (hydrochloride) (Gilenya), (EMEA-000087-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/722994/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2012-ema-decision-21-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-fingolimod-hydrochloride-gilenya-emea-000087-pip01-07-m02_en.pdf"},
    {"id":"34009","name":"P/291/2010: EMA decision of 22 December 2010 on the granting of a product specific waiver for ranibizumab (Lucentis), (EMEA-000527-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/773522/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-291-2010-ema-decision-22-december-2010-granting-product-specific-waiver-ranibizumab-lucentis-emea-000527-pip02-10_en.pdf"},
    {"id":"34010","name":"P/0210/2012: EMA decision of 28 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus\n\nsurface antigens (haemagglutinin (HA) and neuraminidase) (EMEA-000124-PIP...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T17:00:00Z","last_updated_date":"2012-10-17T17:00:00Z","reference_number":"EMA/501330/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2012-ema-decision-28-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-ha-neuraminidase-emea-000124-pip_en.pdf"},
    {"id":"34020","name":"P/0026/2015: EMA decision of 30 January 2015 on the granting of a product specific waiver for candesartan (cilexetil) / amlodipine (besilate) (EMEA-001633-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/776071/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2015-ema-decision-30-january-2015-granting-product-specific-waiver-candesartan-cilexetil-amlodipine-besilate-emea-001633-pip01-14_en.pdf"},
    {"id":"34048","name":"P/0112/2018: EMA decision of 11 April 2018 on the refusal of a modification of an agreed paediatric investigation plan for concentrate of\n\nproteolytic enzymes in bromelain (NexoBrid) (EMEA-000142-PIP02-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/197933/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2018-ema-decision-11-april-2018-refusal-modification-agreed-paediatric-investigation-plan-concentrate-proteolytic-enzymes-bromelain-nexobrid-emea-000142-pip02-09-m06_en.pdf"},
    {"id":"34062","name":"P/0284/2012: EMA decision of 23 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for eslicarbazepine (acetate) (Zebinix), (EMEA-000696-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/717445/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2012-ema-decision-23-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-eslicarbazepine-acetate-zebinix-emea-000696-pip02-10-m02_en.pdf"},
    {"id":"34081","name":"P/0204/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for asfotase alfa (EMEA-\n\n000987-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-29T02:00:00Z","last_updated_date":"2017-09-29T02:00:00Z","reference_number":"EMA/467048/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-asfotase-alfa-emea-000987-pip01-10-m03_en.pdf"},
    {"id":"34092","name":"P/0129/2014: EMA decision of 20 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for insulin degludec (Tresiba), (EMEA-000456-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-25T02:00:00Z","last_updated_date":"2014-06-25T02:00:00Z","reference_number":"EMA/279156/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2014-ema-decision-20-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-insulin-degludec-tresiba-emea-000456-pip01-08-m02_en.pdf"},
    {"id":"34095","name":"P/295/2011: EMA decision of 20 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for tiotropium bromide (monohydrate) (Spiriva Respimat and associated names, Spiriva) (EMEA-0000...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/944891/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-295-2011-ema-decision-20-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-tiotropium-bromide-monohydrate-spiriva-respimat-associated-names-spiriva-emea-0000_en.pdf"},
    {"id":"34104","name":"P/0027/2014: EMA decision of 24 January 2014 on the refusal of a paediatric investigation plan and on the granting of a waiver for diclofenac / levomenthol (EMEA-001536-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/775576/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2014-ema-decision-24-january-2014-refusal-paediatric-investigation-plan-granting-waiver-diclofenac-levomenthol-emea-001536-pip01-13_en.pdf"},
    {"id":"34124","name":"P/0215/2012: EMA decision of 28 September 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant single-chain coagulation factor VIII, (EMEA-001215-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T18:45:00Z","last_updated_date":"2012-10-17T18:45:00Z","reference_number":"EMA/611501/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2012-ema-decision-28-september-2012-agreement-paediatric-investigation-plan-granting-deferral-recombinant-single-chain-coagulation-factor-viii-emea-001215-pip01-11_en.pdf"},
    {"id":"34129","name":"P/0009/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for atazanavir\n\n(sulphate) / cobicistat (Evotaz), (EMEA-001465-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/28175/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-atazanavir-sulphate-cobicistat-evotaz-emea-001465-pip01-13-m02_en.pdf"},
    {"id":"34137","name":"P/48/2010: European Medicines Agency decision of 6 April 2010 on the acceptance of a modification of an agreed Paediatric Investigation Plan for plerixafor (Mozobil) (EMEA-000174-PIP01-07-M02) in accordance with Regulati...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/118889/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-48-2010-european-medicines-agency-decision-6-april-2010-acceptance-modification-agreed-paediatric-investigation-plan-plerixafor-mozobil-emea-000174-pip01-07-m02-accordance-regulati_en.pdf"},
    {"id":"34138","name":"P/0277/2016: EMA decision of 5 October 2016 on the refusal of a product specific waiver for 18F fluoromisonidazole (EMEA-001977-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/593540/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2016-ema-decision-5-october-2016-refusal-product-specific-waiver-18f-fluoromisonidazole-emea-001977-pip02-16_en.pdf"},
    {"id":"34149","name":"P/0287/2015: EMA decision of 26 November 2015 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for dimethyl fumarate (EMEA-001721-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-22T13:00:00Z","last_updated_date":"2015-12-22T13:00:00Z","reference_number":"EMA/690847/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2015-ema-decision-26-november-2015-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-dimethyl-fumarate-emea-001721-pip01-14_en.pdf"},
    {"id":"34178","name":"P/0169/2014: EMA decision of 7 July 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dupilumab (EMEA-001501-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-31T12:00:00Z","last_updated_date":"2014-07-31T12:00:00Z","reference_number":"EMA/393176/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2014-ema-decision-7-july-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dupilumab-emea-001501-pip01-13_en.pdf"},
    {"id":"34186","name":"P/99/2010: European Medicines Agency decision of 4 June 2010 on the  agreement of a paediatric investigation plan and on the granting of a waiver for anagrelide hydrochloride monohydrate, Xagrid (EMEA-000720-PIP01-09) in...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-21T02:00:00Z","last_updated_date":"2010-07-21T02:00:00Z","reference_number":"EMA/282473/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-99-2010-european-medicines-agency-decision-4-june-2010-agreement-paediatric-investigation-plan-granting-waiver-anagrelide-hydrochloride-monohydrate-xagrid-emea-000720-pip01-09_en.pdf"},
    {"id":"34213","name":"P/0306/2013: EMA decision of 5 December 2013 on the acceptance of a modification of an agreed paedia tric investigation plan for asfotase alfa (EMEA-000987-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-17T11:00:00Z","last_updated_date":"2014-01-17T11:00:00Z","reference_number":"EMA/724392/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2013-ema-decision-5-december-2013-acceptance-modification-agreed-paedia-tric-investigation-plan-asfotase-alfa-emea-000987-pip01-10-m01_en.pdf"},
    {"id":"34214","name":"P/113/2012: EMA decision of 29 June 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ozenoxacin (EMEA-000981-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-23T17:00:00Z","last_updated_date":"2012-07-23T17:00:00Z","reference_number":"EMA/332304/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-113-2012-ema-decision-29-june-2012-acceptance-modification-agreed-paediatric-investigation-plan-ozenoxacin-emea-000981-pip01-10-m02_en.pdf"},
    {"id":"34219","name":"P/0158/2013: EMA decision of 5 July 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for glycopyrronium (bromide) (EMEA-001366-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-13T17:30:00Z","last_updated_date":"2013-08-13T17:30:00Z","reference_number":"EMA/332557/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2013-ema-decision-5-july-2013-agreement-paediatric-investigation-plan-granting-waiver-glycopyrronium-bromide-emea-001366-pip01-12_en.pdf"},
    {"id":"34221","name":"P/169/2011: EMA decision of 8 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon alfa-2a\n\n(Pegasys) (EMEA-000298-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/485145/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-169-2011-ema-decision-8-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-peginterferon-alfa-2a-pegasys-emea-000298-pip01-08-m01_en.pdf"},
    {"id":"34239","name":"P/0133/2013: EMA decision of 7 June 2013 on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir (phosphate) (Tamiflu), (EMEA-000365-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T12:00:00Z","last_updated_date":"2013-07-23T12:00:00Z","reference_number":"EMA/309066/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2013-ema-decision-7-june-2013-acceptance-modification-agreed-paediatric-investigation-plan-oseltamivir-phosphate-tamiflu-emea-000365-pip01-08-m05_en.pdf"},
    {"id":"34243","name":"P/0365/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for naltrexone\n\n(hydrochloride) / bupropion (hydrochloride) (Mysimba) (EMEA-001373-PIP01-12-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T11:48:00Z","last_updated_date":"2018-03-02T11:48:00Z","reference_number":"EMA/762883/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0365-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-naltrexone-hydrochloride-bupropion-hydrochloride-mysimba-emea-001373-pip01-12-m03_en.pdf"},
    {"id":"34253","name":"P/111/2011: EMA decision of 6 May 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for autologous cartilage derived cultured chondrocytes (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-09T02:00:00Z","last_updated_date":"2011-06-09T02:00:00Z","reference_number":"EMA/249498/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-111-2011-ema-decision-6-may-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-cartilage-derived-cultured-chondrocytes-emea-0_en.pdf"},
    {"id":"34259","name":"P/147/2011: EMA decision of 9 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chemically modified extract of grass pollen from Holcus la...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/430655/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-147-2011-ema-decision-9-june-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chemically-modified-extract-grass-pollen-holcus-la_en.pdf"},
    {"id":"34291","name":"P/47/2011: EMA decision of 4 March 2011 on the acceptance of a modification of an agreed paediatric investigation plan for purified antigen\n\nfractions of inactivated split virion Influenza A/Indonesia/05/2005 (H5N1) /pur...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-06-10T02:00:00Z","last_updated_date":"2011-04-05T02:00:00Z","reference_number":"EMA/78783/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-47-2011-ema-decision-4-march-2011-acceptance-modification-agreed-paediatric-investigation-plan-purified-antigen-fractions-inactivated-split-virion-influenza-indonesia-05-2005-h5n1-pur_en.pdf"},
    {"id":"34298","name":"P/0011/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for secukinumab (EMEA-000380-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/792644/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-secukinumab-emea-000380-pip01-08-m02_en.pdf"},
    {"id":"34310","name":"P/0092/2012: EMA decision of 29 May 2012 on the granting of a product specific waiver for nifedipine / candesartan (cilexetil), (EMEA-001252-\n\nPIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T18:00:00Z","last_updated_date":"2012-06-25T18:00:00Z","reference_number":"EMA/273012/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2012-ema-decision-29-may-2012-granting-product-specific-waiver-nifedipine-candesartan-cilexetil-emea-001252-pip01-11_en.pdf"},
    {"id":"34319","name":"P/0287/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron\n\n(Betmiga), (EMEA-000597-PIP02-10-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T11:00:00Z","last_updated_date":"2017-01-23T11:00:00Z","reference_number":"EMA/666526/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip02-10-m05_en.pdf"},
    {"id":"34326","name":"P/0028/2015: EMA decision of 30 January 2015 on the granting of a product specific waiver for amlodipine / perindopril (erbumine) (EMEA-001669-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/793014/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2015-ema-decision-30-january-2015-granting-product-specific-waiver-amlodipine-perindopril-erbumine-emea-001669-pip01-14_en.pdf"},
    {"id":"34337","name":"P/0124/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Votubia) (EMEA-000019-PIP08-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/199536/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-votubia-emea-000019-pip08-12-m02_en.pdf"},
    {"id":"34345","name":"P/0388/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for eluxadoline\n\n(Truberzi) (EMEA-001579-PIP01-13-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T13:05:00Z","last_updated_date":"2018-03-07T13:05:00Z","reference_number":"EMA/801077/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0388-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-eluxadoline-truberzi-emea-001579-pip01-13-m02_en.pdf"},
    {"id":"34361","name":"P/0191/2016: EMA decision of of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine\n\n(Valdoxan, Thymanax), (EMEA-001181-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:15:00Z","last_updated_date":"2016-09-22T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-agomelatine-valdoxan-thymanax-emea-001181-pip01-11-m03_en.pdf"},
    {"id":"34399","name":"P/0318/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names / Yantil and associated names / Tap...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T16:26:00Z","last_updated_date":"2018-02-13T16:26:00Z","reference_number":"EMA/679180/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tap_en.pdf"},
    {"id":"34421","name":"P/0026/2012: EMA decision of 27 January 2012 on the granting of a product specific waiver for diltiazem (hydrochloride), (EMEA-001223-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/54650/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2012-ema-decision-27-january-2012-granting-product-specific-waiver-diltiazem-hydrochloride-emea-001223-pip01-11_en.pdf"},
    {"id":"34444","name":"P/0247/2016: EMA decision of 13 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for vedolizumab\n\n(Entyvio), (EMEA-000645-PIP01-09-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/513711/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2016-ema-decision-13-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-vedolizumab-entyvio-emea-000645-pip01-09-m04_en.pdf"},
    {"id":"34447","name":"P/0100/2014: EMA decision of 11 April 2014 on the granting of a product-specific waiver for alirocumab (EMEA-001169-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/169085/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2014-ema-decision-11-april-2014-granting-product-specific-waiver-alirocumab-emea-001169-pip02-13_en.pdf"},
    {"id":"34457","name":"P/286/2011: EMA decision of 30 November 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for alemtuzumab (EMEA-001072-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T12:15:00Z","last_updated_date":"2011-12-21T12:15:00Z","reference_number":"EMA/910511/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-286-2011-ema-decision-30-november-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-alemtuzumab-emea-001072-pip01-10_en.pdf-0"},
    {"id":"34460","name":"P/0233/2014: EMA decision of 5 September 2014 on the granting of a product specific waiver for antisense oligonucleotide (30-mer) with nucleotide sequence 5”²-GTAATTGCGGCAAGAAGAATTGTTTCTGTC-3”²(CODA001) (EMEA-001628-PIP0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/469204/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2014-ema-decision-5-september-2014-granting-product-specific-waiver-antisense-oligonucleotide-30-mer-nucleotide-sequence-52-gtaattgcggcaagaagaattgtttctgtc-32coda001-emea-001628-pip0_en.pdf"},
    {"id":"34485","name":"P/165/2010: EMA decision of 31 August 2010 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone furoate / triphenylacetic acid - 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-07T02:00:00Z","last_updated_date":"2010-10-07T02:00:00Z","reference_number":"EMA/533059/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-165-2010-ema-decision-31-august-2010-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-triphenylacetic-acid-4-1r-2-6-2-26-dichlorobenzyloxyethoxy_en.pdf"},
    {"id":"34501","name":"P/124/2009: European Medicines Agency decision of 19 June 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for Colesevelam hydrochloride , Cholestagel (EMEA-000543-PIP01-09) in acc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/363648/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-124-2009-european-medicines-agency-decision-19-june-2009-agreement-paediatric-investigation-plan-granting-waiver-colesevelam-hydrochloride-cholestagel-emea-000543-pip01-09-acc_en.pdf"},
    {"id":"34532","name":"P/66/2008: European medicines agency decision of 15 August 2008 on the application for agreement of a Paediatric Investigation Plan for aciclovir, hydrocortisone, (EMEA-000110-PIP01-07), in accordance with Regulation (EC...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/424163/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-66-2008-european-medicines-agency-decision-15-august-2008-application-agreement-paediatric-investigation-plan-aciclovir-hydrocortisone-emea-000110-pip01-07-accordance-regulation-ec_en.pdf"},
    {"id":"34552","name":"P/0127/2017: EMA decision of 5 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ponatinib (Iclusig),\n\n(EMEA-001186-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/224412/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2017-ema-decision-5-may-2017-acceptance-modification-agreed-paediatric-investigation-plan-ponatinib-iclusig-emea-001186-pip01-11-m01_en.pdf"},
    {"id":"34565","name":"P/290/2011: EMA decision of 2 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for N-[4-(3-amino-1Hindazol-\n\n4 yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea (ABT-869) (EMEA-0003...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/920517/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-290-2011-ema-decision-2-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-n-4-3-amino-1hindazol-4-ylphenyl-n1-2-fluoro-5-methylphenyl-urea-abt-869-emea-0003_en.pdf"}    {"id":"34577","name":"P/135/2011: EMA decision of 10 June 2011 on the acceptance of a modification of an agreed paediatric investigation plan for benzamide, 4-[4-[[2-\n\n(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/398448/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-135-2011-ema-decision-10-june-2011-acceptance-modification-agreed-paediatric-investigation-plan-benzamide-4-4-2-4-chlorophenyl-55-dimethyl-1-cyclohexen-1-ylmethyl-1-piperazinyl-n_en.pdf"},
    {"id":"34586","name":"P/0180/2013: EMA decision of 30 July 2013 on the granting of a product-specific waiver for amlodipine / ramipril (EMEA-001464-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/419109/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2013-ema-decision-30-july-2013-granting-product-specific-waiver-amlodipine-ramipril-emea-001464-pip01-13_en.pdf"},
    {"id":"34599","name":"P/222/2010: European Medicines Agency decision of 29 October 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for birch/alder/hazel pollen extract...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/629246/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-222-2010-european-medicines-agency-decision-29-october-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-birch-alder-hazel-pollen-extract_en.pdf"},
    {"id":"34605","name":"P/0303/2013: EMA decision of 29 November 2013 on the granting of a product specific waiver for metformin hydrochloride / rosuvastatin calcium (EMEA-001508-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/705687/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2013-ema-decision-29-november-2013-granting-product-specific-waiver-metformin-hydrochloride-rosuvastatin-calcium-emea-001508-pip01-13_en.pdf"},
    {"id":"34614","name":"P/0294/2016: EMA decision of 4 November 2016 on the refusal of a modification of an agreed paediatric investigation plan for tolvaptan (Samsca and associated names), (EMEA-001231-PIP02-13-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-20T11:00:00Z","last_updated_date":"2017-01-20T11:00:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2016-ema-decision-4-november-2016-refusal-modification-agreed-paediatric-investigation-plan-tolvaptan-samsca-associated-names-emea-001231-pip02-13-m04_en.pdf"},
    {"id":"34615","name":"P/0222/2016: EMA decision of 12 August 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for Autologous\n\nCD34+ enriched cell fraction that contains CD34+ cells transduced with len...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T02:00:00Z","reference_number":"EMA/472121/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2016-ema-decision-12-august-2016-agreement-paediatric-investigation-plan-granting-deferral-autologous-cd34-enriched-cell-fraction-contains-cd34-cells-transduced-len_en.pdf"},
    {"id":"34623","name":"P/0274/2013: EMA decision of 30 October 2013 on the granting of a product specific waiver for ezetimibe / rosuvastatin (EMEA-001478-PIP01-13)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/587702/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2013-ema-decision-30-october-2013-granting-product-specific-waiver-ezetimibe-rosuvastatin-emea-001478-pip01-13_en.pdf"},
    {"id":"34634","name":"P/274/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for adsorbed modified allergen extract of a mixture of 50...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-10T01:00:00Z","last_updated_date":"2011-01-10T01:00:00Z","reference_number":"EMA/683360/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-274-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-adsorbed-modified-allergen-extract-mixture-50_en.pdf"},
    {"id":"34675","name":"P/0328/2014: EMA decision of 22 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for posaconazole (Noxafil), (EMEA-000468-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-20T01:00:00Z","last_updated_date":"2015-02-20T01:00:00Z","reference_number":"EMA/737895/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0328-2014-ema-decision-22-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-posaconazole-noxafil-emea-000468-pip02-12-m01_en.pdf"},
    {"id":"34697","name":"P/301/2011: EMA decision of 20 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for rupatadine fumarate\n\n(Rupafin and associated names), (EMEA-000582-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/953992/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-301-2011-ema-decision-20-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-rupatadine-fumarate-rupafin-associated-names-emea-000582-pip01-09-m01_en.pdf"},
    {"id":"34699","name":"P/0222/2013: EMA decision of 16 September 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vorapaxar (EMEA-000778-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-14T01:00:00Z","last_updated_date":"2013-11-14T01:00:00Z","reference_number":"EMA/506135/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2013-ema-decision-16-september-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vorapaxar-emea-000778-pip02-12_en.pdf"},
    {"id":"34704","name":"P/0205/2013: EMA decision of 3 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for alipogene tiparvovec (Glybera), (EMEA-000292-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/515517/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2013-ema-decision-3-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-alipogene-tiparvovec-glybera-emea-000292-pip01-08-m01_en.pdf"},
    {"id":"34751","name":"P/328/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of rye pollen (EMEA-000957-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769511/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-328-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-rye-pollen-emea-000957_en.pdf"},
    {"id":"34753","name":"P/175/2009: N-Acetyl-L-Cysteine (corresponds to L-Cysteine), L-Alanine, L-Alanyl-L-Glutamine (corresponds to to L-Alanine and L-Glutamine), L-Arginine, Glycine, Glycyl-L-Tyrosine (corresponds to Glycine and L-Tyrosine), ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/551360/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-175-2009-n-acetyl-l-cysteine-corresponds-l-cysteine-l-alanine-l-alanyl-l-glutamine-corresponds-l-alanine-l-glutamine-l-arginine-glycine-glycyl-l-tyrosine-corresponds-glycine-l-tyrosine_en.pdf"},
    {"id":"34755","name":"P/0192/2015: EMA decision of 4 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil fumarate) (Viread) (EMEA-000533-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/530860/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2015-ema-decision-4-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-fumarate-viread-emea-000533-pip01-08-m06_en.pdf"},
    {"id":"34767","name":"P/0070/2013: EMA decision of 26 March 2013 on the granting of a product-specific waiver for hexaminolevulinate (Hexvix), (EMEA-001245-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/114799/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2013-ema-decision-26-march-2013-granting-product-specific-waiver-hexaminolevulinate-hexvix-emea-001245-pip01-11_en.pdf"},
    {"id":"34774","name":"P/0057/2015: EMA decision of 1 April 2015 on the agreement of a paediatric investigation plan and on the granting of a waiver for canakinumab (Ilaris), (EMEA-000060-PIP04-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-07T02:00:00Z","last_updated_date":"2015-05-07T02:00:00Z","reference_number":"EMA/153837/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2015-ema-decision-1-april-2015-agreement-paediatric-investigation-plan-granting-waiver-canakinumab-ilaris-emea-000060-pip04-14_en.pdf"},
    {"id":"34808","name":"P/0166/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla), (EMEA-000715-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/507291/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip02-11-m02_en.pdf"},
    {"id":"34809","name":"P/0150/2013: EMA decision of 3 July 2013 on the granting of a product-specific waiver for zolpidem tartrate (EMEA-001444-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-13T17:30:00Z","last_updated_date":"2013-08-13T17:30:00Z","reference_number":"EMA/316665/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2013-ema-decision-3-july-2013-granting-product-specific-waiver-zolpidem-tartrate-emea-001444-pip01-13_en.pdf"},
    {"id":"34829","name":"P/0090/2018: EMA decision of 16 March 2018 on the granting of a product- specific waiver for rosuvastatin / ezetimibe (EMEA-002257-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/91878/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2018-ema-decision-16-march-2018-granting-product-specific-waiver-rosuvastatin-ezetimibe-emea-002257-pip01-17_en.pdf"},
    {"id":"34830","name":"P/0167/2012: EMA decision of 26 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for peginterferon lambda-1a (EMEA-001192-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T16:00:00Z","last_updated_date":"2012-08-23T16:00:00Z","reference_number":"EMA/480796/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2012-ema-decision-26-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-peginterferon-lambda-1a-emea-001192-pip01-11_en.pdf"},
    {"id":"34837","name":"P/0285/2012: EMA decision of 23 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for artemether / lumefantrine (Riamet), (EMEA-000777-PIP01-09-M03","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/739152/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2012-ema-decision-23-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-artemether-lumefantrine-riamet-emea-000777-pip01-09-m03_en.pdf"},
    {"id":"34838","name":"P/0319/2013: EMA decision of 19 December 2013 on the granting of a product specific waiver for solifenacin (succinate) / mirabegron (EMEA-001528-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-05T01:00:00Z","last_updated_date":"2014-02-05T01:00:00Z","reference_number":"EMA/693823/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0319-2013-ema-decision-19-december-2013-granting-product-specific-waiver-solifenacin-succinate-mirabegron-emea-001528-pip01-13_en.pdf"},
    {"id":"34847","name":"P/64/2010: European Medicines Agency decision on the acceptance of a modification of an agreed paediatric investigation plan for iron, aqua carbonate hydroxy oxo starch sucrose complex (EMEA-000100-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/273229/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-64-2010-european-medicines-agency-decision-acceptance-modification-agreed-paediatric-investigation-plan-iron-aqua-carbonate-hydroxy-oxo-starch-sucrose-complex-emea-000100-pip01-07-m01_en.pdf"},
    {"id":"34885","name":"Meningococcal group A oligosaccharide Conjugated to Corynebacterium diphteriae CRM197 protein (MenA-CRM), group C oligosaccharide Conjugated to Corynebacterium diphteriae CRM197 protein (MenC-CRM), group W-135 oligosacch...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/241589/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/meningococcal-group-oligosaccharide-conjugated-corynebacterium-diphteriae-crm197-protein-mena-crm-group-c-oligosaccharide-conjugated-corynebacterium-diphteriae-crm197-protein-menc-crm-group-w-135_en.pdf"},
    {"id":"34906","name":"P/0074/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for binimetinib (EMEA-\n\n001454-PIP03-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/91844/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-binimetinib-emea-001454-pip03-15-m01_en.pdf"},
    {"id":"34914","name":"P/134/2011: EMA decision of 8 June 2011 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (phosphate monohydrate) (Januvia), (EMEA-000470-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-13T02:00:00Z","last_updated_date":"2011-07-13T02:00:00Z","reference_number":"EMA/356070/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-134-2011-ema-decision-8-june-2011-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-phosphate-monohydrate-januvia-emea-000470-pip01-08-m04_en.pdf"},
    {"id":"34928","name":"P/2/2011: EMA decision of 3 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for imatinib mesilate (Glivec) (EMA-000463-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-08T00:09:00Z","last_updated_date":"2011-02-08T00:09:00Z","reference_number":"EMA/729874/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-2-2011-ema-decision-3-january-2011-acceptance-modification-agreed-paediatric-investigation-plan-imatinib-mesilate-glivec-ema-000463-pip01-08-m01_en.pdf"},
    {"id":"34931","name":"P/0269/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for alirocumab\n\n(Praluent), (EMEA-001169-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-25T17:00:00Z","last_updated_date":"2017-10-25T17:00:00Z","reference_number":"EMA/565805/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-alirocumab-praluent-emea-001169-pip01-11-m03_en.pdf"},
    {"id":"34936","name":"P/0109/2015: EMA decision of 1 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant single-chain coagulation factor VIII (EMEA-001215-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/296250/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2015-ema-decision-1-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-single-chain-coagulation-factor-viii-emea-001215-pip01-11-m03_en.pdf"},
    {"id":"34939","name":"P/249/2009: EMA decision of 14 December 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for benzamide, 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cycl...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMEA/790471/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-249-2009-ema-decision-14-december-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-benzamide-4-4-2-4-chlorophenyl-55-dimethyl-1-cycl_en.pdf"},
    {"id":"34949","name":"P/0205/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for canagliflozin\n\n(Invokana) (EMEA-001030-PIP01-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/466842/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-canagliflozin-invokana-emea-001030-pip01-10-m07_en.pdf"},
    {"id":"34953","name":"P/139/2009: European Medicines Agency decision of 15 July 2009 on the granting of a product specific waiver for Clostridium collagenase, EMEA-000508-PIP01-08 in accordance with Regulation (EC) No 1901/2006 of the Europea...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-09-16T02:00:00Z","last_updated_date":"2009-09-16T02:00:00Z","reference_number":"EMEA/415970/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-139-2009-european-medicines-agency-decision-15-july-2009-granting-product-specific-waiver-clostridium-collagenase-emea-000508-pip01-08-accordance-regulation-ec-no-1901-2006-europea_en.pdf"},
    {"id":"34959","name":"P/279/2011: EMA decision of 28 November 2011 on the acceptance of a modification of an agreed paediatric investigation plan for lanthanum carbonate hydrate (Fosrenol and associated names), (EMEA-000637-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T01:00:00Z","last_updated_date":"2011-12-20T01:00:00Z","reference_number":"EMA/878696/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-279-2011-ema-decision-28-november-2011-acceptance-modification-agreed-paediatric-investigation-plan-lanthanum-carbonate-hydrate-fosrenol-associated-names-emea-000637-pip02-10-m01_en.pdf"},
    {"id":"34970","name":"P/0144/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dimethyl fumarate (Tecfidera), (EMEA-000832-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/405166/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-dimethyl-fumarate-tecfidera-emea-000832-pip01-10-m02_en.pdf"},
    {"id":"34981","name":"P/171/2011: EMA decision of 8 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for rivaroxaban,\n\n(Xarelto) (EMEA-000430-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/490576/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-171-2011-ema-decision-8-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-rivaroxaban-xarelto-emea-000430-pip01-08-m02_en.pdf"},
    {"id":"34987","name":"P/180/2011: EMA decision of 28 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil\n\nfumarate) (Viread), (EMEA-000533-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/430497/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-180-2011-ema-decision-28-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-fumarate-viread-emea-000533-pip01-08-m02_en.pdf"},
    {"id":"34998","name":"P/0136/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for drospirenone (EMEA-001495-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T02:00:00Z","last_updated_date":"2016-07-27T02:00:00Z","reference_number":"EMA/265305/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-drospirenone-emea-001495-pip01-13-m01_en.pdf"},
    {"id":"35001","name":"P/0272/2014: EMA decision of 27 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-04T01:00:00Z","last_updated_date":"2014-12-04T01:00:00Z","reference_number":"EMA/624621/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2014-ema-decision-27-october-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-3s11ar-n-24-difluorophenylmethyl-6-hydroxy-3_en.pdf"},
    {"id":"35013","name":"P/0252/2014: EMA decision of 30 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for potassium citrate monohydrated / potassium hydrogen...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/528123/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2014-ema-decision-30-september-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-potassium-citrate-monohydrated-potassium-hydrogen_en.pdf"},
    {"id":"35022","name":"P/0119/2016: EMA decision of 28 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for solithromycin (EMEA-001581-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/249385/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2016-ema-decision-28-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-solithromycin-emea-001581-pip01-13-m02_en.pdf"},
    {"id":"35065","name":"P/0245/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for teduglutide, (Revestive) (EMEA-000482-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/627034/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-teduglutide-revestive-emea-000482-pip01-08-m03_en.pdf"},
    {"id":"35076","name":"P/14/2010: European Medicines Agency decision of 4 February 2010 on the acceptance of a modification of an agreed Paediatric Investigation Plan for denosumab (EMEA-000145-PIP01-07-M02) in accordance with Regulation (EC) ...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMA/59551/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-14-2010-european-medicines-agency-decision-4-february-2010-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-emea-000145-pip01-07-m02-accordance-regulation-ec_en.pdf"},
    {"id":"35083","name":"P/0099/2015: EMA decision of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sofosbuvir/a derivative of (S)-methyl (2-(2-(1H-imidazol-2...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/215118/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2015-ema-decision-8-may-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sofosbuvir-derivative-s-methyl-2-2-1h-imidazol-2_en.pdf"},
    {"id":"35091","name":"P/0236/2013: EMA decision of 24 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for teduglutide (Revestive), (EMEA-000482-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/564670/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2013-ema-decision-24-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-teduglutide-revestive-emea-000482-pip01-08-m01_en.pdf"},
    {"id":"35108","name":"P/214/2009: European Medicines Agency decision of 30 October 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for bromocriptine mesilate (EMEA-000...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/686891/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-214-2009-european-medicines-agency-decision-30-october-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bromocriptine-mesilate-emea-000_en.pdf"},
    {"id":"35124","name":"P/0182/2014: EMA decision of 17 July 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for daclatasvir (EMEA-001485-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/414575/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2014-ema-decision-17-july-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-daclatasvir-emea-001485-pip01-13_en.pdf"},
    {"id":"35143","name":"P/0300/2012: EMA decision of 20 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor (Kalydeco), (EMEA-000335-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/755963/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2012-ema-decision-20-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-kalydeco-emea-000335-pip01-08-m07_en.pdf"},
    {"id":"35153","name":"P/0125/2013: EMA decision of 28 May 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for lenvatinib (EMEA-001119-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-24T13:30:00Z","last_updated_date":"2013-06-24T13:30:00Z","reference_number":"EMA/301820/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2013-ema-decision-28-may-2013-agreement-paediatric-investigation-plan-granting-deferral-lenvatinib-emea-001119-pip02-12_en.pdf"},
    {"id":"35226","name":"P/0133/2015: EMA decision of 12 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (Translarna), (EMEA-000115-PIP02-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-07T02:00:00Z","last_updated_date":"2015-07-07T02:00:00Z","reference_number":"EMA/368499/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2015-ema-decision-12-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-translarna-emea-000115-pip02-09-m02_en.pdf"},
    {"id":"35227","name":"P/0073/2013: EMA decision of 26 March 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for gabapentin (EMEA-001310-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/113704/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2013-ema-decision-26-march-2013-agreement-paediatric-investigation-plan-granting-waiver-gabapentin-emea-001310-pip01-12_en.pdf"},
    {"id":"35231","name":"P/84/2009: European medicines agency decision of 18 May 2009 on the granting of a product specific waiver for bromfenac sodium sesquihydrate (EMEA-000269-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/289744/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-84-2009-european-medicines-agency-decision-18-may-2009-granting-product-specific-waiver-bromfenac-sodium-sesquihydrate-emea-000269-pip01-08-accordance-regulation-ec-no-1901-2006-e_en.pdf"},
    {"id":"35233","name":"P/0153/2012: EMA decision of 25 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for purified antigen fractions of inactivated split virion influenza A/Indonesia/5/05/ (H5N1) (Puma...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-21T17:00:00Z","last_updated_date":"2012-08-21T17:00:00Z","reference_number":"EMA/478120/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2012-ema-decision-25-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-purified-antigen-fractions-inactivated-split-virion-influenza-indonesia-5-05-h5n1-puma_en.pdf"},
    {"id":"35254","name":"P/0286/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for human normal\n\nimmunoglobulin (NAXIGLO and associated names), (EMEA-000454-PIP01-08-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T11:00:00Z","last_updated_date":"2017-01-23T11:00:00Z","reference_number":"EMA/639654/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-naxiglo-associated-names-emea-000454-pip01-08-m07_en.pdf"},
    {"id":"35271","name":"P/0111/2017: EMA decision of 11 April 2017 on the granting of a product specific waiver for prasugrel (hydrochloride) / acetylsalicylic acid (EMEA-\n\n002071-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/176757/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2017-ema-decision-11-april-2017-granting-product-specific-waiver-prasugrel-hydrochloride-acetylsalicylic-acid-emea-002071-pip01-16_en.pdf"},
    {"id":"35280","name":"P/0253/2013: EMA decision of 29 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for plerixafor (Mozobil) (EMEA-000174-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/599869/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2013-ema-decision-29-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-plerixafor-mozobil-emea-000174-pip01-07-m03_en.pdf"},
    {"id":"35288","name":"P/0382/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sildenafil (Revatio),\n\n(EMEA-000671-PIP01-09-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/759117/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0382-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-sildenafil-revatio-emea-000671-pip01-09-m09_en.pdf"},
    {"id":"35292","name":"P/0127/2013: EMA decision of 28 May 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-proprotein-convertase-subtilisin/kexin-type-9 human ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-24T13:30:00Z","last_updated_date":"2013-06-24T13:30:00Z","reference_number":"EMA/249758/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2013-ema-decision-28-may-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-proprotein-convertase-subtilisin-kexin-type-9-human_en.pdf"},
    {"id":"35293","name":"P/0277/2017: EMA decision of 4 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for ceftolozane /\n\ntazobactam (Zerbaxa) (EMEA-001142-PIP02-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T13:11:00Z","last_updated_date":"2018-02-12T13:11:00Z","reference_number":"EMA/671458/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2017-ema-decision-4-october-2017-agreement-paediatric-investigation-plan-granting-deferral-ceftolozane-tazobactam-zerbaxa-emea-001142-pip02-16_en.pdf"},
    {"id":"35303","name":"P/69/2008: European medicines agency decision of 11 August 2008\n\non the application for agreement of a Paediatric Investigation Plan for eplivanserin hemifumarate (EMEA-000114-PIP01-07) in accordance with Regulation (EC)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/416570/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-69-2008-european-medicines-agency-decision-11-august-2008-application-agreement-paediatric-investigation-plan-eplivanserin-hemifumarate-emea-000114-pip01-07-accordance-regulation-ec_en.pdf"},
    {"id":"35322","name":"P/0312/2016: EMA decision of 11 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for naldemedine (tosylate) (EMEA-001893-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-10T01:00:00Z","last_updated_date":"2017-01-10T01:00:00Z","reference_number":"EMA/724892/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2016-ema-decision-11-november-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-naldemedine-tosylate-emea-001893-pip01-15_en.pdf"},
    {"id":"35328","name":"P/0265/2017: EMA decision of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of\n\na waiver for fluticasone (propionate) (EMEA-002140-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/507361/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2017-ema-decision-4-september-2017-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-fluticasone-propionate-emea-002140-pip01-17_en.pdf"},
    {"id":"35334","name":"P/0251/2017: EMA decision of 8 September 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for fenfluramine (hydrochloride) (EMEA-001990-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/503514/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2017-ema-decision-8-september-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fenfluramine-hydrochloride-emea-001990-pip01-16_en.pdf"},
    {"id":"35351","name":"P/0157/2016: EMA decision of 15 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for clostridium botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocoutur...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/314183/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2016-ema-decision-15-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-clostridium-botulinum-neurotoxin-type-150-kd-free-complexing-proteins-xeomin-bocoutur_en.pdf"},
    {"id":"35377","name":"P/138/2011: EMA decision of 10 June 2011 on the granting of a product specific waiver for canagliflozin / metformin (EMEA-001111-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/356048/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-138-2011-ema-decision-10-june-2011-granting-product-specific-waiver-canagliflozin-metformin-emea-001111-pip01-10_en.pdf"},
    {"id":"35386","name":"P/224/2009: European Medicines Agency Decision of 4 November 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for ambrisentan (Volibris) (EMEA-000...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:09:21Z","last_updated_date":"2009-12-23T00:09:21Z","reference_number":"EMEA/683683/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-224-2009-european-medicines-agency-decision-4-november-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ambrisentan-volibris-emea-000_en.pdf"},
    {"id":"35387","name":"P/265/2011: EMA decision of 28 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy)\n\n(EMEA-000117-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T16:00:00Z","last_updated_date":"2011-11-30T16:00:00Z","reference_number":"EMA/849026/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-265-2011-ema-decision-28-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-yervoy-emea-000117-pip02-10-m01_en.pdf"},
    {"id":"35405","name":"P/197/2011: EMA decision of 30 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for golimumab (Simponi)\n\n(EMEA-000265-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/589434/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-197-2011-ema-decision-30-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-golimumab-simponi-emea-000265-pip01-08-m02_en.pdf"},
    {"id":"35420","name":"P/0062/2014: EMA decision of 7 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir (phosphate ) (Tamiflu) (EMEA-000365-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/122026/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2014-ema-decision-7-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-oseltamivir-phosphate-tamiflu-emea-000365-pip01-08-m06_en.pdf"},
    {"id":"35446","name":"P/0111/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol\n\n(hydrochloride) (Palexia and associated names, Yantil and associated names, Tapent...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-24T02:00:00Z","reference_number":"EMA/141780/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tapent_en.pdf"},
    {"id":"35471","name":"P/0044/2016: EMA decision of 26 February 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia and associated names, Yantil and associated names and T...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/133035/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2016-ema-decision-26-february-2016-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-t_en.pdf"},
    {"id":"35499","name":"P/0327/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for loxapine (Adasuve),\n\n(EMEA-001115-PIP01-10-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T11:35:00Z","last_updated_date":"2017-02-03T11:35:00Z","reference_number":"EMA/756856/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0327-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-loxapine-adasuve-emea-001115-pip01-10-m05_en.pdf"},
    {"id":"35504","name":"P/0046/2012: EMA decision of 29 February 2012 on the acceptance of a modification of an agreed paediatric investigation plan for beclometasone dipropionate / formoterol fumarate dihydrate (Foster and associated names, Ka...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/96884/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2012-ema-decision-29-february-2012-acceptance-modification-agreed-paediatric-investigation-plan-beclometasone-dipropionate-formoterol-fumarate-dihydrate-foster-associated-names-ka_en.pdf"},
    {"id":"35515","name":"P/100/2009: European Medicines Agency decision of 19 May 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for abatacept (ORENCIA) (EMEA-000118-PIP01-07-M01) in accordance with Regulatio...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/290591/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-100-2009-european-medicines-agency-decision-19-may-2009-acceptance-modification-agreed-paediatric-investigation-plan-abatacept-orencia-emea-000118-pip01-07-m01-accordance-regulatio_en.pdf"},
    {"id":"35516","name":"P/0317/2016: EMA decision of 5 December 2016\n\non the acceptance of a modification of an agreed paediatric investigation plan for ceftobiprole medocaril (sodium) (Zevtera and associated names), (EMEA-000205-PIP02-11-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T09:55:00Z","last_updated_date":"2017-01-30T09:55:00Z","reference_number":"EMA/757936/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2016-ema-decision-5-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-ceftobiprole-medocaril-sodium-zevtera-associated-names-emea-000205-pip02-11-m02_en.pdf"},
    {"id":"35525","name":"P/0148/2012: EMA decision of 24 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of birch...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/471481/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2012-ema-decision-24-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergen-extract-birch_en.pdf"},
    {"id":"35576","name":"P/0053/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for tasimelteon (Hetlioz), (EMEA-001531-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/133054/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-tasimelteon-hetlioz-emea-001531-pip01-13-m02_en.pdf"},
    {"id":"35588","name":"P/0292/2015: EMA decision of 27 November 2015 on the granting of a product specific waiver for (R)-N-({5-[3-(2,5-Difluorophenyl)-2-(2,3-dihydro-1H-benzimidazol-2-ylidene)-3- oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydro...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/509834/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2015-ema-decision-27-november-2015-granting-product-specific-waiver-r-n-5-3-25-difluorophenyl-2-23-dihydro-1h-benzimidazol-2-ylidene-3-oxopropanoyl-2-fluorophenylsulfonyl-2-hydro_en.pdf"},
    {"id":"35598","name":"P/160/2009:  European Medicines Agency decision of 11 August 2009 on the granting of a product specific waiver for testosterone (Intrinsa) (EMEA-000571-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the Eur...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/420697/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-160-2009-european-medicines-agency-decision-11-august-2009-granting-product-specific-waiver-testosterone-intrinsa-emea-000571-pip01-09-accordance-regulation-ec-no-1901-2006-eur_en.pdf"},
    {"id":"35683","name":"P/0099/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for trifarotene\n\n(EMEA-001492-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/202411/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-trifarotene-emea-001492-pip01-13-m01_en.pdf"},
    {"id":"35699","name":"P/76/2011: EMA decision of 5 April 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dimethyl fumarate (EMEA-000832-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"EMA/247744/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-76-2011-ema-decision-5-april-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dimethyl-fumarate-emea-000832-pip01-10_en.pdf"},
    {"id":"35708","name":"P/0119/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen (EMEA-001208-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/284173/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-emea-001208-pip01-11-m02_en.pdf"},
    {"id":"35742","name":"P/0096/2018: EMA decision of 16 March 2018 on the granting of a product- specific waiver for levothyroxine (sodium) (EMEA-002259-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/91880/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2018-ema-decision-16-march-2018-granting-product-specific-waiver-levothyroxine-sodium-emea-002259-pip01-17_en.pdf"},
    {"id":"35772","name":"P/0330/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for eribulin (Halaven),\n\n(EMEA-001261-PIP01-11-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T12:18:00Z","last_updated_date":"2017-02-03T12:18:00Z","reference_number":"EMA/756864/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0330-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-eribulin-halaven-emea-001261-pip01-11-m03_en.pdf"},
    {"id":"35779","name":"P/0304/2012: EMA decision of 20 December 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for outer membrane vesicles (EMEA-001260-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T11:00:00Z","last_updated_date":"2013-02-11T11:00:00Z","reference_number":"EMA/804585/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2012-ema-decision-20-december-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-outer-membrane-vesicles-emea-001260-pip01-11_en.pdf"},
    {"id":"35794","name":"P/190/2009: European Medicines Agency decision of 22 September 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for clopidogrel (Clopidogrel BMS) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/583696/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-190-2009-european-medicines-agency-decision-22-september-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-clopidogrel-clopidogrel-bms_en.pdf"},
    {"id":"35798","name":"P/0065/2013: European medicines agency decision of 26 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for bimatoprost (Lumigan, Latisse), (EMEA-000917-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/85742/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2013-european-medicines-agency-decision-26-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-bimatoprost-lumigan-latisse-emea-000917-pip01-10-m02_en.pdf"},
    {"id":"35799","name":"P/183/2009: European Medicines Agency decision of 7 September 2009 on the granting of a product specific waiver for ranibizumab (Lucentis), (EMEA-000527-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the Eu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/516566/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-183-2009-european-medicines-agency-decision-7-september-2009-granting-product-specific-waiver-ranibizumab-lucentis-emea-000527-pip01-08-accordance-regulation-ec-no-1901-2006-eu_en.pdf"},
    {"id":"35821","name":"P/0192/2016: EMA decision of of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (EMEA-\n\n001220-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T16:16:00Z","last_updated_date":"2016-09-22T16:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2016-ema-decision-15-july-2016-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-emea-001220-pip01-11-m01_en.pdf"},
    {"id":"35835","name":"P/153/2011: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (EMEA-000176-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/513790/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-153-2011-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-colistimethate-sodium-emea-000176-pip01-07-m03_en.pdf"},
    {"id":"35850","name":"P/0163/2017: EMA decision of 30 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for pazopanib (Votrient) (EMEA-000601-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/398038/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2017-ema-decision-30-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-pazopanib-votrient-emea-000601-pip01-09-m04_en.pdf"},
    {"id":"35856","name":"P/0062/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/155875/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-januvia-emea-000470-pip01-08-m09_en.pdf"},
    {"id":"35857","name":"P/0345/2017: EMA decision of 23 November 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod (EMEA-\n\n001710-PIP02-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-20T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"EMA/704036/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0345-2017-ema-decision-23-november-2017-acceptance-modification-agreed-paediatric-investigation-plan-ozanimod-emea-001710-pip02-14-m02_en.pdf"},
    {"id":"35907","name":"P/288/2011: EMA decision of 2 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant Lasparaginase (EMEA-000013-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/914967/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-288-2011-ema-decision-2-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-lasparaginase-emea-000013-pip01-07-m02_en.pdf"},
    {"id":"35908","name":"P/0088/2017: EMA decision of 29 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ceftolozane /\n\ntazobactam (Zerbaxa), (EMEA-001142-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/168747/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2017-ema-decision-29-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-ceftolozane-tazobactam-zerbaxa-emea-001142-pip01-11-m02_en.pdf"},
    {"id":"35919","name":"P/0091/2014: EMA decision of 4 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-000558-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/169122/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2014-ema-decision-4-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-000558-pip01-09-m02_en.pdf"},
    {"id":"35926","name":"P/161/2010: EMA decision of 27 August 2010 on the agreement of a paediatric investigation plan and on the granting of a product specific waiver for indapamide / amlodipine besilate (EMEA-000896-\n\nPIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/477270/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-161-2010-ema-decision-27-august-2010-agreement-paediatric-investigation-plan-granting-product-specific-waiver-indapamide-amlodipine-besilate-emea-000896-pip01-10_en.pdf"},
    {"id":"35933","name":"P/201/2009: European Medicines Agency decision of 9 October 2009 on the granting of a product specific waiver for ibuprofen / famotidine (EMEA-000616-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the Europ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:21Z","last_updated_date":"2009-12-07T00:09:21Z","reference_number":"EMEA/617482/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-201-2009-european-medicines-agency-decision-9-october-2009-granting-product-specific-waiver-ibuprofen-famotidine-emea-000616-pip01-09-accordance-regulation-ec-no-1901-2006-europ_en.pdf"},
    {"id":"35943","name":"P/0082/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for durvalumab (EMEA-002028-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/88167/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-durvalumab-emea-002028-pip01-16_en.pdf"},
    {"id":"35957","name":"P/58/2008: European medicines agency decision of 20 July 2008\n\non the application for product specific waiver for amlodipine besylate, valsartan, hydrochlorothiazide (fixed combination), EMEA-000225-PIP01-08, in accordan...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-08T02:00:00Z","last_updated_date":"2008-09-08T02:00:00Z","reference_number":"EMEA/358127/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-58-2008-european-medicines-agency-decision-20-july-2008-application-product-specific-waiver-amlodipine-besylate-valsartan-hydrochlorothiazide-fixed-combination-emea-000225-pip01-08-accordan_en.pdf"}    {"id":"35960","name":"P/0111/2016: EMA decision of 15 April 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for human normal immunoglobulin (EMEA-001853-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/203693/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2016-ema-decision-15-april-2016-agreement-paediatric-investigation-plan-granting-waiver-human-normal-immunoglobulin-emea-001853-pip01-15_en.pdf"},
    {"id":"35989","name":"P/0189/2012: EMA decision of 22 August 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for olokizumab (EMEA-001222-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T02:00:00Z","last_updated_date":"2012-09-18T02:00:00Z","reference_number":"EMA/479559/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2012-ema-decision-22-august-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-olokizumab-emea-001222-pip01-11_en.pdf"},
    {"id":"35990","name":"P/0147/2014: EMA decision of 13 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for daclizumab (EMEA-001349-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-28T02:00:00Z","last_updated_date":"2014-07-28T02:00:00Z","reference_number":"EMA/252128/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2014-ema-decision-13-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-daclizumab-emea-001349-pip01-12-m01_en.pdf"},
    {"id":"35999","name":"P/27/2010: European medicines agency decision of of 5 March 2010 on the acceptance of a modification of an agreed Paediatric Investigation Plan for pramipexole dihydrochloride (monohydrate) (Sifrol) (EMEA-000041-PIP01-07...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMEA/466817/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-27-2010-european-medicines-agency-decision-5-march-2010-acceptance-modification-agreed-paediatric-investigation-plan-pramipexole-dihydrochloride-monohydrate-sifrol-emea-000041-pip01-07_en.pdf"},
    {"id":"36007","name":"P/0261/2012: EMA decision of 19 November 2012 on the granting of a product-specific waiver for N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-\n\nylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide dihydrochlori...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"EMA/679908/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2012-ema-decision-19-november-2012-granting-product-specific-waiver-n-tert-butyl-3-5-methyl-2-4-2-pyrrolidin-1-ylethoxyphenylaminopyrimidin-4-ylaminobenzenesulfonamide-dihydrochlori_en.pdf"},
    {"id":"36013","name":"P/0014/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/10894/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised_en.pdf"},
    {"id":"36020","name":"P/0295/2013: EMA decision of 29 November 2013 on the acceptance of a modification of an agreed paediatric investigation plan for certolizumab pegol (Cimzia) (EMEA-001071-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/708155/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2013-ema-decision-29-november-2013-acceptance-modification-agreed-paediatric-investigation-plan-certolizumab-pegol-cimzia-emea-001071-pip02-12-m01_en.pdf"},
    {"id":"36022","name":"P/82/2010: European Medicines Agency decision of of 30 April 2010\n\non the granting of a product specific waiver for vorinostat (EMEA-000805-PIP01-09) in accordance with\n\nRegulation (EC) No 1901/2006 of the European Parli...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/262857/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-82-2010-european-medicines-agency-decision-30-april-2010-granting-product-specific-waiver-vorinostat-emea-000805-pip01-09-accordance-regulation-ec-no-1901-2006-european-parli_en.pdf"},
    {"id":"36043","name":"P/0173/2016: EMA decision of 17 June 2016 on the granting of a product specific waiver for ciclosporin (EMEA-001916-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/385704/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2016-ema-decision-17-june-2016-granting-product-specific-waiver-ciclosporin-emea-001916-pip01-15_en.pdf"},
    {"id":"36090","name":"P/0297/2016: EMA decision of 4 November 2016\n\non the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the h...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-20T16:17:00Z","last_updated_date":"2017-01-20T16:17:00Z","reference_number":"EMA/669484/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-haematopoietic-stem-cells-transduced-lentiviral-vector-encoding-h_en.pdf"},
    {"id":"36105","name":"P/0256/2012: EMA decision of 26 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for aripiprazole (Abilify), (EMEA-000235-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T01:00:00Z","last_updated_date":"2012-11-23T01:00:00Z","reference_number":"EMA/646932/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2012-ema-decision-26-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-aripiprazole-abilify-emea-000235-pip02-10-m02_en.pdf-0"},
    {"id":"36110","name":"P/0307/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for odanacatib (EMEA-001123-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/761887/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-odanacatib-emea-001123-pip01-11-m03_en.pdf"},
    {"id":"36136","name":"P/0073/2012: EMA decision of 24 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for coagulation factor IX (recombinant) (EMEA-000661-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/250284/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2012-ema-decision-24-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-coagulation-factor-ix-recombinant-emea-000661-pip01-09-m05_en.pdf"},
    {"id":"36152","name":"P/0104/2014: EMA decision of 2 May 2014 on the granting of a product specific waiver for anastrozole / levonorgestrel (EMEA-001575-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/232071/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2014-ema-decision-2-may-2014-granting-product-specific-waiver-anastrozole-levonorgestrel-emea-001575-pip01-13_en.pdf"},
    {"id":"36154","name":"P/0099/2018: EMA decision of 15 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for abatacept (Orencia), (EMEA-000118-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/141028/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2018-ema-decision-15-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-abatacept-orencia-emea-000118-pip02-10-m03_en.pdf"},
    {"id":"36177","name":"P/0159/2017: EMA decision of 30 June 2017 on the granting of a product specific waiver for ibuprofen / pseudoephedrine (EMEA-002102-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/398292/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2017-ema-decision-30-june-2017-granting-product-specific-waiver-ibuprofen-pseudoephedrine-emea-002102-pip01-16_en.pdf"},
    {"id":"36183","name":"P/172/2010: European Medicines Agency decision of 10 September 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mirabegron, EMEA-000597-PIP02-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/559076/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-172-2010-european-medicines-agency-decision-10-september-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mirabegron-emea-000597-pip02_en.pdf"},
    {"id":"36185","name":"P/0022/2017: EMA decision of 30 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for nanobody directed towards the fusion protein of human respiratory syncytial virus (ALX-0171)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/2923/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2017-ema-decision-30-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-nanobody-directed-towards-fusion-protein-human-respiratory-syncytial-virus-alx-0171_en.pdf"},
    {"id":"36191","name":"P/0039/2018: EMA decision of 16 February 2018 on the granting of a product specific waiver for rosuvastatin (calcium) / acetylsalicylic acid (EMEA-\n\n002239-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/850787/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2018-ema-decision-16-february-2018-granting-product-specific-waiver-rosuvastatin-calcium-acetylsalicylic-acid-emea-002239-pip01-17_en.pdf"},
    {"id":"36200","name":"P/0023/2015: EMA decision of 30 January 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for elbasvir (EMEA-001603-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/779784/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2015-ema-decision-30-january-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-elbasvir-emea-001603-pip01-13_en.pdf"},
    {"id":"36204","name":"P/0061/2012: EMA decision of 28 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ezetimibe (Ezetrol\n\nand associated names), (EMEA-000007-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T17:42:00Z","last_updated_date":"2012-04-20T17:42:00Z","reference_number":"EMA/182693/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2012-ema-decision-28-march-2012-acceptance-modification-agreed-paediatric-investigation-plan-ezetimibe-ezetrol-associated-names-emea-000007-pip01-07-m02_en.pdf"},
    {"id":"36223","name":"P/0247/2014: EMA decision of 30 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for secukinumab (EMEA-000380-PIP02-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/509571/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2014-ema-decision-30-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-secukinumab-emea-000380-pip02-09-m02_en.pdf"},
    {"id":"36230","name":"P/0079/2013: EMA decision of 27 March 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for vancomycin (EMEA-001311-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-04T02:00:00Z","last_updated_date":"2013-10-04T02:00:00Z","reference_number":"EMA/113893/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2013-ema-decision-27-march-2013-agreement-paediatric-investigation-plan-granting-waiver-vancomycin-emea-001311-pip01-12_en.pdf"},
    {"id":"36233","name":"P/0299/2017: EMA decision of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for liposomal\n\ncombination of cytarabine and daunorubicin (EMEA-001858-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-20T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"EMA/635150/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2017-ema-decision-4-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-liposomal-combination-cytarabine-daunorubicin-emea-001858-pip02-16-m01_en.pdf"},
    {"id":"36239","name":"P/0016/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (EMEA-000727-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/3693/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan-bosutinib-emea-000727-pip01-09-m01_en.pdf"},
    {"id":"36252","name":"P/0096/2012: EMA decision of 30 May 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarb...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T18:00:00Z","last_updated_date":"2012-06-25T18:00:00Z","reference_number":"EMA/273210/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2012-ema-decision-30-may-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-trisodium-3-1s3r-1-biphenyl-4-ylmethyl-3-ethoxycarb_en.pdf"},
    {"id":"36253","name":"P/0130/2014: EMA decision of 10 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon alfa-2a (Pegasys), (EMEA-000298-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/319524/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2014-ema-decision-10-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-peginterferon-alfa-2a-pegasys-emea-000298-pip01-08-m04_en.pdf"},
    {"id":"36264","name":"P/0010/2012: EMA decision of 24 January 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for elvitegravir\n\n(EMEA-000968-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/7469/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2012-ema-decision-24-january-2012-agreement-paediatric-investigation-plan-granting-deferral-elvitegravir-emea-000968-pip02-11_en.pdf"},
    {"id":"36267","name":"P/0177/2014: EMA decision of 7 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tobramycin (Tobi Podhaler), (EMEA-000184-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/391612/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2014-ema-decision-7-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-tobramycin-tobi-podhaler-emea-000184-pip01-08-m02_en.pdf"},
    {"id":"36277","name":"P/0270/2012: EMA decision of 20 November 2012 on the granting of a product-specific waiver for amlodipine (besylate) / valsartan (EMEA-001343-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/646965/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2012-ema-decision-20-november-2012-granting-product-specific-waiver-amlodipine-besylate-valsartan-emea-001343-pip01-12_en.pdf"},
    {"id":"36291","name":"P/0195/2016: EMA decision of 15 July 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for indacaterol (acetate) / glycopyrronium (bromide) / momet...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T02:00:00Z","last_updated_date":"2016-09-22T02:00:00Z","reference_number":"EMA/399748/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2016-ema-decision-15-july-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-indacaterol-acetate-glycopyrronium-bromide-momet_en.pdf"},
    {"id":"36299","name":"P/0132/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for testosterone (EMEA-001529-PIP02-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-24T02:00:00Z","last_updated_date":"2018-07-25T15:20:00Z","reference_number":"EMA/221403/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-testosterone-emea-001529-pip02-14-m01_en.pdf"},
    {"id":"36303","name":"P/93/2010: European Medicines Agency decision of 2 June 2010 on the granting of a product specific waiver for sitagliptin phosphate monohydrate / metformin hydrochloride (Janumet and associated names) (EMEA-000165-PIP02-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-26T02:00:00Z","last_updated_date":"2010-07-26T02:00:00Z","reference_number":"EMA/337455/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-93-2010-european-medicines-agency-decision-2-june-2010-granting-product-specific-waiver-sitagliptin-phosphate-monohydrate-metformin-hydrochloride-janumet-associated-names-emea-000165-pip02_en.pdf"},
    {"id":"36305","name":"P/0250/2017: EMA decision of 8 September 2017 on the granting of a product specific waiver for human normal immunoglobulin (EMEA-002084-PIP01-\n\n16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/526256/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2017-ema-decision-8-september-2017-granting-product-specific-waiver-human-normal-immunoglobulin-emea-002084-pip01-16_en.pdf"},
    {"id":"36311","name":"P/0239/2017: EMA decision of 11 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab\n\n(Nucala), (EMEA-000069-PIP02-10-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-29T02:00:00Z","last_updated_date":"2017-09-29T02:00:00Z","reference_number":"EMA/491414/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2017-ema-decision-11-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-nucala-emea-000069-pip02-10-m08_en.pdf"},
    {"id":"36314","name":"P/140/2010: European Medicines Agency decision of 30 July 2010 on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation factor VIII/von Willebrand factor (EMEA-000312-PIP01-08-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/465096/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-140-2010-european-medicines-agency-decision-30-july-2010-acceptance-modification-agreed-paediatric-investigation-plan-human-coagulation-factor-viii-von-willebrand-factor-emea-000312-pip01-08_en.pdf"},
    {"id":"36318","name":"P/242/2011: EMA decision of 30 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine\n\n(hydrochloride) (EMEA-000317-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/764020/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-242-2011-ema-decision-30-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-emea-000317-pip01-08-m02_en.pdf"},
    {"id":"36330","name":"P/0250/2012: EMA decision of 24 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tazarotene (EMEA-000510-PIP02-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T01:00:00Z","last_updated_date":"2012-11-23T01:00:00Z","reference_number":"EMA/666117/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2012-ema-decision-24-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-tazarotene-emea-000510-pip02-10-m02_en.pdf"},
    {"id":"36364","name":"P/308/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for treprostinil (Remodulin and associated names) (EMEA-000207-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/693864/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-308-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-treprostinil-remodulin-associated-names-emea-000207-pip01-08-m04_en.pdf"},
    {"id":"36376","name":"P/0321/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (EMEA-\n\n000782-PIP01-09-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-14T16:17:00Z","last_updated_date":"2018-02-14T16:17:00Z","reference_number":"EMA/666041/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0321-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-emea-000782-pip01-09-m04_en.pdf"},
    {"id":"36378","name":"P/0263/2016: EMA decision of 5 October 2016 on the granting of a product specific waiver for lifitegrast (EMEA-001979-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/593398/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2016-ema-decision-5-october-2016-granting-product-specific-waiver-lifitegrast-emea-001979-pip01-16_en.pdf"},
    {"id":"36401","name":"P/77/2008: European medicines agency decision of 14 September 2008\n\non the application for product specific waiver for bortezomib (Velcade)\n\nEMEA-000233-PIP01-08 in accordance with Regulation (EC) No 1901/2006 of the Eur...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-10-10T02:00:00Z","last_updated_date":"2008-10-10T02:00:00Z","reference_number":"EMEA/466893/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-77-2008-european-medicines-agency-decision-14-september-2008-application-product-specific-waiver-bortezomib-velcade-emea-000233-pip01-08-accordance-regulation-ec-no-1901-2006-eur_en.pdf"},
    {"id":"36402","name":"P/0238/2016: EMA decision of 9 September 2016 on the granting of a product specific waiver for rosuvastatin (calcium) / ezetimibe (EMEA-001941-\n\nPIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/580043/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2016-ema-decision-9-september-2016-granting-product-specific-waiver-rosuvastatin-calcium-ezetimibe-emea-001941-pip01-16_en.pdf"},
    {"id":"36403","name":"P/109/2012: EMA decision of 8 June 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil fumarate) Viread (EMEA-000533-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-23T17:00:00Z","last_updated_date":"2012-07-23T17:00:00Z","reference_number":"EMA/358603/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-109-2012-ema-decision-8-june-2012-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-fumarate-viread-emea-000533-pip01-08-m03_en.pdf"},
    {"id":"36420","name":"P/0013/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/10910/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised_en.pdf"},
    {"id":"36426","name":"P/0141/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for posaconazole\n\n(Noxafil) (EMEA-000468-PIP02-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/382958/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-posaconazole-noxafil-emea-000468-pip02-12-m02_en.pdf"},
    {"id":"36439","name":"P/0056/2012: EMA decision of 26 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for prucalopride\n\nsuccinate (Resolor), (EMEA-000459-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T17:42:00Z","last_updated_date":"2012-04-20T17:42:00Z","reference_number":"EMA/190327/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2012-ema-decision-26-march-2012-acceptance-modification-agreed-paediatric-investigation-plan-prucalopride-succinate-resolor-emea-000459-pip01-08-m01_en.pdf"},
    {"id":"36453","name":"P/0119/2017: EMA decision of 5 May 2017 on the granting of a product-specific waiver for mepolizumab (Nucala), (EMEA-000069-PIP05-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/255783/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2017-ema-decision-5-may-2017-granting-product-specific-waiver-mepolizumab-nucala-emea-000069-pip05-16_en.pdf"},
    {"id":"36454","name":"P/0185/2013: EMA decision of 30 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tocilizumab\n\n(RoActemra), (EMEA-000309-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/449115/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2013-ema-decision-30-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-tocilizumab-roactemra-emea-000309-pip01-08-m05_en.pdf"},
    {"id":"36459","name":"P/0008/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for idursulfase (EMEA-\n\n000294-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/34943/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-idursulfase-emea-000294-pip02-12-m01_en.pdf"},
    {"id":"36460","name":"P/0060/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for rituximab (MabThera) (EMEA-000308-PIP02-11-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/138312/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-rituximab-mabthera-emea-000308-pip02-11-m01_en.pdf"},
    {"id":"36462","name":"P/0028/2013: EMA decision of 26 February 2013 on the acceptance of a modification of an agreed paediatric investigation plan for poly(oxy-1,2-ethanediyl),alpha-hydro-omega-methoxy-133 ester with granulocyte colony-stimul...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T02:00:00Z","last_updated_date":"2013-04-23T02:00:00Z","reference_number":"EMA/23724/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2013-ema-decision-26-february-2013-acceptance-modification-agreed-paediatric-investigation-plan-polyoxy-12-ethanediylalpha-hydro-omega-methoxy-133-ester-granulocyte-colony-stimul_en.pdf"},
    {"id":"36465","name":"P/0300/2017: EMA decision of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab\n\n(EMEA-001523-PIP02-14-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/637572/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2017-ema-decision-4-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-guselkumab-emea-001523-pip02-14-m01_en.pdf"},
    {"id":"36472","name":"P/0268/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for rivaroxaban (Xarelto) (EMEA-000430-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/766392/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-rivaroxaban-xarelto-emea-000430-pip01-08-m08_en.pdf"},
    {"id":"36479","name":"P/0015/2013: EMA decision of 25 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for laquinimod (sodium) (EMEA-000972-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T18:30:00Z","last_updated_date":"2013-04-03T18:30:00Z","reference_number":"EMA/37454/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2013-ema-decision-25-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-laquinimod-sodium-emea-000972-pip01-10-m02_en.pdf"},
    {"id":"36484","name":"P/0215/2017: EMA decision of 9 August 2017 on the granting of a product-specific waiver for macitentan (Opsumit), (EMEA-001032-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"EMA/459094/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2017-ema-decision-9-august-2017-granting-product-specific-waiver-macitentan-opsumit-emea-001032-pip02-17_en.pdf"},
    {"id":"36492","name":"P/107/2011: EMA decision of 6 May 2011 on the acceptance of a modification of an agreed paediatric investigation plan for human coagulation Factor VIII / von Willebrand Factor, (EMEA-000312-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-07T02:00:00Z","last_updated_date":"2011-06-07T02:00:00Z","reference_number":"EMA/281206/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-107-2011-ema-decision-6-may-2011-acceptance-modification-agreed-paediatric-investigation-plan-human-coagulation-factor-viii-von-willebrand-factor-emea-000312-pip01-08-m02_en.pdf"},
    {"id":"36503","name":"P/216/2011: EMA decision of 1 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deferasirox (Exjade) (EMEA-001103-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/683839/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-216-2011-ema-decision-1-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-deferasirox-exjade-emea-001103-pip01-10_en.pdf"},
    {"id":"36508","name":"P/0048/2018: EMA decision of 22 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat)\n\n(EMEA-000402-PIP03-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T15:28:00Z","last_updated_date":"2018-04-17T15:28:00Z","reference_number":"EMA/83693/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2018-ema-decision-22-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip03-17-m02_en.pdf"},
    {"id":"36522","name":"P/0074/2014: EMA decision of 2 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for ceftaroline fosamil (Zinforo) (EMEA-000769-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/103256/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2014-ema-decision-2-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-ceftaroline-fosamil-zinforo-emea-000769-pip01-09-m04_en.pdf"},
    {"id":"36534","name":"P/0246/2014: EMA decision of 29 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for nanobody directed towards the fusion protein of human respiratory syncytial virus (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/508734/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2014-ema-decision-29-september-2014-agreement-paediatric-investigation-plan-granting-deferral-nanobody-directed-towards-fusion-protein-human-respiratory-syncytial-virus_en.pdf"},
    {"id":"36536","name":"P/104/2012: EMA decision of 1 June 2012 on the granting of a product specific waiver for masitinib (mesylate), (EMEA-001266-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-19T17:00:00Z","last_updated_date":"2012-07-19T17:00:00Z","reference_number":"EMA/331927/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-104-2012-ema-decision-1-june-2012-granting-product-specific-waiver-masitinib-mesylate-emea-001266-pip01-12_en.pdf"},
    {"id":"36539","name":"P/0169/2013: EMA decision of 30 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (EMEA-000576-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/419497/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2013-ema-decision-30-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-emea-000576-pip01-09-m03_en.pdf"},
    {"id":"36549","name":"P/112/2009: European Medicines Agency decision of 15 June 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for dexamethasone/ciprofloxacin hydrochloride (EMEA-000444-PIP01-08) in a...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/347310/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-112-2009-european-medicines-agency-decision-15-june-2009-agreement-paediatric-investigation-plan-granting-waiver-dexamethasone-ciprofloxacin-hydrochloride-emea-000444-pip01-08_en.pdf"},
    {"id":"36563","name":"P/0025/2014: EMA decision of 24 January 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cobimetinib (EMEA-001425-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/738900/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2014-ema-decision-24-january-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cobimetinib-emea-001425-pip01-13_en.pdf"},
    {"id":"36569","name":"P/0316/2014: EMA decision of 5 December 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human immunoglobulin G2Lambda monoclonal antibody dir...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-22T01:00:00Z","reference_number":"EMA/739905/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2014-ema-decision-5-december-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-immunoglobulin-g2lambda-monoclonal-antibody-dir_en.pdf"},
    {"id":"36573","name":"P/98/2010: European Medicines Agency decision of 4 June 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral  for fidaxomicin (EMEA-000636-PIP01-09) in accordance with Regulation (EC...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/335570/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-98-2010-european-medicines-agency-decision-4-june-2010-agreement-paediatric-investigation-plan-granting-deferral-fidaxomicin-emea-000636-pip01-09-accordance-regulation-ec_en.pdf"},
    {"id":"36593","name":"P/0119/2014: EMA decision of 7 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for canagliflozin (EMEA-001030-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-12T16:00:00Z","last_updated_date":"2014-06-12T16:00:00Z","reference_number":"EMA/182181/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2014-ema-decision-7-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-canagliflozin-emea-001030-pip01-10-m02_en.pdf"},
    {"id":"36599","name":"P/59/2011: EMA decision of 21 February 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for chimeric monoclonal antibody against human CD30 coval...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2011-03-08T01:00:00Z","reference_number":"EMA/126246/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-59-2011-ema-decision-21-february-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-chimeric-monoclonal-antibody-against-human-cd30-coval_en.pdf"},
    {"id":"36614","name":"P/0159/2016: EMA decision of 15 June 2016 on the refusal of a modification of an agreed paediatric investigation plan for tafluprost (Taflotan and\n\nassociated names) (EMEA-001187-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/380528/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2016-ema-decision-15-june-2016-refusal-modification-agreed-paediatric-investigation-plan-tafluprost-taflotan-associated-names-emea-001187-pip01-11-m03_en.pdf"},
    {"id":"36629","name":"P/0234/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for decitabine\n\n(Dacogen), (EMEA-000555-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/434829/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-decitabine-dacogen-emea-000555-pip01-09-m06_en.pdf"},
    {"id":"36635","name":"P/0312/2012: European medicines agency decision of 21 December 2012\n\non the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/816339/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2012-european-medicines-agency-decision-21-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-januvia-emea-000470-pip01-08-m06_en.pdf"},
    {"id":"36645","name":"P/156/2010: EMA decision of 27 August 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for ivabradine hydrochloride (Corlentor) (EMEA-000627-PIP01-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-06T02:00:00Z","last_updated_date":"2010-10-06T02:00:00Z","reference_number":"EMA/477307/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-156-2010-ema-decision-27-august-2010-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-ivabradine-hydrochloride-corlentor-emea-000627-pip01_en.pdf"},
    {"id":"36646","name":"P/0323/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris)\n\n(EMEA-000876-PIP05-15-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T10:19:00Z","last_updated_date":"2018-02-15T10:19:00Z","reference_number":"EMA/666038/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip05-15-m02_en.pdf"},
    {"id":"36657","name":"P/340/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for modified allergen extract of Dermatophagoides pteron...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA/708456/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-340-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-dermatophagoides-pteron_en.pdf"},
    {"id":"36677","name":"P/0129/2012: EMA decision of 4 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ulimorelin (EMEA-001144-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-09T14:00:00Z","last_updated_date":"2012-08-09T14:00:00Z","reference_number":"EMA/414917/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2012-ema-decision-4-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ulimorelin-emea-001144-pip01-11_en.pdf"},
    {"id":"36678","name":"P/0335/2017: EMA decision of 31 October 2017 on the granting of a product specific waiver for rosuvastatin / ezetimibe (EMEA-002202-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/666332/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0335-2017-ema-decision-31-october-2017-granting-product-specific-waiver-rosuvastatin-ezetimibe-emea-002202-pip01-17_en.pdf"},
    {"id":"36684","name":"P/120/2010: European Medicines Agency decision of 9 July 2010 on the agreement of a paediatric investigation plan and on the granting of a waiver for human normal immunoglobulin (EMEA-000775-PIP01-09) in accordance with ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/413296/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-120-2010-european-medicines-agency-decision-9-july-2010-agreement-paediatric-investigation-plan-granting-waiver-human-normal-immunoglobulin-emea-000775-pip01-09-accordance_en.pdf"},
    {"id":"36697","name":"P/236/2010: EMA decision of of 26 November 2010 on the acceptance of a modification of an agreed paediatric investigation plan for etanercept (Enbrel)\n\n(EMEA-000299-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/706484/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-236-2010-ema-decision-26-november-2010-acceptance-modification-agreed-paediatric-investigation-plan-etanercept-enbrel-emea-000299-pip01-08-m02_en.pdf"},
    {"id":"36702","name":"P/191/2011: EMA decision of 3 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide (EMEA-000335-PIP...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/591808/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-191-2011-ema-decision-3-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-n-24-di-tert-butyl-5-hydroxyphenyl-14-dihydro-4-oxoquinoline-3-carboxamide-emea-000335-pip_en.pdf"},
    {"id":"36714","name":"P/0109/2014: EMA decision of 5 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for eribulin (Halaven), (EMEA-001261-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-12T16:00:00Z","last_updated_date":"2015-06-02T13:00:00Z","reference_number":"EMA/231361/2014 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2014-ema-decision-5-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-eribulin-halaven-emea-001261-pip01-11-m01_en.pdf"},
    {"id":"36721","name":"P/0145/2012: EMA decision of 23 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lurasidone (hydrochloride), (EMEA-001230-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T17:15:00Z","last_updated_date":"2012-10-08T11:50:00Z","reference_number":"EMA/458276/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2012-ema-decision-23-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lurasidone-hydrochloride-emea-001230-pip01-11_en.pdf"},
    {"id":"36723","name":"P/0059/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for treosulfan (EMEA-\n\n000883-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/104669/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-treosulfan-emea-000883-pip01-10-m03_en.pdf"},
    {"id":"36726","name":"P/82/2008: European medicines agency decision of of 01 October 2008\n\non the application for agreement of a Paediatric Investigation Plan for Bevacizumab, (Avastin) EMEA-000056-PIP01-07 in accordance with Regulation (EC) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-11-24T00:00:00Z","last_updated_date":"2008-11-24T00:00:00Z","reference_number":"EMEA/409573/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-82-2008-european-medicines-agency-decision-01-october-2008-application-agreement-paediatric-investigation-plan-bevacizumab-avastin-emea-000056-pip01-07-accordance-regulation-ec_en.pdf"},
    {"id":"36727","name":"P/0017/2012: EMA decision of 25 January 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for methyl aminolevulinate (hydrochloride), (EMEA-000698...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/994146/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2012-ema-decision-25-january-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-methyl-aminolevulinate-hydrochloride-emea-000698_en.pdf"},
    {"id":"36756","name":"P/0194/2013: EMA decision of 8 August 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for idursulfase (EMEA-000294-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/508748/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2013-ema-decision-8-august-2013-agreement-paediatric-investigation-plan-granting-waiver-idursulfase-emea-000294-pip02-12_en.pdf"},
    {"id":"36761","name":"P/0229/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir /\n\nabacavir / lamivudine (Triumeq), (EMEA-001219-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/434830/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-abacavir-lamivudine-triumeq-emea-001219-pip01-11-m03_en.pdf"},
    {"id":"36768","name":"P/0376/2017: EMA decision of 1 December 2017 on the granting of a product specific waiver for resminostat (EMEA-002211-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T14:03:00Z","last_updated_date":"2018-03-07T14:03:00Z","reference_number":"EMA/711131/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0376-2017-ema-decision-1-december-2017-granting-product-specific-waiver-resminostat-emea-002211-pip01-17_en.pdf"},
    {"id":"36783","name":"P/0311/2016: EMA decision of 7 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for daclatasvir\n\n(Daklinza), (EMEA-001191-PIP01-11-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-20T11:00:00Z","last_updated_date":"2017-01-20T11:00:00Z","reference_number":"EMA/721473/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0311-2016-ema-decision-7-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-daclatasvir-daklinza-emea-001191-pip01-11-m02_en.pdf"},
    {"id":"36788","name":"P/0374/2017: EMA decision of 1 December 2017 on the granting of a product specific waiver for atorvastatin / ezetimibe (EMEA-002207-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T14:03:00Z","last_updated_date":"2018-03-07T14:03:00Z","reference_number":"EMA/763167/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0374-2017-ema-decision-1-december-2017-granting-product-specific-waiver-atorvastatin-ezetimibe-emea-002207-pip01-17_en.pdf"},
    {"id":"36805","name":"P/0397/2017: EMA decision of 19 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for brazikumab (EMEA-001929-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/771133/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0397-2017-ema-decision-19-december-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-brazikumab-emea-001929-pip01-16_en.pdf"},
    {"id":"36827","name":"P/55/2008: European medicines agency decision of 20 July 2008 on the application for product specific waiver for Epoetin theta (EMEA-000217-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parlia...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-08T02:00:00Z","last_updated_date":"2008-09-08T02:00:00Z","reference_number":"EMEA/357428/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-55-2008-european-medicines-agency-decision-20-july-2008-application-product-specific-waiver-epoetin-theta-emea-000217-pip01-08-accordance-regulation-ec-no-1901-2006-european-parlia_en.pdf"},
    {"id":"36846","name":"P/0324/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human A disintegrin and metalloprotease with thrombospondin type-1 motifs 13 (EM...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T10:19:00Z","last_updated_date":"2018-02-15T10:19:00Z","reference_number":"EMA/671585/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0324-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-disintegrin-metalloprotease-thrombospondin-type-1-motifs-13-em_en.pdf"},
    {"id":"36847","name":"P/0322/2014: EMA decision of 19 December 2014 on the granting of a product specific waiver for saxagliptin / dapagliflozin (EMEA-001677-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/759423/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0322-2014-ema-decision-19-december-2014-granting-product-specific-waiver-saxagliptin-dapagliflozin-emea-001677-pip01-14_en.pdf"},
    {"id":"36860","name":"P/0304/2013: EMA decision of 29 November 2013 on the granting of a product specific waiver for synthetic double-stranded siRNA oligonucleotide\n\ndirected against transthyretin mRNA (EMEA-001520-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-01-06T01:00:00Z","last_updated_date":"2014-01-06T01:00:00Z","reference_number":"EMA/647572/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2013-ema-decision-29-november-2013-granting-product-specific-waiver-synthetic-double-stranded-sirna-oligonucleotide-directed-against-transthyretin-mrna-emea-001520-pip01-13_en.pdf"},
    {"id":"36869","name":"P/0372/2017: EMA decision of 1 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for iron hydroxyethyl amylopectin heptonate (EMEA-002094...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-03-05T15:26:00Z","last_updated_date":"2018-03-05T15:26:00Z","reference_number":"EMA/763346/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0372-2017-ema-decision-1-december-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-iron-hydroxyethyl-amylopectin-heptonate-emea-002094_en.pdf"},
    {"id":"36888","name":"P/28/2009: European Medicines Agency decision of 23 February 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for pegylated recombinant Factor VII...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/90244/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-28-2009-european-medicines-agency-decision-23-february-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pegylated-recombinant-factor-vii_en.pdf"},
    {"id":"36929","name":"P/4/2007: European medicines agency decision of 11 December 2007 on the application for a product specific waiver for Blopress Comp and associated names, Candesartan/Hydrochlorothiazide (EMEA-000040-PIP01-07) in accordan...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2007-12-20T00:00:00Z","last_updated_date":"2007-12-20T00:00:00Z","reference_number":"EMEA/575788/2007","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-4-2007-european-medicines-agency-decision-11-december-2007-application-product-specific-waiver-blopress-comp-associated-names-candesartan-hydrochlorothiazide-emea-000040-pip01-07-accordan_en.pdf"},
    {"id":"36937","name":"P/67/2010: European Medicines Agency decision on the granting of a product specific waiver for diamorphine (EMEA-000749-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-28T02:00:00Z","last_updated_date":"2010-07-28T02:00:00Z","reference_number":"EMA/264336/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-67-2010-european-medicines-agency-decision-granting-product-specific-waiver-diamorphine-emea-000749-pip01-09_en.pdf"},
    {"id":"36941","name":"P/0078/2015: EMA decision of 1 April 2015 on the granting of a product-specific waiver for ibuprofen/codeine (EMEA-001713-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-07T02:00:00Z","last_updated_date":"2015-05-07T02:00:00Z","reference_number":"EMA/161012/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2015-ema-decision-1-april-2015-granting-product-specific-waiver-ibuprofen-codeine-emea-001713-pip02-14_en.pdf"}    {"id":"36974","name":"P/0058/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for fidaxomicin (Dificlir), (EMEA-000636-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/104670/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-fidaxomicin-dificlir-emea-000636-pip01-09-m05_en.pdf"},
    {"id":"36987","name":"P/0151/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for isavuconazonium (sulfate), (Cresemba) (EMEA-001301-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/293458/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-isavuconazonium-sulfate-cresemba-emea-001301-pip02-12-m01_en.pdf"},
    {"id":"36991","name":"P/0270/2015: EMA decision of 3 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for EMEA-000673-PIP01-09-M08","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/690926/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2015-ema-decision-3-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-emea-000673-pip01-09-m08_en.pdf"},
    {"id":"37012","name":"P/185/2009: european medicines agency decision of 7 September 2009\n\non the granting of a product specific waiver for tramadol / paracetamol\n\n(EMEA-000598-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/548803/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-185-2009-european-medicines-agency-decision-7-september-2009-granting-product-specific-waiver-tramadol-paracetamol-emea-000598-pip01-09-accordance-regulation-ec-no-1901-2006-e_en.pdf"},
    {"id":"37015","name":"P/0081/2015: EMA decision of 10 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for pixantrone (dimaleate) (Pixuvri), (EMEA-000713-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-19T02:00:00Z","last_updated_date":"2015-05-19T02:00:00Z","reference_number":"EMA/212181/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2015-ema-decision-10-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-pixantrone-dimaleate-pixuvri-emea-000713-pip02-10-m03_en.pdf"},
    {"id":"37026","name":"P/115/2010: European Medicines Agency decision of 7 July 2010\n\non the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for trifluoromethyl-benzyloxyimino-ethy...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/413185/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-115-2010-european-medicines-agency-decision-7-july-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-trifluoromethyl-benzyloxyimino-ethy_en.pdf"},
    {"id":"37041","name":"P/0321/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for sunitinib (Sutent),\n\n(EMEA-000342-PIP01-08-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T11:23:00Z","last_updated_date":"2017-01-30T11:23:00Z","reference_number":"EMA/765279/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0321-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-sunitinib-sutent-emea-000342-pip01-08-m05_en.pdf"},
    {"id":"37050","name":"P/181/2010: European Medicines Agency decision of 24 September 2010 on the granting of a product specific waiver for pasireotide (EMEA-000464-PIP02-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/540808/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-181-2010-european-medicines-agency-decision-24-september-2010-granting-product-specific-waiver-pasireotide-emea-000464-pip02-10_en.pdf"},
    {"id":"37055","name":"P/0052/2013: EMA decision of 1 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for asfotase alfa (EMEA-000987-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/113104/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2013-ema-decision-1-march-2013-agreement-paediatric-investigation-plan-granting-deferral-asfotase-alfa-emea-000987-pip01-10_en.pdf"},
    {"id":"37061","name":"P/124/2011: EMA decision of 7 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for cobicistat (EMEA-000969-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/360007/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-124-2011-ema-decision-7-june-2011-agreement-paediatric-investigation-plan-granting-deferral-cobicistat-emea-000969-pip01-10_en.pdf"},
    {"id":"37081","name":"P/228/2009: European Medicines Agency Decision of 4 November 2009 on the granting of a product specific waiver for olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide (EMEA-000668-PIP01-09) in accordance wit...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:09:21Z","last_updated_date":"2009-12-23T00:09:21Z","reference_number":"EMEA/693326/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-228-2009-european-medicines-agency-decision-4-november-2009-granting-product-specific-waiver-olmesartan-medoxomil-amlodipine-besilate-hydrochlorothiazide-emea-000668-pip01-09-accordance-wit_en.pdf"},
    {"id":"37084","name":"P/0249/2013: EMA decision of 18 October 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for tedizolid (phosphate) (EMEA-001379-PIP01-12)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/585513/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2013-ema-decision-18-october-2013-agreement-paediatric-investigation-plan-granting-deferral-tedizolid-phosphate-emea-001379-pip01-12_en.pdf"},
    {"id":"37099","name":"P/4/2008: European medicines agency decision of 1 February 2008 on the application for product specific waiver for Glycopyrronium bromide EMEA-000058-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the Europe...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-01-15T01:00:00Z","last_updated_date":"2008-01-15T01:00:00Z","reference_number":"EMEA/43454/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-4-2008-european-medicines-agency-decision-1-february-2008-application-product-specific-waiver-glycopyrronium-bromide-emea-000058-pip01-07-accordance-regulation-ec-no-1901-2006-europe_en.pdf"},
    {"id":"37109","name":"P/189/2011: EMA decision of 2 August 2011 on the granting of a product specific waiver for teriparatide (Forsteo), (EMEA-001135-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/507484/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-189-2011-ema-decision-2-august-2011-granting-product-specific-waiver-teriparatide-forsteo-emea-001135-pip01-11_en.pdf"},
    {"id":"37120","name":"P/0066/2013: European medicines agency decision of 26 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for elvitegravir (EMEA-000968-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/103410/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2013-european-medicines-agency-decision-26-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-elvitegravir-emea-000968-pip02-11-m01_en.pdf"},
    {"id":"37123","name":"P/0340/2014: EMA decision of 22 December 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for Clostridium difficile toxin B human monoclonal antibody (EMEA-001645-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/711355/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0340-2014-ema-decision-22-december-2014-agreement-paediatric-investigation-plan-granting-deferral-clostridium-difficile-toxin-b-human-monoclonal-antibody-emea-001645-pip01-14_en.pdf"},
    {"id":"37127","name":"P/0116/2018: EMA decision of 11 April 2018 on the granting of a product specific waiver for rovalpituzumab tesirine (EMEA-002292-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T02:00:00Z","last_updated_date":"2018-07-25T02:00:00Z","reference_number":"EMA/197915/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2018-ema-decision-11-april-2018-granting-product-specific-waiver-rovalpituzumab-tesirine-emea-002292-pip01-17_en.pdf"},
    {"id":"37140","name":"P/0266/2013: EMA decision of 30 October 2013 on the agreement of a paediatric investigation plan for autologous CD34+ cells transduced with lentiviral vector containing the human Wiskott Aldrich Syndrom Protein gene (EME...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/586558/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2013-ema-decision-30-october-2013-agreement-paediatric-investigation-plan-autologous-cd34-cells-transduced-lentiviral-vector-containing-human-wiskott-aldrich-syndrom-protein-gene-eme_en.pdf"},
    {"id":"37162","name":"P/0115/2017: EMA decision of 21 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for doravirine\n\n(EMEA-001676-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/247011/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2017-ema-decision-21-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-doravirine-emea-001676-pip01-14-m01_en.pdf"},
    {"id":"37164","name":"P/259/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for betula alba allergen extract (EMEA-000919-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/670696/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-259-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-betula-alba-allergen-extract-emea-000919-pip01-10_en.pdf"},
    {"id":"37177","name":"P/0162/2016: EMA decision of 15 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for retosiban (EMEA-\n\n001359-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/385668/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2016-ema-decision-15-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-retosiban-emea-001359-pip01-12-m03_en.pdf"},
    {"id":"37187","name":"P/0117/2015: EMA decision of 5 June 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mirabegron (Betmiga), (EMEA-000597-PIP03-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-03T02:00:00Z","last_updated_date":"2015-07-03T02:00:00Z","reference_number":"EMA/297824/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2015-ema-decision-5-june-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mirabegron-betmiga-emea-000597-pip03-15_en.pdf"},
    {"id":"37194","name":"P/0137/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for selumetinib (EMEA-001585-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T02:00:00Z","last_updated_date":"2016-07-27T02:00:00Z","reference_number":"EMA/249389/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-selumetinib-emea-001585-pip01-13-m01_en.pdf"},
    {"id":"37196","name":"P/0171/2017: EMA decision of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for methoxyflurane (Penthrox), (EMEA-000334-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/357762/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-methoxyflurane-penthrox-emea-000334-pip01-08-m06_en.pdf"},
    {"id":"37240","name":"P/115/2009: European Medicines Agency decision of 15 June 2009 on the granting of a product specific waiver for Pravastatin sodium / Fenofibrate (EMEA-000501-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of t...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351862/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-115-2009-european-medicines-agency-decision-15-june-2009-granting-product-specific-waiver-pravastatin-sodium-fenofibrate-emea-000501-pip01-08-accordance-regulation-ec-no-1901-2006-t_en.pdf"},
    {"id":"37244","name":"P/0250/2013: EMA decision of 21 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for human heterologous liver cells (EMEA-000067-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/496850/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2013-ema-decision-21-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-human-heterologous-liver-cells-emea-000067-pip02-11-m01_en.pdf"},
    {"id":"37255","name":"P/0033/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia),\n\n(EMEA-000470-PIP01-08-M10)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T11:41:00Z","last_updated_date":"2018-04-18T11:41:00Z","reference_number":"EMA/848760/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-januvia-emea-000470-pip01-08-m10_en.pdf"},
    {"id":"37284","name":"P/0278/2017: EMA decision of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated, adsorbed) (Ixiaro) (EMEA-000559-PIP01-09-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-14T16:17:00Z","last_updated_date":"2018-02-14T16:17:00Z","reference_number":"EMA/574564/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2017-ema-decision-4-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-japanese-encephalitis-vaccine-inactivated-adsorbed-ixiaro-emea-000559-pip01-09-m04_en.pdf"},
    {"id":"37288","name":"P/261/2009: EMA decision of 23 December 2009 on the granting of a product specific waiver for tramadol hydrochloride / paracetamol (EMEA-000686-PIP01-09) in accordance with Regulation (EC) No 1901/...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMA/749423/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-261-2009-ema-decision-23-december-2009-granting-product-specific-waiver-tramadol-hydrochloride-paracetamol-emea-000686-pip01-09-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"37294","name":"P/0060/2013: European medicines agency decision of 26 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for aprepitant (Emend), (EMEA-000144-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/103532/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2013-european-medicines-agency-decision-26-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-aprepitant-emend-emea-000144-pip01-07-m04_en.pdf"},
    {"id":"37306","name":"P/0264/2012: EMA decision of of 20 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for methoxyflurane (EMEA-000334-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/646936/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2012-ema-decision-20-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-methoxyflurane-emea-000334-pip01-08-m02_en.pdf"},
    {"id":"37321","name":"P/0090/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for letermovir (EMEA-\n\n001631-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/155523/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-letermovir-emea-001631-pip01-14-m02_en.pdf"},
    {"id":"37333","name":"P/0353/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lubiprostone\n\n(Amitiza), (EMEA-000245-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/724547/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0353-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-lubiprostone-amitiza-emea-000245-pip01-08-m04_en.pdf"},
    {"id":"37335","name":"P/0230/2014: EMA decision of 5 September 2014 on the refusal of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (H5N1 or H1N1 strains) (Focetria and associated names, Afluno...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/464766/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2014-ema-decision-5-september-2014-refusal-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-h5n1-or-h1n1-strains-focetria-associated-names-afluno_en.pdf"},
    {"id":"37348","name":"P/0162/2013: EMA decision of 29 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for etravirine (Intelence) (EMEA-000222-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-02T13:15:00Z","last_updated_date":"2013-09-02T13:15:00Z","reference_number":"EMA/392989/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2013-ema-decision-29-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-etravirine-intelence-emea-000222-pip01-08-m07_en.pdf"},
    {"id":"37351","name":"P/0088/2018: EMA decision of 16 March 2018 on the granting of a product- specific waiver for niraparib (EMEA-002268-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/105604/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2018-ema-decision-16-march-2018-granting-product-specific-waiver-niraparib-emea-002268-pip01-17_en.pdf"},
    {"id":"37360","name":"P/0086/2013: EMA decision of 29 April 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for denosumab (Prolia, Xgeva) (EMEA-000145-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/180448/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2013-ema-decision-29-april-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-denosumab-prolia-xgeva-emea-000145-pip02-12_en.pdf"},
    {"id":"37375","name":"P/0016/2012: EMA decision of 25 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (EMEA-000332-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/36974/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2012-ema-decision-25-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-emea-000332-pip01-08-m05_en.pdf"},
    {"id":"37389","name":"P/0107/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (LENVIMA,\n\nKisplyx), (EMEA-001119-PIP02-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/164271/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-lenvima-kisplyx-emea-001119-pip02-12-m03_en.pdf"},
    {"id":"37392","name":"P/0301/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ceftaroline fosamil (Zinforo), (EMEA-000769-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/773328/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-ceftaroline-fosamil-zinforo-emea-000769-pip01-09-m05_en.pdf"},
    {"id":"37440","name":"P/0289/2012: EMA decision of 7 December 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for posaconazole (Noxafil) (EMEA-000468-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T10:40:00Z","last_updated_date":"2013-02-08T10:40:00Z","reference_number":"EMA/756036/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2012-ema-decision-7-december-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-posaconazole-noxafil-emea-000468-pip02-12_en.pdf"},
    {"id":"37443","name":"P/0251/2016: EMA decision of 23 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for nusinersen (EMEA-\n\n001448-PIP01-13-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/576582/2016 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2016-ema-decision-23-september-2016-acceptance-modification-agreed-paediatric-investigation-plan-nusinersen-emea-001448-pip01-13-m02_en.pdf"},
    {"id":"37463","name":"P/0167/2017: EMA decision of 30 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dimethyl fumarate\n\n(Tecfidera), (EMEA-000832-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/370819/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2017-ema-decision-30-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-dimethyl-fumarate-tecfidera-emea-000832-pip01-10-m04_en.pdf"},
    {"id":"37470","name":"P/0106/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for linaclotide (Constella), (EMEA-000927-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/201050/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2013-ema-decision-30-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-linaclotide-constella-emea-000927-pip01-10-m01_en.pdf"},
    {"id":"37474","name":"P/161/2011: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ciclosporin (EMEA-\n\n000575-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/417834/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-161-2011-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-ciclosporin-emea-000575-pip01-09-m01_en.pdf"},
    {"id":"37475","name":"P/0021/2014: EMA decision of 22 January 2014 on the agreement of a paediatric investigation plan and on the granting of a waiver for mesalazine / prednisolone metasulphobenzoate (EMEA-001406-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T01:00:00Z","last_updated_date":"2014-02-20T01:00:00Z","reference_number":"EMA/775440/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2014-ema-decision-22-january-2014-agreement-paediatric-investigation-plan-granting-waiver-mesalazine-prednisolone-metasulphobenzoate-emea-001406-pip01-12_en.pdf"},
    {"id":"37513","name":"P/161/2009: European Medicines Agency decision of 11 August 2009 on the granting of a product specific waiver for testosterone (Livensa) (EMEA-000572-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the Europ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/420706/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-161-2009-european-medicines-agency-decision-11-august-2009-granting-product-specific-waiver-testosterone-livensa-emea-000572-pip01-09-accordance-regulation-ec-no-1901-2006-europ_en.pdf"},
    {"id":"37552","name":"P/0005/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for tiotropium bromide (monohydrate) (Spiriva Respimat, Spiriva), (EMEA-000035-PIP02-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/793410/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-tiotropium-bromide-monohydrate-spiriva-respimat-spiriva-emea-000035-pip02-09-m02_en.pdf"},
    {"id":"37561","name":"P/105/2011: EMA decision of 4 May 2011 on the acceptance of a modification of an agreed paediatric investigation plan for everolimus (Certican\n\nand associated names) (EMEA-000019-PIP06-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-07T02:00:00Z","last_updated_date":"2011-06-07T02:00:00Z","reference_number":"EMA/325926/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-105-2011-ema-decision-4-may-2011-acceptance-modification-agreed-paediatric-investigation-plan-everolimus-certican-associated-names-emea-000019-pip06-09-m01_en.pdf"},
    {"id":"37591","name":"P/0296/2012: EMA decision of 18 December 2012 on the granting of a product-specific waiver for elagolix (EMEA-001323-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T14:00:00Z","last_updated_date":"2013-02-08T14:00:00Z","reference_number":"EMA/802225/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2012-ema-decision-18-december-2012-granting-product-specific-waiver-elagolix-emea-001323-pip01-12_en.pdf"},
    {"id":"37600","name":"P/41/2009: European Medicines Agency decision of 23 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for cannabidiol, delta-9-tetrahydrocannabinol (EMEA-000181-PIP01-08) in...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/162839/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-41-2009-european-medicines-agency-decision-23-march-2009-agreement-paediatric-investigation-plan-granting-deferral-cannabidiol-delta-9-tetrahydrocannabinol-emea-000181-pip01-08_en.pdf"},
    {"id":"37602","name":"P/92/2011: EMA decision of 8 April 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral for Human Cell\n\nLine recombinant human Factor VIII (human-cl rhFVIII), (EMEA-001024-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/193400/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-92-2011-ema-decision-8-april-2011-agreement-paediatric-investigation-plan-granting-deferral-human-cell-line-recombinant-human-factor-viii-human-cl-rhfviii-emea-001024-pip01-10_en.pdf"},
    {"id":"37607","name":"P/0264/2013: EMA decision of 30 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for Diphtheria toxoid / Tetanus toxoid / Bordetella pertussis antigen: Pertussis toxoid / Bordet...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/597534/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2013-ema-decision-30-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-diphtheria-toxoid-tetanus-toxoid-bordetella-pertussis-antigen-pertussis-toxoid-bordet_en.pdf"},
    {"id":"37622","name":"P/0187/2015: EMA decision of 4 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for raltegravir (Isentress) (EMEA-000279-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/568917/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2015-ema-decision-4-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-raltegravir-isentress-emea-000279-pip01-08-m04_en.pdf"},
    {"id":"37626","name":"P/0307/2012: EMA decision of 21 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for eltrombopag (Revolade), (EMEA-000170-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/795942/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2012-ema-decision-21-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-eltrombopag-revolade-emea-000170-pip01-07-m03_en.pdf"},
    {"id":"37629","name":"P/0084/2017: EMA decision of 16 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for bivalent anti-human\n\nmyostatin adnectin recombinant human IgG1-Fc fusion protein (BMS-986089) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/162097/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2017-ema-decision-16-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-bivalent-anti-human-myostatin-adnectin-recombinant-human-igg1-fc-fusion-protein-bms-986089_en.pdf"},
    {"id":"37639","name":"P/0256/2016: EMA decision of 5 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for reslizumab (EMEA-\n\n001202-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/585769/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2016-ema-decision-5-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-reslizumab-emea-001202-pip02-13-m01_en.pdf"},
    {"id":"37642","name":"P/0079/2014: EMA decision of 2 April 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sirolimus (EMEA-001416-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2014-05-13T02:00:00Z","reference_number":"EMA/113590/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2014-ema-decision-2-april-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sirolimus-emea-001416-pip01-12_en.pdf"},
    {"id":"37644","name":"P/0255/2012: EMA decision of 26 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (Brilique, Possia), (EMEA-000480-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/672476/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2012-ema-decision-26-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-ticagrelor-brilique-possia-emea-000480-pip01-08-m04_en.pdf"},
    {"id":"37654","name":"P/0258/2014: EMA decision of 1 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tedizolid (phosphate) (EMEA-001379-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/514192/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2014-ema-decision-1-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-tedizolid-phosphate-emea-001379-pip01-12-m01_en.pdf"},
    {"id":"37656","name":"P/241/2011: EMA decision of 29 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for etanercept (Enbrel)\n\n(EMEA-000299-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/764025/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-241-2011-ema-decision-29-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-etanercept-enbrel-emea-000299-pip01-08-m03_en.pdf"},
    {"id":"37662","name":"P/0249/2014: EMA decision of 30 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil fumarate) (Viread), (EMEA-000533-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/519894/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2014-ema-decision-30-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-fumarate-viread-emea-000533-pip01-08-m05_en.pdf"},
    {"id":"37668","name":"P/0216/2014: EMA decision of 3 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (EMEA-000576-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/453841/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2014-ema-decision-3-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-emea-000576-pip02-11-m03_en.pdf"},
    {"id":"37672","name":"P/0115/2012: EMA decision of 2 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-06T18:00:00Z","last_updated_date":"2012-08-06T18:00:00Z","reference_number":"EMA/405302/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2012-ema-decision-2-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-ipilimumab-yervoy-emea-000117-pip01-07-m04_en.pdf"},
    {"id":"37679","name":"P/0205/2014: EMA decision of 8 August 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant parathyroid hormone (EMEA-001526-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/414997/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2014-ema-decision-8-august-2014-agreement-paediatric-investigation-plan-granting-deferral-recombinant-parathyroid-hormone-emea-001526-pip01-13_en.pdf"},
    {"id":"37680","name":"P/255/2010:  EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aluminium hydroxide adsorbed, depigmented glutaralde...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/670695/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-255-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaralde_en.pdf"},
    {"id":"37698","name":"P/0159/2013: EMA decision of 5 July 2013 on the granting of a product-specific waiver for ixazomib (citrate) (EMEA-001410-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-13T17:30:00Z","last_updated_date":"2013-08-13T17:30:00Z","reference_number":"EMA/332034/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2013-ema-decision-5-july-2013-granting-product-specific-waiver-ixazomib-citrate-emea-001410-pip01-12_en.pdf"},
    {"id":"37709","name":"P/47/2012: EMA decision of 29 February 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for fibrinogen concentrate / thrombin preparation / aprotinin / calcium chloride (EMEA-001...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T17:00:00Z","last_updated_date":"2012-03-26T17:00:00Z","reference_number":"EMA/129779/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-47-2012-ema-decision-29-february-2012-agreement-paediatric-investigation-plan-granting-deferral-fibrinogen-concentrate-thrombin-preparation-aprotinin-calcium-chloride-emea-001_en.pdf"},
    {"id":"37720","name":"P/23/2011: EMA decision of 25 January 2011 on the granting of a product specific waiver for tesamorelin (EMEA-001029-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Counci...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/51098/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-23-2011-ema-decision-25-january-2011-granting-product-specific-waiver-tesamorelin-emea-001029-pip01-10-accordance-regulation-ec-no-1901-2006-european-parliament-counci_en.pdf"},
    {"id":"37727","name":"P/0213/2016: EMA decision of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA-\n\n001214-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/501681/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2016-ema-decision-12-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-benralizumab-emea-001214-pip01-11-m05_en.pdf"},
    {"id":"37740","name":"P/0209/2014: EMA decision of 11 August 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for propan-2-yl N-[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)pr...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/464751/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2014-ema-decision-11-august-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-propan-2-yl-n-s-2r-1-6-amino-9h-purin-9-ylpr_en.pdf"},
    {"id":"37741","name":"P/0049/2018: EMA decision of 22 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for nivolumab (Opdivo),\n\n(EMEA-001407-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/101776/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2018-ema-decision-22-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-nivolumab-opdivo-emea-001407-pip01-12-m01_en.pdf"},
    {"id":"37743","name":"P/43/2010: EMA decision of 11 February 2011 on the acceptance of a modification of an agreed paediatric investigation plan for etravirine (Intelence) (EMEA-000222-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2011-03-08T01:00:00Z","reference_number":"EMA/100929/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-43-2010-ema-decision-11-february-2011-acceptance-modification-agreed-paediatric-investigation-plan-etravirine-intelence-emea-000222-pip01-08-m03_en.pdf"},
    {"id":"37775","name":"P/249/2011: EMA decision of 25 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated, adsorbed) (Ixiaro), (EMEA-000559-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T17:00:00Z","last_updated_date":"2011-11-30T17:00:00Z","reference_number":"EMA/751064/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-249-2011-ema-decision-25-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-japanese-encephalitis-vaccine-inactivated-adsorbed-ixiaro-emea-000559-pip01-09-m03_en.pdf"},
    {"id":"37782","name":"P/0040/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for pegylated human interferon beta-1a (Plegridy) (EMEA-001129-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-25T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/80317/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2015-ema-decision-6-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-pegylated-human-interferon-beta-1a-plegridy-emea-001129-pip01-11-m01_en.pdf"},
    {"id":"37789","name":"P/0355/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol\n\n(hydrochloride) (Palexia and associated names, Yantil and associated names, Tape...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/704024/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0355-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-associated-names-yantil-associated-names-tape_en.pdf"},
    {"id":"37816","name":"P/0085/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) (Foclivia an...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/104851/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-waiver-pandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-foclivia_en.pdf"},
    {"id":"37818","name":"P/0010/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for reslizumab\n\n(Cinqaero), (EMEA-001202-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-18T02:00:00Z","last_updated_date":"2018-04-18T02:00:00Z","reference_number":"EMA/792967/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-reslizumab-cinqaero-emea-001202-pip02-13-m02_en.pdf"},
    {"id":"37832","name":"P/136/2011: EMA decision of 10 June 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal\n\nof a waiver for edoxaban (tosylate) (EMEA-000788-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-14T02:00:00Z","last_updated_date":"2011-07-14T02:00:00Z","reference_number":"EMA/356126/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-136-2011-ema-decision-10-june-2011-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-edoxaban-tosylate-emea-000788-pip02-11_en.pdf"},
    {"id":"37843","name":"P/294/2011: EMA decision of 20 December 2011 on the acceptance of a modification of an agreed paediatric investigation plan for bosentan\n\nmonohydrate (Tracleer), (EMEA-000425-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-18T17:45:00Z","last_updated_date":"2012-01-18T17:45:00Z","reference_number":"EMA/912642/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-294-2011-ema-decision-20-december-2011-acceptance-modification-agreed-paediatric-investigation-plan-bosentan-monohydrate-tracleer-emea-000425-pip02-10-m01_en.pdf"},
    {"id":"37849","name":"P/30/2011: EMA decision of 28 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (EMEA-000480-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the E...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"EMA/37980/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-30-2011-ema-decision-28-january-2011-acceptance-modification-agreed-paediatric-investigation-plan-ticagrelor-emea-000480-pip01-08-m01-accordance-regulation-ec-no-1901-2006-e_en.pdf"},
    {"id":"37872","name":"P/0098/2014: EMA decision of 10 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for atazanavir (sulphate) (Reyataz), (EMEA-000804-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/169115/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2014-ema-decision-10-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-atazanavir-sulphate-reyataz-emea-000804-pip01-09-m02_en.pdf"},
    {"id":"37886","name":"P/0082/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for tetracaine (hydrochloride) / oxymetazoline (hydrochloride) (EMEA-001764-PIP03-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/131632/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-waiver-tetracaine-hydrochloride-oxymetazoline-hydrochloride-emea-001764-pip03-15_en.pdf"},
    {"id":"37887","name":"P/0206/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide\n\n(EMEA-001441-PIP02-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/460851/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-semaglutide-emea-001441-pip02-15-m01_en.pdf"},
    {"id":"37890","name":"P/0212/2012: EMA decision of 28 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ceftobiprole\n\nmedocaril sodium (EMEA-000205-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T17:00:00Z","last_updated_date":"2012-10-17T17:00:00Z","reference_number":"EMA/605951/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2012-ema-decision-28-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-ceftobiprole-medocaril-sodium-emea-000205-pip01-08-m01_en.pdf"},
    {"id":"37899","name":"P/0064/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for osilodrostat (EMEA-000315-PIP02-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/107501/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-osilodrostat-emea-000315-pip02-15-m01_en.pdf"},
    {"id":"37903","name":"P/0314/2014: EMA decision of 24 November 2014 on the acceptance of a modification of an agreed paediatric investigation plan for heterologous human adult liver-derived progenitor cells (HHALPC) (EMEA-001155-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/651534/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2014-ema-decision-24-november-2014-acceptance-modification-agreed-paediatric-investigation-plan-heterologous-human-adult-liver-derived-progenitor-cells-hhalpc-emea-001155-pip01-11-m02_en.pdf"},
    {"id":"37908","name":"P/121/2008: European Medicines Agency decision of 1 December 2008 on the application for agreement of a Paediatric Investigation Plan for treprostinil, (Remodulin and associated names) (EMEA-000207-PIP01-08) in accordanc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/626169/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-121-2008-european-medicines-agency-decision-1-december-2008-application-agreement-paediatric-investigation-plan-treprostinil-remodulin-associated-names-emea-000207-pip01-08-accordanc_en.pdf"},
    {"id":"37910","name":"P/0186/2013: EMA decision of 2 August 2013 on the acceptance of a modification of an agreed paediatric investigation plan for elvitegravir (EMEA-000968-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-09T18:20:00Z","last_updated_date":"2013-09-09T18:20:00Z","reference_number":"EMA/466730/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2013-ema-decision-2-august-2013-acceptance-modification-agreed-paediatric-investigation-plan-elvitegravir-emea-000968-pip02-11-m02_en.pdf"},
    {"id":"37925","name":"P/0143/2012: EMA decision of 23 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for propranolol\n\nhydrochloride (000511-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/471665/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2012-ema-decision-23-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-propranolol-hydrochloride-000511-pip01-08-m03_en.pdf"},
    {"id":"37953","name":"P/0142/2013: EMA decision of 3 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for icatibant acetate (Firazyr), (EMEA-000408-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-08T18:00:00Z","last_updated_date":"2013-08-08T18:00:00Z","reference_number":"EMA/306450/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2013-ema-decision-3-july-2013-acceptance-modification-agreed-paediatric-investigation-plan-icatibant-acetate-firazyr-emea-000408-pip01-08-m04_en.pdf"},
    {"id":"37973","name":"P/0010/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for ranibizumab\n\n(Lucentis), (EMEA-000527-PIP04-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/38628/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-ranibizumab-lucentis-emea-000527-pip04-13-m01_en.pdf"},
    {"id":"37984","name":"P/0101/2014: EMA decision of 11 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tiotropium bromide (monohydrate) (Spiriva Respimat, Spiriva), (EMEA-000035-PIP02-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2014-05-13T02:00:00Z","reference_number":"EMA/195557/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2014-ema-decision-11-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-tiotropium-bromide-monohydrate-spiriva-respimat-spiriva-emea-000035-pip02-09-m01_en.pdf"},
    {"id":"37986","name":"P/254/2009: EMA decision of 22 December 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for Belimumab (EMA-000520-PIP01-08...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMA/815429/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-254-2009-ema-decision-22-december-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-belimumab-ema-000520-pip01-08_en.pdf"},
    {"id":"37991","name":"P/0401/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for blinatumomab\n\n(Blincyto), (EMEA-000574-PIP02-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/771128/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0401-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-blinatumomab-blincyto-emea-000574-pip02-12-m02_en.pdf"},
    {"id":"37994","name":"P/0220/2016: EMA decision of 26 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (Orkambi), (EMEA-001582-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/441054/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2016-ema-decision-26-august-2016-acceptance-modification-agreed-paediatric-investigation-plan-lumacaftor-ivacaftor-orkambi-emea-001582-pip01-13-m04_en.pdf"},
    {"id":"38011","name":"P/0339/2014: EMA decision of 22 December 2014 on the granting of a product specific waiver for ibandronic acid (in combination with calcium (carbonate) / cholecalciferol) (EMEA-001630-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/713538/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0339-2014-ema-decision-22-december-2014-granting-product-specific-waiver-ibandronic-acid-combination-calcium-carbonate-cholecalciferol-emea-001630-pip01-14_en.pdf"},
    {"id":"38013","name":"P/0313/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for elbasvir (EMEA-001603-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/761386/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-elbasvir-emea-001603-pip01-13-m01_en.pdf"},
    {"id":"38024","name":"P/0131/2014: EMA decision of 10 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for conestat alfa (Ruconest) (EMEA-000367-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-15T02:00:00Z","last_updated_date":"2014-07-15T02:00:00Z","reference_number":"EMA/273853/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2014-ema-decision-10-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-conestat-alfa-ruconest-emea-000367-pip01-08-m03_en.pdf"},
    {"id":"38044","name":"P/335/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for aqueous allergen extract of pollen from phleum prate...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/810422/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-335-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aqueous-allergen-extract-pollen-phleum-prate_en.pdf"}    {"id":"38069","name":"P/180/2010: European Medicines Agency decision of of 24 Septemeber 2010 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara), (EMEA-000311-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/587450/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-180-2010-european-medicines-agency-decision-24-septemeber-2010-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip01-08-m01_en.pdf"},
    {"id":"38080","name":"P/0243/2013: EMA decision of 27 September 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for Clostridium difficile toxin A human monoclonal antibody / Clostridium difficile tox...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/582624/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2013-ema-decision-27-september-2013-agreement-paediatric-investigation-plan-granting-deferral-clostridium-difficile-toxin-human-monoclonal-antibody-clostridium-difficile-tox_en.pdf"},
    {"id":"38084","name":"P/0034/2017: European Medicines Agency decision of 30 January 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for Fc- and CDR-modified humanized monoclonal antibody against C5 (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/2916/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2017-european-medicines-agency-decision-30-january-2017-agreement-paediatric-investigation-plan-granting-deferral-fc-cdr-modified-humanized-monoclonal-antibody-against-c5_en.pdf"},
    {"id":"38094","name":"P/40/2008: European medicines agency decision of 24 June 2008\n\non the application for product specific waiver for AP214 Acetate (Αcetyl-(Lys)6-α-MSH, acetate salt) EMEA-000138-PIP01-07 in accordance with Regulation (EC...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/311978/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-40-2008-european-medicines-agency-decision-24-june-2008-application-product-specific-waiver-ap214-acetate-icetyl-lys6-i-msh-acetate-salt-emea-000138-pip01-07-accordance-regulation-ec_en.pdf"},
    {"id":"38096","name":"P/0081/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for tremelimumab\n\n(EMEA-002029-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/75600/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-tremelimumab-emea-002029-pip01-16_en.pdf"},
    {"id":"38106","name":"P/0310/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for obeticholic acid (6 alpha-ethylchenodeoxycholic acid) (EMEA-001304-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-02-04T01:00:00Z","reference_number":"EMA/785819/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0310-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-obeticholic-acid-6-alpha-ethylchenodeoxycholic-acid-emea-001304-pip02-13-m02_en.pdf"},
    {"id":"38113","name":"P/0217/2015: EMA decision of 2 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for azacitidine (Vidaza), (EMEA-001272-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T16:00:00Z","last_updated_date":"2015-11-23T16:00:00Z","reference_number":"EMA/578620/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-azacitidine-vidaza-emea-001272-pip02-13-m01_en.pdf"},
    {"id":"38116","name":"P/0068/2014: EMA decision of 14 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for glycerol phenylbutyrate (EMEA-000297-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/122586/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2014-ema-decision-14-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-glycerol-phenylbutyrate-emea-000297-pip02-12-m01_en.pdf"},
    {"id":"38121","name":"P/0245/2017: EMA decision of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of\n\na waiver for salmeterol (xinafoate) / fluticasone (propionate) (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/497687/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2017-ema-decision-4-september-2017-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-salmeterol-xinafoate-fluticasone-propionate-eme_en.pdf"},
    {"id":"38132","name":"P/277/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allergen extract of 50% grass (equal parts of lolium ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/754263/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-277-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extract-50-grass-equal-parts-lolium_en.pdf"},
    {"id":"38134","name":"P/0138/2014: EMA decision of 11 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant fusion protein linking human coagulation factor IX with human albumin (EMEA-001107-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-28T02:00:00Z","last_updated_date":"2014-07-28T02:00:00Z","reference_number":"EMA/268695/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2014-ema-decision-11-june-2014-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-fusion-protein-linking-human-coagulation-factor-ix-human-albumin-emea-001107_en.pdf"},
    {"id":"38142","name":"P/127/2008: European Medicines Agency decision of 23 December 2008 on the application for agreement of a Paediatric Investigation Plan for telaprevir (EMEA-000196-PIP01-08) in accordance with Regulation (EC) No 1901/2006...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/671617/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-127-2008-european-medicines-agency-decision-23-december-2008-application-agreement-paediatric-investigation-plan-telaprevir-emea-000196-pip01-08-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"38145","name":"European Medicines Agency decision P/0040/2018 of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant Neisseria meningitides…(EMEA-000139-PIP01-07-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T13:35:00Z","last_updated_date":"2018-04-17T13:35:00Z","reference_number":"EMA/77586/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/european-medicines-agency-decision-p-0040-2018-16-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-neisseria-meningitidesemea-000139-pip01-07-m02_en.pdf"},
    {"id":"38151","name":"P/0381/2017: EMA decision of 19 December 2017 on the agreement of a paediatric investigation plan and on the granting of a waiver for susoctocog alfa (Obizur), (EMEA-000753-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/759392/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0381-2017-ema-decision-19-december-2017-agreement-paediatric-investigation-plan-granting-waiver-susoctocog-alfa-obizur-emea-000753-pip02-16_en.pdf"},
    {"id":"38169","name":"P/0113/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for rituximab\n\n(Mabthera), (EMEA-000308-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/155548/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-rituximab-mabthera-emea-000308-pip01-08-m03_en.pdf"},
    {"id":"38171","name":"P/0192/2013: EMA decision of 15 August 2013 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (Edurant) (EMEA-000317-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-09-11T11:20:00Z","last_updated_date":"2013-09-11T11:20:00Z","reference_number":"EMA/484532/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2013-ema-decision-15-august-2013-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-edurant-emea-000317-pip01-08-m04_en.pdf"},
    {"id":"38186","name":"P/0136/2015: EMA decision of 15 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for eribulin (Halaven), (EMEA-001261-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-07T02:00:00Z","last_updated_date":"2015-07-07T02:00:00Z","reference_number":"EMA/384474/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2015-ema-decision-15-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-eribulin-halaven-emea-001261-pip01-11-m02_en.pdf"},
    {"id":"38193","name":"P/0089/2018: EMA decision of 16 March 2018 on the granting of a product- specific waiver for trazodone (hydrochloride) / gabapentin (EMEA-002263-\n\nPIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/87985/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2018-ema-decision-16-march-2018-granting-product-specific-waiver-trazodone-hydrochloride-gabapentin-emea-002263-pip01-17_en.pdf"},
    {"id":"38197","name":"P/3/2010: European Medicines Agency decision on the granting of a product specific waiver for linagliptin, metformin (EMA-000699-PIP01-09)\n\nin accordance with Regulation (EC) No 1901/2006 of the European Parliament and o...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMEA/38450/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-3-2010-european-medicines-agency-decision-granting-product-specific-waiver-linagliptin-metformin-ema-000699-pip01-09-accordance-regulation-ec-no-1901-2006-european-parliament-o_en.pdf"},
    {"id":"38211","name":"P/0200/2013: EMA decision of 2 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for pitolisant (hydrochloride), (EMEA-001176-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/483374/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2013-ema-decision-2-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-pitolisant-hydrochloride-emea-001176-pip01-11-m01_en.pdf"},
    {"id":"38221","name":"P/0242/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (EMEA-000332-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/617380/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-emea-000332-pip01-08-m09_en.pdf"},
    {"id":"38222","name":"P/0003/2013: EMA decision of 21 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Victoza), (EMEA-000128-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/19766/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2013-ema-decision-21-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-victoza-emea-000128-pip01-07-m05_en.pdf"},
    {"id":"38227","name":"P/0215/2013: EMA decision of 4 September 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for daclizumab (EMEA-001349-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/519897/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2013-ema-decision-4-september-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-daclizumab-emea-001349-pip01-12_en.pdf"},
    {"id":"38230","name":"P/85/2009: European medicines agency decision of 18 May 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for tigecycline (Tygacil), (EMEA-000120-PIP01-07-M01) in accordance with Regulat...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/272680/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-85-2009-european-medicines-agency-decision-18-may-2009-acceptance-modification-agreed-paediatric-investigation-plan-tigecycline-tygacil-emea-000120-pip01-07-m01-accordance-regulat_en.pdf"},
    {"id":"38231","name":"P/0254/2012: EMA decision of 22 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for riociguat (EMEA-\n\n000718-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/662557/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2012-ema-decision-22-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-riociguat-emea-000718-pip01-09-m02_en.pdf"},
    {"id":"38273","name":"P/0075/2013: EMA decision of 26 March 2013 on the granting of a product-specific waiver for alendronic acid / colecalciferol (EMEA-001327-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/114867/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2013-ema-decision-26-march-2013-granting-product-specific-waiver-alendronic-acid-colecalciferol-emea-001327-pip01-12_en.pdf"},
    {"id":"38285","name":"P/0082/2015: EMA decision of 10 April 2015 on the agreement of a paediatric investigation plan for recombinant human N-acetylglucosaminidase (rhNAGLU) (EMEA-001653-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-19T02:00:00Z","last_updated_date":"2015-05-19T02:00:00Z","reference_number":"EMA/227590/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2015-ema-decision-10-april-2015-agreement-paediatric-investigation-plan-recombinant-human-n-acetylglucosaminidase-rhnaglu-emea-001653-pip01-14_en.pdf"},
    {"id":"38312","name":"P/0157/2014: EMA decision of 18 June 2014 on the granting of a product specific waiver for clarithromycin (in combination with amoxicillin + metronidazole + pantoprazole) (EMEA-001614-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/259616/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2014-ema-decision-18-june-2014-granting-product-specific-waiver-clarithromycin-combination-amoxicillin-metronidazole-pantoprazole-emea-001614-pip01-13_en.pdf"},
    {"id":"38321","name":"P/0195/2012: EMA decision of 24 August 2012 on the granting of a product specific waiver for co-crystal of tramadol (hydrochloride) / celecoxib\n\n(EMEA-001279-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T13:30:00Z","last_updated_date":"2012-09-18T13:30:00Z","reference_number":"EMA/547672/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2012-ema-decision-24-august-2012-granting-product-specific-waiver-co-crystal-tramadol-hydrochloride-celecoxib-emea-001279-pip01-12_en.pdf"},
    {"id":"38327","name":"P/0157/2012: EMA decision of 25 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for velaglucerase alfa (EMEA-000556-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/475821/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2012-ema-decision-25-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-velaglucerase-alfa-emea-000556-pip01-09-m02_en.pdf"},
    {"id":"38351","name":"P/96/2011: EMA decision of 8 April 2011 on the acceptance of a modification of an agreed paediatric investigation plan for insulin degludec / insulin aspart (EMEA-000479-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/247853/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-96-2011-ema-decision-8-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-insulin-degludec-insulin-aspart-emea-000479-pip01-08-m01_en.pdf"},
    {"id":"38366","name":"P/0274/2016: EMA decision of 7 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for eftrenonacog alfa\n\n(ALPROLIX), (EMEA-000914-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/631038/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2016-ema-decision-7-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-eftrenonacog-alfa-alprolix-emea-000914-pip01-10-m03_en.pdf"},
    {"id":"38376","name":"P/90/2009: European medicines agency decision of 18 May 2009 on the refusal of a Paediatric Investigation Plan and on the granting of a waiver for drospirenone / ethinylestradiol, betadex clathrate / L-5 methyltetrahydro...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/272662/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-90-2009-european-medicines-agency-decision-18-may-2009-refusal-paediatric-investigation-plan-granting-waiver-drospirenone-ethinylestradiol-betadex-clathrate-l-5-methyltetrahydro_en.pdf"},
    {"id":"38378","name":"P/0214/2014: EMA decision of 1 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ertugliflozin (EMEA-001533-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T02:00:00Z","last_updated_date":"2014-09-30T02:00:00Z","reference_number":"EMA/464759/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2014-ema-decision-1-september-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ertugliflozin-emea-001533-pip01-13_en.pdf"},
    {"id":"38389","name":"P/0299/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for C1 inhibitor (human) (Cinryze) (EMEA-000568-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/792884/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-c1-inhibitor-human-cinryze-emea-000568-pip01-09-m06_en.pdf"},
    {"id":"38403","name":"P/0089/2016: EMA decision of 22 March 2016 on the granting of a product specific waiver for azithromycin / miconazole / sulfamethoxazole (EMEA-001769-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/104847/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2016-ema-decision-22-march-2016-granting-product-specific-waiver-azithromycin-miconazole-sulfamethoxazole-emea-001769-pip01-15_en.pdf"},
    {"id":"38419","name":"P/235/2009: European Medicines Agency Decision of 27 November 2009 on the granting of a product specific waiver for simvastatin / ramipril / acetyl salicylic acid (EMEA-000631-PIP01-09) in accordance with Regulation (EC)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:09:21Z","last_updated_date":"2009-12-23T00:09:21Z","reference_number":"EMEA/748470/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-235-2009-european-medicines-agency-decision-27-november-2009-granting-product-specific-waiver-simvastatin-ramipril-acetyl-salicylic-acid-emea-000631-pip01-09-accordance-regulation-ec_en.pdf"},
    {"id":"38427","name":"P/0200/2014: EMA decision of 8 August 2014 on the granting of a product specific waiver for human recombinant follicle-stimulating hormone (FE 999049), (EMEA-001183-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/392128/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2014-ema-decision-8-august-2014-granting-product-specific-waiver-human-recombinant-follicle-stimulating-hormone-fe-999049-emea-001183-pip02-13_en.pdf"},
    {"id":"38447","name":"P/0201/2012: EMA decision of 24 August 2012 on the granting of a product specific waiver for recombinant human antibody against activin type IIB\n\nreceptors (EMEA-001286-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T14:00:00Z","last_updated_date":"2012-09-18T14:00:00Z","reference_number":"EMA/534269/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2012-ema-decision-24-august-2012-granting-product-specific-waiver-recombinant-human-antibody-against-activin-type-iib-receptors-emea-001286-pip01-12_en.pdf"},
    {"id":"38459","name":"P/105/2012: EMA decision of 4 June 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tiotropium bromide (monohydrate) (Spiriva Respimat and associated names, Spiriva), (EMEA-000035-P...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-07-23T17:00:00Z","last_updated_date":"2012-07-23T17:00:00Z","reference_number":"EMA/285017/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-105-2012-ema-decision-4-june-2012-acceptance-modification-agreed-paediatric-investigation-plan-tiotropium-bromide-monohydrate-spiriva-respimat-associated-names-spiriva-emea-000035-p_en.pdf"},
    {"id":"38462","name":"P/0117/2018: EMA decision of 11 April 2018 on the granting of a product specific waiver for polatuzumab vedotin (EMEA-002255-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T02:00:00Z","last_updated_date":"2018-07-25T02:00:00Z","reference_number":"EMA/141773/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2018-ema-decision-11-april-2018-granting-product-specific-waiver-polatuzumab-vedotin-emea-002255-pip01-17_en.pdf"},
    {"id":"38476","name":"P/123/2009: European Medicines Agency decision of 12 June 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for rosuvastatin calcium (EMEA-000022-PIP01-07-M02) in accordance with Regulat...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/348182/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-123-2009-european-medicines-agency-decision-12-june-2009-acceptance-modification-agreed-paediatric-investigation-plan-rosuvastatin-calcium-emea-000022-pip01-07-m02-accordance-regulat_en.pdf"},
    {"id":"38479","name":"P/0247/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin (Forxiga), (EMEA-000694-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/617377/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-forxiga-emea-000694-pip01-09-m06_en.pdf"},
    {"id":"38482","name":"P/0223/2012: EMA decision of 1 October 2012 on the granting of a product specific waiver for rosuvastatin / acetylsalicylic acid (EMEA-001269-PIP01-\n\n12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/559169/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2012-ema-decision-1-october-2012-granting-product-specific-waiver-rosuvastatin-acetylsalicylic-acid-emea-001269-pip01-12_en.pdf"},
    {"id":"38508","name":"P/0186/2017: EMA decision of 30 June 2017 on the granting of a product-specific waiver for rosuvastatin (calcium) / ezetimibe (EMEA-002131-\n\nPIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/371179/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2017-ema-decision-30-june-2017-granting-product-specific-waiver-rosuvastatin-calcium-ezetimibe-emea-002131-pip01-17_en.pdf"},
    {"id":"38533","name":"P/0244/2016: EMA decision of 9 September 2016 on the granting of a product specific waiver for humanized IgG1, kappa anti-serum amyloid A and anti-\n\nAL amyloid antibody (EMEA-001962-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/513695/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2016-ema-decision-9-september-2016-granting-product-specific-waiver-humanized-igg1-kappa-anti-serum-amyloid-anti-al-amyloid-antibody-emea-001962-pip01-16_en.pdf"},
    {"id":"38537","name":"P/149/2011: EMA decision of 9 June 2011 on the acceptance of a modification of an agreed paediatric investigation plan for rotavirus type G1/rotavirus type G2/rotavirus type G3/rotavirus type G4/rotavirus type P1A[8] (Ro...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-07-13T02:00:00Z","last_updated_date":"2011-07-13T02:00:00Z","reference_number":"EMA/387137/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-149-2011-ema-decision-9-june-2011-acceptance-modification-agreed-paediatric-investigation-plan-rotavirus-type-g1-rotavirus-type-g2-rotavirus-type-g3-rotavirus-type-g4-rotavirus-type-p1a8-ro_en.pdf"},
    {"id":"38538","name":"P/0358/2017: EMA decision of 1 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for emapalumab\n\n(EMEA-002031-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/763260/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0358-2017-ema-decision-1-december-2017-agreement-paediatric-investigation-plan-granting-deferral-emapalumab-emea-002031-pip01-16_en.pdf"},
    {"id":"38572","name":"P/0017/2015: EMA decision of 30 January 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for reslizumab (EMEA-001202-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/776144/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2015-ema-decision-30-january-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-reslizumab-emea-001202-pip02-13_en.pdf"},
    {"id":"38587","name":"P/0096/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for oritavancin\n\n(diphosphate) (Orbactiv), (EMEA-001270-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/155550/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-oritavancin-diphosphate-orbactiv-emea-001270-pip01-12-m01_en.pdf"},
    {"id":"38598","name":"P/0266/2016: EMA decision of 5 October 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for ragweed pollen extract (Ambrosia artemisiifolia) (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/576571/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2016-ema-decision-5-october-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ragweed-pollen-extract-ambrosia-artemisiifolia-eme_en.pdf"},
    {"id":"38605","name":"P/119/2008: European Medicines Agency decision of 1 December 2008 on the application for agreement of a Paediatric Investigation Plan for Alipogene tiparvovec, EMEA-000292-PIP01-08 in accordance with Regulation (EC) No 1...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/620398/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-119-2008-european-medicines-agency-decision-1-december-2008-application-agreement-paediatric-investigation-plan-alipogene-tiparvovec-emea-000292-pip01-08-accordance-regulation-ec-no-1_en.pdf"},
    {"id":"38608","name":"P/0035/2014: EMA decision of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (EMEA-000576-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/797036/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2014-ema-decision-5-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-emea-000576-pip01-09-m04_en.pdf"},
    {"id":"38611","name":"P/208/2010: EMEA decision on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H1N1/Influenza virus surface an...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-24T01:00:00Z","last_updated_date":"2010-11-24T01:00:00Z","reference_number":"EMA/615009/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-208-2010-emea-decision-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h1n1-influenza-virus-surface_en.pdf"},
    {"id":"38620","name":"P/0009/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for raltegravir (Isentress), (EMEA-000279-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/793798/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-raltegravir-isentress-emea-000279-pip01-08-m03_en.pdf"},
    {"id":"38630","name":"P/0002/2018: EMA decision of 4 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for artenimol /\n\npiperaquine phosphate anhydride (Eurartesim), (EMEA-000153-PIP01-07-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T13:35:00Z","last_updated_date":"2018-04-17T13:35:00Z","reference_number":"EMA/517/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2018-ema-decision-4-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-artenimol-piperaquine-phosphate-anhydride-eurartesim-emea-000153-pip01-07-m05_en.pdf"},
    {"id":"38640","name":"P/0008/2013: EMA decision of 22 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin (Forxiga), (EMEA-000694-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T18:30:00Z","last_updated_date":"2013-04-03T18:30:00Z","reference_number":"EMA/20983/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2013-ema-decision-22-january-2013-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-forxiga-emea-000694-pip01-09-m02_en.pdf"},
    {"id":"38651","name":"P/0139/2015: EMA decision of 10 July 2015 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab (EMEA - 000069-PIP02-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-24T16:00:00Z","last_updated_date":"2015-08-24T16:00:00Z","reference_number":"EMA/366951/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2015-ema-decision-10-july-2015-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-emea-000069-pip02-10-m05_en.pdf"},
    {"id":"38670","name":"P/116/2011: EMA decision of 18 May 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for perflubutane (EMEA-000194-PIP03-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-09T02:00:00Z","last_updated_date":"2011-06-09T02:00:00Z","reference_number":"EMA/326597/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-116-2011-ema-decision-18-may-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-perflubutane-emea-000194-pip03-10_en.pdf"},
    {"id":"38671","name":"P/0338/2014: EMA decision of 22 December 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glyc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/713528/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0338-2014-ema-decision-22-december-2014-agreement-paediatric-investigation-plan-granting-deferral-covalently-closed-dna-plasmids-coding-cytomegalovirus-phosphoprotein-65-glyc_en.pdf"},
    {"id":"38696","name":"P/64/2008: European medicines agency decision of 15 August 2008 on the application for agreement of a Paediatric Investigation Plan for peginterferon alfa-2b, PegIntron (EMEA-000071-PIP01-07) in accordance with Regulatio...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/424620/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-64-2008-european-medicines-agency-decision-15-august-2008-application-agreement-paediatric-investigation-plan-peginterferon-alfa-2b-pegintron-emea-000071-pip01-07-accordance-regulatio_en.pdf"},
    {"id":"38730","name":"P/240/2009: EMA decision of 1 December 2009 on the granting of a product specific waiver for saxagliptin / metformin (EMEA-000644-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the Eu...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:09:00Z","last_updated_date":"2010-01-25T00:09:00Z","reference_number":"EMEA/757733/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-240-2009-ema-decision-1-december-2009-granting-product-specific-waiver-saxagliptin-metformin-emea-000644-pip01-09-accordance-regulation-ec-no-1901-2006-eu_en.pdf"},
    {"id":"38745","name":"P/0193/2015: EMA decision of 4 September 2015 on the acceptance of a modification of an agreed paediatric investigation plan for indacaterol (acetate) / mometasone (furoate) (EMEA-001217-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/505293/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2015-ema-decision-4-september-2015-acceptance-modification-agreed-paediatric-investigation-plan-indacaterol-acetate-mometasone-furoate-emea-001217-pip01-11-m01_en.pdf"},
    {"id":"38748","name":"P/0069/2012: EMA decision of 4 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (EMEA-000115-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-27T13:00:00Z","last_updated_date":"2012-04-27T13:00:00Z","reference_number":"EMA/202941/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2012-ema-decision-4-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-emea-000115-pip01-07-m02_en.pdf"},
    {"id":"38754","name":"P/0260/2013: EMA decision of 29 October 2013 on the agreement of a paediatric investigation plan for recombinant human tripeptidyl peptidase-1 (EMEA-001362-PIP01-12)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/587131/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2013-ema-decision-29-october-2013-agreement-paediatric-investigation-plan-recombinant-human-tripeptidyl-peptidase-1-emea-001362-pip01-12_en.pdf"},
    {"id":"38756","name":"P/154/2009: EMEA decision of 11 August 2009\n\non the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for recombinant human monoclonal antibody to human interl...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/492748/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-154-2009-emea-decision-11-august-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-monoclonal-antibody-human-interl_en.pdf"},
    {"id":"38762","name":"P/1/2010: European Medicines Agency decision of 25 January 2010\n\non the acceptance of a modification of an agreed Paediatric Investigation Plan\n\nfor Ulipristal acetate (EMEA-000305-PIP01-08-M01) in accordance with Regula...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMEA/28385/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-1-2010-european-medicines-agency-decision-25-january-2010-acceptance-modification-agreed-paediatric-investigation-plan-ulipristal-acetate-emea-000305-pip01-08-m01-accordance-regula_en.pdf"},
    {"id":"38768","name":"P/111/2009: EMEA decision of 16 June 2009 on the agreement of a PIP and on the granting of a waiver for Human Papillomavirus1 Type6 L1 protein / Human Papillomavirus1 Type11 L1 protein /Human Papillomavirus1 Type16 L1 pr...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351468/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-111-2009-emea-decision-16-june-2009-agreement-pip-granting-waiver-human-papillomavirus1-type6-l1-protein-human-papillomavirus1-type11-l1-protein-human-papillomavirus1-type16-l1-pr_en.pdf"},
    {"id":"38781","name":"P/97/2011: EMA decision of 8 April 2011 on the acceptance of a modification of an agreed paediatric investigation plan for saxagliptin (Onglyza), (EMEA-000200-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-12T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/258007/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-97-2011-ema-decision-8-april-2011-acceptance-modification-agreed-paediatric-investigation-plan-saxagliptin-onglyza-emea-000200-pip01-08-m03_en.pdf"},
    {"id":"38788","name":"P/0063/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin (Forxiga), (EMEA-000694-PIP02-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-26T02:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/131043/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-forxiga-emea-000694-pip02-14-m01_en.pdf"},
    {"id":"38794","name":"P/0318/2015: EMA decision of 21 December 2015 on the granting of a product-specific waiver for telotristat etiprate (EMEA-001840-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/759754/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2015-ema-decision-21-december-2015-granting-product-specific-waiver-telotristat-etiprate-emea-001840-pip01-15_en.pdf"},
    {"id":"38810","name":"P/204/2009: European Medicines Agency decision of 21 October 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for mannitol (EMEA-000436-PIP01-08) ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-12-07T00:09:00Z","last_updated_date":"2009-12-07T00:09:00Z","reference_number":"EMEA/659861/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-204-2009-european-medicines-agency-decision-21-october-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mannitol-emea-000436-pip01-08_en.pdf"},
    {"id":"38821","name":"P/0008/2015: EMA decision of 30 January 2015 on the granting of a product specific waiver for human papillomavirus type 18 L1 protein / human papillomavirus type 16 L1 protein (Cervarix), (EMEA-000234-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/793136/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2015-ema-decision-30-january-2015-granting-product-specific-waiver-human-papillomavirus-type-18-l1-protein-human-papillomavirus-type-16-l1-protein-cervarix-emea-000234-pip02-14_en.pdf"},
    {"id":"38833","name":"P/0314/2013: EMA decision of 19 December 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sodium N-{6-[3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropy...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-05T01:00:00Z","last_updated_date":"2014-02-05T01:00:00Z","reference_number":"EMA/693867/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2013-ema-decision-19-december-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sodium-n-6-3-tert-butyl-5-24-dioxo-34-dihydropy_en.pdf"},
    {"id":"38858","name":"P/0262/2012: EMA decision of of 20 November 2012 on the acceptance of a modification of an agreed paediatric investigation plan for nicotinic acid / laropiprant (Tredaptive), (EMEA-000063-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/646946/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2012-ema-decision-20-november-2012-acceptance-modification-agreed-paediatric-investigation-plan-nicotinic-acid-laropiprant-tredaptive-emea-000063-pip01-07-m01_en.pdf"},
    {"id":"38861","name":"P/0066/2016: EMA decision of 18 March 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for romosozumab (EMEA-001075-PIP04-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/139282/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2016-ema-decision-18-march-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-romosozumab-emea-001075-pip04-15_en.pdf"},
    {"id":"38865","name":"P/0055/2018: EMA decision of 9 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lanadelumab (DX-2930) (EMEA-001864-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/123907/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2018-ema-decision-9-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-lanadelumab-dx-2930-emea-001864-pip01-15-m02_en.pdf"},
    {"id":"38877","name":"P/0211/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for elvitegravir /\n\ncobicistat / emtricitabine / tenofovir alafenamide (Genvoya), (EMEA-001460-PIP...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/459569/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya-emea-001460-pip_en.pdf"},
    {"id":"38889","name":"P/0011/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for midostaurin\n\n(EMEA-000780-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/20904/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-midostaurin-emea-000780-pip01-09-m03_en.pdf"},
    {"id":"38896","name":"P/0271/2016: EMA decision of 7 October 2016 on the granting of a product specific waiver for gentamicin (sulphate) (EMEA-001982-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/633120/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2016-ema-decision-7-october-2016-granting-product-specific-waiver-gentamicin-sulphate-emea-001982-pip01-16_en.pdf"},
    {"id":"38900","name":"P/0005/2012: EMA decision of 23 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of bi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-23T13:30:00Z","last_updated_date":"2012-02-23T13:30:00Z","reference_number":"EMA/972927/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2012-ema-decision-23-january-2012-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergen-extract-bi_en.pdf"},
    {"id":"38909","name":"P/246/2010:  EMA decision of 26 November 2010 on the agreement of a PIP and on the granting of a deferral and on the\n\ngranting of a waiver for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/673268/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-246-2010-ema-decision-26-november-2010-agreement-pip-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergi_en.pdf"},
    {"id":"38918","name":"P/0079/2012: EMA decision of 27 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for human normal\n\nimmunoglobulin (Gammagen) (EMEA-000415-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/253072/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2012-ema-decision-27-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-gammagen-emea-000415-pip01-08-m01_en.pdf"},
    {"id":"38920","name":"P/0125/2015: EMA decision of 5 June 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Norovirus GI.1 virus-like particle antigen / Norovirus GI...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-03T02:00:00Z","last_updated_date":"2015-07-03T02:00:00Z","reference_number":"EMA/284196/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2015-ema-decision-5-june-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-norovirus-gi1-virus-particle-antigen-norovirus-gi_en.pdf"},
    {"id":"38925","name":"P/0175/2015: EMA decision of 7 August 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for atrasentan (hydrochloride) (EMEA-001666-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"EMA/473934/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2015-ema-decision-7-august-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-atrasentan-hydrochloride-emea-001666-pip01-14_en.pdf"},
    {"id":"38926","name":"P/320/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of birch and hazel pollen (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769415/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-320-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-birch-hazel-pollen_en.pdf"},
    {"id":"38930","name":"P/0019/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodi...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/12342/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-citric-acid-citric-acid-anhydrous-sodium-chloride-simeticone-macrogol-4000-sodi_en.pdf"},
    {"id":"38942","name":"P/0129/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (phosphate monohydrate) (TESAVEL) EMEA-000472-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-02-28T01:00:00Z","last_updated_date":"2017-02-28T01:00:00Z","reference_number":"EMA/295716/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-phosphate-monohydrate-tesavel-emea-000472-pip01-08-m02_en.pdf"},
    {"id":"38947","name":"P/0340/2017: EMA decision of 10 November 2017 on the acceptance of a modification of an agreed paediatric investigation plan for bumetanide (EMEA-\n\n001303-PIP01-12-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-15T10:19:00Z","last_updated_date":"2018-02-15T10:19:00Z","reference_number":"EMA/711129/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0340-2017-ema-decision-10-november-2017-acceptance-modification-agreed-paediatric-investigation-plan-bumetanide-emea-001303-pip01-12-m02_en.pdf"},
    {"id":"38952","name":"P/0315/2017: EMA decision of 31 October 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for maribavir\n\n(EMEA-000353-PIP02-16)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T13:11:00Z","last_updated_date":"2018-02-12T13:11:00Z","reference_number":"EMA/666643/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0315-2017-ema-decision-31-october-2017-agreement-paediatric-investigation-plan-granting-deferral-maribavir-emea-000353-pip02-16_en.pdf"},
    {"id":"38975","name":"P/259/2011: EMA decision of 26 October 2011 on the granting of a product specific waiver for brinzolamide / brimonidine (tartrate) (EMEA-001172-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T01:00:00Z","last_updated_date":"2011-11-29T01:00:00Z","reference_number":"EMA/764077/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-259-2011-ema-decision-26-october-2011-granting-product-specific-waiver-brinzolamide-brimonidine-tartrate-emea-001172-pip01-11_en.pdf"},
    {"id":"38987","name":"P/0321/2014: EMA decision of 19 December 2014 on the granting of a product specific waiver for urofollitropin (EMEA-001655-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T13:30:00Z","last_updated_date":"2015-02-23T13:30:00Z","reference_number":"EMA/755898/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0321-2014-ema-decision-19-december-2014-granting-product-specific-waiver-urofollitropin-emea-001655-pip01-14_en.pdf"},
    {"id":"39011","name":"P/0239/2013: EMA decision of 24 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for dabrafenib (mesilate) (EMEA-001147-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/496862/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2013-ema-decision-24-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-dabrafenib-mesilate-emea-001147-pip01-11-m01_en.pdf"},
    {"id":"39033","name":"P/0339/2017: EMA decision of 10 November 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pneumococcal polysaccharide serotype 1 – diphtheria...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-12T01:00:00Z","last_updated_date":"2018-02-12T01:00:00Z","reference_number":"EMA/710111/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0339-2017-ema-decision-10-november-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pneumococcal-polysaccharide-serotype-1-diphtheria_en.pdf"},
    {"id":"39034","name":"P/0333/2014: EMA decision of 22 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for serelaxin (EMEA-001168-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-02-23T01:00:00Z","last_updated_date":"2015-02-23T01:00:00Z","reference_number":"EMA/739522/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0333-2014-ema-decision-22-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-serelaxin-emea-001168-pip01-11-m02_en.pdf"},
    {"id":"39051","name":"P/0173/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sebelipase alfa (EMEA-001331-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/434301/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-sebelipase-alfa-emea-001331-pip01-12-m02_en.pdf"},
    {"id":"39059","name":"P/0061/2013: European medicines agency decision of 26 March 2013 on the acceptance of a modification of an agreed paediatric investigation plan for saxagliptin (Onglyza), (EMEA-000200-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/103240/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2013-european-medicines-agency-decision-26-march-2013-acceptance-modification-agreed-paediatric-investigation-plan-saxagliptin-onglyza-emea-000200-pip01-08-m04_en.pdf"},
    {"id":"39063","name":"P/0249/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for split influenza virus, inactivated containing antigens equivalent to the B-like strain (B/Ya...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/619853/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigens-equivalent-b-strain-b-ya_en.pdf"},
    {"id":"39066","name":"P/207/2011: EMA decision of 1 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for colestilan (EMEA-000878-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/697254/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-207-2011-ema-decision-1-september-2011-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-colestilan-emea-000878-pip02-11_en.pdf"},
    {"id":"39068","name":"P/0064/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for sirolimus (EMEA-\n\n001416-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/137079/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-sirolimus-emea-001416-pip01-12-m01_en.pdf"}    {"id":"39079","name":"P/192/2011: EMA decision of 3 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for beclometasone dipropionate / formoterol fumarate dihydrate (Foster and associated names, Kantos...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/591812/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-192-2011-ema-decision-3-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-beclometasone-dipropionate-formoterol-fumarate-dihydrate-foster-associated-names-kantos_en.pdf"},
    {"id":"39092","name":"P/0036/2017: European Medicines Agency decision of 31 January 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for pegvaliase (EMEA-001951-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/12302/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2017-european-medicines-agency-decision-31-january-2017-agreement-paediatric-investigation-plan-granting-deferral-pegvaliase-emea-001951-pip01-16_en.pdf"},
    {"id":"39128","name":"P/0267/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir (phosphate) Tamiflu (EMEA-000365-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/764515/20015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-oseltamivir-phosphate-tamiflu-emea-000365-pip01-08-m07_en.pdf"},
    {"id":"39134","name":"P/0184/2016: EMA decision of 15 July 2016 on the refusal of a modification of an agreed paediatric investigation plan for decitabine (Dacogen)\n\n(EMEA-000555-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T02:00:00Z","last_updated_date":"2016-09-22T02:00:00Z","reference_number":"EMA/408586/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2016-ema-decision-15-july-2016-refusal-modification-agreed-paediatric-investigation-plan-decitabine-dacogen-emea-000555-pip01-09-m04_en.pdf"},
    {"id":"39138","name":"P/0144/2013: EMA decision of 3 July 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for terbinafine hydrochloride (EMEA-001259-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-09T16:30:00Z","last_updated_date":"2013-08-09T16:30:00Z","reference_number":"EMA/306174/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2013-ema-decision-3-july-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-terbinafine-hydrochloride-emea-001259-pip02-13_en.pdf"},
    {"id":"39144","name":"P/0219/2013: EMA decision of 6 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for loxapine (EMEA-001115-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/483218/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2013-ema-decision-6-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-loxapine-emea-001115-pip01-10-m01_en.pdf"},
    {"id":"39162","name":"P/311/2013: EMA decision of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for gadobutrol (Gadovist) (EMEA-000994-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-04T01:00:00Z","last_updated_date":"2014-02-04T01:00:00Z","reference_number":"EMA/722479/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-311-2013-ema-decision-19-december-2013-acceptance-modification-agreed-paediatric-investigation-plan-gadobutrol-gadovist-emea-000994-pip01-10-m01_en.pdf"},
    {"id":"39175","name":"P/0202/2012: EMA decision of 30 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (EMEA-000115-PIP01-07-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T13:20:00Z","last_updated_date":"2012-09-18T13:20:00Z","reference_number":"EMA/501091/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2012-ema-decision-30-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-emea-000115-pip01-07-m03_en.pdf"},
    {"id":"39197","name":"P/0030/2014: European Medicines Agency decision of 21 February 2014\n\non the acceptance of a modification of an agreed paediatric investigation plan for (EMEA-000673-PIP01-09-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-03-20T01:00:00Z","last_updated_date":"2014-03-20T01:00:00Z","reference_number":"EMA/58694/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2014-european-medicines-agency-decision-21-february-2014-acceptance-modification-agreed-paediatric-investigation-plan-emea-000673-pip01-09-m07_en.pdf"},
    {"id":"39208","name":"P/0016/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for conestat alfa\n\n(Ruconest) (EMEA-000367-PIP01-08-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T15:28:00Z","last_updated_date":"2018-04-17T15:28:00Z","reference_number":"EMA/28038/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-conestat-alfa-ruconest-emea-000367-pip01-08-m07_en.pdf"},
    {"id":"39225","name":"P/0149/2016: EMA decision of 14 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for efmorocotocog alfa\n\n(Elocta), (EMEA-001114-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-30T02:00:00Z","last_updated_date":"2016-08-30T02:00:00Z","reference_number":"EMA/334432/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2016-ema-decision-14-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-efmorocotocog-alfa-elocta-emea-001114-pip01-10-m03_en.pdf"},
    {"id":"39226","name":"P/0328/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus\n\nsurface antigens (haemagglutinin and neuraminidase)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-02-20T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"EMA/666631/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0328-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase_en.pdf"},
    {"id":"39227","name":"P/0192/2014: EMA decision of 6 August 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dupilumab (EMEA-001501-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/391491/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2014-ema-decision-6-august-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dupilumab-emea-001501-pip02-13_en.pdf"},
    {"id":"39237","name":"P/0092/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sildenafil (Revatio), (EMEA-000671-PIP01-09-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/215075/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-sildenafil-revatio-emea-000671-pip01-09-m07_en.pdf"},
    {"id":"39253","name":"P/0077/2012: EMA decision of 25 April 2012 on the granting of a product specific waiver for clopidogrel (hydrogen sulfate) / acetyl salicylic acid\n\n(EMEA-001257-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/255555/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2012-ema-decision-25-april-2012-granting-product-specific-waiver-clopidogrel-hydrogen-sulfate-acetyl-salicylic-acid-emea-001257-pip01-11_en.pdf"},
    {"id":"39257","name":"P/0327/2014: EMA decision of 11 December 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten and associated names) (EMEA-000347-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-01-22T01:00:00Z","last_updated_date":"2015-01-22T01:00:00Z","reference_number":"EMA/71305/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0327-2014-ema-decision-11-december-2014-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-associated-names-emea-000347-pip01-08-m04_en.pdf"},
    {"id":"39275","name":"P/0133/2017: EMA decision of 7 June 2017 on the granting of a product specific waiver for soybean oil/medium-chain triglycerides/olive oil/fish oil/acetyl-cysteine/alanine/arginine/glycine/histidine/isoleucin/leucine/lys...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/312725/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2017-ema-decision-7-june-2017-granting-product-specific-waiver-soybean-oil-medium-chain-triglycerides-olive-oil-fish-oil-acetyl-cysteine-alanine-arginine-glycine-histidine-isoleucin-leucine-lys_en.pdf"},
    {"id":"39286","name":"P/0079/2017: EMA decision of 17 March 2017 on the granting of a product specific waiver for alpelisib (EMEA-002016-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/104983/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2017-ema-decision-17-march-2017-granting-product-specific-waiver-alpelisib-emea-002016-pip02-16_en.pdf"},
    {"id":"39296","name":"P/0226/2012: EMA decision of 3 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara) (EMEA-000311-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T01:00:00Z","last_updated_date":"2012-11-23T01:00:00Z","reference_number":"EMA/616794/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2012-ema-decision-3-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip01-08-m02_en.pdf"},
    {"id":"39309","name":"P/0134/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for cabozantinib (Cometriq) (EMEA-001143-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T02:00:00Z","last_updated_date":"2016-07-27T02:00:00Z","reference_number":"EMA/326956/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-cabozantinib-cometriq-emea-001143-pip01-11-m01_en.pdf"},
    {"id":"39316","name":"P/0007/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for eltrombopag\n\n(Revolade), (EMEA-000170-PIP03-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/12343/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-eltrombopag-revolade-emea-000170-pip03-13-m02_en.pdf"},
    {"id":"39320","name":"P/0050/2012: EMA decision of 2 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for guanfacine\n\n(hydrochloride) (EMEA-000745-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-10T02:00:00Z","last_updated_date":"2012-04-10T02:00:00Z","reference_number":"EMA/136005/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2012-ema-decision-2-march-2012-acceptance-modification-agreed-paediatric-investigation-plan-guanfacine-hydrochloride-emea-000745-pip01-09-m01_en.pdf"},
    {"id":"39335","name":"P/172/2011: EMA decision of 4 July 2011 on the acceptance of a modification of an agreed paediatric investigation plan for coagulation factor IX\n\n(recombinant) (EMEA-000661-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/485276/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-172-2011-ema-decision-4-july-2011-acceptance-modification-agreed-paediatric-investigation-plan-coagulation-factor-ix-recombinant-emea-000661-pip01-09-m03_en.pdf"},
    {"id":"39366","name":"P/0111/2015: EMA decision of 5 June 2015 on the acceptance of a modification of an agreed paediatric investigation plan for telavancin (hydrochloride) (Vibativ), (EMEA-000239-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2015-07-06T02:00:00Z","reference_number":"EMA/296255/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2015-ema-decision-5-june-2015-acceptance-modification-agreed-paediatric-investigation-plan-telavancin-hydrochloride-vibativ-emea-000239-pip01-08-m01_en.pdf"},
    {"id":"39397","name":"P/0138/2013: EMA decision of 21 June 2013 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid) (EMEA-000115-PIP02-09-M0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-07-23T12:00:00Z","last_updated_date":"2013-07-23T12:00:00Z","reference_number":"EMA/330461/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2013-ema-decision-21-june-2013-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-3-5-2-fluoro-phenyl-124oxadiazole-3-yl-benzoic-acid-emea-000115-pip02-09-m0_en.pdf"},
    {"id":"39410","name":"P/74/2010: European Medicines Agency decision of 5 May 2010 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis virus, inactivated (attenuated strain SA14-14-2 grown i...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/249213/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-74-2010-european-medicines-agency-decision-5-may-2010-acceptance-modification-agreed-paediatric-investigation-plan-japanese-encephalitis-virus-inactivated-attenuated-strain-sa14-14-2-grown-i_en.pdf"},
    {"id":"39440","name":"P/0121/2017: EMA decision of 5 May 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of\n\na waiver for recombinant modified human growth hormone (EMEA-001152-PIP02...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/250886/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2017-ema-decision-5-may-2017-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-recombinant-modified-human-growth-hormone-emea-001152-pip02_en.pdf"},
    {"id":"39441","name":"P/74/2009: European Medicines Agency decision of 20 April 2009 on the granting of a product specific waiver for Bismuth subcitrate potassium / Metronidazole / Tetracycline hydrochloride (EMEA-000382-PIP01-08) in accordan...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-06-10T02:00:00Z","last_updated_date":"2009-06-10T02:00:00Z","reference_number":"EMEA/230384/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-74-2009-european-medicines-agency-decision-20-april-2009-granting-product-specific-waiver-bismuth-subcitrate-potassium-metronidazole-tetracycline-hydrochloride-emea-000382-pip01-08-accordan_en.pdf"},
    {"id":"39485","name":"P/0245/2016: EMA decision of 12 September 2016 on the granting of a product specific waiver for amlodipine (besylate) / perindopril (erbumine) /\n\nindapamide (EMEA-001948-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/513669/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2016-ema-decision-12-september-2016-granting-product-specific-waiver-amlodipine-besylate-perindopril-erbumine-indapamide-emea-001948-pip01-16_en.pdf"},
    {"id":"39488","name":"P/19/2011: EMA decision of 25 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (phosphate monohydrate) (Januvia), (EMEA-000470-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-30T01:09:21Z","last_updated_date":"2011-02-25T00:09:21Z","reference_number":"EMA/26024/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-19-2011-ema-decision-25-january-2011-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-phosphate-monohydrate-januvia-emea-000470-pip01-08-m03_en.pdf"},
    {"id":"39501","name":"P/0102/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for ivabradine (hydrochloride) (Procoralan) (EMEA-000628-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/203739/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2013-ema-decision-30-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-ivabradine-hydrochloride-procoralan-emea-000628-pip01-09-m04_en.pdf"},
    {"id":"39514","name":"P/0157/2017: EMA decision of 9 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone (furoate) / vilanterol (Relvar Ellipta and associated names), (EMEA-000431-PIP01-08-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T02:00:00Z","last_updated_date":"2017-07-25T02:00:00Z","reference_number":"EMA/350306/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2017-ema-decision-9-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-vilanterol-relvar-ellipta-associated-names-emea-000431-pip01-08_en.pdf"},
    {"id":"39551","name":"P/0239/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for canakinumab, (Ilaris) (EMEA-000060-PIP05-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/627039/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-canakinumab-ilaris-emea-000060-pip05-14-m01_en.pdf"},
    {"id":"39553","name":"P/0024/2017: EMA decision of 31 January 2017 on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine /\n\ntenofovir alafenamide (Descovy), (EMEA-001577-PIP02-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-20T01:00:00Z","last_updated_date":"2017-03-20T01:00:00Z","reference_number":"EMA/34944/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2017-ema-decision-31-january-2017-acceptance-modification-agreed-paediatric-investigation-plan-emtricitabine-tenofovir-alafenamide-descovy-emea-001577-pip02-14-m01_en.pdf"},
    {"id":"39563","name":"P/0170/2012: EMA decision of 27 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for romiplostim (Nplate) (EMEA-000653-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/490002/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2012-ema-decision-27-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-romiplostim-nplate-emea-000653-pip01-09-m02_en.pdf"},
    {"id":"39600","name":"P/0256/2017: EMA decision of 4 September 2017 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat (Rezolsta), (EMEA-001280-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T17:00:00Z","last_updated_date":"2017-10-26T17:00:00Z","reference_number":"EMA/498846/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2017-ema-decision-4-september-2017-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-rezolsta-emea-001280-pip01-12-m01_en.pdf"},
    {"id":"39611","name":"P/0181/2014: EMA decision of 17 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir / ledipasvir (EMEA-001411-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/414174/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2014-ema-decision-17-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-sofosbuvir-ledipasvir-emea-001411-pip01-12-m01_en.pdf"},
    {"id":"39636","name":"P/0225/2013: EMA decision of 23 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for decitabine (Dacogen), (EMEA-000555-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/562590/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2013-ema-decision-23-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-decitabine-dacogen-emea-000555-pip01-09-m04_en.pdf"},
    {"id":"39641","name":"P/0332/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for naltrexone\n\n(hydrochloride) / bupropion (hydrochloride) (Mysimba), (EMEA-001373-PIP01-12-M02...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T13:11:00Z","last_updated_date":"2017-02-03T13:11:00Z","reference_number":"EMA/757941/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0332-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-naltrexone-hydrochloride-bupropion-hydrochloride-mysimba-emea-001373-pip01-12-m02_en.pdf"},
    {"id":"39658","name":"P/0293/2015: EMA decision of 27 November 2015 on the granting of a product specific waiver for olmesartan medoxomil / amlodipine (besilate) (EMEA-001852-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/689489/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2015-ema-decision-27-november-2015-granting-product-specific-waiver-olmesartan-medoxomil-amlodipine-besilate-emea-001852-pip01-15_en.pdf"},
    {"id":"39665","name":"P/0113/2016: EMA decision of 15 April 2016 on the granting of a product specific waiver for finasteride (EMEA-001878-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/203924/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2016-ema-decision-15-april-2016-granting-product-specific-waiver-finasteride-emea-001878-pip01-15_en.pdf"},
    {"id":"39669","name":"P/0106/2014: EMA decision of 5 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for octadecasodium hexakis(4-{[(1S,3R)-1-([1,1´-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]am...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-11T16:00:00Z","last_updated_date":"2014-06-11T16:00:00Z","reference_number":"EMA/169104/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2014-ema-decision-5-may-2014-acceptance-modification-agreed-paediatric-investigation-plan-octadecasodium-hexakis4-1s3r-1-11-biphenyl-4-ylmethyl-4-ethoxy-3-methyl-4-oxobutylam_en.pdf"},
    {"id":"39672","name":"P/0057/2012: EMA decision of 26 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for lanthanum carbonate hydrate (Fosrenol and associated names), (EMEA-000637-PIP02-10-M02","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T17:42:00Z","last_updated_date":"2012-04-20T17:42:00Z","reference_number":"EMA/190322/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2012-ema-decision-26-march-2012-acceptance-modification-agreed-paediatric-investigation-plan-lanthanum-carbonate-hydrate-fosrenol-associated-names-emea-000637-pip02-10-m02_en.pdf"},
    {"id":"39681","name":"P/0122/2014: EMA decision of 7 May 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant human alpha-mannosidase (EMEA-001056-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-06-05T02:00:00Z","last_updated_date":"2014-06-05T02:00:00Z","reference_number":"EMA/182175/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2014-ema-decision-7-may-2014-agreement-paediatric-investigation-plan-granting-deferral-recombinant-human-alpha-mannosidase-emea-001056-pip02-12_en.pdf"},
    {"id":"39704","name":"P/0110/2013: EMA decision of 30 April 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for bumetanide (EMEA-001303-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/201276/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2013-ema-decision-30-april-2013-agreement-paediatric-investigation-plan-granting-waiver-bumetanide-emea-001303-pip01-12_en.pdf"},
    {"id":"39716","name":"P/0275/2013: EMA decision of 30 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for rufinamide (Inovelon), (EMEA-000709-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/592148/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2013-ema-decision-30-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-rufinamide-inovelon-emea-000709-pip01-09-m01_en.pdf"},
    {"id":"39722","name":"P/0220/2014: EMA decision of 3 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for idelalisib (EMEA-001350-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-09-29T02:00:00Z","last_updated_date":"2014-09-29T02:00:00Z","reference_number":"EMA/468296/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2014-ema-decision-3-september-2014-acceptance-modification-agreed-paediatric-investigation-plan-idelalisib-emea-001350-pip02-13-m01_en.pdf"},
    {"id":"39735","name":"P/0020/2017: European Medicines Agency decision of 31 January 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for esketamine (hydrochloride) (EME...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/36031/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2017-european-medicines-agency-decision-31-january-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-esketamine-hydrochloride-eme_en.pdf"},
    {"id":"39740","name":"P/0198/2014: EMA decision of 8 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (EMEA-000782-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-22T02:00:00Z","last_updated_date":"2014-08-22T02:00:00Z","reference_number":"EMA/391829/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2014-ema-decision-8-august-2014-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-emea-000782-pip01-09-m02_en.pdf"},
    {"id":"39751","name":"P/0268/2012: EMA decision of 20 November 2012 on the granting of a product-specific waiver for lopinavir / ritonavir / lamivudine (EMEA-001307-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"EMA/646961/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2012-ema-decision-20-november-2012-granting-product-specific-waiver-lopinavir-ritonavir-lamivudine-emea-001307-pip01-12_en.pdf"},
    {"id":"39763","name":"P/266/2010: EMA decision of of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for mixture of Dermatophagoides pteronyssinus and Der...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-05-05T02:00:00Z","last_updated_date":"2011-05-05T02:00:00Z","reference_number":"EMA/716686/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-266-2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mixture-dermatophagoides-pteronyssinus-der_en.pdf"},
    {"id":"39767","name":"P/0074/2015: EMA decision of 1 April 2015 on the agreement of a paediatric investigation plan and on the granting of a waiver for tetrabenazine (ADV6979) (EMEA-001404-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-07T02:00:00Z","last_updated_date":"2015-05-07T02:00:00Z","reference_number":"EMA/138220/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2015-ema-decision-1-april-2015-agreement-paediatric-investigation-plan-granting-waiver-tetrabenazine-adv6979-emea-001404-pip01-12_en.pdf"},
    {"id":"39775","name":"P/0190/2012: EMA decision of 24 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for lubiprostone (EMEA-000245-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/546451/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2012-ema-decision-24-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-lubiprostone-emea-000245-pip01-08-m01_en.pdf"},
    {"id":"39800","name":"P/103/2010: European Medicines Agency decision of 11 June 2010 on the agreement of a paediatric investigation plan and on the granting of a waiver for Human Papillomavirus Type 6 L1 protein / Type 11 L1 protein / Type 16...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/343650/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-103-2010-european-medicines-agency-decision-11-june-2010-agreement-paediatric-investigation-plan-granting-waiver-human-papillomavirus-type-6-l1-protein-type-11-l1-protein-type-16_en.pdf"},
    {"id":"39804","name":"P/0243/2012: EMA decision of 22 October 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Dermatophagoides pteronyssinus / Dermatophagoides far...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/587325/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2012-ema-decision-22-october-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dermatophagoides-pteronyssinus-dermatophagoides-far_en.pdf"},
    {"id":"39824","name":"P/0042/2018: EMA decision of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel)\n\n(EMEA-000567-PIP01-09-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T11:41:00Z","last_updated_date":"2018-04-18T11:41:00Z","reference_number":"EMA/75416/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2018-ema-decision-16-february-2018-acceptance-modification-agreed-paediatric-investigation-plan-dasatinib-sprycel-emea-000567-pip01-09-m05_en.pdf"},
    {"id":"39834","name":"P/0174/2016: EMA decision of 30 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir /\n\nledipasvir (Harvoni), (EMEA-001411-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/408683/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2016-ema-decision-30-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-sofosbuvir-ledipasvir-harvoni-emea-001411-pip01-12-m03_en.pdf"},
    {"id":"39839","name":"P/0019/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for surotomycin (EMEA-001226-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/779669/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-surotomycin-emea-001226-pip01-11-m01_en.pdf"},
    {"id":"39853","name":"P/303/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for pollen from betula verrucosa, (EMEA-000865-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/683400/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-303-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-betula-verrucosa-emea-000865-pip01-10_en.pdf"},
    {"id":"39864","name":"P/0041/2014: European Medicines Agency decision of 5 March 2014 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for fluocinolone acetonide (EMEA-001494-P...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/43432/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2014-european-medicines-agency-decision-5-march-2014-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-fluocinolone-acetonide-emea-001494-p_en.pdf"},
    {"id":"39869","name":"P/39/2008: European medicines agency decision of 24 June 2008\n\non the application for agreement of a Paediatric Investigation Plan for taranabant (EMEA-000062-PIP01-07) in accordance with Regulation (EC) No 1901/2006 of ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"EMEA/313283/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-39-2008-european-medicines-agency-decision-24-june-2008-application-agreement-paediatric-investigation-plan-taranabant-emea-000062-pip01-07-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"39879","name":"P/250/2011: EMA decision of 25 October 2011 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus type\n\nA, H1N1 / influenza virus type A, H3N2 / influenza virus type B, yamaga...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-11-30T17:00:00Z","last_updated_date":"2011-11-30T17:00:00Z","reference_number":"EMA/834849/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-250-2011-ema-decision-25-october-2011-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-type-h1n1-influenza-virus-type-h3n2-influenza-virus-type-b-yamaga_en.pdf"},
    {"id":"39883","name":"P/0054/2017: EMA decision of 17 March 2017 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (EMEA-\n\n000576-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/90866/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-emea-000576-pip01-09-m06_en.pdf"},
    {"id":"39891","name":"P/0311/2012: EMA decision of 21 December 2012 on the granting and on the refusal of a product-specific waiver for expanded autologous bone-marrow-derived osteoblastic cells (EMEA-001329-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T14:00:00Z","last_updated_date":"2013-02-08T14:00:00Z","reference_number":"EMA/811258/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0311-2012-ema-decision-21-december-2012-granting-refusal-product-specific-waiver-expanded-autologous-bone-marrow-derived-osteoblastic-cells-emea-001329-pip01-12_en.pdf"},
    {"id":"39894","name":"P/0049/2017: EMA decision of 6 March 2017 on the refusal of a modification of an agreed paediatric investigation plan for methoxy polyethylene\n\nglycol - epoetin beta (Mircera), (EMEA-000172-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"EMA/2920/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2017-ema-decision-6-march-2017-refusal-modification-agreed-paediatric-investigation-plan-methoxy-polyethylene-glycol-epoetin-beta-mircera-emea-000172-pip01-07-m02_en.pdf"},
    {"id":"39915","name":"P/166/2011: EMA decision of 6 July 2011 on the granting of a product specific waiver for ciclosporin (EMEA-001007-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-08-09T02:00:00Z","last_updated_date":"2011-08-09T02:00:00Z","reference_number":"EMA/513787/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-166-2011-ema-decision-6-july-2011-granting-product-specific-waiver-ciclosporin-emea-001007-pip01-10_en.pdf"},
    {"id":"39916","name":"P/0229/2016: EMA decision of 1 September 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for eculizumab (Soliris), (EMEA-000876-PIP07-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/514471/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2016-ema-decision-1-september-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eculizumab-soliris-emea-000876-pip07-15_en.pdf"},
    {"id":"39940","name":"P/0298/2017: EMA decision of 4 October 2017 on the granting of a product specific waiver for ibrutinib (Imbruvica) (EMEA-001397-PIP05-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T13:11:00Z","last_updated_date":"2018-02-12T13:11:00Z","reference_number":"EMA/635148/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2017-ema-decision-4-october-2017-granting-product-specific-waiver-ibrutinib-imbruvica-emea-001397-pip05-17_en.pdf"},
    {"id":"39957","name":"P/0145/2014: EMA decision of 13 June 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for blinatumomab (EMEA-000574-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-18T02:00:00Z","last_updated_date":"2014-07-18T02:00:00Z","reference_number":"EMA/252151/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2014-ema-decision-13-june-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-blinatumomab-emea-000574-pip02-12_en.pdf"},
    {"id":"39958","name":"P/0082/2017: EMA decision of 5 May 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for avacopan\n\n(EMEA-002023-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/224404/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2017-ema-decision-5-may-2017-agreement-paediatric-investigation-plan-granting-deferral-avacopan-emea-002023-pip01-16_en.pdf"},
    {"id":"39960","name":"P/192/2010: European Medicines Agency decision of 26 October 2010 on the acceptance of a modification of an agreed paediatric investigation plan for doripenem monohydrate (Doribax), (EMEA-000015-PIP01-07-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-11-24T01:00:00Z","last_updated_date":"2010-11-24T01:00:00Z","reference_number":"EMEA/486009/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-192-2010-european-medicines-agency-decision-26-october-2010-acceptance-modification-agreed-paediatric-investigation-plan-doripenem-monohydrate-doribax-emea-000015-pip01-07-m02_en.pdf"},
    {"id":"39973","name":"P/0021/2013: EMA decision of 15 February 2013 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone furoate / triphenylacetic acid - 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]etho...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T02:00:00Z","last_updated_date":"2013-04-23T02:00:00Z","reference_number":"EMA/87155/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2013-ema-decision-15-february-2013-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-triphenylacetic-acid-4-1r-2-6-2-26-dichlorobenzyloxyetho_en.pdf"},
    {"id":"39995","name":"P/0176/2012: EMA decision of 3 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine /\n\nrilpivirine (hydrochloride) / tenofovir (disoproxil fumarate) [FTC/RPV/TDF] (...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/505530/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2012-ema-decision-3-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-emtricitabine-rilpivirine-hydrochloride-tenofovir-disoproxil-fumarate-ftc-rpv-tdf_en.pdf"},
    {"id":"40010","name":"P/0005/2018: EMA decision of 15 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (Orkambi), (EMEA-001582-PIP01-13-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"EMA/7638/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2018-ema-decision-15-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-lumacaftor-ivacaftor-orkambi-emea-001582-pip01-13-m07_en.pdf"},
    {"id":"40014","name":"P/0243/2015: EMA decision of 30 October 2015 on the acceptance of a modification of an agreed paediatric investigation plan for icatibant acetate (Firazyr), (EMEA-000408-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T01:00:00Z","last_updated_date":"2016-01-06T01:00:00Z","reference_number":"EMA/624869/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan-icatibant-acetate-firazyr-emea-000408-pip01-08-m05_en.pdf"},
    {"id":"40038","name":"P/0182/2015: EMA decision of 7 August 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for influenza virus surface antigens (haemagglutinin and ne...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-24T02:00:00Z","last_updated_date":"2015-09-24T02:00:00Z","reference_number":"EMA/473285/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2015-ema-decision-7-august-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-influenza-virus-surface-antigens-haemagglutinin-ne_en.pdf"},
    {"id":"40048","name":"P/41/2010: European Medicines Agency decision of 31 March 2010 on the granting of a product specific waiver for tartaric acid (EMEA-000772-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliam...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/173479/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-41-2010-european-medicines-agency-decision-31-march-2010-granting-product-specific-waiver-tartaric-acid-emea-000772-pip01-09-accordance-regulation-ec-no-1901-2006-european-parliam_en.pdf"},
    {"id":"40064","name":"P/42/2009: European Medicines Agency decision of 23 March 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for Maribavir (EMEA-000353-PIP01-08) in...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/159851/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-42-2009-european-medicines-agency-decision-23-march-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-maribavir-emea-000353-pip01-08_en.pdf"},
    {"id":"40068","name":"P/302/2011: EMA decision of 20 December 2011 on the granting of a product specific waiver for esketamine (hydrochloride) (EMEA-000770-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-01-19T12:00:00Z","last_updated_date":"2012-01-19T12:00:00Z","reference_number":"EMA/945464/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-302-2011-ema-decision-20-december-2011-granting-product-specific-waiver-esketamine-hydrochloride-emea-000770-pip02-11_en.pdf"},
    {"id":"40083","name":"P/0302/2012: EMA decision of 20 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for N-[6-(cis-2,6-\n\ndimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4’-(trifluoromethoxy) [1,1’-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-07T13:30:00Z","last_updated_date":"2013-02-07T13:30:00Z","reference_number":"EMA/810528/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2012-ema-decision-20-december-2012-acceptance-modification-agreed-paediatric-investigation-plan-n-6-cis-26-dimethylmorpholin-4-ylpyridine-3-yl-2-methyl-4-trifluoromethoxy-11_en.pdf"},
    {"id":"40118","name":"P/0074/2017: EMA decision of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for lamivudine / dolutegravir (EMEA-001940-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/106209/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2017-ema-decision-17-march-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lamivudine-dolutegravir-emea-001940-pip01-16_en.pdf"},
    {"id":"40121","name":"P/0021/2015: EMA decision of 30 January 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for eluxadoline (EMEA-001579-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/792659/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2015-ema-decision-30-january-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eluxadoline-emea-001579-pip01-13_en.pdf"},
    {"id":"40125","name":"P/0060/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for octocog alfa\n\n(Iblias, Kovaltry) (EMEA-001064-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/102305/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-octocog-alfa-iblias-kovaltry-emea-001064-pip01-10-m03_en.pdf"},
    {"id":"40156","name":"P/0313/2013: EMA decision of 19 December 2013 on the agreement of a paediatric investigation plan for Heterologous Human Adult Liver-derived Progenitor Cells (HHALPC) (EMEA-001155-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-05T01:00:00Z","last_updated_date":"2014-02-05T01:00:00Z","reference_number":"EMA/712443/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2013-ema-decision-19-december-2013-agreement-paediatric-investigation-plan-heterologous-human-adult-liver-derived-progenitor-cells-hhalpc-emea-001155-pip01-11_en.pdf"},
    {"id":"40158","name":"P/36/2011: EMA decision of 28 January 2011 on the refusal of a product specific waiver for recombinant human granulocyte colony stimulating\n\nfactor / recombinant human albumin fusion protein (EMEA-001042-PIP01-10) in acc...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/35172/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-36-2011-ema-decision-28-january-2011-refusal-product-specific-waiver-recombinant-human-granulocyte-colony-stimulating-factor-recombinant-human-albumin-fusion-protein-emea-001042-pip01-10-acc_en.pdf"},
    {"id":"40168","name":"P/0006/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Xgeva, Prolia) (EMEA-000145-PIP01-07-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/43926/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-xgeva-prolia-emea-000145-pip01-07-m07_en.pdf"},
    {"id":"40196","name":"P/0293/2014: EMA decision of 30 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bimatoprost (Lumigan and associated names) (EMEA-000917-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-12-09T01:00:00Z","last_updated_date":"2014-12-09T01:00:00Z","reference_number":"EMA/624333/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2014-ema-decision-30-october-2014-acceptance-modification-agreed-paediatric-investigation-plan-bimatoprost-lumigan-associated-names-emea-000917-pip01-10-m04_en.pdf"},
    {"id":"40207","name":"P/75/2008: European medicines agency decision of 12 September 2008 \n\non the application for agreement of a Paediatric Investigation Plan for pramipexole dihydrochloride monohydrate, (Mirapexin) (EMEA-000080-PIP01-07) in ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-10-10T02:00:00Z","last_updated_date":"2008-10-10T02:00:00Z","reference_number":"EMEA/466827/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-75-2008-european-medicines-agency-decision-12-september-2008-application-agreement-paediatric-investigation-plan-pramipexole-dihydrochloride-monohydrate-mirapexin-emea-000080-pip01-07_en.pdf"},
    {"id":"40248","name":"P/166/2010: European Medicines Agency decision of 3 September 2010 on the acceptance of a modification of an agreed paediatric investigation plan for cinacalcet hydrochloride (Mimpara), (EMEA-000078-PIP01-07-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/478292/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-166-2010-european-medicines-agency-decision-3-september-2010-acceptance-modification-agreed-paediatric-investigation-plan-cinacalcet-hydrochloride-mimpara-emea-000078-pip01-07-m01_en.pdf"},
    {"id":"40284","name":"P/0118/2018: EMA decision of 11 April 2018 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for influenza virus H1 haemagglutinin / influenza virus H3 haemagglutinin /influenza ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-26T02:00:00Z","last_updated_date":"2018-07-26T02:00:00Z","reference_number":"EMA/152188/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2018-ema-decision-11-april-2018-agreement-pip-granting-deferral-granting-waiver-influenza-virus-h1-haemagglutinin-influenza-virus-h3-haemagglutinin-influenza_en.pdf"},
    {"id":"40288","name":"P/0024/2012: EMA decision of 27 January 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T12:00:00Z","last_updated_date":"2012-02-24T12:00:00Z","reference_number":"EMA/986418/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2012-ema-decision-27-january-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-n-3-5-2-amino-4-pyrimidinyl-2-11-dimethylethyl_en.pdf"},
    {"id":"40291","name":"P/0070/2015: EMA decision of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for damoctocog alfa pegol (EMEA-001229-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/147275/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2015-ema-decision-1-april-2015-acceptance-modification-agreed-paediatric-investigation-plan-damoctocog-alfa-pegol-emea-001229-pip01-11-m01_en.pdf"},
    {"id":"40305","name":"P/0204/2012: EMA decision of 3 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel) (EMEA-000567-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T17:00:00Z","last_updated_date":"2012-10-17T17:00:00Z","reference_number":"EMA/559565/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2012-ema-decision-3-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-dasatinib-sprycel-emea-000567-pip01-09-m03_en.pdf"},
    {"id":"40321","name":"P/0191/2012: EMA decision of 24 August 2012 on the acceptance of a modification of an agreed paediatric investigation plan for pazopanib (Votrient) (EMEA-000601-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-17T02:00:00Z","last_updated_date":"2012-09-17T02:00:00Z","reference_number":"EMA/547279/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2012-ema-decision-24-august-2012-acceptance-modification-agreed-paediatric-investigation-plan-pazopanib-votrient-emea-000601-pip01-09-m01_en.pdf"},
    {"id":"40326","name":"P/0375/2017: EMA decision of 1 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris),\n\n(EMEA-000876-PIP03-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/711125/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0375-2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip03-14-m01_en.pdf"},
    {"id":"40329","name":"P/0203/2013: EMA decision of 2 September 2013 on the granting of a product-specific waiver for pomalidomide (EMEA-001457-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"EMA/456005/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2013-ema-decision-2-september-2013-granting-product-specific-waiver-pomalidomide-emea-001457-pip01-13_en.pdf"},
    {"id":"40339","name":"P/0106/2015: EMA decision of 13 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for humanised monoclonal antibody IgG2 recognising the interl...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/284200/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2015-ema-decision-13-may-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-humanised-monoclonal-antibody-igg2-recognising-interl_en.pdf"},
    {"id":"40348","name":"P/0085/2012: EMA decision of 21 May 2012 on the acceptance of a modification of an agreed paediatric investigation plan for on the acceptance of a modification of an agreed paediatric investigation plan for L-Cysteinyl-L...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T18:00:00Z","last_updated_date":"2012-06-22T18:00:00Z","reference_number":"EMA/273076/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2012-ema-decision-21-may-2012-acceptance-modification-agreed-paediatric-investigation-plan-acceptance-modification-agreed-paediatric-investigation-plan-l-cysteinyl-l_en.pdf"},
    {"id":"40356","name":"P/0298/2015: EMA decision of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (Brilique), (EMEA-000480-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/773336/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2015-ema-decision-21-december-2015-acceptance-modification-agreed-paediatric-investigation-plan-ticagrelor-brilique-emea-000480-pip01-08-m08_en.pdf"},
    {"id":"40360","name":"P/0297/2012: EMA decision of 18 December 2012 on the granting of a product-specific waiver for elagolix (EMEA-001323-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-03-11T01:00:00Z","last_updated_date":"2013-03-11T01:00:00Z","reference_number":"EMA/802207/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2012-ema-decision-18-december-2012-granting-product-specific-waiver-elagolix-emea-001323-pip02-12_en.pdf"}    {"id":"40404","name":"P/0151/2014: EMA decision of 13 June 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant human beta-glucuronidase (rhGUS, UX003) (EMEA-001540-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-22T02:00:00Z","last_updated_date":"2014-07-22T02:00:00Z","reference_number":"EMA/299615/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2014-ema-decision-13-june-2014-agreement-paediatric-investigation-plan-granting-deferral-recombinant-human-beta-glucuronidase-rhgus-ux003-emea-001540-pip01-13_en.pdf"},
    {"id":"40405","name":"P/0197/2015: EMA decision of 4 September 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for omecamtiv mecarbil (EMEA-001696-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-10-20T02:00:00Z","last_updated_date":"2015-10-20T02:00:00Z","reference_number":"EMA/505437/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2015-ema-decision-4-september-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-omecamtiv-mecarbil-emea-001696-pip01-14_en.pdf"},
    {"id":"40429","name":"P/185/2010: European Medicines Agency decision of 24 September 2010 on the granting of a product specific waiver for afamelanotide (EMEA-000737-PIP01-09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-10-29T02:00:00Z","last_updated_date":"2010-10-29T02:00:00Z","reference_number":"EMA/583062/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-185-2010-european-medicines-agency-decision-24-september-2010-granting-product-specific-waiver-afamelanotide-emea-000737-pip01-09_en.pdf"},
    {"id":"40450","name":"P/1/2011: EMA decision of 3 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira) (EMEA-000366-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/730065/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-1-2011-ema-decision-3-january-2011-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip01-08-m03_en.pdf"},
    {"id":"40461","name":"P/0075/2012: EMA decision of 25 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for artemether /\n\nlumefantrine (Riamet), (EMEA-000777-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-05-24T02:00:00Z","last_updated_date":"2012-05-24T02:00:00Z","reference_number":"EMA/256949/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2012-ema-decision-25-april-2012-acceptance-modification-agreed-paediatric-investigation-plan-artemether-lumefantrine-riamet-emea-000777-pip01-09-m02_en.pdf"},
    {"id":"40463","name":"P/0051/2015: EMA decision of 6 March 2015 on the granting of a product-specific waiver for candesartan / amlodipine (EMEA-001711-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-24T01:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/49322/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2015-ema-decision-6-march-2015-granting-product-specific-waiver-candesartan-amlodipine-emea-001711-pip01-14_en.pdf"},
    {"id":"40492","name":"P/71/2008: European medicines agency decision of 20 August 2008\n\non the application for agreement of a Paediatric Investigation Plan for nicotinic acid, simvastatin and laropiprant (EMEA-000253-PIP01-08), in accordance w...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/431920/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-71-2008-european-medicines-agency-decision-20-august-2008-application-agreement-paediatric-investigation-plan-nicotinic-acid-simvastatin-laropiprant-emea-000253-pip01-08-accordance-w_en.pdf"},
    {"id":"40506","name":"P/0165/2015: EMA decision of 7 August 2015 on the acceptance of a modification of an agreed paediatric investigation plan for tadalafil (Adcirca, Cialis), (EMEA-000452-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/473605/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2015-ema-decision-7-august-2015-acceptance-modification-agreed-paediatric-investigation-plan-tadalafil-adcirca-cialis-emea-000452-pip02-10-m03_en.pdf"},
    {"id":"40508","name":"P/0128/2017: EMA decision of 12 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for cinacalcet\n\n(hydrochloride) (Mimpara), (EMEA-000078-PIP01-07-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/278983/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2017-ema-decision-12-may-2017-acceptance-modification-agreed-paediatric-investigation-plan-cinacalcet-hydrochloride-mimpara-emea-000078-pip01-07-m08_en.pdf"},
    {"id":"40523","name":"P/0155/2015: EMA decision of 10 July 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for letermovir (EMEA-001631-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-25T02:00:00Z","last_updated_date":"2015-08-25T02:00:00Z","reference_number":"EMA/382965/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2015-ema-decision-10-july-2015-agreement-paediatric-investigation-plan-granting-deferral-letermovir-emea-001631-pip01-14_en.pdf"},
    {"id":"40543","name":"P/168/2009:Purified Diphteria toxoid/purified tetanus toxoid/purified pertussis toxoid/purified filamentous haemagglutinin  purified fimbriae types2+3 purified pertactin/inactivated type1 poliovirus/inactivated type2 pol...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/623060/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-168-2009purified-diphteria-toxoid-purified-tetanus-toxoid-purified-pertussis-toxoid-purified-filamentous-haemagglutinin-purified-fimbriae-types23-purified-pertactin-inactivated-type1-poliovirus_en.pdf"},
    {"id":"40550","name":"P/0180/2017: EMA decision of 3 July 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for live, attenuated, chimeric dengue virus, serotype 1/live,...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T02:00:00Z","reference_number":"EMA/348043/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2017-ema-decision-3-july-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-live-attenuated-chimeric-dengue-virus-serotype-1-live_en.pdf"},
    {"id":"40573","name":"P/0176/2014: EMA decision of 2 July 2014 on the acceptance of a modification of an agreed paediatric investigation plan for asfotase alfa (EMEA-000987-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-08-05T15:00:00Z","last_updated_date":"2014-08-05T15:00:00Z","reference_number":"EMA/367080/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2014-ema-decision-2-july-2014-acceptance-modification-agreed-paediatric-investigation-plan-asfotase-alfa-emea-000987-pip01-10-m02_en.pdf"},
    {"id":"40578","name":"P/95/2009: European Medicines Agency decision of 19 May 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral for raltegravir (ISENTRESS ) (EMEA-000279-PIP01-08) in accordance with Re...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-07-09T02:00:00Z","last_updated_date":"2009-07-09T02:00:00Z","reference_number":"EMEA/288499/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-95-2009-european-medicines-agency-decision-19-may-2009-agreement-paediatric-investigation-plan-granting-deferral-raltegravir-isentress-emea-000279-pip01-08-accordance-re_en.pdf"},
    {"id":"40579","name":"P/0126/2015: EMA decision of 5 June 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral for vericiguat (EMEA-001636-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-07-03T02:00:00Z","last_updated_date":"2015-07-03T02:00:00Z","reference_number":"EMA/300765/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2015-ema-decision-5-june-2015-agreement-paediatric-investigation-plan-granting-deferral-vericiguat-emea-001636-pip01-14_en.pdf"},
    {"id":"40584","name":"P/0280/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for allergen extracts of dermatophagoides farinae and dermatophagoides pteronyssinus (EMEA-0008...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/764477/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-allergen-extracts-dermatophagoides-farinae-dermatophagoides-pteronyssinus-emea-0008_en.pdf"},
    {"id":"40587","name":"P/0214/2017: EMA decision of 9 August 2017 on the acceptance of a modification of an agreed paediatric investigation plan for coagulation Factor\n\nVIIa (Recombinant) (EMEA-001203-PIP02-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-02T02:00:00Z","last_updated_date":"2017-10-02T02:00:00Z","reference_number":"EMA/461645/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2017-ema-decision-9-august-2017-acceptance-modification-agreed-paediatric-investigation-plan-coagulation-factor-viia-recombinant-emea-001203-pip02-14-m02_en.pdf"},
    {"id":"40590","name":"P/0288/2015: EMA decision of 27 November 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]py...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/764433/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2015-ema-decision-27-november-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-3s4r-3-ethyl-4-3h-imidazo12-apyrrolo23-epy_en.pdf"},
    {"id":"40600","name":"P/0171/2012: EMA decision of 27 July 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for apremilast (EMEA-000715-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-23T16:00:00Z","last_updated_date":"2012-08-23T16:00:00Z","reference_number":"EMA/436956/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2012-ema-decision-27-july-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-apremilast-emea-000715-pip02-11_en.pdf"},
    {"id":"40601","name":"P/0237/2013: EMA decision of 24 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for sonidegib, (EMEA-000880-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-21T01:00:00Z","last_updated_date":"2013-11-21T01:00:00Z","reference_number":"EMA/565106/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2013-ema-decision-24-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-sonidegib-emea-000880-pip02-11-m02_en.pdf"},
    {"id":"40606","name":"P/0056/2013: EMA decision of 25 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for oritavancin (diphosphate) (EMEA-001270-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T14:00:00Z","last_updated_date":"2013-04-30T14:00:00Z","reference_number":"EMA/85751/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2013-ema-decision-25-march-2013-agreement-paediatric-investigation-plan-granting-deferral-oritavancin-diphosphate-emea-001270-pip01-12_en.pdf"},
    {"id":"40639","name":"P/96/2010: European Medicines Agency decision of 4 June 2010 on the acceptance of a modification of an agreed paediatric investigation plan for canakinumab (EMEA-000060-PIP01-07-M02) in accordance with Regulation (EC) No...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:00:00Z","last_updated_date":"2010-07-28T01:00:00Z","reference_number":"EMA/335510/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-96-2010-european-medicines-agency-decision-4-june-2010-acceptance-modification-agreed-paediatric-investigation-plan-canakinumab-emea-000060-pip01-07-m02-accordance-regulation-ec-no_en.pdf"},
    {"id":"40679","name":"P/0280/2016: EMA decision of 12 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human\n\nnerve growth factor (EMEA-001729-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"EMA/657489/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2016-ema-decision-12-october-2016-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-nerve-growth-factor-emea-001729-pip01-14-m01_en.pdf"},
    {"id":"40687","name":"P/0084/2014: EMA decision of 4 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for rivaroxaban (Xarelto), (EMEA-000430-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/113586/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2014-ema-decision-4-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-rivaroxaban-xarelto-emea-000430-pip01-08-m05_en.pdf"},
    {"id":"40693","name":"P/68/2008: European medicines agency decision of 15 August 2008 on the application for product specific waiver for dexamethasone (EMEA-000198 PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parl...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-09-18T02:00:00Z","last_updated_date":"2008-09-18T02:00:00Z","reference_number":"EMEA/423051/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-68-2008-european-medicines-agency-decision-15-august-2008-application-product-specific-waiver-dexamethasone-emea-000198-pip01-08-accordance-regulation-ec-no-1901-2006-european-parl_en.pdf"},
    {"id":"40694","name":"P/317/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of pollen from Phleum prate...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/697308/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-317-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-pollen-phleum-prate_en.pdf"},
    {"id":"40700","name":"P/0257/2017: EMA decision of 4 September 2017 on the refusal of a modification of an agreed paediatric investigation plan for lurasidone\n\n(hydrochloride) (Latuda), (EMEA-001230-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T17:00:00Z","last_updated_date":"2017-10-26T17:00:00Z","reference_number":"EMA/501660/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2017-ema-decision-4-september-2017-refusal-modification-agreed-paediatric-investigation-plan-lurasidone-hydrochloride-latuda-emea-001230-pip01-11-m03_en.pdf"},
    {"id":"40709","name":"P/0201/2016: EMA decision of 28 July 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for eculizumab (Soliris), (EMEA-000876-PIP06-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-09-22T02:00:00Z","last_updated_date":"2016-09-22T02:00:00Z","reference_number":"EMA/472130/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2016-ema-decision-28-july-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eculizumab-soliris-emea-000876-pip06-15_en.pdf"},
    {"id":"40738","name":"P/0229/2012: EMA decision of 4 October 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for bitopertin (EMEA-000439-PIP02-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/587320/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2012-ema-decision-4-october-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bitopertin-emea-000439-pip02-11_en.pdf"},
    {"id":"40749","name":"P/0303/2012: EMA decision of 20 December 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for dextran, 3-[(2-aminoethyl)thio]propyl 17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T10:40:00Z","last_updated_date":"2013-02-08T10:40:00Z","reference_number":"EMA/810617/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2012-ema-decision-20-december-2012-agreement-paediatric-investigation-plan-granting-deferral-dextran-3-2-aminoethylthiopropyl-17-carboxy-101316-triscarboxymethyl-8-oxo_en.pdf"},
    {"id":"40752","name":"P/0131/2013: EMA decision of 28 May 2013 on the granting of a product-specific waiver for rosuvastatin / ezetimibe (EMEA-001447-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-24T13:30:00Z","last_updated_date":"2013-06-24T13:30:00Z","reference_number":"EMA/249740/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2013-ema-decision-28-may-2013-granting-product-specific-waiver-rosuvastatin-ezetimibe-emea-001447-pip01-12_en.pdf"},
    {"id":"40783","name":"P/0266/2014: EMA decision of 13 October 2014 on the agreement of a paediatric investigation plan for allantoin (EMEA-001590-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/592743/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2014-ema-decision-13-october-2014-agreement-paediatric-investigation-plan-allantoin-emea-001590-pip01-13_en.pdf"},
    {"id":"40806","name":"P/181/2009: European Medicines Agency decision of 7 September 2009 on the granting of a product specific waiver for paracetamol / opium prepared (EMEA-000513-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of t...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/523568/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-181-2009-european-medicines-agency-decision-7-september-2009-granting-product-specific-waiver-paracetamol-opium-prepared-emea-000513-pip01-08-accordance-regulation-ec-no-1901-2006-t_en.pdf"},
    {"id":"40809","name":"P/238/2011: EMA decision of 30 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for icatibant acetate (Firazyr), (EMEA-000408-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T02:00:00Z","last_updated_date":"2011-10-17T02:00:00Z","reference_number":"EMA/698096/201","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-238-2011-ema-decision-30-september-2011-acceptance-modification-agreed-paediatric-investigation-plan-icatibant-acetate-firazyr-emea-000408-pip01-08-m03_en.pdf"},
    {"id":"40816","name":"P/125/2010:  European Medicines Agency decision of 28 July 2010 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for lidocaine/tetracaine (EMEA-000168-PIP...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"EMA/464924/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-125-2010-european-medicines-agency-decision-28-july-2010-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-lidocaine-tetracaine-emea-000168-pip_en.pdf"},
    {"id":"40824","name":"P/0167/2016: EMA decision of 15 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for eltrombopag\n\n(Revolade) (EMEA-000170-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/193031/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2016-ema-decision-15-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-eltrombopag-revolade-emea-000170-pip01-07-m04_en.pdf"},
    {"id":"40825","name":"P/0221/2013: EMA decision of 9 September 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tolvaptan (Samsca), (EMEA-001231-PIP02-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-10-08T02:00:00Z","last_updated_date":"2013-10-08T02:00:00Z","reference_number":"EMA/493083/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2013-ema-decision-9-september-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tolvaptan-samsca-emea-001231-pip02-13_en.pdf"},
    {"id":"40833","name":"P/184/2011: EMA decision of 4 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia) (EMEA-000494-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T02:00:00Z","last_updated_date":"2011-09-15T02:00:00Z","reference_number":"EMA/601915/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-184-2011-ema-decision-4-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-emea-000494-pip01-08-m03_en.pdf"},
    {"id":"40836","name":"P/53/2009: European Medicines Agency decision of 24 March 2009 on the granting of a product specific waiver for bisoprolol fumarate / acetylsalicylic acid (EMEA-000448-PIP01-08) in accordance with Regulation (EC) No 1901...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/167312/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-53-2009-european-medicines-agency-decision-24-march-2009-granting-product-specific-waiver-bisoprolol-fumarate-acetylsalicylic-acid-emea-000448-pip01-08-accordance-regulation-ec-no-1901_en.pdf"},
    {"id":"40876","name":"P/0235/2012: EMA decision of 22 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for bevacizumab (Avastin), (EMEA-000056-PIP03-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-26T01:00:00Z","last_updated_date":"2012-11-26T01:00:00Z","reference_number":"EMA/636944/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2012-ema-decision-22-october-2012-acceptance-modification-agreed-paediatric-investigation-plan-bevacizumab-avastin-emea-000056-pip03-10-m01_en.pdf"},
    {"id":"40899","name":"P/0083/2015: European medicines agency decision of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab (EMEA-000069-PIP01-07-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-15T02:00:00Z","last_updated_date":"2015-06-15T02:00:00Z","reference_number":"EMA/281887/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2015-european-medicines-agency-decision-8-may-2015-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-emea-000069-pip01-07-m03_en.pdf"},
    {"id":"40925","name":"P/0006/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for telbivudine (Sebivo) (EMEA-000065-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-19T01:00:00Z","last_updated_date":"2014-02-19T01:00:00Z","reference_number":"EMA/784553/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-telbivudine-sebivo-emea-000065-pip01-07-m04_en.pdf"},
    {"id":"40927","name":"P/0252/2012: EMA decision of 19 October 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for natalizumab (Tysabri) (EMEA-001095-PIP02-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/659209/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2012-ema-decision-19-october-2012-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-natalizumab-tysabri-emea-001095-pip02-12_en.pdf"},
    {"id":"40949","name":"P/0278/2016: EMA decision of 7 October 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for macrogol 3350 / sodium sulfate / sodium chloride / po...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/501874/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2016-ema-decision-7-october-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-macrogol-3350-sodium-sulfate-sodium-chloride-po_en.pdf"},
    {"id":"40958","name":"P/273/2010: EMA decision of 3 December 2010 on the acceptance of a modification of an agreed paediatric investigation plan for catridecacog (EMEA-\n\n000185-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-10T01:00:00Z","last_updated_date":"2011-01-10T01:00:00Z","reference_number":"EMA/764095/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-273-2010-ema-decision-3-december-2010-acceptance-modification-agreed-paediatric-investigation-plan-catridecacog-emea-000185-pip01-08-m03_en.pdf"},
    {"id":"40970","name":"P/250/2010:  EMA decision of 26 November 2010 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/709885/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-250-2010-ema-decision-26-november-2010-agreement-pip-granting-deferral-granting-waiver-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergic_en.pdf"},
    {"id":"40973","name":"P/0152/2015: EMA decision of 10 July 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for selumetinib (EMEA-001585-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-08-25T02:00:00Z","last_updated_date":"2015-08-25T02:00:00Z","reference_number":"EMA/370542/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2015-ema-decision-10-july-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-selumetinib-emea-001585-pip01-13_en.pdf"},
    {"id":"40976","name":"P/0008/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for pembrolizumab (Keytruda), (EMEA-001474-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"EMA/28103/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-pembrolizumab-keytruda-emea-001474-pip02-16-m02_en.pdf"},
    {"id":"40981","name":"P/0077/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for crizanlizumab (EMEA-002141-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/102437/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2018-ema-decision-16-march-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-crizanlizumab-emea-002141-pip01-17_en.pdf"},
    {"id":"41008","name":"P/118/2009: European Medicines Agency decision of 15 June 2009 on the granting of a product specific waiver for aliskiren hemifumarate / amlodipine besilate (EMEA-000515-PIP01-08) in accordance with Regulation (EC) No 19...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-08-11T02:00:00Z","last_updated_date":"2009-08-11T02:00:00Z","reference_number":"EMEA/351812/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-118-2009-european-medicines-agency-decision-15-june-2009-granting-product-specific-waiver-aliskiren-hemifumarate-amlodipine-besilate-emea-000515-pip01-08-accordance-regulation-ec-no-19_en.pdf"},
    {"id":"41035","name":"P/0333/2016: EMA decision of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for inotuzumab\n\nozogamicin (EMEA-001429-PIP01-13-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-02-03T13:11:00Z","last_updated_date":"2017-02-03T13:11:00Z","reference_number":"EMA/765278/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0333-2016-ema-decision-2-december-2016-acceptance-modification-agreed-paediatric-investigation-plan-inotuzumab-ozogamicin-emea-001429-pip01-13-m01_en.pdf"},
    {"id":"41046","name":"P/0292/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for serelaxin (EMEA-001168-PIP01-11-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-19T11:00:00Z","last_updated_date":"2017-01-19T11:00:00Z","reference_number":"EMA/666205/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-serelaxin-emea-001168-pip01-11-m03_en.pdf"},
    {"id":"41096","name":"P/0244/2013: EMA decision of 4 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate) (EMEA-000788-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/579644/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2013-ema-decision-4-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-emea-000788-pip02-11-m01_en.pdf"},
    {"id":"41100","name":"P/0073/2018: EMA decision of 16 March 2018 on the granting of a product-specific waiver for pemafibrate (EMEA-001573-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-19T02:00:00Z","last_updated_date":"2018-06-19T02:00:00Z","reference_number":"EMA/87925/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2018-ema-decision-16-march-2018-granting-product-specific-waiver-pemafibrate-emea-001573-pip02-17_en.pdf"},
    {"id":"41103","name":"P/0138/2012: EMA decision of 20 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for human normal\n\nimmunoglobulin (EMEA-001110-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-22T14:00:00Z","last_updated_date":"2012-08-22T14:00:00Z","reference_number":"EMA/469914/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2012-ema-decision-20-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-001110-pip01-10-m01_en.pdf"},
    {"id":"41108","name":"P/0224/2013: EMA decision of 23 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for belimumab (Benlysta), (EMEA-000520-PIP01-08-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/493080/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2013-ema-decision-23-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-belimumab-benlysta-emea-000520-pip01-08-m03_en.pdf"},
    {"id":"41116","name":"P/23/2008: European medicines agency decision of 23 May 2008 on the application for agreement of a Paediatric Investigation Plan for albumin interferon alfa-2b, EMEA-000017-PIP01-07, in accordance with Regulation (EC) No...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2008-06-17T02:00:00Z","last_updated_date":"2008-06-17T02:00:00Z","reference_number":"EMEA/258718/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-23-2008-european-medicines-agency-decision-23-may-2008-application-agreement-paediatric-investigation-plan-albumin-interferon-alfa-2b-emea-000017-pip01-07-accordance-regulation-ec-no_en.pdf"},
    {"id":"41119","name":"P/281/2010: EMA decision of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for allergen extract of phleum pratense pollen (EMEA-0009...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-11T01:00:00Z","last_updated_date":"2011-01-11T01:00:00Z","reference_number":"EMA/683389/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-281-2010-ema-decision-3-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allergen-extract-phleum-pratense-pollen-emea-0009_en.pdf"},
    {"id":"41122","name":"P/0247/2012: EMA decision of 22 October 2012 on the granting of a product-specific waiver for atorvastatin / ramipril / acetyl salicylic acid (EMEA-\n\n001342-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/587295/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2012-ema-decision-22-october-2012-granting-product-specific-waiver-atorvastatin-ramipril-acetyl-salicylic-acid-emea-001342-pip01-12_en.pdf"},
    {"id":"41150","name":"P/0038/2014: EMA decision of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for trenonacog alfa (EMEA-000661-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/57221/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2014-ema-decision-5-march-2014-acceptance-modification-agreed-paediatric-investigation-plan-trenonacog-alfa-emea-000661-pip01-09-m06_en.pdf"},
    {"id":"41161","name":"P/0056/2016: EMA decision of 18 March 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dalbavancin (Xydalba) (EMEA-000016-PIP01-07-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/139325/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan-dalbavancin-xydalba-emea-000016-pip01-07-m05_en.pdf"},
    {"id":"41167","name":"P/0097/2015: EMA decision of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human recombinant interleukin-2 (EMEA-001556-PIP01-13)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T02:00:00Z","last_updated_date":"2015-06-16T02:00:00Z","reference_number":"EMA/281879/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2015-ema-decision-8-may-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-recombinant-interleukin-2-emea-001556-pip01-13_en.pdf"},
    {"id":"41170","name":"P/302/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for Pollen from Dactylis glomerata, Festuca pratensis, L...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/778400/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-302-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-dactylis-glomerata-festuca-pratensis-l_en.pdf"},
    {"id":"41175","name":"P/0123/2012: EMA decision of 4 July 2012 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (EMEA-000467-PIP01-08-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-08-06T18:00:00Z","last_updated_date":"2012-08-06T18:00:00Z","reference_number":"EMA/413047/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2012-ema-decision-4-july-2012-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-emea-000467-pip01-08-m02_en.pdf"},
    {"id":"41183","name":"P/0200/2012: EMA decision of 24 August 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for human fibrinogen (EMEA-001208-PIP01-11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-09-18T14:00:00Z","last_updated_date":"2012-09-18T14:00:00Z","reference_number":"EMA/478268/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2012-ema-decision-24-august-2012-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-human-fibrinogen-emea-001208-pip01-11_en.pdf"},
    {"id":"41193","name":"P/0267/2012: EMA decision of 20 November 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for travoprost (Travatan), (EMEA-001271-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"EMA/722248/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2012-ema-decision-20-november-2012-agreement-paediatric-investigation-plan-granting-waiver-travoprost-travatan-emea-001271-pip01-12_en.pdf"},
    {"id":"41211","name":"P/0037/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia) (EMEA-000916-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-25T01:00:00Z","last_updated_date":"2015-03-25T01:00:00Z","reference_number":"EMA/80301/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2015-ema-decision-6-march-2015-acceptance-modification-agreed-paediatric-investigation-plan-lixisenatide-lyxumia-emea-000916-pip01-10-m04_en.pdf"},
    {"id":"41223","name":"P/0119/2013: EMA decision of 3 May 2013 on the agreement of a paediatric investigation plan for autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub-...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-21T14:10:00Z","last_updated_date":"2013-06-21T14:10:00Z","reference_number":"EMA/202333/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2013-ema-decision-3-may-2013-agreement-paediatric-investigation-plan-autologous-haematopoietic-stem-cells-transduced-lentiviral-vector-lenti-d-encoding-human-atp-binding-cassette-sub_en.pdf"},
    {"id":"41255","name":"P/0168/2015: EMA decision of 7 August 2015 on the granting of a product-specific waiver for brentuximab vedotin (Adcetris), (EMEA-000980-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"EMA/473694/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2015-ema-decision-7-august-2015-granting-product-specific-waiver-brentuximab-vedotin-adcetris-emea-000980-pip02-15_en.pdf"},
    {"id":"41257","name":"P/01/2009: European Medicines Agency decision of 15 January 2009 on the granting of a product specific waiver for aliskiren hemifumarate, valsartan (EMEA-000192-PIP01-08) in accordance with Regulation (EC) No 1901/2006 o...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2009-03-06T01:00:00Z","last_updated_date":"2009-03-06T01:00:00Z","reference_number":"EMEA/6774/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-01-2009-european-medicines-agency-decision-15-january-2009-granting-product-specific-waiver-aliskiren-hemifumarate-valsartan-emea-000192-pip01-08-accordance-regulation-ec-no-1901-2006-o_en.pdf"},
    {"id":"41269","name":"P/242/2009: EMEA decision of 2 December 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for Recombinant human monoclonal antibody of the IgG1 class to insulin-like growth factor-1 rece...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2010-01-25T00:00:00Z","last_updated_date":"2010-01-25T00:00:00Z","reference_number":"EMEA/759533/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-242-2009-emea-decision-2-december-2009-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-monoclonal-antibody-igg1-class-insulin-growth-factor-1-rece_en.pdf"},
    {"id":"41275","name":"P/324/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modified allergen extract of grass and rye pollen (EM...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-25T01:00:00Z","last_updated_date":"2011-01-25T01:00:00Z","reference_number":"EMA/769512/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-324-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modified-allergen-extract-grass-rye-pollen-em_en.pdf"},
    {"id":"41291","name":"P/0160/2016: EMA decision of 15 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ferric citrate\n\n(coordination complex) (EMEA-001213-PIP02-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/380513/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2016-ema-decision-15-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-ferric-citrate-coordination-complex-emea-001213-pip02-12-m02_en.pdf"},
    {"id":"41296","name":"P/0123/2017: EMA decision of 5 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dopamine\n\n(EMEA-001105-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/253549/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2017-ema-decision-5-may-2017-acceptance-modification-agreed-paediatric-investigation-plan-dopamine-emea-001105-pip01-10-m03_en.pdf"},
    {"id":"41313","name":"P/0007/2018: EMA decision of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for burosumab (EMEA-001659-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"EMA/28046/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2018-ema-decision-30-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-burosumab-emea-001659-pip01-15-m03_en.pdf"},
    {"id":"41352","name":"P/0024/2015: EMA decision of 30 January 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for grazoprevir / elbasvir (EMEA-001604-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/779785/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2015-ema-decision-30-january-2015-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-grazoprevir-elbasvir-emea-001604-pip01-13_en.pdf"},
    {"id":"41368","name":"P/117/2011: EMA decision of 20 May 2011 on the acceptance of a modification of an agreed paediatric investigation plan for aztreonam (Cayston)\n\n(EMEA-000827-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-06-07T02:00:00Z","last_updated_date":"2011-06-07T02:00:00Z","reference_number":"EMA/370084/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-117-2011-ema-decision-20-may-2011-acceptance-modification-agreed-paediatric-investigation-plan-aztreonam-cayston-emea-000827-pip01-09-m01_en.pdf"},
    {"id":"41377","name":"P/0205/2012: EMA decision of 7 September 2012 on the acceptance of a modification of an agreed paediatric investigation plan for etravirine\n\n(Intelence), (EMEA-000222-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2012-11-23T01:00:00Z","last_updated_date":"2012-12-11T18:00:02Z","reference_number":"EMA/506687/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2012-ema-decision-7-september-2012-acceptance-modification-agreed-paediatric-investigation-plan-etravirine-intelence-emea-000222-pip01-08-m06_en.pdf"},
    {"id":"41413","name":"P/0090/2014: EMA decision of 4 April 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for atazanavir / cobicistat (EMEA-001465-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T02:00:00Z","last_updated_date":"2014-05-13T02:00:00Z","reference_number":"EMA/182559/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2014-ema-decision-4-april-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-atazanavir-cobicistat-emea-001465-pip01-13_en.pdf"},
    {"id":"41419","name":"P/196/2011: EMA decision of 26 August 2011 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten\n\nand associated names), (EMEA-000347-PIP01-08-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T02:00:00Z","last_updated_date":"2011-10-03T02:00:00Z","reference_number":"EMA/669801/2011","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-196-2011-ema-decision-26-august-2011-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-associated-names-emea-000347-pip01-08-m01_en.pdf"},
    {"id":"41436","name":"P/0094/2013: EMA decision of 29 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for rdESAT-6 / rCFP-10 (EMEA-001156-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/188023/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2013-ema-decision-29-april-2013-acceptance-modification-agreed-paediatric-investigation-plan-rdesat-6-rcfp-10-emea-001156-pip01-11-m02_en.pdf"},
    {"id":"41439","name":"P/0269/2012: EMA decision of 20 November 2012 on the granting of a product-specific waiver for perindopril / indapamide / amlodipine (EMEA-001337-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T01:00:00Z","last_updated_date":"2013-01-04T01:00:00Z","reference_number":"EMA/646976/2012","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2012-ema-decision-20-november-2012-granting-product-specific-waiver-perindopril-indapamide-amlodipine-emea-001337-pip01-12_en.pdf"},
    {"id":"41446","name":"P/0109/2013: EMA decision of 30 April 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for epratuzumab (EMEA-001295-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T02:00:00Z","last_updated_date":"2013-05-31T02:00:00Z","reference_number":"EMA/203508/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2013-ema-decision-30-april-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-epratuzumab-emea-001295-pip01-12_en.pdf"},
    {"id":"41470","name":"P/0258/2013: EMA decision of 29 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for lebrikizumab (EMEA-001053-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/598095/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2013-ema-decision-29-october-2013-acceptance-modification-agreed-paediatric-investigation-plan-lebrikizumab-emea-001053-pip01-10-m02_en.pdf"},
    {"id":"41475","name":"P/0124/2017: EMA decision of 5 May 2017 on the granting of a product-specific waiver for nintedanib (Vargatef, Ofev), (EMEA-001006-PIP03-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T02:00:00Z","last_updated_date":"2017-07-03T02:00:00Z","reference_number":"EMA/260237/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2017-ema-decision-5-may-2017-granting-product-specific-waiver-nintedanib-vargatef-ofev-emea-001006-pip03-16_en.pdf"},
    {"id":"41487","name":"P/0036/2016: EMA decision of 5 February 2016 on the granting of a product specific waiver for processed nerve allograft (human) (EMEA-001807-PIP02-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/860243/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2016-ema-decision-5-february-2016-granting-product-specific-waiver-processed-nerve-allograft-human-emea-001807-pip02-15_en.pdf"},
    {"id":"41509","name":"P/0050/2015: EMA decision of 6 March 2015 on the granting of a product-specific waiver for perindopril / amlodipine (EMEA-001702-PIP01-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-24T01:00:00Z","last_updated_date":"2015-03-24T01:00:00Z","reference_number":"EMA/65321/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2015-ema-decision-6-march-2015-granting-product-specific-waiver-perindopril-amlodipine-emea-001702-pip01-14_en.pdf"},
    {"id":"41515","name":"P/0314/2016: EMA decision of 25 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for metreleptin\n\n (EMEA-001701-PIP01-14-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-20T16:17:00Z","last_updated_date":"2017-01-20T16:17:00Z","reference_number":"EMA/757463/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2016-ema-decision-25-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-metreleptin-emea-001701-pip01-14-m01_en.pdf"},
    {"id":"41524","name":"P/0073/2014: EMA decision of 2 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for golimumab (Simponi) (EMEA-000265-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/103499/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2014-ema-decision-2-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-golimumab-simponi-emea-000265-pip02-11-m01_en.pdf"},
    {"id":"41527","name":"P/0366/2016: EMA decision of 21 December 2016 on the granting of a product specific waiver for ibuprofen (EMEA-002017-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/757985/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0366-2016-ema-decision-21-december-2016-granting-product-specific-waiver-ibuprofen-emea-002017-pip01-16_en.pdf"},
    {"id":"41547","name":"P/0114/2016: EMA decision of 15 April 2016 on the granting of a product specific waiver for montelukast (sodium) / levocetirizine (dihydrochloride) (EMEA-001908-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/195529/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0114-2016-ema-decision-15-april-2016-granting-product-specific-waiver-montelukast-sodium-levocetirizine-dihydrochloride-emea-001908-pip01-15_en.pdf"},
    {"id":"41554","name":"P/0377/2017: EMA decision of 1 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for omega-3-carboxylic acids (EMEA-001865-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/704196/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0377-2017-ema-decision-1-december-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-omega-3-carboxylic-acids-emea-001865-pip02-16_en.pdf"},
    {"id":"41564","name":"P/0010/2015: EMA decision of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for conestat alfa (Ruconest) (EMEA-000367-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-03-05T01:00:00Z","last_updated_date":"2015-03-05T01:00:00Z","reference_number":"EMA/43928/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2015-ema-decision-30-january-2015-acceptance-modification-agreed-paediatric-investigation-plan-conestat-alfa-ruconest-emea-000367-pip01-08-m04_en.pdf"},
    {"id":"41594","name":"P/0139/2017: EMA decision of 7 June 2017 on the acceptance of a modification of an agreed paediatric investigation plan for olaratumab (Lartruvo), (EMEA-001760-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-07-26T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/316519/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2017-ema-decision-7-june-2017-acceptance-modification-agreed-paediatric-investigation-plan-olaratumab-lartruvo-emea-001760-pip01-15-m02_en.pdf"},
    {"id":"41605","name":"P/0020/2014: European Medicines Agency decision of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA-001214-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/738870/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2014-european-medicines-agency-decision-22-january-2014-acceptance-modification-agreed-paediatric-investigation-plan-benralizumab-emea-001214-pip01-11-m01_en.pdf"},
    {"id":"41624","name":"P/0228/2013: EMA decision of 23 September 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for iron as iron maltol (iron(III)-maltol complex), (EM...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/493084/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2013-ema-decision-23-september-2013-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-iron-iron-maltol-ironiii-maltol-complex-em_en.pdf"},
    {"id":"41650","name":"P/0311/2015: EMA decision of 21 December 2015 on the granting of a product-specific waiver for dupilumab (EMEA-001501-PIP03-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-02-02T01:00:00Z","reference_number":"EMA/791767/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0311-2015-ema-decision-21-december-2015-granting-product-specific-waiver-dupilumab-emea-001501-pip03-15_en.pdf"},
    {"id":"41670","name":"P/0066/2015: EMA decision of 1 April 2015 on the refusal of a modification of an agreed paediatric investigation plan for canagliflozin (Invokana) (EMEA-001030-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T02:00:00Z","last_updated_date":"2015-05-06T02:00:00Z","reference_number":"EMA/108910/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2015-ema-decision-1-april-2015-refusal-modification-agreed-paediatric-investigation-plan-canagliflozin-invokana-emea-001030-pip01-10-m03_en.pdf"},
    {"id":"41675","name":"P/0150/2014: EMA decision of 13 June 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-m...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-07-18T02:00:00Z","last_updated_date":"2014-07-18T02:00:00Z","reference_number":"EMA/299666/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2014-ema-decision-13-june-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-5-46-dimethyl-1h-benzimidazol-2-yl-4-methyl-n-3-1-m_en.pdf"},
    {"id":"41699","name":"P/0147/2013: EMA decision of 3 July 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for metformin (hydrochloride) (EMEA-001352-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-08-13T17:30:00Z","last_updated_date":"2013-08-13T17:30:00Z","reference_number":"EMA/306201/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2013-ema-decision-3-july-2013-agreement-paediatric-investigation-plan-granting-waiver-metformin-hydrochloride-emea-001352-pip01-12_en.pdf"}    {"id":"41712","name":"P/0107/2016: EMA decision of 15 April 2016 on the acceptance of a modification of an agreed paediatric investigation plan for olesoxime (EMEA-001414-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-06-02T02:00:00Z","reference_number":"EMA/195508/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2016-ema-decision-15-april-2016-acceptance-modification-agreed-paediatric-investigation-plan-olesoxime-emea-001414-pip01-12-m01_en.pdf"},
    {"id":"41714","name":"P/305/2010: EMA decision of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for Pollen from dactylis glomarata (16%), festuca praten...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2011-01-24T01:00:00Z","last_updated_date":"2011-01-24T01:00:00Z","reference_number":"EMA/778415/2010","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-305-2010-ema-decision-22-december-2010-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pollen-dactylis-glomarata-16-festuca-praten_en.pdf"},
    {"id":"41748","name":"P/0237/2016: EMA decision of 9 September 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for elafibranor (EMEA-001857-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/580025/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2016-ema-decision-9-september-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-elafibranor-emea-001857-pip01-15_en.pdf"},
    {"id":"41786","name":"P/0001/2018: EMA decision of 8 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat)\n\n(EMEA-000402-PIP02-11-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T15:28:00Z","last_updated_date":"2018-04-17T15:28:00Z","reference_number":"EMA/850455/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2018-ema-decision-8-january-2018-acceptance-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip02-11-m05_en.pdf"},
    {"id":"41791","name":"P/0227/2013: EMA decision of 23 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for odanacatib, (EMEA-001123-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T01:00:00Z","last_updated_date":"2013-11-15T01:00:00Z","reference_number":"EMA/562204/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2013-ema-decision-23-september-2013-acceptance-modification-agreed-paediatric-investigation-plan-odanacatib-emea-001123-pip01-11-m01_en.pdf"},
    {"id":"41794","name":"P/0128/2013: EMA decision of 28 May 2013 on the granting of a product-specific waiver for menotrophin (EMEA-001403-PIP01-12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2013-06-24T13:30:00Z","last_updated_date":"2013-06-24T13:30:00Z","reference_number":"EMA/246008/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2013-ema-decision-28-may-2013-granting-product-specific-waiver-menotrophin-emea-001403-pip01-12_en.pdf"},
    {"id":"41795","name":"P/0249/2017: EMA decision of 5 September 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for atacicept (EMEA-002004-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/495986/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2017-ema-decision-5-september-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-atacicept-emea-002004-pip01-16_en.pdf"},
    {"id":"41797","name":"P/0099/2014: EMA decision of 11 April 2014 on the acceptance of a modification of an agreed paediatric investigation plan for teriflunomide (AUBAGIO) (EMEA-001094-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-05-15T02:00:00Z","last_updated_date":"2014-05-15T02:00:00Z","reference_number":"EMA/194143/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2014-ema-decision-11-april-2014-acceptance-modification-agreed-paediatric-investigation-plan-teriflunomide-aubagio-emea-001094-pip01-10-m02_en.pdf"},
    {"id":"41798","name":"P/0283/2016: EMA decision of 4 November 2016 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren\n\n(Translarna), (EMEA-000115-PIP01-07-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T12:55:00Z","last_updated_date":"2017-01-23T12:55:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2016-ema-decision-4-november-2016-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-translarna-emea-000115-pip01-07-m08_en.pdf"},
    {"id":"41817","name":"P/0282/2015: EMA decision of 27 November 2015 on the acceptance of a modification of an agreed paediatric investigation plan for lomitapide (Lojuxta), (EMEA-001124-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"EMA/690918/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2015-ema-decision-27-november-2015-acceptance-modification-agreed-paediatric-investigation-plan-lomitapide-lojuxta-emea-001124-pip01-10-m03_en.pdf"},
    {"id":"41819","name":"P/0044/2017: EMA decision of 17 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for naldemedine\n\n(tosylate) (EMEA-001893-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-18T02:00:00Z","last_updated_date":"2017-04-18T02:00:00Z","reference_number":"EMA/91301/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2017-ema-decision-17-february-2017-acceptance-modification-agreed-paediatric-investigation-plan-naldemedine-tosylate-emea-001893-pip01-15-m01_en.pdf"},
    {"id":"41825","name":"P/0098/2017: EMA decision of 11 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for siponimod\n\n(hemifumarate) (EMEA-000716-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/176845/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan-siponimod-hemifumarate-emea-000716-pip01-09-m02_en.pdf"},
    {"id":"41832","name":"P/0264/2015: EMA decision of 30 October 2015 on the granting of a product specific waiver for telmisartan / amlodipine (besilate) (EMEA-001845-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-12-22T13:00:00Z","last_updated_date":"2015-12-22T13:00:00Z","reference_number":"EMA/PDCO/690390/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2015-ema-decision-30-october-2015-granting-product-specific-waiver-telmisartan-amlodipine-besilate-emea-001845-pip01-15_en.pdf"},
    {"id":"41847","name":"P/0257/2014: EMA decision of 1 October 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for potassium citrate monohydrated / potassium hydrogen ca...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-11-05T01:00:00Z","last_updated_date":"2014-11-05T01:00:00Z","reference_number":"EMA/517667/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2014-ema-decision-1-october-2014-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-potassium-citrate-monohydrated-potassium-hydrogen-ca_en.pdf"},
    {"id":"41864","name":"P/0311/2017: EMA decision of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for 1-(2,2-difluoro-1,3-\n\nbenzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydrox...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/666627/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0311-2017-ema-decision-31-october-2017-acceptance-modification-agreed-paediatric-investigation-plan-1-22-difluoro-13-benzodioxol-5-yl-n-1-2r-23-dihydroxypropyl-6-fluoro-2-1-hydrox_en.pdf"},
    {"id":"41867","name":"P/0127/2018: EMA decision of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon beta-1a (Plegridy), (EMEA-001129-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T02:00:00Z","last_updated_date":"2018-07-25T02:00:00Z","reference_number":"EMA/194725/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan-peginterferon-beta-1a-plegridy-emea-001129-pip01-11-m02_en.pdf"},
    {"id":"41875","name":"P/0236/2016: EMA decision of 9 September 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the\n\ngranting of a waiver for derivative of 4H-pyrazolo[3,4-d]pyrimidin-4-one (EM...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-10-27T02:00:00Z","last_updated_date":"2016-10-27T02:00:00Z","reference_number":"EMA/513839/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2016-ema-decision-9-september-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-derivative-4h-pyrazolo34-dpyrimidin-4-one-em_en.pdf"},
    {"id":"41921","name":"P/0030/2016: EMA decision of 29 January 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rilpivirine / dolutegravir (EMEA-001750-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T02:00:00Z","last_updated_date":"2016-03-29T02:00:00Z","reference_number":"EMA/4232/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2016-ema-decision-29-january-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rilpivirine-dolutegravir-emea-001750-pip01-15_en.pdf"},
    {"id":"41922","name":"P/0054/2014: European Medicines Agency decision of 7 March 2014 on the granting of a product specific waiver for ertugliflozin / metformin (EMEA-001532-PIP01-13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2014-04-16T02:00:00Z","last_updated_date":"2014-04-16T02:00:00Z","reference_number":"EMA/58700/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2014-european-medicines-agency-decision-7-march-2014-granting-product-specific-waiver-ertugliflozin-metformin-emea-001532-pip01-13_en.pdf"},
    {"id":"41945","name":"P/0228/2015: EMA decision of 2 October 2015 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for dasabuvir / ombitasvir / paritaprevir / ritonavir (EMEA-0...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2015-11-19T01:00:00Z","last_updated_date":"2015-11-19T01:00:00Z","reference_number":"EMA/617396/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2015-ema-decision-2-october-2015-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-dasabuvir-ombitasvir-paritaprevir-ritonavir-emea-0_en.pdf"},
    {"id":"41964","name":"P/0346/2016: EMA decision of 2 December 2016 on the granting of a product specific waiver for N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-\n\npyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-sulfamide (EMEA-001978-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T01:00:00Z","last_updated_date":"2017-01-30T01:00:00Z","reference_number":"EMA/765272/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0346-2016-ema-decision-2-december-2016-granting-product-specific-waiver-n-5-4-bromophenyl-6-2-5-bromo-2-pyrimidinyloxyethoxy-4-pyrimidinyl-sulfamide-emea-001978-pip01-16_en.pdf"},
    {"id":"41976","name":"P/0045/2017: EMA decision of 17 February 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for testosterone (EMEA-001529-PIP02-14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-04-18T02:00:00Z","last_updated_date":"2017-04-18T02:00:00Z","reference_number":"EMA/94941/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2017-ema-decision-17-february-2017-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-testosterone-emea-001529-pip02-14_en.pdf"},
    {"id":"41984","name":"P/0392/2017: EMA decision of 19 December 2017 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide\n\nadsorbed, depigmented glutaraldehyde polymerised, allergic extract of ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-03-05T01:00:00Z","reference_number":"EMA/792973/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0392-2017-ema-decision-19-december-2017-acceptance-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergic-extract_en.pdf"},
    {"id":"41987","name":"P/0133/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia), (EMEA-000916-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T02:00:00Z","last_updated_date":"2016-07-27T02:00:00Z","reference_number":"EMA/271182/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2016-ema-decision-20-may-2016-acceptance-modification-agreed-paediatric-investigation-plan-lixisenatide-lyxumia-emea-000916-pip01-10-m05_en.pdf"},
    {"id":"41996","name":"P/0104/2017: EMA decision of 11 April 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for entolimod\n\n(EMEA-002020-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/166789/2017","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2017-ema-decision-11-april-2017-agreement-paediatric-investigation-plan-granting-deferral-entolimod-emea-002020-pip01-16_en.pdf"},
    {"id":"42020","name":"P/0058/2018: EMA decision of 16 March 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lonoctocog alfa\n\n(Afstyla), (EMEA-001215-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/91842/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2018-ema-decision-16-march-2018-acceptance-modification-agreed-paediatric-investigation-plan-lonoctocog-alfa-afstyla-emea-001215-pip01-11-m06_en.pdf"},
    {"id":"42031","name":"P/0175/2016: EMA decision of 30 June 2016 on the acceptance of a modification of an agreed paediatric investigation plan for deferasirox (Exjade), (EMEA-001103-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2016-08-26T02:00:00Z","last_updated_date":"2016-08-26T02:00:00Z","reference_number":"EMA/398390/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2016-ema-decision-30-june-2016-acceptance-modification-agreed-paediatric-investigation-plan-deferasirox-exjade-emea-001103-pip01-10-m03_en.pdf"},
    {"id":"42370","name":"P/0136/2018: EMA decision of 7 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for inebilizumab (EMEA-001911-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-10-18T15:51:00Z","last_updated_date":"2018-10-18T15:51:00Z","reference_number":"EMA/259477/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2018-ema-decision-7-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-inebilizumab-emea-001911-pip01-15-m01_en.pdf"},
    {"id":"42566","name":"P/0126/2018: EMA decision of 11 April 2018 on the granting of a product specific waiver for ezetimibe / rosuvastatin (Zenon, Suvezen), (EMEA-001344-PIP02-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-07-26T12:19:00Z","last_updated_date":"2018-07-26T12:19:00Z","reference_number":"EMA/152181/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2018-ema-decision-11-april-2018-granting-product-specific-waiver-ezetimibe-rosuvastatin-zenon-suvezen-emea-001344-pip02-17_en.pdf"},
    {"id":"42743","name":"P/0183/2018: EMA decision of 22 June 2018 on the granting of a product specific waiver for abatacept (Orencia), (EMEA-000118-PIP04-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T12:13:00Z","last_updated_date":"2018-11-22T12:13:00Z","reference_number":"EMA/407702/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2018-ema-decision-22-june-2018-granting-product-specific-waiver-abatacept-orencia-emea-000118-pip04-17_en.pdf"},
    {"id":"42744","name":"P/0190/2018: EMA decision of 17 July 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ustekinumab (Stelara), (EMEA-000311-PIP05-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T12:35:00Z","last_updated_date":"2018-11-22T12:35:00Z","reference_number":"EMA/405374/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2018-ema-decision-17-july-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ustekinumab-stelara-emea-000311-pip05-17_en.pdf"},
    {"id":"42745","name":"P/0206/2018: EMA decision of 19 July 2018 on the granting of a product specific waiver for bilastine (Bilaxten and associated names), (EMEA- 000347-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T12:44:00Z","last_updated_date":"2018-11-22T12:44:00Z","reference_number":"EMA/421220/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2018-ema-decision-19-july-2018-granting-product-specific-waiver-bilastine-bilaxten-associated-names-emea-000347-pip03-18_en.pdf"},
    {"id":"42746","name":"P/0142/2018: EMA decision of 7 May 2018 on the granting of a product specific waiver for ranibizumab (Lucentis), (EMEA-000527-PIP05-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T12:52:00Z","last_updated_date":"2018-11-22T12:52:00Z","reference_number":"EMA/258310/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2018-ema-decision-7-may-2018-granting-product-specific-waiver-ranibizumab-lucentis-emea-000527-pip05-17_en.pdf"},
    {"id":"42747","name":"P/0141/2018: EMA decision of 7 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate) (Lixiana), (EMEA-000788-PIP02-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T12:56:00Z","last_updated_date":"2018-11-22T12:56:00Z","reference_number":"EMA/258436/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2018-ema-decision-7-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-lixiana-emea-000788-pip02-11-m07_en.pdf"},
    {"id":"42748","name":"P/0201/2018: EMA decision of 19 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin (Jardiance), (EMEA-000828-PIP01-09-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T13:03:00Z","last_updated_date":"2018-11-22T13:03:00Z","reference_number":"EMA/421359/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2018-ema-decision-19-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-jardiance-emea-000828-pip01-09-m07_en.pdf"},
    {"id":"42749","name":"P/0165/2018: EMA decision of 15 June on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin (Jardiance), (EMEA-000828-PIP04-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T13:09:00Z","last_updated_date":"2018-11-22T13:09:00Z","reference_number":"EMA/381912/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2018-ema-decision-15-june-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-jardiance-emea-000828-pip04-16-m01_en.pdf"},
    {"id":"42750","name":"P/0200/2018: EMA decision of 19 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris), (EMEA-000876-PIP05-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T13:20:00Z","last_updated_date":"2018-11-22T13:20:00Z","reference_number":"EMA/421364/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2018-ema-decision-19-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip05-15-m03_en.pdf"},
    {"id":"42752","name":"P/0196/2018: EMA decision of 17 July 2018 of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sucroferric oxyhydroxide (mixture of iron (III)-oxyhydroxide, sucrose, starch) (PA21) (EMEA-001061-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T14:23:00Z","last_updated_date":"2018-11-22T14:23:00Z","reference_number":"EMA/379809/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2018-ema-decision-17-july-2018-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-sucroferric-oxyhydroxide-mixture-iron-iii-oxyhydroxide-sucrose-starch-pa21-emea-001061_en.pdf"},
    {"id":"42753","name":"P/0223/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate / sodium sulfate (as sodium","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T14:31:00Z","last_updated_date":"2018-11-22T14:31:00Z","reference_number":"EMA/465448/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-citric-acid-citric-acid-anhydrous-sodium-chloride-simeticone-macrogol-4000-sodium-citrate-sodium_en.pdf"},
    {"id":"42754","name":"P/0197/2018: EMA decision of 19 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sirolimus (EMEA- 001416-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T14:38:00Z","last_updated_date":"2018-11-22T14:38:00Z","reference_number":"EMA/422054/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2018-ema-decision-19-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-sirolimus-emea-001416-pip01-12-m02_en.pdf"},
    {"id":"42755","name":"P/0226/2018: EMA decision of 20 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for febuxostat (Adenuric), (EMEA-001417-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T14:45:00Z","last_updated_date":"2018-11-22T14:45:00Z","reference_number":"EMA/471696/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2018-ema-decision-20-july-2017-acceptance-modification-agreed-paediatric-investigation-plan-febuxostat-adenuric-emea-001417-pip01-12-m04_en.pdf"},
    {"id":"42756","name":"P/0216/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for cobimetinib, (Cotellic) (EMEA-001425-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T14:50:00Z","last_updated_date":"2018-11-22T14:50:00Z","reference_number":"EMA/465437/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-cobimetinib-cotellic-emea-001425-pip01-13-m03_en.pdf"},
    {"id":"42757","name":"P/0222/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant varicella zoster virus (VZV) glycoprotein E (Shingrix), (EMEA-001426-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T15:00:00Z","last_updated_date":"2018-11-22T15:00:00Z","reference_number":"EMA/465427/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-varicella-zoster-virus-vzv-glycoprotein-e-shingrix-emea-001426-pip01-13-m02_en.pdf"},
    {"id":"42758","name":"P/0174/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dasabuvir (sodium monohydrate) (Exviera), (EMEA-001439-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T15:04:00Z","last_updated_date":"2018-11-22T15:04:00Z","reference_number":"EMA/324472/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-dasabuvir-sodium-monohydrate-exviera-emea-001439-pip01-13-m02_en.pdf"},
    {"id":"42759","name":"P/0179/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ombitasvir / paritaprevir / ritonavir (Viekirax), (EMEA-001440-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T15:07:00Z","last_updated_date":"2018-11-22T15:07:00Z","reference_number":"EMA/381909/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-ombitasvir-paritaprevir-ritonavir-viekirax-emea-001440-pip01-13-m02_en.pdf"},
    {"id":"42760","name":"P/0158/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T15:16:00Z","last_updated_date":"2018-11-22T15:16:00Z","reference_number":"EMA/381964/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip01-13-m05_en.pdf"},
    {"id":"42761","name":"P/0185/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for bempedoic acid (EMEA-001872-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-22T15:23:00Z","last_updated_date":"2018-11-22T15:23:00Z","reference_number":"EMA/406248/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-bempedoic-acid-emea-001872-pip01-15-m01_en.pdf"},
    {"id":"42762","name":"P/0344/2016: EMA decision of 2 December 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inebilizumab (EMEA-001911-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2017-01-30T15:27:00Z","last_updated_date":"2017-01-30T15:27:00Z","reference_number":"EMA/765275/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0344-2016-ema-decision-2-december-2016-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-inebilizumab-emea-001911-pip01-15_en.pdf"},
    {"id":"42801","name":"P/0147/2018: EMA decision of 7 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sunitinib (Sutent), (EMEA-000342-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T11:33:00Z","last_updated_date":"2018-11-27T11:33:00Z","reference_number":"EMA/258873/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2018-ema-decision-7-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-sunitinib-sutent-emea-000342-pip01-08-m07_en.pdf"},
    {"id":"42802","name":"P/0147/2018: EMA decision of 12 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tocilizumab (RoActemra) (EMEA-000309-PIP04-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T11:44:00Z","last_updated_date":"2018-11-27T11:44:00Z","reference_number":"EMA/388203/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2018-ema-decision-12-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-tocilizumab-roactemra-emea-000309-pip04-17-m01_en.pdf"},
    {"id":"42803","name":"P/0143/2018: EMA decision of 7 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon alfa-2a (Pegasys), (EMEA-000298-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T12:12:00Z","last_updated_date":"2018-11-27T12:12:00Z","reference_number":"EMA/201224/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2018-ema-decision-7-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-peginterferon-alfa-2a-pegasys-emea-000298-pip01-08-m06_en.pdf"},
    {"id":"42804","name":"P/0202/2018: EMA decision of 19 July 2018 on the granting of a product-specific waiver for dapagliflozin (Forxiga), (EMEA-000694-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T12:30:00Z","last_updated_date":"2018-11-27T12:30:00Z","reference_number":"EMA/421228/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2018-ema-decision-19-july-2018-granting-product-specific-waiver-dapagliflozin-forxiga-emea-000694-pip03-17_en.pdf"},
    {"id":"42805","name":"P/0148/2018: EMA decision of 18 May 2018 on the review of a granted waiver for delafloxacin (EMEA-001080-PIP01-10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T12:25:00Z","last_updated_date":"2018-11-27T12:25:00Z","reference_number":"EMA/267331/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2018-ema-decision-18-may-2018-review-granted-waiver-delafloxacin-emea-001080-pip01-10_en.pdf"},
    {"id":"42806","name":"P/0195/2018: EMA decision of 17 July 2018 on the granting of a product specific-waiver for fostamatinib (EMEA-001196-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T12:33:00Z","last_updated_date":"2018-11-27T12:33:00Z","reference_number":"EMA/376000/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2018-ema-decision-17-july-2018-granting-product-specific-waiver-fostamatinib-emea-001196-pip02-17_en.pdf"},
    {"id":"42807","name":"P/0140/2018: EMA decision of 7 May 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fosnetupitant / palonosetron (Akynzeo), (EMEA-001198-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T12:40:00Z","last_updated_date":"2018-11-27T12:40:00Z","reference_number":"EMA/202260/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2018-ema-decision-7-may-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fosnetupitant-palonosetron-akynzeo-emea-001198-pip03-17_en.pdf"},
    {"id":"42808","name":"P/0194/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for expanded donorderived allogenic T cells transduced...(EMEA-001869-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T12:56:00Z","last_updated_date":"2018-11-27T12:56:00Z","reference_number":"EMA/404134/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-expanded-donorderived-allogenic-t-cells-transducedemea-001869-pip01-15-m01_en.pdf"},
    {"id":"42809","name":"P/0178/2018: EMA decision of 15 June 2018 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for somapacitan (EMEA-001469-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T12:50:00Z","last_updated_date":"2018-11-27T12:50:00Z","reference_number":"EMA/366134/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2018-ema-decision-15-june-2018-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-somapacitan-emea-001469-pip02-17_en.pdf"},
    {"id":"42810","name":"P/0137/2018: EMA decision of 7 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for galcanezumab (EMEA-001860-PIP03-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T13:06:00Z","last_updated_date":"2018-11-27T13:06:00Z","reference_number":"EMA/213205/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2018-ema-decision-7-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-galcanezumab-emea-001860-pip03-16-m01_en.pdf"},
    {"id":"42811","name":"P/0139/2018: EMA decision of 7 May 2018 on the agreement of a paediatric investigation plan and on the granting of a waiver for emtricitabine / tenofovir alafenamide (Descovy), (EMEA-001577-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T13:07:00Z","last_updated_date":"2018-11-27T13:07:00Z","reference_number":"EMA/209254/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2018-ema-decision-7-may-2018-agreement-paediatric-investigation-plan-granting-waiver-emtricitabine-tenofovir-alafenamide-descovy-emea-001577-pip03-17_en.pdf"},
    {"id":"42812","name":"P/0168/2018: EMA decision of 18 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for betrixaban (EMEA-001834-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T13:12:00Z","last_updated_date":"2018-11-27T13:12:00Z","reference_number":"EMA/381968/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2018-ema-decision-18-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-betrixaban-emea-001834-pip02-16-m01_en.pdf"},
    {"id":"42813","name":"P/0187/2018: EMA decision of 17 July 2018 on the granting of a product-specific waiver for upadacitinib (EMEA-001741-PIP05-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T13:20:00Z","last_updated_date":"2018-11-27T13:20:00Z","reference_number":"EMA/403360/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2018-ema-decision-17-july-2018-granting-product-specific-waiver-upadacitinib-emea-001741-pip05-17_en.pdf"},
    {"id":"42814","name":"P/0135/2018: EMA decision of 7 May 2018 on the granting of a product-specific waiver for ibuprofen / paracetamol (EMEA-002002-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T13:28:00Z","last_updated_date":"2018-11-27T13:28:00Z","reference_number":"EMA/258445/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2018-ema-decision-7-may-2018-granting-product-specific-waiver-ibuprofen-paracetamol-emea-002002-pip02-17_en.pdf"},
    {"id":"42815","name":"P/0166/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for glecaprevir/pibrentasvir (Maviret), (EMEA-001832-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T13:32:00Z","last_updated_date":"2018-11-27T13:32:00Z","reference_number":"EMA/324473/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-glecaprevir-pibrentasvir-maviret-emea-001832-pip01-15-m01_en.pdf"},
    {"id":"42816","name":"P/0209/2018: EMA decision of 17 July 2018 on the agreement of a paediatric investigation plan and on the granting of a waiver for palbociclib, (Ibrance), (EMEA-002146-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T13:37:00Z","last_updated_date":"2018-11-27T13:37:00Z","reference_number":"EMA/465362/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2018-ema-decision-17-july-2018-agreement-paediatric-investigation-plan-granting-waiver-palbociclib-ibrance-emea-002146-pip01-17_en.pdf"},
    {"id":"42817","name":"P/0224/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for 2-hydroxypropyl-ßcyclodextrin (HP-ß-CD) (EMEA-001866-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T13:45:00Z","last_updated_date":"2018-11-27T13:45:00Z","reference_number":"EMA/465549/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-2-hydroxypropyl-sscyclodextrin-hp-ss-cd-emea-001866-pip01-15-m02_en.pdf"},
    {"id":"42818","name":"P/0138/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for liquid ethanolic extract 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.) Burm. f. (fresh fruit), Paullinia","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T13:52:00Z","last_updated_date":"2018-11-27T13:52:00Z","reference_number":"EMA/213297/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-liquid-ethanolic-extract-30-cent-w-w-allium-cepa-l-fresh-bulb-citrus-limon-l-burm-f-fresh-fruit_en.pdf"},
    {"id":"42820","name":"P/0221/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ligelizumab, (EMEA-001811-PIP02-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T14:27:00Z","last_updated_date":"2018-11-27T14:27:00Z","reference_number":"EMA/465446/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-ligelizumab-emea-001811-pip02-15-m02_en.pdf"},
    {"id":"42821","name":"P/0211/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains: A/(H1N1), A/(H3N2), B/Yamagata linea","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T14:31:00Z","last_updated_date":"2018-11-27T14:31:00Z","reference_number":"EMA/465552/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-following-strains-h1n1-h3n2-b-yamagata_en.pdf"},
    {"id":"42822","name":"P/0180/2018: EMA decision of 15 June 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for daratumumab (Darzalex) (EMEA-002152-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T14:33:00Z","last_updated_date":"2018-11-27T14:33:00Z","reference_number":"EMA/278527/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2018-ema-decision-15-june-2018-agreement-paediatric-investigation-plan-granting-deferral-daratumumab-darzalex-emea-002152-pip01-17_en.pdf"},
    {"id":"42823","name":"P/0160/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan lurasidone (hydrochloride) (Latuda), (001230-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T14:42:00Z","last_updated_date":"2018-11-27T14:42:00Z","reference_number":"EMA/328327/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-lurasidone-hydrochloride-latuda-001230-pip01-11-m04_en.pdf"},
    {"id":"42824","name":"P/0154/2018: EMA decision on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis), (EMEA-000183-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T14:49:00Z","last_updated_date":"2018-11-27T14:49:00Z","reference_number":"EMA/297918/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2018-ema-decision-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip01-08-m06_en.pdf"},
    {"id":"42825","name":"P/0157/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP01-11-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-11-27T14:57:00Z","last_updated_date":"2018-11-27T14:57:00Z","reference_number":"EMA/366003/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip01-11-m03_en.pdf"},
    {"id":"42826","name":"P/0144/2018: EMA decision of 7 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for treprostinil (Remodulin and associated names), (EMEA-000207-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T15:08:00Z","last_updated_date":"2018-11-27T15:08:00Z","reference_number":"EMA/210453/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2018-ema-decision-7-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-treprostinil-remodulin-associated-names-emea-000207-pip01-08-m06_en.pdf"},
    {"id":"42827","name":"P/0188/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for pitolisant (Wakix),(EMEA-001176-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T15:10:00Z","last_updated_date":"2018-11-27T15:10:00Z","reference_number":"EMA/403688/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-pitolisant-wakixemea-001176-pip01-11-m03_en.pdf"},
    {"id":"42828","name":"P/0175/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lubiprostone (AMITIZA), (EMEA-000245-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T15:14:00Z","last_updated_date":"2018-11-27T15:14:00Z","reference_number":"EMA/324450/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-lubiprostone-amitiza-emea-000245-pip01-08-m05_en.pdf"},
    {"id":"42829","name":"P/0167/2018: EMA decision of 15 June 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lasmiditan (EMEA-002166-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T15:40:00Z","last_updated_date":"2018-11-27T15:40:00Z","reference_number":"EMA/366138/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2018-ema-decision-15-june-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lasmiditan-emea-002166-pip01-17_en.pdf"},
    {"id":"42830","name":"P/0204/2018: EMA decision of 19 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T16:09:00Z","last_updated_date":"2018-11-27T16:09:00Z","reference_number":"EMA/421350/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2018-ema-decision-19-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-linagliptin-trajenta-emea-000498-pip01-08-m08_en.pdf"},
    {"id":"42831","name":"P/0229/2018: EMA decision of 30 July 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant IgG degrading enzyme of Streptococcus pyogenes (EMEA-002183-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T16:11:00Z","last_updated_date":"2018-11-27T16:11:00Z","reference_number":"EMA/375899/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2018-ema-decision-30-july-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-igg-degrading-enzyme-streptococcus-pyogenes-emea-002183-pip01-17_en.pdf"},
    {"id":"42832","name":"P/0208/2018: EMA decision of 17 July 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for itacitinib (EMEA-002178-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T16:14:00Z","last_updated_date":"2018-11-27T16:14:00Z","reference_number":"EMA/465554/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2018-ema-decision-17-july-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-itacitinib-emea-002178-pip01-17_en.pdf"},
    {"id":"42833","name":"P/0207/2018: EMA decision of 17July 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (R)-2-amino-3-phenylpropylcarbamate hydrochloride (solriamfetol) (EMEA-002184-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T16:33:00Z","last_updated_date":"2018-11-27T16:33:00Z","reference_number":"EMA/466443/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2018-ema-decision-17july-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-r-2-amino-3-phenylpropylcarbamate-hydrochloride-solriamfetol-emea-002184-pip01-17_en.pdf"},
    {"id":"42834","name":"P/0193/2018: EMA decision of 17 July 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bimekizumab (EMEA-002189-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T17:01:00Z","last_updated_date":"2018-11-27T17:01:00Z","reference_number":"EMA/375727/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2018-ema-decision-17-july-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bimekizumab-emea-002189-pip01-17_en.pdf"},
    {"id":"42835","name":"P/0205/2018: EMA decision of 19 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for Ticagrelor (Brilique), (EMEA-000480-PIP01-08-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T17:21:00Z","last_updated_date":"2018-11-27T17:21:00Z","reference_number":"EMA/421332/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2018-ema-decision-19-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-ticagrelor-brilique-emea-000480-pip01-08-m11_en.pdf"},
    {"id":"42836","name":"P/0191/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for glycerol phenylbutyrate (Ravicti), (EMEA-000297-PIP02-12-M02","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T17:24:00Z","last_updated_date":"2018-11-27T17:24:00Z","reference_number":"EMA/403996/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-glycerol-phenylbutyrate-ravicti-emea-000297-pip02-12-m02_en.pdf"},
    {"id":"42837","name":"P/0199/2018: EMA decision of 19 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for fibrinogen / thrombin / aprotinin / calcium chloride (EMEA-001079-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T17:31:00Z","last_updated_date":"2018-11-27T17:31:00Z","reference_number":"EMA/421372/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2018-ema-decision-19-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-fibrinogen-thrombin-aprotinin-calcium-chloride-emea-001079-pip01-10-m04_en.pdf"},
    {"id":"42838","name":"P/0164/2018: EMA decision of of 15 June 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for setmelanotide (EMEA-002209-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T17:37:00Z","last_updated_date":"2018-11-27T17:37:00Z","reference_number":"EMA/328767/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2018-ema-decision-15-june-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-setmelanotide-emea-002209-pip01-17_en.pdf"},
    {"id":"42839","name":"P/0189/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for brodalumab (EMEA- 001089-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T17:47:00Z","last_updated_date":"2018-11-27T17:47:00Z","reference_number":"EMA/403852/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-brodalumab-emea-001089-pip02-13-m01_en.pdf"},
    {"id":"42840","name":"P/0155/2018: EMA decision of 25 May 2018 on the granting of a product specific waiver for split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain / split influenza virus, inactivated containing antigens equivalent to th","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T17:59:00Z","last_updated_date":"2018-11-27T17:59:00Z","reference_number":"EMA/324949/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2018-ema-decision-25-may-2018-granting-product-specific-waiver-split-influenza-virus-inactivated-containing-antigens-equivalent-h1n1-strain-split-influenza-virus-inactivated-containing-antigens_en.pdf"},
    {"id":"42841","name":"P/0145/2018: EMA decision of 7 May 2018 on the granting of a product specific waiver for amlodipine / irbesartan (EMEA-002192-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T18:05:00Z","last_updated_date":"2018-11-27T18:05:00Z","reference_number":"EMA/258460/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2018-ema-decision-7-may-2018-granting-product-specific-waiver-amlodipine-irbesartan-emea-002192-pip02-17_en.pdf"},
    {"id":"42842","name":"P/0214/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for potassium citrate monohydrated / potassium hydrogen carbonate (ADV7103) (EMEA-001535-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T18:06:00Z","last_updated_date":"2018-11-27T18:06:00Z","reference_number":"EMA/465548/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-potassium-citrate-monohydrated-potassium-hydrogen-carbonate-adv7103-emea-001535-pip01-13-m01_en.pdf"},
    {"id":"42844","name":"P/0184/2018: EMA decision of 17 July 2018 on the refusal of a product specific waiver for liposomal ciclosporin A (L-CsA) (EMEA-002344-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T18:15:00Z","last_updated_date":"2018-11-27T18:15:00Z","reference_number":"EMA/403599/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2018-ema-decision-17-july-2018-refusal-product-specific-waiver-liposomal-ciclosporin-l-csa-emea-002344-pip01-18_en.pdf"},
    {"id":"42845","name":"P/0173/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for etelcalcetide (Parsabiv), (EMEA-001554-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T18:19:00Z","last_updated_date":"2018-11-27T18:19:00Z","reference_number":"EMA/366017/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-etelcalcetide-parsabiv-emea-001554-pip01-13-m02_en.pdf"},
    {"id":"42846","name":"P/0156/2018: EMA decision of 15 June 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for isatuximab (EMEA-002205-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T18:23:00Z","last_updated_date":"2018-11-27T18:23:00Z","reference_number":"EMA/381998/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2018-ema-decision-15-june-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-isatuximab-emea-002205-pip01-17_en.pdf"},
    {"id":"42848","name":"P/0051/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for purified inactivated rabies virus (WISTAR PM/WI 38-1503-3M strain) (EMEA-002234-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-02T18:36:00Z","last_updated_date":"2025-04-02T18:36:00Z","reference_number":"EMA/53565/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-purified-inactivated-rabies-virus-wistar-pm-wi-38-1503-3m-strain-emea-002234-pip01-17-m02_en.pdf"},
    {"id":"42849","name":"P/0225/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for vonicog alfa (EMEA- 001164-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T09:14:00Z","last_updated_date":"2018-11-28T09:14:00Z","reference_number":"EMA/465546/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-vonicog-alfa-emea-001164-pip01-11-m02_en.pdf"},
    {"id":"42850","name":"P/0146/2018: EMA decision of 7 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for naloxone (hydrochloride), (EMEA-001567-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T09:19:00Z","last_updated_date":"2018-11-28T09:19:00Z","reference_number":"EMA/259091/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2018-ema-decision-7-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-naloxone-hydrochloride-emea-001567-pip01-13-m03_en.pdf"},
    {"id":"42851","name":"P/0150/2018: EMA decision of 18 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir / velpatasvir (Epclusa), (EMEA-001646-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T09:27:00Z","last_updated_date":"2018-11-28T09:27:00Z","reference_number":"EMA/291038/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2018-ema-decision-18-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-sofosbuvir-velpatasvir-epclusa-emea-001646-pip01-14-m02_en.pdf"},
    {"id":"42852","name":"P/0170/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for peanut flour (EMEA-001734-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T09:32:00Z","last_updated_date":"2018-11-28T09:32:00Z","reference_number":"EMA/352391/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-peanut-flour-emea-001734-pip01-14-m02_en.pdf"},
    {"id":"42856","name":"P/0213/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for arimoclomol (citrate), (EMEA-001748-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T10:35:00Z","last_updated_date":"2018-11-28T10:35:00Z","reference_number":"EMA/465443/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-arimoclomol-citrate-emea-001748-pip01-15-m01_en.pdf"},
    {"id":"42857","name":"P/0212/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ enriched cell fraction that contains CD34+ cells transduced... (EMEA-001765-PIP02-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T10:42:00Z","last_updated_date":"2018-11-28T10:42:00Z","reference_number":"EMA/465551/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-enriched-cell-fraction-contains-cd34-cells-transduced-emea-001765-pip02-15-m02_en.pdf"},
    {"id":"42858","name":"P/0217/2018: EMA decision of 19 July 2018 on the granting of a product specific waiver for nitrous oxide (EMEA-002340-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T10:44:00Z","last_updated_date":"2018-11-28T10:44:00Z","reference_number":"EMA/421241/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2018-ema-decision-19-july-2018-granting-product-specific-waiver-nitrous-oxide-emea-002340-pip01-18_en.pdf"}    {"id":"42859","name":"P/0218/2018: EMA decision of 17 July 2018 on the granting of a product specific waiver for patidegib (EMEA-002322-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T11:07:00Z","last_updated_date":"2018-11-28T11:07:00Z","reference_number":"EMA/465553/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2018-ema-decision-17-july-2018-granting-product-specific-waiver-patidegib-emea-002322-pip01-17_en.pdf"},
    {"id":"42860","name":"P/0133/2018: EMA decision of 7 May 2018 on the granting of a product specific waiver for eszopiclone (EMEA-002309-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T12:06:00Z","last_updated_date":"2018-11-28T12:06:00Z","reference_number":"EMA/209351/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2018-ema-decision-7-may-2018-granting-product-specific-waiver-eszopiclone-emea-002309-pip01-17_en.pdf"},
    {"id":"42861","name":"P/0169/2018: EMA decision of 15 June 2018 on the granting of a product specific waiver for andecaliximab (EMEA-002304-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T12:19:00Z","last_updated_date":"2018-11-28T12:19:00Z","reference_number":"EMA/381994/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2018-ema-decision-15-june-2018-granting-product-specific-waiver-andecaliximab-emea-002304-pip01-17_en.pdf"},
    {"id":"42862","name":"P/0134/2018: EMA decision of 7 May 2018 on the granting of a product specific waiver for (2R)-2-Amino-1-[3-({2-[p-(4-{3-[(3,5-diamino-6- chloro-2-pyrazinyl)carbonyl]guanidino}butyl)phenoxy]ethyl}{3-[(2R)-2-amino-6- guanidinohexanoylamino]propyl}amino)prop","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T12:31:00Z","last_updated_date":"2018-11-28T12:31:00Z","reference_number":"EMA/201423/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2018-ema-decision-7-may-2018-granting-product-specific-waiver-2r-2-amino-1-3-2-p-4-3-35-diamino-6-chloro-2-pyrazinylcarbonylguanidinobutylphenoxyethyl3-2r-2-amino-6_en.pdf"},
    {"id":"42863","name":"P/0162/2018: EMA decision of 15 June 2018 on the granting of a product specific waiver for verapamil / trandolapril (EMEA-002276-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T12:39:00Z","last_updated_date":"2018-11-28T12:39:00Z","reference_number":"EMA/366094/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2018-ema-decision-15-june-2018-granting-product-specific-waiver-verapamil-trandolapril-emea-002276-pip01-17_en.pdf"},
    {"id":"42864","name":"P/0228/2018: EMA decision of 29 July 2018 on the refusal of a product specific waiver for moxonidine (EMEA-002275-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T12:43:00Z","last_updated_date":"2018-11-28T12:43:00Z","reference_number":"EMA/480848/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2018-ema-decision-29-july-2018-refusal-product-specific-waiver-moxonidine-emea-002275-pip01-17_en.pdf"},
    {"id":"42865","name":"P/0192/2018: EMA decision of 17 July 2018 on the refusal of a product specific waiver for trandolapril (EMEA-002274-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T12:46:00Z","last_updated_date":"2018-11-28T12:46:00Z","reference_number":"EMA/378944/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2018-ema-decision-17-july-2018-refusal-product-specific-waiver-trandolapril-emea-002274-pip01-17_en.pdf"},
    {"id":"42866","name":"P/0159/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for beclometasone (dipropionate)/formoterol (fumarate dihydrate) (Foster and associated names, Kantos and associated names, Inuvair..","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T12:59:00Z","last_updated_date":"2018-11-28T12:59:00Z","reference_number":"EMA/324470/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-beclometasone-dipropionate-formoterol-fumarate-dihydrate-foster-associated-names-kantos-associated_en.pdf"},
    {"id":"42867","name":"P/0203/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib, (Xeljanz), (EMEA-000576-PIP01-09-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T13:16:00Z","last_updated_date":"2018-11-28T13:16:00Z","reference_number":"EMA/465433/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip01-09-m09_en.pdf"},
    {"id":"42868","name":"P/0227/2018: EMA decision of 20 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for pixantrone (dimaleate) (Pixuvri), (EMEA-000713-PIP02-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T13:24:00Z","last_updated_date":"2018-11-28T13:24:00Z","reference_number":"EMA/469707/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2018-ema-decision-20-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-pixantrone-dimaleate-pixuvri-emea-000713-pip02-10-m05_en.pdf"},
    {"id":"42869","name":"P/0163/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla), (EMEA-000715-PIP03-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T13:33:00Z","last_updated_date":"2018-11-28T13:33:00Z","reference_number":"EMA/352392/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip03-11-m05_en.pdf"},
    {"id":"42870","name":"P/0176/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ceftaroline fosamil (Zinforo), (EMEA-000769-PIP01-09-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T14:20:00Z","last_updated_date":"2018-11-28T14:20:00Z","reference_number":"EMA/381903/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-ceftaroline-fosamil-zinforo-emea-000769-pip01-09-m08_en.pdf"},
    {"id":"42872","name":"P/0161/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for spheroids of human autologous matrix-associated chondrocytes (Spherox), (EMEA-001264-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T15:14:00Z","last_updated_date":"2018-11-28T15:14:00Z","reference_number":"EMA/324452/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-spheroids-human-autologous-matrix-associated-chondrocytes-spherox-emea-001264-pip01-12-m02_en.pdf"},
    {"id":"42873","name":"P/0172/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir (Sovaldi), (EMEA-001276-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T16:05:00Z","last_updated_date":"2018-11-28T16:05:00Z","reference_number":"EMA/366015/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-sofosbuvir-sovaldi-emea-001276-pip01-12-m02_en.pdf"},
    {"id":"42874","name":"P/0198/2018: EMA decision of 19 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for gabapentin (EMEA-001310-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T16:16:00Z","last_updated_date":"2018-11-28T16:16:00Z","reference_number":"EMA/421374/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2018-ema-decision-19-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-gabapentin-emea-001310-pip01-12-m03_en.pdf"},
    {"id":"42875","name":"P/0149/2018: EMA decision of 17 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ceftazidime / avibactam (Zavicefta), (EMEA-001313-PIP01-12-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T16:34:00Z","last_updated_date":"2018-11-28T16:34:00Z","reference_number":"EMA/288608/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2018-ema-decision-17-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-zavicefta-emea-001313-pip01-12-m07_en.pdf"},
    {"id":"42876","name":"P/0186/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for rimiducid (EMEA- 001870-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T16:45:00Z","last_updated_date":"2018-11-28T16:45:00Z","reference_number":"EMA/404189/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-rimiducid-emea-001870-pip01-15-m01_en.pdf"},
    {"id":"42877","name":"P/0151/2018: EMA decision of 18 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lamivudine/dolutegravir (EMEA-001940-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T17:04:00Z","last_updated_date":"2018-11-28T17:04:00Z","reference_number":"EMA/291491/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2018-ema-decision-18-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-lamivudine-dolutegravir-emea-001940-pip01-16-m01_en.pdf"},
    {"id":"42878","name":"P/0182/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for larotrectinib (EMEA-001971-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T17:27:00Z","last_updated_date":"2018-11-28T17:27:00Z","reference_number":"EMA/379661/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-larotrectinib-emea-001971-pip02-16-m01_en.pdf"},
    {"id":"42879","name":"P/0177/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for fenfluramine (hydrochloride) (EMEA-001990-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T17:32:00Z","last_updated_date":"2018-11-28T17:32:00Z","reference_number":"EMA/366018/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-fenfluramine-hydrochloride-emea-001990-pip01-16-m01_en.pdf"},
    {"id":"42880","name":"P/0210/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for mexiletine (hydrochloride) (EMEA-002012-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T17:38:00Z","last_updated_date":"2018-11-28T17:38:00Z","reference_number":"EMA/465562/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-mexiletine-hydrochloride-emea-002012-pip01-16-m01_en.pdf"},
    {"id":"42881","name":"P/0152/2018: EMA decision of 18 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for emapalumab (EMEA-002031-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T17:42:00Z","last_updated_date":"2018-11-28T17:42:00Z","reference_number":"EMA/291263/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2018-ema-decision-18-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-emapalumab-emea-002031-pip01-16-m01_en.pdf"},
    {"id":"42893","name":"P/0231/2018: EMA decision of 3 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for risankizumab (EMEA-001776-PIP04-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-30T13:30:00Z","last_updated_date":"2018-11-30T13:30:00Z","reference_number":"EMA/469730/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2018-ema-decision-3-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-risankizumab-emea-001776-pip04-17_en.pdf-0"},
    {"id":"42894","name":"P/0230/2018: EMA decision of 3 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for risankizumab (EMEA-001776-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-30T13:40:00Z","last_updated_date":"2018-11-30T13:40:00Z","reference_number":"EMA/480849/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2018-ema-decision-3-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-risankizumab-emea-001776-pip03-17_en.pdf-0"},
    {"id":"42984","name":"P/0215/2018: EMA decision of 17 July 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tasimelteon (Hetlioz), (EMEA-001531-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T12:10:00Z","last_updated_date":"2018-11-27T12:10:00Z","reference_number":"EMA/465547/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2018-ema-decision-17-july-2018-acceptance-modification-agreed-paediatric-investigation-plan-tasimelteon-hetlioz-emea-001531-pip01-13-m04_en.pdf"},
    {"id":"42985","name":"P/0201/2015: EMA decision of 4 September 2015 on the granting of a product specific waiver for indapamide / perindopril (tert-butylamine) / rosuvastatin (EMEA-001771-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-12-11T12:22:00Z","last_updated_date":"2018-12-11T12:22:00Z","reference_number":"EMA/568913/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2015-ema-decision-4-september-2015-granting-product-specific-waiver-indapamide-perindopril-tert-butylamine-rosuvastatin-emea-001771-pip01-15_en.pdf"},
    {"id":"43157","name":"P/0257/2018: EMA decision of 14 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for paclitaxel Abraxane), (EMEA-001308-PIP01-12-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T13:55:00Z","last_updated_date":"2018-12-19T13:55:00Z","reference_number":"EMA/521807/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2018-ema-decision-14-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-paclitaxel-abraxane-emea-001308-pip01-12-m02_en.pdf"},
    {"id":"43197","name":"P/0153/2018: EMA decision of 25 May 2018 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis), (EMEA-000183-PIP02-12-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2018-12-20T13:48:00Z","last_updated_date":"2018-12-20T13:48:00Z","reference_number":"EMA/298048/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2018-ema-decision-25-may-2018-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip02-12-m02_en.pdf"},
    {"id":"43208","name":"P/0220/2018: EMA decision of 19 July 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for dasiglucagon (EMEA-002233-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T16:15:00Z","last_updated_date":"2018-11-27T16:15:00Z","reference_number":"EMA/427554/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2018-ema-decision-19-july-2018-agreement-paediatric-investigation-plan-granting-deferral-dasiglucagon-emea-002233-pip01-17_en.pdf"},
    {"id":"43340","name":"P/0255/2018: EMA decision of 14 August 2018 on the granting of a product specific waiver for navitoclax (EMEA-000478-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T12:26:00Z","last_updated_date":"2019-01-11T12:26:00Z","reference_number":"EMA/523594/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2018-ema-decision-14-august-2018-granting-product-specific-waiver-navitoclax-emea-000478-pip02-18_en.pdf"},
    {"id":"43341","name":"P/0256/2018: EMA decision of 14 August 2018 on the granting of a product specific waiver for veliparib (EMEA-000499-PIP05-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T12:47:00Z","last_updated_date":"2019-01-11T12:47:00Z","reference_number":"EMA/522697/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2018-ema-decision-14-august-2018-granting-product-specific-waiver-veliparib-emea-000499-pip05-18_en.pdf"},
    {"id":"43342","name":"P/0327/2018: EMA decision of  8 October 2018 on the granting of a product specific waiver for brentuximab vedotin (Adcetris), (EMEA-000980-PIP04-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T12:55:00Z","last_updated_date":"2019-01-11T12:55:00Z","reference_number":"EMA/646757/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0327-2018-ema-decision-8-october-2018-granting-product-specific-waiver-brentuximab-vedotin-adcetris-emea-000980-pip04-18_en.pdf"},
    {"id":"43343","name":"P/0338/2018: EMA decision of 12 October 2018 on the review of a granted waiver for clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins (Xeomin, Bocouture), (EMEA-001039-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T13:12:00Z","last_updated_date":"2019-01-11T13:12:00Z","reference_number":"EMA/693805/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0338-2018-ema-decision-12-october-2018-review-granted-waiver-clostridium-botulinum-neurotoxin-type-150-kd-free-complexing-proteins-xeomin-bocouture-emea-001039-pip03-17_en.pdf"},
    {"id":"43344","name":"P/0335/2018: EMA decision of 8 October 2018 on the granting of a product specific waiver for sarilumab (Kevzara), (EMEA-001045-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T13:23:00Z","last_updated_date":"2019-01-11T13:23:00Z","reference_number":"EMA/578244/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0335-2018-ema-decision-8-october-2018-granting-product-specific-waiver-sarilumab-kevzara-emea-001045-pip02-18_en.pdf"},
    {"id":"43345","name":"P/0291/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for baricitinib (Olumiant), (EMEA-001220-PIP03-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T13:46:00Z","last_updated_date":"2019-01-11T13:46:00Z","reference_number":"EMA/539767/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-baricitinib-olumiant-emea-001220-pip03-16_en.pdf"},
    {"id":"43346","name":"P/0240/2018: EMA decision of 15 August 2018 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for octenidine (dihydrochloride) (EMEA-001384-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-11T14:27:00Z","last_updated_date":"2019-01-11T14:27:00Z","reference_number":"EMA/469733/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2018-ema-decision-15-august-2018-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-octenidine-dihydrochloride-emea-001384-pip02-17_en.pdf"},
    {"id":"43348","name":"P/0254/2018: EMA decision of 15 August 2018 on the granting of a product specific waiver for luspatercept (EMEA-001521-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-14T10:40:00Z","last_updated_date":"2019-01-14T10:40:00Z","reference_number":"EMA/471686/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2018-ema-decision-15-august-2018-granting-product-specific-waiver-luspatercept-emea-001521-pip02-18_en.pdf"},
    {"id":"43380","name":"P/0262/2018: EMA decision of 15 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for olaparib (Lynparza), (EMEA-002269-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T11:34:00Z","last_updated_date":"2019-01-17T11:34:00Z","reference_number":"EMA/471735/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2018-ema-decision-15-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-olaparib-lynparza-emea-002269-pip01-17_en.pdf"},
    {"id":"43381","name":"P/0321/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inclisiran sodium (EMEA-002214-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T11:46:00Z","last_updated_date":"2019-01-17T11:46:00Z","reference_number":"EMA/541006/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0321-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-inclisiran-sodium-emea-002214-pip01-17_en.pdf"},
    {"id":"43382","name":"P/0282/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a waiver for autologous cartilage derived cultured chondrocytes (EMEA-002217-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T11:54:00Z","last_updated_date":"2019-01-17T11:54:00Z","reference_number":"EMA/543162/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-waiver-autologous-cartilage-derived-cultured-chondrocytes-emea-002217-pip01-17_en.pdf"},
    {"id":"43383","name":"P/0281/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-mucosal addressin cell adhesion molecule antibody (SHP647), (EMEA-002218-PIP01-17","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T12:01:00Z","last_updated_date":"2019-01-17T12:01:00Z","reference_number":"EMA/517239/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-mucosal-addressin-cell-adhesion-molecule-antibody-shp647-emea-002218-pip01-17_en.pdf"},
    {"id":"43384","name":"P/0236/2018: EMA decision of 15 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C, adjuvanted with alumini","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T12:13:00Z","last_updated_date":"2019-01-17T12:13:00Z","reference_number":"EMA/480855/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2018-ema-decision-15-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-trimeric-recombinant-hiv-1-envelope-glycoprotein-140-clade-c-adjuvanted-alumini_en.pdf"},
    {"id":"43385","name":"P/0305/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for interferon beta-1a (EMEA-002238-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T12:21:00Z","last_updated_date":"2019-01-17T12:21:00Z","reference_number":"EMA/539764/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-deferral-interferon-beta-1a-emea-002238-pip01-17_en.pdf"},
    {"id":"43386","name":"P/0326/2018: EMA decision of 14 September 2018 on the granting of a product specific waiver for diphtheria toxin interleukin-3 Fusion Protein (EMEA-002244-PIP02-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T12:35:00Z","last_updated_date":"2019-01-17T12:35:00Z","reference_number":"EMA/597689/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0326-2018-ema-decision-14-september-2018-granting-product-specific-waiver-diphtheria-toxin-interleukin-3-fusion-protein-emea-002244-pip02-18_en.pdf"},
    {"id":"43387","name":"P/0280/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ivosidenib (EMEA-002247-PIP03-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T12:43:00Z","last_updated_date":"2019-01-17T12:43:00Z","reference_number":"EMA/584833/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ivosidenib-emea-002247-pip03-17_en.pdf"},
    {"id":"43388","name":"P/0263/2018: EMA decision of 15 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ferric pyrophosphate citrate (EMEA-002261-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T12:51:00Z","last_updated_date":"2019-01-17T12:51:00Z","reference_number":"EMA/472044/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2018-ema-decision-15-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ferric-pyrophosphate-citrate-emea-002261-pip01-17_en.pdf"},
    {"id":"43390","name":"P/0319/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a waiver for recombinant human acid ceramidase (RVT-801) (EMEA-002266-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T13:01:00Z","last_updated_date":"2019-01-17T13:01:00Z","reference_number":"EMA/540506/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0319-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-waiver-recombinant-human-acid-ceramidase-rvt-801-emea-002266-pip01-17_en.pdf"},
    {"id":"43391","name":"P/0235/2018: EMA decision of 15 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for his-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys(γ-Glu-palmitoyl)-Ser-Glu-Tyr-Leu- Asp-Ser-Glu-Arg","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T13:19:00Z","last_updated_date":"2019-01-17T13:19:00Z","reference_number":"EMA/480850/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2018-ema-decision-15-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-his-ser-gln-gly-thr-phe-thr-ser-asp-lysg-glu-palmitoyl-ser-glu-tyr-leu-asp-ser-glu-arg_en.pdf"},
    {"id":"43392","name":"P/0271/2018: EMA decision of 17 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ibalizumab (EMEA-002311-PIP01-17)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T13:27:00Z","last_updated_date":"2019-01-17T13:27:00Z","reference_number":"EMA/538125/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2018-ema-decision-17-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ibalizumab-emea-002311-pip01-17_en.pdf"},
    {"id":"43393","name":"P/0232/2018: EMA decision of 15 August 2018 on the granting of a product specific waiver for autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3- zeta chimeric antigen receptor (EMEA-002335-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T14:32:00Z","last_updated_date":"2019-01-17T14:32:00Z","reference_number":"EMA/480847/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2018-ema-decision-15-august-2018-granting-product-specific-waiver-autologous-t-cells-transduced-retroviral-vector-encoding-anti-cd19-cd28-cd3-zeta-chimeric-antigen-receptor-emea-002335-pip01-18_en.pdf"},
    {"id":"43394","name":"P/0332/2018: EMA decision of 9 October 2018 on the granting of a product specific waiver for ianalumab (EMEA-002338-PIP02-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T14:46:00Z","last_updated_date":"2019-01-17T14:46:00Z","reference_number":"EMA/651664/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0332-2018-ema-decision-9-october-2018-granting-product-specific-waiver-ianalumab-emea-002338-pip02-18_en.pdf"},
    {"id":"43395","name":"P/0279/2018: EMA decision of 12 September 2018 on the granting of a product specific waiver for tepotinib (EMEA-002345-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T14:51:00Z","last_updated_date":"2019-01-17T14:51:00Z","reference_number":"EMA/539658/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2018-ema-decision-12-september-2018-granting-product-specific-waiver-tepotinib-emea-002345-pip01-18_en.pdf"},
    {"id":"43396","name":"P/0245/2018: EMA decision of 15 August 2018 on the granting of a product specific waiver for irbesartan / amlodipine (EMEA-002352-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T15:08:00Z","last_updated_date":"2019-01-17T15:08:00Z","reference_number":"EMA/469735/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2018-ema-decision-15-august-2018-granting-product-specific-waiver-irbesartan-amlodipine-emea-002352-pip01-18_en.pdf"},
    {"id":"43397","name":"P/0331/2018: EMA decision of 8 October 2018 on the granting of a product specific waiver for telisotuzumab vedotin (EMEA-002361-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T15:28:00Z","last_updated_date":"2019-01-17T15:28:00Z","reference_number":"EMA/670856/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0331-2018-ema-decision-8-october-2018-granting-product-specific-waiver-telisotuzumab-vedotin-emea-002361-pip01-18_en.pdf"},
    {"id":"43398","name":"P/0330/2018: EMA decision of 8 October 2018 on the granting of a product specific waiver for 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4- fluorobenzoic acid (EMEA-002363-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-17T15:52:00Z","last_updated_date":"2019-01-17T15:52:00Z","reference_number":"EMA/670811/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0330-2018-ema-decision-8-october-2018-granting-product-specific-waiver-3-3-35-dimethyl-1h-pyrazol-4-ylpropoxy-4-fluorobenzoic-acid-emea-002363-pip01-18_en.pdf"},
    {"id":"43400","name":"P/0311/2018: EMA decision of 12 September 2018 on the granting of a product specific waiver for acetylsalicylic acid / rosuvastatin (calcium) / perindopril (tert-butylamine) / indapamide (hemihydrate) (EMEA-002366-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T11:04:00Z","last_updated_date":"2019-01-18T11:04:00Z","reference_number":"EMA/539588/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0311-2018-ema-decision-12-september-2018-granting-product-specific-waiver-acetylsalicylic-acid-rosuvastatin-calcium-perindopril-tert-butylamine-indapamide-hemihydrate-emea-002366-pip01-18_en.pdf"},
    {"id":"43402","name":"P/0278/2018: EMA decision of 12 September 2018 on the granting of a product specific waiver for anti-alpha synuclein monoclonal antibody (BIIB054) (EMEA-002367-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T11:15:00Z","last_updated_date":"2019-01-18T11:15:00Z","reference_number":"EMA/517236/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2018-ema-decision-12-september-2018-granting-product-specific-waiver-anti-alpha-synuclein-monoclonal-antibody-biib054-emea-002367-pip01-18_en.pdf"},
    {"id":"43403","name":"P/0277/2018: EMA decision of 12 September 2018 on the granting of a product specific waiver for levofloxacin / dexamethasone (EMEA-002375-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T11:23:00Z","last_updated_date":"2019-02-12T11:42:00Z","reference_number":"EMA/517237/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2018-ema-decision-12-september-2018-granting-product-specific-waiver-levofloxacin-dexamethasone-emea-002375-pip01-18_en.pdf"},
    {"id":"43404","name":"P/0276/2018: EMA decision of 12 September 2018 on the granting of a product specific waiver for nadofaragene firadenovec (EMEA-002376-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T11:48:00Z","last_updated_date":"2019-01-18T11:48:00Z","reference_number":"EMA/539660/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2018-ema-decision-12-september-2018-granting-product-specific-waiver-nadofaragene-firadenovec-emea-002376-pip01-18_en.pdf"},
    {"id":"43405","name":"P/0267/2018: EMA decision of 13 August 2018 on the granting of a product specific waiver for elotuzumab (Empliciti), (EMEA-002377-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T11:54:00Z","last_updated_date":"2019-01-18T11:54:00Z","reference_number":"EMA/534276/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2018-ema-decision-13-august-2018-granting-product-specific-waiver-elotuzumab-empliciti-emea-002377-pip01-18_en.pdf"},
    {"id":"43406","name":"P/0334/2018: EMA decision of 8 October 2018 on the granting of a product specific waiver for autologous dendritic cells pulsed with allogeneic tumour cell lysate (EMEA-002381-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T12:02:00Z","last_updated_date":"2019-01-18T12:02:00Z","reference_number":"EMA/578293/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2018-ema-decision-8-october-2018-granting-product-specific-waiver-autologous-dendritic-cells-pulsed-allogeneic-tumour-cell-lysate-emea-002381-pip01-18_en.pdf"},
    {"id":"43407","name":"P/0309/2018: EMA decision of 12 September 2018 on the granting of a product specific waiver for omega-3-acid ethyl esters 90 / rosuvastatin (calcium) (EMEA-002384-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T12:09:00Z","last_updated_date":"2019-01-18T12:09:00Z","reference_number":"EMA/542281/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0309-2018-ema-decision-12-september-2018-granting-product-specific-waiver-omega-3-acid-ethyl-esters-90-rosuvastatin-calcium-emea-002384-pip01-18_en.pdf"},
    {"id":"43408","name":"P/0336/2018: EMA decision of 8 October 2018 on the refusing of a product specific waiver for eflapegrastim (EMEA-002385-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T12:18:00Z","last_updated_date":"2019-01-18T12:18:00Z","reference_number":"EMA/643737/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2018-ema-decision-8-october-2018-refusing-product-specific-waiver-eflapegrastim-emea-002385-pip01-18_en.pdf"},
    {"id":"43409","name":"P/0329/2018: EMA decision of 8 October 2018 on the granting of a product specific waiver for pamiparib (EMEA-002389-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T12:44:00Z","last_updated_date":"2019-01-18T12:44:00Z","reference_number":"EMA/651667/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0329-2018-ema-decision-8-october-2018-granting-product-specific-waiver-pamiparib-emea-002389-pip01-18_en.pdf"},
    {"id":"43410","name":"P/0328/2018: EMA decision of 8 October 2018 on the granting of a product specific waiver for cell-free solution of lysed Escherichia coli culture, strain Laves (Colibiogen oral / Synerga / Colibiogen mild), (EMEA-002393-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T12:51:00Z","last_updated_date":"2019-01-18T12:51:00Z","reference_number":"EMA/646811/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0328-2018-ema-decision-8-october-2018-granting-product-specific-waiver-cell-free-solution-lysed-escherichia-coli-culture-strain-laves-colibiogen-oral-synerga-colibiogen-mild-emea-002393-pip01-18_en.pdf"},
    {"id":"43496","name":"P/0340/2018: EMA decision of 8 November 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ceftazidime / avibactam (Zavicefta), (EMEA-001313-PIP01-12-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T11:21:00Z","last_updated_date":"2019-01-28T11:21:00Z","reference_number":"EMA/763912/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0340-2018-ema-decision-8-november-2018-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-zavicefta-emea-001313-pip01-12-m08_en.pdf"},
    {"id":"43497","name":"P/0341/2018: EMA decision of 8 November 2018 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / influenza virus surface antigens....","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T10:42:00Z","last_updated_date":"2019-01-28T10:42:00Z","reference_number":"EMA/768448/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0341-2018-ema-decision-8-november-2018-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h3n2-influenza-virus-surface_en.pdf"},
    {"id":"43498","name":"P/0342/2018: EMA decision of 9 November 2018 on the acceptance of a modification of an agreed paediatric investigation plan for peanut allergen extract (EMEA-001481-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T11:45:00Z","last_updated_date":"2019-01-28T11:45:00Z","reference_number":"EMA/762194/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0342-2018-ema-decision-9-november-2018-acceptance-modification-agreed-paediatric-investigation-plan-peanut-allergen-extract-emea-001481-pip01-13-m03_en.pdf"},
    {"id":"43499","name":"P/0343/2018: EMA decision of 8 November 2018 on the acceptance of a modification of an agreed paediatric investigation plan for conestat alfa (Ruconest), (EMEA-000367-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T12:11:00Z","last_updated_date":"2019-01-28T12:11:00Z","reference_number":"EMA/768931/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0343-2018-ema-decision-8-november-2018-acceptance-modification-agreed-paediatric-investigation-plan-conestat-alfa-ruconest-emea-000367-pip01-08-m08_en.pdf"},
    {"id":"43501","name":"P/0344/2018: EMA decision of 8 November 2018 on the acceptance of a modification of an agreed paediatric investigation plan for fosnetupitant / palonosetron (Akynzeo), (EMEA-001198-PIP03-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T12:19:00Z","last_updated_date":"2019-01-28T12:19:00Z","reference_number":"EMA/770101/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0344-2018-ema-decision-8-november-2018-acceptance-modification-agreed-paediatric-investigation-plan-fosnetupitant-palonosetron-akynzeo-emea-001198-pip03-17-m01_en.pdf"},
    {"id":"43503","name":"P/0345/2018: EMA decision of 9 November 2018 on the acceptance of a modification of an agreed paediatric investigation plan for idelalisib (Zydelig) (EMEA-001350-PIP02-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T12:28:00Z","last_updated_date":"2019-01-28T12:28:00Z","reference_number":"EMA/776168/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0345-2018-ema-decision-9-november-2018-acceptance-modification-agreed-paediatric-investigation-plan-idelalisib-zydelig-emea-001350-pip02-13-m04_en.pdf"},
    {"id":"43508","name":"P/0346/2018: EMA decision of 8 November 2018 on the acceptance of a modification of an agreed paediatric investigation plan for amikacin (sulfate) (EMEA-000525-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T12:42:00Z","last_updated_date":"2019-01-28T12:42:00Z","reference_number":"EMA/776353/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0346-2018-ema-decision-8-november-2018-acceptance-modification-agreed-paediatric-investigation-plan-amikacin-sulfate-emea-000525-pip01-08-m06_en.pdf"},
    {"id":"43511","name":"P/0347/2018: EMA decision of 16 November on the acceptance of a modification of an agreed paediatric investigation plan for (EMEA-002215-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T13:11:00Z","last_updated_date":"2019-01-28T13:11:00Z","reference_number":"EMA/775571/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0347-2018-ema-decision-16-november-acceptance-modification-agreed-paediatric-investigation-plan-emea-002215-pip01-17-m01_en.pdf"},
    {"id":"43512","name":"P/0320/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for afatinib (Giotrif), (EMEA-001596-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T14:11:00Z","last_updated_date":"2019-01-28T14:11:00Z","reference_number":"EMA/539758/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-deferral-afatinib-giotrif-emea-001596-pip02-17_en.pdf"},
    {"id":"43513","name":"P/0289/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a waiver for palovarotene (EMEA-001662-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T15:17:00Z","last_updated_date":"2019-01-28T15:17:00Z","reference_number":"EMA/584824/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-waiver-palovarotene-emea-001662-pip03-17_en.pdf"},
    {"id":"43516","name":"P/0248/2018: EMA decision of 15 August 2018 on the refusal of a product specific waiver for venglustat (EMEA-001716-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T14:42:00Z","last_updated_date":"2019-01-28T14:42:00Z","reference_number":"EMA/471687/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2018-ema-decision-15-august-2018-refusal-product-specific-waiver-venglustat-emea-001716-pip03-18_en.pdf"},
    {"id":"43520","name":"P/0317/2018: EMA decision of 12 September 2018 on the granting of a product specific waiver for arimoclomol citrate in the condition treatment of sporadic inclusion body myositis and on the refusal of a product specific waiver for arimoclomol citrate in t","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T15:52:00Z","last_updated_date":"2019-01-28T15:52:00Z","reference_number":"EMA/584837/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2018-ema-decision-12-september-2018-granting-product-specific-waiver-arimoclomol-citrate-condition-treatment-sporadic-inclusion-body-myositis-refusal-product-specific-waiver-arimoclomol-citrate_en.pdf"},
    {"id":"43521","name":"P/0230/2018: EMA decision of 3 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for risankizumab (EMEA-001776-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T15:02:00Z","last_updated_date":"2022-01-06T09:22:00Z","reference_number":"EMA/480849/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2018-ema-decision-3-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-risankizumab-emea-001776-pip03-17_en.pdf"},
    {"id":"43522","name":"P/0231/2018: EMA decision of 3 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for risankizumab (EMEA-001776-PIP04-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T16:15:00Z","last_updated_date":"2019-01-28T16:15:00Z","reference_number":"EMA/469730/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2018-ema-decision-3-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-risankizumab-emea-001776-pip04-17_en.pdf"},
    {"id":"43523","name":"P/0287/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sarizotan (hydrochloride) (EMEA-001808-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T16:23:00Z","last_updated_date":"2019-01-28T16:23:00Z","reference_number":"EMA/517241/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sarizotan-hydrochloride-emea-001808-pip03-17_en.pdf"},
    {"id":"43524","name":"P/0302/2018: EMA decision of 12 September 2018 on the refusal of a product specific waiver for fasinumab (EMEA-002059-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T16:32:00Z","last_updated_date":"2019-01-28T16:32:00Z","reference_number":"EMA/539650/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2018-ema-decision-12-september-2018-refusal-product-specific-waiver-fasinumab-emea-002059-pip01-16_en.pdf"},
    {"id":"43525","name":"P/0265/2018: EMA decision of 1 October 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for alicaforsen (EMEA-002060-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T16:43:00Z","last_updated_date":"2019-01-28T16:43:00Z","reference_number":"EMA/472049/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2018-ema-decision-1-october-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-alicaforsen-emea-002060-pip02-17_en.pdf"},
    {"id":"43526","name":"P/0270/2018: EMA decision of 16 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for entrectinib (EMEA-002096-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T16:49:00Z","last_updated_date":"2019-01-28T16:49:00Z","reference_number":"EMA/536538/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2018-ema-decision-16-august-2018-agreement-paediatric-investigation-plan-granting-deferral-entrectinib-emea-002096-pip01-16_en.pdf"},
    {"id":"43527","name":"P/0266/2018: EMA decision of 14 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for cefiderocol (EMEA-002133-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T16:58:00Z","last_updated_date":"2019-01-28T16:58:00Z","reference_number":"EMA/523782/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2018-ema-decision-14-august-2018-agreement-paediatric-investigation-plan-granting-deferral-cefiderocol-emea-002133-pip01-17_en.pdf"},
    {"id":"43528","name":"P/0312/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a waiver for sodium thiosulfate (STS), (EMEA-002147-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T17:06:00Z","last_updated_date":"2019-01-28T17:06:00Z","reference_number":"EMA/517238/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-waiver-sodium-thiosulfate-sts-emea-002147-pip02-17_en.pdf"},
    {"id":"43529","name":"P/0238/2018: EMA decision of 15 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for serotype 26 adenovirus encoding mosaic 1 HIV-1 group-specific antigen and polymerase...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T17:13:00Z","last_updated_date":"2019-01-28T17:13:00Z","reference_number":"EMA/480852/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2018-ema-decision-15-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-serotype-26-adenovirus-encoding-mosaic-1-hiv-1-group-specific-antigen-polymerase_en.pdf"},
    {"id":"43530","name":"P/0237/2018: EMA decision of 15 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C / trimeric, recombin...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T17:19:00Z","last_updated_date":"2019-01-28T17:19:00Z","reference_number":"EMA/480853/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2018-ema-decision-15-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-trimeric-recombinant-hiv-1-envelope-glycoprotein-140-clade-c-trimeric-recombin_en.pdf"},
    {"id":"43531","name":"P/0272/2018: EMA decision of 14 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for onasemnogenum abeparvovecum (EMEA-002168-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T17:26:00Z","last_updated_date":"2019-01-28T17:26:00Z","reference_number":"EMA/538802/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2018-ema-decision-14-august-2018-agreement-paediatric-investigation-plan-granting-deferral-onasemnogenum-abeparvovecum-emea-002168-pip01-17_en.pdf"},
    {"id":"43532","name":"P/0241/2018: EMA decision of 15 August 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for setrusumab (EMEA-002169-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T17:40:00Z","last_updated_date":"2019-01-28T17:40:00Z","reference_number":"EMA/471709/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2018-ema-decision-15-august-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-setrusumab-emea-002169-pip01-17_en.pdf"},
    {"id":"43533","name":"P/0318/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for monovalent, recombinant, replication-incompetent human adenovirus serotype 26-vectored vaccine encoding the pre-fus...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T17:55:00Z","last_updated_date":"2019-01-28T17:55:00Z","reference_number":"EMA/584829/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-deferral-monovalent-recombinant-replication-incompetent-human-adenovirus-serotype-26-vectored-vaccine_en.pdf"},
    {"id":"43534","name":"P/0284/2018 EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan for human donor haematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with the protein transduction domain of the HIV-1 transacti...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T18:03:00Z","last_updated_date":"2019-01-28T18:03:00Z","reference_number":"EMA/517240/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-human-donor-haematopoietic-stem-progenitor-cells-hspc-have-been-treated-ex-vivo-protein-transduction-domain-hiv-1_en.pdf"},
    {"id":"43535","name":"P/0239/2018: EMA decision of 15 August 2018 on the granting of a product specific waiver for glasdegib (EMEA-002199-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T18:09:00Z","last_updated_date":"2019-01-28T18:09:00Z","reference_number":"EMA/476972/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2018-ema-decision-15-august-2018-granting-product-specific-waiver-glasdegib-emea-002199-pip01-17_en.pdf"},
    {"id":"43536","name":"P/0283/2018: EMA decision of 12 September 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mirikizumab (EMEA-002208-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-28T18:17:00Z","last_updated_date":"2019-01-28T18:17:00Z","reference_number":"EMA/539766/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2018-ema-decision-12-september-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mirikizumab-emea-002208-pip01-17_en.pdf"},
    {"id":"43537","name":"P/0290/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for autologous haematopoietic stem cells transduced with lentiviral vector... (EMEA-001244-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-29T10:37:00Z","last_updated_date":"2019-01-29T10:37:00Z","reference_number":"EMA/538560/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-autologous-haematopoietic-stem-cells-transduced-lentiviral-vector-emea-001244-pip01-11-m02_en.pdf"},
    {"id":"43538","name":"P/0264/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for eribulin (Halaven), (EMEA-001261-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-29T10:46:00Z","last_updated_date":"2019-01-29T10:46:00Z","reference_number":"EMA/480856/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-eribulin-halaven-emea-001261-pip01-11-m05_en.pdf"},
    {"id":"43539","name":"P/0314/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for isavuconazonium (sulfate) (Cresemba), (EMEA-001301-PIP02-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-29T11:08:00Z","last_updated_date":"2019-01-29T11:08:00Z","reference_number":"EMA/538896/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-isavuconazonium-sulfate-cresemba-emea-001301-pip02-12-m02_en.pdf"},
    {"id":"43540","name":"P/0304/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-001501-PIP02-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-29T11:32:00Z","last_updated_date":"2019-01-29T11:32:00Z","reference_number":"EMA/517232/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-emea-001501-pip02-13-m03_en.pdf"},
    {"id":"43541","name":"P/0324/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ertugliflozin (Steglatro), (EMEA-001533-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-29T11:36:00Z","last_updated_date":"2019-01-29T11:36:00Z","reference_number":"EMA/537954/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0324-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-ertugliflozin-steglatro-emea-001533-pip01-13-m01_en.pdf"},
    {"id":"43549","name":"P/0333/2018: EMA decision of 8 October 2018 on the granting of a product-specific waiver for atorvastatin (calcium trihydrate) / perindopril (arginine) / indapamide (EMEA-002395-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-29T17:30:00Z","last_updated_date":"2019-01-29T17:30:00Z","reference_number":"EMA/651668/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0333-2018-ema-decision-8-october-2018-granting-product-specific-waiver-atorvastatin-calcium-trihydrate-perindopril-arginine-indapamide-emea-002395-pip01-18_en.pdf"},
    {"id":"43550","name":"P/0337/2018: EMA decision of 8 October 2018 on the granting of a product specific waiver for synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 (SOD1) messenger ribonucleic acid (EMEA-002403-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-29T17:40:00Z","last_updated_date":"2019-01-29T17:40:00Z","reference_number":"EMA/670855/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0337-2018-ema-decision-8-october-2018-granting-product-specific-waiver-synthetic-ribonucleic-acid-oligonucleotide-directed-against-superoxide-dismutase-1-sod1-messenger-ribonucleic-acid-emea-002403_en.pdf"}    {"id":"43551","name":"P/0300/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab (Nucala), (EMEA-000069-PIP04-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-29T18:05:00Z","last_updated_date":"2019-01-29T18:05:00Z","reference_number":"EMA/538548/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-nucala-emea-000069-pip04-13-m02_en.pdf"},
    {"id":"43556","name":"P/0299/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for retigabine (Trobalt), (EMEA-000116-PIP01-07-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-30T17:00:00Z","last_updated_date":"2019-01-30T17:00:00Z","reference_number":"EMA/584737/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-retigabine-trobalt-emea-000116-pip01-07-m09_en.pdf"},
    {"id":"43557","name":"P/0252/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for osilodrostat (EMEA-000315-PIP02-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-30T17:00:00Z","last_updated_date":"2019-01-30T17:00:00Z","reference_number":"EMA/472032/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-osilodrostat-emea-000315-pip02-15-m02_en.pdf"},
    {"id":"43560","name":"P/0233/2018: EMA decision of 15 August on the refusal of a modification of an agreed paediatric investigation plan for roxadustat (EMEA-001557-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T11:42:00Z","last_updated_date":"2019-01-31T11:42:00Z","reference_number":"EMA/469712/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2018-ema-decision-15-august-refusal-modification-agreed-paediatric-investigation-plan-roxadustat-emea-001557-pip01-13-m02_en.pdf"},
    {"id":"43561","name":"P/0253/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ciprofloxacin (hydrochloride) (EMEA-001563-PIP02-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T11:44:00Z","last_updated_date":"2019-01-31T11:44:00Z","reference_number":"EMA/472033/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-ciprofloxacin-hydrochloride-emea-001563-pip02-15-m01_en.pdf"},
    {"id":"43562","name":"P/0258/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for olipudase alfa (EMEA- 001600-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T11:48:00Z","last_updated_date":"2019-01-31T11:48:00Z","reference_number":"EMA/471702/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-olipudase-alfa-emea-001600-pip01-13-m01_en.pdf"},
    {"id":"43564","name":"P/0301/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for cariprazine (hydrochloride) Reagila (EMEA-001652-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T11:52:00Z","last_updated_date":"2019-01-31T11:52:00Z","reference_number":"EMA/542030/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-cariprazine-hydrochloride-reagila-emea-001652-pip01-14-m02_en.pdf"},
    {"id":"43565","name":"P/0315/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for macrogol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride (NER1006) (EMEA-0017","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T12:00:00Z","last_updated_date":"2019-01-31T12:00:00Z","reference_number":"EMA/584751/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0315-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-macrogol-3350-sodium-ascorbate-sodium-sulfate-ascorbic-acid-sodium-chloride-potassium-chloride_en.pdf"},
    {"id":"43566","name":"P/0288/2018:  EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for vamorolone (EMEA-001794-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T13:11:00Z","last_updated_date":"2019-01-31T13:11:00Z","reference_number":"EMA/584756/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-vamorolone-emea-001794-pip02-16-m01_en.pdf"},
    {"id":"43568","name":"P/0268/2018: EMA decision of 16 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for quizartinib (EMEA- 001821-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T14:22:00Z","last_updated_date":"2019-01-31T14:22:00Z","reference_number":"EMA/517234/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2018-ema-decision-16-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-quizartinib-emea-001821-pip01-15-m02_en.pdf"},
    {"id":"43569","name":"P/0310/2018: EMA decision of 1 October 2018 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat / emtricitabine / tenofovir alafenamide (Symtuza) (EMEA-001825-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T15:01:00Z","last_updated_date":"2019-01-31T15:01:00Z","reference_number":"EMA/652048/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0310-2018-ema-decision-1-october-2018-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza-emea-001825-pip01-15-m02_en.pdf"},
    {"id":"43570","name":"P/0286/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human alpha-galactosidase A (PRX 102) (EMEA-001828-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T15:05:00Z","last_updated_date":"2019-01-31T15:05:00Z","reference_number":"EMA/538565/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-alpha-galactosidase-prx-102-emea-001828-pip01-15-m01_en.pdf"},
    {"id":"43571","name":"P/0260/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), (EMEA-001830-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T15:35:00Z","last_updated_date":"2019-01-31T15:35:00Z","reference_number":"EMA/472034/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-pandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-emea-001830-pip01-15-m01_en.pdf"},
    {"id":"43573","name":"P/0242/2018: EMA decision of on the acceptance of a modification of an agreed paediatric investigation plan for avelumab (Bavencio) (EMEA-001849-PIP02-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T15:44:00Z","last_updated_date":"2019-01-31T15:44:00Z","reference_number":"EMA/480860/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2018-ema-decision-acceptance-modification-agreed-paediatric-investigation-plan-avelumab-bavencio-emea-001849-pip02-15-m02_en.pdf"},
    {"id":"43576","name":"P/0250/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (EMEA-001900-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T16:18:00Z","last_updated_date":"2019-01-31T16:18:00Z","reference_number":"EMA/480857/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-emea-001900-pip02-17-m01_en.pdf"},
    {"id":"43581","name":"P/0243/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for andexanet alfa (EMEA-001902-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T16:40:00Z","last_updated_date":"2019-01-31T16:40:00Z","reference_number":"EMA/480859/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-andexanet-alfa-emea-001902-pip01-15-m03_en.pdf"},
    {"id":"43582","name":"P/0259/2018:  EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for balovaptan (EMEA-001918-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T16:46:00Z","last_updated_date":"2019-01-31T16:46:00Z","reference_number":"EMA/472036/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-balovaptan-emea-001918-pip01-15-m01_en.pdf"},
    {"id":"43583","name":"P/0285/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen concentrate (BT524) (EMEA-001931-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T16:51:00Z","last_updated_date":"2019-01-31T16:51:00Z","reference_number":"EMA/538566/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-concentrate-bt524-emea-001931-pip01-16-m01_en.pdf"},
    {"id":"43584","name":"P/0261/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for Fc- and CDRmodified humanized monoclonal antibody against C5 (ALXN1210) (EMEA-001943-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T16:55:00Z","last_updated_date":"2019-01-31T16:55:00Z","reference_number":"EMA/471049/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-fc-cdrmodified-humanized-monoclonal-antibody-against-c5-alxn1210-emea-001943-pip01-16-m01_en.pdf"},
    {"id":"43585","name":"P/0323/2018: EMA decision of 12 September 2018 on the refusal of a modification of an agreed paediatric investigation plan for gadolinium (EMEA-001949-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T16:59:00Z","last_updated_date":"2019-01-31T16:59:00Z","reference_number":"EMA/584760/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2018-ema-decision-12-september-2018-refusal-modification-agreed-paediatric-investigation-plan-gadolinium-emea-001949-pip01-16-m02_en.pdf"},
    {"id":"43586","name":"P/0306/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for emapalumab (EMEA-002031-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T17:02:00Z","last_updated_date":"2019-01-31T17:02:00Z","reference_number":"EMA/517235/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-emapalumab-emea-002031-pip01-16-m02_en.pdf"},
    {"id":"43597","name":"P/0246/2018: EMA decision of 15 Aug 2018 on the acceptance of a modification of an agreed PIP for (Z)-N-(3-bromo-4- fluorophenyl)-N-hydroxy-4-(2-(sulfamoylamino)ethylamino)-1,2,5-oxadiazole-3-carboximidamide (EMEA-002072-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T10:10:00Z","last_updated_date":"2019-02-01T10:10:00Z","reference_number":"EMA/469681/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2018-ema-decision-15-aug-2018-acceptance-modification-agreed-pip-z-n-3-bromo-4-fluorophenyl-n-hydroxy-4-2-sulfamoylaminoethylamino-125-oxadiazole-3-carboximidamide-emea-002072-pip01-16-m01_en.pdf"},
    {"id":"43621","name":"P/0322/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (EDURANT), (EMEA-000317-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-04T11:35:00Z","last_updated_date":"2019-02-04T11:35:00Z","reference_number":"EMA/538886/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0322-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-edurant-emea-000317-pip01-08-m10_en.pdf"},
    {"id":"43622","name":"P/0251/2018: EMA decision of 14 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir (phosphate) (Tamiflu), (EMEA-000365-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-04T11:40:00Z","last_updated_date":"2019-02-04T11:40:00Z","reference_number":"EMA/521547/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2018-ema-decision-14-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-oseltamivir-phosphate-tamiflu-emea-000365-pip01-08-m10_en.pdf"},
    {"id":"43623","name":"P/0234/2018: of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for vortioxetine (Brintellix), (EMEA-000455-PIP02-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-04T11:00:00Z","last_updated_date":"2019-02-04T11:00:00Z","reference_number":"EMA/472965/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2018-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-vortioxetine-brintellix-emea-000455-pip02-10-m04_en.pdf"},
    {"id":"43624","name":"P/0298/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for eliglustat (tartrate) (Cerdelga), (EMEA-000461-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-04T12:02:00Z","last_updated_date":"2019-02-04T12:02:00Z","reference_number":"EMA/538557/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-eliglustat-tartrate-cerdelga-emea-000461-pip02-11-m03_en.pdf"},
    {"id":"43625","name":"P/0308/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (Fycompa), (EMEA-000467-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-04T12:11:00Z","last_updated_date":"2019-02-04T12:11:00Z","reference_number":"EMA/538888/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-fycompa-emea-000467-pip01-08-m10_en.pdf"},
    {"id":"43626","name":"P/0313/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for belimumab (Benlysta), (EMEA-000520-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-04T12:18:00Z","last_updated_date":"2019-02-04T12:18:00Z","reference_number":"EMA/538890/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-belimumab-benlysta-emea-000520-pip02-13-m02_en.pdf"},
    {"id":"43630","name":"P/0269/2018: EMA decision of 16 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for omadacycline (EMEA-000560-PIP03-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T14:33:00Z","last_updated_date":"2019-02-05T14:33:00Z","reference_number":"EMA/514764/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2018-ema-decision-16-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-omadacycline-emea-000560-pip03-15-m01_en.pdf"},
    {"id":"43631","name":"P/0275/2018: EMA decision of 31 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz) (EMEA-000576-PIP03-12-M01","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T14:39:00Z","last_updated_date":"2019-02-05T14:39:00Z","reference_number":"EMA/517231/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2018-ema-decision-31-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip03-12-m01_en.pdf"},
    {"id":"43632","name":"P/0249/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens - A/turkey/Turkey/1/05 (H5N1) (Aflunov and associated names), (EMEA-000599-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T14:44:00Z","last_updated_date":"2019-02-05T14:44:00Z","reference_number":"EMA/469705/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-turkey-turkey-1-05-h5n1-aflunov-associated-names-emea-000599-pip01_en.pdf"},
    {"id":"43633","name":"P/0325/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for simeprevir (EMEA-000625-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T14:49:00Z","last_updated_date":"2019-02-05T14:49:00Z","reference_number":"EMA/538893/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0325-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-simeprevir-emea-000625-pip01-09-m03_en.pdf"},
    {"id":"43634","name":"P/0303/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lanthanum carbonate hydrate (Fosrenol and associated names), (EMEA-000637-PIP02-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T14:54:00Z","last_updated_date":"2019-02-05T14:54:00Z","reference_number":"EMA/517230/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-lanthanum-carbonate-hydrate-fosrenol-associated-names-emea-000637-pip02-10-m06_en.pdf"},
    {"id":"43635","name":"P/0297/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta, Bydureon), (EMEA-000689-PIP01-09-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T14:58:00Z","last_updated_date":"2019-02-05T14:58:00Z","reference_number":"EMA/559359/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-exenatide-byetta-bydureon-emea-000689-pip01-09-m08_en.pdf"},
    {"id":"43636","name":"P/0307/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin (Forxiga), (EMEA-000694-PIP01-09-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T15:38:00Z","last_updated_date":"2019-02-05T15:38:00Z","reference_number":"EMA/584740/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-forxiga-emea-000694-pip01-09-m07_en.pdf"},
    {"id":"43642","name":"P/0274/2018: EMA decision of 23 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine / rilpivirine (hydrochloride) / tenofovir (disoproxil fumarate (Eviplera), (EMEA-000774-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T15:42:00Z","last_updated_date":"2019-02-05T15:42:00Z","reference_number":"EMA/537553/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2018-ema-decision-23-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-emtricitabine-rilpivirine-hydrochloride-tenofovir-disoproxil-fumarate-eviplera-emea-000774-pip01-09_en.pdf"},
    {"id":"43643","name":"P/0296/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for eftrenonacog alfa (Alprolix), (EMEA-000914-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T15:48:00Z","last_updated_date":"2019-02-05T15:48:00Z","reference_number":"EMA/538894/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-eftrenonacog-alfa-alprolix-emea-000914-pip01-10-m04_en.pdf"},
    {"id":"43644","name":"P/0247/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for romosozumab (EMEA-001075-PIP04-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T15:54:00Z","last_updated_date":"2019-02-05T15:54:00Z","reference_number":"EMA/480858/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-romosozumab-emea-001075-pip04-15-m01_en.pdf"},
    {"id":"43645","name":"P/0295/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for loxapine (Adasuve), (EMEA-001115-PIP01-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T16:02:00Z","last_updated_date":"2019-02-05T16:02:00Z","reference_number":"EMA/538558/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-loxapine-adasuve-emea-001115-pip01-10-m06_en.pdf"},
    {"id":"43646","name":"P/0273/2018: EMA decision of 14 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for landiolol (hydrochloride) (Rapibloc, Landiobloc, Raploc, Runrapiq), (EMEA-001150-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T16:08:00Z","last_updated_date":"2019-02-05T16:08:00Z","reference_number":"EMA/532947/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2018-ema-decision-14-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-landiolol-hydrochloride-rapibloc-landiobloc-raploc-runrapiq-emea-001150-pip02-13-m02_en.pdf"},
    {"id":"43647","name":"P/0294/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for caplacizumab (EMEA-001157-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T16:16:00Z","last_updated_date":"2019-02-05T16:16:00Z","reference_number":"EMA/584742/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-caplacizumab-emea-001157-pip01-11-m02_en.pdf"},
    {"id":"43648","name":"P/0316/2018: EMA decision on the acceptance of a modification of an agreed paediatric investigation plan for brexpiprazole (EMEA-001185-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T16:28:00Z","last_updated_date":"2019-02-05T16:28:00Z","reference_number":"EMA/540097/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2018-ema-decision-acceptance-modification-agreed-paediatric-investigation-plan-brexpiprazole-emea-001185-pip01-11-m05_en.pdf"},
    {"id":"43649","name":"P/0293/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ponatinib (Iclusig), (EMEA-001186-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T16:39:00Z","last_updated_date":"2019-02-05T16:39:00Z","reference_number":"EMA/537846/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-ponatinib-iclusig-emea-001186-pip01-11-m02_en.pdf"},
    {"id":"43650","name":"P/0244/2018: EMA decision of 15 August 2018 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T16:45:00Z","last_updated_date":"2019-02-05T16:45:00Z","reference_number":"EMA/471690/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2018-ema-decision-15-august-2018-acceptance-modification-agreed-paediatric-investigation-plan-benralizumab-fasenra-emea-001214-pip01-11-m08_en.pdf"},
    {"id":"43651","name":"P/0292/2018: EMA decision of 12 September 2018 on the acceptance of a modification of an agreed paediatric investigation plan for indacaterol (acetate)/mometasone (furoate) (EMEA-001217-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T16:50:00Z","last_updated_date":"2019-02-05T16:50:00Z","reference_number":"EMA/540377/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2018-ema-decision-12-september-2018-acceptance-modification-agreed-paediatric-investigation-plan-indacaterol-acetate-mometasone-furoate-emea-001217-pip01-11-m05_en.pdf"},
    {"id":"43697","name":"P/0384/2018: EMA decision of 6 December 2018 on the granting of a product specific waiver for selinexor (EMEA-002387-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-13T12:55:00Z","last_updated_date":"2019-02-13T12:55:00Z","reference_number":"EMA/775712/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0384-2018-ema-decision-6-december-2018-granting-product-specific-waiver-selinexor-emea-002387-pip01-18_en.pdf"},
    {"id":"43698","name":"P/0383/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for ipatasertib (EMEA-002396-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-13T14:23:00Z","last_updated_date":"2019-02-13T14:23:00Z","reference_number":"EMA/797199/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0383-2018-ema-decision-7-december-2018-granting-product-specific-waiver-ipatasertib-emea-002396-pip01-18_en.pdf"},
    {"id":"43699","name":"EMA decision of 7 December 2018 on the granting of a product specific waiver for ibuprofen (EMEA-002400-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-13T14:43:00Z","last_updated_date":"2019-02-13T14:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-decision-7-december-2018-granting-product-specific-waiver-ibuprofen-emea-002400-pip01-18_en.pdf"},
    {"id":"43700","name":"P/0379/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for avadomide (EMEA-002405-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-13T15:06:00Z","last_updated_date":"2019-02-13T15:06:00Z","reference_number":"EMA/812160/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0379-2018-ema-decision-7-december-2018-granting-product-specific-waiver-avadomide-emea-002405-pip01-18_en.pdf"},
    {"id":"43701","name":"P/0375/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for molibresib (EMEA-002406-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-13T15:10:00Z","last_updated_date":"2019-02-13T15:10:00Z","reference_number":"EMA/762543/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0375-2018-ema-decision-7-december-2018-granting-product-specific-waiver-molibresib-emea-002406-pip01-18_en.pdf"},
    {"id":"43703","name":"P/0374/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for atorvastatin / ezetimibe (EMEA-002410-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-13T15:33:00Z","last_updated_date":"2019-02-13T15:33:00Z","reference_number":"EMA/812161/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0374-2018-ema-decision-7-december-2018-granting-product-specific-waiver-atorvastatin-ezetimibe-emea-002410-pip01-18_en.pdf"},
    {"id":"43704","name":"P/0396/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for flurpiridaz F18 (EMEA-002413-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-13T15:50:00Z","last_updated_date":"2019-02-13T15:50:00Z","reference_number":"EMA/790015/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0396-2018-ema-decision-7-december-2018-granting-product-specific-waiver-flurpiridaz-f18-emea-002413-pip01-18_en.pdf"},
    {"id":"43705","name":"P/0359/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for alectinib (Alecensa), (EMEA-002431-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-13T16:02:00Z","last_updated_date":"2019-02-13T16:02:00Z","reference_number":"EMA/797212/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0359-2018-ema-decision-7-december-2018-granting-product-specific-waiver-alectinib-alecensa-emea-002431-pip01-18_en.pdf"},
    {"id":"43712","name":"P/0390/2018: EMA decision of 7 December 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for SER-109 (Eubacterial Spores, Purified Suspension, Encapsulated) (EMEA- 001970-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T11:14:00Z","last_updated_date":"2019-02-14T11:14:00Z","reference_number":"EMA/789884/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0390-2018-ema-decision-7-december-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ser-109-eubacterial-spores-purified-suspension-encapsulated-emea-001970-pip02-17_en.pdf"},
    {"id":"43713","name":"P/0392/2018: EMA decision of 7 December 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cenicriviroc (EMEA-001999-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T11:20:00Z","last_updated_date":"2019-02-14T11:20:00Z","reference_number":"EMA/797264/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0392-2018-ema-decision-7-december-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cenicriviroc-emea-001999-pip02-17_en.pdf"},
    {"id":"43714","name":"P/0339/2018: EMA decision of 8 November 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for calcifediol (EMEA-002093-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T11:31:00Z","last_updated_date":"2019-02-14T11:31:00Z","reference_number":"EMA/767854/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0339-2018-ema-decision-8-november-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-calcifediol-emea-002093-pip02-17_en.pdf"},
    {"id":"43715","name":"P/0393/2018: EMA decision of 6 December 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for evobrutinib (EMEA-002284-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T11:35:00Z","last_updated_date":"2019-02-14T11:35:00Z","reference_number":"EMA/775595/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0393-2018-ema-decision-6-december-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-evobrutinib-emea-002284-pip01-17_en.pdf"},
    {"id":"43716","name":"P/0350/2018: EMA decision of 15 November 2018 on the agreement of a paediatric investigation plan and on the granting of a waiver for brigatinib (EMEA-002296-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T11:41:00Z","last_updated_date":"2019-02-14T11:41:00Z","reference_number":"EMA/762540/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0350-2018-ema-decision-15-november-2018-agreement-paediatric-investigation-plan-granting-waiver-brigatinib-emea-002296-pip01-17_en.pdf"},
    {"id":"43717","name":"P/0404/2018: EMA decision of 20 December 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for evinacumab (EMEA-002298-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T10:00:00Z","last_updated_date":"2019-02-14T10:00:00Z","reference_number":"EMA/829832/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0404-2018-ema-decision-20-december-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-evinacumab-emea-002298-pip01-17_en.pdf"},
    {"id":"43718","name":"P/0391/2018: EMA decision Of 7 December 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Janus Kinase-1 inhibitor (PF-04965842) (EMEA-002312-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T12:01:00Z","last_updated_date":"2019-02-14T12:01:00Z","reference_number":"EMA/789818/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0391-2018-ema-decision-7-december-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-janus-kinase-1-inhibitor-pf-04965842-emea-002312-pip01-17_en.pdf"},
    {"id":"43719","name":"P/0386/2018: EMA decision of 6 December 2018 on the granting of a product specific waiver for pemigatinib (EMEA-002370-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T12:13:00Z","last_updated_date":"2019-02-14T12:13:00Z","reference_number":"EMA/775621/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0386-2018-ema-decision-6-december-2018-granting-product-specific-waiver-pemigatinib-emea-002370-pip01-18_en.pdf"},
    {"id":"43735","name":"P/0372/2018: EMA decision Of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for secukinumab (Cosentyx), (EMEA-000380-PIP02-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T17:45:00Z","last_updated_date":"2019-02-14T17:45:00Z","reference_number":"EMA/710588/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0372-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-secukinumab-cosentyx-emea-000380-pip02-09-m04_en.pdf"},
    {"id":"43736","name":"P/0395/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tadalafil (Adcirca, Cialis), (EMEA-000452-PIP02-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T17:51:00Z","last_updated_date":"2019-02-14T17:51:00Z","reference_number":"EMA/762115/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0395-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-tadalafil-adcirca-cialis-emea-000452-pip02-10-m05_en.pdf"},
    {"id":"43737","name":"P/0405/2018: EMA decision of 20 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for pazopanib (Votrient), (EMEA-000601-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T16:45:00Z","last_updated_date":"2019-02-14T16:45:00Z","reference_number":"EMA/829512/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0405-2018-ema-decision-20-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-pazopanib-votrient-emea-000601-pip01-09-m05_en.pdf"},
    {"id":"43738","name":"P/0368/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate) (Lixiana), (EMEA-000788-PIP02-11-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T18:01:00Z","last_updated_date":"2019-02-14T18:01:00Z","reference_number":"EMA/710591/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0368-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-lixiana-emea-000788-pip02-11-m08_en.pdf"},
    {"id":"43747","name":"P/0401/2018: EMA decision of 3 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for rabeprazole (sodium) (Pariet and associated names), (EMEA-000055-PIP01-07-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-15T11:23:00Z","last_updated_date":"2019-02-15T11:23:00Z","reference_number":"EMA/823217/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0401-2018-ema-decision-3-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-rabeprazole-sodium-pariet-associated-names-emea-000055-pip01-07-m06_en.pdf"},
    {"id":"43748","name":"P/0399/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dabigatran etexilate mesilate (Pradaxa) (EMEA-000081-PIP01-07-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-15T11:27:00Z","last_updated_date":"2019-02-15T11:27:00Z","reference_number":"EMA/812162/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0399-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-dabigatran-etexilate-mesilate-pradaxa-emea-000081-pip01-07-m11_en.pdf"},
    {"id":"43758","name":"P/0406/2018: EMA decision of 20 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ceftobiprole medocaril (sodium) (Zevtera and associated names), (EMEA-000205-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-15T15:03:00Z","last_updated_date":"2019-02-15T15:03:00Z","reference_number":"EMA/829510/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0406-2018-ema-decision-20-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-ceftobiprole-medocaril-sodium-zevtera-associated-names-emea-000205-pip02-11-m03_en.pdf"},
    {"id":"43759","name":"P/0353/2018: EMA decision of 22 November 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor (Kalydeco), (EMEA-000335-PIP01-08-M13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-15T16:08:00Z","last_updated_date":"2019-02-15T16:08:00Z","reference_number":"EMA/762023/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0353-2018-ema-decision-22-november-2018-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-kalydeco-emea-000335-pip01-08-m13_en.pdf"},
    {"id":"43760","name":"P/0398/2018: EMA decision of 6 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla), (EMEA-000715-PIP05-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-15T16:14:00Z","last_updated_date":"2019-02-15T16:14:00Z","reference_number":"EMA/775548/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0398-2018-ema-decision-6-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip05-13-m03_en.pdf"},
    {"id":"43771","name":"P/0364/2018: of 6 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris), (EMEA-000876-PIP03-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-18T11:23:00Z","last_updated_date":"2019-02-18T11:23:00Z","reference_number":"EMA/775550/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0364-2018-6-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip03-14-m02_en.pdf"},
    {"id":"43772","name":"P/0403/2018: of 19 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline (fumarate), (SIRTURO), (EMEA-000912-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-18T11:29:00Z","last_updated_date":"2019-02-18T11:29:00Z","reference_number":"EMA/868576/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0403-2018-19-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-bedaquiline-fumarate-sirturo-emea-000912-pip01-10-m04_en.pdf"},
    {"id":"43773","name":"P/0380/2018: of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia), (EMEA-000916-PIP01-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-18T11:33:00Z","last_updated_date":"2019-02-18T11:33:00Z","reference_number":"EMA/762186/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0380-2018-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-lixisenatide-lyxumia-emea-000916-pip01-10-m06_en.pdf"},
    {"id":"43775","name":"P/0351/2018: EMA decision of 20 November 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz), (EMEA-001050-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-18T15:10:00Z","last_updated_date":"2019-02-18T15:10:00Z","reference_number":"EMA/762188/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0351-2018-ema-decision-20-november-2018-acceptance-modification-agreed-paediatric-investigation-plan-ixekizumab-taltz-emea-001050-pip01-10-m04_en.pdf"},
    {"id":"43776","name":"P/0397/2018: EMA of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for certolizumab pegol (Cimzia), (EMEA-001071-PIP03-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-18T15:19:00Z","last_updated_date":"2019-02-18T15:19:00Z","reference_number":"EMA/796523/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0397-2018-ema-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-certolizumab-pegol-cimzia-emea-001071-pip03-14-m01_en.pdf"},
    {"id":"43777","name":"P/0373/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ex-vivo expanded human autologous epithelium containing stem cells (Holoclar), (EMEA-001082-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-18T15:29:00Z","last_updated_date":"2019-02-18T15:29:00Z","reference_number":"EMA/796524/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0373-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-ex-vivo-expanded-human-autologous-epithelium-containing-stem-cells-holoclar-emea-001082-pip02-11_en.pdf"},
    {"id":"43787","name":"P/0389/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (LENVIMA, Kisplyx) (EMEA-001119-PIP02-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T10:06:00Z","last_updated_date":"2019-02-19T10:06:00Z","reference_number":"EMA/812163/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0389-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-lenvima-kisplyx-emea-001119-pip02-12-m04_en.pdf"},
    {"id":"43788","name":"P/0378/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tolvaptan (Samsca and associated names), (EMEA-001231-PIP02-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T09:11:00Z","last_updated_date":"2019-02-19T09:11:00Z","reference_number":"EMA/812164/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0378-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-tolvaptan-samsca-associated-names-emea-001231-pip02-13-m06_en.pdf"},
    {"id":"43789","name":"P/0362/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for phenylephrine hydrochloride / ketorolac trometamol (OMS302) (EMEA-001256-PIP02-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T10:15:00Z","last_updated_date":"2019-02-19T10:15:00Z","reference_number":"EMA/710628/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0362-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-phenylephrine-hydrochloride-ketorolac-trometamol-oms302-emea-001256-pip02-12-m02_en.pdf"},
    {"id":"43790","name":"P/0355/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for potassium citrate monohydrated / potassium hydrogen carbonate (EMEA-001357-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T10:20:00Z","last_updated_date":"2019-02-19T10:20:00Z","reference_number":"EMA/796526/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0355-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-potassium-citrate-monohydrated-potassium-hydrogen-carbonate-emea-001357-pip01-12-m02_en.pdf"},
    {"id":"43791","name":"P/0376/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for ixazomib (Ninlaro), (EMEA-001410-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T10:38:00Z","last_updated_date":"2019-02-19T10:38:00Z","reference_number":"EMA/762192/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0376-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-ixazomib-ninlaro-emea-001410-pip02-17-m01_en.pdf"},
    {"id":"43792","name":"P/0366/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for 4-((2R,3S,4R,5S)-3- (3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2- carboxamido)-3-meth","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-19T11:19:00Z","last_updated_date":"2019-02-19T11:19:00Z","reference_number":"EMA/710602/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0366-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-4-2r3s4r5s-3-3-chloro-2-fluorophenyl-4-4-chloro-2-fluorophenyl-4-cyano-5-neopentylpyrrolidine-2_en.pdf"},
    {"id":"43814","name":"P/0388/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for liposomal combination of cytarabine and daunorubicin (Vyxeos), (EMEA-001858-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:06:00Z","last_updated_date":"2019-02-20T12:06:00Z","reference_number":"EMA/710550/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0388-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-liposomal-combination-cytarabine-daunorubicin-vyxeos-emea-001858-pip02-16-m02_en.pdf"},
    {"id":"43815","name":"P/0369/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for complex of povidone and iodine / dexamethasone (SHP640) (EMEA-001936-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:11:00Z","last_updated_date":"2019-02-20T12:11:00Z","reference_number":"EMA/762227/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0369-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-complex-povidone-iodine-dexamethasone-shp640-emea-001936-pip01-16-m01_en.pdf"},
    {"id":"43817","name":"P/0400/2018: EMA decision of  26 November 2018 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ hematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for the human adenosine deam","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:19:00Z","last_updated_date":"2019-02-20T12:19:00Z","reference_number":"EMA/762335/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0400-2018-ema-decision-26-november-2018-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-hematopoietic-stem-cells-transduced-ex-vivo-efs-lentiviral-vector-encoding-human_en.pdf"},
    {"id":"43818","name":"P/0361/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for crizotinib (Xalkori), (EMEA-001493-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:22:00Z","last_updated_date":"2019-02-20T12:22:00Z","reference_number":"EMA/762548/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0361-2018-ema-decision-7-december-2018-granting-product-specific-waiver-crizotinib-xalkori-emea-001493-pip02-18_en.pdf"},
    {"id":"43819","name":"P/0354/2018: EMA decision of 30 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for fenfluramine (hydrochloride) (EMEA-001990-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T11:23:00Z","last_updated_date":"2019-02-20T11:23:00Z","reference_number":"EMA/817525/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0354-2018-ema-decision-30-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-fenfluramine-hydrochloride-emea-001990-pip01-16-m02_en.pdf"},
    {"id":"43820","name":"P/0394/2018: EMA decision of 7 December 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for upadacitinib (EMEA-001741-PIP04-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:32:00Z","last_updated_date":"2019-02-20T12:32:00Z","reference_number":"EMA/762538/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0394-2018-ema-decision-7-december-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-upadacitinib-emea-001741-pip04-17_en.pdf"},
    {"id":"43821","name":"P/0387/2018: EMA decision of 6 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) / influenza virus surface antigens (haem","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:39:00Z","last_updated_date":"2019-02-20T12:39:00Z","reference_number":"EMA/775570/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0387-2018-ema-decision-6-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h1n1-influenza-virus-surface_en.pdf"},
    {"id":"43823","name":"P/0388/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for risdiplam (RO7034067), (EMEA-002070-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:43:00Z","last_updated_date":"2019-02-20T12:43:00Z","reference_number":"EMA/812166/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0388-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-risdiplam-ro7034067-emea-002070-pip01-16-m02_en.pdf"},
    {"id":"43824","name":"P/0363/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for (RS)-baclofen / Naltrexone HCl / D-Sorbitol (PXT3003), (EMEA-002164-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:48:00Z","last_updated_date":"2019-02-20T12:48:00Z","reference_number":"EMA/812165/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0363-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-rs-baclofen-naltrexone-hcl-d-sorbitol-pxt3003-emea-002164-pip01-17-m01_en.pdf"},
    {"id":"43825","name":"P/0348/2018: EMA decision of 16 November 2018 on the agreement of a paediatric investigation plan and on the granting of a waiver for brincidofovir (EMEA-001904-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:50:00Z","last_updated_date":"2019-02-20T12:50:00Z","reference_number":"EMA/784346/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0348-2018-ema-decision-16-november-2018-agreement-paediatric-investigation-plan-granting-waiver-brincidofovir-emea-001904-pip02-17_en.pdf"},
    {"id":"43826","name":"P/0388/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lasmiditan, (EMEA-002166-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T12:53:00Z","last_updated_date":"2019-02-20T12:53:00Z","reference_number":"EMA/812167/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0388-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-lasmiditan-emea-002166-pip01-17-m01_en.pdf"},
    {"id":"43827","name":"P/0349/2018: EMA decision of 16 November 2018 on the agreement of a paediatric investigation plan for brincidofovir (EMEA-001904-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T11:30:00Z","last_updated_date":"2019-02-20T11:30:00Z","reference_number":"EMA/784348/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0349-2018-ema-decision-16-november-2018-agreement-paediatric-investigation-plan-brincidofovir-emea-001904-pip03-18_en.pdf"},
    {"id":"43830","name":"P/0373/2018: EMA decision of 7 December 2018 on the granting of a product-specific waiver for dapagliflozin (Forxiga), (EMEA-000694-PIP04-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T14:22:00Z","last_updated_date":"2019-02-20T14:22:00Z","reference_number":"EMA/797210/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0373-2018-ema-decision-7-december-2018-granting-product-specific-waiver-dapagliflozin-forxiga-emea-000694-pip04-18_en.pdf"},
    {"id":"43831","name":"P/0402/2018: EMA decision of 7 December 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bupivacaine (EMEA-000877-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T14:32:00Z","last_updated_date":"2019-02-20T14:32:00Z","reference_number":"EMA/843185/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0402-2018-ema-decision-7-december-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bupivacaine-emea-000877-pip03-17_en.pdf"},
    {"id":"43832","name":"P/0356/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for sarilumab (Kevzara), (EMEA-001045-PIP04-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T14:46:00Z","last_updated_date":"2019-02-20T14:46:00Z","reference_number":"EMA/812158/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0356-2018-ema-decision-7-december-2018-granting-product-specific-waiver-sarilumab-kevzara-emea-001045-pip04-18_en.pdf"},
    {"id":"43833","name":"P/0352/2018: EMA decision of 20 November 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ixekizumab (Taltz), (EMEA-001050-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T14:53:00Z","last_updated_date":"2019-02-20T14:53:00Z","reference_number":"EMA/762536/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0352-2018-ema-decision-20-november-2018-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ixekizumab-taltz-emea-001050-pip02-18_en.pdf"},
    {"id":"43834","name":"P/0381/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for cholera vaccine, live attenuated, oral (strain CVD 103-HgR) (EMEA-001490-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T15:13:00Z","last_updated_date":"2019-02-20T15:13:00Z","reference_number":"EMA/796515/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0381-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-cholera-vaccine-live-attenuated-oral-strain-cvd-103-hgr-emea-001490-pip01-13-m01_en.pdf"},
    {"id":"43835","name":"P/0367/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for nanobody directed towards the fusion protein of human respiratory syncytial virus (ALX-0171) (EMEA-001553-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T15:22:00Z","last_updated_date":"2019-02-20T15:22:00Z","reference_number":"EMA/796427/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0367-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-nanobody-directed-towards-fusion-protein-human-respiratory-syncytial-virus-alx-0171-emea-001553_en.pdf"}    {"id":"43836","name":"P/0407/2018: EMA decision of 19 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (Orkambi), (EMEA-001582-PIP01-13-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T15:37:00Z","last_updated_date":"2019-02-20T15:37:00Z","reference_number":"EMA/816613/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0407-2018-ema-decision-19-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-lumacaftor-ivacaftor-orkambi-emea-001582-pip01-13-m08_en.pdf"},
    {"id":"43848","name":"P/0365/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for tezepelumab (EMEA-001613-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T17:36:00Z","last_updated_date":"2019-02-20T17:36:00Z","reference_number":"EMA/762217/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0365-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-tezepelumab-emea-001613-pip01-14-m02_en.pdf"},
    {"id":"43849","name":"P/0371/2018 EMA decision of 6 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for filgotinib (EMEA- 001619-PIP04-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T17:45:00Z","last_updated_date":"2019-02-20T17:45:00Z","reference_number":"EMA/775551/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0371-2018-ema-decision-6-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-filgotinib-emea-001619-pip04-17-m01_en.pdf"},
    {"id":"43851","name":"P/0385/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for letermovir (Prevymis), (EMEA-001631-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T17:51:00Z","last_updated_date":"2019-02-20T17:51:00Z","reference_number":"EMA/796511/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0385-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-letermovir-prevymis-emea-001631-pip01-14-m03_en.pdf"},
    {"id":"43853","name":"P/0357/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for enalapril (maleate) (EMEA-001706-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T17:56:00Z","last_updated_date":"2019-02-20T17:56:00Z","reference_number":"EMA/710668/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0357-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-enalapril-maleate-emea-001706-pip01-14-m02_en.pdf"},
    {"id":"43855","name":"P/0377/2018: EMA decision of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for peanut flour (EMEA- 001734-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-02-20T17:01:00Z","last_updated_date":"2019-02-20T17:01:00Z","reference_number":"EMA/710563/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0377-2018-ema-decision-7-december-2018-acceptance-modification-agreed-paediatric-investigation-plan-peanut-flour-emea-001734-pip01-14-m03_en.pdf"},
    {"id":"44183","name":"P/0055/2019: EMA decision of 11 February 2019 on the acceptance of a modification of an agreed paediatric investigation plan for gadopiclenol (EMEA-001949-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-08T12:07:00Z","last_updated_date":"2019-04-08T12:07:00Z","reference_number":"EMA/910985/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2019-ema-decision-11-february-2019-acceptance-modification-agreed-paediatric-investigation-plan-gadopiclenol-emea-001949-pip01-16-m03_en.pdf"},
    {"id":"44184","name":"P/0003/2019: EMA decision of 3 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for pimodivir (EMEA-001975-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-08T12:17:00Z","last_updated_date":"2019-04-08T12:17:00Z","reference_number":"EMA/873049/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2019-ema-decision-3-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-pimodivir-emea-001975-pip01-16-m02_en.pdf"},
    {"id":"44185","name":"P/0004/2019: EMA decision of 3 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for axicabtagene ciloleucel (EMEA-002010-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-08T12:39:00Z","last_updated_date":"2019-04-08T12:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2019-ema-decision-3-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-axicabtagene-ciloleucel-emea-002010-pip01-16-m01_en.pdf"},
    {"id":"44196","name":"P/0001/2019: EMA decision of 4 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for venetoclax (Venclyxto), (EMEA-002018-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T15:53:00Z","last_updated_date":"2019-04-09T15:53:00Z","reference_number":"EMA/886036/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2019-ema-decision-4-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-venetoclax-venclyxto-emea-002018-pip02-16-m01_en.pdf"},
    {"id":"44197","name":"P/0010/2019: EMA decision of 4 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for entrectinib (EMEA-002096-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-09T16:23:00Z","last_updated_date":"2019-04-09T16:23:00Z","reference_number":"EMA/902314/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2019-ema-decision-4-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-entrectinib-emea-002096-pip01-16-m01_en.pdf"},
    {"id":"44213","name":"P/0029/2019: EMA decision of 29 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for birch pollen extract (EMEA-000809-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T09:56:00Z","last_updated_date":"2019-04-11T09:56:00Z","reference_number":"EMA/910775/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2019-ema-decision-29-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-birch-pollen-extract-emea-000809-pip01-09-m01_en.pdf"},
    {"id":"44214","name":"P/0035/2019: EMA decision of 29 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for for sodium sulphate / potassium sulphate / magnesium sulphate heptahydrate (BLI800) IZINOVA (and associated names) (EMEA-000816","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T10:03:00Z","last_updated_date":"2019-04-11T10:03:00Z","reference_number":"EMA/895487/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2019-ema-decision-29-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-sodium-sulphate-potassium-sulphate-magnesium-sulphate-heptahydrate-bli800-izinova-associated-names_en.pdf"},
    {"id":"44215","name":"P/0031/2019: EMA decision of 11 February 2019 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin (Jardiance), (EMEA-000828-PIP04-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T10:49:00Z","last_updated_date":"2019-04-11T10:49:00Z","reference_number":"EMA/900464/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2019-ema-decision-11-february-2019-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-jardiance-emea-000828-pip04-16-m02_en.pdf"},
    {"id":"44216","name":"P/0056/2019: EMA decision of 11 February 2019 on the acceptance of a modification of an agreed paediatric investigation plan for naloxegol (Moventig) (EMEA-001146-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T10:57:00Z","last_updated_date":"2019-04-11T10:57:00Z","reference_number":"EMA/886040/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2019-ema-decision-11-february-2019-acceptance-modification-agreed-paediatric-investigation-plan-naloxegol-moventig-emea-001146-pip01-11-m04_en.pdf"},
    {"id":"44217","name":"P/0018/2019: EMA decision of 3 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / abacavir / lamivudine (Triumeq), (EMEA-001219-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T11:03:00Z","last_updated_date":"2019-04-11T11:03:00Z","reference_number":"EMA/871179/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2019-ema-decision-3-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-abacavir-lamivudine-triumeq-emea-001219-pip01-11-m04_en.pdf"},
    {"id":"44218","name":"P/0006/2019: EMA decision of 3 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat (REZOLSTA), (EMEA-001280-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T11:07:00Z","last_updated_date":"2019-04-11T11:07:00Z","reference_number":"EMA/816603/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2019-ema-decision-3-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-rezolsta-emea-001280-pip01-12-m02_en.pdf"},
    {"id":"44219","name":"P/0036/2019: EMA decision of 29 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (Ozempic), (EMEA-001441-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T11:11:00Z","last_updated_date":"2019-04-11T11:11:00Z","reference_number":"EMA/916767/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2019-ema-decision-29-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-semaglutide-ozempic-emea-001441-pip01-13-m02_en.pdf"},
    {"id":"44220","name":"P/0039/2019: EMA decision of 29 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rilpivirine (Edurant), (EMEA-000317-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T13:45:00Z","last_updated_date":"2019-04-11T13:45:00Z","reference_number":"EMA/916772/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2019-ema-decision-29-january-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rilpivirine-edurant-emea-000317-pip02-18_en.pdf"},
    {"id":"44221","name":"P/0009/2019: EMA decision of 3 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bilastine (Bilaxten and associated names), (EMEA-000347-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T14:06:00Z","last_updated_date":"2019-04-11T14:06:00Z","reference_number":"EMA/816627/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2019-ema-decision-3-january-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bilastine-bilaxten-associated-names-emea-000347-pip02-16_en.pdf"},
    {"id":"44222","name":"P/0046/2019: EMA decision of 29 January 2019 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for turoctocog alfa pegol (EMEA-001174-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T14:14:00Z","last_updated_date":"2019-04-11T14:14:00Z","reference_number":"EMA/910859/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2019-ema-decision-29-january-2019-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-turoctocog-alfa-pegol-emea-001174-pip03-18_en.pdf"},
    {"id":"44223","name":"P/0021/2019: EMA decision of 3 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ibrutinib (Imbruvica), (EMEA-001397-PIP04-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T14:23:00Z","last_updated_date":"2019-04-11T14:23:00Z","reference_number":"EMA/871222/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2019-ema-decision-3-january-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ibrutinib-imbruvica-emea-001397-pip04-17_en.pdf"},
    {"id":"44224","name":"P/0007/2019: EMA decision of 3 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for semaglutide (EMEA-001441-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T14:34:00Z","last_updated_date":"2019-04-11T14:34:00Z","reference_number":"EMA/829833/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2019-ema-decision-3-january-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-semaglutide-emea-001441-pip03-17_en.pdf"},
    {"id":"44225","name":"P/0019/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for Germanium (68Ge) chloride / Gallium (68Ga) chloride (EMEA-002436-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T14:45:00Z","last_updated_date":"2019-04-11T14:45:00Z","reference_number":"EMA/887187/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2019-ema-decision-29-january-2019-granting-product-specific-waiver-germanium-68ge-chloride-gallium-68ga-chloride-emea-002436-pip01-18_en.pdf"},
    {"id":"44226","name":"P/0025/2019: EMA decision of 22 February 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for guselkumab (Tremfya), (EMEA-001523-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T14:52:00Z","last_updated_date":"2019-04-11T14:52:00Z","reference_number":"EMA/121245/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2019-ema-decision-22-february-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-guselkumab-tremfya-emea-001523-pip03-18_en.pdf"},
    {"id":"44227","name":"P/0049/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for encorafenib (Braftovi), (EMEA-001588-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-11T14:59:00Z","last_updated_date":"2019-04-11T14:59:00Z","reference_number":"EMA/916771/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2019-ema-decision-29-january-2019-granting-product-specific-waiver-encorafenib-braftovi-emea-001588-pip03-18_en.pdf"},
    {"id":"44241","name":"P/0060/2019: EMA decision of 28 February 2019 on the acceptance of a modification of an agreed paediatric investigation plan for crizanlizumab (EMEA-002141-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-12T11:22:00Z","last_updated_date":"2019-04-12T11:22:00Z","reference_number":"EMA/122323/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2019-ema-decision-28-february-2019-acceptance-modification-agreed-paediatric-investigation-plan-crizanlizumab-emea-002141-pip01-17-m01_en.pdf"},
    {"id":"44242","name":"P/0053/2019: EMA decision of 29 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for dienogest / ethinyl estradiol (lpri-424) (EMEA-002229-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-12T11:27:00Z","last_updated_date":"2019-04-12T11:27:00Z","reference_number":"EMA/900655/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2019-ema-decision-29-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-dienogest-ethinyl-estradiol-lpri-424-emea-002229-pip01-17-m01_en.pdf"},
    {"id":"44243","name":"P/0045/2019: EMA decision of 29 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for filgotinib (EMEA-001619-PIP03-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-12T11:38:00Z","last_updated_date":"2019-04-12T11:38:00Z","reference_number":"EMA/900716/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2019-ema-decision-29-january-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-filgotinib-emea-001619-pip03-16_en.pdf"},
    {"id":"44244","name":"P/0050/2019: EMA decision of 29 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ozanimod (EMEA-001710-PIP04-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-12T11:39:00Z","last_updated_date":"2019-04-12T11:39:00Z","reference_number":"EMA/887311/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2019-ema-decision-29-january-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ozanimod-emea-001710-pip04-17_en.pdf"},
    {"id":"44245","name":"P/0044/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for pexidartinib (EMEA-001939-PIP03-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-12T11:41:00Z","last_updated_date":"2019-04-12T11:41:00Z","reference_number":"EMA/910938/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2019-ema-decision-29-january-2019-granting-product-specific-waiver-pexidartinib-emea-001939-pip03-16_en.pdf"},
    {"id":"44246","name":"P/0038/2019: EMA decision of 29 January 2019 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for givosiran (EMEA-002048-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-12T11:41:00Z","last_updated_date":"2019-04-12T11:41:00Z","reference_number":"EMA/916259/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2019-ema-decision-29-january-2019-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-givosiran-emea-002048-pip02-18_en.pdf"},
    {"id":"44247","name":"P/0058/2019: EMA decision of 26 February 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for pretomanid (EMEA-002115-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-12T11:42:00Z","last_updated_date":"2019-04-12T11:42:00Z","reference_number":"EMA/121650/2019 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2019-ema-decision-26-february-2019-agreement-paediatric-investigation-plan-granting-deferral-pretomanid-emea-002115-pip01-17_en.pdf"},
    {"id":"44248","name":"P/0005/2019: EMA decision of 3 January 2019 on the granting of a product specific waiver for palbociclib (IBRANCE) (EMEA-002146-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-12T11:44:00Z","last_updated_date":"2019-04-12T11:44:00Z","reference_number":"EMA/873059/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2019-ema-decision-3-january-2019-granting-product-specific-waiver-palbociclib-ibrance-emea-002146-pip02-18_en.pdf"},
    {"id":"44249","name":"P/0013/2019: EMA decision of 3 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for bupivacaine / meloxicam (HTX-011) (EMEA-002246-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-12T11:44:00Z","last_updated_date":"2019-04-12T11:44:00Z","reference_number":"EMA/828934/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2019-ema-decision-3-january-2019-agreement-paediatric-investigation-plan-granting-deferral-bupivacaine-meloxicam-htx-011-emea-002246-pip01-17_en.pdf"},
    {"id":"44250","name":"P/0042/2019: EMA decision of 29 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for etripamil (EMEA-002303-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-12T11:46:00Z","last_updated_date":"2019-04-12T11:46:00Z","reference_number":"EMA/916774/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2019-ema-decision-29-january-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-etripamil-emea-002303-pip01-17_en.pdf"},
    {"id":"44271","name":"P/0034/2019: EMA decision of 29 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for azilsartan medoxomil (Edarbi), (EMEA-000237-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-16T09:23:00Z","last_updated_date":"2019-04-16T09:24:00Z","reference_number":"EMA/900651/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2019-ema-decision-29-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-azilsartan-medoxomil-edarbi-emea-000237-pip01-08-m08_en.pdf"},
    {"id":"44272","name":"P/0028/2019: EMA decision of 29 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ocrelizumab (Ocrevus), (EMEA-000310-PIP03-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-16T09:30:00Z","last_updated_date":"2019-04-16T09:30:00Z","reference_number":"EMA/900653/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2019-ema-decision-29-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-ocrelizumab-ocrevus-emea-000310-pip03-10-m03_en.pdf"},
    {"id":"44273","name":"P/0059/2019: EMA decision of 228 February 2019 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat), (EMEA-000402-PIP03-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-16T10:01:00Z","last_updated_date":"2019-04-16T10:01:00Z","reference_number":"EMA/112117/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2019-ema-decision-228-february-2019-acceptance-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip03-17-m03_en.pdf"},
    {"id":"44274","name":"P/0017/2019: EMA decision of 3 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir (Tivicay), (EMEA-000409-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-16T10:10:00Z","last_updated_date":"2019-04-16T10:10:00Z","reference_number":"EMA/871152/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2019-ema-decision-3-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-tivicay-emea-000409-pip01-08-m05_en.pdf"},
    {"id":"44275","name":"P/0029/2024 : EMA decision of 29 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for regadenoson (Rapiscan), (EMEA-000410-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-18T10:16:00Z","last_updated_date":"2025-03-18T10:16:00Z","reference_number":"EMA/29055/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2024-ema-decision-29-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-regadenoson-rapiscan-emea-000410-pip01-08-m06_en.pdf"},
    {"id":"44276","name":"P/0022/2019: EMA decision of 4 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for split influenza virus, inactivated containing antigen equivalent to A/California/7/2009(H1N1)-like strain (A/California/7/2009 (","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-16T10:27:00Z","last_updated_date":"2019-04-16T10:27:00Z","reference_number":"EMA/895159/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2019-ema-decision-4-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigen-equivalent-california-7-2009h1n1-strain_en.pdf"},
    {"id":"44277","name":"P/0016/2019: EMA decision of 3 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for sildenafil (Revatio), (EMEA-000671-PIP01-09-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-16T10:33:00Z","last_updated_date":"2019-04-16T10:33:00Z","reference_number":"EMA/831890/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2019-ema-decision-3-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-sildenafil-revatio-emea-000671-pip01-09-m10_en.pdf"},
    {"id":"44331","name":"P/0014/2019: EMA decision of 3 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral or rezafungin acetate (EMEA-002319-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-24T11:43:00Z","last_updated_date":"2019-04-24T11:43:00Z","reference_number":"EMA/831266/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2019-ema-decision-3-january-2019-agreement-paediatric-investigation-plan-granting-deferral-or-rezafungin-acetate-emea-002319-pip01-17_en.pdf"},
    {"id":"44334","name":"P/0041/2019: EMA decision of 29 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ianalumab (EMEA-002338-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-24T14:07:00Z","last_updated_date":"2019-04-24T14:07:00Z","reference_number":"EMA/887308/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2019-ema-decision-29-january-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ianalumab-emea-002338-pip01-18_en.pdf"},
    {"id":"44336","name":"P/0026/2019: EMA decision of 22 February 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for avapritinib (EMEA-002358-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-24T14:26:00Z","last_updated_date":"2019-04-24T14:26:00Z","reference_number":"EMA/121657/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2019-ema-decision-22-february-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-avapritinib-emea-002358-pip02-18_en.pdf"},
    {"id":"44337","name":"P/0019/2019: EMA decision of 3 January 2019 on the granting of a product specific waiver for Germanium (68Ge) chloride / Gallium (68Ga) chloride (EMEA-002436-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-24T14:31:00Z","last_updated_date":"2019-04-24T14:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2019-ema-decision-3-january-2019-granting-product-specific-waiver-germanium-68ge-chloride-gallium-68ga-chloride-emea-002436-pip01-18_en.pdf"},
    {"id":"44338","name":"P/0023/2019: EMA decision of 4 January 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for split influenza virus, inactivated containing antigens equivalent to the A/H1N1- like str","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-24T14:36:00Z","last_updated_date":"2019-04-24T14:36:00Z","reference_number":"EMA/902281/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2019-ema-decision-4-january-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-split-influenza-virus-inactivated-containing-antigens-equivalent-h1n1-str_en.pdf"},
    {"id":"44339","name":"P/0020/2019: EMA decision of 3 January 2019 on the granting of a product specific waiver for Bruton’s tyrosine kinase inhibitor (EMEA-002438-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-24T14:52:00Z","last_updated_date":"2019-04-24T14:52:00Z","reference_number":"EMA/871200/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2019-ema-decision-3-january-2019-granting-product-specific-waiver-brutons-tyrosine-kinase-inhibitor-emea-002438-pip01-18_en.pdf"},
    {"id":"44340","name":"P/0048/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for ramipril / atorvastatin / amlodipine (EMEA-002416-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-25T09:28:00Z","last_updated_date":"2019-04-25T09:28:00Z","reference_number":"EMA/887203/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2019-ema-decision-29-january-2019-granting-product-specific-waiver-ramipril-atorvastatin-amlodipine-emea-002416-pip01-18_en.pdf"},
    {"id":"44341","name":"P/0012/2019: EMA decision of 3 January 2019 on the granting of a product specific waiver for anti-VEGF and anti-DLL4 dual variable domain immunoglobulin (ABT-165) (EMEA-002420-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-25T09:35:00Z","last_updated_date":"2019-04-25T09:35:00Z","reference_number":"EMA/829754/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2019-ema-decision-3-january-2019-granting-product-specific-waiver-anti-vegf-anti-dll4-dual-variable-domain-immunoglobulin-abt-165-emea-002420-pip01-18_en.pdf"},
    {"id":"44342","name":"P/0011/2019: EMA decision of 3 January 2019 on the granting of a product specific waiver for levodopa / carbidopa monohydrate / entacapone (EMEA-002421-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-25T09:53:00Z","last_updated_date":"2019-04-25T09:53:00Z","reference_number":"EMA/775707/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2019-ema-decision-3-january-2019-granting-product-specific-waiver-levodopa-carbidopa-monohydrate-entacapone-emea-002421-pip01-18_en.pdf"},
    {"id":"44345","name":"P/0015/2019: EMA decision of 3 January 2019 on the granting of a product specific waiver for synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2’- fluoro and t","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-25T14:24:00Z","last_updated_date":"2019-04-25T14:24:00Z","reference_number":"EMA/827640/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2019-ema-decision-3-january-2019-granting-product-specific-waiver-synthetic-double-stranded-sirna-oligonucleotide-targeted-against-transthyretin-mrna-six-phosphorothioate-linkages-backbone-nine_en.pdf"},
    {"id":"44364","name":"P/0052/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for technetium (99mtc) trofolastat chloride (EMEA-002441-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-04-26T11:51:00Z","last_updated_date":"2019-04-26T11:51:00Z","reference_number":"EMA/900699/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2019-ema-decision-29-january-2019-granting-product-specific-waiver-technetium-99mtc-trofolastat-chloride-emea-002441-pip01-18_en.pdf"},
    {"id":"44365","name":"P/0047/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for rifamycin (EMEA-002450-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-04-26T11:57:00Z","last_updated_date":"2019-04-26T11:57:00Z","reference_number":"EMA/910948/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2019-ema-decision-29-january-2019-granting-product-specific-waiver-rifamycin-emea-002450-pip01-18_en.pdf"},
    {"id":"44366","name":"P/0033/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for amantadine (hydrochloride) (EMEA-002460-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-04-26T12:06:00Z","last_updated_date":"2019-04-26T12:06:00Z","reference_number":"EMA/887206/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2019-ema-decision-29-january-2019-granting-product-specific-waiver-amantadine-hydrochloride-emea-002460-pip01-18_en.pdf"},
    {"id":"44367","name":"P/0024/2019: EMA decision of 11 January 2019 on the granting of a product specific waiver for telmisartan / indapamide (EMEA-002462-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-04-26T12:56:00Z","last_updated_date":"2019-04-26T12:56:00Z","reference_number":"EMA/895013/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2019-ema-decision-11-january-2019-granting-product-specific-waiver-telmisartan-indapamide-emea-002462-pip01-18_en.pdf"},
    {"id":"44368","name":"P/0032/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for fibroblast activation protein alpha-targeted interleukin 2 variant immunocytokine (EMEA-002465-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-04-26T13:00:00Z","last_updated_date":"2019-04-26T13:00:00Z","reference_number":"EMA/900682/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2019-ema-decision-29-january-2019-granting-product-specific-waiver-fibroblast-activation-protein-alpha-targeted-interleukin-2-variant-immunocytokine-emea-002465-pip01-18_en.pdf"},
    {"id":"44369","name":"P/0051/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for human ciliary neurotrophic factor (EMEA-002477-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-04-26T13:06:00Z","last_updated_date":"2019-04-26T13:06:00Z","reference_number":"EMA/916770/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2019-ema-decision-29-january-2019-granting-product-specific-waiver-human-ciliary-neurotrophic-factor-emea-002477-pip01-18_en.pdf"},
    {"id":"44382","name":"P/0008/2019: EMA decision of 3 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tisagenlecleucel (Kymriah), (EMEA-001654-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T17:16:00Z","last_updated_date":"2019-04-26T17:16:00Z","reference_number":"EMA/816615/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2019-ema-decision-3-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-tisagenlecleucel-kymriah-emea-001654-pip01-14-m03_en.pdf"},
    {"id":"44386","name":"P/0040/2019: EMA decision of 29 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for fostemsavir (tromethamine) (EMEA-001687-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-29T10:14:00Z","last_updated_date":"2019-04-29T10:14:00Z","reference_number":"EMA/886038/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2019-ema-decision-29-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-fostemsavir-tromethamine-emea-001687-pip01-14-m03_en.pdf"},
    {"id":"44387","name":"P/0057/2019: EMA decision of 25 February 2019 on the acceptance of a modification of an agreed paediatric investigation plan for Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / Influenza virus surface antigens (hae","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-29T10:22:00Z","last_updated_date":"2019-04-29T10:22:00Z","reference_number":"EMA/123854/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2019-ema-decision-25-february-2019-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h3n2-influenza-virus-surface_en.pdf"},
    {"id":"44388","name":"P/0054/2019: EMA decision of 11 February 2019 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine / dolutegravir (Juluca) (EMEA-001750-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-29T10:28:00Z","last_updated_date":"2019-04-29T10:28:00Z","reference_number":"EMA/910916/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2019-ema-decision-11-february-2019-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-dolutegravir-juluca-emea-001750-pip01-15-m02_en.pdf"},
    {"id":"44389","name":"P/0043/2019: EMA decision of 29 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for bivalent anti-human myostatin adnectin recombinant human IgG1-Fc fusion protein (RO7239361) (EMEA-001793-PIP01-15- M03 )","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-29T10:35:00Z","last_updated_date":"2019-04-29T10:35:00Z","reference_number":"EMA/895074/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2019-ema-decision-29-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-bivalent-anti-human-myostatin-adnectin-recombinant-human-igg1-fc-fusion-protein-ro7239361-emea_en.pdf"},
    {"id":"44390","name":"P/0002/2019: EMA decision of 3 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector (...)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-29T10:40:00Z","last_updated_date":"2019-04-29T10:40:00Z","reference_number":"EMA/873056/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2019-ema-decision-3-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-autologous-peripheral-blood-t-cells-cd4-cd8-selected-cd3-cd28-activated-transduced-retroviral_en.pdf"},
    {"id":"44391","name":"P/0027/2019: EMA decision of 29 January 2019 on the acceptance of a modification of an agreed paediatric investigation plan for 2-hydroxypropyl-ßcyclodextrin (HP-ß-CD) (EMEA-001866-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-04-29T10:45:00Z","last_updated_date":"2019-04-29T10:45:00Z","reference_number":"EMA/916769/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2019-ema-decision-29-january-2019-acceptance-modification-agreed-paediatric-investigation-plan-2-hydroxypropyl-sscyclodextrin-hp-ss-cd-emea-001866-pip01-15-m03_en.pdf"},
    {"id":"44764","name":"P/0115/2019: EMA decision of 4 April 2019 on the agreement of a paediatric investigation plan and on the granting of a waiver for aflibercept","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-06-20T11:49:00Z","last_updated_date":"2019-06-20T11:49:00Z","reference_number":"EMA/182951/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2019-ema-decision-4-april-2019-agreement-paediatric-investigation-plan-granting-waiver-aflibercept_en.pdf"},
    {"id":"44765","name":"P/0138/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for l-asparaginase (EMEA-000341-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-20T11:51:00Z","last_updated_date":"2019-06-20T11:51:00Z","reference_number":"EMA/190121/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2019-ema-decision-17-april-2019-granting-product-specific-waiver-l-asparaginase-emea-000341-pip03-18_en.pdf"},
    {"id":"44766","name":"P/0144/2019: EMA decision of 17 April 2019 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for secukinumab (Cosentyx), (EMEA-000380-PIP05-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-20T11:52:00Z","last_updated_date":"2019-06-20T11:52:00Z","reference_number":"EMA/215225/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2019-ema-decision-17-april-2019-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-secukinumab-cosentyx-emea-000380-pip05-18_en.pdf"},
    {"id":"44767","name":"P/0082/2019: EMA decision of 22 March 2019 on the granting of a product specific waiver for empagliflozin (Jardiance), (EMEA-000828-PIP06-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-20T11:54:00Z","last_updated_date":"2019-06-20T11:54:00Z","reference_number":"EMA/122311/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2019-ema-decision-22-march-2019-granting-product-specific-waiver-empagliflozin-jardiance-emea-000828-pip06-18_en.pdf"},
    {"id":"44768","name":"P/0150/2019: EMA decision of 17 April 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nintedanib (Ofev, Vargatef), (EMEA-001006-PIP05-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-20T11:55:00Z","last_updated_date":"2019-06-20T11:55:00Z","reference_number":"EMA/215279/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2019-ema-decision-17-april-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-nintedanib-ofev-vargatef-emea-001006-pip05-18_en.pdf"},
    {"id":"44769","name":"P/0125/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for delafloxacin (EMEA-001080-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-20T11:56:00Z","last_updated_date":"2019-06-20T11:56:00Z","reference_number":"EMA/215324/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2019-ema-decision-17-april-2019-granting-product-specific-waiver-delafloxacin-emea-001080-pip03-18_en.pdf"},
    {"id":"44770","name":"P/0153/2019: EMA decision of 17 April 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ozanimod (EMEA-001710-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-20T11:57:00Z","last_updated_date":"2019-06-20T11:57:00Z","reference_number":"EMA/190141/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2019-ema-decision-17-april-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ozanimod-emea-001710-pip03-17_en.pdf"},
    {"id":"44771","name":"P/0070/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for eltrombopag (Revolade), (EMEA-000170-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-20T16:08:00Z","last_updated_date":"2019-06-20T16:08:00Z","reference_number":"EMA/107435/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-eltrombopag-revolade-emea-000170-pip02-10-m03_en.pdf"},
    {"id":"44772","name":"P/0121/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for etravirine (Intelence), (EMEA-000222-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-20T16:14:00Z","last_updated_date":"2019-06-20T16:14:00Z","reference_number":"EMA/182544/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-etravirine-intelence-emea-000222-pip01-08-m09_en.pdf"},
    {"id":"44773","name":"P/0143/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for corifollitropin alfa (Elonva), (EMEA-000306-PIP01-08-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-20T16:28:00Z","last_updated_date":"2019-06-20T16:28:00Z","reference_number":"EMA/215937/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-corifollitropin-alfa-elonva-emea-000306-pip01-08-m04_en.pdf"},
    {"id":"44782","name":"P/0064/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for rituximab (MabThera)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-21T11:35:00Z","last_updated_date":"2019-06-21T11:35:00Z","reference_number":"EMA/112081/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-rituximab-mabthera_en.pdf"},
    {"id":"44783","name":"P/0096/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara), (EMEA-000311-PIP04-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-21T11:40:00Z","last_updated_date":"2019-06-21T11:40:00Z","reference_number":"EMA/122313/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip04-13-m01_en.pdf"},
    {"id":"44784","name":"P/0063/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for methoxyflurane (Penthrox), (EMEA-000334-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-21T11:55:00Z","last_updated_date":"2019-06-21T11:55:00Z","reference_number":"EMA/169604/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-methoxyflurane-penthrox-emea-000334-pip01-08-m08_en.pdf"},
    {"id":"44787","name":"P/0126/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for rivaroxaban (Xarelto), (EMEA-000430-PIP01-08-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T09:28:00Z","last_updated_date":"2019-06-24T09:28:00Z","reference_number":"EMA/215013/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-rivaroxaban-xarelto-emea-000430-pip01-08-m11_en.pdf"},
    {"id":"44788","name":"P/0077/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ambrisentan (Volibris), (EMEA-000434-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T09:53:00Z","last_updated_date":"2019-06-24T09:53:00Z","reference_number":"EMA/130552/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-ambrisentan-volibris-emea-000434-pip01-08-m05_en.pdf"},
    {"id":"44789","name":"P/0097/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for alogliptin (Vipidia), (EMEA-000496-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T10:05:00Z","last_updated_date":"2019-06-24T10:05:00Z","reference_number":"EMA/169615/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-alogliptin-vipidia-emea-000496-pip01-08-m06_en.pdf"},
    {"id":"44790","name":"P/0108/2019: EMA decision of 22 March 2019 on the granting of a product specific waiver for relugolix / estradiol / norethisterone acetate (EMEA-002428-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T10:34:00Z","last_updated_date":"2019-06-24T10:34:00Z","reference_number":"EMA/170150/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2019-ema-decision-22-march-2019-granting-product-specific-waiver-relugolix-estradiol-norethisterone-acetate-emea-002428-pip01-18_en.pdf"},
    {"id":"44791","name":"P/0103/2019: EMA decision of 25 March 2019 on the granting of a product-specific waiver for upadacitinib (EMEA-001741-PIP06-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T10:36:00Z","last_updated_date":"2019-06-24T10:36:00Z","reference_number":"EMA/145311/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2019-ema-decision-25-march-2019-granting-product-specific-waiver-upadacitinib-emea-001741-pip06-18_en.pdf"},
    {"id":"44792","name":"P/0092/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for isoflurane (EMEA-002320-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T10:38:00Z","last_updated_date":"2019-06-24T10:38:00Z","reference_number":"EMA/122332/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-isoflurane-emea-002320-pip01-17_en.pdf"},
    {"id":"44793","name":"P/0156/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for rogaratinib (EMEA-002439-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T10:42:00Z","last_updated_date":"2019-06-24T10:42:00Z","reference_number":"EMA/215341/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2019-ema-decision-17-april-2019-granting-product-specific-waiver-rogaratinib-emea-002439-pip01-18_en.pdf"},
    {"id":"44794","name":"P/0091/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for N-(1,3- dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H...(EMEA-002324-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T10:48:00Z","last_updated_date":"2019-06-24T10:48:00Z","reference_number":"EMA/107382/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-n-13-dimethyl-1h-pyrazole-4-sulfonyl-6-3-333-trifluoro-22-dimethylpropoxy-1hemea-002324-pip01-17_en.pdf"},
    {"id":"44795","name":"P/0145/2019: EMA decision of 17 April 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for gadopiclenol (EMEA-001949-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T10:52:00Z","last_updated_date":"2019-06-24T10:52:00Z","reference_number":"EMA/215110/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2019-ema-decision-17-april-2019-agreement-paediatric-investigation-plan-granting-deferral-gadopiclenol-emea-001949-pip02-18_en.pdf"},
    {"id":"44796","name":"P/0161/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for inactivated patient's own (autologous) microorganism (Escherichia coli, Candida spp., Enterococcus spp., Streptococcus spp., Staphylococcus spp., Prevotella interm","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T10:53:00Z","last_updated_date":"2019-06-24T10:53:00Z","reference_number":"EMA/224862/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2019-ema-decision-17-april-2019-granting-product-specific-waiver-inactivated-patients-own-autologous-microorganism-escherichia-coli-candida-spp-enterococcus-spp-streptococcus-spp-staphylococcus_en.pdf"},
    {"id":"44797","name":"P/0095/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10atetrahydro- 6H-benzo[c","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T11:22:00Z","last_updated_date":"2019-06-24T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-6ar10ar-1-hydroxy-66-dimethyl-3-2-methyl-2-octanyl-6a71010atetrahydro-6h-benzoc_en.pdf"},
    {"id":"44798","name":"P/0079/2019: EMA decision of 22 March 2019 on the granting of a product specific waiver for rosuvastatin (calcium) / amlodipine (besylate) (EMEA-002456-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T11:25:00Z","last_updated_date":"2019-06-24T11:25:00Z","reference_number":"EMA/65157/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2019-ema-decision-22-march-2019-granting-product-specific-waiver-rosuvastatin-calcium-amlodipine-besylate-emea-002456-pip01-18_en.pdf"},
    {"id":"44799","name":"P/0078/2019: EMA decision of 22 March 2019 on the granting of a product specific waiver for genetically modified Mycobacterium bovis BCG (EMEA-002461-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T11:35:00Z","last_updated_date":"2019-06-24T11:35:00Z","reference_number":"EMA/121698/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2019-ema-decision-22-march-2019-granting-product-specific-waiver-genetically-modified-mycobacterium-bovis-bcg-emea-002461-pip01-18_en.pdf"},
    {"id":"44800","name":"P/0124/2019: EMA decision of 17 April 2019 on the agreement of a paediatric investigation plan and on the granting of a waiver for abemaciclib (Verzenios), (EMEA-002342-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T11:47:00Z","last_updated_date":"2019-06-24T11:47:00Z","reference_number":"EMA/182989/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2019-ema-decision-17-april-2019-agreement-paediatric-investigation-plan-granting-waiver-abemaciclib-verzenios-emea-002342-pip01-18_en.pdf"},
    {"id":"44801","name":"P/0089/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for spartalizumab (EMEA-002351-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T11:51:00Z","last_updated_date":"2019-06-24T11:51:00Z","reference_number":"EMA/65170/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-spartalizumab-emea-002351-pip01-18_en.pdf"},
    {"id":"44802","name":"P/0099/2019: EMA decision of 22 March 2019 on the refusal of a product specific waiver for pyrimidinyl-aminopyridine dual leucine zipper kinase inhibitor (GDC-0134) (EMEA-002469-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T11:52:00Z","last_updated_date":"2019-06-24T11:52:00Z","reference_number":"EMA/145322/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2019-ema-decision-22-march-2019-refusal-product-specific-waiver-pyrimidinyl-aminopyridine-dual-leucine-zipper-kinase-inhibitor-gdc-0134-emea-002469-pip01-18_en.pdf"},
    {"id":"44803","name":"P/0102/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dihomo-γ-linolenic acid (DS107) (EMEA-002364-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T11:56:00Z","last_updated_date":"2019-06-24T11:56:00Z","reference_number":"EMA/170158/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dihomo-g-linolenic-acid-ds107-emea-002364-pip02-18_en.pdf"},
    {"id":"44804","name":"P/0075/2019: EMA decision of 22 March 2019 on the granting of a product specific waiver for n-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl) acetamide (KX2-391) (EMEA-002470-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T11:57:00Z","last_updated_date":"2019-06-24T11:57:00Z","reference_number":"EMA/145319/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2019-ema-decision-22-march-2019-granting-product-specific-waiver-n-benzyl-2-5-4-2-morpholinoethoxyphenyl-pyridin-2-yl-acetamide-kx2-391-emea-002470-pip01-18_en.pdf"},
    {"id":"44806","name":"P/0105/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (R)-azasetron (besylate) (SENS-401) (EMEA-002165-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T12:51:00Z","last_updated_date":"2019-06-24T12:51:00Z","reference_number":"EMA/122334/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-r-azasetron-besylate-sens-401-emea-002165-pip02-18_en.pdf"},
    {"id":"44807","name":"P/0090/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for ivacaftor / tezacaftor/ potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1Hpyrazol- 1-yl)-2-[","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:11:00Z","last_updated_date":"2019-10-01T14:05:00Z","reference_number":"EMA/130877/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-ivacaftor-tezacaftor-potassium-benzenesulfonyl6-3-2-1-trifluoromethylcyclopropylethoxy-1hpyrazol-1-yl-2_en.pdf"},
    {"id":"44808","name":"P/0142/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for tislelizumab (EMEA-002480-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:12:00Z","last_updated_date":"2019-06-24T13:12:00Z","reference_number":"EMA/215378/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2019-ema-decision-17-april-2019-granting-product-specific-waiver-tislelizumab-emea-002480-pip01-18_en.pdf"}    {"id":"44809","name":"P/0155/2019: EMA decision of 17 April 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for liposomal vinorelbine (tartrate) (EMEA-002365-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T12:03:00Z","last_updated_date":"2019-06-24T12:03:00Z","reference_number":"EMA/215265/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2019-ema-decision-17-april-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-liposomal-vinorelbine-tartrate-emea-002365-pip01-18_en.pdf"},
    {"id":"44810","name":"P/0140/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for rivoceranib (mesylate) (EMEA-002489-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:20:00Z","last_updated_date":"2019-06-24T13:20:00Z","reference_number":"EMA/190164/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2019-ema-decision-17-april-2019-granting-product-specific-waiver-rivoceranib-mesylate-emea-002489-pip01-18_en.pdf"},
    {"id":"44811","name":"P/0106/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mavacamten (EMEA-002231-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:21:00Z","last_updated_date":"2019-06-24T13:21:00Z","reference_number":"EMA/122333/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mavacamten-emea-002231-pip01-17_en.pdf"},
    {"id":"44812","name":"P/0149/2019: EMA decision of 17 April 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous T lymphocyte-enriched population of cells transduced...(EMEA-002369-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:22:00Z","last_updated_date":"2019-06-24T13:22:00Z","reference_number":"EMA/190160/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2019-ema-decision-17-april-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-t-lymphocyte-enriched-population-cells-transducedemea-002369-pip01-18_en.pdf"},
    {"id":"44813","name":"P/0135/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for serlopitant (EMEA-002496-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:26:00Z","last_updated_date":"2019-06-24T13:26:00Z","reference_number":"EMA/215104/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2019-ema-decision-17-april-2019-granting-product-specific-waiver-serlopitant-emea-002496-pip01-18_en.pdf"},
    {"id":"44814","name":"P/0132/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for N2’-Deacetyl-N2’-[4-methyl-4-(oxobutyldithio)-1-oxopentyl]-maytansine-hu769_4D4 Antibody (EMEA-002504-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:34:00Z","last_updated_date":"2019-06-24T13:34:00Z","reference_number":"EMA/215102/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2019-ema-decision-17-april-2019-granting-product-specific-waiver-n2-deacetyl-n2-4-methyl-4-oxobutyldithio-1-oxopentyl-maytansine-hu769_4d4-antibody-emea-002504-pip01-18_en.pdf"},
    {"id":"44815","name":"P/0120/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for rosuvastatin (calcium) / fenofibrate (EMEA-002509-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:44:00Z","last_updated_date":"2019-06-24T13:44:00Z","reference_number":"EMA/182619/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2019-ema-decision-17-april-2019-granting-product-specific-waiver-rosuvastatin-calcium-fenofibrate-emea-002509-pip01-18_en.pdf"},
    {"id":"44816","name":"P/0093/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for 1-{[(2S,3S)- 2-carboxylato-3-methyl-4,4,7-trioxo-4-{6}-thia-1-azabi...(EMEA-002240-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:50:00Z","last_updated_date":"2019-06-24T13:50:00Z","reference_number":"EMA/107378/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-1-2s3s-2-carboxylato-3-methyl-447-trioxo-4-6-thia-1-azabiemea-002240-pip02-17_en.pdf"},
    {"id":"44817","name":"P/0148/2019: EMA decision of 17 April 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-IL-21 humanized immunoglobulin G1-kappa ... (BOS161721) (EMEA-002374-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:39:00Z","last_updated_date":"2019-06-24T13:39:00Z","reference_number":"EMA/215119/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2019-ema-decision-17-april-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-il-21-humanized-immunoglobulin-g1-kappa-bos161721-emea-002374-pip01-18_en.pdf"},
    {"id":"44818","name":"P/0119/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for orvepitant (EMEA-002510-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T13:50:00Z","last_updated_date":"2019-06-24T13:50:00Z","reference_number":"EMA/182611/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2019-ema-decision-17-april-2019-granting-product-specific-waiver-orvepitant-emea-002510-pip01-18_en.pdf"},
    {"id":"44819","name":"P/0110/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for N-hydroxy-5-methylfuran-2-sulfonamide (BMS-986231) (EMEA-002378-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T14:03:00Z","last_updated_date":"2019-06-24T14:03:00Z","reference_number":"EMA/173738/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-n-hydroxy-5-methylfuran-2-sulfonamide-bms-986231-emea-002378-pip01-18_en.pdf"},
    {"id":"44820","name":"P/0113/2019: EMA decision of 29 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for chemically modified recombinant human sulfamidase (EMEA-002380-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T14:09:00Z","last_updated_date":"2019-06-24T14:09:00Z","reference_number":"EMA/187096/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2019-ema-decision-29-march-2019-agreement-paediatric-investigation-plan-granting-deferral-chemically-modified-recombinant-human-sulfamidase-emea-002380-pip01-18_en.pdf"},
    {"id":"44821","name":"P/0109/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for ridinilazole (EMEA-002250-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T14:11:00Z","last_updated_date":"2019-06-24T14:11:00Z","reference_number":"EMA/170204/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-ridinilazole-emea-002250-pip02-17_en.pdf"},
    {"id":"44823","name":"P/0147/2019: EMA decision of 17 April 2019 on the agreement of a paediatric investigation plan and on the granting of a waiver for oteseconazole (EMEA-002392-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T14:18:00Z","last_updated_date":"2019-06-24T14:18:00Z","reference_number":"EMA/215121/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2019-ema-decision-17-april-2019-agreement-paediatric-investigation-plan-granting-waiver-oteseconazole-emea-002392-pip01-18_en.pdf"},
    {"id":"44824","name":"P/0088/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Recombinant Influenza Hemagglutinin-strain A (H1N1 subtype)... (EMEA-002418-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T14:26:00Z","last_updated_date":"2019-06-24T14:26:00Z","reference_number":"EMA/170154/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-influenza-hemagglutinin-strain-h1n1-subtype-emea-002418-pip01-18_en.pdf"},
    {"id":"44825","name":"P/0127/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for 177Lu-PSMA-617 (EMEA-002419-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T14:44:00Z","last_updated_date":"2019-06-24T14:44:00Z","reference_number":"EMA/190162/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2019-ema-decision-17-april-2019-granting-product-specific-waiver-177lu-psma-617-emea-002419-pip02-18_en.pdf"},
    {"id":"44826","name":"P/0137/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for migalastat (hydrochloride) (Galafold), (EMEA-001194-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T14:50:00Z","last_updated_date":"2019-06-24T14:50:00Z","reference_number":"EMA/190110/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-migalastat-hydrochloride-galafold-emea-001194-pip01-11-m04_en.pdf"},
    {"id":"44827","name":"P/0131/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for oritavancin (diphosphate) (Orbactiv), (EMEA-001270-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T15:43:00Z","last_updated_date":"2019-06-24T15:43:00Z","reference_number":"EMA/190111/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-oritavancin-diphosphate-orbactiv-emea-001270-pip01-12-m02_en.pdf"},
    {"id":"44828","name":"P/0100/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for migalastat (hydrochloride) (Galafold), (EMEA-001194-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T15:50:00Z","last_updated_date":"2019-06-24T15:50:00Z","reference_number":"EMA/169634/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-migalastat-hydrochloride-galafold-emea-001194-pip01-11-m04_en.pdf"},
    {"id":"44829","name":"P/0152/2019: EMA decision of 17 April 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for voclosporin (EMEA-002264-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T15:51:00Z","last_updated_date":"2019-06-24T15:51:00Z","reference_number":"EMA/215117/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2019-ema-decision-17-april-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-voclosporin-emea-002264-pip01-17_en.pdf"},
    {"id":"44830","name":"P/0157/2019: EMA decision of 17 April 2019 on the refusal of a modification of an agreed paediatric investigation plan for fevipiprant (EMEA-001315-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:03:00Z","last_updated_date":"2019-06-24T16:03:00Z","reference_number":"EMA/215887/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2019-ema-decision-17-april-2019-refusal-modification-agreed-paediatric-investigation-plan-fevipiprant-emea-001315-pip02-16-m01_en.pdf"},
    {"id":"44831","name":"P/0151/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for idarucizumab (Praxbind), (EMEA-001438-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:16:00Z","last_updated_date":"2019-06-24T16:16:00Z","reference_number":"EMA/215040/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-idarucizumab-praxbind-emea-001438-pip01-13-m01_en.pdf"},
    {"id":"44832","name":"P/0130/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for luspatercept (EMEA- 001521-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:23:00Z","last_updated_date":"2019-06-24T16:23:00Z","reference_number":"EMA/190114/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-luspatercept-emea-001521-pip01-13-m03_en.pdf"},
    {"id":"44833","name":"P/0136/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant parathyroid hormone (Natpar), (EMEA-001526-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:30:00Z","last_updated_date":"2019-06-24T16:30:00Z","reference_number":"EMA/190115/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-parathyroid-hormone-natpar-emea-001526-pip01-13-m03_en.pdf"},
    {"id":"44834","name":"P/0094/2019: EMA decision of 22 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for molgramostim (EMEA-002282-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:30:00Z","last_updated_date":"2019-06-24T16:30:00Z","reference_number":"EMA/130699/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2019-ema-decision-22-march-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-molgramostim-emea-002282-pip01-17_en.pdf"},
    {"id":"44835","name":"P/0141/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ertugliflozin (Steglatro), (EMEA-001533-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:39:00Z","last_updated_date":"2019-06-24T16:39:00Z","reference_number":"EMA/215044/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-ertugliflozin-steglatro-emea-001533-pip01-13-m02_en.pdf"},
    {"id":"44836","name":"P/0085/2019: EMA decision of 22 March 2019 on the refusal of a modification of an agreed paediatric investigation plan for chemically modified extract of trees pollen from birch and alder (EMEA-001013-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:47:00Z","last_updated_date":"2019-06-24T16:47:00Z","reference_number":"EMA/112122/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2019-ema-decision-22-march-2019-refusal-modification-agreed-paediatric-investigation-plan-chemically-modified-extract-trees-pollen-birch-alder-emea-001013-pip01-10-m01_en.pdf"},
    {"id":"44837","name":"P/0146/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for roxadustat (EMEA-001557-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:47:00Z","last_updated_date":"2019-06-24T16:47:00Z","reference_number":"EMA/215078/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-roxadustat-emea-001557-pip01-13-m03_en.pdf"},
    {"id":"44838","name":"P/0112/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan and on granting of a waiver in condition for treatment of soft tissue sarcoma for olaratumab (Lartruvo), (EMEA-001760-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:50:00Z","last_updated_date":"2019-06-24T16:50:00Z","reference_number":"EMA/170135/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-granting-waiver-condition-treatment-soft-tissue-sarcoma-olaratumab-lartruvo-emea-001760-pip01-15-m03_en.pdf"},
    {"id":"44839","name":"P/0133/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir alafenamide (as fumarate) (Vemlidy), (EMEA-001584-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:53:00Z","last_updated_date":"2019-06-24T16:53:00Z","reference_number":"EMA/215095/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-alafenamide-fumarate-vemlidy-emea-001584-pip01-13-m04_en.pdf"},
    {"id":"44840","name":"P/0062/2019: EMA decision of 7 15 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for acalabrutinib (EMEA-001796-PIP03-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:54:00Z","last_updated_date":"2019-06-24T16:54:00Z","reference_number":"EMA/112115/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2019-ema-decision-7-15-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-acalabrutinib-emea-001796-pip03-16-m01_en.pdf"},
    {"id":"44841","name":"P/0101/2019: EMA decision of 22 March 2019 on the refusal of a modification of an agreed paediatric investigation plan for chemically modified house dust mites allergen extract (dermatophagoides pteronyssinus and dermatophagoides farinae)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T16:57:00Z","last_updated_date":"2019-06-24T16:57:00Z","reference_number":"EMA/122316/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2019-ema-decision-22-march-2019-refusal-modification-agreed-paediatric-investigation-plan-chemically-modified-house-dust-mites-allergen-extract-dermatophagoides-pteronyssinus-dermatophagoides_en.pdf"},
    {"id":"44842","name":"P/0160/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for finerenone (EMEA- 001623-PIP01-14-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-06-24T17:03:00Z","last_updated_date":"2019-06-24T17:03:00Z","reference_number":"EMA/224548/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-finerenone-emea-001623-pip01-14-m02_en.pdf"},
    {"id":"44843","name":"P/0163/2019: EMA decision of 26 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for quizartinib (EMEA-001821-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:05:00Z","last_updated_date":"2019-06-24T17:05:00Z","reference_number":"EMA/226854/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2019-ema-decision-26-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-quizartinib-emea-001821-pip01-15-m03_en.pdf"},
    {"id":"44844","name":"P/0074/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for autologous cartilage derived cultured chondrocytes (EMEA-001823-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:10:00Z","last_updated_date":"2019-06-24T17:10:00Z","reference_number":"EMA/112125/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cartilage-derived-cultured-chondrocytes-emea-001823-pip01-15-m01_en.pdf"},
    {"id":"44845","name":"P/0061/2019: EMA decision of 8 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for humanised anti-IL-6 receptor (IL-6R) monoclonal antibody (EMEA-001625-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:10:00Z","last_updated_date":"2019-06-24T17:10:00Z","reference_number":"EMA/122322/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2019-ema-decision-8-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-humanised-anti-il-6-receptor-il-6r-monoclonal-antibody-emea-001625-pip01-14-m02_en.pdf"},
    {"id":"44846","name":"P/0084/2019: EMA decision of 22 March 2019 on the refusal of a modification of an agreed paediatric investigation plan for chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis (EMEA-001016-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:11:00Z","last_updated_date":"2019-06-24T17:11:00Z","reference_number":"EMA/130559/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2019-ema-decision-22-march-2019-refusal-modification-agreed-paediatric-investigation-plan-chemically-modified-extract-grass-pollen-holcus-lanatus-phleum-pratense-poa-pratensis-emea-001016-pip01_en.pdf"},
    {"id":"44847","name":"P/0107/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for erenumab (Aimovig), (EMEA-001664-PIP02-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:15:00Z","last_updated_date":"2019-06-24T17:15:00Z","reference_number":"EMA/169637/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-erenumab-aimovig-emea-001664-pip02-15-m03_en.pdf"},
    {"id":"44848","name":"P/0128/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for glecaprevir / pibrentasvir (Maviret) (EMEA-001832-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:19:00Z","last_updated_date":"2019-06-24T17:19:00Z","reference_number":"EMA/190118/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-glecaprevir-pibrentasvir-maviret-emea-001832-pip01-15-m02_en.pdf"},
    {"id":"44849","name":"P/0083/2019: EMA decision of 22 March 2019 on the refusal of a modification of an agreed paediatric investigation plan for chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis (EMEA-001017-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:20:00Z","last_updated_date":"2019-06-24T17:20:00Z","reference_number":"EMA/130571/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2019-ema-decision-22-march-2019-refusal-modification-agreed-paediatric-investigation-plan-chemically-modified-extract-grass-pollen-holcus-lanatus-phleum-pratense-poa-pratensis-emea-001017-pip01_en.pdf"},
    {"id":"44850","name":"P/0114/2019: EMA decision of 29 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for peanut flour (EMEA-001734-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:21:00Z","last_updated_date":"2019-06-24T17:21:00Z","reference_number":"EMA/182558/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0114-2019-ema-decision-29-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-peanut-flour-emea-001734-pip01-14-m04_en.pdf"},
    {"id":"44851","name":"P/0068/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (ABT-494) (EMEA-001741-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:26:00Z","last_updated_date":"2022-03-01T01:17:00Z","reference_number":"EMA/65094/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-abt-494-emea-001741-pip02-16-m01_en.pdf"},
    {"id":"44852","name":"P/0098/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for neisseria meningitidis serogroup B recombinant lipoprotein / neisseria meningitidis serogroup B recombinant lipoprotein","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:26:00Z","last_updated_date":"2019-06-24T17:26:00Z","reference_number":"EMA/122320/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-b-recombinant-lipoprotein-neisseria-meningitidis-serogroup-b_en.pdf"},
    {"id":"44853","name":"P/0069/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (ABT-494) (EMEA-001741-PIP03-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:31:00Z","last_updated_date":"2019-06-24T17:31:00Z","reference_number":"EMA/65110/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-abt-494-emea-001741-pip03-16-m01_en.pdf"},
    {"id":"44854","name":"P/0067/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon beta-1a (Plegridy), (EMEA-001129-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T17:52:00Z","last_updated_date":"2019-06-24T17:52:00Z","reference_number":"EMA/122321/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-peginterferon-beta-1a-plegridy-emea-001129-pip01-11-m03_en.pdf"},
    {"id":"44856","name":"P/0154/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ceftolozane / tazobactam (Zerbaxa), (EMEA-001142-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T18:00:00Z","last_updated_date":"2019-06-24T18:00:00Z","reference_number":"EMA/215034/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-ceftolozane-tazobactam-zerbaxa-emea-001142-pip01-11-m03_en.pdf"},
    {"id":"44857","name":"P/0065/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for dabrafenib (mesilate) (Tafinlar), (EMEA-001147-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-24T18:14:00Z","last_updated_date":"2019-06-24T18:14:00Z","reference_number":"EMA/112114/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-dabrafenib-mesilate-tafinlar-emea-001147-pip01-11-m06_en.pdf"},
    {"id":"44858","name":"P/0116/2019: EMA decision of 28 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for monovalent, live, recombinant, replication-incompetent adenoviral...(EMEA-002307-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T08:47:00Z","last_updated_date":"2019-06-25T08:47:00Z","reference_number":"EMA/197735/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2019-ema-decision-28-march-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-monovalent-live-recombinant-replication-incompetent-adenoviralemea-002307-pip01-17_en.pdf"},
    {"id":"44859","name":"P/0117/2019: EMA decision of 28 March 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for multivalent, live, recombinant, non-replicating in human cells... (EMEA-002308-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T08:52:00Z","last_updated_date":"2019-06-25T08:52:00Z","reference_number":"EMA/197737/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2019-ema-decision-28-march-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-multivalent-live-recombinant-non-replicating-human-cells-emea-002308-pip01-17_en.pdf"},
    {"id":"44860","name":"P/0118/2019: EMA decision of 17 April 2019 on the granting of a product-specific waiver for cenegermin (Oxervate), (EMEA-001729-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T09:00:00Z","last_updated_date":"2019-06-25T09:00:00Z","reference_number":"EMA/182620/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2019-ema-decision-17-april-2019-granting-product-specific-waiver-cenegermin-oxervate-emea-001729-pip02-18_en.pdf"},
    {"id":"44863","name":"P/0111/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for galcanezumab (Emgality), (EMEA-001860-PIP03-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T10:12:00Z","last_updated_date":"2019-06-25T10:12:00Z","reference_number":"EMA/173699/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-galcanezumab-emgality-emea-001860-pip03-16-m02_en.pdf"},
    {"id":"44864","name":"P/0104/2019: EMA decision of 25 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (EMEA- 001900-PIP02-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T10:16:00Z","last_updated_date":"2019-06-25T10:16:00Z","reference_number":"EMA/130578/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2019-ema-decision-25-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-emea-001900-pip02-17-m02_en.pdf"},
    {"id":"44865","name":"P/0129/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for inebilizumab (EMEA- 001911-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T10:20:00Z","last_updated_date":"2019-06-25T10:20:00Z","reference_number":"EMA/215516/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-inebilizumab-emea-001911-pip01-15-m02_en.pdf"},
    {"id":"44866","name":"P/0159/2019: EMA decision of 15 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for angiotensin II (LJPC-501) (EMEA-001912-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T10:26:00Z","last_updated_date":"2019-06-25T10:26:00Z","reference_number":"EMA/218417/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2019-ema-decision-15-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-angiotensin-ii-ljpc-501-emea-001912-pip02-16-m02_en.pdf"},
    {"id":"44867","name":"P/0073/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for avalglucosidase alfa (EMEA-001945-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T10:57:00Z","last_updated_date":"2019-06-25T10:57:00Z","reference_number":"EMA/107423/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-avalglucosidase-alfa-emea-001945-pip01-16-m01_en.pdf"},
    {"id":"44868","name":"P/0066/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for lefamulin (EMEA-002075-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T11:00:00Z","last_updated_date":"2019-06-25T11:00:00Z","reference_number":"EMA/170148/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-lefamulin-emea-002075-pip01-16-m01_en.pdf"},
    {"id":"44869","name":"P/0072/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for carotuximab (EMEA-002138-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T11:07:00Z","last_updated_date":"2019-06-25T11:07:00Z","reference_number":"EMA/65212/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-carotuximab-emea-002138-pip01-17-m01_en.pdf"},
    {"id":"44870","name":"P/0162/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for onasemnogenum abeparvovecum (EMEA-002168-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T11:11:00Z","last_updated_date":"2019-06-25T11:11:00Z","reference_number":"EMA/216870/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-onasemnogenum-abeparvovecum-emea-002168-pip01-17-m01_en.pdf"},
    {"id":"44871","name":"P/0081/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for 3-({5-chloro-1-[3- (methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5- c]pyridin-2","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T11:14:00Z","last_updated_date":"2019-06-25T11:14:00Z","reference_number":"EMA/130575/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-3-5-chloro-1-3-methylsulfonylpropyl-1h-indol-2-ylmethyl-1-222-trifluoroethyl-13-dihydro-2h-imidazo45_en.pdf"},
    {"id":"44872","name":"P/0076/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for trametinib (dimethyl sulfoxide) (Mekinist), (EMEA-001177-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T11:18:00Z","last_updated_date":"2019-06-25T11:18:00Z","reference_number":"EMA/130573/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-trametinib-dimethyl-sulfoxide-mekinist-emea-001177-pip01-11-m05_en.pdf"},
    {"id":"44873","name":"P/0158/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for regorafenib (Stivarga), (EMEA-001178-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T11:24:00Z","last_updated_date":"2019-06-25T11:24:00Z","reference_number":"EMA/215983/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-regorafenib-stivarga-emea-001178-pip01-11-m04_en.pdf"},
    {"id":"44879","name":"P/0134/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz), (EMEA-000576-PIP01-09-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T15:15:00Z","last_updated_date":"2019-06-25T15:15:00Z","reference_number":"EMA/215014/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip01-09-m10_en.pdf"},
    {"id":"44880","name":"P/0071/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz), (EMEA-000576-PIP03-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T15:16:00Z","last_updated_date":"2019-06-25T15:16:00Z","reference_number":"EMA/107429/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip03-12-m02_en.pdf"},
    {"id":"44881","name":"P/0080/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla) (EMEA-000715-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T15:23:00Z","last_updated_date":"2019-06-25T15:23:00Z","reference_number":"EMA/130557/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2019-ema-decision-22-march-2019-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip02-11-m03_en.pdf"},
    {"id":"44882","name":"P/0139/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for nonacog beta pegol (Refixia), (EMEA-000731-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T15:33:00Z","last_updated_date":"2019-06-25T15:33:00Z","reference_number":"EMA/216038/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-nonacog-beta-pegol-refixia-emea-000731-pip01-09-m03_en.pdf"},
    {"id":"44883","name":"P/0123/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for selexipag (Uptravi), (EMEA-000997-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T16:21:00Z","last_updated_date":"2019-06-25T16:21:00Z","reference_number":"EMA/182557/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan-selexipag-uptravi-emea-000997-pip01-10-m02_en.pdf"},
    {"id":"44884","name":"P/0087/2019: EMA decision of 22 March 2019 on the refusal of a modification of an agreed paediatric investigation plan for chemically modified house dust mites allergen extract of Dermatophagoides pteronyssinus and ... (EMEA-001011-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T16:26:00Z","last_updated_date":"2019-06-25T16:26:00Z","reference_number":"EMA/107418/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2019-ema-decision-22-march-2019-refusal-modification-agreed-paediatric-investigation-plan-chemically-modified-house-dust-mites-allergen-extract-dermatophagoides-pteronyssinus-emea-001011-pip01_en.pdf"},
    {"id":"44886","name":"P/0086/2019: EMA decision of 22 March 2019 on the refusal of a modification of an agreed paediatric investigation plan for chemically modified extract of trees pollen from birch and alder (EMEA-001012-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-06-25T16:30:00Z","last_updated_date":"2019-06-25T16:30:00Z","reference_number":"EMA/112119/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2019-ema-decision-22-march-2019-refusal-modification-agreed-paediatric-investigation-plan-chemically-modified-extract-trees-pollen-birch-alder-emea-001012-pip01-10-m01_en.pdf"},
    {"id":"45816","name":"P/0178/2019: EMA decision of 15 May 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ustekinumab (Stelara), (EMEA-000311-PIP06-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/227159/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2019-ema-decision-15-may-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ustekinumab-stelara-emea-000311-pip06-18_en.pdf"},
    {"id":"45817","name":"P/0171/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for carfilzomib (Kyprolis), (EMEA-001806-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/241905/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2019-ema-decision-15-may-2019-granting-product-specific-waiver-carfilzomib-kyprolis-emea-001806-pip03-18_en.pdf"},
    {"id":"45818","name":"P/0186/2019: EMA decision of 15 May 2019 on the agreement of a PIP and on granting of a deferral and waiver for synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/256057/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2019-ema-decision-15-may-2019-agreement-pip-granting-deferral-waiver-synthetic-double-stranded-sirna-oligonucleotide-directed-against-antithrombin-mrna-covalently-linked-ligand-containing_en.pdf"},
    {"id":"45819","name":"P/0179/2019: EMA decision of 15 May 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium bromide","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/227156/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2019-ema-decision-15-may-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-beclometasone-dipropionate-formoterol-fumarate-dihydrate-glycopyrronium-bromide_en.pdf"},
    {"id":"45820","name":"P/0181/2019: EMA decision of 15 May 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efpeglenatide (EMEA-001903-PIP01-15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/241935/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2019-ema-decision-15-may-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-efpeglenatide-emea-001903-pip01-15_en.pdf"},
    {"id":"45821","name":"P/0167/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for niraparib (Zejula), (EMEA-002268-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/227256/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2019-ema-decision-15-may-2019-granting-product-specific-waiver-niraparib-zejula-emea-002268-pip03-18_en.pdf"},
    {"id":"45822","name":"P/0177/2019: EMA decision of 15 May 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for dusquetide (EMEA-002306-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/241937/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2019-ema-decision-15-may-2019-agreement-paediatric-investigation-plan-granting-deferral-dusquetide-emea-002306-pip02-18_en.pdf"},
    {"id":"45823","name":"P/0180/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for ibandronic acid (in the form of ibandronate sodium monohydrate) (EMEA-002331-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/241913/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2019-ema-decision-15-may-2019-granting-product-specific-waiver-ibandronic-acid-form-ibandronate-sodium-monohydrate-emea-002331-pip01-18_en.pdf"},
    {"id":"45824","name":"P/0122/2019: EMA decision of 6 May 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ofatumumab (EMEA-002397-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/182988/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2019-ema-decision-6-may-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ofatumumab-emea-002397-pip01-18_en.pdf"},
    {"id":"45825","name":"P/0191/2019: EMA decision of 17 May 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for N-(trans-3-(5- ((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl) cyclobutyl)-3-phenylisoxazole-5-carboxamide (PTI-428)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/256056/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2019-ema-decision-17-may-2019-agreement-paediatric-investigation-plan-granting-deferral-n-trans-3-5-r-1-hydroxyethyl-134-oxadiazol-2-yl-cyclobutyl-3-phenylisoxazole-5-carboxamide-pti-428_en.pdf"},
    {"id":"45826","name":"P/0168/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for humanized antibody targeting B cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F (EMEA-002468-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/227254/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2019-ema-decision-15-may-2019-granting-product-specific-waiver-humanized-antibody-targeting-b-cell-maturation-antigen-conjugated-maleimidocaproyl-monomethyl-auristatin-f-emea-002468-pip02-18_en.pdf"},
    {"id":"45827","name":"P/0175/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for recombinant human lecithin cholesterol acyltransferase (EMEA-002497-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/216802/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2019-ema-decision-15-may-2019-granting-product-specific-waiver-recombinant-human-lecithin-cholesterol-acyltransferase-emea-002497-pip01-18_en.pdf"},
    {"id":"45828","name":"P/0188/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for pantoprazole (in combination with amoxicillin + clarithromycin) (EMEA-002512-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/256065/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2019-ema-decision-15-may-2019-granting-product-specific-waiver-pantoprazole-combination-amoxicillin-clarithromycin-emea-002512-pip01-18_en.pdf"},
    {"id":"45829","name":"P/0170/2019: EMA decision of 15 May 2019 on the agreement of a paediatric investigation plan and on the granting of a waiver for mometasone (furoate monohydrate) / olopatadine (hydrochloride) (gsp 301 ns) (EMEA-002514-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/227151/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2019-ema-decision-15-may-2019-agreement-paediatric-investigation-plan-granting-waiver-mometasone-furoate-monohydrate-olopatadine-hydrochloride-gsp-301-ns-emea-002514-pip01-18_en.pdf"},
    {"id":"45830","name":"P/0187/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for candesartan / atorvastatin / amlodipine (EMEA-002520-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/216790/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2019-ema-decision-15-may-2019-granting-product-specific-waiver-candesartan-atorvastatin-amlodipine-emea-002520-pip01-18_en.pdf"},
    {"id":"45831","name":"P/0192/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for seladelpar (EMEA-002527-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/216782/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2019-ema-decision-15-may-2019-granting-product-specific-waiver-seladelpar-emea-002527-pip01-18_en.pdf"},
    {"id":"45832","name":"P/0185/2019: EMA decision of 15 May 2019 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for salbutamol sulfate / budesonide (EMEA-002533-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/241977/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2019-ema-decision-15-may-2019-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-salbutamol-sulfate-budesonide-emea-002533-pip01-18_en.pdf"},
    {"id":"45833","name":"P/0184/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for amoxicillin (in combination with pantoprazole + clarithromycin) (EMEA-002548-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/256067/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2019-ema-decision-15-may-2019-granting-product-specific-waiver-amoxicillin-combination-pantoprazole-clarithromycin-emea-002548-pip01-19_en.pdf"},
    {"id":"45838","name":"P/0183/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for clarithromycin (in combination with pantoprazole + amoxicillin) (EMEA-002549-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/256070/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2019-ema-decision-15-may-2019-granting-product-specific-waiver-clarithromycin-combination-pantoprazole-amoxicillin-emea-002549-pip01-19_en.pdf"},
    {"id":"45839","name":"P/0182/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for colecalciferol (EMEA-002553-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-29T10:01:00Z","last_updated_date":"2019-10-29T10:01:00Z","reference_number":"EMA/241908/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2019-ema-decision-15-may-2019-granting-product-specific-waiver-colecalciferol-emea-002553-pip01-19_en.pdf"},
    {"id":"45842","name":"P/0174/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira), (EMEA-000366-PIP02-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/241891/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-adalimumab-humira-emea-000366-pip02-09-m06_en.pdf"},
    {"id":"45843","name":"P/0190/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ruxolitinib (phosphate) (Jakavi), (EMEA-000901-PIP03-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/256023/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-ruxolitinib-phosphate-jakavi-emea-000901-pip03-16-m01_en.pdf"},
    {"id":"45844","name":"P/0176/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for asfotase alfa (Strensiq), (EMEA-000987-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/241894/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-asfotase-alfa-strensiq-emea-000987-pip01-10-m04_en.pdf"},
    {"id":"45845","name":"P/0195/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocouture), (EMEA-001039-PIP02-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/256024/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-clostridium-botulinum-neurotoxin-type-150-kd-free-complexing-proteins-xeomin-bocouture-emea-001039_en.pdf"},
    {"id":"45846","name":"P/0189/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for deferiprone (EMEA-001126-PIP01-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/216915/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-deferiprone-emea-001126-pip01-10-m03_en.pdf"},
    {"id":"45847","name":"P/0165/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/216892/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip01-11-m05_en.pdf"},
    {"id":"45848","name":"P/0196/2019: EMA decision of 20 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for macrogol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride (NER1006) (Plenvu)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/275952/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2019-ema-decision-20-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-macrogol-3350-sodium-ascorbate-sodium-sulfate-ascorbic-acid-sodium-chloride-potassium-chloride-ner1006_en.pdf"},
    {"id":"45849","name":"P/0173/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for imipenem (monohydrate) / cilastatin (sodium) / relebactam (MK-7655A) (EMEA-001809-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/216887/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-imipenem-monohydrate-cilastatin-sodium-relebactam-mk-7655a-emea-001809-pip01-15-m01_en.pdf"},
    {"id":"45850","name":"P/0164/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for EMEA-001930-PIP01-16-M01","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/243698/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-emea-001930-pip01-16-m01_en.pdf"},
    {"id":"45851","name":"P/0194/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for gilteritinib (as fumarate) (EMEA-002064-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/256028/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-gilteritinib-fumarate-emea-002064-pip01-16-m01_en.pdf"},
    {"id":"45852","name":"P/0166/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for Fc- and CDRmodified humanised monoclonal antibody against C5 (EMEA-002077-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/216880/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-fc-cdrmodified-humanised-monoclonal-antibody-against-c5-emea-002077-pip01-16-m02_en.pdf"},
    {"id":"45853","name":"P/0193/2019: EMA decision of 13 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for isatuximab (EMEA-002205-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/254762/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2019-ema-decision-13-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-isatuximab-emea-002205-pip01-17-m01_en.pdf"}    {"id":"45859","name":"P/0172/2019: EMA decision of 15 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for omecamtiv mecarbil (EMEA-001696-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/226842/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2019-ema-decision-15-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-omecamtiv-mecarbil-emea-001696-pip01-14-m01_en.pdf"},
    {"id":"45860","name":"P/0196/2019: EMA decision of 20 May 2019 on the acceptance of a modification of an agreed paediatric investigation plan for macrogol 3350 / sodium ascorbate / sodium sulfate / ascorbic acid / sodium chloride / potassium chloride (NER1006) (Plenvu)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-10-30T10:01:00Z","last_updated_date":"2019-10-30T10:01:00Z","reference_number":"EMA/275952/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2019-ema-decision-20-may-2019-acceptance-modification-agreed-paediatric-investigation-plan-macrogol-3350-sodium-ascorbate-sodium-sulfate-ascorbic-acid-sodium-chloride-potassium-chloride-ner1006_en.pdf-0"},
    {"id":"45902","name":"P/0222/2019: EMA decision of 21 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tilsotolimod (or IMO-2125) (EMEA-002318-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/338388/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2019-ema-decision-21-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-tilsotolimod-or-imo-2125-emea-002318-pip03-19_en.pdf"},
    {"id":"45903","name":"P/0202/2019: EMA decision of 12June 2019 on the granting of a product specific waiver for abemaciclib (Verzenios), (EMEA-002342-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/288547/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2019-ema-decision-12june-2019-granting-product-specific-waiver-abemaciclib-verzenios-emea-002342-pip03-18_en.pdf"},
    {"id":"45904","name":"P/0213/2019: EMA decision of 14 June 2019 on the agreement of a paediatric investigation plan and on the granting of a waiver for lentiviral vector containing the human ABCA4 gene (SAR422459) (EMEA-002407-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/299187/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2019-ema-decision-14-june-2019-agreement-paediatric-investigation-plan-granting-waiver-lentiviral-vector-containing-human-abca4-gene-sar422459-emea-002407-pip01-18_en.pdf"},
    {"id":"45905","name":"P/0210/2019: EMA decision of 12 June 2019 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for dexamethasone (EMEA-002423-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/288637/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2019-ema-decision-12-june-2019-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-dexamethasone-emea-002423-pip01-18_en.pdf"},
    {"id":"45906","name":"P/0218/2019: EMA decision of 17 June 2019 on the agreement of a PIP and on the granting of a deferral for adeno-associated viral vector serotype 5 containing a B domain deleted variant of human coagulation factor VIII gene (BMN 270) (EMEA-002427-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/275986/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2019-ema-decision-17-june-2019-agreement-pip-granting-deferral-adeno-associated-viral-vector-serotype-5-containing-b-domain-deleted-variant-human-coagulation-factor-viii-gene-bmn-270-emea_en.pdf"},
    {"id":"45907","name":"P/0208/2019: EMA decision of 12 June 2019 on the granting of a product specific waiver for Glu-NH-CO-NH-Lys-(Ahx)-[N,N9-bis[2-hydroxy-5-(carboxyethyl) benzyl]ethylenediamine-N,N9-diacetic acid (PSMA11-HBED-CC) (HBED Trasis), (EMEA-002503-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/275977/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2019-ema-decision-12-june-2019-granting-product-specific-waiver-glu-nh-co-nh-lys-ahx-nn9-bis2-hydroxy-5-carboxyethyl-benzylethylenediamine-nn9-diacetic-acid-psma11-hbed-cc-hbed-trasis-emea_en.pdf"},
    {"id":"45908","name":"P/0215/2019: EMA decision of 14 June 2019 on the refusal of a product specific waiver for 2-(2-(3-Butoxy-phenyl)-ethylamino)-N,N-dimethyl-acetamide hydrochloride (EMEA-002519-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/299172/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2019-ema-decision-14-june-2019-refusal-product-specific-waiver-2-2-3-butoxy-phenyl-ethylamino-nn-dimethyl-acetamide-hydrochloride-emea-002519-pip02-18_en.pdf"},
    {"id":"45910","name":"P/0216/2019: EMA decision of 12 June 2019 on the granting of a product specific waiver for tisotumab vedotin (EMEA-002522-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/288515/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2019-ema-decision-12-june-2019-granting-product-specific-waiver-tisotumab-vedotin-emea-002522-pip01-18_en.pdf"},
    {"id":"45911","name":"P/0212/2019: EMA decision of 13 June 2019 on the granting of a product specific waiver for ramipril / bisoprolol (EMEA-002531-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/275981/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2019-ema-decision-13-june-2019-granting-product-specific-waiver-ramipril-bisoprolol-emea-002531-pip01-18_en.pdf"},
    {"id":"45912","name":"P/0200/2019: EMA decision of 12 June 2019 on the granting of a product specific waiver for emiplacel (EMEA-002539-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/304524/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2019-ema-decision-12-june-2019-granting-product-specific-waiver-emiplacel-emea-002539-pip01-18_en.pdf"},
    {"id":"45913","name":"P/0211/2019: EMA decision of 14 June 2019 on the granting of a product specific waiver for sutimlimab (EMEA-002542-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/299175/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2019-ema-decision-14-june-2019-granting-product-specific-waiver-sutimlimab-emea-002542-pip01-18_en.pdf"},
    {"id":"45915","name":"P/0214/2019: EMA decision of 12 June 2019 on the granting of a product specific waiver for capivasertib (EMEA-002551-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-07T10:01:00Z","last_updated_date":"2019-11-07T10:01:00Z","reference_number":"EMA/289392/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2019-ema-decision-12-june-2019-granting-product-specific-waiver-capivasertib-emea-002551-pip01-18_en.pdf"},
    {"id":"45919","name":"P/0205/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (EDURANT), (EMEA-000317-PIP01-08-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/287182/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-edurant-emea-000317-pip01-08-m11_en.pdf"},
    {"id":"45920","name":"P/0217/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (Fycompa), (EMEA-000467-PIP01-08-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/275958/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-fycompa-emea-000467-pip01-08-m11_en.pdf"},
    {"id":"45921","name":"P/0223/2019: EMA decision of 21 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for posaconazole (Noxafil), (EMEA-000468-PIP02-12-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/338825/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2019-ema-decision-21-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-posaconazole-noxafil-emea-000468-pip02-12-m05_en.pdf"},
    {"id":"45922","name":"P/0209/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (LENVIMA, Kisplyx), (EMEA-001119-PIP02-12-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/275963/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-lenvima-kisplyx-emea-001119-pip02-12-m05_en.pdf"},
    {"id":"45923","name":"P/0221/2019: EMA decision of 17 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for terbinafine (hydrochloride) (EMEA-001259-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/327869/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2019-ema-decision-17-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-terbinafine-hydrochloride-emea-001259-pip02-13-m02_en.pdf"},
    {"id":"45924","name":"P/0204/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for obeticholic acid (Ocaliva), (EMEA-001304-PIP02-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/287170/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-obeticholic-acid-ocaliva-emea-001304-pip02-13-m04_en.pdf"},
    {"id":"45925","name":"P/0201/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ibrutinib (Imbruvica), (EMEA-001397-PIP03-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/275965/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-ibrutinib-imbruvica-emea-001397-pip03-14-m04_en.pdf"},
    {"id":"45926","name":"P/0197/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (EMEA-001441-PIP02-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/289393/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-semaglutide-emea-001441-pip02-15-m02_en.pdf"},
    {"id":"45927","name":"P/0220/2019: EMA decision of 17 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for humanised anti-IL-6 receptor (IL-6R) monoclonal antibody (EMEA-001625-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/327378/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2019-ema-decision-17-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-humanised-anti-il-6-receptor-il-6r-monoclonal-antibody-emea-001625-pip01-14-m03_en.pdf"},
    {"id":"45928","name":"P/0207/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for atezolizumab (Tecentriq), (EMEA-001638-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/287009/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-atezolizumab-tecentriq-emea-001638-pip01-14-m02_en.pdf"},
    {"id":"45929","name":"P/0199/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (ALXN1210) (EMEA-001943-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/287178/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-alxn1210-emea-001943-pip01-16-m02_en.pdf"},
    {"id":"45930","name":"P/0198/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (JCAR017) (EMEA-001995-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd4-cd8-t-cells-expressing-cd19-specific-chimeric-antigen-receptor-jcar017-emea-001995_en.pdf"},
    {"id":"45931","name":"P/0203/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for palbociclib (IBRANCE), (EMEA-002146-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/287173/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-palbociclib-ibrance-emea-002146-pip01-17-m01_en.pdf"},
    {"id":"45932","name":"P/0206/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for daratumumab (Darzalex) (EMEA-002152-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/289405/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2019-ema-decision-12-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-daratumumab-darzalex-emea-002152-pip01-17-m01_en.pdf"},
    {"id":"45933","name":"P/0219/2019: EMA decision of 17 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant Influenza Hemagglutinin-strain A (H1N1 and H3N2 subtypes) and strain-B (Victoria lineage and Yamagata lineage)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/324014/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2019-ema-decision-17-june-2019-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-influenza-hemagglutinin-strain-h1n1-h3n2-subtypes-strain-b-victoria-lineage-yamagata_en.pdf"},
    {"id":"45949","name":"P/0249/2019: EMA decision of 17 June 2019 on the granting of a product specific waiver for momelotinib (EMEA-001656-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/364985/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2019-ema-decision-17-june-2019-granting-product-specific-waiver-momelotinib-emea-001656-pip02-19_en.pdf"},
    {"id":"45950","name":"P/0234/2019: EMA decision of 16 June 2019 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human βA-T87Q-globin gene","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T10:01:00Z","last_updated_date":"2019-11-08T10:01:00Z","reference_number":"EMA/369846/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2019-ema-decision-16-june-2019-agreement-pip-granting-deferral-granting-waiver-autologous-cd34-haematopoietic-stem-cells-transduced-lentiviral-vector-encoding-human-ba-t87q-globin-gene_en.pdf"},
    {"id":"45971","name":"P/0233/2019: EMA decision of 16 July 2019 on the granting of a product specific waiver for bempedoic acid (EMEA-001872-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-12T10:01:00Z","last_updated_date":"2019-11-12T10:01:00Z","reference_number":"EMA/369847/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2019-ema-decision-16-july-2019-granting-product-specific-waiver-bempedoic-acid-emea-001872-pip02-19_en.pdf"},
    {"id":"45972","name":"P/0268/2019: EMA decision of 25 July 2019 on the refusal of a paediatric investigation plan and on the granting of a waiver for hydrogen peroxide (45%) (EMEA-001884-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-12T10:01:00Z","last_updated_date":"2019-11-12T10:01:00Z","reference_number":"EMA/408892/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2019-ema-decision-25-july-2019-refusal-paediatric-investigation-plan-granting-waiver-hydrogen-peroxide-45-emea-001884-pip03-18_en.pdf"},
    {"id":"45973","name":"P/0232/2019: EMA decision of 16 July 2019 on the granting of a product specific waiver for bempedoic acid / ezetimibe (EMEA-002200-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-12T10:01:00Z","last_updated_date":"2019-11-12T10:01:00Z","reference_number":"EMA/385584/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2019-ema-decision-16-july-2019-granting-product-specific-waiver-bempedoic-acid-ezetimibe-emea-002200-pip02-19_en.pdf"},
    {"id":"45974","name":"P/0243/2019: EMA decision of 17 July 2019 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for ACH-0144471 (EMEA-002310-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/364990/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2019-ema-decision-17-july-2019-agreement-pip-granting-deferral-granting-waiver-ach-0144471-emea-002310-pip02-17_en.pdf"},
    {"id":"45975","name":"P/0231/2019: EMA decision of 16 July 2019 on the refusal of a paediatric investigation plan and on the granting of a waiver for diphtheria toxoid / tetanus toxoid / pertussis toxoid / pertussis filamentous haemagglutinin / pertactin (EMEA-002343-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/385570/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2019-ema-decision-16-july-2019-refusal-paediatric-investigation-plan-granting-waiver-diphtheria-toxoid-tetanus-toxoid-pertussis-toxoid-pertussis-filamentous-haemagglutinin-pertactin-emea-002343_en.pdf"},
    {"id":"45976","name":"P/0262/2019: EMA decision of 19 July 2019 on the agreement of a PIP and on granting of a deferral and a waiver for 6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4 triazol-3- yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide (BMS-986165)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/393335/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2019-ema-decision-19-july-2019-agreement-pip-granting-deferral-waiver-6-cyclopropaneamido-4-2-methoxy-3-1-methyl-1h-124-triazol-3-ylphenylamino-n-2h3methylpyridazine-3-carboxamide-bms-986165_en.pdf"},
    {"id":"45977","name":"P/0242/2019: EMA decision of 17 July 2019 on the refusal of a paediatric investigation plan and on the granting of a waiver for dexamethasone (sodium phosphate) / levofloxacin (EMEA-002375-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/364992/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2019-ema-decision-17-july-2019-refusal-paediatric-investigation-plan-granting-waiver-dexamethasone-sodium-phosphate-levofloxacin-emea-002375-pip02-18_en.pdf"},
    {"id":"45978","name":"P/0241/2019: EMA decision of 17 July 2019 on the granting of a product specific waiver for bemarituzumab (EMEA-002401-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/390921/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2019-ema-decision-17-july-2019-granting-product-specific-waiver-bemarituzumab-emea-002401-pip01-18_en.pdf"},
    {"id":"45979","name":"P/02430/2019: EMA decision of 16 July 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for emricasan (EMEA-002457-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/339018/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-02430-2019-ema-decision-16-july-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-emricasan-emea-002457-pip01-18_en.pdf"},
    {"id":"45980","name":"P/0229/2019: EMA decision of 16 July 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tropifexor (EMEA-002471-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/339062/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2019-ema-decision-16-july-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tropifexor-emea-002471-pip01-18_en.pdf"},
    {"id":"45981","name":"P/0227/2019: EMA decision of 8 July 2019 on the refusal of a paediatric investigation plan for genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII (EMEA-002472-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/380136/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2019-ema-decision-8-july-2019-refusal-paediatric-investigation-plan-genetically-modified-replication-incompetent-herpes-simplex-virus-1-expressing-collagen-vii-emea-002472-pip02-19_en.pdf"},
    {"id":"45982","name":"P/0258/2019: EMA decision of 16 July 2019 on the agreement of a paediatric investigation plan and on the granting of a waiver for lonafarnib (EMEA-002516-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/339066/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2019-ema-decision-16-july-2019-agreement-paediatric-investigation-plan-granting-waiver-lonafarnib-emea-002516-pip01-18_en.pdf"},
    {"id":"45983","name":"P/0228/2019: EMA decision of 16 July 2019 on the granting of a product specific waiver for moxetumomab pasudotox (EMEA-002525-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/369848/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2019-ema-decision-16-july-2019-granting-product-specific-waiver-moxetumomab-pasudotox-emea-002525-pip01-18_en.pdf"},
    {"id":"45984","name":"P/0259/2019: EMA decision of 29 July 2019 on the granting of a product specific waiver for rosuvastatin (calcium) / ezetimibe (EMEA-002541-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/338928/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2019-ema-decision-29-july-2019-granting-product-specific-waiver-rosuvastatin-calcium-ezetimibe-emea-002541-pip01-18_en.pdf"},
    {"id":"45985","name":"P/0257/2019: EMA decision of 16 July 2019 on the granting of a product specific waiver for heparin (sodium) (EMEA-002557-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/338919/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2019-ema-decision-16-july-2019-granting-product-specific-waiver-heparin-sodium-emea-002557-pip01-19_en.pdf"},
    {"id":"45986","name":"P/0255/2019: EMA decision of 16 July 2019 on the refusal of a paediatric investigation plan and on the granting of a waiver for brimonidine (EMEA-002558-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/339076/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2019-ema-decision-16-july-2019-refusal-paediatric-investigation-plan-granting-waiver-brimonidine-emea-002558-pip01-19_en.pdf"},
    {"id":"45987","name":"P/0254/2019: EMA decision of 17 July 2019 on the granting of a product specific waiver for bisoprolol fumarate / ramipril, (EMEA-002560-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/364987/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2019-ema-decision-17-july-2019-granting-product-specific-waiver-bisoprolol-fumarate-ramipril-emea-002560-pip01-19_en.pdf"},
    {"id":"45988","name":"P/0266/2019: EMA decision of 26 July 2019 on the granting of a product specific waiver for BLU-667, (EMEA-002575-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/404549/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2019-ema-decision-26-july-2019-granting-product-specific-waiver-blu-667-emea-002575-pip01-19_en.pdf"},
    {"id":"45989","name":"P/0240/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for concentrate of proteolytic enzymes in bromelain (NexoBrid), (EMEA-000142-PIP02-09-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/313773/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-concentrate-proteolytic-enzymes-bromelain-nexobrid-emea-000142-pip02-09-m08_en.pdf"},
    {"id":"45991","name":"P/0260/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for belatacept (Nulojix), (EMEA-000157-PIP01-07-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/393680/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-belatacept-nulojix-emea-000157-pip01-07-m04_en.pdf"},
    {"id":"45992","name":"P/0253/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tocilizumab (RoActemra) (EMEA-000309-PIP04-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-13T10:01:00Z","last_updated_date":"2019-11-13T10:01:00Z","reference_number":"EMA/397438/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-tocilizumab-roactemra-emea-000309-pip04-17-m02_en.pdf"},
    {"id":"45993","name":"P/0224/2019: EMA decision of 5 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for birch, hazel and alder pollen extracts (EMEA-000808-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:01:00Z","last_updated_date":"2019-11-14T10:01:00Z","reference_number":"EMA/357144/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2019-ema-decision-5-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-birch-hazel-alder-pollen-extracts-emea-000808-pip01-09-m01_en.pdf"},
    {"id":"45994","name":"P/0225/2019: EMA decision of 5 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for dermatophagoides pteronyssinus and dermatophagoides farinae extracts 50% / 50% (EMEA-000815-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:01:00Z","last_updated_date":"2019-11-14T10:01:00Z","reference_number":"EMA/357099/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2019-ema-decision-5-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-dermatophagoides-pteronyssinus-dermatophagoides-farinae-extracts-50-50-emea-000815-pip01-09-m01_en.pdf"},
    {"id":"45995","name":"P/0252/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP03-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:01:00Z","last_updated_date":"2019-11-14T10:01:00Z","reference_number":"EMA/369854/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip03-14-m03_en.pdf"},
    {"id":"45996","name":"P/0267/2019: EMA decision of 25 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for fosnetupitant / palonosetron (Akynzeo), (EMEA-001198-PIP03-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:01:00Z","last_updated_date":"2019-11-14T10:01:00Z","reference_number":"EMA/408776/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2019-ema-decision-25-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-fosnetupitant-palonosetron-akynzeo-emea-001198-pip03-17-m02_en.pdf"},
    {"id":"45997","name":"P/0239/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant) (EMEA-001220-PIP03-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:01:00Z","last_updated_date":"2019-11-14T10:01:00Z","reference_number":"EMA/369859/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip03-16-m01_en.pdf"},
    {"id":"45998","name":"P/0226/2019: EMA decision of 5 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tedizolid (phosphate) (Sivextro), (EMEA-001379-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:01:00Z","last_updated_date":"2019-11-14T10:01:00Z","reference_number":"EMA/369861/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2019-ema-decision-5-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-tedizolid-phosphate-sivextro-emea-001379-pip01-12-m04_en.pdf"},
    {"id":"45999","name":"P/0261/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ixazomib (Ninlaro) (EMEA-001410-PIP02-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:01:00Z","last_updated_date":"2019-11-14T10:01:00Z","reference_number":"EMA/395082/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-ixazomib-ninlaro-emea-001410-pip02-17-m02_en.pdf"},
    {"id":"46000","name":"P/0238/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for esketamine (hydrochloride) (EMEA-001428-PIP03-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:01:00Z","last_updated_date":"2019-11-14T10:01:00Z","reference_number":"EMA/313726/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-esketamine-hydrochloride-emea-001428-pip03-15-m01_en.pdf"},
    {"id":"46001","name":"P/0237/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for fentanyl (hydrochloride) (EMEA-001509-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:01:00Z","last_updated_date":"2019-11-14T10:01:00Z","reference_number":"EMA/313772/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-fentanyl-hydrochloride-emea-001509-pip01-13-m02_en.pdf"},
    {"id":"46002","name":"P/0236/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for testosterone (EMEA-001529-PIP02-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:01:00Z","last_updated_date":"2019-11-14T10:01:00Z","reference_number":"EMA/385555/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-testosterone-emea-001529-pip02-14-m02_en.pdf"},
    {"id":"46003","name":"P/0251/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for eravacycline (Xerava), (EMEA-001555-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-18T10:01:00Z","last_updated_date":"2019-11-18T10:01:00Z","reference_number":"EMA/369862/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-eravacycline-xerava-emea-001555-pip01-13-m03_en.pdf"},
    {"id":"46004","name":"P/0235/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for afatinib (Giotrif), (EMEA-001596-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-18T10:01:00Z","last_updated_date":"2019-11-18T10:01:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-afatinib-giotrif-emea-001596-pip02-17-m01_en.pdf"},
    {"id":"46005","name":"P/0263/2019: EMA decision of 19 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tezepelumab (EMEA- 001613-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-18T10:01:00Z","last_updated_date":"2019-11-18T10:01:00Z","reference_number":"EMA/399635/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2019-ema-decision-19-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-tezepelumab-emea-001613-pip01-14-m03_en.pdf"},
    {"id":"46006","name":"P/0250/2019: EMA decision of 17 July 2019 on acceptance of a modification of agreed PIP for 1-(2,2-difluoro-1,3- benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2- methylpropan-2-yl)-1Hindol- 5-yl}cyclopropanecarboxamide /ivacaftor","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-18T10:01:00Z","last_updated_date":"2019-11-18T10:01:00Z","reference_number":"EMA/359088/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2019-ema-decision-17-july-2019-acceptance-modification-agreed-pip-1-22-difluoro-13-benzodioxol-5-yl-n-1-2r-23-dihydroxypropyl-6-fluoro-2-1-hydroxy-2-methylpropan-2-yl-1hindol-5_en.pdf"},
    {"id":"46007","name":"P/0264/2019: EMA decision of 23 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-001853-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-18T10:01:00Z","last_updated_date":"2019-11-18T10:01:00Z","reference_number":"EMA/385558/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2019-ema-decision-23-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-emea-001853-pip01-15-m02_en.pdf"},
    {"id":"46008","name":"P/0248/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for galcanezumab (Emgality), (EMEA-001860-PIP03-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-18T10:01:00Z","last_updated_date":"2019-11-18T10:01:00Z","reference_number":"EMA/319272/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-galcanezumab-emgality-emea-001860-pip03-16-m03_en.pdf"},
    {"id":"46009","name":"P/0265/2019: EMA decision of 23 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for lanadelumab (DX-2930) ( Takhzyro), (EMEA-001864-PIP01-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-18T10:01:00Z","last_updated_date":"2019-11-18T10:01:00Z","reference_number":"EMA/385567/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2019-ema-decision-23-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-lanadelumab-dx-2930-takhzyro-emea-001864-pip01-15-m04_en.pdf"},
    {"id":"46010","name":"P/0247/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for balovaptan (EMEA-001918-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-18T10:01:00Z","last_updated_date":"2019-11-18T10:01:00Z","reference_number":"EMA/369864/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-balovaptan-emea-001918-pip01-15-m02_en.pdf"},
    {"id":"46011","name":"P/0246/2019: EMA decision of 17 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for venetoclax (Venclyxto),(EMEA-002018-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-18T10:01:00Z","last_updated_date":"2019-11-18T10:01:00Z","reference_number":"EMA/359091/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2019-ema-decision-17-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-venetoclax-venclyxtoemea-002018-pip02-16-m02_en.pdf"},
    {"id":"46012","name":"P/0256/2019: EMA decision of 16 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for durvalumab (Imfinzi), (EMEA-0020128-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-19T10:01:00Z","last_updated_date":"2019-11-19T10:01:00Z","reference_number":"EMA/313775/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-durvalumab-imfinzi-emea-0020128-pip01-16-m01_en.pdf"},
    {"id":"46013","name":"P/0245/2019: EMA decision of 17 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tremelimumab (EMEA-002029-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-19T10:01:00Z","last_updated_date":"2019-11-19T10:01:00Z","reference_number":"EMA/359092/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2019-ema-decision-17-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-tremelimumab-emea-002029-pip01-16-m01_en.pdf"},
    {"id":"46014","name":"P/0244/2019: EMA decision of 17 July 2019 on the acceptance of a modification of an agreed paediatric investigation plan for EMEA-002215-PIP01-17-M02","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-19T10:01:00Z","last_updated_date":"2019-11-19T10:01:00Z","reference_number":"EMA/364843/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2019-ema-decision-17-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-emea-002215-pip01-17-m02_en.pdf"},
    {"id":"46056","name":"P/0037/2019: EMA decision of 29 January 2019 on the granting of a product specific waiver for binimetinib (Mektovi), (EMEA-001454-PIP05-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2019-11-19T10:37:00Z","last_updated_date":"2019-11-19T10:37:00Z","reference_number":"EMA/887187/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2019-ema-decision-29-january-2019-granting-product-specific-waiver-binimetinib-mektovi-emea-001454-pip05-18_en.pdf"},
    {"id":"46067","name":"P/0273/2019: EMA decision of 14 August 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for oxalobacter formigenes Strain HC-1 (EMEA-000370-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T09:00:00Z","last_updated_date":"2019-11-20T09:00:00Z","reference_number":"EMA/395099/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2019-ema-decision-14-august-2019-agreement-paediatric-investigation-plan-granting-deferral-oxalobacter-formigenes-strain-hc-1-emea-000370-pip02-18_en.pdf"},
    {"id":"46068","name":"P/0276/2019: EMA decision of 14 August 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vedolizumab (Entyvio) (EMEA-000645-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T09:11:00Z","last_updated_date":"2019-11-20T09:11:00Z","reference_number":"EMA/395100/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2019-ema-decision-14-august-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vedolizumab-entyvio-emea-000645-pip03-18_en.pdf"},
    {"id":"46069","name":"P/0295/2019: EMA decision of 14 August 2019 on the granting of a product specific waiver for mifepristone (EMEA-001437-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T11:00:00Z","last_updated_date":"2019-11-20T11:00:00Z","reference_number":"EMA/392854/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2019-ema-decision-14-august-2019-granting-product-specific-waiver-mifepristone-emea-001437-pip02-19_en.pdf"},
    {"id":"46070","name":"P/0296/2019: EMA decision of 26 August 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bulevirtide (EMEA-002399-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T11:11:00Z","last_updated_date":"2019-11-20T11:11:00Z","reference_number":"EMA/436766/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2019-ema-decision-26-august-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bulevirtide-emea-002399-pip01-18_en.pdf"},
    {"id":"46072","name":"P/0274/2019: EMA decision of 16 August 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for humanized anti-CD19, Fc engineered, monoclonal antibody (XmAb5871) (EMEA-002414-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T12:49:00Z","last_updated_date":"2026-05-06T11:11:11Z","reference_number":"EMA/439014/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2019-ema-decision-16-august-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-humanized-anti-cd19-fc-engineered-monoclonal-antibody-xmab5871-emea-002414-pip01-18_en.pdf"},
    {"id":"46074","name":"P/0299/2019: European medicines agency decision of 14 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for purified antigen fractions of inactivated split virion Influenza A/Vietnam/1194/2004 (H5N1)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T14:25:00Z","last_updated_date":"2019-11-20T14:25:00Z","reference_number":"EMA/444271/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2019-european-medicines-agency-decision-14-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-purified-antigen-fractions-inactivated-split-virion-influenza-vietnam-1194_en.pdf"},
    {"id":"46077","name":"P/0277/2019: EMA decision of 16 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for saxagliptin (Onglyza), (EMEA-000200-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T14:33:00Z","last_updated_date":"2019-11-20T14:33:00Z","reference_number":"EMA/444266/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2019-ema-decision-16-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-saxagliptin-onglyza-emea-000200-pip01-08-m08_en.pdf"},
    {"id":"46078","name":"P/0297/2019: EMA decision of 12 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (Briviact and associated names), (EMEA-000332-PIP01-08-M14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T14:42:00Z","last_updated_date":"2019-11-20T14:42:00Z","reference_number":"EMA/438954/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2019-ema-decision-12-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-associated-names-emea-000332-pip01-08-m14_en.pdf"},
    {"id":"46079","name":"P/0272/2019: EMA decision of 14 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for eslicarbazepine (acetate) (Zebinix) (EMEA-000696-PIP02-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T14:46:00Z","last_updated_date":"2019-11-20T14:46:00Z","reference_number":"EMA/395096/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2019-ema-decision-14-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-eslicarbazepine-acetate-zebinix-emea-000696-pip02-10-m06_en.pdf"},
    {"id":"46080","name":"P/0270/2020 : EMA decision of 17 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (Bosulif) (EMEA-000727-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-24T16:45:00Z","last_updated_date":"2021-06-24T16:45:00Z","reference_number":"EMA/366568/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2020-ema-decision-17-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-bosutinib-bosulif-emea-000727-pip01-09-m04_en.pdf"},
    {"id":"46081","name":"P/0280/2019: EMA decision of 16 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz), (EMEA-001050-PIP02-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T15:01:00Z","last_updated_date":"2019-11-20T15:01:00Z","reference_number":"EMA/444267/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2019-ema-decision-16-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-ixekizumab-taltz-emea-001050-pip02-18-m01_en.pdf"},
    {"id":"46082","name":"P/0271/2019: EMA decision of 14 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for delamanid (Deltyba), (EMEA-001113-PIP01-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T15:07:00Z","last_updated_date":"2019-11-20T15:07:00Z","reference_number":"EMA/392697/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2019-ema-decision-14-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-delamanid-deltyba-emea-001113-pip01-10-m06_en.pdf"},
    {"id":"46083","name":"P/0269/2019: EMA decision of 14 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for octenidine (dihydrochloride) (Laryngomedin Octenidin Antisept and associated names), (EMEA-001514-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T15:24:00Z","last_updated_date":"2019-11-20T15:24:00Z","reference_number":"EMA/392672/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2019-ema-decision-14-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-octenidine-dihydrochloride-laryngomedin-octenidin-antisept-associated-names-emea-001514-pip01-13_en.pdf"},
    {"id":"46084","name":"P/0279/2019: EMA decision of 16 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for selumetinib, (EMEA-001585-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T15:33:00Z","last_updated_date":"2019-11-20T15:33:00Z","reference_number":"EMA/441048/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2019-ema-decision-16-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-selumetinib-emea-001585-pip01-13-m03_en.pdf"},
    {"id":"46085","name":"P/0285/2019: EMA decision of 16 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for fluciclovine (18F) (Axumin), (EMEA-001644-PIP02-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T15:45:00Z","last_updated_date":"2019-11-20T15:45:00Z","reference_number":"EMA/436662/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2019-ema-decision-16-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-fluciclovine-18f-axumin-emea-001644-pip02-14-m01_en.pdf"},
    {"id":"46086","name":"P/0286/2019: EMA decision of 16 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for eteplirsen, (EMEA- 001722-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T15:50:00Z","last_updated_date":"2019-11-20T15:50:00Z","reference_number":"EMA/440000/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2019-ema-decision-16-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-eteplirsen-emea-001722-pip01-14-m02_en.pdf"},
    {"id":"46087","name":"P/0292/2019: EMA decision of 14 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for daunorubicin / cytarabine (Vyxeos), (EMEA-001858-PIP02-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T15:56:00Z","last_updated_date":"2019-11-20T15:56:00Z","reference_number":"EMA/392701/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2019-ema-decision-14-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-daunorubicin-cytarabine-vyxeos-emea-001858-pip02-16-m03_en.pdf"},
    {"id":"46088","name":"P/0287/2019: EMA decision of 16 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human monoclonal antibody to GM-CSF (GSK3196165), (EMEA-001882-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T16:01:00Z","last_updated_date":"2019-11-20T16:01:00Z","reference_number":"EMA/439236/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2019-ema-decision-16-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-monoclonal-antibody-gm-csf-gsk3196165-emea-001882-pip02-16-m01_en.pdf"},
    {"id":"46089","name":"P/0291/2019: EMA decision of 14 August 2019 on the acceptance of a modification of an agreed paediatric investigation plan for lasmiditan (EMEA-002166-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-20T16:05:00Z","last_updated_date":"2019-11-20T16:05:00Z","reference_number":"EMA/392704/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2019-ema-decision-14-august-2019-acceptance-modification-agreed-paediatric-investigation-plan-lasmiditan-emea-002166-pip01-17-m02_en.pdf"},
    {"id":"46093","name":"P/0278/2019: EMA decision of 16 August 2019 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for relugolix / estradiol / norethisterone acetate (EMEA-002428-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-21T14:28:00Z","last_updated_date":"2019-11-21T14:28:00Z","reference_number":"EMA/444283/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2019-ema-decision-16-august-2019-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-relugolix-estradiol-norethisterone-acetate-emea-002428-pip02-18_en.pdf"},
    {"id":"46097","name":"P/0275/2019: of 16 August 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human immunoglobulin (Ig) G4-variant monoclonal antibody that binds... (EMEA-002464-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-21T14:40:00Z","last_updated_date":"2019-11-21T14:40:00Z","reference_number":"EMA/444284/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2019-16-august-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-immunoglobulin-ig-g4-variant-monoclonal-antibody-binds-emea-002464-pip01-18_en.pdf"},
    {"id":"46099","name":"P/0293/2019: EMA decision of 14 August 2019 on the granting of a product specific waiver for ciclosporin (EMEA-002491-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-21T15:17:00Z","last_updated_date":"2019-11-21T15:17:00Z","reference_number":"EMA/395098/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2019-ema-decision-14-august-2019-granting-product-specific-waiver-ciclosporin-emea-002491-pip02-19_en.pdf"},
    {"id":"46100","name":"P/0298/2019: EMA decision of 14 August 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for bempegaldesleukin (EMEA-002492-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-21T15:24:00Z","last_updated_date":"2019-11-21T15:24:00Z","reference_number":"EMA/444608/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2019-ema-decision-14-august-2019-agreement-paediatric-investigation-plan-granting-deferral-bempegaldesleukin-emea-002492-pip01-18_en.pdf"},
    {"id":"46101","name":"P/0294/2019: EMA decision of 16 August 2019 on the granting of a product specific waiver for tafasitamab, (EMEA-002499-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-21T15:30:00Z","last_updated_date":"2019-11-21T15:30:00Z","reference_number":"EMA/442338/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2019-ema-decision-16-august-2019-granting-product-specific-waiver-tafasitamab-emea-002499-pip02-19_en.pdf"},
    {"id":"46102","name":"P/0281/2019: EMA decision of 16 August 2019 on the granting of a product specific waiver for botulinum toxin type A (EMEA-002521-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-21T16:04:00Z","last_updated_date":"2019-11-21T16:04:00Z","reference_number":"EMA/444279/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2019-ema-decision-16-august-2019-granting-product-specific-waiver-botulinum-toxin-type-emea-002521-pip01-18_en.pdf"}    {"id":"46103","name":"P/0270/2019: EMA decision of 14 August 2019 on the granting of a product specific waiver for istradefylline (EMEA-002540-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-21T16:28:00Z","last_updated_date":"2019-11-21T16:28:00Z","reference_number":"EMA/392859/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2019-ema-decision-14-august-2019-granting-product-specific-waiver-istradefylline-emea-002540-pip01-18_en.pdf"},
    {"id":"46105","name":"P/0283/2019: EMA decision of 16 August 2019 on the granting of a product specific waiver for human chorionic gonadotrophin, (EMEA-002547-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-21T16:54:00Z","last_updated_date":"2019-11-21T16:54:00Z","reference_number":"EMA/441032/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2019-ema-decision-16-august-2019-granting-product-specific-waiver-human-chorionic-gonadotrophin-emea-002547-pip01-19_en.pdf"},
    {"id":"46112","name":"P/0288/2019: EMA decision of 16 August 2019 on the granting of a product specific waiver for anti-neonatal Fc receptor human monoclonal antibody (EMEA-002559-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-22T14:33:00Z","last_updated_date":"2019-11-22T14:33:00Z","reference_number":"EMA/436685/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2019-ema-decision-16-august-2019-granting-product-specific-waiver-anti-neonatal-fc-receptor-human-monoclonal-antibody-emea-002559-pip01-19_en.pdf"},
    {"id":"46113","name":"P/0289/2019: EMA decision of 16 August 2019 on the granting of a product specific waiver for EGFR-cMET bispecific antibody (EMEA-002573-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-22T14:41:00Z","last_updated_date":"2019-11-22T14:41:00Z","reference_number":"EMA/444280/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2019-ema-decision-16-august-2019-granting-product-specific-waiver-egfr-cmet-bispecific-antibody-emea-002573-pip01-19_en.pdf"},
    {"id":"46114","name":"P/0290/2019: EMA decision of 16 August 2019 on the granting of a product specific waiver for gallium 68-labelled Prostate-Specific Membrane Antigen-11 (68Ga-PSMA-11) (EMEA-002577-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2019-11-22T15:03:00Z","last_updated_date":"2019-11-22T15:03:00Z","reference_number":"EMA/436742/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2019-ema-decision-16-august-2019-granting-product-specific-waiver-gallium-68-labelled-prostate-specific-membrane-antigen-11-68ga-psma-11-emea-002577-pip01-19_en.pdf"},
    {"id":"47061","name":"P/0338/2019: EMA decision of 11 September 2019 on the agreement of a paediatric investigation plan for birch bark extract (EMEA-001299-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-20T02:00:00Z","last_updated_date":"2020-03-20T02:00:00Z","reference_number":"EMA/475043/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0338-2019-ema-decision-11-september-2019-agreement-paediatric-investigation-plan-birch-bark-extract-emea-001299-pip03-17_en.pdf"},
    {"id":"47062","name":"P/0325/2019: EMA decision of 11 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for trifarotene (CD5789) (EMEA-001492-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-20T02:00:00Z","last_updated_date":"2020-03-20T02:00:00Z","reference_number":"EMA/466412/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0325-2019-ema-decision-11-september-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-trifarotene-cd5789-emea-001492-pip02-18_en.pdf"},
    {"id":"47063","name":"P/0320/2019: EMA decision of 11 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for pegvorhyaluronidase alfa (EMEA-001883-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-20T02:00:00Z","last_updated_date":"2020-03-20T02:00:00Z","reference_number":"EMA/466413/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2019-ema-decision-11-september-2019-agreement-paediatric-investigation-plan-granting-deferral-pegvorhyaluronidase-alfa-emea-001883-pip03-17_en.pdf"},
    {"id":"47064","name":"P/0317/2019: EMA decision of 11 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fosmetpantotenate (EMEA-002036-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-20T02:00:00Z","last_updated_date":"2020-03-20T02:00:00Z","reference_number":"EMA/466415/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2019-ema-decision-11-september-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fosmetpantotenate-emea-002036-pip01-16_en.pdf"},
    {"id":"47066","name":"P/0342/2019: EMA decision of 10 September 2019 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for Recombinant Hepatitis B Vaccine (EMEA-002157-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-23T02:00:00Z","last_updated_date":"2020-03-23T02:00:00Z","reference_number":"EMA/476526/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0342-2019-ema-decision-10-september-2019-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-recombinant-hepatitis-b-vaccine-emea-002157-pip01-17_en.pdf"},
    {"id":"47067","name":"P/0314/2019: EMA decision of 11 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for eptinezumab (EMEA-002243-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-23T02:00:00Z","last_updated_date":"2020-03-23T02:00:00Z","reference_number":"EMA/440013/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2019-ema-decision-11-september-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-eptinezumab-emea-002243-pip01-17_en.pdf"},
    {"id":"47068","name":"P/0313/2019: EMA decision of 10 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for niraparib (tosylate monohydrate) (Zejula), (EMEA-002268-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-23T02:00:00Z","last_updated_date":"2020-03-23T02:00:00Z","reference_number":"EMA/467517/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2019-ema-decision-10-september-2019-agreement-paediatric-investigation-plan-granting-deferral-niraparib-tosylate-monohydrate-zejula-emea-002268-pip02-18_en.pdf"},
    {"id":"47069","name":"P/0312/2019: EMA decision of 11 September 2019 on the agreement of a paediatric investigation plan and on the granting of a waiver for liposomal ciclosporin A (L-CsA) (EMEA-002344-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-23T02:00:00Z","last_updated_date":"2020-03-23T02:00:00Z","reference_number":"EMA/475044/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2019-ema-decision-11-september-2019-agreement-paediatric-investigation-plan-granting-waiver-liposomal-ciclosporin-l-csa-emea-002344-pip02-18_en.pdf"},
    {"id":"47070","name":"P/0311/2019: EMA decision of 10 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tirzepatide (EMEA-002360-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-23T02:00:00Z","last_updated_date":"2020-03-23T02:00:00Z","reference_number":"EMA/444610/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0311-2019-ema-decision-10-september-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tirzepatide-emea-002360-pip01-18_en.pdf"},
    {"id":"47071","name":"P/0310/2019: EMA decision of 10 September 2019 on the agreement of a PIP and on the granting of a deferral for Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-23T02:00:00Z","last_updated_date":"2020-03-23T02:00:00Z","reference_number":"EMA/476463/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0310-2019-ema-decision-10-september-2019-agreement-pip-granting-deferral-recombinant-adeno-associated-viral-vector-serotype-2-carrying-gene-human-aromatic-l-amino-acid-decarboxylase-protein_en.pdf"},
    {"id":"47072","name":"P/0300/2019: EMA decision of 2 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for baloxavir marboxil (EMEA-002440-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-23T02:00:00Z","last_updated_date":"2020-03-23T02:00:00Z","reference_number":"EMA/440018/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2019-ema-decision-2-september-2019-agreement-paediatric-investigation-plan-granting-deferral-baloxavir-marboxil-emea-002440-pip01-18_en.pdf"},
    {"id":"47073","name":"P/0304/2019: EMA decision of 10 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for equine Immunoglobulin F(ab')2 fragments targeting Shiga toxin (NEAST) (EMEA-002444-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-23T02:00:00Z","last_updated_date":"2020-03-23T02:00:00Z","reference_number":"EMA/467522/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2019-ema-decision-10-september-2019-agreement-paediatric-investigation-plan-granting-deferral-equine-immunoglobulin-fab2-fragments-targeting-shiga-toxin-neast-emea-002444-pip02-18_en.pdf"},
    {"id":"47074","name":"P/0336/2019: EMA decision of 10 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pegylated-fibroblast growth factor 21 (BMS-986036) (EMEA-002448-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T02:00:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/444611/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2019-ema-decision-10-september-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pegylated-fibroblast-growth-factor-21-bms-986036-emea-002448-pip01-18_en.pdf"},
    {"id":"47075","name":"P/0303/2019: EMA decision of 10 September 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for dostarlimab (EMEA-002463-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T02:00:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/467537/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2019-ema-decision-10-september-2019-agreement-paediatric-investigation-plan-granting-deferral-dostarlimab-emea-002463-pip01-18_en.pdf"},
    {"id":"47076","name":"P/0347/2019: EMA decision of 11 September 2019 on the granting of a product specific waiver for belantamab mafodotin (EMEA-002468-PIP04-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T02:00:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/439999/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0347-2019-ema-decision-11-september-2019-granting-product-specific-waiver-belantamab-mafodotin-emea-002468-pip04-19_en.pdf"},
    {"id":"47077","name":"P/0302/2019: EMA decision of 10 September 2019 on the agreement of a paediatric investigation plan and on the granting of a waiver for levonorgestrel (EMEA-002474-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T02:00:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/467544/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2019-ema-decision-10-september-2019-agreement-paediatric-investigation-plan-granting-waiver-levonorgestrel-emea-002474-pip02-18_en.pdf"},
    {"id":"47078","name":"P/0343/2019: EMA decision of 11 September 2019 on the granting of a product specific waiver for rosuvastatin / ramipril (EMEA-002569-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T02:00:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/466404/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0343-2019-ema-decision-11-september-2019-granting-product-specific-waiver-rosuvastatin-ramipril-emea-002569-pip01-19_en.pdf"},
    {"id":"47079","name":"P/0309/2019: EMA decision of 10 September 2019 on the granting of a product specific waiver for atropine (sulfate) / obidoxime (chloride) (EMEA-002570-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T02:00:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/467502/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0309-2019-ema-decision-10-september-2019-granting-product-specific-waiver-atropine-sulfate-obidoxime-chloride-emea-002570-pip01-19_en.pdf"},
    {"id":"47080","name":"P/0308/2019: EMA decision of 10 September 2019 on the granting of a product specific waiver for zofenopril / nebivolol (EMEA-002593-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T02:00:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/476686/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2019-ema-decision-10-september-2019-granting-product-specific-waiver-zofenopril-nebivolol-emea-002593-pip01-19_en.pdf"},
    {"id":"47081","name":"P/0301/2019: EMA decision of 10 September 2019 on the granting of a product specific waiver for infigratinib (EMEA-002594-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T02:00:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/467512/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2019-ema-decision-10-september-2019-granting-product-specific-waiver-infigratinib-emea-002594-pip01-19_en.pdf"},
    {"id":"47082","name":"P/0346/2019: EMA decision of 11 September 2019 on the granting of a product specific waiver for fexapotide (triflutate) (EMEA-002598-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T02:00:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/467114/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0346-2019-ema-decision-11-september-2019-granting-product-specific-waiver-fexapotide-triflutate-emea-002598-pip01-19_en.pdf"},
    {"id":"47083","name":"P/0307/2019: EMA decision of 10 September 2019 on the granting of a product specific waiver for botulinum toxin type A (EMEA-002628-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T02:00:00Z","last_updated_date":"2020-03-25T02:00:00Z","reference_number":"EMA/467549/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2019-ema-decision-10-september-2019-granting-product-specific-waiver-botulinum-toxin-type-emea-002628-pip01-19_en.pdf"},
    {"id":"47120","name":"P/0352/2019: EMA decision of 4 October 2019 on the granting of a product specific waiver for human fibrinogen (EMEA-001931-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T15:10:00Z","last_updated_date":"2020-03-25T15:10:00Z","reference_number":"EMA/523627/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0352-2019-ema-decision-4-october-2019-granting-product-specific-waiver-human-fibrinogen-emea-001931-pip02-19_en.pdf"},
    {"id":"47122","name":"P/0356/2019: EMA decision of 4 October 2019 on the granting of a product specific waiver for aprocitentan (EMEA-001978-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T15:49:00Z","last_updated_date":"2020-03-25T15:49:00Z","reference_number":"EMA/474734/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0356-2019-ema-decision-4-october-2019-granting-product-specific-waiver-aprocitentan-emea-001978-pip02-19_en.pdf"},
    {"id":"47123","name":"P/0195/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (Translarna), (EMEA-000115-PIP01-07-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-16T02:00:00Z","last_updated_date":"2022-02-16T02:00:00Z","reference_number":"EMA/245211/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-translarna-emea-000115-pip01-07-m11_en.pdf"},
    {"id":"47124","name":"P/0334/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant Neisseria meningitidis group B NHBA fusion protein / recombinant Neisseria meningitidis group B NadA protein...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/466392/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-neisseria-meningitidis-group-b-nhba-fusion-protein-recombinant-neisseria_en.pdf"},
    {"id":"47125","name":"P/0344/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for sacubitril / valsartan (Entresto), (EMEA-000316-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/474721/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0344-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-sacubitril-valsartan-entresto-emea-000316-pip02-11-m04_en.pdf"},
    {"id":"47126","name":"P/0354/2019: EMA decision of 4 October 2019 on the granting of a product specific waiver for 7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-[(3S)- tetrahydrofuran-3-yl]-1,5-dihydro-4H-pyrazolo[4,3- c]quinolin-4-one maleate (EMEA-002424-PIP02- 19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T15:57:00Z","last_updated_date":"2020-03-25T15:57:00Z","reference_number":"EMA/523335/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0354-2019-ema-decision-4-october-2019-granting-product-specific-waiver-7-2-methoxy-35-dimethylpyridin-4-yl-1-3s-tetrahydrofuran-3-yl-15-dihydro-4h-pyrazolo43-cquinolin-4-one-maleate-emea-002424_en.pdf"},
    {"id":"47127","name":"P/0350/2019: EMA decision of 30 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga), (EMEA-000597-PIP02-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/520052/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0350-2019-ema-decision-30-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip02-10-m07_en.pdf"},
    {"id":"47128","name":"P/0333/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for pazopanib (Votrient), (EMEA-000601-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/439197/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0333-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-pazopanib-votrient-emea-000601-pip01-09-m06_en.pdf"},
    {"id":"47129","name":"P/0345/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin (Jardiance), (EMEA-000828-PIP04-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/439200/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0345-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-jardiance-emea-000828-pip04-16-m03_en.pdf"},
    {"id":"47130","name":"P/0332/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for lomitapide (Lojuxta) (EMEA-001124-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/480316/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0332-2019-ema-decision-10-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-lomitapide-lojuxta-emea-001124-pip01-10-m04_en.pdf"},
    {"id":"47131","name":"P/0331/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for cabozantinib (Cometriq), (EMEA-001143-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/466395/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0331-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-cabozantinib-cometriq-emea-001143-pip01-11-m02_en.pdf"},
    {"id":"47132","name":"P/0339/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen / human thrombin (Evicel, Evarrest) (EMEA-001149-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/480345/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0339-2019-ema-decision-10-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-evicel-evarrest-emea-001149-pip01-11-m05_en.pdf"},
    {"id":"47133","name":"P/0330/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ferric maltol (Feraccru), (EMEA-001195-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/439206/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0330-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-ferric-maltol-feraccru-emea-001195-pip01-11-m04_en.pdf"},
    {"id":"47135","name":"P/0284/2019: EMA decision of 30 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for reslizumab (Cinqaero), (EMEA-001202-PIP02-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/440044/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2019-ema-decision-30-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-reslizumab-cinqaero-emea-001202-pip02-13-m03_en.pdf"},
    {"id":"47136","name":"P/0329/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for lonoctocog alfa (Afstyla) (EMEA-001215-PIP01-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/480337/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0329-2019-ema-decision-10-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-lonoctocog-alfa-afstyla-emea-001215-pip01-11-m07_en.pdf"},
    {"id":"47137","name":"P/0328/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for dermatophagoides pteronyssinus / dermatophagoides farinae (ACARIZAX and associated names), (EMEA-001258-PIP0111-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/474720/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0328-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-dermatophagoides-pteronyssinus-dermatophagoides-farinae-acarizax-associated-names-emea-001258_en.pdf"},
    {"id":"47138","name":"P/0341/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for fevipiprant (EMEA-001315-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/467449/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0341-2019-ema-decision-10-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-fevipiprant-emea-001315-pip02-16-m02_en.pdf"},
    {"id":"47139","name":"P/0306/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for cobimetinib (Cotellic), (EMEA-001425-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/467455/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2019-ema-decision-10-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-cobimetinib-cotellic-emea-001425-pip01-13-m04_en.pdf"},
    {"id":"47140","name":"P/0327/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for etrolizumab  (EMEA-001434-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/439207/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0327-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-etrolizumab-emea-001434-pip01-13-m02_en.pdf"},
    {"id":"47141","name":"P/0326/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (Ozempic) (EMEA-001441-PIP03-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/480333/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0326-2019-ema-decision-10-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-semaglutide-ozempic-emea-001441-pip03-17-m01_en.pdf"},
    {"id":"47142","name":"P/0324/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for finerenone (EMEA-001623-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/467485/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0324-2019-ema-decision-10-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-finerenone-emea-001623-pip01-14-m03_en.pdf"},
    {"id":"47143","name":"P/0323/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for tisagenlecleucel (Kymriah), (EMEA-001654-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/474719/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-tisagenlecleucel-kymriah-emea-001654-pip02-17-m01_en.pdf"},
    {"id":"47144","name":"P/0322/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib  (EMEA-001741-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/439211/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0322-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-emea-001741-pip01-14-m02_en.pdf"},
    {"id":"47145","name":"P/0305/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for anti-respiratory syncytial virus human IgG1κ monoclonal antibody (MEDI8897) (EMEA-001784-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/467490/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2019-ema-decision-10-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-anti-respiratory-syncytial-virus-human-igg1k-monoclonal-antibody-medi8897-emea-001784-pip01-15_en.pdf"},
    {"id":"47146","name":"P/0321/2019: EMA decision of 10.09.2019 on the acceptance of a modification of an agreed PIP for Liquid ethanolic extract 30 per cent (w/w) of Allium cepa L.(fresh bulb) & Citrus limon (L.) Burm.f.(fresh fruit), Paullinia cupana Kunth, Theobroma cacao L.","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/467495/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0321-2019-ema-decision-10092019-acceptance-modification-agreed-pip-liquid-ethanolic-extract-30-cent-w-w-allium-cepa-lfresh-bulb-citrus-limon-l-burmffresh-fruit-paullinia-cupana-kunth-theobroma-cacao_en.pdf"},
    {"id":"47147","name":"P/0348/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for 2-hydroxypropyl-ßcyclodextrin (HP-ß-CD) (EMEA-001866-PIP01-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/480344/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0348-2019-ema-decision-10-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-2-hydroxypropyl-sscyclodextrin-hp-ss-cd-emea-001866-pip01-15-m04_en.pdf"},
    {"id":"47148","name":"P/0319/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir (DTG) / lamivudine (3TC), (EMEA-001940-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/474722/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0319-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-dtg-lamivudine-3tc-emea-001940-pip01-16-m02_en.pdf"},
    {"id":"47149","name":"P/0318/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for larotrectinib (EMEA001971-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/474725/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-larotrectinib-emea001971-pip02-16-m02_en.pdf"},
    {"id":"47150","name":"P/0340/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed PIP for influenza virus surface antigens (haemagglutinin) of strain A (H1N1) / influenza virus surface antigens (haemagglutinin) of strain A (H3N2)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/480322/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0340-2019-ema-decision-10-september-2019-acceptance-modification-agreed-pip-influenza-virus-surface-antigens-haemagglutinin-strain-h1n1-influenza-virus-surface-antigens-haemagglutinin-strain-h3n2_en.pdf"},
    {"id":"47151","name":"P/0316/2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for  odevixibat (EMEA-002054-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T02:00:00Z","last_updated_date":"2020-03-26T02:00:00Z","reference_number":"EMA/466397/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-odevixibat-emea-002054-pip01-16-m01_en.pdf"},
    {"id":"47152","name":"P/0349/2019: EMA decision of 16 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for risdiplam (EMEA-002070-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T02:00:00Z","last_updated_date":"2020-03-27T02:00:00Z","reference_number":"EMA/474727/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0349-2019-ema-decision-16-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-risdiplam-emea-002070-pip01-16-m03_en.pdf"},
    {"id":"47153","name":"P/0337/2019: EMA decision of 10 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for pretomanid (EMEA-002115-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T02:00:00Z","last_updated_date":"2020-03-27T02:00:00Z","reference_number":"EMA/480319/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0337-2019-ema-decision-10-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-pretomanid-emea-002115-pip01-17-m01_en.pdf"},
    {"id":"47154","name":"P/0366/2019: EMA decision of 7 November 2019 on the granting of a product specific waiver for canakinumab (Ilaris), (EMEA-000060-PIP07-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T02:00:00Z","last_updated_date":"2020-03-27T02:00:00Z","reference_number":"EMA/588311/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0366-2019-ema-decision-7-november-2019-granting-product-specific-waiver-canakinumab-ilaris-emea-000060-pip07-19_en.pdf"},
    {"id":"47155","name":"P/0351/2019: EMA decision of 4 October 2019 on the refusal of a paediatric investigation plan and on the granting of a waiver for ecopipam (hydrochloride) (EMEA-002564-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T16:30:00Z","last_updated_date":"2020-03-25T16:30:00Z","reference_number":"EMA/526351/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0351-2019-ema-decision-4-october-2019-refusal-paediatric-investigation-plan-granting-waiver-ecopipam-hydrochloride-emea-002564-pip01-19_en.pdf"},
    {"id":"47156","name":"P/0355/2019: EMA decision of 4 October 2019 on the granting of a product specific waiver for timolol (as timolol maleate) / bimatoprost (EMEA-002583-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T16:39:00Z","last_updated_date":"2020-03-25T16:39:00Z","reference_number":"EMA/523325/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0355-2019-ema-decision-4-october-2019-granting-product-specific-waiver-timolol-timolol-maleate-bimatoprost-emea-002583-pip01-19_en.pdf"},
    {"id":"47157","name":"P/0353/2019: EMA decision of 4 October 2019 on the granting of a product specific waiver for autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor (CAR) for B-cell maturation antigen (BCMA) (JN","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T16:46:00Z","last_updated_date":"2020-03-25T16:46:00Z","reference_number":"EMA/526955/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0353-2019-ema-decision-4-october-2019-granting-product-specific-waiver-autologous-human-t-cells-genetically-modified-ex-vivo-lentiviral-vector-encoding-chimeric-antigen-receptor-car-b-cell_en.pdf"},
    {"id":"47158","name":"P/0357/2019: EMA decision of 4 October 2019 on the granting of a product specific waiver for 2-(3-(1-carboxy-5-[(6-[18F]fluoropyridine-3-carbonyl)- amino]-pentyl)-ureido)-pentanedioic acid (EMEA-002608-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-25T16:59:00Z","last_updated_date":"2020-03-25T16:59:00Z","reference_number":"EMA/523628/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0357-2019-ema-decision-4-october-2019-granting-product-specific-waiver-2-3-1-carboxy-5-6-18ffluoropyridine-3-carbonyl-amino-pentyl-ureido-pentanedioic-acid-emea-002608-pip01-19_en.pdf"},
    {"id":"47161","name":"P/0358/2019: EMA decision of 4 October 2019 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia (and associated names)), (EMEA-000470-PIP01-08-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T09:17:00Z","last_updated_date":"2020-03-26T09:17:00Z","reference_number":"EMA/523992/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0358-2019-ema-decision-4-october-2019-acceptance-modification-agreed-paediatric-investigation-plan-sitagliptin-januvia-associated-names-emea-000470-pip01-08-m11_en.pdf"},
    {"id":"47164","name":"P/0169/2019: EMA decision of 11 October 2019 on the acceptance of a modification of an agreed paediatric investigation plan for Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup C polysaccharide con","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-26T10:00:00Z","last_updated_date":"2020-03-26T10:00:00Z","reference_number":"EMA/542840/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2019-ema-decision-11-october-2019-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-polysaccharide-conjugated-tetanus-toxoid-n-meningitidis-serogroup_en.pdf"},
    {"id":"47199","name":"P/0364/2019: EMA decision of 4 November 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for remimazolam (as besylate) (EMEA-001880-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T17:00:00Z","last_updated_date":"2020-03-27T17:00:00Z","reference_number":"EMA/586778/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0364-2019-ema-decision-4-november-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-remimazolam-besylate-emea-001880-pip02-19_en.pdf"},
    {"id":"47200","name":"P/0361/2019: EMA decision of 4 November 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ganaxolone (EMEA-002341-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T17:09:00Z","last_updated_date":"2020-03-27T17:09:00Z","reference_number":"EMA/585049/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0361-2019-ema-decision-4-november-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ganaxolone-emea-002341-pip01-18_en.pdf"},
    {"id":"47201","name":"P/0369/2019: EMA decision of of 8 November 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for selpercatinib (EMEA-002544-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T17:18:00Z","last_updated_date":"2020-03-27T17:18:00Z","reference_number":"EMA/593887/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0369-2019-ema-decision-8-november-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-selpercatinib-emea-002544-pip01-18_en.pdf"},
    {"id":"47202","name":"P/0363/2019: EMA decision of 4 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for lubiprostone (AMITIZA), (EMEA-000245-PIP01-08-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T17:30:00Z","last_updated_date":"2020-03-27T17:30:00Z","reference_number":"EMA/585843/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0363-2019-ema-decision-4-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-lubiprostone-amitiza-emea-000245-pip01-08-m06_en.pdf"},
    {"id":"47203","name":"P/0370/2019: EMA decision of 8 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ambrisentan (Volibris), (EMEA-000434-PIP01-08-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T17:37:00Z","last_updated_date":"2020-03-27T17:37:00Z","reference_number":"EMA/594814/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0370-2019-ema-decision-8-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-ambrisentan-volibris-emea-000434-pip01-08-m06_en.pdf"},
    {"id":"47204","name":"P/0371/2019: EMA decision of 14 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon beta-1a (Plegridy), (EMEA-001129-PIP01-11-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T17:43:00Z","last_updated_date":"2020-03-27T17:43:00Z","reference_number":"EMA/591829/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0371-2019-ema-decision-14-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-peginterferon-beta-1a-plegridy-emea-001129-pip01-11-m04_en.pdf"},
    {"id":"47205","name":"P/0373/2019: EMA decision of 22 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for avatrombopag (maleate) (Doptelet), (EMEA-001136-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T17:51:00Z","last_updated_date":"2020-03-27T17:51:00Z","reference_number":"EMA/557297/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0373-2019-ema-decision-22-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-avatrombopag-maleate-doptelet-emea-001136-pip01-11-m01_en.pdf"},
    {"id":"47206","name":"P/0367/2019: EMA decision of 8 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for daclatasvir (Daklinza), (EMEA-001191-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T09:29:00Z","last_updated_date":"2020-03-30T09:29:00Z","reference_number":"EMA/590910/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0367-2019-ema-decision-8-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-daclatasvir-daklinza-emea-001191-pip01-11-m03_en.pdf"},
    {"id":"47207","name":"P/0359/2019: EMA decision of 4 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for lurasidone (hydrochloride) (Latuda) (EMEA-001230-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T09:34:00Z","last_updated_date":"2020-03-30T09:34:00Z","reference_number":"EMA/584816/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0359-2019-ema-decision-4-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-lurasidone-hydrochloride-latuda-emea-001230-pip01-11-m05_en.pdf"},
    {"id":"47208","name":"P/0374/2019: EMA decision of 22 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP01-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T09:42:00Z","last_updated_date":"2020-03-30T09:42:00Z","reference_number":"EMA/557312/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0374-2019-ema-decision-22-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip01-13-m06_en.pdf"},
    {"id":"47209","name":"P/0362/2019: EMA decision of 4 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for letermovir (Prevymis), (EMEA-001631-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T09:48:00Z","last_updated_date":"2020-03-30T09:48:00Z","reference_number":"EMA/585624/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0362-2019-ema-decision-4-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-letermovir-prevymis-emea-001631-pip01-14-m04_en.pdf"},
    {"id":"47213","name":"P/0365/2019: EMA decision of 7 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium bromide (CHF 5993) (Trimbow and associated names) (","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T14:07:00Z","last_updated_date":"2020-03-30T14:07:00Z","reference_number":"EMA/587514/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0365-2019-ema-decision-7-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-beclometasone-dipropionate-formoterol-fumarate-dihydrate-glycopyrronium-bromide-chf-5993-trimbow_en.pdf"},
    {"id":"47214","name":"P/0372/2019: EMA decision of 15 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain A (H1N1)/ Influenza virus inactivated","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T14:18:00Z","last_updated_date":"2020-03-30T14:18:00Z","reference_number":"EMA/602271/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0372-2019-ema-decision-15-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-inactivated-split-virion-haemagglutinin-neuraminidase-strain-h1n1-influenza-virus_en.pdf"},
    {"id":"47215","name":"P/0399/2019: EMA decision of 4 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for crizotinib (Xalkori), (EMEA-001493-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T14:17:00Z","last_updated_date":"2020-03-30T14:17:00Z","reference_number":"EMA/607431/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0399-2019-ema-decision-4-december-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-crizotinib-xalkori-emea-001493-pip03-18_en.pdf"},
    {"id":"47216","name":"P/0360/2019: EMA decision of 4 November 2019 on the refusal of a modification of an agreed paediatric investigation plan for avacopan (EMEA-002023- PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T14:29:00Z","last_updated_date":"2020-03-30T14:29:00Z","reference_number":"EMA/584882/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0360-2019-ema-decision-4-november-2019-refusal-modification-agreed-paediatric-investigation-plan-avacopan-emea-002023-pip01-16-m03_en.pdf"},
    {"id":"47217","name":"P/0386/2019: EMA decision of 29 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for pevonedistat (EMEA- 002117-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T14:36:00Z","last_updated_date":"2020-03-30T14:36:00Z","reference_number":"EMA/626758/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0386-2019-ema-decision-29-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-pevonedistat-emea-002117-pip01-17-m01_en.pdf"},
    {"id":"47218","name":"P/0368/2019: EMA decision of 8 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for sodium thiosulfate (STS), (EMEA-002147-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T14:40:00Z","last_updated_date":"2020-03-30T14:40:00Z","reference_number":"EMA/591617/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0368-2019-ema-decision-8-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-sodium-thiosulfate-sts-emea-002147-pip02-17-m01_en.pdf"},
    {"id":"47219","name":"P/0419/2019: EMA decision of 6 December 2019 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for eflornithine (hydrochloride monohydrate) / sulindac (EMEA-001518-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T14:45:00Z","last_updated_date":"2020-03-30T14:45:00Z","reference_number":"EMA/631881/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0419-2019-ema-decision-6-december-2019-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-eflornithine-hydrochloride-monohydrate-sulindac-emea-001518-pip03-19_en.pdf"},
    {"id":"47224","name":"P/0413/2019: EMA decision of 6 December 2019 on the agreement of a paediatric investigation plan and on the granting of a waiver for sufentanil (citrate) / ketamine (hydrochloride) (EMEA-001739-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-30T17:28:00Z","last_updated_date":"2020-03-30T17:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0413-2019-ema-decision-6-december-2019-agreement-paediatric-investigation-plan-granting-waiver-sufentanil-citrate-ketamine-hydrochloride-emea-001739-pip02-16_en.pdf"},
    {"id":"47227","name":"P/0377/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for dalbavancin (Xydalba) (EMEA-000016-PIP01-07-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T10:00:00Z","last_updated_date":"2020-03-31T10:00:00Z","reference_number":"EMA/632155/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0377-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-dalbavancin-xydalba-emea-000016-pip01-07-m07_en.pdf"},
    {"id":"47228","name":"P/0383/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Saxenda), (EMEA-000128-PIP02-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T10:07:00Z","last_updated_date":"2020-03-31T10:07:00Z","reference_number":"EMA/626809/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0383-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-saxenda-emea-000128-pip02-09-m03_en.pdf"},
    {"id":"47229","name":"P/0408/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten and associated names), (EMEA-000347-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T10:13:00Z","last_updated_date":"2020-03-31T10:13:00Z","reference_number":"EMA/591837/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0408-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-associated-names-emea-000347-pip02-16-m01_en.pdf"},
    {"id":"47230","name":"P/0433/2019: EMA decision of 6 December 2019 on the granting of a product specific waiver for autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T10:49:00Z","last_updated_date":"2020-03-31T10:49:00Z","reference_number":"EMA/650689/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0433-2019-ema-decision-6-december-2019-granting-product-specific-waiver-autologous-peripheral-blood-t-cells-cd4-cd8-selected-cd3-cd28-activated-transduced-retroviral-vector-expressing-anti-cd19-cd28_en.pdf"},
    {"id":"47232","name":"P/0410/2019: EMA decision of 6 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for teduglutide (Revestive), (EMEA-000482-PIP01-08-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T11:03:00Z","last_updated_date":"2020-03-31T11:03:00Z","reference_number":"EMA/557286/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0410-2019-ema-decision-6-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-teduglutide-revestive-emea-000482-pip01-08-m05_en.pdf"},
    {"id":"47233","name":"P/0401/2019: EMA decision of 4 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for larotrectinib (VITRAKVI), (EMEA-001971-PIP03-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T11:02:00Z","last_updated_date":"2020-03-31T11:02:00Z","reference_number":"EMA/607430/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0401-2019-ema-decision-4-december-2019-agreement-paediatric-investigation-plan-granting-deferral-larotrectinib-vitrakvi-emea-001971-pip03-18_en.pdf"},
    {"id":"47234","name":"P/0382/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for chloroprocaine (hydrochloride) (Ampres), (EMEA-000639-PIP03-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T11:24:00Z","last_updated_date":"2020-03-31T11:24:00Z","reference_number":"EMA/630187/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0382-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-chloroprocaine-hydrochloride-ampres-emea-000639-pip03-16-m01_en.pdf"},
    {"id":"47235","name":"P/0388/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla), (EMEA-000715-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T11:35:00Z","last_updated_date":"2020-03-31T11:35:00Z","reference_number":"EMA/631821/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0388-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip02-11-m04_en.pdf"},
    {"id":"47236","name":"P/0402/2019: EMA decision of 20 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 3-[5-[(1R,2S)-2-(2,2-difluoropropanoylamino)-1-(2,3-dihydro-1,4- benzodioxin-6-yl)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T12:03:00Z","last_updated_date":"2020-03-31T12:03:00Z","reference_number":"EMA/629978/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0402-2019-ema-decision-20-december-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-3-5-1r2s-2-22-difluoropropanoylamino-1-23-dihydro-14-benzodioxin-6-yl_en.pdf"},
    {"id":"47237","name":"P/0315:2019: EMA decision of 11 September 2019 on the acceptance of a modification of an agreed paediatric investigation plan for onasemnogene abeparvovec (EMEA-002168-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T12:12:00Z","last_updated_date":"2020-03-27T12:12:00Z","reference_number":"EMA/466401/2019 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-03152019-ema-decision-11-september-2019-acceptance-modification-agreed-paediatric-investigation-plan-onasemnogene-abeparvovec-emea-002168-pip01-17-m02_en.pdf"},
    {"id":"47244","name":"P/0389/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla), (EMEA-000715-PIP05-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T13:44:00Z","last_updated_date":"2020-03-31T13:44:00Z","reference_number":"EMA/626696/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0389-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip05-13-m04_en.pdf"},
    {"id":"47245","name":"P/0391/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for rubidium (82Rb) chloride (Ruby-Fill (82Sr/82Rb Generator)), (EMEA-000882-PIP03-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T13:55:00Z","last_updated_date":"2020-03-31T13:55:00Z","reference_number":"EMA/591835/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0391-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-rubidium-82rb-chloride-ruby-fill-82sr-82rb-generator-emea-000882-pip03-11-m04_en.pdf"},
    {"id":"47246","name":"P/0384/2019: EMA decision of December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ruxolitinib (phosphate) (Jakavi), (EMEA-000901-PIP04-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T14:07:00Z","last_updated_date":"2020-03-31T14:07:00Z","reference_number":"EMA/591816/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0384-2019-ema-decision-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-ruxolitinib-phosphate-jakavi-emea-000901-pip04-17-m01_en.pdf"},
    {"id":"47262","name":"P/0412/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for aciclovir (Sitavig and associated names) (EMEA-001066-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T12:58:00Z","last_updated_date":"2020-04-01T12:58:00Z","reference_number":"EMA/632116/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0412-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-aciclovir-sitavig-associated-names-emea-001066-pip02-11-m03_en.pdf"},
    {"id":"47263","name":"P/0385/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for loxapine (Adasuve) (EMEA-001115-PIP01-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T13:11:00Z","last_updated_date":"2020-04-01T13:11:00Z","reference_number":"EMA/632042/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0385-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-loxapine-adasuve-emea-001115-pip01-10-m07_en.pdf"}    {"id":"47264","name":"P/0381/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for naloxegol (Moventig) (EMEA-001146-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T13:16:00Z","last_updated_date":"2020-04-01T13:16:00Z","reference_number":"EMA/632137/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0381-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-naloxegol-moventig-emea-001146-pip01-11-m05_en.pdf"},
    {"id":"47265","name":"P/0394/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for vonicog alfa (Veyvondi), (EMEA-001164-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T13:22:00Z","last_updated_date":"2020-04-01T13:22:00Z","reference_number":"EMA/591833/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0394-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-vonicog-alfa-veyvondi-emea-001164-pip01-11-m03_en.pdf"},
    {"id":"47273","name":"P/0432/2019: EMA decision of 6 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine (Valdoxan and associated names), (EMEA-001181-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T14:31:00Z","last_updated_date":"2020-04-01T14:31:00Z","reference_number":"EMA/649448/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0432-2019-ema-decision-6-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-agomelatine-valdoxan-associated-names-emea-001181-pip01-11-m05_en.pdf"},
    {"id":"47274","name":"P/0415/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for zanamivir (Relenza), (EMEA-001318-PIP01-12-M03)","type":"pip-decision","status":"Draft","consultation_date":"","first_published_date":"2020-04-01T14:41:00Z","last_updated_date":"2020-04-01T14:41:00Z","reference_number":"EMA/632032/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0415-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-zanamivir-relenza-emea-001318-pip01-12-m03_en.pdf"},
    {"id":"47275","name":"P/0421/2019: EMA decision of 6 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ibrutinib (Imbruvica), (EMEA-001397-PIP04-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T14:46:00Z","last_updated_date":"2020-04-01T14:46:00Z","reference_number":"EMA/557300/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0421-2019-ema-decision-6-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-ibrutinib-imbruvica-emea-001397-pip04-17-m01_en.pdf"},
    {"id":"47282","name":"P/0409/2019: EMA decision of 6 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for maralixibat chloride (LUM001) (EMEA-001475-PIP03-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T10:50:00Z","last_updated_date":"2020-04-02T10:50:00Z","reference_number":"EMA/557308/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0409-2019-ema-decision-6-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-maralixibat-chloride-lum001-emea-001475-pip03-17-m01_en.pdf"},
    {"id":"47283","name":"P/0431/2019: EMA decision of 6 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (Orkambi), (EMEA-001582-PIP01-13-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T10:54:00Z","last_updated_date":"2020-04-02T10:54:00Z","reference_number":"EMA/649445/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0431-2019-ema-decision-6-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-lumacaftor-ivacaftor-orkambi-emea-001582-pip01-13-m09_en.pdf"},
    {"id":"47284","name":"P/0424/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for synthetic doublestranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T10:57:00Z","last_updated_date":"2020-04-02T10:57:00Z","reference_number":"EMA/632099/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0424-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-synthetic-doublestranded-sirna-oligonucleotide-directed-against-antithrombin-mrna-covalently_en.pdf"},
    {"id":"47285","name":"P/0378/2019: EMA decision of December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for rivogenlecleucel (EMEA-001869-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T11:03:00Z","last_updated_date":"2020-04-02T11:03:00Z","reference_number":"EMA/630189/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0378-2019-ema-decision-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-rivogenlecleucel-emea-001869-pip01-15-m02_en.pdf"},
    {"id":"47286","name":"P/0418/2019: EMA decision of 6 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for rimiducid (EMEA-001870-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T11:06:00Z","last_updated_date":"2020-04-02T11:06:00Z","reference_number":"EMA/557631/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0418-2019-ema-decision-6-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-rimiducid-emea-001870-pip01-15-m02_en.pdf"},
    {"id":"47287","name":"P/0411/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for fremanezumab (AJOVY), (EMEA-001877-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T11:14:00Z","last_updated_date":"2020-04-02T11:14:00Z","reference_number":"EMA/630441/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0411-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-fremanezumab-ajovy-emea-001877-pip01-15-m02_en.pdf"},
    {"id":"47288","name":"P/0404/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for volanesorsen (Waylivra), (EMEA-001915-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T11:19:00Z","last_updated_date":"2020-04-02T11:19:00Z","reference_number":"EMA/591816/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0404-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-volanesorsen-waylivra-emea-001915-pip01-15-m01_en.pdf"},
    {"id":"47289","name":"P/0425/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for mexiletine (hydrochloride), (Namuscla) (EMEA-002012-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T11:34:00Z","last_updated_date":"2020-04-02T11:34:00Z","reference_number":"EMA/631652/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0425-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-mexiletine-hydrochloride-namuscla-emea-002012-pip01-16-m02_en.pdf"},
    {"id":"47290","name":"P/0379/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for crizanlizumab (EMEA-002141-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T11:38:00Z","last_updated_date":"2020-04-02T11:38:00Z","reference_number":"EMA/591830/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0379-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-crizanlizumab-emea-002141-pip01-17-m02_en.pdf"},
    {"id":"47291","name":"P/0414/2019: EMA decision of 6 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for itacitinib (EMEA-002178-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T11:45:00Z","last_updated_date":"2020-04-02T11:45:00Z","reference_number":"EMA/631719/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0414-2019-ema-decision-6-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-itacitinib-emea-002178-pip01-17-m01_en.pdf"},
    {"id":"47292","name":"P/0375/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for bimekizumab (EMEA-002189-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T11:48:00Z","last_updated_date":"2020-04-02T11:48:00Z","reference_number":"EMA/591832/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0375-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-bimekizumab-emea-002189-pip01-17-m01_en.pdf"},
    {"id":"47293","name":"P/0430/2019: EMA decision of 5 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for brigatinib (Alunbrig), (EMEA-002296-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T11:59:00Z","last_updated_date":"2020-04-02T11:59:00Z","reference_number":"EMA/643790/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0430-2019-ema-decision-5-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-brigatinib-alunbrig-emea-002296-pip01-17-m01_en.pdf"},
    {"id":"47294","name":"P/0376/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for Abemaciclib (Verzenios), (EMEA-002342-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T12:03:00Z","last_updated_date":"2020-04-02T12:03:00Z","reference_number":"EMA/630195/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0376-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-abemaciclib-verzenios-emea-002342-pip01-18-m01_en.pdf"},
    {"id":"47295","name":"P/0387/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor t","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T12:07:00Z","last_updated_date":"2020-04-02T12:07:00Z","reference_number":"EMA/631969/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0387-2019-ema-decision-4-december-2019-acceptance-modification-agreed-paediatric-investigation-plan-autologous-t-lymphocyte-enriched-population-cells-transduced-lentiviral-vector-encoding-chimeric_en.pdf"},
    {"id":"47296","name":"P/0405/2019: EMA decision of 4 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for iodine (131-I) murine IgG1 monoclonal antibody against B7-H3 (131I-omburtamab) (EMEA-002101-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T14:32:00Z","last_updated_date":"2020-04-02T14:32:00Z","reference_number":"EMA/607428/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0405-2019-ema-decision-4-december-2019-agreement-paediatric-investigation-plan-granting-deferral-iodine-131-i-murine-igg1-monoclonal-antibody-against-b7-h3-131i-omburtamab-emea-002101-pip02-18_en.pdf"},
    {"id":"47297","name":"P/0406/2019: EMA decision of 4 December 2019 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for ivosidenib (EMEA-002247-PIP02-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T14:48:00Z","last_updated_date":"2020-04-02T14:48:00Z","reference_number":"EMA/593200/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0406-2019-ema-decision-4-december-2019-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-ivosidenib-emea-002247-pip02-17_en.pdf"},
    {"id":"47315","name":"P/0380/2019: EMA decision of 4 December 2019 on the granting of a product specific waiver for gefapixant (citrate) (EMEA-002267-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T10:30:00Z","last_updated_date":"2020-04-03T10:30:00Z","reference_number":"EMA/606271/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0380-2019-ema-decision-4-december-2019-granting-product-specific-waiver-gefapixant-citrate-emea-002267-pip02-19_en.pdf"},
    {"id":"47319","name":"P/0407/2019: EMA decision of 4 December 2019 on the agreement of a paediatric investigation plan and on the granting of a waiver for hydrocortisone (hemisuccinate) (EMEA-002305-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T11:20:00Z","last_updated_date":"2020-04-03T11:20:00Z","reference_number":"EMA/607436/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0407-2019-ema-decision-4-december-2019-agreement-paediatric-investigation-plan-granting-waiver-hydrocortisone-hemisuccinate-emea-002305-pip01-17_en.pdf"},
    {"id":"47321","name":"P/0398/2019: EMA decision of 4 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for zanubrutinib (EMEA-002354-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T12:03:00Z","last_updated_date":"2020-04-03T12:03:00Z","reference_number":"EMA/607434/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0398-2019-ema-decision-4-december-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-zanubrutinib-emea-002354-pip02-18_en.pdf"},
    {"id":"47329","name":"P/0374/2019: EMA decision of 22 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP01-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T14:34:00Z","last_updated_date":"2020-04-03T14:34:00Z","reference_number":"EMA/557312/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0374-2019-ema-decision-22-november-2019-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip01-13-m06_en.pdf-0"},
    {"id":"47330","name":"P/0420/2019: EMA decision of 4 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for iclaprim (mesylate) (EMEA-002391-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T14:53:00Z","last_updated_date":"2020-04-03T14:53:00Z","reference_number":"EMA/631366/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0420-2019-ema-decision-4-december-2019-agreement-paediatric-investigation-plan-granting-deferral-iclaprim-mesylate-emea-002391-pip02-19_en.pdf"},
    {"id":"47331","name":"P/0423/2019: EMA decision of 5 December 2019 on the agreement of a paediatric investigation plan for artesunate (EMEA-002402-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T15:08:00Z","last_updated_date":"2020-04-03T15:08:00Z","reference_number":"EMA/630062/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0423-2019-ema-decision-5-december-2019-agreement-paediatric-investigation-plan-artesunate-emea-002402-pip02-18_en.pdf"},
    {"id":"47332","name":"P/0403/2019: EMA decision of 4 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for marizomib (EMEA-002452-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T15:16:00Z","last_updated_date":"2020-04-03T15:16:00Z","reference_number":"EMA/630196/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0403-2019-ema-decision-4-december-2019-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-marizomib-emea-002452-pip01-18_en.pdf"},
    {"id":"47333","name":"P/0400/2019: EMA decision of 4 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human monoclonal antibody against mannan-binding lectinassociated serine pro","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T15:45:00Z","last_updated_date":"2020-04-03T15:45:00Z","reference_number":"EMA/607137/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0400-2019-ema-decision-4-december-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-human-monoclonal-antibody-against-mannan-binding-lectinassociated-serine_en.pdf"},
    {"id":"47335","name":"P/0426/2019: EMA decision of 6 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral for synthetic double-stranded siRNA oligonucleotide directed against lactate... (EMEA-002493-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T16:17:00Z","last_updated_date":"2020-04-03T16:17:00Z","reference_number":"EMA/631879/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0426-2019-ema-decision-6-december-2019-agreement-paediatric-investigation-plan-granting-deferral-synthetic-double-stranded-sirna-oligonucleotide-directed-against-lactate-emea-002493-pip01-18_en.pdf"},
    {"id":"47337","name":"P/0422/2019: EMA decision of 6 December 2019 on the agreement of a paediatric investigation plan for phenobarbital (EMEA-002532-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T16:29:00Z","last_updated_date":"2020-04-03T16:29:00Z","reference_number":"EMA/631880/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0422-2019-ema-decision-6-december-2019-agreement-paediatric-investigation-plan-phenobarbital-emea-002532-pip01-18_en.pdf"},
    {"id":"47338","name":"P/0397/2019: EMA decision of 4 December 2019 on the granting of a product specific waiver for diclofenac (sodium) / thiocolchicoside (EMEA-002580-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T16:41:00Z","last_updated_date":"2020-04-03T16:41:00Z","reference_number":"EMA/606270/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0397-2019-ema-decision-4-december-2019-granting-product-specific-waiver-diclofenac-sodium-thiocolchicoside-emea-002580-pip01-19_en.pdf"},
    {"id":"47339","name":"P/0428/2019: EMA decision of 6 December 2019 on the granting of a product specific waiver for duvelisib (EMEA-002587-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T16:51:00Z","last_updated_date":"2020-04-03T16:51:00Z","reference_number":"EMA/633947/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0428-2019-ema-decision-6-december-2019-granting-product-specific-waiver-duvelisib-emea-002587-pip01-19_en.pdf"},
    {"id":"47340","name":"P/0396/2019: EMA decision of 4 December 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for atazanavir (sulfate) / ritonavir (EMEA-002588-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T17:01:00Z","last_updated_date":"2020-04-03T17:01:00Z","reference_number":"EMA/623534/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0396-2019-ema-decision-4-december-2019-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-atazanavir-sulfate-ritonavir-emea-002588-pip01-19_en.pdf"},
    {"id":"47341","name":"P/0395/2019: EMA decision of 4 December 2019 on the granting of a product specific waiver for a fully humanized immunoglobulin G4 proline, alanine, alanine (IgG4 PAA) based bispecific antibody directed against cluster of differentiation 3 (CD3) receptor c","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T17:13:00Z","last_updated_date":"2020-04-03T17:13:00Z","reference_number":"EMA/621656/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0395-2019-ema-decision-4-december-2019-granting-product-specific-waiver-fully-humanized-immunoglobulin-g4-proline-alanine-alanine-igg4-paa-based-bispecific-antibody-directed-against-cluster_en.pdf"},
    {"id":"47342","name":"P/0393/2019: EMA decision of 4 December 2019 on the granting of a product specific waiver for (3S,7S)-22-(3-(((2-((5-(2-Carboxyethyl)-2-hydroxybenzyl)(carboxymethyl)amino)ethyl)(carboxymethyl)amino)methyl)-4-hydroxyphenyl)-5,13,20-trioxo-4,6,12,19-tetraaz","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-03T17:19:00Z","last_updated_date":"2020-04-03T17:19:00Z","reference_number":"EMA/622502/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0393-2019-ema-decision-4-december-2019-granting-product-specific-waiver-3s7s-22-3-2-5-2-carboxyethyl-2-hydroxybenzylcarboxymethylaminoethylcarboxymethylaminomethyl-4-hydroxyphenyl-51320-trioxo_en.pdf"},
    {"id":"47349","name":"P/0417/2019: EMA decision of 4 December 2019 on the granting of a product specific waiver for loxoprofen (sodium hydrate) (EMEA-002626-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-06T10:12:00Z","last_updated_date":"2020-04-06T10:12:00Z","reference_number":"EMA/606267/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0417-2019-ema-decision-4-december-2019-granting-product-specific-waiver-loxoprofen-sodium-hydrate-emea-002626-pip01-19_en.pdf"},
    {"id":"47350","name":"P/0169/2019: EMA decision of 4 December 2019 on the granting of a product specific waiver for savolitinib (EMEA-002627-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-06T10:23:00Z","last_updated_date":"2020-04-06T10:23:00Z","reference_number":"EMA/630215/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2019-ema-decision-4-december-2019-granting-product-specific-waiver-savolitinib-emea-002627-pip01-19_en.pdf"},
    {"id":"47352","name":"P/0392/2019: EMA decision of 4 December 2019 on the granting of a product specific waiver for 177Lu-Satoreotide tetraxetan (EMEA-002629-PIP01- 19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-06T11:40:00Z","last_updated_date":"2020-04-06T11:40:00Z","reference_number":"EMA/623546/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0392-2019-ema-decision-4-december-2019-granting-product-specific-waiver-177lu-satoreotide-tetraxetan-emea-002629-pip01-19_en.pdf"},
    {"id":"47353","name":"P/0390/2019: EMA decision of 4 December 2019 on the granting of a product specific waiver for satoreotide trizoxetan, (EMEA-002632-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-06T11:58:00Z","last_updated_date":"2020-04-06T11:58:00Z","reference_number":"EMA/626672/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0390-2019-ema-decision-4-december-2019-granting-product-specific-waiver-satoreotide-trizoxetan-emea-002632-pip01-19_en.pdf"},
    {"id":"47354","name":"P/0416/2019: EMA decision of 4 December 2019 on the granting of a product specific waiver for sitravatinib (malate) (EMEA-002633-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-06T12:05:00Z","last_updated_date":"2020-04-06T12:05:00Z","reference_number":"EMA/632198/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0416-2019-ema-decision-4-december-2019-granting-product-specific-waiver-sitravatinib-malate-emea-002633-pip01-19_en.pdf"},
    {"id":"47356","name":"P/0429/2019: EMA decision of 6 December 2019 on the granting of a product specific waiver for ezetimibe / atorvastatin (EMEA-002649-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-04-06T12:10:00Z","last_updated_date":"2020-04-06T12:10:00Z","reference_number":"EMA/634189/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0429-2019-ema-decision-6-december-2019-granting-product-specific-waiver-ezetimibe-atorvastatin-emea-002649-pip01-19_en.pdf"},
    {"id":"47555","name":"P/71/2009: European Medicines Agency decision of 20 April 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for ulipristal (EMEA-000305-PIP01-08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2020-05-04T12:52:00Z","last_updated_date":"2020-05-04T12:52:00Z","reference_number":"EMEA/232006/2009","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-71-2009-european-medicines-agency-decision-20-april-2009-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ulipristal-emea-000305-pip01-08_en.pdf"},
    {"id":"47865","name":"P/0029/2020: EMA decision of 29 January 2020 on the granting of a product specific waiver for canakinumab (Ilaris), (EMEA-000060-PIP08-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-04T01:00:00Z","last_updated_date":"2020-06-04T01:00:00Z","reference_number":"EMA/27127/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2020-ema-decision-29-january-2020-granting-product-specific-waiver-canakinumab-ilaris-emea-000060-pip08-19_en.pdf"},
    {"id":"47866","name":"P/0066/2020: EMA decision of 28 February 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for mecasermin rinfabate (EMEA-000534-PIP03-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-04T01:00:00Z","last_updated_date":"2020-06-04T01:00:00Z","reference_number":"EMA/86893/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2020-ema-decision-28-february-2020-agreement-paediatric-investigation-plan-granting-waiver-mecasermin-rinfabate-emea-000534-pip03-17_en.pdf"},
    {"id":"47867","name":"P/0010/2020: EMA decision of 6 January 2020 on the refusal of a product specific waiver for chloroprocaine (hydrochloride) (Ampres), (EMEA-000639-PIP04-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-04T01:00:00Z","last_updated_date":"2020-06-04T01:00:00Z","reference_number":"EMA/672155/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2020-ema-decision-6-january-2020-refusal-product-specific-waiver-chloroprocaine-hydrochloride-ampres-emea-000639-pip04-19_en.pdf"},
    {"id":"47869","name":"P/0009/2020: EMA decision of 6 January 2020 on the refusal of a product specific waiver for chloroprocaine (hydrochloride) (Ampres) (EMEA-000639-PIP05-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-04T01:00:00Z","last_updated_date":"2020-06-04T01:00:00Z","reference_number":"EMA/672154/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2020-ema-decision-6-january-2020-refusal-product-specific-waiver-chloroprocaine-hydrochloride-ampres-emea-000639-pip05-19_en.pdf"},
    {"id":"47886","name":"P/0201/2020: EMA decision of 19 May 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for remdesivir (EMEA-002826-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-08T14:00:00Z","last_updated_date":"2020-06-08T14:00:00Z","reference_number":"EMA/269449/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2020-ema-decision-19-may-2020-agreement-paediatric-investigation-plan-granting-deferral-remdesivir-emea-002826-pip01-20_en.pdf"},
    {"id":"47902","name":"P/0046/2020: EMA decision of 29 January 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for atogepant (EMEA-002530-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-09T16:35:00Z","last_updated_date":"2020-06-09T16:35:00Z","reference_number":"EMA/28876/2020 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2020-ema-decision-29-january-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-atogepant-emea-002530-pip01-18_en.pdf"},
    {"id":"47905","name":"P/0001/2020: EMA decision of 3 January 2020 on the granting of a product specific waiver for masitinib (mesylate) (EMEA-001266-PIP04-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-09T14:00:00Z","last_updated_date":"2020-06-09T14:00:00Z","reference_number":"EMA/671590/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2020-ema-decision-3-january-2020-granting-product-specific-waiver-masitinib-mesylate-emea-001266-pip04-19_en.pdf"},
    {"id":"47906","name":"P/0059/2020: EMA decision of 10 February 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dupilumab (Dupixent), (EMEA-001501-PIP04-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-09T14:00:00Z","last_updated_date":"2020-06-09T14:00:00Z","reference_number":"EMA/65322/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2020-ema-decision-10-february-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dupilumab-dupixent-emea-001501-pip04-19_en.pdf"},
    {"id":"47907","name":"P/0053/2020: EMA decision of 29 January 2020 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for anti-CD7 mAb conjugated to ricin toxin A chain / anti-CD3 mAb conjugated to ricin toxin A chain (T-Guard)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-09T14:00:00Z","last_updated_date":"2020-06-09T14:00:00Z","reference_number":"EMA/12468/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2020-ema-decision-29-january-2020-agreement-pip-granting-deferral-granting-waiver-anti-cd7-mab-conjugated-ricin-toxin-chain-anti-cd3-mab-conjugated-ricin-toxin-chain-t-guard_en.pdf"},
    {"id":"47908","name":"P/0022/2020: EMA decision of 6 January 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for aztreonam (ATM)/ avibactam (AVI), (EMEA-002283-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-09T14:00:00Z","last_updated_date":"2020-06-09T14:00:00Z","reference_number":"EMA/672642/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2020-ema-decision-6-january-2020-agreement-paediatric-investigation-plan-granting-deferral-aztreonam-atm-avibactam-avi-emea-002283-pip01-17_en.pdf"},
    {"id":"47909","name":"P/0021/2020: EMA decision of 6 January 2020 on the agreement of a paediatric investigation plan for abemaciclib (Verzenios), (EMEA-002342-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-09T14:00:00Z","last_updated_date":"2020-06-09T14:00:00Z","reference_number":"EMA/659463/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2020-ema-decision-6-january-2020-agreement-paediatric-investigation-plan-abemaciclib-verzenios-emea-002342-pip02-18_en.pdf"},
    {"id":"47910","name":"P/0052/2020: EMA decision of 29 January 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for asciminib (EMEA-002347-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-09T14:00:00Z","last_updated_date":"2020-06-09T14:00:00Z","reference_number":"EMA/23718/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2020-ema-decision-29-january-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-asciminib-emea-002347-pip01-18_en.pdf"},
    {"id":"47911","name":"P/0061/2020: EMA decision of 10 February 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for berotralstat, (EMEA-002449-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-09T14:00:00Z","last_updated_date":"2020-06-09T14:00:00Z","reference_number":"EMA/67983/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2020-ema-decision-10-february-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-berotralstat-emea-002449-pip02-18_en.pdf"},
    {"id":"47912","name":"P/0051/2020: EMA decision of 29 January 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 2-[[8-chloro-3-[(4-chlorophenyl)methyl]-4-(difluoromethoxy)-2-ethyl-5- quinolinyl]oxy]..","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/26710/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2020-ema-decision-29-january-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-2-8-chloro-3-4-chlorophenylmethyl-4-difluoromethoxy-2-ethyl-5-quinolinyloxy_en.pdf"},
    {"id":"47913","name":"P/0050/2020: EMA decision of 29 January 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for norursodeoxycholic acid (EMEA-002485-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/12617/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2020-ema-decision-29-january-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-norursodeoxycholic-acid-emea-002485-pip01-18_en.pdf"},
    {"id":"47914","name":"P/0049/2020: EMA decision of 29 January 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for budesonide (EMEA-002500-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/27396/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2020-ema-decision-29-january-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-budesonide-emea-002500-pip01-18_en.pdf"},
    {"id":"47915","name":"P/0048/2020: EMA decision of 29 January 2020 on the agreement of a paediatric investigation plan for factor VIII Fc – von Willebrand factor – XTEN fusion protein (rFVIIIFc-VWF-XTEN) (EMEA-002501-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/23626/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2020-ema-decision-29-january-2020-agreement-paediatric-investigation-plan-factor-viii-fc-von-willebrand-factor-xten-fusion-protein-rfviiifc-vwf-xten-emea-002501-pip01-18_en.pdf"},
    {"id":"47916","name":"P/0055/2020: EMA decision of 10 February 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human immunoglobulin G2 isotype antibody to IL-33R (EMEA-002515-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/26711/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2020-ema-decision-10-february-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-immunoglobulin-g2-isotype-antibody-il-33r-emea-002515-pip01-18_en.pdf"},
    {"id":"47917","name":"P/0057/2020: EMA decision of 11 February 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-IL-17A/F nanobody (MK 1095) (EMEA-002568-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/12614/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2020-ema-decision-11-february-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-il-17a-f-nanobody-mk-1095-emea-002568-pip01-19_en.pdf"},
    {"id":"47918","name":"P/0015/2020: EMA decision of 6 January 2020 on the granting of a product specific waiver for bispecific T-cell engager antibody with a single-chain fragment crystallizable moiety that binds to B cell maturation antigen surface receptor on tumour cells...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/672673/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2020-ema-decision-6-january-2020-granting-product-specific-waiver-bispecific-t-cell-engager-antibody-single-chain-fragment-crystallizable-moiety-binds-b-cell-maturation-antigen-surface-receptor_en.pdf"},
    {"id":"47919","name":"P/0019/2020: EMA decision of 3 January 2020 on the granting of a product specific waiver for iberdomide (EMEA-002636-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/671589/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2020-ema-decision-3-january-2020-granting-product-specific-waiver-iberdomide-emea-002636-pip01-19_en.pdf"},
    {"id":"47920","name":"P/0018/2020: EMA decision of 6 January 2020 on the granting of a product specific waiver for sacituzumab govitecan (EMEA-002645-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/672902/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2020-ema-decision-6-january-2020-granting-product-specific-waiver-sacituzumab-govitecan-emea-002645-pip01-19_en.pdf"},
    {"id":"47921","name":"P/0056/2020: EMA decision of 10 February 2020 on the granting of a product specific waiver for levocetirizine / montelukast (EMEA-002646-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/28566/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2020-ema-decision-10-february-2020-granting-product-specific-waiver-levocetirizine-montelukast-emea-002646-pip01-19_en.pdf"},
    {"id":"47927","name":"P/0045/2020: EMA decision of 29 January 2020 on the granting of a product specific waiver for futibatinib (EMEA-002647-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/26705/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2020-ema-decision-29-january-2020-granting-product-specific-waiver-futibatinib-emea-002647-pip01-19_en.pdf"},
    {"id":"47928","name":"P/0044/2020: EMA decision of 29.01.2020 on the granting of a product specific waiver for humanized immunoglobulin (Ig) G4 proline, alanine, alanine (IgG4 PAA) based bispecific antibody directed against cluster of differentiation (CD) 3 receptor complex..","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/27231/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2020-ema-decision-29012020-granting-product-specific-waiver-humanized-immunoglobulin-ig-g4-proline-alanine-alanine-igg4-paa-based-bispecific-antibody-directed-against-cluster-differentiation-cd_en.pdf"},
    {"id":"47929","name":"P/0043/2020: EMA decision of 29 January 2020 on the granting of a product specific waiver for glibenclamide (EMEA-002651-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/12840/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2020-ema-decision-29-january-2020-granting-product-specific-waiver-glibenclamide-emea-002651-pip01-19_en.pdf"},
    {"id":"47930","name":"P/0035/2020: EMA decision of 29 January 2020 on the granting of a product specific waiver for benzocaine (EMEA-002654-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/28562/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2020-ema-decision-29-january-2020-granting-product-specific-waiver-benzocaine-emea-002654-pip02-19_en.pdf"},
    {"id":"47931","name":"P/0042/2020: EMA decision of 29 January 2020 on the granting of a product specific waiver for rhPSMA-7.3 (18F) (EMEA-002657-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/26708/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2020-ema-decision-29-january-2020-granting-product-specific-waiver-rhpsma-73-18f-emea-002657-pip01-19_en.pdf"},
    {"id":"47932","name":"P/0041/2020: EMA decision of 29 January 2020 on the granting of a product specific waiver for modified human papillomavirus capsid protein conjugated to the near-infrared dye silicate(5-),bis[N-[3-[(hydroxy-.kappa.O)dimethylsilyl]propyl]-3- sulfo-N,N-b...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/26709/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2020-ema-decision-29-january-2020-granting-product-specific-waiver-modified-human-papillomavirus-capsid-protein-conjugated-near-infrared-dye-silicate5-bisn-3-hydroxy-kappaodimethylsilylpropyl-3_en.pdf"},
    {"id":"47933","name":"P/0016/2020: EMA decision of 6 January 2020 on the granting of a product specific waiver for ethanol (EMEA-002672-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/659448/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2020-ema-decision-6-january-2020-granting-product-specific-waiver-ethanol-emea-002672-pip01-19_en.pdf"},
    {"id":"47934","name":"P/0054/2020: EMA decision of 10 February 2020 on the granting of a product specific waiver for ripasudil (EMEA-002676-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/28567/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2020-ema-decision-10-february-2020-granting-product-specific-waiver-ripasudil-emea-002676-pip01-19_en.pdf"},
    {"id":"47935","name":"P/0040/2020: EMA decision of 29 January 2020 on the granting of a product specific waiver for physostigmine / hyoscine (EMEA-002678-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/12863/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2020-ema-decision-29-january-2020-granting-product-specific-waiver-physostigmine-hyoscine-emea-002678-pip01-19_en.pdf"},
    {"id":"47936","name":"P/0039/2020: EMA decision of 29 January 2020 on the granting of a product specific waiver for autologous dendritic cells activated by transient exposure to killed prostate cancer cells ex vivo (DCVAC/PCa) (EMEA-002679-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/23326/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2020-ema-decision-29-january-2020-granting-product-specific-waiver-autologous-dendritic-cells-activated-transient-exposure-killed-prostate-cancer-cells-ex-vivo-dcvac-pca-emea-002679-pip01-19_en.pdf"},
    {"id":"47937","name":"P/0038/2020: EMA decision of 29 January 2020 on the granting of a product specific waiver for 3-[4-(4-Aminopiperidin-1-yl)-3-(3,5- difluorophenyl)quinolin-6-yl]-2-hydroxybenzonitrile (CRN00808) (EMEA-002682-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T14:00:00Z","last_updated_date":"2020-06-10T14:00:00Z","reference_number":"EMA/23328/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2020-ema-decision-29-january-2020-granting-product-specific-waiver-3-4-4-aminopiperidin-1-yl-3-35-difluorophenylquinolin-6-yl-2-hydroxybenzonitrile-crn00808-emea-002682-pip01-19_en.pdf"},
    {"id":"47955","name":"P/0028/2020: EMA decision of 17 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for zoledronic acid (Aclasta), (EMEA-000057-PIP01-07-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T14:00:00Z","last_updated_date":"2020-06-11T14:00:00Z","reference_number":"EMA/12235/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2020-ema-decision-17-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-zoledronic-acid-aclasta-emea-000057-pip01-07-m07_en.pdf"},
    {"id":"47956","name":"P/0003/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for belimumab (Benlysta) (EMEA-000520-PIP02-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T14:00:00Z","last_updated_date":"2020-06-11T14:00:00Z","reference_number":"EMA/672273/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-belimumab-benlysta-emea-000520-pip02-13-m03_en.pdf"},
    {"id":"47957","name":"P/0017/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta, Bydureon), (EMEA-000689-PIP01-09-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T14:00:00Z","last_updated_date":"2020-06-11T14:00:00Z","reference_number":"EMA/672568/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-exenatide-byetta-bydureon-emea-000689-pip01-09-m09_en.pdf"},
    {"id":"47958","name":"P/0013/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate) (Lixiana), (EMEA-000788-PIP02-11-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T14:00:00Z","last_updated_date":"2020-06-11T14:00:00Z","reference_number":"EMA/658953/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-lixiana-emea-000788-pip02-11-m09_en.pdf"},
    {"id":"47959","name":"P/0036/2020: EMA decision of 29 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine (EMEA- 000877-PIP03-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T14:00:00Z","last_updated_date":"2020-06-11T14:00:00Z","reference_number":"EMA/27422/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2020-ema-decision-29-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-bupivacaine-emea-000877-pip03-17-m01_en.pdf"},
    {"id":"47960","name":"P/0034/2020: EMA decision of 29 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lipegfilgrastim (Lonquex), (EMEA-001019-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T14:00:00Z","last_updated_date":"2020-06-11T14:00:00Z","reference_number":"EMA/26689/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2020-ema-decision-29-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-lipegfilgrastim-lonquex-emea-001019-pip01-10-m05_en.pdf"},
    {"id":"47961","name":"P/0014/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Human Cell Line recombinant human Factor VIII (human-cl rhFVIII) / Human Coagulation Factor VIII (rDNA)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T14:00:00Z","last_updated_date":"2020-06-11T14:00:00Z","reference_number":"EMA/658950/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-human-cell-line-recombinant-human-factor-viii-human-cl-rhfviii-human-coagulation-factor-viii-rdna_en.pdf"},
    {"id":"47962","name":"P/0031/2020: EMA decision of 29 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for albutrepenonacog alfa (Idelvion), (EMEA-001107-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T14:00:00Z","last_updated_date":"2020-06-11T14:00:00Z","reference_number":"EMA/12071/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2020-ema-decision-29-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-albutrepenonacog-alfa-idelvion-emea-001107-pip01-10-m04_en.pdf"},
    {"id":"47963","name":"P/0033/2020: EMA decision of 29 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (Lenvima, Kisplyx), (EMEA-001119-PIP02-12-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T14:00:00Z","last_updated_date":"2020-06-11T14:00:00Z","reference_number":"EMA/26696/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2020-ema-decision-29-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-lenvima-kisplyx-emea-001119-pip02-12-m06_en.pdf"},
    {"id":"47964","name":"P/0025/2020: EMA decision of 7 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for fosnetupitant / palonosetron (Akynzeo), (EMEA-001198-PIP03-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T14:00:00Z","last_updated_date":"2020-06-11T14:00:00Z","reference_number":"EMA/694414/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2020-ema-decision-7-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-fosnetupitant-palonosetron-akynzeo-emea-001198-pip03-17-m03_en.pdf"},
    {"id":"47972","name":"P/0002/2020: EMA decision of 3 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tolvaptan (Samsca and associated names), (EMEA-001231-PIP02-13-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T14:00:00Z","last_updated_date":"2020-06-12T14:00:00Z","reference_number":"EMA/643797/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2020-ema-decision-3-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-tolvaptan-samsca-associated-names-emea-001231-pip02-13-m07_en.pdf"},
    {"id":"47973","name":"P/0005/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for daclizumab (EMEA-001349-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T14:00:00Z","last_updated_date":"2020-06-12T14:00:00Z","reference_number":"EMA/672291/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-daclizumab-emea-001349-pip01-12-m03_en.pdf"},
    {"id":"47974","name":"P/0027/2020: EMA decision of 9 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for nivolumab (Opdivo), (EMEA-001407-PIP02-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T14:00:00Z","last_updated_date":"2020-06-12T14:00:00Z","reference_number":"EMA/6299/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2020-ema-decision-9-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-nivolumab-opdivo-emea-001407-pip02-15-m03_en.pdf"},
    {"id":"47975","name":"P/0062/2020: EMA decision of 10 February 2020 on the acceptance of a modification of an agreed paediatric investigation plan for inotuzumab ozogamicin (Besponsa),(EMEA-001429-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T14:00:00Z","last_updated_date":"2020-06-12T14:00:00Z","reference_number":"EMA/557305/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2020-ema-decision-10-february-2020-acceptance-modification-agreed-paediatric-investigation-plan-inotuzumab-ozogamicin-besponsaemea-001429-pip01-13-m03_en.pdf"},
    {"id":"47976","name":"P/0011/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP02-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T14:00:00Z","last_updated_date":"2020-06-12T14:00:00Z","reference_number":"EMA/672738/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip02-13-m04_en.pdf"},
    {"id":"47977","name":"P/0024/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for luspatercept (EMEA-001521-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T14:00:00Z","last_updated_date":"2020-06-12T14:00:00Z","reference_number":"EMA/672529/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-luspatercept-emea-001521-pip01-13-m04_en.pdf"},
    {"id":"47978","name":"P/0065/2020: EMA decision of 21 February 2020 on the acceptance of a modification of an agreed PIP for live, attenuated, chimeric dengue virus, serotype 1 / live, attenuated, chimeric dengue virus, serotype 2 / live, attenuated, chimeric dengue virus...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T14:00:00Z","last_updated_date":"2025-12-04T12:12:00Z","reference_number":"EMA/85734/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2020-ema-decision-21-february-2020-acceptance-modification-agreed-pip-live-attenuated-chimeric-dengue-virus-serotype-1-live-attenuated-chimeric-dengue-virus-serotype-2-live-attenuated-chimeric_en.pdf"},
    {"id":"47979","name":"P/0063/2020: EMA decision of 20 February 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir alafenamide (as fumarate) (Vemlidy), (EMEA-001584-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T14:00:00Z","last_updated_date":"2020-06-12T14:00:00Z","reference_number":"EMA/73226/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2020-ema-decision-20-february-2020-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-alafenamide-fumarate-vemlidy-emea-001584-pip01-13-m05_en.pdf"},
    {"id":"47983","name":"P/0012/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tezepelumab (EMEA-001613-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/672331/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-tezepelumab-emea-001613-pip01-14-m04_en.pdf"},
    {"id":"47984","name":"P/0008/2020: EMA decision of 3 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod (hydrochloride) (EMEA-001710-PIP03-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/643796/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2020-ema-decision-3-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-ozanimod-hydrochloride-emea-001710-pip03-17-m01_en.pdf"},
    {"id":"47986","name":"P/0020/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/658747/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-haematopoietic-stem-cells-transduced-lentiviral-vector-encoding-human-betaa-t87q_en.pdf"},
    {"id":"47987","name":"P/0037/2020: EMA decision of 29 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2)...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/19103/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2020-ema-decision-29-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h3n2_en.pdf"},
    {"id":"47988","name":"P/0032/2020: EMA decision of 29 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for vamorolone (EMEA-001794-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/12125/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2020-ema-decision-29-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-vamorolone-emea-001794-pip02-16-m02_en.pdf"}    {"id":"47989","name":"P/0006/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir / velpatasvir / voxilaprevir (Vosevi), (EMEA-001822-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/658961/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-sofosbuvir-velpatasvir-voxilaprevir-vosevi-emea-001822-pip01-15-m01_en.pdf"},
    {"id":"47990","name":"P/0047/2020: EMA decision of 29 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for cannabidiol (CBD) (EMEA-001964-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/22234/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2020-ema-decision-29-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-cannabidiol-cbd-emea-001964-pip01-16-m01_en.pdf"},
    {"id":"47991","name":"P/0060/2020: EMA decision of 10 February 2020 on the acceptance of a modification of an agreed paediatric investigation plan for vosoritide (BMN 111), (EMEA-002033-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/67795/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2020-ema-decision-10-february-2020-acceptance-modification-agreed-paediatric-investigation-plan-vosoritide-bmn-111-emea-002033-pip01-16-m01_en.pdf"},
    {"id":"47992","name":"P/0004/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lumasiran (ALN-GO1) (EMEA-002079-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/658963/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-lumasiran-aln-go1-emea-002079-pip01-16-m01_en.pdf"},
    {"id":"47993","name":"P/0058/2020: EMA decision of 14 February 2020 on the refusal of a modification of an agreed paediatric investigation plan for fluticasone furoate / umeclidinium bromide / vilanterol trifenatate (Trelegy Ellipta / Elebrato Ellipta / Temybric Ellipta)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/27242/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2020-ema-decision-14-february-2020-refusal-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-umeclidinium-bromide-vilanterol-trifenatate-trelegy-ellipta-elebrato-ellipta_en.pdf"},
    {"id":"47994","name":"P/0030/2020: EMA decision of 29 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for (RS)-baclofen / Naltrexone HCl / D-Sorbitol (PXT3003) (EMEA-002164-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/12127/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2020-ema-decision-29-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-rs-baclofen-naltrexone-hcl-d-sorbitol-pxt3003-emea-002164-pip01-17-m02_en.pdf"},
    {"id":"47995","name":"P/0023/2020: EMA decision of 3 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for abrocitinib (EMEA- 002312-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/643791/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2020-ema-decision-3-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-abrocitinib-emea-002312-pip01-17-m01_en.pdf"},
    {"id":"47996","name":"P/0007/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for avapritinib (EMEA-002358-PIP02-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/658960/2019","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan-avapritinib-emea-002358-pip02-18-m01_en.pdf"},
    {"id":"47997","name":"P/0064/2020: EMA decision of 20 February 2020 on the acceptance of a modification of an agreed paediatric investigation plan for split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain, A/H3N2-like strain, B-like...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-06-12T11:57:00Z","last_updated_date":"2020-06-12T11:57:00Z","reference_number":"EMA/79374/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2020-ema-decision-20-february-2020-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigens-equivalent-h1n1-strain-h3n2-strain-b_en.pdf"},
    {"id":"48438","name":"P/0123/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for natalizumab (Tysabri), (EMEA-001095-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/136524/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2020-ema-decision-18-march-2020-granting-product-specific-waiver-natalizumab-tysabri-emea-001095-pip03-19_en.pdf"},
    {"id":"48439","name":"P/0096/2020: EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for avatrombopag maleate (Doptelet), (EMEA-001136-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/115517/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2020-ema-decision-18-march-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-avatrombopag-maleate-doptelet-emea-001136-pip02-19_en.pdf"},
    {"id":"48440","name":"P/0070/2020: EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for baricitinib (Olumiant) (EMEA-001220-PIP05-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/83628/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2020-ema-decision-18-march-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-baricitinib-olumiant-emea-001220-pip05-19_en.pdf"},
    {"id":"48441","name":"P/0119/2020: EMA decision of 20 March 2020 on the granting of a product specific waiver for nemolizumab (EMEA-001624-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/100927/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2020-ema-decision-20-march-2020-granting-product-specific-waiver-nemolizumab-emea-001624-pip02-19_en.pdf"},
    {"id":"48442","name":"P/0099/2020: EMA decision of 18 March 2020 on agreement of a PIP and on granting of deferral and waiver for allogeneic, ex vivo expanded, umbilical cord blood-derived, haematopoietic CD34+progenitor cells (CF) / allogeneic, non-expanded, ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/76624/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2020-ema-decision-18-march-2020-agreement-pip-granting-deferral-waiver-allogeneic-ex-vivo-expanded-umbilical-cord-blood-derived-haematopoietic-cd34progenitor-cells-cf-allogeneic-non-expanded_en.pdf"},
    {"id":"48443","name":"P/0095/2020: EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for cannabidiol (Epidyolex), (EMEA-001964-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/115522/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2020-ema-decision-18-march-2020-agreement-paediatric-investigation-plan-granting-waiver-cannabidiol-epidyolex-emea-001964-pip02-19_en.pdf-0"},
    {"id":"48444","name":"P/0116/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for daratumumab (Darzalex), (EMEA-002152-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/124393/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2020-ema-decision-18-march-2020-granting-product-specific-waiver-daratumumab-darzalex-emea-002152-pip03-19_en.pdf"},
    {"id":"48445","name":"P/0079/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for rosuvastatin / ezetimibe (Rosuvastatin/Ezetimibe Elpen and associated names), (EMEA-002257-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/114310/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2020-ema-decision-18-march-2020-granting-product-specific-waiver-rosuvastatin-ezetimibe-rosuvastatin-ezetimibe-elpen-associated-names-emea-002257-pip02-19_en.pdf"},
    {"id":"48446","name":"P/0100/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for gefapixant (citrate salt) (EMEA-002267-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/76893/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2020-ema-decision-18-march-2020-granting-product-specific-waiver-gefapixant-citrate-salt-emea-002267-pip03-19_en.pdf"},
    {"id":"48447","name":"P/0083/2020: EMA decision of 18 March 2020 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for avapritinib (EMEA-002358-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/76608/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2020-ema-decision-18-march-2020-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-avapritinib-emea-002358-pip03-19_en.pdf"},
    {"id":"48449","name":"P/0085/2020: EMA decision of 20 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for timrepigene emparvovec (EMEA-002430-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2020-07-28T14:00:00Z","reference_number":"EMA/101166/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2020-ema-decision-20-march-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-timrepigene-emparvovec-emea-002430-pip01-18_en.pdf"},
    {"id":"48450","name":"EMA/PE/0000181993 : EMA decision of 8 Nov 2024 on the acceptance of a modification of an agreed paediatric investigation plan for mosunetuzumab (Lunsumio)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-28T14:00:00Z","last_updated_date":"2026-05-06T11:11:11Z","reference_number":"EMADOC-1700519818-3003858 Corr.","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181993-ema-decision-8-nov-2024-acceptance-modification-agreed-paediatric-investigation-plan-mosunetuzumab-lunsumio_en.pdf"},
    {"id":"48470","name":"P/0124/2020: EMA decision of 24 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ladarixin (EMEA-002642-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-29T11:53:00Z","last_updated_date":"2020-07-29T11:53:00Z","reference_number":"EMA/140669/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2020-ema-decision-24-march-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ladarixin-emea-002642-pip01-19_en.pdf"},
    {"id":"48471","name":"P/0122/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (EMEA-002526-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-29T11:53:00Z","last_updated_date":"2020-07-29T11:53:00Z","reference_number":"EMA/130405/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2020-ema-decision-18-march-2020-granting-product-specific-waiver-1-4-bromo-5-1-ethyl-7-methylamino-2-oxo-12-dihydro-16-naphthyridin-3-yl-2-fluorophenyl-3-phenylurea-emea-002526-pip02-19_en.pdf"},
    {"id":"48472","name":"P/0098/2020: EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tris(hydroxymethyl)aminomethane trihydrate (PF-05221304-82) (EMEA- 002552-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-29T11:53:00Z","last_updated_date":"2020-07-29T11:53:00Z","reference_number":"EMA/115516/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2020-ema-decision-18-march-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-trishydroxymethylaminomethane-trihydrate-pf-05221304-82-emea-002552-pip01-19_en.pdf"},
    {"id":"48473","name":"P/0117/2020: EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-neonatal Fc receptor human monoclonal antibody(EMEA-002559-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-29T11:53:00Z","last_updated_date":"2020-07-29T11:53:00Z","reference_number":"EMA/124386/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2020-ema-decision-18-march-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-neonatal-fc-receptor-human-monoclonal-antibodyemea-002559-pip02-19_en.pdf"},
    {"id":"48474","name":"P/0106/2020: EMA decision of 20 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous CD34+ haematopoietic stem cells transduced ex vivo with a lentiviral vector...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-29T11:53:00Z","last_updated_date":"2020-07-29T11:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2020-ema-decision-20-march-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-cd34-haematopoietic-stem-cells-transduced-ex-vivo-lentiviral-vector_en.pdf"},
    {"id":"48475","name":"P/0120/2020: EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for cenobamate (EMEA-002563-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-29T11:53:00Z","last_updated_date":"2020-07-29T11:53:00Z","reference_number":"EMA/127868/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2020-ema-decision-18-march-2020-agreement-paediatric-investigation-plan-granting-deferral-cenobamate-emea-002563-pip02-19_en.pdf"},
    {"id":"48476","name":"P/0115/2020: EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for soticlestat (EMEA-002572-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-29T11:53:00Z","last_updated_date":"2020-07-29T11:53:00Z","reference_number":"EMA/76623/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2020-ema-decision-18-march-2020-agreement-paediatric-investigation-plan-granting-deferral-soticlestat-emea-002572-pip01-19_en.pdf"},
    {"id":"48477","name":"P/0002/2024 : EMA decision of 3 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for mozafancogene autotemcel, (EMEA-002578-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T11:53:00Z","last_updated_date":"2025-03-14T11:53:00Z","reference_number":"EMA/879/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2024-ema-decision-3-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-mozafancogene-autotemcel-emea-002578-pip01-19-m01_en.pdf"},
    {"id":"48478","name":"P/0097/2020: EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efgartigimod alfa (EMEA-002597-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-29T11:53:00Z","last_updated_date":"2020-07-29T11:53:00Z","reference_number":"EMA/76622/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2020-ema-decision-18-march-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-efgartigimod-alfa-emea-002597-pip01-19_en.pdf"},
    {"id":"48479","name":"P/0073/2020: EMA decision of 21 March 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for zoliflodacin (EMEA-002599-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-29T11:53:00Z","last_updated_date":"2020-07-29T11:53:00Z","reference_number":"EMA/83593/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2020-ema-decision-21-march-2020-agreement-paediatric-investigation-plan-granting-waiver-zoliflodacin-emea-002599-pip01-19_en.pdf"},
    {"id":"48490","name":"P/0094/2020: EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant anti-human CD20 and anti-human CD3 monoclonal antibody(RO7082859;CD20 CD3 TCB)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-30T12:12:00Z","last_updated_date":"2020-07-30T12:12:00Z","reference_number":"EMA/115521/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2020-ema-decision-18-march-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-anti-human-cd20-anti-human-cd3-monoclonal-antibodyro7082859cd20-cd3-tcb_en.pdf"},
    {"id":"48491","name":"P/0077/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for 5%-Δ9-tetrahydrocannabinol standardised Cannabis extract (EMEA-002668-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-30T12:12:00Z","last_updated_date":"2020-07-30T12:12:00Z","reference_number":"EMA/83650/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2020-ema-decision-18-march-2020-granting-product-specific-waiver-5-d9-tetrahydrocannabinol-standardised-cannabis-extract-emea-002668-pip01-19_en.pdf"},
    {"id":"48492","name":"P/0113/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide (EMEA-002686-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-30T12:12:00Z","last_updated_date":"2020-07-30T12:12:00Z","reference_number":"EMA/124396/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2020-ema-decision-18-march-2020-granting-product-specific-waiver-2s-2-2-4s-4-difluoromethyl-2-oxo-oxazolidin-3-yl-56-dihydroimidazo12-d14benzoxazepin-9-ylaminopropanamide-emea-002686-pip01-19_en.pdf"},
    {"id":"48493","name":"P/0068/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for Levodopa / Carbidopa (EMEA-002687-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-30T12:12:00Z","last_updated_date":"2020-07-30T12:12:00Z","reference_number":"EMA/83476/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2020-ema-decision-18-march-2020-granting-product-specific-waiver-levodopa-carbidopa-emea-002687-pip01-19_en.pdf"},
    {"id":"48494","name":"P/0091/2020: EMA decision of 18.03.20 on the granting of a product specific waiver for 6 fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4- methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3- d]pyrimidin-2(1H)-one","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-30T12:12:00Z","last_updated_date":"2020-07-30T12:12:00Z","reference_number":"EMA/115514/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2020-ema-decision-180320-granting-product-specific-waiver-6-fluoro-7-2-fluoro-6-hydroxyphenyl-1m-1-4-methyl-2-propan-2-ylpyridin-3-yl-4-2s-2-methyl-4-prop-2-enoylpiperazin-1-ylpyrido23_en.pdf"},
    {"id":"48495","name":"P/0112/2020: EMA decision of 20 March 2020 on the granting of a product specific waiver for brolucizumab (EMEA-002691-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T12:12:00Z","last_updated_date":"2020-07-31T12:12:00Z","reference_number":"EMA/100929/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2020-ema-decision-20-march-2020-granting-product-specific-waiver-brolucizumab-emea-002691-pip01-19_en.pdf"},
    {"id":"48496","name":"P/0090/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for zolbetuximab (EMEA-002695-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T12:12:00Z","last_updated_date":"2020-07-31T12:12:00Z","reference_number":"EMA/115515/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2020-ema-decision-18-march-2020-granting-product-specific-waiver-zolbetuximab-emea-002695-pip01-19_en.pdf"},
    {"id":"48497","name":"P/0067/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for Parsaclisib (EMEA-002696-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T12:12:00Z","last_updated_date":"2020-07-31T12:12:00Z","reference_number":"EMA/83522/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2020-ema-decision-18-march-2020-granting-product-specific-waiver-parsaclisib-emea-002696-pip01-19_en.pdf"},
    {"id":"48498","name":"P/0118/2020: EMA decision of 27 March 2020 on the granting of a product specific waiver for eftilagimod alpha (EMEA-002698-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T12:12:00Z","last_updated_date":"2020-07-31T12:12:00Z","reference_number":"EMA/100930/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2020-ema-decision-27-march-2020-granting-product-specific-waiver-eftilagimod-alpha-emea-002698-pip01-19_en.pdf"},
    {"id":"48499","name":"P/0110/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for verdiperstat (EMEA-002708-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T12:12:00Z","last_updated_date":"2020-07-31T12:12:00Z","reference_number":"EMA/124402/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2020-ema-decision-18-march-2020-granting-product-specific-waiver-verdiperstat-emea-002708-pip01-19_en.pdf"},
    {"id":"48518","name":"P/0102/2020: EMA decision of 20 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Prolia, Xgeva), (EMEA-000145-PIP02-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T13:42:00Z","last_updated_date":"2020-07-31T13:42:00Z","reference_number":"EMA/100872/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2020-ema-decision-20-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-prolia-xgeva-emea-000145-pip02-12-m02_en.pdf"},
    {"id":"48519","name":"P/0072/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Perampanel (Fycompa) (EMEA-000467-PIP01-08-M13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T13:46:00Z","last_updated_date":"2020-07-31T13:46:00Z","reference_number":"EMA/82836/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-fycompa-emea-000467-pip01-08-m13_en.pdf"},
    {"id":"48522","name":"P/0101/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for posaconazole, (Noxafil), (EMEA-000468-PIP02-12-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T13:42:00Z","last_updated_date":"2020-07-31T13:42:00Z","reference_number":"EMA/124405/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-posaconazole-noxafil-emea-000468-pip02-12-m06_en.pdf"},
    {"id":"48523","name":"P/0257/2020 : EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for alogliptin (Vipidia) (EMEA-000496-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-24T13:42:00Z","last_updated_date":"2021-06-24T13:42:00Z","reference_number":"EMA/315644/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-alogliptin-vipidia-emea-000496-pip01-08-m08_en.pdf"},
    {"id":"48524","name":"P/0121/2020: EMA decision of 20 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil fumarate) (Viread), (EMEA-000533-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T13:42:00Z","last_updated_date":"2020-07-31T13:42:00Z","reference_number":"EMA/129553/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2020-ema-decision-20-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-fumarate-viread-emea-000533-pip01-08-m08_en.pdf"},
    {"id":"48525","name":"P/0086/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin (Forxiga), (EMEA-000694-PIP01-09-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T13:42:00Z","last_updated_date":"2020-07-31T13:42:00Z","reference_number":"EMA/74167/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-forxiga-emea-000694-pip01-09-m08_en.pdf"},
    {"id":"48528","name":"P/0149/2020: EMA decision 17 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pegcetacoplan (EMEA-002600-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-03T10:25:00Z","last_updated_date":"2020-08-03T10:25:00Z","reference_number":"EMA/173232/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2020-ema-decision-17-april-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pegcetacoplan-emea-002600-pip01-19_en.pdf"},
    {"id":"48531","name":"P/0075/2020: EMA decision of 21 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Eculizumab (Soliris) (EMEA-000876-PIP03-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-03T11:06:00Z","last_updated_date":"2020-08-03T11:06:00Z","reference_number":"EMA/82886/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2020-ema-decision-21-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip03-14-m04_en.pdf"},
    {"id":"48532","name":"P/0111/2020: EMA decision 20 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for sonidegib (Odomzo), (EMEA-000880-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-03T11:16:00Z","last_updated_date":"2020-08-03T11:16:00Z","reference_number":"EMA/100871/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2020-ema-decision-20-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-sonidegib-odomzo-emea-000880-pip02-11-m04_en.pdf"},
    {"id":"48533","name":"P/0071/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Eftrenonacog alfa (Alprolix) (EMEA-000914-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-03T11:24:00Z","last_updated_date":"2020-08-03T11:24:00Z","reference_number":"EMA/83075/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-eftrenonacog-alfa-alprolix-emea-000914-pip01-10-m05_en.pdf"},
    {"id":"48534","name":"P/0125/2020: EMA decision of 30 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins, (Xeomin, Bocouture), (EMEA-001039-PIP02-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-03T11:31:00Z","last_updated_date":"2020-08-03T11:31:00Z","reference_number":"EMA/157768/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2020-ema-decision-30-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-clostridium-botulinum-neurotoxin-type-150-kd-free-complexing-proteins-xeomin-bocouture-emea-001039_en.pdf"},
    {"id":"48535","name":"P/0087/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz) (EMEA-001050-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-03T11:41:00Z","last_updated_date":"2020-08-03T11:41:00Z","reference_number":"EMA/124408/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-ixekizumab-taltz-emea-001050-pip01-10-m05_en.pdf"},
    {"id":"48536","name":"P/0081/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for idasanutlin (EMEA-001489-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-03T11:59:00Z","last_updated_date":"2020-08-03T11:59:00Z","reference_number":"EMA/74170/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-idasanutlin-emea-001489-pip01-13-m02_en.pdf"},
    {"id":"48537","name":"P/0069/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Sodium zirconium cyclosilicate (Lokelma) (EMEA-001539-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-03T12:08:00Z","last_updated_date":"2020-08-03T12:08:00Z","reference_number":"EMA/83093/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-sodium-zirconium-cyclosilicate-lokelma-emea-001539-pip01-13-m04_en.pdf"},
    {"id":"48539","name":"P/0107/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for eluxadoline (Truberzi), (EMEA-001579-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T09:54:00Z","last_updated_date":"2020-08-04T09:54:00Z","reference_number":"EMA/124410/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-eluxadoline-truberzi-emea-001579-pip01-13-m03_en.pdf"},
    {"id":"48540","name":"P/0104/2020: EMA decision of 20 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for bezlotoxumab (Zinplava), (EMEA-001645-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T10:10:00Z","last_updated_date":"2020-08-04T10:10:00Z","reference_number":"EMA/100904/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2020-ema-decision-20-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-bezlotoxumab-zinplava-emea-001645-pip01-14-m03_en.pdf"},
    {"id":"48541","name":"P/0093/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for burosumab (Crysvita), (EMEA-001659-PIP01-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T10:18:00Z","last_updated_date":"2020-08-04T10:18:00Z","reference_number":"EMA/115382/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-burosumab-crysvita-emea-001659-pip01-15-m04_en.pdf"},
    {"id":"48542","name":"P/0082/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for anti-respiratory syncytial virus human IgG1κ monoclonal antibody (MEDI8897) (EMEA-001784-PIP01-15-M02 )","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T11:39:00Z","last_updated_date":"2020-08-04T11:39:00Z","reference_number":"EMA/115384/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-anti-respiratory-syncytial-virus-human-igg1k-monoclonal-antibody-medi8897-emea-001784-pip01-15-m02_en.pdf"},
    {"id":"48543","name":"P/0074/2020: EMA decision of 21 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Vadadustat (EMEA-001944-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T11:46:00Z","last_updated_date":"2020-08-04T11:46:00Z","reference_number":"EMA/83575/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2020-ema-decision-21-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-vadadustat-emea-001944-pip01-16-m01_en.pdf"},
    {"id":"48544","name":"P/0103/2020: EMA decision of 20 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for avacopan (EMEA-002023-PIP01-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T11:54:00Z","last_updated_date":"2020-08-04T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2020-ema-decision-20-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-avacopan-emea-002023-pip01-16-m04_en.pdf"},
    {"id":"48545","name":"P/0109/2020: EMA decision of 20 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for emapalumab (EMEA-002031-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T14:29:00Z","last_updated_date":"2020-08-04T14:29:00Z","reference_number":"EMA/100919/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2020-ema-decision-20-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-emapalumab-emea-002031-pip01-16-m03_en.pdf"},
    {"id":"48546","name":"P/0084/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) / Influenza virus surface antigens (haemag","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T14:34:00Z","last_updated_date":"2020-08-04T14:34:00Z","reference_number":"EMA/125996/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h1n1-influenza-virus-surface_en.pdf"},
    {"id":"48547","name":"P/0089/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for risdiplam (EMEA-002070-PIP01-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T14:39:00Z","last_updated_date":"2020-08-04T14:39:00Z","reference_number":"EMA/124412/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-risdiplam-emea-002070-pip01-16-m04_en.pdf"},
    {"id":"48548","name":"P/0092/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for entrectinib (EMEA-002096-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T14:44:00Z","last_updated_date":"2020-08-04T14:44:00Z","reference_number":"EMA/73697 /2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-entrectinib-emea-002096-pip01-16-m02_en.pdf"},
    {"id":"48549","name":"P/0088/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine / meloxicam (HTX-011) (EMEA-002246-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T16:17:00Z","last_updated_date":"2020-08-04T16:17:00Z","reference_number":"EMA/74174/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-bupivacaine-meloxicam-htx-011-emea-002246-pip01-17-m01_en.pdf"},
    {"id":"48550","name":"P/0105/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for evinacumab (EMEA-002298-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-08-04T16:21:00Z","last_updated_date":"2020-08-04T16:21:00Z","reference_number":"EMA/74175/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2020-ema-decision-18-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-evinacumab-emea-002298-pip01-17-m01_en.pdf"},
    {"id":"49594","name":"P/0480/2020: EMA decision of 27 November 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for highly purified single-stranded, 5’-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2) (EMEA-002861..","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-12-18T11:45:00Z","last_updated_date":"2020-12-18T11:45:00Z","reference_number":"EMA/640530/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0480-2020-ema-decision-27-november-2020-agreement-paediatric-investigation-plan-granting-deferral-highly-purified-single-stranded-5-capped-mrna-encoding-full-length-sars-cov-2-spike-protein-bnt162b2_en.pdf"},
    {"id":"49595","name":"P/0481/2020: EMA decision of 30 November 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for mRNA that encodes for the pre-fusion stabilized spike glycoprotein of SARS-CoV-2 (mRNA-1273) (EMEA-002893- PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2020-12-18T11:45:00Z","last_updated_date":"2020-12-18T11:45:00Z","reference_number":"EMA/639193/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0481-2020-ema-decision-30-november-2020-agreement-paediatric-investigation-plan-granting-deferral-mrna-encodes-pre-fusion-stabilized-spike-glycoprotein-sars-cov-2-mrna-1273-emea-002893-pip01-20_en.pdf"},
    {"id":"49726","name":"P/0003/2021: EMA decision of 5 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for COVID-19 vaccine (ChAdOx1-S [recombinant]) (AZD1222) (EMEA-002862-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-01-05T17:59:00Z","last_updated_date":"2021-01-05T17:59:00Z","reference_number":"EMA/1708/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2021-ema-decision-5-january-2021-agreement-paediatric-investigation-plan-granting-deferral-covid-19-vaccine-chadox1-s-recombinant-azd1222-emea-002862-pip01-20_en.pdf"},
    {"id":"50111","name":"P/0264/2020: EMA decision of 15 July 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tominersen (EMEA-002546-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-02-08T16:21:00Z","last_updated_date":"2021-02-08T16:21:00Z","reference_number":"EMA/366137/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2020-ema-decision-15-july-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tominersen-emea-002546-pip01-19_en.pdf-0"},
    {"id":"50181","name":"P/0365/2020: EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mitapivat (EMEA-002684-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T17:59:00Z","last_updated_date":"2021-02-16T17:59:00Z","reference_number":"EMA/415913/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0365-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mitapivat-emea-002684-pip01-19_en.pdf-0"},
    {"id":"50186","name":"P/0060/2021: EMA decision of 5 February 2021 on the acceptance of a modification of an agreed paediatric investigation plan for remdesivir (Veklury), (EMEA-002826-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T14:00:00Z","last_updated_date":"2021-02-16T14:00:00Z","reference_number":"EMA/71518/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2021-ema-decision-5-february-2021-acceptance-modification-agreed-paediatric-investigation-plan-remdesivir-veklury-emea-002826-pip01-20-m01_en.pdf"},
    {"id":"50187","name":"P/0062/2021: EMA decision of 5 February 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for baricitinib (Olumiant), (EMEA-001220-PIP07-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-02-16T14:00:00Z","last_updated_date":"2021-02-16T14:00:00Z","reference_number":"EMA/501874/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2021-ema-decision-5-february-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-baricitinib-olumiant-emea-001220-pip07-20_en.pdf"},
    {"id":"50188","name":"P/0059/2021: EMA decision of 5 February 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for COVID-19 vaccine (Ad26.COV2-S (recombinant)) (EMEA-002880-PIP01-20)","type":"pip-decision","status":"Draft","consultation_date":"","first_published_date":"2021-02-16T14:07:00Z","last_updated_date":"2021-02-16T14:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2021-ema-decision-5-february-2021-agreement-paediatric-investigation-plan-granting-deferral-covid-19-vaccine-ad26cov2-s-recombinant-emea-002880-pip01-20_en.pdf"},
    {"id":"50333","name":"P/0134/2020: EMA decision of 15 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for alpha1-proteinase inhibitor (human) (A1-PI) (EMEA-001312-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-03T14:00:00Z","last_updated_date":"2021-03-03T14:00:00Z","reference_number":"EMA/132888/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2020-ema-decision-15-april-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-alpha1-proteinase-inhibitor-human-a1-pi-emea-001312-pip02-19_en.pdf"},
    {"id":"50334","name":"P/0140/2020: EMA decision of 18 April 2020 on the granting of a product specific waiver for lanadelumab (Takhzyro) (EMEA-001864-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-03T14:00:00Z","last_updated_date":"2021-03-03T14:00:00Z","reference_number":"EMA/174092/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2020-ema-decision-18-april-2020-granting-product-specific-waiver-lanadelumab-takhzyro-emea-001864-pip02-19_en.pdf"},
    {"id":"50335","name":"P/166/2020: EMA decision of 24 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lenadogene nolparvovec (GS010), (EMEA-001992-PIP02-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-03T14:00:00Z","last_updated_date":"2021-03-03T14:00:00Z","reference_number":"EMA/175725/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-166-2020-ema-decision-24-april-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lenadogene-nolparvovec-gs010-emea-001992-pip02-16_en.pdf"},
    {"id":"50336","name":"P/0152/2020: EMA decision of 18 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for leriglitazone (EMEA-002106-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-03T14:00:00Z","last_updated_date":"2021-03-03T14:00:00Z","reference_number":"EMA/174247/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2020-ema-decision-18-april-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-leriglitazone-emea-002106-pip01-16_en.pdf"},
    {"id":"50338","name":"P/0131/2020: EMA decision of 15.04.2020 on agreement of a PIP and on granting of a deferral and of a waiver for (S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1- yl)(4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-03T14:00:00Z","last_updated_date":"2021-03-03T14:00:00Z","reference_number":"EMA/132886/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2020-ema-decision-15042020-agreement-pip-granting-deferral-waiver-s-2-5-chloro-4-methyl-1h-benzodimidazol-2-yl-2-methylpyrrolidin-1-yl4-methoxy-2-2h-123-triazol-2-ylphenylmethanone_en.pdf"},
    {"id":"50339","name":"P/0148/2020: EMA decision of 18 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-03T14:00:00Z","last_updated_date":"2021-03-03T14:00:00Z","reference_number":"EMA/174870/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2020-ema-decision-18-april-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-2-2-ethyl-6-4-2-3-hydroxyazetidin-1-yl-2-oxoethylpiperazin-1-yl_en.pdf"},
    {"id":"50340","name":"P/0129/2020: EMA decision of 15 April 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for dihomo-γ-linolenic acid (DS107) (EMEA-002364-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-03T14:00:00Z","last_updated_date":"2021-03-03T14:00:00Z","reference_number":"EMA/132884/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2020-ema-decision-15-april-2020-agreement-paediatric-investigation-plan-granting-waiver-dihomo-g-linolenic-acid-ds107-emea-002364-pip03-19_en.pdf"},
    {"id":"50341","name":"P/0128/2020: EMA decision of 15 April 2020 on the granting of a product specific waiver for glycerol / urea (EMEA-002511-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T14:00:00Z","last_updated_date":"2021-03-04T14:00:00Z","reference_number":"EMA/132857/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2020-ema-decision-15-april-2020-granting-product-specific-waiver-glycerol-urea-emea-002511-pip02-19_en.pdf"},
    {"id":"50342","name":"P/0164/2020: EMA decision of 17 April 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for ibrexafungerp (EMEA-002535-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T14:00:00Z","last_updated_date":"2021-03-04T14:00:00Z","reference_number":"EMA/201912/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2020-ema-decision-17-april-2020-agreement-paediatric-investigation-plan-granting-waiver-ibrexafungerp-emea-002535-pip03-19_en.pdf"},
    {"id":"50343","name":"P/0151/2020: EMA decision of 17 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lebrikizumab (EMEA-002536-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T14:00:00Z","last_updated_date":"2021-03-04T14:00:00Z","reference_number":"EMA/173225/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2020-ema-decision-17-april-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lebrikizumab-emea-002536-pip01-18_en.pdf"},
    {"id":"50344","name":"P/0126/2020: EMA decision of 3 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pracinostat (EMEA-002567-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T14:00:00Z","last_updated_date":"2021-03-04T14:00:00Z","reference_number":"EMA/132877/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2020-ema-decision-3-april-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pracinostat-emea-002567-pip01-19_en.pdf"},
    {"id":"50345","name":"P/0158/2020: EMA decision of 17 April 2020 on the agreement of a PIP and on granting of a deferral and a waiver for N-(3-{6-Amino-5-[2-(N-methylprop-2-enamido)ethoxy]pyrimidin-4-yl}-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide (LOU064)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T14:00:00Z","last_updated_date":"2021-03-04T14:00:00Z","reference_number":"EMA/175676/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2020-ema-decision-17-april-2020-agreement-pip-granting-deferral-waiver-n-3-6-amino-5-2-n-methylprop-2-enamidoethoxypyrimidin-4-yl-5-fluoro-2-methylphenyl-4-cyclopropyl-2-fluorobenzamide-lou064_en.pdf"},
    {"id":"50346","name":"P/0150/2020: EMA decision of 18 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for bintrafusp alfa (EMEA-002586-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T14:00:00Z","last_updated_date":"2021-03-04T14:00:00Z","reference_number":"EMA/174909/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2020-ema-decision-18-april-2020-agreement-paediatric-investigation-plan-granting-deferral-bintrafusp-alfa-emea-002586-pip01-19_en.pdf"},
    {"id":"50347","name":"P/0157/2020: EMA decision of 17 April 2020 on the agreement of a paediatric investigation plan for polymyxin B (EMEA-002595-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T14:00:00Z","last_updated_date":"2021-03-04T14:00:00Z","reference_number":"EMA/175677/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2020-ema-decision-17-april-2020-agreement-paediatric-investigation-plan-polymyxin-b-emea-002595-pip01-19_en.pdf"},
    {"id":"50348","name":"P/0154/2020: EMA decision of 17 April 2020 on the granting of a product specific waiver for 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7- (methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (EMEA-002619-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T14:00:00Z","last_updated_date":"2021-03-05T14:00:00Z","reference_number":"EMA/173211/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2020-ema-decision-17-april-2020-granting-product-specific-waiver-3-1s2s3r-23-difluoro-1-hydroxy-7-methylsulfonyl-23-dihydro-1h-inden-4-yloxy-5-fluorobenzonitrile-emea-002619-pip01-19_en.pdf"},
    {"id":"50349","name":"P/0147/2020: EMA decision of 17 April 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for temozolomide (EMEA-002634-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T14:00:00Z","last_updated_date":"2021-03-05T14:00:00Z","reference_number":"EMA/175351/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2020-ema-decision-17-april-2020-agreement-paediatric-investigation-plan-granting-waiver-temozolomide-emea-002634-pip01-19_en.pdf"},
    {"id":"50350","name":"P/0146/2020: EMA decision of 18 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pneumococcal polysaccharides individually biotinylated & complexed with a carrier proteins","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T14:00:00Z","last_updated_date":"2021-03-05T14:00:00Z","reference_number":"EMA/174920/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2020-ema-decision-18-april-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pneumococcal-polysaccharides-individually-biotinylated-complexed-carrier-proteins_en.pdf"},
    {"id":"50351","name":"P/0153/2020: EMA decision of 17 April 2020 on the granting of a product specific waiver for 4-[4-({4-[({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo- 2,3-dihydro-1H-isoindol-4-yl}oxy)methyl]phenyl}methyl)piperazin-1-yl]-3-fluorobenzonitrile (4-[4- ({4-[({2....","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T14:00:00Z","last_updated_date":"2021-03-05T14:00:00Z","reference_number":"EMA/173212/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2020-ema-decision-17-april-2020-granting-product-specific-waiver-4-4-4-2-3s-26-dioxopiperidin-3-yl-1-oxo-23-dihydro-1h-isoindol-4-yloxymethylphenylmethylpiperazin-1-yl-3-fluorobenzonitrile-4-4_en.pdf"},
    {"id":"50352","name":"P/0161/2020: EMA decision of 16 April 2020 on the granting of a product specific waiver for propan-2-yl 2-[5-(acryloylamino)-4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxyanilino]-4-(1methyl-1H-indol-3-yl)pyrimidine-5-carboxylate (TAK-788)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-03T14:00:00Z","last_updated_date":"2021-03-03T14:00:00Z","reference_number":"EMA/194800/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2020-ema-decision-16-april-2020-granting-product-specific-waiver-propan-2-yl-2-5-acryloylamino-4-2-dimethylaminoethylmethylamino-2-methoxyanilino-4-1methyl-1h-indol-3-ylpyrimidine-5-carboxylate_en.pdf"},
    {"id":"50353","name":"P/0127/2020: EMA decision of 15 April 2020 on the granting of a product specific waiver for lazertinib (mesylate) (EMEA-002725-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-03T14:00:00Z","last_updated_date":"2021-03-03T14:00:00Z","reference_number":"EMA/132862/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2020-ema-decision-15-april-2020-granting-product-specific-waiver-lazertinib-mesylate-emea-002725-pip01-19_en.pdf"},
    {"id":"50400","name":"P/0184/2020: EMA decision of 13 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for afatinib (Giotrif), (EMEA-001596-PIP02-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T14:41:00Z","last_updated_date":"2021-03-04T14:41:00Z","reference_number":"EMA/233269/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2020-ema-decision-13-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-afatinib-giotrif-emea-001596-pip02-17-m02_en.pdf"},
    {"id":"50401","name":"P/0219/2020: EMA decision of 17 June 2020 on the refusal of a product specific waiver for bilastine (Bilaxten and associated names), (EMEA- 000347-PIP05-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T14:59:00Z","last_updated_date":"2021-03-04T14:59:00Z","reference_number":"EMA/304407/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2020-ema-decision-17-june-2020-refusal-product-specific-waiver-bilastine-bilaxten-associated-names-emea-000347-pip05-20_en.pdf"},
    {"id":"50402","name":"P/0193/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tezacaftor / ivacaftor (Symkevi), (EMEA-001640-PIP01-14-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T15:14:00Z","last_updated_date":"2021-03-04T15:14:00Z","reference_number":"EMA/233152/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-tezacaftor-ivacaftor-symkevi-emea-001640-pip01-14-m06_en.pdf"},
    {"id":"50403","name":"P/0216/2020: EMA decision of 17 June 2020 on the granting of a product specific waiver for chloroprocaine (hydrochloride) (Ampres), (EMEA-000639-PIP06-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T15:26:00Z","last_updated_date":"2021-03-04T15:26:00Z","reference_number":"EMA/258012/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2020-ema-decision-17-june-2020-granting-product-specific-waiver-chloroprocaine-hydrochloride-ampres-emea-000639-pip06-20_en.pdf"},
    {"id":"50404","name":"P/0194/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for rolapitant (Varuby), (EMEA-001768-PIP02-15-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T15:41:00Z","last_updated_date":"2021-03-04T15:41:00Z","reference_number":"EMA/178696/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-rolapitant-varuby-emea-001768-pip02-15-m03_en.pdf"}    {"id":"50406","name":"P/0210/2020: EMA decision of 16 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lenvatinib (Lenvima, Kisplyx), (EMEA-001119-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T15:46:00Z","last_updated_date":"2021-03-04T15:46:00Z","reference_number":"EMA/288163/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2020-ema-decision-16-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lenvatinib-lenvima-kisplyx-emea-001119-pip03-19_en.pdf"},
    {"id":"50407","name":"P/0188/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) (Foclivia and associated names), (EMEA- 001830-PIP01-1","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T16:02:00Z","last_updated_date":"2021-03-04T16:02:00Z","reference_number":"EMA/233153/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-pandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-foclivia-associated-names-emea_en.pdf"},
    {"id":"50408","name":"P/0185/2020: EMA decision of 13 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for volanesorsen (Waylivra) (EMEA-001915-PIP01-15-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T16:23:00Z","last_updated_date":"2021-03-04T16:23:00Z","reference_number":"EMA/240493/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2020-ema-decision-13-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-volanesorsen-waylivra-emea-001915-pip01-15-m02_en.pdf"},
    {"id":"50409","name":"P/0174/2020: EMA decision of 13 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for avalglucosidase alfa (E MEA-001945-PIP 01-16-M 02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T16:30:00Z","last_updated_date":"2021-03-04T16:30:00Z","reference_number":"EMA/242278/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2020-ema-decision-13-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-avalglucosidase-alfa-e-mea-001945-pip-01-16-m-02_en.pdf"},
    {"id":"50410","name":"P/0180/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for alicaforsen (sodium salt) (EMEA-002060-PIP02-17-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T16:38:00Z","last_updated_date":"2021-03-04T16:38:00Z","reference_number":"EMA/178697/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-alicaforsen-sodium-salt-emea-002060-pip02-17-m01_en.pdf"},
    {"id":"50411","name":"P/0173/2020: EMA decision of 13 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for gilteritinib (as fumarate) (Xospata) (EMEA-002064-PIP01-16-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T16:49:00Z","last_updated_date":"2021-03-04T16:49:00Z","reference_number":"EMA/233464/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2020-ema-decision-13-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-gilteritinib-fumarate-xospata-emea-002064-pip01-16-m02_en.pdf"},
    {"id":"50412","name":"P/0197/2020: EMA decision of 20 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for monovalent, recombinant, replication-incompetent human adenovirus serotype 26-vectored vaccine encoding the pre-fusion conformation","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T16:56:00Z","last_updated_date":"2021-03-04T16:56:00Z","reference_number":"EMA/265369/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2020-ema-decision-20-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-monovalent-recombinant-replication-incompetent-human-adenovirus-serotype-26-vectored-vaccine-encoding_en.pdf"},
    {"id":"50413","name":"P/0179/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for setmelanotide (EMEA-002209-PIP01-17-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T17:12:00Z","last_updated_date":"2021-03-04T17:12:00Z","reference_number":"EMA/178698/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-setmelanotide-emea-002209-pip01-17-m01_en.pdf"},
    {"id":"50414","name":"P/0190/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for isoflurane (EMEA- 002320-PIP01-17-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T17:27:00Z","last_updated_date":"2021-03-04T17:27:00Z","reference_number":"EMA/233156/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-isoflurane-emea-002320-pip01-17-m01_en.pdf"},
    {"id":"50415","name":"P/0196/2020: EMA decision of 15 May 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for idasanutlin (EMEA-001489-PIP02-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T17:34:00Z","last_updated_date":"2021-03-04T17:34:00Z","reference_number":"EMA/240867/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2020-ema-decision-15-may-2020-agreement-paediatric-investigation-plan-granting-deferral-idasanutlin-emea-001489-pip02-19_en.pdf"},
    {"id":"50416","name":"P/0182/2020: EMA decision of 13 May 2020 on the granting of a product specific waiver for arfolitixorin (EMEA-002223-PIP01-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T17:41:00Z","last_updated_date":"2021-03-04T17:41:00Z","reference_number":"EMA/233341/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2020-ema-decision-13-may-2020-granting-product-specific-waiver-arfolitixorin-emea-002223-pip01-19_en.pdf"},
    {"id":"50417","name":"P/0176/2020: EMA decision of 13 May 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for livoletide (EMEA-002455-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T17:51:00Z","last_updated_date":"2021-03-04T17:51:00Z","reference_number":"EMA/233424/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2020-ema-decision-13-may-2020-agreement-paediatric-investigation-plan-granting-waiver-livoletide-emea-002455-pip01-18_en.pdf"},
    {"id":"50418","name":"P/0195/2020: EMA decision of 15 May 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for spesolimab (EMEA-002475-PIP02-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T17:59:00Z","last_updated_date":"2021-03-04T17:59:00Z","reference_number":"EMA/233158/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2020-ema-decision-15-may-2020-agreement-paediatric-investigation-plan-granting-waiver-spesolimab-emea-002475-pip02-19_en.pdf"},
    {"id":"50420","name":"P/0211/2020: EMA decision of 16 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dexamethasone (sodium phosphate) encapsulated in human autologous...(EMEA-001957-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T11:03:00Z","last_updated_date":"2021-03-05T11:03:00Z","reference_number":"EMA/288369/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2020-ema-decision-16-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dexamethasone-sodium-phosphate-encapsulated-human-autologousemea-001957-pip02-19_en.pdf"},
    {"id":"50421","name":"P/0163/2020: EMA decision of 17 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor (Kalydeco) (EMEA-000335-PIP01-08-M14)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T17:51:00Z","last_updated_date":"2021-03-05T17:51:00Z","reference_number":"EMA/200461/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2020-ema-decision-17-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-kalydeco-emea-000335-pip01-08-m14_en.pdf"},
    {"id":"50422","name":"P/0143/2020: EMA decision of 18 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for blinatumomab (Blincyto) (EMEA-000574-PIP02-12-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T17:51:00Z","last_updated_date":"2021-03-05T17:51:00Z","reference_number":"EMA/174040/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2020-ema-decision-18-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-blinatumomab-blincyto-emea-000574-pip02-12-m03_en.pdf"},
    {"id":"50423","name":"P/0138/2020: EMA decision of 17 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for multivalent, live, recombinant, non-replicating in human cells, Modified Vaccinia Ankara vectored vaccine","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T17:51:00Z","last_updated_date":"2021-03-05T17:51:00Z","reference_number":"EMA/173216/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2020-ema-decision-17-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-multivalent-live-recombinant-non-replicating-human-cells-modified-vaccinia-ankara-vectored-vaccine_en.pdf"},
    {"id":"50424","name":"P/0165/2020: EMA decision of 24 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz) (EMEA-000576-PIP03-12-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T17:51:00Z","last_updated_date":"2021-03-05T17:51:00Z","reference_number":"EMA/203001/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2020-ema-decision-24-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip03-12-m03_en.pdf"},
    {"id":"50425","name":"P/0156/2020: EMA decision of 17 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for boceprevir (Victrelis), (EMEA-000583-PIP01-09-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T17:51:00Z","last_updated_date":"2021-03-05T17:51:00Z","reference_number":"EMA/175407/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2020-ema-decision-17-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-boceprevir-victrelis-emea-000583-pip01-09-m08_en.pdf"},
    {"id":"50426","name":"P/0234/2020: EMA decision of 19 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bis-choline tetrathiomolybdate (ALXN1840) (EMEA-002232-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T11:20:00Z","last_updated_date":"2021-03-05T11:20:00Z","reference_number":"EMA/303252/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2020-ema-decision-19-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bis-choline-tetrathiomolybdate-alxn1840-emea-002232-pip02-19_en.pdf"},
    {"id":"50427","name":"P/0235/2020: EMA decision of 19 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sodium alginate oligosaccharide (EMEA-002321-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T11:27:00Z","last_updated_date":"2021-03-05T11:27:00Z","reference_number":"EMA/303246/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2020-ema-decision-19-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sodium-alginate-oligosaccharide-emea-002321-pip01-17_en.pdf"},
    {"id":"50428","name":"P/0222/2020: EMA decision of 17 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for fidanacogene elaparvovec (EMEA-002362-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T11:59:00Z","last_updated_date":"2021-03-05T11:59:00Z","reference_number":"EMA/305473/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2020-ema-decision-17-june-2020-agreement-paediatric-investigation-plan-granting-deferral-fidanacogene-elaparvovec-emea-002362-pip02-19_en.pdf"},
    {"id":"50429","name":"P/0216/2021 : EMA decision of 8 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for linaclotide (Constella) (EMEA-000927-PIP01-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T08:52:00Z","last_updated_date":"2022-04-28T08:52:00Z","reference_number":"EMA/299882/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2021-ema-decision-8-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-linaclotide-constella-emea-000927-pip01-10-m06_en.pdf"},
    {"id":"50430","name":"P/0167/2020: EMA decision of 27 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for pitolisant (Wakix), (EMEA-001176-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T08:52:00Z","last_updated_date":"2021-03-05T08:52:00Z","reference_number":"EMA/211922/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2020-ema-decision-27-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-pitolisant-wakix-emea-001176-pip01-11-m04_en.pdf"},
    {"id":"50431","name":"P/0141/2020: EMA decision of 17 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for regorafenib (Stivarga), (EMEA-001178-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T08:52:00Z","last_updated_date":"2021-03-05T08:52:00Z","reference_number":"EMA/173213/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2020-ema-decision-17-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-regorafenib-stivarga-emea-001178-pip01-11-m05_en.pdf"},
    {"id":"50432","name":"P/0213/2020: EMA decision of 16 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for gepotidacin (EMEA-002443-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T12:11:00Z","last_updated_date":"2021-03-05T12:11:00Z","reference_number":"EMA/300173/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2020-ema-decision-16-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-gepotidacin-emea-002443-pip01-18_en.pdf"},
    {"id":"50433","name":"P/0168/2020: EMA decision of 30 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for etrolizumab (EMEA-001434-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T08:52:00Z","last_updated_date":"2021-03-05T08:52:00Z","reference_number":"EMA/173220/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2020-ema-decision-30-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-etrolizumab-emea-001434-pip01-13-m03_en.pdf"},
    {"id":"50434","name":"P/0137/2020: EMA decision of 18 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (Ozempic) (EMEA-001441-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T08:52:00Z","last_updated_date":"2021-03-05T08:52:00Z","reference_number":"EMA/174056/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2020-ema-decision-18-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-semaglutide-ozempic-emea-001441-pip01-13-m03_en.pdf"},
    {"id":"50435","name":"P/0212/2020: EMA decision of 16 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for gepotidacin (EMEA-002443-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T12:16:00Z","last_updated_date":"2021-03-05T12:16:00Z","reference_number":"EMA/300041/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2020-ema-decision-16-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-gepotidacin-emea-002443-pip02-18_en.pdf"},
    {"id":"50436","name":"P/0160/2020: EMA decision of 16 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for roxadustat (EMEA-001557-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T08:52:00Z","last_updated_date":"2021-03-05T08:52:00Z","reference_number":"EMA/178629/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2020-ema-decision-16-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-roxadustat-emea-001557-pip01-13-m04_en.pdf"},
    {"id":"50437","name":"P/0144/2020: EMA decision of 15 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for palovarotene (EMEA-001662-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T08:52:00Z","last_updated_date":"2021-03-05T08:52:00Z","reference_number":"EMA/176114/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2020-ema-decision-15-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-palovarotene-emea-001662-pip01-14-m03_en.pdf"},
    {"id":"50438","name":"P/0133/2020: EMA decision of 15 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for copanlisib (EMEA-001757-PIP02-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T08:52:00Z","last_updated_date":"2021-03-08T08:52:00Z","reference_number":"EMA/132145/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2020-ema-decision-15-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-copanlisib-emea-001757-pip02-15-m01_en.pdf"},
    {"id":"50439","name":"P/0139/2020: EMA decision of 17 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for elafibranor (EMEA- 001857-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T08:52:00Z","last_updated_date":"2021-03-08T08:52:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2020-ema-decision-17-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-elafibranor-emea-001857-pip01-15-m01_en.pdf"},
    {"id":"50440","name":"P/0136/2020: EMA decision of 15 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for galcanezumab (Emgality), (EMEA-001860-PIP03-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T08:52:00Z","last_updated_date":"2021-03-08T08:52:00Z","reference_number":"EMA/176040/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2020-ema-decision-15-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-galcanezumab-emgality-emea-001860-pip03-16-m04_en.pdf"},
    {"id":"50441","name":"P/0142/2020: EMA decision of 18 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T08:52:00Z","last_updated_date":"2021-03-08T08:52:00Z","reference_number":"EMA/174068/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2020-ema-decision-18-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-autologous-peripheral-blood-t-cells-cd4-cd8-selected-cd3-cd28-activated-transduced_en.pdf"},
    {"id":"50442","name":"P/0145/2020: EMA decision of 15 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (EMEA-001900-PIP02-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T08:52:00Z","last_updated_date":"2021-03-08T08:52:00Z","reference_number":"EMA/176055/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2020-ema-decision-15-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-emea-001900-pip02-17-m03_en.pdf"},
    {"id":"50444","name":"P/0237/2020: EMA decision of 17 June 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for atropine (sulphate) (EMEA-002545-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T13:34:00Z","last_updated_date":"2021-03-05T13:34:00Z","reference_number":"EMA/260105/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2020-ema-decision-17-june-2020-agreement-paediatric-investigation-plan-granting-waiver-atropine-sulphate-emea-002545-pip01-19_en.pdf"},
    {"id":"50450","name":"P/0172/2020: EMA decision of 13 May 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for difelikefalin (EMEA-002565-PIP02-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:29:00Z","last_updated_date":"2021-03-05T14:29:00Z","reference_number":"EMA/233493/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2020-ema-decision-13-may-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-difelikefalin-emea-002565-pip02-19_en.pdf"},
    {"id":"50452","name":"P/0229/2020: of 17 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adeno-associated viral vector serotype 8 containing the human RPGR...(AAV8-RPGR) (EMEA-002601-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T13:50:00Z","last_updated_date":"2021-03-05T13:50:00Z","reference_number":"EMA/305290/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2020-17-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-adeno-associated-viral-vector-serotype-8-containing-human-rpgraav8-rpgr-emea-002601-pip01-19_en.pdf"},
    {"id":"50453","name":"P/0076/2020: EMA decision of 6 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Macimorelin (Macimorelin Aeterna Zentaris) (EMEA-001988-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T08:52:00Z","last_updated_date":"2021-03-08T08:52:00Z","reference_number":"EMA/167090/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2020-ema-decision-6-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-macimorelin-macimorelin-aeterna-zentaris-emea-001988-pip01-16-m01_en.pdf"},
    {"id":"50454","name":"P/0132/2020: EMA decision of 15 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for axicabtagene ciloleucel (YESCARTA), (EMEA-002010-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-09T08:52:00Z","last_updated_date":"2021-03-09T08:52:00Z","reference_number":"EMA/132147/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2020-ema-decision-15-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-axicabtagene-ciloleucel-yescarta-emea-002010-pip01-16-m02_en.pdf"},
    {"id":"50456","name":"P/0162/2020: EMA decision of 16 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for crisaborole (EMEA-002065-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-09T08:52:00Z","last_updated_date":"2021-03-09T08:52:00Z","reference_number":"EMA/195655/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2020-ema-decision-16-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-crisaborole-emea-002065-pip01-16-m02_en.pdf"},
    {"id":"50457","name":"P/0171/2020: EMA decision of 13 May 2020 on the agreement of a paediatric investigation plan for imatinib (EMEA-002643-PIP01-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:37:00Z","last_updated_date":"2021-03-05T14:37:00Z","reference_number":"EMA/242581/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2020-ema-decision-13-may-2020-agreement-paediatric-investigation-plan-imatinib-emea-002643-pip01-19_en.pdf"},
    {"id":"50458","name":"P/0130/2020: EMA decision of 15 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for mirikizumab (EMEA-002208-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-09T08:52:00Z","last_updated_date":"2021-03-09T08:52:00Z","reference_number":"EMA/132148/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2020-ema-decision-15-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-mirikizumab-emea-002208-pip01-17-m01_en.pdf"},
    {"id":"50460","name":"P/0155/2020: EMA decision of 17 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Monovalent, live, recombinant, replication-incompetent adenoviral serotype 26 vectored vaccine","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-09T08:52:00Z","last_updated_date":"2021-03-09T08:52:00Z","reference_number":"EMA/175408/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2020-ema-decision-17-april-2020-acceptance-modification-agreed-paediatric-investigation-plan-monovalent-live-recombinant-replication-incompetent-adenoviral-serotype-26-vectored-vaccine_en.pdf"},
    {"id":"50461","name":"P/0191/2020: EMA decision of 15 May 2020 on the agreement of a paediatric investigation plan for cyclophosphamide (Zenew and associated names) (EMEA-002644-PIP01-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:43:00Z","last_updated_date":"2021-03-05T14:43:00Z","reference_number":"EMA/180112/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2020-ema-decision-15-may-2020-agreement-paediatric-investigation-plan-cyclophosphamide-zenew-associated-names-emea-002644-pip01-19_en.pdf"},
    {"id":"50462","name":"P/0186/2020: EMA decision of 13 May 2020 on the granting of a product specific waiver for tiragolumab (EMEA-002721-PIP01-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:53:00Z","last_updated_date":"2021-03-05T14:53:00Z","reference_number":"EMA/240387/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2020-ema-decision-13-may-2020-granting-product-specific-waiver-tiragolumab-emea-002721-pip01-19_en.pdf"},
    {"id":"50463","name":"P/0159/2020: EMA decision of 17 April 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for EMEA-002330-PIP01-18","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:59:00Z","last_updated_date":"2021-03-05T14:59:00Z","reference_number":"EMA/175878/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2020-ema-decision-17-april-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-emea-002330-pip01-18_en.pdf"},
    {"id":"50464","name":"P/0241/2020: EMA decision of 25 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ravagalimab (EMEA-002617-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-05T14:59:00Z","last_updated_date":"2021-03-05T14:59:00Z","reference_number":"EMA/317104/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2020-ema-decision-25-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ravagalimab-emea-002617-pip01-19_en.pdf"},
    {"id":"50465","name":"P/0181/2020: EMA decision of 13 May 2020 on the granting of a product specific waiver for hydrocortisone acetate / benzocaine (EMEA-002739-PIP01-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T15:21:00Z","last_updated_date":"2021-03-05T15:21:00Z","reference_number":"EMA/233389/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2020-ema-decision-13-may-2020-granting-product-specific-waiver-hydrocortisone-acetate-benzocaine-emea-002739-pip01-19_en.pdf-0"},
    {"id":"50466","name":"P/0181/2020: EMA decision of 13 May 2020 on the granting of a product specific waiver for hydrocortisone acetate / benzocaine (EMEA-002739-PIP01-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T15:34:00Z","last_updated_date":"2021-03-05T15:34:00Z","reference_number":"EMA/233389/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2020-ema-decision-13-may-2020-granting-product-specific-waiver-hydrocortisone-acetate-benzocaine-emea-002739-pip01-19_en.pdf"},
    {"id":"50467","name":"P/0170/2020: EMA decision of 13 May 2020 on the granting of a product specific waiver for rosuvastatin calcium/fenofibrate (EMEA-002743-PIP01- 19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T15:56:00Z","last_updated_date":"2021-03-05T15:56:00Z","reference_number":"EMA/241682/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2020-ema-decision-13-may-2020-granting-product-specific-waiver-rosuvastatin-calcium-fenofibrate-emea-002743-pip01-19_en.pdf"},
    {"id":"50468","name":"P/0169/2020: EMA decision of 13 May 2020 on the granting of a product specific waiver for 18-(p-[131I]-iodophenyl)octadecyl phosphocholine (EMEA-002745-PIP01-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T16:03:00Z","last_updated_date":"2021-03-05T16:03:00Z","reference_number":"EMA/241755/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2020-ema-decision-13-may-2020-granting-product-specific-waiver-18-p-131i-iodophenyloctadecyl-phosphocholine-emea-002745-pip01-19_en.pdf"},
    {"id":"50477","name":"P/0215/2020: EMA decision of 16 June 2020 on the granting of a product specific waiver for ezetimibe / atorvastatin (EMEA-002649-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T15:10:00Z","last_updated_date":"2021-03-08T15:10:00Z","reference_number":"EMA/288454/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2020-ema-decision-16-june-2020-granting-product-specific-waiver-ezetimibe-atorvastatin-emea-002649-pip02-20_en.pdf"},
    {"id":"50478","name":"P/0228/2020: EMA decision of 17 June 2020 on the granting of a product specific waiver for betahistine (dihydrochloride) (EMEA-002652-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T15:35:00Z","last_updated_date":"2021-03-08T15:35:00Z","reference_number":"EMA/304245/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2020-ema-decision-17-june-2020-granting-product-specific-waiver-betahistine-dihydrochloride-emea-002652-pip01-19_en.pdf"},
    {"id":"50479","name":"P/0226/2020: EMA decision of 17 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous haptenised and irradiated cells derived from glioma (EMEA-002661-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T16:05:00Z","last_updated_date":"2021-03-08T16:05:00Z","reference_number":"EMA/259751/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2020-ema-decision-17-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-haptenised-irradiated-cells-derived-glioma-emea-002661-pip01-19_en.pdf"},
    {"id":"50480","name":"P/0225/2020: EMA decision of 17 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for allogeneic haptenised and irradiated cells derived from glioma (EMEA-002662-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T16:12:00Z","last_updated_date":"2021-03-08T16:12:00Z","reference_number":"EMA/259806/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2020-ema-decision-17-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allogeneic-haptenised-irradiated-cells-derived-glioma-emea-002662-pip01-19_en.pdf"},
    {"id":"50481","name":"P/0224/2020: EMA decision of 17 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for allogeneic haptenised and irradiated cell lysates derived from glioma(EMEA-002663-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T16:17:00Z","last_updated_date":"2021-03-08T16:17:00Z","reference_number":"EMA/259810/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2020-ema-decision-17-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-allogeneic-haptenised-irradiated-cell-lysates-derived-gliomaemea-002663-pip01-19_en.pdf"},
    {"id":"50482","name":"P/0223/2020: EMA decision of 17 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous haptenised and irradiated cell lysates derived from glioma(EMEA-002664-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T16:20:00Z","last_updated_date":"2021-03-08T16:20:00Z","reference_number":"EMA/259811/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2020-ema-decision-17-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-haptenised-irradiated-cell-lysates-derived-gliomaemea-002664-pip01-19_en.pdf"},
    {"id":"50483","name":"P/0240/2020: of 19 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rozanolixizumab (EMEA-002681-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T16:53:00Z","last_updated_date":"2021-03-08T16:53:00Z","reference_number":"EMA/501874/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2020-19-june-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rozanolixizumab-emea-002681-pip01-19_en.pdf"},
    {"id":"50485","name":"P/0230/2020: EMA decision of 19 June 2020 on the granting of a product specific waiver for adenovirus encoding vascular endothelial growth factor C (AdAptVEGF-C) (EMEA-002748-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T17:47:00Z","last_updated_date":"2021-03-08T17:47:00Z","reference_number":"EMA/303245/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2020-ema-decision-19-june-2020-granting-product-specific-waiver-adenovirus-encoding-vascular-endothelial-growth-factor-c-adaptvegf-c-emea-002748-pip01-20_en.pdf"},
    {"id":"50486","name":"P/0206/2020: EMA decision of 16 June 2020 on the granting of a product specific waiver for monalizumab (EMEA-002751-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T17:55:00Z","last_updated_date":"2021-03-08T17:55:00Z","reference_number":"EMA/300150/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2020-ema-decision-16-june-2020-granting-product-specific-waiver-monalizumab-emea-002751-pip01-19_en.pdf"},
    {"id":"50492","name":"P/0220/2020: EMA decision of 16 June 2020 on the granting of a product specific waiver for IMG-2789 (EMEA-002752-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-09T09:12:00Z","last_updated_date":"2021-03-09T09:12:00Z","reference_number":"EMA/300166/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2020-ema-decision-16-june-2020-granting-product-specific-waiver-img-2789-emea-002752-pip01-19_en.pdf"},
    {"id":"50495","name":"P/0205/2020: EMA decision of 16 June 2020 on the granting of a product specific waiver for adeno-associated virus serotype 2 (AAV2) encoding human aromatic L-amino acid decarboxylase (hAADC) (EMEA-002753-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-09T09:21:00Z","last_updated_date":"2021-03-09T09:21:00Z","reference_number":"EMA/288478/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2020-ema-decision-16-june-2020-granting-product-specific-waiver-adeno-associated-virus-serotype-2-aav2-encoding-human-aromatic-l-amino-acid-decarboxylase-haadc-emea-002753-pip01-19_en.pdf"},
    {"id":"50496","name":"P/0242/2020: EMA decision of 22 June 2020 on the granting of a product specific waiver for rucaparib (camsylate), (EMEA-002760-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-09T10:56:00Z","last_updated_date":"2021-03-09T10:56:00Z","reference_number":"EMA/324759/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2020-ema-decision-22-june-2020-granting-product-specific-waiver-rucaparib-camsylate-emea-002760-pip01-19_en.pdf"},
    {"id":"50497","name":"P/0218/2020: EMA decision of 17 June 2020 on the granting of a product specific waiver for ribociclib (succinate) (Kisqali), (EMEA-002765-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-09T11:01:00Z","last_updated_date":"2021-03-09T11:01:00Z","reference_number":"EMA/258042/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2020-ema-decision-17-june-2020-granting-product-specific-waiver-ribociclib-succinate-kisqali-emea-002765-pip01-19_en.pdf"},
    {"id":"50577","name":"P/0198/2020: EMA decision of 20 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis), (EMEA-000183-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T14:04:00Z","last_updated_date":"2021-03-16T14:04:00Z","reference_number":"EMA/266985/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2020-ema-decision-20-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip01-08-m08_en.pdf"},
    {"id":"50581","name":"P/0199/2020: EMA decision of 20 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis), (EMEA-000183-PIP02-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T14:17:00Z","last_updated_date":"2021-03-16T14:17:00Z","reference_number":"EMA/267765/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2020-ema-decision-20-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip02-12-m03_en.pdf"},
    {"id":"50583","name":"P/0178/2020: EMA decision of 13 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for methoxyflurane (Penthrox), (EMEA-000334-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T14:36:00Z","last_updated_date":"2021-03-16T14:36:00Z","reference_number":"EMA/242281/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2020-ema-decision-13-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-methoxyflurane-penthrox-emea-000334-pip01-08-m09_en.pdf"},
    {"id":"50584","name":"P/0189/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens - A/turkey/Turkey/1/05 (H5N1) (Aflunov and associated names), (EMEA-000599- PIP01-09-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T14:50:00Z","last_updated_date":"2021-03-16T14:50:00Z","reference_number":"EMA/233132/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-turkey-turkey-1-05-h5n1-aflunov-associated-names-emea-000599-pip01-09_en.pdf"},
    {"id":"50586","name":"P/0175/2020: EMA decision of 13 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity), (EMEA-000783-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T15:12:00Z","last_updated_date":"2021-03-16T15:12:00Z","reference_number":"EMA/242279/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2020-ema-decision-13-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-dulaglutide-trulicity-emea-000783-pip01-09-m05_en.pdf"},
    {"id":"50587","name":"P/0177/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dimethyl fumarate (Tecfidera), (EMEA-000832-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T15:23:00Z","last_updated_date":"2021-03-16T15:23:00Z","reference_number":"EMA/178693/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-dimethyl-fumarate-tecfidera-emea-000832-pip01-10-m05_en.pdf"},
    {"id":"50588","name":"P/0192/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for 2-iminobiotin (EMEA- 001070-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T15:29:00Z","last_updated_date":"2021-03-16T15:29:00Z","reference_number":"EMA/233140/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-2-iminobiotin-emea-001070-pip01-10-m02_en.pdf"},
    {"id":"50589","name":"P/0183/2020: EMA decision of 15 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for romosozumab (Evenity), (EMEA-001075-PIP04-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T15:38:00Z","last_updated_date":"2021-03-16T15:38:00Z","reference_number":"EMA/178695/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-romosozumab-evenity-emea-001075-pip04-15-m02_en.pdf"},
    {"id":"50590","name":"P/0187/2020: EMA decision of 13 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for talimogene laherparepvec (Imlygic) (EMEA-001251-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T15:56:00Z","last_updated_date":"2021-03-16T15:56:00Z","reference_number":"EMA/240515/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2020-ema-decision-13-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-talimogene-laherparepvec-imlygic-emea-001251-pip01-11-m04_en.pdf"},
    {"id":"50591","name":"P/0202/2020: EMA decision of 27 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya), (EMEA-001460-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T16:03:00Z","last_updated_date":"2021-03-16T16:03:00Z","reference_number":"EMA/273929/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2020-ema-decision-27-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya-emea-001460-pip01-13-m04_en.pdf"},
    {"id":"50592","name":"P/0200/2020: EMA decision of 25 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for maralixibat chloride (LUM001) (EMEA-001475-PIP03-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T16:37:00Z","last_updated_date":"2021-03-16T16:37:00Z","reference_number":"EMA/257779/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2020-ema-decision-25-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-maralixibat-chloride-lum001-emea-001475-pip03-17-m02_en.pdf"},
    {"id":"50593","name":"P/0126/2021: EMA decision of 15 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) / matrix-M1","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T16:42:00Z","last_updated_date":"2021-03-16T16:42:00Z","reference_number":"EMA/152609/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2021-ema-decision-15-march-2021-agreement-paediatric-investigation-plan-granting-deferral-severe-acute-respiratory-syndrome-coronavirus-2-recombinant-spike-protein-nanoparticle-vaccine-sars-cov_en.pdf"},
    {"id":"50594","name":"P/0203/2020: EMA decision of 12 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (Briviact) (EMEA-000332-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-16T17:07:00Z","last_updated_date":"2021-03-16T17:07:00Z","reference_number":"EMA/299988/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2020-ema-decision-12-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-emea-000332-pip02-17-m01_en.pdf"},
    {"id":"50597","name":"P/0217/2020: EMA decision of 17 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (Brilique), (EMEA-000480-PIP01-08-M13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T09:55:00Z","last_updated_date":"2021-03-17T09:55:00Z","reference_number":"EMA/256976/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2020-ema-decision-17-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-ticagrelor-brilique-emea-000480-pip01-08-m13_en.pdf"},
    {"id":"50598","name":"P/0227/2020: EMA decision of 17 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz), (EMEA-000576-PIP01-09-M12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T10:40:00Z","last_updated_date":"2021-03-17T10:40:00Z","reference_number":"EMA/305057/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2020-ema-decision-17-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip01-09-m12_en.pdf"},
    {"id":"50599","name":"P/0243/2020: EMA decision of 22 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for brentuximab vedotin (Adcetris) (EMEA-000980-PIP01-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T10:49:00Z","last_updated_date":"2021-03-17T10:49:00Z","reference_number":"EMA/324798/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2020-ema-decision-22-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-brentuximab-vedotin-adcetris-emea-000980-pip01-10-m06_en.pdf"},
    {"id":"50600","name":"P/0231/2020: EMA decision of 19 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Outer Membrane Vesicles (OMV) from N. meningitidis Strain NZ 98/254 / recombinant Neisseria meningitis group B 936-741 (...)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T11:18:00Z","last_updated_date":"2021-03-17T11:18:00Z","reference_number":"EMA/303223/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2020-ema-decision-19-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-outer-membrane-vesicles-omv-n-meningitidis-strain-nz-98-254-recombinant-neisseria-meningitis-group-b_en.pdf"},
    {"id":"50601","name":"P/0239/2020: EMA decision of 16 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for anifrolumab (EMEA-001435-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T11:26:00Z","last_updated_date":"2021-03-17T11:26:00Z","reference_number":"EMA/313851/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2020-ema-decision-16-march-2020-acceptance-modification-agreed-paediatric-investigation-plan-anifrolumab-emea-001435-pip02-16-m01_en.pdf"},
    {"id":"50602","name":"P/0207/2020: EMA decision of 16 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for darvadstrocel (Alofisel), (EMEA-001561-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T11:42:00Z","last_updated_date":"2021-03-17T11:42:00Z","reference_number":"EMA/300006/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2020-ema-decision-16-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-darvadstrocel-alofisel-emea-001561-pip01-13-m01_en.pdf"},
    {"id":"50603","name":"P/0204/2020: EMA decision of 16 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for satralizumab (EMEA-001625-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T11:51:00Z","last_updated_date":"2021-03-17T11:51:00Z","reference_number":"EMA/288279/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2020-ema-decision-16-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-satralizumab-emea-001625-pip01-14-m05_en.pdf"},
    {"id":"50604","name":"P/0233/2020: EMA decision of 19 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for erenumab (Aimovig), (EMEA-001664-PIP02-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T11:59:00Z","last_updated_date":"2021-03-17T11:59:00Z","reference_number":"EMA/303209/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2020-ema-decision-19-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-erenumab-aimovig-emea-001664-pip02-15-m04_en.pdf"},
    {"id":"50605","name":"P/0214/2020: EMA decision of 17 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (RINVOQ), (EMEA-001741-PIP04-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T12:10:00Z","last_updated_date":"2021-03-17T12:10:00Z","reference_number":"EMA/304630/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2020-ema-decision-17-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip04-17-m01_en.pdf"},
    {"id":"50606","name":"P/0208/2020: EMA decision of 16 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ligelizumab (EMEA-001811-PIP02-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T12:25:00Z","last_updated_date":"2021-03-17T12:25:00Z","reference_number":"EMA/299993/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2020-ema-decision-16-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-ligelizumab-emea-001811-pip02-15-m03_en.pdf"},
    {"id":"50607","name":"P/0232/2020: EMA decision of 19 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen concentrate (BT524) (EMEA-001931-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T13:54:00Z","last_updated_date":"2021-03-17T13:54:00Z","reference_number":"EMA/303213/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2020-ema-decision-19-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-concentrate-bt524-emea-001931-pip01-16-m02_en.pdf"},
    {"id":"50609","name":"P/0236/2020: European Medicines Agency decision of 12 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene (EMEA-001933(.)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T14:05:00Z","last_updated_date":"2021-03-17T14:05:00Z","reference_number":"EMA/305826/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2020-european-medicines-agency-decision-12-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-cells-transduced-lentiviral-vector-encoding-human-beta-globin_en.pdf"},
    {"id":"50610","name":"P/0221/2020: EMA decision of 17 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lucerastat (EMEA-002095-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T14:24:00Z","last_updated_date":"2021-03-17T14:24:00Z","reference_number":"EMA/257780/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2020-ema-decision-17-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-lucerastat-emea-002095-pip01-16-m01_en.pdf"},
    {"id":"50611","name":"P/0209/2020: EMA decision of 16 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for eptinezumab (EMEA-002243-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T14:34:00Z","last_updated_date":"2021-03-17T14:34:00Z","reference_number":"EMA/288433/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2020-ema-decision-16-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-eptinezumab-emea-002243-pip01-17-m01_en.pdf"},
    {"id":"50614","name":"P/0238/2020: EMA decision of 16 June 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Factor VIII Fc – von Willebrand factor – XTEN fusion protein (rFVIIIFc-VWF-XTEN) (EMEA-002501-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T14:40:00Z","last_updated_date":"2021-03-17T14:40:00Z","reference_number":"EMA/312889/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2020-ema-decision-16-june-2020-acceptance-modification-agreed-paediatric-investigation-plan-factor-viii-fc-von-willebrand-factor-xten-fusion-protein-rfviiifc-vwf-xten-emea-002501-pip01-18-m01_en.pdf"},
    {"id":"51182","name":"P/0201/2021: EMA decision of 10 May 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for SARS-CoV2 prefusion Spike delta TM (CoV-2 preS dTM) adjuvanted with AS03 (EMEA-002915-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-05-19T11:11:00Z","last_updated_date":"2021-05-19T11:11:00Z","reference_number":"EMA/190499/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2021-ema-decision-10-may-2021-agreement-paediatric-investigation-plan-granting-deferral-sars-cov2-prefusion-spike-delta-tm-cov-2-pres-dtm-adjuvanted-as03-emea-002915-pip01-20_en.pdf"},
    {"id":"51183","name":"P/0179/2021: EMA decision of 23 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for highly purified singlestranded, 5’-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2) (Comirnaty), (EMEA-002861","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-05-19T11:20:00Z","last_updated_date":"2021-05-19T11:20:00Z","reference_number":"EMA/231237/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2021-ema-decision-23-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-highly-purified-singlestranded-5-capped-mrna-encoding-full-length-sars-cov-2-spike-protein-bnt162b2_en.pdf"},
    {"id":"51199","name":"P/0041/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for obeticholic acid (Ocaliva), (EMEA-001304-PIP02-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-05-19T17:48:00Z","last_updated_date":"2021-05-19T17:48:00Z","reference_number":"EMA/18871/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-obeticholic-acid-ocaliva-emea-001304-pip02-13-m05_en.pdf"},
    {"id":"51450","name":"P/0274/2020: EMA decision of 17 July 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for tecovirimat (monohydrate) (EMEA-001205-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T11:54:00Z","last_updated_date":"2021-06-16T11:54:00Z","reference_number":"EMA/366723/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2020-ema-decision-17-july-2020-agreement-paediatric-investigation-plan-granting-deferral-tecovirimat-monohydrate-emea-001205-pip02-19_en.pdf"},
    {"id":"51453","name":"P/0021/2021 EMA decision of 27 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sparsentan (EMEA-001984-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T14:34:00Z","last_updated_date":"2021-06-16T14:34:00Z","reference_number":"EMA/33163/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2021-ema-decision-27-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sparsentan-emea-001984-pip02-20_en.pdf-0"},
    {"id":"51454","name":"P/0252/2020: EMA decision of 15 July 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for pegzilarginase (EMEA-001925-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T15:45:00Z","last_updated_date":"2021-06-16T15:45:00Z","reference_number":"EMA/362119/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2020-ema-decision-15-july-2020-agreement-paediatric-investigation-plan-granting-deferral-pegzilarginase-emea-001925-pip02-19_en.pdf"}    {"id":"51455","name":"P/0248/2020: EMA decision of 15 July 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for ondansetron (hydrochloride) (EMEA-002623-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T16:04:00Z","last_updated_date":"2021-06-16T16:04:00Z","reference_number":"EMA/356098/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2020-ema-decision-15-july-2020-agreement-paediatric-investigation-plan-granting-waiver-ondansetron-hydrochloride-emea-002623-pip01-19_en.pdf"},
    {"id":"51456","name":"P/0275/2020: EMA decision of 15 July 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for lonapegsomatropin (EMEA-002692-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T16:20:00Z","last_updated_date":"2021-06-16T16:20:00Z","reference_number":"EMA/369130/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2020-ema-decision-15-july-2020-agreement-paediatric-investigation-plan-granting-waiver-lonapegsomatropin-emea-002692-pip01-19_en.pdf"},
    {"id":"51457","name":"P/0247/2020: EMA decision on the agreement of 15 July 2020 on the granting of a product specific waiver for sitagliptin (hydrochloride monohydrate) / metformin (hydrochloride) (EMEA-002732-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T16:37:00Z","last_updated_date":"2021-06-16T16:37:00Z","reference_number":"EMA/362161/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2020-ema-decision-agreement-15-july-2020-granting-product-specific-waiver-sitagliptin-hydrochloride-monohydrate-metformin-hydrochloride-emea-002732-pip02-20_en.pdf"},
    {"id":"51458","name":"P/0263/2020: EMA decision of 15 July 2020 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for Insulin 287 (EMEA-002761-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T16:48:00Z","last_updated_date":"2021-06-16T16:48:00Z","reference_number":"EMA/366139/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2020-ema-decision-15-july-2020-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-insulin-287-emea-002761-pip01-20_en.pdf"},
    {"id":"51459","name":"P/0262/2020: EMA decision of 15 July 2020 on the refusal of a product specific waiver for recombinant human IgG1λ monoclonal Fab antibody (EMEA-002766-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T17:00:00Z","last_updated_date":"2021-06-16T17:00:00Z","reference_number":"EMA/366113/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2020-ema-decision-15-july-2020-refusal-product-specific-waiver-recombinant-human-igg1l-monoclonal-fab-antibody-emea-002766-pip01-20_en.pdf"},
    {"id":"51461","name":"P/0261/2020: EMA decision of 17 July 2020 on the granting of a product specific waiver for bisoprolol (fumarate) / trimetazidine (dihydrochloride) (EMEA-002768-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T17:13:00Z","last_updated_date":"2021-06-16T17:13:00Z","reference_number":"EMA/366694/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2020-ema-decision-17-july-2020-granting-product-specific-waiver-bisoprolol-fumarate-trimetazidine-dihydrochloride-emea-002768-pip01-20_en.pdf"},
    {"id":"51462","name":"P/0260/2020: EMA decision of 15 July 2020 on the refusal of a paediatric investigation plan and on the granting of a waiver for human fibrinogen (EMEA-002769-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T17:19:00Z","last_updated_date":"2021-06-16T17:19:00Z","reference_number":"EMA/366114/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2020-ema-decision-15-july-2020-refusal-paediatric-investigation-plan-granting-waiver-human-fibrinogen-emea-002769-pip01-20_en.pdf"},
    {"id":"51463","name":"P/0259/202: EMA decision of 17 July 2020 on the granting of a product specific waiver for humanised antibody targeting the inducible T cell costimulatory receptor (EMEA-002781-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T17:28:00Z","last_updated_date":"2021-06-16T17:28:00Z","reference_number":"EMA/366507/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-202-ema-decision-17-july-2020-granting-product-specific-waiver-humanised-antibody-targeting-inducible-t-cell-costimulatory-receptor-emea-002781-pip01-20_en.pdf"},
    {"id":"51464","name":"P/0246/2020: EMA decision of 15 July 2020 on the granting of a product specific waiver for neratinib (Nerlynx), (EMEA-002783-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-16T17:57:00Z","last_updated_date":"2021-06-16T17:57:00Z","reference_number":"EMA/316758/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2020-ema-decision-15-july-2020-granting-product-specific-waiver-neratinib-nerlynx-emea-002783-pip01-20_en.pdf"},
    {"id":"51466","name":"P/0236/2021: EMA decision of 8 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for tixagevimab (AZD8895) (EMEA-002900-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-17T11:00:00Z","last_updated_date":"2021-06-17T11:00:00Z","reference_number":"EMA/300113/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2021-ema-decision-8-june-2021-agreement-paediatric-investigation-plan-granting-deferral-tixagevimab-azd8895-emea-002900-pip01-20_en.pdf"},
    {"id":"51467","name":"P/0234/2021: EMA decision of 8 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for regdanvimab (EMEA-002961-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-06-17T09:38:00Z","last_updated_date":"2021-06-17T09:38:00Z","reference_number":"EMA/308829/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2021-ema-decision-8-june-2021-agreement-paediatric-investigation-plan-granting-deferral-regdanvimab-emea-002961-pip01-21_en.pdf"},
    {"id":"51468","name":"P/0214/2021: EMA decision of 9 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for etesevimab (EMEA-002966-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-06-17T09:48:00Z","last_updated_date":"2021-06-17T09:48:00Z","reference_number":"EMA/245824/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2021-ema-decision-9-june-2021-agreement-paediatric-investigation-plan-granting-deferral-etesevimab-emea-002966-pip01-21_en.pdf"},
    {"id":"51469","name":"P/0221/2021: EMA decision of 9 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for bamlanivimab (EMEA-002952-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-17T11:00:00Z","last_updated_date":"2021-06-17T11:00:00Z","reference_number":"EMA/245846/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2021-ema-decision-9-june-2021-agreement-paediatric-investigation-plan-granting-deferral-bamlanivimab-emea-002952-pip01-21_en.pdf"},
    {"id":"51470","name":"P/0212/2021: EMA decision of 17 May 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for zorecimeran (EMEA-002986-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-06-17T09:56:00Z","last_updated_date":"2021-06-17T09:56:00Z","reference_number":"EMA/245833/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2021-ema-decision-17-may-2021-agreement-paediatric-investigation-plan-granting-deferral-zorecimeran-emea-002986-pip01-21_en.pdf"},
    {"id":"51471","name":"P/0235/2021: EMA decision of 8 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for cilgavimab (AZD1061) (EMEA-002925-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-17T10:00:00Z","last_updated_date":"2021-06-17T10:00:00Z","reference_number":"EMA/300136/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2021-ema-decision-8-june-2021-agreement-paediatric-investigation-plan-granting-deferral-cilgavimab-azd1061-emea-002925-pip01-20_en.pdf"},
    {"id":"51472","name":"P/0280/2020 : EMA decision of 20 July 2020 on the granting of a product specific waiver for Nivolumab (Opdivo) (EMEA-001407-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-17T11:24:00Z","last_updated_date":"2021-06-17T11:24:00Z","reference_number":"EMA/392270/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2020-ema-decision-20-july-2020-granting-product-specific-waiver-nivolumab-opdivo-emea-001407-pip03-20_en.pdf"},
    {"id":"51473","name":"P/0095/2020 : EMA decision of 18 March 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for cannabidiol (Epidyolex) (EMEA-001964-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-17T11:40:00Z","last_updated_date":"2021-06-17T11:40:00Z","reference_number":"EMA/115522/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2020-ema-decision-18-march-2020-agreement-paediatric-investigation-plan-granting-waiver-cannabidiol-epidyolex-emea-001964-pip02-19_en.pdf"},
    {"id":"51474","name":"P/0251/2020 : EMA decision of 15 July 2020 on the granting of a product specific waiver for rosuvastatin / ezetimibe (Coroswera) (EMEA-002202-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-17T12:00:00Z","last_updated_date":"2021-06-17T12:00:00Z","reference_number":"EMA/316712/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2020-ema-decision-15-july-2020-granting-product-specific-waiver-rosuvastatin-ezetimibe-coroswera-emea-002202-pip02-20_en.pdf"},
    {"id":"51475","name":"P/0265/2020 : EMA decision of 15 July 2020 on the granting of a product specific waiver for sutimlimab (EMEA-002542-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-17T13:01:00Z","last_updated_date":"2021-06-17T13:01:00Z","reference_number":"EMA/366136/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2020-ema-decision-15-july-2020-granting-product-specific-waiver-sutimlimab-emea-002542-pip02-19_en.pdf"},
    {"id":"51476","name":"P/0249/2020 : EMA decision of 15 July 2020 on the granting of a product specific waiver for ravagalimab (EMEA-002617-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-17T13:47:00Z","last_updated_date":"2021-06-17T13:47:00Z","reference_number":"EMA/356096/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2020-ema-decision-15-july-2020-granting-product-specific-waiver-ravagalimab-emea-002617-pip02-19_en.pdf"},
    {"id":"51478","name":"P/0245/2020: EMA decision of 15 July 2020 on the granting of a product-specific waiver for icosasodium{26-[(2-acetamido-2-deoxy-β-Dgalactopyranosyl) oxy]-14,14-bis{[(3-{6-[(2-acetamido-2-deoxy-β-Dgalactopyranosyl) oxy]hexyl}... (EMEA-002786-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-17T16:49:00Z","last_updated_date":"2021-06-17T16:49:00Z","reference_number":"EMA/316760/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2020-ema-decision-15-july-2020-granting-product-specific-waiver-icosasodium26-2-acetamido-2-deoxy-b-dgalactopyranosyl-oxy-1414-bis3-6-2-acetamido-2-deoxy-b-dgalactopyranosyl-oxyhexyl-emea_en.pdf"},
    {"id":"51479","name":"P/0264/2020 : EMA decision of 15 July 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tominersen (EMEA-002546-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T09:13:00Z","last_updated_date":"2021-06-18T09:13:00Z","reference_number":"EMA/366137/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2020-ema-decision-15-july-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tominersen-emea-002546-pip01-19_en.pdf"},
    {"id":"51483","name":"P/0315/2020 : EMA decision of 14 August 2020 on the granting of a product specific waiver for sacubitril / valsartan (Entresto and associated names) (EMEA-000316-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T11:37:00Z","last_updated_date":"2021-06-18T11:37:00Z","reference_number":"EMA/413747/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0315-2020-ema-decision-14-august-2020-granting-product-specific-waiver-sacubitril-valsartan-entresto-associated-names-emea-000316-pip03-20_en.pdf"},
    {"id":"51484","name":"P/0314/2020 : EMA decision of 14 August 2020 on the granting of a product specific waiver for benralizumab (Fasenra) (EMEA-001214-PIP06-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T12:13:00Z","last_updated_date":"2021-06-18T12:13:00Z","reference_number":"EMA/413751/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2020-ema-decision-14-august-2020-granting-product-specific-waiver-benralizumab-fasenra-emea-001214-pip06-20_en.pdf"},
    {"id":"51485","name":"P/0304/2020 : EMA decision of 12 August 2020 on the granting of a product specific waiver for dupilumab, Dupixent (EMEA-001501-PIP05-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T12:29:00Z","last_updated_date":"2021-06-18T12:29:00Z","reference_number":"EMA/414770/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2020-ema-decision-12-august-2020-granting-product-specific-waiver-dupilumab-dupixent-emea-001501-pip05-20_en.pdf"},
    {"id":"51486","name":"P/0293/2020 : EMA decision of 12 August 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for guselkumab (Tremfya) (EMEA-001523-PIP05-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T12:45:00Z","last_updated_date":"2021-06-18T12:45:00Z","reference_number":"EMA/388980/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2020-ema-decision-12-august-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-guselkumab-tremfya-emea-001523-pip05-19_en.pdf"},
    {"id":"51487","name":"P/0295/2020 : EMA decision of 12 August 2020 on the granting of a product specific waiver for elafibranor (EMEA-001857-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T12:54:00Z","last_updated_date":"2021-06-18T12:54:00Z","reference_number":"EMA/413447/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2020-ema-decision-12-august-2020-granting-product-specific-waiver-elafibranor-emea-001857-pip02-20_en.pdf"},
    {"id":"51488","name":"P/0329/2020 : EMA decision of 17 August on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for alpelisib (EMEA-002016-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T13:17:00Z","last_updated_date":"2021-06-18T13:17:00Z","reference_number":"EMA/423373/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0329-2020-ema-decision-17-august-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-alpelisib-emea-002016-pip03-19_en.pdf"},
    {"id":"51489","name":"P/0307/2020 : EMA decision of 13 August 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fasinumab (EMEA-002059-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T13:45:00Z","last_updated_date":"2021-06-18T13:45:00Z","reference_number":"EMA/413449/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2020-ema-decision-13-august-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fasinumab-emea-002059-pip02-19_en.pdf"},
    {"id":"51491","name":"P/0292/2020 : EMA decision of 12 August 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for marstacimab (EMEA-002285-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T13:55:00Z","last_updated_date":"2021-06-18T13:55:00Z","reference_number":"EMA/377926/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2020-ema-decision-12-august-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-marstacimab-emea-002285-pip02-19_en.pdf"},
    {"id":"51492","name":"P/0306/2020 : EMA decision of 12 August 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rilzabrutinib (EMEA-002438-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T14:04:00Z","last_updated_date":"2021-06-18T14:04:00Z","reference_number":"EMA/414842/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2020-ema-decision-12-august-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rilzabrutinib-emea-002438-pip02-19_en.pdf"},
    {"id":"51497","name":"P/0308/2020 : EMA decision of 12 August 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for darunavir / ritonavir (EMEA-002537-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T14:43:00Z","last_updated_date":"2021-06-18T14:43:00Z","reference_number":"EMA/388981/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2020-ema-decision-12-august-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-darunavir-ritonavir-emea-002537-pip02-19_en.pdf"},
    {"id":"51502","name":"P/0294/2020 : EMA decision of 12 August 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cilofexor (EMEA-002554-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T15:19:00Z","last_updated_date":"2021-06-18T15:19:00Z","reference_number":"EMA/377978/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2020-ema-decision-12-august-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cilofexor-emea-002554-pip02-19_en.pdf"},
    {"id":"51503","name":"P/0019/2024 : EMA decision of 31 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for (R)-1-(1- acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one... (EMEA-002566-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T15:39:00Z","last_updated_date":"2025-03-14T15:39:00Z","reference_number":"EMA/25519/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2024-ema-decision-31-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-r-1-1-acryloylpiperidin-3-yl-4-amino-3-4-phenoxyphenyl-1h-imidazo45-cpyridin-23h-one-emea-002566_en.pdf"},
    {"id":"51504","name":"P/0309/2020 : EMA decision of 14 August 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for resamirigene bilparvovec (EMEA-002571-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T15:53:00Z","last_updated_date":"2021-06-18T15:53:00Z","reference_number":"EMA/413764/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0309-2020-ema-decision-14-august-2020-agreement-paediatric-investigation-plan-granting-deferral-resamirigene-bilparvovec-emea-002571-pip01-19_en.pdf"},
    {"id":"51506","name":"P/0317/2020 : EMA decision of 13 August 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for soticlestat (EMEA-002572-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T16:07:00Z","last_updated_date":"2021-06-18T16:07:00Z","reference_number":"EMA/413448/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2020-ema-decision-13-august-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-soticlestat-emea-002572-pip02-19_en.pdf"},
    {"id":"51507","name":"P/0331/2020 : EMA decision of 24 August 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (4S,7aR,9aR,10S,11E,14S,15R)....(EMEA-002631-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T16:23:00Z","last_updated_date":"2021-06-18T16:23:00Z","reference_number":"EMA/436080/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0331-2020-ema-decision-24-august-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-4s7ar9ar10s11e14s15remea-002631-pip01-19_en.pdf"},
    {"id":"51508","name":"P/0303/2020 : EMA decision of 12 August 2020 on the granting of a product specific waiver for half-life extended bispecific T-cell engager (BiTE) antibody construct.......(EMEA-002655-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T16:35:00Z","last_updated_date":"2021-06-18T16:35:00Z","reference_number":"EMA/414860/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2020-ema-decision-12-august-2020-granting-product-specific-waiver-half-life-extended-bispecific-t-cell-engager-bite-antibody-constructemea-002655-pip02-20_en.pdf"},
    {"id":"51514","name":"P/0244/2020: EMA decision of 15 July 2020 on the granting of a product specific waiver for niraparib (tosylate monohydrate) / abiraterone (acetate) (EMEA-002789-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-21T10:30:00Z","last_updated_date":"2021-06-21T10:30:00Z","reference_number":"EMEA-002789-PIP01-20","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2020-ema-decision-15-july-2020-granting-product-specific-waiver-niraparib-tosylate-monohydrate-abiraterone-acetate-emea-002789-pip01-20_en.pdf"},
    {"id":"51529","name":"P/0326/2020 : EMA decision of 14 August 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for relatlimab / nivolumab (EMEA-002727-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T11:04:00Z","last_updated_date":"2021-06-22T11:04:00Z","reference_number":"EMA/417765/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0326-2020-ema-decision-14-august-2020-agreement-paediatric-investigation-plan-granting-waiver-relatlimab-nivolumab-emea-002727-pip01-19_en.pdf"},
    {"id":"51530","name":"P/0297/2020 : EMA decision of 12 August 2020 on the granting of a product specific waiver for balixafortide (EMEA-002718-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T10:58:00Z","last_updated_date":"2021-06-22T10:58:00Z","reference_number":"EMA/413446/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2020-ema-decision-12-august-2020-granting-product-specific-waiver-balixafortide-emea-002718-pip02-20_en.pdf"},
    {"id":"51531","name":"P/0328/2020 : EMA decision of  14 August 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for artesunate (EMEA-002710-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T10:46:00Z","last_updated_date":"2021-06-22T10:46:00Z","reference_number":"EMA/420938/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0328-2020-ema-decision-14-august-2020-agreement-paediatric-investigation-plan-granting-deferral-artesunate-emea-002710-pip01-19_en.pdf"},
    {"id":"51532","name":"P/0290/2020 : EMA decision of 12 August 2020 on the granting of a product specific waiver for sasanlimab (EMEA-002777-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T11:11:00Z","last_updated_date":"2021-06-22T11:11:00Z","reference_number":"EMA/377760/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2020-ema-decision-12-august-2020-granting-product-specific-waiver-sasanlimab-emea-002777-pip01-20_en.pdf"},
    {"id":"51533","name":"P/0285/2020 : EMA decision of 12 August 2020 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for rimegepant (EMEA-002812-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T11:54:00Z","last_updated_date":"2021-06-22T11:54:00Z","reference_number":"EMA/388663/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2020-ema-decision-12-august-2020-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-rimegepant-emea-002812-pip01-20_en.pdf"},
    {"id":"51534","name":"P/0286/2020 : EMA decision of 12 August 2020 on the granting of a product specific waiver for pravastatin (sodium) / ezetimibe (EMEA-002805-PIP01- 20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T11:48:00Z","last_updated_date":"2021-06-22T11:48:00Z","reference_number":"EMA/388977/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2020-ema-decision-12-august-2020-granting-product-specific-waiver-pravastatin-sodium-ezetimibe-emea-002805-pip01-20_en.pdf"},
    {"id":"51535","name":"P/0287/2020 : EMA decision of 12 August 2020 on the granting of a product specific waiver for oportuzumab monatox (EMEA-002797-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T11:41:00Z","last_updated_date":"2021-06-22T11:41:00Z","reference_number":"EMA/377776/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2020-ema-decision-12-august-2020-granting-product-specific-waiver-oportuzumab-monatox-emea-002797-pip01-20_en.pdf"},
    {"id":"51536","name":"P/0323/2020 : EMA decision of 13 August 2020 on the granting of a product specific waiver for prolgolimab (EMEA-002792-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T11:28:00Z","last_updated_date":"2021-06-22T11:28:00Z","reference_number":"EMA/414492/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2020-ema-decision-13-august-2020-granting-product-specific-waiver-prolgolimab-emea-002792-pip01-20_en.pdf-3"},
    {"id":"51537","name":"P/0323/2020 : EMA decision of 13 August 2020 on the granting of a product specific waiver for prolgolimab (EMEA-002792-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T11:28:00Z","last_updated_date":"2021-06-22T11:28:00Z","reference_number":"EMA/414492/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2020-ema-decision-13-august-2020-granting-product-specific-waiver-prolgolimab-emea-002792-pip01-20_en.pdf-2"},
    {"id":"51538","name":"P/0323/2020 : EMA decision of 13 August 2020 on the granting of a product specific waiver for prolgolimab (EMEA-002792-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T11:28:00Z","last_updated_date":"2021-06-22T11:28:00Z","reference_number":"EMA/414492/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2020-ema-decision-13-august-2020-granting-product-specific-waiver-prolgolimab-emea-002792-pip01-20_en.pdf-1"},
    {"id":"51539","name":"P/0323/2020 : EMA decision of 13 August 2020 on the granting of a product specific waiver for prolgolimab (EMEA-002792-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T12:09:00Z","last_updated_date":"2021-06-22T12:09:00Z","reference_number":"EMA/414492/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2020-ema-decision-13-august-2020-granting-product-specific-waiver-prolgolimab-emea-002792-pip01-20_en.pdf-0"},
    {"id":"51540","name":"P/0323/2020 : EMA decision of 13 August 2020 on the granting of a product specific waiver for prolgolimab (EMEA-002792-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T12:42:00Z","last_updated_date":"2021-06-22T12:42:00Z","reference_number":"EMA/414492/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2020-ema-decision-13-august-2020-granting-product-specific-waiver-prolgolimab-emea-002792-pip01-20_en.pdf"},
    {"id":"51541","name":"P/0333/2020 : EMA decision of 28 August 2020 on the granting of a product specific waiver for faricimab (EMEA-002817-PIP04-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T12:55:00Z","last_updated_date":"2021-06-22T12:55:00Z","reference_number":"EMA/441044/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0333-2020-ema-decision-28-august-2020-granting-product-specific-waiver-faricimab-emea-002817-pip04-20_en.pdf"},
    {"id":"51542","name":"P/0332/2020 : EMA decision of 28 August 2020 on the granting of a product specific waiver for faricimab (EMEA-002817-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T12:55:00Z","last_updated_date":"2021-06-22T12:55:00Z","reference_number":"EMA/441042/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0332-2020-ema-decision-28-august-2020-granting-product-specific-waiver-faricimab-emea-002817-pip03-20_en.pdf"},
    {"id":"51567","name":"P/0254/2020: EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for doravirine (Pifeltro), (EMEA-001676-PIP01-14-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-06-23T17:07:00Z","last_updated_date":"2021-06-23T17:07:00Z","reference_number":"EMA/356071/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-doravirine-pifeltro-emea-001676-pip01-14-m03_en.pdf"},
    {"id":"51586","name":"P/0277/2020 : EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for belatacept (Nulojix) (EMEA-000157-PIP01-07-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-24T16:04:00Z","last_updated_date":"2021-06-24T16:04:00Z","reference_number":"EMA/370780/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-belatacept-nulojix-emea-000157-pip01-07-m05_en.pdf"},
    {"id":"51588","name":"P/0469/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tapentadol (hydrochloride) (Palexia, Tapentadol Libra-Pharm, Yantil, and Ationdo), (EMEA-000325-PIP01-08-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-24T16:14:00Z","last_updated_date":"2025-03-06T12:32:05Z","reference_number":"EMA/512496/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0469-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-tapentadol-hydrochloride-palexia-tapentadol-libra-pharm-yantil-ationdo-emea-000325-pip01-08-m11_en.pdf"},
    {"id":"51590","name":"P/0271/2020 : EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for vortioxetine (Brintellix) (EMEA-000455-PIP02-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-24T16:27:00Z","last_updated_date":"2021-06-24T16:27:00Z","reference_number":"EMA/315632/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-vortioxetine-brintellix-emea-000455-pip02-10-m06_en.pdf"},
    {"id":"51600","name":"P/0272/2020 : EMA decision of 13 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for fosnetupitant / palonosetron (Akynzeo) (EMEA-001198-PIP03-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T11:15:00Z","last_updated_date":"2021-06-25T11:15:00Z","reference_number":"EMA/364361/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2020-ema-decision-13-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-fosnetupitant-palonosetron-akynzeo-emea-001198-pip03-17-m04_en.pdf"},
    {"id":"51601","name":"P/0278/2020 : EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dermatophagoides pteronyssinus / dermatophagoides farinae (Acarizax and associated names) (EMEA-001258-PIP01-11- M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T11:22:00Z","last_updated_date":"2021-06-25T11:22:00Z","reference_number":"EMA/361975/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-dermatophagoides-pteronyssinus-dermatophagoides-farinae-acarizax-associated-names-emea-001258-pip01_en.pdf"},
    {"id":"51602","name":"P/0256/2020 : EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for estetrol / drospirenone (EMEA-001332-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T11:31:00Z","last_updated_date":"2021-06-25T11:31:00Z","reference_number":"EMA/315647/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-estetrol-drospirenone-emea-001332-pip01-12-m03_en.pdf"},
    {"id":"51603","name":"P/0255/2020 : EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for Eravacycline (Xerava) (EMEA-001555-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T11:37:00Z","last_updated_date":"2021-06-25T11:37:00Z","reference_number":"EMA/361951/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-eravacycline-xerava-emea-001555-pip01-13-m04_en.pdf"},
    {"id":"51607","name":"P/0282/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for concentrate of proteolytic enzymes in bromelain (NexoBrid) (EMEA-000142-PIP02-09-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T13:15:00Z","last_updated_date":"2021-06-25T13:15:00Z","reference_number":"EMA/371211/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-concentrate-proteolytic-enzymes-bromelain-nexobrid-emea-000142-pip02-09-m09_en.pdf"},
    {"id":"51608","name":"P/0311/2020 : EMA decision of 14 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ceftobiprole medocaril (sodium) (Zevtera and associated names) (EMEA-000205-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T13:25:00Z","last_updated_date":"2021-06-25T13:25:00Z","reference_number":"EMA/413663/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0311-2020-ema-decision-14-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-ceftobiprole-medocaril-sodium-zevtera-associated-names-emea-000205-pip02-11-m04_en.pdf"},
    {"id":"51609","name":"P/0321/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara) (EMEA-000311-PIP04-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T13:32:00Z","last_updated_date":"2021-06-25T13:32:00Z","reference_number":"EMA/388706/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0321-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip04-13-m03_en.pdf"},
    {"id":"51610","name":"P/0281/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara) (EMEA-000311-PIP05-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T13:56:00Z","last_updated_date":"2021-06-25T13:56:00Z","reference_number":"EMA/388711/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip05-17-m01_en.pdf"},
    {"id":"51638","name":"P/0291/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (EDURANT) (EMEA-000317-PIP01-08-M12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T12:11:00Z","last_updated_date":"2021-06-28T12:11:00Z","reference_number":"EMA/388708/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-edurant-emea-000317-pip01-08-m12_en.pdf"},
    {"id":"51639","name":"P/0324/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (Briviact and associated names) (EMEA-000332-PIP01-08-M15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T12:23:00Z","last_updated_date":"2021-06-28T12:23:00Z","reference_number":"EMA/416812/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0324-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-associated-names-emea-000332-pip01-08-m15_en.pdf"},
    {"id":"51640","name":"P/0335/2020 : EMA decision of 31 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for maribavir (EMEA- 000353-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T12:29:00Z","last_updated_date":"2021-06-28T12:29:00Z","reference_number":"EMA/447222/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0335-2020-ema-decision-31-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-maribavir-emea-000353-pip02-16-m01_en.pdf"},
    {"id":"51641","name":"P/0330/2020 : EMA decision of 21 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat) (EMEA-000402-PIP03-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T12:35:00Z","last_updated_date":"2021-06-28T12:35:00Z","reference_number":"EMA/430424/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0330-2020-ema-decision-21-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip03-17-m04_en.pdf"},
    {"id":"51642","name":"P/0296/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (Fycompa) (EMEA-000467-PIP01-08-M14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T12:42:00Z","last_updated_date":"2021-06-28T12:42:00Z","reference_number":"EMA/414600/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-fycompa-emea-000467-pip01-08-m14_en.pdf"},
    {"id":"51643","name":"P/0318/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human glutamic acid decarboxylase (rhGAD65) (EMEA-000609-PIP01-09-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T12:57:00Z","last_updated_date":"2021-06-28T12:57:00Z","reference_number":"EMA/413457/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-glutamic-acid-decarboxylase-rhgad65-emea-000609-pip01-09-m02_en.pdf"},
    {"id":"51644","name":"P/0298/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for pitolisant (Wakix) (EMEA-001176-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T13:06:00Z","last_updated_date":"2021-06-28T13:06:00Z","reference_number":"EMA/414660/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-pitolisant-wakix-emea-001176-pip01-11-m05_en.pdf"},
    {"id":"51645","name":"P/0305/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for reslizumab (Cinqaero) (EMEA-001202-PIP02-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T13:17:00Z","last_updated_date":"2021-06-28T13:17:00Z","reference_number":"EMA/413459/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-reslizumab-cinqaero-emea-001202-pip02-13-m04_en.pdf"},
    {"id":"51646","name":"P/0289/2020 : EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dasabuvir (sodium monohydrate) (Exviera) (EMEA-001439-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T13:31:00Z","last_updated_date":"2024-10-01T17:14:00Z","reference_number":"EMA/371374/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-dasabuvir-sodium-monohydrate-exviera-emea-001439-pip01-13-m03_en.pdf"},
    {"id":"51659","name":"P/0268/2020: EMA decision of 17 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for fostemsavir (tromethamine) (EMEA-001687-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-29T14:24:00Z","last_updated_date":"2021-06-29T14:24:00Z","reference_number":"EMA/366648/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2020-ema-decision-17-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-fostemsavir-tromethamine-emea-001687-pip01-14-m04_en.pdf"},
    {"id":"51660","name":"P/0253/2020: EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for doravirine / lamivudine / tenofovir disoproxil (fumarate) (Delstrigo), (EMEA-001695-PIP01-14-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-06-29T14:32:00Z","last_updated_date":"2021-06-29T14:32:00Z","reference_number":"EMA/356072/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-doravirine-lamivudine-tenofovir-disoproxil-fumarate-delstrigo-emea-001695-pip01-14-m03_en.pdf"},
    {"id":"51661","name":"P/0267/2020: EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for meropenem (trihydrate) / vaborbactam (Vaborem) (EMEA-001731-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-29T15:07:00Z","last_updated_date":"2021-06-29T15:07:00Z","reference_number":"EMA/365938/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-meropenem-trihydrate-vaborbactam-vaborem-emea-001731-pip01-14-m02_en.pdf"},
    {"id":"51662","name":"P/0279/2020: EMA decision of 24 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for imipenem (monohydrate) / cilastatin (sodium) / relebactam (MK-7655A) (Recarbrio), (EMEA-001809-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-29T15:30:00Z","last_updated_date":"2021-06-29T15:30:00Z","reference_number":"EMA/371377/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2020-ema-decision-24-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-imipenem-monohydrate-cilastatin-sodium-relebactam-mk-7655a-recarbrio-emea-001809-pip01-15-m02_en.pdf"},
    {"id":"51663","name":"P/0266/2020: EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human monoclonal antibody to GM-CSF (otilimab) (EMEA-001882-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-29T15:39:00Z","last_updated_date":"2021-06-29T15:39:00Z","reference_number":"EMA/365940/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-monoclonal-antibody-gm-csf-otilimab-emea-001882-pip02-16-m02_en.pdf"},
    {"id":"51664","name":"P/0276/2020: EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for crisaborole (EMEA-002065-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-29T15:51:00Z","last_updated_date":"2021-06-29T15:51:00Z","reference_number":"EMA/370657/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-crisaborole-emea-002065-pip01-16-m03_en.pdf"},
    {"id":"51665","name":"P/0250/2020: EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for olaparib (Lynparza), (EMEA-002269-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-29T16:02:00Z","last_updated_date":"2021-06-29T16:02:00Z","reference_number":"EMA/358974/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-olaparib-lynparza-emea-002269-pip01-17-m01_en.pdf"},
    {"id":"51666","name":"P/0273/2020: EMA decision of 15 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for bempegaldesleukin (EMEA-002492-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-29T16:21:00Z","last_updated_date":"2021-06-29T16:21:00Z","reference_number":"EMA/362017/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2020-ema-decision-15-july-2020-acceptance-modification-agreed-paediatric-investigation-plan-bempegaldesleukin-emea-002492-pip01-18-m01_en.pdf"},
    {"id":"51677","name":"P/0370/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lerodalcibep (EMEA-002720-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T11:24:00Z","last_updated_date":"2021-06-30T11:24:00Z","reference_number":"EMA/414490/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0370-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lerodalcibep-emea-002720-pip01-19_en.pdf"},
    {"id":"51678","name":"P/0362/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for giroctocogene fitelparvovec (EMEA-002724-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T11:35:00Z","last_updated_date":"2021-06-30T11:35:00Z","reference_number":"EMA/432665/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0362-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-giroctocogene-fitelparvovec-emea-002724-pip01-19_en.pdf"},
    {"id":"51679","name":"P/0360/2020 : EMA decision of 9 September 2020 on the granting of a product specific waiver for fruquintinib (EMEA-002784-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T11:55:00Z","last_updated_date":"2021-06-30T11:55:00Z","reference_number":"EMA/432675/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0360-2020-ema-decision-9-september-2020-granting-product-specific-waiver-fruquintinib-emea-002784-pip01-20_en.pdf"},
    {"id":"51680","name":"P/0336/2020 : EMA decision of 9 September 2020 on the granting of a product specific waiver for retifanlimab (EMEA-002798-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T12:09:00Z","last_updated_date":"2021-06-30T12:09:00Z","reference_number":"EMA/450653/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2020-ema-decision-9-september-2020-granting-product-specific-waiver-retifanlimab-emea-002798-pip01-20_en.pdf"},
    {"id":"51681","name":"P/0357/2020 : EMA decision of 9 September 2020 on the refusal of a paediatric investigation plan and on the granting of a waiver for live attenuated poliovirus type 1 / live attenuated poliovirus type 3 (EMEA-002799-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T12:43:00Z","last_updated_date":"2021-06-30T12:43:00Z","reference_number":"EMA/419267/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0357-2020-ema-decision-9-september-2020-refusal-paediatric-investigation-plan-granting-waiver-live-attenuated-poliovirus-type-1-live-attenuated-poliovirus-type-3-emea-002799-pip01-20_en.pdf"},
    {"id":"51683","name":"P/0288/2020: EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ombitasvir / paritaprevir / ritonavir (Viekirax), (EMEA-001440-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T14:09:00Z","last_updated_date":"2024-10-02T09:47:00Z","reference_number":"EMA/388709/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-ombitasvir-paritaprevir-ritonavir-viekirax-emea-001440-pip01-13-m03_en.pdf"},
    {"id":"51684","name":"P/0301/2020: EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for glucagon (Baqsimi), (EMEA-001657-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T14:38:00Z","last_updated_date":"2021-06-30T14:38:00Z","reference_number":"EMA/371376/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-glucagon-baqsimi-emea-001657-pip01-14-m01_en.pdf"},
    {"id":"51685","name":"P/0325/2020: EMA decision of 13 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod (hydrochloride) (Zeposia), (EMEA-001710-PIP02-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T15:01:00Z","last_updated_date":"2021-06-30T15:01:00Z","reference_number":"EMA/416864/2020 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0325-2020-ema-decision-13-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-ozanimod-hydrochloride-zeposia-emea-001710-pip02-14-m05_en.pdf"},
    {"id":"51686","name":"P/0312/2020: EMA decision of 14 August 2020 on the refusal of a modification of an agreed paediatric investigation plan for derivative of 4Hpyrazolo[ 3,4-d]pyrimidin-4-one (BI409306) (EMEA-001742-PIP01-14-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T15:19:00Z","last_updated_date":"2021-06-30T15:19:00Z","reference_number":"EMA/413702/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2020-ema-decision-14-august-2020-refusal-modification-agreed-paediatric-investigation-plan-derivative-4hpyrazolo-34-dpyrimidin-4-one-bi409306-emea-001742-pip01-14-m01_en.pdf"},
    {"id":"51688","name":"P/0334/2020: EMA decision of 24 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy), (EMEA-001766-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T15:34:00Z","last_updated_date":"2021-06-30T15:34:00Z","reference_number":"EMA/419188/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2020-ema-decision-24-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy-emea-001766-pip01-15-m02_en.pdf-0"},
    {"id":"51689","name":"P/0334/2020: EMA decision of 24 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy), (EMEA-001766-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T15:34:00Z","last_updated_date":"2021-06-30T15:34:00Z","reference_number":"EMA/419188/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2020-ema-decision-24-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy-emea-001766-pip01-15-m02_en.pdf"},
    {"id":"51690","name":"P/0316/2020: EMA decision of 14 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for rVSVΔG-ZEBOV-GP (Ebola Zaire Vaccine) (Ervebo) (EMEA-001786-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T15:42:00Z","last_updated_date":"2021-06-30T15:42:00Z","reference_number":"EMA/413706/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2020-ema-decision-14-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-rvsvdg-zebov-gp-ebola-zaire-vaccine-ervebo-emea-001786-pip01-15-m01_en.pdf"},
    {"id":"51691","name":"P/0302/202: EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for synthetic doublestranded siRNA oligonucleotide...(EMEA-001855-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T15:59:00Z","last_updated_date":"2021-06-30T15:59:00Z","reference_number":"EMA/413460/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-202-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-synthetic-doublestranded-sirna-oligonucleotideemea-001855-pip01-15-m02_en.pdf"},
    {"id":"51692","name":"P/0313/2020: EMA decision of 14 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan... (EMEA-001875-PIP02-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T16:06:00Z","last_updated_date":"2021-06-30T16:06:00Z","reference_number":"EMA/413710/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2020-ema-decision-14-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-emea-001875-pip02-18-m02_en.pdf"},
    {"id":"51697","name":"P/0300/2020: EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for efpeglenatide (EMEA-001903-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T16:58:00Z","last_updated_date":"2021-06-30T16:58:00Z","reference_number":"EMA/414689/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-efpeglenatide-emea-001903-pip01-15-m01_en.pdf"},
    {"id":"51698","name":"P/0320/2020: EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for brincidofovir (EMEA- 001904-PIP03-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T17:07:00Z","last_updated_date":"2021-06-30T17:07:00Z","reference_number":"EMA/413464/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-brincidofovir-emea-001904-pip03-18-m01_en.pdf"},
    {"id":"51700","name":"P/0327/2020: EMA decision of 14 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lenadogene nolparvovec (GS010) (EMEA-001992-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T17:27:00Z","last_updated_date":"2021-06-30T17:27:00Z","reference_number":"EMA/420429/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0327-2020-ema-decision-14-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-lenadogene-nolparvovec-gs010-emea-001992-pip02-16-m01_en.pdf"},
    {"id":"51701","name":"P/0322/2020: EMA decision of 10 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for iodine (131-I) murine IgG1 monoclonal antibody against B7-H3 (131I-omburtamab) (EMEA-002101-PIP02-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T17:32:00Z","last_updated_date":"2021-06-30T17:32:00Z","reference_number":"EMA/415352/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0322-2020-ema-decision-10-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-iodine-131-i-murine-igg1-monoclonal-antibody-against-b7-h3-131i-omburtamab-emea-002101-pip02-18-m01_en.pdf"}    {"id":"51702","name":"P/0284/2020: EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ladarixin (EMEA-002642-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T17:48:00Z","last_updated_date":"2021-06-30T17:48:00Z","reference_number":"EMA/371379/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-ladarixin-emea-002642-pip01-19-m01_en.pdf"},
    {"id":"51703","name":"P/0283/2020: EMA decision of 12 August 2020 on the acceptance of a modification of an agreed paediatric investigation plan for olenasufligene relduparvovec (EMEA-002122-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-06-30T17:56:00Z","last_updated_date":"2021-06-30T17:56:00Z","reference_number":"EMA/388710/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan-olenasufligene-relduparvovec-emea-002122-pip02-17-m01_en.pdf"},
    {"id":"51711","name":"P/0337/2020 : EMA decision of 9 September 2020 on the granting of a product specific waiver for linerixibat (EMEA-002800-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T11:40:00Z","last_updated_date":"2021-07-01T11:40:00Z","reference_number":"EMA/450725/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0337-2020-ema-decision-9-september-2020-granting-product-specific-waiver-linerixibat-emea-002800-pip01-20_en.pdf"},
    {"id":"51712","name":"P/0338/2020 : EMA decision of 9 September 2020 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for icosabutate (EMEA-002816-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T11:56:00Z","last_updated_date":"2021-07-01T11:56:00Z","reference_number":"EMA/451993/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0338-2020-ema-decision-9-september-2020-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-icosabutate-emea-002816-pip01-20_en.pdf"},
    {"id":"51713","name":"P/0352/2020 : EMA decision of 9 September 2020 on the granting of a product specific waiver for cluster of differentiation 40 (CD40) ligand antagonist comprising two identical Tn3 modules fused to human serum albumin....(EMEA-002825-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T12:13:00Z","last_updated_date":"2021-07-01T12:13:00Z","reference_number":"EMA/419207/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0352-2020-ema-decision-9-september-2020-granting-product-specific-waiver-cluster-differentiation-40-cd40-ligand-antagonist-comprising-two-identical-tn3-modules-fused-human-serum-albuminemea-002825_en.pdf"},
    {"id":"51714","name":"P/0348/2020 : EMA decision of 9 September 2020 on the granting of a product specific waiver for rosuvastatin (calcium) / acetylsalicylic acid (EMEA-002831-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T12:27:00Z","last_updated_date":"2021-07-01T12:27:00Z","reference_number":"EMA/458022/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0348-2020-ema-decision-9-september-2020-granting-product-specific-waiver-rosuvastatin-calcium-acetylsalicylic-acid-emea-002831-pip01-20_en.pdf"},
    {"id":"51715","name":"P/0345/2020 : EMA decision of 9 September 2020 on the granting of a product specific waiver for ranibizumab (EMEA-002832-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T12:34:00Z","last_updated_date":"2021-07-01T12:34:00Z","reference_number":"EMA/459979/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0345-2020-ema-decision-9-september-2020-granting-product-specific-waiver-ranibizumab-emea-002832-pip01-20_en.pdf"},
    {"id":"51716","name":"P/0355/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2).....(EMEA-001715-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T13:17:00Z","last_updated_date":"2021-07-01T13:17:00Z","reference_number":"P/0355/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0355-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h3n2emea-001715-pip01-14-m04_en.pdf"},
    {"id":"51717","name":"P/0347/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib, (RINVOQ) (EMEA-001741-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T13:29:00Z","last_updated_date":"2021-07-01T13:29:00Z","reference_number":"EMA/415147/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0347-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip01-14-m03_en.pdf"},
    {"id":"51718","name":"P/0359/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine / dolutegravir (Juluca) (EMEA-001750-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T13:44:00Z","last_updated_date":"2021-07-01T13:44:00Z","reference_number":"EMA/418806/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0359-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-dolutegravir-juluca-emea-001750-pip01-15-m03_en.pdf"},
    {"id":"51719","name":"P/0343/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for quizartinib (EMEA- 001821-PIP01-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T13:54:00Z","last_updated_date":"2021-07-01T13:54:00Z","reference_number":"EMA/452022/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0343-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-quizartinib-emea-001821-pip01-15-m04_en.pdf"},
    {"id":"51720","name":"P/0349/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for andexanet alfa (Ondexxya) (EMEA-001902-PIP01-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T14:08:00Z","last_updated_date":"2021-07-01T14:08:00Z","reference_number":"EMA/415148/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0349-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-andexanet-alfa-ondexxya-emea-001902-pip01-15-m04_en.pdf"},
    {"id":"51721","name":"P/0372/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / lamivudine (Dovato) (EMEA-001940-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T14:24:00Z","last_updated_date":"2021-07-01T14:24:00Z","reference_number":"EMA/419189/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0372-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-lamivudine-dovato-emea-001940-pip01-16-m03_en.pdf"},
    {"id":"51722","name":"P/0350/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for cannabidiol (CBD) (Epidyolex) (EMEA-001964-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T14:30:00Z","last_updated_date":"2021-07-01T14:30:00Z","reference_number":"EMA/419191/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0350-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-cannabidiol-cbd-epidyolex-emea-001964-pip01-16-m02_en.pdf"},
    {"id":"51723","name":"P/0356/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for cenicriviroc (EMEA-001999-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T14:40:00Z","last_updated_date":"2021-07-01T14:40:00Z","reference_number":"EMA/415149/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0356-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-cenicriviroc-emea-001999-pip02-17-m01_en.pdf"},
    {"id":"51724","name":"P/0375/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for venetoclax (Venclyxto) (EMEA-002018-PIP02-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-01T14:48:00Z","last_updated_date":"2021-07-01T14:48:00Z","reference_number":"EMA/415154/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0375-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-venetoclax-venclyxto-emea-002018-pip02-16-m03_en.pdf"},
    {"id":"51742","name":"P/0377/2020 : EMA decision of 11 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for odevixibat (EMEA-002054-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-02T12:51:00Z","last_updated_date":"2021-07-02T12:51:00Z","reference_number":"EMA/457990/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0377-2020-ema-decision-11-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-odevixibat-emea-002054-pip01-16-m02_en.pdf"},
    {"id":"51743","name":"P/0340/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for pretomanid (EMEA- 002115-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-02T12:59:00Z","last_updated_date":"2021-07-02T12:59:00Z","reference_number":"EMA/452030/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0340-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-pretomanid-emea-002115-pip01-17-m02_en.pdf"},
    {"id":"51744","name":"P/0382/2020 : EMA decision of 18 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for cefiderocol (Fetcroja) (EMEA-002133-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-02T13:06:00Z","last_updated_date":"2021-07-02T13:06:00Z","reference_number":"EMA/447233/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0382-2020-ema-decision-18-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-cefiderocol-fetcroja-emea-002133-pip01-17-m01_en.pdf"},
    {"id":"51745","name":"P/0379/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for onasemnogene abeparvovec (EMEA-002168-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-02T13:15:00Z","last_updated_date":"2021-07-02T13:15:00Z","reference_number":"EMA/457999/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0379-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-onasemnogene-abeparvovec-emea-002168-pip01-17-m03_en.pdf"},
    {"id":"51746","name":"P/0358/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for hydrocortisone (hemisuccinate) (EMEA-002305-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-02T13:24:00Z","last_updated_date":"2021-07-02T13:24:00Z","reference_number":"EMA/430122/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0358-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-hydrocortisone-hemisuccinate-emea-002305-pip01-17-m01_en.pdf"},
    {"id":"51747","name":"P/0342/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for synthetic doublestranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA.....(EMEA-002493-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-02T13:33:00Z","last_updated_date":"2021-07-02T13:33:00Z","reference_number":"EMA/452024/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0342-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-synthetic-doublestranded-sirna-oligonucleotide-directed-against-lactate-dehydrogenase-mrnaemea_en.pdf"},
    {"id":"51782","name":"P/0057/2021 : EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for pitolisant (Wakix) (EMEA-001176-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-05T13:04:00Z","last_updated_date":"2021-07-05T13:04:00Z","reference_number":"EMA/18865/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-pitolisant-wakix-emea-001176-pip01-11-m06_en.pdf"},
    {"id":"51842","name":"P/0344/2020 : EMA decision of  9 September 2020 on the granting of a product specific waiver for dronabinol (EMEA-000643-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T13:26:00Z","last_updated_date":"2021-07-06T13:26:00Z","reference_number":"EMA/430119/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0344-2020-ema-decision-9-september-2020-granting-product-specific-waiver-dronabinol-emea-000643-pip02-20_en.pdf"},
    {"id":"51843","name":"P/0378/2020 : EMA decision of 9 September 2020 on the granting of a product specific waiver for tezepelumab (EMEA-001613-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T13:43:00Z","last_updated_date":"2021-07-06T13:43:00Z","reference_number":"EMA/419202/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0378-2020-ema-decision-9-september-2020-granting-product-specific-waiver-tezepelumab-emea-001613-pip02-20_en.pdf"},
    {"id":"51844","name":"P/0385/2020 : EMA decision of 25 September 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for the whole range of unmanipulated autologous mononuclear cells... (EMEA-001799-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T13:55:00Z","last_updated_date":"2021-07-06T13:55:00Z","reference_number":"EMA/488671/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0385-2020-ema-decision-25-september-2020-agreement-paediatric-investigation-plan-granting-waiver-whole-range-unmanipulated-autologous-mononuclear-cells-emea-001799-pip03-19_en.pdf"},
    {"id":"51846","name":"P/0368/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for odevixibat (EMEA-002054-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T14:29:00Z","last_updated_date":"2021-07-06T14:29:00Z","reference_number":"EMA/419264/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0368-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-odevixibat-emea-002054-pip02-18_en.pdf-0"},
    {"id":"51847","name":"P/0366/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for rebisufligene etisparvovec (EMEA-002206-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T14:34:00Z","last_updated_date":"2021-07-06T14:34:00Z","reference_number":"EMA/458002/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0366-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-rebisufligene-etisparvovec-emea-002206-pip02-19_en.pdf"},
    {"id":"51848","name":"P/0368/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for odevixibat (EMEA-002054-PIP02-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T14:38:00Z","last_updated_date":"2021-07-06T14:38:00Z","reference_number":"EMA/419264/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0368-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-odevixibat-emea-002054-pip02-18_en.pdf"},
    {"id":"51849","name":"P/0367/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for relamorelin (EMEA-002323-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T14:45:00Z","last_updated_date":"2021-07-06T14:45:00Z","reference_number":"EMA/419263/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0367-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-relamorelin-emea-002323-pip02-19_en.pdf"},
    {"id":"51851","name":"P/0363/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-neonatal Fc receptor human monoclonal antibody (M281) (EMEA-002559-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T14:57:00Z","last_updated_date":"2021-07-06T14:57:00Z","reference_number":"EMA/430125/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0363-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-anti-neonatal-fc-receptor-human-monoclonal-antibody-m281-emea-002559-pip03-19_en.pdf"},
    {"id":"51852","name":"P/0369/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for emixustat (hydrochloride) (EMEA-002581-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T15:02:00Z","last_updated_date":"2021-07-06T15:02:00Z","reference_number":"EMA/432650/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0369-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-emixustat-hydrochloride-emea-002581-pip01-19_en.pdf"},
    {"id":"51853","name":"P/0365/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mitapivat (EMEA-002684-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T15:10:00Z","last_updated_date":"2021-07-06T15:10:00Z","reference_number":"EMA/415913/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0365-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mitapivat-emea-002684-pip01-19_en.pdf"},
    {"id":"51855","name":"P/0381/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for diroximel fumarate (BIIB098) (EMEA-002685-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T15:22:00Z","last_updated_date":"2021-07-06T15:22:00Z","reference_number":"EMA/415911/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0381-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-diroximel-fumarate-biib098-emea-002685-pip02-19_en.pdf"},
    {"id":"51858","name":"P/0364/2020 : EMA decision of 9 September 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for... (EMEA-002699-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-06T15:26:00Z","last_updated_date":"2021-07-06T15:26:00Z","reference_number":"EMA/458006/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0364-2020-ema-decision-9-september-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-emea-002699-pip01-19_en.pdf"},
    {"id":"51874","name":"P/0384/2020: EMA decision of 23 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab (Nucala) (EMEA-000069-PIP01-07-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-08T12:23:00Z","last_updated_date":"2021-07-08T12:23:00Z","reference_number":"EMA/487753/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0384-2020-ema-decision-23-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-nucala-emea-000069-pip01-07-m07_en.pdf"},
    {"id":"51876","name":"P/0241/2021 : EMA decision of 25 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir (phosphate) (Tamiflu) (EMEA-000365-PIP01-08-M12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T11:54:00Z","last_updated_date":"2022-04-28T11:54:00Z","reference_number":"EMA/342337/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2021-ema-decision-25-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-oseltamivir-phosphate-tamiflu-emea-000365-pip01-08-m12_en.pdf"},
    {"id":"51877","name":"P/0374/2020: EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone (furoate) / vilanterol (Relvar Ellipta and associated names), (EMEA-000431-PIP01-08-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-08T13:20:00Z","last_updated_date":"2021-07-08T13:20:00Z","reference_number":"EMA/414473/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0374-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-vilanterol-relvar-ellipta-associated-names-emea-000431-pip01-08-m11_en.pdf"},
    {"id":"51878","name":"P/0376/2020: EMA decision of 11 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tadalafil (Adcirca, Cialis), (EMEA-000452-PIP02-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-08T13:58:00Z","last_updated_date":"2021-07-08T13:58:00Z","reference_number":"EMA/455623/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0376-2020-ema-decision-11-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-tadalafil-adcirca-cialis-emea-000452-pip02-10-m06_en.pdf"},
    {"id":"51879","name":"P/0380/2020: EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz), (EMEA-000576-PIP03-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-08T14:30:00Z","last_updated_date":"2021-07-08T14:30:00Z","reference_number":"EMA/415144/2020 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0380-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip03-12-m04_en.pdf"},
    {"id":"51880","name":"P/0353/2020: EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta, Bydureon), (EMEA-000689-PIP01-09-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-08T14:45:00Z","last_updated_date":"2021-07-08T14:45:00Z","reference_number":"EMA/430120/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0353-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-exenatide-byetta-bydureon-emea-000689-pip01-09-m10_en.pdf"},
    {"id":"51881","name":"P/0388/2020: EMA decision of 29 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP05-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-08T15:12:00Z","last_updated_date":"2021-07-08T15:12:00Z","reference_number":"EMA/501355/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0388-2020-ema-decision-29-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip05-15-m04_en.pdf"},
    {"id":"51882","name":"P/0346/2020: EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for treosulfan (Trecondi), (EMEA-000883-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-08T15:25:00Z","last_updated_date":"2021-07-08T15:25:00Z","reference_number":"EMA/415145/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0346-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-treosulfan-trecondi-emea-000883-pip01-10-m05_en.pdf"},
    {"id":"51883","name":"P/0373/2020: of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline (fumarate) (Sirturo), (EMEA-000912-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-08T15:56:00Z","last_updated_date":"2021-07-08T15:56:00Z","reference_number":"EMA/418799/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0373-2020-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-bedaquiline-fumarate-sirturo-emea-000912-pip01-10-m05_en.pdf"},
    {"id":"51884","name":"P/0339/2020: EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan... (EMEA-001356-PIP02-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-08T16:00:00Z","last_updated_date":"2021-07-08T16:00:00Z","reference_number":"EMA/452033/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0339-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-emea-001356-pip02-12-m03_en.pdf"},
    {"id":"51885","name":"P/0351/2020: EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ixazomib (Ninlaro) (EMEA-001410-PIP02-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-08T16:10:00Z","last_updated_date":"2021-07-08T16:10:00Z","reference_number":"EMA/457987/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0351-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-ixazomib-ninlaro-emea-001410-pip02-17-m03_en.pdf"},
    {"id":"51891","name":"P/0354/2020: EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (EMEA-001418-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-09T09:19:00Z","last_updated_date":"2021-07-09T09:19:00Z","reference_number":"EMA/418800/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0354-2020-ema-decision-9-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-cabotegravir-emea-001418-pip01-13-m02_en.pdf"},
    {"id":"51892","name":"P/0386/2020: EMA decision of 25 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for filgotinib (EMEA-001619-PIP03-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-09T09:46:00Z","last_updated_date":"2021-07-09T09:46:00Z","reference_number":"EMA/492440/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0386-2020-ema-decision-25-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-filgotinib-emea-001619-pip03-16-m01_en.pdf"},
    {"id":"51893","name":"P/0383/2020: EMA decision of 24 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod (hydrochloride) (Zeposia), (EMEA-001710-PIP03-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-09T09:57:00Z","last_updated_date":"2021-07-09T09:57:00Z","reference_number":"EMA/488493/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0383-2020-ema-decision-24-september-2020-acceptance-modification-agreed-paediatric-investigation-plan-ozanimod-hydrochloride-zeposia-emea-001710-pip03-17-m02_en.pdf"},
    {"id":"51973","name":"P/0104/2021 : EMA decision of 17 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for crinecerfont (EMEA-002700-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-20T16:35:00Z","last_updated_date":"2021-07-20T16:35:00Z","reference_number":"EMA/146014/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2021-ema-decision-17-march-2021-agreement-paediatric-investigation-plan-granting-deferral-crinecerfont-emea-002700-pip01-19_en.pdf"},
    {"id":"51988","name":"P/0416/2020 : EMA decision of 23 October 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for plasma kallikrein inhibitor (EMEA-002723-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-21T13:52:00Z","last_updated_date":"2021-07-21T13:52:00Z","reference_number":"EMA/538978/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0416-2020-ema-decision-23-october-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-plasma-kallikrein-inhibitor-emea-002723-pip01-19_en.pdf"},
    {"id":"51989","name":"P/0371/2020 : EMA decision of 23 October 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for BAY 1747846 (EMEA-002778-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-21T14:23:00Z","last_updated_date":"2021-07-21T14:23:00Z","reference_number":"EMA/472024/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0371-2020-ema-decision-23-october-2020-agreement-paediatric-investigation-plan-granting-waiver-bay-1747846-emea-002778-pip01-20_en.pdf"},
    {"id":"51998","name":"P/0361/2020: EMA decision of 5 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for vedolizumab (Entyvio), (EMEA-000645-PIP01-09-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-21T17:11:00Z","last_updated_date":"2021-07-21T17:11:00Z","reference_number":"EMA/503146/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0361-2020-ema-decision-5-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-vedolizumab-entyvio-emea-000645-pip01-09-m07_en.pdf"},
    {"id":"51999","name":"P/0393/2020: EMA decision of 23 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate) (Lixiana), (EMEA-000788-PIP02-11-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-21T17:20:00Z","last_updated_date":"2021-07-21T17:20:00Z","reference_number":"EMA/534963/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0393-2020-ema-decision-23-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-lixiana-emea-000788-pip02-11-m10_en.pdf"},
    {"id":"52000","name":"P/0407/2020: EMA decision of 23 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for velmanase alfa (Lamzede), (EMEA-001056-PIP02-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-21T17:26:00Z","last_updated_date":"2021-07-21T17:26:00Z","reference_number":"EMA/493358/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0407-2020-ema-decision-23-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-velmanase-alfa-lamzede-emea-001056-pip02-12-m01_en.pdf"},
    {"id":"52001","name":"P/0427/2020: EMA decision of 21 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (Lenvima, Kisplyx), (EMEA-001119-PIP02-12-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-21T17:37:00Z","last_updated_date":"2021-07-21T17:37:00Z","reference_number":"EMA/539744/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0427-2020-ema-decision-21-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-lenvima-kisplyx-emea-001119-pip02-12-m07_en.pdf"},
    {"id":"52002","name":"P/0410/2020: EMA decision of 23 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dabrafenib (mesilate) (Tafinlar), (EMEA-001147-PIP01-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-21T17:46:00Z","last_updated_date":"2021-07-21T17:46:00Z","reference_number":"EMA/494516/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0410-2020-ema-decision-23-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-dabrafenib-mesilate-tafinlar-emea-001147-pip01-11-m07_en.pdf"},
    {"id":"52003","name":"P/0392/2020: EMA decision of 23 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for trametinib (dimethyl sulfoxide) (Mekinist), (EMEA-001177-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-21T17:55:00Z","last_updated_date":"2021-07-21T17:55:00Z","reference_number":"EMA/534960/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0392-2020-ema-decision-23-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-trametinib-dimethyl-sulfoxide-mekinist-emea-001177-pip01-11-m06_en.pdf"},
    {"id":"52009","name":"P/0390/2020 : EMA decision of 16 October 2020 on the granting of a product specific waiver for ramipril / bisoprolol (fumarate) (EMEA-002794-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T11:04:00Z","last_updated_date":"2021-07-22T11:04:00Z","reference_number":"EMA/415325/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0390-2020-ema-decision-16-october-2020-granting-product-specific-waiver-ramipril-bisoprolol-fumarate-emea-002794-pip01-20_en.pdf"},
    {"id":"52011","name":"P/0413/2020 : EMA decision of 23 October on the granting of a product specific waiver for alpha-R-lipoic acid choline ester tosilate (EMEA-002811-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T11:14:00Z","last_updated_date":"2021-07-22T11:14:00Z","reference_number":"EMA/539383/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0413-2020-ema-decision-23-october-granting-product-specific-waiver-alpha-r-lipoic-acid-choline-ester-tosilate-emea-002811-pip01-20_en.pdf"},
    {"id":"52012","name":"P/0423/2020 : EMA decision of 23 October 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for dabrafenib (EMEA-001147-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T11:49:00Z","last_updated_date":"2021-07-22T11:49:00Z","reference_number":"EMA/494573/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0423-2020-ema-decision-23-october-2020-agreement-paediatric-investigation-plan-granting-waiver-dabrafenib-emea-001147-pip02-20_en.pdf"},
    {"id":"52013","name":"P/0424/2020 : EMA decision of 23 October 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for trametinib (EMEA-001177-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T11:54:00Z","last_updated_date":"2021-07-22T11:54:00Z","reference_number":"EMA/494583/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0424-2020-ema-decision-23-october-2020-agreement-paediatric-investigation-plan-granting-waiver-trametinib-emea-001177-pip02-20_en.pdf"},
    {"id":"52014","name":"P/0394/2020 : EMA decision of 23 October 2020 on the granting of a product specific waiver for dupilumab (Dupixent), (EMEA-001501-PIP06-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T11:58:00Z","last_updated_date":"2021-07-22T11:58:00Z","reference_number":"EMA/534986/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0394-2020-ema-decision-23-october-2020-granting-product-specific-waiver-dupilumab-dupixent-emea-001501-pip06-20_en.pdf"},
    {"id":"52017","name":"P/0403/2020 : EMA decision of 22 October 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for danicopan (EMEA-002310-PIP01-17))","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T12:16:00Z","last_updated_date":"2021-07-22T12:16:00Z","reference_number":"EMA/485954/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0403-2020-ema-decision-22-october-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-danicopan-emea-002310-pip01-17_en.pdf"},
    {"id":"52018","name":"P/0420/2020 : EMA decision of 23 October 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for glycopyrronium bromide (EMEA-002383-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T12:20:00Z","last_updated_date":"2021-07-22T12:20:00Z","reference_number":"EMA/494714/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0420-2020-ema-decision-23-october-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-glycopyrronium-bromide-emea-002383-pip01-18_en.pdf"},
    {"id":"52019","name":"P/0414/2020 : EMA decision of 23 October 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant human granulocyte colony-stimulating factor... (EMEA-002507-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T12:24:00Z","last_updated_date":"2021-07-22T12:24:00Z","reference_number":"EMA/538451/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0414-2020-ema-decision-23-october-2020-agreement-paediatric-investigation-plan-granting-deferral-recombinant-human-granulocyte-colony-stimulating-factor-emea-002507-pip02-19_en.pdf"},
    {"id":"52021","name":"P/0411/2020 : EMA decision of 23 October 2020 on the granting of a product specific waiver for autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector.......(CT053) (EMEA-002823-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T12:45:00Z","last_updated_date":"2021-07-22T12:45:00Z","reference_number":"EMA/494523/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0411-2020-ema-decision-23-october-2020-granting-product-specific-waiver-autologous-t-lymphocyte-enriched-population-cells-transduced-lentiviral-vectorct053-emea-002823-pip01-20_en.pdf"},
    {"id":"52022","name":"P/0405/2020 : EMA decision of 22 October 2020 on the granting of a product specific waiver for fenofibrate / pravastatin (sodium) / ezetimibe (EMEA-002835-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T12:54:00Z","last_updated_date":"2021-07-22T12:54:00Z","reference_number":"EMA/485839/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0405-2020-ema-decision-22-october-2020-granting-product-specific-waiver-fenofibrate-pravastatin-sodium-ezetimibe-emea-002835-pip01-20_en.pdf"},
    {"id":"52023","name":"P/0396/2020 : EMA decision of 23 October 2020 on the refusal of a paediatric investigation plan and on the granting of a waiver for recombinant humanised monoclonal antibody (IgG1, Kappa) to IL-5 (EMEA-002836-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T13:12:00Z","last_updated_date":"2021-07-22T13:12:00Z","reference_number":"EMA/535015/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0396-2020-ema-decision-23-october-2020-refusal-paediatric-investigation-plan-granting-waiver-recombinant-humanised-monoclonal-antibody-igg1-kappa-il-5-emea-002836-pip01-20_en.pdf"},
    {"id":"52024","name":"P/0422/2020 : EMA decision of 23 October 2020 on the granting of a product specific waiver for colchicine (EMEA-002837-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T13:22:00Z","last_updated_date":"2021-07-22T13:22:00Z","reference_number":"EMA/494631/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0422-2020-ema-decision-23-october-2020-granting-product-specific-waiver-colchicine-emea-002837-pip01-20_en.pdf"},
    {"id":"52025","name":"P/0419/2020 : EMA decision of 22 October 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for rAAVrh74.MHCK7.microdystrophin (SRP-9001) (EMEA-002677-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T13:39:00Z","last_updated_date":"2021-07-22T13:39:00Z","reference_number":"EMA/485958/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0419-2020-ema-decision-22-october-2020-agreement-paediatric-investigation-plan-granting-deferral-raavrh74mhck7microdystrophin-srp-9001-emea-002677-pip01-19_en.pdf"},
    {"id":"52028","name":"P/0408/2020 : EMA decision of 23 October 2020 on the granting of a product specific waiver for brolucizumab (Beovu), (EMEA-002691-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-22T14:32:00Z","last_updated_date":"2021-07-22T14:32:00Z","reference_number":"EMA/539297/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0408-2020-ema-decision-23-october-2020-granting-product-specific-waiver-brolucizumab-beovu-emea-002691-pip02-20_en.pdf"},
    {"id":"52049","name":"P/0425/2020 : EMA decision of 22 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for birch bark extract (EMEA-001299-PIP03-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:17:00Z","last_updated_date":"2021-07-23T12:17:00Z","reference_number":"EMA/485670/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0425-2020-ema-decision-22-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-birch-bark-extract-emea-001299-pip03-17-m01_en.pdf"},
    {"id":"52050","name":"P/0391/2020 : EMA decision of 23 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for zanamivir (Relenza) (EMEA-001318-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:26:00Z","last_updated_date":"2021-07-23T12:26:00Z","reference_number":"EMA/534954/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0391-2020-ema-decision-23-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-zanamivir-relenza-emea-001318-pip01-12-m04_en.pdf"},
    {"id":"52051","name":"P/0389/2020 : EMA decision of 1 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for peanut allergen extract (EMEA-001481-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:43:00Z","last_updated_date":"2021-07-23T12:43:00Z","reference_number":"EMA/511007/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0389-2020-ema-decision-1-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-peanut-allergen-extract-emea-001481-pip01-13-m04_en.pdf"},
    {"id":"52052","name":"EMA/485672/2020 : EMA decision of 22 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent) (EMEA-001501-PIP02-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:50:00Z","last_updated_date":"2021-07-23T12:50:00Z","reference_number":"EMA/485672/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-485672-2020-ema-decision-22-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip02-13-m06_en.pdf"},
    {"id":"52053","name":"P/0402/2020 : EMA decision of 22 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for copanlisib (EMEA- 001757-PIP02-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:57:00Z","last_updated_date":"2021-07-23T12:57:00Z","reference_number":"EMA/485708/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0402-2020-ema-decision-22-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-copanlisib-emea-001757-pip02-15-m02_en.pdf"},
    {"id":"52054","name":"P/0003/2024 : EMA decision of 3 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for dengue tetravalent vaccine (live, attenuated) (Qdenga), (EMEA-001888-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-13T13:02:00Z","last_updated_date":"2025-03-13T13:02:00Z","reference_number":" EMA/885/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2024-ema-decision-3-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-dengue-tetravalent-vaccine-live-attenuated-qdenga-emea-001888-pip01-15-m02_en.pdf"},
    {"id":"52056","name":"P/0428/2020 : EMA decision of 28 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for inebilizumab (EMEA-001911-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T13:34:00Z","last_updated_date":"2021-07-23T13:34:00Z","reference_number":"EMA/562910/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0428-2020-ema-decision-28-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-inebilizumab-emea-001911-pip01-15-m03_en.pdf"},
    {"id":"52057","name":"P/0400/2020 : EMA decision of 23 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris) (EMEA-001943-PIP01-16-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T13:46:00Z","last_updated_date":"2021-07-23T13:46:00Z","reference_number":"EMA/494587/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0400-2020-ema-decision-23-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-001943-pip01-16-m05_en.pdf"},
    {"id":"52058","name":"P/0401/2020 : EMA decision of 23 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for vadadustat (EMEA-001944-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T13:51:00Z","last_updated_date":"2021-07-23T13:51:00Z","reference_number":"EMA/494601/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0401-2020-ema-decision-23-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-vadadustat-emea-001944-pip01-16-m02_en.pdf"},
    {"id":"52059","name":"P/0399/2020 : EMA decision of 23 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris) (EMEA-002077-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T14:03:00Z","last_updated_date":"2021-07-23T14:03:00Z","reference_number":"EMA/494606/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0399-2020-ema-decision-23-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-002077-pip01-16-m03_en.pdf"},
    {"id":"52060","name":"P/0421/2020 : EMA decision of 22 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for daratumumab (Darzalex) (EMEA-002152-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T14:46:00Z","last_updated_date":"2021-07-23T14:46:00Z","reference_number":"EMA/485716/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0421-2020-ema-decision-22-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-daratumumab-darzalex-emea-002152-pip01-17-m02_en.pdf"},
    {"id":"52061","name":"P/0406/2020 : EMA decision of 23 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for etripamil (EMEA-002303-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T14:51:00Z","last_updated_date":"2021-07-23T14:51:00Z","reference_number":"EMA/494517/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0406-2020-ema-decision-23-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-etripamil-emea-002303-pip01-17-m02_en.pdf"},
    {"id":"52062","name":"P/0397/2020 : EMA decision of 23 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for elexacaftor / tezacaftor / ivacaftor (EMEA-002324-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T15:00:00Z","last_updated_date":"2021-07-23T15:00:00Z","reference_number":"EMA/539861/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0397-2020-ema-decision-23-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-elexacaftor-tezacaftor-ivacaftor-emea-002324-pip01-17-m01_en.pdf"},
    {"id":"52063","name":"P/0387/2020 : EMA decision of 1 October 2020 on the acceptance of a modification of an agreed paediatric investigation plan for pegylated-fibroblast growth factor 21 (BMS-986036) (EMEA-002448-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T15:05:00Z","last_updated_date":"2021-07-23T15:05:00Z","reference_number":"EMA/500639/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0387-2020-ema-decision-1-october-2020-acceptance-modification-agreed-paediatric-investigation-plan-pegylated-fibroblast-growth-factor-21-bms-986036-emea-002448-pip01-18-m01_en.pdf"},
    {"id":"52132","name":"P/0418/2020 : EMA decision of 22 October 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver...(EMEA-002693-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-28T17:47:00Z","last_updated_date":"2021-07-28T17:47:00Z","reference_number":"EMA/485959/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0418-2020-ema-decision-22-october-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiveremea-002693-pip01-19_en.pdf"},
    {"id":"52133","name":"P/0426/2020 : EMA decision of  23 October 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral...(EMEA-002694-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-28T17:52:00Z","last_updated_date":"2021-07-28T17:52:00Z","reference_number":"EMA/494546/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0426-2020-ema-decision-23-october-2020-agreement-paediatric-investigation-plan-granting-deferralemea-002694-pip01-19_en.pdf"},
    {"id":"52134","name":"P/0417/2020 : EMA decision of 23 October 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver...(EMEA-002705-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-07-28T17:57:00Z","last_updated_date":"2021-07-28T17:57:00Z","reference_number":"EMA/494645/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0417-2020-ema-decision-23-october-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiveremea-002705-pip01-19_en.pdf"},
    {"id":"52195","name":"P/0415/2020 : EMA decision of 23 October 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver...(EMEA-002705-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-08-04T15:07:00Z","last_updated_date":"2021-08-04T15:07:00Z","reference_number":"EMA/494544/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0415-2020-ema-decision-23-october-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiveremea-002705-pip02-19_en.pdf"},
    {"id":"52196","name":"P/0395/2020 : EMA decision of 23 October 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for doravirine / islatravir (EMEA-002707-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-08-04T15:24:00Z","last_updated_date":"2021-08-04T15:24:00Z","reference_number":"EMA/535009/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0395-2020-ema-decision-23-october-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-doravirine-islatravir-emea-002707-pip01-19_en.pdf"},
    {"id":"52197","name":"P/0412/2020 : EMA decision of 23 October 2020 on the granting of a product specific waiver for tiragolumab (EMEA-002721-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-08-04T15:33:00Z","last_updated_date":"2021-08-04T15:33:00Z","reference_number":"EMA/494522/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0412-2020-ema-decision-23-october-2020-granting-product-specific-waiver-tiragolumab-emea-002721-pip02-20_en.pdf"},
    {"id":"52198","name":"P/0409/2020 : EMA decision of 22 October 2020 on the granting of a product specific waiver for tiragolumab (EMEA-002721-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-08-04T15:37:00Z","last_updated_date":"2021-08-04T15:37:00Z","reference_number":"EMA/485783/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0409-2020-ema-decision-22-october-2020-granting-product-specific-waiver-tiragolumab-emea-002721-pip03-20_en.pdf"},
    {"id":"52236","name":"P/0240/2021: EMA decision of 17 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for sotrovimab (EMEA-002899-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-08-19T11:07:00Z","last_updated_date":"2021-08-19T11:07:00Z","reference_number":"EMA/328640/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2021-ema-decision-17-june-2021-agreement-paediatric-investigation-plan-granting-deferral-sotrovimab-emea-002899-pip01-20_en.pdf"},
    {"id":"52237","name":"P/0028/2024 : EMA decision of 29 January 2024 on the refusal of a modification of an agreed paediatric investigation plan and on the granting of a product-specific waiver for tocilizumab (RoActemra), (EMEA-000309-PIP07-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-08-19T15:07:00Z","last_updated_date":"2025-03-12T16:48:00Z","reference_number":"EMA/29054/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2024-ema-decision-29-january-2024-refusal-modification-agreed-paediatric-investigation-plan-granting-product-specific-waiver-tocilizumab-roactemra-emea-000309-pip07-21-m01_en.pdf"},
    {"id":"52238","name":"P/0338/2021: EMA decision of 9 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for remdesivir (Veklury), (EMEA-002826-PIP01-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-08-19T15:07:00Z","last_updated_date":"2021-08-19T15:07:00Z","reference_number":"EMA/434429/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0338-2021-ema-decision-9-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-remdesivir-veklury-emea-002826-pip01-20-m02_en.pdf"},
    {"id":"52239","name":"P/0345/2021: EMA decision of 12 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for molnupiravir (EMEA-002940-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-08-19T11:16:00Z","last_updated_date":"2021-08-19T11:16:00Z","reference_number":"EMA/444418/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0345-2021-ema-decision-12-august-2021-agreement-paediatric-investigation-plan-granting-deferral-molnupiravir-emea-002940-pip01-20_en.pdf"},
    {"id":"52240","name":"P/0266/2021: EMA decision of 7 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for COVID-19 vaccine (ChAdOx1-S [recombinant]) (Vaxzevria), (EMEA-002862-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-08-19T15:07:00Z","last_updated_date":"2022-07-18T17:07:00Z","reference_number":"EMA/315909/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2021-ema-decision-7-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-covid-19-vaccine-chadox1-s-recombinant-vaxzevria-emea-002862-pip01-20-m01_en.pdf"},
    {"id":"52241","name":"P/0347/2021: EMA decision of of 16 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for casirivimab (REGN10933), (EMEA-002964-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-08-19T11:24:00Z","last_updated_date":"2021-08-19T11:24:00Z","reference_number":"EMA/418667/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0347-2021-ema-decision-16-august-2021-agreement-paediatric-investigation-plan-granting-deferral-casirivimab-regn10933-emea-002964-pip01-21_en.pdf"},
    {"id":"52242","name":"P/0444/2020: EMA decision of 1 December 2020 on the granting of a product specific waiver for dapagliflozin (Forxiga), (EMEA-000694-PIP05-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-08-19T11:29:00Z","last_updated_date":"2021-08-19T11:29:00Z","reference_number":"EMA/599228/2020 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0444-2020-ema-decision-1-december-2020-granting-product-specific-waiver-dapagliflozin-forxiga-emea-000694-pip05-20_en.pdf"}    {"id":"52243","name":"P/0348/2021: EMA decision of 16 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for imdevimab (REGN10987), (EMEA-002965-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-08-19T11:30:00Z","last_updated_date":"2021-08-19T11:30:00Z","reference_number":"EMA/418668/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0348-2021-ema-decision-16-august-2021-agreement-paediatric-investigation-plan-granting-deferral-imdevimab-regn10987-emea-002965-pip01-21_en.pdf"},
    {"id":"52388","name":"P/0398/2020 : EMA decision of 23 October 2020 on the granting of a product-specific waiver for sacituzumab govitecan (EMEA-002645-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-09T10:36:00Z","last_updated_date":"2021-09-09T10:36:00Z","reference_number":"EMA/494619/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0398-2020-ema-decision-23-october-2020-granting-product-specific-waiver-sacituzumab-govitecan-emea-002645-pip02-20_en.pdf"},
    {"id":"52389","name":"P/0431/2020 : EMA decision of 5 November 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adrenaline (epinephrine) (EMEA-002749-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-09T10:56:00Z","last_updated_date":"2021-09-09T10:56:00Z","reference_number":"EMA/575492/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0431-2020-ema-decision-5-november-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-adrenaline-epinephrine-emea-002749-pip01-19_en.pdf"},
    {"id":"52391","name":"P/0430/2020 : EMA decision of 5 November 2020 on the acceptance of a modification of an agreed paediatric investigation plan for concentrate of proteolytic enzyme enriched in bromelain (NexoBrid) (EMEA-000142-PIP02-09-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-09T12:19:00Z","last_updated_date":"2021-09-09T12:19:00Z","reference_number":"EMA/573811/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0430-2020-ema-decision-5-november-2020-acceptance-modification-agreed-paediatric-investigation-plan-concentrate-proteolytic-enzyme-enriched-bromelain-nexobrid-emea-000142-pip02-09-m10_en.pdf"},
    {"id":"52392","name":"P/0437/2020 : EMA decision of 20 November 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil fumarate) (Viread) (EMEA-000533-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-09T12:29:00Z","last_updated_date":"2021-09-09T12:29:00Z","reference_number":"EMA/614606/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0437-2020-ema-decision-20-november-2020-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-fumarate-viread-emea-000533-pip01-08-m09_en.pdf"},
    {"id":"52393","name":"P/0436/2020 : EMA decision of 13 November 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ceftolozane / tazobactam (Zerbaxa) (EMEA-001142-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-09T12:35:00Z","last_updated_date":"2021-09-09T12:35:00Z","reference_number":"EMA/593110/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0436-2020-ema-decision-13-november-2020-acceptance-modification-agreed-paediatric-investigation-plan-ceftolozane-tazobactam-zerbaxa-emea-001142-pip01-11-m04_en.pdf"},
    {"id":"52394","name":"P/0432/2020 : EMA decision of 5 November 2020 on the acceptance of a modification of an agreed paediatric investigation plan for nivolumab (Opdivo) (EMEA-001407-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-09T12:42:00Z","last_updated_date":"2021-09-09T12:42:00Z","reference_number":"EMA/576787/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0432-2020-ema-decision-5-november-2020-acceptance-modification-agreed-paediatric-investigation-plan-nivolumab-opdivo-emea-001407-pip01-12-m03_en.pdf"},
    {"id":"52395","name":"P/0237/2021 : EMA decision of 14 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for nivolumab (Opdivo) (EMEA-001407-PIP02-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T12:48:00Z","last_updated_date":"2022-04-28T12:48:00Z","reference_number":"EMA/318795/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2021-ema-decision-14-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-nivolumab-opdivo-emea-001407-pip02-15-m05_en.pdf"},
    {"id":"52396","name":"P/0435/2020 : EMA decision of 13 November 2020 on the acceptance of a modification of an agreed paediatric investigation plan for elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya) (EMEA-001460-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-09T12:53:00Z","last_updated_date":"2021-09-09T12:53:00Z","reference_number":"EMA/593114/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0435-2020-ema-decision-13-november-2020-acceptance-modification-agreed-paediatric-investigation-plan-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-genvoya-emea-001460-pip01-13-m05_en.pdf"},
    {"id":"52397","name":"P/0434/2020 : EMA decision of 6 November 2020 on the acceptance of a modification of an agreed paediatric investigation plan for birch pollen extract (betula verrucosa) (ITULAZAX) (EMEA-001879-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-09T13:01:00Z","last_updated_date":"2021-09-09T13:01:00Z","reference_number":"EMA/576895/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0434-2020-ema-decision-6-november-2020-acceptance-modification-agreed-paediatric-investigation-plan-birch-pollen-extract-betula-verrucosa-itulazax-emea-001879-pip01-15-m02_en.pdf"},
    {"id":"52481","name":"P/0515/2020 : EMA decision of 22 December 2020 on the granting of a product specific waiver for dapagliflozin (forxiga) (EMEA-000694-PIP06-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T09:29:00Z","last_updated_date":"2021-09-17T09:29:00Z","reference_number":"EMA/631966/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0515-2020-ema-decision-22-december-2020-granting-product-specific-waiver-dapagliflozin-forxiga-emea-000694-pip06-20_en.pdf"},
    {"id":"52482","name":"P/0512/2020 : EMA decision of 22 December 2020 on the refusal of a product specific waiver for obinutuzumab (Gazyvaro) (EMEA-001207-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T09:39:00Z","last_updated_date":"2021-09-17T09:39:00Z","reference_number":"EMA/636283/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0512-2020-ema-decision-22-december-2020-refusal-product-specific-waiver-obinutuzumab-gazyvaro-emea-001207-pip03-20_en.pdf"},
    {"id":"52486","name":"P/0442/2020 : EMA decision of 1 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for alpha1-proteinase inhibitor (human) (EMEA-001312-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T09:51:00Z","last_updated_date":"2021-09-17T09:51:00Z","reference_number":"EMA/599302/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0442-2020-ema-decision-1-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-alpha1-proteinase-inhibitor-human-emea-001312-pip03-19_en.pdf"},
    {"id":"52488","name":"P/0461/2020 : EMA decision of 4 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for guselkumab (Tremfya) (EMEA-001523-PIP04-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T10:46:00Z","last_updated_date":"2021-09-17T10:46:00Z","reference_number":"EMA/623328/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0461-2020-ema-decision-4-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-guselkumab-tremfya-emea-001523-pip04-19_en.pdf"},
    {"id":"52490","name":"P/0457/2020 : EMA decision of 4 December 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for venglustat (EMEA-001716-PIP04-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T11:07:00Z","last_updated_date":"2021-09-17T11:07:00Z","reference_number":"EMA/623415/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0457-2020-ema-decision-4-december-2020-agreement-paediatric-investigation-plan-granting-waiver-venglustat-emea-001716-pip04-19_en.pdf"},
    {"id":"52491","name":"P/0505/2020 : EMA decision of 22 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for venglustat (EMEA-001716-PIP05-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T11:15:00Z","last_updated_date":"2021-09-17T11:15:00Z","reference_number":"EMA/632794/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0505-2020-ema-decision-22-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-venglustat-emea-001716-pip05-20_en.pdf"},
    {"id":"52494","name":"P/0476/2020 : EMA decision of 1 December 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for lanadelumab (Takhzyro) (EMEA-001864-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T11:46:00Z","last_updated_date":"2021-09-17T11:46:00Z","reference_number":"EMA/627311/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0476-2020-ema-decision-1-december-2020-agreement-paediatric-investigation-plan-granting-waiver-lanadelumab-takhzyro-emea-001864-pip03-19_en.pdf"},
    {"id":"52495","name":"P/0490/2020 : EMA decision of 21 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for tabelecleucel (EMEA-002025-PIP04-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T11:58:00Z","last_updated_date":"2021-09-17T11:58:00Z","reference_number":"EMA/635370/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0490-2020-ema-decision-21-december-2020-agreement-paediatric-investigation-plan-granting-deferral-tabelecleucel-emea-002025-pip04-19_en.pdf"},
    {"id":"52497","name":"P/0489/2020 : EMA decision of 21 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for voxelotor (EMEA-002356-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:10:00Z","last_updated_date":"2021-09-17T12:10:00Z","reference_number":"EMA/635386/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0489-2020-ema-decision-21-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-voxelotor-emea-002356-pip02-20_en.pdf"},
    {"id":"52498","name":"P/0474/2020 : EMA decision of 1 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant human acid alpha-glucosidase (ATB200) (EMEA-002447-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:21:00Z","last_updated_date":"2021-09-17T12:21:00Z","reference_number":"EMA/627313/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0474-2020-ema-decision-1-december-2020-agreement-paediatric-investigation-plan-granting-deferral-recombinant-human-acid-alpha-glucosidase-atb200-emea-002447-pip01-18_en.pdf"},
    {"id":"52501","name":"P/0455/2020 : EMA decision of 4 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for cefepime / taniborbactam (EMEA-002576-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T14:15:00Z","last_updated_date":"2021-09-17T14:15:00Z","reference_number":"EMA/623412/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0455-2020-ema-decision-4-december-2020-agreement-paediatric-investigation-plan-granting-deferral-cefepime-taniborbactam-emea-002576-pip01-19_en.pdf"},
    {"id":"52502","name":"P/0488/2020 : EMA decision of 22 December 2020 on the granting of a product specific waiver for efgartigimod alfa (EMEA-002597-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T14:25:00Z","last_updated_date":"2021-09-17T14:25:00Z","reference_number":"EMA/598739/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0488-2020-ema-decision-22-december-2020-granting-product-specific-waiver-efgartigimod-alfa-emea-002597-pip03-20_en.pdf"},
    {"id":"52512","name":"P/0486/2020: EMA decision of 22 December 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for fully human IgG1 RB-1 YTE anti-RSV F monoclonal antibody (MK-1654) (EMEA-002755-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T14:28:00Z","last_updated_date":"2021-09-20T14:28:00Z","reference_number":"EMA/598791/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0486-2020-ema-decision-22-december-2020-agreement-paediatric-investigation-plan-granting-waiver-fully-human-igg1-rb-1-yte-anti-rsv-f-monoclonal-antibody-mk-1654-emea-002755-pip01-19_en.pdf"},
    {"id":"52513","name":"P/0501/2020 : EMA decision of 22 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for olinciguat (EMEA-002759-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T14:45:00Z","last_updated_date":"2021-09-20T14:45:00Z","reference_number":"EMA/628660/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0501-2020-ema-decision-22-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-olinciguat-emea-002759-pip01-19_en.pdf"},
    {"id":"52515","name":"P/0450/2020 : EMA decision of 1 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for bispecific antibody binding to clotting factor IX and X (Mim8) (EMEA-002762-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T14:50:00Z","last_updated_date":"2021-09-20T14:50:00Z","reference_number":"EMA/599313/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0450-2020-ema-decision-1-december-2020-agreement-paediatric-investigation-plan-granting-deferral-bispecific-antibody-binding-clotting-factor-ix-x-mim8-emea-002762-pip02-20_en.pdf"},
    {"id":"52516","name":"P/0500/2020 : EMA decision of 22 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral...(EMEA-002763-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T15:27:00Z","last_updated_date":"2021-09-20T15:27:00Z","reference_number":"EMA/631923/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0500-2020-ema-decision-22-december-2020-agreement-paediatric-investigation-plan-granting-deferralemea-002763-pip01-20_en.pdf"},
    {"id":"52517","name":"P/0449/2020 : EMA decision of 1 December 2020 on the granting of a product specific waiver for chimeric fibril-reactive IgG1k monoclonal antibody 11- 1F4 (EMEA-002791-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T15:37:00Z","last_updated_date":"2021-09-20T15:37:00Z","reference_number":"EMA/621027/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0449-2020-ema-decision-1-december-2020-granting-product-specific-waiver-chimeric-fibril-reactive-igg1k-monoclonal-antibody-11-1f4-emea-002791-pip01-20_en.pdf"},
    {"id":"52518","name":"P/0499/2020 : EMA decision of 22 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for durlobactam / sulbactam (SUL-DUR) (EMEA-002807-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T15:43:00Z","last_updated_date":"2021-09-20T15:43:00Z","reference_number":"EMA/660371/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0499-2020-ema-decision-22-december-2020-agreement-paediatric-investigation-plan-granting-deferral-durlobactam-sulbactam-sul-dur-emea-002807-pip01-20_en.pdf"},
    {"id":"52519","name":"P/0438/2020 : EMA decision of 1 December 2020 on the granting of a product specific waiver for allogeneic B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (EMEA-002834-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T15:49:00Z","last_updated_date":"2021-09-20T15:49:00Z","reference_number":"EMA/599202/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0438-2020-ema-decision-1-december-2020-granting-product-specific-waiver-allogeneic-b-cell-maturation-antigen-bcma-directed-chimeric-antigen-receptor-t-cell-emea-002834-pip01-20_en.pdf"},
    {"id":"52520","name":"P/0498/2020: EMA decision of 22 December 2020 on the granting of a product specific waiver for ziltivekimab (EMEA-002840-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T15:59:00Z","last_updated_date":"2021-09-20T15:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0498-2020-ema-decision-22-december-2020-granting-product-specific-waiver-ziltivekimab-emea-002840-pip01-20_en.pdf"},
    {"id":"52521","name":"P/0446/2020 : EMA decision of 1 December 2020 on the granting of a product specific waiver for lurbinectedin (EMEA-002846-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T16:35:00Z","last_updated_date":"2021-09-20T16:35:00Z","reference_number":"EMA/578894/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0446-2020-ema-decision-1-december-2020-granting-product-specific-waiver-lurbinectedin-emea-002846-pip01-20_en.pdf"},
    {"id":"52522","name":"P/0447/2020 : EMA decision of 1 December 2020 on the granting of a product specific waiver...(EMEA-002843-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T16:30:00Z","last_updated_date":"2021-09-20T16:30:00Z","reference_number":"EMA/579072/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0447-2020-ema-decision-1-december-2020-granting-product-specific-waiveremea-002843-pip02-20_en.pdf"},
    {"id":"52523","name":"P/0448/2020 : EMA decision of 1 December 2020 on the granting of a product specific waiver...(EMEA-002843-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T16:30:00Z","last_updated_date":"2021-09-20T16:30:00Z","reference_number":"EMA/578902/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0448-2020-ema-decision-1-december-2020-granting-product-specific-waiveremea-002843-pip01-20_en.pdf"},
    {"id":"52524","name":"P/0468/2020 : EMA decision of 1 December 2020 on the granting of a product specific waiver for fasudil (hydrochloride) (EMEA-002841-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T16:49:00Z","last_updated_date":"2021-09-20T16:49:00Z","reference_number":"EMA/621031/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0468-2020-ema-decision-1-december-2020-granting-product-specific-waiver-fasudil-hydrochloride-emea-002841-pip01-20_en.pdf"},
    {"id":"52528","name":"P/0470/2020 : EMA decision of 4 December 2020 on the granting of a product specific waiver for amlodipine (besilate)/ indapamide/ perindopril (arginine) (EMEA-002849-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-20T17:55:00Z","last_updated_date":"2021-09-20T17:55:00Z","reference_number":"EMA/622826/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0470-2020-ema-decision-4-december-2020-granting-product-specific-waiver-amlodipine-besilate-indapamide-perindopril-arginine-emea-002849-pip01-20_en.pdf"},
    {"id":"52542","name":"P/0473/2020 : EMA decision of 1 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for BI 425809 (EMEA-002653-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T09:57:00Z","last_updated_date":"2021-09-22T09:57:00Z","reference_number":"EMA/627315/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0473-2020-ema-decision-1-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bi-425809-emea-002653-pip01-19_en.pdf"},
    {"id":"52543","name":"P/0439/2020 : EMA decision of 1 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dapirolizumab pegol (EMEA-002702-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T10:50:00Z","last_updated_date":"2021-09-22T10:50:00Z","reference_number":"EMA/599324/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0439-2020-ema-decision-1-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dapirolizumab-pegol-emea-002702-pip01-19_en.pdf"},
    {"id":"52545","name":"P/0454/2020 : EMA decision of 4 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vonoprazan (EMEA-002703-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T11:18:00Z","last_updated_date":"2021-09-22T11:18:00Z","reference_number":"EMA/581093/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0454-2020-ema-decision-4-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vonoprazan-emea-002703-pip01-19_en.pdf"},
    {"id":"52546","name":"P/0453/2020 : EMA decision of 1 December 2020 on the agreement of a paediatric investigation plan and on the granting of a waiver for allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded (MC0518) (EMEA-002706-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T11:42:00Z","last_updated_date":"2021-09-22T11:42:00Z","reference_number":"EMA/581090/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0453-2020-ema-decision-1-december-2020-agreement-paediatric-investigation-plan-granting-waiver-allogeneic-bone-marrow-derived-mesenchymal-stromal-cells-ex-vivo-expanded-mc0518-emea-002706-pip01-19_en.pdf"},
    {"id":"52547","name":"P/0452/2020 : EMA decision of 1 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cotadutide (EMEA-002712-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T12:20:00Z","last_updated_date":"2021-09-22T12:20:00Z","reference_number":"EMA/621041/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0452-2020-ema-decision-1-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cotadutide-emea-002712-pip01-19_en.pdf"},
    {"id":"52548","name":"P/0487/2020 : EMA decision of 22 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for etrasimod L-arginine (EMEA-002713-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T12:37:00Z","last_updated_date":"2021-09-22T12:37:00Z","reference_number":"EMA/598798/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0487-2020-ema-decision-22-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-etrasimod-l-arginine-emea-002713-pip01-19_en.pdf"},
    {"id":"52549","name":"P/0451/2020 : EMA decision of 1 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for garadacimab (EMEA-002726-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T12:47:00Z","last_updated_date":"2021-09-22T12:47:00Z","reference_number":"EMA/621039/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0451-2020-ema-decision-1-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-garadacimab-emea-002726-pip01-19_en.pdf"},
    {"id":"52550","name":"P/0518/2020 : EMA decision of 21 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral for adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene.... (EMEA-002741-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T12:55:00Z","last_updated_date":"2021-09-22T12:55:00Z","reference_number":"EMA/581052/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0518-2020-ema-decision-21-december-2020-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mini-dystrophin-gene-emea-002741-pip01-20_en.pdf"},
    {"id":"52553","name":"P/0445/2020 : EMA decision of 4 December 2020 on the granting of a product specific waiver for atorvastatin / ezetimibe (EMEA-002852-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T14:58:00Z","last_updated_date":"2021-09-22T14:58:00Z","reference_number":"EMA/622704/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0445-2020-ema-decision-4-december-2020-granting-product-specific-waiver-atorvastatin-ezetimibe-emea-002852-pip01-20_en.pdf"},
    {"id":"52554","name":"P/0472/2020 : EMA decision of 1 December 2020 on the granting of a product specific waiver for (1R,2R,3S,4S,5R,6S)-cyclohexane-1,2,3,4,5,6-hexaylhexakis (dihydrogen phosphate), (EMEA-002854-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T15:05:00Z","last_updated_date":"2021-09-22T15:05:00Z","reference_number":"EMA/627308/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0472-2020-ema-decision-1-december-2020-granting-product-specific-waiver-1r2r3s4s5r6s-cyclohexane-123456-hexaylhexakis-dihydrogen-phosphate-emea-002854-pip01-20_en.pdf"},
    {"id":"52555","name":"P/0471/2020 : EMA decision of 1 December 2020 on the granting of a product specific waiver for serplulimab (EMEA-002859-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T15:11:00Z","last_updated_date":"2021-09-22T15:11:00Z","reference_number":"EMA/627309/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0471-2020-ema-decision-1-december-2020-granting-product-specific-waiver-serplulimab-emea-002859-pip01-20_en.pdf"},
    {"id":"52556","name":"P/0497/2020 : EMA decision of 22 December 2020 on the granting of a product specific waiver for ramipril / bisoprolol (fumarate) (EMEA-002860-PIP01- 20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T15:17:00Z","last_updated_date":"2021-09-22T15:17:00Z","reference_number":"EMA/628688/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0497-2020-ema-decision-22-december-2020-granting-product-specific-waiver-ramipril-bisoprolol-fumarate-emea-002860-pip01-20_en.pdf"},
    {"id":"52557","name":"P/0485/2020 : EMA decision of 21 December 2020 on the granting of a product specific waiver for delolimogene mupadenorepvec (EMEA-002864-PIP01- 20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T15:23:00Z","last_updated_date":"2021-09-22T15:23:00Z","reference_number":"EMA/632005/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0485-2020-ema-decision-21-december-2020-granting-product-specific-waiver-delolimogene-mupadenorepvec-emea-002864-pip01-20_en.pdf"},
    {"id":"52558","name":"P/0484/2020 : EMA decision of 21 December 2020 on the granting of a product specific waiver for N-[(1R)-1-(1H-indol-3-ylmethyl)pentyl]-2-(4- methylpiperazin-1-yl)thiazole-5-carboxamide (UCB0599) (EMEA-002866-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T15:43:00Z","last_updated_date":"2021-09-22T15:43:00Z","reference_number":"EMA/632012/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0484-2020-ema-decision-21-december-2020-granting-product-specific-waiver-n-1r-1-1h-indol-3-ylmethylpentyl-2-4-methylpiperazin-1-ylthiazole-5-carboxamide-ucb0599-emea-002866-pip01-20_en.pdf"},
    {"id":"52559","name":"P/0496/2020 : EMA decision of 22 December 2020 on the granting of a product specific waiver for tipifarnib (EMEA-002871-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T15:47:00Z","last_updated_date":"2021-09-22T15:47:00Z","reference_number":"EMA/653899/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0496-2020-ema-decision-22-december-2020-granting-product-specific-waiver-tipifarnib-emea-002871-pip01-20_en.pdf"},
    {"id":"52560","name":"P/0495/2020 : EMA decision of 22 December 2020 on the granting of a product specific waiver for tauroursodeoxycholic acid / sodium phenylbutyrate (EMEA-002876-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T15:52:00Z","last_updated_date":"2021-09-22T15:52:00Z","reference_number":"EMA/598775/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0495-2020-ema-decision-22-december-2020-granting-product-specific-waiver-tauroursodeoxycholic-acid-sodium-phenylbutyrate-emea-002876-pip01-20_en.pdf"},
    {"id":"52562","name":"P/0509/2020: EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for cholera vaccine, live attenuated, oral (strain CVD 103-HgR) (Vaxchora) (EMEA-001490-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T17:49:00Z","last_updated_date":"2021-09-22T17:49:00Z","reference_number":"EMA/628699/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0509-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-cholera-vaccine-live-attenuated-oral-strain-cvd-103-hgr-vaxchora-emea-001490-pip01-13-m02_en.pdf"},
    {"id":"52563","name":"P/0460/2020: EMA decision of 4 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant parathyroid hormone (Natpar), (EMEA-001526-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T17:54:00Z","last_updated_date":"2021-09-22T17:54:00Z","reference_number":"EMA/622890/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0460-2020-ema-decision-4-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-parathyroid-hormone-natpar-emea-001526-pip01-13-m04_en.pdf"},
    {"id":"52564","name":"P/0508/2020: EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for testosterone (EMEA-001529-PIP02-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-22T17:59:00Z","last_updated_date":"2021-09-22T17:59:00Z","reference_number":"EMA/633001/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0508-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-testosterone-emea-001529-pip02-14-m03_en.pdf"},
    {"id":"52565","name":"P/0516/2020 : EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for eltrombopag (Revolade) (EMEA-000170-PIP03-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T08:49:00Z","last_updated_date":"2021-09-23T08:49:00Z","reference_number":"EMA/633039/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0516-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-eltrombopag-revolade-emea-000170-pip03-13-m04_en.pdf"},
    {"id":"52568","name":"P/0493/2020 : EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ocrelizumab (Ocrevus) (EMEA-000310-PIP03-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T08:56:00Z","last_updated_date":"2021-09-23T08:56:00Z","reference_number":"EMA/598687/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0493-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-ocrelizumab-ocrevus-emea-000310-pip03-10-m04_en.pdf"},
    {"id":"52569","name":"P/0467/2020 : EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara) (EMEA-000311-PIP03-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T09:04:00Z","last_updated_date":"2021-09-23T09:04:00Z","reference_number":"EMA/576874/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0467-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip03-11-m06_en.pdf"},
    {"id":"52570","name":"P/0466/2020 : EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten and associated names) (EMEA-000347-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T09:11:00Z","last_updated_date":"2021-09-23T09:11:00Z","reference_number":"EMA/576889/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0466-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-associated-names-emea-000347-pip02-16-m02_en.pdf"},
    {"id":"52573","name":"P/0479/2020 : EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for teduglutide (Revestive) (EMEA-000482-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T10:46:00Z","last_updated_date":"2021-09-23T10:46:00Z","reference_number":"EMA/627335/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0479-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-teduglutide-revestive-emea-000482-pip01-08-m06_en.pdf"},
    {"id":"52574","name":"P/0465/2020 : EMA decision of 4 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for veliparib (EMEA- 000499-PIP02-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T10:53:00Z","last_updated_date":"2021-09-23T10:53:00Z","reference_number":"EMA/622893/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0465-2020-ema-decision-4-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-veliparib-emea-000499-pip02-10-m01_en.pdf"},
    {"id":"52575","name":"P/0469/2020 : EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla) (EMEA-000715-PIP03-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T11:01:00Z","last_updated_date":"2021-09-23T11:01:00Z","reference_number":"EMA/620964/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0469-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip03-11-m06_en.pdf"},
    {"id":"52576","name":"P/0494/2020 : EMA decision of 21 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for aztreonam (Cayston) (EMEA-000827-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T11:10:00Z","last_updated_date":"2021-09-23T11:10:00Z","reference_number":"EMA/631870/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0494-2020-ema-decision-21-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-aztreonam-cayston-emea-000827-pip01-09-m05_en.pdf"},
    {"id":"52577","name":"P/0514/2020 : EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP03-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T11:20:00Z","last_updated_date":"2021-09-23T11:20:00Z","reference_number":"EMA/598731/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0514-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip03-14-m05_en.pdf"},
    {"id":"52578","name":"P/0443/2020 : EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia) (EMEA-000916-PIP01-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T11:26:00Z","last_updated_date":"2021-09-23T11:26:00Z","reference_number":"EMA/598855/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0443-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-lixisenatide-lyxumia-emea-000916-pip01-10-m07_en.pdf"},
    {"id":"52579","name":"P/0464/2020 : EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for canagliflozin (Invokana) (EMEA-001030-PIP01-10-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T11:31:00Z","last_updated_date":"2021-09-23T11:31:00Z","reference_number":"EMA/620966/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0464-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-canagliflozin-invokana-emea-001030-pip01-10-m08_en.pdf"},
    {"id":"52581","name":"P/0482/2020 : EMA decision of 9 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for avatrombopag (Doptelet) (EMEA-001136-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T13:56:00Z","last_updated_date":"2021-09-23T13:56:00Z","reference_number":"EMA/631901/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0482-2020-ema-decision-9-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-avatrombopag-doptelet-emea-001136-pip02-19-m01_en.pdf"},
    {"id":"52582","name":"P/0513/2020 : EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for naloxegol (Moventig) (EMEA-001146-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T14:03:00Z","last_updated_date":"2021-09-23T14:03:00Z","reference_number":"EMA/658136/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0513-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-naloxegol-moventig-emea-001146-pip01-11-m06_en.pdf"},
    {"id":"52583","name":"P/0463/2020 : EMA decision of 4 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for vonicog alfa (Veyvondi) (EMEA-001164-PIP01-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-23T14:08:00Z","last_updated_date":"2021-09-23T14:08:00Z","reference_number":"EMA/622891/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0463-2020-ema-decision-4-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-vonicog-alfa-veyvondi-emea-001164-pip01-11-m04_en.pdf"},
    {"id":"52596","name":"P/0511/2020 : EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for levofloxacin (hemihydrate) (EMEA-001211-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-24T09:19:00Z","last_updated_date":"2021-09-24T09:19:00Z","reference_number":"EMA/654063/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0511-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-levofloxacin-hemihydrate-emea-001211-pip01-11-m02_en.pdf"},
    {"id":"52597","name":"P/0478/2020 : EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for estetrol / drospirenone (EMEA-001332-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-24T09:26:00Z","last_updated_date":"2021-09-24T09:26:00Z","reference_number":"EMA/627346/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0478-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-estetrol-drospirenone-emea-001332-pip01-12-m04_en.pdf"},
    {"id":"52598","name":"P/0462/2020 : EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tedizolid (phosphate) (Sivextro) (EMEA-001379-PIP01-12-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-24T10:06:00Z","last_updated_date":"2021-09-24T10:06:00Z","reference_number":"EMA/576890/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0462-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-tedizolid-phosphate-sivextro-emea-001379-pip01-12-m05_en.pdf"},
    {"id":"52599","name":"P/0510/2020 : EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for atazanavir (sulphate) / cobicistat (Evotaz) (EMEA-001465-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-24T10:12:00Z","last_updated_date":"2021-09-24T10:12:00Z","reference_number":"EMA/633147/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0510-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-atazanavir-sulphate-cobicistat-evotaz-emea-001465-pip01-13-m03_en.pdf"},
    {"id":"52638","name":"P/0507/2020: EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for captopril (EMEA-001544-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T12:27:00Z","last_updated_date":"2021-09-27T12:27:00Z","reference_number":"EMA/628700/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0507-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-captopril-emea-001544-pip01-13-m02_en.pdf"},
    {"id":"52639","name":"P/0506/2020: EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (Orkambi), (EMEA-001582-PIP01-13-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T12:35:00Z","last_updated_date":"2021-09-27T12:35:00Z","reference_number":"EMA/632918/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0506-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-lumacaftor-ivacaftor-orkambi-emea-001582-pip01-13-m10_en.pdf"},
    {"id":"52641","name":"P/0459/2020: EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for olipudase alfa (EMEA-001600-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T15:28:00Z","last_updated_date":"2021-09-27T15:28:00Z","reference_number":"EMA/621011/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0459-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-olipudase-alfa-emea-001600-pip01-13-m02_en.pdf"},
    {"id":"52642","name":"P/0477/2020: EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for satralizumab (EMEA-001625-PIP01-14-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T15:45:00Z","last_updated_date":"2021-09-27T15:45:00Z","reference_number":"EMA/627350/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0477-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-satralizumab-emea-001625-pip01-14-m06_en.pdf"},
    {"id":"52643","name":"P/0492/2020: EMA decision of 22 December 2020 on the refusal of a modification of an agreed paediatric investigation plan for fluciclovine (18F) (Axumin), (EMEA-001644-PIP02-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T15:53:00Z","last_updated_date":"2021-09-27T15:53:00Z","reference_number":"EMA/598732/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0492-2020-ema-decision-22-december-2020-refusal-modification-agreed-paediatric-investigation-plan-fluciclovine-18f-axumin-emea-001644-pip02-14-m02_en.pdf"},
    {"id":"52644","name":"P/0491/2020: EMA decision of 21 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for burosumab (Crysvita), (EMEA-001659-PIP01-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T16:12:00Z","last_updated_date":"2021-09-27T16:12:00Z","reference_number":"EMA/631959/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0491-2020-ema-decision-21-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-burosumab-crysvita-emea-001659-pip01-15-m05_en.pdf"},
    {"id":"52645","name":"P/0441/2020: EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for palovarotene (EMEA-001662-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T16:16:00Z","last_updated_date":"2021-09-27T16:16:00Z","reference_number":"EMA/598845/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0441-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-palovarotene-emea-001662-pip01-14-m04_en.pdf"},
    {"id":"52646","name":"P/0458/2020: EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan...(EMEA-001705-PIP02-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T16:24:00Z","last_updated_date":"2021-09-27T16:24:00Z","reference_number":"EMA/576891/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0458-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-planemea-001705-pip02-15-m03_en.pdf"},
    {"id":"52647","name":"P/0504/2020: EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for avelumab (Bavencio), (EMEA-001849-PIP02-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T17:06:00Z","last_updated_date":"2021-09-27T17:06:00Z","reference_number":"EMA/632883/2020 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0504-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-avelumab-bavencio-emea-001849-pip02-15-m03_en.pdf"},
    {"id":"52648","name":"P/0440/2020: EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (EMEA-001900-PIP02-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T17:13:00Z","last_updated_date":"2021-09-27T17:13:00Z","reference_number":"EMA/598851/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0440-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-emea-001900-pip02-17-m04_en.pdf"},
    {"id":"52649","name":"P/0475/2020: EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for fenfluramine (hydrochloride), (EMEA-001990-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T17:41:00Z","last_updated_date":"2021-09-27T17:41:00Z","reference_number":"EMA/627382/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0475-2020-ema-decision-1-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-fenfluramine-hydrochloride-emea-001990-pip01-16-m03_en.pdf"},
    {"id":"52650","name":"P/0503/2020: EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for calcifediol (Rayaldee) (EMEA-002093-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T17:56:00Z","last_updated_date":"2021-09-27T17:56:00Z","reference_number":"EMA/628702/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0503-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-calcifediol-rayaldee-emea-002093-pip02-17-m01_en.pdf"},
    {"id":"52654","name":"P/0502/2020: EMA decision of 22 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for cotadutide (EMEA-002287-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-28T16:48:00Z","last_updated_date":"2021-09-28T16:48:00Z","reference_number":"EMA/628703/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0502-2020-ema-decision-22-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-cotadutide-emea-002287-pip01-17-m01_en.pdf"},
    {"id":"52655","name":"P/0483/2020: EMA decision of 9 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for brigatinib (Alunbrig), (EMEA-002296-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-28T17:06:00Z","last_updated_date":"2021-09-28T17:06:00Z","reference_number":"EMA/631996/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0483-2020-ema-decision-9-december-2020-acceptance-modification-agreed-paediatric-investigation-plan-brigatinib-alunbrig-emea-002296-pip01-17-m02_en.pdf"},
    {"id":"52658","name":"P/0050/2021 : EMA decision of 28 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obinutuzumab (Gazyvaro), (EMEA-001207-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T09:59:00Z","last_updated_date":"2021-09-29T09:59:00Z","reference_number":"EMA/694567/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2021-ema-decision-28-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-obinutuzumab-gazyvaro-emea-001207-pip02-19_en.pdf"},
    {"id":"52659","name":"P/0012/2021 : EMA decision of 28 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for arimoclomol (citrate) (EMEA-001748-PIP03-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T10:12:00Z","last_updated_date":"2021-09-29T10:12:00Z","reference_number":"EMA/694570/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2021-ema-decision-28-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-arimoclomol-citrate-emea-001748-pip03-19_en.pdf"},
    {"id":"52660","name":"P/0016/2021 : EMA decision of 27 January 2021 on the agreement of a paediatric investigation plan and on the granting of a waiver for carfilzomib (Kyprolis), (EMEA-001806-PIP04-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T10:40:00Z","last_updated_date":"2021-09-29T10:40:00Z","reference_number":"EMA/19077/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2021-ema-decision-27-january-2021-agreement-paediatric-investigation-plan-granting-waiver-carfilzomib-kyprolis-emea-001806-pip04-19_en.pdf"},
    {"id":"52661","name":"P/0002/2021 : EMA decision of 5 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver...(EMEA-001862-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T11:42:00Z","last_updated_date":"2021-09-29T11:42:00Z","reference_number":"EMA/694552/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2021-ema-decision-5-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiveremea-001862-pip03-20_en.pdf"},
    {"id":"52662","name":"P/0021/2021 : EMA decision of 27 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sparsentan (EMEA-001984-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T11:43:00Z","last_updated_date":"2021-09-29T11:43:00Z","reference_number":"EMA/33163/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2021-ema-decision-27-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sparsentan-emea-001984-pip02-20_en.pdf"},
    {"id":"52663","name":"P/0024/2021 : EMA decision of 27 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sparsentan (EMEA-001984-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T11:43:00Z","last_updated_date":"2021-09-29T11:43:00Z","reference_number":"EMA/33164/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2021-ema-decision-27-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sparsentan-emea-001984-pip03-20_en.pdf"},
    {"id":"52666","name":"P/0004/2021 : EMA decision of 14 January 2021 on the agreement of a paediatric investigation plan for (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)- piperidin-3-yl)chroman-2-carboxamide hydrochloride (KH176) (EMEA-002113-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T12:23:00Z","last_updated_date":"2021-09-29T12:23:00Z","reference_number":"EMA/1822/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2021-ema-decision-14-january-2021-agreement-paediatric-investigation-plan-s-6-hydroxy-2578-tetramethyl-n-r-piperidin-3-ylchroman-2-carboxamide-hydrochloride-kh176-emea-002113-pip01-16_en.pdf"},
    {"id":"52667","name":"P/0054/2021 : EMA decision of 27 January 2021 on the granting of a product specific waiver for acetylcysteine / ibuprofen (sodium dihydrate) (EMEA-002561-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T12:42:00Z","last_updated_date":"2021-09-29T12:42:00Z","reference_number":"EMA/27451/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2021-ema-decision-27-january-2021-granting-product-specific-waiver-acetylcysteine-ibuprofen-sodium-dihydrate-emea-002561-pip02-20_en.pdf"},
    {"id":"52668","name":"P/0006/2021 : EMA decision of 15 January 2021 on the granting of a product specific waiver for lorlatinib (Lorviqua) (EMEA-002669-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T12:47:00Z","last_updated_date":"2021-09-29T12:47:00Z","reference_number":"EMA/11995/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2021-ema-decision-15-january-2021-granting-product-specific-waiver-lorlatinib-lorviqua-emea-002669-pip02-20_en.pdf"},
    {"id":"52669","name":"P/0005/2021 : EMA decision of 15 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lenacapavir (EMEA-002740-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T14:47:00Z","last_updated_date":"2021-09-29T14:47:00Z","reference_number":"EMA/7332/2021 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2021-ema-decision-15-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lenacapavir-emea-002740-pip01-19_en.pdf"},
    {"id":"52670","name":"P/0011/2021 : 28 January 2021 on the granting of a product specific waiver for 18-(p-[131I]-iodophenyl)octadecyl phosphocholine (EMEA-002745-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T15:02:00Z","last_updated_date":"2021-09-29T15:02:00Z","reference_number":"EMA/694634/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2021-28-january-2021-granting-product-specific-waiver-18-p-131i-iodophenyloctadecyl-phosphocholine-emea-002745-pip02-20_en.pdf"},
    {"id":"52671","name":"P/0017/2021 : EMA decision of 29 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for verinurad / allopurinol (EMEA-002754-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T15:39:00Z","last_updated_date":"2021-09-29T15:39:00Z","reference_number":"EMA/33649/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2021-ema-decision-29-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-verinurad-allopurinol-emea-002754-pip01-19_en.pdf"},
    {"id":"52672","name":"P/0018/2021 : 27 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver...(EMEA-002757-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T16:13:00Z","last_updated_date":"2021-09-29T16:13:00Z","reference_number":"EMA/33224/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2021-27-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiveremea-002757-pip01-19_en.pdf"},
    {"id":"52673","name":"P/0001/2021: EMA decision of 5 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Prolia, Xgeva), (EMEA-000145-PIP02-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T16:29:00Z","last_updated_date":"2021-09-29T16:29:00Z","reference_number":"EMA/694456/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2021-ema-decision-5-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-prolia-xgeva-emea-000145-pip02-12-m03_en.pdf"}    {"id":"52674","name":"P/0032/2021 : EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for vortioxetine (Brintellix) (EMEA-000455-PIP02-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T16:37:00Z","last_updated_date":"2021-09-29T16:37:00Z","reference_number":"EMA/34035/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-vortioxetine-brintellix-emea-000455-pip02-10-m07_en.pdf"},
    {"id":"52675","name":"P/0009/2021: EMA decision of 15 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz), (EMEA-000576-PIP03-12-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T16:43:00Z","last_updated_date":"2021-09-29T16:43:00Z","reference_number":"EMA/694467/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2021-ema-decision-15-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip03-12-m05_en.pdf"},
    {"id":"52676","name":"P/0014/2021: EMA decision of 28 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for siponimod (hemifumarate) (Mayzent), (EMEA-000716-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T16:53:00Z","last_updated_date":"2021-09-29T16:53:00Z","reference_number":"EMA/694474/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2021-ema-decision-28-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-siponimod-hemifumarate-mayzent-emea-000716-pip01-09-m03_en.pdf"},
    {"id":"52677","name":"P/0007/2021: EMA decision of 15 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cobicistat (Tybost), (EMEA-000969-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T17:02:00Z","last_updated_date":"2021-09-29T17:02:00Z","reference_number":"EMA/694481/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2021-ema-decision-15-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-cobicistat-tybost-emea-000969-pip01-10-m05_en.pdf"},
    {"id":"52678","name":"P/0013/2021: EMA decision of 28 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for brentuximab vedotin (Adcetris), (EMEA-000980-PIP01-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T17:02:00Z","last_updated_date":"2021-09-29T17:02:00Z","reference_number":"EMA/694485/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2021-ema-decision-28-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-brentuximab-vedotin-adcetris-emea-000980-pip01-10-m07_en.pdf"},
    {"id":"52679","name":"P/0051/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen / human thrombin (Evicel, Evarrest), (EMEA-001149-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T17:02:00Z","last_updated_date":"2021-09-29T17:02:00Z","reference_number":"EMA/18851/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-evicel-evarrest-emea-001149-pip01-11-m06_en.pdf"},
    {"id":"52680","name":"P/0040/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for eribulin (Halaven) (EMEA-001261-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T17:44:00Z","last_updated_date":"2021-09-29T17:44:00Z","reference_number":"EMA/18866/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-eribulin-halaven-emea-001261-pip01-11-m06_en.pdf"},
    {"id":"52681","name":"P/0049/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat (Rezolsta), (EMEA-001280-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T17:49:00Z","last_updated_date":"2021-09-29T17:49:00Z","reference_number":"EMA/18869/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-rezolsta-emea-001280-pip01-12-m03_en.pdf"},
    {"id":"52682","name":"P/0027/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ceftazidime / avibactam (Zavicefta), (EMEA-001313-PIP01-12-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-09-29T17:55:00Z","last_updated_date":"2021-09-29T17:55:00Z","reference_number":"EMA/18873/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-zavicefta-emea-001313-pip01-12-m10_en.pdf"},
    {"id":"52725","name":"P/0047/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for daprodustat (EMEA-001452-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-05T14:34:00Z","last_updated_date":"2021-10-05T14:34:00Z","reference_number":"EMA/34398/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-daprodustat-emea-001452-pip01-13-m03_en.pdf"},
    {"id":"52726","name":"P/0048/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for fosdenopterin (ORGN001), (EMEA-001491-PIP01-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-05T15:00:00Z","last_updated_date":"2021-10-05T15:02:00Z","reference_number":"EMA/34374/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-fosdenopterin-orgn001-emea-001491-pip01-13-m01_en.pdf"},
    {"id":"52727","name":"P/0036/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for crizotinib (Xalkori) (EMEA-001493-PIP03-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-05T15:16:00Z","last_updated_date":"2021-10-05T15:16:00Z","reference_number":"EMA/34215/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-crizotinib-xalkori-emea-001493-pip03-18-m01_en.pdf"},
    {"id":"52731","name":"P/0019/2021 : EMA decision of 29 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dexmedetomidine (hydrochloride) (EMEA-002758-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T10:50:00Z","last_updated_date":"2021-10-06T10:50:00Z","reference_number":"EMA/33676/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2021-ema-decision-29-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dexmedetomidine-hydrochloride-emea-002758-pip01-19_en.pdf"},
    {"id":"52732","name":"P/0020/2021 : EMA decision of 27 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for esketamine (hydrochloride) (EMEA-002772-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T10:50:00Z","last_updated_date":"2021-10-06T10:50:00Z","reference_number":"EMA/4826/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2021-ema-decision-27-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-esketamine-hydrochloride-emea-002772-pip01-20_en.pdf"},
    {"id":"52733","name":"P/0022/2021 : EMA decision of 27 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous tumour-infiltrating lymphocytes (LN-144/LN-145) (EMEA-002776-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T10:50:00Z","last_updated_date":"2021-10-06T10:50:00Z","reference_number":"EMA/4902/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2021-ema-decision-27-january-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-tumour-infiltrating-lymphocytes-ln-144-ln-145-emea-002776-pip01-20_en.pdf"},
    {"id":"52737","name":"P/0023/2021 : EMA decision of 28 January 2021 on the agreement of a paediatric investigation plan and on the granting of a waiver for retinol (vitamin A) (EMEA-002790-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T11:19:00Z","last_updated_date":"2021-10-06T11:19:00Z","reference_number":"EMA/694568/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2021-ema-decision-28-january-2021-agreement-paediatric-investigation-plan-granting-waiver-retinol-vitamin-emea-002790-pip01-20_en.pdf"},
    {"id":"52738","name":"P/0025/2021 : EMA decision of 28 January 2021 on the granting of a product specific waiver for reldesemtiv (EMEA-002868-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T11:19:00Z","last_updated_date":"2021-10-06T11:19:00Z","reference_number":"EMA/694640/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2021-ema-decision-28-january-2021-granting-product-specific-waiver-reldesemtiv-emea-002868-pip01-20_en.pdf"},
    {"id":"52739","name":"P/0055/2021 : EMA decision of 27 January 2021 on the granting of a product specific waiver for nefopam (hydrochloride) / paracetamol (EMEA-002877- PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T11:19:00Z","last_updated_date":"2021-10-06T11:19:00Z","reference_number":"EMA/18941/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2021-ema-decision-27-january-2021-granting-product-specific-waiver-nefopam-hydrochloride-paracetamol-emea-002877-pip01-20_en.pdf"},
    {"id":"52740","name":"P/0053/2021 : EMA decision of 27 January 2021 on the granting of a product specific waiver for catumaxomab (EMEA-002879-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T11:43:00Z","last_updated_date":"2021-10-06T11:43:00Z","reference_number":"EMA/5045/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2021-ema-decision-27-january-2021-granting-product-specific-waiver-catumaxomab-emea-002879-pip01-20_en.pdf"},
    {"id":"52741","name":"P/0031/2021 : EMA decision of 27 January 2021 on the granting of a product specific waiver for eliapixant (EMEA-002882-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T11:43:00Z","last_updated_date":"2021-10-06T11:43:00Z","reference_number":"EMA/5047/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2021-ema-decision-27-january-2021-granting-product-specific-waiver-eliapixant-emea-002882-pip01-20_en.pdf"},
    {"id":"52742","name":"P/0015/2021 : EMA decision of 29 January 2021 on the granting of a product specific waiver for heparin sodium (EMEA-002885-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T11:43:00Z","last_updated_date":"2021-10-06T11:43:00Z","reference_number":"EMA/31785/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2021-ema-decision-29-january-2021-granting-product-specific-waiver-heparin-sodium-emea-002885-pip01-20_en.pdf"},
    {"id":"52744","name":"P/0035/2021 : EMA decision of 27 January 2021 on the granting of a product specific waiver for alpha1-Proteinase Inhibitor (Human), (EMEA-002888-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T14:05:00Z","last_updated_date":"2021-10-06T14:05:00Z","reference_number":"EMA/27140/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2021-ema-decision-27-january-2021-granting-product-specific-waiver-alpha1-proteinase-inhibitor-human-emea-002888-pip01-20_en.pdf"},
    {"id":"52745","name":"P/0046/2021 : EMA decision of 27 January 2021 on the granting of a product specific waiver for ublituximab (EMEA-002889-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T14:11:00Z","last_updated_date":"2021-10-06T14:11:00Z","reference_number":"EMA/18943/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2021-ema-decision-27-january-2021-granting-product-specific-waiver-ublituximab-emea-002889-pip01-20_en.pdf"},
    {"id":"52746","name":"P/0044/2021 : EMA decision of 28 January 2021 on the granting of a product specific waiver for umbralisib tosylate (EMEA-002890-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T14:46:00Z","last_updated_date":"2021-10-06T14:46:00Z","reference_number":"EMA/694642/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2021-ema-decision-28-january-2021-granting-product-specific-waiver-umbralisib-tosylate-emea-002890-pip01-20_en.pdf"},
    {"id":"52747","name":"P/0045/2021 : EMA decision of 27 January 2021 on the granting of a product specific waiver for rosuvastatin (calcium) / acetylsalicylic acid (EMEA- 002891-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T14:50:00Z","last_updated_date":"2021-10-06T14:50:00Z","reference_number":"EMA/18944/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2021-ema-decision-27-january-2021-granting-product-specific-waiver-rosuvastatin-calcium-acetylsalicylic-acid-emea-002891-pip01-20_en.pdf"},
    {"id":"52748","name":"P/0037/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for luspatercept (Reblozyl), (EMEA-001521-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T15:02:00Z","last_updated_date":"2021-10-06T15:02:00Z","reference_number":"EMA/34364/2021 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-luspatercept-reblozyl-emea-001521-pip01-13-m05_en.pdf"},
    {"id":"52749","name":"P/0026/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for darvadstrocel (Alofisel) (EMEA-001561-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T15:32:00Z","last_updated_date":"2021-10-06T15:32:00Z","reference_number":"EMA/33469/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-darvadstrocel-alofisel-emea-001561-pip01-13-m02_en.pdf"},
    {"id":"52750","name":"P/0034/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine / tenofovir alafenamide (Descovy) (EMEA-001577-PIP02-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T15:37:00Z","last_updated_date":"2021-10-06T15:37:00Z","reference_number":"EMA/33462/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-emtricitabine-tenofovir-alafenamide-descovy-emea-001577-pip02-14-m04_en.pdf"},
    {"id":"52752","name":"P/0052/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen/ human thrombin (VeraSeal), (EMEA-001598-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T15:42:00Z","last_updated_date":"2021-10-06T15:42:00Z","reference_number":"EMA/3827/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-veraseal-emea-001598-pip01-13-m03_en.pdf"},
    {"id":"52753","name":"P/0008/2021: EMA decision of 15 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for betibeglogene autotemcel (Zynteglo), (EMEA-001665-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T15:50:00Z","last_updated_date":"2021-10-06T15:50:00Z","reference_number":"EMA/3938/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2021-ema-decision-15-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-betibeglogene-autotemcel-zynteglo-emea-001665-pip01-14-m04_en.pdf"},
    {"id":"52754","name":"P/0038/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy), (EMEA-001766-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T16:01:00Z","last_updated_date":"2021-10-06T16:01:00Z","reference_number":"EMA/4480/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy-emea-001766-pip01-15-m03_en.pdf"},
    {"id":"52755","name":"P/0039/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for risankizumab (Skyrizi), (EMEA-001776-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T16:10:00Z","last_updated_date":"2021-10-06T16:10:00Z","reference_number":"EMA/4608/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-risankizumab-skyrizi-emea-001776-pip02-17-m01_en.pdf"},
    {"id":"52758","name":"P/0043/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for in vitro expanded autologous human articular chondrocytes (EMEA-001823-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T16:36:00Z","last_updated_date":"2021-10-06T16:36:00Z","reference_number":"EMA/4684/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-vitro-expanded-autologous-human-articular-chondrocytes-emea-001823-pip01-15-m02_en.pdf"},
    {"id":"52762","name":"P/0030/2021: EMA decision of 27 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan...(EMEA-001838-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T16:46:00Z","last_updated_date":"2021-10-06T16:46:00Z","reference_number":"EMA/4727/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2021-ema-decision-27-january-2021-acceptance-modification-agreed-paediatric-investigation-planemea-001838-pip01-15-m03_en.pdf"},
    {"id":"52763","name":"P/0033/2021 : EMA decision of 29 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cannabidiol (Epidyolex), (EMEA-001964-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T16:51:00Z","last_updated_date":"2021-10-06T16:51:00Z","reference_number":"EMA/31950/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2021-ema-decision-29-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-cannabidiol-epidyolex-emea-001964-pip01-16-m03_en.pdf"},
    {"id":"52764","name":"P/0056/2021: EMA decision of 29 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for lasmiditan (EMEA-002166-PIP01-17-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T16:54:00Z","last_updated_date":"2021-10-06T16:54:00Z","reference_number":"EMA/31976/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2021-ema-decision-29-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-lasmiditan-emea-002166-pip01-17-m05_en.pdf"},
    {"id":"52765","name":"P/0028/2021: EMA decision of 29 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for aztreonam (ATM)/ avibactam (AVI) (EMEA-002283-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T16:59:00Z","last_updated_date":"2021-10-06T16:59:00Z","reference_number":"EMA/31839/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2021-ema-decision-29-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-aztreonam-atm-avibactam-avi-emea-002283-pip01-17-m01_en.pdf"},
    {"id":"52766","name":"P/0010/2021: EMA decision of 18 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for split influenza virus, inactivated containing antigens...(EMEA-002359-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T17:11:00Z","last_updated_date":"2021-10-06T17:11:00Z","reference_number":"EMA/17336/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2021-ema-decision-18-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigensemea-002359-pip01-18-m02_en.pdf"},
    {"id":"52767","name":"P/0029/2021: EMA decision of 29 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for baloxavir marboxil (EMEA-002440-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T17:24:00Z","last_updated_date":"2021-10-06T17:24:00Z","reference_number":"EMA/31928/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2021-ema-decision-29-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-baloxavir-marboxil-emea-002440-pip01-18-m01_en.pdf"},
    {"id":"52768","name":"P/0042/2021: EMA decision of 29 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ofatumumab (EMEA-002397-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T17:40:00Z","last_updated_date":"2021-10-06T17:40:00Z","reference_number":"EMA/31982/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2021-ema-decision-29-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-ofatumumab-emea-002397-pip01-18-m01_en.pdf"},
    {"id":"52779","name":"P/0058/2021 : EMA decision of 12 February 2021 on the refusal of a paediatric investigation plan and on the granting of a waiver for docosahexaenoic acid (EMEA-002808-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T09:57:00Z","last_updated_date":"2021-10-08T09:57:00Z","reference_number":"EMA/598779/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2021-ema-decision-12-february-2021-refusal-paediatric-investigation-plan-granting-waiver-docosahexaenoic-acid-emea-002808-pip01-20_en.pdf"},
    {"id":"52780","name":"P/0063/2021 : EMA decision of 18 February 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rimegepant (EMEA-002812-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T10:05:00Z","last_updated_date":"2021-10-08T10:05:00Z","reference_number":"EMA/80737/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2021-ema-decision-18-february-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rimegepant-emea-002812-pip02-20_en.pdf"},
    {"id":"52781","name":"P/0061/2021 : EMA decision of 12 February 2021 on the granting of a product specific waiver for recombinant humanised monoclonal immunoglobulin G4, with specificity for human tau (UCB0107) (EMEA-002884-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T10:11:00Z","last_updated_date":"2021-10-08T10:11:00Z","reference_number":"EMA/33773/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2021-ema-decision-12-february-2021-granting-product-specific-waiver-recombinant-humanised-monoclonal-immunoglobulin-g4-specificity-human-tau-ucb0107-emea-002884-pip01-20_en.pdf"},
    {"id":"52784","name":"P/0064/2021 : EMA decision of 18 February 2021 on the acceptance of a modification of an agreed paediatric investigation plan for exenatide (Byetta, Bydureon) (EMEA-000689-PIP01-09-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T13:05:00Z","last_updated_date":"2021-10-08T13:05:00Z","reference_number":"EMA/72987/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2021-ema-decision-18-february-2021-acceptance-modification-agreed-paediatric-investigation-plan-exenatide-byetta-bydureon-emea-000689-pip01-09-m11_en.pdf"},
    {"id":"52785","name":"P/0066/2021 : EMA decision of 18 February 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ponesimod (EMEA- 000798-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T13:14:00Z","last_updated_date":"2021-10-08T13:14:00Z","reference_number":"EMA/79020/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2021-ema-decision-18-february-2021-acceptance-modification-agreed-paediatric-investigation-plan-ponesimod-emea-000798-pip01-09-m03_en.pdf"},
    {"id":"52786","name":"P/0067/2021 : EMA decision of 18 February 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod hydrochloride (Zeposia) (EMEA-001710-PIP04-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T13:21:00Z","last_updated_date":"2021-10-08T13:21:00Z","reference_number":"EMA/11655/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2021-ema-decision-18-february-2021-acceptance-modification-agreed-paediatric-investigation-plan-ozanimod-hydrochloride-zeposia-emea-001710-pip04-17-m02_en.pdf"},
    {"id":"52787","name":"P/0065/2021 : EMA decision of 19 February 2021 on the acceptance of a modification of an agreed paediatric investigation plan for deucravacitinib (EMEA-002350-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T13:29:00Z","last_updated_date":"2021-10-08T13:29:00Z","reference_number":"EMA/86666/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2021-ema-decision-19-february-2021-acceptance-modification-agreed-paediatric-investigation-plan-deucravacitinib-emea-002350-pip01-18-m01_en.pdf"},
    {"id":"52788","name":"P/0068/2021 : EMA decision of 19 February 2021 on the refusal of a modification of an agreed paediatric investigation plan and on the granting of a product-specific waiver for idecabtagene vicleucel (EMEA-002369-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T13:35:00Z","last_updated_date":"2021-10-08T13:35:00Z","reference_number":"EMA/71067/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2021-ema-decision-19-february-2021-refusal-modification-agreed-paediatric-investigation-plan-granting-product-specific-waiver-idecabtagene-vicleucel-emea-002369-pip01-18-m02_en.pdf"},
    {"id":"52898","name":"P/0517/2020 : EMA decision of 2 January 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for etranacogene dezaparvovec (EMEA-002722-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-10-26T09:39:00Z","last_updated_date":"2021-10-26T09:39:00Z","reference_number":"EMA/660338/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0517-2020-ema-decision-2-january-2021-agreement-paediatric-investigation-plan-granting-deferral-etranacogene-dezaparvovec-emea-002722-pip01-19_en.pdf"},
    {"id":"52991","name":"P/0122/2021: EMA decision of 17 March 2021 on the granting of a product specific waiver for alpelisib (Piqray), (EMEA-002016-PIP04-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T10:44:00Z","last_updated_date":"2021-11-05T10:44:00Z","reference_number":"EMA/96297/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2021-ema-decision-17-march-2021-granting-product-specific-waiver-alpelisib-piqray-emea-002016-pip04-20_en.pdf"},
    {"id":"52992","name":"P/0078/2021: EMA desicion of 17 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bimekizumab (EMEA-002189-PIP04-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T10:53:00Z","last_updated_date":"2021-11-05T10:53:00Z","reference_number":"EMA/71529/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2021-ema-desicion-17-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bimekizumab-emea-002189-pip04-20_en.pdf"},
    {"id":"52993","name":"P/0123/2021: EMA decision of 17 March 2021 on the granting of a product specific waiver for eptinezumab (EMEA-002243-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T11:02:00Z","last_updated_date":"2021-11-05T11:02:00Z","reference_number":"EMA/97464/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2021-ema-decision-17-march-2021-granting-product-specific-waiver-eptinezumab-emea-002243-pip02-20_en.pdf"},
    {"id":"52995","name":"P/0108/2021: EMA decision of 17 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for delgocitinib (EMEA-002329-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T11:08:00Z","last_updated_date":"2021-11-05T11:08:00Z","reference_number":"EMA/94228/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2021-ema-decision-17-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-delgocitinib-emea-002329-pip02-20_en.pdf"},
    {"id":"52996","name":"P/0104/2021: EMA decision of 17 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for crinecerfont (EMEA-002700-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T12:01:00Z","last_updated_date":"2021-11-05T12:01:00Z","reference_number":"EMA/146014/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2021-ema-decision-17-march-2021-agreement-paediatric-investigation-plan-granting-deferral-crinecerfont-emea-002700-pip01-19_en.pdf-0"},
    {"id":"52997","name":"P/0124/2021: EMA decision of 17 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for crovalimab, (EMEA-002709-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T12:07:00Z","last_updated_date":"2021-11-05T12:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2021-ema-decision-17-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-crovalimab-emea-002709-pip01-19_en.pdf"},
    {"id":"52998","name":"P/0093/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for enalapril (maleate) (EMEA-001706-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T12:24:00Z","last_updated_date":"2021-11-05T12:24:00Z","reference_number":"EMA/94579/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-enalapril-maleate-emea-001706-pip01-14-m03_en.pdf"},
    {"id":"52999","name":"P/0080/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for vamorolone (EMEA-001794-PIP02-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T12:29:00Z","last_updated_date":"2021-11-05T12:29:00Z","reference_number":"EMA/97223/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-vamorolone-emea-001794-pip02-16-m03_en.pdf"},
    {"id":"53000","name":"P/0094/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium bromide..., (EMEA-001875-PIP02-18-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T14:41:00Z","last_updated_date":"2021-11-05T14:41:00Z","reference_number":"EMA/97304/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-beclometasone-dipropionate-formoterol-fumarate-dihydrate-glycopyrronium-bromide-emea-001875-pip02-18_en.pdf"},
    {"id":"53001","name":"P/0076/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for larotrectinib (Vitrakvi), (EMEA-001971-PIP02-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T14:48:00Z","last_updated_date":"2021-11-05T14:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-larotrectinib-vitrakvi-emea-001971-pip02-16-m03_en.pdf"},
    {"id":"53002","name":"P/0077/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for larotrectinib (Vitrakvi), (EMEA-001971-PIP03-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T14:52:00Z","last_updated_date":"2021-11-05T14:52:00Z","reference_number":"EMA/144925/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-larotrectinib-vitrakvi-emea-001971-pip03-18-m01_en.pdf"},
    {"id":"53003","name":"P/0106/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for durvalumab (Imfinzi), (EMEA-002028-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T15:12:00Z","last_updated_date":"2021-11-05T15:12:00Z","reference_number":"EMA/97469/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-durvalumab-imfinzi-emea-002028-pip01-16-m02_en.pdf"},
    {"id":"53004","name":"P/0107/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tremelimumab (EMEA-002029-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T15:18:00Z","last_updated_date":"2021-11-05T15:18:00Z","reference_number":"EMA/144935/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-tremelimumab-emea-002029-pip01-16-m02_en.pdf"},
    {"id":"53005","name":"P/0110/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for gilteritinib (as fumarate) (Xospata), (EMEA-002064-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-05T15:23:00Z","last_updated_date":"2021-11-05T15:23:00Z","reference_number":"EMA/144934/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-gilteritinib-fumarate-xospata-emea-002064-pip01-16-m03_en.pdf"},
    {"id":"53025","name":"P/0095/2021 : EMA decision of 17 March 2021 on the granting of a product specific waiver for edaravone (EMEA-002897-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T12:50:00Z","last_updated_date":"2021-11-09T12:50:00Z","reference_number":"EMA/97558/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2021-ema-decision-17-march-2021-granting-product-specific-waiver-edaravone-emea-002897-pip01-20_en.pdf"},
    {"id":"53026","name":"P/0087/2021 : EMA decision of 17 March 2021 on the granting of a product specific waiver for anti-C1s Humanized IgG4 Monoclonal Antibody (BIVV020) (EMEA-002903-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T13:03:00Z","last_updated_date":"2021-11-09T13:03:00Z","reference_number":"EMA/97576/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2021-ema-decision-17-march-2021-granting-product-specific-waiver-anti-c1s-humanized-igg4-monoclonal-antibody-bivv020-emea-002903-pip01-20_en.pdf"},
    {"id":"53027","name":"P/0085/2021 : EMA decision of 19 March 2021 on the granting of a product specific waiver for hydrochlorothiazide / amlodipine / ramipril (EMEA- 002906-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T13:14:00Z","last_updated_date":"2021-11-09T13:14:00Z","reference_number":"EMA/73040/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2021-ema-decision-19-march-2021-granting-product-specific-waiver-hydrochlorothiazide-amlodipine-ramipril-emea-002906-pip01-20_en.pdf"},
    {"id":"53028","name":"P/0082/2021 : EMA decision of 19 March 2021 on the granting of a product specific waiver for autologous CD4+ and CD8+ T cells genetically modified with a lentiviral vector encoding a B cell maturation antigen-specific chimeric....(EMEA-002909-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T13:20:00Z","last_updated_date":"2021-11-09T13:20:00Z","reference_number":"EMA/84238/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2021-ema-decision-19-march-2021-granting-product-specific-waiver-autologous-cd4-cd8-t-cells-genetically-modified-lentiviral-vector-encoding-b-cell-maturation-antigen-specific-chimericemea_en.pdf"},
    {"id":"53030","name":"P/0081/2021 : EMA decision of 17 March 2021 on the granting of a product specific waiver for olpasiran (EMEA-002910-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T13:31:00Z","last_updated_date":"2021-11-09T13:31:00Z","reference_number":"EMA/97658/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2021-ema-decision-17-march-2021-granting-product-specific-waiver-olpasiran-emea-002910-pip01-20_en.pdf"},
    {"id":"53031","name":"P/0127/2021 : EMA decision of 26 March 2021 on the granting of a product specific waiver for fluoride 18-labelled prostate-specific membrane antigen-1007 ([18F]PSMA-1007) (EMEA-002918-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T14:13:00Z","last_updated_date":"2021-11-09T14:13:00Z","reference_number":"EMA/169707/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2021-ema-decision-26-march-2021-granting-product-specific-waiver-fluoride-18-labelled-prostate-specific-membrane-antigen-1007-18fpsma-1007-emea-002918-pip01-20_en.pdf"},
    {"id":"53032","name":"P/0083/2021 : EMA decision of 19 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara) (EMEA-000311-PIP04-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T14:49:00Z","last_updated_date":"2021-11-09T14:49:00Z","reference_number":"EMA/72641/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2021-ema-decision-19-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip04-13-m04_en.pdf"},
    {"id":"53033","name":"P/0084/2021 : EMA decision of 19 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara) (EMEA-000311-PIP05-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T15:00:00Z","last_updated_date":"2021-11-09T15:00:00Z","reference_number":"EMA/72931/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2021-ema-decision-19-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip05-17-m02_en.pdf"},
    {"id":"53034","name":"P/0092/2021 : EMA decision of 19 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for fluticasone (furoate) / vilanterol (Relvar Ellipta and associated names) (EMEA-000431-PIP01-08-M12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T15:06:00Z","last_updated_date":"2021-11-09T15:06:00Z","reference_number":"EMA/72934/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2021-ema-decision-19-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-fluticasone-furoate-vilanterol-relvar-ellipta-associated-names-emea-000431-pip01-08-m12_en.pdf"},
    {"id":"53035","name":"P/0088/2021 : EMA decision of 19 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T15:15:00Z","last_updated_date":"2021-11-09T15:15:00Z","reference_number":"EMA/72936/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2021-ema-decision-19-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-linagliptin-trajenta-emea-000498-pip01-08-m09_en.pdf"},
    {"id":"53036","name":"P/0086/2021 : EMA decision of 19 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for midostaurin (Rydapt) (EMEA-000780-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T15:25:00Z","last_updated_date":"2021-11-09T15:25:00Z","reference_number":"P/0086/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2021-ema-decision-19-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-midostaurin-rydapt-emea-000780-pip01-09-m06_en.pdf"},
    {"id":"53037","name":"P/0089/2021 : EMA decision of 19 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin (Jardiance) (EMEA-000828-PIP01-09-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T15:30:00Z","last_updated_date":"2021-11-09T15:30:00Z","reference_number":"EMA/72994/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2021-ema-decision-19-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-jardiance-emea-000828-pip01-09-m08_en.pdf"},
    {"id":"53039","name":"EMEA-000877-PIP03-17-M02 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine (Exparel Liposomal)  (EMEA-000877-PIP03-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-09T15:39:00Z","last_updated_date":"2021-11-09T15:39:00Z","reference_number":"EMA/91955/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-000877-pip03-17-m02-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-bupivacaine-exparel-liposomal-emea-000877-pip03-17-m02_en.pdf"},
    {"id":"53119","name":"P/0075/2021: EMA decision of 17 March 2021 on the granting of a product specific waiver for canakinumab (Ilaris), (EMEA-000060-PIP09-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T14:30:00Z","last_updated_date":"2021-11-15T14:30:00Z","reference_number":"EMA/144829/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2021-ema-decision-17-march-2021-granting-product-specific-waiver-canakinumab-ilaris-emea-000060-pip09-20_en.pdf-2"},
    {"id":"53120","name":"P/0075/2021: EMA decision of 17 March 2021 on the granting of a product specific waiver for canakinumab (Ilaris), (EMEA-000060-PIP09-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T14:30:00Z","last_updated_date":"2021-11-15T14:30:00Z","reference_number":"EMA/144829/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2021-ema-decision-17-march-2021-granting-product-specific-waiver-canakinumab-ilaris-emea-000060-pip09-20_en.pdf-1"},
    {"id":"53121","name":"P/0075/2021: EMA decision of 17 March 2021 on the granting of a product specific waiver for canakinumab (Ilaris), (EMEA-000060-PIP09-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T14:30:00Z","last_updated_date":"2021-11-15T14:30:00Z","reference_number":"EMA/144829/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2021-ema-decision-17-march-2021-granting-product-specific-waiver-canakinumab-ilaris-emea-000060-pip09-20_en.pdf-0"},
    {"id":"53125","name":"P/0075/2021: EMA decision of 17 March 2021 on the granting of a product specific waiver for canakinumab (Ilaris), (EMEA-000060-PIP09-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T16:54:00Z","last_updated_date":"2021-11-15T16:54:00Z","reference_number":"EMA/144829/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2021-ema-decision-17-march-2021-granting-product-specific-waiver-canakinumab-ilaris-emea-000060-pip09-20_en.pdf"},
    {"id":"53126","name":"P/0112/2021: EMA decision of 17 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for secukinumab (Cosentyx), (EMEA-000380-PIP06-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T17:01:00Z","last_updated_date":"2021-11-15T17:01:00Z","reference_number":"EMA/88832/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2021-ema-decision-17-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-secukinumab-cosentyx-emea-000380-pip06-19_en.pdf"},
    {"id":"53127","name":"P/0111/2021: EMA decision of 17 March 2021 on the granting of a product specific waiver for secukinumab (Cosentyx), (EMEA-000380-PIP07-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T17:10:00Z","last_updated_date":"2021-11-15T17:10:00Z","reference_number":"EMA/146109/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2021-ema-decision-17-march-2021-granting-product-specific-waiver-secukinumab-cosentyx-emea-000380-pip07-20_en.pdf"},
    {"id":"53128","name":"P/0121/2021: EMA decision of 17 March 2021 on the refusal of a paediatric investigation plan and on the granting of a waiver for dupilumab (Dupixent), (EMEA-001501-PIP08-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T17:20:00Z","last_updated_date":"2021-11-15T17:20:00Z","reference_number":"EMA/97937/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2021-ema-decision-17-march-2021-refusal-paediatric-investigation-plan-granting-waiver-dupilumab-dupixent-emea-001501-pip08-20_en.pdf"},
    {"id":"53129","name":"P/0101/2021: EMA decision of 17 March 2021 on the agreement of a paediatric investigation plan for tacrolimus (EMEA-001642-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T17:26:00Z","last_updated_date":"2021-11-15T17:26:00Z","reference_number":"EMA/94140/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2021-ema-decision-17-march-2021-agreement-paediatric-investigation-plan-tacrolimus-emea-001642-pip02-20_en.pdf"},
    {"id":"53130","name":"P/0099/2021: EMA decision of 19 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for imetelstat (EMEA-001910-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2021-11-15T17:32:00Z","last_updated_date":"2021-11-15T17:32:00Z","reference_number":"EMA/73051/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2021-ema-decision-19-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-imetelstat-emea-001910-pip03-20_en.pdf"},
    {"id":"53169","name":"P/0091/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for palbociclib (Ibrance) (EMEA-002146-PIP01-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T12:37:00Z","last_updated_date":"2021-11-19T12:37:00Z","reference_number":"EMA/144932/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-palbociclib-ibrance-emea-002146-pip01-17-m02_en.pdf"},
    {"id":"53170","name":"P/0096/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for interferon beta-1a (EMEA-002238-PIP01-17-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T12:46:00Z","last_updated_date":"2021-11-19T12:46:00Z","reference_number":"EMA/144878/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-interferon-beta-1a-emea-002238-pip01-17-m01_en.pdf"},
    {"id":"53171","name":"P/0069/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for evinacumab (EMEA- 002298-PIP01-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T12:54:00Z","last_updated_date":"2021-11-19T12:54:00Z","reference_number":"EMA/144944/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-evinacumab-emea-002298-pip01-17-m02_en.pdf"},
    {"id":"53172","name":"P/0074/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for eladocagene exuparvovec (EMEA-002435-PIP01-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T13:00:00Z","last_updated_date":"2021-11-19T13:00:00Z","reference_number":"EMA/71400/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-eladocagene-exuparvovec-emea-002435-pip01-18-m02_en.pdf"},
    {"id":"53173","name":"P/0071/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for synthetic doublestranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA....(EMEA-002493-PIP01-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T13:06:00Z","last_updated_date":"2021-11-19T13:06:00Z","reference_number":"EMA/71430/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-synthetic-doublestranded-sirna-oligonucleotide-directed-against-lactate-dehydrogenase-mrnaemea_en.pdf"},
    {"id":"53174","name":"P/0090/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bintrafusp alfa (EMEA-002586-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T13:12:00Z","last_updated_date":"2021-11-19T13:12:00Z","reference_number":"EMA/71460/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-bintrafusp-alfa-emea-002586-pip01-19-m01_en.pdf"},
    {"id":"53175","name":"P/0072/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for efgartigimod alfa (EMEA-002597-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T13:21:00Z","last_updated_date":"2021-11-19T13:21:00Z","reference_number":"EMA/71495/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-efgartigimod-alfa-emea-002597-pip01-19-m01_en.pdf"},
    {"id":"53176","name":"P/0073/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for doravirine/islatravir (EMEA-002707-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T13:35:00Z","last_updated_date":"2021-11-19T13:35:00Z","reference_number":"EMA/71511/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-doravirine-islatravir-emea-002707-pip01-19-m01_en.pdf"},
    {"id":"53177","name":"P/0070/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for relatlimab / nivolumab (EMEA-002727-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T12:41:00Z","last_updated_date":"2021-11-19T12:41:00Z","reference_number":"EMA/71516/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-relatlimab-nivolumab-emea-002727-pip01-19-m01_en.pdf"},
    {"id":"53180","name":"P/0079/2021 : EMA decision of 17 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for seltorexant (EMEA-002746-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T14:43:00Z","last_updated_date":"2021-11-19T14:43:00Z","reference_number":"EMA/94275/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2021-ema-decision-17-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-seltorexant-emea-002746-pip01-20_en.pdf"},
    {"id":"53181","name":"P/0102/2021 : EMA decision of 17 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N....(EMEA-00277-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T14:54:00Z","last_updated_date":"2021-11-19T14:54:00Z","reference_number":"EMA/71539/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2021-ema-decision-17-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-s-2-5-3-ethoxypyridin-2-yloxypyridin-3-yl-nemea-00277-pip01-20_en.pdf"},
    {"id":"53182","name":"P/0100/2021 : EMA decision of 17 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rozibafusp alfa (EMEA-002815-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T15:02:00Z","last_updated_date":"2021-11-19T15:02:00Z","reference_number":"EMA/71537/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2021-ema-decision-17-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rozibafusp-alfa-emea-002815-pip01-20_en.pdf"},
    {"id":"53185","name":"P/0098/2021 : EMA decision of 19 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for respiratory Syncytial Virus PreF3 recombinant.......(EMEA-002821-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T15:15:00Z","last_updated_date":"2021-11-19T15:15:00Z","reference_number":"EMA/73054/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2021-ema-decision-19-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-respiratory-syncytial-virus-pref3-recombinantemea-002821-pip01-20_en.pdf"},
    {"id":"53186","name":"P/0097/2021 : EMA decision of 19 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for telitacicept (EMEA-002824-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T15:24:00Z","last_updated_date":"2021-11-19T15:24:00Z","reference_number":"EMA/73059/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2021-ema-decision-19-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-telitacicept-emea-002824-pip01-20_en.pdf"},
    {"id":"53187","name":"P/0125/2021 : EMA decision of 17 March 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for linear single strand of deoxyribonucleic acid........(EMEA-002827-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T15:33:00Z","last_updated_date":"2021-11-19T15:33:00Z","reference_number":"EMA/97583/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2021-ema-decision-17-march-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-linear-single-strand-deoxyribonucleic-acidemea-002827-pip01-20_en.pdf"}    {"id":"53247","name":"P/0115/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine (Valdoxan and associated names) (EMEA-001181-PIP01-11-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T16:36:00Z","last_updated_date":"2021-11-23T16:36:00Z","reference_number":"EMA/93279/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-agomelatine-valdoxan-associated-names-emea-001181-pip01-11-m06_en.pdf"},
    {"id":"53248","name":"P/0116/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / abacavir / lamivudine (Triumeq) (EMEA-001219-PIP01-11-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T16:50:00Z","last_updated_date":"2021-11-23T16:50:00Z","reference_number":"EMA/93290/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-abacavir-lamivudine-triumeq-emea-001219-pip01-11-m05_en.pdf"},
    {"id":"53249","name":"P/0117/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ibrutinib (Imbruvica) (EMEA-001397-PIP03-14-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T16:58:00Z","last_updated_date":"2021-11-23T16:58:00Z","reference_number":"EMA/93299/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-ibrutinib-imbruvica-emea-001397-pip03-14-m05_en.pdf"},
    {"id":"53287","name":"P/0119/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cobimetinib (Cotellic) (EMEA-001425-PIP01-13-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-26T10:30:00Z","last_updated_date":"2021-11-26T10:30:00Z","reference_number":"EMA/93313/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-cobimetinib-cotellic-emea-001425-pip01-13-m05_en.pdf"},
    {"id":"53288","name":"P/0120/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tildrakizumab (Ilumetri) (EMEA-001451-PIP01-13-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-26T10:40:00Z","last_updated_date":"2021-11-26T10:40:00Z","reference_number":"EMA/93320/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-tildrakizumab-ilumetri-emea-001451-pip01-13-m01_en.pdf"},
    {"id":"53289","name":"P/0103/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for roxadustat (EMEA-001557-PIP01-13-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-26T10:50:00Z","last_updated_date":"2021-11-26T10:50:00Z","reference_number":"EMA/94318/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-roxadustat-emea-001557-pip01-13-m05_en.pdf"},
    {"id":"53292","name":"P/0105/2021 : EMA decision of 17 March 2021 on the refusal of a modification of an agreed paediatric investigation plan for cariprazine (hydrochloride) (Reagila) (EMEA-001652-PIP01-14-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-26T11:04:00Z","last_updated_date":"2021-11-26T11:04:00Z","reference_number":"EMA/94420/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2021-ema-decision-17-march-2021-refusal-modification-agreed-paediatric-investigation-plan-cariprazine-hydrochloride-reagila-emea-001652-pip01-14-m03_en.pdf"},
    {"id":"53295","name":"P/0118/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (Vocabria) (EMEA-001418-PIP02-15-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2021-11-26T12:20:00Z","last_updated_date":"2021-11-26T12:20:00Z","reference_number":"EMA/93310/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-cabotegravir-vocabria-emea-001418-pip02-15-m01_en.pdf"},
    {"id":"53650","name":"P/0566/2021: EMA decision of 21 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for (1R,2S,5S)-N- ((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2- trifluoroacetamido)...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-07T13:50:00Z","last_updated_date":"2022-01-07T13:50:00Z","reference_number":"EMA/767367/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0566-2021-ema-decision-21-december-2021-agreement-paediatric-investigation-plan-granting-deferral-1r2s5s-n-1s-1-cyano-2-3s-2-oxopyrrolidin-3-ylethyl-3-2s-33-dimethyl-2-222-trifluoroacetamido_en.pdf"},
    {"id":"53683","name":"P/0153/2021: EMA decision of 16 April 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dupilumab (Dupixent), (EMEA-001501-PIP07-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-12T12:07:00Z","last_updated_date":"2022-01-12T12:07:00Z","reference_number":"EMA/191363/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2021-ema-decision-16-april-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dupilumab-dupixent-emea-001501-pip07-20_en.pdf"},
    {"id":"53684","name":"P/0130/2021: EMA decision of 14 April 2021 on the granting of a product specific waiver for talazoparib (Talzenna), (EMEA-002066-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-12T12:07:00Z","last_updated_date":"2022-01-12T12:07:00Z","reference_number":"EMA/151819/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2021-ema-decision-14-april-2021-granting-product-specific-waiver-talazoparib-talzenna-emea-002066-pip02-20_en.pdf"},
    {"id":"53685","name":"P/0150/2021: EMA decision of 16 April 2021 on the agreement of a paediatric investigation plan and on the granting of a waiver for metformin (hydrochloride) / pioglitazone (hydrochloride) / spironolactone, (EMEA-002187-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-12T12:07:00Z","last_updated_date":"2022-01-12T12:07:00Z","reference_number":"EMA/152108/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2021-ema-decision-16-april-2021-agreement-paediatric-investigation-plan-granting-waiver-metformin-hydrochloride-pioglitazone-hydrochloride-spironolactone-emea-002187-pip01-17_en.pdf"},
    {"id":"53686","name":"P/0149/2021: EMA decision of 16 April 2021 on the granting of a product specific waiver for nadofaragene firadenovec, (EMEA-002376-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-12T12:07:00Z","last_updated_date":"2022-01-12T12:07:00Z","reference_number":"EMA/152090/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2021-ema-decision-16-april-2021-granting-product-specific-waiver-nadofaragene-firadenovec-emea-002376-pip02-20_en.pdf"},
    {"id":"53687","name":"P/0147/2021: EMA decision of 14 April 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ritlecitinib (EMEA-002451-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-12T12:07:00Z","last_updated_date":"2022-01-12T12:07:00Z","reference_number":"EMA/175282/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2021-ema-decision-14-april-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ritlecitinib-emea-002451-pip01-18_en.pdf"},
    {"id":"53688","name":"P/0146/2021: EMA decision of 14 April 2021 on the granting of a product specific waiver for sutimlimab (EMEA-002542-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-13T12:07:00Z","last_updated_date":"2022-01-13T12:07:00Z","reference_number":"EMA/188461/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2021-ema-decision-14-april-2021-granting-product-specific-waiver-sutimlimab-emea-002542-pip03-20_en.pdf"},
    {"id":"53689","name":"P/0145/2021: EMA decision of 16 April 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ruxolitinib (phosphate) (EMEA-002618-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-13T12:07:00Z","last_updated_date":"2022-01-13T12:07:00Z","reference_number":"EMA/190698/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2021-ema-decision-16-april-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ruxolitinib-phosphate-emea-002618-pip02-20_en.pdf"},
    {"id":"53690","name":"P/0159/2021: EMA decision of 16 April 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for chikungunya Virus Virus-Like Particle Vaccine / aluminum hydroxide, (EMEA-002656-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-13T12:07:00Z","last_updated_date":"2022-01-13T12:07:00Z","reference_number":"EMA/152116/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2021-ema-decision-16-april-2021-agreement-paediatric-investigation-plan-granting-deferral-chikungunya-virus-virus-particle-vaccine-aluminum-hydroxide-emea-002656-pip01-19_en.pdf"},
    {"id":"53691","name":"P/0129/2021: EMA decision of 14 April 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for sepofarsen (EMEA-002717-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-13T12:07:00Z","last_updated_date":"2022-01-13T12:07:00Z","reference_number":"EMA/151843/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2021-ema-decision-14-april-2021-agreement-paediatric-investigation-plan-granting-deferral-sepofarsen-emea-002717-pip02-20_en.pdf"},
    {"id":"53694","name":"P/0456/2020: EMA decision of 1 December 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bimekizumab (EMEA-002189-PIP03-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-12T09:09:00Z","last_updated_date":"2022-01-12T09:09:00Z","reference_number":"EMA/621046/2020 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0456-2020-ema-decision-1-december-2020-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bimekizumab-emea-002189-pip03-19_en.pdf"},
    {"id":"53732","name":"P/0143/2021: EMA decision of 14 April 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for zilucoplan (EMEA-002747-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-14T12:07:00Z","last_updated_date":"2022-01-14T12:07:00Z","reference_number":"EMA/175350/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2021-ema-decision-14-april-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-zilucoplan-emea-002747-pip01-20_en.pdf"},
    {"id":"53734","name":"P/0142/2021: EMA decision of 14 April 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for surufatinib (EMEA-002750-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-14T12:07:00Z","last_updated_date":"2022-01-14T12:07:00Z","reference_number":"EMA/151840/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2021-ema-decision-14-april-2021-agreement-paediatric-investigation-plan-granting-deferral-surufatinib-emea-002750-pip01-19_en.pdf"},
    {"id":"53747","name":"P/0128/2021 : EMA decision on the agreement of a PIP and on the granting of a deferral for adenoassociated virus, serotype 9 (AAV9)-based non-replicating, self-complementary recombinant vector containing an expression cassette for the human ASPA transgene","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/151831/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2021-ema-decision-agreement-pip-granting-deferral-adenoassociated-virus-serotype-9-aav9-based-non-replicating-self-complementary-recombinant-vector-containing-expression-cassette-human-aspa_en.pdf"},
    {"id":"53748","name":"P/0162/2021 : EMA decision of 14 April 2021 on the agreement of a paediatric investigation plan for hydroxypropyl-β-cyclodextrin (EMEA-002839- PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/192340/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2021-ema-decision-14-april-2021-agreement-paediatric-investigation-plan-hydroxypropyl-b-cyclodextrin-emea-002839-pip01-20_en.pdf"},
    {"id":"53749","name":"P/0141/2021 : EMA decision of 14 April 2021 on the granting of a product specific waiver for paclitaxel (EMEA-002894-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/188599/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2021-ema-decision-14-april-2021-granting-product-specific-waiver-paclitaxel-emea-002894-pip01-20_en.pdf"},
    {"id":"53750","name":"P/0109/2021 : EMA decision of 17 March 2021 on the granting of a product specific waiver for povidone / isopropyl alcohol (EMEA-002902- PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/119635/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2021-ema-decision-17-march-2021-granting-product-specific-waiver-povidone-isopropyl-alcohol-emea-002902-pip01-20_en.pdf"},
    {"id":"53751","name":"P/0140/2021 : EMA decision of 16 April 2021 on the granting of a product specific waiver for encequidar (EMEA-002913-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/190360/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2021-ema-decision-16-april-2021-granting-product-specific-waiver-encequidar-emea-002913-pip01-20_en.pdf"},
    {"id":"53752","name":"P/0139/2021 : EMA decision of 16 April 2021 on the granting of a product specific waiver for sintilimab (EMEA-002919-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/190318/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2021-ema-decision-16-april-2021-granting-product-specific-waiver-sintilimab-emea-002919-pip01-20_en.pdf"},
    {"id":"53753","name":"P/0138/2021 : EMA decision of 16 April 2021 on the granting of a product specific waiver for tavapadon (EMEA-002920-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/190646/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2021-ema-decision-16-april-2021-granting-product-specific-waiver-tavapadon-emea-002920-pip01-20_en.pdf"},
    {"id":"53754","name":"P/0137/2021 : EMA decision of 14 April 2021 on the granting of a product specific waiver for 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl) acetamide monohydrate (EMEA-002923-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/189020/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2021-ema-decision-14-april-2021-granting-product-specific-waiver-2-4s-6-4-chlorophenyl-1-methyl-4h-benzocisoxazolo45-eazepin-4-yl-acetamide-monohydrate-emea-002923-pip01-20_en.pdf"},
    {"id":"53755","name":"P/0163/2021 : EMA decision of 14 April 2021 on the granting of a product specific waiver for anti-IL-7Rα monoclonal antibody (S95011 / OSE-127) (EMEA-002930-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/192347/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2021-ema-decision-14-april-2021-granting-product-specific-waiver-anti-il-7ra-monoclonal-antibody-s95011-ose-127-emea-002930-pip01-20_en.pdf"},
    {"id":"53756","name":"P/0164/2021 : EMA decision of 14 April 2021 on the granting of a product specific waiver for sabatolimab (EMEA-002931-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/192349/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2021-ema-decision-14-april-2021-granting-product-specific-waiver-sabatolimab-emea-002931-pip01-20_en.pdf"},
    {"id":"53757","name":"P/0136/2021 : EMA decision of 16 April 2021 on the granting of a product specific waiver for anti-(alpha-synuclein) human monoclonal antibody, (EMEA-002936-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/152093/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2021-ema-decision-16-april-2021-granting-product-specific-waiver-anti-alpha-synuclein-human-monoclonal-antibody-emea-002936-pip01-20_en.pdf"},
    {"id":"53758","name":"P/0165/2021 : EMA decision of 14 April 2021 on the granting of a product specific waiver for ensartinib (EMEA-002937-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/192354/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2021-ema-decision-14-april-2021-granting-product-specific-waiver-ensartinib-emea-002937-pip01-20_en.pdf"},
    {"id":"53759","name":"P/0135/2021 : EMA decision of 16 April 2021 on the granting of a product specific waiver for humanised recombinant IgG4, anti-PD-1 monoclonal antibody (CS1003), (EMEA-002939-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T10:30:00Z","last_updated_date":"2022-01-17T10:30:00Z","reference_number":"EMA/152098/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2021-ema-decision-16-april-2021-granting-product-specific-waiver-humanised-recombinant-igg4-anti-pd-1-monoclonal-antibody-cs1003-emea-002939-pip01-20_en.pdf"},
    {"id":"53777","name":"P/0158/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for azilsartan medoxomil (Edarbi), (EMEA-000237-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T09:23:00Z","last_updated_date":"2022-01-18T09:23:00Z","reference_number":"EMA/175422/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2021-ema-decision-14-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-azilsartan-medoxomil-edarbi-emea-000237-pip01-08-m09_en.pdf"},
    {"id":"53778","name":"P/0157/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for golimumab (Simponi), (EMEA-000265-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T09:23:00Z","last_updated_date":"2022-01-18T09:23:00Z","reference_number":"EMA/175484/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2021-ema-decision-14-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-golimumab-simponi-emea-000265-pip02-11-m03_en.pdf"},
    {"id":"53779","name":"P/0174/2021: EMA decision of 9 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (Briviact and associated names), (EMEA-000332-PIP01-08-M16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T09:23:00Z","last_updated_date":"2022-01-18T09:23:00Z","reference_number":"EMA/198072/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2021-ema-decision-9-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-associated-names-emea-000332-pip01-08-m16_en.pdf"},
    {"id":"53780","name":"P/0173/2021: EMA decision of 9 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (Briviact), (EMEA-000332-PIP02-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T09:23:00Z","last_updated_date":"2022-01-18T09:23:00Z","reference_number":"EMA/198014/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2021-ema-decision-9-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-emea-000332-pip02-17-m02_en.pdf"},
    {"id":"53781","name":"P/0175/2021: EMA decision of 9 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ticagrelor (Brilique), (EMEA-000480-PIP01-08-M14)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T09:23:00Z","last_updated_date":"2022-01-18T09:23:00Z","reference_number":"EMA/197967/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2021-ema-decision-9-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-ticagrelor-brilique-emea-000480-pip01-08-m14_en.pdf"},
    {"id":"53782","name":"P/0156/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil fumarate) (Viread), (EMEA-000533-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T09:23:00Z","last_updated_date":"2022-01-18T09:23:00Z","reference_number":"EMA/188374/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2021-ema-decision-14-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-fumarate-viread-emea-000533-pip01-08-m10_en.pdf"},
    {"id":"53783","name":"P/0172/2021: EMA decision of 9 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ruxolitinib (phosphate) (Jakavi), (EMEA-000901-PIP03-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T09:23:00Z","last_updated_date":"2022-01-18T09:23:00Z","reference_number":"EMA/197383/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2021-ema-decision-9-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-ruxolitinib-phosphate-jakavi-emea-000901-pip03-16-m02_en.pdf"},
    {"id":"53784","name":"P/0161/2021: EMA decision of 16 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for landiolol (hydrochloride) (Rapibloc, Landiobloc, Raploc, Runrapiq), (EMEA-001150-PIP02-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T09:23:00Z","last_updated_date":"2022-01-18T09:23:00Z","reference_number":"EMA/191280/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2021-ema-decision-16-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-landiolol-hydrochloride-rapibloc-landiobloc-raploc-runrapiq-emea-001150-pip02-13-m04_en.pdf"},
    {"id":"53785","name":"P/0155/2021: EMA decision of 16 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for indacaterol (acetate) / mometasone (furoate) (EMEA-001217-PIP01-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T09:23:00Z","last_updated_date":"2022-01-18T09:23:00Z","reference_number":"EMA/191239/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2021-ema-decision-16-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-indacaterol-acetate-mometasone-furoate-emea-001217-pip01-11-m07_en.pdf"},
    {"id":"53796","name":"P/0160/2021: EMA decision of 16 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dermatophagoides pteronyssinus / dermatophagoides farinae (Acarizax and associated names), (EMEA-001258-PIP01-11- M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/190398/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2021-ema-decision-16-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-dermatophagoides-pteronyssinus-dermatophagoides-farinae-acarizax-associated-names-emea-001258-pip01_en.pdf"},
    {"id":"53797","name":"P/0154/2021: EMA decision of 16 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for oritavancin (diphosphate) (Orbactiv), (EMEA-001270-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/191215/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2021-ema-decision-16-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-oritavancin-diphosphate-orbactiv-emea-001270-pip01-12-m03_en.pdf"},
    {"id":"53798","name":"P/0170/2021: EMA decision of 9 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bumetanide (EMEA-001303-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/193109/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2021-ema-decision-9-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-bumetanide-emea-001303-pip01-12-m03_en.pdf"},
    {"id":"53799","name":"P/0340/2021: EMA decision of 9 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bumetanide (EMEA-001303-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/439409/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0340-2021-ema-decision-9-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-bumetanide-emea-001303-pip01-12-m04_en.pdf"},
    {"id":"53800","name":"P/0134/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed PIP for citric acid / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate / potassium chloride (Clensia)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/150427/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2021-ema-decision-14-april-2021-acceptance-modification-agreed-pip-citric-acid-sodium-chloride-simeticone-macrogol-4000-sodium-citrate-sodium-sulfate-potassium-chloride-clensia_en.pdf"},
    {"id":"53802","name":"P/0133/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for maralixibat chloride (EMEA-001475-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/150638/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2021-ema-decision-14-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-maralixibat-chloride-emea-001475-pip02-13-m01_en.pdf"},
    {"id":"53803","name":"P/0177/2021: EMA decision of 12 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for doravirine (Pifeltro), (EMEA-001676-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/193122/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2021-ema-decision-12-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-doravirine-pifeltro-emea-001676-pip01-14-m04_en.pdf"},
    {"id":"53806","name":"P/0176/2021: EMA decision of 12 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for doravirine / lamivudine / tenofovir disoproxil (fumarate) (Delstrigo), (EMEA-001695-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/193126/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2021-ema-decision-12-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-doravirine-lamivudine-tenofovir-disoproxil-fumarate-delstrigo-emea-001695-pip01-14-m04_en.pdf"},
    {"id":"53807","name":"P/0132/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for defatted powder of peanuts (PALFORZIA), (EMEA-001734-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/150640/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2021-ema-decision-14-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-defatted-powder-peanuts-palforzia-emea-001734-pip01-14-m05_en.pdf"},
    {"id":"53808","name":"P/0167/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/192367/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2021-ema-decision-14-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip01-14-m04_en.pdf"},
    {"id":"53809","name":"P/0166/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP04-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/192364/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2021-ema-decision-14-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip04-17-m02_en.pdf"},
    {"id":"53810","name":"P/0131/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for volanesorsen (Waylivra), (EMEA-001915-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/150641/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2021-ema-decision-14-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-volanesorsen-waylivra-emea-001915-pip01-15-m03_en.pdf"},
    {"id":"53811","name":"P/0152/2021: EMA decision of 16 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for gadopiclenol (EMEA- 001949-PIP01-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/152078/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2021-ema-decision-16-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-gadopiclenol-emea-001949-pip01-16-m04_en.pdf"},
    {"id":"53812","name":"P/0151/2021: EMA decision of 16 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for gadopiclenol, (EMEA- 001949-PIP02-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/152075/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2021-ema-decision-16-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-gadopiclenol-emea-001949-pip02-18-m01_en.pdf"},
    {"id":"53817","name":"P/0168/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bimekizumab (EMEA-002189-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/192377/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2021-ema-decision-14-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-bimekizumab-emea-002189-pip01-17-m02_en.pdf"},
    {"id":"53818","name":"P/0169/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dienogest / ethinyl estradiol (EMEA-002229-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/192380/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2021-ema-decision-14-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-dienogest-ethinyl-estradiol-emea-002229-pip01-17-m02_en.pdf"},
    {"id":"53819","name":"P/0171/2021: EMA decision of 9 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ganaxolone ,(EMEA- 002341-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/197408/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2021-ema-decision-9-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-ganaxolone-emea-002341-pip01-18-m01_en.pdf"},
    {"id":"53820","name":"P/0148/2021: EMA decision of 16 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for valoctocogene roxaparvovec, (EMEA-002427-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/152079/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2021-ema-decision-16-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-valoctocogene-roxaparvovec-emea-002427-pip01-18-m01_en.pdf"},
    {"id":"53821","name":"P/0178/2021: EMA decision of 19 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for spesolimab (EMEA-002475-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/212135/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2021-ema-decision-19-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-spesolimab-emea-002475-pip02-19-m01_en.pdf"},
    {"id":"53822","name":"P/0144/2021: EMA decision of 16 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ladarixin (EMEA- 002642-PIP01-19-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-01-18T14:51:00Z","last_updated_date":"2022-01-18T14:51:00Z","reference_number":"EMA/152080/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2021-ema-decision-16-april-2021-acceptance-modification-agreed-paediatric-investigation-plan-ladarixin-emea-002642-pip01-19-m03_en.pdf"},
    {"id":"54141","name":"P/0186/2021 : EMA decision of 10 May 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vedolizumab (Entyvio), (EMEA-000645-PIP04-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-11T12:37:00Z","last_updated_date":"2022-02-11T12:37:00Z","reference_number":"EMA/245547/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2021-ema-decision-10-may-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vedolizumab-entyvio-emea-000645-pip04-20_en.pdf"},
    {"id":"54142","name":"P/0188/2021 : EMA decision of 7 May 2021 on the refusal of a product specific waiver for reparixin (EMEA-001693-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-11T12:49:00Z","last_updated_date":"2022-02-11T12:49:00Z","reference_number":"EMA/193163/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2021-ema-decision-7-may-2021-refusal-product-specific-waiver-reparixin-emea-001693-pip02-20_en.pdf"},
    {"id":"54143","name":"P/0194/2021 : EMA decision of 10 May 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rAAV8 viral vector encoding the human UGT1A1 transgene ...(EMEA-002021-PIP01-16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-11T12:58:00Z","last_updated_date":"2022-02-11T12:58:00Z","reference_number":"EMA/216289/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2021-ema-decision-10-may-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-raav8-viral-vector-encoding-human-ugt1a1-transgene-emea-002021-pip01-16_en.pdf"},
    {"id":"54144","name":"P/0206/2021 : EMA decision of 10 May 2021 on the agreement of a paediatric investigation plan for pegfilgrastim (Pelgraz), (EMEA-002671-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-11T13:09:00Z","last_updated_date":"2022-02-11T13:09:00Z","reference_number":"EMA/245270/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2021-ema-decision-10-may-2021-agreement-paediatric-investigation-plan-pegfilgrastim-pelgraz-emea-002671-pip02-20_en.pdf"},
    {"id":"54150","name":"P/0190/2021 : EMA decision of 10 May 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for deferoxamine (mesylate) / histidine / tryptophan / aspartic acid / n-acetyl-histidine (monohydrate)...EMEA-002735-PIP03-20","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-14T15:25:00Z","last_updated_date":"2022-02-14T15:25:00Z","reference_number":"EMA/245271/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2021-ema-decision-10-may-2021-agreement-paediatric-investigation-plan-granting-deferral-deferoxamine-mesylate-histidine-tryptophan-aspartic-acid-n-acetyl-histidine-monohydrateemea-002735-pip03_en.pdf"},
    {"id":"54151","name":"P/0199/2021 : EMA decision of 10 May 2021 on the granting of a product specific waiver for human anti-interleukin-15 (IL-15) monoclonal antibody (EMEA-002775-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-14T15:36:00Z","last_updated_date":"2022-02-14T15:36:00Z","reference_number":"EMA/252793/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2021-ema-decision-10-may-2021-granting-product-specific-waiver-human-anti-interleukin-15-il-15-monoclonal-antibody-emea-002775-pip01-20_en.pdf"},
    {"id":"54152","name":"P/0203/2021 : EMA decision of 10 May 2021 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for edaravone (EMEA-002785-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-14T15:46:00Z","last_updated_date":"2022-02-14T15:46:00Z","reference_number":"EMA/252904/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2021-ema-decision-10-may-2021-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-edaravone-emea-002785-pip01-20_en.pdf"},
    {"id":"54153","name":"P/0202/2021 : EMA decision of 10 May 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for respiratory syncytial virus stabilised prefusion f subunit vaccine...(EMEA-002795-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-14T15:58:00Z","last_updated_date":"2022-02-14T15:58:00Z","reference_number":"EMA/193790/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2021-ema-decision-10-may-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-respiratory-syncytial-virus-stabilised-prefusion-f-subunit-vaccineemea-002795-pip01-20_en.pdf"},
    {"id":"54161","name":"P/0187/2021 : EMA decision of 7 May 2021 on the granting of a product specific waiver for argon / oxygen (EMEA-002921-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-15T09:54:00Z","last_updated_date":"2022-02-15T09:54:00Z","reference_number":"EMA/151826/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2021-ema-decision-7-may-2021-granting-product-specific-waiver-argon-oxygen-emea-002921-pip01-20_en.pdf"},
    {"id":"54170","name":"P/0197/2021 : EMA decision of 10 May 2021 on the granting of a product specific waiver for (S)-5-amino-3-(4-((5-fluoro-2- methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide (EMEA-002943-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-15T11:41:00Z","last_updated_date":"2022-02-15T11:41:00Z","reference_number":"EMA/216221/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2021-ema-decision-10-may-2021-granting-product-specific-waiver-s-5-amino-3-4-5-fluoro-2-methoxybenzamidomethylphenyl-1-111-trifluoropropane-2-yl-1h-pyrazole-4-carboxamide-emea-002943-pip01-20_en.pdf"},
    {"id":"54173","name":"P/0200/2021 : EMA decision of 10 May 2021 on the granting of a product specific waiver for anti-CD40L humanized monoclonal antibody (SAR441344) (EMEA-002945-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-15T11:55:00Z","last_updated_date":"2022-02-15T11:55:00Z","reference_number":"EMA/251427/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2021-ema-decision-10-may-2021-granting-product-specific-waiver-anti-cd40l-humanized-monoclonal-antibody-sar441344-emea-002945-pip01-20_en.pdf"},
    {"id":"54174","name":"P/0183/2021 : EMA decision of 10 May 2021 on the granting of a product specific waiver for (S)-N-(1-amino-4-(dimethylamino)-1-oxobutan-2-yl)- 5-(2,4-difluorophenoxy)-1-isobutyl-1H-indazole-6-carboxamide (EMEA-002948-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-15T12:02:00Z","last_updated_date":"2022-02-15T12:02:00Z","reference_number":"EMA/245805/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2021-ema-decision-10-may-2021-granting-product-specific-waiver-s-n-1-amino-4-dimethylamino-1-oxobutan-2-yl-5-24-difluorophenoxy-1-isobutyl-1h-indazole-6-carboxamide-emea-002948-pip01-20_en.pdf"},
    {"id":"54177","name":"P/0192/2021 : EMA decision of 10 May 2021 on the granting of a product specific waiver for pembrolizumab / quavonlimab (EMEA-002949-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-15T14:00:00Z","last_updated_date":"2022-02-15T14:00:00Z","reference_number":"EMA/245274/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2021-ema-decision-10-may-2021-granting-product-specific-waiver-pembrolizumab-quavonlimab-emea-002949-pip01-20_en.pdf"},
    {"id":"54178","name":"P/0208/2021 : EMA decision of 10 May 2021 on the granting of a product specific waiver for sumatriptan / naproxen (sodium) (EMEA-002959-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-15T14:08:00Z","last_updated_date":"2022-02-15T14:08:00Z","reference_number":"EMA/244109/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2021-ema-decision-10-may-2021-granting-product-specific-waiver-sumatriptan-naproxen-sodium-emea-002959-pip01-21_en.pdf"},
    {"id":"54191","name":"P/0189/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for concentrate of proteolytic enzyme enriched in bromelain (NexoBrid), (EMEA-000142-PIP02-09-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-16T15:06:00Z","last_updated_date":"2022-02-16T15:06:00Z","reference_number":"EMA/245223/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-concentrate-proteolytic-enzyme-enriched-bromelain-nexobrid-emea-000142-pip02-09-m11_en.pdf"},
    {"id":"54192","name":"P/0213/2021 : EMA decision of 21 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Prolia, Xgeva), (EMEA-000145-PIP02-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-16T15:18:00Z","last_updated_date":"2022-02-16T15:18:00Z","reference_number":"EMA/277014/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2021-ema-decision-21-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-prolia-xgeva-emea-000145-pip02-12-m04_en.pdf"},
    {"id":"54193","name":"P/0205/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (Lenvima, Kisplyx), (EMEA-001119-PIP03-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-16T15:23:00Z","last_updated_date":"2022-02-16T15:23:00Z","reference_number":"EMA/251592/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-lenvima-kisplyx-emea-001119-pip03-19-m01_en.pdf"},
    {"id":"54207","name":"P/0191/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for brexpiprazole (Rxulti), (EMEA-001185-PIP01-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T12:08:00Z","last_updated_date":"2022-02-17T12:08:00Z","reference_number":"EMA/252624/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-brexpiprazole-rxulti-emea-001185-pip01-11-m07_en.pdf"},
    {"id":"54208","name":"P/0196/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for obinutuzumab (Gazyvaro), (EMEA-001207-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T12:14:00Z","last_updated_date":"2022-02-17T12:14:00Z","reference_number":"EMA/249298/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-obinutuzumab-gazyvaro-emea-001207-pip01-11-m01_en.pdf"},
    {"id":"54209","name":"P/0209/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine / dolutegravir (Juluca), (EMEA-001750-PIP01-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T12:48:00Z","last_updated_date":"2022-02-17T12:48:00Z","reference_number":"EMA/217619/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-dolutegravir-juluca-emea-001750-pip01-15-m04_en.pdf"},
    {"id":"54210","name":"P/0198/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat / emtricitabine / tenofovir alafenamide (Symtuza), (EMEA-001825-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T13:48:00Z","last_updated_date":"2022-02-17T13:48:00Z","reference_number":"EMA/245244/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza-emea-001825-pip01-15-m03_en.pdf"},
    {"id":"54211","name":"P/0193/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for pegunigalsidase alfa (EMEA-001828-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T13:56:00Z","last_updated_date":"2022-02-17T13:56:00Z","reference_number":"EMA/193129/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-pegunigalsidase-alfa-emea-001828-pip01-15-m02_en.pdf"},
    {"id":"54212","name":"P/0207/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for birch pollen extract (betula verrucosa) (ITULAZAX), (EMEA-001879-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T15:01:00Z","last_updated_date":"2022-02-17T15:01:00Z","reference_number":"EMA/193132/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-birch-pollen-extract-betula-verrucosa-itulazax-emea-001879-pip01-15-m03_en.pdf"},
    {"id":"54213","name":"P/0180/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for remimazolam (as besylate), (Byfavo), (EMEA-001880-PIP02-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T15:10:00Z","last_updated_date":"2022-02-17T15:10:00Z","reference_number":"EMA/251327/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-remimazolam-besylate-byfavo-emea-001880-pip02-19-m02_en.pdf"},
    {"id":"54214","name":"P/0181/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for avacopan (EMEA-002023-PIP01-16-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T15:17:00Z","last_updated_date":"2022-02-17T15:17:00Z","reference_number":"EMA/251326/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-avacopan-emea-002023-pip01-16-m05_en.pdf"},
    {"id":"54215","name":"P/0185/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for isatuximab (Sarclisa), (EMEA-002205-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T15:35:00Z","last_updated_date":"2022-02-17T15:35:00Z","reference_number":"EMA/251319/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-isatuximab-sarclisa-emea-002205-pip01-17-m02_en.pdf"},
    {"id":"54216","name":"P/0182/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine / meloxicam (HTX-011), (Zynrelef), (EMEA-002246-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T15:58:00Z","last_updated_date":"2022-02-17T15:58:00Z","reference_number":"EMA/251324/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-bupivacaine-meloxicam-htx-011-zynrelef-emea-002246-pip01-17-m02_en.pdf"},
    {"id":"54217","name":"P/0184/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for niraparib (tosylate monohydrate), (Zejula), (EMEA-002268-PIP02-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T16:08:00Z","last_updated_date":"2022-02-17T16:08:00Z","reference_number":"EMA/251320/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-niraparib-tosylate-monohydrate-zejula-emea-002268-pip02-18-m01_en.pdf"},
    {"id":"54218","name":"P/0204/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cipaglucosidase alfa, (EMEA-002447-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T16:15:00Z","last_updated_date":"2022-02-17T16:15:00Z","reference_number":"EMA/217793/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-cipaglucosidase-alfa-emea-002447-pip01-18-m01_en.pdf"},
    {"id":"54219","name":"P/0211/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dostarlimab, (EMEA- 002463-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T16:20:00Z","last_updated_date":"2022-02-17T16:20:00Z","reference_number":"EMA/218629/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-dostarlimab-emea-002463-pip01-18-m01_en.pdf"},
    {"id":"54220","name":"P/0210/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for pegcetacoplan, (EMEA-002600-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T16:26:00Z","last_updated_date":"2022-02-17T16:26:00Z","reference_number":"EMA/218859/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2021-ema-decision-10-may-2021-acceptance-modification-agreed-paediatric-investigation-plan-pegcetacoplan-emea-002600-pip01-19-m01_en.pdf"},
    {"id":"54368","name":"P/0320/2021: EMA decision of 13 August 2021 on the agreement of a PIP and on the granting of a deferral & on the granting of a waiver for human, recombinant, non-fucosylated IgG1k monoclonal antibody targeting OX-40 receptor on activated T cells(KHK4083)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-03-07T17:26:00Z","last_updated_date":"2022-03-07T17:26:00Z","reference_number":"EMA/385417/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2021-ema-decision-13-august-2021-agreement-pip-granting-deferral-granting-waiver-human-recombinant-non-fucosylated-igg1k-monoclonal-antibody-targeting-ox-40-receptor-activated-t-cellskhk4083_en.pdf"},
    {"id":"54531","name":"P/0357/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for pevonedistat (EMEA- 002117-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-03-21T15:36:00Z","last_updated_date":"2022-03-21T15:36:00Z","reference_number":"EMA/470767/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0357-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-pevonedistat-emea-002117-pip01-17-m02_en.pdf"},
    {"id":"54534","name":"P/0403/2021 : EMA decision of 1 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for brensocatib (EMEA-002905-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-03-22T10:01:00Z","last_updated_date":"2022-03-22T10:01:00Z","reference_number":"EMA/535381/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0403-2021-ema-decision-1-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-brensocatib-emea-002905-pip01-20_en.pdf"},
    {"id":"54535","name":"P/0453/2021 : EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for crisantaspase (EMEA-002934-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-03-22T10:13:00Z","last_updated_date":"2022-03-22T10:13:00Z","reference_number":"EMA/535417/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0453-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-crisantaspase-emea-002934-pip01-20_en.pdf-0"},
    {"id":"54824","name":"P/0230/2021 : EMA decision of 8 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ravulizumab (Ultomiris) (EMEA-001943-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-26T11:30:00Z","last_updated_date":"2022-04-26T11:30:00Z","reference_number":"EMA/302234/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2021-ema-decision-8-june-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ravulizumab-ultomiris-emea-001943-pip03-20_en.pdf"},
    {"id":"54827","name":"P/0223/2021 : EMA decision of 8 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for erdafitinib (EMEA-002042-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-26T12:51:00Z","last_updated_date":"2022-04-26T12:51:00Z","reference_number":"EMA/299951/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2021-ema-decision-8-june-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-erdafitinib-emea-002042-pip02-20_en.pdf"}    {"id":"54829","name":"P/0224/2021 : EMA decision of 9 June 2021 on the agreement of a paediatric investigation plan and on the granting of a waiver for talazoparib (Talzenna) (EMEA-002066-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-26T14:09:00Z","last_updated_date":"2022-04-26T14:09:00Z","reference_number":"EMA/245845/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2021-ema-decision-9-june-2021-agreement-paediatric-investigation-plan-granting-waiver-talazoparib-talzenna-emea-002066-pip01-20_en.pdf"},
    {"id":"54830","name":"P/0231/2021 : EMA decision of 8 June 2021 on the granting of a product specific waiver for savolitinib (EMEA-002627-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-26T14:17:00Z","last_updated_date":"2022-04-26T14:17:00Z","reference_number":"EMA/303335/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2021-ema-decision-8-june-2021-granting-product-specific-waiver-savolitinib-emea-002627-pip02-21_en.pdf"},
    {"id":"54831","name":"P/0228/2021 : EMA decision of 9 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for deferoxamine (mesylate) / histidine / tryptophan / aspartic acid / n-acetyl-histidine ....... (EMEA-002735-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-26T14:29:00Z","last_updated_date":"2022-04-26T14:29:00Z","reference_number":"EMA/245847/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2021-ema-decision-9-june-2021-agreement-paediatric-investigation-plan-granting-deferral-deferoxamine-mesylate-histidine-tryptophan-aspartic-acid-n-acetyl-histidine-emea-002735-pip01-19_en.pdf"},
    {"id":"54832","name":"P/0229/2021 : EMA decision of 8 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for atropine sulfate (EMEA-002744-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-26T14:39:00Z","last_updated_date":"2022-04-26T14:39:00Z","reference_number":"EMA/303040/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2021-ema-decision-8-june-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-atropine-sulfate-emea-002744-pip01-19_en.pdf"},
    {"id":"54833","name":"P/0227/2021 : EMA decision of 8 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Sotatercept (EMEA-002756-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-26T14:53:00Z","last_updated_date":"2022-04-26T14:53:00Z","reference_number":"EMA/235349/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2021-ema-decision-8-june-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sotatercept-emea-002756-pip01-19_en.pdf"},
    {"id":"54845","name":"P/0323/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for human plasma derived C1-inhibitor (OCTA-C1-INH), (EMEA-002818-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-20T11:22:00Z","last_updated_date":"2025-10-20T11:22:00Z","reference_number":"EMA/411619/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-human-plasma-derived-c1-inhibitor-octa-c1-inh-emea-002818-pip01-20-m01_en.pdf"},
    {"id":"54846","name":"P/0222/2021 : EMA decision of 8 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for iscalimab (EMEA-002842-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T10:58:00Z","last_updated_date":"2022-04-28T10:58:00Z","reference_number":"EMA/301778/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2021-ema-decision-8-june-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-iscalimab-emea-002842-pip01-20_en.pdf"},
    {"id":"54847","name":"P/0219/2021 : EMA decision of 9 June 2021 on the granting of a product specific waiver for immunoglobulin G4 [449-cysteine], anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal OG1950 gamma-4-chain)....(EMEA-002895-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T11:24:00Z","last_updated_date":"2022-04-28T11:24:00Z","reference_number":"EMA/245759/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2021-ema-decision-9-june-2021-granting-product-specific-waiver-immunoglobulin-g4-449-cysteine-anti-human-vascular-endothelial-growth-factor-human-mus-musculus-monoclonal-og1950-gamma-4_en.pdf"},
    {"id":"54848","name":"P/0218/2021 : EMA decision of 8 June 2021 on the granting of a product specific waiver for synthetic hypericin (EMEA-002956-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T11:36:00Z","last_updated_date":"2022-04-28T11:36:00Z","reference_number":"EMA/301680/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2021-ema-decision-8-june-2021-granting-product-specific-waiver-synthetic-hypericin-emea-002956-pip01-21_en.pdf"},
    {"id":"54849","name":"P/0226/2021 : EMA decision of 8 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for sotagliflozin (Zynquista) (EMEA-001517-PIP02-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T12:34:00Z","last_updated_date":"2022-04-28T12:34:00Z","reference_number":"EMA/235313/2021 corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2021-ema-decision-8-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-sotagliflozin-zynquista-emea-001517-pip02-14-m03_en.pdf"},
    {"id":"54850","name":"P/0232/2021 : EMA decision of 16 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for betibeglogene autotemcel, (Zynteglo) (EMEA-001665-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T12:52:00Z","last_updated_date":"2022-04-28T12:52:00Z","reference_number":"EMA/303770/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2021-ema-decision-16-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-betibeglogene-autotemcel-zynteglo-emea-001665-pip01-14-m05_en.pdf"},
    {"id":"54851","name":"P/0233/2021 : EMA decision of 8 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod (hydrochloride) (Zeposia) (EMEA-001710-PIP03-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T13:08:00Z","last_updated_date":"2022-04-28T13:08:00Z","reference_number":"EMA/308733/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2021-ema-decision-8-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-ozanimod-hydrochloride-zeposia-emea-001710-pip03-17-m03_en.pdf"},
    {"id":"54852","name":"P/0220/2021 : EMA decision of 9 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for liquid ethanolic extract 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.)....(EMEA-001835-PIP01-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T13:16:00Z","last_updated_date":"2022-04-28T13:16:00Z","reference_number":"EMA/245659/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2021-ema-decision-9-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-liquid-ethanolic-extract-30-cent-w-w-allium-cepa-l-fresh-bulb-citrus-limon-lemea-001835-pip01-15-m05_en.pdf"},
    {"id":"54853","name":"P/0238/2021 : EMA decision of 17 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris) (EMEA-001943-PIP01-16-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T13:27:00Z","last_updated_date":"2022-04-28T13:27:00Z","reference_number":"EMA/317819/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2021-ema-decision-17-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-001943-pip01-16-m06_en.pdf"},
    {"id":"54855","name":"P/0217/2021 : EMA decision of 9 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for venetoclax (Venclyxto) (EMEA-002018-PIP02-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T14:05:00Z","last_updated_date":"2022-04-28T14:05:00Z","reference_number":"EMA/300372/2021, Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2021-ema-decision-9-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-venetoclax-venclyxto-emea-002018-pip02-16-m04_en.pdf"},
    {"id":"54856","name":"P/0239/2021 : EMA decision of 17 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris) (EMEA-002077-PIP01-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T14:13:00Z","last_updated_date":"2022-04-28T14:13:00Z","reference_number":"EMA/317902/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2021-ema-decision-17-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-002077-pip01-16-m04_en.pdf"},
    {"id":"54857","name":"P/0215/2021 : EMA decision of 8 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for setmelanotide (EMEA-002209-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-04-28T14:19:00Z","last_updated_date":"2022-04-28T14:19:00Z","reference_number":"EMA/299983/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2021-ema-decision-8-june-2021-acceptance-modification-agreed-paediatric-investigation-plan-setmelanotide-emea-002209-pip01-17-m02_en.pdf"},
    {"id":"54908","name":"P/0144/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for sarilumab (Kevzara) (EMEA-001045-PIP01-10-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-05-06T09:00:00Z","last_updated_date":"2022-05-06T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2021-ema-decision-17-march-2021-acceptance-modification-agreed-paediatric-investigation-plan-sarilumab-kevzara-emea-001045-pip01-10-m02_en.pdf"},
    {"id":"54951","name":"P/0455/2021: EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the  granting of a waiver for glepaglutide, (EMEA-002926-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-05-12T09:58:00Z","last_updated_date":"2022-05-12T09:58:00Z","reference_number":"EMA/532157/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0455-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-glepaglutide-emea-002926-pip01-20_en.pdf"},
    {"id":"55175","name":"P/0361/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent) (EMEA-001501-PIP04-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-06-10T09:50:00Z","last_updated_date":"2022-06-10T09:50:00Z","reference_number":"EMA/440400/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0361-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip04-19-m01_en.pdf"},
    {"id":"55177","name":"P/0388/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for benralizumab (Fasenra) (EMEA-001214-PIP05-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-06-10T10:36:00Z","last_updated_date":"2022-06-10T10:36:00Z","reference_number":"EMA/418670/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0388-2021-ema-decision-8-september-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-benralizumab-fasenra-emea-001214-pip05-19_en.pdf"},
    {"id":"55179","name":"P/0375/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cendakimab (EMEA-002640-PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-06-10T10:43:00Z","last_updated_date":"2022-06-10T10:43:00Z","reference_number":"EMA/471081/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0375-2021-ema-decision-8-september-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cendakimab-emea-002640-pip01-19_en.pdf"},
    {"id":"55181","name":"P/0246/2021 : EMA decision of 9 July 2021 on the agreement of a paediatric investigation plan for odevixibat (EMEA-002054-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-06-10T10:48:00Z","last_updated_date":"2022-06-10T10:48:00Z","reference_number":"EMA/360346/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2021-ema-decision-9-july-2021-agreement-paediatric-investigation-plan-odevixibat-emea-002054-pip03-20_en.pdf"},
    {"id":"55238","name":"Tabalumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-06-14T14:39:00Z","last_updated_date":"2022-06-14T14:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/tabalumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"55545","name":"P/0184/2022: EMA decision of 13 May 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for SARS-CoV-2 virus, beta-propiolactone inactivated adjuvanted with CpG 1018 (VLA2001) (EMEA-003077-PIP01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:21:00Z","last_updated_date":"2022-07-14T16:21:00Z","reference_number":"EMA/207903/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2022-ema-decision-13-may-2022-agreement-paediatric-investigation-plan-granting-deferral-sars-cov-2-virus-beta-propiolactone-inactivated-adjuvanted-cpg-1018-vla2001-emea-003077-pip01_en.pdf"},
    {"id":"55572","name":"P/0260/2021: EMA decision of 9 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for meropenem (trihydrate) / vaborbactam (Vaborem) (EMEA-001731-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-18T14:18:00Z","last_updated_date":"2022-07-18T14:18:00Z","reference_number":"EMA/358473/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2021-ema-decision-9-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-meropenem-trihydrate-vaborbactam-vaborem-emea-001731-pip01-14-m03_en.pdf"},
    {"id":"55573","name":"P/0257/2021: EMA decision of 7 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for peramivir (EMEA-001856-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-18T14:49:00Z","last_updated_date":"2022-07-18T14:49:00Z","reference_number":"EMA/312393/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2021-ema-decision-7-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-peramivir-emea-001856-pip02-16-m02_en.pdf"},
    {"id":"55575","name":"P/0264/2021: EMA decision of 7 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for lanadelumab (DX- 2930) (Takhzyro), (EMEA-001864-PIP01-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-18T15:00:00Z","last_updated_date":"2022-07-18T15:00:00Z","reference_number":"EMA/311223/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2021-ema-decision-7-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-lanadelumab-dx-2930-takhzyro-emea-001864-pip01-15-m05_en.pdf"},
    {"id":"55577","name":"P/0285/2021: EMA decision of 29 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for neisseria meningitidis serogroup... (EMEA-001930-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-18T15:12:00Z","last_updated_date":"2022-07-18T15:12:00Z","reference_number":"EMA/393812/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2021-ema-decision-29-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-emea-001930-pip01-16-m03_en.pdf"},
    {"id":"55578","name":"P/0261/2021: EMA decision of 7 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bis-choline tetrathiomolybdate (ALXN1840) (EMEA-002232-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-18T15:30:00Z","last_updated_date":"2022-07-18T15:30:00Z","reference_number":"EMA/314593/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2021-ema-decision-7-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-bis-choline-tetrathiomolybdate-alxn1840-emea-002232-pip02-19-m01_en.pdf"},
    {"id":"55579","name":"P/0270/2021: EMA decision of 9 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cotadutide (EMEA-002287-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-18T15:30:00Z","last_updated_date":"2022-07-18T15:30:00Z","reference_number":"EMA/317985/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2021-ema-decision-9-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-cotadutide-emea-002287-pip01-17-m02_en.pdf"},
    {"id":"55580","name":"P/0248/2021: EMA decision of 9 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ibalizumab (Trogarzo), (EMEA-002311-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-18T16:36:00Z","last_updated_date":"2023-01-16T11:33:00Z","reference_number":"EMA/318043/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2021-ema-decision-9-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-ibalizumab-trogarzo-emea-002311-pip01-17-m02_en.pdf"},
    {"id":"55581","name":"P/0272/2021 : EMA decision of 8 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for rilzabrutinib (EMEA- 002438-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-18T16:55:00Z","last_updated_date":"2022-07-18T16:55:00Z","reference_number":"EMA/359364/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2021-ema-decision-8-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-rilzabrutinib-emea-002438-pip02-19-m01_en.pdf"},
    {"id":"55582","name":"P/0273/2021 : EMA decision of 8 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cotadutide (EMEA-002712-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-18T18:23:00Z","last_updated_date":"2022-07-18T18:23:00Z","reference_number":"EMA/359529/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2021-ema-decision-8-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-cotadutide-emea-002712-pip01-19-m01_en.pdf"},
    {"id":"55583","name":"P/0274/2021 : EMA decision of 8 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for garadacimab (EMEA-002726-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-18T18:25:00Z","last_updated_date":"2022-07-18T18:25:00Z","reference_number":"EMA/359316/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2021-ema-decision-8-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-garadacimab-emea-002726-pip01-19-m01_en.pdf"},
    {"id":"55585","name":"P/0247/2021: EMA decision of 9 July 2021 on the agreement of a paediatric investigation plan for allogeneic skin-derived ATP-binding cassette, sub-family B, member 5 (ABCB5)-positive mesenchymal stem cells (allo-APZ2-EB) (EMEA-002875-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T14:53:00Z","last_updated_date":"2022-07-19T14:53:00Z","reference_number":"EMA/318167/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2021-ema-decision-9-july-2021-agreement-paediatric-investigation-plan-allogeneic-skin-derived-atp-binding-cassette-sub-family-b-member-5-abcb5-positive-mesenchymal-stem-cells-allo-apz2-eb-emea_en.pdf"},
    {"id":"55587","name":"P/0252/2021: EMA decision of 9 July 2021 on the granting of a product specific waiver for anti-C1s humanized IgG4 monoclonal antibody (EMEA- 002903-PIP02-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T15:53:00Z","last_updated_date":"2022-07-19T15:53:00Z","reference_number":"EMA/358148/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2021-ema-decision-9-july-2021-granting-product-specific-waiver-anti-c1s-humanized-igg4-monoclonal-antibody-emea-002903-pip02-21_en.pdf"},
    {"id":"55588","name":"P/0263/2021: EMA decision of 7 July 2021 on the granting of a product specific waiver for selatogrel (EMEA-002967-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T15:53:00Z","last_updated_date":"2022-07-19T15:53:00Z","reference_number":"EMA/315326/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2021-ema-decision-7-july-2021-granting-product-specific-waiver-selatogrel-emea-002967-pip01-21_en.pdf"},
    {"id":"55589","name":"P/0262/2021: EMA decision of 7 July 2021 on the granting of a product specific waiver for mannitol (EMEA-002968-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T16:26:00Z","last_updated_date":"2022-07-19T16:26:00Z","reference_number":"EMA/315363/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2021-ema-decision-7-july-2021-granting-product-specific-waiver-mannitol-emea-002968-pip01-21_en.pdf"},
    {"id":"55590","name":"P/0258/2021: EMA decision of 9 July 2021 on the granting of a product specific waiver for [18F]CTT1057 (EMEA-002975-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T17:16:00Z","last_updated_date":"2022-07-19T17:16:00Z","reference_number":"EMA/317695/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2021-ema-decision-9-july-2021-granting-product-specific-waiver-18fctt1057-emea-002975-pip01-21_en.pdf"},
    {"id":"55591","name":"P/0256/2021: EMA decision of 9 July 2021 on the granting of a product specific waiver for vupanorsen, (EMEA-002973-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T17:16:00Z","last_updated_date":"2022-07-19T17:16:00Z","reference_number":"EMA/360188/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2021-ema-decision-9-july-2021-granting-product-specific-waiver-vupanorsen-emea-002973-pip01-21_en.pdf"},
    {"id":"55592","name":"P/0249/2021: EMA decision of 9 July 2021 on the granting of a product specific waiver for zibotentan / dapagliflozin (propanediol monohydrate), (EMEA-002969-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T17:16:00Z","last_updated_date":"2022-07-19T17:16:00Z","reference_number":"EMA/360235/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2021-ema-decision-9-july-2021-granting-product-specific-waiver-zibotentan-dapagliflozin-propanediol-monohydrate-emea-002969-pip01-21_en.pdf"},
    {"id":"55593","name":"P/0259/2021: EMA decision of 9 July 2021 on the granting of a product specific waiver for datopotamab deruxtecan (EMEA-002976-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T17:49:00Z","last_updated_date":"2022-07-19T17:49:00Z","reference_number":"EMA/317764/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2021-ema-decision-9-july-2021-granting-product-specific-waiver-datopotamab-deruxtecan-emea-002976-pip01-21_en.pdf"},
    {"id":"55594","name":"P/0279/2021: EMA decision of 16 July 2021 on the granting of a product specific waiver for datopotamab deruxtecan (EMEA-002976-PIP02-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T17:49:00Z","last_updated_date":"2022-07-19T17:49:00Z","reference_number":"EMA/382517/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2021-ema-decision-16-july-2021-granting-product-specific-waiver-datopotamab-deruxtecan-emea-002976-pip02-21_en.pdf"},
    {"id":"55595","name":"P/0276/2021: EMA decision of 8 July 2021 on the granting of a product specific waiver for patritumab deruxtecan (EMEA-002977-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T17:49:00Z","last_updated_date":"2022-07-19T17:49:00Z","reference_number":"EMA/359047/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2021-ema-decision-8-july-2021-granting-product-specific-waiver-patritumab-deruxtecan-emea-002977-pip01-21_en.pdf"},
    {"id":"55596","name":"P/0275/2021: EMA decision of 8 July 2021 on the granting of a product specific waiver for trastuzumab deruxtecan (Enhertu), (EMEA-002978-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T18:06:00Z","last_updated_date":"2022-07-19T18:06:00Z","reference_number":"EMA/359044/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2021-ema-decision-8-july-2021-granting-product-specific-waiver-trastuzumab-deruxtecan-enhertu-emea-002978-pip01-21_en.pdf"},
    {"id":"55597","name":"P/0284/2021: EMA decision of 28 July 2021 on the agreement of a paediatric investigation plan and on the granting of a waiver for human immunoglobulin ... (EMEA-002995-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-19T18:11:00Z","last_updated_date":"2022-07-19T18:11:00Z","reference_number":"EMA/410892/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2021-ema-decision-28-july-2021-agreement-paediatric-investigation-plan-granting-waiver-human-immunoglobulin-emea-002995-pip01-21_en.pdf"},
    {"id":"55606","name":"P/0242/2021: EMA decision of 7 July 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for macitentan (Opsumit) (EMEA-001032-PIP03-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-20T14:53:00Z","last_updated_date":"2022-07-20T14:53:00Z","reference_number":"EMA/315432/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2021-ema-decision-7-july-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-macitentan-opsumit-emea-001032-pip03-19_en.pdf"},
    {"id":"55654","name":"P/0271/2021: EMA decision of 9 July 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pralsetinib (EMEA-002575-PIP02-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T12:10:00Z","last_updated_date":"2022-07-22T12:10:00Z","reference_number":"EMA/357806/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2021-ema-decision-9-july-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pralsetinib-emea-002575-pip02-20_en.pdf"},
    {"id":"55656","name":"P/0278/2021: EMA decision of 8 July 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adeno-associated viral vector serotype 8...(EMEA-002734-PIP01-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T12:35:00Z","last_updated_date":"2022-07-22T12:35:00Z","reference_number":"EMA/359172/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2021-ema-decision-8-july-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-adeno-associated-viral-vector-serotype-8emea-002734-pip01-19_en.pdf"},
    {"id":"55657","name":"P/0277/2021: EMA decision of 8 July 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant monoclonal antibody...(EMEA-002856-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T12:35:00Z","last_updated_date":"2022-07-22T12:35:00Z","reference_number":"EMA/359062/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2021-ema-decision-8-july-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-monoclonal-antibodyemea-002856-pip01-20_en.pdf"},
    {"id":"55659","name":"P/0251/2021: EMA decision of 9 July 2021 on the granting of a product specific waiver for human papilloma virus type 16 E6 071-095 / human papilloma virus type 16 E6 109-140 / human papilloma virus type 16 E7 001-035 / ... (EMEA-001055-PIP02-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T13:59:00Z","last_updated_date":"2022-07-22T13:59:00Z","reference_number":"EMA/357082/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2021-ema-decision-9-july-2021-granting-product-specific-waiver-human-papilloma-virus-type-16-e6-071-095-human-papilloma-virus-type-16-e6-109-140-human-papilloma-virus-type-16-e7-001-035-emea_en.pdf"},
    {"id":"55660","name":"P/0265/2021: EMA decision of 7 July 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous selected renal cells (EMEA-002844-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T14:08:00Z","last_updated_date":"2022-07-22T14:08:00Z","reference_number":"EMA/315803/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2021-ema-decision-7-july-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-selected-renal-cells-emea-002844-pip01-20_en.pdf"},
    {"id":"55661","name":"P/0245/2021: EMA decision of 9 July 2021 on the agreement of a paediatric investigation plan for maralixibat chloride (EMEA-001475-PIP04-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T14:17:00Z","last_updated_date":"2022-07-22T14:17:00Z","reference_number":"EMA/358055/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2021-ema-decision-9-july-2021-agreement-paediatric-investigation-plan-maralixibat-chloride-emea-001475-pip04-20_en.pdf"},
    {"id":"55664","name":"P/0267/2021: EMA decision of 9 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir (Tivicay),(EMEA-000409-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T14:41:00Z","last_updated_date":"2022-07-22T14:41:00Z","reference_number":"EMA/359351/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2021-ema-decision-9-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-tivicayemea-000409-pip01-08-m06_en.pdf"},
    {"id":"55666","name":"P/0268/2021: EMA decision of 9 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for canagliflozin (Invokana), (EMEA-001030-PIP01-10-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T14:41:00Z","last_updated_date":"2022-07-22T14:41:00Z","reference_number":"EMA/359518/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2021-ema-decision-9-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-canagliflozin-invokana-emea-001030-pip01-10-m09_en.pdf"},
    {"id":"55667","name":"P/0255/2021: EMA decision of 9 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for romosozumab (Evenity), (EMEA-001075-PIP04-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T15:14:00Z","last_updated_date":"2022-07-22T15:14:00Z","reference_number":"EMA/359907/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2021-ema-decision-9-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-romosozumab-evenity-emea-001075-pip04-15-m03_en.pdf"},
    {"id":"55668","name":"P/0243/2021: EMA decision of 9 July 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for finerenone (EMEA-001623-PIP03-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T16:25:00Z","last_updated_date":"2022-07-22T16:25:00Z","reference_number":"EMA/357803/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2021-ema-decision-9-july-2021-agreement-paediatric-investigation-plan-granting-deferral-finerenone-emea-001623-pip03-20_en.pdf"},
    {"id":"55669","name":"P/0244/2021: EMA decision of 9 July 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ralinepag (EMEA-002432-PIP02-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T16:56:00Z","last_updated_date":"2022-07-22T16:56:00Z","reference_number":"EMA/318092/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2021-ema-decision-9-july-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ralinepag-emea-002432-pip02-20_en.pdf"},
    {"id":"55670","name":"P/0280/2021: EMA decision of 16 July 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bardoxolone (methyl) (EMEA-002488-PIP01-18)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T16:56:00Z","last_updated_date":"2022-07-22T16:56:00Z","reference_number":"EMA/384669/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2021-ema-decision-16-july-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bardoxolone-methyl-emea-002488-pip01-18_en.pdf"},
    {"id":"55672","name":"P/0269/2021: EMA decision of 9 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir alafenamide (Vemlidy), (EMEA-001584-PIP01-13-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T17:45:00Z","last_updated_date":"2022-07-22T17:45:00Z","reference_number":"EMA/358271/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2021-ema-decision-9-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-alafenamide-vemlidy-emea-001584-pip01-13-m06_en.pdf"},
    {"id":"55673","name":"P/0253/2021: EMA decision of 9 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for nemolizumab (EMEA- 001624-PIP01-14-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T17:45:00Z","last_updated_date":"2022-07-22T17:45:00Z","reference_number":"EMA/358444/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2021-ema-decision-9-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-nemolizumab-emea-001624-pip01-14-m03_en.pdf"},
    {"id":"55674","name":"P/0250/2021: EMA decision of 9 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab (Tremfya), (EMEA-001523-PIP03-18-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T18:01:00Z","last_updated_date":"2022-07-22T18:01:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2021-ema-decision-9-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-guselkumab-tremfya-emea-001523-pip03-18-m01_en.pdf"},
    {"id":"55675","name":"P/0254/2021: EMA decision of 9 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat (Rezolsta), (EMEA-001280-PIP01-12-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-25T10:38:00Z","last_updated_date":"2022-07-25T10:38:00Z","reference_number":"EMA/357657/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2021-ema-decision-9-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-rezolsta-emea-001280-pip01-12-m04_en.pdf"},
    {"id":"55676","name":"P/0282/2021: EMA decision of 19 July 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cabozantinib (Cometriq, Cabometyx), (EMEA-001143-PIP01-11-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-07-25T10:38:00Z","last_updated_date":"2022-07-25T10:38:00Z","reference_number":"EMA/394138/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2021-ema-decision-19-july-2021-acceptance-modification-agreed-paediatric-investigation-plan-cabozantinib-cometriq-cabometyx-emea-001143-pip01-11-m03_en.pdf"},
    {"id":"55898","name":"P/0468/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Saxenda), (EMEA-000128-PIP02-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T12:17:00Z","last_updated_date":"2025-03-06T13:11:00Z","reference_number":"EMA/512494/2023 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0468-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-liraglutide-saxenda-emea-000128-pip02-09-m05_en.pdf"},
    {"id":"55899","name":"P/0303/2021 : EMA decision of 13 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tocilizumab (RoActemra) (EMEA-000309-PIP04-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T12:27:00Z","last_updated_date":"2022-08-31T12:27:00Z","reference_number":"EMA/395845/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2021-ema-decision-13-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-tocilizumab-roactemra-emea-000309-pip04-17-m03_en.pdf"},
    {"id":"55900","name":"P/0305/2021 : EMA decision of 13 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ocrelizumab (Ocrevus) (EMEA-000310-PIP03-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T12:45:00Z","last_updated_date":"2022-08-31T12:45:00Z","reference_number":"EMA/395841/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2021-ema-decision-13-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-ocrelizumab-ocrevus-emea-000310-pip03-10-m05_en.pdf"},
    {"id":"55901","name":"P/0327/2021 : EMA decision of 13 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for sacubitril / valsartan (Entresto) (EMEA-000316-PIP02-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T13:09:00Z","last_updated_date":"2022-08-31T13:09:00Z","reference_number":"EMA/395853/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0327-2021-ema-decision-13-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-sacubitril-valsartan-entresto-emea-000316-pip02-11-m05_en.pdf"},
    {"id":"55902","name":"P/0349/2021 : EMA decision of 20 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat) (EMEA-000402-PIP03-17-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T13:17:00Z","last_updated_date":"2022-08-31T13:17:00Z","reference_number":"EMA/439683/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0349-2021-ema-decision-20-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip03-17-m05_en.pdf"},
    {"id":"55905","name":"P/0310/2021 : EMA decision of 13 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for vortioxetine (Brintellix) (EMEA-000455-PIP02-10-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T14:59:00Z","last_updated_date":"2022-08-31T14:59:00Z","reference_number":"EMA/395802/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0310-2021-ema-decision-13-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-vortioxetine-brintellix-emea-000455-pip02-10-m08_en.pdf"},
    {"id":"55907","name":"P/0342/2021 : EMA decision of 9 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine (Exparel) (EMEA-000877-PIP03-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T15:16:00Z","last_updated_date":"2022-08-31T15:16:00Z","reference_number":"EMA/439423/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0342-2021-ema-decision-9-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-bupivacaine-exparel-emea-000877-pip03-17-m03_en.pdf"},
    {"id":"55908","name":"P/0328/2021 : EMA decision of 13 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for selexipag (Uptravi) (EMEA-000997-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T15:27:00Z","last_updated_date":"2022-08-31T15:27:00Z","reference_number":"EMA/395849/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0328-2021-ema-decision-13-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-selexipag-uptravi-emea-000997-pip01-10-m05_en.pdf"},
    {"id":"55910","name":"P/0304/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for hepatitis B (rDNA) surface antigen adjuvanted (HEPLISAV B) (EMEA-001127-PIP02-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T15:36:00Z","last_updated_date":"2022-08-31T15:36:00Z","reference_number":"EMA/427608/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-hepatitis-b-rdna-surface-antigen-adjuvanted-heplisav-b-emea-001127-pip02-11-m01_en.pdf"},
    {"id":"55911","name":"P/0295/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for potassium (chloride) / magnesium (sulphate heptahydrate) / procaine (hydrochloride) / xylitol (EMEA-001171-PIP01-11- M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T15:51:00Z","last_updated_date":"2022-08-31T15:51:00Z","reference_number":"EMA/427604/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-potassium-chloride-magnesium-sulphate-heptahydrate-procaine-hydrochloride-xylitol-emea-001171-pip01_en.pdf"},
    {"id":"55913","name":"P/0316/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ferric maltol (Feraccru) (EMEA-001195-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T16:43:00Z","last_updated_date":"2022-08-31T16:43:00Z","reference_number":"EMA/427611/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-ferric-maltol-feraccru-emea-001195-pip01-11-m05_en.pdf"},
    {"id":"55914","name":"P/0311/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant) (EMEA-001220-PIP03-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-08-31T16:50:00Z","last_updated_date":"2022-08-31T16:50:00Z","reference_number":"EMA/427610/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0311-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip03-16-m02_en.pdf"},
    {"id":"55915","name":"P/0302/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for rurioctocog alfa pegol (ADYNOVI) (EMEA-001296-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T09:30:00Z","last_updated_date":"2022-09-01T09:30:00Z","reference_number":"EMA/427607/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-rurioctocog-alfa-pegol-adynovi-emea-001296-pip01-12-m04_en.pdf"},
    {"id":"55916","name":"P/0337/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ibrutinib (Imbruvica) (EMEA-001397-PIP03-14-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T09:49:00Z","last_updated_date":"2022-09-01T09:49:00Z","reference_number":"EMA/432866/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0337-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-ibrutinib-imbruvica-emea-001397-pip03-14-m06_en.pdf"},
    {"id":"55917","name":"P/0336/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for sirolimus (EMEA-001416-PIP01-12-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T10:20:00Z","last_updated_date":"2022-09-01T10:20:00Z","reference_number":"EMA/434139/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-sirolimus-emea-001416-pip01-12-m03_en.pdf"},
    {"id":"55918","name":"P/0329/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent) (EMEA-001501-PIP01-13-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T10:33:00Z","last_updated_date":"2022-09-01T10:33:00Z","reference_number":"EMA/434296/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0329-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip01-13-m07_en.pdf"},
    {"id":"55919","name":"P/0341/2021 : EMA decision of 12 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for selumetinib (EMEA- 001585-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T10:40:00Z","last_updated_date":"2022-09-01T10:40:00Z","reference_number":"EMA/438008/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0341-2021-ema-decision-12-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-selumetinib-emea-001585-pip01-13-m05_en.pdf"},
    {"id":"55920","name":"P/0298/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for finerenone (EMEA-001623-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T10:49:00Z","last_updated_date":"2022-09-01T10:49:00Z","reference_number":"EMA/434335/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-finerenone-emea-001623-pip01-14-m04_en.pdf"},
    {"id":"55921","name":"P/0296/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for anti-respiratory syncytial virus human IgG1κ monoclonal antibody (MEDI8897) (EMEA-001784-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T11:07:00Z","last_updated_date":"2022-09-01T11:07:00Z","reference_number":"EMA/434365/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-anti-respiratory-syncytial-virus-human-igg1k-monoclonal-antibody-medi8897-emea-001784-pip01-15-m03_en.pdf"},
    {"id":"55923","name":"P/0308/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ligelizumab (EMEA-001811-PIP02-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T11:52:00Z","last_updated_date":"2022-09-01T11:52:00Z","reference_number":"EMA/393809/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-ligelizumab-emea-001811-pip02-15-m04_en.pdf"},
    {"id":"55924","name":"P/0314/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for lactobacillus reuteri (IBP-9414) (EMEA-001895-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T12:02:00Z","last_updated_date":"2022-09-01T12:02:00Z","reference_number":"EMA/393807/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-lactobacillus-reuteri-ibp-9414-emea-001895-pip01-15-m01_en.pdf"},
    {"id":"55925","name":"P/0292/2021 : EMA decision of 11 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (EMEA-001900-PIP02-17-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T12:13:00Z","last_updated_date":"2022-09-01T12:13:00Z","reference_number":"EMA/393814/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2021-ema-decision-11-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-emea-001900-pip02-17-m05_en.pdf"},
    {"id":"55926","name":"EMA/382530/2021 : EMA decision of 12 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cemiplimab (Libtayo) (EMEA-002007-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T12:22:00Z","last_updated_date":"2022-09-01T12:22:00Z","reference_number":"EMA/382530/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-382530-2021-ema-decision-12-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-cemiplimab-libtayo-emea-002007-pip02-17-m01_en.pdf"},
    {"id":"55928","name":"P/0287/2021 : EMA decision of 12 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for fasinumab (EMEA- 002059-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T15:03:00Z","last_updated_date":"2022-09-01T15:03:00Z","reference_number":"EMA/382537/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2021-ema-decision-12-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-fasinumab-emea-002059-pip02-19-m01_en.pdf"},
    {"id":"55929","name":"P/0313/2021 : EMA decision of 12 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for temelimab (EMEA- 002127-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T15:10:00Z","last_updated_date":"2022-09-01T15:10:00Z","reference_number":"EMA/427713/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2021-ema-decision-12-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-temelimab-emea-002127-pip01-17-m01_en.pdf"},
    {"id":"55930","name":"P/0343/2021 : EMA decision of 9 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for pneumococcal polysaccharide serotype......(EMEA-002215-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T15:21:00Z","last_updated_date":"2022-09-01T15:21:00Z","reference_number":"EMA/439333/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0343-2021-ema-decision-9-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-pneumococcal-polysaccharide-serotypeemea-002215-pip01-17-m03_en.pdf"},
    {"id":"55931","name":"P/0315/2021 : EMA decision of 12 August 2021 on the refusal of a modification of an agreed paediatric investigation plan and on the refusal of a deferral and on the granting of a product-specific waiver for in vitro....(EMEA-002217-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-01T15:31:00Z","last_updated_date":"2022-09-01T15:31:00Z","reference_number":"EMA/428127/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0315-2021-ema-decision-12-august-2021-refusal-modification-agreed-paediatric-investigation-plan-refusal-deferral-granting-product-specific-waiver-vitroemea-002217-pip01-17-m02_en.pdf"},
    {"id":"55951","name":"P/0307/2021 : EMA decision of 12 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for Monovalent, live, recombinant, replication-incompetent adenoviral serotype 26 vectored vaccine....(EMEA-002307- PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-02T11:25:00Z","last_updated_date":"2022-09-02T11:25:00Z","reference_number":"EMA/382553/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2021-ema-decision-12-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-monovalent-live-recombinant-replication-incompetent-adenoviral-serotype-26-vectored-vaccineemea_en.pdf"},
    {"id":"55952","name":"P/0334/2021 : EMA decision of 19 August 2021 on acceptance of a modification of an agreed paediatric investigation plan for multivalent, live, recombinant, non-replicating in human cells, Modified Vaccinia Ankara vectored vaccine (EMEA-002308-PIP01-17)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-02T11:32:00Z","last_updated_date":"2022-09-02T11:32:00Z","reference_number":"EMA/382663/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2021-ema-decision-19-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-multivalent-live-recombinant-non-replicating-human-cells-modified-vaccinia-ankara-vectored-vaccine_en.pdf"},
    {"id":"56020","name":"P/0215/2022: EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tisagenlecleucel (Kymriah), (EMEA-001654-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-07T17:16:00Z","last_updated_date":"2022-09-07T17:16:00Z","reference_number":"EMA/366055/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-tisagenlecleucel-kymriah-emea-001654-pip01-14-m04_en.pdf"},
    {"id":"56029","name":"P/0339/2021 : EMA decision of 9 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for baricitinib (Olumiant) (EMEA-001220-PIP08-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T13:32:00Z","last_updated_date":"2022-09-08T13:32:00Z","reference_number":"EMA/439290/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0339-2021-ema-decision-9-august-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-baricitinib-olumiant-emea-001220-pip08-20_en.pdf"},
    {"id":"56030","name":"P/0318/2021 : EMA decision of 11 August 2021 on the agreement of a paediatric investigation plan for vatiquinone (EMEA-001238-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T13:42:00Z","last_updated_date":"2022-09-08T13:42:00Z","reference_number":"EMA/427603/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2021-ema-decision-11-august-2021-agreement-paediatric-investigation-plan-vatiquinone-emea-001238-pip02-20_en.pdf"},
    {"id":"56031","name":"P/0319/2021 : EMA decision of 13 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fenebrutinib (EMEA-002349-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T13:58:00Z","last_updated_date":"2022-09-08T13:58:00Z","reference_number":"EMA/385463/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0319-2021-ema-decision-13-august-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fenebrutinib-emea-002349-pip03-20_en.pdf"},
    {"id":"56036","name":"P/0331/2021 : EMA decision of 13 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for infigratinib (EMEA-002594-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T14:31:00Z","last_updated_date":"2022-09-08T14:31:00Z","reference_number":"EMA/395885/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0331-2021-ema-decision-13-august-2021-agreement-paediatric-investigation-plan-granting-deferral-infigratinib-emea-002594-pip02-20_en.pdf"},
    {"id":"56037","name":"P/0322/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for iptacopan (Fabhalta), (EMEA-002705-PIP03-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-20T10:42:00Z","last_updated_date":"2025-10-20T10:42:00Z","reference_number":"EMA/411560/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0322-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-iptacopan-fabhalta-emea-002705-pip03-20-m01_en.pdf"}    {"id":"56038","name":"P/0290/2021 : EMA decision of 11 August 2021 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for bentracimab (EMEA-002766-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T14:55:00Z","last_updated_date":"2022-09-08T14:55:00Z","reference_number":"EMA/434009/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2021-ema-decision-11-august-2021-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-bentracimab-emea-002766-pip02-21_en.pdf"},
    {"id":"56039","name":"P/0324/2021 : EMA decision of 11 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl).....(EMEA-002863-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T15:20:00Z","last_updated_date":"2022-09-08T15:20:00Z","reference_number":"EMA/418664/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0324-2021-ema-decision-11-august-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-1r3s5r-2-2-3-acetyl-5-2-methylpyrimidin-5-ylemea-002863-pip01-20_en.pdf"},
    {"id":"56040","name":"P/0323/2021 : EMA decision of 12 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for afamitresgene autoleucel (EMEA-002867-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T15:36:00Z","last_updated_date":"2022-09-08T15:36:00Z","reference_number":"EMA/382523/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2021-ema-decision-12-august-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-afamitresgene-autoleucel-emea-002867-pip01-20_en.pdf"},
    {"id":"56041","name":"P/0321/2021 : EMA decision of 11 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for allogeneic anti-CD19 CAR T cells produced using CRISPR/Cas9 to disrupt the T cell receptor....(EMEA-002881-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T15:43:00Z","last_updated_date":"2022-09-08T15:43:00Z","reference_number":"EMA/418665/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0321-2021-ema-decision-11-august-2021-agreement-paediatric-investigation-plan-granting-deferral-allogeneic-anti-cd19-car-t-cells-produced-using-crispr-cas9-disrupt-t-cell-receptoremea-002881-pip01_en.pdf"},
    {"id":"56042","name":"P/0346/2021 : EMA decision of 18 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for pegylated-fibroblast growth factor 21 (BMS-986036) (EMEA-002488-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T15:52:00Z","last_updated_date":"2022-09-08T15:52:00Z","reference_number":"EMA/451036/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0346-2021-ema-decision-18-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-pegylated-fibroblast-growth-factor-21-bms-986036-emea-002488-pip01-18-m02_en.pdf"},
    {"id":"56043","name":"P/0301/2021 :  EMA decision of 13 August 2021 on the agreement of a paediatric investigation plan for phenobarbital (EMEA-002532-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T16:10:00Z","last_updated_date":"2022-09-08T16:10:00Z","reference_number":"EMA/386400/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2021-ema-decision-13-august-2021-agreement-paediatric-investigation-plan-phenobarbital-emea-002532-pip01-18-m01_en.pdf"},
    {"id":"56044","name":"P/0286/2021 : EMA decision of 11 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lebrikizumab (EMEA-002536-PIP01-18-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-09-08T16:18:00Z","last_updated_date":"2022-09-08T16:18:00Z","reference_number":"EMA/386576/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2021-ema-decision-11-august-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lebrikizumab-emea-002536-pip01-18-m01_en.pdf"},
    {"id":"56045","name":"P/0300/2021: EMA decision of 13 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for cenobamate (EMEA-002563-PIP02-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-09-08T16:45:00Z","last_updated_date":"2022-09-08T16:45:00Z","reference_number":"EMA/386634/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2021-ema-decision-13-august-2021-agreement-paediatric-investigation-plan-granting-deferral-cenobamate-emea-002563-pip02-19-m01_en.pdf"},
    {"id":"56046","name":"P/0332/2021 : EMA decision of 5 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for giroctocogene fitelparvovec (EMEA-002724-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-09-08T16:58:00Z","last_updated_date":"2022-09-08T16:58:00Z","reference_number":"EMA/386735/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0332-2021-ema-decision-5-august-2021-agreement-paediatric-investigation-plan-granting-deferral-giroctocogene-fitelparvovec-emea-002724-pip01-19-m01_en.pdf"},
    {"id":"56047","name":"P/0396/2021 : EMA decision of 25 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for highly purified singlestranded, 5’-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2) (Comirnaty) (EMEA-00286","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2022-09-08T17:59:00Z","last_updated_date":"2022-09-08T17:59:00Z","reference_number":"EMA/468411/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0396-2021-ema-decision-25-august-2021-acceptance-modification-agreed-paediatric-investigation-plan-highly-purified-singlestranded-5-capped-mrna-encoding-full-length-sars-cov-2-spike-protein-bnt162b2_en.pdf"},
    {"id":"56065","name":"P/0317/2021 : EMA decision of 11 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ublituximab (EMEA-002889-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-12T12:35:00Z","last_updated_date":"2022-09-12T12:35:00Z","reference_number":"EMA/433846/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2021-ema-decision-11-august-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ublituximab-emea-002889-pip02-20_en.pdf"},
    {"id":"56066","name":"P/0330/2021 : EMA decision of 11 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for cefepime / zidebactam (EMEA-002892-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-12T13:25:00Z","last_updated_date":"2022-09-12T13:25:00Z","reference_number":"EMA/418666/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0330-2021-ema-decision-11-august-2021-agreement-paediatric-investigation-plan-granting-deferral-cefepime-zidebactam-emea-002892-pip01-20_en.pdf"},
    {"id":"56067","name":"P/0344/2021 : EMA decision of 12 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for epcoritamab (EMEA-002907-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-12T14:00:00Z","last_updated_date":"2022-09-12T14:00:00Z","reference_number":"EMA/418671/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0344-2021-ema-decision-12-august-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-epcoritamab-emea-002907-pip01-20_en.pdf"},
    {"id":"56069","name":"P/0312/2021 : EMA decision of 11 August 2021 on the granting of a product specific waiver for insulin icodec / semaglutide (EMEA-002988-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-12T14:50:00Z","last_updated_date":"2022-09-12T14:50:00Z","reference_number":"EMA/434120/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2021-ema-decision-11-august-2021-granting-product-specific-waiver-insulin-icodec-semaglutide-emea-002988-pip01-21_en.pdf"},
    {"id":"56070","name":"P/0335/2021 : EMA decision of 12 August 2021 on the granting of a product specific waiver for gabapentin (EMEA-002994-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-12T15:11:00Z","last_updated_date":"2022-09-12T15:11:00Z","reference_number":"EMA/382518/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0335-2021-ema-decision-12-august-2021-granting-product-specific-waiver-gabapentin-emea-002994-pip01-21_en.pdf"},
    {"id":"56076","name":"P/0299/2021 : EMA decision of 11 August 2021 on the granting of a product specific waiver for immunoglobulin G1 anti-SORT1 human monoclonal antibody (EMEA-002997-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"EMA/427613/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2021-ema-decision-11-august-2021-granting-product-specific-waiver-immunoglobulin-g1-anti-sort1-human-monoclonal-antibody-emea-002997-pip01-21_en.pdf"},
    {"id":"56084","name":"EMA/427612/2021 : EMA decision of 11 August 2021 on the granting of a product specific waiver for ramipril / amlodipine / hydrochlorothiazide (EMEA- 002998-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-12T16:46:00Z","last_updated_date":"2022-09-12T16:46:00Z","reference_number":"EMA/427612/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-427612-2021-ema-decision-11-august-2021-granting-product-specific-waiver-ramipril-amlodipine-hydrochlorothiazide-emea-002998-pip01-21_en.pdf"},
    {"id":"56089","name":"P/0294/2021 : EMA decision of 11 August 2021 on the granting of a product specific waiver for aldafermin (EMEA-003005-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-13T09:47:00Z","last_updated_date":"2022-09-13T09:47:00Z","reference_number":"EMA/418764/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2021-ema-decision-11-august-2021-granting-product-specific-waiver-aldafermin-emea-003005-pip01-21_en.pdf"},
    {"id":"56090","name":"P/0289/2021 : EMA decision of 11 August 2021 on the granting of a product specific waiver for cetrelimab (EMEA-003006-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-13T10:30:00Z","last_updated_date":"2022-09-13T10:30:00Z","reference_number":"EMA/418766/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2021-ema-decision-11-august-2021-granting-product-specific-waiver-cetrelimab-emea-003006-pip01-21_en.pdf"},
    {"id":"56091","name":"P/0288/2021 : EMA decision of 13 August 2021 on the granting of a product specific waiver for gemcitabine (hydrochloride) (EMEA-003007-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-13T10:35:00Z","last_updated_date":"2022-09-13T10:35:00Z","reference_number":"EMA/384852/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2021-ema-decision-13-august-2021-granting-product-specific-waiver-gemcitabine-hydrochloride-emea-003007-pip01-21_en.pdf"},
    {"id":"56092","name":"P/0326/2021 : EMA decision of 13 August 2021 on the granting of a product specific waiver for sivopixant (EMEA-003010-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-13T10:41:00Z","last_updated_date":"2022-09-13T10:41:00Z","reference_number":"EMA/384970/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0326-2021-ema-decision-13-august-2021-granting-product-specific-waiver-sivopixant-emea-003010-pip01-21_en.pdf"},
    {"id":"56095","name":"P/0127/2022 : EMA decision of 13 April 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for abelacimab (EMEA-003017-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2022-09-14T11:39:00Z","last_updated_date":"2022-09-14T11:39:00Z","reference_number":"EMA/194423/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2022-ema-decision-13-april-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-abelacimab-emea-003017-pip01-21_en.pdf"},
    {"id":"57181","name":"P/0306/2021 : EMA decision of 14 September 2021 on the granting of a product specific waiver for empagliflozin (Jardiance), (EMEA-000828-PIP07-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-09T14:41:00Z","last_updated_date":"2023-01-09T14:41:00Z","reference_number":"EMA/517346/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2021-ema-decision-14-september-2021-granting-product-specific-waiver-empagliflozin-jardiance-emea-000828-pip07-21_en.pdf"},
    {"id":"57185","name":"P/0352/2021 : EMA decision of 8 September 2021 on the granting of a product specific waiver for florbetaben (18F) (Neuraceq), (EMEA-001090-PIP02- 21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-09T15:13:00Z","last_updated_date":"2023-01-09T15:13:00Z","reference_number":"EMA/470748/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0352-2021-ema-decision-8-september-2021-granting-product-specific-waiver-florbetaben-18f-neuraceq-emea-001090-pip02-21_en.pdf"},
    {"id":"57189","name":"P/0384/2021 : EMA decision of 8 September 2021 on the granting of a product specific waiver for atezolizumab (Tecentriq), (EMEA-001638-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-09T16:07:00Z","last_updated_date":"2023-01-09T16:07:00Z","reference_number":"EMA/440418/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0384-2021-ema-decision-8-september-2021-granting-product-specific-waiver-atezolizumab-tecentriq-emea-001638-pip02-21_en.pdf"},
    {"id":"57191","name":"P/0372/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ligelizumab (EMEA-001811-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-09T16:39:00Z","last_updated_date":"2023-01-09T16:39:00Z","reference_number":"EMA/463911/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0372-2021-ema-decision-8-september-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ligelizumab-emea-001811-pip03-20_en.pdf"},
    {"id":"57193","name":"P/0355/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ligelizumab (EMEA-001811-PIP04-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T10:44:00Z","last_updated_date":"2023-01-10T10:44:00Z","reference_number":"EMA/463911/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0355-2021-ema-decision-8-september-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ligelizumab-emea-001811-pip04-21_en.pdf"},
    {"id":"57196","name":"P/0399/2021 : EMA decision of 30 September 2021 on the agreement of a paediatric investigation plan and on the granting of a waiver for ravulizumab (Ultomiris), (EMEA-001943-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T11:40:00Z","last_updated_date":"2023-01-10T11:40:00Z","reference_number":"EMA/532125/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0399-2021-ema-decision-30-september-2021-agreement-paediatric-investigation-plan-granting-waiver-ravulizumab-ultomiris-emea-001943-pip02-20_en.pdf"},
    {"id":"57198","name":"P/0371/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for concizumab, (EMEA-002326-PIP04-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T12:14:00Z","last_updated_date":"2023-01-10T12:14:00Z","reference_number":"EMA/472068/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0371-2021-ema-decision-8-september-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-concizumab-emea-002326-pip04-20_en.pdf"},
    {"id":"57200","name":"P/0364/2021 : EMA decision of 8 September 2021 on the granting of a product specific waiver for selinexor (Nexpovio), (EMEA-002387-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T13:16:00Z","last_updated_date":"2023-01-10T13:16:00Z","reference_number":"EMA/440048/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0364-2021-ema-decision-8-september-2021-granting-product-specific-waiver-selinexor-nexpovio-emea-002387-pip02-21_en.pdf"},
    {"id":"57201","name":"P/0392/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efgartigimod alfa, (EMEA-002597-PIP05-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T14:12:00Z","last_updated_date":"2023-01-10T14:12:00Z","reference_number":"EMA/472072/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0392-2021-ema-decision-8-september-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-efgartigimod-alfa-emea-002597-pip05-21_en.pdf"},
    {"id":"57202","name":"P/0373/2021 : EMA decision of 8 September 2021on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for multivalent pneumococcal polysaccharide conjugate.... (SP0202) (EMEA-002780-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T14:25:00Z","last_updated_date":"2023-01-10T14:25:00Z","reference_number":"EMA/439664/2021 corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0373-2021-ema-decision-8-september-2021on-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-multivalent-pneumococcal-polysaccharide-conjugate-sp0202-emea-002780-pip02-20_en.pdf"},
    {"id":"57203","name":"P/0387/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for ribitol (EMEA- 002887-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T15:22:00Z","last_updated_date":"2023-01-10T15:22:00Z","reference_number":"EMA/471086/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0387-2021-ema-decision-8-september-2021-agreement-paediatric-investigation-plan-granting-deferral-ribitol-emea-002887-pip01-20_en.pdf"},
    {"id":"57205","name":"P/0391/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for single chain urokinase plasminogen activator (scuPA) (EMEA-002896-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-10T15:33:00Z","last_updated_date":"2023-01-10T15:33:00Z","reference_number":"EMA/464539/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0391-2021-ema-decision-8-september-2021-agreement-paediatric-investigation-plan-granting-deferral-single-chain-urokinase-plasminogen-activator-scupa-emea-002896-pip01-20_en.pdf"},
    {"id":"57209","name":"P/0378/2021 : EMA decision of 8 September 2021 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for L-lactic acid / citric acid / potassium bitartrate, (EMEA-002917-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-11T10:07:00Z","last_updated_date":"2023-01-11T10:07:00Z","reference_number":"EMA/472041/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0378-2021-ema-decision-8-september-2021-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-l-lactic-acid-citric-acid-potassium-bitartrate-emea-002917-pip01-20_en.pdf"},
    {"id":"57210","name":"P/0377/2021 : EMA decision of 2 September 2021 on the agreement of a paediatric investigation plan and on the granting of a waiver for 3,5-diamino-6- chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R,5R)....(P-1037 inhalation solution) (EMEA-002935-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-11T10:16:00Z","last_updated_date":"2023-01-11T10:16:00Z","reference_number":"EMA/440424/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0377-2021-ema-decision-2-september-2021-agreement-paediatric-investigation-plan-granting-waiver-35-diamino-6-chloro-n-n-4-4-2-hexyl2s3r4r5rp-1037-inhalation-solution-emea-002935-pip01-20_en.pdf"},
    {"id":"57211","name":"P/0359/2021 : EMA decision of 8 September 2021 on the granting of a product specific waiver for prasterone / levonorgestrel / ethinylestradiol (EMEA- 002960-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-11T10:25:00Z","last_updated_date":"2023-01-11T10:25:00Z","reference_number":"EMA/418722/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0359-2021-ema-decision-8-september-2021-granting-product-specific-waiver-prasterone-levonorgestrel-ethinylestradiol-emea-002960-pip02-21_en.pdf"},
    {"id":"57212","name":"P/0376/2021 : EMA decision of 8 September 2021 on the granting of a product specific waiver for prednisolone (EMEA-003004-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-11T10:36:00Z","last_updated_date":"2023-01-11T10:36:00Z","reference_number":"EMA/464761/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0376-2021-ema-decision-8-september-2021-granting-product-specific-waiver-prednisolone-emea-003004-pip01-21_en.pdf"},
    {"id":"57214","name":"P/0366/2021 : EMA decision of 8 September 2021 on the granting of a product specific waiver for indapamide / perindopril (arginine) / amlodipine / bisoprolol (fumarate) (EMEA-003015-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-11T12:13:00Z","last_updated_date":"2023-01-11T12:13:00Z","reference_number":"EMA/440421/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0366-2021-ema-decision-8-september-2021-granting-product-specific-waiver-indapamide-perindopril-arginine-amlodipine-bisoprolol-fumarate-emea-003015-pip01-21_en.pdf"},
    {"id":"57215","name":"P/0381/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a waiver for azithromycin (EMEA-003021-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-11T12:20:00Z","last_updated_date":"2023-01-11T12:20:00Z","reference_number":"EMA/464763/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0381-2021-ema-decision-8-september-2021-agreement-paediatric-investigation-plan-granting-waiver-azithromycin-emea-003021-pip01-21_en.pdf"},
    {"id":"57216","name":"P/0401/2021 : EMA decision of 30 September 2021 on the granting of a product specific waiver for 5’-capped mRNA encoding HPV16 oncoprotein E6 and E7 (EMEA-003023-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-11T13:21:00Z","last_updated_date":"2023-01-11T13:21:00Z","reference_number":"EMA/522104/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0401-2021-ema-decision-30-september-2021-granting-product-specific-waiver-5-capped-mrna-encoding-hpv16-oncoprotein-e6-e7-emea-003023-pip01-21_en.pdf"},
    {"id":"57217","name":"P/0354/2021 : EMA decision of 8 September 2021 on the granting of a product specific waiver for ociperlimab (EMEA-003028-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-11T13:33:00Z","last_updated_date":"2023-01-11T13:33:00Z","reference_number":"EMA/440077/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0354-2021-ema-decision-8-september-2021-granting-product-specific-waiver-ociperlimab-emea-003028-pip01-21_en.pdf"},
    {"id":"57227","name":"P/0385/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for eliglustat (Cerdelga), (EMEA-000461-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T09:09:00Z","last_updated_date":"2023-01-12T09:09:00Z","reference_number":"EMA/439703/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0385-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-eliglustat-cerdelga-emea-000461-pip02-11-m04_en.pdf"},
    {"id":"57228","name":"P/0358/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for amikacin (sulfate) (EMEA-000525-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T09:18:00Z","last_updated_date":"2023-01-12T09:18:00Z","reference_number":"EMA/439771/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0358-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-amikacin-sulfate-emea-000525-pip01-08-m07_en.pdf"},
    {"id":"57229","name":"P/0368/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (Bosulif), (000727-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T09:25:00Z","last_updated_date":"2023-01-12T09:25:00Z","reference_number":"EMA/PDCO/242956/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0368-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-bosutinib-bosulif-000727-pip01-09-m05_en.pdf"},
    {"id":"57231","name":"P/0356/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for rubidium (82Rb) chloride (Ruby-Fill (82Sr/82Rb Generator)), (EMEA-000882-PIP03-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T09:40:00Z","last_updated_date":"2023-01-12T09:40:00Z","reference_number":"EMA/471940/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0356-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-rubidium-82rb-chloride-ruby-fill-82sr-82rb-generator-emea-000882-pip03-11-m05_en.pdf"},
    {"id":"57232","name":"P/0386/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for brodalumab (Kyntheum), (EMEA-001089-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T10:02:00Z","last_updated_date":"2023-01-12T10:02:00Z","reference_number":"EMA/471935/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0386-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-brodalumab-kyntheum-emea-001089-pip02-13-m02_en.pdf"},
    {"id":"57250","name":"P/0397/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen / human thrombin (Evicel, Evarrest), (EMEA-001149-PIP01-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T11:13:00Z","last_updated_date":"2023-01-12T11:13:00Z","reference_number":"EMA/471932/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0397-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-human-thrombin-evicel-evarrest-emea-001149-pip01-11-m07_en.pdf"},
    {"id":"57251","name":"P/0383/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tolvaptan (Samsca and associated names), (EMEA-001231-PIP02-13-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T11:24:00Z","last_updated_date":"2023-01-12T11:24:00Z","reference_number":"EMA/471937/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0383-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-tolvaptan-samsca-associated-names-emea-001231-pip02-13-m08_en.pdf"},
    {"id":"57252","name":"P/0390/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for naltrexone (hydrochloride) / bupropion (hydrochloride) (Mysimba), (EMEA-001373-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T11:36:00Z","last_updated_date":"2023-01-12T11:36:00Z","reference_number":"EMA/440399/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0390-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-naltrexone-hydrochloride-bupropion-hydrochloride-mysimba-emea-001373-pip01-12-m04_en.pdf"},
    {"id":"57253","name":"P/0369/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant parathyroid hormone (Natpar), (EMEA-001526-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T11:45:00Z","last_updated_date":"2023-01-12T11:45:00Z","reference_number":"EMA/440401/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0369-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-parathyroid-hormone-natpar-emea-001526-pip01-13-m05_en.pdf"},
    {"id":"57256","name":"P/0406/2021 : EMA decision of 30 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tezacaftor / ivacaftor (Symkevi), (EMEA-001640-PIP01-14-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T13:34:00Z","last_updated_date":"2023-01-12T13:34:00Z","reference_number":"EMA/521972/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0406-2021-ema-decision-30-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-tezacaftor-ivacaftor-symkevi-emea-001640-pip01-14-m07_en.pdf"},
    {"id":"57257","name":"P/0389/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for metreleptin (Myalepta), (EMEA-001701-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T13:41:00Z","last_updated_date":"2023-01-12T13:41:00Z","reference_number":"EMA/418723/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0389-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-metreleptin-myalepta-emea-001701-pip01-14-m02_en.pdf"},
    {"id":"57258","name":"P/0367/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for patiromer calcium (Veltassa), (EMEA-001720-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T13:47:00Z","last_updated_date":"2023-01-12T13:47:00Z","reference_number":"EMA/418749/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0367-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-patiromer-calcium-veltassa-emea-001720-pip01-14-m02_en.pdf"},
    {"id":"57260","name":"P/0362/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for indacaterol (acetate)/glycopyrronium (bromide)/mometasone (furoate) (Enerzair Breezhaler and...)(EMEA-001812-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T13:55:00Z","last_updated_date":"2023-01-12T13:55:00Z","reference_number":"EMA/418750/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0362-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-indacaterol-acetate-glycopyrronium-bromide-mometasone-furoate-enerzair-breezhaler-andemea-001812_en.pdf"},
    {"id":"57261","name":"P/0379/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for naldemedine (EMEA-001893-PIP01-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T14:13:00Z","last_updated_date":"2023-01-12T14:13:00Z","reference_number":"EMA/464452/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0379-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-naldemedine-emea-001893-pip01-15-m02_en.pdf"},
    {"id":"57262","name":"P/0360/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for avalglucosidase alfa (EMEA-001945-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T14:24:00Z","last_updated_date":"2023-01-12T14:24:00Z","reference_number":"EMA/418754/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0360-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-avalglucosidase-alfa-emea-001945-pip01-16-m03_en.pdf"},
    {"id":"57263","name":"P/0365/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for mexiletine (hydrochloride) (Namuscla), (EMEA-002012-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T14:33:00Z","last_updated_date":"2023-01-12T14:33:00Z","reference_number":"EMA/418757/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0365-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-mexiletine-hydrochloride-namuscla-emea-002012-pip01-16-m03_en.pdf"},
    {"id":"57264","name":"P/0351/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for entrectinib (Rozlytrek), (EMEA-002096-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T14:38:00Z","last_updated_date":"2023-01-12T14:38:00Z","reference_number":"EMA/418758/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0351-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-entrectinib-rozlytrek-emea-002096-pip01-16-m03_en.pdf"},
    {"id":"57265","name":"P/0374/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant Clostridioides difficile toxoid A / recombinant Clostridioides difficile toxoid B (EMEA-002112-PIP01-16- M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-12T14:44:00Z","last_updated_date":"2023-01-12T14:44:00Z","reference_number":"EMA/470764/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0374-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-clostridioides-difficile-toxoid-recombinant-clostridioides-difficile-toxoid-b-emea_en.pdf"},
    {"id":"57272","name":"P/0394/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for solriamfetol (EMEA- 002184-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-13T10:52:00Z","last_updated_date":"2023-01-13T10:52:00Z","reference_number":"EMA/470765/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0394-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-solriamfetol-emea-002184-pip01-17-m01_en.pdf"},
    {"id":"57273","name":"P/0393/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dasiglucagon (EMEA- 002233-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-13T11:05:00Z","last_updated_date":"2023-01-13T11:05:00Z","reference_number":"EMA/470766/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0393-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-dasiglucagon-emea-002233-pip01-17-m01_en.pdf"},
    {"id":"57280","name":"P/0350/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for aztreonam (ATM)/  avibactam (AVI) , (EMEA-002283-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-13T15:08:00Z","last_updated_date":"2023-01-13T15:08:00Z","reference_number":"EMA/471941/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0350-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-aztreonam-atm-avibactam-avi-emea-002283-pip01-17-m02_en.pdf"},
    {"id":"57281","name":"P/0395/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for rezafungin acetate (EMEA-002319-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-13T15:17:00Z","last_updated_date":"2023-01-13T15:17:00Z","reference_number":"EMA/440414/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0395-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-rezafungin-acetate-emea-002319-pip01-17-m01_en.pdf"},
    {"id":"57283","name":"EMA/470768/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for Pneumococcal Polyssacharide Serotype 6A conjugated to CRM197 carrier protein.....(EMEA- 002330-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-13T15:42:00Z","last_updated_date":"2023-01-13T15:42:00Z","reference_number":"EMA/470768/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-470768-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-pneumococcal-polyssacharide-serotype-6a-conjugated-crm197-carrier-proteinemea-002330-pip01-18_en.pdf"},
    {"id":"57284","name":"P/0382/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for fidanacogene elaparvovec (EMEA-002362-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-13T15:51:00Z","last_updated_date":"2023-01-13T15:51:00Z","reference_number":"EMA/464308/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0382-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-fidanacogene-elaparvovec-emea-002362-pip02-19-m01_en.pdf"},
    {"id":"57285","name":"P/0353/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for berotralstat (EMEA-002449-PIP02-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-13T16:05:00Z","last_updated_date":"2023-01-13T16:05:00Z","reference_number":"EMA/464380/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0353-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-berotralstat-emea-002449-pip02-18-m01_en.pdf"},
    {"id":"57286","name":"P/0370/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for narsoplimab (EMEA-002479-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-13T16:12:00Z","last_updated_date":"2023-01-13T16:12:00Z","reference_number":"EMA/464468/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0370-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-narsoplimab-emea-002479-pip01-18-m01_en.pdf"},
    {"id":"57287","name":"P/0398/2021 : EMA decision of 30 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for selpercatinib (Retsevmo), (EMEA-002544-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-13T16:20:00Z","last_updated_date":"2023-01-13T16:20:00Z","reference_number":"EMA/531413/2021 corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0398-2021-ema-decision-30-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-selpercatinib-retsevmo-emea-002544-pip01-18-m01_en.pdf"},
    {"id":"57288","name":"P/0363/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for autologous tumourinfiltrating lymphocytes (LN-144/LN-145) (EMEA-002776-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-13T16:27:00Z","last_updated_date":"2023-01-13T16:27:00Z","reference_number":"EMA/439884/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0363-2021-ema-decision-8-september-2021-acceptance-modification-agreed-paediatric-investigation-plan-autologous-tumourinfiltrating-lymphocytes-ln-144-ln-145-emea-002776-pip01-20-m01_en.pdf"},
    {"id":"57328","name":"P/0071/2022 : EMA decision of 11 March 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (14S)-8-[3-(2-{dispiro[2.0.2^(4).1^(3)]heptan-7-yl}ethoxy).....(EMEA-003052-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-01-19T11:36:00Z","last_updated_date":"2023-01-19T11:36:00Z","reference_number":"EMA/71025/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2022-ema-decision-11-march-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-14s-8-3-2-dispiro202413heptan-7-ylethoxyemea-003052-pip01-21_en.pdf"},
    {"id":"57496","name":"P/0477/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for sodium zirconium cyclosilicate (Lokelma) (EMEA-001539-PIP01-13-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-01T17:46:00Z","last_updated_date":"2023-02-01T17:46:00Z","reference_number":"EMA/627439/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0477-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-sodium-zirconium-cyclosilicate-lokelma-emea-001539-pip01-13-m05_en.pdf"},
    {"id":"57607","name":"P/0466/2021: EMA decision of 29 October 2021 on the refusal of a product specific waiver for tocilizumab (RoActemra), (EMEA-000309-PIP06-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-10T14:47:00Z","last_updated_date":"2023-02-10T14:47:00Z","reference_number":"EMA/535247/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0466-2021-ema-decision-29-october-2021-refusal-product-specific-waiver-tocilizumab-roactemra-emea-000309-pip06-21_en.pdf"},
    {"id":"57608","name":"P/0464/2021: EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for semaglutide (Ozempic), (EMEA-001441-PIP05-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-10T15:04:00Z","last_updated_date":"2023-02-10T15:04:00Z","reference_number":"EMA/532235/2021 corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0464-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-semaglutide-ozempic-emea-001441-pip05-20_en.pdf"},
    {"id":"57613","name":"P/0429/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP, live) (Ervebo) (EMEA-001786-PIP01-15-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T11:25:00Z","last_updated_date":"2023-02-13T11:25:00Z","reference_number":"EMA/550224/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0429-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-ebola-zaire-vaccine-rvsvdg-zebov-gp-live-ervebo-emea-001786-pip01-15-m02_en.pdf"},
    {"id":"57614","name":"P/0447/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for oxalobacter formigenes strain HC-1 (EMEA-000370-PIP02-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T11:23:00Z","last_updated_date":"2023-02-13T11:23:00Z","reference_number":"EMA/534531/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0447-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-oxalobacter-formigenes-strain-hc-1-emea-000370-pip02-18-m01_en.pdf"},
    {"id":"57615","name":"P/0408/2021: EMA decision of 8 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for acalabrutinib (Calquence) (EMEA-001796-PIP03-16-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T11:46:00Z","last_updated_date":"2023-02-13T11:46:00Z","reference_number":"EMA/554972/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0408-2021-ema-decision-8-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-acalabrutinib-calquence-emea-001796-pip03-16-m02_en.pdf"},
    {"id":"57616","name":"P/0446/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T11:58:00Z","last_updated_date":"2023-02-13T11:58:00Z","reference_number":"EMA/534672/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0446-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-linagliptin-trajenta-emea-000498-pip01-08-m10_en.pdf"},
    {"id":"57617","name":"P/0449/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for galcanezumab (Emgality), (EMEA-001860-PIP03-16-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T12:03:00Z","last_updated_date":"2023-02-13T12:03:00Z","reference_number":"EMA/582624/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0449-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-galcanezumab-emgality-emea-001860-pip03-16-m06_en.pdf"},
    {"id":"57618","name":"P/0402/2021: EMA decision of 1 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga) (EMEA-000597-PIP03-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T12:06:00Z","last_updated_date":"2023-02-13T12:06:00Z","reference_number":"EMA/535188/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0402-2021-ema-decision-1-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip03-15-m04_en.pdf"},
    {"id":"57620","name":"P/0441/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human glutamic acid decarboxylase (rhGAD65) (EMEA-000609-PIP01-09-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T12:13:00Z","last_updated_date":"2023-02-13T12:13:00Z","reference_number":"EMA/534827/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0441-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-glutamic-acid-decarboxylase-rhgad65-emea-000609-pip01-09-m03_en.pdf"},
    {"id":"57621","name":"P/0427/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for remimazolam (as besylate), (Byfavo), (EMEA-001880-PIP02-19-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T12:17:00Z","last_updated_date":"2023-02-13T12:17:00Z","reference_number":"EMA/550332/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0427-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-remimazolam-besylate-byfavo-emea-001880-pip02-19-m03_en.pdf"},
    {"id":"57623","name":"P/0411/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for rosuvastatin / ezetimibe (Rosuvastatin/ezetimibe EGIS and associated names), (EMEA-001447-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T12:23:00Z","last_updated_date":"2023-02-13T12:23:00Z","reference_number":"EMA/535334/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0411-2021-ema-decision-29-october-2021-granting-product-specific-waiver-rosuvastatin-ezetimibe-rosuvastatin-ezetimibe-egis-associated-names-emea-001447-pip02-21_en.pdf"},
    {"id":"57624","name":"P/0412/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for leriglitazone (EMEA-002106-PIP01-16-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T12:24:00Z","last_updated_date":"2023-02-13T12:24:00Z","reference_number":"EMA/550544/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0412-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-leriglitazone-emea-002106-pip01-16-m01_en.pdf"},
    {"id":"57625","name":"P/0409/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity), (EMEA-000783-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T12:27:00Z","last_updated_date":"2023-02-13T12:27:00Z","reference_number":"EMA/535222/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0409-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-dulaglutide-trulicity-emea-000783-pip01-09-m06_en.pdf"},
    {"id":"57626","name":"P/0450/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for drospirenone (Slinda and associated names), (EMEA- 001495-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T12:33:00Z","last_updated_date":"2023-02-13T12:33:00Z","reference_number":"EMA/533719/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0450-2021-ema-decision-29-october-2021-granting-product-specific-waiver-drospirenone-slinda-associated-names-emea-001495-pip02-21_en.pdf"},
    {"id":"57627","name":"P/0423/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for edoxaban (tosylate) (Lixiana), (EMEA-000788-PIP02-11-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T12:35:00Z","last_updated_date":"2023-02-13T12:35:00Z","reference_number":"P/0423/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0423-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-edoxaban-tosylate-lixiana-emea-000788-pip02-11-m11_en.pdf"},
    {"id":"57628","name":"P/0426/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for palbociclib (Ibrance) (EMEA-002146-PIP01-17-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T12:40:00Z","last_updated_date":"2023-02-13T12:40:00Z","reference_number":"EMA/550398/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0426-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-palbociclib-ibrance-emea-002146-pip01-17-m03_en.pdf"},
    {"id":"57629","name":"P/0405/2021: EMA decision of 1 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for brigatinib (Alunbrig), (EMEA-002296-PIP01-17-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T12:46:00Z","last_updated_date":"2023-02-13T12:46:00Z","reference_number":"EMA/532839/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0405-2021-ema-decision-1-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-brigatinib-alunbrig-emea-002296-pip01-17-m03_en.pdf"},
    {"id":"57630","name":"P/0416/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for elexacaftor / tezacaftor / ivacaftor (Kaftrio), (EMEA-002324-PIP01-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T12:57:00Z","last_updated_date":"2023-02-13T12:57:00Z","reference_number":"EMA/533018/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0416-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-elexacaftor-tezacaftor-ivacaftor-kaftrio-emea-002324-pip01-17-m02_en.pdf"},
    {"id":"57631","name":"P/0404/2021: EMA decision of 1 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ganaxolone ,(EMEA- 002341-PIP01-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T13:05:00Z","last_updated_date":"2023-02-13T13:05:00Z","reference_number":"EMA/533199/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0404-2021-ema-decision-1-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-ganaxolone-emea-002341-pip01-18-m02_en.pdf"},
    {"id":"57632","name":"P/0440/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for Abemaciclib (Verzenios), (EMEA-002342-PIP01-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T13:12:00Z","last_updated_date":"2023-02-13T13:12:00Z","reference_number":"EMA/533306/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0440-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-abemaciclib-verzenios-emea-002342-pip01-18-m02_en.pdf"},
    {"id":"57633","name":"P/0410/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for doxylamine (succinate) / pyridoxine (hydrochloride) (Xonvea), (EMEA-001608-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T13:15:00Z","last_updated_date":"2023-02-13T13:15:00Z","reference_number":"EMA/533708/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0410-2021-ema-decision-29-october-2021-granting-product-specific-waiver-doxylamine-succinate-pyridoxine-hydrochloride-xonvea-emea-001608-pip02-21_en.pdf"},
    {"id":"57634","name":"P/0439/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for abemaciclib (Verzenios), (EMEA-002342-PIP02-18-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T13:18:00Z","last_updated_date":"2023-02-13T13:18:00Z","reference_number":"EMA/533513/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0439-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-abemaciclib-verzenios-emea-002342-pip02-18-m01_en.pdf"},
    {"id":"57635","name":"P/0460/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for oteseconazole (EMEA-002392-PIP01-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T13:25:00Z","last_updated_date":"2023-02-13T13:25:00Z","reference_number":"EMA/532345/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0460-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-oteseconazole-emea-002392-pip01-18-m02_en.pdf"},
    {"id":"57636","name":"P/0418/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for temozolomide (EMEA-002634-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T13:33:00Z","last_updated_date":"2023-02-13T13:33:00Z","reference_number":"EMA/532380/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0418-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-temozolomide-emea-002634-pip01-19-m01_en.pdf"},
    {"id":"57637","name":"P/0413/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for ravulizumab (Ultomiris), (EMEA-001943-PIP05-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T13:29:00Z","last_updated_date":"2023-02-13T13:29:00Z","reference_number":"EMA/535289/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0413-2021-ema-decision-29-october-2021-granting-product-specific-waiver-ravulizumab-ultomiris-emea-001943-pip05-21_en.pdf"},
    {"id":"57638","name":"P/0424/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for imatinib (as imatinib mesylate) (EMEA-002643-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T13:40:00Z","last_updated_date":"2023-02-13T13:40:00Z","reference_number":"EMA/532461/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0424-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-imatinib-imatinib-mesylate-emea-002643-pip01-19-m01_en.pdf"},
    {"id":"57639","name":"P/0458/2021 : EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pritelivir (mesylate monohydrate), (EMEA-002180-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T13:44:00Z","last_updated_date":"2023-02-13T13:44:00Z","reference_number":"EMA/533747/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0458-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pritelivir-mesylate-monohydrate-emea-002180-pip02-19_en.pdf-0"},
    {"id":"57640","name":"P/0458/2021 : EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pritelivir (mesylate monohydrate), (EMEA-002180-PIP02-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T13:44:00Z","last_updated_date":"2023-02-13T13:44:00Z","reference_number":"EMA/533747/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0458-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pritelivir-mesylate-monohydrate-emea-002180-pip02-19_en.pdf"}    {"id":"57641","name":"P/0442/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for fluocinolone acetonide (EMEA-000801-PIP03-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T13:53:00Z","last_updated_date":"2023-02-13T13:53:00Z","reference_number":"EMA/568167/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0442-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-fluocinolone-acetonide-emea-000801-pip03-16-m01_en.pdf"},
    {"id":"57642","name":"P/0419/2021 / EMA decision of 29 October 2021 on the granting of a product specific waiver for anti-neonatal Fc receptor human monoclonal antibody (EMEA-002559-PIP04-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T14:01:00Z","last_updated_date":"2023-02-13T14:01:00Z","reference_number":"EMA/535273/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0419-2021-ema-decision-29-october-2021-granting-product-specific-waiver-anti-neonatal-fc-receptor-human-monoclonal-antibody-emea-002559-pip04-21_en.pdf"},
    {"id":"57644","name":"P/0428/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for pralsetinib (EMEA-002575-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T14:32:00Z","last_updated_date":"2023-02-13T14:32:00Z","reference_number":"EMA/531488/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0428-2021-ema-decision-29-october-2021-granting-product-specific-waiver-pralsetinib-emea-002575-pip03-21_en.pdf"},
    {"id":"57645","name":"P/0443/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for efgartigimod alfa (EMEA-002597-PIP06-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T14:54:00Z","last_updated_date":"2023-02-13T14:54:00Z","reference_number":"EMA/531663/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0443-2021-ema-decision-29-october-2021-granting-product-specific-waiver-efgartigimod-alfa-emea-002597-pip06-21_en.pdf"},
    {"id":"57646","name":"P/0283/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for empagliflozin (Jardiance) (EMEA-000828-PIP01-09-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T15:09:00Z","last_updated_date":"2023-02-13T15:09:00Z","reference_number":"EMA/568637/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-empagliflozin-jardiance-emea-000828-pip01-09-m09_en.pdf"},
    {"id":"57647","name":"P/0470/2021: EMA decision of 26 November 2021 on the acceptance of a modification of an agreed paediatric investigation plan for risdiplam (Everysdi) (EMEA-002070-PIP01-16-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T15:10:00Z","last_updated_date":"2023-02-13T15:10:00Z","reference_number":"EMA/690024/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0470-2021-ema-decision-26-november-2021-acceptance-modification-agreed-paediatric-investigation-plan-risdiplam-everysdi-emea-002070-pip01-16-m06_en.pdf"},
    {"id":"57648","name":"P/0438/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for nintedanib (Ofev, Vargatef), (EMEA-001006-PIP05-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T15:16:00Z","last_updated_date":"2023-02-13T15:16:00Z","reference_number":"EMA/568301/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0438-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-nintedanib-ofev-vargatef-emea-001006-pip05-18-m01_en.pdf"},
    {"id":"57649","name":"P/0414/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human A disintegrin and metalloprotease with thrombospondin type-1 motifs 13 (EMEA-001160-PIP01-11- M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T15:25:00Z","last_updated_date":"2023-02-13T15:25:00Z","reference_number":"EMA/568463/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0414-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-disintegrin-metalloprotease-thrombospondin-type-1-motifs-13-emea-001160-pip01-11_en.pdf"},
    {"id":"57650","name":"P/0468/2021: EMA decision of 12 November 2021 on the acceptance of a modification of an agreed paediatric investigation plan for sotrovimab (EMEA-002899-PIP01-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T15:25:00Z","last_updated_date":"2023-02-13T15:25:00Z","reference_number":"EMA/627431/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0468-2021-ema-decision-12-november-2021-acceptance-modification-agreed-paediatric-investigation-plan-sotrovimab-emea-002899-pip01-20-m01_en.pdf"},
    {"id":"57651","name":"P/0461/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (Ozempic) (EMEA-001441-PIP03-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T15:32:00Z","last_updated_date":"2023-02-13T15:32:00Z","reference_number":"EMA/521852/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0461-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-semaglutide-ozempic-emea-001441-pip03-17-m02_en.pdf"},
    {"id":"57652","name":"P/0430/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for fostemsavir (tromethamine) (EMEA-001687-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T15:41:00Z","last_updated_date":"2023-02-13T15:41:00Z","reference_number":"EMA/522008/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0430-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-fostemsavir-tromethamine-emea-001687-pip01-14-m05_en.pdf"},
    {"id":"57653","name":"P/0415/2021: EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod (hydrochloride) (Zeposia) (EMEA-001710-PIP02-14-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-13T15:49:00Z","last_updated_date":"2023-02-13T15:49:00Z","reference_number":"EMA/522035/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0415-2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan-ozanimod-hydrochloride-zeposia-emea-001710-pip02-14-m06_en.pdf"},
    {"id":"57659","name":"P/0021/2022 : EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for poly(oxy-1,2- ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1....(EMEA-002955-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T11:48:00Z","last_updated_date":"2023-02-14T11:48:00Z","reference_number":"EMA/8320/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-polyoxy-12-ethanediyl-alpha-hydro-omega-methoxy-ether-n-2-6-1emea-002955-pip01-21_en.pdf"},
    {"id":"57666","name":"P/0400/2021 : EMA decision of 1 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for loncastuximab tesirine (EMEA-002665-PIP02-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T17:08:00Z","last_updated_date":"2023-02-14T17:08:00Z","reference_number":"EMA/532643/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0400-2021-ema-decision-1-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-loncastuximab-tesirine-emea-002665-pip02-20_en.pdf"},
    {"id":"57667","name":"P/0457/2021 : EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for liveattenuated La Reunion strain of chikungunya virus (VLA1553) (EMEA-002873-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T17:19:00Z","last_updated_date":"2023-02-14T17:19:00Z","reference_number":"EMA/582972/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0457-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-liveattenuated-la-reunion-strain-chikungunya-virus-vla1553-emea-002873-pip01-20_en.pdf"},
    {"id":"57668","name":"P/0456/2021 : EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for respiratory syncytial virus (RSV)... (EMEA-002904-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T17:27:00Z","last_updated_date":"2023-02-14T17:27:00Z","reference_number":"EMA/530441/2021 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0456-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-respiratory-syncytial-virus-rsv-emea-002904-pip01-20_en.pdf"},
    {"id":"57669","name":"P/0454/2021 : EMA decision of of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adalimumab... (ABBV- 154) (EMEA-002927-PIP01-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T17:55:00Z","last_updated_date":"2023-02-14T17:55:00Z","reference_number":"EMA/532352/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0454-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-adalimumab-abbv-154-emea-002927-pip01-20_en.pdf"},
    {"id":"57730","name":"P/0435/2021: EMA decision of 22 November 2021 on the refusal of a product-specific waiver for perflubutane (EMEA-003037-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T11:57:00Z","last_updated_date":"2023-02-20T11:57:00Z","reference_number":"EMA/648358/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0435-2021-ema-decision-22-november-2021-refusal-product-specific-waiver-perflubutane-emea-003037-pip01-21_en.pdf"},
    {"id":"57733","name":"P/0469/2021: EMA decision of 19 November 2021 on the granting of a product-specific waiver for rosuvastatin / ezetimibe (EMEA-003039-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T12:12:00Z","last_updated_date":"2023-02-20T12:12:00Z","reference_number":"EMA/533611/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0469-2021-ema-decision-19-november-2021-granting-product-specific-waiver-rosuvastatin-ezetimibe-emea-003039-pip01-21_en.pdf"},
    {"id":"57734","name":"P/0444/2021: EMA decision of 22 November 2021 on the acceptance of a modification of an agreed paediatric investigation plan for single-stranded, 5’- capped messenger RNA (mRNA) ... (EMEA- 002893-PIP01-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-20T12:41:00Z","last_updated_date":"2023-02-20T12:41:00Z","reference_number":"EMA/532503/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0444-2021-ema-decision-22-november-2021-acceptance-modification-agreed-paediatric-investigation-plan-single-stranded-5-capped-messenger-rna-mrna-emea-002893-pip01-20-m01_en.pdf"},
    {"id":"57737","name":"P/0459/2021  EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Thienopyrimidine Derivative (EMEA-002901-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T15:10:00Z","last_updated_date":"2023-02-20T15:10:00Z","reference_number":"EMA/510195/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0459-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-thienopyrimidine-derivative-emea-002901-pip01-20_en.pdf"},
    {"id":"57740","name":"P/0434/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for anti-C1s humanized IgG4 monoclonal antibody (EMEA-002903-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T15:31:00Z","last_updated_date":"2023-02-20T15:31:00Z","reference_number":"P/0434/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0434-2021-ema-decision-29-october-2021-granting-product-specific-waiver-anti-c1s-humanized-igg4-monoclonal-antibody-emea-002903-pip03-21_en.pdf"},
    {"id":"57741","name":"P/0453/2021 : EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for crisantaspase (EMEA-002934-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T15:50:00Z","last_updated_date":"2023-02-20T15:50:00Z","reference_number":"EMA/535417/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0453-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-crisantaspase-emea-002934-pip01-20_en.pdf"},
    {"id":"57742","name":"P/0407/2021 : EMA decision of 8 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for islatravir (EMEA-002938-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T16:02:00Z","last_updated_date":"2023-02-20T16:02:00Z","reference_number":"EMA/549068/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0407-2021-ema-decision-8-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-islatravir-emea-002938-pip01-20_en.pdf"},
    {"id":"57743","name":"P/0452/2021 : EMA decision of  29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver...(EMEA-002944-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T16:27:00Z","last_updated_date":"2023-02-20T16:27:00Z","reference_number":"EMA/521826/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0452-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiveremea-002944-pip01-20_en.pdf"},
    {"id":"57744","name":"P/0437/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide (EMEA-002957-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T16:39:00Z","last_updated_date":"2023-02-20T16:39:00Z","reference_number":"EMA/532591/2021 Corr1","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0437-2021-ema-decision-29-october-2021-granting-product-specific-waiver-humanized-monoclonal-antibody-igg1-sub-type-targeting-human-sema3a-polypeptide-emea-002957-pip02-21_en.pdf"},
    {"id":"57745","name":"P/0465/2021 : EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for AZD8233 sodium, PCSK9-targeted, antisense oligonucleotide (ASO) (EMEA-002962-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T16:49:00Z","last_updated_date":"2023-02-20T16:49:00Z","reference_number":"EMA/509375/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0465-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-azd8233-sodium-pcsk9-targeted-antisense-oligonucleotide-aso-emea-002962-pip01-21_en.pdf"},
    {"id":"57746","name":"P/0462/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for bemnifosbuvir (EMEA-002963-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T16:57:00Z","last_updated_date":"2025-03-06T12:33:00Z","reference_number":"EMA/526334/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0462-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-bemnifosbuvir-emea-002963-pip01-21-m01_en.pdf"},
    {"id":"57747","name":"P/0450/2021 : EMA decision of 29 October 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for terbinafine (hydrochloride) (EMEA-002984-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T17:18:00Z","last_updated_date":"2023-02-20T17:18:00Z","reference_number":"EMA/535477/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0450-2021-ema-decision-29-october-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-terbinafine-hydrochloride-emea-002984-pip01-21_en.pdf"},
    {"id":"57748","name":"P/0462/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for rosuvastatin / ezetimibe (EMEA-003018-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T17:34:00Z","last_updated_date":"2023-02-20T17:34:00Z","reference_number":"EMA/522065/2021 Corr1","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0462-2021-ema-decision-29-october-2021-granting-product-specific-waiver-rosuvastatin-ezetimibe-emea-003018-pip01-21_en.pdf"},
    {"id":"57749","name":"P/0448/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for dexamethasone (sodium phosphate) / ofloxacin (EMEA-003031-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T17:48:00Z","last_updated_date":"2023-02-20T17:48:00Z","reference_number":"EMA/522267/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0448-2021-ema-decision-29-october-2021-granting-product-specific-waiver-dexamethasone-sodium-phosphate-ofloxacin-emea-003031-pip01-21_en.pdf"},
    {"id":"57750","name":"P/0445/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for senaparib (EMEA-003034-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T17:57:00Z","last_updated_date":"2023-02-20T17:57:00Z","reference_number":"EMA/579228/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0445-2021-ema-decision-29-october-2021-granting-product-specific-waiver-senaparib-emea-003034-pip01-21_en.pdf"},
    {"id":"57759","name":"P/0230/2022 : EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for delandistrogene moxeparvovec (EMEA-002677-PIP01-19-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-21T13:13:00Z","last_updated_date":"2023-02-21T13:13:00Z","reference_number":"EMA/575567/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-delandistrogene-moxeparvovec-emea-002677-pip01-19-m02_en.pdf"},
    {"id":"57760","name":"P/0144/2022 : EMA decision of 13 April 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H5N1 (EMEA-002869-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-02-21T13:24:00Z","last_updated_date":"2023-02-21T13:24:00Z","reference_number":"EMA/194390/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2022-ema-decision-13-april-2022-agreement-paediatric-investigation-plan-granting-deferral-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h5n1-emea-002869-pip01-21_en.pdf"},
    {"id":"57766","name":"P/0436/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for zofenopril (calcium) / amlodipine (EMEA-003036-PIP01- 21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T17:16:00Z","last_updated_date":"2023-02-21T17:16:00Z","reference_number":"EMA/579064/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0436-2021-ema-decision-29-october-2021-granting-product-specific-waiver-zofenopril-calcium-amlodipine-emea-003036-pip01-21_en.pdf"},
    {"id":"57767","name":"P/0436/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for zofenopril (calcium) / amlodipine (EMEA-003036-PIP01- 21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T17:16:00Z","last_updated_date":"2023-02-21T17:16:00Z","reference_number":"EMA/579064/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0436-2021-ema-decision-29-october-2021-granting-product-specific-waiver-zofenopril-calcium-amlodipine-emea-003036-pip01-21_en.pdf-0"},
    {"id":"57768","name":"P/0433/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for lutetium (177Lu) chloride (EMEA-003038-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T17:25:00Z","last_updated_date":"2023-02-21T17:25:00Z","reference_number":"EMA/533549/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0433-2021-ema-decision-29-october-2021-granting-product-specific-waiver-lutetium-177lu-chloride-emea-003038-pip01-21_en.pdf"},
    {"id":"57769","name":"P/0432/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for izaflortaucipir (18F) (EMEA-003040-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T17:35:00Z","last_updated_date":"2023-02-21T17:35:00Z","reference_number":"EMA/533649/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0432-2021-ema-decision-29-october-2021-granting-product-specific-waiver-izaflortaucipir-18f-emea-003040-pip01-21_en.pdf"},
    {"id":"57770","name":"P/0431/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for batiraxcept, (EMEA-003042-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T17:47:00Z","last_updated_date":"2023-02-21T17:47:00Z","reference_number":"EMA/532612/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0431-2021-ema-decision-29-october-2021-granting-product-specific-waiver-batiraxcept-emea-003042-pip01-21_en.pdf"},
    {"id":"57771","name":"P/0425/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for anti-CD123 IgG1 humanised monoclonal antibody conjugated... (EMEA-003044- PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-21T17:50:00Z","last_updated_date":"2023-02-21T17:50:00Z","reference_number":"EMA/532708/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0425-2021-ema-decision-29-october-2021-granting-product-specific-waiver-anti-cd123-igg1-humanised-monoclonal-antibody-conjugated-emea-003044-pip01-21_en.pdf"},
    {"id":"57781","name":"P/0422/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for rusfertide, (EMEA-003045-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-22T11:27:00Z","last_updated_date":"2023-02-22T11:27:00Z","reference_number":"EMA/532881/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0422-2021-ema-decision-29-october-2021-granting-product-specific-waiver-rusfertide-emea-003045-pip01-21_en.pdf"},
    {"id":"57782","name":"P/0421/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for alnuctamab, (EMEA-003046-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-22T11:43:00Z","last_updated_date":"2023-02-22T11:43:00Z","reference_number":"EMA/532959/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0421-2021-ema-decision-29-october-2021-granting-product-specific-waiver-alnuctamab-emea-003046-pip01-21_en.pdf"},
    {"id":"57783","name":"P/0420/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for B cell maturation antigen antibody-drug conjugate comprised of an immunoglobulin G1 humanized antibody conjugated... (EMEA-003047-PIP01- 21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-22T11:43:00Z","last_updated_date":"2023-02-22T11:43:00Z","reference_number":"EMA/532999/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0420-2021-ema-decision-29-october-2021-granting-product-specific-waiver-b-cell-maturation-antigen-antibody-drug-conjugate-comprised-immunoglobulin-g1-humanized-antibody-conjugated-emea-003047-pip01_en.pdf"},
    {"id":"57790","name":"P/0467/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for pyridine-3-carboxamide derivative (K-161) (EMEA- 003048-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-22T12:45:00Z","last_updated_date":"2023-02-22T12:45:00Z","reference_number":"EMA/533713/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0467-2021-ema-decision-29-october-2021-granting-product-specific-waiver-pyridine-3-carboxamide-derivative-k-161-emea-003048-pip01-21_en.pdf"},
    {"id":"57791","name":"P/0417/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for depemokimab (EMEA-003051-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-22T12:55:00Z","last_updated_date":"2023-02-22T12:55:00Z","reference_number":"EMA/522277/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0417-2021-ema-decision-29-october-2021-granting-product-specific-waiver-depemokimab-emea-003051-pip01-21_en.pdf"},
    {"id":"57792","name":"P/0036/2022 : EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tildacerfont (EMEA-002970-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-02-22T14:03:00Z","last_updated_date":"2023-02-22T14:03:00Z","reference_number":"EMA/9505/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tildacerfont-emea-002970-pip01-21_en.pdf"},
    {"id":"57858","name":"P/0544/2021 : EMA decision of 31 December 2021 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for plitidepsin (EMEA-000095-PIP02-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-03-02T10:04:00Z","last_updated_date":"2023-03-02T10:04:00Z","reference_number":"EMA/709690/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0544-2021-ema-decision-31-december-2021-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-plitidepsin-emea-000095-pip02-21_en.pdf"},
    {"id":"57859","name":"P/0560/2021 : EMA decision of 31 December 2021 on the granting of a product specific waiver for secukinumab (Cosentyx), (EMEA-000380-PIP08-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-02T10:45:00Z","last_updated_date":"2023-03-02T10:45:00Z","reference_number":"EMA/649533/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0560-2021-ema-decision-31-december-2021-granting-product-specific-waiver-secukinumab-cosentyx-emea-000380-pip08-21_en.pdf"},
    {"id":"57860","name":"P/0497/2021  : EMA decision of 3 December 2021 on the granting of a product specific waiver for benralizumab (Fasenra), (EMEA-001214-PIP08-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-02T10:58:00Z","last_updated_date":"2023-03-02T10:58:00Z","reference_number":"EMA/622955/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0497-2021-ema-decision-3-december-2021-granting-product-specific-waiver-benralizumab-fasenra-emea-001214-pip08-21_en.pdf"},
    {"id":"57869","name":"P/0499/2021 : EMA decision of 3 December 2021 on the granting of a product specific waiver for human alpha1-proteinase inhibitor (EMEA-001525-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-02T17:31:00Z","last_updated_date":"2023-03-02T17:31:00Z","reference_number":"EMA/616526/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0499-2021-ema-decision-3-december-2021-granting-product-specific-waiver-human-alpha1-proteinase-inhibitor-emea-001525-pip02-21_en.pdf"},
    {"id":"57870","name":"P/0543/2021 : EMA decision of 31 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for vatiquinone (EMEA-001238-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-02T17:45:00Z","last_updated_date":"2023-03-02T17:45:00Z","reference_number":"EMA/699703/2021 corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0543-2021-ema-decision-31-december-2021-agreement-paediatric-investigation-plan-granting-deferral-vatiquinone-emea-001238-pip03-21_en.pdf"},
    {"id":"57890","name":"P/0532/2021 : EMA decision of 3 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for satralizumab (EMEA-001625-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-06T16:05:00Z","last_updated_date":"2023-03-06T16:05:00Z","reference_number":"EMA/623698/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0532-2021-ema-decision-3-december-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-satralizumab-emea-001625-pip02-21_en.pdf"},
    {"id":"57891","name":"P/0474/2021 : EMA decision of 21 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ravulizumab (Ultomiris), (EMEA-001943-PIP04-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-06T16:22:00Z","last_updated_date":"2023-03-06T16:22:00Z","reference_number":"EMA/627447/2021 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0474-2021-ema-decision-21-december-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ravulizumab-ultomiris-emea-001943-pip04-20_en.pdf"},
    {"id":"57892","name":"P/0481/2021 : EMA decision of 3 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for marzeptacog alfa (activated) (EMEA-002270-PIP03-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-06T16:30:00Z","last_updated_date":"2023-03-06T16:30:00Z","reference_number":"EMA/632136/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0481-2021-ema-decision-3-december-2021-agreement-paediatric-investigation-plan-granting-deferral-marzeptacog-alfa-activated-emea-002270-pip03-20_en.pdf"},
    {"id":"57893","name":"P/0482/2021 : EMA decision of 3 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for marzeptacog alfa (activated) (EMEA-002270-PIP04-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-06T16:35:00Z","last_updated_date":"2023-03-06T16:35:00Z","reference_number":"EMA/632179/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0482-2021-ema-decision-3-december-2021-agreement-paediatric-investigation-plan-granting-deferral-marzeptacog-alfa-activated-emea-002270-pip04-20_en.pdf"},
    {"id":"57943","name":"P/0563/2021 : EMA decision of 31 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for tosatoxumab (EMEA-002506-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-07T16:23:00Z","last_updated_date":"2023-03-07T16:23:00Z","reference_number":"EMA/705997/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0563-2021-ema-decision-31-december-2021-agreement-paediatric-investigation-plan-granting-deferral-tosatoxumab-emea-002506-pip03-21_en.pdf"},
    {"id":"57944","name":"P/0517/2021 : EMA decision of 3 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for evenamide (EMEA-002519-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-07T16:34:00Z","last_updated_date":"2023-03-07T16:34:00Z","reference_number":"EMA/623108/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0517-2021-ema-decision-3-december-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-evenamide-emea-002519-pip03-21_en.pdf"},
    {"id":"57946","name":"P/0538/2021 : EMA decision of 31 December 2021 on the granting of a product specific waiver for efgartigimod alfa (EMEA-002597-PIP07-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-07T16:40:00Z","last_updated_date":"2023-03-07T16:40:00Z","reference_number":"EMA/699152/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0538-2021-ema-decision-31-december-2021-granting-product-specific-waiver-efgartigimod-alfa-emea-002597-pip07-21_en.pdf"},
    {"id":"57947","name":"P/0542/2021 : EMA decision of 31 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for repotrectinib (EMEA-002635-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-07T17:08:00Z","last_updated_date":"2023-03-07T17:08:00Z","reference_number":"EMA/699630/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0542-2021-ema-decision-31-december-2021-agreement-paediatric-investigation-plan-granting-deferral-repotrectinib-emea-002635-pip02-21_en.pdf"},
    {"id":"57948","name":"P/0523/2021 : EMA Decision of 3 December 2021 on the granting of a product specific waiver for verdiperstat (EMEA-002708-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-07T17:28:00Z","last_updated_date":"2023-03-07T17:28:00Z","reference_number":"EMA/623923/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0523-2021-ema-decision-3-december-2021-granting-product-specific-waiver-verdiperstat-emea-002708-pip02-21_en.pdf"},
    {"id":"57949","name":"P/0548/2021 : EMA decision of 31 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous CD34+ hematopoietic stem cells with... (EMEA-002730-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-07T17:51:00Z","last_updated_date":"2023-03-07T17:51:00Z","reference_number":"EMA/706930/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0548-2021-ema-decision-31-december-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-cd34-hematopoietic-stem-cells-emea-002730-pip03-21_en.pdf"},
    {"id":"57979","name":"P/0549/2021 : EMA decision of 31 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous CD34+ hematopoietic stem cells with... (EMEA-002730-PIP04-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-09T16:01:00Z","last_updated_date":"2023-03-09T16:01:00Z","reference_number":"EMA/706957/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0549-2021-ema-decision-31-december-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-cd34-hematopoietic-stem-cells-emea-002730-pip04-21_en.pdf"},
    {"id":"57988","name":"P/0531/2021 : EMA decision of December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for magrolimab (EMEA-002819-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-10T14:22:00Z","last_updated_date":"2023-03-10T14:22:00Z","reference_number":"EMA/623897/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0531-2021-ema-decision-december-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-magrolimab-emea-002819-pip01-20_en.pdf"},
    {"id":"57989","name":"P/0539/2021 : EMA decision of 31 December 2021 on the agreement of a paediatric investigation plan for 2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glial fibrillary acidic protein pre-mRNA (ION373), (EMEA-002822-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-10T15:03:00Z","last_updated_date":"2023-03-10T15:03:00Z","reference_number":"EMA/706526/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0539-2021-ema-decision-31-december-2021-agreement-paediatric-investigation-plan-2-o-2-methoxyethyl-modified-antisense-oligonucleotide-targeting-glial-fibrillary-acidic-protein-pre-mrna-ion373-emea_en.pdf"},
    {"id":"57990","name":"P/0553/2021 : EMA decision of 31 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for molnupiravir (EMEA-002940-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-10T15:13:00Z","last_updated_date":"2023-03-10T15:13:00Z","reference_number":"EMA/707172/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0553-2021-ema-decision-31-december-2021-agreement-paediatric-investigation-plan-granting-deferral-molnupiravir-emea-002940-pip02-21_en.pdf"},
    {"id":"57991","name":"P/0500/2021 : EMA decision of 3 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for peptide derivative of... (EMEA-002942-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-10T15:28:00Z","last_updated_date":"2023-03-10T15:28:00Z","reference_number":"EMA/616523/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0500-2021-ema-decision-3-december-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-peptide-derivative-emea-002942-pip01-20_en.pdf"},
    {"id":"57992","name":"P/0537/2021 ; EMA decision of 9 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for exebacase (EMEA-002947-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-10T15:52:00Z","last_updated_date":"2023-03-10T15:52:00Z","reference_number":"P/0537/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0537-2021-ema-decision-9-december-2021-agreement-paediatric-investigation-plan-granting-deferral-exebacase-emea-002947-pip01-20_en.pdf"},
    {"id":"57995","name":"P/0461/2023 : EMA decision of of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for lutetium (177Lu)  oxodotreotide (Lutathera), (EMEA-002950-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-10T16:43:00Z","last_updated_date":"2025-03-06T11:43:00Z","reference_number":"EMA/526330/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0461-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-lutetium-177lu-oxodotreotide-lutathera-emea-002950-pip01-20-m01_en.pdf"},
    {"id":"57997","name":"P/0473/2021 - EMA decision of 3 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant Neisseria... (EMEA-002954-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-10T17:37:00Z","last_updated_date":"2023-03-10T17:37:00Z","reference_number":"P/0473/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0473-2021-ema-decision-3-december-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-neisseria-emea-002954-pip02-21_en.pdf"},
    {"id":"58003","name":"P/0508/2021 - EMA decision of of 3 December 2021 on the granting of a product specific waiver for pamrevlumab, (EMEA-002979-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-13T15:09:00Z","last_updated_date":"2023-03-13T15:09:00Z","reference_number":"EMA/624231/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0508-2021-ema-decision-3-december-2021-granting-product-specific-waiver-pamrevlumab-emea-002979-pip03-21_en.pdf"},
    {"id":"58004","name":"P/0504/2021 - EMA decision of of 3 December 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver ... (EMEA-002981-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-13T15:19:00Z","last_updated_date":"2023-03-13T15:19:00Z","reference_number":"EMA/624102/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0504-2021-ema-decision-3-december-2021-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-emea-002981-pip01-21_en.pdf"},
    {"id":"58005","name":"P/0259/2022: EMA decision of 15 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for leniolisib phosphate (EMEA-002989-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-13T15:34:00Z","last_updated_date":"2023-06-29T14:20:00Z","reference_number":"EMA/628925/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2022-ema-decision-15-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-leniolisib-phosphate-emea-002989-pip01-21-m01_en.pdf"},
    {"id":"58006","name":"P/0472/2021 : EMA decision of of 3 December 2021 on the granting of a product specific waiver for otenaproxesul (EMEA-003061-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-13T15:44:00Z","last_updated_date":"2023-03-13T15:44:00Z","reference_number":"EMA/627459/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0472-2021-ema-decision-3-december-2021-granting-product-specific-waiver-otenaproxesul-emea-003061-pip01-21_en.pdf"},
    {"id":"58007","name":"P/0471/2021 : EMA decision of 3 December 2021 on the granting of a product specific waiver for ofranergene obadenovec (EMEA-003062-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-13T16:03:00Z","last_updated_date":"2023-03-13T16:03:00Z","reference_number":"EMA/627460/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0471-2021-ema-decision-3-december-2021-granting-product-specific-waiver-ofranergene-obadenovec-emea-003062-pip01-21_en.pdf"},
    {"id":"58011","name":"P/0485/2021 : EMA decision of 3 December 2021 on the granting of a product specific waiver for vibostolimab / pembrolizumab (EMEA-003063-PIP01- 21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-13T16:31:00Z","last_updated_date":"2023-03-13T16:31:00Z","reference_number":"EMA/631980/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0485-2021-ema-decision-3-december-2021-granting-product-specific-waiver-vibostolimab-pembrolizumab-emea-003063-pip01-21_en.pdf"},
    {"id":"58012","name":"P/0488/2021 : EMA decision of  December 2021 on the granting of a product specific waiver for eplerenone / furosemide (EMEA-003065-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-13T16:52:00Z","last_updated_date":"2023-03-13T16:52:00Z","reference_number":"EMA/632017/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0488-2021-ema-decision-december-2021-granting-product-specific-waiver-eplerenone-furosemide-emea-003065-pip01-21_en.pdf"},
    {"id":"58015","name":"P/0489/2021 : EMA decision of 3 December 2021 on the granting of a product specific waiver for diphtheria toxoid, tetanus toxoid, bordetella pertussis antigen: pertussis toxoid, bordetella pertussis antigen... (EMEA-003066-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-13T17:47:00Z","last_updated_date":"2023-03-13T17:47:00Z","reference_number":"EMA/632050/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0489-2021-ema-decision-3-december-2021-granting-product-specific-waiver-diphtheria-toxoid-tetanus-toxoid-bordetella-pertussis-antigen-pertussis-toxoid-bordetella-pertussis-antigen-emea-003066-pip01_en.pdf"},
    {"id":"58020","name":"P/0511/2021 : EMA decision of 3 December 2021 on the granting of a product specific waiver for adagrasib, (EMEA-003068-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-14T14:31:00Z","last_updated_date":"2023-03-14T14:31:00Z","reference_number":"EMA/623952/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0511-2021-ema-decision-3-december-2021-granting-product-specific-waiver-adagrasib-emea-003068-pip01-21_en.pdf"},
    {"id":"58021","name":"P/0512/2021 : EMA decision of 3 December 2021 on the granting of a product specific waiver for adavosertib, (EMEA-003069-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-14T14:46:00Z","last_updated_date":"2023-03-14T14:46:00Z","reference_number":"EMA/624475/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0512-2021-ema-decision-3-december-2021-granting-product-specific-waiver-adavosertib-emea-003069-pip01-21_en.pdf"},
    {"id":"58022","name":"P/0513/2021 : EMA decision of 3 December 2021 on the granting of a product specific waiver for ramipril / amlodipine (besilate), (EMEA-003070-PIP01- 21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-14T15:14:00Z","last_updated_date":"2023-03-14T15:14:00Z","reference_number":"EMA/624526/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0513-2021-ema-decision-3-december-2021-granting-product-specific-waiver-ramipril-amlodipine-besilate-emea-003070-pip01-21_en.pdf"},
    {"id":"58023","name":"P/0501/2021 - EMA decision of 3 December 2021 on the refusal of a paediatric investigation plan and on the granting of a waiver for human normal immunoglobulin (EMEA-003076-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-14T15:23:00Z","last_updated_date":"2023-03-14T15:23:00Z","reference_number":"EMA/616604/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0501-2021-ema-decision-3-december-2021-refusal-paediatric-investigation-plan-granting-waiver-human-normal-immunoglobulin-emea-003076-pip01-21_en.pdf"},
    {"id":"58024","name":"P/0564/2021 : EMA decision of 31 December 2021 on the granting of a product specific waiver for humanised IgG2k Fc-modified bispecific antibody against CD3 and BCMA (PF-06863135), (EMEA-003083-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-14T15:53:00Z","last_updated_date":"2023-03-14T15:53:00Z","reference_number":"EMA/649839/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0564-2021-ema-decision-31-december-2021-granting-product-specific-waiver-humanised-igg2k-fc-modified-bispecific-antibody-against-cd3-bcma-pf-06863135-emea-003083-pip01-21_en.pdf"},
    {"id":"58025","name":"P/0557/2021 : EMA decision of 31 December 2021 on the granting of a product-specific waiver for paracetamol / acetylcysteine / phenylephrine (EMEA-003091-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-14T16:18:00Z","last_updated_date":"2023-03-14T16:18:00Z","reference_number":"EMA/707275/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0557-2021-ema-decision-31-december-2021-granting-product-specific-waiver-paracetamol-acetylcysteine-phenylephrine-emea-003091-pip01-21_en.pdf"},
    {"id":"58026","name":"P/0467/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for dalbavancin  hydrochloride (Xydalba), (EMEA-000016-PIP01-07-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-14T16:46:00Z","last_updated_date":"2025-03-06T13:04:00Z","reference_number":"EMA/512491/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0467-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-dalbavancin-hydrochloride-xydalba-emea-000016-pip01-07-m09_en.pdf"},
    {"id":"58030","name":"P/0053/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for azilsartan medoxomil (Edarbi), (EMEA-000237-PIP01-08-M12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-02T16:17:00Z","last_updated_date":"2025-04-02T16:17:00Z","reference_number":"EMA/62603/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-azilsartan-medoxomil-edarbi-emea-000237-pip01-08-m12_en.pdf"},
    {"id":"58031","name":"P/0525/2021: EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for methoxyflurane (Penthrox), (EMEA-000334-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-15T16:44:00Z","last_updated_date":"2023-03-15T16:44:00Z","reference_number":"EMA/626393/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0525-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-methoxyflurane-penthrox-emea-000334-pip01-08-m10_en.pdf"},
    {"id":"58032","name":"P/0526/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten and associated names), (EMEA-000347-PIP02-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-15T17:05:00Z","last_updated_date":"2023-03-15T17:05:00Z","reference_number":"EMA/626801/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0526-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-associated-names-emea-000347-pip02-16-m03_en.pdf"},
    {"id":"58033","name":"P/0521/2021 : EMA decision of of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for perampanel (Fycompa), (EMEA-000467-PIP01-08-M15)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-15T17:27:00Z","last_updated_date":"2023-03-15T17:27:00Z","reference_number":"EMA/626828/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0521-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-perampanel-fycompa-emea-000467-pip01-08-m15_en.pdf"},
    {"id":"58034","name":"P/0552/2021 - EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for vedolizumab (Entyvio), (EMEA-000645-PIP01-09-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-15T17:43:00Z","last_updated_date":"2023-03-15T17:43:00Z","reference_number":"EMA/707074/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0552-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-vedolizumab-entyvio-emea-000645-pip01-09-m08_en.pdf"},
    {"id":"58035","name":"P/0527/2021: EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ruxolitinib (phosphate) (Jakavi), (EMEA-000901-PIP04-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-15T17:56:00Z","last_updated_date":"2023-03-15T17:56:00Z","reference_number":"EMA/626980/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0527-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-ruxolitinib-phosphate-jakavi-emea-000901-pip04-17-m02_en.pdf"},
    {"id":"58039","name":"P/0480/2021: EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for macitentan (Opsumit), (EMEA-001032-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-16T11:22:00Z","last_updated_date":"2023-03-16T11:22:00Z","reference_number":"EMA/616445/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0480-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-macitentan-opsumit-emea-001032-pip01-10-m04_en.pdf"},
    {"id":"58040","name":"P/0551/2021: EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for romosozumab (Evenity), (EMEA-001075-PIP04-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-16T11:39:00Z","last_updated_date":"2023-03-16T11:39:00Z","reference_number":"EMA/707021/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0551-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-romosozumab-evenity-emea-001075-pip04-15-m04_en.pdf"},
    {"id":"58041","name":"P/0493/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for naloxegol (Moventig), (EMEA-001146-PIP01-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-16T12:11:00Z","last_updated_date":"2023-03-16T12:11:00Z","reference_number":"EMA/616446/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0493-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-naloxegol-moventig-emea-001146-pip01-11-m07_en.pdf"},
    {"id":"58046","name":"P/0494/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for vonicog alfa (Veyvondi), (EMEA-001164-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-16T13:59:00Z","last_updated_date":"2023-03-16T13:59:00Z","reference_number":"EMA/616450/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0494-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-vonicog-alfa-veyvondi-emea-001164-pip01-11-m05_en.pdf"},
    {"id":"58049","name":"P/0550/2021 : EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for alirocumab (Praluent), (EMEA-001169-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-16T15:01:00Z","last_updated_date":"2023-03-16T15:01:00Z","reference_number":"EMA/706959/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0550-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-alirocumab-praluent-emea-001169-pip01-11-m05_en.pdf"},
    {"id":"58050","name":"P/0495/2021: EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for regorafenib (Stivarga), (EMEA-001178-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-16T15:15:00Z","last_updated_date":"2023-03-16T15:15:00Z","reference_number":"EMA/616451/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0495-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-regorafenib-stivarga-emea-001178-pip01-11-m06_en.pdf"},
    {"id":"58052","name":"P/0496/2021: EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tecovirimat (monohydrate) (EMEA-001205-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-16T15:51:00Z","last_updated_date":"2023-03-16T15:51:00Z","reference_number":"EMA/616460/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0496-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-tecovirimat-monohydrate-emea-001205-pip02-19-m01_en.pdf"},
    {"id":"58055","name":"P/0535/2021: EMA decision of 6 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for eribulin (Halaven), (EMEA-001261-PIP01-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-16T17:25:00Z","last_updated_date":"2023-03-16T17:25:00Z","reference_number":"EMA/699482/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0535-2021-ema-decision-6-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-eribulin-halaven-emea-001261-pip01-11-m07_en.pdf"},
    {"id":"58056","name":"P/0498/2021: EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for oritavancin (diphosphate) (Tenkasi), (EMEA-001270-PIP01-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-16T17:49:00Z","last_updated_date":"2023-03-16T17:49:00Z","reference_number":"EMA/616492/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0498-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-oritavancin-diphosphate-tenkasi-emea-001270-pip01-12-m04_en.pdf"},
    {"id":"58089","name":"P/0502/2021: EMA decision of 2 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for fenfluramine  (hydrochloride) (Fintepla), (EMEA-001990-PIP01-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-21T11:26:00Z","last_updated_date":"2023-03-21T11:26:00Z","reference_number":"EMA/698179/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0502-2021-ema-decision-2-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-fenfluramine-hydrochloride-fintepla-emea-001990-pip01-16-m04_en.pdf"}    {"id":"58093","name":"P/0505/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for lumasiran (ALN-GO1) (Oxlumo), (EMEA-002079-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-21T15:04:00Z","last_updated_date":"2023-03-21T15:04:00Z","reference_number":"EMA/627935/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0505-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-lumasiran-aln-go1-oxlumo-emea-002079-pip01-16-m02_en.pdf"},
    {"id":"58098","name":"P/0506/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cotadutide, (EMEA- 002287-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-21T15:31:00Z","last_updated_date":"2023-03-21T15:31:00Z","reference_number":"EMA/628070/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0506-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-cotadutide-emea-002287-pip01-17-m03_en.pdf"},
    {"id":"58100","name":"P/0507/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for pretomanid, (EMEA-002115-PIP01-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-21T15:53:00Z","last_updated_date":"2023-03-21T15:53:00Z","reference_number":"EMA/627978/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0507-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-pretomanid-emea-002115-pip01-17-m04_en.pdf"},
    {"id":"58103","name":"P/0359/2022: EMA decision of 22 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon beta-1a (Plegridy), (EMEA-001129-PIP01-11-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-03-21T17:43:00Z","last_updated_date":"2023-03-21T17:43:00Z","reference_number":"EMA/693766/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0359-2022-ema-decision-22-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-peginterferon-beta-1a-plegridy-emea-001129-pip01-11-m05_en.pdf"},
    {"id":"58105","name":"P/0509/2021 : EMA decision of  3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for molgramostim, (EMEA-002282-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-21T17:48:00Z","last_updated_date":"2023-03-21T17:48:00Z","reference_number":"EMA/628038/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0509-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-molgramostim-emea-002282-pip01-17-m01_en.pdf"},
    {"id":"58106","name":"P/0510/2021 : EMA decision of  3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-21T17:48:00Z","last_updated_date":"2023-03-21T17:48:00Z","reference_number":"EMA/627654/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0510-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip01-14-m05_en.pdf"},
    {"id":"58111","name":"P/0514/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for evinacumab (Evkeeza), (EMEA-002298-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-22T10:16:00Z","last_updated_date":"2023-03-22T10:16:00Z","reference_number":"EMA/628071/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0514-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-evinacumab-evkeeza-emea-002298-pip01-17-m03_en.pdf"},
    {"id":"58112","name":"P/0515/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for vamorolone, (EMEA-001794-PIP02-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-22T10:16:00Z","last_updated_date":"2023-03-22T10:16:00Z","reference_number":"EMA/627857/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0515-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-vamorolone-emea-001794-pip02-16-m04_en.pdf"},
    {"id":"58113","name":"P/0516/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for marstacimab, (EMEA-002285-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-22T10:16:00Z","last_updated_date":"2023-03-22T10:16:00Z","reference_number":"EMA/628069/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0516-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-marstacimab-emea-002285-pip02-19-m01_en.pdf"},
    {"id":"58125","name":"P/0524/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine / dolutegravir (Juluca), (EMEA-001750-PIP01-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-22T16:36:00Z","last_updated_date":"2023-03-22T16:36:00Z","reference_number":"EMA/627063/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0524-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-dolutegravir-juluca-emea-001750-pip01-15-m05_en.pdf"},
    {"id":"58126","name":"P/0528/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy), (EMEA-001766-PIP01-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-22T17:02:00Z","last_updated_date":"2023-03-22T17:02:00Z","reference_number":"EMA/627163/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0528-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy-emea-001766-pip01-15-m04_en.pdf"},
    {"id":"58127","name":"P/0004/2024 : EMA decision of 11 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan and on the granting of a product-specific waiver for crizanlizumab (EMEA-002141-PIP01-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T17:13:00Z","last_updated_date":"2025-03-14T17:13:00Z","reference_number":"EMA/6414/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2024-ema-decision-11-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-granting-product-specific-waiver-crizanlizumab-emea-002141-pip01-17-m04_en.pdf"},
    {"id":"58128","name":"P/0536/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for alpelisib (Piqray and associated names), (EMEA-002016-PIP03-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-22T17:59:00Z","last_updated_date":"2023-03-22T17:59:00Z","reference_number":"EMA/707287/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0536-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-alpelisib-piqray-associated-names-emea-002016-pip03-19-m01_en.pdf"},
    {"id":"58133","name":"P/0076/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for imlifidase (Idefirix) (EMEA-002183-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-23T12:35:00Z","last_updated_date":"2023-03-23T12:35:00Z","reference_number":"EMA/65167/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-imlifidase-idefirix-emea-002183-pip01-17-m01_en.pdf"},
    {"id":"58135","name":"P/0103/2022 : EMA decision of 21 March 2022 on the agreement of a paediatric investigation plan for censavudine (EMEA-003075-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-23T16:02:00Z","last_updated_date":"2023-03-23T16:02:00Z","reference_number":"EMA/149068/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2022-ema-decision-21-march-2022-agreement-paediatric-investigation-plan-censavudine-emea-003075-pip01-21_en.pdf"},
    {"id":"58171","name":"P/0540/2021 : EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (EMEA-002360-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-27T16:16:00Z","last_updated_date":"2023-03-27T16:16:00Z","reference_number":"EMA/699404/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0540-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-tirzepatide-emea-002360-pip01-18-m01_en.pdf"},
    {"id":"58172","name":"P/0541/2021 : EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for nedosiran (DCRPHXC) (EMEA-002493-PIP01-18-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-27T16:16:00Z","last_updated_date":"2023-03-27T16:16:00Z","reference_number":"EMA/699441/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0541-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-nedosiran-dcrphxc-emea-002493-pip01-18-m03_en.pdf"},
    {"id":"58176","name":"P/0547/2021 : EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tozinameran (Comirnaty), (EMEA-002861-PIP02-20-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-27T16:48:00Z","last_updated_date":"2023-03-27T16:48:00Z","reference_number":"EMA/709824/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0547-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-tozinameran-comirnaty-emea-002861-pip02-20-m03_en.pdf"},
    {"id":"58177","name":"P/0546/2021: EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for avelumab (Bavencio), (EMEA-001849-PIP02-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-27T16:48:00Z","last_updated_date":"2023-03-27T16:48:00Z","reference_number":"EMA/709533/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0546-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-avelumab-bavencio-emea-001849-pip02-15-m04_en.pdf"},
    {"id":"58178","name":"P/0565/2021 : EMA decision of 21 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for glycopyrronium bromide, (EMEA-002383-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-27T18:00:00Z","last_updated_date":"2023-03-27T18:00:00Z","reference_number":"EMA/628072/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0565-2021-ema-decision-21-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-glycopyrronium-bromide-emea-002383-pip01-18-m01_en.pdf"},
    {"id":"58179","name":"P/0561/2021 : EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for estetrol / drospirenone (Lydisilka), (EMEA-001332-PIP01-12-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-28T11:37:00Z","last_updated_date":"2023-03-28T11:37:00Z","reference_number":"EMA/706126/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0561-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-estetrol-drospirenone-lydisilka-emea-001332-pip01-12-m05_en.pdf"},
    {"id":"58180","name":"P/0562/2021 : EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for palovarotene (EMEA-001662-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-28T11:37:00Z","last_updated_date":"2023-03-28T11:37:00Z","reference_number":"EMA/649951/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0562-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-palovarotene-emea-001662-pip01-14-m05_en.pdf"},
    {"id":"58181","name":"P/0554/2021 : EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for fully human IgG1 RB- 1 YTE anti-RSV F monoclonal antibody (MK-1654), (EMEA-002755-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-28T11:57:00Z","last_updated_date":"2023-03-28T11:57:00Z","reference_number":"EMA/709698/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0554-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-fully-human-igg1-rb-1-yte-anti-rsv-f-monoclonal-antibody-mk-1654-emea-002755-pip01-19-m01_en.pdf"},
    {"id":"58182","name":"P/0558/2021 : EMA decision of 31 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for lisocabtagene maraleucel (EMEA-001995-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-28T11:57:00Z","last_updated_date":"2023-03-28T11:57:00Z","reference_number":"EMA/708327/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0558-2021-ema-decision-31-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-lisocabtagene-maraleucel-emea-001995-pip01-16-m03_en.pdf"},
    {"id":"58183","name":"P/0559/2021 : EMA decision of 27 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for COVID-19 vaccine (ChAdOx1-S [recombinant]) (Vaxzevria), (EMEA-002862-PIP01-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-28T11:57:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"EMA/707190/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0559-2021-ema-decision-27-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-covid-19-vaccine-chadox1-s-recombinant-vaxzevria-emea-002862-pip01-20-m02_en.pdf"},
    {"id":"58184","name":"P/0479/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for isavuconazonium (sulfate) (Cresemba), (EMEA-001301-PIP02-12-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-28T12:12:00Z","last_updated_date":"2023-03-28T12:12:00Z","reference_number":"EMA/627435/2021 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0479-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-isavuconazonium-sulfate-cresemba-emea-001301-pip02-12-m04_en.pdf"},
    {"id":"58185","name":"P/0478/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for inotuzumab ozogamicin (Besponsa), (EMEA-001429-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-28T12:12:00Z","last_updated_date":"2023-03-28T12:12:00Z","reference_number":"EMA/627438/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0478-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-inotuzumab-ozogamicin-besponsa-emea-001429-pip01-13-m04_en.pdf"},
    {"id":"58186","name":"P/0475/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for erenumab (Aimovig), (EMEA-001664-PIP02-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-28T13:17:00Z","last_updated_date":"2023-03-28T13:17:00Z","reference_number":"EMA/627444/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0475-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-erenumab-aimovig-emea-001664-pip02-15-m05_en.pdf"},
    {"id":"58187","name":"P/0476/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for vericiguat (Verguvo), (EMEA-001636-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-28T13:17:00Z","last_updated_date":"2023-03-28T13:17:00Z","reference_number":"EMA/627442/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0476-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-vericiguat-verguvo-emea-001636-pip01-14-m02_en.pdf"},
    {"id":"58196","name":"P/0483/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for severe acute respiratory syndrome coronavirus 2 recombinant... (EMEA-002941-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-29T12:20:00Z","last_updated_date":"2023-03-29T12:20:00Z","reference_number":"EMA/627540/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0483-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-severe-acute-respiratory-syndrome-coronavirus-2-recombinant-emea-002941-pip01-20-m01_en.pdf"},
    {"id":"58197","name":"P/0484/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for deferoxamine (mesylate) / histidine / tryptophan / aspartic acid... (EMEA-002735-PIP03-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-29T12:20:00Z","last_updated_date":"2023-03-29T12:20:00Z","reference_number":"EMA/627334/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0484-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-deferoxamine-mesylate-histidine-tryptophan-aspartic-acid-emea-002735-pip03-20-m01_en.pdf"},
    {"id":"58198","name":"P/0490/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for cyclophosphamide (Zenew and associated names), (EMEA-002644-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-29T12:46:00Z","last_updated_date":"2023-03-29T12:46:00Z","reference_number":"EMA/627032/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0490-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-cyclophosphamide-zenew-associated-names-emea-002644-pip01-19-m01_en.pdf"},
    {"id":"58199","name":"P/0491/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for soticlestat (EMEA-002572-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-29T12:46:00Z","last_updated_date":"2023-03-29T12:46:00Z","reference_number":"EMA/626884/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0491-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-soticlestat-emea-002572-pip02-19-m01_en.pdf"},
    {"id":"58200","name":"P/0492/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain... (EMEA- 002068-PIP01-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-29T12:46:00Z","last_updated_date":"2023-03-29T12:46:00Z","reference_number":"EMA/627653/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0492-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-emea-002068-pip01-16-m04_en.pdf"},
    {"id":"58206","name":"P/0486/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for baloxavir marboxil (Xofluza), (EMEA-002440-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-29T16:17:00Z","last_updated_date":"2023-03-29T16:17:00Z","reference_number":"EMA/626832/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0486-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-baloxavir-marboxil-xofluza-emea-002440-pip01-18-m02_en.pdf"},
    {"id":"58207","name":"P/0487/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for larotrectinib (Vitrakvi), (EMEA-001971-PIP02-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-29T16:17:00Z","last_updated_date":"2023-03-29T16:17:00Z","reference_number":"EMA/627624/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0487-2021-ema-decision-3-december-2021-acceptance-modification-agreed-paediatric-investigation-plan-larotrectinib-vitrakvi-emea-001971-pip02-16-m04_en.pdf"},
    {"id":"58217","name":"P/0513/2022 : EMA decision of 4 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for givinostat (EMEA-000551-PIP04-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-30T12:14:00Z","last_updated_date":"2023-03-30T12:14:00Z","reference_number":"EMA/912401/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0513-2022-ema-decision-4-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-givinostat-emea-000551-pip04-21-m01_en.pdf"},
    {"id":"58231","name":"P/0454/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for vericiguat (Verquvo), (EMEA-001636-PIP01-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-03-30T16:31:00Z","last_updated_date":"2023-03-30T16:31:00Z","reference_number":"EMA/775666/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0454-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-vericiguat-verquvo-emea-001636-pip01-14-m03_en.pdf"},
    {"id":"58285","name":"P/0018/2022 : EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for izencitinib (EMEA-002757-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-05T10:51:00Z","last_updated_date":"2023-04-05T10:51:00Z","reference_number":"EMA/8212/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-izencitinib-emea-002757-pip02-21_en.pdf"},
    {"id":"58286","name":"P/0003/2022 : EMA decision of 18 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (Briviact), (EMEA-000332-PIP02-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-05T11:18:00Z","last_updated_date":"2023-04-05T11:18:00Z","reference_number":"EMA/782280/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2022-ema-decision-18-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-emea-000332-pip02-17-m03_en.pdf"},
    {"id":"58288","name":"P/0020/2022 : EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for ribociclib (Kisqali), (EMEA-002765-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-05T12:32:00Z","last_updated_date":"2023-04-05T12:32:00Z","reference_number":"EMA/8294/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-waiver-ribociclib-kisqali-emea-002765-pip02-21_en.pdf"},
    {"id":"58291","name":"P/0007/2022 : EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for vorasidenib (as hemicitrate, hemihydrate salt) (EMEA-002932-PIP02-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-04-05T13:57:00Z","last_updated_date":"2023-04-05T13:57:00Z","reference_number":"EMA/12217/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-waiver-vorasidenib-hemicitrate-hemihydrate-salt-emea-002932-pip02-21_en.pdf"},
    {"id":"58294","name":"P/0023/2022 : EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aficamten (EMEA-002958-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-05T15:22:00Z","last_updated_date":"2023-04-05T15:22:00Z","reference_number":"EMA/8373/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aficamten-emea-002958-pip01-21_en.pdf"},
    {"id":"58297","name":"P/0032/2022 : EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nirogacestat hydrobromide (EMEA-002971-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-05T15:57:00Z","last_updated_date":"2023-04-05T15:57:00Z","reference_number":"EMA/10020/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-nirogacestat-hydrobromide-emea-002971-pip01-21_en.pdf"},
    {"id":"58298","name":"P/0008/2022 : EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for single strain of non-genetically modified Prevotella his...  (EMEA- 002933-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-05T16:12:00Z","last_updated_date":"2023-04-05T16:12:00Z","reference_number":"EMA/9458/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-single-strain-non-genetically-modified-prevotella-his-emea-002933-pip01-20_en.pdf"},
    {"id":"58299","name":"P/0025/2022 : EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 2-Amino-N-(4-hydroxybicyclo[2.2.2]octan...(EMEA-002992-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-05T16:34:00Z","last_updated_date":"2023-04-05T16:34:00Z","reference_number":"EMA/11809/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-2-amino-n-4-hydroxybicyclo222octanemea-002992-pip01-21_en.pdf"},
    {"id":"58300","name":"P/0022/2022 : EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for lanadelumab (Takhzyro), (EMEA-001864-PIP01-15-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-05T17:08:00Z","last_updated_date":"2023-04-05T17:08:00Z","reference_number":"EMA/18778/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-lanadelumab-takhzyro-emea-001864-pip01-15-m06_en.pdf"},
    {"id":"58312","name":"P/0037/2022 : EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for derivative of 6-[2-(pyridin-2-yl) (...) (EMEA-003002-PIP01-21))","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T10:48:00Z","last_updated_date":"2023-04-12T10:48:00Z","reference_number":"EMA/11958/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-derivative-6-2-pyridin-2-yl-emea-003002-pip01-21_en.pdf"},
    {"id":"58313","name":"P/0024/2022: EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for vadadustat (EMEA- 001944-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T11:09:00Z","last_updated_date":"2023-04-12T11:09:00Z","reference_number":"EMA/18986/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-vadadustat-emea-001944-pip01-16-m03_en.pdf"},
    {"id":"58314","name":"P/0028/2022 : EMA decision of 31 January 2022 on the granting of a product specific waiver for colchicine (EMEA-003101-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T11:23:00Z","last_updated_date":"2023-04-12T11:23:00Z","reference_number":"EMA/12322/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2022-ema-decision-31-january-2022-granting-product-specific-waiver-colchicine-emea-003101-pip01-21_en.pdf"},
    {"id":"58315","name":"P/0013/2022: EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for budesonide / glycopyrronium bromide / formoterol (fumarate) (Trixeo Aerosphere), (EMEA-002063-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T11:30:00Z","last_updated_date":"2023-04-12T11:30:00Z","reference_number":"EMA/7910/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-budesonide-glycopyrronium-bromide-formoterol-fumarate-trixeo-aerosphere-emea-002063-pip01-16-m01_en.pdf"},
    {"id":"58317","name":"P/0015/2022: EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for onasemnogene abeparvovec (Zolgensma), (EMEA-002168-PIP01-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T11:44:00Z","last_updated_date":"2023-04-12T11:44:00Z","reference_number":"EMA/7958/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-onasemnogene-abeparvovec-zolgensma-emea-002168-pip01-17-m04_en.pdf"},
    {"id":"58318","name":"P/0009/2022 : EMA decision of 31 January 2022 on the granting of a product-specific waiver for favezelimab / pembrolizumab (EMEA-003104-PIP01- 21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T11:53:00Z","last_updated_date":"2023-04-12T11:53:00Z","reference_number":"EMA/782285/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2022-ema-decision-31-january-2022-granting-product-specific-waiver-favezelimab-pembrolizumab-emea-003104-pip01-21_en.pdf"},
    {"id":"58320","name":"P/0016/2022: EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for avapritinib (Ayvakyt), (EMEA-002358-PIP02-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T12:15:00Z","last_updated_date":"2023-04-12T12:15:00Z","reference_number":"EMA/8025/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-avapritinib-ayvakyt-emea-002358-pip02-18-m02_en.pdf"},
    {"id":"58321","name":"P/0010/2022 : EMA decision of 31 January 2022 on the granting of a product-specific waiver for aumolertinib (EMEA-003106-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T12:27:00Z","last_updated_date":"2023-04-12T12:27:00Z","reference_number":"EMA/782286/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2022-ema-decision-31-january-2022-granting-product-specific-waiver-aumolertinib-emea-003106-pip01-21_en.pdf"},
    {"id":"58322","name":"P/0011/2022 : EMA decision of 31 January 2022 on the granting of a product-specific waiver for gantenerumab (EMEA-003107-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T12:50:00Z","last_updated_date":"2023-04-12T12:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2022-ema-decision-31-january-2022-granting-product-specific-waiver-gantenerumab-emea-003107-pip01-21_en.pdf"},
    {"id":"58323","name":"P/0017/2022: EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for phenobarbital (EMEA- 002532-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T13:03:00Z","last_updated_date":"2023-04-12T13:03:00Z","reference_number":"EMA/8189/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-phenobarbital-emea-002532-pip01-18-m02_en.pdf"},
    {"id":"58324","name":"P/0030/2022: EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for mitapivat (EMEA-002684-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T13:13:00Z","last_updated_date":"2023-04-12T13:13:00Z","reference_number":"EMA/18783/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-mitapivat-emea-002684-pip01-19-m01_en.pdf"},
    {"id":"58325","name":"P/0555/2021: EMA decision of 4 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for giroctocogene fitelparvovec, (EMEA-002724-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T13:20:00Z","last_updated_date":"2023-04-12T13:20:00Z","reference_number":"EMA/709767/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0555-2021-ema-decision-4-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-giroctocogene-fitelparvovec-emea-002724-pip01-19-m02_en.pdf"},
    {"id":"58326","name":"P/0012/2022 : EMA decision of 31 January 2022 on the granting of a product-specific waiver for derivative of pyrrolopyrimidine (EMEA-003109- PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T13:37:00Z","last_updated_date":"2023-04-12T13:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2022-ema-decision-31-january-2022-granting-product-specific-waiver-derivative-pyrrolopyrimidine-emea-003109-pip01-21_en.pdf"},
    {"id":"58329","name":"P/0004/2022 : EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T14:50:00Z","last_updated_date":"2023-04-12T14:50:00Z","reference_number":"EMA/782281/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip01-11-m06_en.pdf"},
    {"id":"58330","name":"P/0002/2022: EMA decision of 7 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for dexmedetomidine (hydrochloride), (EMEA-002758-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T15:31:00Z","last_updated_date":"2023-04-12T15:31:00Z","reference_number":"EMA/3938/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2022-ema-decision-7-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-dexmedetomidine-hydrochloride-emea-002758-pip01-19-m01_en.pdf"},
    {"id":"58331","name":"P/0005/2022 : EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for talimogene laherparepvec (Imlygic), (EMEA-001251-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T15:33:00Z","last_updated_date":"2023-04-12T15:33:00Z","reference_number":"EMA/782282/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-talimogene-laherparepvec-imlygic-emea-001251-pip01-11-m05_en.pdf"},
    {"id":"58332","name":"P/0001/2022 : EMA decision of 7 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ceftazidime / avibactam (Zavicefta), (EMEA-001313-PIP01-12-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T16:21:00Z","last_updated_date":"2023-04-12T16:21:00Z","reference_number":"EMA/5005/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2022-ema-decision-7-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-zavicefta-emea-001313-pip01-12-m11_en.pdf"},
    {"id":"58333","name":"P/0040/2022 : EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (Vocabria), (EMEA-001418-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T17:20:00Z","last_updated_date":"2023-04-12T17:20:00Z","reference_number":"EMA/18253/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-cabotegravir-vocabria-emea-001418-pip01-13-m04_en.pdf"},
    {"id":"58334","name":"P/0026/2022: EMA decision of 4 February 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ExPEC9V (EMEA-002996-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-12T17:36:00Z","last_updated_date":"2023-04-12T17:36:00Z","reference_number":"EMA/11870/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2022-ema-decision-4-february-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-expec9v-emea-002996-pip01-21_en.pdf"},
    {"id":"58338","name":"P/0079/2022 : EMA decision of 11 March 2022 on the granting of a product specific waiver for (1S,3S)-3-({2-methyl-6-[1-methyl-5- ({[methyl(propyl)carbamoyl]oxy}methyl)-1H-1,2,3-triazol-4-yl]pyridin-3-yl}oxy)....(BMS-986278) (EMEA-001649-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-13T14:36:00Z","last_updated_date":"2023-04-13T14:36:00Z","reference_number":"EMA/65197/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2022-ema-decision-11-march-2022-granting-product-specific-waiver-1s3s-3-2-methyl-6-1-methyl-5-methylpropylcarbamoyloxymethyl-1h-123-triazol-4-ylpyridin-3-yloxybms-986278-emea-001649-pip02-21_en.pdf"},
    {"id":"58339","name":"EMA decision of 11 March 2022 on the granting of a product specific waiver for tucatinib (Tukysa) (EMEA-002242-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-13T14:58:00Z","last_updated_date":"2023-04-13T14:58:00Z","reference_number":"EMA/65200/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-decision-11-march-2022-granting-product-specific-waiver-tucatinib-tukysa-emea-002242-pip02-21_en.pdf"},
    {"id":"58340","name":"P/0055/2022 : EMA decision of 11 March 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant humanized anti-blood dendritic cell antigen 2.. (EMEA-002555-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-13T15:32:00Z","last_updated_date":"2023-04-13T15:32:00Z","reference_number":"EMA/94153/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2022-ema-decision-11-march-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-humanized-anti-blood-dendritic-cell-antigen-2-emea-002555-pip02-21_en.pdf"},
    {"id":"58341","name":"P/0078/2022 : EMA decision of 11 March 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efgartigimod alfa (EMEA-002597-PIP04-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-13T15:41:00Z","last_updated_date":"2023-04-13T15:41:00Z","reference_number":"EMA/65203/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2022-ema-decision-11-march-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-efgartigimod-alfa-emea-002597-pip04-21_en.pdf"},
    {"id":"58342","name":"P/0085/2022 : EMA decision of 11 March 2022 on the granting of a product specific waiver for parsaclisib (as hydrochloride) (EMEA-002696-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-13T16:13:00Z","last_updated_date":"2023-04-13T16:13:00Z","reference_number":"EMA/99627/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2022-ema-decision-11-march-2022-granting-product-specific-waiver-parsaclisib-hydrochloride-emea-002696-pip02-21_en.pdf"},
    {"id":"58343","name":"P/0110/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cannabidiol / delta-9- tetrahydrocannabinol (Sativex), (EMEA-000181-PIP01-08-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-04-13T16:47:00Z","last_updated_date":"2023-04-13T16:47:00Z","reference_number":"EMA/145466/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-cannabidiol-delta-9-tetrahydrocannabinol-sativex-emea-000181-pip01-08-m06_en.pdf"},
    {"id":"58344","name":"P/0106/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for saxagliptin (Onglyza), (EMEA-000200-PIP01-08-M09)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-04-13T17:17:00Z","last_updated_date":"2023-04-13T17:17:00Z","reference_number":"EMA/145470/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-saxagliptin-onglyza-emea-000200-pip01-08-m09_en.pdf"},
    {"id":"58345","name":"P/0109/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ferumoxytol, (EMEA-000373-PIP02-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-13T17:59:00Z","last_updated_date":"2023-04-13T17:59:00Z","reference_number":"EMA/145472/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-ferumoxytol-emea-000373-pip02-09-m05_en.pdf"},
    {"id":"58349","name":"P/0039/2022 : EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP02-13-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-14T10:31:00Z","last_updated_date":"2023-04-14T10:31:00Z","reference_number":"EMA/18201/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip02-13-m07_en.pdf"},
    {"id":"58350","name":"P/0545/2021 : EMA decision of 4 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for nemolizumab (EMEA- 001624-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-14T10:56:00Z","last_updated_date":"2023-04-14T10:56:00Z","reference_number":"EMA/709753/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0545-2021-ema-decision-4-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-nemolizumab-emea-001624-pip01-14-m04_en.pdf"},
    {"id":"58352","name":"P/0014/2022 : EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for gemtuzumab ozogamicin (Mylotarg), (EMEA-001733-PIP02-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-14T11:26:00Z","last_updated_date":"2023-04-14T11:26:00Z","reference_number":"EMA/18515/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-gemtuzumab-ozogamicin-mylotarg-emea-001733-pip02-15-m02_en.pdf"},
    {"id":"58357","name":"P/0130/2022 : EMA decision of 13 April 2022 on the granting of a product-specific waiver for secukinumab (Cosentyx), (EMEA-000380-PIP09-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-14T15:35:00Z","last_updated_date":"2023-04-14T15:35:00Z","reference_number":"EMA/193522/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2022-ema-decision-13-april-2022-granting-product-specific-waiver-secukinumab-cosentyx-emea-000380-pip09-21_en.pdf"},
    {"id":"58358","name":"P/0034/2022 : EMA decision of 4 February 2022 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for insulin efsitora alfa (EMEA-003105-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-14T15:49:00Z","last_updated_date":"2023-04-14T15:49:00Z","reference_number":"P/0034/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2022-ema-decision-4-february-2022-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-insulin-efsitora-alfa-emea-003105-pip01-21_en.pdf"},
    {"id":"58359","name":"P/0019/2022 : EMA decision of 3 February 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cysteamine (hydrochloride) (Cystadrops), (EMEA-000322-PIP01-08-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-14T16:01:00Z","last_updated_date":"2023-04-14T16:01:00Z","reference_number":"EMA/782279/2021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2022-ema-decision-3-february-2022-acceptance-modification-agreed-paediatric-investigation-plan-cysteamine-hydrochloride-cystadrops-emea-000322-pip01-08-m06_en.pdf"},
    {"id":"58360","name":"P/0050/2022 : EMA decision of 24 February 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tedizolid phosphate (Sivextro), (EMEA-001379-PIP01-12-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-14T16:08:00Z","last_updated_date":"2023-04-14T16:08:00Z","reference_number":"P/0050/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2022-ema-decision-24-february-2022-acceptance-modification-agreed-paediatric-investigation-plan-tedizolid-phosphate-sivextro-emea-001379-pip01-12-m06_en.pdf"},
    {"id":"58364","name":"P/0041/2022 : EMA decision of of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for atazanavir (sulphate) / cobicistat (Evotaz), (EMEA-001465-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T11:08:00Z","last_updated_date":"2023-04-17T11:08:00Z","reference_number":"EMA/18321/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2022-ema-decision-31-january-2022-acceptance-modification-agreed-paediatric-investigation-plan-atazanavir-sulphate-cobicistat-evotaz-emea-001465-pip01-13-m04_en.pdf"},
    {"id":"58365","name":"P/0120/2022 : EMA decision of 15 April 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dupilumab (Dupixent), (EMEA-001501-PIP09-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T11:38:00Z","last_updated_date":"2023-04-17T11:38:00Z","reference_number":"EMA/149062/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2022-ema-decision-15-april-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dupilumab-dupixent-emea-001501-pip09-21_en.pdf"},
    {"id":"58367","name":"P/0137/2022 : EMA decision of 13 April 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for invimestrocel (EMEA-002317-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T12:09:00Z","last_updated_date":"2023-04-17T12:09:00Z","reference_number":"EMA/157573/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2022-ema-decision-13-april-2022-agreement-paediatric-investigation-plan-granting-deferral-invimestrocel-emea-002317-pip02-21_en.pdf"},
    {"id":"58369","name":"P/0422/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for maribavir (EMEA- 000353-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T12:40:00Z","last_updated_date":"2023-04-17T12:40:00Z","reference_number":"EMA/825074/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0422-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-maribavir-emea-000353-pip02-16-m02_en.pdf"},
    {"id":"58371","name":"P/0084/2022 : EMA decision of 11 March 2022 on the granting of a product specific waiver for vimseltinib (EMEA-002802-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T13:25:00Z","last_updated_date":"2023-04-17T13:25:00Z","reference_number":"EMA/100970/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2022-ema-decision-11-march-2022-granting-product-specific-waiver-vimseltinib-emea-002802-pip02-21_en.pdf"},
    {"id":"58372","name":"P/0138/2022 : EMA decision of 13 April 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for catequentinib (EMEA-002486-PIP04-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T13:26:00Z","last_updated_date":"2023-04-17T13:26:00Z","reference_number":"EMA/157575/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2022-ema-decision-13-april-2022-agreement-paediatric-investigation-plan-granting-deferral-catequentinib-emea-002486-pip04-21_en.pdf"},
    {"id":"58373","name":"P/0080/2022 : EMA decision of 11 March 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for neisseria meningitidis serogroup B fHbp subfamily A / Neisseria....(EMEA-002814-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T13:34:00Z","last_updated_date":"2023-04-17T13:34:00Z","reference_number":"EMA/65205/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2022-ema-decision-11-march-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-neisseria-meningitidis-serogroup-b-fhbp-subfamily-neisseriaemea-002814-pip02-21_en.pdf"},
    {"id":"58374","name":"P/0042/2022 : EMA decision of 10 February 2022 on the acceptance of a modification of an agreed paediatric investigation plan for split influenza virus, inactivated containing antigens... (EMEA- 002359-PIP01-18-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T13:43:00Z","last_updated_date":"2023-04-17T13:43:00Z","reference_number":"EMA/65166/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2022-ema-decision-10-february-2022-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigens-emea-002359-pip01-18-m04_en.pdf"},
    {"id":"58375","name":"P/0049/2022 : EMA decision of 18 February 2022 on the acceptance of a modification of an agreed paediatric investigation plan for spesolimab, (EMEA- 002475-PIP02-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T13:55:00Z","last_updated_date":"2023-04-17T13:55:00Z","reference_number":"EMA/97983/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2022-ema-decision-18-february-2022-acceptance-modification-agreed-paediatric-investigation-plan-spesolimab-emea-002475-pip02-19-m02_en.pdf"},
    {"id":"58376","name":"P/0033/2022 : EMA decision of 1 February 2022 on the acceptance of a modification of an agreed paediatric investigation plan for allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded (MC0518), (EMEA-002706-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T14:12:00Z","last_updated_date":"2023-04-17T14:12:00Z","reference_number":"EMA/18414/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2022-ema-decision-1-february-2022-acceptance-modification-agreed-paediatric-investigation-plan-allogeneic-bone-marrow-derived-mesenchymal-stromal-cells-ex-vivo-expanded-mc0518-emea-002706-pip01_en.pdf"},
    {"id":"58377","name":"P/0118/2022 : EMA decision of 13 April 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rozanolixizumab (EMEA-002681-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T14:13:00Z","last_updated_date":"2023-04-17T14:13:00Z","reference_number":"EMA/149542/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2022-ema-decision-13-april-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rozanolixizumab-emea-002681-pip02-21_en.pdf"},
    {"id":"58378","name":"P/0459/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tixagevimab (EMEA- 002900-PIP01-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T14:22:00Z","last_updated_date":"2025-10-14T10:52:00Z","reference_number":"EMA/526329/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0459-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-tixagevimab-emea-002900-pip01-20-m02_en.pdf"},
    {"id":"58379","name":"P/0139/2022 : EMA decision of 13 April 2022 on the granting of a product-specific waiver for retifanlimab (EMEA-002798-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T14:25:00Z","last_updated_date":"2023-04-17T14:25:00Z","reference_number":"EMA/157576/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2022-ema-decision-13-april-2022-granting-product-specific-waiver-retifanlimab-emea-002798-pip02-21_en.pdf"},
    {"id":"58380","name":"P/0046/2022 : EMA decision of 14 February 2022 on the acceptance of a modification of an agreed paediatric investigation plan for SARS-CoV2 prefusion spike delta TM (CoV-2 preS dTM) adjuvanted with AS03 (EMEA-002915-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T14:27:00Z","last_updated_date":"2024-03-20T13:29:00Z","reference_number":"EMA/65206/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2022-ema-decision-14-february-2022-acceptance-modification-agreed-paediatric-investigation-plan-sars-cov2-prefusion-spike-delta-tm-cov-2-pres-dtm-adjuvanted-as03-emea-002915-pip01-20-m01_en.pdf"},
    {"id":"58382","name":"P/0460/2023 : EMA decision of of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for cilgavimab (Evusheld), (EMEA-002925-PIP01-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T14:47:00Z","last_updated_date":"2025-10-14T11:35:00Z","reference_number":"EMA/526329/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0460-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-cilgavimab-evusheld-emea-002925-pip01-20-m02_en.pdf"},
    {"id":"58383","name":"P/0083/2022 : EMA decision of 11 March 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for viltolarsen (EMEA-002853-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T14:52:00Z","last_updated_date":"2023-04-17T14:52:00Z","reference_number":"EMA/99042/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2022-ema-decision-11-march-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-viltolarsen-emea-002853-pip01-20_en.pdf"},
    {"id":"58384","name":"P/0044/2022 : EMA decision of 3 February 2022 on the acceptance of a modification of an agreed paediatric investigation plan for casirivimab (Ronapreve), (EMEA-002964-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T14:59:00Z","last_updated_date":"2023-04-17T14:59:00Z","reference_number":"EMA/63284/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2022-ema-decision-3-february-2022-acceptance-modification-agreed-paediatric-investigation-plan-casirivimab-ronapreve-emea-002964-pip01-21-m01_en.pdf"},
    {"id":"58385","name":"P/0141/2022 : EMA decision of 13 April 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for influenza virus A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 strain, HA surface antigen (EMEA-002869-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T15:04:00Z","last_updated_date":"2023-04-17T15:04:00Z","reference_number":"EMA/197429/2022 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2022-ema-decision-13-april-2022-agreement-paediatric-investigation-plan-granting-waiver-influenza-virus-turkey-turkey-1-2005-h5n1-nibrg-23-strain-ha-surface-antigen-emea-002869-pip03-21_en.pdf"},
    {"id":"58386","name":"P/0045/2022 : EMA decision of 3 February 2022 on the acceptance of a modification of an agreed paediatric investigation plan for imdevimab (Ronapreve), (EMEA-002965-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T15:07:00Z","last_updated_date":"2023-04-17T15:07:00Z","reference_number":"EMA/63282/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2022-ema-decision-3-february-2022-acceptance-modification-agreed-paediatric-investigation-plan-imdevimab-ronapreve-emea-002965-pip01-21-m01_en.pdf"}    {"id":"58388","name":"P/0140/2022 : EMA decision of 13 April 2022 on the granting of a product-specific waiver for sintilimab (EMEA-002919-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T15:59:00Z","last_updated_date":"2023-04-17T15:59:00Z","reference_number":"EMA/157578/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2022-ema-decision-13-april-2022-granting-product-specific-waiver-sintilimab-emea-002919-pip02-21_en.pdf"},
    {"id":"58390","name":"P/0124/2022 : EMA decision of 15 April 2022 on the granting of a product-specific waiver for adalimumab conjugated with (4S)-4-[2-(2- bromoacetamido)acetamido]-5-{3-[(4-{(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)....(EMEA-002927-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T16:10:00Z","last_updated_date":"2023-04-17T16:10:00Z","reference_number":"EMA/149061/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2022-ema-decision-15-april-2022-granting-product-specific-waiver-adalimumab-conjugated-4s-4-2-2-bromoacetamidoacetamido-5-3-4-4ar4bs5s6as6bs8r9ar10as10bsemea-002927-pip02-21_en.pdf"},
    {"id":"58391","name":"P/0125/2022 : EMA decision of 15 April 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for benzylamine derivative of benzofuran (BCX9930) (EMEA-002974-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T16:19:00Z","last_updated_date":"2023-04-17T16:19:00Z","reference_number":"EMA/149065/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2022-ema-decision-15-april-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-benzylamine-derivative-benzofuran-bcx9930-emea-002974-pip01-21_en.pdf"},
    {"id":"58393","name":"P/0143/2022 : EMA decision of 13 April 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pamrevlumab (EMEA-002979-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T16:27:00Z","last_updated_date":"2023-04-17T16:27:00Z","reference_number":"EMA/149480/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2022-ema-decision-13-april-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pamrevlumab-emea-002979-pip01-21_en.pdf"},
    {"id":"58394","name":"P/0105/2022 : EMA decision of 13 April 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified....(EMEA-003001-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T16:43:00Z","last_updated_date":"2023-04-17T16:43:00Z","reference_number":"EMA/145564/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2022-ema-decision-13-april-2022-agreement-paediatric-investigation-plan-granting-waiver-autologous-cd34-hematopoietic-stem-progenitor-cells-hspcs-genetically-modifiedemea-003001-pip01-21_en.pdf"},
    {"id":"58395","name":"P/0112/2022 : EMA decision of 13 April 2022 on the granting of a product-specific waiver for cevostamab (EMEA-003145-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T17:03:00Z","last_updated_date":"2023-04-17T17:03:00Z","reference_number":"EMA/148907/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2022-ema-decision-13-april-2022-granting-product-specific-waiver-cevostamab-emea-003145-pip01-21_en.pdf"},
    {"id":"58396","name":"P/0107/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for amikacin (sulfate) (Arikayce liposomal), (EMEA-000525-PIP01-08-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T17:10:00Z","last_updated_date":"2023-04-17T17:10:00Z","reference_number":"EMA/145474/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-amikacin-sulfate-arikayce-liposomal-emea-000525-pip01-08-m08_en.pdf"},
    {"id":"58397","name":"P/0113/2022 : EMA decision of 13 April 2022 on the granting of a product-specific waiver for acetylsalicylic acid / ticagrelor (EMEA-003146-PIP01- 21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T17:17:00Z","last_updated_date":"2023-04-17T17:17:00Z","reference_number":"EMA/148949/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2022-ema-decision-13-april-2022-granting-product-specific-waiver-acetylsalicylic-acid-ticagrelor-emea-003146-pip01-21_en.pdf"},
    {"id":"58398","name":"P/0119/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for siponimod (hemifumarate) (Mayzent), (EMEA-000716-PIP01-09-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-17T17:26:00Z","last_updated_date":"2023-04-17T17:26:00Z","reference_number":"EMA/157565/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-siponimod-hemifumarate-mayzent-emea-000716-pip01-09-m04_en.pdf"},
    {"id":"58409","name":"P/0122/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ponatinib (Iclusig), (EMEA-001186-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T10:31:00Z","last_updated_date":"2023-04-19T10:31:00Z","reference_number":"EMA/157567/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-ponatinib-iclusig-emea-001186-pip01-11-m03_en.pdf"},
    {"id":"58411","name":"P/0126/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for migalastat (hydrochloride) (Galafold), (EMEA-001194-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T10:41:00Z","last_updated_date":"2023-04-19T10:41:00Z","reference_number":"EMA/157569/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-migalastat-hydrochloride-galafold-emea-001194-pip01-11-m05_en.pdf"},
    {"id":"58412","name":"P/0111/2022 : EMA decision of 13 April 2022 on the granting of a product-specific waiver for telmisartan / indapamide (EMEA-003151-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T10:45:00Z","last_updated_date":"2023-04-19T10:45:00Z","reference_number":"EMA/145596/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2022-ema-decision-13-april-2022-granting-product-specific-waiver-telmisartan-indapamide-emea-003151-pip01-21_en.pdf"},
    {"id":"58413","name":"P/0129/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T10:49:00Z","last_updated_date":"2023-04-19T10:49:00Z","reference_number":"EMA/157570/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-benralizumab-fasenra-emea-001214-pip01-11-m11_en.pdf"},
    {"id":"58415","name":"P/0136/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for esketamine (hydrochloride) (Spravato), (EMEA-001428-PIP03-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T11:00:00Z","last_updated_date":"2023-04-19T11:00:00Z","reference_number":"EMA/157572/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-esketamine-hydrochloride-spravato-emea-001428-pip03-15-m02_en.pdf"},
    {"id":"58416","name":"P/0108/2022 : EMA decision of 13 April 2022 on the granting of a product-specific waiver for human IgG4 monoclonal antibody against BCMA and CD3 (ABBV-383), (EMEA-003147-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T11:01:00Z","last_updated_date":"2023-04-19T11:01:00Z","reference_number":"EMA/145624/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2022-ema-decision-13-april-2022-granting-product-specific-waiver-human-igg4-monoclonal-antibody-against-bcma-cd3-abbv-383-emea-003147-pip01-21_en.pdf"},
    {"id":"58417","name":"P/0134/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for inotuzumab ozogamicin (Besponsa), (EMEA-001429-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T11:07:00Z","last_updated_date":"2023-04-19T11:07:00Z","reference_number":"EMA/193744/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-inotuzumab-ozogamicin-besponsa-emea-001429-pip01-13-m05_en.pdf"},
    {"id":"58419","name":"P/0082/2022 : EMA decision of 11 March 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for MIJ821 (EMEA-002946-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T11:26:00Z","last_updated_date":"2023-04-19T11:26:00Z","reference_number":"EMA/99133/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2022-ema-decision-11-march-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mij821-emea-002946-pip01-20_en.pdf"},
    {"id":"58420","name":"P/0132/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for fosdenopterin (ORGN001), (EMEA-001491-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T11:35:00Z","last_updated_date":"2023-04-19T11:35:00Z","reference_number":"EMA/193794/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-fosdenopterin-orgn001-emea-001491-pip01-13-m02_en.pdf"},
    {"id":"58421","name":"P/0070/2022 : EMA decision of 11 March 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for CpG 1018/Alum-adjuvanted recombinant SARS-CoV-2 Trimeric Spike (S) protein subunit vaccine....(EMEA-002987-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T11:36:00Z","last_updated_date":"2023-04-19T11:36:00Z","reference_number":"EMA/70884/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2022-ema-decision-11-march-2022-agreement-paediatric-investigation-plan-granting-deferral-cpg-1018-alum-adjuvanted-recombinant-sars-cov-2-trimeric-spike-s-protein-subunit-vaccineemea-002987_en.pdf"},
    {"id":"58422","name":"P/0133/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for etelcalcetide (Parsabiv), (EMEA-001554-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T12:00:00Z","last_updated_date":"2023-04-19T12:00:00Z","reference_number":"P/0133/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-etelcalcetide-parsabiv-emea-001554-pip01-13-m03_en.pdf"},
    {"id":"58423","name":"P/0128/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for eluxadoline, (EMEA- 001579-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T12:08:00Z","last_updated_date":"2023-04-19T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-eluxadoline-emea-001579-pip01-13-m05_en.pdf"},
    {"id":"58424","name":"P/0135/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for bezlotoxumab (Zinplava), (EMEA-001645-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T12:13:00Z","last_updated_date":"2023-04-19T12:13:00Z","reference_number":"EMA/194322/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-bezlotoxumab-zinplava-emea-001645-pip01-14-m04_en.pdf"},
    {"id":"58425","name":"P/0056/2022 : EMA decision of 11 March 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ralmitaront (EMEA-003003-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T12:15:00Z","last_updated_date":"2023-04-19T12:15:00Z","reference_number":"EMA/94168/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2022-ema-decision-11-march-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ralmitaront-emea-003003-pip01-21_en.pdf"},
    {"id":"58426","name":"P/0335/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for zamtocabtagene autoleucel, (EMEA-003009-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-20T11:51:00Z","last_updated_date":"2025-10-20T11:51:00Z","reference_number":"EMA/414032/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0335-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-zamtocabtagene-autoleucel-emea-003009-pip01-21-m01_en.pdf"},
    {"id":"58427","name":"P/0131/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod (Zeposia), (EMEA-001710-PIP04-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T12:22:00Z","last_updated_date":"2023-04-19T12:22:00Z","reference_number":"EMA/194368/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-ozanimod-zeposia-emea-001710-pip04-17-m03_en.pdf"},
    {"id":"58428","name":"P/0142/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for galcanezumab (Emgality), (EMEA-001860-PIP03-16-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T12:27:00Z","last_updated_date":"2023-04-19T12:27:00Z","reference_number":"EMA/149012/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-galcanezumab-emgality-emea-001860-pip03-16-m07_en.pdf"},
    {"id":"58431","name":"P/0101/2022 : EMA decision of 17 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (Edurant), (EMEA-000317-PIP01-08-M13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T12:33:00Z","last_updated_date":"2023-04-19T12:33:00Z","reference_number":"EMA/145471/2022 Corr1","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2022-ema-decision-17-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-hydrochloride-edurant-emea-000317-pip01-08-m13_en.pdf"},
    {"id":"58433","name":"P/0114/2022 - Decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for axicabtagene ciloleucel (Yescarta), (EMEA-002010-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T13:37:00Z","last_updated_date":"2023-04-19T13:37:00Z","reference_number":"P/0114/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0114-2022-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-axicabtagene-ciloleucel-yescarta-emea-002010-pip01-16-m03_en.pdf"},
    {"id":"58434","name":"P/0061/2022 : EMA decision of 11 March 2022 on the granting of a product specific waiver for cosibelimab (EMEA-003041-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T13:34:00Z","last_updated_date":"2023-04-19T13:34:00Z","reference_number":"EMA/67516/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2022-ema-decision-11-march-2022-granting-product-specific-waiver-cosibelimab-emea-003041-pip01-21_en.pdf"},
    {"id":"58435","name":"P/0073/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir disoproxil (Viread), (EMEA-000533-PIP01-08-M11)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T13:40:00Z","last_updated_date":"2023-04-19T13:40:00Z","reference_number":"EMA/65153/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-disoproxil-viread-emea-000533-pip01-08-m11_en.pdf"},
    {"id":"58436","name":"P/0060/2022 - EMA decision of 7 March 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for L-carnitine/glucose/calcium chloride dihydrate/magnesium chloride hexahydrate/sodium lactate/sodium..(EMA-003049-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T13:47:00Z","last_updated_date":"2023-04-19T13:47:00Z","reference_number":"EMA/107971/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2022-ema-decision-7-march-2022-agreement-paediatric-investigation-plan-granting-deferral-l-carnitine-glucose-calcium-chloride-dihydrate-magnesium-chloride-hexahydrate-sodium-lactate-sodiumema_en.pdf"},
    {"id":"58437","name":"P/0115/2022 - EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for leriglitazone (EMEA- 002106-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T13:48:00Z","last_updated_date":"2023-04-19T13:48:00Z","reference_number":"P/0115/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-leriglitazone-emea-002106-pip01-16-m02_en.pdf"},
    {"id":"58438","name":"P/0054/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for daridorexant (Quviviq) (EMEA-002121-PIP03-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-02T13:59:00Z","last_updated_date":"2025-04-02T13:59:00Z","reference_number":"P/0054/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-daridorexant-quviviq-emea-002121-pip03-19-m02_en.pdf"},
    {"id":"58439","name":"P/0117/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for palbociclib (Ibrance), (EMEA-002146-PIP01-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T14:07:00Z","last_updated_date":"2023-04-19T14:07:00Z","reference_number":"EMA/149197/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-palbociclib-ibrance-emea-002146-pip01-17-m04_en.pdf"},
    {"id":"58440","name":"P/0072/2022 : EMA decision of 11 March 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for phospholipid esters from herring roe (HRO350) (EMEA-003053-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T14:11:00Z","last_updated_date":"2023-04-19T14:11:00Z","reference_number":"EMA/71127/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2022-ema-decision-11-march-2022-agreement-paediatric-investigation-plan-granting-deferral-phospholipid-esters-herring-roe-hro350-emea-003053-pip01-21_en.pdf"},
    {"id":"58441","name":"P/0097/2022 : EMA decision of 17 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for lisdexamfetamine (dimesylate), (Elvanse and associated names), (EMEA-000553-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T14:15:00Z","last_updated_date":"2023-04-19T14:15:00Z","reference_number":"EMA/145463/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2022-ema-decision-17-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-lisdexamfetamine-dimesylate-elvanse-associated-names-emea-000553-pip01-09-m05_en.pdf"},
    {"id":"58442","name":"P/0121/2022 : EMA decision of 15 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ofatumumab (Kesimpta), (EMEA-002397-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T14:16:00Z","last_updated_date":"2023-04-19T14:16:00Z","reference_number":"EMA/149052/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2022-ema-decision-15-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-ofatumumab-kesimpta-emea-002397-pip01-18-m02_en.pdf"},
    {"id":"58443","name":"P/0123/2022 - EMA decision of 15 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tapotoclax (EMEA- 002631-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T14:22:00Z","last_updated_date":"2023-04-19T14:22:00Z","reference_number":"EMA/149058/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2022-ema-decision-15-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-tapotoclax-emea-002631-pip01-19-m01_en.pdf"},
    {"id":"58444","name":"P/0074/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris), (EMEA-000876-PIP05-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T14:22:00Z","last_updated_date":"2023-04-19T14:22:00Z","reference_number":"EMA/65171/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip05-15-m05_en.pdf"},
    {"id":"58445","name":"P/0075/2022 : EMA decision of 11 March 2022 on the refusal of a modification of an agreed paediatric investigation plan for modified allergen extract of birch pollen (EMEA-000932-PIP01-10-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T14:35:00Z","last_updated_date":"2023-04-19T14:35:00Z","reference_number":"EMA/65170/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2022-ema-decision-11-march-2022-refusal-modification-agreed-paediatric-investigation-plan-modified-allergen-extract-birch-pollen-emea-000932-pip01-10-m02_en.pdf"},
    {"id":"58446","name":"P/0066/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ex vivo expanded autologous human corneal epithelium cells containing stem cells (Holoclar), (EMEA-001082-PIP02-11- M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T15:04:00Z","last_updated_date":"2023-04-19T15:04:00Z","reference_number":"EMA/68410/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-ex-vivo-expanded-autologous-human-corneal-epithelium-cells-containing-stem-cells-holoclar-emea_en.pdf"},
    {"id":"58447","name":"P/0092/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for dienogest / ethinyl estradiol (EMEA-002229-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T15:08:00Z","last_updated_date":"2023-04-19T15:08:00Z","reference_number":"EMA/99495/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-dienogest-ethinyl-estradiol-emea-002229-pip01-17-m03_en.pdf"},
    {"id":"58448","name":"P/0091/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for eptinezumab (EMEA-002243-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T15:17:00Z","last_updated_date":"2023-04-19T15:17:00Z","reference_number":"EMA/99945/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-eptinezumab-emea-002243-pip01-17-m02_en.pdf"},
    {"id":"58449","name":"P/0087/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ridinilazole (hydrate) (EMEA-002250-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T15:26:00Z","last_updated_date":"2023-04-19T15:26:00Z","reference_number":"EMA/100334/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-ridinilazole-hydrate-emea-002250-pip02-17-m01_en.pdf"},
    {"id":"58450","name":"P/0093/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for dinutuximab beta (Qarziba), (EMEA-001314-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T15:30:00Z","last_updated_date":"2023-04-19T15:30:00Z","reference_number":"EMA/104589/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-dinutuximab-beta-qarziba-emea-001314-pip01-12-m01_en.pdf"},
    {"id":"58451","name":"P/0086/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for isoflurane (Sedaconda and associated names), (EMEA-002320-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T15:36:00Z","last_updated_date":"2023-04-19T15:36:00Z","reference_number":"EMA/99888/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-isoflurane-sedaconda-associated-names-emea-002320-pip01-17-m02_en.pdf"},
    {"id":"58452","name":"P/0098/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for delgocitinib (EMEA- 002329-PIP02-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T15:41:00Z","last_updated_date":"2023-04-19T15:41:00Z","reference_number":"EMA/105314/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-delgocitinib-emea-002329-pip02-20-m01_en.pdf"},
    {"id":"58453","name":"P/0100/2022 : EMA decision of 18 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant influenza hemagglutinin-strain A (H1N1 subtype)/recombinant influenza...(EMEA-002418-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T15:49:00Z","last_updated_date":"2023-04-19T15:49:00Z","reference_number":"EMA/149054/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2022-ema-decision-18-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-influenza-hemagglutinin-strain-h1n1-subtype-recombinant-influenzaemea-002418-pip01-18_en.pdf"},
    {"id":"58454","name":"P/0099/2022 : EMA decision of 18 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for bempegaldesleukin (EMEA-002492-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T15:54:00Z","last_updated_date":"2023-04-19T15:54:00Z","reference_number":"EMA/149056/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2022-ema-decision-18-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-bempegaldesleukin-emea-002492-pip01-18-m02_en.pdf"},
    {"id":"58455","name":"P/0065/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab (Tremfya), (EMEA-001523-PIP05-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T15:59:00Z","last_updated_date":"2023-04-19T15:59:00Z","reference_number":"EMA/68373/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-guselkumab-tremfya-emea-001523-pip05-19-m01_en.pdf"},
    {"id":"58456","name":"P/0095/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for efanesoctocog alfa (EMEA-002501-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T16:06:00Z","last_updated_date":"2023-04-19T16:06:00Z","reference_number":"P/0095/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-efanesoctocog-alfa-emea-002501-pip01-18-m02_en.pdf"},
    {"id":"58457","name":"P/0067/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for fostemsavir (tromethamine) (Rukobia), (EMEA-001687-PIP01-14-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T16:14:00Z","last_updated_date":"2023-04-19T16:14:00Z","reference_number":"EMA/68460/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-fostemsavir-tromethamine-rukobia-emea-001687-pip01-14-m06_en.pdf"},
    {"id":"58458","name":"P/0053/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for etrasimod L-arginine (EMEA-002713-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T16:19:00Z","last_updated_date":"2023-04-19T16:19:00Z","reference_number":"EMA/94160/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0053-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-etrasimod-l-arginine-emea-002713-pip01-19-m01_en.pdf"},
    {"id":"58459","name":"P/0096/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (Adtralza), (EMEA-001900-PIP02-17-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T16:22:00Z","last_updated_date":"2023-04-19T16:22:00Z","reference_number":"EMA/104757/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-adtralza-emea-001900-pip02-17-m06_en.pdf"},
    {"id":"58460","name":"P/0104/2022 - EMA decision of 25 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for etranacogene dezaparvovec (EMEA-002722-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T16:25:00Z","last_updated_date":"2023-04-19T16:25:00Z","reference_number":"EMA/180518/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2022-ema-decision-25-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-etranacogene-dezaparvovec-emea-002722-pip01-19-m01_en.pdf"},
    {"id":"58461","name":"P/0089/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for pegvaliase (Palynziq), (EMEA-001951-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T16:32:00Z","last_updated_date":"2023-04-19T16:32:00Z","reference_number":"EMA/100063/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-pegvaliase-palynziq-emea-001951-pip01-16-m02_en.pdf"},
    {"id":"58462","name":"P/0054/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for adrenaline (epinephrine) (EMEA-002749-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T16:35:00Z","last_updated_date":"2023-04-19T16:35:00Z","reference_number":"EMA/94165/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0054-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-adrenaline-epinephrine-emea-002749-pip01-19-m01_en.pdf"},
    {"id":"58463","name":"P/0068/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for glutamine (EMEA- 001996-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T16:41:00Z","last_updated_date":"2023-04-19T16:41:00Z","reference_number":"EMA/68911/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-glutamine-emea-001996-pip02-16-m01_en.pdf"},
    {"id":"58464","name":"P/0051/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for vosoritide (Voxzogo), (EMEA-002033-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T16:47:00Z","last_updated_date":"2023-04-19T16:47:00Z","reference_number":"EMA/94150/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0051-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-vosoritide-voxzogo-emea-002033-pip01-16-m02_en.pdf"},
    {"id":"58465","name":"P/0088/2022 : EMA decision of 11 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for mirikizumab (EMEA- 002208-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T16:54:00Z","last_updated_date":"2023-04-19T16:54:00Z","reference_number":"EMA/99728/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2022-ema-decision-11-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-mirikizumab-emea-002208-pip01-17-m02_en.pdf"},
    {"id":"58470","name":"P/0063/2022 : EMA decision of 11 March 2022 on the granting of a product specific waiver for dapagliflozin / 2-{(3S)-7-fluoro-4-[(3-oxo-3,4-dihydro- 2H-1,4-benzoxazin-6-yl)carbonyl]-3,4-dihydro- 2H-1,4-benzoxazin-3-yl}.....(AZD9977) (EMEA-003120-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-20T10:20:00Z","last_updated_date":"2023-04-20T10:20:00Z","reference_number":"EMA/67591/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2022-ema-decision-11-march-2022-granting-product-specific-waiver-dapagliflozin-2-3s-7-fluoro-4-3-oxo-34-dihydro-2h-14-benzoxazin-6-ylcarbonyl-34-dihydro-2h-14-benzoxazin-3-ylazd9977-emea-003120_en.pdf"},
    {"id":"58471","name":"P/0094/2022 : EMA decision of 11 March 2022 on the granting of a product specific waiver for human normal immunoglobulin (Flebogamma 5% DIF) (EMEA-003121-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-20T10:29:00Z","last_updated_date":"2023-04-20T10:29:00Z","reference_number":"EMA/105652/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2022-ema-decision-11-march-2022-granting-product-specific-waiver-human-normal-immunoglobulin-flebogamma-5-dif-emea-003121-pip01-21_en.pdf"},
    {"id":"58472","name":"P/0057/2022 : EMA decision of 11 March 2022 on the granting of a product-specific waiver for avexitide (acetate) (EMEA-003125-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-20T10:40:00Z","last_updated_date":"2023-04-20T10:40:00Z","reference_number":"EMA/94186/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2022-ema-decision-11-march-2022-granting-product-specific-waiver-avexitide-acetate-emea-003125-pip01-21_en.pdf"},
    {"id":"58473","name":"P/0064/2022 : EMA decision of 11 March 2022 on the granting of a product specific waiver for ceralasertib (EMEA-003127-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-20T10:49:00Z","last_updated_date":"2023-04-20T10:49:00Z","reference_number":"EMA/67616/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2022-ema-decision-11-march-2022-granting-product-specific-waiver-ceralasertib-emea-003127-pip01-21_en.pdf"},
    {"id":"58474","name":"P/0058/2022 : EMA decision of 11 March 2022 on the granting of a product-specific waiver for sunvozertinib (EMEA-003132-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-20T10:59:00Z","last_updated_date":"2023-04-20T10:59:00Z","reference_number":"EMA/94202/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2022-ema-decision-11-march-2022-granting-product-specific-waiver-sunvozertinib-emea-003132-pip01-21_en.pdf"},
    {"id":"58475","name":"P/0081/2022 : EMA decision of 11 March 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for nifurtimox (EMEA-003134-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-20T11:06:00Z","last_updated_date":"2023-04-20T11:06:00Z","reference_number":"EMA/100581/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2022-ema-decision-11-march-2022-agreement-paediatric-investigation-plan-granting-waiver-nifurtimox-emea-003134-pip01-21_en.pdf"},
    {"id":"58476","name":"P/0059/2022 : EMA decision of 11 March 2022 on the granting of a product specific waiver for nemtabrutinib (EMEA-003135-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-20T11:15:00Z","last_updated_date":"2023-04-20T11:15:00Z","reference_number":"EMA/94204/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2022-ema-decision-11-march-2022-granting-product-specific-waiver-nemtabrutinib-emea-003135-pip01-21_en.pdf"},
    {"id":"58477","name":"P/0090/2022 : EMA decision of 11 March 2022 on the granting of a product specific waiver for tarlatamab (EMEA-003138-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-20T11:21:00Z","last_updated_date":"2023-04-20T11:21:00Z","reference_number":"EMA/101043/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2022-ema-decision-11-march-2022-granting-product-specific-waiver-tarlatamab-emea-003138-pip01-21_en.pdf"},
    {"id":"58481","name":"P/0102/2022 : EMA decision of 17 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (Vocabria) (EMEA-001418-PIP02-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-04-20T14:24:00Z","last_updated_date":"2023-04-20T14:24:00Z","reference_number":"EMA/150156/2022 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2022-ema-decision-17-march-2022-acceptance-modification-agreed-paediatric-investigation-plan-cabotegravir-vocabria-emea-001418-pip02-15-m03_en.pdf"},
    {"id":"58609","name":"P/0145/2022 : EMA decision of 13 May 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for adeno-associated viral vector serotype rh.10 expressing beta-galactosidase (LYS-GM101) (EMEA-003020-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-10T12:32:00Z","last_updated_date":"2023-05-10T12:32:00Z","reference_number":"EMA/206128/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2022-ema-decision-13-may-2022-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-rh10-expressing-beta-galactosidase-lys-gm101-emea-003020-pip01-21_en.pdf"},
    {"id":"58612","name":"P/0146/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for latozinemab (EMEA-002997-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-10T15:06:00Z","last_updated_date":"2023-05-10T15:06:00Z","reference_number":"EMA/206559/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2022-ema-decision-13-may-2022-granting-product-specific-waiver-latozinemab-emea-002997-pip02-22_en.pdf"},
    {"id":"58613","name":"P/0151/2022 : EMA decision of 13 May 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for ibutamoren mesylate (EMEA-003032-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-10T15:57:00Z","last_updated_date":"2023-05-10T15:57:00Z","reference_number":"EMA/206176/2022 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2022-ema-decision-13-may-2022-agreement-paediatric-investigation-plan-granting-waiver-ibutamoren-mesylate-emea-003032-pip01-21_en.pdf"},
    {"id":"58614","name":"P/0152/2022 : EMA decision of 20 May 2022 on the granting of a product specific waiver for atorvastatin / perindopril (arginine) / indapamide / amlodipine (EMEA-003173-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-10T15:57:00Z","last_updated_date":"2023-05-10T15:57:00Z","reference_number":"EMA/205787/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2022-ema-decision-20-may-2022-granting-product-specific-waiver-atorvastatin-perindopril-arginine-indapamide-amlodipine-emea-003173-pip01-21_en.pdf"},
    {"id":"58615","name":"P/0153/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for human IgG4-based bispecific antibody binding to both B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (REGN5458) (EMEA-003175-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-10T15:57:00Z","last_updated_date":"2023-05-10T15:57:00Z","reference_number":"EMA/205812/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2022-ema-decision-13-may-2022-granting-product-specific-waiver-human-igg4-based-bispecific-antibody-binding-both-b-cell-maturation-antigen-bcma-cluster-differentiation-3-cd3-regn5458-emea_en.pdf"},
    {"id":"58616","name":"P/0150/2022 : EMA decision of 13 May 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mitapivat (EMEA-002684-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-10T16:21:00Z","last_updated_date":"2023-05-10T16:21:00Z","reference_number":"EMA/206221/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2022-ema-decision-13-may-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mitapivat-emea-002684-pip02-21_en.pdf"},
    {"id":"58617","name":"P/0171/2022 : EMA decision of 13 May 2022 on the agreement of a paediatric investigation plan for zinc gluconate / alisitol / retinyl palmitate (EMEA-002198-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-10T16:54:00Z","last_updated_date":"2023-05-10T16:54:00Z","reference_number":"EMA/204214/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2022-ema-decision-13-may-2022-agreement-paediatric-investigation-plan-zinc-gluconate-alisitol-retinyl-palmitate-emea-002198-pip01-21_en.pdf"},
    {"id":"58618","name":"P/0172/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for bilastine / pseudoephedrine (EMEA-003164-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-10T16:54:00Z","last_updated_date":"2023-05-10T16:54:00Z","reference_number":"EMA/204941/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2022-ema-decision-13-may-2022-granting-product-specific-waiver-bilastine-pseudoephedrine-emea-003164-pip01-21_en.pdf"},
    {"id":"58619","name":"P/0173/2022 : EMA decision of 13 May 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for peptide derivative of glucagon-like-peptide 1 and... (EMEA-002942-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-10T16:54:00Z","last_updated_date":"2023-05-10T16:54:00Z","reference_number":"EMA/204429/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2022-ema-decision-13-may-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-peptide-derivative-glucagon-peptide-1-emea-002942-pip02-20_en.pdf"},
    {"id":"58626","name":"P/0181/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for sacituzumab govitecan (Trodelvy), (EMEA-002645-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T11:48:00Z","last_updated_date":"2023-05-11T11:48:00Z","reference_number":"EMA/205815/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2022-ema-decision-13-may-2022-granting-product-specific-waiver-sacituzumab-govitecan-trodelvy-emea-002645-pip03-21_en.pdf"},
    {"id":"58627","name":"P/0182/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for adeno-associated virus vector serotype 1 containing the human GRN gene (EMEA-003167-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T11:48:00Z","last_updated_date":"2023-05-11T11:48:00Z","reference_number":"EMA/207941/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2022-ema-decision-13-may-2022-granting-product-specific-waiver-adeno-associated-virus-vector-serotype-1-containing-human-grn-gene-emea-003167-pip01-21_en.pdf"},
    {"id":"58628","name":"P/0183/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for 3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5- yl)-1H-pyrazole-5-carboxamide (EMEA-003169-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T11:48:00Z","last_updated_date":"2023-05-11T11:48:00Z","reference_number":"EMA/207945/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2022-ema-decision-13-may-2022-granting-product-specific-waiver-34-dimethyl-n-2-phenyl-1h-pyrrolo23-bpyridin-5-yl-1h-pyrazole-5-carboxamide-emea-003169-pip01-21_en.pdf"},
    {"id":"58630","name":"P/0186/2022 : EMA decision of 16 May 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for humanised KLB/FGFR1c monoclonal antibody (MK-3655) (EMEA-003058-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T12:05:00Z","last_updated_date":"2023-05-11T12:05:00Z","reference_number":"EMA/258327/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2022-ema-decision-16-may-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-humanised-klb-fgfr1c-monoclonal-antibody-mk-3655-emea-003058-pip01-21_en.pdf"},
    {"id":"58631","name":"P/0156/2022 : EMA decision of 13 May 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deucravacitinib (EMEA-002350-PIP02-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T12:38:00Z","last_updated_date":"2023-05-11T12:38:00Z","reference_number":"EMA/205934/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2022-ema-decision-13-may-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-deucravacitinib-emea-002350-pip02-20_en.pdf"},
    {"id":"58632","name":"P/0158/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for (2S) 4 [2 methoxyethyl [4 (5,6,7,8 tetrahydro 1,8 naphthyridin 2 yl)butyl] amino] 2 (quinazolin 4 ylamino)butanoic acid (EMEA-003159-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T12:38:00Z","last_updated_date":"2023-05-11T12:38:00Z","reference_number":"EMA/169216/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2022-ema-decision-13-may-2022-granting-product-specific-waiver-2s-4-2-methoxyethyl-4-5678-tetrahydro-18-naphthyridin-2-ylbutyl-amino-2-quinazolin-4-ylaminobutanoic-acid-emea-003159-pip01-21_en.pdf"},
    {"id":"58635","name":"P/0162/2022 : EMA decision of 13 May 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for virus-like particle of SARS-CoV-2 spike protein (recombinant, adjuvant) (CoVLP) (EMEA-003008-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T15:42:00Z","last_updated_date":"2023-05-11T15:42:00Z","reference_number":"EMA/207850/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2022-ema-decision-13-may-2022-agreement-paediatric-investigation-plan-granting-deferral-virus-particle-sars-cov-2-spike-protein-recombinant-adjuvant-covlp-emea-003008-pip01-21_en.pdf"},
    {"id":"58636","name":"P/0165/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for izaflortaucipir (18F) (EMEA-003040-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T15:42:00Z","last_updated_date":"2023-05-11T15:42:00Z","reference_number":"EMA/204931/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2022-ema-decision-13-may-2022-granting-product-specific-waiver-izaflortaucipir-18f-emea-003040-pip02-21_en.pdf"},
    {"id":"58637","name":"P/0167/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for anti-CD40L humanised monoclonal antibody (SAR441344) (EMEA-002945-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T16:09:00Z","last_updated_date":"2023-05-11T16:09:00Z","reference_number":"EMA/204558/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2022-ema-decision-13-may-2022-granting-product-specific-waiver-anti-cd40l-humanised-monoclonal-antibody-sar441344-emea-002945-pip02-21_en.pdf"},
    {"id":"58638","name":"P/0169/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for infigratinib (EMEA-002594-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T16:09:00Z","last_updated_date":"2023-05-11T16:09:00Z","reference_number":"EMA/204326/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2022-ema-decision-13-may-2022-granting-product-specific-waiver-infigratinib-emea-002594-pip03-21_en.pdf"},
    {"id":"58639","name":"P/0176/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for zandelisib (EMEA-003158-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T17:07:00Z","last_updated_date":"2023-05-11T17:07:00Z","reference_number":"EMA/205830/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2022-ema-decision-13-may-2022-granting-product-specific-waiver-zandelisib-emea-003158-pip01-21_en.pdf"},
    {"id":"58640","name":"P/0178/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for dupilumab (Dupixent), (EMEA-001501-PIP11-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-11T17:07:00Z","last_updated_date":"2023-05-11T17:07:00Z","reference_number":"EMA/205791/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2022-ema-decision-13-may-2022-granting-product-specific-waiver-dupilumab-dupixent-emea-001501-pip11-21_en.pdf"},
    {"id":"58643","name":"P/0147/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for odevixibat (Bylvay), (EMEA-002054-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-12T10:03:00Z","last_updated_date":"2023-05-12T10:03:00Z","reference_number":"EMA/206556/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-odevixibat-bylvay-emea-002054-pip01-16-m03_en.pdf"},
    {"id":"58644","name":"P/0148/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for venetoclax (Venclyxto), (EMEA-002018-PIP02-16-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-12T10:03:00Z","last_updated_date":"2023-05-12T10:03:00Z","reference_number":"EMA/206375/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-venetoclax-venclyxto-emea-002018-pip02-16-m05_en.pdf"},
    {"id":"58645","name":"P/0149/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride (KH176) (EMEA-002113-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-12T10:03:00Z","last_updated_date":"2023-05-12T10:03:00Z","reference_number":"EMA/206268/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-s-6-hydroxy-2578-tetramethyl-n-r-piperidin-3-ylchroman-2-carboxamide-hydrochloride-kh176-emea-002113_en.pdf"},
    {"id":"58646","name":"P/0154/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (Lenvima, Kisplyx), (EMEA-001119-PIP03-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-12T10:57:00Z","last_updated_date":"2023-05-12T10:57:00Z","reference_number":"EMA/206618/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-lenvima-kisplyx-emea-001119-pip03-19-m02_en.pdf"},
    {"id":"58647","name":"P/0155/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for luspatercept (Reblozyl), (EMEA-001521-PIP01-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-12T10:57:00Z","last_updated_date":"2023-05-12T10:57:00Z","reference_number":"EMA/206730/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-luspatercept-reblozyl-emea-001521-pip01-13-m06_en.pdf"},
    {"id":"58648","name":"P/0157/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tolvaptan (Samsca and associated names), (EMEA-001231-PIP02-13-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-12T10:57:00Z","last_updated_date":"2023-05-12T10:57:00Z","reference_number":"EMA/206659/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-tolvaptan-samsca-associated-names-emea-001231-pip02-13-m09_en.pdf"},
    {"id":"58677","name":"P/0159/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for magnesium sulphate heptahydrate / potassium sulphate / sodium sulphate anhydrous... (EMEA-000816-PIP02-10-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-12T17:15:00Z","last_updated_date":"2023-05-12T17:15:00Z","reference_number":"EMA/169200/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-magnesium-sulphate-heptahydrate-potassium-sulphate-sodium-sulphate-anhydrous-emea-000816-pip02-10-m03_en.pdf"},
    {"id":"58678","name":"P/0160/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for eslicarbazepine acetate (Zebinix), (EMEA-000696-PIP02-10-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-12T17:15:00Z","last_updated_date":"2023-05-12T17:15:00Z","reference_number":"EMA/169198/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-eslicarbazepine-acetate-zebinix-emea-000696-pip02-10-m08_en.pdf"},
    {"id":"58679","name":"P/0161/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for dapagliflozin (Forxiga), (EMEA-000694-PIP02-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-12T17:15:00Z","last_updated_date":"2023-05-12T17:15:00Z","reference_number":"EMA/169194/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-dapagliflozin-forxiga-emea-000694-pip02-14-m03_en.pdf"},
    {"id":"58680","name":"P/0166/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for regdanvimab (Regkirona), (EMEA-002961-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-12T17:57:00Z","last_updated_date":"2023-05-12T17:57:00Z","reference_number":"EMA/204850/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-regdanvimab-regkirona-emea-002961-pip01-21-m01_en.pdf"}    {"id":"58706","name":"P/0163/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cefiderocol (Fetcroja), (EMEA-002133-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-16T15:51:00Z","last_updated_date":"2023-05-16T15:51:00Z","reference_number":"EMA/207939/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-cefiderocol-fetcroja-emea-002133-pip01-17-m02_en.pdf"},
    {"id":"58707","name":"P/0164/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for bis-choline tetrathiomolybdate (EMEA-002232-PIP02-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-16T15:51:00Z","last_updated_date":"2023-05-16T15:51:00Z","reference_number":"EMA/207916/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-bis-choline-tetrathiomolybdate-emea-002232-pip02-19-m02_en.pdf"},
    {"id":"58709","name":"P/0168/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for human, recombinant, non-fucosylated IgG1k monoclonal antibody...(EMEA-002886-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-16T16:19:00Z","last_updated_date":"2023-05-16T16:19:00Z","reference_number":"EMA/204358/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-human-recombinant-non-fucosylated-igg1k-monoclonal-antibodyemea-002886-pip01-20-m01_en.pdf"},
    {"id":"58710","name":"P/0170/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for remibrutinib (EMEA-002582-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-16T16:19:00Z","last_updated_date":"2023-05-16T16:19:00Z","reference_number":"EMA/204227/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-remibrutinib-emea-002582-pip01-19-m01_en.pdf"},
    {"id":"58712","name":"P/0174/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (EMEA- 002360-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-16T17:15:00Z","last_updated_date":"2023-05-16T17:15:00Z","reference_number":"EMA/207913/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-tirzepatide-emea-002360-pip01-18-m02_en.pdf"},
    {"id":"58713","name":"P/0175/2022 : EMA decision of 13 May 2022 on the refusal of a modification of an agreed paediatric investigation plan for betibeglogene autotemcel (Zynteglo), (EMEA-001665-PIP01-14-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-16T17:15:00Z","last_updated_date":"2023-05-16T17:15:00Z","reference_number":"EMA/206734/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2022-ema-decision-13-may-2022-refusal-modification-agreed-paediatric-investigation-plan-betibeglogene-autotemcel-zynteglo-emea-001665-pip01-14-m06_en.pdf"},
    {"id":"58716","name":"P/0177/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for sufentanil (citrate) / ketamine (hydrochloride) (EMEA-001739-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-17T11:10:00Z","last_updated_date":"2023-05-17T11:10:00Z","reference_number":"EMA/205591/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-sufentanil-citrate-ketamine-hydrochloride-emea-001739-pip02-16-m01_en.pdf"},
    {"id":"58717","name":"P/0179/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cemiplimab (Libtayo), (EMEA-002007-PIP02-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-17T11:16:00Z","last_updated_date":"2023-05-17T11:16:00Z","reference_number":"EMA/205775/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-cemiplimab-libtayo-emea-002007-pip02-17-m02_en.pdf"},
    {"id":"58719","name":"P/0180/2022 : EMA decision of 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for brincidofovir (EMEA- 001904-PIP03-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-17T11:27:00Z","last_updated_date":"2023-05-17T11:27:00Z","reference_number":"EMA/205675/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-brincidofovir-emea-001904-pip03-18-m02_en.pdf"},
    {"id":"58720","name":"P/0185/2022 : EMA decision on 13 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for avibactam / aztreonam (EMEA-002283-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-17T11:46:00Z","last_updated_date":"2023-05-17T11:46:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2022-ema-decision-13-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-avibactam-aztreonam-emea-002283-pip01-17-m03_en.pdf"},
    {"id":"58721","name":"P/0187/2022 : EMA decision on 25 May 2022 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga), (EMEA-000597-PIP03-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-05-17T11:46:00Z","last_updated_date":"2023-05-17T11:46:00Z","reference_number":"EMA/274001/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2022-ema-decision-25-may-2022-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip03-15-m05_en.pdf"},
    {"id":"58920","name":"P/0204/2022 : EMA decision on 10 June 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for omaveloxolone (EMEA-002487-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-12T13:40:00Z","last_updated_date":"2023-06-12T13:40:00Z","reference_number":"EMA/275720/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2022-ema-decision-10-june-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-omaveloxolone-emea-002487-pip01-18_en.pdf"},
    {"id":"58923","name":"P/0216/2022: EMA decision of 10 June 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dersimelagon (EMEA-002850-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T09:15:00Z","last_updated_date":"2023-06-13T09:15:00Z","reference_number":"EMA/366139/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2022-ema-decision-10-june-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dersimelagon-emea-002850-pip02-21_en.pdf"},
    {"id":"58924","name":"P/192/2022: EMA decision of 10 June 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for sirolimus (EMEA-002982-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T09:25:00Z","last_updated_date":"2023-06-13T09:25:00Z","reference_number":"EMA/251491/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-192-2022-ema-decision-10-june-2022-agreement-paediatric-investigation-plan-granting-waiver-sirolimus-emea-002982-pip01-21_en.pdf"},
    {"id":"58925","name":"P/193/2022: EMA decision of 10 June 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for recombinant adeno-associated viral (rAAV) vector expressing the human ornithine transcarbamylase (hOTC) gene (EMEA-002983-PIP0","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T09:35:00Z","last_updated_date":"2023-06-13T09:35:00Z","reference_number":"EMA/251505/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-193-2022-ema-decision-10-june-2022-agreement-paediatric-investigation-plan-granting-waiver-recombinant-adeno-associated-viral-raav-vector-expressing-human-ornithine-transcarbamylase-hotc-gene-emea_en.pdf"},
    {"id":"58926","name":"P/197/2022: EMA decision of 9 June 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for apraglutide (EMEA-003016-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T09:41:00Z","last_updated_date":"2023-06-13T09:41:00Z","reference_number":"EMA/352542/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-197-2022-ema-decision-9-june-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-apraglutide-emea-003016-pip01-21_en.pdf"},
    {"id":"58927","name":"P/211/2022: EMA decision of 10 June 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for whole-cell heat-inactivated bacterial strains (EMEA-003026-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T09:55:00Z","last_updated_date":"2023-06-13T09:55:00Z","reference_number":"EMA/365816/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-211-2022-ema-decision-10-june-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-whole-cell-heat-inactivated-bacterial-strains-emea-003026-pip02-21_en.pdf"},
    {"id":"58928","name":"P/0499/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for alprazolam, (EMEA- 003043-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T10:10:00Z","last_updated_date":"2025-03-12T15:16:00Z","reference_number":"EMA/515863/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0499-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-alprazolam-emea-003043-pip01-21-m01_en.pdf"},
    {"id":"58930","name":"P/251/2022 : EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for autologous CD3+CD4+CD25+CD127-FoxP3+ polyclonal regulatory T cells ex vivo expanded (EMEA-002737- PIP01-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T11:05:00Z","last_updated_date":"2023-06-13T11:05:00Z","reference_number":"EMA/579390/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-251-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-waiver-autologous-cd3cd4cd25cd127-foxp3-polyclonal-regulatory-t-cells-ex-vivo-expanded-emea-002737-pip01-19_en.pdf"},
    {"id":"58931","name":"P/255/2022 : EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for respiratory syncytial virus stabilised prefusion F subunit vaccine (EMEA- 002795-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T11:16:00Z","last_updated_date":"2023-06-13T11:16:00Z","reference_number":"EMA/576006/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-255-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-respiratory-syncytial-virus-stabilised-prefusion-f-subunit-vaccine-emea-002795-pip02-21_en.pdf"},
    {"id":"58932","name":"P/229/2022 : EMA decision of 8 July 2022 on the granting of a product specific waiver for lurbinectedin (EMEA-002846-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T11:21:00Z","last_updated_date":"2023-06-13T11:21:00Z","reference_number":"EMA/575429/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-229-2022-ema-decision-8-july-2022-granting-product-specific-waiver-lurbinectedin-emea-002846-pip02-22_en.pdf"},
    {"id":"58934","name":"P/241/2022 : EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cagrilintide / semaglutide (EMEA-003059-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T11:32:00Z","last_updated_date":"2023-06-13T11:32:00Z","reference_number":"EMA/602351/2022 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-241-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cagrilintide-semaglutide-emea-003059-pip01-21_en.pdf"},
    {"id":"58935","name":"P/253/2022 : EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous tumour-infiltrating lymphocytes (TILs) (EMEA-003072-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T11:38:00Z","last_updated_date":"2023-06-13T11:38:00Z","reference_number":"EMA/579392/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-253-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-tumour-infiltrating-lymphocytes-tils-emea-003072-pip01-21_en.pdf"},
    {"id":"58936","name":"P/254/2022 : EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bepirovirsen (EMEA-003082-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-13T11:50:00Z","last_updated_date":"2023-06-13T11:50:00Z","reference_number":"EMA/579397/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-254-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bepirovirsen-emea-003082-pip01-21_en.pdf"},
    {"id":"58982","name":"P/0210/2022 : EMA decision of 10 June 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for reparixin (EMEA-001693-PIP03-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T16:25:00Z","last_updated_date":"2023-06-19T16:25:00Z","reference_number":"EMA/365815/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2022-ema-decision-10-june-2022-agreement-paediatric-investigation-plan-granting-deferral-reparixin-emea-001693-pip03-21_en.pdf"},
    {"id":"58983","name":"P/0199/2022 : EMA decision of 21 June 2022 on the granting of a product specific waiver for flortaucipir F18 (EMEA-003187-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T16:28:00Z","last_updated_date":"2023-06-19T16:28:00Z","reference_number":"EMA/266265/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2022-ema-decision-21-june-2022-granting-product-specific-waiver-flortaucipir-f18-emea-003187-pip01-22_en.pdf"},
    {"id":"58988","name":"P/0234/2022: EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for cannabidiol  (Epidyolex), (EMEA-001964-PIP03-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T14:23:00Z","last_updated_date":"2023-06-19T14:23:00Z","reference_number":"EMA/575947/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-waiver-cannabidiol-epidyolex-emea-001964-pip03-21_en.pdf"},
    {"id":"58990","name":"P/0235/2022: EMA decision of 8 July 2022 on the granting of a product specific waiver for trabectedin (Yondelis), (EMEA-000610-PIP02-22) in accordance with Regulation (EC) No 1901/2006","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T15:26:00Z","last_updated_date":"2023-06-19T15:26:00Z","reference_number":"EMA/602315/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2022-ema-decision-8-july-2022-granting-product-specific-waiver-trabectedin-yondelis-emea-000610-pip02-22-accordance-regulation-ec-no-1901-2006_en.pdf"},
    {"id":"58991","name":"P/0225/2022: EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for benralizumab (Fasenra), (EMEA-001214-PIP09-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T16:08:00Z","last_updated_date":"2023-06-19T16:08:00Z","reference_number":"EMA/609126/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-benralizumab-fasenra-emea-001214-pip09-21_en.pdf"},
    {"id":"58992","name":"P/0202/2022 : EMA decision of 10 June 2022 on the refusal of a paediatric investigation plan and on the granting of a waiver for clonidine (EMEA-003198-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T16:07:00Z","last_updated_date":"2023-06-21T16:07:00Z","reference_number":"EMA/266803/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2022-ema-decision-10-june-2022-refusal-paediatric-investigation-plan-granting-waiver-clonidine-emea-003198-pip01-22_en.pdf"},
    {"id":"58993","name":"P/0203/2022 : EMA decision of 10 June 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for methylphenidate (hydrochloride) (EMEA-003189-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T16:39:00Z","last_updated_date":"2023-06-19T16:39:00Z","reference_number":"EMA/275700/2022 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2022-ema-decision-10-june-2022-agreement-paediatric-investigation-plan-granting-waiver-methylphenidate-hydrochloride-emea-003189-pip01-22_en.pdf"},
    {"id":"58996","name":"P/0224/2022 : EMA decision of 8 July 2022 on the granting of a product specific waiver for autologous bone marrow-derived mononuclear cell  enriched white blood cells (EMEA-003193-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T17:20:00Z","last_updated_date":"2023-06-19T17:20:00Z","reference_number":"EMA/609069/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2022-ema-decision-8-july-2022-granting-product-specific-waiver-autologous-bone-marrow-derived-mononuclear-cell-enriched-white-blood-cells-emea-003193-pip01-22_en.pdf"},
    {"id":"58997","name":"P/0252/2022 : EMA decision of 8 July 2022 on the granting of a product specific waiver for 224Radium adsorbed in calcium carbonate microparticles (EMEA-003199-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T17:49:00Z","last_updated_date":"2023-06-19T17:49:00Z","reference_number":"EMA/579377/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2022-ema-decision-8-july-2022-granting-product-specific-waiver-224radium-adsorbed-calcium-carbonate-microparticles-emea-003199-pip01-22_en.pdf"},
    {"id":"58998","name":"P/0233/2022 : EMA decision of 8 July 2022 on the granting of a product specific waiver for botulinum toxin type A (EMEA-003202-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T17:57:00Z","last_updated_date":"2023-06-19T17:57:00Z","reference_number":"EMA/575495/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2022-ema-decision-8-july-2022-granting-product-specific-waiver-botulinum-toxin-type-emea-003202-pip01-22_en.pdf"},
    {"id":"59000","name":"P/0246/2022: EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lonafarnib (EMEA-002516-PIP02-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-20T11:33:00Z","last_updated_date":"2023-06-20T11:33:00Z","reference_number":"EMA/595664/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lonafarnib-emea-002516-pip02-21_en.pdf"},
    {"id":"59001","name":"P/0228/2022: EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mixture of 2 synthetic double-stranded N-Acetyl-galactosamine conjugated siRNA oligonucleoti","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-20T11:44:00Z","last_updated_date":"2023-06-20T11:44:00Z","reference_number":"EMA/609177/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mixture-2-synthetic-double-stranded-n-acetyl-galactosamine-conjugated-sirna-oligonucleoti_en.pdf"},
    {"id":"59003","name":"P/0240/2022: EMA decision of 8 July 2022 on the granting of a product specific waiver for parsaclisib (hydrochloride) (EMEA-002696-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-20T12:02:00Z","last_updated_date":"2023-06-20T12:02:00Z","reference_number":"EMA/602335/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2022-ema-decision-8-july-2022-granting-product-specific-waiver-parsaclisib-hydrochloride-emea-002696-pip03-22_en.pdf"},
    {"id":"59009","name":"P/0214/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for lanadelumab (Takhzyro), (EMEA-001864-PIP01-15-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T15:24:00Z","last_updated_date":"2023-06-21T15:24:00Z","reference_number":"EMA/366000/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-lanadelumab-takhzyro-emea-001864-pip01-15-m07_en.pdf"},
    {"id":"59011","name":"P/0213/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for inebilizumab (EMEA-001911-PIP01-15-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T14:18:00Z","last_updated_date":"2023-06-21T14:18:00Z","reference_number":"EMA/365879/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-inebilizumab-emea-001911-pip01-15-m04_en.pdf"},
    {"id":"59012","name":"P/0217/2022: EMA decision of 10 June 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cedazuridine / decitabine (EMEA-003071-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-21T14:50:00Z","last_updated_date":"2023-06-21T14:50:00Z","reference_number":"EMA/366238/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2022-ema-decision-10-june-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cedazuridine-decitabine-emea-003071-pip01-21_en.pdf"},
    {"id":"59014","name":"P/0207/2022: EMA decision of 10 June 2022 on the granting of a product specific waiver for anti-TGFbeta fully human monoclonal antibody (NIS793) (EMEA-003178-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-21T15:18:00Z","last_updated_date":"2023-06-21T15:18:00Z","reference_number":"EMA/275703/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2022-ema-decision-10-june-2022-granting-product-specific-waiver-anti-tgfbeta-fully-human-monoclonal-antibody-nis793-emea-003178-pip01-21_en.pdf"},
    {"id":"59016","name":"P/0194/2022: EMA decision of 10 June 2022 on the granting of a product specific waiver for sugemalimab (EMEA-003179-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-21T15:30:00Z","last_updated_date":"2023-06-21T15:30:00Z","reference_number":"EMA/251179/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2022-ema-decision-10-june-2022-granting-product-specific-waiver-sugemalimab-emea-003179-pip01-22_en.pdf"},
    {"id":"59017","name":"P/0222/2022 : EMA decision of 24 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid ... (EMEA-001930-PIP01-16-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T15:38:00Z","last_updated_date":"2023-06-21T15:38:00Z","reference_number":"EMA/595648/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2022-ema-decision-24-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-polysaccharide-conjugated-tetanus-toxoid-emea-001930-pip01-16-m04_en.pdf"},
    {"id":"59018","name":"P/0188/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris), (EMEA-001943-PIP01-16-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T15:53:00Z","last_updated_date":"2023-06-21T15:53:00Z","reference_number":"EMA/251237/2022 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-001943-pip01-16-m07_en.pdf"},
    {"id":"59019","name":"P/0212/2022: EMA decision 10 June 2022 on the granting of a product specific waiver for perindopril (arginine) / indapamide (EMEA-003186- PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-21T16:04:00Z","last_updated_date":"2023-06-21T16:04:00Z","reference_number":"EMA/365818/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2022-ema-decision-10-june-2022-granting-product-specific-waiver-perindopril-arginine-indapamide-emea-003186-pip01-22_en.pdf"},
    {"id":"59020","name":"P/0189/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris), (EMEA-001943-PIP02-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T16:07:00Z","last_updated_date":"2023-06-21T16:07:00Z","reference_number":"EMA/251270/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-001943-pip02-20-m01_en.pdf"},
    {"id":"59021","name":"P/0218/2022 : EMA decision of 8 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cannabidiol (Epidyolex), (EMEA-001964-PIP01-16-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T16:17:00Z","last_updated_date":"2023-06-21T16:17:00Z","reference_number":"EMA/562057/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2022-ema-decision-8-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-cannabidiol-epidyolex-emea-001964-pip01-16-m04_en.pdf"},
    {"id":"59022","name":"P/0232/2022: EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sibeprenlimab (EMEA-003085-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-21T16:19:00Z","last_updated_date":"2023-06-21T16:19:00Z","reference_number":"EMA/575972/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sibeprenlimab-emea-003085-pip01-21_en.pdf-0"},
    {"id":"59023","name":"P/0261/2022: EMA decision of 15 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510) (EMEA-003115-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-21T16:29:00Z","last_updated_date":"2023-06-21T16:29:00Z","reference_number":"EMA/629584/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2022-ema-decision-15-july-2022-agreement-paediatric-investigation-plan-granting-deferral-recombinant-covid-19-subunit-nanoparticle-adjuvanted-as03-gbp510-emea-003115-pip01-21_en.pdf"},
    {"id":"59024","name":"P/0227/2022: EMA decision of 8 July 2022 on the granting of a product specific waiver for peptide KLBPVQLWV / peptide SMPPPGTRV / peptide YLQLVFGIEV / peptide RLLQETELV / peptide YLSGADLNL / peptide LLTFWNPPV / peptide IMIGHLVGV / peptide KVAEIVHFL / pept","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-21T16:36:00Z","last_updated_date":"2023-06-21T16:36:00Z","reference_number":"EMA/575399/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2022-ema-decision-8-july-2022-granting-product-specific-waiver-peptide-klbpvqlwv-peptide-smpppgtrv-peptide-ylqlvfgiev-peptide-rllqetelv-peptide-ylsgadlnl-peptide-lltfwnppv-peptide-imighlvgv_en.pdf"},
    {"id":"59025","name":"P/0223/2022: EMA decision of 8 July 2022 on the granting of a product specific waiver for botulinum toxin type E (EMEA-003190-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-21T16:43:00Z","last_updated_date":"2023-06-21T16:43:00Z","reference_number":"EMA/609038/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2022-ema-decision-8-july-2022-granting-product-specific-waiver-botulinum-toxin-type-e-emea-003190-pip01-22_en.pdf"},
    {"id":"59032","name":"P/0244/2022: EMA decision of 8 July on the acceptance of a modification of an agreed paediatric investigation plan for vadadustat (EMEA-001944-PIP01-16-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-22T11:11:00Z","last_updated_date":"2023-06-22T11:11:00Z","reference_number":"EMA/602327/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2022-ema-decision-8-july-acceptance-modification-agreed-paediatric-investigation-plan-vadadustat-emea-001944-pip01-16-m04_en.pdf"},
    {"id":"59038","name":"P/0238/2022: EMA decision of8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for daratumumab (Darzalex), (EMEA-002152-PIP01-17-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-22T13:44:00Z","last_updated_date":"2023-06-22T13:44:00Z","reference_number":"EMA/602331/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2022-ema-decision-of8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-daratumumab-darzalex-emea-002152-pip01-17-m03_en.pdf"},
    {"id":"59040","name":"P/0265/2022: EMA decision of 22 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for elexacaftor / tezacaftor/ ivacaftor (Kaftrio), (EMEA-002324-PIP01-17-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-22T14:10:00Z","last_updated_date":"2023-06-22T14:10:00Z","reference_number":"EMA/624974/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2022-ema-decision-22-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-elexacaftor-tezacaftor-ivacaftor-kaftrio-emea-002324-pip01-17-m03_en.pdf"},
    {"id":"59042","name":"P/0239/2022: EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) (Apexxnar), (EMEA-002330-PIP01-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-22T14:40:00Z","last_updated_date":"2023-06-22T14:40:00Z","reference_number":"EMA/602333/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-pneumococcal-polysaccharide-conjugate-vaccine-20-valent-adsorbed-apexxnar-emea-002330-pip01-18-m02_en.pdf"},
    {"id":"59076","name":"P/0470/2023 : EMA decision of of 1 December 2023 on the refusal of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat),  (EMEA-000402-PIP03-17-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T12:46:00Z","last_updated_date":"2025-03-06T13:34:00Z","reference_number":"EMA/512497/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0470-2023-ema-decision-1-december-2023-refusal-modification-agreed-paediatric-investigation-plan-lacosamide-vimpat-emea-000402-pip03-17-m08_en.pdf"},
    {"id":"59077","name":"P/0245/2022 : EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for hepatitis B (rDNA) surface antigen adjuvanted (HEPLISAV B), (EMEA-001127-PIP02-11-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T13:02:00Z","last_updated_date":"2023-06-23T13:02:00Z","reference_number":"EMA/595941/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-hepatitis-b-rdna-surface-antigen-adjuvanted-heplisav-b-emea-001127-pip02-11-m02_en.pdf"},
    {"id":"59078","name":"P/0264/2022 : EMA decision of 13 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for modified vaccinia  ankara - bavarian nordic virus (smallpox), (EMEA-001161-PIP02-11-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T13:52:00Z","last_updated_date":"2023-06-23T13:54:00Z","reference_number":"EMA/639617/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2022-ema-decision-13-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-modified-vaccinia-ankara-bavarian-nordic-virus-smallpox-emea-001161-pip02-11-m01_en.pdf"},
    {"id":"59079","name":"P/0226/2022 : EMA decision of 8 July 2022on the acceptance of a modification of an agreed paediatric investigation plan for indacaterol (acetate) / mometasone (furoate) (Atectura Breezhaler and its duplicate authorization ...), (EMEA-001217-PIP01-11-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T14:02:00Z","last_updated_date":"2023-06-23T14:02:00Z","reference_number":"EMA/575722/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2022-ema-decision-8-july-2022on-acceptance-modification-agreed-paediatric-investigation-plan-indacaterol-acetate-mometasone-furoate-atectura-breezhaler-its-duplicate-authorization-emea-001217_en.pdf"},
    {"id":"59080","name":"P/0236/2022 : EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for oritavancin (diphosphate) (Tenkasi), (EMEA-001270-PIP01-12-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T14:31:00Z","last_updated_date":"2023-06-23T14:31:00Z","reference_number":"EMA/602319/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-oritavancin-diphosphate-tenkasi-emea-001270-pip01-12-m05_en.pdf"},
    {"id":"59081","name":"P/0258/2022 : EMA decision of 11 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ceftazidime / avibactam (Zavicefta), (EMEA-001313-PIP01-12-M12)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T14:45:00Z","last_updated_date":"2023-06-23T14:45:00Z","reference_number":"EMA/624968/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2022-ema-decision-11-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-zavicefta-emea-001313-pip01-12-m12_en.pdf"},
    {"id":"59083","name":"P/0237/2022 : EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ixazomib (Ninlaro), (EMEA-001410-PIP02-17-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T14:53:00Z","last_updated_date":"2023-06-23T14:53:00Z","reference_number":"EMA/602320/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-ixazomib-ninlaro-emea-001410-pip02-17-m04_en.pdf"},
    {"id":"59084","name":"P/0242/2022 : EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for daprodustat (EMEA-001452-PIP01-13-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T15:02:00Z","last_updated_date":"2023-06-23T15:02:00Z","reference_number":"EMA/602322/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-daprodustat-emea-001452-pip01-13-m04_en.pdf"},
    {"id":"59086","name":"P/0260/2022 : EMA decision of 15 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for omecamtiv mecarbil (EMEA-001696-PIP01-14-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T15:22:00Z","last_updated_date":"2023-06-23T15:22:00Z","reference_number":"EMA/624973/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2022-ema-decision-15-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-omecamtiv-mecarbil-emea-001696-pip01-14-m02_en.pdf"},
    {"id":"59087","name":"P/0263/2022 : EMA decision of 13 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib  (RINVOQ), (EMEA-001741-PIP03-16-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T15:30:00Z","last_updated_date":"2023-06-23T15:30:00Z","reference_number":"EMA/637879/2022 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2022-ema-decision-13-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip03-16-m03_en.pdf"},
    {"id":"59088","name":"P/0243/2022 : EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for nirsevimab (EMEA-001784-PIP01-15-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T15:37:00Z","last_updated_date":"2023-06-23T15:37:00Z","reference_number":"EMA/602323/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-nirsevimab-emea-001784-pip01-15-m04_en.pdf"},
    {"id":"59089","name":"P/0466/2022 : EMA decision of 7 November 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tozinameran, tozinameran / famtozinameran (Comirnaty) (EMEA-002861-PIP02-20-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-26T11:11:00Z","last_updated_date":"2023-06-26T11:11:00Z","reference_number":"EMA/864103/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0466-2022-ema-decision-7-november-2022-acceptance-modification-agreed-paediatric-investigation-plan-tozinameran-tozinameran-famtozinameran-comirnaty-emea-002861-pip02-20-m05_en.pdf"},
    {"id":"59099","name":"P/0195/2022: EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for efinaconazole (EMEA- 001627-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-27T09:17:00Z","last_updated_date":"2023-06-27T09:17:00Z","reference_number":"EMA/352509/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-efinaconazole-emea-001627-pip01-14-m02_en.pdf"},
    {"id":"59100","name":"P/0196/2022 : EMA decision of 9 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for posaconazole (Noxafil), (EMEA-000468-PIP02-12-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-27T09:34:00Z","last_updated_date":"2023-06-27T09:34:00Z","reference_number":"EMA/273998/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2022-ema-decision-9-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-posaconazole-noxafil-emea-000468-pip02-12-m07_en.pdf"},
    {"id":"59101","name":"P/0200/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for loxapine (Adasuve), (EMEA-001115-PIP01-10-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-27T09:43:00Z","last_updated_date":"2023-06-27T09:43:00Z","reference_number":"EMA/266656/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-loxapine-adasuve-emea-001115-pip01-10-m08_en.pdf"},
    {"id":"59102","name":"P/0201/2022 : EMA decision of 21 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for nemolizumab (EMEA- 001624-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-27T09:48:00Z","last_updated_date":"2023-06-27T09:48:00Z","reference_number":"EMA/266713/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2022-ema-decision-21-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-nemolizumab-emea-001624-pip01-14-m05_en.pdf"},
    {"id":"59103","name":"P/0208/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for canagliflozin (Invokana), (EMEA-001030-PIP01-10-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-27T09:52:00Z","last_updated_date":"2023-06-27T09:52:00Z","reference_number":"EMA/365808/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-canagliflozin-invokana-emea-001030-pip01-10-m10_en.pdf"},
    {"id":"59104","name":"P/0209/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for dopamine (hydrochloride), (EMEA-001105-PIP01-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-27T10:03:00Z","last_updated_date":"2023-06-27T10:03:00Z","reference_number":"EMA/365809/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-dopamine-hydrochloride-emea-001105-pip01-10-m06_en.pdf"},
    {"id":"59105","name":"P/0198/2022 : EMA decision of 2 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP03-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-27T10:06:00Z","last_updated_date":"2023-06-27T10:06:00Z","reference_number":"EMA/352636/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2022-ema-decision-2-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip03-16-m02_en.pdf"},
    {"id":"59106","name":"P/0231/2022 : EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for liposomal ciclosporin A (L-CsA) (EMEA-002344-PIP02-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-27T10:20:00Z","last_updated_date":"2023-06-27T10:20:00Z","reference_number":"EMA/575636/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-liposomal-ciclosporin-l-csa-emea-002344-pip02-18-m01_en.pdf"},
    {"id":"59107","name":"P/0249/2022 : EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for garadacimab (EMEA- 002726-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-27T10:28:00Z","last_updated_date":"2023-06-27T10:28:00Z","reference_number":"EMA/579333/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-garadacimab-emea-002726-pip01-19-m02_en.pdf"},
    {"id":"59108","name":"P/062/2022 : EMA decision of 18 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for rilzabrutinib (EMEA- 002438-PIP02-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-27T10:31:00Z","last_updated_date":"2023-06-27T10:31:00Z","reference_number":"EMA/624978/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-062-2022-ema-decision-18-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-rilzabrutinib-emea-002438-pip02-19-m02_en.pdf"},
    {"id":"59130","name":"P/0191/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris), (EMEA-002077-PIP01-16-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T10:19:00Z","last_updated_date":"2023-06-29T10:19:00Z","reference_number":"EMA/251444/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-002077-pip01-16-m05_en.pdf"},
    {"id":"59132","name":"P/0190/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for erdafitinib (EMEA-002042-PIP02-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T10:13:00Z","last_updated_date":"2023-06-29T10:13:00Z","reference_number":"EMA/251362/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-erdafitinib-emea-002042-pip02-20-m01_en.pdf"},
    {"id":"59135","name":"P/0205/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for zanubrutinib (Brukinsa), (EMEA-002354-PIP02-18-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T11:06:00Z","last_updated_date":"2023-06-29T11:06:00Z","reference_number":"EMA/275723/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-zanubrutinib-brukinsa-emea-002354-pip02-18-m01_en.pdf"},
    {"id":"59139","name":"P/0219/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain, ... (EMEA-002359-PIP01-18-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T11:53:00Z","last_updated_date":"2023-06-29T11:53:00Z","reference_number":"EMA/563099/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-split-influenza-virus-inactivated-containing-antigens-equivalent-h1n1-strain-emea-002359-pip01-18-m05_en.pdf"},
    {"id":"59140","name":"P/0221/2022 : EMA decision of 24 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for remdesivir (Veklury), (EMEA-002826-PIP01-20-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T11:58:00Z","last_updated_date":"2023-06-29T11:58:00Z","reference_number":"EMA/579337/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2022-ema-decision-24-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-remdesivir-veklury-emea-002826-pip01-20-m03_en.pdf"},
    {"id":"59141","name":"P/0256/2022 : EMA decision of 30 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for elasomeran (Spikevax) and elasomeran/imelsomeram (EMEA-002893-PIP01-20-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T12:16:00Z","last_updated_date":"2023-06-29T12:16:00Z","reference_number":"EMA/612853/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2022-ema-decision-30-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-elasomeran-spikevax-elasomeran-imelsomeram-emea-002893-pip01-20-m02_en.pdf"},
    {"id":"59142","name":"P/0206/2022 : EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for 3,5-diamino-6- chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)... (EMEA-002935-PIP01-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T12:25:00Z","last_updated_date":"2023-06-29T12:25:00Z","reference_number":"EMA/275707/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2022-ema-decision-10-june-2022-acceptance-modification-agreed-paediatric-investigation-plan-35-diamino-6-chloro-n-n-4-4-2-hexyl2s3r4r5r-23456-pentahydroxyhexylaminoethoxy-emea-002935-pip01-20_en.pdf"},
    {"id":"59143","name":"P/0232/2022: EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sibeprenlimab (EMEA-003085-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-29T13:56:00Z","last_updated_date":"2023-06-29T13:56:00Z","reference_number":"EMA/575972/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sibeprenlimab-emea-003085-pip01-21_en.pdf"},
    {"id":"59144","name":"P/0250/2022: EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine/ matrix-M1 adjuvant (EMEA-002941-PIP","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-29T14:04:00Z","last_updated_date":"2023-06-29T14:04:00Z","reference_number":"EMA/579371/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-severe-acute-respiratory-syndrome-coronavirus-2-recombinant-spike-protein-nanoparticle-vaccine-matrix_en.pdf"},
    {"id":"59145","name":"P/0257/2022: EMA decision of 8 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for epcoritamab (EMEA-002907-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-06-29T14:13:00Z","last_updated_date":"2023-06-29T14:13:00Z","reference_number":"EMA/620812/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2022-ema-decision-8-july-2022-acceptance-modification-agreed-paediatric-investigation-plan-epcoritamab-emea-002907-pip01-20-m01_en.pdf"},
    {"id":"59622","name":"P/0354/2022 : EMA decision of 10 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tocilizumab (RoActemra) (EMEA-000309-PIP09-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-24T15:16:00Z","last_updated_date":"2023-08-24T15:16:00Z","reference_number":"EMA/676104/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0354-2022-ema-decision-10-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tocilizumab-roactemra-emea-000309-pip09-21_en.pdf"},
    {"id":"59623","name":"P/0288/2022 : EMA decision of 11 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vibegron (EMEA-001415-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-24T15:27:00Z","last_updated_date":"2023-08-24T15:27:00Z","reference_number":"EMA/629508/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2022-ema-decision-11-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vibegron-emea-001415-pip02-21_en.pdf"},
    {"id":"59624","name":"P/0355/2022 : EMA decision of 12 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tezepelumab (EMEA-001613-PIP04-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-24T15:31:00Z","last_updated_date":"2023-08-24T15:31:00Z","reference_number":"EMA/676814/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0355-2022-ema-decision-12-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tezepelumab-emea-001613-pip04-21_en.pdf"},
    {"id":"59625","name":"P/0286/2022 : EMA decision of 11 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deucravacitinib (EMEA-002350-PIP04-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-24T15:39:00Z","last_updated_date":"2023-08-24T15:39:00Z","reference_number":"EMA/629360/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2022-ema-decision-11-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-deucravacitinib-emea-002350-pip04-21_en.pdf"},
    {"id":"59626","name":"P/0333/2022 : EMA decision of 10 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ritlecitinib (EMEA-002451-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-24T15:45:00Z","last_updated_date":"2023-08-24T15:45:00Z","reference_number":"EMA/673784/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0333-2022-ema-decision-10-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ritlecitinib-emea-002451-pip02-21_en.pdf"},
    {"id":"59636","name":"P/0269/2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (1R,2R)-2-[4-(5-methyl-1H-pyrazol-3-yl) benzoyl]-N-(4-oxo-6,7-dihydro-5Hpyrazolo...(EMEA-003098-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-25T14:55:00Z","last_updated_date":"2023-08-25T14:55:00Z","reference_number":"EMA/662865/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-1r2r-2-4-5-methyl-1h-pyrazol-3-yl-benzoyl-n-4-oxo-67-dihydro-5hpyrazoloemea-003098-pip01-21_en.pdf"},
    {"id":"59639","name":"P/0274/2022: EMA decision of 10 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 2’-O-(2’-methoxyethyl)... (EMEA-003112-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-28T09:43:00Z","last_updated_date":"2023-08-28T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2022-ema-decision-10-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-2-o-2-methoxyethyl-emea-003112-pip01-21_en.pdf"},
    {"id":"59640","name":"P/0302/2022: EMA decision of 10 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efruxifermin (EMEA-003114-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-28T10:20:00Z","last_updated_date":"2023-08-28T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2022-ema-decision-10-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-efruxifermin-emea-003114-pip01-21_en.pdf"},
    {"id":"59641","name":"P/0344/2022 : EMA decision of 10 August 2022 on the granting of a product specific waiver for nipocalimab (EMEA-002559-PIP05-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-28T10:25:00Z","last_updated_date":"2023-08-28T10:25:00Z","reference_number":"EMA/638322/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0344-2022-ema-decision-10-august-2022-granting-product-specific-waiver-nipocalimab-emea-002559-pip05-22_en.pdf"},
    {"id":"59642","name":"P/0345/2022 : EMA decision of 10 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for remibrutinib (EMEA-002582-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-28T10:34:00Z","last_updated_date":"2023-08-28T10:34:00Z","reference_number":"EMA/638352/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0345-2022-ema-decision-10-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-remibrutinib-emea-002582-pip02-21_en.pdf"},
    {"id":"59643","name":"P/0030/2024 : EMA decision of 31 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for pegcetacoplan (Aspaveli), (EMEA-002600-PIP03-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-17T11:09:00Z","last_updated_date":"2025-03-17T11:09:00Z","reference_number":"EMA/22599/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2024-ema-decision-31-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-pegcetacoplan-aspaveli-emea-002600-pip03-21-m01_en.pdf"},
    {"id":"59644","name":"P/0268/2022: EMA decision of 11 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for gliadin protease (EMEA-003116-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-28T11:14:00Z","last_updated_date":"2023-08-28T11:14:00Z","reference_number":"EMA/662864/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2022-ema-decision-11-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-gliadin-protease-emea-003116-pip01-21_en.pdf"},
    {"id":"59645","name":"P/0350/2022: EMA decision of 10 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for RSV preF protein (EMEA-003094-PIP02-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-28T11:29:00Z","last_updated_date":"2023-08-28T11:29:00Z","reference_number":"EMA/673786/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0350-2022-ema-decision-10-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rsv-pref-protein-emea-003094-pip02-21_en.pdf"}    {"id":"59648","name":"P/0346/2022 : EMA decision of 10 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for etrasimod L-arginine (EMEA-002713-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-28T12:43:00Z","last_updated_date":"2023-08-28T12:43:00Z","reference_number":"EMA/638356/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0346-2022-ema-decision-10-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-etrasimod-l-arginine-emea-002713-pip02-21_en.pdf"},
    {"id":"59649","name":"P/0336/2022 : EMA decision of 10 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lademirsen (EMEA-003064-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-28T13:13:00Z","last_updated_date":"2023-08-28T13:13:00Z","reference_number":"EMA/673785/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2022-ema-decision-10-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lademirsen-emea-003064-pip01-21_en.pdf"},
    {"id":"59650","name":"P/0348/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for setmelanotide (Imcivree) (EMEA-002209-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-28T15:54:00Z","last_updated_date":"2023-08-28T15:54:00Z","reference_number":"EMA/672726/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0348-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-setmelanotide-imcivree-emea-002209-pip01-17-m03_en.pdf"},
    {"id":"59651","name":"P/0340/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for enmetazobactam / cefepime (EMEA-002240-PIP02-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-28T16:01:00Z","last_updated_date":"2023-08-28T16:01:00Z","reference_number":"EMA/672733/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0340-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-enmetazobactam-cefepime-emea-002240-pip02-17-m01_en.pdf"},
    {"id":"59654","name":"P/0358/2022: EMA decision of 22 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for zuranolone (EMEA-003119-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-29T11:58:00Z","last_updated_date":"2023-08-29T11:58:00Z","reference_number":"EMA/678051/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0358-2022-ema-decision-22-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-zuranolone-emea-003119-pip01-21_en.pdf"},
    {"id":"59655","name":"EMA/638357/2022: EMA decision of 10 August 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for mometasone (furoate) / azelastine (hydrochloride) (EMEA-003122-PIP01-21 )","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-29T12:08:00Z","last_updated_date":"2023-08-29T12:08:00Z","reference_number":"EMA/638357/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-638357-2022-ema-decision-10-august-2022-agreement-paediatric-investigation-plan-granting-waiver-mometasone-furoate-azelastine-hydrochloride-emea-003122-pip01-21_en.pdf"},
    {"id":"59656","name":"P/0271/2022: EMA decision of 10 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy... (EMEA-003133-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-29T13:24:00Z","last_updated_date":"2023-08-29T13:24:00Z","reference_number":"EMA/665639/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2022-ema-decision-10-august-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-r-tetrahydrofuran-3-yl-4-6-5-4-ethoxy-emea-003133-pip01-21_en.pdf"},
    {"id":"59658","name":"P/0341/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for eptinezumab (Vyepti) (EMEA-002243-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-29T14:39:00Z","last_updated_date":"2023-08-29T14:39:00Z","reference_number":"EMA/672882/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0341-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-eptinezumab-vyepti-emea-002243-pip01-17-m03_en.pdf"},
    {"id":"59659","name":"P/0011/2024 : EMA decision of 31 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for etripamil, (EMEA- 002303-PIP01-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T14:45:00Z","last_updated_date":"2025-03-14T14:45:00Z","reference_number":"EMA/25515/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2024-ema-decision-31-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-etripamil-emea-002303-pip01-17-m04_en.pdf"},
    {"id":"59660","name":"P/0342/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for rezafungin acetate (EMEA-002319-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-29T14:51:00Z","last_updated_date":"2023-08-29T14:51:00Z","reference_number":"EMA/673781/2022 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0342-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-rezafungin-acetate-emea-002319-pip01-17-m02_en.pdf"},
    {"id":"59662","name":"P/0008/2024 : EMA decision of 31 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for deucravacitinib (Sotyktu), (EMEA-002350-PIP01-18-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T09:32:00Z","last_updated_date":"2025-03-14T09:32:00Z","reference_number":"EMA/25517/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0008-2024-ema-decision-31-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-deucravacitinib-sotyktu-emea-002350-pip01-18-m03_en.pdf"},
    {"id":"59663","name":"P/0277/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for fidanacogene elaparvovec (EMEA-002362-PIP02-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-30T10:17:00Z","last_updated_date":"2023-08-30T10:17:00Z","reference_number":"EMA/624976/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-fidanacogene-elaparvovec-emea-002362-pip02-19-m02_en.pdf"},
    {"id":"59664","name":"P/0291/2022: EMA decision of 11 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for lasmiditan (EMEA- 002166-PIP01-17-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-30T10:42:00Z","last_updated_date":"2023-08-30T10:42:00Z","reference_number":"EMA/630599/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2022-ema-decision-11-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-lasmiditan-emea-002166-pip01-17-m06_en.pdf"},
    {"id":"59665","name":"P/0272/2022 : EMA decision on 10 August 2022 on the granting of a product specific waiver for atorvastatin / ezetimibe (EMEA-003205-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-30T10:49:00Z","last_updated_date":"2023-08-30T10:49:00Z","reference_number":"EMA/659386/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2022-ema-decision-10-august-2022-granting-product-specific-waiver-atorvastatin-ezetimibe-emea-003205-pip01-22_en.pdf"},
    {"id":"59666","name":"P/0281/2022 : EMA decision on 11 August 2022 on the granting of a product specific waiver for rosuvastatin (calcium) / acetylsalicylic acid (EMEA- 003206-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-30T11:03:00Z","last_updated_date":"2023-08-30T11:03:00Z","reference_number":"EMA/629011/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2022-ema-decision-11-august-2022-granting-product-specific-waiver-rosuvastatin-calcium-acetylsalicylic-acid-emea-003206-pip01-22_en.pdf"},
    {"id":"59667","name":"P/0287/2022 : EMA decision on 11 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for doxecitine / doxribtimine (EMEA-003210-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-30T11:14:00Z","last_updated_date":"2023-08-30T11:14:00Z","reference_number":"EMA/629449/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2022-ema-decision-11-august-2022-agreement-paediatric-investigation-plan-granting-deferral-doxecitine-doxribtimine-emea-003210-pip01-22_en.pdf"},
    {"id":"59668","name":"P/0301/2022 : EMA decision on 9 August 2022 on the granting of a product specific waiver for gold (Au) (EMEA-003211-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-30T11:28:00Z","last_updated_date":"2023-08-30T11:28:00Z","reference_number":"EMA/673865/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2022-ema-decision-9-august-2022-granting-product-specific-waiver-gold-au-emea-003211-pip01-22_en.pdf"},
    {"id":"59669","name":"P/0339/2022: EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for bimekizumab (Bimzelx), (EMEA-002189-PIP01-17-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-30T11:53:00Z","last_updated_date":"2023-08-30T11:53:00Z","reference_number":"EMA/672421/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0339-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-bimekizumab-bimzelx-emea-002189-pip01-17-m03_en.pdf"},
    {"id":"59670","name":"P/0292/2022: EMA decision of 11 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for pretomanid (Dovprela), (EMEA-002115-PIP01-17-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-30T12:04:00Z","last_updated_date":"2023-08-30T12:04:00Z","reference_number":"EMA/630765/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2022-ema-decision-11-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-pretomanid-dovprela-emea-002115-pip01-17-m05_en.pdf"},
    {"id":"59672","name":"P/0266/2022: EMA decision of 1 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for avacopan (Tavneos), (EMEA-002023-PIP01-16-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-30T13:59:00Z","last_updated_date":"2023-08-30T13:59:00Z","reference_number":"EMA/602330/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2022-ema-decision-1-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-avacopan-tavneos-emea-002023-pip01-16-m06_en.pdf"},
    {"id":"59673","name":"P/0289/2022: EMA decision of 11 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for larotrectinib (Vitrakvi), (EMEA-001971-PIP03-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-30T14:11:00Z","last_updated_date":"2023-08-30T14:11:00Z","reference_number":"EMA/630040/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2022-ema-decision-11-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-larotrectinib-vitrakvi-emea-001971-pip03-18-m02_en.pdf"},
    {"id":"59674","name":"P/0267/2022: EMA decision of 4 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for gadopiclenol (EMEA- 001949-PIP02-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-30T14:32:00Z","last_updated_date":"2023-08-30T14:32:00Z","reference_number":"EMA/662817/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2022-ema-decision-4-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-gadopiclenol-emea-001949-pip02-18-m02_en.pdf"},
    {"id":"59676","name":"P/0293/2022: EMA decision of 11 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris), (EMEA-001943-PIP03-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-30T14:59:00Z","last_updated_date":"2023-08-30T14:59:00Z","reference_number":"EMA/631101/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2022-ema-decision-11-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-001943-pip03-20-m01_en.pdf"},
    {"id":"59677","name":"P/0351/2022: EMA decision of 11 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for bempedoic acid (Nilemdo), (EMEA-001872-PIP01-15-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-30T15:06:00Z","last_updated_date":"2023-08-30T15:06:00Z","reference_number":"EMA/631062/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0351-2022-ema-decision-11-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-bempedoic-acid-nilemdo-emea-001872-pip01-15-m02_en.pdf"},
    {"id":"59862","name":"P/0270/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for bulevirtide (Hepcludex) (EMEA-002399-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-31T09:25:00Z","last_updated_date":"2023-08-31T09:25:00Z","reference_number":"EMA/624977/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-bulevirtide-hepcludex-emea-002399-pip01-18-m01_en.pdf"},
    {"id":"59863","name":"P/0299/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for rimegepant (Vydura) (EMEA-002812-PIP02-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-31T10:16:00Z","last_updated_date":"2023-08-31T10:16:00Z","reference_number":"EMA/638303/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-rimegepant-vydura-emea-002812-pip02-20-m01_en.pdf"},
    {"id":"59864","name":"P/0300/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for casirivimab (Ronapreve) (EMEA-002964-PIP01-21-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-31T10:40:00Z","last_updated_date":"2023-08-31T10:40:00Z","reference_number":"EMA/638305/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-casirivimab-ronapreve-emea-002964-pip01-21-m02_en.pdf"},
    {"id":"59865","name":"P/0343/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for imdevimab (Ronapreve) (EMEA-002965-PIP01-21-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-08-31T10:47:00Z","last_updated_date":"2023-08-31T10:47:00Z","reference_number":"EMA/638306/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0343-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-imdevimab-ronapreve-emea-002965-pip01-21-m02_en.pdf"},
    {"id":"59866","name":"P/0335/2022: EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for fluciclovine (18F) (Axumin), (EMEA-001644-PIP02-14-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-31T11:19:00Z","last_updated_date":"2023-08-31T11:19:00Z","reference_number":"EMA/672312/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0335-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-fluciclovine-18f-axumin-emea-001644-pip02-14-m03_en.pdf"},
    {"id":"59867","name":"P/0356/2022: EMA decision of 11 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine / rilpivirine / tenofovir alafenamide (Odefsey), (EMEA-001679-PIP01-14-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-31T11:26:00Z","last_updated_date":"2023-08-31T11:26:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0356-2022-ema-decision-11-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-emtricitabine-rilpivirine-tenofovir-alafenamide-odefsey-emea-001679-pip01-14-m02_en.pdf"},
    {"id":"59868","name":"P/0295/2022: EMA decision on the acceptance of a modification of an agreed paediatric investigation plan for vamorolone (EMEA- 001794-PIP02-16-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-31T11:38:00Z","last_updated_date":"2023-08-31T11:38:00Z","reference_number":"EMA/631111/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2022-ema-decision-acceptance-modification-agreed-paediatric-investigation-plan-vamorolone-emea-001794-pip02-16-m05_en.pdf"},
    {"id":"59869","name":"P/0290/2022: EMA decision of 11 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for pegunigalsidase alfa (EMEA-001828-PIP01-15-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-08-31T11:50:00Z","last_updated_date":"2023-08-31T11:50:00Z","reference_number":"EMA/630274/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2022-ema-decision-11-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-pegunigalsidase-alfa-emea-001828-pip01-15-m03_en.pdf"},
    {"id":"59902","name":"P/0285/2022: EMA decision of 11 August 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for oxytocin (EMEA-003148-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-06T10:53:00Z","last_updated_date":"2023-09-06T10:53:00Z","reference_number":"EMA/629295/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2022-ema-decision-11-august-2022-agreement-paediatric-investigation-plan-granting-deferral-oxytocin-emea-003148-pip01-21_en.pdf"},
    {"id":"59944","name":"P/0276/2022 : EMA decision on the granting of a product specific waiver for nebivolol (as nebivolol hydrochloride) / valsartan (EMEA-003227-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T11:01:00Z","last_updated_date":"2023-09-13T11:01:00Z","reference_number":"EMA/665980/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2022-ema-decision-granting-product-specific-waiver-nebivolol-nebivolol-hydrochloride-valsartan-emea-003227-pip01-22_en.pdf"},
    {"id":"59945","name":"P/0338/2022 : EMA decision on the granting of a product specific waiver for nebivolol (hydrochloride) / amlodipine (besilate) (EMEA-003226-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T11:08:00Z","last_updated_date":"2023-09-13T11:08:00Z","reference_number":"EMA/673867/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0338-2022-ema-decision-granting-product-specific-waiver-nebivolol-hydrochloride-amlodipine-besilate-emea-003226-pip01-22_en.pdf"},
    {"id":"59946","name":"P/0275/2022 : EMA decision on the granting of a product specific waiver for N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4- fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721), (EMEA-003223- PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T11:16:00Z","last_updated_date":"2023-09-13T11:16:00Z","reference_number":"EMA/659414/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2022-ema-decision-granting-product-specific-waiver-n-6-2r3s-34-dihydroxybutan-2-yloxy-2-4-fluorobenzylthiopyrimidin-4-yl-3-methylazetidine-1-sulfonamide-rist-4721-emea-003223-pip01-22_en.pdf"},
    {"id":"59949","name":"P/0282/2022 : EMA decision on the granting of a product specific waiver for modakafusp alfa (EMEA-003217-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T11:24:00Z","last_updated_date":"2023-09-13T11:24:00Z","reference_number":"EMA/629079/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2022-ema-decision-granting-product-specific-waiver-modakafusp-alfa-emea-003217-pip01-22_en.pdf"},
    {"id":"59950","name":"P/0273/2022: EMA decision on the granting of a product specific waiver for tramadol (hydrochloride) / magnesium lactate dihydrate (EMEA-003216-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T11:34:00Z","last_updated_date":"2023-09-13T11:34:00Z","reference_number":"EMA/659404/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2022-ema-decision-granting-product-specific-waiver-tramadol-hydrochloride-magnesium-lactate-dihydrate-emea-003216-pip01-22_en.pdf"},
    {"id":"59951","name":"P/0283/2022 : EMA decision on the granting of a product specific waiver for humanised monoclonal antibody of IgG1 subtype targeting NRP1 (EMEA-003214-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T12:01:00Z","last_updated_date":"2023-09-13T12:01:00Z","reference_number":"EMA/629194/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2022-ema-decision-granting-product-specific-waiver-humanised-monoclonal-antibody-igg1-subtype-targeting-nrp1-emea-003214-pip01-22_en.pdf"},
    {"id":"59952","name":"P/0298/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for maralixibat chloride (EMEA-001475-PIP02-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T14:30:00Z","last_updated_date":"2023-09-13T14:30:00Z","reference_number":"EMA/668766/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-maralixibat-chloride-emea-001475-pip02-13-m02_en.pdf"},
    {"id":"59953","name":"P/0297/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for dermatophagoides pteronyssinus / dermatophagoides farinae (Acarizax and associated names)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T14:36:00Z","last_updated_date":"2023-09-13T14:36:00Z","reference_number":"P/0297/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-dermatophagoides-pteronyssinus-dermatophagoides-farinae-acarizax-associated-names_en.pdf"},
    {"id":"59954","name":"P/0296/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for obinutuzumab (Gazyvaro), (EMEA-001207-PIP02-19-M01)","type":"pip-decision","status":"Draft","consultation_date":"","first_published_date":"2023-09-13T14:46:00Z","last_updated_date":"2023-09-13T14:46:00Z","reference_number":"EMA/638317/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-obinutuzumab-gazyvaro-emea-001207-pip02-19-m01_en.pdf"},
    {"id":"59955","name":"P/0294/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for brexpiprazole (Rxulti), (EMEA-001185-PIP01-11-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T14:54:00Z","last_updated_date":"2023-09-13T14:54:00Z","reference_number":"EMA/638299/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-brexpiprazole-rxulti-emea-001185-pip01-11-m08_en.pdf"},
    {"id":"59956","name":"P/0357/2022 : EMA decision of 11 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cabozantinib (Cometriq, Cabometyx), (EMEA-001143-PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T15:00:00Z","last_updated_date":"2023-09-13T15:00:00Z","reference_number":"EMA/681946/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0357-2022-ema-decision-11-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-cabozantinib-cometriq-cabometyx-emea-001143-pip01-11-m05_en.pdf"},
    {"id":"59958","name":"P/0280/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (Lenvima, Kisplyx), (EMEA-001119-PIP02-12-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T15:09:00Z","last_updated_date":"2023-09-13T15:09:00Z","reference_number":"EMA/624967/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-lenvima-kisplyx-emea-001119-pip02-12-m08_en.pdf"},
    {"id":"59960","name":"P/0360/2022 :EMA decision of 22 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cobicistat (Tybost), (EMEA-000969-PIP01-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T15:15:00Z","last_updated_date":"2023-09-13T15:15:00Z","reference_number":"EMA/697703/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0360-2022-ema-decision-22-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-cobicistat-tybost-emea-000969-pip01-10-m06_en.pdf"},
    {"id":"59961","name":"P/0279/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (Bosulif), (EMEA-000727-PIP01-09-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T15:55:00Z","last_updated_date":"2023-09-13T15:55:00Z","reference_number":"EMA/624966/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-bosutinib-bosulif-emea-000727-pip01-09-m06_en.pdf"},
    {"id":"59962","name":"P/0353/2022 : EMA decision of 11 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla), (EMEA-000715-PIP05-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T16:23:00Z","last_updated_date":"2023-09-13T16:23:00Z","reference_number":"EMA/675386/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0353-2022-ema-decision-11-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip05-13-m05_en.pdf"},
    {"id":"59963","name":"P/0352/2022 : EMA decision of 11 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla), (EMEA-000715-PIP02-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T16:30:00Z","last_updated_date":"2023-09-13T16:30:00Z","reference_number":"EMA/675392/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0352-2022-ema-decision-11-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla-emea-000715-pip02-11-m06_en.pdf"},
    {"id":"59964","name":"P/0334/2022 : EMA decision of 10 August 2022 on the refusal of a modification of an agreed paediatric investigation plan for chloroprocaine (hydrochloride) (Ampres), (EMEA-000639-PIP03-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T16:37:00Z","last_updated_date":"2023-09-13T16:37:00Z","reference_number":"EMA/671995/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2022-ema-decision-10-august-2022-refusal-modification-agreed-paediatric-investigation-plan-chloroprocaine-hydrochloride-ampres-emea-000639-pip03-16-m02_en.pdf"},
    {"id":"59965","name":"P/0337/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for vortioxetine (Brintellix), (EMEA-000455-PIP02-10-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-13T17:00:00Z","last_updated_date":"2023-09-13T17:00:00Z","reference_number":"EMA/671868/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0337-2022-ema-decision-10-august-2022-acceptance-modification-agreed-paediatric-investigation-plan-vortioxetine-brintellix-emea-000455-pip02-10-m09_en.pdf"},
    {"id":"59977","name":"P/0361/2022 : EMA decision of 9 September 2022 on the granting of a product specific waiver for Gallium 68-labelled Prostate-Specific Membrane Antigen-11 (68Ga-PSMA-11) (EMEA-003236-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T14:41:00Z","last_updated_date":"2023-09-14T14:41:00Z","reference_number":"EMA/703426/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0361-2022-ema-decision-9-september-2022-granting-product-specific-waiver-gallium-68-labelled-prostate-specific-membrane-antigen-11-68ga-psma-11-emea-003236-pip01-22_en.pdf"},
    {"id":"59978","name":"P/0407/2022 : EMA decision of 9 September 2022 on the granting of a product specific waiver for dimeric protein comprised of two disulfide-linked monomers....of human IgG1 Fc including the hinge region, CH2 and CH3 domains (KER-050) (EMEA-003239-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T14:56:00Z","last_updated_date":"2023-09-14T14:56:00Z","reference_number":"EMA/709250/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0407-2022-ema-decision-9-september-2022-granting-product-specific-waiver-dimeric-protein-comprised-two-disulfide-linked-monomersof-human-igg1-fc-including-hinge-region-ch2-ch3-domains-ker-050-emea_en.pdf"},
    {"id":"59979","name":"P/0387/2022 : EMA decision of 9 September 2022 on the granting of a product specific waiver for rosuvastatin / valsartan (EMEA-003240-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T15:07:00Z","last_updated_date":"2023-09-14T15:07:00Z","reference_number":"EMA/675752/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0387-2022-ema-decision-9-september-2022-granting-product-specific-waiver-rosuvastatin-valsartan-emea-003240-pip01-22_en.pdf"},
    {"id":"59983","name":"P/0408/2022 : EMA decision of 9 September 2022 on the granting of a product specific waiver for toripalimab (EMEA-003243-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T15:21:00Z","last_updated_date":"2023-09-14T15:21:00Z","reference_number":"EMA/709249/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0408-2022-ema-decision-9-september-2022-granting-product-specific-waiver-toripalimab-emea-003243-pip01-22_en.pdf"},
    {"id":"59985","name":"P/0386/2022 : EMA decision of 9 September 2022 on the granting of a product specific waiver for golidocitinib (EMEA-003246-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T15:40:00Z","last_updated_date":"2023-09-14T15:40:00Z","reference_number":"EMA/675794/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0386-2022-ema-decision-9-september-2022-granting-product-specific-waiver-golidocitinib-emea-003246-pip01-22_en.pdf"},
    {"id":"59990","name":"P/0372/2022 : EMA decision of 9 September 2022 on the granting of a product specific waiver for suvecaltamide (hydrochloride) (EMEA-003248-PIP01- 22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T15:46:00Z","last_updated_date":"2023-09-14T15:46:00Z","reference_number":"EMA/698313/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0372-2022-ema-decision-9-september-2022-granting-product-specific-waiver-suvecaltamide-hydrochloride-emea-003248-pip01-22_en.pdf"},
    {"id":"60000","name":"P/0373/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cannabidiol / delta-9- tetrahydrocannabinol (Sativex), (EMEA-000181-PIP02-13-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T18:07:00Z","last_updated_date":"2023-09-14T18:07:00Z","reference_number":"EMA/705362/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0373-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-cannabidiol-delta-9-tetrahydrocannabinol-sativex-emea-000181-pip02-13-m01_en.pdf"},
    {"id":"60001","name":"P/0401/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara), (EMEA-000311-PIP04-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T18:11:00Z","last_updated_date":"2023-09-14T18:11:00Z","reference_number":"EMA/709431/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0401-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip04-13-m05_en.pdf"},
    {"id":"60002","name":"P/0397/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (Rekambys), (EMEA-000317-PIP02-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T18:18:00Z","last_updated_date":"2023-09-14T18:18:00Z","reference_number":"EMA/709307/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0397-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-rekambys-emea-000317-pip02-18-m01_en.pdf"},
    {"id":"60016","name":"P/0365/2022: EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for finerenone (Kerendia), (EMEA-001623-PIP03-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T09:25:00Z","last_updated_date":"2023-09-15T09:25:00Z","reference_number":"EMA/697757/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0365-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-finerenone-kerendia-emea-001623-pip03-20-m01_en.pdf"},
    {"id":"60035","name":"P/0411/2022: EMA decision of 30 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for burosumab (Crysvita), (EMEA-001659-PIP01-15-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T09:13:00Z","last_updated_date":"2023-09-18T09:13:00Z","reference_number":"EMA/775829/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0411-2022-ema-decision-30-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-burosumab-crysvita-emea-001659-pip01-15-m06_en.pdf"},
    {"id":"60036","name":"P/0392/2022: EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod (hydrochloride) (Zeposia), (EMEA-001710-PIP02-14-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T09:26:00Z","last_updated_date":"2023-09-18T09:26:00Z","reference_number":"EMA/677609/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0392-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-ozanimod-hydrochloride-zeposia-emea-001710-pip02-14-m07_en.pdf"},
    {"id":"60037","name":"P/0385/2022: EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for copanlisib (EMEA- 001757-PIP02-15-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T10:11:00Z","last_updated_date":"2023-09-18T10:12:00Z","reference_number":"EMA/677533/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0385-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-copanlisib-emea-001757-pip02-15-m03_en.pdf"},
    {"id":"60038","name":"P/0391/2022: EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / lamivudine (Dovato), (EMEA-001940-PIP01-16-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T10:54:00Z","last_updated_date":"2023-09-18T11:00:00Z","reference_number":"EMA/677553/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0391-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-lamivudine-dovato-emea-001940-pip01-16-m04_en.pdf"},
    {"id":"60039","name":"P/0390/2022: EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for fenfluramine (hydrochloride) (Fintepla), (EMEA-001990-PIP01-16-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T12:02:00Z","last_updated_date":"2023-09-18T12:02:00Z","reference_number":"EMA/677648/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0390-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-fenfluramine-hydrochloride-fintepla-emea-001990-pip01-16-m05_en.pdf"},
    {"id":"60041","name":"P/0412/2022: EMA decision of 30 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for alpelisib (Piqray and associated names), (EMEA-002016-PIP03-19-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T13:40:00Z","last_updated_date":"2023-09-18T13:40:00Z","reference_number":"EMA/776062/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0412-2022-ema-decision-30-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-alpelisib-piqray-associated-names-emea-002016-pip03-19-m02_en.pdf"},
    {"id":"60042","name":"P/0366/2022: EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for durvalumab (Imfinzi), (EMEA-002028-PIP01-16-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T13:54:00Z","last_updated_date":"2023-09-18T13:54:00Z","reference_number":"EMA/697758/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0366-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-durvalumab-imfinzi-emea-002028-pip01-16-m03_en.pdf"},
    {"id":"60043","name":"P/0367/2022: EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tremelimumab (EMEA-002029-PIP01-16-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T14:14:00Z","last_updated_date":"2023-09-18T14:14:00Z","reference_number":"EMA/697759/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0367-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-tremelimumab-emea-002029-pip01-16-m03_en.pdf"},
    {"id":"60045","name":"P/0368/2022: EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for odevixibat (Bylvay), (EMEA-002054-PIP03-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T14:42:00Z","last_updated_date":"2023-09-18T14:42:00Z","reference_number":"EMA/697761/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0368-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-odevixibat-bylvay-emea-002054-pip03-20-m01_en.pdf"},
    {"id":"60049","name":"P/0369/2022: EMA decision on the acceptance of a modification of an agreed paediatric investigation plan for dafsolimab setaritox/grisnilimab setaritox (EMEA-002087-PIP01-16-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-18T15:42:00Z","last_updated_date":"2023-09-18T15:42:00Z","reference_number":"EMA/697762/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0369-2022-ema-decision-acceptance-modification-agreed-paediatric-investigation-plan-dafsolimab-setaritox-grisnilimab-setaritox-emea-002087-pip01-16-m01_en.pdf"},
    {"id":"60052","name":"P/0394/2022: EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for evinacumab (Evkeeza), (EMEA-002298-PIP01-17-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T16:13:00Z","last_updated_date":"2023-09-27T16:13:00Z","reference_number":"EMA/709268/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0394-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-evinacumab-evkeeza-emea-002298-pip01-17-m04_en.pdf"},
    {"id":"60057","name":"P/0415/2022 : EMA decision of of 29 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for epcoritamab (EMEA- 002907-PIP01-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T14:12:00Z","last_updated_date":"2023-09-19T14:12:00Z","reference_number":"EMA/777575/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0415-2022-ema-decision-29-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-epcoritamab-emea-002907-pip01-20-m02_en.pdf"},
    {"id":"60058","name":"P/0402/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine / tenofovir alafenamide (Descovy), (EMEA-001577-PIP02-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T14:17:00Z","last_updated_date":"2023-09-19T14:17:00Z","reference_number":"EMA/709116/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0402-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-emtricitabine-tenofovir-alafenamide-descovy-emea-001577-pip02-14-m05_en.pdf"},
    {"id":"60059","name":"P/0400/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for roxadustat (Evrenzo), (EMEA-001557-PIP01-13-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-19T14:24:00Z","last_updated_date":"2023-09-19T14:24:00Z","reference_number":"EMA/709114/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0400-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-roxadustat-evrenzo-emea-001557-pip01-13-m06_en.pdf"},
    {"id":"60060","name":"P/0399/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab (Tremfya), (EMEA-001523-PIP04-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T14:28:00Z","last_updated_date":"2023-09-19T14:28:00Z","reference_number":"EMA/709112/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0399-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-guselkumab-tremfya-emea-001523-pip04-19-m01_en.pdf"},
    {"id":"60061","name":"P/0398/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for inotuzumab ozogamicin (Besponsa), (EMEA-001429-PIP01-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T14:32:00Z","last_updated_date":"2023-09-19T14:32:00Z","reference_number":"EMA/709110/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0398-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-inotuzumab-ozogamicin-besponsa-emea-001429-pip01-13-m06_en.pdf"},
    {"id":"60062","name":"P/0396/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (Vocabria), (EMEA-001418-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T14:36:00Z","last_updated_date":"2023-09-19T14:36:00Z","reference_number":"EMA/709107/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0396-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-cabotegravir-vocabria-emea-001418-pip01-13-m05_en.pdf"},
    {"id":"60063","name":"P/0364/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP07-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T14:47:00Z","last_updated_date":"2023-09-19T14:47:00Z","reference_number":"EMA/697754/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0364-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip07-20-m01_en.pdf"},
    {"id":"60064","name":"P/0363/2022 : EMA decision of 7 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for vonicog alfa (Veyvondi), (EMEA-001164-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T17:16:00Z","last_updated_date":"2023-09-19T17:16:00Z","reference_number":"EMA/697750/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0363-2022-ema-decision-7-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-vonicog-alfa-veyvondi-emea-001164-pip01-11-m06_en.pdf"},
    {"id":"60065","name":"P/0362/2022 : EMA decision of 19 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for lomitapide (Lojuxta), (EMEA-001124-PIP01-10-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T17:21:00Z","last_updated_date":"2023-09-19T17:21:00Z","reference_number":"EMA/697719/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0362-2022-ema-decision-19-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-lomitapide-lojuxta-emea-001124-pip01-10-m05_en.pdf"},
    {"id":"60066","name":"P/0395/2022 : EMA decision of 9September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for belimumab (Benlysta), (EMEA-000520-PIP02-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T17:24:00Z","last_updated_date":"2023-09-19T17:24:00Z","reference_number":"P/0395/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0395-2022-ema-decision-9september-2022-acceptance-modification-agreed-paediatric-investigation-plan-belimumab-benlysta-emea-000520-pip02-13-m04_en.pdf"},
    {"id":"60067","name":"P/0371/2022 : EMA decision of 9 September 2022 on the granting of a product specific waiver for bismuth (subcitrate) / metronidazole (benzoate) / tetracycline (hydrochloride) (EMEA-003224-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-19T17:33:00Z","last_updated_date":"2023-09-19T17:33:00Z","reference_number":"EMA/697764/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0371-2022-ema-decision-9-september-2022-granting-product-specific-waiver-bismuth-subcitrate-metronidazole-benzoate-tetracycline-hydrochloride-emea-003224-pip01-22_en.pdf"},
    {"id":"60072","name":"P/0383/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for baloxavir marboxil (Xofluza) (EMEA-002440-PIP01-18-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-20T13:06:00Z","last_updated_date":"2023-09-20T13:06:00Z","reference_number":"EMA/709120/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0383-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-baloxavir-marboxil-xofluza-emea-002440-pip01-18-m03_en.pdf"},
    {"id":"60073","name":"P/0381/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for zoliflodacin (EMEA- 002599-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-20T13:14:00Z","last_updated_date":"2023-09-20T13:14:00Z","reference_number":"EMA/709063/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0381-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-zoliflodacin-emea-002599-pip01-19-m01_en.pdf"},
    {"id":"60074","name":"P/0410/2022 : EMA decision of 29 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for rozanolixizumab (EMEA-002681-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-20T13:23:00Z","last_updated_date":"2023-09-20T13:23:00Z","reference_number":"EMA/777575/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0410-2022-ema-decision-29-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-rozanolixizumab-emea-002681-pip01-19-m01_en.pdf"},
    {"id":"60075","name":"P/0413/2022 : EMA decision of 29 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for diroximel fumarate (BIIB098) (Vumerity) (EMEA-002685-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-20T13:27:00Z","last_updated_date":"2023-09-20T13:27:00Z","reference_number":"EMA/777575/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0413-2022-ema-decision-29-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-diroximel-fumarate-biib098-vumerity-emea-002685-pip02-19-m01_en.pdf"},
    {"id":"60092","name":"P/0409/2022 : EMA decision of 29 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for etrasimod L-arginine (EMEA-002713-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-21T13:58:00Z","last_updated_date":"2023-09-21T13:58:00Z","reference_number":"EMA/777575/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0409-2022-ema-decision-29-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-etrasimod-l-arginine-emea-002713-pip01-19-m02_en.pdf"},
    {"id":"60093","name":"P/0380/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for etranacogene dezaparvovec (EMEA-002722-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-21T14:05:00Z","last_updated_date":"2023-09-21T14:05:00Z","reference_number":"EMA/709050/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0380-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-etranacogene-dezaparvovec-emea-002722-pip01-19-m02_en.pdf"},
    {"id":"60094","name":"P/0379/2022 : EMA decision of 27 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for plasma kallikrein inhibitor (EMEA-002723-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-21T14:15:00Z","last_updated_date":"2023-09-21T14:15:00Z","reference_number":"EMA/709041/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0379-2022-ema-decision-27-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-plasma-kallikrein-inhibitor-emea-002723-pip01-19-m01_en.pdf"},
    {"id":"60095","name":"P/0384/2022 : EMA decision of 23 September 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for corticotropin (EMEA-003097-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-21T14:16:00Z","last_updated_date":"2023-09-21T14:16:00Z","reference_number":"EMA/678481/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0384-2022-ema-decision-23-september-2022-agreement-paediatric-investigation-plan-granting-waiver-corticotropin-emea-003097-pip01-21_en.pdf"},
    {"id":"60096","name":"P/0404/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for adrenaline (epinephrine) (EMEA-002749-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-21T14:20:00Z","last_updated_date":"2023-09-21T14:20:00Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0404-2022-ema-decision-9-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-adrenaline-epinephrine-emea-002749-pip01-19-m02_en.pdf"},
    {"id":"60097","name":"P/0405/2022 : EMA decision of 9 September 2022 on the granting of a product specific waiver for monalizumab (EMEA-002751-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-21T14:21:00Z","last_updated_date":"2023-09-21T14:21:00Z","reference_number":"EMA/709248/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0405-2022-ema-decision-9-september-2022-granting-product-specific-waiver-monalizumab-emea-002751-pip02-22_en.pdf"},
    {"id":"60098","name":"P/0417/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cefepime / taniborbactam (EMEA-002576-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-21T14:29:00Z","last_updated_date":"2023-09-21T14:29:00Z","reference_number":"EMA/777575/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0417-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-cefepime-taniborbactam-emea-002576-pip01-19-m01_en.pdf"},
    {"id":"60099","name":"P/0414/2022 : EMA decision of 29 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for sotatercept (EMEA-002756-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-21T14:35:00Z","last_updated_date":"2023-09-21T14:35:00Z","reference_number":"EMA/777575/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0414-2022-ema-decision-29-september-2022-acceptance-modification-agreed-paediatric-investigation-plan-sotatercept-emea-002756-pip01-19-m01_en.pdf"},
    {"id":"60112","name":"P/0376/2022: EMA decision of 19 September 2022 on the granting of a product specific waiver for rosuvastatin (calcium) / perindopril (tert-butylamin) (EMEA-003228-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-22T12:56:00Z","last_updated_date":"2023-09-22T12:56:00Z","reference_number":"EMA/706940/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0376-2022-ema-decision-19-september-2022-granting-product-specific-waiver-rosuvastatin-calcium-perindopril-tert-butylamin-emea-003228-pip01-22_en.pdf"},
    {"id":"60117","name":"(1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27.....(MK-8669, or AP23573) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-22T15:03:00Z","last_updated_date":"2023-09-22T15:03:00Z","reference_number":"EMEA-000458-PIP01-08","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/1r2r4s-4-2r-2-3s6r7e9r10r12r14s15e17e19e21s23s26r27r34as-927mk-8669-or-ap23573-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"60134","name":"P/0377/2022: EMA decision of 19 September 2022 on the granting of a product specific waiver for telmisartan / amlodipine / hydrochlorothiazide (EMEA- 003229-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T14:31:00Z","last_updated_date":"2023-09-25T14:31:00Z","reference_number":"EMA/706982/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0377-2022-ema-decision-19-september-2022-granting-product-specific-waiver-telmisartan-amlodipine-hydrochlorothiazide-emea-003229-pip01-22_en.pdf"},
    {"id":"60135","name":"P/0406/2022: EMA decision of 9 September 2022 on the granting of a product specific waiver for vepsitamab (EMEA-003230-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T14:47:00Z","last_updated_date":"2023-09-25T14:47:00Z","reference_number":"EMA/709251/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0406-2022-ema-decision-9-september-2022-granting-product-specific-waiver-vepsitamab-emea-003230-pip01-22_en.pdf"},
    {"id":"60136","name":"P/0389/2022: EMA decision of 9 September 2022 on the granting of a product specific waiver for autologous CD4+ and CD8+ T cells transduced with lentiviral vector encoding a chimeric antigen receptor (CAR)...(EMEA-003231-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T15:00:00Z","last_updated_date":"2023-09-25T15:00:00Z","reference_number":"EMA/675291/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0389-2022-ema-decision-9-september-2022-granting-product-specific-waiver-autologous-cd4-cd8-t-cells-transduced-lentiviral-vector-encoding-chimeric-antigen-receptor-caremea-003231-pip01-22_en.pdf"}    {"id":"60137","name":"P/0388/2022: EMA decision of 9 September 2022 on the granting of a product specific waiver for oleclumab (EMEA-003234-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T15:23:00Z","last_updated_date":"2023-09-25T15:23:00Z","reference_number":"EMA/675740/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0388-2022-ema-decision-9-september-2022-granting-product-specific-waiver-oleclumab-emea-003234-pip01-22_en.pdf"},
    {"id":"60139","name":"P/0374/2022: EMA decision of 9 September 2022 on the granting of a product specific waiver for xevinapant (EMEA-003235-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T15:53:00Z","last_updated_date":"2023-09-25T15:53:00Z","reference_number":"EMA/705744/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0374-2022-ema-decision-9-september-2022-granting-product-specific-waiver-xevinapant-emea-003235-pip01-22_en.pdf"},
    {"id":"60172","name":"P/0420/2022 : EMA decision of 28 October 2022 on the granting of a product specific waiver for 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1Hpyrazole (EMEA-003252-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-27T15:51:00Z","last_updated_date":"2023-09-27T15:51:00Z","reference_number":"EMA/824970/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0420-2022-ema-decision-28-october-2022-granting-product-specific-waiver-3-13-benzodioxol-5-yl-5-3-bromophenyl-1hpyrazole-emea-003252-pip01-22_en.pdf"},
    {"id":"60173","name":"P/0419/2022 : EMA decision of 28 October 2022 on the granting of a product specific waiver for lidocaine (hydrochloride monohydrate) (EMEA-003255- PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-27T15:57:00Z","last_updated_date":"2023-09-27T15:57:00Z","reference_number":"EMA/824709/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0419-2022-ema-decision-28-october-2022-granting-product-specific-waiver-lidocaine-hydrochloride-monohydrate-emea-003255-pip01-22_en.pdf"},
    {"id":"60183","name":"P/0459/2022 : EMA decision of 28 October 2022 on the granting of a product specific waiver for derivative of (3S,3'S,3a'S,10a'S)-3'- phenyl-3',3a',10',10a'-tetrahydro-1'H-spiro[indoline....[2',3':4,5]pyrrolo[1,2-b]indazol]-2- one (EMEA-003260-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T08:09:00Z","last_updated_date":"2023-09-28T08:09:00Z","reference_number":"EMA/790454/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0459-2022-ema-decision-28-october-2022-granting-product-specific-waiver-derivative-3s3s3as10as-3-phenyl-33a1010a-tetrahydro-1h-spiroindoline2345pyrrolo12-bindazol-2-one-emea-003260-pip01-22_en.pdf"},
    {"id":"60184","name":"P/0461/2022 : EMA decision of 28 October 2022 on the granting of a product specific waiver for finasteride / tadalafil (EMEA-003261-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T08:21:00Z","last_updated_date":"2023-09-28T08:21:00Z","reference_number":"EMA/790520/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0461-2022-ema-decision-28-october-2022-granting-product-specific-waiver-finasteride-tadalafil-emea-003261-pip01-22_en.pdf"},
    {"id":"60185","name":"P/0460/2022 : EMA decision of 28 October 2022 on the granting of a product specific waiver for telmisartan / rosuvastatin (calcium) (EMEA-003262- PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T08:28:00Z","last_updated_date":"2023-09-28T08:28:00Z","reference_number":"EMA/790490/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0460-2022-ema-decision-28-october-2022-granting-product-specific-waiver-telmisartan-rosuvastatin-calcium-emea-003262-pip01-22_en.pdf"},
    {"id":"60192","name":"P/0453/2022 : EMA decision of 24 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for vosoritide (Voxzogo), (EMEA-002033-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T10:17:00Z","last_updated_date":"2023-09-28T10:17:00Z","reference_number":"EMA/834945/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0453-2022-ema-decision-24-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-vosoritide-voxzogo-emea-002033-pip01-16-m03_en.pdf"},
    {"id":"60193","name":"P/0458/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for insulin human (NTRA-2112/ELGN-2112) (EMEA-002116-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T10:25:00Z","last_updated_date":"2023-09-28T10:25:00Z","reference_number":"EMA/776153/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0458-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-insulin-human-ntra-2112-elgn-2112-emea-002116-pip01-17-m01_en.pdf"},
    {"id":"60194","name":"P/0441/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cefiderocol (Fetcroja), (EMEA-002133-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T10:30:00Z","last_updated_date":"2023-09-28T10:30:00Z","reference_number":"EMA/788938/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0441-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-cefiderocol-fetcroja-emea-002133-pip01-17-m03_en.pdf"},
    {"id":"60195","name":"P/0442/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for monovalent, recombinant, replication-incompetent human adenovirus serotype...from the RSV A2 strain (EMEA-002172-PIP02-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T10:37:00Z","last_updated_date":"2023-09-28T10:37:00Z","reference_number":"EMA/824453/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0442-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-monovalent-recombinant-replication-incompetent-human-adenovirus-serotypefrom-rsv-a2-strain-emea_en.pdf"},
    {"id":"60196","name":"P/0443/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for marstacimab (EMEA- 002285-PIP02-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T10:47:00Z","last_updated_date":"2023-09-28T10:47:00Z","reference_number":"EMA/823989/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0443-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-marstacimab-emea-002285-pip02-19-m02_en.pdf"},
    {"id":"60198","name":"P/0393/2022 : EMA decision of 9 September 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for clazakizumab (EMEA-001371-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T16:44:00Z","last_updated_date":"2023-09-28T16:44:00Z","reference_number":"EMA/677940/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0393-2022-ema-decision-9-september-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-clazakizumab-emea-001371-pip02-21_en.pdf"},
    {"id":"60199","name":"P/0403/2022 : EMA decision of 9 September 2022 on the granting of a product specific waiver for pegcetacoplan (Aspaveli), (EMEA-002600-PIP04-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T16:49:00Z","last_updated_date":"2023-09-28T16:49:00Z","reference_number":"EMA/709243/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0403-2022-ema-decision-9-september-2022-granting-product-specific-waiver-pegcetacoplan-aspaveli-emea-002600-pip04-22_en.pdf"},
    {"id":"60200","name":"P/0347/2024 : of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ibrexafungerp (citrate) (EMEA-002535-PIP04-21-M02) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-20T10:16:00Z","last_updated_date":"2025-10-20T10:16:00Z","reference_number":"EMA/421548/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0347-2024-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-ibrexafungerp-citrate-emea-002535-pip04-21-m02_en.pdf"},
    {"id":"60201","name":"P/0375/2022: EMA decision of 9 September 2022 on the agreement of a paediatric investigation plan for ex vivo expanded autologous human keratinocytes containing epidermal stem cells genetically modified with a gamma-retroviral (RV) (EMEA-003137-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-09-28T17:01:00Z","last_updated_date":"2023-09-28T17:01:00Z","reference_number":"EMA/706927/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0375-2022-ema-decision-9-september-2022-agreement-paediatric-investigation-plan-ex-vivo-expanded-autologous-human-keratinocytes-containing-epidermal-stem-cells-genetically-modified-gamma-retroviral_en.pdf"},
    {"id":"60248","name":"P/0426/2022: EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for odronextamab (EMEA-003149-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-04T15:35:00Z","last_updated_date":"2023-10-04T15:35:00Z","reference_number":"EMA/825329/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0426-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-granting-deferral-odronextamab-emea-003149-pip01-21_en.pdf"},
    {"id":"60250","name":"P/0432/2022: EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efavaleukin alfa (EMEA-003156-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-04T16:01:00Z","last_updated_date":"2023-10-04T16:01:00Z","reference_number":"EMA/808600/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0432-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-efavaleukin-alfa-emea-003156-pip01-21_en.pdf"},
    {"id":"60252","name":"P/0431/2022: EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fusion protein composed of the first 2 immunoglobulin (Ig)-like...(EMEA-003157-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-04T16:14:00Z","last_updated_date":"2023-10-04T16:14:00Z","reference_number":"EMA/808629/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0431-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fusion-protein-composed-first-2-immunoglobulin-ig-likeemea-003157-pip01-21_en.pdf"},
    {"id":"60253","name":"P/0452/2022: EMA decision of 28 October 2022 on the granting of a product specific waiver for batoclimab (EMEA-003162-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-04T16:44:00Z","last_updated_date":"2023-10-04T16:44:00Z","reference_number":"EMA/834765/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0452-2022-ema-decision-28-october-2022-granting-product-specific-waiver-batoclimab-emea-003162-pip02-22_en.pdf"},
    {"id":"60269","name":"P/0418/2022: EMA decision of 28 October 2022 on the granting of a product specific waiver for pridopidine (hydrochloride) (EMEA-003174-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-05T14:27:00Z","last_updated_date":"2023-10-05T14:27:00Z","reference_number":"EMA/824829/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0418-2022-ema-decision-28-october-2022-granting-product-specific-waiver-pridopidine-hydrochloride-emea-003174-pip02-22_en.pdf"},
    {"id":"60270","name":"P/0427/2022: EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan for treprostinil (sodium), (Trisuva and associated names), (EMEA-003182-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-05T14:57:00Z","last_updated_date":"2023-10-05T14:57:00Z","reference_number":"EMA/825327/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0427-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-treprostinil-sodium-trisuva-associated-names-emea-003182-pip01-22_en.pdf"},
    {"id":"60274","name":"P/0437/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for outer membrane vesicles (OMV) from N. meningitidis Strain NZ 98/254..(EMEA-001260-PIP01-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-05T16:38:00Z","last_updated_date":"2023-10-05T16:38:00Z","reference_number":"EMA/808316/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0437-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-outer-membrane-vesicles-omv-n-meningitidis-strain-nz-98-254emea-001260-pip01-11-m02_en.pdf"},
    {"id":"60275","name":"P/0436/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for maralixibat chloride (EMEA-001475-PIP03-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-05T16:48:00Z","last_updated_date":"2023-10-05T16:48:00Z","reference_number":"EMA/638309/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0436-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-maralixibat-chloride-emea-001475-pip03-17-m03_en.pdf"},
    {"id":"60276","name":"P/0435/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab (Tremfya) (EMEA-001523-PIP03-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-05T16:58:00Z","last_updated_date":"2023-10-05T16:58:00Z","reference_number":"EMA/808374/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0435-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-guselkumab-tremfya-emea-001523-pip03-18-m02_en.pdf"},
    {"id":"60277","name":"P/0434/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for finerenone (Kerendia) (EMEA-001623-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-05T17:04:00Z","last_updated_date":"2023-10-05T17:04:00Z","reference_number":"EMA/808511/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0434-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-finerenone-kerendia-emea-001623-pip01-14-m05_en.pdf"},
    {"id":"60278","name":"P/0455/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for atidarsagene autotemcel (Libmeldy), (EMEA-001765-PIP02-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-05T17:14:00Z","last_updated_date":"2023-10-05T17:14:00Z","reference_number":"EMA/775900/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0455-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-atidarsagene-autotemcel-libmeldy-emea-001765-pip02-15-m04_en.pdf"},
    {"id":"60279","name":"P/0456/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for enasidenib (EMEA- 001798-PIP02-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-05T17:21:00Z","last_updated_date":"2023-10-05T17:21:00Z","reference_number":"EMA/775977/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0456-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-enasidenib-emea-001798-pip02-16-m01_en.pdf"},
    {"id":"60280","name":"P/0457/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for 3,6-diamino-2,5- bis{N-[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl}pyrazine (MB-102) (EMEA-001983-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-05T17:33:00Z","last_updated_date":"2023-10-05T17:33:00Z","reference_number":"EMA/776038/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0457-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-36-diamino-25-bisn-1r-1-carboxy-2-hydroxyethylcarbamoylpyrazine-mb-102-emea-001983-pip01-16-m01_en.pdf"},
    {"id":"60368","name":"P/0421/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for golimumab (Simponi), (EMEA-000265-PIP02-11-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T09:06:00Z","last_updated_date":"2023-10-12T09:06:00Z","reference_number":"EMA/825000/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0421-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-golimumab-simponi-emea-000265-pip02-11-m04_en.pdf"},
    {"id":"60369","name":"P/0424/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ocrelizumab (Ocrevus), (EMEA-000310-PIP03-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T09:14:00Z","last_updated_date":"2023-10-12T09:14:00Z","reference_number":"EMA/825317/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0424-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-ocrelizumab-ocrevus-emea-000310-pip03-10-m06_en.pdf"},
    {"id":"60370","name":"P/0423/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for secukinumab (Cosentyx), (EMEA-000380-PIP06-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T10:12:00Z","last_updated_date":"2023-10-12T10:12:00Z","reference_number":"EMA/825174/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0423-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-secukinumab-cosentyx-emea-000380-pip06-19-m01_en.pdf"},
    {"id":"60371","name":"P/0428/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ambrisentan (Volibris), (EMEA-000434-PIP01-08-M09)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-10-12T10:18:00Z","last_updated_date":"2023-10-12T10:18:00Z","reference_number":"EMA/826798/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0428-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-ambrisentan-volibris-emea-000434-pip01-08-m09_en.pdf"},
    {"id":"60372","name":"P/0428/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ambrisentan (Volibris), (EMEA-000434-PIP01-08-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T10:21:00Z","last_updated_date":"2023-10-12T10:21:00Z","reference_number":"EMA/826798/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0428-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-ambrisentan-volibris-emea-000434-pip01-08-m09_en.pdf-0"},
    {"id":"60373","name":"P/0440/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for eliglustat (Cerdelga) (EMEA-000461-PIP02-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T10:29:00Z","last_updated_date":"2023-10-12T10:29:00Z","reference_number":"EMA/808128/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0440-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-eliglustat-cerdelga-emea-000461-pip02-11-m05_en.pdf"},
    {"id":"60375","name":"P/0439/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz) (EMEA-000576-PIP03-12-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T10:45:00Z","last_updated_date":"2023-10-12T10:45:00Z","reference_number":"EMA/808195/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0439-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip03-12-m06_en.pdf"},
    {"id":"60376","name":"P/0438/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine (Exparel liposomal) (EMEA-000877-PIP03-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T10:51:00Z","last_updated_date":"2023-10-12T10:51:00Z","reference_number":"EMA/808271/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0438-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-bupivacaine-exparel-liposomal-emea-000877-pip03-17-m04_en.pdf"},
    {"id":"60383","name":"P/0429/2022: EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan for recombinant fusion protein linking iduronate 2- sulfatase to engineered Fc with binding site for transferrin receptor (DNL310) (EMEA-002845-PIP01- 20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T14:07:00Z","last_updated_date":"2023-10-12T14:07:00Z","reference_number":"EMA/826865/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0429-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-recombinant-fusion-protein-linking-iduronate-2-sulfatase-engineered-fc-binding-site-transferrin-receptor-dnl310-emea_en.pdf"},
    {"id":"60385","name":"P/0425/2022: EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for yellow fever virus, strain vYF-247 (EMEA-003030-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T14:21:00Z","last_updated_date":"2023-10-12T14:21:00Z","reference_number":"EMA/825331/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0425-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-granting-waiver-yellow-fever-virus-strain-vyf-247-emea-003030-pip02-21_en.pdf"},
    {"id":"60386","name":"P/0462/2022: EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for resmetirom (EMEA-003087-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T14:32:00Z","last_updated_date":"2023-10-12T14:32:00Z","reference_number":"EMA/790574/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0462-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-resmetirom-emea-003087-pip01-21_en.pdf"},
    {"id":"60387","name":"P/0469/2022: EMA decision of 14 November 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efavaleukin alfa (EMEA-003156-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T14:28:00Z","last_updated_date":"2023-10-12T14:28:00Z","reference_number":"EMA/884290/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0469-2022-ema-decision-14-november-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-efavaleukin-alfa-emea-003156-pip02-22_en.pdf"},
    {"id":"60388","name":"P/0433/2022: EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cenerimod (EMEA-003108-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T14:43:00Z","last_updated_date":"2023-10-12T14:43:00Z","reference_number":"EMA/808582/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0433-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cenerimod-emea-003108-pip01-21_en.pdf"},
    {"id":"60389","name":"P/0463/2022: EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for freeze-dried allergen extract of Betula pendula pollen (EMEA-003117-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T14:51:00Z","last_updated_date":"2023-10-12T14:51:00Z","reference_number":"EMA/790671/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0463-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-granting-waiver-freeze-dried-allergen-extract-betula-pendula-pollen-emea-003117-pip02-21_en.pdf"},
    {"id":"60390","name":"P/0468/2022: EMA decision of 18 November 2022","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T14:58:00Z","last_updated_date":"2023-10-12T14:58:00Z","reference_number":"EMA/501874/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0468-2022-ema-decision-18-november-2022_en.pdf"},
    {"id":"60391","name":"P/0382/2023 : EMA decision of 7 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for vedolizumab (Entyvio) (EMEA-000645-PIP04-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T15:10:00Z","last_updated_date":"2023-10-12T15:10:00Z","reference_number":"EMA/389683/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0382-2023-ema-decision-7-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-vedolizumab-entyvio-emea-000645-pip04-20-m02_en.pdf"},
    {"id":"60392","name":"P/0448/2022 of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for satralizumab (Enspryng), (EMEA-001625-PIP03-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-10-12T15:30:00Z","last_updated_date":"2023-10-12T15:30:00Z","reference_number":"EMA/834868/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0448-2022-28-october-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-satralizumab-enspryng-emea-001625-pip03-21_en.pdf"},
    {"id":"60394","name":"P/0449/2022 : EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for branaplam (EMEA-002204-PIP02-20)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-10-12T15:46:00Z","last_updated_date":"2023-10-12T15:46:00Z","reference_number":"EMA/834865/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0449-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-granting-waiver-branaplam-emea-002204-pip02-20_en.pdf"},
    {"id":"60395","name":"P/0450/2022 : EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ianalumab (EMEA-002338-PIP03-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-10-12T15:51:00Z","last_updated_date":"2023-10-12T15:51:00Z","reference_number":"EMA/834866/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0450-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ianalumab-emea-002338-pip03-21_en.pdf"},
    {"id":"60396","name":"P/0464/2022 : EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan for beremagene geperpavec (EMEA-002472-PIP03- 22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-10-12T15:58:00Z","last_updated_date":"2023-10-12T15:58:00Z","reference_number":"EMA/790731/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0464-2022-ema-decision-28-october-2022-agreement-paediatric-investigation-plan-beremagene-geperpavec-emea-002472-pip03-22_en.pdf"},
    {"id":"60397","name":"P/0451/2022 : EMA decision of 28 October 2022 on the granting of a product specific waiver for trilaciclib (dihydrochloride) (EMEA-002534-PIP03-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T16:08:00Z","last_updated_date":"2023-10-12T16:08:00Z","reference_number":"EMA/834732/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0451-2022-ema-decision-28-october-2022-granting-product-specific-waiver-trilaciclib-dihydrochloride-emea-002534-pip03-22_en.pdf"},
    {"id":"60398","name":"P/0465/2022: EMA decision of 4 November 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for COVID-19 Vaccine (recombinant, adjuvanted) (EMEA-003191-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T16:09:00Z","last_updated_date":"2023-10-12T16:09:00Z","reference_number":"EMA/853635/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0465-2022-ema-decision-4-november-2022-agreement-paediatric-investigation-plan-granting-deferral-covid-19-vaccine-recombinant-adjuvanted-emea-003191-pip01-22_en.pdf"},
    {"id":"60399","name":"P/0430/2022 : EMA decision of 28 October 2022 on the granting of a product-specific waiver for fluorine (18F) PSMA-1007 (EMEA-003250-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T16:16:00Z","last_updated_date":"2023-10-12T16:16:00Z","reference_number":"EMA/808660/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0430-2022-ema-decision-28-october-2022-granting-product-specific-waiver-fluorine-18f-psma-1007-emea-003250-pip01-22_en.pdf"},
    {"id":"60400","name":"P/0477/2022: EMA decision of 2 December 2022 on the refusal of a modification of an agreed paediatric investigation plan for ataluren (Translarna), (EMEA-000115-PIP01-07-M12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T16:16:00Z","last_updated_date":"2023-10-12T16:16:00Z","reference_number":"EMA/899031/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0477-2022-ema-decision-2-december-2022-refusal-modification-agreed-paediatric-investigation-plan-ataluren-translarna-emea-000115-pip01-07-m12_en.pdf"},
    {"id":"60401","name":"P/0444/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for gepotidacin (EMEA- 002443-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T16:31:00Z","last_updated_date":"2023-10-12T16:31:00Z","reference_number":"EMA/825134/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0444-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-gepotidacin-emea-002443-pip01-18-m01_en.pdf"},
    {"id":"60402","name":"P/0026/2024 : EMA decision of 26 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ritlecitinib (Litfulo), (EMEA-002451-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T17:00:00Z","last_updated_date":"2025-03-14T17:00:00Z","reference_number":"EMA/553390/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2024-ema-decision-26-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-ritlecitinib-litfulo-emea-002451-pip01-18-m02_en.pdf"},
    {"id":"60403","name":"P/0478/2022: EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for saxagliptin (Onglyza), (EMEA-000200-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T17:02:00Z","last_updated_date":"2023-10-12T17:02:00Z","reference_number":"EMA/899035/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0478-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-saxagliptin-onglyza-emea-000200-pip01-08-m10_en.pdf"},
    {"id":"60404","name":"P/0416/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for atropine (sulphate) (EMEA-002545-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T17:05:00Z","last_updated_date":"2023-10-12T17:05:00Z","reference_number":"EMA/777575/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0416-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-atropine-sulphate-emea-002545-pip01-19-m01_en.pdf"},
    {"id":"60405","name":"P/0506/2022: EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten), (EMEA-000347-PIP02-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T17:07:00Z","last_updated_date":"2023-10-12T17:07:00Z","reference_number":"EMA/898469/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0506-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-emea-000347-pip02-16-m04_en.pdf"},
    {"id":"60406","name":"P/0382/2022 : EMA decision of 10 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for efanesoctocog alfa (EMEA-002501-PIP01-18-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T17:10:00Z","last_updated_date":"2023-10-12T17:10:00Z","reference_number":"EMA/709081/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0382-2022-ema-decision-10-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-efanesoctocog-alfa-emea-002501-pip01-18-m03_en.pdf"},
    {"id":"60407","name":"P/0447/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for levonorgestrel (EMEA-002474-PIP02-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T17:15:00Z","last_updated_date":"2023-10-12T17:15:00Z","reference_number":"EMA/827039/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0447-2022-ema-decision-28-october-2022-acceptance-modification-agreed-paediatric-investigation-plan-levonorgestrel-emea-002474-pip02-18-m01_en.pdf"},
    {"id":"60408","name":"P/0549/2022: EMA decision of 30 December 2022 on the refusal of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised...(EMEA-000630-PIP02-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-12T17:18:00Z","last_updated_date":"2023-10-12T17:18:00Z","reference_number":"EMA/934749/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0549-2022-ema-decision-30-december-2022-refusal-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerisedemea-000630-pip02-09-m05_en.pdf"},
    {"id":"60427","name":"P/0539/2022 : EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for modified Vaccinia Ankara - Bavarian Nordic virus (smallpox) (Imvanex) (EMEA-001161-PIP02-11-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T15:47:00Z","last_updated_date":"2023-10-13T15:47:00Z","reference_number":"EMA/876000/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0539-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-modified-vaccinia-ankara-bavarian-nordic-virus-smallpox-imvanex-emea-001161-pip02-11-m02_en.pdf"},
    {"id":"60428","name":"P/0536/2022 : EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for setrusumab (EMEA-002169-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T15:52:00Z","last_updated_date":"2023-10-13T15:52:00Z","reference_number":"EMA/901113/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0536-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-setrusumab-emea-002169-pip01-17-m02_en.pdf"},
    {"id":"60429","name":"P/0494/2022 : EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for isatuximab (Sarclisa) (EMEA-002205-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T15:58:00Z","last_updated_date":"2023-10-13T15:58:00Z","reference_number":"EMA/851802/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0494-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-isatuximab-sarclisa-emea-002205-pip01-17-m03_en.pdf"},
    {"id":"60430","name":"P/0495/2022 : EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for inclisiran (sodium) (Leqvio) (EMEA-002214-PIP01-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T16:05:00Z","last_updated_date":"2023-10-13T16:05:00Z","reference_number":"EMA/851986/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0495-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-inclisiran-sodium-leqvio-emea-002214-pip01-17-m01_en.pdf"},
    {"id":"60432","name":"P/0491/2022 : EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for voxelotor (EMEA- 002356-PIP02-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T16:12:00Z","last_updated_date":"2023-10-13T16:12:00Z","reference_number":"EMA/853094/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0491-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-voxelotor-emea-002356-pip02-20-m01_en.pdf"},
    {"id":"60433","name":"P/0537/2022 : EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for ofatumumab (Kesimpta) (EMEA-002397-PIP01-18-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T16:20:00Z","last_updated_date":"2023-10-13T16:20:00Z","reference_number":"EMA/901114/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0537-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-ofatumumab-kesimpta-emea-002397-pip01-18-m03_en.pdf"},
    {"id":"60434","name":"P/0500/2022 : EMA decision of 1 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for gadoquatrane (BAY 1747846) (EMEA-002778-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T16:26:00Z","last_updated_date":"2023-10-13T16:26:00Z","reference_number":"EMA/873552/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0500-2022-ema-decision-1-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-gadoquatrane-bay-1747846-emea-002778-pip01-20-m01_en.pdf"},
    {"id":"60435","name":"P/0476/2022 : EMA decision of 1 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for durlobactam / sulbactam (SUL-DUR) (EMEA-002807-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T16:31:00Z","last_updated_date":"2023-10-13T16:31:00Z","reference_number":"EMA/873551/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0476-2022-ema-decision-1-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-durlobactam-sulbactam-sul-dur-emea-002807-pip01-20-m01_en.pdf"},
    {"id":"60436","name":"P/0542/2022 : EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for COVID-19 vaccine (Ad26.COV2-S [recombinant]) (JCOVDEN) (EMEA-002880-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T16:36:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"EMA/876009/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0542-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-covid-19-vaccine-ad26cov2-s-recombinant-jcovden-emea-002880-pip01-20-m01_en.pdf"},
    {"id":"60437","name":"P/0503/2022 : EMA decision of 1 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for (1R,2S,5S)-N-((1S)- 1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-....(Paxlovid) (EMEA-003081-PIP01-21-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T16:41:00Z","last_updated_date":"2023-10-13T16:41:00Z","reference_number":"EMA/901099/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0503-2022-ema-decision-1-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-1r2s5s-n-1s-1-cyano-2-3s-2-oxopyrrolidin-3-ylethyl-3-2s-33-paxlovid-emea-003081-pip01-21-m02_en.pdf"},
    {"id":"60470","name":"P/0482/2022 : EMA decision of 2 December 2022 on the granting of a product specific waiver for 2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid (EMEA-003282-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-24T12:25:00Z","last_updated_date":"2023-10-24T12:25:00Z","reference_number":"EMA/871507/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0482-2022-ema-decision-2-december-2022-granting-product-specific-waiver-2-4-methoxy-3-2-m-tolyl-ethoxy-benzoylamino-indan-2-carboxylic-acid-emea-003282-pip01-22_en.pdf"},
    {"id":"60471","name":"P/0547/2022 : EMA decision of 30 December 2022 on the granting of a product specific waiver for valsartan / indapamide (EMEA-003285-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-24T12:37:00Z","last_updated_date":"2023-10-24T12:37:00Z","reference_number":"EMA/934658/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0547-2022-ema-decision-30-december-2022-granting-product-specific-waiver-valsartan-indapamide-emea-003285-pip01-22_en.pdf"},
    {"id":"60472","name":"P/0530/2022 : EMA decision of 30 December 2022 on the granting of a product specific waiver for torasemide / eplerenone (EMEA-003289-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-24T12:44:00Z","last_updated_date":"2023-10-24T12:44:00Z","reference_number":"EMA/929797/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0530-2022-ema-decision-30-december-2022-granting-product-specific-waiver-torasemide-eplerenone-emea-003289-pip01-22_en.pdf"},
    {"id":"60473","name":"P/0516/2022 : EMA decision of 30 December 2022 on the granting of a product specific waiver for rivaroxaban / acetylsalicylic acid (EMEA-003291-PIP01- 22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-24T12:50:00Z","last_updated_date":"2023-10-24T12:50:00Z","reference_number":"EMA/915657/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0516-2022-ema-decision-30-december-2022-granting-product-specific-waiver-rivaroxaban-acetylsalicylic-acid-emea-003291-pip01-22_en.pdf"},
    {"id":"60474","name":"P/0499/2022 : EMA decision of 2 December 2022 on the granting of a product specific waiver for diclofenac (potassium) / thiamine (hydrochloride) / pyridoxine (hydrochloride) / cyanocobalamin (EMEA-003292-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-24T13:05:00Z","last_updated_date":"2023-10-24T13:05:00Z","reference_number":"EMA/853429/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0499-2022-ema-decision-2-december-2022-granting-product-specific-waiver-diclofenac-potassium-thiamine-hydrochloride-pyridoxine-hydrochloride-cyanocobalamin-emea-003292-pip01-22_en.pdf"},
    {"id":"60475","name":"P/0534/2022 : EMA decision of 30 December 2022 on the granting of a product specific waiver for eplontersen (EMEA-003294-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-24T13:10:00Z","last_updated_date":"2023-10-24T13:10:00Z","reference_number":"EMA/930232/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0534-2022-ema-decision-30-december-2022-granting-product-specific-waiver-eplontersen-emea-003294-pip01-22_en.pdf"},
    {"id":"60476","name":"P/0532/2022 : EMA decision of 30 December 2022 on the granting of a product specific waiver for messenger RNA encoding Cas9 and single guide RNA targeting the human TTR gene (EMEA-003298-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-24T14:15:00Z","last_updated_date":"2023-10-24T14:15:00Z","reference_number":"EMA/929798/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0532-2022-ema-decision-30-december-2022-granting-product-specific-waiver-messenger-rna-encoding-cas9-single-guide-rna-targeting-human-ttr-gene-emea-003298-pip01-22_en.pdf"},
    {"id":"60477","name":"P/0538/2022 : EMA decision of 30 December 2022 on the granting of a product specific waiver for ezeprogind (EMEA-003320-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-24T14:26:00Z","last_updated_date":"2023-10-24T14:26:00Z","reference_number":"EMA/931324/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0538-2022-ema-decision-30-december-2022-granting-product-specific-waiver-ezeprogind-emea-003320-pip01-22_en.pdf"},
    {"id":"60482","name":"P/0526/2022: EMA decision of 30 December 2022 on the refusal of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of birch, alder and hazel pollen (EMEA-000","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-25T14:06:00Z","last_updated_date":"2023-10-25T14:06:00Z","reference_number":"EMA/929772/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0526-2022-ema-decision-30-december-2022-refusal-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergen-extract-birch-alder_en.pdf"},
    {"id":"60483","name":"P/0527/2022: EMA decision of 30 December 2022 on the refusal of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of birch pollen (EMEA-000837- PIP01-10-M02","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-25T14:14:00Z","last_updated_date":"2023-10-25T14:14:00Z","reference_number":"EMA/929767/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0527-2022-ema-decision-30-december-2022-refusal-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergen-extract-birch-pollen_en.pdf"},
    {"id":"60485","name":"P/0531/2022: EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for siponimod (hemifumarate) (Mayzent), (EMEA-000716-PIP01-09-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-25T14:54:00Z","last_updated_date":"2023-10-25T14:54:00Z","reference_number":"EMA/929763/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0531-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-siponimod-hemifumarate-mayzent-emea-000716-pip01-09-m05_en.pdf"},
    {"id":"60486","name":"P/0548/2022: EMA decision of 30 December 2022 on the refusal of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of birch, alder and hazel pollen (EMEA-000","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-25T15:19:00Z","last_updated_date":"2023-10-25T15:19:00Z","reference_number":"EMA/934709/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0548-2022-ema-decision-30-december-2022-refusal-modification-agreed-paediatric-investigation-plan-aluminium-hydroxide-adsorbed-depigmented-glutaraldehyde-polymerised-allergen-extract-birch-alder_en.pdf"},
    {"id":"60489","name":"P/0507/2022: EMA decision of 2 December 2022 on the refusal of a modification of an agreed paediatric investigation plan for lanthanum carbonate hydrate (Fosrenol), (EMEA-000637-PIP02-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-25T16:01:00Z","last_updated_date":"2023-10-25T16:01:00Z","reference_number":"EMA/898472/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0507-2022-ema-decision-2-december-2022-refusal-modification-agreed-paediatric-investigation-plan-lanthanum-carbonate-hydrate-fosrenol-emea-000637-pip02-10-m07_en.pdf"},
    {"id":"60493","name":"P/0512/2022: EMA decision of 2 December2022 on the granting of a product specific waiver for cobolimab (EMEA-003273-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-26T14:44:00Z","last_updated_date":"2023-10-26T14:44:00Z","reference_number":"EMA/898523/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0512-2022-ema-decision-2-december2022-granting-product-specific-waiver-cobolimab-emea-003273-pip01-22_en.pdf"},
    {"id":"60494","name":"P/0475/2022: EMA decision of 1 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for exenatide (acetate), (EMEA-003183-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-26T14:56:00Z","last_updated_date":"2023-10-26T14:56:00Z","reference_number":"EMA/898079/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0475-2022-ema-decision-1-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-exenatide-acetate-emea-003183-pip02-22_en.pdf"},
    {"id":"60495","name":"P/0546/2022: EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pridopidine (hydrochloride) (EMEA-003174-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-26T15:32:00Z","last_updated_date":"2023-10-26T15:32:00Z","reference_number":"EMA/934635/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0546-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pridopidine-hydrochloride-emea-003174-pip01-21_en.pdf"},
    {"id":"60496","name":"P/0510/2022: EMA decision of 2 December 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for emactuzumab (EMEA-003172-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-26T15:47:00Z","last_updated_date":"2023-10-26T15:47:00Z","reference_number":"EMA/898536/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0510-2022-ema-decision-2-december-2022-agreement-paediatric-investigation-plan-granting-waiver-emactuzumab-emea-003172-pip01-21_en.pdf"},
    {"id":"60497","name":"P/0480/2022: EMA decision of 2 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sirolimus (EMEA-003168-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-10-26T15:56:00Z","last_updated_date":"2023-10-26T15:56:00Z","reference_number":"EMA/899045/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0480-2022-ema-decision-2-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sirolimus-emea-003168-pip01-21_en.pdf-0"},
    {"id":"60592","name":"P/0171/2018: EMA decision of 15 June 2018 on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine / tenofovir alafenamide (Descovy), (EMEA-001577-PIP02-14-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2018-11-28T09:23:00Z","last_updated_date":"2018-11-28T09:23:00Z","reference_number":"EMA/352390/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2018-ema-decision-15-june-2018-acceptance-modification-agreed-paediatric-investigation-plan-emtricitabine-tenofovir-alafenamide-descovy-emea-001577-pip02-14-m03_en.pdf"},
    {"id":"60814","name":"P/0035/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for diclofenac (sodium) / thiamine (hydrochloride) / pyridoxine (hydrochloride) / cyanocobalamin (EMEA-003292-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T13:45:00Z","last_updated_date":"2023-11-09T13:45:00Z","reference_number":"EMA/21199/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2023-ema-decision-31-january-2023-granting-product-specific-waiver-diclofenac-sodium-thiamine-hydrochloride-pyridoxine-hydrochloride-cyanocobalamin-emea-003292-pip02-22_en.pdf"},
    {"id":"60815","name":"P/0001/2023 : EMA decision of 12 January 2023 on the granting of a product specific waiver for rosuvastatin (calcium) / fenofibrate (EMEA-003295-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T13:52:00Z","last_updated_date":"2023-11-09T13:52:00Z","reference_number":"EMA/876033/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2023-ema-decision-12-january-2023-granting-product-specific-waiver-rosuvastatin-calcium-fenofibrate-emea-003295-pip01-22_en.pdf"},
    {"id":"60819","name":"P/0042/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for rivaroxaban + acetylsalicylic acid1 (EMEA-003308-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T14:17:00Z","last_updated_date":"2023-11-09T14:17:00Z","reference_number":"EMA/950368/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2023-ema-decision-31-january-2023-granting-product-specific-waiver-rivaroxaban-acetylsalicylic-acid1-emea-003308-pip01-22_en.pdf"},
    {"id":"60820","name":"P/0032/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for setanaxib (EMEA-003310-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T14:26:00Z","last_updated_date":"2023-11-09T14:26:00Z","reference_number":"EMA/21189/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2023-ema-decision-31-january-2023-granting-product-specific-waiver-setanaxib-emea-003310-pip01-22_en.pdf"},
    {"id":"60821","name":"P/0043/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for tetanus toxoid (Tetana) (EMEA-003311-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T14:36:00Z","last_updated_date":"2023-11-09T14:36:00Z","reference_number":"EMA/950370/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2023-ema-decision-31-january-2023-granting-product-specific-waiver-tetanus-toxoid-tetana-emea-003311-pip01-22_en.pdf"},
    {"id":"60823","name":"P/0036/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for diclofenac / orphenadrine (citrate) (EMEA-003337- PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T14:44:00Z","last_updated_date":"2023-11-09T14:44:00Z","reference_number":"EMA/21196/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2023-ema-decision-31-january-2023-granting-product-specific-waiver-diclofenac-orphenadrine-citrate-emea-003337-pip01-22_en.pdf"},
    {"id":"60826","name":"P/0048/2023 : EMA decision of 30 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for garadacimab (EMEA- 002726-PIP01-19-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T15:04:00Z","last_updated_date":"2023-11-09T15:04:00Z","reference_number":"EMA/21395/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2023-ema-decision-30-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-garadacimab-emea-002726-pip01-19-m03_en.pdf"},
    {"id":"60827","name":"P/0046/2023 : EMA decision of 24 January 2021 on the acceptance of a modification of an agreed paediatric investigation plan for exagamglogene autotemcel (EMEA-002730-PIP04-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T15:13:00Z","last_updated_date":"2023-11-09T15:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0046-2023-ema-decision-24-january-2021-acceptance-modification-agreed-paediatric-investigation-plan-exagamglogene-autotemcel-emea-002730-pip04-21-m01_en.pdf"},
    {"id":"60828","name":"P/0058/2023 : EMA decision of 24 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for respiratory syncytial virus stabilised prefusion F subunit vaccine (EMEA-002795-PIP02-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T15:20:00Z","last_updated_date":"2023-11-09T15:20:00Z","reference_number":"EMA/36508/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2023-ema-decision-24-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-respiratory-syncytial-virus-stabilised-prefusion-f-subunit-vaccine-emea-002795-pip02-21-m01_en.pdf"},
    {"id":"60829","name":"P/0055/2023 : EMA decision of 30 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for neisseria meningitidis serogroup B fHbp subfamily A / Neisseria meningitidis group C....(EMEA-002814-PIP02-21- M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T15:26:00Z","last_updated_date":"2023-11-09T15:26:00Z","reference_number":"EMA/21391/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2023-ema-decision-30-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-b-fhbp-subfamily-neisseria-meningitidis-group-cemea-002814-pip02_en.pdf"}    {"id":"60830","name":"P/0016/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for evoncabtagene pazurgedleucel (EMEA-002881-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T15:34:00Z","last_updated_date":"2023-11-09T15:34:00Z","reference_number":"EMA/18982/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-evoncabtagene-pazurgedleucel-emea-002881-pip01-20-m01_en.pdf"},
    {"id":"60832","name":"P/0017/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for human, recombinant, non-fucosylated IgG1k monoclonal antibody targeting OX-40 receptor....(EMEA-002886-PIP01-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T15:40:00Z","last_updated_date":"2023-11-09T15:40:00Z","reference_number":"EMA/19115/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-human-recombinant-non-fucosylated-igg1k-monoclonal-antibody-targeting-ox-40-receptoremea-002886_en.pdf"},
    {"id":"60833","name":"P/0057/2023 : EMA decision of 24 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for methylphenidate (hydrochloride) (EMEA-003189-PIP01-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T15:45:00Z","last_updated_date":"2023-11-09T15:45:00Z","reference_number":"EMA/21175/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2023-ema-decision-24-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-methylphenidate-hydrochloride-emea-003189-pip01-22-m01_en.pdf"},
    {"id":"60835","name":"P/0519/2022 : EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obefazimod (EMEA-003196-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-09T17:45:00Z","last_updated_date":"2023-11-09T17:45:00Z","reference_number":"EMA/915818/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0519-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-obefazimod-emea-003196-pip01-22_en.pdf"},
    {"id":"60843","name":"P/0520/2022: EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for stiripentol (EMEA-003200-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T11:15:00Z","last_updated_date":"2023-11-10T11:15:00Z","reference_number":"EMA/915926/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0520-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-granting-deferral-stiripentol-emea-003200-pip01-22_en.pdf"},
    {"id":"60844","name":"P/0479/2022: EMA decision of 2 December 2022 on the granting of a product specific waiver for 2-{4-[4-(4-{5-[(1S)-1-amino-1-(4-fluorophenyl) ethyl]pyrimidin-2-yl}piperazin-1-yl)pyrrolo[2,1-f] [...](EMEA-003269-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T11:38:00Z","last_updated_date":"2023-11-10T11:38:00Z","reference_number":"EMA/899042/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0479-2022-ema-decision-2-december-2022-granting-product-specific-waiver-2-4-4-4-5-1s-1-amino-1-4-fluorophenyl-ethylpyrimidin-2-ylpiperazin-1-ylpyrrolo21-f-emea-003269-pip01-22_en.pdf"},
    {"id":"60858","name":"P/0481/2022 : EMA decision of 2 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for semaglutide (EMEA-001441-PIP07-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T13:05:00Z","last_updated_date":"2023-11-10T13:05:00Z","reference_number":"EMA/899044/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0481-2022-ema-decision-2-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-semaglutide-emea-001441-pip07-21_en.pdf"},
    {"id":"60859","name":"P/0472/2022 : EMA decision of 1 December 2022 on the granting of a product specific waiver for pemigatinib (Pemazyre), (EMEA-002370-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T13:13:00Z","last_updated_date":"2023-11-10T13:13:00Z","reference_number":"EMA/897884/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0472-2022-ema-decision-1-december-2022-granting-product-specific-waiver-pemigatinib-pemazyre-emea-002370-pip03-22_en.pdf"},
    {"id":"60860","name":"P/0509/2022 : EMA decision of 2 December 2022 on the granting of a product specific waiver for nipocalimab (EMEA-002559-PIP06-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T13:20:00Z","last_updated_date":"2023-11-10T13:20:00Z","reference_number":"EMA/898521/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0509-2022-ema-decision-2-december-2022-granting-product-specific-waiver-nipocalimab-emea-002559-pip06-22_en.pdf"},
    {"id":"60861","name":"P/0486/2022 : EMA decision of 2 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ruxolitinib (phosphate) (Jakavi), (EMEA-002618-PIP03-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T13:27:00Z","last_updated_date":"2023-11-10T13:27:00Z","reference_number":"EMA/871497/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0486-2022-ema-decision-2-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ruxolitinib-phosphate-jakavi-emea-002618-pip03-21_en.pdf"},
    {"id":"60862","name":"P/0525/2022 : EMA decision of 30 December 2022 on the granting of a product specific waiver for treprostinil (palmitil) (EMEA-003204-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T13:35:00Z","last_updated_date":"2023-11-10T13:35:00Z","reference_number":"EMA/929791/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0525-2022-ema-decision-30-december-2022-granting-product-specific-waiver-treprostinil-palmitil-emea-003204-pip01-22_en.pdf"},
    {"id":"60863","name":"P/0545/2022 : EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inclacumab (EMEA-003219-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T13:39:00Z","last_updated_date":"2023-11-10T13:39:00Z","reference_number":"EMA/876031/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0545-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-inclacumab-emea-003219-pip01-22_en.pdf"},
    {"id":"60864","name":"P/0502/2022 : EMA decision of 1 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obinutuzumab (Gazyvaro), (EMEA-001207-PIP06-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T13:45:00Z","last_updated_date":"2023-11-10T13:45:00Z","reference_number":"EMA/901090/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0502-2022-ema-decision-1-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-obinutuzumab-gazyvaro-emea-001207-pip06-22_en.pdf"},
    {"id":"60876","name":"P/0467/2022 : EMA decision of 17 November 2022 on the acceptance of a modification of an agreed paediatric investigation plan for glycopyrronium bromide (EMEA-002383-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T09:44:00Z","last_updated_date":"2023-11-13T09:44:00Z","reference_number":"EMA/873549/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0467-2022-ema-decision-17-november-2022-acceptance-modification-agreed-paediatric-investigation-plan-glycopyrronium-bromide-emea-002383-pip01-18-m02_en.pdf"},
    {"id":"60877","name":"P/0470/2022 : EMA decision of of 16 November 2022 on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline (fumarate) (Sirturo), (EMEA-000912-PIP01-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T09:57:00Z","last_updated_date":"2023-11-13T09:57:00Z","reference_number":"EMA/884378/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0470-2022-ema-decision-16-november-2022-acceptance-modification-agreed-paediatric-investigation-plan-bedaquiline-fumarate-sirturo-emea-000912-pip01-10-m06_en.pdf"},
    {"id":"60878","name":"P/0535/2022 : EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for lefamulin (Xenleta) (EMEA-002075-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T10:32:00Z","last_updated_date":"2023-11-13T10:32:00Z","reference_number":"EMA/901112/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0535-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-lefamulin-xenleta-emea-002075-pip01-16-m03_en.pdf"},
    {"id":"60879","name":"P/0518/2022 : EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for entospletinib (EMEA- 002058-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T10:36:00Z","last_updated_date":"2023-11-13T10:36:00Z","reference_number":"EMA/912437/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0518-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-entospletinib-emea-002058-pip01-16-m01_en.pdf"},
    {"id":"60880","name":"P/0515/2022 : EMA decision of 6 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for odevixibat (Bylvay), (EMEA-002054-PIP03-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T10:41:00Z","last_updated_date":"2023-11-13T10:41:00Z","reference_number":"EMA/912385/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0515-2022-ema-decision-6-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-odevixibat-bylvay-emea-002054-pip03-20-m02_en.pdf"},
    {"id":"60881","name":"P/0517/2022 : EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for imetelstat (EMEA- 001910-PIP03-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T10:52:00Z","last_updated_date":"2023-11-13T10:52:00Z","reference_number":"EMA/911953/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0517-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-imetelstat-emea-001910-pip03-20-m01_en.pdf"},
    {"id":"60882","name":"P/0497/2022 : EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for risankizumab (Skyrizi), (EMEA-001776-PIP01-15-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T10:57:00Z","last_updated_date":"2023-11-13T10:57:00Z","reference_number":"EMA/853256/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0497-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-risankizumab-skyrizi-emea-001776-pip01-15-m01_en.pdf"},
    {"id":"60883","name":"P/0496/2022 : EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine / dolutegravir (Juluca), (EMEA-001750-PIP01-15-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T11:07:00Z","last_updated_date":"2023-11-13T11:07:00Z","reference_number":"EMA/852155/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0496-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-dolutegravir-juluca-emea-001750-pip01-15-m06_en.pdf"},
    {"id":"60884","name":"P/0514/2022 : EMA decision of 6 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (ABT- 494) (Rinvoq), (EMEA-001741-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T11:13:00Z","last_updated_date":"2023-11-13T11:13:00Z","reference_number":"EMA/911625/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0514-2022-ema-decision-6-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-abt-494-rinvoq-emea-001741-pip02-16-m02_en.pdf"},
    {"id":"60886","name":"P/0511/2022: EMA decision of 2 December 2023 on the granting of a product specific waiver for tigulixostat (EMEA-003272-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T11:35:00Z","last_updated_date":"2023-11-13T11:35:00Z","reference_number":"EMA/898522/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0511-2022-ema-decision-2-december-2023-granting-product-specific-waiver-tigulixostat-emea-003272-pip01-22_en.pdf"},
    {"id":"60887","name":"P/0471/2022: EMA decision of 1 December 2022 on  the granting of a product specific waiver for namilumab (EMEA-003275-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T11:46:00Z","last_updated_date":"2023-11-13T11:46:00Z","reference_number":"EMA/897866/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0471-2022-ema-decision-1-december-2022-granting-product-specific-waiver-namilumab-emea-003275-pip01-22_en.pdf"},
    {"id":"60888","name":"P/0493/2022: EMA decision of 2 December 2022 on the granting of a product specific waiver for 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1Hpyrazol- 1-yl]-2-azaspiro[3.3] [..] (EMEA-003278-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T11:54:00Z","last_updated_date":"2023-11-13T11:54:00Z","reference_number":"EMA/853387/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0493-2022-ema-decision-2-december-2022-granting-product-specific-waiver-1-6-4m-4-5-chloro-6-methyl-1h-indazol-4-yl-5-methyl-3-1-methyl-1h-indazol-5-yl-1hpyrazol-1-yl-2-azaspiro33-emea-003278-pip01_en.pdf"},
    {"id":"60889","name":"P/0483/2022: EMA decision of 2 December 2022 on the granting of a product specific waiver for lacutamab (EMEA-003281-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T12:04:00Z","last_updated_date":"2023-11-13T12:04:00Z","reference_number":"EMA/871506/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0483-2022-ema-decision-2-december-2022-granting-product-specific-waiver-lacutamab-emea-003281-pip01-22_en.pdf"},
    {"id":"60891","name":"P/0529/2022: EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for linaclotide (Constella), (EMEA-000927-PIP01-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T12:42:00Z","last_updated_date":"2023-11-13T12:42:00Z","reference_number":"EMA/929775/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0529-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-linaclotide-constella-emea-000927-pip01-10-m07_en.pdf"},
    {"id":"60893","name":"P/0523/2022 : EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for HIV-1 maturation inhibitor (GSK3640254) / dolutegravir (EMEA-003152- PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T13:06:00Z","last_updated_date":"2023-11-13T13:06:00Z","reference_number":"EMA/929803/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0523-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-hiv-1-maturation-inhibitor-gsk3640254-dolutegravir-emea-003152-pip01-21_en.pdf"},
    {"id":"60894","name":"P/0544/2022 : EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for enzastaurin (hydrochloride) (EMEA-003096-PIP02-22)","type":"pip-decision","status":"Draft","consultation_date":"","first_published_date":"2023-11-13T13:12:00Z","last_updated_date":"2023-11-13T13:12:00Z","reference_number":"EMA/876030/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0544-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-granting-waiver-enzastaurin-hydrochloride-emea-003096-pip02-22_en.pdf"},
    {"id":"60895","name":"P/0543/2022 : EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for depemokimab (EMEA-003051-PIP04-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T13:17:00Z","last_updated_date":"2023-11-13T13:17:00Z","reference_number":"EMA/876016/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0543-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-depemokimab-emea-003051-pip04-22_en.pdf"},
    {"id":"60896","name":"P/0498/2022 : EMA decision of 2 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for manganese chloride tetrahydrate (EMEA-003035-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T13:22:00Z","last_updated_date":"2023-11-13T13:22:00Z","reference_number":"EMA/853941/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0498-2022-ema-decision-2-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-manganese-chloride-tetrahydrate-emea-003035-pip02-21_en.pdf"},
    {"id":"60897","name":"P/0521/2022 : EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for live, attenuated, dengue virus, serotype 1 (DENV1), live, attenuated, chimeric dengue","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T13:28:00Z","last_updated_date":"2023-11-13T13:28:00Z","reference_number":"EMA/915714/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0521-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-live-attenuated-dengue-virus-serotype-1-denv1-live-attenuated-chimeric-dengue_en.pdf"},
    {"id":"60898","name":"P/0533/2022 : EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan for posoleucel (EMEA-002908-PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T13:35:00Z","last_updated_date":"2023-11-13T13:35:00Z","reference_number":"EMA/930300/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0533-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-posoleucel-emea-002908-pip01-20_en.pdf"},
    {"id":"60899","name":"P/0490/2022: EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for brodalumab (Kyntheum), (EMEA-001089-PIP02-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T13:40:00Z","last_updated_date":"2023-11-13T13:40:00Z","reference_number":"EMA/871488/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0490-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-brodalumab-kyntheum-emea-001089-pip02-13-m03_en.pdf"},
    {"id":"60900","name":"P/0528/2022: EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (Lenvima,  Kisplyx), (EMEA-001119-PIP03-19-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T13:47:00Z","last_updated_date":"2023-11-13T13:47:00Z","reference_number":"EMA/929776/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0528-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-lenvatinib-lenvima-kisplyx-emea-001119-pip03-19-m03_en.pdf"},
    {"id":"60901","name":"P/0489/2022: EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human  A disintegrin and metalloprotease with thrombospondin type-1 Motifs 13 (EMEA-001160-PIP01-11- M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T14:01:00Z","last_updated_date":"2023-11-13T14:01:00Z","reference_number":"EMA/871491/2022 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0489-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-disintegrin-metalloprotease-thrombospondin-type-1-motifs-13-emea-001160-pip01-11_en.pdf"},
    {"id":"60902","name":"P/0540/2022: EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tecovirimat  (monohydrate) (Tecovirimat SIGA), (EMEA-001205-PIP02-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T14:12:00Z","last_updated_date":"2023-11-13T14:12:00Z","reference_number":"EMA/876002/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0540-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-tecovirimat-monohydrate-tecovirimat-siga-emea-001205-pip02-19-m02_en.pdf"},
    {"id":"60903","name":"P/0488/2022: EMA decision of 2 December 2022 on the refusal of a modification of an agreed paediatric investigation plan for binimetinib (Mektovi), (EMEA-001454-PIP03-15-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T14:16:00Z","last_updated_date":"2023-11-13T14:16:00Z","reference_number":"EMA/871493/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0488-2022-ema-decision-2-december-2022-refusal-modification-agreed-paediatric-investigation-plan-binimetinib-mektovi-emea-001454-pip03-15-m02_en.pdf"},
    {"id":"60904","name":"P/0541/2022: EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP04-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T14:21:00Z","last_updated_date":"2023-11-13T14:21:00Z","reference_number":"EMA/876005/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0541-2022-ema-decision-30-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip04-19-m02_en.pdf"},
    {"id":"60905","name":"P/0487/2022: EMA decision of 2 December 2022 on the refusal of a modification of an agreed paediatric investigation plan for encorafenib (Braftovi), (EMEA-001588-PIP01-13-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T14:27:00Z","last_updated_date":"2023-11-13T14:27:00Z","reference_number":"EMA/871494/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0487-2022-ema-decision-2-december-2022-refusal-modification-agreed-paediatric-investigation-plan-encorafenib-braftovi-emea-001588-pip01-13-m02_en.pdf"},
    {"id":"60906","name":"P/0505/2022: EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for doravirine (Pifeltro), (EMEA-001676-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T14:31:00Z","last_updated_date":"2023-11-13T14:31:00Z","reference_number":"EMA/876006/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0505-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-doravirine-pifeltro-emea-001676-pip01-14-m05_en.pdf"},
    {"id":"60907","name":"P/0504/2022: EMA decision of 2 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for doravirine / lamivudine / tenofovir disoproxil (fumarate) (Delstrigo), (EMEA-001695-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T14:37:00Z","last_updated_date":"2023-11-13T14:37:00Z","reference_number":"EMA/876007/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0504-2022-ema-decision-2-december-2022-acceptance-modification-agreed-paediatric-investigation-plan-doravirine-lamivudine-tenofovir-disoproxil-fumarate-delstrigo-emea-001695-pip01-14-m05_en.pdf"},
    {"id":"60909","name":"P/0522/2022: EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for humanized monoclonal IgG1-based antibody (RO7204239) (EMEA-003100- PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T16:36:00Z","last_updated_date":"2023-11-13T16:36:00Z","reference_number":"EMA/929802/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0522-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-humanized-monoclonal-igg1-based-antibody-ro7204239-emea-003100-pip01-21_en.pdf"},
    {"id":"60911","name":"P/0524/2022: EMA decision of 30 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for HIV-1 maturation inhibitor (GSK3640254) (EMEA-003153-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T16:54:00Z","last_updated_date":"2023-11-13T16:54:00Z","reference_number":"EMA/929805/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0524-2022-ema-decision-30-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-hiv-1-maturation-inhibitor-gsk3640254-emea-003153-pip01-21_en.pdf"},
    {"id":"60912","name":"P/0485/2022: EMA decision of 2 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Pneumococcal Polysaccharide Serotype 3...(EMEA-003155-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T17:05:00Z","last_updated_date":"2023-11-13T17:05:00Z","reference_number":"EMA/871501/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0485-2022-ema-decision-2-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pneumococcal-polysaccharide-serotype-3emea-003155-pip01-21_en.pdf"},
    {"id":"60913","name":"P/0484/2022: EMA decision of 2 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for camidanlumab tesirine (EMEA-003160-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T17:12:00Z","last_updated_date":"2023-11-13T17:12:00Z","reference_number":"P/0484/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0484-2022-ema-decision-2-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-camidanlumab-tesirine-emea-003160-pip01-21_en.pdf"},
    {"id":"60914","name":"P/0473/2022: EMA decision of 1 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for batoclimab (EMEA-003162-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T17:22:00Z","last_updated_date":"2023-11-13T17:22:00Z","reference_number":"EMA/897971/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0473-2022-ema-decision-1-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-batoclimab-emea-003162-pip01-21_en.pdf"},
    {"id":"60915","name":"P/0474/2022: EMA decision of 1 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for derivative of 3‐phenyl‐3H,4H,6H,7H‐pyrano[3,4‐d]imidazol‐4‐one (EMEA-003165-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T17:29:00Z","last_updated_date":"2023-11-13T17:29:00Z","reference_number":"EMA/897998/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0474-2022-ema-decision-1-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-derivative-3-phenyl-3h4h6h7h-pyrano34-dimidazol-4-one-emea-003165-pip01-21_en.pdf"},
    {"id":"60916","name":"P/0480/2022: EMA decision of 2 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sirolimus (EMEA-003168-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2023-11-13T17:34:00Z","last_updated_date":"2023-11-13T17:34:00Z","reference_number":"EMA/899045/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0480-2022-ema-decision-2-december-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sirolimus-emea-003168-pip01-21_en.pdf"},
    {"id":"61714","name":"P/0038/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / abacavir / lamivudine (Triumeq), (EMEA-001219-PIP01-11-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T08:46:08Z","last_updated_date":"2024-01-11T08:46:08Z","reference_number":"EMA/950358/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-abacavir-lamivudine-triumeq-emea-001219-pip01-11-m06_en.pdf"},
    {"id":"61715","name":"P/0039/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat (Rezolsta), (EMEA-001280-PIP01-12-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T08:54:51Z","last_updated_date":"2024-01-11T08:54:51Z","reference_number":"EMA/950360/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-rezolsta-emea-001280-pip01-12-m05_en.pdf"},
    {"id":"61716","name":"P/0551/2022 : EMA decision of 4 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ceftazidime / avibactam (Zavicefta), (EMEA-001313-PIP01-12-M13)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T09:05:37Z","last_updated_date":"2024-01-11T09:05:37Z","reference_number":"EMA/950362/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0551-2022-ema-decision-4-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-ceftazidime-avibactam-zavicefta-emea-001313-pip01-12-m13_en.pdf"},
    {"id":"61717","name":"P/0027/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for atazanavir (sulphate) / cobicistat (Evotaz), (EMEA-001465-PIP01-13-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T09:32:41Z","last_updated_date":"2024-01-11T09:32:41Z","reference_number":"EMA/21181/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-atazanavir-sulphate-cobicistat-evotaz-emea-001465-pip01-13-m05_en.pdf"},
    {"id":"61718","name":"P/0029/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat / emtricitabine / tenofovir alafenamide (Symtuza), (EMEA-001825-PIP01-15-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T11:30:41Z","last_updated_date":"2024-01-11T11:30:41Z","reference_number":"EMA/21182/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza-emea-001825-pip01-15-m04_en.pdf"},
    {"id":"61719","name":"P/0030/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for galcanezumab (Emgality), (EMEA-001860-PIP03-16-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T11:40:05Z","last_updated_date":"2024-01-11T11:40:05Z","reference_number":"EMA/21183/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0030-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-galcanezumab-emgality-emea-001860-pip03-16-m08_en.pdf"},
    {"id":"61720","name":"P/0019/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for zuranolone (EMEA- 003119-PIP01-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T11:48:57Z","last_updated_date":"2024-01-11T11:48:57Z","reference_number":"EMA/19428/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0019-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-zuranolone-emea-003119-pip01-21-m01_en.pdf"},
    {"id":"61722","name":"P/0025/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for eftilagimod alpha (EMEA-002698-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T13:45:04Z","last_updated_date":"2024-01-11T13:45:04Z","reference_number":"EMA/18755/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2023-ema-decision-31-january-2023-granting-product-specific-waiver-eftilagimod-alpha-emea-002698-pip02-22_en.pdf"},
    {"id":"61724","name":"P/0026/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for eftilagimod alpha (EMEA-002698-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T13:55:04Z","last_updated_date":"2024-01-11T13:55:04Z","reference_number":"EMA/18865/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0026-2023-ema-decision-31-january-2023-granting-product-specific-waiver-eftilagimod-alpha-emea-002698-pip03-22_en.pdf"},
    {"id":"61726","name":"P/0014/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for retifanlimab (EMEA-002798-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T14:08:58Z","last_updated_date":"2024-01-11T14:08:58Z","reference_number":"EMA/18575/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2023-ema-decision-31-january-2023-granting-product-specific-waiver-retifanlimab-emea-002798-pip03-22_en.pdf"},
    {"id":"61727","name":"P/0195/2023 : EMA decision of 15 May 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-01-11T14:10:04Z","last_updated_date":"2024-01-11T14:10:04Z","reference_number":"EMA/210025/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0195-2023-ema-decision-15-may-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-single-stranded-5-capped-mrna-encoding-respiratory-syncytial-virus-glycoprotein-f-stab_en.pdf"},
    {"id":"61728","name":"P/0011/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for ziltivekimab (EMEA-002840-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T14:16:08Z","last_updated_date":"2024-01-11T14:16:08Z","reference_number":"EMA/29535/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0011-2023-ema-decision-31-january-2023-granting-product-specific-waiver-ziltivekimab-emea-002840-pip02-22_en.pdf"},
    {"id":"61730","name":"P/0101/2023 : EMA decision of 10 March 2023 on the granting of a product specific waiver for finasteride / doxazosin (mesylate) (EMEA-003380-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T14:21:03Z","last_updated_date":"2024-01-11T14:21:03Z","reference_number":"EMA/108879/2023 Corr1","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2023-ema-decision-10-march-2023-granting-product-specific-waiver-finasteride-doxazosin-mesylate-emea-003380-pip01-22_en.pdf"},
    {"id":"61733","name":"P/0044/2023 : EMA decision of 31 January 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for troriluzole (hydrochloride) (EMEA-003084-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T14:41:51Z","last_updated_date":"2024-01-11T14:41:51Z","reference_number":"EMA/34175/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2023-ema-decision-31-january-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-troriluzole-hydrochloride-emea-003084-pip03-22_en.pdf"},
    {"id":"61735","name":"P/0022/2023 ; EMA decision of 31 January 2023 on the granting of a product specific waiver for diclofenac / thiocolchicoside (EMEA-003339-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T14:50:40Z","last_updated_date":"2024-01-11T14:50:40Z","reference_number":"EMA/30270/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2023-ema-decision-31-january-2023-granting-product-specific-waiver-diclofenac-thiocolchicoside-emea-003339-pip01-22_en.pdf"},
    {"id":"61744","name":"P/0015/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for landiolol (hydrochloride) (Rapibloc, Landiobloc, Raploc, Runrapiq), (EMEA-001150-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T17:05:42Z","last_updated_date":"2024-01-11T17:05:42Z","reference_number":"EMA/18675/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2023-ema-decision-31-january-2023-granting-product-specific-waiver-landiolol-hydrochloride-rapibloc-landiobloc-raploc-runrapiq-emea-001150-pip03-22_en.pdf"},
    {"id":"62015","name":"P/0013/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for efgartigimod alfa (Vyvgart), (EMEA-002597-PIP09-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-02-06T15:22:09Z","last_updated_date":"2024-02-06T15:22:09Z","reference_number":"EMA/18446/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2023-ema-decision-31-january-2023-granting-product-specific-waiver-efgartigimod-alfa-vyvgart-emea-002597-pip09-22_en.pdf"},
    {"id":"62016","name":"P/0033/2023 : EMA decision of 31 January 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tirzepatide (Mounjaro) (EMEA-002360-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-02-06T15:28:34Z","last_updated_date":"2024-02-06T15:28:34Z","reference_number":"EMA/PDCO/781854/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2023-ema-decision-31-january-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tirzepatide-mounjaro-emea-002360-pip02-22_en.pdf"},
    {"id":"62089","name":"P/0028/2023 : EMA decision of 31 January 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for satralizumab (Enspryng), (EMEA-001625-PIP04-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-02-13T11:13:13Z","last_updated_date":"2024-02-13T11:13:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0028-2023-ema-decision-31-january-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-satralizumab-enspryng-emea-001625-pip04-22_en.pdf"},
    {"id":"62090","name":"P/0018/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for SARS-CoV-2 virus, beta-propiolactone inactivated adjuvanted with CpG 1018 (VLA2001) (COVID-19 Vaccine (inactivated, adjuvanted","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-13T11:26:34Z","last_updated_date":"2024-02-13T11:26:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-sars-cov-2-virus-beta-propiolactone-inactivated-adjuvanted-cpg-1018-vla2001-covid-19-vaccine_en.pdf"},
    {"id":"62094","name":"P/0552/2022 : EMA decision of 4 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ceftolozane / tazobactam (Zerbaxa), (EMEA-001142-PIP02-16-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-13T11:38:45Z","last_updated_date":"2024-02-13T11:38:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0552-2022-ema-decision-4-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-ceftolozane-tazobactam-zerbaxa-emea-001142-pip02-16-m01_en.pdf"},
    {"id":"62126","name":"P/0023/2023: EMA decision of 31 January 2023 on n the agreement of a paediatric investigation plan for avexitide (acetate) (EMEA-003125-PIP02-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-13T16:28:53Z","last_updated_date":"2024-02-13T16:28:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2023-ema-decision-31-january-2023-n-agreement-paediatric-investigation-plan-avexitide-acetate-emea-003125-pip02-21_en.pdf"},
    {"id":"62127","name":"P/0021/2023: EMA decision of 31 January 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the  granting of a waiver for asundexian (EMEA-003144-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-13T16:59:03Z","last_updated_date":"2024-02-13T16:59:03Z","reference_number":"EMA/20377/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2023-ema-decision-31-january-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-asundexian-emea-003144-pip01-21_en.pdf"},
    {"id":"62133","name":"P/0041/2023: EMA decision of 31 January 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 2'-MOE antisense oligonucleotide targeting apoC-III (ISIS 678354) (EMEA-003177-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-02-14T13:57:45Z","last_updated_date":"2024-02-14T13:57:45Z","reference_number":"EMA/950366/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2023-ema-decision-31-january-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-2-moe-antisense-oligonucleotide-targeting-apoc-iii-isis-678354-emea-003177-pip01-21_en.pdf"},
    {"id":"62134","name":"P/0045/2023: EMA decision of 31 January 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fianlimab (EMEA-003207-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-02-14T14:06:15Z","last_updated_date":"2024-02-14T14:06:15Z","reference_number":"EMA/34193/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2023-ema-decision-31-january-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fianlimab-emea-003207-pip01-22_en.pdf"},
    {"id":"62135","name":"P/0024/2023: EMA decision of 31 January 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous CD4+ and CD8+ T cells transduced [..] (EMEA-003212-PIP-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-02-14T14:17:12Z","last_updated_date":"2024-02-14T14:17:12Z","reference_number":"EMA/20605/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0024-2023-ema-decision-31-january-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-autologous-cd4-cd8-t-cells-transduced-emea-003212-pip-22_en.pdf"},
    {"id":"62136","name":"P/0037/2023: EMA decision of 31 January 2023 on the refusal of a modification of an agreed paediatric investigation plan and on the granting of a  product-specific waiver for lanadelumab (Takhzyro), (EMEA-001864-PIP03-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-02-14T14:30:18Z","last_updated_date":"2024-02-14T14:30:18Z","reference_number":"EMA/21184/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2023-ema-decision-31-january-2023-refusal-modification-agreed-paediatric-investigation-plan-granting-product-specific-waiver-lanadelumab-takhzyro-emea-001864-pip03-19-m01_en.pdf"},
    {"id":"62140","name":"P/0047/2023: EMA decision of 24 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for enmetazobactam (AAI101) / cefepime (EMEA-002240-PIP02-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:14:13Z","last_updated_date":"2024-02-14T16:14:13Z","reference_number":"EMA/35874/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2023-ema-decision-24-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-enmetazobactam-aai101-cefepime-emea-002240-pip02-17-m02_en.pdf"},
    {"id":"62142","name":"P/0553/2022: EMA decision of 4 January 2023 on n the acceptance of a modification of an agreed paediatric investigation plan for avibactam / aztreonam (EMEA-002283-PIP01-17-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:20:02Z","last_updated_date":"2024-02-14T16:20:02Z","reference_number":"EMA/1707/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0553-2022-ema-decision-4-january-2023-n-acceptance-modification-agreed-paediatric-investigation-plan-avibactam-aztreonam-emea-002283-pip01-17-m04_en.pdf"},
    {"id":"62144","name":"P/0031/2023: EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for isoflurane (Sedaconda and associated names), (EMEA-002320-PIP01-17-M03) ","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:23:47Z","last_updated_date":"2024-02-14T16:23:47Z","reference_number":"EMA/21188/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-isoflurane-sedaconda-associated-names-emea-002320-pip01-17-m03_en.pdf"},
    {"id":"62145","name":"P/0056/2023: EMA decision of 30 January 2023  the acceptance of a modification of an agreed paediatric investigation plan for crovalimab (EMEA\u0002002709-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:28:15Z","last_updated_date":"2024-02-14T16:28:15Z","reference_number":"EMA//21389/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2023-ema-decision-30-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-crovalimab-emea%02002709-pip01-19-m01_en.pdf"},
    {"id":"62146","name":"P/0020/2023: EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for mometasone (furoate) / azelastine (hydrochloride) (EMEA-003122-PIP01-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:32:00Z","last_updated_date":"2024-02-14T16:32:00Z","reference_number":"EMA/19486/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-mometasone-furoate-azelastine-hydrochloride-emea-003122-pip01-21-m01_en.pdf"},
    {"id":"62148","name":"P/0010/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for avatrombopag (maleate) (Doptelet), (EMEA-001136-PIP01-11-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:55:51Z","last_updated_date":"2024-02-14T16:55:51Z","reference_number":"EMA/29479/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-avatrombopag-maleate-doptelet-emea-001136-pip01-11-m02_en.pdf"},
    {"id":"62149","name":"P/0009/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for fibrinogen / thrombin / aprotinin / calcium chloride (KolFib; SILKETAL), (EMEA-001079-PIP01-10-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T17:01:18Z","last_updated_date":"2024-02-14T17:01:18Z","reference_number":"EMA/29421/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-fibrinogen-thrombin-aprotinin-calcium-chloride-kolfib-silketal-emea-001079-pip01-10-m06_en.pdf"},
    {"id":"62150","name":"P/0012/2023 : EMA decision of 31 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for macitentan (Opsumit), (EMEA-001032-PIP01-10-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T17:05:12Z","last_updated_date":"2024-02-14T17:05:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2023-ema-decision-31-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-macitentan-opsumit-emea-001032-pip01-10-m05_en.pdf"},
    {"id":"62151","name":"P/0550/2022 : EMA decision of 4 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga), (EMEA-000597-PIP02-10-M09)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T17:12:25Z","last_updated_date":"2024-02-14T17:12:25Z","reference_number":"EMA/678/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0550-2022-ema-decision-4-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip02-10-m09_en.pdf"},
    {"id":"62152","name":"P/0002/2023 : EMA decision of 6 January 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor (Kalydeco), (EMEA-000335-PIP01-08-M15)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T17:15:50Z","last_updated_date":"2024-02-14T17:15:50Z","reference_number":"EMA/1721/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2023-ema-decision-6-january-2023-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-kalydeco-emea-000335-pip01-08-m15_en.pdf"},
    {"id":"62331","name":"P/0040/2023 : EMA decision of 6 February 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for depemokimab (EMEA-003051-PIP05-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T11:46:19Z","last_updated_date":"2024-02-28T11:46:19Z","reference_number":"EMA/950365/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2023-ema-decision-6-february-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-depemokimab-emea-003051-pip05-22_en.pdf"},
    {"id":"62332","name":"P/0059/2023 : EMA decision of 21 February 2023 on the granting of a product specific waiver for candesartan (cilexetil) / amlodipine / hydrochlorothiazide (EMEA-002024-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T11:52:43Z","last_updated_date":"2024-02-28T11:52:43Z","reference_number":"EMA/25295/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2023-ema-decision-21-february-2023-granting-product-specific-waiver-candesartan-cilexetil-amlodipine-hydrochlorothiazide-emea-002024-pip02-22_en.pdf"},
    {"id":"62339","name":"P/0007/2023 : EMA decision of 10 February 2023 on the acceptance of a modification of an agreed paediatric investigation plan for nedosiran (EMEA- 002493-PIP01-18-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T13:24:22Z","last_updated_date":"2024-02-28T13:24:22Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2023-ema-decision-10-february-2023-acceptance-modification-agreed-paediatric-investigation-plan-nedosiran-emea-002493-pip01-18-m05_en.pdf"},
    {"id":"62340","name":"P/0007/2023 : EMA decision of 10 February 2023 on the acceptance of a modification of an agreed paediatric investigation plan for nedosiran (EMEA- 002493-PIP01-18-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T13:28:29Z","last_updated_date":"2024-02-28T13:28:29Z","reference_number":"EMA/640003/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2023-ema-decision-10-february-2023-acceptance-modification-agreed-paediatric-investigation-plan-nedosiran-emea-002493-pip01-18-m05_en.pdf-0"},
    {"id":"62343","name":"P/0061/2023 : EMA decision of 24 February 2023 on the refusal of a modification of an agreed paediatric investigation plan for cariprazine (hydrochloride) (Reagila), (EMEA-001652-PIP01-14-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T14:56:07Z","last_updated_date":"2024-02-28T14:56:07Z","reference_number":"EMA/74599/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2023-ema-decision-24-february-2023-refusal-modification-agreed-paediatric-investigation-plan-cariprazine-hydrochloride-reagila-emea-001652-pip01-14-m04_en.pdf"},
    {"id":"62345","name":"P/0062/2023 : EMA decision of 24 February 2023 on the acceptance of a modification of an agreed paediatric investigation plan for fordadistrogene movaparvovec (EMEA-002741-PIP01-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T15:21:07Z","last_updated_date":"2024-02-28T15:21:07Z","reference_number":"EMA/21390/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2023-ema-decision-24-february-2023-acceptance-modification-agreed-paediatric-investigation-plan-fordadistrogene-movaparvovec-emea-002741-pip01-20-m01_en.pdf"},
    {"id":"62461","name":"P/0083/2023 : EMA decision of 10 March 2023 on the granting of a product specific waiver for upifitamab rilsodotin (EMEA-003340-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T09:30:06Z","last_updated_date":"2024-03-07T09:30:06Z","reference_number":"EMA/37963/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2023-ema-decision-10-march-2023-granting-product-specific-waiver-upifitamab-rilsodotin-emea-003340-pip01-22_en.pdf"},
    {"id":"62463","name":"P/0082/2023 : EMA decision of 10 March 2023 on the granting of a product specific waiver for Rubella virus Wistar RA 27/3 strain (live, attenuated) / Varicella virus OKA strain (live, attenuated), Mumps virus RIT 4385 strain.....(EMEA-003341-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T11:02:52Z","last_updated_date":"2024-03-07T11:02:52Z","reference_number":"EMA/37965/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2023-ema-decision-10-march-2023-granting-product-specific-waiver-rubella-virus-wistar-ra-27-3-strain-live-attenuated-varicella-virus-oka-strain-live-attenuated-mumps-virus-rit-4385-strainemea_en.pdf"},
    {"id":"62464","name":"P/0081/2023 : EMA decision of 10 March 2023 on the granting of a product specific waiver for enpatoran (EMEA-003342-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T11:21:56Z","last_updated_date":"2024-03-07T11:21:56Z","reference_number":"EMA/37968/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2023-ema-decision-10-march-2023-granting-product-specific-waiver-enpatoran-emea-003342-pip01-22_en.pdf"},
    {"id":"62468","name":"P/0087/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for evinacumab (Evkeeza), (EMEA-002298-PIP01-17-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T12:46:50Z","last_updated_date":"2024-03-07T12:46:50Z","reference_number":"EMA/37957/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-evinacumab-evkeeza-emea-002298-pip01-17-m05_en.pdf"},
    {"id":"62469","name":"P/0075/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for eladocagene exuparvovec (Upstaza), (EMEA-002435-PIP01-18-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T13:00:36Z","last_updated_date":"2024-03-07T13:00:36Z","reference_number":"EMA/84338/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-eladocagene-exuparvovec-upstaza-emea-002435-pip01-18-m03_en.pdf"},
    {"id":"62474","name":"P/0098/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for baloxavir marboxil, (Xofluza), (EMEA-002440-PIP01-18-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T15:39:31Z","last_updated_date":"2024-03-07T15:39:31Z","reference_number":"EMA/66787/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-baloxavir-marboxil-xofluza-emea-002440-pip01-18-m04_en.pdf"},
    {"id":"62598","name":"P/0097/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for crinecerfont (EMEA- 002700-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T13:52:40Z","last_updated_date":"2024-03-13T13:52:40Z","reference_number":"EMA/66788/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-crinecerfont-emea-002700-pip01-19-m01_en.pdf"},
    {"id":"62599","name":"P/0095/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for hydroxypropyl-β- cyclodextrin (EMEA-002839-PIP01-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T13:59:12Z","last_updated_date":"2024-03-13T13:59:12Z","reference_number":"EMA/66794/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-hydroxypropyl-b-cyclodextrin-emea-002839-pip01-20-m01_en.pdf"}    {"id":"62604","name":"P/0006/2022: EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for alectinib (Alecensa), (EMEA-002431-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-03-13T16:37:19Z","last_updated_date":"2024-03-13T16:37:19Z","reference_number":"EMA/11685/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-alectinib-alecensa-emea-002431-pip02-21_en.pdf"},
    {"id":"62605","name":"P/0027/2022: EMA of of 31 January 2022 on the granting of a product specific waiver for fostamatinib (Tavlesse), (EMEA-001196-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-03-13T16:53:35Z","last_updated_date":"2024-03-13T16:53:35Z","reference_number":"EMA/12352/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0027-2022-ema-31-january-2022-granting-product-specific-waiver-fostamatinib-tavlesse-emea-001196-pip03-21_en.pdf"},
    {"id":"62606","name":"P/0031/2022: EMA of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for dienogest / ethinylestradiol (EMEA-002229-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-03-13T17:21:10Z","last_updated_date":"2024-03-13T17:21:10Z","reference_number":"EMA/11737/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2022-ema-31-january-2022-agreement-paediatric-investigation-plan-granting-waiver-dienogest-ethinylestradiol-emea-002229-pip02-21_en.pdf"},
    {"id":"62608","name":"P/0029/2022: EMA of 31 January 2022 on the granting of a product specific waiver for acetylsalicylic acid / rosuvastatin calcium (EMEA-002239-PIP02-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T17:26:38Z","last_updated_date":"2024-03-13T17:26:38Z","reference_number":"EMA/12577/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0029-2022-ema-31-january-2022-granting-product-specific-waiver-acetylsalicylic-acid-rosuvastatin-calcium-emea-002239-pip02-21_en.pdf"},
    {"id":"62609","name":"P/0035/2022: of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for benralizumab (Fasenra), (EMEA-001214-PIP04-19)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-03-13T18:06:02Z","last_updated_date":"2024-03-13T18:06:02Z","reference_number":"EMA/8977/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2022-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-benralizumab-fasenra-emea-001214-pip04-19_en.pdf"},
    {"id":"62610","name":"P/0038/2022:  EMA decision of 31 January 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for benralizumab (Fasenra), (EMEA-001214-PIP07-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-03-13T18:45:10Z","last_updated_date":"2024-03-13T18:45:10Z","reference_number":"EMA/12076/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2022-ema-decision-31-january-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-benralizumab-fasenra-emea-001214-pip07-21_en.pdf"},
    {"id":"62836","name":"P/0072/2023 : EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a waiver for humanised IgG2 monoclonal antibody against interleukin-6 (RO7200220) (EMEA-003215-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T11:33:11Z","last_updated_date":"2024-04-05T11:33:11Z","reference_number":"P/0072/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2023-ema-decision-10-march-2023-agreement-paediatric-investigation-plan-granting-waiver-humanised-igg2-monoclonal-antibody-against-interleukin-6-ro7200220-emea-003215-pip01-22_en.pdf"},
    {"id":"62837","name":"P/0064/2023 : EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for insulin lispro (BC222), (EMEA-003166-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T11:39:10Z","last_updated_date":"2024-04-05T11:39:10Z","reference_number":"EMA/77087/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2023-ema-decision-10-march-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-insulin-lispro-bc222-emea-003166-pip01-21_en.pdf"},
    {"id":"62838","name":"P/0094/2023 : EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obecabtagene autoleucel (EMEA-003171-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-04-05T11:57:22Z","last_updated_date":"2024-04-05T11:57:22Z","reference_number":"EMA/66808/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2023-ema-decision-10-march-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-obecabtagene-autoleucel-emea-003171-pip01-21_en.pdf"},
    {"id":"62840","name":"P/0089/2023 : EMA decision of 10 March 2023 on the granting of a product specific waiver for sotorasib (Lumykras), (EMEA-002690-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T14:04:20Z","last_updated_date":"2024-04-05T14:04:20Z","reference_number":"EMA/74651/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2023-ema-decision-10-march-2023-granting-product-specific-waiver-sotorasib-lumykras-emea-002690-pip02-22_en.pdf"},
    {"id":"62841","name":"P/0092/2023 : EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for zilebesiran (sodium) (EMEA-003218-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-04-05T14:17:41Z","last_updated_date":"2024-04-05T14:17:41Z","reference_number":"EMA/74715/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2023-ema-decision-10-march-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-zilebesiran-sodium-emea-003218-pip01-22_en.pdf"},
    {"id":"62842","name":"P/0096/2023 : EMA decision of 10 March 2023 on the granting of a product specific waiver for pembrolizumab (Keytruda), (EMEA-001474-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T14:20:44Z","last_updated_date":"2024-04-05T14:20:44Z","reference_number":"EMA/65237/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2023-ema-decision-10-march-2023-granting-product-specific-waiver-pembrolizumab-keytruda-emea-001474-pip03-22_en.pdf"},
    {"id":"62843","name":"P/0065/2023 : EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cemdisiran (EMEA-003237-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-04-05T14:28:31Z","last_updated_date":"2024-04-05T14:28:31Z","reference_number":"EMA/84291/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2023-ema-decision-10-march-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cemdisiran-emea-003237-pip01-22_en.pdf"},
    {"id":"62844","name":"P/0099/2023 : EMA decision of 10 March 2023 on the granting of a product specific waiver for clazakizumab, (EMEA-001371-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T14:39:03Z","last_updated_date":"2024-04-05T14:39:03Z","reference_number":"EMA/65227/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2023-ema-decision-10-march-2023-granting-product-specific-waiver-clazakizumab-emea-001371-pip03-22_en.pdf"},
    {"id":"62845","name":"P/0071/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for estetrol / drospirenone (Lydisilka, Drovelis and associated names), (EMEA-001332-PIP01-12-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-04-05T14:39:28Z","last_updated_date":"2024-04-05T14:39:28Z","reference_number":"EMA/85010/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-estetrol-drospirenone-lydisilka-drovelis-associated-names-emea-001332-pip01-12-m06_en.pdf"},
    {"id":"62846","name":"P/0079/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for inotuzumab ozogamicin (Besponsa), (EMEA-001429-PIP01-13-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-04-05T15:04:25Z","last_updated_date":"2024-04-05T15:04:25Z","reference_number":"EMA/74598/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-inotuzumab-ozogamicin-besponsa-emea-001429-pip01-13-m07_en.pdf"},
    {"id":"62847","name":"P/0103/2023 : EMA decision of 24 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for defatted powder of peanuts (PALFORZIA), (EMEA-001734-PIP01-14-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-04-05T15:29:48Z","last_updated_date":"2024-04-05T15:29:48Z","reference_number":"EMA/130959/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2023-ema-decision-24-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-defatted-powder-peanuts-palforzia-emea-001734-pip01-14-m06_en.pdf"},
    {"id":"62848","name":"P/0078/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for begelomab (EMEA- 001744-PIP01-14-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-04-05T15:51:10Z","last_updated_date":"2024-04-05T15:51:10Z","reference_number":"EMA/74601/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-begelomab-emea-001744-pip01-14-m02_en.pdf"},
    {"id":"62849","name":"P/0090/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for imipenem (monohydrate) / cilastatin (sodium) / relebactam (MK-7655A) (Recarbrio), (EMEA-001809-PIP01-15- M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-04-05T16:01:06Z","last_updated_date":"2024-04-05T16:01:06Z","reference_number":"EMA/73513/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-imipenem-monohydrate-cilastatin-sodium-relebactam-mk-7655a-recarbrio-emea-001809-pip01-15-m03_en.pdf"},
    {"id":"62851","name":"P/0073/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ibutamoren mesylate (EMEA-003032-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-04-05T16:43:16Z","last_updated_date":"2024-04-05T16:43:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-ibutamoren-mesylate-emea-003032-pip01-21-m01_en.pdf"},
    {"id":"62852","name":"P/0066/2023 : EMA decision of 10 March 2023 on the granting of a product specific waiver for varicella virus OKA strain (live, attenuated) (EMEA-003317-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T16:59:10Z","last_updated_date":"2024-04-05T16:59:10Z","reference_number":"EMA/84288/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2023-ema-decision-10-march-2023-granting-product-specific-waiver-varicella-virus-oka-strain-live-attenuated-emea-003317-pip02-22_en.pdf"},
    {"id":"62853","name":"P/0084/2023 : EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lutetium (177Lu) edotreotide (EMEA-003245-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T17:05:44Z","last_updated_date":"2024-04-05T17:05:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2023-ema-decision-10-march-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lutetium-177lu-edotreotide-emea-003245-pip01-22_en.pdf"},
    {"id":"62854","name":"P/0074/2023 : EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl) nicotinoyl) morpholin-3-yl) methoxy) benzaldehyde","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T17:10:57Z","last_updated_date":"2024-04-05T17:10:57Z","reference_number":"EMA/85287/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2023-ema-decision-10-march-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-s-2-hydroxy-6-4-2-2-hydroxyethyl-nicotinoyl-morpholin-3-yl-methoxy-benzaldehyde_en.pdf"},
    {"id":"62855","name":"P/0077/2023 : EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pozelimab (EMEA-003238-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T17:15:13Z","last_updated_date":"2024-04-05T17:15:13Z","reference_number":"EMA/74611/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2023-ema-decision-10-march-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pozelimab-emea-003238-pip01-22_en.pdf"},
    {"id":"62856","name":"P/0063/2023 : EMA decision of 3 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP01-11-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T17:20:23Z","last_updated_date":"2024-04-05T17:20:23Z","reference_number":"EMA/84139/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2023-ema-decision-3-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip01-11-m07_en.pdf"},
    {"id":"62857","name":"P/0088/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for selexipag (Uptravi), (EMEA-000997-PIP01-10-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T17:26:49Z","last_updated_date":"2024-04-05T17:26:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-selexipag-uptravi-emea-000997-pip01-10-m06_en.pdf"},
    {"id":"62858","name":"P/0102/2023 : EMA decision of 24 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz), (EMEA-000576-PIP01-09-M14)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T17:30:25Z","last_updated_date":"2024-04-05T17:30:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2023-ema-decision-24-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip01-09-m14_en.pdf"},
    {"id":"62859","name":"P/0080/2023 : EMA decision of 13 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for methoxyflurane (Penthrox and associated names) (EMEA-000334-PIP01-08-M11)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T17:34:28Z","last_updated_date":"2024-04-05T17:34:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2023-ema-decision-13-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-methoxyflurane-penthrox-associated-names-emea-000334-pip01-08-m11_en.pdf"},
    {"id":"62860","name":"P/0093/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (Briviact), (EMEA-000332-PIP02-17-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-05T17:54:10Z","last_updated_date":"2024-04-05T17:54:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-emea-000332-pip02-17-m04_en.pdf"},
    {"id":"62861","name":"P/0100/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for glucagon analogue linked to a human immunoglobulin Fc fragment (HM15136) (EMEA-003170-PIP01-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-08T09:34:06Z","last_updated_date":"2024-04-08T09:34:06Z","reference_number":"EMA/108322/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-glucagon-analogue-linked-human-immunoglobulin-fc-fragment-hm15136-emea-003170-pip01-21-m01_en.pdf"},
    {"id":"62862","name":"P/0070/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for lumasiran (Oxlumo), (EMEA-002079-PIP01-16-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-08T09:38:24Z","last_updated_date":"2024-04-08T09:38:24Z","reference_number":"EMA/84334/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-lumasiran-oxlumo-emea-002079-pip01-16-m03_en.pdf"},
    {"id":"62863","name":"P/0086/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for risdiplam (Evrysdi), (EMEA-002070-PIP01-16-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-08T09:51:25Z","last_updated_date":"2024-04-08T09:51:25Z","reference_number":"EMA/37955/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-risdiplam-evrysdi-emea-002070-pip01-16-m07_en.pdf"},
    {"id":"62864","name":"P/0068/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for budesonide / glycopyrronium bromide / formoterol (fumarate), (Trixeo Aerosphere), (EMEA-002063-PIP01-16-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-08T09:55:03Z","last_updated_date":"2024-04-08T09:55:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-budesonide-glycopyrronium-bromide-formoterol-fumarate-trixeo-aerosphere-emea-002063-pip01-16-m02_en.pdf"},
    {"id":"62865","name":"P/0091/2023 : EMA decision of 10 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for quizartinib (EMEA- 001821-PIP01-15-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-08T10:21:47Z","last_updated_date":"2024-04-08T10:21:47Z","reference_number":"EMA/73601/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0091-2023-ema-decision-10-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-quizartinib-emea-001821-pip01-15-m06_en.pdf"},
    {"id":"62923","name":"P/0336/2023 : EMA decision of 7 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (Bosulif), (EMEA-000727-PIP01-09-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T16:20:08Z","last_updated_date":"2024-04-11T16:20:08Z","reference_number":"EMA/351976/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2023-ema-decision-7-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-bosutinib-bosulif-emea-000727-pip01-09-m07_en.pdf"},
    {"id":"63287","name":"P/0001/2024 : EMA decision of 3 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ivosidenib (Tibsovo), (EMEA-002247-PIP03-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-05-21T15:44:00Z","last_updated_date":"2024-05-21T15:44:00Z","reference_number":"EMA/931/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2024-ema-decision-3-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-ivosidenib-tibsovo-emea-002247-pip03-17-m01_en.pdf"},
    {"id":"63289","name":"P/0411/2023 : EMA decision of 25 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deucrictibant (EMEA-003090-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-05-21T16:23:00Z","last_updated_date":"2024-05-21T16:23:00Z","reference_number":"EMA/469125/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0411-2023-ema-decision-25-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-deucrictibant-emea-003090-pip02-22_en.pdf"},
    {"id":"63290","name":"P/0422/2023 : EMA decision of 27 October 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fazirsiran (EMEA-003355-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-05-21T16:38:00Z","last_updated_date":"2024-05-21T16:38:00Z","reference_number":"EMA/429563/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0422-2023-ema-decision-27-october-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fazirsiran-emea-003355-pip01-22_en.pdf"},
    {"id":"63291","name":"P/0480/2023 : EMA decision of 1 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for cobolimab (EMEA-003273-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-05-21T16:48:00Z","last_updated_date":"2024-05-21T16:48:00Z","reference_number":"EMA/498512/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0480-2023-ema-decision-1-december-2023-agreement-paediatric-investigation-plan-granting-deferral-cobolimab-emea-003273-pip02-22_en.pdf"},
    {"id":"63342","name":"P/0179/2023: EMA decision of 17 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for finerenone (Kerendia), (EMEA-001623-PIP01-14-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T14:51:00Z","last_updated_date":"2024-05-28T14:51:00Z","reference_number":"EMA/175863/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2023-ema-decision-17-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-finerenone-kerendia-emea-001623-pip01-14-m06_en.pdf"},
    {"id":"63344","name":"P/0162/2023 : EMA decision of 12 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for cariprazine (hydrochloride), (Reagila), (EMEA-001652-PIP01-14-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T15:12:00Z","last_updated_date":"2024-05-28T15:12:00Z","reference_number":"EMA/170271/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2023-ema-decision-12-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-cariprazine-hydrochloride-reagila-emea-001652-pip01-14-m05_en.pdf"},
    {"id":"63350","name":"P/0193/2023: EMA decision of 12 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for emtricitabine / rilpivirine / tenofovir alafenamide (Odefsey), (EMEA-001679-PIP01-14-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T15:33:00Z","last_updated_date":"2024-05-28T15:33:00Z","reference_number":"EMA/209067/2023 Corri","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2023-ema-decision-12-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-emtricitabine-rilpivirine-tenofovir-alafenamide-odefsey-emea-001679-pip01-14-m03_en.pdf"},
    {"id":"63351","name":"P/0175/2023: EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for lasmiditan (Rayvow), (EMEA-002166-PIP01-17-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T15:47:00Z","last_updated_date":"2024-05-28T15:47:00Z","reference_number":"EMA/177631/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-lasmiditan-rayvow-emea-002166-pip01-17-m07_en.pdf"},
    {"id":"63353","name":"P/0176/2023: EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for dasiglucagon (EMEA- 002233-PIP01-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T15:58:00Z","last_updated_date":"2024-05-28T15:58:00Z","reference_number":"EMA/177613/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-dasiglucagon-emea-002233-pip01-17-m02_en.pdf"},
    {"id":"63354","name":"P/0160/2023: Decision of 12 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine / meloxicam (Zynrelef), (EMEA-002246-PIP01-17-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T16:14:00Z","last_updated_date":"2024-05-28T16:14:00Z","reference_number":"EMA/170272/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2023-decision-12-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-bupivacaine-meloxicam-zynrelef-emea-002246-pip01-17-m03_en.pdf"},
    {"id":"63355","name":"P/0156/2023: EMA decision of 12 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for valoctocogene roxaparvovec (Roctavian), (EMEA-002427-PIP01-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T16:23:00Z","last_updated_date":"2024-05-28T16:23:00Z","reference_number":"EMA/170273/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2023-ema-decision-12-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-valoctocogene-roxaparvovec-roctavian-emea-002427-pip01-18-m02_en.pdf"},
    {"id":"63379","name":"P/0191/2023: EMA decision of 26 May 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ocrelizumab (Ocrevus), (EMEA-000310-PIP05-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T10:43:00Z","last_updated_date":"2024-05-30T10:43:00Z","reference_number":"EMA/184305/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2023-ema-decision-26-may-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ocrelizumab-ocrevus-emea-000310-pip05-22_en.pdf"},
    {"id":"63386","name":"P/0187/2023: EMA decision of 15 May 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for atrasentan (EMEA-001666-PIP02-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T12:47:00Z","last_updated_date":"2024-05-30T12:47:00Z","reference_number":"EMA/184300/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2023-ema-decision-15-may-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-atrasentan-emea-001666-pip02-21_en.pdf"},
    {"id":"63387","name":"P/0163/2023: EMA decision of of 15 May 2023 on the granting of a product specific waiver for nipocalimab (EMEA-002559-PIP07-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T12:57:00Z","last_updated_date":"2024-05-30T12:57:00Z","reference_number":"EMA/160467/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2023-ema-decision-15-may-2023-granting-product-specific-waiver-nipocalimab-emea-002559-pip07-22_en.pdf"},
    {"id":"63388","name":"P/0178/2023 : EMA decision of 15 May 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for itolizumab (EMEA-003208-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T09:00:00Z","last_updated_date":"2024-06-07T09:00:00Z","reference_number":"EMA/171157/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2023-ema-decision-15-may-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-itolizumab-emea-003208-pip02-22_en.pdf"},
    {"id":"63389","name":"P/0184/2023 : EMA decision of 19 May 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for aticaprant (EMEA-003251-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T09:00:00Z","last_updated_date":"2024-06-07T09:00:00Z","reference_number":"EMA/171173/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2023-ema-decision-19-may-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-aticaprant-emea-003251-pip01-22_en.pdf"},
    {"id":"63391","name":"P/0182/2023 : EMA decision of 15 May 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 2’-O-(2-methoxyethyl) modified... (EMEA-003024-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T13:20:00Z","last_updated_date":"2024-05-30T13:20:00Z","reference_number":"EMA/176376/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2023-ema-decision-15-may-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-2-o-2-methoxyethyl-modified-emea-003024-pip01-21_en.pdf"},
    {"id":"63392","name":"P/0174/2023 : EMA decision of 15 May 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vibostolimab/pembrolizumab, (EMEA-003063-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T13:32:00Z","last_updated_date":"2024-05-30T13:32:00Z","reference_number":"EMA/177600/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2023-ema-decision-15-may-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vibostolimab-pembrolizumab-emea-003063-pip02-22_en.pdf"},
    {"id":"63393","name":"P/0168/2023 : EMA decision of 15 May 2023 on the agreement of a paediatric investigation plan and on the granting of a waiver for albaconazole (EMEA-003279-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T13:32:00Z","last_updated_date":"2024-06-07T13:32:00Z","reference_number":"EMA/160497/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2023-ema-decision-15-may-2023-agreement-paediatric-investigation-plan-granting-waiver-albaconazole-emea-003279-pip01-22_en.pdf"},
    {"id":"63394","name":"P/0153/2023 : EMA decision of 12 May 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for favezelimab/pembrolizumab (EMEA-003104-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T13:37:00Z","last_updated_date":"2024-05-30T13:37:00Z","reference_number":"EMA/170247/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2023-ema-decision-12-may-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-favezelimab-pembrolizumab-emea-003104-pip02-22_en.pdf"},
    {"id":"63395","name":"P/0198/2023 : EMA decision of 22 May 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for humanised VHH-type bispecific antibody against complement.....(EMEA-003302-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T09:00:00Z","last_updated_date":"2024-06-07T09:00:00Z","reference_number":"EMA/220354/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2023-ema-decision-22-may-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-humanised-vhh-type-bispecific-antibody-against-complementemea-003302-pip01-22_en.pdf"},
    {"id":"63407","name":"P/0161/2023 : EMA decision of 12 May 2023 on the granting of a product specific waiver for diclofenac / thiocolchicoside (EMEA-003339-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T09:00:00Z","last_updated_date":"2024-06-07T09:00:00Z","reference_number":"EMA/170255/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2023-ema-decision-12-may-2023-granting-product-specific-waiver-diclofenac-thiocolchicoside-emea-003339-pip02-23_en.pdf"},
    {"id":"63409","name":"P/0181/2023 : EMA decision of 15 May 2023 on the granting of a product specific waiver for 1-((S)-4-((R)-7-(6-amino-4-methyl-3- (trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl).....(EMEA-003364-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T09:00:00Z","last_updated_date":"2024-06-07T09:00:00Z","reference_number":"EMA/176269/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2023-ema-decision-15-may-2023-granting-product-specific-waiver-1-s-4-r-7-6-amino-4-methyl-3-trifluoromethylpyridin-2-yl-6-chloro-8-fluoro-2-s-1-methylpyrrolidin-2-ylemea-003364-pip02-22_en.pdf"},
    {"id":"63414","name":"P/0169/2023 : EMA decision of 15 May 2023 on the granting of a product specific waiver for palmitoyl-KSS-MHGDTPTLHEYMLDLQPETT (HPV-16 E7 1-20) / Palmitoyl-KSS-YMLDLQPETT (HPV-16 E7 11-20) / Palmitoyl-KSS-GQAEPDRAHYNIVTF.....(EMEA-003370-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T09:00:00Z","last_updated_date":"2024-06-07T09:00:00Z","reference_number":"EMA/160482/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2023-ema-decision-15-may-2023-granting-product-specific-waiver-palmitoyl-kss-mhgdtptlheymldlqpett-hpv-16-e7-1-20-palmitoyl-kss-ymldlqpett-hpv-16-e7-11-20-palmitoyl-kss-gqaepdrahynivtfemea_en.pdf"},
    {"id":"63458","name":"P/0123/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Prolia, Xgeva), (EMEA-000145-PIP02-12-M05) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-03T14:47:33Z","last_updated_date":"2024-06-03T14:47:33Z","reference_number":"EMA/134107/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-denosumab-prolia-xgeva-emea-000145-pip02-12-m05_en.pdf"},
    {"id":"63467","name":"P/0154/2023 : EMA decision of 12 May 2023 on the granting of a product specific waiver for N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2- yl)oxy)phenyl)...(EMEA-003371-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-06-03T15:26:00Z","last_updated_date":"2024-06-03T15:26:00Z","reference_number":"EMA/170256/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2023-ema-decision-12-may-2023-granting-product-specific-waiver-n-4-4-amino-5-3-fluoro-4-4-methylpyrimidin-2-yloxyphenylemea-003371-pip01-22_en.pdf"},
    {"id":"63468","name":"P/0124/2023 : EMA decision of 14 April 2023 on the refusal of a modification of an agreed paediatric investigation plan for eculizumab (Soliris), (EMEA-000876-PIP03-14-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-03T15:34:27Z","last_updated_date":"2024-06-03T15:34:27Z","reference_number":"EMA/134196/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2023-ema-decision-14-april-2023-refusal-modification-agreed-paediatric-investigation-plan-eculizumab-soliris-emea-000876-pip03-14-m06_en.pdf"},
    {"id":"63469","name":"P/0135/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for osilodrostat (Isturisa), (EMEA-000315-PIP02-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-03T15:48:20Z","last_updated_date":"2024-06-03T15:48:20Z","reference_number":"EMA/134574/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-osilodrostat-isturisa-emea-000315-pip02-15-m03_en.pdf"},
    {"id":"63470","name":"P/0104/2023 : EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for oritavancin (diphosphate) (Tenkasi), (EMEA-001270-PIP01-12-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-03T16:00:36Z","last_updated_date":"2024-06-03T16:00:36Z","reference_number":"P/0104/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2023-ema-decision-13-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-oritavancin-diphosphate-tenkasi-emea-001270-pip01-12-m06_en.pdf"},
    {"id":"63471","name":"P/0105/2023 : EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for obeticholic acid (Ocaliva), (EMEA-001304-PIP02-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-03T19:26:21Z","last_updated_date":"2024-06-03T19:26:21Z","reference_number":"EMA/103714/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2023-ema-decision-13-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-obeticholic-acid-ocaliva-emea-001304-pip02-13-m06_en.pdf"},
    {"id":"63515","name":"P/0196/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ataluren (Translarna), (EMEA-000115-PIP01-07-M13)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-06T15:13:00Z","last_updated_date":"2024-06-06T15:13:00Z","reference_number":"EMA/PDCO/210857/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-ataluren-translarna-emea-000115-pip01-07-m13_en.pdf"},
    {"id":"63516","name":"P/0183/2023 : EMA decision of 19 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for maribavir (Livtencity), (EMEA-000353-PIP02-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-06T15:18:00Z","last_updated_date":"2024-06-06T15:18:00Z","reference_number":"EMA/170667/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2023-ema-decision-19-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-maribavir-livtencity-emea-000353-pip02-16-m03_en.pdf"},
    {"id":"63517","name":"P/0170/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for elosulfase alfa (Vimizim), (EMEA-000973-PIP01-10-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-06T15:29:00Z","last_updated_date":"2024-06-06T15:29:00Z","reference_number":"EMA/170999/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-elosulfase-alfa-vimizim-emea-000973-pip01-10-m04_en.pdf"},
    {"id":"63519","name":"P/0171/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for romosozumab (Evenity), (EMEA-001075-PIP04-15-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-06T15:44:00Z","last_updated_date":"2024-06-06T15:44:00Z","reference_number":"EMA/171049/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-romosozumab-evenity-emea-001075-pip04-15-m06_en.pdf"},
    {"id":"63520","name":"P/0172/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for migalastat (hydrochloride) (Galafold), (EMEA-001194-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-06T15:49:00Z","last_updated_date":"2024-06-06T15:49:00Z","reference_number":"EMA/171090/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-migalastat-hydrochloride-galafold-emea-001194-pip01-11-m06_en.pdf"},
    {"id":"63522","name":"P/0173/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP09-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-06T15:54:00Z","last_updated_date":"2024-06-06T15:54:00Z","reference_number":"EMA/171103/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-benralizumab-fasenra-emea-001214-pip09-21-m01_en.pdf"},
    {"id":"63532","name":"P/0177/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tolvaptan (Samsca and associated names), (EMEA-001231-PIP02-13-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T11:10:00Z","last_updated_date":"2024-06-07T11:10:00Z","reference_number":"EMA/171114/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-tolvaptan-samsca-associated-names-emea-001231-pip02-13-m10_en.pdf"},
    {"id":"63533","name":"P/0192/2023 : EMA decision of 26 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for vatiquinone (EMEA-001238-PIP03-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T11:14:00Z","last_updated_date":"2024-06-07T11:14:00Z","reference_number":"EMA/186780/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2023-ema-decision-26-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-vatiquinone-emea-001238-pip03-21-m01_en.pdf"},
    {"id":"63534","name":"P/0189/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for cholera vaccine, live attenuated, oral (strain CVD 103-HgR) (Vaxchora), (EMEA-001490-PIP01-13-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T11:21:00Z","last_updated_date":"2024-06-07T11:21:00Z","reference_number":"EMA/201813/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-cholera-vaccine-live-attenuated-oral-strain-cvd-103-hgr-vaxchora-emea-001490-pip01-13-m04_en.pdf"},
    {"id":"63535","name":"P/0190/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab (Tremfya), (EMEA-001523-PIP04-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T11:25:00Z","last_updated_date":"2024-06-07T11:25:00Z","reference_number":"EMA/201814/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-guselkumab-tremfya-emea-001523-pip04-19-m02_en.pdf"},
    {"id":"63537","name":"P/0116/2023 : EMA decision of 13 April 2023 on the granting of a product specific waiver for meningococcal group A oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenA-CRM) (EMEA-000032-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T14:54:32Z","last_updated_date":"2024-06-07T14:54:32Z","reference_number":"EMA/103738/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2023-ema-decision-13-april-2023-granting-product-specific-waiver-meningococcal-group-oligosaccharide-conjugated-corynebacterium-diphteriae-crm197-protein-mena-crm-emea-000032-pip02-22_en.pdf"},
    {"id":"63538","name":"P/0151/2023 : EMA decision of 24 April 2023 on the agreement of a paediatric investigation plan and on the granting of a waiver for 2-amino-5- (carbamylamino)pentanoic acid (L-citrulline), (EMEA-002612-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T15:33:00Z","last_updated_date":"2024-06-07T15:33:00Z","reference_number":"EMA/177599/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2023-ema-decision-24-april-2023-agreement-paediatric-investigation-plan-granting-waiver-2-amino-5-carbamylaminopentanoic-acid-l-citrulline-emea-002612-pip02-22_en.pdf"},
    {"id":"63540","name":"P/0119/2023 : EMA decision of 13 April 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for tixagevimab / cilgavimab (Evusheld), (EMEA-003079-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T16:21:09Z","last_updated_date":"2025-10-14T12:22:02Z","reference_number":"EMA/103747/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2023-ema-decision-13-april-2023-agreement-paediatric-investigation-plan-granting-deferral-tixagevimab-cilgavimab-evusheld-emea-003079-pip01-22_en.pdf"},
    {"id":"63541","name":"P/0118/2023 : EMA decision of 13 April 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for vilobelimab (EMEA-003080-PIP03-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T16:49:00Z","last_updated_date":"2024-06-07T16:49:00Z","reference_number":"EMA/103746/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2023-ema-decision-13-april-2023-agreement-paediatric-investigation-plan-granting-deferral-vilobelimab-emea-003080-pip03-22_en.pdf"},
    {"id":"63542","name":"P/0117/2023 : EMA decision of 14 April 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for pudexacianinium chloride (EMEA-003099-PIP01-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T17:15:00Z","last_updated_date":"2024-06-07T17:15:00Z","reference_number":"EMA/144653/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2023-ema-decision-14-april-2023-agreement-paediatric-investigation-plan-granting-deferral-pudexacianinium-chloride-emea-003099-pip01-21_en.pdf"},
    {"id":"63543","name":"P/0139/2023 : EMA decision of 14 April 2023 on on the agreement of a paediatric investigation plan and on the granting of a deferral for AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2), (EMEA-003184-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-06-07T17:31:00Z","last_updated_date":"2024-06-07T17:31:00Z","reference_number":"EMA/108918/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2023-ema-decision-14-april-2023-agreement-paediatric-investigation-plan-granting-deferral-av2-cvlp-rbd-sars-cov-2-abncov2-emea-003184-pip01-22_en.pdf"},
    {"id":"63668","name":"P/0157/2023: EMA decision of 12 May 2023 on the granting of a product-specific waiver for ramipril / indapamide (EMEA-003372-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T14:13:36Z","last_updated_date":"2024-06-18T14:13:36Z","reference_number":"EMA/170257/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2023-ema-decision-12-may-2023-granting-product-specific-waiver-ramipril-indapamide-emea-003372-pip01-22_en.pdf"},
    {"id":"63671","name":"P/0158/2023 : EMA decision of 12 May 2023 on the granting of a product specific waiver for atorvastatin / ezetimibe (EMEA-003373-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T14:36:10Z","last_updated_date":"2024-06-18T14:36:10Z","reference_number":"EMA/170258/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2023-ema-decision-12-may-2023-granting-product-specific-waiver-atorvastatin-ezetimibe-emea-003373-pip01-22_en.pdf"},
    {"id":"63672","name":"P/0188/2023 : EMA decision of 15 May 2023 on the granting of a product specific waiver for adeno-associated viral vector serotype 9 expressing codon-optimized human GRN gene (LY3884963) (EMEA-003374-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T14:52:12Z","last_updated_date":"2024-06-18T14:52:12Z","reference_number":"EMA/198966/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0188-2023-ema-decision-15-may-2023-granting-product-specific-waiver-adeno-associated-viral-vector-serotype-9-expressing-codon-optimized-human-grn-gene-ly3884963-emea-003374-pip01-22_en.pdf"},
    {"id":"63674","name":"P/0180/2023 : EMA decision of 15 May 2023 on the granting of a product specific waiver for recombinant humanized monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1κ) ... (EMEA-003376-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T16:21:32Z","last_updated_date":"2024-06-18T16:21:32Z","reference_number":"EMA/176012/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2023-ema-decision-15-may-2023-granting-product-specific-waiver-recombinant-humanized-monoclonal-antibody-immunoglobulin-gamma-1-kappa-light-chains-igg1k-emea-003376-pip01-22_en.pdf"},
    {"id":"63675","name":"P/0185/2023 : EMA decision of 15 May 2023 on the granting of a product specific waiver for pitavastatin / ezetimibe (EMEA-003390-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T16:29:49Z","last_updated_date":"2024-06-18T16:29:49Z","reference_number":"EMA/176289/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2023-ema-decision-15-may-2023-granting-product-specific-waiver-pitavastatin-ezetimibe-emea-003390-pip01-23_en.pdf"},
    {"id":"63875","name":"P/0159/2023 : EMA decision of 12 May 2023 on on the acceptance of a modification of an agreed paediatric investigation plan for efgartigimod alfa (Vyvgart), (EMEA-002597-PIP05-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-04T14:36:00Z","last_updated_date":"2024-07-04T14:36:00Z","reference_number":"EMA/170275/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2023-ema-decision-12-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-efgartigimod-alfa-vyvgart-emea-002597-pip05-21-m01_en.pdf"},
    {"id":"63876","name":"P/0164/2023 : EMA decision of 15 May 2023 on  the acceptance of a modification of an agreed paediatric investigation plan for iptacopan (EMEA- 002705-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-04T14:42:00Z","last_updated_date":"2024-07-04T14:42:00Z","reference_number":"EMA/160444/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-iptacopan-emea-002705-pip01-19-m01_en.pdf"},
    {"id":"63877","name":"P/0155/2023 : EMA decision of 12 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for gepotidacin (EMEA- 002443-PIP01-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-04T14:47:00Z","last_updated_date":"2024-07-04T14:47:00Z","reference_number":"EMA/170274/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2023-ema-decision-12-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-gepotidacin-emea-002443-pip01-18-m02_en.pdf"},
    {"id":"63878","name":"P/0165/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for idrevloride (EMEA- 002935-PIP01-20-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-04T14:51:00Z","last_updated_date":"2024-07-04T14:51:00Z","reference_number":"EMA/160446/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-idrevloride-emea-002935-pip01-20-m03_en.pdf"},
    {"id":"63879","name":"P/0166/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain (EMEA-002942-PIP02-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-04T14:56:00Z","last_updated_date":"2024-07-04T14:56:00Z","reference_number":"EMA/160447/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-peptide-derivative-glucagon-peptide-1-glucagon-fatty-acid-side-chain-emea-002942-pip02-20-m01_en.pdf"},
    {"id":"63880","name":"P/0167/2023 : EMA decision of 15 May 2023 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified ... (EMEA-003001-PIP01-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-04T15:00:00Z","last_updated_date":"2024-07-04T15:00:00Z","reference_number":"EMA/160450/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2023-ema-decision-15-may-2023-acceptance-modification-agreed-paediatric-investigation-plan-autologous-cd34-hematopoietic-stem-progenitor-cells-hspcs-genetically-modified-emea-003001-pip01-21_en.pdf"},
    {"id":"63881","name":"P/0005/2024 : EMA decision of 10 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for odronextamab (EMEA-003149-PIP01-21-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-19T15:03:00Z","last_updated_date":"2025-03-19T15:03:00Z","reference_number":"EMA/7743/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0005-2024-ema-decision-10-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-odronextamab-emea-003149-pip01-21-m02_en.pdf"},
    {"id":"63887","name":"P/0206/2023 : EMA decision of 14 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for treprostinil (Remodulin) (EMEA-000207-PIP01-08-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T11:28:07Z","last_updated_date":"2024-07-05T11:28:07Z","reference_number":"EMA/236607/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2023-ema-decision-14-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-treprostinil-remodulin-emea-000207-pip01-08-m08_en.pdf"},
    {"id":"63888","name":"P/0209/2023: EMA decision of 14 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten and associated names), (EMEA-000347-PIP02-16-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T11:31:12Z","last_updated_date":"2024-07-05T11:31:12Z","reference_number":"EMA/236606/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2023-ema-decision-14-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-bilastine-bilaxten-associated-names-emea-000347-pip02-16-m05_en.pdf"},
    {"id":"63889","name":"P/0200/2023 : EMA decision of 5 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for posaconazole (Noxafil), (EMEA-000468-PIP02-12-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T11:33:03Z","last_updated_date":"2024-07-05T11:33:03Z","reference_number":"EMA/242867/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2023-ema-decision-5-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-posaconazole-noxafil-emea-000468-pip02-12-m08_en.pdf"},
    {"id":"63890","name":"P/0055/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for givinostat (EMEA- 000551-PIP04-21-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-02T11:34:59Z","last_updated_date":"2025-04-02T11:34:59Z","reference_number":"EMA/62604/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0055-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-givinostat-emea-000551-pip04-21-m03_en.pdf"},
    {"id":"63891","name":"P/0234/2023 : EMA decision of 14 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ponesimod (Ponvory), (EMEA-000798-PIP01-09-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T11:36:02Z","last_updated_date":"2024-07-05T11:36:02Z","reference_number":"EMA/235934/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2023-ema-decision-14-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-ponesimod-ponvory-emea-000798-pip01-09-m04_en.pdf"},
    {"id":"63892","name":"P/0211/2023 : EMA decision of 14 June 2023 on the acceptance of a modification of an agreed PIP for adsorbed modified allergen extract of a mixture of 50% dermatophagoides pteronyssinus and 50% dermatophagoides farinae (EMEA-000902-PIP01-10-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T11:36:58Z","last_updated_date":"2024-07-05T11:36:58Z","reference_number":"EMA/236232/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2023-ema-decision-14-june-2023-acceptance-modification-agreed-pip-adsorbed-modified-allergen-extract-mixture-50-dermatophagoides-pteronyssinus-50-dermatophagoides-farinae-emea-000902-pip01-10_en.pdf"},
    {"id":"63893","name":"P/0212/2023 : EMA decision of 14 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for brodalumab (Kyntheum), (EMEA-001089-PIP02-13-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T11:38:39Z","last_updated_date":"2024-07-05T11:38:39Z","reference_number":"EMA/236234/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2023-ema-decision-14-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-brodalumab-kyntheum-emea-001089-pip02-13-m04_en.pdf"}    {"id":"63915","name":"P/0221/2023 : EMA decision of 14 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for landiolol (hydrochloride) (Rapibloc, Landiobloc, Raploc, Runrapiq), (EMEA-001150-PIP02-13-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:35:34Z","last_updated_date":"2024-07-05T14:35:34Z","reference_number":"EMA/236236/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2023-ema-decision-14-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-landiolol-hydrochloride-rapibloc-landiobloc-raploc-runrapiq-emea-001150-pip02-13-m05_en.pdf"},
    {"id":"63916","name":"P/0202/2023 : EMA decision of 13 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP01-11-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:37:32Z","last_updated_date":"2024-07-05T14:37:32Z","reference_number":"EMA/241941/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0202-2023-ema-decision-13-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip01-11-m08_en.pdf"},
    {"id":"63919","name":"P/0243/2023 : EMA decision of 16 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for birch bark extract (Filsuvez), (EMEA-001299-PIP03-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:44:35Z","last_updated_date":"2024-07-05T14:44:35Z","reference_number":"EMA/273941/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2023-ema-decision-16-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-birch-bark-extract-filsuvez-emea-001299-pip03-17-m02_en.pdf"},
    {"id":"63920","name":"P/0203/2023 : EMA decision of 13 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for efinaconazole (EMEA- 001627-PIP01-14-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:46:51Z","last_updated_date":"2024-07-05T14:46:51Z","reference_number":"EMA/241957/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2023-ema-decision-13-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-efinaconazole-emea-001627-pip01-14-m03_en.pdf"},
    {"id":"63921","name":"P/0010/2024 : EMA decision of 31 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP01-14-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-07-05T14:48:56Z","last_updated_date":"2024-07-05T14:48:56Z","reference_number":"EMA/11085/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0010-2024-ema-decision-31-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip01-14-m07_en.pdf"},
    {"id":"63922","name":"P/0242/2023 : EMA decision of 14 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy), (EMEA-001766-PIP01-15-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:49:59Z","last_updated_date":"2024-07-05T14:49:59Z","reference_number":"EMA/250921/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2023-ema-decision-14-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy-emea-001766-pip01-15-m05_en.pdf"},
    {"id":"63924","name":"P/0012/2024 : EMA decision of 31 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (Adtralza), (EMEA-001900-PIP02-17-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T10:44:57Z","last_updated_date":"2025-03-14T10:44:57Z","reference_number":"EMA/15339/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0012-2024-ema-decision-31-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-adtralza-emea-001900-pip02-17-m08_en.pdf"},
    {"id":"63925","name":"P/0217/2023 : EMA decision of 14 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for dienogest / ethinylestradiol (EMEA-002229-PIP02-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T15:24:09Z","last_updated_date":"2024-07-05T15:24:09Z","reference_number":"EMA/238158/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2023-ema-decision-14-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-dienogest-ethinylestradiol-emea-002229-pip02-21-m01_en.pdf"},
    {"id":"63926","name":"P/0214/2023: EMA decision of 14 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for cenobamate (Ontozry), (EMEA-002563-PIP02-19-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T15:27:38Z","last_updated_date":"2024-07-05T15:27:38Z","reference_number":"EMA/256562/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2023-ema-decision-14-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-cenobamate-ontozry-emea-002563-pip02-19-m02_en.pdf"},
    {"id":"63927","name":"P/0210/2023 : EMA decision of 14 June 2023 on the acceptance of a modification of an agreed PIP for deferoxamine / histidine / tryptophan / aspartic acid / n-acetyl-histidine / glycine / alphaketoglutaric acid / ... (EMEA- 002735-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T15:28:36Z","last_updated_date":"2024-07-05T15:28:36Z","reference_number":"EMA/236601/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2023-ema-decision-14-june-2023-acceptance-modification-agreed-pip-deferoxamine-histidine-tryptophan-aspartic-acid-n-acetyl-histidine-glycine-alphaketoglutaric-acid-emea-002735-pip01-19-m01_en.pdf"},
    {"id":"63929","name":"P/0213/2023 : EMA decision of 14 June 2023 on the acceptance of a modification of an agreed PIP for deferoxamine (mesylate) / histidine / tryptophan / aspartic acid / n-acetyl-histidine ... (EMEA- 002735-PIP03-20-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T15:33:22Z","last_updated_date":"2024-07-05T15:33:22Z","reference_number":"EMA/236603/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2023-ema-decision-14-june-2023-acceptance-modification-agreed-pip-deferoxamine-mesylate-histidine-tryptophan-aspartic-acid-n-acetyl-histidine-emea-002735-pip03-20-m02_en.pdf"},
    {"id":"63930","name":"P/0215/2023 : EMA decision of 14 June 2023 on the acceptance of a modification of an agreed paediatric investigation plan for denecimig (EMEA- 002762-PIP02-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T15:35:28Z","last_updated_date":"2024-07-05T15:35:28Z","reference_number":"EMA/236605/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2023-ema-decision-14-june-2023-acceptance-modification-agreed-paediatric-investigation-plan-denecimig-emea-002762-pip02-20-m01_en.pdf"},
    {"id":"63931","name":"P/0334/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for sotrovimab (Xevudy), (EMEA-002899-PIP01-20-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-10-20T11:30:00Z","last_updated_date":"2025-10-20T11:30:00Z","reference_number":"EMA/414031/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-sotrovimab-xevudy-emea-002899-pip01-20-m03_en.pdf"},
    {"id":"63932","name":"P/0238/2023 : EMA decision of 14 June 2023on the acceptance of a modification of an agreed paediatric investigation plan for regdanvimab (Regkirona), (EMEA-002961-PIP01-21-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T15:37:44Z","last_updated_date":"2024-07-05T15:37:44Z","reference_number":"EMA/236249/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2023-ema-decision-14-june-2023on-acceptance-modification-agreed-paediatric-investigation-plan-regdanvimab-regkirona-emea-002961-pip01-21-m02_en.pdf"},
    {"id":"63938","name":"P/0201/2023 : EMA decision of 13 June 2023 on the granting of a product specific waiver for secukinumab (Cosentyx), (EMEA-000380-PIP10-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T16:27:04Z","last_updated_date":"2024-07-05T16:27:04Z","reference_number":"EMA/241874/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2023-ema-decision-13-june-2023-granting-product-specific-waiver-secukinumab-cosentyx-emea-000380-pip10-23_en.pdf"},
    {"id":"63939","name":"P/0194/2023 : EMA decision of 6 June 2023 on the granting of a product specific waiver for chlorhexidine (digluconate) / isopropyl alcohol (EMEA-001338-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T16:37:58Z","last_updated_date":"2024-07-05T16:37:58Z","reference_number":"EMA/254485/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2023-ema-decision-6-june-2023-granting-product-specific-waiver-chlorhexidine-digluconate-isopropyl-alcohol-emea-001338-pip02-23_en.pdf"},
    {"id":"63940","name":"P/0205/2023 : EMA decision of 14 June 2023 on the granting of a product specific waiver for deutetrabenazine (EMEA-002052-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T16:45:21Z","last_updated_date":"2024-07-05T16:45:21Z","reference_number":"EMA/253093/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2023-ema-decision-14-june-2023-granting-product-specific-waiver-deutetrabenazine-emea-002052-pip02-23_en.pdf"},
    {"id":"63946","name":"P/0208/2023 : EMA decision of 14 June 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efgartigimod alfa (EMEA-002597-PIP08-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T16:08:28Z","last_updated_date":"2024-07-10T16:08:28Z","reference_number":"EMA/253550/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2023-ema-decision-14-june-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-efgartigimod-alfa-emea-002597-pip08-22_en.pdf"},
    {"id":"63975","name":"P/0239/2023 : EMA decision of 14 June 2023 on the granting of a product specific waiver for belzutifan, (EMEA-002619-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T09:44:08Z","last_updated_date":"2024-07-10T09:44:08Z","reference_number":"EMA/238267/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2023-ema-decision-14-june-2023-granting-product-specific-waiver-belzutifan-emea-002619-pip02-23_en.pdf"},
    {"id":"63976","name":"P/0219/2023 : EMA decision of 14 June 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for asunercept (EMEA-003201-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T09:49:28Z","last_updated_date":"2024-07-10T09:49:28Z","reference_number":"EMA/235062/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2023-ema-decision-14-june-2023-agreement-paediatric-investigation-plan-granting-deferral-asunercept-emea-003201-pip01-22_en.pdf"},
    {"id":"63977","name":"P/0216/2023 : EMA decision of 14 June 2023 on the granting of a product specific waiver for (S)-lactic acid (EMEA-003247-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T09:57:28Z","last_updated_date":"2024-07-10T09:57:28Z","reference_number":"EMA/234839/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2023-ema-decision-14-june-2023-granting-product-specific-waiver-s-lactic-acid-emea-003247-pip02-23_en.pdf"},
    {"id":"63978","name":"P/0236/2023 : EMA decision of 14 June 2023 on the granting of a product specific waiver for Derivative of (3S,3'S,3a'S,10a'S)-3'- phenyl-3',3a',10',10a'-tetrahydro-1'H-spiro[indoline-3,2'-pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazol]-2- one, (EMEA-003260-PIP02","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T16:51:40Z","last_updated_date":"2024-07-10T16:51:40Z","reference_number":"EMA/238278/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2023-ema-decision-14-june-2023-granting-product-specific-waiver-derivative-3s3s3as10as-3-phenyl-33a1010a-tetrahydro-1h-spiroindoline-32-pyrrolo2345pyrrolo12-bindazol-2-one-emea-003260-pip02_en.pdf"},
    {"id":"63979","name":"P/0225/2023 : EMA decision of 14 June 2023 on agreement of PIP and on granting of deferral and waiver for adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express achimeric antigen ...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T10:48:46Z","last_updated_date":"2024-07-10T10:48:46Z","reference_number":"EMA/235584/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2023-ema-decision-14-june-2023-agreement-pip-granting-deferral-waiver-adult-differentiated-autologous-t-cells-peripheral-blood-expanded-transduced-lentivirus-express-achimeric-antigen_en.pdf"},
    {"id":"63980","name":"P/0228/2023 : EMA decision of 14 June 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for fosmanogepix, (EMEA-003280-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T10:56:16Z","last_updated_date":"2024-07-10T10:56:16Z","reference_number":"EMA/239204/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2023-ema-decision-14-june-2023-agreement-paediatric-investigation-plan-granting-deferral-fosmanogepix-emea-003280-pip01-22_en.pdf"},
    {"id":"63981","name":"P/0222/2023 : EMA decision of 14 June 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for crofelemer (EMEA-003296-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T12:14:21Z","last_updated_date":"2024-07-10T12:14:21Z","reference_number":"EMA/236242/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2023-ema-decision-14-june-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-crofelemer-emea-003296-pip01-22_en.pdf"},
    {"id":"63985","name":"P/0226/2023 : EMA decision of 14 June 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for obeldesivir (EMEA-003306-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T12:17:14Z","last_updated_date":"2024-07-10T12:17:14Z","reference_number":"EMA/236621/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2023-ema-decision-14-june-2023-agreement-paediatric-investigation-plan-granting-deferral-obeldesivir-emea-003306-pip01-22_en.pdf"},
    {"id":"63986","name":"P/0204/2023 : EMA decision of 5 June 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for zapomeran (EMEA-003349-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T13:30:33Z","last_updated_date":"2024-07-10T13:30:33Z","reference_number":"EMA/245863/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2023-ema-decision-5-june-2023-agreement-paediatric-investigation-plan-granting-deferral-zapomeran-emea-003349-pip01-22_en.pdf"},
    {"id":"63987","name":"P/0218/2023 : EMA decision of 14 June 2023 on the granting of a product specific waiver for inhibitor of receptor-interacting serine/threonineprotein kinase 1 (SAR443820) (EMEA-003383-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T13:33:35Z","last_updated_date":"2024-07-10T13:33:35Z","reference_number":"EMA/236613/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2023-ema-decision-14-june-2023-granting-product-specific-waiver-inhibitor-receptor-interacting-serine-threonineprotein-kinase-1-sar443820-emea-003383-pip02-23_en.pdf"},
    {"id":"63988","name":"P/0220/2023 : EMA decision of 14 June 2023 on the granting of a product specific waiver for levodopa / carbidopa monohydrate (EMEA-003384- PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T13:34:37Z","last_updated_date":"2024-07-10T13:34:37Z","reference_number":"EMA/236617/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2023-ema-decision-14-june-2023-granting-product-specific-waiver-levodopa-carbidopa-monohydrate-emea-003384-pip02-23_en.pdf"},
    {"id":"63989","name":"P/0207/2023 : EMA decision of 14 June 2023 on the refusal of a paediatric investigation plan and on the granting of a waiver for xylometazoline hydrochloride / sodium hyaluronate (EMEA-003387-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T13:41:00Z","last_updated_date":"2024-07-10T13:41:00Z","reference_number":"EMA/253298/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2023-ema-decision-14-june-2023-refusal-paediatric-investigation-plan-granting-waiver-xylometazoline-hydrochloride-sodium-hyaluronate-emea-003387-pip01-22_en.pdf"},
    {"id":"63990","name":"P/0199/2023 : EMA decision of 13 June 2023 on the granting of a product specific waiver for amphotericin B (EMEA-003391-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T13:57:15Z","last_updated_date":"2024-07-10T13:57:15Z","reference_number":"EMA/241151/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2023-ema-decision-13-june-2023-granting-product-specific-waiver-amphotericin-b-emea-003391-pip01-23_en.pdf"},
    {"id":"63991","name":"P/0223/2023 : EMA decision of 26 June 2023 on the refusal of a paediatric investigation plan and on the granting of a waiver for salbutamol (sulfate) (EMEA-003398-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T14:00:52Z","last_updated_date":"2024-07-10T14:00:52Z","reference_number":"EMA/234995/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2023-ema-decision-26-june-2023-refusal-paediatric-investigation-plan-granting-waiver-salbutamol-sulfate-emea-003398-pip01-23_en.pdf"},
    {"id":"63992","name":"P/0224/2023 : EMA decision of 14 June 2023 on the granting of a product specific waiver for candesartan (cilexetil) / indapamide (EMEA-003401-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T14:05:01Z","last_updated_date":"2024-07-10T14:05:01Z","reference_number":"EMA/236264/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2023-ema-decision-14-june-2023-granting-product-specific-waiver-candesartan-cilexetil-indapamide-emea-003401-pip01-23_en.pdf"},
    {"id":"63993","name":"P/0227/2023 : EMA decision of 14 June 2023 on the granting of a product specific waiver for gallium (68Ga) boclatixafortide (EMEA-003408-PIP01- 23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T14:08:32Z","last_updated_date":"2024-07-10T14:08:32Z","reference_number":"EMA/234911/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2023-ema-decision-14-june-2023-granting-product-specific-waiver-gallium-68ga-boclatixafortide-emea-003408-pip01-23_en.pdf"},
    {"id":"63994","name":"P/0241/2023 : EMA decision of 14 June 2023 on the granting of a product specific waiver for irinotecan (Onivyde), (EMEA-003416-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T14:13:10Z","last_updated_date":"2024-07-10T14:13:10Z","reference_number":"EMA/241942/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2023-ema-decision-14-june-2023-granting-product-specific-waiver-irinotecan-onivyde-emea-003416-pip01-23_en.pdf"},
    {"id":"64086","name":"P/0258/2023 : EMA decision of 13 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for sarilumab (Kevzara), (EMEA-001045-PIP01-10-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T14:27:32Z","last_updated_date":"2024-07-12T14:27:32Z","reference_number":"EMA/307256/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2023-ema-decision-13-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-sarilumab-kevzara-emea-001045-pip01-10-m03_en.pdf"},
    {"id":"64087","name":"P/0049/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz), (EMEA-001050-PIP02-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T14:28:40Z","last_updated_date":"2024-07-12T14:28:40Z","reference_number":"EMA/287810/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-ixekizumab-taltz-emea-001050-pip02-18-m02_en.pdf"},
    {"id":"64089","name":"P/0284/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for modified vaccinia Ankara - Bavarian Nordic virus (smallpox) (Imvanex), (EMEA-001161-PIP02-11-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T14:33:44Z","last_updated_date":"2024-07-12T14:33:44Z","reference_number":"EMA/288064/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-modified-vaccinia-ankara-bavarian-nordic-virus-smallpox-imvanex-emea-001161-pip02-11-m03_en.pdf"},
    {"id":"64090","name":"P/0275/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for talimogene laherparepvec (Imlygic), (EMEA-001251-PIP01-11-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T14:35:59Z","last_updated_date":"2024-07-12T14:35:59Z","reference_number":"EMA/282173/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-talimogene-laherparepvec-imlygic-emea-001251-pip01-11-m06_en.pdf"},
    {"id":"64091","name":"P/0257/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat (Rezolsta), (EMEA-001280-PIP01-12-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T14:36:57Z","last_updated_date":"2024-07-12T14:36:57Z","reference_number":"EMA/306614/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-rezolsta-emea-001280-pip01-12-m06_en.pdf"},
    {"id":"64095","name":"P/0276/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant parathyroid hormone (Natpar), (EMEA-001526-PIP01-13-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T14:57:16Z","last_updated_date":"2024-07-12T14:57:16Z","reference_number":"EMA/282640/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-parathyroid-hormone-natpar-emea-001526-pip01-13-m06_en.pdf"},
    {"id":"64096","name":"P/0277/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for nemolizumab (EMEA- 001624-PIP01-14-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:00:17Z","last_updated_date":"2024-07-12T15:00:17Z","reference_number":"EMA/282809/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-nemolizumab-emea-001624-pip01-14-m06_en.pdf"},
    {"id":"64097","name":"P/0259/2023 : EMA decision of 13 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for quizartinib (EMEA- 001821-PIP01-15-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:07:57Z","last_updated_date":"2024-07-12T15:07:57Z","reference_number":"EMA/308500/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2023-ema-decision-13-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-quizartinib-emea-001821-pip01-15-m07_en.pdf"},
    {"id":"64099","name":"P/0267/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for gilteritinib (as fumarate), (Xospata), (EMEA-002064-PIP01-16-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:11:00Z","last_updated_date":"2024-07-12T15:11:00Z","reference_number":"EMA/250923/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-gilteritinib-fumarate-xospata-emea-002064-pip01-16-m05_en.pdf"},
    {"id":"64103","name":"P/0278/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for mavacamten (EMEA- 002231-PIP01-17-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:19:31Z","last_updated_date":"2024-07-12T15:19:31Z","reference_number":"EMA/283075/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-mavacamten-emea-002231-pip01-17-m01_en.pdf"},
    {"id":"64104","name":"P/0246/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) (Apexxnar), (EMEA-002330-PIP01-18-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:22:18Z","last_updated_date":"2024-07-12T15:22:18Z","reference_number":"EMA/287622/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-pneumococcal-polysaccharide-conjugate-vaccine-20-valent-adsorbed-apexxnar-emea-002330-pip01-18-m03_en.pdf"},
    {"id":"64105","name":"P/0281/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for avapritinib (Ayvakyt), (EMEA-002358-PIP02-18-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:32:12Z","last_updated_date":"2024-07-12T15:32:12Z","reference_number":"EMA/315615/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-avapritinib-ayvakyt-emea-002358-pip02-18-m03_en.pdf"},
    {"id":"64106","name":"P/0285/2023 : EMA decision of 24 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (Mounjaro), (EMEA-002360-PIP02-22-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:36:17Z","last_updated_date":"2024-07-12T15:36:17Z","reference_number":"EMA/333490/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2023-ema-decision-24-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-tirzepatide-mounjaro-emea-002360-pip02-22-m01_en.pdf"},
    {"id":"64107","name":"P/0249/2023 : EMA decision of 5 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for beremagene geperpavec (EMEA-002472-PIP03-22-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:38:47Z","last_updated_date":"2024-07-12T15:38:47Z","reference_number":"EMA/289384/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2023-ema-decision-5-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-beremagene-geperpavec-emea-002472-pip03-22-m01_en.pdf"},
    {"id":"64109","name":"P/0251/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for soticlestat (EMEA-002572-PIP02-19-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:42:47Z","last_updated_date":"2024-07-12T15:42:47Z","reference_number":"EMA/302913/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-soticlestat-emea-002572-pip02-19-m03_en.pdf"},
    {"id":"64112","name":"P/0252/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for efgartigimod alfa (Vyvgart), (EMEA-002597-PIP04-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:46:46Z","last_updated_date":"2024-07-12T15:46:46Z","reference_number":"EMA/303410/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-efgartigimod-alfa-vyvgart-emea-002597-pip04-21-m01_en.pdf"},
    {"id":"64114","name":"P/0253/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed PIP for (4S,7aR,9aR,10S,11E,14S,15R)-6'-chloro-10-methoxy-14,15-dimethyl-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,7H-spiro[1,19-ethenocyclobuta[i][1,4]...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:50:28Z","last_updated_date":"2024-07-12T15:50:28Z","reference_number":"EMA/303523/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2023-ema-decision-14-july-2023-acceptance-modification-agreed-pip-4s7ar9ar10s11e14s15r-6-chloro-10-methoxy-1415-dimethyl-347a899a10131415-decahydro-2h7h-spiro119-ethenocyclobutai14_en.pdf"},
    {"id":"64115","name":"P/0263/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for magrolimab (EMEA- 002819-PIP01-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:55:30Z","last_updated_date":"2024-07-12T15:55:30Z","reference_number":"EMA/285601/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0263-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-magrolimab-emea-002819-pip01-20-m01_en.pdf"},
    {"id":"64116","name":"P/0264/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for rocatinlimab (EMEA- 002886-PIP01-20-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:57:54Z","last_updated_date":"2024-07-12T15:57:54Z","reference_number":"EMA/285643/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0264-2023-ema-decision-14-july-2023-acceptance-modification-agreed-paediatric-investigation-plan-rocatinlimab-emea-002886-pip01-20-m03_en.pdf"},
    {"id":"64122","name":"P/0282/2023 : EMA decision of 14 July 2023 on the granting of a product specific waiver for secukinumab (Cosentyx),(EMEA-000380-PIP11-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T16:46:22Z","last_updated_date":"2024-07-12T16:46:22Z","reference_number":"EMA/287965/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2023-ema-decision-14-july-2023-granting-product-specific-waiver-secukinumab-cosentyxemea-000380-pip11-23_en.pdf"},
    {"id":"64123","name":"P/0250/2023 : EMA decision of 14 July 2023 on the granting of a product specific waiver for deucravacitinib (Sotyktu), (EMEA-002350-PIP05-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T17:21:35Z","last_updated_date":"2024-07-12T17:21:35Z","reference_number":"EMA/302856/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2023-ema-decision-14-july-2023-granting-product-specific-waiver-deucravacitinib-sotyktu-emea-002350-pip05-23_en.pdf"},
    {"id":"64124","name":"P/0247/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for spesolimab (Spevigo), (EMEA-002475-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T17:28:24Z","last_updated_date":"2024-07-15T17:28:24Z","reference_number":"EMA/287380/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-granting-deferral-spesolimab-spevigo-emea-002475-pip03-22_en.pdf"},
    {"id":"64125","name":"P/0272/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nipocalimab, (EMEA-002559-PIP08-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T17:33:16Z","last_updated_date":"2024-07-15T17:33:16Z","reference_number":"EMA/251129/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-nipocalimab-emea-002559-pip08-23_en.pdf"},
    {"id":"64126","name":"P/0279/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan for posoleucel (EMEA-002908-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T17:39:05Z","last_updated_date":"2024-07-15T17:39:05Z","reference_number":"EMA/283175/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-posoleucel-emea-002908-pip02-22_en.pdf"},
    {"id":"64127","name":"P/0254/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan for sodium 2,2-dimethylbutyrate (HST5040) (EMEA-003019-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T17:45:43Z","last_updated_date":"2024-07-15T17:45:43Z","reference_number":"EMA/303990/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-sodium-22-dimethylbutyrate-hst5040-emea-003019-pip01-21_en.pdf"},
    {"id":"64128","name":"P/0286/2023 : EMA decision of 25 July 2023 on the granting of a product specific waiver for tazemetostat (EMEA-003055-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:31:33Z","last_updated_date":"2024-07-16T13:31:33Z","reference_number":"EMA/33781/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2023-ema-decision-25-july-2023-granting-product-specific-waiver-tazemetostat-emea-003055-pip02-23_en.pdf"},
    {"id":"64129","name":"P/0269/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a waiver for clindamycin phosphate / benzoyl peroxide (hydrous) / adapalene (micronized) (EMEA-003263-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:36:28Z","last_updated_date":"2024-07-16T13:36:28Z","reference_number":"EMA/285269/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-granting-waiver-clindamycin-phosphate-benzoyl-peroxide-hydrous-adapalene-micronized-emea-003263-pip01-22_en.pdf"},
    {"id":"64130","name":"P/0245/2023 : EMA decision of 14 July 2023 on refusal of PIP and on granting of waiver for influenza virus Type A H3N2, whole virion, inactivated / influenza virus Type B, whole virion, inactivated / influenza virus Type A H1N1, whole virion, inactivated","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:40:51Z","last_updated_date":"2024-07-16T13:40:51Z","reference_number":"EMA/300235/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2023-ema-decision-14-july-2023-refusal-pip-granting-waiver-influenza-virus-type-h3n2-whole-virion-inactivated-influenza-virus-type-b-whole-virion-inactivated-influenza-virus-type-h1n1-whole_en.pdf"},
    {"id":"64131","name":"P/0270/2023 : EMA decision of 14 July 2023 on agreement of PIP and on granting of a deferral and a waiver for 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3- fluorophenyl)ethan-1-one (BBP-671), (EMEA-003268-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T17:53:41Z","last_updated_date":"2024-07-15T17:53:41Z","reference_number":"EMA/251126/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2023-ema-decision-14-july-2023-agreement-pip-granting-deferral-waiver-1-4-6-chloropyridazin-3-ylpiperazin-1-yl-2-4-cyclopropyl-3-fluorophenylethan-1-one-bbp-671-emea-003268-pip01-22_en.pdf"},
    {"id":"64132","name":"P/0248/2023 : EMA decision of 14 July 2023 on agreement of a PIP and on granting of a deferral and a waiver for immunoglobulin G4 [224-proline], anti-(Betula alleghaniensis allergen Bet v 1) (human monoclonal REGN5713 γ4-chain), disulphide with human...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T17:50:28Z","last_updated_date":"2024-07-15T17:50:28Z","reference_number":"EMA/286493/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2023-ema-decision-14-july-2023-agreement-pip-granting-deferral-waiver-immunoglobulin-g4-224-proline-anti-betula-alleghaniensis-allergen-bet-v-1-human-monoclonal-regn5713-g4-chain-disulphide_en.pdf"},
    {"id":"64133","name":"P/0280/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ±3,4-methylenedioxymethamphetamine hydrochloride (MDMA) (EMEA- 003276-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:44:46Z","last_updated_date":"2024-07-16T13:44:46Z","reference_number":"EMA/283234/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-34-methylenedioxymethamphetamine-hydrochloride-mdma-emea-003276-pip01-22_en.pdf"},
    {"id":"64134","name":"P/0283/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for influenza recombinant H7 haemagglutinin (EMEA-003314-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:48:22Z","last_updated_date":"2024-07-16T13:48:22Z","reference_number":"EMA/317156/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-granting-deferral-influenza-recombinant-h7-haemagglutinin-emea-003314-pip01-22_en.pdf"},
    {"id":"64135","name":"P/0255/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for modRNA encoding 4 influenza HA antigens (2 for influenza A and 2 for influenza B strains) ","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:57:33Z","last_updated_date":"2024-07-16T13:57:33Z","reference_number":"EMA/304055/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-modrna-encoding-4-influenza-ha-antigens-2-influenza-2-influenza-b-strains_en.pdf"},
    {"id":"64136","name":"P/0265/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bictegravir / lenacapavir (EMEA-003324-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T14:12:20Z","last_updated_date":"2024-07-16T14:12:20Z","reference_number":"EMA/284569/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0265-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bictegravir-lenacapavir-emea-003324-pip01-22_en.pdf"},
    {"id":"64137","name":"P/0268/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for izokibep (EMEA-003325-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T14:03:46Z","last_updated_date":"2024-07-16T14:03:46Z","reference_number":"EMA/285108/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-izokibep-emea-003325-pip01-22_en.pdf"},
    {"id":"64139","name":"P/0256/2023 : EMA decision of 14 July 2023 on the granting of a product specific waiver for therapeutic DNA plasmid vaccine targeting HPV16 E6 and E7 proteins (VB10.16) (EMEA-003403-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T14:18:08Z","last_updated_date":"2024-07-16T14:18:08Z","reference_number":"EMA/304362/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2023-ema-decision-14-july-2023-granting-product-specific-waiver-therapeutic-dna-plasmid-vaccine-targeting-hpv16-e6-e7-proteins-vb1016-emea-003403-pip01-23_en.pdf"},
    {"id":"64140","name":"P/0260/2023 : EMA decision of 14 July 2023 on the granting of a product specific waiver for opicapone (Ongentys, Ontilyv), (EMEA-003406-PIP01- 23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T14:20:37Z","last_updated_date":"2024-07-16T14:20:37Z","reference_number":"EMA/284059/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2023-ema-decision-14-july-2023-granting-product-specific-waiver-opicapone-ongentys-ontilyv-emea-003406-pip01-23_en.pdf"},
    {"id":"64141","name":"P/0261/2023 : EMA decision of 14 July 2023 on the granting of a product specific waiver for benzo[b]thiophene-3-carbonitrile, 2-amino-4-[(4aS)-8- chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1- d][1,5]...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T14:08:29Z","last_updated_date":"2024-07-16T14:08:29Z","reference_number":"EMA/250883/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0261-2023-ema-decision-14-july-2023-granting-product-specific-waiver-benzobthiophene-3-carbonitrile-2-amino-4-4as-8-chloro-10-fluoro-2344a56-hexahydro-12-oxo-3-1-oxo-2-propen-1-yl-1h12h-pyrazino21_en.pdf"},
    {"id":"64142","name":"P/0266/2023 : EMA decision of 14 July 2023 on the granting of a product specific waiver for acetylsalicylic acid / rosuvastatin (calcium), (EMEA- 003410-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T14:24:27Z","last_updated_date":"2024-07-16T14:24:27Z","reference_number":"EMA/250887/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2023-ema-decision-14-july-2023-granting-product-specific-waiver-acetylsalicylic-acid-rosuvastatin-calcium-emea-003410-pip01-23_en.pdf"},
    {"id":"64143","name":"P/0244/2023 : EMA decision of 14 July 2023 on the granting of a product specific waiver for amlodipine (besilate) / rivaroxaban (EMEA-003412- PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T14:28:46Z","last_updated_date":"2024-07-16T14:28:46Z","reference_number":"EMA/300031/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2023-ema-decision-14-july-2023-granting-product-specific-waiver-amlodipine-besilate-rivaroxaban-emea-003412-pip01-23_en.pdf"},
    {"id":"64144","name":"P/0273/2023 : EMA decision of 14 July 2023 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for povidone-iodine, (EMEA-003413-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T14:31:05Z","last_updated_date":"2024-07-16T14:31:05Z","reference_number":"EMA/251132/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2023-ema-decision-14-july-2023-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-povidone-iodine-emea-003413-pip01-23_en.pdf"},
    {"id":"64145","name":"P/0262/2023 : EMA decision of 14 July 2023 on the granting of a product specific waiver for fuzuloparib (EMEA-003422-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T14:00:41Z","last_updated_date":"2024-07-16T14:00:41Z","reference_number":"EMA/284110/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0262-2023-ema-decision-14-july-2023-granting-product-specific-waiver-fuzuloparib-emea-003422-pip01-23_en.pdf"},
    {"id":"64206","name":"P/0106/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for patiromer calcium (Veltassa), (EMEA-001720-PIP01-14-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-18T16:38:01Z","last_updated_date":"2024-07-18T16:38:01Z","reference_number":"EMA/143484/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-patiromer-calcium-veltassa-emea-001720-pip01-14-m03_en.pdf"},
    {"id":"64207","name":"P/0111/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for acalabrutinib (Calquence), (EMEA-001796-PIP03-16-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-18T16:54:13Z","last_updated_date":"2024-07-18T16:54:13Z","reference_number":"EMA/143821/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-acalabrutinib-calquence-emea-001796-pip03-16-m03_en.pdf"},
    {"id":"64213","name":"P/0107/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for carfilzomib (Kyprolis), (EMEA-001806-PIP04-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T12:12:57Z","last_updated_date":"2024-07-19T12:12:57Z","reference_number":"EMA/143552/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-carfilzomib-kyprolis-emea-001806-pip04-19-m01_en.pdf"},
    {"id":"64214","name":"P/0109/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for fitusiran (EMEA-001855-PIP01-15-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T12:14:47Z","last_updated_date":"2024-07-19T12:14:47Z","reference_number":"EMA/143628/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-fitusiran-emea-001855-pip01-15-m04_en.pdf"},
    {"id":"64215","name":"P/0110/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for remimazolam (besylate) (Byfavo), (EMEA-001880-PIP02-19-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T12:15:51Z","last_updated_date":"2024-07-19T12:15:51Z","reference_number":"EMA/143773/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-remimazolam-besylate-byfavo-emea-001880-pip02-19-m04_en.pdf"},
    {"id":"64216","name":"P/0121/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / lamivudine (Dovato), (EMEA-001940-PIP01-16-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T12:16:52Z","last_updated_date":"2024-07-19T12:16:52Z","reference_number":"EMA/108913/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-lamivudine-dovato-emea-001940-pip01-16-m05_en.pdf"},
    {"id":"64217","name":"P/0128/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris), (EMEA-001943-PIP02-20-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T12:17:54Z","last_updated_date":"2024-07-19T12:17:54Z","reference_number":"EMA/108914/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-001943-pip02-20-m02_en.pdf"},
    {"id":"64218","name":"P/0013/2024 : EMA decision of 31 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for gadopiclenol (EMEA- 001949-PIP01-16-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T10:57:00Z","last_updated_date":"2025-03-14T10:57:00Z","reference_number":"EMA/12591/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0013-2024-ema-decision-31-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-gadopiclenol-emea-001949-pip01-16-m06_en.pdf"},
    {"id":"64219","name":"P/0018/2024 : EMA decision of 31 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for gadopiclenol (EMEA- 001949-PIP02-18-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T12:20:02Z","last_updated_date":"2025-03-14T12:20:02Z","reference_number":"EMA/12676/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0018-2024-ema-decision-31-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-gadopiclenol-emea-001949-pip02-18-m04_en.pdf"},
    {"id":"64220","name":"P/0145/2023 : EMA decision of 21 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for sparsentan, (EMEA- 001984-PIP02-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T12:21:06Z","last_updated_date":"2024-07-19T12:21:06Z","reference_number":"EMA/173847/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2023-ema-decision-21-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-sparsentan-emea-001984-pip02-20-m01_en.pdf"},
    {"id":"64234","name":"P/0144/2023 : EMA decision of 21 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for isatuximab (Sarclisa), (EMEA-002205-PIP01-17-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T15:26:17Z","last_updated_date":"2024-07-19T15:26:17Z","reference_number":"EMA/163887/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2023-ema-decision-21-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-isatuximab-sarclisa-emea-002205-pip01-17-m04_en.pdf"},
    {"id":"64235","name":"P/0136/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for delgocitinib (EMEA-002329-PIP02-20-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T15:28:10Z","last_updated_date":"2024-07-19T15:28:10Z","reference_number":"EMA/108916/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-delgocitinib-emea-002329-pip02-20-m02_en.pdf"},
    {"id":"64236","name":"P/0134/2023 EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for lebrikizumab (EMEA- 002536-PIP01-18-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T15:29:30Z","last_updated_date":"2024-07-19T15:29:30Z","reference_number":"P/0134/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2023-ema-decision-13-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-lebrikizumab-emea-002536-pip01-18-m03_en.pdf"},
    {"id":"64237","name":"P/0133/2023 : EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for selpercatinib (Retsevmo), (EMEA-002544-PIP01-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T15:39:41Z","last_updated_date":"2024-07-19T15:39:41Z","reference_number":"EMA/146941/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2023-ema-decision-13-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-selpercatinib-retsevmo-emea-002544-pip01-18-m02_en.pdf"},
    {"id":"64238","name":"P/0132/2023 : EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for remibrutinib (EMEA- 002582-PIP01-19-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T15:40:38Z","last_updated_date":"2024-07-19T15:40:38Z","reference_number":"EMA/146966/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2023-ema-decision-13-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-remibrutinib-emea-002582-pip01-19-m02_en.pdf"},
    {"id":"64239","name":"P/0131/2023 : EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for temozolomide (EMEA-002634-PIP01-19-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T15:42:09Z","last_updated_date":"2024-07-19T15:42:09Z","reference_number":"EMA/147170/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2023-ema-decision-13-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-temozolomide-emea-002634-pip01-19-m02_en.pdf"},
    {"id":"64240","name":"P/0150/2023 : EMA decision of 26 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for repotrectinib (EMEA- 002635-PIP02-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T15:43:18Z","last_updated_date":"2024-07-19T15:43:18Z","reference_number":"EMA/160443/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2023-ema-decision-26-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-repotrectinib-emea-002635-pip02-21-m01_en.pdf"},
    {"id":"64243","name":"P/0141/2023 : EMA decision of 14 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for zilucoplan (EMEA-002747-PIP01-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T16:10:21Z","last_updated_date":"2024-07-19T16:10:21Z","reference_number":"EMA/127821/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2023-ema-decision-14-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-zilucoplan-emea-002747-pip01-20-m01_en.pdf"},
    {"id":"64245","name":"P/0146/2023 : EMA decision of 21 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for acetyl-L-leucine ((s)- (acetylamino)-4-methylpentanoic acid) (IB001), (EMEA-002796-PIP01-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T16:11:44Z","last_updated_date":"2024-07-19T16:11:44Z","reference_number":"EMA/173849/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2023-ema-decision-21-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-acetyl-l-leucine-s-acetylamino-4-methylpentanoic-acid-ib001-emea-002796-pip01-20-m01_en.pdf"},
    {"id":"64246","name":"P/0320/2024 : EMA decision of 13 September 2025 on the acceptance of a modification of an agreed paediatric investigation plan for rimegepant (Vydura), (EMEA-002812-PIP02-20-M03) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-20T11:10:00Z","last_updated_date":"2025-10-20T11:10:00Z","reference_number":"EMA/410679/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2024-ema-decision-13-september-2025-acceptance-modification-agreed-paediatric-investigation-plan-rimegepant-vydura-emea-002812-pip02-20-m03_en.pdf"},
    {"id":"64247","name":"P/0115/2023 : EMA decision of 13 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for botaretigene sparoparvovec (EMEA-002827-PIP01-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T16:14:20Z","last_updated_date":"2024-07-19T16:14:20Z","reference_number":"EMA/103736/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2023-ema-decision-13-march-2023-acceptance-modification-agreed-paediatric-investigation-plan-botaretigene-sparoparvovec-emea-002827-pip01-20-m01_en.pdf"},
    {"id":"64248","name":"P/0152/2023 : EMA decision of 24 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for elasomeran (Spikevax), elasomeran/imelsomeram and elasomeran/davesomeran, (EMEA-002893-PIP01-20-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T16:15:28Z","last_updated_date":"2024-07-19T16:15:28Z","reference_number":"EMA/177614/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2023-ema-decision-24-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-elasomeran-spikevax-elasomeran-imelsomeram-elasomeran-davesomeran-emea-002893-pip01-20-m03_en.pdf"},
    {"id":"64250","name":"P/0125/2023 : EMA decision of 18 April 2023 on the agreement of a paediatric investigation plan for recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1 (INZ-701) (EMEA-003232-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T18:08:56Z","last_updated_date":"2024-07-19T18:08:56Z","reference_number":"EMA/135005/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2023-ema-decision-18-april-2023-agreement-paediatric-investigation-plan-recombinant-human-ectonucleotide-pyrophosphatase-phosphodiesterase-1-fused-fc-fragment-igg1-inz-701-emea-003232-pip01-22_en.pdf"}    {"id":"64251","name":"P/0130/2023 : EMA decision of 13 April 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for zilovertamab vedotin (EMEA-003257-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T18:27:09Z","last_updated_date":"2024-07-19T18:27:09Z","reference_number":"EMA/146751/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2023-ema-decision-13-april-2023-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-zilovertamab-vedotin-emea-003257-pip01-22_en.pdf"},
    {"id":"64257","name":"P/0112/2023 : EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tedizolid (phosphate) (Sivextro), (EMEA-001379-PIP01-12-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T11:52:09Z","last_updated_date":"2024-07-22T11:52:09Z","reference_number":"EMA/103715/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2023-ema-decision-13-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-tedizolid-phosphate-sivextro-emea-001379-pip01-12-m07_en.pdf"},
    {"id":"64258","name":"P/0149/2023 : EMA decision of 21 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for anifrolumab (Saphnelo), (EMEA-001435-PIP02-16-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T11:53:02Z","last_updated_date":"2024-07-22T11:53:02Z","reference_number":"EMA/170358/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2023-ema-decision-21-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-anifrolumab-saphnelo-emea-001435-pip02-16-m02_en.pdf"},
    {"id":"64259","name":"P/0147/2023 : EMA decision of 21 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for binimetinib (Mektovi), (EMEA-001454-PIP03-15-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T11:53:59Z","last_updated_date":"2024-07-22T11:53:59Z","reference_number":"EMA/170329/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2023-ema-decision-21-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-binimetinib-mektovi-emea-001454-pip03-15-m03_en.pdf"},
    {"id":"64260","name":"P/0148/2023 : EMA decision of 21 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for encorafenib (Braftovi), (EMEA-001588-PIP01-13-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T11:55:03Z","last_updated_date":"2024-07-22T11:55:03Z","reference_number":"EMA/170348/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2023-ema-decision-21-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-encorafenib-braftovi-emea-001588-pip01-13-m03_en.pdf"},
    {"id":"64261","name":"P/0113/2023 : EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for filgotinib (Jyseleca), (EMEA-001619-PIP04-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T11:55:55Z","last_updated_date":"2024-07-22T11:55:55Z","reference_number":"EMA/103716/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2023-ema-decision-13-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-filgotinib-jyseleca-emea-001619-pip04-17-m02_en.pdf"},
    {"id":"64262","name":"P/0114/2023 : EMA decision of 13 April 2023 on the acceptance of a modification of an agreed paediatric investigation plan for satralizumab (Enspryng), (EMEA-001625-PIP02-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T11:56:49Z","last_updated_date":"2024-07-22T11:56:49Z","reference_number":"EMA/103735/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0114-2023-ema-decision-13-april-2023-acceptance-modification-agreed-paediatric-investigation-plan-satralizumab-enspryng-emea-001625-pip02-21-m01_en.pdf"},
    {"id":"64263","name":"P/0120/2023 : EMA decision of 13 April 2023 on the granting of a product specific waiver for tadalafil / finasteride (EMEA-003323-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T12:16:45Z","last_updated_date":"2024-07-22T12:16:45Z","reference_number":"EMA/144889/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2023-ema-decision-13-april-2023-granting-product-specific-waiver-tadalafil-finasteride-emea-003323-pip01-22_en.pdf"},
    {"id":"64264","name":"P/0127/2023 : EMA decision of 14 April 2023 on granting of product specific waiver for sodium ({(2S)-1,4-bis[2-(4-chloro-3- fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl}oxy)methyl hydrogen phosphate-2-amino-2- (hydroxymethyl)propane-1,3-diol (1/1/1)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T12:17:50Z","last_updated_date":"2024-07-22T12:17:50Z","reference_number":"EMA/134835/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2023-ema-decision-14-april-2023-granting-product-specific-waiver-sodium-2s-14-bis2-4-chloro-3-fluorophenoxyacetamidobicyclo222octan-2-yloxymethyl-hydrogen-phosphate-2-amino-2_en.pdf"},
    {"id":"64265","name":"P/0122/2023 : EMA decision of 14 April 2023 on the granting of a product specific waiver for acoltremon (EMEA-003351-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T12:19:22Z","last_updated_date":"2024-07-22T12:19:22Z","reference_number":"EMA/134752/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2023-ema-decision-14-april-2023-granting-product-specific-waiver-acoltremon-emea-003351-pip01-22_en.pdf"},
    {"id":"64266","name":"P/0108/2023 : EMA decision of 14 April 2023 on the granting of a product specific waiver for efzofitimod (EMEA-003352-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T12:20:24Z","last_updated_date":"2024-07-22T12:20:24Z","reference_number":"EMA/143584/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2023-ema-decision-14-april-2023-granting-product-specific-waiver-efzofitimod-emea-003352-pip01-22_en.pdf"},
    {"id":"64271","name":"P/0137/2023 : EMA decision of 14 April 2023 on the granting of a product specific waiver for lutetium 177-labelled radiohybrid prostate-specific membrane antigen-10.1 ((177Lu) rhPSMA-10.1) (EMEA-003353-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T14:52:57Z","last_updated_date":"2024-07-22T14:52:57Z","reference_number":"EMA/108921/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2023-ema-decision-14-april-2023-granting-product-specific-waiver-lutetium-177-labelled-radiohybrid-prostate-specific-membrane-antigen-101-177lu-rhpsma-101-emea-003353-pip01-22_en.pdf"},
    {"id":"64272","name":"P/0138/2023 : EMA decision of 14 April 2023 on granting of product specific waiver for (3S)-3-(5-{4-[(1-{4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl}piperidin-4-yl)methyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2yl)...","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T14:54:01Z","last_updated_date":"2024-07-22T14:54:01Z","reference_number":"EMA/108922/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2023-ema-decision-14-april-2023-granting-product-specific-waiver-3s-3-5-4-1-4-1r2s-6-hydroxy-2-phenyl-1234-tetrahydronaphthalen-1-ylphenylpiperidin-4-ylmethylpiperazin-1-yl-1-oxo-13-dihydro-2h_en.pdf"},
    {"id":"64273","name":"P/0140/2023 : EMA decision of 14 April 2023 on the granting of a product specific waiver for ciclosporin (EMEA-003366-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T14:56:26Z","last_updated_date":"2024-07-22T14:56:26Z","reference_number":"EMA/127645/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2023-ema-decision-14-april-2023-granting-product-specific-waiver-ciclosporin-emea-003366-pip01-22_en.pdf"},
    {"id":"64274","name":"P/0129/2023 : EMA decision of 13 April 2023 on the granting of a product specific waiver for utreloxastat (EMEA-003369-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-07-22T14:57:19Z","last_updated_date":"2024-07-22T14:57:19Z","reference_number":"EMA/146791/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2023-ema-decision-13-april-2023-granting-product-specific-waiver-utreloxastat-emea-003369-pip01-22_en.pdf"},
    {"id":"64302","name":"P/0101/2024 : EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for afamelanotide (Scenesse), (EMEA-000737-PIP02-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-07-25T10:48:00Z","last_updated_date":"2024-07-25T10:48:00Z","reference_number":"EMA/98104/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0101-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-afamelanotide-scenesse-emea-000737-pip02-11-m03_en.pdf"},
    {"id":"64303","name":"P/0455/2023 : EMA decision of 17 November 2023 on the acceptance of a modification of an agreed paediatric investigation plan for letermovir (Prevymis), (EMEA-001631-PIP01-14-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-07-25T10:53:00Z","last_updated_date":"2024-07-25T10:53:00Z","reference_number":"EMA/509228/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0455-2023-ema-decision-17-november-2023-acceptance-modification-agreed-paediatric-investigation-plan-letermovir-prevymis-emea-001631-pip01-14-m05_en.pdf"},
    {"id":"64815","name":"P/0299/2023 : EMA decision of 11 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for erenumab (Aimovig), (EMEA-001664-PIP02-15-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T15:35:58Z","last_updated_date":"2024-09-13T15:35:58Z","reference_number":"EMA/336528/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2023-ema-decision-11-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-erenumab-aimovig-emea-001664-pip02-15-m06_en.pdf"},
    {"id":"64816","name":"P/0320/2023 : EMA decision of 11 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for sufentanil (citrate) / ketamine (hydrochloride) (EMEA-001739-PIP02-16-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:31:40Z","last_updated_date":"2024-09-13T16:31:40Z","reference_number":"EMA/330868/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0320-2023-ema-decision-11-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-sufentanil-citrate-ketamine-hydrochloride-emea-001739-pip02-16-m02_en.pdf"},
    {"id":"64817","name":"P/0300/2023 : EMA decision of 11 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for mexiletine (hydrochloride) (Namuscla), (EMEA-002012-PIP01-16-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:32:47Z","last_updated_date":"2024-09-13T16:32:47Z","reference_number":"EMA/336533/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2023-ema-decision-11-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-mexiletine-hydrochloride-namuscla-emea-002012-pip01-16-m04_en.pdf"},
    {"id":"64818","name":"P/0301/2023 : EMA decision of 11 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for durvalumab (Imfinz), (EMEA-002028-PIP01-16-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:34:09Z","last_updated_date":"2024-09-13T16:34:09Z","reference_number":"EMA/336529/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2023-ema-decision-11-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-durvalumab-imfinz-emea-002028-pip01-16-m04_en.pdf"},
    {"id":"64819","name":"P/0302/2023 : EMA decision of 11 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tremelimumab (Imjudo, Tremelimumab AstraZeneca), (EMEA-002029-PIP01-16-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:35:13Z","last_updated_date":"2024-09-13T16:35:13Z","reference_number":"EMA/336531/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2023-ema-decision-11-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-tremelimumab-imjudo-tremelimumab-astrazeneca-emea-002029-pip01-16-m04_en.pdf"},
    {"id":"64820","name":"P/0322/2023 : EMA decision of 11 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for inclisiran (sodium) (Leqvio), (EMEA-002214-PIP01-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:36:16Z","last_updated_date":"2024-09-13T16:36:16Z","reference_number":"EMA/331021/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0322-2023-ema-decision-11-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-inclisiran-sodium-leqvio-emea-002214-pip01-17-m02_en.pdf"},
    {"id":"64821","name":"P/0321/2023 : EMA decision of 11 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for olaparib (Lynparza), (EMEA-002269-PIP01-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:39:12Z","last_updated_date":"2024-09-13T16:39:12Z","reference_number":"EMA/330964/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0321-2023-ema-decision-11-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-olaparib-lynparza-emea-002269-pip01-17-m02_en.pdf"},
    {"id":"64822","name":"P/0312/2023 : EMA decision of 9 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for abemaciclib (Verzenios), (EMEA-002342-PIP01-18-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:40:42Z","last_updated_date":"2024-09-13T16:40:42Z","reference_number":"EMA/335914/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2023-ema-decision-9-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-abemaciclib-verzenios-emea-002342-pip01-18-m03_en.pdf"},
    {"id":"64823","name":"P/0313/2023 : EMA decision of 9 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for abemaciclib (Verzenios), (EMEA-002342-PIP02-18-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:42:00Z","last_updated_date":"2024-09-13T16:42:00Z","reference_number":"EMA/335935/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2023-ema-decision-9-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-abemaciclib-verzenios-emea-002342-pip02-18-m02_en.pdf"},
    {"id":"64824","name":"P/0335/2023 : EMA decision of 9 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for repotrectinib (EMEA-002635-PIP02-21-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:43:15Z","last_updated_date":"2024-09-13T16:43:15Z","reference_number":"EMA/347489/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0335-2023-ema-decision-9-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-repotrectinib-emea-002635-pip02-21-m02_en.pdf"},
    {"id":"64825","name":"P/0337/2023 : EMA decision of 11 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for iclepertin (EMEA- 002653-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:44:14Z","last_updated_date":"2024-09-13T16:44:14Z","reference_number":"EMA/356342/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0337-2023-ema-decision-11-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-iclepertin-emea-002653-pip01-19-m01_en.pdf"},
    {"id":"64826","name":"P/0325/2023 : EMA decision of 8 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for delandistrogene moxeparvovec, (EMEA-002677-PIP01-19-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:45:15Z","last_updated_date":"2024-09-13T16:45:15Z","reference_number":"EMA/344540/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0325-2023-ema-decision-8-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-delandistrogene-moxeparvovec-emea-002677-pip01-19-m03_en.pdf"},
    {"id":"64827","name":"P/0331/2023 : EMA decision of 10 Aug 2023 on acceptance of a modification of an agreed paediatric investigation plan for bilayer, engineered, collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts (EMEA- 002699-PIP01-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:46:12Z","last_updated_date":"2024-09-13T16:46:12Z","reference_number":"EMA/350898/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0331-2023-ema-decision-10-aug-2023-acceptance-modification-agreed-paediatric-investigation-plan-bilayer-engineered-collagen-hydrogel-based-skin-graft-composed-autologous-keratinocytes-fibroblasts_en.pdf"},
    {"id":"64828","name":"P/0326/2023 : EMA decision of 8 August 2023 on the acceptance of a modification of an agreed PIP for (S)-2-(5-((3- ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran 3 yl) pyrimidine-5-carboxamide (PF- 06865571), (EMEA-002773-PIP01-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:47:20Z","last_updated_date":"2024-09-13T16:47:20Z","reference_number":"EMA/344544/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0326-2023-ema-decision-8-august-2023-acceptance-modification-agreed-pip-s-2-5-3-ethoxypyridin-2-yloxypyridin-3-yl-n-tetrahydrofuran-3-yl-pyrimidine-5-carboxamide-pf-06865571-emea-002773-pip01-20-m01_en.pdf"},
    {"id":"64829","name":"P/0332/2023 : EMA decision of 9 August 2023 on the granting of a product specific waiver for clotrimazole (EMEA-003431-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:49:28Z","last_updated_date":"2024-09-13T16:49:28Z","reference_number":"EMA/347894/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0332-2023-ema-decision-9-august-2023-granting-product-specific-waiver-clotrimazole-emea-003431-pip01-23_en.pdf"},
    {"id":"64830","name":"P/0330/2023 : EMA decision of 8 August 2023 on the granting of a product specific waiver for domvanalimab, (EMEA-003429-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:50:24Z","last_updated_date":"2024-09-13T16:50:24Z","reference_number":"EMA/344572/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0330-2023-ema-decision-8-august-2023-granting-product-specific-waiver-domvanalimab-emea-003429-pip02-23_en.pdf"},
    {"id":"64831","name":"P/0329/2023 : EMA decision of 8 August 2023 on the granting of a product specific waiver for domvanalimab, (EMEA-003429-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:51:29Z","last_updated_date":"2024-09-13T16:51:29Z","reference_number":"EMA/344558/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0329-2023-ema-decision-8-august-2023-granting-product-specific-waiver-domvanalimab-emea-003429-pip01-23_en.pdf"},
    {"id":"64832","name":"P/0319/2023 : EMA decision of 11 August 2023 on the granting of a product specific waiver for zimberelimab (EMEA-003427-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:54:57Z","last_updated_date":"2024-09-13T16:54:57Z","reference_number":"EMA/330316/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0319-2023-ema-decision-11-august-2023-granting-product-specific-waiver-zimberelimab-emea-003427-pip02-23_en.pdf"},
    {"id":"64833","name":"P/0318/2023 : EMA decision of 11 August 2023 on the granting of a product specific waiver for zimberelimab (EMEA-003427-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:56:21Z","last_updated_date":"2024-09-13T16:56:21Z","reference_number":"EMA/330273/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2023-ema-decision-11-august-2023-granting-product-specific-waiver-zimberelimab-emea-003427-pip01-23_en.pdf"},
    {"id":"64834","name":"P/0293/2023 : EMA decision of 4 August 2023 on the refusal of a paediatric investigation plan and on the granting of a waiver for volrustomig (EMEA- 003423-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:57:14Z","last_updated_date":"2024-09-13T16:57:14Z","reference_number":"EMA/339337/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2023-ema-decision-4-august-2023-refusal-paediatric-investigation-plan-granting-waiver-volrustomig-emea-003423-pip01-23_en.pdf"},
    {"id":"64835","name":"P/0328/2023 : EMA decision of 8 August 2023 on the granting of a product specific waiver for tiragolumab/atezolizumab, (EMEA-003418-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:58:14Z","last_updated_date":"2024-09-13T16:58:14Z","reference_number":"EMA/344548/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0328-2023-ema-decision-8-august-2023-granting-product-specific-waiver-tiragolumab-atezolizumab-emea-003418-pip01-23_en.pdf"},
    {"id":"64836","name":"P/0317/2023 : EMA decision of 9 August 2023 on the granting of a product specific waiver for sotuletinib (EMEA-003415-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T16:59:06Z","last_updated_date":"2024-09-13T16:59:06Z","reference_number":"EMA/336122/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2023-ema-decision-9-august-2023-granting-product-specific-waiver-sotuletinib-emea-003415-pip01-23_en.pdf"},
    {"id":"64837","name":"P/0324/2023 : EMA decision of 11 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for encaleret (EMEA-003348-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T17:00:02Z","last_updated_date":"2024-09-13T17:00:02Z","reference_number":"EMA/330466/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0324-2023-ema-decision-11-august-2023-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-encaleret-emea-003348-pip01-22_en.pdf"},
    {"id":"64838","name":"P/0327/2023 : EMA decision of 8 Aug 2023 on agreement of a PIP and on the granting of a deferral and on the granting of a waiver for single-stranded 5' capped mRNA encoding the HAs of the influenza virus strains A and B (mRNA-1010), (EMEA-003346-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T17:02:59Z","last_updated_date":"2024-09-13T17:02:59Z","reference_number":"EMA/343305/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0327-2023-ema-decision-8-aug-2023-agreement-pip-granting-deferral-granting-waiver-single-stranded-5-capped-mrna-encoding-has-influenza-virus-strains-b-mrna-1010-emea-003346-pip01-22_en.pdf"},
    {"id":"64839","name":"P/0316/2023 : EMA decision of 9 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mavodelpar (EMEA-003331-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T17:04:37Z","last_updated_date":"2024-09-13T17:04:37Z","reference_number":"EMA/336102/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2023-ema-decision-9-august-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mavodelpar-emea-003331-pip02-23_en.pdf"},
    {"id":"64840","name":"P/0315/2023 : EMA decision of 9 August 2023 on the agreement of a paediatric investigation plan for furosemide (EMEA-003316-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T17:09:29Z","last_updated_date":"2024-09-13T17:09:29Z","reference_number":"EMA/336065/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0315-2023-ema-decision-9-august-2023-agreement-paediatric-investigation-plan-furosemide-emea-003316-pip01-22_en.pdf"},
    {"id":"64856","name":"P/0513/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for inebilizumab (EMEA-001911-PIP01-15-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:00:00Z","last_updated_date":"2024-09-16T14:00:00Z","reference_number":"EMA/554681/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0513-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-inebilizumab-emea-001911-pip01-15-m05_en.pdf"},
    {"id":"64857","name":"P/0439/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for remdesivir (Veklury), (EMEA-002826-PIP01-20-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:00:00Z","last_updated_date":"2024-09-16T14:00:00Z","reference_number":"EMA/401499/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0439-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-remdesivir-veklury-emea-002826-pip01-20-m04_en.pdf"},
    {"id":"64858","name":"P/0488/2023: EMA decision of 4 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for maralixibat chloride (EMEA-001475-PIP03-17-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:00:00Z","last_updated_date":"2024-09-16T14:00:00Z","reference_number":"EMA/517374/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0488-2023-ema-decision-4-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-maralixibat-chloride-emea-001475-pip03-17-m04_en.pdf"},
    {"id":"64861","name":"P/0449/2023: EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for blinatumomab (Blincyto) (EMEA-000574-PIP02-12-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:00:00Z","last_updated_date":"2024-09-16T14:00:00Z","reference_number":"EMA/480376/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0449-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-blinatumomab-blincyto-emea-000574-pip02-12-m04_en.pdf"},
    {"id":"64915","name":"P/0345/2023 : EMA decision of 8 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obinutuzumab (Gazyvaro), (EMEA-001207-PIP05-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T09:00:00Z","last_updated_date":"2024-09-19T09:00:00Z","reference_number":"EMA/351993/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0345-2023-ema-decision-8-september-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-obinutuzumab-gazyvaro-emea-001207-pip05-22_en.pdf"},
    {"id":"64916","name":"P/0349/2023 : EMA decision of 8 September 2023 on the granting of a product specific waiver for binimetinib (Mektovi), (EMEA-001454-PIP06-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T09:00:00Z","last_updated_date":"2024-09-19T09:00:00Z","reference_number":"EMA/380483/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0349-2023-ema-decision-8-september-2023-granting-product-specific-waiver-binimetinib-mektovi-emea-001454-pip06-23_en.pdf"},
    {"id":"64917","name":"P/0350/2023 : EMA decision of 8 September 2023 on the granting of a product specific waiver for pemafibrate (EMEA-001573-PIP03-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T09:00:00Z","last_updated_date":"2024-09-19T09:00:00Z","reference_number":"EMA/380487/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0350-2023-ema-decision-8-september-2023-granting-product-specific-waiver-pemafibrate-emea-001573-pip03-23_en.pdf"},
    {"id":"64918","name":"P/0351/2023 : EMA decision of 8 September 2023 on the granting of a product specific waiver for encorafenib (Braftovi), (EMEA-001588-PIP04-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T09:10:00Z","last_updated_date":"2024-09-19T09:10:00Z","reference_number":"EMA/380488/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0351-2023-ema-decision-8-september-2023-granting-product-specific-waiver-encorafenib-braftovi-emea-001588-pip04-23_en.pdf"},
    {"id":"64920","name":"P/0383/2023 : EMA decision of 7 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for upadacitinib (Rinvoq), (EMEA-001741-PIP07-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T09:28:00Z","last_updated_date":"2024-09-19T09:28:00Z","reference_number":"EMA/388229/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0383-2023-ema-decision-7-september-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-upadacitinib-rinvoq-emea-001741-pip07-22_en.pdf"},
    {"id":"64922","name":"P/0388/2023 : EMA decision of 7 September 2023 on the granting of a product specific waiver for ravulizumab (Ultomiris), (EMEA-001943-PIP06-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T09:53:00Z","last_updated_date":"2024-09-19T09:53:00Z","reference_number":"EMA/389665/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0388-2023-ema-decision-7-september-2023-granting-product-specific-waiver-ravulizumab-ultomiris-emea-001943-pip06-23_en.pdf"},
    {"id":"64923","name":"P/0381/2023 : EMA decision of 7 September 2023 on the granting of a product specific waiver for teprotumumab, (EMEA-001973-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T10:28:00Z","last_updated_date":"2024-09-19T10:28:00Z","reference_number":"EMA/389821/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0381-2023-ema-decision-7-september-2023-granting-product-specific-waiver-teprotumumab-emea-001973-pip02-23_en.pdf"},
    {"id":"64924","name":"P/0385/2023 : EMA decision of 7 September 2023 on the granting of a product specific waiver for enfortumab vedotin (Padcev), (EMEA-002299-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T10:38:00Z","last_updated_date":"2024-09-19T10:38:00Z","reference_number":"EMA/389081/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0385-2023-ema-decision-7-september-2023-granting-product-specific-waiver-enfortumab-vedotin-padcev-emea-002299-pip02-23_en.pdf"},
    {"id":"64926","name":"EMA/384130/2023 : EMA decision of 8 September 2023 on the granting of a product specific waiver for abemaciclib (Verzenios), (EMEA-002342-PIP05-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T10:45:00Z","last_updated_date":"2024-09-19T10:45:00Z","reference_number":"EMA/384130/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-384130-2023-ema-decision-8-september-2023-granting-product-specific-waiver-abemaciclib-verzenios-emea-002342-pip05-23_en.pdf"},
    {"id":"64928","name":"P/0372/2023 : EMA decision of 8 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for trimodulin (EMEA-002883-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T10:52:00Z","last_updated_date":"2024-09-19T10:52:00Z","reference_number":"EMA/384196/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0372-2023-ema-decision-8-september-2023-agreement-paediatric-investigation-plan-granting-deferral-trimodulin-emea-002883-pip02-22_en.pdf"},
    {"id":"64932","name":"P/0378/2023 : EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for fremanezumab (Ajovy), (EMEA-001877-PIP01-15-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T11:48:00Z","last_updated_date":"2024-09-19T11:48:00Z","reference_number":"EMA/351214/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0378-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-fremanezumab-ajovy-emea-001877-pip01-15-m04_en.pdf"},
    {"id":"64933","name":"P/0379/2023 : EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris), (EMEA-001943-PIP01-16-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T11:55:00Z","last_updated_date":"2024-09-19T11:55:00Z","reference_number":"EMA/351216/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0379-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-001943-pip01-16-m08_en.pdf"},
    {"id":"64934","name":"P/0352/2023 : EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for avacopan (Tavneos), (EMEA-002023-PIP01-16-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T12:00:00Z","last_updated_date":"2024-09-19T12:00:00Z","reference_number":"EMA/380478/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0352-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-avacopan-tavneos-emea-002023-pip01-16-m07_en.pdf"},
    {"id":"64935","name":"P/0353/2023 : EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris), (EMEA-002077-PIP01-16-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T12:04:00Z","last_updated_date":"2024-09-19T12:04:00Z","reference_number":"EMA/380480/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0353-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-002077-pip01-16-m06_en.pdf"},
    {"id":"64936","name":"P/0357/2023 : EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for danicopan (EMEA-002310-PIP01-17-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T12:10:00Z","last_updated_date":"2024-09-19T12:10:00Z","reference_number":"EMA/347097/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0357-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-danicopan-emea-002310-pip01-17-m01_en.pdf"},
    {"id":"64937","name":"P/0392/2023 : EMA decision of 28 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for elexacaftor / tezacaftor/ ivacaftor (Kaftrio), (EMEA-002324-PIP01-17-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T12:16:00Z","last_updated_date":"2024-09-19T12:16:00Z","reference_number":"EMA/400386/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0392-2023-ema-decision-28-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-elexacaftor-tezacaftor-ivacaftor-kaftrio-emea-002324-pip01-17-m05_en.pdf"},
    {"id":"64938","name":"P/0358/2023 : EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for concizumab (EMEA-002326-PIP04-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T12:20:00Z","last_updated_date":"2024-09-19T12:20:00Z","reference_number":"EMA/347165/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0358-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-concizumab-emea-002326-pip04-20-m01_en.pdf"},
    {"id":"65076","name":"P/0338/2023 : EMA decision of 17 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis), (EMEA-000183-PIP02-12-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:18:57Z","last_updated_date":"2024-10-02T19:18:57Z","reference_number":"EMA/351967/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0338-2023-ema-decision-17-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip02-12-m04_en.pdf"},
    {"id":"65077","name":"P/0308/2023 : EMA decision of 7 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz), (EMEA-000576-PIP01-09-M15)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:20:34Z","last_updated_date":"2024-10-02T19:20:34Z","reference_number":"EMA/344151/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2023-ema-decision-7-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip01-09-m15_en.pdf"},
    {"id":"65078","name":"P/0309/2023 : EMA decision of 7 August on the acceptance of a modification of an agreed paediatric investigation plan for cabozantinib (Cometriq, Cabometyx), (EMEA-001143-PIP01-11-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:23:38Z","last_updated_date":"2024-10-02T19:23:38Z","reference_number":"EMA/344395/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0309-2023-ema-decision-7-august-acceptance-modification-agreed-paediatric-investigation-plan-cabozantinib-cometriq-cabometyx-emea-001143-pip01-11-m06_en.pdf"},
    {"id":"65079","name":"P/0287/2023 : EMA decision of 4 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for obeticholic acid (Ocaliva), (EMEA-001304-PIP02-13-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:25:09Z","last_updated_date":"2024-10-02T19:25:09Z","reference_number":"EMA/338823/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2023-ema-decision-4-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-obeticholic-acid-ocaliva-emea-001304-pip02-13-m07_en.pdf"},
    {"id":"65080","name":"P/0294/2023 : EMA decision of 11 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for naltrexone (hydrochloride) / bupropion (hydrochloride) (Mysimba), (EMEA-001373-PIP01-12-M05)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:26:59Z","last_updated_date":"2024-10-02T19:26:59Z","reference_number":"EMA/336519/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2023-ema-decision-11-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-naltrexone-hydrochloride-bupropion-hydrochloride-mysimba-emea-001373-pip01-12-m05_en.pdf"},
    {"id":"65081","name":"P/0340/2023 : EMA decision of 17 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tedizolid (phosphate) (Sivextro), (EMEA-001379-PIP01-12-M08)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:28:08Z","last_updated_date":"2024-10-02T19:28:08Z","reference_number":"EMA/372643/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0340-2023-ema-decision-17-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-tedizolid-phosphate-sivextro-emea-001379-pip01-12-m08_en.pdf"},
    {"id":"65082","name":"P/0295/2023 : EMA decision of 11 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ibrutinib (Imbruvica), (EMEA-001397-PIP04-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:29:06Z","last_updated_date":"2024-10-02T19:29:06Z","reference_number":"EMA/336523/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2023-ema-decision-11-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-ibrutinib-imbruvica-emea-001397-pip04-17-m02_en.pdf"},
    {"id":"65083","name":"P/0339/2023 : EMA decision of 17 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for nivolumab (Opdivo) (EMEA-001407-PIP02-15-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:30:03Z","last_updated_date":"2024-10-02T19:30:03Z","reference_number":"EMA/369956/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0339-2023-ema-decision-17-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-nivolumab-opdivo-emea-001407-pip02-15-m06_en.pdf"},
    {"id":"65084","name":"P/0297/2023 : EMA decision of 11 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP07-20-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:31:03Z","last_updated_date":"2024-10-02T19:31:03Z","reference_number":"EMA/336526/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2023-ema-decision-11-august-2023-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip07-20-m01_en.pdf"},
    {"id":"65085","name":"P/0334/2023 : EMA decision of 9 August 2023 on the granting of a product specific waiver for concentrate of proteolytic enzymes enriched in bromelain (NexoBrid), (EMEA-000142-PIP03-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:32:11Z","last_updated_date":"2024-10-02T19:32:11Z","reference_number":"EMA/352825/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0334-2023-ema-decision-9-august-2023-granting-product-specific-waiver-concentrate-proteolytic-enzymes-enriched-bromelain-nexobrid-emea-000142-pip03-23_en.pdf"},
    {"id":"65086","name":"P/0296/2023 : EMA decision of 11 August 2023 on the granting of a product specific waiver for semaglutide (Wegovy), (EMEA-001441-PIP08-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:37:33Z","last_updated_date":"2024-10-02T19:37:33Z","reference_number":"EMA/336536/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2023-ema-decision-11-august-2023-granting-product-specific-waiver-semaglutide-wegovy-emea-001441-pip08-23_en.pdf"},
    {"id":"65087","name":"P/0298/2023 : EMA decision of 11 August 2023 on the granting of a product specific waiver for satralizumab (Enspryng), (EMEA-001625-PIP05-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:38:33Z","last_updated_date":"2024-10-02T19:38:33Z","reference_number":"EMA/336539/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2023-ema-decision-11-august-2023-granting-product-specific-waiver-satralizumab-enspryng-emea-001625-pip05-23_en.pdf"},
    {"id":"65088","name":"P/0303/2023 : EMA decision of 11 August 2023 on the granting of a product specific waiver for autologous dendritic cells pulsed with allogeneic tumour cell lysate, (EMEA-002381-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:39:35Z","last_updated_date":"2024-10-02T19:39:35Z","reference_number":"EMA/336543/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2023-ema-decision-11-august-2023-granting-product-specific-waiver-autologous-dendritic-cells-pulsed-allogeneic-tumour-cell-lysate-emea-002381-pip02-23_en.pdf"},
    {"id":"65089","name":"P/0288/2023 : EMA decision of 4 August 2023 on the granting of a product specific waiver for rilzabrutinib (EMEA-002438-PIP04-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:40:36Z","last_updated_date":"2024-10-02T19:40:36Z","reference_number":"EMA/335235/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2023-ema-decision-4-august-2023-granting-product-specific-waiver-rilzabrutinib-emea-002438-pip04-23_en.pdf"},
    {"id":"65090","name":"P/0289/2023 : EMA decision of 4 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ritlecitinib (EMEA-002451-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:45:24Z","last_updated_date":"2024-10-02T19:45:24Z","reference_number":"EMA/339196/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2023-ema-decision-4-august-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ritlecitinib-emea-002451-pip03-22_en.pdf"},
    {"id":"65091","name":"P/0290/2023 : EMA decision of 4 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dersimelagon (EMEA-002850-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:47:19Z","last_updated_date":"2024-10-02T19:47:19Z","reference_number":"EMA/339220/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2023-ema-decision-4-august-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dersimelagon-emea-002850-pip03-22_en.pdf"},
    {"id":"65092","name":"P/0307/2023 : EMA decision of 4 August 2023 on the granting of a product specific waiver for cagrilintide / semaglutide (EMEA-003059-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:48:35Z","last_updated_date":"2024-10-02T19:48:35Z","reference_number":"EMA/338964/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2023-ema-decision-4-august-2023-granting-product-specific-waiver-cagrilintide-semaglutide-emea-003059-pip02-23_en.pdf"},
    {"id":"65093","name":"P/0304/2023 : EMA decision of 11 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for repagermanium, (EMEA-003154-PIP01-21)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:49:56Z","last_updated_date":"2024-10-02T19:49:56Z","reference_number":"EMA/336630/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2023-ema-decision-11-august-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-repagermanium-emea-003154-pip01-21_en.pdf"},
    {"id":"65094","name":"P/0305/2023 : EMA decision of 11 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for MVA-BN-RSV vaccine (construct MVA-mBN294B), (EMEA-003185-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T16:51:11Z","last_updated_date":"2024-10-02T16:51:11Z","reference_number":"EMA/336632/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2023-ema-decision-11-august-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mva-bn-rsv-vaccine-construct-mva-mbn294b-emea-003185-pip01-22_en.pdf"},
    {"id":"65095","name":"P/0274/2023 : EMA decision of 7 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for milvexian (EMEA-003220-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:52:25Z","last_updated_date":"2024-10-02T19:52:25Z","reference_number":"EMA/344546/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2023-ema-decision-7-august-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-milvexian-emea-003220-pip01-22_en.pdf"},
    {"id":"65096","name":"P/0291/2023 : EMA decision of 4 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for XEN1101 (EMEA-003271-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:54:45Z","last_updated_date":"2024-10-02T19:54:45Z","reference_number":"EMA/339288/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2023-ema-decision-4-august-2023-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-xen1101-emea-003271-pip01-22_en.pdf"},
    {"id":"65097","name":"P/0292/2023 : EMA decision of 4 August 2023 on the agreement of a paediatric investigation plan and on the granting of a waiver for enomimeran / gindameran / ontasameran / vibosameran (BNT111), (EMEA-003274-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T17:16:38Z","last_updated_date":"2024-10-02T17:16:38Z","reference_number":"EMA/339324/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2023-ema-decision-4-august-2023-agreement-paediatric-investigation-plan-granting-waiver-enomimeran-gindameran-ontasameran-vibosameran-bnt111-emea-003274-pip01-22_en.pdf"},
    {"id":"65098","name":"P/0306/2023 : EMA decision of 11 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for dirloctocogene samoparvovec, (EMEA-003290-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T19:57:32Z","last_updated_date":"2024-10-02T19:57:32Z","reference_number":"EMA/336633/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2023-ema-decision-11-august-2023-agreement-paediatric-investigation-plan-granting-deferral-dirloctocogene-samoparvovec-emea-003290-pip01-22_en.pdf"},
    {"id":"65099","name":"P/0323/2023 : EMA decision of 11 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for interleukin-23 receptor antagonist peptide (EMEA-003301-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-02T17:54:11Z","last_updated_date":"2024-10-02T17:54:11Z","reference_number":"EMA/330382/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0323-2023-ema-decision-11-august-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-interleukin-23-receptor-antagonist-peptide-emea-003301-pip01-22_en.pdf"},
    {"id":"65100","name":"P/0310/2023 : EMA decision of 7 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mocravimod (EMEA-003304-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T20:00:30Z","last_updated_date":"2024-10-02T20:00:30Z","reference_number":"EMA/344819/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0310-2023-ema-decision-7-august-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mocravimod-emea-003304-pip01-22_en.pdf"},
    {"id":"65101","name":"P/0311/2023 : EMA decision of 7 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for povorcitinib (EMEA-003313-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T18:00:00Z","last_updated_date":"2024-10-02T18:00:00Z","reference_number":"EMA/344864/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0311-2023-ema-decision-7-august-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-povorcitinib-emea-003313-pip01-22_en.pdf"},
    {"id":"65102","name":"P/0314/2023 : EMA decision of 9 August 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for mRNA encoding modified human ornithine transcarbamylase (ARCT-810), (EMEA-003315-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-02T18:38:24Z","last_updated_date":"2024-10-02T18:38:24Z","reference_number":"EMA/336054/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2023-ema-decision-9-august-2023-agreement-paediatric-investigation-plan-granting-deferral-mrna-encoding-modified-human-ornithine-transcarbamylase-arct-810-emea-003315-pip01-22_en.pdf"},
    {"id":"65149","name":"P/0390/2023: EMA decision of 8 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant human tissue nonspecific alkaline phosphatase (TNSALP) fragment crystallizable (Fc) deca aspartate fusion..","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T11:29:00Z","last_updated_date":"2024-10-04T11:29:00Z","reference_number":"EMA/351271/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0390-2023-ema-decision-8-september-2023-agreement-paediatric-investigation-plan-granting-deferral-recombinant-human-tissue-nonspecific-alkaline-phosphatase-tnsalp-fragment-crystallizable-fc-deca_en.pdf"},
    {"id":"65150","name":"P/0306/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for fosigotifator sodium tromethamine (EMEA-003344-PIP01-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T11:00:00Z","last_updated_date":"2024-10-04T11:00:00Z","reference_number":"EMA/364886/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0306-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-fosigotifator-sodium-tromethamine-emea-003344-pip01-22-m01_en.pdf"},
    {"id":"65162","name":"P/0366/2023 : EMA decision of 8 September 2023 on the granting of a product specific waiver for 3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate (EMEA-002990-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T13:15:00Z","last_updated_date":"2024-10-04T13:15:00Z","reference_number":"EMA/384112/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0366-2023-ema-decision-8-september-2023-granting-product-specific-waiver-3-2-dimethylaminoethyl-1h-indol-4-yl-dihydrogen-phosphate-emea-002990-pip02-23_en.pdf"},
    {"id":"65163","name":"P/0355/2023: EMA decision of 8 September 2023 on the granting of a product specific waiver for acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin (EMEA- 003345-","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T13:00:00Z","last_updated_date":"2024-10-04T13:00:00Z","reference_number":"EMA/380491/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0355-2023-ema-decision-8-september-2023-granting-product-specific-waiver-acellular-tubular-graft-composed-human-collagen-types-i-iii-other-extracellular-matrix-proteins-including-fibronectin_en.pdf"},
    {"id":"65164","name":"P/0387/2023 ; EMA decision of 7 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for derivative of 6-[2-(pyridin-2-yl)phenoxy]methyl}-1,2,3,4-tetrahydroisoquinoline, (EMEA","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T13:34:00Z","last_updated_date":"2024-10-04T13:34:00Z","reference_number":"EMA/388403/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0387-2023-ema-decision-7-september-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-derivative-6-2-pyridin-2-ylphenoxymethyl-1234-tetrahydroisoquinoline-emea_en.pdf"},
    {"id":"65165","name":"P/0342/2023: EMA decision of 8 September 2023 on the granting of a product specific waiver for ivonescimab (EMEA-003378-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T13:00:00Z","last_updated_date":"2024-10-04T13:00:00Z","reference_number":"EMA/352005/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0342-2023-ema-decision-8-september-2023-granting-product-specific-waiver-ivonescimab-emea-003378-pip01-23_en.pdf"},
    {"id":"65166","name":"P/0343/2023: EMA decision of 8 September 2023 on the granting of a product specific waiver for ramipril / nebivolol (hydrochloride) (EMEA-003430- PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T14:00:00Z","last_updated_date":"2024-10-04T14:00:00Z","reference_number":"EMA/352008/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0343-2023-ema-decision-8-september-2023-granting-product-specific-waiver-ramipril-nebivolol-hydrochloride-emea-003430-pip01-23_en.pdf"},
    {"id":"65167","name":"P/0304/2024 : EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for humanised monoclonal antibody derivative against fibroblast growth factor receptor 3 (SAR442501) (EMEA- 003253-PIP01-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T14:00:00Z","last_updated_date":"2024-10-04T14:00:00Z","reference_number":"EMA/364885/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0304-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-humanised-monoclonal-antibody-derivative-against-fibroblast-growth-factor-receptor-3-sar442501-emea_en.pdf"},
    {"id":"65168","name":"P/0394/2023 : EMA decision of 29 September 2023 on the granting of a product specific waiver for valemetostat tosilate (EMEA-003256-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T14:15:00Z","last_updated_date":"2024-10-04T14:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0394-2023-ema-decision-29-september-2023-granting-product-specific-waiver-valemetostat-tosilate-emea-003256-pip02-23_en.pdf"}    {"id":"65169","name":"P/0362/2023 : EMA decision of 8 September 2023 on the agreement of a paediatric investigation plan for dexmedetomidine (EMEA-003283-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T14:30:00Z","last_updated_date":"2024-10-04T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0362-2023-ema-decision-8-september-2023-agreement-paediatric-investigation-plan-dexmedetomidine-emea-003283-pip01-22_en.pdf"},
    {"id":"65170","name":"P/0344/2023: EMA decision of 8 September 2023 on the granting of a product specific waiver for modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/ mRNA-4157) (EMEA-003434-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T14:00:00Z","last_updated_date":"2024-10-04T14:00:00Z","reference_number":"EMA/352010/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0344-2023-ema-decision-8-september-2023-granting-product-specific-waiver-modified-messenger-ribonucleic-acid-encoding-individual-patient-specific-tumour-neoantigens-v940-mrna-4157-emea-003434-pip01_en.pdf"},
    {"id":"65173","name":"P/0333/2023 : EMA decision of 8 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vesleteplirsen, (EMEA-003305-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T15:15:00Z","last_updated_date":"2024-10-04T15:15:00Z","reference_number":"EMA/351272/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0333-2023-ema-decision-8-september-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-vesleteplirsen-emea-003305-pip01-22_en.pdf"},
    {"id":"65174","name":"P/0374/2023: EMA decision of 8 September 2023 on the granting of a product specific waiver for lerociclib (dihydrochloride) (EMEA-003436-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T14:00:00Z","last_updated_date":"2024-10-04T14:00:00Z","reference_number":"EMA/351239/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0374-2023-ema-decision-8-september-2023-granting-product-specific-waiver-lerociclib-dihydrochloride-emea-003436-pip01-23_en.pdf"},
    {"id":"65175","name":"P/0375/2023: EMA decision of 8 September 2023 on the granting of a product specific waiver for obicetrapib (EMEA-003438-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T15:00:00Z","last_updated_date":"2024-10-04T15:00:00Z","reference_number":"EMA/351240/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0375-2023-ema-decision-8-september-2023-granting-product-specific-waiver-obicetrapib-emea-003438-pip01-23_en.pdf"},
    {"id":"65176","name":"P/0365/2023: EMA decision of 8 September 2023 on the granting of a product specific waiver for rosuvastatin / ezetimibe (EMEA-003444-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T15:00:00Z","last_updated_date":"2024-10-04T15:00:00Z","reference_number":"EMA/347902/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0365-2023-ema-decision-8-september-2023-granting-product-specific-waiver-rosuvastatin-ezetimibe-emea-003444-pip01-23_en.pdf"},
    {"id":"65177","name":"P/0356/2023: EMA decision of 8 September 2023 on the granting of a product specific waiver for 5-{4-[(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- yl)methyl]-1-piperazinyl}-N-methyl-2-pyridinecarboxamide (EMEA-003447-PIP01-23) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T15:00:00Z","last_updated_date":"2024-10-04T15:00:00Z","reference_number":"EMA/380490/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0356-2023-ema-decision-8-september-2023-granting-product-specific-waiver-5-4-7-ethyl-6-oxo-56-dihydro-15-naphthyridin-3-ylmethyl-1-piperazinyl-n-methyl-2-pyridinecarboxamide-emea-003447-pip01-23_en.pdf"},
    {"id":"65178","name":"P/0359/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for baloxavir marboxil (Xofluza), (EMEA-002440-PIP01-18-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T16:00:00Z","last_updated_date":"2024-10-04T16:00:00Z","reference_number":"EMA/347368/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0359-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-baloxavir-marboxil-xofluza-emea-002440-pip01-18-m05_en.pdf"},
    {"id":"65179","name":"P/0360/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for norucholic acid (EMEA-002485-PIP01-18-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T16:00:00Z","last_updated_date":"2024-10-04T16:00:00Z","reference_number":"EMA/347454/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0360-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-norucholic-acid-emea-002485-pip01-18-m01_en.pdf"},
    {"id":"65180","name":"P/0361/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for rozanolixizumab (EMEA-002681-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T16:00:00Z","last_updated_date":"2024-10-04T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0361-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-rozanolixizumab-emea-002681-pip01-19-m02_en.pdf"},
    {"id":"65181","name":"P/0368/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for etranacogene dezaparvovec (Hemgenix), (EMEA-002722-PIP01-19-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T16:00:00Z","last_updated_date":"2024-10-04T16:00:00Z","reference_number":"EMA/385723/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0368-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-etranacogene-dezaparvovec-hemgenix-emea-002722-pip01-19-m03_en.pdf"},
    {"id":"65182","name":"P/0389/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for botaretigene sparoparvovec (EMEA-002827-PIP01-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T16:00:00Z","last_updated_date":"2024-10-04T16:00:00Z","reference_number":"EMA/351220/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0389-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-botaretigene-sparoparvovec-emea-002827-pip01-20-m02_en.pdf"},
    {"id":"65183","name":"P/0393/2023: EMA decision of 28 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tozinameran, tozinameran / famtozinameran (Comirnaty), (EMEA-002861-PIP02-20-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T16:00:00Z","last_updated_date":"2024-10-04T16:00:00Z","reference_number":"EMA/424284/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0393-2023-ema-decision-28-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-tozinameran-tozinameran-famtozinameran-comirnaty-emea-002861-pip02-20-m06_en.pdf"},
    {"id":"65185","name":"P/0373/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for elasomeran, elasomeran / imelasomeran, elasomeran / davesomeran, andusomeran (Spikevax), (EMEA-002893- PIP01-20-M04) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T16:00:00Z","last_updated_date":"2024-10-04T16:00:00Z","reference_number":"EMA/384557/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0373-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-elasomeran-elasomeran-imelasomeran-elasomeran-davesomeran-andusomeran-spikevax-emea-002893-pip01_en.pdf"},
    {"id":"65186","name":"P/0369/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1 (INZ-701) (EMEA-003232-P","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-10-04T17:00:00Z","last_updated_date":"2024-10-04T17:00:00Z","reference_number":"EMA/385776/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0369-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-ectonucleotide-pyrophosphatase-phosphodiesterase-1-fused-fc-fragment-igg1-inz_en.pdf"},
    {"id":"65189","name":"P/0363/2023: EMA decision of 8 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for substituted 3,7-dihydro-1H-purine-2,6-dione (BI 1358894) (EMEA-003319-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T09:00:00Z","last_updated_date":"2024-10-07T09:00:00Z","reference_number":"EMA/347592/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0363-2023-ema-decision-8-september-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-substituted-37-dihydro-1h-purine-26-dione-bi-1358894-emea-003319-pip02-22_en.pdf"},
    {"id":"65190","name":"P/0364/2023: EMA decision of 8 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for substituted 3,7-dihydro-1H-purine-2,6-dione (BI 1358894) (EMEA-003319-PIP03-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T09:00:00Z","last_updated_date":"2024-10-07T09:00:00Z","reference_number":"EMA/347724/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0364-2023-ema-decision-8-september-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-substituted-37-dihydro-1h-purine-26-dione-bi-1358894-emea-003319-pip03-22_en.pdf"},
    {"id":"65191","name":"P/0370/2023: EMA decision of 8 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for funobactam (EMEA-003326-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T09:00:00Z","last_updated_date":"2024-10-07T09:00:00Z","reference_number":"EMA/384157/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0370-2023-ema-decision-8-september-2023-agreement-paediatric-investigation-plan-granting-deferral-funobactam-emea-003326-pip01-22_en.pdf"},
    {"id":"65192","name":"P/0371/2023: EMA decision of 8 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dexpramipexole (dihydrochloride monohydrate) (EMEA-003328-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T09:00:00Z","last_updated_date":"2024-10-07T09:00:00Z","reference_number":"EMA/384173/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0371-2023-ema-decision-8-september-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dexpramipexole-dihydrochloride-monohydrate-emea-003328-pip01-22_en.pdf"},
    {"id":"65198","name":"P/0341/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara), (EMEA-000311-PIP04-13-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T09:30:00Z","last_updated_date":"2024-10-07T09:30:00Z","reference_number":"EMA/351971/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0341-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip04-13-m06_en.pdf"},
    {"id":"65199","name":"P/0347/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (Wegovy), (EMEA-001441-PIP07-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T09:40:00Z","last_updated_date":"2024-10-07T09:40:00Z","reference_number":"EMA/351981/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0347-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-semaglutide-wegovy-emea-001441-pip07-21-m01_en.pdf"},
    {"id":"65201","name":"P/0346/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab (Tremfya), (EMEA-001523-PIP02-14-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T10:00:00Z","last_updated_date":"2024-10-07T10:00:00Z","reference_number":"EMA/351984/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0346-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-guselkumab-tremfya-emea-001523-pip02-14-m03_en.pdf"},
    {"id":"65202","name":"P/0384/2023: EMA decision of 7 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab (Tremfya), (EMEA-001523-PIP03-18-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T10:10:00Z","last_updated_date":"2024-10-07T10:10:00Z","reference_number":"EMA/389483/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0384-2023-ema-decision-7-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-guselkumab-tremfya-emea-001523-pip03-18-m03_en.pdf"},
    {"id":"65208","name":"P/0386/2023: EMA decision of 7 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir alafenamide (Vemlidy), (EMEA-001584-PIP01-13-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T10:50:00Z","last_updated_date":"2024-10-07T10:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0386-2023-ema-decision-7-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-tenofovir-alafenamide-vemlidy-emea-001584-pip01-13-m07_en.pdf"},
    {"id":"65210","name":"P/0380/2023: EMA decision of 7 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for fostemsavir (tromethamine), (Rukobia), (EMEA-001687-PIP01-14-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T11:15:00Z","last_updated_date":"2024-10-07T11:15:00Z","reference_number":"EMA/388640/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0380-2023-ema-decision-7-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-fostemsavir-tromethamine-rukobia-emea-001687-pip01-14-m07_en.pdf"},
    {"id":"65211","name":"P/0376/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for risankizumab (Skyrizi), (EMEA-001776-PIP03-17-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T11:25:00Z","last_updated_date":"2024-10-07T11:25:00Z","reference_number":"EMA/351176/2023 Corr1","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0376-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-risankizumab-skyrizi-emea-001776-pip03-17-m01_en.pdf"},
    {"id":"65212","name":"P/0391/2023: EMA decision of 13 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for risankizumab (Skyrizi), (EMEA-001776-PIP04-17-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T11:45:00Z","last_updated_date":"2024-10-07T11:45:00Z","reference_number":"EMA/412625/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0391-2023-ema-decision-13-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-risankizumab-skyrizi-emea-001776-pip04-17-m01_en.pdf"},
    {"id":"65213","name":"P/0377/2023: EMA decision of 8 September 2023 on the acceptance of a modification of an agreed paediatric investigation plan for brexucabtagene autoleucel (Tecartus), (EMEA-001862-PIP01-15-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T11:50:00Z","last_updated_date":"2024-10-07T11:50:00Z","reference_number":"EMA/351212/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0377-2023-ema-decision-8-september-2023-acceptance-modification-agreed-paediatric-investigation-plan-brexucabtagene-autoleucel-tecartus-emea-001862-pip01-15-m03_en.pdf"},
    {"id":"65609","name":"P/0395/2023 : EMA decision of 6 October 2023 on the granting of a product specific waiver for bezuclastinib (EMEA-003445-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-13T15:09:24Z","last_updated_date":"2024-11-13T15:09:24Z","reference_number":"EMA/401516/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0395-2023-ema-decision-6-october-2023-granting-product-specific-waiver-bezuclastinib-emea-003445-pip01-23_en.pdf"},
    {"id":"65610","name":"P/0401/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for enpatoran (EMEA-003342-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-13T15:16:17Z","last_updated_date":"2024-11-13T15:16:17Z","reference_number":"EMA/400468/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0401-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-enpatoran-emea-003342-pip02-22_en.pdf"},
    {"id":"65611","name":"P/0402/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inhibitor of receptor-interacting protein kinase 1 (ABBV-668), (EMEA-003356-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-13T15:33:53Z","last_updated_date":"2024-11-13T15:33:53Z","reference_number":"EMA/400519/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0402-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-inhibitor-receptor-interacting-protein-kinase-1-abbv-668-emea-003356-pip01-22_en.pdf"},
    {"id":"65614","name":"P/0403/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nemvaleukin alfa (EMEA-003357-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-13T15:55:46Z","last_updated_date":"2024-11-13T15:55:46Z","reference_number":"EMA/400609/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0403-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-nemvaleukin-alfa-emea-003357-pip01-22_en.pdf"},
    {"id":"65617","name":"P/0404/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a waiver for recombinant Neisseria meningitis group B Protein 936-741......(MenACWY-7B vaccine) (EMEA-003359-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-13T16:14:37Z","last_updated_date":"2024-11-13T16:14:37Z","reference_number":"EMA/400645/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0404-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-waiver-recombinant-neisseria-meningitis-group-b-protein-936-741menacwy-7b-vaccine-emea-003359-pip01-22_en.pdf"},
    {"id":"65635","name":"P/0405/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for tiragolumab (EMEA-002721-PIP04-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-14T12:41:35Z","last_updated_date":"2024-11-14T12:41:35Z","reference_number":"EMA/429200/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0405-2023-ema-decision-27-october-2023-granting-product-specific-waiver-tiragolumab-emea-002721-pip04-23_en.pdf"},
    {"id":"65636","name":"P/0406/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for genetically detoxified pertussis toxin (PTgen) / pertussis filamentous haemagglutinin (FHA) (EMEA-003442-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-14T12:50:52Z","last_updated_date":"2024-11-14T12:50:52Z","reference_number":"EMA/429431/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0406-2023-ema-decision-27-october-2023-granting-product-specific-waiver-genetically-detoxified-pertussis-toxin-ptgen-pertussis-filamentous-haemagglutinin-fha-emea-003442-pip01-23_en.pdf"},
    {"id":"65637","name":"P/0407/2023 : EMA decision of 25 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tezepelumab (Tezspire), (EMEA-001613-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-14T13:00:09Z","last_updated_date":"2024-11-14T13:00:09Z","reference_number":"EMA/469059/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0407-2023-ema-decision-25-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tezepelumab-tezspire-emea-001613-pip03-21_en.pdf"},
    {"id":"65641","name":"P/0409/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for actinium chloride (non-carrier added) (EMEA-003482- PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-14T14:06:41Z","last_updated_date":"2024-11-14T14:06:41Z","reference_number":"EMA/424785/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0409-2023-ema-decision-27-october-2023-granting-product-specific-waiver-actinium-chloride-non-carrier-added-emea-003482-pip01-23_en.pdf"},
    {"id":"65642","name":"P/0413/2023 : EMA decision of 25 October 2023 on the granting of a product specific waiver for ulviprubart (EMEA-003474-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-14T14:16:13Z","last_updated_date":"2024-11-14T14:16:13Z","reference_number":"EMA/469144/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0413-2023-ema-decision-25-october-2023-granting-product-specific-waiver-ulviprubart-emea-003474-pip01-23_en.pdf"},
    {"id":"65683","name":"P/0420/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rozanolixizumab (EMEA-002681-PIP03-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T16:21:27Z","last_updated_date":"2024-11-15T16:21:27Z","reference_number":"EMA/421682/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0420-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rozanolixizumab-emea-002681-pip03-21_en.pdf"},
    {"id":"65684","name":"P/0421/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for ciraparantag (EMEA-003321-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T16:30:34Z","last_updated_date":"2024-11-15T16:30:34Z","reference_number":"EMA/429548/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0421-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-ciraparantag-emea-003321-pip01-22_en.pdf"},
    {"id":"65685","name":"P/0424/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a waiver for vibostolimab / pembrolizumab (EMEA-003063-PIP03-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T16:35:36Z","last_updated_date":"2024-11-15T16:35:36Z","reference_number":"EMA/429589/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0424-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-waiver-vibostolimab-pembrolizumab-emea-003063-pip03-22_en.pdf"},
    {"id":"65686","name":"P/0425/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for 2-((R)-3-(1-(1-((R)-1-(2,4-dichlorophenyl)ethyl)-3- (trifluoromethyl)-......benzenesulfonate,(EMEA-003455-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T16:41:22Z","last_updated_date":"2024-11-15T16:41:22Z","reference_number":"EMA/469371/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0425-2023-ema-decision-27-october-2023-granting-product-specific-waiver-2-r-3-1-1-r-1-24-dichlorophenylethyl-3-trifluoromethyl-benzenesulfonateemea-003455-pip01-23_en.pdf"},
    {"id":"65687","name":"P/0426/2023 : EMA decision of 27 October 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for haematopoietic stem cells and blood progenitors umbilical cord-derived...dihydrate (ECT001-CB), (EMEA-003025-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T16:49:00Z","last_updated_date":"2024-11-15T16:49:00Z","reference_number":"EMA/424694/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0426-2023-ema-decision-27-october-2024-agreement-paediatric-investigation-plan-granting-deferral-haematopoietic-stem-cells-blood-progenitors-umbilical-cord-deriveddihydrate-ect001-cb-emea-003025_en.pdf"},
    {"id":"65702","name":"P/0427/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for 2-[3-(dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-oxan-4- yl(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol, (EMEA-003456-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T10:25:45Z","last_updated_date":"2024-11-19T10:25:45Z","reference_number":"EMA/469615/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0427-2023-ema-decision-27-october-2023-granting-product-specific-waiver-2-3-dimethyl-1h-123-triazol-5-yl-5-s-oxan-4-ylphenylmethyl-5h-pyrido32-bindol-7-ylpropan-2-ol-emea-003456-pip01-23_en.pdf"},
    {"id":"65703","name":"P/0428/2023 : EMA decision of 27 October on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for derivative of 6‐(piperidine‐1‐carbonyl)pyridin‐3‐ol (BI 764198), (EMEA-003347-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T10:40:12Z","last_updated_date":"2024-11-19T10:40:12Z","reference_number":"EMA/424721/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0428-2023-ema-decision-27-october-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-derivative-6-piperidine-1-carbonylpyridin-3-ol-bi-764198-emea-003347-pip01-22_en.pdf"},
    {"id":"65704","name":"P/0429/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for humanised IgG1 monoclonal antibody against TROP2, conjugated to a topoisomerase I inhibitor belotecan-derivative, (EMEA-003461-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T10:51:34Z","last_updated_date":"2024-11-19T10:51:34Z","reference_number":"EMA/469858/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0429-2023-ema-decision-27-october-2023-granting-product-specific-waiver-humanised-igg1-monoclonal-antibody-against-trop2-conjugated-topoisomerase-i-inhibitor-belotecan-derivative-emea-003461-pip01_en.pdf"},
    {"id":"65705","name":"P/0430/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inaxaplin, (EMEA-003368-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T11:51:23Z","last_updated_date":"2024-11-19T11:51:23Z","reference_number":"EMA/424746/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0430-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-inaxaplin-emea-003368-pip01-22_en.pdf"},
    {"id":"65706","name":"P/0431/2023 : EMA decision of on the granting of a product specific waiver for modified recombinant version of the human myeloid-derived growth factor (EMEA-003449-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T12:01:35Z","last_updated_date":"2024-11-19T12:01:35Z","reference_number":"EMA/424754/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0431-2023-ema-decision-granting-product-specific-waiver-modified-recombinant-version-human-myeloid-derived-growth-factor-emea-003449-pip01-23_en.pdf"},
    {"id":"65708","name":"P/0432/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for self-complementary adeno-associated virus [AAV]......(DTX301) (EMEA-002830- PIP01-20)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T14:56:11Z","last_updated_date":"2024-11-19T14:56:11Z","reference_number":"EMA/470006/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0432-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-self-complementary-adeno-associated-virus-aavdtx301-emea-002830-pip01-20_en.pdf"},
    {"id":"65709","name":"P/0433/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for zanidatamab (EMEA-003450-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T15:04:54Z","last_updated_date":"2024-11-19T15:04:54Z","reference_number":"EMA/424762/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0433-2023-ema-decision-27-october-2023-granting-product-specific-waiver-zanidatamab-emea-003450-pip01-23_en.pdf"},
    {"id":"65710","name":"P/0433/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for zanidatamab (EMEA-003450-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T15:17:38Z","last_updated_date":"2024-11-19T15:17:38Z","reference_number":"EMA/424762/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0433-2023-ema-decision-27-october-2023-granting-product-specific-waiver-zanidatamab-emea-003450-pip01-23_en.pdf-0"},
    {"id":"65711","name":"P/0435/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for xalnesiran, (EMEA-003362-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T15:34:18Z","last_updated_date":"2024-11-19T15:34:18Z","reference_number":"EMA/470007/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0435-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-xalnesiran-emea-003362-pip01-22_en.pdf"},
    {"id":"65712","name":"P/0436/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for amlodipine / rosuvastatin (EMEA-003446-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T15:41:30Z","last_updated_date":"2024-11-19T15:41:30Z","reference_number":"EMA/401517/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0436-2023-ema-decision-27-october-2023-granting-product-specific-waiver-amlodipine-rosuvastatin-emea-003446-pip01-23_en.pdf"},
    {"id":"65729","name":"P/0437/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for uproleselan (EMEA-003307-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-20T15:44:17Z","last_updated_date":"2024-11-20T15:44:17Z","reference_number":"EMA/401558/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0437-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-uproleselan-emea-003307-pip01-22_en.pdf"},
    {"id":"65731","name":"P/0438/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for pabinafusp alfa (EMEA-003033-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-20T15:52:46Z","last_updated_date":"2024-11-20T15:52:46Z","reference_number":"EMA/401556/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0438-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-pabinafusp-alfa-emea-003033-pip02-22_en.pdf"},
    {"id":"65735","name":"P/0441/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for luspatercept (Reblozyl), (EMEA-001521-PIP03-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-20T15:58:56Z","last_updated_date":"2024-11-20T15:58:56Z","reference_number":"EMA/401553/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0441-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-luspatercept-reblozyl-emea-001521-pip03-22_en.pdf"},
    {"id":"65736","name":"P/0444/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ruzotolimod, (EMEA-003363-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-20T16:10:59Z","last_updated_date":"2024-11-20T16:10:59Z","reference_number":"EMA/470008/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0444-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ruzotolimod-emea-003363-pip01-22_en.pdf"},
    {"id":"65737","name":"P/0445/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Neisseria meningitidis group A.....(MenPenta vaccine) (EMEA-003379-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-20T16:20:10Z","last_updated_date":"2024-11-20T16:20:10Z","reference_number":"EMA/470009/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0445-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-neisseria-meningitidis-group-amenpenta-vaccine-emea-003379-pip01-22_en.pdf"},
    {"id":"65738","name":"P/0446/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a waiver for upadacitinib (Rinvoq), (EMEA-001741-PIP08-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-20T16:31:58Z","last_updated_date":"2024-11-20T16:31:58Z","reference_number":"EMA/478348/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0446-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-waiver-upadacitinib-rinvoq-emea-001741-pip08-22_en.pdf"},
    {"id":"65740","name":"P/0450/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for iptacopan (EMEA-002705-PIP05-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-20T16:37:14Z","last_updated_date":"2024-11-20T16:37:14Z","reference_number":"EMA/481244/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0450-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-iptacopan-emea-002705-pip05-23_en.pdf"},
    {"id":"65741","name":"P/0451/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for upadacitinib (Rinvoq), (EMEA-001741-PIP09-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-20T16:43:08Z","last_updated_date":"2024-11-20T16:43:08Z","reference_number":"EMA/481596/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0451-2023-ema-decision-27-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-upadacitinib-rinvoq-emea-001741-pip09-23_en.pdf"},
    {"id":"65746","name":"P/0396/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP02-13-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-21T11:21:01Z","last_updated_date":"2024-11-21T11:21:01Z","reference_number":"EMA/468097/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0396-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip02-13-m08_en.pdf"},
    {"id":"65747","name":"P/0397/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for eravacycline (Xerava), (EMEA-001555-PIP01-13-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-21T11:25:27Z","last_updated_date":"2024-11-21T11:25:27Z","reference_number":"EMA/468349/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0397-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-eravacycline-xerava-emea-001555-pip01-13-m05_en.pdf"},
    {"id":"65748","name":"P/0398/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for brivaracetam (Briviact), (EMEA-000332-PIP02-17-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-21T11:37:08Z","last_updated_date":"2024-11-21T11:37:08Z","reference_number":"EMA/400670/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0398-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-brivaracetam-briviact-emea-000332-pip02-17-m05_en.pdf"},
    {"id":"65749","name":"P/0399/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for eptinezumab (Vyepti), (EMEA-002243-PIP01-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-21T11:41:38Z","last_updated_date":"2024-11-21T11:41:38Z","reference_number":"EMA/400367/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0399-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-eptinezumab-vyepti-emea-002243-pip01-17-m04_en.pdf"},
    {"id":"65750","name":"P/0400/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for evenamide (EMEA-002519-PIP03-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-21T11:56:53Z","last_updated_date":"2024-11-21T11:56:53Z","reference_number":"EMA/400402/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0400-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-evenamide-emea-002519-pip03-21-m01_en.pdf"},
    {"id":"65751","name":"P/0408/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for carfilzomib (Kyprolis), (EMEA-001806-PIP04-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-21T13:33:06Z","last_updated_date":"2024-11-21T13:33:06Z","reference_number":"EMA/429693/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0408-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-carfilzomib-kyprolis-emea-001806-pip04-19-m02_en.pdf"},
    {"id":"65752","name":"P/0410/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for fitusiran (EMEA- 001855-PIP01-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-21T13:37:53Z","last_updated_date":"2024-11-21T13:37:53Z","reference_number":"EMA/429873/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0410-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-fitusiran-emea-001855-pip01-15-m05_en.pdf"},
    {"id":"65754","name":"P/0453/2023 EMA decision of of 13 November 2023 on the acceptance of a modification of an agreed paediatric investigation plan for remibrutinib (EMEA- 002582-PIP01-19-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T10:50:00Z","last_updated_date":"2024-11-22T10:50:00Z","reference_number":"EMA/486074/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0453-2023-ema-decision-13-november-2023-acceptance-modification-agreed-paediatric-investigation-plan-remibrutinib-emea-002582-pip01-19-m03_en.pdf"},
    {"id":"65758","name":"P/0483/2023: EMA decision of 30 November 2023 on the acceptance of a modification of an agreed paediatric investigation plan for pegzilarginase (EMEA-001925-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T11:05:00Z","last_updated_date":"2024-11-22T11:05:00Z","reference_number":"EMA/494317/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0483-2023-ema-decision-30-november-2023-acceptance-modification-agreed-paediatric-investigation-plan-pegzilarginase-emea-001925-pip02-19-m01_en.pdf"},
    {"id":"65762","name":"P/0484/2023: EMA decision of 30 November 2023 on the acceptance of a modification of an agreed paediatric investigation plan for human fibrinogen concentrate (BT524) (EMEA-001931-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T11:30:00Z","last_updated_date":"2024-11-22T11:30:00Z","reference_number":"EMA/494326/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0484-2023-ema-decision-30-november-2023-acceptance-modification-agreed-paediatric-investigation-plan-human-fibrinogen-concentrate-bt524-emea-001931-pip01-16-m03_en.pdf"},
    {"id":"65763","name":"P/0482/2023: EMA decision of 30 November 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris), (EMEA-001943-PIP04-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T11:40:00Z","last_updated_date":"2024-11-22T11:40:00Z","reference_number":"EMA/494329/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0482-2023-ema-decision-30-november-2023-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris-emea-001943-pip04-20-m01_en.pdf"},
    {"id":"65764","name":"P/0454/2023: EMA decision of 9 November 2023 on the acceptance of a modification of an agreed paediatric investigation plan for abrocitinib (Cibinqo), (EMEA-002312-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T11:45:00Z","last_updated_date":"2024-11-22T11:45:00Z","reference_number":"EMA/494437/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0454-2023-ema-decision-9-november-2023-acceptance-modification-agreed-paediatric-investigation-plan-abrocitinib-cibinqo-emea-002312-pip01-17-m02_en.pdf"},
    {"id":"65765","name":"P/0501/2023: EMA decision of 24 November 2023 on the acceptance of a modification of an agreed paediatric investigation plan for live-attenuated La Reunion strain of chikungunya virus (VLA1553) (EMEA-002873-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T12:00:00Z","last_updated_date":"2024-11-22T12:00:00Z","reference_number":"EMA/533540/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0501-2023-ema-decision-24-november-2023-acceptance-modification-agreed-paediatric-investigation-plan-live-attenuated-la-reunion-strain-chikungunya-virus-vla1553-emea-002873-pip01-20-m01_en.pdf"},
    {"id":"65766","name":"P/0487/2023: EMA decision of 30 November 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for govorestat (EMEA-003365-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T12:15:00Z","last_updated_date":"2024-11-22T12:15:00Z","reference_number":"EMA/530837/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0487-2023-ema-decision-30-november-2023-agreement-paediatric-investigation-plan-granting-deferral-govorestat-emea-003365-pip02-23_en.pdf"},
    {"id":"65767","name":"P/0486/2023: EMA decision of 30 November 2023 on the granting of a product specific waiver for glyceryl trinitrate (Nitromint), (EMEA-003479-PIP01- 23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T12:45:00Z","last_updated_date":"2024-11-22T12:45:00Z","reference_number":"EMA/494466/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0486-2023-ema-decision-30-november-2023-granting-product-specific-waiver-glyceryl-trinitrate-nitromint-emea-003479-pip01-23_en.pdf"},
    {"id":"65768","name":"P/0412/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for onasemnogene abeparvovec (Zolgensma), (EMEA-002168-PIP01-17-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T12:46:50Z","last_updated_date":"2024-11-22T12:46:50Z","reference_number":"EMA/429976/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0412-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-onasemnogene-abeparvovec-zolgensma-emea-002168-pip01-17-m05_en.pdf"},
    {"id":"65769","name":"P/0414/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for cemiplimab (Libtayo), (EMEA-002007-PIP02-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T12:51:13Z","last_updated_date":"2024-11-22T12:51:13Z","reference_number":"EMA/430045/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0414-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-cemiplimab-libtayo-emea-002007-pip02-17-m03_en.pdf"},
    {"id":"65770","name":"P/0415/2023 : EMA decision of 25 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for angiotensin II (LJPC-501), (Giapreza), (EMEA-001912-PIP02-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T12:57:30Z","last_updated_date":"2024-11-22T12:57:30Z","reference_number":"EMA/469423/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0415-2023-ema-decision-25-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-angiotensin-ii-ljpc-501-giapreza-emea-001912-pip02-16-m03_en.pdf"},
    {"id":"65771","name":"P/0416/2023 : EMA decision of 25 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for vonicog alfa (Veyvondi), (EMEA-001164-PIP01-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T13:01:33Z","last_updated_date":"2024-11-22T13:01:33Z","reference_number":"EMA/469263/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0416-2023-ema-decision-25-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-vonicog-alfa-veyvondi-emea-001164-pip01-11-m07_en.pdf"},
    {"id":"65772","name":"P/0417/2023 : EMA decision of 25 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for selexipag (Uptravi), (EMEA-000997-PIP01-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-22T13:05:29Z","last_updated_date":"2024-11-22T13:05:29Z","reference_number":"EMA/469191/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0417-2023-ema-decision-25-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-selexipag-uptravi-emea-000997-pip01-10-m07_en.pdf"},
    {"id":"65782","name":"P/0418/2023 : EMA decision of 25 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for fosnetupitant / palonosetron (Akynzeo), (EMEA-001198-PIP03-17-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-25T11:30:30Z","last_updated_date":"2024-11-25T11:30:30Z","reference_number":"EMA/469388/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0418-2023-ema-decision-25-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-fosnetupitant-palonosetron-akynzeo-emea-001198-pip03-17-m05_en.pdf"},
    {"id":"65783","name":"P/0419/2023 : EMA decision of 25 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon beta-1a (Plegridy), (EMEA-001129-PIP01-11-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-25T11:36:20Z","last_updated_date":"2024-11-25T11:36:20Z","reference_number":"EMA/469210/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0419-2023-ema-decision-25-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-peginterferon-beta-1a-plegridy-emea-001129-pip01-11-m06_en.pdf"},
    {"id":"65784","name":"P/0423/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for severe acute respiratory syndrome coronavirus 2 recombinant spike protein......(Nuvaxovid) (EMEA-002941-PIP01-20-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-25T11:41:59Z","last_updated_date":"2024-11-25T11:41:59Z","reference_number":"EMA/424655/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0423-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-severe-acute-respiratory-syndrome-coronavirus-2-recombinant-spike-proteinnuvaxovid-emea-002941_en.pdf"},
    {"id":"65832","name":"P/0440/2023 : EMA decision of 27 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for autologous tumour-infiltrating lymphocytes (LN-144/LN-145) (EMEA-002776-PIP01-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-27T12:12:44Z","last_updated_date":"2024-11-27T12:12:44Z","reference_number":"EMA/401495/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0440-2023-ema-decision-27-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-autologous-tumour-infiltrating-lymphocytes-ln-144-ln-145-emea-002776-pip01-20-m02_en.pdf"},
    {"id":"65833","name":"P/0442/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tovorafenib (EMEA- 002763-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-27T12:25:06Z","last_updated_date":"2024-11-27T12:25:06Z","reference_number":"EMA/401494/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0442-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-tovorafenib-emea-002763-pip01-20-m01_en.pdf"},
    {"id":"65834","name":"P/0443/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for iptacopan (EMEA- 002705-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-27T12:32:13Z","last_updated_date":"2024-11-27T12:32:13Z","reference_number":"EMA/401493/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0443-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-iptacopan-emea-002705-pip02-19-m01_en.pdf"},
    {"id":"65861","name":"P/0447/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for nirmatrelvir, nirmatrelvir / ritonavir (Paxlovid), (EMEA-003081-PIP01-21-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-28T12:19:12Z","last_updated_date":"2024-11-28T12:19:12Z","reference_number":"EMA/478540/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0447-2023-ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-nirmatrelvir-nirmatrelvir-ritonavir-paxlovid-emea-003081-pip01-21-m03_en.pdf"},
    {"id":"65862","name":"EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for lisocabtagene maraleucel (Breyanzi), (EMEA-001995-PIP01-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-28T12:26:52Z","last_updated_date":"2024-11-28T12:26:52Z","reference_number":"EMA/479827/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-decision-27-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-lisocabtagene-maraleucel-breyanzi-emea-001995-pip01-16-m04_en.pdf"},
    {"id":"65863","name":"P/0452/2023 : EMA decision of 31 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP03-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-28T12:42:01Z","last_updated_date":"2024-11-28T12:42:01Z","reference_number":"EMA/486034/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0452-2023-ema-decision-31-october-2023-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip03-16-m04_en.pdf"},
    {"id":"66233","name":"P/0434/2023 : EMA decision of 27 October 2023 on the granting of a product specific waiver for belrestotug (EMEA-003452-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2024-11-19T10:16:47Z","last_updated_date":"2024-11-19T10:16:47Z","reference_number":"EMA/424775/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0434-2023-ema-decision-27-october-2023-granting-product-specific-waiver-belrestotug-emea-003452-pip01-23_en.pdf"},
    {"id":"66696","name":"P/0144/2024: EMA decision of May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for tozorakimab (EMEA-003360-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-12T12:11:13Z","last_updated_date":"2025-02-12T12:11:13Z","reference_number":"EMA/148128/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0144-2024-ema-decision-may-2024-agreement-paediatric-investigation-plan-granting-deferral-tozorakimab-emea-003360-pip01-22_en.pdf"},
    {"id":"66698","name":"P/0273/2024: EMA decision of 14 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan and on the granting of a waiver for COVID-19 vaccine (ChAdOx1-S [recombinant]), (EMEA-002862-PIP01-20-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-12T14:04:17Z","last_updated_date":"2025-02-12T14:04:17Z","reference_number":"EMA/307483/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0273-2024-ema-decision-14-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-granting-waiver-covid-19-vaccine-chadox1-s-recombinant-emea-002862-pip01-20-m04_en.pdf"},
    {"id":"66713","name":"P/0530/2023: EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for meropenem / vaborbactam (Vaborem), (EMEA-001731-PIP01-14-M04)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T09:51:33Z","last_updated_date":"2025-02-13T09:51:33Z","reference_number":"EMA/513383/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0530-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-meropenem-vaborbactam-vaborem-emea-001731-pip01-14-m04_en.pdf"},
    {"id":"66715","name":"P/0509/2023 : EMA decision of 29 December 2023 on the granting of a product specific waiver for DNA plasmid encoding HPV type 16 consensus E6 and E7 proteins (pGX 3001) / DNA plasmid encoding HPV type 18 consensus......(pGX3002) (EMEA-002022-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T10:45:10Z","last_updated_date":"2025-02-13T10:45:10Z","reference_number":"EMA/554989/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0509-2023-ema-decision-29-december-2023-granting-product-specific-waiver-dna-plasmid-encoding-hpv-type-16-consensus-e6-e7-proteins-pgx-3001-dna-plasmid-encoding-hpv-type-18-consensuspgx3002-emea_en.pdf"},
    {"id":"66716","name":"P/0531/2023: EMA decision of 29 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inebilizumab (Uplizna), (EMEA-001911-PIP03-23) ","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T10:57:03Z","last_updated_date":"2025-02-13T10:57:03Z","reference_number":"EMA/514061/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0531-2023-ema-decision-29-december-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-inebilizumab-uplizna-emea-001911-pip03-23_en.pdf"},
    {"id":"66717","name":"P/0516/2023 : EMA decision of 29 December 2023 on the agreement of a paediatric investigation plan and on the granting of a waiver for 3-(4- acetamidophenyl)-2-(S)-methoxypropionic acid, or (S)-3-(4-acetamidophenyl)-2.....(EMEA-002674-PIP01-19)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T11:01:52Z","last_updated_date":"2025-02-13T11:01:52Z","reference_number":"EMA/555066/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0516-2023-ema-decision-29-december-2023-agreement-paediatric-investigation-plan-granting-waiver-3-4-acetamidophenyl-2-s-methoxypropionic-acid-or-s-3-4-acetamidophenyl-2emea-002674-pip01-19_en.pdf"},
    {"id":"66718","name":"P/0532/2023: EMA decision of 29 December 2023 on the granting of a product specific waiver for retifanlimab (EMEA-002798-PIP04-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T11:09:47Z","last_updated_date":"2025-02-13T11:09:47Z","reference_number":"EMA/517071/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0532-2023-ema-decision-29-december-2023-granting-product-specific-waiver-retifanlimab-emea-002798-pip04-23_en.pdf"},
    {"id":"66719","name":"P/0533/2023: EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for delgocitinib (EMEA- 002329-PIP02-20-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T11:15:59Z","last_updated_date":"2025-02-13T11:15:59Z","reference_number":"EMA/562870/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0533-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-delgocitinib-emea-002329-pip02-20-m03_en.pdf"},
    {"id":"66720","name":"P/0517/2023 : EMA decision of 29 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for complement factor B antisense oligonucleotide (RO7434656) (EMEA-003396- PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T11:18:07Z","last_updated_date":"2025-02-13T11:18:07Z","reference_number":"EMA/555156/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0517-2023-ema-decision-29-december-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-complement-factor-b-antisense-oligonucleotide-ro7434656-emea-003396-pip01-23_en.pdf"}    {"id":"66721","name":"P/0534/2023: EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for mirikizumab (Omvoh), (EMEA-002208-PIP01-17-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T11:21:56Z","last_updated_date":"2025-02-13T11:21:56Z","reference_number":"EMA/562674/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0534-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-mirikizumab-omvoh-emea-002208-pip01-17-m03_en.pdf"},
    {"id":"66722","name":"P/0534/2023: EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for mirikizumab (Omvoh), (EMEA-002208-PIP01-17-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T11:37:45Z","last_updated_date":"2025-02-13T11:37:45Z","reference_number":"EMA/562674/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0534-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-mirikizumab-omvoh-emea-002208-pip01-17-m03_en.pdf-0"},
    {"id":"66723","name":"P/0521/2023 : EMA decision of 29 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for modified messenger ribonucleic acid encoding human propionyl-coenzyme a carboxylase alpha.......(EMEA-003419-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T11:40:21Z","last_updated_date":"2025-02-13T11:40:21Z","reference_number":"EMA/553376/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0521-2023-ema-decision-29-december-2023-agreement-paediatric-investigation-plan-granting-deferral-modified-messenger-ribonucleic-acid-encoding-human-propionyl-coenzyme-carboxylase-alphaemea-003419_en.pdf"},
    {"id":"66724","name":"P/0518/2023 : EMA decision of 29 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for allogeneic cultured postnatal thymus-derived tissue (EMEA-003496-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T11:50:48Z","last_updated_date":"2025-02-13T11:50:48Z","reference_number":"EMA/554964/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0518-2023-ema-decision-29-december-2023-agreement-paediatric-investigation-plan-granting-deferral-allogeneic-cultured-postnatal-thymus-derived-tissue-emea-003496-pip01-23_en.pdf"},
    {"id":"66725","name":"P/0514/2023 : EMA decision of 29 December 2023 on the granting of a product specific waiver for oregovomab (EMEA-003497-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T11:58:28Z","last_updated_date":"2025-02-13T11:58:28Z","reference_number":"EMA/554788/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0514-2023-ema-decision-29-december-2023-granting-product-specific-waiver-oregovomab-emea-003497-pip01-23_en.pdf"},
    {"id":"66726","name":"EMA decision of 29 December 2023 on the granting of a product specific waiver for humanised IgG1kappa monoclonal antibody directed against IGF-1R (EMEA-003499-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T12:30:39Z","last_updated_date":"2025-02-13T12:30:39Z","reference_number":"EMA/553374/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-decision-29-december-2023-granting-product-specific-waiver-humanised-igg1kappa-monoclonal-antibody-directed-against-igf-1r-emea-003499-pip01-23_en.pdf"},
    {"id":"66727","name":"P/0527/2023 : EMA decision of 29 December 2023 on the granting of a product specific waiver for baxdrostat (EMEA-003507-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T12:40:21Z","last_updated_date":"2025-02-13T12:40:21Z","reference_number":"EMA/553372/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0527-2023-ema-decision-29-december-2023-granting-product-specific-waiver-baxdrostat-emea-003507-pip01-23_en.pdf"},
    {"id":"66728","name":"P/0535/2023: EMA decision of 29 December 2023 on the granting of a product specific waiver for lotilaner (EMEA-003488-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T13:09:49Z","last_updated_date":"2025-02-13T13:09:49Z","reference_number":"EMA/562497/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0535-2023-ema-decision-29-december-2023-granting-product-specific-waiver-lotilaner-emea-003488-pip01-23_en.pdf"},
    {"id":"66729","name":"P/0536/2023: EMA decision of 29 December 2023 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for olutasidenib (EMEA-003421-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T13:14:20Z","last_updated_date":"2025-02-13T13:14:20Z","reference_number":"EMA/562549/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0536-2023-ema-decision-29-december-2023-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-olutasidenib-emea-003421-pip01-23_en.pdf"},
    {"id":"66730","name":"P/0537/2023: EMA decision of 29 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for taldefgrobep alfa (EMEA-003386-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T13:20:11Z","last_updated_date":"2025-02-13T13:20:11Z","reference_number":"EMA/517439/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0537-2023-ema-decision-29-december-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-taldefgrobep-alfa-emea-003386-pip01-22_en.pdf"},
    {"id":"66731","name":"P/0538/2023: EMA decision of 29 December 2023 on the granting of a product specific waiver for diflunisal (EMEA-003490-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T13:26:20Z","last_updated_date":"2025-02-13T13:26:20Z","reference_number":"EMA/517747/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0538-2023-ema-decision-29-december-2023-granting-product-specific-waiver-diflunisal-emea-003490-pip01-23_en.pdf"},
    {"id":"66732","name":"P/0539/2023: EMA decision of 29 December 2023 on the granting of a product specific waiver for sitagliptin / dapagliflozin (EMEA-003486-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T13:33:30Z","last_updated_date":"2025-02-13T13:33:30Z","reference_number":"EMA/562282/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0539-2023-ema-decision-29-december-2023-granting-product-specific-waiver-sitagliptin-dapagliflozin-emea-003486-pip01-23_en.pdf"},
    {"id":"66733","name":"P/0540/2023: EMA decision of 29 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for modified mRNA encoding human methylmalonyl-coenzyme A mutase containing a polymorphism at position 671 (mRNA-3705)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T13:38:46Z","last_updated_date":"2025-02-13T13:38:46Z","reference_number":"EMA/562327/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0540-2023-ema-decision-29-december-2023-agreement-paediatric-investigation-plan-granting-deferral-modified-mrna-encoding-human-methylmalonyl-coenzyme-mutase-containing-polymorphism-position-671-mrna_en.pdf"},
    {"id":"66737","name":"P/0541/2023: EMA decision of 14 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for birch bark extract (Filsuvez), (EMEA-001299-PIP03-17-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T14:03:15Z","last_updated_date":"2025-02-13T14:03:15Z","reference_number":"EMA/571559/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0541-2023-ema-decision-14-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-birch-bark-extract-filsuvez-emea-001299-pip03-17-m03_en.pdf"},
    {"id":"66740","name":"P/0542/2023: EMA decision of 21 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for amlitelimab (EMEA-003233-PIP01-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T14:08:02Z","last_updated_date":"2025-02-13T14:08:02Z","reference_number":"EMA/566037/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0542-2023-ema-decision-21-december-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-amlitelimab-emea-003233-pip01-22_en.pdf"},
    {"id":"66746","name":"P/0543/2023: EMA decision of 21 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cedazuridine / decitabine, (EMEA-003071-PIP02-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T15:32:55Z","last_updated_date":"2025-02-13T15:32:55Z","reference_number":"EMA/564095/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0543-2023-ema-decision-21-december-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cedazuridine-decitabine-emea-003071-pip02-23_en.pdf"},
    {"id":"66747","name":"P/0544/2023: EMA decision of 20 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R,4R)-N1-(2-benzyl-7-(2-methyl- 2H-tetr","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T15:38:12Z","last_updated_date":"2025-02-13T15:38:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0544-2023-ema-decision-20-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-haematopoietic-stem-cells-blood-progenitors-umbilical-cord-derived-expanded-1r4r-n1-2-benzyl-7-2_en.pdf"},
    {"id":"66756","name":"P/0494/2023: EMA decision of 1 December 2023 on the granting of a product specific waiver for humanized IgG1 blocking monoclonal antibody targeting CD39 (IPH5201), (EMEA-003469-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-13T16:36:04Z","last_updated_date":"2025-02-13T16:36:04Z","reference_number":"EMA/517389/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0494-2023-ema-decision-1-december-2023-granting-product-specific-waiver-humanized-igg1-blocking-monoclonal-antibody-targeting-cd39-iph5201-emea-003469-pip01-23_en.pdf"},
    {"id":"66757","name":"P/0495/2023: EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for ebola Zaire vaccine (rVSVΔG-ZEBOV-GP, live) (Ervebo), (EMEA-001786-PIP01-15-M03) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-13T16:44:42Z","last_updated_date":"2025-02-13T16:44:42Z","reference_number":"EMA/516932/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0495-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-ebola-zaire-vaccine-rvsvdg-zebov-gp-live-ervebo-emea-001786-pip01-15-m03_en.pdf"},
    {"id":"66762","name":"P/0496/2023: EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for pridopidine (hydrochloride) (EMEA-003174-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-13T16:56:18Z","last_updated_date":"2025-02-13T16:56:18Z","reference_number":"EMA/531238/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0496-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-pridopidine-hydrochloride-emea-003174-pip01-21-m01_en.pdf"},
    {"id":"66773","name":"P/0497/2023: EMA decision of of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for glycopyrronium bromide (Axhidrox), (EMEA-002383-PIP01-18-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-14T13:03:52Z","last_updated_date":"2025-02-14T13:03:52Z","reference_number":"EMA/532192/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0497-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-glycopyrronium-bromide-axhidrox-emea-002383-pip01-18-m03_en.pdf"},
    {"id":"66785","name":"P/0520/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP01-11-M09)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T14:10:37Z","last_updated_date":"2025-02-14T14:10:37Z","reference_number":"EMA/561779/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0520-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip01-11-m09_en.pdf"},
    {"id":"66786","name":"P/0526/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for filgotinib (Jyseleca), (EMEA-001619-PIP03-16-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T14:21:21Z","last_updated_date":"2025-02-14T14:21:21Z","reference_number":"EMA/561838/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0526-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-filgotinib-jyseleca-emea-001619-pip03-16-m02_en.pdf"},
    {"id":"66787","name":"P/0519/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for satralizumab (Enspyng), (EMEA-001625-PIP01-14-M07)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T14:30:04Z","last_updated_date":"2025-02-14T14:30:04Z","reference_number":"EMA/554543/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0519-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-satralizumab-enspyng-emea-001625-pip01-14-m07_en.pdf"},
    {"id":"66789","name":"P/0529/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for venglustat (EMEA- 001716-PIP04-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T14:36:17Z","last_updated_date":"2025-02-14T14:36:17Z","reference_number":"EMA/513173/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0529-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-venglustat-emea-001716-pip04-19-m01_en.pdf"},
    {"id":"66796","name":"P/0485/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for zanamivir (Relenza), (EMEA-001318-PIP01-12-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-14T16:17:36Z","last_updated_date":"2025-02-14T16:17:36Z","reference_number":"EMA/517349/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0485-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-zanamivir-relenza-emea-001318-pip01-12-m05_en.pdf"},
    {"id":"66797","name":"P/0489/2023 : EMA decision of 1 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for venglustat (EMEA-001716-PIP07-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-14T16:19:23Z","last_updated_date":"2025-02-14T16:19:23Z","reference_number":"EMA/529962/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0489-2023-ema-decision-1-december-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-venglustat-emea-001716-pip07-22_en.pdf"},
    {"id":"66798","name":"P/0492/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for risankizumab (Skyrizi), (EMEA-001776-PIP02-17-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T16:21:07Z","last_updated_date":"2025-02-14T16:21:07Z","reference_number":"EMA/530125/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0492-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-risankizumab-skyrizi-emea-001776-pip02-17-m02_en.pdf"},
    {"id":"66800","name":"P/0493/2023 : EMA decision of 1 Dec 2023 on the acceptance of a modification of an agreed PIP for indacaterol (acetate) / glycopyrronium (bromide) / mometasone (furoate), (Enerzair Breezhaler, Zimbus Breezhaler), (EMEA-001812-PIP01-15-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T16:22:48Z","last_updated_date":"2025-02-14T16:22:48Z","reference_number":"EMA/530330/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0493-2023-ema-decision-1-dec-2023-acceptance-modification-agreed-pip-indacaterol-acetate-glycopyrronium-bromide-mometasone-furoate-enerzair-breezhaler-zimbus-breezhaler-emea-001812-pip01-15-m02_en.pdf"},
    {"id":"66803","name":"P/0498/2023 : EMA decision of 1 December 2023 on the granting of a product specific waiver for gotistobart, (EMEA-003467-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-14T16:25:08Z","last_updated_date":"2025-02-14T16:25:08Z","reference_number":"EMA/517080/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0498-2023-ema-decision-1-december-2023-granting-product-specific-waiver-gotistobart-emea-003467-pip01-23_en.pdf"},
    {"id":"66804","name":"P/0478/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for tirzepatide (Mounjaro), (EMEA-002360-PIP02-22-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T17:04:43Z","last_updated_date":"2025-02-14T17:04:43Z","reference_number":"EMA/504548/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0478-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-tirzepatide-mounjaro-emea-002360-pip02-22-m02_en.pdf"},
    {"id":"66805","name":"P/0476/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for sebetralstat (EMEA- 002723-PIP01-19-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T17:05:51Z","last_updated_date":"2025-02-14T17:05:51Z","reference_number":"EMA/504418/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0476-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-sebetralstat-emea-002723-pip01-19-m02_en.pdf"},
    {"id":"66806","name":"P/0479/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for seltorexant (EMEA- 002746-PIP01-20-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T17:07:48Z","last_updated_date":"2025-02-14T17:07:48Z","reference_number":"EMA/505047/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0479-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-seltorexant-emea-002746-pip01-20-m02_en.pdf"},
    {"id":"66807","name":"P/0477/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for denecimig (EMEA- 002762-PIP02-20-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T17:09:28Z","last_updated_date":"2025-02-14T17:09:28Z","reference_number":"EMA/504444/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0477-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-denecimig-emea-002762-pip02-20-m02_en.pdf"},
    {"id":"66808","name":"P/0515/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for vamorolone (EMEA- 001794-PIP02-16-M06)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T17:30:45Z","last_updated_date":"2025-02-14T17:30:45Z","reference_number":"EMA/554826/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0515-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-vamorolone-emea-001794-pip02-16-m06_en.pdf"},
    {"id":"66809","name":"P/0511/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for zinc gluconate / alisitol / retinyl palmitate (EMEA-002198-PIP01-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T17:37:59Z","last_updated_date":"2025-02-14T17:37:59Z","reference_number":"EMA/554245/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0511-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-zinc-gluconate-alisitol-retinyl-palmitate-emea-002198-pip01-21-m01_en.pdf"},
    {"id":"66810","name":"P/0524/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for rilzabrutinib (EMEA- 002438-PIP02-19-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T17:43:27Z","last_updated_date":"2025-02-14T17:43:27Z","reference_number":"EMA/553384/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0524-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-rilzabrutinib-emea-002438-pip02-19-m03_en.pdf"},
    {"id":"66811","name":"P/0522/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for cendakimab (EMEA- 002640-PIP01-19-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T17:49:38Z","last_updated_date":"2025-02-14T17:49:38Z","reference_number":"EMA/553394/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0522-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-cendakimab-emea-002640-pip01-19-m01_en.pdf"},
    {"id":"66812","name":"P/0481/2023 : EMA decision of 1 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for decitabine / tetrahydrouridine (EMEA-003404-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-17T09:37:31Z","last_updated_date":"2025-02-17T09:37:31Z","reference_number":"EMA/498578/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0481-2023-ema-decision-1-december-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-decitabine-tetrahydrouridine-emea-003404-pip01-23_en.pdf"},
    {"id":"66813","name":"P/0491/2023 : EMA decision of 1 December 2023 on the granting of a product specific waiver for ilginatinib maleate, (EMEA-003468-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-17T09:39:18Z","last_updated_date":"2025-02-17T09:39:18Z","reference_number":"EMA/517388/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0491-2023-ema-decision-1-december-2023-granting-product-specific-waiver-ilginatinib-maleate-emea-003468-pip01-23_en.pdf"},
    {"id":"66814","name":"P/0475/2023 : EMA decision of 1 Dec 2023 on the granting of a product specific waiver for humanised IgG1 monoclonal antibody against integrin beta-6 conjugated to monomethyl auristatin E via a valine-citrulline linker (SGN B6A) (EMEA-003471-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-17T09:40:31Z","last_updated_date":"2025-02-17T09:40:31Z","reference_number":"EMA/498422/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0475-2023-ema-decision-1-dec-2023-granting-product-specific-waiver-humanised-igg1-monoclonal-antibody-against-integrin-beta-6-conjugated-monomethyl-auristatin-e-valine-citrulline-linker-sgn-b6a-emea_en.pdf"},
    {"id":"66815","name":"P/0490/2023 : EMA decision of 1 December 2023 on the granting of a product specific waiver for rosuvastatin / ezetimibe (EMEA-003472-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-17T09:41:52Z","last_updated_date":"2025-02-17T09:41:52Z","reference_number":"EMA/530028/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0490-2023-ema-decision-1-december-2023-granting-product-specific-waiver-rosuvastatin-ezetimibe-emea-003472-pip01-23_en.pdf"},
    {"id":"66825","name":"P/0321/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for etrasimod (Velsipity), (EMEA-002713-PIP02-21-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-10-20T14:12:37Z","last_updated_date":"2025-10-20T14:12:37Z","reference_number":"EMA/411537/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0321-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-etrasimod-velsipity-emea-002713-pip02-21-m02_en.pdf"},
    {"id":"66826","name":"P/0523/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for fully human IgG1 RB- 1 YTE anti-RSV F monoclonal antibody (MK-1654) (EMEA-002755-PIP01-19-M02)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-17T14:18:44Z","last_updated_date":"2025-02-17T14:18:44Z","reference_number":"EMA/553405/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0523-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-fully-human-igg1-rb-1-yte-anti-rsv-f-monoclonal-antibody-mk-1654-emea-002755-pip01-19-m02_en.pdf"},
    {"id":"66828","name":"P/0510/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for Pneumococcal Polysaccharide Serotype 3 – Diphtheria CRM197 Conjugate......(EMEA-003155-PIP01-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-17T15:46:19Z","last_updated_date":"2025-02-17T15:46:19Z","reference_number":"EMA/554379/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0510-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-pneumococcal-polysaccharide-serotype-3-diphtheria-crm197-conjugateemea-003155-pip01-21-m01_en.pdf"},
    {"id":"66829","name":"P/0512/2023 : EMA decision of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for interleukin-23 receptor antagonist peptide (EMEA-003301-PIP01-22-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-02-17T15:53:56Z","last_updated_date":"2025-02-17T15:53:56Z","reference_number":"EMA/554411/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0512-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-interleukin-23-receptor-antagonist-peptide-emea-003301-pip01-22-m01_en.pdf"},
    {"id":"66881","name":"P/0502/2023: EMA decision of 1 December 2023 on the refusal of a modification of an agreed paediatric investigation plan and on the granting of a waiver for mirabegron (Betmiga), (EMEA-000597-PIP02-10-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-19T16:57:02Z","last_updated_date":"2025-02-19T16:57:02Z","reference_number":"EMA/528354/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0502-2023-ema-decision-1-december-2023-refusal-modification-agreed-paediatric-investigation-plan-granting-waiver-mirabegron-betmiga-emea-000597-pip02-10-m10_en.pdf"},
    {"id":"66882","name":"P/0503/2023: EMA decision of of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for iron as ferric maltol (Feraccru), (EMEA-001195-PIP01-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-19T17:03:19Z","last_updated_date":"2025-02-19T17:03:19Z","reference_number":"EMA/528355/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0503-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-iron-ferric-maltol-feraccru-emea-001195-pip01-11-m07_en.pdf"},
    {"id":"66883","name":"P/0508/2023: EMA decision of of 29 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for respiratory syncytial virus (RSV) PreF3 recombinant fusion protein/AS01 (RSVPreF3 OA) (EMEA-002904-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-19T17:24:44Z","last_updated_date":"2025-02-19T17:24:44Z","reference_number":"EMA/554228/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0508-2023-ema-decision-29-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-respiratory-syncytial-virus-rsv-pref3-recombinant-fusion-protein-as01-rsvpref3-oa-emea-002904_en.pdf"},
    {"id":"66884","name":"P/0500/2023: EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for treprostinil (sodium) (Trisuva and associated names), (EMEA-003182-PIP01-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-19T17:34:54Z","last_updated_date":"2025-02-19T17:34:54Z","reference_number":"EMA/515863/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0500-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-treprostinil-sodium-trisuva-associated-names-emea-003182-pip01-22-m01_en.pdf"},
    {"id":"66885","name":"P/0504/2023: EMA decision of 29 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for AstraZeneca Anti-SARS-CoV-2 monoclonal antibody (AZD3152), (EMEA-003350-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-19T17:46:42Z","last_updated_date":"2025-02-19T17:46:42Z","reference_number":"EMA/528356/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0504-2023-ema-decision-29-december-2023-agreement-paediatric-investigation-plan-granting-deferral-astrazeneca-anti-sars-cov-2-monoclonal-antibody-azd3152-emea-003350-pip01-23_en.pdf"},
    {"id":"66886","name":"P/0505/2023: EMA decision of 29 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and of a waiver for broadly neutralizing anti-HIV human monoclonal antibody (VH3810109)(EMEA-003392-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-19T17:57:55Z","last_updated_date":"2025-02-19T17:57:55Z","reference_number":"EMA/528359/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0505-2023-ema-decision-29-december-2023-agreement-paediatric-investigation-plan-granting-deferral-waiver-broadly-neutralizing-anti-hiv-human-monoclonal-antibody-vh3810109emea-003392-pip01-23_en.pdf"},
    {"id":"66887","name":"P/0506/2023: EMA decision of of 29 December 2023 on the granting of a product specific waiver for elinzanetant (EMEA-003500-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-19T18:08:40Z","last_updated_date":"2025-02-19T18:08:40Z","reference_number":"EMA/528360/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0506-2023-ema-decision-29-december-2023-granting-product-specific-waiver-elinzanetant-emea-003500-pip01-23_en.pdf"},
    {"id":"66888","name":"P/0507/2023: EMA decision of of 29 December 2023 on the granting of a product specific waiver for rilvegostomig (EMEA-003501-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-02-19T18:20:56Z","last_updated_date":"2025-02-19T18:20:56Z","reference_number":"EMA/528361/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0507-2023-ema-decision-29-december-2023-granting-product-specific-waiver-rilvegostomig-emea-003501-pip01-23_en.pdf"},
    {"id":"67101","name":"P/0456/2023 : EMA decision of 1 December 2023 on on the granting of a product-specific waiver for povidone, iodinated, (EMEA-003484-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-04T14:38:16Z","last_updated_date":"2025-03-04T14:38:16Z","reference_number":"EMA/517390/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0456-2023-ema-decision-1-december-2023-granting-product-specific-waiver-povidone-iodinated-emea-003484-pip01-23_en.pdf"},
    {"id":"67106","name":"P/0458/2023 : EMA decision of 1 December 2023 on the granting of a product-specific waiver for nivolumab / relatlimab (Opdualag), (EMEA-002727PIP02-23) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-04T15:14:07Z","last_updated_date":"2025-03-04T15:14:07Z","reference_number":"EMA/526337/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0458-2023-ema-decision-1-december-2023-granting-product-specific-waiver-nivolumab-relatlimab-opdualag-emea-002727pip02-23_en.pdf"},
    {"id":"67122","name":"P/0457/2023 : EMA decision of 1 December 2023 on the acceptance of a modification of an agreed paediatric investigation plan for macitentan (Opsumit), (EMEA-001032-PIP01-10-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-06T10:10:49Z","last_updated_date":"2025-03-06T10:10:49Z","reference_number":"EMA/517330/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0457-2023-ema-decision-1-december-2023-acceptance-modification-agreed-paediatric-investigation-plan-macitentan-opsumit-emea-001032-pip01-10-m07_en.pdf"},
    {"id":"67127","name":"P/0463/2023 : EMA decision of 1 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cemdisiran (EMEA-003237-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-06T18:45:24Z","last_updated_date":"2025-03-06T18:45:24Z","reference_number":"EMA/526345/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0463-2023-ema-decision-1-december-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cemdisiran-emea-003237-pip02-22_en.pdf"},
    {"id":"67128","name":"P/0463/2023 : EMA decision of 1 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pozelimab (EMEA-003238-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-06T19:06:43Z","last_updated_date":"2025-03-06T19:06:43Z","reference_number":"EMA/526347/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0463-2023-ema-decision-1-december-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pozelimab-emea-003238-pip02-22_en.pdf"},
    {"id":"67140","name":"P/0465/2023 : EMA decision of 1 December 2023 on the granting of a product-specific waiver for amlodipine / atorvastatin / candesartan (EMEA-003466-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-07T13:29:06Z","last_updated_date":"2025-03-07T13:29:06Z","reference_number":"EMA/526338/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0465-2023-ema-decision-1-december-2023-granting-product-specific-waiver-amlodipine-atorvastatin-candesartan-emea-003466-pip01-23_en.pdf"},
    {"id":"67148","name":"P/0466/2023 : EMA decision of 1 December 2023 on the granting of a product-specific waiver for ramipril / indapamide (EMEA-003498-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-07T14:16:28Z","last_updated_date":"2025-03-07T14:16:28Z","reference_number":"EMA/501922/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0466-2023-ema-decision-1-december-2023-granting-product-specific-waiver-ramipril-indapamide-emea-003498-pip01-23_en.pdf"},
    {"id":"67149","name":"P/0471/2023 : EMA decision of 1 December 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inebilizumab (Uplizna), (EMEA-001911-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-07T14:28:01Z","last_updated_date":"2025-03-07T14:28:01Z","reference_number":"EMA/512498/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0471-2023-ema-decision-1-december-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-inebilizumab-uplizna-emea-001911-pip02-22_en.pdf"},
    {"id":"67150","name":"P/0472/2023 : EMA decision of 1 December 2023 on the granting of a product-specific waiver for naproxen / paracetamol (EMEA-003475-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-07T14:52:29Z","last_updated_date":"2025-03-07T14:52:29Z","reference_number":"EMA/512499/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0472-2023-ema-decision-1-december-2023-granting-product-specific-waiver-naproxen-paracetamol-emea-003475-pip01-23_en.pdf"},
    {"id":"67153","name":"P/0473/2023 : EMA decision of 1 December 2023 on the granting of a product-specific waiver for fusion protein consisting of relaxin and Fc domain of IgG1 (EMEA-003476-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-07T15:18:59Z","last_updated_date":"2025-03-07T15:18:59Z","reference_number":"EMA/512500/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0473-2023-ema-decision-1-december-2023-granting-product-specific-waiver-fusion-protein-consisting-relaxin-fc-domain-igg1-emea-003476-pip01-23_en.pdf"},
    {"id":"67157","name":"P/0474/2023 : EMA decision of 1 December 2023 on the granting of a product-specific waiver for derivative of a benzoimidazole substituted pyrimidine (EMEA-003470-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-07T16:25:54Z","last_updated_date":"2025-03-07T16:25:54Z","reference_number":"EMA/498353/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0474-2023-ema-decision-1-december-2023-granting-product-specific-waiver-derivative-benzoimidazole-substituted-pyrimidine-emea-003470-pip01-23_en.pdf"},
    {"id":"67250","name":"P/0009/2024 : EMA decision of 31 January 2024 on the granting of a product-specific waiver for cladribine (EMEA-000383-PIP04-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-13T13:44:36Z","last_updated_date":"2025-03-13T13:44:36Z","reference_number":"EMA/11057/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0009-2024-ema-decision-31-january-2024-granting-product-specific-waiver-cladribine-emea-000383-pip04-23_en.pdf"},
    {"id":"67259","name":"P/0036/2024 : EMA decision of 31 January 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ferric citrate coordination complex (FCCC), (EMEA-001213-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-13T15:25:50Z","last_updated_date":"2025-03-13T15:25:50Z","reference_number":"EMA/22039/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0036-2024-ema-decision-31-january-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ferric-citrate-coordination-complex-fccc-emea-001213-pip03-23_en.pdf"},
    {"id":"67284","name":"P/0032/2024 : EMA decision of 31 January 2024 on the granting of a product-specific waiver for nipocalimab, (EMEA-002559-PIP09-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T13:49:26Z","last_updated_date":"2025-03-14T13:49:26Z","reference_number":"EMA/22825/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0032-2024-ema-decision-31-january-2024-granting-product-specific-waiver-nipocalimab-emea-002559-pip09-23_en.pdf"},
    {"id":"67301","name":"P/0020/2024 : EMA decision of 31 January 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for remibrutinib (EMEA-002582-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-17T11:49:19Z","last_updated_date":"2025-03-17T11:49:19Z","reference_number":"EMA/25522/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2024-ema-decision-31-january-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-remibrutinib-emea-002582-pip03-23_en.pdf"},
    {"id":"67303","name":"P/0020/2024 : EMA decision of 31 January 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for remibrutinib (EMEA-002582-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-17T13:12:29Z","last_updated_date":"2025-03-17T13:12:29Z","reference_number":"EMA/25522/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0020-2024-ema-decision-31-january-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-remibrutinib-emea-002582-pip03-23_en.pdf-0"},
    {"id":"67306","name":"P/0034/2024 : EMA decision of 31 January 2024 on the granting of a product-specific waiver for ruxolitinib (phosphate) (Jakavi, Opzelura), (EMEA- 002618-PIP04-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-17T14:39:43Z","last_updated_date":"2025-03-17T14:39:43Z","reference_number":"EMA/22773/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0034-2024-ema-decision-31-january-2024-granting-product-specific-waiver-ruxolitinib-phosphate-jakavi-opzelura-emea-002618-pip04-23_en.pdf"},
    {"id":"67307","name":"P/0006/2024 : EMA decision of 12 January 2024 on the granting of a product-specific waiver for faricimab (Vabysmo), (EMEA-002817-PIP05-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-17T15:03:16Z","last_updated_date":"2025-03-17T15:03:16Z","reference_number":"EMA/8520/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2024-ema-decision-12-january-2024-granting-product-specific-waiver-faricimab-vabysmo-emea-002817-pip05-23_en.pdf"},
    {"id":"67309","name":"P/0014/2024 : EMA decision of 31 January 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for apitegromab (EMEA-002951-PIP02-21)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-17T15:27:34Z","last_updated_date":"2025-03-17T15:27:34Z","reference_number":"EMA/15341/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0014-2024-ema-decision-31-january-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-apitegromab-emea-002951-pip02-21_en.pdf"},
    {"id":"67315","name":"P/0033/2024 : EMA decision of 29 January 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for zigakibart (EMEA-003300-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-17T15:47:35Z","last_updated_date":"2025-03-17T15:47:35Z","reference_number":"EMA/29579/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0033-2024-ema-decision-29-january-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-zigakibart-emea-003300-pip01-22_en.pdf"},
    {"id":"67317","name":"P/0015/2024 : EMA decision of 31 January 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for dordaviprone (EMEA-003389-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-17T16:34:08Z","last_updated_date":"2025-03-17T16:34:08Z","reference_number":"EMA/15344/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0015-2024-ema-decision-31-january-2024-agreement-paediatric-investigation-plan-granting-deferral-dordaviprone-emea-003389-pip01-23_en.pdf"},
    {"id":"67323","name":"P/0007/2024 : EMA decision of 11 January 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for mRNA encoding for the linked NTD and RBD domains of the spike... (EMEA-003426-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-18T11:48:35Z","last_updated_date":"2025-03-18T11:48:35Z","reference_number":"EMA/11071/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0007-2024-ema-decision-11-january-2024-agreement-paediatric-investigation-plan-granting-deferral-mrna-encoding-linked-ntd-rbd-domains-spike-emea-003426-pip01-23_en.pdf"},
    {"id":"67325","name":"P/0025/2024 : EMA decision of 31 January 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obicetrapib, (EMEA-003438-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-18T12:41:42Z","last_updated_date":"2025-03-18T12:41:42Z","reference_number":"EMA/25525/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0025-2024-ema-decision-31-january-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-obicetrapib-emea-003438-pip02-23_en.pdf"},
    {"id":"67326","name":"P/0031/2024 : EMA decision of 29 January 2024 on the granting of a product-specific waiver for tinengotinib (EMEA-003504-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-18T12:50:51Z","last_updated_date":"2025-03-18T12:50:51Z","reference_number":"EMA/501922/2008","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0031-2024-ema-decision-29-january-2024-granting-product-specific-waiver-tinengotinib-emea-003504-pip01-23_en.pdf"},
    {"id":"67327","name":"P/0017/2024 : EMA decision of 31 January 2024 on the granting of a product-specific waiver for obicetrapib / ezetimibe (EMEA-003514-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-18T13:03:27Z","last_updated_date":"2025-03-18T13:03:27Z","reference_number":"EMA/15349/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0017-2024-ema-decision-31-january-2024-granting-product-specific-waiver-obicetrapib-ezetimibe-emea-003514-pip01-23_en.pdf"},
    {"id":"67328","name":"P/0035/2024 : EMA decision of 31 January 2024 on the granting of a product-specific waiver for obicetrapib / ezetimibe, (EMEA-003514-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-18T13:11:10Z","last_updated_date":"2025-03-18T13:11:10Z","reference_number":"EMA/22725/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0035-2024-ema-decision-31-january-2024-granting-product-specific-waiver-obicetrapib-ezetimibe-emea-003514-pip02-23_en.pdf"},
    {"id":"67396","name":"P/0067/2024 - EMA decision of 8 March 2024 on the granting of a product specific waiver for anti-alpha-synuclein recombinant humanised monoclonal antibody, (EMEA-003541-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-21T15:09:53Z","last_updated_date":"2025-03-21T15:09:53Z","reference_number":"EMA/87758/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0067-2024-ema-decision-8-march-2024-granting-product-specific-waiver-anti-alpha-synuclein-recombinant-humanised-monoclonal-antibody-emea-003541-pip01-23_en.pdf"},
    {"id":"67397","name":"P/0066/2024 : EMA decision of 8 March 2024 on the granting of a product specific waiver for motugivatrep, (EMEA-003520-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-21T15:22:32Z","last_updated_date":"2025-03-21T15:22:32Z","reference_number":"EMA/87529/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0066-2024-ema-decision-8-march-2024-granting-product-specific-waiver-motugivatrep-emea-003520-pip01-23_en.pdf"},
    {"id":"67398","name":"P/0061/2024 : EMA decision of 7 March 2024 on the granting of a product specific waiver for zenocutuzumab (EMEA-003519-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-21T15:31:48Z","last_updated_date":"2025-03-21T15:31:48Z","reference_number":"EMA/81800/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0061-2024-ema-decision-7-march-2024-granting-product-specific-waiver-zenocutuzumab-emea-003519-pip01-23_en.pdf"},
    {"id":"67399","name":"P/0065/2024 : EMA decision of 8 March 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for belumosudil, (EMEA-003425-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-21T15:38:44Z","last_updated_date":"2025-03-21T15:38:44Z","reference_number":"EMA/87429/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0065-2024-ema-decision-8-march-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-belumosudil-emea-003425-pip01-23_en.pdf"},
    {"id":"67400","name":"P/0060/2024","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-21T15:54:45Z","last_updated_date":"2025-03-21T15:54:45Z","reference_number":"EMA/81788/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0060-2024_en.pdf"},
    {"id":"67401","name":"P/0062/2024 : EMA decision of 8 March 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for upadacitinib (Rinvoq), (EMEA-001741-PIP10-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-21T15:59:25Z","last_updated_date":"2025-03-21T15:59:25Z","reference_number":"EMA/87189/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0062-2024-ema-decision-8-march-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-upadacitinib-rinvoq-emea-001741-pip10-23_en.pdf"},
    {"id":"67418","name":"P/0040/2024 : EMA decision of 7 February 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for blinatumomab, (Blincyto) (EMEA-000574-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-24T16:34:32Z","last_updated_date":"2025-03-24T16:34:32Z","reference_number":"EMA/47058/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0040-2024-ema-decision-7-february-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-blinatumomab-blincyto-emea-000574-pip03-23_en.pdf"},
    {"id":"67419","name":"P/0021/2024 : EMA decision of 9 February 2024 on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine (Exparel), (EMEA-000877-PIP03-17-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-24T16:46:33Z","last_updated_date":"2025-03-24T16:46:33Z","reference_number":"EMA/27567/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2024-ema-decision-9-february-2024-acceptance-modification-agreed-paediatric-investigation-plan-bupivacaine-exparel-emea-000877-pip03-17-m05_en.pdf"},
    {"id":"67420","name":"P/0021/2024 : EMA decision of 9 February 2024 on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine (Exparel), (EMEA-000877-PIP03-17-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-24T16:50:11Z","last_updated_date":"2025-03-24T16:50:11Z","reference_number":"EMA/27567/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0021-2024-ema-decision-9-february-2024-acceptance-modification-agreed-paediatric-investigation-plan-bupivacaine-exparel-emea-000877-pip03-17-m05_en.pdf-0"},
    {"id":"67421","name":"P/0037/2024 : EMA decision of 7 February 2024 on the acceptance of a modification of an agreed paediatric investigation plan for abemaciclib (Verzenios), (EMEA-002342-PIP01-18-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-24T16:59:41Z","last_updated_date":"2025-03-24T16:59:41Z","reference_number":"EMA/45038/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0037-2024-ema-decision-7-february-2024-acceptance-modification-agreed-paediatric-investigation-plan-abemaciclib-verzenios-emea-002342-pip01-18-m04_en.pdf"},
    {"id":"67426","name":"P/0038/2024 : EMA decision of 7 February 2024 on the acceptance of a modification of an agreed paediatric investigation plan for abemaciclib (Verzenios), (EMEA-002342-PIP02-18-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-25T09:25:00Z","last_updated_date":"2025-03-25T09:25:00Z","reference_number":"EMA/45039/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0038-2024-ema-decision-7-february-2024-acceptance-modification-agreed-paediatric-investigation-plan-abemaciclib-verzenios-emea-002342-pip02-18-m03_en.pdf"},
    {"id":"67427","name":"P/0044/2024 : EMA decision of 15 February 2024 on the acceptance of a modification of an agreed paediatric investigation plan for pariglasgene brecaparvovec (DTX401) (EMEA-002734-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-25T09:30:00Z","last_updated_date":"2025-03-25T09:30:00Z","reference_number":"EMA/29056/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0044-2024-ema-decision-15-february-2024-acceptance-modification-agreed-paediatric-investigation-plan-pariglasgene-brecaparvovec-dtx401-emea-002734-pip01-19-m01_en.pdf"},
    {"id":"67428","name":"P/0039/2024 : EMA decision of 7 February 2024 on the acceptance of a modification of an agreed paediatric investigation plan for atropine sulfate (EMEA-002744-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-25T09:38:22Z","last_updated_date":"2025-03-25T09:38:22Z","reference_number":"EMA/28206/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0039-2024-ema-decision-7-february-2024-acceptance-modification-agreed-paediatric-investigation-plan-atropine-sulfate-emea-002744-pip01-19-m01_en.pdf"},
    {"id":"67430","name":"P/0043/2024 : EMA decision of 14 February 2024 on the acceptance of a modification of an agreed paediatric investigation plan for acetyl-L-leucine ((s)-(acetylamino)-4-methylpentanoic acid) (IB001) (EMEA-002796-PIP01-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-25T11:24:58Z","last_updated_date":"2025-03-25T11:24:58Z","reference_number":"EMA/28207/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0043-2024-ema-decision-14-february-2024-acceptance-modification-agreed-paediatric-investigation-plan-acetyl-l-leucine-s-acetylamino-4-methylpentanoic-acid-ib001-emea-002796-pip01-20-m02_en.pdf"},
    {"id":"67441","name":"P/0023/2024 : EMA decision of 1 February 2024 on the granting of a product specific waiver for rocatinlimab (EMEA-002886-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-25T14:34:59Z","last_updated_date":"2025-03-25T14:34:59Z","reference_number":"EMA/27712/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0023-2024-ema-decision-1-february-2024-granting-product-specific-waiver-rocatinlimab-emea-002886-pip02-23_en.pdf"},
    {"id":"67442","name":"P/0047/2024 : MA decision of 23 February 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for frexalimab, (EMEA-002945-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-25T14:49:34Z","last_updated_date":"2025-03-25T14:49:34Z","reference_number":"EMA/22503/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0047-2024-ma-decision-23-february-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-frexalimab-emea-002945-pip03-23_en.pdf"},
    {"id":"67465","name":"P/0041/2024 : EMA decision of 2 February 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for sepiapterin (EMEA-003027-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-26T14:57:01Z","last_updated_date":"2025-03-26T14:57:01Z","reference_number":"EMA/50045/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0041-2024-ema-decision-2-february-2024-agreement-paediatric-investigation-plan-granting-deferral-sepiapterin-emea-003027-pip02-23_en.pdf"},
    {"id":"67466","name":"P/0022/2024 : EMA decision of 1 February 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for fibroblast growth factor 21 analogue (NNC194-0499) / semaglutide (EMEA-003402-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-26T15:08:58Z","last_updated_date":"2025-03-26T15:08:58Z","reference_number":"EMA/27698/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0022-2024-ema-decision-1-february-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-fibroblast-growth-factor-21-analogue-nnc194-0499-semaglutide-emea-003402-pip01-23_en.pdf"},
    {"id":"67469","name":"P/0042/2024 : EMA decision of 9 February 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for clobetasol propionate, (EMEA-003458-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-26T15:59:34Z","last_updated_date":"2025-03-26T15:59:34Z","reference_number":"EMA/53064/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0042-2024-ema-decision-9-february-2024-agreement-paediatric-investigation-plan-granting-deferral-clobetasol-propionate-emea-003458-pip01-23_en.pdf"},
    {"id":"67471","name":"P/0016/2024 : EMA decision of 6 February 2024 on the granting of a product specific waiver for tifcemalimab (EMEA-003512-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-26T16:15:31Z","last_updated_date":"2025-03-26T16:15:31Z","reference_number":"EMA/15348/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0016-2024-ema-decision-6-february-2024-granting-product-specific-waiver-tifcemalimab-emea-003512-pip01-23_en.pdf"}    {"id":"67472","name":"P/0045/2024 : EMA decision of 9 February 2024 on the agreement of a paediatric investigation plan and on the granting of a waiver for influenza Virus Type B, Victoria lineage / Influenza Virus Type A, H3N2 / Influenza Virus Type A, H1N1 (EMEA-003589- PIP0","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-03-26T16:23:23Z","last_updated_date":"2025-03-26T16:23:23Z","reference_number":"EMA/57360/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0045-2024-ema-decision-9-february-2024-agreement-paediatric-investigation-plan-granting-waiver-influenza-virus-type-b-victoria-lineage-influenza-virus-type-h3n2-influenza-virus-type-h1n1-emea-003589_en.pdf"},
    {"id":"67563","name":"P/0048/2024 : EMA decision of 8 March 2024 on the granting of a product-specific waiver for IgG-like T cell engager binding to DLL3 and CD3 (EMEA-003516-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-01T12:01:41Z","last_updated_date":"2025-04-01T12:01:41Z","reference_number":"EMA/50883/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0048-2024-ema-decision-8-march-2024-granting-product-specific-waiver-igg-t-cell-engager-binding-dll3-cd3-emea-003516-pip01-23_en.pdf"},
    {"id":"67583","name":"P/0049/2024 : EMA decision of 8 March 2024 on the granting of a product-specific waiver for isatuximab (Sarclisa) (EMEA-002205-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-01T16:14:08Z","last_updated_date":"2025-04-01T16:14:08Z","reference_number":"EMA/50945/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0049-2024-ema-decision-8-march-2024-granting-product-specific-waiver-isatuximab-sarclisa-emea-002205-pip02-23_en.pdf"},
    {"id":"67585","name":"P/0050/2024 : EMA decision of 8 March 2024 on the granting of a product-specific waiver for zanzalintinib (EMEA-003522-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-01T16:29:00Z","last_updated_date":"2025-04-01T16:29:00Z","reference_number":"EMA/51040/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0050-2024-ema-decision-8-march-2024-granting-product-specific-waiver-zanzalintinib-emea-003522-pip01-23_en.pdf"},
    {"id":"67586","name":"P/0052/2024 : EMA decision of of 8 March 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for orforglipron (EMEA-003299-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-01T16:39:00Z","last_updated_date":"2025-04-01T16:39:00Z","reference_number":"EMA/53493/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0052-2024-ema-decision-8-march-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-orforglipron-emea-003299-pip02-22_en.pdf"},
    {"id":"67587","name":"P/0056/2024 : EMA decision of 8 March 2024 on the granting of a product-specific waiver for 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3- (hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl... (EMEA-003515-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-04-01T16:51:34Z","last_updated_date":"2025-04-01T16:51:34Z","reference_number":"EMA/62600/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0056-2024-ema-decision-8-march-2024-granting-product-specific-waiver-2-35-dichloro-1-methyl-indazol-4-yl-1-1s3r-3-hydroxymethyl-5-1-hydroxy-1-methyl-ethyl-1-methyl-emea-003515-pip01-23_en.pdf"},
    {"id":"67589","name":"P/0057/2024 : EMA decision of 8 March 2024 on the granting of a product-specific waiver for Interleukin-2/Interleukin-1 beta, human/Granulocyte colony-stimulating factor/Tumour necrosis factor-alpha/Interferon gamma (EMEA-003523-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-01T17:06:00Z","last_updated_date":"2025-04-01T17:06:00Z","reference_number":"EMA/62601/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0057-2024-ema-decision-8-march-2024-granting-product-specific-waiver-interleukin-2-interleukin-1-beta-human-granulocyte-colony-stimulating-factor-tumour-necrosis-factor-alpha-interferon-gamma-emea_en.pdf"},
    {"id":"67600","name":"P/0059/2024 : EMA decision of 7 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for Chikungunya virus virus-like particle vaccine / aluminum hydroxide (EMEA-002656-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-02T13:32:22Z","last_updated_date":"2025-04-02T13:32:22Z","reference_number":"EMA/81544/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0059-2024-ema-decision-7-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-chikungunya-virus-virus-particle-vaccine-aluminum-hydroxide-emea-002656-pip01-19-m01_en.pdf"},
    {"id":"67601","name":"P/0058/2024 : EMA decision of 7 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for difelikefalin (Kapruvia), (EMEA-002565-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-02T13:37:46Z","last_updated_date":"2025-04-02T13:37:46Z","reference_number":"EMA/81537/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0058-2024-ema-decision-7-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-difelikefalin-kapruvia-emea-002565-pip02-19-m01_en.pdf"},
    {"id":"67778","name":"P/0070/2024 : EMA decision of 8 March 2024 on the granting of a product specific waiver for volrustomig (EMEA-003423-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-14T12:08:19Z","last_updated_date":"2025-04-14T12:08:19Z","reference_number":"EMA/28240/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0070-2024-ema-decision-8-march-2024-granting-product-specific-waiver-volrustomig-emea-003423-pip02-23_en.pdf"},
    {"id":"67779","name":"P/0071/2024 : EMA decision of 8 March 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for synthetic double-stranded siRNA oligonucleotide... (EMEA-003420-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T12:19:42Z","last_updated_date":"2025-04-14T12:19:42Z","reference_number":"EMA/28239/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0071-2024-ema-decision-8-march-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-synthetic-double-stranded-sirna-oligonucleotide-emea-003420-pip01-23_en.pdf"},
    {"id":"67782","name":"P/0072/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for SARS-CoV2 prefusion spike delta TM (CoV-2 preS dTM) adjuvanted with AS03 (VidPrevtyn Beta), (EMEA-002915-PIP01-20-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-14T13:53:52Z","last_updated_date":"2025-04-14T13:53:52Z","reference_number":"EMA/28208/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-sars-cov2-prefusion-spike-delta-tm-cov-2-pres-dtm-adjuvanted-as03-vidprevtyn-beta-emea-002915-pip01_en.pdf"},
    {"id":"67786","name":"P/0073/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for fordadistrogene movaparvovec (EMEA-002741-PIP01-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-14T14:23:24Z","last_updated_date":"2025-04-14T14:23:24Z","reference_number":"EMA/28205/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0073-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-fordadistrogene-movaparvovec-emea-002741-pip01-20-m02_en.pdf"},
    {"id":"67789","name":"P/0075/2024 : EMA decision of 8 March 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ianalumab (EMEA-002338-PIP04-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-14T14:32:29Z","last_updated_date":"2025-04-14T14:32:29Z","reference_number":"EMA/89916/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0075-2024-ema-decision-8-march-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ianalumab-emea-002338-pip04-23_en.pdf"},
    {"id":"67792","name":"P/0078/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for eluxadoline (EMEA- 001579-PIP01-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-14T15:02:01Z","last_updated_date":"2025-04-14T15:02:01Z","reference_number":"EMA/89818/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0078-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-eluxadoline-emea-001579-pip01-13-m06_en.pdf"},
    {"id":"67795","name":"P/0077/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for sodium zirconium cyclosilicate (Lokelma), (EMEA-001539-PIP01-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-14T15:20:16Z","last_updated_date":"2025-04-14T15:20:16Z","reference_number":"EMA/89807/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0077-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-sodium-zirconium-cyclosilicate-lokelma-emea-001539-pip01-13-m06_en.pdf"},
    {"id":"67796","name":"P/0076/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for dinutuximab beta (Qarziba), (EMEA-001314-PIP01-12-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-14T15:34:39Z","last_updated_date":"2025-04-14T15:34:39Z","reference_number":"EMA/89774/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0076-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-dinutuximab-beta-qarziba-emea-001314-pip01-12-m02_en.pdf"},
    {"id":"67797","name":"P/0074/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for oritavancin (diphosphate) (Tenkasi), (EMEA-001270-PIP01-12-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-14T16:10:00Z","last_updated_date":"2025-04-14T16:10:00Z","reference_number":"EMA/28203/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0074-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-oritavancin-diphosphate-tenkasi-emea-001270-pip01-12-m07_en.pdf"},
    {"id":"67888","name":"P/0064/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for nedosiran, (EMEA- 002493-PIP01-18-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T10:17:07Z","last_updated_date":"2025-04-25T10:17:07Z","reference_number":"EMA/PDCO/480620/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0064-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-nedosiran-emea-002493-pip01-18-m06_en.pdf"},
    {"id":"67889","name":"P/0063/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for molgramostim, (EMEA-002282-PIP01-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T10:25:32Z","last_updated_date":"2025-04-25T10:25:32Z","reference_number":"EMA/87258/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0063-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-molgramostim-emea-002282-pip01-17-m02_en.pdf"},
    {"id":"67890","name":"P/0069/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for satralizumab (Enspryng), (EMEA-001625-PIP02-21-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T10:31:09Z","last_updated_date":"2025-04-25T10:31:09Z","reference_number":"EMA/77109/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0069-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-satralizumab-enspryng-emea-001625-pip02-21-m03_en.pdf"},
    {"id":"67891","name":"P/0068/2024 : EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for midostaurin (Rydapt), (EMEA-000780-PIP01-09-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T10:43:55Z","last_updated_date":"2025-04-25T10:43:55Z","reference_number":"EMA/76785/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0068-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-midostaurin-rydapt-emea-000780-pip01-09-m07_en.pdf"},
    {"id":"68217","name":"P/0080/2024 : EMA decision of 15 March 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Borrelia outer surface protein A (OspA) serotypes (ST1-6) lipidated, fusion protein","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-12T12:03:13Z","last_updated_date":"2025-05-12T12:03:13Z","reference_number":"EMA/28245/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0080-2024-ema-decision-15-march-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-borrelia-outer-surface-protein-ospa-serotypes-st1-6-lipidated-fusion-protein_en.pdf"},
    {"id":"68218","name":"P/0079/2024: EMA decision of 8 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP04-17-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-12T12:14:15Z","last_updated_date":"2025-05-12T12:14:15Z","reference_number":"EMA/89850/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0079-2024-ema-decision-8-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip04-17-m05_en.pdf"},
    {"id":"68259","name":"P/0081/2024 : EMA decision of 15 March 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the  granting of a waiver for cannabidiol (EMEA-003176-PIP02-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-13T15:41:17Z","last_updated_date":"2025-05-13T15:41:17Z","reference_number":"EMA/101137/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0081-2024-ema-decision-15-march-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cannabidiol-emea-003176-pip02-22_en.pdf"},
    {"id":"68260","name":"P/0082/2024 : EMA decision of 15 March 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for navepegritide (EMEA-002689-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-13T16:02:00Z","last_updated_date":"2025-05-13T16:02:00Z","reference_number":"EMA/103594/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0082-2024-ema-decision-15-march-2024-agreement-paediatric-investigation-plan-granting-deferral-navepegritide-emea-002689-pip02-23_en.pdf"},
    {"id":"68266","name":"P/0087/2024: EMA decision of 20 March 2024 on the granting of a product specific waiver for sodium phenylbutyrate / ursodoxicoltaurine  (EMEA-002876-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-13T16:35:54Z","last_updated_date":"2025-05-13T16:35:54Z","reference_number":"EMA/114329/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0087-2024-ema-decision-20-march-2024-granting-product-specific-waiver-sodium-phenylbutyrate-ursodoxicoltaurine-emea-002876-pip02-23_en.pdf"},
    {"id":"68269","name":"P/0088/2024 : EMA decision of 15 March 2024 on the agreement of a paediatric investigation plan and on the granting of a waiver for split influenza virus... (EMEA-003603-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-13T17:17:51Z","last_updated_date":"2025-05-13T17:17:51Z","reference_number":"EMA/111601/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0088-2024-ema-decision-15-march-2024-agreement-paediatric-investigation-plan-granting-waiver-split-influenza-virus-emea-003603-pip01-24_en.pdf"},
    {"id":"68270","name":"P/0089/2024 : EMA decision of 27 March 2024 on the on the agreement of a paediatric investigation plan and on the granting of a deferral for sargramostim (EMEA-003568-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-13T17:33:56Z","last_updated_date":"2025-05-13T17:33:56Z","reference_number":"EMA/128509/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0089-2024-ema-decision-27-march-2024-agreement-paediatric-investigation-plan-granting-deferral-sargramostim-emea-003568-pip01-23_en.pdf"},
    {"id":"68287","name":"P/0086/2024: EMA decision of 21 March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for glucagon analogue linked to a human immunoglobulin Fc fragment (HM15136) (EMEA-003170-PIP01-21-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-14T18:17:53Z","last_updated_date":"2025-05-14T18:17:53Z","reference_number":"EMA/108301/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0086-2024-ema-decision-21-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-glucagon-analogue-linked-human-immunoglobulin-fc-fragment-hm15136-emea-003170-pip01-21-m02_en.pdf"},
    {"id":"68288","name":"P/0085/2024: EMA decision of the 15 of March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for mirabegron (Betmiga) (EMEA-000597-PIP03-15-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-14T18:35:47Z","last_updated_date":"2025-05-14T18:35:47Z","reference_number":"EMA/104845/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2024-ema-decision-15-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-mirabegron-betmiga-emea-000597-pip03-15-m06_en.pdf"},
    {"id":"68289","name":"P/0084/2024: EMA decision of the 15 of March 2024 on the acceptance of a modification of an agreed paediatric investigation plan for chloroprocaine (hydrochloride) (Ampres, Associated names: Clorotekal, Decelex) (EMEA-000639-PIP03-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-15T09:30:25Z","last_updated_date":"2025-05-15T09:30:25Z","reference_number":"EMA/103634/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0084-2024-ema-decision-15-march-2024-acceptance-modification-agreed-paediatric-investigation-plan-chloroprocaine-hydrochloride-ampres-associated-names-clorotekal-decelex-emea-000639-pip03-16-m03_en.pdf"},
    {"id":"68290","name":"P/0083/2024: EMA decision of the 15 of March on the acceptance of a modification of an agreed paediatric investigation plan for L-carnitine / glucose / calcium chloride dihydrate / magnesium chloride hexahydrate... (EMEA-003049-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-05-15T09:40:25Z","last_updated_date":"2025-05-15T09:40:25Z","reference_number":"EMA/103624/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0083-2024-ema-decision-15-march-acceptance-modification-agreed-paediatric-investigation-plan-l-carnitine-glucose-calcium-chloride-dihydrate-magnesium-chloride-hexahydrate-emea-003049-pip01-21-m01_en.pdf"},
    {"id":"68580","name":"P/0179/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sevasemten (EMEA-003394-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-06-05T10:41:11Z","last_updated_date":"2025-06-05T10:41:11Z","reference_number":"EMA/105519/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0179-2024-ema-decision-6-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sevasemten-emea-003394-pip01-23_en.pdf"},
    {"id":"68589","name":"P/0072/2023 : EMA decision of 12 april 2024 on the acceptance of a modification of an agreed paediatric investigation plan for vamikibart (EMEA- 003215-PIP01-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-05T16:37:47Z","last_updated_date":"2025-06-05T16:37:47Z","reference_number":"EMA/137672/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0072-2023-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-vamikibart-emea-003215-pip01-22-m01_en.pdf"},
    {"id":"68590","name":"P/0092/2024 : EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for milvexian (EMEA- 003220-PIP01-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-05T16:42:02Z","last_updated_date":"2025-06-05T16:42:02Z","reference_number":"EMA/137674/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0092-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-milvexian-emea-003220-pip01-22-m01_en.pdf"},
    {"id":"68591","name":"P/0098/2024 : EMA decision of 5 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant influenza hemagglutinin-strain A (H1N1 subtype)/Recombinant influenza hemagglutinin-strain A (H3N2 subtype)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-06-05T16:47:03Z","last_updated_date":"2025-06-05T16:47:03Z","reference_number":"EMA/139696/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0098-2024-ema-decision-5-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-influenza-hemagglutinin-strain-h1n1-subtype-recombinant-influenza-hemagglutinin-strain_en.pdf"},
    {"id":"68592","name":"P/0099/2024 : EMA decision of 5 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for pegcetacoplan (Aspaveli), (EMEA-002600-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-05T16:51:39Z","last_updated_date":"2025-06-05T16:51:39Z","reference_number":"EMA/139620/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0099-2024-ema-decision-5-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-pegcetacoplan-aspaveli-emea-002600-pip01-19-m02_en.pdf"},
    {"id":"68598","name":"P/0090/2024: EMA decision of 12 April 2024 on the agreement of a paediatric investigation plan for alpelisib (Piqray), (EMEA-002016-PIP05-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T09:38:37Z","last_updated_date":"2025-06-06T09:38:37Z","reference_number":"EMA/137677/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0090-2024-ema-decision-12-april-2024-agreement-paediatric-investigation-plan-alpelisib-piqray-emea-002016-pip05-23_en.pdf"},
    {"id":"68599","name":"P/0136/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins (Xeomin, Bocouture), (EMEA-001039-PIP04-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T09:24:48Z","last_updated_date":"2025-06-06T09:24:48Z","reference_number":"EMA/153118/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0136-2024-ema-decision-6-may-2024-granting-product-specific-waiver-clostridium-botulinum-neurotoxin-type-150-kd-free-complexing-proteins-xeomin-bocouture-emea-001039-pip04-23_en.pdf"},
    {"id":"68600","name":"P/0145/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for erdafitinib (EMEA-002042-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T09:42:46Z","last_updated_date":"2025-06-06T09:42:46Z","reference_number":"EMA/155774/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0145-2024-ema-decision-6-may-2024-granting-product-specific-waiver-erdafitinib-emea-002042-pip03-23_en.pdf"},
    {"id":"68601","name":"P/0183/2024: EMA decision of 17 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ganaxolone (ZTALMY), (EMEA-002341-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T09:44:07Z","last_updated_date":"2025-06-06T09:44:07Z","reference_number":"EMA/226610/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0183-2024-ema-decision-17-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ganaxolone-ztalmy-emea-002341-pip02-23_en.pdf"},
    {"id":"68602","name":"P/0093/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for empasiprubart (EMEA-003528-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T09:43:27Z","last_updated_date":"2025-06-06T09:43:27Z","reference_number":"EMA/77763/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0093-2024-ema-decision-12-april-2024-granting-product-specific-waiver-empasiprubart-emea-003528-pip01-23_en.pdf"},
    {"id":"68603","name":"P/0094/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for human hydroxysteroid-17ß-dehydrogenase type 1 (HSD17B1) enzyme inhibitor (EMEA-003537-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T09:51:41Z","last_updated_date":"2025-06-06T09:51:41Z","reference_number":"EMA/77764/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0094-2024-ema-decision-12-april-2024-granting-product-specific-waiver-human-hydroxysteroid-17ss-dehydrogenase-type-1-hsd17b1-enzyme-inhibitor-emea-003537-pip01-23_en.pdf"},
    {"id":"68604","name":"P/0095/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for vixarelimab (EMEA-003540-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T09:57:33Z","last_updated_date":"2025-06-06T09:57:33Z","reference_number":"EMA/77767/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0095-2024-ema-decision-12-april-2024-granting-product-specific-waiver-vixarelimab-emea-003540-pip01-23_en.pdf"},
    {"id":"68605","name":"P/0096/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for povorcitinib (EMEA-003313-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T10:38:29Z","last_updated_date":"2025-06-06T10:38:29Z","reference_number":"EMA/77768/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0096-2024-ema-decision-12-april-2024-granting-product-specific-waiver-povorcitinib-emea-003313-pip03-23_en.pdf"},
    {"id":"68606","name":"P/0157/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for spesolimab (Spevigo), (EMEA-002475-PIP04-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T09:44:59Z","last_updated_date":"2025-06-06T09:44:59Z","reference_number":"EMA/170629/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0157-2024-ema-decision-6-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-spesolimab-spevigo-emea-002475-pip04-23_en.pdf"},
    {"id":"68610","name":"P/0097/2024: EMA decision of 12 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for CX-000359 mRNA encoding the UL128 protein in the CMV glycoprotein complex pentamer /","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T12:13:44Z","last_updated_date":"2025-06-06T12:13:44Z","reference_number":"EMA/137691/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0097-2024-ema-decision-12-april-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cx-000359-mrna-encoding-ul128-protein-cmv-glycoprotein-complex-pentamer_en.pdf"},
    {"id":"68611","name":"P/0100/2024: EMA decision of 5 April 2024 on the granting of a product-specific waiver for raludotatug deruxtecan (EMEA-003569-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T15:23:54Z","last_updated_date":"2025-06-06T15:23:54Z","reference_number":"EMA/139618/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0100-2024-ema-decision-5-april-2024-granting-product-specific-waiver-raludotatug-deruxtecan-emea-003569-pip01-23_en.pdf"},
    {"id":"68612","name":"P/0102/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ruxolitinib (phosphate), (Opzelura, Jakavi), (EMEA-002618-PIP02-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T15:27:14Z","last_updated_date":"2025-06-06T15:27:14Z","reference_number":"EMA/98347/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0102-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-ruxolitinib-phosphate-opzelura-jakavi-emea-002618-pip02-20-m01_en.pdf"},
    {"id":"68613","name":"P/0103/2024: EMA decision of 12 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for garetosmab (EMEA-002736-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T15:32:16Z","last_updated_date":"2025-06-06T15:32:16Z","reference_number":"EMA/98369/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0103-2024-ema-decision-12-april-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-garetosmab-emea-002736-pip02-23_en.pdf"},
    {"id":"68614","name":"P/0104/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for seltorexant (EMEA-002746-PIP01-20-M03)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-06-06T15:55:38Z","last_updated_date":"2025-06-06T15:55:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0104-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-seltorexant-emea-002746-pip01-20-m03_en.pdf"},
    {"id":"68615","name":"P/0105/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for tozinameran, tozinameran / famtozinameran, tozinameran/ riltozinameran, raxtozinameran (Comirnaty), (EMEA-002861-PIP02-20-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T16:00:54Z","last_updated_date":"2025-06-06T16:00:54Z","reference_number":"EMA/99159/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0105-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-tozinameran-tozinameran-famtozinameran-tozinameran-riltozinameran-raxtozinameran-comirnaty-emea_en.pdf"},
    {"id":"68616","name":"P/0185/2024: EMA decision of 23 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mavorixafor (EMEA-002490-PIP01-18)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T16:43:50Z","last_updated_date":"2025-06-06T16:43:50Z","reference_number":"EMA/243653/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0185-2024-ema-decision-23-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mavorixafor-emea-002490-pip01-18_en.pdf"},
    {"id":"68617","name":"P/0166/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for amivantamab (Rybrevant), (EMEA-002573-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T16:45:09Z","last_updated_date":"2025-06-06T16:45:09Z","reference_number":"EMA/178740/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0166-2024-ema-decision-6-may-2024-granting-product-specific-waiver-amivantamab-rybrevant-emea-002573-pip02-23_en.pdf"},
    {"id":"68618","name":"P/0169/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a waiver for nivolumab / relatlimab (Opdualag), (EMEA-002727-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T16:46:49Z","last_updated_date":"2025-06-06T16:46:49Z","reference_number":"EMA/178738/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0169-2024-ema-decision-6-may-2024-agreement-paediatric-investigation-plan-granting-waiver-nivolumab-relatlimab-opdualag-emea-002727-pip03-23_en.pdf"},
    {"id":"68619","name":"P/0158/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for etavopivat (EMEA-002924-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-06T16:50:16Z","last_updated_date":"2025-06-06T16:50:16Z","reference_number":"EMA/170630/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0158-2024-ema-decision-6-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-etavopivat-emea-002924-pip02-23_en.pdf"},
    {"id":"68620","name":"P/0153/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for live attenuated respiratory syncytial virus (RSV) (EMEA-003277-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T16:51:15Z","last_updated_date":"2025-06-10T16:51:15Z","reference_number":"EMA/148126/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0153-2024-ema-decision-6-may-2024-agreement-paediatric-investigation-plan-granting-deferral-live-attenuated-respiratory-syncytial-virus-rsv-emea-003277-pip02-23_en.pdf"},
    {"id":"68621","name":"P/0178/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for orforglipron, (EMEA-003299-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T16:52:20Z","last_updated_date":"2025-06-10T16:52:20Z","reference_number":"EMA/105471/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2024-ema-decision-6-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-orforglipron-emea-003299-pip01-22_en.pdf"},
    {"id":"68622","name":"P/0141/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for hemopexin, human, (EMEA-003333-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T16:53:06Z","last_updated_date":"2025-06-10T16:53:06Z","reference_number":"EMA/153127/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0141-2024-ema-decision-6-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-hemopexin-human-emea-003333-pip01-22_en.pdf"},
    {"id":"68624","name":"P/0170/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tanimilast (EMEA-003393-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T16:54:44Z","last_updated_date":"2025-06-10T16:54:44Z","reference_number":"EMA/178739/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0170-2024-ema-decision-6-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tanimilast-emea-003393-pip01-23_en.pdf"},
    {"id":"68645","name":"P/0173/2024: EMA decision of 3 May 2024 on the granting of a product specific waiver for modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/mRNA-4157), (EMEA-003434-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T14:16:21Z","last_updated_date":"2025-06-10T14:16:21Z","reference_number":"EMA/182128/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0173-2024-ema-decision-3-may-2024-granting-product-specific-waiver-modified-messenger-ribonucleic-acid-encoding-individual-patient-specific-tumour-neoantigens-v940-mrna-4157-emea-003434-pip02-23_en.pdf"},
    {"id":"68646","name":"P/0184/2024 : EMA decision of 17 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mometasone furoate (EMEA-003454-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T14:17:27Z","last_updated_date":"2025-06-10T14:17:27Z","reference_number":"EMA/226770/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0184-2024-ema-decision-17-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mometasone-furoate-emea-003454-pip01-23_en.pdf"},
    {"id":"68648","name":"P/0159/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for laruparetigene zovaparvovec (EMEA-003457-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T14:18:17Z","last_updated_date":"2025-06-10T14:18:17Z","reference_number":"EMA/170634/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0159-2024-ema-decision-6-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-laruparetigene-zovaparvovec-emea-003457-pip01-23_en.pdf"},
    {"id":"68649","name":"P/0142/2024: EMA decision of 6 May 2024 on the agreement of a PIP and on the granting of a deferral and on the granting of a waiver for messenger RNA encoding Cas9, single guide RNA targeting the human KLKB1 gene (NTLA-2002) (EMEA-003465-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:19:15Z","last_updated_date":"2025-06-11T14:19:15Z","reference_number":"EMA/153131/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0142-2024-ema-decision-6-may-2024-agreement-pip-granting-deferral-granting-waiver-messenger-rna-encoding-cas9-single-guide-rna-targeting-human-klkb1-gene-ntla-2002-emea-003465-pip01-23_en.pdf"},
    {"id":"68650","name":"P/0182/2024: EMA decision of 15 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for zasocitinib (EMEA-003478-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:44:10Z","last_updated_date":"2025-06-11T14:44:10Z","reference_number":"EMA/224149/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2024-ema-decision-15-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-zasocitinib-emea-003478-pip01-23_en.pdf"},
    {"id":"68651","name":"P/0150/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lutikizumab (EMEA-003481-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:46:48Z","last_updated_date":"2025-06-11T14:46:48Z","reference_number":"EMA/155839/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0150-2024-ema-decision-6-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lutikizumab-emea-003481-pip01-23_en.pdf"},
    {"id":"68652","name":"P/0174/2024: EMA decision of 3 May 2024 on the granting of a product specific waiver for N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4- (1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide methanesulfonate","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:49:44Z","last_updated_date":"2025-06-11T14:49:44Z","reference_number":"EMA/182137/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0174-2024-ema-decision-3-may-2024-granting-product-specific-waiver-n-2-2-dimethylaminoethylmethylamino-5-4-1-methyl-1h-indol-3-ylpyrimidin-2-ylamino-6-222-trifluoroethoxypyridin-3-ylacrylamide_en.pdf"},
    {"id":"68653","name":"P/0175/2024: EMA decision of 3 May 2024 on the agreement of a paediatric investigation plan for Human rabies immune globulin (EMEA-003552- PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:50:54Z","last_updated_date":"2025-06-11T14:50:54Z","reference_number":"EMA/182144/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0175-2024-ema-decision-3-may-2024-agreement-paediatric-investigation-plan-human-rabies-immune-globulin-emea-003552-pip01-23_en.pdf"},
    {"id":"68654","name":"P/0139/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for acetylcysteine amide, (EMEA-003554-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:51:50Z","last_updated_date":"2025-06-11T14:51:50Z","reference_number":"EMA/153120/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0139-2024-ema-decision-6-may-2024-granting-product-specific-waiver-acetylcysteine-amide-emea-003554-pip01-23_en.pdf"},
    {"id":"68655","name":"P/0140/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for alrefimotide / tapderimotide / riletamotide, (EMEA- 003555-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:52:46Z","last_updated_date":"2025-06-11T14:52:46Z","reference_number":"EMA/153122/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0140-2024-ema-decision-6-may-2024-granting-product-specific-waiver-alrefimotide-tapderimotide-riletamotide-emea-003555-pip01-23_en.pdf"},
    {"id":"68656","name":"P/0147/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for petosemtamab (EMEA-003557-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:53:35Z","last_updated_date":"2025-06-11T14:53:35Z","reference_number":"EMA/155809/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0147-2024-ema-decision-6-may-2024-granting-product-specific-waiver-petosemtamab-emea-003557-pip01-23_en.pdf"},
    {"id":"68657","name":"P/0146/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for baxdrostat / dapagliflozin (propanediol monohydrate) (EMEA-003559-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:54:43Z","last_updated_date":"2025-06-11T14:54:43Z","reference_number":"EMA/155785/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0146-2024-ema-decision-6-may-2024-granting-product-specific-waiver-baxdrostat-dapagliflozin-propanediol-monohydrate-emea-003559-pip01-23_en.pdf"},
    {"id":"68658","name":"P/0160/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for carbachol / brimonidine tartrate (EMEA-003561-PIP01- 23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:55:44Z","last_updated_date":"2025-06-11T14:55:44Z","reference_number":"EMA/176533/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0160-2024-ema-decision-6-may-2024-granting-product-specific-waiver-carbachol-brimonidine-tartrate-emea-003561-pip01-23_en.pdf"},
    {"id":"68659","name":"P/0161/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for ezetimibe / fenofibrate / rosuvastatin calcium (EMEA- 003562-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:56:52Z","last_updated_date":"2025-06-11T14:56:52Z","reference_number":"EMA/176534/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0161-2024-ema-decision-6-may-2024-granting-product-specific-waiver-ezetimibe-fenofibrate-rosuvastatin-calcium-emea-003562-pip01-23_en.pdf"},
    {"id":"68660","name":"P/0162/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for atorvastatin calcium / fenofibrate (EMEA-003563- PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:57:46Z","last_updated_date":"2025-06-11T14:57:46Z","reference_number":"EMA/176537/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0162-2024-ema-decision-6-may-2024-granting-product-specific-waiver-atorvastatin-calcium-fenofibrate-emea-003563-pip01-23_en.pdf"},
    {"id":"68661","name":"P/0154/2024: EMA decision of 6 May 2024 on the granting of a product-specific waiver for camreluzimab (EMEA-003566-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:59:15Z","last_updated_date":"2025-06-11T14:59:15Z","reference_number":"EMA/148130/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0154-2024-ema-decision-6-may-2024-granting-product-specific-waiver-camreluzimab-emea-003566-pip01-23_en.pdf"},
    {"id":"68662","name":"P/0155/2024: EMA decision of 6 May 2024 on the granting of a product-specific waiver for Volixibat potassium (EMEA-003567-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T15:02:05Z","last_updated_date":"2025-06-11T15:02:05Z","reference_number":"EMA/148131/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0155-2024-ema-decision-6-may-2024-granting-product-specific-waiver-volixibat-potassium-emea-003567-pip01-23_en.pdf"},
    {"id":"68663","name":"P/0156/2024: EMA decision of 6 May 2024 on the granting of a product-specific waiver for human alpha-1-proteinase inhibitor immunoglobulin G fusion protein, recombinant (EMEA-003570-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T15:02:55Z","last_updated_date":"2025-06-11T15:02:55Z","reference_number":"EMA/148133/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0156-2024-ema-decision-6-may-2024-granting-product-specific-waiver-human-alpha-1-proteinase-inhibitor-immunoglobulin-g-fusion-protein-recombinant-emea-003570-pip01-23_en.pdf"},
    {"id":"68664","name":"P/0143/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for pitavastatin calcium / ezetimibe, (EMEA-003573-PIP01- 23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T15:03:44Z","last_updated_date":"2025-06-11T15:03:44Z","reference_number":"EMA/153124/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2024-ema-decision-6-may-2024-granting-product-specific-waiver-pitavastatin-calcium-ezetimibe-emea-003573-pip01-23_en.pdf"},
    {"id":"68665","name":"P/0181/2024: EMA decision of 15 May 2024 on agreement of PIP and on granting of a waiver for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1), strain A (H3N2), strain B (Victoria lineage) (EMEA-003623-PIP01-24) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T15:04:37Z","last_updated_date":"2025-06-11T15:04:37Z","reference_number":"EMA/176737/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0181-2024-ema-decision-15-may-2024-agreement-pip-granting-waiver-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h1n1-strain-h3n2-strain-b-victoria-lineage-emea-003623-pip01-24_en.pdf"},
    {"id":"68666","name":"P/0120/2024: EMA decision of 12 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for trimodulin (human IgM, IgA, IgG solution) (EMEA-002883-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T15:03:53Z","last_updated_date":"2025-06-10T15:03:53Z","reference_number":"EMA/114596/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0120-2024-ema-decision-12-april-2024-agreement-paediatric-investigation-plan-granting-deferral-trimodulin-human-igm-iga-igg-solution-emea-002883-pip03-23_en.pdf"},
    {"id":"68667","name":"P/0180/2024: EMA decision of 16 May 2024 on the granting of a product specific waiver for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1), strain A (H3N2), strain B (Victoria lineage) (EMEA-003624-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T15:08:52Z","last_updated_date":"2025-06-11T15:08:52Z","reference_number":"EMA/221881/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0180-2024-ema-decision-16-may-2024-granting-product-specific-waiver-influenza-virus-surface-antigens-haemagglutinin-neuraminidase-strain-h1n1-strain-h3n2-strain-b-victoria-lineage-emea-003624-pip01_en.pdf"},
    {"id":"68668","name":"P/0121/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for suvecaltamide hydrochloride (EMEA-003248-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T15:17:52Z","last_updated_date":"2025-06-10T15:17:52Z","reference_number":"EMA/114623/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0121-2024-ema-decision-12-april-2024-granting-product-specific-waiver-suvecaltamide-hydrochloride-emea-003248-pip02-23_en.pdf"},
    {"id":"68669","name":"P/0122/2024: EMA decision of 11 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for iodine (131I) apamistamab (EMEA-003395-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T15:27:34Z","last_updated_date":"2025-06-10T15:27:34Z","reference_number":"EMA/142648/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0122-2024-ema-decision-11-april-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-iodine-131i-apamistamab-emea-003395-pip02-23_en.pdf"},
    {"id":"68671","name":"P/0125/2024: EMA decision of 11 April 2024 on the granting of a product specific waiver for maplirpacept (EMEA-003551-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T15:58:26Z","last_updated_date":"2025-06-10T15:58:26Z","reference_number":"EMA/143927/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0125-2024-ema-decision-11-april-2024-granting-product-specific-waiver-maplirpacept-emea-003551-pip01-23_en.pdf"},
    {"id":"68673","name":"P/0126/2024: EMA decision of on the agreement of 12 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for disitamab vedotin (EMEA-003443-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T16:08:45Z","last_updated_date":"2025-06-10T16:08:45Z","reference_number":"EMA/114598/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0126-2024-ema-decision-agreement-12-april-2024-agreement-paediatric-investigation-plan-granting-deferral-disitamab-vedotin-emea-003443-pip02-23_en.pdf"},
    {"id":"68674","name":"P/0127/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for propylene glycol / urea (EMEA-003542-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-06-10T16:24:02Z","last_updated_date":"2025-06-10T16:24:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0127-2024-ema-decision-12-april-2024-granting-product-specific-waiver-propylene-glycol-urea-emea-003542-pip01-23_en.pdf"},
    {"id":"68675","name":"P/0128/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for autologous T-cells expressing a chimeric antigenic receptor against G protein coupled receptor class C, group 5, member D (GPRC5D)... (EMEA-003543-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T16:30:15Z","last_updated_date":"2025-06-10T16:30:15Z","reference_number":"EMA/114622/2024 ","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0128-2024-ema-decision-12-april-2024-granting-product-specific-waiver-autologous-t-cells-expressing-chimeric-antigenic-receptor-against-g-protein-coupled-receptor-class-c-group-5-member-d-gprc5d_en.pdf"},
    {"id":"68676","name":"P/0129/2024: EMA decision of 11 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mirikizumab (Omvoh) (EMEA-002208-PIP02-24)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-06-10T16:44:11Z","last_updated_date":"2025-06-10T16:44:11Z","reference_number":"EMA/142238/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0129-2024-ema-decision-11-april-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mirikizumab-omvoh-emea-002208-pip02-24_en.pdf"},
    {"id":"68677","name":"P/0131/2024: EMA decision of 11 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for GIPR antagonist/GLP-1R agonist (AMG 133) (EMEA-003439-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T16:52:53Z","last_updated_date":"2025-06-10T16:52:53Z","reference_number":"EMA/142616/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0131-2024-ema-decision-11-april-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-gipr-antagonist-glp-1r-agonist-amg-133-emea-003439-pip02-23_en.pdf"},
    {"id":"68678","name":"P/0132/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for netupitant / palonosetron (Akynzeo) (EMEA-001198- PIP04-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T17:05:03Z","last_updated_date":"2025-06-10T17:05:03Z","reference_number":"EMA/105459/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0132-2024-ema-decision-12-april-2024-granting-product-specific-waiver-netupitant-palonosetron-akynzeo-emea-001198-pip04-23_en.pdf"},
    {"id":"68679","name":"P/0133/2024: EMA decision of 12 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for enlicitide (decanoate) (EMEA-003453-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T17:12:20Z","last_updated_date":"2025-06-10T17:12:20Z","reference_number":"EMA/144124/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0133-2024-ema-decision-12-april-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-enlicitide-decanoate-emea-003453-pip01-23_en.pdf"},
    {"id":"68680","name":"P/0124/2024: EMA decision of 11 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for cedazuridine / decitabine (Inaqovi) (EMEA-003071-PIP01-21-M01)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-06-10T17:22:25Z","last_updated_date":"2025-06-10T17:22:25Z","reference_number":"EMA/143924/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0124-2024-ema-decision-11-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-cedazuridine-decitabine-inaqovi-emea-003071-pip01-21-m01_en.pdf"},
    {"id":"68681","name":"P/0130/2024: EMA decision of 11 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for mirikizumab (Omvoh), (EMEA-002208-PIP01-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T17:30:28Z","last_updated_date":"2025-06-10T17:30:28Z","reference_number":"EMA/142543/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0130-2024-ema-decision-11-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-mirikizumab-omvoh-emea-002208-pip01-17-m04_en.pdf"},
    {"id":"68682","name":"P/0134/2024: EMA decision of 25 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for selumetinib (Koselugo) (EMEA-001585-PIP01-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T17:41:50Z","last_updated_date":"2025-06-10T17:41:50Z","reference_number":"EMA/167583/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0134-2024-ema-decision-25-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-selumetinib-koselugo-emea-001585-pip01-13-m06_en.pdf"},
    {"id":"68683","name":"P/0123/2024: EMA decision of 11 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for aficamten (EMEA-002958-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-10T17:50:41Z","last_updated_date":"2025-06-10T17:50:41Z","reference_number":"EMA/142976/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0123-2024-ema-decision-11-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-aficamten-emea-002958-pip01-21-m01_en.pdf"},
    {"id":"68689","name":"P/0106/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for nebivolol / ramipril (EMEA-003530-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T11:19:00Z","last_updated_date":"2025-06-11T11:19:00Z","reference_number":"EMA/99223/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0106-2024-ema-decision-12-april-2024-granting-product-specific-waiver-nebivolol-ramipril-emea-003530-pip01-23_en.pdf"},
    {"id":"68691","name":"P/0107/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for sitagliptin / dapagliflozin (EMEA-003534-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T11:49:16Z","last_updated_date":"2025-06-11T11:49:16Z","reference_number":"EMA/99287/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0107-2024-ema-decision-12-april-2024-granting-product-specific-waiver-sitagliptin-dapagliflozin-emea-003534-pip01-23_en.pdf"},
    {"id":"68695","name":"P/0108/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for zongertinib (EMEA-003546-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:30:49Z","last_updated_date":"2025-06-11T14:30:49Z","reference_number":"EMA/118759/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0108-2024-ema-decision-12-april-2024-granting-product-specific-waiver-zongertinib-emea-003546-pip01-23_en.pdf"}    {"id":"68696","name":"P/0109/2024: EMA decision on 12 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for belimumab (Benlysta), (EMEA-000520-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:40:38Z","last_updated_date":"2025-06-11T14:40:38Z","reference_number":"EMA/105425/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0109-2024-ema-decision-12-april-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-belimumab-benlysta-emea-000520-pip03-23_en.pdf"},
    {"id":"68697","name":"P/0111/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for efgartigimod alfa (Vyvgart), (EMEA-002597-PIP10-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:50:33Z","last_updated_date":"2025-06-11T14:50:33Z","reference_number":"EMA/105466/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0111-2024-ema-decision-12-april-2024-granting-product-specific-waiver-efgartigimod-alfa-vyvgart-emea-002597-pip10-23_en.pdf"},
    {"id":"68698","name":"P/0112/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for human IgG1 monoclonal antibody targeting amyloid transthyretin (EMEA-003548-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T14:56:46Z","last_updated_date":"2025-06-11T14:56:46Z","reference_number":"EMA/118783/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0112-2024-ema-decision-12-april-2024-granting-product-specific-waiver-human-igg1-monoclonal-antibody-targeting-amyloid-transthyretin-emea-003548-pip01-23_en.pdf"},
    {"id":"68699","name":"P/0116/2024: EMA decision of 12 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for losmapimod (EMEA-003448-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T15:05:51Z","last_updated_date":"2025-06-11T15:05:51Z","reference_number":"EMA/121686/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0116-2024-ema-decision-12-april-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-losmapimod-emea-003448-pip01-23_en.pdf"},
    {"id":"68701","name":"P/0135/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for apixaban (Eliquis), (EMEA-000183-PIP02-12-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T15:32:19Z","last_updated_date":"2025-06-11T15:32:19Z","reference_number":"EMA/153112/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0135-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-apixaban-eliquis-emea-000183-pip02-12-m05_en.pdf"},
    {"id":"68702","name":"P/0177/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for 13 Grass Aqueous Extract (EMEA-000813-PIP01-09-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T15:36:15Z","last_updated_date":"2025-06-11T15:36:15Z","reference_number":"EMA/105457/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0177-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-13-grass-aqueous-extract-emea-000813-pip01-09-m01_en.pdf"},
    {"id":"68703","name":"P/0110/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for catequentinib, (EMEA-002486-PIP04-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T16:03:21Z","last_updated_date":"2025-06-11T16:03:21Z","reference_number":"EMA/105462/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0110-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-catequentinib-emea-002486-pip04-21-m01_en.pdf"},
    {"id":"68704","name":"P/0113/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for multivalent pneumococcal polysaccharide conjugate to carrier protein (PCV21), (EMEA-002780-PIP02-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T16:08:59Z","last_updated_date":"2025-06-11T16:08:59Z","reference_number":"EMA/144177/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0113-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-multivalent-pneumococcal-polysaccharide-conjugate-carrier-protein-pcv21-emea-002780-pip02-20-m01_en.pdf"},
    {"id":"68705","name":"P/0114/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for in vitro expanded autologous human articular chondrocytes (EMEA-001823-PIP01-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T16:28:40Z","last_updated_date":"2025-06-11T16:28:40Z","reference_number":"EMA/121889/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0114-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-vitro-expanded-autologous-human-articular-chondrocytes-emea-001823-pip01-15-m03_en.pdf"},
    {"id":"68706","name":"P/0115/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for fidanacogene elaparvovec (EMEA-002362-PIP02-19-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T16:33:22Z","last_updated_date":"2025-06-11T16:33:22Z","reference_number":"EMA/121937/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0115-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-fidanacogene-elaparvovec-emea-002362-pip02-19-m03_en.pdf"},
    {"id":"68707","name":"P/0117/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP01-11-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-11T16:39:24Z","last_updated_date":"2025-06-11T16:39:24Z","reference_number":"EMA/114607/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0117-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-baricitinib-olumiant-emea-001220-pip01-11-m10_en.pdf"},
    {"id":"68715","name":"P/0118/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for outer membrane vesicles (OMV) from N. meningitidis Strain NZ 98/254..(EMEA-001260-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-12T13:53:39Z","last_updated_date":"2025-06-12T13:53:39Z","reference_number":"EMA/114604/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0118-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-outer-membrane-vesicles-omv-n-meningitidis-strain-nz-98-254emea-001260-pip01-11-m03_en.pdf"},
    {"id":"68717","name":"P/0119/2024: EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for filgotinib (Jyseleca), (EMEA-001619-PIP04-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-12T14:05:35Z","last_updated_date":"2025-06-12T14:05:35Z","reference_number":"EMA/114605/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0119-2024-ema-decision-12-april-2024-acceptance-modification-agreed-paediatric-investigation-plan-filgotinib-jyseleca-emea-001619-pip04-17-m03_en.pdf"},
    {"id":"68720","name":"P/0137/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for avatrombopag maleate (Doptelet), (EMEA-001136-PIP01-11-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-12T15:13:13Z","last_updated_date":"2025-06-12T15:13:13Z","reference_number":"EMA/153113/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0137-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-avatrombopag-maleate-doptelet-emea-001136-pip01-11-m03_en.pdf"},
    {"id":"68721","name":"P/0138/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for nivolumab (Opdivo), (EMEA-001407-PIP02-15-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-12T15:14:28Z","last_updated_date":"2025-06-12T15:14:28Z","reference_number":"EMA/153114/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0138-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-nivolumab-opdivo-emea-001407-pip02-15-m07_en.pdf"},
    {"id":"68722","name":"P/0171/2024: EMA decision of 3 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for atrasentan (hydrochloride), (EMEA-001666-PIP02-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:15:24Z","last_updated_date":"2025-06-16T15:15:24Z","reference_number":"EMA/182112/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0171-2024-ema-decision-3-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-atrasentan-hydrochloride-emea-001666-pip02-21-m01_en.pdf"},
    {"id":"68723","name":"P/0172/2024: EMA decision of 3 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for venglustat (EMEA- 001716-PIP07-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:16:16Z","last_updated_date":"2025-06-16T15:16:16Z","reference_number":"EMA/182551/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0172-2024-ema-decision-3-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-venglustat-emea-001716-pip07-22-m01_en.pdf"},
    {"id":"68724","name":"P/0176/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for brexucabtagene autoleucel (Tecartus), (EMEA-001862-PIP03-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:17:10Z","last_updated_date":"2025-06-16T15:17:10Z","reference_number":"EMA/178727/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0176-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-brexucabtagene-autoleucel-tecartus-emea-001862-pip03-20-m02_en.pdf"},
    {"id":"68725","name":"P/0167/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed PIP for beclometasone (dipropionate) / formoterol (fumarate dihydrate) / glycopyrronium bromide (Trimbow and associated names), (EMEA-001875-PIP02-18-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:18:11Z","last_updated_date":"2025-06-16T15:18:11Z","reference_number":"EMA/178722/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0167-2024-ema-decision-6-may-2024-acceptance-modification-agreed-pip-beclometasone-dipropionate-formoterol-fumarate-dihydrate-glycopyrronium-bromide-trimbow-associated-names-emea-001875-pip02-18-m04_en.pdf"},
    {"id":"68726","name":"P/0186/2024: EMA decision of 29 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid ... (EMEA-001930-PIP01-16-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-12T15:19:41Z","last_updated_date":"2025-06-12T15:19:41Z","reference_number":"EMA/246710/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0186-2024-ema-decision-29-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-polysaccharide-conjugated-tetanus-toxoid-emea-001930-pip01-16-m05_en.pdf"},
    {"id":"68727","name":"P/0168/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for influenza vaccine (surface antigen, inactivated, prepared in cell cultures) [QIVc] (Flucelvax Tetra), (EMEA-002068- PIP01-16-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:21:07Z","last_updated_date":"2025-06-16T15:21:07Z","reference_number":"EMA/178725/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0168-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-influenza-vaccine-surface-antigen-inactivated-prepared-cell-cultures-qivc-flucelvax-tetra-emea-002068_en.pdf"},
    {"id":"68728","name":"P/0149/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for onasemnogene abeparvovec (Zolgensma), (EMEA-002168-PIP01-17-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T15:22:00Z","last_updated_date":"2025-06-13T15:22:00Z","reference_number":"EMA/155951/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0149-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-onasemnogene-abeparvovec-zolgensma-emea-002168-pip01-17-m06_en.pdf"},
    {"id":"68729","name":"P/0148/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for olaparib (Lynparza), (EMEA-002269-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-12T15:22:56Z","last_updated_date":"2025-06-12T15:22:56Z","reference_number":"EMA/155893/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0148-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-olaparib-lynparza-emea-002269-pip01-17-m03_en.pdf"},
    {"id":"68730","name":"P/0151/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for berotralstat (Orladeyo), (EMEA-002449-PIP02-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:23:50Z","last_updated_date":"2025-06-16T15:23:50Z","reference_number":"EMA/148123/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0151-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-berotralstat-orladeyo-emea-002449-pip02-18-m02_en.pdf"},
    {"id":"68731","name":"P/0163/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for levonogestrel (EMEA- 002474-PIP02-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:24:51Z","last_updated_date":"2025-06-16T15:24:51Z","reference_number":"EMA/176728/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0163-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-levonogestrel-emea-002474-pip02-18-m02_en.pdf"},
    {"id":"68732","name":"P/0152/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for loncastuximab tesirine (Zynlonta), (EMEA-002665-PIP02-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:25:38Z","last_updated_date":"2025-06-16T15:25:38Z","reference_number":"EMA/148125/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0152-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-loncastuximab-tesirine-zynlonta-emea-002665-pip02-20-m01_en.pdf"},
    {"id":"68733","name":"P/0164/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for giroctocogene fitelparvovec (EMEA-002724-PIP01-19-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:26:26Z","last_updated_date":"2025-06-16T15:26:26Z","reference_number":"EMA/176730/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0164-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-giroctocogene-fitelparvovec-emea-002724-pip01-19-m03_en.pdf"},
    {"id":"68734","name":"P/0165/2024: EMA decision of 6 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for live, attenuated, dengue virus ... (EMEA-002999-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-12T15:27:28Z","last_updated_date":"2025-06-12T15:27:28Z","reference_number":"EMA/176734/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0165-2024-ema-decision-6-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-live-attenuated-dengue-virus-emea-002999-pip01-21-m01_en.pdf"},
    {"id":"68763","name":"P/0252/2024: EMA decision of 19 July 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for derivative of azabicycloheptane-carboxamide (EMEA-003451-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T17:21:11Z","last_updated_date":"2025-06-13T17:21:11Z","reference_number":"EMA/296571/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0252-2024-ema-decision-19-july-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-derivative-azabicycloheptane-carboxamide-emea-003451-pip01-23_en.pdf"},
    {"id":"68852","name":"P/0250/2024: EMA decision of 19 July 2024 on the granting of a product specific waiver for ifinatamab deruxtecan (EMEA-003613-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T09:38:30Z","last_updated_date":"2025-06-20T09:38:30Z","reference_number":"EMA/324726/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0250-2024-ema-decision-19-july-2024-granting-product-specific-waiver-ifinatamab-deruxtecan-emea-003613-pip01-24_en.pdf"},
    {"id":"68853","name":"P/0251/2024: EMA decision of 19 July 2024 on the granting of a product specific waiver for diclofenac (sodium) / thiocolchicoside (EMEA-003611- PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T09:39:54Z","last_updated_date":"2025-06-20T09:39:54Z","reference_number":"EMA/296527/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0251-2024-ema-decision-19-july-2024-granting-product-specific-waiver-diclofenac-sodium-thiocolchicoside-emea-003611-pip01-24_en.pdf"},
    {"id":"68854","name":"P/0272/2024: EMA decision of 24 July 2024 on the granting of a product specific waiver for acasunlimab (EMEA-003606-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T09:40:55Z","last_updated_date":"2025-06-20T09:40:55Z","reference_number":"EMA/307559/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0272-2024-ema-decision-24-july-2024-granting-product-specific-waiver-acasunlimab-emea-003606-pip01-24_en.pdf"},
    {"id":"68859","name":"P/0258/2024: EMA decision of 19 July 2024 on the granting of a product specific waiver for alvelestat (tosylate) (EMEA-003605-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T10:47:08Z","last_updated_date":"2025-06-20T10:47:08Z","reference_number":"EMA/320746/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0258-2024-ema-decision-19-july-2024-granting-product-specific-waiver-alvelestat-tosylate-emea-003605-pip01-24_en.pdf"},
    {"id":"68860","name":"P/0267/2024: EMA decision of 17 July 2024 on the granting of a product specific waiver for indapamide / ramipril (EMEA-003600-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T10:48:10Z","last_updated_date":"2025-06-20T10:48:10Z","reference_number":"EMA/328778/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0267-2024-ema-decision-17-july-2024-granting-product-specific-waiver-indapamide-ramipril-emea-003600-pip01-24_en.pdf"},
    {"id":"68861","name":"P/0270/2024: EMA decision of 17 July 2024 on the granting of a product specific waiver for trastuzumab-exatecan derivative antibody-drug conjugate (EMEA-003599-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T10:49:12Z","last_updated_date":"2025-06-20T10:49:12Z","reference_number":"EMA/328766/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0270-2024-ema-decision-17-july-2024-granting-product-specific-waiver-trastuzumab-exatecan-derivative-antibody-drug-conjugate-emea-003599-pip01-24_en.pdf"},
    {"id":"68875","name":"P/0226/2024: EMA decision of 10 July 2024 on the granting of a product specific waiver for zanubrutinib (Brukinsa), (EMEA-002354-PIP03-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T16:08:59Z","last_updated_date":"2025-06-20T16:08:59Z","reference_number":"EMA/313177/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0226-2024-ema-decision-10-july-2024-granting-product-specific-waiver-zanubrutinib-brukinsa-emea-002354-pip03-24_en.pdf"},
    {"id":"68881","name":"P/0237/2024: EMA decision of 18 July 2024 on the granting of a product specific waiver for allogeneic skin-derived ABCB5-positive dermal mesenchymal stromal cells (Amesanar), (EMEA-002875-PIP02-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-23T09:57:34Z","last_updated_date":"2025-06-23T09:57:34Z","reference_number":"EMA/319282/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0237-2024-ema-decision-18-july-2024-granting-product-specific-waiver-allogeneic-skin-derived-abcb5-positive-dermal-mesenchymal-stromal-cells-amesanar-emea-002875-pip02-24_en.pdf"},
    {"id":"68887","name":"P/0242/2024: EMA decision of 19 July 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for ensitrelvir, (EMEA-003192-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-23T13:57:29Z","last_updated_date":"2025-06-23T13:57:29Z","reference_number":"EMA/323235/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0242-2024-ema-decision-19-july-2024-agreement-paediatric-investigation-plan-granting-deferral-ensitrelvir-emea-003192-pip02-23_en.pdf"},
    {"id":"68889","name":"P/0233/2024: EMA decision of 19 July 2024 on the granting of a product specific waiver for autologous CD3-positive T cells transduced with a retroviral vector containing an anti-B cell maturation agent chimeric antigen receptor gene (EMEA-003593-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-23T17:37:08Z","last_updated_date":"2025-06-23T17:37:08Z","reference_number":"EMA/321024/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0233-2024-ema-decision-19-july-2024-granting-product-specific-waiver-autologous-cd3-positive-t-cells-transduced-retroviral-vector-containing-anti-b-cell-maturation-agent-chimeric-antigen-receptor_en.pdf"},
    {"id":"68890","name":"P/0234/2024: EMA decision of 18 July 2024 on the granting of a product specific waiver for autologous CD3-positive T cells transduced with a retroviral vector containing an anti-B cell maturation agent chimeric antigen receptor gene (EMEA-003593-PIP02-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-23T17:42:22Z","last_updated_date":"2025-06-23T17:42:22Z","reference_number":"EMA/320747/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0234-2024-ema-decision-18-july-2024-granting-product-specific-waiver-autologous-cd3-positive-t-cells-transduced-retroviral-vector-containing-anti-b-cell-maturation-agent-chimeric-antigen-receptor_en.pdf"},
    {"id":"68891","name":"P/0231/2024: EMA decision of 19 July 2024 on the granting of a product-specific waiver for fulzerasib (EMEA-003594-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-23T17:43:37Z","last_updated_date":"2025-06-23T17:43:37Z","reference_number":"EMA/291608/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0231-2024-ema-decision-19-july-2024-granting-product-specific-waiver-fulzerasib-emea-003594-pip01-24_en.pdf"},
    {"id":"68892","name":"P/0232/2024: EMA decision of 19 July 2024 on the granting of a product-specific waiver for (EMEA-003596-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T17:44:31Z","last_updated_date":"2025-06-24T17:44:31Z","reference_number":"EMA/291622/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0232-2024-ema-decision-19-july-2024-granting-product-specific-waiver-emea-003596-pip01-24_en.pdf"},
    {"id":"68893","name":"P/0257/2024: EMA decision of 19 July 2024 on the granting of a product specific waiver for (EMEA-003597-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T17:45:46Z","last_updated_date":"2025-06-24T17:45:46Z","reference_number":"EMA/296468/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0257-2024-ema-decision-19-july-2024-granting-product-specific-waiver-emea-003597-pip01-24_en.pdf"},
    {"id":"68894","name":"P/0256/2024: EMA decision of 19 July 2024 on the granting of a product specific waiver for anti-human LAG-3 monoclonal antibody, human IgG4 isotype (EMEA-003598-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T17:47:09Z","last_updated_date":"2025-06-24T17:47:09Z","reference_number":"EMA/296479/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0256-2024-ema-decision-19-july-2024-granting-product-specific-waiver-anti-human-lag-3-monoclonal-antibody-human-igg4-isotype-emea-003598-pip01-24_en.pdf"},
    {"id":"68895","name":"P/0238/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for regadenoson (Rapiscan), (EMEA-000410-PIP01-08-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T09:53:27Z","last_updated_date":"2025-06-24T09:53:27Z","reference_number":"EMA/319202/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0238-2024-ema-decision-18-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-regadenoson-rapiscan-emea-000410-pip01-08-m07_en.pdf"},
    {"id":"68896","name":"P/0239/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz), (EMEA-000576-PIP01-09-M16)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T09:54:18Z","last_updated_date":"2025-06-24T09:54:18Z","reference_number":"EMA/319201/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0239-2024-ema-decision-18-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz-emea-000576-pip01-09-m16_en.pdf"},
    {"id":"68897","name":"P/0244/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for vedolizumab (Entyvio), (EMEA-000645-PIP01-09-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T09:55:26Z","last_updated_date":"2025-06-24T09:55:26Z","reference_number":"EMA/319200/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0244-2024-ema-decision-18-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-vedolizumab-entyvio-emea-000645-pip01-09-m09_en.pdf"},
    {"id":"68898","name":"P/0245/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for dermatophagoides farinae extracts 100 %, (EMEA-000834-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T09:56:29Z","last_updated_date":"2025-06-24T09:56:29Z","reference_number":"EMA/319199/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0245-2024-ema-decision-18-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-dermatophagoides-farinae-extracts-100-emea-000834-pip01-10-m01_en.pdf"},
    {"id":"68899","name":"P/0247/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for dermatophagoides pteronyssinus extracts 100%, (EMEA-000835-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:29:37Z","last_updated_date":"2025-06-24T12:29:37Z","reference_number":"EMA/319198/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0247-2024-ema-decision-18-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-dermatophagoides-pteronyssinus-extracts-100-emea-000835-pip01-10-m01_en.pdf"},
    {"id":"68900","name":"P/0248/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for dermatophagoides pteronyssinus / dermatophagoides farinae extracts (50%/50%), (EMEA-000836-PIP01-10-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:32:00Z","last_updated_date":"2025-06-24T12:32:00Z","reference_number":"EMA/319197/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0248-2024-ema-decision-18-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-dermatophagoides-pteronyssinus-dermatophagoides-farinae-extracts-50-50-emea-000836-pip01-10-m01_en.pdf"},
    {"id":"68901","name":"P/0236/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for vonicog alfa (Veyvondi), (EMEA-001164-PIP01-11-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:34:49Z","last_updated_date":"2025-06-24T12:34:49Z","reference_number":"EMA/320605/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0236-2024-ema-decision-18-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-vonicog-alfa-veyvondi-emea-001164-pip01-11-m08_en.pdf"},
    {"id":"68902","name":"P/0235/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for cariprazine (hydrochloride) (Reagila), (EMEA-001652-PIP01-14-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:35:50Z","last_updated_date":"2025-06-24T12:35:50Z","reference_number":"EMA/320584/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0235-2024-ema-decision-18-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-cariprazine-hydrochloride-reagila-emea-001652-pip01-14-m06_en.pdf"},
    {"id":"68903","name":"P/0243/2024: EMA decision of 19 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / lamivudine (Dovato), (EMEA-001940-PIP01-16-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:36:57Z","last_updated_date":"2025-06-24T12:36:57Z","reference_number":"EMA/297553/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0243-2024-ema-decision-19-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-dolutegravir-lamivudine-dovato-emea-001940-pip01-16-m06_en.pdf"},
    {"id":"68904","name":"P/0241/2024: EMA decision of 19 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for pegvaliase (Palynziq), (EMEA-001951-PIP01-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:39:48Z","last_updated_date":"2025-06-24T12:39:48Z","reference_number":"EMA/298061/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0241-2024-ema-decision-19-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-pegvaliase-palynziq-emea-001951-pip01-16-m03_en.pdf"},
    {"id":"68905","name":"P/0227/2024: EMA decision of 19 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for mexiletine (hydrochloride) (Namuscla), (EMEA-002012-PIP01-16-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:40:50Z","last_updated_date":"2025-06-24T12:40:50Z","reference_number":"EMA/291493/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0227-2024-ema-decision-19-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-mexiletine-hydrochloride-namuscla-emea-002012-pip01-16-m05_en.pdf"},
    {"id":"68906","name":"P/0228/2024: EMA decision of 19 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for rAAV8 viral vector encoding the human UGT1A1 transgene (rAAV8-hUGT1A1) (EMEA-002021-PIP01-16-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:41:52Z","last_updated_date":"2025-06-24T12:41:52Z","reference_number":"EMA/291508/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0228-2024-ema-decision-19-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-raav8-viral-vector-encoding-human-ugt1a1-transgene-raav8-hugt1a1-emea-002021-pip01-16-m01_en.pdf"},
    {"id":"68907","name":"P/0225/2024: EMA decision of 5 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for setrusumab (EMEA-002169-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:42:58Z","last_updated_date":"2025-06-24T12:42:58Z","reference_number":"EMA/291519/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0225-2024-ema-decision-5-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-setrusumab-emea-002169-pip01-17-m03_en.pdf"},
    {"id":"68908","name":"P/0229/2024: EMA decision of 19 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for niraparib (tosylate monohydrate) (Zejula), (EMEA-002268-PIP02-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:43:49Z","last_updated_date":"2025-06-24T12:43:49Z","reference_number":"EMA/291561/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0229-2024-ema-decision-19-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-niraparib-tosylate-monohydrate-zejula-emea-002268-pip02-18-m02_en.pdf"},
    {"id":"68909","name":"P/0230/2024: EMA decision of 9 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ralinepag (EMEA-002432-PIP02-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:45:12Z","last_updated_date":"2025-06-24T12:45:12Z","reference_number":"EMA/291603/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0230-2024-ema-decision-9-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-ralinepag-emea-002432-pip02-20-m01_en.pdf"},
    {"id":"68910","name":"P/0260/2024: EMA decision of 17 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for dostarlimab (Jemperli), (EMEA-002463-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:46:21Z","last_updated_date":"2025-06-24T12:46:21Z","reference_number":"EMA/328795/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0260-2024-ema-decision-17-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-dostarlimab-jemperli-emea-002463-pip01-18-m02_en.pdf"},
    {"id":"68911","name":"P/0240/2024: EMA decision of 19 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ibrexafungerp, (EMEA-002535-PIP03-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:47:34Z","last_updated_date":"2025-06-24T12:47:34Z","reference_number":"EMA/322324/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0240-2024-ema-decision-19-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-ibrexafungerp-emea-002535-pip03-19-m01_en.pdf"},
    {"id":"68912","name":"P/0268/2024: EMA decision of 17 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for doravirine / islatravir (EMEA-002707-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:48:36Z","last_updated_date":"2025-06-24T12:48:36Z","reference_number":"EMA/328837/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0268-2024-ema-decision-17-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-doravirine-islatravir-emea-002707-pip01-19-m02_en.pdf"},
    {"id":"68913","name":"P/0271/2024: EMA decision of 19 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for lenacapavir sodium (Sunleca), (EMEA-002740-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:50:41Z","last_updated_date":"2025-06-24T12:50:41Z","reference_number":"EMA/307434/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0271-2024-ema-decision-19-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-lenacapavir-sodium-sunleca-emea-002740-pip01-19-m01_en.pdf"},
    {"id":"68914","name":"P/0266/2024: EMA decision of 17 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ribociclib (Kisqali), (EMEA-002765-PIP02-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:53:37Z","last_updated_date":"2025-06-24T12:53:37Z","reference_number":"EMA/328854/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0266-2024-ema-decision-17-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-ribociclib-kisqali-emea-002765-pip02-21-m01_en.pdf"},
    {"id":"68915","name":"P/0269/2024: EMA decision of 17 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for botaretigene sparoparvovec (EMEA-002827-PIP01-20-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:56:11Z","last_updated_date":"2025-06-24T12:56:11Z","reference_number":"EMA/328869/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0269-2024-ema-decision-17-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-botaretigene-sparoparvovec-emea-002827-pip01-20-m03_en.pdf"},
    {"id":"68916","name":"P/0254/2024: EMA decision of 19 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ublituximab (Briumvi), (EMEA-002889-PIP02-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:57:19Z","last_updated_date":"2025-06-24T12:57:19Z","reference_number":"EMA/296721/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0254-2024-ema-decision-19-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-ublituximab-briumvi-emea-002889-pip02-20-m01_en.pdf"},
    {"id":"68917","name":"P/0255/2024: EMA decision of 19 July 2024 on the acceptance of a modification of an agreed PIP for severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine/ matrix-M1 adjuvant (Nuvaxovid), (EMEA-002941-PIP01-20-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T12:59:14Z","last_updated_date":"2025-06-24T12:59:14Z","reference_number":"EMA/296650/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0255-2024-ema-decision-19-july-2024-acceptance-modification-agreed-pip-severe-acute-respiratory-syndrome-coronavirus-2-recombinant-spike-protein-nanoparticle-vaccine-matrix-m1-adjuvant-nuvaxovid_en.pdf"},
    {"id":"68918","name":"P/0246/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for donidalorsen, (EMEA- 003112-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T13:00:20Z","last_updated_date":"2025-06-24T13:00:20Z","reference_number":"EMA/324334/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0246-2024-ema-decision-18-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-donidalorsen-emea-003112-pip01-21-m01_en.pdf"},
    {"id":"68920","name":"P/0253/2024: EMA decision of 19 July 2024 on  acceptance of a modification of an agreed PIP for SARS-CoV-2 virus recombinant spike protein receptor binding domain fusion homodimer ... (Bimervax), (EMEA-003191-PIP01-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T13:01:28Z","last_updated_date":"2025-06-24T13:01:28Z","reference_number":"EMA/296812/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0253-2024-ema-decision-19-july-2024-acceptance-modification-agreed-pip-sars-cov-2-virus-recombinant-spike-protein-receptor-binding-domain-fusion-homodimer-bimervax-emea-003191-pip01-22-m01_en.pdf"},
    {"id":"68921","name":"P/0249/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for gefurulimab (EMEA-003302-PIP01-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T13:04:17Z","last_updated_date":"2025-06-24T13:04:17Z","reference_number":"EMA/319196/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0249-2024-ema-decision-18-july-2024-acceptance-modification-agreed-paediatric-investigation-plan-gefurulimab-emea-003302-pip01-22-m01_en.pdf"},
    {"id":"68929","name":"P/0221/2024 : EMA decision of 20 June on the acceptance of a modification of an agreed paediatric investigation plan for brexucabtagene autoleucel (Tecartus) (EMEA-001862-PIP01-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T15:39:40Z","last_updated_date":"2025-06-24T15:39:40Z","reference_number":"EMA/278646/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0221-2024-ema-decision-20-june-acceptance-modification-agreed-paediatric-investigation-plan-brexucabtagene-autoleucel-tecartus-emea-001862-pip01-15-m04_en.pdf"},
    {"id":"68930","name":"P/0217/2024 : EMA decision of 13 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for inebilizumab (Uplizna) (EMEA-001911-PIP03-23-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T15:45:04Z","last_updated_date":"2025-06-24T15:45:04Z","reference_number":"EMA/181396/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0217-2024-ema-decision-13-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-inebilizumab-uplizna-emea-001911-pip03-23-m01_en.pdf"},
    {"id":"68932","name":"P/0211/2024 : EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for calcifediol (Rayaldee) (EMEA-002093-PIP02-17-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T15:49:25Z","last_updated_date":"2025-06-24T15:49:25Z","reference_number":"EMA/267114/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0211-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-calcifediol-rayaldee-emea-002093-pip02-17-m02_en.pdf"},
    {"id":"68934","name":"P/0218/2024 : EMA decision of 13 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant influenza hemagglutinin-strain A......(Yamagata lineage) (RIV4) (Supemtek)(EMEA-002418-PIP01-18-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T15:55:08Z","last_updated_date":"2025-06-24T15:55:08Z","reference_number":"EMA/255064/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0218-2024-ema-decision-13-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-influenza-hemagglutinin-strain-ayamagata-lineage-riv4-supemtekemea-002418-pip01-18-m04_en.pdf"},
    {"id":"68935","name":"P/0222/2024 : on the acceptance of a modification of an agreed paediatric investigation plan for iptacopan (EMEA- 002705-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T15:59:53Z","last_updated_date":"2025-06-24T15:59:53Z","reference_number":"EMA/283573/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2024-acceptance-modification-agreed-paediatric-investigation-plan-iptacopan-emea-002705-pip01-19-m02_en.pdf"},
    {"id":"68936","name":"P/0222/2024 : EMA decision of 20 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for iptacopan (EMEA- 002705-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T16:01:39Z","last_updated_date":"2025-06-24T16:01:39Z","reference_number":"EMA/283573/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0222-2024-ema-decision-20-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-iptacopan-emea-002705-pip01-19-m02_en.pdf"},
    {"id":"68937","name":"P/0224/2024 : EMA decision of 27 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for epcoritamab (Tepkinly), (EMEA-002907-PIP01-20-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T16:09:35Z","last_updated_date":"2025-06-24T16:09:35Z","reference_number":"EMA/284891/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0224-2024-ema-decision-27-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-epcoritamab-tepkinly-emea-002907-pip01-20-m03_en.pdf"},
    {"id":"68938","name":"P/0198/2024: EMA decision of 14 June 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ianalumab (EMEA-002338-PIP05-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T16:13:09Z","last_updated_date":"2025-06-24T16:13:09Z","reference_number":"P/0198/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2024-ema-decision-14-june-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ianalumab-emea-002338-pip05-23_en.pdf"},
    {"id":"68940","name":"P/0212/2024 : EMA decision of 14 June 2024 on the granting of a product specific waiver for lebrikizumab (Ebglyss), (EMEA-002536-PIP02-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T16:21:10Z","last_updated_date":"2025-06-24T16:21:10Z","reference_number":"EMA/267179/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0212-2024-ema-decision-14-june-2024-granting-product-specific-waiver-lebrikizumab-ebglyss-emea-002536-pip02-24_en.pdf"},
    {"id":"68941","name":"P/0213/2024 : EMA decision of 14 June 2024 on the granting of a product specific waiver for gallium (68Ga) boclatixafortide (EMEA-003408-PIP02- 24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T16:32:07Z","last_updated_date":"2025-06-24T16:32:07Z","reference_number":"EMA/267201/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0213-2024-ema-decision-14-june-2024-granting-product-specific-waiver-gallium-68ga-boclatixafortide-emea-003408-pip02-24_en.pdf"},
    {"id":"68942","name":"P/0199/2024: EMA decision of 14 June 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the refusal of a waiver for brigimadlin (EMEA-003260-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T16:28:38Z","last_updated_date":"2025-06-24T16:28:38Z","reference_number":"P/0199/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0199-2024-ema-decision-14-june-2024-agreement-paediatric-investigation-plan-granting-deferral-refusal-waiver-brigimadlin-emea-003260-pip03-23_en.pdf"},
    {"id":"68943","name":"P/0200/2024: EMA decision of 14 June 2024 on the granting of a product specific waiver for fenofibrate / rosuvastatin calcium (EMEA-003591- PIP01-24) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T16:50:02Z","last_updated_date":"2025-06-24T16:50:02Z","reference_number":"P/0200/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0200-2024-ema-decision-14-june-2024-granting-product-specific-waiver-fenofibrate-rosuvastatin-calcium-emea-003591-pip01-24_en.pdf"},
    {"id":"68945","name":"P/0201/2024: EMA decision of 14 June 2024 on the refusal of a paediatric investigation plan and on the granting of a waiver for autologous T-cells from a melanoma metastasis (TM001) (EMEA-003535-PIP02-24)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-06-24T17:34:52Z","last_updated_date":"2025-06-24T17:34:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0201-2024-ema-decision-14-june-2024-refusal-paediatric-investigation-plan-granting-waiver-autologous-t-cells-melanoma-metastasis-tm001-emea-003535-pip02-24_en.pdf"},
    {"id":"68946","name":"EMA decision of 14 June 2024 on the granting of a product-specific waiver for (5aSa,17aRa)-20-Chloro-2-[(2S,5R)-2,5-dimethyl-4- (prop-2-enoyl)piperazin-1-yl]-14,17-difluoro-6-(propan-2-yl)-11,12-dihydro-4H-1,18... (EMEA-003586-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T17:46:23Z","last_updated_date":"2025-06-24T17:46:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-decision-14-june-2024-granting-product-specific-waiver-5asa17ara-20-chloro-2-2s5r-25-dimethyl-4-prop-2-enoylpiperazin-1-yl-1417-difluoro-6-propan-2-yl-1112-dihydro-4h-118-emea-003586-pip01-24_en.pdf"},
    {"id":"68947","name":"P/0204/2024: EMA decision of 14 June 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for derivative of pyrindin-2-yl)cyclopropanecarboxamide hydrochloride (EMEA-003480-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T17:54:28Z","last_updated_date":"2025-06-24T17:54:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0204-2024-ema-decision-14-june-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-derivative-pyrindin-2-ylcyclopropanecarboxamide-hydrochloride-emea-003480-pip01-23_en.pdf"},
    {"id":"68948","name":"P/0203/2024: EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for quizartinib (Vanflyta) (EMEA-001821-PIP01-15-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T18:02:25Z","last_updated_date":"2025-06-24T18:02:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0203-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-quizartinib-vanflyta-emea-001821-pip01-15-m08_en.pdf"},
    {"id":"68949","name":"P/0205/2024: EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for obefazimod (EMEA- 003196-PIP01-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T18:09:04Z","last_updated_date":"2025-06-24T18:09:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod-emea-003196-pip01-22-m01_en.pdf"},
    {"id":"68950","name":"P/0206/2024: EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for inebilizumab (Uplizna) (EMEA-001911-PIP02-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T18:15:11Z","last_updated_date":"2025-06-24T18:15:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0206-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-inebilizumab-uplizna-emea-001911-pip02-22-m01_en.pdf"},
    {"id":"68951","name":"P/0207/2024: EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for linaclotide (Constella) (EMEA-000927-PIP01-10-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T18:23:59Z","last_updated_date":"2025-06-24T18:23:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0207-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-linaclotide-constella-emea-000927-pip01-10-m08_en.pdf"},
    {"id":"68952","name":"P/0208/2024: EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for olokizumab (EMEA-001222-PIP01-11-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-24T18:31:00Z","last_updated_date":"2025-06-24T18:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0208-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-olokizumab-emea-001222-pip01-11-m01_en.pdf"},
    {"id":"68954","name":"P/0187/2024 - EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for mecasermin rinfabate (EMEA-000534-PIP03-17-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-25T11:10:17Z","last_updated_date":"2025-06-25T11:10:17Z","reference_number":"EMA/251730/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0187-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-mecasermin-rinfabate-emea-000534-pip03-17-m01_en.pdf"},
    {"id":"68955","name":"P/0189/2024 - EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ertugliflozin (Steglatro), (EMEA-001533-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-25T11:15:40Z","last_updated_date":"2025-06-25T11:15:40Z","reference_number":"EMA/251732/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0189-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-ertugliflozin-steglatro-emea-001533-pip01-13-m03_en.pdf"},
    {"id":"68956","name":"P/0191/2024 - EMA decision of 14 June 2024 on the granting of a product specific waiver for rivoceranib (Tulvegio), (EMEA-002489-PIP02-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-25T11:26:20Z","last_updated_date":"2025-06-25T11:26:20Z","reference_number":"EMA/251752/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0191-2024-ema-decision-14-june-2024-granting-product-specific-waiver-rivoceranib-tulvegio-emea-002489-pip02-24_en.pdf"},
    {"id":"68957","name":"P/0190/2024: EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for imipenem (monohydrate) / cilastatin (sodium) / relebactam (MK-7655A) (Recarbrio), (EMEA-001809-PIP01-15- M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-25T11:34:21Z","last_updated_date":"2025-06-25T11:34:21Z","reference_number":"EMA/251740/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0190-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-imipenem-monohydrate-cilastatin-sodium-relebactam-mk-7655a-recarbrio-emea-001809-pip01-15-m05_en.pdf"},
    {"id":"68958","name":"P/0192/2024 - EMA decision of 14 June 2024 on the granting of a product specific waiver for telisotuzumab conjugated to (2S)-2-(2- bromoacetamido)-N-[(2S)-1-({3-[(7S)-7-ethyl-7-hydroxy-8,11-dioxo-7,8,11,13-tetrahydro-2H,10H- [1,3]dioxolo[4,5-g]pyrano...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-25T11:43:49Z","last_updated_date":"2025-06-25T11:43:49Z","reference_number":"EMA/251757/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0192-2024-ema-decision-14-june-2024-granting-product-specific-waiver-telisotuzumab-conjugated-2s-2-2-bromoacetamido-n-2s-1-3-7s-7-ethyl-7-hydroxy-811-dioxo-781113-tetrahydro-2h10h-13dioxolo45_en.pdf"},
    {"id":"68959","name":"P/0193/2024 - EMA decision of 14 June 2024 on the granting of a product specific waiver for actinium-225-2-(4,7,10-tris-carboxymethyl-1,4,7,10 tetraaza-cyclododec-1-yl)-pentanedioic acid 3-iodo-D-Tyr-D-Phe-D-Lys-OH)-8-oyl-ε-(HO-Glu-ureido- Lys-OH) (EMEA..","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-25T11:56:08Z","last_updated_date":"2025-06-25T11:56:08Z","reference_number":"EMA/251758/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0193-2024-ema-decision-14-june-2024-granting-product-specific-waiver-actinium-225-2-4710-tris-carboxymethyl-14710-tetraaza-cyclododec-1-yl-pentanedioic-acid-3-iodo-d-tyr-d-phe-d-lys-oh-8-oyl-e-ho_en.pdf"},
    {"id":"68978","name":"P/0194/2024: EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for soticlestat, (EMEA- 002572-PIP02-19-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T09:22:30Z","last_updated_date":"2025-06-26T09:22:30Z","reference_number":"EMA/248085/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0194-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-soticlestat-emea-002572-pip02-19-m05_en.pdf"},
    {"id":"68979","name":"P/0348/2024 : EMA decision of 24 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for pegcetacoplan (Aspaveli), (EMEA-002600-PIP03-21-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-20T09:27:36Z","last_updated_date":"2025-10-20T09:27:36Z","reference_number":"EMA/434697/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0348-2024-ema-decision-24-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-pegcetacoplan-aspaveli-emea-002600-pip03-21-m03_en.pdf"},
    {"id":"68980","name":"P/0196/2024: EMA decision of 21 June 2024 on the granting of a product specific waiver for sitagliptin / dapagliflozin, (EMEA-003572-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T09:32:01Z","last_updated_date":"2025-06-26T09:32:01Z","reference_number":"EMA/250643/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0196-2024-ema-decision-21-june-2024-granting-product-specific-waiver-sitagliptin-dapagliflozin-emea-003572-pip01-23_en.pdf"},
    {"id":"68981","name":"P/0197/2024: EMA decision of 13 June 2024 on the agreement of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for radiprodil (EMEA-003462-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T09:39:17Z","last_updated_date":"2025-06-26T09:39:17Z","reference_number":"EMA/257454/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0197-2024-ema-decision-13-june-2024-agreement-paediatric-investigation-plan-refusal-deferral-granting-waiver-radiprodil-emea-003462-pip01-23_en.pdf"}    {"id":"68982","name":"P/0214/2024 : EMA decision of 13 June 2024 on the agreement of a paediatric investigation plan and on the refusal of a deferral for recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA (MYR-101), (EMEA-003459- PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T11:22:25Z","last_updated_date":"2025-06-26T11:22:25Z","reference_number":"EMA/255060/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0214-2024-ema-decision-13-june-2024-agreement-paediatric-investigation-plan-refusal-deferral-recombinant-adeno-associated-virus-olig001-containing-human-aspartoacylase-cdna-myr-101-emea-003459-pip01_en.pdf"},
    {"id":"68983","name":"P/0215/2024 : EMA decision of 13 June 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human alpha-1 proteinase inhibitor, modified (SerpinPC) (EMEA-003463- PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T11:29:59Z","last_updated_date":"2025-06-26T11:29:59Z","reference_number":"EMA/255061/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0215-2024-ema-decision-13-june-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-human-alpha-1-proteinase-inhibitor-modified-serpinpc-emea-003463-pip01-23_en.pdf"},
    {"id":"68984","name":"P/0223/2024 : EMA decision of 20 June 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for mirdametinib (EMEA-003525-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T11:36:07Z","last_updated_date":"2025-06-26T11:36:07Z","reference_number":"EMA/284186/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0223-2024-ema-decision-20-june-2024-agreement-paediatric-investigation-plan-granting-deferral-mirdametinib-emea-003525-pip01-23_en.pdf"},
    {"id":"68985","name":"P/0216/2024 : EMA decision of 13 June 2024 on the granting of a product specific waiver for certepetide (EMEA-003577-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T11:44:56Z","last_updated_date":"2025-06-26T11:44:56Z","reference_number":"EMA/255063/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0216-2024-ema-decision-13-june-2024-granting-product-specific-waiver-certepetide-emea-003577-pip01-24_en.pdf"},
    {"id":"68987","name":"P/0209/2024 : EMA decision of 14 June 2024 on the granting of a product specific waiver for derivative of 1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (EMEA-003581-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T12:23:35Z","last_updated_date":"2025-06-26T12:23:35Z","reference_number":"EMA/234752/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0209-2024-ema-decision-14-june-2024-granting-product-specific-waiver-derivative-1567-tetrahydro-4h-pyrrolo32-cpyridin-4-one-emea-003581-pip01-24_en.pdf"},
    {"id":"68988","name":"P/0210/2024 : EMA decision of 14 June 2024 on the granting of a product specific waiver for rosuvastatin / ezetimibe (EMEA-003582-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T12:29:22Z","last_updated_date":"2025-06-26T12:29:22Z","reference_number":"EMA/234749/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0210-2024-ema-decision-14-june-2024-granting-product-specific-waiver-rosuvastatin-ezetimibe-emea-003582-pip01-24_en.pdf"},
    {"id":"68993","name":"P/0220/2024 : EMA decision of 14 June 2024 on the agreement of a paediatric investigation plan and on the granting of a waiver for recombinant influenza hemagglutinin-strain A (H1N1 subtype).....(EMEA-003640-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T16:50:44Z","last_updated_date":"2025-06-26T16:50:44Z","reference_number":"EMA/272023/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0220-2024-ema-decision-14-june-2024-agreement-paediatric-investigation-plan-granting-waiver-recombinant-influenza-hemagglutinin-strain-h1n1-subtypeemea-003640-pip01-24_en.pdf"},
    {"id":"68994","name":"P/0219/2024 : EMA decision of 13 June 2024 on the agreement of a paediatric investigation plan and on the granting of a waiver for purified antigen fractions of inactivated split virion influenza virus type A, H1N1 (EMEA-003641-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-06-26T16:55:53Z","last_updated_date":"2025-06-26T16:55:53Z","reference_number":"EMA/255062/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0219-2024-ema-decision-13-june-2024-agreement-paediatric-investigation-plan-granting-waiver-purified-antigen-fractions-inactivated-split-virion-influenza-virus-type-h1n1-emea-003641-pip01-24_en.pdf"},
    {"id":"69120","name":"P/0299/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ceftobiprole medocaril (sodium) (Zevtera and associated names), (EMEA-000205-PIP02-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:17:41Z","last_updated_date":"2025-07-07T11:17:41Z","reference_number":"EMA/320724/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0299-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-ceftobiprole-medocaril-sodium-zevtera-associated-names-emea-000205-pip02-11-m07_en.pdf"},
    {"id":"69121","name":"P/0305/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for midostaurin (Rydapt), (EMEA-000780-PIP01-09-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:18:59Z","last_updated_date":"2025-07-07T11:18:59Z","reference_number":"EMA/320725/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0305-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-midostaurin-rydapt-emea-000780-pip01-09-m08_en.pdf"},
    {"id":"69122","name":"P/0307/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP04-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:31:51Z","last_updated_date":"2025-07-07T11:31:51Z","reference_number":"EMA/320727/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0307-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-benralizumab-fasenra-emea-001214-pip04-19-m01_en.pdf"},
    {"id":"69123","name":"P/0303/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (SCNG20%) (EMEA-001290-PIP01-12-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:33:00Z","last_updated_date":"2025-07-07T11:33:00Z","reference_number":"EMA/320731/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0303-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-human-normal-immunoglobulin-scng20-emea-001290-pip01-12-m01_en.pdf"},
    {"id":"69125","name":"P/0280/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for naltrexone (hydrochloride) / bupropion (hydrochloride) (Mysimba), (EMEA-001373-PIP01-12-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:34:02Z","last_updated_date":"2025-07-07T11:34:02Z","reference_number":"EMA/343094/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0280-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-naltrexone-hydrochloride-bupropion-hydrochloride-mysimba-emea-001373-pip01-12-m06_en.pdf"},
    {"id":"69126","name":"P/0281/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for tezepelumab (Tezspire), (EMEA-001613-PIP03-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:34:55Z","last_updated_date":"2025-07-07T11:34:55Z","reference_number":"EMA/343190/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0281-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-tezepelumab-tezspire-emea-001613-pip03-21-m01_en.pdf"},
    {"id":"69127","name":"P/0282/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for sufentanil (citrate) / ketamine (hydrochloride) (EMEA-001739-PIP02-16-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:35:50Z","last_updated_date":"2025-07-07T11:35:50Z","reference_number":"EMA/343346/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0282-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-sufentanil-citrate-ketamine-hydrochloride-emea-001739-pip02-16-m03_en.pdf"},
    {"id":"69128","name":"P/0283/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine / dolutegravir (Juluca), (EMEA-001750-PIP01-15-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:36:42Z","last_updated_date":"2025-07-07T11:36:42Z","reference_number":"EMA/343368/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0283-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-rilpivirine-dolutegravir-juluca-emea-001750-pip01-15-m07_en.pdf"},
    {"id":"69129","name":"P/0284/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for darunavir / cobicistat / emtricitabine / tenofovir alafenamide (Symtuza), (EMEA-001825-PIP01-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:37:36Z","last_updated_date":"2025-07-07T11:37:36Z","reference_number":"EMA/343666/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0284-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-darunavir-cobicistat-emtricitabine-tenofovir-alafenamide-symtuza-emea-001825-pip01-15-m05_en.pdf"},
    {"id":"69130","name":"P/0312/2024: EMA decision of 22 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for avelumab (Bavencio), (EMEA-001849-PIP02-15-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:38:33Z","last_updated_date":"2025-07-07T11:38:33Z","reference_number":"EMA/374089/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0312-2024-ema-decision-22-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-avelumab-bavencio-emea-001849-pip02-15-m05_en.pdf"},
    {"id":"69131","name":"P/0285/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for fitusiran (EMEA-001855-PIP01-15-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:39:35Z","last_updated_date":"2025-07-07T11:39:35Z","reference_number":"EMA/343724/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0285-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-fitusiran-emea-001855-pip01-15-m06_en.pdf"},
    {"id":"69132","name":"P/0290/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for vadadustat (Vafseo), (EMEA-001944-PIP01-16-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:40:26Z","last_updated_date":"2025-07-07T11:40:26Z","reference_number":"EMA/343517/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0290-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-vadadustat-vafseo-emea-001944-pip01-16-m05_en.pdf"},
    {"id":"69133","name":"P/0294/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for gadopiclenol (Elucirem), (EMEA-001949-PIP01-16-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:41:24Z","last_updated_date":"2025-07-07T11:41:24Z","reference_number":"EMA/344055/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0294-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-gadopiclenol-elucirem-emea-001949-pip01-16-m07_en.pdf"},
    {"id":"69134","name":"P/0293/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for gadopiclenol (Elucirem), (EMEA-001949-PIP02-18-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T11:43:54Z","last_updated_date":"2025-07-07T11:43:54Z","reference_number":"EMA/344196/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0293-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-gadopiclenol-elucirem-emea-001949-pip02-18-m05_en.pdf"},
    {"id":"69135","name":"P/0291/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for dexamethasone (sodium phosphate) encapsulated in human autologous erthrocytes (EMEA-001957-PIP02-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T12:05:42Z","last_updated_date":"2025-07-07T12:05:42Z","reference_number":"EMA/343784/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0291-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-dexamethasone-sodium-phosphate-encapsulated-human-autologous-erthrocytes-emea-001957-pip02-19-m01_en.pdf"},
    {"id":"69137","name":"P/0286/2024: EMA decision of 16 August 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for vosoritide (Voxzogo), (EMEA-002033-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T13:54:04Z","last_updated_date":"2025-07-07T13:54:04Z","reference_number":"EMA/344245/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0286-2024-ema-decision-16-august-2024-agreement-paediatric-investigation-plan-granting-deferral-vosoritide-voxzogo-emea-002033-pip02-23_en.pdf"},
    {"id":"69138","name":"P/0295/2024: EMA decision of 20 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for pretomanid (Dovprela), (EMEA-002115-PIP01-17-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T13:59:08Z","last_updated_date":"2025-07-07T13:59:08Z","reference_number":"EMA/364156/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0295-2024-ema-decision-20-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-pretomanid-dovprela-emea-002115-pip01-17-m06_en.pdf"},
    {"id":"69139","name":"P/0296/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for bupivacaine / meloxicam, (EMEA-002246-PIP01-17-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T14:04:22Z","last_updated_date":"2025-07-07T14:04:22Z","reference_number":"EMA/364197/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0296-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-bupivacaine-meloxicam-emea-002246-pip01-17-m05_en.pdf"},
    {"id":"69140","name":"P/0297/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for narsoplimab, (EMEA- 002479-PIP01-18-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T15:08:29Z","last_updated_date":"2025-07-07T15:08:29Z","reference_number":"EMA/364312/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0297-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-narsoplimab-emea-002479-pip01-18-m02_en.pdf"},
    {"id":"69141","name":"P/0279/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for cenobamate (Ontozry), (EMEA-002563-PIP02-19-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T15:13:02Z","last_updated_date":"2025-07-07T15:13:02Z","reference_number":"EMA/362694/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0279-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-cenobamate-ontozry-emea-002563-pip02-19-m03_en.pdf"},
    {"id":"69143","name":"P/0298/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for efgartigimod alfa (Vyvgart), (EMEA-002597-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T15:19:17Z","last_updated_date":"2025-07-07T15:19:17Z","reference_number":"EMA/364330/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0298-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-efgartigimod-alfa-vyvgart-emea-002597-pip01-19-m02_en.pdf"},
    {"id":"69144","name":"P/0275/2024: EMA decision of 14 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for navepegritide (EMEA-002689-PIP02-23-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T15:28:26Z","last_updated_date":"2025-07-07T15:28:26Z","reference_number":"EMA/307239/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0275-2024-ema-decision-14-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-navepegritide-emea-002689-pip02-23-m01_en.pdf"},
    {"id":"69145","name":"P/0278/2024: EMA decision of 14 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for crinecerfont (EMEA-002700-PIP01-19-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T15:32:59Z","last_updated_date":"2025-07-07T15:32:59Z","reference_number":"EMA/307240/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0278-2024-ema-decision-14-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-crinecerfont-emea-002700-pip01-19-m02_en.pdf"},
    {"id":"69146","name":"P/0277/2024: EMA decision of 14 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for vonoprazan (EMEA-002703-PIP01-19-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T15:37:18Z","last_updated_date":"2025-07-07T15:37:18Z","reference_number":"EMA/307256/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0277-2024-ema-decision-14-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-vonoprazan-emea-002703-pip01-19-m01_en.pdf"},
    {"id":"69147","name":"P/0276/2024: EMA decision of 14 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded (MC0518), (EMEA-002706-PIP01-19- M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T15:42:48Z","last_updated_date":"2025-07-07T15:42:48Z","reference_number":"EMA/307425/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0276-2024-ema-decision-14-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-allogeneic-bone-marrow-derived-mesenchymal-stromal-cells-ex-vivo-expanded-mc0518-emea-002706-pip01_en.pdf"},
    {"id":"69150","name":"P/0288/2024: EMA decision of 14 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for multivalent pneumococcal polysaccharide conjugate to carrier protein (PCV21) (EMEA-002780-PIP02-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T15:50:14Z","last_updated_date":"2025-07-07T15:50:14Z","reference_number":"EMA/364892/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0288-2024-ema-decision-14-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-multivalent-pneumococcal-polysaccharide-conjugate-carrier-protein-pcv21-emea-002780-pip02-20-m02_en.pdf"},
    {"id":"69151","name":"P/0259/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for survodutide (EMEA- 002942-PIP02-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T16:00:40Z","last_updated_date":"2025-07-07T16:00:40Z","reference_number":"EMA/364874/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0259-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-survodutide-emea-002942-pip02-20-m02_en.pdf"},
    {"id":"69155","name":"P/0302/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for osivelotor (EMEA- 003241-PIP01-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T16:39:24Z","last_updated_date":"2025-07-07T16:39:24Z","reference_number":"EMA/364883/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0302-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-osivelotor-emea-003241-pip01-22-m01_en.pdf"},
    {"id":"69157","name":"P/0289/2024: EMA decision of 16 August 2024 on the acceptance of a modification of an agreed paediatric investigation plan for gilteritinib (as fumarate) (Xospata), (EMEA-002064-PIP01-16-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-07T16:43:59Z","last_updated_date":"2025-07-07T16:43:59Z","reference_number":"EMA/343426/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0289-2024-ema-decision-16-august-2024-acceptance-modification-agreed-paediatric-investigation-plan-gilteritinib-fumarate-xospata-emea-002064-pip01-16-m06_en.pdf"},
    {"id":"69208","name":"P/0274/2024: EMA decision of 14 August 2024 on the granting of a product specific waiver for buparlisib (EMEA-003607-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-09T18:02:31Z","last_updated_date":"2025-07-09T18:02:31Z","reference_number":"EMA/307578/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0274-2024-ema-decision-14-august-2024-granting-product-specific-waiver-buparlisib-emea-003607-pip01-24_en.pdf"},
    {"id":"69209","name":"P/0287/2024 : EMA decision of on the granting of a product-specific waiver for inobrodib (EMEA-003622-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-09T18:10:54Z","last_updated_date":"2025-07-09T18:10:54Z","reference_number":"EMA/344293/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0287-2024-ema-decision-granting-product-specific-waiver-inobrodib-emea-003622-pip01-24_en.pdf"},
    {"id":"69210","name":"P/0292/2024: EMA decision of 16 August 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mezagitamab (EMEA-003502-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-09T18:21:59Z","last_updated_date":"2025-07-09T18:21:59Z","reference_number":"EMA/343392/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0292-2024-ema-decision-16-august-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mezagitamab-emea-003502-pip01-23_en.pdf"},
    {"id":"69211","name":"P/0300/2024: EMA decision of 14 August 2024 on the granting of a product specific waiver for anitocabtagene autoleucel (EMEA-003628-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-09T18:27:52Z","last_updated_date":"2025-07-09T18:27:52Z","reference_number":"EMA/364617/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0300-2024-ema-decision-14-august-2024-granting-product-specific-waiver-anitocabtagene-autoleucel-emea-003628-pip01-24_en.pdf"},
    {"id":"69212","name":"P/0301/2024: EMA decision of 16 August 2024 on the granting of a product specific waiver for copper (64Cu) oxodotreotide, (EMEA-003610-PIP01- 24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-09T19:04:46Z","last_updated_date":"2025-07-09T19:04:46Z","reference_number":"EMA/364750/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0301-2024-ema-decision-16-august-2024-granting-product-specific-waiver-copper-64cu-oxodotreotide-emea-003610-pip01-24_en.pdf"},
    {"id":"69213","name":"P/0308/2024: EMA decision of 16 August 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for transglutaminase 2 inhibitor (EMEA-003513-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-09T19:19:09Z","last_updated_date":"2025-07-09T19:19:09Z","reference_number":"EMA/364889/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0308-2024-ema-decision-16-august-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-transglutaminase-2-inhibitor-emea-003513-pip01-23_en.pdf"},
    {"id":"69214","name":"P/0309/2024: EMA decision of 16 August 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for single-stranded 5' capped mRNA encoding... (EMEA-003521-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-09T20:27:52Z","last_updated_date":"2025-07-09T20:27:52Z","reference_number":"EMA/364890/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0309-2024-ema-decision-16-august-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-single-stranded-5-capped-mrna-encoding-emea-003521-pip01-23_en.pdf"},
    {"id":"69215","name":"P/0310/2024: EMA decision of 16 August 2024 on the refusal of a product specific waiver for tarumase (EMEA-003616-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-09T20:38:54Z","last_updated_date":"2025-07-09T20:38:54Z","reference_number":"EMA/364891/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0310-2024-ema-decision-16-august-2024-refusal-product-specific-waiver-tarumase-emea-003616-pip01-24_en.pdf"},
    {"id":"69216","name":"EMEA-003549-PIP01-23: EMA decision of 15 August 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efinopegdutide (EMEA-003549-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-07-09T20:51:45Z","last_updated_date":"2025-07-09T20:51:45Z","reference_number":"EMA/373582/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-003549-pip01-23-ema-decision-15-august-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-efinopegdutide-emea-003549-pip01-23_en.pdf"},
    {"id":"70270","name":"P/0372/2024: EMA decision of of 25 October 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lenacapavir sodium (Sunleca), (EMEA-002740-PIP03-24)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T13:34:21Z","last_updated_date":"2025-09-25T13:34:21Z","reference_number":"EMA/483453/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0372-2024-ema-decision-25-october-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lenacapavir-sodium-sunleca-emea-002740-pip03-24_en.pdf"},
    {"id":"70276","name":"P/0085/2023: EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for danuglipron (EMEA-002944-PIP02-22)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T14:37:18Z","last_updated_date":"2025-09-25T14:37:18Z","reference_number":"EMA/37959/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0085-2023-ema-decision-10-march-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-danuglipron-emea-002944-pip02-22_en.pdf"},
    {"id":"70550","name":"P/0333/2024 : EMA decision of 13 September 2024 on the granting of a product specific waiver for aldesleukin, (EMEA-001556-PIP02-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-14T16:06:29Z","last_updated_date":"2025-10-14T16:06:29Z","reference_number":"EMA/413962/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0333-2024-ema-decision-13-september-2024-granting-product-specific-waiver-aldesleukin-emea-001556-pip02-24_en.pdf"},
    {"id":"70552","name":"EMA/PE/0000227301 : EMA decision of 20 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mRNA encoding Influenza A, H1N1 strain, ... (EMA/PE/0000227301)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-14T16:44:12Z","last_updated_date":"2025-10-14T16:44:12Z","reference_number":"EMADOC-1700519818-1683151","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000227301-ema-decision-20-september-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mrna-encoding-influenza-h1n1-strain-ema-pe-0000227301_en.pdf"},
    {"id":"70553","name":"P/0351/2024 : EMA decision of 27 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for belatacept (Nulojix), (EMEA-000157-PIP01-07-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-14T17:06:15Z","last_updated_date":"2025-10-14T17:06:15Z","reference_number":"EMA/441696/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0351-2024-ema-decision-27-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-belatacept-nulojix-emea-000157-pip01-07-m06_en.pdf"},
    {"id":"70555","name":"P/0325/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for osilodrostat (Isturisa), (EMEA-000315-PIP02-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-14T17:16:56Z","last_updated_date":"2025-10-14T17:16:56Z","reference_number":"EMA/412938/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0325-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-osilodrostat-isturisa-emea-000315-pip02-15-m04_en.pdf"},
    {"id":"70561","name":"P/0328/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant varicella zoster virus (VZV) glycoprotein E (Shingrix), (EMEA-001426-PIP01-13-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-15T10:06:30Z","last_updated_date":"2025-10-15T10:06:30Z","reference_number":"EMA/413604/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0328-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-varicella-zoster-virus-vzv-glycoprotein-e-shingrix-emea-001426-pip01-13-m03_en.pdf"},
    {"id":"70562","name":"P/0329/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for tasimelteon (Hetlioz), (EMEA-001531-PIP01-13-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-15T10:13:35Z","last_updated_date":"2025-10-15T10:13:35Z","reference_number":"EMA/413795/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0329-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-tasimelteon-hetlioz-emea-001531-pip01-13-m06_en.pdf"},
    {"id":"70563","name":"EMA/436650/2024 : EMA decision of 24 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid ... (EMEA-001930-PIP01-16-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-15T10:25:13Z","last_updated_date":"2025-10-15T10:25:13Z","reference_number":"EMA/436650/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-436650-2024-ema-decision-24-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-serogroup-polysaccharide-conjugated-tetanus-toxoid-emea-001930-pip01_en.pdf"},
    {"id":"70565","name":"P/0315/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP, live) (Ervebo), (EMEA-001786-PIP01-15-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-15T10:32:49Z","last_updated_date":"2025-10-15T10:32:49Z","reference_number":"EMA/410928/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0315-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-ebola-zaire-vaccine-rvsvdg-zebov-gp-live-ervebo-emea-001786-pip01-15-m04_en.pdf"},
    {"id":"70566","name":"P/0314/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for gemtuzumab ozogamicin (Mylotarg), (EMEA-001733-PIP02-15-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-15T10:49:33Z","last_updated_date":"2025-10-15T10:49:33Z","reference_number":"EMA/410855/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0314-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-gemtuzumab-ozogamicin-mylotarg-emea-001733-pip02-15-m03_en.pdf"},
    {"id":"70567","name":"P/0313/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for patiromer sorbitex calcium (Veltassa), (EMEA-001720-PIP01-14-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-15T11:18:40Z","last_updated_date":"2025-10-15T11:18:40Z","reference_number":"EMA/371127/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0313-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-patiromer-sorbitex-calcium-veltassa-emea-001720-pip01-14-m04_en.pdf"},
    {"id":"70585","name":"P/0336/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for retatrutide (EMEA-003258-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T11:27:28Z","last_updated_date":"2025-10-16T11:27:28Z","reference_number":"EMA/414227/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2024-ema-decision-13-september-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-retatrutide-emea-003258-pip02-23_en.pdf"},
    {"id":"70586","name":"P/0345/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a waiver for hydroxycarbamide, (EMEA-003388-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T11:36:13Z","last_updated_date":"2025-10-16T11:36:13Z","reference_number":"EMA/415238/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0345-2024-ema-decision-13-september-2024-agreement-paediatric-investigation-plan-granting-waiver-hydroxycarbamide-emea-003388-pip01-23_en.pdf"},
    {"id":"70587","name":"P/0346/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for belumosudil, (EMEA-003425-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T11:42:06Z","last_updated_date":"2025-10-16T11:42:06Z","reference_number":"EMA/415351/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0346-2024-ema-decision-13-september-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-belumosudil-emea-003425-pip02-23_en.pdf"},
    {"id":"70588","name":"P/0332/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for mannose-1- phosphate (GLM101), (EMEA-003460-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T11:57:36Z","last_updated_date":"2025-10-16T11:57:36Z","reference_number":"EMA/413936/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0332-2024-ema-decision-13-september-2024-agreement-paediatric-investigation-plan-granting-deferral-mannose-1-phosphate-glm101-emea-003460-pip01-23_en.pdf"},
    {"id":"70589","name":"P/0316/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant humanized IgG1, kappa light chain.....(EMEA-003510-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T12:11:54Z","last_updated_date":"2025-10-16T12:11:54Z","reference_number":"EMA/410959/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0316-2024-ema-decision-13-september-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-humanized-igg1-kappa-light-chainemea-003510-pip01-23_en.pdf"},
    {"id":"70590","name":"P/0340/2024 : EMA decision of 11 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adeno‐associated viral vector serotype 8 containing the 3'....(EMEA-003524-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T12:23:15Z","last_updated_date":"2025-10-16T12:23:15Z","reference_number":"EMA/414602/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0340-2024-ema-decision-11-september-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-adeno-associated-viral-vector-serotype-8-containing-3emea-003524-pip01-23_en.pdf"},
    {"id":"70591","name":"P/0317/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a waiver for rilonacept (EMEA-003571-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T12:31:05Z","last_updated_date":"2025-10-16T12:31:05Z","reference_number":"EMA/410994/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0317-2024-ema-decision-13-september-2024-agreement-paediatric-investigation-plan-granting-waiver-rilonacept-emea-003571-pip01-23_en.pdf"},
    {"id":"70592","name":"P/0318/2024 : EMA decision of 13 September 2024 on the refusal of a product-specific waiver for montelukast sodium / rupatadine fumarate (EMEA-003629-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T12:40:41Z","last_updated_date":"2025-10-16T12:40:41Z","reference_number":"EMA/411054/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0318-2024-ema-decision-13-september-2024-refusal-product-specific-waiver-montelukast-sodium-rupatadine-fumarate-emea-003629-pip01-24_en.pdf"},
    {"id":"70593","name":"P/0326/2024 : EMA decision of 13 September 2025 on the granting of a product specific waiver for empagliflozin / derivative of 3‐phenyl‐3H,4H,6H,7Hpyrano[ 3,4‐d]imidazol‐4‐one (BI 690517), (EMEA-003632-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T12:42:15Z","last_updated_date":"2025-10-16T12:42:15Z","reference_number":"EMA/413681/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0326-2024-ema-decision-13-september-2025-granting-product-specific-waiver-empagliflozin-derivative-3-phenyl-3h4h6h7hpyrano-34-dimidazol-4-one-bi-690517-emea-003632-pip01-24_en.pdf"},
    {"id":"70594","name":"P/0338/2024 : EMA decision of 13 September 2024 on the granting of a product specific waiver for rememulgene arelactibac (EMEA-003638-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T12:49:12Z","last_updated_date":"2025-10-16T12:49:12Z","reference_number":"EMA/414280/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0338-2024-ema-decision-13-september-2024-granting-product-specific-waiver-rememulgene-arelactibac-emea-003638-pip01-24_en.pdf"},
    {"id":"70621","name":"P/0331/2024: EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for macimorelin (Ghryvelin), (EMEA-001988-PIP01-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T10:21:43Z","last_updated_date":"2025-10-17T10:21:43Z","reference_number":"EMA/413906/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0331-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-macimorelin-ghryvelin-emea-001988-pip01-16-m02_en.pdf"},
    {"id":"70623","name":"P/0330/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for leriglitazone (EMEA- 002106-PIP01-16-M03) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T11:07:18Z","last_updated_date":"2025-10-17T11:07:18Z","reference_number":"EMA/413895/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0330-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-leriglitazone-emea-002106-pip01-16-m03_en.pdf"},
    {"id":"70624","name":"P/0337/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for cefiderocol (Fetcroja), (EMEA-002133-PIP01-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T11:15:49Z","last_updated_date":"2025-10-17T11:15:49Z","reference_number":"EMA/414241/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0337-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-cefiderocol-fetcroja-emea-002133-pip01-17-m04_en.pdf"},
    {"id":"70625","name":"P/0339/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for daratumumab (Darzalex), (EMEA-002152-PIP01-17-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T11:21:48Z","last_updated_date":"2025-10-17T11:21:48Z","reference_number":"EMA/414389/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0339-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-daratumumab-darzalex-emea-002152-pip01-17-m04_en.pdf"},
    {"id":"70627","name":"P/0342/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for lasmiditan (Rayvow), (EMEA-002166-PIP01-17-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T11:25:48Z","last_updated_date":"2025-10-17T11:25:48Z","reference_number":"EMA/414754/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0342-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-lasmiditan-rayvow-emea-002166-pip01-17-m08_en.pdf"},
    {"id":"70631","name":"P/0343/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for rezafungin acetate (Rezzayo), (EMEA-002319-PIP01-17-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T12:00:15Z","last_updated_date":"2025-10-17T12:00:15Z","reference_number":"EMA/414909/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0343-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-rezafungin-acetate-rezzayo-emea-002319-pip01-17-m03_en.pdf"},
    {"id":"70633","name":"P/0350/2024 : EMA decision of 27 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ganaxolone (Ztalmy), (EMEA-002341-PIP01-18-M03)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T12:16:32Z","last_updated_date":"2025-10-17T12:16:32Z","reference_number":"EMA/441673/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0350-2024-ema-decision-27-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-ganaxolone-ztalmy-emea-002341-pip01-18-m03_en.pdf"},
    {"id":"70634","name":"P/0319/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for deucravacitinib (Sotyktu), (EMEA-002350-PIP02-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T12:29:52Z","last_updated_date":"2025-10-17T12:29:52Z","reference_number":"EMA/404847/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0319-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-deucravacitinib-sotyktu-emea-002350-pip02-20-m01_en.pdf"},
    {"id":"70635","name":"P/0341/2024 : EMA decision of 13 September 2024 on the acceptance of a modification of an agreed paediatric investigation plan for spesolimab (Spevigo), (EMEA-002475-PIP03-22-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T12:37:04Z","last_updated_date":"2025-10-17T12:37:04Z","reference_number":"EMA/410240/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0341-2024-ema-decision-13-september-2024-acceptance-modification-agreed-paediatric-investigation-plan-spesolimab-spevigo-emea-002475-pip03-22-m01_en.pdf"},
    {"id":"70636","name":"P/0344/2024 : EMA decision of 13 September 2024 on the granting of a product specific waiver for tafasitamab (Minjuvi), (EMEA-002499-PIP03-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T12:46:41Z","last_updated_date":"2025-10-17T12:46:41Z","reference_number":"EMA/415176/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0344-2024-ema-decision-13-september-2024-granting-product-specific-waiver-tafasitamab-minjuvi-emea-002499-pip03-24_en.pdf"},
    {"id":"70662","name":"P/0324/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for Iptacopan (Fabhalta), (EMEA-002705-PIP06-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-20T12:04:43Z","last_updated_date":"2025-10-20T12:04:43Z","reference_number":"EMA/412202/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0324-2024-ema-decision-13-september-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-iptacopan-fabhalta-emea-002705-pip06-23_en.pdf"},
    {"id":"70664","name":"P/0327/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for seralutinib (EMEA-002972-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-20T12:13:02Z","last_updated_date":"2025-10-20T12:13:02Z","reference_number":"EMA/412945/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0327-2024-ema-decision-13-september-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-seralutinib-emea-002972-pip02-23_en.pdf"},
    {"id":"70670","name":"P/0358/2024 : EMA decision of 25 October 2024 on the granting of a product specific waiver for zidesamtinib (EMEA-003649-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T13:35:41Z","last_updated_date":"2025-10-22T13:35:41Z","reference_number":"EMA/444733/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0358-2024-ema-decision-25-october-2024-granting-product-specific-waiver-zidesamtinib-emea-003649-pip01-24_en.pdf"},
    {"id":"70672","name":"P/0378/2024 : EMA decision of 25 October 2024 on the granting of a product specific waiver for ALK inhibitor (NVL-655) (EMEA-003648-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T13:36:39Z","last_updated_date":"2025-10-22T13:36:39Z","reference_number":"EMA/465523/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0378-2024-ema-decision-25-october-2024-granting-product-specific-waiver-alk-inhibitor-nvl-655-emea-003648-pip01-24_en.pdf"},
    {"id":"70673","name":"P/0368/2024 : EMA decision of 25 October 2024 on the granting of a product specific waiver for plinabulin (EMEA-003646-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T13:37:30Z","last_updated_date":"2025-10-22T13:37:30Z","reference_number":"EMA/480708/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0368-2024-ema-decision-25-october-2024-granting-product-specific-waiver-plinabulin-emea-003646-pip01-24_en.pdf"},
    {"id":"70674","name":"P/0361/2024 : EMA decision of 25 October 2024 on the granting of a product specific waiver for recombinant human progranulin fused to an Fc fragment engineered to contain a human transferrin receptor 1 binding domain (DNL593) (EMEA- 003643-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T13:38:23Z","last_updated_date":"2025-10-22T13:38:23Z","reference_number":"EMA/465468/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0361-2024-ema-decision-25-october-2024-granting-product-specific-waiver-recombinant-human-progranulin-fused-fc-fragment-engineered-contain-human-transferrin-receptor-1-binding-domain-dnl593-emea_en.pdf"},
    {"id":"70675","name":"P/0366/2024 : EMA decision of 25 October 2024 on the granting of a product specific waiver for dexfadrostat phosphate, (EMEA-003642-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T14:58:58Z","last_updated_date":"2025-10-22T14:58:58Z","reference_number":"EMA/482812/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0366-2024-ema-decision-25-october-2024-granting-product-specific-waiver-dexfadrostat-phosphate-emea-003642-pip01-24_en.pdf"},
    {"id":"70676","name":"P/0369/2024: EMA decision of 25 October 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral for idroxioleic acid (EMEA-003565-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T15:28:18Z","last_updated_date":"2025-10-22T15:28:18Z","reference_number":"EMA/480700/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0369-2024-ema-decision-25-october-2025-agreement-paediatric-investigation-plan-granting-deferral-idroxioleic-acid-emea-003565-pip01-23_en.pdf"},
    {"id":"70677","name":"P/0357/2024 : EMA decision of 25 October 2024 on agreement of a paediatric investigation plan and on granting of a deferral for (R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide (JNT-517) (EMEA-003531-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T15:39:12Z","last_updated_date":"2025-10-22T15:39:12Z","reference_number":"EMA/443765/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0357-2024-ema-decision-25-october-2024-agreement-paediatric-investigation-plan-granting-deferral-r-3-1-cyclopropyl-3-2-fluoro-4-trifluoromethoxybenzylureidopiperidine-1-carboxamide-jnt-517-emea_en.pdf"},
    {"id":"70678","name":"P/0379/2024 : EMA decision of 25 October 2024 on agreement of a paediatric investigation plan and on granting of a deferral and on the granting of a waiver for recombinant varicella zoster virus glycoprotein E adjuvanted (CRV-101) (EMEA-003526-PIP01-23)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T15:41:49Z","last_updated_date":"2025-10-21T15:41:49Z","reference_number":"EMA/465557/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0379-2024-ema-decision-25-october-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-recombinant-varicella-zoster-virus-glycoprotein-e-adjuvanted-crv-101-emea-003526_en.pdf"},
    {"id":"70679","name":"P/0373/2024 : EMA decision of 25 October 2024 on agreement of a PIP and on granting of deferral and waiver for 3,3-Dimethyl-N-(6-methyl-5-{[2-(1-methyl-1H-pyrazol-4-yl)pyridine-4- yl]oxy}pyridine-2-yl)-2-oxopyrrolidine-1-carboxamide hydrochloride hydrate ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:43:17Z","last_updated_date":"2025-10-21T15:43:17Z","reference_number":"EMA/480695/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0373-2024-ema-decision-25-october-2024-agreement-pip-granting-deferral-waiver-33-dimethyl-n-6-methyl-5-2-1-methyl-1h-pyrazol-4-ylpyridine-4-yloxypyridine-2-yl-2-oxopyrrolidine-1-carboxamide_en.pdf"},
    {"id":"70680","name":"P/0371/2024 : EMA decision of 25 October 2024 on the agreement of a paediatric investigation plan for cyclic GMP-AMP synthase inhibitor (BI 3000202), (EMEA-003440-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T15:45:01Z","last_updated_date":"2025-10-22T15:45:01Z","reference_number":"EMA/483235/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0371-2024-ema-decision-25-october-2024-agreement-paediatric-investigation-plan-cyclic-gmp-amp-synthase-inhibitor-bi-3000202-emea-003440-pip01-23_en.pdf"},
    {"id":"70681","name":"P/0365/2024 : EMA decision of 25 October 2024 on acceptance of a modification of an agreed paediatric investigation plan for mRNA encoding for the linked NTD and RBD domains of the spike glycoprotein of SARS-CoV-2 (mRNA-1283), (EMEA- 003426-PIP01-23-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:45:58Z","last_updated_date":"2025-10-21T15:45:58Z","reference_number":"EMA/482481/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0365-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-mrna-encoding-linked-ntd-rbd-domains-spike-glycoprotein-sars-cov-2-mrna-1283-emea-003426-pip01-23_en.pdf"},
    {"id":"70682","name":"P/0364/2024 : EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for pridopidine (hydrochloride), (EMEA-003174-PIP01-21-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:48:27Z","last_updated_date":"2025-10-21T15:48:27Z","reference_number":"EMA/482304/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0364-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-pridopidine-hydrochloride-emea-003174-pip01-21-m02_en.pdf"},
    {"id":"70683","name":"P/0360/2024 : EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for fidrisertib, (EMEA- 003133-PIP01-21-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:49:19Z","last_updated_date":"2025-10-21T15:49:19Z","reference_number":"EMA/481452/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0360-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-fidrisertib-emea-003133-pip01-21-m01_en.pdf"},
    {"id":"70685","name":"P/0377/2024 : EMA decision of 24 October 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dazukibart (EMEA-003089-PIP02-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:50:15Z","last_updated_date":"2025-10-21T15:50:15Z","reference_number":"EMA/484648/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0377-2024-ema-decision-24-october-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-dazukibart-emea-003089-pip02-23_en.pdf"},
    {"id":"70686","name":"P/0359/2024 : EMA decisio of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for brensocatib, (EMEA- 002905-PIP01-20-M01)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:51:06Z","last_updated_date":"2025-10-21T15:51:06Z","reference_number":"EMA/481253/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0359-2024-ema-decisio-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-brensocatib-emea-002905-pip01-20-m01_en.pdf"},
    {"id":"70730","name":"P/0367/2024: EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for mepolizumab (Nucala), (EMEA-000069-PIP01-07-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T11:23:12Z","last_updated_date":"2025-10-21T11:23:12Z","reference_number":"EMA/465524/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0367-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-mepolizumab-nucala-emea-000069-pip01-07-m09_en.pdf"},
    {"id":"70735","name":"P/0382/2024: EMA decision of 31 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for lebrikizumab (Ebglyss), (EMEA-002536-PIP01-18-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T14:48:20Z","last_updated_date":"2025-10-21T14:48:20Z","reference_number":"EMA/480694/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0382-2024-ema-decision-31-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-lebrikizumab-ebglyss-emea-002536-pip01-18-m04_en.pdf"},
    {"id":"70736","name":"P/0370/2024 : EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara), (EMEA-000311-PIP03-11-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:07:10Z","last_updated_date":"2025-10-21T15:07:10Z","reference_number":"EMA/465525/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0370-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara-emea-000311-pip03-11-m07_en.pdf"},
    {"id":"70737","name":"P/0384/2024: EMA decision of 25 October 2024 on the refusal of a modification of an agreed paediatric investigation plan for ambrisentan (Volibris), (EMEA-000434-PIP01-08-M10)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:13:05Z","last_updated_date":"2025-10-21T15:13:05Z","reference_number":"EMA/485479/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0384-2024-ema-decision-25-october-2024-refusal-modification-agreed-paediatric-investigation-plan-ambrisentan-volibris-emea-000434-pip01-08-m10_en.pdf"},
    {"id":"70738","name":"P/0376/2024: EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for posaconazole (Noxafil), (EMEA-000468-PIP02-12-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:21:12Z","last_updated_date":"2025-10-21T15:21:12Z","reference_number":"EMA/465528/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0376-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-posaconazole-noxafil-emea-000468-pip02-12-m09_en.pdf"}    {"id":"70739","name":"P/0375/2024: EMA decision of 24 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for romosozumab (EMEA-001075-PIP04-15-M07)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:25:04Z","last_updated_date":"2025-10-21T15:25:04Z","reference_number":"EMA/484740/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0375-2024-ema-decision-24-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-romosozumab-emea-001075-pip04-15-m07_en.pdf"},
    {"id":"70740","name":"P/0374/2024: EMA decision of 24 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for lomitapide (Lojuxta), (EMEA-001124-PIP01-10-M06)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T15:28:59Z","last_updated_date":"2025-10-21T15:28:59Z","reference_number":"EMA/484891/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0374-2024-ema-decision-24-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-lomitapide-lojuxta-emea-001124-pip01-10-m06_en.pdf"},
    {"id":"70741","name":"P/0381/2024: EMA decision of 24 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ceftolozane / tazobactam (Zerbaxa) (EMEA-001142-PIP02-16-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T16:08:39Z","last_updated_date":"2025-10-21T16:08:39Z","reference_number":"EMA/484870/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0381-2024-ema-decision-24-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-ceftolozane-tazobactam-zerbaxa-emea-001142-pip02-16-m02_en.pdf"},
    {"id":"70742","name":"P/0354/2024: EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP01-14-M08)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T16:14:36Z","last_updated_date":"2025-10-21T16:14:36Z","reference_number":"EMA/443930/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0354-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-upadacitinib-rinvoq-emea-001741-pip01-14-m08_en.pdf"},
    {"id":"70743","name":"P/0383/2024: EMA decision of 24 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human A disintegrin and metalloprotease with thrombospondin type-1 Motifs 13 (Adzynma), (EMEA-001160- PIP01-11-M05)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T17:17:23Z","last_updated_date":"2025-10-21T17:17:23Z","reference_number":"EMA/484938/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0383-2024-ema-decision-24-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-disintegrin-metalloprotease-thrombospondin-type-1-motifs-13-adzynma-emea-001160_en.pdf"},
    {"id":"70744","name":"P/0353/2024: EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP07-20-M02)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T17:25:12Z","last_updated_date":"2025-10-21T17:25:12Z","reference_number":"EMA/443829/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0353-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-dupilumab-dupixent-emea-001501-pip07-20-m02_en.pdf"},
    {"id":"70745","name":"P/0355/2024: EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for vamorolone (Agamree), (EMEA-001794-PIP02-16-M09)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-21T17:31:03Z","last_updated_date":"2025-10-21T17:31:03Z","reference_number":"EMA/444192/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0355-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-vamorolone-agamree-emea-001794-pip02-16-m09_en.pdf"},
    {"id":"70751","name":"P/0352/2024: EMA decision of 25 October 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bitopertin (EMEA-000439-PIP03-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T10:22:30Z","last_updated_date":"2025-10-22T10:22:30Z","reference_number":"EMA/442341/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0352-2024-ema-decision-25-october-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bitopertin-emea-000439-pip03-23_en.pdf"},
    {"id":"70767","name":"P/0386/2024: EMA decision of 25 October 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for teplizumab, (EMEA-000524-PIP02-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T16:54:05Z","last_updated_date":"2025-10-22T16:54:05Z","reference_number":"EMA/493296/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0386-2024-ema-decision-25-october-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-teplizumab-emea-000524-pip02-24_en.pdf"},
    {"id":"70768","name":"P/0356/2024: EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for daunorubicin / cytarabine (Vyxeos), (EMEA-001858-PIP02-16-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T16:55:13Z","last_updated_date":"2025-10-22T16:55:13Z","reference_number":"EMA/444603/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0356-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-daunorubicin-cytarabine-vyxeos-emea-001858-pip02-16-m04_en.pdf"},
    {"id":"70769","name":"P/0363/2024: EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for avapritinib (Ayvakyt), (EMEA-002358-PIP02-18-M04)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T16:56:11Z","last_updated_date":"2025-10-22T16:56:11Z","reference_number":"EMA/466009/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0363-2024-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-avapritinib-ayvakyt-emea-002358-pip02-18-m04_en.pdf"},
    {"id":"70770","name":"P/0362/2024: EMA decision of 25 October 2024 on the granting of a product specific waiver for zirconium (89Zr) girentuximab senvedoxam (EMEA-002482-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T16:57:00Z","last_updated_date":"2025-10-22T16:57:00Z","reference_number":"EMA/465872/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0362-2024-ema-decision-25-october-2024-granting-product-specific-waiver-zirconium-89zr-girentuximab-senvedoxam-emea-002482-pip01-24_en.pdf"},
    {"id":"70771","name":"P/0385/2024: EMA decision of 25 October 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for venglustat (EMEA-001716-PIP08-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T17:16:18Z","last_updated_date":"2025-10-22T17:16:18Z","reference_number":"EMA/491310/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0385-2024-ema-decision-25-october-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-venglustat-emea-001716-pip08-23_en.pdf"},
    {"id":"70777","name":"EMA/PE/0000181891: EMA decision of 25 October 2024 on the granting of a product specific waiver for sildenafil citrate, testosterone","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-23T09:31:22Z","last_updated_date":"2025-10-23T09:31:22Z","reference_number":"EMADOC-1700519818-1690068","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181891-ema-decision-25-october-2024-granting-product-specific-waiver-sildenafil-citrate-testosterone_en.pdf"},
    {"id":"70778","name":"EMA/PE/0000221282: EMA decision of 30 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for teplizumab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-23T09:32:25Z","last_updated_date":"2025-10-23T09:32:25Z","reference_number":"EMADOC-1700519818-1725433","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221282-ema-decision-30-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-teplizumab_en.pdf"},
    {"id":"70779","name":"EMA/PE/0000225106: EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ibrexafungerp","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-10-23T09:33:56Z","last_updated_date":"2025-10-23T09:33:56Z","reference_number":"EMADOC-1700519818-1723829","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225106-ema-decision-25-october-2024-acceptance-modification-agreed-paediatric-investigation-plan-ibrexafungerp_en.pdf"},
    {"id":"71030","name":"EMA/PE/0000257243 : EMA decision of 4 August 2025 on the acceptance of a modification of an agreed paediatric investigation plan for pozelimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-11-06T10:03:53Z","last_updated_date":"2025-11-06T10:03:53Z","reference_number":"EMADOC-1700519818-2320688","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000257243-ema-decision-4-august-2025-acceptance-modification-agreed-paediatric-investigation-plan-pozelimab_en.pdf"},
    {"id":"71031","name":"EMA/PE/0000231113 : EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for nemvaleukin alfa","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-11-06T10:19:02Z","last_updated_date":"2025-11-06T10:19:02Z","reference_number":"EMADOC-1700519818-1976293","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000231113-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-nemvaleukin-alfa_en.pdf"},
    {"id":"71032","name":"P/0395/2024 : EMA decision of 6 December 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bexicaserin (EMEA-003288-PIP01-22)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-11-06T10:32:31Z","last_updated_date":"2025-11-06T10:32:31Z","reference_number":"EMA/528864/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0395-2024-ema-decision-6-december-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-bexicaserin-emea-003288-pip01-22_en.pdf"},
    {"id":"71033","name":"EMA/PE/0000232853 : EMA decision of 10 September 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nitrosomonas eutropha, strain D23","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-11-06T10:50:41Z","last_updated_date":"2025-11-06T10:50:41Z","reference_number":"EMADOC-1700519818-2327416","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232853-ema-decision-10-september-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-nitrosomonas-eutropha-strain-d23_en.pdf"},
    {"id":"71036","name":"EMA/PE/0000246904 : EMA decision of 12 September 2025 on the acceptance of a modification of an agreed paediatric investigation plan for cobolimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-11-06T14:27:54Z","last_updated_date":"2025-11-06T14:27:54Z","reference_number":"EMADOC-1700519818-2347002","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000246904-ema-decision-12-september-2025-acceptance-modification-agreed-paediatric-investigation-plan-cobolimab_en.pdf"},
    {"id":"71450","name":"EMA/PE/0000232315: EMA decision of 19 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for spesolimab (Spevigo)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-02T11:44:17Z","last_updated_date":"2025-12-02T11:44:17Z","reference_number":"EMADOC-1700519818-1976710","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232315-ema-decision-19-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-spesolimab-spevigo_en.pdf"},
    {"id":"71451","name":"P/0388/2024: EMA decision of 8 November 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tildrakizumab (Ilumetri), (EMEA-001451-PIP02-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-02T11:50:11Z","last_updated_date":"2025-12-02T11:50:11Z","reference_number":"EMA/513587/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0388-2024-ema-decision-8-november-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tildrakizumab-ilumetri-emea-001451-pip02-24_en.pdf"},
    {"id":"71452","name":"P/0387/2024: EMA decision of 8 November 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ravulizumab (Ultomiris), (EMEA-001943-PIP07-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-02T11:51:24Z","last_updated_date":"2025-12-02T11:51:24Z","reference_number":"EMA/506319/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0387-2024-ema-decision-8-november-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ravulizumab-ultomiris-emea-001943-pip07-24_en.pdf"},
    {"id":"71513","name":"EMA/PE/0000254020: EMA decision of 27 June 2025 on the acceptance of a modification of an agreed paediatric investigation plan for risankizumab (Skyrizi)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T08:56:57Z","last_updated_date":"2025-12-05T08:56:57Z","reference_number":"EMADOC-1700519818-2223385","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000254020-ema-decision-27-june-2025-acceptance-modification-agreed-paediatric-investigation-plan-risankizumab-skyrizi_en.pdf"},
    {"id":"71514","name":"EMA/PE/0000274326: EMA decision of 31 October 2025 on the acceptance of a modification of an agreed paediatric investigation plan for risankizumab (Skyrizi)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T08:58:02Z","last_updated_date":"2025-12-05T08:58:02Z","reference_number":"EMADOC-1700519818-2525361","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000274326-ema-decision-31-october-2025-acceptance-modification-agreed-paediatric-investigation-plan-risankizumab-skyrizi_en.pdf"},
    {"id":"71515","name":"EMA/PE/0000221709: EMA decision of 7 November 2024 on the acceptance of a modification of an agreed paediatric investigation plan for apitegromab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T09:26:27Z","last_updated_date":"2025-12-05T09:26:27Z","reference_number":"EMADOC-1700519818-1736438","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221709-ema-decision-7-november-2024-acceptance-modification-agreed-paediatric-investigation-plan-apitegromab_en.pdf"},
    {"id":"71516","name":"EMA/PE/0000182362: EMA decision of 14 November 2024 on the acceptance of a modification of an agreed paediatric investigation plan for tildrakizumab (Ilumetri)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T09:33:55Z","last_updated_date":"2025-12-05T09:33:55Z","reference_number":"EMADOC-1700519818-1760793","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182362-ema-decision-14-november-2024-acceptance-modification-agreed-paediatric-investigation-plan-tildrakizumab-ilumetri_en.pdf"},
    {"id":"71517","name":"EMA/PE/0000183059: EMA decision of 13 November 2024 on the acceptance of a modification of an agreed paediatric investigation plan for abrocitinib (Cibinqo)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T09:40:48Z","last_updated_date":"2025-12-05T09:40:48Z","reference_number":"EMADOC-1700519818-1759464","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183059-ema-decision-13-november-2024-acceptance-modification-agreed-paediatric-investigation-plan-abrocitinib-cibinqo_en.pdf"},
    {"id":"71518","name":"EMA/PE/0000221076: EMA decision of 8 November 2024 on the acceptance of a modification of an agreed paediatric investigation plan for adrenaline (epinephrine) (EURneffy)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T09:42:04Z","last_updated_date":"2025-12-05T09:42:04Z","reference_number":"EMADOC-1700519818-1738916","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221076-ema-decision-8-november-2024-acceptance-modification-agreed-paediatric-investigation-plan-adrenaline-epinephrine-eurneffy_en.pdf"},
    {"id":"71519","name":"EMA/PE/0000183220: EMA decision of 22 November 2024 on the acceptance of a modification of an agreed paediatric investigation plan for iclepertin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T09:43:01Z","last_updated_date":"2025-12-05T09:43:01Z","reference_number":"EMADOC-1700519818-1766863","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183220-ema-decision-22-november-2024-acceptance-modification-agreed-paediatric-investigation-plan-iclepertin_en.pdf"},
    {"id":"71520","name":"EMA/PE/0000221589: EMA decision of 25 Nov 2024 on the acceptance of a modification of an agreed PIP for split influenza virus, inactivated containing antigens equivalent to the A/H1N1 and A/H3N2-like strain, B-like strain (Victoria / Yamagata lineage)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T09:43:53Z","last_updated_date":"2025-12-05T09:43:53Z","reference_number":"EMADOC-1700519818-1773555","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221589-ema-decision-25-nov-2024-acceptance-modification-agreed-pip-split-influenza-virus-inactivated-containing-antigens-equivalent-h1n1-h3n2-strain-b-strain-victoria-yamagata-lineage_en.pdf"},
    {"id":"71521","name":"EMA/PE/0000238005: EMA decision of 27 November 2024 on the acceptance of a modification of an agreed paediatric investigation plan for inebilizumab (Uplinza)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T09:54:25Z","last_updated_date":"2025-12-05T09:54:25Z","reference_number":"EMADOC-1700519818-1776292","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000238005-ema-decision-27-november-2024-acceptance-modification-agreed-paediatric-investigation-plan-inebilizumab-uplinza_en.pdf"},
    {"id":"71522","name":"EMA/PE/0000238074: EMA decision of 27 November 2024 on the acceptance of a modification of an agreed paediatric investigation plan for mitapivat (Pryrukind)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T09:55:17Z","last_updated_date":"2025-12-05T09:55:17Z","reference_number":"EMADOC-1700519818-1789262","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000238074-ema-decision-27-november-2024-acceptance-modification-agreed-paediatric-investigation-plan-mitapivat-pryrukind_en.pdf"},
    {"id":"71565","name":"EMA/PE/0000225184: EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for nirmatrelvir, nirmatrelvir / ritonavir ( Paxlovid)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-08T10:47:39Z","last_updated_date":"2025-12-08T10:47:39Z","reference_number":"EMADOC-1700519818-1788035","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225184-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-nirmatrelvir-nirmatrelvir-ritonavir-paxlovid_en.pdf"},
    {"id":"71566","name":"EMA/PE/0000224486: EMA decision of 5 December 2024 on the granting of a product specific waiver for amlodipine, ramipril, rosuvastatin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-08T10:48:39Z","last_updated_date":"2025-12-08T10:48:39Z","reference_number":"EMADOC-1700519818-1792333","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224486-ema-decision-5-december-2024-granting-product-specific-waiver-amlodipine-ramipril-rosuvastatin_en.pdf"},
    {"id":"71567","name":"EMA/PE/0000224202: EMA decision of 5 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for dengue tetravalent vaccine (live, attenuated) (Qdenga)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-08T10:49:35Z","last_updated_date":"2025-12-08T10:49:35Z","reference_number":"EMADOC-1700519818-1793045","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224202-ema-decision-5-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-dengue-tetravalent-vaccine-live-attenuated-qdenga_en.pdf"},
    {"id":"71568","name":"EMA/PE/0000221803: EMA decision of 6 December 2024 on the refusal of a paediatric investigation plan and on the granting of a waiver for betula pendula pollen extract","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-08T10:50:20Z","last_updated_date":"2025-12-08T10:50:20Z","reference_number":"EMADOC-1700519818-1793589","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221803-ema-decision-6-december-2024-refusal-paediatric-investigation-plan-granting-waiver-betula-pendula-pollen-extract_en.pdf"},
    {"id":"71569","name":"P/0396/2024: EMA decision of 6 December 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for gorilla adenovirus vector expressing HPV6 and HPV11 antigens (PRGN-2012), (EMEA-003592-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T10:51:27Z","last_updated_date":"2025-12-09T10:51:27Z","reference_number":"EMA/534088/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0396-2024-ema-decision-6-december-2024-agreement-paediatric-investigation-plan-granting-deferral-gorilla-adenovirus-vector-expressing-hpv6-hpv11-antigens-prgn-2012-emea-003592-pip01-24_en.pdf"},
    {"id":"71570","name":"P/0402/2024: EMA decision of 18 December 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for diazoxide choline, (EMEA-003614-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T10:52:17Z","last_updated_date":"2025-12-09T10:52:17Z","reference_number":"EMA/591389/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0402-2024-ema-decision-18-december-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-diazoxide-choline-emea-003614-pip01-24_en.pdf"},
    {"id":"71573","name":"P/0393/2024: EMA decision of 6 December 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tulisokibart (EMEA-003556-PIP02-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-08T10:54:33Z","last_updated_date":"2025-12-08T10:54:33Z","reference_number":"EMA/554343/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0393-2024-ema-decision-6-december-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tulisokibart-emea-003556-pip02-24_en.pdf"},
    {"id":"71574","name":"P/0398/2024: EMA decision of 17 December 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for olorofim, (EMEA-003564-PIP01-23) in","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T10:55:52Z","last_updated_date":"2025-12-09T10:55:52Z","reference_number":"EMA/587147/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0398-2024-ema-decision-17-december-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-olorofim-emea-003564-pip01-23_en.pdf"},
    {"id":"71575","name":"P/0397/2024: EMA decision of 5 December 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for trastuzumab deruxtecan (Enhertu), (EMEA-002978-PIP02-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-08T10:57:05Z","last_updated_date":"2025-12-08T10:57:05Z","reference_number":"EMA/556006/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0397-2024-ema-decision-5-december-2024-agreement-paediatric-investigation-plan-granting-deferral-trastuzumab-deruxtecan-enhertu-emea-002978-pip02-24_en.pdf"},
    {"id":"71576","name":"P/0394/2024: EMA decision of 6 December 2024 on the agreement of a paediatric investigation plan for 7-ethyl-10-hydroxy-camptothecin (SN-38) (EMEA-003588-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-08T10:58:01Z","last_updated_date":"2025-12-08T10:58:01Z","reference_number":"EMA/554382/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0394-2024-ema-decision-6-december-2024-agreement-paediatric-investigation-plan-7-ethyl-10-hydroxy-camptothecin-sn-38-emea-003588-pip01-24_en.pdf"},
    {"id":"71577","name":"P/0392/2024: EMA decision of 6 December 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral for linaprazan glurate (EMEA-003558-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T10:59:32Z","last_updated_date":"2025-12-09T10:59:32Z","reference_number":"EMA/554255/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0392-2024-ema-decision-6-december-2024-agreement-paediatric-investigation-plan-granting-deferral-linaprazan-glurate-emea-003558-pip01-23_en.pdf"},
    {"id":"71578","name":"P/0391/2024: EMA decision of 6 December 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for doruxapapogenum ralaplasmidum, (EMEA-003506-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-08T11:06:18Z","last_updated_date":"2025-12-08T11:06:18Z","reference_number":"EMA/552735/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0391-2024-ema-decision-6-december-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-doruxapapogenum-ralaplasmidum-emea-003506-pip01-23_en.pdf"},
    {"id":"71579","name":"P/0390/2024: EMA decision of 6 December 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tulisokibart, (EMEA-003556-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-08T11:10:55Z","last_updated_date":"2025-12-08T11:10:55Z","reference_number":"EMA/552717/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0390-2024-ema-decision-6-december-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-tulisokibart-emea-003556-pip01-23_en.pdf"},
    {"id":"71580","name":"P/0389/2024: EMA decision of 5 Dec 2024 on the agreement of a PIP and on granting of a deferral and a waiver for 6'-([(1S,3S)-3-([5-(difluoromethoxy)-2- pyrimidinyl]amino)cyclopentyl] amino)-2H- [1,3'-bipyridin]-2-one (AZD0780) (EMEA-003580-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T11:12:58Z","last_updated_date":"2025-12-09T11:12:58Z","reference_number":"EMA/552707/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0389-2024-ema-decision-5-dec-2024-agreement-pip-granting-deferral-waiver-6-1s3s-3-5-difluoromethoxy-2-pyrimidinylaminocyclopentyl-amino-2h-13-bipyridin-2-one-azd0780-emea-003580-pip01-24_en.pdf"},
    {"id":"71610","name":"EMA/PE/0000182440 : EMA decision of 6 December 2024 on the granting of a product specific waiver for resiniferatoxin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T11:24:11Z","last_updated_date":"2025-12-09T11:24:11Z","reference_number":"EMADOC-1700519818-1790103","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182440-ema-decision-6-december-2024-granting-product-specific-waiver-resiniferatoxin_en.pdf"},
    {"id":"71612","name":"EMA/PE/0000182447 : EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for amlitelimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T11:34:09Z","last_updated_date":"2025-12-09T11:34:09Z","reference_number":"EMADOC-1700519818-1788084","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182447-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-amlitelimab_en.pdf"},
    {"id":"71613","name":"EMA/PE/0000182462 : EMA decision of 6 December 2024 on the granting of a product specific waiver for bizalimogene ralaplasmid / mavilimogene ralaplasmid / rocakinogene sifuplasmid","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T11:54:52Z","last_updated_date":"2025-12-09T11:54:52Z","reference_number":"EMADOC-1700519818-1789264","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182462-ema-decision-6-december-2024-granting-product-specific-waiver-bizalimogene-ralaplasmid-mavilimogene-ralaplasmid-rocakinogene-sifuplasmid_en.pdf"},
    {"id":"71616","name":"EMA/PE/0000182525 : EMA decision of 6 December 2024 on the granting of a product specific waiver for modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/mRNA-4157)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T12:28:37Z","last_updated_date":"2025-12-09T12:28:37Z","reference_number":"EMADOC-1700519818-1784306","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182525-ema-decision-6-december-2024-granting-product-specific-waiver-modified-messenger-ribonucleic-acid-encoding-individual-patient-specific-tumour-neoantigens-v940-mrna-4157_en.pdf"},
    {"id":"71617","name":"EMA/PE/0000183083 : EMA decision of 6 December 2024 on the granting of a product specific waiver for (S)-(4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridin-8-yl)(3-(4-(trifluoromethyl)phenyl)morpholino)methanone","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T12:45:57Z","last_updated_date":"2025-12-09T12:45:57Z","reference_number":"EMADOC-1700519818-1784096","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183083-ema-decision-6-december-2024-granting-product-specific-waiver-s-4-amino-13-dihydrofuro34-c17naphthyridin-8-yl3-4-trifluoromethylphenylmorpholinomethanone_en.pdf"},
    {"id":"71618","name":"EMA/PE/0000182808 : EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for zoliflodacin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T13:10:55Z","last_updated_date":"2025-12-09T13:10:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182808-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-zoliflodacin_en.pdf"},
    {"id":"71621","name":"EMA/PE/0000183137 : EMA decision of 6 December 2025 on the acceptance of a modification of an agreed paediatric investigation plan for encaleret","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T14:25:15Z","last_updated_date":"2025-12-09T14:25:15Z","reference_number":"EMADOC-1700519818-1759915","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183137-ema-decision-6-december-2025-acceptance-modification-agreed-paediatric-investigation-plan-encaleret_en.pdf"},
    {"id":"71622","name":"EMA/PE/0000183329 : EMA decision of 6 December 2024 on the of a modification of an agreed paediatric investigation plan for interleukin-23 receptor antagonist peptide (JNJ-77242113)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T14:38:09Z","last_updated_date":"2025-12-09T14:38:09Z","reference_number":"EMADOC-1700519818-1793192","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183329-ema-decision-6-december-2024-modification-agreed-paediatric-investigation-plan-interleukin-23-receptor-antagonist-peptide-jnj-77242113_en.pdf"},
    {"id":"71626","name":"EMA/PE/0000183373 : EMA decision of 6 December 2024 on the granting of a product specific waiver for tadalafil, tamsulosin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T15:47:21Z","last_updated_date":"2025-12-09T15:47:21Z","reference_number":"EMADOC-1700519818-1775261","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183373-ema-decision-6-december-2024-granting-product-specific-waiver-tadalafil-tamsulosin_en.pdf"},
    {"id":"71638","name":"EMA/PE/0000183430 : EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for tralokinumab (Adtralza)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-10T10:02:36Z","last_updated_date":"2025-12-10T10:02:36Z","reference_number":"EMADOC-1700519818-1789468","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183430-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-tralokinumab-adtralza_en.pdf"},
    {"id":"71639","name":"EMA/PE/0000183758 : EMA decision of 6 December 2024 on the granting of a product specific waiver for zimislecel","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-10T10:12:31Z","last_updated_date":"2025-12-10T10:12:31Z","reference_number":"EMADOC-1700519818-1793563","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183758-ema-decision-6-december-2024-granting-product-specific-waiver-zimislecel_en.pdf"},
    {"id":"71640","name":"EMA/PE/0000183866 : EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for brexpiprazole (Rxulti)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-10T10:24:32Z","last_updated_date":"2025-12-10T10:24:32Z","reference_number":"EMADOC-1700519818-1791709","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183866-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-brexpiprazole-rxulti_en.pdf"},
    {"id":"71641","name":"EMA/PE/0000184400 : EMA decision of 5 December 2024 on the granting of a product specific waiver for dapagliflozin / eplerenone","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-10T10:30:02Z","last_updated_date":"2025-12-10T10:30:02Z","reference_number":"EMADOC-1700519818-1791938","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000184400-ema-decision-5-december-2024-granting-product-specific-waiver-dapagliflozin-eplerenone_en.pdf"},
    {"id":"71778","name":"EMA/PE/0000221424 : EMA decision of 6 December 2024 on the refusal of a paediatric investigation plan and on the granting of a product-specific waiver for dermatophagoides pteronyssinus extract","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T13:01:14Z","last_updated_date":"2025-12-16T13:01:14Z","reference_number":"EMADOC-1700519818-1793274","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221424-ema-decision-6-december-2024-refusal-paediatric-investigation-plan-granting-product-specific-waiver-dermatophagoides-pteronyssinus-extract_en.pdf"},
    {"id":"71779","name":"EMA/PE/0000221500 : EMA decision of 5 December 2024 on the refusal of a paediatric investigation plan and on the granting of a waiver for Phleum pratense pollen extract","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T13:17:09Z","last_updated_date":"2025-12-16T13:17:09Z","reference_number":"EMADOC-1700519818-1792191","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221500-ema-decision-5-december-2024-refusal-paediatric-investigation-plan-granting-waiver-phleum-pratense-pollen-extract_en.pdf"},
    {"id":"71780","name":"EMA/PE/0000221511 : EMA decision of 6 December 2024 on the granting of a product specific waiver for recombinant human apolipoprotein A-I","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T13:34:48Z","last_updated_date":"2025-12-16T13:34:48Z","reference_number":"EMADOC-1700519818-1793267","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221511-ema-decision-6-december-2024-granting-product-specific-waiver-recombinant-human-apolipoprotein-i_en.pdf"},
    {"id":"71781","name":"EMA/PE/0000221664 : EMA decision of 6 December 2024 on the refusal of a paediatric investigation plan and on the granting of a waiver for parietaria judaica pollen extract","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T13:45:06Z","last_updated_date":"2025-12-16T13:45:06Z","reference_number":"EMADOC-1700519818-1793193","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221664-ema-decision-6-december-2024-refusal-paediatric-investigation-plan-granting-waiver-parietaria-judaica-pollen-extract_en.pdf"},
    {"id":"71782","name":"EMA/PE/0000221674 : EMA decision of 6 December 2024 on the granting of a product specific waiver for xaluritamig","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T13:54:35Z","last_updated_date":"2025-12-16T13:54:35Z","reference_number":"EMADOC-1700519818-1793219","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221674-ema-decision-6-december-2024-granting-product-specific-waiver-xaluritamig_en.pdf"},
    {"id":"71783","name":"EMA/PE/0000221695 : EMA decision of 5 December 2024 on the refusal of a paediatric investigation plan and on the granting of a waiver for Cupressus arizonica pollen extract","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T14:07:28Z","last_updated_date":"2025-12-16T14:07:28Z","reference_number":"EMADOC-1700519818-1792235","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221695-ema-decision-5-december-2024-refusal-paediatric-investigation-plan-granting-waiver-cupressus-arizonica-pollen-extract_en.pdf"},
    {"id":"71784","name":"EMA/PE/0000221772 : EMA decision of 6 December 2024 on the refusal of a paediatric investigation plan and on the granting of a waiver for Olea europaea pollen extract","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T14:10:37Z","last_updated_date":"2025-12-16T14:10:37Z","reference_number":"EMADOC-1700519818-1790725","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221772-ema-decision-6-december-2024-refusal-paediatric-investigation-plan-granting-waiver-olea-europaea-pollen-extract_en.pdf"},
    {"id":"71785","name":"EMA/PE/0000221419 : EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for Pneumococcal Polysaccharide Serotype 3 – Diphtheria CRM197 Conjugate...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T14:39:47Z","last_updated_date":"2025-12-16T14:39:47Z","reference_number":"EMADOC-1700519818-1793577","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221419-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-pneumococcal-polysaccharide-serotype-3-diphtheria-crm197-conjugate_en.pdf"},
    {"id":"71786","name":"EMA/PE/0000221485 : EMA decision of 6 December 2024 on the refusal of a modification of an agreed paediatric investigation plan for cangrelor tetrasodium (Kengrexal)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T15:18:03Z","last_updated_date":"2025-12-16T15:18:03Z","reference_number":"EMADOC-1700519818-1792970","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221485-ema-decision-6-december-2024-refusal-modification-agreed-paediatric-investigation-plan-cangrelor-tetrasodium-kengrexal_en.pdf"},
    {"id":"71787","name":"EMA/PE/0000221199 : EMA decision of 6 December 2024 on the granting of a product specific waiver for bemcentinib","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-16T15:25:05Z","last_updated_date":"2025-12-16T15:25:05Z","reference_number":"EMADOC-1700519818-1793576","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221199-ema-decision-6-december-2024-granting-product-specific-waiver-bemcentinib_en.pdf"},
    {"id":"71798","name":"EMA/PE/0000181219: EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline (fumarate) (Sirturo)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T11:30:47Z","last_updated_date":"2025-12-17T11:30:47Z","reference_number":"EMADOC-1700519818-1775423","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181219-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-bedaquiline-fumarate-sirturo_en.pdf"},
    {"id":"71799","name":"EMA/PE/0000181236: EMA decision of 5 December 2024 on the granting of a product specific waiver for telisotuzumab conjugated to (2S)-2-(2-bromoacetamido)-N-[(2S)-1-({3-[(7S)-7-ethyl-7-hydroxy-8,11-dioxo-7,8,11,13-tetrahydro-2H,10H-[1,3]dioxolo[4,5-g] ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T11:48:05Z","last_updated_date":"2025-12-17T11:48:05Z","reference_number":"EMADOC-1700519818-1791510","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181236-ema-decision-5-december-2024-granting-product-specific-waiver-telisotuzumab-conjugated-2s-2-2-bromoacetamido-n-2s-1-3-7s-7-ethyl-7-hydroxy-811-dioxo-781113-tetrahydro-2h10h_en.pdf"},
    {"id":"71801","name":"EMA/PE/0000181238: EMA decision of 6 December 2024 on the agreement of a paediatric investigation plan and on the granting of a waiver for resiquimod","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T12:07:40Z","last_updated_date":"2025-12-17T12:07:40Z","reference_number":"EMADOC-1700519818-1775491","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181238-ema-decision-6-december-2024-agreement-paediatric-investigation-plan-granting-waiver-resiquimod_en.pdf"},
    {"id":"71802","name":"EMA/PE/0000181294: EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for tolebrutinib","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T12:23:45Z","last_updated_date":"2025-12-17T12:23:45Z","reference_number":"EMADOC-1700519818-1766802","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181294-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-tolebrutinib_en.pdf"},
    {"id":"71803","name":"EMA/PE/0000181300: EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for avalglucosidase alfa (Nexviadyme)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T12:31:22Z","last_updated_date":"2025-12-17T12:31:22Z","reference_number":"EMADOC-1700519818-1793517","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181300-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-avalglucosidase-alfa-nexviadyme_en.pdf"},
    {"id":"71804","name":"EMA/PE/0000221175 : EMA decision of 16 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for vibegron","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T12:57:00Z","last_updated_date":"2025-12-17T12:57:00Z","reference_number":"EMADOC-1700519818-1807888","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221175-ema-decision-16-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-vibegron_en.pdf"},
    {"id":"71807","name":"EMA/PE/0000220986 : EMA decision of 6 December 2024 on the granting of a product specific waiver for tenapanor","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T14:15:21Z","last_updated_date":"2025-12-17T14:15:21Z","reference_number":"EMADOC-1700519818-1793255 Corr","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000220986-ema-decision-6-december-2024-granting-product-specific-waiver-tenapanor_en.pdf"},
    {"id":"71808","name":"EMA/PE/0000221021 : EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for atazanavir (sulphate) / cobicistat (EVOTAZ)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T14:19:52Z","last_updated_date":"2025-12-17T14:19:52Z","reference_number":"EMADOC-1700519818-1793575","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221021-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-atazanavir-sulphate-cobicistat-evotaz_en.pdf"},
    {"id":"71809","name":"EMA/PE/0000181335: EMA decision of 5 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for budesonide / glycopyrronium bromide / formoterol (fumarate) (Trixeo Aerosphere)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T14:21:24Z","last_updated_date":"2025-12-17T14:21:24Z","reference_number":"EMADOC-1700519818-1791535","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181335-ema-decision-5-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-budesonide-glycopyrronium-bromide-formoterol-fumarate-trixeo-aerosphere_en.pdf"},
    {"id":"71810","name":"EMA/PE/0000181441: EMA decision of 6 December 2024 on the granting of a product specific waiver for telisotuzumab conjugated to (2S)-2-(2-bromoacetamido)-N-[(2S)-1-({3-[(7S)-7-ethyl-7-hydroxy-8,11-dioxo-7,8,11,13-tetrahydro-2H,10H-[1,3]dioxolo[4,5-g] ...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T14:27:14Z","last_updated_date":"2025-12-17T14:27:14Z","reference_number":"EMADOC-1700519818-1793529","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181441-ema-decision-6-december-2024-granting-product-specific-waiver-telisotuzumab-conjugated-2s-2-2-bromoacetamido-n-2s-1-3-7s-7-ethyl-7-hydroxy-811-dioxo-781113-tetrahydro-2h10h_en.pdf"},
    {"id":"71811","name":"EMA/PE/0000221101 : EMA decision of 5 December 2024 on the granting of a product specific waiver for esepapogene zalarnarepvec","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T14:29:02Z","last_updated_date":"2025-12-17T14:29:02Z","reference_number":"EMADOC-1700519818-1791979","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221101-ema-decision-5-december-2024-granting-product-specific-waiver-esepapogene-zalarnarepvec_en.pdf"},
    {"id":"71812","name":"EMA/PE/0000181518: EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for lerodalcibep","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T14:34:07Z","last_updated_date":"2025-12-17T14:34:07Z","reference_number":"EMADOC-1700519818-1766926","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181518-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-lerodalcibep_en.pdf"},
    {"id":"71813","name":"EMA/PE/0000221751 : EMA decision of 5 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ascorbic acid, macrogol 3350, potassium chloride, sodium ascorbate, sodium chloride, sodium sulphate (Plenvu)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T14:41:20Z","last_updated_date":"2025-12-17T14:41:20Z","reference_number":"EMADOC-1700519818-1792265","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221751-ema-decision-5-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-ascorbic-acid-macrogol-3350-potassium-chloride-sodium-ascorbate-sodium-chloride-sodium_en.pdf"},
    {"id":"71814","name":"EMA/PE/0000181778: EMA decision of 6 December 2024 on the granting of a product specific waiver for rilvegostomig","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T14:50:39Z","last_updated_date":"2025-12-17T14:50:39Z","reference_number":"EMADOC-1700519818-1793273","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181778-ema-decision-6-december-2024-granting-product-specific-waiver-rilvegostomig_en.pdf"},
    {"id":"71815","name":"EMA/PE/0000182170: EMA decision of 5 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for regorafenib (Stivarga)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T15:09:08Z","last_updated_date":"2025-12-17T15:09:08Z","reference_number":"EMADOC-1700519818-1791595","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182170-ema-decision-5-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-regorafenib-stivarga_en.pdf"},
    {"id":"71816","name":"EMA/PE/0000182217: EMA decision of 6 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for cedazuridine / decitabine (Inaqovi)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T15:15:58Z","last_updated_date":"2025-12-17T15:15:58Z","reference_number":"EMADOC-1700519818-1789714","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182217-ema-decision-6-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-cedazuridine-decitabine-inaqovi_en.pdf"},
    {"id":"71817","name":"EMA/PE/0000182239: EMA decision of 19 December 2024 on the acceptance of a modification of an agreed paediatric investigation plan for setmelanotide (Imcivree) ","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T15:21:52Z","last_updated_date":"2025-12-17T15:21:52Z","reference_number":"EMADOC-1700519818-1796893","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182239-ema-decision-19-december-2024-acceptance-modification-agreed-paediatric-investigation-plan-setmelanotide-imcivree_en.pdf"},
    {"id":"71818","name":"EMA/PE/0000182297: EMA decision of 6 December 2024 on the granting of a product specific waiver for oxybutynin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T15:26:23Z","last_updated_date":"2025-12-17T15:26:23Z","reference_number":"EMADOC-1700519818-1790205","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182297-ema-decision-6-december-2024-granting-product-specific-waiver-oxybutynin_en.pdf"},
    {"id":"71819","name":"EMA/PE/0000182333: EMA decision of 6 December 2024 on the granting of a product specific waiver for precemtabart tocentecan","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T15:32:37Z","last_updated_date":"2025-12-17T15:32:37Z","reference_number":"EMADOC-1700519818-1789267","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182333-ema-decision-6-december-2024-granting-product-specific-waiver-precemtabart-tocentecan_en.pdf"},
    {"id":"71820","name":"EMA/PE/0000182345: EMA decision of 6 December 2024 on the granting of a product specific waiver for inbakicept, nogapendekin alfa","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T15:40:57Z","last_updated_date":"2025-12-17T15:40:57Z","reference_number":"EMADOC-1700519818-1790021","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182345-ema-decision-6-december-2024-granting-product-specific-waiver-inbakicept-nogapendekin-alfa_en.pdf"},
    {"id":"71834","name":"EMA/PE/0000232894 : EMA decision of 14 April 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral for adeno-associated viral vector serotype 9 containing the human MECP2 gene","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-18T10:12:49Z","last_updated_date":"2025-12-18T10:12:49Z","reference_number":"EMADOC-1700519818-2039246","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf"},
    {"id":"71837","name":"EMA/PE/0000232896 : EMA decision of 21 February 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for antisense oligonucleotide against patatin like phospholipase....sodium salt","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2025-12-18T10:19:18Z","last_updated_date":"2025-12-18T10:19:18Z","reference_number":"EMADOC-1700519818-1911730","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232896-ema-decision-21-february-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-antisense-oligonucleotide-against-patatin-phospholipasesodium-salt_en.pdf"},
    {"id":"72206","name":"EMA/PE/0000239079: EMA decision of 16 April 2025 on the acceptance of a modification of an agreed paediatric investigation plan for cangrelor (tetrasodium) (Kengrexal)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-01-22T16:39:29Z","last_updated_date":"2026-01-22T16:39:29Z","reference_number":"EMADOC-1700519818-2038135","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000239079-ema-decision-16-april-2025-acceptance-modification-agreed-paediatric-investigation-plan-cangrelor-tetrasodium-kengrexal_en.pdf"},
    {"id":"72207","name":"EMEA-002828-PIP01-20: EMA decision of 16 May 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for firsocostat / cilofexor","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-01-23T16:49:44Z","last_updated_date":"2026-01-23T16:49:44Z","reference_number":"EMADOC-1700519818-2111879","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-002828-pip01-20-ema-decision-16-may-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-firsocostat-cilofexor_en.pdf"},
    {"id":"72681","name":"P/0002/2025 : EMA decision of 28 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral for 2-isopropyl- 3H-naphtho[1,2-d]imidazole-4,5-dione (KL1333), (EMEA-003618-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-02-25T08:31:52Z","last_updated_date":"2026-02-25T08:31:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0002-2025-ema-decision-28-january-2025-agreement-paediatric-investigation-plan-granting-deferral-2-isopropyl-3h-naphtho12-dimidazole-45-dione-kl1333-emea-003618-pip01-24_en.pdf"},
    {"id":"72705","name":"EMA/PE/0000226303 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for naldemedine tosilate (Rizmoic)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-02-25T16:35:06Z","last_updated_date":"2026-02-25T16:35:06Z","reference_number":"EMADOC-1700519818-1855380","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000226303-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-naldemedine-tosilate-rizmoic_en.pdf"},
    {"id":"72707","name":"EMA/PE/0000226657 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for abelacimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-02-25T16:43:12Z","last_updated_date":"2026-02-25T16:43:12Z","reference_number":"EMADOC-1700519818-1840316","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000226657-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-abelacimab_en.pdf"},
    {"id":"72791","name":"EMA/PE/0000226753 : EMA decision of 3 January 2025 on agreement of PIP, and granting of deferral and waiver for mRNA encoding influenza A, H1N1 strain, haemagglutinin glycoprotein, mRNA encoding influenza A, H3N2 strain, haemagglutinin glycoprotein...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-03T10:42:10Z","last_updated_date":"2026-03-03T10:42:10Z","reference_number":"EMADOC-1700519818-1809706","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000226753-ema-decision-3-january-2025-agreement-pip-granting-deferral-waiver-mrna-encoding-influenza-h1n1-strain-haemagglutinin-glycoprotein-mrna-encoding-influenza-h3n2-strain-haemagglutinin_en.pdf"},
    {"id":"72807","name":"EMA/PE/0000228283 : EMA decision of 28 January 2025 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for balstilimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-03T16:29:53Z","last_updated_date":"2026-03-03T16:29:53Z","reference_number":"EMADOC-1700519818-1856330","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228283-ema-decision-28-january-2025-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-balstilimab_en.pdf"}    {"id":"72820","name":"EMA/PE/0000226957 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for efgartigimod alfa (Vyvgart)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-04T12:27:18Z","last_updated_date":"2026-03-04T12:27:18Z","reference_number":"EMADOC-1700519818-1840317","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000226957-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-efgartigimod-alfa-vyvgart_en.pdf"},
    {"id":"72821","name":"EMA/PE/0000227394 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for ivacaftor / tezacaftor (Symkevi)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-04T12:28:23Z","last_updated_date":"2026-03-04T12:28:23Z","reference_number":"EMADOC-1700519818-1853205","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000227394-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-ivacaftor-tezacaftor-symkevi_en.pdf"},
    {"id":"72822","name":"EMA/PE/0000227425 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for efgartigimod alfa (Vyvgart)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-04T12:29:32Z","last_updated_date":"2026-03-04T12:29:32Z","reference_number":"EMADOC-1700519818-1860426","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000227425-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-efgartigimod-alfa-vyvgart_en.pdf"},
    {"id":"72823","name":"EMA/PE/0000227462 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for deucrictibant monohydrate","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-04T12:30:26Z","last_updated_date":"2026-03-04T12:30:26Z","reference_number":"EMADOC-1700519818-1859760","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000227462-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-deucrictibant-monohydrate_en.pdf"},
    {"id":"72824","name":"EMA/PE/0000227526 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for ceftobiprole medocaril sodium (Zevtera and associated names)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-04T12:31:18Z","last_updated_date":"2026-03-04T12:31:18Z","reference_number":"EMADOC-1700519818-1859875","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000227526-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-ceftobiprole-medocaril-sodium-zevtera-associated-names_en.pdf"},
    {"id":"72826","name":"EMA/PE/0000227558 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for danicopan (Voydeya)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-04T13:44:38Z","last_updated_date":"2026-03-04T13:44:38Z","reference_number":"EMADOC-1700519818-1686602","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000227558-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-danicopan-voydeya_en.pdf"},
    {"id":"72827","name":"EMA/PE/0000227908 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for nerandomilast","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-04T13:50:00Z","last_updated_date":"2026-03-04T13:50:00Z","reference_number":"EMADOC-1700519818-1855405","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000227908-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-nerandomilast_en.pdf"},
    {"id":"72830","name":"EMA/PE/0000181050 : EMA decision of 28 January 2025 on the granting of a product specific waiver for lonigutamab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T14:23:48Z","last_updated_date":"2026-03-06T14:23:48Z","reference_number":"EMADOC-1700519818-1851948","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181050-ema-decision-28-january-2025-granting-product-specific-waiver-lonigutamab_en.pdf"},
    {"id":"72831","name":"EMA/PE/0000181174 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for dasiglucagon (Zegalogue)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T14:29:07Z","last_updated_date":"2026-03-06T14:29:07Z","reference_number":"EMADOC-1700519818-1809705","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181174-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-dasiglucagon-zegalogue_en.pdf"},
    {"id":"72832","name":"EMA/PE/0000181243 : EMA decision of 3 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for glutamatergic neurotransmission enhancer BI 1569912","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T14:38:31Z","last_updated_date":"2026-03-06T14:38:31Z","reference_number":"EMADOC-1700519818-1752876","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000181243-ema-decision-3-january-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-glutamatergic-neurotransmission-enhancer-bi-1569912_en.pdf"},
    {"id":"72833","name":"EMA/PE/0000182075 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for Venetoclax (Venclyxto)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T14:43:06Z","last_updated_date":"2026-03-06T14:43:06Z","reference_number":"EMADOC-1700519818-1796802","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182075-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-venetoclax-venclyxto_en.pdf"},
    {"id":"72834","name":"EMA/PE/0000230484 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for alprazolam","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-04T14:45:28Z","last_updated_date":"2026-03-04T14:45:28Z","reference_number":"EMADOC-1700519818-1840322","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000230484-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-alprazolam_en.pdf"},
    {"id":"72835","name":"EMA/PE/0000182245 : EMA decision of 28 January 2026 on the granting of a product specific waiver for 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T14:49:44Z","last_updated_date":"2026-03-06T14:49:44Z","reference_number":"EMADOC-1700519818-1859798","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182245-ema-decision-28-january-2026-granting-product-specific-waiver-58-dichloro-2-4-methoxy-6-methyl-2-oxo-12-dihydropyridin-3-ylmethyl-7-r-methoxyoxetan-3-ylmethyl-34-dihydroisoquinolin_en.pdf"},
    {"id":"72836","name":"EMA/PE/0000182607 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for maribavir (Livtencity)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T14:59:49Z","last_updated_date":"2026-03-06T14:59:49Z","reference_number":"EMADOC-1700519818-1811036","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000182607-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-maribavir-livtencity_en.pdf"},
    {"id":"72837","name":"EMA/PE/0000183827 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for tabelecleucel (Ebvallo)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T15:04:34Z","last_updated_date":"2026-03-06T15:04:34Z","reference_number":"EMADOC-1700519818-1809724","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183827-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-tabelecleucel-ebvallo_en.pdf"},
    {"id":"72838","name":"EMA/PE/0000184081 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for etrasimod (Velsipity)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T15:09:41Z","last_updated_date":"2026-03-06T15:09:41Z","reference_number":"EMADOC-1700519818-1798766","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000184081-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-etrasimod-velsipity_en.pdf"},
    {"id":"72843","name":"EMA/PE/0000221213 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for blinatumomab (Blincyto)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T11:06:54Z","last_updated_date":"2026-03-06T11:06:54Z","reference_number":"EMADOC-1700519818-1809719","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221213-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-blinatumomab-blincyto_en.pdf"},
    {"id":"72844","name":"EMA/PE/0000221296 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T11:11:31Z","last_updated_date":"2026-03-06T11:11:31Z","reference_number":"EMADOC-1700519818-1807955","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221296-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris_en.pdf"},
    {"id":"72845","name":"EMA/PE/0000221462 : EMA decision of 3 January 2025 on the granting of a product specific waiver for [225Ac]Ac-PSMA-617","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-05T11:18:07Z","last_updated_date":"2026-03-05T11:18:07Z","reference_number":"EMADOC-1700519818-1811118","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221462-ema-decision-3-january-2025-granting-product-specific-waiver-225acac-psma-617_en.pdf"},
    {"id":"72846","name":"EMA/PE/0000225594 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for imlifidase (Idefirix)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T11:30:29Z","last_updated_date":"2026-03-06T11:30:29Z","reference_number":"EMADOC-1700519818-1859783","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225594-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-imlifidase-idefirix_en.pdf"},
    {"id":"72847","name":"EMA/PE/0000221583 : EMA decision of 8 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for famtozinameran, riltozinameran, tozinameran (Comirnaty)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T11:49:57Z","last_updated_date":"2026-03-06T11:49:57Z","reference_number":"EMADOC-1700519818-1834650","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221583-ema-decision-8-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-famtozinameran-riltozinameran-tozinameran-comirnaty_en.pdf"},
    {"id":"72848","name":"EMA/PE/0000221604 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for ravulizumab (Ultomiris)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T11:54:05Z","last_updated_date":"2026-03-06T11:54:05Z","reference_number":"EMADOC-1700519818-1808060","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000221604-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-ravulizumab-ultomiris_en.pdf"},
    {"id":"72849","name":"EMA/PE/0000222532 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for tofacitinib (Xeljanz)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-06T11:58:51Z","last_updated_date":"2026-03-06T11:58:51Z","reference_number":"EMADOC-1700519818-1840302","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000222532-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-tofacitinib-xeljanz_en.pdf"},
    {"id":"72850","name":"EMA/PE/0000222938 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for Neisseria Meningitidis Group A Polysaccharide....(MenPenta vaccine)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-05T12:07:35Z","last_updated_date":"2026-03-05T12:07:35Z","reference_number":"EMADOC-1700519818-1859737","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000222938-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-neisseria-meningitidis-group-polysaccharidemenpenta-vaccine_en.pdf"},
    {"id":"72851","name":"EMA/PE/0000223288 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for evenamide","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-05T12:12:20Z","last_updated_date":"2026-03-05T12:12:20Z","reference_number":"EMADOC-1700519818-1802284","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000223288-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-evenamide_en.pdf"},
    {"id":"72852","name":"EMA/PE/0000223351 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for cipaglucosidase alfa (Pombiliti)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-05T12:41:45Z","last_updated_date":"2026-03-05T12:41:45Z","reference_number":"EMADOC-1700519818-1799764","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000223351-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-cipaglucosidase-alfa-pombiliti_en.pdf"},
    {"id":"72853","name":"EMA/PE/0000223490 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for eptinezumab (Vyepti)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-05T12:46:19Z","last_updated_date":"2026-03-05T12:46:19Z","reference_number":"EMADOC-1700519818-1851877","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000223490-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-eptinezumab-vyepti_en.pdf"},
    {"id":"72854","name":"EMA/PE/0000223498 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for infigratinib","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-05T12:50:20Z","last_updated_date":"2026-03-05T12:50:20Z","reference_number":"EMADOC-1700519818-1810197","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000223498-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-infigratinib_en.pdf"},
    {"id":"72855","name":"EMA/PE/0000225245 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for nedosiran","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-05T12:56:52Z","last_updated_date":"2026-03-05T12:56:52Z","reference_number":"EMADOC-1700519818-1810277","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225245-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-nedosiran_en.pdf"},
    {"id":"72856","name":"EMA/PE/0000225592 : EMA decision of 3 January 2025 on the granting of a product specific waiver for ulixacaltamide hydrochloride","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-05T13:50:31Z","last_updated_date":"2026-03-05T13:50:31Z","reference_number":"EMADOC-1700519818-1799922","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225592-ema-decision-3-january-2025-granting-product-specific-waiver-ulixacaltamide-hydrochloride_en.pdf"},
    {"id":"72857","name":"EMA/PE/0000225681 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-05T13:55:06Z","last_updated_date":"2026-03-05T13:55:06Z","reference_number":"EMADOC-1700519818-1810978","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225681-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-human-ectonucleotide-pyrophosphatase-phosphodiesterase-1-fused-fc-fragment-igg1_en.pdf"},
    {"id":"72889","name":"EMA/PE/0000232848 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for mirikizumab (Omvoh)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-09T10:36:35Z","last_updated_date":"2026-03-09T10:36:35Z","reference_number":"EMADOC-1700519818-1855943","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232848-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-mirikizumab-omvoh_en.pdf"},
    {"id":"72890","name":"EMA/PE/0000232930 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for mirikizumab (Omvoh)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-09T10:37:42Z","last_updated_date":"2026-03-09T10:37:42Z","reference_number":"EMADOC-1700519818-1855569","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232930-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-mirikizumab-omvoh_en.pdf"},
    {"id":"72891","name":"EMA/PE/0000243095 : EMA decision of 16 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for teplizumab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-09T10:38:56Z","last_updated_date":"2026-03-09T10:38:56Z","reference_number":"EMADOC-1700519818-1850257","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000243095-ema-decision-16-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-teplizumab_en.pdf"},
    {"id":"72903","name":"EMEA-003502-PIP02-24 : EMA decision of 28 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mezagitamab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-09T14:45:47Z","last_updated_date":"2026-03-09T14:45:47Z","reference_number":"EMADOC-1700519818-1860477","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-003502-pip02-24-ema-decision-28-january-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-mezagitamab_en.pdf"},
    {"id":"72905","name":"P/0403/2024 : EMA decision of 15 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral for humanized IgG4 Monoclonal Antibody against FIXa and FX (NXT007), (EMEA-003550-PIP01-23)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-09T14:52:19Z","last_updated_date":"2026-03-09T14:52:19Z","reference_number":"EMA/16279/2025","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0403-2024-ema-decision-15-january-2025-agreement-paediatric-investigation-plan-granting-deferral-humanized-igg4-monoclonal-antibody-against-fixa-fx-nxt007-emea-003550-pip01-23_en.pdf"},
    {"id":"72911","name":"EMA/PE/0000227674 : EMA decision of 3 January 2025 on the granting of a product specific waiver for zampilimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-10T10:44:57Z","last_updated_date":"2026-03-10T10:44:57Z","reference_number":"EMADOC-1700519818-1802286","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000227674-ema-decision-3-january-2025-granting-product-specific-waiver-zampilimab_en.pdf"},
    {"id":"72912","name":"EMA/PE/0000228097 : EMA decision of 28 January 2025 on the granting of a product specific waiver for sacituzumab govitecan (Trodelvy)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-10T10:45:51Z","last_updated_date":"2026-03-10T10:45:51Z","reference_number":"EMADOC-1700519818-1854497","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228097-ema-decision-28-january-2025-granting-product-specific-waiver-sacituzumab-govitecan-trodelvy_en.pdf"},
    {"id":"72913","name":"EMA/PE/0000228114 : EMA decision of 17 January 2025 on the granting of a product specific waiver for mesdopetam","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-10T10:46:39Z","last_updated_date":"2026-03-10T10:46:39Z","reference_number":"EMADOC-1700519818-1850464","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228114-ema-decision-17-january-2025-granting-product-specific-waiver-mesdopetam_en.pdf"},
    {"id":"72914","name":"EMA/PE/0000228333 : EMA decision of 24 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for sufentanil (citrate) / ketamine (hydrochloride)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-10T10:47:28Z","last_updated_date":"2026-03-10T10:47:28Z","reference_number":"EMADOC-1700519818-1855179","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228333-ema-decision-24-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-sufentanil-citrate-ketamine-hydrochloride_en.pdf"},
    {"id":"72915","name":"EMA/PE/0000228360 : EMA decision of 28 January 2025 on the granting of a product specific waiver for ezetimibe / rosuvastatin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-10T10:48:17Z","last_updated_date":"2026-03-10T10:48:17Z","reference_number":"EMADOC-1700519818-1856165","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228360-ema-decision-28-january-2025-granting-product-specific-waiver-ezetimibe-rosuvastatin_en.pdf"},
    {"id":"72916","name":"EMA/PE/0000228365 : EMA decision of 28 January 2025 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for botensilimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-10T10:49:10Z","last_updated_date":"2026-03-10T10:49:10Z","reference_number":"EMADOC-1700519818-1856342","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228365-ema-decision-28-january-2025-refusal-paediatric-investigation-plan-refusal-deferral-granting-waiver-botensilimab_en.pdf"},
    {"id":"72917","name":"EMA/PE/0000228776 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for abemaciclib (Verzenios)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-10T10:50:05Z","last_updated_date":"2026-03-10T10:50:05Z","reference_number":"EMADOC-1700519818-1855225","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228776-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-abemaciclib-verzenios_en.pdf"},
    {"id":"72918","name":"EMA/PE/0000228821 : EMA decision of 28 January 2025 on the granting of a product specific waiver for zelenectide pevedotin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-10T10:50:54Z","last_updated_date":"2026-03-10T10:50:54Z","reference_number":"EMADOC-1700519818-1840319","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228821-ema-decision-28-january-2025-granting-product-specific-waiver-zelenectide-pevedotin_en.pdf"},
    {"id":"72919","name":"EMA/PE/0000230373 : EMA decision of 28 January 2025 on the granting of a product specific waiver for rinatabart sesutecan","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-10T10:51:40Z","last_updated_date":"2026-03-10T10:51:40Z","reference_number":"EMADOC-1700519818-1840320","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000230373-ema-decision-28-january-2025-granting-product-specific-waiver-rinatabart-sesutecan_en.pdf"},
    {"id":"72925","name":"EMA/PE/0000230375 : EMA decision of 28 January 2025 on the granting of a product specific waiver for rinatabart sesutecan","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-10T13:21:45Z","last_updated_date":"2026-03-10T13:21:45Z","reference_number":"EMADOC-1700519818-1840321","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000230375-ema-decision-28-january-2025-granting-product-specific-waiver-rinatabart-sesutecan_en.pdf"},
    {"id":"72926","name":"EMEA-003532-PIP01-23 : EMA decision of 28 January 2025 on the granting of a product specific waiver for budigalimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T13:24:50Z","last_updated_date":"2026-03-11T13:24:50Z","reference_number":"EMADOC-1700519818-1859887","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-003532-pip01-23-ema-decision-28-january-2025-granting-product-specific-waiver-budigalimab_en.pdf"},
    {"id":"72927","name":"EMEA-003533-PIP01-23 : EMA decision of 28 January 2025 on the granting of a product specific waiver for livmoniplimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T13:25:38Z","last_updated_date":"2026-03-11T13:25:38Z","reference_number":"EMADOC-1700519818-1859900","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-003533-pip01-23-ema-decision-28-january-2025-granting-product-specific-waiver-livmoniplimab_en.pdf"},
    {"id":"72933","name":"EMA/PE/0000223523 : EMA decision of 28 January 2025 on the granting of a product specific waiver for paltusotine","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T09:00:00Z","last_updated_date":"2026-03-11T09:00:00Z","reference_number":"EMADOC-1700519818-1840303","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000223523-ema-decision-28-january-2025-granting-product-specific-waiver-paltusotine_en.pdf"},
    {"id":"72934","name":"EMA/PE/0000223608 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for molnupiravir","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T09:00:00Z","last_updated_date":"2026-03-11T09:00:00Z","reference_number":"EMADOC-1700519818-1810486","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000223608-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-molnupiravir_en.pdf"},
    {"id":"72935","name":"EMA/PE/0000223656 : EMA decision of 3 January 2025 on the granting of a product specific waiver for givinostat","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T09:00:00Z","last_updated_date":"2026-03-11T09:00:00Z","reference_number":"EMADOC-1700519818-1810372","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000223656-ema-decision-3-january-2025-granting-product-specific-waiver-givinostat_en.pdf"},
    {"id":"72936","name":"EMA/PE/0000223677 : EMA decision of 28 January 2025 on the granting of a product specific waiver for coramitug","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T10:00:21Z","last_updated_date":"2026-03-11T10:00:21Z","reference_number":"EMADOC-1700519818-1852851","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000223677-ema-decision-28-january-2025-granting-product-specific-waiver-coramitug_en.pdf"},
    {"id":"72937","name":"EMA/PE/0000223819 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for modified vaccinia Ankara – bavarian nordic live virus (Imvanex)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T10:26:58Z","last_updated_date":"2026-03-11T10:26:58Z","reference_number":"EMADOC-1700519818-1852052","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000223819-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-modified-vaccinia-ankara-bavarian-nordic-live-virus-imvanex_en.pdf"},
    {"id":"72939","name":"EMA/PE/0000224092 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for zuranolone","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T13:11:22Z","last_updated_date":"2026-03-11T13:11:22Z","reference_number":"EMADOC-1700519818-1792946","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224092-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-zuranolone_en.pdf"},
    {"id":"72943","name":"P/0401/2024 : EMA decision of 3 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for letetresgene autoleucel (EMEA-002476-PIP03-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T13:32:58Z","last_updated_date":"2026-03-11T13:32:58Z","reference_number":"EMA/581771/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0401-2024-ema-decision-3-january-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-letetresgene-autoleucel-emea-002476-pip03-24_en.pdf"},
    {"id":"72944","name":"EMEA-002886-PIP03-24 : EMA decision of 3 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rocatinlimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T13:46:14Z","last_updated_date":"2026-03-11T13:46:14Z","reference_number":"EMA/581540/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-002886-pip03-24-ema-decision-3-january-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-rocatinlimab_en.pdf"},
    {"id":"72945","name":"P/0400/2024 : EMA decision of 3 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for golcadomide (EMEA-003161-PIP02-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T13:49:31Z","last_updated_date":"2026-03-11T13:49:31Z","reference_number":"EMA/566316/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0400-2024-ema-decision-3-january-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-golcadomide-emea-003161-pip02-24_en.pdf"},
    {"id":"72946","name":"EMA/PE/0000224110 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for esketamine (hydrochloride)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T14:00:43Z","last_updated_date":"2026-03-11T14:00:43Z","reference_number":"EMADOC-1700519818-1859738","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224110-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-esketamine-hydrochloride_en.pdf"},
    {"id":"72947","name":"P/0006/2025 : EMA decision of 27 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for luliconazole (EMEA-003604-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T14:50:01Z","last_updated_date":"2026-03-11T14:50:01Z","reference_number":"EMA/25301/2025","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0006-2025-ema-decision-27-january-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-luliconazole-emea-003604-pip01-24_en.pdf"},
    {"id":"72950","name":"P/0003/2025 : EMA decision of 28 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for heterologous intestinal microbiota from healthy donors (MBK-01), (EMEA-003635-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T15:04:09Z","last_updated_date":"2026-03-11T15:04:09Z","reference_number":"EMA/9335/2025","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0003-2025-ema-decision-28-january-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-heterologous-intestinal-microbiota-healthy-donors-mbk-01-emea-003635-pip01-24_en.pdf"},
    {"id":"72951","name":"P/0001/2025 : EMA decision of 28 January 2025 on agreement of PIP and on granting of deferral and waiver for respiratory syncytial virus, prefusion F protein, virus-like particle / human metapneumovirus, prefusion F protein, virus-like particle (IVX-A12)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T15:22:01Z","last_updated_date":"2026-03-11T15:22:01Z","reference_number":"EMA/22215/2025","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0001-2025-ema-decision-28-january-2025-agreement-pip-granting-deferral-waiver-respiratory-syncytial-virus-prefusion-f-protein-virus-particle-human-metapneumovirus-prefusion-f-protein-virus-particle_en.pdf"},
    {"id":"72952","name":"EMA/PE/0000224175 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for azamidugene autotemcel","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T15:21:36Z","last_updated_date":"2026-03-11T15:21:36Z","reference_number":"EMADOC-1700519818-1855254 Corr1","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224175-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-azamidugene-autotemcel_en.pdf"},
    {"id":"72953","name":"P/0004/2025 : EMA decision of 27 January 2025 on the agreement of a PIP and on the granting of a deferral and waiver for adeno-associated virus serotype 9 vector containing the human LAMP2 isoform B transgene (RP-A501) (EMEA-003639-PIP01-24)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T15:30:29Z","last_updated_date":"2026-03-11T15:30:29Z","reference_number":"EMA/25307/2025","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/p-0004-2025-ema-decision-27-january-2025-agreement-pip-granting-deferral-waiver-adeno-associated-virus-serotype-9-vector-containing-human-lamp2-isoform-b-transgene-rp-a501-emea-003639-pip01-24_en.pdf"},
    {"id":"72954","name":"EMA/PE/0000224273 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for whole-cell heatinactivated bacterial strains of Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris and Enterococcu","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T15:38:13Z","last_updated_date":"2026-03-11T15:38:13Z","reference_number":"EMADOC-1700519818-1810838","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224273-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-whole-cell-heatinactivated-bacterial-strains-escherichia-coli-klebsiella-pneumoniae-proteus_en.pdf"},
    {"id":"72957","name":"EMA/PE/0000224283 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for pegcetacoplan (Aspaveli)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T17:37:04Z","last_updated_date":"2026-03-11T17:37:04Z","reference_number":"EMADOC-1700519818-1810950","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224283-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-pegcetacoplan-aspaveli_en.pdf"},
    {"id":"72958","name":"EMA/PE/0000224597 : EMA decision of 6 January 2025 on the refusal of a modification of an agreed paediatric investigation plan for cariprazine hydrochloride (Reagila)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T17:44:17Z","last_updated_date":"2026-03-11T17:44:17Z","reference_number":"EMADOC-1700519818-1809723","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224597-ema-decision-6-january-2025-refusal-modification-agreed-paediatric-investigation-plan-cariprazine-hydrochloride-reagila_en.pdf"},
    {"id":"72959","name":"EMA/PE/0000224768 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for vosoritide (Voxzogo)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-11T17:53:15Z","last_updated_date":"2026-03-11T17:53:15Z","reference_number":"EMADOC-1700519818-1854312","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224768-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-vosoritide-voxzogo_en.pdf"},
    {"id":"72960","name":"EMA/PE/0000224883 : EMA decision of 3 January 2025 on the granting of a product specific waiver for rinatabart sesutecan","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T09:00:00Z","last_updated_date":"2026-03-12T09:00:00Z","reference_number":"EMADOC-1700519818-1799896","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224883-ema-decision-3-january-2025-granting-product-specific-waiver-rinatabart-sesutecan_en.pdf"},
    {"id":"72961","name":"EMA/PE/0000224912 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for cannabidiol (Epidyolex)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T09:00:00Z","last_updated_date":"2026-03-12T09:00:00Z","reference_number":"EMADOC-1700519818-1807917","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224912-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-cannabidiol-epidyolex_en.pdf"},
    {"id":"72962","name":"EMA/PE/0000224955 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for ribitol","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T09:00:00Z","last_updated_date":"2026-03-12T09:00:00Z","reference_number":"EMADOC-1700519818-1802285","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000224955-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-ribitol_en.pdf"},
    {"id":"72963","name":"EMA/PE/0000225023 : EMA decision of 3 January 2025 on the granting of a product specific waiver for efgartigimod alfa (Vyvgart)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T09:00:00Z","last_updated_date":"2026-03-12T09:00:00Z","reference_number":"EMADOC-1700519818-1810349","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225023-ema-decision-3-january-2025-granting-product-specific-waiver-efgartigimod-alfa-vyvgart_en.pdf"},
    {"id":"72964","name":"EMA/PE/0000225073 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for recombinant parathyroid hormone (Natpar)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T09:00:00Z","last_updated_date":"2026-03-12T09:00:00Z","reference_number":"EMADOC-1700519818-1840304","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225073-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-recombinant-parathyroid-hormone-natpar_en.pdf"},
    {"id":"72967","name":"EMA/PE/0000225241 : EMA decision of 3 January 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral for calcium chloride dihydrate, d-glucose, levocarnitine, magnesium chloride hexahydrate, sodium chloride, sodium...","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T09:18:51Z","last_updated_date":"2026-03-12T09:18:51Z","reference_number":"EMA/PE/0000225241","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225241-ema-decision-3-january-2025-agreement-paediatric-investigation-plan-granting-deferral-calcium-chloride-dihydrate-d-glucose-levocarnitine-magnesium-chloride-hexahydrate-sodium_en.pdf"},
    {"id":"72969","name":"EMA/PE/0000225746 : EMA decision of 3 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for atogepant (Aquipta)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T10:30:38Z","last_updated_date":"2026-03-12T10:30:38Z","reference_number":"EMADOC-1700519818-1808237","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225746-ema-decision-3-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-atogepant-aquipta_en.pdf"},
    {"id":"72970","name":"EMA/PE/0000226088 : of 28 January 2025 on the granting of a product specific waiver for relacorilant","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T10:42:37Z","last_updated_date":"2026-03-12T10:42:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000226088-28-january-2025-granting-product-specific-waiver-relacorilant_en.pdf"},
    {"id":"72971","name":"EMA/PE/0000226217 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T12:15:29Z","last_updated_date":"2026-03-12T12:15:29Z","reference_number":"EMADOC-1700519818-1860349","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000226217-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy_en.pdf"},
    {"id":"72972","name":"EMA/PE/0000226246 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for marstacimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T12:23:14Z","last_updated_date":"2026-03-12T12:23:14Z","reference_number":"EMADOC-1700519818-1859872","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000226246-ema-decision-28-january-2025-acceptance-modification-agreed-paediatric-investigation-plan-marstacimab_en.pdf"},
    {"id":"72973","name":"EMA/PE/0000226288 : EMA decision of 28 January 2025 on the granting of a product specific waiver for dupilumab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-03-12T12:30:36Z","last_updated_date":"2026-03-12T12:30:36Z","reference_number":"EMADOC-1700519818-1855159","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000226288-ema-decision-28-january-2025-granting-product-specific-waiver-dupilumab_en.pdf"},
    {"id":"73633","name":"EMA/PE/0000236886 : EMA decision of 10 September 2025 on the agreement of a paediatric investigation plan and on the granting of a waiver for baricitinib (Olumiant)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-05-06T15:17:33Z","last_updated_date":"2026-05-06T15:17:33Z","reference_number":"EMADOC-1700519818-2406264","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000236886-ema-decision-10-september-2025-agreement-paediatric-investigation-plan-granting-waiver-baricitinib-olumiant_en.pdf"},
    {"id":"73634","name":"EMA/PE/0000290054 : EMA decision of 2 January 2026","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-05-06T15:29:35Z","last_updated_date":"2026-05-06T15:29:35Z","reference_number":"EMADOC-1700519818-2751576","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000290054-ema-decision-2-january-2026_en.pdf"},
    {"id":"73635","name":"EMEA-002183-PIP03-23 : EMA decision of 14 April 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for imlifidase","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-05-06T15:41:39Z","last_updated_date":"2026-05-06T15:41:39Z","reference_number":"EMADOC-1700519818-2035629","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-002183-pip03-23-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-imlifidase_en.pdf"},
    {"id":"73644","name":"EMA/PE/0000230710 : EMA decision of 19 February 2025 on the acceptance of a modification of an agreed paediatric investigation plan for rocatinlimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-05-07T14:42:26Z","last_updated_date":"2026-05-07T14:42:26Z","reference_number":"EMADOC-1700519818-1880424","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000230710-ema-decision-19-february-2025-acceptance-modification-agreed-paediatric-investigation-plan-rocatinlimab_en.pdf"},
    {"id":"73645","name":"EMEA-003192-PIP03-23 : EMA decision of 12 February 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral for ensitrelvir","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-05-07T14:46:12Z","last_updated_date":"2026-05-07T14:46:12Z","reference_number":"EMADOC-1700519818-1907112","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-003192-pip03-23-ema-decision-12-february-2025-agreement-paediatric-investigation-plan-granting-deferral-ensitrelvir_en.pdf"},
    {"id":"73963","name":"EMA/PE/0000232765 : EMA decision of 14 April 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sargramostim","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-03T17:12:40Z","last_updated_date":"2026-06-03T17:12:40Z","reference_number":"EMADOC-1700519818-2039232","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232765-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sargramostim_en.pdf"},
    {"id":"73966","name":"EMA/PE/0000232755 : EMA decision of 20 March 2025 on the refusal of a paediatric investigation plan for dasiglucagon","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T10:06:27Z","last_updated_date":"2026-06-04T10:06:27Z","reference_number":"EMADOC-1700519818-1976496","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232755-ema-decision-20-march-2025-refusal-paediatric-investigation-plan-dasiglucagon_en.pdf"},
    {"id":"73967","name":"EMA/PE/0000183637 : EMA decision of 21 March 2025 on the granting of a product specific waiver for humanised afucosylated IgG1 monoclonal antibody against CCR8","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T10:19:29Z","last_updated_date":"2026-06-04T10:19:29Z","reference_number":"EMADOC-1700519818-1974851","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000183637-ema-decision-21-march-2025-granting-product-specific-waiver-humanised-afucosylated-igg1-monoclonal-antibody-against-ccr8_en.pdf"},
    {"id":"73968","name":"EMA/PE/0000227611 : EMA decision of 19 March 2025 on the granting of a product specific waiver for sacituzumab tirumotecan","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T10:32:14Z","last_updated_date":"2026-06-04T10:32:14Z","reference_number":"EMADOC-1700519818-1973583","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000227611-ema-decision-19-march-2025-granting-product-specific-waiver-sacituzumab-tirumotecan_en.pdf"},
    {"id":"73969","name":"EMA/PE/0000229841 : EMA decision of 21 March 2025 on the granting of a product specific waiver for itepekimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T10:42:09Z","last_updated_date":"2026-06-04T10:42:09Z","reference_number":"EMADOC-1700519818-1980448","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000229841-ema-decision-21-march-2025-granting-product-specific-waiver-itepekimab_en.pdf"},
    {"id":"73970","name":"EMA/PE/0000230006 : EMA decision of 21 March 2025 on the granting of a product specific waiver for empagliflozin / sitagliptin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T10:50:31Z","last_updated_date":"2026-06-04T10:50:31Z","reference_number":"EMADOC-1700519818-1978092","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000230006-ema-decision-21-march-2025-granting-product-specific-waiver-empagliflozin-sitagliptin_en.pdf"},
    {"id":"73971","name":"EMA/PE/0000230564 : EMA decision of 21 March 2025 on the granting of a product specific waiver for ezetimibe / rosuvastatin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T10:59:47Z","last_updated_date":"2026-06-04T10:59:47Z","reference_number":"EMADOC-1700519818-1978493","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000230564-ema-decision-21-march-2025-granting-product-specific-waiver-ezetimibe-rosuvastatin_en.pdf"},
    {"id":"73976","name":"EMA/PE/0000232171 : EMA decision of 20 March 2025 on the granting of a product specific waiver for botulinum toxin type A","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T14:02:13Z","last_updated_date":"2026-06-04T14:02:13Z","reference_number":"EMADOC-1700519818-1976392","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232171-ema-decision-20-march-2025-granting-product-specific-waiver-botulinum-toxin-type_en.pdf"},
    {"id":"73977","name":"EMA/PE/0000232638 : EMA decision of 21 March 2025 on the granting of a product specific waiver for ifinatamab deruxtecan","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T14:07:09Z","last_updated_date":"2026-06-04T14:07:09Z","reference_number":"EMADOC-1700519818-1975290","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232638-ema-decision-21-march-2025-granting-product-specific-waiver-ifinatamab-deruxtecan_en.pdf"},
    {"id":"73978","name":"EMA/PE/0000232759 : EMA decision of 21 March 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for telitacicept","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T14:12:01Z","last_updated_date":"2026-06-04T14:12:01Z","reference_number":"EMADOC-1700519818-1978219","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232759-ema-decision-21-march-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-telitacicept_en.pdf"},
    {"id":"73979","name":"EMA/PE/0000232763 : EMA decision of 20 March 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for icotrokinra","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T14:31:00Z","last_updated_date":"2026-06-04T14:31:00Z","reference_number":"EMADOC-1700519818-1976511","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232763-ema-decision-20-march-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-icotrokinra_en.pdf"},
    {"id":"73980","name":"EMA/PE/0000232764 : EMA decision of 21 March 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for zasocitinib","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T14:37:50Z","last_updated_date":"2026-06-04T14:37:50Z","reference_number":"EMADOC-1700519818-1880459","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232764-ema-decision-21-march-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-zasocitinib_en.pdf"},
    {"id":"73981","name":"EMA/PE/0000232769 : EMA decision of 20 March 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pegozafermin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T14:54:26Z","last_updated_date":"2026-06-04T14:54:26Z","reference_number":"EMADOC-1700519818-1976525","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232769-ema-decision-20-march-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pegozafermin_en.pdf"},
    {"id":"73982","name":"EMA/PE/0000232771 : EMA decision of 21 March 2025 on the agreement of a paediatric investigation plan and on the granting of a waiver for tacrolimus","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T15:00:19Z","last_updated_date":"2026-06-04T15:00:19Z","reference_number":"EMADOC-1700519818-1979393","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232771-ema-decision-21-march-2025-agreement-paediatric-investigation-plan-granting-waiver-tacrolimus_en.pdf"},
    {"id":"73983","name":"EMA/PE/0000232781 : EMA decision of 20 March 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lenacapavir sodium / islatravir","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T15:08:30Z","last_updated_date":"2026-06-04T15:08:30Z","reference_number":"EMADOC-1700519818-1976549","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232781-ema-decision-20-march-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-lenacapavir-sodium-islatravir_en.pdf"},
    {"id":"74052","name":"EMA/PE/0000273488 : EMA decision of 2 October 2025 on the acceptance of a modification of an agreed paediatric investigation plan for rocatinlimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-10T15:59:47Z","last_updated_date":"2026-06-10T15:59:47Z","reference_number":"EMADOC-1700519818-2468453","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000273488-ema-decision-2-october-2025-acceptance-modification-agreed-paediatric-investigation-plan-rocatinlimab_en.pdf"},
    {"id":"74135","name":"EMA/PE/0000232936: EMA decision of 21 March 2025 on the granting of a product specific waiver for atigotatug / nivolumab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-17T11:28:53Z","last_updated_date":"2026-06-17T11:28:53Z","reference_number":"EMADOC-1700519818-1979356","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232936-ema-decision-21-march-2025-granting-product-specific-waiver-atigotatug-nivolumab_en.pdf"}    {"id":"74136","name":"EMA/PE/0000232939: EMA decision of 19 March 2025 on the granting of a product specific waiver for surabgene lomparvovec","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-17T11:46:03Z","last_updated_date":"2026-06-17T11:46:03Z","reference_number":"EMADOC-1700519818-1953684","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232939-ema-decision-19-march-2025-granting-product-specific-waiver-surabgene-lomparvovec_en.pdf"},
    {"id":"74137","name":"EMA/PE/0000233446: EMA decision of 21 March 2025 on the granting of a product specific waiver for ifinatamab deruxtecan","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-17T13:33:01Z","last_updated_date":"2026-06-17T13:33:01Z","reference_number":"EMADOC-1700519818-1975657","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000233446-ema-decision-21-march-2025-granting-product-specific-waiver-ifinatamab-deruxtecan_en.pdf"},
    {"id":"74138","name":"EMA/PE/0000233717: EMA decision of 21 March 2025 on the granting of a product specific waiver for benzoyl peroxide (hydrous)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-17T13:58:46Z","last_updated_date":"2026-06-17T13:58:46Z","reference_number":"EMADOC-1700519818-1975046","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000233717-ema-decision-21-march-2025-granting-product-specific-waiver-benzoyl-peroxide-hydrous_en.pdf"},
    {"id":"74139","name":"EMA/PE/0000233807: EMA decision of 19 March 2025 on the granting of a product specific waiver for visugromab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-17T14:49:18Z","last_updated_date":"2026-06-17T14:49:18Z","reference_number":"EMADOC-1700519818-1973487","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000233807-ema-decision-19-march-2025-granting-product-specific-waiver-visugromab_en.pdf"},
    {"id":"74141","name":"EMA/PE/0000239927: EMA decision of 27 March 2025 on the granting of a product specific waiver for [2-Chloro-3-(trifluoromethyl)phenyl][(4R)-1-(5-fluoro- 2-pyrimidinyl)-4-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl]methanone","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-17T15:01:39Z","last_updated_date":"2026-06-17T15:01:39Z","reference_number":"EMADOC-1700519818-2008276","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000239927-ema-decision-27-march-2025-granting-product-specific-waiver-2-chloro-3-trifluoromethylphenyl4r-1-5-fluoro-2-pyrimidinyl-4-methyl-1467-tetrahydro-5h-123triazolo45-cpyridin-5_en.pdf"},
    {"id":"74142","name":"EMEA-002568-PIP02-23: EMA decision of 21 March 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sonelokimab","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-17T15:28:32Z","last_updated_date":"2026-06-17T15:28:32Z","reference_number":"EMADOC-1700519818-1978526","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-002568-pip02-23-ema-decision-21-march-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-sonelokimab_en.pdf"},
    {"id":"74143","name":"EMEA-003553-PIP01-23: EMA decision of 19 March 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for oveporexton","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-17T15:43:18Z","last_updated_date":"2026-06-17T15:43:18Z","reference_number":"EMADOC-1700519818-1944371","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/emea-003553-pip01-23-ema-decision-19-march-2025-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-oveporexton_en.pdf"},
    {"id":"74145","name":"EMA/PE/0000228305: EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for deucravacitinib (Sotyktu)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-18T14:57:11Z","last_updated_date":"2026-06-18T14:57:11Z","reference_number":"EMADOC-1700519818-1979633","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228305-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-deucravacitinib-sotyktu_en.pdf"},
    {"id":"74146","name":"EMA/PE/0000232890: EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for clevidipine (Cleviprex and associated names)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-18T15:04:26Z","last_updated_date":"2026-06-18T15:04:26Z","reference_number":"EMADOC-1700519818-1976294","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232890-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-clevidipine-cleviprex-associated-names_en.pdf"},
    {"id":"74147","name":"EMA/PE/0000229144: EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for respiratory syncytial virus stabilised prefusion F subunit vaccine (RSVpreF) (Abrysvo)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-18T15:16:45Z","last_updated_date":"2026-06-18T15:16:45Z","reference_number":"EMADOC-1700519818-1976219","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000229144-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-respiratory-syncytial-virus-stabilised-prefusion-f-subunit-vaccine-rsvpref-abrysvo_en.pdf"},
    {"id":"74148","name":"EMA/PE/0000233803: EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for Chikungunya virus virus-like particle","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-18T15:27:49Z","last_updated_date":"2026-06-18T15:27:49Z","reference_number":"EMADOC-1700519818-1880478","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000233803-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-chikungunya-virus-virus-particle_en.pdf"},
    {"id":"74149","name":"EMA/PE/0000232680: EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for ustekinumab (Stelara)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-18T15:34:05Z","last_updated_date":"2026-06-18T15:34:05Z","reference_number":"EMADOC-1700519818-1976512","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232680-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-ustekinumab-stelara_en.pdf"},
    {"id":"74150","name":"EMA/PE/0000227963: EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for catequentinib (dihydrochloride)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-18T15:43:55Z","last_updated_date":"2026-06-18T15:43:55Z","reference_number":"EMADOC-1700519818-1976180","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000227963-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-catequentinib-dihydrochloride_en.pdf"},
    {"id":"74156","name":"EMA/PE/0000228536: EMA decision of 19 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for enlicitide (decanoate)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-19T11:37:32Z","last_updated_date":"2026-06-19T11:37:32Z","reference_number":"EMADOC-1700519818-1976306","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228536-ema-decision-19-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-enlicitide-decanoate_en.pdf"},
    {"id":"74157","name":"EMA/PE/0000228081: EMA decision of 19 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for voclosporin (Lupkynis)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-19T11:45:22Z","last_updated_date":"2026-06-19T11:45:22Z","reference_number":"EMADOC-1700519818-1976753 Corr1","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228081-ema-decision-19-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-voclosporin-lupkynis_en.pdf"},
    {"id":"74158","name":"EMA/PE/0000189672: EMA decision of 20 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for obefazimod","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-19T11:53:42Z","last_updated_date":"2026-06-19T11:53:42Z","reference_number":"EMADOC-1700519818-1975045","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf"},
    {"id":"74159","name":"EMA/PE/0000231366: EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for efgartigimod alfa (Vyvgart)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-19T11:59:28Z","last_updated_date":"2026-06-19T11:59:28Z","reference_number":"EMADOC-1700519818-1980436","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000231366-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-efgartigimod-alfa-vyvgart_en.pdf"},
    {"id":"74160","name":"EMA/PE/0000233797: EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for delandistrogene moxeparvovec","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-19T12:15:57Z","last_updated_date":"2026-06-19T12:15:57Z","reference_number":"EMADOC-1700519818-1976248","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000233797-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-delandistrogene-moxeparvovec_en.pdf"},
    {"id":"74186","name":"EMA/PE/0000231892: EMA decision of 20 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for apremilast (Otezla)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-23T09:34:28Z","last_updated_date":"2026-06-23T09:34:28Z","reference_number":"EMADOC-1700519818-1976391","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000231892-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-apremilast-otezla_en.pdf"},
    {"id":"74189","name":"EMA/PE/0000241855: EMA decision of 19 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for brensocatib","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-23T09:39:47Z","last_updated_date":"2026-06-23T09:39:47Z","reference_number":"EMADOC-1700519818-1977965","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000241855-ema-decision-19-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-brensocatib_en.pdf"},
    {"id":"74193","name":"EMA/PE/0000228531: EMA decision of 20 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for davesomeran, elasomeran, imelasomeran, andusomeran, SARS-CoV-2 JN.1 mRNA (Spikevax bivalent Original/Omicron BA.1, Spikevax","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-23T09:45:22Z","last_updated_date":"2026-06-23T09:45:22Z","reference_number":"EMADOC-1700519818-1993726","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228531-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-davesomeran-elasomeran-imelasomeran-andusomeran-sars-cov-2-jn1-mrna-spikevax-bivalent-original_en.pdf"},
    {"id":"74194","name":"EMA/PE/0000233122: EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for fluocinolone acetonide (Iluvien)","type":"pip-decision","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T09:51:21Z","last_updated_date":"2026-06-23T09:51:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000233122-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-fluocinolone-acetonide-iluvien_en.pdf"},
    {"id":"74205","name":"EMA/PE/0000228373: EMA decision of 21 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for gepotidacin","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-23T09:58:51Z","last_updated_date":"2026-06-23T09:58:51Z","reference_number":"EMADOC-1700519818-1880370","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000228373-ema-decision-21-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-gepotidacin_en.pdf"},
    {"id":"74214","name":"EMA/PE/0000225778: EMA decision of 20 March 2025 on the acceptance of a modification of an agreed paediatric investigation plan for sipavibart (Kavigale)","type":"pip-decision","status":"Adopted","consultation_date":"","first_published_date":"2026-06-23T10:05:28Z","last_updated_date":"2026-06-23T10:05:28Z","reference_number":"EMADOC-1700519818-1976387","document_url":"https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000225778-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-sipavibart-kavigale_en.pdf"},
    {"id":"2616","name":"Pollen from Phleum pratense - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-phleum-pratense-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"3592","name":"Tazarotene - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-02-04T10:15:00Z","last_updated_date":"2015-02-04T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/tazarotene-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"3766","name":"Cediranib maleate - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-06-06T12:00:00Z","last_updated_date":"2013-06-06T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cediranib-maleate-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"4333","name":"17 beta-estradiol / etonogestrel - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-07-18T16:17:00Z","last_updated_date":"2016-07-18T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/17-beta-estradiol-etonogestrel-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"4537","name":"Dactylis glomarata, Lolium perenne, Phleum pratense, Poa pratensis and Anthoxhantum odoratum (20 % each) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigatio...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/dactylis-glomarata-lolium-perenne-phleum-pratense-poa-pratensis-anthoxhantum-odoratum-20-each-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigatio_en.pdf"},
    {"id":"5443","name":"Human Normal Immunoglobulin - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-02-17T10:30:00Z","last_updated_date":"2017-02-17T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/human-normal-immunoglobulin-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"7463","name":"Tralokinumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-02-23T18:00:00Z","last_updated_date":"2018-02-23T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/tralokinumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"7702","name":"PF-04950615 - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T01:00:00Z","last_updated_date":"2017-02-17T10:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pf-04950615-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"7917","name":"Bitopertin - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2014-11-19T12:00:00Z","last_updated_date":"2014-11-19T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/bitopertin-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"8071","name":"Pollen from Dactylis glomarata, Festuca pratensis, Lolium perenne, Phleum\n\npratense, Secale cereale (20% each) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-invest...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-dactylis-glomarata-festuca-pratensis-lolium-perenne-phleum-pratense-secale-cereale-20-each-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-invest_en.pdf"},
    {"id":"8191","name":"Simtuzumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-11-14T16:35:00Z","last_updated_date":"2016-11-14T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/simtuzumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"10863","name":"Colestilan - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T15:10:00Z","last_updated_date":"2015-01-29T15:10:00Z","reference_number":"EMEA-000878-PIP02-11","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/colestilan-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"10885","name":"Pollen from Alnus glutinosa, Betula verrucosa and Corylus avellana - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T19:00:00Z","last_updated_date":"2018-06-06T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-alnus-glutinosa-betula-verrucosa-corylus-avellana-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"11281","name":"Suptavumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-04-26T12:25:00Z","last_updated_date":"2018-04-26T12:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/suptavumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"11497","name":"Purified antigen fractions of inactivated split virion Influenza A/Indonesia/05/2005(H5Nl) like strain used (PR8-IBCDC-RG2) - Notification of discontinuation of a paediatric development which is covered by an agreed paed...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-09-18T18:00:00Z","last_updated_date":"2015-09-18T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/purified-antigen-fractions-inactivated-split-virion-influenza-indonesia-05-2005h5nl-strain-used-pr8-ibcdc-rg2-notification-discontinuation-paediatric-development-which-covered-agreed-paed_en.pdf"},
    {"id":"11877","name":"(R)-7-Chloro-benzo[b]thiophene-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide hydrochloride hydrate (EVP-6124) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatri...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-05-25T13:45:00Z","last_updated_date":"2016-05-25T13:45:00Z","reference_number":"EMEA-001519-PIP01-13","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/r-7-chloro-benzobthiophene-2-carboxylic-acid-1-aza-bicyclo222oct-3-yl-amide-hydrochloride-hydrate-evp-6124-notification-discontinuation-paediatric-development-which-covered-agreed-paediatri_en.pdf"},
    {"id":"13253","name":"Telcagepant - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2014-07-31T18:45:00Z","last_updated_date":"2014-07-31T18:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/telcagepant-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"13971","name":"Pollen from Betula verrucosa - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-betula-verrucosa-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf-0"},
    {"id":"14235","name":"Pollen from Dactylis glomerata, Lolium perenne, Phleum pratense, Festuca pratensis, Secale cereal - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan ...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T19:00:00Z","last_updated_date":"2018-06-06T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-dactylis-glomerata-lolium-perenne-phleum-pratense-festuca-pratensis-secale-cereal-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan_en.pdf"},
    {"id":"14890","name":"Eptacog alfa (activated) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-02-26T12:30:00Z","last_updated_date":"2018-02-26T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/eptacog-alfa-activated-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"14977","name":"Recombinant Bet v1 folding variant - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T17:00:00Z","last_updated_date":"2013-10-07T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/recombinant-bet-v1-folding-variant-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"15123","name":"(S)-1-{5-Phenyl-4-[(pyridin-2-ylmethyl)-amino]-thieno[2,3-d]pyrimidin-2-yl}-piperidine-3-carboxylic acid (2-hydroxy-ethyl)-amide - Notification of discontinuation of a paediatric development which is covered by an agreed...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-05-25T13:45:00Z","last_updated_date":"2016-05-25T13:45:00Z","reference_number":"EMEA-001752-PIP01-15","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/s-1-5-phenyl-4-pyridin-2-ylmethyl-amino-thieno23-dpyrimidin-2-yl-piperidine-3-carboxylic-acid-2-hydroxy-ethyl-amide-notification-discontinuation-paediatric-development-which-covered-agreed_en.pdf"},
    {"id":"15356","name":"Cadazolid - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-06-08T12:45:00Z","last_updated_date":"2018-06-08T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cadazolid-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"16142","name":"Cilengitide - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T17:00:00Z","last_updated_date":"2013-10-07T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cilengitide-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"16548","name":"Pollen from Alnus glutinosa (33%), Betula verrucosa (33%) and Corylus avellana (33%) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-alnus-glutinosa-33-betula-verrucosa-33-corylus-avellana-33-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"16754","name":"Faldaprevir - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2014-11-05T15:15:00Z","last_updated_date":"2014-11-05T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/faldaprevir-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"16850","name":"Evacetrapib - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-10-22T11:20:00Z","last_updated_date":"2015-10-22T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/evacetrapib-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"16869","name":"Solithromycin (anthrax) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-04-20T13:45:00Z","last_updated_date":"2018-04-20T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/solithromycin-anthrax-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"17494","name":"Proteinase, metallo- (synthetic nociceptin receptor-binding) 1290102-81-6 (also referred to as AGN-214868 or senrebotase) - Notification of discontinuation of a paediatric development which is covered by an agreed paedia...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-04-13T16:00:00Z","last_updated_date":"2016-04-13T16:00:00Z","reference_number":"EMEA-001200-PIP01-11","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/proteinase-metallo-synthetic-nociceptin-receptor-binding-1290102-81-6-also-referred-agn-214868-or-senrebotase-notification-discontinuation-paediatric-development-which-covered-agreed-paedia_en.pdf"},
    {"id":"17558","name":"Basmisanil - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-10-04T02:00:00Z","last_updated_date":"2016-10-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/basmisanil-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"18049","name":"AllerSlit forte Birch - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-02-16T14:20:00Z","last_updated_date":"2015-02-16T14:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/allerslit-forte-birch-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"19067","name":"Cebranopadol - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-03-09T13:00:00Z","last_updated_date":"2016-03-09T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cebranopadol-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"19614","name":"Eritoran - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-05-30T17:20:00Z","last_updated_date":"2017-05-30T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/eritoran-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"20021","name":"Soliris - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-04-18T17:25:00Z","last_updated_date":"2017-04-18T17:25:00Z","reference_number":"EMEA-000876-PIP07-15","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/soliris-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"20240","name":"Givinostat - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T17:00:00Z","last_updated_date":"2013-10-07T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/givinostat-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"20474","name":"Recombinant respiratory syncytial virus vaccine - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/recombinant-respiratory-syncytial-virus-vaccine-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"21035","name":"Abrilumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-05-25T13:45:00Z","last_updated_date":"2016-05-25T13:45:00Z","reference_number":"EMEA-001200-PIP01-11","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/abrilumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"21697","name":"Allergens from Dermatophagoides pteronyssinus and Dermatophagoides farinae - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T19:00:00Z","last_updated_date":"2018-06-06T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/allergens-dermatophagoides-pteronyssinus-dermatophagoides-farinae-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"21716","name":"Casopitant - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-01-23T15:25:00Z","last_updated_date":"2015-01-23T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/casopitant-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"22203","name":"Enzastaurin (hydrochloride) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-06-06T12:00:00Z","last_updated_date":"2013-06-06T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/enzastaurin-hydrochloride-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"22610","name":"Recombinant human monoclonal antibody to human interleukin (IL)-17A - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-05-08T17:00:00Z","last_updated_date":"2015-05-08T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/recombinant-human-monoclonal-antibody-human-interleukin-il-17a-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"23420","name":"(1R, 4S, 5S, 6S)-4-[[(2s)-2-amino-4-(methylthio)-1-oxobutyl]amino]-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid,2,2-dioxide, monohydrate (LY2140023) - Notification of discontinuation of a paediatric development which...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-02-16T17:45:00Z","last_updated_date":"2015-02-16T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/1r-4s-5s-6s-4-2s-2-amino-4-methylthio-1-oxobutylamino-2-thiabicyclo310hexane-46-dicarboxylic-acid22-dioxide-monohydrate-ly2140023-notification-discontinuation-paediatric-development-which_en.pdf"},
    {"id":"23941","name":"Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense, Poa pratensis, Secale cereale, Betula verrucosa, Corylus avellana and Alnus glutinosa - Notification of discontinuation of a paediatric development ...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/dactylis-glomerata-festuca-pratensis-lolium-perenne-phleum-pratense-poa-pratensis-secale-cereale-betula-verrucosa-corylus-avellana-alnus-glutinosa-notification-discontinuation-paediatric-development_en.pdf"},
    {"id":"24573","name":"Doripenem monohydrate - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-05-06T18:20:00Z","last_updated_date":"2015-05-06T18:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/doripenem-monohydrate-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"24945","name":"Allergen extracts of Dermatophagoides farinae and Dermatophagoides pteronyssinus (each 50%) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decisi...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/allergen-extracts-dermatophagoides-farinae-dermatophagoides-pteronyssinus-each-50-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decisi_en.pdf"},
    {"id":"25123","name":"Recothrom - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-07-06T12:40:00Z","last_updated_date":"2018-07-06T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/recothrom-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"25746","name":"Briakinumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-08-14T18:10:00Z","last_updated_date":"2015-08-14T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/briakinumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"25957","name":"Omarigliptin - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-08-17T17:44:00Z","last_updated_date":"2016-08-17T17:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/omarigliptin-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"26376","name":"Pollen from Betula verrucosa - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T19:00:00Z","last_updated_date":"2018-06-06T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-betula-verrucosa-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"26418","name":"Serelaxin - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-09-29T19:20:00Z","last_updated_date":"2017-09-29T19:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/serelaxin-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"26740","name":"Odanacatib - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T02:00:00Z","last_updated_date":"2016-10-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/odanacatib-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"27142","name":"Ombrabulin - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T13:35:00Z","last_updated_date":"2014-07-07T13:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ombrabulin-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"27244","name":"Nicotinic acid / laropiprant (Tredaptive) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T17:00:00Z","last_updated_date":"2013-10-07T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/nicotinic-acid-laropiprant-tredaptive-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"27488","name":"Lixivaptan - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-02-23T18:00:00Z","last_updated_date":"2018-02-23T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/lixivaptan-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"28454","name":"Pollen from Dactylis glomarata (16%), Festuca pratensis (16%), Lolium perenne (16%), Phleum pratense (16%), Poa pratensis (16%), Secale cereale (20%) - Notification of discontinuation of a paediatric development which is...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-dactylis-glomarata-16-festuca-pratensis-16-lolium-perenne-16-phleum-pratense-16-poa-pratensis-16-secale-cereale-20-notification-discontinuation-paediatric-development-which_en.pdf"},
    {"id":"28601","name":"Olodaterol - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T14:01:00Z","last_updated_date":"2018-07-05T14:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/olodaterol-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"28993","name":"GS-5745 - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-11-24T01:00:00Z","last_updated_date":"2016-11-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/gs-5745-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"30178","name":"Monoclonal IgG1 anti-influenza A antibody - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T13:45:00Z","last_updated_date":"2018-03-06T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/monoclonal-igg1-anti-influenza-antibody-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"31647","name":"Pollen from Phleum pratense - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T19:00:00Z","last_updated_date":"2018-06-06T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-phleum-pratense-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf-0"},
    {"id":"31969","name":"Human normal immunoglobin (Gammagen) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T17:00:00Z","last_updated_date":"2013-10-07T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/human-normal-immunoglobin-gammagen-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"32460","name":"Bisoctrizole, titanium dioxide - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T17:00:00Z","last_updated_date":"2013-10-07T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/bisoctrizole-titanium-dioxide-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"32737","name":"Eculizumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-07-27T02:00:00Z","last_updated_date":"2015-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/eculizumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"32779","name":"Vatreptacog alfa (activated) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T02:00:00Z","last_updated_date":"2014-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/vatreptacog-alfa-activated-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"33378","name":"Zontivity - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-11-30T17:51:00Z","last_updated_date":"2017-11-30T17:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/zontivity-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"33986","name":"Volasertib - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-02-23T18:00:00Z","last_updated_date":"2018-02-23T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/volasertib-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"34054","name":"Anacetrapib - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-12-05T14:54:00Z","last_updated_date":"2017-12-05T14:54:00Z","reference_number":"P/0068/2013","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/anacetrapib-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"34060","name":"Translarna - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-03-23T15:54:00Z","last_updated_date":"2017-03-23T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/translarna-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"34119","name":"Evofosfamide - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T17:30:00Z","last_updated_date":"2017-01-04T17:30:00Z","reference_number":"EMEA-001483-PIP01-13","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/evofosfamide-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"34737","name":"Eleclazine (GS-6615) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-02-17T10:30:00Z","last_updated_date":"2017-02-17T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/eleclazine-gs-6615-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"35060","name":"Elacytarabine - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T14:25:00Z","last_updated_date":"2013-07-22T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/elacytarabine-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"35494","name":"Quilizumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-03-13T16:00:00Z","last_updated_date":"2018-03-13T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/quilizumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"35637","name":"Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense, Poa pratensis, Secale cereale and Artemisia vulgaris - Notification of discontinuation of a paediatric development which is covered by an agreed pae...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/dactylis-glomerata-festuca-pratensis-lolium-perenne-phleum-pratense-poa-pratensis-secale-cereale-artemisia-vulgaris-notification-discontinuation-paediatric-development-which-covered-agreed-pae_en.pdf"},
    {"id":"36221","name":"Mesalazine / prednisolone m-sulphobenzoate - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-02-23T18:00:00Z","last_updated_date":"2018-02-23T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/mesalazine-prednisolone-m-sulphobenzoate-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"36450","name":"Human fibrinogen / human thrombin - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T13:40:00Z","last_updated_date":"2018-03-06T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/human-fibrinogen-human-thrombin-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"36543","name":"Solithromycin - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-04-20T13:45:00Z","last_updated_date":"2018-04-20T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/solithromycin-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"36658","name":"6,7-dihydro-5H-pyrrolo[1,2-c] imidazol-5-yl) - (benzo derivative) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-11-21T13:01:00Z","last_updated_date":"2017-11-21T13:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/67-dihydro-5h-pyrrolo12-c-imidazol-5-yl-benzo-derivative-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"}    {"id":"36766","name":"Ethanol - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T17:00:00Z","last_updated_date":"2013-10-07T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ethanol-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"37021","name":"Lebrikizumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-12-08T10:31:00Z","last_updated_date":"2016-12-08T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/lebrikizumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"38050","name":"Katclari - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-06-19T16:36:00Z","last_updated_date":"2017-06-19T16:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/katclari-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"39093","name":"Ferumoxytol - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2015-05-06T12:30:00Z","last_updated_date":"2015-05-06T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ferumoxytol-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"39360","name":"Maribavir - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2016-08-08T17:26:00Z","last_updated_date":"2016-08-08T17:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/maribavir-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"40776","name":"Eculizumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-04-20T13:45:00Z","last_updated_date":"2018-04-20T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/eculizumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf-0"},
    {"id":"41042","name":"(3aR,4S,7aR)-octahydro-4-hydroxy-4-[(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid methyl ester - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T02:00:00Z","last_updated_date":"2014-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/3ar4s7ar-octahydro-4-hydroxy-4-3-methylphenylethynyl-1h-indole-1-carboxylic-acid-methyl-ester-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"41379","name":"Flublok - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-04-20T13:45:00Z","last_updated_date":"2018-04-20T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/flublok-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"41651","name":"Influenza virus surface antigens inactivated, of H1N1, H3N2 and B strains recommended by World Health Organization (Optaflu) - Notification of discontinuation of a paediatric development which is covered by an agreed pae...","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T17:00:00Z","last_updated_date":"2013-10-07T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/influenza-virus-surface-antigens-inactivated-h1n1-h3n2-b-strains-recommended-world-health-organization-optaflu-notification-discontinuation-paediatric-development-which-covered-agreed-pae_en.pdf"},
    {"id":"41704","name":"Diallertest - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2017-04-18T17:35:00Z","last_updated_date":"2017-04-18T17:35:00Z","reference_number":"EMEA-000201-PIP01-08-M01","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/diallertest-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"42171","name":"Gevokizumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-10-02T15:43:00Z","last_updated_date":"2018-10-02T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/gevokizumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"42172","name":"Furosemide - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2018-10-02T15:58:00Z","last_updated_date":"2018-10-02T15:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/furosemide-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"43911","name":"Human autologous bone marrow-derived osteoblastic cells: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-02-26T15:04:00Z","last_updated_date":"2019-02-26T15:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/human-autologous-bone-marrow-derived-osteoblastic-cells-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"43912","name":"Lumacaftor - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-02-26T15:07:00Z","last_updated_date":"2019-02-26T15:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/lumacaftor-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"43918","name":"Orencia - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-02-27T13:58:00Z","last_updated_date":"2019-02-27T13:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/orencia-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"43919","name":"Etoxybamide - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-02-27T14:01:00Z","last_updated_date":"2019-02-27T14:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/etoxybamide-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"43920","name":"Transvax - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric investigation plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-02-27T14:03:00Z","last_updated_date":"2019-02-27T14:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/transvax-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"43921","name":"Optaflu - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric investigation plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-02-27T14:14:00Z","last_updated_date":"2019-02-27T14:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/optaflu-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"43922","name":"Fluad and associated names - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric investigation plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-02-27T14:20:00Z","last_updated_date":"2019-02-27T14:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/fluad-associated-names-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"43923","name":"(S)-Pyrrolidine-2-carboxylic acid compound with (2S,3R,4R,5S,6R)-2-(3-((2,3- dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethyl - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric investigation plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-02-27T13:23:00Z","last_updated_date":"2019-02-27T13:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/s-pyrrolidine-2-carboxylic-acid-compound-2s3r4r5s6r-2-3-23-dihydrobenzob14dioxin-6-ylmethyl-4-ethyl-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation_en.pdf"},
    {"id":"43924","name":"Domagrozumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric investigation plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-02-27T14:26:00Z","last_updated_date":"2019-02-27T14:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/domagrozumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"43991","name":"Rolofylline - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-03-08T09:58:00Z","last_updated_date":"2019-03-08T09:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/rolofylline-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"44605","name":"Betrixaban - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T10:43:00Z","last_updated_date":"2019-05-29T10:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/betrixaban-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"44609","name":"Carotuximab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T10:42:00Z","last_updated_date":"2019-05-29T10:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/carotuximab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"44909","name":"5-( 4-Fluoro-1-benzothiophen-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[ 4,5- H][2,3]benzodiazepin-2-one (S44819) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-06-27T14:06:00Z","last_updated_date":"2019-06-27T14:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/5-4-fluoro-1-benzothiophen-2-yl-8-methyl-19-dihydro-2h-13oxazolo-45-h23benzodiazepin-2-one-s44819-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan_en.pdf"},
    {"id":"44949","name":"Complex Povidone-Iodine and Dexamethasone (SHP640) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T14:23:00Z","last_updated_date":"2019-06-28T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/complex-povidone-iodine-dexamethasone-shp640-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"45208","name":"Depatuxizumab mafodotin - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2019-08-07T15:21:00Z","last_updated_date":"2019-08-07T15:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/depatuxizumab-mafodotin-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"48653","name":"Fevipiprant - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2020-08-20T10:37:00Z","last_updated_date":"2020-08-20T10:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/fevipiprant-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"48961","name":"Anti-mucosal addressin cell adhesion molecule antibody (SHP647): Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2020-10-07T16:05:00Z","last_updated_date":"2020-10-07T16:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/anti-mucosal-addressin-cell-adhesion-molecule-antibody-shp647-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"49359","name":"Fremanezumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2020-11-25T15:22:00Z","last_updated_date":"2020-11-25T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/fremanezumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"49360","name":"Molidustat sodium (BAY 85-3934) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2020-11-25T15:26:00Z","last_updated_date":"2020-11-25T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/molidustat-sodium-bay-85-3934-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"49372","name":"Purified antigen fractions of inactivated split virion Influenza A/Indonesia/5/05 (H5N1) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2020-11-26T09:20:00Z","last_updated_date":"2020-11-26T09:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/purified-antigen-fractions-inactivated-split-virion-influenza-indonesia-5-05-h5n1-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"49721","name":"Pollen from Betula pendula (33%), Corylus avellana (33%) and Alnus glutinosa (33%) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-01-05T16:00:00Z","last_updated_date":"2021-01-05T16:00:00Z","reference_number":"EMEA-000852-PIP01-10-M01","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-betula-pendula-33-corylus-avellana-33-alnus-glutinosa-33-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"49722","name":"Allergen extracts of Dermatophagoides farinae and Dermatophagoides pteronyssinus (each 50%) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-01-05T16:11:00Z","last_updated_date":"2021-01-05T16:11:00Z","reference_number":"EMEA-000853-PIP01-10-MO1","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/allergen-extracts-dermatophagoides-farinae-dermatophagoides-pteronyssinus-each-50-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"49723","name":"Pollen from Dactylis glomarata(16%), Lolium perenne(16%), Phleum pratense(16%), Poa pratensis(16%), Anthoxhantum odoratum(16%), Secale cereale(20%) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-01-05T16:16:00Z","last_updated_date":"2021-01-05T16:16:00Z","reference_number":"EMEA-000857-PIP01-10-M01","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-dactylis-glomarata16-lolium-perenne16-phleum-pratense16-poa-pratensis16-anthoxhantum-odoratum16-secale-cereale20-notification-discontinuation-paediatric-development-which-covered-agreed-pip_en.pdf"},
    {"id":"49724","name":"Pollen from Betula pendula - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-01-05T16:20:00Z","last_updated_date":"2021-01-05T16:20:00Z","reference_number":"EMEA-000860-PIPOl-10-MOl","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pollen-betula-pendula-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"50390","name":"Grazoprevir - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T10:17:00Z","last_updated_date":"2021-03-04T10:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/grazoprevir-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"50392","name":"Elbasvir - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-03-04T10:23:00Z","last_updated_date":"2022-11-29T16:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/elbasvir-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"50613","name":"Peginesatide - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:39:00Z","last_updated_date":"2021-03-17T14:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/peginesatide-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"50924","name":"Chemically modified house dust mites allergen extract (dermatophagoides pteronyssinus and dermatophagoides farinae) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T14:39:00Z","last_updated_date":"2021-04-21T14:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/chemically-modified-house-dust-mites-allergen-extract-dermatophagoides-pteronyssinus-dermatophagoides-farinae-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric_en.pdf"},
    {"id":"50942","name":"Cenicriviroc - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-04-22T14:40:00Z","last_updated_date":"2021-04-22T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cenicriviroc-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"51371","name":"Alpha tocotrienol quinone - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:08:00Z","last_updated_date":"2021-06-07T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/alpha-tocotrienol-quinone-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"51372","name":"Elafibranor - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:24:00Z","last_updated_date":"2021-06-07T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/elafibranor-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"52510","name":"Tafluprost - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T16:11:00Z","last_updated_date":"2021-09-17T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/tafluprost-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"52783","name":"Olaratumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-10-08T12:55:00Z","last_updated_date":"2021-10-08T12:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/olaratumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"52820","name":"Empagliflozin - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-10-12T16:55:00Z","last_updated_date":"2021-10-12T16:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/empagliflozin-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"53168","name":"[(3S)-6-({2',6'-Dimethyl-4'-[3-(methylsulfonyl) propoxy] biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hydrate (TAK-875) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T16:55:00Z","last_updated_date":"2021-11-19T16:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/3s-6-26-dimethyl-4-3-methylsulfonyl-propoxy-biphenyl-3-ylmethoxy-23-dihydro-1-benzofuran-3-ylacetic-acid-hydrate-tak-875-notification-discontinuation-paediatric-development-which-covered-agreed-pip_en.pdf"},
    {"id":"53195","name":"Carisbamate - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-11-22T09:42:00Z","last_updated_date":"2021-11-22T09:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/carisbamate-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"53334","name":"2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl](methyl)amino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile - Discontinuation of a paediatric development which is covered by agreed PIP decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T17:42:00Z","last_updated_date":"2021-11-29T17:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/2-2-ethyl-6-4-2-3-hydroxyazetidin-1-yl-2-oxoethylpiperazin-1-yl-8-methylimidazo12-apyridin-3-ylmethylamino-4-4-fluorophenyl-13-thiazole-5-carbonitrile-discontinuation-paediatric-development-which_en.pdf"},
    {"id":"53335","name":"Octenidine dihydrochloride - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T17:50:00Z","last_updated_date":"2021-11-29T17:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/octenidine-dihydrochloride-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"53336","name":"Susoctocog alfa - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T09:42:00Z","last_updated_date":"2021-11-29T09:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/susoctocog-alfa-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"53345","name":"Human immunoglobulin G2 isotype antibody to IL-33R - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-12-01T09:42:00Z","last_updated_date":"2021-12-01T09:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/human-immunoglobulin-g2-isotype-antibody-il-33r-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"53346","name":"Retosiban - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-12-01T09:42:00Z","last_updated_date":"2021-12-01T09:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/retosiban-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"53444","name":"Dipalmitoylphosphatidylcholine / 1-palmitoyl-2-oleoyl-sn-glycero-3- phosphoglycerol sodium salt /synthetic surfactant (...) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-12-10T17:42:00Z","last_updated_date":"2021-12-10T17:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/dipalmitoylphosphatidylcholine-1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol-sodium-salt-synthetic-surfactant-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric_en.pdf"},
    {"id":"53445","name":"Fluticasone furoate, vilanterol trifenatate and umeclidinium bromide - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2021-12-10T17:45:00Z","last_updated_date":"2021-12-10T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/fluticasone-furoate-vilanterol-trifenatate-umeclidinium-bromide-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"54058","name":"Bumetanide - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T14:19:00Z","last_updated_date":"2022-02-03T14:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/bumetanide-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"54104","name":"Naloxone hydrochloride - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T16:17:00Z","last_updated_date":"2022-02-08T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/naloxone-hydrochloride-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"54121","name":"Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human βA-T87Q-globin gene - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-02-09T16:17:00Z","last_updated_date":"2022-02-09T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/autologous-cd34-haematopoietic-stem-cells-transduced-lentiviral-vector-encoding-human-ba-t87q-globin-gene-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric_en.pdf"},
    {"id":"54533","name":"Clazakizumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-03-21T09:42:00Z","last_updated_date":"2022-03-21T09:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/clazakizumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"54556","name":"Venglustat - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-03-24T15:45:00Z","last_updated_date":"2022-03-24T15:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/venglustat-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"54557","name":"Pimodivir - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-03-24T15:48:00Z","last_updated_date":"2022-03-24T15:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pimodivir-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"54590","name":"Pevonedistat - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T11:42:00Z","last_updated_date":"2022-03-25T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pevonedistat-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"54728","name":"Zorecimeran - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T17:27:00Z","last_updated_date":"2022-04-11T17:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/zorecimeran-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"54735","name":"Tanezumab - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-04-12T14:44:00Z","last_updated_date":"2022-04-12T14:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/tanezumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"55139","name":"Selonsertib : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-06-07T13:29:00Z","last_updated_date":"2022-06-07T13:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/selonsertib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"55171","name":"Deleobuvir : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-06-09T15:03:00Z","last_updated_date":"2022-06-09T15:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/deleobuvir-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"55183","name":"Arimoclomol citrate : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-06-10T12:04:00Z","last_updated_date":"2022-06-10T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/arimoclomol-citrate-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"55234","name":"Methyl aminolevulinate hydrochloride : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-06-14T12:38:00Z","last_updated_date":"2022-06-14T12:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/methyl-aminolevulinate-hydrochloride-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"55235","name":"Recombinant human heparan-N-sulfatase (rhHNS, SHP610, HGT-1410, Sulfamidase, San-A) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-06-14T12:49:00Z","last_updated_date":"2022-06-14T12:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/recombinant-human-heparan-n-sulfatase-rhhns-shp610-hgt-1410-sulfamidase-san-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"55236","name":"Insulin peglispro : Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-06-14T13:02:00Z","last_updated_date":"2022-06-14T13:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/insulin-peglispro-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"55237","name":"Expanded human autologous mesenchymal adult stem cells extracted from adipose tissue (CX-401) : Notification of discontinuation of a paediatric development which is covered by an agreed  PIP decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-06-14T13:22:00Z","last_updated_date":"2022-06-14T13:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/expanded-human-autologous-mesenchymal-adult-stem-cells-extracted-adipose-tissue-cx-401-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"55403","name":"Isavuconazonium (sulfate) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-06-29T11:57:00Z","last_updated_date":"2022-06-29T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/isavuconazonium-sulfate-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"56558","name":"Vedolizumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-11-09T11:27:00Z","last_updated_date":"2022-11-09T11:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/vedolizumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"56867","name":"(S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt (FBS0701) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T14:06:00Z","last_updated_date":"2022-12-02T14:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/s-3-oh-desazadesferrithiocin-polyether-magnesium-salt-fbs0701-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"56869","name":"Bivalent anti-human myostatin adnectin recombinant human IgG1-Fc fusion protein : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T15:32:00Z","last_updated_date":"2022-12-02T15:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/bivalent-anti-human-myostatin-adnectin-recombinant-human-igg1-fc-fusion-protein-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"56882","name":"Atazanavir / Ritonavir - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-06T09:37:00Z","last_updated_date":"2022-12-06T09:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/atazanavir-ritonavir-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"56969","name":"Testosterone : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T11:58:00Z","last_updated_date":"2022-12-13T11:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/testosterone-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"56970","name":"Chemically modified extract of trees pollen from birch and alder : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T12:07:00Z","last_updated_date":"2022-12-13T12:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/chemically-modified-extract-trees-pollen-birch-alder-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"56971","name":"Chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T12:13:00Z","last_updated_date":"2022-12-13T12:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/chemically-modified-extract-grass-pollen-holcus-lanatus-phleum-pratense-poa-pratensis-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"56972","name":"Chemically modified house dust mites allergen extract (dermatophagoides pteronyssinus and dermatophagoides farinae) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T12:17:00Z","last_updated_date":"2022-12-13T12:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/chemically-modified-house-dust-mites-allergen-extract-dermatophagoides-pteronyssinus-dermatophagoides-farinae-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"56991","name":"Rimiducid : Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision","type":"pip-discontinuation","status":"Adopted","consultation_date":"","first_published_date":"2022-12-13T18:01:00Z","last_updated_date":"2022-12-13T18:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/rimiducid-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"57129","name":"Pradigastat  - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T10:22:00Z","last_updated_date":"2022-12-22T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pradigastat-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"57130","name":"Benralizumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T10:31:00Z","last_updated_date":"2022-12-22T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/benralizumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"57131","name":"Ligelizumab - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T10:36:00Z","last_updated_date":"2022-12-22T10:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ligelizumab-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"57135","name":"Rivogenlecleucel - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T11:00:00Z","last_updated_date":"2022-12-22T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/rivogenlecleucel-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"57166","name":"PEGylated-fibroblast growth factor 21 (BMS-986036) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-01-05T11:00:00Z","last_updated_date":"2023-01-05T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pegylated-fibroblast-growth-factor-21-bms-986036-notification-discontinuation-paediatric-development-which-covered-agreed-paediatric-investigation-plan-decision_en.pdf"},
    {"id":"57188","name":"Baricitinib - Notification of discontinuation of a paediatric development which is covered by an agreed  PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T15:55:00Z","last_updated_date":"2023-01-09T15:55:00Z","reference_number":"EMEA-001220-PIP05-19","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/baricitinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"57190","name":"N-hydroxy-5-methylfuran-2-sulfonamide (BMS-986231) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T16:33:00Z","last_updated_date":"2023-01-09T16:33:00Z","reference_number":"EMEA-002378-PIP01-18","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/n-hydroxy-5-methylfuran-2-sulfonamide-bms-986231-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"57213","name":"Vaborbactam - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-01-11T10:59:00Z","last_updated_date":"2023-01-11T10:59:00Z","reference_number":"EMEA-001740-PIP01-14","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/vaborbactam-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"57255","name":"Relamorelin - Notification of discontinuation of a paediatric development which is covered by an agreed  PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T13:29:00Z","last_updated_date":"2023-01-12T13:29:00Z","reference_number":"EMEA-002323-PIP02-19","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/relamorelin-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"57533","name":"Omega-3-carboxylic acids - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-02-06T14:29:00Z","last_updated_date":"2023-02-06T14:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/omega-3-carboxylic-acids-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"57534","name":"Nanobody directed towards the fusion protein of human respiratory syncytial virus (ALX-0171) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-02-06T14:34:00Z","last_updated_date":"2023-02-06T14:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/nanobody-directed-towards-fusion-protein-human-respiratory-syncytial-virus-alx-0171-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"57701","name":"Surufatinib - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-02-17T10:06:00Z","last_updated_date":"2023-02-17T10:06:00Z","reference_number":"EMEA-002750-PIP01-19","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/surufatinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"58123","name":"(Z)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-(2- (sulfamoylamino)ethylamino)-1,2,5-oxadiazole-3-carboximidamide - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-03-22T15:06:00Z","last_updated_date":"2023-03-22T15:06:00Z","reference_number":"EMEA-002072-PIP01-16-M01","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/z-n-3-bromo-4-fluorophenyl-n-hydroxy-4-2-sulfamoylaminoethylamino-125-oxadiazole-3-carboximidamide-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"58730","name":"Derivative of 4Hpyrazolo[3,4-d]pyrimidin-4-one (BI409306) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T11:30:00Z","last_updated_date":"2023-05-22T11:30:00Z","reference_number":"EMEA-001742-PIP01-14","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/derivative-4hpyrazolo34-dpyrimidin-4-one-bi409306-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"59124","name":"Virus-like particle of SARS-CoV-2 spike protein (recombinant, adjuvanted) (CoVLP) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T09:08:00Z","last_updated_date":"2023-06-29T09:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/virus-particle-sars-cov-2-spike-protein-recombinant-adjuvanted-covlp-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"59279","name":"Ligelizumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-07-06T14:24:00Z","last_updated_date":"2023-07-06T14:24:00Z","reference_number":"EMEA-001811-PIP04-21","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ligelizumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"59280","name":"Benzylamine derivative of benzofuran (BCX9930) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-07-06T14:31:00Z","last_updated_date":"2023-07-06T14:31:00Z","reference_number":"EMEA-002974-PIP01-21","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/benzylamine-derivative-benzofuran-bcx9930-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"59282","name":"AZD8233 sodium, PCSK9-targeted, N-acetylgalactosamine (GalNAc)conjugated antisense oligonucleotide (ASO) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-07-06T14:36:00Z","last_updated_date":"2023-07-06T14:36:00Z","reference_number":"EMEA-002962-PIP01-21","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/azd8233-sodium-pcsk9-targeted-n-acetylgalactosamine-galnacconjugated-antisense-oligonucleotide-aso-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"59303","name":"Molnupiravir : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-07-07T15:08:00Z","last_updated_date":"2023-07-07T15:08:00Z","reference_number":"EMEA-002940-PIP02-21","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/molnupiravir-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"}    {"id":"59545","name":"Adalimumab conjugated with (4S)-4-[2-(2-bromoacetamido)acetamido]-5....(ABBV-154) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-08-03T10:53:00Z","last_updated_date":"2023-08-03T10:53:00Z","reference_number":"EMEA-002927-PIP01-20","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/adalimumab-conjugated-4s-4-2-2-bromoacetamidoacetamido-5abbv-154-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"59615","name":"Iscalimab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-08-22T12:19:00Z","last_updated_date":"2023-08-22T12:19:00Z","reference_number":"EMEA-002842-PIP01-20","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/iscalimab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"59637","name":"Recombinant human monoclonal antibody to GM-CSF (Otilimab) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-08-25T16:15:00Z","last_updated_date":"2023-08-25T16:15:00Z","reference_number":"EMEA-001882-PIP02-16-M02","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/recombinant-human-monoclonal-antibody-gm-csf-otilimab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"59638","name":"3-[[5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridine-2-one (JNJ-53718678): Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-08-25T12:19:00Z","last_updated_date":"2023-08-25T12:19:00Z","reference_number":"EMEA-001838-PIP01-15-M03","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/3-5-chloro-1-3-methylsulfonylpropyl-1h-indol-2-ylmethyl-1-222-trifluoroethyl-13-dihydro-2h-imidazo45-cpyridine-2-one-jnj-53718678-notification-discontinuation-paediatric-development-which-covered_en.pdf"},
    {"id":"59885","name":"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (ACH-0144471) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T12:49:00Z","last_updated_date":"2023-09-01T12:49:00Z","reference_number":"EMEA-002310-PIP02-17","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/2s4r-1-2-3-acetyl-5-2-methylpyrimidin-5-yl-1h-indazol-1-ylacetyl-n-6-bromopyridin-2-yl-4-fluoropyrrolidine-2-carboxamide-ach-0144471-notification-discontinuation-paediatric-development-which-covered_en.pdf"},
    {"id":"59886","name":"Avatrombopag : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T14:14:00Z","last_updated_date":"2023-09-01T14:14:00Z","reference_number":"EMEA-001136-PIP02-19-M01","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/avatrombopag-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"59890","name":"Ioforminol : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-09-04T12:33:00Z","last_updated_date":"2023-09-04T12:33:00Z","reference_number":"EMEA-001197-PIP01-11","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ioforminol-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"60020","name":"Sotrastaurin acetate : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T10:52:00Z","last_updated_date":"2023-09-15T10:52:00Z","reference_number":"EMEA-000093-PIP01-07-M01","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/sotrastaurin-acetate-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"60021","name":"Sotrastaurin acetate : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T10:57:00Z","last_updated_date":"2023-09-15T10:57:00Z","reference_number":"EMEA-000093-PIP02-10","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/sotrastaurin-acetate-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"60023","name":"Erdafitinib : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T11:00:00Z","last_updated_date":"2023-09-15T11:00:00Z","reference_number":"EMEA-002042-PIP02-20-M01","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/erdafitinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"60111","name":"Tofacitinib : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T12:32:00Z","last_updated_date":"2023-09-27T12:32:00Z","reference_number":"EMEA-000576-PIP02-11-M04","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/tofacitinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"60608","name":"Nicardipine: List of nationally authorised medicinal products - PSUSA/00002149/201905","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2020-01-27T13:51:00Z","last_updated_date":"2020-01-27T13:51:00Z","reference_number":"EMA/34502/2020","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/nicardipine-list-nationally-authorised-medicinal-products-psusa-00002149-201905_en.pdf"},
    {"id":"60789","name":"Calcipotriol : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-11-07T15:25:00Z","last_updated_date":"2023-11-07T15:25:00Z","reference_number":"EMEA-001606-PIP02-14","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/calcipotriol-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"60790","name":"Daprodustat : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-11-07T15:30:00Z","last_updated_date":"2023-11-07T15:30:00Z","reference_number":"EMEA-001452-PIP01-13","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/daprodustat-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"60812","name":"Bis-choline tetrathiomolybdate : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-11-09T12:16:00Z","last_updated_date":"2023-11-09T12:16:00Z","reference_number":"EMEA-002232-PIP02-19-M02","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/bis-choline-tetrathiomolybdate-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"61176","name":"(E)-4-[ (5-Phenyl-1,3 ,4-thiadiazol-2-yl)oxy]-1-azoniatricyclo[3.3.1.13,7]decane 3,4-dicarboxy-3-hydroxybutanoate hydrate : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T12:21:41Z","last_updated_date":"2023-12-04T12:21:41Z","reference_number":"EMEA-001468-PIP01-13","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/e-4-5-phenyl-13-4-thiadiazol-2-yloxy-1-azoniatricyclo331137decane-34-dicarboxy-3-hydroxybutanoate-hydrate-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"61177","name":"Deucravacitinib : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T12:26:22Z","last_updated_date":"2023-12-04T12:26:22Z","reference_number":"EMEA-002350-PIP04-21","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/deucravacitinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"61837","name":"Spartalizumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T16:07:27Z","last_updated_date":"2024-01-22T16:07:27Z","reference_number":"EMEA-002351-PIP01-18","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/spartalizumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"61838","name":"Human immunoglobulin (Ig) G4-variant monoclonal antibody that binds and neutralizes soluble human interleukin- (IL-) 33 - LY3375880 : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T16:11:13Z","last_updated_date":"2024-01-22T16:11:13Z","reference_number":"EMEA-002464-PIP01-18","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/human-immunoglobulin-ig-g4-variant-monoclonal-antibody-binds-neutralizes-soluble-human-interleukin-il-33-ly3375880-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"62216","name":"Islatravir - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-02-20T12:50:23Z","last_updated_date":"2024-02-20T12:50:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/islatravir-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"62217","name":"Momelotinib - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-02-20T13:03:55Z","last_updated_date":"2024-02-20T13:03:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/momelotinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"62219","name":" Metformin hydrochloride - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-02-20T14:22:26Z","last_updated_date":"2024-02-20T14:22:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/metformin-hydrochloride-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"62223","name":"(1R,2R)-2-[4-(5-methyl-1H-pyrazol-3-yl) benzoyl]-N-(4-oxo-6,7-dihydro-5H-pyrazolo [1,5-a]pyrazin-3-yl)cyclohexanecarboxamide (AZD5718) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-02-20T16:50:43Z","last_updated_date":"2024-02-20T16:50:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/1r2r-2-4-5-methyl-1h-pyrazol-3-yl-benzoyl-n-4-oxo-67-dihydro-5h-pyrazolo-15-apyrazin-3-ylcyclohexanecarboxamide-azd5718-notification-discontinuation-paediatric-development-which-covered-agreed-pip_en.pdf"},
    {"id":"62224","name":"Entospletinib - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-02-20T17:14:32Z","last_updated_date":"2024-02-20T17:14:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/entospletinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"62225","name":"lademirsen - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T09:25:53Z","last_updated_date":"2024-02-21T09:25:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/lademirsen-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"62226","name":"Secukinumab - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T09:32:03Z","last_updated_date":"2024-02-21T09:32:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/secukinumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"62251","name":"Discontinuation - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-02-22T10:27:59Z","last_updated_date":"2024-02-22T10:27:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/discontinuation-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"62499","name":"Alpha1-proteinase inhibitor (human) (A1-PI) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T15:52:22Z","last_updated_date":"2024-03-08T15:52:22Z","reference_number":"EMEA-001312-PIP03-19","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/alpha1-proteinase-inhibitor-human-a1-pi-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"62500","name":"Alpha1-proteinase inhibitor (human) (A1-PI) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T15:56:04Z","last_updated_date":"2024-03-08T15:56:04Z","reference_number":"EMEA-001312-PIP02-19","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/alpha1-proteinase-inhibitor-human-a1-pi-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"62501","name":"Ibrutinib : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T15:59:31Z","last_updated_date":"2024-03-08T15:59:31Z","reference_number":"EMEA-001397-PIP04-17","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ibrutinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"63160","name":"Atrasentan (hydrochloride) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-05-03T16:07:00Z","last_updated_date":"2024-05-03T16:07:00Z","reference_number":"EMEA-001666-PIP01-14","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/atrasentan-hydrochloride-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"63161","name":"Fusion protein composed of the first 2 immunoglobulin-like domains of the human roundabout guidance receptor 2 fused to a human IgG1....(PF-06730512) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-05-03T16:13:00Z","last_updated_date":"2024-05-03T16:13:00Z","reference_number":"EMEA-003157-PIP01-21","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/fusion-protein-composed-first-2-immunoglobulin-domains-human-roundabout-guidance-receptor-2-fused-human-igg1pf-06730512-notification-discontinuation-paediatric-development-which-covered-agreed-pip_en.pdf"},
    {"id":"63162","name":"N-(3-cyano-4-fluorophenyl)-1-methyl-4-[[(2S)-1,1,1-trifluoro-2- propanyl]sulfamoyl]-1H-pyrrole-2.....(JNJ-56136379) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-05-03T16:17:00Z","last_updated_date":"2024-05-03T16:17:00Z","reference_number":"EMEA-002693-PIP01-19","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/n-3-cyano-4-fluorophenyl-1-methyl-4-2s-111-trifluoro-2-propanylsulfamoyl-1h-pyrrole-2jnj-56136379-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"63163","name":"Verinurad / allopurinol : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-05-03T16:25:00Z","last_updated_date":"2024-05-03T16:25:00Z","reference_number":"EMEA-002754-PIP01-19","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/verinurad-allopurinol-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"64138","name":"P/0271/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nizaracianine triflutate (EMEA-003367-PIP01-22)","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T14:15:00Z","last_updated_date":"2024-07-16T14:15:00Z","reference_number":"EMA/251128/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/p-0271-2023-ema-decision-14-july-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-nizaracianine-triflutate-emea-003367-pip01-22_en.pdf"},
    {"id":"65418","name":"Sirukumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:48:00Z","last_updated_date":"2024-10-24T11:48:00Z","reference_number":"EMEA-001043-PIP01-10-M03","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/sirukumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"65419","name":"(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1- yl)acetyl)- N-(6-bromo-3-methylpyridin-2-yl).....hexane-3-carboxamide : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:55:00Z","last_updated_date":"2024-10-24T11:55:00Z","reference_number":"EMEA-002863-PIP01-20","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/1r3s5r-2-2-3-acetyl-5-2-methylpyrimidin-5-yl-1h-indazol-1-ylacetyl-n-6-bromo-3-methylpyridin-2-ylhexane-3-carboxamide-notification-discontinuation-paediatric-development-which-covered-agreed-pip_en.pdf"},
    {"id":"66480","name":"Trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C, adjuvanted with aluminium phosphate [Clade C gp140] : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-01-28T11:40:28Z","last_updated_date":"2025-01-28T11:40:28Z","reference_number":"EMEA-002221-PIP01-17","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/trimeric-recombinant-hiv-1-envelope-glycoprotein-140-clade-c-adjuvanted-aluminium-phosphate-clade-c-gp140-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66488","name":"Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8 (AK002) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-01-28T16:43:17Z","last_updated_date":"2025-01-28T16:43:17Z","reference_number":"EMEA-002856-PIP01-20","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/recombinant-monoclonal-antibody-sialic-acid-binding-ig-lectin-8-ak002-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66499","name":"Sodium 2,2-dimethylbutyrate : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-01-29T11:23:58Z","last_updated_date":"2025-01-29T11:23:58Z","reference_number":"EMEA-003019-PIP01-21","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/sodium-22-dimethylbutyrate-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66500","name":"Mavodelpar (Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl- prop1ynyl) phenyl]allyloxy}-2-methylphenoxy)acetate) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-01-29T11:26:44Z","last_updated_date":"2025-01-29T11:26:44Z","reference_number":"EMEA-003331-PIP02-23","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/mavodelpar-sodium-4-e-3-4-fluorophenyl-3-4-3-morpholin-4-yl-prop1ynyl-phenylallyloxy-2-methylphenoxyacetate-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66501","name":"2,6-Bis-{(1-napthalenyl-3,6-disulfonic acid)-oxyacetamido}-2,6-bis-2,6-bis- 2,6-bis-(2,6-diamino-hexanoylamino).......polysodium salt : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-01-29T11:29:11Z","last_updated_date":"2025-01-29T11:29:11Z","reference_number":"EMEA-001354-PIP01-12","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/26-bis-1-napthalenyl-36-disulfonic-acid-oxyacetamido-26-bis-26-bis-26-bis-26-diamino-hexanoylaminopolysodium-salt-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66557","name":"EMEA-002160-PIP01-17: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T14:03:42Z","last_updated_date":"2025-01-31T14:03:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/emea-002160-pip01-17-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66558","name":"EMEA-002161-PIP01-17: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T14:05:43Z","last_updated_date":"2025-01-31T14:05:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/emea-002161-pip01-17-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66616","name":"Etrolizumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-02-05T16:05:56Z","last_updated_date":"2025-02-05T16:05:56Z","reference_number":"EMEA-001434-PIP01-13-M03","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/etrolizumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66619","name":"Clindamycin (phosphate) / bituminosulphonate (sodium) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-02-06T10:21:33Z","last_updated_date":"2025-02-06T10:21:33Z","reference_number":"EMEA-000532-PIP01-09","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/clindamycin-phosphate-bituminosulphonate-sodium-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66680","name":"Anti-BAFF monoclonal antibody (LY2127399) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-02-11T15:33:47Z","last_updated_date":"2025-02-11T15:33:47Z","reference_number":"EMEA-000802-PIP01-09","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/anti-baff-monoclonal-antibody-ly2127399-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66975","name":"NAutologous CD34+ cells transduced with lentiviral vector containing the human Wiskott Aldrich: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-02-26T09:06:14Z","last_updated_date":"2025-02-26T09:06:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/nautologous-cd34-cells-transduced-lentiviral-vector-containing-human-wiskott-aldrich-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"66976","name":"Vibostolimab / pembrolizumab: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-02-26T09:13:10Z","last_updated_date":"2025-02-26T09:13:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/vibostolimab-pembrolizumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"68361","name":"Benralizumab (Fasenra) : notification of discontinuation of a paediatric development which is covered by an agreed PIP decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-05-20T11:05:38Z","last_updated_date":"2025-05-20T11:05:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/benralizumab-fasenra-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"68366","name":"MVA-BN-RSV (construct MVA-mBN294B) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-05-20T12:32:10Z","last_updated_date":"2025-05-20T12:32:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/mva-bn-rsv-construct-mva-mbn294b-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"68367","name":"Dupilumab (Dupixent) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-05-20T12:35:09Z","last_updated_date":"2025-05-20T12:35:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/dupilumab-dupixent-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"68368","name":"Baricitinib (Olumiant) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-05-20T13:51:16Z","last_updated_date":"2025-05-20T13:51:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/baricitinib-olumiant-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"68447","name":"Vibostolimab / pembrolizumab: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-05-26T10:43:22Z","last_updated_date":"2025-05-26T10:43:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/vibostolimab-pembrolizumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"68470","name":"Obeldesivir: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-05-27T14:05:53Z","last_updated_date":"2025-05-27T14:05:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/obeldesivir-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"68753","name":"Bemnifosbuvir : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-06-13T15:33:58Z","last_updated_date":"2025-06-13T15:33:58Z","reference_number":"EMEA-002963-PIP01-21-M01","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/bemnifosbuvir-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70472","name":"Obinutuzumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-07T15:23:47Z","last_updated_date":"2025-10-07T15:23:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/obinutuzumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70476","name":"Varicella-zoster virus (inactivated) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-07T16:01:29Z","last_updated_date":"2025-10-07T16:01:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/varicella-zoster-virus-inactivated-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70489","name":"Human alpha-1 proteinase inhibitor, modified (SerpinPC) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-08T10:43:39Z","last_updated_date":"2025-10-08T10:43:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/human-alpha-1-proteinase-inhibitor-modified-serpinpc-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70509","name":"Danuglipron : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-09T14:12:38Z","last_updated_date":"2025-10-09T14:12:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/danuglipron-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70510","name":"Cendakimab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-09T14:14:17Z","last_updated_date":"2025-10-09T14:14:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cendakimab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70549","name":"Ianalumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-14T15:29:03Z","last_updated_date":"2025-10-14T15:29:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ianalumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70733","name":"Avenciguat : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-22T13:49:59Z","last_updated_date":"2025-10-22T13:49:59Z","reference_number":"P/0387/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/avenciguat-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70852","name":"Cotadutide : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-27T16:27:08Z","last_updated_date":"2025-10-27T16:27:08Z","reference_number":"EMEA-002287-PIP01-17-M03","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cotadutide-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70853","name":"Cotadutide : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-27T16:29:12Z","last_updated_date":"2025-10-27T16:29:12Z","reference_number":"EMEA-002712-PIP01-19-M01","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cotadutide-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"70878","name":"Pralsetinib : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-28T13:35:01Z","last_updated_date":"2025-10-28T13:35:01Z","reference_number":"EMEA-002575-PIP02-20","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pralsetinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70879","name":"ExPEC9V : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-28T13:37:25Z","last_updated_date":"2025-10-28T13:37:25Z","reference_number":"EMEA-002996-PIP01-21","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/expec9v-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"70880","name":"Outer membrane vesicles (OMV) from N. meningitidis Strain NZ 98/254.... : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-10-28T13:39:38Z","last_updated_date":"2025-10-28T13:39:38Z","reference_number":"EMEA-001260-PIP01-11-M03","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/outer-membrane-vesicles-omv-n-meningitidis-strain-nz-98-254-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71079","name":"Cobolimab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T17:43:14Z","last_updated_date":"2025-11-10T17:43:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cobolimab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71080","name":"Dolutegravir / HIV-1 maturation inhibitor (GSK3640254) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T17:45:29Z","last_updated_date":"2025-11-10T17:45:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/dolutegravir-hiv-1-maturation-inhibitor-gsk3640254-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71081","name":"Etrasimod : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T17:46:53Z","last_updated_date":"2025-11-10T17:46:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/etrasimod-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71133","name":"Efavaleukin alfa : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T14:49:00Z","last_updated_date":"2025-11-13T14:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/efavaleukin-alfa-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71149","name":"Rozibafusp alfa : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:35:51Z","last_updated_date":"2025-11-13T15:35:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/rozibafusp-alfa-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71184","name":"Single-stranded 5' capped mRNA encoding... : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-14T16:21:00Z","last_updated_date":"2025-11-14T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/single-stranded-5-capped-mrna-encoding-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71185","name":"Cilofexor : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-14T16:32:31Z","last_updated_date":"2025-11-14T16:32:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cilofexor-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71196","name":"Spesolimab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-17T14:11:45Z","last_updated_date":"2025-11-17T14:11:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/spesolimab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71197","name":"Respiratory Syncytial Virus PreF3 recombinant fusion protein (RSVPreF3) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-17T14:13:19Z","last_updated_date":"2025-11-17T14:13:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/respiratory-syncytial-virus-pref3-recombinant-fusion-protein-rsvpref3-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71198","name":"Idasanutlin : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-17T14:15:04Z","last_updated_date":"2025-11-17T14:15:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/idasanutlin-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71199","name":"Idasanutlin : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-17T14:16:47Z","last_updated_date":"2025-11-17T14:16:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/idasanutlin-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"71253","name":"HIV-1 maturation inhibitor (GSK3640254) - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-20T09:17:47Z","last_updated_date":"2025-11-20T09:17:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/hiv-1-maturation-inhibitor-gsk3640254-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71357","name":"Evobrutinib : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T10:26:48Z","last_updated_date":"2025-11-27T10:26:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/evobrutinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71358","name":"Efavaleukin alfa : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T10:29:04Z","last_updated_date":"2025-11-27T10:29:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/efavaleukin-alfa-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"71359","name":"Ganaxolone : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T10:36:39Z","last_updated_date":"2025-11-27T10:36:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ganaxolone-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71360","name":"Losmapimod : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T10:39:14Z","last_updated_date":"2025-11-27T10:39:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/losmapimod-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71362","name":"Magrolimab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T11:17:44Z","last_updated_date":"2025-11-27T11:17:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/magrolimab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71366","name":"Gliadin protease : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T12:16:09Z","last_updated_date":"2025-11-27T12:16:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/gliadin-protease-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71632","name":"Lumicitabine : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T09:20:26Z","last_updated_date":"2025-12-10T09:20:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/lumicitabine-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71633","name":"Tezepelumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T09:22:51Z","last_updated_date":"2025-12-10T09:22:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/tezepelumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71634","name":"Pamrevlumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T09:24:41Z","last_updated_date":"2025-12-10T09:24:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pamrevlumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71635","name":"Favezelimab / pembrolizumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T09:26:09Z","last_updated_date":"2025-12-10T09:26:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/favezelimab-pembrolizumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"71636","name":"Danuglipron : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T09:27:50Z","last_updated_date":"2025-12-10T09:27:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/danuglipron-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"71637","name":"Iclepertin : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T09:30:56Z","last_updated_date":"2025-12-10T09:30:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/iclepertin-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72009","name":"Ozanimod (hydrochloride) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-12T13:50:08Z","last_updated_date":"2026-01-12T13:50:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ozanimod-hydrochloride-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72011","name":"Grass pollen allergen extract from Dactylis glomerata L., Anthoxanthum odoratum L., Lolium perenne L., Poa prantensis L. and Phleum pratense L. : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-12T14:07:33Z","last_updated_date":"2026-01-12T14:07:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/grass-pollen-allergen-extract-dactylis-glomerata-l-anthoxanthum-odoratum-l-lolium-perenne-l-poa-prantensis-l-phleum-pratense-l-notification-discontinuation-paediatric-development-which-covered-agreed_en.pdf"},
    {"id":"72012","name":"Antisense oligonucleotide against patatin like phospholipase domain containing protein 3 gene (PNPLA3), conjugated to....sodium salt : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-12T14:15:16Z","last_updated_date":"2026-01-12T14:15:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/antisense-oligonucleotide-against-patatin-phospholipase-domain-containing-protein-3-gene-pnpla3-conjugated-tosodium-salt-notification-discontinuation-paediatric-development-which-covered-agreed-pip_en.pdf"},
    {"id":"72058","name":"Fibroblast growth factor 21 analogue (NNC194-0499; zalfermin) / semaglutide : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T13:03:12Z","last_updated_date":"2026-01-15T13:03:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/fibroblast-growth-factor-21-analogue-nnc194-0499-zalfermin-semaglutide-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72139","name":"Fosmetpantotenate : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-19T16:20:00Z","last_updated_date":"2026-01-19T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/fosmetpantotenate-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72281","name":"Soticlestat : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T11:13:20Z","last_updated_date":"2026-01-27T11:13:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/soticlestat-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72282","name":"Vesatolimod (GS-9620) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T11:15:29Z","last_updated_date":"2026-01-27T11:15:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/vesatolimod-gs-9620-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72352","name":"Soticlestat : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T15:56:40Z","last_updated_date":"2026-01-29T15:56:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/soticlestat-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"}    {"id":"72353","name":"Tanimilast : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T16:01:57Z","last_updated_date":"2026-01-29T16:01:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/tanimilast-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72354","name":"Cilofexor / firsocostat : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T16:03:47Z","last_updated_date":"2026-01-29T16:03:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cilofexor-firsocostat-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72355","name":"1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]-α,α,5-trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H).. Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T16:05:08Z","last_updated_date":"2026-01-29T16:05:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/14-dihydro-1-2r-2-2-methoxyphenyl-2-tetrahydro-2h-pyran-4-yloxyethyl-aa5-trimethyl-6-2-oxazolyl-24-dioxo-thieno23-dpyrimidine-32h-notification-discontinuation-paediatric-development-which-covered_en.pdf"},
    {"id":"72653","name":"Nemvaleukin alfa : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-02-23T16:47:21Z","last_updated_date":"2026-02-23T16:47:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/nemvaleukin-alfa-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72654","name":"Pozelimab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-02-23T16:58:23Z","last_updated_date":"2026-02-23T16:58:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pozelimab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72696","name":"Vatiquinone : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-02-25T14:02:40Z","last_updated_date":"2026-02-25T14:02:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/vatiquinone-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72697","name":"Iodine (131I) apamistamab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-02-25T14:05:12Z","last_updated_date":"2026-02-25T14:05:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/iodine-131i-apamistamab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72866","name":"Inclacumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-05T15:46:40Z","last_updated_date":"2026-03-05T15:46:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/inclacumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72888","name":"Eteplirsen : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T10:35:21Z","last_updated_date":"2026-03-09T10:35:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/eteplirsen-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"72894","name":"Adeno-associated viral vector serotype 9 containing human sulfamidase gene : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T10:48:29Z","last_updated_date":"2026-03-09T10:48:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/adeno-associated-viral-vector-serotype-9-containing-human-sulfamidase-gene-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73019","name":"Azacitidine: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-16T09:30:46Z","last_updated_date":"2026-03-16T09:30:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/azacitidine-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73020","name":"Fordadistrogene movaparvovec: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-16T09:35:02Z","last_updated_date":"2026-03-16T09:35:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/fordadistrogene-movaparvovec-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73137","name":"Spesolimab: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-20T15:27:25Z","last_updated_date":"2026-03-20T15:27:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/spesolimab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"73174","name":"Live attenuated respiratory syncytial virus (RSV) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T16:13:21Z","last_updated_date":"2026-03-25T16:13:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/live-attenuated-respiratory-syncytial-virus-rsv-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73175","name":"House dust mites allergen extract from Dermatophagoides pteronyssinus and Dermatophagoides farinae (50/50) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T16:15:21Z","last_updated_date":"2026-03-25T16:15:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/house-dust-mites-allergen-extract-dermatophagoides-pteronyssinus-dermatophagoides-farinae-50-50-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73176","name":"Trazodone (hydrochloride) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T16:17:31Z","last_updated_date":"2026-03-25T16:17:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/trazodone-hydrochloride-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73177","name":"Cannabidiol (Epidyolex) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T16:19:52Z","last_updated_date":"2026-03-25T16:19:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cannabidiol-epidyolex-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73178","name":"Cannabidiol (Epidyolex) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T16:25:09Z","last_updated_date":"2026-03-25T16:25:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/cannabidiol-epidyolex-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"73180","name":"Iodine (131-I) murine IgG1 monoclonal antibody against B7-H3 (131I-omburtamab) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T16:28:49Z","last_updated_date":"2026-03-25T16:28:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/iodine-131-i-murine-igg1-monoclonal-antibody-against-b7-h3-131i-omburtamab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73190","name":"Dalcetrapib : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T10:15:42Z","last_updated_date":"2026-03-25T10:15:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/dalcetrapib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73191","name":"12 grass pollen extract, cultivated rye pollen extract and birch/alder/hazel pollen extract : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T10:20:41Z","last_updated_date":"2026-03-25T10:20:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/12-grass-pollen-extract-cultivated-rye-pollen-extract-birch-alder-hazel-pollen-extract-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73192","name":"Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts (50%/50%) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T10:23:43Z","last_updated_date":"2026-03-25T10:23:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/dermatophagoides-pteronyssinus-dermatophagoides-farinae-extracts-50-50-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73193","name":"12 Grass Pollen Extract and Cultivated Rye Pollen Extract : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T10:26:56Z","last_updated_date":"2026-03-25T10:26:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/12-grass-pollen-extract-cultivated-rye-pollen-extract-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73195","name":"Birch, hazel and alder pollen extracts : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T10:50:51Z","last_updated_date":"2026-03-25T10:50:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/birch-hazel-alder-pollen-extracts-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73196","name":"Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts (50%/50%) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T10:53:43Z","last_updated_date":"2026-03-25T10:53:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/dermatophagoides-pteronyssinus-dermatophagoides-farinae-extracts-50-50-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"73197","name":"12 grass pollen extract, cultivated rye pollen extract and mugwort pollen : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T10:56:20Z","last_updated_date":"2026-03-25T10:56:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/12-grass-pollen-extract-cultivated-rye-pollen-extract-mugwort-pollen-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73198","name":"Birch/Alder/Hazel Pollen Extract : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T11:00:23Z","last_updated_date":"2026-03-25T11:00:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/birch-alder-hazel-pollen-extract-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73199","name":"Elobixibat : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T11:03:04Z","last_updated_date":"2026-03-25T11:03:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/elobixibat-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73200","name":"modRNA encoding 4 influenza HA antigens (2 for influenza A and 2 for influenza B stains) (qIRV) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T11:07:14Z","last_updated_date":"2026-03-25T11:07:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/modrna-encoding-4-influenza-ha-antigens-2-influenza-2-influenza-b-stains-qirv-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73410","name":"Decitabine, cedazuridine : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-04-10T10:24:14Z","last_updated_date":"2026-04-10T10:24:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/decitabine-cedazuridine-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73417","name":"1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one (BBP-671) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-04-10T12:35:52Z","last_updated_date":"2026-04-10T12:35:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/1-4-6-chloropyridazin-3-ylpiperazin-1-yl-2-4-cyclopropyl-3-fluorophenylethan-1-one-bbp-671-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73421","name":"Ligelizumab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-04-10T14:57:28Z","last_updated_date":"2026-04-10T14:57:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ligelizumab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"73653","name":"Allopregnanolone : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T09:51:31Z","last_updated_date":"2026-05-08T09:51:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/allopregnanolone-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73654","name":"Exon 45 specific phosphorothioate oligonucleotide : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T09:56:48Z","last_updated_date":"2026-05-08T09:56:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/exon-45-specific-phosphorothioate-oligonucleotide-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73655","name":"Exon 53 specific phosphorothioate oligonucleotide : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T09:57:37Z","last_updated_date":"2026-05-08T09:57:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/exon-53-specific-phosphorothioate-oligonucleotide-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73656","name":"Chemically modified house dust mites allergen extract of Dermatophagoides pteronyssinus and Dermatophagoides farinae : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T09:58:25Z","last_updated_date":"2026-05-08T09:58:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/chemically-modified-house-dust-mites-allergen-extract-dermatophagoides-pteronyssinus-dermatophagoides-farinae-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"73657","name":"3-[5-[(1R,2S)-2-(2,2-difluoropropanoylamino)-1-(2,3-dihydro-1,4-benzodioxin6-yl)propoxy]indazol-1- yl]-N-[(3R)-tetrahydrofuran-3-yl]benzamide (AZD7594): Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T10:20:02Z","last_updated_date":"2026-05-08T10:20:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/3-5-1r2s-2-22-difluoropropanoylamino-1-23-dihydro-14-benzodioxin6-ylpropoxyindazol-1-yl-n-3r-tetrahydrofuran-3-ylbenzamide-azd7594-notification-discontinuation-paediatric-development-which-covered_en.pdf"},
    {"id":"73658","name":"Chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T10:21:04Z","last_updated_date":"2026-05-08T10:21:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/chemically-modified-extract-grass-pollen-holcus-lanatus-phleum-pratense-poa-pratensis-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"73659","name":"Imlifidase : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T10:22:11Z","last_updated_date":"2026-05-08T10:22:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/imlifidase-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73660","name":"Chemically modified extract of trees pollen from birch and alder : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T10:25:11Z","last_updated_date":"2026-05-08T10:25:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/chemically-modified-extract-trees-pollen-birch-alder-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf-0"},
    {"id":"73933","name":"Pritoxaximab, setoxaximab : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-02T13:46:41Z","last_updated_date":"2026-06-02T13:46:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/pritoxaximab-setoxaximab-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"73997","name":"Ciprofloxacin (hydrochloride) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-08T10:07:06Z","last_updated_date":"2026-06-08T10:07:06Z","reference_number":"P/0253/2018","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ciprofloxacin-hydrochloride-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"74230","name":"Dermatophagoides pteronyssinus allergen extract : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T16:13:00Z","last_updated_date":"2026-06-23T16:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/dermatophagoides-pteronyssinus-allergen-extract-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"74231","name":"Mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extracts : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T16:28:11Z","last_updated_date":"2026-06-23T16:28:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/mixture-dermatophagoides-pteronyssinus-dermatophagoides-farinae-allergen-extracts-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"74232","name":"Betula alba allergen extract : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T16:53:06Z","last_updated_date":"2026-06-23T16:53:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/betula-alba-allergen-extract-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"74234","name":"Mixture of Birch, Hazel and Alder allergen extracts : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T16:56:26Z","last_updated_date":"2026-06-23T16:56:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/mixture-birch-hazel-alder-allergen-extracts-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"74235","name":"Mixture of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis allergen extracts : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T17:04:43Z","last_updated_date":"2026-06-23T17:04:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/mixture-phleum-pratense-dactylis-glomerata-festuca-elatior-lolium-perenne-poa-pratensis-allergen-extracts-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"74236","name":"Mixture of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne & Poa pratensis (Grasses-Mix) & Secale cereale (50/50) allergen extracts:Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T17:07:37Z","last_updated_date":"2026-06-23T17:07:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/mixture-phleum-pratense-dactylis-glomerata-festuca-elatior-lolium-perenne-poa-pratensis-grasses-mix-secale-cereale-50-50-allergen-extractsnotification-discontinuation-paediatric-development-which_en.pdf"},
    {"id":"74237","name":"Mixture of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis (Grasses-Mix) & Secale cereale (75/25) allergen extracts: Notification of discontinuation of a paediatric development which is covered by agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T17:11:11Z","last_updated_date":"2026-06-23T17:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/mixture-phleum-pratense-dactylis-glomerata-festuca-elatior-lolium-perenne-poa-pratensis-grasses-mix-secale-cereale-75-25-allergen-extracts-notification-discontinuation-paediatric-development-which_en.pdf"},
    {"id":"74238","name":"Phleum pratense allergen extract : Notification of discontinuation of a paediatric development which is covered by agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T17:15:34Z","last_updated_date":"2026-06-23T17:15:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/phleum-pratense-allergen-extract-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"74264","name":"Ritlecitinib : Notification of discontinuation of a paediatric development which is covered by agreed PIP Decision","type":"pip-discontinuation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T10:30:55Z","last_updated_date":"2026-06-25T10:30:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/pip-discontinuation/ritlecitinib-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"3054","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Nintedanib for the treatment of systemic sclerosis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T16:00:00Z","last_updated_date":"2016-07-11T16:00:00Z","reference_number":"EMA/481785/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-nintedanib-treatment-systemic-sclerosis_en.pdf"},
    {"id":"3852","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Eluxadoline for treatment of diarrhoea-predominant irritable bowel syndrome","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/146397/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-eluxadoline-treatment-diarrhoea-predominant-irritable-bowel-syndrome_en.pdf"},
    {"id":"4681","name":"Public summary of the evaluation of the proposed product-specific waiver: Tirasemtiv for the treatment of amyotrophic lateral sclerosis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T12:55:00Z","last_updated_date":"2014-10-21T12:55:00Z","reference_number":"EMA/510083/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-tirasemtiv-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"5473","name":"Public summary of the evaluation of a proposed product-specific waiver: Azithromycin for treatment of bacterial conjunctivitis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/774547/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-azithromycin-treatment-bacterial-conjunctivitis_en.pdf"},
    {"id":"5728","name":"Public summary of the evaluation of a proposed product-specific waiver:  Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (CTL019)","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/198001/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-autologous-t-cells-transduced-lentiviral-vector-containing-chimeric-antigen-receptor-directed-against-cd19-ctl019_en.pdf"},
    {"id":"5745","name":"Public summary of the evaluation of a proposed product-specific waiver: Levomilnacipran for the treatment of stroke","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-09-02T02:00:00Z","last_updated_date":"2015-09-02T02:00:00Z","reference_number":"EMA/566825/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-levomilnacipran-treatment-stroke_en.pdf"},
    {"id":"6539","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Fluciclovine (18F) for diagnosis of amino acid metabolism in solid malignant tumours","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T16:00:00Z","last_updated_date":"2016-07-11T16:00:00Z","reference_number":"EMA/251728/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-fluciclovine-18f-diagnosis-amino-acid-metabolism-solid-malignant-tumours_en.pdf"},
    {"id":"6690","name":"Public summary of the evaluation of a proposed product-specific waiver: Candesartan / amlodipine for treatment of hypertension","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/49429/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-candesartan-amlodipine-treatment-hypertension_en.pdf"},
    {"id":"6851","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Human immunoglobulin G2Lambda monoclonal antibody directed against thymic stromal lymphopoietin (MEDI9929) for the treatment of asthma","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-02-17T12:30:00Z","last_updated_date":"2015-02-17T12:30:00Z","reference_number":"EMA/66137/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-human-immunoglobulin-g2lambda-monoclonal-antibody-directed-against-thymic-stromal-lymphopoietin-medi9929-treatment-asthma_en.pdf"},
    {"id":"6892","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Ibuprofen (sodium dihydrate) for treatment of pain and treatment of febrile disorders","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-11-25T12:30:00Z","last_updated_date":"2014-11-25T12:30:00Z","reference_number":"EMA/690115/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-ibuprofen-sodium-dihydrate-treatment-pain-treatment-febrile-disorders_en.pdf"},
    {"id":"8020","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Silicic acid, sodium zirconium (4+) salt (3:2:1) hydrate for treatment of hyperkalaemia","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/579541/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-silicic-acid-sodium-zirconium-4-salt-321-hydrate-treatment-hyperkalaemia_en.pdf"},
    {"id":"8465","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Dupilumab for treatment of nasal polyposis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T16:00:00Z","last_updated_date":"2016-07-11T16:00:00Z","reference_number":"EMA/134872/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-dupilumab-treatment-nasal-polyposis_en.pdf"},
    {"id":"8710","name":"Public summary of the evaluation of a proposed product-specific waiver: Ibuprofen / codeine for treatment of pain","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/86209/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-ibuprofen-codeine-treatment-pain_en.pdf"},
    {"id":"9056","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Osilodrostat for the treatment of adrenal cortical hyperfunction","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T16:00:00Z","last_updated_date":"2016-07-11T16:00:00Z","reference_number":"EMA/799607/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-osilodrostat-treatment-adrenal-cortical-hyperfunction_en.pdf"},
    {"id":"9084","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Pandemic live attenuated influenza virus (H5N1) for prevention of influenza infection","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T12:15:00Z","last_updated_date":"2014-12-12T12:15:00Z","reference_number":"EMA/662484/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-pandemic-live-attenuated-influenza-virus-h5n1-prevention-influenza-infection_en.pdf"},
    {"id":"10240","name":"Public summary of the evaluation of a proposed paediatric investigation plan: (3-((4-Benzoyl-1-piperazinyl)(oxo)acetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)methyl dihydrogen phospha...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T16:00:00Z","last_updated_date":"2016-07-11T16:00:00Z","reference_number":"EMA/481796/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-3-4-benzoyl-1-piperazinyloxoacetyl-4-methoxy-7-3-methyl-1h-124-triazol-1-yl-1h-pyrrolo23-cpyridin-1-ylmethyl-dihydrogen-phospha_en.pdf"},
    {"id":"10910","name":"Public summary of the evaluation of a proposed paediatric investigation plan:  Calcipotriol for treatment of psoriasis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/604233/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-calcipotriol-treatment-psoriasis_en.pdf"},
    {"id":"11357","name":"Public summary of the evaluation of a proposed product-specific waiver: Daclatasvir (dihydrochloride) / asunaprevir / (1ar,12bs)-8-Cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-(((1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/399003/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-daclatasvir-dihydrochloride-asunaprevir-1ar12bs-8-cyclohexyl-n-dimethylsulfamoyl-11-methoxy-1a-1r5s-3-methyl-38-diazabicyclo321_en.pdf"},
    {"id":"11449","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Captopril for treatment of heart failure","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/689544/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-captopril-treatment-heart-failure_en.pdf"},
    {"id":"12748","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Peanut flour for treatment of peanut allergy","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/787234/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-peanut-flour-treatment-peanut-allergy_en.pdf"},
    {"id":"12796","name":"Public summary of the evaluation of a proposed product-specific waiver: Rifamycin for treatment of acute infectious diarrhoea","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/759331/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-rifamycin-treatment-acute-infectious-diarrhoea_en.pdf"},
    {"id":"13559","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Elbasvir for the treatment of chronic hepatitis C","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T18:00:00Z","last_updated_date":"2016-07-11T18:00:00Z","reference_number":"EMA/750556/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-elbasvir-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"14441","name":"Public summary of the evaluation of a proposed product-specific waiver: Torasemide / lisinopril for treatment of hypertension and treatment of heart failure","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/781915/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-torasemide-lisinopril-treatment-hypertension-treatment-heart-failure_en.pdf"},
    {"id":"14824","name":"Public summary of the evaluation of a proposed product-specific waiver: Allantoin for treatment of epidermolysis bullosa","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/422646/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-allantoin-treatment-epidermolysis-bullosa_en.pdf"},
    {"id":"15613","name":"Public summary of the evaluation of a proposed product-specific waiver: 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropanecarboxami...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/405832/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-1-22-difluoro-13-benzodioxol-5-yl-n-1-2r-23-dihydroxypropyl-6-fluoro-2-1-hydroxy-2-methylpropan-2-yl-1h-indol-5-ylcyclopropanecarboxami_en.pdf"},
    {"id":"15779","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Grazoprevir/elbasvir for the treatment of chronic hepatitis C","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T18:00:00Z","last_updated_date":"2016-07-11T18:00:00Z","reference_number":"EMA/750477/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-grazoprevir-elbasvir-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"15961","name":"Public summary of the evaluation of a proposed product-specific waiver: Brentuximab vedotin for treatment of Cutaneous T-Cell Lymphoma","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/702731/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-brentuximab-vedotin-treatment-cutaneous-t-cell-lymphoma_en.pdf"},
    {"id":"16034","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Eravacycline for the treatment of complicated intra-abdominal infections and for the treatment of urinary tract infections","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T17:30:00Z","last_updated_date":"2015-05-19T17:30:00Z","reference_number":"EMA/412277/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-eravacycline-treatment-complicated-intra-abdominal-infections-treatment-urinary-tract-infections_en.pdf"},
    {"id":"17740","name":"Public summary of the evaluation of a proposed product-specific waiver: Hydromorphone (hydrochloride) / naloxone (hydrochloride) for treatment of pain and treatment of opioid-induced constipation","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/33305/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-hydromorphone-hydrochloride-naloxone-hydrochloride-treatment-pain-treatment-opioid-induced-constipation_en.pdf"},
    {"id":"17902","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Glucagon for treatment of hypoglycaemia","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/364295/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-glucagon-treatment-hypoglycaemia_en.pdf"},
    {"id":"18803","name":"Public summary of the evaluation of a proposed product-specific waiver: Humanised monoclonal antibody IgG2 recognising the interleukin-31 receptor A (CIM331)","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/422651/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-humanised-monoclonal-antibody-igg2-recognising-interleukin-31-receptor-cim331_en.pdf"},
    {"id":"18994","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Efinaconazole for treatment of onychomycosis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T17:30:00Z","last_updated_date":"2015-05-19T17:30:00Z","reference_number":"EMA/190891/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-efinaconazole-treatment-onychomycosis_en.pdf"},
    {"id":"19074","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Begelomab for the treatment of acute graft-versus-host disease (aGvHD)","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/634502/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-begelomab-treatment-acute-graft-versus-host-disease-agvhd_en.pdf"},
    {"id":"20438","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Natural, unmodified antisense oligonucleotide (30-mer) with nucleotide sequence 5”²-GTAATTGCGGCAAGAAGAATTGTTTCTGTC-3”²(CODA001) for treatmen...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/420714/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-natural-unmodified-antisense-oligonucleotide-30-mer-nucleotide-sequence-52-gtaattgcggcaagaagaattgtttctgtc-32coda001-treatmen_en.pdf"},
    {"id":"22494","name":"Public summary of the evaluation of the proposed product-specific waiver: \n\nSaxagliptin/dapagliflozin for the treatment of type 2 diabetes mellitus","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/141125/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-saxagliptin-dapagliflozin-treatment-type-2-diabetes-mellitus_en.pdf"},
    {"id":"23608","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Bromfenac (sodium sesquihydrate) for prevention and treatment of postoperative pain and inflammation associated with cataract surgery","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/689360/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-bromfenac-sodium-sesquihydrate-prevention-treatment-postoperative-pain-inflammation-associated-cataract-surgery_en.pdf"},
    {"id":"23828","name":"Public summary of the evaluation of a proposed product-specific waiver:  Canakinumab for the treatment of familial Mediterranean fever (FMF) and treatment of hyperimmunoglobulin D syndrome","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/318230/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-canakinumab-treatment-familial-mediterranean-fever-fmf-treatment-hyperimmunoglobulin-d-syndrome_en.pdf"},
    {"id":"23912","name":"Public summary of the evaluation of a proposed product-specific waiver: Simtuzumab for treatment of hepatic fibrosis and hepatic cirrhosis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/51495/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-simtuzumab-treatment-hepatic-fibrosis-hepatic-cirrhosis_en.pdf"},
    {"id":"24374","name":"Public summary of the evaluation of a proposed product-specific waiver:  Sofosbuvir / GS-5816 (a derivative of (S)-methyl (2-(2-(1H-imidazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)carbamate)) for the treatment of chronic hepat...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/76260/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-sofosbuvir-gs-5816-derivative-s-methyl-2-2-1h-imidazol-2-ylpyrrolidin-1-yl-2-oxoethylcarbamate-treatment-chronic-hepat_en.pdf"},
    {"id":"24785","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Peanut allergen extract for the treatment of peanut allergy","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T18:00:00Z","last_updated_date":"2016-07-11T18:00:00Z","reference_number":"EMA/131917/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-peanut-allergen-extract-treatment-peanut-allergy_en.pdf"},
    {"id":"25700","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Human normal immunoglobulin for treatment of primary immunodeficiency","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T16:00:00Z","last_updated_date":"2016-07-11T16:00:00Z","reference_number":"EMA/258812/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-human-normal-immunoglobulin-treatment-primary-immunodeficiency_en.pdf"},
    {"id":"25821","name":"Public summary of the evaluation of a proposed product-specific waiver:  Dapagliflozin for treatment of type 1 diabetes mellitus","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/128725/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-dapagliflozin-treatment-type-1-diabetes-mellitus_en.pdf"},
    {"id":"26353","name":"Public summary of the evaluation of the proposed paediatric investigation plan: (R)-2-[3-({Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl) phenoxy]butanoic acid for the reduction of residual cardiovascular event...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/689646/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-r-2-3-benzoxazol-2-yl3-4-methoxyphenoxypropylaminomethyl-phenoxybutanoic-acid-reduction-residual-cardiovascular-event_en.pdf"},
    {"id":"26894","name":"Public summary of the evaluation of a proposed product-specific waiver: Palovarotene for treatment of fibrodysplasia ossificans progressiva","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-09-02T02:00:00Z","last_updated_date":"2015-09-02T02:00:00Z","reference_number":"EMA/472340/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-palovarotene-treatment-fibrodysplasia-ossificans-progressiva_en.pdf"},
    {"id":"27040","name":"Public summary of the evaluation of a proposed product-specific waiver:  Emtricitabine / rilpivirine / tenofovir alafenamide for the treatment of human immunodeficiency virus (HIV-1) infection","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/75638/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-emtricitabine-rilpivirine-tenofovir-alafenamide-treatment-human-immunodeficiency-virus-hiv-1-infection_en.pdf"},
    {"id":"27420","name":"Public summary of the evaluation of a proposed product-specific waiver: Belimumab for treatment of systemic lupus erythematosus","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/422634/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-belimumab-treatment-systemic-lupus-erythematosus_en.pdf"},
    {"id":"27648","name":"Public summary of the evaluation of a proposed product-specific waiver:  Reparixin for prevention of graft rejection","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/288173/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-reparixin-prevention-graft-rejection_en.pdf"},
    {"id":"27686","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Tofacitinib for treatment of ulcerative colitis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T11:55:00Z","last_updated_date":"2014-10-21T11:55:00Z","reference_number":"EMA/488667/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-tofacitinib-treatment-ulcerative-colitis_en.pdf"},
    {"id":"27756","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Rosuvastatin / valsartan for treatment of hypertension, treatment of dyslipidaemia and prevention of cardiovascular events","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/688859/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-rosuvastatin-valsartan-treatment-hypertension-treatment-dyslipidaemia-prevention-cardiovascular-events_en.pdf"}    {"id":"27901","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Emtricitabine / tenofovir disoproxil fumarate (Truvada) for the treatment of human immunodeficiency virus (HIV-1) infection and for the preven...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T16:00:00Z","last_updated_date":"2016-07-11T16:00:00Z","reference_number":"EMA/755069/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-emtricitabine-tenofovir-disoproxil-fumarate-truvada-treatment-human-immunodeficiency-virus-hiv-1-infection-preven_en.pdf"},
    {"id":"28059","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Dasabuvir/ombitasvir/paritaprevir/ritonavir for the treatment of chronic hepatitis C","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/483000/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-dasabuvir-ombitasvir-paritaprevir-ritonavir-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"29067","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Perindopril / bisoprolol for treatment of ischaemic coronary artery disorders, treatment of hypertension and treatment of heart failure","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/490953/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-perindopril-bisoprolol-treatment-ischaemic-coronary-artery-disorders-treatment-hypertension-treatment-heart-failure_en.pdf"},
    {"id":"29078","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Purified adenylate cyclase recombinant protein carrying subfragments of the early protein E7 antigen from human papillomavirus strain 16 (reco...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T12:15:00Z","last_updated_date":"2014-12-12T12:15:00Z","reference_number":"EMA/662484/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-purified-adenylate-cyclase-recombinant-protein-carrying-subfragments-early-protein-e7-antigen-human-papillomavirus-strain-16-reco_en.pdf"},
    {"id":"29150","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Grazoprevir for the treatment of chronic hepatitis C","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T18:00:00Z","last_updated_date":"2016-07-11T18:00:00Z","reference_number":"EMA/750560/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-grazoprevir-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"29251","name":"Public summary of the evaluation of a proposed product-specific waiver: Misoprostol for induction of labour","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-09-02T02:00:00Z","last_updated_date":"2015-09-02T02:00:00Z","reference_number":"EMA/514404/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-misoprostol-induction-labour_en.pdf"},
    {"id":"29424","name":"Public summary of the evaluation of a proposed product-specific waiver: Oxycodone (hydrochloride) / naloxone (hydrochloride) for treatment of pain with opioid-induced constipation","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/33307/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-oxycodone-hydrochloride-naloxone-hydrochloride-treatment-pain-opioid-induced-constipation_en.pdf"},
    {"id":"30242","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Mirabegron for the treatment of neurogenic detrusor overactivity","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T18:00:00Z","last_updated_date":"2016-07-11T18:00:00Z","reference_number":"EMA/501567/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-mirabegron-treatment-neurogenic-detrusor-overactivity_en.pdf"},
    {"id":"30342","name":"Public summary of the evaluation of a proposed product-specific waiver: Botulinum Neurotoxin Type A for Treatment of muscle induced wrinkles","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/774930/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-botulinum-neurotoxin-type-treatment-muscle-induced-wrinkles_en.pdf"},
    {"id":"30394","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Finerenone for treatment of chronic kidney disease","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-03-10T01:00:00Z","reference_number":"EMA/652539/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-finerenone-treatment-chronic-kidney-disease_en.pdf"},
    {"id":"31257","name":"Public summary of the evaluation of a proposed product-specific waiver: Hydrochlorothiazide / nebivolol (hydrochloride) for treatment of hypertension","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/781918/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-hydrochlorothiazide-nebivolol-hydrochloride-treatment-hypertension_en.pdf"},
    {"id":"31306","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Ozanimod for treatment of multiple sclerosis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/781922/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-ozanimod-treatment-multiple-sclerosis_en.pdf"},
    {"id":"31401","name":"Public summary of the evaluation of the proposed paediatric investigation plan: human autologous bone marrow-derived osteoblastic cells for the treatment of non-traumatic osteonecrosis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-07-31T17:45:00Z","last_updated_date":"2014-07-31T17:45:00Z","reference_number":"EMA/426630/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-human-autologous-bone-marrow-derived-osteoblastic-cells-treatment-non-traumatic-osteonecrosis_en.pdf"},
    {"id":"31817","name":"Public summary of the evaluation of a proposed product-specific waiver: Semaglutide for treatment of type-2 diabetes mellitus","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/400078/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-semaglutide-treatment-type-2-diabetes-mellitus_en.pdf"},
    {"id":"32037","name":"Public summary of the evaluation of a proposed product-specific waiver: Recombinant human N-acetylglucosaminidase (rhNAGLU) for treatment of mucopolysaccharidosis IIIB (Sanfilippo B)","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/423607/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-recombinant-human-n-acetylglucosaminidase-rhnaglu-treatment-mucopolysaccharidosis-iiib-sanfilippo-b_en.pdf"},
    {"id":"33135","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Adenovirus associated viral vector serotype 2 containing the human RPE65 gene for the treatment of genetic congenital retinal disorders","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/556214/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-adenovirus-associated-viral-vector-serotype-2-containing-human-rpe65-gene-treatment-genetic-congenital-retinal-disorders_en.pdf"},
    {"id":"33187","name":"Public summary of the evaluation of a proposed product-specific waiver:  Ibodutant for treatment of diarrhoea-predominant Irritable Bowel Syndrome (IBS-d)","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/396300/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-ibodutant-treatment-diarrhoea-predominant-irritable-bowel-syndrome-ibs-d_en.pdf"},
    {"id":"33365","name":"Public summary of the evaluation of a proposed product-specific waiver: DNA, d(P-thio)([2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rC-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/739394/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-dna-dp-thio2-0-2-methoxyethylm5ru-2-0-2-methoxyethylm5rc-2-0-2-methoxyethylm5ru-2-0-2-methoxyethylm5ru-2-0-2-methoxyethyl_en.pdf"},
    {"id":"33649","name":"Public summary of the evaluation of a proposed product-specific waiver: Hydromorphone (hydrochloride) / naloxone (hydrochloride) for treatment of pain and opioid-induced constipation","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/829309/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-hydromorphone-hydrochloride-naloxone-hydrochloride-treatment-pain-opioid-induced-constipation_en.pdf"},
    {"id":"33903","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Dapagliflozin (Forxiga) for the treatment of type-1 diabetes mellitus","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T18:00:00Z","last_updated_date":"2016-07-11T18:00:00Z","reference_number":"EMA/255315/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-dapagliflozin-forxiga-treatment-type-1-diabetes-mellitus_en.pdf"},
    {"id":"34217","name":"Public summary of the evaluation of a proposed product-specific waiver: Enclomifene for the treatment of hypogonadotropic hypogonadism","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/662484/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-enclomifene-treatment-hypogonadotropic-hypogonadism_en.pdf"},
    {"id":"34966","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Propan-2-yl N-[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]-oxy}methyl)(phenoxy) phosphoryl]-l-alaninate, (2E)-but-2-enedioate (2:1) (G...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/578912/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-propan-2-yl-n-s-2r-1-6-amino-9h-purin-9-ylpropan-2-yl-oxymethylphenoxy-phosphoryl-l-alaninate-2e-2-enedioate-21-g_en.pdf"},
    {"id":"36038","name":"Public summary of the evaluation of a proposed product-specific waiver: Dupilumab for treatment of atopic dermatitis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-09-02T02:00:00Z","last_updated_date":"2015-09-02T02:00:00Z","reference_number":"EMA/422641/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-dupilumab-treatment-atopic-dermatitis_en.pdf"},
    {"id":"36507","name":"Public summary of the evaluation of a proposed product-specific waiver: Masitinib (mesylate) for treatment of mastocytosis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/366250/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-masitinib-mesylate-treatment-mastocytosis_en.pdf"},
    {"id":"36910","name":"Public summary of the evaluation of a proposed product-specific waiver: Norovirus GI.1 and GII.4 virus-like particle antigens for the prevention of acute norovirus gastroenteritis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-09-02T02:00:00Z","last_updated_date":"2015-09-02T02:00:00Z","reference_number":"EMA/78811/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-norovirus-gi1-gii4-virus-particle-antigens-prevention-acute-norovirus-gastroenteritis_en.pdf"},
    {"id":"37054","name":"Public summary of the evaluation of a proposed product-specific\n\nwaiver: Zoledronic acid (monohydrate) (in combination with calcium (carbonate) / cholecalciferol) for prevention of skeletal related events in patients wit...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T12:30:00Z","last_updated_date":"2015-02-23T12:30:00Z","reference_number":"EMA/69027/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-zoledronic-acid-monohydrate-combination-calcium-carbonate-cholecalciferol-prevention-skeletal-related-events-patients-wit_en.pdf"},
    {"id":"37130","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Recombinant parathyroid hormone for treatment of hypoparathyroidism","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T18:00:00Z","last_updated_date":"2016-07-11T18:00:00Z","reference_number":"EMA/224879/2016","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-recombinant-parathyroid-hormone-treatment-hypoparathyroidism_en.pdf"},
    {"id":"37229","name":"Public summary of the evaluation of a proposed product-specific waiver: Human recombinant interleukin-2 for treatment of type-1 diabetes mellitus","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/408266/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-human-recombinant-interleukin-2-treatment-type-1-diabetes-mellitus_en.pdf"},
    {"id":"37438","name":"Public summary of the evaluation of a proposed product-specific waiver: Anti programmed death-ligand 1 (PD-L1) monoclonal antibody (MPDL3280A) for treatment of all conditions included in the category of malignant neoplas...","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/316693/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-anti-programmed-death-ligand-1-pd-l1-monoclonal-antibody-mpdl3280a-treatment-all-conditions-included-category-malignant-neoplas_en.pdf"},
    {"id":"37532","name":"Public summary of the evaluation of a proposed product-specific waiver: Alpha Connexin C-terminal 1 peptide (ACT1) for treatment of venous leg ulcer and for treatment of diabetic foot ulcer","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/662484/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-alpha-connexin-c-terminal-1-peptide-act1-treatment-venous-leg-ulcer-treatment-diabetic-foot-ulcer_en.pdf"},
    {"id":"37689","name":"Public summary of the evaluation of a proposed product-specific waiver: Autologous bone marrow-derived cardiopoietic stem cells for the treatment of ischemic heart disease","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/292145/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-autologous-bone-marrow-derived-cardiopoietic-stem-cells-treatment-ischemic-heart-disease_en.pdf"},
    {"id":"38421","name":"Public summary of the evaluation of a proposed product-specific waiver: Peanut allergen extract for treatment of peanut allergy","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-09-02T02:00:00Z","last_updated_date":"2015-09-02T02:00:00Z","reference_number":"EMA/474696/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-peanut-allergen-extract-treatment-peanut-allergy_en.pdf"},
    {"id":"39746","name":"Public summary of the evaluation of the proposed paediatric investigation plan: Potassium citrate monohydrated / potassium hydrogen carbonate for treatment of renal tubular acidosis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-11-25T12:30:00Z","last_updated_date":"2014-11-25T12:30:00Z","reference_number":"EMA/690282/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-potassium-citrate-monohydrated-potassium-hydrogen-carbonate-treatment-renal-tubular-acidosis_en.pdf"},
    {"id":"40279","name":"Public summary of the evaluation of a proposed product-specific waiver:  Ezetimibe / atorvastatin (calcium trihydrate) for the prevention of coronary artery disease","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/397480/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-ezetimibe-atorvastatin-calcium-trihydrate-prevention-coronary-artery-disease_en.pdf"},
    {"id":"40535","name":"Public summary of the evaluation of a proposed product-specific waiver:  L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser for treatment of sarcoidosis","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-08-20T12:00:00Z","last_updated_date":"2015-08-20T12:00:00Z","reference_number":"EMA/396199/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-l-pyr-l-glu-l-gln-l-leu-l-glu-l-arg-l-ala-l-leu-l-asn-l-ser-l-ser-treatment-sarcoidosis_en.pdf"},
    {"id":"40759","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Inotuzumab ozogamicin for treatment of acute lymphoblastic leukaemia","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T12:15:00Z","last_updated_date":"2014-12-12T12:15:00Z","reference_number":"EMA/662484/2014","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-inotuzumab-ozogamicin-treatment-acute-lymphoblastic-leukaemia_en.pdf"},
    {"id":"40996","name":"Public summary of the evaluation of a proposed product-specific waiver:  Canakinumab for treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T12:30:00Z","last_updated_date":"2015-07-06T12:30:00Z","reference_number":"EMA/318226/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-canakinumab-treatment-tumour-necrosis-factor-tnf-receptor-associated-periodic-syndrome_en.pdf"},
    {"id":"41105","name":"Public summary of the evaluation of a proposed product-specific waiver: Mirabegron for the treatment of neurogenic detrusor overactivity","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-09-02T02:00:00Z","last_updated_date":"2015-09-02T02:00:00Z","reference_number":"EMA/501567/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-mirabegron-treatment-neurogenic-detrusor-overactivity_en.pdf"},
    {"id":"41942","name":"Public summary of the evaluation of a proposed paediatric investigation plan: Acotiamide for treatment of functional dyspepsia","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/774861/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-paediatric-investigation-plan-acotiamide-treatment-functional-dyspepsia_en.pdf"},
    {"id":"42039","name":"Public summary of the evaluation of a proposed product-specific waiver: RoActemra (tocilizumab) for treatment of vasculitides","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2015-09-02T02:00:00Z","last_updated_date":"2015-09-02T02:00:00Z","reference_number":"EMA/566826/2015","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/public-summary-evaluation-proposed-product-specific-waiver-roactemra-tocilizumab-treatment-vasculitides_en.pdf"},
    {"id":"61335","name":"P/0027/2024 : EMA decision of 29 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ceftobiprole medocaril (sodium) (Zevtera and associated names), (EMEA-000205-PIP02-11-M06)","type":"pip-summary","status":"Adopted","consultation_date":"","first_published_date":"2023-03-14T11:43:39Z","last_updated_date":"2023-03-14T11:43:39Z","reference_number":"EMA/29053/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/p-0027-2024-ema-decision-29-january-2024-acceptance-modification-agreed-paediatric-investigation-plan-ceftobiprole-medocaril-sodium-zevtera-associated-names-emea-000205-pip02-11-m06_en.pdf"},
    {"id":"61661","name":"P/0043/2022: EMA decision of 10 February 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral for acetyl-Lleucine ((s)-(acetylamino)-4-methylpentanoic acid) (IB1001) (EMEA-002796-PIP01-20)","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2023-04-12T14:33:19Z","last_updated_date":"2023-04-12T14:33:19Z","reference_number":"EMA/65204/2022","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/p-0043-2022-ema-decision-10-february-2022-agreement-paediatric-investigation-plan-granting-deferral-acetyl-lleucine-s-acetylamino-4-methylpentanoic-acid-ib1001-emea-002796-pip01-20_en.pdf"},
    {"id":"62377","name":"P/0076/2023 : EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a waiver for clascoterone (EMEA-003330-PIP01-22)","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:43:48Z","last_updated_date":"2024-02-29T16:43:48Z","reference_number":"EMA/85651/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/p-0076-2023-ema-decision-10-march-2023-agreement-paediatric-investigation-plan-granting-waiver-clascoterone-emea-003330-pip01-22_en.pdf"},
    {"id":"62380","name":"P/0067/2023 : EMA decision of 10 March 2023 on the granting of a product specific waiver for camlipixant (EMEA-003334-PIP01-22)","type":"pip-summary","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:56:52Z","last_updated_date":"2024-02-29T16:56:52Z","reference_number":"EMA/84285/2023","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/p-0067-2023-ema-decision-10-march-2023-granting-product-specific-waiver-camlipixant-emea-003334-pip01-22_en.pdf"},
    {"id":"70668","name":"P/0380/2024 : EMA decision of 24 October 2024 on the granting of a product specific waiver for zipalertinib (EMEA-003656-PIP01-24)","type":"pip-summary","status":"Adopted","consultation_date":"","first_published_date":"2025-10-22T11:52:43Z","last_updated_date":"2025-10-22T11:52:43Z","reference_number":"EMA/484688/2024","document_url":"https://www.ema.europa.eu/en/documents/pip-summary/p-0380-2024-ema-decision-24-october-2024-granting-product-specific-waiver-zipalertinib-emea-003656-pip01-24_en.pdf"},
    {"id":"2721","name":"Working party on Herbal Medicinal Products: Final position paper on Capsicum/Capsaicin containing Herbal Medicinal Products","type":"position","status":"unknown","consultation_date":"","first_published_date":"2003-12-17T01:00:00Z","last_updated_date":"2003-12-17T01:00:00Z","reference_number":"EMEA/HMPWP/340/03 Final","document_url":"https://www.ema.europa.eu/en/documents/position/working-party-herbal-medicinal-products-final-position-paper-capsicumcapsaicin-containing-herbal-medicinal-products_en.pdf"},
    {"id":"3379","name":"Position paper regarding availability of veterinary medicinal products - extrapolation of maximum residue limits","type":"position","status":"Adopted","consultation_date":"","first_published_date":"2003-12-10T01:00:00Z","last_updated_date":"2003-12-10T01:00:00Z","reference_number":"EMEA/CVMP/457/03","document_url":"https://www.ema.europa.eu/en/documents/position/position-paper-regarding-availability-veterinary-medicinal-products-extrapolation-maximum-residue-limits_en.pdf"},
    {"id":"5609","name":"Working party on Herbal Medicinal Products: Final position paper on the use of Herbal Medicinal Products containing Estragole","type":"position","status":"unknown","consultation_date":"","first_published_date":"2004-03-03T01:00:00Z","last_updated_date":"2004-03-03T01:00:00Z","reference_number":"EMEA/HMPWP/338/03","document_url":"https://www.ema.europa.eu/en/documents/position/working-party-herbal-medicinal-products-final-position-paper-use-herbal-medicinal-products-containing-estragole_en.pdf"},
    {"id":"10841","name":"Position paper on the genotoxic and carcinogenic potential of phenolphthalein","type":"position","status":"Adopted","consultation_date":"","first_published_date":"1997-12-17T01:00:00Z","last_updated_date":"1997-12-17T01:00:00Z","reference_number":"CPMP/818/97","document_url":"https://www.ema.europa.eu/en/documents/position/position-paper-genotoxic-and-carcinogenic-potential-phenolphthalein_en.pdf"},
    {"id":"14752","name":"Draft postition paper on the use of herbal medicinal products containing pulegone and menthofuran","type":"position","status":"unknown","consultation_date":"","first_published_date":"2004-05-24T02:09:21Z","last_updated_date":"2004-05-24T02:09:21Z","reference_number":"EMEA/HMPWP/52/04","document_url":"https://www.ema.europa.eu/en/documents/position/draft-postition-paper-use-herbal-medicinal-products-containing-pulegone-and-menthofuran_en.pdf"},
    {"id":"15404","name":"Working party on Herbal Medicinal Products: Position paper on the concomitant use of laxative bulk producers with medicinal products against diarrhoea","type":"position","status":"unknown","consultation_date":"","first_published_date":"2003-06-11T02:00:00Z","last_updated_date":"2003-06-11T02:00:00Z","reference_number":"EMEA/HMPWP/60/04","document_url":"https://www.ema.europa.eu/en/documents/position/working-party-herbal-medicinal-products-position-paper-concomitant-use-laxative-bulk-producers-medicinal-products-against-diarrhoea_en.pdf"},
    {"id":"15815","name":"Position statement of the CPMP on oral contraceptives containing desogestrel or gestodene of 22 January 1997","type":"position","status":"Adopted","consultation_date":"","first_published_date":"1997-01-22T00:09:21Z","last_updated_date":"1997-01-22T00:09:21Z","reference_number":"CPMP/073/97 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/position/position-statement-cpmp-oral-contraceptives-containing-desogestrel-or-gestodene-22-january-1997_en.pdf"},
    {"id":"15959","name":"Position paper on the risks associated with the use of herbal products containing Aristolochia species","type":"position","status":"unknown","consultation_date":"","first_published_date":"2000-10-31T00:09:21Z","last_updated_date":"2000-10-31T00:09:21Z","reference_number":"EMEA/HMPWP/23/00","document_url":"https://www.ema.europa.eu/en/documents/position/position-paper-risks-associated-use-herbal-products-containing-aristolochia-species_en.pdf"},
    {"id":"15968","name":"CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 2","type":"position","status":"Adopted","consultation_date":"","first_published_date":"2011-06-28T02:00:00Z","last_updated_date":"2011-06-28T02:00:00Z","reference_number":"EMA/CHMP/BWP/303353/2010","document_url":"https://www.ema.europa.eu/en/documents/position/chmp-position-statement-creutzfeldt-jakob-disease-and-plasma-derived-and-urine-derived-medicinal-products-revision-2_en.pdf"},
    {"id":"17526","name":"CPMP position statement: dopaminergic substances and sudden sleep onset","type":"position","status":"unknown","consultation_date":"","first_published_date":"2002-02-28T01:00:00Z","last_updated_date":"2002-02-28T01:00:00Z","reference_number":"CPMP/578/02 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/position/cpmp-position-statement-dopaminergic-substances-and-sudden-sleep-onset_en.pdf"},
    {"id":"20166","name":"CPMP position statement - non-remunerated and remunerated donors: safety and suply of plasma-derived medicinal products","type":"position","status":"Adopted","consultation_date":"","first_published_date":"2002-05-30T02:00:00Z","last_updated_date":"2002-05-30T02:00:00Z","reference_number":"EMEA/CPMP/BWP/1818/02 Final","document_url":"https://www.ema.europa.eu/en/documents/position/cpmp-position-statement-non-remunerated-and-remunerated-donors-safety-and-suply-plasma-derived-medicinal-products_en.pdf"},
    {"id":"22487","name":"CHMP Position Paper on Thiomersal Implementation of the Warning Statement Relating to Sensitisation (2006)","type":"position","status":"unknown","consultation_date":"","first_published_date":"2006-02-23T00:09:21Z","last_updated_date":"2006-02-23T00:09:21Z","reference_number":"CPMP/2612/99","document_url":"https://www.ema.europa.eu/en/documents/position/chmp-position-paper-thiomersal-implementation-warning-statement-relating-sensitisation-2006_en.pdf"},
    {"id":"23172","name":"CPMP concludes its assessment of ‘third generation’ combined oral contraceptives and the risk of venous thromboembolism","type":"position","status":"unknown","consultation_date":"","first_published_date":"2001-09-28T02:00:00Z","last_updated_date":"2001-09-28T02:00:00Z","reference_number":"EMEA/CPMP/2250/01/en/Final","document_url":"https://www.ema.europa.eu/en/documents/position/cpmp-concludes-its-assessment-third-generation-combined-oral-contraceptives-and-risk-venous-thromboembolism_en.pdf"},
    {"id":"24718","name":"CPMP position statement: The use of fibrinolytics in diabetic patients","type":"position","status":"unknown","consultation_date":"","first_published_date":"2003-02-20T01:00:00Z","last_updated_date":"2003-02-20T01:00:00Z","reference_number":"EMEA/CPMP/82/03/en/Final","document_url":"https://www.ema.europa.eu/en/documents/position/cpmp-position-statement-use-fibrinolytics-diabetic-patients_en.pdf"},
    {"id":"24961","name":"CPMP Position Statement on Hib TITER","type":"position","status":"Adopted","consultation_date":"","first_published_date":"1997-01-23T00:09:21Z","last_updated_date":"1997-01-23T00:09:21Z","reference_number":"CPMP/074/97","document_url":"https://www.ema.europa.eu/en/documents/position/cpmp-position-statement-hib-titer_en.pdf"},
    {"id":"26319","name":"Working party on Herbal Medicinal Products: Final position statement on Chamomilla containing Herbal Medicinal Poducts","type":"position","status":"unknown","consultation_date":"","first_published_date":"2004-05-24T02:00:00Z","last_updated_date":"2004-05-24T02:00:00Z","reference_number":"EMEA/HMPWP/345/03/Final","document_url":"https://www.ema.europa.eu/en/documents/position/working-party-herbal-medicinal-products-final-position-statement-chamomilla-containing-herbal-medicinal-poducts_en.pdf"},
    {"id":"26949","name":"Public statement: EMEA opinions on Sildenafil citrate (Viagra)","type":"position","status":"unknown","consultation_date":"","first_published_date":"1998-07-28T02:00:00Z","last_updated_date":"1998-07-28T02:00:00Z","reference_number":"CPMP/1031/98 rev. 1","document_url":"https://www.ema.europa.eu/en/documents/position/public-statement-emea-opinions-sildenafil-citrate-viagra_en.pdf"},
    {"id":"27323","name":"Position paper regarding availability of products for minor uses and minor species (MUMS)","type":"position","status":"Adopted","consultation_date":"","first_published_date":"2004-07-14T02:00:00Z","last_updated_date":"2004-07-14T02:00:00Z","reference_number":"EMEA/CVMP/477/03/Final","document_url":"https://www.ema.europa.eu/en/documents/position/position-paper-regarding-availability-products-minor-uses-and-minor-species-mums_en.pdf"},
    {"id":"30287","name":"EMEA position statement on the use of placebo in clinical trials with regard to the revised Declaration of Helsinki","type":"position","status":"unknown","consultation_date":"","first_published_date":"2001-06-28T02:00:00Z","last_updated_date":"2001-06-28T02:00:00Z","reference_number":"EMEA/17424/01","document_url":"https://www.ema.europa.eu/en/documents/position/emea-position-statement-use-placebo-clinical-trials-regard-revised-declaration-helsinki_en.pdf"},
    {"id":"31104","name":"Working party on Herbal Medicinal Products: Final position paper on the use of Herbal Medicinal Products containing Methyleugenol","type":"position","status":"unknown","consultation_date":"","first_published_date":"2004-03-03T01:00:00Z","last_updated_date":"2004-03-03T01:00:00Z","reference_number":"EMEA/HMPWP/337/03","document_url":"https://www.ema.europa.eu/en/documents/position/working-party-herbal-medicinal-products-final-position-paper-use-herbal-medicinal-products-containing-methyleugenol_en.pdf"},
    {"id":"31329","name":"CPMP assessment on the basis of the ad hoc Expert Working Group concerning gestodene or desogestrel containing products and the risk of cardio-vascular disorders","type":"position","status":"Adopted","consultation_date":"","first_published_date":"1995-10-27T00:09:21Z","last_updated_date":"1995-10-27T00:09:21Z","reference_number":"CPMP/PhV/690/95 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/position/cpmp-assessment-basis-ad-hoc-expert-working-group-concerning-gestodene-or-desogestrel-containing-products-and-risk-cardio-vascular-disorders_en.pdf"},
    {"id":"32521","name":"Working party on Herbal Medicinal Products: Final position paper on the allergenic potency of Herbal Medicinal Products containing soya or peanut protein","type":"position","status":"unknown","consultation_date":"","first_published_date":"2004-06-11T02:00:00Z","last_updated_date":"2004-06-11T02:00:00Z","reference_number":"EMEA/HMPWP/37/04","document_url":"https://www.ema.europa.eu/en/documents/position/working-party-herbal-medicinal-products-final-position-paper-allergenic-potency-herbal-medicinal-products-containing-soya-or-peanut-protein_en.pdf"},
    {"id":"32614","name":"CHMP/CAT position statement on Creutzfeldt-Jakob disease and advanced-therapy medicinal products","type":"position","status":"Adopted","consultation_date":"","first_published_date":"2011-06-28T02:00:00Z","last_updated_date":"2011-06-28T02:00:00Z","reference_number":"EMA/CHMP/BWP/353632/2010","document_url":"https://www.ema.europa.eu/en/documents/position/chmpcat-position-statement-creutzfeldt-jakob-disease-and-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"35150","name":"Position statement of the CPMP on oral contraceptives containing desogestrel or gestodene of 17 April 1996","type":"position","status":"Adopted","consultation_date":"","first_published_date":"1996-04-17T02:09:21Z","last_updated_date":"1996-04-17T02:09:21Z","reference_number":"CPMP/374/96","document_url":"https://www.ema.europa.eu/en/documents/position/position-statement-cpmp-oral-contraceptives-containing-desogestrel-or-gestodene-17-april-1996_en.pdf"},
    {"id":"37115","name":"CPMP position statement on West Nile virus and plasma-derived medicinal products","type":"position","status":"Adopted","consultation_date":"","first_published_date":"2003-07-25T02:00:00Z","last_updated_date":"2003-07-25T02:00:00Z","reference_number":"EMEA/CPMP/BWP/3752/03/adopted","document_url":"https://www.ema.europa.eu/en/documents/position/cpmp-position-statement-west-nile-virus-and-plasma-derived-medicinal-products_en.pdf"},
    {"id":"39403","name":"Working party on Herbal Medicinal Products: Final position paper on the use of Herbal Medicinal Products containing Asarone","type":"position","status":"unknown","consultation_date":"","first_published_date":"2003-12-17T01:00:00Z","last_updated_date":"2003-12-17T01:00:00Z","reference_number":"EMEA/HMPWP/41/03 Final","document_url":"https://www.ema.europa.eu/en/documents/position/working-party-herbal-medicinal-products-final-position-paper-use-herbal-medicinal-products-containing-asarone_en.pdf"},
    {"id":"41388","name":"Position statement of the CPMP on oral contraceptives containing desogestrel or gestodene of 27 October 1995","type":"position","status":"Adopted","consultation_date":"","first_published_date":"1995-10-27T00:09:21Z","last_updated_date":"1995-10-27T00:09:21Z","reference_number":"CPMP/PhV/696/95","document_url":"https://www.ema.europa.eu/en/documents/position/position-statement-cpmp-oral-contraceptives-containing-desogestrel-or-gestodene-27-october-1995_en.pdf"},
    {"id":"50294","name":"CHMP position statement on quality and safety assessment for the Plasma Master File (PMF) certification with regard to donor deferral criteria for sexual risk behaviour","type":"position","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T15:06:00Z","last_updated_date":"2021-02-26T15:06:00Z","reference_number":"EMA/CHMP/BWP/76987/2021","document_url":"https://www.ema.europa.eu/en/documents/position/chmp-position-statement-quality-and-safety-assessment-plasma-master-file-pmf-certification-regard-donor-deferral-criteria-sexual-risk-behaviour_en.pdf"},
    {"id":"60846","name":"Azithromycin Article-31 referral - Notification","type":"position","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T11:52:00Z","last_updated_date":"2023-11-10T11:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/position/azithromycin-article-31-referral-notification_en.pdf"},
    {"id":"66697","name":"P/0188/2024: EMA decision of 14 June 2024 on the agreement of a paediatric investigation plan and on the granting of a waiver for trofinetide (EMEA-003587-PIP01-24) ","type":"position","status":"unknown","consultation_date":"","first_published_date":"2025-02-12T13:59:55Z","last_updated_date":"2025-02-12T13:59:55Z","reference_number":"EMA/251788/2024","document_url":"https://www.ema.europa.eu/en/documents/position/p-0188-2024-ema-decision-14-june-2024-agreement-paediatric-investigation-plan-granting-waiver-trofinetide-emea-003587-pip01-24_en.pdf"},
    {"id":"2547","name":"Fluocinolone acetonide (intravitreal implant in applicator): List of nationally authorised medicinal products - PSUSA/00010224/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-13T02:00:00Z","last_updated_date":"2016-10-18T16:32:02Z","reference_number":"EMA/332750/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-intravitreal-implant-applicator-list-nationally-authorised-medicinal-products-psusa00010224201508_en.pdf"},
    {"id":"2577","name":"Tapentadol: List of nationally authorised medicinal products - PSUSA/00002849/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T12:00:00Z","last_updated_date":"2016-10-19T11:45:00Z","reference_number":"EMA/448789/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tapentadol-list-nationally-authorised-medicinal-products-psusa00002849201411_en.pdf"},
    {"id":"2598","name":"Olodaterol: List of nationally authorised medicinal products - PSUSA/00010245/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-15T02:00:00Z","last_updated_date":"2016-10-18T12:49:00Z","reference_number":"EMA/681144/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodaterol-list-nationally-authorised-medicinal-products-psusa00010245201503_en.pdf"},
    {"id":"2661","name":"Gadodiamide: List of nationally authorised medicinal products - PSUSA/00001503/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-10-19T12:37:30Z","reference_number":"EMA/203316/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadodiamide-list-nationally-authorised-medicinal-products-psusa00001503201504_en.pdf"},
    {"id":"2687","name":"Methylphenidate: List of nationally authorised medicinal products -  PSUSA/00002024/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T18:46:00Z","last_updated_date":"2018-06-19T18:48:42Z","reference_number":"EMA/415385/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-list-nationally-authorised-medicinal-products-psusa00002024201710_en.pdf"},
    {"id":"2778","name":"Lactitol: List of nationally authorised medicinal products - PSUSA/00001819/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-10-17T19:17:15Z","reference_number":"EMA/361589/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/lactitol-list-nationally-authorised-medicinal-products-psusa00001819201509_en.pdf"},
    {"id":"2838","name":"Ropinirole : List of nationally authorised medicinal products - PSUSA/00002661/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-03T16:29:00Z","last_updated_date":"2017-05-03T16:35:41Z","reference_number":"EMA/280628/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropinirole-list-nationally-authorised-medicinal-products-psusa00002661201607_en.pdf"},
    {"id":"2925","name":"Terbinafine: List of nationally authorised medicinal products - PSUSA/00002896/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-18T13:00:00Z","last_updated_date":"2018-05-18T13:00:00Z","reference_number":"EMA/298399/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/terbinafine-list-nationally-authorised-medicinal-products-psusa00002896201709_en.pdf"},
    {"id":"2948","name":"Fluocinolone acetonide (intravitreal implant in applicator): List of nationally authorised medicinal products - PSUSA/00010224/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T02:00:00Z","last_updated_date":"2016-10-18T16:32:01Z","reference_number":"EMA/230007/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-intravitreal-implant-applicator-list-nationally-authorised-medicinal-products-psusa00010224201502_en.pdf"},
    {"id":"3036","name":"Aceclofenac : List of nationally authorised medicinal products - PSUSA/00000022/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T12:13:00Z","last_updated_date":"2017-12-01T12:15:00Z","reference_number":"EMA/787572/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/aceclofenac-list-nationally-authorised-medicinal-products-psusa00000022201703_en.pdf"},
    {"id":"3051","name":"Famotidine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001350/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-12T13:49:00Z","last_updated_date":"2018-07-12T13:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350201709_sv.pdf"}},
    {"id":"3160","name":"Trimetazidine: CMDh scientific conclusions, amendments to product information and implementation timetable - EMEA/H/N/PSR/0001 and EMEA/H/N/PSR/J/0002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-04T02:00:00Z","last_updated_date":"2016-10-04T02:00:00Z","reference_number":"EMA/283107/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsr0001-and-emeahnpsrj0002_en.pdf"},
    {"id":"3220","name":"Amitriptyline / perphenazine: List of nationally authorised medicinal products - PSUSA/00000170/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-17T19:40:18Z","reference_number":"EMA/829495/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-perphenazine-list-nationally-authorised-medicinal-products-psusa00000170201501_en.pdf"},
    {"id":"3231","name":"Fenspiride: List of nationally authorised medicinal products - PSUSA/00001368/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-12T17:52:00Z","last_updated_date":"2017-12-12T17:54:19Z","reference_number":"EMA/776067/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenspiride-list-nationally-authorised-medicinal-products-psusa00001368201704_en.pdf"},
    {"id":"3259","name":"Benserazide / levodopa: List of nationally authorised medicinal products - PSUSA/00000330/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T17:00:00Z","last_updated_date":"2018-02-09T17:00:00Z","reference_number":"EMA/88406/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/benserazide-levodopa-list-nationally-authorised-medicinal-products-psusa00000330201706_en.pdf"},
    {"id":"3346","name":"Mycophenolic acid (apart from mycophenolate mofetil): List of nationally authorised medicinal products - PSUSA/00010243/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-12T10:05:00Z","last_updated_date":"2016-12-12T10:08:00Z","reference_number":"EMA/848467/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/mycophenolic-acid-apart-mycophenolate-mofetil-list-nationally-authorised-medicinal-products-psusa00010243201605_en.pdf"},
    {"id":"3362","name":"Paricalcitol: List of nationally authorised medicinal products - PSUSA/00002316/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-04-10T19:15:00Z","last_updated_date":"2017-04-10T19:15:00Z","reference_number":"EMA/236467/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/paricalcitol-list-nationally-authorised-medicinal-products-psusa00002316201608_en.pdf"},
    {"id":"3468","name":"Daunorubicin: List of nationally authorised medicinal products - PSUSA/00000936/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T14:00:00Z","last_updated_date":"2016-10-17T20:25:31Z","reference_number":"EMA/238885/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/daunorubicin-list-nationally-authorised-medicinal-products-psusa00000936201506_en.pdf"},
    {"id":"3474","name":"Everolimus (indicated for rejection of transplanted organs): List of nationally authorised medicinal products - PSUSA/00010269/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-13T02:00:00Z","last_updated_date":"2016-10-18T14:02:18Z","reference_number":"EMA/333388/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/everolimus-indicated-rejection-transplanted-organs-list-nationally-authorised-medicinal-products-psusa00010269201507_en.pdf"},
    {"id":"3515","name":"Calcium carbonate / famotidine / magnesium hydroxide: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001351/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2016-10-18T15:41:07Z","reference_number":"EMA/540919/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201409_en.pdf"},
    {"id":"3557","name":"Methysergide: List of nationally authorised medicinal products -PSUSA/00002030/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-18T11:46:14Z","reference_number":"EMA/829520/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/methysergide-list-nationally-authorised-medicinal-products-psusa00002030201502_en.pdf"},
    {"id":"3582","name":"Human coagulation factor VIII (inhibitor bypassing fraction): List of nationally authorised medicinal products - PSUSA/00009174/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-05T12:10:00Z","last_updated_date":"2017-10-05T12:10:00Z","reference_number":"EMA/658413/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-viii-inhibitor-bypassing-fraction-list-nationally-authorised-medicinal-products-psusa00009174201702_en.pdf"},
    {"id":"3600","name":"Gadoxetic acid disodium: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00001509/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-10-18T16:56:38Z","reference_number":"EMA/200892/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001509201504_en.pdf"},
    {"id":"3672","name":"Betahistine: List of nationally authorised medicinal products - PSUSA/00000389/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T18:50:00Z","last_updated_date":"2018-09-10T18:53:21Z","reference_number":"EMA/608492/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/betahistine-list-nationally-authorised-medicinal-products-psusa00000389201712_en.pdf"},
    {"id":"3729","name":"Alprostadil (indicated in peripheral arterial occlusive diseases): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000111/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-04T13:20:00Z","last_updated_date":"2018-06-04T13:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000111201707_sv.pdf"}}    {"id":"3746","name":"Alprostadil (erectile dysfunction): List of nationally authorised medicinal products - PSUSA/00000110/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T16:36:00Z","last_updated_date":"2016-11-18T16:43:00Z","reference_number":"EMA/756484/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprostadil-erectile-dysfunction-list-nationally-authorised-medicinal-products-psusa00000110201601_en.pdf"},
    {"id":"3753","name":"Omeprazole: List of nationally authorised medicinal products - PSUSA/00002215/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T16:00:00Z","last_updated_date":"2017-12-08T16:00:00Z","reference_number":"EMA/817628/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/omeprazole-list-nationally-authorised-medicinal-products-psusa00002215201704_en.pdf"},
    {"id":"3758","name":"Varicella zoster-immunoglobulin : List of nationally authorised medicinal products - PSUSA/00010266/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-07T16:43:00Z","last_updated_date":"2017-09-07T16:45:18Z","reference_number":"EMA/594374/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/varicella-zoster-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00010266201612_en.pdf"},
    {"id":"3808","name":"Triamcinolone (intraocular formulations): List of nationally authorised medicinal products - PSUSA/00010292/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-06T17:20:00Z","last_updated_date":"2017-11-06T17:23:00Z","reference_number":"EMA/726434/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/triamcinolone-intraocular-formulations-list-nationally-authorised-medicinal-products-psusa00010292201703_en.pdf"},
    {"id":"3833","name":"Bemetizide / triamterene: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00009076/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-21T02:00:00Z","last_updated_date":"2016-10-18T14:01:11Z","reference_number":"EMA/285585/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/bemetizide-triamterene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009076201506_en.pdf"},
    {"id":"3856","name":"Carboplatin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000559/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T16:24:00Z","last_updated_date":"2017-01-03T16:43:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559201601_no.pdf"}},
    {"id":"3903","name":"Etifoxine: List of nationally authorised medicinal products - PSUSA/00001321/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T02:00:00Z","last_updated_date":"2016-10-18T14:02:15Z","reference_number":"EMA/390483/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/etifoxine-list-nationally-authorised-medicinal-products-psusa00001321201410_en.pdf"},
    {"id":"3915","name":"Bismuth subcitrate potassium / metronidazole / tetracycline: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00010199/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-10-18T14:01:08Z","reference_number":"EMA/194675/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201505_en.pdf"},
    {"id":"3996","name":"Germanium (68Ge) chloride / gallium (68Ga) chloride : List of nationally authorised medicinal products - PSUSA/00010364/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-15T12:10:00Z","last_updated_date":"2017-05-15T12:12:06Z","reference_number":"EMA/305184/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/germanium-68ge-chloride-gallium-68ga-chloride-list-nationally-authorised-medicinal-products-psusa00010364201609_en.pdf"},
    {"id":"4025","name":"Human fibrinogen: List of nationally authorised medicinal products - PSUSA/00001624/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-11T02:00:00Z","last_updated_date":"2016-10-17T17:35:13Z","reference_number":"EMA/256022/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-fibrinogen-list-nationally-authorised-medicinal-products-psusa00001624201506_en.pdf"},
    {"id":"4034","name":"Leuprorelin: List of nationally authorised medicinal products - PSUSA/00001844/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-04T13:30:00Z","last_updated_date":"2018-06-04T13:45:44Z","reference_number":"EMA/365906/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/leuprorelin-list-nationally-authorised-medicinal-products-psusa00001844201707_en.pdf"},
    {"id":"4164","name":"Isoflurane: List of nationally authorised medicinal products - PSUSA/00001786/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T12:35:00Z","last_updated_date":"2017-07-10T12:35:00Z","reference_number":"EMA/433189/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoflurane-list-nationally-authorised-medicinal-products-psusa00001786201610_en.pdf"},
    {"id":"4172","name":"Nitrofurantoin / nifurtoinol: List of nationally authorised medicinal products - PSUSA/00002174/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T02:00:00Z","last_updated_date":"2016-10-18T12:37:33Z","reference_number":"EMA/230060/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrofurantoin-nifurtoinol-list-nationally-authorised-medicinal-products-psusa00002174201502_en.pdf"},
    {"id":"4276","name":"Haemophilus type b conjugate vaccines : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001584/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T17:24:00Z","last_updated_date":"2017-11-23T17:36:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/haemophilus-type-b-conjugate-vaccines-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001584201702_no.pdf"}},
    {"id":"4299","name":"Hydrochlorothiazide / lisinopril: List of nationally authorised medicinal products - PSUSA/00001654/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-30T02:00:00Z","last_updated_date":"2016-10-17T17:35:16Z","reference_number":"EMA/649082/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-lisinopril-list-nationally-authorised-medicinal-products-psusa00001654201602_en.pdf"},
    {"id":"4322","name":"Misoprostol (gastrointestinal indication): List of nationally authorised medicinal products - PSUSA/00010291/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-08T01:00:00Z","last_updated_date":"2016-10-18T12:21:20Z","reference_number":"EMA/178486/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gastrointestinal-indication-list-nationally-authorised-medicinal-products-psusa00010291201506_en.pdf"},
    {"id":"4324","name":"Pilocarpine (ophthalmic formulation): List of nationally authorised medicinal products - PSUSA/00002410/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T16:00:00Z","last_updated_date":"2017-05-12T16:00:00Z","reference_number":"EMA/288255/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/pilocarpine-ophthalmic-formulation-list-nationally-authorised-medicinal-products-psusa00002410201608_en.pdf"},
    {"id":"4340","name":"Ciprofloxacin hydrochloride, hydrocortisone: List of nationally authorised medicinal products - PSUSA/00000774/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-06T14:00:00Z","last_updated_date":"2016-10-17T20:25:32Z","reference_number":"EMA/532296/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-hydrochloride-hydrocortisone-list-nationally-authorised-medicinal-products-psusa00000774201411_en.pdf"},
    {"id":"4416","name":"Ampicillin / sulbactam: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00000197/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-30T01:00:00Z","last_updated_date":"2016-10-17T19:40:13Z","reference_number":"EMA/801362/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/ampicillin-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000197201502_en.pdf"},
    {"id":"4432","name":"Topotecan: List of nationally authorised medicinal products - PSUSA/00002997/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-22T13:00:00Z","last_updated_date":"2016-10-17T20:16:40Z","reference_number":"EMA/52102/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/topotecan-list-nationally-authorised-medicinal-products-psusa00002997201505_en.pdf"},
    {"id":"4463","name":"Glipizide: List of nationally authorised medicinal products - PSUSA/00001535/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-05T02:00:00Z","last_updated_date":"2016-10-17T15:38:43Z","reference_number":"EMA/639604/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/glipizide-list-nationally-authorised-medicinal-products-psusa00001535201601_en.pdf"},
    {"id":"4472","name":"Levocabastine: List of nationally authorised medicinal products - PSUSA/00001849/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T16:45:00Z","last_updated_date":"2018-07-19T16:45:00Z","reference_number":"EMA/498812/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/levocabastine-list-nationally-authorised-medicinal-products-psusa00001849201711_en.pdf"},
    {"id":"4567","name":"Botulinum toxin a - haemagglutinin complex: CMDh scientific conclusions and grounds for the variation, amendments to the product information, conditions to the MA and timetable for the implementation - PSUSA/00000427/201...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-25T02:00:00Z","last_updated_date":"2016-10-25T19:31:49Z","reference_number":"EMA/706150/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-conditions-ma-and-timetable-implementation-psusa00000427201_en.pdf"},
    {"id":"4585","name":"Carvedilol / ivabradine: List of nationally authorised medicinal products - PSUSA/00010586/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T13:00:00Z","last_updated_date":"2018-06-29T13:00:00Z","reference_number":"EMA/437147/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/carvedilol-ivabradine-list-nationally-authorised-medicinal-products-psusa00010586201711_en.pdf"},
    {"id":"4595","name":"Dexamethasone (apart from centrally authorised products): List of nationally authorised medicinal products - PSUSA/00000973/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-30T16:05:00Z","last_updated_date":"2016-11-30T16:14:00Z","reference_number":"EMA/805214/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamethasone-apart-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00000973201601_en.pdf"},
    {"id":"4596","name":"Tretinoin (topical formulations): List of nationally authorised medicinal products - PSUSA/00003016/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-24T18:00:00Z","last_updated_date":"2018-05-24T18:09:40Z","reference_number":"EMA/333549/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/tretinoin-topical-formulations-list-nationally-authorised-medicinal-products-psusa00003016201708_en.pdf"},
    {"id":"4637","name":"Influenza vaccine (split virion, inactivated, prepared in cell cultures): List of nationally authorised medicinal products - PSUSA/00010299/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T17:08:00Z","last_updated_date":"2017-10-26T17:33:46Z","reference_number":"EMA/715528/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-prepared-cell-cultures-list-nationally-authorised-medicinal-products-psusa00010299201703_en.pdf"},
    {"id":"4657","name":"Midodrine: List of nationally authorised medicinal products - PSUSA/00003178/201606","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-13T17:42:00Z","last_updated_date":"2017-02-13T17:44:02Z","reference_number":"EMA/106582/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/midodrine-list-nationally-authorised-medicinal-products-psusa00003178201606_en.pdf"},
    {"id":"4680","name":"Didanosine: List of nationally authorised medicinal products - PSUSA/00001054/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-13T14:00:00Z","last_updated_date":"2016-10-17T19:52:25Z","reference_number":"EMA/406319/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/didanosine-list-nationally-authorised-medicinal-products-psusa00001054201510_en.pdf"},
    {"id":"4682","name":"Dexamfetamine: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000986/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-11T18:30:00Z","last_updated_date":"2018-06-11T18:32:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986201709_no.pdf"}},
    {"id":"4694","name":"Desflurane: List of nationally authorised medicinal products - PSUSA/00000958/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T12:50:00Z","last_updated_date":"2018-05-23T13:08:20Z","reference_number":"EMA/306574/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/desflurane-list-nationally-authorised-medicinal-products-psusa00000958201709_en.pdf"},
    {"id":"4800","name":"Clindamycin phosphate / tretinoin: List of nationally authorised medicinal products - PSUSA/00010080/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-16T12:00:00Z","last_updated_date":"2018-04-16T12:02:18Z","reference_number":"EMA/234056/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/clindamycin-phosphate-tretinoin-list-nationally-authorised-medicinal-products-psusa00010080201707_en.pdf"},
    {"id":"4892","name":"Lisdexamfetamine: List of nationally authorised medicinal products - PSUSA/00010289/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-10-18T10:40:08Z","reference_number":"EMA/249896/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa00010289201508_en.pdf"},
    {"id":"4898","name":"Influenza vaccine (surface antigen, inactivated): List of nationally authorised medicinal products - PSUSA/00001744/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-10-17T18:39:11Z","reference_number":"EMA/75051/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa00001744201504_en.pdf"},
    {"id":"4900","name":"Amikacin: List of nationally authorised medicinal products - PSUSA/00000143/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T13:10:00Z","last_updated_date":"2018-03-06T13:39:17Z","reference_number":"EMA/141741/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amikacin-list-nationally-authorised-medicinal-products-psusa00000143201706_en.pdf"},
    {"id":"4920","name":"Piroxicam: List of nationally authorised medicinal products - PSUSA/00002438/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-05T17:20:00Z","last_updated_date":"2017-12-05T17:20:00Z","reference_number":"EMA/806830/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/piroxicam-list-nationally-authorised-medicinal-products-psusa00002438201704_en.pdf"},
    {"id":"4945","name":"Dextromethorphan: List of nationally authorised medicinal products - PSUSA/00001009/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-30T14:00:00Z","last_updated_date":"2016-10-17T20:37:50Z","reference_number":"EMA/574895/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/dextromethorphan-list-nationally-authorised-medicinal-products-psusa00001009201511_en.pdf"},
    {"id":"4988","name":"Tetanus vaccines: List of nationally authorised medicinal products - PSUSA/00002910/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T18:27:00Z","last_updated_date":"2018-09-10T18:31:21Z","reference_number":"EMA/608212/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/tetanus-vaccines-list-nationally-authorised-medicinal-products-psusa00002910201801_en.pdf"},
    {"id":"5085","name":"Nimesulide (topical formulations): List of nationally authorised medicinal products - PSUSA/00002165/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-10-18T12:37:31Z","reference_number":"EMA/189858/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimesulide-topical-formulations-list-nationally-authorised-medicinal-products-psusa00002165201506_en.pdf"},
    {"id":"5086","name":"Fluocinolone acetonide (intravitreal implant in applicator): List of nationally authorised medicinal products - PSUSA/00010224/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-16T12:09:00Z","last_updated_date":"2018-04-16T12:13:00Z","reference_number":"EMA/231706/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-intravitreal-implant-applicator-list-nationally-authorised-medicinal-products-psusa00010224201708_en.pdf"},
    {"id":"5110","name":"Atomoxetine: List of nationally authorised medicinal products - PSUSA/00000262/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-07T02:00:00Z","last_updated_date":"2016-10-17T19:40:05Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/atomoxetine-list-nationally-authorised-medicinal-products-psusa00000262201411_en.pdf"},
    {"id":"5115","name":"Doxazosin: CMDh Scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00001169/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T17:00:00Z","last_updated_date":"2016-10-19T17:00:00Z","reference_number":"EMA/690455/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/doxazosin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001169201512_en.pdf"},
    {"id":"5116","name":"Diphtheria / tetanus / pertussis (acellular, component) / haemophilus type b conjugate vaccine (adsorbed): List of nationally authorised medicinal products - PSUSA/00001121/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-15T18:00:00Z","last_updated_date":"2018-06-15T18:00:00Z","reference_number":"EMA/373602/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-pertussis-acellular-component-haemophilus-type-b-conjugate-vaccine-adsorbed-list-nationally-authorised-medicinal-products-psusa00001121201710_en.pdf"},
    {"id":"5178","name":"Ethinylestradiol / gestodene (transdermal application): List of nationally authorised medicinal products - PSUSA/00010145/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-16T15:03:00Z","last_updated_date":"2018-04-16T15:05:00Z","reference_number":"EMA/235952/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-gestodene-transdermal-application-list-nationally-authorised-medicinal-products-psusa00010145201708_en.pdf"},
    {"id":"5179","name":"Influenza vaccine (surface antigen, inactivated, virosome): List of nationally authorised medicinal products - PSUSA/00001746/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T01:00:00Z","last_updated_date":"2016-10-17T18:39:10Z","reference_number":"EMA/845175/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-virosome-list-nationally-authorised-medicinal-products-psusa00001746201504_en.pdf"},
    {"id":"5204","name":"Testosterone (all formulations apart from topical use and testosterone undecanoate injection): CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementa...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T16:30:00Z","last_updated_date":"2016-11-07T18:12:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementa_no.pdf"}},
    {"id":"5239","name":"Flunarizine: List of nationally authorised medicinal products - PSUSA/00001416/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-10-18T16:32:00Z","reference_number":"EMA/50389/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/flunarizine-list-nationally-authorised-medicinal-products-psusa00001416201505_en.pdf"},
    {"id":"5278","name":"Ethinylestradiol  / gestodene (transdermal application): List of nationally authorised medicinal products - PSUSA/00010145/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-17T13:10:00Z","last_updated_date":"2017-11-17T13:10:00Z","reference_number":"EMA/757865/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-gestodene-transdermal-application-list-nationally-authorised-medicinal-products-psusa00010145201702_en.pdf"},
    {"id":"5286","name":"Solifenacin/tamsulosine: List of nationally authorised medicinal products - PSUSA/00010285/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-11T12:00:00Z","last_updated_date":"2016-10-18T11:56:08Z","reference_number":"EMA/256117/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/solifenacintamsulosine-list-nationally-authorised-medicinal-products-psusa00010285201507_en.pdf"},
    {"id":"5393","name":"Naltrexone: List of nationally authorised medicinal products - PSUSA/00002117/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T02:00:00Z","last_updated_date":"2016-10-18T12:21:24Z","reference_number":"EMA/437327/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/naltrexone-list-nationally-authorised-medicinal-products-psusa00002117201511_en.pdf"},
    {"id":"5431","name":"Lidocaine / prilocaine (not centrally authorised product): List of nationally authorised medicinal products - PSUSA/00001867/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T13:20:00Z","last_updated_date":"2017-12-08T13:20:00Z","reference_number":"EMA/817351/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-prilocaine-not-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00001867201703_en.pdf"},
    {"id":"5531","name":"Lovastatin: List of nationally authorised medicinal products - PSUSA/00010051/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T12:54:00Z","last_updated_date":"2017-03-10T12:57:29Z","reference_number":"EMA/169827/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/lovastatin-list-nationally-authorised-medicinal-products-psusa00010051201607_en.pdf"},
    {"id":"5547","name":"Mifepristone: List of nationally authorised medicinal products - PSUSA/00002060/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:13:00Z","last_updated_date":"2018-01-16T16:14:50Z","reference_number":"EMA/9653/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/mifepristone-list-nationally-authorised-medicinal-products-psusa00002060201705_en.pdf"},
    {"id":"5560","name":"Sertindole: List of nationally authorised medicinal products - PSUSA/00002695/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-08T11:00:00Z","last_updated_date":"2016-10-18T11:56:07Z","reference_number":"EMA/178759/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/sertindole-list-nationally-authorised-medicinal-products-psusa00002695201507_en.pdf"},
    {"id":"5590","name":"Magnesium sulphate / sodium sulphate / potassium sulphate: List of nationally authorised medicinal products - PSUSA/00010239/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-13T02:00:00Z","last_updated_date":"2016-10-18T10:40:00Z","reference_number":"EMA/608890/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulphate-sodium-sulphate-potassium-sulphate-list-nationally-authorised-medicinal-products-psusa00010239201602_en.pdf"},
    {"id":"5592","name":"Zolmitriptan: List of nationally authorised medicinal products - PSUSA/ 00003150/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T15:55:00Z","last_updated_date":"2017-10-27T15:58:03Z","reference_number":"EMA/716828/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/zolmitriptan-list-nationally-authorised-medicinal-products-psusa-00003150201703_en.pdf"},
    {"id":"5618","name":"Domperidone: List of nationally authorised medicinal products - PSUSA/00001158/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T14:00:00Z","last_updated_date":"2016-10-17T19:52:24Z","reference_number":"EMA/706059/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/domperidone-list-nationally-authorised-medicinal-products-psusa00001158201501_en.pdf"},
    {"id":"5628","name":"Levonorgestrel / ethinylestradiol, ethinylestradiol (combination pack): List of nationally authorised medicinal products - PSUSA/00010442/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-14T17:45:00Z","last_updated_date":"2017-02-14T17:46:00Z","reference_number":"EMA/110538/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-list-nationally-authorised-medicinal-products-psusa00010442201607_en.pdf"},
    {"id":"5630","name":"Diphtheria tetanus vaccines (adsorbed): List of nationally authorised medicinal products - PSUSA/00001128/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-09T13:00:00Z","last_updated_date":"2016-10-17T19:52:26Z","reference_number":"EMA/99511/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-vaccines-adsorbed-list-nationally-authorised-medicinal-products-psusa00001128201505_en.pdf"},
    {"id":"5640","name":"Ethinylestradiol / gestodene (transdermal application): List of nationally authorised medicinal products - PSUSA/00010145/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-04-26T15:30:00Z","last_updated_date":"2017-04-26T15:30:00Z","reference_number":"EMA/265615/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-gestodene-transdermal-application-list-nationally-authorised-medicinal-products-psusa00010145201608_en.pdf"},
    {"id":"5642","name":"Influenza vaccine (split virion, inactivated; non centrally authorised products): List of nationally authorised medicinal products - PSUSA/00010298/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-17T18:39:13Z","reference_number":"EMA/829840/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00010298201504_en.pdf"},
    {"id":"5658","name":"Racecadotril: List of nationally authorised medicinal products - PSUSA/00002602/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T17:00:00Z","last_updated_date":"2017-12-11T17:00:00Z","reference_number":"EMA/812544/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/racecadotril-list-nationally-authorised-medicinal-products-psusa00002602201703_en.pdf"},
    {"id":"5697","name":"Ketamine: List of nationally authorised medicinal products - PSUSA/00001804/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-10-17T19:03:13Z","reference_number":"EMA/580856/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketamine-list-nationally-authorised-medicinal-products-psusa00001804201512_en.pdf"},
    {"id":"5850","name":"Oxaliplatin: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00002229/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T01:00:00Z","last_updated_date":"2016-10-18T13:02:21Z","reference_number":"EMA/190948/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201504_en.pdf"},
    {"id":"5855","name":"Isotretinoin (oral formulations): List of nationally authorised medicinal products - PSUSA/00010488/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-05T15:28:00Z","last_updated_date":"2017-12-05T15:31:00Z","reference_number":"EMA/787886/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa00010488201705_en.pdf"},
    {"id":"5892","name":"Influenza vaccine (split virion, inactivated) (non centrally authorised products): List of nationally authorised medicinal products - PSUSA/00010298/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T17:08:00Z","last_updated_date":"2017-10-26T17:21:00Z","reference_number":"EMA/715509/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00010298201703_en.pdf"},
    {"id":"5933","name":"Lactulose: List of nationally authorised medicinal products - PSUSA/00001821/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-16T15:20:00Z","last_updated_date":"2017-01-16T15:23:02Z","reference_number":"EMA/28658/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/lactulose-list-nationally-authorised-medicinal-products-psusa00001821201605_en.pdf"},
    {"id":"5966","name":"Hydrochlorothiazide / spironolactone: List of nationally authorised medicinal products - PSUSA/00001662/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T18:38:00Z","last_updated_date":"2018-09-13T18:40:47Z","reference_number":"EMA/619695/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-spironolactone-list-nationally-authorised-medicinal-products-psusa00001662201801_en.pdf"},
    {"id":"5999","name":"Beta-alanine: List of nationally authorised medicinal products - PSUSA/00010510/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-29T17:55:00Z","last_updated_date":"2017-09-29T17:56:31Z","reference_number":"EMA/635953/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/beta-alanine-list-nationally-authorised-medicinal-products-psusa00010510201701_en.pdf"},
    {"id":"6009","name":"Gabapentin: List of nationally authorised medicinal products - PSUSA/00001499/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T17:48:00Z","last_updated_date":"2016-11-29T17:53:56Z","reference_number":"EMA/751375/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gabapentin-list-nationally-authorised-medicinal-products-psusa00001499201602_en.pdf"},
    {"id":"6048","name":"Fenofibrate: List of nationally authorised medicinal products - PSUSA/00001362/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T18:40:00Z","last_updated_date":"2018-04-18T18:40:27Z","reference_number":"EMA/243033/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenofibrate-list-nationally-authorised-medicinal-products-psusa00001362201707_en.pdf"},
    {"id":"6063","name":"Furosemide: List of nationally authorised medicinal products - PSUSA/00001491/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-10-18T13:42:37Z","reference_number":"EMA/729829/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/furosemide-list-nationally-authorised-medicinal-products-psusa00001491201501_en.pdf"},
    {"id":"6166","name":"Artemether / lumefantrin (dispersible tablet): List of nationally authorised medicinal products - PSUSA/0009060/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2016-10-17T19:40:11Z","reference_number":"EMA/833224/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/artemether-lumefantrin-dispersible-tablet-list-nationally-authorised-medicinal-products-psusa0009060201504_en.pdf"},
    {"id":"6167","name":"Paroxetine: List of nationally authorised medicinal products -    PSUSA/00002319/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-11T17:45:00Z","last_updated_date":"2018-09-11T17:51:34Z","reference_number":"EMA/612747/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/paroxetine-list-nationally-authorised-medicinal-products-psusa00002319201712_en.pdf"},
    {"id":"6174","name":"Desogestrel: List of nationally authorised medicinal products - PSUSA/00000966/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T11:00:00Z","last_updated_date":"2017-03-16T11:00:00Z","reference_number":"EMA/179039/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/desogestrel-list-nationally-authorised-medicinal-products-psusa00000966201607_en.pdf"},
    {"id":"6190","name":"Benzalkonium chloride / chlorhexidine digluconate: List of nationally authorised medicinal products - PSUSA/00010070/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T12:06:22Z","reference_number":"EMA/422664/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzalkonium-chloride-chlorhexidine-digluconate-list-nationally-authorised-medicinal-products-psusa00010070201611_en.pdf"},
    {"id":"6206","name":"Cefoperazone: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation -  PSUSA/00000597/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-25T02:00:00Z","last_updated_date":"2016-10-25T19:23:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cefoperazone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000597201601_no.pdf"}},
    {"id":"6230","name":"Hydroxycarbamide (except for centrally authorised product): List of nationally authorised medicinal products - PSUSA/00009182/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T12:40:00Z","last_updated_date":"2017-07-10T12:42:39Z","reference_number":"EMA/429979/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00009182201612_en.pdf"},
    {"id":"6306","name":"Nadroparin: List of nationally authorised medicinal products - PSUSA/00002104/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-10T01:00:00Z","last_updated_date":"2016-10-18T12:21:21Z","reference_number":"EMA/838082/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/nadroparin-list-nationally-authorised-medicinal-products-psusa00002104201503_en.pdf"},
    {"id":"6352","name":"Amitriptyline: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation  - PSUSA/00000168/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-01T01:00:00Z","last_updated_date":"2016-10-17T19:40:12Z","reference_number":"EMA/792231/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000168201501_en.pdf"},
    {"id":"6386","name":"Minoxidil (topical formulation): CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00002067/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-05T02:00:00Z","last_updated_date":"2016-10-18T12:21:20Z","reference_number":"EMA/587066/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002067201510_en.pdf"},
    {"id":"6394","name":"Tetrabenazine:List of nationally authorised medicinal products-PSUSA/00002911/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T12:30:00Z","last_updated_date":"2016-10-19T12:44:33Z","reference_number":"EMA/543826/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tetrabenazinelist-nationally-authorised-medicinal-products-psusa00002911201410_en.pdf"},
    {"id":"6554","name":"Candesartan, candesartan / hydrochlorothiazide: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000527/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T13:10:00Z","last_updated_date":"2018-05-02T16:01:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/candesartan-candesartan-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000527201704_no.pdf"}},
    {"id":"6567","name":"Dermatophagoides pteronyssinus / dermatophagoides farina (oromucosal use, products authorised via mutually recognition procedure and decentralised procedure)","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T11:26:00Z","last_updated_date":"2018-05-23T11:34:00Z","reference_number":"EMA/278412/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/dermatophagoides-pteronyssinus-dermatophagoides-farina-oromucosal-use-products-authorised-mutually-recognition-procedure-and-decentralised-procedure_en.pdf"},
    {"id":"6577","name":"Cefuroxime sodium (except for intracameral use): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000615/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T15:36:00Z","last_updated_date":"2018-01-26T15:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615201704_no.pdf"}},
    {"id":"6717","name":"Ipratropium/salbutamol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA-00001781-201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-27T15:00:00Z","last_updated_date":"2017-12-20T14:29:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ipratropiumsalbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001781-201701_sv.pdf"}},
    {"id":"6768","name":"Prulifloxacin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation  - PSUSA/00002569/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-09T14:20:00Z","last_updated_date":"2018-08-09T14:27:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201710_sv.pdf"}},
    {"id":"6777","name":"Amlodipine / atorvastatine: List of nationally authorised medicinal products - PSUSA/00000177/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T19:35:00Z","last_updated_date":"2016-10-19T19:35:00Z","reference_number":"EMA/662266/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-atorvastatine-list-nationally-authorised-medicinal-products-psusa00000177201601_en.pdf"},
    {"id":"6790","name":"Gadobenic acid: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00001500/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T01:00:00Z","last_updated_date":"2016-10-19T12:37:32Z","reference_number":"EMA/182023/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001500201504_en.pdf"},
    {"id":"6794","name":"Gaxilose: List of nationally authorised medicinal products - PSUSA/00010283/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T17:20:00Z","last_updated_date":"2017-09-06T17:20:00Z","reference_number":"EMA/524602/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/gaxilose-list-nationally-authorised-medicinal-products-psusa00010283201701_en.pdf"},
    {"id":"6880","name":"Atovaquone: List of nationally authorised medicinal products - PSUSA/00000265/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-15T02:00:00Z","last_updated_date":"2016-10-17T19:40:06Z","reference_number":"EMA/681035/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/atovaquone-list-nationally-authorised-medicinal-products-psusa00000265201411_en.pdf"},
    {"id":"6893","name":"Manidipine: List of nationally authorised medicinal products - PSUSA/00001932/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-18T11:29:35Z","reference_number":"EMA/346082/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/manidipine-list-nationally-authorised-medicinal-products-psusa00001932201506_en.pdf"},
    {"id":"7010","name":"Clodronic acid : List of nationally authorised medicinal products - PSUSA-00000804-201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T11:30:00Z","last_updated_date":"2017-10-31T11:32:13Z","reference_number":"EMA/663554/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/clodronic-acid-list-nationally-authorised-medicinal-products-psusa-00000804-201702_en.pdf"},
    {"id":"7012","name":"Acetylcysteine: List of nationally authorised medicinal products - PSUSA/00000034/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-17T16:43:25Z","reference_number":"EMA/344225/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylcysteine-list-nationally-authorised-medicinal-products-psusa00000034201509_en.pdf"},
    {"id":"7062","name":"Human plasma (pooled and treated for virus inactivation) : List of nationally authorised medicinal products - PSUSA/00001635/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-30T17:04:00Z","last_updated_date":"2017-10-30T17:06:43Z","reference_number":"EMA/722339/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-plasma-pooled-and-treated-virus-inactivation-list-nationally-authorised-medicinal-products-psusa00001635201702_en.pdf"},
    {"id":"7086","name":"Tick-borne encephalitis vaccine (inactivated) : List of nationally authorised medicinal products - PSUSA/00002951/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-04T11:38:00Z","last_updated_date":"2017-10-04T11:39:35Z","reference_number":"EMA/653963/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tick-borne-encephalitis-vaccine-inactivated-list-nationally-authorised-medicinal-products-psusa00002951201701_en.pdf"},
    {"id":"7102","name":"Cilazapril, cilazapril / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA/00000749/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2016-10-18T15:41:11Z","reference_number":"EMA/706294/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00000749201502_en.pdf"},
    {"id":"7140","name":"Ipratropium: List of nationally authorised medicinal products - PSUSA/00001780/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-06T13:51:00Z","last_updated_date":"2017-10-06T14:14:33Z","reference_number":"EMA/662326/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ipratropium-list-nationally-authorised-medicinal-products-psusa00001780201701_en.pdf"},
    {"id":"7163","name":"Human von willebrand factor: List of nationally authorised medicinal products - PSUSA/00001642/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T02:00:00Z","last_updated_date":"2016-10-20T18:50:42Z","reference_number":"EMA/449047/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-von-willebrand-factor-list-nationally-authorised-medicinal-products-psusa00001642201409_en.pdf"},
    {"id":"7226","name":"Candesartan, candesartan / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA/00000527/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T13:10:00Z","last_updated_date":"2018-03-06T13:39:18Z","reference_number":"EMA/415684/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/candesartan-candesartan-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00000527201704_en.pdf"}    {"id":"7262","name":"Amlodipine besilate / ramipril: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation  - PSUSA/00000181/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-10-17T19:40:07Z","reference_number":"EMA/85620/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-besilate-ramipril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000181201503_en.pdf"},
    {"id":"7269","name":"Milrinone: List of nationally authorised medicinal products - PSUSA/00002064/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-15T02:00:00Z","last_updated_date":"2016-10-18T12:21:23Z","reference_number":"EMA/418285/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/milrinone-list-nationally-authorised-medicinal-products-psusa00002064201510_en.pdf"},
    {"id":"7306","name":"Montelukast: List of nationally authorised medicinal products - PSUSA/00002087/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-11T02:00:00Z","last_updated_date":"2016-10-18T12:21:22Z","reference_number":"EMA/256382/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/montelukast-list-nationally-authorised-medicinal-products-psusa00002087201507_en.pdf"},
    {"id":"7320","name":"Alendronate / alfacalcidol: List of nationally authorised medicinal products - PSUSA/00010308/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T02:00:00Z","last_updated_date":"2016-10-17T17:40:42Z","reference_number":"EMA/459621/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/alendronate-alfacalcidol-list-nationally-authorised-medicinal-products-psusa00010308201512_en.pdf"},
    {"id":"7378","name":"Ambroxol / clenbuterol: List of nationally authorised medicinal products -  PSUSA/00000131/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-15T12:35:00Z","last_updated_date":"2017-06-15T12:35:00Z","reference_number":"EMA/381814/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ambroxol-clenbuterol-list-nationally-authorised-medicinal-products-psusa00000131201609_en.pdf"},
    {"id":"7439","name":"Naratriptan: List of nationally authorised medicinal products - PSUSA/00002126/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T16:04:00Z","last_updated_date":"2017-10-27T16:09:29Z","reference_number":"EMA/716726/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/naratriptan-list-nationally-authorised-medicinal-products-psusa00002126201702_en.pdf"},
    {"id":"7452","name":"Gadoteric acid (IV and intravascular formulations): List of nationally authorised medicinal products - PSUSA/00001506/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T01:00:00Z","last_updated_date":"2016-10-19T12:37:30Z","reference_number":"EMA/194278/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteric-acid-iv-and-intravascular-formulations-list-nationally-authorised-medicinal-products-psusa00001506201504_en.pdf"},
    {"id":"7479","name":"Rabeprazole: List of nationally authorised medicinal products - PSUSA/00002601/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-27T16:15:00Z","last_updated_date":"2017-07-27T16:16:24Z","reference_number":"EMA/475695/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabeprazole-list-nationally-authorised-medicinal-products-psusa00002601201610_en.pdf"},
    {"id":"7485","name":"Cyproterone/ethinylestradiol: List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0003; EMEA/H/N/PSR/J/0005; EMEA/H/N/PSR/J/0006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-23T19:30:00Z","last_updated_date":"2017-02-23T19:30:00Z","reference_number":"EMA/68246/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproteroneethinylestradiol-list-nationally-authorised-medicinal-products-emeahnpsrj0003-emeahnpsrj0005-emeahnpsrj0006_en.pdf"},
    {"id":"7554","name":"Fluticasone propionate / formoterol fumarate dehydrate : List of nationally authorised medicinal products - PSUSA/00010339/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T15:14:00Z","last_updated_date":"2017-03-10T15:19:32Z","reference_number":"EMA/170328/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluticasone-propionate-formoterol-fumarate-dehydrate-list-nationally-authorised-medicinal-products-psusa00010339201607_en.pdf"},
    {"id":"7581","name":"Olodaterol: List of nationally authorised medicinal products - PSUSA/00010245/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-30T02:00:00Z","last_updated_date":"2016-10-18T12:49:40Z","reference_number":"EMA/639666/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodaterol-list-nationally-authorised-medicinal-products-psusa00010245201603_en.pdf"},
    {"id":"7647","name":"Amitriptyline: List of nationally authorised medicinal products - PSUSA/00000168/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-01T01:00:00Z","last_updated_date":"2016-10-17T19:40:09Z","reference_number":"EMA/792231/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-list-nationally-authorised-medicinal-products-psusa00000168201501_en.pdf"},
    {"id":"7648","name":"Itraconazole: List of nationally authorised medicinal products - PSUSA/00001798/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T13:20:00Z","last_updated_date":"2017-12-08T13:20:00Z","reference_number":"EMA/817337/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/itraconazole-list-nationally-authorised-medicinal-products-psusa00001798201703_en.pdf"},
    {"id":"7668","name":"Testosterone undecanoate (injection): List of nationally authorised medicinal products - PSUSA/00010161/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T17:20:00Z","last_updated_date":"2017-09-06T17:20:00Z","reference_number":"EMA/590501/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-undecanoate-injection-list-nationally-authorised-medicinal-products-psusa00010161201612_en.pdf"},
    {"id":"7672","name":"Allopurinol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000095/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T15:27:00Z","last_updated_date":"2017-10-23T15:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201612_no.pdf"}},
    {"id":"7718","name":"Rabbit anti-human thymocyte (concentrate for solution for infusion): List of nationally authorised medicinal products - PSUSA/00010252/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-06T12:00:00Z","last_updated_date":"2016-10-17T19:31:35Z","reference_number":"EMA/532392/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-human-thymocyte-concentrate-solution-infusion-list-nationally-authorised-medicinal-products-psusa00010252201412_en.pdf"},
    {"id":"7720","name":"Acitretin :List of nationally authorised medicinal products - PSUSA/00000051/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-13T11:43:00Z","last_updated_date":"2017-06-13T11:50:21Z","reference_number":"EMA/372643/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-list-nationally-authorised-medicinal-products-psusa00000051201610_en.pdf"},
    {"id":"7775","name":"Androstanolone: List of nationally authorised medicinal products - PSUSA/00000212/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-08T02:00:00Z","last_updated_date":"2016-10-17T19:40:12Z","reference_number":"EMA/801642/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/androstanolone-list-nationally-authorised-medicinal-products-psusa00000212201412_en.pdf"},
    {"id":"7779","name":"Bambuterol: List of nationally authorised medicinal products - PSUSA/00000295/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-18T16:52:00Z","last_updated_date":"2018-07-18T16:54:25Z","reference_number":"EMA/488816/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/bambuterol-list-nationally-authorised-medicinal-products-psusa00000295201712_en.pdf"},
    {"id":"7818","name":"Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-12T02:00:00Z","last_updated_date":"2016-10-18T10:40:12Z","reference_number":"EMA/607492/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-list-nationally-authorised-medicinal-products-psusa00010390201601_en.pdf"},
    {"id":"7843","name":"Pravastatin: List of nationally authorised medicinal products -  PSUSA/00002500/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-05T17:20:00Z","last_updated_date":"2017-12-05T17:32:01Z","reference_number":"EMA/806818/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/pravastatin-list-nationally-authorised-medicinal-products-psusa00002500201703_en.pdf"},
    {"id":"7892","name":"Paroxetine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -  PSUSA/00002319/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-11T17:45:00Z","last_updated_date":"2018-09-11T17:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002319201712_no.pdf"}},
    {"id":"7907","name":"Mycophenolic acid (apart from mycophenolate mofetil): List of nationally authorised medicinal products - PSUSA/00010243/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-07T02:00:00Z","last_updated_date":"2016-12-12T10:13:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/mycophenolic-acid-apart-mycophenolate-mofetil-list-nationally-authorised-medicinal-products-psusa00010243201510_en.pdf"},
    {"id":"7921","name":"Fluconazole: List of nationally authorised medicinal products - PSUSA/00001404/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T18:52:00Z","last_updated_date":"2017-10-26T18:55:44Z","reference_number":"EMA/716513/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluconazole-list-nationally-authorised-medicinal-products-psusa00001404201703_en.pdf"},
    {"id":"7925","name":"Tetrabenazine:CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation-PSUSA/00002911/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T12:30:00Z","last_updated_date":"2016-10-19T12:44:33Z","reference_number":"EMA/517086/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tetrabenazinecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002911201410_en.pdf"},
    {"id":"7932","name":"Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated), haemophilus type b conjugate vaccine: List of nationally authorised medicinal products - PSUSA/00001124/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-17T14:00:00Z","last_updated_date":"2016-10-17T19:52:27Z","reference_number":"EMA/483660/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-pertussis-acellular-component-poliomyelitis-inactivated-haemophilus-type-b-conjugate-vaccine-list-nationally-authorised-medicinal-products-psusa00001124201411_en.pdf"},
    {"id":"7951","name":"Miconazole / hydrocortisone, miconazole nitrate / miconazole nitrate, zinc oxide: CMDh scientific conclusions and grounds for variation, amendments to the product information, and timetable for the implementation -PSUSA/...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T02:00:00Z","last_updated_date":"2016-10-18T11:46:16Z","reference_number":"EMA/269956/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_en.pdf"},
    {"id":"7958","name":"Finasteride : List of nationally authorised medicinal products     - PSUSA/00001392/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-30T19:05:00Z","last_updated_date":"2017-05-30T19:15:17Z","reference_number":"EMA/344631/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392201608_en.pdf"},
    {"id":"7964","name":"5 Fluorouracil (topical application): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010000/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-13T01:00:00Z","last_updated_date":"2016-10-17T16:37:37Z","reference_number":"EMA/757666/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201412_en.pdf"},
    {"id":"7999","name":"Paclitaxel: List of nationally authorised medicinal products - PSUSA/00002264/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-25T02:00:00Z","last_updated_date":"2016-10-25T19:37:13Z","reference_number":"EMA/706629/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/paclitaxel-list-nationally-authorised-medicinal-products-psusa00002264201512_en.pdf"},
    {"id":"8017","name":"Botulinum toxin a - haemagglutinin complex: List of nationally authorised medicinal products - PSUSA/00000427/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-25T02:00:00Z","last_updated_date":"2016-10-25T19:31:49Z","reference_number":"EMA/706149/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-haemagglutinin-complex-list-nationally-authorised-medicinal-products-psusa00000427201512_en.pdf"},
    {"id":"8078","name":"Nafarelin: List of nationally authorised medicinal products - PSUSA/00002105/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2016-10-18T12:21:21Z","reference_number":"EMA/707735/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/nafarelin-list-nationally-authorised-medicinal-products-psusa00002105201502_en.pdf"},
    {"id":"8131","name":"Granisetron: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001568/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-22T12:00:00Z","last_updated_date":"2017-01-18T18:10:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/granisetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001568201602_sv.pdf"}},
    {"id":"8226","name":"Chloroquine: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00000685/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-18T15:41:12Z","reference_number":"EMA/344102/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685201508_en.pdf"},
    {"id":"8325","name":"Glycopyrronium / neostigmine: List of nationally authorised medicinal products - PSUSA/00001557/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-07T02:00:00Z","last_updated_date":"2016-10-17T15:45:54Z","reference_number":"EMA/471844/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/glycopyrronium-neostigmine-list-nationally-authorised-medicinal-products-psusa00001557201509_en.pdf"},
    {"id":"8341","name":"Latanoprost (products with paediatric indication): List of nationally authorised medicinal products - PSUSA/00001834/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T16:00:00Z","last_updated_date":"2017-05-12T16:00:00Z","reference_number":"EMA/267507/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-products-paediatric-indication-list-nationally-authorised-medicinal-products-psusa00001834201610_en.pdf"},
    {"id":"8343","name":"Testosterone undecanoate (injection): List of nationally authorised medicinal products - PSUSA/00010161/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T16:30:00Z","last_updated_date":"2016-11-07T18:12:39Z","reference_number":"EMA/731767/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-undecanoate-injection-list-nationally-authorised-medicinal-products-psusa00010161201512_en.pdf"},
    {"id":"8358","name":"Sodium tetradecyl sulphate: List of nationally authorised medicinal products - PSUSA/00002767/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T11:10:00Z","last_updated_date":"2018-01-18T11:10:00Z","reference_number":"EMA/35069/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-tetradecyl-sulphate-list-nationally-authorised-medicinal-products-psusa00002767201704_en.pdf"},
    {"id":"8394","name":"Lamotrigine : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001825/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T18:00:00Z","last_updated_date":"2018-09-10T18:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001825201711_no.pdf"}},
    {"id":"8459","name":"Carmustine (powder and solvent for solution for infusion): CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00010349/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-09T01:00:00Z","last_updated_date":"2016-10-18T15:41:05Z","reference_number":"EMA/97472/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/carmustine-powder-and-solvent-solution-infusion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010349201504_en.pdf"},
    {"id":"8466","name":"Methylaminolevulinate: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002019/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-14T14:30:00Z","last_updated_date":"2018-05-14T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methylaminolevulinate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002019201706_no.pdf"}},
    {"id":"8514","name":"Prulifloxacin: List of nationally authorised medicinal products -PSUSA/00002569/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T12:00:00Z","last_updated_date":"2016-10-17T18:59:00Z","reference_number":"EMA/544330/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/prulifloxacin-list-nationally-authorised-medicinal-products-psusa00002569201410_en.pdf"},
    {"id":"8515","name":"Cefazolin: List of nationally authorised medicinal products - PSUSA/00000589/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-07T14:00:00Z","last_updated_date":"2017-09-07T14:00:00Z","reference_number":"EMA/590591/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefazolin-list-nationally-authorised-medicinal-products-psusa00000589201611_en.pdf"},
    {"id":"8569","name":"Granisetron: List of nationally authorised medicinal products -PSUSA/00001568/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-22T12:00:00Z","last_updated_date":"2016-12-22T12:00:00Z","reference_number":"EMA/398898/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/granisetron-list-nationally-authorised-medicinal-products-psusa00001568201602_en.pdf"},
    {"id":"8603","name":"Influenza vaccine (surface antigen, inactivated): List of nationally authorised medicinal products - PSUSA/00001744/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T18:52:00Z","last_updated_date":"2017-10-26T18:55:44Z","reference_number":"EMA/717668/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa00001744201703_en.pdf"},
    {"id":"8625","name":"Hydrochlorothiazide, spironolactone: List of nationally authorised medicinal products - PSUSA/00001662/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-17T17:35:14Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-spironolactone-list-nationally-authorised-medicinal-products-psusa00001662201501_en.pdf"},
    {"id":"8673","name":"Bisoprolol / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA/00000420/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-10-18T14:01:07Z","reference_number":"EMA/580844/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/bisoprolol-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00000420201511_en.pdf"},
    {"id":"8692","name":"Dutasteride, dutasteride / tamsulosine: List of nationally authorised medicinal products - PSUSA/00010506/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-14T13:29:00Z","last_updated_date":"2018-08-14T13:32:00Z","reference_number":"EMA/537178/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/dutasteride-dutasteride-tamsulosine-list-nationally-authorised-medicinal-products-psusa00010506201711_en.pdf"},
    {"id":"8784","name":"Miconazole / hydrocortisone, miconazole nitrate / miconazole nitrate, zinc oxide: List of nationally authorised medicinal products -PSUSA/00002052/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T02:00:00Z","last_updated_date":"2016-10-18T11:46:16Z","reference_number":"EMA/398898/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-list-nationally-authorised-medicinal-products-psusa00002052201410_en.pdf"},
    {"id":"8791","name":"Influenza vaccine (surface antigen, inactivated): List of nationally authorised medicinal products - PSUSA/00001744/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-17T18:39:17Z","reference_number":"EMA/346549/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa00001744201508_en.pdf"},
    {"id":"8810","name":"Tetrabenazine: List of nationally authorised medicinal products - PSUSA/00002911/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-14T19:00:00Z","last_updated_date":"2017-06-14T19:00:00Z","reference_number":"EMA/366993/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tetrabenazine-list-nationally-authorised-medicinal-products-psusa00002911201610_en.pdf"},
    {"id":"8828","name":"Alteplase: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000112/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T17:30:00Z","last_updated_date":"2018-03-07T17:36:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/alteplase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000112201705_no.pdf"}},
    {"id":"8962","name":"Flumazenil: List of nationally authorised medicinal products - PSUSA/00001413/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-12T02:00:00Z","last_updated_date":"2016-10-18T16:31:59Z","reference_number":"EMA/606912/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/flumazenil-list-nationally-authorised-medicinal-products-psusa00001413201512_en.pdf"},
    {"id":"8970","name":"Letrozole: List of nationally authorised medicinal products - PSUSA/00001842/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-15T02:00:00Z","last_updated_date":"2016-10-17T19:17:15Z","reference_number":"EMA/418272/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/letrozole-list-nationally-authorised-medicinal-products-psusa00001842201510_en.pdf"},
    {"id":"8999","name":"Norethisterone: List of nationally authorised medicinal products - PSUSA/00002188/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T15:36:00Z","last_updated_date":"2018-04-19T15:41:01Z","reference_number":"EMA/210995/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/norethisterone-list-nationally-authorised-medicinal-products-psusa00002188201708_en.pdf"},
    {"id":"9075","name":"Levosalbutamol, salbutamol : List of nationally authorised medicinal products - PSUSA/00010330/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-06T13:40:00Z","last_updated_date":"2017-10-06T13:42:54Z","reference_number":"EMA/662335/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/levosalbutamol-salbutamol-list-nationally-authorised-medicinal-products-psusa00010330201701_en.pdf"},
    {"id":"9129","name":"Lubiprostone: List of nationally authorised medicinal products - PSUSA/00010290/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-13T02:00:00Z","last_updated_date":"2016-10-18T10:40:10Z","reference_number":"EMA/6088686/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/lubiprostone-list-nationally-authorised-medicinal-products-psusa00010290201601_en.pdf"},
    {"id":"9140","name":"Tobramycin (nebuliser solution) (apart from centrally authorised product): List of nationally authorised medicinal products - PSUSA/00009316/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-11T18:41:00Z","last_updated_date":"2018-09-11T18:43:00Z","reference_number":"EMA/615391/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/tobramycin-nebuliser-solution-apart-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00009316201712_en.pdf"},
    {"id":"9200","name":"Exametazime / technetium (99mTc) exametazime: List of nationally authorised medicinal products - PSUSA/00001344/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T19:35:00Z","last_updated_date":"2016-10-19T19:35:00Z","reference_number":"EMA/662405/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/exametazime-technetium-99mtc-exametazime-list-nationally-authorised-medicinal-products-psusa00001344201601_en.pdf"},
    {"id":"9219","name":"Biperiden : List of nationally authorised medicinal products - PSUSA/00000415/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-15T12:26:00Z","last_updated_date":"2017-05-15T12:28:16Z","reference_number":"EMA/302920/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/biperiden-list-nationally-authorised-medicinal-products-psusa00000415201608_en.pdf"},
    {"id":"9326","name":"Fosfomycin (IV formulation): List of nationally authorised medicinal products - PSUSA/00010336/201607","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2017-04-11T19:40:00Z","last_updated_date":"2017-04-11T19:40:00Z","reference_number":"EMA/235643/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosfomycin-iv-formulation-list-nationally-authorised-medicinal-products-psusa00010336201607_en.pdf"},
    {"id":"9339","name":"Technetium 99mtc sestamibi: List of nationally authorised medicinal products - PSUSA/00002868/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T16:40:00Z","last_updated_date":"2018-02-09T16:40:00Z","reference_number":"EMA/46903/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/technetium-99mtc-sestamibi-list-nationally-authorised-medicinal-products-psusa00002868201706_en.pdf"},
    {"id":"9377","name":"Ranitidine: List of nationally authorised medicinal products - PSUSA/00002610/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-22T11:00:00Z","last_updated_date":"2016-10-17T19:46:20Z","reference_number":"EMA/51946/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ranitidine-list-nationally-authorised-medicinal-products-psusa00002610201505_en.pdf"},
    {"id":"9472","name":"Aprotinin: List of nationally authorised medicinal products - PSUSA/00000230/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-04T16:38:00Z","last_updated_date":"2016-11-04T16:39:56Z","reference_number":"EMA/728577/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/aprotinin-list-nationally-authorised-medicinal-products-psusa00000230201602_en.pdf"},
    {"id":"9515","name":"Pergolide: List of nationally authorised medicinal products -  PSUSA/00002351/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-07T13:30:00Z","last_updated_date":"2017-09-07T13:30:06Z","reference_number":"EMA/592458/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/pergolide-list-nationally-authorised-medicinal-products-psusa00002351201612_en.pdf"},
    {"id":"9562","name":"Dexibuprofen: List of nationally authorised medicinal products - PSUSA/00000996/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-22T15:33:00Z","last_updated_date":"2018-05-22T15:37:31Z","reference_number":"EMA/302974/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexibuprofen-list-nationally-authorised-medicinal-products-psusa00000996201708_en.pdf"},
    {"id":"9597","name":"Paracetamol (IV formulation): List of nationally authorised medicinal products - PSUSA/00002311/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T16:00:00Z","last_updated_date":"2016-12-07T16:00:00Z","reference_number":"EMA/819150/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-iv-formulation-list-nationally-authorised-medicinal-products-psusa00002311201605_en.pdf"},
    {"id":"9748","name":"Mefloquine: List of nationally authorised medicinal products -    PSUSA/00001955/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T16:28:00Z","last_updated_date":"2018-01-03T16:37:35Z","reference_number":"EMA/845940/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/mefloquine-list-nationally-authorised-medicinal-products-psusa00001955201702_en.pdf"},
    {"id":"9759","name":"Human coagulation factor VIII (inhibitor bypassing fraction): List of nationally authorised medicinal products - PSUSA/00009174/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T17:00:00Z","last_updated_date":"2016-10-19T17:00:00Z","reference_number":"EMA/661359/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-viii-inhibitor-bypassing-fraction-list-nationally-authorised-medicinal-products-psusa00009174201602_en.pdf"},
    {"id":"9790","name":"Cyproterone/ethinylestradiol: PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-23T19:31:00Z","last_updated_date":"2017-02-23T19:31:00Z","reference_number":"EMA/101726/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproteroneethinylestradiol-prac-non-interventional-imposed-pass-final-study-report-assessment-report-emeahnpsrj0005_en.pdf"},
    {"id":"9807","name":"Levonorgestrel: List of nationally authorised medicinal products - PSUSA/00001856/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-24T01:00:00Z","last_updated_date":"2016-10-18T10:40:13Z","reference_number":"EMA/589993/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-list-nationally-authorised-medicinal-products-psusa00001856201412_en.pdf"},
    {"id":"9860","name":"Baclofen (oral): CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00000294/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-20T13:39:00Z","last_updated_date":"2017-08-17T12:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201609_sv.pdf"}},
    {"id":"9910","name":"Ziprasidone: List of nationally authorised medicinal products - PSUSA/00003146/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-11T14:00:00Z","last_updated_date":"2016-10-17T20:16:33Z","reference_number":"EMA/257007/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ziprasidone-list-nationally-authorised-medicinal-products-psusa00003146201507_en.pdf"},
    {"id":"9990","name":"Influenza vaccine (surface antigen, inactivated, adjuvanted): List of nationally authorised medicinal products - PSUSA/00010300/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-17T18:39:11Z","reference_number":"EMA/346553/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-adjuvanted-list-nationally-authorised-medicinal-products-psusa00010300201508_en.pdf"},
    {"id":"10020","name":"Influenza vaccine (surface antigen, inactivated, adjuvanted): List of nationally authorised medicinal products - PSUSA/00010300/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T15:22:01Z","reference_number":"EMA/751345/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-adjuvanted-list-nationally-authorised-medicinal-products-psusa00010300201603_en.pdf"},
    {"id":"10043","name":"Dienogest / estradiol (HRT indication): List of nationally authorised medicinal products - PSUSA/00010443/201606","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-22T12:00:00Z","last_updated_date":"2017-02-22T12:14:26Z","reference_number":"EMA/127587/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/dienogest-estradiol-hrt-indication-list-nationally-authorised-medicinal-products-psusa00010443201606_en.pdf"},
    {"id":"10049","name":"Levobunolol (ophthalmic indication): List of nationally authorised medicinal products - PSUSA/00010109/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T12:35:00Z","last_updated_date":"2017-10-23T12:40:00Z","reference_number":"EMA/699912/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/levobunolol-ophthalmic-indication-list-nationally-authorised-medicinal-products-psusa00010109201701_en.pdf"},
    {"id":"10056","name":"Latanoprost (products with paediatric indication): List of nationally authorised medicinal products - PSUSA/00001834/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-10-17T19:17:16Z","reference_number":"EMA/361720/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-products-paediatric-indication-list-nationally-authorised-medicinal-products-psusa00001834201510_en.pdf"},
    {"id":"10067","name":"Diphtheria/tetanus/pertussis (acellular, component) vaccine (adsorbed), diphtheria/tetanus/pertussis (acellular, component) vaccine (adsorbed) reduced antigens contents:List of nationally authorised medicinal pr...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-12T18:00:00Z","last_updated_date":"2017-12-12T18:02:00Z","reference_number":"EMA/827246/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheriatetanuspertussis-acellular-component-vaccine-adsorbed-diphtheriatetanuspertussis-acellular-component-vaccine-adsorbed-reduced-antigens-contentslist-nationally-authorised-medicinal-pr_en.pdf"},
    {"id":"10154","name":"Tetrabenazine:List of nationally authorised medicinal products-PSUSA/00002911/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-21T12:30:00Z","last_updated_date":"2016-10-19T12:44:32Z","reference_number":"EMA/423939/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/tetrabenazinelist-nationally-authorised-medicinal-products-psusa00002911201510_en.pdf"},
    {"id":"10166","name":"Rabeprazole: List of nationally authorised medicinal products - PSUSA/00002601/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-14T12:00:00Z","last_updated_date":"2016-10-17T19:46:19Z","reference_number":"EMA/413334/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabeprazole-list-nationally-authorised-medicinal-products-psusa00002601201510_en.pdf"},
    {"id":"10358","name":"Buserelin: List of nationally authorised medicinal products - PSUSA/00000462/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-04-10T19:15:00Z","last_updated_date":"2017-04-10T19:15:00Z","reference_number":"EMA/238496/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/buserelin-list-nationally-authorised-medicinal-products-psusa00000462201608_en.pdf"},
    {"id":"10398","name":"Triamcinolone (intraocular formulations): CMDh scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA/00010292/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-22T10:00:00Z","last_updated_date":"2016-12-22T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/triamcinolone-intraocular-formulations-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010292201603_no.pdf"}},
    {"id":"10464","name":"Daunorubicin: CMDh Scientific conclusions and grounds for the variation,\n\namendments to the Product Information, and timetable\n\nfor the implementation - PSUSA/00000936/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T14:00:00Z","last_updated_date":"2016-10-17T20:37:52Z","reference_number":"EMA/238721/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000936201506_en.pdf"},
    {"id":"10498","name":"Magnesium hydroxide: List of nationally authorised medicinal products - PSUSA/00001926/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-05T14:00:00Z","last_updated_date":"2017-09-05T14:00:00Z","reference_number":"EMA/581675/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-hydroxide-list-nationally-authorised-medicinal-products-psusa00001926201610_en.pdf"},
    {"id":"10516","name":"Theophylline: List of nationally authorised medicinal products - PSUSA/00002921/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-14T15:30:00Z","last_updated_date":"2018-03-14T15:30:00Z","reference_number":"EMA/135395/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/theophylline-list-nationally-authorised-medicinal-products-psusa00002921201706_en.pdf"},
    {"id":"10522","name":"Dornase alpha: List of nationally authorised medicinal products - PSUSA/00001164/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-24T18:00:00Z","last_updated_date":"2018-05-24T18:09:00Z","reference_number":"EMA/333504/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/dornase-alpha-list-nationally-authorised-medicinal-products-psusa00001164201709_en.pdf"},
    {"id":"10585","name":"Dorzolamide: List of nationally authorised medicinal products - PSUSA/00003168/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-22T10:30:00Z","last_updated_date":"2016-12-22T10:57:39Z","reference_number":"EMA/863720/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-list-nationally-authorised-medicinal-products-psusa00003168201602_en.pdf"},
    {"id":"10598","name":"Spironolactone: List of nationally authorised medicinal products - PSUSA/00002780/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-08T11:00:00Z","last_updated_date":"2016-10-18T11:56:10Z","reference_number":"EMA/16413/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/spironolactone-list-nationally-authorised-medicinal-products-psusa00002780201503_en.pdf"},
    {"id":"10746","name":"Finasteride: List of nationally authorised medicinal products       - PSUSA/00001392/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T17:01:00Z","last_updated_date":"2018-06-07T17:10:06Z","reference_number":"EMA/381051/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392201708_en.pdf"},
    {"id":"10824","name":"Omega-3-acid-ethyl esters: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010312/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T18:10:00Z","last_updated_date":"2017-11-15T18:18:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010312201701_no.pdf"}},
    {"id":"10879","name":"Human hemin: List of nationally authorised medicinal products - PSUSA/00001629/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T16:15:00Z","last_updated_date":"2018-01-15T16:17:23Z","reference_number":"EMA/24790/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-hemin-list-nationally-authorised-medicinal-products-psusa00001629201705_en.pdf"},
    {"id":"10928","name":"Cefuroxime sodium (for intracameral use): List of nationally authorised medicinal products - PSUSA/00010206/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-24T01:00:00Z","last_updated_date":"2016-10-18T15:41:15Z","reference_number":"EMA/151248/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-sodium-intracameral-use-list-nationally-authorised-medicinal-products-psusa00010206201505_en.pdf"},
    {"id":"10939","name":"Erythromycin / tretinoin : List of nationally authorised medicinal products - PSUSA/00001259/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-13T13:33:00Z","last_updated_date":"2017-06-13T13:34:41Z","reference_number":"EMA/373339/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/erythromycin-tretinoin-list-nationally-authorised-medicinal-products-psusa00001259201610_en.pdf"},
    {"id":"10982","name":"Cytomegalovirus immunoglobulin: List of nationally authorised medicinal products - PSUSA/00000914/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-05T14:00:00Z","last_updated_date":"2016-10-17T20:25:31Z","reference_number":"EMA/639856/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cytomegalovirus-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00000914201601_en.pdf"},
    {"id":"11000","name":"Amiodarone: List of nationally authorised medicinal products -PSUSA/00000166/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-04T02:00:00Z","last_updated_date":"2016-10-17T19:40:19Z","reference_number":"EMA/586234/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/amiodarone-list-nationally-authorised-medicinal-products-psusa00000166201412_en.pdf"},
    {"id":"11002","name":"Vecuronium bromide: List of nationally authorised medicinal products - PSUSA/00003102/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-04T18:30:00Z","last_updated_date":"2017-09-04T18:30:00Z","reference_number":"EMA/578853/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/vecuronium-bromide-list-nationally-authorised-medicinal-products-psusa00003102201611_en.pdf"},
    {"id":"11066","name":"Antithrombin iii: List of nationally authorised medicinal products - PSUSA/00003159/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-24T16:57:00Z","last_updated_date":"2016-10-25T11:36:26Z","reference_number":"EMA/701785/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/antithrombin-iii-list-nationally-authorised-medicinal-products-psusa00003159201512_en.pdf"},
    {"id":"11085","name":"Rosuvastatin: List of nationally authorised medicinal products - PSUSA/00002664/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-31T11:27:00Z","last_updated_date":"2018-08-31T11:36:39Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/rosuvastatin-list-nationally-authorised-medicinal-products-psusa00002664201711_en.pdf"},
    {"id":"11089","name":"Hexoprenaline sulphate: List of nationally authorised products - PSUSA/00003170/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-03T02:00:00Z","last_updated_date":"2016-10-17T17:15:00Z","reference_number":"EMA/316582/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/hexoprenaline-sulphate-list-nationally-authorised-products-psusa00003170201508_en.pdf"}    {"id":"11130","name":"Clotiazepam: List of nationally authorised medicinal products - PSUSA/00000827/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T13:00:00Z","last_updated_date":"2016-10-17T20:16:37Z","reference_number":"EMA/60980/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/clotiazepam-list-nationally-authorised-medicinal-products-psusa00000827201505_en.pdf"},
    {"id":"11252","name":"Chloroquine: List of nationally authorised medicinal products - PSUSA/00000685/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-18T15:41:12Z","reference_number":"EMA/344135/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/chloroquine-list-nationally-authorised-medicinal-products-psusa00000685201508_en.pdf"},
    {"id":"11372","name":"Carbetocin: List of nationally authorised medicinal products - PSUSA/00000546/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T12:06:00Z","last_updated_date":"2018-03-09T12:09:09Z","reference_number":"EMA/154294/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbetocin-list-nationally-authorised-medicinal-products-psusa00000546201706_en.pdf"},
    {"id":"11557","name":"Ambroxol : List of nationally authorised medicinal products - PSUSA/00000130/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-15T12:35:00Z","last_updated_date":"2017-06-15T12:35:00Z","reference_number":"EMA/381816/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ambroxol-list-nationally-authorised-medicinal-products-psusa00000130201609_en.pdf"},
    {"id":"11572","name":"Hydromorphone: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001686/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T17:45:00Z","last_updated_date":"2016-10-26T17:59:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686201511_no.pdf"}},
    {"id":"11654","name":"Irinotecan (except for liposomal formulations): List of nationally authorised medicinal products - PSUSA/00001783/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T13:10:00Z","last_updated_date":"2018-03-06T13:39:16Z","reference_number":"EMA/141276/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/irinotecan-except-liposomal-formulations-list-nationally-authorised-medicinal-products-psusa00001783201705_en.pdf"},
    {"id":"11671","name":"Ceftazidime: List of nationally authorised medicinal products - PSUSA/00000608/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-13T02:00:00Z","last_updated_date":"2016-10-18T15:41:07Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftazidime-list-nationally-authorised-medicinal-products-psusa00000608201510_en.pdf"},
    {"id":"11689","name":"Vigabatrin: List of nationally authorised medicinal products - PSUSA/00003112/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T20:00:00Z","last_updated_date":"2018-05-23T20:22:17Z","reference_number":"EMA/303471/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/vigabatrin-list-nationally-authorised-medicinal-products-psusa00003112201709_en.pdf"},
    {"id":"11708","name":"Tretinoin (oral formulations) : List of nationally authorised medicinal products - PSUSA/00003015/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-07T12:51:00Z","last_updated_date":"2017-12-07T12:52:00Z","reference_number":"EMA/812498/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa00003015201703_en.pdf"},
    {"id":"11743","name":"Paracetamol / tramadol: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00002310/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T14:00:00Z","last_updated_date":"2016-10-17T16:59:47Z","reference_number":"EMA/319353/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002310201508_en.pdf"},
    {"id":"11750","name":"Trandolapril / verapamil: CMDh Scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00003005/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T13:00:00Z","last_updated_date":"2016-10-17T20:16:39Z","reference_number":"EMA/1813/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/trandolapril-verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003005201503_en.pdf"},
    {"id":"11753","name":"Nadifloxacin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -    PSUSA/00002102/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T18:37:00Z","last_updated_date":"2017-03-09T18:43:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nadifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002102201605_sv.pdf"}},
    {"id":"11770","name":"Deoxycholic acid : List of nationally authorised medicinal products - PSUSA/00010525/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-05T16:16:00Z","last_updated_date":"2017-12-05T16:19:19Z","reference_number":"EMA/753957/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/deoxycholic-acid-list-nationally-authorised-medicinal-products-psusa00010525201704_en.pdf"},
    {"id":"11801","name":"Strontium [89sr] chloride: List of nationally authorised medicinal products - PSUSA/00002795/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T11:10:00Z","last_updated_date":"2018-01-18T11:10:00Z","reference_number":"EMA/35112/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/strontium-89sr-chloride-list-nationally-authorised-medicinal-products-psusa00002795201705_en.pdf"},
    {"id":"11854","name":"Bupropion: List of nationally authorised medicinal products - PSUSA/00000461/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T17:02:00Z","last_updated_date":"2016-11-18T17:07:54Z","reference_number":"EMA/755927/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/bupropion-list-nationally-authorised-medicinal-products-psusa00000461201512_en.pdf"},
    {"id":"11941","name":"Acipimox: List of nationally authorised medicinal products - PSUSA/00000050/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-10-17T17:40:42Z","reference_number":"EMA/599298/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/acipimox-list-nationally-authorised-medicinal-products-psusa00000050201512_en.pdf"},
    {"id":"11953","name":"Cefoperazone / sulbactam: List of nationally authorised medicinal products - PSUSA/00000598/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T11:36:00Z","last_updated_date":"2016-10-27T11:51:51Z","reference_number":"EMA/714629/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefoperazone-sulbactam-list-nationally-authorised-medicinal-products-psusa00000598201601_en.pdf"},
    {"id":"12078","name":"Iloprost (iv solution): List of nationally authorised medicinal products - PSUSA/00009190/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-15T02:00:00Z","last_updated_date":"2016-10-17T17:46:00Z","reference_number":"EMA/681056/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/iloprost-iv-solution-list-nationally-authorised-medicinal-products-psusa00009190201501_en.pdf"},
    {"id":"12085","name":"Fosinopril: List of nationally authorised medicinal products - PSUSA/00001474/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-10-18T13:42:39Z","reference_number":"EMA/246355/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosinopril-list-nationally-authorised-medicinal-products-psusa00001474201507_en.pdf"},
    {"id":"12156","name":"Aciclovir: List of nationally authorised medicinal products - PSUSA 00000048/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-10-17T17:40:43Z","reference_number":"EMA/244934/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/aciclovir-list-nationally-authorised-medicinal-products-psusa-00000048201506_en.pdf"},
    {"id":"12189","name":"Ofloxacin (topical use): CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00002204/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-10-18T12:49:42Z","reference_number":"EMA/62559/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002204201504_en.pdf"},
    {"id":"12272","name":"Tizanidine: List of nationally authorised medicinal products - PSUSA/00002977/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-05T13:00:00Z","last_updated_date":"2016-10-17T20:16:34Z","reference_number":"EMA/730489/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tizanidine-list-nationally-authorised-medicinal-products-psusa00002977201412_en.pdf"},
    {"id":"12308","name":"Citalopram: List of nationally authorised medicinal products - PSUSA/00000779/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T17:10:00Z","last_updated_date":"2017-09-06T17:10:00Z","reference_number":"EMA/583896/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/citalopram-list-nationally-authorised-medicinal-products-psusa00000779201612_en.pdf"},
    {"id":"12350","name":"Gadoteridol: CMDh scientific conclusions and grounds for the variation,\n\namendments to the product information, and timetable\n\nfor the implementation - PSUSA/00001507/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T01:00:00Z","last_updated_date":"2016-10-18T16:56:39Z","reference_number":"EMA/186716/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001507201504_en.pdf"},
    {"id":"12379","name":"Human prothrombin complex: List of nationally authorised medicinal products - PSUSA/00001638/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-24T11:30:00Z","last_updated_date":"2017-01-24T11:37:34Z","reference_number":"EMA/45481/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-prothrombin-complex-list-nationally-authorised-medicinal-products-psusa00001638201604_en.pdf"},
    {"id":"12428","name":"Pimecrolimus: List of nationally authorised medicinal products - PSUSA/00002411/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T19:00:00Z","last_updated_date":"2017-10-27T19:00:00Z","reference_number":"EMA/716745/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/pimecrolimus-list-nationally-authorised-medicinal-products-psusa00002411201703_en.pdf"},
    {"id":"12468","name":"Terazosin: List of nationally authorised medicinal products: PSUSA/00002895/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T12:00:00Z","last_updated_date":"2016-10-19T12:14:37Z","reference_number":"EMA/437334/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/terazosin-list-nationally-authorised-medicinal-products-psusa00002895201511_en.pdf"},
    {"id":"12469","name":"Treprostinil: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003013/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-02T17:00:00Z","last_updated_date":"2018-08-02T17:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201711_no.pdf"}},
    {"id":"12486","name":"Pilocarpine / timolol: List of nationally authorised medicinal products - PSUSA/00002408/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-13T13:14:35Z","last_updated_date":"2017-03-13T13:18:05Z","reference_number":"EMA/173192/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/pilocarpine-timolol-list-nationally-authorised-medicinal-products-psusa00002408201607_en.pdf"},
    {"id":"12491","name":"Altizide / spironolactone: CMDh scientific conclusions and grounds for variation, amendments to the product information, and timetable for the implementation - PSUSA/000002781/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-06T01:00:00Z","last_updated_date":"2016-10-17T19:40:16Z","reference_number":"EMA/733448/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/altizide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000002781201501_en.pdf"},
    {"id":"12509","name":"Allopurinol: List of nationally authorised medicinal products - PSUSA/00000095/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-10-17T19:40:08Z","reference_number":"EMA/600491/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/allopurinol-list-nationally-authorised-medicinal-products-psusa00000095201512_en.pdf"},
    {"id":"12522","name":"Cyproterone/ethinylestradiol: CMDh scientific conclusions, amendments to product information and implementation timetable - EMEA/H/N/PSR/J/0006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-23T19:30:00Z","last_updated_date":"2017-02-23T19:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_hu.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_pl.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0006_is.pdf"}},
    {"id":"12617","name":"Quetiapine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002589/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-04T13:25:00Z","last_updated_date":"2018-07-03T17:06:02Z","reference_number":"EMA/221551/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589201707_no.pdf"}},
    {"id":"12673","name":"Letrozole: List of nationally authorised medicinal products - PSUSA/00001437/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T02:00:00Z","last_updated_date":"2016-10-17T19:17:14Z","reference_number":"EMA/456386/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/letrozole-list-nationally-authorised-medicinal-products-psusa00001437201410_en.pdf"},
    {"id":"12691","name":"Nicergoline: List of nationally authorised medicinal products - PSUSA/00002150/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2006-01-22T01:00:00Z","last_updated_date":"2016-10-18T12:21:18Z","reference_number":"EMA/49952/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicergoline-list-nationally-authorised-medicinal-products-psusa00002150201505_en.pdf"},
    {"id":"12707","name":"Ibutilide: List of nationally authorised medicinal products - PSUSA/00001713/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T15:48:00Z","last_updated_date":"2018-09-10T15:55:59Z","reference_number":"EMA/PRAC/607905/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibutilide-list-nationally-authorised-medicinal-products-psusa00001713201712_en.pdf"},
    {"id":"12710","name":"Finasteride: List of nationally authorised medicinal products - PSUSA/00001392/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-10-18T16:32:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392201508_en.pdf"},
    {"id":"12723","name":"Valaciclovir: List of nationally authorised medicinal products - PSUSA/00003086/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-12T14:00:00Z","last_updated_date":"2016-10-17T20:16:31Z","reference_number":"EMA/607581/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/valaciclovir-list-nationally-authorised-medicinal-products-psusa00003086201512_en.pdf"},
    {"id":"12761","name":"Landiolol: List of nationally authorised medicinal products - PSUSA/00010570/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T17:24:00Z","last_updated_date":"2018-03-09T17:30:19Z","reference_number":"EMA/113637/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/landiolol-list-nationally-authorised-medicinal-products-psusa00010570201708_en.pdf"},
    {"id":"12777","name":"Influenza vaccine (split virion, inactivated, prepared in cell cultures): List of nationally authorised medicinal products - PSUSA/0010299/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-17T18:39:12Z","reference_number":"EMA/830034/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-prepared-cell-cultures-list-nationally-authorised-medicinal-products-psusa0010299201504_en.pdf"},
    {"id":"12831","name":"Bendamustine hydrochloride: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003162/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T16:00:00Z","last_updated_date":"2017-10-23T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201701_no.pdf"}},
    {"id":"12856","name":"Pitavastatin: List of nationally authorised medicinal products - PSUSA/00010502/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T16:30:00Z","last_updated_date":"2018-02-13T16:30:00Z","reference_number":"EMA/85572/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/pitavastatin-list-nationally-authorised-medicinal-products-psusa00010502201707_en.pdf"},
    {"id":"12887","name":"Propafenone: List of nationally authorised medicinal products - PSUSA/00002550/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T19:35:00Z","last_updated_date":"2016-10-19T19:35:00Z","reference_number":"EMA/645369/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/propafenone-list-nationally-authorised-medicinal-products-psusa00002550201601_en.pdf"},
    {"id":"13040","name":"Risperidone: List of nationally authorised medicinal products - PSUSA/00002649/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T17:30:00Z","last_updated_date":"2018-01-15T17:30:00Z","reference_number":"EMA/27324/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/risperidone-list-nationally-authorised-medicinal-products-psusa00002649201705_en.pdf"},
    {"id":"13058","name":"Calcium carbonate / famotidine / magnesium hydroxide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001351/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-12T15:46:00Z","last_updated_date":"2018-07-12T19:18:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001351201709_no.pdf"}},
    {"id":"13124","name":"Bromazepam: List of nationally authorised medicinal products - PSUSA/00000435/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T20:00:00Z","last_updated_date":"2018-05-23T20:22:17Z","reference_number":"EMA/303456/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromazepam-list-nationally-authorised-medicinal-products-psusa00000435201708_en.pdf"},
    {"id":"13160","name":"Ciclesonide: List of nationally authorised medicinal products - PSUSA/00000742/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-20T02:00:00Z","last_updated_date":"2016-10-18T15:41:13Z","reference_number":"EMA/281184/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciclesonide-list-nationally-authorised-medicinal-products-psusa00000742201508_en.pdf"},
    {"id":"13172","name":"Promestriene (cream and vaginal capsules): List of nationally authorised medicinal products - PSUSA/00009271/201603 IIII","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-12-07T12:18:14Z","reference_number":"EMA/751259/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/promestriene-cream-and-vaginal-capsules-list-nationally-authorised-medicinal-products-psusa00009271201603-iiii_en.pdf"},
    {"id":"13266","name":"Amlodipine: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000174/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T13:00:00Z","last_updated_date":"2017-11-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/amlodipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000174201703_no.pdf"}},
    {"id":"13285","name":"Estradiol, estradiol /prednisolone (only cream/balm/emulsion for application in the female genital area): List of nationally authorised medicinal products - PSUSA/00010441/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T14:32:00Z","last_updated_date":"2018-01-18T14:36:00Z","reference_number":"EMA/34177/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/estradiol-estradiol-prednisolone-only-creambalmemulsion-application-female-genital-area-list-nationally-authorised-medicinal-products-psusa00010441201704_en.pdf"},
    {"id":"13300","name":"Testosterone undecylate (injection): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation-PSUSA/00010161/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-04T12:20:00Z","last_updated_date":"2016-10-19T12:24:52Z","reference_number":"EMA/592574/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-undecylate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201411_en.pdf"},
    {"id":"13306","name":"Tiagabine: List of nationally authorised medicinal products - PSUSA/00002942/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-08T11:47:00Z","last_updated_date":"2016-10-19T12:50:09Z","reference_number":"EMA/178814/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiagabine-list-nationally-authorised-medicinal-products-psusa00002942201506_en.pdf"},
    {"id":"13367","name":"Fluvoxamine: List of nationally authorised medicinal products - PSUSA/00001458/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T12:30:00Z","last_updated_date":"2018-04-13T12:30:00Z","reference_number":"EMA/231137/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluvoxamine-list-nationally-authorised-medicinal-products-psusa00001458201707_en.pdf"},
    {"id":"13373","name":"Etoricoxib: List of nationally authorised medicinal products - PSUSA/00001334/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T13:20:00Z","last_updated_date":"2017-12-08T13:20:00Z","reference_number":"EMA/812634/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/etoricoxib-list-nationally-authorised-medicinal-products-psusa00001334201703_en.pdf"},
    {"id":"13392","name":"Mizolastine: List of nationally authorised medicinal products - PSUSA/00002078/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-05T14:00:00Z","last_updated_date":"2018-09-05T14:00:00Z","reference_number":"EMA/595427/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/mizolastine-list-nationally-authorised-medicinal-products-psusa00002078201711_en.pdf"},
    {"id":"13453","name":"Calcitonin salmon, synthetic analogue of eel calcitonin: List of nationally authorised medicinal products - PSUSA/00000494/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-11T02:00:00Z","last_updated_date":"2016-10-18T14:01:11Z","reference_number":"EMA/255959/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcitonin-salmon-synthetic-analogue-eel-calcitonin-list-nationally-authorised-medicinal-products-psusa00000494201506_en.pdf"},
    {"id":"13466","name":"Finasteride : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001392/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-30T19:05:00Z","last_updated_date":"2017-05-30T19:15:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201608_no.pdf"}},
    {"id":"13477","name":"Ibuprofen / pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00001711/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-13T15:00:00Z","last_updated_date":"2017-02-13T18:29:31Z","reference_number":"EMA/89247/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00001711201607_en.pdf"},
    {"id":"13500","name":"Piribedil: List of nationally authorised medicinal products - PSUSA/00002436/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-05T17:20:00Z","last_updated_date":"2017-12-05T17:20:00Z","reference_number":"EMA/806835/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/piribedil-list-nationally-authorised-medicinal-products-psusa00002436201703_en.pdf"},
    {"id":"13510","name":"Pramiracetam: List of nationally authorised medicinal products - PSUSA/00002492/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-07T12:00:00Z","last_updated_date":"2016-10-17T18:48:34Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/pramiracetam-list-nationally-authorised-medicinal-products-psusa00002492201409_en.pdf"},
    {"id":"13512","name":"Cefuroxime sodium (except for intracameral use): List of nationally authorised medicinal products - PSUSA/00000615/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T15:36:00Z","last_updated_date":"2018-01-26T15:44:00Z","reference_number":"EMA/PRAC/773016/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-sodium-except-intracameral-use-list-nationally-authorised-medicinal-products-psusa00000615201704_en.pdf"},
    {"id":"13524","name":"Celecoxib: List of nationally authorised medicinal products - PSUSA/00000616/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T13:00:00Z","last_updated_date":"2018-09-13T13:02:43Z","reference_number":"EMA/613929/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/celecoxib-list-nationally-authorised-medicinal-products-psusa00000616201712_en.pdf"},
    {"id":"13572","name":"Influenza vaccine (surface antigen, inactivated, adjuvanted): List of nationally authorised medicinal products - PSUSA/00010300/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T01:00:00Z","last_updated_date":"2016-10-17T18:39:12Z","reference_number":"EMA/845107/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-adjuvanted-list-nationally-authorised-medicinal-products-psusa00010300201504_en.pdf"},
    {"id":"13670","name":"Valproic acid / sodium valproate / valproate pivoxil / valproate semisodium / valpromide/valproate bismuth / calcium valproate / valproate magnesium: List of nationally authorised medicinal products - PSUSA/00003090/2015...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-03T13:00:00Z","last_updated_date":"2016-10-17T20:16:34Z","reference_number":"EMA/727149/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromidevalproate-bismuth-calcium-valproate-valproate-magnesium-list-nationally-authorised-medicinal-products-psusa000030902015_en.pdf"},
    {"id":"13702","name":"Hydroquinidine : List of nationally authorised medicinal products - PSUSA/00001688/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-30T17:14:00Z","last_updated_date":"2017-10-30T17:16:14Z","reference_number":"EMA/722496/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroquinidine-list-nationally-authorised-medicinal-products-psusa00001688201703_en.pdf"},
    {"id":"13757","name":"Hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine: List of nationally authorised medicinal products - PSUSA/00001696/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-20T16:40:00Z","last_updated_date":"2017-01-20T16:40:00Z","reference_number":"EMA/36356/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-list-nationally-authorised-medicinal-products-psusa00001696201605_en.pdf"},
    {"id":"13824","name":"Lysine acetylsalicylate: List of nationally authorised medicinal products - PSUSA/00001921/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-24T18:00:00Z","last_updated_date":"2018-05-24T18:09:40Z","reference_number":"EMA/333539/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/lysine-acetylsalicylate-list-nationally-authorised-medicinal-products-psusa00001921201709_en.pdf"},
    {"id":"13850","name":"Furosemide: CMDh scientific conclusions and grounds for variation, amendments to the product information, and timetable for the implementation - PSUSA/00001491/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-05T01:00:00Z","last_updated_date":"2016-10-18T13:42:40Z","reference_number":"EMA/729667/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/furosemide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001491201501_en.pdf"},
    {"id":"13864","name":"Fludarabine: List of nationally authorised medicinal products - PSUSA/00001406/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T12:50:00Z","last_updated_date":"2018-04-13T12:52:09Z","reference_number":"EMA/223740/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fludarabine-list-nationally-authorised-medicinal-products-psusa00001406201708_en.pdf"},
    {"id":"13868","name":"Calcium chloride/ glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00009162/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-18T15:41:00Z","reference_number":"EMA/829696/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-chloride-glutamic-acid-glutathione-histidine-lactobionic-acid-magnesium-chloride-mannitol-potassium-chloride-sodium-hydroxide-list-nationally-authorised-medicinal-products-psusa00009162201503_en.pdf"},
    {"id":"13888","name":"Oxcarbazepine : List of nationally authorised medicinal products - PSUSA/00002235/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-10T16:42:00Z","last_updated_date":"2017-05-10T16:45:09Z","reference_number":"EMA/290427/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxcarbazepine-list-nationally-authorised-medicinal-products-psusa00002235201608_en.pdf"},
    {"id":"13936","name":"Oxatomide: List of nationally authorised medicinal products - PSUSA/00002233/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T13:00:00Z","last_updated_date":"2017-10-03T13:00:00Z","reference_number":"EMA/653118/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxatomide-list-nationally-authorised-medicinal-products-psusa00002233201701_en.pdf"},
    {"id":"13945","name":"Bismuth subcitrate potassium / metronidazole / tetracycline: List of nationally authorised medicinal products - PSUSA/00010199/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-10-18T14:01:12Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-list-nationally-authorised-medicinal-products-psusa00010199201505_en.pdf"},
    {"id":"13995","name":"Nadifloxacin: List of nationally authorised medicinal products    -    PSUSA/00002102/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T18:37:00Z","last_updated_date":"2017-03-09T18:43:29Z","reference_number":"EMA/150639/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/nadifloxacin-list-nationally-authorised-medicinal-products-psusa00002102201605_en.pdf"},
    {"id":"14026","name":"Isotretinoin (oral formulations): CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010488/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-08-31T18:30:00Z","last_updated_date":"2017-08-31T18:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201611_no.pdf"}},
    {"id":"14036","name":"Fluticasone propionate / formoterol fumarate dihydrate: List of nationally authorised medicinal products - PSUSA/00010339/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-18T16:32:00Z","reference_number":"EMA/346216/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluticasone-propionate-formoterol-fumarate-dihydrate-list-nationally-authorised-medicinal-products-psusa00010339201507_en.pdf"},
    {"id":"14069","name":"Caffeine (apnea): List of nationally authorised medicinal products - PSUSA/00000482/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-15T14:41:00Z","last_updated_date":"2018-03-15T14:52:00Z","reference_number":"EMA/163861/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/caffeine-apnea-list-nationally-authorised-medicinal-products-psusa00000482201707_en.pdf"},
    {"id":"14148","name":"Ajmaline: List of nationally authorised medicinal products - PSUSA/00000072/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-04-18T16:07:00Z","last_updated_date":"2017-04-18T16:10:15Z","reference_number":"EMA/242228/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ajmaline-list-nationally-authorised-medicinal-products-psusa00000072201608_en.pdf"},
    {"id":"14154","name":"Ursodeoxycholic acid : List of nationally authorised medicinal products - PSUSA/00003084/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T12:37:00Z","last_updated_date":"2017-09-06T12:38:59Z","reference_number":"EMA/578638/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ursodeoxycholic-acid-list-nationally-authorised-medicinal-products-psusa00003084201611_en.pdf"},
    {"id":"14197","name":"Nitrous oxide, nitrous oxide / oxygen: List of nationally authorised medicinal products - PSUSA/00010572/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-09T15:56:00Z","last_updated_date":"2018-04-09T16:01:00Z","reference_number":"EMA/214871/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-list-nationally-authorised-medicinal-products-psusa00010572201706_en.pdf"},
    {"id":"14223","name":"Latanoprost (except for products with paediatric indication): List of nationally authorised medicinal products - PSUSA/00001832/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-18T12:00:00Z","last_updated_date":"2017-01-18T12:00:06Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-except-products-paediatric-indication-list-nationally-authorised-medicinal-products-psusa00001832201604_en.pdf"},
    {"id":"14229","name":"Idarubicin : List of nationally authorised medicinal products - PSUSA/00001720/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T11:47:00Z","last_updated_date":"2017-09-08T11:48:43Z","reference_number":"EMA/593214/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/idarubicin-list-nationally-authorised-medicinal-products-psusa00001720201611_en.pdf"},
    {"id":"14251","name":"Artemether / lumefantrin (dispersible tablet): List of nationally authorised medicinal products - PSUSA/00009060/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-14T02:00:00Z","last_updated_date":"2016-10-17T19:47:24Z","reference_number":"EMA/413583/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/artemether-lumefantrin-dispersible-tablet-list-nationally-authorised-medicinal-products-psusa00009060201510_en.pdf"},
    {"id":"14269","name":"Indapamide: List of nationally authorised medicinal products - PSUSA/00001731/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T02:00:00Z","last_updated_date":"2016-10-17T17:46:43Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/indapamide-list-nationally-authorised-medicinal-products-psusa00001731201511_en.pdf"},
    {"id":"14281","name":"Isoniazide / rifampicin: List of nationally authorised medicinal products - PSUSA/00001792/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-19T12:51:00Z","last_updated_date":"2017-01-19T12:56:00Z","reference_number":"EMA/37152/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoniazide-rifampicin-list-nationally-authorised-medicinal-products-psusa00001792201605_en.pdf"},
    {"id":"14329","name":"Ofloxacin (topical use): List of nationally authorised medicinal products - PSUSA/00002204/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-10-18T12:49:42Z","reference_number":"EMA/62578/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-topical-use-list-nationally-authorised-medicinal-products-psusa00002204201504_en.pdf"},
    {"id":"14335","name":"Tafluprost: List of nationally authorised medicinal products - PSUSA/00002843/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T11:00:00Z","last_updated_date":"2016-10-18T13:40:20Z","reference_number":"EMA/38055/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/tafluprost-list-nationally-authorised-medicinal-products-psusa00002843201504_en.pdf"},
    {"id":"14474","name":"Lanthanum: List of nationally authorised medicinal products - PSUSA/00003175/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-19T18:20:00Z","last_updated_date":"2018-01-19T18:20:00Z","reference_number":"EMA/789577/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/lanthanum-list-nationally-authorised-medicinal-products-psusa00003175201703_en.pdf"},
    {"id":"14499","name":"Ivermectin (topical use): List of nationally authorised medicinal products - PSUSA/00010376/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-13T10:55:00Z","last_updated_date":"2017-06-13T10:57:00Z","reference_number":"EMA/371228/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-topical-use-list-nationally-authorised-medicinal-products-psusa00010376201610_en.pdf"},
    {"id":"14552","name":"Cyproterone / ethinylestradiol: List of nationally authorised medicinal products - PSUSA/00000906/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T17:30:00Z","last_updated_date":"2018-01-15T17:30:00Z","reference_number":"EMA/28086/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproterone-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa00000906201705_en.pdf"},
    {"id":"14594","name":"Mesalazine: List of nationally authorised medicinal products - PSUSA/00001990/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-18T11:29:37Z","reference_number":"EMA/829587/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesalazine-list-nationally-authorised-medicinal-products-psusa00001990201502_en.pdf"},
    {"id":"14619","name":"Delapril: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information, and timetable for the implementation - PSUSA/00000946/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-06T13:00:00Z","last_updated_date":"2016-10-17T20:25:27Z","reference_number":"EMA/734289/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/delapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000946201501_en.pdf"},
    {"id":"14628","name":"Caffeine / drotaverine hydrochloride / metamizol sodium: List of nationally authorised medicinal products - PSUSA/00001996/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T11:58:00Z","last_updated_date":"2018-07-19T12:00:32Z","reference_number":"EMA/489293/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/caffeine-drotaverine-hydrochloride-metamizol-sodium-list-nationally-authorised-medicinal-products-psusa00001996201711_en.pdf"},
    {"id":"14642","name":"Thiocolchicoside: List of nationally authorised medicinal products-PSUSA/00002927/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T12:35:00Z","last_updated_date":"2016-10-19T12:44:34Z","reference_number":"EMA/345339/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiocolchicoside-list-nationally-authorised-medicinal-products-psusa00002927201507_en.pdf"},
    {"id":"14687","name":"Carvedilol : List of nationally authorised medicinal products - PSUSA/00000575/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T12:21:00Z","last_updated_date":"2017-12-01T12:23:18Z","reference_number":"EMA/787721/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/carvedilol-list-nationally-authorised-medicinal-products-psusa00000575201704_en.pdf"},
    {"id":"14750","name":"Testosterone (topical use): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002908/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-03T15:40:00Z","last_updated_date":"2016-11-03T16:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002908201512_no.pdf"}},
    {"id":"14782","name":"Hydroxyethyl starch: List of nationally authorised medicinal products - PSUSA/00001694/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-04T11:55:00Z","last_updated_date":"2017-10-04T11:55:53Z","reference_number":"EMA/637890/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-list-nationally-authorised-medicinal-products-psusa00001694201703_en.pdf"},
    {"id":"14805","name":"Ketoprofen (topical use only): List of nationally authorised medicinal products - PSUSA/00009205/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-17T19:03:13Z","reference_number":"EMA/345763/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketoprofen-topical-use-only-list-nationally-authorised-medicinal-products-psusa00009205201509_en.pdf"},
    {"id":"14859","name":"Ethinylestradiol / levonorgestrel: List of nationally authorised medicinal products - PSUSA/00001309/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T01:00:00Z","last_updated_date":"2016-12-14T19:03:00Z","reference_number":"EMA/858449/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-levonorgestrel-list-nationally-authorised-medicinal-products-psusa00001309201604_en.pdf"},
    {"id":"14862","name":"Amlodipine / perindopril: List of nationally authorised medicinal products - PSUSA/00000179/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-12T10:45:00Z","last_updated_date":"2017-06-12T11:05:00Z","reference_number":"EMA/369195/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-perindopril-list-nationally-authorised-medicinal-products-psusa00000179201610_en.pdf"}    {"id":"14925","name":"Promestriene (cream and vaginal capsules): List of nationally authorised medicinal products - PSUSA/00009271/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T15:54:00Z","last_updated_date":"2017-12-20T16:03:00Z","reference_number":"EMA/844321/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/promestriene-cream-and-vaginal-capsules-list-nationally-authorised-medicinal-products-psusa00009271201703_en.pdf"},
    {"id":"14986","name":"Isoniazid: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001789/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T02:00:00Z","last_updated_date":"2016-10-17T18:51:24Z","reference_number":"EMA/511244/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoniazid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001789201411_en.pdf"},
    {"id":"15035","name":"Finasteride: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001392/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T17:01:00Z","last_updated_date":"2018-06-07T17:10:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/finasteride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001392201708_no.pdf"}},
    {"id":"15312","name":"Lisdexamfetamine: List of nationally authorised medicinal products - PSUSA/00010289/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2016-10-18T10:40:09Z","reference_number":"EMA/716223/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa00010289201502_en.pdf"},
    {"id":"15362","name":"Ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus): List of nationally authorised medicinal products - PSUSA/00010345/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T12:25:00Z","last_updated_date":"2018-01-03T12:42:48Z","reference_number":"EMA/845743/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-list-nationally-authorised-medicinal-products-psusa00010345201702_en.pdf"},
    {"id":"15367","name":"Gadoteridol: List of nationally authorised medicinal products - PSUSA/00001507/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T01:00:00Z","last_updated_date":"2016-10-18T16:56:40Z","reference_number":"EMA/186911/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteridol-list-nationally-authorised-medicinal-products-psusa00001507201504_en.pdf"},
    {"id":"15388","name":"Mifepristone / misoprostol: List of nationally authorised medicinal products - PSUSA/00010378/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-08T11:15:00Z","last_updated_date":"2018-03-08T11:21:00Z","reference_number":"EMA/44742/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa00010378201705_en.pdf"},
    {"id":"15406","name":"Triptorelin : List of nationally authorised medicinal products - PSUSA/00003048/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-05T15:53:00Z","last_updated_date":"2017-12-05T15:57:03Z","reference_number":"EMA/803254/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/triptorelin-list-nationally-authorised-medicinal-products-psusa00003048201703_en.pdf"},
    {"id":"15424","name":"Olodaterol / tiotropium: List of nationally authorised medicinal products - PSUSA/00010489/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T17:30:00Z","last_updated_date":"2018-01-15T17:30:00Z","reference_number":"EMA/27280/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodaterol-tiotropium-list-nationally-authorised-medicinal-products-psusa00010489201705_en.pdf"},
    {"id":"15445","name":"Mitoxantrone: List of nationally authorised medicinal products - PSUSA/00002076/201606","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T11:00:00Z","last_updated_date":"2017-03-16T11:00:00Z","reference_number":"EMA/178876/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/mitoxantrone-list-nationally-authorised-medicinal-products-psusa00002076201606_en.pdf"},
    {"id":"15452","name":"Chlorquinadol (vaginal tablet) / promestriene: List of nationally authorised medicinal products - PSUSA/00009272/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-10-18T15:41:00Z","reference_number":"EMA/364851/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorquinadol-vaginal-tablet-promestriene-list-nationally-authorised-medicinal-products-psusa00009272201509_en.pdf"},
    {"id":"15476","name":"Rocuronium: List of nationally authorised medicinal products - PSUSA/00002656/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-08T16:00:00Z","last_updated_date":"2016-11-08T16:00:00Z","reference_number":"EMA/735249/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/rocuronium-list-nationally-authorised-medicinal-products-psusa00002656201602_en.pdf"},
    {"id":"15565","name":"Ethinylestradiol  / gestodene (transdermal application): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010145/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-17T13:10:00Z","last_updated_date":"2017-11-17T13:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ethinylestradiol-gestodene-transdermal-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010145201702_no.pdf"}},
    {"id":"15590","name":"Adapalene / benzoyl peroxide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000059/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-12T12:57:00Z","last_updated_date":"2018-08-16T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_es.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_de.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000059201709_no.pdf"}},
    {"id":"15599","name":"Dhydroergocryptine: List of nationally authorised medicinal products - PSUSA/00001074/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-22T13:00:00Z","last_updated_date":"2016-10-17T19:52:23Z","reference_number":"EMA/146687/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/dhydroergocryptine-list-nationally-authorised-medicinal-products-psusa00001074201507_en.pdf"},
    {"id":"15624","name":"Human tetanus immunoglobulin: List of nationally authorised medicinal products - PSUSA/00002909/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-18T18:55:00Z","last_updated_date":"2018-04-18T18:55:00Z","reference_number":"EMA/221460/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-tetanus-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00002909201708_en.pdf"},
    {"id":"15669","name":"Beclometasone / formoterol (inhalative application): List of nationally authorised medicinal products - PSUSA/00010068/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-14T17:30:00Z","last_updated_date":"2017-03-14T17:38:01Z","reference_number":"EMA/171073/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/beclometasone-formoterol-inhalative-application-list-nationally-authorised-medicinal-products-psusa00010068201607_en.pdf"},
    {"id":"15711","name":"Hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine: List of nationally authorised medicinal products - PSUSA/00001696/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-22T17:00:00Z","last_updated_date":"2018-06-22T17:00:00Z","reference_number":"EMA/423869/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-list-nationally-authorised-medicinal-products-psusa00001696201711_en.pdf"},
    {"id":"15759","name":"Diacerein: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001026/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T19:30:00Z","last_updated_date":"2017-10-23T19:44:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/diacerein-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001026201612_sv.pdf"}},
    {"id":"15801","name":"Hydrochlorothiazide moexipril: List of nationally authorised medicinal products - PSUSA/00002082/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-12T16:38:00Z","last_updated_date":"2018-03-12T16:41:15Z","reference_number":"EMA/113527/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-moexipril-list-nationally-authorised-medicinal-products-psusa00002082201706_en.pdf"},
    {"id":"15811","name":"Linezolid : List of nationally authorised medicinal products - PSUSA/00001888/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-07T15:06:00Z","last_updated_date":"2017-12-07T15:10:56Z","reference_number":"EMA/811742/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/linezolid-list-nationally-authorised-medicinal-products-psusa00001888201704_en.pdf"},
    {"id":"15851","name":"Metformin: List of nationally authorised medicinal products - PSUSA/00002001/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2016-10-18T11:29:36Z","reference_number":"EMA/850509/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/metformin-list-nationally-authorised-medicinal-products-psusa00002001201504_en.pdf"},
    {"id":"15865","name":"Eprosartan: List of nationally authorised medicinal products - PSUSA/00001243/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-17T16:06:00Z","last_updated_date":"2018-01-17T16:08:13Z","reference_number":"EMA/32390/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/eprosartan-list-nationally-authorised-medicinal-products-psusa00001243201704_en.pdf"},
    {"id":"15896","name":"Human anti-d immunoglobulin: List of nationally authorised products - PSUSA/00001614/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-10-17T17:15:45Z","reference_number":"EMA/40805/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-anti-d-immunoglobulin-list-nationally-authorised-products-psusa00001614201503_en.pdf"},
    {"id":"15901","name":"Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide : List of nationally authorised medicinal products - PSUSA/00010390/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-23T15:30:00Z","last_updated_date":"2017-03-23T15:30:00Z","reference_number":"EMA/198208/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-list-nationally-authorised-medicinal-products-psusa00010390201607_en.pdf"},
    {"id":"16014","name":"Deoxycholic acid: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010525/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-14T13:00:00Z","last_updated_date":"2018-08-14T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525201710_no.pdf"}},
    {"id":"16055","name":"Buprenorphine: List of nationally authorised medicinal products - PSUSA/00000459/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T15:35:00Z","last_updated_date":"2018-04-19T15:45:29Z","reference_number":"EMA/227734/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/buprenorphine-list-nationally-authorised-medicinal-products-psusa00000459201707_en.pdf"},
    {"id":"16078","name":"Etomidate: List of nationally authorised medicinal products - PSUSA/00001330/20170","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-12T12:42:00Z","last_updated_date":"2018-07-12T12:51:23Z","reference_number":"EMA/473178/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/etomidate-list-nationally-authorised-medicinal-products-psusa0000133020170_en.pdf"},
    {"id":"16093","name":"Gliclazide:  List of nationally authorised medicinal - PSUSA/00001532/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T18:48:00Z","last_updated_date":"2016-10-28T18:49:59Z","reference_number":"EMA/719647/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gliclazide-list-nationally-authorised-medicinal-psusa00001532201602_en.pdf"},
    {"id":"16137","name":"Methyl salicylate / levomenthol / DL-camphor: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010117/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T10:30:00Z","last_updated_date":"2018-03-06T10:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010117201704_sv.pdf"}},
    {"id":"16187","name":"Ipratropium/salbutamol : List of nationally authorised medicinal products - PSUSA-00001781-201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-27T15:00:00Z","last_updated_date":"2017-11-27T15:09:51Z","reference_number":"EMA/784453/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ipratropiumsalbutamol-list-nationally-authorised-medicinal-products-psusa-00001781-201701_en.pdf"},
    {"id":"16268","name":"Enalapril / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA/00001212/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-16T12:32:00Z","last_updated_date":"2018-03-16T12:35:54Z","reference_number":"EMA/170163/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/enalapril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00001212201707_en.pdf"},
    {"id":"16320","name":"Ribavirin (aerosol application): List of nationally authorised medicinal products - PSUSA/00010003/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T12:00:00Z","last_updated_date":"2016-10-17T19:46:17Z","reference_number":"EMA/268896/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ribavirin-aerosol-application-list-nationally-authorised-medicinal-products-psusa00010003201508_en.pdf"},
    {"id":"16344","name":"Erythromycin / isotretinoin: List of nationally authorised medicinal products - PSUSA/00001796/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-27T02:00:00Z","last_updated_date":"2016-10-18T13:42:00Z","reference_number":"EMA/648919/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/erythromycin-isotretinoin-list-nationally-authorised-medicinal-products-psusa00001796201508_en.pdf"},
    {"id":"16426","name":"Rabies vaccine : List of nationally authorised medicinal products: PSUSA/00009277/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T13:22:00Z","last_updated_date":"2016-12-19T13:24:54Z","reference_number":"EMA/865270/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabies-vaccine-list-nationally-authorised-medicinal-products-psusa00009277201603_en.pdf"},
    {"id":"16473","name":"Chlorquinaldol (vaginal tablet) / promestriene: List of nationally authorised medicinal products - PSUSA/00009272/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-04T13:00:00Z","last_updated_date":"2017-07-04T16:12:22Z","reference_number":"EMA/405580/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-list-nationally-authorised-medicinal-products-psusa00009272201609_en.pdf"},
    {"id":"16479","name":"Etidronate: List of nationally authorised medicinal products - PSUSA/00001320/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T20:00:00Z","last_updated_date":"2018-05-23T20:22:17Z","reference_number":"EMA/325505/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/etidronate-list-nationally-authorised-medicinal-products-psusa00001320201709_en.pdf"},
    {"id":"16530","name":"Insulin porcine: List of nationally authorised medicinal products - PSUSA/00001756/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T02:00:00Z","last_updated_date":"2016-10-17T18:51:25Z","reference_number":"EMA/456355/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/insulin-porcine-list-nationally-authorised-medicinal-products-psusa00001756201410_en.pdf"},
    {"id":"16532","name":"Tixocortol, chlorhexidine gluconate / tixocortol pivalate : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010333/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-08-29T12:03:00Z","last_updated_date":"2017-08-29T12:11:09Z","reference_number":"EMA/431386/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010333201611_no.pdf"}},
    {"id":"16581","name":"Mifepristone / misoprostol: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010378/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-08T11:15:00Z","last_updated_date":"2018-03-08T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010378201705_sv.pdf"}},
    {"id":"16609","name":"Leuprorelin: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001844/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-04T13:30:00Z","last_updated_date":"2018-09-10T17:40:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/leuprorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001844201707_no.pdf"}},
    {"id":"16621","name":"Methoxyflurane: List of nationally authorised medicinal products - PSUSA/00010484/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T11:10:00Z","last_updated_date":"2018-01-18T11:10:00Z","reference_number":"EMA/34468/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa00010484201705_en.pdf"},
    {"id":"16690","name":"Furosemide / spironolactone: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00001493/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-25T02:00:00Z","last_updated_date":"2016-10-18T13:42:38Z","reference_number":"EMA/729829/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/furosemide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001493201512_en.pdf"},
    {"id":"16713","name":"Trandolapril / verapamil: List of nationally authorised medicinal products - PSUSA/00003005/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T13:00:00Z","last_updated_date":"2016-10-17T20:16:41Z","reference_number":"EMA/13478/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/trandolapril-verapamil-list-nationally-authorised-medicinal-products-psusa00003005201503_en.pdf"},
    {"id":"16780","name":"Rilmenidine: List of nationally authorised medicinal products - PSUSA/00002643/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-14T12:00:00Z","last_updated_date":"2016-10-17T19:46:20Z","reference_number":"EMA/411814/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/rilmenidine-list-nationally-authorised-medicinal-products-psusa00002643201508_en.pdf"},
    {"id":"16791","name":"Estradiol / norethisterone: List of nationally authorised medicinal products - PSUSA/00001278/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-07T18:20:00Z","last_updated_date":"2017-12-07T18:20:00Z","reference_number":"EMA/811808/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/estradiol-norethisterone-list-nationally-authorised-medicinal-products-psusa00001278201703_en.pdf"},
    {"id":"16828","name":"Diacerein: List of nationally authorised medicinal products - PSUSA/00001026/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T19:30:00Z","last_updated_date":"2017-10-23T19:44:01Z","reference_number":"EMA/704704/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/diacerein-list-nationally-authorised-medicinal-products-psusa00001026201612_en.pdf"},
    {"id":"16862","name":"Paracetamol (IV formulation): List of nationally authorised medicinal products - PSUSA/00002311/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-04T13:00:00Z","last_updated_date":"2016-10-17T16:31:00Z","reference_number":"EMA/1461/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-iv-formulation-list-nationally-authorised-medicinal-products-psusa00002311201505_en.pdf"},
    {"id":"16908","name":"Metamizole: List of nationally authorised medicinal products - PSUSA/00001997/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-10T01:00:00Z","last_updated_date":"2016-10-18T11:29:36Z","reference_number":"EMA/PRAC/798943/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/metamizole-list-nationally-authorised-medicinal-products-psusa00001997201504_en.pdf"},
    {"id":"16913","name":"Levocetirizine: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001850/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T13:55:00Z","last_updated_date":"2018-04-27T13:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levocetirizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001850201707_no.pdf"}},
    {"id":"16947","name":"Cisatracurium: List of nationally authorised medicinal products - PSUSA/00000777/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T14:00:00Z","last_updated_date":"2016-10-17T20:25:29Z","reference_number":"EMA/346187/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cisatracurium-list-nationally-authorised-medicinal-products-psusa00000777201507_en.pdf"},
    {"id":"16967","name":"Alteplase: List of nationally authorised medicinal products - PSUSA/00000112/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T17:30:00Z","last_updated_date":"2018-03-07T17:36:32Z","reference_number":"EMA/145053/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/alteplase-list-nationally-authorised-medicinal-products-psusa00000112201705_en.pdf"},
    {"id":"16978","name":"Timolol (eye preparations): List of nationally authorised medicinal products - PSUSA/00010439/201607","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2017-04-11T19:40:00Z","last_updated_date":"2017-04-11T19:40:00Z","reference_number":"EMA/208664/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/timolol-eye-preparations-list-nationally-authorised-medicinal-products-psusa00010439201607_en.pdf"},
    {"id":"16983","name":"Almotriptan: List of nationally authorised medicinal products - PSUSA/00000101/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T12:30:00Z","last_updated_date":"2018-03-09T12:52:34Z","reference_number":"EMA/154280/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/almotriptan-list-nationally-authorised-medicinal-products-psusa00000101201706_en.pdf"},
    {"id":"16989","name":"Bismuth subcitrate potassium / metronidazole / tetracycline: List of nationally authorised medicinal products - PSUSA/00010199/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T15:55:00Z","last_updated_date":"2018-03-06T15:55:00Z","reference_number":"EMA/142409/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-list-nationally-authorised-medicinal-products-psusa00010199201705_en.pdf"},
    {"id":"16998","name":"Thiocolchicoside: CMDh Scientific conclusions and grounds for the variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002927/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-21T16:49:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002927201507_en.pdf"},
    {"id":"17066","name":"Frovatriptan: List of nationally authorised medicinal products - PSUSA/00001484/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T18:52:00Z","last_updated_date":"2017-10-26T18:55:45Z","reference_number":"EMA/716519/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/frovatriptan-list-nationally-authorised-medicinal-products-psusa00001484201703_en.pdf"},
    {"id":"17079","name":"Urapidil: List of nationally authorised medicinal products - PSUSA/00003078/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T14:00:00Z","last_updated_date":"2016-10-17T20:16:31Z","reference_number":"EMA/346105/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/urapidil-list-nationally-authorised-medicinal-products-psusa00003078201507_en.pdf"},
    {"id":"17130","name":"Influenza vaccine (split virion, inactivated, prepared in cell cultures): List of nationally authorised medicinal products - PSUSA/00010299/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T15:00:00Z","last_updated_date":"2016-10-28T15:00:00Z","reference_number":"EMA/719243/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-prepared-cell-cultures-list-nationally-authorised-medicinal-products-psusa00010299201603_en.pdf"},
    {"id":"17132","name":"Bendamustine hydrochloride: List of nationally authorised medicinal products - PSUSA/00003162/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T16:00:00Z","last_updated_date":"2017-10-23T16:00:00Z","reference_number":"EMA/699929/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendamustine-hydrochloride-list-nationally-authorised-medicinal-products-psusa00003162201701_en.pdf"},
    {"id":"17151","name":"Diphtheria / tetanus / pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed), diphtheria / tetanus / pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed) reduc...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T14:00:00Z","last_updated_date":"2017-02-22T12:47:27Z","reference_number":"EMA/243503/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-pertussis-acellular-component-and-poliomyelitis-inactivated-vaccine-adsorbed-diphtheria-tetanus-pertussis-acellular-component-and-poliomyelitis-inactivated-vaccine-adsorbed-reduc_en.pdf"},
    {"id":"17182","name":"Interferon gamma: List of nationally authorised medicinal products - PSUSA/00001760/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T17:20:00Z","last_updated_date":"2016-10-19T17:24:30Z","reference_number":"EMA/646371/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/interferon-gamma-list-nationally-authorised-medicinal-products-psusa00001760201601_en.pdf"},
    {"id":"17195","name":"Influenza vaccine (surface antigen, inactivated, virosome): List of nationally authorised medicinal products - PSUSA/00001746/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-17T18:39:11Z","reference_number":"EMA/346551/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-virosome-list-nationally-authorised-medicinal-products-psusa00001746201508_en.pdf"},
    {"id":"17196","name":"Chlormadinone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000677/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T12:45:00Z","last_updated_date":"2017-12-08T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/chlormadinone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000677201611_sv.pdf"}},
    {"id":"17249","name":"Mxifloxacin (topical ophthalmic use): List of nationally authorised medicinal products - PSUSA/00002094/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-16T15:20:00Z","last_updated_date":"2017-01-16T15:23:00Z","reference_number":"EMA/28753/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/mxifloxacin-topical-ophthalmic-use-list-nationally-authorised-medicinal-products-psusa00002094201605_en.pdf"},
    {"id":"17266","name":"Minocycline: List of nationally authorised medicinal products - PSUSA/00002065/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T20:00:00Z","last_updated_date":"2018-05-23T20:22:17Z","reference_number":"EMA/326432/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/minocycline-list-nationally-authorised-medicinal-products-psusa00002065201708_en.pdf"},
    {"id":"17315","name":"Terlipressin: List of nationally authorised medicinal products-PSUSA/00002905/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-31T12:15:00Z","last_updated_date":"2016-10-19T12:14:38Z","reference_number":"EMA/230198/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/terlipressin-list-nationally-authorised-medicinal-products-psusa00002905201504_en.pdf"},
    {"id":"17367","name":"Felodipine: List of nationally authorised medicinal products - PSUSA/00001356/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-11T11:28:00Z","last_updated_date":"2018-09-11T11:32:57Z","reference_number":"EMA/609153/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/felodipine-list-nationally-authorised-medicinal-products-psusa00001356201712_en.pdf"},
    {"id":"17373","name":"Fludeoxyglucose (18f): List of nationally authorised medicinal products - PSUSA/00001437/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T12:50:00Z","last_updated_date":"2018-07-19T12:50:00Z","reference_number":"EMA/496103/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fludeoxyglucose-18f-list-nationally-authorised-medicinal-products-psusa00001437201711_en.pdf"},
    {"id":"17409","name":"Tixocortol, chlorhexidine gluconate / tixocortol pivalate : List of nationally authorised medicinal products - PSUSA/00010333/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-08-29T12:03:00Z","last_updated_date":"2017-08-29T12:11:10Z","reference_number":"EMA/431386/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-list-nationally-authorised-medicinal-products-psusa00010333201611_en.pdf"},
    {"id":"17427","name":"Sulprostone: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00002828/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T10:15:00Z","last_updated_date":"2017-03-10T10:31:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/sulprostone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002828201604_sv.pdf"}},
    {"id":"17483","name":"Asparaginase: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00003161/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-15T02:00:00Z","last_updated_date":"2016-10-17T19:40:10Z","reference_number":"EMA/407533/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/asparaginase-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003161201508_en.pdf"},
    {"id":"17489","name":"Hydrochlorothiazide, spironolactone: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00001662/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-17T17:35:00Z","reference_number":"EMA/739537/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662201501_en.pdf"},
    {"id":"17536","name":"Carmustine (implant): List of nationally authorised medicinal products - PSUSA/00010348/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-30T02:00:00Z","last_updated_date":"2016-10-18T15:41:12Z","reference_number":"EMA/375083/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/carmustine-implant-list-nationally-authorised-medicinal-products-psusa00010348201509_en.pdf"},
    {"id":"17541","name":"Ceftibuten: List of nationally authorised medicinal products - PSUSA/00000611/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-15T18:11:00Z","last_updated_date":"2018-03-15T18:15:54Z","reference_number":"EMA/168151/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftibuten-list-nationally-authorised-medicinal-products-psusa00000611201707_en.pdf"},
    {"id":"17594","name":"Morphine morphine-cyclizine: List of nationally authorised medicinal products - PSUSA/00010549/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-02T18:00:00Z","last_updated_date":"2018-08-03T17:00:00Z","reference_number":"EMA/524132/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/morphine-morphine-cyclizine-list-nationally-authorised-medicinal-products-psusa00010549201710_en.pdf"},
    {"id":"17700","name":"Carboprost: List of nationally authorised medicinal products - PSUSA/00000560/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-10-18T15:41:10Z","reference_number":"EMA/599288/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/carboprost-list-nationally-authorised-medicinal-products-psusa00000560201601_en.pdf"},
    {"id":"17727","name":"Sertindole: List of nationally authorised medicinal products - PSUSA/00002695/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-05T16:30:00Z","last_updated_date":"2017-09-05T16:30:00Z","reference_number":"EMA/580033/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/sertindole-list-nationally-authorised-medicinal-products-psusa00002695201701_en.pdf"},
    {"id":"17745","name":"Brimonidine (except for the centrally authorised product): List of nationally authorised medicinal products - PSUSA/00000430/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-14T19:00:00Z","last_updated_date":"2017-06-14T19:00:00Z","reference_number":"EMA/366180/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/brimonidine-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00000430201609_en.pdf"},
    {"id":"17830","name":"Tafluprost / timolol: List of nationally authorised medicinal products - PSUSA/00010324/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T12:50:00Z","last_updated_date":"2018-07-19T12:50:00Z","reference_number":"EMA/497430/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/tafluprost-timolol-list-nationally-authorised-medicinal-products-psusa00010324201712_en.pdf"},
    {"id":"17837","name":"Tenonitrozole: List of nationally authorised medicinal products - PSUSA/00003185/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-14T12:00:00Z","last_updated_date":"2016-10-19T12:14:40Z","reference_number":"EMA/680095/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tenonitrozole-list-nationally-authorised-medicinal-products-psusa00003185201502_en.pdf"},
    {"id":"17914","name":"Ivabradine /metoprolol: List of nationally authorised medicinal products - PSUSA/00010381/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T12:44:00Z","last_updated_date":"2016-12-02T12:48:38Z","reference_number":"EMA/810188/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivabradine-metoprolol-list-nationally-authorised-medicinal-products-psusa00010381201604_en.pdf"},
    {"id":"17921","name":"Aciclovir / hydrocortisone: List of nationally authorised medicinal products - PSUSA/00003065/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T15:35:00Z","last_updated_date":"2018-04-19T15:45:00Z","reference_number":"EMA/230850/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/aciclovir-hydrocortisone-list-nationally-authorised-medicinal-products-psusa00003065201708_en.pdf"},
    {"id":"17981","name":"Chlorquinaldol (vaginal tablet) / promestriene: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00009272/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-04T13:00:00Z","last_updated_date":"2017-07-04T16:12:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009272201609_sv.pdf"}},
    {"id":"17990","name":"Minoxidil (topical formulation): List of nationally authorised medicinal products - PSUSA/00002067/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-05T02:00:00Z","last_updated_date":"2016-10-18T12:21:22Z","reference_number":"EMA/587045/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/minoxidil-topical-formulation-list-nationally-authorised-medicinal-products-psusa00002067201510_en.pdf"},
    {"id":"18000","name":"Saccharomyces boulardii : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00009284/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T12:29:00Z","last_updated_date":"2017-12-01T15:35:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284201702_no.pdf"}},
    {"id":"18077","name":"Ezetimibe / rosuvastatin: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010271/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T11:30:00Z","last_updated_date":"2018-05-07T18:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271201707_no.pdf"}},
    {"id":"18214","name":"Isotretinoin: List of nationally authorised medicinal products - PSUSA/00001795/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-10-20T18:50:42Z","reference_number":"EMA/60776/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-list-nationally-authorised-medicinal-products-psusa00001795201505_en.pdf"},
    {"id":"18225","name":"Tiotropium: List of nationally authorised medicinal products - PSUSA/00002972/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-12T10:45:00Z","last_updated_date":"2017-06-12T11:05:46Z","reference_number":"EMA/356882/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiotropium-list-nationally-authorised-medicinal-products-psusa00002972201610_en.pdf"},
    {"id":"18231","name":"Lenograstim: List of nationally authorised medicinal products - PSUSA/00001839/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-08-25T12:00:00Z","last_updated_date":"2017-08-25T12:04:10Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/lenograstim-list-nationally-authorised-medicinal-products-psusa00001839201610_en.pdf"},
    {"id":"18281","name":"Acetylsalicylic acid / bisoprolol: List of nationally authorised medicinal products - PSUSA/00010287/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-10-17T17:40:44Z","reference_number":"EMA/447103/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-bisoprolol-list-nationally-authorised-medicinal-products-psusa00010287201511_en.pdf"},
    {"id":"18287","name":"Cilostazol: List of nationally authorised medicinal products - PSUSA/00010209/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-18T15:41:06Z","reference_number":"EMA/347157/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilostazol-list-nationally-authorised-medicinal-products-psusa00010209201508_en.pdf"},
    {"id":"18388","name":"Oxytocin: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002263/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T13:55:00Z","last_updated_date":"2018-04-27T14:18:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oxytocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002263201706_no.pdf"}},
    {"id":"18493","name":"Testosterone undecanoate (injection): CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010161/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T16:30:00Z","last_updated_date":"2016-11-07T18:12:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/testosterone-undecanoate-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010161201512_no.pdf"}},
    {"id":"18517","name":"Bromperidol: List of nationally authorised medicinal products - PSUSA/00000439/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T16:40:00Z","last_updated_date":"2018-07-17T16:40:00Z","reference_number":"EMA/475623/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromperidol-list-nationally-authorised-medicinal-products-psusa00000439201711_en.pdf"},
    {"id":"18563","name":"Trimetazidine: List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-04T02:00:00Z","last_updated_date":"2016-10-04T02:00:00Z","reference_number":"EMA/637689/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-list-nationally-authorised-medicinal-products-emeahnpsrj0002_en.pdf"},
    {"id":"18700","name":"Amisulpride: List of nationally authorised medicinal products -PSUSA/00000167/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2016-10-17T19:40:20Z","reference_number":"EMA/701558/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/amisulpride-list-nationally-authorised-medicinal-products-psusa00000167201501_en.pdf"},
    {"id":"18728","name":"Nomegestrol: List of nationally authorised medicinal products - PSUSA/00002181/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-21T01:00:00Z","last_updated_date":"2016-10-18T12:37:33Z","reference_number":"EMA/49392/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/nomegestrol-list-nationally-authorised-medicinal-products-psusa00002181201501_en.pdf"},
    {"id":"18772","name":"Bacillus clausii multi-antibioresistant spores: List of nationally authorised medicinal products - PSUSA/00000284/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T18:40:00Z","last_updated_date":"2017-10-26T18:48:20Z","reference_number":"EMA/715760/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-list-nationally-authorised-medicinal-products-psusa00000284201611_en.pdf"},
    {"id":"18779","name":"F(ab’)2 fragments of equine antirabies immunoglobulin: List of nationally authorised medicinal products - PSUSA/00001348/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-16T15:20:00Z","last_updated_date":"2017-01-16T15:23:01Z","reference_number":"EMA/28510/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fab2-fragments-equine-antirabies-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00001348201605_en.pdf"}    {"id":"18797","name":"Aminosalicylate sodium : List of nationally authorised medicinal products - PSUSA/00000165/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-14T14:05:00Z","last_updated_date":"2017-06-14T14:07:12Z","reference_number":"EMA/375673/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/aminosalicylate-sodium-list-nationally-authorised-medicinal-products-psusa00000165201610_en.pdf"},
    {"id":"18834","name":"Diphtheria / tetanus / pertussis (acellular, component) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed): List of nationally authorised medicinal products - PSUSA/00001124/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T12:35:00Z","last_updated_date":"2018-07-19T12:35:00Z","reference_number":"EMA/495687/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-pertussis-acellular-component-poliomyelitis-inactivated-haemophilus-type-b-conjugate-vaccine-adsorbed-list-nationally-authorised-medicinal-products-psusa00001124201711_en.pdf"},
    {"id":"18852","name":"Paclitaxel: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00002264/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-25T02:00:00Z","last_updated_date":"2016-10-25T19:37:13Z","reference_number":"EMA/706621/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/paclitaxel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002264201512_en.pdf"},
    {"id":"18858","name":"Ondansetron: List of nationally authorised medicinal products -  PSUSA/00002217/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-18T13:02:19Z","reference_number":"EMA/827738/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/ondansetron-list-nationally-authorised-medicinal-products-psusa00002217201502_en.pdf"},
    {"id":"18923","name":"Corticorelin: List of nationally authorised medicinal products - PSUSA/00000876/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T14:00:00Z","last_updated_date":"2016-10-17T20:37:50Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/corticorelin-list-nationally-authorised-medicinal-products-psusa00000876201410_en.pdf"},
    {"id":"18984","name":"Cilostazol : List of nationally authorised medicinal products - PSUSA/00010209/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T12:30:00Z","last_updated_date":"2017-10-03T12:31:15Z","reference_number":"EMA/631207/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilostazol-list-nationally-authorised-medicinal-products-psusa00010209201702_en.pdf"},
    {"id":"18988","name":"Sultamicillin: List of nationally authorised medicinal products - PSUSA/00002829/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-15T12:00:00Z","last_updated_date":"2016-10-18T11:56:10Z","reference_number":"EMA/492708/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/sultamicillin-list-nationally-authorised-medicinal-products-psusa00002829201511_en.pdf"},
    {"id":"19032","name":"Roxithromycin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002669/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-19T13:45:00Z","last_updated_date":"2018-06-04T12:50:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/roxithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002669201612_no.pdf"}},
    {"id":"19038","name":"Mupirocin : List of nationally authorised medicinal products - PSUSA/00002096/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-07T13:01:00Z","last_updated_date":"2017-12-07T13:03:53Z","reference_number":"EMA/812360/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/mupirocin-list-nationally-authorised-medicinal-products-psusa00002096201703_en.pdf"},
    {"id":"19082","name":"Estradiol (without cream/balm/emulsion for application in the female genital area): List of nationally authorised medicinal products - PSUSA/00010440/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T16:00:00Z","last_updated_date":"2017-05-12T16:00:00Z","reference_number":"EMA/269084/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/estradiol-without-creambalmemulsion-application-female-genital-area-list-nationally-authorised-medicinal-products-psusa00010440201608_en.pdf"},
    {"id":"19087","name":"Teicoplanin: List of nationally authorised medicinal products - PSUSA/00002878/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-11T11:17:00Z","last_updated_date":"2017-07-11T11:19:15Z","reference_number":"EMA/438097/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/teicoplanin-list-nationally-authorised-medicinal-products-psusa00002878201611_en.pdf"},
    {"id":"19138","name":"Tramadol: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003002/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T19:00:00Z","last_updated_date":"2018-03-07T19:00:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002201705_no.pdf"}},
    {"id":"19163","name":"Porfimer: List of nationally authorised medicinal products - PSUSA/00010332/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T12:22:00Z","last_updated_date":"2017-12-01T12:25:22Z","reference_number":"EMA/797697/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/porfimer-list-nationally-authorised-medicinal-products-psusa00010332201704_en.pdf"},
    {"id":"19185","name":"Nitrazepam: List of nationally authorised medicinal products - PSUSA/00002170/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2016-10-18T12:37:30Z","reference_number":"EMA/716269/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrazepam-list-nationally-authorised-medicinal-products-psusa00002170201503_en.pdf"},
    {"id":"19265","name":"Sertraline: List of nationally authorised medicinal products - PSUSA/00002696/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-05T17:20:00Z","last_updated_date":"2017-12-05T17:20:00Z","reference_number":"EMA/802792/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/sertraline-list-nationally-authorised-medicinal-products-psusa00002696201703_en.pdf"},
    {"id":"19278","name":"Benazepril / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA/00000314/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-24T11:30:00Z","last_updated_date":"2017-01-24T11:37:33Z","reference_number":"EMA/45667/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/benazepril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00000314201605_en.pdf"},
    {"id":"19297","name":"Bilastine: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003163/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-22T10:45:00Z","last_updated_date":"2017-01-18T15:58:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201603_no.pdf"}},
    {"id":"19321","name":"Ticlopidine: List of nationally authorised medicinal products - PSUSA/00002952/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-10T11:00:00Z","last_updated_date":"2016-10-18T19:12:23Z","reference_number":"EMA/183015/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ticlopidine-list-nationally-authorised-medicinal-products-psusa00002952201505_en.pdf"},
    {"id":"19375","name":"Methylphenidate: List of nationally authorised medicinal products - PSUSA/00002024/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-14T02:00:00Z","last_updated_date":"2016-10-18T11:46:17Z","reference_number":"EMA/415297/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-list-nationally-authorised-medicinal-products-psusa00002024201510_en.pdf"},
    {"id":"19410","name":"Epoprostenol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001242/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T15:20:00Z","last_updated_date":"2018-01-24T15:27:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/epoprostenol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001242201703_no.pdf"}},
    {"id":"19439","name":"Treprostinil: List of nationally authorised medicinal products - PSUSA/00003013/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T12:17:00Z","last_updated_date":"2017-07-10T12:19:14Z","reference_number":"EMA/419279/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/treprostinil-list-nationally-authorised-medicinal-products-psusa00003013201611_en.pdf"},
    {"id":"19445","name":"Dorzolamide: CMDh scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA/00003168/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-22T10:00:00Z","last_updated_date":"2017-01-09T11:23:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00003168201602_no.pdf"}},
    {"id":"19510","name":"Doxylamine: List of nationally authorised medicinal products - PSUSA/00001174/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-07T10:10:00Z","last_updated_date":"2017-12-07T10:10:00Z","reference_number":"EMA/811634/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/doxylamine-list-nationally-authorised-medicinal-products-psusa00001174201704_en.pdf"},
    {"id":"19534","name":"Allergen for diagnostic - skin prick test containing only Phleum Pratense (product authorised via mutually recognition procedure): List of nationally authorised medicinal products - PSUSA/00010466/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T12:50:00Z","last_updated_date":"2017-07-10T12:50:00Z","reference_number":"EMA/435668/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-diagnostic-skin-prick-test-containing-only-phleum-pratense-product-authorised-mutually-recognition-procedure-list-nationally-authorised-medicinal-products-psusa00010466201610_en.pdf"},
    {"id":"19570","name":"Ketorolac (systemic formulations): List of nationally authorised medicinal products - PSUSA/00001811/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T12:30:00Z","last_updated_date":"2018-03-09T12:52:34Z","reference_number":"EMA/154217/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketorolac-systemic-formulations-list-nationally-authorised-medicinal-products-psusa00001811201707_en.pdf"},
    {"id":"19645","name":"Glucosamine: List of nationally authorised medicinal products - PSUSA/00001539/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T16:13:00Z","last_updated_date":"2018-01-24T16:24:10Z","reference_number":"EMA/48730/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/glucosamine-list-nationally-authorised-medicinal-products-psusa00001539201703_en.pdf"},
    {"id":"19665","name":"Hydroxyethyl starch: List of nationally authorised medicinal products - PSUSA/00001694/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-17T02:00:00Z","last_updated_date":"2016-10-17T17:35:16Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-list-nationally-authorised-medicinal-products-psusa00001694201501_en.pdf"},
    {"id":"19669","name":"Amino acid combinations / glucose / triglyceride combinations / with or without electrolytes / mineral compounds - only for the drug Numeta: List of nationally authorised medicinal products - PSUSA/00010190/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-18T14:24:00Z","last_updated_date":"2018-07-18T14:35:00Z","reference_number":"EMA/486667/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amino-acid-combinations-glucose-triglyceride-combinations-or-without-electrolytes-mineral-compounds-only-drug-numeta-list-nationally-authorised-medicinal-products-psusa00010190201712_en.pdf"},
    {"id":"19693","name":"Yellow fever vaccine: List of nationally authorised medicinal products - PSUSA/00003135/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-05T14:00:00Z","last_updated_date":"2017-09-05T14:00:00Z","reference_number":"EMA/579275/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/yellow-fever-vaccine-list-nationally-authorised-medicinal-products-psusa00003135201612_en.pdf"},
    {"id":"19735","name":"Cyproterone/ethinylestradiol: CMDh scientific conclusions, amendments to product information and implementation timetable - EMEA/H/N/PSR/J/0005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-23T19:30:00Z","last_updated_date":"2017-02-23T19:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0005_no.pdf"}},
    {"id":"19749","name":"Gadobutrol: List of nationally authorised medicinal products - PSUSA/00001502/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T01:00:00Z","last_updated_date":"2016-10-19T12:37:29Z","reference_number":"EMA/PRAC/4354/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobutrol-list-nationally-authorised-medicinal-products-psusa00001502201504_en.pdf"},
    {"id":"19818","name":"Saccharomyces boulardii : List of nationally authorised medicinal products  - PSUSA/00009284/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T12:29:00Z","last_updated_date":"2017-11-20T12:37:39Z","reference_number":"EMA/639207/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/saccharomyces-boulardii-list-nationally-authorised-medicinal-products-psusa00009284201702_en.pdf"},
    {"id":"19823","name":"Midazolam (all pharmaceutical forms and indications apart from oromucosal solution indicated for the treatment of prolonged, acute, convulsive seizures): List of nationally authorised medicinal products - PSUSA/00002057/...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-18T13:00:00Z","last_updated_date":"2018-05-18T13:00:00Z","reference_number":"EMA/298388/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-indicated-treatment-prolonged-acute-convulsive-seizures-list-nationally-authorised-medicinal-products-psusa00002057_en.pdf"},
    {"id":"19855","name":"Piperacillin / tazobactam: List of nationally authorised medicinal products - PSUSA/00002425/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-22T16:51:00Z","last_updated_date":"2018-05-22T16:54:19Z","reference_number":"EMA/299652/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/piperacillin-tazobactam-list-nationally-authorised-medicinal-products-psusa00002425201709_en.pdf"},
    {"id":"19970","name":"Rosuvastatin: CMDh Scientific conclusions, amendments to product information and implementation timetable - PSUSA/00002664/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-31T11:27:00Z","last_updated_date":"2018-08-31T11:36:38Z","reference_number":"PSUSA/00002664/201711","document_url":"https://www.ema.europa.eu/en/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/rosuvastatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002664201711_no.pdf"}},
    {"id":"19993","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-19T13:00:00Z","last_updated_date":"2018-01-19T13:00:00Z","reference_number":"EMA/21174/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288201705_en.pdf"},
    {"id":"20009","name":"Cyproheptadine: List of nationally authorised medicinal products - PSUSA/00000902/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-13T13:00:00Z","last_updated_date":"2016-10-17T20:25:30Z","reference_number":"EMA/756220/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproheptadine-list-nationally-authorised-medicinal-products-psusa00000902201412_en.pdf"},
    {"id":"20113","name":"Ethinylestradiol / gestodene (transdermal application): List of nationally authorised medicinal products - PSUSA/00010145/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-18T13:55:56Z","reference_number":"EMA/346191/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-gestodene-transdermal-application-list-nationally-authorised-medicinal-products-psusa00010145201508_en.pdf"},
    {"id":"20167","name":"Brotizolam: List of nationally authorised medicinal products - PSUSA/00000444/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-07T14:00:00Z","last_updated_date":"2017-09-07T14:00:00Z","reference_number":"EMA/590524/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/brotizolam-list-nationally-authorised-medicinal-products-psusa00000444201612_en.pdf"},
    {"id":"20208","name":"Hydroxycarbamide: CMDh Scientific conclusions, amendments to product information and implementation timetable - PSUSA/00009182/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-31T15:15:00Z","last_updated_date":"2018-08-31T15:23:00Z","reference_number":"EMA/584534/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydroxycarbamide-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009182201712_sv.pdf"}},
    {"id":"20213","name":"Ivermectin (topical use): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010376/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T13:10:00Z","last_updated_date":"2018-01-18T13:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201704_no.pdf"}},
    {"id":"20254","name":"Treprostinil: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00003013/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T10:15:00Z","last_updated_date":"2017-03-10T10:19:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/treprostinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003013201605_no.pdf"}},
    {"id":"20260","name":"Amiodarone: List of nationally authorised medicinal products - PSUSA/00000166/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T13:00:00Z","last_updated_date":"2018-09-13T13:02:00Z","reference_number":"EMA/615607/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amiodarone-list-nationally-authorised-medicinal-products-psusa00000166201712_en.pdf"},
    {"id":"20291","name":"Acitretin: List of nationally authorised medicinal products - PSUSA/00000051/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-15T18:00:00Z","last_updated_date":"2018-06-15T18:00:00Z","reference_number":"EMA/409662/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-list-nationally-authorised-medicinal-products-psusa00000051201710_en.pdf"},
    {"id":"20350","name":"Alizapride: List of nationally authorised medicinal products - PSUSA/00000091/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-09T02:00:00Z","last_updated_date":"2016-10-17T19:40:08Z","reference_number":"EMA/599707/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/alizapride-list-nationally-authorised-medicinal-products-psusa00000091201601_en.pdf"},
    {"id":"20401","name":"Mefloquine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001955/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T16:28:00Z","last_updated_date":"2018-01-03T16:37:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/mefloquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001955201702_no.pdf"}},
    {"id":"20470","name":"Acebutolol: List of nationally authorised medicinal products - PSUSA/00000018/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-11T17:27:00Z","last_updated_date":"2018-09-11T17:29:46Z","reference_number":"EMA/612663/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/acebutolol-list-nationally-authorised-medicinal-products-psusa00000018201712_en.pdf"},
    {"id":"20529","name":"Bisoprolol: List of nationally authorised medicinal products - PSUSA/00000419/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-10-18T14:01:09Z","reference_number":"EMA/351661/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/bisoprolol-list-nationally-authorised-medicinal-products-psusa00000419201509_en.pdf"},
    {"id":"20537","name":"Minoxidil (topical formulation): List of nationally authorised medicinal products - PSUSA/00002067/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T13:10:00Z","last_updated_date":"2018-06-18T13:13:29Z","reference_number":"EMA/412789/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/minoxidil-topical-formulation-list-nationally-authorised-medicinal-products-psusa00002067201710_en.pdf"},
    {"id":"20543","name":"Chloroquine phosphate / proguanil hydrochloride: List of nationally authorised medicinal products - PSUSA/00010207/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-13T14:27:00Z","last_updated_date":"2017-07-13T14:29:07Z","reference_number":"EMA/443884/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/chloroquine-phosphate-proguanil-hydrochloride-list-nationally-authorised-medicinal-products-psusa00010207201611_en.pdf"},
    {"id":"20591","name":"Dalteparin sodium: List of nationally authorised medicinal products - PSUSA/00000922/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-20T14:00:00Z","last_updated_date":"2016-10-17T20:25:28Z","reference_number":"EMA/282906/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/dalteparin-sodium-list-nationally-authorised-medicinal-products-psusa00000922201508_en.pdf"},
    {"id":"20656","name":"Propofol: List of nationally authorised medicinal products - PSUSA/00002555/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T13:00:00Z","last_updated_date":"2018-09-13T13:42:55Z","reference_number":"EMA/475638/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/propofol-list-nationally-authorised-medicinal-products-psusa00002555201711_en.pdf"},
    {"id":"20718","name":"Budesonide / formoterol (apart from centrally authorised products): List of nationally authorised medicinal products - PSUSA/00000450/201608","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2017-04-11T19:40:00Z","last_updated_date":"2017-04-11T19:40:00Z","reference_number":"EMA/234846/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/budesonide-formoterol-apart-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00000450201608_en.pdf"},
    {"id":"20782","name":"Buspirone: List of nationally authorised medicinal products - PSUSA/00000463/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T16:15:00Z","last_updated_date":"2018-01-15T16:17:21Z","reference_number":"EMA/24780/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/buspirone-list-nationally-authorised-medicinal-products-psusa00000463201704_en.pdf"},
    {"id":"20888","name":"Ivermectin (topical use): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010376/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T15:00:00Z","last_updated_date":"2017-02-02T15:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201604_no.pdf"}},
    {"id":"20940","name":"Bupropion: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000461/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T17:04:00Z","last_updated_date":"2016-11-18T17:07:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461201512_no.pdf"}},
    {"id":"20947","name":"Argatroban: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00009057/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-03T01:00:00Z","last_updated_date":"2016-10-17T19:40:19Z","reference_number":"EMA/64666/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/argatroban-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009057201501_en.pdf"},
    {"id":"20972","name":"Permethrin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002355/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T17:44:00Z","last_updated_date":"2018-06-07T17:51:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201707_no.pdf"}},
    {"id":"20983","name":"Sulbactam: List of nationally authorised medicinal products - PSUSA/00002800/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-04T18:30:00Z","last_updated_date":"2017-09-04T18:30:00Z","reference_number":"EMA/580068/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulbactam-list-nationally-authorised-medicinal-products-psusa00002800201611_en.pdf"},
    {"id":"21058","name":"Treprostinil: List of nationally authorised medicinal products - PSUSA/00002828/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T10:15:00Z","last_updated_date":"2017-03-10T10:19:10Z","reference_number":"EMA/169484/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/treprostinil-list-nationally-authorised-medicinal-products-psusa00002828201604_en.pdf"},
    {"id":"21065","name":"Amoxicillin : List of nationally authorised medicinal products - PSUSA/00000187/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-06T17:20:00Z","last_updated_date":"2017-11-06T17:23:26Z","reference_number":"EMA/726434/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/amoxicillin-list-nationally-authorised-medicinal-products-psusa00000187201703_en.pdf"},
    {"id":"21082","name":"Captopril / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA/00000536/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T16:15:00Z","last_updated_date":"2017-01-27T16:20:14Z","reference_number":"EMA/45259/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/captopril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00000536201604_en.pdf"},
    {"id":"21093","name":"Asparaginase: List of nationally authorised medicinal products - PSUSA/00003161/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-15T02:00:00Z","last_updated_date":"2016-10-17T19:40:10Z","reference_number":"EMA/407532/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/asparaginase-list-nationally-authorised-medicinal-products-psusa00003161201508_en.pdf"},
    {"id":"21102","name":"Sertindole: List of nationally authorised medicinal products - PSUSA/00002695/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T18:32:00Z","last_updated_date":"2018-09-13T18:34:00Z","reference_number":"EMA/615366/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/sertindole-list-nationally-authorised-medicinal-products-psusa00002695201801_en.pdf"},
    {"id":"21169","name":"Nicardipine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002149/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T15:11:00Z","last_updated_date":"2017-03-09T18:55:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nicardipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002149201605_sv.pdf"}},
    {"id":"21178","name":"Technetium (99mTc) pertechnetate: List of nationally authorised medicinal - PSUSA/00002866/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T19:12:00Z","last_updated_date":"2016-10-28T19:16:37Z","reference_number":"EMA/719535/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/technetium-99mtc-pertechnetate-list-nationally-authorised-medicinal-psusa00002866201603_en.pdf"},
    {"id":"21260","name":"Desmopressin: List of nationally authorised medicinal products - PSUSA/00000964/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T14:00:00Z","last_updated_date":"2016-10-17T20:37:53Z","reference_number":"EMA/627406/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/desmopressin-list-nationally-authorised-medicinal-products-psusa00000964201412_en.pdf"},
    {"id":"21329","name":"Hydroxycarbamide: List of nationally authorised medicinal products - PSUSA/00009182/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-31T15:15:00Z","last_updated_date":"2018-08-31T15:23:25Z","reference_number":"EMA/584534/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxycarbamide-list-nationally-authorised-medicinal-products-psusa00009182201712_en.pdf"},
    {"id":"21332","name":"Celecoxib: List of nationally authorised medicinal products - PSUSA/00000616/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2016-10-18T15:41:15Z","reference_number":"EMA/626602/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/celecoxib-list-nationally-authorised-medicinal-products-psusa00000616201412_en.pdf"},
    {"id":"21335","name":"Typhoid vaccine (live, attenuated): List of nationally authorised medicinal products - PSUSA/00003067/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-22T17:00:00Z","last_updated_date":"2018-03-22T17:00:00Z","reference_number":"EMA/182704/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/typhoid-vaccine-live-attenuated-list-nationally-authorised-medicinal-products-psusa00003067201707_en.pdf"},
    {"id":"21344","name":"Cefepime: List of nationally authorised medicinal products - PSUSA/00000593/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-10-18T15:41:08Z","reference_number":"EMA/187078/2016187078/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefepime-list-nationally-authorised-medicinal-products-psusa00000593201506_en.pdf"},
    {"id":"21346","name":"Atorvastatin: List of nationally authorised medicinal products - PSUSA/00010347/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-13T17:38:00Z","last_updated_date":"2018-08-13T17:44:01Z","reference_number":"EMA/PRAC/384956/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/atorvastatin-list-nationally-authorised-medicinal-products-psusa00010347201710_en.pdf"},
    {"id":"21349","name":"Everolimus (indicated for rejection of transplanted organs): CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00010269/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-13T02:00:00Z","last_updated_date":"2016-10-18T14:02:17Z","reference_number":"EMA/333075/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201507_en.pdf"},
    {"id":"21398","name":"Ivermectin (topical use): List of nationally authorised medicinal products - PSUSA/00010376/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T15:00:00Z","last_updated_date":"2017-02-02T15:09:00Z","reference_number":"EMA/77613/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-topical-use-list-nationally-authorised-medicinal-products-psusa00010376201604_en.pdf"},
    {"id":"21496","name":"Calcium carbonate / famotidine / magnesium hydroxide: List of nationally authorised medicinal products  - PSUSA/00001351/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-12T15:46:00Z","last_updated_date":"2018-07-12T16:01:25Z","reference_number":"EMA/471694/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-list-nationally-authorised-medicinal-products-psusa00001351201709_en.pdf"},
    {"id":"21524","name":"Rubella vaccine (live, attenuated): List of nationally authorised medicinal products - PSUSA/00002670/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-15T12:00:00Z","last_updated_date":"2016-10-18T11:22:48Z","reference_number":"EMA/605631/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/rubella-vaccine-live-attenuated-list-nationally-authorised-medicinal-products-psusa00002670201501_en.pdf"},
    {"id":"21549","name":"Exemestane: List of nationally authorised medicinal products - PSUSA/00001345/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-09T02:00:00Z","last_updated_date":"2016-10-18T16:14:16Z","reference_number":"EMA/603169/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/exemestane-list-nationally-authorised-medicinal-products-psusa00001345201512_en.pdf"},
    {"id":"21584","name":"Potassium para aminobenzoate: List of nationally authorised medicinal products - PSUSA/00010130/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T11:00:00Z","last_updated_date":"2016-10-17T18:42:00Z","reference_number":"EMA/829642/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/potassium-para-aminobenzoate-list-nationally-authorised-medicinal-products-psusa00010130201502_en.pdf"},
    {"id":"21628","name":"Hydrochlorothiazide / quinapril: List of nationally authorised medicinal products - PSUSA/00002592/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-22T01:00:00Z","last_updated_date":"2016-12-22T16:58:45Z","reference_number":"EMA/863940/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-quinapril-list-nationally-authorised-medicinal-products-psusa00002592201604_en.pdf"},
    {"id":"21674","name":"Captopril: List of nationally authorised medicinal products - PSUSA/00000535/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2016-11-03T10:57:14Z","reference_number":"EMA/851887/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/captopril-list-nationally-authorised-medicinal-products-psusa00000535201504_en.pdf"},
    {"id":"21691","name":"Eplerenone : List of nationally authorised medicinal products - PSUSA/00001236/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T10:43:00Z","last_updated_date":"2017-10-31T10:47:00Z","reference_number":"EMA/663798/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/eplerenone-list-nationally-authorised-medicinal-products-psusa00001236201703_en.pdf"},
    {"id":"21719","name":"Cefotaxime: List of nationally authorised medicinal products - PSUSA/00000599/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-10-18T15:41:06Z","reference_number":"EMA/600481/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefotaxime-list-nationally-authorised-medicinal-products-psusa00000599201512_en.pdf"},
    {"id":"21742","name":"Diacerein: List of nationally authorised medicinal products - PSUSA/00001026/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T12:15:00Z","last_updated_date":"2018-07-17T12:15:00Z","reference_number":"EMA/483125/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/diacerein-list-nationally-authorised-medicinal-products-psusa00001026201712_en.pdf"},
    {"id":"21796","name":"Beractant: List of nationally authorised medicinal products - PSUSA/00000384/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-18T14:01:14Z","reference_number":"EMA/345845/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/beractant-list-nationally-authorised-medicinal-products-psusa00000384201510_en.pdf"},
    {"id":"21804","name":"Ivermectin (topical use): List of nationally authorised medicinal products - PSUSA/00010376/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T13:10:00Z","last_updated_date":"2018-01-18T13:10:00Z","reference_number":"EMA/36828/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-topical-use-list-nationally-authorised-medicinal-products-psusa00010376201704_en.pdf"},
    {"id":"21828","name":"Prulifloxacin: List of nationally authorised medicinal products   - PSUSA/00002569/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-09T14:20:00Z","last_updated_date":"2018-08-09T14:27:16Z","reference_number":"EMA/542253/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/prulifloxacin-list-nationally-authorised-medicinal-products-psusa00002569201710_en.pdf"},
    {"id":"21840","name":"Diclofenac / misoprostol: List of national authorised medicinal products - PSUSA/00001040/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T12:40:00Z","last_updated_date":"2018-04-27T12:59:00Z","reference_number":"EMA/265069/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-misoprostol-list-national-authorised-medicinal-products-psusa00001040201707_en.pdf"},
    {"id":"21864","name":"Esomeprazole / naproxen: List of nationally authorised medicinal products - PSUSA/00001270/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-12T17:00:00Z","last_updated_date":"2018-01-12T17:00:00Z","reference_number":"EMA/24585/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/esomeprazole-naproxen-list-nationally-authorised-medicinal-products-psusa00001270201704_en.pdf"},
    {"id":"21870","name":"Econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide: List of nationally authorised medicinal products - PSUSA/00001195/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-18T15:20:00Z","last_updated_date":"2018-07-18T15:24:00Z","reference_number":"EMA/462856/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/econazole-econazole-nitrate-triamcinolone-acetonide-econazole-nitrate-zinc-oxide-list-nationally-authorised-medicinal-products-psusa00001195201711_en.pdf"},
    {"id":"21895","name":"Trimetazidine: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00003043/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-05T14:00:00Z","last_updated_date":"2017-05-05T14:23:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/trimetazidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003043201608_sv.pdf"}},
    {"id":"21987","name":"Calcium salts / colecalciferol: List of nationally authorised medicinal products - PSUSA/00010386/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-11T15:44:00Z","last_updated_date":"2017-07-11T15:46:38Z","reference_number":"EMA/434947/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-salts-colecalciferol-list-nationally-authorised-medicinal-products-psusa00010386201610_en.pdf"},
    {"id":"21993","name":"Tamsulosin: List of nationally authorised medicinal products - PSUSA/00002847/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-13T14:10:00Z","last_updated_date":"2017-03-13T14:21:22Z","reference_number":"EMA/173237/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tamsulosin-list-nationally-authorised-medicinal-products-psusa00002847201607_en.pdf"},
    {"id":"21997","name":"Lorazepam: List of nationally authorised medicinal products - PSUSA/00001909/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T17:20:00Z","last_updated_date":"2016-10-19T17:24:31Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/lorazepam-list-nationally-authorised-medicinal-products-psusa00001909201601_en.pdf"},
    {"id":"22038","name":"Latanoprost (products with paediatric indication): List of nationally authorised medicinal products - PSUSA/00001834/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-04T17:20:00Z","last_updated_date":"2016-11-04T17:27:00Z","reference_number":"EMA/728880/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-products-paediatric-indication-list-nationally-authorised-medicinal-products-psusa00001834201604_en.pdf"},
    {"id":"22072","name":"Flecainide: List of nationally authorised medicinal products - PSUSA/00001396/201706","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2018-03-13T13:00:00Z","last_updated_date":"2018-03-13T13:07:51Z","reference_number":"EMA/156863/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/flecainide-list-nationally-authorised-medicinal-products-psusa00001396201706_en.pdf"},
    {"id":"22099","name":"Alanine / arginine / aspartic acid / cysteine / glucose anhydrous / glutamic acid / glycine / histidine / isoleucine / leucine / lysine / methionine / olive oil refined / ornithine / phenylalanine / proline / serine / so...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-22T01:00:00Z","last_updated_date":"2016-10-17T17:40:00Z","reference_number":"EMA/146018/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/alanine-arginine-aspartic-acid-cysteine-glucose-anhydrous-glutamic-acid-glycine-histidine-isoleucine-leucine-lysine-methionine-olive-oil-refined-ornithine-phenylalanine-proline-serine-so_en.pdf"},
    {"id":"22141","name":"Human hemin: List of nationally authorised medicinal products - PSUSA/00001629/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-16T15:20:00Z","last_updated_date":"2017-01-16T15:23:02Z","reference_number":"EMA/28573/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-hemin-list-nationally-authorised-medicinal-products-psusa00001629201605_en.pdf"},
    {"id":"22158","name":"Iodine (131i) iobenguane: Revised CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00001764/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-10-17T18:51:25Z","reference_number":"EMA/461826/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/iodine-131i-iobenguane-revised-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001764201505_en.pdf"},
    {"id":"22200","name":"Misoprostol (gynaecological indication - termination of pregnancy): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -  PSUSA/00010354/2017...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T16:01:00Z","last_updated_date":"2018-03-09T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000103542017_no.pdf"}},
    {"id":"22208","name":"Butoconazole: List of nationally authorised medicinal products - PSUSA/00000471/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T15:00:00Z","last_updated_date":"2016-10-28T15:00:00Z","reference_number":"EMA/691617/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/butoconazole-list-nationally-authorised-medicinal-products-psusa00000471201602_en.pdf"}    {"id":"22220","name":"Lacidipine: List of nationally authorised medicinal products - PSUSA/00001815/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T12:55:00Z","last_updated_date":"2017-07-10T12:55:00Z","reference_number":"EMA/436040/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/lacidipine-list-nationally-authorised-medicinal-products-psusa00001815201610_en.pdf"},
    {"id":"22237","name":"Rupatadine: List of nationally authorised medicinal products - PSUSA/00002673/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T12:00:00Z","last_updated_date":"2016-10-18T11:22:49Z","reference_number":"EMA/600589/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/rupatadine-list-nationally-authorised-medicinal-products-psusa00002673201512_en.pdf"},
    {"id":"22309","name":"Acarbose: List of nationally authorised medicinal products - PSUSA/00000017/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-09T01:00:00Z","last_updated_date":"2016-10-17T16:41:47Z","reference_number":"EMA/98477/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/acarbose-list-nationally-authorised-medicinal-products-psusa00000017201503_en.pdf"},
    {"id":"22317","name":"Methylprednisolone: CMDh scientific conclusions and grounds for variation, amendments to the product information, and timetable for the implementation - PSUSA/00002026/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-12T01:00:00Z","last_updated_date":"2016-10-18T11:46:15Z","reference_number":"EMA/733977/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002026201411_en.pdf"},
    {"id":"22341","name":"Gaxilose: List of nationally authorised medicinal products - PSUSA/00010283/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-10-18T16:56:40Z","reference_number":"EMA/599321/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gaxilose-list-nationally-authorised-medicinal-products-psusa00010283201601_en.pdf"},
    {"id":"22466","name":"Influenza vaccine (surface antigen, inactivated, adjuvanted): List of nationally authorised medicinal products - PSUSA/00010300/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T17:08:00Z","last_updated_date":"2017-10-26T17:21:06Z","reference_number":"EMA/715559/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-adjuvanted-list-nationally-authorised-medicinal-products-psusa00010300201703_en.pdf"},
    {"id":"22473","name":"Sumatriptan: List of nationally authorised medicinal products - PSUSA/00002832/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T12:00:00Z","last_updated_date":"2016-10-18T11:56:10Z","reference_number":"EMA/449226/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/sumatriptan-list-nationally-authorised-medicinal-products-psusa00002832201409_en.pdf"},
    {"id":"22474","name":"Amlodipine: List of nationally authorised medicinal products- PSUSA/00000174/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T12:56:00Z","last_updated_date":"2016-12-19T12:58:23Z","reference_number":"EMA/863940/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-list-nationally-authorised-medicinal-products-psusa00000174201603_en.pdf"},
    {"id":"22480","name":"Ropinirole : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002661/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-03T16:29:00Z","last_updated_date":"2017-05-03T16:35:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201607_no.pdf"}},
    {"id":"22503","name":"Olmesartan: List of nationally authorised medicinal products - PSUSA/00002207/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-15T13:30:00Z","last_updated_date":"2017-06-15T13:30:00Z","reference_number":"EMA/379666/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/olmesartan-list-nationally-authorised-medicinal-products-psusa00002207201610_en.pdf"},
    {"id":"22614","name":"Magnesium sulphate / sodium sulphate / potassium sulphate: List of nationally authorised medicinal products - PSUSA/00010239/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-08T15:30:00Z","last_updated_date":"2018-03-08T15:37:00Z","reference_number":"EMA/152483/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulphate-sodium-sulphate-potassium-sulphate-list-nationally-authorised-medicinal-products-psusa00010239201708_en.pdf"},
    {"id":"22640","name":"Cetirizine / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000629/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-30T17:15:00Z","last_updated_date":"2017-07-25T12:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cetirizine-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000629201608_sv.pdf"}},
    {"id":"22665","name":"Tetanus vaccines: List of nationally authorised medicinal products-PSUSA/00002910/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-16T12:25:00Z","last_updated_date":"2016-10-19T12:24:52Z","reference_number":"EMA/590690/2015 rev1","document_url":"https://www.ema.europa.eu/en/documents/psusa/tetanus-vaccines-list-nationally-authorised-medicinal-products-psusa00002910201501_en.pdf"},
    {"id":"22670","name":"Glimepiride: List of nationally authorised medicinal products - PSUSA/00001534/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T16:00:00Z","last_updated_date":"2018-01-15T16:00:00Z","reference_number":"EMA/25531/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/glimepiride-list-nationally-authorised-medicinal-products-psusa00001534201706_en.pdf"},
    {"id":"22687","name":"Trimetazidine: List of nationally authorised medicinal products - PSUSA/00003043/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T14:00:00Z","last_updated_date":"2016-10-17T20:16:38Z","reference_number":"EMA/245349/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-list-nationally-authorised-medicinal-products-psusa00003043201508_en.pdf"},
    {"id":"22704","name":"Amlodipine: List of nationally authorised medicinal products - PSUSA/00000174/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T13:00:00Z","last_updated_date":"2017-11-20T13:00:00Z","reference_number":"EMA/764352/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-list-nationally-authorised-medicinal-products-psusa00000174201703_en.pdf"},
    {"id":"22729","name":"Dihydroergotoxine: List of nationally authorised medicinal products - PSUSA/00001079/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T13:00:00Z","last_updated_date":"2016-10-17T19:52:26Z","reference_number":"EMA/842655/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/dihydroergotoxine-list-nationally-authorised-medicinal-products-psusa00001079201504_en.pdf"},
    {"id":"22847","name":"Antithrombin iii: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00003159/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-24T16:57:00Z","last_updated_date":"2016-10-25T11:36:27Z","reference_number":"EMA/694889/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/antithrombin-iii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003159201512_en.pdf"},
    {"id":"22877","name":"Thiocolchicoside: List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-10T15:50:00Z","last_updated_date":"2018-06-26T18:24:00Z","reference_number":"EMA/224020/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiocolchicoside-list-nationally-authorised-medicinal-products-emeahnpsrj0008_en.pdf"},
    {"id":"22919","name":"Corticorelin: CMDh Scientific conclusions and grounds for variation,\n\namendments to the product information, and timetable\n\nfor the implementation - PSUSA/00000876/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T14:00:00Z","last_updated_date":"2016-10-17T20:37:51Z","reference_number":"EMA/539540/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/corticorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000876201410_en.pdf"},
    {"id":"22930","name":"Docosanol: List of nationally authorised medicinal products - PSUSA/00010092/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-18T19:00:00Z","last_updated_date":"2017-01-18T19:00:00Z","reference_number":"EMA/37135/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/docosanol-list-nationally-authorised-medicinal-products-psusa00010092201604_en.pdf"},
    {"id":"22954","name":"Dapoxetine: List of nationally authorised medicinal products - PSUSA/00000928/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-17T14:00:00Z","last_updated_date":"2016-10-17T20:46:31Z","reference_number":"EMA/483529/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/dapoxetine-list-nationally-authorised-medicinal-products-psusa00000928201412_en.pdf"},
    {"id":"22971","name":"Human rabies immunoglobulin: List of nationally authorised medicinal products - PSUSA/00001639/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T15:50:00Z","last_updated_date":"2018-01-16T15:54:37Z","reference_number":"EMA/24814/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-rabies-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00001639201704_en.pdf"},
    {"id":"22975","name":"Cyproterone/ethinylestradiol: CMDh scientific conclusions, amendments to product information and implementation timetable - EMEA/H/N/PSR/J/0003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-23T19:30:00Z","last_updated_date":"2017-02-23T19:30:00Z","reference_number":"EMA/68246/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cyproteroneethinylestradiol-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0003_no.pdf"}},
    {"id":"22987","name":"Nicardipine: List of nationally authorised medicinal products - PSUSA/00002149/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T15:11:00Z","last_updated_date":"2017-03-09T18:55:04Z","reference_number":"EMA/163329/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicardipine-list-nationally-authorised-medicinal-products-psusa00002149201605_en.pdf"},
    {"id":"23017","name":"Poly (o-2-hydroxyethyl) starch: List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-30T16:29:00Z","last_updated_date":"2017-10-30T16:29:00Z","reference_number":"EMA/723696/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/poly-o-2-hydroxyethyl-starch-list-nationally-authorised-medicinal-products-emeahnpsrs0009_en.pdf"},
    {"id":"23043","name":"Ethinylestradiol, gestodene (transdermal application): List of nationally authorised medicinal products - PSUSA/00010145/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-08T02:00:00Z","last_updated_date":"2016-10-18T13:55:57Z","reference_number":"EMA/666639/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-gestodene-transdermal-application-list-nationally-authorised-medicinal-products-psusa00010145201502_en.pdf"},
    {"id":"23060","name":"Chlormadinone acetate / ethinylestradiol: List of nationally authorised medicinal products - PSUSA/00000679/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T17:10:00Z","last_updated_date":"2017-09-06T17:10:00Z","reference_number":"EMA/583978/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlormadinone-acetate-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa00000679201611_en.pdf"},
    {"id":"23086","name":"Albendazole: List of nationally authorised medicinal products - PSUSA/00000073/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T02:00:00Z","last_updated_date":"2016-10-17T17:40:39Z","reference_number":"EMA/243402/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/albendazole-list-nationally-authorised-medicinal-products-psusa00000073201507_en.pdf"},
    {"id":"23115","name":"Amorolfine: List of nationally authorised medicinal products - PSUSA/00000185/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-12T16:21:00Z","last_updated_date":"2018-03-12T16:22:44Z","reference_number":"EMA/113394/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amorolfine-list-nationally-authorised-medicinal-products-psusa00000185201706_en.pdf"},
    {"id":"23144","name":"Moxifloxacin (systemic use): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009231/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T16:10:00Z","last_updated_date":"2017-03-09T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009231201605_no.pdf"}},
    {"id":"23193","name":"Fluocinolone acetonide (intravitreal implant in applicator): List of nationally authorised medicinal products - PSUSA/00010224/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T17:20:00Z","last_updated_date":"2016-10-19T17:24:31Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-intravitreal-implant-applicator-list-nationally-authorised-medicinal-products-psusa00010224201602_en.pdf"},
    {"id":"23209","name":"Germanium (68Ge) chloride / gallium (68Ga) chloride: List of nationally authorised medicinal products - PSUSA/00010364/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T11:30:00Z","last_updated_date":"2017-11-15T11:30:00Z","reference_number":"EMA/727988/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/germanium-68ge-chloride-gallium-68ga-chloride-list-nationally-authorised-medicinal-products-psusa00010364201703_en.pdf"},
    {"id":"23217","name":"Azelastine / fluticasone: List of nationally authorised medicinal products - PSUSA/00010067/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-10-18T14:01:11Z","reference_number":"EMA/447143/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/azelastine-fluticasone-list-nationally-authorised-medicinal-products-psusa00010067201510_en.pdf"},
    {"id":"23249","name":"Diclofenac / misoprostol: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001040/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T12:20:00Z","last_updated_date":"2018-05-14T19:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/diclofenac-misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001040201707_no.pdf"}},
    {"id":"23252","name":"Betamethasone / tetryzoline: List of nationally authorised medicinal products - PSUSA/00010072/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-25T01:00:00Z","last_updated_date":"2016-10-18T14:01:16Z","reference_number":"EMA/483198/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/betamethasone-tetryzoline-list-nationally-authorised-medicinal-products-psusa00010072201409_en.pdf"},
    {"id":"23265","name":"Dexamethasone (apart from centrally authorised products): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000973/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-30T16:08:00Z","last_updated_date":"2017-02-21T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dexamethasone-apart-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000973201601_no.pdf"}},
    {"id":"23273","name":"Meloxicam: List of nationally authorised medicinal products - PSUSA/00010474/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-05T14:00:00Z","last_updated_date":"2017-05-05T14:23:08Z","reference_number":"EMA/284892/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/meloxicam-list-nationally-authorised-medicinal-products-psusa00010474201607_en.pdf"},
    {"id":"23295","name":"Bismuth subcitrate potassium / metronidazole / tetracycline: List of nationally authorised medicinal products - PSUSA/00010199/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-24T17:25:00Z","last_updated_date":"2017-01-24T17:27:24Z","reference_number":"EMA/50914/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-list-nationally-authorised-medicinal-products-psusa00010199201605_en.pdf"},
    {"id":"23302","name":"Methyl salicylate / levomenthol: List of nationally authorised medicinal products - PSUSA/00010241/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T11:10:00Z","last_updated_date":"2018-03-07T11:10:00Z","reference_number":"EMA/21189/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/methyl-salicylate-levomenthol-list-nationally-authorised-medicinal-products-psusa00010241201704_en.pdf"},
    {"id":"23325","name":"Metoclopramide: List of nationally authorised medicinal products -PSUSA/00002036/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-03T02:00:00Z","last_updated_date":"2016-10-18T11:46:15Z","reference_number":"EMA/377009/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/metoclopramide-list-nationally-authorised-medicinal-products-psusa00002036201510_en.pdf"},
    {"id":"23345","name":"Hepatitis a (inactivated) / typhoid polysaccharide vaccine (adsorbed): List of nationally authorised medicinal products - PSUSA/00001594/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T13:10:00Z","last_updated_date":"2018-03-06T13:39:16Z","reference_number":"EMA/141741/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/hepatitis-inactivated-typhoid-polysaccharide-vaccine-adsorbed-list-nationally-authorised-medicinal-products-psusa00001594201706_en.pdf"},
    {"id":"23364","name":"Bendamustine hydrochloride: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information, and timetable for the implementation - PSUSA/00003162/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-04T16:25:00Z","last_updated_date":"2016-11-04T16:32:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162201601_no.pdf"}},
    {"id":"23375","name":"Rabbit anti-human thymocyte (powder for solution for\n\ninfusion): CMDh scientific conclusions and grounds for variation,\n\namendments to the product information and timetable for\n\nthe implementation - PSUSA/00010184/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-04T12:00:00Z","last_updated_date":"2016-10-17T19:31:36Z","reference_number":"EMA/592371/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-human-thymocyte-powder-solution-infusion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010184201412_en.pdf"},
    {"id":"23488","name":"Ofloxacin (systemic use): CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00002203/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-10-18T12:49:43Z","reference_number":"EMA/85725/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203201504_en.pdf"},
    {"id":"23555","name":"Epinastine: List of nationally authorised medicinal products - PSUSA/00001231/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-14T14:00:00Z","last_updated_date":"2018-08-14T14:00:00Z","reference_number":"EMA/553008/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/epinastine-list-nationally-authorised-medicinal-products-psusa00001231201710_en.pdf"},
    {"id":"23583","name":"Iodine (131i) iobenguane: List of nationally authorised medicinal products - PSUSA/00001764/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-10-17T18:51:26Z","reference_number":"EMA/473854/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/iodine-131i-iobenguane-list-nationally-authorised-medicinal-products-psusa00001764201505_en.pdf"},
    {"id":"23626","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-18T15:30:00Z","last_updated_date":"2018-07-18T15:33:25Z","reference_number":"EMA/477218/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288201711_en.pdf"},
    {"id":"23683","name":"Gadopentetic acid: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00001504/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T01:00:00Z","last_updated_date":"2016-10-19T12:37:32Z","reference_number":"EMA/172348/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001504201504_en.pdf"},
    {"id":"23697","name":"Methoxyflurane: List of nationally authorised medicinal products - PSUSA/00010484/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-17T18:30:00Z","last_updated_date":"2017-07-17T18:30:00Z","reference_number":"EMA/454713/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa00010484201611_en.pdf"},
    {"id":"23721","name":"Carbidopa / levodopa (except for centrally authorised product): List of nationally authorised medicinal products - PSUSA/00000548/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T18:00:00Z","last_updated_date":"2017-08-04T18:00:00Z","reference_number":"EMA/506182/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00000548201610_en.pdf"},
    {"id":"23780","name":"Amlodipine lisinopril : List of nationally authorised medicinal products - PSUSA/00010192/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T17:33:00Z","last_updated_date":"2017-09-06T17:36:19Z","reference_number":"EMA/529926/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-lisinopril-list-nationally-authorised-medicinal-products-psusa00010192201612_en.pdf"},
    {"id":"23827","name":"Dexketoprofen: List of nationally authorised medicinal products - PSUSA/00000997/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-17T10:25:00Z","last_updated_date":"2017-03-17T10:29:00Z","reference_number":"EMA/184638/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-list-nationally-authorised-medicinal-products-psusa00000997201510_en.pdf"},
    {"id":"23848","name":"Loratadine / pseudoephedrine : List of nationally authorised medicinal products - PSUSA/00001908/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-05T17:00:00Z","last_updated_date":"2017-10-05T17:08:48Z","reference_number":"EMA/658671/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/loratadine-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00001908201702_en.pdf"},
    {"id":"23854","name":"Cefadroxil: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000584/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-26T15:53:00Z","last_updated_date":"2018-04-26T16:01:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefadroxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000584201707_sv.pdf"}},
    {"id":"23866","name":"Baclofen (oral):  List of nationally authorised medicinal products - PSUSA/00000294/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-20T13:40:00Z","last_updated_date":"2017-08-17T12:58:00Z","reference_number":"EMA/PRAC/343350/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/baclofen-oral-list-nationally-authorised-medicinal-products-psusa00000294201609_en.pdf"},
    {"id":"23926","name":"Methoxyflurane: List of nationally authorised medicinal products - PSUSA/00010484/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-22T17:00:00Z","last_updated_date":"2018-06-22T17:00:00Z","reference_number":"EMA/423973/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa00010484201711_en.pdf"},
    {"id":"23957","name":"Idebenone (non centrally authorised products): List of nationally authorised medicinal products - PSUSA/00001721/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-18T13:00:00Z","last_updated_date":"2018-05-18T13:00:00Z","reference_number":"EMA/301570/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/idebenone-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00001721201709_en.pdf"},
    {"id":"23959","name":"Germanium (68Ge) chloride / gallium (68Ga) chloride: List of nationally authorised medicinal products - PSUSA/00010364/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T02:00:00Z","last_updated_date":"2016-10-18T16:56:41Z","reference_number":"EMA/270823/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/germanium-68ge-chloride-gallium-68ga-chloride-list-nationally-authorised-medicinal-products-psusa00010364201509_en.pdf"},
    {"id":"24028","name":"Ivabradine / metoprolol: List of nationally authorised medicinal products - PSUSA/10381/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-18T11:50:00Z","last_updated_date":"2017-12-18T11:53:07Z","reference_number":"EMA/776879/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivabradine-metoprolol-list-nationally-authorised-medicinal-products-psusa10381201704_en.pdf"},
    {"id":"24040","name":"Meloxicam: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010474/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-05T14:00:00Z","last_updated_date":"2017-05-05T14:23:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474201607_sv.pdf"}},
    {"id":"24124","name":"Phloroglucinol, phloroglucinol / trimethylphloroglucinol: List of nationally authorised medicinal products - PSUSA/00010355/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T14:00:00Z","last_updated_date":"2016-10-17T18:24:00Z","reference_number":"EMA/368222/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-list-nationally-authorised-medicinal-products-psusa00010355201509_en.pdf"},
    {"id":"24157","name":"Eprosartan / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA/00001244/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-17T16:45:00Z","last_updated_date":"2018-01-17T16:48:24Z","reference_number":"EMA/32396/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/eprosartan-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00001244201704_en.pdf"},
    {"id":"24180","name":"Amino acid combinations / glucose / triglyceride combinations / with or without electrolytes / mineral compounds - only for the drug Numeta: List of nationally authorised medicinal products - PSUSA/00010190/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-04T18:30:00Z","last_updated_date":"2017-09-04T18:30:00Z","reference_number":"EMA/580171/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/amino-acid-combinations-glucose-triglyceride-combinations-or-without-electrolytes-mineral-compounds-only-drug-numeta-list-nationally-authorised-medicinal-products-psusa00010190201612_en.pdf"},
    {"id":"24183","name":"Dexchlorpheniramine: List of nationally authorised medicinal products - PSUSA/00000989/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-22T13:00:00Z","last_updated_date":"2016-10-17T20:37:49Z","reference_number":"EMA/146501/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexchlorpheniramine-list-nationally-authorised-medicinal-products-psusa00000989201506_en.pdf"},
    {"id":"24240","name":"Magnesium hydroxide: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001926/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-05T14:00:00Z","last_updated_date":"2017-09-05T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/magnesium-hydroxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001926201610_sv.pdf"}},
    {"id":"24247","name":"Latanoprost/timolol: List of nationally authorised medicinal products - PSUSA/00001833/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T10:20:00Z","last_updated_date":"2018-02-13T10:20:00Z","reference_number":"EMA/92104/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprosttimolol-list-nationally-authorised-medicinal-products-psusa00001833201706_en.pdf"},
    {"id":"24295","name":"Trimetazidine: List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-01T16:20:00Z","last_updated_date":"2017-02-01T16:20:00Z","reference_number":"EMA/68246/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-list-nationally-authorised-medicinal-products-emeahnpsrj0003_en.pdf"},
    {"id":"24423","name":"Atomoxetine: List of nationally authorised medicinal products - PSUSA/00000262/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T02:00:00Z","last_updated_date":"2016-10-17T19:40:05Z","reference_number":"EMA/480379/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/atomoxetine-list-nationally-authorised-medicinal-products-psusa00000262201511_en.pdf"},
    {"id":"24424","name":"Furosemide: List of nationally authorised medicinal products - PSUSA/00001491/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T19:00:00Z","last_updated_date":"2018-09-10T19:04:07Z","reference_number":"EMA/608623/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/furosemide-list-nationally-authorised-medicinal-products-psusa00001491201801_en.pdf"},
    {"id":"24454","name":"Famotidine: List of nationally authorised medicinal products - PSUSA/00001350/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-12T13:49:00Z","last_updated_date":"2018-07-12T13:55:58Z","reference_number":"EMA/475011/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/famotidine-list-nationally-authorised-medicinal-products-psusa00001350201709_en.pdf"},
    {"id":"24507","name":"Levothyroxine: List of nationally authorised medicinal products - PSUSA/00001860/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T17:20:00Z","last_updated_date":"2016-10-19T17:24:32Z","reference_number":"EMA/646404/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/levothyroxine-list-nationally-authorised-medicinal-products-psusa00001860201601_en.pdf"},
    {"id":"24555","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-13T14:00:00Z","last_updated_date":"2016-10-17T20:16:37Z","reference_number":"EMA/483547/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288201511_en.pdf"},
    {"id":"24585","name":"Ganciclovir: List of nationally authorised medicinal products - PSUSA/00001516/201606","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-16T10:53:00Z","last_updated_date":"2017-02-16T10:57:07Z","reference_number":"EMA/112843/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ganciclovir-list-nationally-authorised-medicinal-products-psusa00001516201606_en.pdf"},
    {"id":"24594","name":"Cyproheptadine: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000902/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-13T13:00:00Z","last_updated_date":"2016-10-17T20:37:50Z","reference_number":"EMA/756159/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproheptadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000902201412_en.pdf"},
    {"id":"24613","name":"Eletriptan: List of nationally authorised medicinal products - PSUSA/00001204/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-08T16:00:00Z","last_updated_date":"2016-11-08T16:00:00Z","reference_number":"EMA/735253/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/eletriptan-list-nationally-authorised-medicinal-products-psusa00001204201602_en.pdf"},
    {"id":"24660","name":"Germanium (68Ge) chloride / gallium (68Ga) chloride: List of nationally authorised medicinal products - PSUSA/00010364/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-09T18:00:00Z","last_updated_date":"2016-11-09T18:00:00Z","reference_number":"EMA/740315/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/germanium-68ge-chloride-gallium-68ga-chloride-list-nationally-authorised-medicinal-products-psusa00010364201603_en.pdf"},
    {"id":"24670","name":"Loperamide: List of nationally authorised medicinal products - PSUSA/00001903/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-20T16:40:00Z","last_updated_date":"2017-01-20T16:40:00Z","reference_number":"EMA/36361/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/loperamide-list-nationally-authorised-medicinal-products-psusa00001903201605_en.pdf"},
    {"id":"24684","name":"Ivermectin (systemic use): List of nationally authorised medicinal products - PSUSA/00010377/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T13:00:00Z","last_updated_date":"2016-12-14T13:13:00Z","reference_number":"EMA/807599/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-systemic-use-list-nationally-authorised-medicinal-products-psusa00010377201604_en.pdf"},
    {"id":"24686","name":"Macrogol 3350: List of nationally authorised medicinal products - PSUSA/00001924/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T14:41:00Z","last_updated_date":"2017-02-02T14:42:24Z","reference_number":"EMA/77705/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/macrogol-3350-list-nationally-authorised-medicinal-products-psusa00001924201605_en.pdf"},
    {"id":"24703","name":"Furosemide / spironolactone: List of nationally authorised medicinal products - PSUSA/00001493/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-25T02:00:00Z","last_updated_date":"2016-10-18T13:42:40Z","reference_number":"EMA/572285/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa00001493201512_en.pdf"},
    {"id":"24744","name":"Idebenone: List of nationally authorised medicinal products - PSUSA/00001721/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-20T02:00:00Z","last_updated_date":"2016-10-17T17:46:44Z","reference_number":"EMA/485797/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/idebenone-list-nationally-authorised-medicinal-products-psusa00001721201409_en.pdf"},
    {"id":"24756","name":"Dextromethorphan: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information, and timetable for the implementation - PSUSA/00001009/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-30T14:00:00Z","last_updated_date":"2016-10-17T20:37:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201511_en.pdf"},
    {"id":"24783","name":"Topiramate: List of nationally authorised medicinal products - PSUSA/00002996/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T17:20:00Z","last_updated_date":"2017-10-23T17:20:00Z","reference_number":"EMA/641616/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/topiramate-list-nationally-authorised-medicinal-products-psusa00002996201701_en.pdf"},
    {"id":"24802","name":"Technetium (99mTc) hynic-octeotide: List of nationally authorised medicinal products - PSUSA/00010521/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T11:30:00Z","last_updated_date":"2018-01-18T11:32:29Z","reference_number":"PSUSA/00010521/201706","document_url":"https://www.ema.europa.eu/en/documents/psusa/technetium-99mtc-hynic-octeotide-list-nationally-authorised-medicinal-products-psusa00010521201706_en.pdf"},
    {"id":"24845","name":"Latanoprost (products with paediatric indication): List of nationally authorised medicinal products - PSUSA/00001834/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-01T01:00:00Z","last_updated_date":"2016-10-17T19:17:16Z","reference_number":"EMA/761710/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-products-paediatric-indication-list-nationally-authorised-medicinal-products-psusa00001834201504_en.pdf"},
    {"id":"24855","name":"Allergen for therapy: Phleum Pratense (oromucosal use, product authorised via mutually recognition procedure): List of nationally authorised medicinal products - PSUSA/00010475/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T11:00:00Z","last_updated_date":"2017-03-16T11:00:00Z","reference_number":"EMA/180042/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-phleum-pratense-oromucosal-use-product-authorised-mutually-recognition-procedure-list-nationally-authorised-medicinal-products-psusa00010475201607_en.pdf"},
    {"id":"24866","name":"Folic acid: List of nationally authorised medicinal products - PSUSA/00001459/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T13:10:00Z","last_updated_date":"2018-03-06T13:39:16Z","reference_number":"EMA/144279/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/folic-acid-list-nationally-authorised-medicinal-products-psusa00001459201706_en.pdf"},
    {"id":"24898","name":"Folic acid: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001459/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T13:10:00Z","last_updated_date":"2018-03-06T13:39:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/folic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001459201706_sv.pdf"}},
    {"id":"24962","name":"Amlodipine: List of nationally authorised medicinal products - PSUSA/00000174/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-08T17:18:00Z","last_updated_date":"2016-11-08T17:20:48Z","reference_number":"EMA/737385/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-list-nationally-authorised-medicinal-products-psusa00000174201603_en.pdf-0"},
    {"id":"24983","name":"Solifenacin: List of nationally authorised medicinal products - PSUSA/00002769/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T17:00:00Z","last_updated_date":"2018-02-09T17:00:00Z","reference_number":"EMA/77196/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/solifenacin-list-nationally-authorised-medicinal-products-psusa00002769201706_en.pdf"},
    {"id":"25036","name":"Technetium (99mTc) tetrofosmin, tetrofosmin: List of nationally authorised medicinal products - PSUSA/00002870/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T16:00:00Z","last_updated_date":"2018-01-15T16:00:00Z","reference_number":"EMA/9402/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/technetium-99mtc-tetrofosmin-tetrofosmin-list-nationally-authorised-medicinal-products-psusa00002870201705_en.pdf"},
    {"id":"25087","name":"Aprotinin / calcium chloride / human factor XIII / ... - List of nationally authorised medicinal products - PSUSA/00010346/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T17:20:00Z","last_updated_date":"2017-09-06T17:20:00Z","reference_number":"EMA/530525/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/aprotinin-calcium-chloride-human-factor-xiii-list-nationally-authorised-medicinal-products-psusa00010346201611_en.pdf"},
    {"id":"25107","name":"Ticlopidine: CMDh scientific conclusions and grounds for the variation,\n\namendments to the product information and timetable for\n\nthe implementation - PSUSA/00002952/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-10T11:00:00Z","last_updated_date":"2016-10-18T19:12:22Z","reference_number":"EMA/182932/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ticlopidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002952201505_en.pdf"},
    {"id":"25226","name":"Testosterone undecylate (injection): List of nationally authorised medicinal products-PSUSA/00010161/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-04T12:20:00Z","last_updated_date":"2016-10-19T12:24:51Z","reference_number":"EMA/592574/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-undecylate-injection-list-nationally-authorised-medicinal-products-psusa00010161201411_en.pdf"},
    {"id":"25245","name":"Ciprofloxacin hydrochloride / hydrocortisone: List of nationally authorised medicinal products - PSUSA/00000774/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T18:15:00Z","last_updated_date":"2018-09-10T18:15:00Z","reference_number":"EMA/613008/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-hydrochloride-hydrocortisone-list-nationally-authorised-medicinal-products-psusa00000774201711_en.pdf"},
    {"id":"25258","name":"Salmeterol/fluticasone propionate: List of nationally authorised medicinal products - PSUSA/00001455/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-20T12:00:00Z","last_updated_date":"2016-10-18T11:56:08Z","reference_number":"EMA/485794/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/salmeterolfluticasone-propionate-list-nationally-authorised-medicinal-products-psusa00001455201410_en.pdf"},
    {"id":"25341","name":"Amlodipine besilate / ramipril: List of nationally authorised medicinal products  - PSUSA/00000181/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-10-17T19:40:07Z","reference_number":"EMA/85654/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-besilate-ramipril-list-nationally-authorised-medicinal-products-psusa00000181201503_en.pdf"},
    {"id":"25389","name":"Azelastine: List of nationally authorised medicinal products - PSUSA/00000277/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T17:00:00Z","last_updated_date":"2018-09-10T17:00:00Z","reference_number":"EMA/612350/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/azelastine-list-nationally-authorised-medicinal-products-psusa00000277201712_en.pdf"},
    {"id":"25413","name":"Ketoprofen (topical use only): List of nationally authorised medicinal products - PSUSA/00009205/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T16:00:00Z","last_updated_date":"2017-05-12T16:00:00Z","reference_number":"EMA/2826/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketoprofen-topical-use-only-list-nationally-authorised-medicinal-products-psusa00009205201609_en.pdf"}    {"id":"25442","name":"Dexlansoprazole, lansoprazole: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001827/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-06T17:30:00Z","last_updated_date":"2017-11-06T17:53:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dexlansoprazole-lansoprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001827201612_no.pdf"}},
    {"id":"25444","name":"Phenylephrine: CMDh scientific conclusions and grounds for variation,\n\namendments to the product information and timetable for\n\nthe implementation - PSUSA/00002378/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-03T01:00:00Z","last_updated_date":"2016-10-17T18:19:55Z","reference_number":"EMA/726964/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylephrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002378201501_en.pdf"},
    {"id":"25502","name":"Ciclosporin (systemic use): List of nationally authorised medicinal products - PSUSA/00000745/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-10-18T15:41:10Z","reference_number":"EMA/580924/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciclosporin-systemic-use-list-nationally-authorised-medicinal-products-psusa00000745201512_en.pdf"},
    {"id":"25557","name":"Acetyl salicylic acid / atorvastatin / ramipril: List of nationally authorised medicinal products - PSUSA/00010280/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T18:00:00Z","last_updated_date":"2017-10-27T18:03:19Z","reference_number":"EMA/720706/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetyl-salicylic-acid-atorvastatin-ramipril-list-nationally-authorised-medicinal-products-psusa00010280201702_en.pdf"},
    {"id":"25570","name":"Tapentadol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002849/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-07T12:15:00Z","last_updated_date":"2018-09-07T12:21:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201711_no.pdf"}},
    {"id":"25609","name":"Fish oil/olive oil/soybean oil/triglycerides medium-chain: List of nationally authorised medicinal products - PSUSA/00010223/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T17:08:00Z","last_updated_date":"2017-10-26T17:21:00Z","reference_number":"EMA/690754/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fish-oilolive-oilsoybean-oiltriglycerides-medium-chain-list-nationally-authorised-medicinal-products-psusa00010223201702_en.pdf"},
    {"id":"25634","name":"Lanreotide: List of nationally authorised medicinal products - PSUSA/00001826/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-17T17:41:00Z","last_updated_date":"2018-01-17T17:45:30Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/lanreotide-list-nationally-authorised-medicinal-products-psusa00001826201705_en.pdf"},
    {"id":"25764","name":"Alpha-1-antitrypsin: List of nationally authorised medicinal products - PSUSA/00000108/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2016-10-17T19:40:15Z","reference_number":"EMA/622855/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/alpha-1-antitrypsin-list-nationally-authorised-medicinal-products-psusa00000108201412_en.pdf"},
    {"id":"25779","name":"Hydroxyzine chloride, hydroxyzine pamoate and all fixed combination/ hydroxyzine: List of nationally authorised medicinal products - PSUSA/00001696/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T02:00:00Z","last_updated_date":"2016-10-17T17:35:15Z","reference_number":"EMA/449136/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-list-nationally-authorised-medicinal-products-psusa00001696201411_en.pdf"},
    {"id":"25784","name":"Treosulfan: List of nationally authorised medicinal products - PSUSA/00009319/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T20:00:00Z","last_updated_date":"2018-05-23T20:22:17Z","reference_number":"EMA/326474/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/treosulfan-list-nationally-authorised-medicinal-products-psusa00009319201708_en.pdf"},
    {"id":"25809","name":"Human coagulation factor VIII (antihemophilic factor A): List of nationally authorised products - PSUSA/00001620/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2016-10-17T17:15:43Z","reference_number":"EMA/546145/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-viii-antihemophilic-factor-list-nationally-authorised-products-psusa00001620201411_en.pdf"},
    {"id":"25835","name":"Perindopril: List of nationally authorised medicinal products - PSUSA/00002354/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-05T12:00:00Z","last_updated_date":"2016-10-17T17:09:35Z","reference_number":"EMA/483632/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/perindopril-list-nationally-authorised-medicinal-products-psusa00002354201510_en.pdf"},
    {"id":"25848","name":"Amlodipine besilate/hydrochlorothiazide/olmesartan medoxomil: List of nationally authorised medicinal products - PSUSA/00002210/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T10:20:00Z","last_updated_date":"2018-01-18T10:53:12Z","reference_number":"EMA/34095/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-besilatehydrochlorothiazideolmesartan-medoxomil-list-nationally-authorised-medicinal-products-psusa00002210201704_en.pdf"},
    {"id":"25926","name":"Amitriptyline hydrochloride / chlordiazepoxide: List of nationally authorised medicinal products - PSUSA/00000171/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-09T18:00:00Z","last_updated_date":"2016-11-09T18:00:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-hydrochloride-chlordiazepoxide-list-nationally-authorised-medicinal-products-psusa00000171201602_en.pdf"},
    {"id":"25950","name":"Esketamine : List of nationally authorised medicinal products -  PSUSA/00001266/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-15T12:19:00Z","last_updated_date":"2017-05-15T12:21:00Z","reference_number":"EMA/303127/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/esketamine-list-nationally-authorised-medicinal-products-psusa00001266201608_en.pdf"},
    {"id":"26031","name":"Pamidronate: CMDh scientific conclusions and grounds for the variation, amendments to the product information, conditions to the MA and timetable for the implementation - PSUSA/00002269/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-10T01:00:00Z","last_updated_date":"2016-10-18T13:02:20Z","reference_number":"EMA/185266/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/pamidronate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-conditions-ma-and-timetable-implementation-psusa00002269201505_en.pdf"},
    {"id":"26044","name":"N(2)-L-alanyl-L-glutamine: List of nationally authorised medicinal products - PSUSA/00003158/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-09T12:20:00Z","last_updated_date":"2016-12-09T12:20:00Z","reference_number":"EMA/847829/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/n2-l-alanyl-l-glutamine-list-nationally-authorised-medicinal-products-psusa00003158201603_en.pdf"},
    {"id":"26072","name":"Levobunolol (ophthalmic indication): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010109/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T12:35:00Z","last_updated_date":"2017-10-23T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levobunolol-ophthalmic-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010109201701_no.pdf"}},
    {"id":"26080","name":"Vigabatrin: List of nationally authorised medicinal products - PSUSA/00003112/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T14:00:00Z","last_updated_date":"2016-10-17T20:16:32Z","reference_number":"EMA/456400/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/vigabatrin-list-nationally-authorised-medicinal-products-psusa00003112201409_en.pdf"},
    {"id":"26096","name":"Sulprostone: List of nationally authorised medicinal products - PSUSA/00002828/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T10:15:00Z","last_updated_date":"2017-03-10T10:19:10Z","reference_number":"EMA/169524/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulprostone-list-nationally-authorised-medicinal-products-psusa00002828201604_en.pdf"},
    {"id":"26108","name":"Diclofenac (systemic formulations): CMDh Scientific conclusions and grounds for the variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001048/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T14:00:00Z","last_updated_date":"2016-10-17T20:37:47Z","reference_number":"EMA/474641/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201509_en.pdf"},
    {"id":"26114","name":"Rilmenidine: CMDh scientific conclusions and grounds for the variation,\n\namendments to the product information and timetable for\n\nthe implementation - PSUSA/00002643/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-14T12:00:00Z","last_updated_date":"2016-10-17T19:46:18Z","reference_number":"EMA/411667/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/rilmenidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002643201508_en.pdf"},
    {"id":"26120","name":"Antithrombin iii : List of nationally authorised medicinal products - PSUSA/00003159/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T17:17:00Z","last_updated_date":"2017-09-06T17:19:42Z","reference_number":"EMA/562354/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/antithrombin-iii-list-nationally-authorised-medicinal-products-psusa00003159201612_en.pdf"},
    {"id":"26145","name":"Octreotide : List of nationally authorised medicinal products - PSUSA/00002201/201706","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2018-03-13T13:00:00Z","last_updated_date":"2018-03-13T13:07:51Z","reference_number":"EMA/156950/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/octreotide-list-nationally-authorised-medicinal-products-psusa00002201201706_en.pdf"},
    {"id":"26202","name":"Propofol: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002555/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T13:00:00Z","last_updated_date":"2018-09-13T13:48:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/propofol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002555201711_no.pdf"}},
    {"id":"26204","name":"Sertindole: List of nationally authorised medicinal products - PSUSA/00002695/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T12:00:00Z","last_updated_date":"2016-10-18T11:56:06Z","reference_number":"EMA/599830/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/sertindole-list-nationally-authorised-medicinal-products-psusa00002695201601_en.pdf"},
    {"id":"26234","name":"Bemetizide / triamterene: List of nationally authorised medicinal products - PSUSA/00009076/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-21T02:00:00Z","last_updated_date":"2016-10-18T14:01:16Z","reference_number":"EMA/284356/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/bemetizide-triamterene-list-nationally-authorised-medicinal-products-psusa00009076201506_en.pdf"},
    {"id":"26294","name":"Tobramycin (nebuliser solution): List of nationally authorised medicinal products - PSUSA/00009316/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-16T14:00:00Z","last_updated_date":"2016-10-17T20:16:00Z","reference_number":"EMA/612853/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tobramycin-nebuliser-solution-list-nationally-authorised-medicinal-products-psusa00009316201412_en.pdf"},
    {"id":"26299","name":"Bicalutamide: List of nationally authorised medicinal products - PSUSA/00000407/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T14:35:00Z","last_updated_date":"2017-10-27T14:51:57Z","reference_number":"EMA/716500/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/bicalutamide-list-nationally-authorised-medicinal-products-psusa00000407201702_en.pdf"},
    {"id":"26309","name":"Tirofiban: List of nationally authorised medicinal products - PSUSA/00002974/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T14:25:00Z","last_updated_date":"2017-02-02T14:28:09Z","reference_number":"EMA/77788/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tirofiban-list-nationally-authorised-medicinal-products-psusa00002974201605_en.pdf"},
    {"id":"26323","name":"Rupatadine: List of nationally authorised medicinal products - PSUSA/00002673/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-05T16:30:00Z","last_updated_date":"2017-09-05T16:30:00Z","reference_number":"EMA/579949/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/rupatadine-list-nationally-authorised-medicinal-products-psusa00002673201612_en.pdf"},
    {"id":"26336","name":"Triamcinolone (topical and nasal formulations): List of nationally authorised medicinal products - PSUSA/00003017/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-22T10:50:00Z","last_updated_date":"2018-03-22T10:52:00Z","reference_number":"EMA/182668/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/triamcinolone-topical-and-nasal-formulations-list-nationally-authorised-medicinal-products-psusa00003017201707_en.pdf"},
    {"id":"26360","name":"Ketotifen (oral formulations): List of nationally authorised medicinal products - PSUSA/00001813/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-20T02:00:00Z","last_updated_date":"2016-10-17T19:03:12Z","reference_number":"EMA/485883/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketotifen-oral-formulations-list-nationally-authorised-medicinal-products-psusa00001813201410_en.pdf"},
    {"id":"26395","name":"Indapamide / perindopril: List of nationally authorised medicinal products - PSUSA/00010230/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T17:10:00Z","last_updated_date":"2017-09-06T17:10:00Z","reference_number":"EMA/530377/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/indapamide-perindopril-list-nationally-authorised-medicinal-products-psusa00010230201611_en.pdf"},
    {"id":"26494","name":"Demeclocycline / triamcinolone: List of nationally authorised medicinal products - PSUSA/00010415/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-22T17:00:00Z","last_updated_date":"2018-03-22T17:00:00Z","reference_number":"EMA/182799/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/demeclocycline-triamcinolone-list-nationally-authorised-medicinal-products-psusa00010415201707_en.pdf"},
    {"id":"26533","name":"Bacterial lysate of haemophilus influenzae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus / streptococcus mitis / streptococcus pneumoniae / streptococcus pyogenes, bacterial lysate of ... - List of nationally authorised medicines","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T13:00:00Z","last_updated_date":"2016-12-14T13:13:00Z","reference_number":"EMA/807596/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/bacterial-lysate-haemophilus-influenzae-klebsiella-pneumoniae-moraxella-catarrhalis-staphylococcus-aureus-streptococcus-mitis-streptococcus-pneumoniae-streptococcus-pyogenes-bacterial-lysate-list_en.pdf"},
    {"id":"26556","name":"Paraffin liquid: List of nationally authorised medicinal products - PSUSA/00009251/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-10-17T16:59:48Z","reference_number":"EMA/447158/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/paraffin-liquid-list-nationally-authorised-medicinal-products-psusa00009251201510_en.pdf"},
    {"id":"26570","name":"Modafinil: List of nationally authorised medicinal products - PSUSA/00010242/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T20:00:00Z","last_updated_date":"2018-05-23T20:22:18Z","reference_number":"EMA/326462/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/modafinil-list-nationally-authorised-medicinal-products-psusa00010242201708_en.pdf"},
    {"id":"26577","name":"Epoprostenol: List of nationally authorised medicinal products    - PSUSA/00001242/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T15:20:00Z","last_updated_date":"2018-01-24T15:27:41Z","reference_number":"EMA/46884/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/epoprostenol-list-nationally-authorised-medicinal-products-psusa00001242201703_en.pdf"},
    {"id":"26607","name":"Topiramate: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002996/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T17:20:00Z","last_updated_date":"2017-10-23T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/topiramate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002996201701_no.pdf"}},
    {"id":"26670","name":"Glibenclamide / metformin hydrochloride: List of nationally authorised medicinal products - PSUSA/00002002/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-21T02:00:00Z","last_updated_date":"2016-10-17T15:55:20Z","reference_number":"EMA/284356/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/glibenclamide-metformin-hydrochloride-list-nationally-authorised-medicinal-products-psusa00002002201506_en.pdf"},
    {"id":"26721","name":"Olsalazine: List of nationally authorised medicinal products - PSUSA/00002213/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-19T18:20:00Z","last_updated_date":"2018-01-19T18:20:00Z","reference_number":"EMA/41064/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/olsalazine-list-nationally-authorised-medicinal-products-psusa00002213201705_en.pdf"},
    {"id":"26734","name":"Cefoperazone: List of nationally authorised medicinal products - PSUSA/00000597/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-25T02:00:00Z","last_updated_date":"2016-10-25T19:25:50Z","reference_number":"EMA/703175/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefoperazone-list-nationally-authorised-medicinal-products-psusa00000597201601_en.pdf"},
    {"id":"26743","name":"Bismuth subcitrate potassium / metronidazole / tetracycline: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010199/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T15:55:00Z","last_updated_date":"2018-03-06T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010199201705_sv.pdf"}},
    {"id":"26797","name":"Tramadol: List of nationally authorised medicinal products - PSUSA/00003002/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T19:00:00Z","last_updated_date":"2018-03-07T19:00:54Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tramadol-list-nationally-authorised-medicinal-products-psusa00003002201705_en.pdf"},
    {"id":"26814","name":"Escitalopram : List of nationally authorised medicinal products - PSUSA/00001265/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T18:36:00Z","last_updated_date":"2017-09-06T18:38:30Z","reference_number":"EMA/590630/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/escitalopram-list-nationally-authorised-medicinal-products-psusa00001265201612_en.pdf"},
    {"id":"26827","name":"Cilostazol: List of nationally authorised medicinal products - PSUSA/00010209/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-30T14:00:00Z","last_updated_date":"2016-10-17T20:25:28Z","reference_number":"EMA/648833/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilostazol-list-nationally-authorised-medicinal-products-psusa00010209201602_en.pdf"},
    {"id":"26871","name":"Simvastatin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002709/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T15:34:00Z","last_updated_date":"2018-01-24T15:42:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002709201704_no.pdf"}},
    {"id":"27010","name":"Levonorgestrel / ethinylestradiol, ethinylestradiol(combination pack): List of nationally authorised medicinal products - PSUSA/00010442/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-05T14:00:00Z","last_updated_date":"2017-09-06T17:19:00Z","reference_number":"EMA/580243/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiolcombination-pack-list-nationally-authorised-medicinal-products-psusa00010442201701_en.pdf"},
    {"id":"27104","name":"Rabies vaccine : CMDh Scientific conclusions and grounds for the variation,\n\namendments to the Product Information, and timetable\n\nfor the implementation: PSUSA/00009277/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T13:22:00Z","last_updated_date":"2016-12-19T13:31:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/rabies-vaccine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009277201603_no.pdf"}},
    {"id":"27152","name":"Trimetazidine: List of nationally authorised medicinal products - EMEA/H/N/PSR/0001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-04T20:30:00Z","last_updated_date":"2016-10-04T20:30:00Z","reference_number":"EMA/283098/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-list-nationally-authorised-medicinal-products-emeahnpsr0001_en.pdf"},
    {"id":"27195","name":"Ethinylestradiol / gestodene (except for transdermal application): List of nationally authorised medicinal products - PSUSA/00001308/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T15:00:00Z","last_updated_date":"2016-10-28T15:00:00Z","reference_number":"EMA/719205/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-gestodene-except-transdermal-application-list-nationally-authorised-medicinal-products-psusa00001308201603_en.pdf"},
    {"id":"27213","name":"Amiodarone: CMDh scientific conclusions and grounds for variation, amendments to the product information, and timetable for the implementation - PSUSA/00000166/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-04T02:00:00Z","last_updated_date":"2016-10-17T19:40:16Z","reference_number":"EMA/586086/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/amiodarone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000166201412_en.pdf"},
    {"id":"27246","name":"Lisinopril: List of nationally authorised medicinal products - PSUSA/00001894/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-06T02:00:00Z","last_updated_date":"2016-10-18T10:40:08Z","reference_number":"EMA/388981/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisinopril-list-nationally-authorised-medicinal-products-psusa00001894201509_en.pdf"},
    {"id":"27269","name":"Cyproterone/ethinylestradiol: PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-23T19:31:00Z","last_updated_date":"2017-02-23T19:31:00Z","reference_number":"EMA/101741/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproteroneethinylestradiol-prac-non-interventional-imposed-pass-final-study-report-assessment-report-emeahnpsrj0006_en.pdf"},
    {"id":"27280","name":"Amlodipine / indapamide, amlodipine / indapamide / perindopril: List of nationally authorised medicinal products - PSUSA/00010358/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T16:45:00Z","last_updated_date":"2018-07-19T16:45:00Z","reference_number":"EMA/498820/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-indapamide-amlodipine-indapamide-perindopril-list-nationally-authorised-medicinal-products-psusa00010358201711_en.pdf"},
    {"id":"27291","name":"Apomorphine: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00000227/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-10-17T19:40:13Z","reference_number":"EMA/198769/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000227201505_en.pdf"},
    {"id":"27403","name":"Adenosine: List of nationally authorised medicinal products - PSUSA/00000062/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T12:30:00Z","last_updated_date":"2018-04-13T12:30:00Z","reference_number":"EMA/231148/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/adenosine-list-nationally-authorised-medicinal-products-psusa00000062201708_en.pdf"},
    {"id":"27409","name":"Magnesium sulfate: List of nationally authorised medicinal products - PSUSA/00009225/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-19T01:00:00Z","last_updated_date":"2016-10-18T10:40:10Z","reference_number":"EMA/143971/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulfate-list-nationally-authorised-medicinal-products-psusa00009225201506_en.pdf"},
    {"id":"27450","name":"Bendamustine hydrochloride: List of nationally authorised medicinal products - PSUSA/00003162/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-04T16:25:00Z","last_updated_date":"2016-11-15T12:01:03Z","reference_number":"EMA/574895/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendamustine-hydrochloride-list-nationally-authorised-medicinal-products-psusa00003162201601_en.pdf"},
    {"id":"27455","name":"Fosfomycin (oral formulation): List of nationally authorised medicinal products - PSUSA/00010326/201607","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2017-04-11T19:40:00Z","last_updated_date":"2017-04-11T19:40:00Z","reference_number":"EMA/235642/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosfomycin-oral-formulation-list-nationally-authorised-medicinal-products-psusa00010326201607_en.pdf"},
    {"id":"27472","name":"Triamcinolone (intraocular formulations): List of nationally authorised medicinal products - PSUSA/00010292/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-22T10:00:00Z","last_updated_date":"2016-12-22T10:00:00Z","reference_number":"EMA/852848/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/triamcinolone-intraocular-formulations-list-nationally-authorised-medicinal-products-psusa00010292201603_en.pdf"},
    {"id":"27501","name":"Interferon alpha-2a: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009197/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-03T15:55:00Z","last_updated_date":"2018-04-03T16:01:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/interferon-alpha-2a-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009197201706_no.pdf"}},
    {"id":"27525","name":"Lenograstim: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001839/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-08-25T12:00:00Z","last_updated_date":"2017-08-25T12:04:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201610_sv.pdf"}},
    {"id":"27597","name":"Alanine / arginine / aspartic acid / cysteine / glucose anhydrous / glutamic acid / glycine / histidine / isoleucine / leucine / lysine / methionine / olive oil refined / ornithine / phenylalanine / proline / serine / so...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-13T02:00:00Z","last_updated_date":"2016-10-17T17:40:00Z","reference_number":"EMA/607402/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/alanine-arginine-aspartic-acid-cysteine-glucose-anhydrous-glutamic-acid-glycine-histidine-isoleucine-leucine-lysine-methionine-olive-oil-refined-ornithine-phenylalanine-proline-serine-so_en.pdf-0"},
    {"id":"27620","name":"Phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010430/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T18:15:00Z","last_updated_date":"2018-09-10T18:15:00Z","reference_number":"EMA/613167/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylephrine-hydrochloride-tropicamide-list-nationally-authorised-medicinal-products-psusa00010430201711_en.pdf"},
    {"id":"27708","name":"Mizolastine: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002078/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-05T14:00:00Z","last_updated_date":"2018-09-05T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/mizolastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002078201711_no.pdf"}},
    {"id":"27723","name":"Risedronate: List of nationally authorised medicinal products - PSUSA/00002648/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T12:27:00Z","last_updated_date":"2016-12-02T12:28:22Z","reference_number":"EMA/806387/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/risedronate-list-nationally-authorised-medicinal-products-psusa00002648201603_en.pdf"},
    {"id":"27772","name":"Omega-3-acid-ethyl esters: List of nationally authorised medicinal products - PSUSA/00010312/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T18:10:00Z","last_updated_date":"2017-11-15T18:18:03Z","reference_number":"EMA/641530/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/omega-3-acid-ethyl-esters-list-nationally-authorised-medicinal-products-psusa00010312201701_en.pdf"},
    {"id":"27807","name":"Diclofenac (topical formulations): List of nationally authorised medicinal products - PSUSA/00010342/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-27T14:00:00Z","last_updated_date":"2016-10-17T20:37:49Z","reference_number":"EMA/446349/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-topical-formulations-list-nationally-authorised-medicinal-products-psusa00010342201509_en.pdf"},
    {"id":"27843","name":"Flurbiprofen : List of nationally authorised medicinal products - PSUSA/00001450/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T11:39:00Z","last_updated_date":"2017-09-08T11:48:43Z","reference_number":"EMA/593212/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/flurbiprofen-list-nationally-authorised-medicinal-products-psusa00001450201611_en.pdf"},
    {"id":"27872","name":"Benzydamine: List of nationally authorised medicinal products - PSUSA/00000375/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-05T02:00:00Z","last_updated_date":"2016-10-18T14:01:14Z","reference_number":"EMA/398898/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzydamine-list-nationally-authorised-medicinal-products-psusa00000375201510_en.pdf"},
    {"id":"27895","name":"Olodaterol: List of nationally authorised medicinal products - PSUSA/00010245/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-03T02:00:00Z","last_updated_date":"2016-10-18T12:49:41Z","reference_number":"EMA/316649/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodaterol-list-nationally-authorised-medicinal-products-psusa00010245201509_en.pdf"},
    {"id":"27925","name":"Sodium iodide (131i): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002753/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T12:20:00Z","last_updated_date":"2018-01-04T12:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/sodium-iodide-131i-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002753201703_sv.pdf"}},
    {"id":"27945","name":"Pholcodine: List of nationally authorised medicinal products - PSUSA/00002396/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-02T11:00:00Z","last_updated_date":"2016-10-17T18:27:53Z","reference_number":"EMA/72990/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/pholcodine-list-nationally-authorised-medicinal-products-psusa00002396201505_en.pdf"},
    {"id":"27980","name":"Ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010345/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T12:25:00Z","last_updated_date":"2018-01-03T12:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010345201702_no.pdf"}},
    {"id":"27986","name":"Ropivacaine: List of nationally authorised medicinal products - PSUSA/00002662/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-22T15:41:00Z","last_updated_date":"2018-05-22T15:45:17Z","reference_number":"EMA/299649/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropivacaine-list-nationally-authorised-medicinal-products-psusa00002662201709_en.pdf"},
    {"id":"28103","name":"Calcium carbonate / famotidine / magnesium hydroxide: List of nationally authorised medicinal products - PSUSA/00001351/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2016-10-18T15:41:09Z","reference_number":"EMA/544237/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-list-nationally-authorised-medicinal-products-psusa00001351201409_en.pdf"},
    {"id":"28106","name":"Amisulpride: List of nationally authorised medicinal products - PSUSA/00000167/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-05T12:10:00Z","last_updated_date":"2017-10-05T12:10:00Z","reference_number":"EMA/658194/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/amisulpride-list-nationally-authorised-medicinal-products-psusa00000167201701_en.pdf"},
    {"id":"28215","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T13:00:00Z","last_updated_date":"2017-07-10T13:00:00Z","reference_number":"EMA/435940/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288201611_en.pdf"},
    {"id":"28233","name":"Moxonidine : List of nationally authorised medicinal products -  PSUSA/00002095/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T18:35:00Z","last_updated_date":"2017-10-03T18:37:17Z","reference_number":"EMA/652910/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/moxonidine-list-nationally-authorised-medicinal-products-psusa00002095201701_en.pdf"},
    {"id":"28250","name":"Ciprofloxacin hydrochloride, dexamethasone acetate (ear drops, suspension): List of nationally authorised medicinal products - PSUSA/00010012/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-30T14:00:00Z","last_updated_date":"2016-10-17T20:25:30Z","reference_number":"EMA/648833/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-hydrochloride-dexamethasone-acetate-ear-drops-suspension-list-nationally-authorised-medicinal-products-psusa00010012201504_en.pdf"},
    {"id":"28256","name":"Pseudoephedrine, triprolidine: List of nationally authorised medicinal products -PSUSA/00003047/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-17T12:00:00Z","last_updated_date":"2016-10-17T19:05:45Z","reference_number":"EMA/619753/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/pseudoephedrine-triprolidine-list-nationally-authorised-medicinal-products-psusa00003047201412_en.pdf"},
    {"id":"28289","name":"Flunitrazepam: List of nationally authorised medicinal products - PSUSA/00001418/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-10-18T16:32:01Z","reference_number":"EMA/600649/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/flunitrazepam-list-nationally-authorised-medicinal-products-psusa00001418201601_en.pdf"},
    {"id":"28321","name":"Budesonide: List of nationally authorised medicinal products - PSUSA/00000449/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T15:30:00Z","last_updated_date":"2017-03-10T15:35:39Z","reference_number":"EMA/169538/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/budesonide-list-nationally-authorised-medicinal-products-psusa00000449201604_en.pdf"},
    {"id":"28339","name":"Hypericum perforatum L., herba: List of nationally authorised medicinal products - PSUSA/00001701/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T13:00:00Z","last_updated_date":"2018-09-13T13:02:43Z","reference_number":"EMA/613959/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/hypericum-perforatum-l-herba-list-nationally-authorised-medicinal-products-psusa00001701201801_en.pdf"},
    {"id":"28368","name":"Beclometasone: List of nationally authorised medicinal products - PSUSA/00000306/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T16:00:00Z","last_updated_date":"2017-09-08T16:00:00Z","reference_number":"EMA/594294/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/beclometasone-list-nationally-authorised-medicinal-products-psusa00000306201612_en.pdf"},
    {"id":"28403","name":"Human coagulation factor VII: List of nationally authorised medicinal products - PSUSA/00001619/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T14:30:00Z","last_updated_date":"2017-07-10T14:30:00Z","reference_number":"EMA/437790/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-vii-list-nationally-authorised-medicinal-products-psusa00001619201610_en.pdf"},
    {"id":"28412","name":"Nifedipine: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00002156/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-07T02:00:00Z","last_updated_date":"2016-10-18T12:37:32Z","reference_number":"EMA/394060/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/nifedipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002156201508_en.pdf"},
    {"id":"28419","name":"Nicorandil: List of nationally authorised medicinal products - PSUSA/00002152/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T15:00:00Z","last_updated_date":"2016-10-28T15:00:00Z","reference_number":"EMA/692015/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicorandil-list-nationally-authorised-medicinal-products-psusa00002152201602_en.pdf"},
    {"id":"28442","name":"Glycopyrronium bromide (all indications except for chronic obstructive pulmonary disease): List of nationally authorised medicinal products - PSUSA/00001556/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-07T02:00:00Z","last_updated_date":"2016-10-17T15:38:44Z","reference_number":"EMA/474049/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/glycopyrronium-bromide-all-indications-except-chronic-obstructive-pulmonary-disease-list-nationally-authorised-medicinal-products-psusa00001556201509_en.pdf"},
    {"id":"28513","name":"Rabbit anti-human thymocyte (concentrate for solution for infusion): List of nationally authorised medicinal products - PSUSA/00010252/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-06T12:00:00Z","last_updated_date":"2016-10-17T19:31:35Z","reference_number":"EMA/532392/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-human-thymocyte-concentrate-solution-infusion-list-nationally-authorised-medicinal-products-psusa00010252201412_en.pdf-0"},
    {"id":"28519","name":"Dihydroergotamine: List of nationally authorised medicinal products - PSUSA/00001075/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T13:00:00Z","last_updated_date":"2016-10-17T19:52:26Z","reference_number":"EMA/788899/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/dihydroergotamine-list-nationally-authorised-medicinal-products-psusa00001075201504_en.pdf"},
    {"id":"28609","name":"Flupirtine: List of nationally authorised medicinal products - PSUSA/00010225/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-08T02:00:00Z","last_updated_date":"2016-10-18T16:32:02Z","reference_number":"EMA/666694/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/flupirtine-list-nationally-authorised-medicinal-products-psusa00010225201501_en.pdf"},
    {"id":"28643","name":"Tioconazole, tioconazole / hydrocortisone: List of nationally authorised medicinal products - PSUSA/00010382/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T17:00:00Z","last_updated_date":"2017-12-11T17:00:00Z","reference_number":"EMA/812660/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tioconazole-tioconazole-hydrocortisone-list-nationally-authorised-medicinal-products-psusa00010382201704_en.pdf"},
    {"id":"28650","name":"5 Fluorouracil, salicylic acid: List of nationally authorised medicinal products - PSUSA/00000008/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-11T02:00:00Z","last_updated_date":"2016-10-17T16:40:32Z","reference_number":"EMA/4301/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-salicylic-acid-list-nationally-authorised-medicinal-products-psusa00000008201505_en.pdf"},
    {"id":"28656","name":"Fentanyl (transdermal patches, solution for injection): List of nationally authorised medicinal products - PSUSA/00001370/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-31T02:00:00Z","last_updated_date":"2016-10-18T16:14:17Z","reference_number":"EMA/230161/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-list-nationally-authorised-medicinal-products-psusa00001370201504_en.pdf"},
    {"id":"28662","name":"Fenoterol (obstetric indications): List of nationally authorised medicinal products - PSUSA/00010001/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-18T16:14:15Z","reference_number":"EMA/346558/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenoterol-obstetric-indications-list-nationally-authorised-medicinal-products-psusa00010001201509_en.pdf"},
    {"id":"28679","name":"Brimonidine / timolol: List of nationally authorised medicinal products - PSUSA/00000431/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-14T19:00:00Z","last_updated_date":"2017-06-14T19:00:00Z","reference_number":"EMA/36849/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/brimonidine-timolol-list-nationally-authorised-medicinal-products-psusa00000431201609_en.pdf"},
    {"id":"28697","name":"Nefopam: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002131/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T15:40:00Z","last_updated_date":"2017-03-10T15:42:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nefopam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002131201603_sv.pdf"}}    {"id":"28749","name":"Nefopam: List of nationally authorised medicinal products  - PSUSA/00002131/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T15:40:00Z","last_updated_date":"2017-03-10T15:42:37Z","reference_number":"EMA/153595/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/nefopam-list-nationally-authorised-medicinal-products-psusa00002131201603_en.pdf"},
    {"id":"28767","name":"Etomidate: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001330/20170","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-12T12:42:00Z","last_updated_date":"2018-07-12T12:51:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/etomidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000133020170_sv.pdf"}},
    {"id":"28775","name":"Poliovirus type 1 / poliovirus type 3 (oral, live, attenuated) vaccine: List of nationally authorised medicinal products - PSUSA/00002460/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-11T12:00:00Z","last_updated_date":"2016-10-17T18:38:23Z","reference_number":"EMA/256935/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/poliovirus-type-1-poliovirus-type-3-oral-live-attenuated-vaccine-list-nationally-authorised-medicinal-products-psusa00002460201507_en.pdf"},
    {"id":"28824","name":"Acetylsalicylic acid: List of nationally authorised medicinal products - PSUSA/00000039/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T17:00:00Z","last_updated_date":"2016-10-19T17:00:00Z","reference_number":"EMA/660623/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-list-nationally-authorised-medicinal-products-psusa00000039201602_en.pdf"},
    {"id":"28885","name":"Formoterol: List of nationally authorised medicinal products - PSUSA/00001469/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T11:10:00Z","last_updated_date":"2018-01-18T11:10:00Z","reference_number":"EMA/34978/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/formoterol-list-nationally-authorised-medicinal-products-psusa00001469201705_en.pdf"},
    {"id":"28940","name":"Goserelin: List of nationally authorised medicinal products - PSUSA/00001562/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-24T11:30:00Z","last_updated_date":"2017-01-24T11:37:33Z","reference_number":"EMA/45363/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/goserelin-list-nationally-authorised-medicinal-products-psusa00001562201605_en.pdf"},
    {"id":"29035","name":"Rupatadine: List of nationally authorised medicinal products - PSUSA/00002673/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T12:00:00Z","last_updated_date":"2016-10-18T11:22:49Z","reference_number":"EMA/346098/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/rupatadine-list-nationally-authorised-medicinal-products-psusa00002673201506_en.pdf"},
    {"id":"29085","name":"Flupirtine: List of nationally authorised medicinal products - PSUSA/00010225/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-20T18:14:00Z","last_updated_date":"2018-06-20T18:16:26Z","reference_number":"EMA/417850/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/flupirtine-list-nationally-authorised-medicinal-products-psusa00010225201710_en.pdf"},
    {"id":"29117","name":"Allergen for therapy: Dactylis Glomerata L., Phleum Pratense L., Anthoxanthum Odoratum L., Lolium Perenne L., Poa Pratensis: List of nationally authorised medicinal products - PSUSA/00010465/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T16:00:00Z","last_updated_date":"2017-09-08T16:00:00Z","reference_number":"EMA/596847/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-dactylis-glomerata-l-phleum-pratense-l-anthoxanthum-odoratum-l-lolium-perenne-l-poa-pratensis-list-nationally-authorised-medicinal-products-psusa00010465201612_en.pdf"},
    {"id":"29145","name":"Benzydamine: CMDh scientific conclusions and grounds for the variation,amendments to the product information and timetable for the implementation - PSUSA/00000375/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-05T02:00:00Z","last_updated_date":"2016-10-18T14:01:00Z","reference_number":"EMA/587640/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzydamine-cmdh-scientific-conclusions-and-grounds-variationamendments-product-information-and-timetable-implementation-psusa00000375201510_en.pdf"},
    {"id":"29177","name":"Delapril / manidipine, delapril / indapamide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010496/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-24T14:22:00Z","last_updated_date":"2018-04-24T14:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/delapril-manidipine-delapril-indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010496201706_sv.pdf"}},
    {"id":"29182","name":"Lisdexamfetamine : List of nationally authorised medicinal products -   PSUSA/00010289/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-29T19:06:00Z","last_updated_date":"2017-09-29T19:07:58Z","reference_number":"EMA/639185/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa00010289201702_en.pdf"},
    {"id":"29273","name":"Gentamicin (systemic use): List of nationally authorised medicinal products - PSUSA/00009159/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-29T12:35:00Z","last_updated_date":"2018-01-31T12:02:00Z","reference_number":"EMA/57675/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/gentamicin-systemic-use-list-nationally-authorised-medicinal-products-psusa00009159201703_en.pdf"},
    {"id":"29302","name":"Atenolol / chlortalidone: List of nationally authorised medicinal products - PSUSA/00000260/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2016-10-17T19:40:04Z","reference_number":"EMA/398898/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/atenolol-chlortalidone-list-nationally-authorised-medicinal-products-psusa00000260201409_en.pdf"},
    {"id":"29308","name":"Glucosamine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001539/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T16:13:00Z","last_updated_date":"2018-01-24T16:44:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/glucosamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001539201703_no.pdf"}},
    {"id":"29351","name":"Botulinum toxin a: List of nationally authorised medicinal products - PSUSA/00000426/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T11:17:00Z","last_updated_date":"2016-10-27T11:22:45Z","reference_number":"EMA/705701/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-list-nationally-authorised-medicinal-products-psusa00000426201512_en.pdf"},
    {"id":"29430","name":"Cefoperazone / sulbactam: List of nationally authorised medicinal products - PSUSA/00000598/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T12:19:00Z","last_updated_date":"2016-10-27T12:24:03Z","reference_number":"EMA/714629/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefoperazone-sulbactam-list-nationally-authorised-medicinal-products-psusa00000598201601_en.pdf-0"},
    {"id":"29436","name":"Influenza vaccine (surface antigen, inactivated): List of nationally authorised medicinal products - PSUSA/00001744/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T12:58:00Z","last_updated_date":"2016-11-15T13:01:22Z","reference_number":"EMA/751331/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa00001744201603_en.pdf"},
    {"id":"29488","name":"Nabumetone: List of nationally authorised medicinal products - PSUSA/00002101/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-06T17:30:00Z","last_updated_date":"2017-11-06T17:53:44Z","reference_number":"EMA/727925/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/nabumetone-list-nationally-authorised-medicinal-products-psusa00002101201703_en.pdf"},
    {"id":"29507","name":"Lormetazepam: CMDh scientific conclusions and grounds for variation,\n\namendments to the product information and timetable for\n\nthe implementation - PSUSA/00001910/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-09T01:00:00Z","last_updated_date":"2016-10-18T10:40:07Z","reference_number":"EMA/739294/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/lormetazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001910201412_en.pdf"},
    {"id":"29561","name":"Hydrochlorothiazide, ramipril: List of nationally authorised medicinal products - PSUSA/00001660/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-17T02:00:00Z","last_updated_date":"2016-10-17T17:35:00Z","reference_number":"EMA/619987/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-ramipril-list-nationally-authorised-medicinal-products-psusa00001660201501_en.pdf"},
    {"id":"29573","name":"(18f) Fludeoxyglucose: List of nationally authorised medicinal products - PSUSA/00001437/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-08T02:00:00Z","last_updated_date":"2016-10-17T16:33:00Z","reference_number":"EMA/665781/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/18f-fludeoxyglucose-list-nationally-authorised-medicinal-products-psusa00001437201411_en.pdf"},
    {"id":"29597","name":"Bromocriptine: List of nationally authorised medicinal products - PSUSA/00000438/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-20T02:00:00Z","last_updated_date":"2016-10-18T14:01:08Z","reference_number":"EMA/427938/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromocriptine-list-nationally-authorised-medicinal-products-psusa00000438201510_en.pdf"},
    {"id":"29671","name":"Chloroprocaine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010078/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-30T18:11:00Z","last_updated_date":"2017-11-30T18:12:49Z","reference_number":"EMA/796919/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/chloroprocaine-hydrochloride-list-nationally-authorised-medicinal-products-psusa00010078201703_en.pdf"},
    {"id":"29682","name":"Delapril: List of nationally authorised medicinal products - PSUSA/00000946/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-06T13:00:00Z","last_updated_date":"2016-10-17T20:25:29Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/delapril-list-nationally-authorised-medicinal-products-psusa00000946201501_en.pdf"},
    {"id":"29722","name":"Cidofovir: List of nationally authorised medicinal products - PSUSA/00010558/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-17T16:30:00Z","last_updated_date":"2018-01-17T16:32:38Z","reference_number":"EMA/32409/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cidofovir-list-nationally-authorised-medicinal-products-psusa00010558201706_en.pdf"},
    {"id":"29808","name":"Morphine morphine-cyclizine: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010549/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-02T18:00:00Z","last_updated_date":"2018-08-03T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/morphine-morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010549201710_no.pdf"}},
    {"id":"29853","name":"Latanoprost (products with paediatric indication) : List of nationally authorised medicinal products - PSUSA/00001834/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T15:57:00Z","last_updated_date":"2017-12-01T16:00:00Z","reference_number":"EMA/797779/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-products-paediatric-indication-list-nationally-authorised-medicinal-products-psusa00001834201704_en.pdf"},
    {"id":"29857","name":"Acitretin: List of nationally authorised medicinal products - PSUSA/00000051/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-10T02:00:00Z","last_updated_date":"2016-10-17T17:40:40Z","reference_number":"EMA/540462/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-list-nationally-authorised-medicinal-products-psusa00000051201510_en.pdf"},
    {"id":"29947","name":"Losartan: List of nationally authorised medicinal products - PSUSA/00001912/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T15:19:00Z","last_updated_date":"2018-05-23T15:21:24Z","reference_number":"EMA/309956/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/losartan-list-nationally-authorised-medicinal-products-psusa00001912201709_en.pdf"},
    {"id":"30052","name":"Rabbit anti-human thymocyte (powder for solution for\n\ninfusion): List of nationally authorised medicinal products - PSUSA/00010184/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-04T12:00:00Z","last_updated_date":"2016-10-17T19:31:37Z","reference_number":"EMA/592453/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-human-thymocyte-powder-solution-infusion-list-nationally-authorised-medicinal-products-psusa00010184201412_en.pdf"},
    {"id":"30082","name":"Bemiparin: List of nationally authorised medicinal products - PSUSA/00000312/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-20T16:40:00Z","last_updated_date":"2017-01-20T16:40:00Z","reference_number":"EMA/36362/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/bemiparin-list-nationally-authorised-medicinal-products-psusa00000312201604_en.pdf"},
    {"id":"30107","name":"Nimesulide (systemic formulations): List of nationally authorised medicinal products - PSUSA/00009236/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-11T02:00:00Z","last_updated_date":"2016-10-18T12:37:31Z","reference_number":"EMA/256049/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimesulide-systemic-formulations-list-nationally-authorised-medicinal-products-psusa00009236201506_en.pdf"},
    {"id":"30195","name":"Isoniazid: List of nationally authorised medicinal products - PSUSA/00001789/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T02:00:00Z","last_updated_date":"2016-10-17T18:51:25Z","reference_number":"EMA/544752/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoniazid-list-nationally-authorised-medicinal-products-psusa00001789201411_en.pdf"},
    {"id":"30274","name":"Ketotifen (ophtalmic formulations): List of nationally authorised medicinal products - PSUSA/00001812/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T12:30:00Z","last_updated_date":"2018-03-09T12:52:34Z","reference_number":"EMA/154217/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketotifen-ophtalmic-formulations-list-nationally-authorised-medicinal-products-psusa00001812201706_en.pdf"},
    {"id":"30289","name":"Desogestrel / ethinylestradiol: List of nationally authorised medicinal products - PSUSA/00000967/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T14:00:00Z","last_updated_date":"2016-10-17T20:37:48Z","reference_number":"EMA/364968/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/desogestrel-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa00000967201509_en.pdf"},
    {"id":"30306","name":"Haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus / streptococcus pneumoniae / streptococcus pyogenes / streptococcus viridans vaccine: List of nationally...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T13:00:00Z","last_updated_date":"2018-09-13T13:45:49Z","reference_number":"EMA/619619/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/haemophilus-influenzae-klebsiella-ozaenae-klebsiella-pneumoniae-moraxella-catarrhalis-staphylococcus-aureus-streptococcus-pneumoniae-streptococcus-pyogenes-streptococcus-viridans-vaccine-list_en.pdf"},
    {"id":"30380","name":"Interferon alpha-2a: List of nationally authorised medicinal products - PSUSA/00009197/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-03T15:55:00Z","last_updated_date":"2018-04-03T16:01:37Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/interferon-alpha-2a-list-nationally-authorised-medicinal-products-psusa00009197201706_en.pdf"},
    {"id":"30386","name":"Ketorolac (ophtalmic formulations): List of nationally authorised medicinal products - PSUSA/00001810/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T11:50:00Z","last_updated_date":"2018-03-09T11:55:00Z","reference_number":"EMA/154207/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketorolac-ophtalmic-formulations-list-nationally-authorised-medicinal-products-psusa00001810201707_en.pdf"},
    {"id":"30434","name":"Promestriene (cream and vaginal capsules): List of nationally authorised medicinal products - PSUSA/00009271/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-17T11:00:00Z","last_updated_date":"2016-10-17T18:54:54Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/promestriene-cream-and-vaginal-capsules-list-nationally-authorised-medicinal-products-psusa00009271201503_en.pdf"},
    {"id":"30462","name":"Epinastine: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001231/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-14T14:00:00Z","last_updated_date":"2018-08-14T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/epinastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001231201710_sv.pdf"}},
    {"id":"30503","name":"Cromoglicic acid : List of nationally authorised medicinal products - PSUSA/00000883/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T15:40:00Z","last_updated_date":"2017-10-31T16:01:55Z","reference_number":"EMA/663700/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cromoglicic-acid-list-nationally-authorised-medicinal-products-psusa00000883201702_en.pdf"},
    {"id":"30556","name":"Misoprostol (gastrointestinal indication): List of nationally authorised medicinal products - PSUSA/00010291/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-09T19:00:00Z","last_updated_date":"2018-04-09T19:12:11Z","reference_number":"EMA/221190/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gastrointestinal-indication-list-nationally-authorised-medicinal-products-psusa00010291201706_en.pdf"},
    {"id":"30626","name":"Anastrozole: List of nationally authorised medicinal products - PSUSA/00000210/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T13:30:00Z","last_updated_date":"2018-04-13T14:00:56Z","reference_number":"EMA/223603/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/anastrozole-list-nationally-authorised-medicinal-products-psusa00000210201708_en.pdf"},
    {"id":"30693","name":"Pentamidine: List of nationally authorised medicinal products - PSUSA/00002338/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T15:15:00Z","last_updated_date":"2018-02-13T15:15:00Z","reference_number":"EMA/94268/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/pentamidine-list-nationally-authorised-medicinal-products-psusa00002338201706_en.pdf"},
    {"id":"30694","name":"Sevoflurane: List of nationally authorised medicinal products - PSUSA/00002698/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-14T12:00:00Z","last_updated_date":"2016-10-18T11:56:09Z","reference_number":"EMA/642675/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/sevoflurane-list-nationally-authorised-medicinal-products-psusa00002698201501_en.pdf"},
    {"id":"30711","name":"Pilocarpine (non ophthalmic formulations): List of nationally authorised medicinal products - PSUSA/00002409/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-16T12:48:00Z","last_updated_date":"2018-04-16T12:52:00Z","reference_number":"EMA/235877/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/pilocarpine-non-ophthalmic-formulations-list-nationally-authorised-medicinal-products-psusa00002409201707_en.pdf"},
    {"id":"30735","name":"Ezetimibe: List of nationally authorised medicinal products - PSUSA/00001346/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-22T17:00:00Z","last_updated_date":"2018-06-22T17:00:00Z","reference_number":"EMA/417291/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ezetimibe-list-nationally-authorised-medicinal-products-psusa00001346201710_en.pdf"},
    {"id":"30755","name":"Alprostadil (patency of the ductus arteriosus): List of nationally authorised medicinal products - PSUSA/00010021/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-10-17T19:40:17Z","reference_number":"EMA/246277/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprostadil-patency-ductus-arteriosus-list-nationally-authorised-medicinal-products-psusa00010021201507_en.pdf"},
    {"id":"30813","name":"Lubiprostone : List of nationally authorised medicinal products -  PSUSA/00010290/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T12:12:00Z","last_updated_date":"2017-09-06T12:13:41Z","reference_number":"EMA/583969/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/lubiprostone-list-nationally-authorised-medicinal-products-psusa00010290201701_en.pdf"},
    {"id":"30873","name":"Haemophilus type b and meningococcal group c conjugate vaccine : List of nationally authorised medicinal products - PSUSA/00001583/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T18:55:00Z","last_updated_date":"2017-10-03T18:57:23Z","reference_number":"EMA/631269/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/haemophilus-type-b-and-meningococcal-group-c-conjugate-vaccine-list-nationally-authorised-medicinal-products-psusa00001583201702_en.pdf"},
    {"id":"31015","name":"Carmustine (powder and solvent for solution for infusion): List of nationally authorised medicinal products - PSUSA/00010349/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-09T01:00:00Z","last_updated_date":"2016-10-18T15:41:08Z","reference_number":"EMA/97527/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/carmustine-powder-and-solvent-solution-infusion-list-nationally-authorised-medicinal-products-psusa00010349201504_en.pdf"},
    {"id":"31136","name":"Amoxicillin / clavulanate: List of nationally authorised medicinal products - PSUSA/00000188/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-06T17:20:00Z","last_updated_date":"2017-11-06T17:23:24Z","reference_number":"EMA/726764/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/amoxicillin-clavulanate-list-nationally-authorised-medicinal-products-psusa00000188201703_en.pdf"},
    {"id":"31143","name":"Fluorescein (systemic use): List of nationally authorised medicinal products - PSUSA/00009153/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-12T17:00:00Z","last_updated_date":"2018-01-12T17:00:00Z","reference_number":"EMA/24042/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluorescein-systemic-use-list-nationally-authorised-medicinal-products-psusa00009153201704_en.pdf"},
    {"id":"31173","name":"Adapalene / benzoyl peroxide: List of nationally authorised medicinal products - PSUSA/00000059/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-12T12:57:00Z","last_updated_date":"2018-07-12T13:02:05Z","reference_number":"EMA/474010/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/adapalene-benzoyl-peroxide-list-nationally-authorised-medicinal-products-psusa00000059201709_en.pdf"},
    {"id":"31199","name":"Lubiprostone: List of nationally authorised medicinal products - PSUSA/000010290/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T02:00:00Z","last_updated_date":"2016-10-18T10:40:12Z","reference_number":"EMA/268894/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/lubiprostone-list-nationally-authorised-medicinal-products-psusa000010290201507_en.pdf"},
    {"id":"31232","name":"Clarithromycin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000788/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T15:25:00Z","last_updated_date":"2018-05-07T19:29:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788201704_no.pdf"}},
    {"id":"31240","name":"Ivermectin (topical use): CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for\n\nthe implementation - PSUSA/00010376/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-10T02:00:00Z","last_updated_date":"2016-10-17T19:03:14Z","reference_number":"EMA/540331/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201510_en.pdf"},
    {"id":"31300","name":"Niflumic: List of nationally authorised medicinal products - PSUSA/00002157/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-05T02:00:00Z","last_updated_date":"2016-10-18T12:37:32Z","reference_number":"EMA/546117/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/niflumic-list-nationally-authorised-medicinal-products-psusa00002157201512_en.pdf"},
    {"id":"31396","name":"Tiapride: List of nationally authorised medicinal products - PSUSA/00002944/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T12:00:00Z","last_updated_date":"2016-10-18T19:47:13Z","reference_number":"EMA/268897/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiapride-list-nationally-authorised-medicinal-products-psusa00002944201507_en.pdf"},
    {"id":"31419","name":"Amlodipine/olmesartan: List of nationally authorised medicinal products - PSUSA/00002208/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T10:00:00Z","last_updated_date":"2018-01-18T10:39:30Z","reference_number":"EMA/34084/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipineolmesartan-list-nationally-authorised-medicinal-products-psusa00002208201704_en.pdf"},
    {"id":"31446","name":"Letrozole : List of nationally authorised medicinal products - PSUSA/00001842/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T12:12:00Z","last_updated_date":"2017-07-25T12:20:46Z","reference_number":"EMA/468948/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/letrozole-list-nationally-authorised-medicinal-products-psusa00001842201610_en.pdf"},
    {"id":"31459","name":"Baclofen: List of nationally authorised medicinal products - PSUSA/00000293/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T19:35:00Z","last_updated_date":"2016-10-19T19:35:00Z","reference_number":"EMA/645247/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/baclofen-list-nationally-authorised-medicinal-products-psusa00000293201601_en.pdf"},
    {"id":"31468","name":"Tenoxicam: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation -PSUSA/00002893/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-21T11:05:00Z","last_updated_date":"2016-10-19T12:14:39Z","reference_number":"EMA/47501/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/tenoxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002893201502_en.pdf"},
    {"id":"31469","name":"Permethrin: List of nationally authorised medicinal products -  PSUSA/00002355/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T17:44:00Z","last_updated_date":"2018-06-07T17:51:10Z","reference_number":"EMA/263468/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/permethrin-list-nationally-authorised-medicinal-products-psusa00002355201707_en.pdf"},
    {"id":"31480","name":"Cilostazol: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00010209/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-07T01:00:00Z","last_updated_date":"2016-10-18T15:41:09Z","reference_number":"EMA/269956/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilostazol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010209201502_en.pdf"},
    {"id":"31504","name":"Lanthanum: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003175/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-19T18:20:00Z","last_updated_date":"2018-01-19T18:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175201703_no.pdf"}},
    {"id":"31529","name":"Delapril / manidipine, delapril / indapamide: List of nationally authorised medicinal products - PSUSA/00010496/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-24T14:22:00Z","last_updated_date":"2018-04-24T14:28:00Z","reference_number":"EMA/257641/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/delapril-manidipine-delapril-indapamide-list-nationally-authorised-medicinal-products-psusa00010496201706_en.pdf"},
    {"id":"31679","name":"Letrozole : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001842/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T12:12:00Z","last_updated_date":"2017-07-25T17:53:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001842201610_no.pdf"}},
    {"id":"31722","name":"Methyl salicylate / levomenthol / DL-camphor: List of nationally authorised medicinal products - PSUSA/00010117/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T10:30:00Z","last_updated_date":"2018-03-06T10:33:00Z","reference_number":"EMA/21211/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/methyl-salicylate-levomenthol-dl-camphor-list-nationally-authorised-medicinal-products-psusa00010117201704_en.pdf"},
    {"id":"31736","name":"Hexaminolevulinate hydrochloride: List of nationally authorised products - PSUSA/00001606/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2016-10-17T17:15:44Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/hexaminolevulinate-hydrochloride-list-nationally-authorised-products-psusa00001606201409_en.pdf"},
    {"id":"31803","name":"Diltiazem: List of nationally authorised medicinal products - PSUSA/00001084/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-17T17:04:00Z","last_updated_date":"2018-01-17T17:09:57Z","reference_number":"EMA/10900/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/diltiazem-list-nationally-authorised-medicinal-products-psusa00001084201705_en.pdf"},
    {"id":"31837","name":"Gadoteric acid (IV and intravascular formulations): CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00001506/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T01:00:00Z","last_updated_date":"2016-10-19T12:37:31Z","reference_number":"EMA/194350/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteric-acid-iv-and-intravascular-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001506201504_en.pdf"},
    {"id":"31838","name":"Zanamivir: List of nationally authorised medicinal products - PSUSA/00003141/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-29T17:55:00Z","last_updated_date":"2017-09-29T17:56:31Z","reference_number":"EMA/639167/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/zanamivir-list-nationally-authorised-medicinal-products-psusa00003141201701_en.pdf"},
    {"id":"31844","name":"Cyproheptadine: List of nationally authorised medicinal products - PSUSA/00000902/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-11T18:00:00Z","last_updated_date":"2018-09-11T18:05:30Z","reference_number":"EMA/613960/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproheptadine-list-nationally-authorised-medicinal-products-psusa00000902201712_en.pdf"},
    {"id":"31871","name":"Cilastatin / Imipenem: List of nationally authorised medicinal products - PSUSA/00000748/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T16:30:00Z","last_updated_date":"2018-02-13T16:30:00Z","reference_number":"EMA/88494/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilastatin-imipenem-list-nationally-authorised-medicinal-products-psusa00000748201706_en.pdf"},
    {"id":"31908","name":"Pimecrolimus: List of nationally authorised medicinal products - PSUSA/00002411/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-09T11:00:00Z","last_updated_date":"2016-10-17T18:31:15Z","reference_number":"EMA/740936/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/pimecrolimus-list-nationally-authorised-medicinal-products-psusa00002411201503_en.pdf"},
    {"id":"31913","name":"Suxamethonium: List of nationally authorised medicinal products - PSUSA/00002834/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T15:47:00Z","last_updated_date":"2018-04-19T15:52:42Z","reference_number":"EMA/211167/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/suxamethonium-list-nationally-authorised-medicinal-products-psusa00002834201708_en.pdf"},
    {"id":"31915","name":"Apomorphine: List of nationally authorised medicinal products - PSUSA/00000227/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-10-17T19:40:20Z","reference_number":"EMA/198769/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/apomorphine-list-nationally-authorised-medicinal-products-psusa00000227201505_en.pdf"},
    {"id":"31919","name":"Bromhexine:  List of nationally authorised medicinal products - PSUSA/00000437/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-12T10:45:00Z","last_updated_date":"2017-06-12T11:03:33Z","reference_number":"EMA/367573/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromhexine-list-nationally-authorised-medicinal-products-psusa00000437201609_en.pdf"},
    {"id":"31936","name":"Ibuprofen / pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00001711/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-04T14:00:00Z","last_updated_date":"2018-04-16T17:15:38Z","reference_number":"EMA/208334/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00001711201707_en.pdf"},
    {"id":"31946","name":"Methylprednisolone: List of nationally authorised medicinal products - PSUSA/00002026/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-12T01:00:00Z","last_updated_date":"2016-10-18T11:46:17Z","reference_number":"EMA/749746/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylprednisolone-list-nationally-authorised-medicinal-products-psusa00002026201411_en.pdf"},
    {"id":"31951","name":"Etoposide: List of nationally authorised medicinal products - PSUSA/00001333/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T17:20:00Z","last_updated_date":"2016-10-19T17:24:31Z","reference_number":"EMA/646358/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/etoposide-list-nationally-authorised-medicinal-products-psusa00001333201602_en.pdf"},
    {"id":"32000","name":"Rabbit anti-human thymocyte (powder for solution for\n\ninfusion): List of nationally authorised medicinal products - PSUSA/00010184/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-04T12:00:00Z","last_updated_date":"2016-10-17T19:31:37Z","reference_number":"EMA/592453/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-human-thymocyte-powder-solution-infusion-list-nationally-authorised-medicinal-products-psusa00010184201412_en.pdf-0"},
    {"id":"32015","name":"Amitriptyline/perphenazine: List of nationally authorised medicinal products - PSUSA/00000170/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T13:00:00Z","last_updated_date":"2018-09-13T13:02:46Z","reference_number":"EMA/615026/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptylineperphenazine-list-nationally-authorised-medicinal-products-psusa00000170201801_en.pdf"},
    {"id":"32041","name":"Bilastine: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00003163/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T13:10:00Z","last_updated_date":"2018-04-03T18:58:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_fi.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bilastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003163201703_no.pdf"}},
    {"id":"32052","name":"Lamotrigine : List of nationally authorised medicinal products - PSUSA/00001825/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T18:00:00Z","last_updated_date":"2018-09-10T18:12:00Z","reference_number":"EMA/600046/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/lamotrigine-list-nationally-authorised-medicinal-products-psusa00001825201711_en.pdf"},
    {"id":"32065","name":"Azelastine: List of nationally authorised medicinal products -PSUSA/00000277/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2016-10-18T14:01:12Z","reference_number":"EMA/622830/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/azelastine-list-nationally-authorised-medicinal-products-psusa00000277201412_en.pdf"},
    {"id":"32070","name":"Haemophilus type b conjugate vaccines :  List of nationally authorised medicinal products - PSUSA/00001584/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T17:24:00Z","last_updated_date":"2017-11-23T17:36:22Z","reference_number":"EMA/691535/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/haemophilus-type-b-conjugate-vaccines-list-nationally-authorised-medicinal-products-psusa00001584201702_en.pdf"},
    {"id":"32077","name":"Ondansetron: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation -  PSUSA/00002217/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-18T13:02:18Z","reference_number":"EMA/829758/215","document_url":"https://www.ema.europa.eu/en/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217201502_en.pdf"},
    {"id":"32104","name":"Adapalene / benzoyl peroxide: List of nationally authorised medicinal products - PSUSA/00000059/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2016-10-17T17:40:44Z","reference_number":"EMA/382963/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/adapalene-benzoyl-peroxide-list-nationally-authorised-medicinal-products-psusa00000059201409_en.pdf"},
    {"id":"32117","name":"Tenoxicam: List of nationally authorised medicinal products -PSUSA/00002893/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-21T11:05:00Z","last_updated_date":"2016-10-19T12:14:38Z","reference_number":"EMA/47508/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/tenoxicam-list-nationally-authorised-medicinal-products-psusa00002893201502_en.pdf"},
    {"id":"32137","name":"Methyl salicylate / levomenthol: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010241/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T11:10:00Z","last_updated_date":"2018-03-07T11:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methyl-salicylate-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010241201704_sv.pdf"}},
    {"id":"32149","name":"Lubiprostone: List of nationally authorised medicinal products - PSUSA/00010290/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-13T17:37:00Z","last_updated_date":"2017-03-13T17:39:51Z","reference_number":"EMA/171110/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/lubiprostone-list-nationally-authorised-medicinal-products-psusa00010290201607_en.pdf"},
    {"id":"32199","name":"Testosterone (all formulations apart from topical use and testosterone undecanoate injection): List of nationally authorised medicinal products - PSUSA/00002907/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-07T16:30:00Z","last_updated_date":"2016-11-21T10:52:09Z","reference_number":"EMA/730861/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-all-formulations-apart-topical-use-and-testosterone-undecanoate-injection-list-nationally-authorised-medicinal-products-psusa00002907201512_en.pdf"},
    {"id":"32209","name":"Quetiapine: List of nationally authorised medicinal products -      PSUSA/00002589/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-04T13:25:00Z","last_updated_date":"2018-06-15T16:40:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/quetiapine-list-nationally-authorised-medicinal-products-psusa00002589201707_en.pdf"},
    {"id":"32233","name":"Fluoxetine: List of nationally authorised medicinal products - PSUSA/00001442/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T20:00:00Z","last_updated_date":"2018-05-23T20:22:18Z","reference_number":"EMA/326378/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluoxetine-list-nationally-authorised-medicinal-products-psusa00001442201709_en.pdf"},
    {"id":"32309","name":"Methylaminolevulinate: List of nationally authorised medicinal products - PSUSA/00002019/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-14T14:30:00Z","last_updated_date":"2018-05-14T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylaminolevulinate-list-nationally-authorised-medicinal-products-psusa00002019201706_en.pdf"},
    {"id":"32315","name":"Iron / parenteral preparations : List of nationally authorised medicinal products - PSUSA/00010236/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-11T19:17:00Z","last_updated_date":"2017-09-11T19:18:00Z","reference_number":"EMA/604559/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-parenteral-preparations-list-nationally-authorised-medicinal-products-psusa00010236201701_en.pdf"},
    {"id":"32326","name":"Carboplatin: List of nationally authorised medicinal products - PSUSA/00000559/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T16:21:00Z","last_updated_date":"2016-11-18T16:30:41Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/carboplatin-list-nationally-authorised-medicinal-products-psusa00000559201601_en.pdf"}    {"id":"32333","name":"Domperidone: List of nationally authorised medicinal products - PSUSA/00001158/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-05T14:00:00Z","last_updated_date":"2017-09-05T14:00:00Z","reference_number":"EMA/581726/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/domperidone-list-nationally-authorised-medicinal-products-psusa00001158201611_en.pdf"},
    {"id":"32351","name":"Mannitol (all indications apart from cystic fibrosis): List of nationally authorised medicinal products - PSUSA/00010005/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T17:00:00Z","last_updated_date":"2017-10-27T17:00:00Z","reference_number":"EMA/716838/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/mannitol-all-indications-apart-cystic-fibrosis-list-nationally-authorised-medicinal-products-psusa00010005201702_en.pdf"},
    {"id":"32401","name":"Alendronate: List of nationally authorised medicinal products - PSUSA/00000078/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-13T02:00:00Z","last_updated_date":"2016-10-17T17:40:41Z","reference_number":"EMA/608858/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/alendronate-list-nationally-authorised-medicinal-products-psusa00000078201601_en.pdf"},
    {"id":"32513","name":"Tuberculin purified protein derivative: List of nationally authorised medicinal products - PSUSA/00003063/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T02:00:00Z","last_updated_date":"2017-05-12T13:48:02Z","reference_number":"EMA/294786/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tuberculin-purified-protein-derivative-list-nationally-authorised-medicinal-products-psusa00003063201609_en.pdf"},
    {"id":"32519","name":"Azithromycin (systemic use formulations): List of nationally authorised medicinal products - PSUSA/00010491/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-27T19:30:00Z","last_updated_date":"2018-02-27T19:32:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/azithromycin-systemic-use-formulations-list-nationally-authorised-medicinal-products-psusa00010491201704_en.pdf"},
    {"id":"32548","name":"Donepezil : List of nationally authorised medicinal products - PSUSA/00001160/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T18:30:00Z","last_updated_date":"2017-09-06T18:32:10Z","reference_number":"EMA/590620/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/donepezil-list-nationally-authorised-medicinal-products-psusa00001160201611_en.pdf"},
    {"id":"32581","name":"Technetium (99mtc)mebrofenin: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/0002861/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T12:00:00Z","last_updated_date":"2016-10-19T12:14:39Z","reference_number":"EMA/590045/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/technetium-99mtcmebrofenin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0002861201511_en.pdf"},
    {"id":"32701","name":"Glycopyrronium bromide (all indications except for chronic obstructive pulmonary disease): CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implement...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-07T02:00:00Z","last_updated_date":"2016-10-17T15:48:25Z","reference_number":"EMA/473578/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/glycopyrronium-bromide-all-indications-except-chronic-obstructive-pulmonary-disease-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implement_en.pdf"},
    {"id":"32726","name":"Calcitriol: List of nationally authorised medicinal products - PSUSA/00000495/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-13T02:00:00Z","last_updated_date":"2016-10-18T14:01:10Z","reference_number":"EMA/677233/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcitriol-list-nationally-authorised-medicinal-products-psusa00000495201501_en.pdf"},
    {"id":"32732","name":"Bilastine: List of nationally authorised medicinal products - PSUSA/00003163/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-22T10:45:00Z","last_updated_date":"2016-11-22T10:45:00Z","reference_number":"EMA/761543/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/bilastine-list-nationally-authorised-medicinal-products-psusa00003163201603_en.pdf"},
    {"id":"32751","name":"Azithromycin (ocular use formulations): List of nationally authorised medicinal products - PSUSA/00010492/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-17T14:55:00Z","last_updated_date":"2018-01-17T15:10:00Z","reference_number":"EMA/28946/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/azithromycin-ocular-use-formulations-list-nationally-authorised-medicinal-products-psusa00010492201704_en.pdf"},
    {"id":"32781","name":"Piracetam: List of nationally authorised medicinal products - PSUSA/00002429/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T16:15:00Z","last_updated_date":"2018-01-15T16:17:22Z","reference_number":"EMA/24886/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/piracetam-list-nationally-authorised-medicinal-products-psusa00002429201704_en.pdf"},
    {"id":"32789","name":"Caffeine / ergotamine: List of nationally authorised medicinal products - PSUSA/00000485/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-10-18T14:01:09Z","reference_number":"EMA/600529/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/caffeine-ergotamine-list-nationally-authorised-medicinal-products-psusa00000485201511_en.pdf"},
    {"id":"32934","name":"Phenylephrine: List of nationally authorised medicinal products - PSUSA/00002378/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-03T01:00:00Z","last_updated_date":"2016-10-17T18:19:00Z","reference_number":"EMA/726964/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylephrine-list-nationally-authorised-medicinal-products-psusa00002378201501_en.pdf"},
    {"id":"33046","name":"Oxaliplatin: List of nationally authorised medicinal products -  PSUSA/00002229/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T01:00:00Z","last_updated_date":"2016-10-18T13:02:21Z","reference_number":"EMA/190970/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxaliplatin-list-nationally-authorised-medicinal-products-psusa00002229201504_en.pdf"},
    {"id":"33052","name":"Vancomycin: List of nationally authorised medicinal products - PSUSA/00003097/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-20T14:00:00Z","last_updated_date":"2016-10-17T20:16:33Z","reference_number":"EMA/692387/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/vancomycin-list-nationally-authorised-medicinal-products-psusa00003097201501_en.pdf"},
    {"id":"33062","name":"Irinotecan (except for liposomal formulations): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001783/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T13:10:00Z","last_updated_date":"2018-03-06T13:39:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783201705_no.pdf"}},
    {"id":"33064","name":"Triamcinolone (intraocular formulations): List of nationally authorised medicinal products - PSUSA/00010292/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-13T13:00:00Z","last_updated_date":"2016-10-17T20:16:35Z","reference_number":"EMA/754832/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/triamcinolone-intraocular-formulations-list-nationally-authorised-medicinal-products-psusa00010292201503_en.pdf"},
    {"id":"33129","name":"Tianeptine: List of nationally authorised medicinal products - PSUSA/00002943/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-08T11:47:00Z","last_updated_date":"2016-10-19T12:50:10Z","reference_number":"EMA/179740/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/tianeptine-list-nationally-authorised-medicinal-products-psusa00002943201506_en.pdf"},
    {"id":"33142","name":"Tibolone: List of nationally authorised medicinal products - PSUSA/00002947/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-04T18:30:00Z","last_updated_date":"2017-09-04T18:30:00Z","reference_number":"EMA/578102/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tibolone-list-nationally-authorised-medicinal-products-psusa00002947201612_en.pdf"},
    {"id":"33209","name":"Carbomers : List of nationally authorised medicinal products - PSUSA/00000557/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-29T19:20:00Z","last_updated_date":"2017-09-29T19:21:44Z","reference_number":"EMA/642432/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbomers-list-nationally-authorised-medicinal-products-psusa00000557201701_en.pdf"},
    {"id":"33233","name":"Misoprostol (gynaecological indication - labour induction): List of nationally authorised medicinal products - PSUSA/00010353/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-14T10:36:00Z","last_updated_date":"2017-03-14T10:47:00Z","reference_number":"EMA/173834/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labour-induction-list-nationally-authorised-medicinal-products-psusa00010353201605_en.pdf"},
    {"id":"33288","name":"Cyproterone/ethinylestradiol: PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-23T19:31:00Z","last_updated_date":"2017-02-23T19:31:00Z","reference_number":"EMA/101714/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproteroneethinylestradiol-prac-non-interventional-imposed-pass-final-study-report-assessment-report-emeahnpsrj0003_en.pdf"},
    {"id":"33297","name":"5 Fluorouracil (topical application): List of nationally authorised medicinal products - PSUSA/00010000/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-13T01:00:00Z","last_updated_date":"2016-10-17T16:39:22Z","reference_number":"EMA/757684/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-topical-application-list-nationally-authorised-medicinal-products-psusa00010000201412_en.pdf"},
    {"id":"33359","name":"Quinapril: List of nationally authorised medicinal products - PSUSA/00002591/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-12T10:05:00Z","last_updated_date":"2016-12-12T10:09:00Z","reference_number":"EMA/848711/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/quinapril-list-nationally-authorised-medicinal-products-psusa00002591201604_en.pdf"},
    {"id":"33402","name":"Valproic acid / sodium valproate / valproate pivoxil / valproate semisodium / valpromide/valproate bismuth / calcium valproate / valproate magnesium: CMDh Scientific conclusions and grounds for variation, amendments to t...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-03T13:00:00Z","last_updated_date":"2016-10-17T20:16:36Z","reference_number":"EMA/727148/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromidevalproate-bismuth-calcium-valproate-valproate-magnesium-cmdh-scientific-conclusions-and-grounds-variation-amendments-t_en.pdf"},
    {"id":"33432","name":"Nifedipine: List of nationally authorised medicinal products - PSUSA/00002156/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-07T02:00:00Z","last_updated_date":"2016-10-18T12:37:33Z","reference_number":"EMA/394142/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/nifedipine-list-nationally-authorised-medicinal-products-psusa00002156201508_en.pdf"},
    {"id":"33462","name":"Atorvastatin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010347/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-13T17:38:00Z","last_updated_date":"2018-08-24T14:10:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/atorvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010347201710_no.pdf"}},
    {"id":"33530","name":"Trimetazidine: List of nationally authorised medicinal products - PSUSA/00003043/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-16T12:46:00Z","last_updated_date":"2018-03-16T12:49:49Z","reference_number":"EMA/170172/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-list-nationally-authorised-medicinal-products-psusa00003043201708_en.pdf"},
    {"id":"33536","name":"Clindamycin: List of nationally authorised medicinal products - PSUSA/00000795/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T14:00:00Z","last_updated_date":"2016-10-17T20:16:38Z","reference_number":"EMA/423705/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/clindamycin-list-nationally-authorised-medicinal-products-psusa00000795201510_en.pdf"},
    {"id":"33543","name":"Meningococcal group c polysaccharide conjugate vaccine: List of nationally authorised medicinal products - PSUSA/00001971/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-10-18T11:29:34Z","reference_number":"EMA/423930/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/meningococcal-group-c-polysaccharide-conjugate-vaccine-list-nationally-authorised-medicinal-products-psusa00001971201510_en.pdf"},
    {"id":"33571","name":"Trimetazidine: List of nationally authorised medicinal products - PSUSA/00003043/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-05T14:00:00Z","last_updated_date":"2017-05-05T14:23:09Z","reference_number":"EMA/283391/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-list-nationally-authorised-medicinal-products-psusa00003043201608_en.pdf"},
    {"id":"33575","name":"Valsartan, hydrochlorothiazide / valsartan: List of nationally authorised medicinal products - PSUSA/00010396/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T13:04:00Z","last_updated_date":"2018-01-18T13:06:00Z","reference_number":"EMA/34118/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/valsartan-hydrochlorothiazide-valsartan-list-nationally-authorised-medicinal-products-psusa00010396201704_en.pdf"},
    {"id":"33595","name":"Dihydroergocristine: List of nationally authorised medicinal products - PSUSA/00001071/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-22T13:00:00Z","last_updated_date":"2016-10-17T19:52:25Z","reference_number":"EMA/865167/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/dihydroergocristine-list-nationally-authorised-medicinal-products-psusa00001071201504_en.pdf"},
    {"id":"33643","name":"Tamoxifen: List of nationally authorised medicinal products- PSUSA/00002846/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-09T01:00:00Z","last_updated_date":"2016-10-18T13:51:39Z","reference_number":"EMA/99602/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/tamoxifen-list-nationally-authorised-medicinal-products-psusa00002846201504_en.pdf"},
    {"id":"33665","name":"Dobutamine: List of nationally authorised medicinal products - PSUSA/00001151/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-09T13:00:00Z","last_updated_date":"2016-10-17T19:52:22Z","reference_number":"EMA/739656/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/dobutamine-list-nationally-authorised-medicinal-products-psusa00001151201503_en.pdf"},
    {"id":"33679","name":"Ezetimibe / rosuvastatin: List of nationally authorised medicinal products - PSUSA/00010271/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T11:30:00Z","last_updated_date":"2018-05-02T13:38:00Z","reference_number":"EMA/267099/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ezetimibe-rosuvastatin-list-nationally-authorised-medicinal-products-psusa00010271201707_en.pdf"},
    {"id":"33696","name":"Sulfamethizole: List of nationally authorised medicinal products - PSUSA/00010561/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T16:40:00Z","last_updated_date":"2018-02-09T16:40:00Z","reference_number":"EMA/86929/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulfamethizole-list-nationally-authorised-medicinal-products-psusa00010561201706_en.pdf"},
    {"id":"33714","name":"Human plasma protease C1 inhibitor (nationally authorised products): List of nationally authorised medicinal products - PSUSA/00010163/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-04-10T19:15:00Z","last_updated_date":"2017-04-10T19:15:00Z","reference_number":"EMA/236288/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-plasma-protease-c1-inhibitor-nationally-authorised-products-list-nationally-authorised-medicinal-products-psusa00010163201608_en.pdf"},
    {"id":"33795","name":"Gasiloxe: List of nationally authorised medicinal products - PSUSA/00010283/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-13T02:00:00Z","last_updated_date":"2016-10-18T16:56:41Z","reference_number":"EMA/677351/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/gasiloxe-list-nationally-authorised-medicinal-products-psusa00010283201501_en.pdf"},
    {"id":"33820","name":"Influenza vaccine (split virion, inactivated) (non centrally authorised products): List of nationally authorised medicinal products - PSUSA/00010298/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-21T02:00:00Z","last_updated_date":"2016-10-17T17:46:45Z","reference_number":"EMA/284169/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00010298201508_en.pdf"},
    {"id":"33826","name":"Pimecrolimus: List of nationally authorised medicinal products - PSUSA/00002411/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T15:00:00Z","last_updated_date":"2016-10-28T15:00:00Z","reference_number":"EMA/676059/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/pimecrolimus-list-nationally-authorised-medicinal-products-psusa00002411201603_en.pdf"},
    {"id":"33876","name":"Dexlansoprazole, lansoprazole: List of nationally authorised medicinal products - PSUSA/00001827/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-06T17:30:00Z","last_updated_date":"2017-11-06T17:53:44Z","reference_number":"EMA/727763/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexlansoprazole-lansoprazole-list-nationally-authorised-medicinal-products-psusa00001827201612_en.pdf"},
    {"id":"33879","name":"Reviparin: List of nationally authorised medicinal products - PSUSA/00002634/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T12:00:00Z","last_updated_date":"2016-10-17T19:46:18Z","reference_number":"EMA/622828/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/reviparin-list-nationally-authorised-medicinal-products-psusa00002634201501_en.pdf"},
    {"id":"34113","name":"Dorzolamide / timolol: List of nationally authorised medicinal products - PSUSA/00001166/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-14T15:31:00Z","last_updated_date":"2016-11-15T11:56:56Z","reference_number":"EMA/739666/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-timolol-list-nationally-authorised-medicinal-products-psusa00001166201602_en.pdf"},
    {"id":"34125","name":"Milnacipran: CMDh scientific conclusions and grounds for the variation,\n\namendments to the product information, and timetable\n\nfor the implementation - PSUSA/00002063/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T01:00:00Z","last_updated_date":"2016-10-18T12:21:25Z","reference_number":"EMA/172346/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/milnacipran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002063201504_en.pdf"},
    {"id":"34168","name":"Minoxidil (non topical formulation): List of nationally authorised medicinal products - PSUSA/0002066/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-12T02:00:00Z","last_updated_date":"2016-10-18T12:21:23Z","reference_number":"EMA/483360/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/minoxidil-non-topical-formulation-list-nationally-authorised-medicinal-products-psusa0002066201510_en.pdf"},
    {"id":"34171","name":"Apomorphine: List of nationally authorised medicinal products - PSUSA/00000227/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-12T17:29:00Z","last_updated_date":"2017-07-12T17:31:36Z","reference_number":"EMA/442514/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/apomorphine-list-nationally-authorised-medicinal-products-psusa00000227201611_en.pdf"},
    {"id":"34224","name":"Oxytocin: List of nationally authorised medicinal products - PSUSA/00002263/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T13:55:00Z","last_updated_date":"2018-04-27T14:18:16Z","reference_number":"EMA/266096/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxytocin-list-nationally-authorised-medicinal-products-psusa00002263201706_en.pdf"},
    {"id":"34279","name":"Quinagolide: List of nationally authorised medicinal products - PSUSA/00002590/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T11:28:00Z","last_updated_date":"2018-04-19T11:32:45Z","reference_number":"EMA/243043/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/quinagolide-list-nationally-authorised-medicinal-products-psusa00002590201707_en.pdf"},
    {"id":"34343","name":"Magnesium sulphate, sodium sulphate, potassium sulphate: List of nationally authorised medicinal products - PSUSA/00010239/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-24T01:00:00Z","last_updated_date":"2016-10-18T10:40:00Z","reference_number":"EMA/589063/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulphate-sodium-sulphate-potassium-sulphate-list-nationally-authorised-medicinal-products-psusa00010239201502_en.pdf"},
    {"id":"34382","name":"Fexofenadine: List of nationally authorised medicinal products - PSUSA/00001388/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-30T09:50:00Z","last_updated_date":"2017-10-30T09:55:14Z","reference_number":"EMA/690954/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fexofenadine-list-nationally-authorised-medicinal-products-psusa00001388201703_en.pdf"},
    {"id":"34446","name":"Glatiramer: List of nationally authorised medicinal products - PSUSA/00001529/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-14T13:22:00Z","last_updated_date":"2018-08-14T13:23:46Z","reference_number":"EMA/537197/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/glatiramer-list-nationally-authorised-medicinal-products-psusa00001529201711_en.pdf"},
    {"id":"34540","name":"Botulinum neurotoxin type a (150 kd) free from complexing proteins: List of nationally authorised medicinal products - PSUSA/00009084/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T19:35:00Z","last_updated_date":"2016-10-19T19:35:00Z","reference_number":"EMA/692779/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-list-nationally-authorised-medicinal-products-psusa00009084201512_en.pdf"},
    {"id":"34541","name":"Isotretinoin (oral formulations): List of nationally authorised medicinal products - PSUSA/00010488/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-08-31T18:30:00Z","last_updated_date":"2017-08-31T18:31:00Z","reference_number":"EMA/574447/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa00010488201611_en.pdf"},
    {"id":"34570","name":"Amitriptyline hydrochloride / chlordiazepoxide: List of nationally authorised medicinal products - PSUSA/00000171/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-29T17:55:00Z","last_updated_date":"2017-09-29T17:56:00Z","reference_number":"EMA/639158/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-hydrochloride-chlordiazepoxide-list-nationally-authorised-medicinal-products-psusa00000171201702_en.pdf"},
    {"id":"34583","name":"Rabeprazole: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002601/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-27T16:15:00Z","last_updated_date":"2017-07-27T16:16:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/rabeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002601201610_no.pdf"}},
    {"id":"34659","name":"Beclometasone / salbutamol : List of nationally authorised medicinal products - PSUSA/00000309/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T11:31:00Z","last_updated_date":"2017-09-08T11:34:26Z","reference_number":"EMA/596710/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/beclometasone-salbutamol-list-nationally-authorised-medicinal-products-psusa00000309201701_en.pdf"},
    {"id":"34662","name":"Ivermectin (topical use): List of nationally authorised medicinal products - PSUSA/00010376/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-10T02:00:00Z","last_updated_date":"2016-10-17T19:03:13Z","reference_number":"EMA/540382/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-topical-use-list-nationally-authorised-medicinal-products-psusa00010376201510_en.pdf"},
    {"id":"34733","name":"Betaxolol: List of nationally authorised medicinal products - PSUSA/00000401/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-19T13:00:00Z","last_updated_date":"2018-01-19T13:00:00Z","reference_number":"EMA/21070/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/betaxolol-list-nationally-authorised-medicinal-products-psusa00000401201705_en.pdf"},
    {"id":"34738","name":"Clonazepam: List of nationally authorised medicinal products - PSUSA/00000812/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-22T13:00:00Z","last_updated_date":"2016-10-17T20:16:36Z","reference_number":"EMA/146245/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/clonazepam-list-nationally-authorised-medicinal-products-psusa00000812201506_en.pdf"},
    {"id":"34787","name":"Fluvastatin: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA-00001457-201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-04T12:30:00Z","last_updated_date":"2018-07-04T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fluvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001457-201708_no.pdf"}},
    {"id":"34817","name":"Almagate: List of nationally authorised medicinal products - PSUSA/00000097/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-10-17T19:40:08Z","reference_number":"EMA/316701/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/almagate-list-nationally-authorised-medicinal-products-psusa00000097201505_en.pdf"},
    {"id":"34846","name":"Cefprozil: List of nationally authorised medicinal products - PSUSA/00000605/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T13:00:00Z","last_updated_date":"2018-09-13T13:02:00Z","reference_number":"EMA/613929/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefprozil-list-nationally-authorised-medicinal-products-psusa00000605201712_en.pdf"},
    {"id":"34872","name":"Doxazosin: List of nationally authorised medicinal products - PSUSA/00001169/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T17:00:00Z","last_updated_date":"2016-10-19T17:00:00Z","reference_number":"EMA/690449/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/doxazosin-list-nationally-authorised-medicinal-products-psusa00001169201512_en.pdf"},
    {"id":"34881","name":"Roxithromycin : List of nationally authorised medicinal products - PSUSA/00002669/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-19T13:45:00Z","last_updated_date":"2017-10-19T13:54:30Z","reference_number":"EMA/695016/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/roxithromycin-list-nationally-authorised-medicinal-products-psusa00002669201612_en.pdf"},
    {"id":"34884","name":"Spironolactone: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00002780/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-08T11:00:00Z","last_updated_date":"2016-10-18T11:56:09Z","reference_number":"EMA/14001/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780201503_en.pdf"},
    {"id":"34937","name":"Human von willebrand factor: List of nationally authorised medicinal products - PSUSA/00001642/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T15:00:00Z","last_updated_date":"2018-05-23T15:05:14Z","reference_number":"EMA/307511/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-von-willebrand-factor-list-nationally-authorised-medicinal-products-psusa00001642201709_en.pdf"},
    {"id":"34961","name":"Levocetirizine: List of nationally authorised medicinal products - PSUSA/00001850/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T13:55:00Z","last_updated_date":"2018-04-27T13:55:00Z","reference_number":"EMA/266150/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/levocetirizine-list-nationally-authorised-medicinal-products-psusa00001850201707_en.pdf"},
    {"id":"35212","name":"Epirubicin: List of nationally authorised medicinal products - PSUSA/00001234/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-27T11:50:00Z","last_updated_date":"2018-03-27T11:52:12Z","reference_number":"EMA/191568/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/epirubicin-list-nationally-authorised-medicinal-products-psusa00001234201706_en.pdf"},
    {"id":"35232","name":"Diclofenac (systemic formulations): List of nationally authorised medicinal products - PSUSA/00001048/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T14:00:00Z","last_updated_date":"2016-10-17T20:37:51Z","reference_number":"EMA/475009/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-systemic-formulations-list-nationally-authorised-medicinal-products-psusa00001048201509_en.pdf"},
    {"id":"35365","name":"Moclobemide : List of nationally authorised medicinal products - PSUSA/00002079/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-07T14:30:00Z","last_updated_date":"2017-12-07T14:38:02Z","reference_number":"EMA/812281/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/moclobemide-list-nationally-authorised-medicinal-products-psusa00002079201704_en.pdf"},
    {"id":"35391","name":"Lisuride: List of nationally authorised medicinal products - PSUSA/00001896/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-08T02:00:00Z","last_updated_date":"2016-10-18T10:40:09Z","reference_number":"EMA/666467/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisuride-list-nationally-authorised-medicinal-products-psusa00001896201411_en.pdf"},
    {"id":"35419","name":"Apomorphine: CMDh scientific conclusions and grounds for the variation,\n\namendments to the product information, and timetable\n\nfor the implementation - PSUSA/00000227/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-30T02:00:00Z","last_updated_date":"2016-10-17T19:40:21Z","reference_number":"EMA/578662/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000227201511_en.pdf"},
    {"id":"35470","name":"Fenoterol (respiratory indications): List of nationally authorised medicinal products - PSUSA/00001366/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T17:17:00Z","last_updated_date":"2018-05-23T17:22:00Z","reference_number":"EMA/326275/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenoterol-respiratory-indications-list-nationally-authorised-medicinal-products-psusa00001366201709_en.pdf"},
    {"id":"35518","name":"Tobramycin (ophthalmic and otic use): List of nationally authorised medicinal products - PSUSA/00009317/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-12T10:20:00Z","last_updated_date":"2016-12-12T10:22:00Z","reference_number":"EMA/848854/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/tobramycin-ophthalmic-and-otic-use-list-nationally-authorised-medicinal-products-psusa00009317201603_en.pdf"},
    {"id":"35528","name":"Misoprostol (gynaecological indication - labour induction): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010353/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-14T10:36:00Z","last_updated_date":"2017-03-14T10:47:00Z","reference_number":"EMA/173834/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/misoprostol-gynaecological-indication-labour-induction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201605_no.pdf"}},
    {"id":"35554","name":"Gadopentetic acid: List of nationally authorised medicinal products - PSUSA/00001504/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T01:00:00Z","last_updated_date":"2016-10-19T12:37:31Z","reference_number":"EMA/172347/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadopentetic-acid-list-nationally-authorised-medicinal-products-psusa00001504201504_en.pdf"},
    {"id":"35567","name":"Cefodizime : List of nationally authorised medicinal products - PSUSA/00000595/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T12:29:00Z","last_updated_date":"2017-12-01T12:32:47Z","reference_number":"EMA/787582/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefodizime-list-nationally-authorised-medicinal-products-psusa00000595201703_en.pdf"},
    {"id":"35573","name":"Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T17:20:00Z","last_updated_date":"2017-09-06T17:20:00Z","reference_number":"EMA/524592/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-list-nationally-authorised-medicinal-products-psusa00010390201701_en.pdf"},
    {"id":"35620","name":"Naproxen: List of nationally authorised medicinal products - PSUSA/00002125/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T13:00:00Z","last_updated_date":"2018-06-07T15:52:37Z","reference_number":"EMA/382206/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/naproxen-list-nationally-authorised-medicinal-products-psusa00002125201708_en.pdf"},
    {"id":"35625","name":"Gadoxetic acid disodium: List of nationally authorised medicinal products - PSUSA/00001509/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-10-18T16:56:39Z","reference_number":"EMA/200877/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoxetic-acid-disodium-list-nationally-authorised-medicinal-products-psusa00001509201504_en.pdf"},
    {"id":"35636","name":"indobufen: List of nationally authorised medicinal products - PSUSA/00001736/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-17T16:15:00Z","last_updated_date":"2018-01-17T16:17:48Z","reference_number":"EMA/32400/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/indobufen-list-nationally-authorised-medicinal-products-psusa00001736201705_en.pdf"},
    {"id":"35654","name":"Treprostinil: List of nationally authorised medicinal products - PSUSA/00003013/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-02T17:00:00Z","last_updated_date":"2018-08-02T17:02:00Z","reference_number":"EMA/527312/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/treprostinil-list-nationally-authorised-medicinal-products-psusa00003013201711_en.pdf"},
    {"id":"35660","name":"Methylprednisolone: List of nationally authorised medicinal products - PSUSA/00002026/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T17:10:00Z","last_updated_date":"2018-07-17T17:19:13Z","reference_number":"EMA/475651/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylprednisolone-list-nationally-authorised-medicinal-products-psusa00002026201711_en.pdf"},
    {"id":"35754","name":"Simvastatin: List of nationally authorised medicinal products - PSUSA/00002709/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T15:34:00Z","last_updated_date":"2018-01-24T15:42:22Z","reference_number":"EMA/46974/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/simvastatin-list-nationally-authorised-medicinal-products-psusa00002709201704_en.pdf"},
    {"id":"35931","name":"Typhoid polysaccharide vaccine: List of nationally authorised medicinal products - PSUSA/00003065/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T15:35:00Z","last_updated_date":"2018-04-19T15:45:29Z","reference_number":"EMA/227734/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/typhoid-polysaccharide-vaccine-list-nationally-authorised-medicinal-products-psusa00003065201708_en.pdf"},
    {"id":"35954","name":"Desfluran: List of nationally authorised medicinal products - PSUSA/0000958/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T14:00:00Z","last_updated_date":"2016-10-17T20:37:52Z","reference_number":"EMA/456329/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/desfluran-list-nationally-authorised-medicinal-products-psusa0000958201409_en.pdf"},
    {"id":"35986","name":"Quinine: List of nationally authorised medicinal products - PSUSA/00002598/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-24T19:20:00Z","last_updated_date":"2017-10-24T19:20:00Z","reference_number":"EMA/710254/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/quinine-list-nationally-authorised-medicinal-products-psusa00002598201611_en.pdf"},
    {"id":"36028","name":"Poliovirus type 1 / poliovirus type 2 / poliovirus type 3 vaccine (oral, live, attenuated): List of nationally authorised medicinal products - PSUSA/00002458/201607","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-14T17:30:00Z","last_updated_date":"2017-03-14T17:38:00Z","reference_number":"EMA/174474/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/poliovirus-type-1-poliovirus-type-2-poliovirus-type-3-vaccine-oral-live-attenuated-list-nationally-authorised-medicinal-products-psusa00002458201607_en.pdf"},
    {"id":"36096","name":"Promestriene (cream and vaginal capsules): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009271/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T15:54:00Z","last_updated_date":"2017-12-20T16:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009271201703_no.pdf"}},
    {"id":"36142","name":"Estradiol (17-beta) / trimegestone: List of nationally authorised medicinal products - PSUSA/00001275/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-07T18:20:00Z","last_updated_date":"2017-12-07T18:20:00Z","reference_number":"EMA/811732/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/estradiol-17-beta-trimegestone-list-nationally-authorised-medicinal-products-psusa00001275201703_en.pdf"},
    {"id":"36214","name":"Technetium (99mtc) mebrofenin: CMDh Scientific conclusions and grounds for the variation, amendments to the Product Information and timetable for the implementation - PSUSA/0002861/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T02:00:00Z","last_updated_date":"2016-10-21T16:49:10Z","reference_number":"EMA/590045/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/technetium-99mtc-mebrofenin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0002861201511_en.pdf"},
    {"id":"36220","name":"Etonogestrel: List of nationally authorised medicinal products - PSUSA/00001331/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-20T02:00:00Z","last_updated_date":"2016-10-18T14:02:17Z","reference_number":"EMA/283045/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/etonogestrel-list-nationally-authorised-medicinal-products-psusa00001331201509_en.pdf"},
    {"id":"36238","name":"Fluticasone propionate / formoterol fumarate dihydrate: List of nationally authorised medicinal products - PSUSA/00010339/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-22T17:00:00Z","last_updated_date":"2018-03-22T17:00:00Z","reference_number":"EMA/182904/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluticasone-propionate-formoterol-fumarate-dihydrate-list-nationally-authorised-medicinal-products-psusa00010339201707_en.pdf"},
    {"id":"36297","name":"Glycopyrronium / neostigmine: CMDh Scientific conclusions and grounds for the variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001557/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-07T02:00:00Z","last_updated_date":"2016-10-17T15:59:50Z","reference_number":"EMA/471859/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/glycopyrronium-neostigmine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001557201509_en.pdf"},
    {"id":"36353","name":"Ciprofibrate: List of nationally authorised medicinal products - PSUSA/00000771/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T17:10:00Z","last_updated_date":"2017-09-06T17:10:00Z","reference_number":"EMA/583943/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofibrate-list-nationally-authorised-medicinal-products-psusa00000771201612_en.pdf"},
    {"id":"36359","name":"Mometasone: List of nationally authorised medicinal products - PSUSA/00002085/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T16:00:00Z","last_updated_date":"2018-04-11T11:53:20Z","reference_number":"EMA/25716/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/mometasone-list-nationally-authorised-medicinal-products-psusa00002085201705_en.pdf"},
    {"id":"36366","name":"Magnesium sulphate / sodium sulphate / potassium sulphate: List of nationally authorised medicinal products - PSUSA/00010239/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T11:00:00Z","last_updated_date":"2017-03-16T11:00:00Z","reference_number":"EMA/179052/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulphate-sodium-sulphate-potassium-sulphate-list-nationally-authorised-medicinal-products-psusa00010239201608_en.pdf"},
    {"id":"36371","name":"Atenolol / chlortalidone: CMDh scientific conclusions and grounds for variation,\n\namendments to the product information and timetable for\n\nthe implementation - PSUSA/00000260/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T02:00:00Z","last_updated_date":"2016-10-17T19:40:06Z","reference_number":"EMA/272608/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/atenolol-chlortalidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000260201409_en.pdf"}    {"id":"36432","name":"Olodaterol: List of nationally authorised medicinal products - PSUSA/00010245/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-05T12:10:00Z","last_updated_date":"2017-10-05T12:10:00Z","reference_number":"EMA/658449/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodaterol-list-nationally-authorised-medicinal-products-psusa00010245201703_en.pdf"},
    {"id":"36533","name":"Pamidronate: List of nationally authorised medicinal products - PSUSA/00002269/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-10T01:00:00Z","last_updated_date":"2016-10-18T13:02:19Z","reference_number":"EMA/185266/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/pamidronate-list-nationally-authorised-medicinal-products-psusa00002269201505_en.pdf"},
    {"id":"36550","name":"Botulinum toxin a: CMDh scientific conclusions and grounds for the variation, amendments to the product information, conditions to the MA and timetable for the implementation - PSUSA/00000426/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T11:17:00Z","last_updated_date":"2016-10-27T11:22:45Z","reference_number":"EMA/705327/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-conditions-ma-and-timetable-implementation-psusa00000426201512_en.pdf"},
    {"id":"36567","name":"Alfuzosin: List of nationally authorised medicinal products - PSUSA/00000084/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-14T13:15:00Z","last_updated_date":"2018-08-14T13:17:00Z","reference_number":"EMA/537159/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/alfuzosin-list-nationally-authorised-medicinal-products-psusa00000084201711_en.pdf"},
    {"id":"36574","name":"Drospirenone/estradiol: List of nationally authorised medicinal products - PSUSA/00001184/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-08T02:00:00Z","last_updated_date":"2016-10-18T13:42:41Z","reference_number":"EMA/666127/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/drospirenoneestradiol-list-nationally-authorised-medicinal-products-psusa00001184201412_en.pdf"},
    {"id":"36682","name":"Fluticasone propionate: List of nationally authorised medicinal products-  PSUSA/00001454/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T18:04:00Z","last_updated_date":"2018-01-03T18:10:01Z","reference_number":"EMA/846273/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluticasone-propionate-list-nationally-authorised-medicinal-products-psusa00001454201702_en.pdf"},
    {"id":"36806","name":"Testosterone (topical use): List of nationally authorised medicinal products - PSUSA/00002908/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-03T15:36:00Z","last_updated_date":"2016-11-17T15:35:00Z","reference_number":"EMA/724798/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-topical-use-list-nationally-authorised-medicinal-products-psusa00002908201512_en.pdf"},
    {"id":"36858","name":"Hydrochlorothiazide / olmesartan: List of nationally authorised medicinal products - PSUSA/00002209/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-15T13:30:00Z","last_updated_date":"2017-06-15T13:30:00Z","reference_number":"EMA/379727/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-olmesartan-list-nationally-authorised-medicinal-products-psusa00002209201610_en.pdf"},
    {"id":"36867","name":"Metoclopramide: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation -PSUSA/00002036/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-03T02:00:00Z","last_updated_date":"2016-10-18T11:46:14Z","reference_number":"EMA/190948/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002036201510_en.pdf"},
    {"id":"36897","name":"Flubendazole: List of nationally authorised medicinal products         - PSUSA/00001400/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-14T18:34:00Z","last_updated_date":"2017-11-14T18:39:09Z","reference_number":"EMA/641599/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/flubendazole-list-nationally-authorised-medicinal-products-psusa00001400201702_en.pdf"},
    {"id":"36915","name":"Felbamate: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -PSUSA/00010155/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-18T02:00:00Z","last_updated_date":"2017-09-18T16:54:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/felbamate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010155201609_no.pdf"}},
    {"id":"36945","name":"Loratadine : List of nationally authorised medicinal products - PSUSA/00001907/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-05T17:06:00Z","last_updated_date":"2017-10-05T17:08:49Z","reference_number":"EMA/658556/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/loratadine-list-nationally-authorised-medicinal-products-psusa00001907201702_en.pdf"},
    {"id":"36959","name":"Ampicillin / sulbactam: List of nationally authorised medicinal products - PSUSA/00000197/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-30T01:00:00Z","last_updated_date":"2016-10-17T19:40:14Z","reference_number":"EMA/801642/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/ampicillin-sulbactam-list-nationally-authorised-medicinal-products-psusa00000197201502_en.pdf"},
    {"id":"36973","name":"Tiludronic acid: List of nationally authorised medicinal products - PSUSA/00002959/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-13T14:00:00Z","last_updated_date":"2016-10-17T15:59:33Z","reference_number":"EMA/650026/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiludronic-acid-list-nationally-authorised-medicinal-products-psusa00002959201502_en.pdf"},
    {"id":"36998","name":"Gentamicin (systemic use): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009159/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-29T12:35:00Z","last_updated_date":"2018-01-31T12:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009159201703_no.pdf"}},
    {"id":"37024","name":"Latanoprost (products with paediatric indication): List of nationally authorised medicinal products - PSUSA/00001834/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-24T18:00:00Z","last_updated_date":"2018-05-24T18:09:00Z","reference_number":"EMA/333510/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-products-paediatric-indication-list-nationally-authorised-medicinal-products-psusa00001834201710_en.pdf"},
    {"id":"37086","name":"Amlodipine/candesartan: List of nationally authorised medicinal products - PSUSA/00010191/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-18T11:08:00Z","last_updated_date":"2018-01-18T11:10:00Z","reference_number":"EMA/34107/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipinecandesartan-list-nationally-authorised-medicinal-products-psusa00010191201704_en.pdf"},
    {"id":"37102","name":"Paracetamol (IV formulation): List of nationally authorised medicinal products - PSUSA/00002311/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-05T10:20:00Z","last_updated_date":"2017-12-05T10:20:00Z","reference_number":"EMA/799933/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-iv-formulation-list-nationally-authorised-medicinal-products-psusa00002311201705_en.pdf"},
    {"id":"37124","name":"Salmeterol: List of nationally authorised medicinal products - PSUSA/00002681/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-11T12:00:00Z","last_updated_date":"2016-10-18T11:56:07Z","reference_number":"EMA/478258/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/salmeterol-list-nationally-authorised-medicinal-products-psusa00002681201510_en.pdf"},
    {"id":"37144","name":"Urofollitropin : List of nationally authorised medicinal products - PSUSA/00003082/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T15:02:00Z","last_updated_date":"2017-12-01T15:07:02Z","reference_number":"EMA/797651/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/urofollitropin-list-nationally-authorised-medicinal-products-psusa00003082201703_en.pdf"},
    {"id":"37179","name":"Clarithromycin: List of nationally authorised medicinal products - PSUSA/00000788/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T15:25:00Z","last_updated_date":"2018-02-09T15:25:00Z","reference_number":"EMA/83934/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/clarithromycin-list-nationally-authorised-medicinal-products-psusa00000788201704_en.pdf"},
    {"id":"37243","name":"Penciclovir: List of nationally authorised medicinal products - PSUSA/00002333/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-23T19:23:00Z","last_updated_date":"2017-05-23T19:24:30Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/penciclovir-list-nationally-authorised-medicinal-products-psusa00002333201608_en.pdf"},
    {"id":"37259","name":"Human coagulation factor VIII / human von Willebrand factor: List of nationally authorised products - PSUSA/00001621/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-13T02:00:00Z","last_updated_date":"2016-10-17T17:15:45Z","reference_number":"EMA/406234/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-viii-human-von-willebrand-factor-list-nationally-authorised-products-psusa00001621201510_en.pdf"},
    {"id":"37265","name":"Cetirizine / pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00000629/201608","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-30T17:15:00Z","last_updated_date":"2017-06-30T17:15:00Z","reference_number":"EMA/405164/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cetirizine-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00000629201608_en.pdf"},
    {"id":"37386","name":"Ceftriaxone: List of nationally authorised medicinal products - PSUSA/00000613/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-10-18T15:41:14Z","reference_number":"EMA/72827/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftriaxone-list-nationally-authorised-medicinal-products-psusa00000613201505_en.pdf"},
    {"id":"37414","name":"Tapentadol : List of nationally authorised medicinal products - PSUSA/00002849/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-07T12:15:00Z","last_updated_date":"2018-09-07T12:21:55Z","reference_number":"EMA/607287/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/tapentadol-list-nationally-authorised-medicinal-products-psusa00002849201711_en.pdf"},
    {"id":"37419","name":"Sodium iodide (131i): List of nationally authorised medicinal products - PSUSA/00002753/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T12:20:00Z","last_updated_date":"2018-01-04T12:29:26Z","reference_number":"EMA/849048/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-iodide-131i-list-nationally-authorised-medicinal-products-psusa00002753201703_en.pdf"},
    {"id":"37427","name":"Prulifloxacin: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation -PSUSA/00002569/201410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T12:00:00Z","last_updated_date":"2016-10-17T18:59:00Z","reference_number":"EMA/517095/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/prulifloxacin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002569201410_en.pdf"},
    {"id":"37473","name":"Clobetasol: List of nationally authorised medicinal products - PSUSA/00000799/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T14:00:00Z","last_updated_date":"2016-10-17T20:16:32Z","reference_number":"EMA/707111/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/clobetasol-list-nationally-authorised-medicinal-products-psusa00000799201502_en.pdf"},
    {"id":"37544","name":"Argatroban: List of nationally authorised medicinal products - PSUSA/00009057/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-03T01:00:00Z","last_updated_date":"2016-10-17T19:40:11Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/argatroban-list-nationally-authorised-medicinal-products-psusa00009057201501_en.pdf"},
    {"id":"37559","name":"Nitrous oxide, nitrous oxide / oxygen: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010572/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-09T15:56:00Z","last_updated_date":"2018-04-09T16:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010572201706_sv.pdf"}},
    {"id":"37584","name":"Technetium (99mTc) pertechnetate: List of nationally authorised medicinal products - PSUSA/00002866/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-30T09:50:00Z","last_updated_date":"2017-10-30T09:55:13Z","reference_number":"EMA/691325/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/technetium-99mtc-pertechnetate-list-nationally-authorised-medicinal-products-psusa00002866201703_en.pdf"},
    {"id":"37628","name":"Technetium (99mtc)mebrofenin: List of nationally authorised medicinal products - PSUSA/00002861/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-06T12:00:00Z","last_updated_date":"2016-10-19T11:45:27Z","reference_number":"EMA/591257/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/technetium-99mtcmebrofenin-list-nationally-authorised-medicinal-products-psusa00002861201511_en.pdf"},
    {"id":"37663","name":"Budesonide: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000449/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T15:30:00Z","last_updated_date":"2017-03-16T18:03:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/budesonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000449201604_no.pdf"}},
    {"id":"37715","name":"Galantamine: List of nationally authorised medicinal products - PSUSA/00001512/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-08T16:00:00Z","last_updated_date":"2016-11-08T16:00:00Z","reference_number":"EMA/735162/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/galantamine-list-nationally-authorised-medicinal-products-psusa00001512201603_en.pdf"},
    {"id":"37783","name":"Dinoprostone: List of nationally authorised medicinal products - PSUSA/00001104/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-15T13:30:00Z","last_updated_date":"2017-06-15T13:30:00Z","reference_number":"EMA/376407/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/dinoprostone-list-nationally-authorised-medicinal-products-psusa00001104201609_en.pdf"},
    {"id":"37859","name":"Gadodiamide: CMDh scientific conclusions and grounds for the variation,\n\namendments to the product information and timetable for\n\nthe implementation - PSUSA/00001503/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T01:00:00Z","last_updated_date":"2016-10-19T12:37:29Z","reference_number":"EMA/203319/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadodiamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001503201504_en.pdf"},
    {"id":"37873","name":"Cefoperazone / sulbactam: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000598/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T12:19:00Z","last_updated_date":"2016-10-27T18:59:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cefoperazone-sulbactam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000598201601_no.pdf"}},
    {"id":"37905","name":"Captopril / hydrochlorothiazide: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00000536/201604","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T16:15:00Z","last_updated_date":"2017-01-27T16:20:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/captopril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000536201604_no.pdf"}},
    {"id":"37928","name":"Gadobutrol: CMDh scientific conclusions and grounds for the variation,\n\namendments to the product information, and timetable\n\nfor the implementation - PSUSA/00001502/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T01:00:00Z","last_updated_date":"2016-10-19T12:37:29Z","reference_number":"EMA/PRAC/4354/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobutrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001502201504_en.pdf"},
    {"id":"37947","name":"Hydrochlorothiazide / ramipril: List of nationally authorised medicinal products - PSUSA/00001660/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T17:00:00Z","last_updated_date":"2018-09-10T17:00:00Z","reference_number":"EMA/611352/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-ramipril-list-nationally-authorised-medicinal-products-psusa00001660201801_en.pdf"},
    {"id":"38026","name":"Alprostadil (indicated in peripheral arterial occlusive diseases): List of nationally authorised medicinal products - PSUSA/00000111/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-04T13:20:00Z","last_updated_date":"2018-06-04T13:23:00Z","reference_number":"EMA/221842/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-list-nationally-authorised-medicinal-products-psusa00000111201707_en.pdf"},
    {"id":"38078","name":"Rimexolone:  List of nationally authorised medicinal products - PSUSA/00002647/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T18:25:00Z","last_updated_date":"2017-03-16T18:27:05Z","reference_number":"EMA/184638/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/rimexolone-list-nationally-authorised-medicinal-products-psusa00002647201510_en.pdf"},
    {"id":"38092","name":"Sodium oxybate (intravenous use): List of nationally authorised medicinal products - PSUSA/00010613/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T15:30:00Z","last_updated_date":"2018-05-23T15:36:00Z","reference_number":"EMA/312335/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-oxybate-intravenous-use-list-nationally-authorised-medicinal-products-psusa00010613201710_en.pdf"},
    {"id":"38192","name":"Alfentanil: List of nationally authorised medicinal products - PSUSA/00000082/201509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-02T02:00:00Z","last_updated_date":"2016-10-17T19:40:09Z","reference_number":"EMA/387812/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/alfentanil-list-nationally-authorised-medicinal-products-psusa00000082201509_en.pdf"},
    {"id":"38268","name":"Technetium (99mTc) bicisate : List of nationally authorised medicinal products - PSUSA/00002856/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-13T16:21:00Z","last_updated_date":"2017-06-13T16:25:00Z","reference_number":"EMA/375852/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/technetium-99mtc-bicisate-list-nationally-authorised-medicinal-products-psusa00002856201610_en.pdf"},
    {"id":"38284","name":"Artemether / lumefantrin (apart from the dispersible tablet) : List of nationally authorised medicinal products - PSUSA/00000236/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-13T11:25:00Z","last_updated_date":"2017-06-13T11:27:00Z","reference_number":"EMA/372458/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-list-nationally-authorised-medicinal-products-psusa00000236201610_en.pdf"},
    {"id":"38297","name":"Dexamfetamine: List of nationally authorised medicinal products - PSUSA/00000986/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-11T18:30:00Z","last_updated_date":"2018-06-11T18:32:51Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-psusa00000986201709_en.pdf"},
    {"id":"38330","name":"Benazepril: CMDh scientific conclusions and grounds for the variation, amendments to the product information, and timetable for the implementation - PSUSA/00000313/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-31T02:00:00Z","last_updated_date":"2016-10-18T14:01:15Z","reference_number":"EMA/581863/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313201511_en.pdf"},
    {"id":"38387","name":"Thiopental: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00002929/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T16:15:00Z","last_updated_date":"2017-01-27T16:20:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/thiopental-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002929201603_sv.pdf"}},
    {"id":"38521","name":"Pramiracetam: CMDh scientific conclusions and grounds for variation, amendments to the product information, and timetable for the implementation - PSUSA/00002492/201409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-08-07T12:00:00Z","last_updated_date":"2016-10-17T18:48:34Z","reference_number":"EMA/536968/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/pramiracetam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002492201409_en.pdf"},
    {"id":"38551","name":"Bilastine: List of nationally authorised medicinal products - PSUSA/00003163/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T13:10:00Z","last_updated_date":"2017-11-20T13:10:00Z","reference_number":"EMA/764254/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/bilastine-list-nationally-authorised-medicinal-products-psusa00003163201703_en.pdf"},
    {"id":"38561","name":"Magnesium sulphate / sodium sulphate / potassium sulphate: List of nationally authorised medicinal products - PSUSA/00010239/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-10-18T10:40:00Z","reference_number":"EMA/249824/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulphate-sodium-sulphate-potassium-sulphate-list-nationally-authorised-medicinal-products-psusa00010239201508_en.pdf"},
    {"id":"38610","name":"Zafirlukast: List of nationally authorised medicinal products - PSUSA/00003138/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-05T14:00:00Z","last_updated_date":"2016-10-17T20:16:37Z","reference_number":"EMA/546104/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/zafirlukast-list-nationally-authorised-medicinal-products-psusa00003138201512_en.pdf"},
    {"id":"38649","name":"Ketoprofen (all formulations except topical): List of nationally authorised medicinal products - PSUSA/00001809/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T11:57:00Z","last_updated_date":"2018-04-19T11:59:00Z","reference_number":"EMA//210015/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketoprofen-all-formulations-except-topical-list-nationally-authorised-medicinal-products-psusa00001809201707_en.pdf"},
    {"id":"38709","name":"Misoprostol (gynaecological indication - labor induction): List of nationally authorised medicinal products - PSUSA/00010353/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-10-18T12:21:19Z","reference_number":"EMA/40935/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labor-induction-list-nationally-authorised-medicinal-products-psusa00010353201505_en.pdf"},
    {"id":"38727","name":"Ketotifen (oral formulations): List of nationally authorised medicinal products - PSUSA/00001813/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-22T17:00:00Z","last_updated_date":"2018-06-22T17:00:00Z","reference_number":"EMA/418646/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketotifen-oral-formulations-list-nationally-authorised-medicinal-products-psusa00001813201710_en.pdf"},
    {"id":"38731","name":"Timolol (systemic use) : List of nationally authorised medicinal products - PSUSA/00010432/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-13T13:17:00Z","last_updated_date":"2017-06-13T13:20:00Z","reference_number":"EMA/371481/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/timolol-systemic-use-list-nationally-authorised-medicinal-products-psusa00010432201610_en.pdf"},
    {"id":"38764","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-22T13:00:00Z","last_updated_date":"2016-10-17T20:16:35Z","reference_number":"EMA/51902/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288201505_en.pdf"},
    {"id":"38791","name":"Dienogest : List of nationally authorised medicinal products - PSUSA/00003167/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T16:57:00Z","last_updated_date":"2017-09-06T17:00:29Z","reference_number":"EMA/562418/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/dienogest-list-nationally-authorised-medicinal-products-psusa00003167201612_en.pdf"},
    {"id":"38826","name":"Piretanide: List of nationally authorised medicinal products - PSUSA/00002433/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T12:00:00Z","last_updated_date":"2016-10-17T18:34:52Z","reference_number":"EMA/424241/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/piretanide-list-nationally-authorised-medicinal-products-psusa00002433201510_en.pdf"},
    {"id":"38830","name":"Thiocolchicoside: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/J/0008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-10T15:50:00Z","last_updated_date":"2018-06-26T18:29:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/thiocolchicoside-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0008_sv.pdf"}},
    {"id":"38832","name":"Erdosteine: List of nationally authorised medicinal products - PSUSA/00001248/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-09-30T02:00:00Z","last_updated_date":"2016-10-18T13:42:41Z","reference_number":"EMA/648919/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/erdosteine-list-nationally-authorised-medicinal-products-psusa00001248201602_en.pdf"},
    {"id":"38854","name":"Tolterodine : List of nationally authorised medicinal products - PSUSA/00002993/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-10T19:01:00Z","last_updated_date":"2017-05-10T19:02:42Z","reference_number":"EMA/290528/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/tolterodine-list-nationally-authorised-medicinal-products-psusa00002993201609_en.pdf"},
    {"id":"38919","name":"Octenidine dihydrochloride / phenoxyethanol: List of nationally authorised medicinal products - PSUSA/00002199/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-24T13:30:00Z","last_updated_date":"2017-10-24T13:30:00Z","reference_number":"EMA/706786/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-list-nationally-authorised-medicinal-products-psusa00002199201701_en.pdf"},
    {"id":"38958","name":"Zidovudine : List of nationally authorised medicinal products - PSUSA/00003143/201703","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-04T16:48:00Z","last_updated_date":"2017-12-04T16:57:46Z","reference_number":"EMA/787818/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/zidovudine-list-nationally-authorised-medicinal-products-psusa00003143201703_en.pdf"},
    {"id":"38965","name":"Ethinylestradiol / norethisterone: List of nationally authorised medicinal products - PSUSA/00001312/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-16T12:23:00Z","last_updated_date":"2018-04-16T12:24:38Z","reference_number":"EMA/235814/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-norethisterone-list-nationally-authorised-medicinal-products-psusa00001312201708_en.pdf"},
    {"id":"39038","name":"Levosimendan : List of nationally authorised medicinal products -   PSUSA/00001858/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-12T18:01:00Z","last_updated_date":"2017-06-12T18:04:05Z","reference_number":"EMA/370951/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/levosimendan-list-nationally-authorised-medicinal-products-psusa00001858201609_en.pdf"},
    {"id":"39045","name":"Amitriptyline / perphenazine: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00000170/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T01:00:00Z","last_updated_date":"2016-10-17T19:40:18Z","reference_number":"EMA/829503/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000170201501_en.pdf"},
    {"id":"39139","name":"Influenza vaccine (split virion, inactivated, prepared in cell cultures): List of nationally authorised medicinal products - PSUSA/00010299/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-21T02:00:00Z","last_updated_date":"2016-10-17T18:39:13Z","reference_number":"EMA/285396/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-prepared-cell-cultures-list-nationally-authorised-medicinal-products-psusa00010299201508_en.pdf"},
    {"id":"39140","name":"Ibuprofen / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001711/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-16T16:51:00Z","last_updated_date":"2018-04-16T16:58:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201707_sv.pdf"}},
    {"id":"39148","name":"Ethinylestradiol / norgestimate: List of nationally authorised medicinal products - PSUSA/00001313/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-07-11T19:45:00Z","last_updated_date":"2017-07-11T19:45:00Z","reference_number":"EMA/434927/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-norgestimate-list-nationally-authorised-medicinal-products-psusa00001313201610_en.pdf"},
    {"id":"39163","name":"Tizanidine: CMDh Scientific conclusions and grounds for variation, amendments to the product information, and timetable for the implementation - PSUSA/00002977/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-05T13:00:00Z","last_updated_date":"2016-10-17T20:16:41Z","reference_number":"EMA/730366/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tizanidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002977201412_en.pdf"},
    {"id":"39170","name":"Benazepril: List of nationally authorised medicinal products - PSUSA/00000313/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-31T02:00:00Z","last_updated_date":"2016-10-18T14:01:13Z","reference_number":"EMA/581863/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/benazepril-list-nationally-authorised-medicinal-products-psusa00000313201511_en.pdf"},
    {"id":"39178","name":"Misoprostol (gastrointestinal indication): List of nationally authorised medicinal products - PSUSA/00010291/201606","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-13T01:00:00Z","last_updated_date":"2017-02-13T12:50:00Z","reference_number":"EMA/102464/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gastrointestinal-indication-list-nationally-authorised-medicinal-products-psusa00010291201606_en.pdf"},
    {"id":"39407","name":"Ofloxacin (systemic use): List of nationally authorised medicinal products - PSUSA/00002203/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-04T01:00:00Z","last_updated_date":"2016-10-18T12:49:44Z","reference_number":"EMA/85786/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa00002203201504_en.pdf"},
    {"id":"39472","name":"Misoprostol (gastrointestinal indication): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010291/201706","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-09T19:00:00Z","last_updated_date":"2018-04-09T19:12:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/misoprostol-gastrointestinal-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010291201706_no.pdf"}},
    {"id":"39576","name":"Octenidine dihydrochloride / phenoxyethanol: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002199/201701","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-24T13:30:00Z","last_updated_date":"2017-11-06T12:01:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002199201701_sv.pdf"}},
    {"id":"39628","name":"Cefuroxime sodium (for intracameral use): List of nationally authorised medicinal products - PSUSA/00010206/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-07-16T02:00:00Z","last_updated_date":"2016-10-18T15:41:14Z","reference_number":"EMA/448604/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-sodium-intracameral-use-list-nationally-authorised-medicinal-products-psusa00010206201411_en.pdf"},
    {"id":"39682","name":"Thiopental: List of nationally authorised medicinal products - PSUSA/00002929/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T16:15:00Z","last_updated_date":"2017-01-27T16:20:16Z","reference_number":"EMA/53005/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiopental-list-nationally-authorised-medicinal-products-psusa00002929201603_en.pdf"},
    {"id":"39695","name":"Gabapentin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001499/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T17:45:00Z","last_updated_date":"2016-11-29T17:53:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499201602_no.pdf"}},
    {"id":"39736","name":"Lormetazepam: List of nationally authorised medicinal products - PSUSA/00001910/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-09T01:00:00Z","last_updated_date":"2016-10-18T10:40:09Z","reference_number":"EMA/739247/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/lormetazepam-list-nationally-authorised-medicinal-products-psusa00001910201412_en.pdf"},
    {"id":"39754","name":"Valganciclovir: List of nationally authorised medicinal products - PSUSA/00003089/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T10:07:00Z","last_updated_date":"2016-12-05T10:08:43Z","reference_number":"EMA/750653/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/valganciclovir-list-nationally-authorised-medicinal-products-psusa00003089201603_en.pdf"},
    {"id":"39788","name":"Fusidic acid (systemic use): List of nationally authorised medicinal products - PSUSA/00010226/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-17T12:00:00Z","last_updated_date":"2017-01-17T12:00:00Z","reference_number":"EMA/32524/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fusidic-acid-systemic-use-list-nationally-authorised-medicinal-products-psusa00010226201605_en.pdf"},
    {"id":"39808","name":"Treprostinil: List of nationally authorised medicinal products - PSUSA/00003013/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-12T14:00:00Z","last_updated_date":"2016-10-17T20:16:39Z","reference_number":"EMA/481839/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/treprostinil-list-nationally-authorised-medicinal-products-psusa00003013201511_en.pdf"},
    {"id":"39836","name":"Methylphenidate: List of nationally authorised medicinal products - PSUSA/00002024/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-06-12T10:45:00Z","last_updated_date":"2017-06-12T11:05:47Z","reference_number":"EMA/359582/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-list-nationally-authorised-medicinal-products-psusa00002024201610_en.pdf"},
    {"id":"39854","name":"Antithrombin iii: List of nationally authorised medicinal products - PSUSA/00003159/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-10T19:00:00Z","last_updated_date":"2018-08-14T13:24:05Z","reference_number":"EMA/537207/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/antithrombin-iii-list-nationally-authorised-medicinal-products-psusa00003159201712_en.pdf"},
    {"id":"39859","name":"Etoposide: List of nationally authorised medicinal products -       PSUSA/00001333/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T18:51:00Z","last_updated_date":"2018-04-13T18:56:33Z","reference_number":"EMA/231687/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/etoposide-list-nationally-authorised-medicinal-products-psusa00001333201708_en.pdf"},
    {"id":"39887","name":"Enalapril, nitrendipine: List of nationally authorised medicinal products - PSUSA/00001213/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-15T02:00:00Z","last_updated_date":"2016-10-18T13:42:41Z","reference_number":"EMA/612749/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/enalapril-nitrendipine-list-nationally-authorised-medicinal-products-psusa00001213201501_en.pdf"},
    {"id":"39898","name":"Milnacipran: List of nationally authorised medicinal products - PSUSA/00002063/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T01:00:00Z","last_updated_date":"2016-10-18T12:21:24Z","reference_number":"EMA/172345/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/milnacipran-list-nationally-authorised-medicinal-products-psusa00002063201504_en.pdf"},
    {"id":"40089","name":"Chlorpromazine: List of nationally authorised medicinal products - PSUSA/00000715/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T17:30:00Z","last_updated_date":"2018-01-15T17:30:00Z","reference_number":"EMA/28116/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorpromazine-list-nationally-authorised-medicinal-products-psusa00000715201705_en.pdf"},
    {"id":"40095","name":"Chlormadinone: List of nationally authorised medicinal products - PSUSA/00000677/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T12:45:00Z","last_updated_date":"2017-12-08T12:45:00Z","reference_number":"EMA/817599/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlormadinone-list-nationally-authorised-medicinal-products-psusa00000677201611_en.pdf"},
    {"id":"40097","name":"Levofloxacin: List of nationally authorised medicinal products - PSUSA/00001854/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-18T10:40:13Z","reference_number":"EMA/346564/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/levofloxacin-list-nationally-authorised-medicinal-products-psusa00001854201510_en.pdf"},
    {"id":"40135","name":"Alprazolam: List of nationally authorised medicinal - PSUSA/00000109/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T19:07:00Z","last_updated_date":"2016-10-28T19:08:23Z","reference_number":"EMA/719549/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprazolam-list-nationally-authorised-medicinal-psusa00000109201603_en.pdf"},
    {"id":"40140","name":"Botulinum neurotoxin type a (150 kd) free from complexing proteins: CMDh Scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00009084/2...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T19:35:00Z","last_updated_date":"2016-10-19T19:35:00Z","reference_number":"EMA/692780/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa000090842_en.pdf"},
    {"id":"40143","name":"Enalapril / nitrendipine: List of nationally authorised medicinal products - PSUSA/00001213/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T17:00:00Z","last_updated_date":"2018-09-10T17:00:00Z","reference_number":"EMA/611964/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/enalapril-nitrendipine-list-nationally-authorised-medicinal-products-psusa00001213201801_en.pdf"},
    {"id":"40153","name":"Alprostadil (erectile dysfunction): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000110/201601","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T16:39:00Z","last_updated_date":"2016-11-18T16:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/alprostadil-erectile-dysfunction-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000110201601_no.pdf"}},
    {"id":"40159","name":"Ibuprofen / pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00001711/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-22T01:00:00Z","last_updated_date":"2016-10-17T17:46:45Z","reference_number":"EMA/147027/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00001711201507_en.pdf"},
    {"id":"40190","name":"Cimicifuga racemosa (L.) nutt., rhizome: List of nationally authorised medicinal products - PSUSA/00000755/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-12T19:02:00Z","last_updated_date":"2018-09-12T19:04:27Z","reference_number":"EMA/617506/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cimicifuga-racemosa-l-nutt-rhizome-list-nationally-authorised-medicinal-products-psusa00000755201801_en.pdf"},
    {"id":"40238","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-01-13T10:04:00Z","last_updated_date":"2017-01-13T10:08:17Z","reference_number":"EMA/24845/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288201605_en.pdf"}    {"id":"40268","name":"Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-15T14:49:00Z","last_updated_date":"2018-03-15T14:52:16Z","reference_number":"EMA/164035/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-list-nationally-authorised-medicinal-products-psusa00010390201707_en.pdf"},
    {"id":"40274","name":"Apomorphine: List of nationally authorised medicinal products - PSUSA/00000227/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-30T02:00:00Z","last_updated_date":"2016-10-17T19:40:18Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/apomorphine-list-nationally-authorised-medicinal-products-psusa00000227201511_en.pdf"},
    {"id":"40286","name":"Influenza vaccine (split virion, inactivated) (non centrally authorised products): List of nationally authorised medicinal products - PSUSA/00010298/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T15:00:00Z","last_updated_date":"2016-10-28T15:00:00Z","reference_number":"EMA/719228/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00010298201603_en.pdf"},
    {"id":"40293","name":"Atovaquone / proguanil: List of nationally authorised medicinal products - PSUSA/00000266/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-20T17:38:00Z","last_updated_date":"2018-06-20T17:43:37Z","reference_number":"EMA/418958/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/atovaquone-proguanil-list-nationally-authorised-medicinal-products-psusa00000266201710_en.pdf"},
    {"id":"40343","name":"Triazolam: List of nationally authorised medicinal products - PSUSA/00003023/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-16T16:05:00Z","last_updated_date":"2018-04-16T16:09:10Z","reference_number":"EMA/229108/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/triazolam-list-nationally-authorised-medicinal-products-psusa00003023201707_en.pdf"},
    {"id":"40379","name":"Carbidopa / levodopa (except for centrally authorised product): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000548/201610","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T18:00:00Z","last_updated_date":"2017-09-21T19:27:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/carbidopa-levodopa-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201610_no.pdf"}},
    {"id":"40458","name":"Paracetamol / tramadol: List of nationally authorised medicinal products - PSUSA/00002310/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T14:00:00Z","last_updated_date":"2016-10-17T16:59:47Z","reference_number":"EMA/319353/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-tramadol-list-nationally-authorised-medicinal-products-psusa00002310201508_en.pdf"},
    {"id":"40482","name":"Metronidazole / neomycin / nystatin: List of nationally authorised medicinal products - PSUSA/00010508/201709","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T20:00:00Z","last_updated_date":"2018-05-23T20:22:18Z","reference_number":"EMA/303477/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/metronidazole-neomycin-nystatin-list-nationally-authorised-medicinal-products-psusa00010508201709_en.pdf"},
    {"id":"40554","name":"Acitretin: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation- PSUSA/00000051/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-10T02:00:00Z","last_updated_date":"2016-10-17T17:40:41Z","reference_number":"EMA/540531/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201510_en.pdf"},
    {"id":"40593","name":"Macrogol 4000: List of nationally authorised medicinal products - PSUSA/00010392/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T14:36:00Z","last_updated_date":"2017-02-02T14:37:32Z","reference_number":"EMA/777741/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/macrogol-4000-list-nationally-authorised-medicinal-products-psusa00010392201605_en.pdf"},
    {"id":"40604","name":"Gadobenic acid: List of nationally authorised medicinal products - PSUSA/00001500/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T01:00:00Z","last_updated_date":"2016-10-19T12:37:33Z","reference_number":"EMA/181825/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobenic-acid-list-nationally-authorised-medicinal-products-psusa00001500201504_en.pdf"},
    {"id":"40623","name":"Fluocinolone acetonide (intravitreal implant in applicator): List of nationally authorised medicinal products - PSUSA/00010224/201608","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2017-04-11T19:40:00Z","last_updated_date":"2017-04-11T19:40:00Z","reference_number":"EMA/208427/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-intravitreal-implant-applicator-list-nationally-authorised-medicinal-products-psusa00010224201608_en.pdf"},
    {"id":"40630","name":"Fosinopril / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA/00001475/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-10-18T13:42:39Z","reference_number":"EMA/242304/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosinopril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00001475201507_en.pdf"},
    {"id":"40670","name":"Allopurinol : List of nationally authorised medicinal products - PSUSA/00000095/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T15:27:00Z","last_updated_date":"2017-10-23T15:36:00Z","reference_number":"EMA/697322/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/allopurinol-list-nationally-authorised-medicinal-products-psusa00000095201612_en.pdf"},
    {"id":"40683","name":"Misoprostol (gynaecological indication - termination of pregnancy): List of nationally authorised medicinal products - PSUSA/00010354/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T16:05:00Z","last_updated_date":"2018-03-09T16:07:00Z","reference_number":"EMA/9690/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-list-nationally-authorised-medicinal-products-psusa00010354201705_en.pdf"},
    {"id":"40741","name":"Azithromycin (systemic use formulations): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010491/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-27T19:30:00Z","last_updated_date":"2018-02-27T19:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/azithromycin-systemic-use-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010491201704_no.pdf"}},
    {"id":"40773","name":"Altizide/spironolactone: List of nationally authorised medicinal products - PSUSA/00002781/201501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-06T01:00:00Z","last_updated_date":"2016-10-17T19:40:17Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/altizidespironolactone-list-nationally-authorised-medicinal-products-psusa00002781201501_en.pdf"},
    {"id":"40820","name":"Fluvastatin: List of nationally authorised medicinal products - PSUSA-00001457-201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-04T12:30:00Z","last_updated_date":"2018-07-04T12:30:00Z","reference_number":"EMA/443956/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluvastatin-list-nationally-authorised-medicinal-products-psusa-00001457-201708_en.pdf"},
    {"id":"40826","name":"Moxifloxacin (systemic use):  List of nationally authorised medicinal products - PSUSA/00009231/201605","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T16:10:00Z","last_updated_date":"2017-03-09T16:15:00Z","reference_number":"EMA/167321/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/moxifloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa00009231201605_en.pdf"},
    {"id":"40839","name":"Nitrendipine: List of nationally authorised medicinal products - PSUSA/00002171/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-10T01:00:00Z","last_updated_date":"2016-10-18T12:37:30Z","reference_number":"EMA/838109/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrendipine-list-nationally-authorised-medicinal-products-psusa00002171201503_en.pdf"},
    {"id":"40844","name":"Roxithromycin: List of nationally authorised medicinal products - PSUSA/00002669/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T12:00:00Z","last_updated_date":"2016-10-18T11:22:48Z","reference_number":"EMA/626672/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/roxithromycin-list-nationally-authorised-medicinal-products-psusa00002669201412_en.pdf"},
    {"id":"40920","name":"Venlafaxine:  List of nationally authorised medicinal products - PSUSA/00003104/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T16:15:00Z","last_updated_date":"2018-01-15T16:17:22Z","reference_number":"EMA/24903/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/venlafaxine-list-nationally-authorised-medicinal-products-psusa00003104201705_en.pdf"},
    {"id":"40955","name":"Glatiramer: List of nationally authorised medicinal products - PSUSA/00001529/201411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-13T02:00:00Z","last_updated_date":"2016-10-17T16:05:50Z","reference_number":"EMA/677092/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/glatiramer-list-nationally-authorised-medicinal-products-psusa00001529201411_en.pdf"},
    {"id":"41018","name":"Perindopril: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00002354/201510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-08-05T12:00:00Z","last_updated_date":"2016-10-17T16:59:46Z","reference_number":"EMA/528822/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/perindopril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002354201510_en.pdf"},
    {"id":"41094","name":"Abciximab: List of nationally authorised medicinal products - PSUSA/00000014/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T12:55:00Z","last_updated_date":"2018-07-19T12:55:00Z","reference_number":"EMA/495549/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/abciximab-list-nationally-authorised-medicinal-products-psusa00000014201711_en.pdf"},
    {"id":"41148","name":"Rabbit anti-human thymocyte (powder for solution for\n\ninfusion): CMDh scientific conclusions and grounds for variation,\n\namendments to the product information and timetable for\n\nthe implementation - PSUSA/00010184/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-09-04T12:00:00Z","last_updated_date":"2016-10-17T19:31:36Z","reference_number":"EMA/592371/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-human-thymocyte-powder-solution-infusion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010184201412_en.pdf-0"},
    {"id":"41159","name":"Etifoxine: List of nationally authorised medicinal products - PSUSA/00001321/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-15T18:00:00Z","last_updated_date":"2018-06-15T18:00:00Z","reference_number":"EMA/374606/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/etifoxine-list-nationally-authorised-medicinal-products-psusa00001321201710_en.pdf"},
    {"id":"41190","name":"Gaxilose: List of nationally authorised medicinal products - PSUSA/00010283/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-10-18T16:56:40Z","reference_number":"EMA/346299/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/gaxilose-list-nationally-authorised-medicinal-products-psusa00010283201507_en.pdf"},
    {"id":"41276","name":"Furosemide / spironolactone : List of nationally authorised medicinal products - PSUSA/00001493/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T11:44:00Z","last_updated_date":"2017-09-08T11:48:42Z","reference_number":"EMA/593213/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa00001493201612_en.pdf"},
    {"id":"41325","name":"Naproxen: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002125/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T13:00:00Z","last_updated_date":"2018-09-13T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/naproxen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002125201708_no.pdf"}},
    {"id":"41333","name":"Cilostazol: List of nationally authorised medicinal products - PSUSA/00010209/201502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-07T01:00:00Z","last_updated_date":"2016-10-18T15:41:05Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilostazol-list-nationally-authorised-medicinal-products-psusa00010209201502_en.pdf"},
    {"id":"41406","name":"Amlodipine: List of nationally authorised medicinal products: PSUSA/00000174/201603","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-12-15T18:45:00Z","last_updated_date":"2016-12-15T18:48:03Z","reference_number":"EMA/863940/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-list-nationally-authorised-medicinal-products-psusa00000174201603_en.pdf-1"},
    {"id":"41443","name":"Meningococcal group a and c polysaccharide vaccine: List of nationally authorised medicinal - PSUSA/00001970/201602","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T02:00:00Z","last_updated_date":"2016-10-28T18:52:55Z","reference_number":"EMA/719745/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/meningococcal-group-and-c-polysaccharide-vaccine-list-nationally-authorised-medicinal-psusa00001970201602_en.pdf"},
    {"id":"41467","name":"Diphtheria / tetanus / poliomyelitis (inactivated) vaccine (adsorbed, reduced antigens(s) content): List of nationally authorised medicinal products - PSUSA/00001127/201708","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-17T12:41:00Z","last_updated_date":"2018-04-17T12:44:45Z","reference_number":"EMA/229018/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-poliomyelitis-inactivated-vaccine-adsorbed-reduced-antigenss-content-list-nationally-authorised-medicinal-products-psusa00001127201708_en.pdf"},
    {"id":"41483","name":"Fluticasone propionate: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation-  PSUSA/00001454/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T18:04:00Z","last_updated_date":"2018-01-03T18:10:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fluticasone-propionate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001454201702_no.pdf"}},
    {"id":"41503","name":"Rabbit anti-human thymocyte (powder for solution for\n\ninfusion): List of nationally authorised medicinal products - PSUSA/00010184/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-23T11:00:00Z","last_updated_date":"2016-10-17T19:31:36Z","reference_number":"EMA/148859/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-human-thymocyte-powder-solution-infusion-list-nationally-authorised-medicinal-products-psusa00010184201506_en.pdf"},
    {"id":"41551","name":"5 Fluorouracil (i.v. application): List of nationally authorised medicinal products - PSUSA/00000007/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2016-10-17T16:39:22Z","reference_number":"EMA/706456/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-iv-application-list-nationally-authorised-medicinal-products-psusa00000007201412_en.pdf"},
    {"id":"41558","name":"Lubiprostone: List of nationally authorised medicinal products - PSUSA/00010290/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-12T19:17:00Z","last_updated_date":"2018-09-12T19:20:06Z","reference_number":"EMA/617522/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/lubiprostone-list-nationally-authorised-medicinal-products-psusa00010290201801_en.pdf"},
    {"id":"41578","name":"Glibenclamide / metformin hydrochloride: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00002002/201506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-21T02:00:00Z","last_updated_date":"2016-10-17T15:56:42Z","reference_number":"EMA/284334/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/glibenclamide-metformin-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002002201506_en.pdf"},
    {"id":"41579","name":"Cefadroxil: List of nationally authorised medicinal products - PSUSA/00000584/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-04-26T15:53:00Z","last_updated_date":"2018-04-26T16:01:39Z","reference_number":"EMA/261995/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefadroxil-list-nationally-authorised-medicinal-products-psusa00000584201707_en.pdf"},
    {"id":"41584","name":"Rupatadine: List of nationally authorised medicinal products -   PSUSA/00002673/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-18T14:16:00Z","last_updated_date":"2018-07-18T14:18:34Z","reference_number":"EMA/486464/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/rupatadine-list-nationally-authorised-medicinal-products-psusa00002673201712_en.pdf"},
    {"id":"41621","name":"Cefuroxime axetil : List of nationally authorised medicinal products - PSUSA/00009099/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T12:46:00Z","last_updated_date":"2017-12-01T12:47:55Z","reference_number":"EMA/787932/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-axetil-list-nationally-authorised-medicinal-products-psusa00009099201704_en.pdf"},
    {"id":"41622","name":"Acetylsalicylic acid / bisoprolol: List of nationally authorised medicinal products - PSUSA/00010287/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-12-07T01:00:00Z","last_updated_date":"2016-10-17T16:44:24Z","reference_number":"EMA/826295/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-bisoprolol-list-nationally-authorised-medicinal-products-psusa00010287201505_en.pdf"},
    {"id":"41640","name":"Domperidone: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001158/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-05T14:00:00Z","last_updated_date":"2017-09-05T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001158201611_sv.pdf"}},
    {"id":"41686","name":"Thiamphenicol: List of nationally authorised medicinal products-PSUSA/00002925/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2006-01-22T11:35:00Z","last_updated_date":"2016-10-19T12:44:50Z","reference_number":"EMA/50405/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiamphenicol-list-nationally-authorised-medicinal-products-psusa00002925201505_en.pdf"},
    {"id":"41715","name":"Vinorelbine : List of nationally authorised medicinal products - PSUSA/00003124/201704","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T14:50:00Z","last_updated_date":"2017-12-01T14:54:47Z","reference_number":"EMA/795271/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/vinorelbine-list-nationally-authorised-medicinal-products-psusa00003124201704_en.pdf"},
    {"id":"41760","name":"Cetirizine: List of nationally authorised medicinal products - PSUSA/00000628/201711","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-07-18T18:24:00Z","last_updated_date":"2018-07-18T18:25:49Z","reference_number":"EMA/490585/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cetirizine-list-nationally-authorised-medicinal-products-psusa00000628201711_en.pdf"},
    {"id":"41769","name":"Escherichia coli lysate: List of nationally authorised medicinal products - PSUSA/00001263/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-10-18T13:42:38Z","reference_number":"EMA/243566/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/escherichia-coli-lysate-list-nationally-authorised-medicinal-products-psusa00001263201507_en.pdf"},
    {"id":"41789","name":"Bacillus clausii multi-antibioresistant spores: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000284/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T18:40:00Z","last_updated_date":"2017-10-26T18:48:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201611_sv.pdf"}},
    {"id":"41813","name":"Terbutaline: List of nationally authorised medicinal products - PSUSA/00002897/201612","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-04T18:30:00Z","last_updated_date":"2017-09-04T18:30:00Z","reference_number":"EMA/580096/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/terbutaline-list-nationally-authorised-medicinal-products-psusa00002897201612_en.pdf"},
    {"id":"41844","name":"Misoprostol (gynaecological indication - termination of pregnancy): List of nationally authorised medicinal products - PSUSA/00010354/201505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-10-18T12:21:19Z","reference_number":"EMA/34528/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-list-nationally-authorised-medicinal-products-psusa00010354201505_en.pdf"},
    {"id":"41852","name":"Flubendazole: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001400/201702","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-11-14T18:34:00Z","last_updated_date":"2017-11-14T18:39:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/flubendazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001400201702_sv.pdf"}},
    {"id":"41854","name":"Diacerein: List of nationally authorised medicinal products - PSUSA/0001026/201512","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-07-12T14:00:00Z","last_updated_date":"2016-10-17T20:37:53Z","reference_number":"EMA/483326/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/diacerein-list-nationally-authorised-medicinal-products-psusa0001026201512_en.pdf"},
    {"id":"41876","name":"Levonorgestrel / ethinylestradiol, ethinylestradiol (combination pack): List of nationally authorised medicinal products - PSUSA/00010442/201707","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T12:47:00Z","last_updated_date":"2018-02-13T12:49:00Z","reference_number":"EMA/93869/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-list-nationally-authorised-medicinal-products-psusa00010442201707_en.pdf"},
    {"id":"41924","name":"Influenza vaccine (surface antigen, inactivated): CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00001744/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-02-02T01:00:00Z","last_updated_date":"2016-10-17T18:39:16Z","reference_number":"PSUSA/00001744/201504","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001744201504_en.pdf"},
    {"id":"41928","name":"Deoxycholic acid: List of nationally authorised products - PSUSA/00010525/201710","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-08-14T13:00:00Z","last_updated_date":"2018-08-14T13:00:00Z","reference_number":"EMA/PRAC/380270/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/deoxycholic-acid-list-nationally-authorised-products-psusa00010525201710_en.pdf"},
    {"id":"41943","name":"Felbamate: List of nationally authorised medicinal products - PSUSA/00010155/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-09-18T02:00:00Z","last_updated_date":"2017-09-18T16:54:35Z","reference_number":"EMA/610895/2017","document_url":"https://www.ema.europa.eu/en/documents/psusa/felbamate-list-nationally-authorised-medicinal-products-psusa00010155201609_en.pdf"},
    {"id":"41948","name":"Reboxetine: List of nationally authorised medicinal products - PSUSA/00002615/201504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T11:00:00Z","last_updated_date":"2016-10-17T19:46:19Z","reference_number":"EMA/40845/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/reboxetine-list-nationally-authorised-medicinal-products-psusa00002615201504_en.pdf"},
    {"id":"41965","name":"Meropenem: List of nationally authorised medicinal products - PSUSA/00001989/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-08T02:00:00Z","last_updated_date":"2016-10-18T11:29:35Z","reference_number":"EMA/398004/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/meropenem-list-nationally-authorised-medicinal-products-psusa00001989201508_en.pdf"},
    {"id":"41971","name":"Cabergoline: List of nationally authorised medicinal products - PSUSA/00000477/201503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T02:00:00Z","last_updated_date":"2016-10-18T14:01:10Z","reference_number":"EMA/230130/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/cabergoline-list-nationally-authorised-medicinal-products-psusa00000477201503_en.pdf"},
    {"id":"41982","name":"Misoprostol (gynaecological indication - labour induction): List of nationally authorised medicinal products - PSUSA/00010353/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-12T16:38:00Z","last_updated_date":"2018-01-12T16:40:00Z","reference_number":"EMA/11926/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labour-induction-list-nationally-authorised-medicinal-products-psusa00010353201705_en.pdf"},
    {"id":"41985","name":"Betahistine: List of nationally authorised medicinal products - PSUSA/0000389/201412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2015-11-25T01:00:00Z","last_updated_date":"2016-10-18T14:01:15Z","reference_number":"EMA/587351/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/betahistine-list-nationally-authorised-medicinal-products-psusa0000389201412_en.pdf"},
    {"id":"41998","name":"Halofantrine: List of nationally authorised medicinal products - PSUSA/00001586/201705","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-01-19T13:00:00Z","last_updated_date":"2018-01-19T13:00:00Z","reference_number":"EMA/21173/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/halofantrine-list-nationally-authorised-medicinal-products-psusa00001586201705_en.pdf"},
    {"id":"42014","name":"Drospirenone / ethinylestradiol : List of nationally authorised medicinal products - PSUSA/00010217/201609","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T19:34:00Z","last_updated_date":"2017-05-22T19:36:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/drospirenone-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa00010217201609_en.pdf"},
    {"id":"42024","name":"Quinine: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002598/201611","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2017-10-24T19:20:00Z","last_updated_date":"2017-10-24T19:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/quinine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002598201611_sv.pdf"}},
    {"id":"42036","name":"Meropenem: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00001989/201508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-06-08T02:00:00Z","last_updated_date":"2016-10-18T11:29:37Z","reference_number":"EMA/400367/2016","document_url":"https://www.ema.europa.eu/en/documents/psusa/meropenem-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001989201508_en.pdf"},
    {"id":"42038","name":"Hydromorphone: List of nationally authorised medicinal products - PSUSA/00001686/201511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T17:45:00Z","last_updated_date":"2016-10-26T17:59:23Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydromorphone-list-nationally-authorised-medicinal-products-psusa00001686201511_en.pdf"},
    {"id":"42061","name":"Levobupivacaine: List of nationally authorised medicinal products - PSUSA/00001848/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-17T12:25:00Z","last_updated_date":"2018-09-17T12:26:00Z","reference_number":"EMA/620439/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/levobupivacaine-list-nationally-authorised-medicinal-products-psusa00001848201712_en.pdf"},
    {"id":"42064","name":"Landiolol: List of nationally authorised medicinal products - PSUSA/00010570/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-14T15:50:00Z","last_updated_date":"2018-09-14T15:52:00Z","reference_number":"EMA/622806/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/landiolol-list-nationally-authorised-medicinal-products-psusa00010570201802_en.pdf"},
    {"id":"42088","name":"Desmopressin: List of nationally authorised medicinal products - PSUSA/00000964/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-14T16:26:00Z","last_updated_date":"2018-09-14T16:31:42Z","reference_number":"EMA/PRAC/628699/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/desmopressin-list-nationally-authorised-medicinal-products-psusa00000964201712_en.pdf"},
    {"id":"42090","name":"Felodipine / metoprolol: List of nationally authorised medicinal products - PSUSA/00001357/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-14T15:50:00Z","last_updated_date":"2018-09-14T15:52:02Z","reference_number":"EMA/622778/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/felodipine-metoprolol-list-nationally-authorised-medicinal-products-psusa00001357201712_en.pdf"},
    {"id":"42097","name":"Altizide / spironolactone: List of nationally authorised medicinal products - PSUSA/00002781/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-14T15:50:00Z","last_updated_date":"2018-09-14T15:52:02Z","reference_number":"EMA/622770/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/altizide-spironolactone-list-nationally-authorised-medicinal-products-psusa00002781201801_en.pdf"},
    {"id":"42100","name":"Levonorgestrel / ethinylestradiol, ethinylestradiol (combination pack): List of nationally authorised medicinal products - PSUSA/00010442/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-14T16:44:00Z","last_updated_date":"2018-09-14T16:47:00Z","reference_number":"EMA/622923/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-list-nationally-authorised-medicinal-products-psusa00010442201801_en.pdf"},
    {"id":"42101","name":"5 fluorouracil (topical application): List of nationally authorised medicinal products - PSUSA/00010000/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-17T12:45:00Z","last_updated_date":"2018-09-17T12:48:00Z","reference_number":"EMA/620546/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-topical-application-list-nationally-authorised-medicinal-products-psusa00010000201712_en.pdf"},
    {"id":"42138","name":"Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-09-18T13:00:00Z","last_updated_date":"2018-09-18T13:01:04Z","reference_number":"EMA/634612/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-list-nationally-authorised-medicinal-products-psusa00010390201801_en.pdf"},
    {"id":"42215","name":"Iron parenteral preparations: List of nationally authorised medicinal products - PSUSA/00010236/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T10:39:00Z","last_updated_date":"2018-10-08T10:39:00Z","reference_number":"EMA/596347/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-parenteral-preparations-list-nationally-authorised-medicinal-products-psusa00010236201801_en.pdf"},
    {"id":"42216","name":"Iron parenteral preparations: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010236/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T11:15:00Z","last_updated_date":"2018-10-08T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/iron-parenteral-preparations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236201801_no.pdf"}},
    {"id":"42316","name":"Tauroselcholic (75Se) acid: List of nationally authorised medicinal products - PSUSA/00010486/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-12T13:30:00Z","last_updated_date":"2018-10-12T13:30:00Z","reference_number":"EMA/698769/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/tauroselcholic-75se-acid-list-nationally-authorised-medicinal-products-psusa-00010486-201801_en.pdf"},
    {"id":"42317","name":"Amitriptyline hydrochloride / chlordiazepoxide: List of nationally authorised medicinal products - PSUSA/00000171/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-12T13:35:00Z","last_updated_date":"2018-10-12T13:35:00Z","reference_number":"EMA/699401/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-hydrochloride-chlordiazepoxide-list-nationally-authorised-medicinal-products-psusa00000171201802_en.pdf"},
    {"id":"42318","name":"Nafarelin: List of nationally authorised medicinal products - PSUSA/00002105/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-12T13:45:00Z","last_updated_date":"2018-10-12T13:45:00Z","reference_number":"EMA/699451/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/nafarelin-list-nationally-authorised-medicinal-products-psusa00002105201802_en.pdf"},
    {"id":"42320","name":"Argatroban: List of nationally authorised medicinal products - PSUSA/00009057/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-12T13:50:00Z","last_updated_date":"2018-10-12T13:50:00Z","reference_number":"EMA/701236/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/argatroban-list-nationally-authorised-medicinal-products-psusa00009057201801_en.pdf"},
    {"id":"42336","name":"Lisdexamfetamine: List of nationally authorised medicinal products - PSUSA/00010289/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-15T10:17:00Z","last_updated_date":"2018-10-15T10:17:00Z","reference_number":"EMA/710683/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa00010289201802_en.pdf"},
    {"id":"42338","name":"Iloprost (iv solution): List of nationally authorised medicinal products - PSUSA/00009190/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-15T10:24:00Z","last_updated_date":"2018-10-15T10:24:00Z","reference_number":"EMA/PRAC/710616/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/iloprost-iv-solution-list-nationally-authorised-medicinal-products-psusa00009190201801_en.pdf"},
    {"id":"42348","name":"Hydrochlorothiazide / losartan: List of nationally authorised medicinal products - PSUSA/00001655/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-16T15:15:00Z","last_updated_date":"2018-10-16T15:15:00Z","reference_number":"EMA/715149/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-losartan-list-nationally-authorised-medicinal-products-psusa00001655201802_en.pdf"},
    {"id":"42349","name":"Lomustine: List of nationally authorised medicinal products - PSUSA/00001902/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-16T16:22:00Z","last_updated_date":"2018-10-16T16:22:00Z","reference_number":"EMA/693804/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/lomustine-list-nationally-authorised-medicinal-products-psusa00001902201801_en.pdf"},
    {"id":"42358","name":"Ciprofloxacin (topical use): List of nationally authorised medicinal products - PSUSA/00000776/201801","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2018-10-17T17:10:00Z","last_updated_date":"2018-10-17T17:10:00Z","reference_number":"EMA/684413/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-topical-use-list-nationally-authorised-medicinal-products-psusa00000776201801_en.pdf"},
    {"id":"42359","name":"Olodaterol: List of nationally authorised medicinal products - PSUSA/00010245/201803","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2018-10-17T17:15:00Z","last_updated_date":"2018-10-17T17:15:00Z","reference_number":"EMA/684895/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodaterol-list-nationally-authorised-medicinal-products-psusa00010245201803_en.pdf"},
    {"id":"42419","name":"Aldesleukin: List of nationally authorised medicinal products - PSUSA/00000076/201712","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2018-10-23T12:21:00Z","last_updated_date":"2018-10-23T12:21:00Z","reference_number":"EMA/735443/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/aldesleukin-list-nationally-authorised-medicinal-products-psusa00000076201712_en.pdf"},
    {"id":"42420","name":"Aldesleukin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000076/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-23T12:22:00Z","last_updated_date":"2018-10-23T12:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/aldesleukin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000076201712_sv.pdf"}},
    {"id":"42424","name":"Mivacurium: List of nationally authorised medicinal products - PSUSA/00002077/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-25T09:45:00Z","last_updated_date":"2018-10-25T09:45:00Z","reference_number":"EMA/750469/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/mivacurium-list-nationally-authorised-medicinal-products-psusa00002077201801_en.pdf"},
    {"id":"42425","name":"Hydroxyethyl starch: List of nationally authorised medicinal products - PSUSA/00001694/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-25T09:45:00Z","last_updated_date":"2018-10-25T09:45:00Z","reference_number":"EMA/751895/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-list-nationally-authorised-medicinal-products-psusa00001694201803_en.pdf"},
    {"id":"42426","name":"Lormetazepam: List of nationally authorised medicinal products for maintenance - PSUSA/00001910/201712","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2018-10-25T11:06:00Z","last_updated_date":"2018-10-25T11:06:00Z","reference_number":"EMA/382258/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/lormetazepam-list-nationally-authorised-medicinal-products-maintenance-psusa00001910201712_en.pdf"},
    {"id":"42427","name":"Dacarbazine: List of nationally authorised medicinal products - PSUSA/00000919/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-25T10:15:00Z","last_updated_date":"2018-10-25T10:15:00Z","reference_number":"EMA/751985/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/dacarbazine-list-nationally-authorised-medicinal-products-psusa00000919201802_en.pdf"},
    {"id":"42428","name":"Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpromide, valproate bismuth, calcium valproate, valproate magnesium: List of nationally authorised medicinal products - PSUSA/00003090/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-25T10:40:00Z","last_updated_date":"2018-10-25T10:40:00Z","reference_number":"EMA/752859/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-valproate-bismuth-calcium-valproate-valproate-magnesium-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"42429","name":"Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpromide...: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003090/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-25T10:45:00Z","last_updated_date":"2018-10-25T10:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_no.pdf"}},
    {"id":"42434","name":"Fenoterol / ipratropium: List of nationally authorised medicinal products - PSUSA/00001367/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-25T16:20:00Z","last_updated_date":"2018-10-25T16:20:00Z","reference_number":"EMA/758398/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenoterol-ipratropium-list-nationally-authorised-medicinal-products-psusa00001367201802_en.pdf"},
    {"id":"42465","name":"Ethinylestradiol / gestodene (transdermal application): List of nationally authorised medicinal products - PSUSA/00010145/201802","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2018-10-29T12:43:00Z","last_updated_date":"2018-10-29T12:43:00Z","reference_number":"EMA/758808/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-gestodene-transdermal-application-list-nationally-authorised-medicinal-products-psusa00010145201802_en.pdf"},
    {"id":"42466","name":"Amantadine: List of nationally authorised medicinal products - PSUSA/00000126/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T13:09:00Z","last_updated_date":"2018-10-29T13:09:00Z","reference_number":"EMA/761730/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amantadine-list-nationally-authorised-medicinal-products-psusa00000126201801_en.pdf"},
    {"id":"42468","name":"Amantadine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000126/201801","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2018-10-29T13:11:00Z","last_updated_date":"2018-10-29T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amantadine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000126201801_sv.pdf"}},
    {"id":"42521","name":"Cisplatin: List of nationally authorised medicinal products - PSUSA/00000778/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T09:13:00Z","last_updated_date":"2018-11-05T09:13:00Z","reference_number":"EMA/776051/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cisplatin-list-nationally-authorised-medicinal-products-psusa00000778201712_en.pdf"}    {"id":"42522","name":"Cisplatin: CMDh scientific conclusions, amendments to product information and implementation timetable - PSUSA/00000778/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:21:00Z","last_updated_date":"2018-11-05T10:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cisplatin-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000778201712_no.pdf"}},
    {"id":"42523","name":"5 fluorouracil (i.v. application): List of nationally authorised medicinal products - PSUSA/00000007/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T09:30:00Z","last_updated_date":"2018-11-05T09:30:00Z","reference_number":"EMA/776060/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-iv-application-list-nationally-authorised-medicinal-products-psusa00000007201712_en.pdf"},
    {"id":"42524","name":"5 fluorouracil (i.v. application): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000007/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T09:32:00Z","last_updated_date":"2018-11-05T09:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/5-fluorouracil-iv-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000007201712_no.pdf"}},
    {"id":"42525","name":"Bendroflumethiazide, bendroflumethiazide/potassium chloride: List of nationally authorised medicinal products - PSUSA-00010583-201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:09:00Z","last_updated_date":"2018-11-05T10:09:00Z","reference_number":"EMA/765046/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-list-nationally-authorised-medicinal-products-psusa-00010583-201801_en.pdf"},
    {"id":"42526","name":"Bendroflumethiazide, bendroflumethiazide/potassium chloride: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA-00010583-201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:11:00Z","last_updated_date":"2018-11-05T10:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bendroflumethiazide-bendroflumethiazidepotassium-chloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010583-201801_no.pdf"}},
    {"id":"42527","name":"Amitriptyline, amitriptyline / amitriptylinoxide, amitriptylinoxide: List of nationally authorised medicinal products - PSUSA/00010374/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:20:00Z","last_updated_date":"2018-11-05T10:20:00Z","reference_number":"EMA/764220/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-list-nationally-authorised-medicinal-products-psusa00010374201801_en.pdf"},
    {"id":"42528","name":"Amitriptyline, amitriptyline / amitriptylinoxide, amitriptylinoxide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010374/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T11:22:00Z","last_updated_date":"2018-11-05T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374201801_no.pdf"}},
    {"id":"42529","name":"Famciclovir : List of nationally authorised medicinal products - PSUSA/00001349/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T11:24:00Z","last_updated_date":"2018-11-05T11:24:00Z","reference_number":"EMA/PRAC/583558/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/famciclovir-list-nationally-authorised-medicinal-products-psusa00001349201712_en.pdf"},
    {"id":"42530","name":"Dapoxetine: List of nationally authorised medicinal products - PSUSA/00000928/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:28:00Z","last_updated_date":"2018-11-05T10:28:00Z","reference_number":"EMA/765809/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/dapoxetine-list-nationally-authorised-medicinal-products-psusa00000928201712_en.pdf"},
    {"id":"42531","name":"Dapoxetine: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA-00000928-201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:31:00Z","last_updated_date":"2018-11-05T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dapoxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000928-201712_no.pdf"}},
    {"id":"42532","name":"Calcitriol : List of nationally authorised medicinal products - PSUSA/00000495/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:38:00Z","last_updated_date":"2018-11-05T10:38:00Z","reference_number":"EMA/PRAC/581390/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcitriol-list-nationally-authorised-medicinal-products-psusa00000495201801_en.pdf"},
    {"id":"42533","name":"Cilostazol: List of nationally authorised medicinal products - PSUSA/00010209/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:44:00Z","last_updated_date":"2018-11-05T10:44:00Z","reference_number":"EMA/354578/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilostazol-list-nationally-authorised-medicinal-products-psusa00010209201802_en.pdf"},
    {"id":"42534","name":"Human coagulation factor VIII (inhibitor bypassing fraction) : List of nationally authorised medicinal products - PSUSA/00009174/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:48:00Z","last_updated_date":"2018-11-05T10:48:00Z","reference_number":"EMA/382258/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-viii-inhibitor-bypassing-fraction-list-nationally-authorised-medicinal-products-psusa00009174201802_en.pdf"},
    {"id":"42535","name":"Bendamustine hydrochloride : List of nationally authorised medicinal products - PSUSA/00003162/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:51:00Z","last_updated_date":"2018-11-05T10:51:00Z","reference_number":"EMA/386458/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendamustine-hydrochloride-list-nationally-authorised-medicinal-products-psusa00003162201801_en.pdf"},
    {"id":"42536","name":"Pseudoephedrine / triprolidiner : List of nationally authorised medicinal products - PSUSA/00003047/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-05T10:53:00Z","last_updated_date":"2018-11-05T10:53:00Z","reference_number":"EMA/382258/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/pseudoephedrine-triprolidiner-list-nationally-authorised-medicinal-products-psusa00003047201712_en.pdf"},
    {"id":"42542","name":"Nitrazepam: List of nationally authorised medicinal products - PSUSA/00002170/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T12:05:00Z","last_updated_date":"2018-11-06T12:05:00Z","reference_number":"EMA/775487/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrazepam-list-nationally-authorised-medicinal-products-psusa00002170201803_en.pdf"},
    {"id":"42552","name":"Spironolactone: List of nationally authorised medicinal products - PSUSA/00002780/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T14:16:00Z","last_updated_date":"2018-11-06T14:16:00Z","reference_number":"EMA/775536/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/spironolactone-list-nationally-authorised-medicinal-products-psusa00002780201803_en.pdf"},
    {"id":"42553","name":"Ampicillin / sulbactam: List of nationally authorised medicinal products - PSUSA/00000197/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T15:39:00Z","last_updated_date":"2018-11-06T15:39:00Z","reference_number":"EMA/776421/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ampicillin-sulbactam-list-nationally-authorised-medicinal-products-psusa00000197201802_en.pdf"},
    {"id":"42554","name":"Allopurinol: List of nationally authorised medicinal products - PSUSA/00000095/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T15:48:00Z","last_updated_date":"2018-11-06T15:48:00Z","reference_number":"EMA/769809/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/allopurinol-list-nationally-authorised-medicinal-products-psusa00000095201712_en.pdf"},
    {"id":"42555","name":"Allopurinol: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000095/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T15:56:00Z","last_updated_date":"2018-11-06T15:56:00Z","reference_number":"EMA/769809/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095201712_no.pdf"}},
    {"id":"42558","name":"Meningococcal group a, c, w135, y polysaccharide vaccine : List of nationally authorised medicinal products - PSUSA/00010602/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T16:55:00Z","last_updated_date":"2018-11-06T16:55:00Z","reference_number":"EMA/775347/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/meningococcal-group-c-w135-y-polysaccharide-vaccine-list-nationally-authorised-medicinal-products-psusa00010602201803_en.pdf"},
    {"id":"42559","name":"Latanoprost (products with paediatric indication): List of nationally authorised medicinal products - PSUSA/00001834/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T17:00:00Z","last_updated_date":"2018-11-06T17:00:00Z","reference_number":"EMA/775410/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-products-paediatric-indication-list-nationally-authorised-medicinal-products-psusa00001834201804_en.pdf"},
    {"id":"42579","name":"Pimecrolimus: List of nationally authorised medicinal products - PSUSA/00002411/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T10:39:00Z","last_updated_date":"2018-11-08T10:39:00Z","reference_number":"EMA/776462/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/pimecrolimus-list-nationally-authorised-medicinal-products-psusa00002411201803_en.pdf"},
    {"id":"42582","name":"Cabergoline: List of nationally authorised medicinal products - PSUSA/00000477/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T11:28:00Z","last_updated_date":"2018-11-08T11:28:00Z","reference_number":"EMA/776464/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cabergoline-list-nationally-authorised-medicinal-products-psusa00000477201803_en.pdf"},
    {"id":"42605","name":"Promestriene (cream and vaginal capsules): List of nationally authorised medicinal products - PSUSA/00009271/201803","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2018-11-09T11:51:00Z","last_updated_date":"2018-11-09T11:51:00Z","reference_number":"EMA/785057/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/promestriene-cream-and-vaginal-capsules-list-nationally-authorised-medicinal-products-psusa00009271201803_en.pdf"},
    {"id":"42606","name":"Dienogest / ethinylestradiol: List of nationall authorised medicinal products - PSUSA/00001057/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T11:52:00Z","last_updated_date":"2018-11-09T11:52:00Z","reference_number":"EMA/782577/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/dienogest-ethinylestradiol-list-nationall-authorised-medicinal-products-psusa00001057201803_en.pdf"},
    {"id":"42607","name":"Dobutamine: List of nationally authorised medicinal products - PSUSA/00001151/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T11:56:00Z","last_updated_date":"2018-11-09T11:56:00Z","reference_number":"EMA/783100/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/dobutamine-list-nationally-authorised-medicinal-products-psusa00001151201803_en.pdf"},
    {"id":"42608","name":"Citrulline malate: List of nationally authorised medicinal products - PSUSA/00010579/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T12:08:00Z","last_updated_date":"2018-11-09T12:08:00Z","reference_number":"EMA/784763/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/citrulline-malate-list-nationally-authorised-medicinal-products-psusa00010579201803_en.pdf"},
    {"id":"42609","name":"Influenza vaccine (surface antigen, inactivated, adjuvanted): List of nationally authorised medicinal products - PSUSA/00010300/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T12:18:00Z","last_updated_date":"2018-11-09T12:18:00Z","reference_number":"EMA/785153/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-adjuvanted-list-nationally-authorised-medicinal-products-psusa00010300201803_en.pdf"},
    {"id":"42645","name":"Influenza vaccine (surface antigen, inactivated): List of nationally authorised  medicinal products - PSUSA/00001744/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-12T12:35:00Z","last_updated_date":"2018-11-12T12:35:00Z","reference_number":"EMA/785193/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa00001744201803_en.pdf"},
    {"id":"42646","name":"Influenza vaccine (split virion, inactivated) (non centrally authorised products): List of nationally authorised medicinal products - PSUSA/00010298/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-12T12:40:00Z","last_updated_date":"2018-11-12T12:40:00Z","reference_number":"EMA/785069/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00010298201803_en.pdf"},
    {"id":"42647","name":"Influenza vaccine (split virion, inactivated, prepared in cell cultures): List of nationally authorised medicinal products - PSUSA/00010299/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-12T12:45:00Z","last_updated_date":"2018-11-12T12:45:00Z","reference_number":"EMA/785000/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-prepared-cell-cultures-list-nationally-authorised-medicinal-products-psusa00010299201803_en.pdf"},
    {"id":"42648","name":"Gemcitabine: List of nationally authorised medicinal products - PSUSA/00001519/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-12T12:55:00Z","last_updated_date":"2018-11-12T12:55:00Z","reference_number":"EMA/787363/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/gemcitabine-list-nationally-authorised-medicinal-products-psusa00001519201801_en.pdf"},
    {"id":"42649","name":"Gemcitabine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001519/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-12T12:55:00Z","last_updated_date":"2018-11-12T12:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001519201801_no.pdf"}},
    {"id":"42659","name":"Germanium (68Ge) chloride / gallium (68Ga) chloride: List of nationally authorised medicinal products - PSUSA/00010364/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-13T12:09:00Z","last_updated_date":"2018-11-13T12:09:00Z","reference_number":"EMA/792944/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/germanium-68ge-chloride-gallium-68ga-chloride-list-nationally-authorised-medicinal-products-psusa00010364201803_en.pdf"},
    {"id":"42678","name":"Levonorgestrel: List of nationally authorised medicinal products - PSUSA/00001856/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-14T15:45:00Z","last_updated_date":"2018-11-14T15:45:00Z","reference_number":"EMA/798648/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-list-nationally-authorised-medicinal-products-psusa00001856201712_en.pdf"},
    {"id":"42710","name":"Levonorgestrel: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001856/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T13:07:00Z","last_updated_date":"2018-11-16T13:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201712_no.pdf"}},
    {"id":"42721","name":"Aprotinin: List of nationally authorised medicinal products - PSUSA-00000230-201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-19T14:47:00Z","last_updated_date":"2018-11-19T14:47:00Z","reference_number":"EMA/800879/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/aprotinin-list-nationally-authorised-medicinal-products-psusa-00000230-201802_en.pdf"},
    {"id":"42722","name":"BCG (bacillus calmette-guérin) for immunotherapy: List of nationally authorised medicinal products - PSUSA/00000303/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-19T15:04:00Z","last_updated_date":"2018-11-19T15:04:00Z","reference_number":"EMA/800973/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/bcg-bacillus-calmette-guerin-immunotherapy-list-nationally-authorised-medicinal-products-psusa00000303201803_en.pdf"},
    {"id":"42723","name":"Ioxaglic acid: List of nationally authorised medicinal products - PSUSA/00001777/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-19T15:08:00Z","last_updated_date":"2018-11-19T15:08:00Z","reference_number":"EMA/801042/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ioxaglic-acid-list-nationally-authorised-medicinal-products-psusa00001777201802_en.pdf"},
    {"id":"42843","name":"Enoxaparin (except for biosimilars): List of nationally authorised products - PSUSA/00010560/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-27T18:12:00Z","last_updated_date":"2018-11-27T18:12:00Z","reference_number":"EMA/792944/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/enoxaparin-except-biosimilars-list-nationally-authorised-products-psusa00010560201804_en.pdf"},
    {"id":"42882","name":"Nomegestrol: List of nationally authorised medicinal products - PSUSA/00002181/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-29T10:15:00Z","last_updated_date":"2018-11-29T10:15:00Z","reference_number":"EMA/818133/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/nomegestrol-list-nationally-authorised-medicinal-products-psusa00002181201801_en.pdf"},
    {"id":"42883","name":"Nomegestrol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002181/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-11-29T10:15:00Z","last_updated_date":"2018-11-29T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nomegestrol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002181-201801_sv.pdf"}},
    {"id":"42931","name":"Cilazapril, cilazapril / hydrochlorothiazide: List of nationally authorised medicinal products -  PSUSA-00000749-201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-05T14:33:00Z","last_updated_date":"2018-12-05T14:33:00Z","reference_number":"EMA/831811/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa-00000749-201802_en.pdf"},
    {"id":"42932","name":"Cilazapril, cilazapril / hydrochlorothiazide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -  PSUSA-00000749-201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-05T14:44:00Z","last_updated_date":"2018-12-05T14:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000749-201802_sv.pdf"}},
    {"id":"42935","name":"Foscarnet: List of nationally authorised medicinal products - PSUSA/00001472/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-05T17:25:00Z","last_updated_date":"2018-12-05T17:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/foscarnet-list-nationally-authorised-medicinal-products-psusa00001472201803_en.pdf"},
    {"id":"42947","name":"Human anti-d immunoglobulin: List of nationally authorised medicinal products - PSUSA/00001614/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-06T12:45:00Z","last_updated_date":"2018-12-06T12:45:00Z","reference_number":"EMA/827769/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-anti-d-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00001614201803_en.pdf"},
    {"id":"42951","name":"Amlodipine besilate / ramipril: List of nationally authorised medicinal products - PSUSA/00000181/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-06T17:08:00Z","last_updated_date":"2018-12-06T17:08:00Z","reference_number":"EMA/837411/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-besilate-ramipril-list-nationally-authorised-medicinal-products-psusa00000181201803_en.pdf"},
    {"id":"42953","name":"Acarbose: List of nationally authorised medicinal products - PSUSA/0000017/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-07T11:14:00Z","last_updated_date":"2018-12-07T11:14:00Z","reference_number":"EMA/833306/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/acarbose-list-nationally-authorised-medicinal-products-psusa0000017201803_en.pdf"},
    {"id":"42954","name":"Dihydroergotoxine - List of nationally authorised medicinal products - PSUSA/0001079/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-07T11:17:00Z","last_updated_date":"2018-12-07T11:17:00Z","reference_number":"EMA/841222/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/dihydroergotoxine-list-nationally-authorised-medicinal-products-psusa0001079201804_en.pdf"},
    {"id":"42956","name":"Nebivolol: List of nationally authorised medicinal products - PSUSA/00002129/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-07T13:15:00Z","last_updated_date":"2018-12-07T13:15:00Z","reference_number":"EMA/844888/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/nebivolol-list-nationally-authorised-medicinal-products-psusa00002129201803_en.pdf"},
    {"id":"42957","name":"Ofloxacin (systemic use): List of nationally authorised medicinal products - PSUSA/00002203/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-07T13:27:00Z","last_updated_date":"2018-12-07T13:27:00Z","reference_number":"EMA/827980/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa00002203201804_en.pdf"},
    {"id":"42958","name":"Chlorprothixene: List of nationally authorised medicinal products - PSUSA/00000717/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-07T14:00:00Z","last_updated_date":"2018-12-07T14:00:00Z","reference_number":"EMA/844851/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorprothixene-list-nationally-authorised-medicinal-products-psusa00000717201803_en.pdf"},
    {"id":"42959","name":"Nitrendipine: List of nationally authorised medicinal products - PSUSA/00002171/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-07T14:04:00Z","last_updated_date":"2018-12-07T14:04:00Z","reference_number":"EMA/845666/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrendipine-list-nationally-authorised-medicinal-products-psusa00002171201803_en.pdf"},
    {"id":"42960","name":"Dihydroergotamine: List of nationally authorised medicinal products - PSUSA/00001075/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-07T14:26:00Z","last_updated_date":"2018-12-07T14:26:00Z","reference_number":"EMA/831851/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/dihydroergotamine-list-nationally-authorised-medicinal-products-psusa00001075201804_en.pdf"},
    {"id":"42966","name":"Metamizole: List of nationally authorised medicinal products - PSUSA/00001997/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-10T09:36:00Z","last_updated_date":"2018-12-10T09:36:00Z","reference_number":"EMA/851657/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/metamizole-list-nationally-authorised-medicinal-products-psusa00001997201804_en.pdf"},
    {"id":"42967","name":"Numeta: List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0017","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-10T10:30:00Z","last_updated_date":"2018-12-10T10:30:00Z","reference_number":"EMA/850681/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/numeta-list-nationally-authorised-medicinal-products-emeahnpsrs0017_en.pdf"},
    {"id":"42968","name":"Numeta: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/S/0017","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-10T10:27:00Z","last_updated_date":"2018-12-10T10:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_pl.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/numeta-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0017_is.pdf"}},
    {"id":"42980","name":"Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-11T11:31:00Z","last_updated_date":"2018-12-11T11:31:00Z","reference_number":"EMA/856410/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/epinephrine-mepivacaine-hydrochloride-mepivacaine-norepinephrine-mepivacaine-list-nationally-authorised-medicinal-products-psusa00001979201803_en.pdf"},
    {"id":"42983","name":"Methylphenobarbital: List of nationally authorised medicinal products - PSUSA/00002025/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-11T12:00:00Z","last_updated_date":"2018-12-11T12:00:00Z","reference_number":"EMA/856936/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenobarbital-list-nationally-authorised-medicinal-products-psusa00002025201803_en.pdf"},
    {"id":"42992","name":"Felodipine / ramipril: List of nationally authorised medicinal products - PSUSA/00001358/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-11T18:04:00Z","last_updated_date":"2018-12-11T18:04:00Z","reference_number":"EMA/857539/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/felodipine-ramipril-list-nationally-authorised-medicinal-products-psusa00001358201803_en.pdf"},
    {"id":"42993","name":"Ofloxacin (topical use): List of nationally authorised medicinal products - PSUSA/00002204/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-11T18:08:00Z","last_updated_date":"2018-12-11T18:08:00Z","reference_number":"EMA/857715/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-topical-use-list-nationally-authorised-medicinal-products-psusa00002204201804_en.pdf"},
    {"id":"43009","name":"Metformin: List of nationally authorised medicinal products - PSUSA/00002001/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T12:26:00Z","last_updated_date":"2018-12-12T12:26:00Z","reference_number":"EMA/846372/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/metformin-list-nationally-authorised-medicinal-products-psusa00002001201804_en.pdf"},
    {"id":"43010","name":"Magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate: List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0016","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T12:23:00Z","last_updated_date":"2018-12-12T12:23:00Z","reference_number":"EMA/854912/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-list-nationally-authorised-medicinal-products-emeahnpsrs0016_en.pdf"},
    {"id":"43011","name":"Magnesium sulphate heptahydrate, sodium sulphate anhydrous, potassium sulphate: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - EMEA/H/N/PSR/S/0016","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T13:02:00Z","last_updated_date":"2018-12-12T13:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/magnesium-sulphate-heptahydrate-sodium-sulphate-anhydrous-potassium-sulphate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sv.pdf"}},
    {"id":"43149","name":"Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T18:38:00Z","last_updated_date":"2018-12-18T18:38:00Z","reference_number":"EMA/874826/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-chloride-glutamic-acid-glutathione-histidine-lactobionic-acid-magnesium-chloride-mannitol-potassium-chloride-sodium-hydroxide-list-nationally-authorised-medicinal-products-psusa00010390201801_en.pdf"},
    {"id":"43168","name":"Enalapril: List of nationally authorised medicinal products - PSUSA/00001211/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T17:21:00Z","last_updated_date":"2018-12-19T17:21:00Z","reference_number":"EMA/880324/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/enalapril-list-nationally-authorised-medicinal-products-psusa00001211201803_en.pdf"},
    {"id":"43282","name":"Lorazepam: List of nationally authorised medicinal products - PSUSA/00001909/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:05:00Z","last_updated_date":"2019-01-10T12:05:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/lorazepam-list-nationally-authorised-medicinal-products-psusa00001909201801_en.pdf"},
    {"id":"43283","name":"Lorazepam: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001909/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:07:00Z","last_updated_date":"2019-01-10T12:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lorazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001909201801_sv.pdf"}},
    {"id":"43286","name":"BCG vaccine (freeze-dried): List of nationally authorised medicinal products - PSUSA/00000304/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:13:00Z","last_updated_date":"2019-01-10T12:13:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/bcg-vaccine-freeze-dried-list-nationally-authorised-medicinal-products-psusa00000304201803_en.pdf"},
    {"id":"43287","name":"BCG vaccine (freeze-dried): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation  - PSUSA/00000304/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:17:00Z","last_updated_date":"2019-01-10T12:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bcg-vaccine-freeze-dried-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000304201803_no.pdf"}},
    {"id":"43401","name":"Ivabradine / metoprolol: List of nationally authorised medicinal products - PSUSA/00010381/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T10:42:00Z","last_updated_date":"2019-01-18T10:42:00Z","reference_number":"EMA/6720/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivabradine-metoprolol-list-nationally-authorised-medicinal-products-psusa00010381201804_en.pdf"},
    {"id":"43412","name":"Ciprofloxacin (systemic use):  CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000775/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-21T10:22:00Z","last_updated_date":"2019-10-03T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ciprofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000775201801_no.pdf"}},
    {"id":"43413","name":"Ciprofloxacin (systemic use):  List of nationally authorised medicinal products - PSUSA/00000775/201801","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-21T10:23:00Z","last_updated_date":"2019-01-21T10:23:00Z","reference_number":"EMA/11314/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa00000775201801_en.pdf"},
    {"id":"43414","name":"Nitrofurantoin, nifurtoinol: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002174/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-21T10:27:00Z","last_updated_date":"2019-01-21T10:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/nitrofurantoin-nifurtoinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002174201802_no.pdf"}},
    {"id":"43415","name":"Nitrofurantoin, nifurtoinol: List of nationally authorised medicinal products - PSUSA/00002174/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-21T10:28:00Z","last_updated_date":"2019-01-21T10:28:00Z","reference_number":"EMA/11441/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrofurantoin-nifurtoinol-list-nationally-authorised-medicinal-products-psusa00002174201802_en.pdf"},
    {"id":"43441","name":"Fluorodopa (18F): List of nationally authorised medicinal products - PSUSA/00010002/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T13:30:00Z","last_updated_date":"2019-01-22T13:30:00Z","reference_number":"EMA/729548/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluorodopa-18f-list-nationally-authorised-medicinal-products-psusa00010002201803_en.pdf"},
    {"id":"43442","name":"Fluorodopa (18F): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010002/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T13:30:00Z","last_updated_date":"2019-01-22T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fluorodopa-18f-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010002201803_no.pdf"}},
    {"id":"43443","name":"Isotretinoin (oral formulations): List of nationally authorised medicinal products - PSUSA/00010488/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T15:23:00Z","last_updated_date":"2019-01-22T15:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa00010488201805_en.pdf"},
    {"id":"43444","name":"Isotretinoin (oral formulations): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010488/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T15:25:00Z","last_updated_date":"2019-01-22T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201805_no.pdf"}},
    {"id":"43445","name":"Fenspiride: List of nationally authorised medicinal products - PSUSA/00001368/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T15:31:00Z","last_updated_date":"2019-01-22T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenspiride-list-nationally-authorised-medicinal-products-psusa00001368201804_en.pdf"},
    {"id":"43446","name":"Fenspiride: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001368/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T15:32:00Z","last_updated_date":"2019-01-22T15:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fenspiride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001368201804_sv.pdf"}},
    {"id":"43449","name":"Acemetacin: List of nationally authorised medicinal products - PSUSA/00000026/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T16:20:00Z","last_updated_date":"2019-01-22T16:20:00Z","reference_number":"EMA/26458/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/acemetacin-list-nationally-authorised-medicinal-products-psusa00000026201805_en.pdf"},
    {"id":"43450","name":"Flunarizine: List of nationally authorised medicinal products - PSUSA/00001416/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T17:15:00Z","last_updated_date":"2019-01-22T17:15:00Z","reference_number":"EMA/27060/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/flunarizine-list-nationally-authorised-medicinal-products-psusa00001416201805_en.pdf"},
    {"id":"43451","name":"Tafluprost: List of nationally authorised medicinal products - PSUSA/00002843/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T09:00:00Z","last_updated_date":"2019-01-23T09:00:00Z","reference_number":"EMA/24821/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/tafluprost-list-nationally-authorised-medicinal-products-psusa00002843201804_en.pdf"},
    {"id":"43452","name":"Thiamphenicol: List of nationally authorised medicinal products  - PSUSA/00002925/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T09:10:00Z","last_updated_date":"2019-01-23T09:10:00Z","reference_number":"EMA/27151/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiamphenicol-list-nationally-authorised-medicinal-products-psusa00002925201805_en.pdf"},
    {"id":"43453","name":"Cidofovir: List of nationally authorised medicinal products - PSUSA/00010558/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T09:05:00Z","last_updated_date":"2019-01-23T09:05:00Z","reference_number":"EMA/613929/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/cidofovir-list-nationally-authorised-medicinal-products-psusa00010558201806_en.pdf"},
    {"id":"43455","name":"Acipimox: List of nationally authorised medicinal products - PSUSA/00000050/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T10:16:00Z","last_updated_date":"2019-01-23T10:16:00Z","reference_number":"EMA/30553/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/acipimox-list-nationally-authorised-medicinal-products-psusa00000050201805_en.pdf"},
    {"id":"43456","name":"Deoxycholic acid: List of nationally authorised medicinal products - PSUSA/00010525/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T10:20:00Z","last_updated_date":"2019-01-23T10:20:00Z","reference_number":"EMA/31536/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/deoxycholic-acid-list-nationally-authorised-medicinal-products-psusa00010525201804_en.pdf"},
    {"id":"43457","name":"Deoxycholic acid: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010525/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T10:21:00Z","last_updated_date":"2019-02-26T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010525-201804_no.pdf"}},
    {"id":"43458","name":"Terlipressin: List of nationally authorised medicinal products - PSUSA/00002905/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T10:33:00Z","last_updated_date":"2019-01-23T10:33:00Z","reference_number":"EMA/31815/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/terlipressin-list-nationally-authorised-medicinal-products-psusa00002905201804_en.pdf"},
    {"id":"43460","name":"Human hemin: List of nationally authorised medicinal products - PSUSA/00001629/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T10:55:00Z","last_updated_date":"2019-01-23T10:55:00Z","reference_number":"EMA/31860/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-hemin-list-nationally-authorised-medicinal-products-psusa00001629201805_en.pdf"},
    {"id":"43461","name":"5 fluorouracil / salicylic acid: List of nationally authorised medicinal products - PSUSA/00000008/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T11:02:00Z","last_updated_date":"2019-01-23T11:02:00Z","reference_number":"EMA/32147/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-salicylic-acid-list-nationally-authorised-medicinal-products-psusa00000008201805_en.pdf"},
    {"id":"43468","name":"Ozenoxacin: List of nationally authorised medicinal products - PSUSA/00010651/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T16:40:00Z","last_updated_date":"2019-01-23T16:40:00Z","reference_number":"EMA/31256/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ozenoxacin-list-nationally-authorised-medicinal-products-psusa00010651201805_en.pdf"},
    {"id":"43469","name":"Treprostinil: List of nationally authorised medicinal products - PSUSA/00003013/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-24T10:10:00Z","last_updated_date":"2019-01-24T10:10:00Z","reference_number":"EMA/36490/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/treprostinil-list-nationally-authorised-medicinal-products-psusa00003013201805_en.pdf"},
    {"id":"43470","name":"Nadroparin: List of nationally authorised medicinal products - PSUSA/00002104/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-24T10:12:00Z","last_updated_date":"2019-01-24T10:12:00Z","reference_number":"EMA/34222/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/nadroparin-list-nationally-authorised-medicinal-products-psusa00002104201803_en.pdf"},
    {"id":"43471","name":"Nadroparin: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002104/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-24T10:13:00Z","last_updated_date":"2019-01-24T10:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104201803_sv.pdf"}},
    {"id":"43482","name":"Patent blue V sodium: List of nationally authorised medicinal products - PSUSA/00002320/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-24T17:21:00Z","last_updated_date":"2019-01-24T17:21:00Z","reference_number":"EMA/28707/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/patent-blue-v-sodium-list-nationally-authorised-medicinal-products-psusa00002320201804_en.pdf"},
    {"id":"43484","name":"Ranitidine: List of nationally authorised medicinal products - PSUSA/00002610/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-25T14:49:00Z","last_updated_date":"2019-01-25T14:49:00Z","reference_number":"EMA/39027/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ranitidine-list-nationally-authorised-medicinal-products-psusa00002610201805_en.pdf"},
    {"id":"43485","name":"Oxaliplatin: List of nationally authorised medicinal products - PSUSA/00002229/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-25T14:54:00Z","last_updated_date":"2019-01-25T14:54:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxaliplatin-list-nationally-authorised-medicinal-products-psusa00002229201804_en.pdf"}    {"id":"43486","name":"Oxaliplatin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002229/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-25T14:57:00Z","last_updated_date":"2019-01-25T14:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002229201804_no.pdf"}},
    {"id":"43487","name":"Olodaterol / tiotropium: List of nationally authorised medicinal products - PSUSA/00010489/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-25T14:59:00Z","last_updated_date":"2019-01-25T14:59:00Z","reference_number":"EMA/39084/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodaterol-tiotropium-list-nationally-authorised-medicinal-products-psusa00010489201805_en.pdf"},
    {"id":"43514","name":"Ondansetron: List of nationally authorised medicinal products - PSUSA/00002217/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-28T14:30:00Z","last_updated_date":"2019-01-28T14:30:00Z","reference_number":"EMA/44220/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ondansetron-list-nationally-authorised-medicinal-products-psusa00002217201802_en.pdf"},
    {"id":"43515","name":"Allergen for therapy: Dermatophagoides pteronyssinus / Dermatophagoides farina: List of nationally authorised medicinal products - PSUSA/00010582/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-28T14:40:00Z","last_updated_date":"2019-01-28T14:40:00Z","reference_number":"EMA/44346/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-dermatophagoides-pteronyssinus-dermatophagoides-farina-list-nationally-authorised-medicinal-products-psusa-00010582-201803_en.pdf"},
    {"id":"43517","name":"Tenoxicam: List of nationally authorised medicinal products - PSUSA/00002893/201802","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-28T14:50:00Z","last_updated_date":"2019-01-28T14:50:00Z","reference_number":"EMA/44537/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/tenoxicam-list-nationally-authorised-medicinal-products-psusa00002893201802_en.pdf"},
    {"id":"43519","name":"Benzyl nicotinate / camphor / dimethyl sulfoxide / nonivamide / turpentine oil: List of nationally authorised medicinal products - PSUSA/00010584/20180","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-28T14:55:00Z","last_updated_date":"2019-01-28T14:55:00Z","reference_number":"EMA/45212/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzyl-nicotinate-camphor-dimethyl-sulfoxide-nonivamide-turpentine-oil-list-nationally-authorised-medicinal-products-psusa0001058420180_en.pdf"},
    {"id":"43546","name":"Chlorphenoxamine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010361/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-29T11:37:00Z","last_updated_date":"2019-01-29T11:37:00Z","reference_number":"EMA/28852/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorphenoxamine-hydrochloride-list-nationally-authorised-medicinal-products-psusa00010361201805_en.pdf"},
    {"id":"43547","name":"Praziquantel : List of nationally authorised medicinal products - PSUSA/00002503/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-29T15:58:00Z","last_updated_date":"2019-01-29T15:58:00Z","reference_number":"EMA/28805/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/praziquantel-list-nationally-authorised-medicinal-products-psusa00002503201804_en.pdf"},
    {"id":"43684","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-08T15:50:00Z","last_updated_date":"2019-02-08T15:50:00Z","reference_number":"EMA/92830/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288201805_en.pdf"},
    {"id":"43685","name":"Pamidronate: List of nationally authorised medicinal products - PSUSA/00002269/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-08T16:00:00Z","last_updated_date":"2019-02-08T16:00:00Z","reference_number":"EMA/92938/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/pamidronate-list-nationally-authorised-medicinal-products-psusa00002269201805_en.pdf"},
    {"id":"43782","name":"Pholcodine / biclotymol / chlorphenamine maleate : List of nationally authorised medicinal products - PSUSA/00010437201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-18T17:36:00Z","last_updated_date":"2019-02-18T17:36:00Z","reference_number":"EMA/47500/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/pholcodine-biclotymol-chlorphenamine-maleate-list-nationally-authorised-medicinal-products-psusa00010437201804_en.pdf"},
    {"id":"43783","name":"Pelargonium sidoides dc and/or pelargonium reniforme curt. / radix: List of nationally authorised medicinal products - PSUSA/00002329/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-18T17:44:00Z","last_updated_date":"2019-02-18T17:44:00Z","reference_number":"EMA/47773/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/pelargonium-sidoides-dc-andor-pelargonium-reniforme-curt-radix-list-nationally-authorised-medicinal-products-psusa00002329201806_en.pdf"},
    {"id":"43784","name":"Nortriptyline: List of nationally authorised medicinal products - PSUSA/00002192/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-18T18:05:00Z","last_updated_date":"2019-02-18T18:05:00Z","reference_number":"EMA/817493/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/nortriptyline-list-nationally-authorised-medicinal-products-psusa00002192201803_en.pdf"},
    {"id":"43785","name":"Nortriptyline: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementatio - PSUSA/00002192/201803","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-18T17:13:00Z","last_updated_date":"2019-02-18T17:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00002192201803_no.pdf"}},
    {"id":"43799","name":"Oxycodone: List of nationally authorised medicinal products - PSUSA/00002254/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-19T13:58:00Z","last_updated_date":"2019-02-19T13:58:00Z","reference_number":"EMA/817240/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-list-nationally-authorised-medicinal-products-psusa00002254201804_en.pdf"},
    {"id":"43800","name":"Oxycodone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002254/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-19T14:08:00Z","last_updated_date":"2019-02-19T14:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254201804_no.pdf"}},
    {"id":"43807","name":"Aciclovir: List of nationally authorised medicinal products - PSUSA/00000048/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-19T16:45:00Z","last_updated_date":"2019-02-19T16:45:00Z","reference_number":"EMA/122670/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/aciclovir-list-nationally-authorised-medicinal-products-psusa00000048201806_en.pdf"},
    {"id":"43837","name":"Urapidil: List of nationally authorised medicinal products - PSUSA/00003078/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T15:29:00Z","last_updated_date":"2019-02-20T15:29:00Z","reference_number":"EMA/128069/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/urapidil-list-nationally-authorised-medicinal-products-psusa00003078201807_en.pdf"},
    {"id":"43838","name":"Rizatriptan: List of nationally authorised medicinal products - PSUSA/00002655/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T15:33:00Z","last_updated_date":"2019-02-20T15:33:00Z","reference_number":"EMA/126253/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/rizatriptan-list-nationally-authorised-medicinal-products-psusa00002655201806_en.pdf"},
    {"id":"43839","name":"Pitavastatin: List of nationally authorised medicinal products -  PSUSA/00010502/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T15:35:00Z","last_updated_date":"2019-02-20T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/pitavastatin-list-nationally-authorised-medicinal-products-psusa00010502201807_en.pdf"},
    {"id":"43841","name":"Phenylpropanolamine: List of nationally authorised medicinal products - PSUSA/00010483/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T15:37:00Z","last_updated_date":"2019-02-20T15:37:00Z","reference_number":"EMA/126123/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylpropanolamine-list-nationally-authorised-medicinal-products-psusa00010483201806_en.pdf"},
    {"id":"43842","name":"Tiagabine: List of nationally authorised medicinal products - PSUSA/00002942/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T15:42:00Z","last_updated_date":"2019-02-20T15:42:00Z","reference_number":"EMA/126150/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiagabine-list-nationally-authorised-medicinal-products-psusa00002942201806_en.pdf"},
    {"id":"43843","name":"Cefepime: List of nationally authorised medicinal products - PSUSA/00000593/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T15:44:00Z","last_updated_date":"2019-02-20T15:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefepime-list-nationally-authorised-medicinal-products-psusa00000593201806_en.pdf"},
    {"id":"43844","name":"Nilutamide: List of nationally authorised medicinal products - PSUSA/00002163/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T15:52:00Z","last_updated_date":"2019-02-20T15:52:00Z","reference_number":"EMA/132837/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/nilutamide-list-nationally-authorised-medicinal-products-psusa00002163201807_en.pdf"},
    {"id":"43845","name":"Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/2018","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T15:55:00Z","last_updated_date":"2019-02-20T15:55:00Z","reference_number":"EMA/130599/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-list-nationally-authorised-medicinal-products-psusa000103902018_en.pdf"},
    {"id":"43846","name":"Levonorgestrel / ethinylestradiol, ethinylestradiol (combination pack): List of nationally authorised medicinal products - PSUSA/00010442/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T15:59:00Z","last_updated_date":"2019-02-20T15:59:00Z","reference_number":"EMA/132912/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-list-nationally-authorised-medicinal-products-psusa00010442201807_en.pdf"},
    {"id":"43847","name":"Glibenclamide / metformin hydrochloride: List of nationally authorised medicinal products - PSUSA/00002002/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T16:05:00Z","last_updated_date":"2019-02-20T16:05:00Z","reference_number":"EMA/132972/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/glibenclamide-metformin-hydrochloride-list-nationally-authorised-medicinal-products-psusa00002002201806_en.pdf"},
    {"id":"43850","name":"Fosinopril, fosinopril / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA/00010463/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T17:00:00Z","last_updated_date":"2019-02-20T17:00:00Z","reference_number":"EMA/123602/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosinopril-fosinopril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00010463201807_en.pdf"},
    {"id":"43852","name":"Dexchlorpheniramine: List of nationally authorised medicinal products - PSUSA/00000989/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T17:00:00Z","last_updated_date":"2019-02-20T17:00:00Z","reference_number":"EMA/123741/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexchlorpheniramine-list-nationally-authorised-medicinal-products-psusa00000989201806_en.pdf"},
    {"id":"43854","name":"Nimesulide (systemic formulations): List of nationally authorised medicinal products - PSUSA/00009236/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T17:00:00Z","last_updated_date":"2019-02-20T17:00:00Z","reference_number":"EMA/128842/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimesulide-systemic-formulations-list-nationally-authorised-medicinal-products-psusa00009236201806_en.pdf"},
    {"id":"43856","name":"Pipobroman: List of nationally authorised medicinal products - PSUSA/00002427/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T17:00:00Z","last_updated_date":"2019-02-20T17:00:00Z","reference_number":"EMA/130309/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/pipobroman-list-nationally-authorised-medicinal-products-psusa00002427201806_en.pdf"},
    {"id":"43857","name":"Calcitonin salmon, synthetic analogue of eel calcitonin: List of nationally authorised medicinal products - PSUSA/00000494/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T17:16:00Z","last_updated_date":"2019-02-20T17:16:00Z","reference_number":"EMA/118356/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcitonin-salmon-synthetic-analogue-eel-calcitonin-list-nationally-authorised-medicinal-products-psusa00000494201806_en.pdf"},
    {"id":"43858","name":"Solifenacin / tamsulosin: List of nationally authorised medicinal products - PSUSA/00010285/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T17:20:00Z","last_updated_date":"2019-02-20T17:20:00Z","reference_number":"EMA/118055/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/solifenacin-tamsulosin-list-nationally-authorised-medicinal-products-psusa00010285201807_en.pdf"},
    {"id":"43861","name":"Misoprostol (gastrointestinal indication): List of nationally authorised medicinal products - PSUSA/00010291/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-02-21T10:44:00Z","last_updated_date":"2019-02-21T10:44:00Z","reference_number":"EMA/125319/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gastrointestinal-indication-list-nationally-authorised-medicinal-products-psusa00010291201806_en.pdf"},
    {"id":"43977","name":"Loperamide, loperamide / simeticone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010665/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-13T13:40:00Z","last_updated_date":"2019-03-13T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665201805_no.pdf"}},
    {"id":"44022","name":"Loperamide, loperamide / simeticone: List of nationally authorised medicinal products - PSUSA/00010665/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-13T13:40:00Z","last_updated_date":"2019-03-13T13:40:00Z","reference_number":"EMA/172877/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/loperamide-loperamide-simeticone-list-nationally-authorised-medicinal-products-psusa00010665201805_en.pdf"},
    {"id":"44028","name":"Milnacipran: List of nationally authorised medicinal products - PSUSA/00002063/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-14T11:18:00Z","last_updated_date":"2019-03-14T11:18:00Z","reference_number":"EMA/171540/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/milnacipran-list-nationally-authorised-medicinal-products-psusa00002063201804_en.pdf"},
    {"id":"44029","name":"Milnacipran: CMDh Scientific conclusions, amendments to product information and implementation timetable - PSUSA/00002063/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-14T11:21:00Z","last_updated_date":"2019-03-14T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/milnacipran-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002063-201804_sv.pdf"}},
    {"id":"44036","name":"Nitrous oxide, nitrous oxide / oxygen: List of nationally authorised medicinal products - PSUSA/00010572/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-14T15:38:00Z","last_updated_date":"2019-03-14T15:38:00Z","reference_number":"EMA/173529/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-list-nationally-authorised-medicinal-products-psusa00010572201806_en.pdf"},
    {"id":"44037","name":"Nitrous oxide, nitrous oxide / oxygen: CMDh Scientific conclusions, amendments to product information and implementation timetable - PSUSA/00010572/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-14T15:45:00Z","last_updated_date":"2019-03-14T15:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_cs.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00010572201806_no.pdf"}},
    {"id":"44041","name":"Miglitol: List of nationally authorised medicinal products - PSUSA/00002061/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-15T10:18:00Z","last_updated_date":"2019-03-15T10:18:00Z","reference_number":"EMA/177493/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/miglitol-list-nationally-authorised-medicinal-products-psusa00002061201807_en.pdf"},
    {"id":"44047","name":"Inosine dimepranol acedoben: List of nationally authorised medicinal products - PSUSA/00010425/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-18T09:32:00Z","last_updated_date":"2019-03-18T09:32:00Z","reference_number":"EMA/179176/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/inosine-dimepranol-acedoben-list-nationally-authorised-medicinal-products-psusa00010425201808_en.pdf"},
    {"id":"44048","name":"Poliovirus type 1 / poliovirus type 3 (oral, live, attenuated) vaccine - List of nationally authorised medicinal products - PSUSA/00010642/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-18T09:36:00Z","last_updated_date":"2019-03-18T09:36:00Z","reference_number":"EMA/176832/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/poliovirus-type-1-poliovirus-type-3-oral-live-attenuated-vaccine-list-nationally-authorised-medicinal-products-psusa00010642201807_en.pdf"},
    {"id":"44052","name":"Fentanyl (transdermal patches, solution for injection - nationally authorised product only): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001370/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-19T14:24:00Z","last_updated_date":"2019-03-19T14:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_no.pdf"}},
    {"id":"44053","name":"Fentanyl (transdermal patches, solution for injection - nationally authorised product only): List of nationally authorised medicinal products - PSUSA/00001370/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-19T14:28:00Z","last_updated_date":"2019-03-19T14:28:00Z","reference_number":"EMA/170921/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-list-nationally-authorised-medicinal-products-psusa00001370201804_en.pdf"},
    {"id":"44067","name":"Domperidone: List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0015","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-20T08:55:00Z","last_updated_date":"2019-03-20T08:55:00Z","reference_number":"EMA/185142/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/domperidone-list-nationally-authorised-medicinal-products-emeahnpsrj0015_en.pdf"},
    {"id":"44068","name":"Domperidone: CMDh Scientific conclusions and grounds for variation, conditions and timetable for the implementation - EMEA/H/N/PSR/J/0015","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-20T08:55:00Z","last_updated_date":"2019-03-20T08:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/domperidone-cmdh-scientific-conclusions-and-grounds-variation-conditions-and-timetable-implementation-emeahnpsrj0015_sv.pdf"}},
    {"id":"44069","name":"Amlodipine / rosuvastatin: List of nationally authorised medicinal products - PSUSA/00010434/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-20T09:35:00Z","last_updated_date":"2019-03-20T09:35:00Z","reference_number":"EMA/181063/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-rosuvastatin-list-nationally-authorised-medicinal-products-psusa00010434201807_en.pdf"},
    {"id":"44106","name":"Paracetamol / tramadol: List of nationally authorised medicinal products - PSUSA/00002310/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-26T15:15:00Z","last_updated_date":"2019-03-26T15:15:00Z","reference_number":"EMA/193293/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-tramadol-list-nationally-authorised-medicinal-products-psusa00002310201808_en.pdf"},
    {"id":"44107","name":"Magnesium sulphate / sodium sulphate / potassium sulphate: List of nationally authorised medicinal products - PSUSA/00010239/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-26T15:15:00Z","last_updated_date":"2019-03-26T15:15:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulphate-sodium-sulphate-potassium-sulphate-list-nationally-authorised-medicinal-products-psusa00010239201808_en.pdf"},
    {"id":"44108","name":"Landiolol: List of nationally authorised medicinal products - PSUSA/00010570/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-26T15:15:00Z","last_updated_date":"2019-03-26T15:15:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/landiolol-list-nationally-authorised-medicinal-products-psusa00010570201808_en.pdf"},
    {"id":"44123","name":"Poliovirus type 1 / poliovirus type 3 (oral, live, attenuated) vaccine: List of nationally authorised medicinal products - PSUSA/00010339/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T16:00:00Z","last_updated_date":"2019-03-27T16:00:00Z","reference_number":"EMA/196332/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/poliovirus-type-1-poliovirus-type-3-oral-live-attenuated-vaccine-list-nationally-authorised-medicinal-products-psusa00010339201807_en.pdf"},
    {"id":"44174","name":"Metyrapone: List of nationally authorised medicinal products - PSUSA/00002046/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-05T09:18:00Z","last_updated_date":"2019-04-05T09:18:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/metyrapone-list-nationally-authorised-medicinal-products-psusa00002046201806_en.pdf"},
    {"id":"44175","name":"Metyrapone: CMDh scientific conclusions, amendments to product information and implementation timetable - PSUSA/00002046/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-05T09:22:00Z","last_updated_date":"2019-04-05T09:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/metyrapone-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa-00002046-201806_no.pdf"}},
    {"id":"44180","name":"Paracetamol/pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00002307/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-05T15:09:00Z","last_updated_date":"2019-04-05T15:09:00Z","reference_number":"EMA/214710/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamolpseudoephedrine-list-nationally-authorised-medicinal-products-psusa00002307201806_en.pdf"},
    {"id":"44209","name":"Ibuprofen / pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00001711/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-10T14:40:00Z","last_updated_date":"2019-04-10T14:40:00Z","reference_number":"EMA/129954/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00001711201807_en.pdf"},
    {"id":"44210","name":"Ibuprofen / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001711/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-10T14:40:00Z","last_updated_date":"2019-04-10T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201807_no.pdf"}},
    {"id":"44211","name":"Paracetamol / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002307/201806","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-04-10T15:33:00Z","last_updated_date":"2019-04-17T12:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002307-201806_sv.pdf"}},
    {"id":"44229","name":"Tianeptine: List of nationally authorised medicinal products - PSUSA/00002943/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T09:54:00Z","last_updated_date":"2019-04-12T09:54:00Z","reference_number":"EMA/224018/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/tianeptine-list-nationally-authorised-medicinal-products-psusa00002943201806_en.pdf"},
    {"id":"44230","name":"Tianeptine: CMDh scientific conclusions, amendments to product information and implementation timetable - PSUSA/00002943/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T10:03:00Z","last_updated_date":"2019-04-12T10:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tianeptine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00002943201806_sv.pdf"}},
    {"id":"44252","name":"Pseudoephedrine, acetylsalicylic acid / pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00010667/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T13:33:00Z","last_updated_date":"2019-04-12T13:33:00Z","reference_number":"EMA/223046/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00010667201806_en.pdf"},
    {"id":"44253","name":"Pseudoephedrine, acetylsalicylic acid / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010667/201806","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T13:35:00Z","last_updated_date":"2019-04-12T13:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010667201806_no.pdf"}},
    {"id":"44266","name":"Ceftriaxone: List of nationally authorised medicinal products - PSUSA/00000613/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-15T15:34:00Z","last_updated_date":"2019-04-15T15:34:00Z","reference_number":"EMA/226016/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftriaxone-list-nationally-authorised-medicinal-products-psusa00000613201805_en.pdf"},
    {"id":"44267","name":"Ceftriaxone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -  PSUSA/00000613/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-15T15:38:00Z","last_updated_date":"2019-04-15T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000613201805_no.pdf"}},
    {"id":"44269","name":"Cefuroxime sodium (for intracameral use): List of nationally authorised medicinal products - PSUSA/00010206/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-15T17:03:00Z","last_updated_date":"2019-04-15T17:03:00Z","reference_number":"EMA/226028/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-sodium-intracameral-use-list-nationally-authorised-medicinal-products-psusa00010206201805_en.pdf"},
    {"id":"44270","name":"Cefuroxime sodium (for intracameral use): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010206/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-15T17:05:00Z","last_updated_date":"2019-04-15T17:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cefuroxime-sodium-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010206201805_no.pdf"}},
    {"id":"44291","name":"Rilmenidine: List of nationally authorised medicinal products - PSUSA-00002643-201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-17T13:49:00Z","last_updated_date":"2019-04-17T13:49:00Z","reference_number":"EMA/224876/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/rilmenidine-list-nationally-authorised-medicinal-products-psusa-00002643-201808_en.pdf"},
    {"id":"44292","name":"Ciclesonide: List of nationally authorised medicinal products -  PSUSA-00000742-201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-17T13:55:00Z","last_updated_date":"2019-04-17T13:55:00Z","reference_number":"EMA/224952/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciclesonide-list-nationally-authorised-medicinal-products-psusa-00000742-201808_en.pdf"},
    {"id":"44294","name":"Aztreonam: List of nationally authorised medicinal products - PSUSA/00010178/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-17T14:03:00Z","last_updated_date":"2019-04-17T14:03:00Z","reference_number":"PSUSA/00010178/201808","document_url":"https://www.ema.europa.eu/en/documents/psusa/aztreonam-list-nationally-authorised-medicinal-products-psusa00010178201808_en.pdf"},
    {"id":"44317","name":"Paracetamol (IV formulation): List of nationally authorised medicinal products - PSUSA/00002311/201805","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-04-23T11:22:00Z","last_updated_date":"2019-04-23T11:22:00Z","reference_number":"EMA/224487/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-iv-formulation-list-nationally-authorised-medicinal-products-psusa00002311201805_en.pdf"},
    {"id":"44318","name":"Paracetamol (IV formulation): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002311/201805","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-04-23T11:25:00Z","last_updated_date":"2019-04-23T11:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_bg.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311201805_no.pdf"}},
    {"id":"44319","name":"Fluocinolone acetonide (intravitreal implant in applicator): List of nationally authorised medicinal products - PSUSA/00010224/201808","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-04-23T12:40:00Z","last_updated_date":"2019-04-23T12:40:00Z","reference_number":"EMA/228164/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-intravitreal-implant-applicator-list-nationally-authorised-medicinal-products-psusa00010224201808_en.pdf"},
    {"id":"44347","name":"Dexamfetamine: List of nationally authorised medicinal products - PSUSA/00000986/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-25T14:55:00Z","last_updated_date":"2019-04-25T14:55:00Z","reference_number":"EMA/218030/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-psusa00000986201809_en.pdf"},
    {"id":"44352","name":"Finasteride: List of nationally authorised medicinal products - PSUSA/00001392/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-04-25T16:00:00Z","last_updated_date":"2019-04-25T16:00:00Z","reference_number":"EMA/241954/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392201808_en.pdf"},
    {"id":"44397","name":"Daunorubicin: List of nationally authorised medicinal products - PSUSA/0000936/201806","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-04-30T10:38:00Z","last_updated_date":"2019-04-30T10:38:00Z","reference_number":"EMA/246431/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/daunorubicin-list-nationally-authorised-medicinal-products-psusa0000936201806_en.pdf"},
    {"id":"44398","name":"Daunorubicin: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/0000936/201806","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-04-30T10:41:00Z","last_updated_date":"2019-04-30T10:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/daunorubicin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000936201806_no.pdf"}},
    {"id":"44414","name":"Manidipine: List of nationally authorised products - PSUSA/00001932/201806","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-05-02T11:54:00Z","last_updated_date":"2019-05-02T11:54:00Z","reference_number":"EMA/249437/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/manidipine-list-nationally-authorised-products-psusa00001932201806_en.pdf"},
    {"id":"44415","name":"Manidipine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001932/201806","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-05-02T11:56:00Z","last_updated_date":"2019-05-02T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/manidipine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001932201806_no.pdf"}},
    {"id":"44416","name":"Rabbit anti-humanT-lymphocyte immunoglobulin: List of nationally authorised medicinal products - PSUSA/00010252/201806","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-05-02T12:03:00Z","last_updated_date":"2019-05-02T12:03:00Z","reference_number":"EMA/249447/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00010252201806_en.pdf"},
    {"id":"44417","name":"Rabbit anti-humanT-lymphocyte immunoglobulin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010252/201806","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-05-02T13:03:00Z","last_updated_date":"2019-05-02T13:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_ro.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_fi.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/rabbit-anti-humant-lymphocyte-immunoglobulin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010252201806_no.pdf"}},
    {"id":"44436","name":"Ebastine: List of nationally authorised medicinal products - PSUSA/00001191/201805","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-05-06T14:48:00Z","last_updated_date":"2019-05-06T14:48:00Z","reference_number":"EMA/252546/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ebastine-list-nationally-authorised-medicinal-products-psusa00001191201805_en.pdf"},
    {"id":"44437","name":"Ebastine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001191/201805","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-05-06T14:49:00Z","last_updated_date":"2019-05-06T14:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ebastine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001191201805_no.pdf"}},
    {"id":"44455","name":"Alprostadil (patency of the ductus arteriosus): List of nationally authorised medicinal products - PSUSA/00010021/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-08T10:30:00Z","last_updated_date":"2019-05-08T10:30:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprostadil-patency-ductus-arteriosus-list-nationally-authorised-medicinal-products-psusa00010021201807_en.pdf"},
    {"id":"44456","name":"Alprostadil (patency of the ductus arteriosus): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010021/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-08T10:30:00Z","last_updated_date":"2019-05-08T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/alprostadil-patency-ductus-arteriosus-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010021201807_no.pdf"}},
    {"id":"44457","name":"Montelukast: List of nationally authorised medicinal products - PSUSA/00002087/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-08T10:49:00Z","last_updated_date":"2019-05-08T10:49:00Z","reference_number":"EMA/257680/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/montelukast-list-nationally-authorised-medicinal-products-psusa00002087201807_en.pdf"},
    {"id":"44458","name":"Montelukast: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002087/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-08T10:50:00Z","last_updated_date":"2019-05-08T10:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/montelukast-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002087201807_no.pdf"}},
    {"id":"44474","name":"Colchicine: List of nationally authorised medicinal products - PSUSA/00000858/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-10T11:00:00Z","last_updated_date":"2019-05-10T11:00:00Z","reference_number":"EMA/257224/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/colchicine-list-nationally-authorised-medicinal-products-psusa00000858201807_en.pdf"},
    {"id":"44475","name":"Colchicine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000858/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-10T11:35:00Z","last_updated_date":"2019-05-10T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000858201807_sv.pdf"}},
    {"id":"44476","name":"Adapalene: List of nationally authorised medicinal products - PSUSA/0058/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-10T11:40:00Z","last_updated_date":"2019-05-10T11:40:00Z","reference_number":"EMA/257441/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/adapalene-list-nationally-authorised-medicinal-products-psusa-0058-201807_en.pdf"},
    {"id":"44477","name":"Adapalene: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/0058/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-10T11:45:00Z","last_updated_date":"2019-05-10T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/adapalene-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0058-201807_no.pdf"}},
    {"id":"44545","name":"Opium: List of nationally authorised medicinal products - PSUSA/00010670/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-21T11:14:00Z","last_updated_date":"2019-05-21T11:14:00Z","reference_number":"EMA/278257/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/opium-list-nationally-authorised-medicinal-products-psusa00010670201808_en.pdf"},
    {"id":"44546","name":"Dienogest / estradiol (contraception indication): List of nationally authorised medicinal products - PSUSA/00010444/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-21T11:36:00Z","last_updated_date":"2019-05-21T11:36:00Z","reference_number":"EMA/278136/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/dienogest-estradiol-contraception-indication-list-nationally-authorised-medicinal-products-psusa00010444201809_en.pdf"},
    {"id":"44547","name":"Bismuth subcitrate potassium / metronidazole / tetracycline: List of nationally authorised medicinal products - PSUSA/00010199/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-21T11:40:00Z","last_updated_date":"2019-05-21T11:40:00Z","reference_number":"EMA/277332/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-list-nationally-authorised-medicinal-products-psusa00010199201805_en.pdf"},
    {"id":"44549","name":"Meropenem: List of nationally authorised medicinal products - PSUSA/00001989/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-21T11:55:00Z","last_updated_date":"2019-05-21T11:55:00Z","reference_number":"EMA/277237/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/meropenem-list-nationally-authorised-medicinal-products-psusa00001989201808_en.pdf"},
    {"id":"44550","name":"Alfentanil: List of nationally authorised medicinal products - PSUSA/00000082/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-21T11:58:00Z","last_updated_date":"2019-05-21T11:58:00Z","reference_number":"EMA/278353/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/alfentanil-list-nationally-authorised-medicinal-products-psusa00000082201809_en.pdf"},
    {"id":"44552","name":"Erythromycin / isotretinoin, isotretinoin (topical formulations): List of nationally authorised medicinal products - PSUSA/00010487/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-21T12:15:00Z","last_updated_date":"2019-05-21T12:15:00Z","reference_number":"EMA/280152/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/erythromycin-isotretinoin-isotretinoin-topical-formulations-list-nationally-authorised-medicinal-products-psusa00010487201808_en.pdf"},
    {"id":"44553","name":"Tiapride: List of nationally authorised medicinal products - PSUSA/00002944/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-21T13:28:00Z","last_updated_date":"2019-05-21T13:28:00Z","reference_number":"EMA/278405/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiapride-list-nationally-authorised-medicinal-products-psusa00002944201807_en.pdf"},
    {"id":"44556","name":"Ivermectin: List of nationally authorised medicinal products - PSUSA/00010376/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-22T09:25:00Z","last_updated_date":"2019-05-22T09:25:00Z","reference_number":"EMA/281903/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-list-nationally-authorised-medicinal-products-psusa00010376201804_en.pdf"},
    {"id":"44557","name":"Ivermectin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010376/201804","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-22T09:27:00Z","last_updated_date":"2019-05-22T09:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ivermectin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010376201804_no.pdf"}},
    {"id":"44558","name":"Misoprostol: List of nationally authorised medicinal products - PSUSA/00010353/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-22T10:00:00Z","last_updated_date":"2019-05-22T10:00:00Z","reference_number":"EMA/282073/20199","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-list-nationally-authorised-medicinal-products-psusa00010353201805_en.pdf"}    {"id":"44559","name":"Misoprostol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010353/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-22T10:02:00Z","last_updated_date":"2019-05-22T10:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/misoprostol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010353201805_no.pdf"}},
    {"id":"44565","name":"Clenbuterol: List of nationally authorised medicinal products - PSUSA/00000794/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-22T14:45:00Z","last_updated_date":"2019-05-22T14:45:00Z","reference_number":"EMA/281368/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/clenbuterol-list-nationally-authorised-medicinal-products-psusa00000794201809_en.pdf"},
    {"id":"44566","name":"Asparaginase, crisantaspase, pegaspargase (nationally authorised products): List of nationally authorised medicinal products - PSUSA/00003161/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-22T14:30:00Z","last_updated_date":"2019-05-22T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/asparaginase-crisantaspase-pegaspargase-nationally-authorised-products-list-nationally-authorised-medicinal-products-psusa00003161201808_en.pdf"},
    {"id":"44568","name":"Sodium oxybate (intravenous use): List of nationally authorised medicinal products - PSUSA/00010613/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-22T14:45:00Z","last_updated_date":"2019-05-22T14:45:00Z","reference_number":"EMA/281366/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-oxybate-intravenous-use-list-nationally-authorised-medicinal-products-psusa00010613201810_en.pdf"},
    {"id":"44583","name":"Acetylcysteine: List of nationally authorised medicinal products - PSUSA/00000034/201809","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-05-24T09:18:00Z","last_updated_date":"2019-05-24T09:18:00Z","reference_number":"EMA/280811/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylcysteine-list-nationally-authorised-medicinal-products-psusa00000034201809_en.pdf"},
    {"id":"44584","name":"Diclofenac / omeprazole: List of nationally authorised medicinal products - PSUSA/00010461/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-24T09:22:00Z","last_updated_date":"2019-05-24T09:22:00Z","reference_number":"EMA/286693/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-omeprazole-list-nationally-authorised-medicinal-products-psusa00010461201809_en.pdf"},
    {"id":"44599","name":"Everolimus (indicated for rejection of transplanted organs) : List of nationally authorised medicinal products - PSUSA/00010269/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-27T17:37:00Z","last_updated_date":"2019-05-27T17:37:00Z","reference_number":"EMA/281903/20199","document_url":"https://www.ema.europa.eu/en/documents/psusa/everolimus-indicated-rejection-transplanted-organs-list-nationally-authorised-medicinal-products-psusa00010269201807_en.pdf"},
    {"id":"44600","name":"Everolimus (indicated for rejection of transplanted organs) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010269/201807","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-27T17:43:00Z","last_updated_date":"2019-06-17T12:21:00Z","reference_number":"EMA/281903/20199","document_url":"https://www.ema.europa.eu/en/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/everolimus-indicated-rejection-transplanted-organs-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010269201807_no.pdf"}},
    {"id":"44631","name":"Mirtazapine: List of nationally authorised medicinal products - PSUSA/00002068/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-05-30T11:49:00Z","last_updated_date":"2019-05-30T11:49:00Z","reference_number":"EMA/296287/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/mirtazapine-list-nationally-authorised-medicinal-products-psusa00002068201808_en.pdf"},
    {"id":"44672","name":"Atorvastatin/ezetimibe: List of nationally authorised products - PSUSA/00010385/201807","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-06-06T17:04:00Z","last_updated_date":"2019-06-06T17:04:00Z","reference_number":"EMA/267129/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/atorvastatinezetimibe-list-nationally-authorised-products-psusa00010385201807_en.pdf"},
    {"id":"44673","name":"Atorvastatin/ezetimibe: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation- PSUSA/00010385/201807","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-06-06T17:07:00Z","last_updated_date":"2019-06-06T17:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/atorvastatinezetimibe-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010385201807_no.pdf"}},
    {"id":"44731","name":"Piretanide: List of nationally authorised medicinal products - PSUSA/00002433/201810","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-06-18T09:11:00Z","last_updated_date":"2019-06-18T09:11:00Z","reference_number":"EMA/344210/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/piretanide-list-nationally-authorised-medicinal-products-psusa00002433201810_en.pdf"},
    {"id":"44742","name":"Clindamycin: List of nationally authorised medicinal products - PSUSA/00000795/201810","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-06-18T19:07:00Z","last_updated_date":"2019-06-18T19:07:00Z","reference_number":"EMA/347250/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/clindamycin-list-nationally-authorised-medicinal-products-psusa00000795201810_en.pdf"},
    {"id":"44756","name":"Benzydamine: List of nationally authorised medicinal products - PSUSA/00000375/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T15:30:00Z","last_updated_date":"2019-06-19T15:30:00Z","reference_number":"EMA/342627/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzydamine-list-nationally-authorised-medicinal-products-psusa00000375201810_en.pdf"},
    {"id":"44757","name":"Ceftazidime: List of nationally authorised medicinal products - PSUSA/00000608/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T15:30:00Z","last_updated_date":"2019-06-19T15:30:00Z","reference_number":"EMA/348220/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftazidime-list-nationally-authorised-medicinal-products-psusa00000608201810_en.pdf"},
    {"id":"44758","name":"Azelastine / fluticasone: List of nationally authorised medicinal products - PSUSA/00010067/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T15:30:00Z","last_updated_date":"2019-06-19T15:30:00Z","reference_number":"EMA/348238/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/azelastine-fluticasone-list-nationally-authorised-medicinal-products-psusa00010067201810_en.pdf"},
    {"id":"44774","name":"Methoxyflurane: List of nationally authorised medicinal products - PSUSA/00010484/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-06-20T16:30:00Z","last_updated_date":"2019-06-20T16:30:00Z","reference_number":"EMA/346457/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa00010484201811_en.pdf"},
    {"id":"44904","name":"Flutamide: List of nationally authorised medicinal products - PSUSA/00001453/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-06-27T10:46:00Z","last_updated_date":"2019-06-27T10:46:00Z","reference_number":"EMA/366211/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/flutamide-list-nationally-authorised-medicinal-products-psusa00001453201810_en.pdf"},
    {"id":"44957","name":"Didanosine: List of nationally authorised medicinal products - PSUSA/00001054/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T14:50:00Z","last_updated_date":"2019-06-28T14:50:00Z","reference_number":"EMA/369093/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/didanosine-list-nationally-authorised-medicinal-products-psusa00001054201810_en.pdf"},
    {"id":"44960","name":"Meningococcal group c polysaccharide conjugate vaccine: List of nationally authorised medicinal products - PSUSA/00001971/201810","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T16:00:00Z","last_updated_date":"2019-06-28T16:00:00Z","reference_number":"EMA/369155/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/meningococcal-group-c-polysaccharide-conjugate-vaccine-list-nationally-authorised-medicinal-products-psusa00001971201810_en.pdf"},
    {"id":"44986","name":"Permethrin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002355/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-04T10:00:00Z","last_updated_date":"2019-07-04T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/permethrin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002355201808_no.pdf"}},
    {"id":"44990","name":"Diclofenac (topical formulations): List of nationally authorised medicinal products - PSUSA/00010342/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-04T14:33:00Z","last_updated_date":"2019-07-04T14:33:00Z","reference_number":"EMA/2379050/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-topical-formulations-list-nationally-authorised-medicinal-products-psusa00010342201809_en.pdf"},
    {"id":"44991","name":"Diclofenac (topical formulations): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010342/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-04T14:35:00Z","last_updated_date":"2019-07-04T14:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010342201809_no.pdf"}},
    {"id":"44997","name":"Permethrin: List of nationally authorised medicinal products - PSUSA/00002355/201808","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-05T14:50:00Z","last_updated_date":"2019-07-05T14:50:00Z","reference_number":"EMA/381723/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/permethrin-list-nationally-authorised-medicinal-products-psusa00002355201808_en.pdf"},
    {"id":"45013","name":"Carmustine (implant): List of nationally authorised medicinal products - PSUSA/00010348/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-08T16:28:00Z","last_updated_date":"2019-07-08T16:28:00Z","reference_number":"EMA/392568/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/carmustine-implant-list-nationally-authorised-medicinal-products-psusa00010348201809_en.pdf"},
    {"id":"45014","name":"Carmustine (implant): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010348/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-08T16:27:00Z","last_updated_date":"2019-07-08T16:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_cs.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/carmustine-implant-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010348201809_no.pdf"}},
    {"id":"45037","name":"Levofloxacin (except for the centrally authorised product): List of nationally authorised medicinal products - PSUSA/00001854/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-11T15:49:00Z","last_updated_date":"2019-07-11T15:49:00Z","reference_number":"EMA/397212/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/levofloxacin-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00001854201810_en.pdf"},
    {"id":"45038","name":"Levofloxacin (except for the centrally authorised product): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001854/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-11T15:49:00Z","last_updated_date":"2019-07-11T15:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levofloxacin-except-centrally-authorised-product-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001854201810_no.pdf"}},
    {"id":"45052","name":"Acetylsalicylic acid / bisoprolol: List of nationally authorised medicinal products -  PSUSA/00010287/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T15:22:00Z","last_updated_date":"2019-07-12T15:22:00Z","reference_number":"EMA/400260/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-bisoprolol-list-nationally-authorised-medicinal-products-psusa00010287201811_en.pdf"},
    {"id":"45060","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-15T11:17:00Z","last_updated_date":"2019-07-15T11:17:00Z","reference_number":"EMA/398793/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288201811_en.pdf"},
    {"id":"45062","name":"Indoramin: List of nationally authorised medicinal products - PSUSA/00001740/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-15T12:09:00Z","last_updated_date":"2019-07-15T12:09:00Z","reference_number":"EMA/401589/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/indoramin-list-nationally-authorised-medicinal-products-psusa00001740201809_en.pdf"},
    {"id":"45063","name":"Indoramin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001740/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-15T12:12:00Z","last_updated_date":"2019-07-15T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_pl.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/indoramin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001740201809_sv.pdf"}},
    {"id":"45064","name":"Hydroxycarbamide (except for centrally authorised product): List of nationally authorised medicinal products - PSUSA-00009182-201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-15T12:55:00Z","last_updated_date":"2019-07-15T12:55:00Z","reference_number":"EMA/401819/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa-00009182-201812_en.pdf"},
    {"id":"45068","name":"Terazosin: List of nationally authorised medicinal products - PSUSA/00002895/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-16T12:17:00Z","last_updated_date":"2019-07-16T12:17:00Z","reference_number":"EMA/403763/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/terazosin-list-nationally-authorised-medicinal-products-psusa00002895201811_en.pdf"},
    {"id":"45069","name":"Yellow fever vaccine (live): List of nationally authorised medicinal products - PSUSA/00003135/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-16T12:21:00Z","last_updated_date":"2019-07-16T12:21:00Z","reference_number":"EMA/403921/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/yellow-fever-vaccine-live-list-nationally-authorised-medicinal-products-psusa00003135201812_en.pdf"},
    {"id":"45070","name":"Cefotaxime : List of nationally authorised medicinal products - PSUSA/00000599/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-16T12:22:00Z","last_updated_date":"2019-07-16T12:22:00Z","reference_number":"EMA/403947/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefotaxime-list-nationally-authorised-medicinal-products-psusa00000599201812_en.pdf"},
    {"id":"45074","name":"Sertindole: List of nationally authorised medicinal products - PSUSA00002695201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-17T10:00:00Z","last_updated_date":"2019-07-17T10:00:00Z","reference_number":"EMA/398774/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/sertindole-list-nationally-authorised-medicinal-products-psusa00002695201901_en.pdf"},
    {"id":"45075","name":"Levonorgestrel / ethinylestradiol, ethinylestradiol (combination pack): List of nationally authorised medicinal products - PSUSA/00010442/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-17T10:03:00Z","last_updated_date":"2019-07-17T10:03:00Z","reference_number":"EMA/398799/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-list-nationally-authorised-medicinal-products-psusa00010442201901_en.pdf"},
    {"id":"45082","name":"Amino acid combinations / glucose / triglyceride combinations / with or without electrolytes / mineral compounds - only for the drug Numeta: List of nationally authorised medicinal products - PSUSA/00010190/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-18T10:38:00Z","last_updated_date":"2019-07-18T10:38:00Z","reference_number":"EMA/408522/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/amino-acid-combinations-glucose-triglyceride-combinations-or-without-electrolytes-mineral-compounds-only-drug-numeta-list-nationally-authorised-medicinal-products-psusa00010190201812_en.pdf"},
    {"id":"45084","name":"Hydromorphone: List of nationally authorised medicinal products - PSUSA/00001686/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-18T13:58:00Z","last_updated_date":"2019-07-18T13:58:00Z","reference_number":"EMA/409010/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydromorphone-list-nationally-authorised-medicinal-products-psusa00001686201811_en.pdf"},
    {"id":"45085","name":"Anti-T lymphocyte immunoglobulin for human use, horse: List of nationally authorised medicinal products Maintenance - PSUSA/00010433/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-18T14:10:00Z","last_updated_date":"2019-07-18T14:10:00Z","reference_number":"PSUSA/00010433/201811","document_url":"https://www.ema.europa.eu/en/documents/psusa/anti-t-lymphocyte-immunoglobulin-human-use-horse-list-nationally-authorised-medicinal-products-maintenance-psusa00010433201811_en.pdf"},
    {"id":"45086","name":"Milrinone: List of nationally authorised medicinal products - PSUSA/00002064/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-18T14:54:00Z","last_updated_date":"2019-07-18T14:54:00Z","reference_number":"EMA/341409/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/milrinone-list-nationally-authorised-medicinal-products-psusa00002064201810_en.pdf"},
    {"id":"45087","name":"Etonogestrel: List of nationally authorised medicinal products - PSUSA/00001331/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-18T15:00:00Z","last_updated_date":"2019-07-18T15:00:00Z","reference_number":"EMA/341412/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/etonogestrel-list-nationally-authorised-medicinal-products-psusa00001331201809_en.pdf"},
    {"id":"45089","name":"Naltrexone: List of nationally authorised medicinal products - PSUSA/00002117/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-18T15:55:00Z","last_updated_date":"2019-07-18T15:55:00Z","reference_number":"EMA/408178/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/naltrexone-list-nationally-authorised-medicinal-products-psusa00002117201811_en.pdf"},
    {"id":"45090","name":"Valaciclovir: List of nationally authorised medicinal products - PSUSA/00003086/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-18T15:59:00Z","last_updated_date":"2019-07-18T15:59:00Z","reference_number":"EMA/408177/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/valaciclovir-list-nationally-authorised-medicinal-products-psusa00003086201812_en.pdf"},
    {"id":"45138","name":"Baclofen (oral): List of nationally authorised medicinal products - PSUSA/00000294/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-26T16:49:00Z","last_updated_date":"2019-07-26T16:49:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/baclofen-oral-list-nationally-authorised-medicinal-products-psusa00000294201809_en.pdf"},
    {"id":"45139","name":"Baclofen (oral): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000294/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-26T16:51:00Z","last_updated_date":"2019-07-26T16:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/baclofen-oral-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000294201809_no.pdf"}},
    {"id":"45150","name":"Letrozole: List of nationally authorised medicinal products - PSUSA/00001842/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-30T09:54:00Z","last_updated_date":"2019-07-30T09:54:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/letrozole-list-nationally-authorised-medicinal-products-psusa00001842201810_en.pdf"},
    {"id":"45151","name":"Letrozole: CMDh scientific conclusions and grounds for variation, amendments to product information and implementation timetable - PSUSA/00001842/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-30T09:57:00Z","last_updated_date":"2019-07-30T09:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/letrozole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-implementation-timetable-psusa00001842201810_no.pdf"}},
    {"id":"45167","name":"Diclofenac (systemic formulations): List of nationally authorised medicinal products - PSUSA/00001048/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-31T16:35:00Z","last_updated_date":"2019-07-31T16:35:00Z","reference_number":"EMA/430529/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-systemic-formulations-list-nationally-authorised-medicinal-products-psusa00001048201809_en.pdf"},
    {"id":"45168","name":"Diclofenac (systemic formulations): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001048/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-07-31T16:37:00Z","last_updated_date":"2019-07-31T16:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001048201809_no.pdf"}},
    {"id":"45194","name":"Acitretin: List of nationally authorised medicinal products - PSUSA/00000051/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-02T16:25:00Z","last_updated_date":"2019-08-02T16:25:00Z","reference_number":"EMA/437626/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-list-nationally-authorised-medicinal-products-psusa00000051201810_en.pdf"},
    {"id":"45195","name":"Acitretin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000051/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-02T16:25:00Z","last_updated_date":"2019-08-02T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/acitretin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000051201810_no.pdf"}},
    {"id":"45204","name":"Methylphenidate: List of nationally authorised medicinal products - PSUSA/00002024/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-06T15:51:00Z","last_updated_date":"2019-08-06T15:51:00Z","reference_number":"EMA/443832/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-list-nationally-authorised-medicinal-products-psusa00002024201810_en.pdf"},
    {"id":"45205","name":"Methylphenidate: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002024/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-06T15:53:00Z","last_updated_date":"2019-08-06T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_no.pdf"}},
    {"id":"45206","name":"Danaparoid: List of nationally authorised medicinal products - PSUSA/00000923/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-06T15:58:00Z","last_updated_date":"2019-08-06T15:58:00Z","reference_number":"EMA/445257/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/danaparoid-list-nationally-authorised-medicinal-products-psusa00000923201812_en.pdf"},
    {"id":"45221","name":"Dextromethorphan: List of nationally authorised medicinal products - PSUSA/00001009/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-08T13:37:00Z","last_updated_date":"2019-08-08T13:37:00Z","reference_number":"EMA/450475/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/dextromethorphan-list-nationally-authorised-medicinal-products-psusa00001009201811_en.pdf"},
    {"id":"45222","name":"Dextromethorphan: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001009/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-08T17:39:00Z","last_updated_date":"2019-08-08T17:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dextromethorphan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001009201811_sv.pdf"}},
    {"id":"45288","name":"Phloroglucinol, phloroglucinol trimethylphloroglucinol: List of nationally authorised medicinal products - PSUSA/00010355/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:51:00Z","last_updated_date":"2019-08-20T10:51:00Z","reference_number":"EMA/461008/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-list-nationally-authorised-medicinal-products-psusa00010355201809_en.pdf"},
    {"id":"45289","name":"Phloroglucinol, phloroglucinol trimethylphloroglucinol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010355/201809","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:54:00Z","last_updated_date":"2019-08-20T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010355201809_sv.pdf"}},
    {"id":"45359","name":"Azathioprine: List of nationally authorised medicinal products - PSUSA/00000275/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-30T14:17:00Z","last_updated_date":"2019-08-30T14:17:00Z","reference_number":"EMA/480512/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/azathioprine-list-nationally-authorised-medicinal-products-psusa00000275201812_en.pdf"},
    {"id":"45360","name":"Azathioprine: CMDh Scientific conclusions, amendments to product information and implementation timetable - PSUSA/00000275/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-30T14:20:00Z","last_updated_date":"2019-08-30T14:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/azathioprine-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00000275201812_no.pdf"}},
    {"id":"45361","name":"Iron dextran: List of nationally authorised medicinal products - PSUSA/00010696/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-30T15:15:00Z","last_updated_date":"2019-08-30T15:15:00Z","reference_number":"EMA/478960/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-dextran-list-nationally-authorised-medicinal-products-psusa00010696201901_en.pdf"},
    {"id":"45362","name":"Iron dextran: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010696/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-08-30T15:17:00Z","last_updated_date":"2019-08-30T15:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_es.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_fi.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010696201901_no.pdf"}},
    {"id":"45367","name":"Tapentadol: List of nationally authorised medicinal products - PSUSA/00002849/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-02T14:13:00Z","last_updated_date":"2019-09-02T14:13:00Z","reference_number":"EMA/450564/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/tapentadol-list-nationally-authorised-medicinal-products-psusa00002849201811_en.pdf"},
    {"id":"45368","name":"Tapentadol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002849/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-02T14:15:00Z","last_updated_date":"2019-09-02T14:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tapentadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002849201811_no.pdf"}},
    {"id":"45396","name":"Landiolol: List of nationally authorised medicinal products - PSUSA/00010570/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-09T10:03:00Z","last_updated_date":"2019-09-09T10:03:00Z","reference_number":"EMA/483140/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/landiolol-list-nationally-authorised-medicinal-products-psusa00010570201902_en.pdf"},
    {"id":"45399","name":"Benzydamine / cetylpyridine: List of nationally authorised medicinal products - PSUSA/00000378/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-10T09:20:00Z","last_updated_date":"2019-09-10T09:20:00Z","reference_number":"EMA/493351/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzydamine-cetylpyridine-list-nationally-authorised-medicinal-products-psusa-00000378-201901_en.pdf"},
    {"id":"45404","name":"Protirelin: List of nationally authorised medicinal products - PSUSA/00009273/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-10T11:41:00Z","last_updated_date":"2019-09-10T11:41:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/protirelin-list-nationally-authorised-medicinal-products-psusa00009273201901_en.pdf"},
    {"id":"45405","name":"Niflumic acid: List of nationally authorised products - PSUSA/00002157/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-10T14:00:00Z","last_updated_date":"2019-09-10T14:00:00Z","reference_number":"EMA/497073/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/niflumic-acid-list-nationally-authorised-products-psusa00002157201812_en.pdf"},
    {"id":"45406","name":"Biotin: List of nationally authorised medicinal products - PSUSA/00000414/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-10T14:08:00Z","last_updated_date":"2019-09-10T14:08:00Z","reference_number":"EMA/496630/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/biotin-list-nationally-authorised-medicinal-products-psusa00000414201901_en.pdf"},
    {"id":"45407","name":"Bezafibrate: List of nationally authorised products - PSUSA/00000405/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-10T14:18:00Z","last_updated_date":"2019-09-10T14:18:00Z","reference_number":"EMA/497439/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/bezafibrate-list-nationally-authorised-products-psusa00000405201901_en.pdf"},
    {"id":"45412","name":"Flunitrazepam: List of nationally authorised medicinal products - PSUSA/00001418/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-11T10:03:00Z","last_updated_date":"2019-09-11T10:03:00Z","reference_number":"EMA/497275/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/flunitrazepam-list-nationally-authorised-medicinal-products-psusa00001418201901_en.pdf"},
    {"id":"45413","name":"Ambrosia Artemisiifolia (302) (sublingual use, products authorised via decentralised procedure): List of nationally authorised products - PSUSA/00010693/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-11T10:26:00Z","last_updated_date":"2019-09-11T10:26:00Z","reference_number":"EMA/497809/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-list-nationally-authorised-products-psusa00010693201901_en.pdf"},
    {"id":"45416","name":"Amino acid combinations (only combinations of pure amino acids or combination of amino acids with mineral compounds/electrolytes, i.v. application): List of nationally authorised medicinal products - PSUSA/00010187/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-11T13:55:00Z","last_updated_date":"2019-09-11T13:55:00Z","reference_number":"EMA/496540/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/amino-acid-combinations-only-combinations-pure-amino-acids-or-combination-amino-acids-mineral-compoundselectrolytes-iv-application-list-nationally-authorised-medicinal-products-psusa00010187201901_en.pdf"},
    {"id":"45417","name":"Pentoxyverine: List of nationally authorised medicinal products - PSUSA/00002345/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-11T14:00:00Z","last_updated_date":"2019-09-11T14:00:00Z","reference_number":"EMA/496740/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/pentoxyverine-list-nationally-authorised-medicinal-products-psusa00002345201812_en.pdf"},
    {"id":"45418","name":"Alitretinoin (oral use): List of nationally authorised medicinal products - PSUSA/00010710/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-11T14:10:00Z","last_updated_date":"2019-09-11T14:10:00Z","reference_number":"EMA/496795/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/alitretinoin-oral-use-list-nationally-authorised-medicinal-products-psusa00010710201901_en.pdf"},
    {"id":"45420","name":"Carboplatin: List of nationally authorised medicinal products - PSUSA/00000559/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-11T14:19:00Z","last_updated_date":"2019-09-11T14:19:00Z","reference_number":"EMA/493839/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/carboplatin-list-nationally-authorised-medicinal-products-psusa00000559201901_en.pdf"},
    {"id":"45421","name":"Dexketoprofen / tramadol: List of nationally authorised medicinal products - PSUSA/00010468/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-11T15:32:00Z","last_updated_date":"2019-09-11T15:32:00Z","reference_number":"EMA/494519/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-tramadol-list-nationally-authorised-medicinal-products-psusa00010468201901_en.pdf"},
    {"id":"45422","name":"Roxithromycin: List of nationally authorised medicinal products - PSUSA/00002669/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-11T15:37:00Z","last_updated_date":"2019-09-11T15:37:00Z","reference_number":"EMA/494737/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/roxithromycin-list-nationally-authorised-medicinal-products-psusa00002669201812_en.pdf"},
    {"id":"45423","name":"Hepatitis A vaccines (inactivated, adsorbed): List of nationally authorised medicinal products - PSUSA/00001596/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-11T15:44:00Z","last_updated_date":"2019-09-11T15:44:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/hepatitis-vaccines-inactivated-adsorbed-list-nationally-authorised-medicinal-products-psusa00001596201901_en.pdf"},
    {"id":"45444","name":"Metoclopramide: List of nationally authorised medicinal products - PSUSA/00002036/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-13T11:51:00Z","last_updated_date":"2019-09-13T11:51:00Z","reference_number":"EMA/499718/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/metoclopramide-list-nationally-authorised-medicinal-products-psusa00002036201811_en.pdf"},
    {"id":"45445","name":"Metoclopramide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002036/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-13T11:53:00Z","last_updated_date":"2019-09-13T11:53:00Z","reference_number":"PSUSA/00002036/201811","document_url":"https://www.ema.europa.eu/en/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/metoclopramide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002036-201811_no.pdf"}},
    {"id":"45453","name":"Bisoprolol / hydrochlorothiazide: List of nationally authorised medicinal products - PSUSA/00000420/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-13T16:52:00Z","last_updated_date":"2019-09-13T16:52:00Z","reference_number":"EMA/474202/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/bisoprolol-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00000420201811_en.pdf"},
    {"id":"45455","name":"Caffeine / ergotamine: List of nationally authorised products - PSUSA/00000485/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-16T11:56:00Z","last_updated_date":"2019-09-16T11:56:00Z","reference_number":"EMA/502992/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/caffeine-ergotamine-list-nationally-authorised-products-psusa00000485201811_en.pdf"},
    {"id":"45456","name":"Ciclosporin (systemic use): List of nationally authorised products - PSUSA/00000745/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-16T12:05:00Z","last_updated_date":"2019-09-16T12:05:00Z","reference_number":"EMA/503045/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciclosporin-systemic-use-list-nationally-authorised-products-psusa00000745201812_en.pdf"},
    {"id":"45462","name":"Iron (parenteral preparations, except for iron dextran): List of nationally authorised medicinal products - PSUSA/00010236/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-18T10:17:00Z","last_updated_date":"2019-09-18T10:17:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-parenteral-preparations-except-iron-dextran-list-nationally-authorised-medicinal-products-psusa00010236201901_en.pdf"},
    {"id":"45463","name":"Iron (parenteral preparations, except for iron dextran): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-18T10:20:00Z","last_updated_date":"2019-09-18T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_no.pdf"}},
    {"id":"45480","name":"Ketamine : List of nationally authorised medicinal products - PSUSA/00001804/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-19T14:48:00Z","last_updated_date":"2019-09-19T14:48:00Z","reference_number":"EMA/398958/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketamine-list-nationally-authorised-medicinal-products-psusa00001804201812_en.pdf"},
    {"id":"45481","name":"Ketamine : CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001804/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-19T14:51:00Z","last_updated_date":"2019-09-19T14:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ketamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001804201812_no.pdf"}},
    {"id":"45531","name":"Bupropion: List of nationally authorised medicinal products - PSUSA/00000461/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-09-27T12:21:00Z","last_updated_date":"2019-09-27T12:21:00Z","reference_number":"EMA/517429/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/bupropion-list-nationally-authorised-medicinal-products-psusa00000461201812_en.pdf"},
    {"id":"45545","name":"Ketoprofen (topical use only) - List of nationally authorised medicinal products - PSUSA/00009205/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-02T09:50:00Z","last_updated_date":"2019-10-02T09:50:00Z","reference_number":"EMA/529917/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketoprofen-topical-use-only-list-nationally-authorised-medicinal-products-psusa00009205201901_en.pdf"},
    {"id":"45621","name":"Amitriptyline hydrochloride / chlordiazepoxide: List of nationally authorised medicinal products - PSUSA/00000171/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T10:42:00Z","last_updated_date":"2019-10-09T10:42:00Z","reference_number":"EMA/548242/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-hydrochloride-chlordiazepoxide-list-nationally-authorised-medicinal-products-psusa00000171201902_en.pdf"},
    {"id":"45622","name":"Ethanol-orthophenylphenol: List of nationally authorised medicinal products - PSUSA/00010416/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T12:59:00Z","last_updated_date":"2019-10-09T12:59:00Z","reference_number":"EMA/542694/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethanol-orthophenylphenol-list-nationally-authorised-medicinal-products-psusa00010416201902_en.pdf"},
    {"id":"45623","name":"Octenidine dihydrochloride 1-propanol 2-propanol: List of nationally authorised medicinal products - PSUSA/00010417/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T13:01:00Z","last_updated_date":"2019-10-09T13:01:00Z","reference_number":"EMA/542617/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/octenidine-dihydrochloride-1-propanol-2-propanol-list-nationally-authorised-medicinal-products-psusa00010417201901_en.pdf"},
    {"id":"45626","name":"Cilostazol: List of nationally authorised medicinal products - PSUSA/00010209/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T14:07:00Z","last_updated_date":"2019-10-09T14:07:00Z","reference_number":"EMA/550753/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilostazol-list-nationally-authorised-medicinal-products-psusa00010209201902_en.pdf"},
    {"id":"45629","name":"Dorzolamide / timolol: List of nationally authorised medicinal products - PSUSA/00001166/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T16:10:00Z","last_updated_date":"2019-10-09T16:10:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-timolol-list-nationally-authorised-medicinal-products-psusa00001166201902_en.pdf"},
    {"id":"45636","name":"Trandolapril: List of nationally authorised medicinal products - PSUSA/00003004/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-10T11:20:00Z","last_updated_date":"2019-10-10T11:20:00Z","reference_number":"EMA/552278/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/trandolapril-list-nationally-authorised-medicinal-products-psusa00003004201902_en.pdf"},
    {"id":"45637","name":"Hydroxyethyl starch: List of nationally authorised medicinal products - PSUSA/00001694/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-10T11:56:00Z","last_updated_date":"2019-10-10T11:56:00Z","reference_number":"EMA/553019/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-list-nationally-authorised-medicinal-products-psusa00001694201903_en.pdf"},
    {"id":"45640","name":"Interferon gamma: List of nationally authorised medicinal products - PSUSA/00001760/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-10T15:41:00Z","last_updated_date":"2019-10-10T15:41:00Z","reference_number":"EMA/552694/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/interferon-gamma-list-nationally-authorised-medicinal-products-psusa00001760201901_en.pdf"}    {"id":"45647","name":"Mesterolone: List of nationally authorised medicinal products - PSUSA/00010551/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-10T16:41:00Z","last_updated_date":"2019-10-10T16:41:00Z","reference_number":"EMA/551495/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesterolone-list-nationally-authorised-medicinal-products-psusa00010551201901_en.pdf"},
    {"id":"45700","name":"Gabapentin: List of nationally authorised medicinal products - PSUSA/00001499/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-15T09:40:00Z","last_updated_date":"2019-10-15T09:40:00Z","reference_number":"EMA/556780/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/gabapentin-list-nationally-authorised-medicinal-products-psusa00001499201902_en.pdf"},
    {"id":"45802","name":"Botulinum toxin a: List of nationally authorised medicinal products - PSUSA/00000426/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T15:10:00Z","last_updated_date":"2019-10-25T15:10:00Z","reference_number":"EMA/58116/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-list-nationally-authorised-medicinal-products-psusa00000426201812_en.pdf"},
    {"id":"45803","name":"Botulinum toxin a: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000426/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-25T15:10:00Z","last_updated_date":"2019-10-25T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000426-201812_no.pdf"}},
    {"id":"45811","name":"Botulinum neurotoxin type a (150 kD) free from complexing proteins: List of nationally authorised medicinal products - PSUSA/00009084/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-28T11:45:00Z","last_updated_date":"2019-10-28T11:45:00Z","reference_number":"EMA/583348/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-list-nationally-authorised-medicinal-products-psusa00009084201812_en.pdf"},
    {"id":"45813","name":"Testosterone (topical use) : List of nationally authorised medicinal products - PSUSA/00002908/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-28T17:10:00Z","last_updated_date":"2019-10-28T17:10:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-topical-use-list-nationally-authorised-medicinal-products-psusa00002908201812_en.pdf"},
    {"id":"45814","name":"Testosterone (topical use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002908/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-28T17:10:00Z","last_updated_date":"2019-10-28T17:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002908-201812_no.pdf"}},
    {"id":"45836","name":"Testosterone (all formulations apart from topical use) : List of nationally authorised medicinal products - PSUSA/00010631/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-29T15:10:00Z","last_updated_date":"2019-10-29T15:10:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-all-formulations-apart-topical-use-list-nationally-authorised-medicinal-products-psusa00010631201812_en.pdf"},
    {"id":"45837","name":"Testosterone (all formulations apart from topical use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010631/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-29T15:10:00Z","last_updated_date":"2019-10-29T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010631201812_no.pdf"}},
    {"id":"45862","name":"Botulinum toxin a - haemagglutinin complex : List of nationally authorised medicinal products - PSUSA/00000427/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-30T17:30:00Z","last_updated_date":"2019-10-30T17:30:00Z","reference_number":"EMA/590274/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-haemagglutinin-complex-list-nationally-authorised-medicinal-products-psusa00000427201812_en.pdf"},
    {"id":"45863","name":"Botulinum toxin a - haemagglutinin complex : CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000427/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-10-30T17:30:00Z","last_updated_date":"2019-10-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/botulinum-toxin-haemagglutinin-complex-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000427201812_no.pdf"}},
    {"id":"45883","name":"Alprazolam : List of nationally authorised medicinal products - PSUSA/00000109/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-04T16:00:00Z","last_updated_date":"2019-11-04T16:00:00Z","reference_number":"EMA/591990/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprazolam-list-nationally-authorised-medicinal-products-psusa00000109201903_en.pdf"},
    {"id":"45885","name":"Allergen for therapy: Ambrosia Artemisiifolia (302) (sublingual use, products authorised via decentralised procedure) : List of nationally authorised medicinal products - PSUSA/00010693/201904","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-05T11:20:00Z","last_updated_date":"2019-11-05T11:20:00Z","reference_number":"EMA/596024/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-list-nationally-authorised-medicinal-products-psusa00010693201904_en.pdf"},
    {"id":"45888","name":"Nicorandil : List of nationally authorised medicinal products - PSUSA-00002152-201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-05T17:20:00Z","last_updated_date":"2019-11-05T17:20:00Z","reference_number":"EMA/597965/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicorandil-list-nationally-authorised-medicinal-products-psusa-00002152-201902_en.pdf"},
    {"id":"45914","name":"Enoxaparin (except for biosimilars) : List of nationally authorised medicinal products - PSUSA/00010560/201904","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-07T10:50:00Z","last_updated_date":"2019-11-07T10:50:00Z","reference_number":"EMA/601977/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/enoxaparin-except-biosimilars-list-nationally-authorised-medicinal-products-psusa00010560201904_en.pdf"},
    {"id":"45945","name":"Influenza vaccine (surface antigen, inactivated, adjuvanted) : List of nationally authorised medicinal products - PSUSA/00010300/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-08T14:20:00Z","last_updated_date":"2019-11-08T14:20:00Z","reference_number":"EMA/601121/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-adjuvanted-list-nationally-authorised-medicinal-products-psusa00010300201903_en.pdf"},
    {"id":"45946","name":"Influenza vaccine (surface antigen, inactivated) : List of nationally authorised medicinal products - PSUSA/00001744/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-08T14:20:00Z","last_updated_date":"2019-11-08T14:20:00Z","reference_number":"EMA/600346/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa00001744201903_en.pdf"},
    {"id":"45947","name":"Influenza vaccine (split virion, inactivated, prepared in cell cultures) : List of nationally authorised medicinal products - PSUSA/00010299/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-08T14:20:00Z","last_updated_date":"2019-11-08T14:20:00Z","reference_number":"EMA/601087/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-prepared-cell-cultures-list-nationally-authorised-medicinal-products-psusa00010299201903_en.pdf"},
    {"id":"45948","name":"Influenza vaccine (split virion, inactivated) (non centrally authorised products) : List of nationally authorised medicinal products - PSUSA/00010298/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-08T14:20:00Z","last_updated_date":"2019-11-08T14:20:00Z","reference_number":"EMA/600419/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00010298201903_en.pdf"},
    {"id":"46047","name":"5 fluorouracil (topical application) : List of nationally authorised medicinal products - PSUSA/00010000/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T17:00:00Z","last_updated_date":"2019-11-15T17:00:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-topical-application-list-nationally-authorised-medicinal-products-psusa00010000201901_en.pdf"},
    {"id":"46048","name":"5 fluorouracil (topical application) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010000/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T17:00:00Z","last_updated_date":"2019-11-15T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/5-fluorouracil-topical-application-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010000201901_sv.pdf"}},
    {"id":"46053","name":"Methylphenidate: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002024/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-18T16:28:00Z","last_updated_date":"2019-11-18T16:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_sv.pdf-0","is":"https://www.ema.europa.eu/is/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_is.pdf-0","no":"https://www.ema.europa.eu/no/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002024-201810_no.pdf-0"}},
    {"id":"46064","name":"Germanium (68Ge) chloride / gallium (68Ga) chloride : List of nationally authorised medicinal products - PSUSA/00010364/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-19T17:20:00Z","last_updated_date":"2019-11-19T17:20:00Z","reference_number":"EMA/593886/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/germanium-68ge-chloride-gallium-68ga-chloride-list-nationally-authorised-medicinal-products-psusa00010364201903_en.pdf"},
    {"id":"46065","name":"Glipizide : List of nationally authorised medicinal products - PSUSA/00001535/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-19T17:20:00Z","last_updated_date":"2019-11-19T17:20:00Z","reference_number":"EMA/628588/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/glipizide-list-nationally-authorised-medicinal-products-psusa00001535201901_en.pdf"},
    {"id":"46094","name":"Acetylsalicylic acid: List of nationally authorised medicinal products - PSUSA/00000039/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-21T14:43:00Z","last_updated_date":"2019-11-21T14:43:00Z","reference_number":"EMA/631752/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-list-nationally-authorised-medicinal-products-psusa00000039201902_en.pdf"},
    {"id":"46095","name":"Acetylsalicylic acid: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000039/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-21T14:39:00Z","last_updated_date":"2019-11-21T14:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/acetylsalicylic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000039201902_no.pdf"}},
    {"id":"46128","name":"Dorzolamide: List of nationally authorised medicinal products - PSUSA/00003168/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-25T14:00:00Z","last_updated_date":"2019-11-25T14:00:00Z","reference_number":"EMA/635720/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-list-nationally-authorised-medicinal-products-psusa00003168201902_en.pdf"},
    {"id":"46129","name":"Dorzolamide: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00003168/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-25T14:00:00Z","last_updated_date":"2019-11-25T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168201902_no.pdf"}},
    {"id":"46172","name":"Levothyroxine : List of nationally authorised medicinal products - PSUSA/00001860/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T17:30:00Z","last_updated_date":"2019-11-26T17:30:00Z","reference_number":"EMA/640091/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/levothyroxine-list-nationally-authorised-medicinal-products-psusa00001860201901_en.pdf"},
    {"id":"46173","name":"Levothyroxine : CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001860/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T17:30:00Z","last_updated_date":"2019-11-26T17:30:00Z","reference_number":"EMA/640091/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860201901_no.pdf"}},
    {"id":"46194","name":"Cabergoline: List of nationally authorised medicinal products - PSUSA/00000477/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-28T12:46:00Z","last_updated_date":"2019-11-28T12:46:00Z","reference_number":"EMA/645069/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/cabergoline-list-nationally-authorised-medicinal-products-psusa00000477201903_en.pdf"},
    {"id":"46195","name":"Cabergoline: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000477/20190","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-28T12:51:00Z","last_updated_date":"2019-11-28T12:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cabergoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0000047720190_no.pdf"}},
    {"id":"46207","name":"Triamcinolone (intraocular formulations): List of nationally authorised medicinal products - PSUSA/00010292/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-11-29T17:44:00Z","last_updated_date":"2019-11-29T17:44:00Z","reference_number":"EMA/628318/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/triamcinolone-intraocular-formulations-list-nationally-authorised-medicinal-products-psusa00010292201903_en.pdf"},
    {"id":"46208","name":"Nefopam: List of nationally authorised medicinal products - PSUSA/00002131/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-12-02T09:45:00Z","last_updated_date":"2019-12-02T09:45:00Z","reference_number":"EMA/653040/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/nefopam-list-nationally-authorised-medicinal-products-psusa00002131201903_en.pdf"},
    {"id":"46210","name":"Varicella vaccine (live) : List of nationally authorised medicinal products - PSUSA/000010473/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-12-02T13:38:00Z","last_updated_date":"2019-12-02T13:38:00Z","reference_number":"EMA/650338/2019 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/varicella-vaccine-live-list-nationally-authorised-medicinal-products-psusa000010473201903_en.pdf"},
    {"id":"46211","name":"Carvedilol / ivabradine : List of nationally authorised medicinal products - PSUSA/00010586/201904","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-12-02T13:48:00Z","last_updated_date":"2019-12-02T13:48:00Z","reference_number":"EMA/650666/2019 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/carvedilol-ivabradine-list-nationally-authorised-medicinal-products-psusa00010586201904_en.pdf"},
    {"id":"46218","name":"Carteolol: List of nationally authorised medicinal products - PSUSA/00000574/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-12-03T14:49:00Z","last_updated_date":"2019-12-03T14:49:00Z","reference_number":"EMA/637806/2019 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/carteolol-list-nationally-authorised-medicinal-products-psusa00000574201903_en.pdf"},
    {"id":"46241","name":"Ivermectin (topical use): List of nationally authorised medicinal products - PSUSA/00010376/201904","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-12-05T14:59:00Z","last_updated_date":"2019-12-05T14:59:00Z","reference_number":"EMA/664500/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-topical-use-list-nationally-authorised-medicinal-products-psusa00010376201904_en.pdf"},
    {"id":"46242","name":"Ivermectin (systemic use): List of nationally authorised medicinal products - PSUSA/00010377/201904","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-12-05T15:02:00Z","last_updated_date":"2019-12-05T15:02:00Z","reference_number":"EMA/664534/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-systemic-use-list-nationally-authorised-medicinal-products-psusa00010377201904_en.pdf"},
    {"id":"46408","name":"Ezetimibe / simvastatin: List of nationally authorised medicinal products - PSUSA/00001347/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-10T12:03:00Z","last_updated_date":"2020-01-10T12:03:00Z","reference_number":"EMA/694470/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/ezetimibe-simvastatin-list-nationally-authorised-medicinal-products-psusa00001347201903_en.pdf"},
    {"id":"46411","name":"Ezetimibe / simvastatin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001347/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-10T15:24:00Z","last_updated_date":"2020-01-10T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ezetimibe-simvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001347201903_no.pdf"}},
    {"id":"46424","name":"Erythromycin: List of nationally authorised medicinal products - PSUSA/00001257/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T15:41:00Z","last_updated_date":"2020-01-14T15:41:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/erythromycin-list-nationally-authorised-medicinal-products-psusa00001257201903_en.pdf"},
    {"id":"46425","name":"Erythromycin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001257/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T15:41:00Z","last_updated_date":"2020-01-14T15:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/erythromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001257201903_no.pdf"}},
    {"id":"46427","name":"Lisdexamfetamine: List of nationally authorised medicinal products - PSUSA/00010289/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T16:32:00Z","last_updated_date":"2020-01-14T16:32:00Z","reference_number":"EMA/270645/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa00010289201902_en.pdf"},
    {"id":"46428","name":"Lisdexamfetamine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010289/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-14T16:32:00Z","last_updated_date":"2020-01-14T16:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289201902_no.pdf"}},
    {"id":"46450","name":"Tirofiban: List of nationally authorised medicinal products - PSUSA/00002974/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-17T11:58:00Z","last_updated_date":"2020-01-17T11:58:00Z","reference_number":"EMA/2341/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/tirofiban-list-nationally-authorised-medicinal-products-psusa00002974201905_en.pdf"},
    {"id":"46459","name":"Botulinum neurotoxin type a (150 kD) free from complexing proteins: CMDh Scientific conclusions, amendments to product information and implementation timetable - PSUSA/00009084/201812","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T11:32:00Z","last_updated_date":"2020-01-20T11:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009084201812_no.pdf"}},
    {"id":"46463","name":"Isotretinoin (oral formulations): List of nationally authorised medicinal products - PSUSA/00010488/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T14:48:00Z","last_updated_date":"2020-01-20T14:48:00Z","reference_number":"EMA/28890/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa00010488201905_en.pdf"},
    {"id":"46464","name":"Isotretinoin (oral formulations): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010488/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T14:52:00Z","last_updated_date":"2020-01-20T14:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488201905_no.pdf"}},
    {"id":"46483","name":"Yohimbine: List of nationally authorised medicinal products - PSUSA/00003136/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-22T14:15:00Z","last_updated_date":"2020-01-22T14:15:00Z","reference_number":"EMA/33967/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/yohimbine-list-nationally-authorised-medicinal-products-psusa00003136201905_en.pdf"},
    {"id":"46492","name":"Macrogol 4000, macrogol 4000 combinations (oral use): List of nationally authorised medicinal products - PSUSA/00010392/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T10:20:00Z","last_updated_date":"2020-01-23T10:20:00Z","reference_number":"EMA/36889/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/macrogol-4000-macrogol-4000-combinations-oral-use-list-nationally-authorised-medicinal-products-psusa00010392201905_en.pdf"},
    {"id":"46493","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T10:26:00Z","last_updated_date":"2020-01-23T10:26:00Z","reference_number":"EMA/628079/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288201905_en.pdf"},
    {"id":"46500","name":"Macrogol 3350: List of nationally authorised medicinal products - PSUSA/0001924/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T14:28:00Z","last_updated_date":"2020-01-23T14:28:00Z","reference_number":"EMA/39495/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/macrogol-3350-list-nationally-authorised-medicinal-products-psusa0001924201905_en.pdf"},
    {"id":"46513","name":"Bemiparin: List of nationally authorised medicinal products - PSUSA/00000312/201904","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T16:05:00Z","last_updated_date":"2020-01-23T16:05:00Z","reference_number":"EMA/36860/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/bemiparin-list-nationally-authorised-medicinal-products-psusa00000312201904_en.pdf"},
    {"id":"46514","name":"Misoprostol (gynaecological indication - labour induction): List of nationally authorised medicinal products - PSUSA/00010353/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T16:05:00Z","last_updated_date":"2020-01-23T16:05:00Z","reference_number":"EMA/36948/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labour-induction-list-nationally-authorised-medicinal-products-psusa00010353201905_en.pdf"},
    {"id":"46515","name":"Ozenoxacin: List of nationally authorised medicinal products - PSUSA/00010651/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T16:05:00Z","last_updated_date":"2020-01-23T16:05:00Z","reference_number":"EMA/34676/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ozenoxacin-list-nationally-authorised-medicinal-products-psusa00010651201905_en.pdf"},
    {"id":"46516","name":"Isoniazide / rifampicin: List of nationally authorised medicinal products - PSUSA/00001792/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-23T16:05:00Z","last_updated_date":"2020-01-23T16:05:00Z","reference_number":"EMA/31710/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoniazide-rifampicin-list-nationally-authorised-medicinal-products-psusa00001792201905_en.pdf"},
    {"id":"46519","name":"Treprostinil: List of nationally authorised medicinal products - PSUSA/00003013/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T09:55:00Z","last_updated_date":"2020-01-24T09:55:00Z","reference_number":"EMA/40234/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/treprostinil-list-nationally-authorised-medicinal-products-psusa00003013201905_en.pdf"},
    {"id":"46521","name":"Methoxyflurane: List of nationally authorised medicinal products - PSUSA/00010484/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T11:55:00Z","last_updated_date":"2020-01-24T11:55:00Z","reference_number":"EMA/40500/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa00010484201905_en.pdf"},
    {"id":"46581","name":"Cidofovir : List of nationally authorised medicinal products - PSUSA/00010558/201906","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-27T16:24:00Z","last_updated_date":"2020-01-27T16:24:00Z","reference_number":"EMA/43481/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/cidofovir-list-nationally-authorised-medicinal-products-psusa00010558201906_en.pdf"},
    {"id":"46582","name":"Ethinylestradiol / levonorgestrel: CMDh Scientific conclusions, amendments to product information and implementation timetable - PSUSA/00001309/201904","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-27T15:54:00Z","last_updated_date":"2020-01-27T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ethinylestradiol-levonorgestrel-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001309201904_no.pdf"}},
    {"id":"46593","name":"Ethinylestradiol / levonorgestrel: List of nationally authorised medicinal products - PSUSA/00001309/201904","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-27T10:16:00Z","last_updated_date":"2020-01-27T10:16:00Z","reference_number":"EMA/40774/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-levonorgestrel-list-nationally-authorised-medicinal-products-psusa00001309201904_en.pdf"},
    {"id":"46599","name":"Measles vaccine (live attenuated): List of nationally authorised medicinal products - PSUSA/00001938/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-28T14:05:00Z","last_updated_date":"2020-01-28T14:05:00Z","reference_number":"EMA/43635/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/measles-vaccine-live-attenuated-list-nationally-authorised-medicinal-products-psusa00001938201905_en.pdf"},
    {"id":"46601","name":"Fusidic acid (systemic use): List of nationally authorised medicinal products - PSUSA/00010226/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-01-28T14:05:00Z","last_updated_date":"2020-01-28T14:05:00Z","reference_number":"EMA/43819/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/fusidic-acid-systemic-use-list-nationally-authorised-medicinal-products-psusa00010226201905_en.pdf"},
    {"id":"46749","name":"Sulfametrole / trimethoprim, sulfadiazine / trimethoprim, sulfamethoxazole / trimethoprim (co-trimoxazole): List of nationally authorised medicinal products - PSUSA/00010593/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-02-13T17:00:00Z","last_updated_date":"2020-02-13T17:00:00Z","reference_number":"EMA/80054/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-list-nationally-authorised-medicinal-products-psusa00010593201903_en.pdf"},
    {"id":"46750","name":"Sulfametrole / trimethoprim, sulfadiazine / trimethoprim, sulfamethoxazole / trimethoprim (co-trimoxazole): CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implem - PSUSA/00010593/201903","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-02-13T17:00:00Z","last_updated_date":"2020-02-13T17:00:00Z","reference_number":"EMA/80054/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/sulfametrole-trimethoprim-sulfadiazine-trimethoprim-sulfamethoxazole-trimethoprim-co-trimoxazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implem_no.pdf"}},
    {"id":"46751","name":"Rocuronium : List of nationally authorised medicinal products - PSUSA/00002656/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-02-14T08:40:00Z","last_updated_date":"2020-02-14T08:40:00Z","reference_number":"EMA/80538/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/rocuronium-list-nationally-authorised-medicinal-products-psusa00002656201902_en.pdf"},
    {"id":"46752","name":"Rocuronium : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002656/201902","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-02-14T08:40:00Z","last_updated_date":"2020-02-14T08:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_de.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/rocuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002656201902_no.pdf"}},
    {"id":"46765","name":"Octenidine: List of nationally authorised medicinal products - PSUSA/00010748/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-02-17T09:15:00Z","last_updated_date":"2020-02-17T09:15:00Z","reference_number":"EMA/72221/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/octenidine-list-nationally-authorised-medicinal-products-psusa00010748201907_en.pdf"},
    {"id":"46767","name":"Human plasma proteins with not less than 95% albumin: List of nationally authorised medicinal products - PSUSA/00010605/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-02-17T14:43:00Z","last_updated_date":"2020-02-17T14:43:00Z","reference_number":"EMA/83301/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-plasma-proteins-not-less-95-albumin-list-nationally-authorised-medicinal-products-psusa00010605201907_en.pdf"},
    {"id":"46768","name":"Ganciclovir: List of nationally authorised medicinal products - PSUSA/00001516/201906","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-02-17T15:03:00Z","last_updated_date":"2020-02-17T15:03:00Z","reference_number":"EMA/83528/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ganciclovir-list-nationally-authorised-medicinal-products-psusa00001516201906_en.pdf"},
    {"id":"46808","name":"Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-02-20T09:32:00Z","last_updated_date":"2020-02-20T09:32:00Z","reference_number":"EMA/89998/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-list-nationally-authorised-medicinal-products-psusa00010390201907_en.pdf"},
    {"id":"46817","name":"Clebopride: List of nationally authorised medicinal products - PSUSA/00000789/201906","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-02-21T09:56:00Z","last_updated_date":"2020-02-21T09:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clebopride-list-nationally-authorised-medicinal-products-psusa00000789201906_en.pdf"},
    {"id":"46837","name":"Dienogest / estradiol (HRT indication): List of nationally authorised medicinal products - PSUSA/00010443/201906","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-02-24T16:05:00Z","last_updated_date":"2020-02-24T16:05:00Z","reference_number":"EMA/90195/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/dienogest-estradiol-hrt-indication-list-nationally-authorised-medicinal-products-psusa00010443201906_en.pdf"},
    {"id":"46986","name":"Levonorgestrel: List of nationally authorised medicinal products - PSUSA/00001856/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-10T09:57:00Z","last_updated_date":"2020-03-10T09:57:00Z","reference_number":"EMA/117021/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-list-nationally-authorised-medicinal-products-psusa00001856201905_en.pdf"},
    {"id":"46987","name":"Levonorgestrel: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001856/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-10T09:57:00Z","last_updated_date":"2020-03-10T09:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levonorgestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001856201905_no.pdf"}},
    {"id":"46993","name":"Moxifloxacin (systemic use): List of nationally authorised medicinal products - PSUSA/00009231/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-10T15:28:00Z","last_updated_date":"2020-03-10T15:28:00Z","reference_number":"EMA/123159/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/moxifloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa00009231201905_en.pdf"},
    {"id":"46994","name":"Moxifloxacin (systemic use): CMDh Scientific conclusions, amendments to product information and implementation timetable - PSUSA/00009231/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-10T15:48:00Z","last_updated_date":"2020-03-10T15:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00009231201905_no.pdf"}},
    {"id":"46995","name":"Tolperisone: List of nationally authorised medicinal products - PSUSA/00002991/201906","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-11T09:20:00Z","last_updated_date":"2020-03-11T09:20:00Z","reference_number":"EMA/128326/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/tolperisone-list-nationally-authorised-medicinal-products-psusa00002991201906_en.pdf"},
    {"id":"46996","name":"Tolperisone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002991/201906","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-11T09:23:00Z","last_updated_date":"2020-03-11T09:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tolperisone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002991201906_sv.pdf"}},
    {"id":"47005","name":"Levomethadone: List of nationally authorised medicinal products - PSUSA/00001855/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-12T14:50:00Z","last_updated_date":"2020-03-12T14:50:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/levomethadone-list-nationally-authorised-medicinal-products-psusa00001855201905_en.pdf"},
    {"id":"47006","name":"Levomethadone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001855/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-12T14:50:00Z","last_updated_date":"2020-03-12T14:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855201905_no.pdf"}},
    {"id":"47007","name":"Zaleplon: List of nationally authorised medicinal products - PSUSA/00003140/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-12T14:55:00Z","last_updated_date":"2020-03-12T14:55:00Z","reference_number":"EMA/130316/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/zaleplon-list-nationally-authorised-medicinal-products-psusa00003140201907_en.pdf"},
    {"id":"47033","name":"Methadone: List of nationally authorised medicinal products - PSUSA/00002004/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-17T11:22:00Z","last_updated_date":"2020-03-17T11:22:00Z","reference_number":"EMA/139738/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/methadone-list-nationally-authorised-medicinal-products-psusa00002004201905_en.pdf"},
    {"id":"47036","name":"Human coagulation factor IX: List of nationally authorised medicinal products - PSUSA/00001617/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-17T14:45:00Z","last_updated_date":"2020-03-17T14:45:00Z","reference_number":"EMA/118966/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-ix-list-nationally-authorised-medicinal-products-psusa00001617201907_en.pdf"},
    {"id":"47042","name":"Mitoxantrone: List of nationally authorised medicinal products - PSUSA/00002076/201906","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-18T14:14:00Z","last_updated_date":"2020-03-18T14:14:00Z","reference_number":"EMA/118966/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/mitoxantrone-list-nationally-authorised-medicinal-products-psusa00002076201906_en.pdf"},
    {"id":"47043","name":"Nimodipine: List of nationally authorised medicinal products - PSUSA/00002166/201811","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-18T15:00:00Z","last_updated_date":"2020-03-18T15:00:00Z","reference_number":"EMA/143254/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimodipine-list-nationally-authorised-medicinal-products-psusa00002166201811_en.pdf"},
    {"id":"47045","name":"Human coagulation factor viii / human von willebrand factor : List of nationally authorised medicinal products - PSUSA/00001621/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-18T16:15:00Z","last_updated_date":"2020-03-18T16:15:00Z","reference_number":"EMA/143917/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-viii-human-von-willebrand-factor-list-nationally-authorised-medicinal-products-psusa00001621201810_en.pdf"},
    {"id":"47046","name":"Bromocriptine : List of nationally authorised medicinal products - PSUSA/00000438/201810","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-18T16:15:00Z","last_updated_date":"2020-03-18T16:15:00Z","reference_number":"EMA/144003/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromocriptine-list-nationally-authorised-medicinal-products-psusa00000438201810_en.pdf"},
    {"id":"47053","name":"Allergen for therapy: Phleum Pratense (oromucosal use, product authorised via mutually recognition procedure): List of nationally authorised medicinal products - PSUSA/00010475/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-19T11:07:00Z","last_updated_date":"2020-03-19T11:07:00Z","reference_number":"EMA/143004/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-phleum-pratense-oromucosal-use-product-authorised-mutually-recognition-procedure-list-nationally-authorised-medicinal-products-psusa00010475201907_en.pdf"},
    {"id":"47054","name":"Human hemin: List of nationally authorised medicinal products - PSUSA/00001629/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-19T11:20:00Z","last_updated_date":"2020-03-19T11:20:00Z","reference_number":"EMA/143053/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-hemin-list-nationally-authorised-medicinal-products-psusa00001629201905_en.pdf"},
    {"id":"47058","name":"Amsacrine: List of nationally authorised medicinal products - PSUSA/00000199/201906","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-19T16:36:00Z","last_updated_date":"2020-03-19T16:36:00Z","reference_number":"EMA/142917/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/amsacrine-list-nationally-authorised-medicinal-products-psusa00000199201906_en.pdf"},
    {"id":"47093","name":"Methadone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002004/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-17T11:22:00Z","last_updated_date":"2020-03-17T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002004-201905_no.pdf"}},
    {"id":"47112","name":"Fosfomycin (oral formulation): List of nationally authorised medicinal products - PSUSA/00010326/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-25T11:12:00Z","last_updated_date":"2020-03-25T11:12:00Z","reference_number":"EMA/154431/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosfomycin-oral-formulation-list-nationally-authorised-medicinal-products-psusa00010326201907_en.pdf"},
    {"id":"47134","name":"Fosfomycin (IV formulation): List of nationally authorised medicinal products - PSUSA/00010336/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-03-25T16:05:00Z","last_updated_date":"2020-03-25T16:05:00Z","reference_number":"EMA/154407/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosfomycin-iv-formulation-list-nationally-authorised-medicinal-products-psusa00010336201907_en.pdf"},
    {"id":"47318","name":"Iobitridol: List of nationally authorised medicinal products - PSUSA/00001761/201904","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-03T11:39:00Z","last_updated_date":"2020-04-03T11:39:00Z","reference_number":"EMA/173989/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/iobitridol-list-nationally-authorised-medicinal-products-psusa00001761201904_en.pdf"},
    {"id":"47320","name":"Iobitridol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001761/201904","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-03T11:41:00Z","last_updated_date":"2020-04-03T11:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_el.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/iobitridol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001761201904_no.pdf"}},
    {"id":"47323","name":"Pholcodine: List of nationally authorised medicinal products - PSUSA/00002396/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-03T12:13:00Z","last_updated_date":"2020-04-03T12:13:00Z","reference_number":"EMA/178348/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/pholcodine-list-nationally-authorised-medicinal-products-psusa00002396201905_en.pdf"},
    {"id":"47324","name":"Pholcodine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002396/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-03T12:13:00Z","last_updated_date":"2020-04-03T12:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002396-201905_sv.pdf"}},
    {"id":"47365","name":"Pitavastatin: List of nationally authorised medicinal products - PSUSA/00010502/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-07T12:00:00Z","last_updated_date":"2020-04-07T12:00:00Z","reference_number":"EMA/185150/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/pitavastatin-list-nationally-authorised-medicinal-products-psusa00010502201907_en.pdf"}    {"id":"47366","name":"Pitavastatin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010502/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-07T12:02:00Z","last_updated_date":"2020-04-07T12:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/pitavastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010502201907_no.pdf"}},
    {"id":"47373","name":"Ibuprofen / pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00001711/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-07T09:30:00Z","last_updated_date":"2020-04-07T09:30:00Z","reference_number":"EMA/180675/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00001711201907_en.pdf"},
    {"id":"47374","name":"Ibuprofen / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the product Information and timetable for the implementation - PSUSA/00001711/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-07T09:30:00Z","last_updated_date":"2020-04-07T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001711201907_sv.pdf"}},
    {"id":"47435","name":"Lercanidipine : List of nationally authorised medicinal products - PSUSA/00001841/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-20T11:29:00Z","last_updated_date":"2020-04-20T11:29:00Z","reference_number":"EMA/211991/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/lercanidipine-list-nationally-authorised-medicinal-products-psusa00001841201908_en.pdf"},
    {"id":"47442","name":"Beclometasone / formoterol (inhalative application): List of nationally authorised medicinal products - PSUSA/00010068/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-21T15:36:00Z","last_updated_date":"2020-04-21T15:36:00Z","reference_number":"EMA/218638/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/beclometasone-formoterol-inhalative-application-list-nationally-authorised-medicinal-products-psusa00010068201907_en.pdf"},
    {"id":"47443","name":"Allergen for therapy: Dermatophagoides pteronyssinus / Dermatophagoides farina : List of nationally authorised medicinal products - PSUSA/00010582/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-21T15:49:00Z","last_updated_date":"2020-04-21T15:49:00Z","reference_number":"EMA/218763/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-dermatophagoides-pteronyssinus-dermatophagoides-farina-list-nationally-authorised-medicinal-products-psusa00010582201909_en.pdf"},
    {"id":"47446","name":"Paricalcitol : List of nationally authorised medicinal products - PSUSA/00002316/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-22T10:54:00Z","last_updated_date":"2020-04-22T10:54:00Z","reference_number":"EMA/222031/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/paricalcitol-list-nationally-authorised-medicinal-products-psusa00002316201908_en.pdf"},
    {"id":"47447","name":"Finasteride : List of nationally authorised medicinal products - PSUSA/00001392/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-22T11:00:00Z","last_updated_date":"2020-04-22T11:00:00Z","reference_number":"EMA/222089/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392201908_en.pdf"},
    {"id":"47448","name":"Ce (conjugated estrogens) / mpa (medroxyprogesterone acetate) : List of nationally authorised medicinal products - PSUSA/00000582/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-22T11:03:00Z","last_updated_date":"2020-04-22T11:03:00Z","reference_number":"EMA/221908/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/ce-conjugated-estrogens-mpa-medroxyprogesterone-acetate-list-nationally-authorised-medicinal-products-psusa00000582201908_en.pdf"},
    {"id":"47456","name":"Biperiden: List of nationally authorised medicinal products - PSUSA/00000415/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-22T16:50:00Z","last_updated_date":"2020-04-22T16:50:00Z","reference_number":"EMA/200603/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/biperiden-list-nationally-authorised-medicinal-products-psusa00000415201908_en.pdf"},
    {"id":"47484","name":"Amlodipine / losartan : List of nationally authorised medicinal products - PSUSA/00010512/201901","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-24T12:12:00Z","last_updated_date":"2020-04-24T12:12:00Z","reference_number":"EMA/229121/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-losartan-list-nationally-authorised-medicinal-products-psusa00010512201901_en.pdf"},
    {"id":"47504","name":"Thiocolcicoside: List of nationally authorised medicinal products -  EMEA/H/N/PSR/J/0023","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-28T17:30:00Z","last_updated_date":"2020-04-28T17:30:00Z","reference_number":"EMA/230507/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiocolcicoside-list-nationally-authorised-medicinal-products-emeahnpsrj0023_en.pdf"},
    {"id":"47505","name":"Thiocolcicoside: CMDh Scientific conclusions, amendments to product information and implementation timetable - EMEA/H/N/PSR/J/0023","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-28T17:34:00Z","last_updated_date":"2020-04-28T17:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/thiocolcicoside-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emeahnpsrj0023_sv.pdf"}},
    {"id":"47511","name":"Nifuroxazide : List of nationally authorised medicinal products - PSUSA/00002160/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-04-29T14:12:00Z","last_updated_date":"2020-04-29T14:12:00Z","reference_number":"EMA/222200/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/nifuroxazide-list-nationally-authorised-medicinal-products-psusa00002160201908_en.pdf"},
    {"id":"47632","name":"Ropinirole: List of nationally authorised medicinal products - PSUSA/00002661201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-08T15:11:00Z","last_updated_date":"2020-05-08T15:11:00Z","reference_number":"EMA/249485/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropinirole-list-nationally-authorised-medicinal-products-psusa00002661201907_en.pdf"},
    {"id":"47633","name":"Ropinirole: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002661201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-08T15:15:00Z","last_updated_date":"2020-05-08T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661201907_no.pdf"}},
    {"id":"47635","name":"Brivudine: List of nationally authorised medicinal products - PSUSA/00000434/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-08T16:50:00Z","last_updated_date":"2020-05-08T16:50:00Z","reference_number":"EMA/246826/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/brivudine-list-nationally-authorised-medicinal-products-psusa00000434201907_en.pdf"},
    {"id":"47636","name":"Brivudine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000434/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-08T16:50:00Z","last_updated_date":"2020-05-08T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/brivudine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000434201907_sv.pdf"}},
    {"id":"47639","name":"Oxcarbazepinexcarbazepine : List of nationally authorised medicinal products - PSUSA/00002235/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-11T14:12:00Z","last_updated_date":"2020-05-11T14:12:00Z","reference_number":"EMA/254773/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxcarbazepinexcarbazepine-list-nationally-authorised-medicinal-products-psusa00002235201908_en.pdf"},
    {"id":"47706","name":"Busulfan: List of nationally authorised medicinal products - PSUSA/0464/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T11:18:00Z","last_updated_date":"2020-05-19T11:18:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/busulfan-list-nationally-authorised-medicinal-products-psusa0464201907_en.pdf"},
    {"id":"47708","name":"Busulfan: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/0464/201907","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T11:21:00Z","last_updated_date":"2020-05-19T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/busulfan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa0464201907_no.pdf"}},
    {"id":"47710","name":"Pramiracetam: List of nationally authorised medicinal products - PSUSA/00002492/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T12:20:00Z","last_updated_date":"2020-05-18T12:20:00Z","reference_number":"EMA/268260/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/pramiracetam-list-nationally-authorised-medicinal-products-psusa00002492201909_en.pdf"},
    {"id":"47711","name":"Atenolol / chlortalidone: List of nationally authorised medicinal products - PSUSA/00000260/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T13:32:00Z","last_updated_date":"2020-05-19T13:32:00Z","reference_number":"EMA/268715/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/atenolol-chlortalidone-list-nationally-authorised-medicinal-products-psusa00000260201909_en.pdf"},
    {"id":"47712","name":"Dinoprostone: List of nationally authorised medicinal products - PSUSA/00001104/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T14:17:00Z","last_updated_date":"2020-05-19T14:17:00Z","reference_number":"EMA/273043/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/dinoprostone-list-nationally-authorised-medicinal-products-psusa00001104201909_en.pdf"},
    {"id":"47713","name":"Valsartan / rosuvastatin: List of nationally authorised medicinal products - PSUSA/00010735/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T14:21:00Z","last_updated_date":"2020-05-19T14:21:00Z","reference_number":"EMA/273143/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/valsartan-rosuvastatin-list-nationally-authorised-medicinal-products-psusa00010735201910_en.pdf"},
    {"id":"47740","name":"Ambroxol : List of nationally authorised medicinal products - PSUSA/00000130/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T15:48:00Z","last_updated_date":"2020-05-20T15:48:00Z","reference_number":"EMA/274516/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ambroxol-list-nationally-authorised-medicinal-products-psusa00000130201909_en.pdf"},
    {"id":"47741","name":"Ambroxol / clenbuterol: List of nationally authorised medicinal products - PSUSA/00000131/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T15:50:00Z","last_updated_date":"2020-05-20T15:50:00Z","reference_number":"EMA/276465/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ambroxol-clenbuterol-list-nationally-authorised-medicinal-products-psusa00000131201909_en.pdf"},
    {"id":"47742","name":"Clenbuterol: List of nationally authorised medicinal products - PSUSA/00000794/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T15:52:00Z","last_updated_date":"2020-05-20T15:52:00Z","reference_number":"EMA/276595/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/clenbuterol-list-nationally-authorised-medicinal-products-psusa00000794201909_en.pdf"},
    {"id":"47743","name":"Aminosalicylate sodium: List of nationally authorised medicinal products - PSUSA/00000165/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T15:53:00Z","last_updated_date":"2020-05-20T15:53:00Z","reference_number":"EMA/276392/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/aminosalicylate-sodium-list-nationally-authorised-medicinal-products-psusa00000165201910_en.pdf"},
    {"id":"47744","name":"Chlorquinaldol (vaginal tablet) / promestriene : List of nationally authorised medicinal products - PSUSA/00009272/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T15:56:00Z","last_updated_date":"2020-05-20T15:56:00Z","reference_number":"EMA/276712/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorquinaldol-vaginal-tablet-promestriene-list-nationally-authorised-medicinal-products-psusa00009272201909_en.pdf"},
    {"id":"47746","name":"Drospirenone / ethinylestradiol: List of nationally authorised medicinal products - PSUSA/00010217/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T17:20:00Z","last_updated_date":"2020-05-20T17:20:00Z","reference_number":"EMA/PRAC/274366/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/drospirenone-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa00010217201909_en.pdf"},
    {"id":"47747","name":"Betamethasone / tetryzoline: List of nationally authorised medicinal products - PSUSA/00010072/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T17:20:00Z","last_updated_date":"2020-05-20T17:20:00Z","reference_number":"EMA/277122/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/betamethasone-tetryzoline-list-nationally-authorised-medicinal-products-psusa00010072201909_en.pdf"},
    {"id":"47748","name":"Itopride: List of nationally authorised medicinal products - PSUSA/00010606/201906","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T17:20:00Z","last_updated_date":"2020-05-20T17:20:00Z","reference_number":"EMA/277590/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/itopride-list-nationally-authorised-medicinal-products-psusa00010606201906_en.pdf"},
    {"id":"47750","name":"Acitretin: List of nationally authorised medicinal products - PSUSA/00000051/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-05-25T09:28:00Z","last_updated_date":"2020-05-25T09:28:00Z","reference_number":"EMA/272342/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-list-nationally-authorised-medicinal-products-psusa00000051201910_en.pdf"},
    {"id":"47898","name":"Sotalol: List of nationally authorised medicinal products - PSUSA/00002774/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-09T10:37:00Z","last_updated_date":"2020-06-09T10:37:00Z","reference_number":"EMA/308920/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/sotalol-list-nationally-authorised-medicinal-products-psusa00002774201908_en.pdf"},
    {"id":"47899","name":"Sotalol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002774/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-09T10:43:00Z","last_updated_date":"2020-06-09T10:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/sotalol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_no.pdf"}},
    {"id":"47903","name":"Dexamfetamine: List of nationally authorised medicinal products - PSUSA/00000986/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-09T17:00:00Z","last_updated_date":"2020-06-09T17:00:00Z","reference_number":"EMA/222218/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-psusa00000986201909_en.pdf"},
    {"id":"47904","name":"Dexamfetamine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002774/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-09T17:01:00Z","last_updated_date":"2020-06-09T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002774201908_no.pdf"}},
    {"id":"47944","name":"Hydrocortisone (except for products indicated in adrenal insufficiency in a modified release tablet formulation): List of nationally authorised medicinal products - PSUSA/00010328/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-10T16:55:00Z","last_updated_date":"2020-06-10T16:55:00Z","reference_number":"EMA/311363/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-formulation-list-nationally-authorised-medicinal-products-psusa00010328201908_en.pdf"},
    {"id":"47945","name":"Hydrocortisone (except for products indicated in adrenal insufficiency in a modified release tablet: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010328/201908","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-10T16:59:00Z","last_updated_date":"2020-06-10T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/hydrocortisone-except-products-indicated-adrenal-insufficiency-modified-release-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_no.pdf"}},
    {"id":"48006","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-15T11:24:00Z","last_updated_date":"2020-06-15T11:24:00Z","reference_number":"EMA/307113/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288201911_en.pdf"},
    {"id":"48015","name":"Timolol (systemic use): List of nationally authorised medicinal products - PSUSA/00010432/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-16T10:04:00Z","last_updated_date":"2020-06-16T10:04:00Z","reference_number":"EMA/322289/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/timolol-systemic-use-list-nationally-authorised-medicinal-products-psusa00010432201910_en.pdf"},
    {"id":"48020","name":"Corticorelin: List of nationally authorised medicinal products - PSUSA/00000876/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-16T11:48:00Z","last_updated_date":"2020-06-16T11:48:00Z","reference_number":"EMA/321003/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/corticorelin-list-nationally-authorised-medicinal-products-psusa00000876201910_en.pdf"},
    {"id":"48021","name":"1-propanol / 2-propanol / orthophenylphenol: List of nationally authorised medicinal products - PSUSA/00010406/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-16T11:55:00Z","last_updated_date":"2020-06-16T11:55:00Z","reference_number":"EMA/322011/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/1-propanol-2-propanol-orthophenylphenol-list-nationally-authorised-medicinal-products-psusa00010406201910_en.pdf"},
    {"id":"48022","name":"Calcium salts / colecalciferol: List of nationally authorised medicinal products - PSUSA/00010386/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-16T11:59:00Z","last_updated_date":"2020-06-16T11:59:00Z","reference_number":"EMA/322204/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-salts-colecalciferol-list-nationally-authorised-medicinal-products-psusa00010386201910_en.pdf"},
    {"id":"48026","name":"Fluticasone / salmeterol: List of nationally authorised medicinal products - PSUSA/00001455/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-16T11:59:00Z","last_updated_date":"2020-06-16T11:59:00Z","reference_number":"EMA/326863/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluticasone-salmeterol-list-nationally-authorised-medicinal-products-psusa00001455201910_en.pdf"},
    {"id":"48029","name":"Felbamate: List of nationally authorised medicinal products - PSUSA/00010155/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-16T16:15:00Z","last_updated_date":"2020-06-16T16:15:00Z","reference_number":"EMA/274939/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/felbamate-list-nationally-authorised-medicinal-products-psusa00010155201909_en.pdf"},
    {"id":"48031","name":"Isoniazid: List of nationally authorised medicinal products - PSUSA/00001789/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-17T11:25:00Z","last_updated_date":"2020-06-17T11:25:00Z","reference_number":"EMA/327864/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoniazid-list-nationally-authorised-medicinal-products-psusa00001789201911_en.pdf"},
    {"id":"48033","name":"Tixocortol, chlorhexidine gluconate / tixocortol pivalate: List of nationally authorised medicinal products - PSUSA/00010333/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-17T11:25:00Z","last_updated_date":"2020-06-17T11:25:00Z","reference_number":"EMA/327982/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-list-nationally-authorised-medicinal-products-psusa00010333201911_en.pdf"},
    {"id":"48034","name":"Ozenoxacin: List of nationally authorised medicinal products - PSUSA/00010651/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-17T11:25:00Z","last_updated_date":"2020-06-17T11:25:00Z","reference_number":"EMA/328197/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ozenoxacin-list-nationally-authorised-medicinal-products-psusa00010651201911_en.pdf"},
    {"id":"48041","name":"Isoflurane: List of nationally authorised medicinal products - PSUSA/00001786/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-17T15:31:00Z","last_updated_date":"2020-06-17T15:31:00Z","reference_number":"EMA/329588/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoflurane-list-nationally-authorised-medicinal-products-psusa00001786201910_en.pdf"},
    {"id":"48053","name":"Methoxyflurane: List of nationally authorised medicinal products - PSUSA/00010484/201905","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-06-18T11:51:00Z","last_updated_date":"2020-06-18T11:51:00Z","reference_number":"EMA/331322/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa00010484201905_en.pdf-0"},
    {"id":"48240","name":"Levosimendan: List of nationally authorised medicinal products - PSUSA/00001858/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-07T13:00:00Z","last_updated_date":"2020-07-07T13:00:00Z","reference_number":"EMA/361588/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/levosimendan-list-nationally-authorised-medicinal-products-psusa00001858201909_en.pdf"},
    {"id":"48241","name":"Levosimendan: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001858/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-07T13:00:00Z","last_updated_date":"2020-07-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levosimendan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001858201909_no.pdf"}},
    {"id":"48242","name":"Carbidopa / levodopa: List of nationally authorised medicinal products - PSUSA/00000548/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-07T14:37:00Z","last_updated_date":"2020-07-07T14:37:00Z","reference_number":"EMA/259032/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbidopa-levodopa-list-nationally-authorised-medicinal-products-psusa00000548201910_en.pdf"},
    {"id":"48243","name":"Carbidopa / levodopa: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000548/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-07T14:40:00Z","last_updated_date":"2020-07-07T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548201910_no.pdf"}},
    {"id":"48287","name":"1-propanol / 2-propanol / lactic acid : List of nationally authorised medicinal products - PSUSA/000010414/201909","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2020-07-13T10:42:00Z","last_updated_date":"2020-07-13T10:42:00Z","reference_number":"EMA/374107/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/1-propanol-2-propanol-lactic-acid-list-nationally-authorised-medicinal-products-psusa000010414201909_en.pdf"},
    {"id":"48288","name":"1-propanol / 2-propanol / lactic acid: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010414/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-13T10:48:00Z","last_updated_date":"2020-07-13T10:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/1-propanol-2-propanol-lactic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010414201909_sv.pdf"}},
    {"id":"48289","name":"Flurbiprofen : List of nationally authorised medicinal products - PSUSA/00001450/201911","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2020-07-13T10:59:00Z","last_updated_date":"2020-07-13T10:59:00Z","reference_number":"EMA/374512/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/flurbiprofen-list-nationally-authorised-medicinal-products-psusa00001450201911_en.pdf"},
    {"id":"48294","name":"Brotizolam: List of nationally authorised medicinal products - PSUSA/00000444/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-13T14:35:00Z","last_updated_date":"2020-07-13T14:35:00Z","reference_number":"EMA/314232/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/brotizolam-list-nationally-authorised-medicinal-products-psusa00000444201912_en.pdf"},
    {"id":"48295","name":"Human coagulation factor VIII (antihemophilic factor A): List of nationally authorised medicinal products - PSUSA/00001620/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-13T14:35:00Z","last_updated_date":"2020-07-13T14:35:00Z","reference_number":"EMA/348432/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-viii-antihemophilic-factor-list-nationally-authorised-medicinal-products-psusa00001620201911_en.pdf"},
    {"id":"48296","name":"Cinolazepam: List of nationally authorised medicinal products - PSUSA/00000769/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-13T14:35:00Z","last_updated_date":"2020-07-13T14:35:00Z","reference_number":"EMA/314238/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/cinolazepam-list-nationally-authorised-medicinal-products-psusa00000769201912_en.pdf"},
    {"id":"48301","name":"Artemether-lumefantrin (apart from the dispersible tablet): List of nationally authorised medicinal products - PSUSA/00000236/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-14T12:00:00Z","last_updated_date":"2020-07-14T12:00:00Z","reference_number":"EMA/372797/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-list-nationally-authorised-medicinal-products-psusa00000236201910_en.pdf"},
    {"id":"48302","name":"Artemether-lumefantrin (apart from the dispersible tablet): CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000236/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-14T12:00:00Z","last_updated_date":"2020-07-14T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000236201910_sv.pdf"}},
    {"id":"48307","name":"Sumatriptan : List of nationally authorised medicinal products - PSUSA/00002832/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-15T13:00:00Z","last_updated_date":"2020-07-15T13:00:00Z","reference_number":"EMA/373597/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/sumatriptan-list-nationally-authorised-medicinal-products-psusa00002832201909_en.pdf"},
    {"id":"48308","name":"Sumatriptan : CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002832/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-15T14:00:00Z","last_updated_date":"2020-07-15T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/sumatriptan-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002832201909_no.pdf"}},
    {"id":"48315","name":"Apomorphine: List of nationally authorised medicinal products - PSUSA/00000227/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-16T12:51:00Z","last_updated_date":"2020-07-16T12:51:00Z","reference_number":"EMA/378670/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/apomorphine-list-nationally-authorised-medicinal-products-psusa00000227201911_en.pdf"},
    {"id":"48316","name":"Dienogest:List of nationally authorised medicinal products - PSUSA/00003167/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-16T14:58:00Z","last_updated_date":"2020-07-16T14:58:00Z","reference_number":"EMA/379991/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/dienogestlist-nationally-authorised-medicinal-products-psusa00003167201912_en.pdf"},
    {"id":"48317","name":"Drospirenone / estradiol: List of nationally authorised medicinal products - PSUSA/00001184/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-16T15:06:00Z","last_updated_date":"2020-07-16T15:06:00Z","reference_number":"EMA/379925/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/drospirenone-estradiol-list-nationally-authorised-medicinal-products-psusa00001184201912_en.pdf"},
    {"id":"48318","name":"Tibole: List of nationally authorised medicinal products - PSUSA/00002947/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-16T16:45:00Z","last_updated_date":"2020-07-16T16:45:00Z","reference_number":"EMA/379925/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/tibole-list-nationally-authorised-medicinal-products-psusa00002947201912_en.pdf"},
    {"id":"48319","name":"Sulbactam: List of nationally authorised medicinal products - PSUSA/00002800/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-16T16:45:00Z","last_updated_date":"2020-07-16T16:45:00Z","reference_number":"EMA/383810/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulbactam-list-nationally-authorised-medicinal-products-psusa00002800201911_en.pdf"},
    {"id":"48320","name":"Domperidone: List of nationally authorised medicinal products - PSUSA/00001158/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-16T17:15:00Z","last_updated_date":"2020-07-16T17:15:00Z","reference_number":"EMA/383847/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/domperidone-list-nationally-authorised-medicinal-products-psusa00001158201911_en.pdf"},
    {"id":"48321","name":"Anthrax vaccine: List of nationally authorised medicinal products - PSUSA/00010771/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-16T17:30:00Z","last_updated_date":"2020-07-16T17:30:00Z","reference_number":"EMA/385148/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/anthrax-vaccine-list-nationally-authorised-medicinal-products-psusa00010771201912_en.pdf"},
    {"id":"48322","name":"Dexamfetamine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/0000986/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-17T11:26:00Z","last_updated_date":"2020-07-17T11:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-0000986-201909_no.pdf"}},
    {"id":"48352","name":"Chloroquine phosphate / proguanil hydrochloride: List of nationally authorised medicinal products - PSUSA/00010207/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-22T10:00:00Z","last_updated_date":"2020-07-22T10:00:00Z","reference_number":"EMA/385380/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/chloroquine-phosphate-proguanil-hydrochloride-list-nationally-authorised-medicinal-products-psusa00010207201911_en.pdf"},
    {"id":"48430","name":"Opium: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010670/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-27T17:01:00Z","last_updated_date":"2020-07-27T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/opium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010670201909_no.pdf"}},
    {"id":"48466","name":"Methylphenidate: List of nationally authorised medicinal products - PSUSA/00002024/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-28T17:37:00Z","last_updated_date":"2020-07-28T17:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-list-nationally-authorised-medicinal-products-psusa00002024201910_en.pdf"},
    {"id":"48467","name":"Methylphenidate: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002024/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-28T17:49:00Z","last_updated_date":"2020-07-28T17:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methylphenidate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002024201910_no.pdf"}},
    {"id":"48605","name":"Lenograstim: List of nationally authorised medicinal products - PSUSA/00001839/201910","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2020-08-13T16:38:00Z","last_updated_date":"2020-08-13T16:38:00Z","reference_number":"EMA/422908/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/lenograstim-list-nationally-authorised-medicinal-products-psusa00001839201910_en.pdf"},
    {"id":"48606","name":"Lenograstim: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation  - PSUSA/00001839/201910","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-08-13T16:42:00Z","last_updated_date":"2020-08-13T16:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lenograstim-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001839201910_sv.pdf"}},
    {"id":"48716","name":"Pancuronium: List of nationally authorised medicinal products - PSUSA/00002275/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-08-28T12:14:00Z","last_updated_date":"2020-08-28T12:14:00Z","reference_number":"EMA/453105/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/pancuronium-list-nationally-authorised-medicinal-products-psusa00002275201912_en.pdf"},
    {"id":"48717","name":"Pancuronium: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002275/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-08-28T12:16:00Z","last_updated_date":"2020-08-28T12:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/pancuronium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002275201912_no.pdf"}},
    {"id":"48764","name":"Iron (parenteral preparations, except for iron dextran): List of nationally authorised medicinal products - PSUSA/00010236/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-07T16:10:00Z","last_updated_date":"2020-09-07T16:10:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-parenteral-preparations-except-iron-dextran-list-nationally-authorised-medicinal-products-psusa00010236202001_en.pdf"},
    {"id":"48765","name":"Iron (parenteral preparations, except for iron dextran): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010236/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-07T16:10:00Z","last_updated_date":"2020-09-07T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010236202001_no.pdf"}},
    {"id":"48771","name":"Varicella zoster-immunoglobulin: List of nationally authorised medicinal products - PSUSA/00010266/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-09T11:47:00Z","last_updated_date":"2020-09-09T11:47:00Z","reference_number":"EMA/464940/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/varicella-zoster-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00010266201912_en.pdf"},
    {"id":"48772","name":"Human alpha1-proteinase inhibitor (apart from the centrally authorised product): List of nationally authorised medicinal products - PSUSA/00000108/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-09T11:50:00Z","last_updated_date":"2020-09-09T11:50:00Z","reference_number":"EMA/351582/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-alpha1-proteinase-inhibitor-apart-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00000108201912_en.pdf"},
    {"id":"48773","name":"Sodium benzoate / grindelia tincture / polygala syrup: List of nationally authorised medicinal products - PSUSA/00010543/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-09T11:51:00Z","last_updated_date":"2020-09-09T11:51:00Z","reference_number":"EMA/453705/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-benzoate-grindelia-tincture-polygala-syrup-list-nationally-authorised-medicinal-products-psusa00010543201912_en.pdf"},
    {"id":"48783","name":"Landiolol: List of nationally authorised medicinal products - PSUSA/00010570/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T11:29:00Z","last_updated_date":"2020-09-11T11:29:00Z","reference_number":"EMA/472025/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/landiolol-list-nationally-authorised-medicinal-products-psusa00010570202002_en.pdf"},
    {"id":"48784","name":"Alitretinoin (oral use): List of nationally authorised medicinal products - PSUSA/00010710/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T11:32:00Z","last_updated_date":"2020-09-11T11:32:00Z","reference_number":"EMA/472049/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/alitretinoin-oral-use-list-nationally-authorised-medicinal-products-psusa00010710202001_en.pdf"},
    {"id":"48785","name":"Celiprolol: List of nationally authorised medicinal products - PSUSA/00000617/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T11:32:00Z","last_updated_date":"2020-09-11T11:32:00Z","reference_number":"EMA/PRAC/473760/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/celiprolol-list-nationally-authorised-medicinal-products-psusa00000617202001_en.pdf"},
    {"id":"48786","name":"Omega-3-acid ethyl esters: List of nationally authorised medicinal products - PSUSA/00010312/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T11:32:00Z","last_updated_date":"2020-09-11T11:32:00Z","reference_number":"EMA/474212/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/omega-3-acid-ethyl-esters-list-nationally-authorised-medicinal-products-psusa00010312202001_en.pdf"},
    {"id":"48787","name":"Metamizole sodium / triacetonamine tosilate: List of nationally authorised medicinal products - PSUSA/00001999/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T11:32:00Z","last_updated_date":"2020-09-11T11:32:00Z","reference_number":"EMA/470386/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/metamizole-sodium-triacetonamine-tosilate-list-nationally-authorised-medicinal-products-psusa00001999202001_en.pdf"},
    {"id":"48788","name":"Allergen for therapy: Dactylis Glomerata L., Phleum Pratense L., Anthoxanthum Odoratum L., Lolium Perenne L., Poa Pratensis L. (sublingual tablet): List of nationally authorised medicinal products - PSUSA/00010465/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T11:32:00Z","last_updated_date":"2020-09-11T11:32:00Z","reference_number":"EMA/470436/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-dactylis-glomerata-l-phleum-pratense-l-anthoxanthum-odoratum-l-lolium-perenne-l-poa-pratensis-l-sublingual-tablet-list-nationally-authorised-medicinal-products-psusa00010465201912_en.pdf"},
    {"id":"48789","name":"Sertindole: List of nationally authorised medicinal products - PSUSA/00002695/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T11:32:00Z","last_updated_date":"2020-09-11T11:32:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/sertindole-list-nationally-authorised-medicinal-products-psusa00002695202001_en.pdf"},
    {"id":"48790","name":"Bacillus clausii multi-antibioresistant spores: List of nationally authorised medicinal products - PSUSA/00000284/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T11:32:00Z","last_updated_date":"2020-09-11T11:32:00Z","reference_number":"EMA/474604/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-list-nationally-authorised-medicinal-products-psusa00000284201911_en.pdf"},
    {"id":"48791","name":"Bacillus clausii multi-antibioresistant spores: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000284/201911","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T11:32:00Z","last_updated_date":"2020-09-11T11:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_ro.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000284201911_fi.pdf"}},
    {"id":"48808","name":"Lidocaine / phenazone: List of nationally authorised medicinal products - PSUSA/00002359/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-14T15:48:00Z","last_updated_date":"2020-09-14T15:48:00Z","reference_number":"EMA/470429/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-phenazone-list-nationally-authorised-medicinal-products-psusa00002359202001_en.pdf"},
    {"id":"48809","name":"Cyanocobalamin / diclofenac / pyridoxine / thiamine: List of nationally authorised medicinal products - PSUSA/00001041/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-14T15:48:00Z","last_updated_date":"2020-09-14T15:48:00Z","reference_number":"EMA/476702/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyanocobalamin-diclofenac-pyridoxine-thiamine-list-nationally-authorised-medicinal-products-psusa00001041202001_en.pdf"},
    {"id":"48810","name":"Tizanidine: List of nationally authorised medicinal products - PSUSA/00002977/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-14T15:48:00Z","last_updated_date":"2020-09-14T15:48:00Z","reference_number":"EMA/476734/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/tizanidine-list-nationally-authorised-medicinal-products-psusa00002977201912_en.pdf"},
    {"id":"48812","name":"Amisulpride: List of nationally authorised medicinal products - PSUSA/00000167/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-14T15:48:00Z","last_updated_date":"2020-09-14T15:48:00Z","reference_number":"EMA/476801/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/amisulpride-list-nationally-authorised-medicinal-products-psusa00000167202001_en.pdf"}    {"id":"48866","name":"Beta-alanine: List of nationally authorised medicinal products - PSUSA/00010510/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-09-21T15:30:00Z","last_updated_date":"2020-09-21T15:30:00Z","reference_number":"EMA/475166/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/beta-alanine-list-nationally-authorised-medicinal-products-psusa00010510202001_en.pdf"},
    {"id":"48936","name":"Clobazam: List of nationally authorised medicinal products - PSUSA/00000798/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-02T12:14:00Z","last_updated_date":"2020-10-02T12:14:00Z","reference_number":"EMA/521021/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/clobazam-list-nationally-authorised-medicinal-products-psusa00000798202002_en.pdf"},
    {"id":"48937","name":"Labetalol: List of nationally authorised medicinal products - PSUSA/00001814/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-02T12:15:00Z","last_updated_date":"2020-10-02T12:15:00Z","reference_number":"EMA/494419/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/labetalol-list-nationally-authorised-medicinal-products-psusa00001814202002_en.pdf"},
    {"id":"48938","name":"Acetyl salicylic acid / atorvastatin / ramipril: List of nationally authorised medicinal products - PSUSA/00010280/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-02T12:18:00Z","last_updated_date":"2020-10-02T12:18:00Z","reference_number":"EMA/494405/2020 ","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetyl-salicylic-acid-atorvastatin-ramipril-list-nationally-authorised-medicinal-products-psusa00010280202002_en.pdf"},
    {"id":"48963","name":"Ipratropium salbutamol: List of nationally authorised medicinal products - PSUSA/00001781/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-07T18:30:00Z","last_updated_date":"2020-10-07T18:30:00Z","reference_number":"EMA/525348/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ipratropium-salbutamol-list-nationally-authorised-medicinal-products-psusa00001781202001_en.pdf"},
    {"id":"48981","name":"Amitriptyline hydrochloride / chlordiazepoxide: List of nationally authorised medicinal products - PSUSA/00000171/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-09T12:33:00Z","last_updated_date":"2020-10-09T12:33:00Z","reference_number":"EMA/PRAC/535405/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-hydrochloride-chlordiazepoxide-list-nationally-authorised-medicinal-products-psusa00000171202002_en.pdf"},
    {"id":"48983","name":"Lorazepam: List of nationally authorised medicinal products - PSUSA/00001909/202001","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2020-10-09T14:25:00Z","last_updated_date":"2020-10-09T14:25:00Z","reference_number":"EMA/PRAC/535566/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/lorazepam-list-nationally-authorised-medicinal-products-psusa00001909202001_en.pdf"},
    {"id":"48990","name":"Haemophilus type b and meningococcal group c conjugate vaccine: List of nationally authorised medicinal products - PSUSA/00001583/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-12T10:09:00Z","last_updated_date":"2020-10-12T10:09:00Z","reference_number":"EMA/537226/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/haemophilus-type-b-and-meningococcal-group-c-conjugate-vaccine-list-nationally-authorised-medicinal-products-psusa00001583202002_en.pdf"},
    {"id":"48993","name":"Sevoflurane: List of nationally authorised medicinal products - PSUSA/00002698/202001","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2020-10-12T12:18:00Z","last_updated_date":"2020-10-12T12:18:00Z","reference_number":"EMA/PRAC/535637/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/sevoflurane-list-nationally-authorised-medicinal-products-psusa00002698202001_en.pdf"},
    {"id":"48994","name":"Mannitol (all indications apart from cystic fibrosis): List of nationally authorised medicinal products - PSUSA/00010005/202002","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2020-10-12T12:23:00Z","last_updated_date":"2020-10-12T12:23:00Z","reference_number":"EMA/PRAC/535721/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/mannitol-all-indications-apart-cystic-fibrosis-list-nationally-authorised-medicinal-products-psusa00010005202002_en.pdf"},
    {"id":"49015","name":"Haemophilus type b conjugate vaccines: List of nationally authorised medicinal products - PSUSA/00001584/202002","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2020-10-15T10:19:00Z","last_updated_date":"2020-10-15T10:19:00Z","reference_number":"EMA/541185/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/haemophilus-type-b-conjugate-vaccines-list-nationally-authorised-medicinal-products-psusa00001584202002_en.pdf"},
    {"id":"49046","name":"Mefloquine: List of nationally authorised medicinal products - PSUSA/00001955/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-19T11:40:00Z","last_updated_date":"2020-10-19T11:40:00Z","reference_number":"EMA/542515/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/mefloquine-list-nationally-authorised-medicinal-products-psusa00001955202002_en.pdf"},
    {"id":"49050","name":"Cilostazol: List of nationally authorised medicinal products - PSUSA/00010209/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-19T13:50:00Z","last_updated_date":"2020-10-19T13:50:00Z","reference_number":"EMA/542634/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilostazol-list-nationally-authorised-medicinal-products-psusa00010209202002_en.pdf"},
    {"id":"49051","name":"Influenza vaccine (split virion, inactivated, prepared in cell cultures) : List of nationally authorised medicinal products - PSUSA/00010299/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-19T14:56:00Z","last_updated_date":"2020-10-19T14:56:00Z","reference_number":"EMA/536363/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-prepared-cell-cultures-list-nationally-authorised-medicinal-products-psusa00010299202003_en.pdf"},
    {"id":"49053","name":"Influenza vaccine (surface antigen, inactivated, adjuvanted) : List of nationally authorised medicinal products - PSUSA/00010300/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-19T14:57:00Z","last_updated_date":"2020-10-19T14:57:00Z","reference_number":"EMA/550675/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-adjuvanted-list-nationally-authorised-medicinal-products-psusa00010300202003_en.pdf"},
    {"id":"49054","name":"Influenza vaccine (surface antigen, inactivated) : List of nationally authorised medicinal products - PSUSA/00001744/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-19T15:00:00Z","last_updated_date":"2020-10-19T15:00:00Z","reference_number":"EMA/535987/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa00001744202003_en.pdf"},
    {"id":"49057","name":"Influenza vaccine (split virion, inactivated) (non centrally authorised products): List of nationally authorised medicinal products - PSUSA/00010298/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-19T17:06:00Z","last_updated_date":"2020-10-19T17:06:00Z","reference_number":"EMA/536230/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00010298202003_en.pdf"},
    {"id":"49063","name":"Gaxilose: List of nationally authorised medicinal products - PSUSA/00010283/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T11:02:00Z","last_updated_date":"2020-10-21T11:02:00Z","reference_number":"EMA/557677/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/gaxilose-list-nationally-authorised-medicinal-products-psusa00010283202001_en.pdf"},
    {"id":"49065","name":"Levosalbutamol, salbutamol: List of nationally authorised medicinal products - PSUSA/00010330/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T12:05:00Z","last_updated_date":"2020-10-21T12:05:00Z","reference_number":"EMA/558447/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/levosalbutamol-salbutamol-list-nationally-authorised-medicinal-products-psusa00010330202001_en.pdf"},
    {"id":"49178","name":"Levonorgestrel/ethinylestradiol, ethinylestradiol (combination pack): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010442/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-04T16:25:00Z","last_updated_date":"2020-11-04T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010442-202001_sv.pdf"}},
    {"id":"49181","name":"Phenylephrine (ophthalmic formulations): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010402/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-05T08:40:00Z","last_updated_date":"2020-11-05T08:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/phenylephrine-ophthalmic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010402-202001_no.pdf"}},
    {"id":"49192","name":"Iopamidol: List of nationally authorised medicinal products - PSUSA/00001771/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-06T15:56:00Z","last_updated_date":"2020-11-06T15:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iopamidol-list-nationally-authorised-medicinal-products-psusa00001771201912_en.pdf"},
    {"id":"49193","name":"Iopamidol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001771/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-06T15:56:00Z","last_updated_date":"2020-11-06T15:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/iopamidol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001771201912_sv.pdf"}},
    {"id":"49203","name":"Bendamustine hydrochloride: List of nationally authorised medicinal products - PSUSA/00003162/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-10T11:41:00Z","last_updated_date":"2020-11-10T11:41:00Z","reference_number":"EMA/599638/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendamustine-hydrochloride-list-nationally-authorised-medicinal-products-psusa00003162202001_en.pdf"},
    {"id":"49204","name":"Bendamustine hydrochloride: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003162/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-10T11:41:00Z","last_updated_date":"2020-11-10T11:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003162202001_no.pdf"}},
    {"id":"49205","name":"Codeine camphosulphonate / sodium benzoate, codeine camphosulphonate / sulfogaiacol / grindelia soft extract: List of nationally authorised medicinal products - PSUSA/00010542/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-10T12:04:00Z","last_updated_date":"2020-11-10T12:04:00Z","reference_number":"EMA/599982/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonate-sulfogaiacol-grindelia-soft-extract-list-nationally-authorised-medicinal-products-psusa00010542201912_en.pdf"},
    {"id":"49206","name":"Codeine camphosulphonate / sodium benzoate, codeine camphosulphonate...:CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010542/201912","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-10T12:04:00Z","last_updated_date":"2020-11-10T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonatecmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010542201912_sv.pdf"}},
    {"id":"49374","name":"Clobetasol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000799/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-26T11:19:00Z","last_updated_date":"2020-11-26T11:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/clobetasol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000799202002_no.pdf"}},
    {"id":"49375","name":"Clobetasol: List of nationally authorised medicinal products - PSUSA/00000799/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-26T11:25:00Z","last_updated_date":"2020-11-26T11:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clobetasol-list-nationally-authorised-medicinal-products-psusa00000799202002_en.pdf"},
    {"id":"49400","name":"Lamivudine / tenofovir disoproxil: List of nationally authorised medicinal products - PSUSA/00010751/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-30T10:50:00Z","last_updated_date":"2020-11-30T10:50:00Z","reference_number":"EMA/634109/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/lamivudine-tenofovir-disoproxil-list-nationally-authorised-medicinal-products-psusa00010751202003_en.pdf"},
    {"id":"49407","name":"Mequitazine : List of nationally authorised medicinal products - PSUSA/00001986/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-01T10:04:00Z","last_updated_date":"2020-12-01T10:04:00Z","reference_number":"EMA/639912/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/mequitazine-list-nationally-authorised-medicinal-products-psusa00001986202001_en.pdf"},
    {"id":"49408","name":"Mequitazine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001986/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-01T10:10:00Z","last_updated_date":"2020-12-01T10:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mequitazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001986-202001_sv.pdf"}},
    {"id":"49412","name":"Gentamicin : List of nationally authorised medicinal products - PSUSA/00009159/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-01T11:37:00Z","last_updated_date":"2020-12-01T11:37:00Z","reference_number":"EMA/640938/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/gentamicin-list-nationally-authorised-medicinal-products-psusa00009159202003_en.pdf"},
    {"id":"49418","name":"Ivermectin (topical use): List of nationally authorised medicinal products - PSUSA/00010376/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-01T16:58:00Z","last_updated_date":"2020-12-01T16:58:00Z","reference_number":"EMA/634109/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-topical-use-list-nationally-authorised-medicinal-products-psusa00010376202004_en.pdf"},
    {"id":"49424","name":"Saccharomyces boulardii : List of nationally authorised medicinal products - PSUSA/00009284/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-02T12:12:00Z","last_updated_date":"2020-12-02T12:12:00Z","reference_number":"EMA/645508/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/saccharomyces-boulardii-list-nationally-authorised-medicinal-products-psusa00009284202002_en.pdf"},
    {"id":"49425","name":"Saccharomyces boulardii : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation  - PSUSA/00009284/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-02T12:14:00Z","last_updated_date":"2020-12-02T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/saccharomyces-boulardii-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009284202002_no.pdf"}},
    {"id":"49426","name":"Pravastatin : List of nationally authorised medicinal products - PSUSA/00002500/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-02T14:41:00Z","last_updated_date":"2020-12-02T14:41:00Z","reference_number":"EMA/646100/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/pravastatin-list-nationally-authorised-medicinal-products-psusa00002500202003_en.pdf"},
    {"id":"49429","name":"Hydroxyethyl starch : List of nationally authorised medicinal products - PSUSA/00001694/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-03T11:30:00Z","last_updated_date":"2020-12-03T11:30:00Z","reference_number":"EMA/646222/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-list-nationally-authorised-medicinal-products-psusa00001694202003_en.pdf"},
    {"id":"49432","name":"Racecadotril : List of nationally authorised medicinal products - PSUSA/00002602/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-03T11:46:00Z","last_updated_date":"2020-12-03T11:46:00Z","reference_number":"EMA/646224/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/racecadotril-list-nationally-authorised-medicinal-products-psusa00002602202003_en.pdf"},
    {"id":"49435","name":"Verapamil: List of nationally authorised medicinal products - PSUSA/00003105/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-03T12:55:00Z","last_updated_date":"2020-12-03T12:55:00Z","reference_number":"EMA/785069/2018","document_url":"https://www.ema.europa.eu/en/documents/psusa/verapamil-list-nationally-authorised-medicinal-products-psusa00003105202001_en.pdf"},
    {"id":"49436","name":"Verapamil: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003105/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-03T12:55:00Z","last_updated_date":"2020-12-03T12:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/verapamil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003105202001_no.pdf"}},
    {"id":"49448","name":"Ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine : List of nationally authorised medicinal products - PSUSA/00010649/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-03T15:33:00Z","last_updated_date":"2020-12-03T15:33:00Z","reference_number":"EMA/649664/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-list-nationally-authorised-medicinal-products-psusa00010649202002_en.pdf"},
    {"id":"49450","name":"Vancomycin: List of nationally authorised medicinal products - PSUSA/00003097/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-03T16:11:00Z","last_updated_date":"2020-12-03T16:11:00Z","reference_number":"EMA/647607/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/vancomycin-list-nationally-authorised-medicinal-products-psusa00003097202001_en.pdf"},
    {"id":"49451","name":"Vancomycin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003097/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-03T16:12:00Z","last_updated_date":"2020-12-03T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/vancomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003097202001_no.pdf"}},
    {"id":"49459","name":"Piribedil: List of nationally authorised medicinal products - PSUSA/00002436/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T13:39:00Z","last_updated_date":"2020-12-04T13:39:00Z","reference_number":"EMA/646822/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/piribedil-list-nationally-authorised-medicinal-products-psusa00002436202003_en.pdf"},
    {"id":"49460","name":"Aceclofenac: List of nationally authorised medicinal products - PSUSA/00000022/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T13:39:00Z","last_updated_date":"2020-12-04T13:39:00Z","reference_number":"EMA/646694/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/aceclofenac-list-nationally-authorised-medicinal-products-psusa00000022202003_en.pdf"},
    {"id":"49462","name":"Phenol: List of nationally authorised medicinal products - PSUSA/00009256/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T17:30:00Z","last_updated_date":"2020-12-04T17:30:00Z","reference_number":"EMA/646700/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenol-list-nationally-authorised-medicinal-products-psusa00009256202004_en.pdf"},
    {"id":"49463","name":"Reboxetine : List of nationally authorised medicinal products - PSUSA/00002615/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-07T09:24:00Z","last_updated_date":"2020-12-07T09:24:00Z","reference_number":"EMA/656698/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/reboxetine-list-nationally-authorised-medicinal-products-psusa00002615202004_en.pdf"},
    {"id":"49507","name":"Potassium para aminobenzoate: List of nationally authorised medicinal products - PSUSA/00010130/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-10T11:11:00Z","last_updated_date":"2020-12-10T11:11:00Z","reference_number":"EMA/669452/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/potassium-para-aminobenzoate-list-nationally-authorised-medicinal-products-psusa00010130202002_en.pdf"},
    {"id":"49508","name":"Potassium para aminobenzoate: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010130/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-10T11:12:00Z","last_updated_date":"2020-12-10T11:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/potassium-para-aminobenzoate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010130202002_no.pdf"}},
    {"id":"49566","name":"Mesalazine: List of nationally authorised medicinal products - PSUSA/00001990/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T11:54:00Z","last_updated_date":"2020-12-15T11:54:00Z","reference_number":"EMA/686825/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesalazine-list-nationally-authorised-medicinal-products-psusa00001990202002_en.pdf"},
    {"id":"49567","name":"Mesalazine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001990/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T11:58:00Z","last_updated_date":"2020-12-15T11:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202002_no.pdf"}},
    {"id":"49620","name":"Galantamine:  List of nationally authorised medicinal products - PSUSA/00001512/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T09:39:00Z","last_updated_date":"2020-12-18T09:39:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/galantamine-list-nationally-authorised-medicinal-products-psusa00001512202003_en.pdf"},
    {"id":"49621","name":"Galantamine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001512/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T09:43:00Z","last_updated_date":"2020-12-18T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/galantamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001512202003_no.pdf"}},
    {"id":"49649","name":"Metamizole:  List of nationally authorised medicinal products - PSUSA/00001997/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T17:00:00Z","last_updated_date":"2020-12-18T17:00:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/metamizole-list-nationally-authorised-medicinal-products-psusa00001997202003_en.pdf"},
    {"id":"49650","name":"Metamizole: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001997/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T17:00:00Z","last_updated_date":"2020-12-18T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001997-202003_sv.pdf"}},
    {"id":"49652","name":"Fluconazole:  List of nationally authorised medicinal products - PSUSA/00001404/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T08:58:00Z","last_updated_date":"2020-12-21T08:58:00Z","reference_number":"EMA/698316/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluconazole-list-nationally-authorised-medicinal-products-psusa00001404202003_en.pdf"},
    {"id":"49653","name":"Fluconazole: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001404/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T08:59:00Z","last_updated_date":"2020-12-21T08:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001404202003_no.pdf"}},
    {"id":"49679","name":"Lisdexamfetamine : List of nationally authorised medicinal products - PSUSA/00010289/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-22T11:34:00Z","last_updated_date":"2020-12-22T11:34:00Z","reference_number":"PSUSA/00010289/202002","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa00010289202002_en.pdf"},
    {"id":"49680","name":"Lisdexamfetamine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010289/202002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-22T11:38:00Z","last_updated_date":"2020-12-22T11:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lisdexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010289202002_no.pdf"}},
    {"id":"49681","name":"Estradiol, estradiol /prednisolone : List of nationally authorised medicinal products - PSUSA/00010441/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-22T11:43:00Z","last_updated_date":"2020-12-22T11:43:00Z","reference_number":"EMA/700849/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/estradiol-estradiol-prednisolone-list-nationally-authorised-medicinal-products-psusa00010441202004_en.pdf"},
    {"id":"49682","name":"Ascorbic acid / paracetamol / pheniramine maleate : List of nationally authorised medicinal products - PSUSA/00002368/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-22T11:51:00Z","last_updated_date":"2020-12-22T11:51:00Z","reference_number":"EMA/700848/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/ascorbic-acid-paracetamol-pheniramine-maleate-list-nationally-authorised-medicinal-products-psusa00002368202003_en.pdf"},
    {"id":"49683","name":"Trandolapril / verapamil : List of nationally authorised medicinal products - PSUSA/00003005/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-12-22T12:04:00Z","last_updated_date":"2020-12-22T12:04:00Z","reference_number":"EMA/700852/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/trandolapril-verapamil-list-nationally-authorised-medicinal-products-psusa00003005202003_en.pdf"},
    {"id":"49759","name":"Ethosuximide: List of nationally authorised medicinal products - PSUSA/00001316/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-08T14:33:00Z","last_updated_date":"2021-01-08T14:33:00Z","reference_number":"EMA/10382/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethosuximide-list-nationally-authorised-medicinal-products-psusa00001316202003_en.pdf"},
    {"id":"49760","name":"Ethosuximide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementatio - PSUSA/00001316/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-08T14:33:00Z","last_updated_date":"2021-01-08T14:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ethosuximide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementatio-psusa00001316202003_no.pdf"}},
    {"id":"49772","name":"Flucloxacillin: List of nationally authorised medicinal products - PSUSA/00001402/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-11T12:34:00Z","last_updated_date":"2021-01-11T12:34:00Z","reference_number":"EMA/14202/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/flucloxacillin-list-nationally-authorised-medicinal-products-psusa00001402202003_en.pdf"},
    {"id":"49773","name":"Flucloxacillin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001402/202003","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-11T12:39:00Z","last_updated_date":"2021-01-11T12:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/flucloxacillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001402202003_is.pdf"}},
    {"id":"49811","name":"Ozenoxacin: List of nationally authorised medicinal products - PSUSA/00010651/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-15T14:34:00Z","last_updated_date":"2021-01-15T14:34:00Z","reference_number":"EMA/1973/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ozenoxacin-list-nationally-authorised-medicinal-products-psusa00010651202005_en.pdf"},
    {"id":"49812","name":"Gadodiamide: List of nationally authorised medicinal products - PSUSA/00001503/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T10:47:00Z","last_updated_date":"2021-01-18T10:47:00Z","reference_number":"EMA/21095/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadodiamide-list-nationally-authorised-medicinal-products-psusa00001503202004_en.pdf"},
    {"id":"49813","name":"Azithromycin: List of nationally authorised medicinal products - PSUSA/00010491/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T10:55:00Z","last_updated_date":"2021-01-18T10:55:00Z","reference_number":"EMA/2872/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/azithromycin-list-nationally-authorised-medicinal-products-psusa00010491202004_en.pdf"},
    {"id":"49814","name":"Ivabradine / metoprolol : List of nationally authorised medicinal products - PSUSA/00010381/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T11:37:00Z","last_updated_date":"2021-01-18T11:37:00Z","reference_number":"EMA/32393/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivabradine-metoprolol-list-nationally-authorised-medicinal-products-psusa00010381202004_en.pdf"},
    {"id":"49815","name":"Cyproterone / ethinylestradiol : List of nationally authorised medicinal products - PSUSA/00000906/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T11:42:00Z","last_updated_date":"2021-01-18T11:42:00Z","reference_number":"EMA/32642/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproterone-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa00000906202005_en.pdf"},
    {"id":"49816","name":"Teicoplanin : List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0025","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T11:54:00Z","last_updated_date":"2021-01-18T11:54:00Z","reference_number":"EMA/33992/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/teicoplanin-list-nationally-authorised-medicinal-products-emeahnpsrs0025_en.pdf"},
    {"id":"49817","name":"Teicoplanin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/S/0025","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T12:00:00Z","last_updated_date":"2021-01-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/teicoplanin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0025_sv.pdf"}},
    {"id":"49830","name":"Simvastatin: List of nationally authorised medicinal products - PSUSA/00002709/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T16:31:00Z","last_updated_date":"2021-01-18T16:31:00Z","reference_number":"EMA/29029/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/simvastatin-list-nationally-authorised-medicinal-products-psusa00002709202004_en.pdf"},
    {"id":"49842","name":"Amfepramone: List of nationally authorised medicinal products - PSUSA/00000138/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-19T16:13:00Z","last_updated_date":"2021-01-19T16:13:00Z","reference_number":"EMA/34106/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/amfepramone-list-nationally-authorised-medicinal-products-psusa00000138202006_en.pdf"},
    {"id":"49843","name":"Mifepristone / misoprostol: List of nationally authorised medicinal products - PSUSA/00010378/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-19T17:31:00Z","last_updated_date":"2021-01-19T17:31:00Z","reference_number":"EMA/34506/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa00010378202005_en.pdf"},
    {"id":"49844","name":"Gadopentetic acid: List of nationally authorised medicinal products - PSUSA/00001504/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-19T17:31:00Z","last_updated_date":"2021-01-19T17:31:00Z","reference_number":"EMA/34623/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadopentetic-acid-list-nationally-authorised-medicinal-products-psusa00001504202004_en.pdf"},
    {"id":"49845","name":"Misoprostol (gynaecological indication - labour induction): List of nationally authorised medicinal products - PSUSA/00010353/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-20T14:06:00Z","last_updated_date":"2021-01-20T14:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labour-induction-list-nationally-authorised-medicinal-products-psusa00010353202005_en.pdf"},
    {"id":"49846","name":"valsartan, hydrochlorothiazide / valsartan: List of nationally authorised medicinal products - PSUSA/00010396/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-20T14:11:00Z","last_updated_date":"2021-01-20T14:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/valsartan-hydrochlorothiazide-valsartan-list-nationally-authorised-medicinal-products-psusa00010396202004_en.pdf"},
    {"id":"49852","name":"Ticlopidine: List of nationally authorised medicinal products - PSUSA/00002952/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-20T17:22:00Z","last_updated_date":"2021-01-20T17:22:00Z","reference_number":"EMA/34401/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ticlopidine-list-nationally-authorised-medicinal-products-psusa00002952202005_en.pdf"},
    {"id":"49853","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-20T17:37:00Z","last_updated_date":"2021-01-20T17:37:00Z","reference_number":"EMA/34438/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288202005_en.pdf"},
    {"id":"49854","name":"Gadoteric acid (intra articular formulation): List of nationally authorised medicinal products - PSUSA/00001505/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T09:20:00Z","last_updated_date":"2021-01-21T09:20:00Z","reference_number":"EMA/702111/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteric-acid-intra-articular-formulation-list-nationally-authorised-medicinal-products-psusa00001505202004_en.pdf"},
    {"id":"49872","name":"Dexpanthenol xylometazoline: List of nationally authorised medicinal products - PSUSA/00010030/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T11:00:00Z","last_updated_date":"2021-01-21T11:00:00Z","reference_number":"EMA/36692/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexpanthenol-xylometazoline-list-nationally-authorised-medicinal-products-psusa00010030202005_en.pdf"},
    {"id":"49873","name":"Peppermint oil: List of nationally authorised medicinal products - PSUSA/00010436/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T11:00:00Z","last_updated_date":"2021-01-21T11:00:00Z","reference_number":"EMA/36968/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/peppermint-oil-list-nationally-authorised-medicinal-products-psusa00010436202005_en.pdf"},
    {"id":"49874","name":"Misoprostol (gastrointestinal indication): List of nationally authorised medicinal products - PSUSA/00010291/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T11:30:00Z","last_updated_date":"2021-01-21T11:30:00Z","reference_number":"EMA/37144/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gastrointestinal-indication-list-nationally-authorised-medicinal-products-psusa00010291202006_en.pdf"},
    {"id":"49886","name":"Mometasone: List of nationally authorised medicinal products - PSUSA/00002085/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T17:45:00Z","last_updated_date":"2021-01-21T17:45:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/mometasone-list-nationally-authorised-medicinal-products-psusa00002085202005_en.pdf"},
    {"id":"49891","name":"Formoterol : List of nationally authorised medicinal products - PSUSA/00001469/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T10:28:00Z","last_updated_date":"2021-01-22T10:28:00Z","reference_number":"EMA/37560/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/formoterol-list-nationally-authorised-medicinal-products-psusa00001469202005_en.pdf"},
    {"id":"49897","name":"Methoxyflurane: List of nationally authorised medicinal products - PSUSA/00010484/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T11:33:00Z","last_updated_date":"2021-01-22T11:33:00Z","reference_number":"EMA/46815/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa00010484202005_en.pdf"},
    {"id":"49901","name":"Deoxycholic acid: List of nationally authorised medicinal products - PSUSA/00010525/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T13:50:00Z","last_updated_date":"2021-01-22T13:50:00Z","reference_number":"EMA/37234/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/deoxycholic-acid-list-nationally-authorised-medicinal-products-psusa00010525202004_en.pdf"},
    {"id":"49902","name":"Deoxycholic acid: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010525/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T13:53:00Z","last_updated_date":"2021-01-22T13:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/deoxycholic-acid-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010525202004_no.pdf"}},
    {"id":"49904","name":"Captopril: List of nationally authorised medicinal products - PSUSA/00000535/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T14:45:00Z","last_updated_date":"2021-01-22T14:45:00Z","reference_number":"EMA/29276/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/captopril-list-nationally-authorised-medicinal-products-psusa00000535202004_en.pdf"},
    {"id":"49928","name":"Ketobemidone: List of nationally authorised medicinal products - PSUSA/0001807/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-25T11:18:00Z","last_updated_date":"2021-01-25T11:18:00Z","reference_number":"EMA/44756/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketobemidone-list-nationally-authorised-medicinal-products-psusa0001807202005_en.pdf"},
    {"id":"49940","name":"Chlorpromazine: List of nationally authorised  medicinal products - PSUSA/00000715/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-25T17:20:00Z","last_updated_date":"2021-01-25T17:20:00Z","reference_number":"EMA/44743/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorpromazine-list-nationally-authorised-medicinal-products-psusa00000715202005_en.pdf"},
    {"id":"49941","name":"Nicergoline: List of nationally authorised  medicinal products - PSUSA/00002150/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-25T17:30:00Z","last_updated_date":"2021-01-25T17:30:00Z","reference_number":"EMA/44757/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicergoline-list-nationally-authorised-medicinal-products-psusa00002150202005_en.pdf"},
    {"id":"49951","name":"Clarithromycin: List of nationally authorised  medicinal products - PSUSA/00000788/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-27T17:30:00Z","last_updated_date":"2021-01-27T17:30:00Z","reference_number":"EMA/38030/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/clarithromycin-list-nationally-authorised-medicinal-products-psusa00000788202004_en.pdf"},
    {"id":"49952","name":"Clarithromycin: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation  - PSUSA/00000788/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-27T17:30:00Z","last_updated_date":"2021-01-27T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000788202004_no.pdf"}},
    {"id":"49954","name":"Piroxicam: List of nationally authorised medicinal products - PSUSA/00002438/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-27T17:15:00Z","last_updated_date":"2021-01-27T17:15:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/piroxicam-list-nationally-authorised-medicinal-products-psusa00002438202004_en.pdf"},
    {"id":"49955","name":"Piroxicam: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002438/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-27T17:17:00Z","last_updated_date":"2021-01-27T17:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002438202004_no.pdf"}},
    {"id":"49959","name":"Diphtheria / tetanus vaccines (adsorbed), diphtheria vaccines (adsorbed): List of nationally authorised  medicinal products - PSUSA/00001128/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-28T11:00:00Z","last_updated_date":"2021-01-28T11:00:00Z","reference_number":"EMA/50004/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-vaccines-adsorbed-diphtheria-vaccines-adsorbed-list-nationally-authorised-medicinal-products-psusa00001128202005_en.pdf"}    {"id":"49960","name":"ciprofloxacin hydrochloride / dexamethasone acetate (ear drops, suspension): List of nationally authorised  medicinal products - PSUSA/00010012/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-01-28T11:00:00Z","last_updated_date":"2021-01-28T11:00:00Z","reference_number":"EMA/50033/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-hydrochloride-dexamethasone-acetate-ear-drops-suspension-list-nationally-authorised-medicinal-products-psusa00010012202004_en.pdf"},
    {"id":"50190","name":"Hepatitis a (inactivated) / typhoid polysaccharide vaccine (adsorbed): List of nationally authorised medicinal products - PSUSA/00001594/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-16T14:40:00Z","last_updated_date":"2021-02-16T14:40:00Z","reference_number":"EMA/85541/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/hepatitis-inactivated-typhoid-polysaccharide-vaccine-adsorbed-list-nationally-authorised-medicinal-products-psusa00001594202006_en.pdf"},
    {"id":"50191","name":"Benzylpenicillin: List of nationally authorised medicinal products - PSUSA/00000383/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-16T14:54:00Z","last_updated_date":"2021-02-16T14:54:00Z","reference_number":"EMA/85487/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzylpenicillin-list-nationally-authorised-medicinal-products-psusa00000383202006_en.pdf"},
    {"id":"50192","name":"Diphtheria/tetanus/pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed), diphtheria/tetanus/pertussis (acellular, component) and poliomyelitis:List of nationally authorised medicinal products - PSUSA/00001126/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-16T14:54:00Z","last_updated_date":"2021-02-16T14:54:00Z","reference_number":"EMA/61734/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheriatetanuspertussis-acellular-component-and-poliomyelitis-inactivated-vaccine-adsorbed-diphtheriatetanuspertussis-acellular-component-and-poliomyelitislist-nationally-authorised-medicinal_en.pdf"},
    {"id":"50194","name":"Almotriptan: List of nationally authorised medicinal products - PSUSA/00000101/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-17T10:21:00Z","last_updated_date":"2021-02-17T10:21:00Z","reference_number":"EMA/96054/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/almotriptan-list-nationally-authorised-medicinal-products-psusa00000101202006_en.pdf"},
    {"id":"50195","name":"Ibuprofen / pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00001711/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-17T10:47:00Z","last_updated_date":"2021-02-17T10:47:00Z","reference_number":"EMA/96159/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00001711202007_en.pdf"},
    {"id":"50196","name":"Alfacalcidol: List of nationally authorised medicinal products - PSUSA/00000080/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-17T10:46:00Z","last_updated_date":"2021-02-17T10:46:00Z","reference_number":"EMA/93946/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/alfacalcidol-list-nationally-authorised-medicinal-products-psusa00000080202006_en.pdf"},
    {"id":"50197","name":"Bethanechol: List of nationally authorised medicinal products - PSUSA/00000402/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-17T10:57:00Z","last_updated_date":"2021-02-17T10:57:00Z","reference_number":"EMA/96674/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/bethanechol-list-nationally-authorised-medicinal-products-psusa00000402202006_en.pdf"},
    {"id":"50198","name":"Nitrous oxide, nitrous oxide / oxygen: List of nationally authorised medicinal products - PSUSA/00010572/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-17T11:02:00Z","last_updated_date":"2021-02-17T11:02:00Z","reference_number":"EMA/96569/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-list-nationally-authorised-medicinal-products-psusa00010572202006_en.pdf"},
    {"id":"50199","name":"Carrageenin / titanium dioxide / zinc oxide, carrageenin / lidocaine / titanium dioxide / zinc oxide, titanium dioxide / zinc oxide / tetracaine hydrochloride: List of nationally authorised medicinal products - PSUSA/00001869/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-17T11:20:00Z","last_updated_date":"2021-02-17T11:20:00Z","reference_number":"EMA/99398/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/carrageenin-titanium-dioxide-zinc-oxide-carrageenin-lidocaine-titanium-dioxide-zinc-oxide-titanium-dioxide-zinc-oxide-tetracaine-hydrochloride-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"50204","name":"Magnesium sulfate: List of nationally authorised medicinal products - PSUSA/00009225/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-17T17:34:00Z","last_updated_date":"2021-02-17T17:34:00Z","reference_number":"EMA/99533/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulfate-list-nationally-authorised-medicinal-products-psusa00009225202006_en.pdf"},
    {"id":"50243","name":"Octenidine: List of nationally authorised medicinal products - PSUSA/00010748/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-19T11:03:00Z","last_updated_date":"2021-02-19T11:03:00Z","reference_number":"EMA/101365/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/octenidine-list-nationally-authorised-medicinal-products-psusa00010748202007_en.pdf"},
    {"id":"50286","name":"Clonazepam: List of nationally authorised medicinal products - PSUSA/00000812/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T09:12:00Z","last_updated_date":"2021-02-26T09:12:00Z","reference_number":"EMA/112475/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/clonazepam-list-nationally-authorised-medicinal-products-psusa00000812202006_en.pdf"},
    {"id":"50500","name":"Tramadol: List of nationally authorised medicinal products - PSUSA/00003002/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:04:00Z","last_updated_date":"2021-03-24T14:41:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tramadol-list-nationally-authorised-medicinal-products-psusa00003002202005_en.pdf"},
    {"id":"50501","name":"Tramadol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003002/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:04:00Z","last_updated_date":"2021-03-24T14:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003002202005_no.pdf"}},
    {"id":"50550","name":"Irinotecan (except for liposomal formulations): List of nationally authorised medicinal products - PSUSA/00001783/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-15T10:23:00Z","last_updated_date":"2021-03-15T10:23:00Z","reference_number":"EMA/150667/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/irinotecan-except-liposomal-formulations-list-nationally-authorised-medicinal-products-psusa00001783202005_en.pdf"},
    {"id":"50551","name":"Irinotecan (except for liposomal formulations): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001783/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-15T10:28:00Z","last_updated_date":"2021-03-15T10:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/irinotecan-except-liposomal-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001783202005_no.pdf"}},
    {"id":"50552","name":"Niclosamide: List of nationally authorised medicinal products - PSUSA/00002151/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-15T10:45:00Z","last_updated_date":"2021-03-15T10:45:00Z","reference_number":"EMA/19912/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/niclosamide-list-nationally-authorised-medicinal-products-psusa00002151202008_en.pdf"},
    {"id":"50556","name":"Glyceryl trinitrate : List of nationally authorised medicinal products - PSUSA/00001552/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-15T13:16:00Z","last_updated_date":"2021-03-15T13:16:00Z","reference_number":"EMA/158016/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/glyceryl-trinitrate-list-nationally-authorised-medicinal-products-psusa00001552202007_en.pdf"},
    {"id":"50557","name":"Escherichia coli lysate : List of nationally authorised medicinal products - PSUSA/00001263/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-15T13:33:00Z","last_updated_date":"2021-03-15T13:33:00Z","reference_number":"EMA/45518/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/escherichia-coli-lysate-list-nationally-authorised-medicinal-products-psusa00001263202007_en.pdf"},
    {"id":"50558","name":"Imipramine : List of nationally authorised medicinal products - PSUSA/00001728/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-15T14:40:00Z","last_updated_date":"2021-03-15T14:40:00Z","reference_number":"EMA/146463/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/imipramine-list-nationally-authorised-medicinal-products-psusa00001728202007_en.pdf"},
    {"id":"50559","name":"Indium (111In) pentetate : List of nationally authorised medicinal products - PSUSA/00009191/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-15T14:45:00Z","last_updated_date":"2021-03-15T14:45:00Z","reference_number":"EMA/159423/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/indium-111in-pentetate-list-nationally-authorised-medicinal-products-psusa00009191202007_en.pdf"},
    {"id":"50563","name":"Indometacin: List of nationally authorised medicinal products - PSUSA/00001738/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T09:27:00Z","last_updated_date":"2021-03-16T09:27:00Z","reference_number":"EMA/146401/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/indometacin-list-nationally-authorised-medicinal-products-psusa00001738202007_en.pdf"},
    {"id":"50564","name":"Ifosfamide: List of nationally authorised medicinal products - PSUSA/00001723/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T09:27:00Z","last_updated_date":"2021-03-16T09:27:00Z","reference_number":"EMA/156149/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ifosfamide-list-nationally-authorised-medicinal-products-psusa00001723202007_en.pdf"},
    {"id":"50565","name":"Xylometazoline: List of nationally authorised medicinal products - PSUSA/00003134/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T09:36:00Z","last_updated_date":"2021-03-16T09:36:00Z","reference_number":"EMA/161057/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/xylometazoline-list-nationally-authorised-medicinal-products-psusa00003134202005_en.pdf"},
    {"id":"50566","name":"Xylometazoline: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003134/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T09:36:00Z","last_updated_date":"2021-03-16T09:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/xylometazoline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003134202005_no.pdf"}},
    {"id":"50568","name":"Iomeprol: List of nationally authorised medicinal products - PSUSA/00001769/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T11:36:00Z","last_updated_date":"2021-03-16T11:36:00Z","reference_number":"EMA/149623/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/iomeprol-list-nationally-authorised-medicinal-products-psusa00001769202004_en.pdf"},
    {"id":"50571","name":"Iomeprol: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001769/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T13:10:00Z","last_updated_date":"2021-03-16T13:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/iomeprol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001769202004_no.pdf"}},
    {"id":"50572","name":"Typhoid polysaccharide vaccine : List of nationally authorised medicinal products - PSUSA/00003065/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T11:51:00Z","last_updated_date":"2021-03-16T11:51:00Z","reference_number":"EMA/131553/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/typhoid-polysaccharide-vaccine-list-nationally-authorised-medicinal-products-psusa00003065202008_en.pdf"},
    {"id":"50573","name":"Pethidine: List of nationally authorised medicinal products - PSUSA/00002357/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T12:19:00Z","last_updated_date":"2021-03-16T12:19:00Z","reference_number":"EMA/162181/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/pethidine-list-nationally-authorised-medicinal-products-psusa00002357202008_en.pdf"},
    {"id":"50574","name":"Iodixanol: List of nationally authorised medicinal products - PSUSA/00001766/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T13:36:00Z","last_updated_date":"2023-10-10T14:26:00Z","reference_number":"EMA/21300/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/iodixanol-list-nationally-authorised-medicinal-products-psusa-00001766-202004_en.pdf"},
    {"id":"50575","name":"Iodixanol: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001766/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-16T13:36:00Z","last_updated_date":"2021-03-16T13:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/iodixanol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001766-202004_no.pdf"}},
    {"id":"50596","name":"Indium (111In) pentetreotide: List of nationally authorised medicinal products - PSUSA/00009192/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T09:41:00Z","last_updated_date":"2021-03-17T09:41:00Z","reference_number":"EMA/145095/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/indium-111in-pentetreotide-list-nationally-authorised-medicinal-products-psusa00009192202007_en.pdf"},
    {"id":"50639","name":"Ziprasidone: List of nationally authorised medicinal products - PSUSA/00003146/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-18T12:21:00Z","last_updated_date":"2021-03-18T12:21:00Z","reference_number":"EMA/166520/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ziprasidone-list-nationally-authorised-medicinal-products-psusa00003146202007_en.pdf"},
    {"id":"50641","name":"Oxymetazoline: List of nationally authorised medicinal products - PSUSA/00002258/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-18T14:00:00Z","last_updated_date":"2021-03-18T14:00:00Z","reference_number":"EMA/164735/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxymetazoline-list-nationally-authorised-medicinal-products-psusa00002258202008_en.pdf"},
    {"id":"50642","name":"Clotiazepam: List of nationally authorised medicinal products - PSUSA/00000827/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-18T15:00:00Z","last_updated_date":"2021-03-18T15:00:00Z","reference_number":"EMA/167501/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/clotiazepam-list-nationally-authorised-medicinal-products-psusa00000827202005_en.pdf"},
    {"id":"50643","name":"Clotiazepam: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000827/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-18T15:00:00Z","last_updated_date":"2021-03-18T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/clotiazepam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000827202005_no.pdf"}},
    {"id":"50645","name":"Naproxen: List of nationally authorised medicinal products - PSUSA/00002125/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-18T15:30:00Z","last_updated_date":"2021-03-18T15:30:00Z","reference_number":"EMA/165987/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/naproxen-list-nationally-authorised-medicinal-products-psusa00002125202008_en.pdf"},
    {"id":"50669","name":"Lidocaine tetracaine: List of nationally authorised medicinal products - PSUSA/00001868/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-23T08:59:00Z","last_updated_date":"2021-03-23T08:59:00Z","reference_number":"EMA/172058/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-tetracaine-list-nationally-authorised-medicinal-products-psusa00001868202006_en.pdf"},
    {"id":"50689","name":"Lidocaine hydrochloride/methylprednisolone acetate: List of nationally authorised medicinal products - PSUSA/00001879/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-24T12:20:00Z","last_updated_date":"2021-03-24T12:20:00Z","reference_number":"EMA/164837/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloridemethylprednisolone-acetate-list-nationally-authorised-medicinal-products-psusa00001879202008_en.pdf"},
    {"id":"50741","name":"Azithromycin: List of nationally authorised medicinal products - PSUSA/00010492/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-03-30T12:42:00Z","last_updated_date":"2021-03-30T12:42:00Z","reference_number":"EMA/187942/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/azithromycin-list-nationally-authorised-medicinal-products-psusa00010492202004_en.pdf"},
    {"id":"50774","name":"Primidone: List of nationally authorised medicinal products - PSUSA/00002525/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-07T15:52:00Z","last_updated_date":"2021-04-07T15:52:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/primidone-list-nationally-authorised-medicinal-products-psusa00002525202006_en.pdf"},
    {"id":"50775","name":"Primidone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002525/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-07T15:52:00Z","last_updated_date":"2021-04-07T15:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/primidone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002525-202006_sv.pdf"}},
    {"id":"50776","name":"Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-07T17:35:00Z","last_updated_date":"2021-04-07T17:35:00Z","reference_number":"EMA/197324/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-list-nationally-authorised-medicinal-products-psusa00010390202007_en.pdf"},
    {"id":"50777","name":"Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010390/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-07T17:35:00Z","last_updated_date":"2021-04-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010390202007_no.pdf"}},
    {"id":"50826","name":"Pefloxacin: List of nationally authorised medicinal products - PSUSA/00002322/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T12:19:00Z","last_updated_date":"2021-04-14T12:19:00Z","reference_number":"EMA/116496/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/pefloxacin-list-nationally-authorised-medicinal-products-psusa00002322202008_en.pdf"},
    {"id":"50833","name":"Permethrin: List of nationally authorised medicinal products - PSUSA/00002355/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T15:49:00Z","last_updated_date":"2021-04-14T15:49:00Z","reference_number":"EMA/210511/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/permethrin-list-nationally-authorised-medicinal-products-psusa00002355202008_en.pdf"},
    {"id":"50854","name":"Nifedipine: List of nationally authorised medicinal products - PSUSA/00002156/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-15T11:43:00Z","last_updated_date":"2021-04-15T11:43:00Z","reference_number":"EMA/210716/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/nifedipine-list-nationally-authorised-medicinal-products-psusa00002156202008_en.pdf"},
    {"id":"50856","name":"Octreotide: List of nationally authorised medicinal products - PSUSA/00002201/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-15T13:47:00Z","last_updated_date":"2021-04-15T13:47:00Z","reference_number":"EMA/203553/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/octreotide-list-nationally-authorised-medicinal-products-psusa00002201202006_en.pdf"},
    {"id":"50857","name":"Octreotide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002201/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-15T13:47:00Z","last_updated_date":"2021-04-15T13:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/octreotide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002201202006_no.pdf"}},
    {"id":"50869","name":"Ethinylestradiol / etonogestrel: List of nationally authorised medicinal products - PSUSA/00001307/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-15T15:54:00Z","last_updated_date":"2021-04-15T15:54:00Z","reference_number":"EMA/211776/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-etonogestrel-list-nationally-authorised-medicinal-products-psusa00001307202007_en.pdf"},
    {"id":"50870","name":"Ethinylestradiol / etonogestrel: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001307/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-15T15:54:00Z","last_updated_date":"2021-04-15T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ethinylestradiol-etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001307-202007_no.pdf"}},
    {"id":"50871","name":"Suxamethonium: List of nationally authorised medicinal products - PSUSA/00002834/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-15T16:06:00Z","last_updated_date":"2021-04-15T16:06:00Z","reference_number":"EMA/212240/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/suxamethonium-list-nationally-authorised-medicinal-products-psusa00002834202008_en.pdf"},
    {"id":"50905","name":"Hexoprenaline sulfate: List of nationally authorised medicinal products - PSUSA/00003170/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-19T16:06:00Z","last_updated_date":"2021-04-19T16:06:00Z","reference_number":"EMA/213490/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/hexoprenaline-sulfate-list-nationally-authorised-medicinal-products-psusa00003170202008_en.pdf"},
    {"id":"50908","name":"Dexamfetamine: List of nationally authorised medicinal products - PSUSA/00001307/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-19T16:32:00Z","last_updated_date":"2021-04-19T16:32:00Z","reference_number":"EMA/214158/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-psusa00001307202007_en.pdf"},
    {"id":"50917","name":"Dalteparin sodium: List of nationally authorised medicinal products - PSUSA/00000922/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-20T16:00:00Z","last_updated_date":"2021-04-20T16:00:00Z","reference_number":"EMA/211175/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dalteparin-sodium-list-nationally-authorised-medicinal-products-psusa00000922202008_en.pdf"},
    {"id":"50925","name":"Porfimer: List of nationally authorised medicinal products - PSUSA/00010332/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T09:49:00Z","last_updated_date":"2021-04-21T09:49:00Z","reference_number":"EMA/649712/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/porfimer-list-nationally-authorised-medicinal-products-psusa00010332202004_en.pdf"},
    {"id":"50926","name":"Gadoteric acid (IV and intravascular formulations): List of nationally authorised medicinal products - PSUSA/00001506/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T10:00:00Z","last_updated_date":"2021-04-21T10:00:00Z","reference_number":"EMA/217377/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteric-acid-iv-and-intravascular-formulations-list-nationally-authorised-medicinal-products-psusa00001506202004_en.pdf"},
    {"id":"50927","name":"Fluorescein (systemic use): List of nationally authorised medicinal products - PSUSA/00009153/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T10:07:00Z","last_updated_date":"2021-04-21T10:07:00Z","reference_number":"EMA/217379/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluorescein-systemic-use-list-nationally-authorised-medicinal-products-psusa00009153202004_en.pdf"},
    {"id":"50928","name":"Gadobenic acid: List of nationally authorised medicinal products - PSUSA/00001500/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T10:10:00Z","last_updated_date":"2021-04-21T10:10:00Z","reference_number":"EMA/217399/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobenic-acid-list-nationally-authorised-medicinal-products-psusa00001500202004_en.pdf"},
    {"id":"50929","name":"Gadoteridol: List of nationally authorised medicinal products - PSUSA/00001507/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T10:19:00Z","last_updated_date":"2021-04-21T10:19:00Z","reference_number":"EMA/217490/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteridol-list-nationally-authorised-medicinal-products-psusa00001507202004_en.pdf"},
    {"id":"50931","name":"Oxcarbazepine : List of nationally authorised medicinal products - PSUSA/00002235/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T11:00:00Z","last_updated_date":"2021-04-21T11:00:00Z","reference_number":"EMA/PRAC/222202/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxcarbazepine-list-nationally-authorised-medicinal-products-psusa00002235202008_en.pdf"},
    {"id":"50932","name":"Modafinil : List of nationally authorised medicinal products - PSUSA/00010242/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T11:00:00Z","last_updated_date":"2021-04-21T11:00:00Z","reference_number":"EMA/PRAC/222466/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/modafinil-list-nationally-authorised-medicinal-products-psusa00010242202008_en.pdf"},
    {"id":"50934","name":"Human hemin: List of nationally authorised medicinal products - PSUSA/00001629/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T12:34:00Z","last_updated_date":"2021-04-21T12:34:00Z","reference_number":"EMA/217572/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-hemin-list-nationally-authorised-medicinal-products-psusa00001629202005_en.pdf"},
    {"id":"50935","name":"Epirubicin: List of nationally authorised medicinal products - PSUSA/00001234/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T12:43:00Z","last_updated_date":"2021-04-21T12:43:00Z","reference_number":"EMA/217651/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/epirubicin-list-nationally-authorised-medicinal-products-psusa00001234202006_en.pdf"},
    {"id":"50936","name":"Gadoxetic acid disodium: List of nationally authorised medicinal products - PSUSA/00001509/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-21T12:55:00Z","last_updated_date":"2021-04-21T12:55:00Z","reference_number":"EMA/14237/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoxetic-acid-disodium-list-nationally-authorised-medicinal-products-psusa00001509202004_en.pdf"},
    {"id":"50951","name":"Tamoxifen: List of nationally authorised medicinal products - PSUSA/00002846/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-23T09:04:00Z","last_updated_date":"2021-04-23T09:04:00Z","reference_number":"EMA/222801/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/tamoxifen-list-nationally-authorised-medicinal-products-psusa00002846202004_en.pdf"},
    {"id":"50952","name":"Tamoxifen: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002846/202004","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-23T09:07:00Z","last_updated_date":"2021-04-23T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tamoxifen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002846202004_sv.pdf"}},
    {"id":"50954","name":"Iohexol: List of nationally authorised medicinal products - PSUSA/00001768/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-23T09:25:00Z","last_updated_date":"2021-04-23T09:25:00Z","reference_number":"EMA/226005/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/iohexol-list-nationally-authorised-medicinal-products-psusa00001768202006_en.pdf"},
    {"id":"50955","name":"Iohexol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001768/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-23T09:27:00Z","last_updated_date":"2021-04-23T09:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/iohexol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001768202006_no.pdf"}},
    {"id":"50956","name":"Iopromide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001773/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-23T09:34:00Z","last_updated_date":"2021-04-23T09:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/iopromide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001773202006_no.pdf"}},
    {"id":"50957","name":"Iopromide: List of nationally authorised medicinal products - PSUSA/00001773/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-23T09:33:00Z","last_updated_date":"2021-04-23T09:33:00Z","reference_number":"EMA/226121/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/iopromide-list-nationally-authorised-medicinal-products-psusa00001773202006_en.pdf"},
    {"id":"50997","name":"Solifenacin: List of nationally authorised medicinal products - PSUSA/00002769/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-28T16:18:00Z","last_updated_date":"2021-04-28T16:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/solifenacin-list-nationally-authorised-medicinal-products-psusa00002769202006_en.pdf"},
    {"id":"51008","name":"Ascorbic acid/paracetamol/phenylephrine hydrochloride: List of nationally authorised medicinal products - PSUSA/00000255/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T09:59:00Z","last_updated_date":"2021-04-30T09:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ascorbic-acidparacetamolphenylephrine-hydrochloride-list-nationally-authorised-medicinal-products-psusa00000255202006_en.pdf"},
    {"id":"51009","name":"Epinephrine: List of nationally authorised medicinal products - PSUSA/00001232/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T10:34:00Z","last_updated_date":"2021-04-30T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/epinephrine-list-nationally-authorised-medicinal-products-psusa00001232202007_en.pdf"},
    {"id":"51010","name":"Dimetindene / phenylephrine: List of nationally authorised medicinal products - PSUSA/00001102/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T10:45:00Z","last_updated_date":"2021-04-30T10:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dimetindene-phenylephrine-list-nationally-authorised-medicinal-products-psusa00001102202007_en.pdf"},
    {"id":"51011","name":"Dexibuprofen: List of nationally authorised medicinal products - PSUSA/00000996/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T10:48:00Z","last_updated_date":"2021-04-30T10:48:00Z","reference_number":"EMA/179938/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexibuprofen-list-nationally-authorised-medicinal-products-psusa00000996202008_en.pdf"},
    {"id":"51012","name":"Bromazepam: List of nationally authorised medicinal products - PSUSA/00000435/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T10:51:00Z","last_updated_date":"2021-04-30T10:51:00Z","reference_number":"EMA/183024/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromazepam-list-nationally-authorised-medicinal-products-psusa00000435202008_en.pdf"},
    {"id":"51013","name":"Metronidazole / neomycin / nystatin: List of nationally authorised medicinal products - PSUSA/00010508/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T10:54:00Z","last_updated_date":"2021-04-30T10:54:00Z","reference_number":"EMA/187574/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/metronidazole-neomycin-nystatin-list-nationally-authorised-medicinal-products-psusa00010508202009_en.pdf"},
    {"id":"51014","name":"Trimetazidine: List of nationally authorised medicinal products - PSUSA/00003043/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T10:58:00Z","last_updated_date":"2021-04-30T10:58:00Z","reference_number":"EMA/78560/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-list-nationally-authorised-medicinal-products-psusa00003043202008_en.pdf"},
    {"id":"51015","name":"Mifepristone: List of nationally authorised medicinal products - PSUSA/00002060/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T11:09:00Z","last_updated_date":"2021-04-30T11:09:00Z","reference_number":"EMA/3063/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/mifepristone-list-nationally-authorised-medicinal-products-psusa00002060202005_en.pdf"},
    {"id":"51018","name":"Mifepristone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002060/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T11:15:00Z","last_updated_date":"2021-04-30T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/mifepristone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002060-202005_no.pdf"}},
    {"id":"51024","name":"Betula verrucosa: List of nationally authorised medicinal products - PSUSA/00010815/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T11:57:00Z","last_updated_date":"2021-04-30T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/betula-verrucosa-list-nationally-authorised-medicinal-products-psusa00010815202007_en.pdf"},
    {"id":"51027","name":"Cisatracurium: List of nationally authorised medicinal products - PSUSA/00000777/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T16:25:00Z","last_updated_date":"2021-04-30T16:25:00Z","reference_number":"EMA/145847/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/cisatracurium-list-nationally-authorised-medicinal-products-psusa00000777202007_en.pdf"},
    {"id":"51028","name":"Cisatracurium: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000777/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T16:25:00Z","last_updated_date":"2021-04-30T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cisatracurium-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000777202007_no.pdf"}},
    {"id":"51029","name":"Fosphenytoin: List of nationally authorised medicinal products - PSUSA/00001476/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T16:31:00Z","last_updated_date":"2021-04-30T16:31:00Z","reference_number":"EMA/246760/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosphenytoin-list-nationally-authorised-medicinal-products-psusa00001476202008_en.pdf"},
    {"id":"51030","name":"Fosphenytoin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001476/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-04-30T16:31:00Z","last_updated_date":"2021-04-30T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fosphenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001476202008_no.pdf"}},
    {"id":"51060","name":"Quetiapine: List of nationally authorised medicinal products - PSUSA/00002589/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-04T12:27:00Z","last_updated_date":"2021-05-04T12:27:00Z","reference_number":"EMA/146362/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/quetiapine-list-nationally-authorised-medicinal-products-psusa00002589202006_en.pdf"},
    {"id":"51061","name":"Quetiapine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002589/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-04T12:30:00Z","last_updated_date":"2021-05-04T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/quetiapine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002589202006_no.pdf"}},
    {"id":"51083","name":"Ibuprofen / levomenthol: List of nationally authorised medicinal products - PSUSA/00001708/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T16:37:00Z","last_updated_date":"2021-05-05T16:37:00Z","reference_number":"EMA/252267/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-levomenthol-list-nationally-authorised-medicinal-products-psusa00001708202007_en.pdf"},
    {"id":"51085","name":"Ibuprofen / levomenthol: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001708/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T16:38:00Z","last_updated_date":"2021-05-05T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ibuprofen-levomenthol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001708-202007_no.pdf"}},
    {"id":"51091","name":"Lanreotide: List of nationally authorised medicinal products - PSUSA/00001826/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T18:00:00Z","last_updated_date":"2021-05-05T18:00:00Z","reference_number":"EMA/4790/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/lanreotide-list-nationally-authorised-medicinal-products-psusa00001826202005_en.pdf"},
    {"id":"51092","name":"Misoprostol (gynaecological indication - termination of pregnancy) : List of nationally authorised medicinal products - PSUSA/00010354/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T18:00:00Z","last_updated_date":"2021-05-05T18:00:00Z","reference_number":"EMA/706074/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-list-nationally-authorised-medicinal-products-psusa00010354202005_en.pdf"},
    {"id":"51102","name":"Oxytocin : List of nationally authorised medicinal products - PSUSA/00002263/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-06T16:00:00Z","last_updated_date":"2021-05-06T16:00:00Z","reference_number":"EMA/78560/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxytocin-list-nationally-authorised-medicinal-products-psusa00002263202006_en.pdf"},
    {"id":"51130","name":"Ezetimibe / rosuvastatin: List of nationally authorised medicinal products - PSUSA/00010271/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-11T08:48:00Z","last_updated_date":"2021-05-11T08:48:00Z","reference_number":"EMA/259778/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ezetimibe-rosuvastatin-list-nationally-authorised-medicinal-products-psusa00010271202007_en.pdf"},
    {"id":"51131","name":"Ezetimibe / rosuvastatin: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010271/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-11T08:49:00Z","last_updated_date":"2021-05-11T08:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ezetimibe-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010271202007_no.pdf"}},
    {"id":"51132","name":"Silver sulfadiazine: List of nationally authorised medicinal products - PSUSA/00002702/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-11T09:00:00Z","last_updated_date":"2021-05-11T09:00:00Z","reference_number":"EMA/238738/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/silver-sulfadiazine-list-nationally-authorised-medicinal-products-psusa00002702202009_en.pdf"},
    {"id":"51133","name":"Podophyllotoxin: List of nationally authorised medicinal products - PSUSA/00002454/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-11T09:03:00Z","last_updated_date":"2021-05-11T09:03:00Z","reference_number":"EMA/143326/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/podophyllotoxin-list-nationally-authorised-medicinal-products-psusa00002454202009_en.pdf"},
    {"id":"51134","name":"Cidofovir : List of nationally authorised medicinal products - PSUSA/00010558/202006","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-11T09:09:00Z","last_updated_date":"2021-05-11T09:09:00Z","reference_number":"EMA/43481/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/cidofovir-list-nationally-authorised-medicinal-products-psusa00010558202006_en.pdf"},
    {"id":"51135","name":"Albendazole: List of nationally authorised medicinal products - PSUSA/00000073/201507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-11T09:19:00Z","last_updated_date":"2021-05-11T09:19:00Z","reference_number":"EMA/260351/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/albendazole-list-nationally-authorised-medicinal-products-psusa00000073201507_en.pdf-0"}    {"id":"51136","name":"Aciclovir / hydrocortisone: List of nationally authorised medicinal products - PSUSA/00009004/202007","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-11T09:24:00Z","last_updated_date":"2021-05-11T09:24:00Z","reference_number":"EMA/260351/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/aciclovir-hydrocortisone-list-nationally-authorised-medicinal-products-psusa00009004202007_en.pdf"},
    {"id":"51149","name":"Lactitiol: List of nationally authorised medicinal products - PSUSA/00001819/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-12T16:27:00Z","last_updated_date":"2021-05-12T16:27:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/lactitiol-list-nationally-authorised-medicinal-products-psusa00001819202009_en.pdf"},
    {"id":"51150","name":"Opium: List of nationally authorised medicinal products - PSUSA/00010670/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-12T16:42:00Z","last_updated_date":"2021-05-12T16:42:00Z","reference_number":"EMA/264681/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/opium-list-nationally-authorised-medicinal-products-psusa00010670202009_en.pdf"},
    {"id":"51151","name":"Fluocinolone acetonide: List of nationally authorised medicinal products - PSUSA/00010224/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-12T16:56:00Z","last_updated_date":"2021-05-12T16:56:00Z","reference_number":"EMA/255019/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-list-nationally-authorised-medicinal-products-psusa00010224202008_en.pdf"},
    {"id":"51153","name":"Fluocinolone acetonide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010224/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-12T17:00:00Z","last_updated_date":"2021-05-12T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fluocinolone-acetonide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010224202008_no.pdf"}},
    {"id":"51177","name":"Phenobarbital: List of nationally authorised medicinal products - PSUSA/00002370/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-18T10:34:00Z","last_updated_date":"2021-05-18T10:34:00Z","reference_number":"EMA/273764/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenobarbital-list-nationally-authorised-medicinal-products-psusa00002370202001_en.pdf"},
    {"id":"51178","name":"Phenobarbital: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002370/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-05-18T10:46:00Z","last_updated_date":"2021-05-18T10:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/phenobarbital-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002370202001_no.pdf"}},
    {"id":"51324","name":"Phenytoin: List of nationally authorised medicinal products - PSUSA/00002392/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-01T10:36:00Z","last_updated_date":"2021-06-01T10:36:00Z","reference_number":"EMA/305569/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenytoin-list-nationally-authorised-medicinal-products-psusa00002392202008_en.pdf"},
    {"id":"51325","name":"Phenytoin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002392/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-01T10:36:00Z","last_updated_date":"2021-06-01T10:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/phenytoin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002392202008_no.pdf"}},
    {"id":"51350","name":"Naftifine: List of nationally authorised medicinal products - PSUSA/00002109/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-03T09:24:00Z","last_updated_date":"2021-06-03T09:24:00Z","reference_number":"EMA/127237/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/naftifine-list-nationally-authorised-medicinal-products-psusa00002109202008_en.pdf"},
    {"id":"51351","name":"Naftifine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002109/202008","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-03T09:27:00Z","last_updated_date":"2021-06-03T09:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/naftifine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002109202008_sv.pdf"}},
    {"id":"51417","name":"Desflurane : List of nationally authorised medicinal products - PSUSA/00000958/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T11:37:00Z","last_updated_date":"2021-06-11T11:37:00Z","reference_number":"EMA/333304/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/desflurane-list-nationally-authorised-medicinal-products-psusa00000958202009_en.pdf"},
    {"id":"51418","name":"Lidocaine : List of nationally authorised medicinal products - PSUSA/00001861/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T11:48:00Z","last_updated_date":"2021-06-11T11:48:00Z","reference_number":"EMA/333431/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-list-nationally-authorised-medicinal-products-psusa00001861202009_en.pdf"},
    {"id":"51420","name":"Idebenone : List of nationally authorised medicinal products - PSUSA/00001721/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T13:27:00Z","last_updated_date":"2021-06-11T13:27:00Z","reference_number":"EMA/333772/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/idebenone-list-nationally-authorised-medicinal-products-psusa00001721202009_en.pdf"},
    {"id":"51436","name":"Bivalrudin : List of nationally authorised medicinal products - PSUSA/00000421/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-15T10:46:00Z","last_updated_date":"2021-06-15T10:46:00Z","reference_number":"EMA/246488/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/bivalrudin-list-nationally-authorised-medicinal-products-psusa00000421202009_en.pdf"},
    {"id":"51437","name":"Rubidium chloride RB-82 - List of nationally authorised medicinal products - PSUSA-00010806-202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-15T11:58:00Z","last_updated_date":"2021-06-15T11:58:00Z","reference_number":"EMA/301053/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/rubidium-chloride-rb-82-list-nationally-authorised-medicinal-products-psusa-00010806-202010_en.pdf"},
    {"id":"51442","name":"Amlodipine / atorvastatin / perindopril - List of nationally authorised medicinal products - PSUSA/00010431/202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-15T17:20:00Z","last_updated_date":"2021-06-15T17:20:00Z","reference_number":"EMA/338907/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-atorvastatin-perindopril-list-nationally-authorised-medicinal-products-psusa00010431202010_en.pdf"},
    {"id":"51452","name":"Minoxidil : List of nationally authorised medicines - PSUSA-00002067-202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-16T13:26:00Z","last_updated_date":"2021-06-16T13:26:00Z","reference_number":"EMA/343225/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/minoxidil-list-nationally-authorised-medicines-psusa-00002067-202010_en.pdf"},
    {"id":"51480","name":"13C-methacetin : List of nationally authorised medicinal products - PSUSA/00010846/202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-18T10:01:00Z","last_updated_date":"2021-06-18T10:01:00Z","reference_number":"EMA/346670/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/13c-methacetin-list-nationally-authorised-medicinal-products-psusa00010846202010_en.pdf"},
    {"id":"51528","name":"Isotretinoin (oral formulations) - List of the nationally authorised medicinal products - PSUSA/00010488/202005","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-22T10:22:00Z","last_updated_date":"2021-06-22T10:22:00Z","reference_number":"EMA/353110/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa00010488202005_en.pdf"},
    {"id":"51554","name":"Human von willebrand factor - List of nationally authorised medicinal products - PSUSA/00001642/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-23T11:18:00Z","last_updated_date":"2021-06-23T11:18:00Z","reference_number":"EMA/353501/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-von-willebrand-factor-list-nationally-authorised-medicinal-products-psusa00001642202009_en.pdf"},
    {"id":"51631","name":"Tetrabenazine: List of nationally authorised medicinal products - PSUSA/00002911/202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-28T11:14:00Z","last_updated_date":"2021-06-28T11:14:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/tetrabenazine-list-nationally-authorised-medicinal-products-psusa00002911202010_en.pdf"},
    {"id":"51654","name":"Tobramycin (systemic use): List of nationally authorised medicinal products - PSUSA/00009318/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-28T16:36:00Z","last_updated_date":"2021-06-28T16:36:00Z","reference_number":"EMA/353328/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/tobramycin-systemic-use-list-nationally-authorised-medicinal-products-psusa00009318202009_en.pdf"},
    {"id":"51655","name":"Tobramycin (systemic use): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009318/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-28T16:50:00Z","last_updated_date":"2021-06-28T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tobramycin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009318202009_no.pdf"}},
    {"id":"51894","name":"Vecuronium bromide : list of nationally authorised medicinal products - PSUSA/00003102/202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T10:08:00Z","last_updated_date":"2021-07-09T10:08:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/vecuronium-bromide-list-nationally-authorised-medicinal-products-psusa00003102202011_en.pdf"},
    {"id":"51905","name":"Phenylephrine / tropicamide - List of nationally authorised medicinal products - PSUSA-00010430-202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-07-12T10:51:00Z","last_updated_date":"2021-07-12T10:51:00Z","reference_number":"EMA/392177/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylephrine-tropicamide-list-nationally-authorised-medicinal-products-psusa-00010430-202011_en.pdf"},
    {"id":"51906","name":"Sultamicillin - List of nationally authorised medicinal products - PSUSA-00002829-202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-07-12T11:32:00Z","last_updated_date":"2021-07-12T11:32:00Z","reference_number":"EMA/393891/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/sultamicillin-list-nationally-authorised-medicinal-products-psusa-00002829-202011_en.pdf"},
    {"id":"51907","name":"Yellow fever vaccine (live) - List of nationally authorised medicinal products - PSUSA-00003135-202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-07-12T12:04:00Z","last_updated_date":"2021-07-12T12:04:00Z","reference_number":"EMA/393892/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/yellow-fever-vaccine-live-list-nationally-authorised-medicinal-products-psusa-00003135-202012_en.pdf"},
    {"id":"51909","name":"Tafluprost / timolol - List of nationally authorised medicinal products - PSUSA-00010324-202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-07-12T14:48:00Z","last_updated_date":"2021-07-12T14:48:00Z","reference_number":"EMA/394630/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/tafluprost-timolol-list-nationally-authorised-medicinal-products-psusa-00010324-202012_en.pdf"},
    {"id":"52036","name":"Overview of comments received on the draft guideline on manufacture of the veterinary finished dosage form","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-07-23T16:40:00Z","last_updated_date":"2021-07-23T16:40:00Z","reference_number":"EMA/CVMP/QWP/485008/2019","document_url":"https://www.ema.europa.eu/en/documents/psusa/overview-comments-received-draft-guideline-manufacture-veterinary-finished-dosage-form_en.pdf"},
    {"id":"52125","name":"Baclofen (oral) - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation - PSUSA/00000294/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-07-28T15:39:00Z","last_updated_date":"2021-07-28T15:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/baclofen-oral-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00000294202009_no.pdf"}},
    {"id":"52126","name":"Baclofen (oral) - List of nationally authorised medicinal products - PSUSA/00000294/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-07-28T15:35:00Z","last_updated_date":"2021-07-28T15:35:00Z","reference_number":"EMA/CMDh/422905/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/baclofen-oral-list-nationally-authorised-medicinal-products-psusa00000294202009_en.pdf"},
    {"id":"52177","name":"Perindopril - List of nationally authorised medicinal products - PSUSA-00002354-202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-08-03T10:02:00Z","last_updated_date":"2021-08-03T10:02:00Z","reference_number":"EMA/435106/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/perindopril-list-nationally-authorised-medicinal-products-psusa-00002354-202010_en.pdf"},
    {"id":"52178","name":"Perindopril - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA-00002354-202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-08-03T10:02:00Z","last_updated_date":"2021-08-03T10:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/perindopril-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002354-202010_no.pdf"}},
    {"id":"52183","name":"Polystyrene sulfonate - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA-00002472-202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-08-03T14:54:00Z","last_updated_date":"2021-08-03T14:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/polystyrene-sulfonate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00002472-202010_no.pdf"}},
    {"id":"52269","name":"Hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine: List of nationally authorised medicinal products -  PSUSA/00001696/202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-08-25T13:10:00Z","last_updated_date":"2021-08-25T13:10:00Z","reference_number":"EMA/474182/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-list-nationally-authorised-medicinal-products-psusa00001696202011_en.pdf"},
    {"id":"52270","name":"Hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001696/202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-08-25T13:13:00Z","last_updated_date":"2021-08-25T13:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/hydroxyzine-chloride-hydroxyzine-pamoate-and-all-fixed-combination-hydroxyzine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_no.pdf"}},
    {"id":"52283","name":"Benazepril : List of nationally authorised medicinal products - PSUSA/00000313/202011","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-08-26T15:29:00Z","last_updated_date":"2021-08-26T15:29:00Z","reference_number":"EMA/476817/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/benazepril-list-nationally-authorised-medicinal-products-psusa00000313202011_en.pdf"},
    {"id":"52284","name":"Benazepril : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000313/202011","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-08-26T15:33:00Z","last_updated_date":"2021-08-26T15:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/benazepril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000313202011_sv.pdf"}},
    {"id":"52324","name":"Diacerin : List of the nationally authorised medicinal products - PSUSA/00001026/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-03T09:05:00Z","last_updated_date":"2021-09-03T09:05:00Z","reference_number":"EMA/474110/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/diacerin-list-nationally-authorised-medicinal-products-psusa00001026202012_en.pdf"},
    {"id":"52325","name":"Dapoxetine : List of the nationally authorised medicinal products - PSUSA/00000928/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-03T09:17:00Z","last_updated_date":"2021-09-03T09:17:00Z","reference_number":"EMA/473995/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dapoxetine-list-nationally-authorised-medicinal-products-psusa00000928202012_en.pdf"},
    {"id":"52327","name":"Cyproheptadine : List of the nationally authorised medicinal products - PSUSA/00000902/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-03T09:34:00Z","last_updated_date":"2021-09-03T09:34:00Z","reference_number":"EMA/473810/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproheptadine-list-nationally-authorised-medicinal-products-psusa00000902202012_en.pdf"},
    {"id":"52328","name":"Rupatadine : List of the nationally authorised medicinal products - PSUSA/00002673/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-03T09:42:00Z","last_updated_date":"2021-09-03T09:42:00Z","reference_number":"EMA/474309/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/rupatadine-list-nationally-authorised-medicinal-products-psusa00002673202012_en.pdf"},
    {"id":"52330","name":"Hydroxycarbamide : List of nationally authorised medicinal products - PSUSA/00009182/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-03T09:51:00Z","last_updated_date":"2021-09-03T09:51:00Z","reference_number":"EMA/494031/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxycarbamide-list-nationally-authorised-medicinal-products-psusa00009182202012_en.pdf"},
    {"id":"52331","name":"Hydroxycarbamide : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation, amendments to the Product Information and timetable for the implementation  - PSUSA/00009182/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-03T09:54:00Z","last_updated_date":"2021-09-03T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/hydroxycarbamide-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-amendments-product-information-and-timetable-implementation-psusa00009182202012_no.pdf"}},
    {"id":"52334","name":"Iron sucrose : List of nationally authorised medicinal products - PSUSA/00010864/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-03T11:39:00Z","last_updated_date":"2021-09-03T11:39:00Z","reference_number":"EMA/495002/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-sucrose-list-nationally-authorised-medicinal-products-psusa00010864202101_en.pdf"},
    {"id":"52340","name":"Glatiramer - List of nationally authorised medicinal products - PSUSA-00001529-202011","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-09-06T14:12:00Z","last_updated_date":"2021-09-06T14:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/glatiramer-list-nationally-authorised-medicinal-products-psusa-00001529-202011_en.pdf"},
    {"id":"52341","name":"Glatiramer - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA-00001529-202011","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-09-06T14:12:00Z","last_updated_date":"2022-01-20T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/glatiramer-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00001529-202011_no.pdf"}},
    {"id":"52342","name":"Betamethasone dipropionate clotrimazole - List of nationally authorised medicinal products - PSUSA-00000394-202101","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-09-06T14:27:00Z","last_updated_date":"2021-09-06T14:27:00Z","reference_number":"EMA/260262/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/betamethasone-dipropionate-clotrimazole-list-nationally-authorised-medicinal-products-psusa-00000394-202101_en.pdf"},
    {"id":"52347","name":"Famciclovir - List of nationally authorised medicinal products - PSUSA-00001349-202012","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-09-06T15:40:00Z","last_updated_date":"2021-09-06T15:40:00Z","reference_number":"EMA/260273/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/famciclovir-list-nationally-authorised-medicinal-products-psusa-00001349-202012_en.pdf"},
    {"id":"52351","name":"Betamethasone valerate / fusidic acid: List of nationally authorised medicinal products - PSUSA/00000399/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-06T16:47:00Z","last_updated_date":"2021-09-06T16:47:00Z","reference_number":"EMA/260271/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/betamethasone-valerate-fusidic-acid-list-nationally-authorised-medicinal-products-psusa00000399202101_en.pdf"},
    {"id":"52352","name":"Betamethasone valerate / clioquinol: List of nationally authorised medicinal products - PSUSA/00000398/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-06T17:34:00Z","last_updated_date":"2021-09-06T17:34:00Z","reference_number":"EMA/260265/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/betamethasone-valerate-clioquinol-list-nationally-authorised-medicinal-products-psusa00000398202101_en.pdf"},
    {"id":"52362","name":"Doxazosin : List of nationally authorised medicinal products - PSUSA/00001169/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-08T12:57:00Z","last_updated_date":"2021-09-08T12:57:00Z","reference_number":"EMA/501908/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/doxazosin-list-nationally-authorised-medicinal-products-psusa00001169202012_en.pdf"},
    {"id":"52363","name":"Levonorgestrel / ethinylestradiol, ethinylestradiol : List of nationally authorised medicinal products - PSUSA/00010442/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-08T13:04:00Z","last_updated_date":"2021-09-08T13:04:00Z","reference_number":"EMA/502098/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa00010442202101_en.pdf"},
    {"id":"52375","name":"Pseudoephedrine / triprolidine : List of nationally authorised medicinal products - PSUSA/00003047/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-08T15:43:00Z","last_updated_date":"2021-09-08T15:43:00Z","reference_number":"EMA/502957/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/pseudoephedrine-triprolidine-list-nationally-authorised-medicinal-products-psusa00003047202012_en.pdf"},
    {"id":"52376","name":"Alitretinoin (oral use) : List of nationally authorised medicinal products - PSUSA/00010710/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-08T15:49:00Z","last_updated_date":"2021-09-08T15:49:00Z","reference_number":"EMA/503442/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/alitretinoin-oral-use-list-nationally-authorised-medicinal-products-psusa00010710202101_en.pdf"},
    {"id":"52377","name":"Allergen for therapy: betula verrucosa (sublingual tablet) : List of nationally authorised medicinal products - PSUSA/00010815/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-08T15:53:00Z","last_updated_date":"2021-09-08T15:53:00Z","reference_number":"EMA/504007/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-betula-verrucosa-sublingual-tablet-list-nationally-authorised-medicinal-products-psusa00010815202101_en.pdf"},
    {"id":"52384","name":"Indapamide: List of nationally authorised medicinal products - PSUSA/00001731/202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-08T17:11:00Z","last_updated_date":"2021-09-08T17:11:00Z","reference_number":"EMA/500741/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/indapamide-list-nationally-authorised-medicinal-products-psusa00001731202011_en.pdf"},
    {"id":"52385","name":"Indapamide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001731/202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-08T17:11:00Z","last_updated_date":"2021-09-08T17:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/indapamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001731202011_no.pdf"}},
    {"id":"52398","name":"Lormetazepam : List of nationally authorised medicinal products - PSUSA/00001910/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-09T14:49:00Z","last_updated_date":"2021-09-09T14:49:00Z","reference_number":"EMA/507606/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/lormetazepam-list-nationally-authorised-medicinal-products-psusa00001910202012_en.pdf"},
    {"id":"52399","name":"Caffeine / drotaverine hydrochloride / metamizol sodium : List of nationally authorised medicinal products - PSUSA/00001996/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-09T14:53:00Z","last_updated_date":"2021-09-09T14:53:00Z","reference_number":"EMA/505443/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/caffeine-drotaverine-hydrochloride-metamizol-sodium-list-nationally-authorised-medicinal-products-psusa00001996202101_en.pdf"},
    {"id":"52405","name":"Celecoxib : List of nationally authorised medicinal products - PSUSA/00000616/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-09T16:01:00Z","last_updated_date":"2021-09-09T16:01:00Z","reference_number":"EMA/505439/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/celecoxib-list-nationally-authorised-medicinal-products-psusa00000616202012_en.pdf"},
    {"id":"52406","name":"Betahistine : List of nationally authorised medicinal products - PSUSA/00000389/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-09T16:05:00Z","last_updated_date":"2021-09-09T16:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/betahistine-list-nationally-authorised-medicinal-products-psusa00000389202012_en.pdf"},
    {"id":"52424","name":"Methylprednisolone : List of nationally authorised medicinal products - PSUSA/00002026/202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-10T16:22:00Z","last_updated_date":"2021-09-10T16:22:00Z","reference_number":"EMA/511056/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylprednisolone-list-nationally-authorised-medicinal-products-psusa00002026202011_en.pdf"},
    {"id":"52434","name":"Carboprost - List of nationally authorised medicinal products - PSUSA-0000560-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-13T16:51:00Z","last_updated_date":"2021-09-13T16:51:00Z","reference_number":"EMA/509535/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/carboprost-list-nationally-authorised-medicinal-products-psusa-0000560-202101_en.pdf"},
    {"id":"52438","name":"Desmopressin - List of nationally authorised medicinal products - PSUSA-00000964-202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-14T12:13:00Z","last_updated_date":"2021-09-14T12:13:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/desmopressin-list-nationally-authorised-medicinal-products-psusa-00000964-202012_en.pdf"},
    {"id":"52444","name":"Alizapride: List of nationally authorised medicinal products - PSUSA-00000091-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-15T10:33:00Z","last_updated_date":"2021-09-15T10:33:00Z","reference_number":"EMA/517927/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/alizapride-list-nationally-authorised-medicinal-products-psusa-00000091-202101_en.pdf"},
    {"id":"52445","name":"Azelastine - List of nationally authorised medicinal products - PSUSA/00000277/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-15T10:46:00Z","last_updated_date":"2021-09-15T10:46:00Z","reference_number":"EMA/517929/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/azelastine-list-nationally-authorised-medicinal-products-psusa00000277201712_en.pdf-0"},
    {"id":"52452","name":"Sodium iron gluconate (parenteral preparations) - List of nationally authorised medicinal products - PSUSA-00010867-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-15T14:32:00Z","last_updated_date":"2021-09-15T14:32:00Z","reference_number":"EMA/520175/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-iron-gluconate-parenteral-preparations-list-nationally-authorised-medicinal-products-psusa-00010867-202101_en.pdf"},
    {"id":"52453","name":"Antithrombin iii - List of nationally authorised medicinal products - PSUSA-00003159-202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-15T14:32:00Z","last_updated_date":"2021-09-15T14:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/antithrombin-iii-list-nationally-authorised-medicinal-products-psusa-00003159-202012_en.pdf"},
    {"id":"52540","name":"Ethanol extracts of: Iberis amara../Angelica archangelica../Matricaria recutita../Carum carvi../Silybum marianum../Melissa offic../Mentha piperita../Chelidonium majus../Glycyrrhiza glabra.. : List of nationally authorised products - PSUSA-00010800-202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-22T09:01:00Z","last_updated_date":"2021-09-22T09:01:00Z","reference_number":"EMA/533721/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethanol-extracts-iberis-amaraangelica-archangelicamatricaria-recutitacarum-carvisilybum-marianummelissa-officmentha-piperitachelidonium-majusglycyrrhiza-glabra-list-nationally-authorised-products_en.pdf"},
    {"id":"52541","name":"Ethanol extracts of: Iberis amara../Angelica archangelica../Matricaria recutita../Carum carvi../Silybum marianum../Melissa offic../Mentha piperita../Chelidonium majus../Glycyrrhiza glabra.. : CMDh scientific conclusions - PSUSA-00010800-202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-22T09:22:00Z","last_updated_date":"2021-09-22T09:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ethanol-extracts-iberis-amara-angelica-archangelica-matricaria-recutita-carum-carvi-silybum-marianum-melissa-offic-mentha-piperita-chelidonium-majus-glycyrrhiza-glabra-cmdh-scientific-conclusions_no.pdf"}},
    {"id":"52594","name":"Iron dextran : list of nationally authorised medicinal products - PSUSA/00010696/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T08:45:00Z","last_updated_date":"2021-09-24T08:45:00Z","reference_number":"EMA/540044/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-dextran-list-nationally-authorised-medicinal-products-psusa00010696202101_en.pdf"},
    {"id":"52595","name":"Iron isomaltoside : List of nationally authorised medicinal products - PSUSA/00010866/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T08:57:00Z","last_updated_date":"2021-09-24T08:57:00Z","reference_number":"EMA/540123/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-isomaltoside-list-nationally-authorised-medicinal-products-psusa00010866202101_en.pdf"},
    {"id":"52601","name":"Cefoperazone / sulbactam : List of nationally authorised medicinal products - PSUSA/00000598/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T10:40:00Z","last_updated_date":"2021-09-24T10:40:00Z","reference_number":"EMA/540538/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefoperazone-sulbactam-list-nationally-authorised-medicinal-products-psusa00000598202101_en.pdf"},
    {"id":"52602","name":"Tobramycin (nebuliser solution) : List of nationally authorised medicinal products - PSUSA/00009316/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T10:47:00Z","last_updated_date":"2021-09-24T10:47:00Z","reference_number":"EMA/467432/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/tobramycin-nebuliser-solution-list-nationally-authorised-medicinal-products-psusa00009316202012_en.pdf"},
    {"id":"52603","name":"Anthrax vaccine : List of nationally authorised medicinal products - PSUSA/00010771/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T11:03:00Z","last_updated_date":"2021-09-24T11:03:00Z","reference_number":"EMA/PRAC/467975/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/anthrax-vaccine-list-nationally-authorised-medicinal-products-psusa00010771202012_en.pdf"},
    {"id":"52710","name":"Granisetron (other formulations except for transdermal patch) - List of nationally authorised medicinal products - PSUSA-00001568-202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-04T12:13:00Z","last_updated_date":"2021-10-04T12:13:00Z","reference_number":"EMA/548740/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/granisetron-other-formulations-except-transdermal-patch-list-nationally-authorised-medicinal-products-psusa-00001568-202102_en.pdf"},
    {"id":"52711","name":"Lisdexamfetamine - List of nationally authorised medicinal products - PSUSA-00010289-202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-04T13:15:00Z","last_updated_date":"2021-10-04T13:15:00Z","reference_number":"EMA/550339/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa-00010289-202102_en.pdf"},
    {"id":"52712","name":"Amitriptyline hydrochloride/chlordiazepoxide - List of nationally authorised medicinal products - PSUSA-00000171-202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-04T13:15:00Z","last_updated_date":"2021-10-04T13:15:00Z","reference_number":"EMA/550796/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-hydrochloridechlordiazepoxide-list-nationally-authorised-medicinal-products-psusa-00000171-202102_en.pdf"},
    {"id":"52721","name":"Nomegestrol - List of nationally authorised medicinal products - PSUSA-00002181-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-04T17:35:00Z","last_updated_date":"2021-10-04T17:35:00Z","reference_number":"EMA/538762/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/nomegestrol-list-nationally-authorised-medicinal-products-psusa-00002181-202101_en.pdf"},
    {"id":"52728","name":"Baclofen (intrathecal) - List of nationally authorised medicinal products - PSUSA/00000293/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-05T17:25:00Z","last_updated_date":"2021-10-05T17:25:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/baclofen-intrathecal-list-nationally-authorised-medicinal-products-psusa00000293202101_en.pdf"},
    {"id":"52729","name":"Iloprost (i.v. solution only) - List of nationally authorised medicinal products - PSUSA-00009190-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-05T17:41:00Z","last_updated_date":"2021-10-05T17:41:00Z","reference_number":"EMA/564487/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/iloprost-iv-solution-only-list-nationally-authorised-medicinal-products-psusa-00009190-202101_en.pdf"},
    {"id":"52751","name":"Eletriptan : List of nationally authorised medicinal products - PSUSA/00001204/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-06T15:40:00Z","last_updated_date":"2021-10-06T15:40:00Z","reference_number":"EMA/568259/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/eletriptan-list-nationally-authorised-medicinal-products-psusa00001204202102_en.pdf"},
    {"id":"52901","name":"Amiodarone - List of nationally authorised medicinal products - PSUSA-00000166-202012","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-10-26T11:08:00Z","last_updated_date":"2021-10-26T11:08:00Z","reference_number":"EMA/606309/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/amiodarone-list-nationally-authorised-medicinal-products-psusa-00000166-202012_en.pdf"},
    {"id":"52902","name":"Amiodarone - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA-00000166-202012","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-10-26T11:12:00Z","last_updated_date":"2021-10-26T11:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/amiodarone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000166-202012_no.pdf"}},
    {"id":"52905","name":"Intravenous iron: List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0026","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-26T11:55:00Z","last_updated_date":"2021-10-26T11:55:00Z","reference_number":"EMA/607374/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/intravenous-iron-list-nationally-authorised-medicinal-products-emeahnpsrj0026_en.pdf"},
    {"id":"52906","name":"Intravenous iron: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/J/0026","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-26T11:59:00Z","last_updated_date":"2021-10-26T11:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/intravenous-iron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrj0026_no.pdf"}},
    {"id":"52908","name":"Influenza vaccine (split virion, inactivated) (non centrally authorised products) - List of nationally authorised medicinal products - PSUSA-00010298-202103","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-10-26T15:33:00Z","last_updated_date":"2021-10-26T15:33:00Z","reference_number":"EMA/499957/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa-00010298-202103_en.pdf"},
    {"id":"52909","name":"Hydroxyethyl starch - List of nationally authorised medicinal products - PSUSA-00001694-202103","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-10-26T15:33:00Z","last_updated_date":"2021-10-26T15:33:00Z","reference_number":"EMA/609295/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-list-nationally-authorised-medicinal-products-psusa-00001694-202103_en.pdf"},
    {"id":"52914","name":"Influenza vaccine (surface antigen, inactivated) : List of nationally authorised medicinal products - PSUSA/00001744/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-27T10:39:00Z","last_updated_date":"2021-10-27T10:39:00Z","reference_number":"EMA/610630/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa00001744202103_en.pdf"},
    {"id":"52919","name":"5 fluorouracil (i.v. application) - List of nationally authorised medicinal products - PSUSA-00000007-202012","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-10-27T12:15:00Z","last_updated_date":"2021-10-27T12:15:00Z","reference_number":"EMA/606750/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-iv-application-list-nationally-authorised-medicinal-products-psusa-00000007-202012_en.pdf"},
    {"id":"52920","name":"5 fluorouracil (i.v. application) - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA-00000007-202012","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-10-27T12:15:00Z","last_updated_date":"2021-10-27T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/5-fluorouracil-iv-application-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000007-202012_no.pdf"}},
    {"id":"52921","name":"Carbamazepine - List of nationally authorised medicinal products - PSUSA-00000539-202012","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-10-27T15:45:00Z","last_updated_date":"2021-10-27T15:45:00Z","reference_number":"EMA/398898/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbamazepine-list-nationally-authorised-medicinal-products-psusa-00000539-202012_en.pdf"},
    {"id":"52922","name":"Carbamazepine - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA-00000539-202012","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-10-27T15:45:00Z","last_updated_date":"2021-10-27T15:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/carbamazepine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000539-202012_no.pdf"}},
    {"id":"52923","name":"Cefoperazone - List of nationally authorised medicinal products - PSUSA-00000597-202101","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-10-27T16:26:00Z","last_updated_date":"2021-10-27T16:26:00Z","reference_number":"EMA/473765/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefoperazone-list-nationally-authorised-medicinal-products-psusa-00000597-202101_en.pdf"},
    {"id":"52924","name":"Cefoperazone - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA-00000597-202101","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-10-27T16:26:00Z","last_updated_date":"2021-10-27T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cefoperazone-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa-00000597-202101_no.pdf"}},
    {"id":"52940","name":"Ampicillin / sulbactam : List of nationally authorised medicinal products - PSUSA/00000197/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T10:53:00Z","last_updated_date":"2021-10-29T10:53:00Z","reference_number":"EMA/483457/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ampicillin-sulbactam-list-nationally-authorised-medicinal-products-psusa00000197202102_en.pdf"},
    {"id":"52941","name":"Rabies vaccine : List of nationally authorised medicinal products - PSUSA/00009277/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T11:02:00Z","last_updated_date":"2021-10-29T11:02:00Z","reference_number":"EMA/609302/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabies-vaccine-list-nationally-authorised-medicinal-products-psusa00009277202103_en.pdf"},
    {"id":"52942","name":"Butoconazole : List of nationally authorised medicinal products - PSUSA/00000471/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T11:17:00Z","last_updated_date":"2021-10-29T11:17:00Z","reference_number":"EMA/616984/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/butoconazole-list-nationally-authorised-medicinal-products-psusa00000471202102_en.pdf"}    {"id":"52943","name":"Nitrofurantoin, nifurtoinol : List of nationally authorised medicinal products - PSUSA/00002174/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T11:24:00Z","last_updated_date":"2021-10-29T11:24:00Z","reference_number":"EMA/617000/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrofurantoin-nifurtoinol-list-nationally-authorised-medicinal-products-psusa00002174202102_en.pdf"},
    {"id":"52946","name":"Citrulline malate : List of the nationally authorised medicinal products - PSUSA/00010579/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T12:24:00Z","last_updated_date":"2021-10-29T12:24:00Z","reference_number":"EMA/612197/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/citrulline-malate-list-nationally-authorised-medicinal-products-psusa00010579202103_en.pdf"},
    {"id":"52947","name":"Fluorodopa (18F) : List of nationally authorised medicinal products - PSUSA/00010002/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T12:51:00Z","last_updated_date":"2021-10-29T12:51:00Z","reference_number":"EMA/617404/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluorodopa-18f-list-nationally-authorised-medicinal-products-psusa00010002202103_en.pdf"},
    {"id":"52949","name":"Allopurinol : List of nationally authorised medicinal products - PSUSA/00000095/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T13:07:00Z","last_updated_date":"2021-10-29T13:07:00Z","reference_number":"EMA/617623/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/allopurinol-list-nationally-authorised-medicinal-products-psusa00000095202012_en.pdf"},
    {"id":"52951","name":"Allopurinol : CMDh Scientific conclusions and grounds for the variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000095/202012","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T13:11:00Z","last_updated_date":"2021-10-29T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/allopurinol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000095202012_no.pdf"}},
    {"id":"52956","name":"Betamethasone : List of nationally authorised medicinal products - PSUSA/00000391/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T14:18:00Z","last_updated_date":"2021-10-29T14:18:00Z","reference_number":"EMA/618045/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/betamethasone-list-nationally-authorised-medicinal-products-psusa00000391202101_en.pdf"},
    {"id":"52957","name":"Betamethasone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000391/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T14:20:00Z","last_updated_date":"2022-10-18T12:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/betamethasone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000391202101_no.pdf"}},
    {"id":"52958","name":"Gliclazide : List of nationally authorised medicinal products - PSUSA/00001532/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T14:26:00Z","last_updated_date":"2021-10-29T14:26:00Z","reference_number":"EMA/618168/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/gliclazide-list-nationally-authorised-medicinal-products-psusa00001532202102_en.pdf"},
    {"id":"52959","name":"Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide : List of nationally authorised medicinal products - PSUSA/0009162202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T14:31:00Z","last_updated_date":"2021-10-29T14:31:00Z","reference_number":"EMA/618196/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-chloride-glutamic-acid-glutathione-histidine-lactobionic-acid-magnesium-chloride-mannitol-potassium-chloride-sodium-hydroxide-list-nationally-authorised-medicinal-products-psusa0009162202103_en.pdf"},
    {"id":"52960","name":"Olodaterol : List of nationally authorised medicinal products - PSUSA/00010245/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T14:41:00Z","last_updated_date":"2021-10-29T14:41:00Z","reference_number":"EMA/618298/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodaterol-list-nationally-authorised-medicinal-products-psusa00010245202103_en.pdf"},
    {"id":"52973","name":"Hydrochlorothiazide / spironolactone : List of nationally authorised medicinal products - PSUSA/00001662/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-03T09:42:00Z","last_updated_date":"2021-11-03T09:42:00Z","reference_number":"EMA/619421/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-spironolactone-list-nationally-authorised-medicinal-products-psusa00001662202101_en.pdf"},
    {"id":"52974","name":"Hydrochlorothiazide / spironolactone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001662/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-03T09:52:00Z","last_updated_date":"2021-11-03T09:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydrochlorothiazide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001662202101_sv.pdf"}},
    {"id":"52975","name":"Lisdexamfetamine dimesylate : List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0033","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-03T10:48:00Z","last_updated_date":"2021-11-03T10:48:00Z","reference_number":"EMA/619644/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-dimesylate-list-nationally-authorised-medicinal-products-emeahnpsrs0033_en.pdf"},
    {"id":"52976","name":"Lisdexamfetamine dimesylate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/S/0033","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-03T10:53:00Z","last_updated_date":"2021-11-03T10:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_es.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lisdexamfetamine-dimesylate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0033_no.pdf"}},
    {"id":"52981","name":"Amitriptyline, amitriptyline / amitriptylinoxide, amitriptylinoxide : List of nationally authorised medicinal products - PSUSA/00010374/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-03T15:58:00Z","last_updated_date":"2021-11-03T15:58:00Z","reference_number":"EMA/617089/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-list-nationally-authorised-medicinal-products-psusa00010374202101_en.pdf"},
    {"id":"52982","name":"Amitriptyline, amitriptyline / amitriptylinoxide, amitriptylinoxide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010374/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-03T16:01:00Z","last_updated_date":"2021-11-03T16:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010374202101_no.pdf"}},
    {"id":"53043","name":"Nitrazepam : List of nationally authorised medicinal products - PSUSA/00010292/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-09T17:15:00Z","last_updated_date":"2021-11-09T17:15:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrazepam-list-nationally-authorised-medicinal-products-psusa00010292202103_en.pdf"},
    {"id":"53102","name":"Argatroban : List of nationally authorised medicinal products - PSUSA/00009057/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:34:00Z","last_updated_date":"2021-11-12T09:34:00Z","reference_number":"EMA/656136/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/argatroban-list-nationally-authorised-medicinal-products-psusa00009057202101_en.pdf"},
    {"id":"53107","name":"Tenoxicam : List of nationally authorised medicinal products - PSUSA/00002893/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T14:19:00Z","last_updated_date":"2021-11-12T14:19:00Z","reference_number":"EMA/677353/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/tenoxicam-list-nationally-authorised-medicinal-products-psusa00002893202102_en.pdf"},
    {"id":"53178","name":"Dexamfetamine: List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0028","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T14:43:00Z","last_updated_date":"2021-11-19T14:43:00Z","reference_number":"EMA/619644/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-emeahnpsrs0028_en.pdf"},
    {"id":"53179","name":"Dexamfetamine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/S/0028","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T14:45:00Z","last_updated_date":"2021-11-19T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0028_no.pdf"}},
    {"id":"53183","name":"Dexamfetamine: List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0029","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T14:56:00Z","last_updated_date":"2021-11-19T14:56:00Z","reference_number":"EMA/619644/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-emeahnpsrs0029_en.pdf"},
    {"id":"53184","name":"Dexamfetamine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/S/0029","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-19T15:05:00Z","last_updated_date":"2021-11-19T15:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0029_no.pdf"}},
    {"id":"53293","name":"Lanthanum : List of nationally authorised medicinal products - PSUSA/00003175/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-26T11:54:00Z","last_updated_date":"2021-11-26T11:54:00Z","reference_number":"EMA/703638/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/lanthanum-list-nationally-authorised-medicinal-products-psusa00003175202103_en.pdf"},
    {"id":"53294","name":"Lanthanum : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003175/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-26T12:03:00Z","last_updated_date":"2021-11-26T12:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lanthanum-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003175202103_no.pdf"}},
    {"id":"53299","name":"valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium - List of nationally authorised medicinal products - PSUSA-00003090-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T09:45:00Z","last_updated_date":"2021-11-29T09:45:00Z","reference_number":"EMA/700665/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-list-nationally-authorised-medicinal-products-psusa-00003090_en.pdf"},
    {"id":"53300","name":"valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium - Scientific conclusions and grounds for variation, amendments to the Product Informat - PSUSA-00003090-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T10:22:00Z","last_updated_date":"2021-11-29T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-valproate-bismuth-calcium-valproate-valproate-magnesium-scientific-conclusions-and-grounds-variation-amendments_no.pdf"}},
    {"id":"53318","name":"Amitriptyline / perphenazine - List of nationally authorised medicinal products - PSUSA-00000170-202101","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-11-29T14:36:00Z","last_updated_date":"2021-11-29T14:36:00Z","reference_number":"EMA/708781/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-perphenazine-list-nationally-authorised-medicinal-products-psusa-00000170-202101_en.pdf"},
    {"id":"53319","name":"Amitriptyline / perphenazine - Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA-00000170-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T14:36:00Z","last_updated_date":"2021-11-29T14:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amitriptyline-perphenazine-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000170-202101_sv.pdf"}},
    {"id":"53337","name":"Dexamethasone - List of nationally authorised medicinal products - PSUSA-00000973-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-30T10:57:00Z","last_updated_date":"2021-11-30T10:57:00Z","reference_number":"EMA/709165/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamethasone-list-nationally-authorised-medicinal-products-psusa-00000973-202101_en.pdf"},
    {"id":"53338","name":"Dexamethasone - Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA-00000973-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-30T10:57:00Z","last_updated_date":"2021-11-30T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dexamethasone-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000973-202101_no.pdf"}},
    {"id":"53360","name":"Ozenoxacin - List of nationally authorised medicinal products - PSUSA/00010651/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-03T15:00:00Z","last_updated_date":"2021-12-03T15:00:00Z","reference_number":"EMA/689651/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ozenoxacin-list-nationally-authorised-medicinal-products-psusa00010651202105_en.pdf"},
    {"id":"53361","name":"Oxaliplatin - List of nationally authorised medicinal products - PSUSA/00002229/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-03T15:16:00Z","last_updated_date":"2021-12-03T15:16:00Z","reference_number":"EMA/719030/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxaliplatin-list-nationally-authorised-medicinal-products-psusa00002229202104_en.pdf"},
    {"id":"53364","name":"Plasma protein fraction: List of nationally authorised medicinal products - PSUSA/00002449/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-06T11:55:00Z","last_updated_date":"2021-12-06T11:55:00Z","reference_number":"EMA/717468/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/plasma-protein-fraction-list-nationally-authorised-medicinal-products-psusa00002449202104_en.pdf"},
    {"id":"53371","name":"Tafluprost: List of nationally authorised medicinal products -  PSUSA/00002843/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-06T14:54:00Z","last_updated_date":"2021-12-06T14:54:00Z","reference_number":"EMA/721991/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/tafluprost-list-nationally-authorised-medicinal-products-psusa00002843202104_en.pdf"},
    {"id":"53373","name":"List of nationally authorised medicinal products - PSUSA/00002786/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-06T16:00:00Z","last_updated_date":"2021-12-06T16:00:00Z","reference_number":"EMA/689851/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/list-nationally-authorised-medicinal-products-psusa00002786202103_en.pdf"},
    {"id":"53374","name":"Tobramycin (ophthalmic and otic use): List of nationally authorised medicinal products -  PSUSA/00009317/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-06T16:08:00Z","last_updated_date":"2021-12-06T16:08:00Z","reference_number":"EMA/609316/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/tobramycin-ophthalmic-and-otic-use-list-nationally-authorised-medicinal-products-psusa00009317202103_en.pdf"},
    {"id":"53376","name":"Budesonide: List of nationally authorised medicinal products - PSUSA/00000449/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-06T16:55:00Z","last_updated_date":"2021-12-06T16:55:00Z","reference_number":"EMA/695847/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/budesonide-list-nationally-authorised-medicinal-products-psusa00000449202104_en.pdf"},
    {"id":"53379","name":"Dexamethasone / netilmicin: List of nationally authorised medicinal products - PSUSA/00010854/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-07T09:53:00Z","last_updated_date":"2021-12-07T09:53:00Z","reference_number":"EMA/724898/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamethasone-netilmicin-list-nationally-authorised-medicinal-products-psusa00010854202104_en.pdf"},
    {"id":"53380","name":"Dihydroergotamine: List of nationally authorised medicinal products - PSUSA/00001075/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-07T10:06:00Z","last_updated_date":"2021-12-07T10:06:00Z","reference_number":"EMA/724961/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dihydroergotamine-list-nationally-authorised-medicinal-products-psusa00001075202104_en.pdf"},
    {"id":"53413","name":"Amlodipine besilate / ramipril, amlodipine / hydrochlorothiazide / ramipril, hydrochlorothiazide / ramipril : List of nationally authorised medicinal products - PSUSA/00010774/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T11:44:00Z","last_updated_date":"2021-12-08T11:44:00Z","reference_number":"EMA/731539/202121","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-besilate-ramipril-amlodipine-hydrochlorothiazide-ramipril-hydrochlorothiazide-ramipril-list-nationally-authorised-medicinal-products-psusa00010774202103_en.pdf"},
    {"id":"53415","name":"Metformin : List of nationally authorised medicinal products - PSUSA/00002001/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T11:54:00Z","last_updated_date":"2021-12-08T11:54:00Z","reference_number":"EMA/731509/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/metformin-list-nationally-authorised-medicinal-products-psusa00002001202104_en.pdf"},
    {"id":"53423","name":"N(2)-L-alanyl-L-glutamine : List of nationally authorised medicinal products - PSUSA/00003158/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T16:35:00Z","last_updated_date":"2021-12-08T16:35:00Z","reference_number":"EMA/734732/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/n2-l-alanyl-l-glutamine-list-nationally-authorised-medicinal-products-psusa00003158202103_en.pdf"},
    {"id":"53457","name":"Metamizole : List of nationally authorised medicines - PSUSA/00001997/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-13T17:29:00Z","last_updated_date":"2021-12-13T17:29:00Z","reference_number":"EMA/749047/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/metamizole-list-nationally-authorised-medicines-psusa00001997202103_en.pdf"},
    {"id":"53458","name":"Metamizole : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001997/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-13T17:31:00Z","last_updated_date":"2021-12-13T17:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/metamizole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001997202103_sv.pdf"}},
    {"id":"53465","name":"Deoxycholic acid : List of nationally authorised medicinal products - PSUSA/00010525/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T09:29:00Z","last_updated_date":"2021-12-14T09:29:00Z","reference_number":"EMA/751094/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/deoxycholic-acid-list-nationally-authorised-medicinal-products-psusa00010525202104_en.pdf"},
    {"id":"53477","name":"Pholcodine / biclotymol / chlorphenamine maleate : List of nationally authorised medicinal products - PSUSA/00010437/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T11:25:00Z","last_updated_date":"2021-12-14T11:25:00Z","reference_number":"EMA/751683/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/pholcodine-biclotymol-chlorphenamine-maleate-list-nationally-authorised-medicinal-products-psusa00010437202104_en.pdf"},
    {"id":"53509","name":"Argipressin : List of nationally authorised medicinal products - PSUSA/00010749/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T17:33:00Z","last_updated_date":"2021-12-14T17:33:00Z","reference_number":"EMA/756827/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/argipressin-list-nationally-authorised-medicinal-products-psusa00010749202103_en.pdf"},
    {"id":"53530","name":"Risedronate: List of nationally authorised medicinal products - PSUSA-00002648-202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-15T16:39:00Z","last_updated_date":"2021-12-15T16:39:00Z","reference_number":"EMA/756993/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/risedronate-list-nationally-authorised-medicinal-products-psusa-00002648-202103_en.pdf"},
    {"id":"53531","name":"Terlipressin: List of nationally authorised medicinal products - PSUSA/00002905/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-15T16:53:00Z","last_updated_date":"2021-12-15T16:53:00Z","reference_number":"EMA/757577/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/terlipressin-list-nationally-authorised-medicinal-products-psusa00002905202104_en.pdf"},
    {"id":"53538","name":"Ivermectin: List of nationally authorised medicinal products - PSUSA/00010376/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-12-16T09:37:00Z","last_updated_date":"2021-12-16T09:37:00Z","reference_number":"EMA/756742/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-list-nationally-authorised-medicinal-products-psusa00010376202104_en.pdf"},
    {"id":"53625","name":"Ondansetron: List of nationally authorised medicinal products - PSUSA/00002217/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-04T09:34:00Z","last_updated_date":"2022-01-04T09:34:00Z","reference_number":"EMA/731956/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ondansetron-list-nationally-authorised-medicinal-products-psusa00002217202102_en.pdf"},
    {"id":"53626","name":"Ondansetron: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002217/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-04T09:37:00Z","last_updated_date":"2022-01-04T09:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ondansetron-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002217202102_no.pdf"}},
    {"id":"53628","name":"Human anti-d immunoglobulin: List of nationally authorised medicinal products - PSUSA/00001614/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-04T10:20:00Z","last_updated_date":"2022-01-04T10:20:00Z","reference_number":"EMA/762845/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-anti-d-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00001614202103_en.pdf"},
    {"id":"53635","name":"Cytarabine: List of nationally authorised medicinal products - PSUSA/00000911/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-05T11:24:00Z","last_updated_date":"2022-01-05T11:24:00Z","reference_number":"EMA/772410/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/cytarabine-list-nationally-authorised-medicinal-products-psusa00000911202103_en.pdf"},
    {"id":"53636","name":"Carmustine: List of nationally authorised medicinal products - PSUSA/00010349/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-05T11:33:00Z","last_updated_date":"2022-01-05T11:33:00Z","reference_number":"EMA/772526/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/carmustine-list-nationally-authorised-medicinal-products-psusa00010349202104_en.pdf"},
    {"id":"53637","name":"Methoxyflurane: List of nationally authorised medicinal products - PSUSA/00010484/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-05T11:47:00Z","last_updated_date":"2022-01-05T11:47:00Z","reference_number":"EMA/772781/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa00010484202105_en.pdf"},
    {"id":"53640","name":"Dexamethasone / tobramycin: List of nationally authorised medicinal products - PSUSA/00000979/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-05T15:01:00Z","last_updated_date":"2022-01-05T15:01:00Z","reference_number":"EMA/772643/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamethasone-tobramycin-list-nationally-authorised-medicinal-products-psusa00000979202103_en.pdf"},
    {"id":"53693","name":"Nafarelin: List of nationally authorised medicinal products - PSUSA/00002105/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-12T09:07:00Z","last_updated_date":"2022-01-12T09:07:00Z","reference_number":"EMA/CMDh/540986/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/nafarelin-list-nationally-authorised-medicinal-products-psusa00002105202102_en.pdf"},
    {"id":"53695","name":"Nafarelin: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002105/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-12T09:09:00Z","last_updated_date":"2022-01-14T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/nafarelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002105202102_no.pdf"}},
    {"id":"53696","name":"Spironolactone: List of nationally authorised medicinal products - PSUSA/00002780/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-12T09:12:00Z","last_updated_date":"2022-01-12T09:12:00Z","reference_number":"EMA/784388/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/spironolactone-list-nationally-authorised-medicinal-products-psusa00002780202103_en.pdf"},
    {"id":"53697","name":"Spironolactone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002780/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-12T09:14:00Z","last_updated_date":"2022-01-12T09:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002780202103_no.pdf"}},
    {"id":"53705","name":"Captopril / hydrochlorothiazide : List of nationally authorised medicinal products - PSUSA/00000536/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-13T11:30:00Z","last_updated_date":"2022-01-13T11:30:00Z","reference_number":"EMA/294429/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/captopril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00000536202104_en.pdf"},
    {"id":"53706","name":"Dobutamine : List of nationally authorised medicinal products - PSUSA/00001151/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-13T11:33:00Z","last_updated_date":"2022-01-13T11:33:00Z","reference_number":"EMA/294429/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/dobutamine-list-nationally-authorised-medicinal-products-psusa00001151202103_en.pdf"},
    {"id":"53707","name":"Dobutamine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001151/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-13T11:38:00Z","last_updated_date":"2022-03-09T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dobutamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001151202103_no.pdf"}},
    {"id":"53722","name":"Human prothrombin complex : List of nationally authorised medicinal products - PSUSA/00001638/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T13:56:00Z","last_updated_date":"2022-01-14T13:56:00Z","reference_number":"EMA/15908/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-prothrombin-complex-list-nationally-authorised-medicinal-products-psusa00001638202104_en.pdf"},
    {"id":"53723","name":"Lanreotide : List of nationally authorised medicinal products - PSUSA/00001826/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T14:07:00Z","last_updated_date":"2022-01-14T14:07:00Z","reference_number":"EMA/24065/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/lanreotide-list-nationally-authorised-medicinal-products-psusa00001826202105_en.pdf"},
    {"id":"53724","name":"Moxifloxacin (topical ophthalmic use) : List of nationally authorised medicinal products - PSUSA/00002094/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T14:15:00Z","last_updated_date":"2022-01-14T14:15:00Z","reference_number":"EMA/683961/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/moxifloxacin-topical-ophthalmic-use-list-nationally-authorised-medicinal-products-psusa00002094202105_en.pdf"},
    {"id":"53725","name":"Nadifloxacin : List of nationally authorised medicinal products - PSUSA/00002102/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T14:20:00Z","last_updated_date":"2022-01-14T14:20:00Z","reference_number":"EMA/683828/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/nadifloxacin-list-nationally-authorised-medicinal-products-psusa00002102202105_en.pdf"},
    {"id":"53727","name":"Flunarizine : List of nationally authorised medicinal products - PSUSA/00001416/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T14:53:00Z","last_updated_date":"2022-01-14T14:53:00Z","reference_number":"EMA/25628/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/flunarizine-list-nationally-authorised-medicinal-products-psusa00001416202105_en.pdf"},
    {"id":"53728","name":"Bismuth subcitrate potassium / metronidazole / tetracycline : List of nationally authorised medicinal products - PSUSA/00010199/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T14:57:00Z","last_updated_date":"2022-01-14T14:57:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-list-nationally-authorised-medicinal-products-psusa00010199202105_en.pdf"},
    {"id":"53729","name":"Milnalcipran : List of nationally authorised medicinal products - PSUSA/00002063/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T15:01:00Z","last_updated_date":"2022-01-14T15:01:00Z","reference_number":"EMA/25995/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/milnalcipran-list-nationally-authorised-medicinal-products-psusa00002063202104_en.pdf"},
    {"id":"53730","name":"Ranitidine : List of the nationally authorised medicinal products - PSUSA/00002610/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T15:04:00Z","last_updated_date":"2022-01-14T15:04:00Z","reference_number":"EMA/26959/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ranitidine-list-nationally-authorised-medicinal-products-psusa00002610202105_en.pdf"},
    {"id":"53735","name":"Phenylpropanolamine : List of nationally authorised medicinal products - PSUSA/00010483/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T16:31:00Z","last_updated_date":"2022-01-14T16:31:00Z","reference_number":"EMA/27832/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylpropanolamine-list-nationally-authorised-medicinal-products-psusa00010483202106_en.pdf"},
    {"id":"53745","name":"Olodaterol/tiotropium : List of nationally authorised medicinal products - PSUSA/00010489/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T11:00:00Z","last_updated_date":"2022-01-17T11:00:00Z","reference_number":"EMA/28179/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodateroltiotropium-list-nationally-authorised-medicinal-products-psusa00010489202105_en.pdf"},
    {"id":"53746","name":"Clevidipine : List of nationally authorised medicines - PSUSA/00010288/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T11:09:00Z","last_updated_date":"2022-01-17T11:09:00Z","reference_number":"EMA/27992/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicines-psusa00010288202105_en.pdf"},
    {"id":"53760","name":"Docosanol : List of nationally authorised medicinal products - PSUSA/00010092/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T12:34:00Z","last_updated_date":"2022-01-17T12:34:00Z","reference_number":"EMA/690088/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/docosanol-list-nationally-authorised-medicinal-products-psusa00010092202104_en.pdf"},
    {"id":"53761","name":"Valganciclovir : List of nationally authorised medicinal products - PSUSA/00003089/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T12:37:00Z","last_updated_date":"2022-01-17T12:37:00Z","reference_number":"EMA/690020/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/valganciclovir-list-nationally-authorised-medicinal-products-psusa00003089202103_en.pdf"},
    {"id":"53762","name":"Bacterial lysate of haemophilus influenzae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus / streptococcus mitis / strep. pneumoniae / strep. pyogenes : List of nationally authorised medicinal products - PSUSA/00002786/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T14:08:00Z","last_updated_date":"2022-01-17T14:08:00Z","reference_number":"EMA/689851/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/bacterial-lysate-haemophilus-influenzae-klebsiella-pneumoniae-moraxella-catarrhalis-staphylococcus-aureus-streptococcus-mitis-strep-pneumoniae-strep-pyogenes-list-nationally-authorised-medicinal_en.pdf"},
    {"id":"53765","name":"Ofloxacin (systemic use) - List of nationally authorised medicinal products - PSUSA/00002203/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T15:09:00Z","last_updated_date":"2022-01-17T15:09:00Z","reference_number":"EMA/502701/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa00002203202104_en.pdf"},
    {"id":"53766","name":"Ofloxacin (systemic use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002203/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T15:12:00Z","last_updated_date":"2022-01-17T15:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_da.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_et.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_is.pdf"}},
    {"id":"53767","name":"Levofloxacin/dexamethasone (ocular use) : List of nationally authorised medicinal products - PSUSA/00010881/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T15:18:00Z","last_updated_date":"2022-01-17T15:18:00Z","reference_number":"EMA/25295/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/levofloxacindexamethasone-ocular-use-list-nationally-authorised-medicinal-products-psusa00010881202106_en.pdf"},
    {"id":"53768","name":"Cidofovir : List of nationally authorised medicinal products - PSUSA/00010558/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T15:25:00Z","last_updated_date":"2022-01-17T15:25:00Z","reference_number":"EMA/25291/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cidofovir-list-nationally-authorised-medicinal-products-psusa00010558202106_en.pdf"},
    {"id":"53801","name":"Iodine (131i) iobenguane : List of nationally authorised medicinal products - PSUSA/00001764/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-18T10:47:00Z","last_updated_date":"2022-01-18T10:47:00Z","reference_number":"EMA/30003/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/iodine-131i-iobenguane-list-nationally-authorised-medicinal-products-psusa00001764202105_en.pdf"},
    {"id":"53816","name":"Triglyceride combinations (e.g. olive oil, soya bean oil, fish oil)/ with or without mineral compounds/electrolytes (i.v. application) : List of nationally authorised medicinal products - PSUSA/00010648/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-18T16:08:00Z","last_updated_date":"2022-01-18T16:08:00Z","reference_number":"EMA/32337/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/triglyceride-combinations-eg-olive-oil-soya-bean-oil-fish-oil-or-without-mineral-compoundselectrolytes-iv-application-list-nationally-authorised-medicinal-products-psusa00010648202106_en.pdf"},
    {"id":"53847","name":"Chloroquine : List of nationally authorised medicinal products - PSUSA/00000685/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-20T11:10:00Z","last_updated_date":"2022-01-20T11:10:00Z","reference_number":"EMA/502656/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/chloroquine-list-nationally-authorised-medicinal-products-psusa00000685202104_en.pdf"},
    {"id":"53848","name":"Chloroquine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000685/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-20T11:12:00Z","last_updated_date":"2022-01-20T11:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/chloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000685202104_no.pdf"}},
    {"id":"53849","name":"Praziquantel : List of the nationally authorised medicinal products - PSUSA/00002503/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-20T11:30:00Z","last_updated_date":"2022-01-20T11:30:00Z","reference_number":"EMA/37314/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/praziquantel-list-nationally-authorised-medicinal-products-psusa00002503202104_en.pdf"},
    {"id":"53851","name":"Praziquantel : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002503/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-20T11:32:00Z","last_updated_date":"2022-01-20T11:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/praziquantel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002503202104_no.pdf"}},
    {"id":"53864","name":"Bisoprolol - List of nationally authorised medicinal products - PSUSA/00000419/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T10:42:00Z","last_updated_date":"2022-01-21T10:42:00Z","reference_number":"EMA/270645/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/bisoprolol-list-nationally-authorised-medicinal-products-psusa-00000419-202009_en.pdf"},
    {"id":"53865","name":"Atorvastatin / perindopril - List of nationally authorised medicinal products - PSUSA/00010679/202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T10:46:00Z","last_updated_date":"2022-01-21T10:46:00Z","reference_number":"EMA/294429/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/atorvastatin-perindopril-list-nationally-authorised-medicinal-products-psusa00010679202010_en.pdf"},
    {"id":"53866","name":"Calcitriol - List of nationally authorised medicinal products - PSUSA/00000495/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T10:52:00Z","last_updated_date":"2022-01-21T10:52:00Z","reference_number":"EMA/294429/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcitriol-list-nationally-authorised-medicinal-products-psusa00000495202101_en.pdf"},
    {"id":"53868","name":"Altizide / spironolactone - List of nationally authorised medicinal products - PSUSA/00002781/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T11:00:00Z","last_updated_date":"2022-01-21T11:00:00Z","reference_number":"EMA/294429/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/altizide-spironolactone-list-nationally-authorised-medicinal-products-psusa00002781202101_en.pdf"},
    {"id":"53871","name":"Ofloxacin (systemic use) - List of nationally authorised medicinal products - PSUSA/00002203/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T12:22:00Z","last_updated_date":"2022-01-21T12:22:00Z","reference_number":"EMA/502701/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa00002203202104_en.pdf-0"},
    {"id":"53872","name":"Ofloxacin (systemic use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002203/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T12:25:00Z","last_updated_date":"2022-01-21T12:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_fr.pdf-0","ga":"https://www.ema.europa.eu/ga/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_ga.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_sv.pdf-0","is":"https://www.ema.europa.eu/is/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_is.pdf-0","no":"https://www.ema.europa.eu/no/documents/psusa/ofloxacin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002203202104_no.pdf"}},
    {"id":"53879","name":"Amino acid combinations / glucose / triglyceride combinations : List of nationally authorised medicinal products - PSUSA/00010565/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T16:31:00Z","last_updated_date":"2022-01-21T16:31:00Z","reference_number":"EMA/41438/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amino-acid-combinations-glucose-triglyceride-combinations-list-nationally-authorised-medicinal-products-psusa00010565202106_en.pdf"},
    {"id":"53880","name":"Amino acid combinations/ glucose/ with or without electrolytes / mineral compounds : List of nationally authorised medicinal products - PSUSA/00010566/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T16:37:00Z","last_updated_date":"2022-01-21T16:37:00Z","reference_number":"EMA/41532/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amino-acid-combinations-glucose-or-without-electrolytes-mineral-compounds-list-nationally-authorised-medicinal-products-psusa00010566202106_en.pdf"},
    {"id":"53892","name":"Isotretinoin (oral formulations) : List of nationally authorised medicinal products - PSUSA/00010488/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-24T14:36:00Z","last_updated_date":"2022-01-24T14:36:00Z","reference_number":"EMA/46466/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa00010488202105_en.pdf"},
    {"id":"53893","name":"Isotretinoin (oral formulations) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -  PSUSA/00010488/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-24T14:39:00Z","last_updated_date":"2022-05-31T11:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/isotretinoin-oral-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010488202105_no.pdf"}},
    {"id":"53895","name":"Misoprostol : List of nationally authorised medicinal products - PSUSA00010291202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-24T15:21:00Z","last_updated_date":"2022-01-24T15:21:00Z","reference_number":"EMA/46833/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-list-nationally-authorised-medicinal-products-psusa00010291202106_en.pdf"}    {"id":"53896","name":"5 fluorouracil / salicylic acid : List of nationally authorised medicinal products - PSUSA/00000008/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-24T15:34:00Z","last_updated_date":"2022-01-24T15:34:00Z","reference_number":"EMA/46876/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-salicylic-acid-list-nationally-authorised-medicinal-products-psusa00000008202105_en.pdf"},
    {"id":"53898","name":"Hydroxychloroquine : List of nationally authorised medicinal products - PSUSA/00001693/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-24T16:49:00Z","last_updated_date":"2022-01-24T16:49:00Z","reference_number":"EMA/502667/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxychloroquine-list-nationally-authorised-medicinal-products-psusa00001693202104_en.pdf"},
    {"id":"53899","name":"Hydroxychloroquine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001693/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-24T16:51:00Z","last_updated_date":"2022-01-24T16:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/hydroxychloroquine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001693202104_no.pdf"}},
    {"id":"53903","name":"Oxycodone : List of nationally authorised medicinal products - PSUSA/00002254/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-25T15:33:00Z","last_updated_date":"2022-01-25T15:33:00Z","reference_number":"EMA/46766/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-list-nationally-authorised-medicinal-products-psusa00002254202104_en.pdf"},
    {"id":"53904","name":"Oxycodone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002254/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-25T15:35:00Z","last_updated_date":"2022-02-01T17:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202104_no.pdf"}},
    {"id":"53917","name":"Fentanyl (transdermal patches, solution for injection - nationally authorised product only) : List of nationally authorised medicinal products - PSUSA/00001370/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-26T11:42:00Z","last_updated_date":"2022-01-26T11:42:00Z","reference_number":"EMA/51965/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-list-nationally-authorised-medicinal-products-psusa00001370202104_en.pdf"},
    {"id":"53918","name":"Fentanyl (transdermal patches, solution for injection....) - CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001370/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-26T11:44:00Z","last_updated_date":"2022-01-26T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fentanyl-transdermal-patches-solution-injection-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001370202104_no.pdf"}},
    {"id":"53932","name":"Latanoprost (except for products with paediatric indication) : List of nationally authorised medicinal products - PSUSA/00001832/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-26T17:19:00Z","last_updated_date":"2022-01-26T17:19:00Z","reference_number":"EMA/53162/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-except-products-paediatric-indication-list-nationally-authorised-medicinal-products-psusa00001832202104_en.pdf"},
    {"id":"53933","name":"Latanoprost (except for products with paediatric indication) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001832/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-26T17:21:00Z","last_updated_date":"2022-01-26T17:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/latanoprost-except-products-paediatric-indication-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001832202104_no.pdf"}},
    {"id":"53934","name":"Human hemin : List of nationally authorised medicinal products - PSUSA/00001629/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-26T17:25:00Z","last_updated_date":"2022-01-26T17:25:00Z","reference_number":"EMA/53411/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-hemin-list-nationally-authorised-medicinal-products-psusa00001629202105_en.pdf"},
    {"id":"54038","name":"Promestriene (cream and vaginal capsules) : List of nationally authorised medicinal products - PSUSA/00009271/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T12:33:00Z","last_updated_date":"2022-01-31T12:33:00Z","reference_number":"EMA/51911/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/promestriene-cream-and-vaginal-capsules-list-nationally-authorised-medicinal-products-psusa00009271202103_en.pdf"},
    {"id":"54039","name":"Promestriene (cream and vaginal capsules) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009271/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T11:18:00Z","last_updated_date":"2022-01-31T11:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/promestriene-cream-and-vaginal-capsules-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00009271-202103_sv.pdf"}},
    {"id":"54101","name":"Quinapril : List of nationally authorised medicinal products - PSUSA/00002591/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T16:05:00Z","last_updated_date":"2022-02-08T16:05:00Z","reference_number":"EMA/76805/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/quinapril-list-nationally-authorised-medicinal-products-psusa00002591202104_en.pdf"},
    {"id":"54102","name":"Quinapril : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002591/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T16:09:00Z","last_updated_date":"2022-02-15T14:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002591202104_sv.pdf"}},
    {"id":"54105","name":"Hydrochlorothiazide / quinapril : List of nationally authorised medicinal products - PSUSA/00002592/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T16:15:00Z","last_updated_date":"2022-02-08T16:15:00Z","reference_number":"EMA/76996/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-quinapril-list-nationally-authorised-medicinal-products-psusa00002592202104_en.pdf"},
    {"id":"54106","name":"Hydrochlorothiazide / quinapril : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002592/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T16:17:00Z","last_updated_date":"2022-02-08T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydrochlorothiazide-quinapril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002592-202104_sv.pdf"}},
    {"id":"54132","name":"Ibuprofen / pseudoephedrine : List of nationally authorised medicinal products - PSUSA/00001711/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-11T09:22:00Z","last_updated_date":"2022-02-11T09:22:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00001711202107_en.pdf"},
    {"id":"54133","name":"Solifenacin-tamsulosin : List of nationally authorised medicinal products - PSUSA/00010285/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-11T09:27:00Z","last_updated_date":"2022-02-11T09:27:00Z","reference_number":"EMA/64676/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/solifenacin-tamsulosin-list-nationally-authorised-medicinal-products-psusa00010285202107_en.pdf"},
    {"id":"54134","name":"Lidocaine hydrochloride/phenylephrine hydrochloride/tropicamide : List of nationally authorised medicinal products : PSUSA/00010390/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-11T09:31:00Z","last_updated_date":"2022-02-11T09:31:00Z","reference_number":"EMA/64849/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloridephenylephrine-hydrochloridetropicamide-list-nationally-authorised-medicinal-products-psusa00010390202107_en.pdf"},
    {"id":"54136","name":"Cefepime : List of nationally authorised medicinal products - PSUSA/00000593/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-11T09:34:00Z","last_updated_date":"2022-02-11T09:34:00Z","reference_number":"EMA/47273/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefepime-list-nationally-authorised-medicinal-products-psusa00000593202106_en.pdf"},
    {"id":"54146","name":"Daunorubicin : List of nationally authorised medicinal products - PSUSA/00000936/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-11T14:05:00Z","last_updated_date":"2022-02-11T14:05:00Z","reference_number":"EMA/95998/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/daunorubicin-list-nationally-authorised-medicinal-products-psusa00000936202106_en.pdf"},
    {"id":"54155","name":"Fosinopril, fosinopril / hydrochlorothiazide : List of nationally authorised medicinal products - PSUSA/00010463/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-14T16:41:00Z","last_updated_date":"2022-02-14T16:41:00Z","reference_number":"EMA/100375/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosinopril-fosinopril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00010463202107_en.pdf"},
    {"id":"54156","name":"Desogestrel : List of nationally authorised medicinal products - PSUSA/00000966/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-14T17:25:00Z","last_updated_date":"2022-02-14T17:25:00Z","reference_number":"EMA/100780/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/desogestrel-list-nationally-authorised-medicinal-products-psusa00000966202107_en.pdf"},
    {"id":"54175","name":"Bovine lung phospholipid : List of nationally authorised medicinal products - PSUSA/00010791/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-15T12:59:00Z","last_updated_date":"2022-02-15T12:59:00Z","reference_number":"EMA/102264/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/bovine-lung-phospholipid-list-nationally-authorised-medicinal-products-psusa00010791202106_en.pdf"},
    {"id":"54176","name":"Allergen for therapy: betula verrucosa (sublingual tablet) : List of nationally authorised medicinal products - PSUSA/00010815/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-15T13:07:00Z","last_updated_date":"2022-02-15T13:07:00Z","reference_number":"EMA/102642/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-betula-verrucosa-sublingual-tablet-list-nationally-authorised-medicinal-products-psusa00010815202107_en.pdf"},
    {"id":"54186","name":"Dexchlorpheniramine : List of nationally authorised medicinal products - PSUSA/00000989/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-15T17:30:00Z","last_updated_date":"2022-02-15T17:30:00Z","reference_number":"EMA/103358/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexchlorpheniramine-list-nationally-authorised-medicinal-products-psusa00000989202106_en.pdf"},
    {"id":"54187","name":"Tamsulosin : List of nationally authorised medicinal products : PSUSA/00002847/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-15T17:38:00Z","last_updated_date":"2022-02-15T17:38:00Z","reference_number":"EMA/103393/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/tamsulosin-list-nationally-authorised-medicinal-products-psusa00002847202107_en.pdf"},
    {"id":"54194","name":"Nadroparin : List of nationally authorised medicinal products - PSUSA/00002104/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-16T15:31:00Z","last_updated_date":"2022-02-16T15:31:00Z","reference_number":"EMA/711659/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/nadroparin-list-nationally-authorised-medicinal-products-psusa00002104202103_en.pdf"},
    {"id":"54195","name":"Nadroparin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002104/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-16T15:33:00Z","last_updated_date":"2022-02-16T15:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nadroparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002104202103_sv.pdf"}},
    {"id":"54229","name":"Urapidil : List of nationally authorised medicinal products - PSUSA/00003078/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-21T11:45:00Z","last_updated_date":"2022-02-21T11:45:00Z","reference_number":"EMA/111333/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/urapidil-list-nationally-authorised-medicinal-products-psusa00003078202107_en.pdf"},
    {"id":"54230","name":"Acenocoumarol : List of nationally authorised medicinal products - PSUSA/00000027/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-02-21T11:49:00Z","last_updated_date":"2022-02-21T11:49:00Z","reference_number":"EMA/111334/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/acenocoumarol-list-nationally-authorised-medicinal-products-psusa00000027202107_en.pdf"},
    {"id":"54347","name":"Thiocolchicoside, paracetamol / thiocolchicoside : List of nationally authorised medicinal products - PSUSA/00010464/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-03T11:11:00Z","last_updated_date":"2022-03-03T11:11:00Z","reference_number":"EMA/135315/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-list-nationally-authorised-medicinal-products-psusa00010464202107_en.pdf"},
    {"id":"54351","name":"Paracetamol (IV formulation) : List of nationally authorised medicinal products - PSUSA/00002311/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-04T13:55:00Z","last_updated_date":"2022-03-04T13:55:00Z","reference_number":"EMA/138000/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-iv-formulation-list-nationally-authorised-medicinal-products-psusa00002311202105_en.pdf"},
    {"id":"54352","name":"Paracetamol (IV formulation) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002311/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-04T13:57:00Z","last_updated_date":"2022-04-07T13:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/paracetamol-iv-formulation-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002311202105_no.pdf"}},
    {"id":"54388","name":"Remifentanil : List of nationally authorised medicinal products - PSUSA/00002617/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:45:00Z","last_updated_date":"2022-03-08T11:45:00Z","reference_number":"EMA/137844/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/remifentanil-list-nationally-authorised-medicinal-products-psusa00002617202105_en.pdf"},
    {"id":"54389","name":"Remifentanil : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002617/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:47:00Z","last_updated_date":"2022-04-06T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/remifentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002617202105_no.pdf"}},
    {"id":"54410","name":"Everolimus (indicated for rejection of transplanted organs) : List of nationally authorised medicinal products - PSUSA/00010269/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-10T13:59:00Z","last_updated_date":"2022-03-10T13:59:00Z","reference_number":"EMA/114004/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/everolimus-indicated-rejection-transplanted-organs-list-nationally-authorised-medicinal-products-psusa00010269202107_en.pdf"},
    {"id":"54420","name":"Levonorgestrel (all indications except emergency contraception) : List of nationally authorised medicinal products - PSUSA/00010828/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-11T10:51:00Z","last_updated_date":"2022-03-11T10:51:00Z","reference_number":"EMA/152813/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-list-nationally-authorised-medicinal-products-psusa00010828202105_en.pdf"},
    {"id":"54421","name":"Levonorgestrel (all indications except emergency contraception) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010828/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-11T10:54:00Z","last_updated_date":"2022-03-11T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levonorgestrel-all-indications-except-emergency-contraception-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010828202105_no.pdf"}},
    {"id":"54423","name":"Indium (In-111) chloride, indium (In-111) oxine : List of nationally authorised medicinal products - PSUSA/00001734/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-11T12:42:00Z","last_updated_date":"2022-03-11T12:42:00Z","reference_number":"EMA/153648/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/indium-111-chloride-indium-111-oxine-list-nationally-authorised-medicinal-products-psusa00001734202107_en.pdf"},
    {"id":"54431","name":"Lisinopril, lisinopril / hydrochlorothiazide : List of nationally authorised medicinal products - PSUSA/00010532/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-11T16:13:00Z","last_updated_date":"2022-03-11T16:13:00Z","reference_number":"EMA/154395/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisinopril-lisinopril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00010532202009_en.pdf"},
    {"id":"54434","name":"Minoxidil (non-topical formulations) : List of nationally authorised medicinal products - PSUSA/00002066/202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-11T16:57:00Z","last_updated_date":"2022-03-11T16:57:00Z","reference_number":"EMA/PRAC/308836/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/minoxidil-non-topical-formulations-list-nationally-authorised-medicinal-products-psusa00002066202010_en.pdf"},
    {"id":"54435","name":"Loperamide, loperamide / simeticone : List of nationally authorised medicinal products - PSUSA/00010665/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T11:26:00Z","last_updated_date":"2022-03-14T11:26:00Z","reference_number":"EMA/148029/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/loperamide-loperamide-simeticone-list-nationally-authorised-medicinal-products-psusa00010665202105_en.pdf"},
    {"id":"54436","name":"Loperamide, loperamide / simeticone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010665/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T11:28:00Z","last_updated_date":"2022-03-14T11:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/loperamide-loperamide-simeticone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010665202105_no.pdf"}},
    {"id":"54441","name":"Pilocarpine / timolol : List of nationally authorised medicinal products - PSUSA/00002408/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T14:36:00Z","last_updated_date":"2022-03-14T14:36:00Z","reference_number":"EMA/PRAC/155930/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/pilocarpine-timolol-list-nationally-authorised-medicinal-products-psusa00002408202107_en.pdf"},
    {"id":"54442","name":"Tiapride : List of nationally authorised medicinal products - PSUSA/00002944/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T14:39:00Z","last_updated_date":"2022-03-14T14:39:00Z","reference_number":"EMA/PRAC/156359/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiapride-list-nationally-authorised-medicinal-products-psusa00002944202107_en.pdf"},
    {"id":"54443","name":"fluocinolone acetonide (intravitreal implant in applicator) : List of nationally authorised medicinal products - PSUSA/00010224/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T15:31:00Z","last_updated_date":"2022-03-14T15:31:00Z","reference_number":"EMA/PRAC/156633/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-intravitreal-implant-applicator-list-nationally-authorised-medicinal-products-psusa00010224202108_en.pdf"},
    {"id":"54444","name":"magnesium sulphate sodium sulphate potassium sulphate : List of nationally authorised medicinal products - PSUSA 00010239202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T15:35:00Z","last_updated_date":"2022-03-14T15:35:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulphate-sodium-sulphate-potassium-sulphate-list-nationally-authorised-medicinal-products-psusa-00010239202108_en.pdf"},
    {"id":"54445","name":"Timolol (eye preparations) : List of nationally authorised medicinal products - PSUSA/00010439/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T15:39:00Z","last_updated_date":"2022-03-14T15:39:00Z","reference_number":"EMA/PRAC/156696/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/timolol-eye-preparations-list-nationally-authorised-medicinal-products-psusa00010439202107_en.pdf"},
    {"id":"54446","name":"Montelukast : List of nationally authorised medicinal products - PSUSA/00002087/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T15:45:00Z","last_updated_date":"2022-03-14T15:45:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/montelukast-list-nationally-authorised-medicinal-products-psusa00002087202107_en.pdf"},
    {"id":"54450","name":"Pholcodine : List of nationally authorised medicinal products - PSUSA/00002396/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T17:19:00Z","last_updated_date":"2022-03-14T17:19:00Z","reference_number":"EMA/156842/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/pholcodine-list-nationally-authorised-medicinal-products-psusa00002396202105_en.pdf"},
    {"id":"54451","name":"Pholcodine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002396/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T17:21:00Z","last_updated_date":"2022-03-14T17:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/pholcodine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002396202105_sv.pdf"}},
    {"id":"54452","name":"Lactulose : List of nationally authorised medicinal products - PSUSA/00001821/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T17:27:00Z","last_updated_date":"2022-03-14T17:27:00Z","reference_number":"EMA/156898/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/lactulose-list-nationally-authorised-medicinal-products-psusa00001821202105_en.pdf"},
    {"id":"54454","name":"Lactulose : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001821/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T17:29:00Z","last_updated_date":"2022-03-14T17:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lactulose-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001821202105_no.pdf"}},
    {"id":"54458","name":"Alendronate : List of nationally authorised medicinal products - PSUSA/00000078/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-15T08:49:00Z","last_updated_date":"2022-03-15T08:49:00Z","reference_number":"EMA/PRAC/468922/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/alendronate-list-nationally-authorised-medicinal-products-psusa00000078202101_en.pdf"},
    {"id":"54459","name":"Ethinylestradiol / gestodene : List of nationally authorised medicinal products - PSUSA/00001308/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-15T08:51:00Z","last_updated_date":"2022-03-15T08:51:00Z","reference_number":"EMA/PRAC/604922/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-gestodene-list-nationally-authorised-medicinal-products-psusa00001308202103_en.pdf"},
    {"id":"54469","name":"Tianeptine : List of nationally authorised medicinal products - PSUSA/00002943/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-15T16:01:00Z","last_updated_date":"2022-03-15T16:01:00Z","reference_number":"EMA/PRAC/159531/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/tianeptine-list-nationally-authorised-medicinal-products-psusa00002943202106_en.pdf"},
    {"id":"54470","name":"Nitrendipine : List of nationally authorised medicinal products - PSUSA/00002171/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T09:11:00Z","last_updated_date":"2022-03-16T09:11:00Z","reference_number":"EMA/PRAC/703038/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrendipine-list-nationally-authorised-medicinal-products-psusa00002171202103_en.pdf"},
    {"id":"54471","name":"Pamidronate : List of nationally authorised medicinal products - PSUSA/00002269/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T09:14:00Z","last_updated_date":"2022-03-16T09:14:00Z","reference_number":"EMA/PRAC/14996/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/pamidronate-list-nationally-authorised-medicinal-products-psusa00002269202105_en.pdf"},
    {"id":"54472","name":"Calcitonin salmon, synthetic analogue of eel calcitonin : List of nationally authorised medicinal products - PSUSA/00000494/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T09:17:00Z","last_updated_date":"2022-03-16T09:17:00Z","reference_number":"EMA/PRAC/75101/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcitonin-salmon-synthetic-analogue-eel-calcitonin-list-nationally-authorised-medicinal-products-psusa00000494202106_en.pdf"},
    {"id":"54473","name":"Propranolol (except for centrally authorised product) : List of nationally authorised medicinal products - PSUSA/00010251/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T09:20:00Z","last_updated_date":"2022-03-16T09:20:00Z","reference_number":"EMA/PRAC/75089/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/propranolol-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00010251202106_en.pdf"},
    {"id":"54474","name":"Misoprostol (gynaecological indication - labour induction) : List of nationally authorised medicinal products - PSUSA/00010353/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T09:24:00Z","last_updated_date":"2022-03-16T09:24:00Z","reference_number":"EMA/PRAC/15035/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labour-induction-list-nationally-authorised-medicinal-products-psusa00010353202105_en.pdf"},
    {"id":"54475","name":"Alprostadil (erectile dysfunction) : List of nationally authorised medicinal products - PSUSA/00000110/202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T09:27:00Z","last_updated_date":"2022-03-16T09:27:00Z","reference_number":"EMA/PRAC/538498/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprostadil-erectile-dysfunction-list-nationally-authorised-medicinal-products-psusa00000110202101_en.pdf"},
    {"id":"54476","name":"Alprostadil (patency of the ductus arteriosus) : List of nationally authorised medicinal products - PSUSA/00010021/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T09:29:00Z","last_updated_date":"2022-03-16T09:29:00Z","reference_number":"EMA/PRAC/142881/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprostadil-patency-ductus-arteriosus-list-nationally-authorised-medicinal-products-psusa00010021202107_en.pdf"},
    {"id":"54477","name":"Glibenclamide / metformin hydrochloride : List of nationally authorised medicinal products - PSUSA/00002002/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T09:32:00Z","last_updated_date":"2022-03-16T09:32:00Z","reference_number":"EMA/PRAC/55413/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/glibenclamide-metformin-hydrochloride-list-nationally-authorised-medicinal-products-psusa00002002202106_en.pdf"},
    {"id":"54479","name":"Budesonide / salmeterol : List of nationally authorised medicinal products - PSUSA/00010511/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T11:39:00Z","last_updated_date":"2022-03-16T11:39:00Z","reference_number":"EMA/164850/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/budesonide-salmeterol-list-nationally-authorised-medicinal-products-psusa00010511202107_en.pdf"},
    {"id":"54486","name":"Fluticasone propionate / formoterol fumarate dihydrate : List of nationally authorised medicinal products - PSUSA/00010339/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T14:32:00Z","last_updated_date":"2022-03-16T14:32:00Z","reference_number":"EMA/164942/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluticasone-propionate-formoterol-fumarate-dihydrate-list-nationally-authorised-medicinal-products-psusa00010339202107_en.pdf"},
    {"id":"54488","name":"Calcifediol : List of nationally authorised medicinal products - PSUSA/00000491/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T16:21:00Z","last_updated_date":"2022-03-16T16:21:00Z","reference_number":"EMA/PRAC/77562/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcifediol-list-nationally-authorised-medicinal-products-psusa00000491202106_en.pdf"},
    {"id":"54492","name":"Lovastatin : List of nationally authorised medicinal products - PSUSA/00010051/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T17:12:00Z","last_updated_date":"2022-03-16T17:12:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/lovastatin-list-nationally-authorised-medicinal-products-psusa00010051202107_en.pdf"},
    {"id":"54597","name":"Cefuroxime sodium (for intracameral use) : List of nationally authorised medicinal products - PSUSA/00010206/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-28T09:20:00Z","last_updated_date":"2022-03-28T09:20:00Z","reference_number":"EMA/187173/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-sodium-intracameral-use-list-nationally-authorised-medicinal-products-psusa00010206202105_en.pdf"},
    {"id":"54634","name":"Nimesulide (systemic formulations) : List of nationally authorised medicinal products - PSUSA/00009236/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-31T11:22:00Z","last_updated_date":"2022-03-31T11:22:00Z","reference_number":"EMA/194907/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimesulide-systemic-formulations-list-nationally-authorised-medicinal-products-psusa00009236202106_en.pdf"},
    {"id":"54635","name":"Nimesulide (systemic formulations) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009236/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-31T11:24:00Z","last_updated_date":"2022-03-31T11:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nimesulide-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009236202106_sv.pdf"}},
    {"id":"54637","name":"Goserelin : List of nationally authorised medicinal products - PSUSA/00001562/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-31T11:55:00Z","last_updated_date":"2022-03-31T11:55:00Z","reference_number":"EMA/195107/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/goserelin-list-nationally-authorised-medicinal-products-psusa00001562202105_en.pdf"},
    {"id":"54638","name":"Rabbit anti-human T-lymphocyte immunoglobulin : List of nationally authorised medicinal products - PSUSA/00010252/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-03-31T15:05:00Z","last_updated_date":"2022-03-31T15:05:00Z","reference_number":"EMA/195695/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-human-t-lymphocyte-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00010252202106_en.pdf"},
    {"id":"54688","name":"Tiagabine : List of nationally authorised medicinal products - PSUSA/00002942/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-06T16:05:00Z","last_updated_date":"2022-04-06T16:05:00Z","reference_number":"EMA/206866/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiagabine-list-nationally-authorised-medicinal-products-psusa00002942202106_en.pdf"},
    {"id":"54689","name":"Tiagabine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002942/202106","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-06T16:07:00Z","last_updated_date":"2022-04-06T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tiagabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002942202106_sv.pdf"}},
    {"id":"54694","name":"Finasteride : List of nationally authorised medicinal products - PSUSA/00001392/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-07T16:52:00Z","last_updated_date":"2022-04-07T16:52:00Z","reference_number":"EMA/208932/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa00001392202108_en.pdf"},
    {"id":"54695","name":"Allergen for therapy: Dermatophagoides pteronyssinus / Dermatophagoides farina (oromucosal use, products authorised via mutually recognition procedure and decentralised procedure) : List of nationally authorised medicinal products - PSUSA/00010582/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-07T16:58:00Z","last_updated_date":"2022-04-07T16:58:00Z","reference_number":"EMA/210096/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-dermatophagoides-pteronyssinus-dermatophagoides-farina-oromucosal-use-products-authorised-mutually-recognition-procedure-and-decentralised-procedure-list-nationally-authorised_en.pdf"},
    {"id":"54697","name":"Ciclesonide : List of nationally authorised medicinal products : PSUSA/00000742/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-08T09:37:00Z","last_updated_date":"2022-04-08T09:37:00Z","reference_number":"EMA/205788/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciclesonide-list-nationally-authorised-medicinal-products-psusa00000742202108_en.pdf"},
    {"id":"54701","name":"Buserelin : List of nationally authorised medicinal products - PSUSA/00000462/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-08T11:23:00Z","last_updated_date":"2022-04-08T11:23:00Z","reference_number":"EMA/210741/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/buserelin-list-nationally-authorised-medicinal-products-psusa00000462202108_en.pdf"},
    {"id":"54705","name":"Gadoteridol : List of nationally authorised medicinal products - PSUSA/00001507/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-08T15:15:00Z","last_updated_date":"2022-04-08T15:15:00Z","reference_number":"EMA/213423/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteridol-list-nationally-authorised-medicinal-products-psusa00001507202108_en.pdf"},
    {"id":"54713","name":"Rilmenidine : List of nationally authorised medicinal products - PSUSA/00002643/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T09:22:00Z","last_updated_date":"2022-04-11T09:22:00Z","reference_number":"EMA/PRAC/155543/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/rilmenidine-list-nationally-authorised-medicinal-products-psusa00002643202108_en.pdf"},
    {"id":"54720","name":"Aniracetam : List of nationally authorised medicinal products : PSUSA/00010790/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T12:57:00Z","last_updated_date":"2022-04-11T12:57:00Z","reference_number":"EMA/PRAC/215190/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/aniracetam-list-nationally-authorised-medicinal-products-psusa00010790202108_en.pdf"},
    {"id":"54729","name":"Gadopentetic acid : List of nationally authorised medicinal products - PSUSA/00001504/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T17:32:00Z","last_updated_date":"2022-04-11T17:32:00Z","reference_number":"EMA/215695/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadopentetic-acid-list-nationally-authorised-medicinal-products-psusa00001504202108_en.pdf"},
    {"id":"54733","name":"Benazepril / hydrochlorothiazide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation  - PSUSA/00000314/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-12T14:54:00Z","last_updated_date":"2022-04-12T14:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_es.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/benazepril-hydrochlorothiazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000314202105_sv.pdf"}},
    {"id":"54734","name":"Benazepril / hydrochlorothiazide : List of nationally authorised medicinal products for variation - PSUSA/00000314/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-12T15:00:00Z","last_updated_date":"2022-04-12T15:00:00Z","reference_number":"PSUSA/00000314/202105","document_url":"https://www.ema.europa.eu/en/documents/psusa/benazepril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-variation-psusa00000314202105_en.pdf"},
    {"id":"54760","name":"Penciclovir : List of nationally authorised medicinal products - PSUSA/00002333/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-20T09:17:00Z","last_updated_date":"2022-04-20T09:17:00Z","reference_number":"EMA/75489/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/penciclovir-list-nationally-authorised-medicinal-products-psusa00002333202108_en.pdf"},
    {"id":"54761","name":"Tuberculin purified protein derivative : List of nationally authorised medicinal products - PSUSA/00003063/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-20T09:21:00Z","last_updated_date":"2022-04-20T09:21:00Z","reference_number":"EMA/75501/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/tuberculin-purified-protein-derivative-list-nationally-authorised-medicinal-products-psusa00003063202109_en.pdf"},
    {"id":"54783","name":"Cetirizine pseudoephedrine : List of nationally authorised medicinal products - PSUSA/00000629/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-21T14:11:00Z","last_updated_date":"2022-04-21T14:11:00Z","reference_number":"EMA/228799/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cetirizine-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00000629202108_en.pdf"},
    {"id":"54825","name":"Gadobenic acid : List of nationally authorised medicinal products - PSUSA/00001500/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-26T12:27:00Z","last_updated_date":"2022-04-26T12:27:00Z","reference_number":"EMA/236421/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobenic-acid-list-nationally-authorised-medicinal-products-psusa00001500202108_en.pdf"},
    {"id":"54836","name":"Gadobutrol : List of nationally authorised medicinal products - PSUSA/00001502/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-26T17:03:00Z","last_updated_date":"2022-04-26T17:03:00Z","reference_number":"EMA/237119/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobutrol-list-nationally-authorised-medicinal-products-psusa00001502202108_en.pdf"},
    {"id":"54838","name":"Human plasma protease C1 inhibitor : List of nationally authorised medicinal products - PSUSA/00010163/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-04-26T17:36:00Z","last_updated_date":"2022-04-26T17:36:00Z","reference_number":"EMA/237337/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-plasma-protease-c1-inhibitor-list-nationally-authorised-medicinal-products-psusa00010163202108_en.pdf"},
    {"id":"54920","name":"Opium : List of nationally authorised medicinal products - PSUSA/00010670/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-10T08:05:00Z","last_updated_date":"2022-05-10T08:05:00Z","reference_number":"EMA/254662/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/opium-list-nationally-authorised-medicinal-products-psusa00010670202109_en.pdf"},
    {"id":"54938","name":"Gadoteric acid (IV and intravascular formulations) : List of nationally authorised medicinal products - PSUSA/00001506/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-11T13:36:00Z","last_updated_date":"2022-05-11T13:36:00Z","reference_number":"EMA/262849/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteric-acid-iv-and-intravascular-formulations-list-nationally-authorised-medicinal-products-psusa00001506202108_en.pdf"},
    {"id":"54939","name":"Leuprorelin (depot formulations) : List of nationally authorised medicinal products - PSUSA/00010877/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-11T13:42:00Z","last_updated_date":"2022-05-11T13:42:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/leuprorelin-depot-formulations-list-nationally-authorised-medicinal-products-psusa00010877202107_en.pdf"},
    {"id":"54940","name":"Leuprorelin (depot formulations) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010877/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-11T13:45:00Z","last_updated_date":"2022-05-11T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/leuprorelin-depot-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010877202107_no.pdf"}},
    {"id":"54953","name":"Tolterodine : List of nationally authorised medicinal products - PSUSA 00002993 202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-12T15:48:00Z","last_updated_date":"2022-05-12T15:48:00Z","reference_number":"EMA/267394/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/tolterodine-list-nationally-authorised-medicinal-products-psusa-00002993-202109_en.pdf"},
    {"id":"54965","name":"Amlodipine / rosuvastatin, perindopril / amlodipine / rosuvastatin : List of nationally authorised medicinal products - PSUSA/00010434/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-16T14:30:00Z","last_updated_date":"2022-05-16T14:30:00Z","reference_number":"EMA/273963/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-list-nationally-authorised-medicinal-products-psusa00010434202107_en.pdf"},
    {"id":"54966","name":"Amlodipine / rosuvastatin, perindopril / amlodipine / rosuvastatin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -  PSUSA/00010434/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-16T14:35:00Z","last_updated_date":"2022-05-16T14:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_sv.pdf"}},
    {"id":"55055","name":"Allergen for therapy: Ambrosia Artemisiifolia (302) (sublingual use, products authorised via decentralised procedure) : List of nationally authorised medicinal products - PSUSA/00010693/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T17:28:00Z","last_updated_date":"2022-05-20T17:28:00Z","reference_number":"EMA/254322/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-list-nationally-authorised-medicinal-products-psusa00010693202110_en.pdf"}    {"id":"55110","name":"Dexketoprofen and tramadol : List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0035","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-30T16:49:00Z","last_updated_date":"2022-05-30T16:49:00Z","reference_number":"EMA/559241/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-and-tramadol-list-nationally-authorised-medicinal-products-emeahnpsrs0035_en.pdf"},
    {"id":"55111","name":"Dexketoprofen and tramadol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/S/0035","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-30T16:52:00Z","last_updated_date":"2022-05-30T16:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexketoprofen-and-tramadol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emeahnpsrs0035_sv.pdf"}},
    {"id":"55116","name":"Modafinil : List of nationally authorised medicinal products - PSUSA/00010242/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-31T12:02:00Z","last_updated_date":"2022-05-31T12:02:00Z","reference_number":"EMA/561024/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/modafinil-list-nationally-authorised-medicinal-products-psusa00010242202108_en.pdf"},
    {"id":"55117","name":"Modafinil : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010242/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-31T12:05:00Z","last_updated_date":"2022-05-31T12:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/modafinil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010242202108_no.pdf"}},
    {"id":"55118","name":"Dexamfetamine : List of nationally authorised medicinal products - PSUSA/00000986/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-31T16:12:00Z","last_updated_date":"2022-05-31T16:12:00Z","reference_number":"EMA/560257/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-psusa00000986202109_en.pdf"},
    {"id":"55119","name":"Dexamfetamine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000986/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-05-31T13:27:00Z","last_updated_date":"2022-05-31T13:27:00Z","reference_number":"PSUSA/00000986/202109","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dexamfetamine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000986202109_no.pdf"}},
    {"id":"55121","name":"Oxcarbazepine : List of nationally authorised medicinal products - PSUSA/00002235/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-02T12:26:00Z","last_updated_date":"2022-06-02T12:26:00Z","reference_number":"EMA/566174/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxcarbazepine-list-nationally-authorised-medicinal-products-psusa00002235202108_en.pdf"},
    {"id":"55122","name":"Oxcarbazepin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002235/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-02T12:28:00Z","last_updated_date":"2022-06-02T12:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oxcarbazepin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002235202108_no.pdf"}},
    {"id":"55136","name":"Etonogestrel : List of nationally authorised medicinal products - PSUSA/00001331/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-07T11:27:00Z","last_updated_date":"2022-06-07T11:27:00Z","reference_number":"EMA/569364/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/etonogestrel-list-nationally-authorised-medicinal-products-psusa00001331202109_en.pdf"},
    {"id":"55137","name":"Etonogestrel : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001331/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-07T11:30:00Z","last_updated_date":"2022-06-07T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/etonogestrel-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001331202109_no.pdf"}},
    {"id":"55147","name":"Nifuroxazide : List of nationally authorised medicinal products - PSUSA/00002160/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-08T11:04:00Z","last_updated_date":"2022-06-08T11:04:00Z","reference_number":"EMA/738449/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/nifuroxazide-list-nationally-authorised-medicinal-products-psusa00002160202108_en.pdf"},
    {"id":"55148","name":"Nifuroxazide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002160/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-08T11:07:00Z","last_updated_date":"2022-06-08T11:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nifuroxazide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002160202108_sv.pdf"}},
    {"id":"55172","name":"Estradiol (except cream/balm/emulsion for application in female genital area) : List of nationally authorised medicinal products - PSUSA/00010440/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-09T17:15:00Z","last_updated_date":"2022-06-09T17:15:00Z","reference_number":"EMA/579444/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-list-nationally-authorised-medicinal-products-psusa00010440202108_en.pdf"},
    {"id":"55173","name":"Estradiol (except cream/balm/emulsion for application in female genital area) : CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010440/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-09T17:15:00Z","last_updated_date":"2022-06-09T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/estradiol-except-creambalmemulsion-application-female-genital-area-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010440202108_no.pdf"}},
    {"id":"55195","name":"13C-methacetin : List of nationally authorised medicinal products - PSUSA/00010846/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T09:21:00Z","last_updated_date":"2022-06-13T09:21:00Z","reference_number":"EMA/579312/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/13c-methacetin-list-nationally-authorised-medicinal-products-psusa00010846202110_en.pdf"},
    {"id":"55201","name":"Magnesium hydroxide : List of nationally authorised medicinal products - PSUSA/00001926/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:11:00Z","last_updated_date":"2022-06-13T11:11:00Z","reference_number":"EMA/584575/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-hydroxide-list-nationally-authorised-medicinal-products-psusa00001926202110_en.pdf"},
    {"id":"55202","name":"Polystyrene sulfonate : List of nationally authorised medicinal products - PSUSA/00002472/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:15:00Z","last_updated_date":"2022-06-13T11:15:00Z","reference_number":"EMA/584606/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/polystyrene-sulfonate-list-nationally-authorised-medicinal-products-psusa00002472202110_en.pdf"},
    {"id":"55215","name":"Acitretin : List of nationally authorised medicinal products - PSUSA/00000051/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T12:26:00Z","last_updated_date":"2022-06-13T12:26:00Z","reference_number":"EMA/584914/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-list-nationally-authorised-medicinal-products-psusa00000051202110_en.pdf"},
    {"id":"55216","name":"Tiotropium : List of nationally authorised medicinal products - PSUSA/00002972/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T12:51:00Z","last_updated_date":"2022-06-13T12:51:00Z","reference_number":"EMA/581555/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiotropium-list-nationally-authorised-medicinal-products-psusa00002972202110_en.pdf"},
    {"id":"55217","name":"Azelastine / fluticasone : List of nationally authorised medicinal products - PSUSA/00010067/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T12:56:00Z","last_updated_date":"2022-06-13T12:56:00Z","reference_number":"EMA/579324/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/azelastine-fluticasone-list-nationally-authorised-medicinal-products-psusa00010067202110_en.pdf"},
    {"id":"55218","name":"Phloroglucinol, phloroglucinol/trimethylphloroglucinol : List of nationally authorised medicinal products - PSUSA/00010355/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T13:00:00Z","last_updated_date":"2022-06-13T13:00:00Z","reference_number":"EMA/579234/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/phloroglucinol-phloroglucinoltrimethylphloroglucinol-list-nationally-authorised-medicinal-products-psusa00010355202109_en.pdf"},
    {"id":"55219","name":"Dextromethorphan : List of nationally authorised medicinal products - PSUSA/00001009/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T13:12:00Z","last_updated_date":"2022-06-13T13:12:00Z","reference_number":"EMA/585273/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/dextromethorphan-list-nationally-authorised-medicinal-products-psusa00001009202111_en.pdf"},
    {"id":"55222","name":"Erythromycin / tretinoin : List of nationally authorised medicinal products - PSUSA/00001259/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T15:25:00Z","last_updated_date":"2022-06-13T15:25:00Z","reference_number":"EMA/585845/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/erythromycin-tretinoin-list-nationally-authorised-medicinal-products-psusa00001259202110_en.pdf"},
    {"id":"55223","name":"Drospirenone : List of nationally authorised medicinal products - PSUSA/00010853/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T15:51:00Z","last_updated_date":"2022-06-13T15:51:00Z","reference_number":"EMA/585891/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/drospirenone-list-nationally-authorised-medicinal-products-psusa00010853202111_en.pdf"},
    {"id":"55226","name":"Olmesartan : List of nationally authorised medicinal products - PSUSA/00002207/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T16:39:00Z","last_updated_date":"2022-06-13T16:39:00Z","reference_number":"EMA/586078/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/olmesartan-list-nationally-authorised-medicinal-products-psusa00002207202110_en.pdf"},
    {"id":"55227","name":"Ethinylestradiol / norgestimate : List of nationally authorised medicinal products - PSUSA/00001313/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T16:43:00Z","last_updated_date":"2022-06-13T16:43:00Z","reference_number":"EMA/PRAC/586129/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-norgestimate-list-nationally-authorised-medicinal-products-psusa00001313202110_en.pdf"},
    {"id":"55228","name":"Acetylsalicylic acid / bisoprolol : List of nationally authorised medicinal products - PSUSA/00010287/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T16:46:00Z","last_updated_date":"2022-06-13T16:46:00Z","reference_number":"PSUSA/00010287/202111","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-bisoprolol-list-nationally-authorised-medicinal-products-psusa00010287202111_en.pdf"},
    {"id":"55230","name":"Rubidium chloride RB-82 : List of nationally authorised medicinal products - PSUSA/00010806/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-14T11:36:00Z","last_updated_date":"2022-06-14T11:36:00Z","reference_number":"EMA/587449/20222","document_url":"https://www.ema.europa.eu/en/documents/psusa/rubidium-chloride-rb-82-list-nationally-authorised-medicinal-products-psusa00010806202110_en.pdf"},
    {"id":"55240","name":"Letrozole : List of nationally authorised medicinal products - PSUSA/00001842/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-14T17:12:00Z","last_updated_date":"2022-06-14T17:12:00Z","reference_number":"EMA/589094/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/letrozole-list-nationally-authorised-medicinal-products-psusa00001842202110_en.pdf"},
    {"id":"55250","name":"Lacidipine : List of nationally authorised medicinal products - PSUSA/00001815/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-15T15:57:00Z","last_updated_date":"2022-06-15T15:57:00Z","reference_number":"EMA/PRAC/591665/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/lacidipine-list-nationally-authorised-medicinal-products-psusa00001815202110_en.pdf"},
    {"id":"55251","name":"Clevidipine : List of nationally authorised medicinal products - PSUSA/00010288/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-15T16:01:00Z","last_updated_date":"2022-06-15T16:01:00Z","reference_number":"EMA/PRAC/591770/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288202111_en.pdf"},
    {"id":"55253","name":"Brimonidine/timolol : List of nationally authorised medicinal products -  PSUSA/00000431/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-16T09:13:00Z","last_updated_date":"2022-06-16T09:13:00Z","reference_number":"EMA/591702/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/brimonidinetimolol-list-nationally-authorised-medicinal-products-psusa00000431202109_en.pdf"},
    {"id":"55259","name":"Diclofenac / omeprazole : List of nationally authorised medicinal products - PSUSA/00010461/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-16T13:44:00Z","last_updated_date":"2022-06-16T13:44:00Z","reference_number":"EMA/593786/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-omeprazole-list-nationally-authorised-medicinal-products-psusa00010461202109_en.pdf"},
    {"id":"55264","name":"Amlodipine / perindopril : List of nationally authorised medicinal products -  PSUSA/00000179/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-16T15:39:00Z","last_updated_date":"2022-06-16T15:39:00Z","reference_number":"EMA/PRAC/594248/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-perindopril-list-nationally-authorised-medicinal-products-psusa00000179202110_en.pdf"},
    {"id":"55265","name":"Hydrochlorothiazide / olmesartan : List of nationally authorised medicinal products - PSUSA/00002209/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-16T15:43:00Z","last_updated_date":"2022-06-16T15:43:00Z","reference_number":"EMA/PRAC/594307/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-olmesartan-list-nationally-authorised-medicinal-products-psusa00002209202110_en.pdf"},
    {"id":"55266","name":"Brimonidine (except for the centrally authorised product) : List of nationally authorised medicinal products - PSUSA/00000430/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-16T16:26:00Z","last_updated_date":"2022-06-16T16:26:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/brimonidine-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00000430202109_en.pdf"},
    {"id":"55299","name":"Amlodipine / rosuvastatin, perindopril / amlodipine / rosuvastatin : List of nationally authorised medicinal products -  PSUSA/00010434/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-20T11:52:00Z","last_updated_date":"2022-06-20T11:52:00Z","reference_number":"EMA/598317/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-list-nationally-authorised-medicinal-products-psusa00010434202107_en.pdf-0"},
    {"id":"55300","name":"Amlodipine / rosuvastatin, perindopril / amlodipine / rosuvastatin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -  PSUSA/00010434/202107","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-20T11:56:00Z","last_updated_date":"2022-06-20T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/psusa/amlodipine-rosuvastatin-perindopril-amlodipine-rosuvastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010434202107_sv.pdf-0"}},
    {"id":"55313","name":"Benzydamine: List of nationally authorised medicinal products - PSUSA/00000375/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-21T15:19:00Z","last_updated_date":"2022-06-21T15:19:00Z","reference_number":"EMA/591676/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzydamine-list-nationally-authorised-medicinal-products-psusa00000375202110_en.pdf"},
    {"id":"55315","name":"Milrinone : List of nationally authorised medicinal products - PSUSA/00002064/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-21T16:41:00Z","last_updated_date":"2022-06-21T16:41:00Z","reference_number":"EMA/596955/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/milrinone-list-nationally-authorised-medicinal-products-psusa00002064202110_en.pdf"},
    {"id":"55316","name":"Piretanide : List of nationally authorised medicinal products - PSUSA/00002433/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-21T16:48:00Z","last_updated_date":"2022-06-21T16:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/piretanide-list-nationally-authorised-medicinal-products-psusa00002433202110_en.pdf"},
    {"id":"55317","name":"Alfentanil : List of nationally authorised medicinal products - PSUSA/00000082/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-22T10:12:00Z","last_updated_date":"2022-06-22T10:12:00Z","reference_number":"EMA/PRAC/596144/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/alfentanil-list-nationally-authorised-medicinal-products-psusa00000082202109_en.pdf"},
    {"id":"55318","name":"Alfentanil : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000082/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-22T10:18:00Z","last_updated_date":"2022-06-22T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/alfentanil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000082202109_no.pdf"}},
    {"id":"55376","name":"Hydroxyethyl starch : List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0031","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:30:00Z","last_updated_date":"2022-06-24T15:30:00Z","reference_number":"EMA/605749/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-list-nationally-authorised-medicinal-products-emeahnpsrj0031_en.pdf"},
    {"id":"55378","name":"Hydroxyethyl starch : CMDh Scientific conclusions and Conditions for lifting the suspension of the marketing authorisations - EMEA/H/N/PSR/J/0031","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:34:00Z","last_updated_date":"2022-06-24T15:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-cmdh-scientific-conclusions-and-conditions-lifting-suspension-marketing-authorisations-emeahnpsrj0031_en.pdf"},
    {"id":"55379","name":"Hydroxyethyl starch : CMDh Divergent position - EMEA/H/N/PSR/J/0031","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:38:00Z","last_updated_date":"2022-06-24T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-cmdh-divergent-position-emeahnpsrj0031_en.pdf"},
    {"id":"55380","name":"Hydroxyethyl starch : PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0031","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T15:40:00Z","last_updated_date":"2022-06-24T15:40:00Z","reference_number":"EMA/596511/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-prac-non-interventional-imposed-pass-final-study-report-assessment-report-emeahnpsrj0031_en.pdf"},
    {"id":"55453","name":"Benzalkonium chloride / chlorhexidine digluconate : List of nationally authorised medicinal products - PSUSA/00010070/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-05T10:12:00Z","last_updated_date":"2022-07-05T10:12:00Z","reference_number":"EMA/95628/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzalkonium-chloride-chlorhexidine-digluconate-list-nationally-authorised-medicinal-products-psusa00010070202111_en.pdf"},
    {"id":"55454","name":"Isopropyl alcohol / propyl alcohol / mecetronium ethyl sulfate : List of nationally authorised medicinal products - PSUSA/00010108/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-05T10:18:00Z","last_updated_date":"2022-07-05T10:18:00Z","reference_number":"EMA/95623/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/isopropyl-alcohol-propyl-alcohol-mecetronium-ethyl-sulfate-list-nationally-authorised-medicinal-products-psusa00010108202109_en.pdf"},
    {"id":"55456","name":"Zidovudine - List of nationally authorised medicinal products - PSUSA/00003143/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-05T10:43:00Z","last_updated_date":"2022-07-05T10:43:00Z","reference_number":"EMA/95633/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/zidovudine-list-nationally-authorised-medicinal-products-psusa00003143202109_en.pdf"},
    {"id":"55498","name":"Metoclopramide : List of nationally authorised medicinal products - PSUSA/00002036/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-08T09:21:00Z","last_updated_date":"2022-07-08T09:21:00Z","reference_number":"EMA/PRAC/633711/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/metoclopramide-list-nationally-authorised-medicinal-products-psusa00002036202111_en.pdf"},
    {"id":"55520","name":"Gadoxetic acid disodium : List of nationally authorised medicinal products - PSUSA/00001509/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-12T14:58:00Z","last_updated_date":"2022-07-12T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoxetic-acid-disodium-list-nationally-authorised-medicinal-products-psusa00001509202108_en.pdf"},
    {"id":"55525","name":"Carmustine (implant) : List of nationally authorised medicinal products - PSUSA/00010348/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-12T15:58:00Z","last_updated_date":"2022-07-12T15:58:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/carmustine-implant-list-nationally-authorised-medicinal-products-psusa00010348202109_en.pdf"},
    {"id":"55526","name":"Asparaginase, crisantaspase (nationally authorised products) : List of nationally authorised medicinal products - PSUSA/00003161/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-12T17:34:00Z","last_updated_date":"2022-07-12T17:34:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/asparaginase-crisantaspase-nationally-authorised-products-list-nationally-authorised-medicinal-products-psusa00003161202108_en.pdf"},
    {"id":"55527","name":"Bisoprolol / hydrochlorothiazide : List of nationally authorised medicinal products - PSUSA/00000420/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-12T17:54:00Z","last_updated_date":"2022-07-13T14:46:00Z","reference_number":"EMA/640852/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/bisoprolol-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00000420202111_en.pdf"},
    {"id":"55528","name":"Ciprofibrate : List of nationally authorised medicinal products - PSUSA/00000771/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-13T08:33:00Z","last_updated_date":"2022-07-13T08:33:00Z","reference_number":"EMA/PRAC/640942/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofibrate-list-nationally-authorised-medicinal-products-psusa00000771202112_en.pdf"},
    {"id":"55531","name":"Sodium oxybate (intravenous use) : List of nationally authorised medicinal products - PSUSA/0010613/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-13T12:08:00Z","last_updated_date":"2022-07-13T12:08:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-oxybate-intravenous-use-list-nationally-authorised-medicinal-products-psusa0010613202110_en.pdf"},
    {"id":"55532","name":"Caffeine / ergotamine : List of nationally authorised medicinal products - PSUSA/00000485/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-13T15:51:00Z","last_updated_date":"2022-07-13T15:51:00Z","reference_number":"EMA/642802/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/caffeine-ergotamine-list-nationally-authorised-medicinal-products-psusa00000485202111_en.pdf"},
    {"id":"55533","name":"indapamide / perindopril : List of nationally authorised medicinal products - PSUSA/00010230/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-13T16:38:00Z","last_updated_date":"2022-07-13T16:38:00Z","reference_number":"EMA/643011/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/indapamide-perindopril-list-nationally-authorised-medicinal-products-psusa00010230202111_en.pdf"},
    {"id":"55543","name":"Ketamine : List of nationally authorised medicinal products - PSUSA/00001804/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T14:19:00Z","last_updated_date":"2022-07-14T14:19:00Z","reference_number":"EMA/644666/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketamine-list-nationally-authorised-medicinal-products-psusa00001804202112_en.pdf"},
    {"id":"55739","name":"Soybean phospholipids (oral use) : List of nationally authorised medicinal products - PSUSA/00010707/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-01T10:25:00Z","last_updated_date":"2022-08-01T10:25:00Z","reference_number":"EMA/665634/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/soybean-phospholipids-oral-use-list-nationally-authorised-medicinal-products-psusa00010707202110_en.pdf"},
    {"id":"55741","name":"Soybean phospholipids (oral use) : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00010707/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-01T10:30:00Z","last_updated_date":"2022-08-01T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/soybean-phospholipids-oral-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010707202110_sv.pdf"}},
    {"id":"55746","name":"Rabeprazole : List of nationally authorised medicinal products - PSUSA/00002601/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-01T14:09:00Z","last_updated_date":"2022-08-01T14:09:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabeprazole-list-nationally-authorised-medicinal-products-psusa00002601202110_en.pdf"},
    {"id":"55747","name":"Rabeprazole : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00002601/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-01T14:16:00Z","last_updated_date":"2022-08-01T14:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/rabeprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002601202110_no.pdf"}},
    {"id":"55748","name":"Dexketoprofen : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) -  PSUSA/00000997/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-01T15:07:00Z","last_updated_date":"2022-08-01T15:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexketoprofen-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000997202110_sv.pdf"}},
    {"id":"55781","name":"teicoplanin : List of nationally authorised medicinal products - PSUSA/00002878/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-05T10:44:00Z","last_updated_date":"2022-08-05T10:44:00Z","reference_number":"EMA/75555/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/teicoplanin-list-nationally-authorised-medicinal-products-psusa00002878202111_en.pdf"},
    {"id":"55782","name":"Teicoplanin : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00002878/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-05T10:59:00Z","last_updated_date":"2022-08-05T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/teicoplanin-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002878202111_sv.pdf"}},
    {"id":"55783","name":"methylphenidate : List of nationally authorised medicinal products - PSUSA/00002024/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-05T11:52:00Z","last_updated_date":"2022-08-05T11:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-list-nationally-authorised-medicinal-products-psusa00002024202110_en.pdf"},
    {"id":"55784","name":"methylphenidate : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00002024/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-05T11:58:00Z","last_updated_date":"2022-08-05T11:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methylphenidate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002024202110_no.pdf"}},
    {"id":"55796","name":"Diclofenac (systemic formulations) : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00001048/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-08T13:55:00Z","last_updated_date":"2022-08-08T13:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/diclofenac-systemic-formulations-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001048202109_no.pdf"}},
    {"id":"55797","name":"Diclofenac (systemic formulations) : List of nationally authorised medicinal products - PSUSA/00001048/202109","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-08T15:20:00Z","last_updated_date":"2022-08-08T15:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-systemic-formulations-list-nationally-authorised-medicinal-products-psusa00001048202109_en.pdf"},
    {"id":"55940","name":"Cefotaxime : List of nationally authorised medicinal products - PSUSA/00000599/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-01T17:37:00Z","last_updated_date":"2022-09-01T17:37:00Z","reference_number":"EMA/621305/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefotaxime-list-nationally-authorised-medicinal-products-psusa00000599202112_en.pdf"},
    {"id":"55941","name":"Roxithromycin : List of nationally authorised medicinal products - PSUSA/00002669/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T09:06:00Z","last_updated_date":"2022-09-02T09:06:00Z","reference_number":"EMA/654141/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/roxithromycin-list-nationally-authorised-medicinal-products-psusa00002669202112_en.pdf"},
    {"id":"55942","name":"Octenidine dihydrochloride / phenoxyethanol : List of nationally authorised medicinal products - PSUSA/00002199/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T09:21:00Z","last_updated_date":"2022-09-02T09:21:00Z","reference_number":"EMA/709939/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/octenidine-dihydrochloride-phenoxyethanol-list-nationally-authorised-medicinal-products-psusa00002199202201_en.pdf"},
    {"id":"55946","name":"Anthrax vaccine : List of nationally authorised medicinal products - PSUSA/00010771/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T09:48:00Z","last_updated_date":"2022-09-02T09:48:00Z","reference_number":"EMA/709945/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/anthrax-vaccine-list-nationally-authorised-medicinal-products-psusa00010771202112_en.pdf"},
    {"id":"55948","name":"Typhoid vaccine (live, attenuated) : List of nationally authorised medicinal products - PSUSA/00003067/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T09:55:00Z","last_updated_date":"2022-09-02T09:55:00Z","reference_number":"EMA/710128/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/typhoid-vaccine-live-attenuated-list-nationally-authorised-medicinal-products-psusa00003067202112_en.pdf"},
    {"id":"55966","name":"Camellia sinensis : List of nationally authorised medicinal products - PSUSA/00010569/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T15:39:00Z","last_updated_date":"2022-09-02T15:39:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/camellia-sinensis-list-nationally-authorised-medicinal-products-psusa00010569202112_en.pdf"},
    {"id":"55967","name":"Alpha amylase : List of nationally authorised medicinal products - PSUSA/00000104/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T15:49:00Z","last_updated_date":"2022-09-02T15:49:00Z","reference_number":"EMA/PRAC/721141/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/alpha-amylase-list-nationally-authorised-medicinal-products-psusa00000104202201_en.pdf"},
    {"id":"55970","name":"Alitretinoin (oral use) : List of nationally authorised medicinal products - PSUSA/00010710/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T09:15:00Z","last_updated_date":"2022-09-05T09:15:00Z","reference_number":"EMA/723792/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/alitretinoin-oral-use-list-nationally-authorised-medicinal-products-psusa00010710202201_en.pdf"},
    {"id":"55971","name":"Beclometason : List of nationally authorised medicinal products - PSUSA/00000306/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T09:23:00Z","last_updated_date":"2022-09-05T09:23:00Z","reference_number":"EMA/723871/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/beclometason-list-nationally-authorised-medicinal-products-psusa00000306202112_en.pdf"},
    {"id":"55972","name":"Allergen for therapy: betula verrucosa (sublingual use) : List of nationally authorised medicinal products - PSUSA/00010815/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T09:23:00Z","last_updated_date":"2022-09-05T09:23:00Z","reference_number":"EMA/723821/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-betula-verrucosa-sublingual-use-list-nationally-authorised-medicinal-products-psusa00010815202201_en.pdf"},
    {"id":"55974","name":"Beclometasone / salbutamol : List of nationally authorised medicinal products - PSUSA/00000309/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T14:09:00Z","last_updated_date":"2022-09-05T14:09:00Z","reference_number":"EMA/724591/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/beclometasone-salbutamol-list-nationally-authorised-medicinal-products-psusa00000309202201_en.pdf"},
    {"id":"55975","name":"Tapentadol : List of nationally authorised medicinal products - PSUSA/00002849/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T14:23:00Z","last_updated_date":"2022-09-05T14:23:00Z","reference_number":"EMA/724645/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/tapentadol-list-nationally-authorised-medicinal-products-psusa00002849202111_en.pdf"},
    {"id":"55976","name":"Tapentadol : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00002849/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T14:28:00Z","last_updated_date":"2022-09-05T14:28:00Z","reference_number":"EMA/724645/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tapentadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002849202111_no.pdf"}},
    {"id":"55977","name":"Topiramate : List of nationally authorised medicinal products - PSUSA/00002996/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T14:35:00Z","last_updated_date":"2022-09-05T14:35:00Z","reference_number":"EMA/724076/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/topiramate-list-nationally-authorised-medicinal-products-psusa00002996202201_en.pdf"},
    {"id":"55979","name":"Escitalopram : List of nationally authorised medicinal products - PSUSA/00001265/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T15:12:00Z","last_updated_date":"2022-09-05T15:12:00Z","reference_number":"EMA/724081/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/escitalopram-list-nationally-authorised-medicinal-products-psusa00001265202112_en.pdf"},
    {"id":"55980","name":"amlodipine / lisinopril : List of nationally authorised medicinal products - PSUSA/00010192/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T15:18:00Z","last_updated_date":"2022-09-05T15:18:00Z","reference_number":"EMA/725519/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-lisinopril-list-nationally-authorised-medicinal-products-psusa00010192202112_en.pdf"},
    {"id":"55982","name":"Amlodipine / lisinopril : List of nationally authorised medicinal products - PSUSA/00010192/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T15:39:00Z","last_updated_date":"2022-09-05T15:39:00Z","reference_number":"EMA/725519/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-lisinopril-list-nationally-authorised-medicinal-products-psusa00010192202112_en.pdf-0"},
    {"id":"55985","name":"Amino acid combinations : List of nationally authorised medicinal products - PSUSA/00010190/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T16:11:00Z","last_updated_date":"2022-09-05T16:11:00Z","reference_number":"EMA/632064/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amino-acid-combinations-list-nationally-authorised-medicinal-products-psusa00010190202112_en.pdf"},
    {"id":"55986","name":"Testosterone (topical use) : List of nationally authorised medicinal products - PSUSA/00002908/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T17:05:00Z","last_updated_date":"2022-09-05T17:05:00Z","reference_number":"EMA/725590/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-topical-use-list-nationally-authorised-medicinal-products-psusa00002908202112_en.pdf"},
    {"id":"55988","name":"Levobunolol (ophthalmic indication) : List of nationally authorised medicinal products : PSUSA/00010109/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T17:09:00Z","last_updated_date":"2022-09-05T17:09:00Z","reference_number":"EMA/725788/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/levobunolol-ophthalmic-indication-list-nationally-authorised-medicinal-products-psusa00010109202201_en.pdf"},
    {"id":"55989","name":"Testosterone (all formulations apart from topical use) : List of nationally authorised medicinal products - PSUSA/00010631/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T17:37:00Z","last_updated_date":"2022-09-05T17:37:00Z","reference_number":"EMA/725899/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-all-formulations-apart-topical-use-list-nationally-authorised-medicinal-products-psusa00010631202112_en.pdf"},
    {"id":"55990","name":"chlormadinone acetate / ethinylestradiol : List of nationally authorised medicinal products - PSUSA/00000679/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T17:49:00Z","last_updated_date":"2022-09-05T17:49:00Z","reference_number":"EMA/726018/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlormadinone-acetate-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa00000679202111_en.pdf"},
    {"id":"55991","name":"chlormadinone acetate / ethinylestradiol : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00000679/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T17:55:00Z","last_updated_date":"2022-09-05T17:55:00Z","reference_number":"EMA/726018/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/chlormadinone-acetate-ethinylestradiol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00000679202111_no.pdf"}},
    {"id":"55995","name":"Botulinum toxin a - haemagglutinin complex : List of nationally authorised medicinal products - PSUSA/00000427/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-06T11:20:00Z","last_updated_date":"2022-09-06T11:20:00Z","reference_number":"EMA/724087/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-haemagglutinin-complex-list-nationally-authorised-medicinal-products-psusa00000427202112_en.pdf"},
    {"id":"56015","name":"Niflumic acid : List of nationally authorised medicinal products - PSUSA/00002157/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-07T15:32:00Z","last_updated_date":"2022-09-07T15:32:00Z","reference_number":"EMA/734348/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/niflumic-acid-list-nationally-authorised-medicinal-products-psusa00002157202112_en.pdf"},
    {"id":"56018","name":"Bendamustine hydrochloride : List of nationally authorised medicinal products - PSUSA/00003162/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-07T15:40:00Z","last_updated_date":"2022-09-07T15:40:00Z","reference_number":"EMA/733484/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendamustine-hydrochloride-list-nationally-authorised-medicinal-products-psusa00003162202201_en.pdf"},
    {"id":"56022","name":"Hydromorphone : List of nationally authorised medicinal products - PSUSA/00001686/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-07T16:57:00Z","last_updated_date":"2022-09-07T16:57:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydromorphone-list-nationally-authorised-medicinal-products-psusa00001686202111_en.pdf"},
    {"id":"56023","name":"Hydromorphone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001686/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-07T17:00:00Z","last_updated_date":"2022-09-07T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/hydromorphone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001686202111_no.pdf"}},
    {"id":"56032","name":"Flunitrazepam : List of nationally authorised medicinal products - PSUSA/00001418/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-08T13:50:00Z","last_updated_date":"2022-09-08T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/flunitrazepam-list-nationally-authorised-medicinal-products-psusa00001418202201_en.pdf"}    {"id":"56033","name":"P/0325/2021 : EMA decision of 12 August 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deucravacitinib (EMEA-002350-PIP03-20)","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T14:14:00Z","last_updated_date":"2022-09-08T14:14:00Z","reference_number":"EMA/382520/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/p03252021-ema-decision-12-august-2021-agreement-paediatric-investigation-plan-and-granting-deferral-and-granting-waiver-deucravacitinib-emea-002350-pip03-20_en.pdf"},
    {"id":"56034","name":"Citalopram : List of nationally authorised medicinal products - PSUSA/00000779/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-08T14:15:00Z","last_updated_date":"2022-09-08T14:15:00Z","reference_number":"EMA/757582/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/citalopram-list-nationally-authorised-medicinal-products-psusa00000779202112_en.pdf"},
    {"id":"56048","name":"Flumazenil : List of nationally authorised medicinal products - PSUSA/00001413/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-09T09:02:00Z","last_updated_date":"2022-09-09T09:02:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/flumazenil-list-nationally-authorised-medicinal-products-psusa00001413202112_en.pdf"},
    {"id":"56049","name":"Pilocarpine (ophthalmic formulation) : List of nationally authorised medicinal products - PSUSA/00002410/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-09T13:15:00Z","last_updated_date":"2022-09-09T13:15:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/pilocarpine-ophthalmic-formulation-list-nationally-authorised-medicinal-products-psusa00002410202108_en.pdf"},
    {"id":"56054","name":"Methohexital : List of nationally authorised medicinal products - PSUSA/00010656/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-09T16:24:00Z","last_updated_date":"2022-09-09T16:24:00Z","reference_number":"EMA/734182/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/methohexital-list-nationally-authorised-medicinal-products-psusa00010656202201_en.pdf"},
    {"id":"56056","name":"Esketamine (except for centrally authorised products) : list of nationally authorised medicinal products - PSUSA/00001266/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-09T16:42:00Z","last_updated_date":"2022-09-09T16:42:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/esketamine-except-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00001266202108_en.pdf"},
    {"id":"56213","name":"Ofloxacin (topical use) : List of nationally authorised medicinal products - PSUSA/00002204/202104","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T08:56:00Z","last_updated_date":"2022-09-28T08:56:00Z","reference_number":"EMA/788063/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-topical-use-list-nationally-authorised-medicinal-products-psusa00002204202104_en.pdf"},
    {"id":"56214","name":"Triamcinolone (intraocular formulations) : List of nationally authorised medicinal products - PSUSA/00010292/202103","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T09:12:00Z","last_updated_date":"2022-09-28T09:12:00Z","reference_number":"EMA/788270/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/triamcinolone-intraocular-formulations-list-nationally-authorised-medicinal-products-psusa00010292202103_en.pdf"},
    {"id":"56253","name":"Alverine / simeticone : List of nationally authorised medicinal products - PSUSA/00000125/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T15:20:00Z","last_updated_date":"2022-09-29T15:20:00Z","reference_number":"EMA/793021/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/alverine-simeticone-list-nationally-authorised-medicinal-products-psusa00000125202202_en.pdf"},
    {"id":"56254","name":"Alverine : List of nationally authorised medicinal products - PSUSA/00000124/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T15:27:00Z","last_updated_date":"2022-09-29T15:27:00Z","reference_number":"EMA/793085/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/alverine-list-nationally-authorised-medicinal-products-psusa00000124202202_en.pdf"},
    {"id":"56261","name":"Zanamivir (except for centrally authorised products) : List of nationally authorised medicinal products - PSUSA/00003141/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-30T11:19:00Z","last_updated_date":"2022-09-30T11:19:00Z","reference_number":"EMA/638586/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/zanamivir-except-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00003141202201_en.pdf"},
    {"id":"56262","name":"Influenza vaccine (split virion, inactivated) (non centrally authorised products) : List of nationally authorised medicinal products - PSUSA/00010298/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-30T11:26:00Z","last_updated_date":"2022-09-30T11:26:00Z","reference_number":"EMA/674694/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00010298202203_en.pdf"},
    {"id":"56263","name":"Influenza vaccine (surface antigen, inactivated) : List of nationally authorised medicinal products - PSUSA/00001744/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-30T11:31:00Z","last_updated_date":"2022-09-30T11:31:00Z","reference_number":"EMA/674604/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa00001744202203_en.pdf"},
    {"id":"56264","name":"Loratadine : List of nationally authorised medicinal products - PSUSA/00001907/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-30T11:46:00Z","last_updated_date":"2022-09-30T11:46:00Z","reference_number":"EMA/794351/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/loratadine-list-nationally-authorised-medicinal-products-psusa00001907202202_en.pdf"},
    {"id":"56266","name":"Cromoglicic acid : List of nationally authorised medicinal products - PSUSA/00000883/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-30T11:52:00Z","last_updated_date":"2022-09-30T11:52:00Z","reference_number":"EMA/781338/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cromoglicic-acid-list-nationally-authorised-medicinal-products-psusa00000883202202_en.pdf"},
    {"id":"56267","name":"Loratadine / pseudoephedrine : List of nationally authorised medicinal products - PSUSA/00001908/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-09-30T12:41:00Z","last_updated_date":"2022-09-30T12:41:00Z","reference_number":"EMA/794502/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/loratadine-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00001908202202_en.pdf"},
    {"id":"56318","name":"Lorazepam : List of nationally authorised medicinal products - PSUSA/00001909/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-05T10:15:00Z","last_updated_date":"2022-10-05T10:15:00Z","reference_number":"EMA/PRAC/800404/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/lorazepam-list-nationally-authorised-medicinal-products-psusa00001909202201_en.pdf"},
    {"id":"56319","name":"Donepezil : List of nationally authorised medicinal products - PSUSA/00001160/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-05T10:32:00Z","last_updated_date":"2022-10-05T10:32:00Z","reference_number":"EMA/CMDh/800411/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/donepezil-list-nationally-authorised-medicinal-products-psusa00001160202111_en.pdf"},
    {"id":"56320","name":"Donepezil : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001160/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-05T10:35:00Z","last_updated_date":"2022-10-05T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/donepezil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001160202111_no.pdf"}},
    {"id":"56321","name":"Acetylsalicylic acid : List of nationally authorised medicinal products - PSUSA/00000039/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-05T10:43:00Z","last_updated_date":"2022-10-05T10:43:00Z","reference_number":"EMA/801199/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-list-nationally-authorised-medicinal-products-psusa00000039202202_en.pdf"},
    {"id":"56323","name":"Lisdexamfetamine : List of nationally authorised medicinal products - PSUSA/00010289/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-05T12:39:00Z","last_updated_date":"2022-10-05T12:39:00Z","reference_number":"EMA/803039/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa00010289202202_en.pdf"},
    {"id":"56333","name":"Amlodipine / atorvastatin : List of nationally authorised medicinal products - PSUSA/00000177/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-06T12:36:00Z","last_updated_date":"2022-10-06T12:36:00Z","reference_number":"EMA/805538/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-atorvastatin-list-nationally-authorised-medicinal-products-psusa00000177202201_en.pdf"},
    {"id":"56337","name":"Moxonidine : List of nationally authorised medicinal products - PSUSA/00002095/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-06T14:55:00Z","last_updated_date":"2022-10-06T14:55:00Z","reference_number":"EMA/806061/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/moxonidine-list-nationally-authorised-medicinal-products-psusa00002095202201_en.pdf"},
    {"id":"56338","name":"Ketoprofen (all formulations except topical) : List of nationally authorised medicinal products - PSUSA/00001809/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-06T16:08:00Z","last_updated_date":"2022-10-06T16:08:00Z","reference_number":"EMA/806370/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketoprofen-all-formulations-except-topical-list-nationally-authorised-medicinal-products-psusa00001809202201_en.pdf"},
    {"id":"56344","name":"Glipizide : List of nationally authorised medicinal products - PSUSA/00001535/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-07T08:59:00Z","last_updated_date":"2022-10-07T08:59:00Z","reference_number":"EMA/806489/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/glipizide-list-nationally-authorised-medicinal-products-psusa00001535202201_en.pdf"},
    {"id":"56433","name":"Ciclosporin (systemic use) : List of nationally authorised medicinal products - PSUSA/00000745/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-19T14:03:00Z","last_updated_date":"2022-10-19T14:03:00Z","reference_number":"EMA/837430/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciclosporin-systemic-use-list-nationally-authorised-medicinal-products-psusa00000745202112_en.pdf"},
    {"id":"56434","name":"Ciclosporin (systemic use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000745/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-19T14:05:00Z","last_updated_date":"2022-10-19T14:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000745202112_no.pdf"}},
    {"id":"56439","name":"Terbutaline - List of nationally authorised medicinal products - PSUSA/00002897/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-20T11:58:00Z","last_updated_date":"2022-10-20T11:58:00Z","reference_number":"EMA/836559/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/terbutaline-list-nationally-authorised-medicinal-products-psusa00002897202112_en.pdf"},
    {"id":"56440","name":"Terbutaline - CMDh Scientific conclusions and grounds for the variation to the terms of the Marketing  Authorisation(s) - PSUSA/00002897/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-20T12:01:00Z","last_updated_date":"2022-10-20T12:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/terbutaline-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00002897202112_no.pdf"}},
    {"id":"56447","name":"Valaciclovir : List of nationally authorised medicinal products - PSUSA/00003086/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-21T09:12:00Z","last_updated_date":"2022-10-21T09:12:00Z","reference_number":"EMA/622432/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/valaciclovir-list-nationally-authorised-medicinal-products-psusa00003086202112_en.pdf"},
    {"id":"56448","name":"Valaciclovir : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003086/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-21T09:14:00Z","last_updated_date":"2022-10-21T09:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/valaciclovir-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003086202112_no.pdf"}},
    {"id":"56450","name":"Botulinum toxin a : List of nationally authorised medicinal products - PSUSA/00000426/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-21T10:09:00Z","last_updated_date":"2022-10-21T10:09:00Z","reference_number":"EMA/724085/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-list-nationally-authorised-medicinal-products-psusa00000426202112_en.pdf"},
    {"id":"56451","name":"Botulinum toxin a : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000426/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-21T10:11:00Z","last_updated_date":"2022-10-21T10:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_no.pdf"}},
    {"id":"56452","name":"Bupropion : List of nationally authorised medicinal products - PSUSA/00000461/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-21T10:52:00Z","last_updated_date":"2022-10-21T10:52:00Z","reference_number":"EMA/842375/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/bupropion-list-nationally-authorised-medicinal-products-psusa00000461202112_en.pdf"},
    {"id":"56453","name":"Bupropion : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000461/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-21T10:54:00Z","last_updated_date":"2022-10-21T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bupropion-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000461202112_no.pdf"}},
    {"id":"56461","name":"Dexketoprofen / tramadol - List of nationally authorised medicinal products - PSUSA/00010468/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-24T16:17:00Z","last_updated_date":"2022-10-24T16:17:00Z","reference_number":"EMA/846866/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-tramadol-list-nationally-authorised-medicinal-products-psusa00010468202201_en.pdf"},
    {"id":"56462","name":"Dexketoprofen / tramadol - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00010468/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-24T16:19:00Z","last_updated_date":"2024-11-29T11:38:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010468-202201_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexketoprofen-tramadol-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00010468202201_sv.pdf"}},
    {"id":"56464","name":"Botulinum neurotoxin type a (150 kD) free from complexing proteins - List of nationally authorised medicinal products - PSUSA/00009084/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-24T17:10:00Z","last_updated_date":"2022-10-24T17:10:00Z","reference_number":"EMA/848154/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-list-nationally-authorised-medicinal-products-psusa00009084202112_en.pdf"},
    {"id":"56465","name":"Hydroxyethyl starch - List of nationally authorised medicinal products - PSUSA/00001694/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-24T17:57:00Z","last_updated_date":"2022-10-24T17:57:00Z","reference_number":"EMA/849688/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-list-nationally-authorised-medicinal-products-psusa00001694202203_en.pdf"},
    {"id":"56468","name":"Dexlansoprazole, lansoprazole - List of nationally authorised medicinal products - PSUSA/00001827/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-25T11:48:00Z","last_updated_date":"2022-10-25T11:48:00Z","reference_number":"EMA/665499/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexlansoprazole-lansoprazole-list-nationally-authorised-medicinal-products-psusa00001827202112_en.pdf"},
    {"id":"56469","name":"Dexlansoprazole, lansoprazole - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00001827/202112","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-25T11:50:00Z","last_updated_date":"2022-10-25T11:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dexlansoprazole-lansoprazole-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-psusa00001827202112_no.pdf"}},
    {"id":"56487","name":"Carbomers : List of nationally authorised medicinal products - PSUSA/00000557/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-27T11:25:00Z","last_updated_date":"2022-10-27T11:25:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbomers-list-nationally-authorised-medicinal-products-psusa00000557202201_en.pdf"},
    {"id":"56493","name":"Rocuronium - List of nationally authorised medicinal products - PSUSA-00002656-202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-27T16:12:00Z","last_updated_date":"2022-10-27T16:12:00Z","reference_number":"EMA/855258/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/rocuronium-list-nationally-authorised-medicinal-products-psusa-00002656-202202_en.pdf"},
    {"id":"56494","name":"Aviptadil / phentolamine mesilate - List of nationally authorised medicinal products - PSUSA/00010814/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-27T16:46:00Z","last_updated_date":"2022-10-27T16:46:00Z","reference_number":"EMA/855871/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/aviptadil-phentolamine-mesilate-list-nationally-authorised-medicinal-products-psusa00010814202202_en.pdf"},
    {"id":"56495","name":"Alprazolam - List of nationally authorised medicinal products - PSUSA/00000109/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-27T16:58:00Z","last_updated_date":"2022-10-27T16:58:00Z","reference_number":"EMA/855442/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprazolam-list-nationally-authorised-medicinal-products-psusa00000109202203_en.pdf"},
    {"id":"56496","name":"Zolmitriptan : List of nationally authorised medicinal products - PSUSA/00003150/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-27T17:30:00Z","last_updated_date":"2022-10-27T17:30:00Z","reference_number":"EMA/852875/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/zolmitriptan-list-nationally-authorised-medicinal-products-psusa00003150202203_en.pdf"},
    {"id":"56513","name":"Fluticasone propionate : List of nationally authorised medicinal products - PSUSA/00001454/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-10-31T10:25:00Z","last_updated_date":"2022-10-31T10:25:00Z","reference_number":"EMA/841608/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluticasone-propionate-list-nationally-authorised-medicinal-products-psusa00001454202202_en.pdf"},
    {"id":"56520","name":"Allergen for therapy: Phleum Pratense (oromucosal use, product authorised via mutually recognition procedure) : List of nationally authorised medicinal products - PSUSA/00010475/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-03T11:57:00Z","last_updated_date":"2022-11-03T11:57:00Z","reference_number":"EMA/862198/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-phleum-pratense-oromucosal-use-product-authorised-mutually-recognition-procedure-list-nationally-authorised-medicinal-products-psusa00010475202203_en.pdf"},
    {"id":"56521","name":"Amlodipine : List of nationally authorised medicinal products - PSUSA/00000174/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-03T12:16:00Z","last_updated_date":"2022-11-03T12:16:00Z","reference_number":"EMA/862347/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-list-nationally-authorised-medicinal-products-psusa00000174202203_en.pdf"},
    {"id":"56523","name":"Cabergoline : List of nationally authorised medicinal products - PSUSA/00000477/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-03T13:33:00Z","last_updated_date":"2022-11-03T13:33:00Z","reference_number":"EMA/862568/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cabergoline-list-nationally-authorised-medicinal-products-psusa00000477202203_en.pdf"},
    {"id":"56524","name":"Aprotinin : List of nationally authorised medicinal products - PSUSA/00000230/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-03T13:44:00Z","last_updated_date":"2022-11-03T13:44:00Z","reference_number":"EMA/862666/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/aprotinin-list-nationally-authorised-medicinal-products-psusa00000230202202_en.pdf"},
    {"id":"56525","name":"Nicorandil : List of nationally authorised medicinal products - PSUSA/00002152/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-03T13:52:00Z","last_updated_date":"2022-11-03T13:52:00Z","reference_number":"EMA/862945/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicorandil-list-nationally-authorised-medicinal-products-psusa00002152202202_en.pdf"},
    {"id":"56527","name":"Eplerenone : List of nationally authorised medicinal products - PSUSA/00001236/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-03T14:46:00Z","last_updated_date":"2022-11-03T14:46:00Z","reference_number":"EMA/863084/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/eplerenone-list-nationally-authorised-medicinal-products-psusa00001236202203_en.pdf"},
    {"id":"56531","name":"Clodronic acid / lidocaine : List of nationally authorised medicinal products - PSUSA/00010650/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-04T11:08:00Z","last_updated_date":"2022-11-04T11:08:00Z","reference_number":"EMA/863934/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/clodronic-acid-lidocaine-list-nationally-authorised-medicinal-products-psusa00010650202202_en.pdf"},
    {"id":"56562","name":"Naratriptan : List of nationally authorised medicinal products - PSUSA/00002126/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-09T11:44:00Z","last_updated_date":"2022-11-09T11:44:00Z","reference_number":"EMA/PRAC/852055/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/naratriptan-list-nationally-authorised-medicinal-products-psusa00002126202202_en.pdf"},
    {"id":"56563","name":"Chloroprocaine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010078/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-09T12:24:00Z","last_updated_date":"2022-11-09T12:24:00Z","reference_number":"EMA/PRAC/851962/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/chloroprocaine-hydrochloride-list-nationally-authorised-medicinal-products-psusa00010078202203_en.pdf"},
    {"id":"56674","name":"Dorzolamide : List of nationally authorised medicinal products - PSUSA/00003168/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-16T15:34:00Z","last_updated_date":"2022-11-16T15:34:00Z","reference_number":"EMA/CMDh/889761/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-list-nationally-authorised-medicinal-products-psusa00003168202202_en.pdf"},
    {"id":"56675","name":"Dorzolamide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -  PSUSA/00003168/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-16T15:36:00Z","last_updated_date":"2022-11-25T12:54:00Z","reference_number":"EMA/CMDh/889761/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dorzolamide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003168202202_no.pdf"}},
    {"id":"56677","name":"Ketoprofen (topical use only) : List of nationally authorised medicinal products - PSUSA/00009205/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T08:46:00Z","last_updated_date":"2022-11-17T08:46:00Z","reference_number":"EMA/CMDh/890125/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketoprofen-topical-use-only-list-nationally-authorised-medicinal-products-psusa00009205202201_en.pdf"},
    {"id":"56678","name":"Ketoprofen (topical use only) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009205/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T09:01:00Z","last_updated_date":"2022-11-17T09:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ketoprofen-topical-use-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00009205202201_no.pdf"}},
    {"id":"56709","name":"Mesalazine : List of nationally authorised medicinal products - PSUSA/00001990/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T12:17:00Z","last_updated_date":"2022-11-18T12:17:00Z","reference_number":"EMA/781634/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesalazine-list-nationally-authorised-medicinal-products-psusa00001990202202_en.pdf"},
    {"id":"56710","name":"Mesalazine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001990/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T12:19:00Z","last_updated_date":"2022-11-18T12:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/mesalazine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001990202202_no.pdf"}},
    {"id":"56740","name":"Carboplatin : List of nationally authorised medicinal products - PSUSA/00000559/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-22T11:24:00Z","last_updated_date":"2022-11-22T11:24:00Z","reference_number":"EMA/777898/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/carboplatin-list-nationally-authorised-medicinal-products-psusa00000559202201_en.pdf"},
    {"id":"56741","name":"Carboplatin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000559/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-22T11:26:00Z","last_updated_date":"2022-11-22T11:26:00Z","reference_number":"EMA/777898/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/carboplatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000559202201_no.pdf"}},
    {"id":"56762","name":"Frovatriptan : List of nationally authorised medicinal products - PSUSA/00001484/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-23T14:47:00Z","last_updated_date":"2022-11-23T14:47:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/frovatriptan-list-nationally-authorised-medicinal-products-psusa00001484202203_en.pdf"},
    {"id":"56765","name":"Gabapentin : List of nationally authorised medicinal products - PSUSA/00001499/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-24T08:59:00Z","last_updated_date":"2022-11-24T08:59:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/gabapentin-list-nationally-authorised-medicinal-products-psusa00001499202202_en.pdf"},
    {"id":"56766","name":"Gabapentin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001499/202202","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-24T09:02:00Z","last_updated_date":"2025-11-24T11:59:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202202_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202202_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202202_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gabapentin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001499202202_no.pdf"}},
    {"id":"56767","name":"Mesterolone : List of nationally authorised medicinal products - PSUSA/00010551/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-24T09:12:00Z","last_updated_date":"2022-11-24T09:12:00Z","reference_number":"EMA/902999/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesterolone-list-nationally-authorised-medicinal-products-psusa00010551202201_en.pdf"},
    {"id":"56768","name":"Mesterolone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010551/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-24T09:14:00Z","last_updated_date":"2022-11-24T09:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mesterolone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010551202201_sv.pdf"}},
    {"id":"56832","name":"Levothyroxine : List of nationally authorised medicinal products - PSUSA/00001860/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-29T16:30:00Z","last_updated_date":"2022-11-29T16:30:00Z","reference_number":"EMA/910482/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/levothyroxine-list-nationally-authorised-medicinal-products-psusa00001860202201_en.pdf"},
    {"id":"56839","name":"Levothyroxine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001860/202201","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-11-30T12:47:00Z","last_updated_date":"2022-11-30T12:47:00Z","reference_number":"EMA/910482/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levothyroxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001860202201_no.pdf"}},
    {"id":"56846","name":"Human rabies immunoglobulin : List of nationally authorised medicinal products - PSUSA/00001639/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-01T13:00:00Z","last_updated_date":"2022-12-01T13:00:00Z","reference_number":"EMA/794164/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-rabies-immunoglobulin-list-nationally-authorised-medicinal-products-psusa00001639202204_en.pdf"},
    {"id":"56847","name":"Itraconazole : List of nationally authorised medicinal products - PSUSA/00001798/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-01T13:07:00Z","last_updated_date":"2022-12-01T13:07:00Z","reference_number":"EMA/780567/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/itraconazole-list-nationally-authorised-medicinal-products-psusa00001798202203_en.pdf"},
    {"id":"56848","name":"Linezolid : List of nationally authorised medicinal products - PSUSA/00001888/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-01T13:13:00Z","last_updated_date":"2022-12-01T13:13:00Z","reference_number":"EMA/794423/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/linezolid-list-nationally-authorised-medicinal-products-psusa00001888202204_en.pdf"},
    {"id":"56849","name":"Mupirocin : List of nationally authorised medicinal products - PSUSA/00002096/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-01T13:19:00Z","last_updated_date":"2022-12-01T13:19:00Z","reference_number":"EMA/794425/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/mupirocin-list-nationally-authorised-medicinal-products-psusa00002096202203_en.pdf"},
    {"id":"56850","name":"Gentamicin (implant) : List of nationally authorised medicinal products - PSUSA/00010628/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-01T13:38:00Z","last_updated_date":"2022-12-01T13:38:00Z","reference_number":"EMA/794442/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/gentamicin-implant-list-nationally-authorised-medicinal-products-psusa00010628202203_en.pdf"},
    {"id":"56851","name":"Ozenoxacin : List of nationally authorised medicinal products - PSUSA/00010651/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-01T13:45:00Z","last_updated_date":"2022-12-01T13:45:00Z","reference_number":"EMA/794448/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ozenoxacin-list-nationally-authorised-medicinal-products-psusa00010651202205_en.pdf"},
    {"id":"56852","name":"Isotretinoin (oral formulations) : List of nationally authorised medicinal products - PSUSA/00010488/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-01T17:37:00Z","last_updated_date":"2022-12-01T17:37:00Z","reference_number":"EMA/894509/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa00010488202205_en.pdf"},
    {"id":"56853","name":"Lidocaine / prilocaine (not centrally authorised product) : List of nationally authorised medicinal products - PSUSA/00001867/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-01T17:44:00Z","last_updated_date":"2022-12-01T17:44:00Z","reference_number":"EMA/901823/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-prilocaine-not-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00001867202203_en.pdf"},
    {"id":"56854","name":"Tretinoin (oral formulations) : List of nationally authorised medicinal products - PSUSA/00003015/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-01T17:54:00Z","last_updated_date":"2022-12-01T17:54:00Z","reference_number":"EMA/916934/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/tretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa00003015202203_en.pdf"},
    {"id":"56861","name":"Glucosamine : List of nationally authorised medicinal products - PSUSA/00001539/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T12:21:00Z","last_updated_date":"2022-12-02T12:21:00Z","reference_number":"EMA/894267/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/glucosamine-list-nationally-authorised-medicinal-products-psusa00001539202203_en.pdf"},
    {"id":"56862","name":"Diphtheria/tetanus/pertussis (acellular, component) vaccine (adsorbed), diphtheria/tetanus/pertussis (acellular, component) vaccine (adsorbed) reduced antigens contents: List of nationally authorised medicinal pr...","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T12:32:00Z","last_updated_date":"2022-12-02T12:32:00Z","reference_number":"EMA/759342/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheriatetanuspertussis-acellular-component-vaccine-adsorbed-diphtheriatetanuspertussis-acellular-component-vaccine-adsorbed-reduced-antigens-contents-list-nationally-authorised-medicinal-pr_en.pdf"},
    {"id":"56863","name":"Varicella vaccine (live) : List of nationally authorised medicinal products - PSUSA/00010473/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T12:53:00Z","last_updated_date":"2022-12-02T12:53:00Z","reference_number":"EMA/759353/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/varicella-vaccine-live-list-nationally-authorised-medicinal-products-psusa00010473202203_en.pdf"},
    {"id":"56870","name":"Methyl salicylate, menthol/methyl salicylate, menthol/methyl salicylate/camphor, methyl salicylate/camphor, methyl salicylate/menthol/camphor....benzyl nicotinate : List of nationally authorised medicinal products - PSUSA/00010658/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T15:47:00Z","last_updated_date":"2022-12-02T15:47:00Z","reference_number":"EMA/918215/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/methyl-salicylate-mentholmethyl-salicylate-mentholmethyl-salicylatecamphor-methyl-salicylatecamphor-methyl-salicylatementholcamphorbenzyl-nicotinate-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"56877","name":"Etoricoxib : List of nationally authorised medicinal products - PSUSA/00001334/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-05T11:40:00Z","last_updated_date":"2022-12-05T11:40:00Z","reference_number":"EMA/919649/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/etoricoxib-list-nationally-authorised-medicinal-products-psusa00001334202203_en.pdf"},
    {"id":"56878","name":"Mometasone furoate/olopatadine : List of nationally authorised medicinal products - PSUSA/00010957/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-05T11:52:00Z","last_updated_date":"2022-12-05T11:52:00Z","reference_number":"EMA/918585/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/mometasone-furoateolopatadine-list-nationally-authorised-medicinal-products-psusa00010957202204_en.pdf"},
    {"id":"56880","name":"Nefopam : List of nationally authorised medicinal products - PSUSA/00002131/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-06T09:15:00Z","last_updated_date":"2022-12-06T09:15:00Z","reference_number":"EMA/PRAC/918197/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/nefopam-list-nationally-authorised-medicinal-products-psusa00002131202203_en.pdf"},
    {"id":"56881","name":"Sertraline : List of nationally authorised medicinal products - PSUSA/00002696/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-06T09:20:00Z","last_updated_date":"2022-12-06T09:20:00Z","reference_number":"EMA/PRAC/918194/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/sertraline-list-nationally-authorised-medicinal-products-psusa00002696202203_en.pdf"},
    {"id":"56912","name":"Epoprostenol : List of nationally authorised medicinal products - PSUSA/00001242/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-08T16:19:00Z","last_updated_date":"2022-12-08T16:19:00Z","reference_number":"EMA/931498/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/epoprostenol-list-nationally-authorised-medicinal-products-psusa00001242202203_en.pdf"},
    {"id":"56917","name":"Candesartan, candesartan / hydrochlorothiazide - List of nationally authorised medicinal products - PSUSA/00000527/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-08T17:28:00Z","last_updated_date":"2022-12-08T17:28:00Z","reference_number":"EMA/929096/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/candesartan-candesartan-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00000527202204_en.pdf"},
    {"id":"56918","name":"Carvedilol - List of nationally authorised medicinal products - PSUSA/00000575/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-08T17:54:00Z","last_updated_date":"2022-12-08T17:54:00Z","reference_number":"EMA/929400/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/carvedilol-list-nationally-authorised-medicinal-products-psusa00000575202204_en.pdf"},
    {"id":"56920","name":"Certoparin : List of nationally authorised medicinal products - PSUSA/00000625/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-09T08:57:00Z","last_updated_date":"2022-12-09T08:57:00Z","reference_number":"EMA/929591/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/certoparin-list-nationally-authorised-medicinal-products-psusa00000625202204_en.pdf"},
    {"id":"56922","name":"Amlodipine / olmesartan : List of nationally authorised medicinal products - PSUSA/00002208/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-09T13:27:00Z","last_updated_date":"2022-12-09T13:27:00Z","reference_number":"EMA/933404/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-olmesartan-list-nationally-authorised-medicinal-products-psusa00002208202204_en.pdf"},
    {"id":"56923","name":"Ethinylestradiol / levonorgestrel : List of nationally authorised medicinal products - PSUSA/00001309/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-09T13:38:00Z","last_updated_date":"2022-12-09T13:38:00Z","reference_number":"EMA/933038/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-levonorgestrel-list-nationally-authorised-medicinal-products-psusa00001309202204_en.pdf"},
    {"id":"56924","name":"Amlodipine besilate / hydrochlorothiazide / olmesartan medoxomil : List of nationally authorised medicinal products - PSUSA/00002210/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-09T13:56:00Z","last_updated_date":"2022-12-09T13:56:00Z","reference_number":"EMA/933936/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-besilate-hydrochlorothiazide-olmesartan-medoxomil-list-nationally-authorised-medicinal-products-psusa00002210202204_en.pdf"},
    {"id":"56931","name":"Sulprostone : List of nationally authorised medicinal products - PSUSA/00002828/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-09T15:19:00Z","last_updated_date":"2022-12-09T15:19:00Z","reference_number":"EMA/933959/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulprostone-list-nationally-authorised-medicinal-products-psusa00002828202204_en.pdf"},
    {"id":"56932","name":"Amlodipine / candesartan : List of nationally authorised medicinal products - PSUSA/00010191/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-09T15:24:00Z","last_updated_date":"2022-12-09T15:24:00Z","reference_number":"EMA/934243/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-candesartan-list-nationally-authorised-medicinal-products-psusa00010191202204_en.pdf"},
    {"id":"56933","name":"Carvedilol / ivabradine : List of nationally authorised medicinal products - PSUSA/00010883/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-09T15:50:00Z","last_updated_date":"2022-12-09T15:50:00Z","reference_number":"EMA/934540/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/carvedilol-ivabradine-list-nationally-authorised-medicinal-products-psusa00010883202204_en.pdf"},
    {"id":"56937","name":"Estradiol / norethisterone - List of nationally authorised medicinal products - PSUSA/00001278/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-12T12:26:00Z","last_updated_date":"2022-12-12T12:26:00Z","reference_number":"EMA/934662/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/estradiol-norethisterone-list-nationally-authorised-medicinal-products-psusa00001278202203_en.pdf"},
    {"id":"57100","name":"Oxycodone : List of nationally authorised medicinal products - PSUSA/00002254/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-20T14:45:00Z","last_updated_date":"2022-12-20T14:45:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-list-nationally-authorised-medicinal-products-psusa00002254202204_en.pdf"}    {"id":"57101","name":"Oxycodone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002254/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-12-20T14:49:00Z","last_updated_date":"2022-12-20T14:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002254202204_no.pdf"}},
    {"id":"57156","name":"Fexofenadine - List of nationally authorised medicinal products - PSUSA/00001388/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-04T17:14:00Z","last_updated_date":"2023-01-04T17:14:00Z","reference_number":"EMA/2586/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fexofenadine-list-nationally-authorised-medicinal-products-psusa00001388202203_en.pdf"},
    {"id":"57157","name":"Fexofenadine - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA/00001388/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-04T17:18:00Z","last_updated_date":"2023-01-04T17:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fexofenadine-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001388202203_no.pdf"}},
    {"id":"57175","name":"Amoxicillin/clavulanate : List of nationally authorised medicinal products - PSUSA/00000188/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T10:13:00Z","last_updated_date":"2023-01-09T10:13:00Z","reference_number":"EMA/759338/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amoxicillinclavulanate-list-nationally-authorised-medicinal-products-psusa00000188202203_en.pdf"},
    {"id":"57176","name":"Amoxicillin/clavulanate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000188/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T10:21:00Z","last_updated_date":"2023-01-09T10:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/amoxicillinclavulanate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000188202203_no.pdf"}},
    {"id":"57177","name":"Amoxicillin - List of nationally authorised medicinal products - PSUSA/00000187/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T10:55:00Z","last_updated_date":"2023-01-09T10:55:00Z","reference_number":"EMA/759336/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amoxicillin-list-nationally-authorised-medicinal-products-psusa00000187202203_en.pdf"},
    {"id":"57178","name":"Erythromycin (systemic use) - List of nationally authorised medicinal products - PSUSA/00010808/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T11:15:00Z","last_updated_date":"2023-01-09T11:15:00Z","reference_number":"EMA/759360/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/erythromycin-systemic-use-list-nationally-authorised-medicinal-products-psusa00010808202203_en.pdf"},
    {"id":"57180","name":"Erythromycin (systemic use) - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA/00010808/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-10T10:15:00Z","last_updated_date":"2023-01-10T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/erythromycin-systemic-use-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00010808202203_no.pdf"}},
    {"id":"57274","name":"Macrogol 3350 : List of nationally authorised medicinal products - PSUSA/00001924/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-13T11:25:00Z","last_updated_date":"2023-01-13T11:25:00Z","reference_number":"EMA/20257/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/macrogol-3350-list-nationally-authorised-medicinal-products-psusa00001924202205_en.pdf"},
    {"id":"57275","name":"Macrogol 4000, macrogol 4000 combinations (oral use) : List of nationally authorised medicinal products - PSUSA/00010392/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-13T11:35:00Z","last_updated_date":"2023-01-13T11:35:00Z","reference_number":"EMA/20274/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/macrogol-4000-macrogol-4000-combinations-oral-use-list-nationally-authorised-medicinal-products-psusa00010392202205_en.pdf"},
    {"id":"57277","name":"Fusidic acid (systemic use) - List of nationally authorised medicinal products - PSUSA/00010226/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-13T13:11:00Z","last_updated_date":"2023-01-13T13:11:00Z","reference_number":"EMA/20644/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fusidic-acid-systemic-use-list-nationally-authorised-medicinal-products-psusa00010226202205_en.pdf"},
    {"id":"57278","name":"Levofloxacin/dexamethasone (ocular use) - List of nationally authorised medicinal products - PSUSA/00010881/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-13T13:20:00Z","last_updated_date":"2023-01-13T13:20:00Z","reference_number":"EMA/441/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/levofloxacindexamethasone-ocular-use-list-nationally-authorised-medicinal-products-psusa00010881202206_en.pdf"},
    {"id":"57279","name":"Risperidone : List of nationally authorised medicinal products - PSUSA/00002649/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-13T14:12:00Z","last_updated_date":"2023-01-13T14:12:00Z","reference_number":"EMA/21406/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/risperidone-list-nationally-authorised-medicinal-products-psusa00002649202205_en.pdf"},
    {"id":"57308","name":"Alteplase - List of nationally authorised medicinal products - PSUSA/00000112/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-17T14:55:00Z","last_updated_date":"2023-01-17T14:55:00Z","reference_number":"EMA/27316/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/alteplase-list-nationally-authorised-medicinal-products-psusa00000112202205_en.pdf"},
    {"id":"57309","name":"Calcifediol - List of nationally authorised medicinal products - PSUSA/00000491/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-17T15:10:00Z","last_updated_date":"2023-01-17T15:10:00Z","reference_number":"EMA/27758/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcifediol-list-nationally-authorised-medicinal-products-psusa00000491202206_en.pdf"},
    {"id":"57322","name":"Tirofiban : List of nationally authorised medicinal products - PSUSA/00002974/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-18T15:11:00Z","last_updated_date":"2023-01-18T15:11:00Z","reference_number":"EMA/30527/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/tirofiban-list-nationally-authorised-medicinal-products-psusa00002974202205_en.pdf"},
    {"id":"57323","name":"Eprosartan hydrochlorothiazide - List of nationally authorised medicinal products - PSUSA/00001244/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-18T16:24:00Z","last_updated_date":"2023-01-18T16:24:00Z","reference_number":"EMA/30573/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/eprosartan-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa00001244202204_en.pdf"},
    {"id":"57324","name":"Eprosartan - List of nationally authorised medicinal products - PSUSA/00001243/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-18T16:40:00Z","last_updated_date":"2023-01-18T16:40:00Z","reference_number":"EMA/30612/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/eprosartan-list-nationally-authorised-medicinal-products-psusa00001243202204_en.pdf"},
    {"id":"57329","name":"Valsartan, hydrochlorothiazide / valsartan - List of nationally authorised medicinal products - PSUSA/00010396/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-19T11:56:00Z","last_updated_date":"2023-01-19T11:56:00Z","reference_number":"EMA/32202/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/valsartan-hydrochlorothiazide-valsartan-list-nationally-authorised-medicinal-products-psusa00010396202204_en.pdf"},
    {"id":"57335","name":"Latanoprost / timolol - List of nationally authorised medicinal products - PSUSA/00001833/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-19T14:27:00Z","last_updated_date":"2023-01-19T14:27:00Z","reference_number":"EMA/20658/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-timolol-list-nationally-authorised-medicinal-products-psusa00001833202206_en.pdf"},
    {"id":"57338","name":"Olsalazine - List of nationally authorised medicinal products - PSUSA/00002213/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-19T17:50:00Z","last_updated_date":"2023-01-19T17:50:00Z","reference_number":"EMA/33067/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/olsalazine-list-nationally-authorised-medicinal-products-psusa00002213202205_en.pdf"},
    {"id":"57340","name":"Cefuroxime axetil - List of nationally authorised medicinal products - PSUSA/00009099/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-20T11:40:00Z","last_updated_date":"2023-01-20T11:40:00Z","reference_number":"EMA/794434/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-axetil-list-nationally-authorised-medicinal-products-psusa00009099202204_en.pdf"},
    {"id":"57341","name":"Cefuroxime axetil - Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA/00009099/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-20T11:44:00Z","last_updated_date":"2023-01-20T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cefuroxime-axetil-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00009099202204_no.pdf"}},
    {"id":"57345","name":"Tolperisone : List of nationally authorised medicinal products - PSUSA/00002991/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-20T15:08:00Z","last_updated_date":"2023-01-20T15:08:00Z","reference_number":"EMA/34634/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/tolperisone-list-nationally-authorised-medicinal-products-psusa00002991202206_en.pdf"},
    {"id":"57346","name":"Cefuroxime sodium (except for intracameral use) : List of nationally authorised medicinal products - PSUSA/00000615/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-20T15:14:00Z","last_updated_date":"2023-01-20T15:14:00Z","reference_number":"EMA/794410/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-sodium-except-intracameral-use-list-nationally-authorised-medicinal-products-psusa00000615202204_en.pdf"},
    {"id":"57347","name":"Cefuroxime sodium (except for intracameral use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000615/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-20T15:20:00Z","last_updated_date":"2023-01-20T15:20:00Z","reference_number":"EMA/794410/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cefuroxime-sodium-except-intracameral-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000615202204_no.pdf"}},
    {"id":"57348","name":"Omeprazole : List of nationally authorised medicinal products - PSUSA/00002215/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-20T15:32:00Z","last_updated_date":"2023-01-20T15:32:00Z","reference_number":"EMA/34136/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/omeprazole-list-nationally-authorised-medicinal-products-psusa00002215202204_en.pdf"},
    {"id":"57349","name":"Omeprazole : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002215/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-20T15:34:00Z","last_updated_date":"2023-01-20T15:34:00Z","reference_number":"EMA/34136/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/omeprazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002215202204_no.pdf"}},
    {"id":"57353","name":"Lamivudine / tenofovir disoproxil : List of nationally authorised medicinal products - PSUSA/00010751/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-23T10:06:00Z","last_updated_date":"2023-01-23T10:06:00Z","reference_number":"EMA/794451/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/lamivudine-tenofovir-disoproxil-list-nationally-authorised-medicinal-products-psusa00010751202203_en.pdf"},
    {"id":"57354","name":"Lamivudine / tenofovir disoproxil : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010751/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-23T10:07:00Z","last_updated_date":"2023-01-23T10:07:00Z","reference_number":"EMA/794451/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lamivudine-tenofovir-disoproxil-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010751202203_sv.pdf"}},
    {"id":"57356","name":"Ivermectin (systemic use) : List of nationally authorised medicinal products - PSUSA/00010377/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-23T11:02:00Z","last_updated_date":"2023-01-23T11:02:00Z","reference_number":"EMA/794436/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-systemic-use-list-nationally-authorised-medicinal-products-psusa00010377202204_en.pdf"},
    {"id":"57357","name":"Ivermectin (systemic use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010377/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-23T11:07:00Z","last_updated_date":"2023-01-23T11:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ivermectin-systemic-use-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010377202204_sv.pdf"}},
    {"id":"57361","name":"Fentanyl (transdermal patches, solution for injection - nationally authorised product only) - List of nationally authorised medicinal products - PSUSA/00001370/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-23T17:14:00Z","last_updated_date":"2023-01-23T17:14:00Z","reference_number":"EMA/37490/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-list-nationally-authorised-medicinal-products-psusa00001370202204_en.pdf"},
    {"id":"57362","name":"Fentanyl (transdermal patches, solution for injection - nationally authorised product only) - CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001370/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-23T17:16:00Z","last_updated_date":"2023-01-23T17:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sv.pdf-0","is":"https://www.ema.europa.eu/is/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_is.pdf-0","no":"https://www.ema.europa.eu/no/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_no.pdf-0"}},
    {"id":"57363","name":"Aprotinin / calcium chloride / human factor xiii / human fibrinogen / human thrombin, aprotinin / fibrinogen / fibronectin / human coagulation factor XIII / ... - List of nationally authorised medicinal products - PSUSA/00010346/202111","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-23T17:50:00Z","last_updated_date":"2023-01-23T17:50:00Z","reference_number":"EMA/38012/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/aprotinin-calcium-chloride-human-factor-xiii-human-fibrinogen-human-thrombin-aprotinin-fibrinogen-fibronectin-human-coagulation-factor-xiii-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"57364","name":"Vinorelbine : List of nationally authorised medicinal products - PSUSA/00003124/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-24T09:24:00Z","last_updated_date":"2023-01-24T09:24:00Z","reference_number":"EMA/37632/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/vinorelbine-list-nationally-authorised-medicinal-products-psusa00003124202204_en.pdf"},
    {"id":"57365","name":"Vinorelbine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003124/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-24T09:26:00Z","last_updated_date":"2023-01-24T09:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/vinorelbine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003124202204_no.pdf"}},
    {"id":"57369","name":"Presentation - Second Veterinary Big Data Stakeholder Forum - Academia (M. Hostens)","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-24T11:45:00Z","last_updated_date":"2023-01-24T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/presentation-second-veterinary-big-data-stakeholder-forum-academia-m-hostens_en.pdf"},
    {"id":"57392","name":"Triptorelin : List of nationally authorised medicinal products - PSUSA/00003048/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-26T10:39:00Z","last_updated_date":"2023-01-26T10:39:00Z","reference_number":"EMA/917972/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/triptorelin-list-nationally-authorised-medicinal-products-psusa00003048202203_en.pdf"},
    {"id":"57393","name":"Triptorelin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003048/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-26T10:41:00Z","last_updated_date":"2023-01-26T10:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/triptorelin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003048202203_no.pdf"}},
    {"id":"57449","name":"Bleomycin : List of nationally authorised medicinal products - PSUSA/00000422/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-30T14:06:00Z","last_updated_date":"2023-01-30T14:06:00Z","reference_number":"EMA/48042/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/bleomycin-list-nationally-authorised-medicinal-products-psusa00000422202203_en.pdf"},
    {"id":"57450","name":"Bleomycin - CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000422/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-30T14:08:00Z","last_updated_date":"2023-01-30T14:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bleomycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000422202203_no.pdf"}},
    {"id":"57473","name":"Methoxyflurane : List of nationally authorised medicinal products - PSUSA/00010484/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T12:50:00Z","last_updated_date":"2023-01-31T12:50:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa00010484202205_en.pdf"},
    {"id":"57474","name":"Methoxyflurane : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010484/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T12:52:00Z","last_updated_date":"2023-01-31T12:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methoxyflurane-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010484202205_no.pdf"}},
    {"id":"57539","name":"Betaxolol : List of nationally authorised medicinal products - PSUSA/00000401/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-07T11:54:00Z","last_updated_date":"2023-02-07T11:54:00Z","reference_number":"EMA/60182/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/betaxolol-list-nationally-authorised-medicinal-products-psusa00000401202205_en.pdf"},
    {"id":"57540","name":"Levonorgestrel (for emergency contraception only) : List of nationally authorised medicinal products - PSUSA/00010827/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-07T11:52:00Z","last_updated_date":"2023-02-07T11:52:00Z","reference_number":"EMA/60229/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-emergency-contraception-only-list-nationally-authorised-medicinal-products-psusa00010827202205_en.pdf"},
    {"id":"57580","name":"Moclobemide : List of nationally authorised medicinal products - PSUSA/00002079/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T16:05:00Z","last_updated_date":"2023-02-08T16:05:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/moclobemide-list-nationally-authorised-medicinal-products-psusa00002079202204_en.pdf"},
    {"id":"57584","name":"Acamprosate : List of nationally authorised medicinal products - PSUSA/00000016/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-09T14:24:00Z","last_updated_date":"2023-02-09T14:24:00Z","reference_number":"EMA/65272/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/acamprosate-list-nationally-authorised-medicinal-products-psusa00000016202207_en.pdf"},
    {"id":"57588","name":"Amorolfine : List of nationally authorised medicinal products - PSUSA/00000185/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T09:06:00Z","last_updated_date":"2023-02-10T09:06:00Z","reference_number":"EMA/923657/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/amorolfine-list-nationally-authorised-medicinal-products-psusa00000185202206_en.pdf"},
    {"id":"57589","name":"Cilastatin / Imipenem : List of nationally authorised medicinal products - PSUSA/00000748/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T09:27:00Z","last_updated_date":"2023-02-10T09:27:00Z","reference_number":"EMA/923713/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilastatin-imipenem-list-nationally-authorised-medicinal-products-psusa00000748202206_en.pdf"},
    {"id":"57590","name":"Ganciclovir : List of nationally authorised medicinal products - PSUSA/00001516/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T09:33:00Z","last_updated_date":"2023-02-10T09:33:00Z","reference_number":"EMA/943452/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/ganciclovir-list-nationally-authorised-medicinal-products-psusa00001516202206_en.pdf"},
    {"id":"57591","name":"Pentamidine : List of nationally authorised medicinal products - PSUSA/00002338/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T09:37:00Z","last_updated_date":"2023-02-10T09:37:00Z","reference_number":"EMA/923642/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/pentamidine-list-nationally-authorised-medicinal-products-psusa00002338202206_en.pdf"},
    {"id":"57599","name":"Allergen for diagnostic and or therapy Vespula SPP. (802) (with or without adjuvant), Wasp venom - nationally authorised product only) - List of nationally authorised medicinal products - PSUSA/00010721/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T11:48:00Z","last_updated_date":"2023-02-10T11:48:00Z","reference_number":"EMA/65819/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-diagnostic-and-or-therapy-vespula-spp-802-or-without-adjuvant-wasp-venom-nationally-authorised-product-only-list-nationally-authorised-medicinal-products-psusa00010721202207_en.pdf"},
    {"id":"57601","name":"Theophylline - List of nationally authorised medicinal products - PSUSA/00002921/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T12:28:00Z","last_updated_date":"2023-02-10T12:28:00Z","reference_number":"EMA/66072/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/theophylline-list-nationally-authorised-medicinal-products-psusa00002921202206_en.pdf"},
    {"id":"57602","name":"Methylaminolevulinate : List of nationally authorised medicinal products - PSUSA/00002019/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T12:42:00Z","last_updated_date":"2023-02-10T12:42:00Z","reference_number":"EMA/55954/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylaminolevulinate-list-nationally-authorised-medicinal-products-psusa00002019202206_en.pdf"},
    {"id":"57603","name":"Apis mellifera (801) (with or without adjuvant), Apis mellifera venom - List of nationally authorised medicinal products - PSUSA/00010722/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T12:52:00Z","last_updated_date":"2023-02-10T12:52:00Z","reference_number":"EMA/66152/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/apis-mellifera-801-or-without-adjuvant-apis-mellifera-venom-list-nationally-authorised-medicinal-products-psusa00010722202207_en.pdf"},
    {"id":"57604","name":"Sulfamethizole - List of nationally authorised medicinal products - PSUSA/00010561/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T13:20:00Z","last_updated_date":"2023-02-10T13:20:00Z","reference_number":"EMA/915820/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulfamethizole-list-nationally-authorised-medicinal-products-psusa00010561202206_en.pdf"},
    {"id":"57606","name":"Nitrous oxide, nitrous oxide / oxygen - List of nationally authorised medicinal products - PSUSA/00010572/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T14:16:00Z","last_updated_date":"2023-02-10T14:16:00Z","reference_number":"EMA/67039/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-list-nationally-authorised-medicinal-products-psusa00010572202206_en.pdf"},
    {"id":"57611","name":"Human coagulation factor XIII : List of nationally authorised medicinal products - PSUSA/00001622/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T15:49:00Z","last_updated_date":"2023-02-10T15:49:00Z","reference_number":"EMA/67648/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-xiii-list-nationally-authorised-medicinal-products-psusa00001622202206_en.pdf"},
    {"id":"57612","name":"Germanium (68Ge) chloride / gallium (68Ga) chloride : List of nationally authorised medicinal products - PSUSA/00010364/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T15:56:00Z","last_updated_date":"2023-02-10T15:56:00Z","reference_number":"EMA/67667/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/germanium-68ge-chloride-gallium-68ga-chloride-list-nationally-authorised-medicinal-products-psusa00010364202203_en.pdf"},
    {"id":"57660","name":"Ibuprofen / pseudoephedrine - List of nationally authorised medicinal products - PSUSA/00001711/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T12:01:00Z","last_updated_date":"2023-02-14T12:01:00Z","reference_number":"EMA/71236/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa00001711202207_en.pdf"},
    {"id":"57661","name":"Allergen for therapy: betula verrucosa (sublingual use) : List of nationally authorised medicinal products - PSUSA/00010815/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T12:15:00Z","last_updated_date":"2023-02-14T12:15:00Z","reference_number":"EMA/71191/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-betula-verrucosa-sublingual-use-list-nationally-authorised-medicinal-products-psusa00010815202207_en.pdf"},
    {"id":"57662","name":"Phentermine/ topiramate - List of nationally authorised medicinal products - PSUSA/00010956/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T12:56:00Z","last_updated_date":"2023-02-14T12:56:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/phentermine-topiramate-list-nationally-authorised-medicinal-products-psusa00010956202207_en.pdf"},
    {"id":"57665","name":"Itopride : List of nationally authorised medicinal products - PSUSA/00010606/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T15:11:00Z","last_updated_date":"2023-02-14T15:11:00Z","reference_number":"PRAC/69849/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/itopride-list-nationally-authorised-medicinal-products-psusa00010606202206_en.pdf"},
    {"id":"57674","name":"Amoxicillin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000187/202203","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T11:45:00Z","last_updated_date":"2023-01-09T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/amoxicillin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000187202203_is.pdf"}},
    {"id":"57700","name":"Flecainide - List of nationally authorised medicinal products - PSUSA/00001396/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-16T16:18:00Z","last_updated_date":"2023-02-16T16:18:00Z","reference_number":"EMA/76569/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/flecainide-list-nationally-authorised-medicinal-products-psusa00001396202206_en.pdf"},
    {"id":"57764","name":"Glimepiride : List of nationally authorised medicinal products - PSUSA/00001534/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-21T16:17:00Z","last_updated_date":"2023-02-21T16:17:00Z","reference_number":"EMA/PRAC/83881/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/glimepiride-list-nationally-authorised-medicinal-products-psusa00001534202206_en.pdf"},
    {"id":"57773","name":"Piracetam : List of nationally authorised medicinal products - PSUSA/00002429/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-02-22T09:33:00Z","last_updated_date":"2023-02-22T09:33:00Z","reference_number":"EMA/84120/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/piracetam-list-nationally-authorised-medicinal-products-psusa00002429202204_en.pdf"},
    {"id":"57856","name":"Benserazide / levodopa - List of nationally authorised medicinal products - PSUSA/000000330/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-01T17:28:00Z","last_updated_date":"2023-03-01T17:28:00Z","reference_number":"EMA/99859/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/benserazide-levodopa-list-nationally-authorised-medicinal-products-psusa000000330202206_en.pdf"},
    {"id":"57857","name":"Ketotifen (ophthalmic formulations) - List of nationally authorised medicinal products - PSUSA/00001812/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-01T17:28:00Z","last_updated_date":"2023-03-01T17:28:00Z","reference_number":"EMA/100177/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketotifen-ophthalmic-formulations-list-nationally-authorised-medicinal-products-psusa00001812202206_en.pdf"},
    {"id":"57868","name":"Mitoxantrone : List of nationally authorised medicinal products - PSUSA/00002076/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-02T17:05:00Z","last_updated_date":"2023-03-02T17:05:00Z","reference_number":"EMA/101604/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/mitoxantrone-list-nationally-authorised-medicinal-products-psusa00002076202206_en.pdf"},
    {"id":"57885","name":"Methadone - List of nationally authorised medicinal products - PSUSA/00002004/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-06T12:04:00Z","last_updated_date":"2023-03-06T12:04:00Z","reference_number":"EMA/99341/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/methadone-list-nationally-authorised-medicinal-products-psusa00002004202205_en.pdf"},
    {"id":"57886","name":"Methadone - CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002004/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-06T12:07:00Z","last_updated_date":"2023-03-06T12:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002004202205_no.pdf"}},
    {"id":"57887","name":"Levomethadone - List of nationally authorised medicinal products - PSUSA/00001855/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-06T12:12:00Z","last_updated_date":"2023-03-06T12:12:00Z","reference_number":"EMA/101192/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/levomethadone-list-nationally-authorised-medicinal-products-psusa00001855202205_en.pdf"},
    {"id":"57888","name":"Levomethadone - CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001855/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-06T12:15:00Z","last_updated_date":"2023-03-06T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_de.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levomethadone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001855202205_no.pdf"}},
    {"id":"57980","name":"Esomeprazole / naproxen : List of nationally authorised medicinal products - PSUSA/00001270/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T16:41:00Z","last_updated_date":"2023-03-09T16:41:00Z","reference_number":"EMA/108915/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/esomeprazole-naproxen-list-nationally-authorised-medicinal-products-psusa00001270202204_en.pdf"},
    {"id":"57981","name":"Esomeprazole / naproxen : CMDh scientific conclusions, amendments to product information and implementation timetable - PSUSA/00001270/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T16:45:00Z","last_updated_date":"2023-03-09T16:45:00Z","reference_number":"EMA/108915/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/esomeprazole-naproxen-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-psusa00001270202204_no.pdf"}},
    {"id":"57993","name":"Venlafaxine : List of nationally authorised medicinal products - PSUSA/00003104/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-10T16:32:00Z","last_updated_date":"2023-03-10T16:32:00Z","reference_number":"EMA/115290/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/venlafaxine-list-nationally-authorised-medicinal-products-psusa00003104202205_en.pdf"},
    {"id":"57994","name":"Venlafaxine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003104/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-10T16:35:00Z","last_updated_date":"2023-03-10T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00003104202205_no.pdf"}},
    {"id":"58009","name":"Bemiparin : List of nationally authorised medicinal products - PSUSA/00000312/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-13T16:24:00Z","last_updated_date":"2023-03-13T16:24:00Z","reference_number":"EMA/119432/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/bemiparin-list-nationally-authorised-medicinal-products-psusa00000312202204_en.pdf"},
    {"id":"58010","name":"Bemiparin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000312/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-13T16:26:00Z","last_updated_date":"2023-03-13T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bemiparin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000312202204_sv.pdf"}},
    {"id":"58042","name":"Cefadroxil : List of nationally authorised medicinal products - PSUSA/00000584/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-16T12:24:00Z","last_updated_date":"2023-03-16T12:24:00Z","reference_number":"EMA/36145/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefadroxil-list-nationally-authorised-medicinal-products-psusa00000584202207_en.pdf"},
    {"id":"58043","name":"Diphtheria/tetanus/poliomyelitis (inactivated) vaccine (adsorbed, reduced antigens(s) content) : List of nationally authorised medicinal products - PSUSA/00001127/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-16T12:34:00Z","last_updated_date":"2023-03-16T12:34:00Z","reference_number":"EMA/36153/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheriatetanuspoliomyelitis-inactivated-vaccine-adsorbed-reduced-antigenss-content-list-nationally-authorised-medicinal-products-psusa00001127202208_en.pdf"},
    {"id":"58044","name":"Fosfomycin (oral formulation) : List of nationally authorised medicinal products - PSUSA/00010326/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-16T12:47:00Z","last_updated_date":"2023-03-16T12:47:00Z","reference_number":"EMA/36185/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosfomycin-oral-formulation-list-nationally-authorised-medicinal-products-psusa00010326202207_en.pdf"},
    {"id":"58045","name":"Fosfomycin (IV formulation) : List of nationally authorised medicinal products - PSUSA/00010336/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-16T14:30:00Z","last_updated_date":"2023-03-16T14:30:00Z","reference_number":"EMA/36183/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosfomycin-iv-formulation-list-nationally-authorised-medicinal-products-psusa00010336202207_en.pdf"},
    {"id":"58047","name":"Human coagulation factor IX : List of nationally authorised medicinal products - PSUSA/00001617/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-16T14:36:00Z","last_updated_date":"2023-03-16T14:36:00Z","reference_number":"EMA/101502/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-ix-list-nationally-authorised-medicinal-products-psusa00001617202207_en.pdf"},
    {"id":"58048","name":"Poliovirus type 1 / poliovirus type 2 / poliovirus type 3 vaccine (oral, live, attenuated), poliovirus type 1 / poliovirus type... : List of nationally authorised medicinal products - PSUSA/00010801/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-16T15:12:00Z","last_updated_date":"2023-03-16T15:12:00Z","reference_number":"EMA/36187/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/poliovirus-type-1-poliovirus-type-2-poliovirus-type-3-vaccine-oral-live-attenuated-poliovirus-type-1-poliovirus-type-list-nationally-authorised-medicinal-products-psusa00010801202207_en.pdf"},
    {"id":"58051","name":"Fludarabine : List of nationally authorised medicinal products - PSUSA/00001406/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-16T15:43:00Z","last_updated_date":"2023-03-16T15:43:00Z","reference_number":"EMA/30311/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fludarabine-list-nationally-authorised-medicinal-products-psusa00001406202208_en.pdf"},
    {"id":"58057","name":"Amikacin (except for centrally authorised products) : List of nationally authorised medicinal products - PSUSA/00000143/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-17T08:39:00Z","last_updated_date":"2023-03-17T08:39:00Z","reference_number":"EMA/3792/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/amikacin-except-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa00000143202206_en.pdf"},
    {"id":"58058","name":"Amikacin (except for centrally authorised products) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000143/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-17T08:42:00Z","last_updated_date":"2023-03-17T08:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amikacin-except-centrally-authorised-products-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000143202206_sv.pdf"}},
    {"id":"58059","name":"Triazolam : List of nationally authorised medicinal products - PSUSA/00003023/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-17T08:48:00Z","last_updated_date":"2023-03-17T08:48:00Z","reference_number":"EMA/126617/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/triazolam-list-nationally-authorised-medicinal-products-psusa00003023202207_en.pdf"},
    {"id":"58061","name":"Fluvoxamine : List of nationally authorised medicinal products - PSUSA/00001458/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-17T13:55:00Z","last_updated_date":"2023-03-17T13:55:00Z","reference_number":"EMA/105810/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluvoxamine-list-nationally-authorised-medicinal-products-psusa00001458202207_en.pdf"},
    {"id":"58063","name":"Pilocarpine (non-ophthalmic formulations) : List of nationally authorised medicinal products - PSUSA/00002409/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-17T16:02:00Z","last_updated_date":"2023-03-17T16:02:00Z","reference_number":"EMA/127680/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/pilocarpine-non-ophthalmic-formulations-list-nationally-authorised-medicinal-products-psusa00002409202207_en.pdf"},
    {"id":"58065","name":"Diclofenac / misoprostol : List of nationally authorised medicinal products - PSUSA/00001040/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-20T10:58:00Z","last_updated_date":"2023-03-20T10:58:00Z","reference_number":"EMA/129262/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-misoprostol-list-nationally-authorised-medicinal-products-psusa00001040202207_en.pdf"},
    {"id":"58084","name":"Triamcinolone topical and nasal formulations - List of nationally authorised medicinal products - PSUSA/00003017/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-20T16:50:00Z","last_updated_date":"2023-03-20T16:50:00Z","reference_number":"EMA/105079/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/triamcinolone-topical-and-nasal-formulations-list-nationally-authorised-medicinal-products-psusa00003017202207_en.pdf"},
    {"id":"58085","name":"Beclometasone formoterol (inhalative application) - List of nationally authorised medicinal products - PSUSA/00010068/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-20T16:58:00Z","last_updated_date":"2023-03-20T16:58:00Z","reference_number":"EMA/130085/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/beclometasone-formoterol-inhalative-application-list-nationally-authorised-medicinal-products-psusa00010068202207_en.pdf"},
    {"id":"58086","name":"Alprostadil (indicated in peripheral arterial occlusive diseases) - List of nationally authorised medicinal products - PSUSA/00000111/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-21T10:13:00Z","last_updated_date":"2023-03-21T10:13:00Z","reference_number":"EMA/132142/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprostadil-indicated-peripheral-arterial-occlusive-diseases-list-nationally-authorised-medicinal-products-psusa00000111202207_en.pdf"},
    {"id":"58087","name":"Ethinylestradiol / norethisterone : List of nationally authorised medicinal products - PSUSA/00001312/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-21T11:48:00Z","last_updated_date":"2023-03-21T11:48:00Z","reference_number":"EMA/131957/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-norethisterone-list-nationally-authorised-medicinal-products-psusa00001312202208_en.pdf"},
    {"id":"58104","name":"Ketorolac (ophthalmic formulations) - List of nationally authorised medicinal products - PSUSA/00001810/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-21T17:21:00Z","last_updated_date":"2023-03-21T17:21:00Z","reference_number":"EMA/134870/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketorolac-ophthalmic-formulations-list-nationally-authorised-medicinal-products-psusa00001810202207_en.pdf"},
    {"id":"58117","name":"Diltiazem - List of nationally authorised medicinal products - PSUSA/00001084/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-22T11:31:00Z","last_updated_date":"2023-03-22T11:31:00Z","reference_number":"EMA/134593/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/diltiazem-list-nationally-authorised-medicinal-products-psusa00001084202205_en.pdf"}    {"id":"58118","name":"Diltiazem - CMDh Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA/00001084/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-22T11:41:00Z","last_updated_date":"2023-03-22T11:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/diltiazem-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation-psusa00001084202205_no.pdf"}},
    {"id":"58129","name":"Clindamycin phosphate / tretinoin : List of nationally authorised medicinal products - PSUSA/00010080/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-03-23T09:08:00Z","last_updated_date":"2023-03-23T09:08:00Z","reference_number":"EMA/105133/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/clindamycin-phosphate-tretinoin-list-nationally-authorised-medicinal-products-psusa00010080202207_en.pdf"},
    {"id":"58284","name":"Pitavastatin - List of nationally authorised medicinal products - PSUSA/00010502/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-05T10:49:00Z","last_updated_date":"2023-04-05T10:49:00Z","reference_number":"EMA/159165/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/pitavastatin-list-nationally-authorised-medicinal-products-psusa00010502202207_en.pdf"},
    {"id":"58301","name":"Carbetocin - List of nationally authorised medicinal products - PSUSA/00000546/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-05T17:07:00Z","last_updated_date":"2023-04-05T17:07:00Z","reference_number":"EMA/160430/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbetocin-list-nationally-authorised-medicinal-products-psusa00000546202206_en.pdf"},
    {"id":"58302","name":"Carbetocin - CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000546/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-05T17:22:00Z","last_updated_date":"2023-04-05T17:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/carbetocin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000546202206_no.pdf"}},
    {"id":"58305","name":"Procyanidolic oligomers - List of nationally authorised medicinal products - PSUSA/00002537/202205","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-11T09:45:00Z","last_updated_date":"2023-04-11T09:45:00Z","reference_number":"EMA/163351/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/procyanidolic-oligomers-list-nationally-authorised-medicinal-products-psusa00002537202205_en.pdf"},
    {"id":"58306","name":"Norethisterone : List of nationally authorised medicinal products - PSUSA/00002188/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-11T10:15:00Z","last_updated_date":"2023-04-11T10:15:00Z","reference_number":"EMA/163351/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/norethisterone-list-nationally-authorised-medicinal-products-psusa00002188202208_en.pdf"},
    {"id":"58307","name":"Delapril / manidipine, delapril / indapamide : List of nationally authorised medicinal products - PSUSA/00010496/202206","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-11T10:20:00Z","last_updated_date":"2023-04-11T10:20:00Z","reference_number":"EMA/163351/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/delapril-manidipine-delapril-indapamide-list-nationally-authorised-medicinal-products-psusa00010496202206_en.pdf"},
    {"id":"58308","name":"Sodium tetradecyl sulphate - List of nationally authorised medicinal products - PSUSA/00002767/202204","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-11T10:50:00Z","last_updated_date":"2023-04-11T10:50:00Z","reference_number":"EMA/163351/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-tetradecyl-sulphate-list-nationally-authorised-medicinal-products-psusa00002767202204_en.pdf"},
    {"id":"58327","name":"Ropinirole - List of nationally authorised medicinal products - PSUSA/00002661/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-12T13:42:00Z","last_updated_date":"2023-04-12T13:42:00Z","reference_number":"EMA/164678/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropinirole-list-nationally-authorised-medicinal-products-psusa00002661202207_en.pdf"},
    {"id":"58328","name":"Ropinirole - CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002661/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-12T13:45:00Z","last_updated_date":"2023-04-12T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ropinirole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002661202207_no.pdf"}},
    {"id":"58356","name":"Minocycline  - List of nationally authorised medicinal products - PSUSA/00002065/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-14T15:32:00Z","last_updated_date":"2023-04-14T15:32:00Z","reference_number":"EMA/74502/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/minocycline-list-nationally-authorised-medicinal-products-psusa00002065202208_en.pdf"},
    {"id":"58361","name":"Piperacillin / tazobactam - List of nationally authorised medicinal products - PSUSA/00002425/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-14T16:56:00Z","last_updated_date":"2023-04-14T16:56:00Z","reference_number":"EMA/88670/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/piperacillin-tazobactam-list-nationally-authorised-medicinal-products-psusa00002425202209_en.pdf"},
    {"id":"58362","name":"Dornase alpha - List of nationally authorised medicinal products - PSUSA/00001164/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-14T17:59:00Z","last_updated_date":"2023-04-14T17:59:00Z","reference_number":"EMA/172208/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/dornase-alpha-list-nationally-authorised-medicinal-products-psusa00001164202209_en.pdf"},
    {"id":"58366","name":"Allergen for therapy: dermatophagoides pteronyssinus/dermatophagoides farina (oromucosal use, products authorised via mutually recognition and decentralised procedure) : List of nationally authorised medicinal products - PSUSA/00010582/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-17T11:39:00Z","last_updated_date":"2023-04-17T11:39:00Z","reference_number":"EMA/173365/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-dermatophagoides-pteronyssinusdermatophagoides-farina-oromucosal-use-products-authorised-mutually-recognition-and-decentralised-procedure-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"58368","name":"Tretinoin (topical formulations) : List of nationally authorised medicinal products - PSUSA/00003016/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-17T12:24:00Z","last_updated_date":"2023-04-17T12:24:00Z","reference_number":"EMA/173475/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/tretinoin-topical-formulations-list-nationally-authorised-medicinal-products-psusa00003016202208_en.pdf"},
    {"id":"58370","name":"Treosulfan (except for centrally authorised product) : List of nationally authorised medicinal products - PSUSA/00009319/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-17T13:00:00Z","last_updated_date":"2023-04-17T13:00:00Z","reference_number":"EMA/136484/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/treosulfan-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00009319202208_en.pdf"},
    {"id":"58387","name":"Choline alfoscerate : List of nationally authorised medicinal products - PSUSA/00010599/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-17T15:57:00Z","last_updated_date":"2023-04-17T15:57:00Z","reference_number":"EMA/174242/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/choline-alfoscerate-list-nationally-authorised-medicinal-products-psusa00010599202208_en.pdf"},
    {"id":"58389","name":"Dexamfetamine : List of nationally authorised medicinal products - PSUSA/00000986/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-17T16:03:00Z","last_updated_date":"2023-04-17T16:03:00Z","reference_number":"EMA/174356/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-psusa00000986202209_en.pdf"},
    {"id":"58392","name":"Biperiden : List of nationally authorised medicinal products - PSUSA/00000415/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-17T16:23:00Z","last_updated_date":"2023-04-17T16:23:00Z","reference_number":"EMA/174484/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/biperiden-list-nationally-authorised-medicinal-products-psusa00000415202208_en.pdf"},
    {"id":"58399","name":"Paricalcitol - List of nationally authorised medicinal products - PSUSA/00002316/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-17T17:53:00Z","last_updated_date":"2023-04-17T17:53:00Z","reference_number":"EMA/174310/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/paricalcitol-list-nationally-authorised-medicinal-products-psusa00002316202208_en.pdf"},
    {"id":"58401","name":"Fluoxetine - List of nationally authorised medicinal products - PSUSA/00001442/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-18T11:28:00Z","last_updated_date":"2023-04-18T11:28:00Z","reference_number":"EMA/175273/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluoxetine-list-nationally-authorised-medicinal-products-psusa00001442202209_en.pdf"},
    {"id":"58402","name":"Drospirenone / ethinylestradiol - List of nationally authorised medicinal products - PSUSA/00010217/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-18T11:57:00Z","last_updated_date":"2023-04-18T11:57:00Z","reference_number":"EMA/175074/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/drospirenone-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa00010217202209_en.pdf"},
    {"id":"58414","name":"Fluvastatin : List of nationally authorised medicinal products - PSUSA/00001457/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-04-19T10:52:00Z","last_updated_date":"2023-04-19T10:52:00Z","reference_number":"EMA/163351/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluvastatin-list-nationally-authorised-medicinal-products-psusa00001457202208_en.pdf"},
    {"id":"58589","name":"Ketorolac (systemic formulations) : List of nationally authorised medicinal products - PSUSA-00001811-202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-05T09:24:00Z","last_updated_date":"2023-05-05T09:24:00Z","reference_number":"EMA/205290/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketorolac-systemic-formulations-list-nationally-authorised-medicinal-products-psusa-00001811-202207_en.pdf"},
    {"id":"58590","name":"Ketorolac (systemic formulations) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA-00001811-202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-05T09:31:00Z","last_updated_date":"2023-05-05T09:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ketorolac-systemic-formulations-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001811-202207_is.pdf"}},
    {"id":"58621","name":"Meloxicam : List of nationally authorised medicinal products - PSUSA/00010474/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-11T09:16:00Z","last_updated_date":"2023-06-02T10:08:00Z","reference_number":"EMA/215601/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/meloxicam-list-nationally-authorised-medicinal-products-psusa00010474202207_en.pdf"},
    {"id":"58622","name":"Meloxicam : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010474/202207","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-11T09:29:00Z","last_updated_date":"2023-05-11T09:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/meloxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00010474202207_sv.pdf"}},
    {"id":"58670","name":"Artemether / lumefantrin (apart from the dispersible tablet) : List of nationally authorised medicinal products - PSUSA/00000236/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:20:00Z","last_updated_date":"2023-05-12T16:20:00Z","reference_number":"EMA/88681/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-list-nationally-authorised-medicinal-products-psusa00000236202210_en.pdf"},
    {"id":"58671","name":"Terbinafine : List of nationally authorised medicinal products - PSUSA/00002896/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:26:00Z","last_updated_date":"2023-05-12T16:26:00Z","reference_number":"EMA/88707/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/terbinafine-list-nationally-authorised-medicinal-products-psusa00002896202209_en.pdf"},
    {"id":"58672","name":"Bromhexine : List of nationally authorised medicinal products - PSUSA/00000437/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:31:00Z","last_updated_date":"2023-05-12T16:31:00Z","reference_number":"EMA/219604/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromhexine-list-nationally-authorised-medicinal-products-psusa00000437202209_en.pdf"},
    {"id":"58691","name":"Trifarotene : List of nationally authorised medicinal products - PSUSA/00010929/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-15T16:07:00Z","last_updated_date":"2023-05-15T16:07:00Z","reference_number":"EMA/199890/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/trifarotene-list-nationally-authorised-medicinal-products-psusa00010929202210_en.pdf"},
    {"id":"58695","name":"Lysine acetylsalicylate : List of nationally authorised medicinal products - PSUSA/00001921/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-16T09:17:00Z","last_updated_date":"2023-05-16T09:17:00Z","reference_number":"EMA/PRAC/222132/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/lysine-acetylsalicylate-list-nationally-authorised-medicinal-products-psusa00001921202209_en.pdf"},
    {"id":"58697","name":"Ambroxol : List of nationally authorised medicinal products - PSUSA/00000130/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-16T11:52:00Z","last_updated_date":"2023-05-16T11:52:00Z","reference_number":"EMA/221899/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ambroxol-list-nationally-authorised-medicinal-products-psusa00000130202209_en.pdf"},
    {"id":"58698","name":"Ambroxol / clenbuterol : List of nationally authorised medicinal products - PSUSA/00000131/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-16T11:59:00Z","last_updated_date":"2023-05-16T11:59:00Z","reference_number":"EMA/221901/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ambroxol-clenbuterol-list-nationally-authorised-medicinal-products-psusa00000131202209_en.pdf"},
    {"id":"58700","name":"Aminosalicylic acid - List of nationally authorised medicinal products - PSUSA/00000165/202210","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2023-05-16T14:41:00Z","last_updated_date":"2023-05-16T14:41:00Z","reference_number":"EMA/223477/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/aminosalicylic-acid-list-nationally-authorised-medicinal-products-psusa00000165202210_en.pdf"},
    {"id":"58764","name":"Felbamate : List of nationally authorised medicinal products - PSUSA/00010155/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T13:09:00Z","last_updated_date":"2023-05-24T13:09:00Z","reference_number":"EMA/236371/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/felbamate-list-nationally-authorised-medicinal-products-psusa00010155202209_en.pdf"},
    {"id":"58765","name":"Etomidate : List of nationally authorised medicinal products - PSUSA/00001330/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T13:17:00Z","last_updated_date":"2023-05-24T13:17:00Z","reference_number":"EMA/236429/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/etomidate-list-nationally-authorised-medicinal-products-psusa00001330202209_en.pdf"},
    {"id":"58767","name":"Etidronate : List of nationally authorised medicinal products - PSUSA/00001320/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T13:40:00Z","last_updated_date":"2023-05-24T13:40:00Z","reference_number":"EMA/238177/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/etidronate-list-nationally-authorised-medicinal-products-psusa00001320202209_en.pdf"},
    {"id":"58843","name":"Dinoprostone : List of nationally authorised medicinal products - PSUSA/00001104/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-01T10:39:00Z","last_updated_date":"2023-06-01T10:39:00Z","reference_number":"EMA/249962/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/dinoprostone-list-nationally-authorised-medicinal-products-psusa00001104202209_en.pdf"},
    {"id":"58862","name":"Midazolam (all pharmaceutical forms and indications apart from oromucosal solution indicated for the treatment of prolonged, acute, convulsive seizures) : List of nationally authorised medicinal products -  PSUSA/00002057/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-02T13:41:00Z","last_updated_date":"2023-06-02T13:41:00Z","reference_number":"EMA/253285/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-indicated-treatment-prolonged-acute-convulsive-seizures-list-nationally-authorised-medicinal-products-psusa00002057202209_en.pdf"},
    {"id":"58863","name":"Midazolam (all pharmaceutical forms and indications apart from oromucosal solution....) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002057/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-02T13:46:00Z","last_updated_date":"2023-06-02T13:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/midazolam-all-pharmaceutical-forms-and-indications-apart-oromucosal-solution-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation_no.pdf"}},
    {"id":"58871","name":"Adenosine : List of nationally authorised medicinal products - PSUSA/00000062/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-05T16:06:00Z","last_updated_date":"2023-06-05T16:06:00Z","reference_number":"EMA/256826/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/adenosine-list-nationally-authorised-medicinal-products-psusa00000062202208_en.pdf"},
    {"id":"58872","name":"Adenosine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000062/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-05T16:08:00Z","last_updated_date":"2023-06-05T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/adenosine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000062202208_no.pdf"}},
    {"id":"58889","name":"Tixocortol, chlorhexidine gluconate / tixocortol pivalate : List of nationally authorised medicinal products - PSUSA/00010333/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-08T13:20:00Z","last_updated_date":"2023-06-08T13:20:00Z","reference_number":"EMA/74545/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/tixocortol-chlorhexidine-gluconate-tixocortol-pivalate-list-nationally-authorised-medicinal-products-psusa00010333202211_en.pdf"},
    {"id":"58890","name":"Atovaquone / proguanil : List of nationally authorised medicinal products - PSUSA/00000266/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-08T13:26:00Z","last_updated_date":"2023-06-08T13:26:00Z","reference_number":"EMA/74537/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/atovaquone-proguanil-list-nationally-authorised-medicinal-products-psusa00000266202210_en.pdf"},
    {"id":"58892","name":"Human coagulation factor VII : List of nationally authorised medicinal products - PSUSA/00001619/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-08T15:22:00Z","last_updated_date":"2023-06-08T15:22:00Z","reference_number":"EMA/250686/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-vii-list-nationally-authorised-medicinal-products-psusa00001619202210_en.pdf"},
    {"id":"58895","name":"Epinastine : List of nationally authorised medicinal products - PSUSA/00001231/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-08T16:28:00Z","last_updated_date":"2023-06-08T16:28:00Z","reference_number":"EMA/264551/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/epinastine-list-nationally-authorised-medicinal-products-psusa00001231202210_en.pdf"},
    {"id":"58906","name":"Isoflurane : List of nationally authorised medicinal products - PSUSA/00001786/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-09T13:00:00Z","last_updated_date":"2023-06-09T13:00:00Z","reference_number":"EMA/265290/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoflurane-list-nationally-authorised-medicinal-products-psusa00001786202211_en.pdf"},
    {"id":"58912","name":"Acitretin : List of nationally authorised medicinal products - PSUSA/00000051/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-09T15:21:00Z","last_updated_date":"2023-06-09T15:21:00Z","reference_number":"EMA/267123/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-list-nationally-authorised-medicinal-products-psusa00000051202210_en.pdf"},
    {"id":"58921","name":"Clevidipine : List of nationally authorised medicinal products - PSUSA/00010288/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-12T15:21:00Z","last_updated_date":"2023-06-12T15:21:00Z","reference_number":"EMA/269644/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa00010288202211_en.pdf"},
    {"id":"58922","name":"Rubidium (82Rb) chloride : List of nationally authorised medicinal products - PSUSA/00010806/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-12T16:07:00Z","last_updated_date":"2023-06-12T16:07:00Z","reference_number":"EMA/269013/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/rubidium-82rb-chloride-list-nationally-authorised-medicinal-products-psusa00010806202210_en.pdf"},
    {"id":"58933","name":"Lenograstim : List of nationally authorised medicinal products - PSUSA/00001839/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-13T11:27:00Z","last_updated_date":"2023-06-13T11:27:00Z","reference_number":"EMA/270213/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/lenograstim-list-nationally-authorised-medicinal-products-psusa00001839202210_en.pdf"},
    {"id":"58963","name":"Valsartan / rosuvastatin : List of nationally authorised medicinal products - PSUSA/00010735/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-15T14:12:00Z","last_updated_date":"2023-06-15T14:12:00Z","reference_number":"EMA/276650/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/valsartan-rosuvastatin-list-nationally-authorised-medicinal-products-psusa00010735202210_en.pdf"},
    {"id":"58967","name":"Ezetimibe : List of nationally authorised medicinal products - PSUSA/00001346/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-16T09:20:00Z","last_updated_date":"2023-06-16T09:20:00Z","reference_number":"EMA/275106/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ezetimibe-list-nationally-authorised-medicinal-products-psusa00001346202210_en.pdf"},
    {"id":"59095","name":"Clenbuterol : List of nationally authorised medicinal products - PSUSA/00000794/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-26T16:52:00Z","last_updated_date":"2023-06-26T16:52:00Z","reference_number":"EMA/294361/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/clenbuterol-list-nationally-authorised-medicinal-products-psusa00000794202209_en.pdf"},
    {"id":"59096","name":"Clenbuterol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000794/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-26T16:54:00Z","last_updated_date":"2023-06-26T16:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_bg.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/clenbuterol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000794202209_sv.pdf"}},
    {"id":"59109","name":"Famotidine : List of nationally authorised medicinal products - PSUSA/00001350/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-27T11:19:00Z","last_updated_date":"2023-06-27T11:19:00Z","reference_number":"EMA/295187/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/famotidine-list-nationally-authorised-medicinal-products-psusa00001350202209_en.pdf"},
    {"id":"59110","name":"Famotidine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001350/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-27T11:33:00Z","last_updated_date":"2023-06-27T11:33:00Z","reference_number":"EMA/295187/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/famotidine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001350202209_no.pdf"}},
    {"id":"59152","name":"Carbidopa / levodopa : List of nationally authorised medicinal products - PSUSA/00000548/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T09:33:00Z","last_updated_date":"2023-06-30T09:33:00Z","reference_number":"EMA/301745/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbidopa-levodopa-list-nationally-authorised-medicinal-products-psusa00000548202210_en.pdf"},
    {"id":"59154","name":"Carbidopa / levodopa : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000548/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T09:35:00Z","last_updated_date":"2023-06-30T09:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/carbidopa-levodopa-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000548202210_no.pdf"}},
    {"id":"59215","name":"Fenoterol (respiratory indications) : List of nationally authorised medicinal products - PSUSA/00001366/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-04T13:15:00Z","last_updated_date":"2023-07-04T13:15:00Z","reference_number":"EMA/224103/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenoterol-respiratory-indications-list-nationally-authorised-medicinal-products-psusa00001366202209_en.pdf"},
    {"id":"59216","name":"Fenoterol (respiratory indications) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001366/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-04T13:18:00Z","last_updated_date":"2023-07-04T13:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fenoterol-respiratory-indications-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00001366202209_no.pdf"}},
    {"id":"59218","name":"Ropivacaine : List of nationally authorised medicinal products - PSUSA/00002662/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-04T15:54:00Z","last_updated_date":"2023-07-04T15:54:00Z","reference_number":"EMA/297380/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropivacaine-list-nationally-authorised-medicinal-products-psusa00002662202209_en.pdf"},
    {"id":"59219","name":"Ropivacaine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002662/202209","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-04T15:57:00Z","last_updated_date":"2023-07-04T15:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ropivacaine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002662202209_no.pdf"}},
    {"id":"59276","name":"Polystyrene sulfonate : List of nationally authorised medicinal products - PSUSA/00002472/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-06T14:09:00Z","last_updated_date":"2023-07-06T14:09:00Z","reference_number":"EMA/313560/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/polystyrene-sulfonate-list-nationally-authorised-medicinal-products-psusa00002472202210_en.pdf"},
    {"id":"59277","name":"Polystyrene sulfonate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002472/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-06T14:11:00Z","last_updated_date":"2023-07-06T14:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/polystyrene-sulfonate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00002472202210_no.pdf"}},
    {"id":"59283","name":"Anti-T lymphocyte immunoglobulin for human use, horse : List of nationally authorised medicinal products - PSUSA/00010433/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-06T15:15:00Z","last_updated_date":"2023-07-06T15:15:00Z","reference_number":"EMA/292426/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/anti-t-lymphocyte-immunoglobulin-human-use-horse-list-nationally-authorised-medicinal-products-psusa00010433202211_en.pdf"},
    {"id":"59284","name":"Propofol : List of nationally authorised medicinal products - PSUSA/00002555/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-06T15:36:00Z","last_updated_date":"2023-07-06T15:36:00Z","reference_number":"EMA/315299/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/propofol-list-nationally-authorised-medicinal-products-psusa00002555202211_en.pdf"},
    {"id":"59289","name":"Econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide : List of nationally authorised medicinal products - PSUSA/00001195/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-07T09:19:00Z","last_updated_date":"2023-07-07T09:19:00Z","reference_number":"EMA/315456/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/econazole-econazole-nitrate-triamcinolone-acetonide-econazole-nitrate-zinc-oxide-list-nationally-authorised-medicinal-products-psusa00001195202211_en.pdf"},
    {"id":"59290","name":"Bambuterol : List of nationally authorised medicinal products - PSUSA/00000295/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-07T09:25:00Z","last_updated_date":"2023-07-07T09:25:00Z","reference_number":"EMA/315617/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/bambuterol-list-nationally-authorised-medicinal-products-psusa00000295202212_en.pdf"},
    {"id":"59294","name":"Bacillus clausii multi-antibioresistant spores : List of nationally authorised medicinal products - PSUSA/00000284/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-07T11:42:00Z","last_updated_date":"2023-07-07T11:42:00Z","reference_number":"EMA/112269/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/bacillus-clausii-multi-antibioresistant-spores-list-nationally-authorised-medicinal-products-psusa00000284202211_en.pdf"},
    {"id":"59300","name":"Caffeine / ergotamine : List of nationally authorised medicinal products - PSUSA/00000485/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-07T13:24:00Z","last_updated_date":"2023-07-07T13:24:00Z","reference_number":"EMA/314675/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/caffeine-ergotamine-list-nationally-authorised-medicinal-products-psusa00000485202211_en.pdf"},
    {"id":"59307","name":"Cetirizine : List of nationally authorised medicinal products - PSUSA/00000628/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-07T16:43:00Z","last_updated_date":"2023-07-07T16:43:00Z","reference_number":"EMA/316182/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/cetirizine-list-nationally-authorised-medicinal-products-psusa00000628202211_en.pdf"},
    {"id":"59310","name":"Alfuzosin : List of nationally authorised medicinal products - PSUSA/00000084/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-10T14:01:00Z","last_updated_date":"2023-07-10T14:01:00Z","reference_number":"EMA/319330/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/alfuzosin-list-nationally-authorised-medicinal-products-psusa00000084202211_en.pdf"},
    {"id":"59312","name":"Dutasteride, dutasteride / tamsulosine : List of nationally authorised medicinal products - PSUSA/00010506/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-10T15:46:00Z","last_updated_date":"2023-07-10T15:46:00Z","reference_number":"EMA/319544/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/dutasteride-dutasteride-tamsulosine-list-nationally-authorised-medicinal-products-psusa00010506202211_en.pdf"},
    {"id":"59314","name":"Brotizolam : List of nationally authorised medicinal products - PSUSA/00000444/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-10T16:38:00Z","last_updated_date":"2023-07-10T16:38:00Z","reference_number":"EMA/320180/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/brotizolam-list-nationally-authorised-medicinal-products-psusa00000444202212_en.pdf"},
    {"id":"59318","name":"Naltrexone : List of nationally authorised medicinal products - PSUSA/00002117/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-11T09:28:00Z","last_updated_date":"2023-07-11T09:28:00Z","reference_number":"EMA/320303/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/naltrexone-list-nationally-authorised-medicinal-products-psusa00002117202211_en.pdf"},
    {"id":"59325","name":"Dienogest : List of nationally authorised medicinal products - PSUSA/00003167/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T08:45:00Z","last_updated_date":"2023-07-12T08:45:00Z","reference_number":"EMA/321856/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/dienogest-list-nationally-authorised-medicinal-products-psusa00003167202212_en.pdf"},
    {"id":"59337","name":"Levocabastine : List of nationally authorised medicinal products - PSUSA/00001849/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T11:46:00Z","last_updated_date":"2023-07-12T11:46:00Z","reference_number":"EMA/323829/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/levocabastine-list-nationally-authorised-medicinal-products-psusa00001849202211_en.pdf"},
    {"id":"59338","name":"Sodium fluoride (18F) : List of nationally authorised medicinal products - PSUSA/00010706/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T11:51:00Z","last_updated_date":"2023-07-12T11:51:00Z","reference_number":"EMA/275473/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-fluoride-18f-list-nationally-authorised-medicinal-products-psusa00010706202211_en.pdf"},
    {"id":"59388","name":"Bromperidol: List of nationally authorised medicinal products - PSUSA/00000439/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-18T16:14:00Z","last_updated_date":"2023-07-18T16:14:00Z","reference_number":"EMA/328244/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromperidol-list-nationally-authorised-medicinal-products-psusa00000439202211_en.pdf"},
    {"id":"59389","name":"Amlodipine / indapamide, amlodipine / indapamide / perindopril: List of nationally authorised medicinal products - PSUSA/00010358/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-18T16:25:00Z","last_updated_date":"2023-07-18T16:25:00Z","reference_number":"EMA/327585/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-indapamide-amlodipine-indapamide-perindopril-list-nationally-authorised-medicinal-products-psusa00010358202211_en.pdf"},
    {"id":"59390","name":"Hydroxycarbamide (except for centrally authorised product): List of nationally authorised medicinal products - PSUSA/00009182/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-07-18T16:28:00Z","last_updated_date":"2023-07-18T16:28:00Z","reference_number":"EMA/327388/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa00009182202212_en.pdf"},
    {"id":"59546","name":"Yellow fever vaccine (live) : List of nationally authorised medicinal products - PSUSA/00003135/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-03T12:39:00Z","last_updated_date":"2023-08-03T12:39:00Z","reference_number":"EMA/312009/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/yellow-fever-vaccine-live-list-nationally-authorised-medicinal-products-psusa00003135202212_en.pdf"},
    {"id":"59547","name":"Inactivated leptospire vaccine : List of nationally authorised medicinal products - PSUSA/00010813/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-03T12:45:00Z","last_updated_date":"2023-08-03T12:45:00Z","reference_number":"EMA/312210/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/inactivated-leptospire-vaccine-list-nationally-authorised-medicinal-products-psusa00010813202211_en.pdf"},
    {"id":"59568","name":"morphine / cyclizine : List of nationally authorised medicinal products - PSUSA/00010549/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-08T15:26:00Z","last_updated_date":"2023-08-08T15:26:00Z","reference_number":"EMA/356967/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/morphine-cyclizine-list-nationally-authorised-medicinal-products-psusa00010549202210_en.pdf"},
    {"id":"59569","name":"Morphine / cyclizine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010549/202210","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-08T15:40:00Z","last_updated_date":"2023-08-08T15:40:00Z","reference_number":"EMA/356967/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/morphine-cyclizine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010549-202210_no.pdf"}},
    {"id":"59619","name":"Yellow fever vaccine (live) : List of nationally authorised medicinal products - PSUSA/00003135/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-24T12:37:00Z","last_updated_date":"2023-08-24T12:37:00Z","reference_number":"EMA/312009/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/yellow-fever-vaccine-live-list-nationally-authorised-medicinal-products-psusa00003135202212_en.pdf-0"},
    {"id":"59633","name":"Apomorphine : List of nationally authorised medicinal products - PSUSA/00000227/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-25T11:45:00Z","last_updated_date":"2023-08-25T11:45:00Z","reference_number":"EMA/384442/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/apomorphine-list-nationally-authorised-medicinal-products-psusa00000227202211_en.pdf"},
    {"id":"59634","name":"Apomorphine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000227/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-25T11:48:00Z","last_updated_date":"2023-08-25T11:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/apomorphine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000227-202211_no.pdf"}},
    {"id":"59870","name":"Cisplatin : List of nationally authorised medicinal products - PSUSA-00000778-202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-31T13:42:00Z","last_updated_date":"2023-08-31T13:42:00Z","reference_number":"EMA/385671/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/cisplatin-list-nationally-authorised-medicinal-products-psusa-00000778-202212_en.pdf"},
    {"id":"59871","name":"Amisulpride : List of nationally authorised medicinal products - PSUSA/00000167/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-31T14:58:00Z","last_updated_date":"2023-08-31T14:58:00Z","reference_number":"EMA/376318/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/amisulpride-list-nationally-authorised-medicinal-products-psusa-00000167-202301_en.pdf"},
    {"id":"59872","name":"Hypericum perforatum L., herba : List of nationally authorised medicinal products - PSUSA/00001701/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-31T15:04:00Z","last_updated_date":"2023-08-31T15:04:00Z","reference_number":"EMA/367459/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/hypericum-perforatum-l-herba-list-nationally-authorised-medicinal-products-psusa-00001701-202301_en.pdf"},
    {"id":"59873","name":"Atracurium : List of nationally authorised medicinal products - PSUSA/00000267/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-31T15:09:00Z","last_updated_date":"2023-08-31T15:09:00Z","reference_number":"EMA/384684/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/atracurium-list-nationally-authorised-medicinal-products-psusa-00000267-202212_en.pdf"},
    {"id":"59874","name":"Codeine camphosulphonate / sodium benzoate, codeine camphosulphonate / sulfogaiacol / grindelia soft extract : List of nationally authorised medicinal products - PSUSA/00010542/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-08-31T15:15:00Z","last_updated_date":"2023-08-31T15:15:00Z","reference_number":"EMA/384917/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/codeine-camphosulphonate-sodium-benzoate-codeine-camphosulphonate-sulfogaiacol-grindelia-soft-extract-list-nationally-authorised-medicinal-products-psusa-00010542-202212_en.pdf"},
    {"id":"59877","name":"Allergen for therapy: Dactylis Glomerata L., Phleum Pratense L., Anthoxanthum Odoratum L., Lolium Perenne L., Poa Pratensis L.(sublingual tablet) : List of nationally authorised medicinal products - PSUSA/00010465/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T08:55:00Z","last_updated_date":"2023-09-01T08:55:00Z","reference_number":"EMA/395418/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-dactylis-glomerata-l-phleum-pratense-l-anthoxanthum-odoratum-l-lolium-perenne-l-poa-pratensis-lsublingual-tablet-list-nationally-authorised-medicinal-products-psusa-00010465-202212_en.pdf"},
    {"id":"59880","name":"Cefprozil : List of nationally authorised medicinal products - PSUSA/00000605/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T11:51:00Z","last_updated_date":"2023-09-01T11:51:00Z","reference_number":"EMA/297212/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefprozil-list-nationally-authorised-medicinal-products-psusa-00000605-202212_en.pdf"},
    {"id":"59881","name":"Tetanus vaccines : List of nationally authorised medicinal products - PSUSA/00002910/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T11:55:00Z","last_updated_date":"2023-09-01T11:55:00Z","reference_number":"EMA/319020/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/tetanus-vaccines-list-nationally-authorised-medicinal-products-psusa-00002910-202301_en.pdf"},
    {"id":"59883","name":"5 fluorouracil (topical application) : List of nationally authorised medicinal products - PSUSA/00010000/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T12:05:00Z","last_updated_date":"2023-09-01T12:05:00Z","reference_number":"EMA/380530/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-topical-application-list-nationally-authorised-medicinal-products-psusa-00010000-202301_en.pdf"}    {"id":"59887","name":"Alitretinoin (oral use) : List of nationally authorised medicinal products - PSUSA/00010710/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T17:03:00Z","last_updated_date":"2023-09-01T17:03:00Z","reference_number":"EMA/397638/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/alitretinoin-oral-use-list-nationally-authorised-medicinal-products-psusa-00010710-202301_en.pdf"},
    {"id":"59900","name":"Flurbiprofen : List of nationally authorised medicinal products - PSUSA/00001450/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-05T12:31:00Z","last_updated_date":"2023-09-05T12:31:00Z","reference_number":"EMA/384493/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/flurbiprofen-list-nationally-authorised-medicinal-products-psusa-00001450-202211_en.pdf"},
    {"id":"59901","name":"Flurbiprofen : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001450/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-05T12:34:00Z","last_updated_date":"2023-09-08T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/flurbiprofen-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001450-202211_no.pdf"}},
    {"id":"59917","name":"Sertindole : List of nationally authorised medicinal products - PSUSA/00002695/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-08T11:48:00Z","last_updated_date":"2023-09-08T11:48:00Z","reference_number":"EMA/408426/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/sertindole-list-nationally-authorised-medicinal-products-psusa-00002695-202301_en.pdf"},
    {"id":"59923","name":"Levobupivacaine : List of nationally authorised medicinal products - PSUSA/00001848/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-08T14:17:00Z","last_updated_date":"2023-09-08T14:17:00Z","reference_number":"EMA/409045/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/levobupivacaine-list-nationally-authorised-medicinal-products-psusa-00001848-202212_en.pdf"},
    {"id":"59932","name":"Lamotrigine : List of nationally authorised medicinal products - PSUSA/00001825/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-12T08:24:00Z","last_updated_date":"2023-09-12T08:24:00Z","reference_number":"EMA/412983/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/lamotrigine-list-nationally-authorised-medicinal-products-psusa-00001825-202211_en.pdf"},
    {"id":"59933","name":"Lamotrigine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001825/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-12T08:26:00Z","last_updated_date":"2023-09-12T08:26:00Z","reference_number":"EMA/412983/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lamotrigine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001825-202211_no.pdf"}},
    {"id":"59939","name":"Cimicifuga racemosa (L.) nutt., rhizoma : List of nationally authorised medicinal products - PSUSA/00000755/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-12T16:53:00Z","last_updated_date":"2023-09-12T16:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cimicifuga-racemosa-l-nutt-rhizoma-list-nationally-authorised-medicinal-products-psusa-00000755-202301_en.pdf"},
    {"id":"59940","name":"Cilostazol : List of nationally authorised medicinal products - PSUSA/00010209/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-12T17:01:00Z","last_updated_date":"2023-09-12T17:01:00Z","reference_number":"PSUSA/00010209/202301","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilostazol-list-nationally-authorised-medicinal-products-psusa-00010209-202301_en.pdf"},
    {"id":"60070","name":"Calcium chloride dihydrate/magnesium chloride hexahydrate/malic acid/sodium acetate trihydrate/sodium chloride....potassium chloride : List of nationally authorised medicinal products - PSUSA/00010622/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-20T10:20:00Z","last_updated_date":"2023-09-20T10:20:00Z","reference_number":"EMA/38225/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-chloride-dihydrate-magnesium-chloride-hexahydrate-malic-acid-sodium-acetate-trihydrate-sodium-chloridepotassium-chloride-list-nationally-authorised-medicinal-products-psusa-00010622-202301_en.pdf"},
    {"id":"60197","name":"Fenoterol / ipratropium : List of nationally authorised medicinal products - PSUSA/00001367/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-28T16:08:00Z","last_updated_date":"2023-09-28T16:08:00Z","reference_number":"EMA/438193/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenoterol-ipratropium-list-nationally-authorised-medicinal-products-psusa-00001367-202302_en.pdf"},
    {"id":"60202","name":"Influenza vaccine (surface antigen, inactivated) : List of nationally authorised medicinal products - PSUSA/00001744/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T10:08:00Z","last_updated_date":"2023-09-29T10:08:00Z","reference_number":"EMA/348780/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa-00001744-202303_en.pdf"},
    {"id":"60203","name":"Haemophilus type b and meningococcal group C conjugate vaccine : List of nationally authorised medicinal products - PSUSA/00001583/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T10:28:00Z","last_updated_date":"2023-09-29T10:28:00Z","reference_number":"EMA/396846/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/haemophilus-type-b-and-meningococcal-group-c-conjugate-vaccine-list-nationally-authorised-medicinal-products-psusa-00001583-202302_en.pdf"},
    {"id":"60204","name":"Influenza vaccine (split virion, inactivated) (non centrally authorised products) : List of nationally authorised medicinal products - PSUSA/00010298/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T10:35:00Z","last_updated_date":"2023-09-29T10:35:00Z","reference_number":"EMA/348784/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa-00010298-202303_en.pdf"},
    {"id":"60205","name":"Sodium citrate (extracorporeal use) : List of nationally authorised medicinal products - PSUSA/00010986/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T10:38:00Z","last_updated_date":"2023-09-29T10:38:00Z","reference_number":"EMA/433904/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-citrate-extracorporeal-use-list-nationally-authorised-medicinal-products-psusa-00010986-202301_en.pdf"},
    {"id":"60206","name":"Ipratropium : List of nationally authorised medicinal products - PSUSA/00001780/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T10:50:00Z","last_updated_date":"2023-09-29T10:50:00Z","reference_number":"EMA/437314/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ipratropium-list-nationally-authorised-medicinal-products-psusa-00001780-202301_en.pdf"},
    {"id":"60207","name":"Ipratropium / salbutamol : List of nationally authorised medicinal products - PSUSA/00001781/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T10:57:00Z","last_updated_date":"2023-09-29T10:57:00Z","reference_number":"EMA/437316/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ipratropium-salbutamol-list-nationally-authorised-medicinal-products-psusa-00001781-202301_en.pdf"},
    {"id":"60208","name":"Haemophilus type b conjugate vaccines : List of nationally authorised medicinal products - PSUSA/00001584/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T11:04:00Z","last_updated_date":"2023-09-29T11:04:00Z","reference_number":"EMA/415567/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/haemophilus-type-b-conjugate-vaccines-list-nationally-authorised-medicinal-products-psusa-00001584-202302_en.pdf"},
    {"id":"60209","name":"Saccharomyces boulardii : List of nationally authorised medicinal products - PSUSA/00009284/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T11:24:00Z","last_updated_date":"2023-09-29T11:24:00Z","reference_number":"EMA/439094/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/saccharomyces-boulardii-list-nationally-authorised-medicinal-products-psusa-00009284-202302_en.pdf"},
    {"id":"60210","name":"Mefloquine : List of nationally authorised medicinal products - PSUSA/00001955/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T11:31:00Z","last_updated_date":"2023-09-29T11:31:00Z","reference_number":"EMA/319035/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/mefloquine-list-nationally-authorised-medicinal-products-psusa-00001955-202302_en.pdf"},
    {"id":"60244","name":"Dacarbazine : List of nationally authorised medicinal products - PSUSA/00000919/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-04T09:26:00Z","last_updated_date":"2023-10-04T09:26:00Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/dacarbazine-list-nationally-authorised-medicinal-products-psusa-00000919-202302_en.pdf"},
    {"id":"60249","name":"Tauroselcholic [75Se] acid : List of nationally authorised medicinal products - PSUSA/00010486/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-04T15:50:00Z","last_updated_date":"2023-10-04T15:50:00Z","reference_number":"EMA/448857/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/tauroselcholic-75se-acid-list-nationally-authorised-medicinal-products-psusa-00010486-202301_en.pdf"},
    {"id":"60447","name":"Lisdexamfetamine: List of nationally authorised medicinal products - PSUSA/00010289/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-17T16:46:00Z","last_updated_date":"2023-10-17T16:46:00Z","reference_number":"EMA/467828/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa-00010289-202302_en.pdf"},
    {"id":"60458","name":"Paroxetine : List of nationally authorised medicinal products - PSUSA/00002319/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-20T11:36:00Z","last_updated_date":"2023-10-20T11:36:00Z","reference_number":"EMA/419197/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/paroxetine-list-nationally-authorised-medicinal-products-psusa-00002319-202212_en.pdf"},
    {"id":"60459","name":"Paroxetine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002319/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-20T11:38:00Z","last_updated_date":"2023-10-20T11:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/paroxetine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002319-202212_no.pdf"}},
    {"id":"60478","name":"Anastrozole : List of nationally authorised medicinal products - PSUSA/00000210/202208","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-24T14:45:00Z","last_updated_date":"2023-10-24T14:45:00Z","reference_number":"EMA/480308/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/anastrozole-list-nationally-authorised-medicinal-products-psusa-00000210-202208_en.pdf"},
    {"id":"60479","name":"Idarubicin : List of nationally authorised medicinal products - PSUSA/00001720/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-24T14:50:00Z","last_updated_date":"2023-10-24T14:50:00Z","reference_number":"EMA/480303/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/idarubicin-list-nationally-authorised-medicinal-products-psusa-00001720-202211_en.pdf"},
    {"id":"60487","name":"Gemcitabine : List of nationally authorised medicinal products - PSUSA/00001519/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-25T15:21:00Z","last_updated_date":"2023-10-25T15:21:00Z","reference_number":"EMA/481908/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/gemcitabine-list-nationally-authorised-medicinal-products-psusa-00001519-202301_en.pdf"},
    {"id":"60488","name":"Gemcitabine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001519/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-25T15:24:00Z","last_updated_date":"2023-10-25T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gemcitabine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001519-202301_no.pdf"}},
    {"id":"60498","name":"Ethosuximide : List of nationally authorised medicinal products - PSUSA/00001316/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-27T10:08:00Z","last_updated_date":"2023-10-27T10:08:00Z","reference_number":"EMA/484920/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethosuximide-list-nationally-authorised-medicinal-products-psusa-00001316-202303_en.pdf"},
    {"id":"60508","name":"Mefloquine: List of nationally authorised medicinal products - PSUSA/00000304/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-30T10:17:00Z","last_updated_date":"2023-10-30T10:17:00Z","reference_number":"EMA/319038/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/mefloquine-list-nationally-authorised-medicinal-products-psusa-00000304-202303_en.pdf"},
    {"id":"60522","name":"Acebutolol : CMDh Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-03T17:34:00Z","last_updated_date":"2023-11-03T17:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/acebutolol-cmdh-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_sv.pdf"}},
    {"id":"60523","name":"Acebutolol : List of nationally authorised medicinal products - PSUSA/00000018/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-03T17:37:00Z","last_updated_date":"2023-11-03T17:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/acebutolol-list-nationally-authorised-medicinal-products-psusa-00000018-202212_en.pdf"},
    {"id":"60594","name":"Methoxyflurane: List of nationally authorised medicinal products - PSUSA/00010484/201805","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T08:57:00Z","last_updated_date":"2019-01-23T08:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa-00010484-201805_en.pdf"},
    {"id":"60614","name":"Opium: List of nationally authorised medicinal products - PSUSA/00010670/201909","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-07-27T15:49:00Z","last_updated_date":"2020-07-27T15:49:00Z","reference_number":"EMA/398721/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/opium-list-nationally-authorised-medicinal-products-psusa-00010670-201909_en.pdf"},
    {"id":"60621","name":"Levonorgestrel/ethinylestradiol, ethinylestradiol (combination pack): List of nationally authorised medicinal products - PSUSA/00010442/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-04T16:25:00Z","last_updated_date":"2020-11-04T16:25:00Z","reference_number":"EMA/587168/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-list-nationally-authorised-medicinal-products-psusa-00010442-202001_en.pdf"},
    {"id":"60622","name":"Phenylephrine (ophthalmic formulations): List of nationally authorised medicinal products - PSUSA/00010402/202001","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2020-11-05T08:40:00Z","last_updated_date":"2020-11-05T08:40:00Z","reference_number":"EMA/587137/2020","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylephrine-ophthalmic-formulations-list-nationally-authorised-medicinal-products-psusa-00010402-202001_en.pdf"},
    {"id":"60639","name":"Bisoprolol / perindopril : List of nationally authorised medicines - PSUSA/00010462/202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-16T12:38:00Z","last_updated_date":"2021-06-16T12:38:00Z","reference_number":"EMA/341983/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/bisoprolol-perindopril-list-nationally-authorised-medicines-psusa-00010462-202010_en.pdf"},
    {"id":"60640","name":"Clevidipine : List of nationally authorised medicines - PSUSA/00010288/202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-16T12:43:00Z","last_updated_date":"2021-06-16T12:43:00Z","reference_number":"EMA/341975/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicines-psusa-00010288-202011_en.pdf"},
    {"id":"60641","name":"Ketotifen : List of nationally authorised medicines - PSUSA/00001813/202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-16T13:33:00Z","last_updated_date":"2021-06-16T13:33:00Z","reference_number":"EMA/343291/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketotifen-list-nationally-authorised-medicines-psusa-00001813-202010_en.pdf"},
    {"id":"60642","name":"Epinephrine / lidocaine : List of nationally authorised medicinal products -  PSUSA/00001233/202009","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-17T10:51:00Z","last_updated_date":"2021-06-17T10:51:00Z","reference_number":"EMA/344502/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/epinephrine-lidocaine-list-nationally-authorised-medicinal-products-psusa-00001233-202009_en.pdf"},
    {"id":"60643","name":"Etifoxine : List of nationally authorised medicinal products - PSUSA/00001321/202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-17T12:20:00Z","last_updated_date":"2021-06-17T12:20:00Z","reference_number":"EMA/344705/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/etifoxine-list-nationally-authorised-medicinal-products-psusa-00001321-202010_en.pdf"},
    {"id":"60645","name":"Fenofibrate : List of nationally authorised medicinal products - PSUSA/00001362/202007","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2021-06-23T12:07:00Z","last_updated_date":"2021-06-23T12:07:00Z","reference_number":"EMA/353788/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenofibrate-list-nationally-authorised-medicinal-products-psusa-00001362-202007_en.pdf"},
    {"id":"60646","name":"Prulifloxacin : List of nationally authorised medicinal products - PSUSA/00002569/202010","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-06-23T16:56:00Z","last_updated_date":"2021-06-23T16:56:00Z","reference_number":"EMA/356899/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/prulifloxacin-list-nationally-authorised-medicinal-products-psusa-00002569-202010_en.pdf"},
    {"id":"60648","name":"Diphtheria / tetanus / pertussis (acellular, component) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed) : List of nationally authorised medicinal products - PSUSA/00001124/202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-07-08T13:08:00Z","last_updated_date":"2021-07-08T13:08:00Z","reference_number":"EMA/PRAC/239748/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-pertussis-acellular-component-poliomyelitis-inactivated-haemophilus-type-b-conjugate-vaccine-adsorbed-list-nationally-authorised-medicinal-products-psusa-00001124-202011_en.pdf"},
    {"id":"60649","name":"Ciprofloxacin hydrochloride / hydrocortisone : list of nationally authorised medicinal products - PSUSA/00000774/202011","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-07-08T13:57:00Z","last_updated_date":"2021-07-08T13:57:00Z","reference_number":"EMA/239716/2021","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-hydrochloride-hydrocortisone-list-nationally-authorised-medicinal-products-psusa-00000774-202011_en.pdf"},
    {"id":"60665","name":"Acipimox : List of nationally authorised medicinal products - PSUSA/00000050/202105","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-01-19T12:48:00Z","last_updated_date":"2022-01-19T12:48:00Z","reference_number":"EMA/35549/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/acipimox-list-nationally-authorised-medicinal-products-psusa-00000050-202105_en.pdf"},
    {"id":"60676","name":"Clindamycin : List of nationally authorised medicinal products - PSUSA/00000795/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-05T10:38:00Z","last_updated_date":"2022-07-05T10:38:00Z","reference_number":"EMA/75532/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/clindamycin-list-nationally-authorised-medicinal-products-psusa-00000795-202110_en.pdf"},
    {"id":"60678","name":"Meningococcal group c polysaccharide conjugate vaccine : List of nationally authorised medicinal products -","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-07-05T11:22:00Z","last_updated_date":"2022-07-05T11:22:00Z","reference_number":"EMA/75547/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/meningococcal-group-c-polysaccharide-conjugate-vaccine-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"60682","name":"Dexketoprofen : List of nationally authorised medicinal products - PSUSA/00000997/202110","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2022-08-01T14:58:00Z","last_updated_date":"2022-08-01T14:58:00Z","reference_number":"EMA/669920/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-list-nationally-authorised-medicinal-products-psusa-00000997-202110_en.pdf"},
    {"id":"60763","name":"Aldesleukin : List of nationally authorised medicinal products - PSUSA/00000076/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-10T12:11:00Z","last_updated_date":"2023-10-10T12:11:00Z","reference_number":"EMA/PRAC/453290/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/aldesleukin-list-nationally-authorised-medicinal-products-psusa-00000076-202212_en.pdf"},
    {"id":"60981","name":"Ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine : List of nationally authorised medicinal products - PSUSA/00010649/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-27T14:04:43Z","last_updated_date":"2023-10-27T14:04:43Z","reference_number":"EMA/485899/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-list-nationally-authorised-medicinal-products-psusa-00010649-202302_en.pdf"},
    {"id":"60982","name":"Ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus)...caffeine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010649/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-10-27T14:07:37Z","last_updated_date":"2023-10-27T14:07:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosuscaffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010649-202302_no.pdf"}},
    {"id":"61014","name":"Lomustine : List of nationally authorised medicinal products - PSUSA/00001902/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T14:55:51Z","last_updated_date":"2023-11-28T14:55:51Z","reference_number":"EMA/539218/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/lomustine-list-nationally-authorised-medicinal-products-psusa-00001902-202301_en.pdf"},
    {"id":"61015","name":" Lomustine : CMDh Scientific conclusions and grounds for variation, amendments to the ProductInformation and timetable for the implementation - PSUSA/00001902/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:03:15Z","last_updated_date":"2023-11-28T15:03:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lomustine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa-00001902-202301_sv.pdf"}},
    {"id":"61065","name":"Landiolol : List of nationally authorised medicinal products","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-27T12:20:47Z","last_updated_date":"2023-11-27T12:20:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/landiolol-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"61069","name":"Bicalutamide : List of nationally authorised medicinal products - PSUSA/00000407/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T13:51:58Z","last_updated_date":"2023-11-28T13:51:58Z","reference_number":"EMA/299590/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/bicalutamide-list-nationally-authorised-medicinal-products-psusa-00000407-202302_en.pdf"},
    {"id":"61079","name":"Levosalbutamol, salbutamol : List of nationally authorised medicinal products - PSUSA/000010330/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:43:22Z","last_updated_date":"2023-11-28T15:43:22Z","reference_number":"EMA/538390/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/levosalbutamol-salbutamol-list-nationally-authorised-medicinal-products-psusa-000010330-202301_en.pdf"},
    {"id":"61080","name":"Levosalbutamol, salbutamol : CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010330/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:55:37Z","last_updated_date":"2023-11-28T15:55:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levosalbutamol-salbutamol-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00010330-202301_no.pdf"}},
    {"id":"61089","name":"Beta-alanine : List of nationally authorised medicinal products - PSUSA/10510/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-29T16:36:00Z","last_updated_date":"2023-11-29T16:36:00Z","reference_number":"EMA/535777/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/beta-alanine-list-nationally-authorised-medicinal-products-psusa-10510-202301_en.pdf"},
    {"id":"61090","name":"Beta-alanine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/10510/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-29T16:37:25Z","last_updated_date":"2023-11-29T16:37:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/beta-alanine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-10510-202301_sv.pdf"}},
    {"id":"61091","name":"Etoposide : List of nationally authorised medicinal products - PSUSA/00001333/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-29T16:45:21Z","last_updated_date":"2023-11-29T16:45:21Z","reference_number":"EMA/535777/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/etoposide-list-nationally-authorised-medicinal-products-psusa-00001333-202302_en.pdf"},
    {"id":"61092","name":"Etoposide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001333/202302 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-29T16:46:38Z","last_updated_date":"2023-11-29T16:46:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/etoposide-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001333-202302_no.pdf"}},
    {"id":"61093","name":"Omega-3-acid ethyl esters : List of nationally authorised medicinal products - PSUSA-00010312-202301","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2023-11-30T17:14:53Z","last_updated_date":"2023-11-30T17:14:53Z","reference_number":"EMA/542082/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/omega-3-acid-ethyl-esters-list-nationally-authorised-medicinal-products-psusa-00010312-202301_en.pdf"},
    {"id":"61094","name":"Omega-3-acid ethyl esters : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA-00010312-202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-30T17:19:33Z","last_updated_date":"2023-11-30T17:19:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/omega-3-acid-ethyl-esters-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010312-202301_no.pdf"}},
    {"id":"61095","name":"Ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine : List of nationally authorised medicinal products - PSUSA/00010649/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-29T17:21:37Z","last_updated_date":"2023-11-29T17:21:37Z","reference_number":"EMA/485899/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-list-nationally-authorised-medicinal-products-psusa-00010649-202302_en.pdf-0"},
    {"id":"61096","name":"Ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010649/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-29T17:23:30Z","last_updated_date":"2023-12-11T15:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ibuprofen-ibuprofen-lysine-not-indicated-ductus-arteriosus-ibuprofen-caffeine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa_no.pdf"}},
    {"id":"61099","name":"Valproate: Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - EMEA/H/N/PSR/J/0036","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-30T18:19:47Z","last_updated_date":"2023-11-30T18:19:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/valproate-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations-emea-h-n-psr-j-0036_no.pdf"}},
    {"id":"61100","name":"Valproate : List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0036","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-30T18:21:02Z","last_updated_date":"2023-11-30T18:21:02Z","reference_number":"EMA/490085/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproate-list-nationally-authorised-medicinal-products-emea-h-n-psr-j-0036_en.pdf"},
    {"id":"61101","name":"Valproate : PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0036","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2023-11-30T18:22:35Z","last_updated_date":"2023-11-30T18:22:35Z","reference_number":"EMA/490085/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproate-prac-non-interventional-imposed-pass-final-study-report-assessment-report-emea-h-n-psr-j-0036_en.pdf"},
    {"id":"61103","name":"Oral retinoids: List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0002","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-30T18:44:59Z","last_updated_date":"2023-11-30T18:44:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oral-retinoids-list-nationally-authorised-medicinal-products-emea-h-n-psr-j-0002_en.pdf"},
    {"id":"61104","name":"Oral retinoids: CMDh scientific conclusions, amendments to product information and implementation timetable - EMEA/H/N/PSR/J/0040","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-11-30T18:48:23Z","last_updated_date":"2023-11-30T18:48:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oral-retinoids-cmdh-scientific-conclusions-amendments-product-information-and-implementation-timetable-emea-h-n-psr-j-0040_no.pdf"}},
    {"id":"61119","name":"BCG (bacillus calmette-guérin) for Immunotherapy : List of nationally authorised medicinal products - PSUSA/00000303/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T13:19:26Z","last_updated_date":"2023-12-01T13:19:26Z","reference_number":"EMA/299583/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/bcg-bacillus-calmette-guerin-immunotherapy-list-nationally-authorised-medicinal-products-psusa-00000303-202303_en.pdf"},
    {"id":"61123","name":"Ciprofloxacin (systemic use) : List of nationally authorised medicinal products - PSUSA/00000775/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T13:29:59Z","last_updated_date":"2023-12-01T13:29:59Z","reference_number":"EMA/545001/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa-00000775-202304_en.pdf"},
    {"id":"61124","name":"Drospirenone : List of nationally authorised medicinal products - PSUSA/00010853/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T13:43:11Z","last_updated_date":"2023-12-01T13:43:11Z","reference_number":"EMA/547438/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/drospirenone-list-nationally-authorised-medicinal-products-psusa-00010853-202211_en.pdf"},
    {"id":"61125","name":"Enalapril / nitrendipine : List of nationally authorised medicinal products - PSUSA/00001213/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T13:53:34Z","last_updated_date":"2023-12-01T13:53:34Z","reference_number":"EMA/547463/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/enalapril-nitrendipine-list-nationally-authorised-medicinal-products-psusa-00001213-202301_en.pdf"},
    {"id":"61158","name":"Furosemide: List of nationally authorised medicinal products - PSUSA/00001491/202301","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T15:41:33Z","last_updated_date":"2023-12-01T15:41:33Z","reference_number":"EMA/547473/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/furosemide-list-nationally-authorised-medicinal-products-psusa-00001491-202301_en.pdf"},
    {"id":"61159","name":"Hydroxyethyl starch : List of nationally authorised medicinal products - PSUSA/00001694/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T15:50:59Z","last_updated_date":"2023-12-01T15:50:59Z","reference_number":"EMA/547480/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-list-nationally-authorised-medicinal-products-psusa-00001694-202303_en.pdf"},
    {"id":"61160","name":"Deproteinised hemoderivative of calf blood.... : List of nationally authorised medicinal products - PSUSA/00010600/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T16:02:04Z","last_updated_date":"2023-12-01T16:02:04Z","reference_number":"EMA/547816/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/deproteinised-hemoderivative-calf-blood-list-nationally-authorised-medicinal-products-psusa-00010600-202303_en.pdf"},
    {"id":"61178","name":"Human plasma (pooled and treated for virus inactivation) : List of nationally authorised medicinal products - PSUSA/00001635/202302","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T13:13:59Z","last_updated_date":"2023-12-04T13:13:59Z","reference_number":"EMA/299600/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-plasma-pooled-and-treated-virus-inactivation-list-nationally-authorised-medicinal-products-psusa-00001635-202302_en.pdf"},
    {"id":"61179","name":"Mometasone furoate/olopatadine : List of nationally authorised medicinal products - PSUSA/00010957/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T13:27:57Z","last_updated_date":"2023-12-04T13:27:57Z","reference_number":"EMA/549684/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/mometasone-furoate-olopatadine-list-nationally-authorised-medicinal-products-psusa-00010957-202304_en.pdf"},
    {"id":"61180","name":"Triamcinolone (intraocular formulations) : List of nationally authorised medicinal products - PSUSA/00010292/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T13:39:09Z","last_updated_date":"2023-12-04T13:39:09Z","reference_number":"EMA/549531/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/triamcinolone-intraocular-formulations-list-nationally-authorised-medicinal-products-psusa-00010292-202303_en.pdf"},
    {"id":"61181","name":"Methylphenobarbital : List of nationally authorised medicinal products - PSUSA/00002025/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T13:45:55Z","last_updated_date":"2023-12-04T13:45:55Z","reference_number":"EMA/549530/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenobarbital-list-nationally-authorised-medicinal-products-psusa-00002025-202303_en.pdf"},
    {"id":"61182","name":"Benzyl nicotinate/camphor/dimethyl sulfoxide/nonivamide/turpentine oil, Nicoboxil/Nonivamide : List of nationally authorised medicinal products - PSUSA/00010584/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T13:55:53Z","last_updated_date":"2023-12-04T13:55:53Z","reference_number":"EMA/549859/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzyl-nicotinate-camphor-dimethyl-sulfoxide-nonivamide-turpentine-oil-nicoboxil-nonivamide-list-nationally-authorised-medicinal-products-psusa-00010584-202303_en.pdf"},
    {"id":"61183","name":"Isotretinoin (oral formulations) : List of nationally authorised medicinal products - PSUSA/00010488/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-04T14:03:14Z","last_updated_date":"2023-12-04T14:03:14Z","reference_number":"EMA/550356/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa-00010488-202305_en.pdf"},
    {"id":"61228","name":"Enalapril : List of nationally authorised medicinal products - PSUSA/00001211/202303","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2023-12-04T18:42:43Z","last_updated_date":"2023-12-04T18:42:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/enalapril-list-nationally-authorised-medicinal-products-psusa-00001211-202303_en.pdf"},
    {"id":"61250","name":"Epinephrine / mepivacaine hydrochloride, mepivacaine / norepinephrine, mepivacaine : List of nationally authorised medicinal products - PSUSA/00001979/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-05T14:21:35Z","last_updated_date":"2023-12-05T14:21:35Z","reference_number":"EMA/553768/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/epinephrine-mepivacaine-hydrochloride-mepivacaine-norepinephrine-mepivacaine-list-nationally-authorised-medicinal-products-psusa-00001979-202303_en.pdf"},
    {"id":"61272","name":"Ivabradine / metoprolol : List of nationally authorised medicinal products - PSUSA/00010381/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T15:05:11Z","last_updated_date":"2023-12-06T15:05:11Z","reference_number":"EMA/559695/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivabradine-metoprolol-list-nationally-authorised-medicinal-products-psusa-00010381-202304_en.pdf"},
    {"id":"61285","name":"Porfimer : List of nationally authorised medicinal products - PSUSA/00010332/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T16:39:10Z","last_updated_date":"2023-12-06T16:39:10Z","reference_number":"EMA/560742/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/porfimer-list-nationally-authorised-medicinal-products-psusa-00010332-202304_en.pdf"},
    {"id":"61286","name":"Cytarabine : List of nationally authorised medicinal products - PSUSA/00000911/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T16:56:57Z","last_updated_date":"2023-12-06T16:56:57Z","reference_number":"EMA/560815/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/cytarabine-list-nationally-authorised-medicinal-products-psusa-00000911-202303_en.pdf"},
    {"id":"61291","name":"Rifamycin : List of nationally authorised medicinal products - PSUSA/00002641/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T10:07:51Z","last_updated_date":"2023-12-07T10:07:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rifamycin-list-nationally-authorised-medicinal-products-psusa-00002641-202304_en.pdf"},
    {"id":"61292","name":"Dronabinol / cannabidiol : List of nationally authorised medicinal products - PSUSA/00010844/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T10:20:37Z","last_updated_date":"2023-12-07T10:20:37Z","reference_number":"EMA/553768/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/dronabinol-cannabidiol-list-nationally-authorised-medicinal-products-psusa-00010844-202304_en.pdf"},
    {"id":"61293","name":"Ofloxacin (systemic use) : List of nationally authorised medicinal products - PSUSA/00002203/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T12:31:28Z","last_updated_date":"2023-12-07T12:31:28Z","reference_number":"EMA/348805/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa-00002203-202304_en.pdf"},
    {"id":"61548","name":"Human coagulation factor VIII (inhibitor bypassing fraction) : List of nationally authorised medicinal products - PSUSA /00009174/202102","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-10-14T15:41:09Z","last_updated_date":"2021-10-14T15:41:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-viii-inhibitor-bypassing-fraction-list-nationally-authorised-medicinal-products-psusa-00009174-202102_en.pdf"},
    {"id":"61580","name":"Oxycodone : List of nationally authorised medicinal products - PSUSA/00002254/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T16:53:10Z","last_updated_date":"2023-12-21T16:53:10Z","reference_number":"EMA/577152/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-list-nationally-authorised-medicinal-products-psusa-00002254-202304_en.pdf"},
    {"id":"61581","name":"Oxycodone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information - PSUSA/00002254/202304and timetable for the implementation  ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T16:55:37Z","last_updated_date":"2023-12-21T16:55:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oxycodone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-psusa-00002254-202304and-timetable-implementation_no.pdf"}},
    {"id":"61582","name":"Furosemide-spironolactone : List of nationally authorised medicinal products - PSUSA/00001493/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T10:06:40Z","last_updated_date":"2023-12-22T10:06:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_en.pdf"},
    {"id":"61583","name":"Furosemide-spironolactone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001493/202303","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2023-12-22T10:22:15Z","last_updated_date":"2023-12-22T10:22:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/furosemide-spironolactone-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001493-202303_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_no.pdf"}},
    {"id":"61584","name":"Furosemide-spironolactone : List of nationally authorised medicinal products - PSUSA/00001493/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T10:57:57Z","last_updated_date":"2023-12-22T10:57:57Z","reference_number":"EMA/PRAC/464397/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/furosemide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001493-202303_en.pdf-1"},
    {"id":"61585","name":"Lavender oil : List of nationally authorised medicinal products - PSUSA/00010810/202304          ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T11:04:57Z","last_updated_date":"2023-12-22T11:04:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lavender-oil-list-nationally-authorised-medicinal-products-psusa-00010810-202304_en.pdf"}    {"id":"61586","name":"Piribedil : List of nationally authorised medicinal products - PSUSA/00002436/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T11:15:36Z","last_updated_date":"2023-12-22T11:15:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/piribedil-list-nationally-authorised-medicinal-products-psusa-00002436-202303_en.pdf"},
    {"id":"61588","name":"Doxylamine : List of nationally authorised medicinal products - PSUSA/00001174/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T11:22:20Z","last_updated_date":"2023-12-22T11:22:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/doxylamine-list-nationally-authorised-medicinal-products-psusa-00001174-202304_en.pdf"},
    {"id":"61590","name":"Fluconazole : List of nationally authorised medicinal products - PSUSA/00001404/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T11:27:40Z","last_updated_date":"2023-12-22T11:27:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluconazole-list-nationally-authorised-medicinal-products-psusa-00001404-202303_en.pdf"},
    {"id":"61591","name":"Fluconazole : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001404/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T11:29:15Z","last_updated_date":"2023-12-22T11:29:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fluconazole-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00001404-202303_no.pdf"}},
    {"id":"61618","name":"Valproate : List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0045","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T17:45:40Z","last_updated_date":"2023-12-22T17:45:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproate-list-nationally-authorised-medicinal-products-emea-h-n-psr-j-0045_en.pdf"},
    {"id":"61619","name":"Valproate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/J/0045","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T17:46:44Z","last_updated_date":"2023-12-22T17:46:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/valproate-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-j-0045_no.pdf"}},
    {"id":"61620","name":"Valproate : PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0045","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T17:48:16Z","last_updated_date":"2023-12-22T17:48:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproate-prac-non-interventional-imposed-pass-final-study-report-assessment-report-emea-h-n-psr-j-0045_en.pdf"},
    {"id":"61729","name":"Azithromycin (systemic use formulations) : List of nationally authorised medicinal products - PSUSA/00010491/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T14:19:41Z","last_updated_date":"2024-01-11T14:19:41Z","reference_number":"EMA/504337/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/azithromycin-systemic-use-formulations-list-nationally-authorised-medicinal-products-psusa-00010491-202304_en.pdf"},
    {"id":"61732","name":"Azithromycin (ocular use formulations) : List of nationally authorised medicinal products - PSUSA/00010492/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T14:33:07Z","last_updated_date":"2024-01-11T14:33:07Z","reference_number":"EMA/504279/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/azithromycin-ocular-use-formulations-list-nationally-authorised-medicinal-products-psusa-00010492-202304_en.pdf"},
    {"id":"61740","name":"Irinotecan (except for liposomal formulations) : List of nationally authorised medicinal products - PSUSA/00001783/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T15:41:43Z","last_updated_date":"2024-01-11T15:41:43Z","reference_number":"EMA/16501/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/irinotecan-except-liposomal-formulations-list-nationally-authorised-medicinal-products-psusa-00001783-202305_en.pdf"},
    {"id":"61741","name":"Thiamphenicol : List of nationally authorised medicinal products - PSUSA/00002925/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T15:46:54Z","last_updated_date":"2024-01-11T15:46:54Z","reference_number":"EMA/PRAC/539877/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiamphenicol-list-nationally-authorised-medicinal-products-psusa-00002925-202305_en.pdf"},
    {"id":"61742","name":"Aciclovir : List of nationally authorised medicinal products - PSUSA/00000048/202306         ","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2024-01-11T16:11:53Z","last_updated_date":"2024-01-11T16:11:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/aciclovir-list-nationally-authorised-medicinal-products-psusa-00000048-202306_en.pdf"},
    {"id":"61743","name":"pelargonium sidoides dc and/or pelargonium reniforme curt. / radix : List of nationally authorised medicinal products - PSUSA/00002329/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T16:46:28Z","last_updated_date":"2024-01-11T16:46:28Z","reference_number":"EMA/509495/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/pelargonium-sidoides-dc-or-pelargonium-reniforme-curt-radix-list-nationally-authorised-medicinal-products-psusa-00002329-202306_en.pdf"},
    {"id":"61746","name":"Ebastine : List of nationally authorised medicinal products - PSUSA/00001191/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-12T11:04:39Z","last_updated_date":"2024-01-12T11:04:39Z","reference_number":"EMA/16935/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ebastine-list-nationally-authorised-medicinal-products-psusa-00001191-202305_en.pdf"},
    {"id":"61747","name":"Norfloxacin : List of nationally authorised medicinal products - PSUSA/00002190/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-12T11:10:31Z","last_updated_date":"2024-01-12T11:10:31Z","reference_number":"EMA/17202/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/norfloxacin-list-nationally-authorised-medicinal-products-psusa-00002190-202306_en.pdf"},
    {"id":"61759","name":"Latanoprost (products with paediatric indication) : List of nationally authorised medicinal products - PSUSA/00001834/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-15T12:31:48Z","last_updated_date":"2024-01-15T12:31:48Z","reference_number":"EMA/17281/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/latanoprost-products-paediatric-indication-list-nationally-authorised-medicinal-products-psusa-00001834-202304_en.pdf"},
    {"id":"61768","name":"Chlorpromazine : List of nationally authorised medicinal products - PSUSA/00000715/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-15T15:37:35Z","last_updated_date":"2024-01-15T15:37:35Z","reference_number":"EMA/795/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorpromazine-list-nationally-authorised-medicinal-products-psusa-00000715-202305_en.pdf"},
    {"id":"61776","name":"Patent blue V sodium : List of nationally authorised medicinal products - PSUSA/00002320/202304","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2024-01-16T12:13:13Z","last_updated_date":"2024-01-16T12:13:13Z","reference_number":"EMA/23637/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/patent-blue-v-sodium-list-nationally-authorised-medicinal-products-psusa-00002320-202304_en.pdf"},
    {"id":"61779","name":"Zuclopenthixol : List of nationally authorised medicinal products - PSUSA/00003155/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-16T13:07:47Z","last_updated_date":"2024-01-16T13:07:47Z","reference_number":"EMA/21143/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/zuclopenthixol-list-nationally-authorised-medicinal-products-psusa-00003155-202305_en.pdf"},
    {"id":"61814","name":"Nortriptyline : List of nationally authorised medicinal products - PSUSA/00002192/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-19T15:42:32Z","last_updated_date":"2024-01-19T15:42:32Z","reference_number":"EMA/555754/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/nortriptyline-list-nationally-authorised-medicinal-products-psusa-00002192-202303_en.pdf"},
    {"id":"61815","name":"Nortriptyline : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002192/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-19T15:47:22Z","last_updated_date":"2024-01-19T15:47:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/nortriptyline-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002192-202303_no.pdf"}},
    {"id":"61844","name":"Mometasone : List of nationally authorised medicinal products - PSUSA/00002085/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-23T14:13:08Z","last_updated_date":"2024-01-23T14:13:08Z","reference_number":"EMA/34986/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/mometasone-list-nationally-authorised-medicinal-products-psusa-00002085-202305_en.pdf"},
    {"id":"61851","name":"Pravastatin : List of nationally authorised medicinal products - PSUSA/00002500/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-23T17:19:36Z","last_updated_date":"2024-01-23T17:19:36Z","reference_number":"EMA/35243/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/pravastatin-list-nationally-authorised-medicinal-products-psusa-00002500-202303_en.pdf"},
    {"id":"61852","name":"Pravastatin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002500/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-23T17:29:53Z","last_updated_date":"2024-01-23T17:29:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/pravastatin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002500-202303_no.pdf"}},
    {"id":"61857","name":"Clarithromycin : List of nationally authorised medicinal products - PSUSA/00000788/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-24T10:29:25Z","last_updated_date":"2024-01-24T10:29:25Z","reference_number":"EMA/515639/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/clarithromycin-list-nationally-authorised-medicinal-products-psusa-00000788-202304_en.pdf"},
    {"id":"61858","name":"Clarithromycin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000788/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-24T10:31:45Z","last_updated_date":"2024-05-15T14:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/clarithromycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000788-202304_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/clarithromycin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000788-202304_no.pdf"}},
    {"id":"61859","name":"Venlafaxine : List of nationally authorised medicinal products - PSUSA/00003104/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-24T10:35:26Z","last_updated_date":"2024-01-24T10:35:26Z","reference_number":"EMA/555773/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/venlafaxine-list-nationally-authorised-medicinal-products-psusa-00003104-202305_en.pdf"},
    {"id":"61860","name":"Venlafaxine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003104/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-24T10:48:09Z","last_updated_date":"2024-01-24T10:48:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/venlafaxine-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00003104-202305_no.pdf"}},
    {"id":"61864","name":"Piroxicam : List of nationally authorised medicinal products - PSUSA/00002438/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-24T12:44:50Z","last_updated_date":"2024-01-24T12:44:50Z","reference_number":"EMA/37809/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/piroxicam-list-nationally-authorised-medicinal-products-psusa-00002438-202304_en.pdf"},
    {"id":"61865","name":"Piroxicam : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002438/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-24T12:47:05Z","last_updated_date":"2024-01-24T12:47:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/piroxicam-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002438-202304_no.pdf"}},
    {"id":"61888","name":"Aprotinin : List of nationally authorised medicinal products - EMEA/H/N/PSR/S/0030","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-25T13:41:58Z","last_updated_date":"2024-01-25T13:41:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/aprotinin-list-nationally-authorised-medicinal-products-emea-h-n-psr-s-0030_en.pdf"},
    {"id":"61889","name":"Aprotinin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMEA/H/N/PSR/S/0030","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-25T13:45:16Z","last_updated_date":"2024-01-25T13:45:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/aprotinin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-emea-h-n-psr-s-0030_sv.pdf"}},
    {"id":"61893","name":"Aceclofenac : List of nationally authorised medicinal products  - PSUSA/00000022/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-25T16:17:19Z","last_updated_date":"2024-01-25T16:17:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/aceclofenac-list-nationally-authorised-medicinal-products-psusa-00000022-202303_en.pdf"},
    {"id":"61894","name":"Aceclofenac : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000022/202303 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-25T16:21:54Z","last_updated_date":"2024-01-25T16:21:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/aceclofenac-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00000022-202303_sv.pdf"}},
    {"id":"61954","name":"Racecadotril : List of nationally authorised medicinal products - PSUSA/00002602/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-30T17:05:11Z","last_updated_date":"2024-01-30T17:05:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/racecadotril-list-nationally-authorised-medicinal-products-psusa-00002602-202303_en.pdf"},
    {"id":"61955","name":"Racecadotril : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002602/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-01-30T17:06:23Z","last_updated_date":"2024-01-30T17:06:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/racecadotril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002602-202303_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/racecadotril-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa-00002602-202303_no.pdf"}},
    {"id":"61973","name":"Gentamicin (systemic use): List of nationally authorised medicinal products - PSUSA/00009159/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-01T15:16:04Z","last_updated_date":"2024-02-01T15:16:04Z","reference_number":"EMA/355871/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/gentamicin-systemic-use-list-nationally-authorised-medicinal-products-psusa-00009159-202303_en.pdf"},
    {"id":"61974","name":"Gentamicin (systemic use): CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009159/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-01T15:19:17Z","last_updated_date":"2024-02-01T15:19:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gentamicin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009159-202303_no.pdf"}},
    {"id":"62013","name":"Fentanyl (transdermal patches, solution for injection - nationally authorised product only) : List of nationally authorised medicinal products - PSUSA/00001370/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-06T15:05:32Z","last_updated_date":"2024-02-06T15:05:32Z","reference_number":"EMA/51342/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-list-nationally-authorised-medicinal-products-psusa-00001370-202304_en.pdf"},
    {"id":"62014","name":"Fentanyl (transdermal patches, solution for injection - nationally authorised product only) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001370/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-06T15:08:07Z","last_updated_date":"2024-02-06T15:08:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_no.pdf"}},
    {"id":"62054","name":"Epirubicin: List of nationally authorised medicinal products - PSUSA/00001234/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-08T15:12:49Z","last_updated_date":"2024-02-08T15:12:49Z","reference_number":"EMA/35274/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/epirubicin-list-nationally-authorised-medicinal-products-psusa-00001234-202306_en.pdf"},
    {"id":"62064","name":"Allergen for therapy: betula verrucosa (sublingual use) : List of nationally authorised medicinal products - PSUSA/00010815/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-09T15:41:53Z","last_updated_date":"2024-02-09T15:41:53Z","reference_number":"EMA/60890/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-betula-verrucosa-sublingual-use-list-nationally-authorised-medicinal-products-psusa-00010815-202307_en.pdf"},
    {"id":"62065","name":"Misoprostol (gastrointestinal indication) : List of nationally authorised medicinal products - PSUSA/00010291/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-09T15:47:35Z","last_updated_date":"2024-02-09T15:47:35Z","reference_number":"EMA/61133/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gastrointestinal-indication-list-nationally-authorised-medicinal-products-psusa-00010291-202306_en.pdf"},
    {"id":"62066","name":"Hepatitis a (inactivated) / typhoid polysaccharide vaccine (adsorbed) : List of nationally authorised medicinal products - PSUSA/00001594/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-09T15:52:50Z","last_updated_date":"2024-02-09T15:52:50Z","reference_number":"EMA/571599/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/hepatitis-inactivated-typhoid-polysaccharide-vaccine-adsorbed-list-nationally-authorised-medicinal-products-psusa-00001594-202306_en.pdf"},
    {"id":"62067","name":"Ferucarbotran: List of nationally authorised medicinal products - PSUSA/00001382/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-09T17:40:00Z","last_updated_date":"2024-02-09T17:40:00Z","reference_number":"EMA/28356/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ferucarbotran-list-nationally-authorised-medicinal-products-psusa-00001382-202306_en.pdf"},
    {"id":"62070","name":"Almotriptan : List of nationally authorised medicinal products - PSUSA/00000101/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-12T11:55:24Z","last_updated_date":"2024-02-12T11:55:24Z","reference_number":"EMA/64229/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/almotriptan-list-nationally-authorised-medicinal-products-psusa-00000101-202306_en.pdf"},
    {"id":"62073","name":"Pseudoephedrine, acetylsalicylic acid / pseudoephedrine : List of nationally authorised medicinal products - PSUSA/00010667/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-12T13:25:31Z","last_updated_date":"2024-02-12T13:25:31Z","reference_number":"EMA/65114/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/pseudoephedrine-acetylsalicylic-acid-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa-00010667-202306_en.pdf"},
    {"id":"62174","name":"Phentermine / topiramate : List of nationally authorised medicinal products - PSUSA/00010956/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T12:21:04Z","last_updated_date":"2024-02-15T12:21:04Z","reference_number":"EMA/67971/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/phentermine-topiramate-list-nationally-authorised-medicinal-products-psusa-00010956-202307_en.pdf"},
    {"id":"62307","name":"Octreotide : List of nationally authorised medicinal products - PSUSA/00002201/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-27T10:44:22Z","last_updated_date":"2024-02-27T10:44:22Z","reference_number":"EMA/80368/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/octreotide-list-nationally-authorised-medicinal-products-psusa-00002201-202306_en.pdf"},
    {"id":"62350","name":"Gadoteridol : List of nationally authorised medicinal products - PSUSA/00001507/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T09:09:40Z","last_updated_date":"2024-02-29T09:09:40Z","reference_number":"EMA/90538/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteridol-list-nationally-authorised-medicinal-products-psusa-00001507-202304_en.pdf"},
    {"id":"62351","name":"Gadoteridol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001507/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T09:11:05Z","last_updated_date":"2024-02-29T09:11:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gadoteridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001507-202304_no.pdf"}},
    {"id":"62354","name":"Gadoxetic acid disodium :  List of nationally authorised medicinal products - PSUSA/00001509/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T11:24:50Z","last_updated_date":"2024-02-29T11:24:50Z","reference_number":"EMA/49699/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoxetic-acid-disodium-list-nationally-authorised-medicinal-products-psusa-00001509-202304_en.pdf"},
    {"id":"62355","name":"Gadoxetic acid disodium : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001509/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T11:28:35Z","last_updated_date":"2024-02-29T11:28:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gadoxetic-acid-disodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001509-202304_no.pdf"}},
    {"id":"62356","name":"Gadobutrol : List of nationally authorised medicinal products - PSUSA/00001502/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T11:37:04Z","last_updated_date":"2024-02-29T11:37:04Z","reference_number":"EMA/49544/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobutrol-list-nationally-authorised-medicinal-products-psusa-00001502-202304_en.pdf"},
    {"id":"62357","name":"Gadobutrol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001502/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T11:38:56Z","last_updated_date":"2024-02-29T11:38:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gadobutrol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001502-202304_no.pdf"}},
    {"id":"62365","name":"Moxifloxacin (systemic use) : List of nationally authorised medicinal products - PSUSA/00009231/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T15:58:54Z","last_updated_date":"2024-02-29T15:58:54Z","reference_number":"EMA/15401/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/moxifloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa-00009231-202305_en.pdf"},
    {"id":"62367","name":"Moxifloxacin (systemic use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009231/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:03:02Z","last_updated_date":"2024-02-29T16:03:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/moxifloxacin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009231-202305_no.pdf"}},
    {"id":"62403","name":"Gadobenic acid : List of nationally authorised medicinal products - PSUSA/00001500/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T16:07:24Z","last_updated_date":"2024-03-01T16:07:24Z","reference_number":"EMA/94339/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobenic-acid-list-nationally-authorised-medicinal-products-psusa-00001500-202304_en.pdf"},
    {"id":"62404","name":"Gadobenic acid : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001500/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T16:09:06Z","last_updated_date":"2024-03-01T16:09:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gadobenic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001500-202304_no.pdf"}},
    {"id":"62405","name":"Ceftriaxone : List of nationally authorised medicinal products - PSUSA/00000613/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T16:14:28Z","last_updated_date":"2024-03-01T16:14:28Z","reference_number":"EMA/509005/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftriaxone-list-nationally-authorised-medicinal-products-psusa-00000613-202305_en.pdf"},
    {"id":"62407","name":"Ceftriaxone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000613/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T16:16:15Z","last_updated_date":"2024-03-01T16:16:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ceftriaxone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000613-202305_sv.pdf"}},
    {"id":"62409","name":"Nalbuphine : List of nationally authorised medicinal products - PSUSA-00002110-202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T16:24:14Z","last_updated_date":"2024-03-01T16:24:14Z","reference_number":"EMA/94832/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/nalbuphine-list-nationally-authorised-medicinal-products-psusa-00002110-202305_en.pdf"},
    {"id":"62410","name":"Nalbuphine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMA/94832/2024","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-01T16:26:27Z","last_updated_date":"2024-03-01T16:26:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nalbuphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-94832-2024_fi.pdf"}},
    {"id":"62429","name":"Gadoteric acid (IV and intravascular formulations) : List of nationally authorised medicinal products - PSUSA/00001506/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-04T16:14:08Z","last_updated_date":"2024-03-04T16:14:08Z","reference_number":"EMA/95353/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteric-acid-iv-intravascular-formulations-list-nationally-authorised-medicinal-products-psusa-00001506-202304_en.pdf"},
    {"id":"62430","name":"Gadoteric acid (IV and intravascular formulations) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001506/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-04T16:16:25Z","last_updated_date":"2024-03-04T16:16:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gadoteric-acid-iv-intravascular-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001506-202304_no.pdf"}},
    {"id":"62447","name":"Gadopentetic acid : List of nationally authorised medicinal products - PSUSA/00001504/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-06T12:53:25Z","last_updated_date":"2024-03-06T12:53:25Z","reference_number":"EMA/27098/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadopentetic-acid-list-nationally-authorised-medicinal-products-psusa-00001504-202304_en.pdf"},
    {"id":"62448","name":"Gadopentetic acid : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001504/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-06T12:55:40Z","last_updated_date":"2024-03-06T12:55:40Z","reference_number":"EMA/27098/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gadopentetic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001504-202304_no.pdf"}},
    {"id":"62467","name":"Niclosamide : List of nationally authorised medicinal products - PSUSA/00002151/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T12:31:27Z","last_updated_date":"2024-03-07T12:31:27Z","reference_number":"EMA/21937/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/niclosamide-list-nationally-authorised-medicinal-products-psusa-00002151-202308_en.pdf"},
    {"id":"62476","name":"Donepezil / memantine : List of nationally authorised medicinal products - PSUSA/00011039/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T15:50:41Z","last_updated_date":"2024-03-07T15:50:41Z","reference_number":"EMA/105053/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/donepezil-memantine-list-nationally-authorised-medicinal-products-psusa-00011039-202307_en.pdf"},
    {"id":"62477","name":"Anastrozole : List of nationally authorised medicinal products - PSUSA/00000210/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T15:54:39Z","last_updated_date":"2024-03-07T15:54:39Z","reference_number":"EMA/11786/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/anastrozole-list-nationally-authorised-medicinal-products-psusa-00000210-202308_en.pdf"},
    {"id":"62498","name":"Indometacin : List of nationally authorised medicinal products - PSUSA/00001738/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T15:35:10Z","last_updated_date":"2024-03-08T15:35:10Z","reference_number":"EMA/106682/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/indometacin-list-nationally-authorised-medicinal-products-psusa-00001738-202307_en.pdf"},
    {"id":"62523","name":"Ribavirin: List of nationally authorised medicinal products - PSUSA/00010007/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:50:25Z","last_updated_date":"2024-03-08T16:50:25Z","reference_number":"EMA/104321/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ribavirin-list-nationally-authorised-medicinal-products-psusa-00010007-202307_en.pdf"},
    {"id":"62557","name":"Oxytocin (systemic use) : List of nationally authorised medicinal products - PSUSA/00010913/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T15:16:59Z","last_updated_date":"2024-03-12T15:16:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxytocin-systemic-use-list-nationally-authorised-medicinal-products-psusa-00010913-202306_en.pdf"},
    {"id":"62569","name":"Cyproterone / Ethinylestradiol List of nationally authorised medicinal products - PSUSA/00000906/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T16:24:06Z","last_updated_date":"2024-03-12T16:24:06Z","reference_number":"EMA/110565/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproterone-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa-00000906-202305_en.pdf"},
    {"id":"62614","name":"Ezetimibe / Rosuvastatin: List of nationally authorised medicinal products - PSUSA/00010271/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-14T10:52:04Z","last_updated_date":"2024-03-14T10:52:04Z","reference_number":"EMA/112517/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ezetimibe-rosuvastatin-list-nationally-authorised-medicinal-products-psusa-00010271-202307_en.pdf"},
    {"id":"62617","name":"Mifepristone : List of nationally authorised medicinal products - PSUSA/00002060/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-15T10:57:57Z","last_updated_date":"2024-03-15T10:57:57Z","reference_number":"EMA/115648/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/mifepristone-list-nationally-authorised-medicinal-products-psusa-00002060-202305_en.pdf"},
    {"id":"62618","name":"Mifepristone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002060/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-15T11:00:02Z","last_updated_date":"2024-03-15T11:00:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/mifepristone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002060-202305_no.pdf"}},
    {"id":"62677","name":"Misoprostol (gynaecological indication - termination of pregnancy) : List of nationally authorised medicinal products - PSUSA/00010354/202305 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-21T14:35:33Z","last_updated_date":"2024-03-21T14:35:33Z","reference_number":"EMA/125243/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-list-nationally-authorised-medicinal-products-psusa-00010354-202305_en.pdf"},
    {"id":"62678","name":"Misoprostol (gynaecological indication - termination of pregnancy) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010354/202305 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-21T14:39:20Z","last_updated_date":"2024-03-21T14:39:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/misoprostol-gynaecological-indication-termination-pregnancy-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010354-202305_no.pdf"}},
    {"id":"62721","name":"Acebutolol: CMDh scientific conclusions and grounds for variation, amendments to the product Information and timetable for the implementation  - PSUSA/00000018/201712","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-25T12:14:27Z","last_updated_date":"2024-03-25T12:14:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/acebutolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000018-201712_sv.pdf"}},
    {"id":"62725","name":"Estradiol, estradiol /prednisolone (only cream/balm/emulsion for application in the female genital area) : List of nationally authorised medicinal products - PSUSA/00010441/202304","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-25T16:00:22Z","last_updated_date":"2024-03-25T16:00:22Z","reference_number":"EMA/PRAC/535217/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/estradiol-estradiol-prednisolone-only-cream-balm-emulsion-application-female-genital-area-list-nationally-authorised-medicinal-products-psusa-00010441-202304_en.pdf"},
    {"id":"62726","name":"Lanreotide : List of nationally authorised medicinal products - PSUSA/00001826/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-25T16:05:46Z","last_updated_date":"2024-03-25T16:05:46Z","reference_number":"EMA/PRAC/750/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/lanreotide-list-nationally-authorised-medicinal-products-psusa-00001826-202305_en.pdf"},
    {"id":"62727","name":"Cyproterone : List of nationally authorised medicinal products - PSUSA/00000905/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-25T16:10:01Z","last_updated_date":"2024-03-25T16:10:01Z","reference_number":"EMA/PRAC/44298/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproterone-list-nationally-authorised-medicinal-products-psusa-00000905-202307_en.pdf"},
    {"id":"62728","name":"Fenofibrate : List of nationally authorised medicinal products - PSUSA/00001362/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-25T16:14:04Z","last_updated_date":"2024-03-25T16:14:04Z","reference_number":"EMA/PRAC/96860/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenofibrate-list-nationally-authorised-medicinal-products-psusa-00001362-202307_en.pdf"},
    {"id":"62729","name":"Mifepristone/Misoprostol:  CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA-00010378-202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-25T16:32:05Z","last_updated_date":"2024-03-25T16:32:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mifepristone-misoprostol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010378-202305_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_sv.pdf"}},
    {"id":"62755","name":"Dienogest / ethinylestradiol : List of nationally authorised medicinal products - PSUSA/00001057/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T16:58:40Z","last_updated_date":"2024-03-26T16:58:40Z","reference_number":"EMA/134265/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/dienogest-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa-00001057-202303_en.pdf"},
    {"id":"62766","name":"Mifepristone/Misoprostol: List of nationally authorised medicinal products - PSUSA-00010378-202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-02T10:35:27Z","last_updated_date":"2024-04-02T10:35:27Z","reference_number":"EMA/PRAC/4056/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/mifepristone-misoprostol-list-nationally-authorised-medicinal-products-psusa-00010378-202305_en.pdf-0"},
    {"id":"62779","name":"Nimesulide (topical formulations) : List of nationally authorised medicinal products - PSUSA/00002655/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-02T13:53:45Z","last_updated_date":"2024-04-02T13:53:45Z","reference_number":"EMA/94455/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimesulide-topical-formulations-list-nationally-authorised-medicinal-products-psusa-00002655-202306_en.pdf"},
    {"id":"62780","name":"Nimesulide (topical formulations) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002655/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-02T15:23:39Z","last_updated_date":"2024-04-02T15:23:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimesulide-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_sv.pdf"}},
    {"id":"62784","name":"Oxycodone hydrochloride / paracetamol : List of nationally authorised medicinal products - PSUSA/00002256/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-03T11:06:46Z","last_updated_date":"2024-04-03T11:06:46Z","reference_number":"EMA/124914/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-hydrochloride-paracetamol-list-nationally-authorised-medicinal-products-psusa-00002256-202307_en.pdf"},
    {"id":"62785","name":"Oxycodone hydrochloride / paracetamol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002256/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-03T11:09:19Z","last_updated_date":"2024-04-03T11:09:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_ro.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202307_fi.pdf"}},
    {"id":"62802","name":"Tramadol : List of nationally authorised medicinal products - PSUSA/00003002/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T11:31:06Z","last_updated_date":"2024-04-04T11:31:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tramadol-list-nationally-authorised-medicinal-products-psusa-00003002-202306_en.pdf"},
    {"id":"62803","name":"Tramadol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - - PSUSA/00003002/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T11:35:02Z","last_updated_date":"2024-04-04T11:35:02Z","reference_number":"PSUSA/00003002/202306","document_url":"https://www.ema.europa.eu/en/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003002-202306_no.pdf"}},
    {"id":"62805","name":"Rosuvastatin : List of nationally authorised medicinal products - PSUSA/00002664/202211","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T12:22:02Z","last_updated_date":"2024-04-04T12:22:02Z","reference_number":"EMA/544521/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/rosuvastatin-list-nationally-authorised-medicinal-products-psusa-00002664-202211_en.pdf"},
    {"id":"62806","name":"Felodipine : List of nationally authorised medicinal products : PSUSA/00001356/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T12:26:12Z","last_updated_date":"2024-04-04T12:26:12Z","reference_number":"EMA/141568/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/felodipine-list-nationally-authorised-medicinal-products-psusa-00001356-202212_en.pdf"},
    {"id":"62807","name":"Ibutilide : List of nationally authorised medicinal products - PSUSA/00001713/202212","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T12:30:14Z","last_updated_date":"2024-04-04T12:30:14Z","reference_number":"EMA/141917/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibutilide-list-nationally-authorised-medicinal-products-psusa-00001713-202212_en.pdf"},
    {"id":"62809","name":"Rizatriptan : List of nationally authorised medicinal products - PSUSA/00002655/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T13:51:59Z","last_updated_date":"2024-04-04T13:51:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rizatriptan-list-nationally-authorised-medicinal-products-psusa-00002655-202306_en.pdf"},
    {"id":"62810","name":"Rizatriptan : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002655/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T13:53:19Z","last_updated_date":"2024-08-16T15:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_sv.pdf-0","is":"https://www.ema.europa.eu/is/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/rizatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002655-202306_no.pdf"}},
    {"id":"62830","name":"Ibuprofen / pseudoephedrine : List of nationally authorised medicinal products - PSUSA/00001711/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T15:58:27Z","last_updated_date":"2024-04-04T15:58:27Z","reference_number":"EMA/145084/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa-00001711-202307_en.pdf"},
    {"id":"62831","name":"Ibuprofen / pseudoephedrine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001711/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T16:00:42Z","last_updated_date":"2024-04-04T16:00:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ibuprofen-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001711-202307_no.pdf"}}    {"id":"62832","name":"Paracetamol / pseudoephedrine : List of nationally authorised medicinal products - PSUSA/00002307/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T16:06:15Z","last_updated_date":"2024-04-04T16:06:15Z","reference_number":"EMA/145166/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa-00002307-202306_en.pdf"},
    {"id":"62833","name":"Paracetamol / pseudoephedrine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002307/202306","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T16:08:29Z","last_updated_date":"2024-04-04T16:08:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/paracetamol-pseudoephedrine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002307-202306_no.pdf"}},
    {"id":"62921","name":"Finasteride : List of nationally authorised medicinal products - PSUSA/00001392/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T14:46:12Z","last_updated_date":"2024-04-11T14:46:12Z","reference_number":"EMA/155021/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa-00001392-202308_en.pdf"},
    {"id":"62928","name":"Aztreonam (parenteral use) : List of nationally authorised medicinal products - PSUSA/00010178/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T10:09:37Z","last_updated_date":"2024-04-12T10:09:37Z","reference_number":"EMA/574760/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/aztreonam-parenteral-use-list-nationally-authorised-medicinal-products-psusa-00010178-202308_en.pdf"},
    {"id":"62930","name":"Pimecrolimus : List of nationally authorised medicinal products - PSUSA/00002411/202303","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T11:51:17Z","last_updated_date":"2024-04-12T11:51:17Z","reference_number":"EMA/156924/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/pimecrolimus-list-nationally-authorised-medicinal-products-psusa-00002411-202303_en.pdf"},
    {"id":"62932","name":"Xylometazoline : List of nationally authorised medicinal products - PSUSA/00003134/202305","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T12:04:04Z","last_updated_date":"2024-04-12T12:04:04Z","reference_number":"EMA/156951/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/xylometazoline-list-nationally-authorised-medicinal-products-psusa-00003134-202305_en.pdf"},
    {"id":"62934","name":"Diclofenac / misoprostol : List of nationally authorised medicinal products - PSUSA/00001040/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T12:34:10Z","last_updated_date":"2024-04-12T12:34:10Z","reference_number":"EMA/156960/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-misoprostol-list-nationally-authorised-medicinal-products-psusa-00001040-202307_en.pdf"},
    {"id":"62935","name":"Levocetirizine : List of nationally authorised medicinal products - PSUSA/00001850/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T12:39:17Z","last_updated_date":"2024-04-12T12:39:17Z","reference_number":"EMA/156984/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/levocetirizine-list-nationally-authorised-medicinal-products-psusa-00001850-202307_en.pdf"},
    {"id":"62936","name":"Colchicine : List of nationally authorised medicinal products - PSUSA/00000858/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T12:45:06Z","last_updated_date":"2024-04-12T12:45:06Z","reference_number":"EMA/157009/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/colchicine-list-nationally-authorised-medicinal-products-psusa-00000858-202307_en.pdf"},
    {"id":"62937","name":"Prednisolone : List of nationally authorised medicinal products - PSUSA/00002506/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T12:49:41Z","last_updated_date":"2024-04-12T12:49:41Z","reference_number":"EMA/157052/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/prednisolone-list-nationally-authorised-medicinal-products-psusa-00002506-202308_en.pdf"},
    {"id":"62953","name":"Dexamfetamine : List of nationally authorised medicinal products - PSUSA/00000986/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-15T13:13:08Z","last_updated_date":"2024-04-15T13:13:08Z","reference_number":"EMA/145385/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-psusa-00000986-202309_en.pdf"},
    {"id":"62954","name":"Trazodone : List of nationally authorised medicinal products - PSUSA/00003012/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-15T13:19:00Z","last_updated_date":"2024-04-15T13:19:00Z","reference_number":"EMA/144698/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/trazodone-list-nationally-authorised-medicinal-products-psusa-00003012-202308_en.pdf"},
    {"id":"62955","name":"Phenytoin : List of nationally authorised medicinal products - PSUSA/00002392/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-15T13:26:53Z","last_updated_date":"2024-04-15T13:26:53Z","reference_number":"EMA/144701/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenytoin-list-nationally-authorised-medicinal-products-psusa-00002392-202308_en.pdf"},
    {"id":"62956","name":"Pefloxacin : List of nationally authorised medicinal products - PSUSA/00002322/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-15T13:32:47Z","last_updated_date":"2024-04-15T13:32:47Z","reference_number":"EMA/159914/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/pefloxacin-list-nationally-authorised-medicinal-products-psusa-00002322-202308_en.pdf"},
    {"id":"62957","name":"Bromazepam : List of nationally authorised medicinal products - PSUSA/00000435/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-15T13:36:59Z","last_updated_date":"2024-04-15T13:36:59Z","reference_number":"EMA/159728/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromazepam-list-nationally-authorised-medicinal-products-psusa-00000435-202308_en.pdf"},
    {"id":"62958","name":"Suxamethonium : List of nationally authorised medicinal products - PSUSA/00002834/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-15T15:07:43Z","last_updated_date":"2024-04-15T15:07:43Z","reference_number":"EMA/160190/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/suxamethonium-list-nationally-authorised-medicinal-products-psusa-00002834-202308_en.pdf"},
    {"id":"62959","name":"Zolpidem : List of nationally authorised medicinal products - PSUSA-00003151-202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-15T15:18:49Z","last_updated_date":"2024-04-15T15:18:49Z","reference_number":"EMA/160401/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/zolpidem-list-nationally-authorised-medicinal-products-psusa-00003151-202308_en.pdf"},
    {"id":"62961","name":"Modafinil : List of nationally authorised medicinal products - PSUSA/00010242/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-15T16:10:22Z","last_updated_date":"2024-04-15T16:10:22Z","reference_number":"EMA/160525/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/modafinil-list-nationally-authorised-medicinal-products-psusa-00010242-202308_en.pdf"},
    {"id":"62962","name":"Fluocinolone acetonide (intravitreal implant in applicator) : List of nationally authorised medicinal products - PSUSA/00010224/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-15T16:13:51Z","last_updated_date":"2024-04-15T16:13:51Z","reference_number":"EMA/160607/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-intravitreal-implant-applicator-list-nationally-authorised-medicinal-products-psusa-00010224-202308_en.pdf"},
    {"id":"62989","name":"Ipratropium / xylometazoline : List of nationally authorised medicinal products - PSUSA/00009201/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-17T15:35:49Z","last_updated_date":"2024-04-17T15:35:49Z","reference_number":"EMA/167330/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ipratropium-xylometazoline-list-nationally-authorised-medicinal-products-psusa-00009201-202308_en.pdf"},
    {"id":"62990","name":"Dienogest / estradiol (contraception indication) : List of nationally authorised medicinal products - PSUSA/00010444/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-17T15:40:14Z","last_updated_date":"2024-04-17T15:40:14Z","reference_number":"EMA/167446/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/dienogest-estradiol-contraception-indication-list-nationally-authorised-medicinal-products-psusa-00010444-202309_en.pdf"},
    {"id":"63039","name":"Human plasma protease C1 inhibitor (nationally authorised products) : EPAR - PSUSA/00010163/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-22T16:21:56Z","last_updated_date":"2024-04-22T16:21:56Z","reference_number":"EMA/173853/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-plasma-protease-c1-inhibitor-nationally-authorised-products-epar-psusa-00010163-202308_en.pdf"},
    {"id":"63041","name":"Inosine pranobex : List of nationally authorised medicinal products - PSUSA/00010425/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-22T16:27:04Z","last_updated_date":"2024-04-22T16:27:04Z","reference_number":"EMA/174062/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/inosine-pranobex-list-nationally-authorised-medicinal-products-psusa-00010425-202308_en.pdf"},
    {"id":"63062","name":"Mirtazapine : List of nationally authorised medicinal products - PSUSA/00002068/202308          ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-04-25T13:44:01Z","last_updated_date":"2024-04-25T13:44:01Z","reference_number":"EMA/177093/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/mirtazapine-list-nationally-authorised-medicinal-products-psusa-00002068-202308_en.pdf"},
    {"id":"63152","name":"Quetiapine : List of nationally authorised medicinal products - PSUSA/00002589/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-03T13:35:00Z","last_updated_date":"2024-05-03T13:35:00Z","reference_number":"EMA/189486/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/quetiapine-list-nationally-authorised-medicinal-products-psusa-00002589-202307_en.pdf"},
    {"id":"63153","name":"Quetiapine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002589/202307","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-03T13:38:00Z","last_updated_date":"2024-08-13T15:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/quetiapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002589-202307_no.pdf"}},
    {"id":"63172","name":"Paracetamol/tramadol : List of nationally authorised medicinal products - PSUSA/00002310/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-06T14:27:00Z","last_updated_date":"2024-05-06T14:27:00Z","reference_number":"EMA/178796/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-tramadol-list-nationally-authorised-medicinal-products-psusa-00002310-202308_en.pdf"},
    {"id":"63173","name":"Paracetamol/tramadol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002310/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-06T14:31:00Z","last_updated_date":"2024-05-23T14:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/paracetamol-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002310-202308_sv.pdf"}},
    {"id":"63236","name":"Rubidium (82Rb) chloride : List of nationally authorised medicinal products - PSUSA/00010806/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T14:16:00Z","last_updated_date":"2024-05-16T14:16:00Z","reference_number":"EMA/30022/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/rubidium-82rb-chloride-list-nationally-authorised-medicinal-products-psusa-00010806-202310_en.pdf"},
    {"id":"63238","name":"Acetylcysteine : List of nationally authorised medicinal products - PSUSA/00000034/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T14:44:00Z","last_updated_date":"2024-05-16T14:44:00Z","reference_number":"EMA/235059/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylcysteine-list-nationally-authorised-medicinal-products-psusa-00000034-202309_en.pdf"},
    {"id":"63239","name":"Prulifloxacin : List of nationally authorised medicinal products - PSUSA/00002569/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T15:32:00Z","last_updated_date":"2024-05-16T15:32:00Z","reference_number":"EMA/234778/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/prulifloxacin-list-nationally-authorised-medicinal-products-psusa-00002569-202309_en.pdf"},
    {"id":"63240","name":"Sodium tetradecyl sulphate: List of nationally authorised medicinal products - PSUSA/00002767/202304 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T15:39:12Z","last_updated_date":"2024-05-16T15:39:12Z","reference_number":"EMA/2512/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-tetradecyl-sulphate-list-nationally-authorised-medicinal-products-psusa-00002767-202304_en.pdf"},
    {"id":"63251","name":"valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide ......  - CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA-00003090-202101","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T11:45:00Z","last_updated_date":"2021-11-29T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpriomide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090_no.pdf"}},
    {"id":"63254","name":"Levofloxacin (ocular use) : List of nationally authorised medicinal products - PSUSA/00010768/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-17T13:21:00Z","last_updated_date":"2024-05-17T13:21:00Z","reference_number":"EMA/121791/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/levofloxacin-ocular-use-list-nationally-authorised-medicinal-products-psusa-00010768-202310_en.pdf"},
    {"id":"63286","name":"Desflurane : List of nationally authorised medicinal products - PSUSA/00000958/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-21T15:32:00Z","last_updated_date":"2024-05-21T15:32:00Z","reference_number":"EMA/239900/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/desflurane-list-nationally-authorised-medicinal-products-psusa-00000958-202309_en.pdf"},
    {"id":"63337","name":"Human von willebrand factor : List of nationally authorised medicinal products - PSUSA/00001642/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T14:00:00Z","last_updated_date":"2024-05-28T14:00:00Z","reference_number":"EMA/248135/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-von-willebrand-factor-list-nationally-authorised-medicinal-products-psusa-00001642-202309_en.pdf"},
    {"id":"63383","name":"Dexibuprofen : List of nationally authorised medicinal products - PSUSA/00000996/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T11:00:39Z","last_updated_date":"2024-05-30T11:00:39Z","reference_number":"EMA/221424/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexibuprofen-list-nationally-authorised-medicinal-products-psusa-00000996-202308_en.pdf"},
    {"id":"63384","name":"Dexibuprofen : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000996/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-05-30T11:03:14Z","last_updated_date":"2024-06-20T11:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_cs.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000996-202308_sv.pdf"}},
    {"id":"63472","name":"Naloxone / oxycodone : List of nationally authorised medicinal products - PSUSA/00002114/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-04T12:45:00Z","last_updated_date":"2024-06-04T12:45:00Z","reference_number":"EMA/255632/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/naloxone-oxycodone-list-nationally-authorised-medicinal-products-psusa-00002114-202308_en.pdf"},
    {"id":"63473","name":"Naloxone / oxycodone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002114/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-04T12:48:00Z","last_updated_date":"2024-11-05T08:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/naloxone-oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002114-202308_no.pdf"}},
    {"id":"63480","name":"Vincristine : List of nationally authorised medicinal products - PSUSA/00003121/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-05T09:46:00Z","last_updated_date":"2024-06-05T09:46:00Z","reference_number":"EMA/574755/2023","document_url":"https://www.ema.europa.eu/en/documents/psusa/vincristine-list-nationally-authorised-medicinal-products-psusa-00003121-202308_en.pdf"},
    {"id":"63482","name":"Vincristine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003121/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-05T09:48:00Z","last_updated_date":"2024-06-05T09:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/vincristine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003121-202308_no.pdf"}},
    {"id":"63502","name":"Trimetazidine : List of nationally authorised medicinal products - PSUSA/00003043/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T09:54:00Z","last_updated_date":"2024-06-06T09:54:00Z","reference_number":"EMA/263401/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-list-nationally-authorised-medicinal-products-psusa-00003043-202308_en.pdf"},
    {"id":"63503","name":"Trimetazidine - CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMA/263401/2024","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T09:56:00Z","last_updated_date":"2024-07-02T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/trimetazidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-263401-2024_sv.pdf"}},
    {"id":"63564","name":"Naproxen : List of nationally authorised medicinal products - PSUSA/00002125/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-11T13:36:00Z","last_updated_date":"2024-06-11T13:36:00Z","reference_number":"EMA/272182/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/naproxen-list-nationally-authorised-medicinal-products-psusa-00002125-202308_en.pdf"},
    {"id":"63566","name":"Naproxen : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002125/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-11T13:39:00Z","last_updated_date":"2024-06-26T15:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_de.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/naproxen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002125-202308_no.pdf"}},
    {"id":"63567","name":"Lithium : List of nationally authorised medicinal products - PSUSA/00001897/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-11T13:44:00Z","last_updated_date":"2024-06-11T13:44:00Z","reference_number":"EMA/159597/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/lithium-list-nationally-authorised-medicinal-products-psusa-00001897-202308_en.pdf"},
    {"id":"63568","name":"Lithium : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001897/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-11T13:46:00Z","last_updated_date":"2025-02-06T09:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lithium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001897-202308_no.pdf"}},
    {"id":"63578","name":"Ramipril : List of nationally authorised medicinal products - PSUSA/00002607/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-12T10:45:20Z","last_updated_date":"2024-06-12T10:45:20Z","reference_number":"EMA/274921/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ramipril-list-nationally-authorised-medicinal-products-psusa-00002607-202308_en.pdf"},
    {"id":"63651","name":"Hydroxyzine, hydroxyzine combination : List of nationally authorised medicinal products - PSUSA/00001696/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-17T13:40:00Z","last_updated_date":"2024-06-17T13:40:00Z","reference_number":"EMA/275072/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyzine-hydroxyzine-combination-list-nationally-authorised-medicinal-products-psusa-00001696-202311_en.pdf"},
    {"id":"63652","name":"Ascorbic acid / chlorphenamine maleate / paracetamol : List of nationally authorised medicinal products - PSUSA/00000696/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-17T13:55:00Z","last_updated_date":"2024-06-17T13:55:00Z","reference_number":"EMA/273650/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ascorbic-acid-chlorphenamine-maleate-paracetamol-list-nationally-authorised-medicinal-products-psusa-00000696-202311_en.pdf"},
    {"id":"63655","name":"Flutamide : List of nationally authorised medicinal products - PSUSA/00001453/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-17T14:35:00Z","last_updated_date":"2024-06-17T14:35:00Z","reference_number":"EMA/73511/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/flutamide-list-nationally-authorised-medicinal-products-psusa-00001453-202310_en.pdf"},
    {"id":"63669","name":"Citric acid / potassium salts, potassium citrate : List of nationally authorised medicinal products - PSUSA/00000783/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T14:33:00Z","last_updated_date":"2024-06-18T14:33:00Z","reference_number":"EMA/280357/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/citric-acid-potassium-salts-potassium-citrate-list-nationally-authorised-medicinal-products-psusa-00000783-202311_en.pdf"},
    {"id":"63670","name":"Methacholine : List of nationally authorised medicinal products - PSUSA/00010891/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T14:38:00Z","last_updated_date":"2024-06-18T14:38:00Z","reference_number":"EMA/282355/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/methacholine-list-nationally-authorised-medicinal-products-psusa-00010891-202310_en.pdf"},
    {"id":"63676","name":"Etifoxine: List of nationally authorised medicinal products - PSUSA/00001321/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T17:29:57Z","last_updated_date":"2024-06-18T17:29:57Z","reference_number":"EMA/275078/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/etifoxine-list-nationally-authorised-medicinal-products-psusa-00001321-202310_en.pdf"},
    {"id":"63686","name":"Bromocriptine : List of nationally authorised medicinal products - PSUSA/00000438/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-19T13:00:00Z","last_updated_date":"2024-06-19T13:00:00Z","reference_number":"EMA/282361/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromocriptine-list-nationally-authorised-medicinal-products-psusa-00000438-202310_en.pdf"},
    {"id":"63687","name":"Tetrabenazine : List of nationally authorised medicinal products - PSUSA/00002911/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-06-19T13:08:00Z","last_updated_date":"2024-06-19T13:08:00Z","reference_number":"EMA/275409/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/tetrabenazine-list-nationally-authorised-medicinal-products-psusa-00002911-202310_en.pdf"},
    {"id":"63882","name":"Diclofenac (topical formulations) : List of nationally authorised medicinal products - PSUSA/00010342/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T09:10:00Z","last_updated_date":"2024-07-05T09:10:00Z","reference_number":"EMA/302227/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-topical-formulations-list-nationally-authorised-medicinal-products-psusa-00010342-202309_en.pdf"},
    {"id":"63883","name":"Diclofenac (topical formulations) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010342/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T09:10:00Z","last_updated_date":"2024-11-05T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/diclofenac-topical-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010342-202309_no.pdf"}},
    {"id":"63884","name":"Adapalene / benzoyl peroxide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000059/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T09:15:00Z","last_updated_date":"2024-07-05T09:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/adapalene-benzoyl-peroxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000059-202309_no.pdf"}},
    {"id":"63885","name":"Adapalene / benzoyl peroxide : List of nationally authorised medicinal products - PSUSA/00000059/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T09:17:00Z","last_updated_date":"2024-07-05T09:17:00Z","reference_number":"EMA/186512/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/adapalene-benzoyl-peroxide-list-nationally-authorised-medicinal-products-psusa-00000059-202309_en.pdf"},
    {"id":"64081","name":"Acitretin : List of nationally authorised medicinal products - PSUSA/00000051/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T13:57:00Z","last_updated_date":"2024-07-12T13:57:00Z","reference_number":"EMA/325484/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-list-nationally-authorised-medicinal-products-psusa-00000051-202310_en.pdf"},
    {"id":"64082","name":"Acitretin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000051/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T14:00:00Z","last_updated_date":"2024-07-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/acitretin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000051-202310_no.pdf"}},
    {"id":"64120","name":"Baclofen (oral use, for muscle spasticity indication) : List of nationally authorised medicinal products - PSUSA/00000294/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T16:25:00Z","last_updated_date":"2024-07-12T16:25:00Z","reference_number":"EMA/320173/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-list-nationally-authorised-medicinal-products-psusa-00000294-202309_en.pdf"},
    {"id":"64121","name":"Baclofen (oral use, for muscle spasticity indication) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000294/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T16:27:00Z","last_updated_date":"2024-07-12T16:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/baclofen-oral-use-muscle-spasticity-indication-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000294-202309_no.pdf"}},
    {"id":"64155","name":"Sulfasalazine : List of nationally authorised medicinal products - PSUSA/00002816/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T12:32:59Z","last_updated_date":"2024-07-15T12:32:59Z","reference_number":"EMA/304856/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulfasalazine-list-nationally-authorised-medicinal-products-psusa-00002816-202312_en.pdf"},
    {"id":"64169","name":"Tafluprost / timolol : List of nationally authorised medicinal products - PSUSA/00010324/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T15:00:00Z","last_updated_date":"2024-07-16T15:00:00Z","reference_number":"EMA/320225/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/tafluprost-timolol-list-nationally-authorised-medicinal-products-psusa-00010324-202312_en.pdf"},
    {"id":"64175","name":"Flupentixol : List of nationally authorised medicinal products - PSUSA/00001444/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T00:00:00Z","last_updated_date":"2024-07-16T00:00:00Z","reference_number":"EMA/320228/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/flupentixol-list-nationally-authorised-medicinal-products-psusa-00001444-202311_en.pdf"},
    {"id":"64176","name":"Levofloxacin (intravenous and oral use) : List of nationally authorised medicinal products - PSUSA/00010767/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T17:00:00Z","last_updated_date":"2024-07-16T17:00:00Z","reference_number":"EMA/320231/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/levofloxacin-intravenous-oral-use-list-nationally-authorised-medicinal-products-psusa-00010767-202310_en.pdf"},
    {"id":"64179","name":"Levofloxacin (intravenous and oral use) : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010767/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T11:11:01Z","last_updated_date":"2024-07-16T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levofloxacin-intravenous-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010767-202310_no.pdf"}},
    {"id":"64182","name":"Ethanol extracts of: Iberis amara L., planta tota recens / Angelica archangelica L., radix / Matricaria recutita L., flos / Carum carvi L., fructus / Silybum marianum (L.) Gaertn., : List of nationally authorised medicinal products - PSUSA/00010800/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T11:11:01Z","last_updated_date":"2024-07-16T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethanol-extracts-iberis-amara-l-planta-tota-recens-angelica-archangelica-l-radix-matricaria-recutita-l-flos-carum-carvi-l-fructus-silybum-marianum-l-gaertn-list-nationally-authorised-medicinal_en.pdf"},
    {"id":"64184","name":"Flupentixol / melitracene : List of nationally authorised medicinal products - PSUSA/00001445/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T11:11:01Z","last_updated_date":"2024-07-16T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/flupentixol-melitracene-list-nationally-authorised-medicinal-products-psusa-00001445-202311_en.pdf"},
    {"id":"64241","name":"Nabilone : List of nationally authorised medicinal products - PSUSA/00002100/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T16:06:00Z","last_updated_date":"2024-07-19T16:06:00Z","reference_number":"EMA/328912/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/nabilone-list-nationally-authorised-medicinal-products-psusa-00002100-202312_en.pdf"},
    {"id":"64244","name":"diphtheria / tetanus / pertussis (acellular, component) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed) : List of nationally authorised medicinal products - PSUSA/00001124/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T16:12:00Z","last_updated_date":"2024-07-19T16:12:00Z","reference_number":"EMA/226886/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-pertussis-acellular-component-poliomyelitis-inactivated-haemophilus-type-b-conjugate-vaccine-adsorbed-list-nationally-authorised-medicinal-products-psusa-00001124-202311_en.pdf"},
    {"id":"64249","name":"Lisinopril / torasemide : List of nationally authorised medicinal products - PSUSA/00010685/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T16:17:00Z","last_updated_date":"2024-07-19T16:17:00Z","reference_number":"EMA/330241/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisinopril-torasemide-list-nationally-authorised-medicinal-products-psusa-00010685-202312_en.pdf"},
    {"id":"64500","name":"Ceftazidime : List of nationally authorised medicinal products - PSUSA/00000608/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-02T15:50:01Z","last_updated_date":"2024-08-02T15:50:01Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftazidime-list-nationally-authorised-medicinal-products-psusa-00000608-202310_en.pdf"},
    {"id":"64501","name":"Ceftazidime : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000608/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-02T15:51:52Z","last_updated_date":"2024-08-02T15:53:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ceftazidime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000608-202310_no.pdf"}},
    {"id":"64522","name":"Nimodipine: List of nationally authorised medicinal products - PSUSA/00002166/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-07T09:50:34Z","last_updated_date":"2024-08-07T09:50:34Z","reference_number":"EMA/360854/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimodipine-list-nationally-authorised-medicinal-products-psusa-00002166-202311_en.pdf"},
    {"id":"64523","name":"Nimodipine: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002166/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-07T09:56:23Z","last_updated_date":"2024-08-07T09:56:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/nimodipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002166-202311_no.pdf"}},
    {"id":"64548","name":"Clevidipine: List of nationally authorised medicinal products - PSUSA/00010288/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-09T12:42:05Z","last_updated_date":"2024-08-09T12:42:05Z","reference_number":"EMA/370887/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-list-nationally-authorised-medicinal-products-psusa-00010288-202311_en.pdf"},
    {"id":"64549","name":"Clevidipine: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010288/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-09T12:46:58Z","last_updated_date":"2024-08-09T12:49:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/clevidipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010288-202311_sv.pdf"}},
    {"id":"64557","name":"Minoxidil (topical formulation): List of nationally authorised medicinal products - PSUSA/00002067/202310 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-13T09:43:48Z","last_updated_date":"2024-08-13T09:43:48Z","reference_number":"EMA/365078/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/minoxidil-topical-formulation-list-nationally-authorised-medicinal-products-psusa-00002067-202310_en.pdf"},
    {"id":"64558","name":"Minoxidil (topical formulation): CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002067/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-13T09:49:25Z","last_updated_date":"2024-08-13T09:52:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/minoxidil-topical-formulation-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002067-202310_no.pdf"}},
    {"id":"64561","name":"Atorvastatin :  CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00010347/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-13T14:21:31Z","last_updated_date":"2024-08-30T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010347-202310_no.pdf"}},
    {"id":"64562","name":"Atorvastatin : List of nationally authorised medicinal products - PSUSA/00010347/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-13T14:17:46Z","last_updated_date":"2024-08-13T14:17:46Z","reference_number":"EMA/372134/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/atorvastatin-list-nationally-authorised-medicinal-products-psusa-00010347-202310_en.pdf"},
    {"id":"64627","name":"Hydrochlorothiazide / nebivolol : List of nationally authorised medicinal products - PSUSA/00001658/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-23T15:53:57Z","last_updated_date":"2024-08-23T15:53:57Z","reference_number":"EMA/391410/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-nebivolol-list-nationally-authorised-medicinal-products-psusa-00001658-202311_en.pdf"},
    {"id":"64628","name":"Hydrochlorothiazide / nebivolol : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001658/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-23T15:56:27Z","last_updated_date":"2024-08-23T15:56:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydrochlorothiazide-nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001658-202311_sv.pdf"}},
    {"id":"64640","name":"Hydroxycarbamide (except for centrally authorised product) : List of nationally authorised medicinal products - PSUSA/00009182/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-27T13:59:06Z","last_updated_date":"2024-08-27T13:59:06Z","reference_number":"EMA/330561/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa-00009182-202312_en.pdf"},
    {"id":"64642","name":"Hydroxycarbamide (except for centrally authorised product) : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00009182/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-27T14:39:59Z","last_updated_date":"2024-08-27T14:41:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydroxycarbamide-except-centrally-authorised-product-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009182-202312_sv.pdf"}},
    {"id":"64658","name":"Methylprednisolone: List of nationally authorised medicinal products - PSUSA/00002026/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-29T14:40:07Z","last_updated_date":"2024-08-29T14:40:07Z","reference_number":"EMA/396973/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylprednisolone-list-nationally-authorised-medicinal-products-psusa-00002026-202311_en.pdf"},
    {"id":"64659","name":"Methylprednisolone: CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002026/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-08-29T14:41:43Z","last_updated_date":"2024-08-29T14:44:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methylprednisolone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002026-202311_no.pdf"}},
    {"id":"64675","name":"Glatiramer : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00001529/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-02T09:53:12Z","last_updated_date":"2024-09-02T09:55:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/glatiramer-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001529-202311_no.pdf"}},
    {"id":"64676","name":"Glatiramer : List of nationally authorised medicinal products - PSUSA/00001529/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-02T09:56:26Z","last_updated_date":"2024-09-02T09:56:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/glatiramer-list-nationally-authorised-medicinal-products-psusa-00001529-202311_en.pdf"},
    {"id":"64685","name":"Atomoxetine : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000262/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-03T11:15:43Z","last_updated_date":"2024-09-03T11:15:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/atomoxetine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000262-202311_no.pdf"}},
    {"id":"64686","name":"Atomoxetine : List of nationally authorised medicinal products - PSUSA/00000262/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-03T11:19:49Z","last_updated_date":"2024-09-03T11:19:49Z","reference_number":"EMA/407133/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/atomoxetine-list-nationally-authorised-medicinal-products-psusa-00000262-202311_en.pdf"},
    {"id":"64731","name":"Codeine / ibuprofen : List of nationally authorised medicinal products - PSUSA/00000850/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T10:56:55Z","last_updated_date":"2024-09-06T10:56:55Z","reference_number":"EMA/415615/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/codeine-ibuprofen-list-nationally-authorised-medicinal-products-psusa-00000850-202312_en.pdf"},
    {"id":"64732","name":"Codeine / ibuprofen : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000850/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T10:58:54Z","last_updated_date":"2024-09-06T10:58:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/codeine-ibuprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000850-202312_sv.pdf"}},
    {"id":"64735","name":"Alitretinoin (oral use) : List of nationally authorised medicinal products - PSUSA/00010710/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T11:32:28Z","last_updated_date":"2024-09-06T11:32:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/alitretinoin-oral-use-list-nationally-authorised-medicinal-products-psusa-00010710-202401_en.pdf"},
    {"id":"64742","name":"Balsalazide : List of nationally authorised medicinal products - PSUSA/00009074/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T14:17:00Z","last_updated_date":"2024-09-06T14:17:00Z","reference_number":"EMA/418248/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/balsalazide-list-nationally-authorised-medicinal-products-psusa-00009074-202401_en.pdf"},
    {"id":"64743","name":"Altizide / spironolactone : List of nationally authorised medicinal products - PSUSA/00002781/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T14:23:00Z","last_updated_date":"2024-09-06T14:23:00Z","reference_number":"EMA/419122/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/altizide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00002781-202401_en.pdf"}    {"id":"64744","name":"Dapoxetine : List of nationally authorised medicinal products - PSUSA/00000928/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T14:27:00Z","last_updated_date":"2024-09-06T14:27:00Z","reference_number":"EMA/419119/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/dapoxetine-list-nationally-authorised-medicinal-products-psusa-00000928-202312_en.pdf"},
    {"id":"64749","name":"Salicylic acid (topical use) : List of nationally authorised medicinal products - PSUSA/00002680/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T15:00:00Z","last_updated_date":"2024-09-06T15:00:00Z","reference_number":"EMA/419190/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/salicylic-acid-topical-use-list-nationally-authorised-medicinal-products-psusa-00002680-202312_en.pdf"},
    {"id":"64750","name":"Salicylic acid (topical use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002680/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T15:03:00Z","last_updated_date":"2024-09-06T15:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/salicylic-acid-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002680-202312_sv.pdf"}},
    {"id":"64751","name":"Celecoxib : List of nationally authorised medicinal products - PSUSA/00000616/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T15:07:00Z","last_updated_date":"2024-09-06T15:07:00Z","reference_number":"EMA/383229/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/celecoxib-list-nationally-authorised-medicinal-products-psusa-00000616-202312_en.pdf"},
    {"id":"64752","name":"Caffeine / drotaverine hydrochloride / metamizole sodium : List of nationally authorised medicinal products - PSUSA/00001996/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T15:32:00Z","last_updated_date":"2024-09-06T15:32:00Z","reference_number":"EMA/381795/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/caffeine-drotaverine-hydrochloride-metamizole-sodium-list-nationally-authorised-medicinal-products-psusa-00001996-202401_en.pdf"},
    {"id":"64759","name":"Hepatitis A vaccines (inactivated, adsorbed) : List of nationally authorised medicinal products - PSUSA/00001596/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T11:55:10Z","last_updated_date":"2024-09-09T11:55:10Z","reference_number":"EMA/365619/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/hepatitis-vaccines-inactivated-adsorbed-list-nationally-authorised-medicinal-products-psusa-00001596-202401_en.pdf"},
    {"id":"64760","name":"Povidone iodinated : List of nationally authorised medicinal products - PSUSA/00002487/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T12:10:17Z","last_updated_date":"2024-09-09T12:10:17Z","reference_number":"EMA/365603/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/povidone-iodinated-list-nationally-authorised-medicinal-products-psusa-00002487-202401_en.pdf"},
    {"id":"64762","name":"Hydrochlorothiazide / spironolactone : List of nationally authorised medicinal products - PSUSA/00001662/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T12:25:23Z","last_updated_date":"2024-09-09T12:25:23Z","reference_number":"EMA/364990/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-spironolactone-list-nationally-authorised-medicinal-products-psusa-00001662-202401_en.pdf"},
    {"id":"64772","name":"Azelastine : List of nationally authorised medicinal products - PSUSA/00000277/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-10T13:08:50Z","last_updated_date":"2024-09-10T13:08:50Z","reference_number":"EMA/420871/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/azelastine-list-nationally-authorised-medicinal-products-psusa-00000277-202312_en.pdf"},
    {"id":"64773","name":"Calcium carbonate / famotidine / magnesium hydroxide : List of nationally authorised medicinal products - PSUSA/00001351/202309","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-10T13:12:00Z","last_updated_date":"2024-09-10T13:12:00Z","reference_number":"EMA/420885/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-carbonate-famotidine-magnesium-hydroxide-list-nationally-authorised-medicinal-products-psusa-00001351-202309_en.pdf"},
    {"id":"64774","name":"Ketotifen (oral formulations) : List of nationally authorised medicinal products - PSUSA/00001813/202310","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-10T13:15:00Z","last_updated_date":"2024-09-10T13:15:00Z","reference_number":"EMA/420924/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketotifen-oral-formulations-list-nationally-authorised-medicinal-products-psusa-00001813-202310_en.pdf"},
    {"id":"64775","name":"Ketoprofen / sucralfate : List of nationally authorised medicinal products - PSUSA/00002797/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-10T13:24:50Z","last_updated_date":"2024-09-10T13:24:50Z","reference_number":"EMA/420962/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ketoprofen-sucralfate-list-nationally-authorised-medicinal-products-psusa-00002797-202312_en.pdf"},
    {"id":"64776","name":"Pseudoephedrine / triprolidine : List of nationally authorised medicinal products - PSUSA/00003047/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-10T14:00:00Z","last_updated_date":"2024-09-10T14:00:00Z","reference_number":"EMA/423220/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/pseudoephedrine-triprolidine-list-nationally-authorised-medicinal-products-psusa-00003047-202312_en.pdf"},
    {"id":"64779","name":"Lormetazepam : List of nationally authorised medicinal products - PSUSA/00001910/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-10T16:01:00Z","last_updated_date":"2024-09-10T16:01:00Z","reference_number":"EMA/423653/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/lormetazepam-list-nationally-authorised-medicinal-products-psusa-00001910-202312_en.pdf"},
    {"id":"64805","name":"Doxazosin : List of nationally authorised medicinal products - PSUSA/00001169/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-12T10:56:49Z","last_updated_date":"2024-09-12T10:56:49Z","reference_number":"EMA/420355/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/doxazosin-list-nationally-authorised-medicinal-products-psusa-00001169-202312_en.pdf"},
    {"id":"64807","name":"Dydrogesterone-estradiol  : List of nationally authorised medicinal products - PSUSA-00001276-202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-12T11:07:56Z","last_updated_date":"2024-09-12T11:07:56Z","reference_number":"EMA/420291/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/dydrogesterone-estradiol-list-nationally-authorised-medicinal-products-psusa-00001276-202312_en.pdf"},
    {"id":"64809","name":"Dydrogesterone-estradiol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA-00001276-202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-12T11:16:19Z","last_updated_date":"2024-09-12T11:16:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001276-202312_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dydrogesterone-estradiol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation_no.pdf"}},
    {"id":"64813","name":"Betahistine : List of nationally authorised medicinal products - PSUSA/00000389/202312 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-12T15:28:20Z","last_updated_date":"2024-09-12T15:28:20Z","reference_number":"EMA/428122/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/betahistine-list-nationally-authorised-medicinal-products-psusa-00000389-202312_en.pdf"},
    {"id":"64814","name":"Levodropropizine : List of nationally authorised medicinal products - PSUSA/00001853/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-12T15:35:39Z","last_updated_date":"2024-09-12T15:35:39Z","reference_number":"EMA/428229/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/levodropropizine-list-nationally-authorised-medicinal-products-psusa-00001853-202401_en.pdf"},
    {"id":"64845","name":"Cyproheptadine : List of nationally authorised medicinal products - PSUSA/00000902/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-13T12:10:00Z","last_updated_date":"2024-09-13T12:10:00Z","reference_number":"EMA/429052/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyproheptadine-list-nationally-authorised-medicinal-products-psusa-00000902-202312_en.pdf"},
    {"id":"64931","name":"Dexpanthenol : EPAR - List of nationally authorised medicinal products - PSUSA/00000999/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T11:15:00Z","last_updated_date":"2024-09-19T11:15:00Z","reference_number":"EMA/439633/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexpanthenol-epar-list-nationally-authorised-medicinal-products-psusa-00000999-202401_en.pdf"},
    {"id":"64941","name":"Meropenem : List of nationally authorised medicinal products - PSUSA/00001989/202108","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T15:21:00Z","last_updated_date":"2024-09-19T15:21:00Z","reference_number":"EMA/738442/2022","document_url":"https://www.ema.europa.eu/en/documents/psusa/meropenem-list-nationally-authorised-medicinal-products-psusa-00001989-202108_en.pdf"},
    {"id":"65023","name":"Cefpodoxim : List of nationally authorised medicinal products - PSUSA/00000604/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-25T15:00:00Z","last_updated_date":"2024-09-25T15:00:00Z","reference_number":"EMA/444611/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefpodoxim-list-nationally-authorised-medicinal-products-psusa-00000604-202312_en.pdf"},
    {"id":"65024","name":"Cefpodoxim : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000604/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-09-25T17:00:00Z","last_updated_date":"2024-09-25T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefpodoxim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000604-202312_sv.pdf"}},
    {"id":"65070","name":"Bendroflumethiazide, bendroflumethiazide / potassium chloride : List of nationally authorised medicinal products - PSUSA/00010583/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-01T12:22:00Z","last_updated_date":"2024-10-01T12:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendroflumethiazide-bendroflumethiazide-potassium-chloride-list-nationally-authorised-medicinal-products-psusa-00010583-202401_en.pdf"},
    {"id":"65125","name":"Chlormadinone : List of nationally authorised medicinal products - PSUSA/00000677/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T13:14:00Z","last_updated_date":"2024-10-03T13:14:00Z","reference_number":"EMA/434956/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlormadinone-list-nationally-authorised-medicinal-products-psusa-00000677-202401_en.pdf"},
    {"id":"65126","name":"Nomegestrol : List of nationally authorised medicinal products - PSUSA/00002181/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T13:51:00Z","last_updated_date":"2024-10-03T13:51:00Z","reference_number":"EMA/446952/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/nomegestrol-list-nationally-authorised-medicinal-products-psusa-00002181-202401_en.pdf"},
    {"id":"65127","name":"Influenza vaccine (surface antigen, inactivated) : List of nationally authorised medicinal products - PSUSA/00001744/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T13:55:00Z","last_updated_date":"2024-10-03T13:55:00Z","reference_number":"EMA/435385/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa-00001744-202403_en.pdf"},
    {"id":"65128","name":"Flubendazole : List of nationally authorised medicinal products - PSUSA/00001400/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T14:03:00Z","last_updated_date":"2024-10-03T14:03:00Z","reference_number":"EMA/435346/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/flubendazole-list-nationally-authorised-medicinal-products-psusa-00001400-202402_en.pdf"},
    {"id":"65129","name":"Influenza vaccine (split virion, inactivated) (non centrally authorised products) : List of nationally authorised medicinal products - PSUSA/00010298/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T14:08:00Z","last_updated_date":"2024-10-03T14:08:00Z","reference_number":"EMA/435357/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-split-virion-inactivated-non-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa-00010298-202403_en.pdf"},
    {"id":"65130","name":"Ondansetron : List of nationally authorised medicinal products - PSUSA/00002217/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T14:35:00Z","last_updated_date":"2024-10-03T14:35:00Z","reference_number":"EMA/268423/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ondansetron-list-nationally-authorised-medicinal-products-psusa-00002217-202402_en.pdf"},
    {"id":"65131","name":"Lisdexamfetamine : List of nationally authorised medicinal products - PSUSA/00010289/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T14:46:00Z","last_updated_date":"2024-10-03T14:46:00Z","reference_number":"EMA/461260/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa-00010289-202402_en.pdf"},
    {"id":"65144","name":"Ampicillin / sulbactam : List of nationally authorised medicinal products - PSUSA/00000197/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T16:05:00Z","last_updated_date":"2024-10-03T16:05:00Z","reference_number":"EMA/461916/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ampicillin-sulbactam-list-nationally-authorised-medicinal-products-psusa-00000197-202402_en.pdf"},
    {"id":"65221","name":"Sterculia, frangula / sterculia : List of nationally authorised medicinal products - PSUSA/00010428/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T16:03:00Z","last_updated_date":"2024-10-07T16:03:00Z","reference_number":"EMA/462766/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/sterculia-frangula-sterculia-list-nationally-authorised-medicinal-products-psusa-00010428-202402_en.pdf"},
    {"id":"65222","name":"Chlormadinone acetate / ethinylestradiol : List of nationally authorised medicinal products - PSUSA/00000679/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T12:00:00Z","last_updated_date":"2024-10-07T12:00:00Z","reference_number":"EMA/466465/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlormadinone-acetate-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa-00000679-202401_en.pdf"},
    {"id":"65223","name":"Sodium iron gluconate (parenteral use) : List of nationally authorised medicinal products - PSUSA/00010867/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T16:10:00Z","last_updated_date":"2024-10-07T16:10:00Z","reference_number":"EMA/466608/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-iron-gluconate-parenteral-use-list-nationally-authorised-medicinal-products-psusa-00010867-202401_en.pdf"},
    {"id":"65224","name":"Dorzolamide / timolol : List of nationally authorised medicinal products - PSUSA/00001166/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T16:14:00Z","last_updated_date":"2024-10-07T16:14:00Z","reference_number":"EMA/423872/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-timolol-list-nationally-authorised-medicinal-products-psusa-00001166-202402_en.pdf"},
    {"id":"65235","name":"Ferric derisomaltose (parenteral use) : List of nationally authorised medicinal products - PSUSA/00010866/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-08T11:45:00Z","last_updated_date":"2024-10-08T11:45:00Z","reference_number":"EMA/467627/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ferric-derisomaltose-parenteral-use-list-nationally-authorised-medicinal-products-psusa-00010866-202401_en.pdf"},
    {"id":"65244","name":"Aprotinin : List of nationally authorised medicinal products - PSUSA/00000230/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-09T10:38:00Z","last_updated_date":"2024-10-09T10:38:00Z","reference_number":"EMA/470061/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/aprotinin-list-nationally-authorised-medicinal-products-psusa-00000230-202402_en.pdf"},
    {"id":"65245","name":"Iron dextran : List of nationally authorised medicinal products - PSUSA/00010696/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-09T11:25:00Z","last_updated_date":"2024-10-09T11:25:00Z","reference_number":"EMA/470113/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-dextran-list-nationally-authorised-medicinal-products-psusa-00010696-202401_en.pdf"},
    {"id":"65247","name":"Iron sucrose (parenteral use) : List of nationally authorised medicinal products - PSUSA/00010864/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-09T11:47:00Z","last_updated_date":"2024-10-09T11:47:00Z","reference_number":"EMA/470193/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/iron-sucrose-parenteral-use-list-nationally-authorised-medicinal-products-psusa-00010864-202401_en.pdf"},
    {"id":"65248","name":"Rupatadine : List of nationally authorised medicinal products - PSUSA/00002673/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-09T12:28:00Z","last_updated_date":"2024-10-09T12:28:00Z","reference_number":"EMA/470269/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/rupatadine-list-nationally-authorised-medicinal-products-psusa-00002673-202312_en.pdf"},
    {"id":"65284","name":"Ferric carboxymaltose (parenteral use) : List of nationally authorised medicinal products - PSUSA/00010865/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-11T16:31:00Z","last_updated_date":"2024-10-11T16:31:00Z","reference_number":"EMA/475270/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ferric-carboxymaltose-parenteral-use-list-nationally-authorised-medicinal-products-psusa-00010865-202401_en.pdf"},
    {"id":"65285","name":"Pentoxyverine : List of nationally authorised medicinal products - PSUSA/00002345/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-11T16:34:00Z","last_updated_date":"2024-10-11T16:34:00Z","reference_number":"EMA/475205/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/pentoxyverine-list-nationally-authorised-medicinal-products-psusa-00002345-202312_en.pdf"},
    {"id":"65286","name":"Human coagulation factor VIII (inhibitor bypassing fraction) : List of nationally authorised medicinal products - PSUSA/00009174/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-11T16:37:00Z","last_updated_date":"2024-10-11T16:37:00Z","reference_number":"EMA/475430/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-coagulation-factor-viii-inhibitor-bypassing-fraction-list-nationally-authorised-medicinal-products-psusa-00009174-202402_en.pdf"},
    {"id":"65311","name":"cilazapril, cilazapril / hydrochlorothiazide : List of nationally authorised medicinal products - PSUSA/00000749/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-16T17:50:00Z","last_updated_date":"2024-10-16T17:50:00Z","reference_number":"EMA/473677/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/cilazapril-cilazapril-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa-00000749-202402_en.pdf"},
    {"id":"65320","name":"amlodipine / losartan : List of nationally authorised medicinal products - PSUSA/00010512/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T11:45:00Z","last_updated_date":"2024-10-17T11:45:00Z","reference_number":"EMA/483180/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-losartan-list-nationally-authorised-medicinal-products-psusa-00010512-202401_en.pdf"},
    {"id":"65321","name":"protirelin : List of nationally authorised medicinal products - PSUSA/00009273/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T11:51:18Z","last_updated_date":"2024-10-17T11:51:18Z","reference_number":"EMA/483478/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/protirelin-list-nationally-authorised-medicinal-products-psusa-00009273-202401_en.pdf"},
    {"id":"65322","name":"Galantamine : List of nationally authorised medicinal products - PSUSA/00001512/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T12:01:21Z","last_updated_date":"2024-10-17T12:01:21Z","reference_number":"EMA/483497/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/galantamine-list-nationally-authorised-medicinal-products-psusa-00001512-202403_en.pdf"},
    {"id":"65424","name":"Allopurinol : List of nationally authorised medicinal products - PSUSA/00000095/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T12:56:00Z","last_updated_date":"2024-10-24T12:56:00Z","reference_number":"EMA/496476/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/allopurinol-list-nationally-authorised-medicinal-products-psusa-00000095-202312_en.pdf"},
    {"id":"65425","name":"Allopurinol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000095/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T13:02:00Z","last_updated_date":"2024-10-24T13:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/allopurinol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000095-202312_no.pdf"}},
    {"id":"65436","name":"Amitriptyline / perphenazine : List of nationally authorised medicinal products - PSUSA/00000170/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T10:32:00Z","last_updated_date":"2024-10-25T10:32:00Z","reference_number":"EMA/497973/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-perphenazine-list-nationally-authorised-medicinal-products-psusa-00000170-202401_en.pdf"},
    {"id":"65437","name":"Amitriptyline / perphenazine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000170/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T10:35:00Z","last_updated_date":"2024-10-25T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amitriptyline-perphenazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000170-202401_sv.pdf"}},
    {"id":"65449","name":"Macrogol 3350 combinations (oral use) : List of nationally authorised medicinal products - PSUSA/00010705/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T15:19:00Z","last_updated_date":"2024-10-25T15:19:00Z","reference_number":"EMA/395372/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/macrogol-3350-combinations-oral-use-list-nationally-authorised-medicinal-products-psusa-00010705-202401_en.pdf"},
    {"id":"65450","name":"Macrogol 3350 combinations (oral use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010705/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T15:21:00Z","last_updated_date":"2024-10-25T15:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/macrogol-3350-combinations-oral-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010705-202401_no.pdf"}},
    {"id":"65452","name":"Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpromide, valproate bismuth, calcium valproate, valproate magnesium : List of nationally authorised medicinal products - PSUSA/00003090/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T10:38:00Z","last_updated_date":"2024-10-28T10:38:00Z","reference_number":"EMA/270645/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxil-valproate-semisodium-valpromide-valproate-bismuth-calcium-valproate-valproate-magnesium-list-nationally-authorised-medicinal-products-psusa-00003090_en.pdf"},
    {"id":"65453","name":"Valproic acid, sodium valproate, valproate pivoxil.....valproate magnesium : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003090/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T10:46:00Z","last_updated_date":"2024-10-28T10:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/valproic-acid-sodium-valproate-valproate-pivoxilvalproate-magnesium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003090-202401_no.pdf"}},
    {"id":"65461","name":"Amitriptyline, amitriptyline / amitriptylinoxide, amitriptylinoxide: List of nationally authorised medicinal products -  PSUSA/00010374/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T16:00:00Z","last_updated_date":"2024-10-28T16:00:00Z","reference_number":"EMA/423920/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-list-nationally-authorised-medicinal-products-psusa-00010374-202401_en.pdf"},
    {"id":"65462","name":"Amitriptyline, amitriptyline / amitriptylinoxide, amitriptylinoxide: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010374/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T16:00:00Z","last_updated_date":"2024-10-28T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/amitriptyline-amitriptyline-amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010374-202401_no.pdf"}},
    {"id":"65474","name":"Amantadine : List of nationally authorised medicinal products - PSUSA/00000126/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T11:42:43Z","last_updated_date":"2024-10-29T11:42:43Z","reference_number":"EMA/500726/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/amantadine-list-nationally-authorised-medicinal-products-psusa-00000126-202401_en.pdf"},
    {"id":"65475","name":"Amantadine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000126/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T11:45:17Z","last_updated_date":"2024-10-29T11:45:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amantadine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000126-202401_sv.pdf"}},
    {"id":"65502","name":"Fluorodopa (18F) : List of nationally authorised medicinal products - PSUSA/00010002/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T11:34:00Z","last_updated_date":"2024-10-31T11:34:00Z","reference_number":"EMA/316805/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluorodopa-18f-list-nationally-authorised-medicinal-products-psusa-00010002-202403_en.pdf"},
    {"id":"65503","name":"Human anti-d immunoglobulin : List of nationally authorised medicinal products - PSUSA/00001614/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T14:20:32Z","last_updated_date":"2024-10-31T14:20:32Z","reference_number":"EMA/480206/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-anti-d-immunoglobulin-list-nationally-authorised-medicinal-products-psusa-00001614-202403_en.pdf"},
    {"id":"65504","name":"Fluprednidene / gentamicin : List of nationally authorised medicinal products - PSUSA/00010098/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T14:26:18Z","last_updated_date":"2024-10-31T14:26:18Z","reference_number":"EMA/493462/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluprednidene-gentamicin-list-nationally-authorised-medicinal-products-psusa-00010098-202403_en.pdf"},
    {"id":"65505","name":"Erythromycin (topical use) : List of nationally authorised medicinal products - PSUSA/00010809/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T14:36:24Z","last_updated_date":"2024-10-31T14:36:24Z","reference_number":"EMA/493558/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/erythromycin-topical-use-list-nationally-authorised-medicinal-products-psusa-00010809-202403_en.pdf"},
    {"id":"65508","name":"Olodaterol : List of nationally authorised medicinal products - PSUSA/00010245/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T15:32:24Z","last_updated_date":"2024-10-31T15:32:24Z","reference_number":"EMA/508740/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodaterol-list-nationally-authorised-medicinal-products-psusa-00010245-202403_en.pdf"},
    {"id":"65509","name":"Fluprednidene : List of nationally authorised medicinal products - PSUSA/00010097/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T15:46:07Z","last_updated_date":"2024-10-31T15:46:07Z","reference_number":"EMA/508765/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluprednidene-list-nationally-authorised-medicinal-products-psusa-00010097-202403_en.pdf"},
    {"id":"65526","name":"Metamizole : List of nationally authorised medicinal products - PSUSA/00001997/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-04T10:07:35Z","last_updated_date":"2024-11-04T10:07:35Z","reference_number":"EMA/509256/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/metamizole-list-nationally-authorised-medicinal-products-psusa-00001997-202403_en.pdf"},
    {"id":"65527","name":"Calcium chloride/glutamic acid/glutathione/histidine/lactobionic acid/magnesium chloride/mannitol/potassium chloride/sodium hydroxide : List of nationally authorised medicinal products - PSUSA/00009162/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-04T10:21:04Z","last_updated_date":"2024-11-04T10:21:04Z","reference_number":"EMA/510665/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcium-chloride-glutamic-acid-glutathione-histidine-lactobionic-acid-magnesium-chloride-mannitol-potassium-chloride-sodium-hydroxide-list-nationally-authorised-medicinal-products-psusa-00009162_en.pdf"},
    {"id":"65529","name":"Highly refined fish oil, glycerol, purified egg phosphatide : List of nationally authorised medicinal products - PSUSA/00010802/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-04T13:18:02Z","last_updated_date":"2024-11-04T13:18:02Z","reference_number":"EMA/511188/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/highly-refined-fish-oil-glycerol-purified-egg-phosphatide-list-nationally-authorised-medicinal-products-psusa-00010802-202403_en.pdf"},
    {"id":"65531","name":"Nitrazepam : List of nationally authorised medicinal products - PSUSA/00002170/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-04T15:45:29Z","last_updated_date":"2024-11-04T15:45:29Z","reference_number":"EMA/511573/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrazepam-list-nationally-authorised-medicinal-products-psusa-00002170-202403_en.pdf"},
    {"id":"65536","name":"5 fluorouracil (IV use) : List of nationally authorised medicinal products - PSUSA/00000007/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-05T09:02:33Z","last_updated_date":"2024-11-05T09:02:33Z","reference_number":"EMA/224383/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-iv-use-list-nationally-authorised-medicinal-products-psusa-00000007-202312_en.pdf"},
    {"id":"65537","name":"5 fluorouracil (IV use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000007/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-05T09:04:10Z","last_updated_date":"2024-11-05T09:04:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/5-fluorouracil-iv-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000007-202312_no.pdf"}},
    {"id":"65557","name":"Barnidipine : List of nationally authorised medicinal products - PSUSA/00000300/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-06T14:10:48Z","last_updated_date":"2024-11-06T14:10:48Z","reference_number":"EMA/515521/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/barnidipine-list-nationally-authorised-medicinal-products-psusa-00000300-202403_en.pdf"},
    {"id":"65562","name":"Zoledronic acid: List of nationally authorised medicinal products - PSUSA/00003149/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-07T13:50:40Z","last_updated_date":"2024-11-07T13:50:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/zoledronic-acid-list-nationally-authorised-medicinal-products-psusa-00003149-202308_en.pdf"},
    {"id":"65563","name":"Zoledronic acid: Scientific conclusions and grounds for variation, amendments to the Product Information - PSUSA/00003149/202308","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-07T13:52:00Z","last_updated_date":"2024-11-07T13:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/zoledronic-acid-scientific-conclusions-grounds-variation-amendments-product-information-psusa-00003149-202308_sv.pdf"}},
    {"id":"65596","name":"Liothyronine : List of nationally authorised medicinal products - PSUSA/00001890/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-12T14:56:53Z","last_updated_date":"2024-11-12T14:56:53Z","reference_number":"EMA/500549/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/liothyronine-list-nationally-authorised-medicinal-products-psusa-00001890-202401_en.pdf"},
    {"id":"65600","name":"Liothyronine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001890/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-12T16:01:25Z","last_updated_date":"2025-02-12T14:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/liothyronine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001890-202401_no.pdf"}},
    {"id":"65606","name":"Levonorgestrel / ethinylestradiol, ethinylestradiol (combination pack) : List of nationally authorised medicinal products - PSUSA/00010442/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-13T11:54:30Z","last_updated_date":"2024-11-13T11:54:30Z","reference_number":"EMA/390583/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-list-nationally-authorised-medicinal-products-psusa-00010442-202401_en.pdf"},
    {"id":"65607","name":"Levonorgestrel / ethinylestradiol, ethinylestradiol (combination pack) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010442/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-13T11:56:46Z","last_updated_date":"2024-11-13T11:56:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levonorgestrel-ethinylestradiol-ethinylestradiol-combination-pack-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010442-202401_no.pdf"}},
    {"id":"65743","name":"Amiodarone : List of nationally authorised medicinal products - PSUSA/00000166/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-21T09:19:37Z","last_updated_date":"2024-11-21T09:19:37Z","reference_number":"EMA/CHMP/544052/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/amiodarone-list-nationally-authorised-medicinal-products-psusa-00000166-202312_en.pdf"},
    {"id":"65744","name":"Amiodarone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000166/202312","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-21T09:21:51Z","last_updated_date":"2024-11-21T09:21:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/amiodarone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000166-202312_no.pdf"}},
    {"id":"65755","name":"Zofenopril : List of nationally authorised medicinal products - PSUSA/00003147/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-22T10:54:34Z","last_updated_date":"2024-11-22T10:54:34Z","reference_number":"EMA/545639/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/zofenopril-list-nationally-authorised-medicinal-products-psusa-00003147-202401_en.pdf"},
    {"id":"65756","name":"Zofenopril : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation  - PSUSA/00003147/202401","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-22T10:57:37Z","last_updated_date":"2024-11-22T10:57:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/zofenopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003147-202401_sv.pdf"}},
    {"id":"65757","name":"Terazosin : List of nationally authorised medicinal products - PSUSA/00002895/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-22T11:01:22Z","last_updated_date":"2024-11-22T11:01:22Z","reference_number":"EMA/545639/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/terazosin-list-nationally-authorised-medicinal-products-psusa-00002895-202311_en.pdf"},
    {"id":"65759","name":"Terazosin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation  - PSUSA/00002895/202311","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-22T11:17:11Z","last_updated_date":"2024-11-22T11:17:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/terazosin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002895-202311_no.pdf"}},
    {"id":"65760","name":"Mesalazine : List of nationally authorised medicinal products - PSUSA/00001990/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-22T11:22:54Z","last_updated_date":"2024-11-22T11:22:54Z","reference_number":"EMA/459995/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesalazine-list-nationally-authorised-medicinal-products-psusa-00001990-202402_en.pdf"},
    {"id":"65761","name":"Mesalazine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001990/202402","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-22T11:25:18Z","last_updated_date":"2024-11-22T11:25:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/mesalazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001990-202402_no.pdf"}},
    {"id":"65873","name":"Bupivacaine, bupivacaine / epinephrine : List of nationally authorised medicinal products - PSUSA/00010335/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-28T15:22:03Z","last_updated_date":"2024-11-28T15:22:03Z","reference_number":"EMA/PRAC/539781/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/bupivacaine-bupivacaine-epinephrine-list-nationally-authorised-medicinal-products-psusa-00010335-202404_en.pdf"},
    {"id":"65874","name":"Carteolol : List of nationally authorised medicinal products - PSUSA/00000574/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-28T15:39:00Z","last_updated_date":"2024-11-28T15:39:00Z","reference_number":"EMA/555893/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/carteolol-list-nationally-authorised-medicinal-products-psusa-00000574-202403_en.pdf"},
    {"id":"65877","name":"Isotretinoin (oral formulations) : List of nationally authorised medicinal products - PSUSA/00010488/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-28T16:52:16Z","last_updated_date":"2024-11-28T16:52:16Z","reference_number":"EMA/535406/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa-00010488-202405_en.pdf"},
    {"id":"65886","name":"Chlorprothixene : List of nationally authorised medicinal products - PSUSA/00000717/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-29T16:10:26Z","last_updated_date":"2024-11-29T16:10:26Z","reference_number":"EMA/557829/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorprothixene-list-nationally-authorised-medicinal-products-psusa-00000717-202403_en.pdf"},
    {"id":"65887","name":"Dihydroergotamine : List of nationally authorised medicinal products - PSUSA/00001075/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-11-29T16:15:23Z","last_updated_date":"2024-11-29T16:15:23Z","reference_number":"EMA/556906/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/dihydroergotamine-list-nationally-authorised-medicinal-products-psusa-00001075-202404_en.pdf"},
    {"id":"65889","name":"Ofloxacin (topical use) : List of nationally authorised medicinal products - PSUSA/00002204/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-12-02T12:26:32Z","last_updated_date":"2024-12-02T12:26:32Z","reference_number":"EMA/459239/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-topical-use-list-nationally-authorised-medicinal-products-psusa-00002204-202404_en.pdf"},
    {"id":"65937","name":"Ciprofloxacin / fluocinolone acetonide : List of nationally authorised medicinal products - PSUSA/00000772/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2024-12-04T10:22:30Z","last_updated_date":"2024-12-04T10:22:30Z","reference_number":"EMA/563900/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-fluocinolone-acetonide-list-nationally-authorised-medicinal-products-psusa-00000772-202404_en.pdf"},
    {"id":"66239","name":"Oxycodone : List of nationally authorised medicinal products - PSUSA/00002254/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-06T14:28:46Z","last_updated_date":"2025-01-06T14:28:46Z","reference_number":"EMA/596129/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-list-nationally-authorised-medicinal-products-psusa-00002254-202404_en.pdf"},
    {"id":"66240","name":"Oxycodone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002254/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-06T14:31:19Z","last_updated_date":"2025-01-06T14:31:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_no.pdf"}},
    {"id":"66241","name":"Oxycodone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002254/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-06T14:33:29Z","last_updated_date":"2025-01-06T14:33:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_sv.pdf-0","is":"https://www.ema.europa.eu/is/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_is.pdf-0","no":"https://www.ema.europa.eu/no/documents/psusa/oxycodone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002254-202404_no.pdf-0"}},
    {"id":"66242","name":"Lanthanum : List of nationally authorised medicinal products - PSUSA/00003175/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-06T14:37:17Z","last_updated_date":"2025-01-06T14:37:17Z","reference_number":"EMA/596073/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/lanthanum-list-nationally-authorised-medicinal-products-psusa-00003175-202403_en.pdf"},
    {"id":"66243","name":"Lanthanum : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003175/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-06T14:39:07Z","last_updated_date":"2025-01-06T14:39:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/lanthanum-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003175-202403_no.pdf"}}    {"id":"66249","name":"Chlorphenamine maleate / paracetamol : List of nationally authorised medicinal products - PSUSA/00000703/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-06T16:42:01Z","last_updated_date":"2025-01-06T16:42:01Z","reference_number":"EMA/598255/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorphenamine-maleate-paracetamol-list-nationally-authorised-medicinal-products-psusa-00000703-202403_en.pdf"},
    {"id":"66250","name":"Chlorphenamine maleate / paracetamol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000703/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-06T16:43:51Z","last_updated_date":"2025-01-06T16:43:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_lt.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/chlorphenamine-maleate-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000703-202403_sv.pdf"}},
    {"id":"66259","name":"Bilastine : List of nationally authorised medicinal products - PSUSA/00003163/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-07T15:46:34Z","last_updated_date":"2025-01-07T15:46:34Z","reference_number":"EMA/487378/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/bilastine-list-nationally-authorised-medicinal-products-psusa-00003163-202403_en.pdf"},
    {"id":"66260","name":"Bilastine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003163/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-07T15:48:18Z","last_updated_date":"2025-01-07T15:48:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bilastine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003163-202403_no.pdf"}},
    {"id":"66332","name":"Iodine (131i) iobenguane : List of nationally authorised medicinal products - PSUSA/00001764/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-16T14:51:55Z","last_updated_date":"2025-01-16T14:51:55Z","reference_number":"EMA/441417/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/iodine-131i-iobenguane-list-nationally-authorised-medicinal-products-psusa-00001764-202405_en.pdf"},
    {"id":"66334","name":"Alginic acid / aluminium oxide hydrated / sodium hydrogen carbonate, alginic acid / aluminium hydroxide / calcium carbonate / sodium carbonate : List of nationally authorised medicinal products - PSUSA/00000123/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-16T16:27:28Z","last_updated_date":"2025-01-16T16:27:28Z","reference_number":"EMA/369/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/alginic-acid-aluminium-oxide-hydrated-sodium-hydrogen-carbonate-alginic-acid-aluminium-hydroxide-calcium-carbonate-sodium-carbonate-list-nationally-authorised-medicinal-products-psusa-00000123-202406_en.pdf"},
    {"id":"66335","name":"Yohimbine : List of nationally authorised medicinal products - PSUSA/00003136/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-16T16:51:17Z","last_updated_date":"2025-01-16T16:51:17Z","reference_number":"EMA/362/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/yohimbine-list-nationally-authorised-medicinal-products-psusa-00003136-202405_en.pdf"},
    {"id":"66336","name":"Indocyanine green : List of nationally authorised medicinal products - PSUSA/00001737/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-16T16:55:43Z","last_updated_date":"2025-01-16T16:55:43Z","reference_number":"EMA/441483/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/indocyanine-green-list-nationally-authorised-medicinal-products-psusa-00001737-202405_en.pdf"},
    {"id":"66338","name":"Ferucarbotran : List of nationally authorised medicinal products - PSUSA/00001382/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-16T17:16:02Z","last_updated_date":"2025-01-16T17:16:02Z","reference_number":"EMA/441093/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/ferucarbotran-list-nationally-authorised-medicinal-products-psusa-00001382-202406_en.pdf"},
    {"id":"66339","name":"Daunorubicin : List of nationally authorised medicinal products - PSUSA/00000936/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-16T17:19:30Z","last_updated_date":"2025-01-16T17:19:30Z","reference_number":"EMA/441389/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/daunorubicin-list-nationally-authorised-medicinal-products-psusa-00000936-202406_en.pdf"},
    {"id":"66343","name":"Tafluprost : List of nationally authorised medicinal products - PSUSA/00002843/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-17T10:36:52Z","last_updated_date":"2025-01-17T10:36:52Z","reference_number":"EMA/PRAC/21370/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/tafluprost-list-nationally-authorised-medicinal-products-psusa-00002843-202404_en.pdf"},
    {"id":"66348","name":"Metformin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002001/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-17T12:34:14Z","last_updated_date":"2025-01-17T12:34:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/metformin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002001-202404_no.pdf"}},
    {"id":"66349","name":"Metformin : List of nationally authorised medicinal products - PSUSA/00002001/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-17T12:36:54Z","last_updated_date":"2025-01-17T12:36:54Z","reference_number":"EMA/PRAC/540435/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/metformin-list-nationally-authorised-medicinal-products-psusa-00002001-202404_en.pdf"},
    {"id":"66358","name":"Deoxycholic acid : List of nationally authorised medicinal products : PSUSA/00010525/202404 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-17T15:11:09Z","last_updated_date":"2025-01-17T15:11:09Z","reference_number":"EMA/22003/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/deoxycholic-acid-list-nationally-authorised-medicinal-products-psusa-00010525-202404_en.pdf"},
    {"id":"66359","name":"Loperamide, loperamide / simethicone : List of nationally authorised medicinal products - PSUSA/00010665/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-17T15:24:27Z","last_updated_date":"2025-01-17T15:24:27Z","reference_number":"EMA/22279/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/loperamide-loperamide-simethicone-list-nationally-authorised-medicinal-products-psusa-00010665-202405_en.pdf"},
    {"id":"66372","name":"Praziquantel : List of nationally authorised medicinal products - PSUSA/00002503/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-20T13:02:25Z","last_updated_date":"2025-01-20T13:02:25Z","reference_number":"EMA/23098/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/praziquantel-list-nationally-authorised-medicinal-products-psusa-00002503-202404_en.pdf"},
    {"id":"66373","name":"Metyrapone : List of nationally authorised medicinal products - PSUSA/00002046/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-20T14:03:07Z","last_updated_date":"2025-01-20T14:03:07Z","reference_number":"EMA/24132/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/metyrapone-list-nationally-authorised-medicinal-products-psusa-00002046-202406_en.pdf"},
    {"id":"66392","name":"Fentanyl (transdermal patches, solution for injection - nationally authorised product only) : List of nationally authorised medicinal products - PSUSA/00001370/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-21T12:05:47Z","last_updated_date":"2025-01-21T12:05:47Z","reference_number":"EMA/540656/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-list-nationally-authorised-medicinal-products-psusa-00001370-202404_en.pdf"},
    {"id":"66393","name":"Fentanyl (transdermal patches, solution for injection - nationally authorised product only) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001370/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-21T12:09:26Z","last_updated_date":"2025-01-21T12:09:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_fr.pdf-0","ga":"https://www.ema.europa.eu/ga/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_sv.pdf-0","is":"https://www.ema.europa.eu/is/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_is.pdf-0","no":"https://www.ema.europa.eu/no/documents/psusa/fentanyl-transdermal-patches-solution-injection-nationally-authorised-product-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001370_no.pdf-0"}},
    {"id":"66394","name":"Ranitidine : List of nationally authorised medicinal products - PSUSA/00002610/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-21T12:15:07Z","last_updated_date":"2025-01-21T12:15:07Z","reference_number":"EMA/25527/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/ranitidine-list-nationally-authorised-medicinal-products-psusa-00002610-202405_en.pdf"},
    {"id":"66408","name":"Acemetacin : List of nationally authorised medicinal products - PSUSA/00000026/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-21T17:38:48Z","last_updated_date":"2025-01-21T17:38:48Z","reference_number":"EMA/26483/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/acemetacin-list-nationally-authorised-medicinal-products-psusa-00000026-202405_en.pdf"},
    {"id":"66413","name":"Ambrosia Artemisiifolia (302) (sublingual use, products authorised via decentralised procedure) : List of nationally authorised medicinal products - PSUSA/00010693/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-22T13:10:34Z","last_updated_date":"2025-01-22T13:10:34Z","reference_number":"EMA/28467/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-list-nationally-authorised-medicinal-products-psusa-00010693-202404_en.pdf"},
    {"id":"66414","name":"Ambrosia Artemisiifolia (302) (sublingual use, products authorised via decentralised procedure) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation  - PSUSA/00010693/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-22T13:12:39Z","last_updated_date":"2025-01-22T13:12:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ambrosia-artemisiifolia-302-sublingual-use-products-authorised-decentralised-procedure-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_sv.pdf"}},
    {"id":"66420","name":"Loteprednol : List of nationally authorised medicinal products - PSUSA/00001913/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-22T16:45:15Z","last_updated_date":"2025-01-22T16:45:15Z","reference_number":"EMA/28300/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/loteprednol-list-nationally-authorised-medicinal-products-psusa-00001913-202405_en.pdf"},
    {"id":"66421","name":"Buspirone : List of nationally authorised medicinal products - PSUSA/00000463/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-22T16:48:23Z","last_updated_date":"2025-01-22T16:48:23Z","reference_number":"EMA/28295/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/buspirone-list-nationally-authorised-medicinal-products-psusa-00000463-202404_en.pdf"},
    {"id":"66422","name":"Enalapril maleate / lercanidipine : List of nationally authorised medicinal products - PSUSA/00001215/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-22T16:52:46Z","last_updated_date":"2025-01-22T16:52:46Z","reference_number":"EMA/28269/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/enalapril-maleate-lercanidipine-list-nationally-authorised-medicinal-products-psusa-00001215-202406_en.pdf"},
    {"id":"66425","name":"Flunarizine : List of nationally authorised medicinal products - PSUSA/00001416/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-23T10:19:35Z","last_updated_date":"2025-01-23T10:19:35Z","reference_number":"EMA/29529/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/flunarizine-list-nationally-authorised-medicinal-products-psusa-00001416-202405_en.pdf"},
    {"id":"66427","name":"Tolperisone : List of nationally authorised medicinal products - PSUSA/00002991/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-23T10:24:27Z","last_updated_date":"2025-01-23T10:24:27Z","reference_number":"EMA/29577/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/tolperisone-list-nationally-authorised-medicinal-products-psusa-00002991-202406_en.pdf"},
    {"id":"66436","name":"Nebivolol : List of nationally authorised medicinal products - PSUSA/00002129/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-23T17:01:07Z","last_updated_date":"2025-01-23T17:01:07Z","reference_number":"EMA/31166/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/nebivolol-list-nationally-authorised-medicinal-products-psusa-00002129-202403_en.pdf"},
    {"id":"66437","name":"Nebivolol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002129/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-23T17:02:36Z","last_updated_date":"2025-01-23T17:02:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nebivolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002129-202403_sv.pdf"}},
    {"id":"66470","name":"Promethazine : List of nationally authorised medicinal products - PSUSA/00002545/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-27T14:58:42Z","last_updated_date":"2025-01-27T14:58:42Z","reference_number":"EMA/34446/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/promethazine-list-nationally-authorised-medicinal-products-psusa-00002545-202404_en.pdf"},
    {"id":"66471","name":"Promethazine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002545/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-27T15:00:49Z","last_updated_date":"2025-04-10T12:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/promethazine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002545-202404_no.pdf"}},
    {"id":"66496","name":"Olodaterol / tiotropium : List of nationally authorised medicinal products - PSUSA/00010489/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-01-29T09:19:06Z","last_updated_date":"2025-01-29T09:19:06Z","reference_number":"EMA/25572/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/olodaterol-tiotropium-list-nationally-authorised-medicinal-products-psusa-00010489-202405_en.pdf"},
    {"id":"66573","name":"Biclotymol : List of nationally authorised medicinal products - PSUSA/00000408/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-03T13:22:00Z","last_updated_date":"2025-02-03T13:22:00Z","reference_number":"EMA/574832/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/biclotymol-list-nationally-authorised-medicinal-products-psusa-00000408-202405_en.pdf"},
    {"id":"66603","name":"Amlodipine besilate / ramipril, amlodipine / hydrochlorothiazide / ramipril, hydrochlorothiazide / ramipril : List of nationally authorised medicinal products - PSUSA/00010774/202403","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-05T10:27:34Z","last_updated_date":"2025-02-05T10:27:34Z","reference_number":"EMA/47751/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-besilate-ramipril-amlodipine-hydrochlorothiazide-ramipril-hydrochlorothiazide-ramipril-list-nationally-authorised-medicinal-products-psusa-00010774-202403_en.pdf"},
    {"id":"66613","name":"Oxaliplatin : List of nationally authorised medicinal products - PSUSA/00002229/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-05T15:08:20Z","last_updated_date":"2025-02-05T15:08:20Z","reference_number":"EMA/360417/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxaliplatin-list-nationally-authorised-medicinal-products-psusa-00002229-202404_en.pdf"},
    {"id":"66614","name":"Oxaliplatin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002229/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-05T15:10:06Z","last_updated_date":"2025-03-05T14:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oxaliplatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002229-202404_no.pdf"}},
    {"id":"66630","name":"Hydrochlorothiazide / zofenopril : List of nationally authorised medicinal products - PSUSA/00003148/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-07T11:31:15Z","last_updated_date":"2025-02-07T11:31:15Z","reference_number":"EMA/51602/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrochlorothiazide-zofenopril-list-nationally-authorised-medicinal-products-psusa-00003148-202405_en.pdf"},
    {"id":"66748","name":"Benzalkonium chloride / ethyl alcohol, benzalkonium chloride / isopropyl alcohol : List of nationally authorised medicinal products - PSUSA/00000342/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T15:49:47Z","last_updated_date":"2025-02-13T15:49:47Z","reference_number":"EMA/42086/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzalkonium-chloride-ethyl-alcohol-benzalkonium-chloride-isopropyl-alcohol-list-nationally-authorised-medicinal-products-psusa-00000342-202407_en.pdf"},
    {"id":"66749","name":"Nimesulide (systemic formulations) : List of nationally authorised medicinal products - PSUSA/00009236/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T15:55:34Z","last_updated_date":"2025-02-13T15:55:34Z","reference_number":"EMA/PRAC/46708/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/nimesulide-systemic-formulations-list-nationally-authorised-medicinal-products-psusa-00009236-202406_en.pdf"},
    {"id":"66750","name":"Rabbit anti-human thymocyte immunoglobulin : List of nationally authorised medicinal products - PSUSA/00010184/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T16:00:24Z","last_updated_date":"2025-08-01T11:11:01Z","reference_number":"EMA/49157/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/rabbit-anti-human-thymocyte-immunoglobulin-list-nationally-authorised-medicinal-products-psusa-00010184-202406_en.pdf"},
    {"id":"66751","name":"Anti-t lymphocyte immunoglobulin for human use, rabbit : List of nationally authorised medicinal products - PSUSA/00010252/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T16:05:19Z","last_updated_date":"2025-07-23T09:25:00Z","reference_number":"EMA/49179/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/anti-t-lymphocyte-immunoglobulin-human-use-rabbit-list-nationally-authorised-medicinal-products-psusa-00010252-202406_en.pdf"},
    {"id":"66754","name":"Human plasma proteins with no less than 95% albumin : List of nationally authorised medicinal product - PSUSA/00010605/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T16:32:33Z","last_updated_date":"2025-02-13T16:32:33Z","reference_number":"EMA/53721/2025EMA/53721/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-plasma-proteins-no-less-95-albumin-list-nationally-authorised-medicinal-product-psusa-00010605-202407_en.pdf"},
    {"id":"66780","name":"Nilutamide : List of nationally authorised medicinal products - PSUSA/00002163/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T13:47:00Z","last_updated_date":"2025-02-14T13:47:00Z","reference_number":"EMA/487410/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/nilutamide-list-nationally-authorised-medicinal-products-psusa-00002163-202407_en.pdf"},
    {"id":"66781","name":"Dexchlorpheniramine : List of nationally authorised medicinal products - PSUSA/00000989/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T13:50:02Z","last_updated_date":"2025-02-14T13:50:02Z","reference_number":"EMA/58813/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexchlorpheniramine-list-nationally-authorised-medicinal-products-psusa-00000989-202406_en.pdf"},
    {"id":"66783","name":"Clebopride : List of nationally authorised medicinal products - PSUSA/00000789/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T13:52:43Z","last_updated_date":"2025-02-14T13:52:43Z","reference_number":"EMA/58840/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/clebopride-list-nationally-authorised-medicinal-products-psusa-00000789-202406_en.pdf"},
    {"id":"66880","name":"Brivudine : List of nationally authorised medicinal products - PSUSA/00000434/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-19T16:54:00Z","last_updated_date":"2025-02-19T16:54:00Z","reference_number":"EMA/62438/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/brivudine-list-nationally-authorised-medicinal-products-psusa-00000434-202407_en.pdf"},
    {"id":"66944","name":"Propranolol (except for centrally authorised product): List of nationally authorised medicinal products - PSUSA/00010251/202406 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T13:23:25Z","last_updated_date":"2025-02-25T13:23:25Z","reference_number":"EMA/24132/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/propranolol-except-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa-00010251-202406_en.pdf"},
    {"id":"67080","name":"Tianeptine : List of nationally authorised medicinal products - PSUSA/00002943/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-03T14:53:08Z","last_updated_date":"2025-03-03T14:53:08Z","reference_number":"EMA/77513/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/tianeptine-list-nationally-authorised-medicinal-products-psusa-00002943-202406_en.pdf"},
    {"id":"67120","name":"Phenylpropanolamine : List of nationally authorised medicinal products - PSUSA/00010483/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-06T09:56:07Z","last_updated_date":"2025-03-06T09:56:07Z","reference_number":"EMA/82944/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylpropanolamine-list-nationally-authorised-medicinal-products-psusa-00010483-202406_en.pdf"},
    {"id":"67121","name":"Phenylpropanolamine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010483/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-06T09:58:26Z","last_updated_date":"2025-03-06T09:58:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/phenylpropanolamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010483-202406_no.pdf"}},
    {"id":"67141","name":"Aciclovir : List of nationally authorised medicinal products - PSUSA/00000048/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-07T13:34:48Z","last_updated_date":"2025-03-07T13:34:48Z","reference_number":"EMA/574822/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/aciclovir-list-nationally-authorised-medicinal-products-psusa-00000048-202406_en.pdf"},
    {"id":"67142","name":"Aciclovir : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000048/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-07T13:36:33Z","last_updated_date":"2025-03-07T13:36:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/aciclovir-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000048-202406_no.pdf"}},
    {"id":"67143","name":"Iobitridol : List of nationally authorised medicinal products - PSUSA/00001761/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-07T13:42:47Z","last_updated_date":"2025-03-07T13:42:47Z","reference_number":"EMA/440826/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/iobitridol-list-nationally-authorised-medicinal-products-psusa-00001761-202404_en.pdf"},
    {"id":"67144","name":"Iobitridol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001761/202404","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-07T13:44:30Z","last_updated_date":"2025-03-07T13:44:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/iobitridol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001761-202404_no.pdf"}},
    {"id":"67151","name":"Bismuth subcitrate potassium / metronidazole / tetracycline : List of nationally authorised medicinal products - PSUSA/00010199/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-07T15:01:23Z","last_updated_date":"2025-03-07T15:01:23Z","reference_number":"EMA/54617/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-list-nationally-authorised-medicinal-products-psusa-00010199-202405_en.pdf"},
    {"id":"67152","name":"Bismuth subcitrate potassium / metronidazole / tetracycline : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010199/202405","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-07T15:03:40Z","last_updated_date":"2025-03-07T15:03:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_pl.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bismuth-subcitrate-potassium-metronidazole-tetracycline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010199-202405_sv.pdf"}},
    {"id":"67244","name":"Oxycodone hydrochloride / paracetamol : List of nationally authorised medicinal products - PSUSA/00002256/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T10:58:17Z","last_updated_date":"2025-03-13T10:58:17Z","reference_number":"EMA/92621/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-hydrochloride-paracetamol-list-nationally-authorised-medicinal-products-psusa-00002256-202407_en.pdf"},
    {"id":"67245","name":"Oxycodone hydrochloride / paracetamol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002256/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T11:01:00Z","last_updated_date":"2025-03-13T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxycodone-hydrochloride-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002256-202407_sv.pdf"}},
    {"id":"67257","name":"Lactobacillus all subspecies and combinations of subspecies : List of nationally authorised medicinal products - PSUSA/00010598/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T15:21:51Z","last_updated_date":"2025-03-13T15:21:51Z","reference_number":"EMA/PRAC/94282/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/lactobacillus-all-subspecies-combinations-subspecies-list-nationally-authorised-medicinal-products-psusa-00010598-202407_en.pdf"},
    {"id":"67258","name":"Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide : List of nationally authorised medicinal products - PSUSA/00010390/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T15:25:57Z","last_updated_date":"2025-03-13T15:25:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-hydrochloride-phenylephrine-hydrochloride-tropicamide-list-nationally-authorised-medicinal-products-psusa-00010390-202407_en.pdf"},
    {"id":"67270","name":"Bibrocathol : List of nationally authorised medicinal products - PSUSA/00000406/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-14T10:23:03Z","last_updated_date":"2025-03-14T10:23:03Z","reference_number":"EMA/66753/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/bibrocathol-list-nationally-authorised-medicinal-products-psusa-00000406-202408_en.pdf"},
    {"id":"67348","name":"Neomycin / triamcinolone : List of nationally authorised medicinal products - PSUSA/00000081/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-19T13:26:17Z","last_updated_date":"2025-03-19T13:26:17Z","reference_number":"EMA/39071/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/neomycin-triamcinolone-list-nationally-authorised-medicinal-products-psusa-00000081-202408_en.pdf"},
    {"id":"67349","name":"Montelukast : List of nationally authorised medicinal products - PSUSA/00002087/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-19T14:23:32Z","last_updated_date":"2025-03-19T14:23:32Z","reference_number":"EMA/96425/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/montelukast-list-nationally-authorised-medicinal-products-psusa-00002087-202407_en.pdf"},
    {"id":"67350","name":"Tiapride : List of nationally authorised medicinal products - PSUSA/00002944/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-19T15:04:29Z","last_updated_date":"2025-03-19T15:04:29Z","reference_number":"EMA/94547/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiapride-list-nationally-authorised-medicinal-products-psusa-00002944-202407_en.pdf"},
    {"id":"67351","name":"Budesonide / salmeterol : List of nationally authorised medicinal products - PSUSA/00010511/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-19T15:26:32Z","last_updated_date":"2025-03-19T15:26:32Z","reference_number":"EMA/99800/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/budesonide-salmeterol-list-nationally-authorised-medicinal-products-psusa-00010511-202407_en.pdf"},
    {"id":"67366","name":"Benperidol : List of nationally authorised medicinal products - PSUSA/00000329/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-03-20T12:30:24Z","last_updated_date":"2025-03-20T12:30:24Z","reference_number":"EMA/101662/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/benperidol-list-nationally-authorised-medicinal-products-psusa-00000329-202407_en.pdf"},
    {"id":"67630","name":"Tiagabine : List of nationally authorised medicinal products - PSUSA/00002942/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T10:47:10Z","last_updated_date":"2025-04-04T10:47:10Z","reference_number":"EMA/85817/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiagabine-list-nationally-authorised-medicinal-products-psusa-00002942-202406_en.pdf"},
    {"id":"67631","name":"Tiagabine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002942/202406","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T10:48:45Z","last_updated_date":"2025-04-04T10:48:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tiagabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002942-202406_sv.pdf"}},
    {"id":"67741","name":"Hydrocortisone (all formulations apart from systemic use) : List of nationally authorised medicinal products - PSUSA/00010856/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-10T16:12:45Z","last_updated_date":"2025-04-10T16:12:45Z","reference_number":"EMA/111258/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrocortisone-all-formulations-apart-systemic-use-list-nationally-authorised-medicinal-products-psusa-00010856-202408_en.pdf"},
    {"id":"67753","name":"Dexamfetamine : List of nationally authorised medicinal products - PSUSA/00000986/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-11T13:08:59Z","last_updated_date":"2025-04-11T13:08:59Z","reference_number":"EMA/129679/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexamfetamine-list-nationally-authorised-medicinal-products-psusa-00000986-202409_en.pdf"},
    {"id":"67755","name":"Ciclesonide : List of nationally authorised medicinal products - PSUSA/00000742/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-11T13:30:09Z","last_updated_date":"2025-04-11T13:30:09Z","reference_number":"EMA/128781/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciclesonide-list-nationally-authorised-medicinal-products-psusa-00000742-202408_en.pdf"},
    {"id":"67835","name":"Busulfan : List of nationally authorised medicinal products - PSUSA/00000464/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-15T09:15:14Z","last_updated_date":"2025-04-15T09:15:14Z","reference_number":"EMA/130846/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/busulfan-list-nationally-authorised-medicinal-products-psusa-00000464-202407_en.pdf"},
    {"id":"67836","name":"Busulfan : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000464/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-15T09:16:54Z","last_updated_date":"2025-04-15T09:16:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/busulfan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000464-202407_no.pdf"}},
    {"id":"67854","name":"Thallium [201TL] : List of nationally authorised medicinal products - PSUSA/00002920/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-15T14:10:47Z","last_updated_date":"2025-04-15T14:10:47Z","reference_number":"EMA/PRAC/583151/2024","document_url":"https://www.ema.europa.eu/en/documents/psusa/thallium-201tl-list-nationally-authorised-medicinal-products-psusa-00002920-202408_en.pdf"},
    {"id":"67871","name":"Acenocoumarol : List of nationally authorised medicinal products - PSUSA/00000027/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-16T12:12:12Z","last_updated_date":"2025-04-16T12:12:12Z","reference_number":"EMA/134239/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/acenocoumarol-list-nationally-authorised-medicinal-products-psusa-00000027-202407_en.pdf"},
    {"id":"67872","name":"Acenocoumarol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000027/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-16T12:13:51Z","last_updated_date":"2025-04-16T12:13:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/acenocoumarol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000027-202407_sv.pdf"}},
    {"id":"67873","name":"Sotalol : List of nationally authorised medicinal products - PSUSA/00002774/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-04-16T12:18:25Z","last_updated_date":"2025-04-16T12:18:25Z","reference_number":"EMA/134275/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/sotalol-list-nationally-authorised-medicinal-products-psusa-00002774-202408_en.pdf"},
    {"id":"68103","name":"Thiocolchicoside, paracetamol / thiocolchicoside : List of nationally authorised medicinal products - PSUSA/00010464/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-06T09:17:27Z","last_updated_date":"2025-05-06T09:17:27Z","reference_number":"EMA/153049/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-list-nationally-authorised-medicinal-products-psusa-00010464-202407_en.pdf"},
    {"id":"68104","name":"Thiocolchicoside, paracetamol / thiocolchicoside : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010464/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-06T09:19:24Z","last_updated_date":"2025-05-06T09:19:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/thiocolchicoside-paracetamol-thiocolchicoside-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010464-202407_sv.pdf"}},
    {"id":"68113","name":"Cinchocaine hydrochloride / hydrocortisone : List of nationally authorised medicinal products - PSUSA/00000761/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-06T12:37:15Z","last_updated_date":"2025-05-06T12:37:15Z","reference_number":"EMA/154287/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/cinchocaine-hydrochloride-hydrocortisone-list-nationally-authorised-medicinal-products-psusa-00000761-202408_en.pdf"},
    {"id":"68115","name":"Everolimus : List of nationally authorised medicinal products - PSUSA/00010269/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-06T14:46:43Z","last_updated_date":"2025-05-06T14:46:43Z","reference_number":"EMA/154422/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/everolimus-list-nationally-authorised-medicinal-products-psusa-00010269-202407_en.pdf"},
    {"id":"68143","name":"Magnesium sulfate / sodium sulfate / potassium sulfate : List of nationally authorised medicinal products - PSUSA/00010239/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-07T12:38:40Z","last_updated_date":"2025-05-07T12:38:40Z","reference_number":"EMA/83293/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-list-nationally-authorised-medicinal-products-psusa-00010239-202408_en.pdf"},
    {"id":"68144","name":"Magnesium sulfate / sodium sulfate / potassium sulfate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010239/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-07T12:40:43Z","last_updated_date":"2025-05-07T12:40:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/magnesium-sulfate-sodium-sulfate-potassium-sulfate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010239-202408_sv.pdf"}},
    {"id":"68227","name":"Opium : List of nationally authorised medicinal products - PSUSA/00010670/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T14:46:08Z","last_updated_date":"2025-05-12T14:46:08Z","reference_number":"EMA/160332/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/opium-list-nationally-authorised-medicinal-products-psusa-00010670-202409_en.pdf"},
    {"id":"68228","name":"Rilmenidine : EPAR - List of nationally authorised medicinal products - PSUSA/00002643/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T14:51:19Z","last_updated_date":"2025-05-12T14:51:19Z","reference_number":"EMA/160599/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/rilmenidine-epar-list-nationally-authorised-medicinal-products-psusa-00002643-202408_en.pdf"},
    {"id":"68229","name":"Zidovudine : EPAR - List of nationally authorised medicinal products - PSUSA/00003143/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T14:54:59Z","last_updated_date":"2025-05-12T14:54:59Z","reference_number":"EMA/148474/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/zidovudine-epar-list-nationally-authorised-medicinal-products-psusa-00003143-202409_en.pdf"},
    {"id":"68231","name":"Naphazoline, naphazoline, zinc sulphate : List of nationally authorised medicinal products - PSUSA/00010571/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T15:01:35Z","last_updated_date":"2025-05-12T15:01:35Z","reference_number":"EMA/85820/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/naphazoline-naphazoline-zinc-sulphate-list-nationally-authorised-medicinal-products-psusa-00010571-202407_en.pdf"},
    {"id":"68232","name":"Naphazoline, naphazoline, zinc sulphate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010571/202407","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T15:03:26Z","last_updated_date":"2025-05-12T15:03:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/naphazoline-naphazoline-zinc-sulphate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010571-202407_is.pdf"}},
    {"id":"68236","name":"Betamethasone/tetryzoline : List of nationally authorised medicinal products - PSUSA/00010072/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T15:37:00Z","last_updated_date":"2025-05-12T15:37:00Z","reference_number":"EMA/158268/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/betamethasone-tetryzoline-list-nationally-authorised-medicinal-products-psusa-00010072-202409_en.pdf"},
    {"id":"68251","name":"Trifarotene : List of nationally authorised medicinal products - PSUSA/00010929/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-13T12:06:28Z","last_updated_date":"2025-05-13T12:06:28Z","reference_number":"EMA/163059/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/trifarotene-list-nationally-authorised-medicinal-products-psusa-00010929-202410_en.pdf"},
    {"id":"68252","name":"Carmustine (implant) : List of nationally authorised medicinal products - PSUSA/00010348/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-13T12:09:56Z","last_updated_date":"2025-05-13T12:09:56Z","reference_number":"EMA/9840/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/carmustine-implant-list-nationally-authorised-medicinal-products-psusa-00010348-202409_en.pdf"},
    {"id":"68253","name":"Hexaminolevulinate hydrochloride : List of nationally authorised medicinal products - PSUSA/00001606/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-13T12:13:45Z","last_updated_date":"2025-05-13T12:13:45Z","reference_number":"EMA/PRAC/9837/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/hexaminolevulinate-hydrochloride-list-nationally-authorised-medicinal-products-psusa-00001606-202409_en.pdf"},
    {"id":"68359","name":"Pramiracetam : List of nationally authorised medicinal products - PSUSA/00002492/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-19T17:24:36Z","last_updated_date":"2025-05-19T17:24:36Z","reference_number":"EMA/169859/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/pramiracetam-list-nationally-authorised-medicinal-products-psusa-00002492-202409_en.pdf"},
    {"id":"68469","name":"Phloroglucinol, phloroglucinol / trimethylphloroglucinol : List of nationally authorised medicinal products - PSUSA/00010355/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-27T13:57:15Z","last_updated_date":"2025-05-27T13:57:15Z","reference_number":"EMA/176770/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/phloroglucinol-phloroglucinol-trimethylphloroglucinol-list-nationally-authorised-medicinal-products-psusa-00010355-202409_en.pdf"},
    {"id":"68480","name":"Anastrozole : List of nationally authorised medicinal products - PSUSA/00000210/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-28T09:32:50Z","last_updated_date":"2025-05-28T09:32:50Z","reference_number":"EMA/77052/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/anastrozole-list-nationally-authorised-medicinal-products-psusa-00000210-202408_en.pdf"},
    {"id":"68481","name":"Anastrozole : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000210/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-28T09:34:35Z","last_updated_date":"2025-05-28T09:34:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/anastrozole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000210-202408_no.pdf"}},
    {"id":"68482","name":"Chlorocresol / chlorhexidine / hexamidine : List of nationally authorised medicinal products - PSUSA/00001603/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-28T09:43:28Z","last_updated_date":"2025-05-28T09:43:28Z","reference_number":"EMA/177186/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorocresol-chlorhexidine-hexamidine-list-nationally-authorised-medicinal-products-psusa-00001603-202408_en.pdf"},
    {"id":"68483","name":"Chlorocresol / chlorhexidine / hexamidine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001603/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-05-28T09:46:06Z","last_updated_date":"2025-05-28T09:46:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/chlorocresol-chlorhexidine-hexamidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001603-202408_sv.pdf"}},
    {"id":"68507","name":"Oxcarbazepine : List of nationally authorised medicinal products - PSUSA/00002235/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-02T09:19:50Z","last_updated_date":"2025-06-02T09:19:50Z","reference_number":"EMA/185109/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxcarbazepine-list-nationally-authorised-medicinal-products-psusa-00002235-202408_en.pdf"}    {"id":"68508","name":"Oxcarbazepine : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00002235/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-02T09:23:26Z","last_updated_date":"2025-06-02T09:23:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/oxcarbazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002235-202408_no.pdf"}},
    {"id":"68509","name":"Alfentanil : List of nationally authorised medicinal products - PSUSA/00000082/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-02T09:31:10Z","last_updated_date":"2025-06-02T09:31:10Z","reference_number":"EMA/185276/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/alfentanil-list-nationally-authorised-medicinal-products-psusa-00000082-202409_en.pdf"},
    {"id":"68568","name":"Hydrocortisone (systemic formulations) :  List of nationally authorised medicinal products - PSUSA/00010855/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-04T11:03:14Z","last_updated_date":"2025-06-04T11:03:14Z","reference_number":"EMA/189473/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrocortisone-systemic-formulations-list-nationally-authorised-medicinal-products-psusa-00010855-202408_en.pdf"},
    {"id":"68569","name":"Hydrocortisone (systemic formulations) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010855/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-04T11:06:01Z","last_updated_date":"2025-06-04T11:06:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrocortisone-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/hydrocortisone-paediatric-use-only-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010855-202408_no.pdf"}},
    {"id":"68585","name":"Acitretin : List of nationally authorised medicinal products - PSUSA/00000051/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-05T14:34:32Z","last_updated_date":"2025-06-05T14:34:32Z","reference_number":"EMADOC-1700519818-2191524","document_url":"https://www.ema.europa.eu/en/documents/psusa/acitretin-list-nationally-authorised-medicinal-products-psusa-00000051-202410_en.pdf"},
    {"id":"68586","name":"Clindamycin : List of nationally authorised medicinal products - PSUSA/00000795/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-05T15:26:27Z","last_updated_date":"2025-06-05T15:26:27Z","reference_number":"EMA/382258/2015","document_url":"https://www.ema.europa.eu/en/documents/psusa/clindamycin-list-nationally-authorised-medicinal-products-psusa-00000795-202410_en.pdf"},
    {"id":"68596","name":"Letrozole : List of nationally authorised medicinal products - PSUSA/00001842/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-06T09:21:22Z","last_updated_date":"2025-06-06T09:21:22Z","reference_number":"EMA/193200/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/letrozole-list-nationally-authorised-medicinal-products-psusa-00001842-202410_en.pdf"},
    {"id":"68643","name":"Ascorbic acid / magnesium aspartate / leucine L / lysine L / phenylalanine L / valine L : List of nationally authorised medicinal products - PSUSA/00010988/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-10T13:45:07Z","last_updated_date":"2025-06-10T13:45:07Z","reference_number":"EMADOC-1700519818-2203817","document_url":"https://www.ema.europa.eu/en/documents/psusa/ascorbic-acid-magnesium-aspartate-leucine-l-lysine-l-phenylalanine-l-valine-l-list-nationally-authorised-medicinal-products-psusa-00010988-202410_en.pdf"},
    {"id":"68684","name":"Colecalciferol, colecalciferol / calcium, ergocalciferol, ergocalciferol / calcium : List of nationally authorised medicinal products - PSUSA/00010386/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-11T09:44:15Z","last_updated_date":"2025-06-11T09:44:15Z","reference_number":"EMA/198277/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/colecalciferol-colecalciferol-calcium-ergocalciferol-ergocalciferol-calcium-list-nationally-authorised-medicinal-products-psusa-00010386-202410_en.pdf"},
    {"id":"68690","name":"Fluticasone / salmeterol (for nationally authorised products) : List of nationally authorised medicinal products - PSUSA/00001455/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-11T11:32:22Z","last_updated_date":"2025-06-11T11:32:22Z","reference_number":"EMADOC-1700519818-2206399","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluticasone-salmeterol-nationally-authorised-products-list-nationally-authorised-medicinal-products-psusa-00001455-202410_en.pdf"},
    {"id":"68693","name":"Meropenem : List of nationally authorised medicinal products - PSUSA/00001989/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-11T14:02:17Z","last_updated_date":"2025-06-11T14:02:17Z","reference_number":"EMA/56732/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/meropenem-list-nationally-authorised-medicinal-products-psusa-00001989-202408_en.pdf"},
    {"id":"68694","name":"Meropenem : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001989/202408","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-11T14:04:07Z","last_updated_date":"2025-06-11T14:04:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/meropenem-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001989-202408_no.pdf"}},
    {"id":"68708","name":"Azelastine / fluticasone : List of nationally authorised medicinal products - PSUSA/00010067/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-12T08:33:36Z","last_updated_date":"2025-06-12T08:33:36Z","reference_number":"EMA/PSUR/0000248486","document_url":"https://www.ema.europa.eu/en/documents/psusa/azelastine-fluticasone-list-nationally-authorised-medicinal-products-psusa-00010067-202410_en.pdf"},
    {"id":"68738","name":"Etonogestrel : List of nationally authorised medicinal products - PSUSA/00001331/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-13T12:46:42Z","last_updated_date":"2025-06-13T12:46:42Z","reference_number":"EMA/201683/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/etonogestrel-list-nationally-authorised-medicinal-products-psusa-00001331-202409_en.pdf"},
    {"id":"68739","name":"Etonogestrel : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001331/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-13T12:48:37Z","last_updated_date":"2025-06-13T12:48:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_no.pdf"}},
    {"id":"68740","name":"Etonogestrel : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001331/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-06-13T12:51:10Z","last_updated_date":"2025-06-13T12:51:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_sv.pdf-0","is":"https://www.ema.europa.eu/is/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_is.pdf-0","no":"https://www.ema.europa.eu/no/documents/psusa/etonogestrel-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001331-202409_no.pdf-0"}},
    {"id":"69148","name":"Diclofenac (systemic formulations) : List of nationally authorised medicinal products - PSUSA/00001048/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-07T15:45:46Z","last_updated_date":"2025-07-07T15:45:46Z","reference_number":"EMA/139612/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-systemic-formulations-list-nationally-authorised-medicinal-products-psusa-00001048-202409_en.pdf"},
    {"id":"69149","name":"Diclofenac (systemic formulations) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001048/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-07T15:47:36Z","last_updated_date":"2025-08-19T20:18:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/diclofenac-systemic-formulations-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001048-202409_no.pdf"}},
    {"id":"69161","name":"Sumatriptan, naproxen / sumatriptan : List of nationally authorised medicinal products - PSUSA/00002832/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-08T12:50:47Z","last_updated_date":"2025-07-08T12:50:47Z","reference_number":"EMA/178301/2025","document_url":"https://www.ema.europa.eu/en/documents/psusa/sumatriptan-naproxen-sumatriptan-list-nationally-authorised-medicinal-products-psusa-00002832-202409_en.pdf"},
    {"id":"69162","name":"Sumatriptan, naproxen / sumatriptan : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002832/202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-08T12:52:52Z","last_updated_date":"2025-07-08T12:52:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/sumatriptan-naproxen-sumatriptan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002832-202409_no.pdf"}},
    {"id":"69228","name":"Diphenhydramine / paracetamol : List of nationally authorised medicinal products - PSUSA/00001110/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-10T14:27:28Z","last_updated_date":"2025-07-10T14:27:28Z","reference_number":"EMADOC-1700519818-2275617","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphenhydramine-paracetamol-list-nationally-authorised-medicinal-products-psusa-00001110-202411_en.pdf"},
    {"id":"69229","name":"Acrivastine, acrivastine / pseudoephedrine : List of nationally authorised medicinal products - PSUSA/00000054/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-10T14:32:43Z","last_updated_date":"2025-07-10T14:32:43Z","reference_number":"EMADOC-1700519818-2275709","document_url":"https://www.ema.europa.eu/en/documents/psusa/acrivastine-acrivastine-pseudoephedrine-list-nationally-authorised-medicinal-products-psusa-00000054-202412_en.pdf"},
    {"id":"69230","name":"Cyanocobalamin / folic acid / pyridoxine : List of nationally authorised medicinal products - PSUSA/00000893/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-10T14:36:19Z","last_updated_date":"2025-07-10T14:36:19Z","reference_number":"EMADOC-1700519818-2275788","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyanocobalamin-folic-acid-pyridoxine-list-nationally-authorised-medicinal-products-psusa-00000893-202411_en.pdf"},
    {"id":"69231","name":"Dihydroxyaluminum sodium carbonate, dihydroxyaluminum sodium carbonate / dimeticone : List of nationally authorised medicinal products - PSUSA/00001098/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-10T14:41:02Z","last_updated_date":"2025-07-10T14:41:02Z","reference_number":"EMADOC-1700519818-2276867","document_url":"https://www.ema.europa.eu/en/documents/psusa/dihydroxyaluminum-sodium-carbonate-dihydroxyaluminum-sodium-carbonate-dimeticone-list-nationally-authorised-medicinal-products-psusa-00001098-202411_en.pdf"},
    {"id":"69238","name":"Oxygen : List of nationally authorised medicinal products - PSUSA/00002257/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-11T10:39:57Z","last_updated_date":"2025-07-11T10:39:57Z","reference_number":"EMADOC-1700519818-2281883","document_url":"https://www.ema.europa.eu/en/documents/psusa/oxygen-list-nationally-authorised-medicinal-products-psusa-00002257-202412_en.pdf"},
    {"id":"69242","name":"Mexazolam : List of nationally authorised medicinal products - PSUSA/00002047/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-11T13:09:03Z","last_updated_date":"2025-07-11T13:09:03Z","reference_number":"EMADOC-1700519818-2282864","document_url":"https://www.ema.europa.eu/en/documents/psusa/mexazolam-list-nationally-authorised-medicinal-products-psusa-00002047-202412_en.pdf"},
    {"id":"69243","name":"Dextromethorphan hydrobromide / diphenhydramine hydrochloride / levomenthol : List of nationally authorised medicinal products - PSUSA/00001013/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-11T13:31:57Z","last_updated_date":"2025-07-11T13:31:57Z","reference_number":"EMADOC-1700519818-2283017","document_url":"https://www.ema.europa.eu/en/documents/psusa/dextromethorphan-hydrobromide-diphenhydramine-hydrochloride-levomenthol-list-nationally-authorised-medicinal-products-psusa-00001013-202411_en.pdf"},
    {"id":"69256","name":"Dextromethorphan hydrobromide / pseudoephedrine hydrochloride / triprolidine hydrochloride : List of nationally authorised medicinal products - PSUSA/00001021/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-14T11:07:37Z","last_updated_date":"2025-07-14T11:07:37Z","reference_number":"EMADOC-1700519818-2240047","document_url":"https://www.ema.europa.eu/en/documents/psusa/dextromethorphan-hydrobromide-pseudoephedrine-hydrochloride-triprolidine-hydrochloride-list-nationally-authorised-medicinal-products-psusa-00001021-202411_en.pdf"},
    {"id":"69258","name":"Dextromethorphan / paracetamol / phenylephrine : List of nationally authorised medicinal products - PSUSA/00009247/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-14T11:14:23Z","last_updated_date":"2025-07-14T11:14:23Z","reference_number":"EMADOC-1700519818-2281620","document_url":"https://www.ema.europa.eu/en/documents/psusa/dextromethorphan-paracetamol-phenylephrine-list-nationally-authorised-medicinal-products-psusa-00009247-202411_en.pdf"},
    {"id":"69259","name":"Chlorphenamine / dextromethorphan hydrobromide/ paracetamol : List of nationally authorised medicinal products - PSUSA/00000699/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-14T11:18:07Z","last_updated_date":"2025-07-14T11:18:07Z","reference_number":"EMADOC-1700519818-2285455","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorphenamine-dextromethorphan-hydrobromide-paracetamol-list-nationally-authorised-medicinal-products-psusa-00000699-202411_en.pdf"},
    {"id":"69260","name":"Paracetamol / pseudoephedrine hydrochloride / triprolidine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010270/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-17T11:22:35Z","last_updated_date":"2025-07-17T11:22:35Z","reference_number":"EMADOC-1700519818-2295885","document_url":"https://www.ema.europa.eu/en/documents/psusa/paracetamol-pseudoephedrine-hydrochloride-triprolidine-hydrochloride-list-nationally-authorised-medicinal-products-psusa-00010270-202411_en.pdf"},
    {"id":"69261","name":"Urea hydrogen peroxide : List of nationally authorised medicinal products - PSUSA/00009326/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-14T11:27:21Z","last_updated_date":"2025-07-14T11:27:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/urea-hydrogen-peroxide-list-nationally-authorised-medicinal-products-psusa-00009326-202411_en.pdf"},
    {"id":"69277","name":"Dextromethorphan hydrobromide / paracetamol / promethazine hydrochloride : List of nationally authorised medicinal products - PSUSA/00002300/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T09:41:18Z","last_updated_date":"2025-07-15T09:41:18Z","reference_number":"EMADOC-1700519818-2286842","document_url":"https://www.ema.europa.eu/en/documents/psusa/dextromethorphan-hydrobromide-paracetamol-promethazine-hydrochloride-list-nationally-authorised-medicinal-products-psusa-00002300-202411_en.pdf"},
    {"id":"69279","name":"Antazoline / tetryzoline : List of nationally authorised medicinal products - PSUSA/00000219/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T09:59:38Z","last_updated_date":"2025-07-15T09:59:38Z","reference_number":"EMADOC-1700519818-2286976","document_url":"https://www.ema.europa.eu/en/documents/psusa/antazoline-tetryzoline-list-nationally-authorised-medicinal-products-psusa-00000219-202412_en.pdf"},
    {"id":"69283","name":"Cinolazepam : List of nationally authorised medicinal products - PSUSA/00000769/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T11:16:24Z","last_updated_date":"2025-07-15T11:16:24Z","reference_number":"EMADOC-1700519818-2286861","document_url":"https://www.ema.europa.eu/en/documents/psusa/cinolazepam-list-nationally-authorised-medicinal-products-psusa-00000769-202412_en.pdf"},
    {"id":"69284","name":"Ceftobiprole : List of nationally authorised medicinal products - PSUSA/00010734/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T11:21:03Z","last_updated_date":"2025-07-15T11:21:03Z","reference_number":"EMADOC-1700519818-2286838","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftobiprole-list-nationally-authorised-medicinal-products-psusa-00010734-202411_en.pdf"},
    {"id":"69285","name":"Metamizole sodium / pitofenone hydrochloride : List of nationally authorised medicinal products - PSUSA/00002443/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T11:25:21Z","last_updated_date":"2025-07-15T11:25:21Z","reference_number":"EMADOC-1700519818-2286811","document_url":"https://www.ema.europa.eu/en/documents/psusa/metamizole-sodium-pitofenone-hydrochloride-list-nationally-authorised-medicinal-products-psusa-00002443-202412_en.pdf"},
    {"id":"69286","name":"Natamycin : List of nationally authorised medicinal products - PSUSA/00003179/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T11:34:43Z","last_updated_date":"2025-07-15T11:34:43Z","reference_number":"EMADOC-1700519818-2287409","document_url":"https://www.ema.europa.eu/en/documents/psusa/natamycin-list-nationally-authorised-medicinal-products-psusa-00003179-202411_en.pdf"},
    {"id":"69287","name":"Acetylsalicylic acid / caffeine / paracetamol : List of nationally authorised medicinal products - PSUSA/00002291/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T11:38:17Z","last_updated_date":"2025-07-15T11:38:17Z","reference_number":"EMADOC-1700519818-2288925","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-caffeine-paracetamol-list-nationally-authorised-medicinal-products-psusa-00002291-202412_en.pdf"},
    {"id":"69343","name":"Methocarbamol : List of nationally authorised medicinal products - PSUSA/00002011/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-17T11:39:42Z","last_updated_date":"2025-07-17T11:39:42Z","reference_number":"EMADOC-1700519818-2282541","document_url":"https://www.ema.europa.eu/en/documents/psusa/methocarbamol-list-nationally-authorised-medicinal-products-psusa-00002011-202412_en.pdf"},
    {"id":"69344","name":"Metoclopramide : List of nationally authorised medicinal products - PSUSA/00002036/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-17T11:43:57Z","last_updated_date":"2025-07-17T11:43:57Z","reference_number":"EMADOC-1700519818-2285119","document_url":"https://www.ema.europa.eu/en/documents/psusa/metoclopramide-list-nationally-authorised-medicinal-products-psusa-00002036-202411_en.pdf"},
    {"id":"69346","name":"Neomycin sulfate / nystatin / polymyxin b sulfate : List of nationally authorised medicinal products - PSUSA/00002139/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-17T11:57:05Z","last_updated_date":"2025-07-17T11:57:05Z","reference_number":"EMADOC-1700519818-2281239","document_url":"https://www.ema.europa.eu/en/documents/psusa/neomycin-sulfate-nystatin-polymyxin-b-sulfate-list-nationally-authorised-medicinal-products-psusa-00002139-202411_en.pdf"},
    {"id":"69557","name":"Lornoxicam : List of nationally authorised medicinal products - PSUSA/00001911/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-29T10:06:44Z","last_updated_date":"2025-07-29T10:06:44Z","reference_number":"EMADOC-1700519818-2315708","document_url":"https://www.ema.europa.eu/en/documents/psusa/lornoxicam-list-nationally-authorised-medicinal-products-psusa-00001911-202412_en.pdf"},
    {"id":"69558","name":"Benzydamine : List of nationally authorised medicinal products - PSUSA/00000375/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-29T10:11:05Z","last_updated_date":"2025-07-29T10:11:05Z","reference_number":"EMADOC-1700519818-2305404","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzydamine-list-nationally-authorised-medicinal-products-psusa-00000375-202410_en.pdf"},
    {"id":"69559","name":"Benzydamine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000375/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-29T10:12:58Z","last_updated_date":"2025-07-29T10:12:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/benzydamine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000375-202410_no.pdf"}},
    {"id":"69597","name":"Clotrimazole / metronidazole : List of nationally authorised medicinal products - PSUSA/00000832/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-07-31T15:00:33Z","last_updated_date":"2025-07-31T15:00:33Z","reference_number":"EMADOC-1700519818-2331291","document_url":"https://www.ema.europa.eu/en/documents/psusa/clotrimazole-metronidazole-list-nationally-authorised-medicinal-products-psusa-00000832-202411_en.pdf"},
    {"id":"69633","name":"Clotrimazole / dexamethasone : List of nationally authorised medicinal products - PSUSA/00000830/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-01T16:49:56Z","last_updated_date":"2025-08-01T16:49:56Z","reference_number":"EMADOC-1700519818-2335275","document_url":"https://www.ema.europa.eu/en/documents/psusa/clotrimazole-dexamethasone-list-nationally-authorised-medicinal-products-psusa-00000830-202411_en.pdf"},
    {"id":"69634","name":"Clotrimazole / hydrocortisone : List of nationally authorised medicinal products - PSUSA/00000831/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-01T16:53:33Z","last_updated_date":"2025-08-01T16:53:33Z","reference_number":"EMADOC-1700519818-2335312","document_url":"https://www.ema.europa.eu/en/documents/psusa/clotrimazole-hydrocortisone-list-nationally-authorised-medicinal-products-psusa-00000831-202411_en.pdf"},
    {"id":"69646","name":"Dexketoprofen : List of nationally authorised medicinal products - PSUSA/00000997/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-05T08:15:30Z","last_updated_date":"2025-08-05T08:15:30Z","reference_number":"EMADOC-1700519818-2340229","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-list-nationally-authorised-medicinal-products-psusa-00000997-202410_en.pdf"},
    {"id":"69647","name":"Dexketoprofen : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000997/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-05T08:17:39Z","last_updated_date":"2025-08-13T13:38:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexketoprofen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000997-202410_sv.pdf"}},
    {"id":"69648","name":"Methylphenidate : List of nationally authorised medicinal products - PSUSA/00002024/202410 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-05T08:30:49Z","last_updated_date":"2025-08-05T08:30:49Z","reference_number":"EMADOC-1700519818-2340477","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-list-nationally-authorised-medicinal-products-psusa-00002024-202410_en.pdf"},
    {"id":"69649","name":"Methylphenidate : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002024/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-05T08:32:48Z","last_updated_date":"2025-09-22T17:08:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methylphenidate-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002024-202410_no.pdf"}},
    {"id":"69650","name":"Methocarbamol / paracetamol : List of nationally authorised medicinal products - PSUSA/00002013/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-05T08:38:37Z","last_updated_date":"2025-08-05T08:38:37Z","reference_number":"EMADOC-1700519818-2340504","document_url":"https://www.ema.europa.eu/en/documents/psusa/methocarbamol-paracetamol-list-nationally-authorised-medicinal-products-psusa-00002013-202412_en.pdf"},
    {"id":"69699","name":"Miconazole, hydrocortisone / miconazole nitrate, miconazole nitrate / zinc oxide : CMDh Scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002052/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T15:09:16Z","last_updated_date":"2025-08-12T15:09:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002052-202410_no.pdf"}},
    {"id":"69700","name":"Miconazole, hydrocortisone / miconazole nitrate, miconazole nitrate / zinc oxide: List of nationally authorised medicinal products - PSUSA/00002052/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-12T15:13:57Z","last_updated_date":"2025-08-12T15:13:57Z","reference_number":"EMADOC-1700519818-2354019","document_url":"https://www.ema.europa.eu/en/documents/psusa/miconazole-hydrocortisone-miconazole-nitrate-miconazole-nitrate-zinc-oxide-list-nationally-authorised-medicinal-products-psusa-00002052-202410_en.pdf"},
    {"id":"69732","name":"Isoniazid : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001789/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-13T17:53:07Z","last_updated_date":"2025-08-29T13:49:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/isoniazid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001789-202411_sv.pdf"}},
    {"id":"69733","name":"Isoniazid : List of nationally authorised medicinal products - PSUSA/00001789/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-13T17:58:01Z","last_updated_date":"2025-08-13T17:58:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoniazid-list-nationally-authorised-medicinal-products-psusa-00001789-202411_en.pdf"},
    {"id":"69795","name":"Domperidone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001158/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-20T14:41:56Z","last_updated_date":"2025-08-20T14:41:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/domperidone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001158-202411_fi.pdf"}},
    {"id":"69796","name":"Domperidone : List of nationally authorised medicinal products - PSUSA/00002024/202410 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-20T14:38:12Z","last_updated_date":"2025-08-20T14:38:12Z","reference_number":"EMADOC-1700519818-2318129","document_url":"https://www.ema.europa.eu/en/documents/psusa/domperidone-list-nationally-authorised-medicinal-products-psusa-00002024-202410_en.pdf"},
    {"id":"69819","name":"Levosimendan : List of nationally authorised medicinal products - PSUSA00001858202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-21T14:10:47Z","last_updated_date":"2025-08-21T14:10:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levosimendan-list-nationally-authorised-medicinal-products-psusa00001858202409_en.pdf"},
    {"id":"69884","name":"Levosimendan: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA00001858202409","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-08-21T15:00:00Z","last_updated_date":"2025-08-21T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levosimendan-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa00001858202409_no.pdf"}},
    {"id":"69943","name":"Nicotine : List of nationally authorised medicinal products - PSUSA/00002153/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-03T14:38:53Z","last_updated_date":"2025-09-03T14:38:53Z","reference_number":"EMADOC-1700519818-2411267","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicotine-list-nationally-authorised-medicinal-products-psusa-00002153-202412_en.pdf"},
    {"id":"69944","name":"Nicotine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002153/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-03T14:40:28Z","last_updated_date":"2025-09-03T14:40:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/nicotine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002153-202412_no.pdf"}},
    {"id":"69950","name":"Alitretinoin (oral use) : List of nationally authorised medicinal products - PSUSA/00010710/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-04T13:03:15Z","last_updated_date":"2025-09-04T13:03:15Z","reference_number":"EMADOC-1700519818-2417234","document_url":"https://www.ema.europa.eu/en/documents/psusa/alitretinoin-oral-use-list-nationally-authorised-medicinal-products-psusa-00010710-202501_en.pdf"},
    {"id":"69953","name":"Anthrax vaccine : List of nationally authorised medicinal products - PSUSA/00010771/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-04T15:12:05Z","last_updated_date":"2025-09-04T15:12:05Z","reference_number":"EMADOC-1700519818-2417859","document_url":"https://www.ema.europa.eu/en/documents/psusa/anthrax-vaccine-list-nationally-authorised-medicinal-products-psusa-00010771-202412_en.pdf"},
    {"id":"69954","name":"Tizanidine : List of nationally authorised medicinal products - PSUSA/00002977/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-04T15:15:00Z","last_updated_date":"2025-09-04T15:15:00Z","reference_number":"EMADOC-1700519818-2418014","document_url":"https://www.ema.europa.eu/en/documents/psusa/tizanidine-list-nationally-authorised-medicinal-products-psusa-00002977-202412_en.pdf"},
    {"id":"69955","name":"Pirenoxine : List of nationally authorised medicinal products - PSUSA/00002431/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-04T15:26:54Z","last_updated_date":"2025-09-04T15:26:54Z","reference_number":"EMADOC-1700519818-2418120","document_url":"https://www.ema.europa.eu/en/documents/psusa/pirenoxine-list-nationally-authorised-medicinal-products-psusa-00002431-202501_en.pdf"},
    {"id":"69956","name":"Roxithromycin : List of nationally authorised medicinal products - PSUSA/00002669/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T08:33:15Z","last_updated_date":"2025-09-05T08:33:15Z","reference_number":"EMADOC-1700519818-2418834","document_url":"https://www.ema.europa.eu/en/documents/psusa/roxithromycin-list-nationally-authorised-medicinal-products-psusa-00002669-202412_en.pdf"},
    {"id":"69990","name":"bendamustine hydrochloride : List of nationally authorised medicinal products - PSUSA/00003162/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-08T10:25:23Z","last_updated_date":"2025-09-08T10:25:23Z","reference_number":"EMADOC-1700519818-2419189","document_url":"https://www.ema.europa.eu/en/documents/psusa/bendamustine-hydrochloride-list-nationally-authorised-medicinal-products-psusa-00003162-202501_en.pdf"},
    {"id":"69991","name":"Tapentadol : List of nationally authorised medicinal products - PSUSA/00002849/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-08T11:40:46Z","last_updated_date":"2025-09-08T11:40:46Z","reference_number":"EMADOC-1700519818-2419828","document_url":"https://www.ema.europa.eu/en/documents/psusa/tapentadol-list-nationally-authorised-medicinal-products-psusa-00002849-202411_en.pdf"},
    {"id":"69992","name":"Tapentadol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002849/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-08T13:27:25Z","last_updated_date":"2025-09-08T13:27:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tapentadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002849-202411_no.pdf"}},
    {"id":"69994","name":"Lidocaine / Phenazone : List of nationally authorised medicinal products - PSUSA/00002359/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-08T14:47:29Z","last_updated_date":"2025-09-08T14:47:29Z","reference_number":"EMADOC-1700519818-2421129","document_url":"https://www.ema.europa.eu/en/documents/psusa/lidocaine-phenazone-list-nationally-authorised-medicinal-products-psusa-00002359-202501_en.pdf"},
    {"id":"70007","name":"Metamizole sodium / triacetonamine tosilate : List of nationally authorised medicinal products - PSUSA/00001999/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-09T09:45:00Z","last_updated_date":"2025-09-09T09:45:00Z","reference_number":"EMADOC-1700519818-2421622","document_url":"https://www.ema.europa.eu/en/documents/psusa/metamizole-sodium-triacetonamine-tosilate-list-nationally-authorised-medicinal-products-psusa-00001999-202501_en.pdf"},
    {"id":"70009","name":"Phenylephrine (ophthalmic formulations) : List of nationally authorised medicinal products - PSUSA/00010402/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-09T09:48:07Z","last_updated_date":"2025-09-09T09:48:07Z","reference_number":"EMADOC-1700519818-2418782","document_url":"https://www.ema.europa.eu/en/documents/psusa/phenylephrine-ophthalmic-formulations-list-nationally-authorised-medicinal-products-psusa-00010402-202501_en.pdf"},
    {"id":"70025","name":"amino acid combinations / glucose / triglyceride combinations : List of nationally authorised medicinal products - PSUSA/00010190/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-09T15:38:24Z","last_updated_date":"2025-09-09T15:38:24Z","reference_number":"EMADOC-1700519818-2421851","document_url":"https://www.ema.europa.eu/en/documents/psusa/amino-acid-combinations-glucose-triglyceride-combinations-list-nationally-authorised-medicinal-products-psusa-00010190-202412_en.pdf"},
    {"id":"70029","name":"Nitric oxide : List of nationally authorised medicinal products - PSUSA/00002172/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-09T16:05:50Z","last_updated_date":"2025-09-09T16:05:50Z","reference_number":"EMADOC-1700519818-2422178","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitric-oxide-list-nationally-authorised-medicinal-products-psusa-00002172-202412_en.pdf"},
    {"id":"70035","name":"Cefotaxime : List of nationally authorised medicinal products - PSUSA/00000599/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-10T10:14:27Z","last_updated_date":"2025-09-10T10:14:27Z","reference_number":"EMADOC-1700519818-2422541","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefotaxime-list-nationally-authorised-medicinal-products-psusa-00000599-202412_en.pdf"},
    {"id":"70036","name":"Typhoid vaccine (live, attenuated): List of nationally authorised medicinal products - PSUSA/00003067/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-10T10:20:51Z","last_updated_date":"2025-09-10T10:20:51Z","reference_number":"EMADOC-1700519818-2422542","document_url":"https://www.ema.europa.eu/en/documents/psusa/typhoid-vaccine-live-attenuated-list-nationally-authorised-medicinal-products-psusa-00003067-202412_en.pdf"},
    {"id":"70037","name":"Varicella-zoster immunoglobuline: List of nationally authorised medicinal products - PSUSA/00010266/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-10T10:27:25Z","last_updated_date":"2025-09-10T10:27:25Z","reference_number":"EMADOC-1700519818-2422545","document_url":"https://www.ema.europa.eu/en/documents/psusa/varicella-zoster-immunoglobuline-list-nationally-authorised-medicinal-products-psusa-00010266-202412_en.pdf"},
    {"id":"70038","name":"Human alfa1-proteinase inhibitor (apart from the centrally authorised product) : List of nationally authorised medicinal products - PSUSA/00000108/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-10T10:34:22Z","last_updated_date":"2025-09-10T10:34:22Z","reference_number":"EMADOC-1700519818-2425606","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-alfa1-proteinase-inhibitor-apart-centrally-authorised-product-list-nationally-authorised-medicinal-products-psusa-00000108-202412_en.pdf"},
    {"id":"70039","name":"Hydromorphone: List of nationally authorised medicinal products - PSUSA/00001686/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-10T10:45:54Z","last_updated_date":"2025-09-10T10:45:54Z","reference_number":"EMADOC-1700519818-2424948","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydromorphone-list-nationally-authorised-medicinal-products-psusa-00001686-202411_en.pdf"},
    {"id":"70040","name":"Hydromorphone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001686/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-10T10:47:45Z","last_updated_date":"2025-09-10T10:47:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/hydromorphone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001686-202411_no.pdf"}},
    {"id":"70042","name":"Flunitrazepam: List of nationally authorised medicinal products - PSUSA/00001418/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-10T11:31:21Z","last_updated_date":"2025-09-10T11:31:21Z","reference_number":"EMADOC-1700519818-2424614","document_url":"https://www.ema.europa.eu/en/documents/psusa/flunitrazepam-list-nationally-authorised-medicinal-products-psusa-00001418-202501_en.pdf"},
    {"id":"70043","name":"Myristalkonium, benzalkonium (vaginal use only): List of nationally authorised medicinal products - PSUSA/00010987/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-10T11:35:16Z","last_updated_date":"2025-09-10T11:35:16Z","reference_number":"EMADOC-1700519818-2428244","document_url":"https://www.ema.europa.eu/en/documents/psusa/myristalkonium-benzalkonium-vaginal-use-only-list-nationally-authorised-medicinal-products-psusa-00010987-202501_en.pdf"},
    {"id":"70069","name":"Botulinum toxin a - haemagglutinin complex : List of nationally authorised medicinal products - PSUSA/00000427/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-11T17:47:28Z","last_updated_date":"2025-09-11T17:47:28Z","reference_number":"EMADOC-1700519818-2431167","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-haemagglutinin-complex-list-nationally-authorised-medicinal-products-psusa-00000427-202412_en.pdf"},
    {"id":"70070","name":"Acetylsalicylic acid / bisoprolol : List of nationally authorised medicinal products - PSUSA/00010287/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-11T17:52:24Z","last_updated_date":"2025-09-11T17:52:24Z","reference_number":"EMADOC-1700519818-2428564","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-bisoprolol-list-nationally-authorised-medicinal-products-psusa-00010287-202411_en.pdf"},
    {"id":"70071","name":" Acetylsalicylic acid / bisoprolol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010287/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-11T17:54:20Z","last_updated_date":"2025-09-11T17:54:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/acetylsalicylic-acid-bisoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010287-202411_sv.pdf"}},
    {"id":"70073","name":"Cyanocobalamin / diclofenac / pyridoxine / thiamine : List of nationally authorised medicinal products - PSUSA/00001041/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-12T12:00:44Z","last_updated_date":"2025-09-12T12:00:44Z","reference_number":"EMADOC-1700519818-2421502","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyanocobalamin-diclofenac-pyridoxine-thiamine-list-nationally-authorised-medicinal-products-psusa-00001041-202501_en.pdf"},
    {"id":"70076","name":"Phosphocreatine : List of nationally authorised medicinal products - PSUSA/00002398/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-12T16:23:47Z","last_updated_date":"2025-09-12T16:23:47Z","reference_number":"EMADOC-1700519818-2433422","document_url":"https://www.ema.europa.eu/en/documents/psusa/phosphocreatine-list-nationally-authorised-medicinal-products-psusa-00002398-202411_en.pdf"},
    {"id":"70077","name":"Phosphocreatine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002398/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-12T16:27:15Z","last_updated_date":"2025-09-12T16:27:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/phosphocreatine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002398-202411_sv.pdf"}},
    {"id":"70233","name":"Haloperidol  : List of nationally authorised medicinal products - PSUSA/00001587/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-23T15:59:38Z","last_updated_date":"2025-09-23T15:59:38Z","reference_number":"EMADOC-1700519818-2463062","document_url":"https://www.ema.europa.eu/en/documents/psusa/haloperidol-list-nationally-authorised-medicinal-products-psusa-00001587-202501_en.pdf"},
    {"id":"70234","name":"Flumazenil : List of nationally authorised medicinal products - PSUSA/00000427/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-23T16:13:27Z","last_updated_date":"2025-09-23T16:13:27Z","reference_number":"PSUSA/00001413/202412","document_url":"https://www.ema.europa.eu/en/documents/psusa/flumazenil-list-nationally-authorised-medicinal-products-psusa-00000427-202412_en.pdf"},
    {"id":"70287","name":"Omega-3-acid ethyl esters 90 : List of nationally authorised medicinal products - PSUSA/00010312/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T17:34:25Z","last_updated_date":"2025-09-25T17:34:25Z","reference_number":"EMADOC-1700519818-2470379","document_url":"https://www.ema.europa.eu/en/documents/psusa/omega-3-acid-ethyl-esters-90-list-nationally-authorised-medicinal-products-psusa-00010312-202501_en.pdf"},
    {"id":"70364","name":"Timolol (systemic use) : List of nationally authorised medicinal products - PSUSA/00010432/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T14:07:23Z","last_updated_date":"2025-09-30T14:07:23Z","reference_number":"EMADOC-1700519818-1903153","document_url":"https://www.ema.europa.eu/en/documents/psusa/timolol-systemic-use-list-nationally-authorised-medicinal-products-psusa-00010432-202410_en.pdf"},
    {"id":"70365","name":"Timolol (systemic use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010432/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T14:09:23Z","last_updated_date":"2025-09-30T14:09:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/timolol-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/timolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010432-202410_sv.pdf"}},
    {"id":"70411","name":"Diamorphine : List of nationally authorised medicinal products - PSUSA/00001028/202411 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T15:52:10Z","last_updated_date":"2025-10-02T15:52:10Z","reference_number":"EMADOC-1700519818-2435364","document_url":"https://www.ema.europa.eu/en/documents/psusa/diamorphine-list-nationally-authorised-medicinal-products-psusa-00001028-202411_en.pdf"},
    {"id":"70412","name":"Diamorphine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001028/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T15:53:44Z","last_updated_date":"2025-10-02T15:53:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/diamorphine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001028-202411_sv.pdf"}},
    {"id":"70420","name":"Interferon gamma : List of nationally authorised medicinal products - PSUSA/00001760/202501 - ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T16:33:51Z","last_updated_date":"2025-10-02T16:33:51Z","reference_number":"EMADOC-1700519818-2469030","document_url":"https://www.ema.europa.eu/en/documents/psusa/interferon-gamma-list-nationally-authorised-medicinal-products-psusa-00001760-202501_en.pdf"},
    {"id":"70423","name":"Cyclophosphamide : List of nationally authorised medicinal products - PSUSA/00000901/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T09:22:11Z","last_updated_date":"2025-10-03T09:22:11Z","reference_number":"EMADOC-1700519818-2421448","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyclophosphamide-list-nationally-authorised-medicinal-products-psusa-00000901-202501_en.pdf"},
    {"id":"70424","name":"Tofisopam : List of nationally authorised medicinal products - PSUSA/00002982/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T09:25:40Z","last_updated_date":"2025-10-03T09:25:40Z","reference_number":"EMADOC-1700519818-2497511","document_url":"https://www.ema.europa.eu/en/documents/psusa/tofisopam-list-nationally-authorised-medicinal-products-psusa-00002982-202501_en.pdf"}    {"id":"70425","name":"Lisdexamfetamine : List of nationally authorised medicinal products - PSUSA/00010289/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T09:28:28Z","last_updated_date":"2025-10-03T09:28:28Z","reference_number":"EMADOC-1700519818-2497675","document_url":"https://www.ema.europa.eu/en/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa-00010289-202502_en.pdf"},
    {"id":"70426","name":"Lorazepam : List of nationally authorised medicinal products - PSUSA/00001909/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T09:31:21Z","last_updated_date":"2025-10-03T09:31:21Z","reference_number":"EMADOC-1700519818-2498095","document_url":"https://www.ema.europa.eu/en/documents/psusa/lorazepam-list-nationally-authorised-medicinal-products-psusa-00001909-202501_en.pdf"},
    {"id":"70428","name":"Xipamide, triamterene / xipamide : List of nationally authorised medicinal products - PSUSA/00003133/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T09:35:03Z","last_updated_date":"2025-10-03T09:35:03Z","reference_number":"EMADOC-1700519818-2497792","document_url":"https://www.ema.europa.eu/en/documents/psusa/xipamide-triamterene-xipamide-list-nationally-authorised-medicinal-products-psusa-00003133-202501_en.pdf"},
    {"id":"70430","name":"Mesterolone : List of nationally authorised medicinal products - PSUSA/00010551/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T09:37:53Z","last_updated_date":"2025-10-03T09:37:53Z","reference_number":"EMADOC-1700519818-2498333","document_url":"https://www.ema.europa.eu/en/documents/psusa/mesterolone-list-nationally-authorised-medicinal-products-psusa-00010551-202501_en.pdf"},
    {"id":"70431","name":"Influenza vaccine (surface antigen, inactivated) : List of nationally authorised medicinal products - PSUSA/00001744/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T09:41:01Z","last_updated_date":"2025-10-03T09:41:01Z","reference_number":"EMADOC-1700519818-2497282","document_url":"https://www.ema.europa.eu/en/documents/psusa/influenza-vaccine-surface-antigen-inactivated-list-nationally-authorised-medicinal-products-psusa-00001744-202503_en.pdf"},
    {"id":"70443","name":"Hydroxyethyl starch / sodium chloride : List of nationally authorised medicinal products - PSUSA/00001694/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T16:02:27Z","last_updated_date":"2025-10-03T16:02:27Z","reference_number":"EMADOC-1700519818-2501566","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydroxyethyl-starch-sodium-chloride-list-nationally-authorised-medicinal-products-psusa-00001694-202503_en.pdf"},
    {"id":"70450","name":"Warfarin : List of nationally authorised medicinal products - PSUSA/00003129/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-06T10:37:13Z","last_updated_date":"2025-10-06T10:37:13Z","reference_number":"EMADOC-1700519818-2501966","document_url":"https://www.ema.europa.eu/en/documents/psusa/warfarin-list-nationally-authorised-medicinal-products-psusa-00003129-202501_en.pdf"},
    {"id":"70453","name":"Pimozide : List of nationally authorised medicinal products - PSUSA/00002413/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-06T11:48:07Z","last_updated_date":"2025-10-06T11:48:07Z","reference_number":"EMADOC-1700519818-2502815","document_url":"https://www.ema.europa.eu/en/documents/psusa/pimozide-list-nationally-authorised-medicinal-products-psusa-00002413-202502_en.pdf"},
    {"id":"70469","name":"Potassium para-aminobenzoate : List of nationally authorised medicinal products - PSUSA/00010130/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-07T12:26:01Z","last_updated_date":"2025-10-07T12:26:01Z","reference_number":"EMADOC-1700519818-2504076","document_url":"https://www.ema.europa.eu/en/documents/psusa/potassium-para-aminobenzoate-list-nationally-authorised-medicinal-products-psusa-00010130-202502_en.pdf"},
    {"id":"70548","name":"Sevoflurane : List of nationally authorised medicinal products - PSUSA/00002698/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-14T15:27:02Z","last_updated_date":"2025-10-14T15:27:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/sevoflurane-list-nationally-authorised-medicinal-products-psusa-00002698-202501_en.pdf"},
    {"id":"70756","name":"Bisoprolol / hydrochlorothiazide : List of nationally authorised medicinal products - PSUSA/00000420/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-22T11:38:16Z","last_updated_date":"2025-10-22T11:38:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bisoprolol-hydrochlorothiazide-list-nationally-authorised-medicinal-products-psusa-00000420-202411_en.pdf"},
    {"id":"70757","name":"Bisoprolol / hydrochlorothiazide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000420/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-22T11:42:44Z","last_updated_date":"2025-10-24T15:43:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bisoprolol-hydrochlorothiazide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_no.pdf"}},
    {"id":"70791","name":"Disodium hydrogen phosphate / sodium dihydrogen phosphate, phosphate sodium : List of nationally authorised medicinal products - PSUSA/00002737/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T17:13:53Z","last_updated_date":"2025-10-23T17:13:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-list-nationally-authorised-medicinal-products-psusa-00002737-202501_en.pdf"},
    {"id":"70792","name":"Disodium hydrogen phosphate / sodium dihydrogen phosphate, phosphate sodium : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002737/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T17:16:12Z","last_updated_date":"2025-10-23T17:16:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/disodium-hydrogen-phosphate-sodium-dihydrogen-phosphate-phosphate-sodium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002737-202501_sv.pdf"}},
    {"id":"70793","name":"Ciclosporin (systemic use) : List of nationally authorised medicinal products - PSUSA/00000745/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T17:20:12Z","last_updated_date":"2025-10-23T17:20:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciclosporin-systemic-use-list-nationally-authorised-medicinal-products-psusa-00000745-202412_en.pdf"},
    {"id":"70794","name":"Ciclosporin (systemic use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000745/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T17:22:08Z","last_updated_date":"2025-10-23T17:22:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ciclosporin-systemic-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000745-202412_no.pdf"}},
    {"id":"70795","name":"Botulinum neurotoxin type a (150 kd) free from complexing proteins : List of nationally authorised medicinal products - PSUSA/00009084/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T17:52:23Z","last_updated_date":"2025-10-23T17:52:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-proteins-list-nationally-authorised-medicinal-products-psusa-00009084-202412_en.pdf"},
    {"id":"70796","name":"Botulinum neurotoxin type a (150 kd) free from complexing protein: s : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009084/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T17:53:59Z","last_updated_date":"2025-10-23T17:53:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/botulinum-neurotoxin-type-150-kd-free-complexing-protein-s-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00009084-202412_no.pdf"}},
    {"id":"70797","name":"Dexketoprofen / tramadol : List of nationally authorised medicinal products - PSUSA/00010468/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T17:59:39Z","last_updated_date":"2025-10-23T17:59:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-tramadol-list-nationally-authorised-medicinal-products-psusa-00010468-202501_en.pdf"},
    {"id":"70798","name":"Dexketoprofen / tramadol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010468/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-23T18:00:29Z","last_updated_date":"2025-10-23T18:00:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dexketoprofen-tramadol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010468-202501_sv.pdf"}},
    {"id":"70850","name":"Testosterone (all formulations apart from topical use) : List of nationally authorised medicinal products - PSUSA/00000420/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-27T15:35:44Z","last_updated_date":"2025-10-27T15:35:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-all-formulations-apart-topical-use-list-nationally-authorised-medicinal-products-psusa-00000420-202411_en.pdf"},
    {"id":"70851","name":"Testosterone (all formulations apart from topical use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000420/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-27T15:37:30Z","last_updated_date":"2025-10-27T15:37:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/testosterone-all-formulations-apart-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000420-202411_no.pdf"}},
    {"id":"70931","name":"Dermatan sulfate : List of nationally authorised medicinal products - PSUSA/00000957/202411","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-30T12:49:21Z","last_updated_date":"2025-10-30T12:49:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dermatan-sulfate-list-nationally-authorised-medicinal-products-psusa-00000957-202411_en.pdf"},
    {"id":"70932","name":"Glipizide : List of nationally authorised medicinal products - PSUSA/00001535/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-30T13:08:23Z","last_updated_date":"2025-10-30T13:08:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/glipizide-list-nationally-authorised-medicinal-products-psusa-00001535-202501_en.pdf"},
    {"id":"70961","name":"Milrinone : List of nationally authorised medicinal products - PSUSA/00002064/202410","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T11:34:28Z","last_updated_date":"2025-10-31T11:34:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/milrinone-list-nationally-authorised-medicinal-products-psusa-00002064-202410_en.pdf"},
    {"id":"70962","name":"Doxycycline : List of nationally authorised medicinal products - PSUSA/00001173/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T11:38:10Z","last_updated_date":"2025-10-31T11:38:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/doxycycline-list-nationally-authorised-medicinal-products-psusa-00001173-202503_en.pdf"},
    {"id":"70963","name":"Trandolapril / verapamil : List of nationally authorised medicinal products - PSUSA/00003005/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T11:43:41Z","last_updated_date":"2025-10-31T11:43:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/trandolapril-verapamil-list-nationally-authorised-medicinal-products-psusa-00003005-202503_en.pdf"},
    {"id":"70964","name":"Thiamazole : List of nationally authorised medicinal products - PSUSA/00002922/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T11:52:09Z","last_updated_date":"2025-11-10T16:30:00Z","reference_number":"EMADOC-1700519818-2580546","document_url":"https://www.ema.europa.eu/en/documents/psusa/thiamazole-list-nationally-authorised-medicinal-products-psusa-00002922-202503_en.pdf"},
    {"id":"70965","name":"Mannitol (all indications apart from cystic fibrosis) : List of nationally authorised medicinal products - PSUSA/00010005/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T12:00:56Z","last_updated_date":"2025-10-31T12:00:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mannitol-all-indications-apart-cystic-fibrosis-list-nationally-authorised-medicinal-products-psusa-00010005-202502_en.pdf"},
    {"id":"70966","name":"Ethinylestradiol : List of nationally authorised medicinal products - PSUSA/00001306/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T12:05:36Z","last_updated_date":"2025-10-31T12:05:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-list-nationally-authorised-medicinal-products-psusa-00001306-202503_en.pdf"},
    {"id":"70967","name":"Urokinase : List of nationally authorised medicinal products - PSUSA/00003083/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T12:09:34Z","last_updated_date":"2025-10-31T12:09:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/urokinase-list-nationally-authorised-medicinal-products-psusa-00003083-202503_en.pdf"},
    {"id":"70968","name":"Niflumic acid : List of nationally authorised medicinal products - PSUSA/00002157/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T12:14:46Z","last_updated_date":"2025-10-31T12:14:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/niflumic-acid-list-nationally-authorised-medicinal-products-psusa-00002157-202412_en.pdf"},
    {"id":"70969","name":"Niflumic acid : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002157/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T12:17:19Z","last_updated_date":"2025-10-31T12:17:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/niflumic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002157-202412_sv.pdf"}},
    {"id":"70973","name":"Bupropion : List of nationally authorised medicinal products - PSUSA/00000461/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-03T11:20:02Z","last_updated_date":"2025-11-03T11:20:02Z","reference_number":"EMADOC-1700519818-2576258","document_url":"https://www.ema.europa.eu/en/documents/psusa/bupropion-list-nationally-authorised-medicinal-products-psusa-00000461-202412_en.pdf"},
    {"id":"70974","name":"Bupropion : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000461/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-03T11:21:59Z","last_updated_date":"2025-11-03T11:21:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/bupropion-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000461-202412_no.pdf"}},
    {"id":"70975","name":"Hepatitis B vaccine (rDNA) : List of nationally authorised medicinal products - PSUSA/00001597/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-03T11:26:21Z","last_updated_date":"2025-11-03T11:26:21Z","reference_number":"EMADOC-1700519818-2550366","document_url":"https://www.ema.europa.eu/en/documents/psusa/hepatitis-b-vaccine-rdna-list-nationally-authorised-medicinal-products-psusa-00001597-202502_en.pdf"},
    {"id":"70995","name":"Erythromycin (systemic use) : List of nationally authorised medicinal products - PSUSA/00010808/202503 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-04T11:40:05Z","last_updated_date":"2025-11-04T11:40:05Z","reference_number":"EMADOC-1700519818-2587817","document_url":"https://www.ema.europa.eu/en/documents/psusa/erythromycin-systemic-use-list-nationally-authorised-medicinal-products-psusa-00010808-202503_en.pdf"},
    {"id":"70997","name":"Diazepam : List of nationally authorised medicinal products - PSUSA/00001029/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-04T12:03:37Z","last_updated_date":"2025-11-04T12:03:37Z","reference_number":"EMADOC-1700519818-2585677","document_url":"https://www.ema.europa.eu/en/documents/psusa/diazepam-list-nationally-authorised-medicinal-products-psusa-00001029-202503_en.pdf"},
    {"id":"71016","name":"Fomepizole : List of nationally authorised medicinal products - PSUSA/00001466/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-05T16:57:18Z","last_updated_date":"2025-11-05T16:57:18Z","reference_number":"EMADOC-1700519818-2589658","document_url":"https://www.ema.europa.eu/en/documents/psusa/fomepizole-list-nationally-authorised-medicinal-products-psusa-00001466-202503_en.pdf"},
    {"id":"71017","name":"Ethyl loflazepate : List of nationally authorised medicinal products - PSUSA/00001317/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-05T17:20:24Z","last_updated_date":"2025-11-05T17:20:24Z","reference_number":"EMADOC-1700519818-2590151","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethyl-loflazepate-list-nationally-authorised-medicinal-products-psusa-00001317-202503_en.pdf"},
    {"id":"71018","name":"Cyamemazine  : List of nationally authorised medicinal products - PSUSA/00000886/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-05T17:25:10Z","last_updated_date":"2025-11-05T17:25:10Z","reference_number":"EMADOC-1700519818-2590132","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyamemazine-list-nationally-authorised-medicinal-products-psusa-00000886-202503_en.pdf"},
    {"id":"71019","name":"Clobetasol  : List of nationally authorised medicinal products - PSUSA/00000799/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-05T17:31:33Z","last_updated_date":"2025-11-05T17:31:33Z","reference_number":"EMADOC-1700519818-2593975","document_url":"https://www.ema.europa.eu/en/documents/psusa/clobetasol-list-nationally-authorised-medicinal-products-psusa-00000799-202502_en.pdf"},
    {"id":"71020","name":"Alprazolam : List of nationally authorised medicinal products - PSUSA/00000109/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-05T17:35:32Z","last_updated_date":"2025-11-05T17:35:32Z","reference_number":"EMADOC-1700519818-2594276","document_url":"https://www.ema.europa.eu/en/documents/psusa/alprazolam-list-nationally-authorised-medicinal-products-psusa-00000109-202503_en.pdf"},
    {"id":"71021","name":"Botulinum toxin a (except for centrally authorised products) : List of nationally authorised medicinal products - PSUSA/00000426/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-05T17:42:06Z","last_updated_date":"2025-11-05T17:42:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-except-centrally-authorised-products-list-nationally-authorised-medicinal-products-psusa-00000426-202412_en.pdf"},
    {"id":"71022","name":"Botulinum toxin a (except for centrally authorised products) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000426/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-05T17:43:25Z","last_updated_date":"2025-11-05T17:43:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/botulinum-toxin-except-centrally-authorised-products-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000426-202412_no.pdf"}},
    {"id":"71103","name":"Estradiol (17-beta) / progesterone : List of nationally authorised medicinal products - PSUSA/00009145/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-12T13:38:09Z","last_updated_date":"2025-11-12T13:38:09Z","reference_number":"EMADOC-1700519818-2618504","document_url":"https://www.ema.europa.eu/en/documents/psusa/estradiol-17-beta-progesterone-list-nationally-authorised-medicinal-products-psusa-00009145-202412_en.pdf"},
    {"id":"71226","name":"Sodium citrate / sodium lauryl sulfoacetate, sodium citrate / sodium lauryl sulfoacetate / sorbitol : List of nationally authorised medicinal products - PSUSA/00002735/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-18T14:36:29Z","last_updated_date":"2025-11-18T14:36:29Z","reference_number":"EMADOC-1700519818-2631280","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-list-nationally-authorised-medicinal-products-psusa-00002735-202501_en.pdf"},
    {"id":"71227","name":"Sodium citrate / sodium lauryl sulfoacetate, sodium citrate / sodium lauryl sulfoacetate / sorbitol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002735/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-18T14:40:27Z","last_updated_date":"2026-01-05T14:40:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/sodium-citrate-sodium-lauryl-sulfoacetate-sodium-citrate-sodium-lauryl-sulfoacetate-sorbitol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa_no.pdf"}},
    {"id":"71301","name":"Trimethoprim : List of nationally authorised medicinal products - PSUSA/00003045/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-24T09:21:17Z","last_updated_date":"2025-11-24T09:21:17Z","reference_number":"EMADOC-1700519818-2643515","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimethoprim-list-nationally-authorised-medicinal-products-psusa-00003045-202501_en.pdf"},
    {"id":"71302","name":"Trimethoprim : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003045/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-24T09:26:20Z","last_updated_date":"2025-11-24T09:26:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/trimethoprim-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003045-202501_no.pdf"}},
    {"id":"71308","name":"Prednisone : List of nationally authorised medicinal products - PSUSA/00002510/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-24T11:20:07Z","last_updated_date":"2025-11-24T11:20:07Z","reference_number":"EMADOC-1700519818-2645981","document_url":"https://www.ema.europa.eu/en/documents/psusa/prednisone-list-nationally-authorised-medicinal-products-psusa-00002510-202501_en.pdf"},
    {"id":"71309","name":"Prednisone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002510/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-24T11:22:07Z","last_updated_date":"2025-11-24T11:22:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/prednisone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002510-202501_sv.pdf"}},
    {"id":"71346","name":"Dorzolamide : List of nationally authorised medicinal products - PSUSA/00003168/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T16:00:14Z","last_updated_date":"2025-11-26T16:00:14Z","reference_number":"EMADOC-1700519818-2654851","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-list-nationally-authorised-medicinal-products-psusa-00003168-202502_en.pdf"},
    {"id":"71347","name":"Dorzolamide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003168/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T16:01:38Z","last_updated_date":"2025-11-26T16:01:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/dorzolamide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003168-202502_no.pdf"}},
    {"id":"71348","name":"Atenolol : List of nationally authorised medicinal products - PSUSA/00000259/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T16:05:24Z","last_updated_date":"2025-11-26T16:05:24Z","reference_number":"EMADOC-1700519818-2646718","document_url":"https://www.ema.europa.eu/en/documents/psusa/atenolol-list-nationally-authorised-medicinal-products-psusa-00000259-202502_en.pdf"},
    {"id":"71349","name":"Atenolol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000259/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T16:08:01Z","last_updated_date":"2025-11-26T16:08:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_de.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/atenolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000259-202502_no.pdf"}},
    {"id":"71350","name":"Rosuvastatin / Omega-3-acid ethyl esters : List of nationally authorised medicinal products - PSUSA/00010915/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T16:10:21Z","last_updated_date":"2025-11-26T16:10:21Z","reference_number":"EMADOC-1700519818-2655853","document_url":"https://www.ema.europa.eu/en/documents/psusa/rosuvastatin-omega-3-acid-ethyl-esters-list-nationally-authorised-medicinal-products-psusa-00010915-202501_en.pdf"},
    {"id":"71352","name":"Gabapentin : List of nationally authorised medicinal products - PSUSA/00001499/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T16:23:15Z","last_updated_date":"2025-11-26T16:23:15Z","reference_number":"EMADOC-1700519818-2663923","document_url":"https://www.ema.europa.eu/en/documents/psusa/gabapentin-list-nationally-authorised-medicinal-products-psusa-00001499-202502_en.pdf"},
    {"id":"71353","name":"Gabapentin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001499/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-26T16:24:54Z","last_updated_date":"2026-03-09T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/gabapentin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001499-202502_no.pdf"}},
    {"id":"71355","name":"Codeine : List of nationally authorised medicinal products - PSUSA/00000843/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T09:59:11Z","last_updated_date":"2025-11-27T09:59:11Z","reference_number":"EMADOC-1700519818-2657087","document_url":"https://www.ema.europa.eu/en/documents/psusa/codeine-list-nationally-authorised-medicinal-products-psusa-00000843-202501_en.pdf"},
    {"id":"71356","name":"Codeine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000843/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T10:01:43Z","last_updated_date":"2025-11-27T10:01:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_sv.pdf"}},
    {"id":"71374","name":"Triamcinolone (intraocular formulations) : List of nationally authorised medicinal products - PSUSA/00010292/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T15:56:40Z","last_updated_date":"2025-11-27T15:56:40Z","reference_number":"EMADOC-1700519818-2675181","document_url":"https://www.ema.europa.eu/en/documents/psusa/triamcinolone-intraocular-formulations-list-nationally-authorised-medicinal-products-psusa-00010292-202503_en.pdf"},
    {"id":"71379","name":"Ivermectin (systemic use) : List of nationally authorised medicinal products - PSUSA/00010377/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T08:50:44Z","last_updated_date":"2025-11-28T08:50:44Z","reference_number":"EMADOC-1700519818-2636244","document_url":"https://www.ema.europa.eu/en/documents/psusa/ivermectin-systemic-use-list-nationally-authorised-medicinal-products-psusa-00010377-202504_en.pdf"},
    {"id":"71380","name":"Ofloxacin (systemic use) : List of nationally authorised medicinal products - PSUSA/00002203/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T08:54:08Z","last_updated_date":"2025-11-28T08:54:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ofloxacin-systemic-use-list-nationally-authorised-medicinal-products-psusa-00002203-202504_en.pdf"},
    {"id":"71391","name":"Reboxetine : List of nationally authorised medicinal products - PSUSA/00002615/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T14:27:22Z","last_updated_date":"2025-11-28T14:27:22Z","reference_number":"EMADOC-1700519818-2679815","document_url":"https://www.ema.europa.eu/en/documents/psusa/reboxetine-list-nationally-authorised-medicinal-products-psusa-00002615-202504_en.pdf"},
    {"id":"71416","name":"Vancomycin : List of nationally authorised medicinal products - PSUSA/00003097/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T11:35:44Z","last_updated_date":"2025-12-01T11:35:44Z","reference_number":"EMADOC-1700519818-2681358","document_url":"https://www.ema.europa.eu/en/documents/psusa/vancomycin-list-nationally-authorised-medicinal-products-psusa-00003097-202501_en.pdf"},
    {"id":"71417","name":"Vancomycin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003097/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T11:37:01Z","last_updated_date":"2026-05-21T12:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/vancomycin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00003097-202501_no.pdf"}},
    {"id":"71430","name":"Carvedilol / ivabradine : List of nationally authorised medicinal products - PSUSA/00010883/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T13:03:24Z","last_updated_date":"2025-12-01T13:03:24Z","reference_number":"EMADOC-1700519818-2684478","document_url":"https://www.ema.europa.eu/en/documents/psusa/carvedilol-ivabradine-list-nationally-authorised-medicinal-products-psusa-00010883-202504_en.pdf"},
    {"id":"71453","name":"Methylphenidate hydrochloride : List of nationally authorised medicinal products - EMA/PASS/0000248031","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-02T16:08:00Z","last_updated_date":"2025-12-02T16:08:00Z","reference_number":"EMADOC-1700519818-2688035","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-hydrochloride-list-nationally-authorised-medicinal-products-ema-pass-0000248031_en.pdf"},
    {"id":"71454","name":"Methylphenidate hydrochloride : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - EMA/PASS/0000248031","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-02T16:09:00Z","last_updated_date":"2025-12-02T16:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methylphenidate-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-ema-pass-0000248031_no.pdf"}},
    {"id":"71455","name":"Propylthiouracil : List of nationally authorised medicinal products - PSUSA/00002558/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-02T15:31:41Z","last_updated_date":"2025-12-02T15:31:41Z","reference_number":"EMADOC-1700519818-2688635","document_url":"https://www.ema.europa.eu/en/documents/psusa/propylthiouracil-list-nationally-authorised-medicinal-products-psusa-00002558-202501_en.pdf"},
    {"id":"71456","name":"Propylthiouracil : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002558/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-02T15:33:06Z","last_updated_date":"2025-12-05T13:35:00Z","reference_number":"EMADOC-1700519818-2688635","document_url":"https://www.ema.europa.eu/en/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/propylthiouracil-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002558-202501_sv.pdf"}},
    {"id":"71466","name":"Tibolone : List of nationally authorised medicinal products - PSUSA/00002947/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-03T10:21:31Z","last_updated_date":"2025-12-03T10:21:31Z","reference_number":"EMADOC-1700519818-1987499","document_url":"https://www.ema.europa.eu/en/documents/psusa/tibolone-list-nationally-authorised-medicinal-products-psusa-00002947-202412_en.pdf"},
    {"id":"71481","name":"Caspofungin : List of nationally authorised medicinal products - PSUSA/00000576/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-03T16:11:48Z","last_updated_date":"2025-12-03T16:11:48Z","reference_number":"EMADOC-1700519818-2694579","document_url":"https://www.ema.europa.eu/en/documents/psusa/caspofungin-list-nationally-authorised-medicinal-products-psusa-00000576-202412_en.pdf"},
    {"id":"71482","name":"Caspofungin : CHMP Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000576/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-03T16:13:06Z","last_updated_date":"2025-12-03T16:13:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/caspofungin-chmp-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/caspofungin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000576-202412_no.pdf"}},
    {"id":"71684","name":"Amlodipine / atorvastatin : List of nationally authorised medicinal products - PSUSA/00000177/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-11T12:01:45Z","last_updated_date":"2025-12-11T12:01:45Z","reference_number":"EMADOC-1700519818-2658372","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-atorvastatin-list-nationally-authorised-medicinal-products-psusa-00000177-202501_en.pdf"},
    {"id":"71685","name":"Amlodipine / atorvastatin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000177/202501","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-11T12:04:17Z","last_updated_date":"2025-12-11T12:04:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/amlodipine-atorvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000177-202501_sv.pdf"}},
    {"id":"71845","name":"Prazepam : List of nationally authorised medicinal products - PSUSA/00002502/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-18T12:57:21Z","last_updated_date":"2025-12-18T12:57:21Z","reference_number":"EMADOC-1700519818-2770702","document_url":"https://www.ema.europa.eu/en/documents/psusa/prazepam-list-nationally-authorised-medicinal-products-psusa-00002502-202503_en.pdf"},
    {"id":"71846","name":"Prazepam : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002502/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-18T12:58:59Z","last_updated_date":"2025-12-18T12:58:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/prazepam-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002502-202503_sv.pdf"}},
    {"id":"71861","name":"Varicella vaccine (live) : List of nationally authorised medicinal products - PSUSA/00010473/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T09:04:47Z","last_updated_date":"2025-12-19T09:04:47Z","reference_number":"EMADOC-1700519818-2588438","document_url":"https://www.ema.europa.eu/en/documents/psusa/varicella-vaccine-live-list-nationally-authorised-medicinal-products-psusa-00010473-202503_en.pdf"},
    {"id":"71862","name":"Varicella vaccine (live) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010473/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T09:06:11Z","last_updated_date":"2025-12-19T09:06:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/varicella-vaccine-live-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010473-202503_no.pdf"}},
    {"id":"71863","name":"Varicella vaccine (live) : List of nationally authorised medicinal products - PSUSA/00010473/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T09:12:47Z","last_updated_date":"2025-12-19T09:12:47Z","reference_number":"EMADOC-1700519818-2588438","document_url":"https://www.ema.europa.eu/en/documents/psusa/varicella-vaccine-live-list-nationally-authorised-medicinal-products-psusa-00010473-202503_en.pdf-0"},
    {"id":"71871","name":"Metoprolol : List of nationally authorised medicinal products - PSUSA/00002039/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T12:47:09Z","last_updated_date":"2025-12-19T12:47:09Z","reference_number":"EMADOC-1700519818-2771118","document_url":"https://www.ema.europa.eu/en/documents/psusa/metoprolol-list-nationally-authorised-medicinal-products-psusa-00002039-202503_en.pdf"},
    {"id":"71872","name":"Metoprolol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002039/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T12:49:53Z","last_updated_date":"2025-12-19T12:49:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/metoprolol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002039-202503_no.pdf"}},
    {"id":"71880","name":"Rifampicin : List of nationally authorised medicinal products - PSUSA/00002640/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T13:27:19Z","last_updated_date":"2025-12-19T13:27:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rifampicin-list-nationally-authorised-medicinal-products-psusa-00002640-202503_en.pdf"},
    {"id":"71881","name":"Rifampicin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002640/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T13:32:53Z","last_updated_date":"2025-12-19T13:32:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/rifampicin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002640-202503_no.pdf"}},
    {"id":"71883","name":"Rocuronium : List of nationally authorised medicinal products - PSUSA/00002656/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T14:48:22Z","last_updated_date":"2025-12-19T14:48:22Z","reference_number":"EMADOC-1700519818-2775133","document_url":"https://www.ema.europa.eu/en/documents/psusa/rocuronium-list-nationally-authorised-medicinal-products-psusa-00002656-202502_en.pdf"},
    {"id":"71884","name":"Rocuronium : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002656/202502","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T14:50:51Z","last_updated_date":"2025-12-19T14:50:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/rocuronium-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002656-202502_no.pdf"}},
    {"id":"71887","name":"Selegiline : List of nationally authorised medicinal products - PSUSA/00002688/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T15:18:31Z","last_updated_date":"2025-12-19T15:18:31Z","reference_number":"EMADOC-1700519818-2775121","document_url":"https://www.ema.europa.eu/en/documents/psusa/selegiline-list-nationally-authorised-medicinal-products-psusa-00002688-202503_en.pdf"},
    {"id":"71888","name":"Selegiline : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002688/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T15:20:02Z","last_updated_date":"2025-12-19T15:20:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_de.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/selegiline-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002688-202503_no.pdf"}},
    {"id":"71949","name":"Clozapine : List of nationally authorised medicinal products - PSUSA/00000836/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-08T12:13:13Z","last_updated_date":"2026-01-08T12:13:13Z","reference_number":"EMADOC-1700519818-2797839","document_url":"https://www.ema.europa.eu/en/documents/psusa/clozapine-list-nationally-authorised-medicinal-products-psusa-00000836-202503_en.pdf"},
    {"id":"71985","name":"Clozapine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000836/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-08T08:30:51Z","last_updated_date":"2026-01-08T08:30:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/clozapine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000836-202503_no.pdf"}},
    {"id":"71994","name":"Clomipramine : List of nationally authorised medicinal products - PSUSA/00000811/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-08T15:41:02Z","last_updated_date":"2026-01-08T15:41:02Z","reference_number":"EMADOC-1700519818-2804911","document_url":"https://www.ema.europa.eu/en/documents/psusa/clomipramine-list-nationally-authorised-medicinal-products-psusa-00000811-202503_en.pdf"},
    {"id":"71995","name":"Clomipramine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000811/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-08T15:42:28Z","last_updated_date":"2026-01-08T15:42:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/clomipramine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000811-202503_no.pdf"}},
    {"id":"72049","name":"Codeine / paracetamol : List of nationally authorised medicinal products - PSUSA/00000851/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-14T16:17:07Z","last_updated_date":"2026-01-14T16:17:07Z","reference_number":"EMADOC-1700519818-2822399","document_url":"https://www.ema.europa.eu/en/documents/psusa/codeine-paracetamol-list-nationally-authorised-medicinal-products-psusa-00000851-202503_en.pdf"},
    {"id":"72050","name":"Codeine / paracetamol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000851/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-14T16:18:43Z","last_updated_date":"2026-01-14T16:18:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000851-202503_no.pdf"}},
    {"id":"72063","name":"Cefditoren : List of nationally authorised medicinal products - PSUSA/00000592/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T14:25:55Z","last_updated_date":"2026-01-15T14:25:55Z","reference_number":"EMADOC-1700519818-2828091","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefditoren-list-nationally-authorised-medicinal-products-psusa-00000592-202503_en.pdf"},
    {"id":"72064","name":"Cefditoren : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000592/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T14:27:15Z","last_updated_date":"2026-01-15T14:27:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefditoren-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000592-202503_sv.pdf"}},
    {"id":"72065","name":"Calcipotriol : List of nationally authorised medicinal products - PSUSA/00000492/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T14:33:06Z","last_updated_date":"2026-01-15T14:33:06Z","reference_number":"EMADOC-1700519818-2783116","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcipotriol-list-nationally-authorised-medicinal-products-psusa-00000492-202506_en.pdf"},
    {"id":"72066","name":"Etamsylate : List of nationally authorised medicinal products - PSUSA/00001294/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T14:36:37Z","last_updated_date":"2026-01-15T14:36:37Z","reference_number":"EMADOC-1700519818-2783294","document_url":"https://www.ema.europa.eu/en/documents/psusa/etamsylate-list-nationally-authorised-medicinal-products-psusa-00001294-202506_en.pdf"}    {"id":"72067","name":"Carmellose (eye preparation) : List of nationally authorised medicinal products - PSUSA/00000562/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T14:40:39Z","last_updated_date":"2026-01-15T14:40:39Z","reference_number":"EMADOC-1700519818-2828413","document_url":"https://www.ema.europa.eu/en/documents/psusa/carmellose-eye-preparation-list-nationally-authorised-medicinal-products-psusa-00000562-202506_en.pdf"},
    {"id":"72069","name":"Ceftriaxone sodium / lidocaine hydrochloride : List of nationally authorised medicinal products - PSUSA/00000614/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T15:17:04Z","last_updated_date":"2026-01-15T15:17:04Z","reference_number":"EMADOC-1700519818-2828744","document_url":"https://www.ema.europa.eu/en/documents/psusa/ceftriaxone-sodium-lidocaine-hydrochloride-list-nationally-authorised-medicinal-products-psusa-00000614-202505_en.pdf"},
    {"id":"72070","name":"Ciprofloxacin / dexamethasone (ear drops, suspension) : List of nationally authorised medicinal products - PSUSA/00010012/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T15:32:29Z","last_updated_date":"2026-01-15T15:32:29Z","reference_number":"EMADOC-1700519818-2824467","document_url":"https://www.ema.europa.eu/en/documents/psusa/ciprofloxacin-dexamethasone-ear-drops-suspension-list-nationally-authorised-medicinal-products-psusa-00010012-202504_en.pdf"},
    {"id":"72073","name":"Clotiazepam : List of nationally authorised medicinal products - PSUSA/00000827/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T15:37:15Z","last_updated_date":"2026-01-15T15:37:15Z","reference_number":"EMADOC-1700519818-2825353","document_url":"https://www.ema.europa.eu/en/documents/psusa/clotiazepam-list-nationally-authorised-medicinal-products-psusa-00000827-202505_en.pdf"},
    {"id":"72075","name":"Misoprostol (gynaecological indication - labour induction) : List of nationally authorised medicinal products - PSUSA/00010353/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T15:40:26Z","last_updated_date":"2026-01-15T15:40:26Z","reference_number":"EMADOC-1700519818-2829509","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gynaecological-indication-labour-induction-list-nationally-authorised-medicinal-products-psusa-00010353-202505_en.pdf"},
    {"id":"72092","name":"Lodoxamide : List of nationally authorised medicinal products - PSUSA/00001898/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T10:12:17Z","last_updated_date":"2026-01-16T10:12:17Z","reference_number":"EMADOC-1700519818-2593298","document_url":"https://www.ema.europa.eu/en/documents/psusa/lodoxamide-list-nationally-authorised-medicinal-products-psusa-00001898-202506_en.pdf"},
    {"id":"72093","name":" Fenticonazole : List of nationally authorised medicinal products -  PSUSA/00001371/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T10:16:35Z","last_updated_date":"2026-01-16T10:16:35Z","reference_number":"EMADOC-1700519818-2829886","document_url":"https://www.ema.europa.eu/en/documents/psusa/fenticonazole-list-nationally-authorised-medicinal-products-psusa-00001371-202506_en.pdf"},
    {"id":"72094","name":"Mebendazole : List of nationally authorised medicinal products - PSUSA/00001939/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T10:20:25Z","last_updated_date":"2026-01-16T10:20:25Z","reference_number":"EMADOC-1700519818-2829891","document_url":"https://www.ema.europa.eu/en/documents/psusa/mebendazole-list-nationally-authorised-medicinal-products-psusa-00001939-202505_en.pdf"},
    {"id":"72095","name":"Rifaximin : List of nationally authorised medicinal products - PSUSA/00002642/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T10:23:06Z","last_updated_date":"2026-01-16T10:23:06Z","reference_number":"EMADOC-1700519818-2824520","document_url":"https://www.ema.europa.eu/en/documents/psusa/rifaximin-list-nationally-authorised-medicinal-products-psusa-00002642-202505_en.pdf"},
    {"id":"72096","name":"Ozenoxacin : List of nationally authorised medicinal products - PSUSA/00010651/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T10:25:54Z","last_updated_date":"2026-01-16T10:25:54Z","reference_number":"EMADOC-1700519818-2830723","document_url":"https://www.ema.europa.eu/en/documents/psusa/ozenoxacin-list-nationally-authorised-medicinal-products-psusa-00010651-202505_en.pdf"},
    {"id":"72097","name":"Diphtheria / tetanus vaccines (adsorbed), diphtheria vaccines (adsorbed) : List of nationally authorised medicinal products - PSUSA/00001128/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T10:31:47Z","last_updated_date":"2026-01-16T10:31:47Z","reference_number":"EMADOC-1700519818-2830891","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-vaccines-adsorbed-diphtheria-vaccines-adsorbed-list-nationally-authorised-medicinal-products-psusa-00001128-202505_en.pdf"},
    {"id":"72098","name":"Fusidic acid (systemic use) : List of nationally authorised medicinal products - PSUSA/00010226/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T10:36:22Z","last_updated_date":"2026-01-16T10:36:22Z","reference_number":"EMADOC-1700519818-2830896","document_url":"https://www.ema.europa.eu/en/documents/psusa/fusidic-acid-systemic-use-list-nationally-authorised-medicinal-products-psusa-00010226-202505_en.pdf"},
    {"id":"72099","name":"Bifonazole : List of nationally authorised medicinal products - PSUSA/00000411/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T10:40:58Z","last_updated_date":"2026-01-16T10:40:58Z","reference_number":"EMADOC-1700519818-2831274","document_url":"https://www.ema.europa.eu/en/documents/psusa/bifonazole-list-nationally-authorised-medicinal-products-psusa-00000411-202505_en.pdf"},
    {"id":"72126","name":"Somatostatin : CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002771/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-19T11:30:29Z","last_updated_date":"2026-01-19T11:30:29Z","reference_number":"EMADOC-1700519818-2832272","document_url":"https://www.ema.europa.eu/en/documents/psusa/somatostatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002771-202506_en.pdf"},
    {"id":"72174","name":"Gadoteric acid (IV and intravascular formulations) : List of nationally authorised medicinal products - PSUSA/00001506/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T16:49:03Z","last_updated_date":"2026-01-20T16:49:03Z","reference_number":"EMADOC-1700519818-2834040","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteric-acid-iv-intravascular-formulations-list-nationally-authorised-medicinal-products-psusa-00001506-202504_en.pdf"},
    {"id":"72180","name":"Indobufen : List of nationally authorised medicinal products - PSUSA/00001736/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T13:08:54Z","last_updated_date":"2026-01-21T13:08:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/indobufen-list-nationally-authorised-medicinal-products-psusa-00001736-202505_en.pdf"},
    {"id":"72182","name":"Nicergoline : List of nationally authorised medicinal products - PSUSA/00002150/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T14:09:29Z","last_updated_date":"2026-01-21T14:09:29Z","reference_number":"EMADOC-1700519818-2834090","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicergoline-list-nationally-authorised-medicinal-products-psusa-00002150-202505_en.pdf"},
    {"id":"72184","name":"Levonorgestrel : List of nationally authorised medicinal products - PSUSA/00010827/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T14:20:59Z","last_updated_date":"2026-01-21T14:20:59Z","reference_number":"EMADOC-1700519818-2834160","document_url":"https://www.ema.europa.eu/en/documents/psusa/levonorgestrel-list-nationally-authorised-medicinal-products-psusa-00010827-202505_en.pdf"},
    {"id":"72186","name":"Methoxyflurane : List of nationally authorised medicinal products - PSUSA/00010484/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T14:46:03Z","last_updated_date":"2026-01-21T14:46:03Z","reference_number":"EMADOC-1700519818-2834218","document_url":"https://www.ema.europa.eu/en/documents/psusa/methoxyflurane-list-nationally-authorised-medicinal-products-psusa-00010484-202505_en.pdf"},
    {"id":"72189","name":"Benzoyl peroxide / clindamycin phosphate : List of nationally authorised medicinal products - PSUSA/00000796/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T14:52:15Z","last_updated_date":"2026-01-21T14:52:15Z","reference_number":"EMADOC-1700519818-2834195","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzoyl-peroxide-clindamycin-phosphate-list-nationally-authorised-medicinal-products-psusa-00000796-202505_en.pdf"},
    {"id":"72193","name":"Levofloxacin/dexamethasone (ocular use) : List of nationally authorised medicinal products - PSUSA/00010881/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T14:58:08Z","last_updated_date":"2026-01-21T14:58:08Z","reference_number":"EMADOC-1700519818-2834304","document_url":"https://www.ema.europa.eu/en/documents/psusa/levofloxacin-dexamethasone-ocular-use-list-nationally-authorised-medicinal-products-psusa-00010881-202506_en.pdf"},
    {"id":"72194","name":"Azelaic acid : List of nationally authorised medicinal products - PSUSA/00000276/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T15:04:01Z","last_updated_date":"2026-01-21T15:04:01Z","reference_number":"EMADOC-1700519818-2834306","document_url":"https://www.ema.europa.eu/en/documents/psusa/azelaic-acid-list-nationally-authorised-medicinal-products-psusa-00000276-202506_en.pdf"},
    {"id":"72195","name":"Solifenacin : List of nationally authorised medicinal products - PSUSA/00002769/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T15:07:42Z","last_updated_date":"2026-01-21T15:07:42Z","reference_number":"EMADOC-1700519818-2834394","document_url":"https://www.ema.europa.eu/en/documents/psusa/solifenacin-list-nationally-authorised-medicinal-products-psusa-00002769-202506_en.pdf"},
    {"id":"72231","name":"Gadoteric acid : List of nationally authorised medicinal products - PSUSA/00001505/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-23T15:57:44Z","last_updated_date":"2026-01-23T15:57:44Z","reference_number":"EMADOC-1700519818-2835294","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoteric-acid-list-nationally-authorised-medicinal-products-psusa-00001505-202504_en.pdf"},
    {"id":"72232","name":"Fotemustine : List of nationally authorised medicinal products - PSUSA/00001477/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-23T16:07:35Z","last_updated_date":"2026-01-23T16:07:35Z","reference_number":"EMADOC-1700519818-2835361","document_url":"https://www.ema.europa.eu/en/documents/psusa/fotemustine-list-nationally-authorised-medicinal-products-psusa-00001477-202506_en.pdf"},
    {"id":"72233","name":"Ticlopidine : List of nationally authorised medicinal products - PSUSA/00002952/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-23T16:30:56Z","last_updated_date":"2026-01-23T16:30:56Z","reference_number":"EMADOC-1700519818-2835600","document_url":"https://www.ema.europa.eu/en/documents/psusa/ticlopidine-list-nationally-authorised-medicinal-products-psusa-00002952-202505_en.pdf"},
    {"id":"72234","name":"Magnesium pidolate : List of nationally authorised medicinal products - PSUSA/00010041/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-23T16:40:34Z","last_updated_date":"2026-01-23T16:40:34Z","reference_number":"EMADOC-1700519818-2836274","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-pidolate-list-nationally-authorised-medicinal-products-psusa-00010041-202506_en.pdf"},
    {"id":"72238","name":"Sertaconazole : List of nationally authorised medicinal products - PSUSA/00002694/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-23T17:01:44Z","last_updated_date":"2026-01-23T17:01:44Z","reference_number":"EMADOC-1700519818-2836977","document_url":"https://www.ema.europa.eu/en/documents/psusa/sertaconazole-list-nationally-authorised-medicinal-products-psusa-00002694-202506_en.pdf"},
    {"id":"72250","name":"Piritramide : List of nationally authorised medicinal products - PSUSA/00002437/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-26T13:20:00Z","last_updated_date":"2026-01-26T13:20:00Z","reference_number":"EMADOC-1700519818-2837474","document_url":"https://www.ema.europa.eu/en/documents/psusa/piritramide-list-nationally-authorised-medicinal-products-psusa-00002437-202503_en.pdf"},
    {"id":"72251","name":"Piritramide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002437/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-26T13:22:16Z","last_updated_date":"2026-01-26T13:22:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/piritramide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002437-202503_sv.pdf"}},
    {"id":"72265","name":"Gadobutrol : List of nationally authorised medicinal products - PSUSA/00001502/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-26T17:48:04Z","last_updated_date":"2026-01-26T17:48:04Z","reference_number":"EMADOC-1700519818-2839073","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobutrol-list-nationally-authorised-medicinal-products-psusa-00001502-202504_en.pdf"},
    {"id":"72266","name":"Gadodiamide : List of nationally authorised medicinal products - PSUSA/00001503/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-26T17:52:16Z","last_updated_date":"2026-01-26T17:52:16Z","reference_number":"EMADOC-1700519818-2839132","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadodiamide-list-nationally-authorised-medicinal-products-psusa-00001503-202504_en.pdf"},
    {"id":"72270","name":"Gadopentetic acid : List of nationally authorised medicinal products - PSUSA/00001504/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T10:14:38Z","last_updated_date":"2026-01-27T10:14:38Z","reference_number":"EMADOC-1700519818-2840055","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadopentetic-acid-list-nationally-authorised-medicinal-products-psusa-00001504-202504_en.pdf"},
    {"id":"72272","name":"Gadoxetic acid disodium : List of nationally authorised medicinal products - PSUSA/00001509/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T10:22:49Z","last_updated_date":"2026-01-27T10:22:49Z","reference_number":"EMADOC-1700519818-2840430","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadoxetic-acid-disodium-list-nationally-authorised-medicinal-products-psusa-00001509-202504_en.pdf"},
    {"id":"72273","name":"Zotepine : List of nationally authorised medicinal products - PSUSA/00003154/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T10:27:59Z","last_updated_date":"2026-01-27T10:27:59Z","reference_number":"EMADOC-1700519818-2842460","document_url":"https://www.ema.europa.eu/en/documents/psusa/zotepine-list-nationally-authorised-medicinal-products-psusa-00003154-202505_en.pdf"},
    {"id":"72276","name":"Gadobenic acid : List of nationally authorised medicinal products - PSUSA/00001500/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T10:32:01Z","last_updated_date":"2026-01-27T10:32:01Z","reference_number":"EMADOC-1700519818-2838356","document_url":"https://www.ema.europa.eu/en/documents/psusa/gadobenic-acid-list-nationally-authorised-medicinal-products-psusa-00001500-202504_en.pdf"},
    {"id":"72284","name":"Nefopam : List of nationally authorised medicinal products - PSUSA/00002131/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T11:31:13Z","last_updated_date":"2026-01-27T11:31:13Z","reference_number":"EMADOC-1700519818-2845165","document_url":"https://www.ema.europa.eu/en/documents/psusa/nefopam-list-nationally-authorised-medicinal-products-psusa-00002131-202503_en.pdf"},
    {"id":"72285","name":"Nefopam : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00002131/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T11:33:21Z","last_updated_date":"2026-01-27T11:33:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/nefopam-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00002131-202503_no.pdf"}},
    {"id":"72286","name":"Levosulpiride, sulpiride : List of nationally authorised medicinal products - PSUSA/00001859/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T11:42:07Z","last_updated_date":"2026-01-27T11:42:07Z","reference_number":"EMADOC-1700519818-2845541","document_url":"https://www.ema.europa.eu/en/documents/psusa/levosulpiride-sulpiride-list-nationally-authorised-medicinal-products-psusa-00001859-202506_en.pdf"},
    {"id":"72287","name":"Metolazone : List of nationally authorised medicinal products - PSUSA/00002037/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T11:50:05Z","last_updated_date":"2026-01-27T11:50:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/metolazone-list-nationally-authorised-medicinal-products-psusa-00002037-202506_en.pdf"},
    {"id":"72288","name":"Hyoscine butylbromide / paracetamol : List of nationally authorised medicinal products - PSUSA/00002303/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T12:00:40Z","last_updated_date":"2026-01-27T12:00:40Z","reference_number":"EMADOC-1700519818-2850276","document_url":"https://www.ema.europa.eu/en/documents/psusa/hyoscine-butylbromide-paracetamol-list-nationally-authorised-medicinal-products-psusa-00002303-202505_en.pdf"},
    {"id":"72295","name":"Isotretinoin (oral formulations) : List of nationally authorised medicinal products - PSUSA/00010488/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T14:16:50Z","last_updated_date":"2026-01-27T14:16:50Z","reference_number":"EMADOC-1700519818-2824312","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-list-nationally-authorised-medicinal-products-psusa-00010488-202505_en.pdf"},
    {"id":"72296","name":"Isotretinoin (oral formulations) : Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) - PSUSA/00010488/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T14:21:34Z","last_updated_date":"2026-01-27T14:21:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/isotretinoin-oral-formulations-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00010488-202505_no.pdf"}},
    {"id":"72297","name":"Formoterol : List of nationally authorised medicinal products - PSUSA/00001469/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T15:18:53Z","last_updated_date":"2026-01-27T15:18:53Z","reference_number":"EMADOC-1700519818-2860495","document_url":"https://www.ema.europa.eu/en/documents/psusa/formoterol-list-nationally-authorised-medicinal-products-psusa-00001469-202505_en.pdf"},
    {"id":"72300","name":"Dienogest / ethinylestradiol (prolonged-release tablet) : List of nationally authorised medicinal products - PSUSA/00011084/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T16:14:10Z","last_updated_date":"2026-01-27T16:14:10Z","reference_number":"EMADOC-1700519818-2862062","document_url":"https://www.ema.europa.eu/en/documents/psusa/dienogest-ethinylestradiol-prolonged-release-tablet-list-nationally-authorised-medicinal-products-psusa-00011084-202503_en.pdf"},
    {"id":"72339","name":"Linezolid : List of nationally authorised medicinal products - PSUSA/00001888/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T10:24:32Z","last_updated_date":"2026-01-29T10:24:32Z","reference_number":"EMADOC-1700519818-2864496","document_url":"https://www.ema.europa.eu/en/documents/psusa/linezolid-list-nationally-authorised-medicinal-products-psusa-00001888-202504_en.pdf"},
    {"id":"72340","name":"Linezolid : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001888/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T10:26:50Z","last_updated_date":"2026-01-29T10:26:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/linezolid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001888-202504_no.pdf"}},
    {"id":"72341","name":"Torasemide : List of nationally authorised medicinal products - PSUSA/00002998/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T10:36:46Z","last_updated_date":"2026-01-29T10:36:46Z","reference_number":"EMADOC-1700519818-2865013","document_url":"https://www.ema.europa.eu/en/documents/psusa/torasemide-list-nationally-authorised-medicinal-products-psusa-00002998-202506_en.pdf"},
    {"id":"72344","name":"Cytarabine : List of nationally authorised medicinal products - PSUSA/00000911/202503 ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T12:36:04Z","last_updated_date":"2026-01-29T12:36:04Z","reference_number":"EMADOC-1700519818-2680252","document_url":"https://www.ema.europa.eu/en/documents/psusa/cytarabine-list-nationally-authorised-medicinal-products-psusa-00000911-202503_en.pdf"},
    {"id":"72345","name":"Cytarabine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000911/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T12:38:38Z","last_updated_date":"2026-01-29T12:38:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/cytarabine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000911-202503_no.pdf"}},
    {"id":"72349","name":"Isradipine : List of nationally authorised medicinal products - PSUSA/00001797/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-29T14:05:16Z","last_updated_date":"2026-01-29T14:05:16Z","reference_number":"EMADOC-1700519818-2866134","document_url":"https://www.ema.europa.eu/en/documents/psusa/isradipine-list-nationally-authorised-medicinal-products-psusa-00001797-202506_en.pdf"},
    {"id":"72397","name":"Cefaclor : List of nationally authorised medicinal products - PSUSA/00000583/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T17:13:53Z","last_updated_date":"2026-01-30T17:13:53Z","reference_number":"EMADOC-1700519818-2560536","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefaclor-list-nationally-authorised-medicinal-products-psusa-00000583-202503_en.pdf"},
    {"id":"72398","name":"Valsartan, hydrochlorothiazide / valsartan : List of nationally authorised medicinal products - PSUSA/00010396/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T17:16:53Z","last_updated_date":"2026-01-30T17:16:53Z","reference_number":"EMADOC-1700519818-2873421","document_url":"https://www.ema.europa.eu/en/documents/psusa/valsartan-hydrochlorothiazide-valsartan-list-nationally-authorised-medicinal-products-psusa-00010396-202504_en.pdf"},
    {"id":"72447","name":"Tranexamic acid : List of nationally authorised medicinal products - PSUSA/00003006/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-06T14:15:54Z","last_updated_date":"2026-02-06T14:15:54Z","reference_number":"EMADOC-1700519818-2852321","document_url":"https://www.ema.europa.eu/en/documents/psusa/tranexamic-acid-list-nationally-authorised-medicinal-products-psusa-00003006-202503_en.pdf"},
    {"id":"72449","name":"Tranexamic acid : Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) - PSUSA/00003006/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-06T14:25:10Z","last_updated_date":"2026-05-22T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tranexamic-acid-scientific-conclusions-grounds-variation-terms-marketing-authorisations-psusa-00003006-202503_no.pdf"}},
    {"id":"72511","name":"Chlorhexidine : List of nationally authorised medicinal products - PSUSA/00000662/202503","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-11T14:04:28Z","last_updated_date":"2026-02-11T14:04:28Z","reference_number":"EMADOC-1700519818-2901423","document_url":"https://www.ema.europa.eu/en/documents/psusa/chlorhexidine-list-nationally-authorised-medicinal-products-psusa-00000662-202503_en.pdf"},
    {"id":"72520","name":"Testosterone (topical use) : List of nationally authorised medicinal products - PSUSA/00002908/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T08:44:24Z","last_updated_date":"2026-02-12T08:44:24Z","reference_number":"EMADOC-1700519818-2124174","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-topical-use-list-nationally-authorised-medicinal-products-psusa-00002908-202412_en.pdf"},
    {"id":"72521","name":"Testosterone (topical use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002908/202412","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T08:46:26Z","last_updated_date":"2026-02-12T08:46:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/testosterone-topical-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002908-202412_no.pdf"}},
    {"id":"72533","name":"Misoprostol (gastrointestinal indication) : EPAR - List of nationally authorised medicinal products - PSUSA/00010291/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T13:19:58Z","last_updated_date":"2026-02-12T13:19:58Z","reference_number":"EMADOC-1700519818-2867091","document_url":"https://www.ema.europa.eu/en/documents/psusa/misoprostol-gastrointestinal-indication-epar-list-nationally-authorised-medicinal-products-psusa-00010291-202506_en.pdf"},
    {"id":"72534","name":"Ganciclovir : List of nationally authorised medicinal products - PSUSA/00001516/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T14:38:24Z","last_updated_date":"2026-02-12T14:38:24Z","reference_number":"EMADOC-1700519818-2912667","document_url":"https://www.ema.europa.eu/en/documents/psusa/ganciclovir-list-nationally-authorised-medicinal-products-psusa-00001516-202506_en.pdf"},
    {"id":"72537","name":"Rifabutin : List of nationally authorised medicinal products - PSUSA/00002639/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T15:23:30Z","last_updated_date":"2026-02-12T15:23:30Z","reference_number":"EMADOC-1700519818-2859748","document_url":"https://www.ema.europa.eu/en/documents/psusa/rifabutin-list-nationally-authorised-medicinal-products-psusa-00002639-202507_en.pdf"},
    {"id":"72539","name":"Clonazepam : List of nationally authorised medicinal products - PSUSA/00000812/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T16:15:13Z","last_updated_date":"2026-02-12T16:15:13Z","reference_number":"EMADOC-1700519818-2913239","document_url":"https://www.ema.europa.eu/en/documents/psusa/clonazepam-list-nationally-authorised-medicinal-products-psusa-00000812-202506_en.pdf"},
    {"id":"72540","name":"Mitoxantrone : List of nationally authorised medicinal products - PSUSA/00002076/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T16:20:11Z","last_updated_date":"2026-02-12T16:20:11Z","reference_number":"EMADOC-1700519818-2913321","document_url":"https://www.ema.europa.eu/en/documents/psusa/mitoxantrone-list-nationally-authorised-medicinal-products-psusa-00002076-202506_en.pdf"},
    {"id":"72562","name":"Alfacalcidol : List of nationally authorised medicinal products - PSUSA/00000080/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-16T08:59:45Z","last_updated_date":"2026-02-16T08:59:45Z","reference_number":"EMADOC-1700519818-2913530","document_url":"https://www.ema.europa.eu/en/documents/psusa/alfacalcidol-list-nationally-authorised-medicinal-products-psusa-00000080-202506_en.pdf"},
    {"id":"72563","name":"Metronidazole / miconazole, chlorquinaldol / metronidazole : List of nationally authorised medicinal products - PSUSA/00002042/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-16T10:04:17Z","last_updated_date":"2026-04-07T16:32:00Z","reference_number":"EMADOC-1700519818-3053862","document_url":"https://www.ema.europa.eu/en/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-list-nationally-authorised-medicinal-products-psusa-00002042-202507_en.pdf"},
    {"id":"72573","name":"Itopride : List of nationally authorised medicinal products - PSUSA/00010606/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-16T16:10:56Z","last_updated_date":"2026-02-16T16:10:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/itopride-list-nationally-authorised-medicinal-products-psusa-00010606-202506_en.pdf"},
    {"id":"72574","name":"Nitrous oxide, nitrous oxide / oxygen : List of nationally authorised medicinal products - PSUSA/00010572/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-16T16:15:46Z","last_updated_date":"2026-02-16T16:15:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nitrous-oxide-nitrous-oxide-oxygen-list-nationally-authorised-medicinal-products-psusa-00010572-202506_en.pdf"},
    {"id":"72584","name":"Amlodipine/irbesartan : List of nationally authorised medicinal products - PSUSA/00010876/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-17T15:49:02Z","last_updated_date":"2026-02-17T15:49:02Z","reference_number":"EMADOC-1700519818-2916886","document_url":"https://www.ema.europa.eu/en/documents/psusa/amlodipine-irbesartan-list-nationally-authorised-medicinal-products-psusa-00010876-202506_en.pdf"},
    {"id":"72596","name":"Magnesium sulfate : List of nationally authorised medicinal products - PSUSA/00009225/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-19T09:41:36Z","last_updated_date":"2026-02-19T09:41:36Z","reference_number":"EMADOC-1700519818-2919760","document_url":"https://www.ema.europa.eu/en/documents/psusa/magnesium-sulfate-list-nationally-authorised-medicinal-products-psusa-00009225-202506_en.pdf"},
    {"id":"72621","name":"Ethinylestradiol / etonogestrel : List of nationally authorised medicinal products - PSUSA/00001307/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-20T11:52:23Z","last_updated_date":"2026-02-20T11:52:23Z","reference_number":"EMADOC-1700519818-2928437","document_url":"https://www.ema.europa.eu/en/documents/psusa/ethinylestradiol-etonogestrel-list-nationally-authorised-medicinal-products-psusa-00001307-202507_en.pdf"},
    {"id":"72745","name":"Simvastatin : List of nationally authorised medicinal products - PSUSA/00002709/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-27T12:29:55Z","last_updated_date":"2026-02-27T12:29:55Z","reference_number":"EMADOC-1700519818-2954775","document_url":"https://www.ema.europa.eu/en/documents/psusa/simvastatin-list-nationally-authorised-medicinal-products-psusa-00002709-202504_en.pdf"},
    {"id":"72746","name":"Simvastatin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation : PSUSA/00002709/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-02-27T12:31:23Z","last_updated_date":"2026-02-27T12:31:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/simvastatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002709-202504_no.pdf"}},
    {"id":"72864","name":"Levomethadone : List of nationally authorised medicinal products - PSUSA/00001855/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-05T15:39:39Z","last_updated_date":"2026-03-05T15:39:39Z","reference_number":"EMADOC-1700519818-2971691","document_url":"https://www.ema.europa.eu/en/documents/psusa/levomethadone-list-nationally-authorised-medicinal-products-psusa-00001855-202505_en.pdf"},
    {"id":"72865","name":"Levomethadone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001855/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-05T15:41:04Z","last_updated_date":"2026-03-05T15:41:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/levomethadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001855-202505_no.pdf"}},
    {"id":"72868","name":"Tamoxifen : List of nationally authorised medicinal products - PSUSA/00002846/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-06T08:26:15Z","last_updated_date":"2026-03-06T08:26:15Z","reference_number":"EMADOC-1700519818-2841338","document_url":"https://www.ema.europa.eu/en/documents/psusa/tamoxifen-list-nationally-authorised-medicinal-products-psusa-00002846-202504_en.pdf"},
    {"id":"72869","name":"Tamoxifen : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002846/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-06T08:27:52Z","last_updated_date":"2026-03-06T08:27:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/tamoxifen-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002846-202504_no.pdf"}},
    {"id":"72875","name":"Cefixime : List of nationally authorised medicinal products - PSUSA/00000594/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-06T13:44:42Z","last_updated_date":"2026-03-06T13:44:42Z","reference_number":"EMADOC-1700519818-2975609","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefixime-list-nationally-authorised-medicinal-products-psusa-00000594-202506_en.pdf"},
    {"id":"72876","name":"Cefixime : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000594/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-06T13:46:00Z","last_updated_date":"2026-03-10T09:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/cefixime-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000594-202506_sv.pdf"}},
    {"id":"72886","name":"Caffeine / codeine / paracetamol / propyphenazone, acetylsalicylic acid / caffeine / codeine / paracetamol : List of nationally authorised medicinal products - PSUSA/00002312/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-10T10:12:08Z","last_updated_date":"2026-04-07T11:23:00Z","reference_number":"EMADOC-1700519818-2965430","document_url":"https://www.ema.europa.eu/en/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-caffeine-codeine-paracetamol-list-nationally-authorised-medicinal-products-psusa-00002312-202506_en.pdf"},
    {"id":"72887","name":"Caffeine / codeine / paracetamol / propyphenazone, acetylsalicylic acid... : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002312/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-10T10:14:10Z","last_updated_date":"2026-03-10T10:14:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/caffeine-codeine-paracetamol-propyphenazone-acetylsalicylic-acid-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002312-202506_sv.pdf"}},
    {"id":"72920","name":"Pneumococcal polysaccharide vaccine : List of nationally authorised medicinal products - PSUSA/00002453/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-10T11:11:39Z","last_updated_date":"2026-03-10T11:11:39Z","reference_number":"EMADOC-1700519818-2982755","document_url":"https://www.ema.europa.eu/en/documents/psusa/pneumococcal-polysaccharide-vaccine-list-nationally-authorised-medicinal-products-psusa-00002453-202505_en.pdf"},
    {"id":"72921","name":"Pneumococcal polysaccharide vaccine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002453/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-10T11:13:08Z","last_updated_date":"2026-03-10T11:13:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/pneumococcal-polysaccharide-vaccine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002453-202505_no.pdf"}},
    {"id":"72923","name":"Diphtheria / tetanus / pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed)....(adsorbed, reduced antigen(s) content) - List of nationally authorised medicinal products - PSUSA/00001126/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-10T12:00:02Z","last_updated_date":"2026-03-10T12:00:02Z","reference_number":"EMADOC-1700519818-2982954","document_url":"https://www.ema.europa.eu/en/documents/psusa/diphtheria-tetanus-pertussis-acellular-component-poliomyelitis-inactivated-vaccine-adsorbedadsorbed-reduced-antigens-content-list-nationally-authorised-medicinal-products-psusa-00001126-202507_en.pdf"},
    {"id":"72924","name":"Benzylpenicillin, benzathine benzylpenicillin, benzathine benzylpenicillin / lidocaine, procaine benzylpenicillin, benzathine benzylpenicillin / procaine benzylpenicillin - List of nationally authorised medicinal products - PSUSA/00000383/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-10T12:06:45Z","last_updated_date":"2026-03-10T12:06:45Z","reference_number":"EMADOC-1700519818-2983056","document_url":"https://www.ema.europa.eu/en/documents/psusa/benzylpenicillin-benzathine-benzylpenicillin-benzathine-benzylpenicillin-lidocaine-procaine-benzylpenicillin-benzathine-benzylpenicillin-procaine-benzylpenicillin-list-nationally-authorised-medicinal_en.pdf"},
    {"id":"72932","name":"Sulprostone : List of nationally authorised medicinal products - PSUSA/00002828/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-10T15:43:43Z","last_updated_date":"2026-03-10T15:43:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/sulprostone-list-nationally-authorised-medicinal-products-psusa-00002828-202504_en.pdf"},
    {"id":"72941","name":"Methadone : List of nationally authorised medicinal products - PSUSA/00002004/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-11T13:21:50Z","last_updated_date":"2026-03-11T13:21:50Z","reference_number":"EMADOC-1700519818-2988210","document_url":"https://www.ema.europa.eu/en/documents/psusa/methadone-list-nationally-authorised-medicinal-products-psusa-00002004-202505_en.pdf"},
    {"id":"72942","name":"Methadone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002004/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-11T13:23:18Z","last_updated_date":"2026-03-11T13:23:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/methadone-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002004-202505_no.pdf"}},
    {"id":"73001","name":"Ademetionine : List of nationally authorised medicinal products - PSUSA/00000061/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-13T10:47:30Z","last_updated_date":"2026-03-13T10:47:30Z","reference_number":"EMADOC-1700519818-2944422","document_url":"https://www.ema.europa.eu/en/documents/psusa/ademetionine-list-nationally-authorised-medicinal-products-psusa-00000061-202508_en.pdf"},
    {"id":"73003","name":"Dimetindene / phenylephrine : List of nationally authorised medicinal products - PSUSA/00001102/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-13T11:25:15Z","last_updated_date":"2026-03-13T11:25:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/dimetindene-phenylephrine-list-nationally-authorised-medicinal-products-psusa-00001102-202507_en.pdf"},
    {"id":"73044","name":"Poliovirus : List of nationally authorised medicinal products - PSUSA/00010801/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-16T14:02:25Z","last_updated_date":"2026-03-16T14:02:25Z","reference_number":"EMADOC-1700519818-2992191","document_url":"https://www.ema.europa.eu/en/documents/psusa/poliovirus-list-nationally-authorised-medicinal-products-psusa-00010801-202507_en.pdf"},
    {"id":"73049","name":"Lamivudine : List of nationally authorised medicinal products - PSUSA/00001824/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T09:57:18Z","last_updated_date":"2026-03-17T09:57:18Z","reference_number":"EMADOC-1700519818-2992835","document_url":"https://www.ema.europa.eu/en/documents/psusa/lamivudine-list-nationally-authorised-medicinal-products-psusa-00001824-202507_en.pdf"},
    {"id":"73050","name":"Amoxicillin / clarithromycin / pantoprazole : List of nationally authorised medicinal products - PSUSA/00002286/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T10:33:38Z","last_updated_date":"2026-03-17T10:33:38Z","reference_number":"EMADOC-1700519818-2992473","document_url":"https://www.ema.europa.eu/en/documents/psusa/amoxicillin-clarithromycin-pantoprazole-list-nationally-authorised-medicinal-products-psusa-00002286-202508_en.pdf"},
    {"id":"73051","name":"Cetylpyridinium / lysozyme, lysozyme / pyridoxine : List of nationally authorised medicinal products - PSUSA/00000640/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T10:47:25Z","last_updated_date":"2026-03-17T10:47:25Z","reference_number":"EMADOC-1700519818-2992557","document_url":"https://www.ema.europa.eu/en/documents/psusa/cetylpyridinium-lysozyme-lysozyme-pyridoxine-list-nationally-authorised-medicinal-products-psusa-00000640-202508_en.pdf"},
    {"id":"73053","name":"Octenidine : List of nationally authorised medicinal products - PSUSA/00010748/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T11:03:27Z","last_updated_date":"2026-03-17T11:03:27Z","reference_number":"EMADOC-1700519818-2992605","document_url":"https://www.ema.europa.eu/en/documents/psusa/octenidine-list-nationally-authorised-medicinal-products-psusa-00010748-202507_en.pdf"},
    {"id":"73054","name":"Anastrozole : List of nationally authorised medicinal products - PSUSA/00000210/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T11:25:55Z","last_updated_date":"2026-03-17T11:25:55Z","reference_number":"EMADOC-1700519818-2993587","document_url":"https://www.ema.europa.eu/en/documents/psusa/anastrozole-list-nationally-authorised-medicinal-products-psusa-00000210-202508_en.pdf"},
    {"id":"73055","name":"Iodine (123i) iobenguane : List of nationally authorised medicinal products - PSUSA/00001763/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T11:48:10Z","last_updated_date":"2026-03-17T11:48:10Z","reference_number":"EMADOC-1700519818-2993594","document_url":"https://www.ema.europa.eu/en/documents/psusa/iodine-123i-iobenguane-list-nationally-authorised-medicinal-products-psusa-00001763-202508_en.pdf"},
    {"id":"73056","name":"Ioversol : List of nationally authorised medicinal products - PSUSA/00001775/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T11:54:08Z","last_updated_date":"2026-03-17T11:54:08Z","reference_number":"EMADOC-1700519818-2976578","document_url":"https://www.ema.europa.eu/en/documents/psusa/ioversol-list-nationally-authorised-medicinal-products-psusa-00001775-202506_en.pdf"},
    {"id":"73057","name":"Ioversol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001775/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T11:56:30Z","last_updated_date":"2026-03-17T11:56:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ioversol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001775-202506_no.pdf"}},
    {"id":"73067","name":"Glyceryl trinitrate : List of nationally authorised medicinal products - PSUSA/00001552/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T14:25:58Z","last_updated_date":"2026-03-17T14:25:58Z","reference_number":"EMADOC-1700519818-2994512","document_url":"https://www.ema.europa.eu/en/documents/psusa/glyceryl-trinitrate-list-nationally-authorised-medicinal-products-psusa-00001552-202507_en.pdf"},
    {"id":"73068","name":"Beclometasone / formoterol : List of nationally authorised medicinal products - PSUSA/00010068/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T14:33:17Z","last_updated_date":"2026-03-17T14:33:17Z","reference_number":"EMADOC-1700519818-2937113","document_url":"https://www.ema.europa.eu/en/documents/psusa/beclometasone-formoterol-list-nationally-authorised-medicinal-products-psusa-00010068-202507_en.pdf"}    {"id":"73072","name":"Cisatracurium : List of nationally authorised medicinal products - PSUSA/00000777/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T15:56:30Z","last_updated_date":"2026-03-17T15:56:30Z","reference_number":"EMADOC-1700519818-2995289","document_url":"https://www.ema.europa.eu/en/documents/psusa/cisatracurium-list-nationally-authorised-medicinal-products-psusa-00000777-202507_en.pdf"},
    {"id":"73075","name":"Pitavastatin : List of nationally authorised medicinal products - PSUSA/00010502/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T16:07:36Z","last_updated_date":"2026-03-17T16:07:36Z","reference_number":"EMADOC-1700519818-2995674","document_url":"https://www.ema.europa.eu/en/documents/psusa/pitavastatin-list-nationally-authorised-medicinal-products-psusa-00010502-202507_en.pdf"},
    {"id":"73105","name":"Ziprasidone : List of nationally authorised medicinal products - PSUSA/00003146/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-18T15:11:33Z","last_updated_date":"2026-03-18T15:11:33Z","reference_number":"EMADOC-1700519818-2996054","document_url":"https://www.ema.europa.eu/en/documents/psusa/ziprasidone-list-nationally-authorised-medicinal-products-psusa-00003146-202507_en.pdf"},
    {"id":"73106","name":"Fosphenytoin : List of nationally authorised medicinal products - PSUSA/00001476/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-18T15:19:20Z","last_updated_date":"2026-03-18T15:19:20Z","reference_number":"EMADOC-1700519818-2996574","document_url":"https://www.ema.europa.eu/en/documents/psusa/fosphenytoin-list-nationally-authorised-medicinal-products-psusa-00001476-202508_en.pdf"},
    {"id":"73110","name":"Nicardipine : List of nationally authorised medicinal products - PSUSA/00002149/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-18T17:15:12Z","last_updated_date":"2026-03-18T17:15:12Z","reference_number":"EMADOC-1700519818-2999299","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicardipine-list-nationally-authorised-medicinal-products-psusa-00002149-202505_en.pdf"},
    {"id":"73111","name":"Nicardipine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002149/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-18T17:18:05Z","last_updated_date":"2026-03-18T17:18:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/nicardipine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002149-202505_sv.pdf"}},
    {"id":"73112","name":"Hydrocortisone / natamycin / neomycine sulphate : List of nationally authorised medicinal products - PSUSA/00001672/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-18T17:21:44Z","last_updated_date":"2026-03-18T17:21:44Z","reference_number":"EMADOC-1700519818-2999166","document_url":"https://www.ema.europa.eu/en/documents/psusa/hydrocortisone-natamycin-neomycine-sulphate-list-nationally-authorised-medicinal-products-psusa-00001672-202508_en.pdf"},
    {"id":"73113","name":"Diclofenac / misoprostol : List of nationally authorised medicinal products - PSUSA/00001040/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-19T09:35:14Z","last_updated_date":"2026-03-19T09:35:14Z","reference_number":"EMADOC-1700519818-2996711","document_url":"https://www.ema.europa.eu/en/documents/psusa/diclofenac-misoprostol-list-nationally-authorised-medicinal-products-psusa-00001040-202507_en.pdf"},
    {"id":"73114","name":"Etodolac : List of nationally authorised medicinal products - PSUSA/00001324/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-19T09:59:26Z","last_updated_date":"2026-03-19T09:59:26Z","reference_number":"EMADOC-1700519818-2996792","document_url":"https://www.ema.europa.eu/en/documents/psusa/etodolac-list-nationally-authorised-medicinal-products-psusa-00001324-202505_en.pdf"},
    {"id":"73115","name":"Etodolac : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001324/202505","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-19T10:03:14Z","last_updated_date":"2026-03-19T10:03:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/etodolac-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001324-202505_sv.pdf"}},
    {"id":"73138","name":"Bethanechol : List of nationally authorised medicinal products - PSUSA/00000402/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-20T16:10:53Z","last_updated_date":"2026-03-20T16:10:53Z","reference_number":"EMADOC-1700519818-3004865","document_url":"https://www.ema.europa.eu/en/documents/psusa/bethanechol-list-nationally-authorised-medicinal-products-psusa-00000402-202506_en.pdf"},
    {"id":"73151","name":"Human plasma protease C1 inhibitor (nationally authorised products) : List of nationally authorised medicinal products - PSUSA/00010163/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T08:33:15Z","last_updated_date":"2026-03-24T08:33:15Z","reference_number":"EMADOC-1700519818-3016289","document_url":"https://www.ema.europa.eu/en/documents/psusa/human-plasma-protease-c1-inhibitor-nationally-authorised-products-list-nationally-authorised-medicinal-products-psusa-00010163-202508_en.pdf"},
    {"id":"73152","name":"Copper chloride dihydrate / manganese chloride tetrahydrate / potassium iodide / sodium fluoride / sodium selenite anhydrous / zinc chloride : List of nationally authorised medicinal products - PSUSA/00010803/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T08:40:35Z","last_updated_date":"2026-03-24T08:40:35Z","reference_number":"EMADOC-1700519818-3016423","document_url":"https://www.ema.europa.eu/en/documents/psusa/copper-chloride-dihydrate-manganese-chloride-tetrahydrate-potassium-iodide-sodium-fluoride-sodium-selenite-anhydrous-zinc-chloride-list-nationally-authorised-medicinal-products-psusa-00010803-202508_en.pdf"},
    {"id":"73153","name":"Flutrimazole : List of nationally authorised medicinal products - PSUSA/00001456/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T08:46:13Z","last_updated_date":"2026-03-24T08:46:13Z","reference_number":"EMADOC-1700519818-3020031","document_url":"https://www.ema.europa.eu/en/documents/psusa/flutrimazole-list-nationally-authorised-medicinal-products-psusa-00001456-202508_en.pdf"},
    {"id":"73188","name":"Captopril : List of nationally authorised medicinal products - PSUSA/00000535/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T09:53:22Z","last_updated_date":"2026-03-25T09:53:22Z","reference_number":"EMADOC-1700519818-3021398","document_url":"https://www.ema.europa.eu/en/documents/psusa/captopril-list-nationally-authorised-medicinal-products-psusa-00000535-202504_en.pdf"},
    {"id":"73189","name":"Captopril : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000535/202504","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T09:54:43Z","last_updated_date":"2026-03-25T09:54:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_sv.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/captopril-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000535-202504_no.pdf"}},
    {"id":"73339","name":"Ropinirole : List of nationally authorised medicinal products - PSUSA/00002661/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T16:25:02Z","last_updated_date":"2026-04-07T16:25:02Z","reference_number":"EMADOC-1700519818-3052528","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropinirole-list-nationally-authorised-medicinal-products-psusa-00002661-202507_en.pdf"},
    {"id":"73340","name":"Ropinirole : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002661/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T16:26:28Z","last_updated_date":"2026-04-07T16:26:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/ropinirole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002661-202507_no.pdf"}},
    {"id":"73341","name":"Metronidazole / miconazole, chlorquinaldol / metronidazole : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002042/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T16:33:45Z","last_updated_date":"2026-04-07T16:33:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/metronidazole-miconazole-chlorquinaldol-metronidazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002042-202507_sv.pdf"}},
    {"id":"73415","name":"Hexoprenaline sulfate : List of nationally authorised medicinal products - PSUSA/00003170/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-10T12:33:48Z","last_updated_date":"2026-04-10T12:33:48Z","reference_number":"EMADOC-1700519818-3062709","document_url":"https://www.ema.europa.eu/en/documents/psusa/hexoprenaline-sulfate-list-nationally-authorised-medicinal-products-psusa-00003170-202508_en.pdf"},
    {"id":"73424","name":"Raltitrexed : List of nationally authorised medicinal products - PSUSA/00002605/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-13T11:30:32Z","last_updated_date":"2026-04-13T11:30:32Z","reference_number":"EMADOC-1700519818-3064709","document_url":"https://www.ema.europa.eu/en/documents/psusa/raltitrexed-list-nationally-authorised-medicinal-products-psusa-00002605-202509_en.pdf"},
    {"id":"73426","name":"Fluocinolone acetonide (intravitreal implant in applicator) : List of nationally authorised medicinal products - PSUSA/00010224/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-13T15:27:12Z","last_updated_date":"2026-04-13T15:27:12Z","reference_number":"EMADOC-1700519818-3073226","document_url":"https://www.ema.europa.eu/en/documents/psusa/fluocinolone-acetonide-intravitreal-implant-applicator-list-nationally-authorised-medicinal-products-psusa-00010224-202508_en.pdf"},
    {"id":"73427","name":"Meclozine : List of nationally authorised medicinal products - PSUSA/00001945/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-13T15:31:43Z","last_updated_date":"2026-04-13T15:31:43Z","reference_number":"EMADOC-1700519818-3074433","document_url":"https://www.ema.europa.eu/en/documents/psusa/meclozine-list-nationally-authorised-medicinal-products-psusa-00001945-202508_en.pdf"},
    {"id":"73428","name":"Nifedipine : List of nationally authorised medicinal products - PSUSA/00002156/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-13T15:34:47Z","last_updated_date":"2026-04-13T15:34:47Z","reference_number":"EMADOC-1700519818-3074286","document_url":"https://www.ema.europa.eu/en/documents/psusa/nifedipine-list-nationally-authorised-medicinal-products-psusa-00002156-202508_en.pdf"},
    {"id":"73433","name":"Clonidine : List of nationally authorised medicinal products - PSUSA/00000813/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-14T09:52:30Z","last_updated_date":"2026-04-14T09:52:30Z","reference_number":"EMADOC-1700519818-3074715","document_url":"https://www.ema.europa.eu/en/documents/psusa/clonidine-list-nationally-authorised-medicinal-products-psusa-00000813-202508_en.pdf"},
    {"id":"73434","name":"Biperiden : List of nationally authorised medicinal products - PSUSA/00000415/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-14T09:56:56Z","last_updated_date":"2026-04-14T09:56:56Z","reference_number":"EMADOC-1700519818-3075014","document_url":"https://www.ema.europa.eu/en/documents/psusa/biperiden-list-nationally-authorised-medicinal-products-psusa-00000415-202508_en.pdf"},
    {"id":"73439","name":"Losartan : List of nationally authorised medicinal products - PSUSA/00001912/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-14T16:34:29Z","last_updated_date":"2026-04-14T16:34:29Z","reference_number":"EMADOC-1700519818-3078564","document_url":"https://www.ema.europa.eu/en/documents/psusa/losartan-list-nationally-authorised-medicinal-products-psusa-00001912-202509_en.pdf"},
    {"id":"73447","name":"Albendazole : List of nationally authorised medicinal products - PSUSA/00000073/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-15T12:27:25Z","last_updated_date":"2026-04-15T12:27:25Z","reference_number":"EMADOC-1700519818-3028141","document_url":"https://www.ema.europa.eu/en/documents/psusa/albendazole-list-nationally-authorised-medicinal-products-psusa-00000073-202507_en.pdf"},
    {"id":"73448","name":"Albendazole : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000073/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-15T12:34:18Z","last_updated_date":"2026-04-15T12:34:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/albendazole-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000073-202507_no.pdf"}},
    {"id":"73467","name":"Finasteride : List of nationally authorised medicinal products - PSUSA/00001392/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-15T16:17:48Z","last_updated_date":"2026-04-15T16:17:48Z","reference_number":"EMADOC-1700519818-3081836","document_url":"https://www.ema.europa.eu/en/documents/psusa/finasteride-list-nationally-authorised-medicinal-products-psusa-00001392-202508_en.pdf"},
    {"id":"73469","name":"Povidone, polyvinyl alcohol / povidone : List of nationally authorised medicinal products - PSUSA/00002475/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-04-16T08:18:32Z","last_updated_date":"2026-04-16T08:18:32Z","reference_number":"EMADOC-1700519818-3082641","document_url":"https://www.ema.europa.eu/en/documents/psusa/povidone-polyvinyl-alcohol-povidone-list-nationally-authorised-medicinal-products-psusa-00002475-202509_en.pdf"},
    {"id":"73648","name":"Pethidine : List of nationally authorised medicinal products - PSUSA/00002357/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T08:48:46Z","last_updated_date":"2026-05-08T08:48:46Z","reference_number":"EMADOC-1700519818-3144252","document_url":"https://www.ema.europa.eu/en/documents/psusa/pethidine-list-nationally-authorised-medicinal-products-psusa-00002357-202508_en.pdf"},
    {"id":"73669","name":"Buclizine / codeine / paracetamol, caffeine / codeine / paracetamol : List of nationally authorised medicinal products - PSUSA/00000448/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T14:35:22Z","last_updated_date":"2026-05-08T14:35:22Z","reference_number":"EMADOC-1700519818-3141070","document_url":"https://www.ema.europa.eu/en/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-list-nationally-authorised-medicinal-products-psusa-00000448-202508_en.pdf"},
    {"id":"73670","name":"Buclizine / codeine / paracetamol, caffeine / codeine / paracetamol : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000448/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T14:36:58Z","last_updated_date":"2026-05-08T14:36:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/buclizine-codeine-paracetamol-caffeine-codeine-paracetamol-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000448-202508_sv.pdf"}},
    {"id":"73672","name":"Piretanide / ramipril, piretanide : List of nationally authorised medicinal products - PSUSA/00002434/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T15:25:09Z","last_updated_date":"2026-05-08T15:25:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/piretanide-ramipril-piretanide-list-nationally-authorised-medicinal-products-psusa-00002434-202508_en.pdf"},
    {"id":"73673","name":"Piretanide / ramipril, piretanide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002434/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T15:27:39Z","last_updated_date":"2026-05-08T15:27:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/piretanide-ramipril-piretanide-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002434-202508_no.pdf"}},
    {"id":"73680","name":"Epinephrine (except for nasal use) : List of nationally authorised medicinal products - PSUSA/00001232/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T16:09:40Z","last_updated_date":"2026-05-08T16:09:40Z","reference_number":"EMADOC-1700519818-3145445","document_url":"https://www.ema.europa.eu/en/documents/psusa/epinephrine-except-nasal-use-list-nationally-authorised-medicinal-products-psusa-00001232-202507_en.pdf"},
    {"id":"73681","name":"Epinephrine (except for nasal use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00001232/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T16:11:08Z","last_updated_date":"2026-05-08T16:11:08Z","reference_number":"EMADOC-1700519818-3145445","document_url":"https://www.ema.europa.eu/en/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_sv.pdf","is":"https://www.ema.europa.eu/is/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_is.pdf","no":"https://www.ema.europa.eu/no/documents/psusa/epinephrine-except-nasal-use-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00001232-202507_no.pdf"}},
    {"id":"73709","name":"Allergen for therapy: dermatophagoides pteronyssinus / dermatophagoides farina (oromucosal use, products authorised via mutually recognition procedure and decentralised procedure) : List of nationally authorised medicinal products - PSUSA/00010582/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-11T16:09:11Z","last_updated_date":"2026-05-11T16:09:11Z","reference_number":"EMADOC-1700519818-2802158","document_url":"https://www.ema.europa.eu/en/documents/psusa/allergen-therapy-dermatophagoides-pteronyssinus-dermatophagoides-farina-oromucosal-use-products-authorised-mutually-recognition-procedure-decentralised-procedure-list-nationally-authorised-medicinal_en.pdf"},
    {"id":"73710","name":"Terizidone : List of nationally authorised medicinal products - PSUSA/00002904/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-11T16:13:25Z","last_updated_date":"2026-05-11T16:13:25Z","reference_number":"EMADOC-1700519818-3144396","document_url":"https://www.ema.europa.eu/en/documents/psusa/terizidone-list-nationally-authorised-medicinal-products-psusa-00002904-202509_en.pdf"},
    {"id":"73711","name":"Silver sulfadiazine : List of nationally authorised medicinal products - PSUSA/00002702/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-11T16:18:55Z","last_updated_date":"2026-05-11T16:18:55Z","reference_number":"EMADOC-1700519818-3144482","document_url":"https://www.ema.europa.eu/en/documents/psusa/silver-sulfadiazine-list-nationally-authorised-medicinal-products-psusa-00002702-202509_en.pdf"},
    {"id":"73712","name":"Choline salicylate/cetalkonium chloride : List of nationally authorised medicinal products - PSUSA/00000626/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-11T16:43:08Z","last_updated_date":"2026-05-11T16:43:08Z","reference_number":"EMADOC-1700519818-3149105","document_url":"https://www.ema.europa.eu/en/documents/psusa/choline-salicylate-cetalkonium-chloride-list-nationally-authorised-medicinal-products-psusa-00000626-202508_en.pdf"},
    {"id":"73713","name":"Choline salicylate/cetalkonium chloride : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000626/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-11T16:50:54Z","last_updated_date":"2026-05-11T16:50:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/choline-salicylate-cetalkonium-chloride-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000626-202508_sv.pdf"}},
    {"id":"73718","name":"Progesterone : List of nationally authorised medicinal products - PSUSA/00002540/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-12T12:30:00Z","last_updated_date":"2026-05-12T12:30:00Z","reference_number":"EMADOC-1700519818-3153474","document_url":"https://www.ema.europa.eu/en/documents/psusa/progesterone-list-nationally-authorised-medicinal-products-psusa-00002540-202509_en.pdf"},
    {"id":"73866","name":"Lactitol : List of nationally authorised medicinal products - PSUSA/00001819/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-27T16:16:24Z","last_updated_date":"2026-05-27T16:16:24Z","reference_number":"EMADOC-1700519818-3192024","document_url":"https://www.ema.europa.eu/en/documents/psusa/lactitol-list-nationally-authorised-medicinal-products-psusa-00001819-202509_en.pdf"},
    {"id":"73876","name":"Poractant alfa : List of nationally authorised medicinal products - PSUSA/00002478/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-28T13:10:17Z","last_updated_date":"2026-05-28T13:10:17Z","reference_number":"EMADOC-1700519818-3184366","document_url":"https://www.ema.europa.eu/en/documents/psusa/poractant-alfa-list-nationally-authorised-medicinal-products-psusa-00002478-202508_en.pdf"},
    {"id":"73939","name":"Escherichia coli lysate : List of nationally authorised medicinal products - PSUSA/00001263/202507","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-02T16:28:46Z","last_updated_date":"2026-06-02T16:28:46Z","reference_number":"EMADOC-1700519818-2912800","document_url":"https://www.ema.europa.eu/en/documents/psusa/escherichia-coli-lysate-list-nationally-authorised-medicinal-products-psusa-00001263-202507_en.pdf"},
    {"id":"73949","name":"Metronidazole / neomycin / nystatin : List of nationally authorised medicinal products - PSUSA/00010508/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T10:56:28Z","last_updated_date":"2026-06-03T10:56:28Z","reference_number":"EMADOC-1700519818-3215414","document_url":"https://www.ema.europa.eu/en/documents/psusa/metronidazole-neomycin-nystatin-list-nationally-authorised-medicinal-products-psusa-00010508-202509_en.pdf"},
    {"id":"73950","name":"Metronidazole / neomycin / nystatin : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010508/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T10:58:46Z","last_updated_date":"2026-06-12T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_et.pdf","el":"https://www.ema.europa.eu/el/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/metronidazole-neomycin-nystatin-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00010508-202509_sv.pdf"}},
    {"id":"73986","name":"Pethidine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002357/202508","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T15:51:05Z","last_updated_date":"2026-05-08T15:51:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_bg.pdf","es":"https://www.ema.europa.eu/es/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_cs.pdf","da":"https://www.ema.europa.eu/da/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_da.pdf","de":"https://www.ema.europa.eu/de/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_de.pdf","et":"https://www.ema.europa.eu/et/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_et.pdf","fr":"https://www.ema.europa.eu/fr/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_hr.pdf","it":"https://www.ema.europa.eu/it/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_it.pdf","lt":"https://www.ema.europa.eu/lt/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/psusa/pethidine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00002357-202508_sv.pdf"}},
    {"id":"73988","name":"Calcifediol : List of nationally authorised medicinal products - PSUSA/00000491/202506","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-05T08:55:05Z","last_updated_date":"2026-06-05T08:55:05Z","reference_number":"EMADOC-1700519818-3223251","document_url":"https://www.ema.europa.eu/en/documents/psusa/calcifediol-list-nationally-authorised-medicinal-products-psusa-00000491-202506_en.pdf"},
    {"id":"74055","name":"Drospirenone / ethinylestradiol : List of nationally authorised medicinal products - PSUSA/00010217/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-11T08:23:46Z","last_updated_date":"2026-06-11T08:23:46Z","reference_number":"EMADOC-1700519818-3144147","document_url":"https://www.ema.europa.eu/en/documents/psusa/drospirenone-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa-00010217-202509_en.pdf"},
    {"id":"74071","name":"Cyanocobalamin / folic acid, cyanocobalamin / folic acid / potassium iodide - List of nationally authorised medicinal products - PSUSA/00000892/202511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-12T10:31:16Z","last_updated_date":"2026-06-12T10:31:16Z","reference_number":"EMADOC-1700519818-3241272","document_url":"https://www.ema.europa.eu/en/documents/psusa/cyanocobalamin-folic-acid-cyanocobalamin-folic-acid-potassium-iodide-list-nationally-authorised-medicinal-products-psusa-00000892-202511_en.pdf"},
    {"id":"74105","name":"Minoxidil (non topical formulations) : List of nationally authorised medicinal products - PSUSA/00002066/202510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T08:46:35Z","last_updated_date":"2026-06-16T08:46:35Z","reference_number":"EMADOC-1700519818-3241569","document_url":"https://www.ema.europa.eu/en/documents/psusa/minoxidil-non-topical-formulations-list-nationally-authorised-medicinal-products-psusa-00002066-202510_en.pdf"},
    {"id":"74106","name":"Salmeterol : List of nationally authorised medicinal products - PSUSA/00002681/202510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T08:49:43Z","last_updated_date":"2026-06-16T08:49:43Z","reference_number":"EMA/PSUR/0000327888","document_url":"https://www.ema.europa.eu/en/documents/psusa/salmeterol-list-nationally-authorised-medicinal-products-psusa-00002681-202510_en.pdf"},
    {"id":"74107","name":"Clenbuterol : List of nationally authorised medicinal products - PSUSA/00000794/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T08:53:20Z","last_updated_date":"2026-06-16T08:53:20Z","reference_number":"EMADOC-1700519818-3242469","document_url":"https://www.ema.europa.eu/en/documents/psusa/clenbuterol-list-nationally-authorised-medicinal-products-psusa-00000794-202509_en.pdf"},
    {"id":"74108","name":"Bromhexine : List of nationally authorised medicinal products - PSUSA/00000437/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T08:57:24Z","last_updated_date":"2026-06-16T08:57:24Z","reference_number":"EMADOC-1700519818-3242613","document_url":"https://www.ema.europa.eu/en/documents/psusa/bromhexine-list-nationally-authorised-medicinal-products-psusa-00000437-202509_en.pdf"},
    {"id":"74109","name":"Aminosalicylic acid : List of nationally authorised medicinal products - PSUSA/00000165/202510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T09:00:57Z","last_updated_date":"2026-06-16T09:00:57Z","reference_number":"EMADOC-1700519818-3242529","document_url":"https://www.ema.europa.eu/en/documents/psusa/aminosalicylic-acid-list-nationally-authorised-medicinal-products-psusa-00000165-202510_en.pdf"},
    {"id":"74110","name":"Artemether / lumefantrin (apart from the dispersible tablet) : List of nationally authorised medicinal products - PSUSA/00000236/202510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T09:04:13Z","last_updated_date":"2026-06-16T09:04:13Z","reference_number":"EMADOC-1700519818-3242706","document_url":"https://www.ema.europa.eu/en/documents/psusa/artemether-lumefantrin-apart-dispersible-tablet-list-nationally-authorised-medicinal-products-psusa-00000236-202510_en.pdf"},
    {"id":"74111","name":"Valsartan / rosuvastatin : List of nationally authorised medicinal products - PSUSA/00010735/202510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T09:08:00Z","last_updated_date":"2026-06-16T09:08:00Z","reference_number":"EMADOC-1700519818-3243643","document_url":"https://www.ema.europa.eu/en/documents/psusa/valsartan-rosuvastatin-list-nationally-authorised-medicinal-products-psusa-00010735-202510_en.pdf"},
    {"id":"74112","name":"Isoflurane : List of nationally authorised medicinal products - PSUSA/00001786/202510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T09:14:33Z","last_updated_date":"2026-06-16T09:14:33Z","reference_number":"EMADOC-1700519818-3245110","document_url":"https://www.ema.europa.eu/en/documents/psusa/isoflurane-list-nationally-authorised-medicinal-products-psusa-00001786-202510_en.pdf"},
    {"id":"74114","name":"Desogestrel / ethinylestradiol : List of nationally authorised medicinal products - PSUSA/00000967/202509","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T09:59:18Z","last_updated_date":"2026-06-16T09:59:18Z","reference_number":"EMADOC-1700519818-3248282","document_url":"https://www.ema.europa.eu/en/documents/psusa/desogestrel-ethinylestradiol-list-nationally-authorised-medicinal-products-psusa-00000967-202509_en.pdf"},
    {"id":"74116","name":"Prothipendyl : List of nationally authorised medicinal products - PSUSA/00002564/202510","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T10:21:02Z","last_updated_date":"2026-06-16T10:21:02Z","reference_number":"EMADOC-1700519818-3250236","document_url":"https://www.ema.europa.eu/en/documents/psusa/prothipendyl-list-nationally-authorised-medicinal-products-psusa-00002564-202510_en.pdf"},
    {"id":"74117","name":"Acetylsalicylic acid / chlorphenamine / phenylephrine : List of nationally authorised medicinal products - PSUSA/00000694/202511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T11:00:31Z","last_updated_date":"2026-06-16T11:00:31Z","reference_number":"EMADOC-1700519818-3251686","document_url":"https://www.ema.europa.eu/en/documents/psusa/acetylsalicylic-acid-chlorphenamine-phenylephrine-list-nationally-authorised-medicinal-products-psusa-00000694-202511_en.pdf"},
    {"id":"74118","name":"Cinnarizine / dimenhydrinate : List of nationally authorised medicinal products - PSUSA/00000767/202511","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T12:27:13Z","last_updated_date":"2026-06-16T12:27:13Z","reference_number":"EMADOC-1700519818-3249578","document_url":"https://www.ema.europa.eu/en/documents/psusa/cinnarizine-dimenhydrinate-list-nationally-authorised-medicinal-products-psusa-00000767-202511_en.pdf"},
    {"id":"74120","name":"PSUSA/00002305/202511 - List of nationally authorised medicinal products","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T14:59:31Z","last_updated_date":"2026-06-16T14:59:31Z","reference_number":"EMADOC-1700519818-3078793","document_url":"https://www.ema.europa.eu/en/documents/psusa/psusa-00002305-202511-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"74121","name":"PSUSA/00010155/202509 - List of nationally authorised medicinal products","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T15:44:38Z","last_updated_date":"2026-06-16T15:44:38Z","reference_number":"EMADOC-1700519818-3245340","document_url":"https://www.ema.europa.eu/en/documents/psusa/psusa-00010155-202509-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"74122","name":"PSUSA/00001104/202509 - List of nationally authorised medicinal products ","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T16:22:33Z","last_updated_date":"2026-06-16T16:22:33Z","reference_number":"EMADOC-1700519818-3246613","document_url":"https://www.ema.europa.eu/en/documents/psusa/psusa-00001104-202509-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"74239","name":"Mixture of Phleum pratense and Secale cereale allergen extracts : Notification of discontinuation of a paediatric development which is covered by agreed PIP Decision","type":"psusa","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T17:16:17Z","last_updated_date":"2026-06-23T17:16:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/psusa/mixture-phleum-pratense-secale-cereale-allergen-extracts-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf"},
    {"id":"74259","name":"PSUSA/00009050/202511: List of nationally authorised medicinal products","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2026-06-25T09:25:41Z","last_updated_date":"2026-06-25T09:25:41Z","reference_number":"EMADOC-1700519818-3255078","document_url":"https://www.ema.europa.eu/en/documents/psusa/psusa-00009050-202511-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"74261","name":"PSUSA/00002633/202511: List of nationally authorised medicinal products ","type":"psusa","status":"Adopted","consultation_date":"","first_published_date":"2026-06-25T09:47:04Z","last_updated_date":"2026-06-25T09:47:04Z","reference_number":"EMADOC-1700519818-3259028","document_url":"https://www.ema.europa.eu/en/documents/psusa/psusa-00002633-202511-list-nationally-authorised-medicinal-products_en.pdf"},
    {"id":"3312","name":"PRAC recommendations on signals adopted at the PRAC meeting of 26-29 September 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-10-25T16:20:00Z","last_updated_date":"2017-11-22T16:50:00Z","reference_number":"EMA/PRAC/634818/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-26-29-september-2016_en.pdf"},
    {"id":"3984","name":"PRAC recommendations on signals adopted at the PRAC meeting of 6-9 February 2017","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-06T12:00:00Z","last_updated_date":"2017-03-06T12:00:00Z","reference_number":"EMA/PRAC/68642/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-6-9-february-2017_en.pdf"},
    {"id":"5715","name":"PRAC recommendations on signals adopted at the PRAC meeting of 6-9 July 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-07T12:00:00Z","last_updated_date":"2015-08-07T12:00:00Z","reference_number":"EMA/PRAC/450903/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-6-9-july-2015_en.pdf"},
    {"id":"6431","name":"PRAC recommendations on signals adopted at the PRAC meeting of 3-6 March 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-03-25T12:10:00Z","last_updated_date":"2014-03-25T12:10:00Z","reference_number":"EMA/PRAC/144622/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-3-6-march-2014_en.pdf"},
    {"id":"7280","name":"PRAC recommendations on signals adopted at the 23-26 October 2017 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-11-20T11:00:00Z","last_updated_date":"2017-11-20T11:00:00Z","reference_number":"EMA/PRAC/610976/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-23-26-october-2017-prac-meeting_en.pdf"},
    {"id":"7301","name":"PRAC recommendations on signals adopted at the PRAC meeting of 2-5 December 2013","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2013-12-17T13:10:00Z","last_updated_date":"2013-12-17T13:10:00Z","reference_number":"EMA/PRAC/773133/2013","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-2-5-december-2013_en.pdf"},
    {"id":"8597","name":"PRAC recommendations on signals adopted at the 3-6 September 2018 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-01T12:00:00Z","last_updated_date":"2018-10-01T12:00:00Z","reference_number":"EMA/PRAC/595691/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en.pdf"},
    {"id":"8919","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 14-17 March 2016 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-11T14:25:00Z","last_updated_date":"2016-04-11T14:25:00Z","reference_number":"EMA/PRAC/136000/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-march-2016-prac_no.pdf"}},
    {"id":"9395","name":"PRAC recommendations on signals adopted at the PRAC meeting of 10-13 May 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-06T18:10:00Z","last_updated_date":"2016-06-06T18:10:00Z","reference_number":"EMA/PRAC/313187/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-10-13-may-2016_en.pdf"},
    {"id":"9448","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 29 August-1 September 2017 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2017-09-25T17:16:00Z","last_updated_date":"2017-10-06T17:16:00Z","reference_number":"EMA/PRAC/600977/2017 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2017-prac_no.pdf"}},
    {"id":"10055","name":"PRAC recommendations on signals adopted at the PRAC meeting of 6-9 March 2017","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-04-04T18:00:00Z","last_updated_date":"2017-04-04T18:00:00Z","reference_number":"EMA/PRAC/146565/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-6-9-march-2017_en.pdf"},
    {"id":"10241","name":"PRAC recommendations on signals adopted at the PRAC meeting of 7-10 July 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-29T11:35:00Z","last_updated_date":"2014-07-29T11:35:00Z","reference_number":"EMA/PRAC/425079/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-7-10-july-2014_en.pdf"},
    {"id":"10733","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 8-11 January 2018 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-02-05T16:00:00Z","last_updated_date":"2018-02-05T16:00:00Z","reference_number":"EMA/PRAC/8436/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2018-prac_no.pdf"}},
    {"id":"10914","name":"PRAC recommendations on signals adopted at the 3-6 July 2017 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-08-07T17:00:00Z","last_updated_date":"2017-08-07T17:00:00Z","reference_number":"EMA/PRAC/406987/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-july-2017-prac-meeting_en.pdf"},
    {"id":"11348","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 9-12 April 2018 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-05-07T12:30:00Z","last_updated_date":"2018-05-07T12:30:00Z","reference_number":"EMA/PRAC/211550/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-april-2018-prac_no.pdf"}},
    {"id":"12957","name":"PRAC recommendations on signals adopted at the PRAC meeting of 6-9 January 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-01-27T15:00:00Z","last_updated_date":"2015-02-05T13:03:00Z","reference_number":"EMA/PRAC/734433/2014 Corr.","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-6-9-january-2015_en.pdf"},
    {"id":"13251","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 11-14 April 2016 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-10T17:00:00Z","last_updated_date":"2016-05-10T17:00:00Z","reference_number":"EMA/PRAC/259913/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-april-2016-prac_no.pdf"}},
    {"id":"13422","name":"PRAC recommendations on signals adopted at the PRAC meeting of 9-12 January 2017","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-02-06T13:45:00Z","last_updated_date":"2017-02-06T13:45:00Z","reference_number":"EMA/PRAC/5653/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-9-12-january-2017_en.pdf"},
    {"id":"13429","name":"PRAC recommendations on signals adopted at the PRAC meeting of 7-10 April 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-28T16:00:00Z","last_updated_date":"2015-04-28T16:00:00Z","reference_number":"EMA/PRAC/234960/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-7-10-april-2015_en.pdf"},
    {"id":"13541","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 5-8 October 2015 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-03T12:00:00Z","last_updated_date":"2015-11-03T12:00:00Z","reference_number":"EMA/PRAC/661880/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-october-2015-prac_no.pdf"}},
    {"id":"14314","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 25-30 November 2017 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T12:44:00Z","last_updated_date":"2018-01-04T12:44:00Z","reference_number":"EMA/PRAC/611010/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-30-november-2017-prac_no.pdf"}},
    {"id":"14350","name":"PRAC recommendations on signals adopted at the PRAC meeting of 1-4 December 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-12-22T13:00:00Z","last_updated_date":"2014-12-22T13:00:00Z","reference_number":"EMA/PRAC/734095/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-1-4-december-2014_en.pdf"},
    {"id":"14364","name":"PRAC recommendations on signals adopted at the PRAC meeting of 30 August-2 September 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-09-26T16:30:00Z","last_updated_date":"2016-10-28T14:00:00Z","reference_number":"EMA/PRAC/551805/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-30-august-2-september-2016_en.pdf"},
    {"id":"14473","name":"PRAC recommendations on signals adopted at the PRAC meeting of 6-9 January 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-01-28T17:10:00Z","last_updated_date":"2014-01-28T17:10:00Z","reference_number":"EMA/PRAC/25732/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-6-9-january-2014_en.pdf"},
    {"id":"16319","name":"New product information wording: extracts from  PRAC recommendations on signals adopted at the 28 November-1 December 2016 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T17:30:00Z","last_updated_date":"2017-01-03T17:30:00Z","reference_number":"EMA/PRAC/740435/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-november-1-december-2016-prac_no.pdf"}},
    {"id":"16562","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 3-6 July 2017 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2017-08-07T17:00:00Z","last_updated_date":"2017-08-07T17:00:00Z","reference_number":"EMA/PRAC/406976/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2017-prac_no.pdf"}},
    {"id":"17028","name":"PRAC recommendations on signals adopted at the PRAC meeting of 3-6 November 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-30T11:00:00Z","last_updated_date":"2015-11-30T11:00:00Z","reference_number":"EMA/PRAC/711550/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-3-6-november-2015_en.pdf"},
    {"id":"17819","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 11-14 January 2016 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-08T16:20:00Z","last_updated_date":"2016-02-08T16:20:00Z","reference_number":"EMA/PRAC/1320/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2016-prac_no.pdf"}},
    {"id":"17937","name":"New product information wording: extracts from  PRAC recommendations on signals adopted at the 4-8 July 2016 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2016-08-02T11:07:00Z","last_updated_date":"2016-08-02T11:07:00Z","reference_number":"EMA/PRAC/452713/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-8-july-2016-prac_no.pdf"}}    {"id":"18173","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 9-12 January 2017 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-02-06T13:45:00Z","last_updated_date":"2017-02-06T13:45:00Z","reference_number":"EMA/PRAC/5725/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2017-prac_no.pdf"}},
    {"id":"18295","name":"PRAC recommendations on signals adopted at the 9-12 April 2018 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-05-07T12:30:00Z","last_updated_date":"2018-05-07T12:30:00Z","reference_number":"EMA/PRAC/211744/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-9-12-april-2018-prac-meeting_en.pdf"},
    {"id":"18333","name":"PRAC recommendations on signals adopted at the PRAC meeting of 5-8 May 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-05-27T13:20:00Z","last_updated_date":"2014-05-27T13:20:00Z","reference_number":"EMA/PRAC/272621/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-5-8-may-2014_en.pdf"},
    {"id":"18944","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 2-5 May 2017 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2017-05-29T16:00:01Z","last_updated_date":"2017-05-29T16:00:01Z","reference_number":"EMA/PRAC/252868/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-may-2017-prac_no.pdf"}},
    {"id":"19050","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 6-9 July 2015 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-08-07T12:00:00Z","last_updated_date":"2015-08-07T12:00:00Z","reference_number":"EMA/PRAC/450962/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2015-prac_no.pdf"}},
    {"id":"19187","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 6-9 June 2017 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2017-07-03T16:00:00Z","last_updated_date":"2017-07-03T16:00:00Z","reference_number":"EMA/PRAC/337624/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2017-prac_no.pdf"}},
    {"id":"19281","name":"PRAC recommendations on signals adopted at the PRAC meeting of 8-11 June 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T15:55:00Z","last_updated_date":"2015-06-30T15:55:00Z","reference_number":"EMA/PRAC/383371/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-8-11-june-2015_en.pdf"},
    {"id":"19345","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 8-11 February 2016 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-03-07T17:40:00Z","last_updated_date":"2016-03-07T17:40:00Z","reference_number":"EMA/PRAC/87260/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2016-prac_no.pdf"}},
    {"id":"20180","name":"New product information wording: extracts from  PRAC recommendations on signals adopted at the 30 August-2 September 2016 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2016-09-26T16:30:00Z","last_updated_date":"2016-09-26T16:30:00Z","reference_number":"EMA/PRAC/551910/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2016-prac_no.pdf"}},
    {"id":"20269","name":"PRAC recommendations on signals adopted at the PRAC meeting of 7-10 September 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-10-06T12:40:00Z","last_updated_date":"2015-10-06T12:40:00Z","reference_number":"EMA/PRAC/590240/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-7-10-september-2015_en.pdf"},
    {"id":"20726","name":"PRAC recommendations on signals adopted at the PRAC meeting of 11-14 April 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-05-10T17:30:00Z","last_updated_date":"2016-05-10T17:30:00Z","reference_number":"EMA/PRAC/259909/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-11-14-april-2016_en.pdf"},
    {"id":"20878","name":"PRAC recommendations on signals adopted at the PRAC meeting of 8-11 September 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-09-30T10:55:00Z","last_updated_date":"2014-09-30T10:55:00Z","reference_number":"EMA/PRAC/490498/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-8-11-september-2014_en.pdf"},
    {"id":"20918","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 6-9 March 2017 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2017-04-04T18:00:00Z","last_updated_date":"2017-04-04T18:00:00Z","reference_number":"EMA/PRAC/146563/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-march-2017-prac_no.pdf"}},
    {"id":"21385","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 September 2016 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2016-10-25T14:20:00Z","last_updated_date":"2016-10-25T14:20:00Z","reference_number":"EMA/PRAC/636169/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2016-prac_no.pdf"}},
    {"id":"21573","name":"PRAC recommendations on signals adopted at the 5-8 February 2018 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-03-05T01:00:00Z","last_updated_date":"2018-08-06T13:00:00Z","reference_number":"EMA/PRAC/59224/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-5-8-february-2018-prac-meeting_en.pdf"},
    {"id":"21834","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 9-12 July 2018 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-08-06T13:00:00Z","last_updated_date":"2018-08-06T13:00:00Z","reference_number":"EMA/PRAC/414649/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-july-2018-prac_no.pdf"}},
    {"id":"21886","name":"PRAC recommendations on signals adopted at the PRAC meeting of 11-14 January 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-08T16:20:00Z","last_updated_date":"2016-02-08T16:20:00Z","reference_number":"EMA/PRAC/1275/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-11-14-january-2016_en.pdf"},
    {"id":"22171","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 6-9 June 2016 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2016-07-04T13:35:00Z","last_updated_date":"2016-07-04T13:35:00Z","reference_number":"EMA/PRAC/400813/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-june-2016-prac_no.pdf"}},
    {"id":"22834","name":"PRAC recommendations on signals adopted at the PRAC meeting of 14-17 March 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-11T14:20:00Z","last_updated_date":"2016-04-11T14:20:00Z","reference_number":"EMA/PRAC/135876/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-14-17-march-2016_en.pdf"},
    {"id":"23413","name":"PRAC recommendations on signals adopted at the PRAC meeting of 8-11 January 2018 meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-02-05T16:00:00Z","last_updated_date":"2018-02-15T15:30:00Z","reference_number":"EMA/PRAC/8429/2018 Corr","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-8-11-january-2018-meeting_en.pdf"},
    {"id":"24106","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 14-17 May 2018 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-06-11T18:00:00Z","last_updated_date":"2018-06-11T18:00:00Z","reference_number":"EMA/PRAC/287233/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-may-2018-prac_no.pdf"}},
    {"id":"25643","name":"New product information wording: extracts from  PRAC recommendations on signals adopted at the 30 November-3 December PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T16:20:00Z","last_updated_date":"2016-01-06T16:20:00Z","reference_number":"EMA/PRAC/711684/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-november-3-december-prac_no.pdf"}},
    {"id":"26165","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 7-10 September 2015 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:40:00Z","last_updated_date":"2015-10-06T12:40:00Z","reference_number":"EMA/PRAC/590265/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-september-2015-prac_no.pdf"}},
    {"id":"26626","name":"PRAC recommendations on signals adopted at the PRAC meeting of 27-30 November 2017","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-01-04T12:45:00Z","last_updated_date":"2018-01-04T12:45:00Z","reference_number":"EMA/PRAC/610978/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-27-30-november-2017_en.pdf"},
    {"id":"26853","name":"PRAC recommendations on signals adopted at the PRAC meeting of 2-5 May 2017","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-29T16:00:00Z","last_updated_date":"2017-05-29T16:00:00Z","reference_number":"EMA/PRAC/252869/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-2-5-may-2017_en.pdf"},
    {"id":"26897","name":"PRAC recommendations on signals adopted at the PRAC meeting of 2-5 September 2013","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2013-10-04T14:00:00Z","last_updated_date":"2013-10-04T14:00:00Z","reference_number":"EMA/PRAC/550442/2013","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-2-5-september-2013_en.pdf"},
    {"id":"26926","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 10-13 May 2016 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-06T18:10:00Z","last_updated_date":"2016-06-06T18:10:00Z","reference_number":"EMA/PRAC/313237/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-may-2016-prac_no.pdf"}},
    {"id":"27580","name":"PRAC recommendations on signals adopted at the PRAC meeting of 24-27 October 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-11-21T10:30:00Z","last_updated_date":"2016-11-21T10:30:00Z","reference_number":"EMA/PRAC/700146/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-24-27-october-2016_en.pdf"},
    {"id":"27613","name":"PRAC recommendations on signals adopted at the PRAC meeting of 4-7 November 2013","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2013-11-28T12:30:00Z","last_updated_date":"2013-11-28T12:30:00Z","reference_number":"EMA/PRAC/693228/2013","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-4-7-november-2013_en.pdf"},
    {"id":"28002","name":"PRAC recommendations on signals adopted at the 14-17 May 2018 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-06-11T18:00:00Z","last_updated_date":"2018-06-11T18:00:00Z","reference_number":"EMA/PRAC/287231/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-14-17-may-2018-prac-meeting_en.pdf"},
    {"id":"28065","name":"PRAC recommendations on signals for update of the product information\n\nadopted at the 7-10 April 2015 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-05-13T02:00:00Z","last_updated_date":"2015-05-13T02:00:00Z","reference_number":"EMA/PRAC/239532/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-7-10-april-2015-prac_no.pdf"}},
    {"id":"28117","name":"PRAC recommendations on signals adopted at the PRAC meeting of 6-9 October 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-10-28T10:30:00Z","last_updated_date":"2014-10-28T10:30:00Z","reference_number":"EMA/PRAC/618934/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-6-9-october-2014_en.pdf"},
    {"id":"28484","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 24-27 October 2016 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2016-11-21T14:49:00Z","last_updated_date":"2016-11-21T14:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2016-prac_no.pdf"}},
    {"id":"29752","name":"PRAC recommendations on signals adopted at the PRAC meeting of 7-10 April 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-04-29T11:00:00Z","last_updated_date":"2014-04-29T11:00:00Z","reference_number":"EMA/PRAC/229812/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-7-10-april-2014_en.pdf"},
    {"id":"29844","name":"PRAC recommendations on signals for update of the product information adopted at the PRAC meeting of 6-9 January 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-02-18T01:00:00Z","last_updated_date":"2015-02-18T01:00:00Z","reference_number":"EMA/PRAC/62352/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-meeting-6-9-january-2015_no.pdf"}},
    {"id":"30837","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 11-14 June 2018 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-07-09T12:36:00Z","last_updated_date":"2018-07-09T12:36:00Z","reference_number":"EMA/PRAC/397088/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2018-prac_no.pdf"}},
    {"id":"31275","name":"PRAC recommendations on signals for update of the product information adopted at the 4-7 May 2015 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-01T18:20:00Z","last_updated_date":"2015-06-01T18:20:00Z","reference_number":"EMA/PRAC/277134/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-4-7-may-2015-prac_no.pdf"}},
    {"id":"31291","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 6-9 February 2017 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-03-06T12:00:01Z","last_updated_date":"2017-03-06T12:00:01Z","reference_number":"EMA/PRAC/68687/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2017-prac_no.pdf"}},
    {"id":"31474","name":"PRAC recommendations on signals adopted at the PRAC meeting of 30 November - 3 December 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-01-06T16:20:00Z","last_updated_date":"2016-01-06T16:20:00Z","reference_number":"EMA/PRAC/788914/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-30-november-3-december-2015_en.pdf"},
    {"id":"31589","name":"PRAC recommendations on signals adopted at the 9-12 July 2018 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-08-06T13:00:00Z","last_updated_date":"2018-08-06T13:00:00Z","reference_number":"EMA/PRAC/414645/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-9-12-july-2018-prac-meeting_en.pdf"},
    {"id":"31626","name":"PRAC recommendations on signals adopted at the PRAC meeting of 3-6 February 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-02-25T10:55:00Z","last_updated_date":"2014-02-25T10:55:00Z","reference_number":"EMA/PRAC/65788/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-3-6-february-2014_en.pdf"},
    {"id":"31738","name":"PRAC recommendations on signals adopted at the PRAC meeting of 9-12 February 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-03T10:00:00Z","last_updated_date":"2015-03-19T11:45:00Z","reference_number":"EMA/PRAC/107418/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-9-12-february-2015_en.pdf"},
    {"id":"31877","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 3-6 April 2017 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2017-05-02T16:45:00Z","last_updated_date":"2017-05-02T16:45:00Z","reference_number":"EMA/PRAC/221996/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-april-2017-prac_no.pdf"}},
    {"id":"32227","name":"PRAC recommendations on signals adopted at the 11-14 June 2018 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-07-09T12:35:00Z","last_updated_date":"2018-07-09T12:35:00Z","reference_number":"EMA/PRAC/397086/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-11-14-june-2018-prac-meeting_en.pdf"},
    {"id":"32708","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 5-8 March 2018 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-04-03T14:05:00Z","last_updated_date":"2018-04-03T14:05:00Z","reference_number":"EMA/PRAC/136578/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-march-2018-prac_no.pdf"}},
    {"id":"32858","name":"PRAC recommendations on signals adopted at the PRAC meeting of 4-8 July 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-08-02T11:07:00Z","last_updated_date":"2017-02-27T17:40:00Z","reference_number":"EMA/PRAC/452657/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-4-8-july-2016_en.pdf"},
    {"id":"33002","name":"PRAC recommendations on signals adopted at the PRAC meeting of 6-9 June 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-07-04T13:35:00Z","last_updated_date":"2016-07-04T13:35:00Z","reference_number":"EMA/PRAC/394327/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-6-9-june-2016_en.pdf"},
    {"id":"34785","name":"PRAC recommendations on signals adopted at the PRAC meeting of 28 November-1 December 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-01-03T17:30:00Z","last_updated_date":"2017-01-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-28-november-1-december-2016_en.pdf"},
    {"id":"35127","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 5-8 February 2018 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-03-05T10:45:00Z","last_updated_date":"2018-03-05T10:45:00Z","reference_number":"EMA/PRAC/59227/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-february-2018-prac_no.pdf"}},
    {"id":"35183","name":"PRAC recommendations on signals adopted at the PRAC meeting of 8-11 February 2016","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2016-03-07T17:40:00Z","last_updated_date":"2016-03-07T17:40:00Z","reference_number":"EMA/PRAC/87046/2016","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-8-11-february-2016_en.pdf"},
    {"id":"35200","name":"PRAC recommendations on signals adopted at the PRAC meeting of 3-6 November 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-11-25T12:25:00Z","last_updated_date":"2014-11-25T12:25:00Z","reference_number":"EMA/PRAC/683212/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-3-6-november-2014_en.pdf"},
    {"id":"35928","name":"PRAC recommendations on signals adopted at the PRAC meeting of 4-7 May 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-06-01T18:20:00Z","last_updated_date":"2015-06-01T18:20:00Z","reference_number":"EMA/PRAC/274321/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-4-7-may-2015_en.pdf"},
    {"id":"36835","name":"PRAC recommendations on signals adopted at the 25-29 September 2017 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-10-23T12:00:00Z","last_updated_date":"2017-10-23T12:00:00Z","reference_number":"EMA/PRAC/610975/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-25-29-september-2017-prac-meeting_en.pdf"},
    {"id":"37113","name":"PRAC recommendations on signals adopted at the PRAC meeting of 10-13 June 2014","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T11:50:00Z","last_updated_date":"2014-07-01T11:50:00Z","reference_number":"EMA/PRAC/337405/2014","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-10-13-june-2014_en.pdf"},
    {"id":"37747","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 25-29 September 2017 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T12:00:00Z","last_updated_date":"2017-10-23T12:00:00Z","reference_number":"EMA/PRAC/610988/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-29-september-2017-prac_no.pdf"}},
    {"id":"38451","name":"PRAC recommendations on signals adopted at the 6-9 June 2017 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T16:00:00Z","last_updated_date":"2017-07-03T16:00:00Z","reference_number":"EMA/PRAC/337620/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-6-9-june-2017-prac-meeting_en.pdf"},
    {"id":"38568","name":"PRAC recommendations on signals for update of the product information adopted by PRAC at the 9-12 March 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-04-22T12:10:00Z","last_updated_date":"2015-04-22T12:10:00Z","reference_number":"EMA/PRAC/194999/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-march-2015_no.pdf"}},
    {"id":"38577","name":"PRAC recommendations on signals adopted at the 29 August - 1 September 2017 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-09-25T17:49:00Z","last_updated_date":"2017-10-06T16:38:00Z","reference_number":"EMA/PRAC/407007/2017 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-29-august-1-september-2017-prac-meeting_en.pdf"},
    {"id":"38770","name":"PRAC recommendations on signals adopted at the PRAC meeting of 5-8 October 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-11-03T01:00:00Z","last_updated_date":"2015-11-03T12:07:00Z","reference_number":"EMA/PRAC/661789/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-5-8-october-2015_en.pdf"},
    {"id":"39537","name":"PRAC recommendations on signals adopted at the PRAC meeting of 9-12 March 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-31T13:30:00Z","last_updated_date":"2015-04-09T13:30:00Z","reference_number":"EMA/PRAC/176901/2015 corr.","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-9-12-march-2015_en.pdf"},
    {"id":"40668","name":"PRAC recommendations on signals for update of the product information adopted by PRAC at the 9-12 February 2015","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2015-03-23T12:40:00Z","last_updated_date":"2015-03-23T12:40:00Z","reference_number":"EMA/PRAC/118045/2015","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/prac-recommendations-signals-update-product-information-adopted-prac-9-12-february-2015_no.pdf"}},
    {"id":"40747","name":"PRAC recommendations on signals adopted at the PRAC meeting of 3-6 April 2017","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-02T16:45:00Z","last_updated_date":"2017-05-02T16:45:00Z","reference_number":"EMA/PRAC/221998/2017","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-3-6-april-2017_en.pdf"},
    {"id":"41546","name":"PRAC recommendations on signals adopted at the 5-8 March 2018 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-04-03T14:02:00Z","last_updated_date":"2018-04-03T14:02:00Z","reference_number":"EMA/PRAC/136563/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-5-8-march-2018-prac-meeting_en.pdf"},
    {"id":"41827","name":"PRAC recommendations on signals adopted at the PRAC meeting of 7-10 October 2013","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2013-11-06T18:00:01Z","last_updated_date":"2013-11-18T10:20:00Z","reference_number":"EMA/PRAC/625262/2013","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-7-10-october-2013_en.pdf"},
    {"id":"42140","name":"PRAC recommendations on signals adopted at the 3-6 September 2018 PRAC meeting","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-10-01T14:11:00Z","last_updated_date":"2018-10-01T14:11:00Z","reference_number":"EMA/PRAC/595691/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en.pdf-0"},
    {"id":"42158","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 3-6 September 2018 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-10-01T14:39:00Z","last_updated_date":"2018-10-12T13:00:00Z","reference_number":"EMA/PRAC/595696/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-september-2018-prac_no.pdf"}},
    {"id":"42325","name":"PRAC recommendations on signals adopted at the 1-4 October 2018 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-10-29T12:15:00Z","last_updated_date":"2018-10-29T12:15:00Z","reference_number":"EMA/PRAC/689235/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-1-4-october-2018-prac-meeting_en.pdf"},
    {"id":"42467","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 1-4 October 2018 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T12:08:00Z","last_updated_date":"2018-10-29T12:08:00Z","reference_number":"EMA/PRAC/689237/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-october-2018-prac_no.pdf"}},
    {"id":"42794","name":"PRAC recommendations on signals adopted at the 29-31 October 2018 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2018-11-26T15:51:00Z","last_updated_date":"2018-11-26T15:51:00Z","reference_number":"EMA/PRAC/758152/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-29-31-october-2018-prac-meeting_en.pdf"},
    {"id":"42795","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 29-31 October 2018 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2018-11-26T15:56:00Z","last_updated_date":"2018-11-26T15:56:00Z","reference_number":"EMA/PRAC/758155/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-31-october-2018-prac_no.pdf"}},
    {"id":"43013","name":"PRAC recommendations on signals adopted at the 26-29 November 2018 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-01-04T14:30:00Z","last_updated_date":"2019-01-04T14:30:00Z","reference_number":"EMA/PRAC/826440/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-november-2018-prac-meeting_en.pdf"},
    {"id":"43216","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 November 2018 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2019-01-04T15:30:00Z","last_updated_date":"2019-01-04T15:30:00Z","reference_number":"EMA/PRAC/595696/2018","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018-prac_no.pdf"}},
    {"id":"43481","name":"PRAC recommendations on signals adopted at the 14-17 January 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-02-11T11:32:00Z","last_updated_date":"2019-02-20T16:43:00Z","reference_number":"EMA/PRAC/905027/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-14-17-january-2019-prac-meeting_en.pdf"},
    {"id":"43689","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 14-17 January 2019 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2019-02-11T12:26:00Z","last_updated_date":"2019-02-11T12:26:00Z","reference_number":"EMA/PRAC/905277/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-january-2019-prac_no.pdf"}},
    {"id":"44001","name":"PRAC recommendations on signals adopted at the PRAC meeting of 11-14 February 2019","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-03-11T08:19:00Z","last_updated_date":"2019-03-11T08:19:00Z","reference_number":"EMA/PRAC/97587/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-prac-meeting-11-14-february-2019_en.pdf"},
    {"id":"44080","name":"PRAC recommendations on signals adopted at the 12-15 March 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-04-08T11:00:00Z","last_updated_date":"2019-04-08T11:00:00Z","reference_number":"EMA/PRAC/157165/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-12-15-march-2019-prac-meeting_en.pdf"},
    {"id":"44182","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 12-15 March 2019 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2019-04-08T11:00:00Z","last_updated_date":"2019-04-08T11:00:00Z","reference_number":"EMA/PRAC/157160/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-march-2019-prac_no.pdf"}},
    {"id":"44314","name":"PRAC recommendations on signals adopted at the 8-11 April 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-05-06T17:39:00Z","last_updated_date":"2019-05-06T17:39:00Z","reference_number":"EMA/PRAC/219985/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-8-11-april-2019-prac-meeting_en.pdf"},
    {"id":"44439","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 8-11 April 2019 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-05-06T17:13:00Z","last_updated_date":"2019-05-06T17:13:00Z","reference_number":"EMA/PRAC/234257/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_no.pdf"}},
    {"id":"44586","name":"PRAC recommendations on signals adopted at the 13-16 May 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-11T10:13:00Z","last_updated_date":"2019-06-11T10:13:00Z","reference_number":"EMA/PRAC/265212/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-13-16-may-2019-prac-meeting_en.pdf"},
    {"id":"44683","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 13-16 May 2019 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-06-11T10:19:00Z","last_updated_date":"2019-06-11T10:19:00Z","reference_number":"EMA/PRAC/265221/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_no.pdf"}},
    {"id":"45010","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 11-14 June 2019 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-07-08T10:44:00Z","last_updated_date":"2019-07-08T10:44:00Z","reference_number":"EMA/PRAC/303948/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-june-2019-prac_no.pdf"}},
    {"id":"45011","name":"PRAC recommendations on signals adopted at the 11-14 June 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-07-08T10:45:00Z","last_updated_date":"2019-07-08T10:45:00Z","reference_number":"EMA/PRAC/303951/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-11-14-june-2019-prac-meeting_en.pdf-0"},
    {"id":"45071","name":"PRAC recommendations on signals adopted at the 8-11 July 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-08-06T12:00:00Z","last_updated_date":"2019-08-06T12:00:00Z","reference_number":"EMA/PRAC/347675/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-8-11-july-2019-prac-meeting_en.pdf"},
    {"id":"45202","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 8-11 July 2019 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2019-08-06T12:00:00Z","last_updated_date":"2019-10-17T11:44:00Z","reference_number":"EMA/PRAC/347724/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2019-prac_no.pdf"}},
    {"id":"45534","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 2-5 September 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-09-30T09:50:00Z","last_updated_date":"2019-09-30T09:50:00Z","reference_number":"EMA/PRAC/474668/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_no.pdf"}},
    {"id":"45535","name":"PRAC recommendations on signals adopted at the 2-5 September 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-09-30T09:52:00Z","last_updated_date":"2019-10-11T12:30:00Z","reference_number":"EMA/PRAC/474667/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-2-5-september-2019-prac-meeting_en.pdf"},
    {"id":"45649","name":"PRAC recommendations on signals adopted at the 30 September-3 October 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-10-28T13:30:00Z","last_updated_date":"2019-10-28T13:30:00Z","reference_number":"EMA/PRAC/532014/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-30-september-3-october-2019-prac-meeting_en.pdf"},
    {"id":"45900","name":"PRAC recommendations on signals adopted at the 28-31 October 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-11-25T11:40:00Z","last_updated_date":"2019-11-25T11:40:00Z","reference_number":"EMA/PRAC/580132/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-28-31-october-2019-prac-meeting_en.pdf"},
    {"id":"46120","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 28-31 October 2019 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2019-11-25T11:33:00Z","last_updated_date":"2019-11-25T11:33:00Z","reference_number":"EMA/PRAC/580133/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2019-prac_no.pdf"}},
    {"id":"46223","name":"Updated signal assessment report on birth defects following in-utero exposure during the first trimester of pregnancy arising from recent publications with ondansetr","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2019-12-03T16:36:00Z","last_updated_date":"2019-12-03T16:36:00Z","reference_number":"EMA/610728/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/updated-signal-assessment-report-birth-defects-following-utero-exposure-during-first-trimester-pregnancy-arising-recent-publications-ondansetr_en.pdf"},
    {"id":"46391","name":"PRAC recommendations on signals adopted at the 25-28 November 2019 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-01-07T15:50:00Z","last_updated_date":"2020-01-07T15:50:00Z","reference_number":"EMA/PRAC/629269/2019","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-25-28-november-2019-prac-meeting_en.pdf"},
    {"id":"46698","name":"PRAC recommendations on signals adopted at the 13-16 January 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-10T15:48:00Z","last_updated_date":"2020-02-10T15:48:00Z","reference_number":"EMA/PRAC/8637/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_en.pdf"},
    {"id":"46700","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 13-16 January 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-10T15:51:00Z","last_updated_date":"2020-02-10T15:51:00Z","reference_number":"EMA/PRAC/38161/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_no.pdf"}},
    {"id":"46838","name":"PRAC recommendations on signals adopted at the 10-13 February 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-03-10T14:21:00Z","last_updated_date":"2020-03-31T11:50:00Z","reference_number":"EMA/PRAC/64581/2020 Corr.","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-10-13-february-2020-prac-meeting_en.pdf"},
    {"id":"47039","name":"PRAC recommendations on signals adopted at the 9-12 March 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-04-06T10:52:00Z","last_updated_date":"2020-04-08T13:50:00Z","reference_number":"EMA/PRAC/111214/2020 Corr. 4","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-9-12-march-2020-prac-meeting_en.pdf"},
    {"id":"47351","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 9-12 March 2020 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-04-08T10:51:00Z","last_updated_date":"2020-04-08T16:00:00Z","reference_number":"EMA/PRAC/111218/2020 Corr. 3","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2020-prac_no.pdf"}},
    {"id":"47466","name":"PRAC recommendations on signals adopted at the 14-17 April 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-11T14:32:00Z","last_updated_date":"2020-05-11T14:32:00Z","reference_number":"EMA/PRAC/201784/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-14-17-april-2020-prac-meeting_en.pdf"},
    {"id":"47638","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 14-17 April 2020 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-05-11T14:08:00Z","last_updated_date":"2020-05-11T14:08:00Z","reference_number":"EMA/PRAC/201788/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-14-17-april-2020-prac_no.pdf"}},
    {"id":"47714","name":"PRAC recommendations on signals adopted at the 11-14 May 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-06-23T09:30:00Z","last_updated_date":"2020-10-16T11:58:00Z","reference_number":"EMA/PRAC/257435/2020 Corr.4","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-11-14-may-2020-prac-meeting_en.pdf"}    {"id":"48066","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 11-14 May 2020 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T09:30:00Z","last_updated_date":"2020-08-11T15:50:00Z","reference_number":"EMA/PRAC/257439/2020 Corr 2","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-may-2020-prac_no.pdf"}},
    {"id":"48093","name":"PRAC recommendations on signals adopted at the 8-11 June 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-07-06T10:30:00Z","last_updated_date":"2020-07-06T10:30:00Z","reference_number":"EMA/PRAC/311314/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-8-11-june-2020-prac-meeting_en.pdf"},
    {"id":"48227","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 8-11 June 2020 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2020-07-06T10:33:00Z","last_updated_date":"2020-07-06T10:33:00Z","reference_number":"EMA/PRAC/311316/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-june-2020-prac_no.pdf"}},
    {"id":"48526","name":"PRAC recommendations on signals adopted at the 6-9 July 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-03T09:32:00Z","last_updated_date":"2020-08-03T09:32:00Z","reference_number":"EMA/PRAC/367621/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-6-9-july-2020-prac-meeting_en.pdf"},
    {"id":"48527","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 6-9 July 2020 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-08-03T09:40:00Z","last_updated_date":"2020-08-03T09:40:00Z","reference_number":"EMA/PRAC/367622/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-july-2020-prac_no.pdf"}},
    {"id":"48774","name":"PRAC recommendations on signals adopted at the 31 August-3 September 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-28T12:00:00Z","last_updated_date":"2020-09-28T12:00:00Z","reference_number":"EMA/PRAC/458924/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-31-august-3-september-2020-prac-meeting_en.pdf"},
    {"id":"48898","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 31 August-3 September 2020 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-09-28T12:00:00Z","last_updated_date":"2020-09-28T12:00:00Z","reference_number":"EMA/PRAC/458930/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-31-august-3-september-2020-prac_no.pdf"}},
    {"id":"49127","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 28 September-1 October 2020 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-10-26T13:24:00Z","last_updated_date":"2020-10-26T13:24:00Z","reference_number":"EMA/PRAC/513093/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-september-1-october-2020-prac_no.pdf"}},
    {"id":"49128","name":"PRAC recommendations on signals adopted at the 28 September-1 October 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-10-26T13:28:00Z","last_updated_date":"2020-10-26T13:28:00Z","reference_number":"EMA/PRAC/513083/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-28-september-1-october-2020-prac-meeting_en.pdf"},
    {"id":"49310","name":"PRAC recommendations on signals adopted at the 26-29 October 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-23T11:34:00Z","last_updated_date":"2021-07-06T15:50:00Z","reference_number":"EMA/PRAC/570588/2020 Corr.3","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-october-2020-prac-meeting_en.pdf"},
    {"id":"49311","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 October 2020 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2020-11-23T11:41:00Z","last_updated_date":"2020-11-23T11:41:00Z","reference_number":"EMA/PRAC/592306/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-october-2020-prac_no.pdf"}},
    {"id":"49433","name":"PRAC recommendations on signals adopted at the 23-26 November 2020 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-01-06T15:50:00Z","last_updated_date":"2021-01-06T15:50:00Z","reference_number":"EMA/PRAC/630091/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-23-26-november-2020-prac-meeting_en.pdf"},
    {"id":"49740","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 23-26 November 2020 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-01-06T15:56:00Z","last_updated_date":"2021-01-06T15:56:00Z","reference_number":"EMA/PRAC/654443/2020","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-november-2020-prac_no.pdf"}},
    {"id":"49878","name":"PRAC recommendations on signals adopted at the 11-14 January 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-08T10:42:00Z","last_updated_date":"2021-02-08T10:42:00Z","reference_number":"EMA/PRAC/19647/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-11-14-january-2021-prac-meeting_en.pdf"},
    {"id":"50077","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 11-14 January 2021 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-02-08T10:45:00Z","last_updated_date":"2021-02-08T10:45:00Z","reference_number":"EMA/PRAC/19650/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-11-14-january-2021-prac_no.pdf"}},
    {"id":"50256","name":"PRAC recommendations on signals adopted at the 8-11 February 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T18:00:00Z","last_updated_date":"2021-03-08T18:00:00Z","reference_number":"EMA/PRAC/82059/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-8-11-february-2021-prac-meeting_en.pdf"},
    {"id":"50487","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 8-11 February 2021 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T18:00:00Z","last_updated_date":"2021-03-08T18:00:00Z","reference_number":"EMA/PRAC/82060/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-february-2021-prac_no.pdf"}},
    {"id":"50750","name":"Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVID-19 Vaccine AstraZeneca (Other viral vaccines)","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-03-31T15:00:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"EMA/PRAC/157045/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid-19-vaccine-astrazeneca-other-viral-vaccines_en.pdf"},
    {"id":"50758","name":"PRAC recommendations on signals adopted at the 8-11 March 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-04-06T11:30:00Z","last_updated_date":"2021-04-06T11:30:00Z","reference_number":"EMA/PRAC/146285/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-8-11-march-2021-prac-meeting_en.pdf"},
    {"id":"50759","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 8-11 March 2021 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-04-06T11:29:00Z","last_updated_date":"2021-04-06T11:29:00Z","reference_number":"EMA/PRAC/146288/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-march-2021-prac_no.pdf"}},
    {"id":"50797","name":"Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (Other viral vaccines)","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-04-13T12:30:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"EMA/205598/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-vaxzevria-previously-covid-19-vaccine-astrazeneca-other-viral-vaccines_en.pdf"},
    {"id":"50906","name":"PRAC recommendations on signals adopted at the 6-9 April 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-03T12:06:00Z","last_updated_date":"2021-05-03T12:06:00Z","reference_number":"EMA/PRAC/199751/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_en.pdf"},
    {"id":"51042","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 6-9 April 2021 PRAC meeting","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2021-05-03T12:07:00Z","last_updated_date":"2021-05-03T12:07:00Z","reference_number":"EMA/PRAC/219605/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-april-2021-prac-meeting_no.pdf"}},
    {"id":"51139","name":"Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) adopted at PRAC meeting 20 April 2021","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-12T09:33:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"EMA/268126/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-janssen-ad26cov2-s-recombinant-adopted-prac-meeting-20-april-2021_en.pdf"},
    {"id":"51162","name":"PRAC recommendations on signals adopted at the 3-6 May 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-31T12:25:00Z","last_updated_date":"2021-08-26T17:25:00Z","reference_number":"EMA/PRAC/250777/2021 Corr 2","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_en.pdf"},
    {"id":"51231","name":"Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) adopted at PRAC meeting 3-6 May 2021","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T16:33:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"EMA/PRAC/227875/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-janssen-ad26cov2-s-recombinant-adopted-prac-meeting-3-6-may-2021_en.pdf"},
    {"id":"51301","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 3-6 May 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-05-31T12:25:00Z","last_updated_date":"2021-08-26T17:25:00Z","reference_number":"EMA/PRAC/250778/2021 Corr 2","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-may-2021-prac-meeting_no.pdf"}},
    {"id":"51544","name":"New product information wording: extracts from PRAC recommendations on signals - Part 1 - adopted at the PRAC meeting of 7-10 June 2021","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T15:10:00Z","last_updated_date":"2021-06-22T15:10:00Z","reference_number":"EMA/PRAC/319262/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-adopted-prac-meeting-7-10-june-2021_no.pdf"}},
    {"id":"51783","name":"New product information wording: extracts from PRAC recommendations on signals - Part 2 - adopted at the PRAC meeting of 7-10 June 2021","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-07-05T14:09:00Z","last_updated_date":"2021-07-05T14:09:00Z","reference_number":"EMA/PRAC/333370/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-prac-meeting-7-10-june-2021_no.pdf"}},
    {"id":"51784","name":"PRAC recommendations on signals adopted at the 7-10 June 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-07-05T14:16:00Z","last_updated_date":"2021-07-05T14:16:00Z","reference_number":"EMA/PRAC/319259/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-june-2021-prac-meeting_en.pdf"},
    {"id":"52171","name":"PRAC recommendations on signals adopted at the 5-8 July 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-08-02T17:22:00Z","last_updated_date":"2021-08-02T17:22:00Z","reference_number":"EMA/PRAC/380226/2021 Corr. 3","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_en.pdf"},
    {"id":"52175","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 5-8 July 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-08-02T17:26:00Z","last_updated_date":"2021-10-26T10:10:00Z","reference_number":"EMA/PRAC/380228/2021 Corr. 2","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-july-2021-prac-meeting_no.pdf"}},
    {"id":"52499","name":"Updated signal assessment report on myocarditis, pericarditis with Tozinameran (COVID-19 mRNA vaccine (nucleoside-modified) – Comirnaty)","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T14:00:00Z","last_updated_date":"2021-09-17T14:00:00Z","reference_number":"EMA/PRAC/325882/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/updated-signal-assessment-report-myocarditis-pericarditis-tozinameran-covid-19-mrna-vaccine-nucleoside-modified-comirnaty_en.pdf"},
    {"id":"52500","name":"Signal assessment report on myocarditis and pericarditis with Spikevax (previously COVID-19 Vaccine Moderna)","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T14:00:00Z","last_updated_date":"2021-09-17T14:00:00Z","reference_number":"EMA/PRAC/326194/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-myocarditis-and-pericarditis-spikevax-previously-covid-19-vaccine-moderna_en.pdf"},
    {"id":"52567","name":"PRAC recommendations on signals adopted at the 30 August - 2 September 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T10:30:00Z","last_updated_date":"2021-09-27T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-30-august-2-september-2021-prac-meeting_en.pdf"},
    {"id":"52635","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 30 August - 2 September 2021 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-09-27T10:30:00Z","last_updated_date":"2021-09-27T10:30:00Z","reference_number":"EMA/PRAC/468916/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-30-august-2-september-2021-prac_no.pdf"}},
    {"id":"52730","name":"PRAC recommendations on signals adopted at the 27-30 September 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-10-26T10:10:00Z","last_updated_date":"2021-10-26T10:10:00Z","reference_number":"EMA/PRAC/540066/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-27-30-september-2021-prac-meeting_en.pdf"},
    {"id":"52778","name":"New product information wording – Extracts from PRAC recommendations on signals – Part 1 – Vaxzevria - adopted at the PRAC meeting of 27-30 September 2021","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T09:42:00Z","last_updated_date":"2021-10-08T09:42:00Z","reference_number":"EMA/PRAC/540071/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-1-vaxzevria-adopted-prac-meeting-27-30-september-2021_no.pdf"}},
    {"id":"52899","name":"New product information wording: extracts from PRAC recommendations on signals - Part 2 - adopted at the 27-30 September 2021 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-10-26T10:10:00Z","last_updated_date":"2021-10-26T10:10:00Z","reference_number":"EMA/PRAC/548106/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-part-2-adopted-27-30-september-2021-prac_no.pdf"}},
    {"id":"53044","name":"PRAC recommendations on signals adopted at the 25-28 October 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-11-22T08:52:00Z","last_updated_date":"2021-12-10T17:33:00Z","reference_number":"EMA/PRAC/605613/2021 1 Corr2","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_en.pdf"},
    {"id":"53192","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 25-28 October 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2021-11-22T08:51:00Z","last_updated_date":"2021-11-22T08:51:00Z","reference_number":"EMA/PRAC/605615/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-october-2021-prac-meeting_no.pdf"}},
    {"id":"53398","name":"PRAC recommendations on signals adopted at the 29 November-2 December 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-01-06T09:05:00Z","last_updated_date":"2022-01-06T09:05:00Z","reference_number":"EMA/PRAC/683817/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_en.pdf"},
    {"id":"53644","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 29 November - 2 December 2021 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-01-06T09:09:00Z","last_updated_date":"2022-01-06T09:09:00Z","reference_number":"EMA/PRAC/683818/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-november-2-december-2021-prac-meeting_no.pdf"}},
    {"id":"53834","name":"PRAC recommendations on signals adopted at the 10-13 January 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-02-07T09:24:00Z","last_updated_date":"2022-02-07T09:24:00Z","reference_number":"EMA/PRAC/13254/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-10-13-january-2022-prac-meeting_en.pdf"},
    {"id":"53835","name":"Signal assessment report on myocarditis, pericarditis with Tozinameran (COVID-19 mRNA vaccine (nucleosidemodified) – Comirnaty)","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-01-19T14:40:00Z","last_updated_date":"2022-01-19T14:40:00Z","reference_number":"EMA/PRAC/575791/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-myocarditis-pericarditis-tozinameran-covid-19-mrna-vaccine-nucleosidemodified-comirnaty_en.pdf"},
    {"id":"53836","name":"Signal assessment report on myocarditis and pericarditis with Spikevax  (previously COVID-19 Vaccine Moderna) - COVID-19 mRNA vaccine (nucleosidemodified)","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-01-19T14:45:00Z","last_updated_date":"2022-01-19T14:45:00Z","reference_number":"EMA/PRAC/759618/2021","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-myocarditis-and-pericarditis-spikevax-previously-covid-19-vaccine-moderna-covid-19-mrna-vaccine-nucleosidemodified_en.pdf"},
    {"id":"54091","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 10-13 January 2022 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-02-07T09:25:00Z","last_updated_date":"2022-02-07T09:25:00Z","reference_number":"EMA/PRAC/13256/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-january-2022-prac_no.pdf"}},
    {"id":"54240","name":"PRAC recommendations on signals adopted at the 7-10 February 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-03-07T14:02:00Z","last_updated_date":"2022-03-07T14:02:00Z","reference_number":"EMA/PRAC/75386/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-february-2022-prac-meeting_en.pdf"},
    {"id":"54363","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 7-10 February 2022 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-03-07T14:03:00Z","last_updated_date":"2022-03-07T14:03:00Z","reference_number":"EMA/PRAC/75387/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-february-2022-prac_no.pdf"}},
    {"id":"54511","name":"PRAC recommendations on signals adopted at the 7-10 March 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-04-04T09:43:00Z","last_updated_date":"2022-04-04T09:43:00Z","reference_number":"EMA/PRAC/139810/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-march-2022-prac-meeting_en.pdf"},
    {"id":"54651","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 7-10 March 2022 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-04-04T09:43:00Z","last_updated_date":"2022-07-18T09:55:00Z","reference_number":"EMA/PRAC/139811/2022 Corr.","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-march-2022-prac_no.pdf"}},
    {"id":"54871","name":"PRAC recommendations on signals adopted at the 4-7 April 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-05-02T13:08:00Z","last_updated_date":"2022-05-02T13:08:00Z","reference_number":"EMA/PRAC/201501/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-4-7-april-2022-prac-meeting_en.pdf"},
    {"id":"55107","name":"PRAC recommendations on signals adopted at the 2-5 May 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-05-30T11:08:00Z","last_updated_date":"2022-05-30T11:08:00Z","reference_number":"EMA/PRAC/242991/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-2-5-may-2022-prac-meeting_en.pdf"},
    {"id":"55449","name":"PRAC recommendations on signals adopted at the 7-10 June 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-07-04T12:26:00Z","last_updated_date":"2022-07-04T12:26:00Z","reference_number":"EMA/PRAC/407574/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-june-2022-prac-meeting_en.pdf"},
    {"id":"55740","name":"PRAC recommendations on signals adopted at the 4-7 July 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-08-01T10:41:00Z","last_updated_date":"2022-08-01T10:41:00Z","reference_number":"EMA/PRAC/610990/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-4-7-july-2022-prac-meeting_en.pdf"},
    {"id":"56186","name":"PRAC recommendations on signals adopted at the 29 August - 1 September 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-09-26T15:28:00Z","last_updated_date":"2022-09-26T15:28:00Z","reference_number":"EMA/PRAC/699721/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-29-august-1-september-2022-prac-meeting_en.pdf"},
    {"id":"56187","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 29 August - 1 September 2022 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-09-26T15:35:00Z","last_updated_date":"2022-09-26T15:35:00Z","reference_number":"EMA/PRAC/699722/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-29-august-1-september-2022-prac_no.pdf"}},
    {"id":"56297","name":"PRAC recommendations on signals adopted at the 26-29 September 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-10-24T14:15:00Z","last_updated_date":"2022-10-24T14:15:00Z","reference_number":"EMA/PRAC/781568/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_en.pdf"},
    {"id":"56459","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 September 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-10-24T14:15:00Z","last_updated_date":"2022-10-24T14:15:00Z","reference_number":"EMA/PRAC/781569/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-september-2022-prac-meeting_no.pdf"}},
    {"id":"56519","name":"PRAC recommendations on signals adopted at the 24-27 October 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-11-21T12:11:00Z","last_updated_date":"2022-11-21T12:11:00Z","reference_number":"EMA/PRAC/845793/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_en.pdf"},
    {"id":"56722","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 24-27 October 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2022-11-21T12:13:00Z","last_updated_date":"2022-12-07T11:54:00Z","reference_number":"EMA/PRAC/845794/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-24-27-october-2022-prac-meeting_no.pdf"}},
    {"id":"57161","name":"PRAC recommendations on signals adopted at the 28 November - 1 December 2022 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-01-05T10:25:00Z","last_updated_date":"2023-01-05T10:25:00Z","reference_number":"EMA/PRAC/900558/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-28-november-1-december-2022-prac-meeting_en.pdf"},
    {"id":"57419","name":"PRAC recommendations on signals adopted at the 9-12 January 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-02-06T09:34:00Z","last_updated_date":"2023-06-23T15:13:00Z","reference_number":"EMA/PRAC/4770/2023 ","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_en.pdf"},
    {"id":"57518","name":"Signal assessment report on heavy menstrual bleeding with tozinameran / Comirnaty (COVID-19 mRNA vaccine)","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-02-03T15:12:00Z","last_updated_date":"2023-02-03T15:12:00Z","reference_number":"EMA/PRAC/897622/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-heavy-menstrual-bleeding-tozinameran-comirnaty-covid-19-mrna-vaccine_en.pdf"},
    {"id":"57519","name":"Signal assessment on heavy menstrual bleeding with COVID-19 mRNA vaccine (Spikevax)","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-02-03T15:16:00Z","last_updated_date":"2023-02-03T15:16:00Z","reference_number":"EMA/PRAC/897385/2022","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-heavy-menstrual-bleeding-covid-19-mrna-vaccine-spikevax_en.pdf"},
    {"id":"57521","name":"New product information wording : extracts from PRAC recommendations on signals adopted at the 9-12 January 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-02-06T09:54:00Z","last_updated_date":"2023-02-06T09:54:00Z","reference_number":"EMA/PRAC/4771/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-january-2023-prac-meeting_no.pdf"}},
    {"id":"57676","name":"PRAC recommendations on signals adopted at the 6-9 February 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-03-06T10:25:00Z","last_updated_date":"2023-03-06T10:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_en.pdf"},
    {"id":"57883","name":"New product information wording : extracts from PRAC recommendations on signals adopted at the 6-9 February 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-03-06T10:25:00Z","last_updated_date":"2023-03-06T10:25:00Z","reference_number":"EMA/PRAC/74665/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-6-9-february-2023-prac-meeting_no.pdf"}},
    {"id":"58083","name":"PRAC recommendations on signals adopted at the 13-16 March 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-04-11T16:44:00Z","last_updated_date":"2023-04-11T16:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-13-16-march-2023-prac-meeting_en.pdf"},
    {"id":"58304","name":"New product information wording : extracts from PRAC recommendations on signals adopted at the 13-16 March 2023 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-04-11T09:09:00Z","last_updated_date":"2023-04-11T09:09:00Z","reference_number":"EMA/PRAC/103894/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-march-2023-prac_no.pdf"}},
    {"id":"58592","name":"PRAC recommendations on signals adopted at the 11-14 April 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-05-08T14:43:00Z","last_updated_date":"2023-05-08T14:43:00Z","reference_number":"EMA/PRAC/164741/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-11-14-april-2023-prac-meeting_en.pdf"},
    {"id":"58711","name":"PRAC recommendations on signals adopted at the 10-12 May 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-06-05T09:17:00Z","last_updated_date":"2023-06-05T09:17:00Z","reference_number":"EMA/PRAC/207872/2023 ","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_en.pdf"},
    {"id":"58864","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 10-12 May 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-06-05T09:21:00Z","last_updated_date":"2023-06-05T09:21:00Z","reference_number":"EMA/PRAC/207873/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-12-may-2023-prac-meeting_no.pdf"}},
    {"id":"59185","name":"PRAC recommendations on signals adopted at the 5-8 June 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-07-03T11:42:00Z","last_updated_date":"2023-07-03T11:42:00Z","reference_number":"EMA/PRAC/248309/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_en.pdf"},
    {"id":"59187","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 5-8 June 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-07-03T11:44:00Z","last_updated_date":"2023-07-03T11:44:00Z","reference_number":"EMA/PRAC/248310/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-june-2023-prac-meeting_no.pdf"}},
    {"id":"59317","name":"PRAC recommendations on signals adopted at the 3-6 July 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-07-31T10:15:00Z","last_updated_date":"2023-07-31T10:15:00Z","reference_number":"EMA/PRAC/294541/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_en.pdf"},
    {"id":"59520","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 3-6 July 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-07-31T10:46:00Z","last_updated_date":"2023-07-31T10:46:00Z","reference_number":"EMA/PRAC/294581/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_no.pdf"}},
    {"id":"59934","name":"PRAC recommendations on signals adopted at the 28-31 August 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-09-25T10:15:00Z","last_updated_date":"2023-09-25T10:15:00Z","reference_number":"EMA/PRAC/359902/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_en.pdf"},
    {"id":"60123","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 28-31 August 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-09-25T09:41:00Z","last_updated_date":"2023-09-25T09:41:00Z","reference_number":"EMA/PRAC/359903/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-august-2023-prac-meeting_no.pdf"}},
    {"id":"60462","name":"New product information wording – Extracts from PRAC recommendations on signals Adopted at the 25-28 September 2023 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2023-10-23T09:29:00Z","last_updated_date":"2023-10-23T09:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_en.pdf"},
    {"id":"60463","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 25-28 September 2023 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2023-10-23T10:50:00Z","last_updated_date":"2023-10-23T10:50:00Z","reference_number":"EMA/PRAC/416581/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_no.pdf"}},
    {"id":"60769","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 25-28 September 2023 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-10-23T09:18:00Z","last_updated_date":"2023-10-23T09:18:00Z","reference_number":"EMA/PRAC/416581/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_en.pdf-1","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_sv.pdf-0","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_is.pdf-0","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-september-2023-prac_no.pdf-0"}},
    {"id":"60874","name":"PRAC recommendations on signals adopted at the 23-26 October 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T18:15:00Z","last_updated_date":"2023-11-10T18:15:00Z","reference_number":"EMA/PRAC/477436/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-23-26-october-2023-prac-meeting_en.pdf"},
    {"id":"60988","name":"PRAC recommendations on signals adopted at the 23-26 October 2023 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2023-11-20T13:38:01Z","last_updated_date":"2023-11-20T13:38:01Z","reference_number":"EMA/PRAC/477436/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-23-26-october-2023-prac_en.pdf"},
    {"id":"60989","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 23-26 October PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2023-11-20T13:42:36Z","last_updated_date":"2025-12-16T09:35:12Z","reference_number":"EMA/PRAC/477437/2023","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-23-26-october-prac_no.pdf"}},
    {"id":"61423","name":"PRAC recommendations on signals adopted at the 27-30 November 2023 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2024-01-05T15:44:22Z","last_updated_date":"2024-01-19T14:47:00Z","reference_number":"EMA/PRAC/539397/2023 Corr ","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-27-30-november-2023-prac-meeting_en.pdf"},
    {"id":"61643","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 27-30 November 2023 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T15:12:46Z","last_updated_date":"2025-12-16T09:45:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-2023-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-2023-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-november-prac_no.pdf"}},
    {"id":"62004","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 8-11 January 2024 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2024-02-05T16:13:47Z","last_updated_date":"2025-12-16T09:45:12Z","reference_number":"EMA/PRAC/2749/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-january-2024-prac_no.pdf"}},
    {"id":"62773","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 4-7 March 2024 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2024-04-02T11:15:27Z","last_updated_date":"2025-12-16T09:48:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-march-2024-prac_no.pdf"}},
    {"id":"63167","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 8-11 April 2024 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2024-05-06T10:34:12Z","last_updated_date":"2024-05-06T10:34:12Z","reference_number":"EMA/PRAC/147680/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2024-prac_no.pdf"}},
    {"id":"63544","name":"PRAC recommendations on signals adopted at the 13-16 May 2024 PRAC meeting","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2024-06-10T10:36:00Z","last_updated_date":"2024-06-10T10:36:00Z","reference_number":"EMA/PRAC/222449/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-13-16-may-2024-prac-meeting_en.pdf"},
    {"id":"63545","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 13-16 May 2024 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2024-06-10T10:40:00Z","last_updated_date":"2024-06-10T10:40:00Z","reference_number":"EMA/PRAC/222450/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2024-prac_no.pdf"}},
    {"id":"63942","name":"PRAC recommendations on signals adopted at the 10-13 June 2024 PRAC meeting","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2024-07-08T10:40:00Z","last_updated_date":"2024-07-08T10:40:00Z","reference_number":"EMA/PRAC/260033/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-10-13-june-2024-prac-meeting_en.pdf"},
    {"id":"63944","name":"\tNew product information wording – Extracts from PRAC recommendations on signals adopted at the 10-13 June 2024 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2024-07-08T13:30:00Z","last_updated_date":"2024-07-08T13:30:00Z","reference_number":"EMA/PRAC/260034/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-june-2024-prac_no.pdf"}},
    {"id":"64552","name":"PRAC recommendations on signals adopted at the 8-11 July 2024 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2024-08-12T11:27:36Z","last_updated_date":"2024-08-12T11:27:36Z","reference_number":"EMA/PRAC/312286/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-8-11-july-2024-prac-meeting_en.pdf"},
    {"id":"64553","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 8-11 July 2024 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2024-08-12T11:31:46Z","last_updated_date":"2024-08-12T11:31:46Z","reference_number":"EMA/PRAC/312288/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_no.pdf"}},
    {"id":"64554","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 8-11 July 2024 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2024-08-12T11:50:00Z","last_updated_date":"2024-08-12T11:51:03Z","reference_number":"EMA/PRAC/312288/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-july-2024-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-12-july-2024-prac_no.pdf"}},
    {"id":"65054","name":"PRAC recommendations on signals adopted at the 2-5 September 2024 PRAC meeting","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2024-09-30T10:34:00Z","last_updated_date":"2024-09-30T10:34:00Z","reference_number":"EMA/PRAC/373353/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-2-5-september-2024-prac-meeting_en.pdf"},
    {"id":"65055","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 2-5 September 2024 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2024-09-30T10:37:00Z","last_updated_date":"2024-09-30T10:37:00Z","reference_number":"EMA/PRAC/373355/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-september-2024-prac_no.pdf"}},
    {"id":"65451","name":"PRAC recommendations on signals adopted at the 30 September - 3 October 2024 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2024-10-28T09:30:00Z","last_updated_date":"2024-10-28T09:30:00Z","reference_number":"EMA/PRAC/449363/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-30-september-3-october-2024-prac-meeting_en.pdf"}    {"id":"65778","name":"PRAC recommendations on signals adopted at the 28-31 October 2024 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2024-11-25T10:20:36Z","last_updated_date":"2024-11-25T10:20:36Z","reference_number":"EMA/PRAC/499603/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-28-31-october-2024-prac-meeting_en.pdf"},
    {"id":"65780","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 28-31 October 2024 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2024-11-25T10:25:44Z","last_updated_date":"2026-02-26T12:15:00Z","reference_number":"EMA/PRAC/499604/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-28-31-october-2024-prac_no.pdf"}},
    {"id":"66261","name":"PRAC recommendations on signals adopted at the 25-28 November 2024 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-01-07T15:59:19Z","last_updated_date":"2025-01-07T15:59:19Z","reference_number":"EMA/PRAC/537837/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-25-28-november-2024-prac-meeting_en.pdf"},
    {"id":"66262","name":"New product information wording – Extracts from PRAC recommendations on signals adopted at the 25-28 November 2024 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2025-01-07T16:18:13Z","last_updated_date":"2025-01-07T16:18:13Z","reference_number":"EMA/PRAC/537838/2024","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-25-28-november-2024-prac_no.pdf"}},
    {"id":"66647","name":"PRAC recommendations on signals Adopted at the 13-16 January 2025 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-02-10T13:40:00Z","last_updated_date":"2025-02-10T13:40:00Z","reference_number":"EMA/PRAC/6377/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-13-16-january-2025-prac-meeting_en.pdf"},
    {"id":"66648","name":"New product information wording – Extracts from PRAC recommendations on signals Adopted at the 13-16 January 2025 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T13:45:00Z","last_updated_date":"2025-02-10T13:45:00Z","reference_number":"EMA/PRAC/6379/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-january-2025-prac_no.pdf"}},
    {"id":"67295","name":"PRAC recommendations on signals adopted at the 10-13 February 2025 meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-03-17T09:22:43Z","last_updated_date":"2025-03-17T09:22:43Z","reference_number":"EMA/PRAC/43844/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-10-13-february-2025-meeting_en.pdf"},
    {"id":"67298","name":"New product information wording – Extracts from PRAC recommendations on signals Adopted at the 10-13 February 2025 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2025-03-17T10:55:57Z","last_updated_date":"2025-03-17T10:55:57Z","reference_number":"EMA/PRAC/43845/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-february-2025-prac_no.pdf"}},
    {"id":"67667","name":"PRAC recommendations on signals adopted at the 10-13 March 2025 meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-04-07T15:41:11Z","last_updated_date":"2025-04-07T15:41:11Z","reference_number":"EMA/PRAC/78750/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-10-13-march-2025-meeting_en.pdf"},
    {"id":"67668","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 10-13 March 2025 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-04-07T15:58:10Z","last_updated_date":"2025-04-07T15:58:10Z","reference_number":"EMA/PRAC/78751/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-2025-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-10-13-march-prac_no.pdf"}},
    {"id":"68083","name":"PRAC recommendations on signals adopted at the 7-10 April 2025 meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-05-05T13:55:08Z","last_updated_date":"2025-05-05T13:55:08Z","reference_number":"EMA/PRAC/111860/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-april-2025-meeting_en.pdf"},
    {"id":"68084","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 7-10 April 2025 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-05-05T13:57:08Z","last_updated_date":"2025-06-19T10:53:00Z","reference_number":"EMA/PRAC/111861/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2025-prac_no.pdf"}},
    {"id":"68516","name":"PRAC recommendations on signals adopted at the 5-8 May 2025 meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-06-02T10:52:16Z","last_updated_date":"2025-06-02T10:52:16Z","reference_number":"EMA/PRAC/143099/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-5-8-may-2025-meeting_en.pdf"},
    {"id":"68517","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 5-8 May 2025 PRAC","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2025-06-02T10:54:36Z","last_updated_date":"2025-06-02T10:54:36Z","reference_number":"EMA/PRAC/143100/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-5-8-may-2025-prac_no.pdf"}},
    {"id":"69028","name":"PRAC recommendations on signals adopted at the 2-5 June 2025 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T09:47:28Z","last_updated_date":"2025-06-30T09:47:28Z","reference_number":"EMA/PRAC/179172/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-2-5-june-2025-prac-meeting_en.pdf"},
    {"id":"69029","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 2-5 June 2025 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T09:49:05Z","last_updated_date":"2025-06-30T09:49:05Z","reference_number":"EMA/PRAC/179173/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-2-5-june-2025-prac_no.pdf"}},
    {"id":"69792","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 7-10 July 2025 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-08-20T14:25:46Z","last_updated_date":"2026-01-22T11:11:01Z","reference_number":"EMA/PRAC/224803/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-july-2025-prac_no.pdf"}},
    {"id":"69794","name":"PRAC recommendations on signals adopted at the 7-10 July 2025 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-08-20T14:28:29Z","last_updated_date":"2025-08-20T14:28:29Z","reference_number":"EMA/PRAC/224799/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-july-2025-prac-meeting_en.pdf"},
    {"id":"70314","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 1-4 September 2025 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-09-29T13:39:36Z","last_updated_date":"2025-09-29T13:39:36Z","reference_number":"EMA/PRAC/271799/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-1-4-september-2025-prac_no.pdf"}},
    {"id":"70315","name":"PRAC recommendations on signals adopted at the 1-4 September 2025 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-09-29T13:42:44Z","last_updated_date":"2025-09-29T13:42:44Z","reference_number":"EMA/PRAC/271798/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-1-4-september-2025-prac-meeting_en.pdf"},
    {"id":"70826","name":"PRAC recommendations on signals adopted at the 29 September - 2 October 2025 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-10-27T08:18:41Z","last_updated_date":"2025-10-27T08:18:41Z","reference_number":"EMA/PRAC/303684/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-29-september-2-october-2025-prac-meeting_en.pdf"},
    {"id":"71299","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 27-30 October 2025 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-11-24T09:22:35Z","last_updated_date":"2026-01-20T11:11:11Z","reference_number":"EMA/PRAC/323708/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-27-30-october-2025-prac_no.pdf"}},
    {"id":"71300","name":"PRAC recommendations on signals adopted at the 27-30 October 2025 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2025-11-24T09:24:37Z","last_updated_date":"2025-11-24T09:24:37Z","reference_number":"EMA/PRAC/323705/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-27-30-october-2025-prac-meeting_en.pdf"},
    {"id":"71927","name":"PRAC recommendations on signals adopted at the 24-27 November 2025 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2026-01-06T09:49:37Z","last_updated_date":"2026-01-06T09:49:37Z","reference_number":"EMA/PRAC/366013/2025","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-24-27-november-2025-prac-meeting_en.pdf"},
    {"id":"72454","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2026-02-09T14:25:56Z","last_updated_date":"2026-06-01T11:11:01Z","reference_number":"EMA/PRAC/1401/2026","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_no.pdf"}},
    {"id":"72455","name":"PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2026-02-09T14:28:36Z","last_updated_date":"2026-02-09T14:28:36Z","reference_number":"EMA/PRAC/1387/2026","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-12-15-january-2026-prac-meeting_en.pdf"},
    {"id":"72902","name":"PRAC recommendations on signals adopted at the 9-12 February 2026 PRAC meeting","type":"prac-recommendation","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T14:45:00Z","last_updated_date":"2026-03-09T14:45:00Z","reference_number":"EMA/PRAC/27091/2026","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-9-12-february-2026-prac-meeting_en.pdf"},
    {"id":"73312","name":"PRAC recommendations on signals adopted at the 9-12 March 2026 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2026-04-07T10:09:36Z","last_updated_date":"2026-04-07T10:09:36Z","reference_number":"EMA/PRAC/44423/2026","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-9-12-march-2026-prac-meeting_en.pdf"},
    {"id":"73313","name":"New product information wording - Extracts from PRAC recommendations on signals adopted at the 9-12 March 2026 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2026-04-07T10:10:49Z","last_updated_date":"2026-04-07T10:10:49Z","reference_number":"EMA/PRAC/44424/2026","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-9-12-march-2026-prac_no.pdf"}},
    {"id":"73602","name":"PRAC recommendations on signals adopted at the 7-10 April 2026 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2026-05-04T08:54:53Z","last_updated_date":"2026-05-04T08:54:53Z","reference_number":"EMA/PRAC/74504/2026","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-april-2026-prac-meeting_en.pdf"},
    {"id":"73603","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 7-10 April 2026 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2026-05-04T08:57:34Z","last_updated_date":"2026-05-04T08:57:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-7-10-april-2026-prac_no.pdf"}},
    {"id":"74178","name":"PRAC recommendations on signals adopted at the 4-7 May 2026 PRAC meeting","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2026-06-22T16:07:10Z","last_updated_date":"2026-06-22T16:07:10Z","reference_number":"EMA/PRAC/98634/2026","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-4-7-may-2026-prac-meeting_en.pdf"},
    {"id":"74179","name":"New product information wording: extracts from PRAC recommendations on signals adopted at the 4-7 May 2026 PRAC","type":"prac-recommendation","status":"Adopted","consultation_date":"","first_published_date":"2026-06-22T16:18:24Z","last_updated_date":"2026-06-22T16:18:24Z","reference_number":"EMA/PRAC/114645/2026","document_url":"https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_sv.pdf","is":"https://www.ema.europa.eu/is/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_is.pdf","no":"https://www.ema.europa.eu/no/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-4-7-may-2026-prac_no.pdf"}},
    {"id":"2396","name":"Presentation - Applications of pharmacogenomics in pharmacokinetics at the European Medicines Agency: Experience and expectations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-applications-pharmacogenomics-pharmacokinetics-european-medicines-agency-experience-and-expectations_en.pdf"},
    {"id":"2411","name":"Neuroimaging in trials in AD - Nick Fox","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-11T00:09:21Z","last_updated_date":"2008-02-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/neuroimaging-trials-ad-nick-fox_en.pdf"},
    {"id":"2416","name":"The Regulation on advanced therapies - Nicolas Rossignol","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/regulation-advanced-therapies-nicolas-rossignol_en.pdf"},
    {"id":"2417","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Fernand Sauer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-fernand-sauer_en.pdf"},
    {"id":"2430","name":"Presentation - Case 4: Integrating pharmacogenomics early into drug development: Pharmacokinetics as a working example","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-4-integrating-pharmacogenomics-early-drug-development-pharmacokinetics-working-example_en.pdf"},
    {"id":"2435","name":"Presentation - Liposomal nanomedicines and innovative formulations, Daan Crommelin, Utrecht University","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-liposomal-nanomedicines-and-innovative-formulations-daan-crommelin-utrecht-university_en.pdf"},
    {"id":"2456","name":"Presentation - ICH and EU regulatory framework and the role of the European Medicines Agency (EMA), Falk Ehmann, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T00:00:00Z","last_updated_date":"2011-06-23T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-and-eu-regulatory-framework-and-role-european-medicines-agency-ema-falk-ehmann-ema_en.pdf"},
    {"id":"2464","name":"Reflection paper on the use of fluoroquinolones in food producing animals - Cristina Muà±oz Madero","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/reflection-paper-use-fluoroquinolones-food-producing-animals-cristina-mua-oz-madero_en.pdf"},
    {"id":"2470","name":"Elements of Design of FIM Clinical Trials - Ian Hudson","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/elements-design-fim-clinical-trials-ian-hudson_en.pdf"},
    {"id":"2473","name":"Immune-response and adverse reactions: PRCA case example - Nicole Casadevall","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-09-04T02:09:21Z","last_updated_date":"2007-09-04T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/immune-response-and-adverse-reactions-prca-case-example-nicole-casadevall_en.pdf"},
    {"id":"2482","name":"Next steps & closing remarks - Fergus Sweeney, Mike James","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/next-steps-closing-remarks-fergus-sweeney-mike-james_en.pdf"},
    {"id":"2493","name":"Presentation - Current network structure for pediatrics (Ronald Portman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T14:00:00Z","last_updated_date":"2013-07-22T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-network-structure-pediatrics-ronald-portman_en.pdf"},
    {"id":"2541","name":"Presentation - Section 4.1: Therapeutic indications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-41-therapeutic-indications_en.pdf"},
    {"id":"2554","name":"EU GMP requirements - Sterile medicinal product - Martin Melzer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-20T02:09:21Z","last_updated_date":"2009-10-20T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-gmp-requirements-sterile-medicinal-product-martin-melzer_en.pdf"},
    {"id":"2565","name":"Presentation - PCWP and HCPWP work plans for 2014 (Ivana Silva, Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-12-11T01:00:00Z","last_updated_date":"2013-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwp-and-hcpwp-work-plans-2014-ivana-silva-nathalie-bere_en.pdf"},
    {"id":"2567","name":"Dealing with Quality Defects and Rapid Alerts - David Cockburn","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-20T02:09:21Z","last_updated_date":"2009-10-20T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/dealing-quality-defects-and-rapid-alerts-david-cockburn_en.pdf"},
    {"id":"2602","name":"Presentation – Cystic fibrosis workshop - Pre-work package","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T00:00:00Z","last_updated_date":"2017-10-13T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cystic-fibrosis-workshop-pre-work-package_en.pdf"},
    {"id":"2607","name":"Presentation - Highlights of 2017 (M. Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T15:44:00Z","last_updated_date":"2017-12-11T15:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-highlights-2017-m-mavris_en.pdf"},
    {"id":"2618","name":"Presentation - Status quo of ERNs and clinical research: results of the ERN-wide survey","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T14:02:00Z","last_updated_date":"2018-06-18T14:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-status-quo-erns-and-clinical-research-results-ern-wide-survey_en.pdf"},
    {"id":"2642","name":"Presentation - 4.2 Evidence and decisions (Carl-Fredrik Burman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-42-evidence-and-decisions-carl-fredrik-burman_en.pdf"},
    {"id":"2643","name":"Presentation - Long-term PHARMacovigilance for adverse effects in childhood arthritis focusing on Immune modulatory drugs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-22T01:00:00Z","last_updated_date":"2011-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-long-term-pharmacovigilance-adverse-effects-childhood-arthritis-focusing-immune-modulatory-drugs_en.pdf"},
    {"id":"2647","name":"Presentation - Current Issues in Biosimilar Regulatory Submission in US (S-C. Chow, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-issues-biosimilar-regulatory-submission-us-s-c-chow-fda_en.pdf"},
    {"id":"2651","name":"Case Study: Ad2/HIF-1a/VP16: Experience with Viral Shedding & Circulation Testing - Ingrid Boltje","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/case-study-ad2hif-1avp16-experience-viral-shedding-circulation-testing-ingrid-boltje_en.pdf"},
    {"id":"2654","name":"Presentation - Revised immunogenicity guideline: assays and methods- presentation of the draft guideline and introduction of the topics for discussion (Robin Thorpe, Meenu Wadhwa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revised-immunogenicity-guideline-assays-and-methods-presentation-draft-guideline-and-introduction-topics-discussion-robin-thorpe-meenu-wadhwa_en.pdf"},
    {"id":"2659","name":"Presentation - Outcomes of recent European Medicines Agency-Committee for Medicinal Products for Human Use (CHMP) benefit-risk project-EPAR (Francesco Pignatti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcomes-recent-european-medicines-agency-committee-medicinal-products-human-use-chmp-benefit-risk-project-epar-francesco-pignatti_en.pdf"},
    {"id":"2679","name":"Presentation - Introduction and objectives of the medication-errors workshop (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-and-objectives-medication-errors-workshop-peter-arlett_en.pdf"},
    {"id":"2681","name":"Presentation - Change management protocols","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-change-management-protocols_en.pdf"},
    {"id":"2690","name":"Presentation - How are patients involved in SAGs? (Francesco Pignatti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-are-patients-involved-sags-francesco-pignatti_en.pdf"},
    {"id":"2691","name":"Presentation - Day 1: Dry AMD – industry view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-dry-amd-industry-view_en.pdf"},
    {"id":"2700","name":"Presentation - Polymer conjugates, Ruth Duncan, Cardiff University","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-polymer-conjugates-ruth-duncan-cardiff-university_en.pdf"},
    {"id":"2701","name":"Presentation - Enpr-EMA Working Groups","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-working-groups_en.pdf"},
    {"id":"2707","name":"Presentation - Agenda item 6: Falsified Medicines Directive and European Medicines verification system update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-15T15:00:00Z","last_updated_date":"2016-03-15T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-6-falsified-medicines-directive-and-european-medicines-verification-system-update_en.pdf"},
    {"id":"2709","name":"Presentation - Pharmacogenomic data submission to biomarker scientific advice: Task: What does the team do next?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenomic-data-submission-biomarker-scientific-advice-task-what-does-team-do-next_en.pdf"},
    {"id":"2714","name":"Presentation: Good pharmacovigilance practice module VII – Periodic safety update report","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practice-module-vii-periodic-safety-update-report_en.pdf"},
    {"id":"2723","name":"Presentation - Regulatory Optimisation Group update (Joris Kampmeijer, MEB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-optimisation-group-update-joris-kampmeijer-meb_en.pdf"},
    {"id":"2728","name":"Presentation - July 2012 – September 2013: do patients see an impact of the new pharmacovigilance measures? (Franà§ois Houà¿ez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-july-2012-september-2013-do-patients-see-impact-new-pharmacovigilance-measures-franassois-houaez_en.pdf"},
    {"id":"2735","name":"Presentation - EMA/FDA/Health Canada workshop on paediatric pulmonary arterial hypertension: Hemodynamic Endpoints (C.Garnett, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emafdahealth-canada-workshop-paediatric-pulmonary-arterial-hypertension-hemodynamic-endpoints-cgarnett-fda_en.pdf"},
    {"id":"2742","name":"Presentation - Assessment of current shortcomings in the summary of product characteristics (SmPC) and the package leaflet (PIL) (Martin Dorazil)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-assessment-current-shortcomings-summary-product-characteristics-smpc-and-package-leaflet-pil-martin-dorazil_en.pdf"},
    {"id":"2744","name":"Presentation - Phase 2b dose selection, leveraging comparator data through multidisciplinary modelling and simulation - Break-out session 1 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:45:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-phase-2b-dose-selection-leveraging-comparator-data-through-multidisciplinary-modelling-and-simulation-break-out-session-1-theme-3_en.pdf"},
    {"id":"2752","name":"Presentation - Clinical outcome measures - an industry perspective (Veronika Logovinsky)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-outcome-measures-industry-perspective-veronika-logovinsky_en.pdf"},
    {"id":"2755","name":"Presentation - Excipients: Safe or not safe?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-excipients-safe-or-not-safe_en.pdf"},
    {"id":"2761","name":"Presentation - Better processes to facilitate earlier authorisation (Victoria Palmi, Sabrina Spinosa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-19T02:00:00Z","last_updated_date":"2016-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-better-processes-facilitate-earlier-authorisation-victoria-palmi-sabrina-spinosa_en.pdf"},
    {"id":"2762","name":"Presentation - The outcomes of drug-induced PML, Joseph Berger","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcomes-drug-induced-pml-joseph-berger_en.pdf"},
    {"id":"2772","name":"Presentation - Inter-association task force: prevention of drug shortages based on quality and manufacturing issues","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-inter-association-task-force-prevention-drug-shortages-based-quality-and-manufacturing-issues_en.pdf"},
    {"id":"2779","name":"Presentation - EMA medical literature monitoring (MLM) service (Sabine Brosch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-medical-literature-monitoring-mlm-service-sabine-brosch_en.pdf"},
    {"id":"2784","name":"Presentation - Raise the game (Enrica Alteri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T02:00:00Z","last_updated_date":"2015-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-raise-game-enrica-alteri_en.pdf"},
    {"id":"2817","name":"EMEA FIM Guideline - A Cournot","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-fim-guideline-cournot_en.pdf"},
    {"id":"2842","name":"Presentation - Guidance on the sSubmission of clinical reports intended for publication in accordance with Policy 0070 (Frances Nuttall)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-29T02:00:00Z","last_updated_date":"2015-06-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-ssubmission-clinical-reports-intended-publication-accordance-policy-0070-frances-nuttall_en.pdf"},
    {"id":"2844","name":"Presentation - Clinical trials in the European Union: how European Reference Networks can add value to clinical research (Laura Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-european-union-how-european-reference-networks-can-add-value-clinical-research-laura-pioppo_en.pdf"},
    {"id":"2847","name":"The next 10 years: Focal Points from the Industry: Dr. Erik Tambuyzer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/next-10-years-focal-points-industry-dr-erik-tambuyzer_en.pdf"},
    {"id":"2864","name":"Presentation - Questions and answers on off-label use ( Sabine Brosch and Anja Haren)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-questions-and-answers-label-use-sabine-brosch-and-anja-haren_en.pdf"},
    {"id":"2866","name":"Presentation - EU IDMP/SPOR Task Force meeting: EU Implementation guides - SPOR benefits (4. agenda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-idmpspor-task-force-meeting-eu-implementation-guides-spor-benefits-4-agenda_en.pdf"},
    {"id":"2887","name":"Presentation - Topic 2 - International collaborations in pediatrics: FDA and EMA growing together - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Sandra L. Kweder)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-2-international-collaborations-pediatrics-fda-and-ema-growing-together-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-sandra-l-kweder_en.pdf"},
    {"id":"2890","name":"Presentation - Early paediatric interaction meeting: Initial consultation on paediatric development (Chrissi Pallidis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-early-paediatric-interaction-meeting-initial-consultation-paediatric-development-chrissi-pallidis_en.pdf"},
    {"id":"2917","name":"Presentation - Additional monitoring of medicinal products – update of the implementation (Alexios Skarlatos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-additional-monitoring-medicinal-products-update-implementation-alexios-skarlatos_en.pdf"},
    {"id":"2929","name":"Presentation - Session 3.2: Updates on networks - Nordic network (Kalle Hoppu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-32-updates-networks-nordic-network-kalle-hoppu_en.pdf"},
    {"id":"2931","name":"Presentation - Herbal medicinal products – an area of patient involvement? (Steffen Bager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-herbal-medicinal-products-area-patient-involvement-steffen-bager_en.pdf"},
    {"id":"2975","name":"Presentation: EPCTRI: Paediatrics in 2016. Roadmap of European Strategy Forum for Research Infrastructure (ESFRI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-epctri-paediatrics-2016-roadmap-european-strategy-forum-research-infrastructure-esfri_en.pdf"},
    {"id":"2985","name":"Presentation - Supply shortages of medicines in Europe (Francois Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-12-11T01:00:00Z","last_updated_date":"2013-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supply-shortages-medicines-europe-francois-houyez_en.pdf"},
    {"id":"3000","name":"Presentation - AVC","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-avc_en.pdf"},
    {"id":"3017","name":"Overview of Regulation of Stem Cell-based products by the USA FDA: Dr Kimberly Benton, Division of Cellular and Gene Therapies, Office for Cellular, Tissue and Gene Therapy, CBER, FDA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-regulation-stem-cell-based-products-usa-fda-dr-kimberly-benton-division-cellular-and-gene-therapies-office-cellular-tissue-and-gene-therapy-cber-fda_en.pdf"},
    {"id":"3043","name":"Presentation - Committee for Advanced Therapies (CAT) considerations for minimally manipulated advanced-therapy medicinal products (ATMPs) and the use of RBA for such products (Metoda Lipnik-Š tangelj)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-advanced-therapies-cat-considerations-minimally-manipulated-advanced-therapy-medicinal-products-atmps-and-use-rba-such-products-metoda-lipnik-s-tangelj_en.pdf"},
    {"id":"3058","name":"Presentation - Treatment of chronic hepatitis C virus infection in children and adolescents: Guidance for clinical trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-12T03:00:00Z","last_updated_date":"2011-07-12T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-treatment-chronic-hepatitis-c-virus-infection-children-and-adolescents-guidance-clinical-trials_en.pdf"},
    {"id":"3077","name":"Presentation - Sub population: the elderly - How can modelling and simulation inform understanding of safety and efficacy? (Amy S. Y. Cheung)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sub-population-elderly-how-can-modelling-and-simulation-inform-understanding-safety-and-efficacy-amy-s-y-cheung_en.pdf"},
    {"id":"3092","name":"Presentation - PIP session: Overview of paediatric investigation plans for uveitis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pip-session-overview-paediatric-investigation-plans-uveitis_en.pdf"},
    {"id":"3102","name":"Presentation - 10th anniversary of European Medicines Agency’s Patients' and Consumers' Working Party (PCWP): Patients and Consumers: a 360o view (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-10th-anniversary-european-medicines-agencys-patients-and-consumers-working-party-pcwp-patients-and-consumers-360o-view-nathalie-bere_en.pdf"},
    {"id":"3104","name":"Presentation - Regulatory evaluation and perspectives on dose-exposure-response information in new drug applications (Naoyuki Yabana, Naomi Nagai)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-evaluation-and-perspectives-dose-exposure-response-information-new-drug-applications-naoyuki-yabana-naomi-nagai_en.pdf"}    {"id":"3112","name":"Presentation - EMA/FDA/Health Canada workshop on paediatric pulmonary arterial hypertension: Endpoints (Health Canada)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emafdahealth-canada-workshop-paediatric-pulmonary-arterial-hypertension-endpoints-health-canada_en.pdf"},
    {"id":"3114","name":"Presentation - Potential of GI outcome measures in CFTR modulation (Frank Bodewes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-26T01:00:00Z","last_updated_date":"2016-01-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-potential-gi-outcome-measures-cftr-modulation-frank-bodewes_en.pdf"},
    {"id":"3121","name":"Presentation - Pharmacovigilance information systems and services (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-information-systems-and-services-peter-arlett_en.pdf"},
    {"id":"3125","name":"Presentation - Facilitating engagement with the FDA to allow shaping paediatric development programmes (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T18:21:00Z","last_updated_date":"2017-05-12T18:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-facilitating-engagement-fda-allow-shaping-paediatric-development-programmes-irmgard-eichler_en.pdf"},
    {"id":"3127","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - The impatient patient - From anger to activism (EATG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-impatient-patient-anger-activism-eatg_en.pdf"},
    {"id":"3142","name":"Presentation - Agenda item 1: update from the European Medicines Agency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2015-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-1-update-european-medicines-agency_en.pdf"},
    {"id":"3153","name":"Presentation - The PRIME scheme experience 1 year on (Jordi Llinares Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prime-scheme-experience-1-year-jordi-llinares-garcia_en.pdf"},
    {"id":"3155","name":"Presentation - MHLW/PMDA-EMA orphan medicines collaboration","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mhlwpmda-ema-orphan-medicines-collaboration_en.pdf"},
    {"id":"3174","name":"Presentation - Process analytical technologies: view point of the regulators (Jean-Louis Robert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-07-29T02:00:00Z","last_updated_date":"2004-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-process-analytical-technologies-view-point-regulators-jean-louis-robert_en.pdf"},
    {"id":"3192","name":"Invented Name Review Group (NRG) 2005-2006 - Zaide Frias","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-09-11T02:09:21Z","last_updated_date":"2006-09-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/invented-name-review-group-nrg-2005-2006-zaide-frias_en.pdf"},
    {"id":"3204","name":"Presentation - Interaction with healthcare professionals: Overview of involvement in European Medicines Agency activities during 2013 (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-healthcare-professionals-overview-involvement-european-medicines-agency-activities-during-2013-ivana-silva_en.pdf"},
    {"id":"3216","name":"Presentation - Risk-management planning (Luis Prieto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-management-planning-luis-prieto_en.pdf"},
    {"id":"3222","name":"Presentation - Update on post-authorisation collaboration: Post-authorisation efficacy studies (PAES), other (Kevin Blake, Jane Moseley, Christelle Bouygues)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-post-authorisation-collaboration-post-authorisation-efficacy-studies-paes-other-kevin-blake-jane-moseley-christelle-bouygues_en.pdf"},
    {"id":"3230","name":"Presentation - International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use E7 requirements and how they are translated in practice","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-e7-requirements-and-how-they-are-translated-practice_en.pdf"},
    {"id":"3235","name":"Presentation - 3.3 Training for patients' and consumers' organisations - Frequently asked questions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-33-training-patients-and-consumers-organisations-frequently-asked-questions_en.pdf"},
    {"id":"3241","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Osamu Doi","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-osamu-doi_en.pdf"},
    {"id":"3250","name":"Directive amending for traditional herbal medicinal products, Directive 2001/83/EC - Giuseppe Nistico","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-09-27T02:09:21Z","last_updated_date":"2004-09-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/directive-amending-traditional-herbal-medicinal-products-directive-200183ec-giuseppe-nistico_en.pdf"},
    {"id":"3252","name":"Presentation - PML London Clinical Researchers perspective, Igor Koralnik","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pml-london-clinical-researchers-perspective-igor-koralnik_en.pdf"},
    {"id":"3253","name":"Presentation - EMBL-EBI resources and groups (Andrew Leach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-embl-ebi-resources-and-groups-andrew-leach_en.pdf"},
    {"id":"3263","name":"Presentation - Involvement of patients' and consumers' organisations and healthcare professionals in safety communications (Nathalie Bere, Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-involvement-patients-and-consumers-organisations-and-healthcare-professionals-safety-communications-nathalie-bere-ivana-silva_en.pdf"},
    {"id":"3266","name":"Presentation - Control of veterinary drug residue in European Union","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-control-veterinary-drug-residue-european-union_en.pdf"},
    {"id":"3271","name":"Presentation - GMP Inspection in Serbia","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gmp-inspection-serbia_en.pdf"},
    {"id":"3286","name":"Presentation - Overview of the Paediatric Rheumatology Expert Meeting","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-paediatric-rheumatology-expert-meeting_en.pdf"},
    {"id":"3289","name":"Presentation - Setting health-based exposure limits for highly hazardous products to ensure patient safety – application of the Q&A (R. Frà¶tschl, BfArm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-setting-health-based-exposure-limits-highly-hazardous-products-ensure-patient-safety-application-qa-r-fraptschl-bfarm_en.pdf"},
    {"id":"3293","name":"Presentation - Delivering the benefits of the new PSUR for healthcare professionals and patients – efficient and effective implementation An Industry perspective (Klaudija Marijanovic Barac)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-delivering-benefits-new-psur-healthcare-professionals-and-patients-efficient-and-effective-implementation-industry-perspective-klaudija-marijanovic-barac_en.pdf"},
    {"id":"3305","name":"Presentation - 10th anniversary of European Medicines Agency’s Patients' and Consumers' Working Party (PCWP): PCWP 10 years (David Haerry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-10th-anniversary-european-medicines-agencys-patients-and-consumers-working-party-pcwp-pcwp-10-years-david-haerry_en.pdf"},
    {"id":"3309","name":"Presentation - Translating regulatory science into better processes (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-translating-regulatory-science-better-processes-xavier-kurz_en.pdf"},
    {"id":"3320","name":"Presentation - IRDiRC: EU Research funding for rare disease research (Irene Norstedt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-irdirc-eu-research-funding-rare-disease-research-irene-norstedt_en.pdf"},
    {"id":"3330","name":"Presentation - COMP's perspective: Regulatory challenges and opportunities - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines (Bru...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comps-perspective-regulatory-challenges-and-opportunities-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-medicines_en.pdf"},
    {"id":"3359","name":"Presentation - Best expertise vs conflicts of interests: Striking the right balance - PDCO experience (Daniel Brasseur)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-expertise-vs-conflicts-interests-striking-right-balance-pdco-experience-daniel-brasseur_en.pdf"},
    {"id":"3384","name":"Presentation - Perspective of EPL and PM regarding interactions with applicants (Pavel Balabanov, Leonor Enes, Viktor Vlcek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T02:00:00Z","last_updated_date":"2015-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-perspective-epl-and-pm-regarding-interactions-applicants-pavel-balabanov-leonor-enes-viktor-vlcek_en.pdf"},
    {"id":"3432","name":"Presentation - Advanced-therapy medicinal product (ATMP) development challenges: From scientific advice to market authorisation (Lisbeth Barkholt, Caroline Voltz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advanced-therapy-medicinal-product-atmp-development-challenges-scientific-advice-market-authorisation-lisbeth-barkholt-caroline-voltz_en.pdf"},
    {"id":"3435","name":"Presentation - 3.1 EudraCT database and EU Clinical Trials Register (EU-CTR)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2011-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-31-eudract-database-and-eu-clinical-trials-register-eu-ctr_en.pdf"},
    {"id":"3449","name":"Presentation - Involving patients and healthcare professionals - MHRA(Janine Jolly)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-involving-patients-and-healthcare-professionals-mhrajanine-jolly_en.pdf"},
    {"id":"3457","name":"Presentation - Update on public hearing (J.Garcia Burgos, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T02:00:00Z","last_updated_date":"2017-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-public-hearing-jgarcia-burgos-ema_en.pdf"},
    {"id":"3465","name":"Presentation - Marketing Authorisation Issues for SMEs (Anna-Maria Brady)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-marketing-authorisation-issues-smes-anna-maria-brady_en.pdf"},
    {"id":"3479","name":"Brief summary of the existing systems on collecting data: Denmark","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/brief-summary-existing-systems-collecting-data-denmark_en.pdf"},
    {"id":"3483","name":"Presentation - Case study 2 - Development and verification of design space","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-2-development-and-verification-design-space_en.pdf"},
    {"id":"3487","name":"Presentation - Key concepts of orphan designation and latest developments (Jordi Llinares)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-concepts-orphan-designation-and-latest-developments-jordi-llinares_en.pdf"},
    {"id":"3516","name":"The Food and Environment Research Agency (FERA), National Bee Unit, Selwyn Wilkins, FERA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/food-and-environment-research-agency-fera-national-bee-unit-selwyn-wilkins-fera_en.pdf"},
    {"id":"3517","name":"Presentation - Enabling precision medicine and the transformation of healthcare: thoughts on data and technology strategies (Brian Kelly)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enabling-precision-medicine-and-transformation-healthcare-thoughts-data-and-technology-strategies-brian-kelly_en.pdf"},
    {"id":"3522","name":"Presentation - How can healthcare professionals contribute to generate data on behavioural changes? (Jamie Wilkinson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-can-healthcare-professionals-contribute-generate-data-behavioural-changes-jamie-wilkinson_en.pdf"},
    {"id":"3526","name":"Presentation - The Interface of Academia and Clinical Practice, Joseph Berger","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interface-academia-and-clinical-practice-joseph-berger_en.pdf"},
    {"id":"3535","name":"Presentation - Elimination of carriage","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:53Z","last_updated_date":"2011-04-26T18:05:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-elimination-carriage_en.pdf"},
    {"id":"3543","name":"Presentation - Case 1: Pharmacogenomic design in phase I based on in-vitro data","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-1-pharmacogenomic-design-phase-i-based-vitro-data_en.pdf"},
    {"id":"3555","name":"The International Association of Anthroposophic Pharmacists (IAAP) presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/international-association-anthroposophic-pharmacists-iaap-presentation_en.pdf"},
    {"id":"3570","name":"Presentation - SPOR communication and training update (Gabriel Boronat, Agnieszka Laka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T17:00:00Z","last_updated_date":"2017-12-20T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-communication-and-training-update-gabriel-boronat-agnieszka-laka_en.pdf"},
    {"id":"3583","name":"Experience from an SME in initiating clinical trials, Dr Tom Vanthienen","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/experience-sme-initiating-clinical-trials-dr-tom-vanthienen_en.pdf"},
    {"id":"3589","name":"Writing an assessment report - Malcolm Dash","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/writing-assessment-report-malcolm-dash_en.pdf"},
    {"id":"3605","name":"Received Comments to the Draft Guideline (Rev1) for treatment of Alzheimer's disease and other dementias - Susanna Del Signore","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-11T00:09:21Z","last_updated_date":"2008-02-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/received-comments-draft-guideline-rev1-treatment-alzheimers-disease-and-other-dementias-susanna-del-signore_en.pdf"},
    {"id":"3606","name":"Presentation - FDA approaches to analytical challenges posed by big data (David Martin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-approaches-analytical-challenges-posed-big-data-david-martin_en.pdf"},
    {"id":"3610","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - CPMP / CHMP consultations with patients on benefits/risks(Franà§ois Houà¿ez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-cpmp-chmp-consultations-patients-benefitsrisksfranassois-houaez_en.pdf"},
    {"id":"3612","name":"Presentation - Agenda item 5: organisations - Reports from  subgroup","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2015-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-5-organisations-reports-subgroup_en.pdf"},
    {"id":"3622","name":"Presentation - Breakout session 4: Special issues","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T17:35:00Z","last_updated_date":"2013-11-27T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-4-special-issues_en.pdf"},
    {"id":"3633","name":"Evaluation of the Soluble and Solid Phase Cytokine Release Assay: Thomas Kawabata, Pfizer, St. Louis, MO.","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/evaluation-soluble-and-solid-phase-cytokine-release-assay-thomas-kawabata-pfizer-st-louis-mo_en.pdf"},
    {"id":"3643","name":"Presentation - Difficulties encountered - regulatory perspective: focus on endpoints used in clinical trials (Concha Prieto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-difficulties-encountered-regulatory-perspective-focus-endpoints-used-clinical-trials-concha-prieto_en.pdf"},
    {"id":"3647","name":"Presentation - Pharmacokinetic-pharmacodynamic modelling to support go / no-go decisions for a novel gp120 inhibitor - Break-out session 1 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:45:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacokinetic-pharmacodynamic-modelling-support-go-no-go-decisions-novel-gp120-inhibitor-break-out-session-1-theme-3_en.pdf"},
    {"id":"3674","name":"Shedding after in situ rAAV delivery - Review of the literature and 8 years of experience in Nantes in large animal models - Caroline Le Guiner","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/shedding-after-situ-raav-delivery-review-literature-and-8-years-experience-nantes-large-animal-models-caroline-le-guiner_en.pdf"},
    {"id":"3679","name":"Presentation - Implementation of risk minimisation measures in clinical practice: Challenges and opportunities (Jamie Wilkinson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-risk-minimisation-measures-clinical-practice-challenges-and-opportunities-jamie-wilkinson_en.pdf"},
    {"id":"3696","name":"Presentation - Case study 3 - Use of platform technologies for adenovirus-vectored vaccines - Session 2 (Mark van Ooij)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-3-use-platform-technologies-adenovirus-vectored-vaccines-session-2-mark-van-ooij_en.pdf"},
    {"id":"3697","name":"The Off patent Priority List - Paediatric Working Party - Agnà©s Saint Raymond","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:09:21Z","last_updated_date":"2007-06-06T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/patent-priority-list-paediatric-working-party-agnacs-saint-raymond_en.pdf"},
    {"id":"3714","name":"Presentation - Paediatric medicines development - The need for different approaches (Sam Maldonado)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-medicines-development-need-different-approaches-sam-maldonado_en.pdf"},
    {"id":"3721","name":"Presentation - European Commission’s policy development in the field of personalised medicine - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personal...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-commissions-policy-development-field-personalised-medicine-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personal_en.pdf"},
    {"id":"3723","name":"Albania - Food Safety and Veterinary Institute, H Allmuca","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/albania-food-safety-and-veterinary-institute-h-allmuca_en.pdf"},
    {"id":"3727","name":"Kosovo - Medicines Agency, Z Gashi","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/kosovo-medicines-agency-z-gashi_en.pdf"},
    {"id":"3749","name":"Presentation -  MUMS Designation and latest develompments (Karen Quigley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mums-designation-and-latest-develompments-karen-quigley_en.pdf"},
    {"id":"3754","name":"Presentation - Module II - Pharmacovigilance system master file","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-ii-pharmacovigilance-system-master-file_en.pdf"},
    {"id":"3757","name":"Presentation - Medical literature monitoring (Tom Paternoster-Howe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-literature-monitoring-tom-paternoster-howe_en.pdf"},
    {"id":"3775","name":"Presentation - Stakeholder experiences: Benefits of AE Reporting by AVC","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stakeholder-experiences-benefits-ae-reporting-avc_en.pdf"},
    {"id":"3811","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Community Authorisation for Veterinary Medicines-the Contribution to Animal Health in the EU - Paul-Pierre Pastoret","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-community-authorisation-veterinary-medicines-contribution-animal-health-eu-paul-pierre-pastoret_en.pdf"},
    {"id":"3813","name":"Presentation - Subjective cognitive decline as the first symptom of Alzheimer’s disease (Frank Jessen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-subjective-cognitive-decline-first-symptom-alzheimers-disease-frank-jessen_en.pdf"},
    {"id":"3835","name":"Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focusing on Immune modulatory drugs, Dr Nico Wulffraat","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/long-term-pharmacovigilance-adverse-effects-childhood-arthritis-focusing-immune-modulatory-drugs-dr-nico-wulffraat_en.pdf"},
    {"id":"3836","name":"Presentation - How to make compassionate use become a reality for all in need (F.Houà¿ez, EURORDIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T02:00:00Z","last_updated_date":"2017-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-make-compassionate-use-become-reality-all-need-fhouaez-eurordis_en.pdf"},
    {"id":"3865","name":"Presentation - The interface between Industry – CRO and Clinical Trials Networks: Defining the roles (Martine Dehlinger-Kremer, RPS Inc. / EUCROF)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interface-between-industry-cro-and-clinical-trials-networks-defining-roles-martine-dehlinger-kremer-rps-inc-eucrof_en.pdf"},
    {"id":"3892","name":"Presentation - European Medicines Agency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T16:00:00Z","last_updated_date":"2016-02-15T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency_en.pdf"},
    {"id":"3895","name":"Presentation - PIP session: Paediatric glaucoma","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pip-session-paediatric-glaucoma_en.pdf"},
    {"id":"3912","name":"Presentation - Copa Cogeca","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-copa-cogeca_en.pdf"},
    {"id":"3949","name":"Presentation - Opportunities and challenges for the European Network of MS Registries in 2016 -2020","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-and-challenges-european-network-ms-registries-2016-2020_en.pdf"},
    {"id":"3965","name":"Presentation - Adverse reactions from medication errors: regulatory experience in European Union (Dolores Montero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adverse-reactions-medication-errors-regulatory-experience-european-union-dolores-montero_en.pdf"},
    {"id":"3992","name":"Presentation - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting - PCWP 2016-2019 mandate (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-pcwp-2016-2019-mandate-nathalie-bere_en.pdf"},
    {"id":"4000","name":"Presentation - III Foresight Training Course, Gianni Benzi Foundation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2011-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-iii-foresight-training-course-gianni-benzi-foundation_en.pdf"},
    {"id":"4029","name":"Presentation - Periodic safety update single assessment (PSUSA)  assessment aspects (Margarida Guimaraes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-periodic-safety-update-single-assessment-psusa-assessment-aspects-margarida-guimaraes_en.pdf"},
    {"id":"4038","name":"Presentation - Trends in marketing authorisation applications - EMA's PCWP and HCPWP joint meeting (Alexios M. Skarlatos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-trends-marketing-authorisation-applications-emas-pcwp-and-hcpwp-joint-meeting-alexios-m-skarlatos_en.pdf"},
    {"id":"4045","name":"Presentation - Setting specifications for biotech products, Nanna Aaby Kruse, Danish Medicines Agency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T02:00:00Z","last_updated_date":"2011-10-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-setting-specifications-biotech-products-nanna-aaby-kruse-danish-medicines-agency_en.pdf"},
    {"id":"4051","name":"Presentation - Safe medication practice – What can we learn from root cause analysis and related methods? (David Gerrett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safe-medication-practice-what-can-we-learn-root-cause-analysis-and-related-methods-david-gerrett_en.pdf"},
    {"id":"4053","name":"CVMP Reflection paper on the use of fluoroquinolones in foodproducing animals in the EU: Development of resistance and impact on human and animal health - Liisa Kaartinen","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/cvmp-reflection-paper-use-fluoroquinolones-foodproducing-animals-eu-development-resistance-and-impact-human-and-animal-health-liisa-kaartinen_en.pdf"},
    {"id":"4055","name":"Presentation - Regulation, innovation and personalised medicine","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulation-innovation-and-personalised-medicine_en.pdf"},
    {"id":"4058","name":"Presentation - Mechanism-based concepts of size and maturity","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mechanism-based-concepts-size-and-maturity_en.pdf"},
    {"id":"4082","name":"Presentation - PRAC’s perspective on implementation: strengthening public-health protection (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pracs-perspective-implementation-strengthening-public-health-protection-june-raine_en.pdf"},
    {"id":"4090","name":"Overview of PIPs and paediatric trials proposed per therapeutic area  - Dr Ralf Herold","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T00:09:21Z","last_updated_date":"2009-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-pips-and-paediatric-trials-proposed-therapeutic-area-dr-ralf-herold_en.pdf"},
    {"id":"4097","name":"Presentation - Exchange between European Medicines Agency and health technology assessment (HTA) bodies to facilitate joint production of relative effectiveness assessments (Michael Berntgen, Michelle Mujoomdar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:30:00Z","last_updated_date":"2018-01-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-exchange-between-european-medicines-agency-and-health-technology-assessment-hta-bodies-facilitate-joint-production-relative-effectiveness-assessments-michael-berntgen-michelle-mujoomdar_en.pdf"},
    {"id":"4107","name":"Presentation - \n\nRegulatory compliance in non-clinical development (Milton Bonelli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T18:12:00Z","last_updated_date":"2016-10-26T18:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-compliance-non-clinical-development-milton-bonelli_en.pdf"},
    {"id":"4109","name":"Presentation - Veterinarians experiences: Other species - Horses (C.Scicluna)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinarians-experiences-other-species-horses-cscicluna_en.pdf"},
    {"id":"4118","name":"Presentation - An oncology systems pharmacology approach to dose selection (James Yates)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-oncology-systems-pharmacology-approach-dose-selection-james-yates_en.pdf"},
    {"id":"4139","name":"Presentation - Topic 2 - Trial design considerations for evaluation of new treatment regimens, an academic perspective (Andrew Nunn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-2-trial-design-considerations-evaluation-new-treatment-regimens-academic-perspective-andrew-nunn_en.pdf"},
    {"id":"4145","name":"Presentation - How to make legislation more supportive for innovation (Peter Oostenbach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-make-legislation-more-supportive-innovation-peter-oostenbach_en.pdf"},
    {"id":"4151","name":"Presentation - Use of big data to support regulatory decision making (A.Cave)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-18T02:00:00Z","last_updated_date":"2017-09-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-big-data-support-regulatory-decision-making-acave_en.pdf"},
    {"id":"4163","name":"Pharmaceutical Industry views","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pharmaceutical-industry-views_en.pdf"},
    {"id":"4170","name":"Presentation - Section 5.3: Preclinical safety data","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-53-preclinical-safety-data_en.pdf"},
    {"id":"4181","name":"Presentation - Views of the Paediatric Committee and European Medicines Agency paediatric medicines on discussing and using modelling and simulation as a tool to bridge pharmacokinetics, efficacy and safety data - Break-...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-views-paediatric-committee-and-european-medicines-agency-paediatric-medicines-discussing-and-using-modelling-and-simulation-tool-bridge-pharmacokinetics-efficacy-and-safety-data-break_en.pdf"}    {"id":"4185","name":"Presentation - Update on VICH activities (Nick Jarrett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-vich-activities-nick-jarrett_en.pdf"},
    {"id":"4202","name":"Quality documentation for investigational medicinal products, Dr Elaine Godfrey","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/quality-documentation-investigational-medicinal-products-dr-elaine-godfrey_en.pdf"},
    {"id":"4219","name":"EU GMP Requirements - Validation - Bernd Boedecker","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-20T02:09:21Z","last_updated_date":"2009-10-20T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-gmp-requirements-validation-bernd-boedecker_en.pdf"},
    {"id":"4234","name":"Presentation - Comparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry (N. Galià¨)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comparison-between-adult-and-pediatric-populations-ihpah-and-pah-chd-bologna-arca-registry-n-galia_en.pdf"},
    {"id":"4249","name":"EMEA/CHMP Workshop on draft guideline on requirements for first-inman clinical trials for potential high-risk medicinal products - T Hammond","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emeachmp-workshop-draft-guideline-requirements-first-inman-clinical-trials-potential-high-risk-medicinal-products-t-hammond_en.pdf"},
    {"id":"4257","name":"Presentation - Acquis communautaire: Perspectives of industry: Perspective of IFAH-Europe, representing the animal health industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-acquis-communautaire-perspectives-industry-perspective-ifah-europe-representing-animal-health-industry_en.pdf"},
    {"id":"4269","name":"Presentation - Module III pharmacovigilance inspections (Suvi Loikkanen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-iii-pharmacovigilance-inspections-suvi-loikkanen_en.pdf"},
    {"id":"4281","name":"Presentation - Topic 3 - Timely completion of paediatric investigation plans (PIPs) - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-3-timely-completion-paediatric-investigation-plans-pips-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation_en.pdf"},
    {"id":"4286","name":"European Medicines Agency: Overview and Structure, M Harvey Allchurch, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-medicines-agency-overview-and-structure-m-harvey-allchurch-ema_en.pdf"},
    {"id":"4295","name":"Presentation - General considerations from industry - Session 1 (Markus Goese)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-considerations-industry-session-1-markus-goese_en.pdf"},
    {"id":"4304","name":"Presentation - Update on pharmacovigilance legislation (Helen Lee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-pharmacovigilance-legislation-helen-lee_en.pdf"},
    {"id":"4307","name":"Presentation - The Adaptive Pathways pilot: complementing the EMA early access tools (Francesca Cerreta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-pathways-pilot-complementing-ema-early-access-tools-francesca-cerreta_en.pdf"},
    {"id":"4338","name":"Presentation - Patients' and Consumers' Working Party and Healthcare Professionals' Working Party work programmes for 2013 (Ivana Silva, Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-and-consumers-working-party-and-healthcare-professionals-working-party-work-programmes-2013-ivana-silva-nathalie-bere_en.pdf"},
    {"id":"4352","name":"Presentation - EU IDMP/SPOR Task Force meeting: Falsified medicines workshop 27 June 2016 - Meeting outcome (7. agenda) (Paolo Alcini)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-idmpspor-task-force-meeting-falsified-medicines-workshop-27-june-2016-meeting-outcome-7-agenda-paolo-alcini_en.pdf"},
    {"id":"4364","name":"EU Procedures, Z Frias, M Leivers, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-procedures-z-frias-m-leivers-ema_en.pdf"},
    {"id":"4374","name":"Presentation - Pharmacovigilance in Serbia","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-serbia_en.pdf"},
    {"id":"4393","name":"Presentation - European Medicines Agency survey on post-authorisation procedures (Marie-Hà©là¨ne Pinheiro, Alberto Ganan-Jimenez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-12T14:00:01Z","last_updated_date":"2015-11-12T14:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-survey-post-authorisation-procedures-marie-haclane-pinheiro-alberto-ganan-jimenez_en.pdf"},
    {"id":"4398","name":"Presentation - Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency (MLM Service)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency-mlm-service_en.pdf"},
    {"id":"4401","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Brian Ager","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-brian-ager_en.pdf"},
    {"id":"4410","name":"Presentation - Objectives of the training session for patients and consumers involved in EMA activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-objectives-training-session-patients-and-consumers-involved-ema-activities_en.pdf"},
    {"id":"4422","name":"Presentation - Our first experience with a European Medicines Agency adaptive licensing pilot project (Fabrizia Bignami)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-our-first-experience-european-medicines-agency-adaptive-licensing-pilot-project-fabrizia-bignami_en.pdf"},
    {"id":"4438","name":"Presentation - Proposal for communicating on measures to prevent medication errors (Inga Abed)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposal-communicating-measures-prevent-medication-errors-inga-abed_en.pdf"},
    {"id":"4453","name":"Presentation -  Patients’ views on the products selected for the adaptive pathways pilot (Rafal Swierzewski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-views-products-selected-adaptive-pathways-pilot-rafal-swierzewski_en.pdf"},
    {"id":"4457","name":"Presentation - Clinical and regulatory challenges in the development of CAR-modified and TCR-modified T-cells in the EU (Martina Schà¼àŸler-Lenz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T11:11:00Z","last_updated_date":"2016-12-02T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-and-regulatory-challenges-development-car-modified-and-tcr-modified-t-cells-eu-martina-scha-14ayler-lenz_en.pdf"},
    {"id":"4474","name":"Presentation - Spectrum of market-research programmes: Type of safety data collected","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spectrum-market-research-programmes-type-safety-data-collected_en.pdf"},
    {"id":"4480","name":"Presentation - European strategy for SMEs in the pharmaceutical legislation: Directorate General for Health and Consumers (Andrzej Rys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-strategy-smes-pharmaceutical-legislation-directorate-general-health-and-consumers-andrzej-rys_en.pdf"},
    {"id":"4510","name":"Presentation - Early paediatric interaction meeting: initial consultation on paediatric development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T17:00:00Z","last_updated_date":"2016-05-27T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-early-paediatric-interaction-meeting-initial-consultation-paediatric-development_en.pdf"},
    {"id":"4524","name":"Presentation - Session 3: A regulatory approach to validation of the common data model (J. Slattery)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-regulatory-approach-validation-common-data-model-j-slattery_en.pdf"},
    {"id":"4529","name":"Presentation - Encouraging development of paediatric medicines: the experience in the European Union.","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-encouraging-development-paediatric-medicines-experience-european-union_en.pdf"},
    {"id":"4532","name":"Presentation - Activities related to the use of antimicrobials in animals - Session 2 (Jordi Torren Edo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-activities-related-use-antimicrobials-animals-session-2-jordi-torren-edo_en.pdf"},
    {"id":"4546","name":"Presentation - Subgroup analyses: from nasty business to stratified medicine – an HTA perspective (Lange)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-subgroup-analyses-nasty-business-stratified-medicine-hta-perspective-lange_en.pdf"},
    {"id":"4573","name":"Presentation - PDCO perspectives and proposals: Enpr-EMA coordinating group","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T16:02:00Z","last_updated_date":"2018-06-18T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-perspectives-and-proposals-enpr-ema-coordinating-group_en.pdf"},
    {"id":"4580","name":"Non-clinical documentation - Overview of Requirements - Jean-Marc Vidal","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T00:00:00Z","last_updated_date":"2009-02-02T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/non-clinical-documentation-overview-requirements-jean-marc-vidal_en.pdf"},
    {"id":"4583","name":"Presentation - Objectives: EMA workshop on the collaboration with general practitioners/family physicians (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T02:00:00Z","last_updated_date":"2016-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-objectives-ema-workshop-collaboration-general-practitionersfamily-physicians-isabelle-moulon_en.pdf"},
    {"id":"4625","name":"Regulators perspective on 'Quality by Design': GMP/GDP Inspectors Working Group - David Cockburn","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/regulators-perspective-quality-design-gmpgdp-inspectors-working-group-david-cockburn_en.pdf"},
    {"id":"4629","name":"Problems with medicines for bees: current situation and future aspects, Wolfgang Ritter, National and International (OIE) Reference laboratory at CVUA Freiburg","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/problems-medicines-bees-current-situation-and-future-aspects-wolfgang-ritter-national-and-international-oie-reference-laboratory-cvua-freiburg_en.pdf"},
    {"id":"4631","name":"Presentation - When can field trials contribute practically to understanding of efficacy (and when do they not)  (J.  Wood)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T13:16:00Z","last_updated_date":"2017-11-16T13:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-when-can-field-trials-contribute-practically-understanding-efficacy-and-when-do-they-not-j-wood_en.pdf"},
    {"id":"4662","name":"Presentation - Impact of multiple active products on resistance development (Thomas Geurden)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-multiple-active-products-resistance-development-thomas-geurden_en.pdf"},
    {"id":"4666","name":"Presentation - Practical proposals on recruitment improvement: Research and development approach and focus on possible bottleneck issues","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-practical-proposals-recruitment-improvement-research-and-development-approach-and-focus-possible-bottleneck-issues_en.pdf"},
    {"id":"4675","name":"Presentation - Potential use of biomarkers and their temporal relationship with the different phases of Alzheimer's disease in different stages of drug development (Olivier Blin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-potential-use-biomarkers-and-their-temporal-relationship-different-phases-alzheimers-disease-different-stages-drug-development-olivier-blin_en.pdf"},
    {"id":"4716","name":"Presentation - Session 1 – Documentation, resources and implementation  milestones","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-12T12:30:00Z","last_updated_date":"2016-05-12T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-documentation-resources-and-implementation-milestones_en.pdf"},
    {"id":"4721","name":"Presentation - CAT’s views on classification of advanced-therapy medicinal products (Nicolas Ferry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T02:00:00Z","last_updated_date":"2014-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cats-views-classification-advanced-therapy-medicinal-products-nicolas-ferry_en.pdf"},
    {"id":"4722","name":"Presentation - European hub introduction and data set requirements (Paul Mills)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-14T02:00:00Z","last_updated_date":"2015-07-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-hub-introduction-and-data-set-requirements-paul-mills_en.pdf"},
    {"id":"4728","name":"Presentation - Developing a framework of collaboration between EMA and academia (Marisa Papaluca)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-30T02:00:00Z","last_updated_date":"2016-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-developing-framework-collaboration-between-ema-and-academia-marisa-papaluca_en.pdf"},
    {"id":"4739","name":"Revised EudraVigilance access policy: impact on stakeholders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-27T13:18:00Z","last_updated_date":"2016-10-10T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/revised-eudravigilance-access-policy-impact-stakeholders_en.pdf"},
    {"id":"4746","name":"Veterinary Centralised Procedure, J Kieffer, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/veterinary-centralised-procedure-j-kieffer-ema_en.pdf"},
    {"id":"4748","name":"Presentation - What endpoints should be used in clinical trials of hospital- and ventilator-acquired pneumonia?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:48Z","last_updated_date":"2011-04-26T18:05:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-endpoints-should-be-used-clinical-trials-hospital-and-ventilator-acquired-pneumonia_en.pdf"},
    {"id":"4753","name":"Presentation - Expectations to the European paediatric network from a research-based pharmaceutical company","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:52Z","last_updated_date":"2011-05-27T15:25:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-expectations-european-paediatric-network-research-based-pharmaceutical-company_en.pdf"},
    {"id":"4759","name":"Presentation - Case study: large scale analytics for electronic health records: lessons from Observational Health Data Science and Informatics (OHDSI) (Patrick Ryan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-large-scale-analytics-electronic-health-records-lessons-observational-health-data-science-and-informatics-ohdsi-patrick-ryan_en.pdf"},
    {"id":"4761","name":"Presentation - Capitalising on EU Network Training Centre for capacity and capability building in the EU network (Zaide Frias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-30T02:00:00Z","last_updated_date":"2016-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-capitalising-eu-network-training-centre-capacity-and-capability-building-eu-network-zaide-frias_en.pdf"},
    {"id":"4780","name":"Presentation - European Patients’ Academy (EUPATI) update (Maria Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-patients-academy-eupati-update-maria-mavris_en.pdf"},
    {"id":"4806","name":"Presentation - Working to protect public health in the European Union (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-protect-public-health-european-union-ivana-silva_en.pdf"},
    {"id":"4816","name":"Presentation - Active pharmaceutical ingredients – The new approach for third countries: Perspectives from an acceding country (Anita SuÄić)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-active-pharmaceutical-ingredients-new-approach-third-countries-perspectives-acceding-country-anita-suaia_en.pdf"},
    {"id":"4821","name":"Presentation - Regulatory tools for managing the risk of medication errors: labelling and patient information (Jan MacDonald)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-tools-managing-risk-medication-errors-labelling-and-patient-information-jan-macdonald_en.pdf"},
    {"id":"4833","name":"Presentation - Industry proposals: How to interact with and use EnprEMA (Ali Harrison, AstraZeneca)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-proposals-how-interact-and-use-enprema-ali-harrison-astrazeneca_en.pdf"},
    {"id":"4836","name":"Presentation - Regulatory HTA parallel scientific advice throughout the life-cycle of the product (Jane Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T18:21:00Z","last_updated_date":"2017-05-12T18:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-hta-parallel-scientific-advice-throughout-life-cycle-product-jane-moseley_en.pdf"},
    {"id":"4841","name":"Presentation - CAT’s views on classification of ATMPs: homologous use (Nicolas Ferry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-12T19:00:00Z","last_updated_date":"2015-05-12T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cats-views-classification-atmps-homologous-use-nicolas-ferry_en.pdf"},
    {"id":"4872","name":"Presentation - How to find the path to SmPC harmonisation? (Caroline Toulemonde, Emmanuelle Royer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-find-path-smpc-harmonisation-caroline-toulemonde-emmanuelle-royer_en.pdf"},
    {"id":"4875","name":"Presentation - Publication of risk management plan (RMP) summaries (Juan Garcia Burgos and Caroline Voltz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-publication-risk-management-plan-rmp-summaries-juan-garcia-burgos-and-caroline-voltz_en.pdf"},
    {"id":"4901","name":"Pharmacokinetic-pharmacodynamic integration in veterinary drug development: An overview - P.L. Toutain","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-09-24T02:09:21Z","last_updated_date":"2008-09-24T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pharmacokinetic-pharmacodynamic-integration-veterinary-drug-development-overview-pl-toutain_en.ppt"},
    {"id":"4904","name":"Presentation - Change management","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-change-management_en.pdf"},
    {"id":"4910","name":"Presentation - Session 1.1: Non-clinical issues: Off-target toxicity – does it occur and how should we detect it?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:51Z","last_updated_date":"2012-06-15T17:10:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-11-non-clinical-issues-target-toxicity-does-it-occur-and-how-should-we-detect-it_en.pdf"},
    {"id":"4914","name":"Presentation - Environmental risk assessments: EU clinical trials with GMO-based ATMPs (Ann Gorman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-environmental-risk-assessments-eu-clinical-trials-gmo-based-atmps-ann-gorman_en.pdf"},
    {"id":"4924","name":"European Directorate for the Quality of Medicines (EDQM) - Isabelle Mercier","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-directorate-quality-medicines-edqm-isabelle-mercier_en.pdf"},
    {"id":"4933","name":"Presentation - Agenda item 2: referentials (Isabel Chicharo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-15T15:00:00Z","last_updated_date":"2016-03-15T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-2-referentials-isabel-chicharo_en.pdf"},
    {"id":"4941","name":"Presentation - European Medicines Agency Technical Anonymisation Group (TAG) (Monica Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-technical-anonymisation-group-tag-monica-dias_en.pdf"},
    {"id":"4958","name":"Presentation - Update on the PSUR roadmap: achieving a common understanding of the PSUR single assessment in Europe (Irene Rager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:30:00Z","last_updated_date":"2018-01-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-psur-roadmap-achieving-common-understanding-psur-single-assessment-europe-irene-rager_en.pdf"},
    {"id":"4963","name":"Presentation - Key points to recognize quality in health based exposure limits and associated monograph (E. Lovsin Barle, PDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-points-recognize-quality-health-based-exposure-limits-and-associated-monograph-e-lovsin-barle-pda_en.pdf"},
    {"id":"4967","name":"Presentation - How and where to control and what to put in the file, Kowid Ho, afssaps","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T02:00:00Z","last_updated_date":"2011-10-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-and-where-control-and-what-put-file-kowid-ho-afssaps_en.pdf"},
    {"id":"4968","name":"Presentation - Reinforcing the collaboration with healthcare professionals and patient associations - ANSM (Dany Bonnet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reinforcing-collaboration-healthcare-professionals-and-patient-associations-ansm-dany-bonnet_en.pdf"},
    {"id":"4977","name":"Presentation - Validating the extrapolation concept – methodological considerations (Andrew Thomson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-validating-extrapolation-concept-methodological-considerations-andrew-thomson_en.pdf"},
    {"id":"4992","name":"Presentation - European Medicines Agency collaboration with health technology assessment bodies (Jane Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-collaboration-health-technology-assessment-bodies-jane-moseley_en.pdf"},
    {"id":"5003","name":"Presentation - Pharmacovigilance at the European Medicines Agency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T16:00:00Z","last_updated_date":"2016-02-15T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-european-medicines-agency_en.pdf"},
    {"id":"5009","name":"Presentation - International regulatory activities based on PMDA International Strategic Plan 2015 (Hideyuki Kondo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-regulatory-activities-based-pmda-international-strategic-plan-2015-hideyuki-kondo_en.pdf"},
    {"id":"5040","name":"Presentation - Modelling to guide regulatory guidelines and decision making during development - Break-out session 4 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:15:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-guide-regulatory-guidelines-and-decision-making-during-development-break-out-session-4-theme-3_en.pdf"},
    {"id":"5047","name":"Q11 Update - Brian Withers","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/q11-update-brian-withers_en.pdf"},
    {"id":"5060","name":"Presentation - Dose-finding in the cardiovascular therapeutic area: the novel oral anticoagulants (Antonio Gà³mez-Outes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-finding-cardiovascular-therapeutic-area-novel-oral-anticoagulants-antonio-ga3mez-outes_en.pdf"},
    {"id":"5092","name":"Presentation - Session 3.3: Updates on networks - Irish network (Geraldine Boylan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-33-updates-networks-irish-network-geraldine-boylan_en.pdf"},
    {"id":"5104","name":"Presentation - Session IV - Precision medicine","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-18T02:00:00Z","last_updated_date":"2016-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-iv-precision-medicine_en.pdf"},
    {"id":"5132","name":"Presentation - Pharmacovigilance through the Product Lifecycle and the Central Role of the PSUR (Michael Richardson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-through-product-lifecycle-and-central-role-psur-michael-richardson_en.pdf"},
    {"id":"5143","name":"Presentation - Paediatrics, Dr. Matthew Thatcher","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatrics-dr-matthew-thatcher_en.pdf"},
    {"id":"5147","name":"EMEA Performance Indicators pre-authorisation  - Bo Aronsson","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-performance-indicators-pre-authorisation-bo-aronsson_en.pdf"},
    {"id":"5169","name":"Paediatric Medicines and the Health theme in the Co-operation Programme of FP7 - Fergal Donnelly","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:09:21Z","last_updated_date":"2007-06-06T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/paediatric-medicines-and-health-theme-co-operation-programme-fp7-fergal-donnelly_en.pdf"},
    {"id":"5184","name":"Presentation - Topic 3 - Timely completion of paediatric investigation plans (PIPs): Clinical trial application perspective - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-25T12:39:00Z","last_updated_date":"2018-05-25T12:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-3-timely-completion-paediatric-investigation-plans-pips-clinical-trial-application-perspective-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation_en.pdf"},
    {"id":"5185","name":"Presentation - The Variations Regulation (EC) No 1234/2008: The legal framework after the revision","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-variations-regulation-ec-no-12342008-legal-framework-after-revision_en.pdf"},
    {"id":"5202","name":"Presentation - Working group on antibiotics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-06T01:00:00Z","last_updated_date":"2017-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-antibiotics_en.pdf"},
    {"id":"5219","name":"Presentation - Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem (Andrzej Rys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-use-medicines-legislation-bring-new-antibiotics-patients-and-combat-resistance-problem-andrzej-rys_en.pdf"},
    {"id":"5230","name":"Presentation - European Medicines Agency/European Federation of Pharmaceutical Industries and Associations workshop: Integrating pharmacogenomics early into drug development: Pharmacokinetics as a working example","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agencyeuropean-federation-pharmaceutical-industries-and-associations-workshop-integrating-pharmacogenomics-early-drug-development-pharmacokinetics-working-example_en.pdf"},
    {"id":"5233","name":"Presentation - Subgroup analysis: A view from an industry statistician (Keene)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-subgroup-analysis-view-industry-statistician-keene_en.pdf"},
    {"id":"5237","name":"Presentation - Patient and Healthcare Professional Involvement in EUnetHTA Activities (Michelle Mujoomdar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-and-healthcare-professional-involvement-eunethta-activities-michelle-mujoomdar_en.pdf"},
    {"id":"5244","name":"Presentation - Commission call for expression of interest for the position of member of the Pharmacovigilance Risk Assessment Committee","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-commission-call-expression-interest-position-member-pharmacovigilance-risk-assessment-committee_en.pdf"},
    {"id":"5248","name":"Use of in-line near-infrared spectroscopy to monitor segregation of a pharmaceutical powder blend in a tablet press","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/use-line-near-infrared-spectroscopy-monitor-segregation-pharmaceutical-powder-blend-tablet-press_en.pdf"},
    {"id":"5249","name":"Presentation - PIBD Cancer & Mortality (Lissy de Ridder)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pibd-cancer-mortality-lissy-de-ridder_en.pdf"},
    {"id":"5257","name":"Group working procedures – Dr Isabelle Moulon","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2003-05-08T02:00:00Z","last_updated_date":"2003-05-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/group-working-procedures-dr-isabelle-moulon_en.pdf"},
    {"id":"5292","name":"Presentation - Guidance on the anonymisation of clinical reports for the purpose of publication - Meeting on redacting commercially confidential information (CCI) in clinical reports and anonymising clinical reports for ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-anonymisation-clinical-reports-purpose-publication-meeting-redacting-commercially-confidential-information-cci-clinical-reports-and-anonymising-clinical-reports_en.pdf"},
    {"id":"5296","name":"Presentation - Kite Pharma: Industry perspective - PRIME medicines (Rizwana Sproule)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-07T02:00:00Z","last_updated_date":"2017-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-kite-pharma-industry-perspective-prime-medicines-rizwana-sproule_en.pdf"},
    {"id":"5298","name":"Presentation - Architecture of the European medicines agency: How to improve the architecture of the EMA to make it better equipped for the future","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-13T01:00:00Z","last_updated_date":"2010-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-architecture-european-medicines-agency-how-improve-architecture-ema-make-it-better-equipped-future_en.pdf"},
    {"id":"5300","name":"European Paediatric Network at the EMEA - Objectives of the European network - Dr Irmgard Eichler","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T00:09:21Z","last_updated_date":"2009-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-paediatric-network-emea-objectives-european-network-dr-irmgard-eichler_en.pdf"},
    {"id":"5327","name":"Presentation - Challenges in performing field trials to support efficacy - companion animal vaccines (K.  Hellmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T13:30:00Z","last_updated_date":"2017-11-16T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-performing-field-trials-support-efficacy-companion-animal-vaccines-k-hellmann_en.pdf"},
    {"id":"5337","name":"Presentation - Day 1: Industry view on DME and macular edema secondary to RVO","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-industry-view-dme-and-macular-edema-secondary-rvo_en.pdf"}    {"id":"5341","name":"Presentation - Endorsement of new or updated applications for Enpr-EMA membership (Benjamin Pelle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-endorsement-new-or-updated-applications-enpr-ema-membership-benjamin-pelle_en.pdf"},
    {"id":"5343","name":"Presentation - cGMP virus manufacture and evolving release tests","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cgmp-virus-manufacture-and-evolving-release-tests_en.pdf"},
    {"id":"5347","name":"Presentation - Methodological considerations (A. Thomson, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-methodological-considerations-thomson-ema_en.pdf"},
    {"id":"5364","name":"Presentation - The health-technology-assessment view (David Barnett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-health-technology-assessment-view-david-barnett_en.pdf"},
    {"id":"5389","name":"Presentation - How are medicines evaluated at EMA (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-are-medicines-evaluated-ema-nathalie-bere_en.pdf"},
    {"id":"5415","name":"The CHMP scientific advice/protocol assistance - Marco Cavaleri","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/chmp-scientific-adviceprotocol-assistance-marco-cavaleri_en.pdf"},
    {"id":"5446","name":"Presentation - NORDIC investigators network for PEDiatric MEDicines (NordicPEDMED) - Nordic Network (Kalle Hoppu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nordic-investigators-network-pediatric-medicines-nordicpedmed-nordic-network-kalle-hoppu_en.pdf"},
    {"id":"5452","name":"Presentation - Patient reported outcomes in an era of immunotherapy drug development (David Cella) - S6.4","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-reported-outcomes-era-immunotherapy-drug-development-david-cella-s64_en.pdf"},
    {"id":"5474","name":"Presentation - Joint industry presentation: One-year industry experience – Eligibility to PRIME (Aimad Torqui)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-07T02:00:00Z","last_updated_date":"2017-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-industry-presentation-one-year-industry-experience-eligibility-prime-aimad-torqui_en.pdf"},
    {"id":"5475","name":"Reduction and prevention of antimicrobial Resistance in the veterinary sector: From a global perspective to the field level usage - How may HMA contribute - Patrick Dehaumont","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:09:21Z","last_updated_date":"2009-05-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/reduction-and-prevention-antimicrobial-resistance-veterinary-sector-global-perspective-field-level-usage-how-may-hma-contribute-patrick-dehaumont_en.pdf"},
    {"id":"5500","name":"Presentation - Integration of data using modelling and simulation can provide evidence for evaluation of efficacy-safety risks without the need for a separate study - Break-out session 2 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-integration-data-using-modelling-and-simulation-can-provide-evidence-evaluation-efficacy-safety-risks-without-need-separate-study-break-out-session-2-theme-2_en.pdf"},
    {"id":"5502","name":"Presentation - Interaction with patients and consumers (2013): Review of package leaflets (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-patients-and-consumers-2013-review-package-leaflets-nathalie-bere_en.pdf"},
    {"id":"5503","name":"Presentation - Support available to SMEs nationally and internationally – PEI, Ms Bettina Ziegele","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-support-available-smes-nationally-and-internationally-pei-ms-bettina-ziegele_en.pdf"},
    {"id":"5509","name":"Presentation - Cystic fibrosis endpoints: difficulties encountered in the orphan procedures (Laura Fregonese)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cystic-fibrosis-endpoints-difficulties-encountered-orphan-procedures-laura-fregonese_en.pdf"},
    {"id":"5510","name":"Situation in the UK – Bee treatments, Martha Spagnuolo-Weaver, Veterinary Medicines Directorate (UK)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/situation-uk-bee-treatments-martha-spagnuolo-weaver-veterinary-medicines-directorate-uk_en.pdf"},
    {"id":"5513","name":"Quality by Design - Process analytical technology and risk-based CMC development - Kowid Ho","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/quality-design-process-analytical-technology-and-risk-based-cmc-development-kowid-ho_en.pdf"},
    {"id":"5527","name":"Presentation - Increasing enrolment in clinical trials and the Increasing the Participation of the Elderly In Clinical Trials (PREDICT) study","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-increasing-enrolment-clinical-trials-and-increasing-participation-elderly-clinical-trials-predict-study_en.pdf"},
    {"id":"5573","name":"Presentation - EudraVigilance and risk management","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-and-risk-management_en.pdf"},
    {"id":"5601","name":"Presentation - Early access tools: accelerated assessment and conditional marketing authorisation (Michael Berntgen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-early-access-tools-accelerated-assessment-and-conditional-marketing-authorisation-michael-berntgen_en.pdf"},
    {"id":"5611","name":"Presentation - Delivering the benefits of the new PSUR for healthcare professionals and patients – efficient and effective implementation –A Regulator’s perspective (Kora Doorduyn-van der Stoep)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-delivering-benefits-new-psur-healthcare-professionals-and-patients-efficient-and-effective-implementation-regulators-perspective-kora-doorduyn-van-der-stoep_en.pdf"},
    {"id":"5613","name":"Presentation - Case Study 3 - Applying QbD for a legacy product and achieving real time release testing by a design space approach with supportive PAT and soft sensor based models: Challenges in the implementations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-03T11:40:00Z","last_updated_date":"2014-03-03T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-3-applying-qbd-legacy-product-and-achieving-real-time-release-testing-design-space-approach-supportive-pat-and-soft-sensor-based-models-challenges-implementations_en.pdf"},
    {"id":"5623","name":"Presentation - Reporting and evaluation of predictive performance - what is missing in submissions today? (Sue Cole)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reporting-and-evaluation-predictive-performance-what-missing-submissions-today-sue-cole_en.pdf"},
    {"id":"5657","name":"Centre for BioNano Interactions - Kenneth Dawson","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-29T02:09:21Z","last_updated_date":"2009-04-29T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/centre-bionano-interactions-kenneth-dawson_en.pdf"},
    {"id":"5664","name":"Presentation - Update on EMA Brexit preparedness (N. Wathion, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-10T02:00:00Z","last_updated_date":"2017-10-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ema-brexit-preparedness-n-wathion-ema_en.pdf"},
    {"id":"5691","name":"Presentation - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting - PCWP plenary: COMP update June 2016 (Daniel O’Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-pcwp-plenary-comp-update-june-2016-daniel-oconnor_en.pdf"},
    {"id":"5694","name":"Presentation - Improving and harmonising the Summary of Product Characteristics and the conditions for use of old antibacterials (Radu Botgros)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-improving-and-harmonising-summary-product-characteristics-and-conditions-use-old-antibacterials-radu-botgros_en.pdf"},
    {"id":"5720","name":"Committee international des pharmaciens homeopathes (CIPH) - Homeopathic workshop - Introduction","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/committee-international-des-pharmaciens-homeopathes-ciph-homeopathic-workshop-introduction_en.pdf"},
    {"id":"5724","name":"Presentation - Practical implementation of the Falsified-medicines Directive (Belà©n Romero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-practical-implementation-falsified-medicines-directive-belacn-romero_en.pdf"},
    {"id":"5726","name":"Presentation - Drug evaluation in paediatrics using kinetic-pharmacodynamic models: Perspectives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-13T02:09:21Z","last_updated_date":"2008-04-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drug-evaluation-paediatrics-using-kinetic-pharmacodynamic-models-perspectives_en.pdf"},
    {"id":"5727","name":"Presentation - Public hearings","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:11Z","last_updated_date":"2011-06-24T22:06:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-hearings_en.pdf"},
    {"id":"5732","name":"Shedding Studies: Are We Ready for Harmonization? - Stephanie Simek","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/shedding-studies-are-we-ready-harmonization-stephanie-simek_en.pdf"},
    {"id":"5738","name":"Presentation - Impact of pharmacometric analysis on drug approvals and therapeutics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:30:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-pharmacometric-analysis-drug-approvals-and-therapeutics_en.pdf"},
    {"id":"5742","name":"Presentation - Case study title: Evaluation of fixed-dose combinations in paediatric indications - Use of pharmacokinetic bridging - Break-out session 3 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-title-evaluation-fixed-dose-combinations-paediatric-indications-use-pharmacokinetic-bridging-break-out-session-3-theme-3_en.pdf"},
    {"id":"5746","name":"Presentation - Referrals update from the regulators (Almath Spooner and Tania Teixeira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-referrals-update-regulators-almath-spooner-and-tania-teixeira_en.pdf"},
    {"id":"5757","name":"Presentation - The role of modelling/simulation in paediatric population (J. Karres, N. Benda, J. Standing)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-modellingsimulation-paediatric-population-j-karres-n-benda-j-standing_en.pdf"},
    {"id":"5763","name":"Presentation - The staggered two-step approach for treatments with profound effect on immunity (Gavin Giovannoni)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-staggered-two-step-approach-treatments-profound-effect-immunity-gavin-giovannoni_en.pdf"},
    {"id":"5769","name":"Presentation - Update on ADVANCE project follow-up of EMA workshop of 13 November 2013 (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-advance-project-follow-ema-workshop-13-november-2013-peter-arlett_en.pdf"},
    {"id":"5789","name":"Presentation - Comments and proposals on the results of the EFPIA survey","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comments-and-proposals-results-efpia-survey_en.pdf"},
    {"id":"5807","name":"Presentation - Types 2 and 3 SMA: Industry perspective (Omar Khwaja)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-types-2-and-3-sma-industry-perspective-omar-khwaja_en.pdf"},
    {"id":"5813","name":"Presentation - 1995 – 2015: 20 years of European Medicines Agency (Marie-Agnes Heine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-1995-2015-20-years-european-medicines-agency-marie-agnes-heine_en.pdf"},
    {"id":"5834","name":"Presentation - Optical coherence tomography: A role in monitoring multiple sclerosis (Celia Oreja-Guevara)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-optical-coherence-tomography-role-monitoring-multiple-sclerosis-celia-oreja-guevara_en.pdf"},
    {"id":"5849","name":"Presentation - Wacean: a patient-driven innovative tool for data capture (Julian Isla)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-wacean-patient-driven-innovative-tool-data-capture-julian-isla_en.pdf"},
    {"id":"5851","name":"Presentation - Treatment of sepsis (Radu Botgros)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-treatment-sepsis-radu-botgros_en.pdf"},
    {"id":"5854","name":"Presentation - EPAR summaries: Introduction to review by patients and consumers (Paul Blake)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-epar-summaries-introduction-review-patients-and-consumers-paul-blake_en.pdf"},
    {"id":"5871","name":"Presentation - The importance of clarity in relationships and transparency, Henry FItt","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-importance-clarity-relationships-and-transparency-henry-fitt_en.pdf"},
    {"id":"5879","name":"Presentation - PCWP – all eligible meeting: COMP update November 2017 (D. O'Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T16:50:00Z","last_updated_date":"2017-12-11T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwp-all-eligible-meeting-comp-update-november-2017-d-oconnor_en.pdf"},
    {"id":"5880","name":"Presentation - Overview of 3-years of operation (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-3-years-operation-peter-arlett_en.pdf"},
    {"id":"5902","name":"Presentation - UK’s withdrawal from the EU - preparedness activities update (T. Humphreys, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T02:00:00Z","last_updated_date":"2018-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-uks-withdrawal-eu-preparedness-activities-update-t-humphreys-ema_en.pdf"},
    {"id":"5931","name":"Presentation - The place for treatments of associated neuropsychiatric and other symptoms in Alzheimer's disease and other dementias - patient and carers' perspective (Mary-Frances Morris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-place-treatments-associated-neuropsychiatric-and-other-symptoms-alzheimers-disease-and-other-dementias-patient-and-carers-perspective-mary-frances-morris_en.pdf"},
    {"id":"5950","name":"Presentation - How does the EU Regulatory Network communicates about risk minimisation? (Viola Macolić-Š arinić, Juan Garcia-Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-does-eu-regulatory-network-communicates-about-risk-minimisation-viola-macolia-s-arinia-juan-garcia-burgos_en.pdf"},
    {"id":"5954","name":"Presentation - Joint industry presentation: One-year industry experience – Eligibility to PRIME (Simon Bennet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-07T02:00:00Z","last_updated_date":"2017-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-industry-presentation-one-year-industry-experience-eligibility-prime-simon-bennet_en.pdf"},
    {"id":"5961","name":"Presentation - Changing diagnostic criteria for Alzheimer’s disease - impact on clinical trials (Bruno Dubois)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-changing-diagnostic-criteria-alzheimers-disease-impact-clinical-trials-bruno-dubois_en.pdf"},
    {"id":"5978","name":"Presentation - Issues regarding use of placebo in multiple sclerosis drug trials (Peter Scott Chin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-issues-regarding-use-placebo-multiple-sclerosis-drug-trials-peter-scott-chin_en.pdf"},
    {"id":"6003","name":"Presentation - Public summaries of PDCO opinions on agreed PIPs and waivers (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-summaries-pdco-opinions-agreed-pips-and-waivers-irmgard-eichler_en.pdf"},
    {"id":"6024","name":"Presentation - Session 2: Overview of the OMOP common data model (Peter Rijnbeek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-overview-omop-common-data-model-peter-rijnbeek_en.pdf"},
    {"id":"6026","name":"Presentation - Session V - Long-term outcomes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-18T02:00:00Z","last_updated_date":"2016-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-v-long-term-outcomes_en.pdf"},
    {"id":"6035","name":"Presentation - Clinical aspects for cell-based therapies for cardiac repair (Pieter A. Doevendans)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T02:00:00Z","last_updated_date":"2014-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-aspects-cell-based-therapies-cardiac-repair-pieter-doevendans_en.pdf"},
    {"id":"6046","name":"Primary Endpoints in 'Alzheimer's Dementia' - Karl Broich","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-11T00:09:21Z","last_updated_date":"2008-02-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/primary-endpoints-alzheimers-dementia-karl-broich_en.pdf"},
    {"id":"6075","name":"GxP Inspections within the centralised procedure - Brendan Cuddy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gxp-inspections-within-centralised-procedure-brendan-cuddy_en.pdf"},
    {"id":"6082","name":"Presentation - Drugs for multiple drug resistant (MDR) pathogens: Issues in development (Mark Goldberger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drugs-multiple-drug-resistant-mdr-pathogens-issues-development-mark-goldberger_en.pdf"},
    {"id":"6098","name":"A short overview of procedural aspects, the roles of the EMEA and the PDCO - Cecile Ollivier","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-11-16T00:09:21Z","last_updated_date":"2009-11-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/short-overview-procedural-aspects-roles-emea-and-pdco-cecile-ollivier_en.pdf"},
    {"id":"6112","name":"Presentation - World Organisation for Animal Health activities related to antimicrobial resistance and the use of antimicrobial agents in animals (Francois Diaz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T13:00:00Z","last_updated_date":"2013-04-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-world-organisation-animal-health-activities-related-antimicrobial-resistance-and-use-antimicrobial-agents-animals-francois-diaz_en.pdf"},
    {"id":"6122","name":"Presentation - Workshop on data requirements for vaccines March 2015: industry reflections","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-data-requirements-vaccines-march-2015-industry-reflections_en.pdf"},
    {"id":"6154","name":"Presentation - Good pharmacovigilance practices (GVP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-gvp_en.pdf"},
    {"id":"6159","name":"Presentation - User test","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-user-test_en.pdf"},
    {"id":"6183","name":"Presentation - Extrapolation of dosing, efficacy and safety of biologics in JIA, IBD and psoriasis - EMA history (Richard Veselà½)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extrapolation-dosing-efficacy-and-safety-biologics-jia-ibd-and-psoriasis-ema-history-richard-vesela-12_en.pdf"},
    {"id":"6218","name":"Presentation - Neonatal seizures (Geraldine Boylan, Ronit Pressler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-neonatal-seizures-geraldine-boylan-ronit-pressler_en.pdf"},
    {"id":"6221","name":"Presentation - Implementation of the pharmacovigilance directive (John Chave)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-pharmacovigilance-directive-john-chave_en.pdf"},
    {"id":"6223","name":"Why is the availability of VMP for bees so narrow? What could be done to increase this availability?, Bill Vandaele, Association of Veterinary Consultants (AVC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/why-availability-vmp-bees-so-narrow-what-could-be-done-increase-availability-bill-vandaele-association-veterinary-consultants-avc_en.pdf"},
    {"id":"6231","name":"Presentation - Revision of the European Union Directive on in-vitro diagnostic medical devices","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revision-european-union-directive-vitro-diagnostic-medical-devices_en.pdf"},
    {"id":"6233","name":"Montenegro - Agency for Medicines and Medical Devices, Z Besovic","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/montenegro-agency-medicines-medical-devices-z-besovic_en.pdf"},
    {"id":"6238","name":"Presentation - World Health Organization (WHO) - Efforts to reduce the impact on public and animal health of antibiotic use in animals (Danilo Lo Fo Wong)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-world-health-organization-who-efforts-reduce-impact-public-and-animal-health-antibiotic-use-animals-danilo-lo-fo-wong_en.pdf"},
    {"id":"6240","name":"Presentation - The immunotherapy of cancer: past, present and the next frontier (Ira Mellman) - S1.1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunotherapy-cancer-past-present-and-next-frontier-ira-mellman-s11_en.pdf"},
    {"id":"6271","name":"Presentation - Impact of future legislation on availability (Pablo Hervà¡s Calle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-future-legislation-availability-pablo-hervas-calle_en.pdf"},
    {"id":"6274","name":"Presentation - Phasing in Issues – Impact on Nationally authorised products MA status from traditional herbal to advanced therapy medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-phasing-issues-impact-nationally-authorised-products-ma-status-traditional-herbal-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"6275","name":"Presentation - The role of intestinal organoid function for evaluation of CFTR modulators (Jeffrey Beekman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-26T01:00:00Z","last_updated_date":"2016-01-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-intestinal-organoid-function-evaluation-cftr-modulators-jeffrey-beekman_en.pdf"},
    {"id":"6289","name":"Presentation - Encouraging joint PASS submissions (I. Rager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T15:08:00Z","last_updated_date":"2018-01-04T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-encouraging-joint-pass-submissions-i-rager_en.pdf"},
    {"id":"6312","name":"Presentation - Making best use of the PSUR Repository (Jean Louis Hottart)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-making-best-use-psur-repository-jean-louis-hottart_en.pdf"},
    {"id":"6329","name":"Presentation - Drug shortages project of law in France (Dominique Debourges)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drug-shortages-project-law-france-dominique-debourges_en.pdf"},
    {"id":"6349","name":"Presentation - EU funded research projects and the link with authorisation of new antimicrobials (Arjon van Hengel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-funded-research-projects-and-link-authorisation-new-antimicrobials-arjon-van-hengel_en.pdf"},
    {"id":"6357","name":"Presentation - Day 1: Visual function endpoints the regulatory perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-visual-function-endpoints-regulatory-perspective_en.pdf"},
    {"id":"6358","name":"Presentation - European Medicines Agency questions and answers on risk management plan (RMP) updates for centrally authorised medicinal products (Iordanis Gravanis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T16:15:00Z","last_updated_date":"2016-08-15T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-questions-and-answers-risk-management-plan-rmp-updates-centrally-authorised-medicinal-products-iordanis-gravanis_en.pdf"},
    {"id":"6369","name":"Presentation - Viral subtypes and the development of the disease: what is the evidence, Igor Koralnik","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-viral-subtypes-and-development-disease-what-evidence-igor-koralnik_en.pdf"},
    {"id":"6383","name":"Presentation - EudraVigilance: New developments and access to EudraVigilance data","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:10Z","last_updated_date":"2011-06-24T22:06:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-new-developments-and-access-eudravigilance-data_en.pdf"},
    {"id":"6415","name":"Presentation - OIE initiative establishing a global database on consumption of antimicrobials for animals: state of play (Barbara Freischem, Franà§ois Diaz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T13:00:00Z","last_updated_date":"2015-04-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-oie-initiative-establishing-global-database-consumption-antimicrobials-animals-state-play-barbara-freischem-franassois-diaz_en.pdf"},
    {"id":"6428","name":"Presentation - Pharmacovigilance and signal management: experience and trend for future (Peter Ekstrà¶m)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-and-signal-management-experience-and-trend-future-peter-ekstrapm_en.pdf"},
    {"id":"6456","name":"Presentation - Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to less than 10 years of age - Break-out session 3 theme 4","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacokinetic-pharmacodynamic-assessment-topiramate-dosing-regimens-children-epilepsy-2-less-10-years-age-break-out-session-3-theme-4_en.pdf"},
    {"id":"6467","name":"Presentation - Discussion of case study 3: a phase-3 study with two doses and secondary endpoints (Franz Konig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-discussion-case-study-3-phase-3-study-two-doses-and-secondary-endpoints-franz-konig_en.pdf"},
    {"id":"6484","name":"Presentation - Electronic submission of medicinal product information by marketing authorisation holders – Regulation (EC) No 726/2004, Article 57(2), 2nd subparagraph","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:13Z","last_updated_date":"2011-06-24T22:06:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-electronic-submission-medicinal-product-information-marketing-authorisation-holders-regulation-ec-no-7262004-article-572-2nd-subparagraph_en.pdf"},
    {"id":"6490","name":"Presentation - Healthcare Innovation Hub: Societal implications of personalised medicine - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-healthcare-innovation-hub-societal-implications-personalised-medicine-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop_en.pdf"},
    {"id":"6510","name":"How to Assess Pain in Newborn Babies? - Linda Franck","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-10-28T02:09:21Z","last_updated_date":"2004-10-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/how-assess-pain-newborn-babies-linda-franck_en.pdf"},
    {"id":"6516","name":"Presentation - mRNA- and peptide-based anticancer immunotherapies (Michael Platten) - S4.1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mrna-and-peptide-based-anticancer-immunotherapies-michael-platten-s41_en.pdf"},
    {"id":"6534","name":"Presentation - CMDh subgroup on RMP, for same active substances CMDh RMP webpage/cover note /list of safety concerns per approved Risk Management Plan (RMP) of active substances per product (Kora Doorduyn-van der Stoep)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T16:00:00Z","last_updated_date":"2015-06-25T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cmdh-subgroup-rmp-same-active-substances-cmdh-rmp-webpagecover-note-list-safety-concerns-approved-risk-management-plan-rmp-active-substances-product-kora-doorduyn-van-der-stoep_en.pdf"},
    {"id":"6591","name":"Presentation - Preparing patients' representatives for protocol assistance (Maria Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparing-patients-representatives-protocol-assistance-maria-mavris_en.pdf"},
    {"id":"6599","name":"Presentation - Session 1: Non-clinical models: tumour models - proof of concept (Edward Rosfjord)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-non-clinical-models-tumour-models-proof-concept-edward-rosfjord_en.pdf"},
    {"id":"6607","name":"Presentation - Introduction to physiologically based pharmacokinetics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-physiologically-based-pharmacokinetics_en.pdf"},
    {"id":"6613","name":"Presentation - Gaining consensus on emerging science: The Absorption, Distribution, Metabolism and Excretion Panel as an exemplar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gaining-consensus-emerging-science-absorption-distribution-metabolism-and-excretion-panel-exemplar_en.pdf"},
    {"id":"6641","name":"Presentation - ATMPs classification (Belaà¯d Sekkali)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-12T19:00:00Z","last_updated_date":"2015-05-12T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-atmps-classification-belaa-d-sekkali_en.pdf"},
    {"id":"6648","name":"Presentation - Clinical trials in community-acquired pneumonia (CAP) (Francesco Blasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-community-acquired-pneumonia-cap-francesco-blasi_en.pdf"},
    {"id":"6671","name":"Presentation - Current issues on quality of phage products (Alan Fauconnier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-22T02:00:00Z","last_updated_date":"2015-06-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-issues-quality-phage-products-alan-fauconnier_en.pdf"}    {"id":"6681","name":"Public ICH Regional Meeting - Welcome","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/public-ich-regional-meeting-welcome_en.pdf"},
    {"id":"6684","name":"Presentation - Brainstorming on targeting European Medicines Agency information to patients and healthcare professionals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T14:00:00Z","last_updated_date":"2012-07-06T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-brainstorming-targeting-european-medicines-agency-information-patients-and-healthcare-professionals_en.pdf"},
    {"id":"6726","name":"Presentation - Agenda item 4: referentials - Reports from the subgroup","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2015-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-4-referentials-reports-subgroup_en.pdf"},
    {"id":"6744","name":"Presentation - European Union experiences with patient reporting","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:06Z","last_updated_date":"2011-06-24T22:06:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-experiences-patient-reporting_en.pdf"},
    {"id":"6756","name":"Presentation - EMA's first public hearing (N. Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T16:44:00Z","last_updated_date":"2017-12-11T16:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-first-public-hearing-n-bere_en.pdf"},
    {"id":"6767","name":"Presentation - Do we have a common understanding of medication errors? (Jeffrey Aronson, Robin Ferner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-do-we-have-common-understanding-medication-errors-jeffrey-aronson-robin-ferner_en.pdf"},
    {"id":"6769","name":"Presentation - European Medicines Agency product team and applicant/marketing authorisation holder interaction (Michael Berntgen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T02:00:00Z","last_updated_date":"2015-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-product-team-and-applicantmarketing-authorisation-holder-interaction-michael-berntgen_en.pdf"},
    {"id":"6778","name":"Presentation - Feedback from the European Network of Paediatric Research at the European Medicines Agency workshop: Background information","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T14:00:00Z","last_updated_date":"2012-07-06T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-european-network-paediatric-research-european-medicines-agency-workshop-background-information_en.pdf"},
    {"id":"6781","name":"Workshop on medicines for bees - Report from breakout session 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/workshop-medicines-bees-report-breakout-session-2_en.pdf"},
    {"id":"6782","name":"Presentation - Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products – an update (Christiane Niederlaender)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-quality-non-clinical-and-clinical-aspects-gene-therapy-medicinal-products-update-christiane-niederlaender_en.pdf"},
    {"id":"6800","name":"Presentation - Alternatives provided by recent system modelling in animal health for the upscaling of vaccine efficacy (H. Thulke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T14:30:00Z","last_updated_date":"2017-11-16T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-alternatives-provided-recent-system-modelling-animal-health-upscaling-vaccine-efficacy-h-thulke_en.pdf"},
    {"id":"6812","name":"Presentation - Session 4: Accuracy of diagnostic methods and impact on clinical management : the lymphopath network experience (Philippe Gaulard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-accuracy-diagnostic-methods-and-impact-clinical-management-lymphopath-network-experience-philippe-gaulard_en.pdf"},
    {"id":"6830","name":"Presentation - Continuous progress in the area of paediatrics (E. Desfontaine, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T01:00:00Z","last_updated_date":"2017-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-continuous-progress-area-paediatrics-e-desfontaine-ema_en.pdf"},
    {"id":"6864","name":"Requirements for gene therapy products: Non-clinical and clinical aspects - Gopalan Narayanan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/requirements-gene-therapy-products-non-clinical-and-clinical-aspects-gopalan-narayanan_en.pdf"},
    {"id":"6870","name":"Presentation - Mapping EU initiatives on electronic product information - EMA's PCWP and HCPWP joint meeting (Cà©sar Hernà¡ndez Garcà­a)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mapping-eu-initiatives-electronic-product-information-emas-pcwp-and-hcpwp-joint-meeting-cacsar-hernandez-garca_en.pdf"},
    {"id":"6909","name":"Presentation - General considerations for accelerated access schemes (PRIME/adaptive/accelerated pathways) - Session 5 (Ronald Imhoff, Richard Keane)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-considerations-accelerated-access-schemes-primeadaptiveaccelerated-pathways-session-5-ronald-imhoff-richard-keane_en.pdf"},
    {"id":"6926","name":"Presentation - Agenda point 2: Revised ESVAC strategy 2016-2020 (Jordi Torren)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-03T02:00:00Z","last_updated_date":"2017-04-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-point-2-revised-esvac-strategy-2016-2020-jordi-torren_en.pdf"},
    {"id":"6941","name":"Presentation - Is product / indication specific guidance already necessary and meaningful?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:47Z","last_updated_date":"2012-06-15T17:10:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-indication-specific-guidance-already-necessary-and-meaningful_en.pdf"},
    {"id":"6956","name":"ICH Q8 Pharmaceutical Development, workshop: Quality by design in pharmaceutical development and manufacture - Stockholm 2006-03-28","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-07-21T02:00:00Z","last_updated_date":"2006-07-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ich-q8-pharmaceutical-development-workshop-quality-design-pharmaceutical-development-and-manufacture-stockholm-2006-03-28_en.pdf"},
    {"id":"6968","name":"Maximum residue limits for veterinary medicinal products - Jordi Torren Edo","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/maximum-residue-limits-veterinary-medicinal-products-jordi-torren-edo_en.pdf"},
    {"id":"6981","name":"Presentation - SPIRIT (Standard Protocol Items for Randomized Trials) and CONSORT (Consolidated Standards of Reporting Trials) (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spirit-standard-protocol-items-randomized-trials-and-consort-consolidated-standards-reporting-trials-irmgard-eichler_en.pdf"},
    {"id":"6985","name":"Legal basis for collection of data","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/legal-basis-collection-data_en.pdf"},
    {"id":"6988","name":"Presentation - Periodic safety update report (PSUR) repository (Irene Rager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-periodic-safety-update-report-psur-repository-irene-rager_en.pdf"},
    {"id":"6989","name":"Presentation - Consideration of some other specific indications: Bacteraemia","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:48Z","last_updated_date":"2011-04-26T18:05:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-consideration-some-other-specific-indications-bacteraemia_en.pdf"},
    {"id":"6993","name":"Presentation - How the European Medicines Agency works with healthcare professionals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T16:00:00Z","last_updated_date":"2016-02-15T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-european-medicines-agency-works-healthcare-professionals_en.pdf"},
    {"id":"7006","name":"Presentation - HCPWP observers for PCWP, ENCePP and Enpr-EMA (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-12-11T01:00:00Z","last_updated_date":"2013-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hcpwp-observers-pcwp-encepp-and-enpr-ema-ivana-silva_en.pdf"},
    {"id":"7022","name":"Presentation - EMA Scientific Advice SME (Rory Breathnach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-scientific-advice-sme-rory-breathnach_en.pdf"},
    {"id":"7052","name":"Presentation - Feasibility and effectiveness of interventions: the valproate case study- EAN-ILAE joint task force (Marianne de Visser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feasibility-and-effectiveness-interventions-valproate-case-study-ean-ilae-joint-task-force-marianne-de-visser_en.pdf"},
    {"id":"7063","name":"Presentation - An ongoing adaptive phase II/III trial with dose selection: A pragmatic solution for a development programme","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ongoing-adaptive-phase-iiiii-trial-dose-selection-pragmatic-solution-development-programme_en.pdf"},
    {"id":"7076","name":"Presentation - New pharmacovigilance legislation: Questions and answers on practical transitional measures","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmacovigilance-legislation-questions-and-answers-practical-transitional-measures_en.pdf"},
    {"id":"7080","name":"Presentation - An overview of EMA initiatives supporting SMEs - European Medicines Agency veterinary medicines innovation day (Helene Casaert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-ema-initiatives-supporting-smes-european-medicines-agency-veterinary-medicines-innovation-day-helene-casaert_en.pdf"},
    {"id":"7087","name":"Presentation - How and Where to Control, Karin Sewerin, representing EBE","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T02:00:00Z","last_updated_date":"2011-10-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-and-where-control-karin-sewerin-representing-ebe_en.pdf"},
    {"id":"7090","name":"Presentation - General framework on managing uncertainties (Kevin Blake)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-framework-managing-uncertainties-kevin-blake_en.pdf"},
    {"id":"7093","name":"Presentation - Formulations, packaging and medication practice considerations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-formulations-packaging-and-medication-practice-considerations_en.pdf"},
    {"id":"7094","name":"Presentation - Scientific advice/protocol assistance and patients (Francesca Cerreta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-adviceprotocol-assistance-and-patients-francesca-cerreta_en.pdf"},
    {"id":"7125","name":"Presentation: NICHD - Pediatric Trials Network","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nichd-pediatric-trials-network_en.pdf"},
    {"id":"7129","name":"Presentation - Neonatal guideline: revision (Siri Wang)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-neonatal-guideline-revision-siri-wang_en.pdf"},
    {"id":"7160","name":"Presentation - International standards","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-standards_en.pdf"},
    {"id":"7162","name":"Presentation - Clinical type II variations: latest process improvements to improve quality of submissions (Iordanis Gravanis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:30:00Z","last_updated_date":"2018-01-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-type-ii-variations-latest-process-improvements-improve-quality-submissions-iordanis-gravanis_en.pdf"},
    {"id":"7165","name":"Presentation - Clinical trials – experience of the pediatric IBD Porto group","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-22T01:00:00Z","last_updated_date":"2011-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-experience-pediatric-ibd-porto-group_en.pdf"},
    {"id":"7168","name":"Presentation - 1.3 InSPiRe: innovative methodology for small-populations research -  An overview of research (Nigel Stallard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-13-inspire-innovative-methodology-small-populations-research-overview-research-nigel-stallard_en.pdf"},
    {"id":"7187","name":"Presentation - EMA/EGA workshop - Session 4: Line Extension of Immediate Release Products (Andrzej Dzierbicki)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T02:00:00Z","last_updated_date":"2015-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaega-workshop-session-4-line-extension-immediate-release-products-andrzej-dzierbicki_en.pdf"},
    {"id":"7191","name":"Presentation - Patient, consumer and health care provider involvement in EUnetHTA JA3 - EMA's PCWP and HCPWP joint meeting (Rosa Anne Willemsen,Chantal Guilhaume)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-consumer-and-health-care-provider-involvement-eunethta-ja3-emas-pcwp-and-hcpwp-joint-meeting-rosa-anne-willemsenchantal-guilhaume_en.pdf"},
    {"id":"7200","name":"Presentation - Estimating the probability of target attainment (George Drusano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-estimating-probability-target-attainment-george-drusano_en.pdf"},
    {"id":"7202","name":"Presentation - State Institute for Drug Control (SàšKL): Highlights from recent scientific advice and protocol assistance on quality issues (Blanka Hirschlerovà¡)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-state-institute-drug-control-saskl-highlights-recent-scientific-advice-and-protocol-assistance-quality-issues-blanka-hirschlerova_en.pdf"},
    {"id":"7217","name":"Presentation - New European Union pharmacovigilance legislation: Early industry experience, challenges for implementation and some proposals (Laurent Auclert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-european-union-pharmacovigilance-legislation-early-industry-experience-challenges-implementation-and-some-proposals-laurent-auclert_en.pdf"},
    {"id":"7220","name":"Presentation - Operational preparedness for Brexit and re-allocation of United Kingdom product portfolio in the centralised procedure","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T02:00:00Z","last_updated_date":"2018-05-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-operational-preparedness-brexit-and-re-allocation-united-kingdom-product-portfolio-centralised-procedure_en.pdf"},
    {"id":"7245","name":"Presentation - Feedback to the draft guideline on qualification and reporting of PBPK modelling and simulation (N. Parrott)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-draft-guideline-qualification-and-reporting-pbpk-modelling-and-simulation-n-parrott_en.pdf"},
    {"id":"7248","name":"Presentation - Supply shortages of medicines (Franà§ois Houà¿ez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supply-shortages-medicines-franassois-houaez_en.pdf"},
    {"id":"7263","name":"Scientific Recommendation on the Classification of ATMPs - Marie-Helene Pinheiro","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-recommendation-classification-atmps-marie-helene-pinheiro_en.pdf"},
    {"id":"7289","name":"Presentation - Update from SME Office (Constantinos Ziogas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-sme-office-constantinos-ziogas_en.pdf"},
    {"id":"7315","name":"Presentation - Recent experiences with the centralised procedure (Teresa Potter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recent-experiences-centralised-procedure-teresa-potter_en.pdf"},
    {"id":"7318","name":"Presentation - Nomination of members to the Pharmacovigilance Risk Assessment Committee","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nomination-members-pharmacovigilance-risk-assessment-committee_en.pdf"},
    {"id":"7325","name":"Involvement of patients in PRAC benefit-risk (J. M. Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-02-12T01:00:00Z","last_updated_date":"2013-02-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/involvement-patients-prac-benefit-risk-j-m-raine_en.pdf"},
    {"id":"7340","name":"Medicines for Bees: Establishment of maximum residue limits; Principles for marketing authorisations, Isaura Duarte, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/medicines-bees-establishment-maximum-residue-limits-principles-marketing-authorisations-isaura-duarte-ema_en.pdf"},
    {"id":"7348","name":"Presentation - EFSA/EMA opinion to reduce overall need of use of antimicrobials (RONAFA): updates on JIACRA and AMEG (Zoltan Kunsagi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T17:00:00Z","last_updated_date":"2016-03-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-efsaema-opinion-reduce-overall-need-use-antimicrobials-ronafa-updates-jiacra-and-ameg-zoltan-kunsagi_en.pdf"},
    {"id":"7359","name":"Presentation - 10th anniversary of European Medicines Agency’s Patients' and Consumers' Working Party (PCWP): The years of exploration and innovation (Nikos Dedes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-10th-anniversary-european-medicines-agencys-patients-and-consumers-working-party-pcwp-years-exploration-and-innovation-nikos-dedes_en.pdf"},
    {"id":"7379","name":"Presentation - 2.1 eHealth involvement of users in EU initiatives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2011-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-21-ehealth-involvement-users-eu-initiatives_en.pdf"},
    {"id":"7399","name":"Presentation - PD targets in non-clinical models: how much bacterial killing? (Michael Dudley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pd-targets-non-clinical-models-how-much-bacterial-killing-michael-dudley_en.pdf"},
    {"id":"7405","name":"Presentation - FDA experience with measuring the impact of pharmacovigilance (Gerald Dal Pan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-experience-measuring-impact-pharmacovigilance-gerald-dal-pan_en.pdf"},
    {"id":"7409","name":"Presentation - Stakeholder interaction in EMA innovation support - European Medicines Agency veterinary medicines innovation day (Ivo Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stakeholder-interaction-ema-innovation-support-european-medicines-agency-veterinary-medicines-innovation-day-ivo-claassen_en.pdf"},
    {"id":"7419","name":"Presentation - The New PV Legislation Perspective from a Member State","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pv-legislation-perspective-member-state_en.pdf"},
    {"id":"7425","name":"Presentation - Environmental Risk Assessment Recent developments (Chris Van den Eede)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-environmental-risk-assessment-recent-developments-chris-van-den-eede_en.pdf"},
    {"id":"7426","name":"IFAH-Europe views","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ifah-europe-views_en.pdf"},
    {"id":"7427","name":"Presentation - U.S. regulatory and economic incentives for antibiotic research and development (Amanda Jezek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-us-regulatory-and-economic-incentives-antibiotic-research-and-development-amanda-jezek_en.pdf"},
    {"id":"7433","name":"Presentation - Topic 1 - Patients perspective: Eurordis- Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Virginie Hivert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-patients-perspective-eurordis-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-virginie-hivert_en.pdf"},
    {"id":"7434","name":"Presentation - ESVAC state of play (Jordi Torren Edo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T13:00:00Z","last_updated_date":"2015-04-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esvac-state-play-jordi-torren-edo_en.pdf"},
    {"id":"7435","name":"Presentation - Paediatric Rheumatology InterNational Trials Organization (PRINTO) experience with trials in paediatric rheumatology","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-22T01:00:00Z","last_updated_date":"2011-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-rheumatology-international-trials-organization-printo-experience-trials-paediatric-rheumatology_en.pdf"},
    {"id":"7443","name":"A Regulation addressing the needs for drug development in rare diseases: Martin Terberger, Mirjam Sà¶derholm","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/regulation-addressing-needs-drug-development-rare-diseases-martin-terberger-mirjam-sapderholm_en.pdf"},
    {"id":"7445","name":"Presentation - PRAC Work Plan 2018 (J.  Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T02:00:00Z","last_updated_date":"2018-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prac-work-plan-2018-j-raine_en.pdf"},
    {"id":"7468","name":"Presentation - Lumpy skin disease situation in Bulgaria (Georgi Chobanov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-08-07T16:09:00Z","last_updated_date":"2017-08-07T16:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lumpy-skin-disease-situation-bulgaria-georgi-chobanov_en.pdf"},
    {"id":"7470","name":"Presentation - FDA International, Europe (Colin McKiff)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-international-europe-colin-mckiff_en.pdf"},
    {"id":"7476","name":"Presentation - EMA/PDCO approach to neonatology: opportunities (Ralph Bax)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emapdco-approach-neonatology-opportunities-ralph-bax_en.pdf"},
    {"id":"7488","name":"Presentation - The refocussed PSUR and a new approach to assessment (Menno van der Elst)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-refocussed-psur-and-new-approach-assessment-menno-van-der-elst_en.pdf"},
    {"id":"7500","name":"Presentation - Biomarkers for PD-1/L1 inhibitors: regulatory considerations (Marc Theoret) - S3.1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-biomarkers-pd-1l1-inhibitors-regulatory-considerations-marc-theoret-s31_en.pdf"},
    {"id":"7516","name":"Presentation - Update on PRIME (Jordi Llinares and Zahra Hanaizi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T17:31:00Z","last_updated_date":"2018-06-06T17:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-prime-jordi-llinares-and-zahra-hanaizi_en.pdf"},
    {"id":"7523","name":"Presentation - Defining engagement - awareness and perception of public health measures (Patrick Brown)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-defining-engagement-awareness-and-perception-public-health-measures-patrick-brown_en.pdf"},
    {"id":"7524","name":"Presentation - EMA/EGA workshop - Session 1: Orally Administered Modified Release Products (Gerald Beuerle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T02:00:00Z","last_updated_date":"2015-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaega-workshop-session-1-orally-administered-modified-release-products-gerald-beuerle_en.pdf"},
    {"id":"7526","name":"Presentation - Community-acquired pneumonia (CAP) (Keith Barker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-community-acquired-pneumonia-cap-keith-barker_en.pdf"},
    {"id":"7527","name":"Presentation - The new Pharmacovigilance legislation: an EMA perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmacovigilance-legislation-ema-perspective_en.pdf"},
    {"id":"7534","name":"Presentation -  The c-path vision: Sharing data and expertise to accelerate the development of safe and effective therapies for neonates (Martha Brumfield)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-c-path-vision-sharing-data-and-expertise-accelerate-development-safe-and-effective-therapies-neonates-martha-brumfield_en.pdf"},
    {"id":"7535","name":"Presentation given by The Association of the European Self-Medication Industry (AESGP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-given-association-european-self-medication-industry-aesgp_en.pdf"},
    {"id":"7542","name":"Presentation - Working group 4: Dialogue and interaction with ethics committees (P. Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-4-dialogue-and-interaction-ethics-committees-p-lepola_en.pdf"},
    {"id":"7555","name":"EU GMP Requirements - Quality Systems - Bernd Boedecker","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-20T02:09:21Z","last_updated_date":"2009-10-20T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-gmp-requirements-quality-systems-bernd-boedecker_en.pdf"},
    {"id":"7562","name":"Presentation - Good pharmacovigilance practices (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-priya-bahri_en.pdf"},
    {"id":"7606","name":"Presentation - Ethics Guideline – Review of Ethical Considerations (Agnes Saint-Raymond)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ethics-guideline-review-ethical-considerations-agnes-saint-raymond_en.pdf"},
    {"id":"7609","name":"Presentation - Draft revised guideline on similar biological medicinal products: Relevant changes (Martina Weise)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-revised-guideline-similar-biological-medicinal-products-relevant-changes-martina-weise_en.pdf"},
    {"id":"7614","name":"Presentation - Support offered by the European Medicines Agency for the development of paediatric medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-17T15:55:00Z","last_updated_date":"2011-10-17T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-support-offered-european-medicines-agency-development-paediatric-medicines_en.pdf"},
    {"id":"7621","name":"Presentation - Natural history of SMA and impact of standards of care on survival and motor function (Richard Finkel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-natural-history-sma-and-impact-standards-care-survival-and-motor-function-richard-finkel_en.pdf"},
    {"id":"7642","name":"Presentation - Leveraging big data for better health outcomes: the need for a collaborative space and common solutions (Richard Bergstrom)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-leveraging-big-data-better-health-outcomes-need-collaborative-space-and-common-solutions-richard-bergstrom_en.pdf"},
    {"id":"7656","name":"GCP inspections and Phase I (F.I.M.) clinical trials - Pierre Henri Bertoye","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gcp-inspections-and-phase-i-fim-clinical-trials-pierre-henri-bertoye_en.pdf"},
    {"id":"7682","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Incorporating patient views during EMA’s evaluation of benefit-risk of medicines (Juan Garcà­a Burgos, Concepcià³n Prieto Yerro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-incorporating-patient-views-during-emas-evaluation-benefit-risk-medicines-juan-garca-burgos-concepcia3n-prieto-yerro_en.pdf"},
    {"id":"7697","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Mandatory therapeutic fields in the centralised procedure, and scientific/public health challenges for the future - Oncology - Paris Kosmidis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-mandatory-therapeutic-fields-centralised-procedure-and-scientificpublic-health-challenges-future-oncology-paris-kosmidis_en.pdf"},
    {"id":"7700","name":"Presentation - Strategy and pilot phase for patient registries (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strategy-and-pilot-phase-patient-registries-xavier-kurz_en.pdf"},
    {"id":"7717","name":"Presentation - Antibiotic development for resistant bacteria: A Pharmacometric-based solution (Paul Ambrose)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antibiotic-development-resistant-bacteria-pharmacometric-based-solution-paul-ambrose_en.pdf"},
    {"id":"7748","name":"Presentation - Medicines for Europe’s view on the application of statistical methodology for comparability (M. Schiestl, Sandoz Biopharmaceuticals)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicines-europes-view-application-statistical-methodology-comparability-m-schiestl-sandoz-biopharmaceuticals_en.pdf"},
    {"id":"7750","name":"Presentation - Public funding of research - EU perspective, Stefanie Prilla","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-funding-research-eu-perspective-stefanie-prilla_en.pdf"},
    {"id":"7752","name":"Presentation - Scientific Advisory Groups (SAG) - Experience and impact of patient involvement (Francesco Pignatti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advisory-groups-sag-experience-and-impact-patient-involvement-francesco-pignatti_en.pdf"},
    {"id":"7762","name":"Presentation - Sponsor involvement: Current regulatory recommendations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sponsor-involvement-current-regulatory-recommendations_en.pdf"},
    {"id":"7798","name":"The EMEA innovation task force - Constantinos Ziogas","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-innovation-task-force-constantinos-ziogas_en.pdf"}    {"id":"7813","name":"Presentation - Difficulties encountered – regulatory perspective:\n\nPaediatric Investigation Plans (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-difficulties-encountered-regulatory-perspective-paediatric-investigation-plans-irmgard-eichler_en.pdf"},
    {"id":"7829","name":"Presentation - PRIority MEdicines (PRIME) Support to development of priority medicines for unmet medical needs (Jordi Llinares)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-priority-medicines-prime-support-development-priority-medicines-unmet-medical-needs-jordi-llinares_en.pdf"},
    {"id":"7844","name":"Presentation - 4.2 EMA geriatric medicines strategy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2011-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-42-ema-geriatric-medicines-strategy_en.pdf"},
    {"id":"7864","name":"Global development challenges: Classical and advanced therapy medicinal products - Beatriz Silva Lima","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T00:00:00Z","last_updated_date":"2009-02-02T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/global-development-challenges-classical-and-advanced-therapy-medicinal-products-beatriz-silva-lima_en.pdf"},
    {"id":"7865","name":"What has changed for drug development?: Kerstin Westermark","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/what-has-changed-drug-development-kerstin-westermark_en.pdf"},
    {"id":"7873","name":"Presentation - 3.3 IVRS/IWRS and the patient and HCP","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2011-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-33-ivrsiwrs-and-patient-and-hcp_en.pdf"},
    {"id":"7883","name":"Presentation - EGA’s perspective on the draft quality guideline (Joerg Windisch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-egas-perspective-draft-quality-guideline-joerg-windisch_en.pdf"},
    {"id":"7884","name":"Presentation - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting - Implementation of PRIME: update from the first experience (Jordi Llinares)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-implementation-prime-update-first-experience-jordi-llinares_en.pdf"},
    {"id":"7885","name":"Presentation - Expectations for the European Network of Paediatric Research at the European Medicines Agency from patient perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:51Z","last_updated_date":"2011-05-27T15:25:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-expectations-european-network-paediatric-research-european-medicines-agency-patient-perspective_en.pdf"},
    {"id":"7901","name":"Presentation - Developments in European Medicines Agency’s communications: what’s coming up? (Monika Benstetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-developments-european-medicines-agencys-communications-whats-coming-monika-benstetter_en.pdf"},
    {"id":"7902","name":"Presentation - Paediatric Pulmonary arterial hypertension - Regulatory Perspective (Amany El-gazayerly)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-pulmonary-arterial-hypertension-regulatory-perspective-amany-el-gazayerly_en.pdf"},
    {"id":"7903","name":"Presentation - Genomics in patients with Japanese ancestry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-genomics-patients-japanese-ancestry_en.pdf"},
    {"id":"7913","name":"Presentation - Immune Reconstitution Inflammatory Syndrome, Joseph Berger","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immune-reconstitution-inflammatory-syndrome-joseph-berger_en.pdf"},
    {"id":"7969","name":"Presentation - PK data for supporting PK-PD analyses: essential PK data (Elisabet Nielsen, Lena Friberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pk-data-supporting-pk-pd-analyses-essential-pk-data-elisabet-nielsen-lena-friberg_en.pdf"},
    {"id":"7971","name":"Presentation - A Subgroup or a Subpopulation (Wang)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-subgroup-or-subpopulation-wang_en.pdf"},
    {"id":"7974","name":"Presentation - Topics specific to veterinary medicinal products (VMPs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-13T01:00:00Z","last_updated_date":"2010-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topics-specific-veterinary-medicinal-products-vmps_en.pdf"},
    {"id":"7995","name":"Presentation - Variations - progress in worksharing CMDv comments (Esther Werner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-variations-progress-worksharing-cmdv-comments-esther-werner_en.pdf"},
    {"id":"8001","name":"Presentation - Regulatory view (Jan Mueller-Berghaus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-view-jan-mueller-berghaus_en.pdf"},
    {"id":"8003","name":"Brief summary of the existing systems on collecting data: United Kingdom","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/brief-summary-existing-systems-collecting-data-united-kingdom_en.pdf"},
    {"id":"8005","name":"Presentation - Key points from introductory session: Setting the scene (Karri Penttila)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-points-introductory-session-setting-scene-karri-penttila_en.pdf"},
    {"id":"8028","name":"Presentation - 1.4 Regulatory pathways for supporting novel methodologies and opportunities for interactions with regulators (Ine Skottheim Rusten, Anja Schiel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-14-regulatory-pathways-supporting-novel-methodologies-and-opportunities-interactions-regulators-ine-skottheim-rusten-anja-schiel_en.pdf"},
    {"id":"8030","name":"Presentation - The update of the multiplicity guideline (Norbert Benda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-multiplicity-guideline-norbert-benda_en.pdf"},
    {"id":"8031","name":"Presentation - Approaches to advancing patient focussed outcomes assessment in clinical trials (Jeremy Hobart)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-approaches-advancing-patient-focussed-outcomes-assessment-clinical-trials-jeremy-hobart_en.pdf"},
    {"id":"8036","name":"Presentation - Medication errors in children (Ian Chi Kei Wong)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medication-errors-children-ian-chi-kei-wong_en.pdf"},
    {"id":"8045","name":"Dissemination of information - Martin Harvey","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2003-05-08T02:00:00Z","last_updated_date":"2003-05-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/dissemination-information-martin-harvey_en.pdf"},
    {"id":"8085","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Mars Di Bartolomeo","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-mars-di-bartolomeo_en.pdf"},
    {"id":"8089","name":"Presentation - Life-cycle approach to error prevention – An overview (Kathryn Ord)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-life-cycle-approach-error-prevention-overview-kathryn-ord_en.pdf"},
    {"id":"8097","name":"Implementation of Q8, Q9 & Q10 - Georges France","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/implementation-q8-q9-q10-georges-france_en.pdf"},
    {"id":"8111","name":"Presentation - Interaction with patients and consumers (2013): Review of safety communications (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-patients-and-consumers-2013-review-safety-communications-nathalie-bere_en.pdf"},
    {"id":"8126","name":"Presentation - Changing phage cocktails to match developing resistance (Gilbert Verbeken)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-22T02:00:00Z","last_updated_date":"2015-06-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-changing-phage-cocktails-match-developing-resistance-gilbert-verbeken_en.pdf"},
    {"id":"8132","name":"Centralised Procedure Analysis of Performance Indicators; Extensions of Indications 2006 EMEA analysis - Anabela Luis De Lima Marà§al","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/centralised-procedure-analysis-performance-indicators-extensions-indications-2006-emea-analysis-anabela-luis-de-lima-marassal_en.pdf"},
    {"id":"8136","name":"Presentation - PML consortium - industry, Susan Goelz","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pml-consortium-industry-susan-goelz_en.pdf"},
    {"id":"8142","name":"Presentation - Fifth report on the interaction with patients' and consumers' organisations: 2011 (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fifth-report-interaction-patients-and-consumers-organisations-2011-nathalie-bere_en.pdf"},
    {"id":"8144","name":"How to define high-risk medicinal products? - C Schneider","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/how-define-high-risk-medicinal-products-c-schneider_en.pdf"},
    {"id":"8151","name":"Presentation - Challenges of anti-cancer immunotherapy development- industry perspective (Eric Rubin) - S1.3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-anti-cancer-immunotherapy-development-industry-perspective-eric-rubin-s13_en.pdf"},
    {"id":"8164","name":"Presentation - Additional monitoring – proposals on the black symbol for the summary of product characteristics and package leaflet (Ana Sempere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-additional-monitoring-proposals-black-symbol-summary-product-characteristics-and-package-leaflet-ana-sempere_en.pdf"},
    {"id":"8172","name":"Presentation - Management of safety data from patient-support programmes and market-research programmes: Overview of legal requirements applicable to marketing-authorisation holders' (Gilles Touraille)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-management-safety-data-patient-support-programmes-and-market-research-programmes-overview-legal-requirements-applicable-marketing-authorisation-holders-gilles-touraille_en.pdf"},
    {"id":"8183","name":"Presentation - Procedural updates and organisation: Update on variations and progress in work-sharing (Melanie Leivers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-procedural-updates-and-organisation-update-variations-and-progress-work-sharing-melanie-leivers_en.pdf"},
    {"id":"8201","name":"Presentation - Ethical principles and practices in paediatric trials: emerging issues","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T11:00:00Z","last_updated_date":"2012-01-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ethical-principles-and-practices-paediatric-trials-emerging-issues_en.pdf"},
    {"id":"8209","name":"Presentation - Industry perspective: Pfizer - Eliquis® (apixaban)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-pfizer-eliquisr-apixaban_en.pdf"},
    {"id":"8217","name":"Presentation - Multivariate analysis of treatment in multiple sclerosis using the Wei-Lachin procedure (Thomas Zwingers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multivariate-analysis-treatment-multiple-sclerosis-using-wei-lachin-procedure-thomas-zwingers_en.pdf"},
    {"id":"8221","name":"Overview of Paediatric Investigation Plans in Paediatric Rheumatology, Dr Richard Vesely, Dr Emma Sala Soriano","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-paediatric-investigation-plans-paediatric-rheumatology-dr-richard-vesely-dr-emma-sala-soriano_en.pdf"},
    {"id":"8228","name":"Presentation - Medication errors: what patients can do to minimise them (Francois Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medication-errors-what-patients-can-do-minimise-them-francois-houyez_en.pdf"},
    {"id":"8236","name":"Presentation - Impact of D-E-R information on regulatory approval and post-authorisation commitments: FDA perspective (Yaning Wang, Vikram Sinha)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-d-e-r-information-regulatory-approval-and-post-authorisation-commitments-fda-perspective-yaning-wang-vikram-sinha_en.pdf"},
    {"id":"8238","name":"Presentation - eSubmissions update (Dorota Stark)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esubmissions-update-dorota-stark_en.pdf"},
    {"id":"8253","name":"Presentation - An overview of EUEC initiatives targeting SMEs (Laszlo Helmle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-euec-initiatives-targeting-smes-laszlo-helmle_en.pdf"},
    {"id":"8256","name":"Presentation - The role of PSURs in pharmacovigilance inspections –Getting it right and practical experience (Sue Rees)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-psurs-pharmacovigilance-inspections-getting-it-right-and-practical-experience-sue-rees_en.pdf"},
    {"id":"8265","name":"Presentation - Committee for Advanced Therapies feedback (Kieran Breen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-advanced-therapies-feedback-kieran-breen-ema_en.pdf"},
    {"id":"8268","name":"Presentation - Patient perspective after three years of PRAC (A. Van der Zeijden)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-perspective-after-three-years-prac-van-der-zeijden_en.pdf"},
    {"id":"8272","name":"Presentation - Management of safety data from patient-support programmes (PSPs) and market-research programmes (MRPs) (Gilles Touraille)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-02T17:00:00Z","last_updated_date":"2013-07-02T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-management-safety-data-patient-support-programmes-psps-and-market-research-programmes-mrps-gilles-touraille_en.pdf"},
    {"id":"8294","name":"Presentation - EMA Working Groups on Committees' Operational Preparedness (M. Dias, A. Humphreys, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-10T02:00:00Z","last_updated_date":"2017-10-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-working-groups-committees-operational-preparedness-m-dias-humphreys-ema_en.pdf"},
    {"id":"8297","name":"Presentation - European haemophilia safety surveillance (EUHASS) (Mike Makris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-haemophilia-safety-surveillance-euhass-mike-makris_en.pdf"},
    {"id":"8301","name":"Breakout Workgroup 1 - Organization and Communications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T00:09:21Z","last_updated_date":"2009-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/breakout-workgroup-1-organization-and-communications_en.pdf"},
    {"id":"8313","name":"Presentation - Take home messages (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-take-home-messages-june-raine_en.pdf"},
    {"id":"8318","name":"Presentation - Proposed amendment to the policy on transparency and handling of potential conflicts of interests (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposed-amendment-policy-transparency-and-handling-potential-conflicts-interests-irmgard-eichler_en.pdf"},
    {"id":"8319","name":"Presentation - Introduction to SPOR data services","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-16T11:35:00Z","last_updated_date":"2016-08-16T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-spor-data-services_en.pdf"},
    {"id":"8322","name":"Presentation - Report from conference \"Shortages of human medicines in the European Union\" (F. Houà¿ez, EURORDIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-conference-shortages-human-medicines-european-union-f-houaez-eurordis_en.pdf"},
    {"id":"8342","name":"Presentation - Clinical trials designs in neuromyelitis optica and spectrum disorders: Europen Union clinical view (M. Isabel Leite)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-designs-neuromyelitis-optica-and-spectrum-disorders-europen-union-clinical-view-m-isabel-leite_en.pdf"},
    {"id":"8344","name":"Presentation - Medication-errors workshop: Closing remarks (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medication-errors-workshop-closing-remarks-peter-arlett_en.pdf"},
    {"id":"8345","name":"Presentation - Advantages of Minor Use Minor Species (MUMS)/limited market classification to innovative products - European Medicines Agency veterinary medicines innovation day (Miia Jakava-Viljanen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advantages-minor-use-minor-species-mumslimited-market-classification-innovative-products-european-medicines-agency-veterinary-medicines-innovation-day-miia-jakava-viljanen_en.pdf"},
    {"id":"8351","name":"Presentation - Modelling and simulation for paediatric investigation plans (PIPs): Challenges and opportunities for drug development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-paediatric-investigation-plans-pips-challenges-and-opportunities-drug-development_en.pdf"},
    {"id":"8353","name":"Presentation - Breakout session 3: Process and procedures","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T17:35:00Z","last_updated_date":"2013-11-27T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-3-process-and-procedures_en.pdf"},
    {"id":"8359","name":"Presentation - Guideline on similar biological medicinal products: Overarching guideline","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-similar-biological-medicinal-products-overarching-guideline_en.pdf"},
    {"id":"8360","name":"Presentation - 3.4 Annual report on the interaction with patients’ and consumers’ organisations 2010","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-34-annual-report-interaction-patients-and-consumers-organisations-2010_en.pdf"},
    {"id":"8375","name":"The Committee for Advanced Therapies (CAT) - Lucia D'Apote","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/committee-advanced-therapies-cat-lucia-dapote_en.pdf"},
    {"id":"8379","name":"Presentation - Collection of data by species - state of play (Marian Bos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T13:00:00Z","last_updated_date":"2015-04-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collection-data-species-state-play-marian-bos_en.pdf"},
    {"id":"8388","name":"Presentation - GVP paediatric population and “direction of travel” (R. De Lisa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T15:08:00Z","last_updated_date":"2018-01-04T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gvp-paediatric-population-and-direction-travel-r-de-lisa_en.pdf"},
    {"id":"8401","name":"Presentation - EU Biosimilar Regulatory Framework II, Falk Ehmann, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-biosimilar-regulatory-framework-ii-falk-ehmann-ema_en.pdf"},
    {"id":"8403","name":"Presentation - Good pharmacovigilance practices for the European Union (EU-GVP) (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-european-union-eu-gvp-priya-bahri_en.pdf"},
    {"id":"8413","name":"Presentation - EFPIA position on Compliance Check (including validation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-efpia-position-compliance-check-including-validation_en.pdf"},
    {"id":"8418","name":"Presentation - Industry PML consortium view, Sophie Banzet","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-pml-consortium-view-sophie-banzet_en.pdf"},
    {"id":"8455","name":"Presentation - PIP session: Overview of childhood visual impairment and blindness","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pip-session-overview-childhood-visual-impairment-and-blindness_en.pdf"},
    {"id":"8478","name":"Presentation - Post-authorisation safety studies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-authorisation-safety-studies_en.pdf"},
    {"id":"8480","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Patient input into benefit/risk issues during evaluation (EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-patient-input-benefitrisk-issues-during-evaluation-efpia_en.pdf"},
    {"id":"8483","name":"Presentation - Committee for Orphan Medicinal Products (COMP) update (Daniel O'Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-orphan-medicinal-products-comp-update-daniel-oconnor_en.pdf"},
    {"id":"8496","name":"Presentation - The new pharmacovigilance legislation and implementation planning","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:14Z","last_updated_date":"2011-06-24T22:06:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmacovigilance-legislation-and-implementation-planning_en.pdf"},
    {"id":"8522","name":"Presentation - Developing drugs for the treatment of Alzheimer’s disease (Eric Bastings, Billy Dunn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-developing-drugs-treatment-alzheimers-disease-eric-bastings-billy-dunn_en.pdf"},
    {"id":"8556","name":"Presentation - Status update of changes to the operations in the centralised procedure (Evdokia Korakianiti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T02:00:00Z","last_updated_date":"2015-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-status-update-changes-operations-centralised-procedure-evdokia-korakianiti_en.pdf"},
    {"id":"8558","name":"Presentation - Accession preparation - Phasing-in","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accession-preparation-phasing_en.pdf"},
    {"id":"8567","name":"Presentation - Modelling to support Benefit/Risk assessment – Will it enhance our capability and improve transparency?, Dr Phillips","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-support-benefitrisk-assessment-will-it-enhance-our-capability-and-improve-transparency-dr-phillips_en.pdf"},
    {"id":"8580","name":"Presentation - Update on implementation of the clinical trial regulation (A. M. Janson Lang)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-implementation-clinical-trial-regulation-m-janson-lang_en.pdf"},
    {"id":"8588","name":"EudraVigilance to support EU Pharmacovigilance Activities - Thomas Goedecke","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eudravigilance-support-eu-pharmacovigilance-activities-thomas-goedecke_en.pdf"},
    {"id":"8607","name":"Presentation - Production and validation of CAR-T cells and T-cell receptors (TCRs) in an academic setting (Martin Hildebrandt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T10:22:00Z","last_updated_date":"2016-12-02T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-production-and-validation-car-t-cells-and-t-cell-receptors-tcrs-academic-setting-martin-hildebrandt_en.pdf"},
    {"id":"8609","name":"Presentation - Regulatory milestones in European Union with respect to process analytical technology (Christina Graffner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-11-30T01:00:00Z","last_updated_date":"2004-11-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-milestones-european-union-respect-process-analytical-technology-christina-graffner_en.pdf"},
    {"id":"8610","name":"Presentation - Industry perspective and proposals for action plan 2018-2019","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T16:02:00Z","last_updated_date":"2018-06-18T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-and-proposals-action-plan-2018-2019_en.pdf"},
    {"id":"8624","name":"Presentation - Procedure for election of HCPWP Co-Chair","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-12-11T01:00:00Z","last_updated_date":"2013-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-procedure-election-hcpwp-co-chair_en.pdf"},
    {"id":"8641","name":"Presentation - Emerging networks: Learning from successful networks (Tim Lee, European Cystic Fibrosis Society Clinical Trials Network)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emerging-networks-learning-successful-networks-tim-lee-european-cystic-fibrosis-society-clinical-trials-network_en.pdf"},
    {"id":"8659","name":"Presentation - Member of the Copa-Cogeca Working Party on Animal Health and Welfare (Catherine McLaughlin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-member-copa-cogeca-working-party-animal-health-and-welfare-catherine-mclaughlin_en.pdf"},
    {"id":"8671","name":"Presentation - Impact of the single market and availability of veterinary medicines Member state perspectives: Slovakia","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-single-market-and-availability-veterinary-medicines-member-state-perspectives-slovakia_en.pdf"},
    {"id":"8674","name":"Presentation - Topic 2 - Industry developers perspective (Robert Wallis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-2-industry-developers-perspective-robert-wallis_en.pdf"},
    {"id":"8679","name":"Presentation - Introduction to EnprEMA and role of EMA in EnprEMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T17:10:00Z","last_updated_date":"2017-01-04T17:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-enprema-and-role-ema-enprema_en.pdf"},
    {"id":"8698","name":"Mesenchymal stem cells - Science and therapeutic applications: Dr Dirk Buscher, Grifols","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/mesenchymal-stem-cells-science-and-therapeutic-applications-dr-dirk-buscher-grifols_en.pdf"},
    {"id":"8704","name":"Presentation - PRAC feedback (M. Greco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T16:50:00Z","last_updated_date":"2017-12-11T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prac-feedback-m-greco_en.pdf"},
    {"id":"8715","name":"Presentation - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting - EUPATI WP7 Guidances: Public consultation (David Haerry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-eupati-wp7-guidances-public-consultation-david-haerry_en.pdf"},
    {"id":"8717","name":"Presentation - Benefit-risk assessment throughout the drug lifecycle: future challenges? (Hans-Georg Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-benefit-risk-assessment-throughout-drug-lifecycle-future-challenges-hans-georg-eichler_en.pdf"},
    {"id":"8753","name":"Presentation - Immunogenicity guideline: basic description (Venke Skibeli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunogenicity-guideline-basic-description-venke-skibeli_en.pdf"},
    {"id":"8759","name":"Presentation - Interaction with healthcare professionals (I.Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-healthcare-professionals-isilva-ema_en.pdf"},
    {"id":"8760","name":"Presentation and discussion of various case studies - Matthew Thatcher","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-11-16T00:09:21Z","last_updated_date":"2009-11-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-and-discussion-various-case-studies-matthew-thatcher_en.pdf"},
    {"id":"8776","name":"Presentation - Ph 2/3 trial for selepressin in the treatment of vasopressor-dependent septic shock (Scott Berry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ph-23-trial-selepressin-treatment-vasopressor-dependent-septic-shock-scott-berry_en.pdf"},
    {"id":"8787","name":"Presentation - The impact on public and animal health of the use of antibiotics in animals (John Threlfall)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-public-and-animal-health-use-antibiotics-animals-john-threlfall_en.pdf"}    {"id":"8795","name":"Regulators perspective on 'Quality by Design': QWP perspective - Jean-Louis Robert","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/regulators-perspective-quality-design-qwp-perspective-jean-louis-robert_en.pdf"},
    {"id":"8797","name":"Presentation - The patient perspective: Adaptive licensing (Emily Crossley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-perspective-adaptive-licensing-emily-crossley_en.pdf"},
    {"id":"8825","name":"Presentation - Accession preparation: The legal framework","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accession-preparation-legal-framework_en.pdf"},
    {"id":"8837","name":"Presentation - Framework on the interaction between the European Medicines Agency and healthcare professionals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-framework-interaction-between-european-medicines-agency-and-healthcare-professionals_en.pdf"},
    {"id":"8838","name":"Lessons learnt from medicinal products used in neonates - What are the needs with regard to formulation? - J. Breitkreutz","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-11T02:09:21Z","last_updated_date":"2006-10-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/lessons-learnt-medicinal-products-used-neonates-what-are-needs-regard-formulation-j-breitkreutz_en.pdf"},
    {"id":"8849","name":"EGA-EBG's Non-Clinical perspective on Biosimilar mAbs - Alexander Berghout","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ega-ebgs-non-clinical-perspective-biosimilar-mabs-alexander-berghout_en.pdf"},
    {"id":"8852","name":"Presentation - EMA framework of collaboration with academia - European Medicines Agency veterinary medicines innovation day (Monica Ensini)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-framework-collaboration-academia-european-medicines-agency-veterinary-medicines-innovation-day-monica-ensini_en.pdf"},
    {"id":"8858","name":"Presentation - Good pharmacovigilance practices for the European Union (EU-GVP) (P. Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T15:08:00Z","last_updated_date":"2018-01-04T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-european-union-eu-gvp-p-bahri_en.pdf"},
    {"id":"8871","name":"Overview of diabetes PIPs - Meeting of the Paediatric Diabetes Mellitus Experts Group","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-06T02:00:00Z","last_updated_date":"2010-05-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-diabetes-pips-meeting-paediatric-diabetes-mellitus-experts-group_en.pdf"},
    {"id":"8901","name":"Presentation - Functioning of the PRAC (Almath Spooner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-functioning-prac-almath-spooner_en.pdf"},
    {"id":"8909","name":"Update on the guidance of ICH S6 - Jennifer Sims","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/update-guidance-ich-s6-jennifer-sims_en.pdf"},
    {"id":"8923","name":"Common elements of the CTA review process in National Competent Authorities, Dr Ingrid Wallenbeck","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/common-elements-cta-review-process-national-competent-authorities-dr-ingrid-wallenbeck_en.pdf"},
    {"id":"8945","name":"Presentation – Update on the implementation of EMA policy on publication of clinical data (Policy 0070) – industry associations webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-05T02:00:00Z","last_updated_date":"2017-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-implementation-ema-policy-publication-clinical-data-policy-0070-industry-associations-webinar_en.pdf"},
    {"id":"8952","name":"Presentation - European Network for Hyperkinetic Disorders (Dave Coghill, University of Dundee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-hyperkinetic-disorders-dave-coghill-university-dundee_en.pdf"},
    {"id":"8975","name":"Presentation - Generics in the Centralised Procedure","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-generics-centralised-procedure_en.pdf"},
    {"id":"8977","name":"Presentation - PCWP meeting guidelines on the summary of clinical trial results for laypersons (Amanda Hunn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-10T18:30:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwp-meeting-guidelines-summary-clinical-trial-results-laypersons-amanda-hunn_en.pdf"},
    {"id":"8978","name":"EU GMP Requirements - Biological medicinal product for human use - Martin Melzer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-20T02:09:21Z","last_updated_date":"2009-10-20T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-gmp-requirements-biological-medicinal-product-human-use-martin-melzer_en.pdf"},
    {"id":"8990","name":"Presentation - French National Agency for Medicines and Health Products Safety: Innovation Office (Francois Cuenot)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-french-national-agency-medicines-and-health-products-safety-innovation-office-francois-cuenot_en.pdf"},
    {"id":"9002","name":"Presentation - Objectives expert meeting: List of questions: Preliminary answers","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-12T03:00:00Z","last_updated_date":"2011-07-12T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-objectives-expert-meeting-list-questions-preliminary-answers_en.pdf"},
    {"id":"9004","name":"Presentation - Working group : young persons advisory groups (P. Dicks, B. Nafria, S. Gaillard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-young-persons-advisory-groups-p-dicks-b-nafria-s-gaillard_en.pdf"},
    {"id":"9008","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Hubertus Cranz","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-hubertus-cranz_en.pdf"},
    {"id":"9011","name":"Presentation - Regulatory initiatives for measuring the impact of pharmacovigilance (Dolores Montero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-initiatives-measuring-impact-pharmacovigilance-dolores-montero_en.pdf"},
    {"id":"9019","name":"Presentation - Working group on public - private partnership (Susan Tansey)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-public-private-partnership-susan-tansey_en.pdf"},
    {"id":"9031","name":"Presentation - Non-small cell lung cancer (NSCLC) regulatory – industry perspective (Catherine Weil) - S2.5","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-small-cell-lung-cancer-nsclc-regulatory-industry-perspective-catherine-weil-s25_en.pdf"},
    {"id":"9032","name":"Presentation - Lessons learned on scientific-ethical issues from the Task-force in Europe for Drug Development for the Young (TEDDY) survey among European ethics committees","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T11:00:00Z","last_updated_date":"2012-01-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lessons-learned-scientific-ethical-issues-task-force-europe-drug-development-young-teddy-survey-among-european-ethics-committees_en.pdf"},
    {"id":"9042","name":"Presentation - Key comments from the public consultation and the regulatory challenge (Armin Koch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-comments-public-consultation-and-regulatory-challenge-armin-koch_en.pdf"},
    {"id":"9045","name":"Presentation - The value of Bayesian statistics for assessing comparability (T. Mutsvari, EFSPI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-value-bayesian-statistics-assessing-comparability-t-mutsvari-efspi_en.pdf"},
    {"id":"9061","name":"Presentation - Quality attributes impacting immunogenicity of therapeutic proteins (Steffen Gross)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-attributes-impacting-immunogenicity-therapeutic-proteins-steffen-gross_en.pdf"},
    {"id":"9074","name":"Presentation - Off-target toxicity – a regulator's view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:56Z","last_updated_date":"2012-06-15T17:10:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-target-toxicity-regulators-view_en.pdf"},
    {"id":"9096","name":"Presentation - Example summary of the risk management plan (RMP) for Intuniv (guanfacine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-example-summary-risk-management-plan-rmp-intuniv-guanfacine_en.pdf"},
    {"id":"9099","name":"Module 04 - Presentation - Specificities of products for veterinary use","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/module-04-presentation-specificities-products-veterinary-use_en.pdf"},
    {"id":"9104","name":"Presentation - Regulatory discussant: Rob Hemmings preliminary conclusions - Break-out session 4 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-discussant-rob-hemmings-preliminary-conclusions-break-out-session-4-theme-3_en.pdf"},
    {"id":"9111","name":"Presentation - Personalised medicine challenges: hype or hope? (Marisa Papaluca, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-personalised-medicine-challenges-hype-or-hope-marisa-papaluca-ema_en.pdf"},
    {"id":"9143","name":"Presentation - Acquis communautaire: Perspectives for regulators","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-acquis-communautaire-perspectives-regulators_en.pdf"},
    {"id":"9154","name":"Presentation - How patients are involved in the review of documents","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-31T19:00:00Z","last_updated_date":"2016-08-31T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-patients-are-involved-review-documents_en.pdf"},
    {"id":"9167","name":"How Modified PEM supports Risk Management: a selected brief overview - S. Shakir","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/how-modified-pem-supports-risk-management-selected-brief-overview-s-shakir_en.pdf"},
    {"id":"9169","name":"Development of Off-patent Medicines for Paediatric Use: Generic Industry Perspective - Michael Banks","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:09:21Z","last_updated_date":"2007-06-06T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/development-patent-medicines-paediatric-use-generic-industry-perspective-michael-banks_en.pdf"},
    {"id":"9185","name":"Presentation - Outcome of Federation of Veterinarians of Europe (FVE) survey on adverse event reporting","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcome-federation-veterinarians-europe-fve-survey-adverse-event-reporting_en.pdf"},
    {"id":"9191","name":"Presentation - Module 11 - International cooperation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T02:00:00Z","last_updated_date":"2018-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-11-international-cooperation_en.pdf"},
    {"id":"9196","name":"Presentation - European Medicines Agency (EMA) on social media- EMA's PCWP and HCPWP joint meeting (Monika Benstetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-ema-social-media-emas-pcwp-and-hcpwp-joint-meeting-monika-benstetter_en.pdf"},
    {"id":"9216","name":"Presentation - Progress update: CMDv/Industry Joint Task Force on variations (Kevin Yount)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-progress-update-cmdvindustry-joint-task-force-variations-kevin-yount_en.pdf"},
    {"id":"9221","name":"Presentation - HMPC feedback (Steffen Bager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hmpc-feedback-steffen-bager_en.pdf"},
    {"id":"9222","name":"Presentation - Update from the CVMP's Environmental Risk Assessment Working Party: Assessment of veterinary medicinal products (VMPs) containing persistent, bioaccumulative and toxic substances (PBTs) (Boris Kolar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-cvmps-environmental-risk-assessment-working-party-assessment-veterinary-medicinal-products-vmps-containing-persistent-bioaccumulative-and-toxic-substances-pbts-boris-kolar_en.pdf"},
    {"id":"9228","name":"Presentation - Classification of advanced-therapy medicinal products (Egbert Flory)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T02:00:00Z","last_updated_date":"2014-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-classification-advanced-therapy-medicinal-products-egbert-flory_en.pdf"},
    {"id":"9248","name":"Interaction with stakeholders communication, J Garcia, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/interaction-stakeholders-communication-j-garcia-ema_en.pdf"},
    {"id":"9267","name":"Presentation - EPAR summary template (E. Scanlan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T17:06:00Z","last_updated_date":"2017-12-11T17:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-epar-summary-template-e-scanlan_en.pdf"},
    {"id":"9271","name":"Presentation - Evidence about plasma exchange in natalizumab related PML, Ralf Gold","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evidence-about-plasma-exchange-natalizumab-related-pml-ralf-gold_en.pdf"},
    {"id":"9272","name":"Presentation - Holistic approach to paediatric research: health technologies assessment bodies (Y. Schmidt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:04:00Z","last_updated_date":"2018-06-18T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-health-technologies-assessment-bodies-y-schmidt_en.pdf"},
    {"id":"9273","name":"Presentation - Paediatric organ failure scores in neonatal sepsis (Shane Tibby)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-organ-failure-scores-neonatal-sepsis-shane-tibby_en.pdf"},
    {"id":"9275","name":"Presentation - Rare diseases, European and UK approaches: setting the scene (Julian Thomas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rare-diseases-european-and-uk-approaches-setting-scene-julian-thomas_en.pdf"},
    {"id":"9281","name":"Presentation - ClinicoBru The Brussels clinical trial network (Florence Bosco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinicobru-brussels-clinical-trial-network-florence-bosco_en.pdf"},
    {"id":"9287","name":"Presentation - Academic perspective (Marie L De Bruin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-academic-perspective-marie-l-de-bruin_en.pdf"},
    {"id":"9292","name":"Presentation - How to weigh the strength of prior information and clarify the expected level of evidence? (M. Posch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-weigh-strength-prior-information-and-clarify-expected-level-evidence-m-posch_en.pdf"},
    {"id":"9304","name":"Presentation - European Union collaborative framework for patient registries (Jacoline Bouvy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-collaborative-framework-patient-registries-jacoline-bouvy_en.pdf"},
    {"id":"9312","name":"Presentation - Geriatrician’s perspective on implementation of the new pharmacovigilance legislation (Jean-Pierre Baeyens)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-geriatricians-perspective-implementation-new-pharmacovigilance-legislation-jean-pierre-baeyens_en.pdf"},
    {"id":"9314","name":"Presentation - Determining the predicative ability of in vitro microphysiological systems to answer critical regulatory questions (S. Fitzpatrick)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T10:54:00Z","last_updated_date":"2017-11-15T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-determining-predicative-ability-vitro-microphysiological-systems-answer-critical-regulatory-questions-s-fitzpatrick_en.pdf"},
    {"id":"9345","name":"Presentation - United Kingdom's withdrawal from the European Union (Olga Solomon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T02:00:00Z","last_updated_date":"2018-05-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-united-kingdoms-withdrawal-european-union-olga-solomon_en.pdf"},
    {"id":"9346","name":"Presentation - Opening remarks: EMA workshop on the collaboration with general practitioners/family physicians (Guido Rasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T02:00:00Z","last_updated_date":"2016-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-remarks-ema-workshop-collaboration-general-practitionersfamily-physicians-guido-rasi_en.pdf"},
    {"id":"9358","name":"Presentation - Module 6 - EMA support to innovation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T02:00:00Z","last_updated_date":"2018-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-6-ema-support-innovation_en.pdf"},
    {"id":"9360","name":"Presentation - Modelling and simulation to support evaluation of safety and efficacy of drugs in older patients","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-support-evaluation-safety-and-efficacy-drugs-older-patients_en.pdf"},
    {"id":"9366","name":"Presentation - Signal detection and management (G. Genov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-signal-detection-and-management-g-genov_en.pdf"},
    {"id":"9378","name":"Ethics of Clinical Trials in Children - F Hirsch, P Zilgalvis, M Fitzgerald, E Pauwels","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:09:21Z","last_updated_date":"2007-06-06T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ethics-clinical-trials-children-f-hirsch-p-zilgalvis-m-fitzgerald-e-pauwels_en.pdf"},
    {"id":"9380","name":"Presentation - Day 1: Gene and molecular therapy; an industry view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-gene-and-molecular-therapy-industry-view_en.pdf"},
    {"id":"9386","name":"Presentation - Issues to address for a Tier B development plan (Barry Eisenstein)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-issues-address-tier-b-development-plan-barry-eisenstein_en.pdf"},
    {"id":"9392","name":"Presentation - The importance of D-E-R characterisation in dose selection, labelling and B/R - Children (Anne Brochot)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-importance-d-e-r-characterisation-dose-selection-labelling-and-br-children-anne-brochot_en.pdf"},
    {"id":"9405","name":"Presentation - Module 2 - Engagement with stakeholders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-26T02:00:00Z","last_updated_date":"2018-03-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-2-engagement-stakeholders_en.pdf"},
    {"id":"9417","name":"Presentation - Organ-on-chip networking in Europe (J. van den Eijnden-van Raaij)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T11:22:00Z","last_updated_date":"2017-11-15T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organ-chip-networking-europe-j-van-den-eijnden-van-raaij_en.pdf"},
    {"id":"9420","name":"Anthroposophic Medicine a key prescriber of Homeopathic Medicinal Products - Frank Mulder","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/anthroposophic-medicine-key-prescriber-homeopathic-medicinal-products-frank-mulder_en.pdf"},
    {"id":"9424","name":"Presentation - 2018 European Medicines Agency (EMA) and industry stakeholder interactions on Brexit related topics (Marie-Helene Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T02:00:00Z","last_updated_date":"2018-05-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2018-european-medicines-agency-ema-and-industry-stakeholder-interactions-brexit-related-topics-marie-helene-pinheiro_en.pdf"},
    {"id":"9435","name":"Presentation - The role of the European Network of Paediatric Research at the European Medicines Agency - A neonatal network‘s perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:54Z","last_updated_date":"2011-05-27T15:25:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-european-network-paediatric-research-european-medicines-agency-neonatal-networks-perspective_en.pdf"},
    {"id":"9449","name":"Presentation - Update on patient involvement in evaluation activities (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-19T02:00:00Z","last_updated_date":"2016-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-patient-involvement-evaluation-activities-isabelle-moulon_en.pdf"},
    {"id":"9459","name":"Presentation - PRAC's perspective: Regulatory challenges and opportunities - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines (Jun...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pracs-perspective-regulatory-challenges-and-opportunities-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-medicines_en.pdf"},
    {"id":"9461","name":"Presentation - Update on the implementation of the pharmacovigilance legislation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-implementation-pharmacovigilance-legislation_en.pdf"},
    {"id":"9505","name":"Presentation - Case study: Sample size estimation for a paediatric clinical trial utilising external information from historical trials in adults and children - Break-out session 3 theme 4","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-sample-size-estimation-paediatric-clinical-trial-utilising-external-information-historical-trials-adults-and-children-break-out-session-3-theme-4_en.pdf"},
    {"id":"9509","name":"Presentation - Industry challenges for developing emergency vaccines (David John)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T11:37:00Z","last_updated_date":"2017-05-18T11:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-challenges-developing-emergency-vaccines-david-john_en.pdf"},
    {"id":"9510","name":"EU initiatives for research on rare diseases: Charles Kessler","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-initiatives-research-rare-diseases-charles-kessler_en.pdf"},
    {"id":"9517","name":"Presentation - Identification and traceability of biological products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-identification-and-traceability-biological-products_en.pdf"},
    {"id":"9519","name":"Overview of GMP Inspections conducted by Irish Medicines Board - Lorraine Nolan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-gmp-inspections-conducted-irish-medicines-board-lorraine-nolan_en.pdf"},
    {"id":"9525","name":"Presentation - Identifying centres and networks with the capacity and expertise to conduct PASS in children (Dirk Mentzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-identifying-centres-and-networks-capacity-and-expertise-conduct-pass-children-dirk-mentzer_en.pdf"},
    {"id":"9544","name":"Presentation - Identification of medicinal products (IDMP) actions log on Substance, Product, Organisation and Referential (SPOR)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-identification-medicinal-products-idmp-actions-log-substance-product-organisation-and-referential-spor_en.pdf"},
    {"id":"9546","name":"Presentation - Support available to SMEs nationally and internationally – Afssaps, Dr. Stephane Palies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-support-available-smes-nationally-and-internationally-afssaps-dr-stephane-palies_en.pdf"},
    {"id":"9554","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Patient involvement in the PRAC (Jane Ahlqvist Rastad)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-patient-involvement-prac-jane-ahlqvist-rastad_en.pdf"},
    {"id":"9564","name":"Presentation - Pharmacokinetics and pharmacogenomics: Building blocks for the cases in session 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacokinetics-and-pharmacogenomics-building-blocks-cases-session-3_en.pdf"},
    {"id":"9581","name":"Presentation - Section 4.4: Special warnings and precautions for use","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-44-special-warnings-precautions-use_en.pdf"},
    {"id":"9585","name":"Presentation - Scientific developments: VICH update on work on biological (Esther Werner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-developments-vich-update-work-biological-esther-werner_en.pdf"},
    {"id":"9586","name":"Presentation - Update on investigational ATMP concept paper guideline (Ilona Reischl)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-investigational-atmp-concept-paper-guideline-ilona-reischl_en.pdf"},
    {"id":"9590","name":"Presentation - Regulatory view (Flora Musuamba Tshinanu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-view-flora-musuamba-tshinanu_en.pdf"},
    {"id":"9633","name":"Presentation - Overview of recent changes in the centralised procedure (Michael Berntgen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-12T14:00:01Z","last_updated_date":"2015-11-12T14:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-recent-changes-centralised-procedure-michael-berntgen_en.pdf"},
    {"id":"9681","name":"Presentation - Early dialogue: Focus on PRIME (Rob Hemmings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-early-dialogue-focus-prime-rob-hemmings_en.pdf"},
    {"id":"9693","name":"Presentation - Challenges in newborn drug development: US perspective (Jon Davis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-newborn-drug-development-us-perspective-jon-davis_en.pdf"},
    {"id":"9694","name":"Presentation - Orphan medicinal products in the United States: current marketing authorisations for Gaucher disease (Carla Epps)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-28T01:00:00Z","last_updated_date":"2012-11-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orphan-medicinal-products-united-states-current-marketing-authorisations-gaucher-disease-carla-epps_en.pdf"},
    {"id":"9697","name":"Presentation - Impact of reimbursement policies on prudent use, availability and pipeline of new antibacterials (Ad Schuurman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-reimbursement-policies-prudent-use-availability-and-pipeline-new-antibacterials-ad-schuurman_en.pdf"},
    {"id":"9701","name":"Presentation - 2.3 Some considerations about combining / borrowing evidence in clinical trials for rare disease (Armin Koch, Kristina Weber)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-23-some-considerations-about-combining-borrowing-evidence-clinical-trials-rare-disease-armin-koch-kristina-weber_en.pdf"},
    {"id":"9703","name":"Presentation - Do children need adult type trials (J. Taminiau)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-do-children-need-adult-type-trials-j-taminiau_en.pdf"},
    {"id":"9710","name":"Presentation - EMA position on Compliance Check (including validation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-position-compliance-check-including-validation_en.pdf"},
    {"id":"9731","name":"Presentation - Going digital: Current initiatives (Andrea Johnson, Olivier Simoen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-going-digital-current-initiatives-andrea-johnson-olivier-simoen_en.pdf"},
    {"id":"9737","name":"Recent experience in quality assessment - Sol Ruiz","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/recent-experience-quality-assessment-sol-ruiz_en.pdf"},
    {"id":"9742","name":"Presentation - Registry initiative - April 2018","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T16:30:00Z","last_updated_date":"2018-05-02T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-registry-initiative-april-2018_en.pdf"},
    {"id":"9746","name":"Presentation - Presentation - Biomarkers (Arthur Burghes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-presentation-biomarkers-arthur-burghes_en.pdf"},
    {"id":"9777","name":"Presentation - Workshop on data requirements for vaccines March 2015: impact on availability (Faye Ioannou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-data-requirements-vaccines-march-2015-impact-availability-faye-ioannou_en.pdf"}    {"id":"9783","name":"Presentation - Working group: Public-private partnership (S. Tansey)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-public-private-partnership-s-tansey_en.pdf"},
    {"id":"9789","name":"Presentation - Dose - response - anticoagulants (Robert Temple)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-response-anticoagulants-robert-temple_en.pdf"},
    {"id":"9793","name":"Presentation - Objectives and problem statement (Janina Karres)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-objectives-and-problem-statement-janina-karres_en.pdf"},
    {"id":"9809","name":"Transparency at the MEB: a necessity","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/transparency-meb-necessity_en.pdf"},
    {"id":"9824","name":"Presentation - Agenda item 4: Federal Institute for Drugs and Medical Devices (UCUM) - current situation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2015-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-4-federal-institute-drugs-medical-devices-ucum-current-situation_en.pdf"},
    {"id":"9842","name":"Presentation - Module 3 - Early engagement on medicine development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T02:00:00Z","last_updated_date":"2018-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-3-early-engagement-medicine-development_en.pdf"},
    {"id":"9854","name":"Presentation - Data retrieval using the new standardised medical  dictionary for regulatory activities queries (SMQs) medication errors (Christina Winter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-retrieval-using-new-standardised-medical-dictionary-regulatory-activities-queries-smqs-medication-errors-christina-winter_en.pdf"},
    {"id":"9874","name":"Presentation - Safety of new products: do we have enough tools in place? (Flora Peyvandi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safety-new-products-do-we-have-enough-tools-place-flora-peyvandi_en.pdf"},
    {"id":"9895","name":"Presentation - Diagnostic criteria for neuromyelitis optica 2014 (Brian G. Weinshenker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-diagnostic-criteria-neuromyelitis-optica-2014-brian-g-weinshenker_en.pdf"},
    {"id":"9922","name":"Presentation - Session 2 discussion and questions (Richard Finkel, Eduardo Tizzano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-discussion-and-questions-richard-finkel-eduardo-tizzano_en.pdf"},
    {"id":"9943","name":"Presentation - Minor Use / Minor Species policy industry feedback (Alexander Bà¶ttner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-minor-use-minor-species-policy-industry-feedback-alexander-bapttner_en.pdf"},
    {"id":"9945","name":"EP RUMA - turning aspiration into reality - Declan O' Brien","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ep-ruma-turning-aspiration-reality-declan-o-brien_en.pdf"},
    {"id":"9978","name":"Presentation - Nanomedicines - Current initiatives in Canada, Duc Vu, Health Canada","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nanomedicines-current-initiatives-canada-duc-vu-health-canada_en.pdf"},
    {"id":"9985","name":"The role of the Paediatric Committee and short history of previous activities - Dr Paolo Rossi","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T00:09:21Z","last_updated_date":"2009-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/role-paediatric-committee-and-short-history-previous-activities-dr-paolo-rossi_en.pdf"},
    {"id":"10010","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Greg Perry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-greg-perry_en.pdf"},
    {"id":"10011","name":"Presentation - The importance of D-E-R characterisation in dose selection, labelling and B/R - children (Dirk Mentzer, Ine Rusten)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-importance-d-e-r-characterisation-dose-selection-labelling-and-br-children-dirk-mentzer-ine-rusten_en.pdf"},
    {"id":"10029","name":"EMEA experience in oncology drug approval - Francesco Pignatti","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-12-16T00:09:21Z","last_updated_date":"2005-12-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-experience-oncology-drug-approval-francesco-pignatti_en.pdf"},
    {"id":"10038","name":"Presentation - Implementation of new eligibility requirements and working party mandates for 2016-2019 (Nathalie Bere and Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-new-eligibility-requirements-and-working-party-mandates-2016-2019-nathalie-bere-and-ivana-silva_en.pdf"},
    {"id":"10039","name":"Presentation - EBG’s perspective on the draft guideline on the non-clinical/clinical issues (Mark McCamish)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ebgs-perspective-draft-guideline-non-clinicalclinical-issues-mark-mccamish_en.pdf"},
    {"id":"10062","name":"Presentation - Post-authorisation safety studies and the European Union post-authorisation-safety-study register (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-authorisation-safety-studies-and-european-union-post-authorisation-safety-study-register-xavier-kurz_en.pdf"},
    {"id":"10090","name":"Boosting drug development through public-private partnerships: The Innovative Medicines Initiative model (H. Laverty)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-02-12T01:00:00Z","last_updated_date":"2013-02-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/boosting-drug-development-through-public-private-partnerships-innovative-medicines-initiative-model-h-laverty_en.pdf"},
    {"id":"10101","name":"Presentation - How scientific advice procedures can support innovation - European Medicines Agency veterinary medicines innovation day (Rory Breathnach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-scientific-advice-procedures-can-support-innovation-european-medicines-agency-veterinary-medicines-innovation-day-rory-breathnach_en.pdf"},
    {"id":"10111","name":"Presentation -  CMC aspects of gene therapy medicinal products (Matthias Renner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-27T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cmc-aspects-gene-therapy-medicinal-products-matthias-renner_en.pdf"},
    {"id":"10132","name":"Presentation - Sections 7 to 10 related to the marketing authorisation; Sections 11 and 12 related to radiopharmaceuticals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sections-7-10-related-marketing-authorisation-sections-11-12-related-radiopharmaceuticals_en.pdf"},
    {"id":"10133","name":"Session 2 - Non-Clinical Issues - Innovator Industry Presentation - Danuta Herzyk","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-2-non-clinical-issues-innovator-industry-presentation-danuta-herzyk_en.pdf"},
    {"id":"10144","name":"Presentation - International workshop on the ethical and good-clinical-practice aspects of clinical trials conducted in third countries","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-17T18:34:04Z","last_updated_date":"2011-05-17T18:34:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-workshop-ethical-and-good-clinical-practice-aspects-clinical-trials-conducted-third-countries_en.pdf"},
    {"id":"10152","name":"Presentation - Subgroup analyses in confirmatory trials – European Federation of Pharmaceutical Industries and Associations (EFPIA) perspectives (Albert Radlmaier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-subgroup-analyses-confirmatory-trials-european-federation-pharmaceutical-industries-and-associations-efpia-perspectives-albert-radlmaier_en.pdf"},
    {"id":"10155","name":"Presentation - Access to EudraVigilance data – demonstration","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-08-14T14:00:00Z","last_updated_date":"2012-08-14T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-access-eudravigilance-data-demonstration_en.pdf"},
    {"id":"10161","name":"Presentation - Session 2.1: Clinical issues: Could we accept non-inferiority instead of equivalence trials in specific situations?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:52Z","last_updated_date":"2012-06-15T17:10:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-21-clinical-issues-could-we-accept-non-inferiority-instead-equivalence-trials-specific-situations_en.pdf"},
    {"id":"10185","name":"Presentation: OKIDS activity update, learnings and improvements","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-okids-activity-update-learnings-and-improvements_en.pdf"},
    {"id":"10189","name":"Presentation - We are here for our fellow patients (E. Deschamps)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T17:06:00Z","last_updated_date":"2017-12-11T17:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-we-are-here-our-fellow-patients-e-deschamps_en.pdf"},
    {"id":"10193","name":"Presentation - Novel and innovative nanotechnology-based delivery systems, Alexander Kabanov, University of Nebraska Medical Center","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-novel-and-innovative-nanotechnology-based-delivery-systems-alexander-kabanov-university-nebraska-medical-center_en.pdf"},
    {"id":"10202","name":"Presentation - Update on the IMI2 Proposal to Build a Sustainable pan-European Paediatric Clinical Trials Network (William R Treem)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T13:45:00Z","last_updated_date":"2016-10-28T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-imi2-proposal-build-sustainable-pan-european-paediatric-clinical-trials-network-william-r-treem_en.pdf"},
    {"id":"10206","name":"Presentation - General considerations from industry- Session 2 (Keith Watson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-considerations-industry-session-2-keith-watson_en.pdf"},
    {"id":"10211","name":"Presentation - Preservatives: Are they safe?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preservatives-are-they-safe_en.pdf"},
    {"id":"10214","name":"Presentation - EGGVP","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eggvp_en.pdf"},
    {"id":"10220","name":"Presentation - A European network of paediatric research: the contribution of regulators","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:47Z","last_updated_date":"2011-05-27T15:25:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-paediatric-research-contribution-regulators_en.pdf"},
    {"id":"10229","name":"Presentation - e-DoI and e-CV submission: Why – Who – What – How? (Luc Van Santvliet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-e-doi-and-e-cv-submission-why-who-what-how-luc-van-santvliet_en.pdf"},
    {"id":"10237","name":"Presentation - Setting the scene: Steering Group introduction to focus group and objectives (J.  Orand and F. Ioannou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T13:30:00Z","last_updated_date":"2017-11-16T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-setting-scene-steering-group-introduction-focus-group-and-objectives-j-orand-and-f-ioannou_en.pdf"},
    {"id":"10250","name":"Presentation - Dose–exposure-response relationship - Break-out session 2 theme 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-exposure-response-relationship-break-out-session-2-theme-1_en.pdf"},
    {"id":"10260","name":"Presentation - Practical aspects of working electronically in the network: Croatian experience (Dubravka Sudić)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-practical-aspects-working-electronically-network-croatian-experience-dubravka-sudia_en.pdf"},
    {"id":"10262","name":"Centralised Procedure EFPIA Analysis of Performance Indicators New Applications 2005-2006 - Edwin Ruighaver","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/centralised-procedure-efpia-analysis-performance-indicators-new-applications-2005-2006-edwin-ruighaver_en.pdf"},
    {"id":"10267","name":"Presentation - Agenda point 4: ESVAC guidance on species data – State of play (Claire Chauvin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-03T02:00:00Z","last_updated_date":"2017-04-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-point-4-esvac-guidance-species-data-state-play-claire-chauvin_en.pdf"},
    {"id":"10268","name":"Presentation - RMP template (Caroline Voltz-Girolt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T16:00:00Z","last_updated_date":"2015-06-25T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rmp-template-caroline-voltz-girolt_en.pdf"},
    {"id":"10271","name":"Presentation - Paediatric regulation: an update on submissions of paediatric investigation plans","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-regulation-update-submissions-paediatric-investigation-plans_en.pdf"},
    {"id":"10274","name":"Quality by Design - Application and perspectives for biologicals - Evdokia Korakianiti","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/quality-design-application-and-perspectives-biologicals-evdokia-korakianiti_en.pdf"},
    {"id":"10277","name":"Presentation - How are medicines evaluated at the EMA (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-are-medicines-evaluated-ema-nathalie-bere_en.pdf-0"},
    {"id":"10289","name":"Presentation - What is a package leaflet – How to review it? (Claire Espinasse)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-package-leaflet-how-review-it-claire-espinasse_en.pdf"},
    {"id":"10317","name":"Presentation - The cluster medicine approach","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cluster-medicine-approach_en.pdf"},
    {"id":"10320","name":"EMEA Performance Indicators - Extensions of indications  - Manuel Haas","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-performance-indicators-extensions-indications-manuel-haas_en.pdf"},
    {"id":"10321","name":"Presentation - Industry view (Britta Paschen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-view-britta-paschen_en.pdf"},
    {"id":"10334","name":"Presentation - Transitional arrangements","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transitional-arrangements_en.pdf"},
    {"id":"10341","name":"Presentation - FVE point of view on principles for assignment of DDDA and DCDA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T13:00:00Z","last_updated_date":"2015-04-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fve-point-view-principles-assignment-ddda-and-dcda_en.pdf"},
    {"id":"10379","name":"Presentation - Introduction: Regulation of allergen products and the German Regulation for Therapy Allergens","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-21T02:00:00Z","last_updated_date":"2011-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-regulation-allergen-products-and-german-regulation-therapy-allergens_en.pdf"},
    {"id":"10384","name":"Pharmacovigilance, H Fitt, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pharmacovigilance-h-fitt-ema_en.pdf"},
    {"id":"10394","name":"Presentation - Industry perspective: Bayer/Janssen (Scott D. Berkowitz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-bayerjanssen-scott-d-berkowitz_en.pdf"},
    {"id":"10400","name":"Presentation - Overview of CFTR Modifier Pipeline (Tim Lee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-cftr-modifier-pipeline-tim-lee_en.pdf"},
    {"id":"10414","name":"Presentation - Pharmacovigilance: Latest developments - industry perspective (Yvonne Hausmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-latest-developments-industry-perspective-yvonne-hausmann_en.pdf"},
    {"id":"10415","name":"Presentation -  The Salford Lung Study (Ashley Woodcock and David Leather)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-salford-lung-study-ashley-woodcock-and-david-leather_en.pdf"},
    {"id":"10417","name":"The voluntary harmonisation procedure (VHP) for the assessment of multinational clinical trial applications, Dr Hartmut Krafft","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/voluntary-harmonisation-procedure-vhp-assessment-multinational-clinical-trial-applications-dr-hartmut-krafft_en.pdf"},
    {"id":"10419","name":"Presentation - Inflammatory bowel disease (IBD) - Overview of the paediatric investigation plans","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-22T01:00:00Z","last_updated_date":"2011-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-inflammatory-bowel-disease-ibd-overview-paediatric-investigation-plans_en.pdf"},
    {"id":"10420","name":"Presentation - Industry perspective: Non-prescription medicines (Hubertus Cranz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-non-prescription-medicines-hubertus-cranz_en.pdf"},
    {"id":"10435","name":"Presentation - PGEU launches The European Pharmacists’ Professional Forum (EPPF) (Jamie Wilkinson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pgeu-launches-european-pharmacists-professional-forum-eppf-jamie-wilkinson_en.pdf"},
    {"id":"10440","name":"Presentation - ISO IDMP implementation – small agency’s perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T02:00:00Z","last_updated_date":"2015-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-iso-idmp-implementation-small-agencys-perspective_en.pdf"},
    {"id":"10465","name":"Presentation - Marketing-authorisation application pre-submission issues and European Medicines Agency meeting opportunities (Irene Rager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-marketing-authorisation-application-pre-submission-issues-and-european-medicines-agency-meeting-opportunities-irene-rager_en.pdf"},
    {"id":"10481","name":"Frontotemporal Dementia: More than an exclusion diagnosis? - Alessandro Padovani","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-11T00:09:21Z","last_updated_date":"2008-02-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/frontotemporal-dementia-more-exclusion-diagnosis-alessandro-padovani_en.pdf"},
    {"id":"10483","name":"Biologics in inflammatory disease - a novel European network for pharmacovigilance and pharmacoepidemiology - Dr. J. Askling","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/biologics-inflammatory-disease-novel-european-network-pharmacovigilance-and-pharmacoepidemiology-dr-j-askling_en.pdf"},
    {"id":"10494","name":"Presentation - EMA SPOR master data management roadmap (Kepa Amutxastegi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T02:00:00Z","last_updated_date":"2015-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-spor-master-data-management-roadmap-kepa-amutxastegi_en.pdf"},
    {"id":"10504","name":"Presentation - Topic 6 - Conclusions and next steps - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Michael Berntgen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-6-conclusions-and-next-steps-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-michael-berntgen_en.pdf"},
    {"id":"10558","name":"Presentation - Clinical trial safety reporting requirements (Sophia Mylona)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T12:14:00Z","last_updated_date":"2017-03-30T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trial-safety-reporting-requirements-sophia-mylona_en.pdf"},
    {"id":"10564","name":"Presentation - Detection of toxicity to reproduction for human pharmaceuticals (G. Waxenecker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T10:54:00Z","last_updated_date":"2017-11-15T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-detection-toxicity-reproduction-human-pharmaceuticals-g-waxenecker_en.pdf"},
    {"id":"10578","name":"Presentation - European Medicines Agency update on Clinical Data Publication (CDP) (Anne-Sophie Henry-Eude)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-update-clinical-data-publication-cdp-anne-sophie-henry-eude_en.pdf"},
    {"id":"10584","name":"Presentation - Session III - Narcotics for sedation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-18T02:00:00Z","last_updated_date":"2016-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-iii-narcotics-sedation_en.pdf"},
    {"id":"10588","name":"Presentation - The possible mechanisms of the disease, Eugene Major","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-possible-mechanisms-disease-eugene-major_en.pdf"},
    {"id":"10603","name":"Presentation - European-public-assessment-report summaries (D. Glanville)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-public-assessment-report-summaries-d-glanville_en.pdf"},
    {"id":"10623","name":"Presentation - European Medicines Agency survey on \"Centralised post-marketing authorisation procedures\" 2015 (Marie-Helene Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T02:00:00Z","last_updated_date":"2015-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-survey-centralised-post-marketing-authorisation-procedures-2015-marie-helene-pinheiro_en.pdf"},
    {"id":"10636","name":"Presentation - Holistic approach to paediatric research: clinical trial facilitation group (A.M. Jason Lang)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:04:00Z","last_updated_date":"2018-06-18T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-clinical-trial-facilitation-group-am-jason-lang_en.pdf"},
    {"id":"10642","name":"Presentation - General considerations from industry - Session 4 (Andrew Lennard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-considerations-industry-session-4-andrew-lennard_en.pdf"},
    {"id":"10650","name":"Presentation - Update on Working Group 6 (Saul Faust, Ron Portman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-working-group-6-saul-faust-ron-portman_en.pdf"},
    {"id":"10696","name":"Presentation - Complementary initiatives for public health (Franck Diafouka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-complementary-initiatives-public-health-franck-diafouka_en.pdf"},
    {"id":"10698","name":"Presentation - Pharmacogenomics in rare diseases: Development strategy for ivacaftor as a therapy for cystic fibrosis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenomics-rare-diseases-development-strategy-ivacaftor-therapy-cystic-fibrosis_en.pdf"},
    {"id":"10703","name":"Presentation - Information for the use of medicines in the elderly (F. Cerreta, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-use-medicines-elderly-f-cerreta-ema_en.pdf"},
    {"id":"10710","name":"Presentation - Shortages survey 2015 (Maria-Jesus Alcaraz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-shortages-survey-2015-maria-jesus-alcaraz_en.pdf"},
    {"id":"10714","name":"Presentation - The new veterinary medicines regulation and other new legislative acts - European Medicines Agency veterinary medicines innovation day (Josa Preuss)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-veterinary-medicines-regulation-and-other-new-legislative-acts-european-medicines-agency-veterinary-medicines-innovation-day-josa-preuss_en.pdf"},
    {"id":"10725","name":"Presentation - Pharmacovigilance in the European Union (Andrej Segec)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-european-union-andrej-segec_en.pdf"},
    {"id":"10729","name":"Presentation - Clinical exposure - response relationships (Evelyn Ellis-Grosse)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-exposure-response-relationships-evelyn-ellis-grosse_en.pdf"},
    {"id":"10734","name":"Presentation - Paediatric Rheumatology InterNational Trials Organization (Nicola Ruperto, PRINTO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-rheumatology-international-trials-organization-nicola-ruperto-printo_en.pdf"},
    {"id":"10752","name":"Presentation - Holistic approach to paediatric research: ethics committees (M.A. Ribeiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:04:00Z","last_updated_date":"2018-06-18T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-ethics-committees-ma-ribeiro_en.pdf"},
    {"id":"10764","name":"Presentation - Histology-independent indications (Kristina Larsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T17:16:00Z","last_updated_date":"2018-06-06T17:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-histology-independent-indications-kristina-larsson_en.pdf"},
    {"id":"10777","name":"Presentation - Extrapolation challenges in pediatric PAH  - Possible solutions for a feasible, global study (M. Bacchi, A. Morganti, P. Cornelisse, J. Bolognese, C. Lesage, A. Kà¼mmel, P. Nilsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extrapolation-challenges-pediatric-pah-possible-solutions-feasible-global-study-m-bacchi-morganti-p-cornelisse-j-bolognese-c-lesage-ka-14mmel-p-nilsson_en.pdf"},
    {"id":"10778","name":"Presentation - Summary of product characteristics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-product-characteristics_en.pdf"},
    {"id":"10792","name":"Presentation - Periodic safety update single assessment (PSUSA)  procedure EU reference dates (EURD) list and submission aspect (Menno Van Der Elst)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-periodic-safety-update-single-assessment-psusa-procedure-eu-reference-dates-eurd-list-and-submission-aspect-menno-van-der-elst_en.pdf"},
    {"id":"10794","name":"Presentation - 2.1 Borrowing information at the planning stage (Kit Roes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-21-borrowing-information-planning-stage-kit-roes_en.pdf"},
    {"id":"10800","name":"Presentation - Regulators perspective: using prior knowledge in applications - Session 1 (Mats Welin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulators-perspective-using-prior-knowledge-applications-session-1-mats-welin_en.pdf"},
    {"id":"10806","name":"Presentation - Patient interaction with consumers - 10 years of PCWP (Francesca Cattarin, BEUC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-interaction-consumers-10-years-pcwp-francesca-cattarin-beuc_en.pdf"},
    {"id":"10812","name":"Presentation - An SME perspective on the implementation of the EU Clinical Trials Regulation (Kate Darwin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T12:14:00Z","last_updated_date":"2017-03-30T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-perspective-implementation-eu-clinical-trials-regulation-kate-darwin_en.pdf"},
    {"id":"10818","name":"Presentation - Topic 3 - Timely completion of the studies of paediatric investigation plans (PIPs): Industry perspective - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (H....","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-3-timely-completion-studies-paediatric-investigation-plans-pips-industry-perspective-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-h_en.pdf"},
    {"id":"10820","name":"Presentation - Traditional validation: Upstream (Vijay Chiruvolu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-traditional-validation-upstream-vijay-chiruvolu_en.pdf"},
    {"id":"10855","name":"Presentation - EV Reporting process for users: Export functions in EVWEB - Training Module EV-M3c","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-06T15:00:00Z","last_updated_date":"2017-01-06T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ev-reporting-process-users-export-functions-evweb-training-module-ev-m3c_en.pdf"},
    {"id":"10883","name":"Presentation - PIP session: Retinopathy of prematurity","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pip-session-retinopathy-prematurity_en.pdf"}    {"id":"10894","name":"The ethical review process: perspectives from an Ethics Committee, David Neal","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ethical-review-process-perspectives-ethics-committee-david-neal_en.pdf"},
    {"id":"10920","name":"Guideline on acceptability of invented names - Hanne Brokopp","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-09-11T02:09:21Z","last_updated_date":"2006-09-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/guideline-acceptability-invented-names-hanne-brokopp_en.pdf"},
    {"id":"10933","name":"Presentation - Pharmacovigilance Risk Assessment Committee (PRAC) feedback - EMA's PCWP and HCPWP joint meeting (R. Anderson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-risk-assessment-committee-prac-feedback-emas-pcwp-and-hcpwp-joint-meeting-r-anderson_en.pdf"},
    {"id":"10941","name":"Presentation - Welcome, PML - Balancing risks and benefits - the patients' view, Christoph Thalheim","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-welcome-pml-balancing-risks-and-benefits-patients-view-christoph-thalheim_en.pdf"},
    {"id":"10961","name":"Presentation - 2.2 Hierarchical models: a framework for evidence synthesis (Tim Friede)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-22-hierarchical-models-framework-evidence-synthesis-tim-friede_en.pdf"},
    {"id":"10969","name":"Presentation - Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA) report (Jordi Torren)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T13:00:00Z","last_updated_date":"2015-04-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-interagency-antimicrobial-consumption-and-resistance-analysis-jiacra-report-jordi-torren_en.pdf"},
    {"id":"10970","name":"Presentation - Trials with neonates: desirable scientific approaches, their ethical issues and potential solutions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T11:00:00Z","last_updated_date":"2012-01-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-trials-neonates-desirable-scientific-approaches-their-ethical-issues-and-potential-solutions_en.pdf"},
    {"id":"10971","name":"Continuous Quality Verification: an approach to process validation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/continuous-quality-verification-approach-process-validation_en.pdf"},
    {"id":"10978","name":"Presentation - GVP paediatrics highlights. Product- or population-specific considerations IV: Paediatric population (R. De Lisa, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T02:00:00Z","last_updated_date":"2018-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gvp-paediatrics-highlights-product-or-population-specific-considerations-iv-paediatric-population-r-de-lisa-ema_en.pdf"},
    {"id":"10981","name":"Presentation - Day 2: Uveiitiis - Clinician/Academic view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-uveiitiis-clinicianacademic-view_en.pdf"},
    {"id":"10987","name":"Presentation - Update on European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) organisation. ESVAC 2011 data / report (Kari Grave, Jordi Torren, David Mackay, Arno Muller)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T13:00:00Z","last_updated_date":"2013-04-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-european-surveillance-veterinary-antimicrobial-consumption-esvac-organisation-esvac-2011-data-report-kari-grave-jordi-torren-david-mackay-arno-muller_en.pdf"},
    {"id":"10996","name":"Presentation - Conflicts of interests: Striking the right balance (Anja Holm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-conflicts-interests-striking-right-balance-anja-holm_en.pdf"},
    {"id":"11007","name":"Presentation - Closing remarks (David Tainsh, Keith Pugh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-closing-remarks-david-tainsh-keith-pugh_en.pdf"},
    {"id":"11020","name":"Paediatric Medicines - Fergal Donnelly","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-11-16T00:09:21Z","last_updated_date":"2009-11-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/paediatric-medicines-fergal-donnelly_en.pdf"},
    {"id":"11042","name":"Presentation - European CRO Federation (EUCROF) (Stefano Marini)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-cro-federation-eucrof-stefano-marini_en.pdf"},
    {"id":"11062","name":"Presentation - CAT feedback (K. Breen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T16:50:00Z","last_updated_date":"2017-12-11T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cat-feedback-k-breen_en.pdf"},
    {"id":"11063","name":"Presentation - Regulatory scene setting: Benefits and risks of seamless phase I / II trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-scene-setting-benefits-and-risks-seamless-phase-i-ii-trials_en.pdf"},
    {"id":"11068","name":"Manure degradation studies experiences - Gregor Scheef","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-06-23T02:09:21Z","last_updated_date":"2009-06-23T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/manure-degradation-studies-experiences-gregor-scheef_en.pdf"},
    {"id":"11095","name":"Presentation - Proposal for an Enpr-EMA webinar (John Watson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T13:45:00Z","last_updated_date":"2016-10-28T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposal-enpr-ema-webinar-john-watson_en.pdf"},
    {"id":"11110","name":"Presentation - Procedures and support to developers (Patrick Celis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T02:00:00Z","last_updated_date":"2014-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-procedures-and-support-developers-patrick-celis_en.pdf"},
    {"id":"11115","name":"Presentation - Multiplicity and estimation (Peter Bauer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multiplicity-and-estimation-peter-bauer_en.pdf"},
    {"id":"11141","name":"Data Elements for Transmission of Individual Case Safety Reports (ICSRs) - Ayumi Endo","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/data-elements-transmission-individual-case-safety-reports-icsrs-ayumi-endo_en.pdf"},
    {"id":"11142","name":"Presentation - Patients' and Consumers' Working Party (PCWP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T16:00:00Z","last_updated_date":"2016-02-15T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-and-consumers-working-party-pcwp_en.pdf"},
    {"id":"11157","name":"Implementation of the HMA Strategic Plan on Antimicrobial Issues (CZ/SE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:09:21Z","last_updated_date":"2009-05-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/implementation-hma-strategic-plan-antimicrobial-issues-czse_en.pdf"},
    {"id":"11168","name":"Presentation - Centralised-procedure extension to Croatia: Industry perspective (Mislav VuÄić)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-centralised-procedure-extension-croatia-industry-perspective-mislav-vuaia_en.pdf"},
    {"id":"11169","name":"Presentation - Dose finding under model uncertainty – A case study based on a multi-regional clinical trial - Break-out session 2 theme 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-finding-under-model-uncertainty-case-study-based-multi-regional-clinical-trial-break-out-session-2-theme-1_en.pdf"},
    {"id":"11171","name":"Presentation - Advanced therapy medicinal products (ATMPs) and ATMP Regulation (Patrick Celis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advanced-therapy-medicinal-products-atmps-and-atmp-regulation-patrick-celis_en.pdf"},
    {"id":"11176","name":"Presentation - Case Study on Statistical Comparison of Stability Data - Importance of Data Quality (F. Innerbichler, Novartis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-statistical-comparison-stability-data-importance-data-quality-f-innerbichler-novartis_en.pdf"},
    {"id":"11193","name":"Presentation - Pharmacovigilance fees (Michael Lenihan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-fees-michael-lenihan_en.pdf"},
    {"id":"11216","name":"S2(R1) Revision of the Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use - Peter Kasper","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/s2r1-revision-guidance-genotoxicity-testing-and-data-interpretation-pharmaceuticals-intended-human-use-peter-kasper_en.pdf"},
    {"id":"11223","name":"Presentation - Access to EudraVigilance data – demonstration","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T14:00:00Z","last_updated_date":"2012-07-06T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-access-eudravigilance-data-demonstration_en.pdf-0"},
    {"id":"11233","name":"Quality requirements for cell-based medicinal products - Paula Salmikangas","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/quality-requirements-cell-based-medicinal-products-paula-salmikangas_en.pdf"},
    {"id":"11238","name":"Product information – Hilde Boone","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2003-05-08T02:00:00Z","last_updated_date":"2003-05-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/product-information-hilde-boone_en.pdf"},
    {"id":"11247","name":"Presentation - Accelerated assessment (AA): review of 10 months experience with the new AA process (Victoria Palmi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:30:00Z","last_updated_date":"2018-01-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accelerated-assessment-aa-review-10-months-experience-new-aa-process-victoria-palmi_en.pdf"},
    {"id":"11260","name":"Presentation - Session 2.3 - Working Group on Young People Advisory Groups (Pamela Dicks)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-16T02:00:00Z","last_updated_date":"2017-06-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-23-working-group-young-people-advisory-groups-pamela-dicks_en.pdf"},
    {"id":"11274","name":"Presentation - PRIME: Observations post-launch (Jordi Llinares, Zahra Hanaizi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-19T02:00:00Z","last_updated_date":"2016-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prime-observations-post-launch-jordi-llinares-zahra-hanaizi_en.pdf"},
    {"id":"11275","name":"Presentation - Helping doctors and patients make sense of health statistics (Wolfgang Gaissmaier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-helping-doctors-and-patients-make-sense-health-statistics-wolfgang-gaissmaier_en.pdf"},
    {"id":"11280","name":"Presentation - Preparing the CMC section of IMPD for biological/biotechnology derived substances (Una Moore)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-27T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparing-cmc-section-impd-biologicalbiotechnology-derived-substances-una-moore_en.pdf"},
    {"id":"11285","name":"Business Pipeline Activity - Enrico Tognana","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/business-pipeline-activity-enrico-tognana_en.pdf"},
    {"id":"11321","name":"Presentation - ESVAC 2014 report. Interactive database (Kristine Ignate)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T17:00:00Z","last_updated_date":"2016-03-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esvac-2014-report-interactive-database-kristine-ignate_en.pdf"},
    {"id":"11333","name":"Presentation - Introduction of the PBPK Guideline and expectations of the day (Anna Nordmark)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-pbpk-guideline-and-expectations-day-anna-nordmark_en.pdf"},
    {"id":"11346","name":"Presentation - Nanosystems in regenerative medicine, Jà¶ns Hilborn, Uppsala University","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nanosystems-regenerative-medicine-japns-hilborn-uppsala-university_en.pdf"},
    {"id":"11349","name":"Presentation - The European Medicines Agency geriatric medicines strategy report from the March 2012 workshop to the Healthcare Professionals' Working Group meeting","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-08-14T14:00:00Z","last_updated_date":"2012-08-14T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-geriatric-medicines-strategy-report-march-2012-workshop-healthcare-professionals-working-group-meeting_en.pdf"},
    {"id":"11351","name":"Presentation - The role of single arm trials in Oncology drug development(Gideon Blumenthal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-single-arm-trials-oncology-drug-developmentgideon-blumenthal_en.pdf"},
    {"id":"11371","name":"Presentation - Paediatrics: Paediatric investigation plan: National agency assessor’s point of view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatrics-paediatric-investigation-plan-national-agency-assessors-point-view_en.pdf"},
    {"id":"11374","name":"Presentation - How could social media data be relevant to regulatory decision-making? (June M Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-could-social-media-data-be-relevant-regulatory-decision-making-june-m-raine_en.pdf"},
    {"id":"11375","name":"Implementation on the Paediatric regulation EMEA views - Nathalie Seigneuret","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/implementation-paediatric-regulation-emea-views-nathalie-seigneuret_en.pdf"},
    {"id":"11386","name":"Presentation - Family involvement in research projects: a parental perspective (Silke Mader)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-family-involvement-research-projects-parental-perspective-silke-mader_en.pdf"},
    {"id":"11390","name":"Presentation - Good pharmacovigilance practices for the European Union (EU-GVP) (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:30:00Z","last_updated_date":"2017-03-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-european-union-eu-gvp-priya-bahri_en.pdf-0"},
    {"id":"11400","name":"Pharmacogenomic markers in EGFR-targeted therapy of lung cancer - Rafal Dziadziuszko","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pharmacogenomic-markers-egfr-targeted-therapy-lung-cancer-rafal-dziadziuszko_en.pdf"},
    {"id":"11425","name":"Presentation - Innovation in medicines and manufacturing (David Tainsh, Keith Pugh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovation-medicines-and-manufacturing-david-tainsh-keith-pugh_en.pdf"},
    {"id":"11426","name":"Presentation - How can summary-of-product-characteristics and European-public-assessment-report information contribute to the safe and effective use of medicines in the older population?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-can-summary-product-characteristics-and-european-public-assessment-report-information-contribute-safe-and-effective-use-medicines-older-population_en.pdf"},
    {"id":"11429","name":"Presentation - CT design - combinations (Samir Khleif) - S5.3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ct-design-combinations-samir-khleif-s53_en.pdf"},
    {"id":"11431","name":"Presentation - Adverse drug reactions in paediatric oncology (Ralf Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T02:00:00Z","last_updated_date":"2014-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adverse-drug-reactions-paediatric-oncology-ralf-herold_en.pdf"},
    {"id":"11433","name":"Presentation - CAT feedback (Kieran Breen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cat-feedback-kieran-breen-ema_en.pdf"},
    {"id":"11441","name":"Presentation - Update on Enpr-EMA activities, achievements and challenges","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-enpr-ema-activities-achievements-and-challenges_en.pdf"},
    {"id":"11450","name":"Presentation - Online reporting for patients and healthcare professionals: a practical example (Phil Tregunno)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-online-reporting-patients-and-healthcare-professionals-practical-example-phil-tregunno_en.pdf"},
    {"id":"11453","name":"Presentation - Agenda point 5: Consideration on the ESVAC project from  the Federation of Veterinarians of Europe (FVE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-03T02:00:00Z","last_updated_date":"2017-04-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-point-5-consideration-esvac-project-federation-veterinarians-europe-fve_en.pdf"},
    {"id":"11458","name":"Presentation - Specific methodological issues and implications for risk assessment, Silvia Berkner, German Federal Environmental Agency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-specific-methodological-issues-and-implications-risk-assessment-silvia-berkner-german-federal-environmental-agency_en.pdf"},
    {"id":"11461","name":"Presentation -  Payer opinions in context (Ad Schuurman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-payer-opinions-context-ad-schuurman_en.pdf"},
    {"id":"11476","name":"Presentation - Overview of one-year experience of PRIME eligibility assessment (Robert Hemmings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-07T02:00:00Z","last_updated_date":"2017-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-one-year-experience-prime-eligibility-assessment-robert-hemmings_en.pdf"},
    {"id":"11488","name":"Presentation - Encouraging prudent use of antibiotics (V. J. Chave)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-encouraging-prudent-use-antibiotics-v-j-chave_en.pdf"},
    {"id":"11489","name":"Presentation - Procedure for election of PCWP-HCPWP co-chairs 2016-2019","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-procedure-election-pcwp-hcpwp-co-chairs-2016-2019_en.pdf"},
    {"id":"11499","name":"Biomarkers in the new European regulatory environment - Bruno Flamion","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-12-16T00:09:21Z","last_updated_date":"2005-12-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/biomarkers-new-european-regulatory-environment-bruno-flamion_en.pdf"},
    {"id":"11500","name":"Presentation - Communication campaign: medicines under additional monitoring (Christopher Gadd)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-12-11T01:00:00Z","last_updated_date":"2013-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-campaign-medicines-under-additional-monitoring-christopher-gadd_en.pdf"},
    {"id":"11501","name":"Workshop on the development of an EMEA transparency policy - Draft key principles","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/workshop-development-emea-transparency-policy-draft-key-principles_en.pdf"},
    {"id":"11502","name":"Presentation - Early interactions on innovation at EMA (ITF) (Falk Ehmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-early-interactions-innovation-ema-itf-falk-ehmann_en.pdf"},
    {"id":"11514","name":"Presentation - General considerations from industry - Session 3 (Ron Ogilvie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-considerations-industry-session-3-ron-ogilvie_en.pdf"},
    {"id":"11532","name":"Presentation - Digital Media and Health Topic Group - EMA's PCWP and HCPWP joint meeting (Kathi Apostolidis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-digital-media-and-health-topic-group-emas-pcwp-and-hcpwp-joint-meeting-kathi-apostolidis_en.pdf"},
    {"id":"11534","name":"Presentation - Pharmacovigilance Working Party: Patients' and consumers' experience","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-working-party-patients-and-consumers-experience_en.pdf"},
    {"id":"11539","name":"Presentation - Spontaneous reporting: detecting medication errors and suitability of current systems (Phil Tregunno)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spontaneous-reporting-detecting-medication-errors-and-suitability-current-systems-phil-tregunno_en.pdf"},
    {"id":"11553","name":"Meeting requirements for clinical trials and marketing authorisation reprotoxicity - Peter Kasper","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T00:00:00Z","last_updated_date":"2009-02-02T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/meeting-requirements-clinical-trials-and-marketing-authorisation-reprotoxicity-peter-kasper_en.pdf"},
    {"id":"11558","name":"Paediatric Project / Development Planning 'Key Points to Consider' - Angelika Joos","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/paediatric-project-development-planning-key-points-consider-angelika-joos_en.pdf"},
    {"id":"11575","name":"Presentation: Young Persons Advisory Groups Terms of Reference and updated Work Plan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-young-persons-advisory-groups-terms-reference-and-updated-work-plan_en.pdf"},
    {"id":"11601","name":"Presentation - Cardiology network (Sylvie di Filippo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cardiology-network-sylvie-di-filippo_en.pdf"},
    {"id":"11604","name":"Stem cell-based medicinal products as ATMPs in the EU: Dr Tiina Palomà¤ki","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/stem-cell-based-medicinal-products-atmps-eu-dr-tiina-palomaki_en.pdf"},
    {"id":"11616","name":"Presentation - Involvement of healthcare professionals’ organisations in European Medicines Agency activities in 2011","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T01:00:00Z","last_updated_date":"2011-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-involvement-healthcare-professionals-organisations-european-medicines-agency-activities-2011_en.pdf"},
    {"id":"11621","name":"Presentation - HMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hma_en.pdf"},
    {"id":"11631","name":"Presentation - Use of single arm cohorts/trials to demonstrate clinical benefit for breakthrough therapies and results (Eric H. Rubin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-single-arm-cohortstrials-demonstrate-clinical-benefit-breakthrough-therapies-and-results-eric-h-rubin_en.pdf"},
    {"id":"11634","name":"Presentation - Real World Evidence (RWE) – what have we learned recently at EMA? - EMA's PCWP and HCPWP joint meeting (Kieran Breen, Jamie Wilkinson, Courtney Coleman, Isabel Proano, Sofia Marcha, Birgit Bauer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-real-world-evidence-rwe-what-have-we-learned-recently-ema-emas-pcwp-and-hcpwp-joint-meeting-kieran-breen-jamie-wilkinson-courtney-coleman-isabel-proano-sofia-marcha-birgit-bauer_en.pdf"},
    {"id":"11653","name":"Presentation - Agenda item 2: Ginas meeting highlights","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2015-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-2-ginas-meeting-highlights_en.pdf"},
    {"id":"11657","name":"Commercial confidential information - Principles to be considered","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/commercial-confidential-information-principles-be-considered_en.pdf"},
    {"id":"11682","name":"Presentation - SME workshop: Session 2: Statistical considerations in exploratory studies (Byron Jones)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-29T10:00:00Z","last_updated_date":"2016-02-29T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-workshop-session-2-statistical-considerations-exploratory-studies-byron-jones_en.pdf"},
    {"id":"11683","name":"Presentation - Early dialogue for paediatric development plans (Gunter Egger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T18:21:00Z","last_updated_date":"2017-05-12T18:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-early-dialogue-paediatric-development-plans-gunter-egger_en.pdf"},
    {"id":"11691","name":"Orphan Regulation - The Academic View","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/orphan-regulation-academic-view_en.pdf"},
    {"id":"11716","name":"Presentation - EURORDIS Summer School (Virginie Hivert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eurordis-summer-school-virginie-hivert_en.pdf"},
    {"id":"11737","name":"Presentation - Risk communication, transparency (David Haerry, EATG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-communication-transparency-david-haerry-eatg_en.pdf"},
    {"id":"11741","name":"Presentation - Dutch medicines for children research network (Edwin Spaans)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T16:00:00Z","last_updated_date":"2013-07-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dutch-medicines-children-research-network-edwin-spaans_en.pdf"},
    {"id":"11754","name":"Presentation - The use of antibiotics in humans in the EU: assessing the community and hospital settings (Anna-Pelagia Magiorakos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-antibiotics-humans-eu-assessing-community-and-hospital-settings-anna-pelagia-magiorakos_en.pdf"},
    {"id":"11759","name":"Presentation - EMA Veterinary Portfolio Reviews “Horizon scanning” (Fia Westerholm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-veterinary-portfolio-reviews-horizon-scanning-fia-westerholm_en.pdf"},
    {"id":"11765","name":"Presentation - European Medicines Agency (EMA) - Substance, product, organisation and referential data (SPOR) impact on veterinary stakeholders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-27T01:00:00Z","last_updated_date":"2018-02-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-ema-substance-product-organisation-and-referential-data-spor-impact-veterinary-stakeholders_en.pdf"},
    {"id":"11766","name":"Presentation - Clinical trials designs in neuromyelitis optica and spectrum disorders: Endpoints industry (Ayesh Perera)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-designs-neuromyelitis-optica-and-spectrum-disorders-endpoints-industry-ayesh-perera_en.pdf"},
    {"id":"11791","name":"Presentation - Evaluation, classification and weighting of medication errors from an industry perspective (Liz Swain)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluation-classification-and-weighting-medication-errors-industry-perspective-liz-swain_en.pdf"},
    {"id":"11795","name":"Presentation - Veterinarians experiences: Cattle (I.Lorenz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinarians-experiences-cattle-ilorenz_en.pdf"},
    {"id":"11823","name":"Presentation - Single arm trials in the context (era) of platforms (R. Kaplan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-single-arm-trials-context-era-platforms-r-kaplan_en.pdf"},
    {"id":"11849","name":"Presentation - Joint industry presentation - Industry stakeholder meeting on Brexit and operation of the centralised procedure for human medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T02:00:00Z","last_updated_date":"2018-05-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-industry-presentation-industry-stakeholder-meeting-brexit-and-operation-centralised-procedure-human-medicinal-products_en.pdf"},
    {"id":"11850","name":"Presentation - European Commission (Flora Giorgio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-commission-flora-giorgio_en.pdf"},
    {"id":"11857","name":"fYRoM - Ministry of Health, M Hadzihamza","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/fyrom-ministry-health-m-hadzihamza_en.pdf"},
    {"id":"11859","name":"Presentation - Agenda item 5: ISO IDMP actions log","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2015-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-5-iso-idmp-actions-log_en.pdf"},
    {"id":"11862","name":"Presentation - Keynote lecture - Key ongoing applications in nanosciences and how they apply to pharmaceuticals, Rutledge Ellis-Behnke, MIT","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-keynote-lecture-key-ongoing-applications-nanosciences-and-how-they-apply-pharmaceuticals-rutledge-ellis-behnke-mit_en.pdf"}    {"id":"11873","name":"Presentation - EMA activities in the fight against antimicrobial resistance: Human medicines aspects - Session 2 (Marco Cavaleri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-activities-fight-against-antimicrobial-resistance-human-medicines-aspects-session-2-marco-cavaleri_en.pdf"},
    {"id":"11882","name":"Presentation - Identification and traceability of biological products: European Generic Medicines Association views","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-identification-and-traceability-biological-products-european-generic-medicines-association-views_en.pdf"},
    {"id":"11893","name":"Presentation - European child and  adolescent psychopharmacology network (ECAPN) (A. Zuddas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-child-and-adolescent-psychopharmacology-network-ecapn-zuddas_en.pdf"},
    {"id":"11904","name":"Presentation - Session 5: Histology independent indications - the HTA view (Anja Schiel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-histology-independent-indications-hta-view-anja-schiel_en.pdf"},
    {"id":"11911","name":"Presentation - EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn’s disease (Elmer Schabel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-workshop-development-new-medicinal-products-treatment-ulcerative-colitis-and-crohns-disease-elmer-schabel_en.pdf"},
    {"id":"11919","name":"Presentation - Regulatory view (Robert Hemmings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-view-robert-hemmings_en.pdf"},
    {"id":"11925","name":"Presentation - The policy context of the request for advice on the impact on public and animal health of the use of antibiotics in animals (Mario Nagtzaam)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-policy-context-request-advice-impact-public-and-animal-health-use-antibiotics-animals-mario-nagtzaam_en.pdf"},
    {"id":"11927","name":"Presentation - Summary of 2018 annual workshop","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T16:02:00Z","last_updated_date":"2018-06-18T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-2018-annual-workshop_en.pdf"},
    {"id":"11939","name":"Presentation - Pharmacovigilance Risk Assessment Committee - Five years of operation (J. Raine, PRAC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-risk-assessment-committee-five-years-operation-j-raine-prac_en.pdf"},
    {"id":"11943","name":"Brief summary of the existing systems on collecting data: Sweden","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/brief-summary-existing-systems-collecting-data-sweden_en.pdf"},
    {"id":"11948","name":"Biomarkers - EMEA initiatives and SAWP experience - Bruno Flamion","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/biomarkers-emea-initiatives-and-sawp-experience-bruno-flamion_en.pdf"},
    {"id":"11959","name":"Presentation - ISTH and EAHAD perspective on haemophilia registries (Flora Peyvandi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-isth-and-eahad-perspective-haemophilia-registries-flora-peyvandi_en.pdf"},
    {"id":"11965","name":"Presentation - External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use (Policy 0070):  Second stakeholder meeting on the im...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-policy-0070-second-stakeholder-meeting-im_en.pdf"},
    {"id":"11970","name":"Presentation - 6.3 Incorporating pharmacokinetic information in phase I studies in small populations (Moreno Ursino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-63-incorporating-pharmacokinetic-information-phase-i-studies-small-populations-moreno-ursino_en.pdf"},
    {"id":"11976","name":"Presentation - Publication of the Orphan Maintenance Assessment Report (K. Larsson, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T01:00:00Z","last_updated_date":"2017-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-publication-orphan-maintenance-assessment-report-k-larsson-ema_en.pdf"},
    {"id":"11981","name":"Presentation - European Academy of paediatrics research in ambulatory settings network (EAPRASnet) (A. Hadjipanayis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-academy-paediatrics-research-ambulatory-settings-network-eaprasnet-hadjipanayis_en.pdf"},
    {"id":"11986","name":"Presentation - Outcomes of the annual Enpr-EMA workshop (Mark Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcomes-annual-enpr-ema-workshop-mark-turner_en.pdf"},
    {"id":"11992","name":"Presentation - Statistical considerations in setting acceptance criteria, Kay-Martin Hanschmann, Paul Ehrlich Institut","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T02:00:00Z","last_updated_date":"2011-10-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-statistical-considerations-setting-acceptance-criteria-kay-martin-hanschmann-paul-ehrlich-institut_en.pdf"},
    {"id":"12004","name":"Presentation - Meeting with civil society representatives on EMA scientific committees (M.Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T02:00:00Z","last_updated_date":"2017-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-meeting-civil-society-representatives-ema-scientific-committees-mmavris-ema_en.pdf"},
    {"id":"12005","name":"Presentation - Adaptive licensing: a useful approach for drug licensing in the European Union?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-licensing-useful-approach-drug-licensing-european-union_en.pdf"},
    {"id":"12006","name":"Presentation - Non-clinical models to identify PK-PD indices and PD targets: industry perspective (Kevin Krause)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-clinical-models-identify-pk-pd-indices-and-pd-targets-industry-perspective-kevin-krause_en.pdf"},
    {"id":"12041","name":"Presentation - Significant benefit: origins and experience up to date (Kerstin Westermark)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T17:00:00Z","last_updated_date":"2015-12-15T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-significant-benefit-origins-and-experience-date-kerstin-westermark_en.pdf"},
    {"id":"12063","name":"Presentation - Confirmatory subgroup analyses: Case studies (Bretz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-confirmatory-subgroup-analyses-case-studies-bretz_en.pdf"},
    {"id":"12086","name":"Presentation - Advice on classes or groups of antibiotics ranked according to their relative importance for their use in human medicine (Marco Cavaleri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advice-classes-or-groups-antibiotics-ranked-according-their-relative-importance-their-use-human-medicine-marco-cavaleri_en.pdf"},
    {"id":"12100","name":"Presentation - Session 3: Data quality checking and validation of the sentinel common data model and tools (Jeffrey Brown)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-data-quality-checking-and-validation-sentinel-common-data-model-and-tools-jeffrey-brown_en.pdf"},
    {"id":"12111","name":"Presentation - Modelling and simulation support to the bridging of a drug with ethnic pharmacokinetic differences - Break-out session 3 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-support-bridging-drug-ethnic-pharmacokinetic-differences-break-out-session-3-theme-2_en.pdf"},
    {"id":"12114","name":"Presentation - Reporting adverse events from solicited sources to the Food and Drug Association (Gerald Pan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reporting-adverse-events-solicited-sources-food-and-drug-association-gerald-pan_en.pdf"},
    {"id":"12128","name":"Presentation - 4.1 Active and healthy ageing innovation partnership","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2011-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-41-active-and-healthy-ageing-innovation-partnership_en.pdf"},
    {"id":"12129","name":"Coordination of collection of data on sales of antimicrobials - Jordi Torren","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/coordination-collection-data-sales-antimicrobials-jordi-torren_en.pdf"},
    {"id":"12133","name":"Presentation - Regulatory discussant - Break-out session 1 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-discussant-break-out-session-1-theme-2_en.pdf"},
    {"id":"12140","name":"Presentation - Establishing DDDvet and DCDvet – history and state of play (Kari Grave)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T17:00:00Z","last_updated_date":"2016-03-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-establishing-dddvet-and-dcdvet-history-and-state-play-kari-grave_en.pdf"},
    {"id":"12141","name":"Presentation - Veterinarians experiences: Adverse event reporting in pigs (K.Steen Pedersen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinarians-experiences-adverse-event-reporting-pigs-ksteen-pedersen_en.pdf"},
    {"id":"12153","name":"Presentation - Topic Groups: lessons learnt and way forward (I. Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-groups-lessons-learnt-and-way-forward-i-silva-ema_en.pdf"},
    {"id":"12174","name":"Presentation - Public webpage on summary of product characteristics (SmPC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-webpage-summary-product-characteristics-smpc_en.pdf"},
    {"id":"12177","name":"Presentation - Case study 2 - Oligonucleotide control strategy - Session 4 (Rachel Orr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-2-oligonucleotide-control-strategy-session-4-rachel-orr_en.pdf"},
    {"id":"12187","name":"Presentation - Dose response assessments: guidance, experience, expectations (Vikram Sinha)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-response-assessments-guidance-experience-expectations-vikram-sinha_en.pdf"},
    {"id":"12188","name":"Presentation - AMEG’s proposal for an early hazard characterisation to encourage the development of novel antimicrobial veterinary medicinal products - European Medicines Agency veterinary medicines innovation day (Helen...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-amegs-proposal-early-hazard-characterisation-encourage-development-novel-antimicrobial-veterinary-medicinal-products-european-medicines-agency-veterinary-medicines-innovation-day-helen_en.pdf"},
    {"id":"12198","name":"Presentation - Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals Working Party (HCPWP) feedback from PRAC (Jane Ahlqvist Rastad)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-working-party-hcpwp-feedback-prac-jane-ahlqvist-rastad_en.pdf"},
    {"id":"12208","name":"Presentation - EMA report on the survey of all paediatric uses of medicinal products in Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-report-survey-all-paediatric-uses-medicinal-products-europe_en.pdf"},
    {"id":"12217","name":"Medicines for the Treatment of Pain in Children: Introduction - Daniel Brasseur","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-10-28T02:09:00Z","last_updated_date":"2004-10-28T02:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/medicines-treatment-pain-children-introduction-daniel-brasseur_en.pdf"},
    {"id":"12224","name":"Presentation - PDCO perspectives & proposals - Enpr-EMA coordinating group","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-perspectives-proposals-enpr-ema-coordinating-group_en.pdf"},
    {"id":"12252","name":"Regulators perspective on 'Quality by Design': BWP perspective - Kowid Ho","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/regulators-perspective-quality-design-bwp-perspective-kowid-ho_en.pdf"},
    {"id":"12254","name":"Presentation - TEDDY network (D. Bonifazi and A. Ceci)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-teddy-network-d-bonifazi-and-ceci_en.pdf"},
    {"id":"12261","name":"Presentation - Clinical Practice Consensus Guidelines International Society for Pediatric and Adolescent Diabetes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-practice-consensus-guidelines-international-society-pediatric-and-adolescent-diabetes_en.pdf"},
    {"id":"12266","name":"Presentation - Paediatric clinical research: Commission's perspective (Florian Schmidt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-clinical-research-commissions-perspective-florian-schmidt_en.pdf"},
    {"id":"12283","name":"Presentation - Update on the SPUR and PSUSA roadmap (Ana Zanoletty)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-spur-and-psusa-roadmap-ana-zanoletty_en.pdf"},
    {"id":"12294","name":"Presentation - Model based dose finding: discussion of presentations given by Bjà¶rn Bornkamp and Andrew Hooker (Norbert Benda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-model-based-dose-finding-discussion-presentations-given-bjaprn-bornkamp-and-andrew-hooker-norbert-benda_en.pdf"},
    {"id":"12295","name":"Presentation - Health-based exposure limits and Q&As (G. McKilligan, MHRA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-health-based-exposure-limits-and-qas-g-mckilligan-mhra_en.pdf"},
    {"id":"12301","name":"Presentation - 1.5 Patient perspective (Christine Laver)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-15-patient-perspective-christine-laver_en.pdf"},
    {"id":"12303","name":"Presentation: Paediatric specific and ethics issues related to implementation of Clinical Trial Regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-specific-and-ethics-issues-related-implementation-clinical-trial-regulation_en.pdf"},
    {"id":"12320","name":"Presentation - Session 2.7: Examples of interactions - PRINTO (Nicola Ruperto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-27-examples-interactions-printo-nicola-ruperto_en.pdf"},
    {"id":"12321","name":"Presentation - Sensitivity (Leon Aarons)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sensitivity-leon-aarons_en.pdf"},
    {"id":"12326","name":"Presentation - Workshop on patient-support programmes and market-research programmes: Reflections from the patient side (David Haerry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patient-support-programmes-and-market-research-programmes-reflections-patient-side-david-haerry_en.pdf"},
    {"id":"12331","name":"Presentation - Virtual interaction with real patients (Alessia Daturi, Paolo Avesani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-virtual-interaction-real-patients-alessia-daturi-paolo-avesani_en.pdf"},
    {"id":"12333","name":"Presentation - Discussion of legal consequences of reporting for healthcare professionals (Carlos Maria Romeo-Casabona)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-discussion-legal-consequences-reporting-healthcare-professionals-carlos-maria-romeo-casabona_en.pdf"},
    {"id":"12336","name":"Presentation - Experience from the Phagorburn clinical trial (Jerome Gabard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-22T02:00:00Z","last_updated_date":"2015-06-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-phagorburn-clinical-trial-jerome-gabard_en.pdf"},
    {"id":"12339","name":"Presentation - Measuring impact: a review of survey studies to evaluate the effectiveness of additional risk minimisation measures in Europe (Nawab Qizilbash)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-measuring-impact-review-survey-studies-evaluate-effectiveness-additional-risk-minimisation-measures-europe-nawab-qizilbash_en.pdf"},
    {"id":"12340","name":"Presentation - New pharmacovigilance legislation: focus on first year of operation (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmacovigilance-legislation-focus-first-year-operation-peter-arlett_en.pdf"},
    {"id":"12341","name":"Presentation - The Pharmacovigilance Risk Assessment Committee mandate, composition and tasks (R. De Lisa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-risk-assessment-committee-mandate-composition-and-tasks-r-de-lisa_en.pdf"},
    {"id":"12347","name":"Presentation - Discussion of multiplicity corrections in bioequivalence trials (Thomas Lang)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-discussion-multiplicity-corrections-bioequivalence-trials-thomas-lang_en.pdf"},
    {"id":"12355","name":"Presentation - 6.6 Innovative designs pharmacometrics and optimal designs (Joe Standing)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-66-innovative-designs-pharmacometrics-and-optimal-designs-joe-standing_en.pdf"},
    {"id":"12363","name":"Presentation - Packaging and labelling (Johann M. Lenhardsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-packaging-and-labelling-johann-m-lenhardsson_en.pdf"},
    {"id":"12371","name":"Presentation - EudraVigilance and signal detection","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-and-signal-detection_en.pdf"},
    {"id":"12377","name":"Presentation - Session 4 : Pharmacogenomics-guided treatments in clinical care: experience from patients and healthcare professionals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-pharmacogenomics-guided-treatments-clinical-care-experience-patients-and-healthcare-professionals_en.pdf"},
    {"id":"12384","name":"Presentation - Why are rare diseases of interest to industry (Brihad Abhyankar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-why-are-rare-diseases-interest-industry-brihad-abhyankar_en.pdf"},
    {"id":"12402","name":"Presentation: Involvement of children - iCAN","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-involvement-children-ican_en.pdf"},
    {"id":"12407","name":"Presentation - European Medicines Agency Adaptive Pathways Pilot presentation at the Safe and Timely Access to Medicines for Patients (STAMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-20T11:00:00Z","last_updated_date":"2015-11-20T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-adaptive-pathways-pilot-presentation-safe-and-timely-access-medicines-patients-stamp_en.pdf"},
    {"id":"12409","name":"Presentation - Module 5 - Clinical trials in the European Union","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T02:00:00Z","last_updated_date":"2018-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-5-clinical-trials-european-union_en.pdf"},
    {"id":"12423","name":"Presentation - European Surveillance of Veterinary Antimicrobial Consumption data on consumption of veterinary antimicrobial agents in 2010 from 19 European Union / European Economic Area countries (Kari Grave, Arno Mull...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T13:00:00Z","last_updated_date":"2013-04-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-surveillance-veterinary-antimicrobial-consumption-data-consumption-veterinary-antimicrobial-agents-2010-19-european-union-european-economic-area-countries-kari-grave-arno-mull_en.pdf"},
    {"id":"12425","name":"Role of the European Commission, S Atzor, EC","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/role-european-commission-s-atzor-ec_en.pdf"},
    {"id":"12430","name":"Presentation - Vaccine acceptance or refusal? Individual choice vs societal needs or my risks vs 'our' risks (Heidi Larson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vaccine-acceptance-or-refusal-individual-choice-vs-societal-needs-or-my-risks-vs-our-risks-heidi-larson_en.pdf"},
    {"id":"12439","name":"Paediatric European Network for Treatment of AIDS (PENTA) since 1993 - Dr Carlo Giaquinto","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T00:09:21Z","last_updated_date":"2009-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/paediatric-european-network-treatment-aids-penta-1993-dr-carlo-giaquinto_en.pdf"},
    {"id":"12449","name":"Presentation - Capturing added value in immuno-oncology: balancing rapid access and new metrics for valuation (Patrick Hopkinson) - S6.2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-capturing-added-value-immuno-oncology-balancing-rapid-access-and-new-metrics-valuation-patrick-hopkinson-s62_en.pdf"},
    {"id":"12459","name":"Presentation - Summaries of risk management plan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summaries-risk-management-plan_en.pdf"},
    {"id":"12460","name":"Presentation - An adaptive dose-finding study in postoperative dental pain. MCP-Mod (Bjà¶rn Bornkamp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-dose-finding-study-postoperative-dental-pain-mcp-mod-bjaprn-bornkamp_en.pdf"},
    {"id":"12461","name":"GxP inspections within the centralised procedure - Brendan Cuddy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gxp-inspections-within-centralised-procedure-brendan-cuddy_en.pdf-0"},
    {"id":"12475","name":"Presentation - Committee for Orphan Medicinal Products feedback (Daniel O'Connor, COMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-orphan-medicinal-products-feedback-daniel-oconnor-comp_en.pdf"},
    {"id":"12480","name":"Presentation - Assessments for maximum utility: transparency supporting our work (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-assessments-maximum-utility-transparency-supporting-our-work-juan-garcia-burgos_en.pdf"},
    {"id":"12493","name":"Presentation - Are regulators up to speed to address the challenges of biotechnological medicinal products?, Dr Schneider","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-are-regulators-speed-address-challenges-biotechnological-medicinal-products-dr-schneider_en.pdf"},
    {"id":"12494","name":"Presentation - Outcomes from break-out session 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcomes-break-out-session-1_en.pdf"},
    {"id":"12510","name":"Rare metabolic diseases, the miglusat experience: Fran Pratt","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-21T02:00:00Z","last_updated_date":"2010-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/rare-metabolic-diseases-miglusat-experience-fran-pratt_en.pdf"},
    {"id":"12517","name":"Presentation - Survey to industry, rapporteurs and European Medicines Agency: marketing authorisation application survey results (Fiona Reekie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:30:00Z","last_updated_date":"2018-01-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-industry-rapporteurs-and-european-medicines-agency-marketing-authorisation-application-survey-results-fiona-reekie_en.pdf"},
    {"id":"12550","name":"Presentation - Benefit-risk communication: perspective from PRAC (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-benefit-risk-communication-perspective-prac-june-raine_en.pdf"},
    {"id":"12576","name":"Presentation - PRAC experience with regulatory tools for medication errors (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prac-experience-regulatory-tools-medication-errors-june-raine_en.pdf"},
    {"id":"12603","name":"Brief summary of the existing systems on collecting data: The Czech Republic","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/brief-summary-existing-systems-collecting-data-czech-republic_en.pdf"},
    {"id":"12609","name":"Presentation - Workshop on nanomedicines - Introduction, Patrick le Courtois, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-nanomedicines-introduction-patrick-le-courtois-ema_en.pdf"},
    {"id":"12611","name":"Presentation - 2.5 Discussion on evidence synthesis (Sà©golà¨ne Aymà©)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-25-discussion-evidence-synthesis-sacgolane-aymac_en.pdf"},
    {"id":"12612","name":"Presentation - Characterizing the contribution of monotherapy components (Ramy Ibrahim) - S5.5","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-characterizing-contribution-monotherapy-components-ramy-ibrahim-s55_en.pdf"},
    {"id":"12634","name":"Regulation and Introduction - Patrick Celis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/regulation-and-introduction-patrick-celis_en.pdf"},
    {"id":"12653","name":"Presentation -   Adaptive pathways workshop (Evert Jan van Lente)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-pathways-workshop-evert-jan-van-lente_en.pdf"},
    {"id":"12658","name":"Developments in biomarker identification and validation for lung cancer - Alexandre Passioukov","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-12-16T00:09:21Z","last_updated_date":"2005-12-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/developments-biomarker-identification-and-validation-lung-cancer-alexandre-passioukov_en.pdf"},
    {"id":"12672","name":"Presentation - Cell-based therapies for cardiac repair (Martina Schà¼àŸler-Lenz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T02:00:00Z","last_updated_date":"2014-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cell-based-therapies-cardiac-repair-martina-scha-14ayler-lenz_en.pdf"},
    {"id":"12679","name":"Presentation - Assumption setting in a semi-mechanistic population pharmacokinetic-pharmacodynamic model across a wide range of patients - Break-out session 3 theme 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-assumption-setting-semi-mechanistic-population-pharmacokinetic-pharmacodynamic-model-across-wide-range-patients-break-out-session-3-theme-1_en.pdf"},
    {"id":"12685","name":"Presentation - Lifecycle CMC management: ICH Q12 progress to date (Jean-Louis Robert, Graham Cook)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lifecycle-cmc-management-ich-q12-progress-date-jean-louis-robert-graham-cook_en.pdf"},
    {"id":"12696","name":"Presentation - Management of safety data originating from patient-support programmes and market-research programmes - Current challenges from pharmaceutical industry and proposals to move forward","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-management-safety-data-originating-patient-support-programmes-and-market-research-programmes-current-challenges-pharmaceutical-industry-and-proposals-move-forward_en.pdf"},
    {"id":"12706","name":"Presentation - Revision 2 of CVMP guideline: conduct of bioequivalence studies for veterinary medicinal products - Main changes to the guideline","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-06T02:09:00Z","last_updated_date":"2009-05-06T02:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revision-2-cvmp-guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-main-changes-guideline_en.pdf"},
    {"id":"12725","name":"Presentation - Using Organisations Management Service (OMS) data in electronic application forms (eAF): SPOR webinar, 27 June 2018","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-using-organisations-management-service-oms-data-electronic-application-forms-eaf-spor-webinar-27-june-2018_en.pdf"},
    {"id":"12744","name":"Introduction to the International Coalition of Medicines Regulatory Authorities (ICMRA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-20T16:00:00Z","last_updated_date":"2014-11-20T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/introduction-international-coalition-medicines-regulatory-authorities-icmra_en.pdf"},
    {"id":"12746","name":"Recommendations in the area of interaction between EMEA CHMP and Patients Organisations - Dr Isabelle Moulon","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-12-03T01:00:00Z","last_updated_date":"2004-12-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/recommendations-area-interaction-between-emea-chmp-and-patients-organisations-dr-isabelle-moulon_en.pdf"},
    {"id":"12749","name":"Presentation - Committee on Herbal Medicinal Products (HMPC) update (Steinar Madsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-herbal-medicinal-products-hmpc-update-steinar-madsen_en.pdf"}    {"id":"12765","name":"Workshop on regulatory and scientific issues related to the Investigation of medicinal products intended for neonatal use: Welcome and Introduction - John van den Anker","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-11T02:09:21Z","last_updated_date":"2006-10-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/workshop-regulatory-and-scientific-issues-related-investigation-medicinal-products-intended-neonatal-use-welcome-and-introduction-john-van-den-anker_en.pdf"},
    {"id":"12770","name":"Summary of Terms of reference from the Commission","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/summary-terms-reference-commission_en.pdf"},
    {"id":"12772","name":"Presentation - Data exploration at the speed of thought: lessons learned from inside Google (Nico Gaviola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-exploration-speed-thought-lessons-learned-inside-google-nico-gaviola_en.pdf"},
    {"id":"12773","name":"Presentation - Enpr-EMA collaboration with PDCO (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T16:00:00Z","last_updated_date":"2013-07-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-collaboration-pdco-irmgard-eichler_en.pdf"},
    {"id":"12785","name":"Presentation - Communication to patients, consumers and healthcare professionals (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-patients-consumers-and-healthcare-professionals-juan-garcia-burgos_en.pdf"},
    {"id":"12797","name":"General remarks on the recommendations - Dr Frits Lekkerkerker","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-12-03T01:00:00Z","last_updated_date":"2004-12-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/general-remarks-recommendations-dr-frits-lekkerkerker_en.pdf"},
    {"id":"12804","name":"Presentation - Modelling and simulation for dose adjustment in renally impaired patients - Break-out session 2 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-dose-adjustment-renally-impaired-patients-break-out-session-2-theme-2_en.pdf"},
    {"id":"12825","name":"Presentation - Reporting experience from national patient-safety organisations (Maria Jose Otero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reporting-experience-national-patient-safety-organisations-maria-jose-otero_en.pdf"},
    {"id":"12837","name":"Presentation - How to join efforts for improving communication, education and training: Prescription by general practitioners/family physicians - Session 4 (Walter Marrocco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-join-efforts-improving-communication-education-and-training-prescription-general-practitionersfamily-physicians-session-4-walter-marrocco_en.pdf"},
    {"id":"12839","name":"Presentation - Chimeric antigen receptor T cells charting the course from clinical trials to commercialization (Stanley Frankel) - S4.2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chimeric-antigen-receptor-t-cells-charting-course-clinical-trials-commercialization-stanley-frankel-s42_en.pdf"},
    {"id":"12845","name":"Presentation - The Committee for Advanced Therapies (CAT) update (Kieran Breen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-advanced-therapies-cat-update-kieran-breen_en.pdf"},
    {"id":"12850","name":"Presentation - Challenges experienced or anticipated by other regulators and payers and proposals for dealing with them - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-experienced-or-anticipated-other-regulators-and-payers-and-proposals-dealing-them-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp_en.pdf"},
    {"id":"12858","name":"Presentation - Implementation of ICH Q3D in the CEP procedure (Helene Bruguera)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-ich-q3d-cep-procedure-helene-bruguera_en.pdf"},
    {"id":"12871","name":"Presentation - Nanotechnology - What about safety? How do we determine risk? Wim H de Jong, National Institute for Public Health and the Environment, Bilthoven","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nanotechnology-what-about-safety-how-do-we-determine-risk-wim-h-de-jong-national-institute-public-health-and-environment-bilthoven_en.pdf"},
    {"id":"12881","name":"Presentation - French Agency for Food , Environmental and Occupational Health and safety (ANSES), The French Agency for Veterinary Medicinal Products (ANMV) - Substance, product, organisation and referential data (SPOR) ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-27T01:00:00Z","last_updated_date":"2018-02-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-french-agency-food-environmental-and-occupational-health-and-safety-anses-french-agency-veterinary-medicinal-products-anmv-substance-product-organisation-and-referential-data-spor_en.pdf"},
    {"id":"12892","name":"Presentation - EU cooperation on HTA (Flora Giorgio, DG SANTE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-cooperation-hta-flora-giorgio-dg-sante_en.pdf"},
    {"id":"12896","name":"Presentation - Impact of pharmacovigilance systems (Jacoline Bouvy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T16:00:00Z","last_updated_date":"2015-06-25T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-pharmacovigilance-systems-jacoline-bouvy_en.pdf"},
    {"id":"12898","name":"Presentation – Topics raised by EFPIA - Update on the implementation of EMA policy on publication of clinical data (Policy 0070) – industry associations webinar (EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-05T02:00:00Z","last_updated_date":"2017-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topics-raised-efpia-update-implementation-ema-policy-publication-clinical-data-policy-0070-industry-associations-webinar-efpia_en.pdf"},
    {"id":"12901","name":"Presentation - Challenges to develop diagnostics for treatment of multiple drug resistant (MDR) pathogens (Herman Goossens)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-develop-diagnostics-treatment-multiple-drug-resistant-mdr-pathogens-herman-goossens_en.pdf"},
    {"id":"12910","name":"Presentation - Holistic approach to paediatric research: paediatric clinical trial networks (N. Ruperto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:00:00Z","last_updated_date":"2018-06-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-paediatric-clinical-trial-networks-n-ruperto_en.pdf"},
    {"id":"12917","name":"Presentation - US Food and Drug Administration (FDA): The precision medicine initiative - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised m...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-us-food-and-drug-administration-fda-precision-medicine-initiative-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-m_en.pdf"},
    {"id":"12921","name":"Presentation - Root-cause analysis in context of World Health Organization international classification for patient safety (David Cousins)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-root-cause-analysis-context-world-health-organization-international-classification-patient-safety-david-cousins_en.pdf"},
    {"id":"12936","name":"Pharmacovigilance needs and opportunities for ENCePP - Hubert G. Leufkens","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pharmacovigilance-needs-and-opportunities-encepp-hubert-g-leufkens_en.pdf"},
    {"id":"12948","name":"Presentation - EU/EC Acquis caummunautaire: perspectives from a member state","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-euec-acquis-caummunautaire-perspectives-member-state_en.pdf"},
    {"id":"12951","name":"Presentation - Industry perspective (efpia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T02:00:00Z","last_updated_date":"2015-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-efpia_en.pdf"},
    {"id":"12969","name":"Presentation - Session 5: Design concept for a confirmatory basket trial (Robert Beckman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-design-concept-confirmatory-basket-trial-robert-beckman_en.pdf"},
    {"id":"12973","name":"Presentation - Activities in USA, the experience of FDA Neurology Division, Russel Katz","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-activities-usa-experience-fda-neurology-division-russel-katz_en.pdf"},
    {"id":"12975","name":"Presentation - CMDh project on ideas for WS of assessment of RMPs and informal WS procedure for follow up requests after a PSUSA for NAPs (K. van der Stoep)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T15:08:00Z","last_updated_date":"2018-01-04T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cmdh-project-ideas-ws-assessment-rmps-and-informal-ws-procedure-follow-requests-after-psusa-naps-k-van-der-stoep_en.pdf"},
    {"id":"12981","name":"Session 1 - CMC - Kowid Ho","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-1-cmc-kowid-ho_en.pdf"},
    {"id":"13006","name":"Presentation - Partnering to optimize and accelerate pediatric clinical trials (C. Hovinga)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-partnering-optimize-and-accelerate-pediatric-clinical-trials-c-hovinga_en.pdf"},
    {"id":"13009","name":"Presentation - Procedural update: post-authorisation procedures (Melanie Leivers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-procedural-update-post-authorisation-procedures-melanie-leivers_en.pdf"},
    {"id":"13024","name":"'Neuroprotection' in Neurodegenerative disorders. Towards a change in the paradigm?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-11T00:09:21Z","last_updated_date":"2008-02-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/neuroprotection-neurodegenerative-disorders-towards-change-paradigm_en.pdf"},
    {"id":"13034","name":"Presentation - Scientific advice and its impact on marketing authorisation reviews (Jan Rengstrom)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advice-and-its-impact-marketing-authorisation-reviews-jan-rengstrom_en.pdf"},
    {"id":"13069","name":"Presentation - Meeting rapporteur/co-rapporteur prior to filing, Dr. Bertil Jonsson","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-meeting-rapporteurco-rapporteur-prior-filing-dr-bertil-jonsson_en.pdf"},
    {"id":"13092","name":"Presentation - PCWP / HCPWP working methodology (Nathalie Bere, Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwp-hcpwp-working-methodology-nathalie-bere-ivana-silva_en.pdf"},
    {"id":"13096","name":"Presentation - Committee for Advanced Therapies update (Kieran Breen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-advanced-therapies-update-kieran-breen_en.pdf"},
    {"id":"13097","name":"Presentation - New pharmacovigilance legislation and implementing measures – Minimum requirements for quality systems (marleting authorisation holder, European Medicines Agency, national competent authority), minimum req...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:07Z","last_updated_date":"2011-06-24T22:06:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmacovigilance-legislation-and-implementing-measures-minimum-requirements-quality-systems-marleting-authorisation-holder-european-medicines-agency-national-competent-authority_en.pdf"},
    {"id":"13108","name":"Presentation - PIP session: Paediatric glaucoma overview of existing PIP decisions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pip-session-paediatric-glaucoma-overview-existing-pip-decisions_en.pdf"},
    {"id":"13205","name":"Efficacy Topics - Lois Hinman, Spiros Vamvakas, Salange Rohou","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/efficacy-topics-lois-hinman-spiros-vamvakas-salange-rohou_en.pdf"},
    {"id":"13213","name":"Presentation - New EudraVigilance system – Progress update (S. Brosch, F. Domergue)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T02:00:00Z","last_updated_date":"2018-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-eudravigilance-system-progress-update-s-brosch-f-domergue_en.pdf"},
    {"id":"13237","name":"Development of a Consolidated Pediatric Rheumatology Observational Registry, Dr Jeffrey Siegel","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/development-consolidated-pediatric-rheumatology-observational-registry-dr-jeffrey-siegel_en.pdf"},
    {"id":"13257","name":"Presentation - Day 2: Meibomian gland dysfunction","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-meibomian-gland-dysfunction_en.pdf"},
    {"id":"13292","name":"Presentation - Research Agendas, Eugene Major","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-research-agendas-eugene-major_en.pdf"},
    {"id":"13310","name":"Initial clinical trial protocol design considerations, Dr Walter Janssens","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/initial-clinical-trial-protocol-design-considerations-dr-walter-janssens_en.pdf"},
    {"id":"13311","name":"Presentation - PSUR roadmap (Irene Rager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:30:00Z","last_updated_date":"2017-03-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-psur-roadmap-irene-rager_en.pdf"},
    {"id":"13331","name":"Presentation - How does United European Gastroenterology communicate and disseminate information released by the European Medicines Agency? (Michel Delvaux)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-does-united-european-gastroenterology-communicate-and-disseminate-information-released-european-medicines-agency-michel-delvaux_en.pdf"},
    {"id":"13333","name":"Q8 (R1) Annex to Q8, Pharmaceutical development - Robert Baum","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/q8-r1-annex-q8-pharmaceutical-development-robert-baum_en.pdf"},
    {"id":"13336","name":"WHO - Pharmaceutical Policies - Milan Smid","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/who-pharmaceutical-policies-milan-smid_en.pdf"},
    {"id":"13347","name":"Presentation - Measuring time from identification of a new risk to regulatory action with focus on signalling tools and processes (Amie Goulbourne)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-measuring-time-identification-new-risk-regulatory-action-focus-signalling-tools-and-processes-amie-goulbourne_en.pdf"},
    {"id":"13369","name":"Presentation - Guideline on Similar biological medicinal products\n\ncontaining biotechnology-derived proteins as active\n\nsubstance: Non-clinical and clinical issues (Pekka Kurki)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-pekka-kurki_en.pdf"},
    {"id":"13377","name":"Presentation - Modelling and simulation examples that failed to meet regulator's expectations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:30:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-examples-failed-meet-regulators-expectations_en.pdf"},
    {"id":"13380","name":"Presentation - Setting cpecifications - Statistical considerations, Enda Moran, Pfizer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T02:00:00Z","last_updated_date":"2011-10-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-setting-cpecifications-statistical-considerations-enda-moran-pfizer_en.pdf"},
    {"id":"13395","name":"Presentation - Overview of key improvements (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-key-improvements-june-raine_en.pdf"},
    {"id":"13397","name":"Presentation - Session 3.10: Update on the EU Portal and Database (Kevin Cunningham)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-310-update-eu-portal-and-database-kevin-cunningham_en.pdf"},
    {"id":"13413","name":"Presentation - Belgian Centre of Pharmacotherapeutical Information: The EMA and Primary Health Care - An ambiguous relation? (Thierry Christiaens)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T02:00:00Z","last_updated_date":"2016-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-belgian-centre-pharmacotherapeutical-information-ema-and-primary-health-care-ambiguous-relation-thierry-christiaens_en.pdf"},
    {"id":"13420","name":"Immunogenicity Assessment of Therapeutic Proteins: Strategy of RMP - Adrian Thomas","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-09-04T02:09:21Z","last_updated_date":"2007-09-04T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/immunogenicity-assessment-therapeutic-proteins-strategy-rmp-adrian-thomas_en.pdf"},
    {"id":"13440","name":"Presentation - Session 4 – Testing with EMA new process","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-12T12:30:00Z","last_updated_date":"2016-05-12T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-testing-ema-new-process_en.pdf"},
    {"id":"13454","name":"Presentation - Session 2 - User, manufacturer and academic viewpoints","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-05T01:00:00Z","last_updated_date":"2013-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-user-manufacturer-and-academic-viewpoints_en.pdf"},
    {"id":"13456","name":"Presentation - Session 2.1: Working Group on GCP training","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-21-working-group-gcp-training_en.pdf"},
    {"id":"13506","name":"Presentation - Workshop programme and objectives - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Gunter Egger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-programme-and-objectives-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-gunter-egger_en.pdf"},
    {"id":"13509","name":"Presentation - Pandemic lessons learnt","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pandemic-lessons-learnt_en.pdf"},
    {"id":"13514","name":"Presentation - Revatio in paediatric pulmonary arterial hypertension, an orphan indication - Break-out session 3 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revatio-paediatric-pulmonary-arterial-hypertension-orphan-indication-break-out-session-3-theme-2_en.pdf"},
    {"id":"13525","name":"Presentation - Public hearings","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:08Z","last_updated_date":"2011-06-24T22:06:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-hearings_en.pdf-0"},
    {"id":"13536","name":"Presentation - Session 5: Considerations in development of pembrolizumab in msi-h cancers (Christine Gause)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-considerations-development-pembrolizumab-msi-h-cancers-christine-gause_en.pdf"},
    {"id":"13537","name":"Presentation - Eligibility issues and meeting opportunities (Fia Westerholm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eligibility-issues-and-meeting-opportunities-fia-westerholm_en.pdf"},
    {"id":"13551","name":"Creating Biomedical R&D Leadership for Europeto Benefit Patients and Society - Karima Boubekeur","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/creating-biomedical-rd-leadership-europeto-benefit-patients-and-society-karima-boubekeur_en.pdf"},
    {"id":"13569","name":"Presentation - Gatekeeping strategies in phase III clinical trials with multiple endpoints and doses (Alex Dmitrienko, Olga Marchenko)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gatekeeping-strategies-phase-iii-clinical-trials-multiple-endpoints-and-doses-alex-dmitrienko-olga-marchenko_en.pdf"},
    {"id":"13574","name":"Presentation - Direct patient reporting: the Dutch case","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:10Z","last_updated_date":"2011-06-24T22:06:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-direct-patient-reporting-dutch-case_en.pdf"},
    {"id":"13583","name":"Presentation - 5.1 Surrogate marker evaluation when data are small,\n\nlarge, or very large (Geert Molenberghs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-51-surrogate-marker-evaluation-when-data-are-small-large-or-very-large-geert-molenberghs_en.pdf"},
    {"id":"13589","name":"Presentation - The role and place of European society of clinical microbiology and infections diseases (ESCMID) in global antimicrobial resistance - Session 4 (Murat Akova)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-and-place-european-society-clinical-microbiology-and-infections-diseases-escmid-global-antimicrobial-resistance-session-4-murat-akova_en.pdf"},
    {"id":"13602","name":"EMEA/CHMP-Think Tank Group on Innovation, Research and Drug Development - Xavier Luria","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emeachmp-think-tank-group-innovation-research-and-drug-development-xavier-luria_en.pdf"},
    {"id":"13617","name":"Brief summary of the existing systems on collecting data: Switzerland","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/brief-summary-existing-systems-collecting-data-switzerland_en.pdf"},
    {"id":"13639","name":"Presentation: The EU Clinical Trial Regulation and children and young people (minors) - Ethical and procedural issues","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-clinical-trial-regulation-and-children-and-young-people-minors-ethical-and-procedural-issues_en.pdf"},
    {"id":"13664","name":"Presentation - ALIMS web portal (Igor Vanevski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-alims-web-portal-igor-vanevski_en.pdf"},
    {"id":"13676","name":"Presentation - The place for treatments and trial design considerations for associated neuropsychiatric symptoms in Alzheimer's disease (Rachel Schindler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-place-treatments-and-trial-design-considerations-associated-neuropsychiatric-symptoms-alzheimers-disease-rachel-schindler_en.pdf"},
    {"id":"13685","name":"Presentation - Results from the questionnaire to PDCO members (Sofia Nordenmalm, Benjamin Pelle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-results-questionnaire-pdco-members-sofia-nordenmalm-benjamin-pelle_en.pdf"},
    {"id":"13692","name":"Presentation - Generic, hybrid and biosimilar products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-generic-hybrid-biosimilar-products_en.pdf"},
    {"id":"13713","name":"Introduction to nanotechnologies and medicinal products at the EMEA - Marisa Papaluca Amati","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-29T02:09:21Z","last_updated_date":"2009-04-29T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/introduction-nanotechnologies-and-medicinal-products-emea-marisa-papaluca-amati_en.pdf"},
    {"id":"13736","name":"Presentation - KEYTRUDA® (pembrolizumab): melanoma lessons learnt (Roger Dansey) - S2.2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-keytrudar-pembrolizumab-melanoma-lessons-learnt-roger-dansey-s22_en.pdf"},
    {"id":"13744","name":"Presentation - The role of PRAC in pharmacovigilance decisions (June M Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-prac-pharmacovigilance-decisions-june-m-raine_en.pdf"},
    {"id":"13772","name":"Presentation - Experience with CF in scientific advice (Efthymios Manolis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-cf-scientific-advice-efthymios-manolis_en.pdf"},
    {"id":"13790","name":"Presentation - Conflicts of interest – industry view (Richard Bergstrom)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-conflicts-interest-industry-view-richard-bergstrom_en.pdf"},
    {"id":"13817","name":"Presentation - Guidance to pharmaceutical industry on redacting commercially confidential information (CCI) in clinical reports and process: Meeting on redacting commercially confidential information (CCI) in clinical re...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-pharmaceutical-industry-redacting-commercially-confidential-information-cci-clinical-reports-and-process-meeting-redacting-commercially-confidential-information-cci-clinical-re_en.pdf"},
    {"id":"13845","name":"Presentation - Japanese Orphan Drug Designation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-japanese-orphan-drug-designation_en.pdf"},
    {"id":"13859","name":"Presentation - Introduction to population pharmacokinetic-pharmacodynamic modelling in paediatric clinical pharmacology","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-05-13T02:09:21Z","last_updated_date":"2008-05-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-population-pharmacokinetic-pharmacodynamic-modelling-paediatric-clinical-pharmacology_en.pdf"},
    {"id":"13870","name":"Module 10 - Presentation - Stakeholders engagement","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/module-10-presentation-stakeholders-engagement_en.pdf"},
    {"id":"13903","name":"Presentation - Standards of care in SMA and implications for clinical trials (Richard Finkel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-standards-care-sma-and-implications-clinical-trials-richard-finkel_en.pdf"},
    {"id":"13928","name":"Presentation - Manufacturing challenges - now and how will we ensure patient access to these medicines (Bo Kara)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T10:22:00Z","last_updated_date":"2016-12-02T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-manufacturing-challenges-now-and-how-will-we-ensure-patient-access-these-medicines-bo-kara_en.pdf"},
    {"id":"13938","name":"Presentation - Challenges in evaluating relative effectiveness (Mira Pavlovic) - S6.1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-evaluating-relative-effectiveness-mira-pavlovic-s61_en.pdf"},
    {"id":"13947","name":"Presentation - Guidance on user safety evaluation for pharmaceutical veterinary medicinal products – development of existing and future guidance (Nicholas Jarrett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-user-safety-evaluation-pharmaceutical-veterinary-medicinal-products-development-existing-and-future-guidance-nicholas-jarrett_en.pdf"},
    {"id":"13959","name":"Presentation - Design of PK/PD Studies (Mats Karlsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-design-pkpd-studies-mats-karlsson_en.pdf"},
    {"id":"13972","name":"Presentation - Good pharmacovigilance practices for the European Union (EU-GVP) (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T16:03:00Z","last_updated_date":"2017-07-25T16:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-european-union-eu-gvp-priya-bahri_en.pdf-1"},
    {"id":"14000","name":"Presentation - Review of pre-submission interactions in the centralised procedure and best practices (Michael Berntgen, Hextor Boix Perales)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-19T02:00:00Z","last_updated_date":"2016-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-review-pre-submission-interactions-centralised-procedure-and-best-practices-michael-berntgen-hextor-boix-perales_en.pdf"},
    {"id":"14001","name":"Presentation - Impact on the product information of the additional monitoring of medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-product-information-additional-monitoring-medicines_en.pdf"},
    {"id":"14034","name":"Presentation - Diabetes and endocrinology network (David Dunger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-diabetes-and-endocrinology-network-david-dunger_en.pdf"},
    {"id":"14041","name":"Presentation - World Organisation for Animal Health (OIE): List of Antimicrobial Agents of Veterinary Importance and OIE Standards and Activities (Franà§ois Diaz, Nadà¨ge Leboucq)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-world-organisation-animal-health-oie-list-antimicrobial-agents-veterinary-importance-and-oie-standards-and-activities-franassois-diaz-nadage-leboucq_en.pdf"},
    {"id":"14045","name":"Presentation - Use of real world data in development programmes (Dr Alison Cave and Dr Francesca Cerreta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T18:21:00Z","last_updated_date":"2017-05-12T18:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-real-world-data-development-programmes-dr-alison-cave-and-dr-francesca-cerreta_en.pdf"},
    {"id":"14060","name":"Presentation - FDA orphan products grants program overview (Erica K McNeilly)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-orphan-products-grants-program-overview-erica-k-mcneilly_en.pdf"},
    {"id":"14072","name":"Presentation - PDCO and SAWP interactions (Cecile Ollivier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T17:00:00Z","last_updated_date":"2016-05-27T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-and-sawp-interactions-cecile-ollivier_en.pdf"},
    {"id":"14093","name":"Presentation - Off-target toxicity","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:48Z","last_updated_date":"2012-06-15T17:10:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-target-toxicity_en.pdf"}    {"id":"14100","name":"Presentation - Session 3.6: Updates on networks - PedCRIN (Mark Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-36-updates-networks-pedcrin-mark-turner_en.pdf"},
    {"id":"14119","name":"Presentation - Evaluating methods to capture stakeholder preferences (Andrea Beyer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluating-methods-capture-stakeholder-preferences-andrea-beyer_en.pdf"},
    {"id":"14124","name":"CHMP work programme: Practical aspects","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/chmp-work-programme-practical-aspects_en.pdf"},
    {"id":"14126","name":"Presentation - Financial disclosure on source of network funding (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-financial-disclosure-source-network-funding-irmgard-eichler_en.pdf"},
    {"id":"14140","name":"Presentation - Break out session 2 - Proposals on how to encourage clinicians to participate in clinical trials Proposals on how industry can refer and use networks (Saskia de Wildt, MRRN-NL)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-break-out-session-2-proposals-how-encourage-clinicians-participate-clinical-trials-proposals-how-industry-can-refer-and-use-networks-saskia-de-wildt-mrrn-nl_en.pdf"},
    {"id":"14163","name":"Collaboration between COMP and CHMP: Patrick Salmon","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-21T02:00:00Z","last_updated_date":"2010-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/collaboration-between-comp-and-chmp-patrick-salmon_en.pdf"},
    {"id":"14166","name":"Presentation - The European Union paediatric regulation in 5 minutes (Paolo Tomasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-paediatric-regulation-5-minutes-paolo-tomasi_en.pdf"},
    {"id":"14199","name":"Certification Procedure - Elisa Pedone","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/certification-procedure-elisa-pedone_en.pdf"},
    {"id":"14202","name":"Presentation - Active substances from starting materials to Active Substance Master Files (ASMFs) (Ruben Pita)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-active-substances-starting-materials-active-substance-master-files-asmfs-ruben-pita_en.pdf"},
    {"id":"14219","name":"Presentation - Healthcare Professionals' Working Party (HCPWP) vis-a-vis the European Medicines Agency’s structure and activities: Roles and responsibilities of the HCPWP members (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T17:00:00Z","last_updated_date":"2013-07-12T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-healthcare-professionals-working-party-hcpwp-vis-vis-european-medicines-agencys-structure-and-activities-roles-and-responsibilities-hcpwp-members-ivana-silva_en.pdf"},
    {"id":"14230","name":"Presentation - Innovation in veterinary medicines in Europe including antibiotics (Erik De Ridder)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovation-veterinary-medicines-europe-including-antibiotics-erik-de-ridder_en.pdf"},
    {"id":"14232","name":"Presentation - Policy on Conflicts of Interests: What it means in practice for you","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2011-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-policy-conflicts-interests-what-it-means-practice-you_en.pdf"},
    {"id":"14247","name":"Presentation - Proposals to European Medicines Agency from European Federation of Pharmaceutical Industries and Associations (EFPIA) (Julie Holtzople, Anne Cutting)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposals-european-medicines-agency-european-federation-pharmaceutical-industries-and-associations-efpia-julie-holtzople-anne-cutting_en.pdf"},
    {"id":"14263","name":"Presentation - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) e-learning - Introduction (version 5.6)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2026-02-11T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extended-eudravigilance-medicinal-product-dictionary-xevmpd-e-learning-introduction-version-56_en.pdf"},
    {"id":"14266","name":"Presentation - Good-pharmacovigilance-practice modules I-IV: Pharmacovigilance quality assurance and control (Fergus Sweeney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practice-modules-i-iv-pharmacovigilance-quality-assurance-and-control-fergus-sweeney_en.pdf"},
    {"id":"14279","name":"Presentation - Draft guideline on pharmaceutical development of medicines for paediatric use","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf"},
    {"id":"14285","name":"Presentation - Genomics in patients with Hispanic ancestry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-genomics-patients-hispanic-ancestry_en.pdf"},
    {"id":"14297","name":"Presentation - Topic 3 - Clinical development strategies and trial designs for new TB treatment regimens (Carl Mendel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-3-clinical-development-strategies-and-trial-designs-new-tb-treatment-regimens-carl-mendel_en.pdf"},
    {"id":"14303","name":"Presentation - Performance characteristics of quality range methods and equivalence testing in the comparative assessment of quality attributes (T. Stangler, Novartis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-performance-characteristics-quality-range-methods-and-equivalence-testing-comparative-assessment-quality-attributes-t-stangler-novartis_en.pdf"},
    {"id":"14319","name":"Presentation - Good pharmacovigilance practices (P. Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-p-bahri_en.pdf"},
    {"id":"14326","name":"Presentation - Session 2 summary: designs and methods (Jose Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-summary-designs-and-methods-jose-pinheiro_en.pdf"},
    {"id":"14332","name":"Presentation - Joint Horizon Scanning for pharmaceuticals (I. Cleemput, KCE Belgium; A.Golja, Dutch Ministry of Health)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-horizon-scanning-pharmaceuticals-i-cleemput-kce-belgium-agolja-dutch-ministry-health_en.pdf"},
    {"id":"14352","name":"Presentation - Results from the questionnaire to PDCO members","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-11T16:00:00Z","last_updated_date":"2015-05-11T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-results-questionnaire-pdco-members_en.pdf"},
    {"id":"14363","name":"Recent actions by the European Commission concerning bee health, Emma Soto, European Commission","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/recent-actions-european-commission-concerning-bee-health-emma-soto-european-commission_en.pdf"},
    {"id":"14368","name":"Presentation - Formulations: PIPs evaluation-case studies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-formulations-pips-evaluation-case-studies_en.pdf"},
    {"id":"14378","name":"Presentation - Best expertise vs conflicts of interests: Striking the right balance. Experience from a scientific advisory group (Serge Bakchine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-expertise-vs-conflicts-interests-striking-right-balance-experience-scientific-advisory-group-serge-bakchine_en.pdf"},
    {"id":"14379","name":"Use of Fluoroquinolones and Development of Resistance - Pascal Sanders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/use-fluoroquinolones-and-development-resistance-pascal-sanders_en.pdf"},
    {"id":"14380","name":"Presentation - Lifecycle of a new medicinal product (N. Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lifecycle-new-medicinal-product-n-bere_en.pdf"},
    {"id":"14384","name":"Presentation - Endpoints in a treatment trial in neuromyelitis optica: Clinician’s view (Anu Jacob)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-endpoints-treatment-trial-neuromyelitis-optica-clinicians-view-anu-jacob_en.pdf"},
    {"id":"14386","name":"Presentation - Acute bacterial exacerbations of chronic obstructive airways disease (ABECB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:45Z","last_updated_date":"2011-04-26T18:05:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-acute-bacterial-exacerbations-chronic-obstructive-airways-disease-abecb_en.pdf"},
    {"id":"14389","name":"Presentation - Horizon Scanning for pharmaceuticals (M.Berntgen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-horizon-scanning-pharmaceuticals-mberntgen-ema_en.pdf"},
    {"id":"14391","name":"Presentation - Belgian Veterinary Surveillence of Antimicrobial Consumption","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-22T13:01:28Z","last_updated_date":"2010-12-22T13:01:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-belgian-veterinary-surveillence-antimicrobial-consumption_en.pdf"},
    {"id":"14412","name":"Presentation - Extrapolation in inflammatory bowel disease (Richard Veselà½)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extrapolation-inflammatory-bowel-disease-richard-vesela-12_en.pdf"},
    {"id":"14422","name":"Product information recommendations and proposals for action - Lesley Greene","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-12-03T01:00:00Z","last_updated_date":"2004-12-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/product-information-recommendations-and-proposals-action-lesley-greene_en.pdf"},
    {"id":"14464","name":"Presentation - Challenges encountered in clinical trials in CF: patient perspective (Emma Lake)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-encountered-clinical-trials-cf-patient-perspective-emma-lake_en.pdf"},
    {"id":"14470","name":"Presentation - The role of the pharmaceutical industry, Sophie Banzet","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-pharmaceutical-industry-sophie-banzet_en.pdf"},
    {"id":"14479","name":"Presentation - Support to paediatric medicines development (Rocio Fernandez Fresquet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-support-paediatric-medicines-development-rocio-fernandez-fresquet_en.pdf"},
    {"id":"14485","name":"Presentation - Norwegian Medicines Agency: Quality aspects in IMP developments (Tone Agasà¸ster)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-norwegian-medicines-agency-quality-aspects-imp-developments-tone-agasaster_en.pdf"},
    {"id":"14486","name":"Presentation - Looking towards 2020 – Our strategy for public engagement (Melanie Carr, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-looking-towards-2020-our-strategy-public-engagement-melanie-carr-ema_en.pdf"},
    {"id":"14489","name":"Presentation - Case study Brivact UCB","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-brivact-ucb_en.pdf"},
    {"id":"14494","name":"EMEA activities to foster implementation of CVMP recommendations on antimicrobials - David Mackay","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:09:21Z","last_updated_date":"2009-05-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-activities-foster-implementation-cvmp-recommendations-antimicrobials-david-mackay_en.pdf"},
    {"id":"14497","name":"Presentation - Gene therapy case study: Adenosine deaminase severe combined immunodeficiency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gene-therapy-case-study-adenosine-deaminase-severe-combined-immunodeficiency_en.pdf"},
    {"id":"14498","name":"Presentation - The investigation of subgroups in confirmatory clinical trials - The Pharmaceutical and Medical Devices Agency (PMDA) perspective  (Yuki Ando)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-investigation-subgroups-confirmatory-clinical-trials-pharmaceutical-medical-devices-agency-pmda-perspective-yuki-ando_en.pdf"},
    {"id":"14502","name":"Presentation - Drug Safety Surveillance Initiatives, Gerald Dal Pan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drug-safety-surveillance-initiatives-gerald-dal-pan_en.pdf"},
    {"id":"14511","name":"Presentation - PMDA experience with measuring the impact of pharmacovigilance (Shinobu Uzu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pmda-experience-measuring-impact-pharmacovigilance-shinobu-uzu_en.pdf"},
    {"id":"14518","name":"Fighting the Parmaceutical Crime and Counterfeit Medicines - Roy Vancauwenberghe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/fighting-parmaceutical-crime-and-counterfeit-medicines-roy-vancauwenberghe_en.pdf"},
    {"id":"14521","name":"Presentation - Worldwide involvement of children in clinical research (Pamela Dicks, Jenny Preston, Charles Thompson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-worldwide-involvement-children-clinical-research-pamela-dicks-jenny-preston-charles-thompson_en.pdf"},
    {"id":"14536","name":"Presentation - Medical and Regulatory Policy Plasma Protein Therapeutics Association: Industry perspectives (Mary Gustafson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-and-regulatory-policy-plasma-protein-therapeutics-association-industry-perspectives-mary-gustafson_en.pdf"},
    {"id":"14556","name":"Presentation - Consultation on the explanatory note to GVP Module VII (CBG MEB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:30:00Z","last_updated_date":"2017-03-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-consultation-explanatory-note-gvp-module-vii-cbg-meb_en.pdf"},
    {"id":"14562","name":"Presentation - Regulatory tools : Current standard information included in the summary of product characteristics / product literature (Stephan Steuber)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-tools-current-standard-information-included-summary-product-characteristics-product-literature-stephan-steuber_en.pdf"},
    {"id":"14564","name":"Presentation - Health-technology-assessment-body (HTA) view (Seren Phillips)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-health-technology-assessment-body-hta-view-seren-phillips_en.pdf"},
    {"id":"14571","name":"Welcome and introduction - Dr Fritis Lekkerkerker","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2003-05-01T02:00:00Z","last_updated_date":"2003-05-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/welcome-and-introduction-dr-fritis-lekkerkerker_en.pdf"},
    {"id":"14576","name":"Presentation - Subgroup analyses clinical, non-statistical perspective (Jens Heisterberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-subgroup-analyses-clinical-non-statistical-perspective-jens-heisterberg_en.pdf"},
    {"id":"14623","name":"Presentation - EU PASS/PAES requirements for disclosure (Thomas Goedecke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:30:00Z","last_updated_date":"2017-03-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-passpaes-requirements-disclosure-thomas-goedecke_en.pdf"},
    {"id":"14634","name":"Presentation - Topic 1 - Patients perspective: Unite 2 Cure - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-patients-perspective-unite-2-cure-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation_en.pdf"},
    {"id":"14648","name":"European database networking models - Miriam C.J.M. Sturkenboom","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-database-networking-models-miriam-cjm-sturkenboom_en.pdf"},
    {"id":"14650","name":"Presentation - Position of Federation of Veterinarians of Europe (FVE) (Rens van Dobbenburgh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-position-federation-veterinarians-europe-fve-rens-van-dobbenburgh_en.pdf"},
    {"id":"14680","name":"Presentation - Leveraging prior knowledge in guiding paediatric drug development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-leveraging-prior-knowledge-guiding-paediatric-drug-development_en.pdf"},
    {"id":"14681","name":"Presentation - European antibiotic awareness day: National perspective - UK and antibiotic guardian - Session 3 (Diane Ashiru-Oredope)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-antibiotic-awareness-day-national-perspective-uk-and-antibiotic-guardian-session-3-diane-ashiru-oredope_en.pdf"},
    {"id":"14691","name":"Presentation - Healthcare Professionals' Working Party (HCPWP): Electronic declaration of interests, Eudralink and conference services support (Malika Holleyman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T17:00:00Z","last_updated_date":"2013-07-12T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-healthcare-professionals-working-party-hcpwp-electronic-declaration-interests-eudralink-and-conference-services-support-malika-holleyman_en.pdf"},
    {"id":"14710","name":"Presentation - Detecting Safety issues: will new scientific developments strengthen public health protection?, Prof. dr. Sturkenboom","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-detecting-safety-issues-will-new-scientific-developments-strengthen-public-health-protection-prof-dr-sturkenboom_en.pdf"},
    {"id":"14740","name":"Product Management Services and Substance Management Services projects","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-25T16:30:00Z","last_updated_date":"2018-01-25T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/product-management-services-and-substance-management-services-projects_en.pdf"},
    {"id":"14774","name":"Presentation - Good pharmacovigilance practice risk management systems","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practice-risk-management-systems_en.pdf"},
    {"id":"14779","name":"EMA guidelines, Dr Marion Haberkamp","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ema-guidelines-dr-marion-haberkamp_en.pdf"},
    {"id":"14799","name":"Presentation - Interaction with healthcare professionals (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-healthcare-professionals-ivana-silva_en.pdf"},
    {"id":"14801","name":"Presentation - Ph 2/3 trial for selepressin (Martin Posch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ph-23-trial-selepressin-martin-posch_en.pdf"},
    {"id":"14808","name":"Presentation - Active substance master file procedure (Isabel Ugalde)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-active-substance-master-file-procedure-isabel-ugalde_en.pdf"},
    {"id":"14823","name":"Presentation - Topic 5 - Clinical trial transparency - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Fergus Sweeney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-5-clinical-trial-transparency-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-fergus-sweeney_en.pdf"},
    {"id":"14839","name":"Presentation - Lessons learnt - Melanoma: academic perspective (Paolo Ascierto) - S2.1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lessons-learnt-melanoma-academic-perspective-paolo-ascierto-s21_en.pdf"},
    {"id":"14841","name":"Presentation - The organisational and functional structure of the European Network of Paediatric Research at the European Medicines Agency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:50Z","last_updated_date":"2011-05-27T15:25:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organisational-and-functional-structure-european-network-paediatric-research-european-medicines-agency_en.pdf"},
    {"id":"14843","name":"Presentation - EMA-HMA Network international initiatives on innovation (Martin Harvey Allchurch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-hma-network-international-initiatives-innovation-martin-harvey-allchurch_en.pdf"},
    {"id":"14869","name":"Presentation - Good pharmacovigilance practice module IX: Signal management","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practice-module-ix-signal-management_en.pdf"},
    {"id":"14872","name":"Presentation - Dose finding for a β-lactam – β-lactamase inhibitor combination (Shampa Das, Astra Zeneca)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-finding-i2-lactam-i2-lactamase-inhibitor-combination-shampa-das-astra-zeneca_en.pdf"},
    {"id":"14880","name":"Presentation - CVMP","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp_en.pdf"},
    {"id":"14882","name":"Homeopathy Workshop at the European Medicines Agency - Aude Sapere","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/homeopathy-workshop-european-medicines-agency-aude-sapere_en.pdf"},
    {"id":"14884","name":"Presentation - How do we transform big data into knowledge to support decision making? (Thomas Senderovitz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-do-we-transform-big-data-knowledge-support-decision-making-thomas-senderovitz_en.pdf"},
    {"id":"14886","name":"Presentation - Discussion on specific indications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:47Z","last_updated_date":"2011-04-26T18:05:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-discussion-specific-indications_en.pdf"},
    {"id":"14901","name":"Presentation - Minimising risk: a health professional perspective (Donald RJ Singer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-minimising-risk-health-professional-perspective-donald-rj-singer_en.pdf"},
    {"id":"14904","name":"Presentation - Young research subjects - old problems","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T11:00:00Z","last_updated_date":"2012-01-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-young-research-subjects-old-problems_en.pdf"},
    {"id":"14908","name":"Presentation - Antimicrobial use in animals: OIE collection of data on antimicrobial agents used in animals (2015) (Gerard Moulin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T17:00:00Z","last_updated_date":"2016-03-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antimicrobial-use-animals-oie-collection-data-antimicrobial-agents-used-animals-2015-gerard-moulin_en.pdf"},
    {"id":"14913","name":"Presentation - Basis for regulatory decision-making:  Objectives of paediatric development (A.El-Gazayerly, Dutch Medicines Evaluation Board)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-basis-regulatory-decision-making-objectives-paediatric-development-ael-gazayerly-dutch-medicines-evaluation-board_en.pdf"},
    {"id":"14918","name":"Risk Management Plans - Stella Blackburn","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/risk-management-plans-stella-blackburn_en.pdf"},
    {"id":"14919","name":"Presentation: What ever happened to the IMI2 proposal?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-ever-happened-imi2-proposal_en.pdf"},
    {"id":"14921","name":"Presentation - Section 3: Pharmaceutical form","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-3-pharmaceutical-form_en.pdf"},
    {"id":"14927","name":"Presentation - The industry's views on geriatric medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industrys-views-geriatric-medicines_en.pdf"},
    {"id":"14959","name":"E-Submission: From 2005 to 2008, A great step forward - Andrà© Lhoir","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/e-submission-2005-2008-great-step-forward-andrac-lhoir_en.pdf"},
    {"id":"14968","name":"Presentation - European Medicines Network Coordinating role of the Agency within the network- clarifying roles and responsibilities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-13T01:00:00Z","last_updated_date":"2010-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-network-coordinating-role-agency-within-network-clarifying-roles-and-responsibilities_en.pdf"},
    {"id":"14982","name":"Presentation - Pharmacovigilance system impact - EU regulatory network collaboration and initiaves (Xavier Kurz on behalf of Julie Williams)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-system-impact-eu-regulatory-network-collaboration-and-initiaves-xavier-kurz-behalf-julie-williams_en.pdf"},
    {"id":"14989","name":"Presentation - Development of drugs in paediatric neuromyelitis optica and neuromyelitis optica spectrum disorders: Industry perspective (Josephine Glover)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-drugs-paediatric-neuromyelitis-optica-and-neuromyelitis-optica-spectrum-disorders-industry-perspective-josephine-glover_en.pdf"},
    {"id":"15000","name":"Presentation - The place for treatments of associated neuropsychiatric and other symptoms (Luca Pani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-place-treatments-associated-neuropsychiatric-and-other-symptoms-luca-pani_en.pdf"},
    {"id":"15024","name":"Presentation - Data analysis based on overview of EudraVigilance data (Victoria Newbould)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-analysis-based-overview-eudravigilance-data-victoria-newbould_en.pdf"},
    {"id":"15029","name":"Presentation - Additional monitoring: public communication","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-additional-monitoring-public-communication_en.pdf"},
    {"id":"15031","name":"Presentation - 1.1 Reporting of adverse drug reactions by patients and consumers","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11-reporting-adverse-drug-reactions-patients-and-consumers_en.pdf"},
    {"id":"15064","name":"Presentation - What is Pharmacovigilance for patients (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-pharmacovigilance-patients-priya-bahri_en.pdf"},
    {"id":"15083","name":"Presentation - 4.4 A decision theoretic approach to optimize clinical trial designs for targeted therapies (Martin Posch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-44-decision-theoretic-approach-optimize-clinical-trial-designs-targeted-therapies-martin-posch_en.pdf"},
    {"id":"15087","name":"Presentation - Early access session (Martine Zimmermann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-early-access-session-martine-zimmermann_en.pdf"},
    {"id":"15105","name":"Presentation - Interacting with industry stakeholders at the European Medicines Agency (Melanie Carr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interacting-industry-stakeholders-european-medicines-agency-melanie-carr_en.pdf"},
    {"id":"15111","name":"Presentation - Visualizing uncertainty among laypersons and experts (Andrea Beyer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-visualizing-uncertainty-among-laypersons-and-experts-andrea-beyer_en.pdf"},
    {"id":"15120","name":"Presentation - EuroNeoNet","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-euroneonet_en.pdf"},
    {"id":"15129","name":"Presentation - Extrapolation plan and statistical tools - Panel discussion (Flora Musuamba, Alexander Staab)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extrapolation-plan-and-statistical-tools-panel-discussion-flora-musuamba-alexander-staab_en.pdf"}    {"id":"15135","name":"Presentation - NOAC future perspectives: academic perspective (Hugo ten Cate)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-noac-future-perspectives-academic-perspective-hugo-ten-cate_en.pdf"},
    {"id":"15154","name":"Presentation - Age-appropriate formulations – paediatric needs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-age-appropriate-formulations-paediatric-needs_en.pdf"},
    {"id":"15158","name":"Presentation - Introduction to the work of the PDCO Formulation Working Group","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-work-pdco-formulation-working-group_en.pdf"},
    {"id":"15159","name":"Presentation - PRIME first experiences (James Kennard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prime-first-experiences-james-kennard_en.pdf"},
    {"id":"15176","name":"Presentation - GMP phage production for clinical trials (Laurent Bretaudeau)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-22T02:00:00Z","last_updated_date":"2015-06-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gmp-phage-production-clinical-trials-laurent-bretaudeau_en.pdf"},
    {"id":"15177","name":"Presentation - Forward (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-forward-peter-arlett_en.pdf"},
    {"id":"15178","name":"Presentation - Involving patients and healthcare professionals in regulatory decisions - MEB (Sandra Kruger-Peters)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-involving-patients-and-healthcare-professionals-regulatory-decisions-meb-sandra-kruger-peters_en.pdf"},
    {"id":"15190","name":"Presentation - Novel therapies: Innovation Task Force (ITF), scientific advice and new Ad Hoc group on Veterinary Novel Therapies (ADVENT) (Fia Westerholm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-novel-therapies-innovation-task-force-itf-scientific-advice-and-new-ad-hoc-group-veterinary-novel-therapies-advent-fia-westerholm_en.pdf"},
    {"id":"15197","name":"Presentation - Case study: EURACAN clinical research (Stephane Lejeune)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-euracan-clinical-research-stephane-lejeune_en.pdf"},
    {"id":"15201","name":"Presentation - Good pharmacovigilance practice module VI","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practice-module-vi_en.pdf"},
    {"id":"15209","name":"Presentation - Experience with the review of the orphan designation in the context of extension of indication (Kristina Larsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T17:16:00Z","last_updated_date":"2018-06-06T17:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-review-orphan-designation-context-extension-indication-kristina-larsson_en.pdf"},
    {"id":"15212","name":"Presentation - Break out session 3 Proposals on how patients can be involved in networks (trial design etc) and in trials (Elizabeth Vroom, Duchene Parent Project and Juan Garcia Burgos, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-break-out-session-3-proposals-how-patients-can-be-involved-networks-trial-design-etc-and-trials-elizabeth-vroom-duchene-parent-project-and-juan-garcia-burgos-ema_en.pdf"},
    {"id":"15224","name":"Handling conflicts of interest for patients’ and consumers’ organisations (J. Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-02-12T01:00:00Z","last_updated_date":"2013-02-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/handling-conflicts-interest-patients-and-consumers-organisations-j-garcia_en.pdf"},
    {"id":"15266","name":"Presentation - Section 4.7: Effects on the ability to drive and use machines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T10:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-47-effects-ability-drive-use-machines_en.pdf"},
    {"id":"15280","name":"Presentation - Pediatric trials network: Duke Clinical Research Institute (C. Hornik)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pediatric-trials-network-duke-clinical-research-institute-c-hornik_en.pdf"},
    {"id":"15282","name":"Numerical validation of biomarkers in oncology - Tomasz Burzykowski","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-12-16T00:09:21Z","last_updated_date":"2005-12-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/numerical-validation-biomarkers-oncology-tomasz-burzykowski_en.pdf"},
    {"id":"15294","name":"Presentation - IPFA’s perspective on haemophilia registries usage (Franà§oise Rossi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ipfas-perspective-haemophilia-registries-usage-franassoise-rossi_en.pdf"},
    {"id":"15307","name":"Presentation - Modelling and simulation examples that failed or succeeded to meet regulators regulators’ expectations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:30:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-examples-failed-or-succeeded-meet-regulators-regulators-expectations_en.pdf"},
    {"id":"15321","name":"Presentation - Disability assessment: can we combine responsiveness and clinical relevance? (Bernard Uitdehaag)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-disability-assessment-can-we-combine-responsiveness-and-clinical-relevance-bernard-uitdehaag_en.pdf"},
    {"id":"15324","name":"Presentation - PSUR roadmap - Achieving a common understanding of the PSUR single assessment in Europe (Irene Rager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-psur-roadmap-achieving-common-understanding-psur-single-assessment-europe-irene-rager_en.pdf"},
    {"id":"15325","name":"Presentation - Additional monitoring of medicines and side-effect reporting: Impact on the product information (C. Espinasse)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-additional-monitoring-medicines-and-side-effect-reporting-impact-product-information-c-espinasse_en.pdf"},
    {"id":"15332","name":"Presentation - Module 10 - Patient safety and pharmacovigilance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T02:00:00Z","last_updated_date":"2018-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-10-patient-safety-and-pharmacovigilance_en.pdf"},
    {"id":"15337","name":"Presentation - Factor VIII and factor IX development plans at the Paediatric Committee: overview (Thorsten Olski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-factor-viii-and-factor-ix-development-plans-paediatric-committee-overview-thorsten-olski_en.pdf"},
    {"id":"15363","name":"All presentations combined","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-03T02:09:21Z","last_updated_date":"2007-10-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/all-presentations-combined_en.pdf"},
    {"id":"15386","name":"Presentation - Phase II/III adaptive design with treatment selection: A case study","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-phase-iiiii-adaptive-design-treatment-selection-case-study_en.pdf"},
    {"id":"15403","name":"Presentation - Modellers perspectives: how modelling and simulation can address gaps in knowledge (I. Skottheim Rusten)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modellers-perspectives-how-modelling-and-simulation-can-address-gaps-knowledge-i-skottheim-rusten_en.pdf"},
    {"id":"15408","name":"Presentation - User testing of the clinical data publication website prototype (Frances Nuttall)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-user-testing-clinical-data-publication-website-prototype-frances-nuttall_en.pdf"},
    {"id":"15421","name":"Presentation - Rationale for issuing the guideline and main Points (Rob Hemmings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rationale-issuing-guideline-and-main-points-rob-hemmings_en.pdf"},
    {"id":"15425","name":"Presentation - Case 4: Goal: What does team plan for phase 2b trial?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-4-goal-what-does-team-plan-phase-2b-trial_en.pdf"},
    {"id":"15427","name":"Presentation - CAT workplan 2015-2016 (Patrick Celis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-12T19:00:00Z","last_updated_date":"2015-05-12T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cat-workplan-2015-2016-patrick-celis_en.pdf"},
    {"id":"15428","name":"Presentation - Session 1: Defining and selecting populations, extrapolation of benefit between populations (Jan Mà¼ller-Berghaus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-09T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-defining-and-selecting-populations-extrapolation-benefit-between-populations-jan-ma-14ller-berghaus_en.pdf"},
    {"id":"15430","name":"'New quality paradigm: Quality by Design Design' ICH Q8 Q8-9-10 - Evdokia Korakianiti","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/new-quality-paradigm-quality-design-design-ich-q8-q8-9-10-evdokia-korakianiti_en.pdf"},
    {"id":"15438","name":"Presentation - Lessons learnt by a national, generic network","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:51Z","last_updated_date":"2011-05-27T15:25:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lessons-learnt-national-generic-network_en.pdf"},
    {"id":"15439","name":"Presentation - Supply shortages of medicines in Europe (Franà§ois Houà¿ez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supply-shortages-medicines-europe-franassois-houaez_en.pdf"},
    {"id":"15453","name":"Presentation - Conference on the outcomes of the evaluation of the European Medicines Agency (EMA): European Medicines Network presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-13T01:00:00Z","last_updated_date":"2010-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-conference-outcomes-evaluation-european-medicines-agency-ema-european-medicines-network-presentation_en.pdf"},
    {"id":"15458","name":"Presentation - Paediatric extrapolation in FDA submissions: sources of data (G. Burckart)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-extrapolation-fda-submissions-sources-data-g-burckart_en.pdf"},
    {"id":"15462","name":"Presentation - 2.2 Suggestions for collaboration between the European Network of Paediatric Research at the European Medicines Agency and the Patients' and Consumers' Working Party","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-22-suggestions-collaboration-between-european-network-paediatric-research-european-medicines-agency-and-patients-and-consumers-working-party_en.pdf"},
    {"id":"15484","name":"Presentation - EMA Technical Anonymisation Group (TAG) (Monica Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-31T13:11:00Z","last_updated_date":"2017-03-31T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-technical-anonymisation-group-tag-monica-dias_en.pdf"},
    {"id":"15490","name":"Biomarker in Oncology - Research and early development - Hans Winkler","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/biomarker-oncology-research-and-early-development-hans-winkler_en.pdf"},
    {"id":"15494","name":"Presentation - Update on GVP Module P.II. Biologicals (Xavier Kurz, Sabine Brosch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-gvp-module-pii-biologicals-xavier-kurz-sabine-brosch_en.pdf"},
    {"id":"15496","name":"Presentation - Selection and estimation in exploratory subgroup analyses – a proposal (Gerd Rosenkranz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-selection-and-estimation-exploratory-subgroup-analyses-proposal-gerd-rosenkranz_en.pdf"},
    {"id":"15498","name":"Presentation - Status quo of ERNs and clinical research: results of the ERN-wide survey (Luca Sangiorgi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-status-quo-erns-and-clinical-research-results-ern-wide-survey-luca-sangiorgi_en.pdf"},
    {"id":"15569","name":"Presentation - European Union Network strategy vision for veterinary medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-network-strategy-vision-veterinary-medicines_en.pdf"},
    {"id":"15571","name":"Presentation - Big data meets Medicines Regulation: which data and when? (Luca Pani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-meets-medicines-regulation-which-data-and-when-luca-pani_en.pdf"},
    {"id":"15573","name":"Presentation - Setting the scene: New European Union pharmacovigilance legislation (P. Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-setting-scene-new-european-union-pharmacovigilance-legislation-p-arlett_en.pdf"},
    {"id":"15577","name":"Presentation - Regulatory comments: pharmacometric principles in dose finding (Terry Shepard, Sofia Friberg Hietala)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-comments-pharmacometric-principles-dose-finding-terry-shepard-sofia-friberg-hietala_en.pdf"},
    {"id":"15580","name":"Presentation - EMA Extrapolation Framework Regulatory tools (Paolo Tomasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-extrapolation-framework-regulatory-tools-paolo-tomasi_en.pdf"},
    {"id":"15588","name":"Advances in Croatia's rapproachment to the EU - Sinisa Tomic","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/advances-croatias-rapproachment-eu-sinisa-tomic_en.pdf"},
    {"id":"15591","name":"Presentation - Public funding of research - US, Eugene Major","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-funding-research-us-eugene-major_en.pdf"},
    {"id":"15611","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Values and Preferences for Treatment Outcomes: the MACBETH Approach (Andrea Beyer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-values-and-preferences-treatment-outcomes-macbeth-approach-andrea-beyer_en.pdf"},
    {"id":"15612","name":"Presentation - Session 1: Update on Enpr-EMA activities, achievements and challenges (Mark Turner, Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-update-enpr-ema-activities-achievements-and-challenges-mark-turner-irmgard-eichler_en.pdf"},
    {"id":"15615","name":"Presentation - Next steps - timelines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:46Z","last_updated_date":"2011-05-27T15:25:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-next-steps-timelines_en.pdf"},
    {"id":"15620","name":"Presentation - Directorate General  for Research and Innovation perspective (Antoine Mialhe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-directorate-general-research-and-innovation-perspective-antoine-mialhe_en.pdf"},
    {"id":"15631","name":"Presentation - EMA/EGA workshop - Session 4: Line extension of immediate release products (Alfredo Garcia Arieta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T02:00:00Z","last_updated_date":"2015-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaega-workshop-session-4-line-extension-immediate-release-products-alfredo-garcia-arieta_en.pdf"},
    {"id":"15639","name":"Animal health companies experience, Guillaume Agede, IFAH-Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/animal-health-companies-experience-guillaume-agede-ifah-europe_en.pdf"},
    {"id":"15672","name":"Presentation - Role of modelling and simulation in regulatory decision making in Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:30:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-modelling-and-simulation-regulatory-decision-making-europe_en.pdf"},
    {"id":"15675","name":"Surrogate endpoints in cardiovascular research and regulatory implications - Pieter de Graeff","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-12-16T00:09:21Z","last_updated_date":"2005-12-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/surrogate-endpoints-cardiovascular-research-and-regulatory-implications-pieter-de-graeff_en.pdf"},
    {"id":"15704","name":"Presentation - Day 2: Prevention of graft rejection","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-prevention-graft-rejection_en.pdf"},
    {"id":"15708","name":"Transparency - Leng Heng","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2003-05-08T02:00:00Z","last_updated_date":"2003-05-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/transparency-leng-heng_en.pdf"},
    {"id":"15728","name":"Presentation - PHARMACHILD: A European collaboration on long term outcome and pharmacovigilance for biologics used in Juvenile Idiopathic Arthritis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmachild-european-collaboration-long-term-outcome-and-pharmacovigilance-biologics-used-juvenile-idiopathic-arthritis_en.pdf"},
    {"id":"15741","name":"Presentation - Current knowledge of best practice for promoting prudent use  (L. Stubbings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-knowledge-best-practice-promoting-prudent-use-l-stubbings_en.pdf"},
    {"id":"15745","name":"Presentation - Control of biologics, Kowid Ho, Afssaps","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-control-biologics-kowid-ho-afssaps_en.pdf"},
    {"id":"15747","name":"Presentation - Paediatric pulmonary arterial hypertension current treatment, needs and challenges (Rolf M.F. Berger, University Medical Center Groningen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-pulmonary-arterial-hypertension-current-treatment-needs-and-challenges-rolf-mf-berger-university-medical-center-groningen_en.pdf"},
    {"id":"15777","name":"Presentation - Organisations management service (OMS) and referentials management service and user acceptance testing (RMS UATs) - Webinar with all testers (Kepa Amutxastegi and Nuno Lopes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-15T19:00:00Z","last_updated_date":"2019-07-11T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organisations-management-service-oms-and-referentials-management-service-and-user-acceptance-testing-rms-uats-webinar-all-testers-kepa-amutxastegi-and-nuno-lopes_en.pdf"},
    {"id":"15795","name":"Presentation - Multi-stakeholder late and early dialogue (S. Vamvakas, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multi-stakeholder-late-and-early-dialogue-s-vamvakas-ema_en.pdf"},
    {"id":"15814","name":"Presentation - Accession Preparation: Situation in Croatia","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accession-preparation-situation-croatia_en.pdf"},
    {"id":"15816","name":"Presentation - Key aspects related to the submission of clinical reports for the purpose of publication in accordance with EMA Policy 0070:  Second stakeholder meeting on the implementation of EMA policy 0070 (on the pub...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-22T02:00:00Z","last_updated_date":"2015-09-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-aspects-related-submission-clinical-reports-purpose-publication-accordance-ema-policy-0070-second-stakeholder-meeting-implementation-ema-policy-0070-pub_en.pdf"},
    {"id":"15820","name":"Presentation: Dialogue and interaction with ethics committees","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dialogue-and-interaction-ethics-committees_en.pdf"},
    {"id":"15822","name":"Presentation - Maximum Residue Limits (MRLs) and Consumer safety","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-maximum-residue-limits-mrls-and-consumer-safety_en.pdf"},
    {"id":"15842","name":"Presentation - Minimising harm through education (Tony West)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-minimising-harm-through-education-tony-west_en.pdf"},
    {"id":"15857","name":"Presentation - Agenda item 3: substances and products - Reports from  the subgroup","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2015-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-3-substances-and-products-reports-subgroup_en.pdf"},
    {"id":"15866","name":"Presentation - “Phasing-in” issues in Marketing authorizations – Lithuanian perspectives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-phasing-issues-marketing-authorizations-lithuanian-perspectives_en.pdf"},
    {"id":"15871","name":"Presentation - What is new in terms of transparency (Kevin Cunningham)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T12:14:00Z","last_updated_date":"2017-03-30T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-new-terms-transparency-kevin-cunningham_en.pdf"},
    {"id":"15872","name":"10 years of the Orphan Regulation in Europe conference - The experience up to date: S. Aarum, S.Tsigkos","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/10-years-orphan-regulation-europe-conference-experience-date-s-aarum-stsigkos_en.pdf"},
    {"id":"15877","name":"Presentation - The risk of asthma therapy as assessed from real-life data ASTRO-LAB & SNIIRAM (Eric van Ganse)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-asthma-therapy-assessed-real-life-data-astro-lab-sniiram-eric-van-ganse_en.pdf"},
    {"id":"15909","name":"Presentation - Signal management (Sabine Straus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-signal-management-sabine-straus_en.pdf"},
    {"id":"15912","name":"Presentation - Key messages from industry / associations (J. Berridge)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-messages-industry-associations-j-berridge_en.pdf"},
    {"id":"15925","name":"PART II: The Innovative Medicines Initiative; EMEA Viewpoint on the Innovative Medicines Initiative - Stimulating research and innovation - Marisa Papaluca-Amati","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/part-ii-innovative-medicines-initiative-emea-viewpoint-innovative-medicines-initiative-stimulating-research-and-innovation-marisa-papaluca-amati_en.pdf"},
    {"id":"15927","name":"Presentation - Update from SME office, Ms Melanie Carr","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-sme-office-ms-melanie-carr_en.pdf"},
    {"id":"15936","name":"Presentation - Encouraging paediatric clinical research in the European Union (Benjamin Pelle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-encouraging-paediatric-clinical-research-european-union-benjamin-pelle_en.pdf"},
    {"id":"15943","name":"Presentation - Trial of ESVAC protocol for per-species consumption in pigs (Marian Bos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T17:00:00Z","last_updated_date":"2016-03-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-trial-esvac-protocol-species-consumption-pigs-marian-bos_en.pdf"},
    {"id":"15970","name":"Presentation - Implementing the pharmacovigilance legislation: focus on European Union level activities (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementing-pharmacovigilance-legislation-focus-european-union-level-activities-peter-arlett_en.pdf"},
    {"id":"15991","name":"Presentation - EPRUMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-epruma_en.pdf"},
    {"id":"15994","name":"Presentation - Revision of clinical data publication guidance - Update on the implementation of EMA policy on publication of clinical data (Policy 0070) and revisions to the guidance to industry – industry associations w...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-09T01:00:00Z","last_updated_date":"2016-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revision-clinical-data-publication-guidance-update-implementation-ema-policy-publication-clinical-data-policy-0070-and-revisions-guidance-industry-industry-associations-w_en.pdf"},
    {"id":"16007","name":"Presentation - Scientific advice, protocol assistance and patient representatives (Jane Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advice-protocol-assistance-and-patient-representatives-jane-moseley_en.pdf"},
    {"id":"16008","name":"Presentation - Advanced therapy medicinal products (ATMPs), Prof. Jean-Hugues Trouvin","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advanced-therapy-medicinal-products-atmps-prof-jean-hugues-trouvin_en.pdf"},
    {"id":"16016","name":"Presentation - Framework for interaction between European Medicines Agency and healthcare professionals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-22T02:00:00Z","last_updated_date":"2016-08-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-framework-interaction-between-european-medicines-agency-and-healthcare-professionals_en.pdf-0"},
    {"id":"16036","name":"Presentation - Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to less than 10 years of age - Break-out session 3 theme 4","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacokinetic-pharmacodynamic-assessment-topiramate-dosing-regimens-children-epilepsy-2-less-10-years-age-break-out-session-3-theme-4_en.pdf-0"},
    {"id":"16091","name":"Presentation - EU Biosimilar regulatory framework – Non-Clinical and Clinical Aspects III, Falk Ehmann, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-biosimilar-regulatory-framework-non-clinical-and-clinical-aspects-iii-falk-ehmann-ema_en.pdf"},
    {"id":"16096","name":"Presentation - Initiatives to improve ATMPs access to patients (Ana Hidalgo-Simon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-initiatives-improve-atmps-access-patients-ana-hidalgo-simon_en.pdf"},
    {"id":"16112","name":"Presentation - Introduction and goals of the workshop (Georges France)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-and-goals-workshop-georges-france_en.pdf"},
    {"id":"16119","name":"Presentation - Topic 3 - Views of networks: trial preparedness - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-3-views-networks-trial-preparedness-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation_en.pdf"},
    {"id":"16136","name":"Presentation - Dose selection in drug development and regulation: possible future direction concluding industry thinking (Richard Lalonde, Donald Stanski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-selection-drug-development-and-regulation-possible-future-direction-concluding-industry-thinking-richard-lalonde-donald-stanski_en.pdf"},
    {"id":"16162","name":"Presentation - Feedback from CHMP (F. Ventura, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-chmp-f-ventura-ema_en.pdf"},
    {"id":"16171","name":"Presentation - Session 4: future perspectives - What could be done? Industry perspective (Daiichi Sankyo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-future-perspectives-what-could-be-done-industry-perspective-daiichi-sankyo_en.pdf"},
    {"id":"16178","name":"Presentation - Current position and expectation for use of modelling and simulation in drug development and regulatory decision making","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:30:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-position-and-expectation-use-modelling-and-simulation-drug-development-and-regulatory-decision-making_en.pdf"},
    {"id":"16193","name":"Biosimilar mAbs - Clinical issues - Regulatory perspective - Christian K Schneider","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/biosimilar-mabs-clinical-issues-regulatory-perspective-christian-k-schneider_en.pdf"},
    {"id":"16202","name":"Presentation - Closing remarks on the workshop on process validation (Kowid Ho)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-closing-remarks-workshop-process-validation-kowid-ho_en.pdf"},
    {"id":"16208","name":"Presentation - Committee for Advanced Therapies (CAT) interested parties focus groups: A new model for a fruitful interaction between CAT and its stakeholders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-advanced-therapies-cat-interested-parties-focus-groups-new-model-fruitful-interaction-between-cat-and-its-stakeholders_en.pdf"},
    {"id":"16230","name":"Presentation - Interface Enpr-EMA and ENCePP (Kevin Blake)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interface-enpr-ema-and-encepp-kevin-blake_en.pdf"}    {"id":"16245","name":"Presentation - EMA framework of collaboration with academia (Monica Ensini, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-framework-collaboration-academia-monica-ensini-ema_en.pdf"},
    {"id":"16277","name":"Presentation - Session 3.7: EMA framework of collaboration with academia (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-37-ema-framework-collaboration-academia-isabelle-moulon_en.pdf"},
    {"id":"16289","name":"Presentation - Case study 2 - Validation efficiencies from quality by design (QbD) and prior knowledge - Session 3 (Frank Zettl)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-2-validation-efficiencies-quality-design-qbd-and-prior-knowledge-session-3-frank-zettl_en.pdf"},
    {"id":"16290","name":"Presentation - The role of PSURS in pharmacovigilance inspections - Getting it right and practical experience (Ernesto Vera Sà¡nchez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-psurs-pharmacovigilance-inspections-getting-it-right-and-practical-experience-ernesto-vera-sanchez_en.pdf"},
    {"id":"16300","name":"Presentation - Variations and progress in worksharing (Melanie Leivers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-variations-and-progress-worksharing-melanie-leivers_en.pdf"},
    {"id":"16310","name":"Presentation - Federation of Veterinarians of Europe (Nancy De Briyne)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T13:00:00Z","last_updated_date":"2013-04-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-federation-veterinarians-europe-nancy-de-briyne_en.pdf"},
    {"id":"16311","name":"Presentation - Guidelines HAP/VAP: Standpoint from (some) academics (Serge Kouzan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidelines-hapvap-standpoint-some-academics-serge-kouzan_en.pdf"},
    {"id":"16341","name":"Presentation - Biosimilar industry perspective on draft guideline on immunogenicity assessment of monoclonal antibodies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:53Z","last_updated_date":"2012-06-15T17:10:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-biosimilar-industry-perspective-draft-guideline-immunogenicity-assessment-monoclonal-antibodies_en.pdf"},
    {"id":"16380","name":"Presentation - Implementing good practice – Industry experience with medication errors (Jo Emmott)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementing-good-practice-industry-experience-medication-errors-jo-emmott_en.pdf"},
    {"id":"16385","name":"Presentation - Modelling methods to estimate the public health impact of regulatory decisions (Saad Shakir)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-methods-estimate-public-health-impact-regulatory-decisions-saad-shakir_en.pdf"},
    {"id":"16398","name":"European Medicines Agency training strategy for patients and consumers (N. Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-02-12T01:00:00Z","last_updated_date":"2013-02-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-medicines-agency-training-strategy-patients-and-consumers-n-bere_en.pdf"},
    {"id":"16409","name":"Presentation - Patient expectations for meaningful engagement in ERN-related clinical research (Russell Wheeler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-expectations-meaningful-engagement-ern-related-clinical-research-russell-wheeler_en.pdf"},
    {"id":"16432","name":"Presentation - Session 1: A common data model - Why? Strengths and limitations of a common data approach (Patrick Ryan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-common-data-model-why-strengths-and-limitations-common-data-approach-patrick-ryan_en.pdf"},
    {"id":"16458","name":"Presentation - European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations workplan 2012","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-workplan-2012_en.pdf"},
    {"id":"16460","name":"Presentation - On the utility of subgroup analyses in confirmatory clinical trials (Brian A. Millen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-utility-subgroup-analyses-confirmatory-clinical-trials-brian-millen_en.pdf"},
    {"id":"16470","name":"Presentation - Scientific advice: what to expect and how to prepare","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-31T19:00:00Z","last_updated_date":"2016-08-31T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advice-what-expect-and-how-prepare_en.pdf"},
    {"id":"16510","name":"Presentation - EudraVigilance veterinary and pharmacovigilance of veterinary medicinal products in Serbia","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-veterinary-and-pharmacovigilance-veterinary-medicinal-products-serbia_en.pdf"},
    {"id":"16516","name":"Presentation - Generics/Non prescription medicines - Non-prescription switching","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-genericsnon-prescription-medicines-non-prescription-switching_en.pdf"},
    {"id":"16534","name":"Presentation - Modelling and simulation to optimise the design of confirmatory trials - Break-out session 4 theme 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-optimise-design-confirmatory-trials-break-out-session-4-theme-1_en.pdf"},
    {"id":"16559","name":"Presentation - Tailored immunogenicity program - why? (Florian Deisenhammer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-tailored-immunogenicity-program-why-florian-deisenhammer_en.pdf"},
    {"id":"16603","name":"Presentation - Inspection findings on health-based exposure limits and cross contamination (G. McKilligan, MHRA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-inspection-findings-health-based-exposure-limits-and-cross-contamination-g-mckilligan-mhra_en.pdf"},
    {"id":"16605","name":"Presentation - Pharmacovigilance through the Product Lifecycle and the Central Role of the PSUR (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-through-product-lifecycle-and-central-role-psur-june-raine_en.pdf"},
    {"id":"16610","name":"Presentation -  Multiplicity: Is it of value to make it so complicated? (Andrew Stone)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multiplicity-it-value-make-it-so-complicated-andrew-stone_en.pdf"},
    {"id":"16611","name":"Presentation - Immunogenicity guideline pharmacovigilance (Thijs Giezen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunogenicity-guideline-pharmacovigilance-thijs-giezen_en.pdf"},
    {"id":"16612","name":"Presentation - ESVAC (Declan O'Brien)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-22T13:01:30Z","last_updated_date":"2010-12-22T13:01:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esvac-declan-obrien_en.pdf"},
    {"id":"16620","name":"EMEA Innovation Task Force Experience - Marisa Papaluca","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-innovation-task-force-experience-marisa-papaluca_en.pdf"},
    {"id":"16632","name":"Presentation - Cooperation between EMA and patients' and healthcare professionals' organisations (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cooperation-between-ema-and-patients-and-healthcare-professionals-organisations-isabelle-moulon_en.pdf"},
    {"id":"16639","name":"Presentation - EMA questions - Overview of expert responses","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-22T01:00:00Z","last_updated_date":"2011-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-questions-overview-expert-responses_en.pdf"},
    {"id":"16660","name":"Presentation - Objectives of  session on communication and information on medicines (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-objectives-session-communication-and-information-medicines-isabelle-moulon_en.pdf"},
    {"id":"16661","name":"Presentation - European Union regulatory perspective on the potential use of biomarkers in Alzheimer's disease drug development (Valentina Mantua)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-regulatory-perspective-potential-use-biomarkers-alzheimers-disease-drug-development-valentina-mantua_en.pdf"},
    {"id":"16663","name":"Presentation - Summary of substance sessions at task force and built upon at the follow up identification of medicinal products (IDMP) workshop","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-substance-sessions-task-force-and-built-upon-follow-identification-medicinal-products-idmp-workshop_en.pdf"},
    {"id":"16672","name":"Presentation - Perspectives for the future: Member States perspective (Sabine Straus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-perspectives-future-member-states-perspective-sabine-straus_en.pdf"},
    {"id":"16693","name":"IAAP statements at EMEA 'Homeopathic workshop'","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/iaap-statements-emea-homeopathic-workshop_en.pdf"},
    {"id":"16698","name":"Presentation - Section 4.8: Undesirable effects","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2020-06-25T11:55:00Z","reference_number":"Rev.1","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-48-undesirable-effects_en.pdf"},
    {"id":"16760","name":"Questions on session 2: Focus group 'better system to navigate advanced-therapy-medicinal-product guidance documents","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/questions-session-2-focus-group-better-system-navigate-advanced-therapy-medicinal-product-guidance-documents_en.pdf"},
    {"id":"16766","name":"Presentation - Regulators initiative, research agenda, Ana Hidalgo","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulators-initiative-research-agenda-ana-hidalgo_en.pdf"},
    {"id":"16767","name":"Presentation - Clinical trials designs in neuromyelitis optica and spectrum disorders: United States Perspective (Wiley A. Chambers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-designs-neuromyelitis-optica-and-spectrum-disorders-united-states-perspective-wiley-chambers_en.pdf"},
    {"id":"16768","name":"Presentation - Session II - Working groups update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-18T02:00:00Z","last_updated_date":"2016-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-ii-working-groups-update_en.pdf"},
    {"id":"16769","name":"Presentation - High level overview of pharmacovigilance in the EU for veterinary medicinal products (J.Olaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-high-level-overview-pharmacovigilance-eu-veterinary-medicinal-products-jolaerts_en.pdf"},
    {"id":"16774","name":"Presentation - SME survey 2015 – Taking stock of the experience gained with the Agency’s SME initiative 10 years after its launch (Angela-Christina Schmidt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-survey-2015-taking-stock-experience-gained-agencys-sme-initiative-10-years-after-its-launch-angela-christina-schmidt_en.pdf"},
    {"id":"16808","name":"Presentation - Feedback from 6th annual workshop of European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) (Adamos Hadjipanayis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-6th-annual-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema-adamos-hadjipanayis_en.pdf"},
    {"id":"16809","name":"Presentation - Manufacturing Change for a Biological Product (V. LeBras, Merck)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-manufacturing-change-biological-product-v-lebras-merck_en.pdf"},
    {"id":"16815","name":"Presentation - 6.1 Historical controls: think cluster not parallel (Stephen Senn, Olivier Collignon, Anna Schritz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-61-historical-controls-think-cluster-not-parallel-stephen-senn-olivier-collignon-anna-schritz_en.pdf"},
    {"id":"16824","name":"Presentation - PIP session: PDCO evaluation of ophthalmology paediatric investigation plans","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pip-session-pdco-evaluation-ophthalmology-paediatric-investigation-plans_en.pdf"},
    {"id":"16864","name":"Presentation - Topic 4 - Improving the handling of paediatric investigation plan (PIP) applications- Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-4-improving-handling-paediatric-investigation-plan-pip-applications-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation_en.pdf"},
    {"id":"16868","name":"Presentation - Clinical development and innovation in engineered T cell therapies (Bruce Levine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T10:22:00Z","last_updated_date":"2016-12-02T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-development-and-innovation-engineered-t-cell-therapies-bruce-levine_en.pdf"},
    {"id":"16893","name":"Presentation - Applications of pharmacogenomics in pharmacokinetics at the Pharmaceuticals and Medical Devices Agency: Experience and expectations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-applications-pharmacogenomics-pharmacokinetics-pharmaceuticals-medical-devices-agency-experience-expectations_en.pdf"},
    {"id":"16896","name":"An overview of the clinical trial authorisation framework in Europe, Dr Chantal Bà©lorgey","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-clinical-trial-authorisation-framework-europe-dr-chantal-baclorgey_en.pdf"},
    {"id":"16897","name":"Presentation - The latest developments in scientific review, regulation and marketing authorisation procedures: Update on specific points from Immunologicals Working Party (Esther Werner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-latest-developments-scientific-review-regulation-and-marketing-authorisation-procedures-update-specific-points-immunologicals-working-party-esther-werner_en.pdf"},
    {"id":"16901","name":"Presentation - PRIME: One year experience and highlights from 19 May stakeholder meeting (Zahra Hanaizi, Jordi Llinares, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prime-one-year-experience-and-highlights-19-may-stakeholder-meeting-zahra-hanaizi-jordi-llinares-ema_en.pdf"},
    {"id":"16940","name":"Presentation - Risk assessment and mitigation strategies for immune Responses to therapeutic proteins: the FDA perspective (Amy Rosenberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-assessment-and-mitigation-strategies-immune-responses-therapeutic-proteins-fda-perspective-amy-rosenberg_en.pdf"},
    {"id":"16952","name":"Presentation - Differences in a biomarker’s predictive ability across racial groups","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-differences-biomarkers-predictive-ability-across-racial-groups_en.pdf"},
    {"id":"16953","name":"Presentation - Application of pharmacogenomics in pharmacokinetics at the Food and Drug Administration: Experience and expectations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-application-pharmacogenomics-pharmacokinetics-food-and-drug-administration-experience-and-expectations_en.pdf"},
    {"id":"16954","name":"Presentation - Session 3: Extrapolation plan and PK/PD studies\n\nPanel Discussion (Martin Posch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-extrapolation-plan-and-pkpd-studies-panel-discussion-martin-posch_en.pdf"},
    {"id":"16955","name":"Presentation - Update on PRAC work plan and impact strategy (June M. Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T16:03:00Z","last_updated_date":"2017-07-25T16:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-prac-work-plan-and-impact-strategy-june-m-raine_en.pdf"},
    {"id":"16959","name":"Presentation - Going viral. The state of play and potential of social media in 2016 (Mun-Keat Looi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-going-viral-state-play-and-potential-social-media-2016-mun-keat-looi_en.pdf"},
    {"id":"16961","name":"Presentation - Implementation of Clinical Trial Regulation – Update on EU-CT portal and database - EMA's PCWP and HCPWP joint meeting (Laura Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-clinical-trial-regulation-update-eu-ct-portal-and-database-emas-pcwp-and-hcpwp-joint-meeting-laura-pioppo_en.pdf"},
    {"id":"16969","name":"Presentation - Regulatory experience in application of modelling in dose selection","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-experience-application-modelling-dose-selection_en.pdf"},
    {"id":"16995","name":"Presentation - Pharmacovigilance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:53Z","last_updated_date":"2012-06-15T17:10:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance_en.pdf"},
    {"id":"17002","name":"Presentation - What is a European safety referral","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-07T01:00:00Z","last_updated_date":"2017-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-european-safety-referral_en.pdf"},
    {"id":"17007","name":"Industry Proposals for Implementation of Prudent Use Wording","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/industry-proposals-implementation-prudent-use-wording_en.pdf"},
    {"id":"17022","name":"Presentation - Draft principles for assignment of technical units of measurement (Kari Grave, Marian Bos, Jordi Torren Edo, Arno Muller)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T13:00:00Z","last_updated_date":"2015-04-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-principles-assignment-technical-units-measurement-kari-grave-marian-bos-jordi-torren-edo-arno-muller_en.pdf"},
    {"id":"17056","name":"Use of flow cytometry for investigating immunomodulatory effects of medicines: Richard Stebbings, NIBSC, England","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/use-flow-cytometry-investigating-immunomodulatory-effects-medicines-richard-stebbings-nibsc-england_en.pdf"},
    {"id":"17057","name":"Presentation - Global research in paediatrics (GRiP) – Tools for Interoperability(Allison Needham, Anne Junker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-global-research-paediatrics-grip-tools-interoperabilityallison-needham-anne-junker_en.pdf"},
    {"id":"17063","name":"Focus Group Meeting on Fluoroquinolones - Liisa Kaartinen/Gerard Moulin","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/focus-group-meeting-fluoroquinolones-liisa-kaartinengerard-moulin_en.pdf"},
    {"id":"17075","name":"Presentation - Workshop on patient-support programmes and market-research programmes: Spectrum of programmes falling under the terms of patient-support and market-research programmes and the type of safety data collected...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patient-support-programmes-and-market-research-programmes-spectrum-programmes-falling-under-terms-patient-support-and-market-research-programmes-and-type-safety-data-collected_en.pdf"},
    {"id":"17078","name":"Presentation - EVDAS training for Marketing Authorisation Holders - Training module EV-M5b","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-06T15:00:00Z","last_updated_date":"2017-01-06T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evdas-training-marketing-authorisation-holders-training-module-ev-m5b_en.pdf"},
    {"id":"17082","name":"Presentation - Workshop on access to clinical-trial data – next steps (Hans-Georg Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-05T17:00:00Z","last_updated_date":"2012-12-05T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-access-clinical-trial-data-next-steps-hans-georg-eichler_en.pdf"},
    {"id":"17090","name":"Presentation - European Medicines Agency/PDCO summary report for PIP / waiver applications: revision of template and use in applications (Ralf Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T17:00:00Z","last_updated_date":"2016-05-27T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agencypdco-summary-report-pip-waiver-applications-revision-template-and-use-applications-ralf-herold_en.pdf"},
    {"id":"17091","name":"Module 11 - Presentation - EMA and international cooperation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/module-11-presentation-ema-and-international-cooperation_en.pdf"},
    {"id":"17127","name":"Presentation - Periodic-safety-update-report procedure and concept of benefit-risk evaluation (R. Postigo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-periodic-safety-update-report-procedure-and-concept-benefit-risk-evaluation-r-postigo_en.pdf"},
    {"id":"17128","name":"Presentation - The potential use of biomarkers in Alzheimer’s disease in different stages of drug development (Johan Luthman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-potential-use-biomarkers-alzheimers-disease-different-stages-drug-development-johan-luthman_en.pdf"},
    {"id":"17136","name":"Presentation - The patient’s perspectives on significant benefit (Yann Le Cam)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T17:00:00Z","last_updated_date":"2015-12-15T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-perspectives-significant-benefit-yann-le-cam_en.pdf"},
    {"id":"17148","name":"Presentation - eCTD lifecycle - capture of industry issues and proposals relating to Policy 0070 (Alastair Nixon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-31T13:11:00Z","last_updated_date":"2017-03-31T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ectd-lifecycle-capture-industry-issues-and-proposals-relating-policy-0070-alastair-nixon_en.pdf"},
    {"id":"17176","name":"Presentation - Agenda item 4: PMS iteration 1 - Analysis of the data efforts and value results and recommendation on the scope","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-15T15:00:00Z","last_updated_date":"2016-03-15T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-4-pms-iteration-1-analysis-data-efforts-and-value-results-and-recommendation-scope_en.pdf"},
    {"id":"17183","name":"Joint EMEA/ EFPIA Information Session - Ann Robins","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-09-11T02:09:21Z","last_updated_date":"2006-09-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/joint-emea-efpia-information-session-ann-robins_en.pdf"},
    {"id":"17188","name":"GCP Inspection - Gabrielle Schwarz","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gcp-inspection-gabrielle-schwarz_en.pdf"},
    {"id":"17190","name":"Presentation - COMP feedback (Daniel O'Connor, MHRA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comp-feedback-daniel-oconnor-mhra_en.pdf"},
    {"id":"17201","name":"Presentation - Determination of the probability of target attainment (Matthew Rizk)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-determination-probability-target-attainment-matthew-rizk_en.pdf"},
    {"id":"17214","name":"Gene therapy-based orphan drugs: Alessandro Aiuti","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gene-therapy-based-orphan-drugs-alessandro-aiuti_en.pdf"},
    {"id":"17241","name":"Presentation -  European Union legislative and policy developments in the medicinal products area (Stefano Soro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-legislative-and-policy-developments-medicinal-products-area-stefano-soro_en.pdf"},
    {"id":"17251","name":"Presentation - First webinar on regulatory and procedural aspects of type I variations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-14T01:00:00Z","last_updated_date":"2016-11-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-first-webinar-regulatory-and-procedural-aspects-type-i-variations_en.pdf"},
    {"id":"17257","name":"Presentation - Chronic Intractable Diarrhoea of infancy (Nick Croft)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chronic-intractable-diarrhoea-infancy-nick-croft_en.pdf"},
    {"id":"17269","name":"Presentation - Regulatory discussant: Case 1 - Break-out session 3 theme 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-discussant-case-1-break-out-session-3-theme-1_en.pdf"},
    {"id":"17289","name":"Presentation - Module 8 - Dealing with specific populations and types of products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T02:00:00Z","last_updated_date":"2018-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-8-dealing-specific-populations-and-types-products_en.pdf"},
    {"id":"17296","name":"Presentation - Making best use of the PSUR Repository (Ana Zanoletty)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-making-best-use-psur-repository-ana-zanoletty_en.pdf"},
    {"id":"17325","name":"Presentation - 2.4 Combining evidence : purpose is everything (Stephen Senn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-24-combining-evidence-purpose-everything-stephen-senn_en.pdf"},
    {"id":"17330","name":"Presentation - Cognition and fatigue as major determinants of disability (Bernd C. Kieseier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cognition-and-fatigue-major-determinants-disability-bernd-c-kieseier_en.pdf"},
    {"id":"17332","name":"Presentation - EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema_en.pdf"},
    {"id":"17337","name":"Presentation - Digital Media and Health Topic Group- EMA's PCWP and HCPWP joint meeting (Caroline Morton-Gallagher)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-digital-media-and-health-topic-group-emas-pcwp-and-hcpwp-joint-meeting-caroline-morton-gallagher_en.pdf"},
    {"id":"17352","name":"CHMP draft Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products; Bioindustry Perspective - Christiane Abouzeid","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/chmp-draft-guideline-requirements-first-man-clinical-trials-potential-high-risk-medicinal-products-bioindustry-perspective-christiane-abouzeid_en.pdf"},
    {"id":"17357","name":"Guideline on requirements for First-in-man clinical trials For potential high-risk Medicinal products - JW van der Laan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/guideline-requirements-first-man-clinical-trials-potential-high-risk-medicinal-products-jw-van-der-laan_en.pdf"},
    {"id":"17363","name":"Pharmacovigilance – Priya Bahri","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2003-05-08T02:00:00Z","last_updated_date":"2003-05-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pharmacovigilance-priya-bahri_en.pdf"},
    {"id":"17370","name":"Presentation - Implementation of the EudraVigilance Access Policy for Centrally Authorised Products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T01:00:00Z","last_updated_date":"2011-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-eudravigilance-access-policy-centrally-authorised-products_en.pdf"},
    {"id":"17378","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Benefit/Risk survey (M Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-benefitrisk-survey-m-mavris_en.pdf"},
    {"id":"17392","name":"Presentation - Novel biomarkers: pitfalls, limitations, emerging options (Bernard Fox) - S3.3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-novel-biomarkers-pitfalls-limitations-emerging-options-bernard-fox-s33_en.pdf"},
    {"id":"17400","name":"Presentation - What is a package leaflet – How to review it? (Claire Espinasse)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-package-leaflet-how-review-it-claire-espinasse_en.pdf-0"},
    {"id":"17472","name":"Invented Name Review Group 2005-2006 - Zaide Frias","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-09-11T02:09:21Z","last_updated_date":"2006-09-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/invented-name-review-group-2005-2006-zaide-frias_en.pdf"},
    {"id":"17474","name":"Presentation - EMA Clinical Data Publication (CDP) - EMA's PCWP and HCPWP joint meeting (Karen Quigley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-clinical-data-publication-cdp-emas-pcwp-and-hcpwp-joint-meeting-karen-quigley_en.pdf"},
    {"id":"17478","name":"Presentation - An inspector’s perspective – Considerations for patient-support and reimbursement programmes (Anya Sookoo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-inspectors-perspective-considerations-patient-support-and-reimbursement-programmes-anya-sookoo_en.pdf"}    {"id":"17480","name":"Presentation - How we communicate the outcome of safety reviews (M. Benstetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-we-communicate-outcome-safety-reviews-m-benstetter_en.pdf"},
    {"id":"17487","name":"Presentation - Substance, Product, Organisation and Referential (SPOR) impacts on processes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-product-organisation-and-referential-spor-impacts-processes_en.pdf"},
    {"id":"17505","name":"Presentation - Topic Group Academia, Learned Societies and HCP organisations proposals (how to move forward) (Rosa Giuliani, Sergio Bonini)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-30T02:00:00Z","last_updated_date":"2016-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-group-academia-learned-societies-and-hcp-organisations-proposals-how-move-forward-rosa-giuliani-sergio-bonini_en.pdf"},
    {"id":"17510","name":"Involvement of patients in CHMP benefit-risk (J. Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-02-12T01:00:00Z","last_updated_date":"2013-02-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/involvement-patients-chmp-benefit-risk-j-garcia_en.pdf"},
    {"id":"17518","name":"Presentation - Regulatory interactions: Expectations on extrapolation approaches (Lynne Yao)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-interactions-expectations-extrapolation-approaches-lynne-yao_en.pdf"},
    {"id":"17519","name":"Presentation - Road map to 2015: High-level overview of the outcome of the public consultation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-13T01:00:00Z","last_updated_date":"2010-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-road-map-2015-high-level-overview-outcome-public-consultation_en.pdf"},
    {"id":"17537","name":"Presentation - Adverse-drug-reaction reporting – United Kingdom view (Mick Foy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adverse-drug-reaction-reporting-united-kingdom-view-mick-foy_en.pdf"},
    {"id":"17543","name":"Presentation - Guideline on similar biological medicinal products containing biotechnologically-derived proteins as active substances: quality issues (Niklas Ekman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-similar-biological-medicinal-products-containing-biotechnologically-derived-proteins-active-substances-quality-issues-niklas-ekman_en.pdf"},
    {"id":"17546","name":"Module 01 - Presentation - Introduction to the EU Regulatory Network: Transparency, Trust and Reliance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-14T01:00:00Z","last_updated_date":"2017-11-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/module-01-presentation-introduction-eu-regulatory-network-transparency-trust-and-reliance_en.pdf"},
    {"id":"17548","name":"Quality Topics - Jean-Lois Robert","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/quality-topics-jean-lois-robert_en.pdf"},
    {"id":"17553","name":"Presentation - Session 2: European Medicines Agency consultation meeting on the rheumatoid arthritis guideline (Arantxa Sancho-Là³pez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-09T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-european-medicines-agency-consultation-meeting-rheumatoid-arthritis-guideline-arantxa-sancho-la3pez_en.pdf"},
    {"id":"17575","name":"Presentation - Network's perspective - What networks can offer (Kalle Hoppu, FINPEDMED)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-networks-perspective-what-networks-can-offer-kalle-hoppu-finpedmed_en.pdf"},
    {"id":"17577","name":"Presentation - Enpr-EMA work group on clinical trial preparedness (A. Siapkara)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-work-group-clinical-trial-preparedness-siapkara_en.pdf"},
    {"id":"17584","name":"Presentation - Proposals for strengthening the interaction between PDCO and PRAC (Benjamin Pelle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T02:00:00Z","last_updated_date":"2014-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposals-strengthening-interaction-between-pdco-and-prac-benjamin-pelle_en.pdf"},
    {"id":"17600","name":"Presentation - Overview of methodologies and studies evaluating risk minimisation measures (Giampiero Mazzaglia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-methodologies-and-studies-evaluating-risk-minimisation-measures-giampiero-mazzaglia_en.pdf"},
    {"id":"17618","name":"Presentation - Extrapolation framework: status quo and issues to be resolved (C. Male)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extrapolation-framework-status-quo-and-issues-be-resolved-c-male_en.pdf"},
    {"id":"17627","name":"Presentation - Scientific advisory group meetings 'pilot phase' report","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advisory-group-meetings-pilot-phase-report_en.pdf"},
    {"id":"17636","name":"Presentation - The European reference networks: a vision from inside (Maurizio Scarpa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-reference-networks-vision-inside-maurizio-scarpa_en.pdf"},
    {"id":"17645","name":"Presentation - Towards increased engagement through social media. \n\nEMA’s current experience and way forward with social media (Sophie Labbe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-towards-increased-engagement-through-social-media-emas-current-experience-and-way-forward-social-media-sophie-labbe_en.pdf"},
    {"id":"17657","name":"Presentation - IMI WEB-RADR (recognising adverse reactions) project: goals and current activities (Sabine Brosch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-imi-web-radr-recognising-adverse-reactions-project-goals-and-current-activities-sabine-brosch_en.pdf"},
    {"id":"17668","name":"Presentation - The use of EudraVigilance: perspective from a NCA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-eudravigilance-perspective-nca_en.pdf"},
    {"id":"17669","name":"Presentation - EU Support to ATMP developers (Patrick Celis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T10:22:00Z","last_updated_date":"2016-12-02T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-support-atmp-developers-patrick-celis_en.pdf"},
    {"id":"17681","name":"Presentation - Healthcare Professionals' Working Party (HCPWP) 2016-2019 mandate","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-22T02:00:00Z","last_updated_date":"2016-08-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-healthcare-professionals-working-party-hcpwp-2016-2019-mandate_en.pdf"},
    {"id":"17703","name":"Presentation - 3.3 Equivalence of dose-response curves (Holger Dette)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-33-equivalence-dose-response-curves-holger-dette_en.pdf"},
    {"id":"17709","name":"Presentation - Medication errors – A challenge of pharmacovigilance –The Federal Institute for Drugs and Medical Devices (BfArM) experience (Claudia Kayser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medication-errors-challenge-pharmacovigilance-federal-institute-drugs-medical-devices-bfarm-experience-claudia-kayser_en.pdf"},
    {"id":"17715","name":"Presentation - Evolving framework for the co-development of medicinal products with companion diagnostics (Falk Ehmann and Armin Ritzhaupt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T17:16:00Z","last_updated_date":"2018-06-06T17:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evolving-framework-co-development-medicinal-products-companion-diagnostics-falk-ehmann-and-armin-ritzhaupt_en.pdf"},
    {"id":"17734","name":"Presentation - Significant benefit of oncology products at MA: the COMP experience (Frauke Naumann-Winter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T17:00:00Z","last_updated_date":"2015-12-15T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-significant-benefit-oncology-products-ma-comp-experience-frauke-naumann-winter_en.pdf"},
    {"id":"17738","name":"Presentation - Understanding which technologies are coming into the healthcare systems (Michael Berntgen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T17:31:00Z","last_updated_date":"2018-06-06T17:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-understanding-which-technologies-are-coming-healthcare-systems-michael-berntgen_en.pdf"},
    {"id":"17752","name":"Presentation - Manufacturing process of biologics, Kowid Ho, Afssaps","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-manufacturing-process-biologics-kowid-ho-afssaps_en.pdf"},
    {"id":"17759","name":"Implementation of recommendations by the CVMP on prudent use guidance - Liisa Kaartinen","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/implementation-recommendations-cvmp-prudent-use-guidance-liisa-kaartinen_en.pdf"},
    {"id":"17762","name":"Presentation - Orphan drug designation in the European Union (Stiina Aarum)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orphan-drug-designation-european-union-stiina-aarum_en.pdf"},
    {"id":"17768","name":"Presentation - Current involvement of European Medicines Agency in research and development and future perspectives (Marco Cavaleri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-involvement-european-medicines-agency-research-and-development-and-future-perspectives-marco-cavaleri_en.pdf"},
    {"id":"17777","name":"Presentation - Focus on immunogenicity of FVIII and FIX products and general reflections on registries (H. Marijke van den Berg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-immunogenicity-fviii-and-fix-products-and-general-reflections-registries-h-marijke-van-den-berg_en.pdf"},
    {"id":"17790","name":"Presentation - Swedish Medicines Agency proposals for patient engagement (Lena Ring)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-swedish-medicines-agency-proposals-patient-engagement-lena-ring_en.pdf"},
    {"id":"17794","name":"Presentation - Innovative Medicines Initiative (IMI) (Salah-Dine Chibout)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovative-medicines-initiative-imi-salah-dine-chibout_en.pdf"},
    {"id":"17796","name":"Presentation - Agenda item 3: organisations (Kepa Amutxastegi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-15T15:00:00Z","last_updated_date":"2016-03-15T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-3-organisations-kepa-amutxastegi_en.pdf"},
    {"id":"17818","name":"Presentation - Public-health burden of medication errors and how this might be addressed through the European Union pharmacovigilance system (David Cousins)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-health-burden-medication-errors-and-how-might-be-addressed-through-european-union-pharmacovigilance-system-david-cousins_en.pdf"},
    {"id":"17824","name":"Presentation - Section 4.3: Contra-indications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-43-contra-indications_en.pdf"},
    {"id":"17862","name":"Requirements for the first In-Human clinical trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T00:00:00Z","last_updated_date":"2009-02-02T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/requirements-first-human-clinical-trials_en.pdf"},
    {"id":"17888","name":"Presentation - Federation of Veterinarians of Europe (FVE): Impact on public and animal health of the use of antibiotics in animals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-federation-veterinarians-europe-fve-impact-public-and-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"17905","name":"Stem cell-based medicinal products as ATMPs in the EU: Dr Paula Salmikangas","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/stem-cell-based-medicinal-products-atmps-eu-dr-paula-salmikangas_en.pdf"},
    {"id":"17919","name":"Presentation - Product information management - Annex: Example package leaflet","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-information-management-annex-example-package-leaflet_en.pdf"},
    {"id":"17927","name":"Evaluation of degradation studies of veterinary drugs in manures - A regulatory viewpoint - Joop de Knecht","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-06-23T02:09:21Z","last_updated_date":"2009-06-23T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/evaluation-degradation-studies-veterinary-drugs-manures-regulatory-viewpoint-joop-de-knecht_en.pdf"},
    {"id":"17936","name":"Presentation - Professionalisation and representativeness among civil-society representatives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-professionalisation-and-representativeness-among-civil-society-representatives_en.pdf"},
    {"id":"17939","name":"Overview of the Procedure and interactions between CAT and CHMP - Marie-Helene Pinheiro","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-procedure-and-interactions-between-cat-and-chmp-marie-helene-pinheiro_en.pdf"},
    {"id":"17940","name":"Presentation - Challenges and concerns implementing SPOR - Industry perspective - The voice of the animal medicines industry and European Group for Generic Veterinary Products (EGGVP) - Substance, product, organisation a...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-27T01:00:00Z","last_updated_date":"2018-02-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-and-concerns-implementing-spor-industry-perspective-voice-animal-medicines-industry-and-european-group-generic-veterinary-products-eggvp-substance-product-organisation_en.pdf"},
    {"id":"17950","name":"Presentation - ERNs and research: state of play from the European Commission\n\nperspective (Helene Le Borgne)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-erns-and-research-state-play-european-commission-perspective-helene-le-borgne_en.pdf"},
    {"id":"17957","name":"The Common Technical Document- Quality (CTD-Q) - George Wade","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/common-technical-document-quality-ctd-q-george-wade_en.pdf"},
    {"id":"17984","name":"Presentation - The Committee for Orphan Medicinal Products (COMP) update (Daniel O’Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-orphan-medicinal-products-comp-update-daniel-oconnor_en.pdf-0"},
    {"id":"18013","name":"Presentation - Manufacturing of gene-therapy products: common issues and advice","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-manufacturing-gene-therapy-products-common-issues-and-advice_en.pdf"},
    {"id":"18015","name":"Presentation - Supervision of manufacturers: What is expected of national competent authorities? (Fergus Sweeney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supervision-manufacturers-what-expected-national-competent-authorities-fergus-sweeney_en.pdf"},
    {"id":"18019","name":"Presentation - Differences between the use of immunotherapy in the adjuvant as opposed to advanced setting (Jessica Menis) - S5.1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-differences-between-use-immunotherapy-adjuvant-opposed-advanced-setting-jessica-menis-s51_en.pdf"},
    {"id":"18021","name":"Presentation - Big data and the new European Union data protection Regulation: the role of big data in healthcare (Sophie Louveaux)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-and-new-european-union-data-protection-regulation-role-big-data-healthcare-sophie-louveaux_en.pdf"},
    {"id":"18036","name":"Presentation - International Federation for Animal Health global benchmarking survey 2011 (Barbara Freischem)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-federation-animal-health-global-benchmarking-survey-2011-barbara-freischem_en.pdf"},
    {"id":"18079","name":"Presentation - Herbal summaries for the public - Involvement of  patients’ and consumers’ organisations’ in preparation of herbal summaries (Federica Castellani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-02T17:00:00Z","last_updated_date":"2013-07-02T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-herbal-summaries-public-involvement-patients-and-consumers-organisations-preparation-herbal-summaries-federica-castellani_en.pdf"},
    {"id":"18081","name":"Introduction to quality assessment - Diana van Riet","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/introduction-quality-assessment-diana-van-riet_en.pdf"},
    {"id":"18083","name":"Presentation - Involvement of young people and families in Enpr-EMA networks (Benjamin Pelle, Peter Helms and Jenny Newman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T16:00:00Z","last_updated_date":"2013-07-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-involvement-young-people-and-families-enpr-ema-networks-benjamin-pelle-peter-helms-and-jenny-newman_en.pdf"},
    {"id":"18095","name":"Presentation: 2009 report on the interaction with Patients’ and Consumers’ Organisations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-08-20T02:00:00Z","last_updated_date":"2010-08-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2009-report-interaction-patients-and-consumers-organisations_en.pdf"},
    {"id":"18108","name":"Presentation - The choice of outcome parameters and need for distinct assessment tools with regard to the different disease stages in Alzheimer’s disease (Iva Holmerovà¡)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-choice-outcome-parameters-and-need-distinct-assessment-tools-regard-different-disease-stages-alzheimers-disease-iva-holmerova_en.pdf"},
    {"id":"18116","name":"Presentation - EMA/EGA workshop - Session 5 : Q&A on Other Important Topics (Susana Almeida, Grupo Tecnimede)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T02:00:00Z","last_updated_date":"2015-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaega-workshop-session-5-qa-other-important-topics-susana-almeida-grupo-tecnimede_en.pdf"},
    {"id":"18126","name":"Presentation - Analytical Similarity Assessment (S-C. Chow, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-analytical-similarity-assessment-s-c-chow-fda_en.pdf"},
    {"id":"18155","name":"Presentation - Making medicines affordable (Ana Maria Tomà©)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-making-medicines-affordable-ana-maria-tomac_en.pdf"},
    {"id":"18162","name":"Our challenges in pain Management in Neonates - Vineta Fellman","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-10-28T02:09:21Z","last_updated_date":"2004-10-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/our-challenges-pain-management-neonates-vineta-fellman_en.pdf"},
    {"id":"18167","name":"Presentation - Field efficacy trials versus laboratory challenge experiments (E.  Thiry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T13:30:00Z","last_updated_date":"2017-11-16T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-field-efficacy-trials-versus-laboratory-challenge-experiments-e-thiry_en.pdf"},
    {"id":"18174","name":"Presentation - Phase 2a trial design is being planned: How does pharmacokinetic variation observed in phase I affect trial design?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-phase-2a-trial-design-being-planned-how-does-pharmacokinetic-variation-observed-phase-i-affect-trial-design_en.pdf"},
    {"id":"18177","name":"Presentation - Variations and worksharing – regulatory perspective (Melanie Leivers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-variations-and-worksharing-regulatory-perspective-melanie-leivers_en.pdf"},
    {"id":"18189","name":"Presentation - Assessing the probability of drug-induced QTc-interval prolongation during early clinical drug development - Break-out session 2 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-assessing-probability-drug-induced-qtc-interval-prolongation-during-early-clinical-drug-development-break-out-session-2-theme-2_en.pdf"},
    {"id":"18205","name":"Presentation - The ethics of placebo controlled studies - Speech (Simon Woods)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ethics-placebo-controlled-studies-speech-simon-woods_en.pdf"},
    {"id":"18244","name":"Presentation - Good practice: Medical Dictionary for Regulatory Activities coding of case reports resulting in harm (Sabine Brosch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-practice-medical-dictionary-regulatory-activities-coding-case-reports-resulting-harm-sabine-brosch_en.pdf"},
    {"id":"18245","name":"Presentation - Session 3 – ISO ICSR Implementation technical aspects - Part 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-12T12:30:00Z","last_updated_date":"2016-05-12T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-iso-icsr-implementation-technical-aspects-part-2_en.pdf"},
    {"id":"18263","name":"Presentation - The MidPharma and the European Network of Paediatric Research at the European Medicines Agency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:48Z","last_updated_date":"2011-05-27T15:25:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-midpharma-and-european-network-paediatric-research-european-medicines-agency_en.pdf"},
    {"id":"18269","name":"Presentation - Drug information by public health institutions: results of an 8-country survey in Europe (Giulio Formoso)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drug-information-public-health-institutions-results-8-country-survey-europe-giulio-formoso_en.pdf"},
    {"id":"18296","name":"Presentation - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: Quality issues","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substances-quality-issues_en.pdf"},
    {"id":"18306","name":"Presentation - Paediatric-investigation-plan applications assessed by the Paediatric Commitee for the treatment of chronic hepatitis C in children","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-12T03:00:00Z","last_updated_date":"2011-07-12T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-investigation-plan-applications-assessed-paediatric-commitee-treatment-chronic-hepatitis-c-children_en.pdf"},
    {"id":"18318","name":"Presentation - How do we sequence or combine immunotherapies with targeted therapies: European perspective (Paolo Ascierto) - S5.4","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-do-we-sequence-or-combine-immunotherapies-targeted-therapies-european-perspective-paolo-ascierto-s54_en.pdf"},
    {"id":"18326","name":"Presentation - Scanning the horizon - a regulatory perspective (David Mackay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scanning-horizon-regulatory-perspective-david-mackay_en.pdf"},
    {"id":"18327","name":"Presentation - Aims and objectives of the workshop on development of antimycobacterial medicinal products (to treat Mycobacterium tuberculosis) (Mair Powell)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-aims-and-objectives-workshop-development-antimycobacterial-medicinal-products-treat-mycobacterium-tuberculosis-mair-powell_en.pdf"},
    {"id":"18338","name":"Presentation - Factors promoting anthelmintic resistance (Edwin\n\nClaerebout)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-factors-promoting-anthelmintic-resistance-edwin-claerebout_en.pdf"},
    {"id":"18368","name":"Presentation - Interaction with patients and consumers: participation in SAG meetings (2013) (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-patients-and-consumers-participation-sag-meetings-2013-nathalie-bere_en.pdf"},
    {"id":"18404","name":"Presentation - Scale down models for cell culture (Christian Hakemeyer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scale-down-models-cell-culture-christian-hakemeyer_en.pdf"},
    {"id":"18422","name":"Presentation - Additional monitoring of medicines and direct patient reporting – impact on the package leaflet","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-additional-monitoring-medicines-and-direct-patient-reporting-impact-package-leaflet_en.pdf"},
    {"id":"18449","name":"ICH regulators forum - Peter Arlett","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ich-regulators-forum-peter-arlett_en.pdf"},
    {"id":"18450","name":"Presentation - Acquis communautaire: Perspectives for industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-acquis-communautaire-perspectives-industry_en.pdf"},
    {"id":"18452","name":"Presentation - Multi-stakeholder late and early dialogue – The MoCa experience and potential contribution (Bucsics, MoCa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multi-stakeholder-late-and-early-dialogue-moca-experience-and-potential-contribution-bucsics-moca_en.pdf"},
    {"id":"18453","name":"Presentation - Accession preparation II- Preparing for dossiers evaluation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accession-preparation-ii-preparing-dossiers-evaluation_en.pdf"},
    {"id":"18463","name":"Presentation - Communication of difficulties with paediatric studies to PDCO","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T16:02:00Z","last_updated_date":"2018-06-18T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-difficulties-paediatric-studies-pdco_en.pdf"},
    {"id":"18469","name":"Presentation - European Patient Ambassador Programme (EPAP) (Kerstin Morrison)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-patient-ambassador-programme-epap-kerstin-morrison_en.pdf"},
    {"id":"18485","name":"Presentation - e-DoI and e-CV: Who/Why/How? (Marianna Kozikova)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-e-doi-and-e-cv-whowhyhow-marianna-kozikova_en.pdf"},
    {"id":"18521","name":"Presentation - Celebration in 2016 (Maria Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-10T18:30:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-celebration-2016-maria-mavris_en.pdf"},
    {"id":"18526","name":"Presentation - Day 1: Macular edema","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-macular-edema_en.pdf"},
    {"id":"18537","name":"Presentation - Regulatory discussant - Break-out session 1 theme 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-discussant-break-out-session-1-theme-1_en.pdf"},
    {"id":"18547","name":"TGN1412: What happened? - Suntharalingam & N Panoskaltsis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/tgn1412-what-happened-suntharalingam-n-panoskaltsis_en.pdf"},
    {"id":"18551","name":"Presentation - Orphan medicinal products: Challenges faced by companies in implementing the existing guidelines (Robert Morgan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orphan-medicinal-products-challenges-faced-companies-implementing-existing-guidelines-robert-morgan_en.pdf"},
    {"id":"18569","name":"Presentation - Europharm SMC feedback (Telma Costa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-europharm-smc-feedback-telma-costa_en.pdf"},
    {"id":"18601","name":"Presentation - Strengthening collaborations for operating pharmacovigilance in Europe Joint Action (L. Loughlin, MHRA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strengthening-collaborations-operating-pharmacovigilance-europe-joint-action-l-loughlin-mhra_en.pdf"},
    {"id":"18623","name":"Presentation - Update on the new clinical trial regulation (Fabio D'Atri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-new-clinical-trial-regulation-fabio-datri_en.pdf"},
    {"id":"18642","name":"Presentation - EMA/EGA workshop - Session 2: Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms - Injectable modified release products (Sotiris Michaleas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T02:00:00Z","last_updated_date":"2015-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaega-workshop-session-2-guideline-pharmacokinetic-and-clinical-evaluation-modified-release-dosage-forms-injectable-modified-release-products-sotiris-michaleas_en.pdf"},
    {"id":"18647","name":"Presentation - Preparing for the simplified reporting of suspected adverse reactions in the European Union: training module PhV-M3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2016-10-10T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparing-simplified-reporting-suspected-adverse-reactions-european-union-training-module-phv-m3_en.pdf"},
    {"id":"18654","name":"Presentation - Transparency and risk communication: Feedback from the Ditchley Group (David H.-U. Haerry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transparency-and-risk-communication-feedback-ditchley-group-david-h-u-haerry_en.pdf"},
    {"id":"18659","name":"Presentation - High-level perspective of the biosimilars industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:47Z","last_updated_date":"2012-06-15T17:10:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-high-level-perspective-biosimilars-industry_en.pdf"}    {"id":"18681","name":"Current regulatory thinking For viral shedding studies in The European Union - Sharon Longhurst","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/current-regulatory-thinking-viral-shedding-studies-european-union-sharon-longhurst_en.pdf"},
    {"id":"18682","name":"Presentation - EMA/EGA workshop - Session 1: Orally administered Modified Release Products - European Regulatory Requirements (Henrike Potthast)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T02:00:00Z","last_updated_date":"2015-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaega-workshop-session-1-orally-administered-modified-release-products-european-regulatory-requirements-henrike-potthast_en.pdf"},
    {"id":"18691","name":"Presentation - Immunologicals/ New developments","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunologicals-new-developments_en.pdf"},
    {"id":"18707","name":"Presentation - An industry perspective on big data: from genomics to big data to real world data (Bart Vannieuwenhuyse)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-big-data-genomics-big-data-real-world-data-bart-vannieuwenhuyse_en.pdf"},
    {"id":"18725","name":"Presentation - The ethical considerations of placebo study design in neuromyelitis optica (M. Rosa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ethical-considerations-placebo-study-design-neuromyelitis-optica-m-rosa_en.pdf"},
    {"id":"18726","name":"Welcome to participants and objectives of the meeting - Alfred Hera","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:09:21Z","last_updated_date":"2009-05-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/welcome-participants-and-objectives-meeting-alfred-hera_en.pdf"},
    {"id":"18732","name":"Presentation - Dose–exposure–response relationships: the basis of effective dose-regimen selection - Break-out session 2 theme 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-exposure-response-relationships-basis-effective-dose-regimen-selection-break-out-session-2-theme-1_en.pdf"},
    {"id":"18741","name":"Presentation - PK data for supporting PK-PD analyses (David Tenero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pk-data-supporting-pk-pd-analyses-david-tenero_en.pdf"},
    {"id":"18785","name":"Presentation - Involvement of patients: Outcome of pilot project (N. Bere, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-involvement-patients-outcome-pilot-project-n-bere-ema_en.pdf"},
    {"id":"18787","name":"Presentation - Non-clinical approaches for immunogenicity assessment: predictive models (Mark Fogg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-clinical-approaches-immunogenicity-assessment-predictive-models-mark-fogg_en.pdf"},
    {"id":"18795","name":"Objectives of the Working Group - Noel Wathion","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2003-05-08T02:00:00Z","last_updated_date":"2003-05-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/objectives-working-group-noel-wathion_en.pdf"},
    {"id":"18812","name":"Presentation - Novel regulatory sience research on drugs for Alzheimer's disease - a guideline on the clinical evaluation of drugs for Alzheimer’s disease (Interim report) (Takashi Moritoyo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-novel-regulatory-sience-research-drugs-alzheimers-disease-guideline-clinical-evaluation-drugs-alzheimers-disease-interim-report-takashi-moritoyo_en.pdf"},
    {"id":"18832","name":"Presentation - Immunotherapies in lung cancer: regulatory perspective (Jorge Camarero) - S2.6","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunotherapies-lung-cancer-regulatory-perspective-jorge-camarero-s26_en.pdf"},
    {"id":"18838","name":"Presentation - How have eligible products benefited from PRIME so far? (Jordi Llinares Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-07T02:00:00Z","last_updated_date":"2017-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-have-eligible-products-benefited-prime-so-far-jordi-llinares-garcia_en.pdf"},
    {"id":"18840","name":"Presentation - Persistent pulmonary hypertension (PPHN) of the newborn: clinical vs regulatory needs (Marek Migdal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-persistent-pulmonary-hypertension-pphn-newborn-clinical-vs-regulatory-needs-marek-migdal_en.pdf"},
    {"id":"18865","name":"Presentation - The application of the 3Rs in regulatory testing of veterinary medicinal products (Nick Jarrett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-application-3rs-regulatory-testing-veterinary-medicinal-products-nick-jarrett_en.pdf"},
    {"id":"18867","name":"Presentation - Case study 1- Risk assessment and lifecycle management learning","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-1-risk-assessment-and-lifecycle-management-learning_en.pdf"},
    {"id":"18870","name":"Presentation - Challenges related to the translation of TCRs to the clinic – the view of an academic developer(Gerald Willimsky)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T11:11:00Z","last_updated_date":"2016-12-02T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-related-translation-tcrs-clinic-view-academic-developergerald-willimsky_en.pdf"},
    {"id":"18875","name":"Presentation - Orphan medicinal products: Activities of the Committee for Orphan Medicinal Products (COMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orphan-medicinal-products-activities-committee-orphan-medicinal-products-comp_en.pdf"},
    {"id":"18876","name":"Presentation - Systematic review of clinical PK-PD studies of antibacterials (Alasdair MacGowan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-systematic-review-clinical-pk-pd-studies-antibacterials-alasdair-macgowan_en.pdf"},
    {"id":"18893","name":"Presentation - 3.3 Training for patients' and consumers' organisations - Website developments","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-33-training-patients-and-consumers-organisations-website-developments_en.pdf"},
    {"id":"18897","name":"Presentation - Considerations on the assessment of safety data originating from patient-support programmes (Qun-Ying Yue)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-assessment-safety-data-originating-patient-support-programmes-qun-ying-yue_en.pdf"},
    {"id":"18902","name":"Presentation - Strengthening the prospective discussions on post-licensing evidence generation (J. Moseley, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T01:00:00Z","last_updated_date":"2017-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strengthening-prospective-discussions-post-licensing-evidence-generation-j-moseley-ema_en.pdf"},
    {"id":"18906","name":"Presentation - Immunogenicity of biological therapeutics product quality attributes (Susan Kirshner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunogenicity-biological-therapeutics-product-quality-attributes-susan-kirshner_en.pdf"},
    {"id":"18916","name":"Presentation - Reflections and experiences of healthcare professionals on the implementation of the directive so far (Jurate Svarcaite)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reflections-and-experiences-healthcare-professionals-implementation-directive-so-far-jurate-svarcaite_en.pdf"},
    {"id":"18921","name":"Presentation - Section 4.2: Posology and method of administration","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-42-posology-method-administration_en.pdf"},
    {"id":"18930","name":"Proposal for an international registry for juvenile idiopathic arthritis patients treated with methotrexate, Dr Nicolino Ruperto","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/proposal-international-registry-juvenile-idiopathic-arthritis-patients-treated-methotrexate-dr-nicolino-ruperto_en.pdf"},
    {"id":"18939","name":"Presentation - Organisations Management Services (OMS) project report (Kepa Amutxastegi, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organisations-management-services-oms-project-report-kepa-amutxastegi-ema_en.pdf"},
    {"id":"18949","name":"Presentation - How patients and healthcare professionals can be involved in public hearings (J. Garcia Burgos, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-patients-and-healthcare-professionals-can-be-involved-public-hearings-j-garcia-burgos-ema_en.pdf"},
    {"id":"18955","name":"Presentation - The future clinical trial authorisation process: the new evaluation process (Massimiliano Sarra)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T12:14:00Z","last_updated_date":"2017-03-30T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-future-clinical-trial-authorisation-process-new-evaluation-process-massimiliano-sarra_en.pdf"},
    {"id":"18957","name":"Presentation - Data monitoring committee member experience: Studies with an adaptive design/confidentiality","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-monitoring-committee-member-experience-studies-adaptive-designconfidentiality_en.pdf"},
    {"id":"18965","name":"Presentation – Multiple sclerosis workshop - Pre-work package","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multiple-sclerosis-workshop-pre-work-package_en.pdf"},
    {"id":"18986","name":"Presentation - Quality aspects of nano-based medicines (Dolores Hernà¡n Pà©rez de la Ossa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-aspects-nano-based-medicines-dolores-hernan-pacrez-de-la-ossa_en.pdf"},
    {"id":"18998","name":"Presentation - European network of paediatric research-European Medicines Agency working groups 3 / 5: How to establish communication between Enpr-EMA networks and industry / sharing good practice within Enpr-EMA and wit...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T16:00:00Z","last_updated_date":"2014-03-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-paediatric-research-european-medicines-agency-working-groups-3-5-how-establish-communication-between-enpr-ema-networks-and-industry-sharing-good-practice-within-enpr-ema_en.pdf"},
    {"id":"19009","name":"Presentation -  Adaptive pathways: patient safety at risk?\n\n (Francesca Cattarin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-pathways-patient-safety-risk-francesca-cattarin_en.pdf"},
    {"id":"19011","name":"The post-accession experience - Rodica Badescu","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/post-accession-experience-rodica-badescu_en.pdf"},
    {"id":"19047","name":"Presentation - ChondroCelect case study","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chondrocelect-case-study_en.pdf"},
    {"id":"19049","name":"Presentation - Case study 4 - Use of prior knowledge for setting acceptance criteria - Session 4 (Thomas Stangler, Koen Nauwelaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-4-use-prior-knowledge-setting-acceptance-criteria-session-4-thomas-stangler-koen-nauwelaerts_en.pdf"},
    {"id":"19055","name":"Presentation - The ABCs of regulatory science (Susan McCune)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-abcs-regulatory-science-susan-mccune_en.pdf"},
    {"id":"19058","name":"Presentation - CVMP work plan 2014 (Anja Holm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-work-plan-2014-anja-holm_en.pdf"},
    {"id":"19129","name":"Presentation - Novel multiple testing procedures for structured study objectives and families of hypotheses – a case study (Guenther Mueller-Velten)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-novel-multiple-testing-procedures-structured-study-objectives-and-families-hypotheses-case-study-guenther-mueller-velten_en.pdf"},
    {"id":"19135","name":"Presentation - Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) – work package (WP) 5: Extension / validation of benefit-risk methods, tools and processes evaluated in PROTE...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacoepidemiological-research-outcomes-therapeutics-european-consortium-protect-work-package-wp-5-extension-validation-benefit-risk-methods-tools-and-processes-evaluated-prote_en.pdf"},
    {"id":"19145","name":"Presentation - DOACs: the patient perspective (Christine Dehn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-doacs-patient-perspective-christine-dehn_en.pdf"},
    {"id":"19151","name":"Presentation - Rob Hemmings preliminary comments - Break-out session 4 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rob-hemmings-preliminary-comments-break-out-session-4-theme-2_en.pdf"},
    {"id":"19157","name":"Presentation - Implementation of the new pharmacovigilance legislation: \n\nplanning and processes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-new-pharmacovigilance-legislation-planning-and-processes_en.pdf"},
    {"id":"19171","name":"Introduction to the EMEA - Martin Harvey","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/introduction-emea-martin-harvey_en.pdf"},
    {"id":"19192","name":"Presentation - European Commission multi-stakeholder workshop:\n\nBiosimilar Medicinal Products, 5 May 2017 (H. Juhà¡sz, European Commission)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-commission-multi-stakeholder-workshop-biosimilar-medicinal-products-5-may-2017-h-juhasz-european-commission_en.pdf"},
    {"id":"19195","name":"Presentation - Sparse sampling design in population pharmacokinetic/pharmacodynamic studies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-13T02:09:21Z","last_updated_date":"2008-04-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sparse-sampling-design-population-pharmacokineticpharmacodynamic-studies_en.pdf"},
    {"id":"19215","name":"Presentation - POS (Partial onset seizures) Extrapolation from adults to  children Clinical setting (Catherine Chiron, Gerard Pons)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pos-partial-onset-seizures-extrapolation-adults-children-clinical-setting-catherine-chiron-gerard-pons_en.pdf"},
    {"id":"19227","name":"Croatia - Veterinary Directorate, S Separovic","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/croatia-veterinary-directorate-s-separovic_en.pdf"},
    {"id":"19247","name":"Presentation - European Medicines Agency experience on the use of the B/R to the effect table: from rapporteurship to CHMP discussion, to EPAR (Andreas Kouroumalis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:30:00Z","last_updated_date":"2018-01-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-experience-use-br-effect-table-rapporteurship-chmp-discussion-epar-andreas-kouroumalis_en.pdf"},
    {"id":"19270","name":"Presentation - E-Submission: An European perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-e-submission-european-perspective_en.pdf"},
    {"id":"19275","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Patient input into benefit/risk issues during drug development(EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-patient-input-benefitrisk-issues-during-drug-developmentefpia_en.pdf"},
    {"id":"19307","name":"Presentation -  Adaptive pathways:\n\nperspectives of patients and\n\nhealthcare professionals on addressing patient needs\n\n (Rosa Giuliani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-pathways-perspectives-patients-and-healthcare-professionals-addressing-patient-needs-rosa-giuliani_en.pdf"},
    {"id":"19308","name":"Presentation - Pharmacogenetic clinical implementation: a seven-year experience","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenetic-clinical-implementation-seven-year-experience_en.pdf"},
    {"id":"19311","name":"Presentation - Nanomedicines - Current initiatives in the US, Carlos Peà±a, FDA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nanomedicines-current-initiatives-us-carlos-pea-fda_en.pdf"},
    {"id":"19323","name":"Presentation - Overview of good-pharmacovigilance-practice modules V (risk-management systems) and VIII (post-authorisation safety studies), and the European Network of Centres for Pharmacoepidemiology and Pharmacovigila...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-good-pharmacovigilance-practice-modules-v-risk-management-systems-and-viii-post-authorisation-safety-studies-and-european-network-centres-pharmacoepidemiology-and-pharmacovigila_en.pdf"},
    {"id":"19327","name":"Presentation - Reproductive toxicity: An introduction to regulatory aspects on detection of toxicity to reproduction for medicinal products (Gà¼nter Waxenecker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T18:12:00Z","last_updated_date":"2016-10-26T18:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reproductive-toxicity-introduction-regulatory-aspects-detection-toxicity-reproduction-medicinal-products-ga-14nter-waxenecker_en.pdf"},
    {"id":"19337","name":"Presentation - New EMA shareable communications (M. Benstetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T16:44:00Z","last_updated_date":"2017-12-11T16:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-ema-shareable-communications-m-benstetter_en.pdf"},
    {"id":"19355","name":"Presentation - MAH compliance with PRAC signal recommendations for PI update of CAPs (Aniello Santoro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:30:00Z","last_updated_date":"2017-03-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mah-compliance-prac-signal-recommendations-pi-update-caps-aniello-santoro_en.pdf"},
    {"id":"19356","name":"Presentation - PML: Risk communication in the EU, Rafe Suvarna","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pml-risk-communication-eu-rafe-suvarna_en.pdf"},
    {"id":"19361","name":"Presentation - Conclusions - Training session for patients and consumers involved in EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-conclusions-training-session-patients-and-consumers-involved-ema_en.pdf"},
    {"id":"19368","name":"Presentation - Day 2: Dry eye disease: a tear film and ocular surface challenge","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-dry-eye-disease-tear-film-and-ocular-surface-challenge_en.pdf"},
    {"id":"19380","name":"Presentation - Cell-based medicinal product - case study 1: Cardioficticell","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cell-based-medicinal-product-case-study-1-cardioficticell_en.pdf"},
    {"id":"19402","name":"Presentation - Changes in the incidence of PML in Tysabri-treated patiens, Alice Hughes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-changes-incidence-pml-tysabri-treated-patiens-alice-hughes_en.pdf"},
    {"id":"19422","name":"Presentation - Update on Enpr-EMA activities,\n\nachievements and challenges (M.Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-enpr-ema-activities-achievements-and-challenges-mturner_en.pdf"},
    {"id":"19435","name":"High level objectives of M2 and involvement of SDOs - Andrew Marr","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/high-level-objectives-m2-and-involvement-sdos-andrew-marr_en.pdf"},
    {"id":"19443","name":"Presentation - Project Data Sphere®: Progress & Promise - Single-arm trials in cancer drug evaluation workshop (Martin J. Murphy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-project-data-spherer-progress-promise-single-arm-trials-cancer-drug-evaluation-workshop-martin-j-murphy_en.pdf"},
    {"id":"19450","name":"Presentation - Session 4.5: Interaction and cooperation between the EU and US on global paediatric research: ICAN’s experience (Joana Claverol)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-45-interaction-and-cooperation-between-eu-and-us-global-paediatric-research-icans-experience-joana-claverol_en.pdf"},
    {"id":"19462","name":"Presentation - Signal management process (G. Genov, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-signal-management-process-g-genov-ema_en.pdf"},
    {"id":"19467","name":"Presentation - Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…)  (Mattias Neyt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-single-arm-trials-good-step-towards-faster-accessreimbursement-drugs-added-value-all-patient-mattias-neyt_en.pdf"},
    {"id":"19478","name":"Presentation - Qualification of the PBPK platform for the Intended Purpose:\n\nEFPIA comments overview (S. Y. Amy Cheung and Solange Rohou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qualification-pbpk-platform-intended-purpose-efpia-comments-overview-s-y-amy-cheung-and-solange-rohou_en.pdf"},
    {"id":"19505","name":"Presentation - How we communicate the outcome of safety reviews (Rebecca Harding)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-we-communicate-outcome-safety-reviews-rebecca-harding_en.pdf"},
    {"id":"19509","name":"Induced pluripotent stem cells: Prof Marc Peschanski, I-stem, Evry, France","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/induced-pluripotent-stem-cells-prof-marc-peschanski-i-stem-evry-france_en.pdf"},
    {"id":"19547","name":"Presentation - HMA/EMA Taskforce on availability of authorised medicines (Brendan Cuddy, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hmaema-taskforce-availability-authorised-medicines-brendan-cuddy-ema_en.pdf"},
    {"id":"19548","name":"Presentation - ISO IDMP (Remco Munnik, Anjana Pindoria, Kelly Hnat, Vito Strasberger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T02:00:00Z","last_updated_date":"2015-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-iso-idmp-remco-munnik-anjana-pindoria-kelly-hnat-vito-strasberger_en.pdf"},
    {"id":"19558","name":"Presentation - Guidance on transitional measures for the pharmacovigilance legislation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-transitional-measures-pharmacovigilance-legislation_en.pdf"},
    {"id":"19560","name":"Presentation - Qualification of PBPK platform – experience with PK-Sim (Michael Block)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qualification-pbpk-platform-experience-pk-sim-michael-block_en.pdf"},
    {"id":"19578","name":"Presentation - Summary of product characteristics (SmPC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T13:00:00Z","last_updated_date":"2017-09-06T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-product-characteristics-smpc_en.pdf"},
    {"id":"19582","name":"Presentation - PRAC interaction with SAWP (Anna Tavridou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prac-interaction-sawp-anna-tavridou_en.pdf"},
    {"id":"19588","name":"Presentation - Case Study 4 - Challenges in the implementation of model based and PAT based RTRT for a new product","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-4-challenges-implementation-model-based-and-pat-based-rtrt-new-product_en.pdf"},
    {"id":"19605","name":"Presentation - Enpr-EMA Coordinating Group: Achievements and challenges","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-26T02:00:00Z","last_updated_date":"2013-06-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-coordinating-group-achievements-and-challenges_en.pdf"},
    {"id":"19612","name":"Presentation - Non-clinical assessment of immunogenicity (Leon van Aerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-clinical-assessment-immunogenicity-leon-van-aerts_en.pdf"},
    {"id":"19621","name":"Presentation - Summary of product characteristics: What is it and what does it contain?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2013-01-21T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-product-characteristics-what-it-and-what-does-it-contain_en.pdf"},
    {"id":"19634","name":"Presentation - HAP-VAP (David Friedland)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hap-vap-david-friedland_en.pdf"},
    {"id":"19653","name":"Presentation - Experience from the ongoing Phagoburn clinical trial (Patrick Jault)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-22T02:00:00Z","last_updated_date":"2015-06-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-ongoing-phagoburn-clinical-trial-patrick-jault_en.pdf"},
    {"id":"19660","name":"Presentation - Healthcare Professionals Working Group (HCPWG): Reporting of adverse drug reactions by web-based forms","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T01:00:00Z","last_updated_date":"2011-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-healthcare-professionals-working-group-hcpwg-reporting-adverse-drug-reactions-web-based-forms_en.pdf"},
    {"id":"19668","name":"Presentation - Member State’s view on encouraging appropriate use (Hugo Hurts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-member-states-view-encouraging-appropriate-use-hugo-hurts_en.pdf"},
    {"id":"19689","name":"Presentation - Modelling and simulation support for design of first-in-man studies: the minimum acceptable biological effect level (MABEL) approach - Break-out session 1 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:45:00Z","last_updated_date":"2011-11-30T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-support-design-first-man-studies-minimum-acceptable-biological-effect-level-mabel-approach-break-out-session-1-theme-2_en.pdf"},
    {"id":"19706","name":"Presentation - Session of first experiences: black symbol and product information (Alexios Skarlatos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-first-experiences-black-symbol-and-product-information-alexios-skarlatos_en.pdf"},
    {"id":"19708","name":"Presentation - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting - Transparency – Clinical data release/publication at the EMA (Anne-Sophie He...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-transparency-clinical-data-releasepublication-ema-anne-sophie-he_en.pdf"},
    {"id":"19712","name":"Presentation - Equivalence vs. non-inferiority: Introduction","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:44Z","last_updated_date":"2012-06-15T17:10:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-equivalence-vs-non-inferiority-introduction_en.pdf"},
    {"id":"19715","name":"Presentation - Publication of Risk Management Plan summaries: proposal for analysis of the experience of the 1-year pilot phase (Juan Garcia Burgos, Rosa Gonzalez-Quevedo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-publication-risk-management-plan-summaries-proposal-analysis-experience-1-year-pilot-phase-juan-garcia-burgos-rosa-gonzalez-quevedo_en.pdf"},
    {"id":"19750","name":"Presentation - One Health: coordinating prudent use of antimicrobials in human and veterinary medicine (David Mackay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-one-health-coordinating-prudent-use-antimicrobials-human-and-veterinary-medicine-david-mackay_en.pdf"},
    {"id":"19752","name":"Presentation - Session 4.2: Global collaboration between regulatory agencies with paediatric research networks (Irmgard Eichler, Susan McCune)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-42-global-collaboration-between-regulatory-agencies-paediatric-research-networks-irmgard-eichler-susan-mccune_en.pdf"},
    {"id":"19758","name":"Presentation - Additional monitoring of medicines and side-effect reporting – impact on the product information","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T14:00:00Z","last_updated_date":"2012-07-06T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-additional-monitoring-medicines-and-side-effect-reporting-impact-product-information_en.pdf"},
    {"id":"19759","name":"Presentation - EMA Patients and Consumers’ Annual Training Overview: 2007-2016 (M.Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T02:00:00Z","last_updated_date":"2017-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-patients-and-consumers-annual-training-overview-2007-2016-mmavris-ema_en.pdf"},
    {"id":"19764","name":"Presentation - Session 1: Definition of a driver. Cellular/tissular mechanisms supporting that a driver becomes a target multiple drivers, mechanisms of resistance (Christian Rolfo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-definition-driver-cellulartissular-mechanisms-supporting-driver-becomes-target-multiple-drivers-mechanisms-resistance-christian-rolfo_en.pdf"},
    {"id":"19770","name":"Presentation - New Variations Regulation – “Quality Related Changes”","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-variations-regulation-quality-related-changes_en.pdf"},
    {"id":"19788","name":"Presentation - Averaged model based decision making for dose selection studies (Yasunori Aoki, Bengt Hamrà©n, Daniel Rà¶shammar, Andrew C. Hooker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-averaged-model-based-decision-making-dose-selection-studies-yasunori-aoki-bengt-hamracn-daniel-rapshammar-andrew-c-hooker_en.pdf"}    {"id":"19822","name":"Presentation - Replacing and interpreting clinical data (John Rex)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-replacing-and-interpreting-clinical-data-john-rex_en.pdf"},
    {"id":"19828","name":"Presentation - ESVAC Strategy 2016-2020 (David Mackay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T17:00:00Z","last_updated_date":"2016-03-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esvac-strategy-2016-2020-david-mackay_en.pdf"},
    {"id":"19837","name":"Presentation - A common case definition for PML, Dirk Mentzer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-common-case-definition-pml-dirk-mentzer_en.pdf"},
    {"id":"19843","name":"Presentation - EU Incentives for Orphan Medicines (Melanie Carr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-incentives-orphan-medicines-melanie-carr_en.pdf"},
    {"id":"19853","name":"Presentation - Veterinary academic perspective (Rory Breathnach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-academic-perspective-rory-breathnach_en.pdf"},
    {"id":"19890","name":"First experiences with the PRAC","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/first-experiences-prac_en.pdf"},
    {"id":"19902","name":"Presentation - PIP session: Current clinical and research picture in paediatric anterior segment disorders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pip-session-current-clinical-and-research-picture-paediatric-anterior-segment-disorders_en.pdf"},
    {"id":"19927","name":"Presentation - Development of drugs for acute otitis media and acute bacterial sinusitis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:46Z","last_updated_date":"2011-04-26T18:05:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-drugs-acute-otitis-media-and-acute-bacterial-sinusitis_en.pdf"},
    {"id":"19934","name":"Presentation - Drug development for behavioral and psychological symptoms of dementia in Japan (Akifumi Kamata)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drug-development-behavioral-and-psychological-symptoms-dementia-japan-akifumi-kamata_en.pdf"},
    {"id":"19938","name":"Presentation - Stockouts in Europe 2011 (David H.-U. Haerry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stockouts-europe-2011-david-h-u-haerry_en.pdf"},
    {"id":"19941","name":"Presentation - Topic 1 - Identification of paediatric medical needs – methodology - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-identification-paediatric-medical-needs-methodology-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation_en.pdf"},
    {"id":"19942","name":"Presentation - Assessment challenges in the non-clinical development of CAR and TCR modified effector cells (Bjà¶rn Carlsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T11:11:00Z","last_updated_date":"2016-12-02T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-assessment-challenges-non-clinical-development-car-and-tcr-modified-effector-cells-bjaprn-carlsson_en.pdf"},
    {"id":"19954","name":"Presentation - Communication and dissemination of European Medicines Agency information: perspective from healthcare professionals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-and-dissemination-european-medicines-agency-information-perspective-healthcare-professionals_en.pdf"},
    {"id":"19956","name":"Presentation - Patient-reported outcomes, biomarkers and\n\nnovel methodologies, and their role in the\n\ndevelopment of new multiple sclerosis medicines (Frank Dahlke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-reported-outcomes-biomarkers-and-novel-methodologies-and-their-role-development-new-multiple-sclerosis-medicines-frank-dahlke_en.pdf"},
    {"id":"19972","name":"Presentation - Brainstorming on training strategy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-23T02:00:00Z","last_updated_date":"2011-05-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-brainstorming-training-strategy_en.pdf"},
    {"id":"20031","name":"Presentation - Clinical trial design optimisation in paediatrics using prior knowledge combined with modelling and simulations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trial-design-optimisation-paediatrics-using-prior-knowledge-combined-modelling-and-simulations_en.pdf"},
    {"id":"20074","name":"IPA project description","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ipa-project-description_en.pdf"},
    {"id":"20092","name":"Presentation - Meta-analysis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-meta-analysis_en.pdf"},
    {"id":"20108","name":"Presentation - Industry perspective on challenges meeting the requirements for authorisation of vaccines in the European Union (Jacques Lechenet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T14:00:00Z","last_updated_date":"2015-04-29T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-challenges-meeting-requirements-authorisation-vaccines-european-union-jacques-lechenet_en.pdf"},
    {"id":"20121","name":"Presentation - General presentation by stakeholders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:52Z","last_updated_date":"2012-06-15T17:10:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-presentation-stakeholders_en.pdf"},
    {"id":"20139","name":"Presentation - European Patients' Academy on Therapeutic Innovation(EUPATI): preparing guidance for interaction Interactive session at DIA Europe 2015 (David Haerry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-10T18:30:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-patients-academy-therapeutic-innovationeupati-preparing-guidance-interaction-interactive-session-dia-europe-2015-david-haerry_en.pdf"},
    {"id":"20149","name":"Name Variations: A Proposal for Increased Flexibility under the EU Single Trade Mark Requirement - Gordon Wright","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-09-11T02:09:21Z","last_updated_date":"2006-09-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/name-variations-proposal-increased-flexibility-under-eu-single-trade-mark-requirement-gordon-wright_en.pdf"},
    {"id":"20186","name":"Presentation - Supporting a Pediatric Investigational Plan for Everolimus - Defining the extrapolation plan (Thomas Dumortier, Mick Looby)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supporting-pediatric-investigational-plan-everolimus-defining-extrapolation-plan-thomas-dumortier-mick-looby_en.pdf"},
    {"id":"20203","name":"Presentation - Case study: specific challenges around data analytics for\n\nsocial media data (Marcel Salathà©)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-specific-challenges-around-data-analytics-social-media-data-marcel-salathac_en.pdf"},
    {"id":"20224","name":"Presentation - The EU regulatory framework for new antibacterial agents (Mair Powell)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-regulatory-framework-new-antibacterial-agents-mair-powell_en.pdf"},
    {"id":"20228","name":"Presentation - Recent experience in scientific advice and marketing authorisations (Brigitte Brake)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-27T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recent-experience-scientific-advice-and-marketing-authorisations-brigitte-brake_en.pdf"},
    {"id":"20231","name":"Presentation - Holistic approach to paediatric research: European Reference Network (L. Sangiorgi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:00:00Z","last_updated_date":"2018-06-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-european-reference-network-l-sangiorgi_en.pdf"},
    {"id":"20234","name":"Presentation - Questions to panel members and for the general debate in the afternoon (Fernand Sauer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-questions-panel-members-and-general-debate-afternoon-fernand-sauer_en.pdf"},
    {"id":"20241","name":"Presentation - Collecting data by species, establishing technical units of measurements and indicators: State of play (Jordi Torren, Kari Grave, Arno Muller, David Mackay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T13:00:00Z","last_updated_date":"2013-04-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collecting-data-species-establishing-technical-units-measurements-and-indicators-state-play-jordi-torren-kari-grave-arno-muller-david-mackay_en.pdf"},
    {"id":"20286","name":"Presentation - Stakeholder feedback : Vaccines Europe (Christopher Bailey)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stakeholder-feedback-vaccines-europe-christopher-bailey_en.pdf"},
    {"id":"20297","name":"Presentation - Objectives of the training","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-objectives-training_en.pdf"},
    {"id":"20301","name":"ECPM presentation - Homeopathic Workshop at the EMEA - Robert Kempenich","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ecpm-presentation-homeopathic-workshop-emea-robert-kempenich_en.pdf"},
    {"id":"20309","name":"Presentation - PCWP/HCPWP topic groups: Consolidated interim report (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwphcpwp-topic-groups-consolidated-interim-report-ivana-silva_en.pdf"},
    {"id":"20338","name":"The use of invented names for non-prescription medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-09-11T02:09:21Z","last_updated_date":"2006-09-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/use-invented-names-non-prescription-medicines_en.pdf"},
    {"id":"20345","name":"Presentation - Overview of EMA’s interaction with patients and consumers organisations (2013) (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-emas-interaction-patients-and-consumers-organisations-2013-nathalie-bere_en.pdf"},
    {"id":"20363","name":"Presentation - Neuromyelitis optica: Is there a standard of care? (Eliezer Katz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-neuromyelitis-optica-there-standard-care-eliezer-katz_en.pdf"},
    {"id":"20367","name":"Presentation - Barriers to growth for the biopharmaceutical sector in Europe: European Federation of Pharmaceutical Industries and Associations (EFPIA) (Marc de Garidel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-barriers-growth-biopharmaceutical-sector-europe-european-federation-pharmaceutical-industries-and-associations-efpia-marc-de-garidel_en.pdf"},
    {"id":"20373","name":"Presentation - Building on 15 years of Orphan legislation: current and future approaches (Stelios Tsigkos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-building-15-years-orphan-legislation-current-and-future-approaches-stelios-tsigkos_en.pdf"},
    {"id":"20380","name":"Presentation - Update on PROTECT (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-protect-xavier-kurz_en.pdf"},
    {"id":"20382","name":"EU GMP Requirements - Investigational Medicinal Products - Bernd Boedecker","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-20T02:09:00Z","last_updated_date":"2009-10-20T02:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-gmp-requirements-investigational-medicinal-products-bernd-boedecker_en.pdf"},
    {"id":"20388","name":"Presentation - Medication names and medication errors (Annemarie Hellebek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medication-names-and-medication-errors-annemarie-hellebek_en.pdf"},
    {"id":"20394","name":"Presentation - The Commission activities on AMR","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-commission-activities-amr_en.pdf"},
    {"id":"20398","name":"Shedding studies - Didier Guilhem","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/shedding-studies-didier-guilhem_en.pdf"},
    {"id":"20399","name":"Presentation - SME experience with EnprEMA (Helen Shaw, Proveca Ltd)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-experience-enprema-helen-shaw-proveca-ltd_en.pdf"},
    {"id":"20405","name":"Presentation - The summary of product characteristics and older people","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-product-characteristics-older-people_en.pdf"},
    {"id":"20414","name":"Presentation - \n\nApproaches to the non-clinical development of advanced therapy medicinal products (Fernando Mà©ndez-Hermida)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T18:12:00Z","last_updated_date":"2016-10-26T18:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-approaches-non-clinical-development-advanced-therapy-medicinal-products-fernando-macndez-hermida_en.pdf"},
    {"id":"20419","name":"Presentation - How researchers contribute to measuring impact? (Agnes Kant)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-researchers-contribute-measuring-impact-agnes-kant_en.pdf"},
    {"id":"20422","name":"Presentation - Modelling and simulation as a tool to bridge pharmacokinetics, efficacy and safety data in special populations, ethnic groups and rare diseases - Break-out session 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-tool-bridge-pharmacokinetics-efficacy-and-safety-data-special-populations-ethnic-groups-and-rare-diseases-break-out-session-3_en.pdf"},
    {"id":"20473","name":"Presentation - Focus group: a better system to navigate guidelines on advanced-therapy medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-better-system-navigate-guidelines-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"20481","name":"Presentation - EMA new premises (Agneta Brandt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-new-premises-agneta-brandt_en.pdf"},
    {"id":"20506","name":"Presentation - ADRreports.eu portal - Training module EV-M6","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-06T15:00:00Z","last_updated_date":"2017-01-06T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adrreportseu-portal-training-module-ev-m6_en.pdf"},
    {"id":"20547","name":"Presentation - Towards rules of procedures for public hearings – an update (Monika Benstetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-towards-rules-procedures-public-hearings-update-monika-benstetter_en.pdf"},
    {"id":"20550","name":"Presentation - Veterinary experience with scientific and regulatory advice, Dr. Karen Quigley","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-experience-scientific-and-regulatory-advice-dr-karen-quigley_en.pdf"},
    {"id":"20559","name":"Presentation - 10th anniversary of European Medicines Agency’s Patients' and Consumers' Working Party (PCWP): A privilege and a challenge – to strengthen the PCWP (Lise Murphy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-10th-anniversary-european-medicines-agencys-patients-and-consumers-working-party-pcwp-privilege-and-challenge-strengthen-pcwp-lise-murphy_en.pdf"},
    {"id":"20565","name":"Presentation - Patient perspective to clinical benefit (Kenneth Hobby, Luca Binetti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-perspective-clinical-benefit-kenneth-hobby-luca-binetti_en.pdf"},
    {"id":"20586","name":"Presentation - Day 2: Intra-ocular inflammation: industry view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-intra-ocular-inflammation-industry-view_en.pdf"},
    {"id":"20598","name":"Presentation - Is product / indication specific guidance already necessary and meaningful?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:42Z","last_updated_date":"2012-06-15T17:10:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-indication-specific-guidance-already-necessary-and-meaningful_en.pdf-0"},
    {"id":"20603","name":"Presentation - Session 2: The FDA sentinel common data model (Jeffrey Brown)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-fda-sentinel-common-data-model-jeffrey-brown_en.pdf"},
    {"id":"20618","name":"Presentation - Proactive publication of clinical-trial data: Feedback from the European Medicines Agency workshop (Francesco Pignatti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proactive-publication-clinical-trial-data-feedback-european-medicines-agency-workshop-francesco-pignatti_en.pdf"},
    {"id":"20625","name":"Presentation - Novel methodologies for clinical trials - do we still need to recruit patients? Mr Hemmings","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-novel-methodologies-clinical-trials-do-we-still-need-recruit-patients-mr-hemmings_en.pdf"},
    {"id":"20634","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Hannes Wahlroos","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-hannes-wahlroos_en.pdf"},
    {"id":"20640","name":"Presentation - Perspective of veterinary SMEs on challenges meeting the requirements for authorisation of vaccines in the European Union (Rhona Banks)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T14:00:00Z","last_updated_date":"2015-04-29T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-perspective-veterinary-smes-challenges-meeting-requirements-authorisation-vaccines-european-union-rhona-banks_en.pdf"},
    {"id":"20645","name":"Presentation - Research plan for the International Neonatal Consortium: specimen topic (Jon Davis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-research-plan-international-neonatal-consortium-specimen-topic-jon-davis_en.pdf"},
    {"id":"20648","name":"Presentation - Minor-use-minor-species (MUMS) policy: An update (Kornelia Grein)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-minor-use-minor-species-mums-policy-update-kornelia-grein_en.pdf"},
    {"id":"20652","name":"Presentation - EudraVigilance change management planning: latest updates, new webpage and training support (Francois Domergue)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T16:15:00Z","last_updated_date":"2016-08-15T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-change-management-planning-latest-updates-new-webpage-and-training-support-francois-domergue_en.pdf"},
    {"id":"20684","name":"Presentation - Voriconazole paediatric dose: An example","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-13T02:09:21Z","last_updated_date":"2008-04-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-voriconazole-paediatric-dose-example_en.pdf"},
    {"id":"20721","name":"Presentation - Questions to panel on reporting and evaluation of predictive performance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-questions-panel-reporting-and-evaluation-predictive-performance_en.pdf"},
    {"id":"20730","name":"Presentation - Section 6: Pharmaceutical particulars","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-6-pharmaceutical-particulars_en.pdf"},
    {"id":"20738","name":"Presentation - CT for prevention/treatment of BPD (Ninna Gullber)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ct-preventiontreatment-bpd-ninna-gullber_en.pdf"},
    {"id":"20740","name":"Presentation - Development of drugs for skin infections","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:52Z","last_updated_date":"2011-04-26T18:05:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-drugs-skin-infections_en.pdf"},
    {"id":"20747","name":"Presentation - The regulator’s perspective - Session 3 (Seà¡n Barry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulators-perspective-session-3-sean-barry_en.pdf"},
    {"id":"20749","name":"Evaluation of immunogenicity of pharmaceuticals - Geoff Hale","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-09-04T02:09:21Z","last_updated_date":"2007-09-04T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/evaluation-immunogenicity-pharmaceuticals-geoff-hale_en.pdf"},
    {"id":"20781","name":"Presentation - Pharmacovigilance – vision and needs for the future: EMA perspective (Jos Olaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-vision-and-needs-future-ema-perspective-jos-olaerts_en.pdf"},
    {"id":"20785","name":"Presentation - Good manufacturing practice considerations for advanced-therapy medicinal products (ATMPs) (Alec Orphanidis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-manufacturing-practice-considerations-advanced-therapy-medicinal-products-atmps-alec-orphanidis_en.pdf"},
    {"id":"20786","name":"Presentation - Collection of antimicrobial sales data in Ireland – progress update (J.G. Beechinor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-22T13:01:29Z","last_updated_date":"2010-12-22T13:01:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collection-antimicrobial-sales-data-ireland-progress-update-jg-beechinor_en.pdf"},
    {"id":"20820","name":"Presentation - Falsified medicines legislation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T01:00:00Z","last_updated_date":"2011-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-falsified-medicines-legislation_en.pdf"},
    {"id":"20821","name":"Presentation - SME workshop on CMC of biological medicinal products (Margarida Menezes Ferreira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-27T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-workshop-cmc-biological-medicinal-products-margarida-menezes-ferreira_en.pdf"},
    {"id":"20822","name":"Presentation - Listening to the stakeholders of innovative medicinal products: The patient perspective (Martine Pergent)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-listening-stakeholders-innovative-medicinal-products-patient-perspective-martine-pergent_en.pdf"},
    {"id":"20826","name":"Presentation - Package leaflet initiatives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-package-leaflet-initiatives_en.pdf"},
    {"id":"20852","name":"Presentation - Session 2.6: Examples of interactions - Accelerate (Gilles Vassal, Gustave Roussy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-26-examples-interactions-accelerate-gilles-vassal-gustave-roussy_en.pdf"},
    {"id":"20866","name":"Presentation - Adapting to Community referrals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adapting-community-referrals_en.pdf"},
    {"id":"20875","name":"Presentation - The added value of Twitter (K. Plass, EAU)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-added-value-twitter-k-plass-eau_en.pdf"},
    {"id":"20889","name":"The 24-hour whole-blood assay as potential in vitro tool to predict in vivo cytokine release following treatment with monoclonal antibodies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/24-hour-whole-blood-assay-potential-vitro-tool-predict-vivo-cytokine-release-following-treatment-monoclonal-antibodies_en.pdf"},
    {"id":"20893","name":"Presentation - Regulatory discussant - Discussion: sildenafil case - Break-out session 3 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-discussant-discussion-sildenafil-case-break-out-session-3-theme-2_en.pdf"},
    {"id":"20898","name":"Presentation - Signal Management in the EU and future extended access to EudraVigilance for industry (Georgy Genov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-signal-management-eu-and-future-extended-access-eudravigilance-industry-georgy-genov_en.pdf"},
    {"id":"20904","name":"Presentation - Why consider involving paediatric networks when preparing the PIP (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-why-consider-involving-paediatric-networks-when-preparing-pip-irmgard-eichler_en.pdf"},
    {"id":"20905","name":"Presentation - Interaction with healthcare professionals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-23T02:00:00Z","last_updated_date":"2011-05-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-healthcare-professionals_en.pdf"},
    {"id":"20907","name":"Presentation - Future Legislation: Pharmacovigilance – Industry vision (Tony Simon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-future-legislation-pharmacovigilance-industry-vision-tony-simon_en.pdf"},
    {"id":"20921","name":"Presentation - Follow-up on medication error action plan (Thomas Goedecke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-follow-medication-error-action-plan-thomas-goedecke_en.pdf"},
    {"id":"20939","name":"Human Embryonic Stem Cells: Considerations for Therapeutic Product Development, Dr Jane S. Lebkowski, Geron Corporation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/human-embryonic-stem-cells-considerations-therapeutic-product-development-dr-jane-s-lebkowski-geron-corporation_en.pdf"},
    {"id":"20942","name":"Presentation - Topic 1 - Assessment of paediatric medical needs through the Dutch Paediatric Formulary - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Tjitske van der Zand...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-assessment-paediatric-medical-needs-through-dutch-paediatric-formulary-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-tjitske-van-der-zand_en.pdf"},
    {"id":"20948","name":"Presentation - PDCO's perspective: Regulatory challenges and opportunities - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines (D. ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdcos-perspective-regulatory-challenges-and-opportunities-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-medicines_en.pdf"},
    {"id":"20950","name":"Presentation - 3.2 Feedback from the Heads of Medicines Agencies meeting in April","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-32-feedback-heads-medicines-agencies-meeting-april_en.pdf"},
    {"id":"20961","name":"Presentation - III Revision of the guideline on conduct of pharmacovigilance for medicines used by the paediatric population (Dirk Mentzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-iii-revision-guideline-conduct-pharmacovigilance-medicines-used-paediatric-population-dirk-mentzer_en.pdf"},
    {"id":"20965","name":"Presentation - SPOR Workshop (defining a business case for the EU network) (Francisco Penaranda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T02:00:00Z","last_updated_date":"2015-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-workshop-defining-business-case-eu-network-francisco-penaranda_en.pdf"},
    {"id":"20967","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Scientific Advisory Groups (Francesco Pignatti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-scientific-advisory-groups-francesco-pignatti_en.pdf"},
    {"id":"20978","name":"Presentation - EMA/FDA/Health Canada workshop on paediatric pulmonary arterial hypertension: Endpoints – Patients perspective (P. Hassel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emafdahealth-canada-workshop-paediatric-pulmonary-arterial-hypertension-endpoints-patients-perspective-p-hassel_en.pdf"},
    {"id":"20988","name":"Presentation - New mandates for PCWP and HCPWP (2016-2019) (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-mandates-pcwp-and-hcpwp-2016-2019-nathalie-bere_en.pdf"},
    {"id":"21038","name":"Lewy body dementias - Target population and specific end points - Ian McKeith","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-11T00:09:21Z","last_updated_date":"2008-02-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/lewy-body-dementias-target-population-and-specific-end-points-ian-mckeith_en.pdf"},
    {"id":"21044","name":"Presentation - Involvement of children and young people in the Paediatric Committee activities (Elin Haf Davies)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-involvement-children-and-young-people-paediatric-committee-activities-elin-haf-davies_en.pdf"}    {"id":"21045","name":"Presentation - EMA and partners: a unity of purpose (J. Peppard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-and-partners-unity-purpose-j-peppard_en.pdf"},
    {"id":"21059","name":"Presentation - Product information management","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-information-management_en.pdf"},
    {"id":"21071","name":"Presentation - Feedback from PDCO (J. Taminiau, PDCO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-pdco-j-taminiau-pdco_en.pdf"},
    {"id":"21075","name":"Presentation - Survey on the communication practices during a pandemic influenza crisis (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-communication-practices-during-pandemic-influenza-crisis-ivana-silva_en.pdf"},
    {"id":"21081","name":"Presentation - Background to the meeting: paediatric investigation plans for Gaucher (Elin Haf Davies)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-28T01:00:00Z","last_updated_date":"2012-11-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-background-meeting-paediatric-investigation-plans-gaucher-elin-haf-davies_en.pdf"},
    {"id":"21090","name":"Presentation - Heterogeneity: How much is too much?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-heterogeneity-how-much-too-much_en.pdf"},
    {"id":"21097","name":"Presentation - Report from the coordinating group (CG): Update on Enpr-EMA activities achievements and challenges (Mark Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-coordinating-group-cg-update-enpr-ema-activities-achievements-and-challenges-mark-turner_en.pdf"},
    {"id":"21098","name":"Presentation - Current experience with multiplicity issues in Pharmaceuticals and Medical Devices Agency (Eisuke Hida, Yuki Ando)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-experience-multiplicity-issues-pharmaceuticals-medical-devices-agency-eisuke-hida-yuki-ando_en.pdf"},
    {"id":"21109","name":"Presentation - Inhalational antibacterial regimens in non-cystic fibrosis patients (Jeff Alder)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-inhalational-antibacterial-regimens-non-cystic-fibrosis-patients-jeff-alder_en.pdf"},
    {"id":"21123","name":"Presentation - What is an ideal PSUR? – A new focus based on aligned expectations (Margarida Guimarà£es)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-ideal-psur-new-focus-based-aligned-expectations-margarida-guimarapses_en.pdf"},
    {"id":"21152","name":"The Paediatric Regulation - Agnà©s Saint Raymond","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:09:21Z","last_updated_date":"2007-06-06T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/paediatric-regulation-agnacs-saint-raymond_en.pdf"},
    {"id":"21170","name":"Presentation - The choice of outcome parameters and need for distinct assessment tools with regard to the different disease stages in Alzheimer's disease - regulator’s perspective (Jens Heisterberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-choice-outcome-parameters-and-need-distinct-assessment-tools-regard-different-disease-stages-alzheimers-disease-regulators-perspective-jens-heisterberg_en.pdf"},
    {"id":"21188","name":"Presentation - Session 2: Parameters guiding a site/histology - independent drug development (Jan Schellens)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-parameters-guiding-sitehistology-independent-drug-development-jan-schellens_en.pdf"},
    {"id":"21191","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Scientific advice/protocol assistance and patient representatives (Kristina Larsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-scientific-adviceprotocol-assistance-and-patient-representatives-kristina-larsson_en.pdf"},
    {"id":"21212","name":"Presentation -  Moving neonatology into the modern era of drug development - Overview of potential consortium projects and deliverables (Mark Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-moving-neonatology-modern-era-drug-development-overview-potential-consortium-projects-and-deliverables-mark-turner_en.pdf"},
    {"id":"21235","name":"The reference manure concept - Robert Kreuzig","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-06-23T02:09:21Z","last_updated_date":"2009-06-23T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/reference-manure-concept-robert-kreuzig_en.pdf"},
    {"id":"21241","name":"Teddy Networking Experience - Prof Adriana Ceci","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T00:09:21Z","last_updated_date":"2009-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/teddy-networking-experience-prof-adriana-ceci_en.pdf"},
    {"id":"21245","name":"Presentation - Reliably basing conclusions on subgroups of clinical trials (Koch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reliably-basing-conclusions-subgroups-clinical-trials-koch_en.pdf"},
    {"id":"21287","name":"Presentation - 2.1 Essential innovation and access to medicines: towards new models of research and development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-21-essential-innovation-and-access-medicines-towards-new-models-research-and-development_en.pdf"},
    {"id":"21292","name":"Presentation - New perception of disability – including cognition, fatigue, pain and other impairments related to multiple sclerosis (Diego Cadavid)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-perception-disability-including-cognition-fatigue-pain-and-other-impairments-related-multiple-sclerosis-diego-cadavid_en.pdf"},
    {"id":"21302","name":"Presentation - International regulators’ perspectives in handling patient-support programmes and market-research programmes (Junko Sato)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-regulators-perspectives-handling-patient-support-programmes-and-market-research-programmes-junko-sato_en.pdf"},
    {"id":"21317","name":"Presentation - Core data set: CYP2D6 metabolism","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-core-data-set-cyp2d6-metabolism_en.pdf"},
    {"id":"21318","name":"Presentation - EURO-NMD case study (Teresinha Evangelista)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-euro-nmd-case-study-teresinha-evangelista_en.pdf"},
    {"id":"21323","name":"eCTD/Non eCTD electronic Submission (Nees): Impact on the centralised procedure Claire Holmes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ectdnon-ectd-electronic-submission-nees-impact-centralised-procedure-claire-holmes_en.pdf"},
    {"id":"21339","name":"Presentation - Information to patients","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-patients_en.pdf"},
    {"id":"21355","name":"Presentation - Pharmacovigilance in the elderly: Conclusions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-elderly-conclusions_en.pdf"},
    {"id":"21369","name":"Presentation - Inspection of cross contamination controls in shared facilities (G. McKilligan, MHRA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-inspection-cross-contamination-controls-shared-facilities-g-mckilligan-mhra_en.pdf"},
    {"id":"21377","name":"Biomarkers and clinical trials, Dr Patricia Woo","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/biomarkers-and-clinical-trials-dr-patricia-woo_en.pdf"},
    {"id":"21396","name":"Presentation - Dose regimen selection for biologics in IBD (Christine Hon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-regimen-selection-biologics-ibd-christine-hon_en.pdf"},
    {"id":"21413","name":"Presentation - Referral procedures (A. Marcal, H. Matos and V. Seguin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-referral-procedures-marcal-h-matos-and-v-seguin_en.pdf"},
    {"id":"21416","name":"National Experience on collection and analysis of data on AM sales and use - Vibeke Frà¸kjà¦r Jensen","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/national-experience-collection-and-analysis-data-am-sales-and-use-vibeke-frakjar-jensen_en.pdf"},
    {"id":"21438","name":"Presentation - Key elements of the review of veterinary legislation (David Mackay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-elements-review-veterinary-legislation-david-mackay_en.pdf"},
    {"id":"21460","name":"Presentation - One size doesn’t fit all - Why it should be different guidances (B. Boulanger, EFSPI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-one-size-doesnt-fit-all-why-it-should-be-different-guidances-b-boulanger-efspi_en.pdf"},
    {"id":"21498","name":"Presentation - European Medicines Agency initiatives on product shortages due to manufacturing/GMP issues (Brendan Cuddy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-initiatives-product-shortages-due-manufacturinggmp-issues-brendan-cuddy_en.pdf"},
    {"id":"21521","name":"Are We Doing Enough for Children's Pain? - Richard F Howard","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-10-28T02:09:21Z","last_updated_date":"2004-10-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/are-we-doing-enough-childrens-pain-richard-f-howard_en.pdf"},
    {"id":"21544","name":"Presentation - CHMP feedback (H. Enzmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T16:50:00Z","last_updated_date":"2017-12-11T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chmp-feedback-h-enzmann_en.pdf"},
    {"id":"21556","name":"Presentation - Session 2: Applying the sentinel common data model to electronic medical records: PCORnet Experience (Lesley H Curtis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-applying-sentinel-common-data-model-electronic-medical-records-pcornet-experience-lesley-h-curtis_en.pdf"},
    {"id":"21559","name":"Presentation - Projects to deliver better IT systems and business change management (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-projects-deliver-better-it-systems-and-business-change-management-peter-arlett_en.pdf"},
    {"id":"21578","name":"Presentation - PSUR repository (Ana Zanoletty)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-psur-repository-ana-zanoletty_en.pdf"},
    {"id":"21590","name":"Presentation - Challenges for the different stakeholders: regulatory perspective (Francesco Pignatti) - S1.4","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-different-stakeholders-regulatory-perspective-francesco-pignatti-s14_en.pdf"},
    {"id":"21600","name":"Presentation - Superiority and organism-specific clinical trials of anitbacterial agents (Helen Boucher)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-superiority-and-organism-specific-clinical-trials-anitbacterial-agents-helen-boucher_en.pdf"},
    {"id":"21601","name":"Presentation - Maternal infant child and youth research network (MICYRN) (Anne Junker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-maternal-infant-child-and-youth-research-network-micyrn-anne-junker_en.pdf"},
    {"id":"21606","name":"Presentation - Key learnings from otamixaban development (Christophe Gaudin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-learnings-otamixaban-development-christophe-gaudin_en.pdf"},
    {"id":"21613","name":"Presentation - When do clinicians usually extrapolate in their practice? (Daniel Brasseur, Christoph Male)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-when-do-clinicians-usually-extrapolate-their-practice-daniel-brasseur-christoph-male_en.pdf"},
    {"id":"21615","name":"Aspects of Pharmacovigilance in Neonates - Dirk Mentzer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-11T02:09:21Z","last_updated_date":"2006-10-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/aspects-pharmacovigilance-neonates-dirk-mentzer_en.pdf"},
    {"id":"21619","name":"Presentation - Working with young cancer patients: from experience to activity (R. Swierzewski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-10T18:30:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-young-cancer-patients-experience-activity-r-swierzewski_en.pdf"},
    {"id":"21644","name":"Presentation - Procedure for election of PCWP/HCPWP Co-Chairs 2016-2019 (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-procedure-election-pcwphcpwp-co-chairs-2016-2019-nathalie-bere_en.pdf"},
    {"id":"21646","name":"Presentation - Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) (Marco Cavaleri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-trans-atlantic-task-force-antimicrobial-resistance-tatfar-marco-cavaleri_en.pdf"},
    {"id":"21659","name":"Presentation - Invasive fungal infections (IFI) in neonates: the state of the art (Paolo Manzoni)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-invasive-fungal-infections-ifi-neonates-state-art-paolo-manzoni_en.pdf"},
    {"id":"21661","name":"Presentation - Meeting with stakeholders on monitoring sales of veterinary antimicrobials in Europe - Conclusions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-22T13:01:28Z","last_updated_date":"2010-12-22T13:01:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-meeting-stakeholders-monitoring-sales-veterinary-antimicrobials-europe-conclusions_en.pdf"},
    {"id":"21672","name":"Presentation - Endpoints and indications for the older population","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-endpoints-and-indications-older-population_en.pdf"},
    {"id":"21682","name":"Presentation - What do I expect from the European Medicines Agency in the next five years? (Mark Walport)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-20T01:00:00Z","last_updated_date":"2015-03-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-do-i-expect-european-medicines-agency-next-five-years-mark-walport_en.pdf"},
    {"id":"21688","name":"Presentation - What do manufacturers and importers have to do to prepare for European Union membership? (Vesna Koblar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-do-manufacturers-and-importers-have-do-prepare-european-union-membership-vesna-koblar_en.pdf"},
    {"id":"21689","name":"EFPIA position paper proposals - Geoff Barton","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/efpia-position-paper-proposals-geoff-barton_en.pdf"},
    {"id":"21702","name":"Presentation - Why biomarkers in clinical drug development and use (Marisa Papaluca, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-why-biomarkers-clinical-drug-development-and-use-marisa-papaluca-ema_en.pdf"},
    {"id":"21703","name":"Presentation -  Multiplicity corrections in bioequivalence trials (Jiri Hofmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multiplicity-corrections-bioequivalence-trials-jiri-hofmann_en.pdf"},
    {"id":"21727","name":"Presentation - Reporting medication errors at national level: what should be reported and to whom (Mick Foy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reporting-medication-errors-national-level-what-should-be-reported-and-whom-mick-foy_en.pdf"},
    {"id":"21728","name":"Reflection on evolution and value of GCG - Mike Ward","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/reflection-evolution-and-value-gcg-mike-ward_en.pdf"},
    {"id":"21731","name":"Presentation - Roadmap to periodic safety update reports (PSUR) (Irene Rager, Menno van der Elst, Kora Doorduyn van der Stoep)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-roadmap-periodic-safety-update-reports-psur-irene-rager-menno-van-der-elst-kora-doorduyn-van-der-stoep_en.pdf"},
    {"id":"21734","name":"The treatment of pain in children: What can the EMEA do? - Agnà¨s Saint Raymond and Nathalie Seigneuret","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-10-28T02:09:21Z","last_updated_date":"2004-10-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/treatment-pain-children-what-can-emea-do-agnas-saint-raymond-and-nathalie-seigneuret_en.pdf"},
    {"id":"21737","name":"Presentation - Declarations of interests: a practical guide","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-31T19:00:00Z","last_updated_date":"2016-08-31T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-declarations-interests-practical-guide_en.pdf"},
    {"id":"21739","name":"Presentation - What are safety communications and how to review them (Federica Castellani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-are-safety-communications-and-how-review-them-federica-castellani_en.pdf"},
    {"id":"21763","name":"Presentation - EMA/HMA action plan on availability for veterinary vaccines (Faye Ioannou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emahma-action-plan-availability-veterinary-vaccines-faye-ioannou_en.pdf"},
    {"id":"21769","name":"Presentation - Post licensing evidence generation (PLEG) (Jane Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T17:31:00Z","last_updated_date":"2018-06-06T17:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-licensing-evidence-generation-pleg-jane-moseley_en.pdf"},
    {"id":"21790","name":"Presentation - Introduction on the background, rationale and expected outputs (Jean-Pierre Orand)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T14:00:00Z","last_updated_date":"2015-04-29T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-background-rationale-and-expected-outputs-jean-pierre-orand_en.pdf"},
    {"id":"21808","name":"Presentation - International Neonatal Consortium: Welcome","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-neonatal-consortium-welcome_en.pdf"},
    {"id":"21818","name":"Presentation - Experience in benefit risk referral procedure – Combined hormonal contraceptives (Hildrun Sundseth)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-benefit-risk-referral-procedure-combined-hormonal-contraceptives-hildrun-sundseth_en.pdf"},
    {"id":"21843","name":"Presentation - Development of drugs for paediatric neuromyelitis optica (Cheryl Hemingway)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-drugs-paediatric-neuromyelitis-optica-cheryl-hemingway_en.pdf"},
    {"id":"21849","name":"Presentation - Overview of comments on the guideline received so far and a summary of major areas that require attention (Eva Gil Berglund)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-comments-guideline-received-so-far-and-summary-major-areas-require-attention-eva-gil-berglund_en.pdf"},
    {"id":"21855","name":"Presentation - Update on pharmacovigilance guidances (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T16:15:00Z","last_updated_date":"2016-08-15T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-pharmacovigilance-guidances-peter-arlett_en.pdf"},
    {"id":"21874","name":"Presentation - Evaluation of treatment effect in adult UC and CD (Simon Travis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluation-treatment-effect-adult-uc-and-cd-simon-travis_en.pdf"},
    {"id":"21881","name":"Presentation - Potency and stability testing for ATMP (Marcel Hoefnagel, Charlotte De Wolf)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-27T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-potency-and-stability-testing-atmp-marcel-hoefnagel-charlotte-de-wolf_en.pdf"},
    {"id":"21893","name":"Presentation - Implementation of the ICH Q3D guideline in the Ph. Eur. (Bruno Spieldenner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-ich-q3d-guideline-ph-eur-bruno-spieldenner_en.pdf"},
    {"id":"21904","name":"Presentation - Performance and context based established conditions for analytical procedures","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-performance-and-context-based-established-conditions-analytical-procedures_en.pdf"},
    {"id":"21906","name":"Presentation - Current position and expectation for use of modelling and simulation in drug development and regulatory decision making: The Pharmaceuticals and Medical Devices Agency viewpoint","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:30:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-position-expectation-use-modelling-simulation-drug-development-regulatory-decision-making-pharmaceuticals-medical-devices-agency-viewpoint_en.pdf"},
    {"id":"21927","name":"Presentation - Utility of preclinical pharmacokinetic-pharmacodynamic modelling in QT safety testing - Break-out session 1 theme 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:45:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-utility-preclinical-pharmacokinetic-pharmacodynamic-modelling-qt-safety-testing-break-out-session-1-theme-1_en.pdf"},
    {"id":"21949","name":"EMEA Workshop on the feasibility of Biosimilar monoclonal Antibodies - Welcome - Xavier Luria","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-workshop-feasibility-biosimilar-monoclonal-antibodies-welcome-xavier-luria_en.pdf"},
    {"id":"21956","name":"Presentation - Experience and opportunities for the co-development (process) of companion diagnostics and medicinal products (in the EU) (Falk Ehmann, Efthymios Manolis and Armin Ritzhaupt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T18:21:00Z","last_updated_date":"2017-05-12T18:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-and-opportunities-co-development-process-companion-diagnostics-and-medicinal-products-eu-falk-ehmann-efthymios-manolis-and-armin-ritzhaupt_en.pdf"},
    {"id":"21958","name":"The beekeeper’s perspective on medicines for bees, Walter Haefeker, European Professional Beekeepers Association","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/beekeepers-perspective-medicines-bees-walter-haefeker-european-professional-beekeepers-association_en.pdf"},
    {"id":"21967","name":"Presentation - When do clinicians usually extrapolate in their practice? (D. Brasseur)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-when-do-clinicians-usually-extrapolate-their-practice-d-brasseur_en.pdf"},
    {"id":"21978","name":"Presentation - European Union regulatory workshop on medication errors (Thomas Goedecke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-regulatory-workshop-medication-errors-thomas-goedecke_en.pdf"},
    {"id":"22008","name":"Presentation - Patient perspective to clinical benefit (Elena Mazzone)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-perspective-clinical-benefit-elena-mazzone_en.pdf"},
    {"id":"22014","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Tibor Soà³s","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-tibor-soa3s_en.pdf"},
    {"id":"22016","name":"Presentation - The research in the field: Where to progress?, Eugene Major","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-research-field-where-progress-eugene-major_en.pdf"},
    {"id":"22050","name":"Presentation - Publication of Risk Management Plan (RMP) summaries: Analysis of the experience of the 1-year pilot phase (Juan Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-publication-risk-management-plan-rmp-summaries-analysis-experience-1-year-pilot-phase-juan-garcia_en.pdf"},
    {"id":"22058","name":"Presentation - The risk in transplanted patients, Marco Tuccori","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-transplanted-patients-marco-tuccori_en.pdf"},
    {"id":"22067","name":"Presentation - Introduction and regulatory update (Paula Salmikangas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T10:22:00Z","last_updated_date":"2016-12-02T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-and-regulatory-update-paula-salmikangas_en.pdf"},
    {"id":"22100","name":"Presentation - CAT's perspective: Regulatory challenges and opportunities - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines (Marg...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cats-perspective-regulatory-challenges-and-opportunities-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-medicines_en.pdf"},
    {"id":"22104","name":"Presentation - Alternative study designs and their suitability for paediatric development (Frank Pà©tavy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-alternative-study-designs-and-their-suitability-paediatric-development-frank-pactavy_en.pdf"},
    {"id":"22107","name":"Presentation - Standards for approval of paediatric medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-25T02:00:00Z","last_updated_date":"2011-07-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-standards-approval-paediatric-medicines_en.pdf"},
    {"id":"22111","name":"Presentation - Development of models for testing possible treatments, Igor Koralnik","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-models-testing-possible-treatments-igor-koralnik_en.pdf"},
    {"id":"22115","name":"Overview current EMEA transparency measures","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-current-emea-transparency-measures_en.pdf"},
    {"id":"22120","name":"HMPWG in the view of the NCA Objectives, Achievements, Roles and Responsibilities - Werner Knà¶ss","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/hmpwg-view-nca-objectives-achievements-roles-and-responsibilities-werner-knapss_en.pdf"},
    {"id":"22122","name":"Presentation - Benefits, impacts, risks (Ilaria Del Seppia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T02:00:00Z","last_updated_date":"2015-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-benefits-impacts-risks-ilaria-del-seppia_en.pdf"},
    {"id":"22124","name":"Presentation - Key expectations on inspection with regard to risk management of required organisational and technical control measures based on an established health based exposure limits (H. Carstensen, State Social Ser...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-expectations-inspection-regard-risk-management-required-organisational-and-technical-control-measures-based-established-health-based-exposure-limits-h-carstensen-state-social-ser_en.pdf"},
    {"id":"22136","name":"Presentation - Creation of a pan-European Paediatric Clinical Trials Network","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-06T01:00:00Z","last_updated_date":"2017-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-creation-pan-european-paediatric-clinical-trials-network_en.pdf"},
    {"id":"22138","name":"Key considerations for a biological product - K. Ho","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/key-considerations-biological-product-k-ho_en.pdf"},
    {"id":"22142","name":"Presentation - Traditional approach: Upstream process (Kowid Ho)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-traditional-approach-upstream-process-kowid-ho_en.pdf"},
    {"id":"22159","name":"Presentation - HCPWP and PCWP Work Plans for 2017 (Ivana Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hcpwp-and-pcwp-work-plans-2017-ivana-silva-ema_en.pdf"},
    {"id":"22164","name":"Presentation - Breakout session - Neonatal gastrointestinal injury (Kate Costeloe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-neonatal-gastrointestinal-injury-kate-costeloe_en.pdf"}    {"id":"22174","name":"Presentation - Croatian Agency for Medicinal Products and Medical Devices achievements during the instrument-for-pre-accession project (Viola Sarinic)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-croatian-agency-medicinal-products-medical-devices-achievements-during-instrument-pre-accession-project-viola-sarinic_en.pdf"},
    {"id":"22183","name":"Presentation - Key features and objectives of Regulation EU  No. 536/2014        (Laura Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T12:14:00Z","last_updated_date":"2017-03-30T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-features-and-objectives-regulation-eu-no-5362014-laura-pioppo_en.pdf"},
    {"id":"22192","name":"Presentation - Emerging methodological standards: Overview of current international benefit-risk initiatives (Hans Hillege)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emerging-methodological-standards-overview-current-international-benefit-risk-initiatives-hans-hillege_en.pdf"},
    {"id":"22195","name":"Presentation - Patients’ organisations' use of EudraVigilance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:09Z","last_updated_date":"2011-06-24T22:06:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-organisations-use-eudravigilance_en.pdf"},
    {"id":"22213","name":"Presentation - Meeting objectives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-05T17:00:00Z","last_updated_date":"2016-01-05T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-meeting-objectives_en.pdf"},
    {"id":"22215","name":"Design of paediatric rheumatology studies time to move to active comparator, Dr Nicolino Ruperto","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/design-paediatric-rheumatology-studies-time-move-active-comparator-dr-nicolino-ruperto_en.pdf"},
    {"id":"22224","name":"Presentation - Connectivity testing instructions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-connectivity-testing-instructions_en.pdf"},
    {"id":"22236","name":"Presentation - Challenges of developing cell and gene therapy products in Europe (Sven Kili)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-developing-cell-and-gene-therapy-products-europe-sven-kili_en.pdf"},
    {"id":"22251","name":"Presentation - 2.2 European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-22-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"22261","name":"Presentation - Session 2.5: Working group antibiotics (Laura Folgori)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-25-working-group-antibiotics-laura-folgori_en.pdf"},
    {"id":"22269","name":"Presentation - The European Medicines Agency Patient Registries Initiative (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-patient-registries-initiative-xavier-kurz_en.pdf"},
    {"id":"22275","name":"Presentation - Session 2: Case study: challenges faced by EMIF in utilising the OMOP common data model (Johan van der Lei)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-case-study-challenges-faced-emif-utilising-omop-common-data-model-johan-van-der-lei_en.pdf"},
    {"id":"22288","name":"Workshop on the guideline for First-in-Man Clinical trials for potential high-risk\n\nmedicinal products - Overview of comments - Highlights - J-M Vidal","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/workshop-guideline-first-man-clinical-trials-potential-high-risk-medicinal-products-overview-comments-highlights-j-m-vidal_en.pdf"},
    {"id":"22320","name":"Presentation - Clinical view on current standard of care in neuromyelitis optica (R. Marignier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-view-current-standard-care-neuromyelitis-optica-r-marignier_en.pdf"},
    {"id":"22360","name":"One database – two answers, Ten databases – million answers - Tjeerd-Pieter van Staa","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/one-database-two-answers-ten-databases-million-answers-tjeerd-pieter-van-staa_en.pdf"},
    {"id":"22369","name":"Presentation - European Group for Generic Veterinary Products considerations (Elsa Vecino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T13:00:00Z","last_updated_date":"2013-04-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-group-generic-veterinary-products-considerations-elsa-vecino_en.pdf"},
    {"id":"22394","name":"Presentation - Value of fundamental scientific approaches to understanding stability in lifecycle change management (Ron Ogilvie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-value-fundamental-scientific-approaches-understanding-stability-lifecycle-change-management-ron-ogilvie_en.pdf"},
    {"id":"22401","name":"Brief summary of the existing systems on collecting data: France","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/brief-summary-existing-systems-collecting-data-france_en.pdf"},
    {"id":"22402","name":"Presentation - 3.4 Discussion on extrapolation (Heinz Schmidli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-34-discussion-extrapolation-heinz-schmidli_en.pdf"},
    {"id":"22414","name":"Presentation - The Paediatric Regulation as an instrument for\n\nEuropean paediatric research","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:52Z","last_updated_date":"2011-05-27T15:25:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-regulation-instrument-european-paediatric-research_en.pdf"},
    {"id":"22426","name":"Presentation - Summary of interim results from analysis of field efficacy data for centrally authorised products (M.  Ilott)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T13:30:00Z","last_updated_date":"2017-11-16T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-interim-results-analysis-field-efficacy-data-centrally-authorised-products-m-ilott_en.pdf"},
    {"id":"22430","name":"Presentation - Nanoparticles, Rogà©rio Gaspar, University of Lisbon","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nanoparticles-rogacrio-gaspar-university-lisbon_en.pdf"},
    {"id":"22444","name":"Presentation - Looking to the future: Use of smartphones and beyond (Mick Foy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-looking-future-use-smartphones-and-beyond-mick-foy_en.pdf"},
    {"id":"22451","name":"Presentation - Heterogeneity over time in clinical trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-heterogeneity-over-time-clinical-trials_en.pdf"},
    {"id":"22461","name":"Presentation - The PRAC strategy for measuring impact of pharmacovigilance activities (Thomas Goedecke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prac-strategy-measuring-impact-pharmacovigilance-activities-thomas-goedecke_en.pdf"},
    {"id":"22475","name":"Overview of Review Process Interactions - Anthony Humphreys","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-review-process-interactions-anthony-humphreys_en.pdf"},
    {"id":"22478","name":"Presentation - Session 3: Post-approval pharmacogenomics: impact on risk management","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-post-approval-pharmacogenomics-impact-risk-management_en.pdf"},
    {"id":"22484","name":"Presentation - EU Regulators perspective, Peter Arlett","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-regulators-perspective-peter-arlett_en.pdf"},
    {"id":"22485","name":"Presentation - Clinically relevant advantage and major contribution to patient care (Laura Fregonese)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T17:00:00Z","last_updated_date":"2015-12-15T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinically-relevant-advantage-and-major-contribution-patient-care-laura-fregonese_en.pdf"},
    {"id":"22490","name":"Presentation - Conclusions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-conclusions_en.pdf"},
    {"id":"22498","name":"Presentation - Session 4.6: Action points and conclusions (Mark Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-46-action-points-and-conclusions-mark-turner_en.pdf"},
    {"id":"22500","name":"Presentation - Dissemination of European Medicines Agency information (Susanna Palkonen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dissemination-european-medicines-agency-information-susanna-palkonen_en.pdf"},
    {"id":"22509","name":"Presentation - Antimicrobial resistance (AMR): Joint EMA/EFSA RONAFA opinion and harmonisation of SPCs of antimicrobial veterinary medicines (Helen Jukes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antimicrobial-resistance-amr-joint-emaefsa-ronafa-opinion-and-harmonisation-spcs-antimicrobial-veterinary-medicines-helen-jukes_en.pdf"},
    {"id":"22539","name":"Presentation - Demonstrating impact for public health and stakeholders: Focus on pharmacovigilance (Peter Arlett, Corinne de Vries, Henry Fitt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-demonstrating-impact-public-health-and-stakeholders-focus-pharmacovigilance-peter-arlett-corinne-de-vries-henry-fitt_en.pdf"},
    {"id":"22543","name":"Presentation - Industry perspective (Christoph Kox, Andreas Franken, Andy Thornley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T02:00:00Z","last_updated_date":"2015-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-christoph-kox-andreas-franken-andy-thornley_en.pdf"},
    {"id":"22551","name":"Presentation - Incentives and regulatory considerations: Situation in Europe (Segundo Mariz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-incentives-and-regulatory-considerations-situation-europe-segundo-mariz_en.pdf"},
    {"id":"22553","name":"Presentation - Session 4.3: Immunogenicity of monoclonal antibodies: Risk-based approach – What are the risk factors?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:58Z","last_updated_date":"2012-06-15T17:10:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-43-immunogenicity-monoclonal-antibodies-risk-based-approach-what-are-risk-factors_en.pdf"},
    {"id":"22595","name":"Presentation - Variations & worksharing - an industry perspective (Rà©mon van Aubel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-variations-worksharing-industry-perspective-racmon-van-aubel_en.pdf"},
    {"id":"22600","name":"Potential biomarkers to be used for osteoporosis drug development - Dominique Ethgen","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/potential-biomarkers-be-used-osteoporosis-drug-development-dominique-ethgen_en.pdf"},
    {"id":"22605","name":"Recent experience in non-clinical assessment: Scientific advice and marketing authorization applications - Beatriz Silva Lima","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T00:00:00Z","last_updated_date":"2009-02-02T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/recent-experience-non-clinical-assessment-scientific-advice-and-marketing-authorization-applications-beatriz-silva-lima_en.pdf"},
    {"id":"22613","name":"Presentation - Pharmacometrics: a solid scientific basis for pharmacostatistical dose finding (Mick Looby)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacometrics-solid-scientific-basis-pharmacostatistical-dose-finding-mick-looby_en.pdf"},
    {"id":"22620","name":"Presentation - Irish Medicines Board: Considerations for veterinary scientific advice and marketing authorisations (Mary O’Grady)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-irish-medicines-board-considerations-veterinary-scientific-advice-and-marketing-authorisations-mary-ogrady_en.pdf"},
    {"id":"22645","name":"Presentation - New pharmacovigilance systems and services (Helen Vella)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmacovigilance-systems-and-services-helen-vella_en.pdf"},
    {"id":"22647","name":"Paediatric Regulation - Paolo Tomasi","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-11-16T00:09:21Z","last_updated_date":"2009-11-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/paediatric-regulation-paolo-tomasi_en.pdf"},
    {"id":"22655","name":"Presentation - Veterinarians experiences: Pharmacovigilance in poultry experience from the field (J.Van Erum)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinarians-experiences-pharmacovigilance-poultry-experience-field-jvan-erum_en.pdf"},
    {"id":"22658","name":"Presentation - Evaluation and implementation challenges with genomic signatures in clinical drug development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluation-and-implementation-challenges-genomic-signatures-clinical-drug-development_en.pdf"},
    {"id":"22667","name":"Presentation - Pharmacogenomics information in the summary of product characteristics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenomics-information-summary-product-characteristics_en.pdf"},
    {"id":"22679","name":"Medical Dictionary for Regulatory Activities (MedDRA) Update - Patricia Mozzicato","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/medical-dictionary-regulatory-activities-meddra-update-patricia-mozzicato_en.pdf"},
    {"id":"22681","name":"Presentation - An overview of US efficacy requirements to support licensing veterinary vaccines (P. Hauer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T13:30:00Z","last_updated_date":"2017-11-16T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-us-efficacy-requirements-support-licensing-veterinary-vaccines-p-hauer_en.pdf"},
    {"id":"22693","name":"Presentation - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) e-learning - Registration with EudraVigilance (version 5.7)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2026-02-11T15:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extended-eudravigilance-medicinal-product-dictionary-xevmpd-e-learning-registration-eudravigilance-version-57_en.pdf"},
    {"id":"22716","name":"Presentation - EudraVigilance auditable requirement project: ADRreports.eu portal update (Francois Domergue, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-auditable-requirement-project-adrreportseu-portal-update-francois-domergue-ema_en.pdf"},
    {"id":"22726","name":"Presentation - Efpia survey on impact of the paediatric regulation on\n\nmarketing authorization holders (Jan 2007 – Jun 2010)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-efpia-survey-impact-paediatric-regulation-marketing-authorization-holders-jan-2007-jun-2010_en.pdf"},
    {"id":"22748","name":"Presentation - Streamlined procedure for evaluation of eligibility criteria of patients' and consumers' organisations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-streamlined-procedure-evaluation-eligibility-criteria-patients-and-consumers-organisations_en.pdf"},
    {"id":"22752","name":"Presentation - Specific aspects concerning GMP and GCP inspections in Accelerated Assessment procedures (Andrei Spinei, Sophia Mylona)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-19T02:00:00Z","last_updated_date":"2016-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-specific-aspects-concerning-gmp-and-gcp-inspections-accelerated-assessment-procedures-andrei-spinei-sophia-mylona_en.pdf"},
    {"id":"22779","name":"Presentation - Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals Working Party (HCPWP) feedback from CHMP (H. Enzmann, C. Prieto and D. Duarte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-working-party-hcpwp-feedback-chmp-h-enzmann-c-prieto-and-d-duarte_en.pdf"},
    {"id":"22782","name":"Presentation - PML Final Conclusions, Peter Arlett","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pml-final-conclusions-peter-arlett_en.pdf"},
    {"id":"22796","name":"Introduction of AESGP","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/introduction-aesgp_en.pdf"},
    {"id":"22809","name":"Presentation - An approach to outcome measure development - a regulatory perspective (Elektra Papadopoulos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-approach-outcome-measure-development-regulatory-perspective-elektra-papadopoulos_en.pdf"},
    {"id":"22818","name":"Presentation - Day 2: Prevention of corneal graft rejection: clinical view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-prevention-corneal-graft-rejection-clinical-view_en.pdf"},
    {"id":"22822","name":"Presentation - A historical overview of the therapeutic use of bacteriophages (Andrzej Gorski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-22T02:00:00Z","last_updated_date":"2015-06-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-historical-overview-therapeutic-use-bacteriophages-andrzej-gorski_en.pdf"},
    {"id":"22824","name":"Presentation - Study of liver function monitoring in patients receiving agomelatine in the EHI database (Maia Uuskula)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-study-liver-function-monitoring-patients-receiving-agomelatine-ehi-database-maia-uuskula_en.pdf"},
    {"id":"22825","name":"Presentation - Post designation and orphan medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-designation-and-orphan-medicines_en.pdf"},
    {"id":"22829","name":"Presentation - Traditional validation: Downstream (Marco Strohmeier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-traditional-validation-downstream-marco-strohmeier_en.pdf"},
    {"id":"22844","name":"Presentation - General discussion, summing up and way forward - Session 6 (Brian Dooley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-discussion-summing-and-way-forward-session-6-brian-dooley_en.pdf"},
    {"id":"22863","name":"Presentation - Levels of evidence in drug development: Paediatric dose selection for fondaparinux","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:30:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-levels-evidence-drug-development-paediatric-dose-selection-fondaparinux_en.pdf"},
    {"id":"22876","name":"Integrated application of a QbD Development Approach across Chemical and Formulation Manufacturing Process","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/integrated-application-qbd-development-approach-across-chemical-and-formulation-manufacturing-process_en.pdf"},
    {"id":"22883","name":"Presentation - Placing microphysiological systems in the pharmaceutical R&D strategy (L. Ewart)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T11:22:00Z","last_updated_date":"2017-11-15T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-placing-microphysiological-systems-pharmaceutical-rd-strategy-l-ewart_en.pdf"},
    {"id":"22892","name":"Calculation of the Minimum Anticipated Biological Effect Level (MABEL) and 1st dose in human - Jennifer Sims","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/calculation-minimum-anticipated-biological-effect-level-mabel-and-1st-dose-human-jennifer-sims_en.pdf"},
    {"id":"22903","name":"Presentation - Industry perspective on formulation and packaging considerations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-formulation-and-packaging-considerations_en.pdf"},
    {"id":"22905","name":"Presentation - Session 2.9: Examples of interactions - PENTA (Carlo Giaquinto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-29-examples-interactions-penta-carlo-giaquinto_en.pdf"},
    {"id":"22911","name":"Presentation - Overview of reflection paper on promotion of pharmacovigilance reporting (L.Woods)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-reflection-paper-promotion-pharmacovigilance-reporting-lwoods_en.pdf"},
    {"id":"22914","name":"Presentation - Diagnostics: A focus on use in development of drugs for multiple drug resistant (MDR) pathogens (John Rex)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-diagnostics-focus-use-development-drugs-multiple-drug-resistant-mdr-pathogens-john-rex_en.pdf"},
    {"id":"22917","name":"Presentation - Feedback from COMP (D. O'Connor, COMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-comp-d-oconnor-comp_en.pdf"},
    {"id":"22926","name":"Osteoporosis - Regulatory perspective - Frits Lekkerkerker","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/osteoporosis-regulatory-perspective-frits-lekkerkerker_en.pdf"},
    {"id":"22951","name":"Presentation - A year of experience at the PRAC (Albert van der Zeijden)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-year-experience-prac-albert-van-der-zeijden_en.pdf"},
    {"id":"22956","name":"Presentation - Pharmacovigilance in European Union: where have we come from?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-european-union-where-have-we-come_en.pdf"},
    {"id":"22968","name":"Presentation - Comparability, Kowid Ho, Afssaps","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comparability-kowid-ho-afssaps_en.pdf"},
    {"id":"22973","name":"Presentation - Workshop on access to clinical-trial data (Guido Rasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-05T17:00:00Z","last_updated_date":"2012-12-05T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-access-clinical-trial-data-guido-rasi_en.pdf"},
    {"id":"22994","name":"Presentation - Challenges and opportunities to measuring the impact of regulatory actions (Sabine Straus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-and-opportunities-measuring-impact-regulatory-actions-sabine-straus_en.pdf"},
    {"id":"23001","name":"Presentation - European Union Clinical Trials Register: presentation of results information (Noà©mie Manent)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-02T17:00:00Z","last_updated_date":"2013-07-02T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-clinical-trials-register-presentation-results-information-noacmie-manent_en.pdf"},
    {"id":"23020","name":"Presentation - Uncertainty quantification (Ine Skottheim Rusten)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-uncertainty-quantification-ine-skottheim-rusten_en.pdf"},
    {"id":"23041","name":"Presentation - Medicines and Healthcare products Regulatory Agency (MHRA): Overview of applications for Marketing Authorisations – recent experience in assessment of quality (Keith Pugh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicines-and-healthcare-products-regulatory-agency-mhra-overview-applications-marketing-authorisations-recent-experience-assessment-quality-keith-pugh_en.pdf"},
    {"id":"23087","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Patient involvement in the PRAC (Albert van der Zeijden)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-patient-involvement-prac-albert-van-der-zeijden_en.pdf"},
    {"id":"23108","name":"Presentation - Pharmacovigilance: Latest development (Peter Ekstrà¶m)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-latest-development-peter-ekstrapm_en.pdf"},
    {"id":"23111","name":"Vector Shedding and Biodistribution Following Intratumoral Delivery of Adenoviral p53 Gene (ADVEXIN) in Patients with Advanced Non-small Cell Lung Cancer - Toshiyoshi Fujiwara, Noriaki Tanaka","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/vector-shedding-and-biodistribution-following-intratumoral-delivery-adenoviral-p53-gene-advexin-patients-advanced-non-small-cell-lung-cancer-toshiyoshi-fujiwara-noriaki-tanaka_en.pdf"},
    {"id":"23117","name":"Presentation - World Health Organization (WHO): Consumption of antimicrobials in food animals outside EU/EEA (Hilde Kruse)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-world-health-organization-who-consumption-antimicrobials-food-animals-outside-eueea-hilde-kruse_en.pdf"},
    {"id":"23121","name":"Presentation - Holistic approach to paediatric research: regulators (G. Egger, R. Bax)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:04:00Z","last_updated_date":"2018-06-18T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-regulators-g-egger-r-bax_en.pdf"},
    {"id":"23134","name":"Presentation - Patient focus at the International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2014 (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-focus-international-conference-pharmacoepidemiology-therapeutic-risk-management-2014-priya-bahri_en.pdf"},
    {"id":"23157","name":"Presentation - Optimising early access tools: revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation (Tomas Salmonson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-12T14:00:00Z","last_updated_date":"2015-11-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-optimising-early-access-tools-revision-guidelines-accelerated-assessment-and-conditional-marketing-authorisation-tomas-salmonson_en.pdf"},
    {"id":"23163","name":"Presentation - EudraVigilance: Preparing for change (Francois Domergue)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-preparing-change-francois-domergue_en.pdf"},
    {"id":"23166","name":"Presentation - Implementation of the new pharmacovigilance legislation: Overall update and activities in 2013 (Franck Diafouka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-new-pharmacovigilance-legislation-overall-update-and-activities-2013-franck-diafouka_en.pdf"},
    {"id":"23187","name":"Presentation - Studies in neonatal fungal infections (Irja Lutsar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-studies-neonatal-fungal-infections-irja-lutsar_en.pdf"},
    {"id":"23199","name":"Presentation - Breakout session - Neonatal brain Injury (Heike Rabe and Ronit Pressler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-neonatal-brain-injury-heike-rabe-and-ronit-pressler_en.pdf"},
    {"id":"23205","name":"Presentation - Extrapolation & Pediatric Development: A case study from pediatric Ulcerative Colitis (Richard Strauss)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extrapolation-pediatric-development-case-study-pediatric-ulcerative-colitis-richard-strauss_en.pdf"},
    {"id":"23206","name":"Presentation - Mutual-recognition-procedure and decentralised-procedure step-by-step instructions: How to apply and how the procedures are conducted (Peter Bachmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mutual-recognition-procedure-and-decentralised-procedure-step-step-instructions-how-apply-and-how-procedures-are-conducted-peter-bachmann_en.pdf"},
    {"id":"23254","name":"Presentation - Bridging the bench to bedside divide: Optimal dosing regimens of novel antimicrobials against multi drug resistant (MDR) pathogens (George Drusano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bridging-bench-bedside-divide-optimal-dosing-regimens-novel-antimicrobials-against-multi-drug-resistant-mdr-pathogens-george-drusano_en.pdf"},
    {"id":"23269","name":"Presentation - Approaches to genotoxicity and carcinogenicity assessment (Peter Kasper)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T18:12:00Z","last_updated_date":"2016-10-26T18:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-approaches-genotoxicity-and-carcinogenicity-assessment-peter-kasper_en.pdf"},
    {"id":"23275","name":"Presentation - Agenda item 7: Report on international activities - European Medicines Agency/European Union-Food and Drug Administration activity update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-15T15:00:00Z","last_updated_date":"2016-03-15T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-7-report-international-activities-european-medicines-agencyeuropean-union-food-and-drug-administration-activity-update_en.pdf"},
    {"id":"23288","name":"Presentation - Revised framework of European Medicines Agency interaction with patients, consumers and their organisations (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revised-framework-european-medicines-agency-interaction-patients-consumers-and-their-organisations-isabelle-moulon_en.pdf"},
    {"id":"23303","name":"Public Health Impact of the Orphan Drug Regulation: Sà©golà¨ne Aymà©","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/public-health-impact-orphan-drug-regulation-sacgolane-aymac_en.pdf"}    {"id":"23304","name":"Presentation - Overview","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview_en.pdf"},
    {"id":"23305","name":"Presentation - Procedure management of variations (Alberto Ganan, Iordanis Gravanis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T02:00:00Z","last_updated_date":"2015-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-procedure-management-variations-alberto-ganan-iordanis-gravanis_en.pdf"},
    {"id":"23309","name":"Presentation - Public consultation on a concept paper on implementing measures for the performance of pharmacovigilance activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-consultation-concept-paper-implementing-measures-performance-pharmacovigilance-activities_en.pdf"},
    {"id":"23317","name":"Presentation - Do information tools need adapting for an effective communication in healthcare? (Sara Rubinelli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-do-information-tools-need-adapting-effective-communication-healthcare-sara-rubinelli_en.pdf"},
    {"id":"23329","name":"Presentation - Management of medicines shortages in Ireland (John Lynch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-management-medicines-shortages-ireland-john-lynch_en.pdf"},
    {"id":"23407","name":"Module 05 - Presentation - Dealing with unmet medical needs and support to innovation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/module-05-presentation-dealing-unmet-medical-needs-and-support-innovation_en.pdf"},
    {"id":"23448","name":"Presentation - Implementation of the pharmacovigilance legislation. The views of physicians (Erzsà©bet Podmaniczky)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-pharmacovigilance-legislation-views-physicians-erzsacbet-podmaniczky_en.pdf"},
    {"id":"23455","name":"Recommendations in the area of pharmacovigilance - Emmanuel Trenado","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-12-03T01:00:00Z","last_updated_date":"2004-12-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/recommendations-area-pharmacovigilance-emmanuel-trenado_en.pdf"},
    {"id":"23471","name":"Presentation - 2015 shortages workshop (Brendan Cuddy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2015-shortages-workshop-brendan-cuddy_en.pdf"},
    {"id":"23480","name":"Polymer Therapeutics as Nanomedicines - Ruth Duncan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-29T02:09:21Z","last_updated_date":"2009-04-29T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/polymer-therapeutics-nanomedicines-ruth-duncan_en.pdf"},
    {"id":"23485","name":"Presentation - Oversight of clinical trials in the EU - EMA perspective (Thania Spathopoulou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-oversight-clinical-trials-eu-ema-perspective-thania-spathopoulou_en.pdf"},
    {"id":"23507","name":"Presentation - eHealth at EU level: perspectives from the European Commission - EMA's PCWP and HCPWP joint meeting (Katja Neubauer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ehealth-eu-level-perspectives-european-commission-emas-pcwp-and-hcpwp-joint-meeting-katja-neubauer_en.pdf"},
    {"id":"23508","name":"Presentation - MRLs for active substances and excipients (Isaura Duarte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mrls-active-substances-and-excipients-isaura-duarte_en.pdf"},
    {"id":"23541","name":"Presentation - Neuromyelitis optica: Is there treatment equipoise? (Bruce Cree)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-neuromyelitis-optica-there-treatment-equipoise-bruce-cree_en.pdf"},
    {"id":"23543","name":"Presentation - The age of big data and the power of Watson (Lisa Latts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-age-big-data-and-power-watson-lisa-latts_en.pdf"},
    {"id":"23563","name":"Presentation - Day 2: Dry eye","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-dry-eye_en.pdf"},
    {"id":"23579","name":"Presentation - European Association of Hospital Pharmacists (EAHP)'s current priorities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T02:00:00Z","last_updated_date":"2017-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-association-hospital-pharmacists-eahps-current-priorities_en.pdf"},
    {"id":"23605","name":"Presentation - Day 1: Regulation of products for macular oedema","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-regulation-products-macular-oedema_en.pdf"},
    {"id":"23610","name":"Presentation - Implementation of the EudraVigilance access policy for\n\ncentrally authorised products - Phase 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-eudravigilance-access-policy-centrally-authorised-products-phase-1_en.pdf"},
    {"id":"23622","name":"Presentation - A pharmacometric-based approach to facilitate critically needed new antibiotic development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:51Z","last_updated_date":"2011-04-26T18:05:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacometric-based-approach-facilitate-critically-needed-new-antibiotic-development_en.pdf"},
    {"id":"23631","name":"Presentation - Proposed global pediatric clinical research network - Overview (William R. Treem)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposed-global-pediatric-clinical-research-network-overview-william-r-treem_en.pdf"},
    {"id":"23643","name":"Presentation - Feasibility of stratification of sales data (Jordi Torren)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T17:00:00Z","last_updated_date":"2016-03-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feasibility-stratification-sales-data-jordi-torren_en.pdf"},
    {"id":"23650","name":"Presentation - Identification of preventable adverse drug reactions from a regulatory perspective (Almath Spooner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-identification-preventable-adverse-drug-reactions-regulatory-perspective-almath-spooner_en.pdf"},
    {"id":"23652","name":"Presentation - IFAH-Europe: The impact on public and animal health of the use of antibiotics in animals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ifah-europe-impact-public-and-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"23653","name":"Transatlantic simplification of administrative procedures - Arielle North","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/transatlantic-simplification-administrative-procedures-arielle-north_en.pdf"},
    {"id":"23658","name":"Presentation - Pharmacovigilance and risk minimisation plans, Jan Petracek, PharmInvent","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-and-risk-minimisation-plans-jan-petracek-pharminvent_en.pdf"},
    {"id":"23661","name":"Presentation - Session 3: Clinical trial designs in rheumatoid arthritis (Andreas Kouroumalis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-09T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-clinical-trial-designs-rheumatoid-arthritis-andreas-kouroumalis_en.pdf"},
    {"id":"23664","name":"Presentation: Outline of revised EudraVigilance access policy (medicines for human use)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-11-22T01:00:00Z","last_updated_date":"2010-11-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outline-revised-eudravigilance-access-policy-medicines-human-use_en.pdf"},
    {"id":"23674","name":"Presentation - Non-clinical development of cell-based medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-clinical-development-cell-based-medicinal-products_en.pdf"},
    {"id":"23712","name":"Presentation - Treatment of infections due to pan-drug resistant pathogens: Difficulties in conducting clinical trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:47Z","last_updated_date":"2011-04-26T18:05:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-treatment-infections-due-pan-drug-resistant-pathogens-difficulties-conducting-clinical-trials_en.pdf"},
    {"id":"23750","name":"Presentation - Strategies for drug development in spinal muscular atrophy (SMA) Type 1 - A regulatory perspective (Marion Haberkamp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strategies-drug-development-spinal-muscular-atrophy-sma-type-1-regulatory-perspective-marion-haberkamp_en.pdf"},
    {"id":"23752","name":"Module 07 - Presentation - Good practice and inspections","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T01:00:00Z","last_updated_date":"2017-11-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/module-07-presentation-good-practice-and-inspections_en.pdf"},
    {"id":"23769","name":"Antibiotic Residues in Honey: The situation for the trade and industry, Frank Filodda, European Federation of Honey Packers and Distributors (FEEDM)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/antibiotic-residues-honey-situation-trade-and-industry-frank-filodda-european-federation-honey-packers-and-distributors-feedm_en.pdf"},
    {"id":"23792","name":"Presentation - SPOR data services: questions and answers webinar with industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-06T01:00:00Z","last_updated_date":"2018-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-data-services-questions-and-answers-webinar-industry_en.pdf"},
    {"id":"23822","name":"Presentation - Industry experience with Art. 46 of Regulation (EC) No 1901/2006","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-experience-art-46-regulation-ec-no-19012006_en.pdf"},
    {"id":"23832","name":"Presentation - When science and regulatory action meet reality: barriers and critical succes factors to managing risk (Peter Mol)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-when-science-and-regulatory-action-meet-reality-barriers-and-critical-succes-factors-managing-risk-peter-mol_en.pdf"},
    {"id":"23839","name":"Presentation - Good pharmacovigilance practice module IX: Signal management","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practice-module-ix-signal-management_en.pdf-0"},
    {"id":"23844","name":"Presentation -  Regulatory issues in the run-up to dossier submission Inspections (Claudio Facchini)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-issues-run-dossier-submission-inspections-claudio-facchini_en.pdf"},
    {"id":"23862","name":"Presentation - Communication campaign: medicines under additional monitoring (Daniel Glanville)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-campaign-medicines-under-additional-monitoring-daniel-glanville_en.pdf"},
    {"id":"23870","name":"Presentation - Retinopathy of prematurity (Dina Apele Freimane)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-retinopathy-prematurity-dina-apele-freimane_en.pdf"},
    {"id":"23881","name":"Rational Design of Less Immunogenic Biotherapeutics - Joy A. Cavagnaro","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-09-04T02:09:21Z","last_updated_date":"2007-09-04T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/rational-design-less-immunogenic-biotherapeutics-joy-cavagnaro_en.pdf"},
    {"id":"23883","name":"Presentation - PHA Europe: PH kids","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T02:00:00Z","last_updated_date":"2017-06-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pha-europe-ph-kids_en.pdf"},
    {"id":"23903","name":"Presentation - Public hearings: Draft rules (Monika Benstetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-12-11T01:00:00Z","last_updated_date":"2013-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-hearings-draft-rules-monika-benstetter_en.pdf"},
    {"id":"23910","name":"Recommendations and proposals for action - Dr Daniel Brasseur","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-12-03T01:00:00Z","last_updated_date":"2004-12-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/recommendations-and-proposals-action-dr-daniel-brasseur_en.pdf"},
    {"id":"23918","name":"Presentation - Modelling and simulation to optimise the design of confirmatory trials, to analyse phase 3 data and to characterise risk-benefit and support label claims - Break-out session 4 plenary feedback","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-optimise-design-confirmatory-trials-analyse-phase-3-data-and-characterise-risk-benefit-and-support-label-claims-break-out-session-4-plenary-feedback_en.pdf"},
    {"id":"23922","name":"Presentation - Advantages and challenges of a mechanism-based modelling approach to drug development and testing","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advantages-and-challenges-mechanism-based-modelling-approach-drug-development-and-testing_en.pdf"},
    {"id":"23934","name":"Presentation - Product and Substance project overview","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-02T02:00:00Z","last_updated_date":"2017-05-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-and-substance-project-overview_en.pdf"},
    {"id":"23937","name":"Presentation - The proposed ‘two-step approach’ for MS treatments with a significant effect on immunity (Hideki Garren)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposed-two-step-approach-ms-treatments-significant-effect-immunity-hideki-garren_en.pdf"},
    {"id":"23945","name":"Presentation - 5.3 Leveraging multiple endpoints in small clinical trials (Robin Ristl)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-53-leveraging-multiple-endpoints-small-clinical-trials-robin-ristl_en.pdf"},
    {"id":"23962","name":"Presentation - Satisfaction survey on involvement of patients, consumers and healthcare professionals during 2016 (N. Bere, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-satisfaction-survey-involvement-patients-consumers-and-healthcare-professionals-during-2016-n-bere-ema_en.pdf"},
    {"id":"23965","name":"Presentation - EMA workshop on framework of collaboration with academia (Hans H. Linden)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-30T02:00:00Z","last_updated_date":"2016-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-workshop-framework-collaboration-academia-hans-h-linden_en.pdf"},
    {"id":"23973","name":"Presentation for Drug Regimens Consortium (CPTR) scientific-advice meeting with the European Medicines Agency: Hollow-fiber system for tuberculosis (HFS-TB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-18T15:00:00Z","last_updated_date":"2014-11-18T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drug-regimens-consortium-cptr-scientific-advice-meeting-european-medicines-agency-hollow-fiber-system-tuberculosis-hfs-tb_en.pdf"},
    {"id":"23977","name":"Presentation - Immunogenicity of therapeutic antibodies (Gertjan Wolbink)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunogenicity-therapeutic-antibodies-gertjan-wolbink_en.pdf"},
    {"id":"23979","name":"Presentation - Committee for Orphan Medicinal Products (COMP) feedback - EMA's PCWP and HCPWP joint meeting (Lesley Greene, Daniel O’Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-orphan-medicinal-products-comp-feedback-emas-pcwp-and-hcpwp-joint-meeting-lesley-greene-daniel-oconnor_en.pdf"},
    {"id":"23985","name":"Using a primary care database to evaluate drug safety in pregnancy: possibilities & limitations - Corinne de Vries","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/using-primary-care-database-evaluate-drug-safety-pregnancy-possibilities-limitations-corinne-de-vries_en.pdf"},
    {"id":"23988","name":"Presentation - Bayesian prior elicitation: an application to the MYPAN trial in\n\nchildhood polyarteritis nodosa (Lisa Hampson, John Whitehead, Despina Eleftheriou, Paul Brogan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bayesian-prior-elicitation-application-mypan-trial-childhood-polyarteritis-nodosa-lisa-hampson-john-whitehead-despina-eleftheriou-paul-brogan_en.pdf"},
    {"id":"24020","name":"Advanced Therapy, G Silvester, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/advanced-therapy-g-silvester-ema_en.pdf"},
    {"id":"24023","name":"Presentation - General overview of novel experimental therapeutic approaches in SMA (Francesco Muntoni)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-overview-novel-experimental-therapeutic-approaches-sma-francesco-muntoni_en.pdf"},
    {"id":"24029","name":"Presentation - Collaborations with general practitioners (GPs) in evaluation procedures: Experience and opportunities (Heidi Janssen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T02:00:00Z","last_updated_date":"2016-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collaborations-general-practitioners-gps-evaluation-procedures-experience-and-opportunities-heidi-janssen_en.pdf"},
    {"id":"24051","name":"Presentation - Pharmacovigilance and the elderly: Some proposals for improvement","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-and-elderly-some-proposals-improvement_en.pdf"},
    {"id":"24066","name":"Presentation - Experience from scientific advices for CARs/TCRs (Olli Tenhunen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T11:11:00Z","last_updated_date":"2016-12-02T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-scientific-advices-carstcrs-olli-tenhunen_en.pdf"},
    {"id":"24071","name":"Presentation - (One) Statistician(’)s perspectives on extrapolation (Rob Hemmings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-one-statisticians-perspectives-extrapolation-rob-hemmings_en.pdf"},
    {"id":"24078","name":"Presentation - Sarm I/Tadalafil pgase II combination study for erectile dysfunction: modeling and simulation to optimize study design (Charles Benson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sarm-itadalafil-pgase-ii-combination-study-erectile-dysfunction-modeling-and-simulation-optimize-study-design-charles-benson_en.pdf"},
    {"id":"24079","name":"Presentation - Quality defects, falsified products and rapid alerts","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-defects-falsified-products-and-rapid-alerts_en.pdf"},
    {"id":"24083","name":"Presentation - Beta-lactamase inhibitors (Shampa Das)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-beta-lactamase-inhibitors-shampa-das_en.pdf"},
    {"id":"24095","name":"Presentation - Ph2a dose selection based on the relationship between PK and target occupancy (Mona Alameddine, Patricia Sanwald Ducray)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ph2a-dose-selection-based-relationship-between-pk-and-target-occupancy-mona-alameddine-patricia-sanwald-ducray_en.pdf"},
    {"id":"24096","name":"Presentation - CVMP activities regarding antimicrobials: on-going and recent activities (Helen Jukes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-activities-regarding-antimicrobials-going-and-recent-activities-helen-jukes_en.pdf"},
    {"id":"24101","name":"Presentation - Animal infection models: identifying the pharmacologic determinants of efficacy (Sujata M. Bhavnani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-animal-infection-models-identifying-pharmacologic-determinants-efficacy-sujata-m-bhavnani_en.pdf"},
    {"id":"24127","name":"Presentation - Innovation Task Force (ITF) and ITF briefing meetings: What can be gained - European Medicines Agency veterinary medicines innovation day (Minna Leppà¤nen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovation-task-force-itf-and-itf-briefing-meetings-what-can-be-gained-european-medicines-agency-veterinary-medicines-innovation-day-minna-leppanen_en.pdf"},
    {"id":"24145","name":"Presentation - Anthelmintic resistance (Gesine Hahn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-anthelmintic-resistance-gesine-hahn_en.pdf"},
    {"id":"24169","name":"Presentation - Overview of process for VeDDRA revision (Raquel Gopal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-11T18:20:00Z","last_updated_date":"2014-02-11T18:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-process-veddra-revision-raquel-gopal_en.pdf"},
    {"id":"24192","name":"Presentation - Biogen: Industry perspective - PRIME medicines (James Kennard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-07T02:00:00Z","last_updated_date":"2017-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-biogen-industry-perspective-prime-medicines-james-kennard_en.pdf"},
    {"id":"24193","name":"Workshop - Topic areas - Malcolm Dash","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-26T00:09:21Z","last_updated_date":"2009-10-26T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/workshop-topic-areas-malcolm-dash_en.ppt"},
    {"id":"24200","name":"Special areas, J Llinares, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/special-areas-j-llinares-ema_en.pdf"},
    {"id":"24202","name":"Presentation - Extrapolation in paediatric juvenile idiopathic arthritis: case study (Ruth Oliver, Laura Shaughnessy, Philippa Charlton)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extrapolation-paediatric-juvenile-idiopathic-arthritis-case-study-ruth-oliver-laura-shaughnessy-philippa-charlton_en.pdf"},
    {"id":"24238","name":"Presentation - Draft good-pharmacovigilance-practice module XV: Safety communications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-good-pharmacovigilance-practice-module-xv-safety-communications_en.pdf"},
    {"id":"24246","name":"Presentation - Paediatric osteoporosis - regulatory issues (Viveca Odlind)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-09T02:00:00Z","last_updated_date":"2014-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-osteoporosis-regulatory-issues-viveca-odlind_en.pdf"},
    {"id":"24251","name":"Presentation - Medicine shortages (J.Švarcaitė, PGEU)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicine-shortages-jsvarcaite-pgeu_en.pdf"},
    {"id":"24273","name":"Presentation - Best-practice communication for healthcare professionals and patients (Angeles Alonso-Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-practice-communication-healthcare-professionals-and-patients-angeles-alonso-garcia_en.pdf"},
    {"id":"24274","name":"Presentation - Non-clinical models to identify PK/PD indices and PD targets In Vitro (George Drusano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-clinical-models-identify-pkpd-indices-and-pd-targets-vitro-george-drusano_en.pdf"},
    {"id":"24287","name":"Presentation -  Patients reporting in Croatia - Patients' associations' experiences (Jurica Ester)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-reporting-croatia-patients-associations-experiences-jurica-ester_en.pdf"},
    {"id":"24301","name":"Presentation - Exposure - response (Johan Mouton)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-exposure-response-johan-mouton_en.pdf"},
    {"id":"24306","name":"Presentation - How to improve the reliability of single arm trials (Paolo Bruzzi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-improve-reliability-single-arm-trials-paolo-bruzzi_en.pdf"},
    {"id":"24307","name":"Presentation - Availability of veterinary vaccines: Industry perspectives (Frà©dà©ric Descamps)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-availability-veterinary-vaccines-industry-perspectives-fracdacric-descamps_en.pdf"},
    {"id":"24308","name":"Presentation - Acceptability and palatability - methods available for assessment","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-acceptability-and-palatability-methods-available-assessment_en.pdf"},
    {"id":"24309","name":"Presentation - Assessment of a MAA: Awareness of the PIP recommendation: Generic applications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-assessment-maa-awareness-pip-recommendation-generic-applications_en.pdf"},
    {"id":"24311","name":"Presentation - Centralised procedure at the European Medicines Agency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T16:00:00Z","last_updated_date":"2016-02-15T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-centralised-procedure-european-medicines-agency_en.pdf"},
    {"id":"24314","name":"Presentation - European Medicines Agency policy on the handling of conflicts of interests of scientific committees’ members and experts","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T14:00:00Z","last_updated_date":"2012-07-06T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-policy-handling-conflicts-interests-scientific-committees-members-and-experts_en.pdf"},
    {"id":"24335","name":"Presentation - Statistical methodology for biosimilars, comparison of process changes and comparison of dissolution profiles (M. Denham, EFSPI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-statistical-methodology-biosimilars-comparison-process-changes-and-comparison-dissolution-profiles-m-denham-efspi_en.pdf"},
    {"id":"24339","name":"AAV specific issues pertaining to vector shedding in gene therapy clinical trials - Samuel Wadsworth","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/aav-specific-issues-pertaining-vector-shedding-gene-therapy-clinical-trials-samuel-wadsworth_en.pdf"},
    {"id":"24347","name":"Presentation - Best practice guide on adherence to timetables (Piotr Kozarewicz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-practice-guide-adherence-timetables-piotr-kozarewicz_en.pdf"},
    {"id":"24355","name":"Presentation - European Medicines Agency information to European Multiple Sclerosis Platform members (Christoph Thalheim)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-information-european-multiple-sclerosis-platform-members-christoph-thalheim_en.pdf"},
    {"id":"24359","name":"Presentation - Quality development considerations - Regulatory perspective (Christiane Niederlaender)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T11:11:00Z","last_updated_date":"2016-12-02T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-development-considerations-regulatory-perspective-christiane-niederlaender_en.pdf"},
    {"id":"24369","name":"Presentation - EMA/EGA workshop - Session 3: Transdermal Products (PK + Adhesion + Irritation/Sensitization) (Bjà¶rn Schurad)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T02:00:00Z","last_updated_date":"2015-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaega-workshop-session-3-transdermal-products-pk-adhesion-irritationsensitization-bjaprn-schurad_en.pdf"},
    {"id":"24380","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Jean Marimbert","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-jean-marimbert_en.pdf"},
    {"id":"24392","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Study design (Andrea Beyer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-study-design-andrea-beyer_en.pdf"},
    {"id":"24396","name":"Presentation - Day 1: Inherited retinal disease","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-inherited-retinal-disease_en.pdf"},
    {"id":"24427","name":"Presentation - Global dementia integrated development (Raj Long)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-global-dementia-integrated-development-raj-long_en.pdf"},
    {"id":"24433","name":"Presentation - International Federation for Animal Health Europe (Olivier Espeisse)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T13:00:00Z","last_updated_date":"2013-04-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-federation-animal-health-europe-olivier-espeisse_en.pdf"},
    {"id":"24437","name":"Presentation - 2017 PRAC work plan (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:30:00Z","last_updated_date":"2017-03-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2017-prac-work-plan-june-raine_en.pdf"}    {"id":"24452","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Pharmacovigilance in the Future - Munir Pirmohamed","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-pharmacovigilance-future-munir-pirmohamed_en.pdf"},
    {"id":"24453","name":"Presentation - Way forward, Marisa Papaluca, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-way-forward-marisa-papaluca-ema_en.pdf"},
    {"id":"24467","name":"Presentation - European Medicines Agency - focus on the future (Guido Rasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-focus-future-guido-rasi_en.pdf"},
    {"id":"24480","name":"Presentation - Panitumumab: The KRAS Story (Fletcher)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-panitumumab-kras-story-fletcher_en.pdf"},
    {"id":"24481","name":"Presentation - European Union Clinical Trial Register and EudraCT (Ana Rodriguez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-clinical-trial-register-and-eudract-ana-rodriguez_en.pdf"},
    {"id":"24488","name":"Regulator, Thinking - Non-clinical session - B. Silva Lima","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/regulator-thinking-non-clinical-session-b-silva-lima_en.pdf"},
    {"id":"24495","name":"Presentation - ERNs and research - State of play from the European Commission perspective (Iiro Eerola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-erns-and-research-state-play-european-commission-perspective-iiro-eerola_en.pdf"},
    {"id":"24500","name":"Presentation - Difficulties and challenges encountered - look into the future: academia perspective (Kris De Boeck)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-difficulties-and-challenges-encountered-look-future-academia-perspective-kris-de-boeck_en.pdf"},
    {"id":"24501","name":"Bee surveillance programmes, bee mortality and risk assessment, Jane Richardson, EFSA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/bee-surveillance-programmes-bee-mortality-and-risk-assessment-jane-richardson-efsa_en.pdf"},
    {"id":"24506","name":"Presentation - Day 1: Visual function endpoints industry view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-visual-function-endpoints-industry-view_en.pdf"},
    {"id":"24525","name":"Presentation - ISO IDMP status update & EU implementation guide","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T02:00:00Z","last_updated_date":"2015-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-iso-idmp-status-update-eu-implementation-guide_en.pdf"},
    {"id":"24541","name":"Presentation - First experiences: PRAC transparency (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-first-experiences-prac-transparency-june-raine_en.pdf"},
    {"id":"24558","name":"Presentation - Setting the scene: Neuromyelitis optica (Jackie Palace)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-setting-scene-neuromyelitis-optica-jackie-palace_en.pdf"},
    {"id":"24576","name":"Presentation - Regulatory comments - Break-out session 4 themes 1 and 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-comments-break-out-session-4-themes-1-and-3_en.pdf"},
    {"id":"24579","name":"Presentation - Session VI - Neonatal Necrotizing Enterocolitis (NEC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-18T02:00:00Z","last_updated_date":"2016-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-vi-neonatal-necrotizing-enterocolitis-nec_en.pdf"},
    {"id":"24580","name":"Presentation - Discovery and development of PML treatments, Teresa Compton","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-discovery-and-development-pml-treatments-teresa-compton_en.pdf"},
    {"id":"24582","name":"Presentation - Closing remarks (Spiros Vamvakas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-closing-remarks-spiros-vamvakas_en.pdf"},
    {"id":"24588","name":"Presentation - Expert meeting on paediatric development of fixed-dose combinations for the treatment of the human immunodeficiency virus (HIV) (Thorsten Olski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T17:00:00Z","last_updated_date":"2016-05-27T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-expert-meeting-paediatric-development-fixed-dose-combinations-treatment-human-immunodeficiency-virus-hiv-thorsten-olski_en.pdf"},
    {"id":"24603","name":"Regulatory Requirements for Viral Shedding Studies for Gene Therapy Vectors in Switzerland - Andreas Marti","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/regulatory-requirements-viral-shedding-studies-gene-therapy-vectors-switzerland-andreas-marti_en.pdf"},
    {"id":"24606","name":"Presentation - Combined industry view on EudraVigilance developments and access","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:12Z","last_updated_date":"2011-06-24T22:06:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-combined-industry-view-eudravigilance-developments-and-access_en.pdf"},
    {"id":"24609","name":"Presentation - The future partly FAIR, partly Cloudy (Barend Mons)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-future-partly-fair-partly-cloudy-barend-mons_en.pdf"},
    {"id":"24622","name":"Presentation - Objectives - Training session for patients and consumers involved in EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-objectives-training-session-patients-and-consumers-involved-ema_en.pdf"},
    {"id":"24634","name":"Presentation - Gene therapy ATMPs: High Council for the biotechnology’s scientific committee expertise for contained use and deliberate release (Nils Braun and Jean-Christophe Pagà¨s)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gene-therapy-atmps-high-council-biotechnologys-scientific-committee-expertise-contained-use-and-deliberate-release-nils-braun-and-jean-christophe-pagas_en.pdf"},
    {"id":"24640","name":"Presentation - EudraVigilance reporting process for users: Create and send individual case safety reports (ICSRs) using EVWEB - Training Module EV-M3d - Part II","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-08-02T18:10:00Z","last_updated_date":"2017-08-02T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-reporting-process-users-create-and-send-individual-case-safety-reports-icsrs-using-evweb-training-module-ev-m3d-part-ii_en.pdf"},
    {"id":"24659","name":"Role of EMA in Patient Registries, Dr Jan Petracek","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/role-ema-patient-registries-dr-jan-petracek_en.pdf"},
    {"id":"24666","name":"Presentation - Level of evidence from Orphan designation to European Union  marketing authorisation (Laura Fregonese)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-level-evidence-orphan-designation-european-union-marketing-authorisation-laura-fregonese_en.pdf"},
    {"id":"24667","name":"Presentation - Some statistical issues of modelling and extrapolation - Break-out session 3 theme 4","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-some-statistical-issues-modelling-and-extrapolation-break-out-session-3-theme-4_en.pdf"},
    {"id":"24680","name":"Presentation - Non-animal approaches in support of medicinal product development - setting the scene (S. Beken)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T11:22:00Z","last_updated_date":"2017-11-15T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-animal-approaches-support-medicinal-product-development-setting-scene-s-beken_en.pdf"},
    {"id":"24687","name":"Presentation - European Patients Forum member survey on pharmacovigilance. First results and tentative conclusions (Kaisa Immonen-Charalambous)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-patients-forum-member-survey-pharmacovigilance-first-results-and-tentative-conclusions-kaisa-immonen-charalambous_en.pdf"},
    {"id":"24689","name":"GMP requirements, Dr Walter Janssens","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gmp-requirements-dr-walter-janssens_en.pdf"},
    {"id":"24709","name":"Framework of collaboration with academia - Discussion session","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-01T02:00:00Z","last_updated_date":"2015-09-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/framework-collaboration-academia-discussion-session_en.pdf"},
    {"id":"24717","name":"Presentation - Update on Working Group 4 (Allison Needham, Pirkko Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-working-group-4-allison-needham-pirkko-lepola_en.pdf"},
    {"id":"24728","name":"Presentation - European Union collaborative framework for patient registries: Pilot phase (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-collaborative-framework-patient-registries-pilot-phase-xavier-kurz_en.pdf"},
    {"id":"24729","name":"Presentation - Module 1 - Setting the scene: Introduction to the EU regulatory network","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T02:00:00Z","last_updated_date":"2018-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-1-setting-scene-introduction-eu-regulatory-network_en.pdf"},
    {"id":"24735","name":"Presentation - Strengthening interaction with stakeholders (Marie-Agnes Heine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strengthening-interaction-stakeholders-marie-agnes-heine_en.pdf"},
    {"id":"24738","name":"Presentation - The experience of biotech SMEs with Commission Regulation (EC) No 2049/2005 (SME Regulation) : The Europa Association for Bioindustries (EuropaBio)  (Miriam Gargesi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-biotech-smes-commission-regulation-ec-no-20492005-sme-regulation-europa-association-bioindustries-europabio-miriam-gargesi_en.pdf"},
    {"id":"24746","name":"Presentation - Key considerations in risk-management plans (Maarten Lagendijk)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-considerations-risk-management-plans-maarten-lagendijk_en.pdf"},
    {"id":"24748","name":"Presentation - European Surveillance of Veterinary Antimicrobial Consumption 2012 - Results and state of play","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-03-29T12:14:00Z","last_updated_date":"2012-03-29T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-surveillance-veterinary-antimicrobial-consumption-2012-results-and-state-play_en.pdf"},
    {"id":"24759","name":"EMA working groups on Committees' operational preparedness (M. Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-17T16:41:00Z","last_updated_date":"2017-10-17T16:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ema-working-groups-committees-operational-preparedness-m-dias_en.ppt"},
    {"id":"24762","name":"Presentation - Registries and trial readiness (Hanns Lochmuller)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-registries-and-trial-readiness-hanns-lochmuller_en.pdf"},
    {"id":"24776","name":"Presentation - Interactive flowchart for gene-therapy guidelines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interactive-flowchart-gene-therapy-guidelines_en.pdf"},
    {"id":"24787","name":"Presentation - Focussing on risk communication: Why now? What next? - Global lessons learnt from the Drug Safety theme edition (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focussing-risk-communication-why-now-what-next-global-lessons-learnt-drug-safety-theme-edition-priya-bahri_en.pdf"},
    {"id":"24820","name":"Presentation - EudraVigilance project: launch of the new system (F. Domergue)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T15:08:00Z","last_updated_date":"2018-01-04T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-project-launch-new-system-f-domergue_en.pdf"},
    {"id":"24841","name":"Presentation - Pharmacovigilance legislation: Our implementation journey... (F. Diafouka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-legislation-our-implementation-journey-f-diafouka_en.pdf"},
    {"id":"24879","name":"Presentation - Conditional marketing authorisation - Report on ten years of experience at the EMA (Zigmars Sebris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-conditional-marketing-authorisation-report-ten-years-experience-ema-zigmars-sebris-ema_en.pdf"},
    {"id":"24883","name":"European Commission DG Enterprise activities in the field of antimicrobials - Martin Terberger","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:09:21Z","last_updated_date":"2009-05-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-commission-dg-enterprise-activities-field-antimicrobials-martin-terberger_en.pdf"},
    {"id":"24890","name":"Presentation - Update on pharmacovigilance systems and services (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T16:00:00Z","last_updated_date":"2015-06-25T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-pharmacovigilance-systems-and-services-peter-arlett_en.pdf"},
    {"id":"24891","name":"Presentation - Benefit- Risk assessment and communication","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-benefit-risk-assessment-and-communication_en.pdf"},
    {"id":"24893","name":"Presentation - Immunology session","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunology-session_en.pdf"},
    {"id":"24909","name":"Presentation - European Patients’ Academy: Overview and status quo (Jan Geissler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-patients-academy-overview-and-status-quo-jan-geissler_en.pdf"},
    {"id":"24929","name":"Presentation - Targeting “histology-independent indications” and resulting challenges in the context of orphan designations (Francesco Pignatti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T17:16:00Z","last_updated_date":"2018-06-06T17:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-targeting-histology-independent-indications-and-resulting-challenges-context-orphan-designations-francesco-pignatti_en.pdf"},
    {"id":"24931","name":"Presentation - Regulator's view: A risk-based approach - rationale and decision points","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:41Z","last_updated_date":"2012-06-15T17:10:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulators-view-risk-based-approach-rationale-and-decision-points_en.pdf"},
    {"id":"24936","name":"Session 1 - CMC - Innovator Industry Presentation - Prof. Georg-B. Kresse","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-1-cmc-innovator-industry-presentation-prof-georg-b-kresse_en.pdf"},
    {"id":"24937","name":"Overview of bee diseases and available treatment options, Vlasta JenÄiÄ, Veterinary Faculty, University of Ljubljana","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-bee-diseases-and-available-treatment-options-vlasta-jenaia-veterinary-faculty-university-ljubljana_en.pdf"},
    {"id":"24951","name":"Presentation - Agonists with different levels of affinity (Peter Mol)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agonists-different-levels-affinity-peter-mol_en.pdf"},
    {"id":"25015","name":"Presentation - Target/drug interference considerations in immunogenicity assessment (Eric Wakshull)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-targetdrug-interference-considerations-immunogenicity-assessment-eric-wakshull_en.pdf"},
    {"id":"25049","name":"Presentation - Emerging safety issues (Georgy Genov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emerging-safety-issues-georgy-genov_en.pdf"},
    {"id":"25050","name":"Presentation - Innovative medicines initiative (IMI) WEB-RADR project - EMA's PCWP and HCPWP joint meeting (Cà©sar Hernà¡ndez Garcà­a)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovative-medicines-initiative-imi-web-radr-project-emas-pcwp-and-hcpwp-joint-meeting-cacsar-hernandez-garca_en.pdf"},
    {"id":"25057","name":"Presentation - Contribution from the veterinary side of the EMA and EU Regulatory Network on antimicrobial resistance - Session 2 (Helen Jukes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-contribution-veterinary-side-ema-and-eu-regulatory-network-antimicrobial-resistance-session-2-helen-jukes_en.pdf"},
    {"id":"25072","name":"Presentation - Pharmacovigilance system master file – an approach towards system simplification","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-system-master-file-approach-towards-system-simplification_en.pdf"},
    {"id":"25073","name":"Experience of PIP/waiver/deferral process from an SME perspective - Simon Bryson","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-11-16T00:09:21Z","last_updated_date":"2009-11-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/experience-pipwaiverdeferral-process-sme-perspective-simon-bryson_en.pdf"},
    {"id":"25074","name":"Presentation - How can pharmaceutical industry contribute to measuring impact? (David Lewis on behalf of Vicky Edwards)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-can-pharmaceutical-industry-contribute-measuring-impact-david-lewis-behalf-vicky-edwards_en.pdf"},
    {"id":"25077","name":"Presentation - Building on perspectives of 3 years of operation of the European Union pharmacovigilance legislation: opportunities for the future (Sini Eskola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-building-perspectives-3-years-operation-european-union-pharmacovigilance-legislation-opportunities-future-sini-eskola_en.pdf"},
    {"id":"25089","name":"Presentation - Administration by other routes and other safety aspects (Anja Slikkerveer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-administration-other-routes-and-other-safety-aspects-anja-slikkerveer_en.pdf"},
    {"id":"25090","name":"Experience and Observations on Implementing Prudent Use of Fluoroquinolones - Ludwig Klostermann","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/experience-and-observations-implementing-prudent-use-fluoroquinolones-ludwig-klostermann_en.pdf"},
    {"id":"25094","name":"Presentation - Upcoming actions for the implementation of Regulation (EC) 470/2009 (MRL-Regulation) (Mario Nagtzaam)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-upcoming-actions-implementation-regulation-ec-4702009-mrl-regulation-mario-nagtzaam_en.pdf"},
    {"id":"25104","name":"Presentation - Quality variations: simplification opportunities and improvement of quality of submissions (Alberto Ganan Jimenez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:30:00Z","last_updated_date":"2018-01-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-variations-simplification-opportunities-and-improvement-quality-submissions-alberto-ganan-jimenez_en.pdf"},
    {"id":"25108","name":"Presentation - Session 2: What can already be improved following the evaluation of the Agency and the Network (without changing the legislation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-18T02:00:00Z","last_updated_date":"2011-07-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-what-can-already-be-improved-following-evaluation-agency-and-network-without-changing-legislation_en.pdf"},
    {"id":"25116","name":"EU GMP Requirements - Good Distribution Practices - Martin Melzer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-20T02:09:21Z","last_updated_date":"2009-10-20T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-gmp-requirements-good-distribution-practices-martin-melzer_en.pdf"},
    {"id":"25141","name":"Presentation - EMA activities related to synergies between regulators and HTA bodies (M. Berntgen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-activities-related-synergies-between-regulators-and-hta-bodies-m-berntgen-ema_en.pdf"},
    {"id":"25142","name":"Presentation - EnprEMA (Jose Drabwell, IPOPI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enprema-jose-drabwell-ipopi_en.pdf"},
    {"id":"25147","name":"Presentation - Challenges and opportunities from public private partnerships, Richard Bergstrà¶m","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-and-opportunities-public-private-partnerships-richard-bergstrapm_en.pdf"},
    {"id":"25152","name":"Presentation - Reporting side effects of medicines (V. Newbould)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reporting-side-effects-medicines-v-newbould_en.pdf"},
    {"id":"25158","name":"Presentation - Key concepts of the Paediatric Regulation and latest developments (Paolo Tomasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-concepts-paediatric-regulation-and-latest-developments-paolo-tomasi_en.pdf"},
    {"id":"25166","name":"Presentation - Case studies on established conditions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-studies-established-conditions_en.pdf"},
    {"id":"25180","name":"Presentation - Recent experience in non-clinical scientific advice, Dr. Jan-Willem van der Laan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recent-experience-non-clinical-scientific-advice-dr-jan-willem-van-der-laan_en.pdf"},
    {"id":"25187","name":"Presentation - Why measuring the impact of regulatory actions? (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-why-measuring-impact-regulatory-actions-june-raine_en.pdf"},
    {"id":"25191","name":"Presentation - Urgent union procedure","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-urgent-union-procedure_en.pdf"},
    {"id":"25192","name":"Off-Patent Medicines Developed for Children - Chistine-Lise Julou","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:09:21Z","last_updated_date":"2007-06-06T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/patent-medicines-developed-children-chistine-lise-julou_en.pdf"},
    {"id":"25196","name":"Presentation - Management of the risk management plan for centrally authorised products in post-authorisation: European Medicines Agency perspective (Iordanis Gravanis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-12T14:00:01Z","last_updated_date":"2015-11-12T14:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-management-risk-management-plan-centrally-authorised-products-post-authorisation-european-medicines-agency-perspective-iordanis-gravanis_en.pdf"},
    {"id":"25205","name":"Highlight report of the Industry stakeholder platform on research and development support (from the meeting on 25 April 2017)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-23T18:42:00Z","last_updated_date":"2017-05-23T18:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/highlight-report-industry-stakeholder-platform-research-and-development-support-meeting-25-april-2017_en.pdf"},
    {"id":"25209","name":"Presentation - Patient Access Partnership (Stanimir Hasardzhiev, PACT)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-access-partnership-stanimir-hasardzhiev-pact_en.pdf"},
    {"id":"25227","name":"Presentation - Session 2: Comparing the use of OMOP and sentinel common data models for drug safety - Implications for European data (Andrew Bate)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-comparing-use-omop-and-sentinel-common-data-models-drug-safety-implications-european-data-andrew-bate_en.pdf"},
    {"id":"25228","name":"Transparency and dissemination of information - Francois Houyvez","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-12-03T01:00:00Z","last_updated_date":"2004-12-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/transparency-and-dissemination-information-francois-houyvez_en.pdf"},
    {"id":"25251","name":"Presentation - β-Lactamase inhibitors: the pharmacological basis of therapeutics (Paul Ambrose)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-i2-lactamase-inhibitors-pharmacological-basis-therapeutics-paul-ambrose_en.pdf"},
    {"id":"25261","name":"Presentation - Overview of the new process for signal detection and management (Georgy Genov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-new-process-signal-detection-and-management-georgy-genov_en.pdf"},
    {"id":"25279","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Patient involvement in the CHMP (Patrick Salmon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-patient-involvement-chmp-patrick-salmon_en.pdf"},
    {"id":"25322","name":"Presentation - EU Telematics strategy for veterinary medicines - Status update (David Mackay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-telematics-strategy-veterinary-medicines-status-update-david-mackay_en.pdf"},
    {"id":"25364","name":"Presentation - Submission of referentials management services (RMS) and organisations management Services (OMS) change requests","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-27T12:30:00Z","last_updated_date":"2018-02-27T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-submission-referentials-management-services-rms-and-organisations-management-services-oms-change-requests_en.pdf"},
    {"id":"25380","name":"Presentation - New active substance categorisation and orphan similarity (Piotr Kozarewicz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-active-substance-categorisation-and-orphan-similarity-piotr-kozarewicz_en.pdf"},
    {"id":"25401","name":"Presentation - Multi-stakeholder parallel regulatorsHTA advice (Jane Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multi-stakeholder-parallel-regulatorshta-advice-jane-moseley_en.pdf"},
    {"id":"25454","name":"Presentation - Role of Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT) in innovation support - European Medicines Agency veterinary medicines innovation day (Esther Werner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-ad-hoc-expert-group-veterinary-novel-therapies-advent-innovation-support-european-medicines-agency-veterinary-medicines-innovation-day-esther-werner_en.pdf"},
    {"id":"25461","name":"Presentation - Improve certainty of regulatory outcome: An incentive identified by stakeholders to foster translation of research into commercial products: A small and medium-sized enterprise perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-improve-certainty-regulatory-outcome-incentive-identified-stakeholders-foster-translation-research-commercial-products-small-and-medium-sized-enterprise-perspective_en.pdf"},
    {"id":"25503","name":"Presentation - Regulatory pathways to new medicines (Tony Humphreys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-pathways-new-medicines-tony-humphreys_en.pdf"},
    {"id":"25514","name":"Presentation of mandate and rules - Dr Isabelle Moulon","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2003-05-08T02:00:00Z","last_updated_date":"2003-05-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mandate-and-rules-dr-isabelle-moulon_en.pdf"},
    {"id":"25518","name":"Presentation: Standard Operating Procedure for meetings about generic issues in paediatric drug development convened by Enpr-EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-standard-operating-procedure-meetings-about-generic-issues-paediatric-drug-development-convened-enpr-ema_en.pdf"},
    {"id":"25525","name":"Presentation - FIMMG: Involvement of general practitioners (GPs) in EMA activities (Walter Marrocco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T02:00:00Z","last_updated_date":"2016-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fimmg-involvement-general-practitioners-gps-ema-activities-walter-marrocco_en.pdf"},
    {"id":"25547","name":"Evaluation of Seneca Valley Virus Levels Mouse to Man - Paul Hallenbeck","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/evaluation-seneca-valley-virus-levels-mouse-man-paul-hallenbeck_en.pdf"},
    {"id":"25563","name":"Application of PGx in PK in medical practise: How does PGx inform decisions? - Munir Pirmohamed","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/application-pgx-pk-medical-practise-how-does-pgx-inform-decisions-munir-pirmohamed_en.pdf"},
    {"id":"25564","name":"Presentation - eAF integration with OMS (Hanna Palyszka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T17:00:00Z","last_updated_date":"2017-12-20T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eaf-integration-oms-hanna-palyszka_en.pdf"}    {"id":"25575","name":"Presentation - The first experience with the newly launched Parallel Consultation platform (J. Moseley, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T01:00:00Z","last_updated_date":"2017-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-first-experience-newly-launched-parallel-consultation-platform-j-moseley-ema_en.pdf"},
    {"id":"25615","name":"Presentation - Case study 1 - Atezolizumab: Accelerated development - Session 5 (Andrea Challand)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-1-atezolizumab-accelerated-development-session-5-andrea-challand_en.pdf"},
    {"id":"25631","name":"Presentation - Single-arm trials in cancer drug evaluation - Problem statement (Francesco Pignatti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-single-arm-trials-cancer-drug-evaluation-problem-statement-francesco-pignatti_en.pdf"},
    {"id":"25633","name":"Questionaire on prescribing practices - JiŠ™à­ BureŠ¡","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:09:21Z","last_updated_date":"2009-05-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/questionaire-prescribing-practices-jistma-bures_en.pdf"},
    {"id":"25637","name":"Presentation - COMP update (Daniel O’Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comp-update-daniel-oconnor_en.pdf"},
    {"id":"25648","name":"Presentation - Patients' interest for public hearings on medicines in Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-interest-public-hearings-medicines-europe_en.pdf"},
    {"id":"25664","name":"Presentation - Workshop on the Use of Statistical Methodologies in the Comparability Assessment of Quality Attributes (H. Park, Samsung Bioepis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-use-statistical-methodologies-comparability-assessment-quality-attributes-h-park-samsung-bioepis_en.pdf"},
    {"id":"25695","name":"Presentation - Focus on pharmacovigilance: Introduction","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-pharmacovigilance-introduction_en.pdf"},
    {"id":"25713","name":"Presentation - What to control? CQAs and CPPs, Thomas Stangler, on behalf of EGA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T02:00:00Z","last_updated_date":"2011-10-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-control-cqas-and-cpps-thomas-stangler-behalf-ega_en.pdf"},
    {"id":"25718","name":"Presentation - On the road to clinical extrapolation (Kristina Weber, Armin Koch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-road-clinical-extrapolation-kristina-weber-armin-koch_en.pdf"},
    {"id":"25726","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Objective and introduction (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-objective-and-introduction-isabelle-moulon_en.pdf"},
    {"id":"25744","name":"Presentation - Federation of Veterinarians of Europe (FVE): Antimicrobial drug prescribing habits of veterinarians in Europe (Nancy De Briyne)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-federation-veterinarians-europe-fve-antimicrobial-drug-prescribing-habits-veterinarians-europe-nancy-de-briyne_en.pdf"},
    {"id":"25757","name":"Evolution and achievements of ICH - GCG (Global Cooperation Group) - Kohei Wada","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/evolution-and-achievements-ich-gcg-global-cooperation-group-kohei-wada_en.pdf"},
    {"id":"25769","name":"Presentation - World Federation of Hemophilia (Mark Brooker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-world-federation-hemophilia-mark-brooker_en.pdf"},
    {"id":"25772","name":"Presentation - The industry's views on 'older' old patients","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industrys-views-older-old-patients_en.pdf"},
    {"id":"25776","name":"Trademark Creation in a Global Pharma Environment - Anja Manz and Joanne Green","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-09-11T02:09:21Z","last_updated_date":"2006-09-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/trademark-creation-global-pharma-environment-anja-manz-and-joanne-green_en.pdf"},
    {"id":"25792","name":"Presentation - FDA Orphan Drug Designation 101 (James H. Reese)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-orphan-drug-designation-101-james-h-reese_en.pdf"},
    {"id":"25796","name":"Presentation - Similarities and discrepancies between adult and paediatric disease and differential drug effects (Frank M. Ruemmele)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-similarities-and-discrepancies-between-adult-and-paediatric-disease-and-differential-drug-effects-frank-m-ruemmele_en.pdf"},
    {"id":"25800","name":"Presentation - Break out session 1 - Proposals on how to develop and foster new networks (Peter Helms, chair of EnprEMA CG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-break-out-session-1-proposals-how-develop-and-foster-new-networks-peter-helms-chair-enprema-cg_en.pdf"},
    {"id":"25807","name":"Presentation - Session 4.1: Collaboration European Cystic Fibrosis Society Clinical Trials Network (ECFS-CTN) with US Cystic Fibrosis Foundation –Therapeutics Development Network (CFF-TDN) (Tim Lee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-41-collaboration-european-cystic-fibrosis-society-clinical-trials-network-ecfs-ctn-us-cystic-fibrosis-foundation-therapeutics-development-network-cff-tdn-tim-lee_en.pdf"},
    {"id":"25815","name":"Cardiovascular - Regulatory perspective - Gonzalo Calvo","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/cardiovascular-regulatory-perspective-gonzalo-calvo_en.pdf"},
    {"id":"25820","name":"Presentation - The new pharmacovigilance legislation. A national agency’s views (Sabine Straus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmacovigilance-legislation-national-agencys-views-sabine-straus_en.pdf"},
    {"id":"25844","name":"Scientific Advice on Quality Aspects for Biologicals - Jean-Hugues Trouvin","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-08T00:09:21Z","last_updated_date":"2007-02-08T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-advice-quality-aspects-biologicals-jean-hugues-trouvin_en.pdf"},
    {"id":"25851","name":"Turkey - Ministry of Agriculture and Rural Affairs, H. Haluk AŠŸkaroÄŸlu","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/turkey-ministry-agriculture-and-rural-affairs-h-haluk-asykaroaylu_en.pdf"},
    {"id":"25861","name":"Presentation - The summary-of-product-characteristics guideline and paediatric aspects","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2025-10-10T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-product-characteristics-guideline-paediatric-aspects_en.pdf"},
    {"id":"25862","name":"Shedding of viral vectors during clinical gene therapy - Ellen Schenk","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/shedding-viral-vectors-during-clinical-gene-therapy-ellen-schenk_en.pdf"},
    {"id":"25874","name":"Oncology - Regulatory perspective - Bertil Jonsson","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/oncology-regulatory-perspective-bertil-jonsson_en.pdf"},
    {"id":"25875","name":"Presentation - Pre-submission phase and guidance for novel products (Fia Westerholm, Nikolaus Kriz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pre-submission-phase-and-guidance-novel-products-fia-westerholm-nikolaus-kriz_en.pdf"},
    {"id":"25882","name":"Presentation - The evolving natural history of SMA types I and II  (Eugenio Mercuri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evolving-natural-history-sma-types-i-and-ii-eugenio-mercuri_en.pdf"},
    {"id":"25884","name":"Presentation - 7 Summary of sessions and way forward (Frank Pà©tavy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-7-summary-sessions-and-way-forward-frank-pactavy_en.pdf"},
    {"id":"25897","name":"Presentation - Some current United States Food and Drug Administration thinking on adaptive design clinical trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-some-current-united-states-food-and-drug-administration-thinking-adaptive-design-clinical-trials_en.pdf"},
    {"id":"25912","name":"NIHR Medicines for Children Research Network - Prof David Edwards","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T00:09:21Z","last_updated_date":"2009-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/nihr-medicines-children-research-network-prof-david-edwards_en.pdf"},
    {"id":"25939","name":"Presentation - Patient involvement at Food and Drug Administration (FDA) (Andrea Furia-Helms)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-10T18:30:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-involvement-food-and-drug-administration-fda-andrea-furia-helms_en.pdf"},
    {"id":"25941","name":"Presentation - PML development, Heinz Wiendl","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pml-development-heinz-wiendl_en.pdf"},
    {"id":"25948","name":"Presentation - Translating benefit-risk information into product information (Laurent Brassart)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-translating-benefit-risk-information-product-information-laurent-brassart_en.pdf"},
    {"id":"25951","name":"Presentation - Dealing with risk and uncertainties (A. Nordmark, N. Benda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dealing-risk-and-uncertainties-nordmark-n-benda_en.pdf"},
    {"id":"25952","name":"Guidance on applications for potential high risk medicinal product trials - Brian Davis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/guidance-applications-potential-high-risk-medicinal-product-trials-brian-davis_en.pdf"},
    {"id":"25966","name":"Presentation - Possible scenarios to address issues in non-clinical studies for advanced-therapy medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-possible-scenarios-address-issues-non-clinical-studies-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"25967","name":"Presentation - PENTA-ID and Pharma collaborations Enpr-EMA 2013 (M. Sharland)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T16:00:00Z","last_updated_date":"2013-07-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-penta-id-and-pharma-collaborations-enpr-ema-2013-m-sharland_en.pdf"},
    {"id":"25973","name":"Presentation - United Kingdom's withdrawal from the European Union preparedness activities - Q&A session on PhV Brexit related topic (M. Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T15:08:00Z","last_updated_date":"2018-01-04T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-united-kingdoms-withdrawal-european-union-preparedness-activities-qa-session-phv-brexit-related-topic-m-pinheiro_en.pdf"},
    {"id":"25978","name":"Presentation - The risk-based approach for ATMP (Egbert Flory)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-12T19:00:00Z","last_updated_date":"2015-05-12T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-based-approach-atmp-egbert-flory_en.pdf"},
    {"id":"26002","name":"Presentation - Lessons learnt by EU regulators from the authorisations of foot-and-mouth disease, avian influenza, bluetongue and schmallenberg vaccines in the EU (Esther Werner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-14T17:20:00Z","last_updated_date":"2017-06-14T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lessons-learnt-eu-regulators-authorisations-foot-and-mouth-disease-avian-influenza-bluetongue-and-schmallenberg-vaccines-eu-esther-werner_en.pdf"},
    {"id":"26004","name":"Presentation - COMP update June 2015 (Daniel O’Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-10T18:30:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comp-update-june-2015-daniel-oconnor_en.pdf"},
    {"id":"26006","name":"Presentation - Innovation task force (ITF), Dr. Marisa Papaluca Amati","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovation-task-force-itf-dr-marisa-papaluca-amati_en.pdf"},
    {"id":"26027","name":"Presentation - Gadolinium-containing magnetic resonance contrast agents and communication practices in European Union Member States","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T01:00:00Z","last_updated_date":"2011-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gadolinium-containing-magnetic-resonance-contrast-agents-and-communication-practices-european-union-member-states_en.pdf"},
    {"id":"26035","name":"IMI strategic research agenda as it applies to surrogates - Lindpaintner","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/imi-strategic-research-agenda-it-applies-surrogates-lindpaintner_en.pdf"},
    {"id":"26036","name":"Presentation - Case study 3 - Use of prior knowledge in the control strategy for biotechnology products - Session 4 (Darrin Cowley, Jette Wypych)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-3-use-prior-knowledge-control-strategy-biotechnology-products-session-4-darrin-cowley-jette-wypych_en.pdf"},
    {"id":"26040","name":"Presentation - Framework of EMA interaction with patients’ and consumers’ organisations (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-framework-ema-interaction-patients-and-consumers-organisations-isabelle-moulon_en.pdf"},
    {"id":"26057","name":"Presentation - Multiplicity issues in Food and Drug Administration - reviewed clinical trials (Kathleen Fritsch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multiplicity-issues-food-and-drug-administration-reviewed-clinical-trials-kathleen-fritsch_en.pdf"},
    {"id":"26064","name":"Presentation - European Directorate for the Quality of Medicines and Healthcare (EDQM): The European Pharmacopoeia and certificates of suitability (CEP) (Andrew McMath)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-directorate-quality-medicines-and-healthcare-edqm-european-pharmacopoeia-and-certificates-suitability-cep-andrew-mcmath_en.pdf"},
    {"id":"26074","name":"Presentation - Highlights of the European Medicines Agency medical literature monitoring stakeholder survey (Thomas Paternoster-Howe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T16:15:00Z","last_updated_date":"2016-08-15T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-highlights-european-medicines-agency-medical-literature-monitoring-stakeholder-survey-thomas-paternoster-howe_en.pdf"},
    {"id":"26084","name":"Presentation - European Medicines Agency (EMA) update on Brexit preparedness activities and EMA working group on committees operational preparedness for veterinary medicines (Isaura Duarte, Tony Humphreys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-ema-update-brexit-preparedness-activities-and-ema-working-group-committees-operational-preparedness-veterinary-medicines-isaura-duarte-tony-humphreys_en.pdf"},
    {"id":"26085","name":"Presentation - Elderly patients and clinical trials: European Medicines Agency notes for guidance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-elderly-patients-and-clinical-trials-european-medicines-agency-notes-guidance_en.pdf"},
    {"id":"26109","name":"Presentation - Understanding off-label use and the information needs of patients: a pilot Eurordis survey in rare diseases (Rob Camp, Richard West)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-understanding-label-use-and-information-needs-patients-pilot-eurordis-survey-rare-diseases-rob-camp-richard-west_en.pdf"},
    {"id":"26135","name":"Presentation - Considerations on draft ESVAC strategy 2016-2020 from IFAH Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T17:00:00Z","last_updated_date":"2016-03-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-draft-esvac-strategy-2016-2020-ifah-europe_en.pdf"},
    {"id":"26143","name":"Presentation - Demonstration of efficacy for veterinary medicines containing antimicrobials (Gesine Hahn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-demonstration-efficacy-veterinary-medicines-containing-antimicrobials-gesine-hahn_en.pdf"},
    {"id":"26150","name":"Presentation - The scientific and regulatory approaches to facilitating disease-modifying drug development and registration in a global environment (Thomas Blaettler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-and-regulatory-approaches-facilitating-disease-modifying-drug-development-and-registration-global-environment-thomas-blaettler_en.pdf"},
    {"id":"26157","name":"Presentation - EMA experience on mHealth technology - EMA's PCWP and HCPWP joint meeting (Francesca Cerreta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-experience-mhealth-technology-emas-pcwp-and-hcpwp-joint-meeting-francesca-cerreta_en.pdf"},
    {"id":"26177","name":"Identity and access management (IAM2) training documentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-03T19:00:00Z","last_updated_date":"2018-07-03T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/identity-and-access-management-iam2-training-documentation_en.pdf"},
    {"id":"26183","name":"Presentation -  Public Hearings (Nathalie Bere) - Ninth industry stakeholder platform on the operation of EU pharmacovigilance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T01:00:00Z","last_updated_date":"2017-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-hearings-nathalie-bere-ninth-industry-stakeholder-platform-operation-eu-pharmacovigilance_en.pdf"},
    {"id":"26192","name":"Presentation - Evaluation of treatment effect in UC and CD (children) (Nick Croft)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluation-treatment-effect-uc-and-cd-children-nick-croft_en.pdf"},
    {"id":"26214","name":"Presentation - Overview of the new pharmacovigilance legislation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"26220","name":"Presentation - In vitro in vivo extrapolation (IVIVE): why it is not as easy as you may think (A.  Rostami)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T11:22:00Z","last_updated_date":"2017-11-15T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vitro-vivo-extrapolation-ivive-why-it-not-easy-you-may-think-rostami_en.pdf"},
    {"id":"26232","name":"Presentation - A new way of managing procedures - Pilot for Orphan Medicine designation activities (V. Johnson, P. Tomasi, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T01:00:00Z","last_updated_date":"2017-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-way-managing-procedures-pilot-orphan-medicine-designation-activities-v-johnson-p-tomasi-ema_en.pdf"},
    {"id":"26238","name":"Presentation - Special aspects of nanomedicines: development, manufacturing and characterisation, Simon Holland, GlaxoSmithKline","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-special-aspects-nanomedicines-development-manufacturing-and-characterisation-simon-holland-glaxosmithkline_en.pdf"},
    {"id":"26261","name":"Presentation - PBPK for Paediatric Development (R. Burghaus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pbpk-paediatric-development-r-burghaus_en.pdf"},
    {"id":"26265","name":"Presentation - European Group for Generic Veterinary Products (EGGVP): Concerns on data collection from MAHs (Elsa Vecino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-group-generic-veterinary-products-eggvp-concerns-data-collection-mahs-elsa-vecino_en.pdf"},
    {"id":"26286","name":"Presentation - Towards electronic product information in the EU - EMA action plan related to the European Commission’s recommendations on product information - EMA's PCWP and HCPWP joint meeting (A. Skarlatos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-towards-electronic-product-information-eu-ema-action-plan-related-european-commissions-recommendations-product-information-emas-pcwp-and-hcpwp-joint-meeting-skarlatos_en.pdf"},
    {"id":"26301","name":"Croatia - Agency for Medicinal Products and Medical Devices, S Tomic","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/croatia-agency-medicinal-products-medical-devices-s-tomic_en.pdf"},
    {"id":"26303","name":"Presentation - Guideline on good pharmacovigilance practices (GVP) - Module I: Pharmacovigilance systems and their quality systems","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-good-pharmacovigilance-practices-gvp-module-i-pharmacovigilance-systems-and-their-quality-systems_en.pdf"},
    {"id":"26306","name":"Presentation - Safety specification - Identification and methodologies, Annalisa Rubino, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safety-specification-identification-and-methodologies-annalisa-rubino-ema_en.pdf"},
    {"id":"26315","name":"Presentation - PRIME (Jordi Llinares and Zahra Hanaizi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T18:12:00Z","last_updated_date":"2016-10-26T18:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prime-jordi-llinares-and-zahra-hanaizi_en.pdf"},
    {"id":"26330","name":"Proteomics Analytical clinical and future aspects - H.H. Helgason","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-12-16T00:09:21Z","last_updated_date":"2005-12-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/proteomics-analytical-clinical-and-future-aspects-hh-helgason_en.pdf"},
    {"id":"26341","name":"Presentation - Dosing: examples from antipsychotics (Luca Pani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dosing-examples-antipsychotics-luca-pani_en.pdf"},
    {"id":"26367","name":"Quality Assessment & GMP - Similarities & Differences - Cormac Dalton","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/quality-assessment-gmp-similarities-differences-cormac-dalton_en.pdf"},
    {"id":"26388","name":"Presentation - Preclinical safety testing of enhanced-affinity TCRs for adoptive T-cell therapy (Andrew Gerry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T11:11:00Z","last_updated_date":"2016-12-02T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preclinical-safety-testing-enhanced-affinity-tcrs-adoptive-t-cell-therapy-andrew-gerry_en.pdf"},
    {"id":"26392","name":"Presentation - Implementation of the new pharmacovigilance legislation: Key achievements and status of prioritised implementation (Franck Diafouka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-new-pharmacovigilance-legislation-key-achievements-and-status-prioritised-implementation-franck-diafouka_en.pdf"},
    {"id":"26412","name":"Presentation - Case study 1- Use of prior knowledge to support specification setting for a multivalent vaccine - Session 4 (Charles Kline)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-1-use-prior-knowledge-support-specification-setting-multivalent-vaccine-session-4-charles-kline_en.pdf"},
    {"id":"26419","name":"Presentation - Operational definition of medication error for European Union reporting requirements (Thomas Goedecke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-operational-definition-medication-error-european-union-reporting-requirements-thomas-goedecke_en.pdf"},
    {"id":"26430","name":"Presentation - Equivalence vs. non-inferiority: Regulator‘s view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:55Z","last_updated_date":"2012-06-15T17:10:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-equivalence-vs-non-inferiority-regulators-view_en.pdf"},
    {"id":"26435","name":"Presentation - Regulatory perspective (Mario Miguel Rosa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspective-mario-miguel-rosa_en.pdf"},
    {"id":"26438","name":"Presentation - Holistic approach to paediatric research: European society for paediatric research (K. Allegaert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:04:00Z","last_updated_date":"2018-06-18T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-european-society-paediatric-research-k-allegaert_en.pdf"},
    {"id":"26450","name":"Presentation - Paediatric Pulmonary Arterial Hypertension: Regulators perspective on a global challenge (Cà©cile Ollivier, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-pulmonary-arterial-hypertension-regulators-perspective-global-challenge-caccile-ollivier-ema_en.pdf"},
    {"id":"26460","name":"Presentation - Breakout session -  Retinopathy of prematurity (Boubou Hallberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-retinopathy-prematurity-boubou-hallberg_en.pdf"},
    {"id":"26468","name":"Presentation - Update on EudraVigilance Auditable Requirements project (Georgy Genov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T16:03:00Z","last_updated_date":"2017-07-25T16:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-eudravigilance-auditable-requirements-project-georgy-genov_en.pdf"},
    {"id":"26516","name":"Presentation - Welcome to HunPedNet","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T16:02:00Z","last_updated_date":"2018-06-18T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-welcome-hunpednet_en.pdf"},
    {"id":"26538","name":"Consumer safety and MRLs, Isaura Duarte, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/consumer-safety-and-mrls-isaura-duarte-ema_en.pdf"},
    {"id":"26572","name":"Presentation - Considerations on guideline requirements in relation to homogeneity","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-guideline-requirements-relation-homogeneity_en.pdf"},
    {"id":"26573","name":"Presentation - New European Union pharmacovigilance legislation. Innovative industry’s perspective on implementation. First year experience (Laurent Auclert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-european-union-pharmacovigilance-legislation-innovative-industrys-perspective-implementation-first-year-experience-laurent-auclert_en.pdf"},
    {"id":"26574","name":"Presentation - The use of historical control data to assess the benefits of new therapies: A case study of blinatumomab versus standard therapy of adults relapsed/refractory acute lymphoblastic leukaemia (Maurille Feudjo...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-historical-control-data-assess-benefits-new-therapies-case-study-blinatumomab-versus-standard-therapy-adults-relapsedrefractory-acute-lymphoblastic-leukaemia-maurille-feudjo_en.pdf"},
    {"id":"26586","name":"Presentation - Future perspectives: how to better use the available data, how to fill the gaps in our knowledge about PK/PD, future ways on how knowledge can be obtained (Jà¶rg Kreuzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-future-perspectives-how-better-use-available-data-how-fill-gaps-our-knowledge-about-pkpd-future-ways-how-knowledge-can-be-obtained-japrg-kreuzer_en.pdf"},
    {"id":"26595","name":"Converting a biomarker to a surrogate - Andrew Stone and Andrew Hughes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/converting-biomarker-surrogate-andrew-stone-and-andrew-hughes_en.pdf"},
    {"id":"26614","name":"Presentation - Pharmacovigilance legislation present situation and perspectives for Polish patients (Rafal Swierzewski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-legislation-present-situation-and-perspectives-polish-patients-rafal-swierzewski_en.pdf"},
    {"id":"26629","name":"Presentation - Quality by design: A global implementation perspective. The European Union perspective (Riccardo Luigetti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-10-30T01:00:00Z","last_updated_date":"2008-10-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-design-global-implementation-perspective-european-union-perspective-riccardo-luigetti_en.pdf"},
    {"id":"26676","name":"Presentation - Class waiver list review: background, approach and outcome Consequences for regulatory submissions (Ralf Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-class-waiver-list-review-background-approach-and-outcome-consequences-regulatory-submissions-ralf-herold_en.pdf"},
    {"id":"26699","name":"Presentation - Presentation - Industry perspective on drug development for Type 1 SMA (Kathie Bishop)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-presentation-industry-perspective-drug-development-type-1-sma-kathie-bishop_en.pdf"},
    {"id":"26708","name":"Presentation -  Adaptive pathways: why involve other decision-makers (Sarah Garner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-pathways-why-involve-other-decision-makers-sarah-garner_en.pdf"},
    {"id":"26709","name":"Regulatory aspects of PK/PD - (modelling) - Karolina Torneke","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-09-24T02:09:21Z","last_updated_date":"2008-09-24T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/regulatory-aspects-pkpd-modelling-karolina-torneke_en.ppt"},
    {"id":"26726","name":"Presentation - Workshop on generation and use of health based exposure limits (J-L. Golnez, FAMHP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-generation-and-use-health-based-exposure-limits-j-l-golnez-famhp_en.pdf"},
    {"id":"26731","name":"Genetic variations and genomic biomarkers in cardiovascular medicines - Alhenc-Gelas","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-12-16T00:09:21Z","last_updated_date":"2005-12-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/genetic-variations-and-genomic-biomarkers-cardiovascular-medicines-alhenc-gelas_en.pdf"}    {"id":"26756","name":"Presentation - Section 4.9: Overdose","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-49-overdose_en.pdf"},
    {"id":"26757","name":"Perspective from Regional Harmonisation Initiative (RHI) - Saleh Bawazir","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/perspective-regional-harmonisation-initiative-rhi-saleh-bawazir_en.pdf"},
    {"id":"26771","name":"Presentation - Topic 1 - In vitro models and animal models (Debra Hanna)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-vitro-models-and-animal-models-debra-hanna_en.pdf"},
    {"id":"26779","name":"Presentation - Implementation of the pharmacovigilance legislation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-pharmacovigilance-legislation_en.pdf"},
    {"id":"26796","name":"Presentation - Update to the European Union guideline on antibacterial agents","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:52Z","last_updated_date":"2011-04-26T18:05:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-european-union-guideline-antibacterial-agents_en.pdf"},
    {"id":"26805","name":"Presentation - EMA’s perception survey (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-perception-survey-juan-garcia-burgos_en.pdf"},
    {"id":"26807","name":"Information on benefits and risks of medicines: Patients’, consumers’ and healthcare professionals’ expectations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-06T02:00:00Z","last_updated_date":"2009-07-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/information-benefits-and-risks-medicines-patients-consumers-and-healthcare-professionals-expectations_en.pdf"},
    {"id":"26810","name":"Presentation - Paediatric European Digestive Diseases Clinical Research Network Project (Nick Croft)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-european-digestive-diseases-clinical-research-network-project-nick-croft_en.pdf"},
    {"id":"26816","name":"Presentation - How the EMA EU support treatment development in rare diseases (Laura Fregonese)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-ema-eu-support-treatment-development-rare-diseases-laura-fregonese_en.pdf"},
    {"id":"26833","name":"Presentation - Encouraging paediatric clinical research in the European Union – current challenges (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-encouraging-paediatric-clinical-research-european-union-current-challenges-isabelle-moulon_en.pdf"},
    {"id":"26838","name":"Presentation - Norms related to ethical clinical trials - Patients' perspective (Nikos Dedes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-norms-related-ethical-clinical-trials-patients-perspective-nikos-dedes_en.pdf"},
    {"id":"26846","name":"Presentation - Licensing requirements for vaccines: US perspective (Larry R. Ludemann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T14:00:00Z","last_updated_date":"2015-04-29T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-licensing-requirements-vaccines-us-perspective-larry-r-ludemann_en.pdf"},
    {"id":"26854","name":"Presentation - Evaluation of patient reporting to the Yellow Card System","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:13Z","last_updated_date":"2011-06-24T22:06:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluation-patient-reporting-yellow-card-system_en.pdf"},
    {"id":"26883","name":"Presentation - Dravet Foundation: What does ‘personalised’ mean to patients and healthcare professionals - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dravet-foundation-what-does-personalised-mean-patients-and-healthcare-professionals-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint_en.pdf"},
    {"id":"26899","name":"Considerations on methodology, Study design and statistical Approaches - Gerard Pons","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-11T02:09:21Z","last_updated_date":"2006-10-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/considerations-methodology-study-design-and-statistical-approaches-gerard-pons_en.pdf"},
    {"id":"26902","name":"Enpr-EMA European Network of Paediatric Research at the European Medicines Agency - Background information","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-10-22T15:30:00Z","last_updated_date":"2012-10-22T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/enpr-ema-european-network-paediatric-research-european-medicines-agency-background-information_en.ppt"},
    {"id":"26917","name":"CVMP/SAGAM recommendations on antimicrobials - Karolina Tà¶rneke","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:09:21Z","last_updated_date":"2009-05-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/cvmpsagam-recommendations-antimicrobials-karolina-taprneke_en.pdf"},
    {"id":"26918","name":"Presentation - Use of quantitative tools for study planning purposes and study design optimisation (V. Gigante, AIFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-quantitative-tools-study-planning-purposes-and-study-design-optimisation-v-gigante-aifa_en.pdf"},
    {"id":"26940","name":"Presentation - GMP inspection system in the EEA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gmp-inspection-system-eea_en.pdf"},
    {"id":"26958","name":"Clinical trials in Europe - Introductory remarks, Dr Chantal Bà©lorgey","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/clinical-trials-europe-introductory-remarks-dr-chantal-baclorgey_en.pdf"},
    {"id":"26971","name":"Questions on session 3: Focus group 'incentives for academia, hospitals and charities developing advanced-therapy medicinal products'","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/questions-session-3-focus-group-incentives-academia-hospitals-and-charities-developing-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"26981","name":"Safety monitoring and reporting, Dr Ingrid Wallenbeck","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/safety-monitoring-and-reporting-dr-ingrid-wallenbeck_en.pdf"},
    {"id":"26992","name":"Presentation - Holistic approach to paediatric research: multistakeholder collaboration (C. Ollivier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:04:00Z","last_updated_date":"2018-06-18T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-multistakeholder-collaboration-c-ollivier_en.pdf"},
    {"id":"26995","name":"Presentation - The European Clinical Trials Register (EU-CTR V1.1)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-clinical-trials-register-eu-ctr-v11_en.pdf"},
    {"id":"27008","name":"A Workshop on Bio-Markers EMEA / CHMP meeting - Introduction - Daniel Brasseur","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-12-16T00:09:21Z","last_updated_date":"2005-12-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/workshop-bio-markers-emea-chmp-meeting-introduction-daniel-brasseur_en.pdf"},
    {"id":"27056","name":"Initiative of the EU Commission: Follow up to the Public consultation on the future of the pharmaceutical sector - Martin Terberger","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/initiative-eu-commission-follow-public-consultation-future-pharmaceutical-sector-martin-terberger_en.pdf"},
    {"id":"27059","name":"Presentation - Meta-analyses of clinical dose response (N. Thomas,  D. Roy, V. Somayaji, K. Sweeney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-meta-analyses-clinical-dose-response-n-thomas-d-roy-v-somayaji-k-sweeney_en.pdf"},
    {"id":"27062","name":"Presentation - EudraVigilance – new functionalities and EudraVigilance access policy (patient access) (S. Brosch, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-new-functionalities-and-eudravigilance-access-policy-patient-access-s-brosch-ema_en.pdf"},
    {"id":"27064","name":"Presentation - Safety – immune related adverse events (irAE) focus on non-small cell lung cancer (NSCLC) (Aaron Hansen) - S2.7","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safety-immune-related-adverse-events-irae-focus-non-small-cell-lung-cancer-nsclc-aaron-hansen-s27_en.pdf"},
    {"id":"27070","name":"Presentation - Key points from session 2: registries (Christine Keipert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-points-session-2-registries-christine-keipert_en.pdf"},
    {"id":"27099","name":"Presentation - Supply shortages of medicines in Europe (Franà§ois Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supply-shortages-medicines-europe-franassois-houyez_en.pdf"},
    {"id":"27111","name":"Presentation - Dose and schedule determination and amendments of EU centrally approved products (CAPs) (Falk Ehmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-and-schedule-determination-and-amendments-eu-centrally-approved-products-caps-falk-ehmann_en.pdf"},
    {"id":"27117","name":"Presentation - Summary of discussions - Consultation meeting with stakeholders: Request from EC for advice on the impact on public and animal health of the use of antibiotics in animals (Jordi Torren-Edo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-discussions-consultation-meeting-stakeholders-request-ec-advice-impact-public-and-animal-health-use-antibiotics-animals-jordi-torren-edo_en.pdf"},
    {"id":"27121","name":"Presentation - Survey to estimate patients and HCP awareness of the additional monitoring concept (Justina Januskiene, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-estimate-patients-and-hcp-awareness-additional-monitoring-concept-justina-januskiene-ema_en.pdf"},
    {"id":"27135","name":"Presentation - Medication errors: older patients and their caregivers (Denis O’Mahony)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medication-errors-older-patients-and-their-caregivers-denis-omahony_en.pdf"},
    {"id":"27141","name":"Presentation - European Medicines Agency geriatric medicines strategy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-geriatric-medicines-strategy_en.pdf"},
    {"id":"27160","name":"Presentation - Periodic safety update reports (PSUR) repository and the EU single assessment (Irene Rager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-periodic-safety-update-reports-psur-repository-and-eu-single-assessment-irene-rager_en.pdf"},
    {"id":"27164","name":"Presentation - SMA type I  outcome measures (Basil Darras)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sma-type-i-outcome-measures-basil-darras_en.pdf"},
    {"id":"27169","name":"Presentation - Decision making, revisited","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-decision-making-revisited_en.pdf"},
    {"id":"27179","name":"Imaging Biomarkers - Utilisation for the purpose of registration - Vennart","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/imaging-biomarkers-utilisation-purpose-registration-vennart_en.pdf"},
    {"id":"27208","name":"The EMEA policy on invented names Zaide Frias - EMEA - Chair of Name Review Group","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-policy-invented-names-zaide-frias-emea-chair-name-review-group_en.pdf"},
    {"id":"27210","name":"Presentation - IFAH-Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ifah-europe_en.pdf"},
    {"id":"27211","name":"Presentation - Communication-liaison between veterinarians and competent authorities - Role of national veterinarian associations (T.Chambon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-liaison-between-veterinarians-and-competent-authorities-role-national-veterinarian-associations-tchambon_en.pdf"},
    {"id":"27230","name":"Presentation - e-Paediatrics: electronic distribution of application documents to PDCO, and of PDCO opinions and EMA decisions to applicants (Paolo Tomasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T17:00:00Z","last_updated_date":"2016-05-27T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-e-paediatrics-electronic-distribution-application-documents-pdco-and-pdco-opinions-and-ema-decisions-applicants-paolo-tomasi_en.pdf"},
    {"id":"27233","name":"Presentation - Risk communication in a more transparent regulatory environment (Frederic Bouder)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-communication-more-transparent-regulatory-environment-frederic-bouder_en.pdf"},
    {"id":"27238","name":"Presentation - Guideline on similar biological medicinal products\n\ncontaining biotechnology-derived proteins as active substance: quality\n\nissues (Niklas Ekman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality-issues-niklas-ekman_en.pdf"},
    {"id":"27245","name":"Presentation - Lumpy skin disease experience in Greece (Sotiria-Eleni Antoniou and Ioannis Malemis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T11:37:00Z","last_updated_date":"2017-05-18T11:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lumpy-skin-disease-experience-greece-sotiria-eleni-antoniou-and-ioannis-malemis_en.pdf"},
    {"id":"27247","name":"Presentation - Section 4.5: Interaction with other medicinal products and other forms of interaction","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-45-interaction-other-medicinal-products-other-forms-interaction_en.pdf"},
    {"id":"27256","name":"Presentation - Performance indicator questionnaire analysis 2010","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-23T02:00:00Z","last_updated_date":"2011-05-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-performance-indicator-questionnaire-analysis-2010_en.pdf"},
    {"id":"27262","name":"Presentation - EMA workshop on adaptive pathways: PCWP and HCPWP contribution (Francesca Cerreta, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-workshop-adaptive-pathways-pcwp-and-hcpwp-contribution-francesca-cerreta-ema_en.pdf"},
    {"id":"27263","name":"Presentation - The challenges of the different stakeholders: an academic perspective (Heinz Zwierzina) - S1.2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-different-stakeholders-academic-perspective-heinz-zwierzina-s12_en.pdf"},
    {"id":"27267","name":"Presentation - Adaptive Pathways: Can we build better links between decision makers? (Francesca Cerreta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-pathways-can-we-build-better-links-between-decision-makers-francesca-cerreta_en.pdf"},
    {"id":"27277","name":"Presentation - Modelling and simulation to characterise risk-benefit and support label claims - Break-out session 4 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:15:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-characterise-risk-benefit-and-support-label-claims-break-out-session-4-theme-3_en.pdf"},
    {"id":"27285","name":"Presentation - Topic 4 - Paediatric investigation plans (PIPs): problems and solutions - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Stephanie Laer, Jenny Walsh, Gene De...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-4-paediatric-investigation-plans-pips-problems-and-solutions-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-stephanie-laer-jenny-walsh-gene-de_en.pdf"},
    {"id":"27287","name":"Questions/comments received after the conference","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-03T02:09:21Z","last_updated_date":"2007-10-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/questionscomments-received-after-conference_en.pdf"},
    {"id":"27293","name":"Presentation - Committee for Advanced Therapies interested parties focus group 3 on incentives for academia, hospitals and charities: Objectives and outcome of the focus group meeting in 2011","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-advanced-therapies-interested-parties-focus-group-3-incentives-academia-hospitals-and-charities-objectives-and-outcome-focus-group-meeting-2011_en.pdf"},
    {"id":"27299","name":"Presentation - Day 1: Advanced therapy in retinal and macular degeneration","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-advanced-therapy-retinal-and-macular-degeneration_en.pdf"},
    {"id":"27310","name":"Presentation - Day 1: The orphan perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-orphan-perspective_en.pdf"},
    {"id":"27312","name":"Presentation - Opportunities for public-private partnerships in pediatric research networks (Charles Thomson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-public-private-partnerships-pediatric-research-networks-charles-thomson_en.pdf"},
    {"id":"27315","name":"Presentation - Integrated management of helminths in goats and cattle (Carine Paraud)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-integrated-management-helminths-goats-and-cattle-carine-paraud_en.pdf"},
    {"id":"27326","name":"Presentation - Impact of Brexit on veterinary applications/marketing authorisations (Sandra Vanlievendael, Beyhan Mustafov, Andrei Spinei)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-brexit-veterinary-applicationsmarketing-authorisations-sandra-vanlievendael-beyhan-mustafov-andrei-spinei_en.pdf"},
    {"id":"27328","name":"Presentation - Introduction to the summary-of-product-characteristics guideline","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2013-01-21T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-summary-product-characteristics-guideline_en.pdf"},
    {"id":"27330","name":"Presentation - Strategies to support neonatal development in Europe (Dirk Mentzer, Ine Skottheim-Rusten)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T02:00:00Z","last_updated_date":"2015-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strategies-support-neonatal-development-europe-dirk-mentzer-ine-skottheim-rusten_en.pdf"},
    {"id":"27335","name":"Nonclinical evaluation for anticancer pharmaceuticals - Step 2 - Klaus Olejniczak","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/nonclinical-evaluation-anticancer-pharmaceuticals-step-2-klaus-olejniczak_en.pdf"},
    {"id":"27336","name":"Presentation - Completion of the development of a formulation: Requirements for compliance check vs. requirements for marketing authorisation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-completion-development-formulation-requirements-compliance-check-vs-requirements-marketing-authorisation_en.pdf"},
    {"id":"27350","name":"Presentation - The changing diagnostic criteria for Alzheimer's disease - regulatory challenges (Marion Haberkamp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-changing-diagnostic-criteria-alzheimers-disease-regulatory-challenges-marion-haberkamp_en.pdf"},
    {"id":"27366","name":"Presentation - Agenda item 2: update on international activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2015-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-2-update-international-activities_en.pdf"},
    {"id":"27370","name":"Presentation - Health-technology assessment of companion diagnostics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-health-technology-assessment-companion-diagnostics_en.pdf"},
    {"id":"27373","name":"Presentation - 10-Year anniversary of the SME Office (Constantinos Ziogas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-10-year-anniversary-sme-office-constantinos-ziogas_en.pdf"},
    {"id":"27387","name":"Presentation - The interface: Industry – CRO - Clinical trials networks (Andrew Rose, MCRN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interface-industry-cro-clinical-trials-networks-andrew-rose-mcrn_en.pdf"},
    {"id":"27415","name":"Presentation - A modelling and simulation perspective on extrapolation (Ine Skottheim Rusten)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-perspective-extrapolation-ine-skottheim-rusten_en.pdf"},
    {"id":"27419","name":"Presentation - Session 5: Approval of pembrolizumab (MSI-H/dMMR) and considerations for site-agnostic development of drugs in oncology (Steven Lemery)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-approval-pembrolizumab-msi-hdmmr-and-considerations-site-agnostic-development-drugs-oncology-steven-lemery_en.pdf"},
    {"id":"27426","name":"Presentation - How to integrate risk assessment and risk stratification into a risk-based approach for immunogenicity assessment (Christian Schneider)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-integrate-risk-assessment-and-risk-stratification-risk-based-approach-immunogenicity-assessment-christian-schneider_en.pdf"},
    {"id":"27448","name":"Presentation - Day 1: Advanced therapy in retinal disease regulatory view CAT","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-advanced-therapy-retinal-disease-regulatory-view-cat_en.pdf"},
    {"id":"27451","name":"Authorising Antimicrobials based on Fluoroquinolones - Steve Dean","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/authorising-antimicrobials-based-fluoroquinolones-steve-dean_en.pdf"},
    {"id":"27461","name":"Presentation - Session 1: FDA experience with the sentinel common data model: addressing data sufficiency (Michael D. Nguyen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-fda-experience-sentinel-common-data-model-addressing-data-sufficiency-michael-d-nguyen_en.pdf"},
    {"id":"27462","name":"Presentation - Implementing ISO ICSR/ICH E2B(R3): key changes for pharmacovigilance - training module PhV-M2a","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2016-10-10T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementing-iso-icsrich-e2br3-key-changes-pharmacovigilance-training-module-phv-m2a_en.pdf"},
    {"id":"27464","name":"Presentation - Special aspects of nanomedicines: Viewpoint from the industry, Jan Mà¶schwitzer, Abbott Healthcare Products B.V.","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-special-aspects-nanomedicines-viewpoint-industry-jan-mapschwitzer-abbott-healthcare-products-bv_en.pdf"},
    {"id":"27477","name":"Presentation - Reporting of adverse drug reactions by patients and consumers (Sabine Brosch, Victoria Newbould)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reporting-adverse-drug-reactions-patients-and-consumers-sabine-brosch-victoria-newbould_en.pdf"},
    {"id":"27478","name":"Presentation - Topic 1 - Patients perspective: PHA Europe - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Hall Skà¥ra)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-patients-perspective-pha-europe-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-hall-skayra_en.pdf"},
    {"id":"27487","name":"Presentation - Accelerating drug development for Alzheimer’s disease through regulatory science (Martha Brumfield)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accelerating-drug-development-alzheimers-disease-through-regulatory-science-martha-brumfield_en.pdf"},
    {"id":"27493","name":"Presentation - Clarification of MUMS policy (David Murphy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clarification-mums-policy-david-murphy_en.pdf"},
    {"id":"27505","name":"Presentation - Collaborative data resources: TIPharma pharmacokinetic-pharmacodynamic modelling platform - Break-out session 1 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:45:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collaborative-data-resources-tipharma-pharmacokinetic-pharmacodynamic-modelling-platform-break-out-session-1-theme-3_en.pdf"},
    {"id":"27508","name":"Presentation - Survey to National Competent Authorities in EU (Maria Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-national-competent-authorities-eu-maria-mavris_en.pdf"},
    {"id":"27529","name":"Presentation - Expectations for the European Network of Paediatric Research at the European Medicines Agency from a small- and medium-sized-enterprise perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:00Z","last_updated_date":"2011-05-27T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-expectations-european-network-paediatric-research-european-medicines-agency-small-and-medium-sized-enterprise-perspective_en.pdf"},
    {"id":"27579","name":"Neural stem cells: Prof Gianvito Martino, Division of Neuroscience San Raffaele Hospital, Italy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/neural-stem-cells-prof-gianvito-martino-division-neuroscience-san-raffaele-hospital-italy_en.pdf"},
    {"id":"27588","name":"Pharmacovigilance and risk management - F. Maignen","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pharmacovigilance-and-risk-management-f-maignen_en.pdf"},
    {"id":"27622","name":"Presentation - One PIP or multiple PIPs? - EMA policy on changes in scope of PIP Decisions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-one-pip-or-multiple-pips-ema-policy-changes-scope-pip-decisions_en.pdf"},
    {"id":"27639","name":"Resistance against anti-microbial resistance: Veterinarians' goals and initiative - Jan Vaarten","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/resistance-against-anti-microbial-resistance-veterinarians-goals-and-initiative-jan-vaarten_en.pdf"},
    {"id":"27657","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - The Patient's Perspective - Rodney Elgie","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-patients-perspective-rodney-elgie_en.pdf"},
    {"id":"27675","name":"Presentation - Update on the list of Union reference dates and frequency of periodic-safety-update-report submission","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-list-union-reference-dates-and-frequency-periodic-safety-update-report-submission_en.pdf"},
    {"id":"27685","name":"Presentation - Community counts! CDC Public Health Surveillance for Bleeding Disorders (Mike Soucie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-community-counts-cdc-public-health-surveillance-bleeding-disorders-mike-soucie_en.pdf"},
    {"id":"27704","name":"Presentation - Induction and maintenance of remission in IBD: Where are we coming from; Where could we go? (Geert D’Haens)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-induction-and-maintenance-remission-ibd-where-are-we-coming-where-could-we-go-geert-dhaens_en.pdf"},
    {"id":"27721","name":"Immunogenicity: Impact on the Design of Clinical Trials for Biosimilars - Alexander Berghout","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-09-04T02:09:21Z","last_updated_date":"2007-09-04T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/immunogenicity-impact-design-clinical-trials-biosimilars-alexander-berghout_en.pdf"},
    {"id":"27732","name":"Presentation - Changes in Patient Population - Insufficient Treatment Response (Gordon Francis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-changes-patient-population-insufficient-treatment-response-gordon-francis_en.pdf"},
    {"id":"27743","name":"GxP Inspections and related IWGs, A Rodriguez, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gxp-inspections-and-related-iwgs-rodriguez-ema_en.pdf"},
    {"id":"27748","name":"Presentation - Working Group on ethics update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-18T13:40:00Z","last_updated_date":"2017-12-18T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-ethics-update_en.pdf"},
    {"id":"27801","name":"Presentation - SME workshop: Session 1: Statistical common types of clinical trial design, study objectives, randomisation and blinding, hypothesis testing, p-values and confidence intervals, sample size calculation (Dav...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-29T10:40:00Z","last_updated_date":"2016-02-29T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-workshop-session-1-statistical-common-types-clinical-trial-design-study-objectives-randomisation-and-blinding-hypothesis-testing-p-values-and-confidence-intervals-sample-size_en.pdf"},
    {"id":"27814","name":"Presentation - Brexit: implications for companies (Rick Clayton)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-brexit-implications-companies-rick-clayton_en.pdf"},
    {"id":"27828","name":"Presentation - Impact on administrative burden and fees (Rose-Marie Molina)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-administrative-burden-and-fees-rose-marie-molina_en.pdf"}    {"id":"27835","name":"Presentation - FranceCoag network (Roseline d'Oiron)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-francecoag-network-roseline-doiron_en.pdf"},
    {"id":"27858","name":"Presentation - Scientific advice throughout the life-cycle of the product (Spiros Vamvakas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advice-throughout-life-cycle-product-spiros-vamvakas_en.pdf"},
    {"id":"27861","name":"Presentation - Session 1: Use of real world data pre-authorisation – what can it answer? (Peter Mol)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-use-real-world-data-pre-authorisation-what-can-it-answer-peter-mol_en.pdf"},
    {"id":"27893","name":"Presentation - Adoption of the procedural advice on the evaluation of advanced therapy medicinal product in accordance with Article 8 of Regulation (EC) No 1394/2007","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-01T11:40:00Z","last_updated_date":"2018-02-01T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adoption-procedural-advice-evaluation-advanced-therapy-medicinal-product-accordance-article-8-regulation-ec-no-13942007_en.pdf"},
    {"id":"27907","name":"Presentation - GVP V update (Corinne de Vries)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T16:00:00Z","last_updated_date":"2015-06-25T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gvp-v-update-corinne-de-vries_en.pdf"},
    {"id":"27912","name":"Presentation - Traceability of biopharmaceuticals in spontaneous reporting systems","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-traceability-biopharmaceuticals-spontaneous-reporting-systems_en.pdf"},
    {"id":"27913","name":"Presentation - Considerations for Implementing the EMA Extrapolation Approach: A Global Drug Developer’s Perspective (Christina Bucci-Rechtweg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-implementing-ema-extrapolation-approach-global-drug-developers-perspective-christina-bucci-rechtweg_en.pdf"},
    {"id":"27935","name":"Presentation - How should antibodies against monoclonal antibody therapeutics be assessed?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:45Z","last_updated_date":"2012-06-15T17:10:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-should-antibodies-against-monoclonal-antibody-therapeutics-be-assessed_en.pdf"},
    {"id":"27970","name":"Presentation - State of health in the EU: the community pharmacy contribution (Jamie Wilkinson, PGEU)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-state-health-eu-community-pharmacy-contribution-jamie-wilkinson-pgeu_en.pdf"},
    {"id":"27973","name":"Presentation - The Italian natalizumab registry, G. Tedeschi","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-italian-natalizumab-registry-g-tedeschi_en.pdf"},
    {"id":"27989","name":"Presentation - Extrapolation for antiepileptic drugs (AED) in paediatrics (G. Pons, C. Chiron)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extrapolation-antiepileptic-drugs-aed-paediatrics-g-pons-c-chiron_en.pdf"},
    {"id":"27990","name":"International Harmonisation of pharmacopoeial monographs - Michael Wierer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/international-harmonisation-pharmacopoeial-monographs-michael-wierer_en.pdf"},
    {"id":"27998","name":"Presentation - Implementation report on the patient safety recommendation 2009/C151/01 (Directorate General for Health and Consumers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-report-patient-safety-recommendation-2009c15101-directorate-general-health-and-consumers_en.pdf"},
    {"id":"28009","name":"Presentation - General principles of antiviral dose selection (Filip Josephson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-principles-antiviral-dose-selection-filip-josephson_en.pdf"},
    {"id":"28019","name":"Presentation - EMA monitoring sales of veterinary antimicrobial agents in Europe (Jan Vaarten)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-22T13:01:29Z","last_updated_date":"2010-12-22T13:01:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-monitoring-sales-veterinary-antimicrobial-agents-europe-jan-vaarten_en.pdf"},
    {"id":"28022","name":"Presentation - Patients and healthcare professionals involvement in regulatory decisions - MPA (Jane Ahlqvist Rastad)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-and-healthcare-professionals-involvement-regulatory-decisions-mpa-jane-ahlqvist-rastad_en.pdf"},
    {"id":"28031","name":"Presentation - The new outcome measures in MS: possible better ways to assess disability that overcome the limitations of the EDSS (Gilmore O'Neill)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-outcome-measures-ms-possible-better-ways-assess-disability-overcome-limitations-edss-gilmore-oneill_en.pdf"},
    {"id":"28035","name":"Presentation - Measuring concentrations of Rivaroxaban, Apixaban, Edoxaban: methods and challenges (Steve Kitchen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-measuring-concentrations-rivaroxaban-apixaban-edoxaban-methods-and-challenges-steve-kitchen_en.pdf"},
    {"id":"28066","name":"Presentation - Advanced cell models, organs on a chip and\n\nmicrophysiological systems in drug development (A. Roth)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T10:54:00Z","last_updated_date":"2017-11-15T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advanced-cell-models-organs-chip-and-microphysiological-systems-drug-development-roth_en.pdf"},
    {"id":"28078","name":"Presentation - Good pharmacovigilance practices module II: Pharmacovigilance system master file","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file_en.pdf"},
    {"id":"28086","name":"Presentation - Take-home messages (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-13T01:00:00Z","last_updated_date":"2017-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-take-home-messages-juan-garcia-burgos_en.pdf"},
    {"id":"28127","name":"Presentation - EU network pharmacovigilance governance (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-network-pharmacovigilance-governance-peter-arlett_en.pdf"},
    {"id":"28145","name":"Presentation - Elemental impurity risk assessment: case studies (Andrew Teasdale, Laura Rutter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-elemental-impurity-risk-assessment-case-studies-andrew-teasdale-laura-rutter_en.pdf"},
    {"id":"28158","name":"Presentation - Statisticians perspectives on extrapolation (D. Wright)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-statisticians-perspectives-extrapolation-d-wright_en.pdf"},
    {"id":"28183","name":"Presentation - Breakout session 1: Principles and policy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T17:35:00Z","last_updated_date":"2013-11-27T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-1-principles-and-policy_en.pdf"},
    {"id":"28203","name":"Presentation - The first experience with the newly launched Parallel Consultations (C. Guilhaume, EUnetTHA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T01:00:00Z","last_updated_date":"2017-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-first-experience-newly-launched-parallel-consultations-c-guilhaume-eunettha_en.pdf"},
    {"id":"28224","name":"Presentation - SME workshop: Session 3: Statistical considerations in confirmatory clinical trials I (Norbert Benda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-29T10:40:00Z","last_updated_date":"2016-02-29T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-workshop-session-3-statistical-considerations-confirmatory-clinical-trials-i-norbert-benda_en.pdf"},
    {"id":"28227","name":"Towards Quality by Design: Modelling Nano-Particles & their Formulation in Relation to Product Physical Properties - Kevin J Roberts","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-29T02:09:21Z","last_updated_date":"2009-04-29T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/towards-quality-design-modelling-nano-particles-their-formulation-relation-product-physical-properties-kevin-j-roberts_en.pdf"},
    {"id":"28232","name":"Herbal medicinal producta: New Committee & European dimension, 23 September 2004 - Dagmar Roth-Behrendt","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-09-27T02:09:21Z","last_updated_date":"2004-09-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/herbal-medicinal-producta-new-committee-european-dimension-23-september-2004-dagmar-roth-behrendt_en.pdf"},
    {"id":"28234","name":"Demonstration of Relevance of the Animal Model - B. Silva Lima","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T02:09:21Z","last_updated_date":"2007-06-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/demonstration-relevance-animal-model-b-silva-lima_en.pdf"},
    {"id":"28236","name":"Presentation - Open discussion","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-open-discussion_en.pdf"},
    {"id":"28243","name":"Presentation - PD targets for various infection types: Stasis vs. 1-Log Kill vs. 2 Log Kill (George Drusano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pd-targets-various-infection-types-stasis-vs-1-log-kill-vs-2-log-kill-george-drusano_en.pdf"},
    {"id":"28257","name":"Presentation - Day 2: Ocular surface biomarkers and inflammation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-ocular-surface-biomarkers-and-inflammation_en.pdf"},
    {"id":"28262","name":"Presentation - Diabetes and endocrinology European research network (David Dunger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T16:00:00Z","last_updated_date":"2013-07-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-diabetes-and-endocrinology-european-research-network-david-dunger_en.pdf"},
    {"id":"28267","name":"Presentation - The Joint Programming Initiative: translate research into policy and regulation (Herman Goossens)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-programming-initiative-translate-research-policy-and-regulation-herman-goossens_en.pdf"},
    {"id":"28269","name":"Presentation - Diagnosing PML, Joseph Berger","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-diagnosing-pml-joseph-berger_en.pdf"},
    {"id":"28270","name":"Presentation - Holistic approach to paediatric research: industry perspective (T. Tillmann, L.R. Arfelt, M. Dehlinger-Kremer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:00:00Z","last_updated_date":"2018-06-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-industry-perspective-t-tillmann-lr-arfelt-m-dehlinger-kremer_en.pdf"},
    {"id":"28273","name":"Presentation - Framework on the interaction between the European Medicines Agency and healthcare professionals (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-framework-interaction-between-european-medicines-agency-and-healthcare-professionals-ivana-silva_en.pdf"},
    {"id":"28277","name":"Presentation - Intestinal Pseudo-obstruction (Gut Motility Disorders) (Nikhil Thapar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-intestinal-pseudo-obstruction-gut-motility-disorders-nikhil-thapar_en.pdf"},
    {"id":"28306","name":"Presentation - Day 1: Dry AMD - the regulatory view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-dry-amd-regulatory-view_en.pdf"},
    {"id":"28312","name":"Presentation - Data exclusivity, market protection and paediatric rewards (Zaide Frias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-exclusivity-market-protection-and-paediatric-rewards-zaide-frias_en.pdf"},
    {"id":"28313","name":"Presentation - European Network for Health Technology Assessment joint action 2 work programme 7: Multi-health-technology-assessment early dialogues (Mira Pavlovic, Francois Meyer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-health-technology-assessment-joint-action-2-work-programme-7-multi-health-technology-assessment-early-dialogues-mira-pavlovic-francois-meyer_en.pdf"},
    {"id":"28314","name":"Honey bee diseases in France, Marie-Pierre Chauzat, Agence Franà§aise de Sà©curità© Sanitaire des Produits de Santà©","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/honey-bee-diseases-france-marie-pierre-chauzat-agence-franassaise-de-saccuritac-sanitaire-des-produits-de-santac_en.pdf"},
    {"id":"28318","name":"Presentation - Process validation: Enhanced approach scale down models (Frank Zettl)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-process-validation-enhanced-approach-scale-down-models-frank-zettl_en.pdf"},
    {"id":"28334","name":"Presentation - Herbal summaries for the public (Jill Kieffer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-herbal-summaries-public-jill-kieffer_en.pdf"},
    {"id":"28342","name":"Presentation - EMA Policy on the Handling of Conflicts of Interests of Scientific Committee Members and Experts","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-07T01:00:00Z","last_updated_date":"2011-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-policy-handling-conflicts-interests-scientific-committee-members-and-experts_en.pdf"},
    {"id":"28349","name":"Serbia - Ministry of Health, Z Pavlovic","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/serbia-ministry-health-z-pavlovic_en.pdf"},
    {"id":"28352","name":"Presentation - 10 year report to the European Commission on the public health effects of the Paediatric Regulation: request for data collection from the Enpr-EMA networks (Benjamin Pelle & Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-10-year-report-european-commission-public-health-effects-paediatric-regulation-request-data-collection-enpr-ema-networks-benjamin-pelle-irmgard-eichler_en.pdf"},
    {"id":"28384","name":"Presentation: Applied ethics & societal aspects in applied human\n\npharmacology","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-08-20T02:00:00Z","last_updated_date":"2010-08-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-applied-ethics-societal-aspects-applied-human-pharmacology_en.pdf"},
    {"id":"28388","name":"Focus Group meeting on Bioequivalence - IFAH-Europe topics for discussion","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-06T02:09:21Z","last_updated_date":"2009-05-06T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/focus-group-meeting-bioequivalence-ifah-europe-topics-discussion_en.pdf"},
    {"id":"28392","name":"Presentation - Module 4 - Advanced therapy medicinal products (ATMPs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-4-advanced-therapy-medicinal-products-atmps_en.pdf"},
    {"id":"28398","name":"Presentation: Copa-Cogeca’s views on Critically Important Antibiotics (CIA) (Miguel Angel Higuera)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-copa-cogecas-views-critically-important-antibiotics-cia-miguel-angel-higuera_en.pdf"},
    {"id":"28399","name":"Presentation - Advanced-therapy medicinal product (ATMP) development challenges: From scientific advice to market authorisation (Peter McArdle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advanced-therapy-medicinal-product-atmp-development-challenges-scientific-advice-market-authorisation-peter-mcardle_en.pdf"},
    {"id":"28405","name":"Presentation - Paediatric investigation plans for medicines to treat high-grade glioma","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-06T02:00:00Z","last_updated_date":"2011-07-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-investigation-plans-medicines-treat-high-grade-glioma_en.pdf"},
    {"id":"28416","name":"Presentation - Safety communication and its role in risk minimisation (June M Raine, Juan Garcia-Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safety-communication-and-its-role-risk-minimisation-june-m-raine-juan-garcia-burgos_en.pdf"},
    {"id":"28433","name":"Presentation - Procedure for election of PCWP Co-Chair 2013-2016","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-12-11T01:00:00Z","last_updated_date":"2013-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-procedure-election-pcwp-co-chair-2013-2016_en.pdf"},
    {"id":"28437","name":"Fluoroquinolones and the SOS response - Cà³ilà­n Nunan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/fluoroquinolones-and-sos-response-ca3ila-n-nunan_en.pdf"},
    {"id":"28438","name":"Presentation - Genomics in science and clinical care","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-genomics-science-and-clinical-care_en.pdf"},
    {"id":"28440","name":"Presentation - ERN case studies: BOND ERN (Luca Sangiorgi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ern-case-studies-bond-ern-luca-sangiorgi_en.pdf"},
    {"id":"28470","name":"Presentation - Update on Working Group 10 (Mark Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-working-group-10-mark-turner_en.pdf"},
    {"id":"28474","name":"Presentation - Implementation of the new pharmacovigilance legislation: update on status (Franck Diafouka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-new-pharmacovigilance-legislation-update-status-franck-diafouka_en.pdf"},
    {"id":"28495","name":"Presentation - Relaunch of EMA corporate website- EMA's PCWP and HCPWP joint meeting (Angela-Christina Schmidt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-relaunch-ema-corporate-website-emas-pcwp-and-hcpwp-joint-meeting-angela-christina-schmidt_en.pdf"},
    {"id":"28502","name":"Presentation - Good pharmacovigilance practices module X - additional monitoring of medicines (Mick Foy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-module-x-additional-monitoring-medicines-mick-foy_en.pdf"},
    {"id":"28505","name":"Presentation - BMWP-Interested Party Meeting 2017 (C. Vleminckx, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bmwp-interested-party-meeting-2017-c-vleminckx-ema_en.pdf"},
    {"id":"28531","name":"Presentation - From Social to Medical: How is digital information being used? (Ciro Cattuto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-social-medical-how-digital-information-being-used-ciro-cattuto_en.pdf"},
    {"id":"28542","name":"Presentation - Periodic safety update reports under the new European Union pharmacovigilance legislation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-periodic-safety-update-reports-under-new-european-union-pharmacovigilance-legislation_en.pdf"},
    {"id":"28543","name":"Presentation - Extrapolation: which is the patient perspective? (Marco Greco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extrapolation-which-patient-perspective-marco-greco_en.pdf"},
    {"id":"28546","name":"Presentation - Proposal for EU network of patients acting as contact point for PhV (F. Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T17:06:00Z","last_updated_date":"2017-12-11T17:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposal-eu-network-patients-acting-contact-point-phv-f-houyez_en.pdf"},
    {"id":"28574","name":"Presentation - PedNet registry (Rolf Ljung)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pednet-registry-rolf-ljung_en.pdf"},
    {"id":"28579","name":"Presentation: Improving new drug development for children and adolescents: The ACCELERATE initiative","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-improving-new-drug-development-children-and-adolescents-accelerate-initiative_en.pdf"},
    {"id":"28593","name":"Presentation - European Medicines Agency progress and status - what is needed to document scientific understanding in a process-analytical-technology application (Claus Mortensen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-07-21T02:00:00Z","last_updated_date":"2006-07-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-progress-and-status-what-needed-document-scientific-understanding-process-analytical-technology-application-claus-mortensen_en.pdf"},
    {"id":"28613","name":"Presentation - How to get better data on medicines post-licensing","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-get-better-data-medicines-post-licensing_en.pdf"},
    {"id":"28634","name":"Monitoring of Sales of Veterinary Antimicrobial Agents in Europe: Considerations from Industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/monitoring-sales-veterinary-antimicrobial-agents-europe-considerations-industry_en.pdf"},
    {"id":"28642","name":"Presentation - The changing diagnostic criteria for Alzheimer's disease, including early and asymptomatic disease stages and their impact on clinical trial design (Eric Siemers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-changing-diagnostic-criteria-alzheimers-disease-including-early-and-asymptomatic-disease-stages-and-their-impact-clinical-trial-design-eric-siemers_en.pdf"},
    {"id":"28644","name":"Presentation - EudraVigilance components and functionality introduction: training module PhV-M2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-27T13:18:00Z","last_updated_date":"2016-10-10T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-components-and-functionality-introduction-training-module-phv-m2_en.pdf"},
    {"id":"28678","name":"Presentation - Mock ups and specimen review: labelling review and Standards Office (Monica Prizzi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-12T14:00:01Z","last_updated_date":"2015-11-12T14:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mock-ups-and-specimen-review-labelling-review-and-standards-office-monica-prizzi_en.pdf"},
    {"id":"28691","name":"Presentation - Development of safe levels of elemental impurities: ICH Q3D (Dominique Masset)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-safe-levels-elemental-impurities-ich-q3d-dominique-masset_en.pdf"},
    {"id":"28713","name":"Reflection paper on medicinal-product supply shortages caused by manufacturing or good-manufacturing-practice-compliance problems","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/reflection-paper-medicinal-product-supply-shortages-caused-manufacturing-or-good-manufacturing-practice-compliance-problems_en.pdf"},
    {"id":"28715","name":"Presentation - Brexit regulatory preparedness: small and medium-sized enterprises (SMEs) (Declan O'Rourke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-brexit-regulatory-preparedness-small-and-medium-sized-enterprises-smes-declan-orourke_en.pdf"},
    {"id":"28729","name":"Presentation - Paediatric networks for clinical trial in children - regulatory authorities perspectives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:49Z","last_updated_date":"2011-05-27T15:25:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-networks-clinical-trial-children-regulatory-authorities-perspectives_en.pdf"},
    {"id":"28732","name":"Presentation - Case study 2 - Development of a lower dose paediatric strength IR tablet - Session 2 (Matt Popkin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-2-development-lower-dose-paediatric-strength-ir-tablet-session-2-matt-popkin_en.pdf"},
    {"id":"28738","name":"Presentation - 3.1 Extrapolation and bridging of adult information in early-phase dose-finding pediatric studies (Sarah Zohar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-31-extrapolation-and-bridging-adult-information-early-phase-dose-finding-pediatric-studies-sarah-zohar_en.pdf"},
    {"id":"28755","name":"Presentation - European Medicines Verification Organisation update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-02T02:00:00Z","last_updated_date":"2017-05-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-verification-organisation-update_en.pdf"},
    {"id":"28788","name":"Biosimilar mAbs - Outlook - Christian K Schneider","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/biosimilar-mabs-outlook-christian-k-schneider_en.pdf"},
    {"id":"28792","name":"Presentation: Severe Paediatric Asthma Collaborative in Europe (SPACE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-severe-paediatric-asthma-collaborative-europe-space_en.pdf"},
    {"id":"28794","name":"European Directorate for the Quality of Medicines & HealthCare: Structure, Aims and Role in Providing Safety and Quality of Medicines in Europe - Susanne Keitel","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-directorate-quality-medicines-healthcare-structure-aims-and-role-providing-safety-and-quality-medicines-europe-susanne-keitel_en.pdf"},
    {"id":"28799","name":"Presentation - Issues to address for a Tier C development (Aaron Dane)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-issues-address-tier-c-development-aaron-dane_en.pdf"},
    {"id":"28801","name":"Presentation - Innovative trial approaches (David Dunger, Ronald Portman, James Wason, Jack Bowden)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovative-trial-approaches-david-dunger-ronald-portman-james-wason-jack-bowden_en.pdf"},
    {"id":"28803","name":"Presentation - Mechanisms to meet privacy requirements for clinical data management in large observational and experimental studies (Ronald Brand)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mechanisms-meet-privacy-requirements-clinical-data-management-large-observational-and-experimental-studies-ronald-brand_en.pdf"},
    {"id":"28813","name":"Serbia - Medicines and Medical Devices Agency, T Sipetic","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/serbia-medicines-medical-devices-agency-t-sipetic_en.pdf"},
    {"id":"28838","name":"Presentation - Opportunities for public health and pharmacogenomics from the new pharmacovigilance legislation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-public-health-and-pharmacogenomics-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"28840","name":"Safety Pharmacology - Klaus Olejniczak","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T00:00:00Z","last_updated_date":"2009-02-02T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/safety-pharmacology-klaus-olejniczak_en.pdf"},
    {"id":"28843","name":"Preclinical requirements, Dr David Jones","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/preclinical-requirements-dr-david-jones_en.pdf"},
    {"id":"28847","name":"Presentation - Confirmation of extrapolation based on PK/PD data and modeling (Jacob Brogren)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-confirmation-extrapolation-based-pkpd-data-and-modeling-jacob-brogren_en.pdf"},
    {"id":"28852","name":"Presentation - Update on WEB-RADR: main aspects raised by HCPs (Adamos Hadjipanayis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-web-radr-main-aspects-raised-hcps-adamos-hadjipanayis_en.pdf"},
    {"id":"28863","name":"Presentation - Conclusions of the training session for patients and consumers interested in European Medicines Agency activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-conclusions-training-session-patients-and-consumers-interested-european-medicines-agency-activities_en.pdf"},
    {"id":"28871","name":"Presentation - FVE","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fve_en.pdf"},
    {"id":"28892","name":"Impurities in drug substances and medicinal products - Hilda Kà¶szegi-Szalai","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/impurities-drug-substances-and-medicinal-products-hilda-kapszegi-szalai_en.pdf"},
    {"id":"28901","name":"Nanomedicine: Current view, present and future main regulatory challenges - Rogà©rio Gaspar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-29T02:09:21Z","last_updated_date":"2009-04-29T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/nanomedicine-current-view-present-and-future-main-regulatory-challenges-rogacrio-gaspar_en.pdf"},
    {"id":"28912","name":"Presentation - Implementation of new eligibility requirements (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-new-eligibility-requirements-nathalie-bere_en.pdf"}    {"id":"28925","name":"Presentation - Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency (Sabine Brosch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency-sabine-brosch_en.pdf"},
    {"id":"28929","name":"Presentation - COMP update to the Patients' and Consumers' Working Party (Daniel O’Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comp-update-patients-and-consumers-working-party-daniel-oconnor_en.pdf"},
    {"id":"28930","name":"Presentation - Immunogenicity of biologicals: a pharmacovigilance perspective (Niels Vermeer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunogenicity-biologicals-pharmacovigilance-perspective-niels-vermeer_en.pdf"},
    {"id":"28952","name":"Presentation - MPS – development status, first industrial adoption and current challenges (U. Marx)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T11:22:00Z","last_updated_date":"2017-11-15T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mps-development-status-first-industrial-adoption-and-current-challenges-u-marx_en.pdf"},
    {"id":"28964","name":"Presentation - Industry perspective on public–private partnerships and the link between new business models and the regulatory framework (John H. Rex)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-public-private-partnerships-and-link-between-new-business-models-and-regulatory-framework-john-h-rex_en.pdf"},
    {"id":"28970","name":"Presentation - Strengthening collaborations for operating pharmacovigilance in Europe (SCOPE) (Paul Barrow)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strengthening-collaborations-operating-pharmacovigilance-europe-scope-paul-barrow_en.pdf"},
    {"id":"28976","name":"Presentation - Risk-benefit communication: managing media channels (Monika Benstetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-benefit-communication-managing-media-channels-monika-benstetter_en.pdf"},
    {"id":"28986","name":"Presentation - Governance and SPOR TF ToR","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T17:00:00Z","last_updated_date":"2017-12-20T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-governance-and-spor-tf-tor_en.pdf"},
    {"id":"28989","name":"Presentation - Functional outcome measures for type 2 and 3 Spinal Muscular Atrophy (Anna Mayhew, Jacqueline Montes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-functional-outcome-measures-type-2-and-3-spinal-muscular-atrophy-anna-mayhew-jacqueline-montes_en.pdf"},
    {"id":"29011","name":"Presentation - EU IDMP/SPOR Task Force meeting: Referentials Management Services (RMS) (6. agenda) (Jaume Nogueras)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-idmpspor-task-force-meeting-referentials-management-services-rms-6-agenda-jaume-nogueras_en.pdf"},
    {"id":"29022","name":"Presentation - Interaction with patients and consumers (N. Bere, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-patients-and-consumers-n-bere-ema_en.pdf"},
    {"id":"29028","name":"Presentation - Case study: Setting health based exposure limits throughout the product life cycle (B.D. Naumann, ISPE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-setting-health-based-exposure-limits-throughout-product-life-cycle-bd-naumann-ispe_en.pdf"},
    {"id":"29033","name":"Presentation - Establishing a signal management process: Experience to date with new procedures (Karen Quine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-establishing-signal-management-process-experience-date-new-procedures-karen-quine_en.pdf"},
    {"id":"29041","name":"Presentation - European Union regulatory perspective and expectations (Sven-Erik Hillver)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-regulatory-perspective-and-expectations-sven-erik-hillver_en.pdf"},
    {"id":"29042","name":"Presentation - 1.3 Report from follow-up meeting with thalidomide patients’ and victims’ organisations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-13-report-follow-meeting-thalidomide-patients-and-victims-organisations_en.pdf"},
    {"id":"29047","name":"Objectives - PCWP and HCPWP joint meeting - Workshop on social media","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/objectives-pcwp-and-hcpwp-joint-meeting-workshop-social-media_en.pdf"},
    {"id":"29053","name":"Update on product shortages due to manufacturing/GMP and quality issues (Brendan Cuddy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-01T02:00:00Z","last_updated_date":"2015-09-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/update-product-shortages-due-manufacturinggmp-and-quality-issues-brendan-cuddy_en.pdf"},
    {"id":"29088","name":"Presentation - Extrapolation in antibacterial agents (I. Lutsar, M. Fernandez Cortizo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extrapolation-antibacterial-agents-i-lutsar-m-fernandez-cortizo_en.pdf"},
    {"id":"29090","name":"Presentation - Alternative methods in risk assessment and kinetics in paediatric pharmacology: A common need for physiologically based pharmacokinetic modelling","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-alternative-methods-risk-assessment-and-kinetics-paediatric-pharmacology-common-need-physiologically-based-pharmacokinetic-modelling_en.pdf"},
    {"id":"29112","name":"Presentation - Use of Placebo in Pediatric trials in IBD (Dan Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-placebo-pediatric-trials-ibd-dan-turner_en.pdf"},
    {"id":"29124","name":"Presentation - Residue control in Serbia & MRLs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-residue-control-serbia-mrls_en.pdf"},
    {"id":"29130","name":"Presentation - Regulator’s perspective and experience on prior knowledge and accelerated access - Session 5 (Veronika Jekerle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulators-perspective-and-experience-prior-knowledge-and-accelerated-access-session-5-veronika-jekerle_en.pdf"},
    {"id":"29136","name":"Presentation - Topic 3 - WHO perspective (Christian Lienhardt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-3-who-perspective-christian-lienhardt_en.pdf"},
    {"id":"29137","name":"Presentation - EPAR summaries - Introduction to review by patients and consumers (Paul Blake)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-epar-summaries-introduction-review-patients-and-consumers-paul-blake_en.pdf-0"},
    {"id":"29147","name":"Everlasting problem with paediatric forms for pain control - F. Brion","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-10-28T02:09:21Z","last_updated_date":"2004-10-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/everlasting-problem-paediatric-forms-pain-control-f-brion_en.pdf"},
    {"id":"29168","name":"Presentation - A re-design evaluation from the real world (Annemarie Hellebek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-re-design-evaluation-real-world-annemarie-hellebek_en.pdf"},
    {"id":"29174","name":"Presentation - Yellow Card reporting – Engaging with patients","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:08Z","last_updated_date":"2011-06-24T22:06:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-yellow-card-reporting-engaging-patients_en.pdf"},
    {"id":"29180","name":"Presentation - Integration of multiple biomarkers, translation to surrogate / outcomes and their application in early drug development – A case study to support phase IIa design - Break-out session 1 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:45:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-integration-multiple-biomarkers-translation-surrogate-outcomes-and-their-application-early-drug-development-case-study-support-phase-iia-design-break-out-session-1-theme-3_en.pdf"},
    {"id":"29205","name":"Presentation - Making medicines affordable","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-making-medicines-affordable_en.pdf"},
    {"id":"29207","name":"Presentation - Industry challenges on supplying emergency vaccines in Africa – OBP perspectives (Bethuel Nthangeni)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-23T16:39:00Z","last_updated_date":"2017-05-23T16:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-challenges-supplying-emergency-vaccines-africa-obp-perspectives-bethuel-nthangeni_en.pdf"},
    {"id":"29208","name":"Presentation - Public hearings","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-hearings_en.pdf-1"},
    {"id":"29218","name":"Update from 'SME Office' for micro small & medium-sized enterprises - Melanie Carr","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/update-sme-office-micro-small-medium-sized-enterprises-melanie-carr_en.pdf"},
    {"id":"29224","name":"European Commission's proposal for Pharmacovigilence - Martin Terberger","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-commissions-proposal-pharmacovigilence-martin-terberger_en.pdf"},
    {"id":"29252","name":"QbD Development (derivation of CQAs, CPPs and design space using quality risk assessment and design of experiments on a scale-down model of the manufacturing process) of a novel therapeutic protein","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/qbd-development-derivation-cqas-cpps-and-design-space-using-quality-risk-assessment-and-design-experiments-scale-down-model-manufacturing-process-novel-therapeutic-protein_en.pdf"},
    {"id":"29283","name":"Presentation - Traditional validation: Downstream (Norbert Hentschel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-traditional-validation-downstream-norbert-hentschel_en.pdf"},
    {"id":"29284","name":"Presentation - HCPWP/PCWP meeting: feedback from CAT (B.Gà¤nsbacher, CAT)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T02:00:00Z","last_updated_date":"2017-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hcpwppcwp-meeting-feedback-cat-bgansbacher-cat_en.pdf"},
    {"id":"29299","name":"Presentation - Regulatory comments - Break-out session 4 themes 1 and 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-comments-break-out-session-4-themes-1-and-3_en.pdf-0"},
    {"id":"29309","name":"Presentation - Non-small cell lung cancer (NSCLC), academic perspective: lessons learnt (Enriqueta Felip) - S2.4","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-small-cell-lung-cancer-nsclc-academic-perspective-lessons-learnt-enriqueta-felip-s24_en.pdf"},
    {"id":"29310","name":"Presentation - Autologous cell therapies manufactured in the hospital: Advanced-therapy medicinal products or not? (Kenneth K. Kleinhenz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T02:00:00Z","last_updated_date":"2014-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-autologous-cell-therapies-manufactured-hospital-advanced-therapy-medicinal-products-or-not-kenneth-k-kleinhenz_en.pdf"},
    {"id":"29317","name":"Proposal for the organisation and structure of the EMEA network - Ms Elin Haf Davies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T00:09:21Z","last_updated_date":"2009-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/proposal-organisation-and-structure-emea-network-ms-elin-haf-davies_en.pdf"},
    {"id":"29354","name":"Presentation - Welcome of EMA – Payer community meeting (G.Rasi, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-welcome-ema-payer-community-meeting-grasi-ema_en.pdf"},
    {"id":"29383","name":"Presentation - Inhaled antibiotics in non-CF (Michael Loebinger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-inhaled-antibiotics-non-cf-michael-loebinger_en.pdf"},
    {"id":"29393","name":"Presentation - Significant benefit of orphan medicinal products: industry views (Adam  Heathfield)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T17:00:00Z","last_updated_date":"2015-12-15T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-significant-benefit-orphan-medicinal-products-industry-views-adam-heathfield_en.pdf"},
    {"id":"29396","name":"Presentation - Scientific advice/protocol assistance and patient representatives (Kristina Larsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-adviceprotocol-assistance-and-patient-representatives-kristina-larsson_en.pdf"},
    {"id":"29407","name":"Presentation - Pharmacovigilance pre-accession challenges: Industry view (Tatjana Äuretek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-pre-accession-challenges-industry-view-tatjana-auretek_en.pdf"},
    {"id":"29457","name":"Presentation - HCPWP/PCWP meeting: feedback from CHMP (C.Prieto, CHMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T02:00:00Z","last_updated_date":"2017-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hcpwppcwp-meeting-feedback-chmp-cprieto-chmp_en.pdf"},
    {"id":"29463","name":"Presentation - Best practice guide on measures improving predictability of submissions/responses and adherence to communicated submission/responses deadlines (Presentation of revised BPG after consultation with industry ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:30:00Z","last_updated_date":"2018-01-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-practice-guide-measures-improving-predictability-submissionsresponses-and-adherence-communicated-submissionresponses-deadlines-presentation-revised-bpg-after-consultation-industry_en.pdf"},
    {"id":"29471","name":"Presentation - Agreed PIPs for FDCs for the treatment of HIV-1 infection (Andrea Ecker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-05T17:00:00Z","last_updated_date":"2016-01-05T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agreed-pips-fdcs-treatment-hiv-1-infection-andrea-ecker_en.pdf"},
    {"id":"29478","name":"Presentation - Organ maturation tables (Janina Karres)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T02:00:00Z","last_updated_date":"2014-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organ-maturation-tables-janina-karres_en.pdf"},
    {"id":"29493","name":"Presentation - Interchangeability of generics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interchangeability-generics_en.pdf"},
    {"id":"29498","name":"Presentation - Antimicrobial resistance in food safety perspective - current situation in Croatia","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antimicrobial-resistance-food-safety-perspective-current-situation-croatia_en.pdf"},
    {"id":"29505","name":"Presentation - Patients' and families' priorities: Gaucher disease (Tanya Collin-Histed)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-28T01:00:00Z","last_updated_date":"2012-11-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-and-families-priorities-gaucher-disease-tanya-collin-histed_en.pdf"},
    {"id":"29518","name":"Presentation - GMP, quality by design and validation (Mats Welin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-27T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gmp-quality-design-and-validation-mats-welin_en.pdf"},
    {"id":"29527","name":"Presentation - Strengthening collaborations for operating pharmacovigilance in Europe (Dolores Montero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strengthening-collaborations-operating-pharmacovigilance-europe-dolores-montero_en.pdf"},
    {"id":"29532","name":"Presentation - Workshop on endpoints: cystic fibrosis clinical trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-endpoints-cystic-fibrosis-clinical-trials_en.pdf"},
    {"id":"29534","name":"Presentation - Case study 3 - Prior knowledge to streamline viral safety and resin lifetime studies - Session 3 (Marie Murphy, Paul Talierco, Nancy Cauwenberghs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-3-prior-knowledge-streamline-viral-safety-and-resin-lifetime-studies-session-3-marie-murphy-paul-talierco-nancy-cauwenberghs_en.pdf"},
    {"id":"29552","name":"Presentation - Summary and future steps: European Federation of Pharmaceutical Industries and Associations perspectives - Session 7","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-and-future-steps-european-federation-pharmaceutical-industries-and-associations-perspectives-session-7_en.pdf"},
    {"id":"29563","name":"Presentation - EudraVigilance reporting process for users: Create and send individual case safety reports (ICSRs) using EVWEB - Training Module EV-M3d - Part I","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-06T15:00:00Z","last_updated_date":"2017-01-06T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-reporting-process-users-create-and-send-individual-case-safety-reports-icsrs-using-evweb-training-module-ev-m3d-part-i_en.pdf"},
    {"id":"29564","name":"Presentation - Role of the European Medicines Agency and national authorities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-european-medicines-agency-and-national-authorities_en.pdf"},
    {"id":"29569","name":"Presentation - Good pharmacovigilance practice risk-management systems","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practice-risk-management-systems_en.pdf-0"},
    {"id":"29582","name":"Presentation - Big data in health: current and future initiatives of the Commission (Roger Lim)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-health-current-and-future-initiatives-commission-roger-lim_en.pdf"},
    {"id":"29592","name":"Presentation - Welcome, introduction and goals of the workshop - Joint BWP/QWP workshop with stakeholders in relation to prior knowledge and its use in regulatory applications (V Jekerle/B Dooley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-welcome-introduction-and-goals-workshop-joint-bwpqwp-workshop-stakeholders-relation-prior-knowledge-and-its-use-regulatory-applications-v-jekerleb-dooley_en.pdf"},
    {"id":"29594","name":"Continuous dialogue from product development throughout product lifecycle Tomas Salmonson - Vice Chair CHMP","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/continuous-dialogue-product-development-throughout-product-lifecycle-tomas-salmonson-vice-chair-chmp_en.pdf"},
    {"id":"29609","name":"Presentation - Agenda item 4: substances and products subgroup","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-15T15:00:00Z","last_updated_date":"2016-03-15T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-4-substances-and-products-subgroup_en.pdf"},
    {"id":"29660","name":"Presentation - Welcome and opening remarks (Christian Siebert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-welcome-and-opening-remarks-christian-siebert_en.pdf"},
    {"id":"29665","name":"Presentation - Learnings & next steps for EMSP as initiator and driver (C.Thalheim, J.Hlavacova)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-learnings-next-steps-emsp-initiator-and-driver-cthalheim-jhlavacova_en.pdf"},
    {"id":"29670","name":"Presentation - Web-RADR: use of mobile applications for ADRs reporting and social media data mining (Franà§ois Houà¿ez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-web-radr-use-mobile-applications-adrs-reporting-and-social-media-data-mining-franassois-houaez_en.pdf"},
    {"id":"29688","name":"Presentation - CVMP ad hoc veterinary expert group on novel therapies ADVENT (Fia Westerholm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-27T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-ad-hoc-veterinary-expert-group-novel-therapies-advent-fia-westerholm_en.pdf"},
    {"id":"29689","name":"Presentation - Promoting innovation through the veterinary regulatory framework: Role of EMA - European Medicines Agency veterinary medicines innovation day (David Mackay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-promoting-innovation-through-veterinary-regulatory-framework-role-ema-european-medicines-agency-veterinary-medicines-innovation-day-david-mackay_en.pdf"},
    {"id":"29713","name":"Presentation - Introduction: development of the draft guideline rheumatoid arthritis 2015 (revision 2004) (Liesbeth Rook)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-09T02:00:00Z","last_updated_date":"2016-06-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-development-draft-guideline-rheumatoid-arthritis-2015-revision-2004-liesbeth-rook_en.pdf"},
    {"id":"29718","name":"Presentation - Development of veterinary novel therapies: update (Minna Leppà¤nen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-veterinary-novel-therapies-update-minna-leppanen_en.pdf"},
    {"id":"29721","name":"Meeting Requirements for EU Marketing Authorization: Genotoxicity and Carcinogenicity - Dr Peter Kasper","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T00:00:00Z","last_updated_date":"2009-02-02T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/meeting-requirements-eu-marketing-authorization-genotoxicity-and-carcinogenicity-dr-peter-kasper_en.pdf"},
    {"id":"29723","name":"Presentation - Update on implementation of pharmacovigilance legislation (Franck Diafouka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-implementation-pharmacovigilance-legislation-franck-diafouka_en.pdf"},
    {"id":"29751","name":"Presentation - ISPE paper 'Evaluating the effectiveness of additional risk minimisation measures via surveys in Europe: Challenges and recommendations (Rachel Sobel, Terry Madison)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ispe-paper-evaluating-effectiveness-additional-risk-minimisation-measures-surveys-europe-challenges-and-recommendations-rachel-sobel-terry-madison_en.pdf"},
    {"id":"29755","name":"Brief summary of the existing systems on collecting data: Germany","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/brief-summary-existing-systems-collecting-data-germany_en.pdf"},
    {"id":"29756","name":"Towards biosimilar monoclonal antibodies - Pros and cons - Christian K Schneider","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/towards-biosimilar-monoclonal-antibodies-pros-and-cons-christian-k-schneider_en.pdf"},
    {"id":"29768","name":"Presentation - EudraVigilance Data Analysis System (EVDAS) training for National Competent Authorities - Training module EV-M5a","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-06T15:00:00Z","last_updated_date":"2017-01-06T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-data-analysis-system-evdas-training-national-competent-authorities-training-module-ev-m5a_en.pdf"},
    {"id":"29771","name":"Presentation - European consortium study on the availability of anti-neoplastic medicines (Alexandru Eniu and Nathan I Cherny)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-consortium-study-availability-anti-neoplastic-medicines-alexandru-eniu-and-nathan-i-cherny_en.pdf"},
    {"id":"29772","name":"Presentation - Engineering nanoparticles for biomedical applications, Mamoun Muhammed, Royal Institute of Technology, Stockholm","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-engineering-nanoparticles-biomedical-applications-mamoun-muhammed-royal-institute-technology-stockholm_en.pdf"},
    {"id":"29776","name":"Presentation -  Patients’ and Consumers’ Organisations Working Party (PCWP) / Healthcare Professionals’ Organisations Working Party (HCPWP) presentation on update on work in the area of pandemic preparedness (Ragini Shiv...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-and-consumers-organisations-working-party-pcwp-healthcare-professionals-organisations-working-party-hcpwp-presentation-update-work-area-pandemic-preparedness-ragini-shiv_en.pdf"},
    {"id":"29783","name":"Nonclinical approaches to study shedding of gene therapy vectors - E.S. van Amersfoort","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/nonclinical-approaches-study-shedding-gene-therapy-vectors-es-van-amersfoort_en.pdf"},
    {"id":"29804","name":"Presentation - Orphan designation – key concepts and evaluation criteria, Dr. Jordi Llinares","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orphan-designation-key-concepts-and-evaluation-criteria-dr-jordi-llinares_en.pdf"},
    {"id":"29810","name":"Presentation - 3.3 Training for patients' and consumers' organisations - Mentorship and training at the Patients' and Consumers' Working Party","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-33-training-patients-and-consumers-organisations-mentorship-and-training-patients-and-consumers-working-party_en.pdf"},
    {"id":"29815","name":"Presentation - Regulatory life cycle management: examples (Nancy Cauwenberghs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-life-cycle-management-examples-nancy-cauwenberghs_en.pdf"},
    {"id":"29835","name":"Presentation -  Chemistry, manufacturing, and control (CMC) development and manufacturing challenges (Steven Howe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chemistry-manufacturing-and-control-cmc-development-and-manufacturing-challenges-steven-howe_en.pdf"},
    {"id":"29849","name":"Presentation - Guideline on similar biological medicinal products\n\ncontaining biotechnology-derived proteins as active substance: non-clinical and clinical issues (Hans-Karl Heim)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-hans-karl-heim_en.pdf"},
    {"id":"29856","name":"IFAH-Europe meeting with CVMP and SAGAM - Anno de Jong","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ifah-europe-meeting-cvmp-and-sagam-anno-de-jong_en.pdf"},
    {"id":"29880","name":"Presentation - Key aspects of non-clinical pharmacology and pharmacokinetics in the evaluation of safety (David R Jones)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T18:12:00Z","last_updated_date":"2016-10-26T18:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-aspects-non-clinical-pharmacology-and-pharmacokinetics-evaluation-safety-david-r-jones_en.pdf"},
    {"id":"29887","name":"Presentation - Longitudinal model-based test as primary analysis in phase III - Break-out session 4 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:15:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-longitudinal-model-based-test-primary-analysis-phase-iii-break-out-session-4-theme-2_en.pdf"},
    {"id":"29906","name":"Presentation - Progress update: MLM and EV auditable requirements project (Georgy Genov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:30:00Z","last_updated_date":"2017-03-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-progress-update-mlm-and-ev-auditable-requirements-project-georgy-genov_en.pdf"},
    {"id":"29917","name":"Presentation - In vivo evaluation of lumpy skin disease vaccine efficacy in controlled environment (Kris De Clercq)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T11:37:00Z","last_updated_date":"2017-05-18T11:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vivo-evaluation-lumpy-skin-disease-vaccine-efficacy-controlled-environment-kris-de-clercq_en.pdf"},
    {"id":"29919","name":"EU network strategy to 2020 (Noel Wathion and Monica Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-01T02:00:00Z","last_updated_date":"2015-09-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-network-strategy-2020-noel-wathion-and-monica-dias_en.pdf"},
    {"id":"29932","name":"Presentation - SME’s perspective on scientific and regulatory advice, Dr. Lene Rose Arfelt","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-smes-perspective-scientific-and-regulatory-advice-dr-lene-rose-arfelt_en.pdf"},
    {"id":"29943","name":"Presentation - 1.1 ENCePP: Where are we  and where are we going?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2011-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11-encepp-where-are-we-and-where-are-we-going_en.pdf"},
    {"id":"29949","name":"Presentation - Day 2: Limbal stem cell therapy: industry view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-limbal-stem-cell-therapy-industry-view_en.pdf"},
    {"id":"29978","name":"Presentation - Application of ICH Q12 tools and enablers: post-approval lifecycle management protocols","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-application-ich-q12-tools-and-enablers-post-approval-lifecycle-management-protocols_en.pdf"},
    {"id":"29998","name":"Presentation - Overview of good-pharmacovigilance-practice modules on adverse drug reactions, periodic safety update reports, signal management and additional monitoring (Mick Foy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-good-pharmacovigilance-practice-modules-adverse-drug-reactions-periodic-safety-update-reports-signal-management-and-additional-monitoring-mick-foy_en.pdf"},
    {"id":"30007","name":"Presentation - Blood-brain-barrier maturation: Implications for drug development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-blood-brain-barrier-maturation-implications-drug-development_en.pdf"},
    {"id":"30010","name":"GCP compliance, Dr Katalina Mettke","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gcp-compliance-dr-katalina-mettke_en.pdf"},
    {"id":"30011","name":"Presentation - Challenges in performing field trials to support efficacy: companion animal vaccines  (K. Hellmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T15:12:00Z","last_updated_date":"2017-11-15T15:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-performing-field-trials-support-efficacy-companion-animal-vaccines-k-hellmann_en.pdf-0"}    {"id":"30013","name":"How to prepare PIP/Waiver dossier? - Anu Tummavuori-Liemann","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-11-16T00:09:21Z","last_updated_date":"2009-11-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/how-prepare-pipwaiver-dossier-anu-tummavuori-liemann_en.pdf"},
    {"id":"30020","name":"Presentation - Taking CARs/TCRs from first-in-man trials to marketing authorisation – the view from a pharmaceutical developer (Stanley Frankel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T11:11:00Z","last_updated_date":"2016-12-02T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-taking-carstcrs-first-man-trials-marketing-authorisation-view-pharmaceutical-developer-stanley-frankel_en.pdf"},
    {"id":"30036","name":"Presentation - MAHs access to EudraVigilance (Rodrigo Postigo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T16:03:00Z","last_updated_date":"2017-07-25T16:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mahs-access-eudravigilance-rodrigo-postigo_en.pdf"},
    {"id":"30062","name":"Presentation - FDA incentives (John D. Milto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-incentives-john-d-milto_en.pdf"},
    {"id":"30064","name":"Presentation - Transparency in Europe: patients and doctors (Dominic Way and Frederic Bouder)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transparency-europe-patients-and-doctors-dominic-way-and-frederic-bouder_en.pdf"},
    {"id":"30065","name":"Presentation - EU US mutual recognition agreement (B.Cuddy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-18T02:00:00Z","last_updated_date":"2017-09-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-us-mutual-recognition-agreement-bcuddy_en.pdf"},
    {"id":"30072","name":"Presentation - Perspective on the implementation of a pharmacovigilance system","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-perspective-implementation-pharmacovigilance-system_en.pdf"},
    {"id":"30073","name":"Paediatric Pharmacovigilance, Dr Dirk Mentzer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/paediatric-pharmacovigilance-dr-dirk-mentzer_en.pdf"},
    {"id":"30074","name":"Presentation - Evidence-based guidance for risk communication planning (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evidence-based-guidance-risk-communication-planning-priya-bahri_en.pdf"},
    {"id":"30085","name":"In vitro tests and experimental animal models for investigation of the allergenic potential of biotechnology-derived proteins - Attila Bacsi","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-09-04T02:09:21Z","last_updated_date":"2007-09-04T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/vitro-tests-and-experimental-animal-models-investigation-allergenic-potential-biotechnology-derived-proteins-attila-bacsi_en.pdf"},
    {"id":"30089","name":"Presentation - How are medicines evaluated at the European Medicines Agency (part 2)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-are-medicines-evaluated-european-medicines-agency-part-2_en.pdf"},
    {"id":"30093","name":"European Patients’ Academy on Therapeutic Innovation (J. Geissler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-02-12T01:00:00Z","last_updated_date":"2013-02-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-patients-academy-therapeutic-innovation-j-geissler_en.pdf"},
    {"id":"30102","name":"Presentation - Qualification of the Simcyp platform for the intended purposes(Masoud Jamei)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qualification-simcyp-platform-intended-purposesmasoud-jamei_en.pdf"},
    {"id":"30103","name":"Analysis of Performance Indicators for Initial Applications/Full Applications The 2007 trends: EMEA analysis - Francesco Pignatti","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/analysis-performance-indicators-initial-applicationsfull-applications-2007-trends-emea-analysis-francesco-pignatti_en.pdf"},
    {"id":"30120","name":"Presentation - Session 3.9: Potential interaction with Enpr-EMA networks","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-39-potential-interaction-enpr-ema-networks_en.pdf"},
    {"id":"30122","name":"Regulatory requirements to prevent viral shedding during gene therapy in Japan - Teruyo Arato, Daisuke Maeda, Teruhide Yamaguchi","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/regulatory-requirements-prevent-viral-shedding-during-gene-therapy-japan-teruyo-arato-daisuke-maeda-teruhide-yamaguchi_en.pdf"},
    {"id":"30146","name":"Presentation - Scientific advice on quality aspects – key considerations, Prof. Dieter Deforce","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advice-quality-aspects-key-considerations-prof-dieter-deforce_en.pdf"},
    {"id":"30176","name":"Presentation - Session 2: What can we do now and what are the gaps in our knowledge? The direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) (Antonio Gà³mez-Outes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-13T17:00:00Z","last_updated_date":"2016-01-13T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-what-can-we-do-now-and-what-are-gaps-our-knowledge-direct-factor-xa-inhibitors-rivaroxaban-apixaban-edoxaban-antonio-ga3mez-outes_en.pdf"},
    {"id":"30177","name":"Presentation - Introduction and goals of the workshop (Jean-Louis Robert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-and-goals-workshop-jean-louis-robert_en.pdf"},
    {"id":"30193","name":"Overview of applications for mMarketing authorisation - Recent experience in quality assessment - Dr Cornelia Nopitsch-Mai","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-applications-mmarketing-authorisation-recent-experience-quality-assessment-dr-cornelia-nopitsch-mai_en.pdf"},
    {"id":"30235","name":"Presentation - Regulatory update on guidelines relevant to paediatric formulations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-update-guidelines-relevant-paediatric-formulations_en.pdf"},
    {"id":"30243","name":"Presentation - Signal detection: Experience to date (Jos Olaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-signal-detection-experience-date-jos-olaerts_en.pdf"},
    {"id":"30254","name":"Presentation - Guideline on biosimilar monoclonal antibodies: Non-clinical issues: A risk-based approach - rationale and decision points","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:58Z","last_updated_date":"2012-06-15T17:10:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-biosimilar-monoclonal-antibodies-non-clinical-issues-risk-based-approach-rationale-and-decision-points_en.pdf"},
    {"id":"30266","name":"Presentation - Role of European and national regulatory authorities: who advises on what?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-european-and-national-regulatory-authorities-who-advises-what_en.pdf"},
    {"id":"30269","name":"Presentation - Referentials Management Services (RMS) project report (Isabel Chicharo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-referentials-management-services-rms-project-report-isabel-chicharo-ema_en.pdf"},
    {"id":"30271","name":"Presentation - EMA policy on publication of clinical data – Update on implementation (Noel Wathion)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-29T02:00:00Z","last_updated_date":"2015-06-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-policy-publication-clinical-data-update-implementation-noel-wathion_en.pdf"},
    {"id":"30299","name":"Training program : ASMF and CEP procedure - Cornelia Nopitsch-Mai","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/training-program-asmf-and-cep-procedure-cornelia-nopitsch-mai_en.pdf"},
    {"id":"30323","name":"Presentation - The Paediatric Regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-01-01T01:00:00Z","last_updated_date":"2007-01-01T01:00:00Z","reference_number":"n/a","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-regulation_en.pdf"},
    {"id":"30340","name":"Presentation - Committee for Advanced Therapies (CAT) update (Kieran Breen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-advanced-therapies-cat-update-kieran-breen_en.pdf-0"},
    {"id":"30362","name":"Presentation - Regulatory tools for risk minimisation and their effectiveness: monitoring health outcomes and patient compliance (Sabine Straus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-tools-risk-minimisation-and-their-effectiveness-monitoring-health-outcomes-and-patient-compliance-sabine-straus_en.pdf"},
    {"id":"30375","name":"Presentation - Scientific advice delivers planning throughout development (Thorsten Vetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advice-delivers-planning-throughout-development-thorsten-vetter_en.pdf"},
    {"id":"30387","name":"Presentation - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting - PCWP 10 year anniversary: Its finally here! (Maria Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-pcwp-10-year-anniversary-its-finally-here-maria-mavris_en.pdf"},
    {"id":"30390","name":"Presentation - Update on the ESVAC project (David Mackay, Kari Grave and Jordi Torren Edo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-22T13:01:28Z","last_updated_date":"2010-12-22T13:01:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-esvac-project-david-mackay-kari-grave-and-jordi-torren-edo_en.pdf"},
    {"id":"30419","name":"Viewpoint from Industry : Comità© International des Pharmaciens Homà©opathes CIPH","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/viewpoint-industry-comitac-international-des-pharmaciens-homacopathes-ciph_en.pdf"},
    {"id":"30441","name":"Presentation - Paediatric high-grade glioma: Clinical background","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-06T02:00:00Z","last_updated_date":"2011-07-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-high-grade-glioma-clinical-background_en.pdf"},
    {"id":"30482","name":"Presentation - Introducing the Innovation Office at the Swedish Medical Products Agency (Lars Dagerholt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introducing-innovation-office-swedish-medical-products-agency-lars-dagerholt_en.pdf"},
    {"id":"30485","name":"Presentation - Clinical data publication webinar (Anne-Sophie Henry-Eude)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-31T13:11:00Z","last_updated_date":"2017-03-31T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-data-publication-webinar-anne-sophie-henry-eude_en.pdf"},
    {"id":"30487","name":"Presentation - Providing information to the older population: An industry perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-providing-information-older-population-industry-perspective_en.pdf"},
    {"id":"30499","name":"Presentation - Evidence synthesis in drug development for special populations, ethnic groups and rare diseases - Break-out session 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evidence-synthesis-drug-development-special-populations-ethnic-groups-and-rare-diseases-break-out-session-3_en.pdf"},
    {"id":"30514","name":"Presentation - HEY YA! HEalth Literacy, Young Patients with Asthma and Adherence to Treatment (Erna Botjes, EFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hey-ya-health-literacy-young-patients-asthma-and-adherence-treatment-erna-botjes-efa_en.pdf"},
    {"id":"30521","name":"Presentation - A pharmacovigilance project in juvenile idiopathic arthritis (JIA) - Pharmachild the PRINTO perspective (Nicola Ruperto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T02:00:00Z","last_updated_date":"2014-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-project-juvenile-idiopathic-arthritis-jia-pharmachild-printo-perspective-nicola-ruperto_en.pdf"},
    {"id":"30526","name":"Presentation - EORTC’s lessons learned for precision medicine in Europe: Opportunities for clinical research transformation - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCP...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eortcs-lessons-learned-precision-medicine-europe-opportunities-clinical-research-transformation-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcp_en.pdf"},
    {"id":"30530","name":"European Federation of Patients' Associations for Anthroposophic Medicine (EFPAM)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-federation-patients-associations-anthroposophic-medicine-efpam_en.pdf"},
    {"id":"30531","name":"Presentation - Implementation of the European Medicines Agency policy on the publication of clinical data: status report (Noel Wathion)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-european-medicines-agency-policy-publication-clinical-data-status-report-noel-wathion_en.pdf"},
    {"id":"30558","name":"FDA Practices - J. Sanit-Hugot","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-09-11T02:09:21Z","last_updated_date":"2006-09-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/fda-practices-j-sanit-hugot_en.pdf"},
    {"id":"30566","name":"Presentation - Update on EMA Brexit preparedness (A. Humphreys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-17T16:27:00Z","last_updated_date":"2017-10-17T16:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ema-brexit-preparedness-humphreys_en.ppt"},
    {"id":"30593","name":"Presentation - European Centre for disease prevention and control (ECDC) – focus on consumption data and campaign support - Session 3 (Giovanni Mancarella, Andrea Nilsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-centre-disease-prevention-and-control-ecdc-focus-consumption-data-and-campaign-support-session-3-giovanni-mancarella-andrea-nilsson_en.pdf"},
    {"id":"30600","name":"Human Centralised Procedure, G Wade, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/human-centralised-procedure-g-wade-ema_en.pdf"},
    {"id":"30638","name":"EPARs survey - Similarities and divergences between Europe and USA - Solange Corriol-Rohou","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/epars-survey-similarities-and-divergences-between-europe-and-usa-solange-corriol-rohou_en.pdf"},
    {"id":"30658","name":"Presentation - EMA report to the European Commission – Article 50","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-report-european-commission-article-50_en.pdf"},
    {"id":"30659","name":"Presentation - European Commission Directorate Health and Food Safety Health Systems and Products: medicinal products - quality, safety and efficacy (Agnieszka Kasperek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T14:00:00Z","last_updated_date":"2015-04-29T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-commission-directorate-health-and-food-safety-health-systems-and-products-medicinal-products-quality-safety-and-efficacy-agnieszka-kasperek_en.pdf"},
    {"id":"30668","name":"Presentation - How can patients and caregivers contribute to generate data on behavioural changes? (Elisa Ferrer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-can-patients-and-caregivers-contribute-generate-data-behavioural-changes-elisa-ferrer_en.pdf"},
    {"id":"30670","name":"Presentation - Moving away from traditional networks towards interactive dataset sharing (Dominique Haumont)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-moving-away-traditional-networks-towards-interactive-dataset-sharing-dominique-haumont_en.pdf"},
    {"id":"30671","name":"NorPEN The Nordic Pharmacoepidemiological Network for knowledge exchange, research and research training - H. Kieler","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/norpen-nordic-pharmacoepidemiological-network-knowledge-exchange-research-and-research-training-h-kieler_en.pdf"},
    {"id":"30675","name":"Presentation - Post-authorisation safety studies – PRAC experience (Almath Spooner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-authorisation-safety-studies-prac-experience-almath-spooner_en.pdf"},
    {"id":"30692","name":"Presentation - Considerations in the development of beta-lactamase inhibitor combination products for multiple drug resistant (MDR) pathogens (Michael Dudley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-development-beta-lactamase-inhibitor-combination-products-multiple-drug-resistant-mdr-pathogens-michael-dudley_en.pdf"},
    {"id":"30699","name":"Presentation -  Adaptive pathways workshop (Alison Cave)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-pathways-workshop-alison-cave_en.pdf"},
    {"id":"30714","name":"Kosovo - Food and Veterinary Agency, K Uka","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/kosovo-food-and-veterinary-agency-k-uka_en.pdf"},
    {"id":"30715","name":"Presentation - Healthcare Professionals' Working Party (HCPWP): Nomination of observers (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T17:00:00Z","last_updated_date":"2013-07-12T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-healthcare-professionals-working-party-hcpwp-nomination-observers-ivana-silva_en.pdf"},
    {"id":"30716","name":"Presentation - Agenda point 3: ESVAC Report 2015 - Interactive database (Kristine Ignate)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-03T02:00:00Z","last_updated_date":"2017-04-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-point-3-esvac-report-2015-interactive-database-kristine-ignate_en.pdf"},
    {"id":"30722","name":"EMEA-EFPIA 'Quality by Design' application workshop - Introduction","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-efpia-quality-design-application-workshop-introduction_en.pdf"},
    {"id":"30723","name":"Presentation - Welcome to NETSTAP","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T16:02:00Z","last_updated_date":"2018-06-18T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-welcome-netstap_en.pdf"},
    {"id":"30740","name":"National Experience on collection and analysis of data on AM sales and use - Gà©rard Moulin","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/national-experience-collection-and-analysis-data-am-sales-and-use-gacrard-moulin_en.pdf"},
    {"id":"30741","name":"Presentation - Session 3.1: Updates on networks - Spanish network (Cristina Serà©n Trasorras)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-31-updates-networks-spanish-network-cristina-seracn-trasorras_en.pdf"},
    {"id":"30749","name":"Presentation - Discussion 'progress for the benefit of public health', Ralf Gold","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-discussion-progress-benefit-public-health-ralf-gold_en.pdf"},
    {"id":"30753","name":"Presentation - Session 1: List of Questions from Participants on non-clinical development of ATMPs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-list-questions-participants-non-clinical-development-atmps_en.pdf"},
    {"id":"30754","name":"Presentation - GVP Module VI – ADR, pharmacovigilance guideline for paediatric medicines (Roberto De Lisa and Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T16:03:00Z","last_updated_date":"2017-07-25T16:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gvp-module-vi-adr-pharmacovigilance-guideline-paediatric-medicines-roberto-de-lisa-and-priya-bahri_en.pdf"},
    {"id":"30761","name":"Presentation - Pharmacovigilance and product data (Jos Olaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-and-product-data-jos-olaerts_en.pdf"},
    {"id":"30769","name":"Presentation - Modelling and simulation to optimise the design of confirmatory trials, to analyse phase 3 data and to characterise risk-benefit and support label claims - Break-out session 4","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:15:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-optimise-design-confirmatory-trials-analyse-phase-3-data-and-characterise-risk-benefit-and-support-label-claims-break-out-session-4_en.pdf"},
    {"id":"30770","name":"All submissions combined","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-03T02:09:21Z","last_updated_date":"2007-10-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/all-submissions-combined_en.pdf"},
    {"id":"30774","name":"Presentation - When is it appropriate to combine phases","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-when-it-appropriate-combine-phases_en.pdf"},
    {"id":"30785","name":"The Concerns of the Homeopathy Profession in Relation to Homeopathic Medicines in Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/concerns-homeopathy-profession-relation-homeopathic-medicines-europe_en.pdf"},
    {"id":"30791","name":"Presentation - Best expertise vs conflicts of interests: Striking the right balance (Martin Pigeon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-expertise-vs-conflicts-interests-striking-right-balance-martin-pigeon_en.pdf"},
    {"id":"30793","name":"Presentation - Natalizumab (Tysabri) and PML - the current figures, Brigitte Keller-Stanislawski","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-natalizumab-tysabri-and-pml-current-figures-brigitte-keller-stanislawski_en.pdf"},
    {"id":"30805","name":"Presentation - General concepts on process validation (Kowid Ho)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-concepts-process-validation-kowid-ho_en.pdf"},
    {"id":"30823","name":"Presentation - Electronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission (Ilaria Del Seppia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-electronic-submission-information-medicinal-products-accordance-article-572-requirements-maintenance-submission-ilaria-del-seppia_en.pdf"},
    {"id":"30850","name":"Presentation -  Multiplicity issues in defining the testing strategy for two large outcome studies (Jennifer Shannon, Rebekkah Brown,\n\nGreg Cicconetti, Rich Davies)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multiplicity-issues-defining-testing-strategy-two-large-outcome-studies-jennifer-shannon-rebekkah-brown-greg-cicconetti-rich-davies_en.pdf"},
    {"id":"30852","name":"Presentation -  GMP phage production for clinical trials (Frenk Smrekar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-22T02:00:00Z","last_updated_date":"2015-06-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gmp-phage-production-clinical-trials-frenk-smrekar_en.pdf"},
    {"id":"30860","name":"Brief summary of the existing systems on collecting data: Norway","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/brief-summary-existing-systems-collecting-data-norway_en.pdf"},
    {"id":"30885","name":"Presentation - Patient reporting in EudraVigilance - a measure of patient engagement? (Marin Banovac)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-reporting-eudravigilance-measure-patient-engagement-marin-banovac_en.pdf"},
    {"id":"30925","name":"Presentation - Topic 3 - Evaluation of new treatment regimens, a clinicians perspective (Andreas Diacon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-3-evaluation-new-treatment-regimens-clinicians-perspective-andreas-diacon_en.pdf"},
    {"id":"30926","name":"Presentation - Procedure for election of Patients’ and Consumers’ Working Party’ co-chair 2013-2016","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-02T17:00:00Z","last_updated_date":"2013-07-02T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-procedure-election-patients-and-consumers-working-party-co-chair-2013-2016_en.pdf"},
    {"id":"30941","name":"Presentation - National experience of application of the requirements for marketing authorisations and other ways of making vaccines available - small MS perspective (Jiri Bures)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T14:00:00Z","last_updated_date":"2015-04-29T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-national-experience-application-requirements-marketing-authorisations-and-other-ways-making-vaccines-available-small-ms-perspective-jiri-bures_en.pdf"},
    {"id":"30942","name":"Presentation - Industry perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective_en.pdf"},
    {"id":"30959","name":"Presentation - PRAC patient representative (Marco Greco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prac-patient-representative-marco-greco_en.pdf"},
    {"id":"30967","name":"Presentation - Session 3: CNODES common data model pilot project: challenges and opportunities (Robert Platt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-cnodes-common-data-model-pilot-project-challenges-and-opportunities-robert-platt_en.pdf"},
    {"id":"30969","name":"Presentation - Introduction to training offering by European Medicines Agency: Training module PhV-M0","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2016-10-10T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-training-offering-european-medicines-agency-training-module-phv-m0_en.pdf"},
    {"id":"30993","name":"Presentation - Regulatory vision of paediatric applications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-vision-paediatric-applications_en.pdf"},
    {"id":"31003","name":"Presentation - Session 1.4: Non-clinical issues: Risk-based approach - rationale and decision points","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:43Z","last_updated_date":"2012-06-15T17:10:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-14-non-clinical-issues-risk-based-approach-rationale-and-decision-points_en.pdf"},
    {"id":"31007","name":"Presentation - Assessing benefit/risk profile of novel immunomodulatory drugs with significant efficacy but potential risks. What data should be presented at MAA? (Michael Panzara)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-assessing-benefitrisk-profile-novel-immunomodulatory-drugs-significant-efficacy-potential-risks-what-data-should-be-presented-maa-michael-panzara_en.pdf"},
    {"id":"31025","name":"Presentation - Update on revision of risk management plan (RMP) guidance and on pilot of new RMP template (Michael Berntgen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-revision-risk-management-plan-rmp-guidance-and-pilot-new-rmp-template-michael-berntgen_en.pdf"},
    {"id":"31027","name":"Presentation - Haemophilia registries: patients’ perspective - European Haemophilia Consortium (EHC) (Radoslaw Kaczmarek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-haemophilia-registries-patients-perspective-european-haemophilia-consortium-ehc-radoslaw-kaczmarek_en.pdf"},
    {"id":"31030","name":"Presentation - Case study 1- First-in-man  (FIM) to commercial for a lyophilised (NBE) product - Session 2 (Michael Siedler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-1-first-man-fim-commercial-lyophilised-nbe-product-session-2-michael-siedler_en.pdf"},
    {"id":"31089","name":"Presentation - Introduction to the workshop: aims and expected outputs (Victoria Hedley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-workshop-aims-and-expected-outputs-victoria-hedley_en.pdf"},
    {"id":"31095","name":"Presentation - Regulators' perspective - Session 4 (R. Martijn van der Plas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulators-perspective-session-4-r-martijn-van-der-plas_en.pdf"},
    {"id":"31099","name":"Submission of the dossier: Update on electronic submissions and PIM - Paul Kershaw","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/submission-dossier-update-electronic-submissions-and-pim-paul-kershaw_en.pdf"},
    {"id":"31106","name":"Presentation - Patient Registries Initiative Lessons learned from the recent workshops (X. Kurz, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-registries-initiative-lessons-learned-recent-workshops-x-kurz-ema_en.pdf"},
    {"id":"31148","name":"How can non-conributing agencies be encouraged to participate - Kristin Raudsepp","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/how-can-non-conributing-agencies-be-encouraged-participate-kristin-raudsepp_en.pdf"},
    {"id":"31150","name":"Presentation - Grant frameworks: Japan (Hirofumi Kusunoki)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-grant-frameworks-japan-hirofumi-kusunoki_en.pdf"},
    {"id":"31195","name":"FDA Perspectives On Viral & Vector Shedding Studies - Daniel Takefman","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/fda-perspectives-viral-vector-shedding-studies-daniel-takefman_en.pdf"}    {"id":"31196","name":"Presentation - Clinical trials regulation: European Medicines Agency's role (Anabela Marcal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-regulation-european-medicines-agencys-role-anabela-marcal_en.pdf"},
    {"id":"31207","name":"Presentation - Considerations behind the reflection paper on confirmatory trials with and adaptive design","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-behind-reflection-paper-confirmatory-trials-and-adaptive-design_en.pdf"},
    {"id":"31233","name":"Presentation - European Medicines Agency: The next 5 years - The innovators perspective (Elias Zerhouni)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-20T01:00:00Z","last_updated_date":"2015-03-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-next-5-years-innovators-perspective-elias-zerhouni_en.pdf"},
    {"id":"31234","name":"Presentation - Objectives of the workshop (Guido Rasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-objectives-workshop-guido-rasi_en.pdf"},
    {"id":"31267","name":"Presentation - PMDA perspectives (Yoshihiro Matsuda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pmda-perspectives-yoshihiro-matsuda_en.pdf"},
    {"id":"31276","name":"Presentation - Basis for setting acceptance criteria, Brian Withers, representing EBE","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T02:00:00Z","last_updated_date":"2011-10-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-basis-setting-acceptance-criteria-brian-withers-representing-ebe_en.pdf"},
    {"id":"31293","name":"Presentation - CVMP work plan for 2016: highlights and potential implications for new applications and developments (Anja Holm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-work-plan-2016-highlights-and-potential-implications-new-applications-and-developments-anja-holm_en.pdf"},
    {"id":"31309","name":"ECDC – future perspectives and integrated approach","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ecdc-future-perspectives-and-integrated-approach_en.pdf"},
    {"id":"31328","name":"Presentation - Session 1: Non-clinical issues: Introduction","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:55Z","last_updated_date":"2012-06-15T17:10:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-non-clinical-issues-introduction_en.pdf"},
    {"id":"31331","name":"Presentation - What do we need to consider to ensure medication adherence of older adults?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-do-we-need-consider-ensure-medication-adherence-older-adults_en.pdf"},
    {"id":"31362","name":"Presentation - Effect of a single market: Availability of veterinary medicines: Perspective of IFAH-Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-effect-single-market-availability-veterinary-medicines-perspective-ifah-europe_en.pdf"},
    {"id":"31372","name":"Presentation - Implementation of the EudraVigilance access policy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-eudravigilance-access-policy_en.pdf"},
    {"id":"31373","name":"Presentation - Challenges in assessing relative immunogenicity (Paul Chamberlain)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-assessing-relative-immunogenicity-paul-chamberlain_en.pdf"},
    {"id":"31390","name":"Presentation - Optimising the use of the EURD list – the key to the single assessment: Procedural aspects (Robin Ruepp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-optimising-use-eurd-list-key-single-assessment-procedural-aspects-robin-ruepp_en.pdf"},
    {"id":"31398","name":"Risk Management of Advanced Therapies, Dossier Requirements - Jan Petracek","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/risk-management-advanced-therapies-dossier-requirements-jan-petracek_en.pdf"},
    {"id":"31399","name":"Presentation - Product subgroup report to task force","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-02T02:00:00Z","last_updated_date":"2017-05-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-subgroup-report-task-force_en.pdf"},
    {"id":"31406","name":"Presentation - Global strategies to address antimicrobial resistance - Session 1 (Carmem Làºcia Pessoa-Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-global-strategies-address-antimicrobial-resistance-session-1-carmem-laocia-pessoa-silva_en.pdf"},
    {"id":"31417","name":"Presentation of European Surveillance of Antimicrobial Consumption (ESAC) in human medicine","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-surveillance-antimicrobial-consumption-esac-human-medicine_en.pdf"},
    {"id":"31436","name":"Presentation - European Medicines Agency advice on the impact of the use of antibiotics on public and animal health: Potential impact on the authorisation of antimicrobials (Helen Jukes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-advice-impact-use-antibiotics-public-and-animal-health-potential-impact-authorisation-antimicrobials-helen-jukes_en.pdf"},
    {"id":"31444","name":"Presentation - Section 5.1: Pharmacodynamic properties","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-51-pharmacodynamic-properties_en.pdf"},
    {"id":"31460","name":"Presentation - Towards rules of procedures for public hearings (June Raine, Monika Benstetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-towards-rules-procedures-public-hearings-june-raine-monika-benstetter_en.pdf"},
    {"id":"31496","name":"Presentation - Clinical pharmacogenomics: Premarketing evaluation in early-phase clinical studies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-pharmacogenomics-premarketing-evaluation-early-phase-clinical-studies_en.pdf"},
    {"id":"31505","name":"Centralised Procedure: EFPIA Analysis of PerformanceIndicators Extension of Indications 2005-2006 - Suresh Nair and Marianne Poulmaire","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/centralised-procedure-efpia-analysis-performanceindicators-extension-indications-2005-2006-suresh-nair-and-marianne-poulmaire_en.pdf"},
    {"id":"31513","name":"Presentation - How to evaluate medications in Multiple Sclerosis when placebo controlled RCTs are not feasible (Luca Massacesi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-evaluate-medications-multiple-sclerosis-when-placebo-controlled-rcts-are-not-feasible-luca-massacesi_en.pdf"},
    {"id":"31534","name":"Presentation - Update on EMA Brexit preparedness (Anthony Humphreys, Monica Dias, Marie-Helene Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ema-brexit-preparedness-anthony-humphreys-monica-dias-marie-helene-pinheiro_en.pdf"},
    {"id":"31562","name":"The next 10 years: A regulatory view: Jordi Llinares","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/next-10-years-regulatory-view-jordi-llinares_en.pdf"},
    {"id":"31583","name":"Presentation - 2018 European Medicines Agency-industry stakeholder interactions on Brexit related topics (Marie-Helene Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2018-european-medicines-agency-industry-stakeholder-interactions-brexit-related-topics-marie-helene-pinheiro_en.pdf"},
    {"id":"31584","name":"Presentation - Introduction to the programme of the day and panel discussion (Fernand Sauer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-programme-day-and-panel-discussion-fernand-sauer_en.pdf"},
    {"id":"31619","name":"Presentation - Product information management - Annex: Example label","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-information-management-annex-example-label_en.pdf"},
    {"id":"31628","name":"Presentation - EU IDMP/SPOR Task Force meeting: Organisations Management Services (OMS) (6. agenda) (Kepa Amutxastegi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-idmpspor-task-force-meeting-organisations-management-services-oms-6-agenda-kepa-amutxastegi_en.pdf"},
    {"id":"31644","name":"Presentation - Nonclinical and clinical considerations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nonclinical-and-clinical-considerations_en.pdf"},
    {"id":"31659","name":"Presentation - Dose selection in early paediatric development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-13T02:09:21Z","last_updated_date":"2008-04-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-selection-early-paediatric-development_en.pdf"},
    {"id":"31670","name":"Presentation - Introduction (Marie-Helene Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T17:00:00Z","last_updated_date":"2016-05-27T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-marie-helene-pinheiro_en.pdf"},
    {"id":"31677","name":"Presentation - When science and regulatory action meet reality: barriers and critical success factors to managing risk and the salience of trust (Patrick Brown)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-when-science-and-regulatory-action-meet-reality-barriers-and-critical-success-factors-managing-risk-and-salience-trust-patrick-brown_en.pdf"},
    {"id":"31684","name":"Presentation - Health Technology Assessment: Impact on Regulators","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-18T02:00:00Z","last_updated_date":"2011-07-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-health-technology-assessment-impact-regulators_en.pdf"},
    {"id":"31699","name":"Presentation - Draft action plan: Collection of data by animal species  (Kari Grave, Jordi Torren)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-action-plan-collection-data-animal-species-kari-grave-jordi-torren_en.pdf"},
    {"id":"31705","name":"Presentation - Preliminary results of survey on collaboration between Enpr-EMA networks and industry for the conduct of industry-funded clinical trials (Benjamin Pelle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T16:00:00Z","last_updated_date":"2013-07-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preliminary-results-survey-collaboration-between-enpr-ema-networks-and-industry-conduct-industry-funded-clinical-trials-benjamin-pelle_en.pdf"},
    {"id":"31730","name":"Presentation: Working Group on public-private partnership","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-public-private-partnership_en.pdf"},
    {"id":"31763","name":"Presentation - European Food Safety (EFSA), antimicrobial resistance, stakeholders - Session 4 (Pietro Stella)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-food-safety-efsa-antimicrobial-resistance-stakeholders-session-4-pietro-stella_en.pdf"},
    {"id":"31766","name":"Presentation - Update on the revision of the new package leaflet (PL) template","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-23T02:00:00Z","last_updated_date":"2011-05-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-revision-new-package-leaflet-pl-template_en.pdf"},
    {"id":"31768","name":"Presentation - Impact of specific formulations on anthelmintic resistance development (D. Murphy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-specific-formulations-anthelmintic-resistance-development-d-murphy_en.pdf"},
    {"id":"31777","name":"Presentation - Pharmacovigilance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:54Z","last_updated_date":"2012-06-15T17:10:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance_en.pdf-0"},
    {"id":"31783","name":"Presentation - Experience of paediatric formulations in marketing authorisation applications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-paediatric-formulations-marketing-authorisation-applications_en.pdf"},
    {"id":"31787","name":"Turkey - Ministry of Health, General Directorate, Y Karabey","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/turkey-ministry-health-general-directorate-y-karabey_en.pdf"},
    {"id":"31792","name":"Presentation - Medicines shortages issues and recent actions: Eurordis perspective (Franà§ois Houà¿ez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicines-shortages-issues-and-recent-actions-eurordis-perspective-franassois-houaez_en.pdf"},
    {"id":"31829","name":"Presentation - Efficacy and effectiveness models","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-efficacy-and-effectiveness-models_en.pdf"},
    {"id":"31833","name":"Presentation - The new EU Innovation Network (Esa Heinonen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-eu-innovation-network-esa-heinonen_en.pdf"},
    {"id":"31860","name":"Research in newborn infants. Ethical aspects, recruitment and informed consent - Pieter J.J. Sauer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-11T02:09:21Z","last_updated_date":"2006-10-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/research-newborn-infants-ethical-aspects-recruitment-and-informed-consent-pieter-jj-sauer_en.pdf"},
    {"id":"31867","name":"Presentation - Considerations on regulatory aspects (Zigmars Sebris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-22T02:00:00Z","last_updated_date":"2015-06-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-regulatory-aspects-zigmars-sebris_en.pdf"},
    {"id":"31878","name":"Presentation - Pre-clinical requirements to support development of paediatric medicines (Janina Karres)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T18:12:00Z","last_updated_date":"2016-10-26T18:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pre-clinical-requirements-support-development-paediatric-medicines-janina-karres_en.pdf"},
    {"id":"31887","name":"Presentation - Modelling and simulation in preclinical development: Predicting thyroid hormone side effects in humans from preclinical toxicity studies - Break-out session 1 theme 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T12:45:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-preclinical-development-predicting-thyroid-hormone-side-effects-humans-preclinical-toxicity-studies-break-out-session-1-theme-1_en.pdf"},
    {"id":"31898","name":"Presentation - PIP session: Paediatric uveitis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pip-session-paediatric-uveitis_en.pdf"},
    {"id":"31907","name":"Presentation - A European common data model? Why? Which and how? - meeting objectives (Alison Cave)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-common-data-model-why-which-and-how-meeting-objectives-alison-cave_en.pdf"},
    {"id":"31918","name":"Assays and Strategies for Immunogenicity Assessment - Steven J Swanson","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-09-04T02:09:21Z","last_updated_date":"2007-09-04T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/assays-and-strategies-immunogenicity-assessment-steven-j-swanson_en.pdf"},
    {"id":"31937","name":"Suggestion by the Agency on collating data on use of veterinary AM agents in Europe (ESVAC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/suggestion-agency-collating-data-use-veterinary-am-agents-europe-esvac_en.pdf"},
    {"id":"31952","name":"Presentation - Signal management GVP IX: pilot on signals from MAHs (A. Szmigiel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T15:08:00Z","last_updated_date":"2018-01-04T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-signal-management-gvp-ix-pilot-signals-mahs-szmigiel_en.pdf"},
    {"id":"31954","name":"General Concepts in the European Pharmacopoeia - Anne-Sophie Bouin","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/general-concepts-european-pharmacopoeia-anne-sophie-bouin_en.pdf"},
    {"id":"31961","name":"Key messages in relation to the importance of commercially confidential information","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/key-messages-relation-importance-commercially-confidential-information_en.pdf"},
    {"id":"31973","name":"Presentation - Report on medication-errors (ME) workshop (Thomas Goedecke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-medication-errors-me-workshop-thomas-goedecke_en.pdf"},
    {"id":"31985","name":"Presentation - A national-competent-authority analysis of approval documents","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-national-competent-authority-analysis-approval-documents_en.pdf"},
    {"id":"31993","name":"Presentation - Module 7 - Benefit-risk assessment and good regulatory practice","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T02:00:00Z","last_updated_date":"2018-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-7-benefit-risk-assessment-and-good-regulatory-practice_en.pdf"},
    {"id":"31998","name":"Presentation - Session 4: Statistical considerations for the development of diagnostic tests (Olivier Collignon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-statistical-considerations-development-diagnostic-tests-olivier-collignon_en.pdf"},
    {"id":"32009","name":"Presentation - Introduction and objectives - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines (Guido Rasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-and-objectives-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-medicines-guido-rasi_en.pdf"},
    {"id":"32021","name":"Presentation - Dose selection in drug development and regulation: possible future direction (Richard Lalonde, Donald Stanski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dose-selection-drug-development-and-regulation-possible-future-direction-richard-lalonde-donald-stanski_en.pdf"},
    {"id":"32032","name":"Presentation - Section 5.2: Pharmacokinetic properties","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-52-pharmacokinetic-properties_en.pdf"},
    {"id":"32053","name":"Presentation 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-1_en.pdf"},
    {"id":"32068","name":"Presentation - Paediatric investigation plan assessment procedure","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-investigation-plan-assessment-procedure_en.pdf"},
    {"id":"32081","name":"Presentation - Workshop on patient’s voice in the evaluation of medicines - Introduction (June M Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-introduction-june-m-raine_en.pdf"},
    {"id":"32084","name":"Presentation - EU Risk Management Plans: Update of the GVP Module V (Emil Cochino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-risk-management-plans-update-gvp-module-v-emil-cochino_en.pdf"},
    {"id":"32088","name":"Presentation - Integrating pharmacogenomics into decision making (Munir Pirmohamed)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-integrating-pharmacogenomics-decision-making-munir-pirmohamed_en.pdf"},
    {"id":"32109","name":"Presentation - Adaptive designs for the development of targeted therapies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-designs-development-targeted-therapies_en.pdf"},
    {"id":"32111","name":"Presentation - Going digital: General aspects (Klaus Menges, Olivier Simoen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-going-digital-general-aspects-klaus-menges-olivier-simoen_en.pdf"},
    {"id":"32112","name":"Presentation - Session 3.11: Update on EU member state harmonisation (Seà¡n Kilbride)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-311-update-eu-member-state-harmonisation-sean-kilbride_en.pdf"},
    {"id":"32133","name":"Overview of recent developments in ICH - Thomas Là¶nngren","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overview-recent-developments-ich-thomas-lapnngren_en.pdf"},
    {"id":"32187","name":"Presentation - Session 2 – ISO ICSR Implementation technical aspects - Part 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-12T12:30:00Z","last_updated_date":"2016-05-12T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-iso-icsr-implementation-technical-aspects-part-1_en.pdf"},
    {"id":"32193","name":"Presentation - PKD presentation of outcomes: Consortium / European Medicines Agency Scientific Advice Working Party teleconference (Third list of issues)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-22T11:00:00Z","last_updated_date":"2015-07-22T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pkd-presentation-outcomes-consortium-european-medicines-agency-scientific-advice-working-party-teleconference-third-list-issues_en.pdf"},
    {"id":"32200","name":"Presentation - e-Submission roadmap: Veterinary perspective (Anne-Christine Lantin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-e-submission-roadmap-veterinary-perspective-anne-christine-lantin_en.pdf"},
    {"id":"32222","name":"Presentation - Preview of new medical  dictionary for regulatory activities (MedDRA) hierarchy for medication errors – Coding and retrieval considerations (Judy Harrison)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preview-new-medical-dictionary-regulatory-activities-meddra-hierarchy-medication-errors-coding-and-retrieval-considerations-judy-harrison_en.pdf"},
    {"id":"32251","name":"Presentation - Topic 3 - Obstacles to a timely completion of paediatric development plan studies - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-3-obstacles-timely-completion-paediatric-development-plan-studies-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation_en.pdf"},
    {"id":"32276","name":"Presentation - Optimising the use of the EURD list – the key to the single assessment (Menno van der Elst)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-optimising-use-eurd-list-key-single-assessment-menno-van-der-elst_en.pdf"},
    {"id":"32285","name":"Presentation - Working group on ethics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-06T01:00:00Z","last_updated_date":"2017-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-ethics_en.pdf"},
    {"id":"32289","name":"Presentation - Estimating probability of target attainment (Johan Mouton)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-estimating-probability-target-attainment-johan-mouton_en.pdf"},
    {"id":"32346","name":"Presentation - Theranostics nanoparticles, Peter Dobson, Oxford University","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-theranostics-nanoparticles-peter-dobson-oxford-university_en.pdf"},
    {"id":"32360","name":"Presentation - Patient’s/parent’s view on clinical trial challenges (Deutsche Herzstiftung)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patientsparents-view-clinical-trial-challenges-deutsche-herzstiftung_en.pdf"},
    {"id":"32363","name":"Presentation - EU- RMP and Paediatric pharmacovigilance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-rmp-and-paediatric-pharmacovigilance_en.pdf"},
    {"id":"32428","name":"Transparency and commercially confidential information - EGA’s perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/transparency-and-commercially-confidential-information-egas-perspective_en.pdf"},
    {"id":"32439","name":"Presentation - Immunologicals (Nikolaus KriŠ¾)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunologicals-nikolaus-kris-34_en.pdf"},
    {"id":"32461","name":"Presentation - ESMO magnitude of clinical benefit scale (ESMO-MCBS)\n\nfor new anticancer therapies (Richard Sullivan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T17:00:00Z","last_updated_date":"2015-12-15T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esmo-magnitude-clinical-benefit-scale-esmo-mcbs-new-anticancer-therapies-richard-sullivan_en.pdf"},
    {"id":"32466","name":"Presentation - Medicines Evaluation Board in the Netherlands: Paediatric formulations (Diana van Riet-Nales)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicines-evaluation-board-netherlands-paediatric-formulations-diana-van-riet-nales_en.pdf"},
    {"id":"32469","name":"Presentation - Harmonisation: Vision for the future","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-harmonisation-vision-future_en.pdf"},
    {"id":"32471","name":"Presentation - Public impact of communication (Frederic Bouder)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-impact-communication-frederic-bouder_en.pdf"},
    {"id":"32532","name":"Annual report of the interaction with patients and consumers","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/annual-report-interaction-patients-and-consumers_en.pdf"},
    {"id":"32539","name":"Presentation - General update on paediatric medicines: new and ongoing activities of relevance for Industry stakeholders (Paolo Tomasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-update-paediatric-medicines-new-and-ongoing-activities-relevance-industry-stakeholders-paolo-tomasi_en.pdf"},
    {"id":"32541","name":"Presentation - Veterinarians experiences: Pharmacovigilance and Aquaculture (T.Wall)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinarians-experiences-pharmacovigilance-and-aquaculture-twall_en.pdf"},
    {"id":"32556","name":"Development of an efficient regulatory system in Europe - Point of view of the NCA - Jean Marimbert","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/development-efficient-regulatory-system-europe-point-view-nca-jean-marimbert_en.pdf"},
    {"id":"32559","name":"Presentation - CHMP position paper on medication errors in the context of benefit/risk (Andrea Laslop)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chmp-position-paper-medication-errors-context-benefitrisk-andrea-laslop_en.pdf"},
    {"id":"32563","name":"Presentation - EMA Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation (Viera Lukacova)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-guideline-qualification-and-reporting-physiologically-based-pharmacokinetic-pbpk-modeling-and-simulation-viera-lukacova_en.pdf"},
    {"id":"32585","name":"Presentation - Using the knowledge of biology in the prediction of clearance as the main determinant of drug exposure in paediatric populations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-using-knowledge-biology-prediction-clearance-main-determinant-drug-exposure-paediatric-populations_en.pdf"},
    {"id":"32589","name":"Presentation - European Medicines Agency and health-technology-assessment advice in Europe: Experience of biotech small and medium-sized enterprises (Paolo Morgese)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-and-health-technology-assessment-advice-europe-experience-biotech-small-and-medium-sized-enterprises-paolo-morgese_en.pdf"},
    {"id":"32607","name":"Presentation - Uncontrolled evidence in rare cancers (Paolo G. Casali)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-uncontrolled-evidence-rare-cancers-paolo-g-casali_en.pdf"}    {"id":"32644","name":"Legislative framework and scientific guidance in European assessment - Riccardo Luigetti","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/legislative-framework-and-scientific-guidance-european-assessment-riccardo-luigetti_en.pdf"},
    {"id":"32655","name":"Marketing authorisation: The evaluation process - Dr Evdokia Korakianiti","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/marketing-authorisation-evaluation-process-dr-evdokia-korakianiti_en.pdf"},
    {"id":"32672","name":"Presentation - 'Snapshot' of transversal activities regarding ERNs and clinical research (Eduardo Là³pez Granados, Eileen Treacy, Daria Julkowska)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-snapshot-transversal-activities-regarding-erns-and-clinical-research-eduardo-la3pez-granados-eileen-treacy-daria-julkowska_en.pdf"},
    {"id":"32692","name":"Orphan Designation - Key concepts and evaluation criteria - Jordi Llinares","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/orphan-designation-key-concepts-and-evaluation-criteria-jordi-llinares_en.pdf"},
    {"id":"32697","name":"Presentation - Veterinary antimicrobials: State of play and future developments (Mario Nagtzaam)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-antimicrobials-state-play-and-future-developments-mario-nagtzaam_en.pdf"},
    {"id":"32702","name":"Presentation - Outcome of consultation on additional monitoring of medicines and adverse-drug-reaction reporting – impact on the product information","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcome-consultation-additional-monitoring-medicines-and-adverse-drug-reaction-reporting-impact-product-information_en.pdf"},
    {"id":"32706","name":"Presentation - Best expertise vs conflicts of interest: Striking the right balance (Nikos Dedes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-expertise-vs-conflicts-interest-striking-right-balance-nikos-dedes_en.pdf"},
    {"id":"32713","name":"Presentation - European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) (Alexander Natz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-confederation-pharmaceutical-entrepreneurs-eucope-alexander-natz_en.pdf"},
    {"id":"32719","name":"Presentation - SME workshop: Session 4: Statistical considerations in confirmatory clinical trials II (Oliver Keene)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-29T10:40:00Z","last_updated_date":"2016-02-29T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-workshop-session-4-statistical-considerations-confirmatory-clinical-trials-ii-oliver-keene_en.pdf"},
    {"id":"32739","name":"Presentation - Experience from patient observer in Pharmacovigilance Working Party","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:07Z","last_updated_date":"2011-06-24T22:06:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-patient-observer-pharmacovigilance-working-party_en.pdf"},
    {"id":"32749","name":"Presentation - An Agency on the move (David Mackay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agency-move-david-mackay_en.pdf"},
    {"id":"32771","name":"Presentation - Reflection paper on the use of patient reported outcome (PRO) measures in oncology studies (Daniel O’Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reflection-paper-use-patient-reported-outcome-pro-measures-oncology-studies-daniel-oconnor_en.pdf"},
    {"id":"32782","name":"Presentation - Quantitative challenges of extrapolation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-18T18:58:00Z","last_updated_date":"2016-10-18T18:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quantitative-challenges-extrapolation_en.pdf"},
    {"id":"32799","name":"Presentation - Agenda item 5: SPOR Communications Strategy (Agnieszka Laka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-15T15:00:00Z","last_updated_date":"2016-03-15T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-5-spor-communications-strategy-agnieszka-laka_en.pdf"},
    {"id":"32825","name":"Vascular Dementia or Dementia with Cerebro-Vascular Disease: Changes in Concepts - Jean-Marc Orgogozo","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-11T00:09:21Z","last_updated_date":"2008-02-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/vascular-dementia-or-dementia-cerebro-vascular-disease-changes-concepts-jean-marc-orgogozo_en.pdf"},
    {"id":"32830","name":"Presentation - Session 5: Post-approval confirmatory/supplementary data: registries and observational trials (Vincent Ho)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-post-approval-confirmatorysupplementary-data-registries-and-observational-trials-vincent-ho_en.pdf"},
    {"id":"32835","name":"Presentation - D-E-R characterisation in dose selection, labelling and B/R assessment: focus on the elderly (Terry Shepard, Sue Morgan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-d-e-r-characterisation-dose-selection-labelling-and-br-assessment-focus-elderly-terry-shepard-sue-morgan_en.pdf"},
    {"id":"32836","name":"Presentation - Report on measures of impact of pharmacovigilance processes (Marieke De Bruin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-measures-impact-pharmacovigilance-processes-marieke-de-bruin_en.pdf"},
    {"id":"32851","name":"Presentation - Example of joint symposium organized by UEG and EMA (Michel Delvaux)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-example-joint-symposium-organized-ueg-and-ema-michel-delvaux_en.pdf"},
    {"id":"32867","name":"EMEA SME workshop biological GMP issues - Ian Rees","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-sme-workshop-biological-gmp-issues-ian-rees_en.pdf"},
    {"id":"32869","name":"Presentation - Orphan designation system in Japan (Ministry of Health,\n\nLabour and Welfare)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orphan-designation-system-japan-ministry-health-labour-and-welfare_en.pdf"},
    {"id":"32878","name":"Conclusions of ECHAMP (European Coalition on Homeopathic and Anthroposophic Medicinal Products)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/conclusions-echamp-european-coalition-homeopathic-and-anthroposophic-medicinal-products_en.pdf"},
    {"id":"32881","name":"Presentation - European Group for Generic Veterinary Products (EGGVP): Advice on the impact on the use of antibiotics in animals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-group-generic-veterinary-products-eggvp-advice-impact-use-antibiotics-animals_en.pdf"},
    {"id":"32884","name":"Presentation - Clinical development issues in progressive multiple sclerosis(Volker Knappertz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-development-issues-progressive-multiple-sclerosisvolker-knappertz_en.pdf"},
    {"id":"32885","name":"Presentation - Participation of civil society in scientific advisory groups","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-participation-civil-society-scientific-advisory-groups_en.pdf"},
    {"id":"32896","name":"Revision of ICH M3 - Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals - David R Jones","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/revision-ich-m3-non-clinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorisation-pharmaceuticals-david-r-jones_en.pdf"},
    {"id":"32901","name":"Compliance check & Validation of applications with an agreed PIP Ali Harrison - AstraZeneca","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/compliance-check-validation-applications-agreed-pip-ali-harrison-astrazeneca_en.pdf"},
    {"id":"32906","name":"Presentation - Nuffield Council on Bioethics’ report: Children and clinical research: ethical issues","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nuffield-council-bioethics-report-children-and-clinical-research-ethical-issues_en.pdf"},
    {"id":"32907","name":"Presentation - Annual general meeting (AGM) - Progress report","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-02T17:00:00Z","last_updated_date":"2013-07-02T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-annual-general-meeting-agm-progress-report_en.pdf"},
    {"id":"32911","name":"Highlight report of the Industry stakeholder platform on research and development support","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-23T18:39:00Z","last_updated_date":"2017-05-23T18:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/highlight-report-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"32912","name":"Presentation - Time for the European reference relative efficacy assessment (Francesco De Lorenzo) - S6.3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-time-european-reference-relative-efficacy-assessment-francesco-de-lorenzo-s63_en.pdf"},
    {"id":"32918","name":"Presentation - Looking forward: better communications for better healthcare decisions (Monika Benstetter, Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-looking-forward-better-communications-better-healthcare-decisions-monika-benstetter-juan-garcia-burgos_en.pdf"},
    {"id":"32929","name":"Presentation - 6.5 Optimal design for trials with discrete longitudinal studies with uncertainty on model and parameters (France Mentrà©, Florence Loingeville, Marie Karelle Rivià¨re, Thu Thuy Nguyen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-65-optimal-design-trials-discrete-longitudinal-studies-uncertainty-model-and-parameters-france-mentrac-florence-loingeville-marie-karelle-riviare-thu-thuy-nguyen_en.pdf"},
    {"id":"32937","name":"Presentation - Nanomedicines interaction with biological systems, Kenneth Dawson, University College of Dublin","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nanomedicines-interaction-biological-systems-kenneth-dawson-university-college-dublin_en.pdf"},
    {"id":"32941","name":"Presentation - Methodological issues in paediatric trial design","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T11:00:00Z","last_updated_date":"2012-01-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-methodological-issues-paediatric-trial-design_en.pdf"},
    {"id":"32954","name":"Presentation - Central European Pediatric Oncology Early Trial Alliance (CEPOETA) (R. Demlova)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-central-european-pediatric-oncology-early-trial-alliance-cepoeta-r-demlova_en.pdf"},
    {"id":"32983","name":"Presentation - Development of drugs for bacteremia (Charles Knirsch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-drugs-bacteremia-charles-knirsch_en.pdf"},
    {"id":"33006","name":"Presentation - Objectives of the focus group on non-clinical development of advanced-therapy medicinal products and outcome of discussions in 2011","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-objectives-focus-group-non-clinical-development-advanced-therapy-medicinal-products-and-outcome-discussions-2011_en.pdf"},
    {"id":"33025","name":"Presentation - Work sharing variations (Gavin Hall)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-work-sharing-variations-gavin-hall_en.pdf"},
    {"id":"33037","name":"Presentation - Medicines Evaluation Board in the Netherlands: ICH Q3D elemental impurities and ICH M7 mutagenic impurities recent considerations (Diana van Riet-Nales)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicines-evaluation-board-netherlands-ich-q3d-elemental-impurities-and-ich-m7-mutagenic-impurities-recent-considerations-diana-van-riet-nales_en.pdf"},
    {"id":"33039","name":"Presentation - English version labelling review: overview of the new process for initial MAAs and data from two years experience (Alexios Skarlatos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:30:00Z","last_updated_date":"2018-01-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-english-version-labelling-review-overview-new-process-initial-maas-and-data-two-years-experience-alexios-skarlatos_en.pdf"},
    {"id":"33047","name":"Bosnia & Herzegovina, Agency for Medicinal Products and Medical Devices, B Tubic","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/bosnia-herzegovina-agency-medicinal-products-medical-devices-b-tubic_en.pdf"},
    {"id":"33050","name":"Presentation - Substance and Product (S&P) project(s) and sub-group status update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-and-product-sp-projects-and-sub-group-status-update_en.pdf"},
    {"id":"33053","name":"Development, validation and regulatory approval of a cytokine release test for contaminants: Peter Brà¼gger, Novartis, Switzerland.","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/development-validation-and-regulatory-approval-cytokine-release-test-contaminants-peter-bra-14gger-novartis-switzerland_en.pdf"},
    {"id":"33066","name":"Presentation - Bacteraemia or severe sepsis as indication? (Bart Rijnders)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bacteraemia-or-severe-sepsis-indication-bart-rijnders_en.pdf"},
    {"id":"33072","name":"GMP Training Course Quality Control - Lesley Graham","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-20T02:09:21Z","last_updated_date":"2009-10-20T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gmp-training-course-quality-control-lesley-graham_en.pdf"},
    {"id":"33082","name":"Presentation - Crizotinib in patients with ROS1+ non-small cell lung cancer: rationale and results (Mace L. Rothenberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-crizotinib-patients-ros1-non-small-cell-lung-cancer-rationale-and-results-mace-l-rothenberg_en.pdf"},
    {"id":"33087","name":"Presentation - PK-PD target selection: it’s all about the goal (Paul Ambrose)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pk-pd-target-selection-its-all-about-goal-paul-ambrose_en.pdf"},
    {"id":"33091","name":"Presentation - Development of drugs for bacteraemia","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:50Z","last_updated_date":"2011-04-26T18:05:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-drugs-bacteraemia_en.pdf"},
    {"id":"33098","name":"Presentation - Session 1: Nonclinical Models: proof of concept (Jan Willem van der Laan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-nonclinical-models-proof-concept-jan-willem-van-der-laan_en.pdf"},
    {"id":"33118","name":"eCTD/Nees impact on the centralised procedure Goeffrey Williams - Roche","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ectdnees-impact-centralised-procedure-goeffrey-williams-roche_en.pdf"},
    {"id":"33196","name":"Presentation - In focus – The paediatric PAH population clinicians perspectives (M.Beghetti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-paediatric-pah-population-clinicians-perspectives-mbeghetti_en.pdf"},
    {"id":"33208","name":"Presentation - HIV and FDC: aspects of two guidelines (Filip Josephson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-05T17:00:00Z","last_updated_date":"2016-01-05T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hiv-and-fdc-aspects-two-guidelines-filip-josephson_en.pdf"},
    {"id":"33214","name":"Presentation - Good practice guide on medication errors – Highlights and EU regulatory initiatives (Thomas Goedecke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-practice-guide-medication-errors-highlights-and-eu-regulatory-initiatives-thomas-goedecke_en.pdf"},
    {"id":"33216","name":"Presentation - Discussion about the proposed different levels of subgroup analysis (Claudia Schmoor, Frank Langer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-discussion-about-proposed-different-levels-subgroup-analysis-claudia-schmoor-frank-langer_en.pdf"},
    {"id":"33236","name":"Presentation - Section 1: Name of medicinal product","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-1-name-medicinal-product_en.pdf"},
    {"id":"33248","name":"Presentation - Indications and endpoints for complicated skin and soft-tissue infections","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:47Z","last_updated_date":"2011-04-26T18:05:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-indications-and-endpoints-complicated-skin-and-soft-tissue-infections_en.pdf"},
    {"id":"33273","name":"Presentation - Feedback from CAT (K. Breen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-cat-k-breen-ema_en.pdf"},
    {"id":"33291","name":"Presentation - FDA pilot project to develop a clinical database to examine safety in trials using CAR T-cells (Maura O’Leary)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T11:11:00Z","last_updated_date":"2016-12-02T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-pilot-project-develop-clinical-database-examine-safety-trials-using-car-t-cells-maura-oleary_en.pdf"},
    {"id":"33321","name":"Presentation - Public Private Partnerships as funders, Hugh Laverty","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-private-partnerships-funders-hugh-laverty_en.pdf"},
    {"id":"33394","name":"Presentation - New EudraVigilance functionalities and the 2010 pharmacovigilance legislation – preparing for change: training module PhV-M1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2016-10-10T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-eudravigilance-functionalities-and-2010-pharmacovigilance-legislation-preparing-change-training-module-phv-m1_en.pdf"},
    {"id":"33421","name":"Presentation - Public hearings (Nathalie Bere, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T01:00:00Z","last_updated_date":"2017-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-hearings-nathalie-bere-ema_en.pdf"},
    {"id":"33427","name":"Presentation - Indications and labelling - Specific aspects cross reference within the SmPC (M. Ermisch, GKV-Spitzenverband)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-indications-and-labelling-specific-aspects-cross-reference-within-smpc-m-ermisch-gkv-spitzenverband_en.pdf"},
    {"id":"33434","name":"Presentation - European Medicines Agency re-organisation: Supporting the work of the committees (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-12-11T01:00:00Z","last_updated_date":"2013-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-re-organisation-supporting-work-committees-isabelle-moulon_en.pdf"},
    {"id":"33435","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Mandatory therapeutic fields in the centralised procedure, and scientific/public health challenges for the future - HIV and Vaccines - Luc Montagnier","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-mandatory-therapeutic-fields-centralised-procedure-and-scientificpublic-health-challenges-future-hiv-and-vaccines-luc-montagnier_en.pdf"},
    {"id":"33451","name":"Biodistribution/shedding of AAV1-LPLS447X Vector Sequences after Intramuscular Administration to Lipoprotein Lipase Deficient Patients - Janneke Meulenberg","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/biodistributionshedding-aav1-lpls447x-vector-sequences-after-intramuscular-administration-lipoprotein-lipase-deficient-patients-janneke-meulenberg_en.pdf"},
    {"id":"33456","name":"Session 3 - Clinical Issues - Innovator Industry Presentation - Jay P. Siegel","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-3-clinical-issues-innovator-industry-presentation-jay-p-siegel_en.pdf"},
    {"id":"33458","name":"Presentation - Benefit-risk decisions in the licensing of medicines - Current European Union practice and challenges (Harald Enzmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-benefit-risk-decisions-licensing-medicines-current-european-union-practice-and-challenges-harald-enzmann_en.pdf"},
    {"id":"33475","name":"Presentation - European Medicines Agency shortages workshop: the European Association of hospitals pharmacists perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-shortages-workshop-european-association-hospitals-pharmacists-perspective_en.pdf"},
    {"id":"33500","name":"Presentation - Update on Working Groups 3 and 5 (Susan Tansey)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-working-groups-3-and-5-susan-tansey_en.pdf"},
    {"id":"33518","name":"Presentation - European Hematology Association: What does personalised mean to healthcare professionals - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop o...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-hematology-association-what-does-personalised-mean-healthcare-professionals-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint_en.pdf"},
    {"id":"33523","name":"Presentation - Agenda item 5: communication strategy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2015-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-5-communication-strategy_en.pdf"},
    {"id":"33541","name":"Presentation - Isotretinoin : Review of the pregnancy prevention programme","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T01:00:00Z","last_updated_date":"2011-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-isotretinoin-review-pregnancy-prevention-programme_en.pdf"},
    {"id":"33548","name":"Presentation - Neutralising assay methodologies (Shalini Gupta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-neutralising-assay-methodologies-shalini-gupta_en.pdf"},
    {"id":"33556","name":"Discussion on the EMEA transparency policy - Perspectives from Healthcare Professionals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/discussion-emea-transparency-policy-perspectives-healthcare-professionals_en.pdf"},
    {"id":"33557","name":"Presentation - Registries in pediatric IBD","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-22T01:00:00Z","last_updated_date":"2011-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-registries-pediatric-ibd_en.pdf"},
    {"id":"33566","name":"Review of answers from experts to EMA questions, Dr Richard Vesely","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/review-answers-experts-ema-questions-dr-richard-vesely_en.pdf"},
    {"id":"33592","name":"Presentation - EU CT portal and database (Noemie Manent)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T12:14:00Z","last_updated_date":"2017-03-30T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-ct-portal-and-database-noemie-manent_en.pdf"},
    {"id":"33601","name":"Presentation - Orphan medicinal products in the European centralised procedure: current marketing authorisations for Gaucher disease (Andrea Taft)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-28T01:00:00Z","last_updated_date":"2012-11-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orphan-medicinal-products-european-centralised-procedure-current-marketing-authorisations-gaucher-disease-andrea-taft_en.pdf"},
    {"id":"33612","name":"Presentation - Exploring changes in treatment effects across design stages in adaptive trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-exploring-changes-treatment-effects-across-design-stages-adaptive-trials_en.pdf"},
    {"id":"33615","name":"Presentation - Neuromyelitis optica testimonial - Speech (Irene Wilson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-neuromyelitis-optica-testimonial-speech-irene-wilson_en.pdf"},
    {"id":"33620","name":"Presentation - Subgroup analyses – scene setting from the EU regulators perspective (Hemmings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-subgroup-analyses-scene-setting-eu-regulators-perspective-hemmings_en.pdf"},
    {"id":"33657","name":"Presentation - Veterinary and Substance, Product, Organisation and Referential (SPOR)  (Jos Olaerts, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-and-substance-product-organisation-and-referential-spor-jos-olaerts-ema_en.pdf"},
    {"id":"33662","name":"EU Innovation Network: core profile within the network","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T17:35:00Z","last_updated_date":"2017-05-22T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-innovation-network-core-profile-within-network_en.pdf"},
    {"id":"33715","name":"Priorities of the Regulatory Authorities - Aginus A.W. Kalis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-13T00:09:21Z","last_updated_date":"2008-11-13T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/priorities-regulatory-authorities-aginus-aw-kalis_en.pdf"},
    {"id":"33731","name":"Workshop on medicines for bees - Report from breakout session 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/workshop-medicines-bees-report-breakout-session-1_en.pdf"},
    {"id":"33742","name":"Presentation - European Antibiotic Awareness Day: Promoting prudent antibiotic use in Europe (D. Monnet, ARHAI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-antibiotic-awareness-day-promoting-prudent-antibiotic-use-europe-d-monnet-arhai_en.pdf"},
    {"id":"33743","name":"Presentation - The European Union process-analytical-technology team and its activities (Christina Graffner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-07-21T02:00:00Z","last_updated_date":"2006-07-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-process-analytical-technology-team-and-its-activities-christina-graffner_en.pdf"},
    {"id":"33775","name":"Presentation - International Federation for Animal Health Europe (IFAH-Europe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-federation-animal-health-europe-ifah-europe_en.pdf"},
    {"id":"33779","name":"Presentation - European Medicines Agency/Committee for Medicinal Products for Human Use draft guidance on paediatric hepatitis C virus drug development; what, when, who, how?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-12T03:00:00Z","last_updated_date":"2011-07-12T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agencycommittee-medicinal-products-human-use-draft-guidance-paediatric-hepatitis-c-virus-drug-development-what-when-who-how_en.pdf"},
    {"id":"33781","name":"Presentation - Session 1 - EDQM, EMA and the RCG working party","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-05T01:00:00Z","last_updated_date":"2013-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-edqm-ema-and-rcg-working-party_en.pdf"},
    {"id":"33787","name":"Presentation - EU IDMP/SPOR Task Force meeting: Project proposal: IMI FaCE facts (5. agenda) (David Lewis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-idmpspor-task-force-meeting-project-proposal-imi-face-facts-5-agenda-david-lewis_en.pdf"},
    {"id":"33792","name":"Presentation - How Paediatric Research Networks can help drug development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T17:10:00Z","last_updated_date":"2017-01-04T17:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-paediatric-research-networks-can-help-drug-development_en.pdf"},
    {"id":"33802","name":"Presentation - Best expertise vs conflicts of interests: Striking the right balance - Academia (human medicines) (Ludwig Wolf-Dieter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-expertise-vs-conflicts-interests-striking-right-balance-academia-human-medicines-ludwig-wolf-dieter_en.pdf"},
    {"id":"33804","name":"Presentation - Non-clinical Assessment Requirements - Perspectives from a Member State","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-clinical-assessment-requirements-perspectives-member-state_en.pdf"},
    {"id":"33825","name":"Presentation - EU reference network - Directive 2011-24-EU (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-reference-network-directive-2011-24-eu-irmgard-eichler_en.pdf"},
    {"id":"33847","name":"Presentation - Substance, Product, Organisation and Referential (SPOR) programme timelines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-product-organisation-and-referential-spor-programme-timelines_en.pdf"},
    {"id":"33896","name":"Presentation - FDA, EuPFI, WHO Collaborations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-eupfi-who-collaborations_en.pdf"},
    {"id":"33899","name":"Presentation - Medicines shortages in Europe: A picture of the problem from the hospital-pharmacy perspective (Roberto Frontini)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicines-shortages-europe-picture-problem-hospital-pharmacy-perspective-roberto-frontini_en.pdf"},
    {"id":"33907","name":"Presentation - Clinical trials in CF - regulatory perspective: endpoints for added clinical benefit in view of HTA (Paolo D. Siviero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-cf-regulatory-perspective-endpoints-added-clinical-benefit-view-hta-paolo-d-siviero_en.pdf"}    {"id":"33922","name":"Presentation - Committee for Advanced Therapies (CAT) feedback: Chimeric antigen receptor (CAR) T cell therapies - EMA's PCWP and HCPWP joint meeting (Kieran Breen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-advanced-therapies-cat-feedback-chimeric-antigen-receptor-car-t-cell-therapies-emas-pcwp-and-hcpwp-joint-meeting-kieran-breen_en.pdf"},
    {"id":"33950","name":"Presentation - Shortages of medicinal products due to manufacturing and quality problems: Update from working groups (Andrea Taft)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-shortages-medicinal-products-due-manufacturing-and-quality-problems-update-working-groups-andrea-taft_en.pdf"},
    {"id":"33975","name":"Presentation - Management of DOAC in clinical praxis (Peter J Svensson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-management-doac-clinical-praxis-peter-j-svensson_en.pdf"},
    {"id":"33993","name":"Presentation - Medicinal products subject to additional monitoring (M. Arriegas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicinal-products-subject-additional-monitoring-m-arriegas_en.pdf"},
    {"id":"33995","name":"Presentation - Update on the standard EudraVigilance paediatric query (Cosimo Zaccaria)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T02:00:00Z","last_updated_date":"2014-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-standard-eudravigilance-paediatric-query-cosimo-zaccaria_en.pdf"},
    {"id":"34005","name":"Presentation - The Adaptive Pathways: concept and critical issues (Hans-Georg Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-pathways-concept-and-critical-issues-hans-georg-eichler_en.pdf"},
    {"id":"34006","name":"Presentation - WHO: the draft Global AMR action plan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T13:00:00Z","last_updated_date":"2015-04-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-who-draft-global-amr-action-plan_en.pdf"},
    {"id":"34011","name":"Presentation - Topic 5 - Transparency measures - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-5-transparency-measures-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation_en.pdf"},
    {"id":"34016","name":"Presentation - Implementation of Article 57(2), second subparagraph of Regulation (EC) No. 726/2004","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-article-572-second-subparagraph-regulation-ec-no-7262004_en.pdf"},
    {"id":"34019","name":"Presentation - Risk management summary publication - Review of experience – update CMDh activities since 12 June 2015 (Kora Doorduyn-van der Stoep)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-management-summary-publication-review-experience-update-cmdh-activities-12-june-2015-kora-doorduyn-van-der-stoep_en.pdf"},
    {"id":"34038","name":"Presentation - Good pharmacovigilance practices module IV: Pharmacovigilance audit (Edit Weidlich)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-module-iv-pharmacovigilance-audit-edit-weidlich_en.pdf"},
    {"id":"34078","name":"Presentation - Current clinical evidence for the therapeutic use of bacteriophages (Xavier Wittebole)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-22T02:00:00Z","last_updated_date":"2015-06-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-clinical-evidence-therapeutic-use-bacteriophages-xavier-wittebole_en.pdf"},
    {"id":"34079","name":"Presentation - Immunologicals – industry perspective (Ariane van de Moer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunologicals-industry-perspective-ariane-van-de-moer_en.pdf"},
    {"id":"34099","name":"Presentation - Good pharmacovigilance practices module XV (Jane Ahlqvist Rastad, Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-module-xv-jane-ahlqvist-rastad-juan-garcia-burgos_en.pdf"},
    {"id":"34105","name":"Presentation - Non-clinical development of gene-therapy medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-clinical-development-gene-therapy-medicinal-products_en.pdf"},
    {"id":"34110","name":"Presentation - Health-technology-assessment-body (HTA) view (Leeza Osipenko)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-health-technology-assessment-body-hta-view-leeza-osipenko_en.pdf"},
    {"id":"34118","name":"Presentation - Data for executing the consortium’s research plan: applying regulatory science to neonatal electronic data (Neena Modi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-executing-consortiums-research-plan-applying-regulatory-science-neonatal-electronic-data-neena-modi_en.pdf"},
    {"id":"34127","name":"Biomarker validation - Why, which and how? - Charles T. Benson","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/biomarker-validation-why-which-and-how-charles-t-benson_en.pdf"},
    {"id":"34130","name":"Presentation - The Pharmacovigilance Risk Assessment Committee","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:09Z","last_updated_date":"2011-06-24T22:06:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-risk-assessment-committee_en.pdf"},
    {"id":"34139","name":"Presentation - The Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE) project on vaccines (Jose Drabwell)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accelerated-development-vaccine-benefit-risk-collaboration-europe-advance-project-vaccines-jose-drabwell_en.pdf"},
    {"id":"34144","name":"Presentation - Breakout session - Neonatal sepsis (Danny Benjamin and Catherine Sherwin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-neonatal-sepsis-danny-benjamin-and-catherine-sherwin_en.pdf"},
    {"id":"34155","name":"Presentation - Haemophilia registries quantity versus quality: the current situation in Europe (Christine Keipert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-haemophilia-registries-quantity-versus-quality-current-situation-europe-christine-keipert_en.pdf"},
    {"id":"34167","name":"Presentation - Cardiology Network (Sylvie DI FILIPPO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T16:00:00Z","last_updated_date":"2013-07-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cardiology-network-sylvie-di-filippo_en.pdf-0"},
    {"id":"34175","name":"Presentation - Review of requirements for immunological medicinal products and their evolution since the start of Community legislation on medicines (Carmen Jungback)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T14:00:00Z","last_updated_date":"2015-04-29T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-review-requirements-immunological-medicinal-products-and-their-evolution-start-community-legislation-medicines-carmen-jungback_en.pdf"},
    {"id":"34183","name":"Presentation - Breakout session 2: Science and data","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T17:35:00Z","last_updated_date":"2013-11-27T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-2-science-and-data_en.pdf"},
    {"id":"34225","name":"Presentation - Frailty: Challenges and possible solutions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-frailty-challenges-and-possible-solutions_en.pdf"},
    {"id":"34228","name":"Challenges with Advanced Therapy Medicinal Products - Christian K Schneider","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/challenges-advanced-therapy-medicinal-products-christian-k-schneider_en.pdf"},
    {"id":"34236","name":"Presentation - Patient organisations' considerations (David Haerry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-organisations-considerations-david-haerry_en.pdf"},
    {"id":"34244","name":"Results of HMA survey of collection of data on sales and use of AMs in Member States - Alfred Hera","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/results-hma-survey-collection-data-sales-and-use-ams-member-states-alfred-hera_en.pdf"},
    {"id":"34248","name":"Implications of the EMEA Naming Policy - An industry perspective Anja Manz - Novartis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/implications-emea-naming-policy-industry-perspective-anja-manz-novartis_en.pdf"},
    {"id":"34250","name":"Presentation - Consumer safety issues - Approach for injection site residues (Bruno Urbain)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-consumer-safety-issues-approach-injection-site-residues-bruno-urbain_en.pdf"},
    {"id":"34256","name":"Presentation - Topic 1 - Stakeholder perspectives on the development\n\nof new methodologies BOND ERN perspective - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Luca Sangio...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-stakeholder-perspectives-development-new-methodologies-bond-ern-perspective-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-luca-sangio_en.pdf"},
    {"id":"34265","name":"Presentation - The relationship between PML-rituximab and other immunobiologicals: an overview, Renaud Du Pasquier","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-relationship-between-pml-rituximab-and-other-immunobiologicals-overview-renaud-du-pasquier_en.pdf"},
    {"id":"34280","name":"Presentation - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals Working Party (HCPWP) meeting dates for 2015 (Nathalie B...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-working-party-hcpwp-meeting-dates-2015-nathalie_en.pdf"},
    {"id":"34284","name":"Presentation - Case study: Evaluation of health based exposure limits and potential impact on manufacturing equipment cleaning limits (G. Allison, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-evaluation-health-based-exposure-limits-and-potential-impact-manufacturing-equipment-cleaning-limits-g-allison-efpia_en.pdf"},
    {"id":"34294","name":"Presentation - NK Cells (Evren Alici)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T10:22:00Z","last_updated_date":"2016-12-02T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nk-cells-evren-alici_en.pdf"},
    {"id":"34302","name":"EMEA meeting with interested parties on the review process on names for medicinal products - Ann Robins","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-09-11T02:09:21Z","last_updated_date":"2006-09-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-meeting-interested-parties-review-process-names-medicinal-products-ann-robins_en.pdf"},
    {"id":"34327","name":"Presentation - Committee for Medicinal Products for Human Use feedback (Fà¡tima Ventura, CHMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-medicinal-products-human-use-feedback-fatima-ventura-chmp_en.pdf"},
    {"id":"34330","name":"NewPresentation - Endorsement of new or updated applications for Enpr-EMA membership (Benjamin Pelle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/newpresentation-endorsement-new-or-updated-applications-enpr-ema-membership-benjamin-pelle_en.pdf"},
    {"id":"34352","name":"Presentation - Day 1: ‘Dry’ Age-related macular degeneration (AMD)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-dry-age-related-macular-degeneration-amd_en.pdf"},
    {"id":"34370","name":"Presentation - Biosimilar industry perspective on clinical issues - Equivalence versus non-inferiority","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:56Z","last_updated_date":"2012-06-15T17:10:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-biosimilar-industry-perspective-clinical-issues-equivalence-versus-non-inferiority_en.pdf"},
    {"id":"34374","name":"Presentation - Implementation of the pharmacovigilance legislation: Building on two years of operation (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-pharmacovigilance-legislation-building-two-years-operation-peter-arlett_en.pdf"},
    {"id":"34395","name":"ESGCT/ICH Workshop on Viral Vector Shedding 1 - Klaus Cichutek","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/esgctich-workshop-viral-vector-shedding-1-klaus-cichutek_en.pdf"},
    {"id":"34409","name":"Presentation - Croatia’s perspective on implementation of the new pharmacovigilance legislation (Marina Dimov Di Giusti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-croatias-perspective-implementation-new-pharmacovigilance-legislation-marina-dimov-di-giusti_en.pdf"},
    {"id":"34416","name":"Presentation - FDA Reflections on Joint Regulators/Industry QbD Workshop (Christine M. V. Moore)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-reflections-joint-regulatorsindustry-qbd-workshop-christine-m-v-moore_en.pdf"},
    {"id":"34429","name":"Presentation - Session 2.2  - Working Group on Ethics (Pirkko Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-22-working-group-ethics-pirkko-lepola_en.pdf"},
    {"id":"34434","name":"Presentation - Substance, Product, Organisation and Referential (SPOR) communication update (Agnieszka Laka, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-product-organisation-and-referential-spor-communication-update-agnieszka-laka-ema_en.pdf"},
    {"id":"34439","name":"Presentation - 3.2 Draft reflection paper on ethical and good-clinical-practice aspects of clinical trials of medicinal products for human use conducted outside of the European Union (EU) / European Economic Area and sub...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2011-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-32-draft-reflection-paper-ethical-and-good-clinical-practice-aspects-clinical-trials-medicinal-products-human-use-conducted-outside-european-union-eu-european-economic-area-and-sub_en.pdf"},
    {"id":"34451","name":"Presentation - Risk management (S. Blackburn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-management-s-blackburn_en.pdf"},
    {"id":"34465","name":"Presentation - Monitoring methods and systems (Georg Himmelstjerna, Jà¼rgen Krà¼cken)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-methods-and-systems-georg-himmelstjerna-ja-14rgen-kra-14cken_en.pdf"},
    {"id":"34471","name":"Presentation - Methods to go from process outcomes to health outcomes (Stephen Evans)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-methods-go-process-outcomes-health-outcomes-stephen-evans_en.pdf"},
    {"id":"34475","name":"Presentation - Adaptive clinical trials with subgroup selection (Stallard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adaptive-clinical-trials-subgroup-selection-stallard_en.pdf"},
    {"id":"34478","name":"Presentation - Routine signal detection and statistical tools on paediatrics (Cosimo Zaccaria)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T02:00:00Z","last_updated_date":"2014-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-routine-signal-detection-and-statistical-tools-paediatrics-cosimo-zaccaria_en.pdf"},
    {"id":"34480","name":"Presentation - IFAH-Europe: Elements for discussion on the principles for assignment of DDDA and DCDA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T13:00:00Z","last_updated_date":"2015-04-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ifah-europe-elements-discussion-principles-assignment-ddda-and-dcda_en.pdf"},
    {"id":"34494","name":"Presentation - 4.1 A value-of-information approach to sample size determination in confirmatory clinical trials in small populations (Nigel Stallard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-41-value-information-approach-sample-size-determination-confirmatory-clinical-trials-small-populations-nigel-stallard_en.pdf"},
    {"id":"34500","name":"Presentation - Session 3.8: European Reference Networks (Enrique Terol)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-38-european-reference-networks-enrique-terol_en.pdf"},
    {"id":"34505","name":"Presentation - Agenda item 1: update from the industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-10-29T01:00:00Z","last_updated_date":"2015-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-item-1-update-industry_en.pdf"},
    {"id":"34518","name":"Presentation - Clinical Researchers, Eugene Major","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-researchers-eugene-major_en.pdf"},
    {"id":"34549","name":"Revised Guidelines on Bioequivalence - Monica Edholm","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:00Z","last_updated_date":"2008-11-14T00:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/revised-guidelines-bioequivalence-monica-edholm_en.pdf"},
    {"id":"34553","name":"Presentation - Industry Experience with PML, Carmen Bozic","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-experience-pml-carmen-bozic_en.pdf"},
    {"id":"34554","name":"Degradation in poultry manure: How to express concentrations? - Leo Van Leemput","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-06-23T02:09:21Z","last_updated_date":"2009-06-23T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/degradation-poultry-manure-how-express-concentrations-leo-van-leemput_en.pdf"},
    {"id":"34564","name":"Presentation - Working Group on public-private partnership update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-18T13:40:00Z","last_updated_date":"2017-12-18T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-public-private-partnership-update_en.pdf"},
    {"id":"34576","name":"Presentation - Module 9 - Good practice and inspections","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T02:00:00Z","last_updated_date":"2018-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-module-9-good-practice-and-inspections_en.pdf"},
    {"id":"34578","name":"Update from 'SME Office' for micro, small & medium-sized enterprises - Melanie Carr","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/update-sme-office-micro-small-medium-sized-enterprises-melanie-carr_en.pdf-0"},
    {"id":"34591","name":"Presentation - Orphan designation in the EU (Jordi Llinares)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T02:00:00Z","last_updated_date":"2013-10-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orphan-designation-eu-jordi-llinares_en.pdf"},
    {"id":"34606","name":"Presentation - Day 2: Limbal stem cell therapy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-limbal-stem-cell-therapy_en.pdf"},
    {"id":"34636","name":"Presentation - Working group on young people advisory groups","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-06T01:00:00Z","last_updated_date":"2017-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-young-people-advisory-groups_en.pdf"},
    {"id":"34640","name":"Presentation - Introduction to ALIMS (Pavle Zelic)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-alims-pavle-zelic_en.pdf"},
    {"id":"34656","name":"Presentation - Model Informed Drug Discovery and Development (MID3) Good Practice: use of prior knowledge and setting up assumptions (Scott Marshall, \n\nLutz Harnisch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-model-informed-drug-discovery-and-development-mid3-good-practice-use-prior-knowledge-and-setting-assumptions-scott-marshall-lutz-harnisch_en.pdf"},
    {"id":"34665","name":"Presentation - The International Consortium for Personalised Medicine (PerMed) - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-consortium-personalised-medicine-permed-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-medicines_en.pdf"},
    {"id":"34670","name":"Presentation - Challenges developing an RSV therapeutic in paediatrics (Matthew W. McClure)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T16:00:00Z","last_updated_date":"2013-07-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-developing-rsv-therapeutic-paediatrics-matthew-w-mcclure_en.pdf"},
    {"id":"34672","name":"Presentation - Interaction with patients and consumers: Overview of involvement in EMA activities during 2015 (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-patients-and-consumers-overview-involvement-ema-activities-during-2015-nathalie-bere_en.pdf"},
    {"id":"34679","name":"Presentation - Cell-based products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cell-based-products_en.pdf"},
    {"id":"34681","name":"Presentation - Workshop on patient's voice in the evaluation of medicines -European Register for Multiple Sclerosis: Pooling European data to better understand and fight multiple sclerosis (Christoph Thalheim)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T01:00:00Z","last_updated_date":"2013-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-patients-voice-evaluation-medicines-european-register-multiple-sclerosis-pooling-european-data-better-understand-and-fight-multiple-sclerosis-christoph-thalheim_en.pdf"},
    {"id":"34686","name":"Presentation - Use of dose-exposure-response model in immunology/transplantation: general considerations and case study (T Dumortier, M Looby, Y Wang)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-dose-exposure-response-model-immunologytransplantation-general-considerations-and-case-study-t-dumortier-m-looby-y-wang_en.pdf"},
    {"id":"34690","name":"Presentation - Pediatric inflammatory bowel disease clinical trials: is there a role for placebo? (Athos Bousvaros)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pediatric-inflammatory-bowel-disease-clinical-trials-there-role-placebo-athos-bousvaros_en.pdf"},
    {"id":"34702","name":"Presentation - Quality systems for pharmacovigilance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-systems-pharmacovigilance_en.pdf"},
    {"id":"34713","name":"Presentation - Current status and update of the Article 57(2) implementation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-status-and-update-article-572-implementation_en.pdf"},
    {"id":"34714","name":"Presentation: Successful IMI project: INNODIA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-successful-imi-project-innodia_en.pdf"},
    {"id":"34715","name":"Presentation - 3.2 Adaptive levels of evidence: an extrapolation framework to specify requirements for drug development in children (Franz Konig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-32-adaptive-levels-evidence-extrapolation-framework-specify-requirements-drug-development-children-franz-k%7Fonig_en.pdf"},
    {"id":"34730","name":"Presentation - EMA’s collaboration with Health Technology Assessment bodies (Hans-Georg Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-collaboration-health-technology-assessment-bodies-hans-georg-eichler_en.pdf"},
    {"id":"34743","name":"Presentation - Findings from the PCWP/HCPWP topic group on social media (Donald Singer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-findings-pcwphcpwp-topic-group-social-media-donald-singer_en.pdf"},
    {"id":"34744","name":"Presentation - Topic 3 - Clinical development strategies and trial designs for new TB treatment regimens, Bedaquiline case study (Myriam Theeuwes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-3-clinical-development-strategies-and-trial-designs-new-tb-treatment-regimens-bedaquiline-case-study-myriam-theeuwes_en.pdf"},
    {"id":"34756","name":"Presentation - Medication errors: development of prevention strategies for medicines and medical devices (Laurent Auclert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medication-errors-development-prevention-strategies-medicines-medical-devices-laurent-auclert_en.pdf"},
    {"id":"34759","name":"European Committee for Homeopathy - Contribution to discussion at homeopathic workshop","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-committee-homeopathy-contribution-discussion-homeopathic-workshop_en.pdf"},
    {"id":"34763","name":"Presentation - EBG’s comments on the draft revised guideline on similar biological medicinal products (Karl Heinz Emmert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ebgs-comments-draft-revised-guideline-similar-biological-medicinal-products-karl-heinz-emmert_en.pdf"},
    {"id":"34778","name":"Presentation - Regulatory discussant - Break-out session 1 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-discussant-break-out-session-1-theme-3_en.pdf"},
    {"id":"34795","name":"Presentation - International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products/outreach, session IV: Future legislation and international affairs (Brigitte Boenisch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-cooperation-harmonisation-technical-requirements-registration-veterinary-medicinal-productsoutreach-session-iv-future-legislation-and-international-affairs-brigitte-boenisch_en.pdf"},
    {"id":"34804","name":"Presentation - Medical literature monitoring start-up phase (Sabine Brosch, Tom Paternoster-Howe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-02T12:20:00Z","last_updated_date":"2015-07-02T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-literature-monitoring-start-phase-sabine-brosch-tom-paternoster-howe_en.pdf"},
    {"id":"34806","name":"Presentation - Electronic submissions in the EU","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-electronic-submissions-eu_en.pdf"},
    {"id":"34839","name":"Presentation - Topic 4 - Improving the handling of paediatric investigation plan (PIP) applications: Industry perspective - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (G...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-4-improving-handling-paediatric-investigation-plan-pip-applications-industry-perspective-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-g_en.pdf"},
    {"id":"34855","name":"Presentation - Procedural update: pre-authorisation procedures (Fia Westerholm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-procedural-update-pre-authorisation-procedures-fia-westerholm_en.pdf"},
    {"id":"34858","name":"Scientific requirements for cell therapy and tissue engineered products: Non-clinical and clinical aspects - Giovanni Migliaccio","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-requirements-cell-therapy-and-tissue-engineered-products-non-clinical-and-clinical-aspects-giovanni-migliaccio_en.pdf"},
    {"id":"34861","name":"Presentation - Overview of European Medicines Agency's interaction with patients and consumers during 2015 (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-european-medicines-agencys-interaction-patients-and-consumers-during-2015-nathalie-bere_en.pdf"},
    {"id":"34870","name":"Update on the eCTD - Joseph Cipollina","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/update-ectd-joseph-cipollina_en.pdf"},
    {"id":"34877","name":"Presentation - The investor’s perspective (Joep Muijrers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-investors-perspective-joep-muijrers_en.pdf"},
    {"id":"34892","name":"Generic products in the EU, G Wade, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/generic-products-eu-g-wade-ema_en.pdf"},
    {"id":"34913","name":"Workshop - Deficiency Points - Malcolm Dash","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/workshop-deficiency-points-malcolm-dash_en.pdf"},
    {"id":"34919","name":"Presentation - Regulatory Perspective on Real World Evidence (RWE) in scientific advice - EMA's PCWP and HCPWP joint meeting (Jane Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspective-real-world-evidence-rwe-scientific-advice-emas-pcwp-and-hcpwp-joint-meeting-jane-moseley_en.pdf"},
    {"id":"34922","name":"Presentation - The Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE) (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accelerated-development-vaccine-benefit-risk-collaboration-europe-advance-xavier-kurz_en.pdf"}    {"id":"34954","name":"Presentation - The latest advances in the understanding of the pathophysiology of Alzheimer’s disease and the development of disease-modifying therapies (Gary Romano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-latest-advances-understanding-pathophysiology-alzheimers-disease-and-development-disease-modifying-therapies-gary-romano_en.pdf"},
    {"id":"34968","name":"Presentation - A randomized, double-blind trial of anti-TNF chimeric monoclonal antibody (Infliximab) in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-randomized-double-blind-trial-anti-tnf-chimeric-monoclonal-antibody-infliximab-combination-methotrexate-treatment-patients-polyarticular-juvenile-rheumatoid-arthritis_en.pdf"},
    {"id":"34971","name":"Introductory remarks - Use of Fluoroquinolones in Europe - Gerard Moulin","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/introductory-remarks-use-fluoroquinolones-europe-gerard-moulin_en.pdf"},
    {"id":"34972","name":"Presentation - Croatia - Decision-making phasing-in (Tony Humphreys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-croatia-decision-making-phasing-tony-humphreys_en.pdf"},
    {"id":"34983","name":"Presentation - Assessment of a MAA: Awareness of the PIP recommendation: Generic applications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-assessment-maa-awareness-pip-recommendation-generic-applications_en.pdf-0"},
    {"id":"34988","name":"Presentation - \n\nConsiderations for the development of biological medicinal products (Camilla Svensson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T18:12:00Z","last_updated_date":"2016-10-26T18:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-development-biological-medicinal-products-camilla-svensson_en.pdf"},
    {"id":"34993","name":"Presentation - Peptides, cell therapy (Thomas Hinz) - S4.3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-peptides-cell-therapy-thomas-hinz-s43_en.pdf"},
    {"id":"35002","name":"Presentation - Case study 2 - Avelumab integrated Mab example - Session 5 (Isabelle Colmagne-Poulard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-2-avelumab-integrated-mab-example-session-5-isabelle-colmagne-poulard_en.pdf"},
    {"id":"35017","name":"Presentation - Innovation Task Force (Marisa Papaluca)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovation-task-force-marisa-papaluca_en.pdf"},
    {"id":"35030","name":"Presentation - Multi-arm trials with repurposed drugs in progressive MS (Jeremy Chataway)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multi-arm-trials-repurposed-drugs-progressive-ms-jeremy-chataway_en.pdf"},
    {"id":"35036","name":"Quality assessors training - Diana van Riet","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/quality-assessors-training-diana-van-riet_en.pdf"},
    {"id":"35079","name":"Presentation - Descriptive overview of paediatric versus adult adverse drug reactions in EudraVigilance (Kevin Blake)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T02:00:00Z","last_updated_date":"2014-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-descriptive-overview-paediatric-versus-adult-adverse-drug-reactions-eudravigilance-kevin-blake_en.pdf"},
    {"id":"35099","name":"Presentation - Enhanced approach (Kowid Ho)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enhanced-approach-kowid-ho_en.pdf"},
    {"id":"35103","name":"Presentation - Non-Placebo and Add on Clinical Trials (Warren W Wasiewski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-placebo-and-add-clinical-trials-warren-w-wasiewski_en.pdf"},
    {"id":"35104","name":"Presentation - Pharmacometric approaches for extrapolation from adult to paediatric type-2 diabetes mellitus (Tarek Leil, Satyendra Suryawanshi, Ronald Portman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacometric-approaches-extrapolation-adult-paediatric-type-2-diabetes-mellitus-tarek-leil-satyendra-suryawanshi-ronald-portman_en.pdf"},
    {"id":"35107","name":"Presentation: Direct patient reporting of adverse drug reactions: a 15-country survey","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-08-20T02:00:00Z","last_updated_date":"2010-08-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-direct-patient-reporting-adverse-drug-reactions-15-country-survey_en.pdf"},
    {"id":"35123","name":"Presentation - Physiologically based pharmacokinetic modeling with PK-Sim and MoBi in support of the paediatric investigation plan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-physiologically-based-pharmacokinetic-modeling-pk-sim-and-mobi-support-paediatric-investigation-plan_en.pdf"},
    {"id":"35126","name":"Presentation - Session 3.1: Clinical issues: Is product / indication specific guidance necessary and meaningful?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:46Z","last_updated_date":"2012-06-15T17:10:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-31-clinical-issues-product-indication-specific-guidance-necessary-and-meaningful_en.pdf"},
    {"id":"35131","name":"Presentation - Questionnaire overview (Janina Karres)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-questionnaire-overview-janina-karres_en.pdf"},
    {"id":"35154","name":"Presentation - Survey on post authorisation procedures: Update on improvement actions (Evdokia Korakianiti, Alberto Ganan Jimenez, Ana Zanoletty)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-19T02:00:00Z","last_updated_date":"2016-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-post-authorisation-procedures-update-improvement-actions-evdokia-korakianiti-alberto-ganan-jimenez-ana-zanoletty_en.pdf"},
    {"id":"35178","name":"Presentation: Update from EMA Workshop on extrapolation of efficacy in children","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ema-workshop-extrapolation-efficacy-children_en.pdf"},
    {"id":"35238","name":"Presentation: Educational Training of Research Staff Involved in Paediatric Clinical Trials / GCP Training across multispecialty and countries","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-educational-training-research-staff-involved-paediatric-clinical-trials-gcp-training-across-multispecialty-and-countries_en.pdf"},
    {"id":"35255","name":"Presentation - Pharmaceutical Group of European Union (Jamie Wilkinson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmaceutical-group-european-union-jamie-wilkinson_en.pdf"},
    {"id":"35257","name":"Presentation - Scientific advice on clinical aspects – key considerations, Dr. Bertil Jonsson","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advice-clinical-aspects-key-considerations-dr-bertil-jonsson_en.pdf"},
    {"id":"35262","name":"Time to standardize our Practices of pain management In Europe - C. Wood","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-10-28T02:09:21Z","last_updated_date":"2004-10-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/time-standardize-our-practices-pain-management-europe-c-wood_en.pdf"},
    {"id":"35281","name":"Presentation - Incentives for development of advanced-therapy medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-incentives-development-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"35284","name":"Presentation - European Medicines Agency Human Scientific Committees' Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting - Adaptive Pathways – Learnings from pilot (Francesca Cerreta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-meeting-adaptive-pathways-learnings-pilot-francesca-cerreta_en.pdf"},
    {"id":"35298","name":"Presentation - Support available to SMEs nationally and internationally – FDA, Ms Brenda Stodart","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-support-available-smes-nationally-and-internationally-fda-ms-brenda-stodart_en.pdf"},
    {"id":"35299","name":"Presentation - Follow-up from the EC/EMA workshop on paediatrics (Ralph Bax)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T17:31:00Z","last_updated_date":"2018-06-06T17:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-follow-ecema-workshop-paediatrics-ralph-bax_en.pdf"},
    {"id":"35353","name":"Presentation - 1.2 EudraVigilance access policy and access to EudraVigilance data","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-12-eudravigilance-access-policy-and-access-eudravigilance-data_en.pdf"},
    {"id":"35357","name":"Presentation - Guidance on the anonymisation of clinical reports for the purpose of publication in accordance with policy 0070 (Monica Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-29T02:00:00Z","last_updated_date":"2015-06-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-anonymisation-clinical-reports-purpose-publication-accordance-policy-0070-monica-dias_en.pdf"},
    {"id":"35372","name":"Presentation - Development of drugs for eradication of nasal carriage of s. aureus to reduce s. aureus infections in vulnerable surgical patients (Richard Bax)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-drugs-eradication-nasal-carriage-s-aureus-reduce-s-aureus-infections-vulnerable-surgical-patients-richard-bax_en.pdf"},
    {"id":"35402","name":"Presentation: How can the informed consent process better address the needs of parents/children?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-can-informed-consent-process-better-address-needs-parentschildren_en.pdf"},
    {"id":"35411","name":"Presentation - What patients and caregivers want to happen now - priorities for action, Christoph Thalheim","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-patients-and-caregivers-want-happen-now-priorities-action-christoph-thalheim_en.pdf"},
    {"id":"35415","name":"EGA-EBG's quality perspective on Biosimilar mAbs - Martin Schiestl","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-07-02T02:09:21Z","last_updated_date":"2009-07-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ega-ebgs-quality-perspective-biosimilar-mabs-martin-schiestl_en.pdf"},
    {"id":"35418","name":"Presentation - Regulators perspective - Session 2 (Keith Pugh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulators-perspective-session-2-keith-pugh_en.pdf"},
    {"id":"35425","name":"Presentation - Biomarkers of response/safety for anti-CD19 CAR T cell therapy(Margo Roberts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T11:11:00Z","last_updated_date":"2016-12-02T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-biomarkers-responsesafety-anti-cd19-car-t-cell-therapymargo-roberts_en.pdf"},
    {"id":"35431","name":"Presentation - What can we do now and what are the gaps in our knowledge? The direct thrombin inhibitor (dabigatran etexilate) (Marie Louise S. Christiansen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-can-we-do-now-and-what-are-gaps-our-knowledge-direct-thrombin-inhibitor-dabigatran-etexilate-marie-louise-s-christiansen_en.pdf"},
    {"id":"35433","name":"Presentation - Workshop opening (Rob Hemmings, Efthymios Manolis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-opening-rob-hemmings-efthymios-manolis_en.pdf"},
    {"id":"35436","name":"Presentation - Enpr-EMA WG6: A framework for networks to interact with industry and regulators when implementation/conduct of clinical trials agreed in PIPs is no longer possible (Saul Faust)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-wg6-framework-networks-interact-industry-and-regulators-when-implementationconduct-clinical-trials-agreed-pips-no-longer-possible-saul-faust_en.pdf"},
    {"id":"35437","name":"Presentation - Best expertise vs conflicts of interest: Striking the right balance? (Pierre Chirac)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-expertise-vs-conflicts-interest-striking-right-balance-pierre-chirac_en.pdf"},
    {"id":"35463","name":"Presentation - Electronic submission – industry perspective (Michael Colmorgen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-electronic-submission-industry-perspective-michael-colmorgen_en.pdf"},
    {"id":"35477","name":"Presentation - 10th anniversary of European Medicines Agency’s Patients' and Consumers' Working Party (PCWP): A forward look (Noà«l Wathion)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-10th-anniversary-european-medicines-agencys-patients-and-consumers-working-party-pcwp-forward-look-noal-wathion_en.pdf"},
    {"id":"35492","name":"Presentation - Can pharmacokinetics and modelling help?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-can-pharmacokinetics-and-modelling-help_en.pdf"},
    {"id":"35510","name":"Presentation - Summary of key positions from the discussions: Regulatory (dis)agreement","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-key-positions-discussions-regulatory-disagreement_en.pdf"},
    {"id":"35512","name":"Presentation - Biological raw materials and viral/TSE safety (Johannes Bluemel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-27T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-biological-raw-materials-and-viraltse-safety-johannes-bluemel_en.pdf"},
    {"id":"35559","name":"Presentation - New practice for the management of clarification meetings (Pavel Balabanov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T02:00:00Z","last_updated_date":"2015-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-practice-management-clarification-meetings-pavel-balabanov_en.pdf"},
    {"id":"35566","name":"Presentation - Publication of the list of Union reference dates and frequency of periodic safety update reports (European Union reference dates list) and the list of active substances subject to worksharing for signal ma...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-publication-list-union-reference-dates-and-frequency-periodic-safety-update-reports-european-union-reference-dates-list-and-list-active-substances-subject-worksharing-signal-ma_en.pdf"},
    {"id":"35596","name":"Presentation - Future Training Programme (Ana Rodriguez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T12:14:00Z","last_updated_date":"2017-03-30T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-future-training-programme-ana-rodriguez_en.pdf"},
    {"id":"35599","name":"Presentation - Traditional approach: Downstream process (Kowid Ho)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-traditional-approach-downstream-process-kowid-ho_en.pdf"},
    {"id":"35604","name":"EMEA Viewpoint on the Innovative Medicines Initiative - Pharmacovigilance - Xavier Kurz","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/emea-viewpoint-innovative-medicines-initiative-pharmacovigilance-xavier-kurz_en.pdf"},
    {"id":"35605","name":"Presentation - The TYSEDMUS Study, Christian Confavreux","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-tysedmus-study-christian-confavreux_en.pdf"},
    {"id":"35627","name":"Veterinarians and bee health involvement, taking France as an example, Nicolas Vidal-Naquet, Federation of Veterinarians of Europe (FVE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/veterinarians-and-bee-health-involvement-taking-france-example-nicolas-vidal-naquet-federation-veterinarians-europe-fve_en.pdf"},
    {"id":"35633","name":"Presentation - Treatment guidelines for relapsing MS and the ‘two step approach’ for disease modifying therapy (Klaus Schmierer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-treatment-guidelines-relapsing-ms-and-two-step-approach-disease-modifying-therapy-klaus-schmierer_en.pdf"},
    {"id":"35635","name":"Presentation - EMA experience with Art. 46 of Regulation (EC) No 1901/2006","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-experience-art-46-regulation-ec-no-19012006_en.pdf"},
    {"id":"35651","name":"Presentation - Pharmacovigilance (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-priya-bahri_en.pdf"},
    {"id":"35657","name":"Presentation - Disease modifying drug development - statistical design and analysis (David Brown)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-disease-modifying-drug-development-statistical-design-and-analysis-david-brown_en.pdf"},
    {"id":"35661","name":"Presentation - EMA/EGA workshop - Session 2 :Injectable Modified Release Products (Yu Chung Tsang)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T02:00:00Z","last_updated_date":"2015-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaega-workshop-session-2-injectable-modified-release-products-yu-chung-tsang_en.pdf"},
    {"id":"35678","name":"Presentation - Working group on Good Clinical Practice (GCP) training","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-06T01:00:00Z","last_updated_date":"2017-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-good-clinical-practice-gcp-training_en.pdf"},
    {"id":"35692","name":"The role of the PDCO - Gà©rard Pons","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/role-pdco-gacrard-pons_en.pdf"},
    {"id":"35695","name":"Presentation - Session I - Research culture","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-18T02:00:00Z","last_updated_date":"2016-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-i-research-culture_en.pdf"},
    {"id":"35719","name":"Presentation - Comparability study to support commercial\n\nprocess change via stability study (B. Teodorescu, EBE, UCB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comparability-study-support-commercial-process-change-stability-study-b-teodorescu-ebe-ucb_en.pdf"},
    {"id":"35720","name":"Presentation - SmPC training presentations user guide","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2013-01-21T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-smpc-training-presentations-user-guide_en.pdf"},
    {"id":"35736","name":"EFPIA Performance Indicators: extension of indications 2007-2008 Elisabeth Vromans - Schering-Plough","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/efpia-performance-indicators-extension-indications-2007-2008-elisabeth-vromans-schering-plough_en.pdf"},
    {"id":"35750","name":"Presentation - Information updates (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-updates-peter-arlett_en.pdf"},
    {"id":"35757","name":"Presentation - Pharmacovigilance system master file: discussion of the need to revise GVP guidance (Sophia Mylona)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-16T02:00:00Z","last_updated_date":"2016-08-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-system-master-file-discussion-need-revise-gvp-guidance-sophia-mylona_en.pdf"},
    {"id":"35763","name":"Presentation - Clinical trial design- the patient standpoint (Bettina Ryll)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trial-design-patient-standpoint-bettina-ryll_en.pdf"},
    {"id":"35775","name":"Presentation - Summary of immunogenicity program and risk assessment (Pekka Kurki)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T14:00:00Z","last_updated_date":"2016-03-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-immunogenicity-program-and-risk-assessment-pekka-kurki_en.pdf"},
    {"id":"35788","name":"Implementation of the paediatric regulation - Nathalie Seigneuret","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/implementation-paediatric-regulation-nathalie-seigneuret_en.pdf"},
    {"id":"35820","name":"Presentation - Antimicrobial drug development: Role and importance of the regulatory requirements - Session 2 (Mair Powell)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antimicrobial-drug-development-role-and-importance-regulatory-requirements-session-2-mair-powell_en.pdf"},
    {"id":"35829","name":"Presentation - Type-2-diabetes-paediatric-investigation-plan overview (Janina Karres)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-type-2-diabetes-paediatric-investigation-plan-overview-janina-karres_en.pdf"},
    {"id":"35830","name":"Presentation - Cabozantinib (Cometriq) (Frans Opdam)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cabozantinib-cometriq-frans-opdam_en.pdf"},
    {"id":"35832","name":"Presentation - Stakeholder experiences: Stakeholder experiences - Marketing Authorisation Holder view by EGGVP and IFAH-Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stakeholder-experiences-stakeholder-experiences-marketing-authorisation-holder-view-eggvp-and-ifah-europe_en.pdf"},
    {"id":"35837","name":"Presentation - CHMP qualification of novel methodologies (Efthymios Manolis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chmp-qualification-novel-methodologies-efthymios-manolis_en.pdf"},
    {"id":"35842","name":"Presentation - European Orphan Designation: Legal basis (Agnes Mathieu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-orphan-designation-legal-basis-agnes-mathieu_en.pdf"},
    {"id":"35852","name":"Presentation - Study recruitment issues (Phillip Ambery)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-study-recruitment-issues-phillip-ambery_en.pdf"},
    {"id":"35855","name":"Presentation - Health data to support medicines regulation, Dr Arlett","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-health-data-support-medicines-regulation-dr-arlett_en.pdf"},
    {"id":"35865","name":"Presentation - Reinforcing the collaboration with healthcare professionals and patient associations - ANSM (Dany Bonnet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reinforcing-collaboration-healthcare-professionals-and-patient-associations-ansm-dany-bonnet_en.pdf-0"},
    {"id":"35874","name":"Presentation - Scientific and regulatory evaluation procedure support [S-REPS] pilot update / system preview (Sylvie Beausuroy, Paolo Tomasi, Bob Coggins)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T17:16:00Z","last_updated_date":"2018-06-06T17:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-and-regulatory-evaluation-procedure-support-s-reps-pilot-update-system-preview-sylvie-beausuroy-paolo-tomasi-bob-coggins_en.pdf"},
    {"id":"35895","name":"Presentation - Communicating risk effectively - the core project","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-08-14T14:00:00Z","last_updated_date":"2012-08-14T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communicating-risk-effectively-core-project_en.pdf"},
    {"id":"35899","name":"General toxicity study designs - Jan Willem van der Laan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T00:00:00Z","last_updated_date":"2009-02-02T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/general-toxicity-study-designs-jan-willem-van-der-laan_en.pdf"},
    {"id":"35940","name":"Presentation - Basis for setting acceptance criteria, Mats Welin, Swedish Medical Products Agency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-06T02:00:00Z","last_updated_date":"2011-10-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-basis-setting-acceptance-criteria-mats-welin-swedish-medical-products-agency_en.pdf"},
    {"id":"35947","name":"Presentation - Interaction with patients, consumers and healthcare professionals: Raising awareness (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-patients-consumers-and-healthcare-professionals-raising-awareness-nathalie-bere_en.pdf"},
    {"id":"35951","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Susanne Zà¤nker","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-susanne-zanker_en.pdf"},
    {"id":"35953","name":"Presentation - The European Centre for Disease Prevention and Control (ECDC) point of view on the requests from the European Commission (Anna-Pelagia Magiorakos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-centre-disease-prevention-and-control-ecdc-point-view-requests-european-commission-anna-pelagia-magiorakos_en.pdf"},
    {"id":"35956","name":"Presentation - A dedicated post-authorisation measure submission form: an improved way of submitting your PAM to the EMA (Hector Boix Perales)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-16T16:30:00Z","last_updated_date":"2018-01-16T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dedicated-post-authorisation-measure-submission-form-improved-way-submitting-your-pam-ema-hector-boix-perales_en.pdf"},
    {"id":"35958","name":"Presentation - Gadolinium-containing magnetic resonance contrast agents and communication practices in European Union Member States","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T01:00:00Z","last_updated_date":"2011-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gadolinium-containing-magnetic-resonance-contrast-agents-and-communication-practices-european-union-member-states_en.pdf-0"},
    {"id":"35961","name":"Presentation - Populating organs-on-chip with cells derived from human stem cells (C. Mummery)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T11:22:00Z","last_updated_date":"2017-11-15T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-populating-organs-chip-cells-derived-human-stem-cells-c-mummery_en.pdf"},
    {"id":"35994","name":"Presentation - CHMP's view on multiplicity through assessment, advice and guidelines (Rob Hemmings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chmps-view-multiplicity-through-assessment-advice-and-guidelines-rob-hemmings_en.pdf"},
    {"id":"35996","name":"Presentation -  Reporting of adverse drug reactions by patients – Croatian experience (Marina Giusti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reporting-adverse-drug-reactions-patients-croatian-experience-marina-giusti_en.pdf"},
    {"id":"36002","name":"Presentation - European Union -  lumpy skin disease and other exotic diseases antigen/vaccine banks:  Current status, policy and future considerations (Andrea Gavinelli and Dimitrios Dilaveris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T11:37:00Z","last_updated_date":"2017-05-18T11:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-lumpy-skin-disease-and-other-exotic-diseases-antigenvaccine-banks-current-status-policy-and-future-considerations-andrea-gavinelli-and-dimitrios-dilaveris_en.pdf"},
    {"id":"36006","name":"Presentation - Active pharmaceutical ingredients – The new approach for third countries: What are the consequences? Should we expect shortage of medicinal products in the country? - Perspectives from an acceding country ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-active-pharmaceutical-ingredients-new-approach-third-countries-what-are-consequences-should-we-expect-shortage-medicinal-products-country-perspectives-acceding-country_en.pdf"},
    {"id":"36030","name":"Presentation - Cell-based medicinal products for global market: Food and Drug Administration perspectives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cell-based-medicinal-products-global-market-food-and-drug-administration-perspectives_en.pdf"},
    {"id":"36042","name":"Presentation - Pharmacogenomics: a long(er) learning curve?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenomics-longer-learning-curve_en.pdf"},
    {"id":"36047","name":"Presentation - European Medicines Agency communication strategy: Strategic planning for the future and vision for veterinary medicines (Marie-Agnes Heine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-communication-strategy-strategic-planning-future-and-vision-veterinary-medicines-marie-agnes-heine_en.pdf"},
    {"id":"36057","name":"Presentation - Launch of the adaptive licencing project (Spiros Vamvakas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-launch-adaptive-licencing-project-spiros-vamvakas_en.pdf"},
    {"id":"36069","name":"Presentation - Regulatory and physician view (Lisbeth Barkholt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T01:00:00Z","last_updated_date":"2015-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-and-physician-view-lisbeth-barkholt_en.pdf"},
    {"id":"36078","name":"Presentation - Involvement of young people in Enpr-EMA networks (Jennifer Preston & Dr Pamela Dicks)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T16:00:00Z","last_updated_date":"2013-07-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-involvement-young-people-enpr-ema-networks-jennifer-preston-dr-pamela-dicks_en.pdf"},
    {"id":"36084","name":"Presentation - Pre-accession regulatory challenges: Industry view (V. Kartelo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pre-accession-regulatory-challenges-industry-view-v-kartelo_en.pdf"},
    {"id":"36091","name":"Presentation - International activities and IDMP (Panagiotis Telonis, Rik Smithies)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-14T02:00:00Z","last_updated_date":"2015-07-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-activities-and-idmp-panagiotis-telonis-rik-smithies_en.pdf"}    {"id":"36112","name":"Presentation - Good pharmacovigilance practices for the European Union (EU-GVP) (P. Bahri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T02:00:00Z","last_updated_date":"2018-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-european-union-eu-gvp-p-bahri-ema_en.pdf"},
    {"id":"36115","name":"Responsible use of veterinary antimicrobials in the UK - John FitzGerald","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:09:21Z","last_updated_date":"2009-05-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/responsible-use-veterinary-antimicrobials-uk-john-fitzgerald_en.pdf"},
    {"id":"36121","name":"Presentation - Clinical research in small patient populations: the investigator point of view (Jordi Rodon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T02:00:00Z","last_updated_date":"2016-08-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-research-small-patient-populations-investigator-point-view-jordi-rodon_en.pdf"},
    {"id":"36123","name":"Presentation - Industry perspective on partnering with academia and agencies in drug development for children with PAH (J. Strait, Merck Sharp & Dohme)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-partnering-academia-and-agencies-drug-development-children-pah-j-strait-merck-sharp-dohme_en.pdf"},
    {"id":"36129","name":"Presentation - US Regulators perspective, Russell Katz","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-us-regulators-perspective-russell-katz_en.pdf"},
    {"id":"36160","name":"Presentation - Implementing ISO ICSR-ICH E2B(R3): Submodule b - backwards and forwards conversion","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-10-12T16:00:00Z","last_updated_date":"2016-10-12T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementing-iso-icsr-ich-e2br3-submodule-b-backwards-and-forwards-conversion_en.pdf"},
    {"id":"36198","name":"Presentation - Session 5.1: Pharmacovigilance: What data / studies could be deferred to the post-authorisation phase?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:51Z","last_updated_date":"2012-06-15T17:10:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-51-pharmacovigilance-what-data-studies-could-be-deferred-post-authorisation-phase_en.pdf"},
    {"id":"36202","name":"Virus Shedding - David Eckland","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/virus-shedding-david-eckland_en.pdf"},
    {"id":"36217","name":"Presentation - The patient-advocate view (Yann Le Cam)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-advocate-view-yann-le-cam_en.pdf"},
    {"id":"36228","name":"Presentation - Endpoints and their relevance to older people: cancer and palliative care and the work of the European Organization for Research and Treatment of Cancer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-endpoints-and-their-relevance-older-people-cancer-and-palliative-care-and-work-european-organization-research-and-treatment-cancer_en.pdf"},
    {"id":"36243","name":"Presentation - 2012 addendum to the EU guideline on antibacterial agents (Mair Powell)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2012-addendum-eu-guideline-antibacterial-agents-mair-powell_en.pdf"},
    {"id":"36244","name":"Presentation - 1.1 The Asterix project: overview (Kit Roes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11-asterix-project-overview-kit-roes_en.pdf"},
    {"id":"36250","name":"Presentation: Report from the coordinating group (CG) Update on Enpr-EMA activities, achievements and challenges","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-coordinating-group-cg-update-enpr-ema-activities-achievements-and-challenges_en.pdf"},
    {"id":"36259","name":"Presentation - Nanomedicines - Current initiatives in Japan, Kumiko Sakai-Kato, Toru Kawanishi, National Institute of Health Sciences/MHLW","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nanomedicines-current-initiatives-japan-kumiko-sakai-kato-toru-kawanishi-national-institute-health-sciencesmhlw_en.pdf"},
    {"id":"36278","name":"Presentation - Challenges during the development of advanced-therapy medicinal products (Paula Salmikangas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T02:00:00Z","last_updated_date":"2014-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-during-development-advanced-therapy-medicinal-products-paula-salmikangas_en.pdf"},
    {"id":"36288","name":"Presentation - Joint ECDC/EFSA/EMA report (JIACRA) on consumption of antimicrobials and antimicrobial resistance in animals, food and humans  (Jordi Torren, Kari Grave, Arno Muller, David Mackay, Christina Greko, Gerard ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-ecdcefsaema-report-jiacra-consumption-antimicrobials-and-antimicrobial-resistance-animals-food-and-humans-jordi-torren-kari-grave-arno-muller-david-mackay-christina-greko-gerard_en.pdf"},
    {"id":"36289","name":"Presentation - Evaluation of fixed dose combination in paediatric indications - Use of pharmacokinetic briding across ethnic groups - Break-out session 3 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluation-fixed-dose-combination-paediatric-indications-use-pharmacokinetic-briding-across-ethnic-groups-break-out-session-3-theme-3_en.pdf"},
    {"id":"36294","name":"Presentation - Issues for Immunologicals for SME applicants (Jean-Claude Rouby)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-issues-immunologicals-sme-applicants-jean-claude-rouby_en.pdf"},
    {"id":"36300","name":"Presentation - Update on Working Group 9 (Mark Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-working-group-9-mark-turner_en.pdf"},
    {"id":"36306","name":"Presentation - Perspectives on analysing subgroup effects of clinical trials and their meta”analyses (Roes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-perspectives-analysing-subgroup-effects-clinical-trials-and-their-metaanalyses-roes_en.pdf"},
    {"id":"36317","name":"Presentation - An overview of EMA initiatives supporting SMEs (Leonor Enes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-ema-initiatives-supporting-smes-leonor-enes_en.pdf"},
    {"id":"36329","name":"Presentation - Holistic approach to paediatric research: introduction (M.Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:00:00Z","last_updated_date":"2018-06-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-introduction-mturner_en.pdf"},
    {"id":"36338","name":"Breakout group II - Report","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T00:09:21Z","last_updated_date":"2009-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/breakout-group-ii-report_en.pdf"},
    {"id":"36340","name":"Presentation - EU IDMP/SPOR Task Force meeting: Falsified medicines workshop 27 June 2016 - Meeting outcome (7. agenda) (EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-idmpspor-task-force-meeting-falsified-medicines-workshop-27-june-2016-meeting-outcome-7-agenda-efpia_en.pdf"},
    {"id":"36354","name":"Presentation - Comments from the U.S. Food and Drug Administration (FDA)Working Group on Subgroup Analyses (Estelle Russek-Cohen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comments-us-food-and-drug-administration-fdaworking-group-subgroup-analyses-estelle-russek-cohen_en.pdf"},
    {"id":"36379","name":"Industry Activities on Collection of Data on Volume (Sales) of Antimicrobials and Proposals for the Future - Ludwig Klostermann","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/industry-activities-collection-data-volume-sales-antimicrobials-and-proposals-future-ludwig-klostermann_en.pdf"},
    {"id":"36386","name":"Presentation - Transparency: Publication of agendas and minutes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transparency-publication-agendas-and-minutes_en.pdf"},
    {"id":"36388","name":"Presentation - Report on enablers and barriers to measuring impact - patient and healthcare professional engagement (Martin Huber)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-enablers-and-barriers-measuring-impact-patient-and-healthcare-professional-engagement-martin-huber_en.pdf"},
    {"id":"36394","name":"Presentation - Introduction to European Medicines Agency annual training day 2017 (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-13T01:00:00Z","last_updated_date":"2017-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-european-medicines-agency-annual-training-day-2017-juan-garcia-burgos_en.pdf"},
    {"id":"36397","name":"Presentation - Session 3: the analytical part - Measuring the concentration of the direct thrombin inhibitor (dabigatran etexilate) (Franà§ois Mullier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-analytical-part-measuring-concentration-direct-thrombin-inhibitor-dabigatran-etexilate-franassois-mullier_en.pdf"},
    {"id":"36405","name":"Presentation - PDCO perspective and proposals (Angelika Siapkara)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-perspective-and-proposals-angelika-siapkara_en.pdf"},
    {"id":"36419","name":"Presentation - European pharmacovigilance overview of 3 years of operation: thoughts from health care professionals (Kirsten Myhr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-pharmacovigilance-overview-3-years-operation-thoughts-health-care-professionals-kirsten-myhr_en.pdf"},
    {"id":"36421","name":"Presentation - Optimising resources: Incentives for academia, hospital and charities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-optimising-resources-incentives-academia-hospital-and-charities_en.pdf"},
    {"id":"36429","name":"Homoeopathy and European Pharmacopoeia: current status and future development - Isabelle Mercier","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/homoeopathy-and-european-pharmacopoeia-current-status-and-future-development-isabelle-mercier_en.pdf"},
    {"id":"36440","name":"Presentation - Quality of pharmaceutical veterinary medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-pharmaceutical-veterinary-medicines_en.pdf"},
    {"id":"36442","name":"Presentation - Practical experiences of risk minimisation (Ciara Kirke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-practical-experiences-risk-minimisation-ciara-kirke_en.pdf"},
    {"id":"36477","name":"Presentation - Working group on dialogue and interaction with Ethics Committees (Allison Needham, Pirkko Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-dialogue-and-interaction-ethics-committees-allison-needham-pirkko-lepola_en.pdf"},
    {"id":"36513","name":"Presentation - PENTA-ID - The future (Mike Sharland)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-penta-id-future-mike-sharland_en.pdf"},
    {"id":"36516","name":"Presentation - Methods to manage risk in a placebo trial (Susan VanMeter, Sarah Kavanagh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-methods-manage-risk-placebo-trial-susan-vanmeter-sarah-kavanagh_en.pdf"},
    {"id":"36520","name":"Presentation - Predictors of outcome and renal clearance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-predictors-outcome-and-renal-clearance_en.pdf"},
    {"id":"36541","name":"Presentation - Risk minimisation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-minimisation_en.pdf"},
    {"id":"36566","name":"Presentation - Legislation and available guidance for the evaluation of PIPs (quality): Viewpoint from the EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-legislation-and-available-guidance-evaluation-pips-quality-viewpoint-ema_en.pdf"},
    {"id":"36605","name":"Presentation - Design of a model based dose-finding study in diabetes - Break-out session 2 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-design-model-based-dose-finding-study-diabetes-break-out-session-2-theme-2_en.pdf"},
    {"id":"36611","name":"Presentation - Pre-accession challenges: Croatian Agency for Medicinal Products and Medical Devices perspective (Maja Lovrek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pre-accession-challenges-croatian-agency-medicinal-products-medical-devices-perspective-maja-lovrek_en.pdf"},
    {"id":"36628","name":"Presentation - Gene therapy case studies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gene-therapy-case-studies_en.pdf"},
    {"id":"36672","name":"Presentation - Development of drugs for hospital- and ventilator-acquired pneumonia","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:45Z","last_updated_date":"2011-04-26T18:05:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-drugs-hospital-and-ventilator-acquired-pneumonia_en.pdf"},
    {"id":"36681","name":"Presentation - New paediatric clinical trials network in Japan (Nao Tsuchida)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T16:00:00Z","last_updated_date":"2013-07-22T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-paediatric-clinical-trials-network-japan-nao-tsuchida_en.pdf"},
    {"id":"36685","name":"Quality and manufacturing aspects of GTMPs - Sol Ruiz","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/quality-and-manufacturing-aspects-gtmps-sol-ruiz_en.pdf"},
    {"id":"36687","name":"Presentation - Signal management guidelines on good pharmacovigilance practices (GVP) IX: pilot on signals from marketing authorisation holders (Agnieszka Szmigiel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-26T02:00:00Z","last_updated_date":"2018-04-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-signal-management-guidelines-good-pharmacovigilance-practices-gvp-ix-pilot-signals-marketing-authorisation-holders-agnieszka-szmigiel_en.pdf"},
    {"id":"36699","name":"Presentation - Neuromyelitis optica testimonial (Irene Wilson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-neuromyelitis-optica-testimonial-irene-wilson_en.pdf"},
    {"id":"36701","name":"Is the Orphan Regulation addressing patient needs?: Yann Le Cam","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/orphan-regulation-addressing-patient-needs-yann-le-cam_en.pdf"},
    {"id":"36703","name":"Presentation - Pharmacogenomics in early drug development: Industry's view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenomics-early-drug-development-industrys-view_en.pdf"},
    {"id":"36708","name":"Presentation - Industry views on opportunities for adaptive designs to enhance clinical development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-views-opportunities-adaptive-designs-enhance-clinical-development_en.pdf"},
    {"id":"36719","name":"Presentation - Implementation of new eligibility requirements (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-new-eligibility-requirements-nathalie-bere_en.pdf-0"},
    {"id":"36735","name":"Presentation - EMA experience with the review of digital technology proposals in medicine development programmes (Francesca Cerreta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-06T17:16:00Z","last_updated_date":"2018-06-06T17:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-experience-review-digital-technology-proposals-medicine-development-programmes-francesca-cerreta_en.pdf"},
    {"id":"36763","name":"Presentation - Scientific advisory groups","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advisory-groups_en.pdf"},
    {"id":"36770","name":"Compliance check & Validation of applications with an agreed PIP Thorsten Olski","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/compliance-check-validation-applications-agreed-pip-thorsten-olski_en.pdf"},
    {"id":"36775","name":"Presentation - Better packaging and labelling for better informed patients","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-23T02:00:00Z","last_updated_date":"2011-05-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-better-packaging-and-labelling-better-informed-patients_en.pdf"},
    {"id":"36796","name":"Presentation - Redaction consultation process (Anne-Sophie Henry-Eude)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-29T02:00:00Z","last_updated_date":"2015-06-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-redaction-consultation-process-anne-sophie-henry-eude_en.pdf"},
    {"id":"36804","name":"Presentation - Interaction with patients and consumers (2013): Review of EPAR summaries (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-03T01:00:00Z","last_updated_date":"2014-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-patients-and-consumers-2013-review-epar-summaries-nathalie-bere_en.pdf"},
    {"id":"36821","name":"Presentation - Draft guideline on biosimilar monoclonal antibodies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:44Z","last_updated_date":"2012-06-15T17:10:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-guideline-biosimilar-monoclonal-antibodies_en.pdf"},
    {"id":"36823","name":"Presentation - Best practices in VeDDRA coding (Giles Davis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-11T18:20:00Z","last_updated_date":"2014-02-11T18:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-practices-veddra-coding-giles-davis_en.pdf"},
    {"id":"36828","name":"Presentation - Session 1: A regulatory perspective: what do I want to know? (June M Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-regulatory-perspective-what-do-i-want-know-june-m-raine_en.pdf"},
    {"id":"36853","name":"Presentation - The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP): Facilitating the conduct of post-authorisation study (PAS) (Henry Fitt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-centres-pharmacoepidemiology-and-pharmacovigilance-encepp-facilitating-conduct-post-authorisation-study-pas-henry-fitt_en.pdf"},
    {"id":"36865","name":"Risk Management Plans; Review of Experience - Stella Blackburn","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/risk-management-plans-review-experience-stella-blackburn_en.pdf"},
    {"id":"36884","name":"Presentation - How to facilitate the communicationsdata exchange, Janice Soreth","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-facilitate-communicationsdata-exchange-janice-soreth_en.pdf"},
    {"id":"36892","name":"Presentation - What are risk minimisation measures and why are they imposed (Sabine Straus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-are-risk-minimisation-measures-and-why-are-they-imposed-sabine-straus_en.pdf"},
    {"id":"36894","name":"Presentation - Paediatric formulations: The clinical perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-formulations-clinical-perspective_en.pdf"},
    {"id":"36898","name":"Presentation - ESMO study of formulary listing, out of pocket cost and actual availability of anti neoplastic agents in Europe: preliminary findings (Nathan I Cherny)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esmo-study-formulary-listing-out-pocket-cost-and-actual-availability-anti-neoplastic-agents-europe-preliminary-findings-nathan-i-cherny_en.pdf"},
    {"id":"36901","name":"Presentation - The European Network of Paediatric Research at the European Medicines Agency: a patient/parent perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:49Z","last_updated_date":"2011-05-27T15:25:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-paediatric-research-european-medicines-agency-patientparent-perspective_en.pdf"},
    {"id":"36920","name":"Presentation - Non imposed post authorisation safety studies (PASS) protocols (Jane Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-imposed-post-authorisation-safety-studies-pass-protocols-jane-moseley_en.pdf"},
    {"id":"36923","name":"Prudent use of cephalosporins, Experience and observations - Valà©rie Thomas","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/prudent-use-cephalosporins-experience-and-observations-valacrie-thomas_en.pdf"},
    {"id":"36928","name":"Presentation - HCPWP/PCWP feedback from CHMP (Fà¡tima Ventura, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hcpwppcwp-feedback-chmp-fatima-ventura-ema_en.pdf"},
    {"id":"36933","name":"Presentation - PCWP and HCPWP topic groups update (N. Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T17:12:00Z","last_updated_date":"2017-12-11T17:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwp-and-hcpwp-topic-groups-update-n-bere_en.pdf"},
    {"id":"36938","name":"Presentation - Practical aspects of working electronically in the network (Pieter Vankeerberghen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-practical-aspects-working-electronically-network-pieter-vankeerberghen_en.pdf"},
    {"id":"36939","name":"Presentation - Topic 1 - Academia-health care professionals perspective Accelerate-SIOPE-ITCC - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Gilles Vassal, Gustave Roussy...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-academia-health-care-professionals-perspective-accelerate-siope-itcc-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-gilles-vassal-gustave-roussy_en.pdf"},
    {"id":"36950","name":"Presentation - Industry representation within the Enpr-EMA Coordinating Group (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-representation-within-enpr-ema-coordinating-group-irmgard-eichler_en.pdf"},
    {"id":"36953","name":"Presentation - Update on Pharmacovigilance systems and services (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-pharmacovigilance-systems-and-services-peter-arlett_en.pdf-0"},
    {"id":"36960","name":"Presentation - Excipients general approach","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-excipients-general-approach_en.pdf"},
    {"id":"36965","name":"Presentation - Working group to address issues with European Union multi-languages of young patient advisory groups","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-address-issues-european-union-multi-languages-young-patient-advisory-groups_en.pdf"},
    {"id":"36975","name":"Expectations from pharmacokinetic-pharmacodynamic modelling and simulation in the evaluation of medicinal products in children","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-05-15T02:09:21Z","last_updated_date":"2008-05-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/expectations-pharmacokinetic-pharmacodynamic-modelling-and-simulation-evaluation-medicinal-products-children_en.pdf"},
    {"id":"36995","name":"Presentation - Medicinal product shortages: GMP update and ICH Q12 (David Cockburn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T01:00:00Z","last_updated_date":"2016-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicinal-product-shortages-gmp-update-and-ich-q12-david-cockburn_en.pdf"},
    {"id":"37001","name":"Presentation - Section 4.6: Fertility, pregnancy and lactation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-46-fertility-pregnancy-lactation_en.pdf"},
    {"id":"37014","name":"Presentation - Spanish Surveillance of Veterinary Antimicrobial Consumption (Cristina Muà±oz Madero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-22T13:01:31Z","last_updated_date":"2010-12-22T13:01:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spanish-surveillance-veterinary-antimicrobial-consumption-cristina-mua-oz-madero_en.pdf"},
    {"id":"37016","name":"Presentation - Subgroups: The quest for enlightenment (Alan Phillips)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-subgroups-quest-enlightenment-alan-phillips_en.pdf"},
    {"id":"37018","name":"Viral Shedding Review of experience of shedding data for in vivo gene therapy - Teruhide Yamaguchi","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/viral-shedding-review-experience-shedding-data-vivo-gene-therapy-teruhide-yamaguchi_en.pdf"},
    {"id":"37022","name":"Presentation - Patient reporting update (Franà§ois Houà¿ez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-reporting-update-franassois-houaez_en.pdf"},
    {"id":"37052","name":"Presentation - Survey on involvement of healthcare professionals, patients and consumers in 2014: results (Merel Stroucken)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T02:00:00Z","last_updated_date":"2015-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-involvement-healthcare-professionals-patients-and-consumers-2014-results-merel-stroucken_en.pdf"},
    {"id":"37069","name":"Presentation - CARs and TRUCKs: how engineered T cells become living factories(Hinrich Abken)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T10:22:00Z","last_updated_date":"2016-12-02T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cars-and-trucks-how-engineered-t-cells-become-living-factorieshinrich-abken_en.pdf"},
    {"id":"37071","name":"Presentation - Guideline on good pharmacovigilance practices GVP module XVI addendum I - Educational materials (Margarida Guimaraes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-i-educational-materials-margarida-guimaraes_en.pdf"},
    {"id":"37078","name":"Presentation - Cell-based therapy advanced-therapy medicinal products: Manufacturing of cell-based therapy products: common issues and advice","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cell-based-therapy-advanced-therapy-medicinal-products-manufacturing-cell-based-therapy-products-common-issues-and-advice_en.pdf"},
    {"id":"37090","name":"Presentation - Subgroup analysis: trying to get more from less? (Stephen Senn et al.)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-subgroup-analysis-trying-get-more-less-stephen-senn-et-al_en.pdf"},
    {"id":"37098","name":"Presentation - Working group 6: educational training of research staff involved in paediatric clinical trials / GCP training across multispecialty and countries (G. Veal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T17:36:00Z","last_updated_date":"2018-06-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-6-educational-training-research-staff-involved-paediatric-clinical-trials-gcp-training-across-multispecialty-and-countries-g-veal_en.pdf"},
    {"id":"37108","name":"Presentation - ERNs and research: state of play from the European Commission\n\nperspective - 'Snapshot' of ERNs and medicinal product point of view (Anneli Torronen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-erns-and-research-state-play-european-commission-perspective-snapshot-erns-and-medicinal-product-point-view-anneli-torronen_en.pdf"},
    {"id":"37137","name":"Presentation - Type-2 diabetes in children and adolescents (William Tamborlane)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-type-2-diabetes-children-and-adolescents-william-tamborlane_en.pdf"},
    {"id":"37150","name":"Presentation - Population pharmacokinetics/pharmacodynamics in paediatrics: A perspective on the way forward","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-population-pharmacokineticspharmacodynamics-paediatrics-perspective-way-forward_en.pdf"},
    {"id":"37155","name":"Presentation - Guidance to patients and consumers on medication-error reporting (Kaisa Immonen-Charalambous)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-patients-and-consumers-medication-error-reporting-kaisa-immonen-charalambous_en.pdf"},
    {"id":"37165","name":"Presentation - β-Lactamase inhibitors properties, microbiology and enzymology (David Livermore)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-i2-lactamase-inhibitors-properties-microbiology-and-enzymology-david-livermore_en.pdf"},
    {"id":"37189","name":"Presentation - Expectations from pharmacokinetic-pharmacodynamic modelling and simulation in the evaluation of medicinal products in children","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-05-13T02:09:21Z","last_updated_date":"2008-05-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-expectations-pharmacokinetic-pharmacodynamic-modelling-and-simulation-evaluation-medicinal-products-children_en.pdf"},
    {"id":"37190","name":"Presentation - Evaluation of paediatric investigation plans (PIPs) and ethical aspects of the design of paediatric trials proposed in the PIPs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T11:00:00Z","last_updated_date":"2012-01-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluation-paediatric-investigation-plans-pips-and-ethical-aspects-design-paediatric-trials-proposed-pips_en.pdf"}    {"id":"37202","name":"Presentation - Experience of EMA innovation support - European Medicines Agency veterinary medicines innovation day (Almudena Pradera)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-ema-innovation-support-european-medicines-agency-veterinary-medicines-innovation-day-almudena-pradera_en.pdf"},
    {"id":"37212","name":"Presentation - Paediatric Pharmacovigilance of biologicals - a myth or a challenge","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-03-22T01:00:00Z","last_updated_date":"2011-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-pharmacovigilance-biologicals-myth-or-challenge_en.pdf"},
    {"id":"37227","name":"Presentation - Organ failure scores in neonatal sepsis (Hugo Devlieger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organ-failure-scores-neonatal-sepsis-hugo-devlieger_en.pdf"},
    {"id":"37233","name":"Presentation - Case studies and questions and answers - Session 3 (Nancy Cauwenberghs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-studies-and-questions-and-answers-session-3-nancy-cauwenberghs_en.pdf"},
    {"id":"37234","name":"Presentation - Pharmacovigilance requirements for Member States (June M Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-requirements-member-states-june-m-raine_en.pdf"},
    {"id":"37235","name":"Presentation - Improving processes: referrals as a case study (Ulla Wandel Liminga)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-improving-processes-referrals-case-study-ulla-wandel-liminga_en.pdf"},
    {"id":"37236","name":"Presentation - Outcomes from break-out session 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcomes-break-out-session-2_en.pdf"},
    {"id":"37237","name":"Presentation - Session 2.4: Working group on interactions networks-industry-regulators (Susan Tansey, Pirkko Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-24-working-group-interactions-networks-industry-regulators-susan-tansey-pirkko-lepola_en.pdf"},
    {"id":"37241","name":"Presentation - FVE viewpoint on draft ESVAC strategy 2016-2020","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T17:00:00Z","last_updated_date":"2016-03-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fve-viewpoint-draft-esvac-strategy-2016-2020_en.pdf"},
    {"id":"37261","name":"Presentation - Industry experience with ethical review of paediatric trials: Result of survey by the European Contract Research Organisation Foundation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T11:00:00Z","last_updated_date":"2012-01-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-experience-ethical-review-paediatric-trials-result-survey-european-contract-research-organisation-foundation_en.pdf"},
    {"id":"37277","name":"Navigating the regulatory maze - Marisa Papaluca","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/navigating-regulatory-maze-marisa-papaluca_en.pdf"},
    {"id":"37279","name":"Presentation - Study design and analysis in late-stage cancer immunotherapy trials (Tai-Tsang Chen) - S5.2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-study-design-and-analysis-late-stage-cancer-immunotherapy-trials-tai-tsang-chen-s52_en.pdf"},
    {"id":"37282","name":"Linguistic aspects, A Skarlatos, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/linguistic-aspects-skarlatos-ema_en.pdf"},
    {"id":"37296","name":"Presentation - GVP V and RMP template Rev 2 – update on implementation (Nàºria Semis-Costa and Emil Cochino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T16:03:00Z","last_updated_date":"2017-07-25T16:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gvp-v-and-rmp-template-rev-2-update-implementation-naoria-semis-costa-and-emil-cochino_en.pdf"},
    {"id":"37298","name":"Presentation - Aims of the workshop (Mair Powell)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-aims-workshop-mair-powell_en.pdf"},
    {"id":"37309","name":"Presentation - Future opportunities for pharmacovigilance (à. Spooner, HPRA and PRAC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-28T02:00:00Z","last_updated_date":"2017-09-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-future-opportunities-pharmacovigilance-spooner-hpra-and-prac_en.pdf"},
    {"id":"37317","name":"Presentation - Increasing access to adverse drug reaction reports on the web (Steven Le Meur)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-increasing-access-adverse-drug-reaction-reports-web-steven-le-meur_en.pdf"},
    {"id":"37318","name":"Presentation - Results of the European Medicines Agency survey among European ethics committees","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T11:00:00Z","last_updated_date":"2012-01-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-results-european-medicines-agency-survey-among-european-ethics-committees_en.pdf"},
    {"id":"37319","name":"Presentation - US FDA’s experience with medicines communication using social media (Catherine Chew, Kimberly Chiu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-us-fdas-experience-medicines-communication-using-social-media-catherine-chew-kimberly-chiu_en.pdf"},
    {"id":"37325","name":"Presentation - Role of real world evidence to foster access to innovative diabetes medicine (Agathe Le Lay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-real-world-evidence-foster-access-innovative-diabetes-medicine-agathe-le-lay_en.pdf"},
    {"id":"37337","name":"Presentation - EATG Training programme (Svilen Konov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eatg-training-programme-svilen-konov_en.pdf"},
    {"id":"37342","name":"Presentation - A systems pharmacology perspective on the clinical development of fatty acid amide hydrolase inhibitors for pain (Piet van der Graaf)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-systems-pharmacology-perspective-clinical-development-fatty-acid-amide-hydrolase-inhibitors-pain-piet-van-der-graaf_en.pdf"},
    {"id":"37347","name":"Presentation - European Multiple Sclerosis Platform (EMSP) - EMA's PCWP and HCPWP joint meeting (Andreea Antonovici)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-multiple-sclerosis-platform-emsp-emas-pcwp-and-hcpwp-joint-meeting-andreea-antonovici_en.pdf"},
    {"id":"37357","name":"Pharmaceutical Industry Perspective: Dr. Catarina Edfjà¤ll","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pharmaceutical-industry-perspective-dr-catarina-edfjall_en.pdf"},
    {"id":"37361","name":"EFPIA position on CHMP work programme: Evaluation of risk benefit - Scientific Advisory Groups","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/efpia-position-chmp-work-programme-evaluation-risk-benefit-scientific-advisory-groups_en.pdf"},
    {"id":"37379","name":"Presentation - Application of physiologically-based pharmacokinetic modeling to support dosing recommendations – The US Food and Drug Administration Experience (Ping Zhao)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-application-physiologically-based-pharmacokinetic-modeling-support-dosing-recommendations-us-food-and-drug-administration-experience-ping-zhao_en.pdf"},
    {"id":"37403","name":"Presentation - 1.2 Overview on Integrated DEsign and AnaLysis (IDeAl ) of small population group trials (Ralf-Dieter Hilgers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-12-overview-integrated-design-and-analysis-ideal-small-population-group-trials-ralf-dieter-hilgers_en.pdf"},
    {"id":"37404","name":"Presentation - Methodological issues (some) relating to patient selection -\n\nCHMP reflection paper","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-methodological-issues-some-relating-patient-selection-chmp-reflection-paper_en.pdf"},
    {"id":"37415","name":"Presentation: Networking of European REC's","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-networking-european-recs_en.pdf"},
    {"id":"37433","name":"Presentation - Good pharmacovigilance practices (GVP): module P-II biological medicinal products (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T16:00:00Z","last_updated_date":"2015-06-25T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-gvp-module-p-ii-biological-medicinal-products-xavier-kurz_en.pdf"},
    {"id":"37434","name":"Presentation - Management and reporting of adverse reactions to medicinal products: Good pharmacovigilance practice module VI","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-03T17:30:00Z","last_updated_date":"2012-05-03T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-management-and-reporting-adverse-reactions-medicinal-products-good-pharmacovigilance-practice-module-vi_en.pdf"},
    {"id":"37444","name":"Presentation - Two years of operation of the Pharmacovigilance Risk Assessment Committee (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-two-years-operation-pharmacovigilance-risk-assessment-committee-june-raine_en.pdf"},
    {"id":"37449","name":"Presentation - EUGenMed roadmap for including sex and gender in biomedical and public health research (Hildrun Sundseth)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-10T18:30:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eugenmed-roadmap-including-sex-and-gender-biomedical-and-public-health-research-hildrun-sundseth_en.pdf"},
    {"id":"37461","name":"Presentation - Collecting and reporting information on off-label use (Gilles Touraille, Sabine Brosch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collecting-and-reporting-information-label-use-gilles-touraille-sabine-brosch_en.pdf"},
    {"id":"37467","name":"Presentation - Bringing real-life experience into the evaluation of medicines (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-28T02:00:00Z","last_updated_date":"2016-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bringing-real-life-experience-evaluation-medicines-ivana-silva_en.pdf"},
    {"id":"37469","name":"Presentation - Supporting orphan medicines development and addressing significant benefit requirements through protocol assistance (Matthias Hofer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supporting-orphan-medicines-development-and-addressing-significant-benefit-requirements-through-protocol-assistance-matthias-hofer_en.pdf"},
    {"id":"37501","name":"Presentation - Latest development: European Union cooperation on Health Technology Assessment (HTA) (Flora Giorgio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-11-24T18:30:00Z","last_updated_date":"2014-11-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-latest-development-european-union-cooperation-health-technology-assessment-hta-flora-giorgio_en.pdf"},
    {"id":"37519","name":"Presentation - European-public-assessment-report summary template (Daniel Glanville)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-public-assessment-report-summary-template-daniel-glanville_en.pdf"},
    {"id":"37542","name":"Presentation - Direct patient reporting","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:12Z","last_updated_date":"2011-06-24T22:06:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-direct-patient-reporting_en.pdf"},
    {"id":"37560","name":"Introduction to EU Regulatory system and GMP Inspection system. The Qualified Person - David Cockburn","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-20T02:09:21Z","last_updated_date":"2009-10-20T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/introduction-eu-regulatory-system-and-gmp-inspection-system-qualified-person-david-cockburn_en.pdf"},
    {"id":"37567","name":"Presentation - EMA extrapolation framework (Christoph Male)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-extrapolation-framework-christoph-male_en.pdf"},
    {"id":"37571","name":"Presentation - Modelling and simulation in paediatric drug development and regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-paediatric-drug-development-and-regulation_en.pdf"},
    {"id":"37595","name":"Presentation - Indications and labelling (K. Dunder, CHMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-indications-and-labelling-k-dunder-chmp_en.pdf"},
    {"id":"37605","name":"Presentation - Overview of regulator's experience: Adaptive designs seen in scientific advice and by the Committee for Medicinal Products for Human Use","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-regulators-experience-adaptive-designs-seen-scientific-advice-and-committee-medicinal-products-human-use_en.pdf"},
    {"id":"37613","name":"Presentation - Guidance on post-authorisation efficacy studies (Jane Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-post-authorisation-efficacy-studies-jane-moseley_en.pdf"},
    {"id":"37624","name":"Presentation - Working group on public-private interactions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-06T01:00:00Z","last_updated_date":"2017-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-public-private-interactions_en.pdf"},
    {"id":"37660","name":"Presentation - Non-clinical Assessment Requirements","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-clinical-assessment-requirements_en.pdf"},
    {"id":"37670","name":"Presentation - How are medicines evaluated at the European Medicines Agency (part 1)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-01T01:00:00Z","last_updated_date":"2016-02-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-are-medicines-evaluated-european-medicines-agency-part-1_en.pdf"},
    {"id":"37675","name":"Presentation - The new European action plan against antimicrobial resistance - Session 1 (Martial Plantady)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-european-action-plan-against-antimicrobial-resistance-session-1-martial-plantady_en.pdf"},
    {"id":"37688","name":"Presentation - Monitoring processes and data monitoring committee composition","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-processes-and-data-monitoring-committee-composition_en.pdf"},
    {"id":"37693","name":"Presentation - Indications and labelling (M. van der Graaff, Zorginstituut Nederland)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-indications-and-labelling-m-van-der-graaff-zorginstituut-nederland_en.pdf"},
    {"id":"37708","name":"Presentation - Strengthening the planning and implementation of risk minimisation (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strengthening-planning-and-implementation-risk-minimisation-peter-arlett_en.pdf"},
    {"id":"37716","name":"Presentation - World Organisation for Animal Health (OIE) initiative to collect quantitative data on the use of antimicrobial agents in animals to establish a global database (Franà§ois Diaz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-world-organisation-animal-health-oie-initiative-collect-quantitative-data-use-antimicrobial-agents-animals-establish-global-database-franassois-diaz_en.pdf"},
    {"id":"37723","name":"Presentation - Update on change management activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-02T02:00:00Z","last_updated_date":"2017-05-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-change-management-activities_en.pdf"},
    {"id":"37744","name":"Presentation - Case study title: Improvement of clinical benefit for a sub-sub-group of paediatric systemic juvenile idiopathic arthritis patients utilising model-based dose adjustment optimisation (Roche #4) - Break-out...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-title-improvement-clinical-benefit-sub-sub-group-paediatric-systemic-juvenile-idiopathic-arthritis-patients-utilising-model-based-dose-adjustment-optimisation-roche-4-break-out_en.pdf"},
    {"id":"37780","name":"Presentation - Risk management plan guidance and templates: feedback from the public consultation (Emil Cochino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T16:15:00Z","last_updated_date":"2016-08-15T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-management-plan-guidance-and-templates-feedback-public-consultation-emil-cochino_en.pdf"},
    {"id":"37791","name":"EU Support for Stem Cell Research, Dr Charles Kessler, EC DG Research","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-support-stem-cell-research-dr-charles-kessler-ec-dg-research_en.pdf"},
    {"id":"37795","name":"Presentation - National competent authorities experience with environmental risk assessment (ERA) before setting clinic trials: Procedure and experience in Germany (Brigitte Anliker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-national-competent-authorities-experience-environmental-risk-assessment-era-setting-clinic-trials-procedure-and-experience-germany-brigitte-anliker_en.pdf"},
    {"id":"37800","name":"Presentation - Topic 2 - Efficacy endpoints in clinical trials (Lawrence Geiter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-2-efficacy-endpoints-clinical-trials-lawrence-geiter_en.pdf"},
    {"id":"37829","name":"Presentation - Manufacturing process changes, biologic product comparability and post approval changes (Nanna Aaby Kruse)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-27T02:00:00Z","last_updated_date":"2015-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-manufacturing-process-changes-biologic-product-comparability-and-post-approval-changes-nanna-aaby-kruse_en.pdf"},
    {"id":"37862","name":"Haematopoietic stem cells: Dr Neil Rodrigues, NIH Centre of Biomedical Research Excellence in Tissue Repair and Stem Cells, USA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/haematopoietic-stem-cells-dr-neil-rodrigues-nih-centre-biomedical-research-excellence-tissue-repair-and-stem-cells-usa_en.pdf"},
    {"id":"37863","name":"Presentation - How is industry approaching the impact of pharmacovigilance activities (Robert Reynolds)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-industry-approaching-impact-pharmacovigilance-activities-robert-reynolds_en.pdf"},
    {"id":"37866","name":"Presentation - Session on identification and traceability of biological products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-identification-and-traceability-biological-products_en.pdf"},
    {"id":"37867","name":"Presentation - Communication of additional monitoring","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-additional-monitoring_en.pdf"},
    {"id":"37877","name":"Presentation - European Medicines Agency / Heads of Medicines Agencies questions and answers – practical transitional measures - November update (Christelle Bouygues)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-07T01:00:00Z","last_updated_date":"2012-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-heads-medicines-agencies-questions-and-answers-practical-transitional-measures-november-update-christelle-bouygues_en.pdf"},
    {"id":"37882","name":"Presentation - Statistical tests, Bayesian analysis, or heuristic rules for demonstration of analytical biosimilarity? (R. Burdick, Elion Labs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-statistical-tests-bayesian-analysis-or-heuristic-rules-demonstration-analytical-biosimilarity-r-burdick-elion-labs_en.pdf"},
    {"id":"37884","name":"Continuous dialogue from product development throughout product lifecycle Andre Broekmans - Schering-Plough","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/continuous-dialogue-product-development-throughout-product-lifecycle-andre-broekmans-schering-plough_en.pdf"},
    {"id":"37892","name":"Presentation - European Network of Paediatric Research at the European Medicines Agency: update on recent activities (Irmgard Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T17:00:00Z","last_updated_date":"2016-05-27T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-paediatric-research-european-medicines-agency-update-recent-activities-irmgard-eichler_en.pdf"},
    {"id":"37895","name":"Presentation - Benefits of Public Health, Eugene Major","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-benefits-public-health-eugene-major_en.pdf"},
    {"id":"37914","name":"Presentation - Developmental pharmacokinetics/pharmacodynamics: What have we learnt?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-05-13T02:09:21Z","last_updated_date":"2008-05-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-developmental-pharmacokineticspharmacodynamics-what-have-we-learnt_en.pdf"},
    {"id":"37915","name":"Presentation - Overview of EMA's interaction with patients' and consumers' organisations in 2013 (David Haerry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-emas-interaction-patients-and-consumers-organisations-2013-david-haerry_en.pdf"},
    {"id":"37918","name":"Presentation - Workshop on paediatric investigation plans in type-2 diabetes mellitus - conclusions (Paolo Tomasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-paediatric-investigation-plans-type-2-diabetes-mellitus-conclusions-paolo-tomasi_en.pdf"},
    {"id":"37923","name":"Presentation - Communication on medication errors - What does the patient need to know? (Franà§ois Houà¿ez and Rob Camp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-medication-errors-what-does-patient-need-know-franassois-houaez-and-rob-camp_en.pdf"},
    {"id":"37933","name":"Presentation - CMDh: Coordination Group for Mutual Recognition and Decentralised Procedures - Human (Anne Ambrose)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-10T18:30:00Z","last_updated_date":"2015-08-10T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cmdh-coordination-group-mutual-recognition-and-decentralised-procedures-human-anne-ambrose_en.pdf"},
    {"id":"37946","name":"Presentation - Paediatric Investigation Plans for treatment of osteoporosis (Richard Veselà½)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-09T02:00:00Z","last_updated_date":"2014-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-investigation-plans-treatment-osteoporosis-richard-vesela-12_en.pdf"},
    {"id":"37957","name":"Presentation - Proposals on how patients can be involved in networks (trial design etc.) and in trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T14:00:00Z","last_updated_date":"2012-07-06T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposals-how-patients-can-be-involved-networks-trial-design-etc-and-trials_en.pdf"},
    {"id":"37962","name":"Presentation - Working Group on young patient advisory groups update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-18T13:40:00Z","last_updated_date":"2017-12-18T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-young-patient-advisory-groups-update_en.pdf"},
    {"id":"37966","name":"Presentation - Design strategies to minimise the use of placebo in MS clinical trials (Maria Pia Sormani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-design-strategies-minimise-use-placebo-ms-clinical-trials-maria-pia-sormani_en.pdf"},
    {"id":"37970","name":"Presentation - Beyond HER2 CAR T-cells: consider how far you have fallen… (Nabil Ahmed)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T11:11:00Z","last_updated_date":"2016-12-02T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-beyond-her2-car-t-cells-consider-how-far-you-have-fallen-nabil-ahmed_en.pdf"},
    {"id":"37979","name":"Presentation - Holistic approach to paediatric research: young people and patient involvement (J. Preston)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T12:00:00Z","last_updated_date":"2018-06-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-holistic-approach-paediatric-research-young-people-and-patient-involvement-j-preston_en.pdf"},
    {"id":"37990","name":"Presentation - Oversight of clinical trials in Europe - Member State perspective (Gunnar Danielsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-oversight-clinical-trials-europe-member-state-perspective-gunnar-danielsson_en.pdf"},
    {"id":"37998","name":"Introduction - Meeting of the Paediatric Diabetes Mellitus Experts Group","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-06T02:00:00Z","last_updated_date":"2010-05-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/introduction-meeting-paediatric-diabetes-mellitus-experts-group_en.pdf"},
    {"id":"38005","name":"Presentation - Population pharmacokinetics and optimal design of paediatric studies for famciclovir","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-population-pharmacokinetics-and-optimal-design-paediatric-studies-famciclovir_en.pdf"},
    {"id":"38023","name":"Presentation - Modelling and simulation good practices and next steps - Session 7","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-good-practices-and-next-steps-session-7_en.pdf"},
    {"id":"38046","name":"Presentation - Healthy ageing and medicines: the patients' perspective of ageing","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-healthy-ageing-and-medicines-patients-perspective-ageing_en.pdf"},
    {"id":"38063","name":"Presentation - Statistical modelling issues arising from pharmacokinetic/pharmacodynamic bridging in paediatrics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-statistical-modelling-issues-arising-pharmacokineticpharmacodynamic-bridging-paediatrics_en.pdf"},
    {"id":"38071","name":"Presentation - Medication errors and screening tool of older persons’\n\npotentially inappropriate prescriptions (STOPP) / screening tool to alert doctors to\n\nright treatment (START) criteria","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medication-errors-and-screening-tool-older-persons-potentially-inappropriate-prescriptions-stopp-screening-tool-alert-doctors-right-treatment-start-criteria_en.pdf"},
    {"id":"38076","name":"Presentation - PDCO current approach (Chrissi Pallidis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-current-approach-chrissi-pallidis_en.pdf"},
    {"id":"38081","name":"Presentation - EMA/EGA workshop - Session 3: TDDS and Appendix I + II (Jan Neuhauser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T02:00:00Z","last_updated_date":"2015-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaega-workshop-session-3-tdds-and-appendix-i-ii-jan-neuhauser_en.pdf"},
    {"id":"38098","name":"Presentation - European Medicines Agency reorganisation (Kornelia Grein)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-reorganisation-kornelia-grein_en.pdf"},
    {"id":"38117","name":"Presentation - Immunotherapies in melanoma: regulatory perspective (Jorge Camarero) - S2.3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunotherapies-melanoma-regulatory-perspective-jorge-camarero-s23_en.pdf"},
    {"id":"38129","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Gà¼nter Verheugen","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-ga-14nter-verheugen_en.pdf"},
    {"id":"38139","name":"Presentation - RMS and OMS: industry on-boarding to SPOR webinar with Industry Change Liaisons","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T16:20:00Z","last_updated_date":"2017-11-15T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rms-and-oms-industry-boarding-spor-webinar-industry-change-liaisons_en.pdf"},
    {"id":"38152","name":"Outline and objectives - Alex Tait","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-06-23T02:09:21Z","last_updated_date":"2009-06-23T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/outline-and-objectives-alex-tait_en.pdf"},
    {"id":"38183","name":"Presentation - Pharmacovigilance – risk-benefit monitoring cycle. A global undertaking (Fergus Sweeney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-risk-benefit-monitoring-cycle-global-undertaking-fergus-sweeney_en.pdf"},
    {"id":"38216","name":"Presentation - Blueprint project: PD-L1 IUO assay characterization (Rasika Kalamegham) - S3.2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-blueprint-project-pd-l1-iuo-assay-characterization-rasika-kalamegham-s32_en.pdf"},
    {"id":"38218","name":"'A Scientific Perspective on the Future of Medicines' 11 March 2005 - Daniel Brasseur","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T00:09:21Z","last_updated_date":"2005-03-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/scientific-perspective-future-medicines-11-march-2005-daniel-brasseur_en.pdf"},
    {"id":"38224","name":"Presentation - Challenges of measuring impact of new pharmacovigilance processes (Judith Sanabria)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-measuring-impact-new-pharmacovigilance-processes-judith-sanabria_en.pdf"},
    {"id":"38225","name":"Presentation - Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-use-pharmacogenetic-methodologies-pharmacokinetic-evaluation-medicinal-products_en.pdf"},
    {"id":"38263","name":"Presentation - Communication on medicine shortages (Inga Abed)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-medicine-shortages-inga-abed_en.pdf"}    {"id":"38287","name":"Presentation - Interaction with healthcare professionals: Overview of involvement in EMA activities during 2013 (Gonzalo Calvo Rojas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-08T16:00:00Z","last_updated_date":"2014-07-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-healthcare-professionals-overview-involvement-ema-activities-during-2013-gonzalo-calvo-rojas_en.pdf"},
    {"id":"38291","name":"Presentation - Heads of Medicines Agencies (HMA) update on Substance, Product, Organisation and Referential (SPOR) (Francisco Penaranda, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-heads-medicines-agencies-hma-update-substance-product-organisation-and-referential-spor-francisco-penaranda-ema_en.pdf"},
    {"id":"38298","name":"Presentation - Process validation: Enhanced approach - continuous process verification (Brendan Hughes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T19:00:00Z","last_updated_date":"2013-04-22T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-process-validation-enhanced-approach-continuous-process-verification-brendan-hughes_en.pdf"},
    {"id":"38310","name":"Presentation - Quantitative systems pharmacology in drug development\n\n- A pharma perspective - Break-out session 1 theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quantitative-systems-pharmacology-drug-development-pharma-perspective-break-out-session-1-theme-3_en.pdf"},
    {"id":"38328","name":"Presentation - Use of physiologically based pharmacokinetics in simulating drug concentrations in paediatric populations: Case studies of midazolam and gabapentin","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-physiologically-based-pharmacokinetics-simulating-drug-concentrations-paediatric-populations-case-studies-midazolam-and-gabapentin_en.pdf"},
    {"id":"38334","name":"Presentation - Using totality of evidence for antibiotic approval, interpretive breakpoint setting, and pediatric development (Barry Eisenstein)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-using-totality-evidence-antibiotic-approval-interpretive-breakpoint-setting-and-pediatric-development-barry-eisenstein_en.pdf"},
    {"id":"38340","name":"Presentation - Accelerated Development of VAccine beNefit-risk Collaboration in Europe (Malgorzata Leszczynska)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-12-11T01:00:00Z","last_updated_date":"2013-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accelerated-development-vaccine-benefit-risk-collaboration-europe-malgorzata-leszczynska_en.pdf"},
    {"id":"38355","name":"Presentation - Immunology and immunotoxicity of nanomedicines, Jacques Descotes, Lyon University Hospitals, France","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunology-and-immunotoxicity-nanomedicines-jacques-descotes-lyon-university-hospitals-france_en.pdf"},
    {"id":"38373","name":"Presentation - Case Study 5 - Control strategy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-5-control-strategy_en.pdf"},
    {"id":"38393","name":"Presentation - Viewpoint from a health care professional (Christoph Hoeller)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-viewpoint-health-care-professional-christoph-hoeller_en.pdf"},
    {"id":"38407","name":"Presentation - Concept paper on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T01:00:00Z","last_updated_date":"2012-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-concept-paper-key-aspects-use-pharmacogenomic-methodologies-pharmacovigilance-evaluation-medicinal-products_en.pdf"},
    {"id":"38414","name":"Presentation - Patient perspectives on monitoring effectiveness of risk minimisation measures in the field of multiple sclerosis (Christoph Thalheim)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-perspectives-monitoring-effectiveness-risk-minimisation-measures-field-multiple-sclerosis-christoph-thalheim_en.pdf"},
    {"id":"38426","name":"Presentation - US FDA expedited programs and expanded access (Ke Liu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-us-fda-expedited-programs-and-expanded-access-ke-liu_en.pdf"},
    {"id":"38432","name":"Presentation - Health Canada experience with measuring the impact of pharmacovigilance (John Patrick Stewart)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-health-canada-experience-measuring-impact-pharmacovigilance-john-patrick-stewart_en.pdf"},
    {"id":"38433","name":"Validation of biomarkers in HIV - Michael D. Hughes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2005-12-16T00:09:21Z","last_updated_date":"2005-12-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/validation-biomarkers-hiv-michael-d-hughes_en.pdf"},
    {"id":"38440","name":"Presentation - PDCO perspectives & proposals Enpr-EMA coordinating group (A. Siapkara, C. Male)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-perspectives-proposals-enpr-ema-coordinating-group-siapkara-c-male_en.pdf"},
    {"id":"38441","name":"Presentation - The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium project: Work package 5: Benefit-risk integration and representation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T14:00:00Z","last_updated_date":"2012-07-06T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacoepidemiological-research-outcomes-therapeutics-european-consortium-project-work-package-5-benefit-risk-integration-and-representation_en.pdf"},
    {"id":"38449","name":"Presentation - The value of a Neonatal Consortium - A regulators perspective (Ralph Bax)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-value-neonatal-consortium-regulators-perspective-ralph-bax_en.pdf"},
    {"id":"38453","name":"Presentation - Public website of side effects (V. Newbould)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-website-side-effects-v-newbould_en.pdf"},
    {"id":"38455","name":"Presentation - EnprEMA network perspectives (M. Turner, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enprema-network-perspectives-m-turner-ema_en.pdf"},
    {"id":"38456","name":"Presentation - Chimeric antigen receptor (CAR)-T cells (David Lebwohl)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T10:22:00Z","last_updated_date":"2016-12-02T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chimeric-antigen-receptor-car-t-cells-david-lebwohl_en.pdf"},
    {"id":"38503","name":"Presentation - Recent learnings from the IMI WEB-RADR project (Phil Tregunno)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recent-learnings-imi-web-radr-project-phil-tregunno_en.pdf"},
    {"id":"38513","name":"Presentation - Consumption of antimicrobials in food animals outside the European Union / European Economic Area (Hilde Kruse)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-15T13:00:00Z","last_updated_date":"2013-04-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-consumption-antimicrobials-food-animals-outside-european-union-european-economic-area-hilde-kruse_en.pdf"},
    {"id":"38542","name":"European Network of Paediatric Research at the European Medicines Agency - Introduction","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-24T12:00:00Z","last_updated_date":"2020-10-23T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-network-paediatric-research-european-medicines-agency-introduction_en.pdf"},
    {"id":"38547","name":"Impact on new variation system on NCAs - Susanne Winterscheid","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/impact-new-variation-system-ncas-susanne-winterscheid_en.pdf"},
    {"id":"38565","name":"Presentation - Providing information to the older population: Understanding the needs of older people","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-providing-information-older-population-understanding-needs-older-people_en.pdf"},
    {"id":"38566","name":"Presentation - Cell-based therapies for cardiac repair (Claire Beuneu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T02:00:00Z","last_updated_date":"2014-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cell-based-therapies-cardiac-repair-claire-beuneu_en.pdf"},
    {"id":"38581","name":"Presentation - The new submission process (Tomas Boran)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T12:14:00Z","last_updated_date":"2017-03-30T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-submission-process-tomas-boran_en.pdf"},
    {"id":"38590","name":"Presentation - Good-manufacturing-practice (GMP) issues for start-ups, quality in the supply chain and role of the qualified person (QP) (Patrick Costello)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-15T02:00:00Z","last_updated_date":"2014-04-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-manufacturing-practice-gmp-issues-start-ups-quality-supply-chain-and-role-qualified-person-qp-patrick-costello_en.pdf"},
    {"id":"38613","name":"Presentation - EMA communication perception survey (E. Scanlan, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-communication-perception-survey-e-scanlan-ema_en.pdf"},
    {"id":"38614","name":"Presentation - Summaries of risk management plan (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summaries-risk-management-plan-juan-garcia-burgos_en.pdf"},
    {"id":"38615","name":"Presentation - Interaction with healthcare professionals: Overview of  involvement in EMA activities during 2015 (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-healthcare-professionals-overview-involvement-ema-activities-during-2015-ivana-silva_en.pdf"},
    {"id":"38657","name":"Presentation - Access to EudraVigilance data to Patients and Health Care professionals (Francois Domergue)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-access-eudravigilance-data-patients-and-health-care-professionals-francois-domergue_en.pdf"},
    {"id":"38665","name":"Presentation - Break-out session 1 regulatory expectations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-break-out-session-1-regulatory-expectations_en.pdf"},
    {"id":"38679","name":"Presentation - Pilot of MAH signal detection in EudraVigilance (J. Durand, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T02:00:00Z","last_updated_date":"2018-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pilot-mah-signal-detection-eudravigilance-j-durand-ema_en.pdf"},
    {"id":"38683","name":"Presentation - Implementation of falsified medicines Directive","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-falsified-medicines-directive_en.pdf"},
    {"id":"38690","name":"Brief summary of the existing systems on collecting data: The Netherlands","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/brief-summary-existing-systems-collecting-data-netherlands_en.pdf"},
    {"id":"38699","name":"Presentation - Revision of the guideline on conduct of pharmacovigilance for medicines used by the paediatric population (Dirk Mentzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T02:00:00Z","last_updated_date":"2014-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revision-guideline-conduct-pharmacovigilance-medicines-used-paediatric-population-dirk-mentzer_en.pdf"},
    {"id":"38703","name":"Presentation - EMA Workshop Case Study on Analytical Similarity (J.G. Ramirez, Amgen Inc.)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-workshop-case-study-analytical-similarity-jg-ramirez-amgen-inc_en.pdf"},
    {"id":"38733","name":"Presentation - Guidance to pharmaceutical industry on redacting commercially confidential information (CCI) in clinical reports (Anne-Sophie Henry-Eude)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-29T02:00:00Z","last_updated_date":"2015-06-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-pharmaceutical-industry-redacting-commercially-confidential-information-cci-clinical-reports-anne-sophie-henry-eude_en.pdf"},
    {"id":"38740","name":"Presentation - Healthcare Professionals' Working Party (HCPWP): Procedure for election of co-chair (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T17:00:00Z","last_updated_date":"2013-07-12T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-healthcare-professionals-working-party-hcpwp-procedure-election-co-chair-juan-garcia-burgos_en.pdf"},
    {"id":"38752","name":"Securing bee health and honey quality, Etienne Bruneau, COPA-COGECA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/securing-bee-health-and-honey-quality-etienne-bruneau-copa-cogeca_en.pdf"},
    {"id":"38761","name":"Presentation - Role of OMCLs for control of emergency vaccines (Julie Barà©)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-14T17:20:00Z","last_updated_date":"2017-06-14T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-omcls-control-emergency-vaccines-julie-barac_en.pdf"},
    {"id":"38763","name":"Presentation - Update of questions and answers on biosimilar medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T17:15:00Z","last_updated_date":"2012-05-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-questions-and-answers-biosimilar-medicines_en.pdf"},
    {"id":"38767","name":"Presentation - Compassionate use programmes in Europe and role of EMA and member states (C.Bouygues, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T02:00:00Z","last_updated_date":"2017-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-compassionate-use-programmes-europe-and-role-ema-and-member-states-cbouygues-ema_en.pdf"},
    {"id":"38774","name":"Pre-submission issues & EMEA meeting opportunities - Hilde Boone","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-02T01:00:00Z","last_updated_date":"2007-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pre-submission-issues-emea-meeting-opportunities-hilde-boone_en.pdf"},
    {"id":"38805","name":"Presentation - Setting up a Young Person’s Advisory Group (Jenny Newman, MCRN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-setting-young-persons-advisory-group-jenny-newman-mcrn_en.pdf"},
    {"id":"38828","name":"Presentation - The European Union paediatric medicine regulation: is it working? A view from a paediatric oncology network","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:45Z","last_updated_date":"2011-05-27T15:25:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-paediatric-medicine-regulation-it-working-view-paediatric-oncology-network_en.pdf"},
    {"id":"38847","name":"The EU Risk Management Plan: Does A Common Standard Exist? - BDC Arnold","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-risk-management-plan-does-common-standard-exist-bdc-arnold_en.pdf"},
    {"id":"38857","name":"Presentation - CVMP work plan for 2015: Highlights and potential implications for new applications and developments (Anja Holm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-work-plan-2015-highlights-and-potential-implications-new-applications-and-developments-anja-holm_en.pdf"},
    {"id":"38863","name":"Conditional Marketing Authorisation - Francesco Pignatti","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T00:09:21Z","last_updated_date":"2007-02-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/conditional-marketing-authorisation-francesco-pignatti_en.pdf"},
    {"id":"38868","name":"Presentation - Update on the revision of the veterinary legislation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-revision-veterinary-legislation_en.pdf"},
    {"id":"38875","name":"Presentation - EU IDMP/SPOR Task Force meeting: SPOR for veterinary (2. agenda) (Jos Olaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-idmpspor-task-force-meeting-spor-veterinary-2-agenda-jos-olaerts_en.pdf"},
    {"id":"38913","name":"Presentation - Overview of key principles of the EU good practice guide (GPG) on medication errors (Thomas Goedecke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-01T01:00:00Z","last_updated_date":"2017-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-key-principles-eu-good-practice-guide-gpg-medication-errors-thomas-goedecke_en.pdf"},
    {"id":"38914","name":"Questions to panel on qualification of the PBPK platform for the intended purpose","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T15:35:00Z","last_updated_date":"2016-12-05T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/questions-panel-qualification-pbpk-platform-intended-purpose_en.pdf"},
    {"id":"38928","name":"Presentation - Update on post-authorisation efficacy studies (Kevin Blake, Jane Moseley, Christelle Bouygues)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-post-authorisation-efficacy-studies-kevin-blake-jane-moseley-christelle-bouygues_en.pdf"},
    {"id":"38938","name":"Presentation - Optimising resources","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T12:00:00Z","last_updated_date":"2012-02-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-optimising-resources_en.pdf"},
    {"id":"38943","name":"Presentation - ICH E6 Addendum on Good Clinical Practice (Fergus Sweeney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T02:00:00Z","last_updated_date":"2016-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-e6-addendum-good-clinical-practice-fergus-sweeney_en.pdf"},
    {"id":"38960","name":"Presentation - ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy (Michael Vasconcelles)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T10:22:00Z","last_updated_date":"2016-12-02T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-actr-antibody-coupled-t-cell-receptor-universal-approach-t-cell-therapy-michael-vasconcelles_en.pdf"},
    {"id":"38972","name":"Presentation - Micro-, small- and medium-sized-enterprise (SME) Policy : DG Internal market (Krista De Spiegeleer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-micro-small-and-medium-sized-enterprise-sme-policy-dg-internal-market-krista-de-spiegeleer_en.pdf"},
    {"id":"38977","name":"Presentation - Experience of EMA innovation support from a university perspective - European Medicines Agency veterinary medicines innovation day (Sven Arnouts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-05-17T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-ema-innovation-support-university-perspective-european-medicines-agency-veterinary-medicines-innovation-day-sven-arnouts_en.pdf"},
    {"id":"38982","name":"Presentation - Stem cell therapy for myocardial repair (Birgit Assmus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T02:00:00Z","last_updated_date":"2014-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stem-cell-therapy-myocardial-repair-birgit-assmus_en.pdf"},
    {"id":"39012","name":"Presentation - New pharmacovigilance systems and services (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmacovigilance-systems-and-services-peter-arlett_en.pdf"},
    {"id":"39014","name":"Overlap between VaD and AD: An epidemiological perspective - Miia\n\nKivipelto","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-11T00:09:21Z","last_updated_date":"2008-02-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/overlap-between-vad-and-ad-epidemiological-perspective-miia-kivipelto_en.pdf"},
    {"id":"39016","name":"Presentation - Exploratory outcome measures (including MRI) (Laurent Servais)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-05T01:00:00Z","last_updated_date":"2016-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-exploratory-outcome-measures-including-mri-laurent-servais_en.pdf"},
    {"id":"39017","name":"Presentation - Addressing the efficacy-effectiveness gap, Prof Eichler","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2011-01-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-addressing-efficacy-effectiveness-gap-prof-eichler_en.pdf"},
    {"id":"39019","name":"Presentation - Approaching the Agency - Session 7","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T17:00:00Z","last_updated_date":"2012-04-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-approaching-agency-session-7_en.pdf"},
    {"id":"39044","name":"Presentation - Considerations on biological APIs extracted from material of human and animal origin (R. van Herpen, APIC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-biological-apis-extracted-material-human-and-animal-origin-r-van-herpen-apic_en.pdf"},
    {"id":"39048","name":"Presentation - European Medicines Agency-Food and Drug Administration Gaucher's disease workshop: Opening remarks (Andrew E. Mulberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-28T01:00:00Z","last_updated_date":"2012-11-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-food-and-drug-administration-gauchers-disease-workshop-opening-remarks-andrew-e-mulberg_en.pdf"},
    {"id":"39070","name":"Presentation - Cooperation between Croatian Agency for Medicinal Products and Medical Devices and the good-manufacturing-practice inspectorate in supervision of manufacturers: Croatia’s experience so far (Ana Boban)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T02:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cooperation-between-croatian-agency-medicinal-products-medical-devices-good-manufacturing-practice-inspectorate-supervision-manufacturers-croatias-experience-so-far-ana-boban_en.pdf"},
    {"id":"39077","name":"Presentation - Overview of CVMP activities on antimicrobial resistance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-cvmp-activities-antimicrobial-resistance_en.pdf"},
    {"id":"39080","name":"Presentation - Revised framework of interaction with HCPs (Ivana Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revised-framework-interaction-hcps-ivana-silva-ema_en.pdf"},
    {"id":"39090","name":"Presentation - Quality of biologicals, Kowid Ho, Afssaps","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-biologicals-kowid-ho-afssaps_en.pdf"},
    {"id":"39098","name":"Presentation - Recent update of the guidance for Parallel EMA/FDA scientific advice (T. Vetter, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-23T01:00:00Z","last_updated_date":"2017-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recent-update-guidance-parallel-emafda-scientific-advice-t-vetter-ema_en.pdf"},
    {"id":"39111","name":"Presentation - Formulations for clinical trials in children: Possibilities and pitfalls?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-formulations-clinical-trials-children-possibilities-and-pitfalls_en.pdf"},
    {"id":"39146","name":"Presentation - EudraVigilance: Expectations of pharmacists","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:07Z","last_updated_date":"2011-06-24T22:06:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-expectations-pharmacists_en.pdf"},
    {"id":"39169","name":"Presentation - Development of paediatric formulations - points to consider","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-paediatric-formulations-points-consider_en.pdf"},
    {"id":"39179","name":"Identification of Medicinal Products (IDMP) - Sabine Brosch","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/identification-medicinal-products-idmp-sabine-brosch_en.pdf"},
    {"id":"39199","name":"Presentation - 3.3 Role of patients as members of European Medicines Agency scientific committees","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T12:00:00Z","last_updated_date":"2011-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-33-role-patients-members-european-medicines-agency-scientific-committees_en.pdf"},
    {"id":"39200","name":"Presentation - Requirements for vaccines in other regions of the world industry considerations (Vaughn Kubiak)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T14:00:00Z","last_updated_date":"2015-04-29T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-requirements-vaccines-other-regions-world-industry-considerations-vaughn-kubiak_en.pdf"},
    {"id":"39220","name":"Presentation - The Importance of Properly Designed Experiments for Comparative Studies (R. Shaw, AstraZeneca)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-importance-properly-designed-experiments-comparative-studies-r-shaw-astrazeneca_en.pdf"},
    {"id":"39221","name":"Presentation - Objectives of the workshop (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-objectives-workshop-isabelle-moulon_en.pdf"},
    {"id":"39224","name":"Presentation - Nanomedicines on the market and in clinical development - Introduction,  Eric Abadie, CHMP chair","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nanomedicines-market-and-clinical-development-introduction-eric-abadie-chmp-chair_en.pdf"},
    {"id":"39241","name":"Use of flouroquinolones EMEA/CVMP/SAGAM/184651\n\n/2005 - Consultation - Klaus Hellmann","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T02:09:21Z","last_updated_date":"2006-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/use-flouroquinolones-emeacvmpsagam184651-2005-consultation-klaus-hellmann_en.pdf"},
    {"id":"39246","name":"Utilisation of QbD principles for the management of post approval changes for a novel recombinant monoclonal antibody","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/utilisation-qbd-principles-management-post-approval-changes-novel-recombinant-monoclonal-antibody_en.pdf"},
    {"id":"39303","name":"Presentation - EMA/EGA workshop - Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (Beata Stepniewska)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T02:00:00Z","last_updated_date":"2015-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaega-workshop-guideline-pharmacokinetic-and-clinical-evaluation-modified-release-dosage-forms-beata-stepniewska_en.pdf"},
    {"id":"39317","name":"Biographies of chairs, speakers and panellists","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-03T02:09:21Z","last_updated_date":"2007-10-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/biographies-chairs-speakers-and-panellists_en.pdf"},
    {"id":"39327","name":"Presentation - Pharmacovigilance system - Regulatory tools: report on lack of efficacy (P. Ekstrom)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-system-regulatory-tools-report-lack-efficacy-p-ekstrom_en.pdf"},
    {"id":"39332","name":"Presentation - The impact on public and animal health of the use of antibiotics in animals - Discussion on question two (Karolina Tà¶rneke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-public-and-animal-health-use-antibiotics-animals-discussion-question-two-karolina-taprneke_en.pdf"},
    {"id":"39333","name":"Presentation - Pharmacovigilance impact: Update and collaboration with Industry - Ninth industry stakeholder platform on the operation of EU pharmacovigilance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T01:00:00Z","last_updated_date":"2017-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-impact-update-and-collaboration-industry-ninth-industry-stakeholder-platform-operation-eu-pharmacovigilance_en.pdf"},
    {"id":"39334","name":"GMP Training Course Inspections from an industry perspective - Fiona Routley","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-20T02:09:21Z","last_updated_date":"2009-10-20T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gmp-training-course-inspections-industry-perspective-fiona-routley_en.pdf"},
    {"id":"39336","name":"Presentation - HTA/payers’ perspective on significant benefit (Niklas Hedberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T17:00:00Z","last_updated_date":"2015-12-15T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-htapayers-perspective-significant-benefit-niklas-hedberg_en.pdf"},
    {"id":"39371","name":"Presentation - Implementation of Regulation 1235/2010, Article 57(2)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-regulation-12352010-article-572_en.pdf"},
    {"id":"39381","name":"Presentation - Session 2: The BRAF story (Yibing Yan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-braf-story-yibing-yan_en.pdf"},
    {"id":"39396","name":"Presentation: Ethical considerations for clinical trials on medicinal products conducted with the paediatric population","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ethical-considerations-clinical-trials-medicinal-products-conducted-paediatric-population_en.pdf"},
    {"id":"39424","name":"Presentation - European challenges and the way forward (Denis Hogan, EAPM)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-challenges-and-way-forward-denis-hogan-eapm_en.pdf"},
    {"id":"39425","name":"Presentation - How Industry can improve PSURs and achieve alignment of expectations (Dave Lewis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-11-29T01:00:00Z","last_updated_date":"2016-11-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-industry-can-improve-psurs-and-achieve-alignment-expectations-dave-lewis_en.pdf"},
    {"id":"39434","name":"Presentation - Substance subgroup report to task force","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-02T02:00:00Z","last_updated_date":"2017-05-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-subgroup-report-task-force_en.pdf"},
    {"id":"39437","name":"Presentation - EU Innovation Network : Paul-Ehrlich-Institut (Bettina Ziegele)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-innovation-network-paul-ehrlich-institut-bettina-ziegele_en.pdf"},
    {"id":"39442","name":"Presentation - Packaging and labelling: Current\n\n& future opportunities (Emily Drury)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-packaging-and-labelling-current-future-opportunities-emily-drury_en.pdf"}    {"id":"39461","name":"Presentation - Post-approval life cycle management","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-approval-life-cycle-management_en.pdf"},
    {"id":"39470","name":"Medicines for Bees: An introduction to the subject and aim of the workshop; Role of the Agency in the initiative, Ifigenia Koudouna, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/medicines-bees-introduction-subject-and-aim-workshop-role-agency-initiative-ifigenia-koudouna-ema_en.pdf"},
    {"id":"39478","name":"Presentation - The European Medicines Agency (EMA) (Nathalie Bere, Maria Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-13T01:00:00Z","last_updated_date":"2017-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-ema-nathalie-bere-maria-mavris_en.pdf"},
    {"id":"39484","name":"Presentation - Feedback from teleconference on handling of conflicts of interest for patients' and consumers' organisations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T18:30:00Z","last_updated_date":"2013-05-24T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-teleconference-handling-conflicts-interest-patients-and-consumers-organisations_en.pdf"},
    {"id":"39496","name":"Presentation - Early engagement and support for medicine development (Stiina Aarum)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-early-engagement-and-support-medicine-development-stiina-aarum_en.pdf"},
    {"id":"39497","name":"Presentation - Engineered CAR-T therapies (Julianne Smith)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T10:22:00Z","last_updated_date":"2016-12-02T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-engineered-car-t-therapies-julianne-smith_en.pdf"},
    {"id":"39503","name":"Presentation - European Group for Generic Veterinary Products (EGGVP) comments (Elsa Vecino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-group-generic-veterinary-products-eggvp-comments-elsa-vecino_en.pdf"},
    {"id":"39517","name":"ESGCT/ICH Workshop on Viral Vector Shedding 2 - Klaus Cichutek","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-10-30T00:09:21Z","last_updated_date":"2007-10-30T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/esgctich-workshop-viral-vector-shedding-2-klaus-cichutek_en.pdf"},
    {"id":"39529","name":"Pharmacovigilance Inspections - Johanna Piper","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pharmacovigilance-inspections-johanna-piper_en.pdf"},
    {"id":"39532","name":"Presentation - Breakout session - Neonatal abstinence syndrome (John Van Den Anker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-neonatal-abstinence-syndrome-john-van-den-anker_en.pdf"},
    {"id":"39559","name":"Presentation - Exploratory subgroup analysis: Post-hoc subgroup identification in clinical trials (Alex Dmitrienko, Ilya Lipkovich)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-exploratory-subgroup-analysis-post-hoc-subgroup-identification-clinical-trials-alex-dmitrienko-ilya-lipkovich_en.pdf"},
    {"id":"39560","name":"Definition of Starting Materials - Christina Hoejelse","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T00:09:21Z","last_updated_date":"2009-10-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/definition-starting-materials-christina-hoejelse_en.pdf"},
    {"id":"39587","name":"Presentation - 6.2 Optimal use of sequential trial designs in small populations (Stavros Nikolakopoulos, Susanne Urach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-62-optimal-use-sequential-trial-designs-small-populations-stavros-nikolakopoulos-susanne-urach_en.pdf"},
    {"id":"39593","name":"Presentation - Shortages of medicinal products (Andrea Taft & Brendan Cuddy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T17:00:00Z","last_updated_date":"2013-07-18T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-shortages-medicinal-products-andrea-taft-brendan-cuddy_en.pdf"},
    {"id":"39594","name":"Presentation - Session 3: Designs for basket clinical trials and the exploratory/confirmatory paradigm (Richard Simon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-designs-basket-clinical-trials-and-exploratoryconfirmatory-paradigm-richard-simon_en.pdf"},
    {"id":"39602","name":"Presentation - Multiple testing methodology in the context of subgroup analysis (Dmitrienko)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multiple-testing-methodology-context-subgroup-analysis-dmitrienko_en.pdf"},
    {"id":"39613","name":"Presentation - Case study: a phase-3 study with two doses and secondary endpoints (Vincent Haddad)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-phase-3-study-two-doses-and-secondary-endpoints-vincent-haddad_en.pdf"},
    {"id":"39618","name":"Presentation - Update on ADVENT and progress on Q&A documents: experience with pre-drafting consultations (Minna Leppà¤nen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-advent-and-progress-qa-documents-experience-pre-drafting-consultations-minna-leppanen_en.pdf"},
    {"id":"39644","name":"Presentation - Regulatory experience of paediatric data: Focusing on modelling aspects","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-05-13T02:09:21Z","last_updated_date":"2008-05-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-experience-paediatric-data-focusing-modelling-aspects_en.pdf"},
    {"id":"39651","name":"Presentation - Efficacy Claims and Subset Analyses in Phase III (Carroll)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-efficacy-claims-and-subset-analyses-phase-iii-carroll_en.pdf"},
    {"id":"39659","name":"Presentation - CVMP achievements 2016 (David Murphy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-achievements-2016-david-murphy_en.pdf"},
    {"id":"39666","name":"Presentation - Stakeholder perspectives in assessing the benefit-risk balance for medicines (Deborah Ashby, Alain Micaleff)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stakeholder-perspectives-assessing-benefit-risk-balance-medicines-deborah-ashby-alain-micaleff_en.pdf"},
    {"id":"39705","name":"Presentation - Disseminating European Medicines Agency information (Monika Benstetter, Sarah Weatherley, Christopher Gadd)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-disseminating-european-medicines-agency-information-monika-benstetter-sarah-weatherley-christopher-gadd_en.pdf"},
    {"id":"39709","name":"Presentation - Poorly water soluble substances: challenges, options and limitations for children","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-poorly-water-soluble-substances-challenges-options-and-limitations-children_en.pdf"},
    {"id":"39723","name":"Presentation - Session 4: What defines the disease and populations? How to deal with large subgroups within an indication? Heterogeneity, lack of historical real-life data, rarest subtype (Jan Bogaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-what-defines-disease-and-populations-how-deal-large-subgroups-within-indication-heterogeneity-lack-historical-real-life-data-rarest-subtype-jan-bogaerts_en.pdf"},
    {"id":"39737","name":"Honey bee diseases – the current situation in Greece, Angeliki Tsigouri, National Organisation for Medicines (Greece)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-22T01:00:00Z","last_updated_date":"2010-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/honey-bee-diseases-current-situation-greece-angeliki-tsigouri-national-organisation-medicines-greece_en.pdf"},
    {"id":"39752","name":"Presentation - Natural history of neuromyelitis optica (Friedemann Paul)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-23T02:00:00Z","last_updated_date":"2014-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-natural-history-neuromyelitis-optica-friedemann-paul_en.pdf"},
    {"id":"39759","name":"EU Telematics, HG Wagner, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-telematics-hg-wagner-ema_en.pdf"},
    {"id":"39778","name":"Presentation - The place for treatments of associated neuropsychiatric and other symptoms - focus on challenges of the clinical diagnosis of Alzheimer's disease (Reinhold Schmidt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T13:00:00Z","last_updated_date":"2014-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-place-treatments-associated-neuropsychiatric-and-other-symptoms-focus-challenges-clinical-diagnosis-alzheimers-disease-reinhold-schmidt_en.pdf"},
    {"id":"39786","name":"Presentation - Use of Subgroups to “Rescue” a Trial or Improve Benefit-Risk (King)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-subgroups-rescue-trial-or-improve-benefit-risk-king_en.pdf"},
    {"id":"39794","name":"Presentation - Unmet medical need (J. Llinares, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-unmet-medical-need-j-llinares-ema_en.pdf"},
    {"id":"39805","name":"Presentation - Veterinary pharmacovigilance: Outline of the EU pharmacovigilance system","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-pharmacovigilance-outline-eu-pharmacovigilance-system_en.pdf"},
    {"id":"39831","name":"Experience following implementation of revised policy on handling of conflicts of interests - Guidance on completion of electronic declaration of interests (S. Kennedy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-02-12T01:00:00Z","last_updated_date":"2013-02-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/experience-following-implementation-revised-policy-handling-conflicts-interests-guidance-completion-electronic-declaration-interests-s-kennedy_en.pdf"},
    {"id":"39843","name":"Presentation - Advice on regulatory strategy, Ms Zaide Frias","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advice-regulatory-strategy-ms-zaide-frias_en.pdf"},
    {"id":"39848","name":"Presentation - Session 3: How could molecular profiling impact histology independent labels in the future? (Marlene Thomas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-how-could-molecular-profiling-impact-histology-independent-labels-future-marlene-thomas_en.pdf"},
    {"id":"39867","name":"Presentation - Development of drugs for resistant organisms","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:49Z","last_updated_date":"2011-04-26T18:05:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-drugs-resistant-organisms_en.pdf"},
    {"id":"39906","name":"Presentation - Case study: Application of health based exposure limits in a cleaning validation (A. Engwicht-Lassmann, IFAH)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-application-health-based-exposure-limits-cleaning-validation-engwicht-lassmann-ifah_en.pdf"},
    {"id":"39910","name":"Presentation - What should be the source data when considering a paediatric development (S. Cole)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-should-be-source-data-when-considering-paediatric-development-s-cole_en.pdf"},
    {"id":"39911","name":"Presentation - Study design and conduct efficiency evaluation via discrete event simulation: Applications in paediatric oncology","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-13T02:09:21Z","last_updated_date":"2008-04-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-study-design-and-conduct-efficiency-evaluation-discrete-event-simulation-applications-paediatric-oncology_en.pdf"},
    {"id":"39912","name":"Presentation - EMA/FDA/Health Canada workshop on paediatric pulmonary arterial hypertension","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emafdahealth-canada-workshop-paediatric-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"39914","name":"Presentation - Critical review of outcomes used in MS clinical trials (George Ebers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-12T01:00:00Z","last_updated_date":"2013-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-critical-review-outcomes-used-ms-clinical-trials-george-ebers_en.pdf"},
    {"id":"39920","name":"Presentation - Development of drugs for eradication of carriage","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:45Z","last_updated_date":"2011-04-26T18:05:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-drugs-eradication-carriage_en.pdf"},
    {"id":"39922","name":"Presentation - Session 4.3: Feedback from EC/EMA-FDA bilateral on paediatric research (Peter Karolyi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-43-feedback-ecema-fda-bilateral-paediatric-research-peter-karolyi_en.pdf"},
    {"id":"39928","name":"Presentation - Topic 2 - Endpoints that may correlate with cure (Gerry Davies)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-2-endpoints-may-correlate-cure-gerry-davies_en.pdf"},
    {"id":"39934","name":"Presentation - RMS and OMS - Industry on-boarding to SPOR (Kepa Amutxastegi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T17:00:00Z","last_updated_date":"2017-12-20T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rms-and-oms-industry-boarding-spor-kepa-amutxastegi_en.pdf"},
    {"id":"39955","name":"Presentation - Completion of the development of a formulation: Requirements for compliance check vs. requirements for Marketing Authorisation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-completion-development-formulation-requirements-compliance-check-vs-requirements-marketing-authorisation_en.pdf-0"},
    {"id":"39962","name":"Presentation - Crisis management – Case studies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-crisis-management-case-studies_en.pdf"},
    {"id":"39964","name":"Presentation - Healthcare Professionals’ Organisations (HCPWP) feedback from CHMP - EMA's PCWP and HCPWP joint meeting (Fà¡tima Ventura)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-healthcare-professionals-organisations-hcpwp-feedback-chmp-emas-pcwp-and-hcpwp-joint-meeting-fatima-ventura_en.pdf"},
    {"id":"39967","name":"Presentation - Application of ICH Q12 tools and enablers: Lifecycle strategy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-application-ich-q12-tools-and-enablers-lifecycle-strategy_en.pdf"},
    {"id":"39979","name":"Presentation - Post-authorisation safety studies (PASS) (Irene Rager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-authorisation-safety-studies-pass-irene-rager_en.pdf"},
    {"id":"39989","name":"Presentation - Challenging patients on DOACs and need for monitoring (Menno Huisman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T01:00:00Z","last_updated_date":"2016-01-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenging-patients-doacs-and-need-monitoring-menno-huisman_en.pdf"},
    {"id":"39992","name":"Presentation - Agenda point 6: RONAFA report (Helen Jukes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-03T02:00:00Z","last_updated_date":"2017-04-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agenda-point-6-ronafa-report-helen-jukes_en.pdf"},
    {"id":"40022","name":"Presentation - Session 2.8: Examples of interactions - ECFS (Tim Lee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-22T02:00:00Z","last_updated_date":"2017-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-28-examples-interactions-ecfs-tim-lee_en.pdf"},
    {"id":"40035","name":"Presentation and Analysis of the EFPIA questionnaire 06/08 on the centralised procedure new applications David Jefferys - Eisai","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-24T00:09:21Z","last_updated_date":"2009-02-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-and-analysis-efpia-questionnaire-0608-centralised-procedure-new-applications-david-jefferys-eisai_en.pdf"},
    {"id":"40053","name":"Presentation - Personalised medicines: what does experience tell us so far? - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines (Ro...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T02:00:00Z","last_updated_date":"2017-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-personalised-medicines-what-does-experience-tell-us-so-far-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-medicines_en.pdf"},
    {"id":"40058","name":"The use of in vitro and in vivo data to define both design space and control strategy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:09:21Z","last_updated_date":"2009-09-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/use-vitro-and-vivo-data-define-both-design-space-and-control-strategy_en.pdf"},
    {"id":"40063","name":"Presentation - Case Study 6 - Novo Nordisk experience in the application of QbD","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-6-novo-nordisk-experience-application-qbd_en.pdf"},
    {"id":"40071","name":"Presentation - Evaluation of the European Medicines Agency (EMA): Findings, conclusions and recommendations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-13T01:00:00Z","last_updated_date":"2010-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluation-european-medicines-agency-ema-findings-conclusions-and-recommendations_en.pdf"},
    {"id":"40072","name":"Presentation - Specialist nurses and antimicrobial resistance (AMR): The inclusion of specialist nursing workforce on AMR- Session 4 (Ber Oomen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-specialist-nurses-and-antimicrobial-resistance-amr-inclusion-specialist-nursing-workforce-amr-session-4-ber-oomen_en.pdf"},
    {"id":"40084","name":"Presentation - Registries: Recommendations from the registries workshop (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:30:00Z","last_updated_date":"2017-03-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-registries-recommendations-registries-workshop-xavier-kurz_en.pdf"},
    {"id":"40129","name":"Presentation - The integration of data (e.g. across studies or clinical and in-vitro data) using modelling and simulation along with reasonable assumptions can provide evidence for evaluation of efficacy / safety risks w...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:00:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-integration-data-eg-across-studies-or-clinical-and-vitro-data-using-modelling-and-simulation-along-reasonable-assumptions-can-provide-evidence-evaluation-efficacy-safety-risks-w_en.pdf"},
    {"id":"40184","name":"GLP Inspections in the Centralised Procedure - Brendan Cuddy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T00:00:00Z","last_updated_date":"2009-02-02T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/glp-inspections-centralised-procedure-brendan-cuddy_en.pdf"},
    {"id":"40192","name":"Presentation - Need for collaboration in pharmacovigilance to ensure effective health protection and promotion (Jacoline Bouvy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-need-collaboration-pharmacovigilance-ensure-effective-health-protection-and-promotion-jacoline-bouvy_en.pdf"},
    {"id":"40202","name":"Presentation - Update on Working Group 7 (Mark Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T14:00:00Z","last_updated_date":"2014-07-07T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-working-group-7-mark-turner_en.pdf"},
    {"id":"40213","name":"Presentation - Process analytical technology European Union regulatory update: The inspector's view (Claus Mortensen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-10-29T01:00:00Z","last_updated_date":"2008-10-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-process-analytical-technology-european-union-regulatory-update-inspectors-view-claus-mortensen_en.pdf"},
    {"id":"40220","name":"Presentation - MEA assays using human iPSC-derived cardiomyocytes, challenges and opportunities (T. de Korte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-15T11:02:00Z","last_updated_date":"2017-11-15T11:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mea-assays-using-human-ipsc-derived-cardiomyocytes-challenges-and-opportunities-t-de-korte_en.pdf"},
    {"id":"40230","name":"Presentation - Risk management for vaccines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-management-vaccines_en.pdf"},
    {"id":"40232","name":"Presentation - The Commission report on SmPC and package leaflet for medicinal products for human use (K.Kurgonaite)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-commission-report-smpc-and-package-leaflet-medicinal-products-human-use-kkurgonaite_en.pdf"},
    {"id":"40243","name":"Presentation - Save the date Enpr-EMA annual workshop 2016","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-save-date-enpr-ema-annual-workshop-2016_en.pdf"},
    {"id":"40251","name":"Presentation - Adverse-reaction reporting and patient-support programmes / market-research programmes at Health Canada (Christopher Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adverse-reaction-reporting-and-patient-support-programmes-market-research-programmes-health-canada-christopher-turner_en.pdf"},
    {"id":"40259","name":"Presentation - Article 8 – Paediatric Regulation: Interpretation of pharmaceutical form","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-10-05T02:00:00Z","last_updated_date":"2010-10-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-article-8-paediatric-regulation-interpretation-pharmaceutical-form_en.pdf"},
    {"id":"40263","name":"Presentation - EU variations system","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-variations-system_en.pdf"},
    {"id":"40276","name":"Presentation - Section 2: Qualitative and quantitative composition","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-21T18:25:00Z","last_updated_date":"2019-06-04T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-section-2-qualitative-quantitative-composition_en.pdf"},
    {"id":"40310","name":"Presentation - Topic 3 - Timely completion of paediatric investigation plans (PIPs): World Duchenne Organization - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Elizabeth ...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-3-timely-completion-paediatric-investigation-plans-pips-world-duchenne-organization-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-elizabeth_en.pdf"},
    {"id":"40311","name":"Presentation - Perspectives from a new Member State","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-perspectives-new-member-state_en.pdf"},
    {"id":"40316","name":"Presentation - Good pharmacovigilance practice module VIII - Post-authorisation safety studies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practice-module-viii-post-authorisation-safety-studies_en.pdf"},
    {"id":"40330","name":"Presentation - E-presentations: Latest developments (Kornelia Grein)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-e-presentations-latest-developments-kornelia-grein_en.pdf"},
    {"id":"40331","name":"Presentation - Session 2: Challenges faced by Europe in implementing a common data model (Olaf Klungel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-challenges-faced-europe-implementing-common-data-model-olaf-klungel_en.pdf"},
    {"id":"40341","name":"Presentation - Patient-support programmes and market-research programmes in pharmacies: Managing safety information (Suzete Costa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-06-20T02:00:00Z","last_updated_date":"2013-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-support-programmes-and-market-research-programmes-pharmacies-managing-safety-information-suzete-costa_en.pdf"},
    {"id":"40367","name":"Presentation - Topic 1 -  Identification of paediatric medical needs - Drug Commission of the German Medical Association (DCGMA) - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regula...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-identification-paediatric-medical-needs-drug-commission-german-medical-association-dcgma-multi-stakeholder-workshop-further-improve-implementation-paediatric-regula_en.pdf"},
    {"id":"40378","name":"Presentation - Ethical considerations for paediatric trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T11:00:00Z","last_updated_date":"2012-01-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ethical-considerations-paediatric-trials_en.pdf"},
    {"id":"40399","name":"Presentation - Industry perspective on advice models (Christine Mayer-Nicolai, Adrian Griffin, Judith Creba and James Anderson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-11-26T01:00:00Z","last_updated_date":"2013-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-advice-models-christine-mayer-nicolai-adrian-griffin-judith-creba-and-james-anderson_en.pdf"},
    {"id":"40423","name":"Presentation - Good manufacturing practice for advanced-therapy medicinal products (ATMPs) (Rocio Salvador Roldan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-manufacturing-practice-advanced-therapy-medicinal-products-atmps-rocio-salvador-roldan_en.pdf"},
    {"id":"40426","name":"Presentation - The case of isotretinoin compliance with the pregnancy prevention programme in the European Union","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T01:00:00Z","last_updated_date":"2011-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-isotretinoin-compliance-pregnancy-prevention-programme-european-union_en.pdf"},
    {"id":"40430","name":"Presentation - Update on IDMP/SPOR stakeholder engagement approach (Agnieszka Laka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T16:15:00Z","last_updated_date":"2016-08-15T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-idmpspor-stakeholder-engagement-approach-agnieszka-laka_en.pdf"},
    {"id":"40442","name":"Presentation - Implementation of the new pharmacovigilance legislation - 2012 implementation plan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T13:00:00Z","last_updated_date":"2012-02-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-new-pharmacovigilance-legislation-2012-implementation-plan_en.pdf"},
    {"id":"40447","name":"Presentation - Linking SPOR implementation and optimisation of regulatory processes - EMA perspective (Francisco Peà±aranda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-22T01:00:00Z","last_updated_date":"2017-02-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-linking-spor-implementation-and-optimisation-regulatory-processes-ema-perspective-francisco-pea-aranda_en.pdf"},
    {"id":"40454","name":"Presentation - Topic 1 - Industry perspective - Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation (Marie-Yvonne Douste-Blazy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-04-19T02:00:00Z","last_updated_date":"2018-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-industry-perspective-multi-stakeholder-workshop-further-improve-implementation-paediatric-regulation-marie-yvonne-douste-blazy_en.pdf"},
    {"id":"40466","name":"Presentation - Mixed-effect models for trials of disease-modifying treatments - Break-out session 4 theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-30T13:15:00Z","last_updated_date":"2012-04-30T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mixed-effect-models-trials-disease-modifying-treatments-break-out-session-4-theme-2_en.pdf"},
    {"id":"40475","name":"Presentation - Indications and labelling - Specific aspects cross reference within the SmPC (K.Dunder, CHMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-indications-and-labelling-specific-aspects-cross-reference-within-smpc-kdunder-chmp_en.pdf"},
    {"id":"40478","name":"Presentation - New pharmacovigilance legislation: Update on implementation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmacovigilance-legislation-update-implementation_en.pdf"},
    {"id":"40496","name":"Presentation - A micro-, small- and medium-sized-enterprise perspective on the marketing-authorisation-application process (including e-dossier preparation and submission)(Martine Zimmermann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-micro-small-and-medium-sized-enterprise-perspective-marketing-authorisation-application-process-including-e-dossier-preparation-and-submissionmartine-zimmermann_en.pdf"},
    {"id":"40516","name":"Presentation - The PRAC in PRACtice","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prac-practice_en.pdf"},
    {"id":"40526","name":"Presentation - Pharmacovigilance Risk Assessment Committee (PRAC) update (Raymond Anderson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-risk-assessment-committee-prac-update-raymond-anderson_en.pdf"},
    {"id":"40534","name":"Presentation - Good pharmacovigilance practices (GVP) and requirements for marketing-authorisation holders (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-gvp-and-requirements-marketing-authorisation-holders-priya-bahri_en.pdf"},
    {"id":"40542","name":"Presentation - Sixth report on European Medicines Agency’s interaction with patients' and consumer's organisations - 2012 (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-07-02T17:00:00Z","last_updated_date":"2013-07-02T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sixth-report-european-medicines-agencys-interaction-patients-and-consumers-organisations-2012-nathalie-bere_en.pdf"},
    {"id":"40552","name":"Presentation - Day 1: Visual function endpoints in clinical trials clinical view","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-1-visual-function-endpoints-clinical-trials-clinical-view_en.pdf"},
    {"id":"40564","name":"Presentation - Product information management - Annex: Example SmPC","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-information-management-annex-example-smpc_en.pdf"},
    {"id":"40596","name":"Implementation of Advanced therapies - Anthony Humphreys","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:09:21Z","last_updated_date":"2008-11-14T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/implementation-advanced-therapies-anthony-humphreys_en.pdf"},
    {"id":"40626","name":"Presentation - Mechanism-based PKPD-models for selection of dosing regimens for antibiotics (Lena Friberg, Anders Kristoffersson, Elisabet Nielsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mechanism-based-pkpd-models-selection-dosing-regimens-antibiotics-lena-friberg-anders-kristoffersson-elisabet-nielsen_en.pdf"}    {"id":"40628","name":"Presentation - Progressing gene-therapy products to the clinic – a platform-based approach","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-progressing-gene-therapy-products-clinic-platform-based-approach_en.pdf"},
    {"id":"40629","name":"Presentation - Biomedical discovery through data mining and data science (Nicholas Tatonetti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-biomedical-discovery-through-data-mining-and-data-science-nicholas-tatonetti_en.pdf"},
    {"id":"40645","name":"Presentation - Modelling and simulation in support of adaptive designs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-04-14T02:09:21Z","last_updated_date":"2008-04-14T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-and-simulation-support-adaptive-designs_en.pdf"},
    {"id":"40650","name":"Presentation - Update on development of pharmacovigilance information systems (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-12T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-development-pharmacovigilance-information-systems-peter-arlett_en.pdf"},
    {"id":"40651","name":"Presentation - CVMP work programme 2013 (Anja Holm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-04-08T14:00:00Z","last_updated_date":"2013-04-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-work-programme-2013-anja-holm_en.pdf"},
    {"id":"40652","name":"European Commission DG Sanco activities in the field of antimicrobial resistance - Kris De Smet","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/european-commission-dg-sanco-activities-field-antimicrobial-resistance-kris-de-smet_en.pdf"},
    {"id":"40664","name":"Key considerations for a new chemical entity (NCE) - Ryan Tomlinson","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-08T01:00:00Z","last_updated_date":"2008-02-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/key-considerations-new-chemical-entity-nce-ryan-tomlinson_en.pdf"},
    {"id":"40666","name":"Presentation - Day 2: Dry eyes – regulatory perspectives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-dry-eyes-regulatory-perspectives_en.pdf"},
    {"id":"40672","name":"Presentation - PIP session: Overview of paediatric legislation for pharmaceuticals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pip-session-overview-paediatric-legislation-pharmaceuticals_en.pdf"},
    {"id":"40675","name":"Presentation - Industry challenges for producing emergency vaccines in Europe (Alasdair King)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T11:37:00Z","last_updated_date":"2017-05-18T11:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-challenges-producing-emergency-vaccines-europe-alasdair-king_en.pdf"},
    {"id":"40717","name":"Presentation - Introduction to EMA - Training session for patients and consumers involved in EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-ema-training-session-patients-and-consumers-involved-ema_en.pdf"},
    {"id":"40718","name":"Presentation - The European Network of Paediatric Research (Peter Helms)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-paediatric-research-peter-helms_en.pdf"},
    {"id":"40724","name":"Presentation - The research potentials of MetabERN: a survey to investigate and prioritise actions (Jean Michel Heard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T19:00:00Z","last_updated_date":"2018-06-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-research-potentials-metabern-survey-investigate-and-prioritise-actions-jean-michel-heard_en.pdf"},
    {"id":"40739","name":"Presentation - Minor-use-minor-species (MUMS) policy: Industry feedback (Ludwig Klostermann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-minor-use-minor-species-mums-policy-industry-feedback-ludwig-klostermann_en.pdf"},
    {"id":"40755","name":"Presentation - Brainstorming on targeting European Medicines Agency information to patients and healthcare professionals","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-08-14T14:00:00Z","last_updated_date":"2012-08-14T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-brainstorming-targeting-european-medicines-agency-information-patients-and-healthcare-professionals_en.pdf-0"},
    {"id":"40785","name":"Presentation - Cystic fibrosis demographic challenges for Europe (J Stuart Elborn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cystic-fibrosis-demographic-challenges-europe-j-stuart-elborn_en.pdf"},
    {"id":"40791","name":"Presentation - Scientific advice (Jane Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T18:00:00Z","last_updated_date":"2013-05-06T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advice-jane-moseley_en.pdf"},
    {"id":"40808","name":"Presentation - Drafting work plan 2018 - 2019 (I. Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T17:12:00Z","last_updated_date":"2017-12-11T17:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drafting-work-plan-2018-2019-i-silva_en.pdf"},
    {"id":"40834","name":"Presentation - What are the real-world evidence tools and how can they support decision making? (Dr Alison Cave)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-are-real-world-evidence-tools-and-how-can-they-support-decision-making-dr-alison-cave_en.pdf"},
    {"id":"40846","name":"Presentation - European Medicines Agency public workshop - Best expertise versus conflicts of interests: Striking the right balance (Guido Rasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-10-02T14:00:00Z","last_updated_date":"2013-10-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-public-workshop-best-expertise-versus-conflicts-interests-striking-right-balance-guido-rasi_en.pdf"},
    {"id":"40879","name":"Presentation - Substance and product management services (P&SMS) update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-06T11:40:00Z","last_updated_date":"2018-07-06T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-and-product-management-services-psms-update_en.pdf"},
    {"id":"40885","name":"Preclinical immunogenicity testing - Christian Ross, Lisbeth Bjerring Jensen, Inger Mollerup","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2007-09-04T02:09:21Z","last_updated_date":"2007-09-04T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/preclinical-immunogenicity-testing-christian-ross-lisbeth-bjerring-jensen-inger-mollerup_en.pdf"},
    {"id":"40944","name":"Presentation - Public hearings (Francois Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-hearings-francois-houyez_en.pdf"},
    {"id":"40945","name":"Presentation - Field efficacy trials for vaccines for food-producing animals-challenges faced by industry  (F. Descamps)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-11-16T13:30:00Z","last_updated_date":"2017-11-16T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-field-efficacy-trials-vaccines-food-producing-animals-challenges-faced-industry-f-descamps_en.pdf"},
    {"id":"40950","name":"Presentation - Feedback from the informal Heads of Medicines Agencies (HMA) meeting on 5th October 2011","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-informal-heads-medicines-agencies-hma-meeting-5th-october-2011_en.pdf"},
    {"id":"40957","name":"Presentation - Session 4: What have we learnt from the anti PD1- PDL1 story? (Jorge Camarero )","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-what-have-we-learnt-anti-pd1-pdl1-story-jorge-camarero_en.pdf"},
    {"id":"41017","name":"Presentation - Operating characteristics of frequently used similarity rules (F. Klinglmueller, Austrian Medicines and Medical Devices Agency)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-operating-characteristics-frequently-used-similarity-rules-f-klinglmueller-austrian-medicines-medical-devices-agency_en.pdf"},
    {"id":"41038","name":"Presentation - Commission call on patient and healthcare representatives for PRAC and CAT (Florian Schmidt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T13:00:00Z","last_updated_date":"2012-11-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-commission-call-patient-and-healthcare-representatives-prac-and-cat-florian-schmidt_en.pdf"},
    {"id":"41050","name":"Introduction of ECHAMP (European Coalition on Homeopathic and\n\nAnthroposophic Medicinal Products)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2006-10-27T02:09:21Z","last_updated_date":"2006-10-27T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/introduction-echamp-european-coalition-homeopathic-and-anthroposophic-medicinal-products_en.pdf"},
    {"id":"41063","name":"Presentation - Introduction: summary of product characteristics (SmPC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T13:00:00Z","last_updated_date":"2017-09-06T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-summary-product-characteristics-smpc_en.pdf"},
    {"id":"41064","name":"Presentation - Immunogenicity guideline monoclonal antibodies - A risk-based approach - rationale and decision points","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:57Z","last_updated_date":"2012-06-15T17:10:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-immunogenicity-guideline-monoclonal-antibodies-risk-based-approach-rationale-and-decision-points_en.pdf"},
    {"id":"41066","name":"Presentation - Treatment of serious infections due to multiple drug resistant (MDR) acinetobacter baumannii: Presentation of a multicenter randomised clinical trial (Riccardo Utili)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-treatment-serious-infections-due-multiple-drug-resistant-mdr-acinetobacter-baumannii-presentation-multicenter-randomised-clinical-trial-riccardo-utili_en.pdf"},
    {"id":"41069","name":"Presentation - PDCO feedback (D. Athanasiou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T16:50:00Z","last_updated_date":"2017-12-11T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-feedback-d-athanasiou_en.pdf"},
    {"id":"41078","name":"Presentation - Pharmacovigilance in paediatric population - The PRAC's perspective (June Raine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T02:00:00Z","last_updated_date":"2014-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-paediatric-population-pracs-perspective-june-raine_en.pdf"},
    {"id":"41079","name":"Alzheimer's disease - Target population and development of biomarkers - Harald Hampel","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-02-11T00:09:21Z","last_updated_date":"2008-02-11T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/alzheimers-disease-target-population-and-development-biomarkers-harald-hampel_en.pdf"},
    {"id":"41081","name":"Presentation - Optimising the guidance on significant benefit demonstration in the context of protocol assistance (Matthias Hofer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T18:21:00Z","last_updated_date":"2017-05-12T18:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-optimising-guidance-significant-benefit-demonstration-context-protocol-assistance-matthias-hofer_en.pdf"},
    {"id":"41086","name":"Presentation - National experience of application of the requirements for marketing authorisations - considering the situation with detachment (Jean-Claude Rouby)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T14:00:00Z","last_updated_date":"2015-04-29T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-national-experience-application-requirements-marketing-authorisations-considering-situation-detachment-jean-claude-rouby_en.pdf"},
    {"id":"41088","name":"Presentation - Real world evidence (RWE) – an introduction; how is it relevant for the medicines regulatory system? - EMA's PCWP and HCPWP joint meeting (Hans-Georg Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-real-world-evidence-rwe-introduction-how-it-relevant-medicines-regulatory-system-emas-pcwp-and-hcpwp-joint-meeting-hans-georg-eichler_en.pdf"},
    {"id":"41092","name":"Presentation - Implementation of the road map to 2015; implications for patients/consumers","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-road-map-2015-implications-patientsconsumers_en.pdf"},
    {"id":"41114","name":"Presentation - What are safety communications and how to review them (Federica Castellani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T01:00:00Z","last_updated_date":"2015-01-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-are-safety-communications-and-how-review-them-federica-castellani_en.pdf-0"},
    {"id":"41121","name":"Presentation - Case 3: Integrating pharmacogenomics early into drug development: Pharmacokinetics as a working example","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-3-integrating-pharmacogenomics-early-drug-development-pharmacokinetics-working-example_en.pdf"},
    {"id":"41134","name":"Presentation - Multiregional Regulatory Considerations in Pediatric Drug Development (L.Yao, U.S. FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-06-20T02:00:00Z","last_updated_date":"2017-06-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multiregional-regulatory-considerations-pediatric-drug-development-lyao-us-fda_en.pdf"},
    {"id":"41145","name":"Presentation - Day 2: Intraocular Inflammation regulatory views","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T13:00:00Z","last_updated_date":"2011-11-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-day-2-intraocular-inflammation-regulatory-views_en.pdf"},
    {"id":"41154","name":"IPA selected activities, S Benefice, EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ipa-selected-activities-s-benefice-ema_en.pdf"},
    {"id":"41162","name":"Presentation - Overview of European Medicines Agency’s interaction with patients and consumers organisations - 2014 (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-european-medicines-agencys-interaction-patients-and-consumers-organisations-2014-nathalie-bere_en.pdf"},
    {"id":"41177","name":"Technical requirements for Annex I - Patrick Celis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2009-04-03T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/technical-requirements-annex-i-patrick-celis_en.pdf"},
    {"id":"41181","name":"Presentation - Fee system of the European Medicines Agency: Ensuring long-term sustainability","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-13T01:00:00Z","last_updated_date":"2010-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fee-system-european-medicines-agency-ensuring-long-term-sustainability_en.pdf"},
    {"id":"41182","name":"Reduction of antimicrobial use and resistance: Any other options than reducing triggers for bacterial disease? - Klaus Hellmann","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:00:00Z","last_updated_date":"2009-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/reduction-antimicrobial-use-and-resistance-any-other-options-reducing-triggers-bacterial-disease-klaus-hellmann_en.pdf"},
    {"id":"41189","name":"Presentation - Measuring the effectiveness of risk-minimisation measures (A. Rubino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-measuring-effectiveness-risk-minimisation-measures-rubino_en.pdf"},
    {"id":"41228","name":"Presentation - Crisis management","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-crisis-management_en.pdf"},
    {"id":"41232","name":"Presentation - Reports from subgroups","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-14T02:00:00Z","last_updated_date":"2015-07-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reports-subgroups_en.pdf"},
    {"id":"41238","name":"Presentation - Pharmaceutical quality system and assessment-inspection interactions session (G. France, D. Cockburn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmaceutical-quality-system-and-assessment-inspection-interactions-session-g-france-d-cockburn_en.pdf"},
    {"id":"41240","name":"Presentation - ESVAC","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esvac_en.pdf"},
    {"id":"41259","name":"Presentation - Quality aspects for cell-based products for cardiac repair (Paula Salmikangas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T02:00:00Z","last_updated_date":"2014-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-aspects-cell-based-products-cardiac-repair-paula-salmikangas_en.pdf"},
    {"id":"41281","name":"Workshop on the development of an EMEA transparency policy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/workshop-development-emea-transparency-policy_en.pdf"},
    {"id":"41282","name":"Presentation - Good pharmacovigilance practices: Key themes from the public consultation and next steps","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-05-30T18:10:00Z","last_updated_date":"2012-05-30T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-key-themes-public-consultation-and-next-steps_en.pdf"},
    {"id":"41295","name":"Presentation - Pharmacovigilance: Vision and needs for the future (Karen Quine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-26T12:00:00Z","last_updated_date":"2014-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-vision-and-needs-future-karen-quine_en.pdf"},
    {"id":"41299","name":"Presentation - Non-interventional post-authorisation safety studies: Definition, obligations and requirements (A. Rubino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T12:00:00Z","last_updated_date":"2013-01-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-interventional-post-authorisation-safety-studies-definition-obligations-and-requirements-rubino_en.pdf"},
    {"id":"41308","name":"Presentation -  Avenues of knowledge generation throughout a medicine’s lifespan: methodological issues (Rob Hemmings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T10:16:00Z","last_updated_date":"2016-12-21T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-avenues-knowledge-generation-throughout-medicines-lifespan-methodological-issues-rob-hemmings_en.pdf"},
    {"id":"41314","name":"Presentation - The challenges of Personalised Medicine: Contributions from the Research Infrastructures (Jan-Eric Litton)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-30T02:00:00Z","last_updated_date":"2016-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-personalised-medicine-contributions-research-infrastructures-jan-eric-litton_en.pdf"},
    {"id":"41318","name":"Presentation - Case study 1 - Application of prior knowledge for process parameter definition - Session 3 (Bob Kuhn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T01:00:00Z","last_updated_date":"2017-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-1-application-prior-knowledge-process-parameter-definition-session-3-bob-kuhn_en.pdf"},
    {"id":"41342","name":"Presentation - Specific issues that research ethics committees face with paediatric trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T11:00:00Z","last_updated_date":"2012-01-16T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-specific-issues-research-ethics-committees-face-paediatric-trials_en.pdf"},
    {"id":"41347","name":"Presentation - Proposal for guidance on medical research for and with older people in Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2012-04-10T14:00:00Z","last_updated_date":"2012-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposal-guidance-medical-research-and-older-people-europe_en.pdf"},
    {"id":"41349","name":"Clinical trials in paediatric pain treatment - Katri Hamunen","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2004-10-28T02:09:21Z","last_updated_date":"2004-10-28T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/clinical-trials-paediatric-pain-treatment-katri-hamunen_en.pdf"},
    {"id":"41366","name":"Presentation - Action on antimicrobial resistance – A brief overview of EPHA’s advocacy campaign - Session 4 (Sascha Marschang)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-action-antimicrobial-resistance-brief-overview-ephas-advocacy-campaign-session-4-sascha-marschang_en.pdf"},
    {"id":"41382","name":"Presentation - Integration concept OMS-PHAROS - Austrian Federal Office for Safety in Health Care (AGES) - Substance, product, organisation and referential data (SPOR) impact on veterinary stakeholders (Georg Neuwirther)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-02-27T01:00:00Z","last_updated_date":"2018-02-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-integration-concept-oms-pharos-austrian-federal-office-safety-health-care-ages-substance-product-organisation-and-referential-data-spor-impact-veterinary-stakeholders-georg-neuwirther_en.pdf"},
    {"id":"41387","name":"Presentation - Session 3: OMOP common data model: validation approach (Jon Duke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T01:00:00Z","last_updated_date":"2018-01-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-omop-common-data-model-validation-approach-jon-duke_en.pdf"},
    {"id":"41399","name":"Presentation - Rare liver diseases (Ulrich Baumann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-19T01:00:00Z","last_updated_date":"2016-01-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rare-liver-diseases-ulrich-baumann_en.pdf"},
    {"id":"41414","name":"Presentation - Cell Therapy Limited (Ajan Reginald)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2015-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cell-therapy-limited-ajan-reginald_en.pdf"},
    {"id":"41415","name":"Presentation - Supporting the European Immunization Week - EMA's PCWP and HCPWP joint meeting (Camelia Enachioiu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supporting-european-immunization-week-emas-pcwp-and-hcpwp-joint-meeting-camelia-enachioiu_en.pdf"},
    {"id":"41432","name":"Presentation - Listening to the stakeholders of innovative medicinal products – Payer viewpoint (Anna Bucsics)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-listening-stakeholders-innovative-medicinal-products-payer-viewpoint-anna-bucsics_en.pdf"},
    {"id":"41437","name":"Presentation - EnprEMA/PDCO interactions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-18T16:02:00Z","last_updated_date":"2018-06-18T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpremapdco-interactions_en.pdf"},
    {"id":"41442","name":"Presentation - Young people involvement in the work of the Paediatric Committee (PDCO) - EMA's PCWP and HCPWP joint meeting (Viviana Giannuzzi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-young-people-involvement-work-paediatric-committee-pdco-emas-pcwp-and-hcpwp-joint-meeting-viviana-giannuzzi_en.pdf"},
    {"id":"41444","name":"Presentation - Medication errors: FDA perspective (Carol Holquist)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-03-11T13:00:00Z","last_updated_date":"2013-03-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medication-errors-fda-perspective-carol-holquist_en.pdf"},
    {"id":"41496","name":"Presentation - Enhancing evidence generation across the product life cycle: learnings from a series of workshops - EMA's PCWP and HCPWP joint meeting (Alison Cave)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enhancing-evidence-generation-across-product-life-cycle-learnings-series-workshops-emas-pcwp-and-hcpwp-joint-meeting-alison-cave_en.pdf"},
    {"id":"41501","name":"EudraVigilance reporting process for users: Introduction to EVWEB - Training Module EV-M3b","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-06T15:00:00Z","last_updated_date":"2018-07-26T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eudravigilance-reporting-process-users-introduction-evweb-training-module-ev-m3b_en.pdf"},
    {"id":"41520","name":"Presentation - EU IDMP/SPOR Task Force meeting: SPOR communications and change Management (8. agenda) (Agnieszka Laka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-idmpspor-task-force-meeting-spor-communications-and-change-management-8-agenda-agnieszka-laka_en.pdf"},
    {"id":"41522","name":"Presentation - Breakout session - Neonatal lung injury (Robin Steinhorn and Mary Short)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-11T02:00:00Z","last_updated_date":"2015-06-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-neonatal-lung-injury-robin-steinhorn-and-mary-short_en.pdf"},
    {"id":"41530","name":"Presentation - Finnish Investigators Network for Pediatric Medicines (FINPEDMED) - IT development for e-Services 2006-2015 (Pirkko Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-25T02:00:00Z","last_updated_date":"2015-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-finnish-investigators-network-pediatric-medicines-finpedmed-it-development-e-services-2006-2015-pirkko-lepola_en.pdf"},
    {"id":"41534","name":"Presentation - SCOPE Joint action work package 6 on risk communication (Dolores Montero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scope-joint-action-work-package-6-risk-communication-dolores-montero_en.pdf"},
    {"id":"41538","name":"Presentation - Establishing, Assessing, and Comparing Quality Attributes from a Small Sample of Development Batches through Full-scale Production (K. Vukovinsky, Pfizer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-establishing-assessing-and-comparing-quality-attributes-small-sample-development-batches-through-full-scale-production-k-vukovinsky-pfizer_en.pdf"},
    {"id":"41559","name":"Presentation - Introduction to posters (Peter Richardson, David Tainsh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-posters-peter-richardson-david-tainsh_en.pdf"},
    {"id":"41570","name":"Presentation - 5.2 Goal attainment scaling: individualized instrument with potential for outcome measurement in rare diseases (Hanneke van der Lee, Charlotte Gaasterland, Susanne Urach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-52-goal-attainment-scaling-individualized-instrument-potential-outcome-measurement-rare-diseases-hanneke-van-der-lee-charlotte-gaasterland-susanne-urach_en.pdf"},
    {"id":"41588","name":"Presentation - ISO ICSR standard implementation for IT system developers - Training module IT-M1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-06T15:00:00Z","last_updated_date":"2017-01-06T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-iso-icsr-standard-implementation-it-system-developers-training-module-it-m1_en.pdf"},
    {"id":"41602","name":"Presentation - AIFA and the ISO IDMP implementation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T02:00:00Z","last_updated_date":"2015-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-aifa-and-iso-idmp-implementation_en.pdf"},
    {"id":"41614","name":"Presentation - EU IDMP/SPOR Task Force meeting: Outcome of the ISO Plenary meeting held in Amsterdam on 2-6 May 2016 (3. agenda) (Paolo Alcini)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-idmpspor-task-force-meeting-outcome-iso-plenary-meeting-held-amsterdam-2-6-may-2016-3-agenda-paolo-alcini_en.pdf"},
    {"id":"41619","name":"Presentation - Approaches for quality control testing\n\nof LSD vaccines (Annebel De Vleeschauwer and Kris De Clercq)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-23T16:39:00Z","last_updated_date":"2017-05-23T16:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-approaches-quality-control-testing-lsd-vaccines-annebel-de-vleeschauwer-and-kris-de-clercq_en.pdf"},
    {"id":"41637","name":"Presentation - 6.4 Improved methodology for use of non-linear mixed effect models (NLMEM) in decision making (Mats O. Karlsson, Andrew Hooker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-64-improved-methodology-use-non-linear-mixed-effect-models-nlmem-decision-making-mats-o-karlsson-andrew-hooker_en.pdf"},
    {"id":"41648","name":"Presentation - EV Reporting process for users: EV Gateway, WEB-Trader, EV-Post functions - Training Module EV-M3a","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-06T15:00:00Z","last_updated_date":"2017-01-06T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ev-reporting-process-users-ev-gateway-web-trader-ev-post-functions-training-module-ev-m3a_en.pdf"},
    {"id":"41659","name":"Presentation - Incentives and regulatory considerations in orphan drug/medical device development - Situation in Japan (Hiroshi Takeda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-28T14:00:00Z","last_updated_date":"2014-03-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-incentives-and-regulatory-considerations-orphan-drugmedical-device-development-situation-japan-hiroshi-takeda_en.pdf"},
    {"id":"41666","name":"Presentation - EMA support to and involvement in regulatory science (Corinne de Vries)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-30T02:00:00Z","last_updated_date":"2016-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-support-and-involvement-regulatory-science-corinne-de-vries_en.pdf"},
    {"id":"41682","name":"Presentation - Signal  management: industry viewpoint","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-signal-management-industry-viewpoint_en.pdf"},
    {"id":"41684","name":"Presentation - User safety and environmental safety","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-user-safety-and-environmental-safety_en.pdf"},
    {"id":"41691","name":"Presentation - Shifting the MTD paradigm in oncology (Kevin Smart, Georgina Meneses-Lorente)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-07T13:00:00Z","last_updated_date":"2015-01-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-shifting-mtd-paradigm-oncology-kevin-smart-georgina-meneses-lorente_en.pdf"},
    {"id":"41695","name":"Presentation - Patients/healthcare professionals involvement in benefit/risk assessments (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-09-22T13:00:00Z","last_updated_date":"2014-09-22T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patientshealthcare-professionals-involvement-benefitrisk-assessments-nathalie-bere_en.pdf"},
    {"id":"41696","name":"Collaboration and exchange of information between the COMP and the Paediatric Committee","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/collaboration-and-exchange-information-between-comp-and-paediatric-committee_en.pdf"},
    {"id":"41708","name":"Presentation: Antimicrobial Advice ad hoc Expert Group (AMEG) - The impact on public and animal health of the use of antibiotics in animals - Discussion on question three (Catry Boudewijn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-03T03:00:00Z","last_updated_date":"2014-04-03T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antimicrobial-advice-ad-hoc-expert-group-ameg-impact-public-and-animal-health-use-antibiotics-animals-discussion-question-three-catry-boudewijn_en.pdf"},
    {"id":"41709","name":"Presentation - PNH indication update based on data from  Global  Registry(Martine Zimmermann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T11:36:00Z","last_updated_date":"2016-12-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pnh-indication-update-based-data-global-registrymartine-zimmermann_en.pdf"},
    {"id":"41729","name":"Presentation - Eradication of carriage (Jan Kluytmans)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T18:00:00Z","last_updated_date":"2013-09-25T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eradication-carriage-jan-kluytmans_en.pdf"},
    {"id":"41734","name":"Presentation - Update on preparation for Signal Management (Georgy Genov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-preparation-signal-management-georgy-genov_en.pdf"}    {"id":"41744","name":"Presentation - Implementation of the 2016 Notice on the application of the orphan regulation (Kristina Larsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-05-12T18:21:00Z","last_updated_date":"2017-05-12T18:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-2016-notice-application-orphan-regulation-kristina-larsson_en.pdf"},
    {"id":"41754","name":"Presentation - How the European Medicines Agency interacts with patients and consumers","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T16:00:00Z","last_updated_date":"2016-02-15T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-european-medicines-agency-interacts-patients-and-consumers_en.pdf"},
    {"id":"41755","name":"Presentation - Increasing access to adverse drug reaction reports on the web (Steven Le Meur) AA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-increasing-access-adverse-drug-reaction-reports-web-steven-le-meur-aa_en.pdf"},
    {"id":"41757","name":"Presentation: Update on new Enpr-EMA Paediatric Antibiotic Clinical Trial Working Group","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-06-28T02:00:00Z","last_updated_date":"2016-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-new-enpr-ema-paediatric-antibiotic-clinical-trial-working-group_en.pdf"},
    {"id":"41779","name":"Presentation - Interaction with patients and consumers: Training session questionnaire results (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T13:40:00Z","last_updated_date":"2014-04-28T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interaction-patients-and-consumers-training-session-questionnaire-results-nathalie-bere_en.pdf"},
    {"id":"41804","name":"Presentation - EMA procedural updates (Emily Drury)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T02:00:00Z","last_updated_date":"2017-03-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-procedural-updates-emily-drury_en.pdf"},
    {"id":"41829","name":"Presentation - Survey on the use of medicines’ information (Laurent Brassart (EMA) and Joan Peppard (EAHP))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-use-medicines-information-laurent-brassart-ema-and-joan-peppard-eahp_en.pdf"},
    {"id":"41830","name":"Presentation - Communicating benefits and risks of medicines within the European Union regulatory network (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communicating-benefits-and-risks-medicines-within-european-union-regulatory-network-juan-garcia-burgos_en.pdf"},
    {"id":"41831","name":"Presentation - 4.3 Does the level of evidence depend on randomization? (Ralf-Dieter Hilgers, Nicole Heussen, Diane Uschner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-04-20T02:00:00Z","last_updated_date":"2017-04-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-43-does-level-evidence-depend-randomization-ralf-dieter-hilgers-nicole-heussen-diane-uschner_en.pdf"},
    {"id":"41835","name":"Presentation - European Union Medicines Agencies Network strategy to 2020: working together to improve health (Roxane Feller)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-04-18T02:00:00Z","last_updated_date":"2016-04-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-medicines-agencies-network-strategy-2020-working-together-improve-health-roxane-feller_en.pdf"},
    {"id":"41838","name":"Presentation - ELF data: study designs, interpretation, role in dose selection (William Hope)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T15:00:00Z","last_updated_date":"2016-03-16T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-elf-data-study-designs-interpretation-role-dose-selection-william-hope_en.pdf"},
    {"id":"41855","name":"Presentation - Identifying the future needs for big data in Medicines Regulation (Hans Hillege)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-01-04T16:30:00Z","last_updated_date":"2017-01-04T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-identifying-future-needs-big-data-medicines-regulation-hans-hillege_en.pdf"},
    {"id":"41861","name":"Presentation - Case study: Risk assessments for cross contamination (S. Wilkins, ISPE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-risk-assessments-cross-contamination-s-wilkins-ispe_en.pdf"},
    {"id":"41863","name":"Presentation - Case studies looking at regulatory action and communication – a national experience (Rafe Suvarna)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-studies-looking-regulatory-action-and-communication-national-experience-rafe-suvarna_en.pdf"},
    {"id":"41869","name":"Presentation - The UK national haemophilia database: a thumbnail sketch!(Charles RM Hay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-uk-national-haemophilia-database-thumbnail-sketchcharles-rm-hay_en.pdf"},
    {"id":"41883","name":"Presentation - Update on implementation of public hearings at the PRAC (Isabelle Moulon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-09-29T18:30:00Z","last_updated_date":"2015-09-29T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-implementation-public-hearings-prac-isabelle-moulon_en.pdf"},
    {"id":"41920","name":"Presentation - EMA Technical Anonymisation Group (TAG) - EMA's PCWP and HCPWP joint meeting (Monica Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-technical-anonymisation-group-tag-emas-pcwp-and-hcpwp-joint-meeting-monica-dias_en.pdf"},
    {"id":"41931","name":"Presentation - Industry and assessors' joint training on how to improve to improve the content of PSURs - PSUR roadmap: joint industry/assessor training","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-18T02:00:00Z","last_updated_date":"2017-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-and-assessors-joint-training-how-improve-improve-content-psurs-psur-roadmap-joint-industryassessor-training_en.pdf"},
    {"id":"41944","name":"Presentation - Federation of Veterinarians of Europe (FVE): Collection of data by species : Draft action plan  (Nancy De Briyne)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-federation-veterinarians-europe-fve-collection-data-species-draft-action-plan-nancy-de-briyne_en.pdf"},
    {"id":"41946","name":"Presentation - Practical considerations in the statistical evaluation of biosimilarity - a laboratory perspective (H. Kuehne, Coherus Biosciencies)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-practical-considerations-statistical-evaluation-biosimilarity-laboratory-perspective-h-kuehne-coherus-biosciencies_en.pdf"},
    {"id":"41951","name":"Presentation - Methodology for extrapolation in the EU FP7 ASTERIX, IDeAl and InSPiRe projects (Nigel Stallard, Ralf-Dieter Hilgers, Kit Roes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T18:00:00Z","last_updated_date":"2016-05-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-methodology-extrapolation-eu-fp7-asterix-ideal-and-inspire-projects-nigel-stallard-ralf-dieter-hilgers-kit-roes_en.pdf"},
    {"id":"41952","name":"Presentation - The Community Pharmacy Contribution to Tackling AMR - Session 4 (Jamie Wilkinson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-community-pharmacy-contribution-tackling-amr-session-4-jamie-wilkinson_en.pdf"},
    {"id":"41963","name":"Presentation - European Medicines Agency adaptive licensing: a tool concept for accelerated access to innovative medicines? (Rob Hemmings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-adaptive-licensing-tool-concept-accelerated-access-innovative-medicines-rob-hemmings_en.pdf"},
    {"id":"41978","name":"Presentation - Topic 1 - Selection of agents, doses and regimens for clinical study (David Barros)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T01:00:00Z","last_updated_date":"2017-03-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-topic-1-selection-agents-doses-and-regimens-clinical-study-david-barros_en.pdf"},
    {"id":"41983","name":"Presentation - Key points from session 3: industry perspective (Karri Penttila)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-08-03T02:00:00Z","last_updated_date":"2015-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-points-session-3-industry-perspective-karri-penttila_en.pdf"},
    {"id":"41986","name":"Presentation - Report on 'from regulatory outputs to health outcomes' (Daniel Morales)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T01:00:00Z","last_updated_date":"2016-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-regulatory-outputs-health-outcomes-daniel-morales_en.pdf"},
    {"id":"41994","name":"Presentation - European Medicines Agency (EMA)-Heads of Medicines Agency (HMA) collaboration on shortages and availability of medicines - EMA's PCWP and HCPWP joint meeting (Rosa Gonzalez-Quevedo, Annette Byrholt Hansen,...","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T02:00:00Z","last_updated_date":"2018-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-ema-heads-medicines-agency-hma-collaboration-shortages-and-availability-medicines-emas-pcwp-and-hcpwp-joint-meeting-rosa-gonzalez-quevedo-annette-byrholt-hansen_en.pdf"},
    {"id":"41997","name":"Presentation - Molecular comparison of ulcerative colitis different in age and extent of disease by colon biopsy mRNA expression profiling (Richard Strauss)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2015-07-09T02:00:00Z","last_updated_date":"2015-07-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-molecular-comparison-ulcerative-colitis-different-age-and-extent-disease-colon-biopsy-mrna-expression-profiling-richard-strauss_en.pdf"},
    {"id":"42006","name":"Presentation - Anthelmintic resistance in Europe - Cattle, sheep and horses (Anita Bottger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-anthelmintic-resistance-europe-cattle-sheep-and-horses-anita-bottger_en.pdf"},
    {"id":"42217","name":"Presentation - Overview of current patient involvement (M. Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:01:00Z","last_updated_date":"2018-10-08T13:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-current-patient-involvement-m-mavris_en.pdf"},
    {"id":"42218","name":"Presentation - Public Hearings; experience so far (N. Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:02:00Z","last_updated_date":"2018-10-08T13:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-hearings-experience-so-far-n-bere_en.pdf"},
    {"id":"42219","name":"Presentation - The engagement of patients and healthcare professionals in regulatory pharmacovigilance: developing a conceptualisation (P. Brown)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:03:00Z","last_updated_date":"2018-10-08T13:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-engagement-patients-and-healthcare-professionals-regulatory-pharmacovigilance-developing-conceptualisation-p-brown_en.pdf"},
    {"id":"42220","name":"Presentation - Valproate case study: industry perspective (E. Teo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:09:00Z","last_updated_date":"2018-10-08T13:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-valproate-case-study-industry-perspective-e-teo_en.pdf"},
    {"id":"42221","name":"Presentation - Public hearing on valproate: Account of events and outcomes (E. Vatzaki)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:10:00Z","last_updated_date":"2018-10-08T13:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-hearing-valproate-account-events-and-outcomes-e-vatzaki_en.pdf"},
    {"id":"42222","name":"Presentation - Valproate case study: patients' perspective (F.Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:11:00Z","last_updated_date":"2018-10-08T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-valproate-case-study-patients-perspective-fhouyez_en.pdf"},
    {"id":"42223","name":"Presentation - Valproate case study: pharmacists' perspective (R. Anderson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:14:00Z","last_updated_date":"2018-10-08T13:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-valproate-case-study-pharmacists-perspective-r-anderson_en.pdf"},
    {"id":"42224","name":"Presentation - Valproate case study: doctors' perspective (R. Kalvianen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:17:00Z","last_updated_date":"2018-10-08T13:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-valproate-case-study-doctors-perspective-r-kalvianen_en.pdf"},
    {"id":"42225","name":"Presentation - Valproate case study: engagement of patients and healthcare professionals (P. Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:20:00Z","last_updated_date":"2018-10-08T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-valproate-case-study-engagement-patients-and-healthcare-professionals-p-bahri_en.pdf"},
    {"id":"42226","name":"Presentation - Pharmacovigilance in the next 5 years, doctors' vision (C. Matias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:21:00Z","last_updated_date":"2018-10-08T13:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-next-5-years-doctors-vision-c-matias_en.pdf"},
    {"id":"42227","name":"Presentation - Pharmacovigilance in the next 5 years, pharmacists' vision (J. De Belie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:23:00Z","last_updated_date":"2018-10-08T13:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-next-5-years-pharmacists-vision-j-de-belie_en.pdf"},
    {"id":"42228","name":"Presentation - Pharmacovigilance in the next 5 years, industry vision (V. Edwards)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T13:27:00Z","last_updated_date":"2018-10-08T13:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-next-5-years-industry-vision-v-edwards_en.pdf"},
    {"id":"42271","name":"Presentation - Negotiations with the United Kingdom (Stefan Fuehring)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T16:09:00Z","last_updated_date":"2018-10-10T16:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-negotiations-united-kingdom-stefan-fuehring_en.pdf"},
    {"id":"42272","name":"Presentation - Operational preparedness for Brexit and next phase of the Business continuity plan (BCP) (Noël Wathion)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T16:14:00Z","last_updated_date":"2018-10-10T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-operational-preparedness-brexit-and-next-phase-business-continuity-plan-bcp-noel-wathion_en.pdf"},
    {"id":"42273","name":"Presentation - Update on European Medicines Agency Committees’ Operational Preparedness (Monica Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T16:17:00Z","last_updated_date":"2018-10-10T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-european-medicines-agency-committees-operational-preparedness-monica-dias_en.pdf"},
    {"id":"42274","name":"Presentation - European Medicines Agency industry survey summary results (Alberto Jimenez,)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T16:18:00Z","last_updated_date":"2018-10-10T16:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agency-industry-survey-summary-results-alberto-jimenez_en.pdf"},
    {"id":"42275","name":"Presentation - Joint human medicines industry presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T16:22:00Z","last_updated_date":"2018-10-10T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-human-medicines-industry-presentation_en.pdf"},
    {"id":"42276","name":"Presentation - Joint veterinary medicines industry presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T16:24:00Z","last_updated_date":"2018-10-10T16:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-veterinary-medicines-industry-presentation_en.pdf"},
    {"id":"42331","name":"Presentation – Feedback on EudraVigilance & new functionalities (Anja van Haren, Sabine Brosch, F. Domergue)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-12T16:33:00Z","last_updated_date":"2018-10-12T16:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-eudravigilance-new-functionalities-anja-van-haren-sabine-brosch-f-domergue_en.pdf"},
    {"id":"42332","name":"Presentation – Issues and update from the CMDh (Kora Doorduyn-van der Stoep)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-12T17:22:00Z","last_updated_date":"2018-10-12T17:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-issues-and-update-cmdh-kora-doorduyn-van-der-stoep_en.pdf"},
    {"id":"42333","name":"Presentation – EudraVigilance registration updates (Oana Agheorghiesei)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-12T17:25:00Z","last_updated_date":"2018-10-12T17:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-registration-updates-oana-agheorghiesei_en.pdf"},
    {"id":"42334","name":"Presentation – UK’s withdrawal from the EU: Preparedness activities update (Marie-Helene Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-12T17:27:00Z","last_updated_date":"2018-10-12T17:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-uks-withdrawal-eu-preparedness-activities-update-marie-helene-pinheiro_en.pdf"},
    {"id":"42335","name":"OMS Data Quality Standard","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-12T17:56:00Z","last_updated_date":"2018-10-12T17:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/oms-data-quality-standard_en.pdf"},
    {"id":"42384","name":"Presentation - Referentials Management Service (RMS) and Organisations Management Service (OMS) status (Kepa Amutxastegi and Jaume Gonzalez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T15:23:00Z","last_updated_date":"2018-10-19T15:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-referentials-management-service-rms-and-organisations-management-service-oms-status-kepa-amutxastegi-and-jaume-gonzalez_en.pdf"},
    {"id":"42385","name":"Presentation - Substance management system (SMS) / EU-SRS update (Frits Stulp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T15:31:00Z","last_updated_date":"2018-10-19T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-management-system-sms-eu-srs-update-frits-stulp_en.pdf"},
    {"id":"42386","name":"Presentation - Substance management system (SMS) update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T15:37:00Z","last_updated_date":"2018-10-19T15:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-management-system-sms-update_en.pdf"},
    {"id":"42388","name":"Presentation - Product management system (PMS) workshop","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T15:38:00Z","last_updated_date":"2018-10-19T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-system-pms-workshop_en.pdf"},
    {"id":"42389","name":"Presentation - Product management system (PMS) data quality (Jeff Martin, Martha Schei Hynne)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T15:40:00Z","last_updated_date":"2018-10-19T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-system-pms-data-quality-jeff-martin-martha-schei-hynne_en.pdf"},
    {"id":"42390","name":"Presentation - Target operating model (part of the Product management system (PMS) data quality (Jeff Martin, Martha Schei Hynne) presentation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:10:00Z","last_updated_date":"2018-10-19T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-target-operating-model-part-product-management-system-pms-data-quality-jeff-martin-martha-schei-hynne-presentation_en.pdf"},
    {"id":"42391","name":"Presentation - Regulatory Optimisation Group (ROG) update on Type IAs business case: opportunities and challenges (Evdokia Korakianiti,)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:11:00Z","last_updated_date":"2018-10-19T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-optimisation-group-rog-update-type-ias-business-case-opportunities-and-challenges-evdokia-korakianiti_en.pdf"},
    {"id":"42392","name":"Presentation - Industry points for discussion","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:14:00Z","last_updated_date":"2018-10-19T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-points-discussion_en.pdf"},
    {"id":"42393","name":"Presentation - Substance, product, organisation and referential (SPOR) data impact on veterinary stakeholders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:15:00Z","last_updated_date":"2018-10-19T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-product-organisation-and-referential-spor-data-impact-veterinary-stakeholders_en.pdf"},
    {"id":"42394","name":"Presentation - IRISS (Implementation of Regulatory Information Submission Standards) IDMP Topic Group (Frits Stulp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:16:00Z","last_updated_date":"2018-10-19T16:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-iriss-implementation-regulatory-information-submission-standards-idmp-topic-group-frits-stulp_en.pdf"},
    {"id":"42398","name":"Presentation - Product Management system (PMS) update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:42:00Z","last_updated_date":"2018-10-19T16:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-system-pms-update_en.pdf"},
    {"id":"42399","name":"Presentation - Feedback to Substance, Product, Organisation and Referential data (SPOR) task force on EU-SRS","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:44:00Z","last_updated_date":"2018-10-19T16:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-substance-product-organisation-and-referential-data-spor-task-force-eu-srs_en.pdf"},
    {"id":"42400","name":"Presentation - Type IA notification process optimisation - Regulatory Optimisation Group (ROG) presentation to Heads of Medicines Agencies (HMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:47:00Z","last_updated_date":"2018-10-19T16:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-type-ia-notification-process-optimisation-regulatory-optimisation-group-rog-presentation-heads-medicines-agencies-hma_en.pdf"},
    {"id":"42401","name":"Presentation - Submission of legacy data - Veterinary","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:50:00Z","last_updated_date":"2018-10-19T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-submission-legacy-data-veterinary_en.pdf"},
    {"id":"42402","name":"Presentation - New veterinary regulation (NVR): impact on Information Technology / Telematics (Jos Olaerts, Jana Schalansky)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:51:00Z","last_updated_date":"2018-10-19T16:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-veterinary-regulation-nvr-impact-information-technology-telematics-jos-olaerts-jana-schalansky_en.pdf"},
    {"id":"42403","name":"Presentation - Industry points for discussion","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:53:00Z","last_updated_date":"2018-10-19T16:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-points-discussion_en.pdf-0"},
    {"id":"42404","name":"Presentation - Substance, Product, Organisation and Referential data (SPOR) -  Referentials Management Service (RMS) and Organisations Management Service (OMS) communication update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T16:54:00Z","last_updated_date":"2018-10-19T16:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-product-organisation-and-referential-data-spor-referentials-management-service-rms-and-organisations-management-service-oms-communication-update_en.pdf"},
    {"id":"42451","name":"Presentation - Anti-infective drug development in neonates (S.Nambiar, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T11:43:00Z","last_updated_date":"2018-10-29T11:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-anti-infective-drug-development-neonates-snambiar-fda_en.pdf"},
    {"id":"42452","name":"Presentation - Studying neonates: A not-for-profit developers perspective (M.Balasegaram, GARDP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T11:45:00Z","last_updated_date":"2018-10-29T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-studying-neonates-not-profit-developers-perspective-mbalasegaram-gardp_en.pdf"},
    {"id":"42453","name":"Presentation - Anti-Infectives and Neonates (D.Benjamin, Duke University)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T11:46:00Z","last_updated_date":"2018-10-29T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-anti-infectives-and-neonates-dbenjamin-duke-university_en.pdf"},
    {"id":"42455","name":"Presentation - General considerations for the development of antibacterial drugs for children - U.S. FDA perspective (J.Farley, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T11:51:00Z","last_updated_date":"2018-10-29T11:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-considerations-development-antibacterial-drugs-children-us-fda-perspective-jfarley-fda_en.pdf"},
    {"id":"42456","name":"Presentation - Issues in conducting clinical trials in children and neonates: site PI perspective (T.Metsvaht, University of Tartu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T11:56:00Z","last_updated_date":"2018-10-29T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-issues-conducting-clinical-trials-children-and-neonates-site-pi-perspective-tmetsvaht-university-tartu_en.pdf"},
    {"id":"42457","name":"Presentation - Neonates need more finesse in dosing of antibiotics (K.Allegaert, KU Leuven)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T11:59:00Z","last_updated_date":"2018-10-29T11:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-neonates-need-more-finesse-dosing-antibiotics-kallegaert-ku-leuven_en.pdf"},
    {"id":"42458","name":"Presentation - Overview of neonatal studies in paediatric investigational plans (M.Cortizo, IDWP/PDCO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T12:01:00Z","last_updated_date":"2018-10-29T12:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-neonatal-studies-paediatric-investigational-plans-mcortizo-idwppdco_en.pdf"},
    {"id":"42459","name":"Presentation - Pharmacokinetic-Pharmacodynamic (PKPD) modelling to inform efficacyin paediatric antimicrobial trials (J.Standing, UCL)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T12:03:00Z","last_updated_date":"2018-10-29T12:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacokinetic-pharmacodynamic-pkpd-modelling-inform-efficacyin-paediatric-antimicrobial-trials-jstanding-ucl_en.pdf"},
    {"id":"42460","name":"Presentation - PMDA perspective: Ongoing activities and requirements for developing antibacterial agents for children (J.Sato, PMDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T12:07:00Z","last_updated_date":"2018-10-29T12:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pmda-perspective-ongoing-activities-and-requirements-developing-antibacterial-agents-children-jsato-pmda_en.pdf"},
    {"id":"42461","name":"Presentation - Safety assessment in paediatric antibiotics clinical trials (M.Sharland, St.George's University of London)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T12:10:00Z","last_updated_date":"2018-10-29T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safety-assessment-paediatric-antibiotics-clinical-trials-msharland-stgeorges-university-london_en.pdf"},
    {"id":"42462","name":"Presentation - Studying neonates: Workshop on development of antibacterial products for paediatric patients (M.Johnson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T12:13:00Z","last_updated_date":"2018-10-29T12:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-studying-neonates-workshop-development-antibacterial-products-paediatric-patients-mjohnson_en.pdf"},
    {"id":"42463","name":"Presentation - The paediatrica ddendum to the antibacterial agents guideline (M.Fernandez Cortizo, IDWP/PDCO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T12:18:00Z","last_updated_date":"2018-10-29T12:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatrica-ddendum-antibacterial-agents-guideline-mfernandez-cortizo-idwppdco_en.pdf"},
    {"id":"42464","name":"Presentation - The right dose - Application of PK/PD modeling in pediatric antibiotic development (M.Cohen-Wolkowiez, Duke University)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-29T12:22:00Z","last_updated_date":"2018-10-29T12:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-right-dose-application-pkpd-modeling-pediatric-antibiotic-development-mcohen-wolkowiez-duke-university_en.pdf"},
    {"id":"42484","name":"Presentation - TAG mandate (A Spina)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T13:13:00Z","last_updated_date":"2018-10-30T13:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-tag-mandate-spina_en.pdf"},
    {"id":"42485","name":"Presentation - EMA guidance on anonymisation (K Quigley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T13:15:00Z","last_updated_date":"2018-10-30T13:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-guidance-anonymisation-k-quigley_en.pdf"},
    {"id":"42486","name":"Presentation - Analysis of clinical reports published (A Adriano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T13:23:00Z","last_updated_date":"2018-10-30T13:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-analysis-clinical-reports-published-adriano_en.pdf"},
    {"id":"42487","name":"Presentation -  PhUSE's analysis of clinical reports published (L Kniola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T13:26:00Z","last_updated_date":"2018-10-30T13:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-phuses-analysis-clinical-reports-published-l-kniola_en.pdf"},
    {"id":"42488","name":"Presentation -  Case study: Carfilzomib MAA (C Fletcher)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T13:30:00Z","last_updated_date":"2018-10-30T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-carfilzomib-maa-c-fletcher_en.pdf"},
    {"id":"42489","name":"Presentation -  Anonymisation of clinical reports: Zinbryta (L Kniola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T13:38:00Z","last_updated_date":"2018-10-30T13:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-anonymisation-clinical-reports-zinbryta-l-kniola_en.pdf"},
    {"id":"42490","name":"Presentation - How to improve the quality of anonymisation reports (AS Henry-Eude)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T13:48:00Z","last_updated_date":"2018-10-30T13:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-improve-quality-anonymisation-reports-henry-eude_en.pdf"},
    {"id":"42491","name":"Presentation -  Quantitative methods to measure the risk of re-identification (B Malin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T14:02:00Z","last_updated_date":"2018-10-30T14:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quantitative-methods-measure-risk-re-identification-b-malin_en.pdf"},
    {"id":"42492","name":"Presentation - Data utility in anonymised clinical reports (JM Ferran, S Nevitt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T14:06:00Z","last_updated_date":"2018-10-30T14:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-utility-anonymised-clinical-reports-jm-ferran-s-nevitt_en.pdf"},
    {"id":"42493","name":"Presentation - Adversary Knowledge (K El Emam)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T14:26:00Z","last_updated_date":"2018-10-30T14:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adversary-knowledge-k-el-emam_en.pdf"},
    {"id":"42494","name":"Presentation - Adversary Knowledge (K El Emam)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T14:26:00Z","last_updated_date":"2018-10-30T14:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adversary-knowledge-k-el-emam_en.pdf-0"},
    {"id":"42502","name":"Presentation - Legal issues with the anonymisation of clinical reports (N Orlandi, L Parker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T14:35:00Z","last_updated_date":"2018-10-30T14:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-legal-issues-anonymisation-clinical-reports-n-orlandi-l-parker_en.pdf"},
    {"id":"42503","name":"Presentation - Impact of the general data protection regulation on the anonymisation of clinical reports (UW Fiedler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T16:42:00Z","last_updated_date":"2018-10-30T16:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-general-data-protection-regulation-anonymisation-clinical-reports-uw-fiedler_en.pdf"},
    {"id":"42544","name":"Presentation - Data exclusivity, market protection, orphan and paediatric rewards (S. Ribeiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T14:11:00Z","last_updated_date":"2018-11-06T14:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-exclusivity-market-protection-orphan-and-paediatric-rewards-s-ribeiro_en.pdf"},
    {"id":"42545","name":"Presentation - Legal basis and types of approvals (S. Prilla)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T14:12:00Z","last_updated_date":"2018-11-06T14:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-legal-basis-and-types-approvals-s-prilla_en.pdf"},
    {"id":"42546","name":"Presentation - Experience with the review of the orphan designation in the context of extension of indication (M. Sheean)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T14:13:00Z","last_updated_date":"2018-11-06T14:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-review-orphan-designation-context-extension-indication-m-sheean_en.pdf"},
    {"id":"42547","name":"Presentation - Advanced therapy medicinal products (ATMPs) and support to developers (P. Celis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T14:14:00Z","last_updated_date":"2018-11-06T14:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advanced-therapy-medicinal-products-atmps-and-support-developers-p-celis_en.pdf"},
    {"id":"42548","name":"Presentation - An SME perspective on combined medicines and devices development (L. Hyveled-Nielsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T14:17:00Z","last_updated_date":"2018-11-06T14:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-perspective-combined-medicines-and-devices-development-l-hyveled-nielsen_en.pdf"}    {"id":"42549","name":"Presentation - Guidance on preparing for Brexit in the centralised procedure (L. Enes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T14:19:00Z","last_updated_date":"2018-11-06T14:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-preparing-brexit-centralised-procedure-l-enes_en.pdf"},
    {"id":"42551","name":"Presentation - Interface between medicinal product and medical devices development: Update on EMA implementation of the new medical devices legislation (A. Ritzhaupt & I. Hayes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T15:07:00Z","last_updated_date":"2018-11-06T15:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interface-between-medicinal-product-medical-devices-development-update-ema-implementation-new-medical-devices-legislation-ritzhaupt-i-hayes_en.pdf"},
    {"id":"42589","name":"Presentation - Responding to the needs of the 21st century patient: Addressing challenges and opportunities across the European regulatory framework (Hans-Georg Eichler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T15:41:00Z","last_updated_date":"2018-11-08T15:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-responding-needs-21st-century-patient-addressing-challenges-and-opportunities-across-european-regulatory-framework-hans-georg-eichler_en.pdf"},
    {"id":"42590","name":"Presentation - European Organisation for Rare Diseases (EURORDIS): The point of view of patients (Simone Boselli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T15:43:00Z","last_updated_date":"2018-11-08T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-organisation-rare-diseases-eurordis-point-view-patients-simone-boselli_en.pdf"},
    {"id":"42591","name":"Presentation - Session 1.04 - Responding to the needs of the 21st century patient: Addressing challenges and opportunities across the European regulatory framework (Olga Solomon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T15:47:00Z","last_updated_date":"2018-11-08T15:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-104-responding-needs-21st-century-patient-addressing-challenges-and-opportunities-across-european-regulatory-framework-olga-solomon_en.pdf"},
    {"id":"42592","name":"Presentation - Session 1.05 - View from European Medicines Regulatory Network (Karl Broich)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T15:52:00Z","last_updated_date":"2018-11-08T15:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-105-view-european-medicines-regulatory-network-karl-broich_en.pdf"},
    {"id":"42593","name":"Presentation - Session 2 - Catalysing the integration of science and technology in drug development - EMA’s core recommendations (Enrica Alteri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T15:57:00Z","last_updated_date":"2018-11-08T15:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-catalysing-integration-science-and-technology-drug-development-emas-core-recommendations-enrica-alteri_en.pdf"},
    {"id":"42594","name":"Presentation - Session 3 - Driving collaborative evidence generation - Improving the scientific quality of evaluations - EMA’s core recommendations (Zaide Frias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T15:58:00Z","last_updated_date":"2018-11-08T15:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-driving-collaborative-evidence-generation-improving-scientific-quality-evaluations-emas-core-recommendations-zaide-frias_en.pdf"},
    {"id":"42595","name":"Presentation - Session 4 - Advancing patient-centred access to medicines in partnership with healthcare systems - EMA’s core recommendations (Michael Berntgen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T16:00:00Z","last_updated_date":"2018-11-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-advancing-patient-centred-access-medicines-partnership-healthcare-systems-emas-core-recommendations-michael-berntgen_en.pdf"},
    {"id":"42596","name":"Presentation -Session 5 - Addressing emerging health threats and availability/therapeutic challenges - EMA’s core recommendations (Marco Cavaleri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T16:03:00Z","last_updated_date":"2018-11-08T16:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-addressing-emerging-health-threats-and-availabilitytherapeutic-challenges-emas-core-recommendations-marco-cavaleri_en.pdf"},
    {"id":"42597","name":"Presentation - Session 6 - Enabling and leveraging research and innovation in regulatory science - EMA’s core recommendations (Alison Cave)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T16:07:00Z","last_updated_date":"2018-11-08T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-6-enabling-and-leveraging-research-and-innovation-regulatory-science-emas-core-recommendations-alison-cave_en.pdf"},
    {"id":"42599","name":"Presentation - Patient engagement along the regulatory lifecycle (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T16:49:00Z","last_updated_date":"2018-11-08T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-engagement-along-regulatory-lifecycle-nathalie-bere_en.pdf"},
    {"id":"42600","name":"Presentation - Visibility of patient input throughout scientific procedures (Maria Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T16:50:00Z","last_updated_date":"2018-11-08T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-visibility-patient-input-throughout-scientific-procedures-maria-mavris_en.pdf"},
    {"id":"42601","name":"Presentation - Relaunch of EMA corporate website (Angela-Christina Schmidt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T16:52:00Z","last_updated_date":"2018-11-08T16:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-relaunch-ema-corporate-website-angela-christina-schmidt_en.pdf"},
    {"id":"42602","name":"Presentation - COMP feedback to EMA's Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) Article 8.2 et all (Daniel O’Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T16:54:00Z","last_updated_date":"2018-11-08T16:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comp-feedback-emas-human-scientific-committees-working-parties-patients-and-consumers-organisations-pcwp-article-82-et-all-daniel-oconnor_en.pdf"},
    {"id":"42603","name":"Presentation - The Committee for Advanced Therapies (CAT) update (Kieran Breen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T16:57:00Z","last_updated_date":"2018-11-08T16:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-committee-advanced-therapies-cat-update-kieran-breen_en.pdf-1"},
    {"id":"42622","name":"Presentation - Survey on HCPWP role to address upcoming scientific / regulatory challenges impacting clinical practice: Identifying priorities for 2020-2025 (Ivana Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T17:32:00Z","last_updated_date":"2018-11-09T17:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-hcpwp-role-address-upcoming-scientific-regulatory-challenges-impacting-clinical-practice-identifying-priorities-2020-2025-ivana-silva_en.pdf"},
    {"id":"42623","name":"Presentation - Statement Implementation Learning Collaborative Centres (SILCC) (Joan Peppard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T17:35:00Z","last_updated_date":"2018-11-09T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-statement-implementation-learning-collaborative-centres-silcc-joan-peppard_en.pdf"},
    {"id":"42624","name":"Presentation - EAU Associates training programme (Karin Plass)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T17:36:00Z","last_updated_date":"2018-11-09T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eau-associates-training-programme-karin-plass_en.pdf"},
    {"id":"42625","name":"Presentation - EFIM / FDIME clinical research seminar (Daniel Sereni)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T17:38:00Z","last_updated_date":"2018-11-09T17:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-efim-fdime-clinical-research-seminar-daniel-sereni_en.pdf"},
    {"id":"42626","name":"Presentation - Italian experience on regulatory science (Walter Marrocco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T17:40:00Z","last_updated_date":"2018-11-09T17:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-italian-experience-regulatory-science-walter-marrocco_en.pdf"},
    {"id":"42627","name":"Presentation - Training Infarmed’s experience (Fátima Ventura)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T17:41:00Z","last_updated_date":"2018-11-09T17:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-training-infarmeds-experience-fatima-ventura_en.pdf"},
    {"id":"42628","name":"Presentation - COMP feedback - September 2018 (Daniel O’Connor)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T17:43:00Z","last_updated_date":"2018-11-09T17:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comp-feedback-september-2018-daniel-oconnor_en.pdf"},
    {"id":"42629","name":"Presentation - HCPWP feedback from CHMP (Fátima Ventura)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T17:44:00Z","last_updated_date":"2018-11-09T17:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hcpwp-feedback-chmp-fatima-ventura_en.pdf"},
    {"id":"42630","name":"Presentation - Annual report and webpages: reporting (Maria Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T17:45:00Z","last_updated_date":"2018-11-09T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-annual-report-and-webpages-reporting-maria-mavris_en.pdf"},
    {"id":"42631","name":"Presentation - Relaunch of EMA corporate website (Angela-Christina Schmidt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T17:46:00Z","last_updated_date":"2018-11-09T17:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-relaunch-ema-corporate-website-angela-christina-schmidt_en.pdf-0"},
    {"id":"42633","name":"Presentation - Introduction and points for information: update since April 2018 (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:01:00Z","last_updated_date":"2018-11-09T18:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-and-points-information-update-april-2018-juan-garcia-burgos_en.pdf"},
    {"id":"42634","name":"Presentation - Perception survey 2017 (Elizabeth Scanlan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:02:00Z","last_updated_date":"2018-11-09T18:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-perception-survey-2017-elizabeth-scanlan_en.pdf"},
    {"id":"42635","name":"Presentation - EMA Regulatory Science to 2025: a work in progress (Tony Humphreys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:03:00Z","last_updated_date":"2018-11-09T18:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-work-progress-tony-humphreys_en.pdf"},
    {"id":"42636","name":"Presentation - Good pharmacovigilance practices for the European Union (EU-GVP) (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:06:00Z","last_updated_date":"2018-11-09T18:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-european-union-eu-gvp-priya-bahri_en.pdf-2"},
    {"id":"42637","name":"Presentation - Progress report to PCWP/HCPWP: what has happened since April 2018 (Donald Singer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:07:00Z","last_updated_date":"2018-11-09T18:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-progress-report-pcwphcpwp-what-has-happened-april-2018-donald-singer_en.pdf"},
    {"id":"42638","name":"Presentation - Proposal on interaction with EMA for social media campaigns (Camelia Enachioiu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:08:00Z","last_updated_date":"2018-11-09T18:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposal-interaction-ema-social-media-campaigns-camelia-enachioiu_en.pdf"},
    {"id":"42639","name":"Presentation - Electronic product information: update on ongoing work (Alexios Skarlatos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:09:00Z","last_updated_date":"2018-11-09T18:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-electronic-product-information-update-ongoing-work-alexios-skarlatos_en.pdf"},
    {"id":"42640","name":"Presentation - Update on ongoing work on availability of authorised medicines (Esther Martinez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:10:00Z","last_updated_date":"2018-11-09T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ongoing-work-availability-authorised-medicines-esther-martinez_en.pdf"},
    {"id":"42641","name":"Presentation - Preparation for the HMA / EMA multi-stakeholder workshop: contribution from PCWP and HCPWP (Inga Abed)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T18:11:00Z","last_updated_date":"2018-11-09T18:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparation-hma-ema-multi-stakeholder-workshop-contribution-pcwp-and-hcpwp-inga-abed_en.pdf"},
    {"id":"42665","name":"Presentation - Overview: guideline on the assessment of the risk to public health from AMR due to use of an antimicrobial VMP in food-producing animals (Helen Jukes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-13T16:17:00Z","last_updated_date":"2018-11-13T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-guideline-assessment-risk-public-health-amr-due-use-antimicrobial-vmp-food-producing-animals-helen-jukes_en.pdf"},
    {"id":"42666","name":"Presentation - Industry view on the draft guideline on the assessment of the risk to public health from AMR due to the use of an antimicrobial VMP in livestock (Alexander Boettner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-13T16:19:00Z","last_updated_date":"2018-11-13T16:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-view-draft-guideline-assessment-risk-public-health-amr-due-use-antimicrobial-vmp-livestock-alexander-boettner_en.pdf"},
    {"id":"42667","name":"Presentation - Use of EMA’s risk assessment guideline - Danish experience (Lis Alban)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-13T16:21:00Z","last_updated_date":"2018-11-13T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-emas-risk-assessment-guideline-danish-experience-lis-alban_en.pdf"},
    {"id":"42668","name":"Presentation - Risk assessment of AMR: discussion and further thoughts (Johanne Ellis-Iversen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-13T16:23:00Z","last_updated_date":"2018-11-13T16:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-assessment-amr-discussion-and-further-thoughts-johanne-ellis-iversen_en.pdf"},
    {"id":"42669","name":"Presentation - Guideline on the assessment of the risk to public health from AMR due to use of an antimicrobial VMP in food-producing animals: key updates after public consultation (Helen Jukes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-13T16:26:00Z","last_updated_date":"2018-11-13T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-assessment-risk-public-health-amr-due-use-antimicrobial-vmp-food-producing-animals-key-updates-after-public-consultation-helen-jukes_en.pdf"},
    {"id":"42670","name":"Presentation - Guideline on the assessment of the risk to public health from AMR due to use of an antimicrobial VMP in food-producing animals: categorisation of risk factors, risk assessment steps and overall risk estimation (Christine Schwarz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-13T16:28:00Z","last_updated_date":"2018-11-13T16:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-assessment-risk-public-health-amr-due-use-antimicrobial-vmp-food-producing-animals-categorisation-risk-factors-risk-assessment-steps-and-overall-risk-estimation-christine_en.pdf"},
    {"id":"42671","name":"Presentation - Guideline on the assessment of the risk to public health from AMR due to use of an antimicrobial VMP in food-producing animals: pragmatic consequence assessment (Damien Bouchard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-13T16:30:00Z","last_updated_date":"2018-11-13T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-assessment-risk-public-health-amr-due-use-antimicrobial-vmp-food-producing-animals-pragmatic-consequence-assessment-damien-bouchard_en.pdf"},
    {"id":"42683","name":"Presentation - Focus group meeting the pilot project on dose optimisation of established veterinary antibiotics in the context of SPC harmonisation: overview (Johan Schefferlie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-15T12:33:00Z","last_updated_date":"2018-11-15T12:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-meeting-pilot-project-dose-optimisation-established-veterinary-antibiotics-context-spc-harmonisation-overview-johan-schefferlie_en.pdf"},
    {"id":"42684","name":"Presentation - Industry view on the draft RP on dose optimisation of established veterinary antibiotics in the context of SPC harmonisation - EMA/CVMP/849775/2017 (Hilde Moyaert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-15T12:36:00Z","last_updated_date":"2018-11-15T12:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-view-draft-rp-dose-optimisation-established-veterinary-antibiotics-context-spc-harmonisation-emacvmp8497752017-hilde-moyaert_en.pdf"},
    {"id":"42685","name":"Presentation - Pilot project on dose optimisation of established veterinary antibiotics in the context of SPC harmonisation: industry view (Elsa Vecino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-15T12:38:00Z","last_updated_date":"2018-11-15T12:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pilot-project-dose-optimisation-established-veterinary-antibiotics-context-spc-harmonisation-industry-view-elsa-vecino_en.pdf"},
    {"id":"42686","name":"Presentation - Focus group meeting the pilot project on dose optimisation of established veterinary antibiotics in the context of SPC harmonisation: PK/PD approach for dose optimisation (Damien Bouchard, Pascal Sanders)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-15T12:41:00Z","last_updated_date":"2018-11-15T12:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-meeting-pilot-project-dose-optimisation-established-veterinary-antibiotics-context-spc-harmonisation-pkpd-approach-dose-optimisation-damien-bouchard-pascal-sanders_en.pdf"},
    {"id":"42687","name":"Presentation - Focus group meeting the pilot project on dose optimisation of established veterinary antibiotics in the context of SPC harmonisation: target animal safety (Helen Jukes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-15T12:43:00Z","last_updated_date":"2018-11-15T12:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-meeting-pilot-project-dose-optimisation-established-veterinary-antibiotics-context-spc-harmonisation-target-animal-safety-helen-jukes_en.pdf"},
    {"id":"42688","name":"Presentation - Focus group meeting the pilot project on dose optimisation of established veterinary antibiotics in the context of SPC harmonisation: environmental risk assessment (Johan Schefferlie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-15T12:45:00Z","last_updated_date":"2018-11-15T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-meeting-pilot-project-dose-optimisation-established-veterinary-antibiotics-context-spc-harmonisation-environmental-risk-assessment-johan-schefferlie_en.pdf"},
    {"id":"42689","name":"Presentation - Focus group meeting the pilot project on dose optimisation of established veterinary antibiotics in the context of SPC harmonisation: dose dependent withdrawal periods (Peter Hekman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-15T12:47:00Z","last_updated_date":"2018-11-15T12:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-meeting-pilot-project-dose-optimisation-established-veterinary-antibiotics-context-spc-harmonisation-dose-dependent-withdrawal-periods-peter-hekman_en.pdf"},
    {"id":"42767","name":"Presentation - Workshop objectives (K. Raudsepp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:28:00Z","last_updated_date":"2018-11-23T18:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-objectives-k-raudsepp_en.pdf"},
    {"id":"42768","name":"Presentation - Availability of medicines: Impact on public health","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:29:00Z","last_updated_date":"2018-11-23T18:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-availability-medicines-impact-public-health_en.pdf"},
    {"id":"42769","name":"Presentation - Medicines and vaccines shortages: a global concern (F. Blanco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:31:00Z","last_updated_date":"2018-11-23T18:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicines-and-vaccines-shortages-global-concern-f-blanco_en.pdf"},
    {"id":"42770","name":"Presentation - Preparing for the unexpected: when your medicine is not available anymore (F. Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:33:00Z","last_updated_date":"2018-11-23T18:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparing-unexpected-when-your-medicine-not-available-anymore-f-houyez_en.pdf"},
    {"id":"42771","name":"Presentation - Availability of medicines: Impact on public health (E. de Vries)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:34:00Z","last_updated_date":"2018-11-23T18:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-availability-medicines-impact-public-health-e-de-vries_en.pdf"},
    {"id":"42772","name":"Presentation - How regulators are working to improve prevention and management of availability problems (K. Raudsepp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:35:00Z","last_updated_date":"2018-11-23T18:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-regulators-are-working-improve-prevention-and-management-availability-problems-k-raudsepp_en.pdf"},
    {"id":"42773","name":"Presentation - Prevention and management of availability problems: An industry perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:36:00Z","last_updated_date":"2018-11-23T18:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prevention-and-management-availability-problems-industry-perspective_en.pdf"},
    {"id":"42774","name":"Presentation - Impact of Brexit on medicines availability Centrally Authorised Products (CAPs) (M. Dias, I. Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:39:00Z","last_updated_date":"2018-11-23T18:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-brexit-medicines-availability-centrally-authorised-products-caps-m-dias-i-claassen_en.pdf"},
    {"id":"42775","name":"Presentation - CMDh Brexit update (L. Oliveira, H. Hurts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:42:00Z","last_updated_date":"2018-11-23T18:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cmdh-brexit-update-l-oliveira-h-hurts_en.pdf"},
    {"id":"42776","name":"Presentation - Impact of Brexit on veterinary medicines availability (L. Le Letty)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:43:00Z","last_updated_date":"2018-11-23T18:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-brexit-veterinary-medicines-availability-l-le-letty_en.pdf"},
    {"id":"42777","name":"Presentation - Industry stakeholders’ perspective: Impact of Brexit on medicines availability (Y. Stewart)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:45:00Z","last_updated_date":"2018-11-23T18:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-stakeholders-perspective-impact-brexit-medicines-availability-y-stewart_en.pdf"},
    {"id":"42778","name":"Presentation - Presentation from veterinary industry EU/EEA Brexit preparedness: status and impact (R. Clayton)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:46:00Z","last_updated_date":"2018-11-23T18:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-presentation-veterinary-industry-eueea-brexit-preparedness-status-and-impact-r-clayton_en.pdf"},
    {"id":"42779","name":"Presentation - Improving reporting and monitoring: EU-wide shortage definition and metrics (B. Cuddy, A. Hansen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:50:00Z","last_updated_date":"2018-11-23T18:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-improving-reporting-and-monitoring-eu-wide-shortage-definition-and-metrics-b-cuddy-hansen_en.pdf"},
    {"id":"42780","name":"Presentation - Draft guidance for industry to improve reporting and best practice (B. Escribano, E. Martinez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:52:00Z","last_updated_date":"2018-11-23T18:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-guidance-industry-improve-reporting-and-best-practice-b-escribano-e-martinez_en.pdf"},
    {"id":"42781","name":"Presentation - Current public communication practices by regulators on medicines availability and shortages (Y. Knudsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:53:00Z","last_updated_date":"2018-11-23T18:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-public-communication-practices-regulators-medicines-availability-and-shortages-y-knudsen_en.pdf"},
    {"id":"42782","name":"Presentation - Best practice guidance for EU authorities on public communication (J. Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:54:00Z","last_updated_date":"2018-11-23T18:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-practice-guidance-eu-authorities-public-communication-j-burgos_en.pdf"},
    {"id":"42783","name":"Presentation - Concluding remarks and next steps (N. Wathion)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-23T18:55:00Z","last_updated_date":"2018-11-23T18:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-concluding-remarks-and-next-steps-n-wathion_en.pdf"},
    {"id":"43076","name":"Presentation - Session 1: Patient perspective (Robert Mitchell-Thain)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:06:00Z","last_updated_date":"2018-12-14T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-patient-perspective-robert-mitchell-thain_en.pdf"},
    {"id":"43077","name":"Presentation - Session 1: Authorisation of Ocaliva for PBC in the EU (J. Musaus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:08:00Z","last_updated_date":"2018-12-14T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-authorisation-ocaliva-pbc-eu-j-musaus_en.pdf"},
    {"id":"43078","name":"Presentation - Session 1: PBC: Definition, natural history and current therapeutic interventions (Gideon Hirschfield)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:10:00Z","last_updated_date":"2018-12-14T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-pbc-definition-natural-history-and-current-therapeutic-interventions-gideon-hirschfield_en.pdf"},
    {"id":"43079","name":"Presentation - Session 1: Historical outcome parameters used in PBC and the search for potential alternatives (Bettina E Hansen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:13:00Z","last_updated_date":"2018-12-14T16:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-historical-outcome-parameters-used-pbc-and-search-potential-alternatives-bettina-e-hansen_en.pdf"},
    {"id":"43080","name":"Presentation - Session 1: Potential trial designs and suitable study populations (Bettina E Hansen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:14:00Z","last_updated_date":"2018-12-14T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-potential-trial-designs-and-suitable-study-populations-bettina-e-hansen_en.pdf"},
    {"id":"43081","name":"Presentation - Session 2: EMA stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (Martine Walmsley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:17:00Z","last_updated_date":"2018-12-14T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-ema-stakeholder-interaction-development-medicinal-products-chronic-non-infectious-liver-diseases-martine-walmsley_en.pdf"},
    {"id":"43082","name":"Presentation - Session 2: Definition, natural history and the lack of approved therapeutic interventions (Douglas Thorburn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:19:00Z","last_updated_date":"2018-12-14T16:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-definition-natural-history-and-lack-approved-therapeutic-interventions-douglas-thorburn_en.pdf"},
    {"id":"43083","name":"Presentation - Session 2: Currently proposed endpoints in PSC: the search for reliable surrogate outcome parameters (Cyriel Ponsioen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:20:00Z","last_updated_date":"2018-12-14T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-currently-proposed-endpoints-psc-search-reliable-surrogate-outcome-parameters-cyriel-ponsioen_en.pdf"},
    {"id":"43084","name":"Presentation - Session 2: Potential trial design and suitable study populations (Michael Trauner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:22:00Z","last_updated_date":"2018-12-14T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-potential-trial-design-and-suitable-study-populations-michael-trauner_en.pdf"},
    {"id":"43085","name":"Presentation - Session 2: The need for paediatric developments in PSC, trial duration and endpoints (Henkjan J. Verkade)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:23:00Z","last_updated_date":"2018-12-14T16:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-need-paediatric-developments-psc-trial-duration-and-endpoints-henkjan-j-verkade_en.pdf"},
    {"id":"43086","name":"Presentation - Session 3: NASH - The patient perspective (Yvonne Gray)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:26:00Z","last_updated_date":"2018-12-14T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-nash-patient-perspective-yvonne-gray_en.pdf"},
    {"id":"43087","name":"Presentation - Session 3: PDCO current approach (Chrissi Pallidis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:27:00Z","last_updated_date":"2018-12-14T16:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-pdco-current-approach-chrissi-pallidis_en.pdf"},
    {"id":"43088","name":"Presentation - Session 3: Non-alcoholic steatohepatitis (NASH): Definition, natural history and current therapeutic interventions (Frank Tacke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:29:00Z","last_updated_date":"2018-12-14T16:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-non-alcoholic-steatohepatitis-nash-definition-natural-history-and-current-therapeutic-interventions-frank-tacke_en.pdf"},
    {"id":"43089","name":"Presentation - Session 3: Outcome in NASH trials: From histology and “hard outcomes” to less invasive reliable surrogates (Laurent Castera)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:31:00Z","last_updated_date":"2018-12-14T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-outcome-nash-trials-histology-and-hard-outcomes-less-invasive-reliable-surrogates-laurent-castera_en.pdf"},
    {"id":"43090","name":"Presentation - Session 3: Potential trial designs and suitable study populations (Quentin M. Anstee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:33:00Z","last_updated_date":"2018-12-14T16:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-potential-trial-designs-and-suitable-study-populations-quentin-m-anstee_en.pdf"},
    {"id":"43091","name":"Presentation - Session 3: NAFLD: Population in need, clinical trial duration and endpoints (Piotr Socha)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:35:00Z","last_updated_date":"2018-12-14T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-nafld-population-need-clinical-trial-duration-and-endpoints-piotr-socha_en.pdf"},
    {"id":"43175","name":"Presentation - Towards digital transformation of health and care (K. Kurgonaite and P. Tosetti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:21:00Z","last_updated_date":"2018-12-19T18:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-towards-digital-transformation-health-and-care-k-kurgonaite-and-p-tosetti_en.pdf"},
    {"id":"43176","name":"Presentation - ePI: Getting the focus right (F. Tabatabaei)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:23:00Z","last_updated_date":"2018-12-19T18:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-epi-getting-focus-right-f-tabatabaei_en.pdf"},
    {"id":"43177","name":"Presentation - Opportunities for expanding access to produce information for medicines: a patient perspective (K. Immonen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:25:00Z","last_updated_date":"2018-12-19T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-expanding-access-produce-information-medicines-patient-perspective-k-immonen_en.pdf"},
    {"id":"43178","name":"Presentation - Workshop on electronic product information (S. Jensen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:27:00Z","last_updated_date":"2018-12-19T18:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-electronic-product-information-s-jensen_en.pdf"},
    {"id":"43179","name":"Presentation - Opportunities for expanding access to product information for medicines: Stakeholders’ needs and challenges’ from a perspective of a healthcare professional (D. J O'Loughlin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:29:00Z","last_updated_date":"2018-12-19T18:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-expanding-access-product-information-medicines-stakeholders-needs-and-challenges-perspective-healthcare-professional-d-j-oloughlin_en.pdf"},
    {"id":"43180","name":"Presentation - Electronic dissemination of product information (G. Bejeuhr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:35:00Z","last_updated_date":"2018-12-19T18:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-electronic-dissemination-product-information-g-bejeuhr_en.pdf"},
    {"id":"43181","name":"Presentation - Current landscape - How does ePI fit in with other initiatives? (M. Diaz and J. Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:37:00Z","last_updated_date":"2018-12-19T18:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-landscape-how-does-epi-fit-other-initiatives-m-diaz-and-j-burgos_en.pdf"},
    {"id":"43182","name":"Presentation - Overview of initiatives from the EMA-HMA mapping (R. Gonzalez-Quevedo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:39:00Z","last_updated_date":"2018-12-19T18:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-initiatives-ema-hma-mapping-r-gonzalez-quevedo_en.pdf"},
    {"id":"43183","name":"Presentation - Current landscape: How does ePI fit in with other initiatives - AEMPS (C. Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:42:00Z","last_updated_date":"2018-12-19T18:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-landscape-how-does-epi-fit-other-initiatives-aemps-c-garcia_en.pdf"},
    {"id":"43184","name":"Presentation - Collaboration with the Norwegian Pharmaceutical Compendium (V. Abyholm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:45:00Z","last_updated_date":"2018-12-19T18:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collaboration-norwegian-pharmaceutical-compendium-v-abyholm_en.pdf"},
    {"id":"43185","name":"Presentation - Electronically structured coded PI Swedish (human and veterinary) (K. Sherwood)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T18:46:00Z","last_updated_date":"2018-12-19T18:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-electronically-structured-coded-pi-swedish-human-and-veterinary-k-sherwood_en.pdf"},
    {"id":"43190","name":"Presentation - Fass – Electronic product information in Sweden (G. Englund)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-20T12:26:00Z","last_updated_date":"2018-12-20T12:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fass-electronic-product-information-sweden-g-englund_en.pdf"},
    {"id":"43191","name":"Presentation - Digitising product information: Greater accessibility for public health and all patients (N. Knight and J. Moreland)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-20T12:27:00Z","last_updated_date":"2018-12-20T12:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-digitising-product-information-greater-accessibility-public-health-and-all-patients-n-knight-and-j-moreland_en.pdf"},
    {"id":"43192","name":"Presentation - E-PIL Belgium & Luxembourg Pioneer Pilot Project (N. Lambot)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-20T12:30:00Z","last_updated_date":"2018-12-20T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-e-pil-belgium-luxembourg-pioneer-pilot-project-n-lambot_en.pdf"},
    {"id":"43193","name":"Presentation - Product Information 4.0 “Gebrauchsinformation 4.0 (GI 4.0)” (G. Lang)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-20T12:32:00Z","last_updated_date":"2018-12-20T12:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-information-40-gebrauchsinformation-40-gi-40-g-lang_en.pdf"},
    {"id":"43194","name":"Presentation - A future perspective: Tailored, integrated digital health information","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-20T12:35:00Z","last_updated_date":"2018-12-20T12:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-future-perspective-tailored-integrated-digital-health-information_en.pdf"},
    {"id":"43195","name":"Presentation - Common electronic standard: potential features and use cases (E. Scanlan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-12-20T12:38:00Z","last_updated_date":"2018-12-20T12:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-common-electronic-standard-potential-features-and-use-cases-e-scanlan_en.pdf"},
    {"id":"43230","name":"Presentation - Session 3 - MT - Answers to breakout sessions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-mt-answers-breakout-sessions_en.pdf"}    {"id":"43232","name":"Presentation - Session 1 - New clinical trial regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-new-clinical-trial-regulation_en.pdf"},
    {"id":"43233","name":"Presentation - Session 1 - The role of EMA in promoting innovation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-role-ema-promoting-innovation_en.pdf"},
    {"id":"43234","name":"Presentation - Session 1 - What is the EU Innovation Network","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-what-eu-innovation-network_en.pdf"},
    {"id":"43235","name":"Presentation - Session 2 - DG RTD perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-dg-rtd-perspective_en.pdf"},
    {"id":"43236","name":"Presentation - Session 2 - EU funded  initiatives - EU infrastructures - EATRIS","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-eu-funded-initiatives-eu-infrastructures-eatris_en.pdf"},
    {"id":"43237","name":"Presentation - Session 2 - EU funded  initiatives - EU infrastructures - ECRIN","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-eu-funded-initiatives-eu-infrastructures-ecrin_en.pdf"},
    {"id":"43238","name":"Presentation - Session 2 - EU funded  initiatives - EU infrastructures - ELIXIR","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-eu-funded-initiatives-eu-infrastructures-elixir_en.pdf"},
    {"id":"43239","name":"Presentation - Session 2 - EU funded initiatives - CSA STARS","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-eu-funded-initiatives-csa-stars_en.pdf"},
    {"id":"43240","name":"Presentation - Session 2 - EU funded initiatives - EU infrastructures - BBMRI","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-eu-funded-initiatives-eu-infrastructures-bbmri_en.pdf"},
    {"id":"43241","name":"Presentation - Session 3 - AT - Answers to breakout sessions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-answers-breakout-sessions_en.pdf"},
    {"id":"43242","name":"Presentation - Session 3 - CZ - Answers to breakout sessions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-cz-answers-breakout-sessions_en.pdf"},
    {"id":"43243","name":"Presentation - Session 3 - ES - Answers to breakout sessions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-es-answers-breakout-sessions_en.pdf"},
    {"id":"43244","name":"Presentation - Session 3 - IE - Answers to breakout sessions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-07T14:59:00Z","last_updated_date":"2019-01-07T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-ie-answers-breakout-sessions_en.pdf"},
    {"id":"43273","name":"Presentation - Perspective from European Union - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (V. Jekerle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:37:00Z","last_updated_date":"2019-01-10T12:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-perspective-european-union-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-v-jekerle_en.pdf"},
    {"id":"43274","name":"Presentation - Session 1 - Setting the scene - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (E. Alteri, V. Jekerle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:41:00Z","last_updated_date":"2019-01-10T12:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-setting-scene-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-e-alteri-v-jekerle_en.pdf"},
    {"id":"43275","name":"Presentation - Session 1 - FDA perspective - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (Ramesh K. Sood)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:44:00Z","last_updated_date":"2019-01-10T12:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-fda-perspective-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-ramesh-k-sood_en.pdf"},
    {"id":"43276","name":"Presentation - Session 2 - Process validation and accelerated access - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (S. Barry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:45:00Z","last_updated_date":"2019-01-10T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-process-validation-and-accelerated-access-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-s-barry_en.pdf"},
    {"id":"43277","name":"Presentation - Session 2 - Innovative validation - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (S. Finn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:52:00Z","last_updated_date":"2019-01-10T12:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-innovative-validation-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-s-finn_en.pdf"},
    {"id":"43278","name":"Presentation - Session 3.1 - Control strategy: Regulators perspective - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (M. Wellin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:57:00Z","last_updated_date":"2019-01-10T12:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-31-control-strategy-regulators-perspective-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-m-wellin_en.pdf"},
    {"id":"43279","name":"Presentation - Session 3.2 - Control strategy: Industry perspective - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (D. Wilkinson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T12:59:00Z","last_updated_date":"2019-01-10T12:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-32-control-strategy-industry-perspective-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-d-wilkinson_en.pdf"},
    {"id":"43280","name":"Presentation - Session 3.3 - Control strategy: Industry perspective - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (C. Campa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:01:00Z","last_updated_date":"2019-01-10T13:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-33-control-strategy-industry-perspective-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-c-campa_en.pdf"},
    {"id":"43281","name":"Presentation - Session 4.1 - Good manufacturing practice - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (G. Lorenti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:04:00Z","last_updated_date":"2019-01-10T13:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-41-good-manufacturing-practice-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-g-lorenti_en.pdf"},
    {"id":"43284","name":"Presentation - Session 4.2 - Good manufacturing practice considerations for accelerated access - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (M. Popkin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:07:00Z","last_updated_date":"2019-01-10T13:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-42-good-manufacturing-practice-considerations-accelerated-access-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-m_en.pdf"},
    {"id":"43285","name":"Presentation - Session 5.1 - Setting specification acceptance criteria - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (R. Keane, N. Frantz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:11:00Z","last_updated_date":"2019-01-10T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-51-setting-specification-acceptance-criteria-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-r-keane-n-frantz_en.pdf"},
    {"id":"43288","name":"Presentation - Session 5.2 - Ebola case study- Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (T. Pepper)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:18:00Z","last_updated_date":"2019-01-10T13:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-52-ebola-case-study-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-t-pepper_en.pdf"},
    {"id":"43289","name":"Presentation - Session 5b - Case study on control strategy: impurity control strategy for an oncology drug  - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (A. Teasdale)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:21:00Z","last_updated_date":"2019-01-10T13:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5b-case-study-control-strategy-impurity-control-strategy-oncology-drug-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough_en.pdf"},
    {"id":"43290","name":"Presentation - Session 6.1 - Risk-based assessment of comparability for a mAb undergoing accelerated development - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (A. Clinch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:24:00Z","last_updated_date":"2019-01-10T13:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-61-risk-based-assessment-comparability-mab-undergoing-accelerated-development-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough_en.pdf"},
    {"id":"43291","name":"Presentation - Session 6.2 - Advanced therapy medicinal products (ATMPs) comparability challenge case study - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (M. Jeschke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:27:00Z","last_updated_date":"2019-01-10T13:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-62-advanced-therapy-medicinal-products-atmps-comparability-challenge-case-study-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and_en.pdf"},
    {"id":"43292","name":"Presentation - Session 6.3 - Advanced therapy medicinal products (ATMPs) comparability challenge case study - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (M. Alai-Safar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:34:00Z","last_updated_date":"2019-01-10T13:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-63-advanced-therapy-medicinal-products-atmps-comparability-challenge-case-study-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and_en.pdf"},
    {"id":"43293","name":"Presentation - Session 6b - Stability approaches - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (R. Ogilvie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:37:00Z","last_updated_date":"2019-01-10T13:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-6b-stability-approaches-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-r-ogilvie_en.pdf"},
    {"id":"43294","name":"Presentation - Session 7.1 - Predictive stability models to extrapolate shelf-life - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (A. Lennard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:41:00Z","last_updated_date":"2019-01-10T13:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-71-predictive-stability-models-extrapolate-shelf-life-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-lennard_en.pdf"},
    {"id":"43295","name":"Presentation - Session 9.1 - Regulatory tools - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (Y. Momonoi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:44:00Z","last_updated_date":"2019-01-10T13:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-91-regulatory-tools-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-y-momonoi_en.pdf"},
    {"id":"43296","name":"Presentation - Session 9.3 - Regulatory tools - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (C. Blanc, C. Bouygues)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:47:00Z","last_updated_date":"2019-01-10T13:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-93-regulatory-tools-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-c-blanc-c-bouygues_en.pdf"},
    {"id":"43297","name":"Presentation - Session 9.4 - Regulatory tools - FDA - Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies (A. Byrnes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-10T13:50:00Z","last_updated_date":"2019-01-10T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-94-regulatory-tools-fda-stakeholder-workshop-support-quality-development-early-access-approaches-such-prime-and-breakthrough-therapies-byrnes_en.pdf"},
    {"id":"43312","name":"Presentation - Session 1: Regulation of veterinary medicinal products in the 21st century: addressing challenges and opportunities across the European Regulatory Framework (Ivo Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:07:00Z","last_updated_date":"2019-01-11T11:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-regulation-veterinary-medicinal-products-21st-century-addressing-challenges-and-opportunities-across-european-regulatory-framework-ivo-claassen_en.pdf"},
    {"id":"43313","name":"Presentation - Session 1: Integration of Agency Committees and Network into delivery of the strategy (David Murphy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:09:00Z","last_updated_date":"2019-01-11T11:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-integration-agency-committees-and-network-delivery-strategy-david-murphy_en.pdf"},
    {"id":"43315","name":"Presentation - Session 1: Regulatory Science to 2025: view from the European Commission (Christian Siebert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:11:00Z","last_updated_date":"2019-01-11T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-regulatory-science-2025-view-european-commission-christian-siebert_en.pdf"},
    {"id":"43316","name":"Presentation - Session 1: View from European Medicines Regulatory Network (Jean-Pierre Orand)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:15:00Z","last_updated_date":"2019-01-11T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-view-european-medicines-regulatory-network-jean-pierre-orand_en.pdf"},
    {"id":"43317","name":"Presentation - Session 1: Challenges and opportunities across theregulatory framework: view from veterinarians (Nancy De Briyne)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:18:00Z","last_updated_date":"2019-01-11T11:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-challenges-and-opportunities-across-theregulatory-framework-view-veterinarians-nancy-de-briyne_en.pdf"},
    {"id":"43319","name":"Presentation - Session 1: Challenges and opportunities across the European Regulatory Framework: view for the animal medicines industry (Alexander Böttner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:36:00Z","last_updated_date":"2019-01-11T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-challenges-and-opportunities-across-european-regulatory-framework-view-animal-medicines-industry-alexander-bottner_en.pdf"},
    {"id":"43320","name":"Presentation - Session 2: Veterinary vaccines: proposal to facilitate licensing in general (Carmen Jungbaeck)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:38:00Z","last_updated_date":"2019-01-11T11:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-veterinary-vaccines-proposal-facilitate-licensing-general-carmen-jungbaeck_en.pdf"},
    {"id":"43321","name":"Presentation - Session 2: Catalysing the integration of science and technology in drug development (Rory Breathnach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:39:00Z","last_updated_date":"2019-01-11T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-catalysing-integration-science-and-technology-drug-development-rory-breathnach_en.pdf"},
    {"id":"43322","name":"Presentation - Session 2: Catalysing the integration of science and technology in development (Jackie Atkinson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:40:00Z","last_updated_date":"2019-01-11T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-catalysing-integration-science-and-technology-development-jackie-atkinson_en.pdf"},
    {"id":"43323","name":"Presentation - Session 2: Association of Veterinary Consultants (Klaus Hellmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:41:00Z","last_updated_date":"2019-01-11T11:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-association-veterinary-consultants-klaus-hellmann_en.pdf"},
    {"id":"43324","name":"Presentation - Session 2: RS to 2025: catalysing the integration of science and technology in drug development (Lindsay Marshall)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:44:00Z","last_updated_date":"2019-01-11T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-rs-2025-catalysing-integration-science-and-technology-drug-development-lindsay-marshall_en.pdf"},
    {"id":"43326","name":"Presentation - Session 3: Driving collaborative evidence generation and improving the scientific quality of evaluations (Nicholas Jarrett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:46:00Z","last_updated_date":"2019-01-11T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-driving-collaborative-evidence-generation-and-improving-scientific-quality-evaluations-nicholas-jarrett_en.pdf"},
    {"id":"43327","name":"Presentation - Veterinary Stakeholders Workshop: European Group for Generic Veterinary Products (EGGVP) (Elsa Vecino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:49:00Z","last_updated_date":"2019-01-11T11:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-stakeholders-workshop-european-group-generic-veterinary-products-eggvp-elsa-vecino_en.pdf"},
    {"id":"43328","name":"Presentation - Session 3: Driving collaborative evidence generation: improving the scientific quality of evaluations (Jaques Lechenet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T11:51:00Z","last_updated_date":"2019-01-11T11:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-driving-collaborative-evidence-generation-improving-scientific-quality-evaluations-jaques-lechenet_en.pdf"},
    {"id":"43329","name":"Presentation - Session 4: Addressing emerging health threats and availability/therapeutic challenges (Helen Jukes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T12:02:00Z","last_updated_date":"2019-01-11T12:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-addressing-emerging-health-threats-and-availabilitytherapeutic-challenges-helen-jukes_en.pdf"},
    {"id":"43330","name":"Presentation - Session 4: Addressing emerging health threats and availability/therapeutic challenges (Alexander Boettner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T12:11:00Z","last_updated_date":"2019-01-11T12:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-addressing-emerging-health-threats-and-availabilitytherapeutic-challenges-alexander-boettner_en.pdf"},
    {"id":"43331","name":"Presentation - Session 4: Veterinary vaccines: proposal to facilitate licensing in exceptional circumstances (emergency) (Carmen Jungbaeck)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T12:12:00Z","last_updated_date":"2019-01-11T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-veterinary-vaccines-proposal-facilitate-licensing-exceptional-circumstances-emergency-carmen-jungbaeck_en.pdf"},
    {"id":"43332","name":"Presentation - Session 4: Addressing emerging health threats and availability/therapeutic challenges (Georg von Samson-Himmelstjerna)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T12:14:00Z","last_updated_date":"2019-01-11T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-addressing-emerging-health-threats-and-availabilitytherapeutic-challenges-georg-von-samson-himmelstjerna_en.pdf"},
    {"id":"43333","name":"Presentation - Session 4: Addressing emerging health threats and availability/therapeutic challenges (Rens van Dobbenburgh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T12:17:00Z","last_updated_date":"2019-01-11T12:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-addressing-emerging-health-threats-and-availabilitytherapeutic-challenges-rens-van-dobbenburgh_en.pdf"},
    {"id":"43334","name":"Presentation - Session 5: Enabling and leveraging research and innovation in regulatory science (Tony Humphreys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-11T12:22:00Z","last_updated_date":"2019-01-11T12:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-enabling-and-leveraging-research-and-innovation-regulatory-science-tony-humphreys_en.pdf"},
    {"id":"43366","name":"Presentation - Exchange on the practical considerations for the future regulation of integrated drug-device combinations (I. Hayes, A. Ritzhaupt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-16T12:19:00Z","last_updated_date":"2019-01-16T12:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-exchange-practical-considerations-future-regulation-integrated-drug-device-combinations-i-hayes-ritzhaupt_en.pdf"},
    {"id":"43367","name":"Presentation - Important considerations for successful qualification proposals for digital technologies (F. Cerreta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-16T12:20:00Z","last_updated_date":"2019-01-16T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-important-considerations-successful-qualification-proposals-digital-technologies-f-cerreta_en.pdf"},
    {"id":"43368","name":"Presentation - Parallel Consultations (J. Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-16T12:22:00Z","last_updated_date":"2019-01-16T12:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-parallel-consultations-j-moseley_en.pdf"},
    {"id":"43369","name":"Presentation - PDCO-CHMP interaction (C. Pallidis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-16T12:23:00Z","last_updated_date":"2019-01-16T12:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-chmp-interaction-c-pallidis_en.pdf"},
    {"id":"43370","name":"Presentation - Post Licensing Evidence Generation (PLEG) (J. Moseley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-16T12:24:00Z","last_updated_date":"2019-01-16T12:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-licensing-evidence-generation-pleg-j-moseley_en.pdf"},
    {"id":"43371","name":"Presentation - Reflection on similarity assessment (L. Liebers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-16T12:25:00Z","last_updated_date":"2019-01-16T12:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reflection-similarity-assessment-l-liebers_en.pdf"},
    {"id":"43372","name":"Presentation - Significant benefit (SB) and relative effetiveness assessment (REA) for orphan medicinal products (OMP) (K. Larsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-16T12:27:00Z","last_updated_date":"2019-01-16T12:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-significant-benefit-sb-and-relative-effetiveness-assessment-rea-orphan-medicinal-products-omp-k-larsson_en.pdf"},
    {"id":"43373","name":"Presentation - Targeting histology-independent indications and resulting challenges in the context of orphan designations (F. Pignatti, P. Demolis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-01-16T12:29:00Z","last_updated_date":"2019-01-16T12:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-targeting-histology-independent-indications-and-resulting-challenges-context-orphan-designations-f-pignatti-p-demolis_en.pdf"},
    {"id":"43765","name":"Presentation - Withdrawal from the EU: Update from the European Commission (M.Dorazil, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-02-18T10:57:00Z","last_updated_date":"2019-02-18T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-withdrawal-eu-update-european-commission-mdorazil-ec_en.pdf"},
    {"id":"43766","name":"Presentation - EMA Operation and Procedural Preparedness Update (N.Wathion, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-02-18T10:59:00Z","last_updated_date":"2019-02-18T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-operation-and-procedural-preparedness-update-nwathion-ema_en.pdf"},
    {"id":"43767","name":"Presentation - EMA Operational and Procedural preparedness update (A.Ganan Jimenez, EMA; B. Mustafov, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-02-18T11:00:00Z","last_updated_date":"2019-02-18T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-operational-and-procedural-preparedness-update-aganan-jimenez-ema-b-mustafov-ema_en.pdf"},
    {"id":"43768","name":"Presentation - Impact of Brexit on medicines availability and supply for Centrally Authorised Products (CAPs) (M.Diaz, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-02-18T11:01:00Z","last_updated_date":"2019-02-18T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-brexit-medicines-availability-and-supply-centrally-authorised-products-caps-mdiaz-ema_en.pdf"},
    {"id":"43769","name":"Presentation - EMA Brexit Interested Parties Meeting Joint Industry Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-02-18T11:02:00Z","last_updated_date":"2019-02-18T11:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-brexit-interested-parties-meeting-joint-industry-presentation_en.pdf"},
    {"id":"44431","name":"Presentation - Target Operating Model update to SPOR task force","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-05-06T10:51:00Z","last_updated_date":"2019-05-06T10:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-target-operating-model-update-spor-task-force_en.pdf"},
    {"id":"44432","name":"Presentation - EU-SRS project update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-05-06T10:54:00Z","last_updated_date":"2019-05-06T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-srs-project-update_en.pdf"},
    {"id":"44433","name":"Presentation - New veterinary regulation: impact on IT/Telematics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-05-06T10:56:00Z","last_updated_date":"2019-05-06T10:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-veterinary-regulation-impact-ittelematics_en.pdf"},
    {"id":"44434","name":"Presentation - SPOR data services update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-05-06T10:58:00Z","last_updated_date":"2019-05-06T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-data-services-update_en.pdf"},
    {"id":"44645","name":"Presentation - The summary of product characteristics of fixed combination medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-06-04T11:43:00Z","last_updated_date":"2019-06-04T11:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-product-characteristics-fixed-combination-medicinal-products_en.pdf"},
    {"id":"45169","name":"Presentation - SPOR Task Force meeting: Industry Points","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T09:50:00Z","last_updated_date":"2019-08-01T09:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-industry-points_en.pdf"},
    {"id":"45170","name":"Presentation - SPOR Task Force meeting: Animalhealth Europe priorities for DoA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T09:52:00Z","last_updated_date":"2019-08-01T09:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-animalhealth-europe-priorities-doa_en.pdf"},
    {"id":"45171","name":"Presentation - SPOR Task Force meeting: IDMP data pilot (Martha Schei Hynne, Jeff Martin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T09:55:00Z","last_updated_date":"2019-08-01T09:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-idmp-data-pilot-martha-schei-hynne-jeff-martin_en.pdf"},
    {"id":"45172","name":"Presentation - SPOR Task Force meeting: EU-SRS PoC project update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T09:56:00Z","last_updated_date":"2019-08-01T09:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-eu-srs-poc-project-update_en.pdf"},
    {"id":"45173","name":"Presentation - SPOR Task Force meeting: SMS - update to SPOR TF (Jaume Gonzalez Nogueras)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T10:00:00Z","last_updated_date":"2019-08-01T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-sms-update-spor-tf-jaume-gonzalez-nogueras_en.pdf"},
    {"id":"45174","name":"Presentation - SPOR Task Force meeting: Industry position on the OMS KUG","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T10:30:00Z","last_updated_date":"2019-08-01T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-industry-position-oms-kug_en.pdf"},
    {"id":"45175","name":"Presentation - SPOR Task Force meeting: SPOR data services - update to SPOR TF (Agnieszka Laka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T10:31:00Z","last_updated_date":"2019-08-01T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-spor-data-services-update-spor-tf-agnieszka-laka_en.pdf"},
    {"id":"45176","name":"Presentation - SPOR Task Force meeting: S&PMS plan & progress - update to SPOR TF (Olivier Simoen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T10:33:00Z","last_updated_date":"2019-08-01T10:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-spms-plan-progress-update-spor-tf-olivier-simoen_en.pdf"},
    {"id":"45177","name":"Presentation - SPOR Task Force meeting: PMS - Target Operating Model (TOM) next steps (Carlos Aicardo Muñoz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T10:35:00Z","last_updated_date":"2019-08-01T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-pms-target-operating-model-tom-next-steps-carlos-aicardo-munoz_en.pdf"},
    {"id":"45178","name":"Presentation - SPOR Task Force meeting: EU IG - EU Implementation guide (Carlos Aicardo Muñoz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T10:40:00Z","last_updated_date":"2019-08-01T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-eu-ig-eu-implementation-guide-carlos-aicardo-munoz_en.pdf"},
    {"id":"45179","name":"Presentation - SPOR Task Force meeting: The target operating model (Jeff Martin, Ly Rootslane)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T10:44:00Z","last_updated_date":"2019-08-01T10:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-target-operating-model-jeff-martin-ly-rootslane_en.pdf"},
    {"id":"45180","name":"Presentation - SPOR Task Force meeting: Update on the New Veterinary Regulation (NVR) (Ivo Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T10:45:00Z","last_updated_date":"2019-08-01T10:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-update-new-veterinary-regulation-nvr-ivo-claassen_en.pdf"},
    {"id":"45181","name":"Presentation - SPOR Task Force meeting: SPOR data services - update to SPOR TF (Francisco Penaranda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T10:47:00Z","last_updated_date":"2019-08-01T10:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-spor-data-services-update-spor-tf-francisco-penaranda_en.pdf"},
    {"id":"45182","name":"Presentation - SPOR Task Force meeting: Dutch Royal Award","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T10:48:00Z","last_updated_date":"2019-08-01T10:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-task-force-meeting-dutch-royal-award_en.pdf"},
    {"id":"45274","name":"Presentation - Prospective planning of evidence generation for orphan medicinal products - Opportunities for multi-stakeholder dialogue (payers' perspective) (E.Van Lente)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prospective-planning-evidence-generation-orphan-medicinal-products-opportunities-multi-stakeholder-dialogue-payers-perspective-evan-lente_en.pdf"},
    {"id":"45275","name":"Presentation - Prospective planning of evidence generation for orphan medicinal products - Opportunities for multi-stakeholder dialogue and MoCA (S.Boselli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prospective-planning-evidence-generation-orphan-medicinal-products-opportunities-multi-stakeholder-dialogue-and-moca-sboselli_en.pdf"},
    {"id":"45276","name":"Presentation - Prospective planning of evidence generation for orphan medicinal products - Opportunities for multi-stakeholder dialogue and MoCA (company perspective)  (W.Hughes-Wilson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prospective-planning-evidence-generation-orphan-medicinal-products-opportunities-multi-stakeholder-dialogue-and-moca-company-perspective-whughes-wilson_en.pdf"},
    {"id":"45277","name":"Presentation - Defining unmet medical need (J.Stokx)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-defining-unmet-medical-need-jstokx_en.pdf"},
    {"id":"45278","name":"Presentation - Unmet medical need: an introduction to definitions and stakeholder perceptions (J.Llinares Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-unmet-medical-need-introduction-definitions-and-stakeholder-perceptions-jllinares-garcia_en.pdf"},
    {"id":"45279","name":"Presentation - Wording of indication, labelling and assessment report (H.Hillege, K.Dunder)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-wording-indication-labelling-and-assessment-report-hhillege-kdunder_en.pdf"},
    {"id":"45280","name":"Presentation - Indication and Labelling (J.Llinares Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-indication-and-labelling-jllinares-garcia_en.pdf"},
    {"id":"45281","name":"Presentation - Draft reflection paper on the wording of therapeutic indication (M.Ermisch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-reflection-paper-wording-therapeutic-indication-mermisch_en.pdf"},
    {"id":"45282","name":"Presentation - International Horizon Scanning Initiative (E.Klein Lankhorst)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-horizon-scanning-initiative-eklein-lankhorst_en.pdf"},
    {"id":"45283","name":"Presentation - Follow-up discussion on Horizon Scanning activities (M.Berntgen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-follow-discussion-horizon-scanning-activities-mberntgen-ema_en.pdf"},
    {"id":"45284","name":"Presentation - Post licensing evidence generation through reimbursement data (D.Lingri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-licensing-evidence-generation-through-reimbursement-data-dlingri_en.pdf"},
    {"id":"45285","name":"Presentation - CAR-T RWD DLBCL: A case study on the use of Real World Data (L.Timmers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-car-t-rwd-dlbcl-case-study-use-real-world-data-ltimmers_en.pdf"},
    {"id":"45286","name":"Presentation - Regulatory Perspective on Post-licensing Evidence Generation (PLEG) Qualification of EBMT registry for post-licencing evidence generation for CAR-T cells authorised for haematological malignancies (S.Vamvakas, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspective-post-licensing-evidence-generation-pleg-qualification-ebmt-registry-post-licencing-evidence-generation-car-t-cells-authorised-haematological-malignancies-svamvakas_en.pdf"},
    {"id":"45287","name":"Presentation - Post-licensing evidence in medicines regulation (X.Kurz, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-08-20T10:52:00Z","last_updated_date":"2019-08-20T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-licensing-evidence-medicines-regulation-xkurz-ema_en.pdf"}    {"id":"45603","name":"Presentation - CIOMS \"Guidance on patient involvement in the development and safe use of medicines\" (F. Houÿez, EURORDIS and I. Moulon, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:20:00Z","last_updated_date":"2019-10-09T09:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cioms-guidance-patient-involvement-development-and-safe-use-medicines-f-houyez-eurordis-and-i-moulon-ema_en.pdf"},
    {"id":"45605","name":"Presentation - Drug regulation in the 2020s: Key roles to play by HCPs and Academia (G.Calvo Rojas, EACPT)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:31:00Z","last_updated_date":"2019-10-09T09:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drug-regulation-2020s-key-roles-play-hcps-and-academia-gcalvo-rojas-eacpt_en.pdf"},
    {"id":"45607","name":"Presentation - Council recommendation on vaccine preventable diseases (I.de la Mata, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-council-recommendation-vaccine-preventable-diseases-ide-la-mata-ec_en.pdf"},
    {"id":"45608","name":"Presentation - Vaccination portal (J.Kinsman, ECDC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vaccination-portal-jkinsman-ecdc_en.pdf"},
    {"id":"45609","name":"Presentation - Towards an EMA vaccines outreach strategy (M.Carr, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-towards-ema-vaccines-outreach-strategy-mcarr-ema_en.pdf"},
    {"id":"45610","name":"Presentation - Impact of pharmacovigilance activities (S.Straus, PRAC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-pharmacovigilance-activities-sstraus-prac_en.pdf"},
    {"id":"45611","name":"Presentation - Pharmacovigilance (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-parlett-ema_en.pdf"},
    {"id":"45612","name":"Presentation - Repurposing of established substances (C.Bouygues, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-repurposing-established-substances-cbouygues-ema_en.pdf"},
    {"id":"45613","name":"Presentation - STAMP initiative on medicines repurposing (F.Houyez, EURORDIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stamp-initiative-medicines-repurposing-fhouyez-eurordis_en.pdf"},
    {"id":"45615","name":"Presentation - CHMP feedback to working parties (F. Ventura, CHMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chmp-feedback-working-parties-f-ventura-chmp_en.pdf"},
    {"id":"45616","name":"Presentation - COMP feedback to working parties (D. Duarte, T. Leest, COMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comp-feedback-working-parties-d-duarte-t-leest-comp_en.pdf"},
    {"id":"45617","name":"Presentation - HMPC feedback to working parties (S.Bager, HMPC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hmpc-feedback-working-parties-sbager-hmpc_en.pdf"},
    {"id":"45618","name":"Presentation - PRAC feedback to working parties (V. Hivert, R.Anderson, PRAC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prac-feedback-working-parties-v-hivert-randerson-prac_en.pdf"},
    {"id":"45619","name":"Presentation - Highlights of involvement in EMA activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T09:39:00Z","last_updated_date":"2019-10-09T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-highlights-involvement-ema-activities_en.pdf"},
    {"id":"46134","name":"Presentation - Addresssing future challenges and key priorities (Guido Rasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T09:59:00Z","last_updated_date":"2019-11-26T09:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-addresssing-future-challenges-and-key-priorities-guido-rasi_en.pdf"},
    {"id":"46135","name":"Presentation - EMA Regulatory Science to 2025 - Welcome","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-welcome_en.pdf"},
    {"id":"46136","name":"Presentation - 1.2 - From relocation towards a business recovery pathway (Noel Wathion)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:01:00Z","last_updated_date":"2019-11-26T10:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-12-relocation-towards-business-recovery-pathway-noel-wathion_en.pdf"},
    {"id":"46137","name":"Presentation - EMA Regulatory Science to 2025 - Overview of the outcome of the publication consultation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-overview-outcome-publication-consultation_en.pdf"},
    {"id":"46138","name":"Presentation - EMA Regulatory Science to 2025 - Support developments in precision medicine, biomarkers and ‘omics’","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-support-developments-precision-medicine-biomarkers-and-omics_en.pdf"},
    {"id":"46139","name":"Presentation - EMA Regulatory Science to 2025 - Support translation of advanced therapy medicinal products (ATMPs) into patient treatments","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-support-translation-advanced-therapy-medicinal-products-atmps-patient-treatments_en.pdf"},
    {"id":"46140","name":"Presentation : 1.3 - Move to the permanent premises (Tiago Freitas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:09:00Z","last_updated_date":"2019-11-26T10:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-13-move-permanent-premises-tiago-freitas_en.pdf"},
    {"id":"46141","name":"Presentation : 2.1 - New veterinary regulation (Jordi Torren Edo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:13:00Z","last_updated_date":"2019-11-26T10:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-21-new-veterinary-regulation-jordi-torren-edo_en.pdf"},
    {"id":"46142","name":"Presentation : 2.2 - Medical devices and in vitro medical devices (Zaide Frias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:17:00Z","last_updated_date":"2019-11-26T10:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-22-medical-devices-vitro-medical-devices-zaide-frias_en.pdf"},
    {"id":"46143","name":"Presentation : 2.3 - Clinical trial regulation (Anabela Marcal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:21:00Z","last_updated_date":"2019-11-26T10:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-23-clinical-trial-regulation-anabela-marcal_en.pdf"},
    {"id":"46144","name":"Presentation - 3.1 - Findings from ECDC's survey on healthcare workers' knowledge and attitudes about antibiotics and antibiotics resistance (J. Kinsman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:27:00Z","last_updated_date":"2019-11-26T10:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-31-findings-ecdcs-survey-healthcare-workers-knowledge-and-attitudes-about-antibiotics-and-antibiotics-resistance-j-kinsman_en.pdf"},
    {"id":"46145","name":"Presentation - EMA Regulatory Science to 2025 - Create an integrated evaluation pathway for the assessment of medical devices, in vitro diagnostics and borderline products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-create-integrated-evaluation-pathway-assessment-medical-devices-vitro-diagnostics-borderline-products_en.pdf"},
    {"id":"46146","name":"Presentation - EMA Regulatory Science to 2025 - Diversify and integrate the provision of regulatory advice along the development continuum","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-diversify-and-integrate-provision-regulatory-advice-along-development-continuum_en.pdf"},
    {"id":"46147","name":"Presentation - EMA Regulatory Science to 2025 - Recommendations related to downstream decision making, HTA’s preparedness, and collaboration with payers","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-recommendations-related-downstream-decision-making-htas-preparedness-and-collaboration-payers_en.pdf"},
    {"id":"46148","name":"Presentation - EMA Regulatory Science to 2025 - Promote use of high-quality real-world data (RWD) in decision making","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-promote-use-high-quality-real-world-data-rwd-decision-making_en.pdf"},
    {"id":"46149","name":"Presentation - 3.2 - EMA communication campaign for European Antibiotic Awareness Day 2019 (Alessandro Faia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:31:00Z","last_updated_date":"2019-11-26T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-32-ema-communication-campaign-european-antibiotic-awareness-day-2019-alessandro-faia_en.pdf"},
    {"id":"46150","name":"Presentation - EMA Regulatory Science to 2025 - Foster innovation in clinical trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-foster-innovation-clinical-trials_en.pdf"},
    {"id":"46151","name":"Presentation - EMA Regulatory Science to 2025 - Develop the regulatory framework for emerging clinical data generation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-develop-regulatory-framework-emerging-clinical-data-generation_en.pdf"},
    {"id":"46152","name":"Presentation - EMA Regulatory Science to 2025 - Optimise capabilities in modelling, simulation and extrapolation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-optimise-capabilities-modelling-simulation-and-extrapolation_en.pdf"},
    {"id":"46153","name":"Presentation - EMA Regulatory Science to 2025 - Reinforce patient relevance in evidence generation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-reinforce-patient-relevance-evidence-generation_en.pdf"},
    {"id":"46154","name":"Presentation - EMA Regulatory Science to 2025 - Develop network-led partnerships with academia to undertake fundamental research in strategic areas of regulatory science","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-develop-network-led-partnerships-academia-undertake-fundamental-research-strategic-areas-regulatory-science_en.pdf"},
    {"id":"46155","name":"Presentation - EMA Regulatory Science to 2025 - Developing scientific advice/assessment pathways - Feedback from breakout session 3A","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-developing-scientific-adviceassessment-pathways-feedback-breakout-session-3a_en.pdf"},
    {"id":"46156","name":"Presentation : 4.1 - EMA training and training strategy (Maria Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:34:00Z","last_updated_date":"2019-11-26T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-41-ema-training-and-training-strategy-maria-mavris_en.pdf"},
    {"id":"46157","name":"Presentation - EMA Regulatory Science to 2025 - Optimising evidence incl. RWD for decision making and communication - Feedback from session 3B","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-optimising-evidence-incl-rwd-decision-making-and-communication-feedback-session-3b_en.pdf"},
    {"id":"46158","name":"Presentation - EMA Regulatory Science to 2025 - Continue to support development of new antibacterial agents and their alternatives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-continue-support-development-new-antibacterial-agents-and-their-alternatives_en.pdf"},
    {"id":"46159","name":"Presentation - EMA Regulatory Science to 2025 - Reinforcing patient relevance in evidence generation - Feedback from breakout session 5C","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-reinforcing-patient-relevance-evidence-generation-feedback-breakout-session-5c_en.pdf"},
    {"id":"46160","name":"Presentation - EMA Regulatory Science to 2025 - Developing research partnerships with academia - Feedback from breakout session 5D","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-developing-research-partnerships-academia-feedback-breakout-session-5d_en.pdf"},
    {"id":"46161","name":"Presentation - EMA Regulatory Science to 2025 - Delivering the strategy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-delivering-strategy_en.pdf"},
    {"id":"46162","name":"Presentation - EMA Regulatory Science to 2025 - Human Workshop - Draft briefing materials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-human-workshop-draft-briefing-materials_en.pdf"},
    {"id":"46163","name":"Presentation - EMA Regulatory Science to 2025 - Support innovative approaches to the development, approval and post-authorisation monitoring of vaccines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-11-26T10:06:00Z","last_updated_date":"2019-11-26T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-science-2025-support-innovative-approaches-development-approval-and-post-authorisation-monitoring-vaccines_en.pdf"},
    {"id":"46243","name":"Presentation - Workshop on the role of registries in the monitoring of cancer therapies based on genetic and molecular features: Introduction from the chair (Peter Mol)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-05T15:03:00Z","last_updated_date":"2019-12-05T15:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-role-registries-monitoring-cancer-therapies-based-genetic-and-molecular-features-introduction-chair-peter-mol_en.pdf"},
    {"id":"46244","name":"Presentation - A regulatory view on the role of registries for generating data on cancer therapies (Filip Josephson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-05T15:10:00Z","last_updated_date":"2019-12-05T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-view-role-registries-generating-data-cancer-therapies-filip-josephson_en.pdf"},
    {"id":"46245","name":"Presentation - The European Network of Cancer Registries (ENCR) (Otto Visser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-05T15:12:00Z","last_updated_date":"2019-12-05T15:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-cancer-registries-encr-otto-visser_en.pdf"},
    {"id":"46246","name":"Presentation - Registries for European Reference Networks (ERNs) (Hélène Le Borgne)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-05T15:14:00Z","last_updated_date":"2019-12-05T15:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-registries-european-reference-networks-erns-helene-le-borgne_en.pdf"},
    {"id":"46247","name":"Presentation - The National Cancer Registration and Analysis Service (NCRAS) England: Data collection for tumour agnostic treatments (Alice Turnbull)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-05T16:39:00Z","last_updated_date":"2019-12-05T16:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-national-cancer-registration-and-analysis-service-ncras-england-data-collection-tumour-agnostic-treatments-alice-turnbull_en.pdf"},
    {"id":"46262","name":"Presentation - Session 1 - Multi-stakeholder workshop on draft 'Regulatory Science to 2025' strategy (stakeholders for veterinary medicines): Overview of the outcome of the publication consultation (Ivo Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T15:48:00Z","last_updated_date":"2019-12-09T15:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-multi-stakeholder-workshop-draft-regulatory-science-2025-strategy-stakeholders-veterinary-medicines-overview-outcome-publication-consultation-ivo-claassen_en.pdf"},
    {"id":"46263","name":"Presentation - Session 2 - Develop new approaches to improve the benefit-risk assessment of veterinary medicinal product: Underlying actions (David Murphy, Supported by Jordi Torren Edo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T15:57:00Z","last_updated_date":"2019-12-09T15:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-develop-new-approaches-improve-benefit-risk-assessment-veterinary-medicinal-product-underlying-actions-david-murphy-supported-jordi-torren-edo_en.pdf"},
    {"id":"46264","name":"Presentation - Session 3a - Continue to promote the responsible use of antimicrobials and their alternatives: Underlying actions (Christine Schwarz, Thomas Heberer, Helen Jukes, Javier Pozo Gonzalez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T16:00:00Z","last_updated_date":"2019-12-09T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3a-continue-promote-responsible-use-antimicrobials-and-their-alternatives-underlying-actions-christine-schwarz-thomas-heberer-helen-jukes-javier-pozo-gonzalez_en.pdf"},
    {"id":"46265","name":"Presentation - Session 3b - Reinforce and further embed application of the 3Rs principles (Raffaella Corvi , Ellen-Margrethe Vestergaard , Nicholas Jarrett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T16:02:00Z","last_updated_date":"2019-12-09T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3b-reinforce-and-further-embed-application-3rs-principles-raffaella-corvi-ellen-margrethe-vestergaard-nicholas-jarrett_en.pdf"},
    {"id":"46266","name":"Presentation - Session 4 - Collaborate with stakeholders to modernise veterinary pharmacoepidemiology and pharmacovigilance (Frank Verheijen, Gabriel Beechinor, Barbara Freischem)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T16:13:00Z","last_updated_date":"2019-12-09T16:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-collaborate-stakeholders-modernise-veterinary-pharmacoepidemiology-and-pharmacovigilance-frank-verheijen-gabriel-beechinor-barbara-freischem_en.pdf"},
    {"id":"46267","name":"Presentation - Session 5 - Promote and support development of veterinary vaccines (Esther Werner, Javier Pozo Gonzalez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T16:17:00Z","last_updated_date":"2019-12-09T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-promote-and-support-development-veterinary-vaccines-esther-werner-javier-pozo-gonzalez_en.pdf"},
    {"id":"46268","name":"Presentation - Session 6 - Feedback from session 3a: Continue to promote the responsible use of antimicrobials and their alternatives (Christine Schwarz, Thomas Heberer, Helen Jukes, Javier Pozo Gonzalez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T16:21:00Z","last_updated_date":"2019-12-09T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-6-feedback-session-3a-continue-promote-responsible-use-antimicrobials-and-their-alternatives-christine-schwarz-thomas-heberer-helen-jukes-javier-pozo-gonzalez_en.pdf"},
    {"id":"46269","name":"Presentation - Session 6 - Feedback from session 3b: Reinforce and further embed application of the 3Rs principles (Raffaella Corvi , Ellen-Margrethe Vestergaard , Nicholas Jarrett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T16:47:00Z","last_updated_date":"2019-12-09T16:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-6-feedback-session-3b-reinforce-and-further-embed-application-3rs-principles-raffaella-corvi-ellen-margrethe-vestergaard-nicholas-jarrett_en.pdf"},
    {"id":"46270","name":"Presentation - Session 7 - Transform the regulatory framework for innovative veterinary medicines (Jean Pierre Orand,  Ivo Claassen, Noemi Garcia del Blanco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T16:56:00Z","last_updated_date":"2019-12-09T16:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-7-transform-regulatory-framework-innovative-veterinary-medicines-jean-pierre-orand-ivo-claassen-noemi-garcia-del-blanco_en.pdf"},
    {"id":"46271","name":"Presentation - Session 8 - Delivering the strategy (Guido Rasi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2019-12-09T17:13:00Z","last_updated_date":"2019-12-09T17:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-8-delivering-strategy-guido-rasi_en.pdf"},
    {"id":"46857","name":"Presentation - SPOR data services update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:00:00Z","last_updated_date":"2020-02-25T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-data-services-update_en.pdf-0"},
    {"id":"46858","name":"Presentation - Update on the New Veterinary Regulation with a focus on the Union Product Database","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:00:00Z","last_updated_date":"2020-02-25T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-new-veterinary-regulation-focus-union-product-database_en.pdf"},
    {"id":"46859","name":"Presentation - IDMP PMS TOM - Industry perspectives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:00:00Z","last_updated_date":"2020-02-25T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-idmp-pms-tom-industry-perspectives_en.pdf"},
    {"id":"46860","name":"Presentation - Implementation of the UPD / Architectural Advice considering the data feed process for human and veterinary synergies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:00:00Z","last_updated_date":"2020-02-25T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-upd-architectural-advice-considering-data-feed-process-human-and-veterinary-synergies_en.pdf"},
    {"id":"46861","name":"Presentation - EU Implementation Guide","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:00:00Z","last_updated_date":"2020-02-25T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-implementation-guide_en.pdf"},
    {"id":"46862","name":"Presentation - S&PMS plan and progress","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:00:00Z","last_updated_date":"2020-02-25T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spms-plan-and-progress_en.pdf"},
    {"id":"46863","name":"Presentation - Report from the WHO workshop on IDMP","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:00:00Z","last_updated_date":"2020-02-25T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-who-workshop-idmp_en.pdf"},
    {"id":"46864","name":"Presentation - EU-SRS PoC project update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:00:00Z","last_updated_date":"2020-02-25T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-srs-poc-project-update_en.pdf"},
    {"id":"46865","name":"Presentation - SMS update to ISO IDMP task force","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:00:00Z","last_updated_date":"2020-02-25T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sms-update-iso-idmp-task-force_en.pdf"},
    {"id":"46950","name":"Presentation - 1.1 EMA recommendations from the Regulatory Science Strategy to 2025: implications for patients and healthcare professionals (T. Humphreys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11-ema-recommendations-regulatory-science-strategy-2025-implications-patients-and-healthcare-professionals-t-humphreys_en.pdf"},
    {"id":"46951","name":"Presentation - 1.2 European Medicines Regulatory Network Strategy to 2025: introduction on the route to joint strategy, stakeholder consultation process, timelines (M. Carr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-12-european-medicines-regulatory-network-strategy-2025-introduction-route-joint-strategy-stakeholder-consultation-process-timelines-m-carr_en.pdf"},
    {"id":"46952","name":"Presentation - 3.1 Update on the activities of the HMA/EMA Task Force (J. Ferreira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-31-update-activities-hmaema-task-force-j-ferreira_en.pdf"},
    {"id":"46953","name":"Presentation - 4.1 Renovation of ICH guidelines. What is changing and how is EMA contributing? (F. Sweeney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-41-renovation-ich-guidelines-what-changing-and-how-ema-contributing-f-sweeney_en.pdf"},
    {"id":"46954","name":"Presentation - 5.1 Survey on rare disease patient perspectives on data sharing and data protection (S. Courbier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:37:00Z","last_updated_date":"2020-03-06T10:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-51-survey-rare-disease-patient-perspectives-data-sharing-and-data-protection-s-courbier_en.pdf"},
    {"id":"46955","name":"Presentation - 5.2 Patient data platform (E. Vroom, J. Isla)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:40:00Z","last_updated_date":"2020-03-06T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-52-patient-data-platform-e-vroom-j-isla_en.pdf"},
    {"id":"46956","name":"Presentation - 5.3 HMA/EMA Big data task force recommendations and future actions (N. Brun, P. Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-53-hmaema-big-data-task-force-recommendations-and-future-actions-n-brun-p-arlett_en.pdf"},
    {"id":"46957","name":"Presentation - 6. Feedback from committee members: CAT (K. Breen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-6-feedback-committee-members-cat-k-breen_en.pdf"},
    {"id":"46958","name":"Presentation - 6. Feedback from committee members: CHMP (F. Ventura, C. Prieto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-6-feedback-committee-members-chmp-f-ventura-c-prieto_en.pdf"},
    {"id":"46959","name":"Presentation - 6. Feedback from committee members: COMP (D. Duarte, T. Leest)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-6-feedback-committee-members-comp-d-duarte-t-leest_en.pdf"},
    {"id":"46960","name":"Presentation - 6. Feedback from committee members: HMPC (Steffen Bager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-6-feedback-committee-members-hmpc-steffen-bager_en.pdf"},
    {"id":"46961","name":"Presentation - 6. Feedback from committee members: PRAC (V. Hivert, R. Anderson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-6-feedback-committee-members-prac-v-hivert-r-anderson_en.pdf"},
    {"id":"46962","name":"Presentation - 6. Feedback from committee members: PDCO (J. Taminiau)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T10:00:00Z","last_updated_date":"2020-03-06T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-6-feedback-committee-members-pdco-j-taminiau_en.pdf"},
    {"id":"46963","name":"Presentation - 7.1 Update on electronic product information for EU medicines (E. Scanlan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T09:14:00Z","last_updated_date":"2020-03-06T09:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-71-update-electronic-product-information-eu-medicines-e-scanlan_en.pdf"},
    {"id":"46964","name":"Presentation - 8.1 Global Guidance on patient involvement (L. Rägo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T09:15:00Z","last_updated_date":"2020-03-06T09:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-81-global-guidance-patient-involvement-l-rago_en.pdf"},
    {"id":"46965","name":"Presentation - 8.2 Incorporating EMA and patient organisations’ experience (F. Houÿez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T09:16:00Z","last_updated_date":"2020-03-06T09:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-82-incorporating-ema-and-patient-organisations-experience-f-houyez_en.pdf"},
    {"id":"46966","name":"Presentation - 9.1 Sharing real examples to identify specific areas where action is needed (J. de Belie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T09:18:00Z","last_updated_date":"2020-03-06T09:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-91-sharing-real-examples-identify-specific-areas-where-action-needed-j-de-belie_en.pdf"},
    {"id":"46967","name":"Presentation - 9.2 Summary of discussions related with developing a concept paper on best practices to prevent shortages (C. Roffiaen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T09:19:00Z","last_updated_date":"2020-03-06T09:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-92-summary-discussions-related-developing-concept-paper-best-practices-prevent-shortages-c-roffiaen_en.pdf"},
    {"id":"46968","name":"Presentation - 9.3 Discussion on revision of the common position between patients’, consumers, and healthcare professionals’ organisations on supply shortages of medicines (F. Houÿez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T09:21:00Z","last_updated_date":"2020-03-06T09:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-93-discussion-revision-common-position-between-patients-consumers-and-healthcare-professionals-organisations-supply-shortages-medicines-f-houyez_en.pdf"},
    {"id":"47645","name":"Presentation - Enpr-EMA Nurse - Coordinator Working Group","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-13T11:30:00Z","last_updated_date":"2020-05-13T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-nurse-coordinator-working-group_en.pdf"},
    {"id":"47721","name":"Presentation - Cohesion in the conduct of clinical trials among Member States (L.Sangiorgi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T16:56:00Z","last_updated_date":"2020-05-19T16:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cohesion-conduct-clinical-trials-among-member-states-lsangiorgi_en.pdf"},
    {"id":"47722","name":"Presentation - European research landscape (M. Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T16:57:00Z","last_updated_date":"2020-05-19T16:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-research-landscape-m-turner_en.pdf"},
    {"id":"47723","name":"Presentation - Labelling information (S. de Wildt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T16:59:00Z","last_updated_date":"2020-05-19T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-labelling-information-s-de-wildt_en.pdf"},
    {"id":"47724","name":"Presentation - Opportunities for European patients in global programmes (T. Lee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T17:00:00Z","last_updated_date":"2020-05-19T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-european-patients-global-programmes-t-lee_en.pdf"},
    {"id":"47725","name":"Presentation - Update on Enpr-EMA activities, achievements and challenges (M.Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T17:02:00Z","last_updated_date":"2020-05-19T17:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-enpr-ema-activities-achievements-and-challenges-mturner_en.pdf-0"},
    {"id":"47726","name":"Presentation - Working group on educational training for research staff (G. Veal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T17:09:00Z","last_updated_date":"2020-05-19T17:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-educational-training-research-staff-g-veal_en.pdf"},
    {"id":"47727","name":"Presentation - Working group on ethics (P. Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T17:12:00Z","last_updated_date":"2020-05-19T17:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-ethics-p-lepola_en.pdf"},
    {"id":"47728","name":"Presentation - Working group on international collaboration (T. Lacaze)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T17:14:00Z","last_updated_date":"2020-05-19T17:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-international-collaboration-t-lacaze_en.pdf"},
    {"id":"47729","name":"Presentation - Working group on parents and patients (D. Athanasiou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T17:17:00Z","last_updated_date":"2020-05-19T17:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-parents-and-patients-d-athanasiou_en.pdf"},
    {"id":"47730","name":"Presentation - Working group on public-private partnership (P. Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T17:19:00Z","last_updated_date":"2020-05-19T17:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-group-public-private-partnership-p-lepola_en.pdf"},
    {"id":"47731","name":"Presentation - Young persons advisory groups (P. Dicks)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T17:27:00Z","last_updated_date":"2020-05-19T17:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-young-persons-advisory-groups-p-dicks_en.pdf"},
    {"id":"47852","name":"Presentation - 2.1 ICH E6 R3 Expert Working Group Perspectives (R. Stanbrook)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T15:06:00Z","last_updated_date":"2020-06-04T15:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-21-ich-e6-r3-expert-working-group-perspectives-r-stanbrook_en.pdf"}    {"id":"47853","name":"Presentation - 3.1 A flavour of patients’ organisations views on ICH E6 guidelines (F. Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T15:08:00Z","last_updated_date":"2020-06-04T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-31-flavour-patients-organisations-views-ich-e6-guidelines-f-houyez_en.pdf"},
    {"id":"47854","name":"Presentation - 3.1 Patient perspective on renovation of ICH guideline on GCP in clinical trials (M. Greco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T15:09:00Z","last_updated_date":"2020-06-04T15:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-31-patient-perspective-renovation-ich-guideline-gcp-clinical-trials-m-greco_en.pdf"},
    {"id":"47855","name":"Presentation - 3.2.1 Good Clinical Practice: patient centered, investigator friendly (M. Dreyling)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T15:15:00Z","last_updated_date":"2020-06-04T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-321-good-clinical-practice-patient-centered-investigator-friendly-m-dreyling_en.pdf"},
    {"id":"47856","name":"Presentation - 3.2.2 ICH E6: Good Clinical Practice stick to the principles (M. Landray)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T15:17:00Z","last_updated_date":"2020-06-04T15:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-322-ich-e6-good-clinical-practice-stick-principles-m-landray_en.pdf"},
    {"id":"47857","name":"Presentation - 3.2.3 ICH guideline renovation clinical researchers perspectives: ECRIN (J. Demotes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T15:19:00Z","last_updated_date":"2020-06-04T15:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-323-ich-guideline-renovation-clinical-researchers-perspectives-ecrin-j-demotes_en.pdf"},
    {"id":"47858","name":"Presentation - 3.2.4 ICH GCP Stakeholder workshop: European Organisation for Research and Treatment of Cancer (EORTC) perspective (D. Lacombe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T15:21:00Z","last_updated_date":"2020-06-04T15:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-324-ich-gcp-stakeholder-workshop-european-organisation-research-and-treatment-cancer-eortc-perspective-d-lacombe_en.pdf"},
    {"id":"47859","name":"Presentation - 1.1 Introduction to the ICH guideline development process (L. Lindstrom, M. Bonelli, E. Szepessy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T15:26:00Z","last_updated_date":"2020-06-04T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11-introduction-ich-guideline-development-process-l-lindstrom-m-bonelli-e-szepessy_en.pdf"},
    {"id":"47862","name":"Presentation - 1.2 Introduction to ICH E6(R3) and stakeholder engagement plan (L. Bregnhøj, F. Sweeney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T15:28:00Z","last_updated_date":"2020-06-04T15:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-12-introduction-ich-e6r3-and-stakeholder-engagement-plan-l-bregnhoj-f-sweeney_en.pdf"},
    {"id":"47863","name":"Presentation - 1.3 ICH E6 findings from Clinical Trials Transformation Initiative (CTTI) (P. Tenaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T15:30:00Z","last_updated_date":"2020-06-04T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-13-ich-e6-findings-clinical-trials-transformation-initiative-ctti-p-tenaerts_en.pdf"},
    {"id":"47871","name":"Presentation - 1.1 Agency’s contribution to the pandemic response (N. Wathion)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:36:00Z","last_updated_date":"2020-06-05T10:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11-agencys-contribution-pandemic-response-n-wathion_en.pdf"},
    {"id":"47872","name":"Presentation - 1.2 COVID-19 pandemic: update (M. Cavaleri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:38:00Z","last_updated_date":"2020-06-05T10:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-12-covid-19-pandemic-update-m-cavaleri_en.pdf"},
    {"id":"47873","name":"Presentation - 1.3.1 Clinical Trials and COVID-19 (F. Sweeney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:40:00Z","last_updated_date":"2020-06-05T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-131-clinical-trials-and-covid-19-f-sweeney_en.pdf"},
    {"id":"47874","name":"Presentation - 1.3.2 COVID 19: EMA activities in relation to observational studies on use of medicines (X. Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:42:00Z","last_updated_date":"2020-06-05T10:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-132-covid-19-ema-activities-relation-observational-studies-use-medicines-x-kurz_en.pdf"},
    {"id":"47875","name":"Presentation - 1.4 Securing availability of medicines across the EU (M. Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:43:00Z","last_updated_date":"2020-06-05T10:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-14-securing-availability-medicines-across-eu-m-dias_en.pdf"},
    {"id":"47876","name":"Presentation - 1.5 Providing public health advice and communicating during a crisis (M. Carr, M-A. Heine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:45:00Z","last_updated_date":"2020-06-05T10:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-15-providing-public-health-advice-and-communicating-during-crisis-m-carr-m-heine_en.pdf"},
    {"id":"47877","name":"Presentation - 2.1 HMA/EMA Task Force on Availability of Authorised Medicines: update on progress (K. Raudsepp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:46:00Z","last_updated_date":"2020-06-05T10:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-21-hmaema-task-force-availability-authorised-medicines-update-progress-k-raudsepp_en.pdf"},
    {"id":"47878","name":"Presentation - 2.2 PCWP/HCPWP input to the HMA/EMA concept paper on best practices to prevent shortages (P. Kolczynski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:49:00Z","last_updated_date":"2020-06-05T10:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-22-pcwphcpwp-input-hmaema-concept-paper-best-practices-prevent-shortages-p-kolczynski_en.pdf"},
    {"id":"47879","name":"Presentation - 3.1 Electronic Health Record: Access, Share, Expand project (S. Brosch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:51:00Z","last_updated_date":"2020-06-05T10:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-31-electronic-health-record-access-share-expand-project-s-brosch_en.pdf"},
    {"id":"47880","name":"Presentation - 3.2 Electronic Health Record: Access, Share, Expand project: Secondary use of healthcare data; groundwork for Q&A (O. Eotvos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:52:00Z","last_updated_date":"2020-06-05T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-32-electronic-health-record-access-share-expand-project-secondary-use-healthcare-data-groundwork-qa-o-eotvos_en.pdf"},
    {"id":"47881","name":"Presentation - 3.3 Electronic Health Record: Access, Share, Expand project: Overview of stakeholder feedback received (S. Brosch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-05T10:54:00Z","last_updated_date":"2020-06-05T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-33-electronic-health-record-access-share-expand-project-overview-stakeholder-feedback-received-s-brosch_en.pdf"},
    {"id":"48077","name":"Presentation - Current analytical testing methodology and capacity (A. Teasdale)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-analytical-testing-methodology-and-capacity-teasdale_en.pdf"},
    {"id":"48078","name":"Presentation - Cohort of concern compounds–current guidance on impurities (especially genotoxic/ carcinogenic impurities) (A. Hartmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cohort-concern-compounds-current-guidance-impurities-especially-genotoxic-carcinogenic-impurities-hartmann_en.pdf"},
    {"id":"48079","name":"Presentation - Supply Chain Management and Surveillance (M. Wierer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supply-chain-management-and-surveillance-m-wierer_en.pdf"},
    {"id":"48080","name":"Presentation - What is the role of General Practitioners / Family Physicians in ARB recalls? (T. Villanueva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-role-general-practitioners-family-physicians-arb-recalls-t-villanueva_en.pdf"},
    {"id":"48082","name":"Presentation - ICH M7 Principles -Impurity Identification and Control (R. Ogilvie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-m7-principles-impurity-identification-and-control-r-ogilvie_en.pdf"},
    {"id":"48083","name":"Presentation - Prevention of contamination with nitrosamine impurities (B. Hirschlerová)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prevention-contamination-nitrosamine-impurities-b-hirschlerova_en.pdf"},
    {"id":"48084","name":"Presentation - Patients‘ concerns and reactions to Sartans with N-nitrosamine impurities (C. Dehn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-concerns-and-reactions-sartans-n-nitrosamine-impurities-c-dehn_en.pdf"},
    {"id":"48085","name":"Presentation - Information, coordination and public communication (L. Tonel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-coordination-and-public-communication-l-tonel_en.pdf"},
    {"id":"48086","name":"Presentation - Experiences from the Belgian & European Community Pharmacists Associations on the communication of the sartansrecall in 2018 (B. Machlien)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experiences-belgian-european-community-pharmacists-associations-communication-sartansrecall-2018-b-machlien_en.pdf"},
    {"id":"48089","name":"Presentation - Information, coordination and public communication (N. Mbaeliachi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-coordination-and-public-communication-n-mbaeliachi_en.pdf"},
    {"id":"48090","name":"Presentation - Recall and supply chain traceability (L.Paulo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recall-and-supply-chain-traceability-lpaulo_en.pdf"},
    {"id":"48091","name":"Presentation - Incident Management (K. O'Donnell)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-incident-management-k-odonnell_en.pdf"},
    {"id":"48092","name":"Presentation - Sartan Case Study- Session 4: Prevention Part II (A. Teasdale)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sartan-case-study-session-4-prevention-part-ii-teasdale_en.pdf"},
    {"id":"48094","name":"Presentation - Regulatory, Manufacturing and Supply Chain Aspects (M. Senis, J. M. de Ciura)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-manufacturing-and-supply-chain-aspects-m-senis-j-m-de-ciura_en.pdf"},
    {"id":"48204","name":"Presentation - Risk minimisationmeasures (Ulrich Jaeger, Priya Bahri, NúriaSemis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-07-02T17:02:00Z","last_updated_date":"2020-07-02T17:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-minimisationmeasures-ulrich-jaeger-priya-bahri-nuriasemis_en.pdf"},
    {"id":"48205","name":"Presentation - Remarks from the perspectives of healthcare professionals (J. de Belie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-07-02T17:05:00Z","last_updated_date":"2020-07-02T17:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-remarks-perspectives-healthcare-professionals-j-de-belie_en.pdf"},
    {"id":"48206","name":"Presentation - Remarks from the perspectives of patients (F. Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-07-02T17:09:00Z","last_updated_date":"2020-07-02T17:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-remarks-perspectives-patients-f-houyez_en.pdf"},
    {"id":"48207","name":"Presentation - Public consultation on draft guideline (X. Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-07-02T17:12:00Z","last_updated_date":"2020-07-02T17:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-public-consultation-draft-guideline-x-kurz_en.pdf"},
    {"id":"48208","name":"Presentation - International Coalition of Medicines Regulatory Authorities (ICMRA) statements (Marie-Agnes Heine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-07-02T17:15:00Z","last_updated_date":"2020-07-02T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-coalition-medicines-regulatory-authorities-icmra-statements-marie-agnes-heine_en.pdf"},
    {"id":"48209","name":"Presentation - Feedback on EMA virtual meetings (N. Lazaro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-07-02T17:23:00Z","last_updated_date":"2020-07-02T17:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-ema-virtual-meetings-n-lazaro_en.pdf"},
    {"id":"49049","name":"Presentation - PMS, UPD and FHIR","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T10:10:00Z","last_updated_date":"2020-10-21T10:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pms-upd-and-fhir_en.pdf"},
    {"id":"49109","name":"Presentation - 1.3 Overview of core recommendations of the draft guideline and comments received (Xavier Kurz, Valerie Strassmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T08:17:00Z","last_updated_date":"2020-10-23T08:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-13-overview-core-recommendations-draft-guideline-and-comments-received-xavier-kurz-valerie-strassmann_en.pdf"},
    {"id":"49110","name":"Presentation - 2.6 Industry perspective on registry (Chris Chinn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T08:21:00Z","last_updated_date":"2020-10-23T08:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-26-industry-perspective-registry-chris-chinn_en.pdf"},
    {"id":"49111","name":"Presentation - 2.6 Registry holders perspective (Eoin McGrath)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T08:22:00Z","last_updated_date":"2020-10-23T08:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-26-registry-holders-perspective-eoin-mcgrath_en.pdf"},
    {"id":"49112","name":"Presentation - 2.6 Patients association perspective (Mariette Driessens)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T08:24:00Z","last_updated_date":"2020-10-23T08:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-26-patients-association-perspective-mariette-driessens_en.pdf"},
    {"id":"49113","name":"Presentation - 2.6 Regulators example MS registry (VMarion Haberkamp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T08:26:00Z","last_updated_date":"2020-10-23T08:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-26-regulators-example-ms-registry-vmarion-haberkamp_en.pdf"},
    {"id":"49114","name":"Presentation - 2.6 Stakeholder perspective regulator (Milena Stain)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T08:28:00Z","last_updated_date":"2020-10-23T08:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-26-stakeholder-perspective-regulator-milena-stain_en.pdf"},
    {"id":"49115","name":"Presentation - 3.10 Survey on the collection of data on adverse events related to medicinal products through registries (Kelly Plueschke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T08:29:00Z","last_updated_date":"2020-10-23T08:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-310-survey-collection-data-adverse-events-related-medicinal-products-through-registries-kelly-plueschke_en.pdf"},
    {"id":"49116","name":"Presentation - 3.8 Experience of randomisation within a registry (Barbara Casadei)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T08:30:00Z","last_updated_date":"2020-10-23T08:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-38-experience-randomisation-within-registry-barbara-casadei_en.pdf"},
    {"id":"49117","name":"Presentation - 3.9 Data quality and data verification in registries - results of a stakeholders survey (Carla Jonker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T08:32:00Z","last_updated_date":"2020-10-23T08:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-39-data-quality-and-data-verification-registries-results-stakeholders-survey-carla-jonker_en.pdf"},
    {"id":"49222","name":"Presentation - Why is it so difficult to treat pregnant & breastfeeding womenand what can EMA do to help? (C. deVries, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T09:21:00Z","last_updated_date":"2020-11-12T09:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-why-it-so-difficult-treat-pregnant-breastfeeding-womenand-what-can-ema-do-help-c-devries-ema_en.pdf"},
    {"id":"49223","name":"Presentation - Information gap on safe use of medicines in pregnancy & breastfeeding (H. Sundseth, EIWH)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T09:21:00Z","last_updated_date":"2020-11-12T09:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-gap-safe-use-medicines-pregnancy-breastfeeding-h-sundseth-eiwh_en.pdf"},
    {"id":"49225","name":"Presentation - Treating pregnant and breastfeeding women - The reality of clinical practice (P. Ryan, ICGP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T09:21:00Z","last_updated_date":"2020-11-12T09:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-treating-pregnant-and-breastfeeding-women-reality-clinical-practice-p-ryan-icgp_en.pdf"},
    {"id":"49226","name":"Presentation - How pharmacovigilance guidelines are addressing this special population (U. Liminga, Swedish Medical Products Agency)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T09:21:00Z","last_updated_date":"2020-11-12T09:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-pharmacovigilance-guidelines-are-addressing-special-population-u-liminga-swedish-medical-products-agency_en.pdf"},
    {"id":"49227","name":"Presentation - Covid-19 infection and medicines in pregnancy (EU PE & PV Research Network)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T09:21:00Z","last_updated_date":"2020-11-12T09:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-infection-and-medicines-pregnancy-eu-pe-pv-research-network_en.pdf"},
    {"id":"49228","name":"Presentation - How to achieve a paradigm shift in clinical research and practice (H. Dolk, euromedicat)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T09:21:00Z","last_updated_date":"2020-11-12T09:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-achieve-paradigm-shift-clinical-research-and-practice-h-dolk-euromedicat_en.pdf"},
    {"id":"49264","name":"Presentation - Update of EudraVigilance operational plan (milestones 2020-2022) (Rodrigo Postigo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-17T17:30:00Z","last_updated_date":"2020-11-17T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-eudravigilance-operational-plan-milestones-2020-2022-rodrigo-postigo_en.pdf"},
    {"id":"49265","name":"Presentation - Good pharmacovigilance practices (GVP) - GVP PIII update after public consultation (Corinne de Vries)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-17T17:34:00Z","last_updated_date":"2020-11-17T17:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-gvp-gvp-piii-update-after-public-consultation-corinne-de-vries_en.pdf"},
    {"id":"49266","name":"Presentation - Good pharmacovigilance practices (GVP) - GVPs updates including GVP XVI and PASS addendum (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-17T17:37:00Z","last_updated_date":"2020-11-17T17:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-gvp-gvps-updates-including-gvp-xvi-and-pass-addendum-priya-bahri_en.pdf"},
    {"id":"49267","name":"Presentation - Monitoring of COVID-19 products (vaccines and therapeutics) (Georgy Genov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-17T17:39:00Z","last_updated_date":"2020-11-17T17:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-covid-19-products-vaccines-and-therapeutics-georgy-genov_en.pdf"},
    {"id":"49268","name":"Presentation - Preparations for the end of transition period for UK’s withdrawal from the EU (Marie-Helene Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-11-17T18:02:00Z","last_updated_date":"2020-11-17T18:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparations-end-transition-period-uks-withdrawal-eu-marie-helene-pinheiro_en.pdf"},
    {"id":"49437","name":"Presentation - Towards European Health Data Space (M.Dorazil, DG SANTE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T14:38:00Z","last_updated_date":"2020-12-04T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-towards-european-health-data-space-mdorazil-dg-sante_en.pdf"},
    {"id":"49438","name":"Presentation - Role of European Health Data Space in the German presidency (N. Schneider, German Federal Ministry of Health)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T14:38:00Z","last_updated_date":"2020-12-04T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-european-health-data-space-german-presidency-n-schneider-german-federal-ministry-health_en.pdf"},
    {"id":"49439","name":"Presentation - Joint action to support the work on the European Health Data Space (M. Kalliola, TEHDAS Joint Action)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T14:38:00Z","last_updated_date":"2020-12-04T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-action-support-work-european-health-data-space-m-kalliola-tehdas-joint-action_en.pdf"},
    {"id":"49440","name":"Presentation - Overview of Big Data Steering Group workplan (N.C. Brun, DKMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T14:38:00Z","last_updated_date":"2020-12-04T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-big-data-steering-group-workplan-nc-brun-dkma_en.pdf"},
    {"id":"49441","name":"Presentation - Proposal for DARWIN EU (Data Analytics and Real World Interrogation Network) (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T14:38:00Z","last_updated_date":"2020-12-04T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposal-darwin-eu-data-analytics-and-real-world-interrogation-network-parlett-ema_en.pdf"},
    {"id":"49442","name":"Presentation - Big data challenges - Patients perspectives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T14:38:00Z","last_updated_date":"2020-12-04T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-challenges-patients-perspectives_en.pdf"},
    {"id":"49443","name":"Presentation - Big data challenges - Academia perspectives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T14:38:00Z","last_updated_date":"2020-12-04T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-challenges-academia-perspectives_en.pdf"},
    {"id":"49444","name":"Presentation - EMA’s targeted consultation on data protection and secondary use of data for medicines and public health purposes - Summary of stakeholder survey (S.Brosch, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T14:38:00Z","last_updated_date":"2020-12-04T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-targeted-consultation-data-protection-and-secondary-use-data-medicines-and-public-health-purposes-summary-stakeholder-survey-sbrosch-ema_en.pdf"},
    {"id":"49445","name":"Presentation - Q&As on data protection and the secondary use of personal data for medicines development and public health purposes (O. Eotvos, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T14:38:00Z","last_updated_date":"2020-12-04T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qas-data-protection-and-secondary-use-personal-data-medicines-development-and-public-health-purposes-o-eotvos-ema_en.pdf"},
    {"id":"49457","name":"Presentation - EMA operational and procedural preparedness update (Alberto Ganan Jimenez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T13:27:00Z","last_updated_date":"2020-12-04T13:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-operational-and-procedural-preparedness-update-alberto-ganan-jimenez_en.pdf"},
    {"id":"49458","name":"Presentation - Updates on the Ireland and Northern Ireland Protocol implementation (Zigmars Sebris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T13:29:00Z","last_updated_date":"2020-12-04T13:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-ireland-and-northern-ireland-protocol-implementation-zigmars-sebris_en.pdf"},
    {"id":"49490","name":"Joint industry presentation - Industry stakeholders webinar on the UK withdrawal from the European Union","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-09T15:01:00Z","last_updated_date":"2020-12-09T15:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/joint-industry-presentation-industry-stakeholders-webinar-uk-withdrawal-european-union_en.pdf"},
    {"id":"49541","name":"Presentation - EU’s regulatory process for evaluation and approval of vaccines (Fergus Sweeney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eus-regulatory-process-evaluation-and-approval-vaccines-fergus-sweeney_en.pdf"},
    {"id":"49542","name":"Presentation - Safety monitoring of COVID-19 vaccines (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safety-monitoring-covid-19-vaccines-peter-arlett_en.pdf"},
    {"id":"49543","name":"Presentation - Transparency, engagement and communication (Melanie Carr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transparency-engagement-and-communication-melanie-carr_en.pdf"},
    {"id":"49544","name":"Presentation - How are COVID-19 vaccines developed? (Marco Cavaleri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-are-covid-19-vaccines-developed-marco-cavaleri_en.pdf"},
    {"id":"49552","name":"Presentation - SME Strategy for sustainable, digital and resilient industrial ecosystems in Europe (M. Nyman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T12:00:00Z","last_updated_date":"2020-12-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-strategy-sustainable-digital-and-resilient-industrial-ecosystems-europe-m-nyman_en.pdf"},
    {"id":"49553","name":"Presentation - SME participation in EU-funded research (S. Hogan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T10:19:00Z","last_updated_date":"2020-12-15T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-participation-eu-funded-research-s-hogan_en.pdf"},
    {"id":"49554","name":"Presentation - EIB support to the life science sector (Y. Zhang)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T12:00:00Z","last_updated_date":"2020-12-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eib-support-life-science-sector-y-zhang_en.pdf"},
    {"id":"49555","name":"Presentation - Key achievements of the EMA’s SME regulation (L. Enes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T12:00:00Z","last_updated_date":"2021-07-09T11:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-achievements-emas-sme-regulation-l-enes_en.pdf"},
    {"id":"49556","name":"Presentation - Supporting Innovation through Regulation and Science (L. O’Dwyer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T10:19:00Z","last_updated_date":"2020-12-15T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supporting-innovation-through-regulation-and-science-l-odwyer_en.pdf"},
    {"id":"49558","name":"Presentation - EMA SME Survey 2020 (C. Provansal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T12:00:00Z","last_updated_date":"2020-12-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-sme-survey-2020-c-provansal_en.pdf"},
    {"id":"49559","name":"Presentation - Orchard’s experience (D. Uguen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T12:00:00Z","last_updated_date":"2020-12-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orchards-experience-d-uguen_en.pdf"},
    {"id":"49560","name":"Presentation - Human medicines industry organisations - Session 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T12:00:00Z","last_updated_date":"2020-12-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-human-medicines-industry-organisations-session-3_en.pdf"},
    {"id":"49561","name":"Presentation - Veterinary medicines organisations (M. Saarteinen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T10:00:00Z","last_updated_date":"2020-12-15T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-medicines-organisations-m-saarteinen_en.pdf"},
    {"id":"49571","name":"Presentation - Laboratorios SYVA experience (C. Carnicer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T13:54:00Z","last_updated_date":"2020-12-15T13:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-laboratorios-syva-experience-c-carnicer_en.pdf"},
    {"id":"49573","name":"Presentation - c4c Business Continuity Planning (M. Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T14:27:00Z","last_updated_date":"2020-12-15T14:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-c4c-business-continuity-planning-m-turner_en.pdf"},
    {"id":"49574","name":"Presentation - c4c update for Enpr-EMA (M. Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T14:29:00Z","last_updated_date":"2020-12-15T14:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-c4c-update-enpr-ema-m-turner_en.pdf"},
    {"id":"49575","name":"Presentation - Providing high-quality care remotely to patients with Rare Bone Diseases during COVID-19 pandemic (L. Sangiorgi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T14:59:00Z","last_updated_date":"2020-12-15T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-providing-high-quality-care-remotely-patients-rare-bone-diseases-during-covid-19-pandemic-l-sangiorgi_en.pdf"},
    {"id":"49576","name":"Presentation - COVID-19 and Clinical Research in Canada (T. Lacaze)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:01:00Z","last_updated_date":"2020-12-15T15:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-and-clinical-research-canada-t-lacaze_en.pdf"},
    {"id":"49577","name":"Presentation - COVID-19 impact on paediatric clinical trials, and how to overcome the challenges. Can some new approaches be taken forward for future paediatric trials? Industry perspective (M. Dehlinger-Kremer, C. Ollivier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:03:00Z","last_updated_date":"2020-12-15T15:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-impact-paediatric-clinical-trials-and-how-overcome-challenges-can-some-new-approaches-be-taken-forward-future-paediatric-trials-industry-perspective-m-dehlinger-kremer-c-ollivier_en.pdf"},
    {"id":"49578","name":"Presentation - ERICA - ERN rare disease research coordination & support action (L. Sangiorgi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:08:00Z","last_updated_date":"2020-12-15T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-erica-ern-rare-disease-research-coordination-support-action-l-sangiorgi_en.pdf"},
    {"id":"49579","name":"Presentation - European Paediatric Translational Research Infrastructure (EPTRI) (D. Bonifazi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:10:00Z","last_updated_date":"2020-12-15T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-paediatric-translational-research-infrastructure-eptri-d-bonifazi_en.pdf"},
    {"id":"49580","name":"Presentation - Evaluation of the legislation on medicines for children and rare diseases (F. D’Atri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:16:00Z","last_updated_date":"2020-12-15T15:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluation-legislation-medicines-children-and-rare-diseases-f-datri_en.pdf"},
    {"id":"49581","name":"Presentation - Multi-Regional Clinical Trials (MRCT) Centerand its initiative on promoting global clinical research in children (D. Karres)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:20:00Z","last_updated_date":"2020-12-15T15:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multi-regional-clinical-trials-mrct-centerand-its-initiative-promoting-global-clinical-research-children-d-karres_en.pdf"},
    {"id":"49582","name":"Presentation - Multisystem inflammatory syndrome in children and adolescents (temporally related to COVID-19) (L. Fregonese)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:27:00Z","last_updated_date":"2020-12-15T15:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multisystem-inflammatory-syndrome-children-and-adolescents-temporally-related-covid-19-l-fregonese_en.pdf"},
    {"id":"49583","name":"Presentation - Pharmaceutical strategy for Europe (A. Rodiadis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:31:00Z","last_updated_date":"2020-12-15T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmaceutical-strategy-europe-rodiadis_en.pdf"},
    {"id":"49584","name":"Presentation - Preparedness for paediatric COVID vaccine trials (L. Fregonese)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:43:00Z","last_updated_date":"2020-12-15T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparedness-paediatric-covid-vaccine-trials-l-fregonese_en.pdf"},
    {"id":"49585","name":"Presentation - Enpr-EMA Annual Report 2019-2020 (P. Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:44:00Z","last_updated_date":"2020-12-15T15:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-annual-report-2019-2020-p-lepola_en.pdf"}    {"id":"49586","name":"Presentation - WG on clinical practice evidence in the labelling (S. de Wildt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:46:00Z","last_updated_date":"2020-12-15T15:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-wg-clinical-practice-evidence-labelling-s-de-wildt_en.pdf"},
    {"id":"49587","name":"Presentation - Enpr-EMA Nurse - Coordinator Working Group (V.O’Mahony, P. Dicks)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T15:49:00Z","last_updated_date":"2020-12-15T15:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-nurse-coordinator-working-group-vomahony-p-dicks_en.pdf"},
    {"id":"49610","name":"Presentation - Workshop on support for orphan medicines development: Academic perspective (Juan A. Bueren)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T16:16:00Z","last_updated_date":"2020-12-17T16:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-support-orphan-medicines-development-academic-perspective-juan-bueren_en.pdf"},
    {"id":"49611","name":"Presentation - Workshop on support for orphan medicines development: EMA support to SMEs and academia (Hélène Casaert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T16:21:00Z","last_updated_date":"2020-12-17T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-support-orphan-medicines-development-ema-support-smes-and-academia-helene-casaert_en.pdf"},
    {"id":"49612","name":"Presentation - Workshop on support for orphan medicines development: EMA supporting the orphan medicinal product development (Andrea Braun-Scherhag)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T16:23:00Z","last_updated_date":"2020-12-17T16:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-support-orphan-medicines-development-ema-supporting-orphan-medicinal-product-development-andrea-braun-scherhag_en.pdf"},
    {"id":"49613","name":"Presentation - Workshop on support for orphan medicines development: European joint programme on rare diseases (Daria Julkowska)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T16:26:00Z","last_updated_date":"2020-12-17T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-support-orphan-medicines-development-european-joint-programme-rare-diseases-daria-julkowska_en.pdf"},
    {"id":"49615","name":"Presentation - Workshop on support for orphan medicines development: International rare diseases research consortium (IRDiRC) drug development guidebook (Virginie Hivert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T16:29:00Z","last_updated_date":"2020-12-17T16:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-support-orphan-medicines-development-international-rare-diseases-research-consortium-irdirc-drug-development-guidebook-virginie-hivert_en.pdf"},
    {"id":"49616","name":"Presentation - Workshop on support for orphan medicines development: Orphan designation and orphan medicines in the EU (Frauke Naumann-Winter, Darius Matusevicius)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T16:35:00Z","last_updated_date":"2020-12-17T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-support-orphan-medicines-development-orphan-designation-and-orphan-medicines-eu-frauke-naumann-winter-darius-matusevicius_en.pdf"},
    {"id":"49617","name":"Presentation - Workshop on support for orphan medicines development: Protocol assistance, PRIME and parallel distribution (Armando Magrelli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T16:38:00Z","last_updated_date":"2020-12-17T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-support-orphan-medicines-development-protocol-assistance-prime-and-parallel-distribution-armando-magrelli_en.pdf"},
    {"id":"49618","name":"Presentation - Workshop on support for orphan medicines development: The patients’ perspective on the value of orphan designation (Nicolas Sireau)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T17:01:00Z","last_updated_date":"2020-12-17T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workshop-support-orphan-medicines-development-patients-perspective-value-orphan-designation-nicolas-sireau_en.pdf"},
    {"id":"49624","name":"Presentation - EU big data stakeholder virtual forum - Opening remarks (E.Cooke, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-opening-remarks-ecooke-ema_en.pdf"},
    {"id":"49625","name":"Presentation - EU big data stakeholder virtual forum - Opening remarks (European Health Data Space)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-opening-remarks-european-health-data-space_en.pdf"},
    {"id":"49626","name":"Presentation - EU big data stakeholder virtual forum - Implementation of the HMA-EMA Big Data Task Force priority recommendations (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-implementation-hma-ema-big-data-task-force-priority-recommendations-parlett-ema_en.pdf"},
    {"id":"49627","name":"Presentation - EU big data stakeholder virtual forum - Stakeholders' priorities (F.Domergue, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-stakeholders-priorities-fdomergue-ema_en.pdf"},
    {"id":"49628","name":"Presentation - EU big data stakeholder virtual forum - Patients' perspectives (EHN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-patients-perspectives-ehn_en.pdf"},
    {"id":"49629","name":"Presentation - EU big data stakeholder virtual forum - Consumers' perspectives (BEUC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-consumers-perspectives-beuc_en.pdf"},
    {"id":"49630","name":"Presentation - EU big data stakeholder virtual forum - Doctors' perspectives (EAACI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-doctors-perspectives-eaaci_en.pdf"},
    {"id":"49631","name":"Presentation - EU big data stakeholder virtual forum - Pharmacists' perspectives (University of Athens)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-pharmacists-perspectives-university-athens_en.pdf"},
    {"id":"49632","name":"Presentation - EU big data stakeholder virtual forum - Nurses' perspectives (ESN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-nurses-perspectives-esn_en.pdf"},
    {"id":"49633","name":"Presentation - EU big data stakeholder virtual forum - Pharmaceutical industry perspective (EuropaBio and EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-pharmaceutical-industry-perspective-europabio-and-efpia_en.pdf"},
    {"id":"49634","name":"Presentation - EU big data stakeholder virtual forum - Pharmaceutical industry perspective (EUCOPE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-pharmaceutical-industry-perspective-eucope_en.pdf"},
    {"id":"49635","name":"Presentation - EU big data stakeholder virtual forum - Pharmaceutical industry perspective (Medicines for Europe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-pharmaceutical-industry-perspective-medicines-europe_en.pdf"},
    {"id":"49636","name":"Presentation - EU big data stakeholder virtual forum - Pharmaceutical industry perspective (AESGP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-pharmaceutical-industry-perspective-aesgp_en.pdf"},
    {"id":"49637","name":"Presentation - EU big data stakeholder virtual forum - Medical technology industry perspective (MedTech Europe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-medical-technology-industry-perspective-medtech-europe_en.pdf"},
    {"id":"49638","name":"Presentation - EU big data stakeholder virtual forum - Researchers' perspective (ENCePP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-researchers-perspective-encepp_en.pdf"},
    {"id":"49639","name":"Presentation - EU big data stakeholder virtual forum - Academia perspective (EORTC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-academia-perspective-eortc_en.pdf"},
    {"id":"49640","name":"Presentation - EU big data stakeholder virtual forum - Concluding remarks (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-18T12:31:00Z","last_updated_date":"2020-12-18T12:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-big-data-stakeholder-virtual-forum-concluding-remarks-parlett-ema_en.pdf"},
    {"id":"49655","name":"Presentation - Big Data Steering Group: BDSG workplan update and DARWIN EU implementation approach","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T09:38:00Z","last_updated_date":"2020-12-21T09:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-steering-group-bdsg-workplan-update-and-darwin-eu-implementation-approach_en.pdf"},
    {"id":"49765","name":"Presentation - The European Commission’s role in the authorisation process and facilitation of roll-out vaccination (J.F. Ryan, DG SANTE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-11T10:31:00Z","last_updated_date":"2021-01-11T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-commissions-role-authorisation-process-and-facilitation-roll-out-vaccination-jf-ryan-dg-sante_en.pdf"},
    {"id":"49766","name":"Presentation - Basis for the EU approval of new vaccines (H.Enzmann, CHMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-11T10:31:00Z","last_updated_date":"2021-01-11T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-basis-eu-approval-new-vaccines-henzmann-chmp_en.pdf"},
    {"id":"49767","name":"Presentation - Ongoing actions for vaccine roll out at national level - Denmark as a case (N.Brun, HMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-11T10:31:00Z","last_updated_date":"2021-01-11T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ongoing-actions-vaccine-roll-out-national-level-denmark-case-nbrun-hma_en.pdf"},
    {"id":"49768","name":"Presentation - How the safety of the new COVID-19 vaccines will be monitored (S.Straus, PRAC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-11T10:31:00Z","last_updated_date":"2021-01-11T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-safety-new-covid-19-vaccines-will-be-monitored-sstraus-prac_en.pdf"},
    {"id":"49777","name":"Presentation - Fifth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines - Introduction (R.Cherif, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-12T17:56:00Z","last_updated_date":"2021-01-12T17:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fifth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines-introduction-rcherif-ema_en.pdf"},
    {"id":"49778","name":"Presentation - KPIs Centralised Procedure: Initial marketing authorization application and use of checklist (C.Blanc, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-12T17:56:00Z","last_updated_date":"2021-01-12T17:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-kpis-centralised-procedure-initial-marketing-authorization-application-and-use-checklist-cblanc-ema_en.pdf"},
    {"id":"49779","name":"Presentation - Reporting marketing status to EMA via IRIS (A.Ganan Jimenez, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-12T17:56:00Z","last_updated_date":"2021-01-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reporting-marketing-status-ema-iris-aganan-jimenez-ema_en.pdf"},
    {"id":"49780","name":"Presentation - EMA experience on eCPPs (A.Ganan Jimenez, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-12T17:56:00Z","last_updated_date":"2021-01-12T17:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-experience-ecpps-aganan-jimenez-ema_en.pdf"},
    {"id":"49781","name":"Presentation - Accelerating patients’ access to medicines that address unmet medical needs (V.Palmi, C.Pothet, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-12T17:56:00Z","last_updated_date":"2021-01-12T17:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accelerating-patients-access-medicines-address-unmet-medical-needs-vpalmi-cpothet-ema_en.pdf"},
    {"id":"49782","name":"Presentation - Working parties new operational model (T.Humphreys, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-12T17:56:00Z","last_updated_date":"2021-01-12T17:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-parties-new-operational-model-thumphreys-ema_en.pdf"},
    {"id":"49856","name":"Presentation - Welcome to the fifth industry stakeholder platform on research and development support (M.Berntgen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-welcome-fifth-industry-stakeholder-platform-research-and-development-support-mberntgen-ema_en.pdf"},
    {"id":"49857","name":"Presentation - Experience with the R&D stakeholder platform (M.Berntgen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-rd-stakeholder-platform-mberntgen-ema_en.pdf"},
    {"id":"49858","name":"Presentation - Reflections on iterative advice (V.Jekerle, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reflections-iterative-advice-vjekerle-ema_en.pdf"},
    {"id":"49859","name":"Presentation - First learnings from accelerated scientific advice for COVID 19 medicines (E.Manolis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-first-learnings-accelerated-scientific-advice-covid-19-medicines-emanolis-ema_en.pdf"},
    {"id":"49860","name":"Presentation - Experience from the pilot for tailored scientific advice on biosimilars (A.Baron, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-pilot-tailored-scientific-advice-biosimilars-abaron-ema_en.pdf"},
    {"id":"49861","name":"Presentation - Launch of IRIS for Scientific Advice (P.Tomasi, T.Toufexi, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-launch-iris-scientific-advice-ptomasi-ttoufexi-ema_en.pdf"},
    {"id":"49862","name":"Presentation - Follow-up on the practical arrangements regarding integrated drug-device combination products (A.Ritzhaupt, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-follow-practical-arrangements-regarding-integrated-drug-device-combination-products-aritzhaupt-ema_en.pdf"},
    {"id":"49863","name":"Presentation - Enhancement of the PRIME scheme (F.Cerreta, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enhancement-prime-scheme-fcerreta-ema_en.pdf"},
    {"id":"49864","name":"Presentation - EMA EC Action Plan on Paediatrics - Progress update (G.Egger, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-ec-action-plan-paediatrics-progress-update-gegger-ema_en.pdf"},
    {"id":"49865","name":"Presentation - Including patient preferences and patientreported outcomes in global development programmes, submissions and labels (F.Pignatti, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-including-patient-preferences-and-patientreported-outcomes-global-development-programmes-submissions-and-labels-fpignatti-ema_en.pdf"},
    {"id":"49866","name":"Presentation - Patient Engagement at EMA - Progressing the concept of patient-centered development in practice (N.Bere, J.Garcia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-engagement-ema-progressing-concept-patient-centered-development-practice-nbere-jgarcia-ema_en.pdf"},
    {"id":"49912","name":"Presentation - Welcome and introduction - Multi-stakeholder webinar to support implementation of the Medical Devices Regulation on drug-device combinations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T17:19:00Z","last_updated_date":"2021-01-22T17:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-welcome-introduction-multi-stakeholder-webinar-support-implementation-medical-devices-regulation-drug-device-combinations_en.pdf"},
    {"id":"49913","name":"Presentation - Team NB: Feedback on notified body opinions to date (Julia Frese, Jonathan Sutch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T17:21:00Z","last_updated_date":"2021-01-22T17:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-team-nb-feedback-notified-body-opinions-date-julia-frese-jonathan-sutch_en.pdf"},
    {"id":"49915","name":"Presentation - Lifecycle management: Substantial and non-substantial changes for drug-device combinations (Amanda Matthews, Tim Chesworth)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T17:30:00Z","last_updated_date":"2021-01-22T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lifecycle-management-substantial-and-non-substantial-changes-drug-device-combinations-amanda-matthews-tim-chesworth_en.pdf"},
    {"id":"49916","name":"Presentation - The notified body opinion: An assessor’s view (Maeve Lally)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T17:38:00Z","last_updated_date":"2021-01-22T17:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-notified-body-opinion-assessors-view-maeve-lally_en.pdf"},
    {"id":"49917","name":"Presentation - EMA considerations on lifecycle management in the context of Article 117 (Pascal Venneugues)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T17:41:00Z","last_updated_date":"2021-01-22T17:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-considerations-lifecycle-management-context-article-117-pascal-venneugues_en.pdf"},
    {"id":"49918","name":"Presentation - The notified body opinion: Industry experiences (Bjorg Hunter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T18:10:00Z","last_updated_date":"2021-01-22T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-notified-body-opinion-industry-experiences-bjorg-hunter_en.pdf"},
    {"id":"50301","name":"Presentation - CTIS benefits - SME and Academia Clinical Trials Information System (CTIS) training (F.Sweeney, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T16:59:00Z","last_updated_date":"2021-02-26T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-benefits-sme-and-academia-clinical-trials-information-system-ctis-training-fsweeney-ema_en.pdf"},
    {"id":"50307","name":"Presentation - Clinical Trials Regulation, what is changing in practice - SME and Academia Clinical Trials Information System (CTIS) training (S.Kromar, EORTC))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T16:59:00Z","last_updated_date":"2021-02-26T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-regulation-what-changing-practice-sme-and-academia-clinical-trials-information-system-ctis-training-skromar-eortc_en.pdf"},
    {"id":"50308","name":"Presentation - Sponsor user management - SME and Academia Clinical Trials Information System (CTIS) training (S.Kromar, EORTC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T16:59:00Z","last_updated_date":"2021-02-26T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sponsor-user-management-sme-and-academia-clinical-trials-information-system-ctis-training-skromar-eortc_en.pdf"},
    {"id":"50309","name":"Presentation - User access management - SME and Academia Clinical Trials Information System (CTIS) training (A.Rodriquez, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T16:59:00Z","last_updated_date":"2021-02-26T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-user-access-management-sme-and-academia-clinical-trials-information-system-ctis-training-arodriquez-ema_en.pdf"},
    {"id":"50310","name":"Presentation - Introduction to Clinical Trials Regulation - SME and Academia Clinical Trials Information System (CTIS) training (A.Mathieu-Mendes, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T16:59:00Z","last_updated_date":"2021-02-26T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-clinical-trials-regulation-sme-and-academia-clinical-trials-information-system-ctis-training-amathieu-mendes-ec_en.pdf"},
    {"id":"50311","name":"Presentation - Overview of CTIS - SME and Academia Clinical Trials Information System (CTIS) training","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T16:59:00Z","last_updated_date":"2021-02-26T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-ctis-sme-and-academia-clinical-trials-information-system-ctis-training_en.pdf"},
    {"id":"50312","name":"Presentation - Sponsor roles and permissions in CTIS - SME and Academia Clinical Trials Information System (CTIS) training (A.Rodriguez, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T16:59:00Z","last_updated_date":"2021-02-26T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sponsor-roles-and-permissions-ctis-sme-and-academia-clinical-trials-information-system-ctis-training-arodriguez-ema_en.pdf"},
    {"id":"50313","name":"Presentation - Trial centric and organisation centric approach in CTIS - SME and Academia Clinical Trials Information System (CTIS) training (A.Seidel-Glätzer, University Hospital Heidelberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T16:59:00Z","last_updated_date":"2021-02-26T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-trial-centric-and-organisation-centric-approach-ctis-sme-and-academia-clinical-trials-information-system-ctis-training-aseidel-glatzer-university-hospital-heidelberg_en.pdf"},
    {"id":"50379","name":"Presentation - Sponsor activities during the life cycle of a clinical trial: submission of notifications (Stéphanie Kromar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-03T16:11:00Z","last_updated_date":"2021-03-03T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sponsor-activities-during-life-cycle-clinical-trial-submission-notifications-stephanie-kromar_en.pdf"},
    {"id":"50380","name":"Presentation - Submission of an initial Clinical Trial Application in CTIS – structure, data and documents of an initial application dossier (Laura Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-03T16:13:00Z","last_updated_date":"2021-03-03T16:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-submission-initial-clinical-trial-application-ctis-structure-data-and-documents-initial-application-dossier-laura-pioppo_en.pdf"},
    {"id":"50381","name":"Presentation - Submission of trial results and layperson summary (Andrea Seidel Glätzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-03T16:16:00Z","last_updated_date":"2021-03-03T16:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-submission-trial-results-and-layperson-summary-andrea-seidel-glatzer_en.pdf"},
    {"id":"50382","name":"Presentation - Transparency publication of clinical trial information contained in CTIS (Laura Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-03T16:17:00Z","last_updated_date":"2021-03-03T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transparency-publication-clinical-trial-information-contained-ctis-laura-pioppo_en.pdf"},
    {"id":"50383","name":"Presentation - Changes done to an application via NON SM and RFI responses (Laura Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-03T16:19:00Z","last_updated_date":"2021-03-03T16:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-changes-done-application-non-sm-and-rfi-responses-laura-pioppo_en.pdf"},
    {"id":"50384","name":"Presentation - Update of an initial application (Laura Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-03T16:22:00Z","last_updated_date":"2021-03-03T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-initial-application-laura-pioppo_en.pdf"},
    {"id":"50385","name":"Presentation - Work planning and management tools (Stéphanie Kromar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-03T16:26:00Z","last_updated_date":"2021-03-03T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-work-planning-and-management-tools-stephanie-kromar_en.pdf"},
    {"id":"50445","name":"Presentation - Towards European health data space (Martin Dorazil)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:02:00Z","last_updated_date":"2021-03-05T14:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-towards-european-health-data-space-martin-dorazil_en.pdf"},
    {"id":"50446","name":"Presentation - Role of the European Health Data Space (EHDS) in the German presidency (A. Brandes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:06:00Z","last_updated_date":"2021-03-05T14:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-european-health-data-space-ehds-german-presidency-brandes_en.pdf"},
    {"id":"50447","name":"Presentation - Towards European Health Data Space Joint Action (TEHDAS) for the European Health Data Space (Markus Kalliola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:08:00Z","last_updated_date":"2021-03-05T14:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-towards-european-health-data-space-joint-action-tehdas-european-health-data-space-markus-kalliola_en.pdf"},
    {"id":"50448","name":"Presentation - Brief Introduction to EMA’s survey (Sabine Brosch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:20:00Z","last_updated_date":"2021-03-05T14:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-brief-introduction-emas-survey-sabine-brosch_en.pdf"},
    {"id":"50449","name":"Presentation -  General Data Protection Regulation (GDPR): ESMO’S concerns (Paolo Casali)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:23:00Z","last_updated_date":"2021-03-05T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-general-data-protection-regulation-gdpr-esmos-concerns-paolo-casali_en.pdf"},
    {"id":"50451","name":"Presentation - Academia feedback General Data Protection Regulation (GDPR) and secondary data use","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:28:00Z","last_updated_date":"2021-03-05T14:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-academia-feedback-general-data-protection-regulation-gdpr-and-secondary-data-use_en.pdf"},
    {"id":"50455","name":"Presentation - Questions and answers on data protection and the secondary use of personal data for medicines development and public health purposes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:32:00Z","last_updated_date":"2021-03-05T14:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-questions-and-answers-data-protection-and-secondary-use-personal-data-medicines-development-and-public-health-purposes_en.pdf"},
    {"id":"50459","name":"Presentation - Secondary use of personal data for medicines development (Martijn Ten Bloemendal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T14:37:00Z","last_updated_date":"2021-03-05T14:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-secondary-use-personal-data-medicines-development-martijn-ten-bloemendal_en.pdf"},
    {"id":"50511","name":"Presentation - ENCePP webinar for Academia -Real world research on medicines (X. Kurz, F.Salvo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:55:00Z","last_updated_date":"2021-03-10T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-encepp-webinar-academia-real-world-research-medicines-x-kurz-fsalvo-ema_en.pdf"},
    {"id":"50512","name":"Presentation - The EU register of post-authorisation studies: why is it important to register studies and lessons learned? (G.Trifiro, FISPE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:55:00Z","last_updated_date":"2021-03-10T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-register-post-authorisation-studies-why-it-important-register-studies-and-lessons-learned-gtrifiro-fispe_en.pdf"},
    {"id":"50513","name":"Presentation - How can ENCePP contribute to research? Experience from an EU academic (J.Overbeek, PHARMO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:55:00Z","last_updated_date":"2021-03-10T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-can-encepp-contribute-research-experience-eu-academic-joverbeek-pharmo_en.pdf"},
    {"id":"50514","name":"Presentation - How can ENCePP contribute to research? Experience from a non-EU academics (K.A. Chan, NTUDHRC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:55:00Z","last_updated_date":"2021-03-10T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-can-encepp-contribute-research-experience-non-eu-academics-ka-chan-ntudhrc_en.pdf"},
    {"id":"50515","name":"Presentation - ENCePP and COVID-19: Consideration on good practice in observational research on COVID-19 (H. Gardarsdottir, Utrecht University)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:55:00Z","last_updated_date":"2021-03-10T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-encepp-and-covid-19-consideration-good-practice-observational-research-covid-19-h-gardarsdottir-utrecht-university_en.pdf"},
    {"id":"50516","name":"Presentation - ENCePP and Covid 19: How does ENCePP contribute to the monitoring of therapeutics and vaccines? (D. Prieto-Alhambra, EHDEN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:55:00Z","last_updated_date":"2021-03-10T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-encepp-and-covid-19-how-does-encepp-contribute-monitoring-therapeutics-and-vaccines-d-prieto-alhambra-ehden_en.pdf"},
    {"id":"50517","name":"Presentation - What has ENCePP achieved and what is next (S. Perez-Gutthann, G. Candore, ENCePP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-10T11:55:00Z","last_updated_date":"2021-03-10T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-has-encepp-achieved-and-what-next-s-perez-gutthann-g-candore-encepp_en.pdf"},
    {"id":"50615","name":"Presentation - Update on COVID-19 vaccines and therapeutics (M.Cavaleri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-covid-19-vaccines-and-therapeutics-mcavaleri-ema_en.pdf"},
    {"id":"50616","name":"Presentation - Pharmacovigilance and public safety updates for COVID-19 vaccines (G.Genov, P.Bahri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-and-public-safety-updates-covid-19-vaccines-ggenov-pbahri-ema_en.pdf"},
    {"id":"50617","name":"Presentation - COVID-19 vaccines outreach strategy (M.Carr, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-vaccines-outreach-strategy-mcarr-ema_en.pdf"},
    {"id":"50618","name":"Presentation - EMA's third public stakeholder meeting (N.Bere, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-third-public-stakeholder-meeting-nbere-ema_en.pdf"},
    {"id":"50619","name":"Presentation - The European Reference Network model in the European Data Space: Potential collaboration between European research networks and EMA (J.Llinares Garcia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-reference-network-model-european-data-space-potential-collaboration-between-european-research-networks-and-ema-jllinares-garcia-ema_en.pdf"},
    {"id":"50620","name":"Presentation - The European Reference Network model in the European Data Space: European Joint Programme on Rare Diseases (R.Nabbout, APHP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-reference-network-model-european-data-space-european-joint-programme-rare-diseases-rnabbout-aphp_en.pdf"},
    {"id":"50621","name":"Presentation - Timely patient access to Advanced Therapy Medicinal Products (ATMPs) (M.Schüssler-Lenz, CAT)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-timely-patient-access-advanced-therapy-medicinal-products-atmps-mschussler-lenz-cat_en.pdf"},
    {"id":"50622","name":"Presentation - Personalised medicine approaches for the next generation of medicines (E.Moltzen, IC PerMed)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-personalised-medicine-approaches-next-generation-medicines-emoltzen-ic-permed_en.pdf"},
    {"id":"50623","name":"Presentation - Implementation of HMA-EMA Big Data Steering Group deliverables (P.Arlett, EMA; N.Brun, DKMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-hma-ema-big-data-steering-group-deliverables-parlett-ema-nbrun-dkma_en.pdf"},
    {"id":"50624","name":"Presentation - Good Clinical Practice (F.Sweeney, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-clinical-practice-fsweeney-ema_en.pdf"},
    {"id":"50625","name":"Presentation - EMA/FDA Patient-Focused Drug Development ICH Reflection Paper (M.Bonelli, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emafda-patient-focused-drug-development-ich-reflection-paper-mbonelli-ema_en.pdf"},
    {"id":"50626","name":"Presentation - Satisfaction survey:  What fo the 2020 results tell us? (M.Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-17T14:58:00Z","last_updated_date":"2021-03-17T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-satisfaction-survey-what-fo-2020-results-tell-us-mmavris-ema_en.pdf"},
    {"id":"50731","name":"Presentation - Update on approved and candidate COVID-19 vaccines in the EU (M.Cavaleri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-29T14:52:00Z","last_updated_date":"2021-03-29T14:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-approved-and-candidate-covid-19-vaccines-eu-mcavaleri-ema_en.pdf"},
    {"id":"50732","name":"Presentation - COVID-19 vaccines safety monitoring (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-29T14:52:00Z","last_updated_date":"2021-03-29T14:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-vaccines-safety-monitoring-parlett-ema_en.pdf"},
    {"id":"50733","name":"Presentation - Expected impact of COVID-19 vaccination in the European Union (E.Colzani, ECDC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-29T14:52:00Z","last_updated_date":"2021-03-29T14:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-expected-impact-covid-19-vaccination-european-union-ecolzani-ecdc_en.pdf"}    {"id":"50734","name":"Presentation - Transparency and publication of clinical data for COVID-19 vaccines (M.Carr,  EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-03-29T14:52:00Z","last_updated_date":"2021-03-29T14:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transparency-and-publication-clinical-data-covid-19-vaccines-mcarr-ema_en.pdf"},
    {"id":"50787","name":"Presentation - Veterinary Medicinal Products Regulation (VMP-Reg) (EU) 2019/6 Pharmacovigilance and the Veterinarian (J. Olaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-09T15:38:00Z","last_updated_date":"2021-04-09T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-medicinal-products-regulation-vmp-reg-eu-20196-pharmacovigilance-and-veterinarian-j-olaerts_en.pdf"},
    {"id":"50788","name":"Presentation - PhV reporting - EV VET3 - Implementation (L. Descalzo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-09T15:40:00Z","last_updated_date":"2021-04-09T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-phv-reporting-ev-vet3-implementation-l-descalzo_en.pdf"},
    {"id":"50792","name":"Presentation - Means of operation and interaction","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-12T15:32:00Z","last_updated_date":"2021-04-12T15:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-means-operation-and-interaction_en.pdf"},
    {"id":"50793","name":"Presentation - Workplan and topics for QWP and SWP IP Meetings","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-12T15:46:00Z","last_updated_date":"2021-04-12T15:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-workplan-and-topics-qwp-and-swp-ip-meetings_en.pdf"},
    {"id":"50841","name":"Presentation - EMA implementation activities and preparedness (I. Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T17:39:00Z","last_updated_date":"2021-04-14T17:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-implementation-activities-and-preparedness-i-claassen_en.pdf"},
    {"id":"50842","name":"Presentation - EU Regulation 2019/6: towards 28 January 2022 - Industry perspective (E. Waterdrinker, E. Motte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T17:41:00Z","last_updated_date":"2021-04-14T17:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-regulation-20196-towards-28-january-2022-industry-perspective-e-waterdrinker-e-motte_en.pdf"},
    {"id":"50843","name":"Presentation - The VMP Regulation in 2022 and beyond (E. Zamora Escribano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T17:44:00Z","last_updated_date":"2021-04-14T17:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vmp-regulation-2022-and-beyond-e-zamora-escribano_en.pdf"},
    {"id":"50844","name":"Presentation - CVMP update on activities relating to Regulation 2019/6 (D. Murphy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T17:47:00Z","last_updated_date":"2021-04-14T17:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-update-activities-relating-regulation-20196-d-murphy_en.pdf"},
    {"id":"50845","name":"Presentation - CMDv work on the implementation of the VMP Regulation (L. Le Letty)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T17:48:00Z","last_updated_date":"2021-04-14T17:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cmdv-work-implementation-vmp-regulation-l-le-letty_en.pdf"},
    {"id":"50846","name":"Presentation - Regulatory Science Strategy (RSS) and European Medicines Agencies network strategy to 2025 (J. Torren Edo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T17:49:00Z","last_updated_date":"2021-04-14T17:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-science-strategy-rss-and-european-medicines-agencies-network-strategy-2025-j-torren-edo_en.pdf"},
    {"id":"50847","name":"Presentation - Regulatory Science Strategy and European medicines agencies network strategy to 2025 - Industry perspective (C. Stirling)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T17:51:00Z","last_updated_date":"2021-04-14T17:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-science-strategy-and-european-medicines-agencies-network-strategy-2025-industry-perspective-c-stirling_en.pdf"},
    {"id":"50848","name":"Presentation - What’s new in Annex II: Scientific developments (S. Girault, N. Garcia del Blanco, J. Pozo Gonzalez, B. Cyrus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T17:54:00Z","last_updated_date":"2021-04-14T17:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-whats-new-annex-ii-scientific-developments-s-girault-n-garcia-del-blanco-j-pozo-gonzalez-b-cyrus_en.pdf"},
    {"id":"50849","name":"Presentation - Update on pharmacovigilance, signal detection and surveillance (J. Olaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T18:00:00Z","last_updated_date":"2021-04-14T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-pharmacovigilance-signal-detection-and-surveillance-j-olaerts_en.pdf"},
    {"id":"50850","name":"Presentation - Update on pharmacovigilance, signal detection and surveillance - Industry perspective (R. van Lieshout)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T18:01:00Z","last_updated_date":"2021-04-14T18:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-pharmacovigilance-signal-detection-and-surveillance-industry-perspective-r-van-lieshout_en.pdf"},
    {"id":"50851","name":"Presentation - Antimicrobials: status update (A. Vidal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T18:03:00Z","last_updated_date":"2021-04-14T18:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antimicrobials-status-update-vidal_en.pdf"},
    {"id":"51069","name":"Presentation - International Coalition of Medicines Regulatory Authority (ICMRA) - Artificial intelligence recommendation (Agnes Saint-Raymond)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T14:56:00Z","last_updated_date":"2021-05-05T14:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-coalition-medicines-regulatory-authority-icmra-artificial-intelligence-recommendation-agnes-saint-raymond_en.pdf"},
    {"id":"51070","name":"Presentation - Artificial Intelligence to improve the lives of patients (Andre Dekker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T15:14:00Z","last_updated_date":"2021-05-05T15:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-artificial-intelligence-improve-lives-patients-andre-dekker_en.pdf"},
    {"id":"51071","name":"Presentation - Translating a trillion points of data into real world evidence and enabled intelligence for medicine (Atul Butte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T15:18:00Z","last_updated_date":"2021-05-05T15:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-translating-trillion-points-data-real-world-evidence-and-enabled-intelligence-medicine-atul-butte_en.pdf"},
    {"id":"51072","name":"Presentation - Company experience of using artificial intelligence to aid drug development (Boris Braylyan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T15:22:00Z","last_updated_date":"2021-05-05T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-company-experience-using-artificial-intelligence-aid-drug-development-boris-braylyan_en.pdf"},
    {"id":"51073","name":"Presentation - Big Data Taskforce recommendations and regulatory science strategy on artificial intelligence (Gianmario Candore)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T15:24:00Z","last_updated_date":"2021-05-05T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-taskforce-recommendations-and-regulatory-science-strategy-artificial-intelligence-gianmario-candore_en.pdf"},
    {"id":"51074","name":"Presentation - EMA's network strategy to 2025 - Strategy for digital transformation (Jesper Kjær)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T15:28:00Z","last_updated_date":"2021-05-05T15:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-network-strategy-2025-strategy-digital-transformation-jesper-kjaer_en.pdf"},
    {"id":"51077","name":"Presentation - Artificial intelligence and digitalisation at EMA (Joaquim Jornet, Florence Butlen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T15:34:00Z","last_updated_date":"2021-05-05T15:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-artificial-intelligence-and-digitalisation-ema-joaquim-jornet-florence-butlen_en.pdf"},
    {"id":"51078","name":"Presentation - Big data training survey (Jörg Zinserling)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T16:03:00Z","last_updated_date":"2021-05-05T16:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-training-survey-jorg-zinserling_en.pdf"},
    {"id":"51079","name":"Presentention - Artificial intelligence in therapeutic development - A policy perspective (Khair El Zarrad)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T16:08:00Z","last_updated_date":"2021-05-05T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentention-artificial-intelligence-therapeutic-development-policy-perspective-khair-el-zarrad_en.pdf"},
    {"id":"51080","name":"Presentation - Artificial intelligence, digital twins and the promise of personalised medicine (Liesbet Geris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T16:17:00Z","last_updated_date":"2021-05-05T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-artificial-intelligence-digital-twins-and-promise-personalised-medicine-liesbet-geris_en.pdf"},
    {"id":"51081","name":"Presentation - Novel methods in pharmacovigilance - Use cases in VigiBase (Lucie Gattepaille)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T16:21:00Z","last_updated_date":"2021-05-05T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-novel-methods-pharmacovigilance-use-cases-vigibase-lucie-gattepaille_en.pdf"},
    {"id":"51082","name":"Presentation - Putting machine learning into real-world practice patient-level prediction development and validation in observational data (Peter Rijnbeek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T16:28:00Z","last_updated_date":"2021-05-05T16:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-putting-machine-learning-real-world-practice-patient-level-prediction-development-and-validation-observational-data-peter-rijnbeek_en.pdf"},
    {"id":"51084","name":"Presentation - Artificial intelligence in medical devices and digital healthcare applications – the BfArM perspective (Wolfgang Lauer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T16:33:00Z","last_updated_date":"2021-05-05T16:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-artificial-intelligence-medical-devices-digital-healthcare-applications-bfarm-perspective-wolfgang-lauer_en.pdf"},
    {"id":"51113","name":"Presentation - Technical workshop on real-world metadata for regulatory purposes - Opening remarks (Nikolai Brun)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T12:54:00Z","last_updated_date":"2021-05-10T12:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-technical-workshop-real-world-metadata-regulatory-purposes-opening-remarks-nikolai-brun_en.pdf"},
    {"id":"51114","name":"Presentation - Overview of the project Metadata for data dIscoverabilityaNdstudy rEplicabilityin obseRVAtionalstudies (MINERVA) (EMA/2017/09/PE/16) (Susana Perez-Gutthann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T12:56:00Z","last_updated_date":"2021-05-10T12:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-project-metadata-data-discoverabilityandstudy-replicabilityin-observationalstudies-minerva-ema201709pe16-susana-perez-gutthann_en.pdf"},
    {"id":"51115","name":"Presentation - Overview of the HMA-EMA Big Data Taskforce priority 3: recommendation to enable data discoverability (Stefania Simou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T12:57:00Z","last_updated_date":"2021-05-10T12:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-hma-ema-big-data-taskforce-priority-3-recommendation-enable-data-discoverability-stefania-simou_en.pdf"},
    {"id":"51116","name":"Presentation - Stakeholders feedback from pre-meeting survey: Session 1 Feedback process overview (Susana Perez-Gutthann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T14:09:00Z","last_updated_date":"2021-05-10T14:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stakeholders-feedback-pre-meeting-survey-session-1-feedback-process-overview-susana-perez-gutthann_en.pdf"},
    {"id":"51117","name":"Presentation - Session 1: Overview of the regulatory use case (Romin Pajouheshnia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T14:10:00Z","last_updated_date":"2021-05-10T14:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-overview-regulatory-use-case-romin-pajouheshnia_en.pdf"},
    {"id":"51118","name":"Presentation - Session 1: Overview of the regulatory use case (Romin Pajouheshnia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T14:17:00Z","last_updated_date":"2021-05-10T14:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-overview-regulatory-use-case-romin-pajouheshnia_en.pptx"},
    {"id":"51119","name":"Presentation - Session 1: Conceptual framework (Rosa Gini)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T14:19:00Z","last_updated_date":"2021-05-10T14:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-conceptual-framework-rosa-gini_en.pdf"},
    {"id":"51120","name":"Presentation - Session 2: Preliminary list of metadata (Romin Pajouheshnia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T14:21:00Z","last_updated_date":"2021-05-10T14:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-preliminary-list-metadata-romin-pajouheshnia_en.pdf"},
    {"id":"51121","name":"Presentation - Session 2: Stakeholders feedback from pre-meeting survey: metadata (Romin Pajouheshnia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T14:25:00Z","last_updated_date":"2021-05-10T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-stakeholders-feedback-pre-meeting-survey-metadata-romin-pajouheshnia_en.pdf"},
    {"id":"51122","name":"Presentation - Session 3: FAIR catalogue sustainability (Miriam Sturkenboom)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T14:27:00Z","last_updated_date":"2021-05-10T14:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-fair-catalogue-sustainability-miriam-sturkenboom_en.pdf"},
    {"id":"51123","name":"Presentation - Session 3: Stakeholders feedback from pre-meeting survey: sustainability & collection","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T16:11:00Z","last_updated_date":"2021-05-10T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-stakeholders-feedback-pre-meeting-survey-sustainability-collection_en.pdf"},
    {"id":"51124","name":"Presentation - Session 4: Preliminary proof-of-concept catalogue tool (Morris Swertz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T16:12:00Z","last_updated_date":"2021-05-10T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-preliminary-proof-concept-catalogue-tool-morris-swertz_en.pdf"},
    {"id":"51125","name":"Presentation - Session 4: Stakeholders feedback from pre-meeting survey: proof-of concept catalogue tool (Morris Swertz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-10T16:14:00Z","last_updated_date":"2021-05-10T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-stakeholders-feedback-pre-meeting-survey-proof-concept-catalogue-tool-morris-swertz_en.pdf"},
    {"id":"51234","name":"Presentation - Data initiatives in the veterinary domain (I. Del Seppia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-initiatives-veterinary-domain-i-del-seppia-ema_en.pdf"},
    {"id":"51235","name":"Presentation - Importance of Data Standards in the European Health Data Space (L. Kustra-Mano, DG SANTE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-importance-data-standards-european-health-data-space-l-kustra-mano-dg-sante_en.pdf"},
    {"id":"51236","name":"Presentation - Overview of the HMA EMA Big Data Taskforce priority 9 and the need for the EMRN Data Standardisation Strategy (J. Kjær, Danish Medicines Agency)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-hma-ema-big-data-taskforce-priority-9-and-need-emrn-data-standardisation-strategy-j-kjaer-danish-medicines-agency_en.pdf"},
    {"id":"51237","name":"Presentation - Session 1: EMRN Data Standardisation Strategy development process and status (N. Halsey, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-emrn-data-standardisation-strategy-development-process-and-status-n-halsey-ema_en.pdf"},
    {"id":"51238","name":"Presentation - Session 1: Potential synergies from existing standards and projects CDISC (D. Evans, CDISC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-potential-synergies-existing-standards-and-projects-cdisc-d-evans-cdisc_en.pdf"},
    {"id":"51240","name":"Presentation - Session 1: Potential synergies from existing standards and projects EHDEN OHDSI (P. Rijnbeek, EHDEN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-potential-synergies-existing-standards-and-projects-ehden-ohdsi-p-rijnbeek-ehden_en.pdf"},
    {"id":"51241","name":"Presentation - Session 1: Potential synergies from existing standards and projects HL7 (W. Kubick, HL7 International)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-potential-synergies-existing-standards-and-projects-hl7-w-kubick-hl7-international_en.pdf"},
    {"id":"51242","name":"Presentation - Session 1: Potential synergies from existing standards and projects ISO CEN (C. Hay, GS1)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-potential-synergies-existing-standards-and-projects-iso-cen-c-hay-gs1_en.pdf"},
    {"id":"51243","name":"Presentation - Session 1: Potential synergies from existing standards and projects TEHDAS (E. Bernal Delgado, IACS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-potential-synergies-existing-standards-and-projects-tehdas-e-bernal-delgado-iacs_en.pdf"},
    {"id":"51244","name":"Presentation - Session 1: Stakeholder consultation (preliminary) main highlights (N. Halsey, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-stakeholder-consultation-preliminary-main-highlights-n-halsey-ema_en.pdf"},
    {"id":"51245","name":"Presentation - Session 2: Stakeholder perspective - European Network Data Board (P. Bachman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-stakeholder-perspective-european-network-data-board-p-bachman_en.pdf"},
    {"id":"51246","name":"Presentation - Session 2: Stakeholder perspective and use cases - Patients Consumers (M. Vrana, EHN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-stakeholder-perspective-and-use-cases-patients-consumers-m-vrana-ehn_en.pdf"},
    {"id":"51247","name":"Presentation - Session 2: Stakeholder perspective and use cases - Pharmaceutical industry EFPIA EuropaBio (V. Perkins)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-stakeholder-perspective-and-use-cases-pharmaceutical-industry-efpia-europabio-v-perkins_en.pdf"},
    {"id":"51248","name":"Presentation - Session 2: Stakeholder perspective and use cases - Pharmaceutical industry EUCOPE (T. Case, M. Ericson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-stakeholder-perspective-and-use-cases-pharmaceutical-industry-eucope-t-case-m-ericson_en.pdf"},
    {"id":"51249","name":"Presentation - Session 2: Stakeholder perspective and use cases - Pharmaceutical industry Medicines for Europe (K. Zou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-stakeholder-perspective-and-use-cases-pharmaceutical-industry-medicines-europe-k-zou_en.pdf"},
    {"id":"51250","name":"Presentation - Session 2: Stakeholder perspective and use cases - Researchers (J-W. Boiten)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-21T17:03:00Z","last_updated_date":"2021-05-21T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-stakeholder-perspective-and-use-cases-researchers-j-w-boiten_en.pdf"},
    {"id":"51258","name":"Instructor exercise: How to evaluate an Initial clinical trial application: Assessment and decision CTIS training programme - Module 08","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-05-25T16:15:00Z","last_updated_date":"2021-05-25T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/instructor-exercise-how-evaluate-initial-clinical-trial-application-assessment-and-decision-ctis-training-programme-module-08_en.pptx"},
    {"id":"51352","name":"Presentation - Session 2: Stakeholder perspective and use cases healthcare professionals (I. Agache)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-03T11:42:00Z","last_updated_date":"2021-06-03T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-stakeholder-perspective-and-use-cases-healthcare-professionals-i-agache_en.pdf"},
    {"id":"51375","name":"Presentation - EC’s legal proposal for EMA’s reinforced role in crisis preparedness and how it fits with other EC strategic initiatives (A.Rys, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:54:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ecs-legal-proposal-emas-reinforced-role-crisis-preparedness-and-how-it-fits-other-ec-strategic-initiatives-arys-ec_en.pdf"},
    {"id":"51376","name":"Presentation - How is EMA preparing for an extended mandate (N.Wathion, Z.Frias, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:54:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-ema-preparing-extended-mandate-nwathion-zfrias-ema_en.pdf"},
    {"id":"51377","name":"Presentation - COVID 19 vaccines and therapeutics - An update to the PCWP/HCPWP (M.Cavaleri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:54:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-vaccines-and-therapeutics-update-pcwphcpwp-mcavaleri-ema_en.pdf"},
    {"id":"51378","name":"Presentation - Monitoring the safety of COVID-19 vaccines using real-world data (C.Cohet, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:54:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-safety-covid-19-vaccines-using-real-world-data-ccohet-ema_en.pdf"},
    {"id":"51379","name":"Presentation - COVID-19 vaccines safety surveillance (G.Genov, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:54:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-vaccines-safety-surveillance-ggenov-ema_en.pdf"},
    {"id":"51380","name":"Presentation - Survey results of patient representatives attending Scientific Advisory Groups or Ad Hoc Expert Meetings (S.Groeneveld, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:54:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-results-patient-representatives-attending-scientific-advisory-groups-or-ad-hoc-expert-meetings-sgroeneveld-ema_en.pdf"},
    {"id":"51381","name":"Presentation - Scientific Advisory Groups (SAGs) re-nominations (F.Pignatti, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:54:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advisory-groups-sags-re-nominations-fpignatti-ema_en.pdf"},
    {"id":"51382","name":"Presentation - Recent progress on data and analytics and looking to the future (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:54:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recent-progress-data-and-analytics-and-looking-future-parlett-ema_en.pdf"},
    {"id":"51383","name":"Presentation - EMA’s Regulatory Science Research Agenda (L.Liu, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:54:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-regulatory-science-research-agenda-lliu-ema_en.pdf"},
    {"id":"51384","name":"Presentation - Electronic Product Information (ePI) for EU medicines (E.Scanlan, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:54:00Z","last_updated_date":"2021-06-07T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-electronic-product-information-epi-eu-medicines-escanlan-ema_en.pdf"},
    {"id":"51393","name":"Presentation - Veterinary Big Data stakeholder forum - Stakeholder's perspective (J. van de Ven)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-big-data-stakeholder-forum-stakeholders-perspective-j-van-de-ven_en.pdf"},
    {"id":"51394","name":"Presentation - The veterinary profession and big data: a growing partnership (N. De Briyne, FVE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-profession-and-big-data-growing-partnership-n-de-briyne-fve_en.pdf"},
    {"id":"51395","name":"Presentation - Precision livestock farming (J. Lübbo Kleen, CowConsult)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-precision-livestock-farming-j-lubbo-kleen-cowconsult_en.pdf"},
    {"id":"51396","name":"Presentation - Veterinary use of Big Data (E. Strömfelt,  U. Göggerle, AniCura Group)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-use-big-data-e-stromfelt-u-goggerle-anicura-group_en.pdf"},
    {"id":"51397","name":"Presentation - Use of big data in regulatory medicine (E.Tatone, Health Canada)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-big-data-regulatory-medicine-etatone-health-canada_en.pdf"},
    {"id":"51398","name":"Presentation - Community for emerging and zoonotic diseases (A.Osborn, CEZD)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-community-emerging-and-zoonotic-diseases-aosborn-cezd_en.pdf"},
    {"id":"51399","name":"Presentation - Big Data at the FDA Center for Veterinary Medicine (E.Strain, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-fda-center-veterinary-medicine-estrain-fda_en.pdf"},
    {"id":"51400","name":"Presentation - Data driven surveillance (F.Dórea, SVA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-driven-surveillance-fdorea-sva_en.pdf"},
    {"id":"51401","name":"Presentation - Update on big data activities (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-big-data-activities-parlett-ema_en.pdf"},
    {"id":"51402","name":"Presentation - Big data in antimicrobial use and biosecurity in animal production (J.Dewulf, Ghent University)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-antimicrobial-use-and-biosecurity-animal-production-jdewulf-ghent-university_en.pdf"},
    {"id":"51403","name":"Presentation - The PREMIER project: Managing big data for environmental risk assessment of human pharmaceuticals (A.Ragas, IMI / EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-premier-project-managing-big-data-environmental-risk-assessment-human-pharmaceuticals-aragas-imi-efpia_en.pdf"},
    {"id":"51404","name":"Presentation - Big data and veterinary pharmacovigilance (R.Bhui, Boehringer Ingelheim)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-and-veterinary-pharmacovigilance-rbhui-boehringer-ingelheim_en.pdf"},
    {"id":"51405","name":"Presentation - RWE Examples of Big data & biodevices to support efficacy and effectiveness (C.Stirling, A.Wright, Zoetis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rwe-examples-big-data-biodevices-support-efficacy-and-effectiveness-cstirling-awright-zoetis_en.pdf"},
    {"id":"51407","name":"Presentation - Data Science emerging opportunities and challenges for regulatory decision making (C. Cattuto, University of Torino and ISI Foundation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-07-05T01:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-science-emerging-opportunities-and-challenges-regulatory-decision-making-c-cattuto-university-torino-and-isi-foundation_en.pdf"},
    {"id":"51408","name":"Presentation - Next level animal sciences: Big data in the livestock domain (C.Kamphuis, A.Rebel, Wageningen Livestock Research)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-next-level-animal-sciences-big-data-livestock-domain-ckamphuis-arebel-wageningen-livestock-research_en.pdf"},
    {"id":"51409","name":"Presentation - Experiences in implementation of new digital solutions in the regulatory domain (E.Cavalli, EFSA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experiences-implementation-new-digital-solutions-regulatory-domain-ecavalli-efsa_en.pdf"},
    {"id":"51410","name":"Presentation - Proposal for an European Veterinary Big Data Strategy (I.Claassen, T.Heberer, EMA, HMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposal-european-veterinary-big-data-strategy-iclaassen-theberer-ema-hma_en.pdf"},
    {"id":"51411","name":"Presentation - Veterinary Big Data Stakeholder forum - Association of Veterinary Consultants (K.Hellmann, AVC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-big-data-stakeholder-forum-association-veterinary-consultants-khellmann-avc_en.pdf"},
    {"id":"51412","name":"Presentation - Veterinary Big Data Stakeholder forum - The way ahead for AnimalhealthEurope (R.Clayton)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-big-data-stakeholder-forum-way-ahead-animalhealtheurope-rclayton_en.pdf"},
    {"id":"51413","name":"Presentation - What are FDA CVM ‘s main expectations from Big Data Strategy for the veterinary domain (H.Duggirala, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-are-fda-cvm-s-main-expectations-big-data-strategy-veterinary-domain-hduggirala-fda_en.pdf"},
    {"id":"51414","name":"Presentation - Veterinary Big Data Stakeholder forum - Federation of Veterinarians of Europe (R. Van Dobbenburgh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-big-data-stakeholder-forum-federation-veterinarians-europe-r-van-dobbenburgh_en.pdf"},
    {"id":"51415","name":"Presentation - The European Veterinary Big Data Strategy: Next steps (R.Carapeto, Spanish Medicines Agency)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T09:17:00Z","last_updated_date":"2021-06-11T09:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-veterinary-big-data-strategy-next-steps-rcarapeto-spanish-medicines-agency_en.pdf"},
    {"id":"51635","name":"Presentation - AMEG-Categorisationof antibiotics in the European Union (G. Moulin, AMEG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-28T12:03:00Z","last_updated_date":"2021-06-28T12:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ameg-categorisationof-antibiotics-european-union-g-moulin-ameg_en.pdf"},
    {"id":"51637","name":"Presentation - Categorisation of antimicrobials and its impact for veterinary practice (P. Kwiecinski, FVE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-06-28T12:05:00Z","last_updated_date":"2021-06-30T17:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-categorisation-antimicrobials-and-its-impact-veterinary-practice-p-kwiecinski-fve_en.pdf"},
    {"id":"51861","name":"Presentation - Overview of patient involvement in EMA public communications (M.Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T16:17:00Z","last_updated_date":"2021-07-06T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-patient-involvement-ema-public-communications-mmavris-ema_en.pdf"},
    {"id":"51862","name":"Presentation - Young patient engagement at EMA and European Patients Forum (EPF) (K.Immonen, EPF)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T16:17:00Z","last_updated_date":"2021-07-06T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-young-patient-engagement-ema-and-european-patients-forum-epf-kimmonen-epf_en.pdf"},
    {"id":"51863","name":"Presentation - Insights from FDA Listening Session with Transgender Youth (S.Chittooran, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T16:17:00Z","last_updated_date":"2021-07-06T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-insights-fda-listening-session-transgender-youth-schittooran-fda_en.pdf"},
    {"id":"51864","name":"Presentation - Overview of Patients and Consumers Working Party (PCWP) (J.Garcia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T16:17:00Z","last_updated_date":"2021-07-06T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-patients-and-consumers-working-party-pcwp-jgarcia-ema_en.pdf"},
    {"id":"51865","name":"Presentation - Overview of Patient Engagement Collaborative (PEC) (S.Monroe, PEC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T16:17:00Z","last_updated_date":"2021-07-06T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-patient-engagement-collaborative-pec-smonroe-pec_en.pdf"},
    {"id":"51866","name":"Presentation - Patient Engagement Collaborative (PEC) projects on development and review of communications (D.White, PEC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T16:17:00Z","last_updated_date":"2021-07-06T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-engagement-collaborative-pec-projects-development-and-review-communications-dwhite-pec_en.pdf"}    {"id":"51991","name":"Presentation - Background of ePI initiative (J. Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-21T14:52:00Z","last_updated_date":"2021-07-21T14:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-background-epi-initiative-j-garcia_en.pdf"},
    {"id":"51992","name":"Presentation - Description and demo of ePI API (A. Voutsas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-21T15:02:00Z","last_updated_date":"2021-07-21T15:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-description-and-demo-epi-api-voutsas_en.pdf"},
    {"id":"51993","name":"Presentation -  ePI proof of concept prototype (E. Scanlan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-21T16:11:00Z","last_updated_date":"2021-07-21T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-epi-proof-concept-prototype-e-scanlan_en.pdf"},
    {"id":"51994","name":"Presentation - FHIR and  EU common standard for ePI (G. Rodriguez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-21T16:14:00Z","last_updated_date":"2021-07-21T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fhir-and-eu-common-standard-epi-g-rodriguez_en.pdf"},
    {"id":"51995","name":"Presentation - Next steps for ePI and roadmap development (J. Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-21T16:25:00Z","last_updated_date":"2021-07-21T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-next-steps-epi-and-roadmap-development-j-garcia_en.pdf"},
    {"id":"52159","name":"Presentation - CTIS: harmonising the submission, authorisation and supervision of clinical trials (P. Vankeerberghen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T16:11:00Z","last_updated_date":"2021-07-30T16:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-harmonising-submission-authorisation-and-supervision-clinical-trials-p-vankeerberghen_en.pdf"},
    {"id":"52160","name":"Presentation - CTIS personas and sponsor organisation modelling for sponsor preparedness (S. Scales)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T16:14:00Z","last_updated_date":"2021-09-16T09:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-personas-and-sponsor-organisation-modelling-sponsor-preparedness-s-scales_en.pdf"},
    {"id":"52161","name":"Presentation - EMA training and support for sponsors (F. Westerholm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T16:16:00Z","last_updated_date":"2021-09-16T09:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-training-and-support-sponsors-f-westerholm_en.pdf"},
    {"id":"52162","name":"Presentation - How Sponsor organisations can prepare for CTIS: Academia perspective (A. Seidel Glätzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T16:24:00Z","last_updated_date":"2021-07-30T16:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-sponsor-organisations-can-prepare-ctis-academia-perspective-seidel-glatzer_en.pdf"},
    {"id":"52163","name":"Presentation - How sponsor organisations can prepare for CTIS: SME perspective (T. B. Moulvad)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T16:25:00Z","last_updated_date":"2021-07-30T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-sponsor-organisations-can-prepare-ctis-sme-perspective-t-b-moulvad_en.pdf"},
    {"id":"52164","name":"Presentation - How sponsors are preparing for CTIS: Large sponsor perspective (R-M. Swallow)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T16:28:00Z","last_updated_date":"2021-07-30T16:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-sponsors-are-preparing-ctis-large-sponsor-perspective-r-m-swallow_en.pdf"},
    {"id":"52165","name":"Presentation - Member State support for sponsor preparedness and adoption (M. Elgaard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T16:31:00Z","last_updated_date":"2021-07-30T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-member-state-support-sponsor-preparedness-and-adoption-m-elgaard_en.pdf"},
    {"id":"52166","name":"Presentation - Clinical Trials Regulation: why, when, what and how? (S. Giraud)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T16:32:00Z","last_updated_date":"2021-07-30T16:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-regulation-why-when-what-and-how-s-giraud_en.pdf"},
    {"id":"52167","name":"Presentation - What is needed to work in CTIS: Organisation , Admin and User Registration (A. Rodriguez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T16:34:00Z","last_updated_date":"2021-07-30T16:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-needed-work-ctis-organisation-admin-and-user-registration-rodriguez_en.pdf"},
    {"id":"52174","name":"Presentation - Academia Collaboration Matrix Action Plan (L. Liu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-08-02T17:35:00Z","last_updated_date":"2021-08-02T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-academia-collaboration-matrix-action-plan-l-liu_en.pdf"},
    {"id":"52585","name":"Presentation - Study on submission of RWD/RWE in MAAs and EoIs-2018-2019: Preliminary results (X Kurz, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-23T15:53:00Z","last_updated_date":"2021-09-23T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-study-submission-rwdrwe-maas-and-eois-2018-2019-preliminary-results-x-kurz-ema_en.pdf"},
    {"id":"52586","name":"Presentation - Focus group on the concept of an ‘evolutionary’ PIP: Interim feedback (R. Bax, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-23T15:53:00Z","last_updated_date":"2021-09-23T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-concept-evolutionary-pip-interim-feedback-r-bax-ema_en.pdf"},
    {"id":"52587","name":"Presentation - Five year review of the PRIME scheme (S. Ribeiro, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-23T15:53:00Z","last_updated_date":"2021-09-23T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-five-year-review-prime-scheme-s-ribeiro-ema_en.pdf"},
    {"id":"52588","name":"Presentation - Progressing the concept of patient-centred development in practice (N. Bere, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-23T15:53:00Z","last_updated_date":"2021-09-23T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-progressing-concept-patient-centred-development-practice-n-bere-ema_en.pdf"},
    {"id":"52589","name":"Presentation - Updated EC Q&A on similarity for ATMPs in the context of the Orphan legislation (C. Pothet, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-23T15:53:00Z","last_updated_date":"2021-09-23T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updated-ec-qa-similarity-atmps-context-orphan-legislation-c-pothet-ema_en.pdf"},
    {"id":"52590","name":"Presentation - Update on the implementation of the consultation procedure on Companion Diagnostic (CDx) (C. Bouygues, C. Vleminckx, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-23T15:53:00Z","last_updated_date":"2021-09-23T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-implementation-consultation-procedure-companion-diagnostic-cdx-c-bouygues-c-vleminckx-ema_en.pdf"},
    {"id":"52591","name":"Presentation - Medicinal products in combination with medical devices (C. Bouygues, P. Venneugues, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-23T15:53:00Z","last_updated_date":"2021-09-23T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicinal-products-combination-medical-devices-c-bouygues-p-venneugues-ema_en.pdf"},
    {"id":"52605","name":"Presentation - Accelerated Assessment and Conditional Marketing authorisation (V. Palmi, C. Pothet, M. Schüssler-Lenz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T15:25:00Z","last_updated_date":"2021-09-24T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accelerated-assessment-and-conditional-marketing-authorisation-v-palmi-c-pothet-m-schussler-lenz_en.pdf"},
    {"id":"52606","name":"Presentation - Pilot project ‘Market launch of CAPs' (R. Almeida)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T15:38:00Z","last_updated_date":"2021-09-24T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pilot-project-market-launch-caps-r-almeida_en.pdf"},
    {"id":"52607","name":"Presentation - Launch of IRIS for reporting changes on Marketing Status (A. Gañán Jiménez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T15:40:00Z","last_updated_date":"2021-09-24T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-launch-iris-reporting-changes-marketing-status-ganan-jimenez_en.pdf"},
    {"id":"52608","name":"Presentation - Additional measures to allow experts to focus on COVID-19 activities: Committee's workload and co-Rapporteur involvement (V. Palmi, T. Castelnovo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T15:45:00Z","last_updated_date":"2021-09-24T15:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-additional-measures-allow-experts-focus-covid-19-activities-committees-workload-and-co-rapporteur-involvement-v-palmi-t-castelnovo_en.pdf"},
    {"id":"52609","name":"Presentation - Interactions with patients across the product lifecycle (N. Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T15:51:00Z","last_updated_date":"2021-09-24T15:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interactions-patients-across-product-lifecycle-n-bere_en.pdf"},
    {"id":"52611","name":"Presentation - EMA Strategy on digitalisation (Z. Frias, P. Arlett, H. Hamann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T16:15:00Z","last_updated_date":"2021-09-24T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-strategy-digitalisation-z-frias-p-arlett-h-hamann_en.pdf"},
    {"id":"52612","name":"Presentation - Review of EMA Working Parties (T. Humphreys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T16:26:00Z","last_updated_date":"2021-09-24T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-review-ema-working-parties-t-humphreys_en.pdf"},
    {"id":"52613","name":"Presentation - Update on cyberattack (A. Nolte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T16:28:00Z","last_updated_date":"2021-09-24T16:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-cyberattack-nolte_en.pdf"},
    {"id":"52616","name":"Presentation - COVID 19 vaccines and therapeutics - An update to the PCWP/HCPWP: September 2021 (M.Cavaleri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T15:54:00Z","last_updated_date":"2021-09-27T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-vaccines-and-therapeutics-update-pcwphcpwp-september-2021-mcavaleri-ema_en.pdf"},
    {"id":"52617","name":"Presentation - Pharmacovigilance for COVID 19 Vaccines - One year of strong safety surveillance (G. Genov, P. Bahri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-covid-19-vaccines-one-year-strong-safety-surveillance-g-genov-p-bahri-ema_en.pdf"},
    {"id":"52618","name":"Presentation - Understanding COVID-19 vaccines by healthcare professionals and patients - User testing at EU and regional level (R. Gonzales-Quevedo, EMA; C. Constantino, University of Palermo, Sicily)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-understanding-covid-19-vaccines-healthcare-professionals-and-patients-user-testing-eu-and-regional-level-r-gonzales-quevedo-ema-c-constantino-university-palermo-sicily_en.pdf"},
    {"id":"52619","name":"Presentation - Enhancing PRAC engagement with patients and healthcare professionals (P. Bahri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enhancing-prac-engagement-patients-and-healthcare-professionals-p-bahri-ema_en.pdf"},
    {"id":"52620","name":"Presentation - Update on new guidance on risk minimisation measures (GVP modules XVI RMM) (N. Semis-Costa, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-new-guidance-risk-minimisation-measures-gvp-modules-xvi-rmm-n-semis-costa-ema_en.pdf"},
    {"id":"52621","name":"Presentation - Update on new guidance on risk minimisation measures (GVP modules XVI RMM) (T. Goedecke, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-new-guidance-risk-minimisation-measures-gvp-modules-xvi-rmm-t-goedecke-ema_en.pdf"},
    {"id":"52622","name":"Presentation - Review and publication of direct healthcare professional communications (DHPCs) (M. De Verdiere, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-review-and-publication-direct-healthcare-professional-communications-dhpcs-m-de-verdiere-ema_en.pdf"},
    {"id":"52623","name":"Presentation - Reflections on publication and dissemination of DHPCs (T. Villanueva, UEMO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reflections-publication-and-dissemination-dhpcs-t-villanueva-uemo_en.pdf"},
    {"id":"52624","name":"Presentation - Community pharmacists’ reflections on publication and dissemination of DHPCs (J. De Belie, PGEU)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-community-pharmacists-reflections-publication-and-dissemination-dhpcs-j-de-belie-pgeu_en.pdf"},
    {"id":"52625","name":"Presentation - Clinical Trial Regulation and Clinical Trials Information System (CTIS) what changes in 2022 (F. Sweeney, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trial-regulation-and-clinical-trials-information-system-ctis-what-changes-2022-f-sweeney-ema_en.pdf"},
    {"id":"52626","name":"Presentation - CTIS: functionalities and support for clinical trial sponsors, availability of clinical trial data to the public (F. Westerholm, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-functionalities-and-support-clinical-trial-sponsors-availability-clinical-trial-data-public-f-westerholm-ema_en.pdf"},
    {"id":"52627","name":"Presentation - Big Data Steering Group: workplan and deep-dive on clinical trials raw data project (F. Domergue, E. Psarelli, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-steering-group-workplan-and-deep-dive-clinical-trials-raw-data-project-f-domergue-e-psarelli-ema_en.pdf"},
    {"id":"52628","name":"Presentation - Outcome of public consultation on the registry-based studies guideline (X. Kurz, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcome-public-consultation-registry-based-studies-guideline-x-kurz-ema_en.pdf"},
    {"id":"52629","name":"Presentation - PCWP/HCPWP workplan 2019-2022 and EMAN Strategy to 2025 (I. Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwphcpwp-workplan-2019-2022-and-eman-strategy-2025-i-silva-ema_en.pdf"},
    {"id":"52630","name":"Presentation - Looking ahead into 2022: Meeting dates, new mandate and annual eligibility re-evaluation (N. Bere, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-looking-ahead-2022-meeting-dates-new-mandate-and-annual-eligibility-re-evaluation-n-bere-ema_en.pdf"},
    {"id":"52631","name":"Presentation - Update on EC legal proposal for extending the mandate of the EMA (H. Boone, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ec-legal-proposal-extending-mandate-ema-h-boone-ema_en.pdf"},
    {"id":"52632","name":"Presentation - Plans for Communication and Stakeholders’ Engagement on Extended Mandate (M. Carr, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:54:00Z","last_updated_date":"2021-09-27T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-plans-communication-and-stakeholders-engagement-extended-mandate-m-carr-ema_en.pdf"},
    {"id":"52714","name":"Presentation - Union Product Database (UPD): webinar for marketing authorisation holders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-10-04T14:44:00Z","last_updated_date":"2021-10-04T14:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-product-database-upd-webinar-marketing-authorisation-holders_en.pdf"},
    {"id":"52890","name":"Presentation: Industry webinar - Introduction to Organisation Management Services (OMS) and activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-10-21T11:06:00Z","last_updated_date":"2021-10-21T11:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-webinar-introduction-organisation-management-services-oms-and-activities_en.pdf"},
    {"id":"52904","name":"Presentation - Integration of EudraGMDP and OMS: implications for industry users (M. Filancia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-10-26T11:39:00Z","last_updated_date":"2021-10-26T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-integration-eudragmdp-and-oms-implications-industry-users-m-filancia-ema_en.pdf"},
    {"id":"53014","name":"Presentation - A pan-EU Paediatric Clinical Trial Network (M.Turner, IMI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-09T16:31:00Z","last_updated_date":"2021-11-09T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pan-eu-paediatric-clinical-trial-network-mturner-imi_en.pdf"},
    {"id":"53016","name":"Presentation - Big Data Steering Group update (F.Domerque, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-09T16:31:00Z","last_updated_date":"2021-11-09T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-steering-group-update-fdomerque-ema_en.pdf"},
    {"id":"53017","name":"Presentation - COVID-19 Update on development of therapeutics and vaccines for paediatric use (L.Fregonese, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-09T16:31:00Z","last_updated_date":"2021-11-09T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-update-development-therapeutics-and-vaccines-paediatric-use-lfregonese-ema_en.pdf"},
    {"id":"53018","name":"Presentation - Introduction to the Clinical Trials Information System (CTIS) (A.Rodriquez, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-09T16:31:00Z","last_updated_date":"2021-11-09T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-clinical-trials-information-system-ctis-arodriquez-ema_en.pdf"},
    {"id":"53019","name":"Presentation - Real-world evidence to contribute to medicine development and access (R.Herold, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-09T16:31:00Z","last_updated_date":"2021-11-09T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-real-world-evidence-contribute-medicine-development-and-access-rherold-ema_en.pdf"},
    {"id":"53020","name":"Presentation - Revision of the legislations on medicines for children and rare diseases - Pharmaceutical Strategy (F.D'Atri, DG SANTE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-09T16:31:00Z","last_updated_date":"2021-11-09T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revision-legislations-medicines-children-and-rare-diseases-pharmaceutical-strategy-fdatri-dg-sante_en.pdf"},
    {"id":"53021","name":"Presentation - Enpr-EMA Annual Report 2020-2021 (P.Lepola, Enpr-EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-09T16:31:00Z","last_updated_date":"2021-11-09T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-annual-report-2020-2021-plepola-enpr-ema_en.pdf"},
    {"id":"53059","name":"Presentation - CTIS The future user perspective: Welcome (P. Vankeerberghen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-11T10:34:00Z","last_updated_date":"2021-11-11T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-future-user-perspective-welcome-p-vankeerberghen_en.pdf"},
    {"id":"53060","name":"Presentation - CTR & CTIS: Key Aspects for Users to Consider when Preparing for CTIS (Dr. S. Strasser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-11T10:34:00Z","last_updated_date":"2021-11-11T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctr-ctis-key-aspects-users-consider-when-preparing-ctis-dr-s-strasser_en.pdf"},
    {"id":"53062","name":"Presentation - How to prepare for CTIS: a User Perspective (G. Di Matteo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-11T10:34:00Z","last_updated_date":"2021-11-11T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-prepare-ctis-user-perspective-g-di-matteo_en.pdf"},
    {"id":"53063","name":"Presentation - How to access CTIS training materials and support (F. Westerholm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-11T10:34:00Z","last_updated_date":"2021-11-11T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-access-ctis-training-materials-and-support-f-westerholm_en.pdf"},
    {"id":"53064","name":"Presentation - CTIS The future user perspective: Closing (P. Vankeerberghen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-11T10:34:00Z","last_updated_date":"2021-11-11T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-future-user-perspective-closing-p-vankeerberghen_en.pdf"},
    {"id":"53091","name":"Presentation - Changes in pharmacovigilance, signal detection and surveillance (J.Olaerts, L. Descalzo , EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:07:00Z","last_updated_date":"2021-11-12T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-changes-pharmacovigilance-signal-detection-and-surveillance-jolaerts-l-descalzo-ema_en.pdf"},
    {"id":"53092","name":"Presentation - Introduction to the UPD (J. Schalansky, A. Vincente, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:07:00Z","last_updated_date":"2021-11-12T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-upd-j-schalansky-vincente-ema_en.pdf"},
    {"id":"53093","name":"Presentation - Limited markets: what is in for SMEs? (S. Thiele, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:07:00Z","last_updated_date":"2021-11-12T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-limited-markets-what-smes-s-thiele-ema_en.pdf"},
    {"id":"53094","name":"Presentation - Status update on implementation of Veterinary Medicinal Products Regulation (J. Torren Edo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:07:00Z","last_updated_date":"2021-11-12T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-status-update-implementation-veterinary-medicinal-products-regulation-j-torren-edo-ema_en.pdf"},
    {"id":"53095","name":"Presentation - Path to marketing authorisation: SMEs’ experiences and peer-to-peer considerations (S. Kennedy, TriviumVet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:07:00Z","last_updated_date":"2021-11-12T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-path-marketing-authorisation-smes-experiences-and-peer-peer-considerations-s-kennedy-triviumvet_en.pdf"},
    {"id":"53096","name":"Presentation - Path to marketing authorisation SMEs’ experience and considerations (A. Pradera, Equi Cord)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:07:00Z","last_updated_date":"2021-11-12T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-path-marketing-authorisation-smes-experience-and-considerations-pradera-equi-cord_en.pdf"},
    {"id":"53097","name":"Presentation - Need for MRL evaluation for biological substances (S. Girault, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:07:00Z","last_updated_date":"2021-11-12T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-need-mrl-evaluation-biological-substances-s-girault-ema_en.pdf"},
    {"id":"53098","name":"Presentation - The role of Novel Therapies Working Party (NTWP) (S. Casado,  Vice-Chair of the NTWP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:07:00Z","last_updated_date":"2021-11-12T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-novel-therapies-working-party-ntwp-s-casado-vice-chair-ntwp_en.pdf"},
    {"id":"53099","name":"Presentation - Early support to innovation (F. Hasslung Wikström, Chair of the SAWP-V)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:07:00Z","last_updated_date":"2021-11-12T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-early-support-innovation-f-hasslung-wikstrom-chair-sawp-v_en.pdf"},
    {"id":"53100","name":"Presentation - Overview of EMA initiatives supporting SMEs (C. Provansal, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T09:07:00Z","last_updated_date":"2021-11-12T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-ema-initiatives-supporting-smes-c-provansal-ema_en.pdf"},
    {"id":"53147","name":"Presentation - VGVP module on collection and recording of suspected adverse events for veterinary medicinal products and EVV system functionalities (L. Descalzo and G. Spyrou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-18T11:16:00Z","last_updated_date":"2021-11-18T11:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vgvp-module-collection-and-recording-suspected-adverse-events-veterinary-medicinal-products-and-evv-system-functionalities-l-descalzo-and-g-spyrou_en.pdf"},
    {"id":"53255","name":"Presentation - Introduction (day 1): Signal management following veterinary good pharmacovigilance practices (J. Olaerts, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-24T12:49:00Z","last_updated_date":"2021-11-24T12:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-day-1-signal-management-following-veterinary-good-pharmacovigilance-practices-j-olaerts-ema_en.pdf"},
    {"id":"53257","name":"Presentation - Analysis (day 1): Signal management following veterinary good pharmacovigilance practices (D. Zondag, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-24T12:51:00Z","last_updated_date":"2021-11-24T12:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-analysis-day-1-signal-management-following-veterinary-good-pharmacovigilance-practices-d-zondag-ema_en.pdf"},
    {"id":"53268","name":"Presentation - Transgene: Stakeholders’ experience with the Clinical Trials Regulation No 536/2014 implementation (Julien Romanetto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T13:51:00Z","last_updated_date":"2021-11-25T13:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transgene-stakeholders-experience-clinical-trials-regulation-no-5362014-implementation-julien-romanetto_en.pdf"},
    {"id":"53269","name":"Presentation - Access and user management, roles and permissions (A. Rodriguez Sanchez-Beato)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T13:58:00Z","last_updated_date":"2021-11-25T13:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-access-and-user-management-roles-and-permissions-rodriguez-sanchez-beato_en.pdf"},
    {"id":"53271","name":"Presentation - High-level overview of CTIS, JCA and publication rules (Laura Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T14:03:00Z","last_updated_date":"2021-11-25T14:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-high-level-overview-ctis-jca-and-publication-rules-laura-pioppo_en.pdf"},
    {"id":"53272","name":"Presentation - The new process for submitting clinical trials information in the EU-EEA (M. Elgaard Sørensen, DKMA & R. Pankow, Parexel International GmbH)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T14:06:00Z","last_updated_date":"2021-11-25T14:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-process-submitting-clinical-trials-information-eu-eea-m-elgaard-sorensen-dkma-r-pankow-parexel-international-gmbh_en.pdf"},
    {"id":"53274","name":"Presentation - Benefits and challenges of antimicrobial data collection: view from a veterinary practitioner (Giovanbattista Guadagnini,)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T16:06:00Z","last_updated_date":"2021-11-25T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-benefits-and-challenges-antimicrobial-data-collection-view-veterinary-practitioner-giovanbattista-guadagnini_en.pdf"},
    {"id":"53275","name":"Presentation - Collecting use data: Denmark as an example - Update on the ASU-project (Laura Mie Jensen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T16:12:00Z","last_updated_date":"2021-11-25T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collecting-use-data-denmark-example-update-asu-project-laura-mie-jensen_en.pdf"},
    {"id":"53276","name":"Presentation - Data collection on sales and use of antimicrobials in France (ANSE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T16:14:00Z","last_updated_date":"2021-11-25T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-collection-sales-and-use-antimicrobials-france-anse_en.pdf"},
    {"id":"53279","name":"Presentation - Update on approved and candidate COVID-19 vaccines and therapeutics (M. Cavaleri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T17:19:00Z","last_updated_date":"2021-11-25T17:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-approved-and-candidate-covid-19-vaccines-and-therapeutics-m-cavaleri-ema_en.pdf"},
    {"id":"53280","name":"Presentation - Update on vaccine safety monitoring (G. Genov, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T17:21:00Z","last_updated_date":"2021-11-25T17:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-vaccine-safety-monitoring-g-genov-ema_en.pdf"},
    {"id":"53281","name":"Presentation - COVID-19 surveillance and vaccination coverage in the EU (P. Kramarz, ECDC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T17:22:00Z","last_updated_date":"2021-11-25T17:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-surveillance-and-vaccination-coverage-eu-p-kramarz-ecdc_en.pdf"},
    {"id":"53282","name":"Presentation - Addressing misinformation on COVID-19 vaccines (M. Carr, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T17:24:00Z","last_updated_date":"2021-11-25T17:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-addressing-misinformation-covid-19-vaccines-m-carr-ema_en.pdf"},
    {"id":"53283","name":"Presentation - Addressing misinformation on COVID-19 vaccines (M. Carr, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T17:24:00Z","last_updated_date":"2021-11-25T17:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-addressing-misinformation-covid-19-vaccines-m-carr-ema_en.pdf-0"},
    {"id":"53291","name":"Presentation - Introduction to EMA training session (N. Bere, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-26T10:59:00Z","last_updated_date":"2021-11-26T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-ema-training-session-n-bere-ema_en.pdf"},
    {"id":"53315","name":"Presentation - Union Pharmacovigilance Database:webinar on signal detection and analysis (L. Descalzo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T14:06:00Z","last_updated_date":"2021-11-29T14:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-pharmacovigilance-databasewebinar-signal-detection-and-analysis-l-descalzo-ema_en.pdf"},
    {"id":"53347","name":"Presentation - European collaboration between regulators  and Health Technology Assessment (HTA) bodies (M. Bertgen, EMA), B. Sepodes (CHMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-01T17:53:00Z","last_updated_date":"2021-12-01T17:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-collaboration-between-regulators-and-health-technology-assessment-hta-bodies-m-bertgen-ema-b-sepodes-chmp_en.pdf"},
    {"id":"53348","name":"Presentation - ICH E8(R1) – General Considerations for Clinical Studies – Finalised (F. Sweeney, EMA), (S. Vamvakas, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-01T17:54:00Z","last_updated_date":"2021-12-01T17:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-e8r1-general-considerations-clinical-studies-finalised-f-sweeney-ema-s-vamvakas-ema_en.pdf"},
    {"id":"53349","name":"Presentation - CTR, CTIS functionalities and availability of clinical trial data to the public (P. Vankeerberghen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-01T17:57:00Z","last_updated_date":"2021-12-01T17:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctr-ctis-functionalities-and-availability-clinical-trial-data-public-p-vankeerberghen-ema_en.pdf"},
    {"id":"53350","name":"Presentation - Medicine repurposing pilot project (C. Hernandez, HMA), (C. Bouygues, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-01T17:58:00Z","last_updated_date":"2021-12-01T17:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicine-repurposing-pilot-project-c-hernandez-hma-c-bouygues-ema_en.pdf"},
    {"id":"53351","name":"Presentation - Civil society members in EMA scientific  committees: an overview (M. Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-01T18:01:00Z","last_updated_date":"2021-12-01T18:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-civil-society-members-ema-scientific-committees-overview-m-mavris-ema_en.pdf"},
    {"id":"53353","name":"Presentation - Monitoring of COVID-19 products: toolkit (Agnieszka Szmigiel, Emil Cochino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-02T17:53:00Z","last_updated_date":"2021-12-02T17:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-covid-19-products-toolkit-agnieszka-szmigiel-emil-cochino_en.pdf"},
    {"id":"53354","name":"Presentation - Good Pharmacovigilance Practices (EU-GVP) (Priya Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-02T17:57:00Z","last_updated_date":"2021-12-02T17:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-eu-gvp-priya-bahri_en.pdf"},
    {"id":"53355","name":"Presentation - Guideline on registry-based studies (Kelly Plüschke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-02T17:59:00Z","last_updated_date":"2021-12-02T17:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guideline-registry-based-studies-kelly-pluschke_en.pdf"},
    {"id":"53356","name":"Presentation - EMA medical literature monitoring service update (Tom Paternoster-Howe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-02T18:02:00Z","last_updated_date":"2021-12-02T18:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-medical-literature-monitoring-service-update-tom-paternoster-howe_en.pdf"},
    {"id":"53358","name":"Presentation - Periodic safety update report (PSUR): Adherence to PRAC recommendations for national authorized products (NAPs) (Viola Sarinic)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-03T13:35:00Z","last_updated_date":"2021-12-03T13:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-periodic-safety-update-report-psur-adherence-prac-recommendations-national-authorized-products-naps-viola-sarinic_en.pdf"},
    {"id":"53405","name":"Presentation - Updates on the implementation of Veterinary Medicines Regulation (EU) 2019/6 and secondary legislation (Ivo Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T11:17:00Z","last_updated_date":"2021-12-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-implementation-veterinary-medicines-regulation-eu-20196-and-secondary-legislation-ivo-claassen_en.pdf"}    {"id":"53406","name":"Presentation - Veterinary Medicines Regulation (EU) 2019/6 state of play (Eva Zamora)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T11:21:00Z","last_updated_date":"2021-12-08T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-medicines-regulation-eu-20196-state-play-eva-zamora_en.pdf"},
    {"id":"53407","name":"Presentation - CVMP update on activities relating to the Veterinary Medicines Regulation (EU) 2019/6 (David Murphy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T11:23:00Z","last_updated_date":"2021-12-08T11:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-update-activities-relating-veterinary-medicines-regulation-eu-20196-david-murphy_en.pdf"},
    {"id":"53408","name":"Presentation - Implementation of the Veterinary Medicines Regulation (EU) 2019/6: Industry preparedness","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T11:26:00Z","last_updated_date":"2021-12-08T11:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-veterinary-medicines-regulation-eu-20196-industry-preparedness_en.pdf"},
    {"id":"53409","name":"Presentation - Variations for centrally authorised products (Catherine Griffin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T11:29:00Z","last_updated_date":"2021-12-08T11:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-variations-centrally-authorised-products-catherine-griffin_en.pdf"},
    {"id":"53410","name":"Presentation - Pharmacovigilance, signal detection and surveillance (Jos Olaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T11:36:00Z","last_updated_date":"2021-12-08T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-signal-detection-and-surveillance-jos-olaerts_en.pdf"},
    {"id":"53411","name":"Presentation - Environmental risk assessment for generics (Kristina Paterson, Michael Empl)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T11:40:00Z","last_updated_date":"2021-12-08T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-environmental-risk-assessment-generics-kristina-paterson-michael-empl_en.pdf"},
    {"id":"53414","name":"Presentation - Actions for industry until January 2022 and beyond (Jana Schalansky)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T11:44:00Z","last_updated_date":"2021-12-08T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-actions-industry-until-january-2022-and-beyond-jana-schalansky_en.pdf"},
    {"id":"53442","name":"Presentation - VGVP module on controls and pharmacovigilance inspections: Introduction and principles (Calogero Cannavo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-10T16:55:00Z","last_updated_date":"2021-12-10T16:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vgvp-module-controls-and-pharmacovigilance-inspections-introduction-and-principles-calogero-cannavo_en.pdf"},
    {"id":"53443","name":"Presentation - VGVP module on pharmacovigilance systems, their quality management systems and pharmacovigilance system master files (Sophia Mylona)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-10T17:03:00Z","last_updated_date":"2021-12-10T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vgvp-module-pharmacovigilance-systems-their-quality-management-systems-and-pharmacovigilance-system-master-files-sophia-mylona_en.pdf"},
    {"id":"53467","name":"Presentation - FDA Guidance on real-world data (John Concato)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T10:16:00Z","last_updated_date":"2021-12-14T10:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-guidance-real-world-data-john-concato_en.pdf"},
    {"id":"53468","name":"Presentation - CHMP guideline on registry-based studies (Kelly Plüschke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T10:21:00Z","last_updated_date":"2021-12-14T10:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chmp-guideline-registry-based-studies-kelly-pluschke_en.pdf"},
    {"id":"53469","name":"Presentation - Breakout session 2: Platform for stakeholders’ consultation (EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T10:24:00Z","last_updated_date":"2021-12-14T10:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-2-platform-stakeholders-consultation-efpia_en.pdf"},
    {"id":"53470","name":"Presentation - Breakout session 2: Platform for stakeholders’ consultation (Marie-Helene Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T10:28:00Z","last_updated_date":"2021-12-14T10:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-2-platform-stakeholders-consultation-marie-helene-pinheiro_en.pdf"},
    {"id":"53471","name":"Presentation - Breakout session 3: Process optimisation (Andrej Segec)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T10:31:00Z","last_updated_date":"2021-12-14T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-3-process-optimisation-andrej-segec_en.pdf"},
    {"id":"53472","name":"Presentation - Breakout session 4: Training and expertise (Gianmario Candore, Stefania Simou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T10:34:00Z","last_updated_date":"2021-12-14T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-4-training-and-expertise-gianmario-candore-stefania-simou_en.pdf"},
    {"id":"53473","name":"Presentation - Breakout session 5 - Heterogeneity of results between data sources (Catherine Cohet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T10:43:00Z","last_updated_date":"2021-12-14T10:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakout-session-5-heterogeneity-results-between-data-sources-catherine-cohet_en.pdf"},
    {"id":"53474","name":"Presentation - Lessons learned from the applications submitted to EMA for marketing authorisation and extension of indication, 2018- 2019 (Elisabeth Bakker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T10:47:00Z","last_updated_date":"2021-12-14T10:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lessons-learned-applications-submitted-ema-marketing-authorisation-and-extension-indication-2018-2019-elisabeth-bakker_en.pdf"},
    {"id":"53475","name":"Presentation - The role of RWE in FDA approvals (J. Rassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T10:54:00Z","last_updated_date":"2021-12-14T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-rwe-fda-approvals-j-rassen_en.pdf"},
    {"id":"53476","name":"Presentation -  Plenary session 1: Pharmaceutical industry’s experience and challenges with RWE submission in marketing authorisation applications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T11:08:00Z","last_updated_date":"2021-12-14T11:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-plenary-session-1-pharmaceutical-industrys-experience-and-challenges-rwe-submission-marketing-authorisation-applications_en.pdf"},
    {"id":"53478","name":"Presentation - Plenary session 1: The Charybdis project – Use of real-world data from multiple countries and opportunities for regulatory purpose (Talita Duarte-Salles)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T11:32:00Z","last_updated_date":"2021-12-14T11:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-plenary-session-1-charybdis-project-use-real-world-data-multiple-countries-and-opportunities-regulatory-purpose-talita-duarte-salles_en.pdf"},
    {"id":"53479","name":"Presentation - Introduction to the breakout sessions (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T11:37:00Z","last_updated_date":"2021-12-14T11:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-breakout-sessions-xavier-kurz_en.pdf"},
    {"id":"53481","name":"Presentation - Plenary session 1: Report from the breakout session 1: Fitness of real-world data for regulatory purpose (Kelly Plueschke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T11:44:00Z","last_updated_date":"2021-12-14T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-plenary-session-1-report-breakout-session-1-fitness-real-world-data-regulatory-purpose-kelly-plueschke_en.pdf"},
    {"id":"53482","name":"Presentation - Plenary session 2: Report from the breakout session 2: Platform for stakeholders’ consultation (Carla Jonker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T11:58:00Z","last_updated_date":"2021-12-14T11:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-plenary-session-2-report-breakout-session-2-platform-stakeholders-consultation-carla-jonker_en.pdf"},
    {"id":"53483","name":"Presentation - Plenary session 2: Report from the breakout session 3: Process optimisation (Andrej Segec)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T12:03:00Z","last_updated_date":"2021-12-14T12:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-plenary-session-2-report-breakout-session-3-process-optimisation-andrej-segec_en.pdf"},
    {"id":"53484","name":"Presentation - Plenary session 2: Report from the breakout session 4: Training and expertise","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T12:09:00Z","last_updated_date":"2021-12-14T12:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-plenary-session-2-report-breakout-session-4-training-and-expertise_en.pdf"},
    {"id":"53485","name":"Presentation - Plenary session 2:  Report from the breakout session 5: Heterogeneity of results between data sources (Daniel Prieto-Alhambra)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T12:28:00Z","last_updated_date":"2021-12-14T12:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-plenary-session-2-report-breakout-session-5-heterogeneity-results-between-data-sources-daniel-prieto-alhambra_en.pdf"},
    {"id":"53488","name":"Presentation - Plenary session 3: Wrap-up and next steps (Jesper Kjær)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T12:35:00Z","last_updated_date":"2021-12-14T12:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-plenary-session-3-wrap-and-next-steps-jesper-kjaer_en.pdf"},
    {"id":"53489","name":"Presentation - Concluding remarks (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T12:50:00Z","last_updated_date":"2021-12-14T12:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-concluding-remarks-peter-arlett_en.pdf"},
    {"id":"53490","name":"Presentation - Plenary session 3: Analysis and interpretation of realworld data: A 5-year outlook (Patrick Ryan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T13:00:00Z","last_updated_date":"2021-12-14T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-plenary-session-3-analysis-and-interpretation-realworld-data-5-year-outlook-patrick-ryan_en.pdf"},
    {"id":"53589","name":"Presentation - Nitrosamine Implementation Oversight Group (NIOG) - second meeting with pharmaceutical industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-17T14:23:00Z","last_updated_date":"2021-12-17T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nitrosamine-implementation-oversight-group-niog-second-meeting-pharmaceutical-industry_en.pdf"},
    {"id":"53590","name":"Presentation - Industry stakeholder supporting presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-12-17T14:25:00Z","last_updated_date":"2021-12-17T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-stakeholder-supporting-presentation_en.pdf"},
    {"id":"53655","name":"Presentation - Second annual EU Big Data Stakeholder Forum 2021: Concluding remarks (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-second-annual-eu-big-data-stakeholder-forum-2021-concluding-remarks-parlett-ema_en.pdf"},
    {"id":"53656","name":"Presentation - Second annual EU Big Data Stakeholder Forum 2021: Opening remarks (A. Rys, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-second-annual-eu-big-data-stakeholder-forum-2021-opening-remarks-rys-ec_en.pdf"},
    {"id":"53657","name":"Presentation - Session 1.1: Report on implementation of the HMA-EMA Big Data Task Force priority recommendations - Overview of 2021 deliverables and plan for 2022 (P. Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-11-report-implementation-hma-ema-big-data-task-force-priority-recommendations-overview-2021-deliverables-and-plan-2022-p-arlett-ema_en.pdf"},
    {"id":"53658","name":"Presentation - Session 1.2: Big Data Veterinary workstream - Overview of 2021 deliverables and plan for 2022 (I. Del Seppia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-12-big-data-veterinary-workstream-overview-2021-deliverables-and-plan-2022-i-del-seppia-ema_en.pdf"},
    {"id":"53659","name":"Presentation - Session 2.1: Data Analysis and Real World Interrogation Network (DARWIN EU) (M. Vrana, EHN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-21-data-analysis-and-real-world-interrogation-network-darwin-eu-m-vrana-ehn_en.pdf"},
    {"id":"53660","name":"Presentation - Session 2.2: Data quality and representativeness (C. Hernadez Garcia, AEMPS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-22-data-quality-and-representativeness-c-hernadez-garcia-aemps_en.pdf"},
    {"id":"53661","name":"Presentation - Session 2.3: Data discoverability (E. Agricola, AIFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-23-data-discoverability-e-agricola-aifa_en.pdf"},
    {"id":"53662","name":"Presentation - Session 2.4: EU Network skills in Big Data (J. Zinserling, BfArM)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-24-eu-network-skills-big-data-j-zinserling-bfarm_en.pdf"},
    {"id":"53663","name":"Presentation - Session 2.5: Regulatory processes for data (M. Pasmooij, MEB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-25-regulatory-processes-data-m-pasmooij-meb_en.pdf"},
    {"id":"53664","name":"Presentation - Session 2.6: Regulatory capability to analyse data (A. Schiel, NOMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-26-regulatory-capability-analyse-data-schiel-noma_en.pdf"},
    {"id":"53665","name":"Presentation - Session 2.7: Delivery of experts advice (A. Irs, Ravimiamet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-27-delivery-experts-advice-irs-ravimiamet_en.pdf"},
    {"id":"53666","name":"Presentation - Session 2.8: Data governance (A. Schiel, NOMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-28-data-governance-schiel-noma_en.pdf"},
    {"id":"53667","name":"Presentation - Session 2.9: International initiatives (P. Bachman, BfArM)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-10T12:08:00Z","last_updated_date":"2022-01-10T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-29-international-initiatives-p-bachman-bfarm_en.pdf"},
    {"id":"53860","name":"Presentation - EVV DWH dashboard and reports (L. Descalzo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-20T14:55:00Z","last_updated_date":"2022-01-20T14:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evv-dwh-dashboard-and-reports-l-descalzo-ema_en.pdf"},
    {"id":"53861","name":"Presentation - Union Pharmacovigilance Database: webinar on signal detection and analysis - Signal management highlights (D. Zondag, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-20T14:56:00Z","last_updated_date":"2022-01-20T14:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-pharmacovigilance-database-webinar-signal-detection-and-analysis-signal-management-highlights-d-zondag-ema_en.pdf"},
    {"id":"53910","name":"Presentation - Pilot Signal Management Expert Group (P-SMEG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-26T09:26:00Z","last_updated_date":"2022-01-26T09:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pilot-signal-management-expert-group-p-smeg_en.pdf"},
    {"id":"53911","name":"Presentation - EVV DWH Dashboard and Reports (L.Descalzo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-26T09:28:00Z","last_updated_date":"2022-01-26T09:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evv-dwh-dashboard-and-reports-ldescalzo-ema_en.pdf"},
    {"id":"53912","name":"Presentation - UPD: Follow up webinar on signal detection, evaluation and yearly reporting - Signal management highlights (D.Zondag, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-26T09:29:00Z","last_updated_date":"2022-01-26T09:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-upd-follow-webinar-signal-detection-evaluation-and-yearly-reporting-signal-management-highlights-dzondag-ema_en.pdf"},
    {"id":"53913","name":"Presentation - UPD: follow up webinar on collection and recording of suspected adverse events for veterinary medicinal products (L.Descalzo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-26T09:38:00Z","last_updated_date":"2022-01-26T09:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-upd-follow-webinar-collection-and-recording-suspected-adverse-events-veterinary-medicinal-products-ldescalzo-ema_en.pdf"},
    {"id":"53938","name":"Presentation - Union Product Database: follow up webinar for marketing authorisation holders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-27T10:00:00Z","last_updated_date":"2022-01-27T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-product-database-follow-webinar-marketing-authorisation-holders_en.pdf"},
    {"id":"54030","name":"Presentation - An update on EC pilot on intent to launch of orphan and oncology medicinal products (S. Almeida)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T10:18:00Z","last_updated_date":"2022-01-31T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ec-pilot-intent-launch-orphan-and-oncology-medicinal-products-s-almeida_en.pdf"},
    {"id":"54031","name":"Presentations - Changes to pre-submission interactions (M.Kollb-Sielecka, T. Castelnovo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T10:19:00Z","last_updated_date":"2022-01-31T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentations-changes-pre-submission-interactions-mkollb-sielecka-t-castelnovo-ema_en.pdf"},
    {"id":"54032","name":"Presentation - Repurposing pilot from EMA (C.Bouygues, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T10:33:00Z","last_updated_date":"2022-01-31T10:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-repurposing-pilot-ema-cbouygues-ema_en.pdf"},
    {"id":"54033","name":"Presentation - Irish language derogation (A.Skarlatos, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T10:34:00Z","last_updated_date":"2022-01-31T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-irish-language-derogation-askarlatos-ema_en.pdf"},
    {"id":"54034","name":"Presentation - Measures Taken to help the EU regulatory network to cope with increased workload (F.Day, A.Nolte, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T10:35:00Z","last_updated_date":"2022-01-31T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-measures-taken-help-eu-regulatory-network-cope-increased-workload-fday-anolte-ema_en.pdf"},
    {"id":"54035","name":"Presentation - Update on implementation of IRIS Marketing Status (V.Rojo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T10:37:00Z","last_updated_date":"2022-01-31T10:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-implementation-iris-marketing-status-vrojo-ema_en.pdf"},
    {"id":"54036","name":"Presentation - Working Party Implementation Project (S.Da Rocha, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T10:39:00Z","last_updated_date":"2022-01-31T10:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-party-implementation-project-sda-rocha-ema_en.pdf"},
    {"id":"54037","name":"Presentation - Use of master data and IDMP implementation (K.Puusaari, F.Penaranda, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-01-31T10:41:00Z","last_updated_date":"2022-01-31T10:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-master-data-and-idmp-implementation-kpuusaari-fpenaranda-ema_en.pdf"},
    {"id":"54057","name":"Presentation - Introducing DADI: The digital application dataset integration network project to replace electronic application forms","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T14:03:00Z","last_updated_date":"2022-02-03T14:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introducing-dadi-digital-application-dataset-integration-network-project-replace-electronic-application-forms_en.pdf"},
    {"id":"54075","name":"Presentation - Introduction to the regulatory science research needs list (L. Liu and P. Hines, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-04T13:37:00Z","last_updated_date":"2022-02-04T13:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-regulatory-science-research-needs-list-l-liu-and-p-hines-ema_en.pdf"},
    {"id":"54076","name":"Presentation - Academic perspectives on the need for regulatory scientific research (R.H. Guy, University of Bath)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-04T13:37:00Z","last_updated_date":"2022-02-04T13:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-academic-perspectives-need-regulatory-scientific-research-rh-guy-university-bath_en.pdf"},
    {"id":"54077","name":"Presentation - Regulatory science in Horizon Europe and the Innovative Health Initiative (C. Laplaza Santos, DG Research and Innovation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-04T13:37:00Z","last_updated_date":"2022-02-04T13:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-science-horizon-europe-and-innovative-health-initiative-c-laplaza-santos-dg-research-and-innovation_en.pdf"},
    {"id":"54078","name":"Presentation - Opportunities for academia to collaborate on and receive funding for regulatory science research (F.Koenig, M. Posch, Center for Medical Statistics, Informatics and Intelligent Systems","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-04T13:37:00Z","last_updated_date":"2022-02-04T13:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-academia-collaborate-and-receive-funding-regulatory-science-research-fkoenig-m-posch-center-medical-statistics-informatics-and-intelligent-systems_en.pdf"},
    {"id":"54109","name":"ATMP lifecycle support and patient access","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T17:36:00Z","last_updated_date":"2022-02-08T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/atmp-lifecycle-support-and-patient-access_en.pdf"},
    {"id":"54110","name":"CHMP-CAT inter-committee ad hoc working group on comprehensiveness of clinical data in marketing authorisations (Maura O’Donovan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T17:38:00Z","last_updated_date":"2022-02-08T17:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/chmp-cat-inter-committee-ad-hoc-working-group-comprehensiveness-clinical-data-marketing-authorisations-maura-odonovan_en.pdf"},
    {"id":"54112","name":"EMA-FDA parallel scientific advice (PSA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T17:47:00Z","last_updated_date":"2022-02-08T17:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ema-fda-parallel-scientific-advice-psa_en.pdf"},
    {"id":"54113","name":"GMO / ERA in clinical trials (Tomas Boran)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T17:52:00Z","last_updated_date":"2022-02-08T17:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gmo-era-clinical-trials-tomas-boran_en.pdf"},
    {"id":"54114","name":"GMO / ERA in marketing authorisation applications of ATMPs containing GMOs (Patrick Celis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T17:55:00Z","last_updated_date":"2022-02-08T17:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/gmo-era-marketing-authorisation-applications-atmps-containing-gmos-patrick-celis_en.pdf"},
    {"id":"54115","name":"Real world evidence (data) in CAT decision making (Kieran Breen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T17:59:00Z","last_updated_date":"2022-02-08T17:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/real-world-evidence-data-cat-decision-making-kieran-breen_en.pdf"},
    {"id":"54116","name":"New HTA regulation: key elements and next steps (Flora Giorgio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T18:04:00Z","last_updated_date":"2022-02-08T18:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/new-hta-regulation-key-elements-and-next-steps-flora-giorgio_en.pdf"},
    {"id":"54117","name":"Update on real-world evidence and DARWIN EU (Gianmario Candore)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T18:05:00Z","last_updated_date":"2022-02-08T18:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/update-real-world-evidence-and-darwin-eu-gianmario-candore_en.pdf"},
    {"id":"54125","name":"Presentation - Demonstration on Clinical Trial Information System (CTIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-02-10T14:27:00Z","last_updated_date":"2022-02-10T14:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-demonstration-clinical-trial-information-system-ctis_en.pdf"},
    {"id":"54318","name":"Presentation - Clinical Trials Information System (CTIS) bitesize talk: User access and role management","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-01T15:48:00Z","last_updated_date":"2022-03-01T15:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-user-access-and-role-management_en.pdf"},
    {"id":"54319","name":"Speakers' biographies -  Clinical Trials Information System (CTIS) bitesize talk: User access and role management","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-01T15:51:00Z","last_updated_date":"2022-03-01T15:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/speakers-biographies-clinical-trials-information-system-ctis-bitesize-talk-user-access-and-role-management_en.pdf"},
    {"id":"54353","name":"Presentation - DARWIN EU: multi-stakeholder information webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-04T16:07:00Z","last_updated_date":"2022-03-04T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-darwin-eu-multi-stakeholder-information-webinar_en.pdf"},
    {"id":"54354","name":"Presentation - DARWIN EU: multi-stakeholder information webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-04T16:07:00Z","last_updated_date":"2022-03-04T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-darwin-eu-multi-stakeholder-information-webinar_en.pdf-0"},
    {"id":"54365","name":"Presentation - Common factors in the Fast Healthcare Interoperability Resources (FHIR) data standard for Art57(2) and eAF (V.Lipucci Di Paola, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-07T16:59:00Z","last_updated_date":"2022-03-07T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-common-factors-fast-healthcare-interoperability-resources-fhir-data-standard-art572-and-eaf-vlipucci-di-paola-ema_en.pdf"},
    {"id":"54371","name":"Presentation - Update of approved and candidate COVID 19 vaccines and therapeutics (M.Cavaleri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-approved-and-candidate-covid-19-vaccines-and-therapeutics-mcavaleri-ema_en.pdf"},
    {"id":"54372","name":"Presentation - Pharmacovigilance for COVID 19 Vaccines Prospects and Plans for 2022 (G.Genov, P.Bahri, C.Zaccaria, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-covid-19-vaccines-prospects-and-plans-2022-ggenov-pbahri-czaccaria-ema_en.pdf"},
    {"id":"54373","name":"Presentation - Accelerating Clinical Trials in the EU (ACT EU) (I.den Rooijen, F.Petavy, F.Sweeney, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accelerating-clinical-trials-eu-act-eu-iden-rooijen-fpetavy-fsweeney-ema_en.pdf"},
    {"id":"54374","name":"Presentation - Big Data Steering Group progress report (J.Kjaer, DKMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-steering-group-progress-report-jkjaer-dkma_en.pdf"},
    {"id":"54375","name":"Presentation - Data Analysis and Real World Interrogation Network (DARWIN EU®) (A.Segec, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-analysis-and-real-world-interrogation-network-darwin-eur-asegec-ema_en.pdf"},
    {"id":"54376","name":"Presentation - Electronic Product Information (ePI) for EU medicines (E.Scanlan, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-electronic-product-information-epi-eu-medicines-escanlan-ema_en.pdf-0"},
    {"id":"54377","name":"Presentation - Update on activities linked to presence of N nitrosamines in human medicines (M.Filancia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-activities-linked-presence-n-nitrosamines-human-medicines-mfilancia-ema_en.pdf"},
    {"id":"54378","name":"Presentation - Communication and Stakeholders’ Engagement Plan on extended mandate (I.Abed, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-and-stakeholders-engagement-plan-extended-mandate-iabed-ema_en.pdf"},
    {"id":"54379","name":"Presentation - Awareness raising on the development and evaluation of ATMPs (P.Celis, A.Hidalgo-Simon, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-awareness-raising-development-and-evaluation-atmps-pcelis-ahidalgo-simon-ema_en.pdf"},
    {"id":"54380","name":"Presentation - European Federation for Primary Care “Convey Family Medicine principles in Health care and in Pharmaceutical care” (P.van den Hombergh, EFPC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-federation-primary-care-convey-family-medicine-principles-health-care-and-pharmaceutical-care-pvan-den-hombergh-efpc_en.pdf"},
    {"id":"54381","name":"Presentation - European Hematology Association “Recommendations for reducing bureaucracy in Clinical Trials” (N.Bolanos, EHA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-hematology-association-recommendations-reducing-bureaucracy-clinical-trials-nbolanos-eha_en.pdf"},
    {"id":"54382","name":"Presentation - European Heart Network “EU Medical Device Regulation implementation and availability of cardiac devices (C. Dhen, EHN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-heart-network-eu-medical-device-regulation-implementation-availability-cardiac-devices-c-dhen-ehn_en.pdf"},
    {"id":"54383","name":"Presentation - European Federation of Allergy and Airways Diseases  “Improving lung health through the future European Health Data Space” (I.Proano, EFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-federation-allergy-and-airways-diseases-improving-lung-health-through-future-european-health-data-space-iproano-efa_en.pdf"},
    {"id":"54384","name":"Presentation - International Patient Organisation for Primary Immunodeficiencies “Status of Primary Immunodeficiency Healthcare\" (J.Drabwell, IPOPI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-patient-organisation-primary-immunodeficiencies-status-primary-immunodeficiency-healthcare-jdrabwell-ipopi_en.pdf"},
    {"id":"54385","name":"Presentation - Call for new PCWP/HCPWP mandate 2022-2025 (I.Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-call-new-pcwphcpwp-mandate-2022-2025-isilva-ema_en.pdf"},
    {"id":"54386","name":"Presentation - PCWP/HCPWP workplan 2022-2025: development and topic prioritisation (N.Bere, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwphcpwp-workplan-2022-2025-development-and-topic-prioritisation-nbere-ema_en.pdf"},
    {"id":"54387","name":"Presentation - PCWP/HCPWP 2019 -2022 working party mandate highlights (M.Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-08T11:17:00Z","last_updated_date":"2022-03-08T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwphcpwp-2019-2022-working-party-mandate-highlights-mmavris-ema_en.pdf"},
    {"id":"54501","name":"Presentation - Revamping the Scientific Advice process (I.Gravanis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-17T13:40:00Z","last_updated_date":"2022-03-17T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revamping-scientific-advice-process-igravanis-ema_en.pdf"},
    {"id":"54502","name":"Presentation - Revamping the Scientific Advice process (I.Gravanis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-17T13:40:00Z","last_updated_date":"2022-03-17T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revamping-scientific-advice-process-igravanis-ema_en.pdf-0"},
    {"id":"54505","name":"Presentation - HTA collaboration parallel EMA/ HTA Joint Scientific Consultation (A.Behring, G-BA, EUnetHTA21; T.Olski, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-17T13:45:00Z","last_updated_date":"2022-03-17T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hta-collaboration-parallel-ema-hta-joint-scientific-consultation-abehring-g-ba-eunethta21-tolski-ema_en.pdf"},
    {"id":"54507","name":"Presentation - Review of the PRIME scheme: learnings and opportunities (S.Ribeiro, F.Cerreta, EMA); B.Sepodes (CHMP); M.Schussler-Lenz (CAT)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-17T13:46:00Z","last_updated_date":"2022-03-17T13:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-review-prime-scheme-learnings-and-opportunities-sribeiro-fcerreta-ema-bsepodes-chmp-mschussler-lenz-cat_en.pdf"},
    {"id":"54508","name":"Presentation - Report from the Focus group on the concept of an ‘evolutionary’ PIP (R.Bax, EMA; A.Braun-Scherhag, EUCOPE; A.Joos, EFPIA; R.Vart, EuropaBio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-17T13:47:00Z","last_updated_date":"2022-03-17T13:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-focus-group-concept-evolutionary-pip-rbax-ema-abraun-scherhag-eucope-ajoos-efpia-rvart-europabio_en.pdf"}    {"id":"54509","name":"Presentation - Seventh Industry stakeholder platform on research and development support (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-03-17T13:50:00Z","last_updated_date":"2022-03-17T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-seventh-industry-stakeholder-platform-research-and-development-support-parlett-ema_en.pdf"},
    {"id":"54671","name":"Presentation - Opening statements from stakeholders (A. van der Hoven)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-04-05T10:30:00Z","last_updated_date":"2022-04-05T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-statements-stakeholders-van-der-hoven_en.pdf"},
    {"id":"54672","name":"Presentation - Session 1: Monitoring and mitigating shortages of medicines and devices (J. Ferreira, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-04-05T10:32:00Z","last_updated_date":"2022-04-05T10:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-monitoring-and-mitigating-shortages-medicines-and-devices-j-ferreira-ema_en.pdf"},
    {"id":"54673","name":"Presentation - Session 2: Addressing public health emergencies through the ETF (M. Mura, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-04-05T10:33:00Z","last_updated_date":"2022-04-05T10:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-addressing-public-health-emergencies-through-etf-m-mura-ema_en.pdf"},
    {"id":"54674","name":"Presentation - Session 3: Coordinating expert panels on high-risk medical devices and in vitro diagnostics (S. da Rocha Dias, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-04-05T10:36:00Z","last_updated_date":"2022-04-05T10:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-coordinating-expert-panels-high-risk-medical-devices-vitro-diagnostics-s-da-rocha-dias-ema_en.pdf"},
    {"id":"54675","name":"Presentation - The European Health Union","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-04-05T10:39:00Z","last_updated_date":"2022-04-05T10:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-health-union_en.pdf"},
    {"id":"54693","name":"Presentation - Clinical Trials Information System (CTIS) bitesize talk: Initial clinical trial application","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-04-07T16:37:00Z","last_updated_date":"2022-04-07T16:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-initial-clinical-trial-application_en.pdf"},
    {"id":"54828","name":"Presentation - Clinical Trials Information System (CTIS) bitesize talk: Requests for information","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-04-26T14:03:00Z","last_updated_date":"2022-04-26T14:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-requests-information_en.pdf"},
    {"id":"54971","name":"Presentation - Digital application dataset integration (DADI) and Product Management Service (PMS) webinar - Variations form for human medicinal products - What will happen at go-live","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-16T16:18:00Z","last_updated_date":"2022-05-16T16:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-digital-application-dataset-integration-dadi-and-product-management-service-pms-webinar-variations-form-human-medicinal-products-what-will-happen-go-live_en.pdf"},
    {"id":"55046","name":"Presentation - Pharmacovigilance, signal detection and surveillance – industry perspective (Sonja Schwab)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T14:29:00Z","last_updated_date":"2022-05-20T14:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-signal-detection-and-surveillance-industry-perspective-sonja-schwab_en.pdf"},
    {"id":"55047","name":"Presentation - CVMP update on activities relating to Regulation 2019-6 (David Murphy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T14:38:00Z","last_updated_date":"2022-05-20T14:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-update-activities-relating-regulation-2019-6-david-murphy_en.pdf"},
    {"id":"55048","name":"Presentation - Pharmacovigilance, signal detection and surveillance (Jos Olaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T14:39:00Z","last_updated_date":"2022-05-20T14:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-signal-detection-and-surveillance-jos-olaerts_en.pdf-0"},
    {"id":"55049","name":"Presentation - Regulatory policy - Industry perspective (Cat Stirling)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T14:41:00Z","last_updated_date":"2022-05-20T14:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-policy-industry-perspective-cat-stirling_en.pdf"},
    {"id":"55050","name":"Presentation - Regulatory update (Emily Drury)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T14:43:00Z","last_updated_date":"2022-05-20T14:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-update-emily-drury_en.pdf"},
    {"id":"55051","name":"Presentation - Revision of good manufacturing practice guidelines for medicinal products for veterinary use (Brendan Cuddy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T14:47:00Z","last_updated_date":"2022-05-20T14:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revision-good-manufacturing-practice-guidelines-medicinal-products-veterinary-use-brendan-cuddy_en.pdf"},
    {"id":"55052","name":"Presentation - Updates on the implementation of Veterinary Medicinal Products Regulation and secondary legislation (Ivo Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T14:50:00Z","last_updated_date":"2022-05-20T14:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-implementation-veterinary-medicinal-products-regulation-and-secondary-legislation-ivo-claassen_en.pdf"},
    {"id":"55053","name":"Presentation - Veterinary Medicinal Products Regulation – State of play of implementation and beyond January 2022 (Eva Zamora)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T14:54:00Z","last_updated_date":"2022-05-20T14:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-medicinal-products-regulation-state-play-implementation-and-beyond-january-2022-eva-zamora_en.pdf"},
    {"id":"55096","name":"Presentation - Nitrosamine Implementation Oversight Group (NIOG) - third meeting with pharmaceutical industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-25T14:23:00Z","last_updated_date":"2022-05-25T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nitrosamine-implementation-oversight-group-niog-third-meeting-pharmaceutical-industry_en.pdf"},
    {"id":"55099","name":"Industry presentation - Nitrosamine Implementation Oversight Group (NIOG) - third meeting with pharmaceutical industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-25T14:23:00Z","last_updated_date":"2022-05-25T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/industry-presentation-nitrosamine-implementation-oversight-group-niog-third-meeting-pharmaceutical-industry_en.pdf"},
    {"id":"55104","name":"Presentation - Clinical Trials Information System (CTIS) bitesize talk: Modifications","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-05-25T16:45:00Z","last_updated_date":"2022-05-25T16:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-modifications_en.pdf"},
    {"id":"55123","name":"Presentation - Analyses of Data Quality Frameworks (P. Alcini, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-02T14:41:00Z","last_updated_date":"2022-06-02T14:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-analyses-data-quality-frameworks-p-alcini-ema_en.pdf"},
    {"id":"55124","name":"Presentation - Maturity Model for Medical Device Registries and  Coordinated Registry Networks  (CRNs) (D. Marinac-Dabic, FDA/CDRH)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-02T15:15:00Z","last_updated_date":"2022-06-02T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-maturity-model-medical-device-registries-coordinated-registry-networks-crns-d-marinac-dabic-fda-cdrh_en.pdf"},
    {"id":"55125","name":"Presentation - Building a data quality framework for the European Health Data Space on Secondary Use (E. Bernal-Delgado, IACS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-02T15:17:00Z","last_updated_date":"2022-06-02T15:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-building-data-quality-framework-european-health-data-space-secondary-use-e-bernal-delgado-iacs_en.pdf"},
    {"id":"55126","name":"Presentation - Quality Control Systems for  Secondary Use Data (P. Berzin, Odysseus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-02T15:20:00Z","last_updated_date":"2022-06-02T15:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-control-systems-secondary-use-data-p-berzin-odysseus_en.pdf"},
    {"id":"55127","name":"Presentation - Preparation for breakout sessions (P. Alcini, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-02T15:23:00Z","last_updated_date":"2022-06-02T15:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparation-breakout-sessions-p-alcini-ema_en.pdf"},
    {"id":"55128","name":"Presentation - Drafting a data quality framework structure (C. Reich, IQVIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-02T15:24:00Z","last_updated_date":"2022-06-02T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drafting-data-quality-framework-structure-c-reich-iqvia_en.pdf"},
    {"id":"55129","name":"Presentation - Opening remarks (P. Bachmann, BfArM)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-02T15:31:00Z","last_updated_date":"2022-06-02T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-remarks-p-bachmann-bfarm_en.pdf"},
    {"id":"55203","name":"Presentation - 7.3 Election of co-chairs - I Silva (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:36:00Z","last_updated_date":"2022-06-13T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-73-election-co-chairs-i-silva-ema_en.pdf"},
    {"id":"55204","name":"Presentation - 7.1 Feedback from streamlining eligibility self-certification - N Bere","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:39:00Z","last_updated_date":"2022-06-13T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-71-feedback-streamlining-eligibility-self-certification-n-bere_en.pdf"},
    {"id":"55205","name":"Presentation - 3.1 Update on objectives, progress and timelines of ICH GCP E6 revision - M Bonelli and C Mihaescu (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:42:00Z","last_updated_date":"2022-06-13T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-31-update-objectives-progress-and-timelines-ich-gcp-e6-revision-m-bonelli-and-c-mihaescu-ema_en.pdf"},
    {"id":"55206","name":"Presentation - 4.1 Update on vaccines and therapeutics - M Cavaleri (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:44:00Z","last_updated_date":"2022-06-13T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-41-update-vaccines-and-therapeutics-m-cavaleri-ema_en.pdf"},
    {"id":"55207","name":"Presentation - 4.2 Safety surveillance on vaccines and therapeutics - G Genov, C Zaccaria, P Bahri (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-07T11:45:00Z","last_updated_date":"2022-07-07T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-42-safety-surveillance-vaccines-and-therapeutics-g-genov-c-zaccaria-p-bahri-ema_en.pdf"},
    {"id":"55208","name":"Presentation - 4.3 Opening our Procedures at EMA to Non-EU authorities (OPEN) pilot - M Harvey","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:47:00Z","last_updated_date":"2022-06-13T11:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-43-opening-our-procedures-ema-non-eu-authorities-open-pilot-m-harvey_en.pdf"},
    {"id":"55209","name":"Presentation - 5.1 General update on big data - P Arlett (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:48:00Z","last_updated_date":"2022-06-13T11:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-51-general-update-big-data-p-arlett-ema_en.pdf"},
    {"id":"55211","name":"Presentation - 3.1 Clinical study data pilot interim results - F Petavy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:50:00Z","last_updated_date":"2024-10-18T14:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-31-clinical-study-data-pilot-interim-results-f-petavy_en.pdf"},
    {"id":"55212","name":"Presentation - 5.3 DARWIN EU - A Segec (EMA), A Maggioni (ESC) and E Vroom (UPPMD)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:51:00Z","last_updated_date":"2022-06-13T11:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-53-darwin-eu-segec-ema-maggioni-esc-and-e-vroom-uppmd_en.pdf"},
    {"id":"55213","name":"Presentation - 6.1 Use of EMA communications - E Fleck","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T11:52:00Z","last_updated_date":"2022-06-13T11:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-61-use-ema-communications-e-fleck_en.pdf"},
    {"id":"55343","name":"Presentation - Clinical Trials Information System (CTIS) bitesize talk: Transitional trials and additional Member State concerned (MSC) application","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-23T17:01:00Z","last_updated_date":"2022-06-23T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-transitional-trials-and-additional-member-state-concerned-msc-application_en.pdf"},
    {"id":"55373","name":"Presentation - Industry Standing Group (ISG) - Mandate, scope and composition (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:19:00Z","last_updated_date":"2022-06-24T15:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-standing-group-isg-mandate-scope-and-composition-juan-garcia-burgos_en.pdf"},
    {"id":"55374","name":"Presentation - EMA Mandate extension - high level status updates (M.Cavaleri, M.Dias, S. Da Rocha)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:22:00Z","last_updated_date":"2022-06-24T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-mandate-extension-high-level-status-updates-mcavaleri-mdias-s-da-rocha_en.pdf"},
    {"id":"55375","name":"Presentation - The Emergency task force (ETF) - EMA extended mandate – update on implementation (Manuela Mura)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:26:00Z","last_updated_date":"2022-06-24T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emergency-task-force-etf-ema-extended-mandate-update-implementation-manuela-mura_en.pdf"},
    {"id":"55377","name":"Presentation - Medicines shortages activities (Monica Dias, Joao Ferreira, Nektaria Varela)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:31:00Z","last_updated_date":"2022-06-24T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicines-shortages-activities-monica-dias-joao-ferreira-nektaria-varela_en.pdf"},
    {"id":"55381","name":"Presentation - Medical devices expert panels (Silvy da Rocha Dias, Alexey Shiryaev, Sabina Hoekstra, Miguel Antunes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-24T15:50:00Z","last_updated_date":"2022-06-24T15:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-devices-expert-panels-silvy-da-rocha-dias-alexey-shiryaev-sabina-hoekstra-miguel-antunes_en.pdf"},
    {"id":"55459","name":"Presentation - Clinical Trials Information System (CTIS) webinar: Six months of CTIS and looking forward","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-05T13:41:00Z","last_updated_date":"2022-07-05T13:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-webinar-six-months-ctis-and-looking-forward_en.pdf"},
    {"id":"55473","name":"Presentation - Thrombosis with thrombocytopenia background rates, historical comparisons, and cohort studies (Daniel Prieto Alhambra)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T14:37:00Z","last_updated_date":"2022-07-06T14:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-thrombosis-thrombocytopenia-background-rates-historical-comparisons-and-cohort-studies-daniel-prieto-alhambra_en.pdf"},
    {"id":"55474","name":"Presentation - Thromboembolic- and thrombocytopenic safety of SARS-CoV-2 vaccination in the Nordic countries three observational approaches (Anders Peter Hviid)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T14:40:00Z","last_updated_date":"2022-07-06T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-thromboembolic-and-thrombocytopenic-safety-sars-cov-2-vaccination-nordic-countries-three-observational-approaches-anders-peter-hviid_en.pdf"},
    {"id":"55476","name":"Presentation - The WHO Interim Emergency Guideline on detecting and managing TTS proposed updates (Rita Helfand and David Garcia Azorin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T14:41:00Z","last_updated_date":"2022-07-06T14:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-who-interim-emergency-guideline-detecting-and-managing-tts-proposed-updates-rita-helfand-and-david-garcia-azorin_en.pdf"},
    {"id":"55477","name":"Presentation - Janssen epidemiology activities to characterize the risk of TTS (Nicolas Praet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T14:47:00Z","last_updated_date":"2022-07-06T14:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-janssen-epidemiology-activities-characterize-risk-tts-nicolas-praet_en.pdf"},
    {"id":"55478","name":"Presentation - TTS - insights from epidemiology and pharmacovigilance (Nadia Foskett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T14:48:00Z","last_updated_date":"2022-07-06T14:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-tts-insights-epidemiology-and-pharmacovigilance-nadia-foskett_en.pdf"},
    {"id":"55479","name":"Presentation - Clinical features of VITT (Sue Pavord)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T14:59:00Z","last_updated_date":"2022-07-06T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-features-vitt-sue-pavord_en.pdf"},
    {"id":"55480","name":"Presentation - Anti-PF4 antibodies in TTSVITT (Andreas Greinacher)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T15:01:00Z","last_updated_date":"2022-07-06T15:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-anti-pf4-antibodies-ttsvitt-andreas-greinacher_en.pdf"},
    {"id":"55481","name":"Presentation - An update on TTS in Australia clinical + laboratory features and research plans (Nigel Crawford and Huyen Tran)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T15:02:00Z","last_updated_date":"2022-07-06T15:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-tts-australia-clinical-laboratory-features-and-research-plans-nigel-crawford-and-huyen-tran_en.pdf"},
    {"id":"55482","name":"Presentation - VITT A pan-vaccine reaction in need for sensitive and specific diagnosis (Anand Padmanabhan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T15:04:00Z","last_updated_date":"2022-07-06T15:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vitt-pan-vaccine-reaction-need-sensitive-and-specific-diagnosis-anand-padmanabhan_en.pdf"},
    {"id":"55483","name":"Presentation - Understanding the mechanism of TTS – work sponsored by AstraZeneca (Taylor Cohen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T15:14:00Z","last_updated_date":"2022-07-06T15:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-understanding-mechanism-tts-work-sponsored-astrazeneca-taylor-cohen_en.pdf"},
    {"id":"55484","name":"Presentation - Janssen perspective on clinical and nonclinical aspects of TTS MoA (Kerstin Luhn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T15:18:00Z","last_updated_date":"2022-07-06T15:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-janssen-perspective-clinical-and-nonclinical-aspects-tts-moa-kerstin-luhn_en.pdf"},
    {"id":"55485","name":"Presentation - Structural Biology Enabled Identification of PF4 In Adenoviral Vaccine Associated TTS (Alexander Baker and Mitesh Borad)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T15:22:00Z","last_updated_date":"2022-07-06T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-structural-biology-enabled-identification-pf4-adenoviral-vaccine-associated-tts-alexander-baker-and-mitesh-borad_en.pdf"},
    {"id":"55486","name":"Presentation - Disease mechanisms in Vaccine-Induced Immune Thrombotic Thrombocytopenia (Ishac Nazy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T15:23:00Z","last_updated_date":"2022-07-06T15:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-disease-mechanisms-vaccine-induced-immune-thrombotic-thrombocytopenia-ishac-nazy_en.pdf"},
    {"id":"55488","name":"Presentation - Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine (Stefan Kochanek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-06T15:25:00Z","last_updated_date":"2022-07-06T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-process-and-product-related-impurities-chadox1-ncov-19-vaccine-stefan-kochanek_en.pdf"},
    {"id":"55493","name":"Presentation - Organisation Management System (OMS) Trouble Shooting Session for CTIS users - June 2022","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-07T16:04:00Z","last_updated_date":"2022-07-07T16:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organisation-management-system-oms-trouble-shooting-session-ctis-users-june-2022_en.pdf"},
    {"id":"55500","name":"Presentation - Webinar on submissions of parallel distribution notifications for centrally authorised products (CAPs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-08T11:02:00Z","last_updated_date":"2022-07-08T11:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-webinar-submissions-parallel-distribution-notifications-centrally-authorised-products-caps_en.pdf"},
    {"id":"55510","name":"Presentation - Quarterly system demo - 2022","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-11T12:01:00Z","last_updated_date":"2022-07-11T12:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quarterly-system-demo-2022_en.pdf"},
    {"id":"55534","name":"Presentation - Digital application dataset integration (DADI) Q&A webinar - variations form for human medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-13T17:11:00Z","last_updated_date":"2022-07-13T17:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-digital-application-dataset-integration-dadi-qa-webinar-variations-form-human-medicinal-products_en.pdf"},
    {"id":"55544","name":"Presentation - Status update in terms of scientific advice capacity and development of proposals moving forward (Iordanis Gravanis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:10:00Z","last_updated_date":"2022-07-14T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-status-update-terms-scientific-advice-capacity-and-development-proposals-moving-forward-iordanis-gravanis_en.pdf"},
    {"id":"55546","name":"Presentation - Repurposing pilot project: Update and first insights (Christelle Bouygues, Anna Tavridou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:20:00Z","last_updated_date":"2022-07-14T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-repurposing-pilot-project-update-and-first-insights-christelle-bouygues-anna-tavridou_en.pdf"},
    {"id":"55547","name":"Presentation - Experience with the ITF framework for 3Rs and new approach methodologies (NAMs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:27:00Z","last_updated_date":"2022-07-14T16:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-itf-framework-3rs-and-new-approach-methodologies-nams_en.pdf"},
    {"id":"55548","name":"Presentation - Report from the focus group on the practical application of principles relevant for the  paediatric investigation plan (PIP) framework (Chrissi Pallidis, Gesine Bejeuhr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:29:00Z","last_updated_date":"2022-07-14T16:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-focus-group-practical-application-principles-relevant-paediatric-investigation-plan-pip-framework-chrissi-pallidis-gesine-bejeuhr_en.pdf"},
    {"id":"55549","name":"Presentation - Status of paediatric investigation plan (PIP) compliance check procedure (Peter Karolyi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:31:00Z","last_updated_date":"2022-07-14T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-status-paediatric-investigation-plan-pip-compliance-check-procedure-peter-karolyi_en.pdf"},
    {"id":"55550","name":"Presentation - Multi-stakeholder workshop: Patient experience data in medicines development and regulatory decision-making (Nathalie Bere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:33:00Z","last_updated_date":"2022-07-14T16:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multi-stakeholder-workshop-patient-experience-data-medicines-development-and-regulatory-decision-making-nathalie-bere_en.pdf"},
    {"id":"55551","name":"Presentation - Collaboration at the regulatory/HTA interface Progressing parallel Joint Scientific Consultations: Experience from the first call and preparation of the second one (Antje Behring,Thorsten Olski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:38:00Z","last_updated_date":"2022-07-14T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collaboration-regulatoryhta-interface-progressing-parallel-joint-scientific-consultations-experience-first-call-and-preparation-second-one-antje-behringthorsten-olski_en.pdf"},
    {"id":"55552","name":"Presentation - PRIME: Implementation of recommendations based on first 5 years’ experience with the scheme (Stefanie Prilla)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:40:00Z","last_updated_date":"2022-07-14T16:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prime-implementation-recommendations-based-first-5-years-experience-scheme-stefanie-prilla_en.pdf"},
    {"id":"55553","name":"Presentation - Outcomes of the EMA Survey on Orphan Maintenance Assessment Reports (OMARs) (Kristina Larsson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:47:00Z","last_updated_date":"2022-07-14T16:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcomes-ema-survey-orphan-maintenance-assessment-reports-omars-kristina-larsson_en.pdf"},
    {"id":"55554","name":"Presentation - Progress with the implementation of the companion diagnostics framework under the EU In-vitro diagnostic Regulation (IVDR) (Ana Trullas, Ciska Verbaanderd)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-14T16:51:00Z","last_updated_date":"2022-07-14T16:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-progress-implementation-companion-diagnostics-framework-under-eu-vitro-diagnostic-regulation-ivdr-ana-trullas-ciska-verbaanderd_en.pdf"},
    {"id":"55683","name":"Presentation - Organisation Management System (OMS) Trouble Shooting Session for CTIS users (July 2022)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-25T17:18:00Z","last_updated_date":"2022-07-25T17:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organisation-management-system-oms-trouble-shooting-session-ctis-users-july-2022_en.pdf"},
    {"id":"55709","name":"Presentation - Clinical Trials Information System (CTIS) bitesize talk: Deferral rules and Public website","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-27T17:32:00Z","last_updated_date":"2022-07-27T17:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-deferral-rules-and-public-website_en.pdf"},
    {"id":"55713","name":"Presentation - Clinical Trials Information System (CTIS) bitesize talk: Deferral rules and Public website","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-07-28T09:43:00Z","last_updated_date":"2022-07-28T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-deferral-rules-and-public-website_en.pdf-0"},
    {"id":"55766","name":"Presentation - How can veterinarians use the UPD public website in their practice (J. Schalansky, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-06-29T16:18:00Z","last_updated_date":"2022-08-02T11:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-can-veterinarians-use-upd-public-website-their-practice-j-schalansky-ema_en.pdf"},
    {"id":"55768","name":"Presentation - DADI PDF electronic application forms (eAF) training webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-08-02T17:02:00Z","last_updated_date":"2022-08-02T17:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dadi-pdf-electronic-application-forms-eaf-training-webinar_en.pdf"},
    {"id":"55826","name":"Presentation - EMA’s Raw Data project (E.Psarelli, M.Rueckbeil, U.Burger, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-08-17T14:28:00Z","last_updated_date":"2022-08-17T14:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-raw-data-project-epsarelli-mrueckbeil-uburger-ema_en.pdf"},
    {"id":"55827","name":"Presentation - Update on the working parties (S.Da Rocha Dias, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-08-17T14:32:00Z","last_updated_date":"2022-08-17T14:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-working-parties-sda-rocha-dias-ema_en.pdf"},
    {"id":"55828","name":"Presentation - QIG (Quality innovation Group) Overview (R.Bream, V.Jekerle, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-08-17T14:34:00Z","last_updated_date":"2022-08-17T14:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qig-quality-innovation-group-overview-rbream-vjekerle-ema_en.pdf"},
    {"id":"55829","name":"Presentation - EMA experience with the MDR implementation (C.Bouygues, P.Venneugues, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-08-17T14:36:00Z","last_updated_date":"2022-08-17T14:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-experience-mdr-implementation-cbouygues-pvenneugues-ema_en.pdf"},
    {"id":"55830","name":"Presentation - Opening our procedures at EMA to Non-EU authorities OPEN Pilot (M.Harvey, F.Day. EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-08-17T14:37:00Z","last_updated_date":"2022-08-17T14:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-our-procedures-ema-non-eu-authorities-open-pilot-mharvey-fday-ema_en.pdf"},
    {"id":"55831","name":"Presentation - Updates on IRIS (K.Hamilton, P.Pina Ferreira, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-08-17T14:40:00Z","last_updated_date":"2022-08-17T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-iris-khamilton-ppina-ferreira-ema_en.pdf"},
    {"id":"55832","name":"Presentation - RMP publications in EPARs (E.Vatzaki, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-08-17T14:42:00Z","last_updated_date":"2022-08-17T14:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rmp-publications-epars-evatzaki-ema_en.pdf"},
    {"id":"55833","name":"Presentation - Predictability in marketing authorisation submissions","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-08-17T14:53:00Z","last_updated_date":"2022-08-17T14:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-predictability-marketing-authorisation-submissions_en.pdf"},
    {"id":"55834","name":"Presentation - Predictability in marketing authorisation submissions (F.Day, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-08-17T14:53:00Z","last_updated_date":"2022-08-17T14:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-predictability-marketing-authorisation-submissions-fday-ema_en.pdf"},
    {"id":"55987","name":"Presentation - DADI PDF electronic application forms (eAF) training webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-05T17:11:00Z","last_updated_date":"2022-09-05T17:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dadi-pdf-electronic-application-forms-eaf-training-webinar_en.pdf-0"},
    {"id":"56027","name":"Presentation - EMA IRIS industry training for GVP Inspections","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-08T11:32:00Z","last_updated_date":"2022-09-08T11:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-iris-industry-training-gvp-inspections_en.pdf"},
    {"id":"56055","name":"Presentation - Union Product Database: webinar on variations not requiring assessment (VNRAs) for marketing authorisation holders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-09T16:39:00Z","last_updated_date":"2022-09-09T16:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-product-database-webinar-variations-not-requiring-assessment-vnras-marketing-authorisation-holders_en.pdf"},
    {"id":"56075","name":"Presentation - Session 1.a: Key functionalities to protect personal data and CCI in CTIS (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1a-key-functionalities-protect-personal-data-and-cci-ctis-ema_en.pdf"},
    {"id":"56077","name":"Presentation - Session 1.b: Users’ feedback on CTIS use (C. Jacobs-Blom, EUCROF)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1b-users-feedback-ctis-use-c-jacobs-blom-eucrof_en.pdf"},
    {"id":"56078","name":"Presentation - Session 1.c: Protection of personal data and CCI for documents uploaded to CTIS (R.Pankow, ACRO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1c-protection-personal-data-and-cci-documents-uploaded-ctis-rpankow-acro_en.pdf"},
    {"id":"56079","name":"Presentation - Session 1.d: EMA personal data CCI documents workshop (L.Liebers, EuropaBio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1d-ema-personal-data-cci-documents-workshop-lliebers-europabio_en.pdf"},
    {"id":"56080","name":"Presentation - Session 2.a: Personal data protection principles governing CTIS (R.Popescu, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2a-personal-data-protection-principles-governing-ctis-rpopescu-ema_en.pdf"},
    {"id":"56081","name":"Presentation - Session 1.e: Use of deferrals in CTIS, feedback from Member States (A.M. Janson Lang, Swedish MPA; S. Strasser, Austrian MPA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1e-use-deferrals-ctis-feedback-member-states-am-janson-lang-swedish-mpa-s-strasser-austrian-mpa_en.pdf"},
    {"id":"56082","name":"Presentation - Session 2.b: Protection of Personal Data and CCI for documents uploaded and published via CTIS (EuropaBio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2b-protection-personal-data-and-cci-documents-uploaded-and-published-ctis-europabio_en.pdf"},
    {"id":"56083","name":"Presentation - Session 2.c: Protection of Personal Data and CCI for documents uploaded and published via CTIS (ACRO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2c-protection-personal-data-and-cci-documents-uploaded-and-published-ctis-acro_en.pdf"},
    {"id":"56085","name":"Presentation - Session 3.a: Main principles for commercially confidential information (CCI) in the Clinical Trial Information System (CTIS) (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3a-main-principles-commercially-confidential-information-cci-clinical-trial-information-system-ctis-ema_en.pdf"},
    {"id":"56086","name":"Presentation - Session 3.b: Protection of Personal Data and CCI for documents uploaded and published via CTIS (EuropaBio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:35:00Z","last_updated_date":"2022-09-12T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3b-protection-personal-data-and-cci-documents-uploaded-and-published-ctis-europabio_en.pdf"},
    {"id":"56200","name":"Presentation - EMA framework for engagement (M. Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T13:55:00Z","last_updated_date":"2022-09-27T13:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-framework-engagement-m-mavris-ema_en.pdf"}    {"id":"56201","name":"Presentation - How patient engagement can contribute to the development and approval of medicines (Y. La Cam, EURORDIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T13:59:00Z","last_updated_date":"2022-09-27T13:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-patient-engagement-can-contribute-development-and-approval-medicines-y-la-cam-eurordis_en.pdf"},
    {"id":"56202","name":"Presentation - How patients can contribute to the safety monitoring of medicines (S. Strauss, MEPRAC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T14:02:00Z","last_updated_date":"2022-09-27T14:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-patients-can-contribute-safety-monitoring-medicines-s-strauss-meprac_en.pdf"},
    {"id":"56203","name":"Presentation - Survey results, proposed themes (L. D'Apote, EUCOPE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T14:12:00Z","last_updated_date":"2022-09-27T14:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-results-proposed-themes-l-dapote-eucope_en.pdf"},
    {"id":"56204","name":"Presentation - How patients can contribute to the development and regulation of medicines (J. Veldwijk, ESHPM)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T14:14:00Z","last_updated_date":"2022-09-27T14:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-patients-can-contribute-development-and-regulation-medicines-j-veldwijk-eshpm_en.pdf"},
    {"id":"56205","name":"Presentation - Considerations and learnings from use-cases (M. Muller, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T14:16:00Z","last_updated_date":"2022-09-27T14:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-and-learnings-use-cases-m-muller-efpia_en.pdf"},
    {"id":"56206","name":"Presentation - Patient Preference Research (K. Morrigan, MPE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T14:21:00Z","last_updated_date":"2022-09-27T14:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-preference-research-k-morrigan-mpe_en.pdf"},
    {"id":"56207","name":"Presentation - PRO data generation in practice (C. Torre, UL)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T14:26:00Z","last_updated_date":"2022-09-27T14:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pro-data-generation-practice-c-torre-ul_en.pdf"},
    {"id":"56208","name":"Presentation - Clinical Outcome Assessment (COA) Implementation and Utility (E. Dashiell-Aje, EuropaBio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T14:29:00Z","last_updated_date":"2022-09-27T14:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-outcome-assessment-coa-implementation-and-utility-e-dashiell-aje-europabio_en.pdf"},
    {"id":"56209","name":"Presentation - European Health Data Space (J. De Barros, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T14:35:00Z","last_updated_date":"2022-09-27T14:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-health-data-space-j-de-barros-ec_en.pdf"},
    {"id":"56210","name":"Presentation - Data platforms (E. Vroom, WDO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T14:42:00Z","last_updated_date":"2022-09-27T14:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-platforms-e-vroom-wdo_en.pdf"},
    {"id":"56215","name":"Presentation - EMA framework for engagement (M. Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:07:00Z","last_updated_date":"2022-09-28T10:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-framework-engagement-m-mavris-ema_en.pdf-0"},
    {"id":"56216","name":"Presentation - How patient engagement can contribute to the development and approval of medicines (Y. Le Cam, EURORDIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:08:00Z","last_updated_date":"2022-09-28T10:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-patient-engagement-can-contribute-development-and-approval-medicines-y-le-cam-eurordis_en.pdf"},
    {"id":"56217","name":"Presentation - How patients can contribute to the safety monitoring of medicines (S. Strauss, MEPRAC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:09:00Z","last_updated_date":"2022-09-28T10:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-patients-can-contribute-safety-monitoring-medicines-s-strauss-meprac_en.pdf-0"},
    {"id":"56218","name":"Presentation - Survey results, proposed themes (L. D'Apote, EUCOPE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:11:00Z","last_updated_date":"2022-09-28T10:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-results-proposed-themes-l-dapote-eucope_en.pdf-0"},
    {"id":"56219","name":"Presentation - how patient preferences can contribute to development and regulation of medicines (J. Veldwijk, ESHPM)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:20:00Z","last_updated_date":"2022-09-28T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-patient-preferences-can-contribute-development-and-regulation-medicines-j-veldwijk-eshpm_en.pdf"},
    {"id":"56220","name":"Presentation - Considerations and learnings from use-cases (M. Muller, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:23:00Z","last_updated_date":"2022-09-28T10:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-considerations-and-learnings-use-cases-m-muller-efpia_en.pdf-0"},
    {"id":"56221","name":"Presentation - Patient Preference Research (K. Morgan, MPE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:25:00Z","last_updated_date":"2022-09-28T10:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-preference-research-k-morgan-mpe_en.pdf"},
    {"id":"56222","name":"Presentation - PRO data generation in practice (C. Torre, UL)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:28:00Z","last_updated_date":"2022-09-28T10:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pro-data-generation-practice-c-torre-ul_en.pdf-0"},
    {"id":"56224","name":"Presentation - Clinical Outcome Assessment (COA) Implementation and Utility (E. Dashiell-Aje, EuropaBio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:36:00Z","last_updated_date":"2022-09-28T10:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-outcome-assessment-coa-implementation-and-utility-e-dashiell-aje-europabio_en.pdf-0"},
    {"id":"56225","name":"Presentation - European Health Data Space (J. De Barros, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:43:00Z","last_updated_date":"2022-09-28T10:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-health-data-space-j-de-barros-ec_en.pdf-0"},
    {"id":"56227","name":"Presentation - Data platforms (E. Vroom, WDO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T10:49:00Z","last_updated_date":"2022-09-28T10:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-platforms-e-vroom-wdo_en.pdf-0"},
    {"id":"56228","name":"Presentation - Qualification of novel methodologies (T. Vetter, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T11:11:00Z","last_updated_date":"2022-09-28T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qualification-novel-methodologies-t-vetter-ema_en.pdf"},
    {"id":"56229","name":"Presentation - Patient experience data in decision making and future guidance (S. Bhatti, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T11:17:00Z","last_updated_date":"2022-09-28T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-experience-data-decision-making-and-future-guidance-s-bhatti-efpia_en.pdf"},
    {"id":"56232","name":"Presentation - ICH Patient-focused drug development (PFDD) initiative (M. Bonelli, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T11:23:00Z","last_updated_date":"2022-09-28T11:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-patient-focused-drug-development-pfdd-initiative-m-bonelli-ema_en.pdf"},
    {"id":"56235","name":"Presentation - Tools to collect patient generated data (T. Stamm, MUV)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T11:28:00Z","last_updated_date":"2022-09-28T11:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-tools-collect-patient-generated-data-t-stamm-muv_en.pdf"},
    {"id":"56241","name":"Presentation - Update on COVID-19 and Monkeypoxvaccines and therapeutics (M.Cavaleri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T09:41:00Z","last_updated_date":"2022-09-29T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-covid-19-and-monkeypoxvaccines-and-therapeutics-mcavaleri-ema_en.pdf"},
    {"id":"56242","name":"Presentation - Updates on pharmacovigilance and new initiatives for risk minimisation (P.Bahri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T09:41:00Z","last_updated_date":"2022-09-29T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-pharmacovigilance-and-new-initiatives-risk-minimisation-pbahri-ema_en.pdf"},
    {"id":"56243","name":"Presentation - Policy Brief on medicines for children and rare diseases (I.Proano Gomez, EFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T09:41:00Z","last_updated_date":"2022-09-29T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-policy-brief-medicines-children-and-rare-diseases-iproano-gomez-efa_en.pdf"},
    {"id":"56244","name":"Presentation - PCWP/HCPWP contribution to ICH E6(R3) guidance on good clinical practice (GCP) (F.Houyez, PCWP; P.Szymanski, HCPWP; K.Pietsch, EMA; I.Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T09:41:00Z","last_updated_date":"2022-09-29T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwphcpwp-contribution-ich-e6r3-guidance-good-clinical-practice-gcp-fhouyez-pcwp-pszymanski-hcpwp-kpietsch-ema-isilva-ema_en.pdf"},
    {"id":"56245","name":"Presentation - Engagement and communication with EMA eligible HCP organisations - Policy Officers’ Group progress update from drafting groups (I.Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T09:41:00Z","last_updated_date":"2022-09-29T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-engagement-and-communication-ema-eligible-hcp-organisations-policy-officers-group-progress-update-drafting-groups-isilva-ema_en.pdf"},
    {"id":"56246","name":"Presentation - Feedback on ATMP dedicated webinar on 28 June 2022 (M.Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T09:41:00Z","last_updated_date":"2022-09-29T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-atmp-dedicated-webinar-28-june-2022-mmavris-ema_en.pdf"},
    {"id":"56247","name":"Presentation - Election of PCWP co-chair, 2022-2025 (M.Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T09:41:00Z","last_updated_date":"2022-09-29T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-election-pcwp-co-chair-2022-2025-mmavris-ema_en.pdf"},
    {"id":"56248","name":"Presentation - Election of HCPWP co-chair, 2022-2025 (I.Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T09:41:00Z","last_updated_date":"2022-09-29T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-election-hcpwp-co-chair-2022-2025-isilva-ema_en.pdf"},
    {"id":"56249","name":"Presentation - Consumer group surveys on drug shortages (A.la Santos, BEUC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T09:41:00Z","last_updated_date":"2022-09-29T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-consumer-group-surveys-drug-shortages-ala-santos-beuc_en.pdf"},
    {"id":"56252","name":"Presentation - Patient's Reported Outcomes (PRO) role in clinical development and approval decisions (A.Elferink, MEBSAWP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T10:28:00Z","last_updated_date":"2022-09-29T10:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-reported-outcomes-pro-role-clinical-development-and-approval-decisions-aelferink-mebsawp_en.pdf"},
    {"id":"56269","name":"Presentation - Product Management Services (PMS) Sub-Groups (SG) Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-09-30T15:57:00Z","last_updated_date":"2022-09-30T15:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-services-pms-sub-groups-sg-webinar_en.pdf"},
    {"id":"56275","name":"Presentation - Overview of PEC and PCWP (Andrea Furia-Helms, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-03T11:02:00Z","last_updated_date":"2022-10-03T11:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-pec-and-pcwp-andrea-furia-helms-fda_en.pdf"},
    {"id":"56276","name":"Presentation - Patient engagement at EMA (Maria Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-03T11:07:00Z","last_updated_date":"2022-10-03T11:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-engagement-ema-maria-mavris-ema_en.pdf"},
    {"id":"56277","name":"Presentation - Emerging lessons on communication and engagement during the pandemic (Rosa Gonzales-Quevedo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-03T11:09:00Z","last_updated_date":"2022-10-03T11:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emerging-lessons-communication-and-engagement-during-pandemic-rosa-gonzales-quevedo-ema_en.pdf"},
    {"id":"56278","name":"Presentation - COVID-19 Joint Information Center (JIC) Lessons Learned (April L. Finnen, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-03T11:10:00Z","last_updated_date":"2022-10-03T11:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-joint-information-center-jic-lessons-learned-april-l-finnen-fda_en.pdf"},
    {"id":"56293","name":"Presentation - Clinical Trials Information System (CTIS) bitesize talk: Notifications - Part 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-03T17:52:00Z","last_updated_date":"2022-10-03T17:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-notifications-part-1_en.pdf"},
    {"id":"56299","name":"Presentation - Emergency task force - update on ETF activities (M. Mura, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T11:04:00Z","last_updated_date":"2022-10-04T11:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emergency-task-force-update-etf-activities-m-mura-ema_en.pdf"},
    {"id":"56300","name":"Presentation - Medicine shortages activities (J. Ferreira, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T11:06:00Z","last_updated_date":"2022-10-04T11:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicine-shortages-activities-j-ferreira-ema_en.pdf"},
    {"id":"56301","name":"Presentation - Monitoring and mitigating shortages of critical medical devices in the context of a public health emergency (M. Dias, P. Ferreira, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T11:08:00Z","last_updated_date":"2022-10-04T11:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-mitigating-shortages-critical-medical-devices-context-public-health-emergency-m-dias-p-ferreira-ema_en.pdf"},
    {"id":"56302","name":"Presentation - Update on medical devices expert panels implementation (S. Walsh, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T11:11:00Z","last_updated_date":"2022-10-04T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-medical-devices-expert-panels-implementation-s-walsh-ema_en.pdf"},
    {"id":"56303","name":"Presentation - Update on medical devices expert panels implementation (S. da Rocha Dias, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T11:13:00Z","last_updated_date":"2022-10-04T11:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-medical-devices-expert-panels-implementation-s-da-rocha-dias-ema_en.pdf"},
    {"id":"56304","name":"Presentation - Update on Shortages of Medicines - ESMP and Agile governance (P. Ferreira, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T11:16:00Z","last_updated_date":"2022-10-04T11:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-shortages-medicines-esmp-and-agile-governance-p-ferreira-ema_en.pdf"},
    {"id":"56359","name":"Presentation - EMA Account Management Training Session","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-11T11:43:00Z","last_updated_date":"2022-10-11T11:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-account-management-training-session_en.pdf"},
    {"id":"56438","name":"Presentation - OMS Troubleshooting for CTIS users session - 19 October 2022","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-20T10:14:00Z","last_updated_date":"2022-10-20T10:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-oms-troubleshooting-ctis-users-session-19-october-2022_en.pdf"},
    {"id":"56456","name":"Presentation - Webinar on the draft Data Quality Framework for EU medicines regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-10-24T12:12:00Z","last_updated_date":"2022-10-24T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-webinar-draft-data-quality-framework-eu-medicines-regulation_en.pdf"},
    {"id":"56552","name":"Presentations - ACT EU multi-stakeholder meeting on decentralised clinical trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-08T16:14:00Z","last_updated_date":"2022-11-08T16:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentations-act-eu-multi-stakeholder-meeting-decentralised-clinical-trials_en.pdf"},
    {"id":"56593","name":"Presentation - Human variations eAF Form (DADI) training session","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T10:37:00Z","last_updated_date":"2022-11-11T10:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-human-variations-eaf-form-dadi-training-session_en.pdf"},
    {"id":"56681","name":"Presentation - Implementation of Regulation (EU) 20212282 on Health Technology Assessment - C Barbuto (EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T15:57:00Z","last_updated_date":"2022-11-17T15:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-regulation-eu-20212282-health-technology-assessment-c-barbuto-ec_en.pdf"},
    {"id":"56682","name":"Presentation - ”Sequential decision making” how regulatory and HTA activities interconnect under the new HTA Regulation - M Berntgen (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:04:00Z","last_updated_date":"2022-11-17T16:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sequential-decision-making-how-regulatory-and-hta-activities-interconnect-under-new-hta-regulation-m-berntgen-ema_en.pdf"},
    {"id":"56683","name":"Presentation - CIOMS report on ‘Patient involvement in the development, regulation and safe use of medicines’ - F Houÿez (EURORDIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:06:00Z","last_updated_date":"2022-11-17T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cioms-report-patient-involvement-development-regulation-and-safe-use-medicines-f-houyez-eurordis_en.pdf"},
    {"id":"56684","name":"Presentation - CIOMS report on ‘Patient involvement in the development, regulation and safe use of medicines’ - L Rägo (CIOMS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:08:00Z","last_updated_date":"2022-11-17T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cioms-report-patient-involvement-development-regulation-and-safe-use-medicines-l-rago-cioms_en.pdf"},
    {"id":"56685","name":"Presentation - Lessons learnt from COVID-19 - M Carr (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:17:00Z","last_updated_date":"2022-11-17T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lessons-learnt-covid-19-m-carr-ema_en.pdf"},
    {"id":"56686","name":"Presentation - Preparation for multistakeholder workshop in 2023 - M Dias (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:19:00Z","last_updated_date":"2022-11-17T16:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparation-multistakeholder-workshop-2023-m-dias-ema_en.pdf"},
    {"id":"56687","name":"Presentation - Preparation for multistakeholder workshop on AMR in 2023 - R Botgros (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:20:00Z","last_updated_date":"2022-11-17T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparation-multistakeholder-workshop-amr-2023-r-botgros-ema_en.pdf"},
    {"id":"56688","name":"Presentation - Report from EMA Multistakeholder Workshop on Patient Experience Data - R Gonzalez-Quevedo (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:22:00Z","last_updated_date":"2022-11-17T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-ema-multistakeholder-workshop-patient-experience-data-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"56689","name":"Presentation - Reporting of shortages by EU patient and healthcare professional organisations - I Abed (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:26:00Z","last_updated_date":"2022-11-17T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reporting-shortages-eu-patient-and-healthcare-professional-organisations-i-abed-ema_en.pdf"},
    {"id":"56690","name":"Presentation - The delivery under the EMA/EUnetHTA 21 work plan focus on engagement with patients and HCPs - S. Said and A. Willemsen (EunetHTA 21)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:27:00Z","last_updated_date":"2022-11-17T16:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-delivery-under-emaeunethta-21-work-plan-focus-engagement-patients-and-hcps-s-said-and-willemsen-eunethta-21_en.pdf"},
    {"id":"56691","name":"Presentation - Update of the HMA/EMA Task Force on availability of authorised medicines for human and veterinary use (TF AAM)- M Dias (EMA) and H Malonne (HMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:29:00Z","last_updated_date":"2022-11-17T16:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-hmaema-task-force-availability-authorised-medicines-human-and-veterinary-use-tf-aam-m-dias-ema-and-h-malonne-hma_en.pdf"},
    {"id":"56692","name":"Presentation - Update on EU guidance on shortage prevention and communication to the public - I Abed (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:31:00Z","last_updated_date":"2022-11-17T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-eu-guidance-shortage-prevention-and-communication-public-i-abed-ema_en.pdf"},
    {"id":"56693","name":"Presentation - Introduction to discussion topics on \"Access to medicines\"","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-17T16:32:00Z","last_updated_date":"2022-11-17T16:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-discussion-topics-access-medicines_en.pdf"},
    {"id":"56753","name":"Presentation - Clinical Trials Information System (CTIS) bitesize talk: Notifications - Part 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-23T16:08:00Z","last_updated_date":"2022-11-23T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-notifications-part-2_en.pdf"},
    {"id":"56776","name":"Presentation - European Network for Health Technology Assessment (EUnetHTA) - Health Technology Assessment regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-24T14:43:00Z","last_updated_date":"2022-11-24T14:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-health-technology-assessment-eunethta-health-technology-assessment-regulation_en.pdf"},
    {"id":"56799","name":"Presentation - Monitoring and mitigating shortages of critical medical devices in the context of a public health emergency (K.Kruttwig, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T10:19:00Z","last_updated_date":"2022-11-28T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-mitigating-shortages-critical-medical-devices-context-public-health-emergency-kkruttwig-ema_en.pdf"},
    {"id":"56800","name":"Presentation - Update on Medicine Shortages Activities (J.Ferreira, S.Zastavnik, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T10:19:00Z","last_updated_date":"2022-11-28T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-medicine-shortages-activities-jferreira-szastavnik-ema_en.pdf"},
    {"id":"56801","name":"Presentation - Update on the Expert Panels’ activities (S.da Rocha Dias, M.Antunes, EPG/EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T10:19:00Z","last_updated_date":"2022-11-28T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-expert-panels-activities-sda-rocha-dias-mantunes-epgema_en.pdf"},
    {"id":"56802","name":"Presentation - Quality Innovation Group: status update and listen-learn focus group meeting (V.Jekerle, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T10:19:00Z","last_updated_date":"2022-11-28T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-innovation-group-status-update-and-listen-learn-focus-group-meeting-vjekerle-ema_en.pdf"},
    {"id":"56803","name":"Presentation - Agile transformation update (H.Hamann, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T10:19:00Z","last_updated_date":"2022-11-28T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agile-transformation-update-hhamann-ema_en.pdf"},
    {"id":"56804","name":"Presentation - IT security at EMA -update on additional measures in place (I.Claassen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T10:19:00Z","last_updated_date":"2022-11-28T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-it-security-ema-update-additional-measures-place-iclaassen-ema_en.pdf"},
    {"id":"56805","name":"Presentation - Update on CTIS and ACT EU (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T10:19:00Z","last_updated_date":"2022-11-28T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ctis-and-act-eu-parlett-ema_en.pdf"},
    {"id":"56823","name":"Presentation - Organisation Management System (OMS) Trouble Shooting Session for CTIS users - November 2022","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-29T09:01:00Z","last_updated_date":"2022-11-29T09:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organisation-management-system-oms-trouble-shooting-session-ctis-users-november-2022_en.pdf"},
    {"id":"56834","name":"Presentation - Good Pharmacovigilance Practices (EU-GVP) - Update (P.Bahri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-30T09:25:00Z","last_updated_date":"2022-11-30T09:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-pharmacovigilance-practices-eu-gvp-update-pbahri-ema_en.pdf"},
    {"id":"56835","name":"Presentation - International transfer of personal (health) data in ICSRs originating from EudraVigilance (S.Brosch, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-30T09:25:00Z","last_updated_date":"2022-11-30T09:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-transfer-personal-health-data-icsrs-originating-eudravigilance-sbrosch-ema_en.pdf"},
    {"id":"56836","name":"Presentation - PSUR frequencies for active substances with DLP 2025 based on a risk-based approach (M.Lopez Fauqued, GPAG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-30T09:25:00Z","last_updated_date":"2022-11-30T09:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-psur-frequencies-active-substances-dlp-2025-based-risk-based-approach-mlopez-fauqued-gpag_en.pdf"},
    {"id":"56837","name":"Presentation - Update on PRAC Impact Strategy (Rev. 2) and impact research projects (T.Goedecke, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-30T09:25:00Z","last_updated_date":"2022-11-30T09:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-prac-impact-strategy-rev-2-and-impact-research-projects-tgoedecke-ema_en.pdf"},
    {"id":"56838","name":"Highlights - 17th industry stakeholder platform - operation of European Union (EU) pharmacovigilance","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-11-30T11:56:00Z","last_updated_date":"2022-11-30T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/highlights-17th-industry-stakeholder-platform-operation-european-union-eu-pharmacovigilance_en.pdf"},
    {"id":"56841","name":"Presentation - EMA/HMA Big Data Steering Group: recommendations & workplan (P. Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T09:28:00Z","last_updated_date":"2022-12-02T09:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emahma-big-data-steering-group-recommendations-workplan-p-arlett_en.pdf"},
    {"id":"56842","name":"Presentation - Veterinary Big Data highlights (R. Carapeto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T09:35:00Z","last_updated_date":"2022-12-02T09:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-big-data-highlights-r-carapeto_en.pdf"},
    {"id":"56843","name":"Presentation - Second Veterinary Big Data Stakeholder Forum - Federation of Veterinarians of Europe (D. Iatridou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T09:37:00Z","last_updated_date":"2022-12-02T09:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-second-veterinary-big-data-stakeholder-forum-federation-veterinarians-europe-d-iatridou_en.pdf"},
    {"id":"56844","name":"Presentation - Second Veterinary Big Data Stakeholder Forum - AnimalhealthEurope (R. Clayton)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T09:40:00Z","last_updated_date":"2022-12-02T09:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-second-veterinary-big-data-stakeholder-forum-animalhealtheurope-r-clayton_en.pdf"},
    {"id":"56845","name":"Presentation - Second Veterinary Big Data Stakeholder Forum - The DECIDE Project (G. v. Schaik)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T09:42:00Z","last_updated_date":"2022-12-02T09:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-second-veterinary-big-data-stakeholder-forum-decide-project-g-v-schaik_en.pdf"},
    {"id":"56894","name":"Presentation - Clinical Trials Regulation (A. Solli Karlsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:35:00Z","last_updated_date":"2022-12-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-regulation-solli-karlsen_en.pdf"},
    {"id":"56895","name":"Presentation - HTA - EU perspectives (G. Vassal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:35:00Z","last_updated_date":"2022-12-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hta-eu-perspectives-g-vassal_en.pdf"},
    {"id":"56896","name":"Presentation - HTA - evidentiary challenges (A. Denburg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:35:00Z","last_updated_date":"2022-12-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hta-evidentiary-challenges-denburg_en.pdf"},
    {"id":"56897","name":"Presentation - HTA - introduction (M. Berntgen, N. Hedberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:35:00Z","last_updated_date":"2022-12-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hta-introduction-m-berntgen-n-hedberg_en.pdf"},
    {"id":"56898","name":"Presentation - Report from CG 2022 (P. Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:35:00Z","last_updated_date":"2022-12-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-cg-2022-p-lepola_en.pdf"},
    {"id":"56899","name":"Presentation - Report from site standard workshop (G. Egger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:35:00Z","last_updated_date":"2022-12-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-site-standard-workshop-g-egger_en.pdf"},
    {"id":"56900","name":"Presentation - Role of academic clinical trials (D. Karres)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:35:00Z","last_updated_date":"2022-12-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-academic-clinical-trials-d-karres_en.pdf"},
    {"id":"56901","name":"Presentation - WG on cross-border trials (B. Nafria)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:35:00Z","last_updated_date":"2022-12-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-wg-cross-border-trials-b-nafria_en.pdf"},
    {"id":"56902","name":"Presentation - WG on off-label evidence (S. De Wildt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:35:00Z","last_updated_date":"2022-12-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-wg-label-evidence-s-de-wildt_en.pdf"},
    {"id":"56903","name":"Presentation - WG on research nurses (P. Dicks)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-07T17:35:00Z","last_updated_date":"2022-12-07T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-wg-research-nurses-p-dicks_en.pdf"},
    {"id":"56949","name":"Session 1 - Overview of 2022 deliverables and the new plan for 2022-2025 (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T09:46:00Z","last_updated_date":"2022-12-13T09:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-1-overview-2022-deliverables-and-new-plan-2022-2025-peter-arlett_en.pdf"},
    {"id":"56950","name":"Session 2-1 - DARWIN EU ® – first experiences and regulatory use case (Xavier Kurz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T09:55:00Z","last_updated_date":"2022-12-13T09:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-2-1-darwin-eu-r-first-experiences-and-regulatory-use-case-xavier-kurz_en.pdf"},
    {"id":"56951","name":"Session 2-2 - HTA DARWIN use case examples (Niklas Hedberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T09:57:00Z","last_updated_date":"2022-12-13T09:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-2-2-hta-darwin-use-case-examples-niklas-hedberg_en.pdf"},
    {"id":"56952","name":"Session 2-3 - Payers DARWIN Use case examples (Wim Goettsch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:14:00Z","last_updated_date":"2022-12-13T10:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-2-3-payers-darwin-use-case-examples-wim-goettsch_en.pdf"},
    {"id":"56953","name":"Session 2-4 - EU Data Quality Framework for medicines regulation – launch and collaboration (Ana Cochino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:18:00Z","last_updated_date":"2022-12-13T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-2-4-eu-data-quality-framework-medicines-regulation-launch-and-collaboration-ana-cochino_en.pdf"}    {"id":"56954","name":"Session 3-1 - EU Real World metadata list, good practice guide and catalogues of data sources and studies (Katerina Deli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:18:00Z","last_updated_date":"2022-12-13T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-3-1-eu-real-world-metadata-list-good-practice-guide-and-catalogues-data-sources-and-studies-katerina-deli_en.pdf"},
    {"id":"56955","name":"Session 3-2 Artificial Intelligence in Medicines Regulation (Gabriel Westman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:18:00Z","last_updated_date":"2022-12-13T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-3-2-artificial-intelligence-medicines-regulation-gabriel-westman_en.pdf"},
    {"id":"56956","name":"Session 3-3 Regulatory capability to analyse data - Clinical trial raw data (Joerg Zinserling)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:18:00Z","last_updated_date":"2022-12-13T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-3-3-regulatory-capability-analyse-data-clinical-trial-raw-data-joerg-zinserling_en.pdf"},
    {"id":"56957","name":"Session 4-1 European Health Data Space (Jerome De Barros)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:18:00Z","last_updated_date":"2022-12-13T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-4-1-european-health-data-space-jerome-de-barros_en.pdf"},
    {"id":"56958","name":"Session 4-2 -Towards European Health Data Space (TEHDAS) (Shona Cosgrove)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:18:00Z","last_updated_date":"2022-12-13T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-4-2-towards-european-health-data-space-tehdas-shona-cosgrove_en.pdf"},
    {"id":"56959","name":"Session 4-3 - EHDS2 (Pilot Mario Jendrossek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:18:00Z","last_updated_date":"2022-12-13T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-4-3-ehds2-pilot-mario-jendrossek_en.pdf"},
    {"id":"56960","name":"Session 4-4 - Implementation status of the ERMN Data standardization strategy (Nick Halsey)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:18:00Z","last_updated_date":"2022-12-13T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-4-4-implementation-status-ermn-data-standardization-strategy-nick-halsey_en.pdf"},
    {"id":"56961","name":"Session 4-5 - Collaboration on international initiatives (Sean Barry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:51:00Z","last_updated_date":"2022-12-13T10:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-4-5-collaboration-international-initiatives-sean-barry_en.pdf"},
    {"id":"56962","name":"Session 4-6 - RWE international collaboration and next steps (Melissa Kampman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:52:00Z","last_updated_date":"2022-12-13T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-4-6-rwe-international-collaboration-and-next-steps-melissa-kampman_en.pdf"},
    {"id":"56963","name":"Session 4-7 - Advanced analytics to support animal and public health - Report from the 2nd Veterinary Big Data Stakeholders Forum (Ilaria Del Seppia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:55:00Z","last_updated_date":"2022-12-13T10:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-4-7-advanced-analytics-support-animal-and-public-health-report-2nd-veterinary-big-data-stakeholders-forum-ilaria-del-seppia_en.pdf"},
    {"id":"56964","name":"Session 5-1 - EU Research & Innovation activities (Christina Kyriakopoulou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T10:58:00Z","last_updated_date":"2022-12-13T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-5-1-eu-research-innovation-activities-christina-kyriakopoulou_en.pdf"},
    {"id":"56965","name":"Session 5-2 - Preparing for the future horizon scanning for big data topics (Ralf Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T11:00:00Z","last_updated_date":"2022-12-13T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-5-2-preparing-future-horizon-scanning-big-data-topics-ralf-herold_en.pdf"},
    {"id":"56966","name":"Presentation 1a - Update on electronic submissions & DADI- (K. Hamilton, K. Puusaar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T11:43:00Z","last_updated_date":"2022-12-13T11:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-1a-update-electronic-submissions-dadi-k-hamilton-k-puusaar_en.pdf"},
    {"id":"56967","name":"Presentation 2b - EMA International collaboration in the review of medicines (V. Palmi-Reig, M. Harvey-Allchurch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T11:46:00Z","last_updated_date":"2022-12-13T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2b-ema-international-collaboration-review-medicines-v-palmi-reig-m-harvey-allchurch_en.pdf"},
    {"id":"56968","name":"Presentation 3b - Pre-submissions meetings (M. Kollb-Sielecka, G. Bec)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T11:46:00Z","last_updated_date":"2022-12-13T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-3b-pre-submissions-meetings-m-kollb-sielecka-g-bec_en.pdf"},
    {"id":"56973","name":"Presentation 6 - EMA's Clinical Trials Raw Data project (E. Psarelli & F. Lasch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T11:46:00Z","last_updated_date":"2022-12-13T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-6-emas-clinical-trials-raw-data-project-e-psarelli-f-lasch_en.pdf"},
    {"id":"56974","name":"Presentation 4a - Network sustainability and update on CHMP AR revamp project (F. Day)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T11:46:00Z","last_updated_date":"2022-12-13T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-4a-network-sustainability-and-update-chmp-ar-revamp-project-f-day_en.pdf"},
    {"id":"56975","name":"Presentation 7b - ePI - Update on Electronic Product Information (J. Garcia, E. Scanlan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T11:46:00Z","last_updated_date":"2022-12-13T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-7b-epi-update-electronic-product-information-j-garcia-e-scanlan_en.pdf"},
    {"id":"57046","name":"Presentation - Recent developments to address scientific advice capacity and scope (Iordanis Gravanis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T15:53:00Z","last_updated_date":"2022-12-15T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recent-developments-address-scientific-advice-capacity-and-scope-iordanis-gravanis_en.pdf"},
    {"id":"57047","name":"Presentation - Focus Group on review and strengthening the framework for Qualification of Novel Methodologies (QoNM) (Thorsten Vetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T15:56:00Z","last_updated_date":"2022-12-15T15:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-review-and-strengthening-framework-qualification-novel-methodologies-qonm-thorsten-vetter_en.pdf"},
    {"id":"57048","name":"Presentation - Progressing parallel Joint Scientific Consultations (Antje Behring, Thorsten Olski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T15:58:00Z","last_updated_date":"2022-12-15T15:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-progressing-parallel-joint-scientific-consultations-antje-behring-thorsten-olski_en.pdf"},
    {"id":"57049","name":"Presentation - PRIME Implementation of recommendations based on first 5 years’ experience with the scheme (Kevin Cunningham)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T16:00:00Z","last_updated_date":"2022-12-15T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prime-implementation-recommendations-based-first-5-years-experience-scheme-kevin-cunningham_en.pdf"},
    {"id":"57050","name":"Presentation - EMA/EC action plan on paediatrics 2018-2022 (Gunter Egger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T16:02:00Z","last_updated_date":"2022-12-15T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emaec-action-plan-paediatrics-2018-2022-gunter-egger_en.pdf"},
    {"id":"57051","name":"Presentation - Closing report from the Focus group on the practical application of principles relevant for the PIP framework (Chrissi Pallidis, Sabine Scherer, Gesine Bejeuhr, Marcello Milano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T16:04:00Z","last_updated_date":"2022-12-15T16:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-closing-report-focus-group-practical-application-principles-relevant-pip-framework-chrissi-pallidis-sabine-scherer-gesine-bejeuhr-marcello-milano_en.pdf"},
    {"id":"57052","name":"Presentation - Changes to the preparation of the Paediatric Annual Report to the EC (Isabel Sanchez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T16:06:00Z","last_updated_date":"2022-12-15T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-changes-preparation-paediatric-annual-report-ec-isabel-sanchez_en.pdf"},
    {"id":"57054","name":"Presentation - Medical Device Expert Panels’ Activities (Silvy da Rocha Dias, Miguel Antunes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T16:08:00Z","last_updated_date":"2022-12-15T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-device-expert-panels-activities-silvy-da-rocha-dias-miguel-antunes_en.pdf"},
    {"id":"57055","name":"Presentation - Follow-up on strengthening patient-centric development (Juan Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T16:10:00Z","last_updated_date":"2022-12-15T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-follow-strengthening-patient-centric-development-juan-garcia-burgos_en.pdf"},
    {"id":"57056","name":"Presentation - Human Variations eAF Form training session","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-15T16:22:00Z","last_updated_date":"2022-12-15T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-human-variations-eaf-form-training-session_en.pdf"},
    {"id":"57102","name":"Presentation - Clinical Trials Information System (CTIS) bitesize talk: Annual safety report (ASR)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-20T15:13:00Z","last_updated_date":"2022-12-20T15:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-annual-safety-report-asr_en.pdf"},
    {"id":"57107","name":"Presentation 5 - Update on Type II validation team (F. Day, L. Liebers, A. Begic, C. Forster)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2022-12-21T11:35:00Z","last_updated_date":"2022-12-21T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-5-update-type-ii-validation-team-f-day-l-liebers-begic-c-forster_en.pdf"},
    {"id":"57233","name":"Presentation 01. SARS-CoV-2 Monoclonal Antibody Workshop: FDA Perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:24:00Z","last_updated_date":"2023-01-12T10:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-01-sars-cov-2-monoclonal-antibody-workshop-fda-perspective_en.pdf"},
    {"id":"57234","name":"Presentation 01a. SARS-CoV-2 Monoclonal Antibody Workshop: EMA Perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:27:00Z","last_updated_date":"2023-01-12T10:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-01a-sars-cov-2-monoclonal-antibody-workshop-ema-perspective_en.pdf"},
    {"id":"57235","name":"Presentation 02. Overview of the clinical trials that led to the authorisation of monoclonal antibody therapies in the EU","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:28:00Z","last_updated_date":"2023-01-12T10:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-02-overview-clinical-trials-led-authorisation-monoclonal-antibody-therapies-eu_en.pdf"},
    {"id":"57236","name":"Presentation 03. Viral diversity and antibody breadth","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:31:00Z","last_updated_date":"2023-01-12T10:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-03-viral-diversity-and-antibody-breadth_en.pdf"},
    {"id":"57237","name":"Presentation 04. Utility of virologic assessments as a marker of progression to severe disease based on data from the ACTIV-2 trial","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:34:00Z","last_updated_date":"2023-01-12T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-04-utility-virologic-assessments-marker-progression-severe-disease-based-data-activ-2-trial_en.pdf"},
    {"id":"57238","name":"Presentation 05. Translational PK-PD Modeling During COVID-19_Evusheld and Points to Consider","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:35:00Z","last_updated_date":"2023-01-12T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-05-translational-pk-pd-modeling-during-covid-19_evusheld-and-points-consider_en.pdf"},
    {"id":"57239","name":"Presentation 06. Evidence in support of the use of serum neutralization data to justify a dose increase of monoclonal antibodies to tackle new variant","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:38:00Z","last_updated_date":"2023-01-12T10:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-06-evidence-support-use-serum-neutralization-data-justify-dose-increase-monoclonal-antibodies-tackle-new-variant_en.pdf"},
    {"id":"57240","name":"06. Evidence in support of the use of serum neutralization data to justify a dose increase of monoclonal antibodies to tackle new variant","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:38:00Z","last_updated_date":"2023-01-12T10:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/06-evidence-support-use-serum-neutralization-data-justify-dose-increase-monoclonal-antibodies-tackle-new-variant_en.pdf"},
    {"id":"57241","name":"Presentation 07. Lessons on Correlates of Protection from COVID-19 Vaccines and HIV-1 Monoclonal Antibodies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:46:00Z","last_updated_date":"2023-01-12T10:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-07-lessons-correlates-protection-covid-19-vaccines-and-hiv-1-monoclonal-antibodies_en.pdf"},
    {"id":"57242","name":"Presentation 08. Correlation Between Protection and ex vivo Neutralization in the Context of Pre-exposure Prophylaxis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:51:00Z","last_updated_date":"2023-01-12T10:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-08-correlation-between-protection-and-ex-vivo-neutralization-context-pre-exposure-prophylaxis_en.pdf"},
    {"id":"57243","name":"Presentation 09. Correlates of protection using a neutralisation approach","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:53:00Z","last_updated_date":"2023-01-12T10:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-09-correlates-protection-using-neutralisation-approach_en.pdf"},
    {"id":"57244","name":"Presentation 10. Considerations Regarding Assessment of a Modified Monoclonal Antibody (mAb) Product Related to a Prototype mAb Production Addressing Emerging SARS-COV-2 Variants– a CMC Perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:55:00Z","last_updated_date":"2023-01-12T10:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-10-considerations-regarding-assessment-modified-monoclonal-antibody-mab-product-related-prototype-mab-production-addressing-emerging-sars-cov-2-variants-cmc-perspective_en.pdf"},
    {"id":"57245","name":"Presentation 11. Development Approach for Anti-Spike Monoclonal Antibodies to Keep Pace with SARS-CoV-2 Variants","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T10:58:00Z","last_updated_date":"2023-01-12T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11-development-approach-anti-spike-monoclonal-antibodies-keep-pace-sars-cov-2-variants_en.pdf"},
    {"id":"57246","name":"Presentation 11a. Use of neutralizing antibody or PK_IC50 threshold to expedite clinical development for prophylactic monoclonal antibodies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T11:00:00Z","last_updated_date":"2023-01-12T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11a-use-neutralizing-antibody-or-pk_ic50-threshold-expedite-clinical-development-prophylactic-monoclonal-antibodies_en.pdf"},
    {"id":"57247","name":"Presentation 11b. Neutralising antibodies for the treatment of ambulatory patients","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T11:03:00Z","last_updated_date":"2023-01-12T11:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11b-neutralising-antibodies-treatment-ambulatory-patients_en.pdf"},
    {"id":"57248","name":"Presentation 11c. QSP Strategy to Support Development of Adintrevimab for Prevention and Treatment of COVID-19","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T11:06:00Z","last_updated_date":"2023-01-12T11:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11c-qsp-strategy-support-development-adintrevimab-prevention-and-treatment-covid-19_en.pdf"},
    {"id":"57249","name":"Presentation 11d. Molecules Against Novel Targets","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T11:09:00Z","last_updated_date":"2023-01-12T11:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-11d-molecules-against-novel-targets_en.pdf"},
    {"id":"57366","name":"Lanreotide : List of nationally authorised medicinal products - PSUSA/00001826/202205","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-24T11:28:00Z","last_updated_date":"2023-01-24T11:28:00Z","reference_number":"EMA/37767/2023","document_url":"https://www.ema.europa.eu/en/documents/presentation/lanreotide-list-nationally-authorised-medicinal-products-psusa00001826202205_en.pdf"},
    {"id":"57368","name":"Presentation - Second Veterinary Big Data Stakeholder Forum - FDA (H. J. Duggirala)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-24T11:42:00Z","last_updated_date":"2023-01-24T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-second-veterinary-big-data-stakeholder-forum-fda-h-j-duggirala_en.pdf"},
    {"id":"57370","name":"Presentation - Second Veterinary Big Data Stakeholder Forum - ANSES (L. Baduel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-24T11:47:00Z","last_updated_date":"2023-01-24T11:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-second-veterinary-big-data-stakeholder-forum-anses-l-baduel_en.pdf"},
    {"id":"57371","name":"Presentation - Second Veterinary Big Data Stakeholder Forum - EFSA (K. Paraskevopoulos, M. Rossi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-24T11:49:00Z","last_updated_date":"2023-01-24T11:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-second-veterinary-big-data-stakeholder-forum-efsa-k-paraskevopoulos-m-rossi_en.pdf"},
    {"id":"57372","name":"Presentation - Second Veterinary Big Data Stakeholder Forum - Stakeholders’ insights on key business areas (S. Bertulat)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-24T11:53:00Z","last_updated_date":"2023-01-24T11:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-second-veterinary-big-data-stakeholder-forum-stakeholders-insights-key-business-areas-s-bertulat_en.pdf"},
    {"id":"57373","name":"Presentation - Second Veterinary Big Data Stakeholder Forum - WOAH (L. Awada, A. Campos","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-24T11:56:00Z","last_updated_date":"2023-01-24T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-second-veterinary-big-data-stakeholder-forum-woah-l-awada-campos_en.pdf"},
    {"id":"57451","name":"Presentation - Global overview of vaccine related myocarditis (Kristine Macartney)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T17:23:00Z","last_updated_date":"2023-01-31T17:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-global-overview-vaccine-related-myocarditis-kristine-macartney_en.pdf"},
    {"id":"57452","name":"Presentation - Risk of myocarditis after Covid-19 mRNA vaccination: Impact of booster dose and dosing interval (Le Vu et al.)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T17:26:00Z","last_updated_date":"2023-01-31T17:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-myocarditis-after-covid-19-mrna-vaccination-impact-booster-dose-and-dosing-interval-le-vu-et-al_en.pdf"},
    {"id":"57453","name":"Presentation - Incidence, follow-up, and pathophysiology of myocarditis following mRNA vaccine in Israel: Results of an active surveillance (Mevorach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T17:36:00Z","last_updated_date":"2023-01-31T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-incidence-follow-and-pathophysiology-myocarditis-following-mrna-vaccine-israel-results-active-surveillance-mevorach_en.pdf"},
    {"id":"57454","name":"Presentation - Myocarditis after mRNA COVID-19 vaccines in the United States: children aged ≤11 years, and follow-up among people aged 12-29 years at least 90 days after symptom onset of myocarditis (John R. Su)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T17:38:00Z","last_updated_date":"2023-01-31T17:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-myocarditis-after-mrna-covid-19-vaccines-united-states-children-aged-11-years-and-follow-among-people-aged-12-29-years-least-90-days-after-symptom-onset-myocarditis-john-r-su_en.pdf"},
    {"id":"57455","name":"Presentation - COVID-19 Vaccine BNT162b2 myocarditis (Pfizer / BioNTech)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T17:42:00Z","last_updated_date":"2023-01-31T17:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid-19-vaccine-bnt162b2-myocarditis-pfizer-biontech_en.pdf"},
    {"id":"57456","name":"Presentation - Moderna COVID-19 vaccines and the risk of myocarditis: review of current data and planned studies (Walter Straus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T17:45:00Z","last_updated_date":"2023-01-31T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-moderna-covid-19-vaccines-and-risk-myocarditis-review-current-data-and-planned-studies-walter-straus_en.pdf"},
    {"id":"57457","name":"Presentation - Myocarditis post-marketing reporting rates for Nuvaxovid (Christopher Mast)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T17:54:00Z","last_updated_date":"2023-01-31T17:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-myocarditis-post-marketing-reporting-rates-nuvaxovid-christopher-mast_en.pdf"},
    {"id":"57458","name":"Presentation - Integrated analysis of transcriptomic and epigenomic signatures of peripheral immune cells in the patient of BNT162b2-induced myocarditis (Bo Kyung Yoon, M.D.)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T17:58:00Z","last_updated_date":"2023-01-31T17:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-integrated-analysis-transcriptomic-and-epigenomic-signatures-peripheral-immune-cells-patient-bnt162b2-induced-myocarditis-bo-kyung-yoon-md_en.pdf"},
    {"id":"57459","name":"Presentation - Circulating spike protein detected in post-COVID-19 mRNA vaccine myocarditis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T18:01:00Z","last_updated_date":"2023-01-31T18:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-circulating-spike-protein-detected-post-covid-19-mrna-vaccine-myocarditis_en.pdf"},
    {"id":"57460","name":"Presentation - Circulating spike protein detected in post-COVID-19 mRNA vaccine myocarditis (Lael M. Yonker et al.)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T18:01:00Z","last_updated_date":"2023-01-31T18:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-circulating-spike-protein-detected-post-covid-19-mrna-vaccine-myocarditis-lael-m-yonker-et-al_en.pdf"},
    {"id":"57461","name":"Presentation - Implication of sex differences in myocarditis (Katelyn Bruno)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T18:06:00Z","last_updated_date":"2023-01-31T18:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implication-sex-differences-myocarditis-katelyn-bruno_en.pdf"},
    {"id":"57462","name":"Presentation - Innate immune mechanisms of mRNA vaccines (Rein Verbeke et al.)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T18:09:00Z","last_updated_date":"2023-01-31T18:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innate-immune-mechanisms-mrna-vaccines-rein-verbeke-et-al_en.pdf"},
    {"id":"57463","name":"Presentation - IL-RA antibodies in myocarditis after SARS-CoV-2 vaccination (Thurner L et al.)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T18:14:00Z","last_updated_date":"2023-01-31T18:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-il-ra-antibodies-myocarditis-after-sars-cov-2-vaccination-thurner-l-et-al_en.pdf"},
    {"id":"57464","name":"Presentation - Lack of evidence of significant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens (Alessandro Sette)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T18:16:00Z","last_updated_date":"2023-01-31T18:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lack-evidence-significant-homology-sars-cov-2-spike-sequences-myocarditis-associated-antigens-alessandro-sette_en.pdf"},
    {"id":"57465","name":"Presentation - Mechanisms of myocarditis post-COVID vaccination (Alida LP Caforio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T18:18:00Z","last_updated_date":"2023-01-31T18:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mechanisms-myocarditis-post-covid-vaccination-alida-lp-caforio_en.pdf"},
    {"id":"57466","name":"Presentation - SARS CoV 2 vaccination autopsies (Peter Schirmacher)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T18:21:00Z","last_updated_date":"2023-01-31T18:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sars-cov-2-vaccination-autopsies-peter-schirmacher_en.pdf"},
    {"id":"57467","name":"Presentation - Genetic study of vaccine-induced myocarditis (Alexandre Bolze, Elena Hsieh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T18:23:00Z","last_updated_date":"2023-01-31T18:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-genetic-study-vaccine-induced-myocarditis-alexandre-bolze-elena-hsieh_en.pdf"},
    {"id":"57499","name":"Presentation - European Union (EU) International Organisation for Standardization (ISO) for identification of medical products (IDMP)/Substance, Product, Organisation and Referential (SPOR) data Task Force meeting - January 2023","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-02T10:25:00Z","last_updated_date":"2023-02-02T10:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-union-eu-international-organisation-standardization-iso-identification-medical-products-idmpsubstance-product-organisation-and-referential-spor-data-task-force-meeting-january_en.pdf"},
    {"id":"57523","name":"Presentation - Information session on the pilot for expert panels’ scientific advice to manufacturers of certain high-risk medical devices","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-06T10:15:00Z","last_updated_date":"2023-02-06T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-session-pilot-expert-panels-scientific-advice-manufacturers-certain-high-risk-medical-devices_en.pdf"},
    {"id":"57546","name":"Presentation - Fourth meeting of the Nitrosamine Implementation Oversight Group (NIOG) and pharmaceutical Industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-07T14:16:00Z","last_updated_date":"2023-02-07T14:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fourth-meeting-nitrosamine-implementation-oversight-group-niog-and-pharmaceutical-industry_en.pdf"},
    {"id":"57547","name":"Industry presentation - Fourth meeting of the Nitrosamine Implementation Oversight Group (NIOG) and pharmaceutical Industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-07T14:16:00Z","last_updated_date":"2023-02-07T14:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/industry-presentation-fourth-meeting-nitrosamine-implementation-oversight-group-niog-and-pharmaceutical-industry_en.pdf"},
    {"id":"57549","name":"Industry presentation (2) - Fourth meeting of the Nitrosamine Implementation Oversight Group (NIOG) and pharmaceutical Industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-07T14:16:00Z","last_updated_date":"2023-02-07T14:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/industry-presentation-2-fourth-meeting-nitrosamine-implementation-oversight-group-niog-and-pharmaceutical-industry_en.pdf"},
    {"id":"57553","name":"Presentation - State of the Art of RNA Technologies_EU regulators’ perspective (Sol Ruiz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T10:33:00Z","last_updated_date":"2023-02-08T10:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-state-art-rna-technologies_eu-regulators-perspective-sol-ruiz_en.pdf"},
    {"id":"57556","name":"Presentation - A brief introduction into oligonucleotide therapies (Annemieke Aartsma-Rus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T10:40:00Z","last_updated_date":"2023-02-08T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-brief-introduction-oligonucleotide-therapies-annemieke-aartsma-rus_en.pdf"},
    {"id":"57557","name":"Presentation - State of the Art of RNA Technologies \"Industry Perspective\" (Tal Zaks)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T10:44:00Z","last_updated_date":"2023-02-08T10:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-state-art-rna-technologies-industry-perspective-tal-zaks_en.pdf"},
    {"id":"57558","name":"Presentation - EU Regulators’ experience with synthetic oligonucleotides and mRNA technology (René Thürmer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T10:50:00Z","last_updated_date":"2023-02-08T10:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-regulators-experience-synthetic-oligonucleotides-and-mrna-technology-rene-thurmer_en.pdf"},
    {"id":"57559","name":"Presentation - Industry perspective on synthetic oligonucleotide (Daniel Capaldi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T10:52:00Z","last_updated_date":"2023-02-08T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-synthetic-oligonucleotide-daniel-capaldi_en.pdf"},
    {"id":"57560","name":"Presentation - Industry perspective on mRNA technology (Pawel Widomski)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T10:56:00Z","last_updated_date":"2023-02-08T10:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-mrna-technology-pawel-widomski_en.pdf"},
    {"id":"57561","name":"Presentation - Opportunities and challenges in non-clinical development - Academic Perspective (Haiyan Zhou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T11:02:00Z","last_updated_date":"2023-02-08T11:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-and-challenges-non-clinical-development-academic-perspective-haiyan-zhou_en.pdf"},
    {"id":"57562","name":"Presentation - Application of RNA Technologies Non-Clinical Industry perspective (Susan Goody)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T11:11:00Z","last_updated_date":"2023-02-08T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-application-rna-technologies-non-clinical-industry-perspective-susan-goody_en.pdf"},
    {"id":"57563","name":"Presentation - Opportunities and challenges in non-clinical development - The regulator's perspective (Camilla Svensson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T11:20:00Z","last_updated_date":"2023-02-08T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-and-challenges-non-clinical-development-regulators-perspective-camilla-svensson_en.pdf"},
    {"id":"57564","name":"Presentation - Applications of RNA technologies - Clinical_Academia perspective (David Henshall)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T11:26:00Z","last_updated_date":"2023-02-08T11:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-applications-rna-technologies-clinical_academia-perspective-david-henshall_en.pdf"},
    {"id":"57565","name":"Presentation - Applications of RNA technologies - Clinical - An Industry Perspective (Michael Wenger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T11:29:00Z","last_updated_date":"2023-02-08T11:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-applications-rna-technologies-clinical-industry-perspective-michael-wenger_en.pdf"},
    {"id":"57566","name":"Presentation - Applications of RNA technologies - Clinical - Regulators' perspective (Joop van Gerven)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T11:35:00Z","last_updated_date":"2023-02-08T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-applications-rna-technologies-clinical-regulators-perspective-joop-van-gerven_en.pdf"},
    {"id":"57872","name":"Presentation - Update from the Commission on the VMP-Reg (Alfonso Las Heras)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-03T10:57:00Z","last_updated_date":"2023-03-03T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-commission-vmp-reg-alfonso-las-heras_en.pdf"},
    {"id":"57873","name":"Presentation - EMA retrospective - a year into the VMP-Reg (Ivo Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-03T10:57:00Z","last_updated_date":"2023-03-03T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-retrospective-year-vmp-reg-ivo-claassen_en.pdf"},
    {"id":"57874","name":"Presentation - CVMP workplan for 2023 and beyond (Johan Schefferlie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-03T10:57:00Z","last_updated_date":"2023-03-03T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-workplan-2023-and-beyond-johan-schefferlie_en.pdf"},
    {"id":"57875","name":"Presentation - One year implementing Reg 2019-6 - industry perspective (Heidi Schwer & Aafke Huizenga)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-03T10:57:00Z","last_updated_date":"2023-03-03T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-one-year-implementing-reg-2019-6-industry-perspective-heidi-schwer-aafke-huizenga_en.pdf"},
    {"id":"57876","name":"Presentation - Clarifications on actions for industry in 2023 and beyond (Jana Schalansky)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-03T10:57:00Z","last_updated_date":"2023-03-03T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clarifications-actions-industry-2023-and-beyond-jana-schalansky_en.pdf"},
    {"id":"57877","name":"Presentation - Pharmacovigilance - Signal Management (Daniel Zondag)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-03T10:57:00Z","last_updated_date":"2023-03-03T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-signal-management-daniel-zondag_en.pdf"},
    {"id":"57878","name":"Presentation - Pharmacovigilance Industry perspective (Tony Simon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-03T10:57:00Z","last_updated_date":"2023-03-03T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-industry-perspective-tony-simon_en.pdf"},
    {"id":"57879","name":"Presentation - Impact of the new regulatory framework on innovation (Raffaele Bruno)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-03T10:57:00Z","last_updated_date":"2023-03-03T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-new-regulatory-framework-innovation-raffaele-bruno_en.pdf"},
    {"id":"57902","name":"Presentation - 1.2 European Medicines Agencies Network initiatives - Lorraine Nolan (HMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T12:48:00Z","last_updated_date":"2023-03-07T12:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-12-european-medicines-agencies-network-initiatives-lorraine-nolan-hma_en.pdf"},
    {"id":"57903","name":"Presentation - 1.4 Monitoring of events and preparedness for Public Health Emergencies (PHE) - Anthony Humphreys (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T12:54:00Z","last_updated_date":"2023-03-07T12:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-14-monitoring-events-and-preparedness-public-health-emergencies-phe-anthony-humphreys-ema_en.pdf"},
    {"id":"57904","name":"Presentation - 1.5 What happened with the HMA-EMA Task Force on availability of authorised medicines (TF AAM) since 2018","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T12:56:00Z","last_updated_date":"2023-03-07T12:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-15-what-happened-hma-ema-task-force-availability-authorised-medicines-tf-aam-2018_en.pdf"},
    {"id":"57905","name":"Presentation - 2A.1 Overview of immunoglobulins supply situation in the EU - Klaus Kruttwig (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T12:58:00Z","last_updated_date":"2023-03-07T12:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2a1-overview-immunoglobulins-supply-situation-eu-klaus-kruttwig-ema_en.pdf"},
    {"id":"57906","name":"Presentation - 2A.2 EU legislation and policy on blood and blood components - Stefaan van der Spiegel (DG SANTE, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:02:00Z","last_updated_date":"2023-03-07T13:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2a2-eu-legislation-and-policy-blood-and-blood-components-stefaan-van-der-spiegel-dg-sante-ec_en.pdf"}    {"id":"57907","name":"Presentation - 2A.4 Rapporteur session - Emilija Matelytė (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:11:00Z","last_updated_date":"2023-03-07T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2a4-rapporteur-session-emilija-matelyte-ema_en.pdf"},
    {"id":"57908","name":"Presentation - 2B Breakout session - Biosimilars - Steffen Thirstrup (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:16:00Z","last_updated_date":"2023-03-07T13:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2b-breakout-session-biosimilars-steffen-thirstrup-ema_en.pdf"},
    {"id":"57909","name":"Presentation - 2B.1 Work plan of the HMA Biosimilar Working Group (BSWG) - Esa Heinonen (HMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:16:00Z","last_updated_date":"2023-03-07T13:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2b1-work-plan-hma-biosimilar-working-group-bswg-esa-heinonen-hma_en.pdf"},
    {"id":"57910","name":"Presentation - 2B.2 Scientific rationale for interchangeability of biosimilars in the EU - Elena Wolff-Holz (PEI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:16:00Z","last_updated_date":"2023-03-07T13:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2b2-scientific-rationale-interchangeability-biosimilars-eu-elena-wolff-holz-pei_en.pdf"},
    {"id":"57911","name":"Presentation - 2B.3 HMA-EMA statement on interchangeability of biosimilars - Steffen Thirstrup (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:16:00Z","last_updated_date":"2023-03-07T13:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2b3-hma-ema-statement-interchangeability-biosimilars-steffen-thirstrup-ema_en.pdf"},
    {"id":"57912","name":"Presentation - 2B.4 Rapporteur session - Rosa Gonzalez-Quevedo (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:16:00Z","last_updated_date":"2023-03-07T13:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2b4-rapporteur-session-rosa-gonzalez-quevedo-ema_en.pdf"},
    {"id":"57913","name":"Presentation - 2C.1 Medicines for veterinary use - Nancy de Briyne (FVE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:43:00Z","last_updated_date":"2023-03-07T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2c1-medicines-veterinary-use-nancy-de-briyne-fve_en.pdf"},
    {"id":"57914","name":"Presentation - 2C.2 Medicines for veterinary use - Elsa Vecino (Accessvetmed)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:43:00Z","last_updated_date":"2023-03-07T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2c2-medicines-veterinary-use-elsa-vecino-accessvetmed_en.pdf"},
    {"id":"57915","name":"Presentation - 2C.3 Medicines for veterinary use - Rick Clayton (AnimalHealthEurope)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:43:00Z","last_updated_date":"2023-03-07T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2c3-medicines-veterinary-use-rick-clayton-animalhealtheurope_en.pdf"},
    {"id":"57916","name":"Presentation - 2C.4 Medicines for veterinary use - Paule Carnat-Gautier (ANSES)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:43:00Z","last_updated_date":"2023-03-07T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2c4-medicines-veterinary-use-paule-carnat-gautier-anses_en.pdf"},
    {"id":"57917","name":"Presentation - 2C.5 Medicines for veterinary use - Inke Reimer (BVL)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:43:00Z","last_updated_date":"2023-03-07T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2c5-medicines-veterinary-use-inke-reimer-bvl_en.pdf"},
    {"id":"57918","name":"Presentation - 2C.6 Rapporteur session - Janos Kovacs (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:44:00Z","last_updated_date":"2023-03-07T13:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2c6-rapporteur-session-janos-kovacs-ema_en.pdf"},
    {"id":"57919","name":"Presentation - 3.1 Prevention of shortages - Ancel.la Santos (BEUC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:50:00Z","last_updated_date":"2023-03-07T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-31-prevention-shortages-ancella-santos-beuc_en.pdf"},
    {"id":"57920","name":"Presentation - 3.2 Prevention of shortages - Stephan Roenninger (Industry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:50:00Z","last_updated_date":"2023-03-07T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-32-prevention-shortages-stephan-roenninger-industry_en.pdf"},
    {"id":"57921","name":"Presentation - 3.3 Prevention of shortages - Jorge Batista (PGEU)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:50:00Z","last_updated_date":"2023-03-07T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-33-prevention-shortages-jorge-batista-pgeu_en.pdf"},
    {"id":"57922","name":"Presentation - 3.4 Prevention of shortages - Nancy De Biyne (FVE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:50:00Z","last_updated_date":"2023-03-07T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-34-prevention-shortages-nancy-de-biyne-fve_en.pdf"},
    {"id":"57923","name":"Presentation - 3.5 Network priorities to 2025 TF AAM workplan - Maria-Jesus Alcaraz Tomas (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:51:00Z","last_updated_date":"2023-03-07T13:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-35-network-priorities-2025-tf-aam-workplan-maria-jesus-alcaraz-tomas-ema_en.pdf"},
    {"id":"57924","name":"Presentation - 4 Permanent withdrawals of medicinal products from the market - Momir Radulovic (HMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:57:00Z","last_updated_date":"2023-03-07T13:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-4-permanent-withdrawals-medicinal-products-market-momir-radulovic-hma_en.pdf"},
    {"id":"57925","name":"Presentation - 4.1 Permanent withdrawals from the market - Charlotte Roffiaen (EPHA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:57:00Z","last_updated_date":"2023-03-07T13:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-41-permanent-withdrawals-market-charlotte-roffiaen-epha_en.pdf"},
    {"id":"57926","name":"Presentation - 4.2 Permanent withdrawals from the market - Mary McCarthy (UEMO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:57:00Z","last_updated_date":"2023-03-07T13:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-42-permanent-withdrawals-market-mary-mccarthy-uemo_en.pdf"},
    {"id":"57927","name":"Presentation - 4.3 Permanent withdrawals from the market - Adrian van den Hoven (Industry)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:57:00Z","last_updated_date":"2023-03-07T13:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-43-permanent-withdrawals-market-adrian-van-den-hoven-industry_en.pdf"},
    {"id":"57928","name":"Presentation - 4.4 Permanent withdrawals from the market - Michael Ermisch (GKV-Spitzenverband)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:57:00Z","last_updated_date":"2023-03-07T13:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-44-permanent-withdrawals-market-michael-ermisch-gkv-spitzenverband_en.pdf"},
    {"id":"57929","name":"Presentation - 4.5 Permanent withdrawals from the market - Matjaz Marc (JAZMP, SPOC WP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:58:00Z","last_updated_date":"2023-03-07T13:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-45-permanent-withdrawals-market-matjaz-marc-jazmp-spoc-wp_en.pdf"},
    {"id":"57930","name":"Presentation - 4.6 Network priorities to 2025 - TF AAM workplan - Joao Ferreira (EMA), Michael Berntgen (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T13:58:00Z","last_updated_date":"2023-03-07T13:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-46-network-priorities-2025-tf-aam-workplan-joao-ferreira-ema-michael-berntgen-ema_en.pdf"},
    {"id":"57931","name":"Presentation - 5.1 Patients’ perspective on communication and transparency - Marko KorenjaK (PCWP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T14:08:00Z","last_updated_date":"2023-03-07T14:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-51-patients-perspective-communication-and-transparency-marko-korenjak-pcwp_en.pdf"},
    {"id":"57932","name":"Presentation - 5.2 Communication and transparency - Jean-François Duliere (Industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T14:08:00Z","last_updated_date":"2023-03-07T14:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-52-communication-and-transparency-jean-francois-duliere-industry_en.pdf"},
    {"id":"57933","name":"Presentation - 5.3 Communication and transparency - the Healthcare Professionals' perspective - Rosa Giuliani (HCPWP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T14:14:00Z","last_updated_date":"2023-03-07T14:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-53-communication-and-transparency-healthcare-professionals-perspective-rosa-giuliani-hcpwp_en.pdf"},
    {"id":"57934","name":"Presentation - 5.4 Shortages and communication - paralel timelines - Diego Pernas (AEMSP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T14:19:00Z","last_updated_date":"2023-03-07T14:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-54-shortages-and-communication-paralel-timelines-diego-pernas-aemsp_en.pdf"},
    {"id":"57935","name":"Presentation - 5.5 Network priorities to 2025 - TF AAM workplan - Juan Garcia Burgos, Inga Abed (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T14:19:00Z","last_updated_date":"2023-03-07T14:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-55-network-priorities-2025-tf-aam-workplan-juan-garcia-burgos-inga-abed-ema_en.pdf"},
    {"id":"57956","name":"Presentation 2A.3 - SUPPLY Project: Availability of IV/SC human normal immunoglobulins in the EU/EEA - Fabio Candura (ISS) Daphne Thijssen-Timmer (European Blood Alliance)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-08T16:58:00Z","last_updated_date":"2023-03-08T16:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2a3-supply-project-availability-ivsc-human-normal-immunoglobulins-eueea-fabio-candura-iss-daphne-thijssen-timmer-european-blood-alliance_en.pdf"},
    {"id":"57957","name":"Presentation: Clinical Trials Information System (CTIS) bitesize talk: Document and personal data in CTIS","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-08T13:00:00Z","last_updated_date":"2023-03-08T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-document-and-personal-data-ctis_en.pdf"},
    {"id":"57964","name":"Presentation - Reorganisation of EMA working parties - A. Ganan Jimenez (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T14:57:00Z","last_updated_date":"2023-03-09T14:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reorganisation-ema-working-parties-ganan-jimenez-ema_en.pdf"},
    {"id":"57965","name":"Presentation - The Scientific Advice Working Party (SAWP) and its interaction with other WPs and groups - I. Gravanis (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:00:00Z","last_updated_date":"2023-03-09T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-advice-working-party-sawp-and-its-interaction-other-wps-and-groups-i-gravanis-ema_en.pdf"},
    {"id":"57966","name":"Presentation - Methodology Working Party - A. Thomson (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:04:00Z","last_updated_date":"2023-03-09T15:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-methodology-working-party-thomson-ema_en.pdf"},
    {"id":"57967","name":"Presentation - CHMP/CVMP 3Rs Working party (3RsWP) - S. Ponzano (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:06:00Z","last_updated_date":"2023-03-09T15:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chmpcvmp-3rs-working-party-3rswp-s-ponzano-ema_en.pdf"},
    {"id":"57968","name":"Presentation - Highlights on the Committee for Advanced Therapies - M. de Lemus Belmonte (CAT)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:08:00Z","last_updated_date":"2023-03-09T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-highlights-committee-advanced-therapies-m-de-lemus-belmonte-cat_en.pdf"},
    {"id":"57969","name":"Presentation - PCWP/HCPWP feedback from CHMP - F. Ventura and C. Prieto (CHMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:10:00Z","last_updated_date":"2023-03-09T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwphcpwp-feedback-chmp-f-ventura-and-c-prieto-chmp_en.pdf"},
    {"id":"57970","name":"Presentation - PCWP/HCPWP feedback from COMP - E. Rook and T. Leest (COMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:12:00Z","last_updated_date":"2023-03-09T15:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwphcpwp-feedback-comp-e-rook-and-t-leest-comp_en.pdf"},
    {"id":"57971","name":"Presentation - PCWP/HCPWP feedback from HMPC - O. Palomino and A. Lê (HMPC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:17:00Z","last_updated_date":"2023-03-09T15:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwphcpwp-feedback-hmpc-o-palomino-and-le-hmpc_en.pdf"},
    {"id":"57972","name":"Presentation - PCWP/HCPWP feedback from PDCO - J. Taminiau (PDCO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:22:00Z","last_updated_date":"2023-03-09T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwphcpwp-feedback-pdco-j-taminiau-pdco_en.pdf"},
    {"id":"57973","name":"Presentation - Medical Device Regulation - M. Antunes (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:24:00Z","last_updated_date":"2023-03-09T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-device-regulation-m-antunes-ema_en.pdf"},
    {"id":"57974","name":"Presentation - ACT EU Multistakeholder platform concept paper consultation and kick-off meeting - M. Filancia (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:26:00Z","last_updated_date":"2023-03-09T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-multistakeholder-platform-concept-paper-consultation-and-kick-meeting-m-filancia-ema_en.pdf"},
    {"id":"57975","name":"Presentation - Biosimilar Breakout Session : HMA-EMA Multi-stakeholder workshop on shortages - S. Thirstrup and R. Gonzalez-Quevedo (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:28:00Z","last_updated_date":"2023-03-09T15:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-biosimilar-breakout-session-hma-ema-multi-stakeholder-workshop-shortages-s-thirstrup-and-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"57976","name":"Presentation - Interchangeability of biosimilars: Joint EMA-HMA statement - R. Gonzalez-Quevedo (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:31:00Z","last_updated_date":"2023-03-09T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interchangeability-biosimilars-joint-ema-hma-statement-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"57977","name":"Presentation - Campaigns - M. Benstetter (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:34:00Z","last_updated_date":"2023-03-09T15:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-campaigns-m-benstetter-ema_en.pdf"},
    {"id":"57978","name":"Presentation - Multilingualism on the EMA website and in external communications - M. Benstetter (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T15:36:00Z","last_updated_date":"2023-03-09T15:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multilingualism-ema-website-and-external-communications-m-benstetter-ema_en.pdf"},
    {"id":"58072","name":"Presentation -  Product Management Service (PMS) Webinar on Data Migration","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-20T14:23:00Z","last_updated_date":"2023-05-11T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-pms-webinar-data-migration_en.pdf"},
    {"id":"58136","name":"Presentation - Trial to optimize immunotherapy in early TNBC (M. Ignatiadis, Institut Bordet, Université Libre de Bruxelles)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T10:15:00Z","last_updated_date":"2023-03-24T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-trial-optimize-immunotherapy-early-tnbc-m-ignatiadis-institut-bordet-universite-libre-de-bruxelles_en.pdf"},
    {"id":"58137","name":"Presentation - pragmatic clinical trials : Preliminary shared experience under the CTR (D. Lacombe, EORTC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T10:24:00Z","last_updated_date":"2024-04-12T10:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pragmatic-clinical-trials-preliminary-shared-experience-under-ctr-d-lacombe-eortc_en.pdf"},
    {"id":"58138","name":"Presentation - Case study on TNBC optimisation trial (Institut Bordet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T10:28:00Z","last_updated_date":"2023-03-24T10:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-tnbc-optimisation-trial-institut-bordet_en.pdf"},
    {"id":"58140","name":"Presentation - Post-authorisation Safety and Efficacy studies (C. Voltz-Girolt, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T10:42:00Z","last_updated_date":"2023-03-24T10:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-authorisation-safety-and-efficacy-studies-c-voltz-girolt-ema_en.pdf"},
    {"id":"58141","name":"Presentation - Feasibility of post- authorization randomized controlled trials for conditionally authorized anticancer medicines - a multistakeholder perspective (C. van Hattem; A. de Jong; J. de Groot; L. Bloem, Utrecht University)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T10:43:00Z","last_updated_date":"2023-03-24T10:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feasibility-post-authorization-randomized-controlled-trials-conditionally-authorized-anticancer-medicines-multistakeholder-perspective-c-van-hattem-de-jong-j-de-groot-l-bloem-utrecht_en.pdf"},
    {"id":"58142","name":"Presentation - factors affecting the feasibility of post-authorization RCTs for conditionally authorized anticancer medicines (C. van Hattem, A. de Jong, L. Bloem, Utrecht University)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T15:00:00Z","last_updated_date":"2024-04-12T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-factors-affecting-feasibility-post-authorization-rcts-conditionally-authorized-anticancer-medicines-c-van-hattem-de-jong-l-bloem-utrecht-university_en.pdf"},
    {"id":"58143","name":"Presentation - Outcome from 2022 ISG Survey and Key Industry stakeholder 2023 meetings (M.Filancia, L.Malaguti, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T11:01:00Z","last_updated_date":"2023-03-24T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcome-2022-isg-survey-and-key-industry-stakeholder-2023-meetings-mfilancia-lmalaguti-ema_en.pdf"},
    {"id":"58144","name":"Presentation - Agile transformation update (Z.Frias, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T11:01:00Z","last_updated_date":"2023-03-24T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agile-transformation-update-zfrias-ema_en.pdf"},
    {"id":"58145","name":"Presentation - Lessons learnt from COVID-19 (M. Carr, Z.Sebris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T11:01:00Z","last_updated_date":"2023-03-24T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lessons-learnt-covid-19-m-carr-zsebris-ema_en.pdf"},
    {"id":"58146","name":"Presentation - Clinical Trials Regulation (CTR) implementation and ACT EU update (P.Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T11:01:00Z","last_updated_date":"2023-03-24T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-regulation-ctr-implementation-and-act-eu-update-parlett-ema_en.pdf"},
    {"id":"58147","name":"Presentation - Emergency Task Force (ETF) implementation update including preparedness activities (M.Mura, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T11:01:00Z","last_updated_date":"2023-03-24T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emergency-task-force-etf-implementation-update-including-preparedness-activities-mmura-ema_en.pdf"},
    {"id":"58148","name":"Presentation - Medical device expert panels (S.Da Rocha, M.Antunes, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T11:01:00Z","last_updated_date":"2023-03-24T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-device-expert-panels-sda-rocha-mantunes-ema_en.pdf"},
    {"id":"58149","name":"Presentation - Health Emergency Preparedness and Response Advisory (HERA) - EMA Joint Industrial Cooperation Forum (JICF) joint working group on data collection update (O.Girard, HERA and M.Dias, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T11:01:00Z","last_updated_date":"2023-03-24T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-health-emergency-preparedness-and-response-advisory-hera-ema-joint-industrial-cooperation-forum-jicf-joint-working-group-data-collection-update-ogirard-hera-and-mdias-ema_en.pdf"},
    {"id":"58150","name":"Presentation - Update on European Shortages Monitoring Platform (ESMP) development progress and roadmap (P. Pina Ferreira, S. Zastavnik, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T11:01:00Z","last_updated_date":"2023-03-24T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-european-shortages-monitoring-platform-esmp-development-progress-and-roadmap-p-pina-ferreira-s-zastavnik-ema_en.pdf"},
    {"id":"58151","name":"Presentation - Update on medicine shortages activities (J. Ferreira, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T11:01:00Z","last_updated_date":"2023-03-24T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-medicine-shortages-activities-j-ferreira-ema_en.pdf"},
    {"id":"58161","name":"Presentation - Monitoring and mitigating shortages of critical medical devices in the context of a public health emergency (S. Mc Mahon, K. Kruttwig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T16:53:00Z","last_updated_date":"2023-03-24T16:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-mitigating-shortages-critical-medical-devices-context-public-health-emergency-s-mc-mahon-k-kruttwig_en.pdf-0"},
    {"id":"58162","name":"Presentation - Monitoring and mitigating shortages of critical medical devices in the context of a public health emergency (S. Mc Mahon, K. Kruttwig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-03-24T16:53:00Z","last_updated_date":"2023-03-24T16:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-mitigating-shortages-critical-medical-devices-context-public-health-emergency-s-mc-mahon-k-kruttwig_en.pdf"},
    {"id":"58430","name":"Presentation - Human Variations eAF training session","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-19T12:56:00Z","last_updated_date":"2023-04-19T12:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-human-variations-eaf-training-session_en.pdf"},
    {"id":"58507","name":"Product Management Service (XEVMPD) Webinar Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T17:05:00Z","last_updated_date":"2023-04-28T13:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/product-management-service-xevmpd-webinar-presentation_en.pdf"},
    {"id":"58508","name":"Organisation Management Service (OMS) Webinar Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T17:27:00Z","last_updated_date":"2023-04-28T13:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/organisation-management-service-oms-webinar-presentation_en.pdf"},
    {"id":"58509","name":"Substance, product, organisation and referential (SPOR) application programming interface (API) - SPOR API Webinar Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T17:30:00Z","last_updated_date":"2023-04-24T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/substance-product-organisation-and-referential-spor-application-programming-interface-api-spor-api-webinar-presentation_en.pdf"},
    {"id":"58510","name":"EMA Account Management Webinar Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T17:32:00Z","last_updated_date":"2023-04-24T17:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ema-account-management-webinar-presentation_en.pdf"},
    {"id":"58511","name":"SPOR and XEVMPD Data Governance Webinar Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T17:37:00Z","last_updated_date":"2023-04-28T13:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/spor-and-xevmpd-data-governance-webinar-presentation_en.pdf"},
    {"id":"58512","name":"Referentials Management Service (RMS) Webinar Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T17:44:00Z","last_updated_date":"2023-04-28T13:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/referentials-management-service-rms-webinar-presentation_en.pdf"},
    {"id":"58513","name":"Service Desk for SPOR and XEVMPD Webinar Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T17:47:00Z","last_updated_date":"2023-04-24T17:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/service-desk-spor-and-xevmpd-webinar-presentation_en.pdf"},
    {"id":"58514","name":"Service Desk for SPOR and XEVMPD Webinar Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T17:47:00Z","last_updated_date":"2023-04-24T17:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/service-desk-spor-and-xevmpd-webinar-presentation_en.pdf-0"},
    {"id":"58515","name":"Service Desk for SPOR and XEVMPD Webinar Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T17:47:00Z","last_updated_date":"2023-04-24T17:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/service-desk-spor-and-xevmpd-webinar-presentation_en.pdf-1"},
    {"id":"58516","name":"Service Desk for SPOR and XEVMPD Webinar Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-24T17:47:00Z","last_updated_date":"2023-04-24T17:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/service-desk-spor-and-xevmpd-webinar-presentation_en.pdf-2"},
    {"id":"58551","name":"Substance Management Service (SMS) Presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-04-28T13:14:00Z","last_updated_date":"2023-04-28T13:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/substance-management-service-sms-presentation_en.pdf"},
    {"id":"58568","name":"Presentation - Union Product Database – Volume of sales webinar for UPD industry users (B.Mustafov, A.Vicente, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-03T10:54:00Z","last_updated_date":"2023-05-03T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-product-database-volume-sales-webinar-upd-industry-users-bmustafov-avicente-ema_en.pdf"},
    {"id":"58675","name":"Presentation - Adverse events among children ages 5-11 years after COVID-19 vaccination: updates from v-safe and the Vaccine Adverse Event Reporting System (VAERS) - CDC COVID-19 Vaccine Task Force","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:45:00Z","last_updated_date":"2023-05-12T16:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adverse-events-among-children-ages-5-11-years-after-covid-19-vaccination-updates-v-safe-and-vaccine-adverse-event-reporting-system-vaers-cdc-covid-19-vaccine-task-force_en.pdf"},
    {"id":"58734","name":"Presentation - 3RsWP 2023 Workplan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T12:02:00Z","last_updated_date":"2023-05-22T12:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-3rswp-2023-workplan_en.pdf"},
    {"id":"58738","name":"Presentation - Step I - Scope and updates","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T17:35:00Z","last_updated_date":"2023-05-22T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-step-i-scope-and-updates_en.pdf"},
    {"id":"58739","name":"Presentation - CDP Procedural timelines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T17:36:00Z","last_updated_date":"2023-05-22T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cdp-procedural-timelines_en.pdf"},
    {"id":"58740","name":"Presentation - Guidance and new Q&A document","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T17:37:00Z","last_updated_date":"2023-05-22T17:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-and-new-qa-document_en.pdf"},
    {"id":"58741","name":"Presentation - Anonymisation Report template","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T17:39:00Z","last_updated_date":"2023-05-22T17:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-anonymisation-report-template_en.pdf"},
    {"id":"58745","name":"Introduction - EMA multi-stakeholder workshop on qualification of novel methodologies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T09:52:00Z","last_updated_date":"2023-05-24T09:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/introduction-ema-multi-stakeholder-workshop-qualification-novel-methodologies_en.pdf"},
    {"id":"58746","name":"Presentation - The journey of innovation (Ana Drmic)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T09:57:00Z","last_updated_date":"2023-05-24T09:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-journey-innovation-ana-drmic_en.pdf"},
    {"id":"58748","name":"Presentation - The Pharma perspective (Solange Corriol-Rohoul)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T09:59:00Z","last_updated_date":"2023-05-24T09:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharma-perspective-solange-corriol-rohoul_en.pdf"},
    {"id":"58749","name":"Presentation - EU public-private funded project landscape (Nathalie Seigneuret (IHI))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:18:00Z","last_updated_date":"2023-05-24T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-public-private-funded-project-landscape-nathalie-seigneuret-ihi_en.pdf"},
    {"id":"58753","name":"Presentation - Development of a PRO for upper limb function (Elizabeth Vroom)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:39:00Z","last_updated_date":"2023-05-24T10:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-development-pro-upper-limb-function-elizabeth-vroom_en.pdf"},
    {"id":"58754","name":"Presentation - Qualifying PROs for rheumatology studies – update from EULAR (Robert B.M. Landewé)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:39:00Z","last_updated_date":"2023-05-24T10:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qualifying-pros-rheumatology-studies-update-eular-robert-bm-landewe_en.pdf"},
    {"id":"58755","name":"Presentation - Regulatory perspective (Elmer Schabel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:43:00Z","last_updated_date":"2023-10-13T14:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspective-elmer-schabel_en.pdf"},
    {"id":"58756","name":"Presentation - Regulatory perspective on qualification of Modelling and Simulation based methods (Flora Musuamba Tshinanu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:39:00Z","last_updated_date":"2023-05-24T10:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspective-qualification-modelling-and-simulation-based-methods-flora-musuamba-tshinanu_en.pdf"},
    {"id":"58757","name":"Presentation - Digital measures of nocturnal scratch (Cathelijne de Gram)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:49:00Z","last_updated_date":"2023-05-24T10:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-digital-measures-nocturnal-scratch-cathelijne-de-gram_en.pdf"},
    {"id":"58758","name":"Presentation - AI-based pathology tools to improve clinical evidence (Katy Wack)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:49:00Z","last_updated_date":"2023-05-24T10:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ai-based-pathology-tools-improve-clinical-evidence-katy-wack_en.pdf"},
    {"id":"58759","name":"Presentation - Regulatory perspective (Joerg Zinserling)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:49:00Z","last_updated_date":"2023-05-24T10:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspective-joerg-zinserling_en.pdf"},
    {"id":"58760","name":"Presentation - Regulatory perspective (Peter Mol)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:59:00Z","last_updated_date":"2023-05-24T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspective-peter-mol_en.pdf"},
    {"id":"58761","name":"Presentation - The Cystic Fibrosis experience (Lutz Naehrlich)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:59:00Z","last_updated_date":"2023-05-24T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cystic-fibrosis-experience-lutz-naehrlich_en.pdf"},
    {"id":"58762","name":"Presentation - The TREAT-NMD experience (Neil Bennett TREAT-NMD)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:59:00Z","last_updated_date":"2023-05-24T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-treat-nmd-experience-neil-bennett-treat-nmd_en.pdf"},
    {"id":"58763","name":"Presentation - The Notified Bodies perspective (Daniela Seneca)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T10:58:00Z","last_updated_date":"2023-05-24T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-notified-bodies-perspective-daniela-seneca_en.pdf"},
    {"id":"58802","name":"Presentation - Bacteriophages - activities of the European Pharmacopoeia (Olga Kolaj-Robin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T16:21:00Z","last_updated_date":"2023-05-26T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bacteriophages-activities-european-pharmacopoeia-olga-kolaj-robin_en.pdf"},
    {"id":"58803","name":"Presentation - Case studies on the Guideline on quality, safey and efficacy of veterinary medicinal products specifically designed for phage therapy (Frederic Klein)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T16:22:00Z","last_updated_date":"2023-05-26T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-studies-guideline-quality-safey-and-efficacy-veterinary-medicinal-products-specifically-designed-phage-therapy-frederic-klein_en.pdf"}    {"id":"58804","name":"Presentation - Draft Guideline on quality, safety and efficacy of veterinary medicinal products specifically designed for phage therapy (efficacy part) (Belén Gutiérrez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T16:23:00Z","last_updated_date":"2023-05-26T16:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-guideline-quality-safety-and-efficacy-veterinary-medicinal-products-specifically-designed-phage-therapy-efficacy-part-belen-gutierrez_en.pdf"},
    {"id":"58805","name":"Presentation - Case study on a VMP with flexible composition to treat diarrhea caused by ETEC in post-weaning piglets (Susana Casado)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T16:25:00Z","last_updated_date":"2023-05-26T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-vmp-flexible-composition-treat-diarrhea-caused-etec-post-weaning-piglets-susana-casado_en.pdf"},
    {"id":"58806","name":"Presentation - Draft Guideline on quality, safey and efficacy of veterinary medicinal products specifically designed for phage therapy (quality part) (Martin B. Oleksiewicz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T16:39:00Z","last_updated_date":"2023-05-26T16:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-guideline-quality-safey-and-efficacy-veterinary-medicinal-products-specifically-designed-phage-therapy-quality-part-martin-b-oleksiewicz_en.pdf"},
    {"id":"58807","name":"Presentation - Draft Guideline on quality, safey and efficacy of veterinary medicinal products specifically designed for phage therapy (safey part) (Sandra-Maria Wienhold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T16:42:00Z","last_updated_date":"2023-05-26T16:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-guideline-quality-safey-and-efficacy-veterinary-medicinal-products-specifically-designed-phage-therapy-safey-part-sandra-maria-wienhold_en.pdf"},
    {"id":"58808","name":"Presentation - Setting the scene introduction on the background and expected outputs for the meeting (Susana Casado)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T16:45:00Z","last_updated_date":"2023-05-26T16:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-setting-scene-introduction-background-and-expected-outputs-meeting-susana-casado_en.pdf"},
    {"id":"58813","name":"Presentation - Product Lifecycle Management (PLM) Portal Access Management Training Session","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-30T14:30:00Z","last_updated_date":"2023-05-30T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-lifecycle-management-plm-portal-access-management-training-session_en.pdf"},
    {"id":"58840","name":"Presentation - Product Management Service (PMS) Progress Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-05-31T15:35:00Z","last_updated_date":"2023-05-31T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-pms-progress-webinar_en.pdf"},
    {"id":"59091","name":"Presentation - CurrentHTA Experience withReal World Data (B. Wieseler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-26T11:45:00Z","last_updated_date":"2023-06-26T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-currenthta-experience-withreal-world-data-b-wieseler_en.pdf"},
    {"id":"59092","name":"Presentation - The Optimal Cancer Care Alliance (OCCA) view and experience (D. Goldstein)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-26T11:50:00Z","last_updated_date":"2023-06-26T11:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-optimal-cancer-care-alliance-occa-view-and-experience-d-goldstein_en.pdf"},
    {"id":"59093","name":"Presentation - Developments from the Cancer Medicines Forum and impact across cancer field (Denis Lacombe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-26T11:52:00Z","last_updated_date":"2023-06-26T11:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-developments-cancer-medicines-forum-and-impact-across-cancer-field-denis-lacombe_en.pdf"},
    {"id":"59125","name":"Presentation - OPEN – International collaboration (R.Cherif, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T10:10:00Z","last_updated_date":"2023-06-29T10:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-open-international-collaboration-rcherif-ema_en.pdf"},
    {"id":"59126","name":"Presentation - Update on Policy 0070 (K. Quigley, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T10:14:00Z","last_updated_date":"2023-06-29T10:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-policy-0070-k-quigley-ema_en.pdf"},
    {"id":"59127","name":"Presentation - Update on CHMP AR Revamp project (F. Day, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T10:15:00Z","last_updated_date":"2023-06-29T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-chmp-ar-revamp-project-f-day-ema_en.pdf"},
    {"id":"59128","name":"Presentation - Scientific Committees organisational aspects post EMA business continuity plan (BCP) (S. Ribeiro, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T10:17:00Z","last_updated_date":"2023-06-29T10:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-scientific-committees-organisational-aspects-post-ema-business-continuity-plan-bcp-s-ribeiro-ema_en.pdf"},
    {"id":"59129","name":"Presentation - Update on RMP publication (E. Cochino, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T10:19:00Z","last_updated_date":"2023-06-29T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-rmp-publication-e-cochino-ema_en.pdf"},
    {"id":"59131","name":"Presentation - Update on submission predictability focus group (F. Day, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T10:22:00Z","last_updated_date":"2023-06-29T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-submission-predictability-focus-group-f-day-ema_en.pdf"},
    {"id":"59133","name":"Presentation - Patient engagement from a patient centric drug development to authorisation (M. Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T10:24:00Z","last_updated_date":"2023-06-29T10:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-engagement-patient-centric-drug-development-authorisation-m-mavris-ema_en.pdf"},
    {"id":"59134","name":"Presentation - Patient Experience Data (PED) in medicines regulation (R. Gonzalez-Quevedo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T10:26:00Z","last_updated_date":"2023-06-29T10:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-experience-data-ped-medicines-regulation-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"59160","name":"Presentation - session 1 - Accelerating Clinical Trials in the EU (ACT EU) (Monique Al, HMA-CCMO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:35:00Z","last_updated_date":"2023-06-30T14:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-accelerating-clinical-trials-eu-act-eu-monique-al-hma-ccmo_en.pdf"},
    {"id":"59161","name":"Presentation - Session 1 - Accelerating Clinical Trials in the EU (ACT EU)  (G. Capone, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:39:00Z","last_updated_date":"2023-06-30T14:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-accelerating-clinical-trials-eu-act-eu-g-capone-ema_en.pdf"},
    {"id":"59162","name":"Presentation - Session 1: Panel and audience discussion on CT environment (J. Isla, European Dravet Syndrome Federation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:46:00Z","last_updated_date":"2023-06-30T14:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-panel-and-audience-discussion-ct-environment-j-isla-european-dravet-syndrome-federation_en.pdf"},
    {"id":"59163","name":"Presentation - Session 1: Panel and audience discussion on CT environment (L. D'Apote, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:48:00Z","last_updated_date":"2023-06-30T14:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-panel-and-audience-discussion-ct-environment-l-dapote-efpia_en.pdf"},
    {"id":"59164","name":"Presentation - Session 1: Panel and audience discussion on CT environment (S. Badreh, European Hematology Association)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:50:00Z","last_updated_date":"2023-06-30T14:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-panel-and-audience-discussion-ct-environment-s-badreh-european-hematology-association_en.pdf"},
    {"id":"59165","name":"Presentation - Session 1: Panel and audience discussion on CT environment (S. Gold, Charité Universitätsmedizin Berlin-CTCG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:53:00Z","last_updated_date":"2023-06-30T14:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-panel-and-audience-discussion-ct-environment-s-gold-charite-universitatsmedizin-berlin-ctcg_en.pdf"},
    {"id":"59166","name":"Presentation - Session 1: ACRO Panel discussion topics (Z. Thacker, ACRO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:55:00Z","last_updated_date":"2023-06-30T14:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-acro-panel-discussion-topics-z-thacker-acro_en.pdf"},
    {"id":"59167","name":"Presentation - Session 2: Clinical Trial Regulation and implementation update (C. Didion, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:58:00Z","last_updated_date":"2023-06-30T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-clinical-trial-regulation-and-implementation-update-c-didion-ec_en.pdf"},
    {"id":"59168","name":"Presentation - Session 2: Member States support to the CTR implementation (M. Lunzer, HMA-CTCG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:02:00Z","last_updated_date":"2023-06-30T15:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-member-states-support-ctr-implementation-m-lunzer-hma-ctcg_en.pdf"},
    {"id":"59169","name":"Presentation - Session 2: Panel and audience discussion on CTR (A. Michon, ECRIN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:06:00Z","last_updated_date":"2023-06-30T15:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-ctr-michon-ecrin_en.pdf"},
    {"id":"59170","name":"Presentation - Session 2: Panel and audience discussion on CTR (D. Johnston, ACRO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:21:00Z","last_updated_date":"2023-06-30T15:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-ctr-d-johnston-acro_en.pdf"},
    {"id":"59171","name":"Presentation - Session 2: Panel and audience discussion on CTR (J. Isla, European Dravet Syndrome Federation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:22:00Z","last_updated_date":"2023-06-30T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-ctr-j-isla-european-dravet-syndrome-federation_en.pdf"},
    {"id":"59172","name":"Presentation - Session 2: Panel and audience discussion on ethics (D. Lo, EATRIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:23:00Z","last_updated_date":"2023-06-30T15:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-ethics-d-lo-eatris_en.pdf"},
    {"id":"59173","name":"Presentation - Session 2: Panel and audience discussion on ethics (F. Greenhalgh, EATG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:25:00Z","last_updated_date":"2023-06-30T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-ethics-f-greenhalgh-eatg_en.pdf"},
    {"id":"59174","name":"Presentation - Session 2: Panel and audience discussion on ethics (M. Carson, REK KULMU, Norwegian ethics committee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:26:00Z","last_updated_date":"2023-06-30T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-ethics-m-carson-rek-kulmu-norwegian-ethics-committee_en.pdf"},
    {"id":"59175","name":"Presentation - Session 2: Panel and audience discussion on ethics (M. Zwaan, NVMETC, Dutch ethics committee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:28:00Z","last_updated_date":"2023-06-30T15:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-ethics-m-zwaan-nvmetc-dutch-ethics-committee_en.pdf"},
    {"id":"59176","name":"Presentation - Session 2: panel and audience discussion on ethics (R. Stanbrook, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:29:00Z","last_updated_date":"2023-06-30T15:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-ethics-r-stanbrook-efpia_en.pdf"},
    {"id":"59177","name":"Presentation - Session 2: Panel and audience discussion on ethics - Wolfgang Berdel (AKEK, German ethics committee member)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:31:00Z","last_updated_date":"2023-06-30T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-ethics-wolfgang-berdel-akek-german-ethics-committee-member_en.pdf"},
    {"id":"59179","name":"Presentation - Session 2: Panel and audience discussion on transparency (D. Navarro Llobet, Spanish Network for Clinical Research)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T16:46:00Z","last_updated_date":"2023-06-30T16:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-transparency-d-navarro-llobet-spanish-network-clinical-research_en.pdf"},
    {"id":"59180","name":"Presentation - Session 2: panel and audience discussion on transparency (J. Holtzople, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T16:48:00Z","last_updated_date":"2023-06-30T16:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-transparency-j-holtzople-efpia_en.pdf"},
    {"id":"59181","name":"Presentation - Session 2: Panel and audience discussion on transparency (R. Castro, EPHA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T16:49:00Z","last_updated_date":"2023-06-30T16:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-transparency-r-castro-epha_en.pdf"},
    {"id":"59182","name":"Presentation - Session 2 - Panel and audience discussion on transparency  (Z. Thacker ,ACRO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T16:51:00Z","last_updated_date":"2023-06-30T16:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-transparency-z-thacker-acro_en.pdf"},
    {"id":"59183","name":"Presentation - Session 2: The role of ethics committees in clinical trials (H. Christiansen, DKETIK, Danish Centre for Ethics)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T16:53:00Z","last_updated_date":"2023-06-30T16:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-role-ethics-committees-clinical-trials-h-christiansen-dketik-danish-centre-ethics_en.pdf"},
    {"id":"59184","name":"Presentation - Session 2: Transparency of clinical trials (L. Pioppo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T16:57:00Z","last_updated_date":"2023-06-30T16:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-transparency-clinical-trials-l-pioppo-ema_en.pdf"},
    {"id":"59188","name":"Presentation - Session 3: Clinical trials in situations of public health emergency (M. Cavaleri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T14:10:00Z","last_updated_date":"2023-07-03T14:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-clinical-trials-situations-public-health-emergency-m-cavaleri-ema_en.pdf"},
    {"id":"59189","name":"Presentation - Session 3: Optimising the EU infrastructure for methodology guidance (F. Lasch, EMA) and (D. Zerlang Andersson, HMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T14:11:00Z","last_updated_date":"2023-07-03T14:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-optimising-eu-infrastructure-methodology-guidance-f-lasch-ema-and-d-zerlang-andersson-hma_en.pdf"},
    {"id":"59190","name":"Presentation - Session 3: Panel and audience discussion on non-commercial CTs (A. Michon, ECRIN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T14:27:00Z","last_updated_date":"2023-07-03T14:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-non-commercial-cts-michon-ecrin_en.pdf"},
    {"id":"59191","name":"Presentation - Session 3: Panel and audience discussion on non-commercial CTs (D. Lacombe, EORTC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T14:28:00Z","last_updated_date":"2023-07-03T14:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-non-commercial-cts-d-lacombe-eortc_en.pdf"},
    {"id":"59195","name":"Presentation - Session 3: Panel and audience discussion on non-commercial CTs (D. Navarro Llobet, Spanish Network for Clinical Research)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T16:24:00Z","last_updated_date":"2023-07-03T16:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-non-commercial-cts-d-navarro-llobet-spanish-network-clinical-research_en.pdf"},
    {"id":"59196","name":"Presentation - Session 3: Panel and audience discussion on non-commercial CTs (D. Lo, EATRIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T16:26:00Z","last_updated_date":"2023-07-03T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-non-commercial-cts-d-lo-eatris_en.pdf"},
    {"id":"59197","name":"Presentation - Session 3: Panel and audience discussion on non-commercial CTs (M. Landray, Oxford University - CTCG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T16:28:00Z","last_updated_date":"2023-07-03T16:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-non-commercial-cts-m-landray-oxford-university-ctcg_en.pdf"},
    {"id":"59198","name":"Presentation - Session 3 - Panel and audience discussion on non-commercial CTs (M. de Lemus, SMA Europe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T16:29:00Z","last_updated_date":"2023-07-03T16:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-non-commercial-cts-m-de-lemus-sma-europe_en.pdf"},
    {"id":"59199","name":"Presentation - Session 3: Panel and audience discussion on non-commercial CTs (Mira Zuidgeest, UMCU)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T16:58:00Z","last_updated_date":"2023-07-03T16:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-non-commercial-cts-mira-zuidgeest-umcu_en.pdf"},
    {"id":"59200","name":"Presentation - Session 3: Panel and audience discussion on SA (D. Lacombe, EORTC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T16:59:00Z","last_updated_date":"2023-07-03T16:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-sa-d-lacombe-eortc_en.pdf"},
    {"id":"59201","name":"Presentation - Session 3: Panel and audience discussion on SA (D. Lo, EATRIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:01:00Z","last_updated_date":"2023-07-03T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-sa-d-lo-eatris_en.pdf"},
    {"id":"59202","name":"Presentation - Session 3: Panel and audience discussion on SA (M. Mokou, Mosaiques Diagnostics).","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:04:00Z","last_updated_date":"2023-07-03T17:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-sa-m-mokou-mosaiques-diagnostics_en.pdf"},
    {"id":"59203","name":"Presentation - Session 3: Panel and audience discussion on SA (Mireille Muller, EFPIA_EuropaBio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:05:00Z","last_updated_date":"2023-07-03T17:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-and-audience-discussion-sa-mireille-muller-efpia_europabio_en.pdf"},
    {"id":"59204","name":"Presentation - Session 3: Reinforcing coordination between scientific advice and CT approval (Jane Moseley, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:06:00Z","last_updated_date":"2023-07-03T17:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-reinforcing-coordination-between-scientific-advice-and-ct-approval-jane-moseley-ema_en.pdf"},
    {"id":"59205","name":"Presentation - Session 3: Reinforcing coordination between scientific advice and CT approval (L. O'Dwyer, HMA EU-IN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:08:00Z","last_updated_date":"2023-07-03T17:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-reinforcing-coordination-between-scientific-advice-and-ct-approval-l-odwyer-hma-eu_en.pdf"},
    {"id":"59206","name":"Presentation - Session 3: Reinforcing coordination between scientific advice and CT approval (S. Petraglia, HMA-CTCG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:10:00Z","last_updated_date":"2023-07-03T17:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-reinforcing-coordination-between-scientific-advice-and-ct-approval-s-petraglia-hma-ctcg_en.pdf"},
    {"id":"59207","name":"Presentation - Session 3: Supporting non-commercial clinical trials (E. Stahl, HMA-CTCG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:11:00Z","last_updated_date":"2023-07-03T17:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-supporting-non-commercial-clinical-trials-e-stahl-hma-ctcg_en.pdf"},
    {"id":"59208","name":"Presentation - Session 4: Opportunities from a European CT multi-stakeholder platform (G. Andrew-Nielsen, HMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:12:00Z","last_updated_date":"2023-07-03T17:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-opportunities-european-ct-multi-stakeholder-platform-g-andrew-nielsen-hma_en.pdf"},
    {"id":"59209","name":"Presentation - Session 4: Panel and audience discussion on MSP (D. Johnston, ACRO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:15:00Z","last_updated_date":"2023-07-03T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-panel-and-audience-discussion-msp-d-johnston-acro_en.pdf"},
    {"id":"59210","name":"Presentation - Session 4: Panel and audience discussion on MSP (H. Goossens, Antwerp University Hospital)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:18:00Z","last_updated_date":"2023-07-03T17:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-panel-and-audience-discussion-msp-h-goossens-antwerp-university-hospital_en.pdf"},
    {"id":"59211","name":"Presentation - Session 4: Panel and audience discussion on MSP (L. Leyens, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:20:00Z","last_updated_date":"2023-07-03T17:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-panel-and-audience-discussion-msp-l-leyens-efpia_en.pdf"},
    {"id":"59212","name":"Presentation - Session 4: Panel and audience discussion on MSP (M. Rataj, EPF)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:22:00Z","last_updated_date":"2023-07-03T17:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-panel-and-audience-discussion-msp-m-rataj-epf_en.pdf"},
    {"id":"59213","name":"Presentation - Session 4 - Panel and audience discussion on MSP (R. Giuliani, HCPWP Chair)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T17:24:00Z","last_updated_date":"2023-07-03T17:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-panel-and-audience-discussion-msp-r-giuliani-hcpwp-chair_en.pdf"},
    {"id":"59222","name":"Presentation - Satisfaction survey - PCO engagement with EMA (G. Gabrielli, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T10:15:00Z","last_updated_date":"2023-07-05T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-satisfaction-survey-pco-engagement-ema-g-gabrielli-ema_en.pdf"},
    {"id":"59223","name":"Presentation - Follow up on suggestions for new mandate proposed by PCWP members (A. Bradshaw, Alzheimer Europe, and M. Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T10:30:00Z","last_updated_date":"2023-07-05T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-follow-suggestions-new-mandate-proposed-pcwp-members-bradshaw-alzheimer-europe-and-m-mavris-ema_en.pdf"},
    {"id":"59224","name":"Presentation - Adressing mis- and disinformation (M. Benstetter, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T10:35:00Z","last_updated_date":"2023-07-05T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adressing-mis-and-disinformation-m-benstetter-ema_en.pdf"},
    {"id":"59225","name":"Presentation - EMA communication perception survey 2022 (C. Gadd, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T10:38:00Z","last_updated_date":"2023-07-05T10:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-communication-perception-survey-2022-c-gadd-ema_en.pdf"},
    {"id":"59226","name":"Presentation - Highlights of HCPWP involvement in EMA activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T10:51:00Z","last_updated_date":"2023-07-05T10:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-highlights-hcpwp-involvement-ema-activities_en.pdf"},
    {"id":"59227","name":"Presentation - Where is science, technology and medicines regulation heading to? (A. Humphreys, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T10:54:00Z","last_updated_date":"2023-07-05T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-where-science-technology-and-medicines-regulation-heading-humphreys-ema_en.pdf"},
    {"id":"59228","name":"Presentation - The importance of stakeholders’ engagement to support implementation of the European Medicines Agencies Network Strategy (J. Garcia Burgos, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T11:03:00Z","last_updated_date":"2023-07-05T11:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-importance-stakeholders-engagement-support-implementation-european-medicines-agencies-network-strategy-j-garcia-burgos-ema_en.pdf"},
    {"id":"59229","name":"Presentation - 2023 Satisfaction survey – HCPO engagement with EMA (G. Gabrielli, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T11:57:00Z","last_updated_date":"2023-07-05T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-2023-satisfaction-survey-hcpo-engagement-ema-g-gabrielli-ema_en.pdf"},
    {"id":"59230","name":"Presentation - EMA’s framework of engagement with healthcare professionals and their organisations (I. Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T11:59:00Z","last_updated_date":"2023-07-05T11:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-framework-engagement-healthcare-professionals-and-their-organisations-i-silva-ema_en.pdf"},
    {"id":"59231","name":"Presentation - Update on RWE including DARWIN EU (A. Segec, K. Plueschke, D. Umuhire, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:09:00Z","last_updated_date":"2023-07-05T12:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-rwe-including-darwin-eu-segec-k-plueschke-d-umuhire-ema_en.pdf"},
    {"id":"59232","name":"Presentation - Piloting creation of electronic product information (ePI) for EU medicines (E. Scanlan, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:12:00Z","last_updated_date":"2023-07-05T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-piloting-creation-electronic-product-information-epi-eu-medicines-e-scanlan-ema_en.pdf"},
    {"id":"59233","name":"Presentation - Monitoring of events and preparedness for public health emergencies / major events (M. Dias, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:13:00Z","last_updated_date":"2023-07-05T12:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-events-and-preparedness-public-health-emergencies-major-events-m-dias-ema_en.pdf"},
    {"id":"59234","name":"Presentation - Pilot on reporting of shortages by eligible patients and healthcare professional organisations (I. Abed, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:16:00Z","last_updated_date":"2023-07-05T12:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pilot-reporting-shortages-eligible-patients-and-healthcare-professional-organisations-i-abed-ema_en.pdf"},
    {"id":"59235","name":"Presentation - Implementation of the Good practice guide on prevention of shortages (I. Abed, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:17:00Z","last_updated_date":"2023-07-05T12:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-good-practice-guide-prevention-shortages-i-abed-ema_en.pdf"},
    {"id":"59236","name":"Presentation - Update on activities linked to presence of N-nitrosamines in human medicines (A. Azevado, R. Ruepp, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:20:00Z","last_updated_date":"2023-07-05T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-activities-linked-presence-n-nitrosamines-human-medicines-azevado-r-ruepp-ema_en.pdf"},
    {"id":"59237","name":"Presentation - Patient Experience Data (PED) - Update on progress (R. Gonzalez-Quevedo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:22:00Z","last_updated_date":"2023-07-05T12:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-experience-data-ped-update-progress-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"59238","name":"Presentation - Report on pharmacovigilance tasks of the EU Member States and EMA, 2019-2022 (A. Santoro, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:24:00Z","last_updated_date":"2023-07-05T12:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-pharmacovigilance-tasks-eu-member-states-and-ema-2019-2022-santoro-ema_en.pdf"},
    {"id":"59239","name":"Presentation - ACT EU - Feedback from kick-off meeting of Multi-Stakeholder Platform (P. Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:26:00Z","last_updated_date":"2023-07-05T12:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-feedback-kick-meeting-multi-stakeholder-platform-p-arlett-ema_en.pdf"},
    {"id":"59240","name":"Presentation - EU Recommendations on Decentralised Elements in Clinical Trials (M. Al, CCMO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:27:00Z","last_updated_date":"2023-07-05T12:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-recommendations-decentralised-elements-clinical-trials-m-al-ccmo_en.pdf"},
    {"id":"59241","name":"Presentation - Renewal of the Human Medicines highlights newsletter: results of the satisfaction survey (K. Immonen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T12:30:00Z","last_updated_date":"2023-07-05T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-renewal-human-medicines-highlights-newsletter-results-satisfaction-survey-k-immonen-ema_en.pdf"},
    {"id":"59242","name":"Presentation - The EU Pharmaceutical Reform (S. Rafael Almeida, DG SANTE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:09:00Z","last_updated_date":"2023-07-05T13:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-pharmaceutical-reform-s-rafael-almeida-dg-sante_en.pdf"},
    {"id":"59243","name":"Presentation - TEHDAS Data Quality Framework: Excellence in data quality (E. Bernal Delgado, TEHDAS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:11:00Z","last_updated_date":"2023-07-05T13:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-tehdas-data-quality-framework-excellence-data-quality-e-bernal-delgado-tehdas_en.pdf"},
    {"id":"59244","name":"Presentation - EU Data Quality Framework and development of the RWD deep dive (A. Cochino, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:14:00Z","last_updated_date":"2023-07-05T13:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-data-quality-framework-and-development-rwd-deep-dive-cochino-ema_en.pdf"},
    {"id":"59245","name":"Presentation - RWD Data Quality Experience in Finland (P. Rannanheimo, FIMEA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:15:00Z","last_updated_date":"2023-07-05T13:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rwd-data-quality-experience-finland-p-rannanheimo-fimea_en.pdf"},
    {"id":"59246","name":"Presentation - Real World Data (RWD) quality and experience Danish national health registers (S. Knudstrup, K. Holt Nielsen, Danish Health Data Authority)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:17:00Z","last_updated_date":"2023-07-05T13:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-real-world-data-rwd-quality-and-experience-danish-national-health-registers-s-knudstrup-k-holt-nielsen-danish-health-data-authority_en.pdf"},
    {"id":"59247","name":"Presentation - RWD Data Quality Experience in France (E. Bacry, Health Data Hub)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:20:00Z","last_updated_date":"2023-07-05T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rwd-data-quality-experience-france-e-bacry-health-data-hub_en.pdf"},
    {"id":"59248","name":"Presentation – RWD Data Quality Experience by Industry (K.H. Zou, Viatris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:21:00Z","last_updated_date":"2023-07-05T13:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rwd-data-quality-experience-industry-kh-zou-viatris_en.pdf"},
    {"id":"59249","name":"Presentation - Systems and processes underpinning Real-World Data : Characterisation and maturity model consideration (A. Cochino, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:23:00Z","last_updated_date":"2023-07-05T13:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-systems-and-processes-underpinning-real-world-data-characterisation-and-maturity-model-consideration-cochino-ema_en.pdf"},
    {"id":"59250","name":"Presentation - Data quality metrics in the context of DARWIN EU (M. Moinat, DARWIN EU Coordinating Centre)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:25:00Z","last_updated_date":"2023-07-05T13:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-quality-metrics-context-darwin-eu-m-moinat-darwin-eu-coordinating-centre_en.pdf"},
    {"id":"59251","name":"Presentation - Data Quality metrics for Real-World Data (K.Deli, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:26:00Z","last_updated_date":"2023-07-05T13:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-quality-metrics-real-world-data-kdeli-ema_en.pdf"},
    {"id":"59252","name":"Presentation - Data quality requirements and study design and analysis aspects (O. Klungel, Utrecht University)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:27:00Z","last_updated_date":"2023-07-05T13:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-quality-requirements-and-study-design-and-analysis-aspects-o-klungel-utrecht-university_en.pdf"},
    {"id":"59253","name":"Presentation - Data quality in fit for purpose assessments (J. Abellan, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:29:00Z","last_updated_date":"2023-07-05T13:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-quality-fit-purpose-assessments-j-abellan-ema_en.pdf"},
    {"id":"59254","name":"Presentation - A report on the experience with regulatory led RWD studies (S. Prilla, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:30:00Z","last_updated_date":"2023-07-05T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-report-experience-regulatory-led-rwd-studies-s-prilla-ema_en.pdf"},
    {"id":"59255","name":"Presentation - Use of RWE in medicines development and regulatory submissions - an industry perspective (A. Spooner, AbbVie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:32:00Z","last_updated_date":"2023-07-05T13:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-rwe-medicines-development-and-regulatory-submissions-industry-perspective-spooner-abbvie_en.pdf"},
    {"id":"59256","name":"Presentation - Use of RWE in medicines development and regulatory submissions - a regulator’s perspective (C. Torre, University of Lisbon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:33:00Z","last_updated_date":"2023-07-10T11:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-rwe-medicines-development-and-regulatory-submissions-regulators-perspective-c-torre-university-lisbon_en.pdf"}    {"id":"59257","name":"Presentation - Survey results : Use (-fulness) of RWE in regulatory decisions (S. Prilla, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:35:00Z","last_updated_date":"2023-07-05T13:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-results-use-fulness-rwe-regulatory-decisions-s-prilla-ema_en.pdf"},
    {"id":"59258","name":"Presentation - DARWIN EU: where we are in the Phase 2 of its implementation (A. Segec, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:37:00Z","last_updated_date":"2023-07-05T13:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-darwin-eu-where-we-are-phase-2-its-implementation-segec-ema_en.pdf"},
    {"id":"59259","name":"Presentation - DARWIN EU to support HTA and payers’ research RWE needs (J. Abellan, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:38:00Z","last_updated_date":"2023-07-05T13:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-darwin-eu-support-hta-and-payers-research-rwe-needs-j-abellan-ema_en.pdf"},
    {"id":"59260","name":"Presentation - DARWIN EU to support EHDS2 pilot (M. Jendrossek, EHDS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:39:00Z","last_updated_date":"2023-07-05T13:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-darwin-eu-support-ehds2-pilot-m-jendrossek-ehds_en.pdf"},
    {"id":"59261","name":"Presentation - DARWIN EU in the context of infectious diseases and health emergencies (E. Duffell, ECDC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:42:00Z","last_updated_date":"2023-07-05T13:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-darwin-eu-context-infectious-diseases-and-health-emergencies-e-duffell-ecdc_en.pdf"},
    {"id":"59262","name":"Presentation - Patient registries in regulatory decision making : Regulator’s vision and experiences (P. McGettigan, PRAC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:44:00Z","last_updated_date":"2023-07-05T13:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-registries-regulatory-decision-making-regulators-vision-and-experiences-p-mcgettigan-prac_en.pdf"},
    {"id":"59263","name":"Presentation - Assessing the EMA data quality framework (DQF) dimensions using REQUeST: a decentralized registry use case (P. Dobay, Meritxell Sabidó)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:46:00Z","last_updated_date":"2023-07-05T13:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-assessing-ema-data-quality-framework-dqf-dimensions-using-request-decentralized-registry-use-case-p-dobay-meritxell-sabido_en.pdf"},
    {"id":"59264","name":"Presentation - Registry based randomized clinical trials (R-RCT) - from SWEDEHEART to EuroHeart (L. Wallentin, Uppsala University)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:48:00Z","last_updated_date":"2023-07-05T13:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-registry-based-randomized-clinical-trials-r-rct-swedeheart-euroheart-l-wallentin-uppsala-university_en.pdf"},
    {"id":"59265","name":"Presentation - Survey results on the EMA guideline on registry based studies (K. Plueschke, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:49:00Z","last_updated_date":"2023-07-05T13:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-results-ema-guideline-registry-based-studies-k-plueschke-ema_en.pdf"},
    {"id":"59266","name":"Presentation - Patient representative perspective - panel discussion (M. De Lemus, CAT)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:51:00Z","last_updated_date":"2023-07-05T13:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-representative-perspective-panel-discussion-m-de-lemus-cat_en.pdf"},
    {"id":"59267","name":"Presentation - Measuring vaccine performance under emergency situations - case studies and learnings for RWE generation (M. Goossens, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-05T13:53:00Z","last_updated_date":"2023-07-05T13:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-measuring-vaccine-performance-under-emergency-situations-case-studies-and-learnings-rwe-generation-m-goossens-ema_en.pdf"},
    {"id":"59278","name":"Presentation - Clinical Trial Information System (CTIS) Webinar - Second Year of Transition","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-06T14:16:00Z","last_updated_date":"2023-07-06T14:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trial-information-system-ctis-webinar-second-year-transition_en.pdf"},
    {"id":"59327","name":"Presentation - Industry Standing Group (ISG) - 1 year of experience (M-H. Pinheiro, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T10:20:00Z","last_updated_date":"2023-07-12T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-standing-group-isg-1-year-experience-m-h-pinheiro-ema_en.pdf"},
    {"id":"59328","name":"Presentation - ESMP Development Progress & Roadmap (P. Pina, S. Zastavnik, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T10:25:00Z","last_updated_date":"2023-07-12T10:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esmp-development-progress-roadmap-p-pina-s-zastavnik-ema_en.pdf"},
    {"id":"59329","name":"Presentation - Joint EMA/HERA exercise on the monitoring of a subset of antibiotics in preparation for the autumn/winter 2023-2024 (E. Matelyte, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T10:27:00Z","last_updated_date":"2023-07-12T10:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-emahera-exercise-monitoring-subset-antibiotics-preparation-autumnwinter-2023-2024-e-matelyte-ema_en.pdf"},
    {"id":"59330","name":"Presentation - Update on Medicine Shortages Activities (J. Ferreira, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T10:29:00Z","last_updated_date":"2023-07-12T10:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-medicine-shortages-activities-j-ferreira-ema_en.pdf-0"},
    {"id":"59331","name":"Presentation - Monitoring and mitigating shortages of critical medical devices in the context of a public health emergency (P. Ferreira, K. Kruttwig, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T10:33:00Z","last_updated_date":"2023-07-12T10:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-mitigating-shortages-critical-medical-devices-context-public-health-emergency-p-ferreira-k-kruttwig-ema_en.pdf"},
    {"id":"59332","name":"Presentation - Medical device expert panels’ activities: update on CECP/PECP and additional activities (S. da Rocha Dias, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T10:35:00Z","last_updated_date":"2023-07-12T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-device-expert-panels-activities-update-cecp-pecp-additional-activities-s-da-rocha-dias-ema_en.pdf"},
    {"id":"59333","name":"Presentation - ACT EU and CTIS update (P. Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T10:36:00Z","last_updated_date":"2023-07-12T10:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-and-ctis-update-p-arlett-ema_en.pdf"},
    {"id":"59334","name":"Presentation - The EU Pharmaceutical Reform (L. Luchianov, DG SANTE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T10:37:00Z","last_updated_date":"2023-07-12T10:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-pharmaceutical-reform-l-luchianov-dg-sante_en.pdf"},
    {"id":"59335","name":"Presentation - Reorganisation of EMA working parties (S. da Rocha Dias, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T10:39:00Z","last_updated_date":"2023-07-12T10:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reorganisation-ema-working-parties-s-da-rocha-dias-ema_en.pdf"},
    {"id":"59336","name":"Presentation - Patient access through innovation (E. Korakianiti, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-12T10:41:00Z","last_updated_date":"2023-07-12T10:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-access-through-innovation-e-korakianiti-ema_en.pdf"},
    {"id":"59419","name":"Presentation - Update on latest developments in scientific advice (I.Gravanis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-20T11:21:00Z","last_updated_date":"2023-07-20T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-latest-developments-scientific-advice-igravanis-ema_en.pdf"},
    {"id":"59420","name":"Presentation - PRIME: Implementation of new initiatives to further strengthen the PRIME scheme (K. Cunningham, A. Gross, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-20T11:21:00Z","last_updated_date":"2023-07-20T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prime-implementation-new-initiatives-further-strengthen-prime-scheme-k-cunningham-gross-ema_en.pdf"},
    {"id":"59421","name":"Presentation - EMA multistakeholder workshop on Qualification of Novel Methodologies (QoNM) - initial feedback from the discussions (T. Vetter, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-20T11:21:00Z","last_updated_date":"2023-07-20T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-multistakeholder-workshop-qualification-novel-methodologies-qonm-initial-feedback-discussions-t-vetter-ema_en.pdf"},
    {"id":"59422","name":"Presentation - Cooperation at the HTA/regulatory interface (S.Said, G-BA; T.Olski, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-20T11:21:00Z","last_updated_date":"2023-07-20T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cooperation-htaregulatory-interface-ssaid-g-ba-tolski-ema_en.pdf"},
    {"id":"59423","name":"Presentation - Experience from sPIP pilot (C, Pallidis, S. Scherer, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-20T11:21:00Z","last_updated_date":"2023-07-20T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-spip-pilot-c-pallidis-s-scherer-ema_en.pdf"},
    {"id":"59424","name":"Presentation - Revision of the key elements and the summary report template (R. De Lisa, C. Pallidis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-20T11:21:00Z","last_updated_date":"2023-07-20T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revision-key-elements-and-summary-report-template-r-de-lisa-c-pallidis-ema_en.pdf"},
    {"id":"59425","name":"Presentation - Proposals moving forward to facilitate the scientific dialogue on drug-device and drug-companion diagnostic combinations within the current regulatory framework and potentially in the future (S. Aarum, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-20T11:21:00Z","last_updated_date":"2023-07-20T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposals-moving-forward-facilitate-scientific-dialogue-drug-device-and-drug-companion-diagnostic-combinations-within-current-regulatory-framework-and-potentially-future-s-aarum-ema_en.pdf"},
    {"id":"59483","name":"Presentation - Setting the scene on the current regulatory framework (I. Clamou, European Commission)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:19:00Z","last_updated_date":"2023-07-25T13:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-setting-scene-current-regulatory-framework-i-clamou-european-commission_en.pdf"},
    {"id":"59484","name":"Presentation - Role of the MS NCA, Ethics Committee, CT-CURE and ACT EU (G. Musch, K. Vanmolkot, S. Vanhiebecq)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:22:00Z","last_updated_date":"2023-07-25T13:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-ms-nca-ethics-committee-ct-cure-and-act-eu-g-musch-k-vanmolkot-s-vanhiebecq_en.pdf"},
    {"id":"59485","name":"Presentation - Role of EMA Emergency Task Force (M. Mura, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:26:00Z","last_updated_date":"2023-07-25T13:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-ema-emergency-task-force-m-mura-ema_en.pdf"},
    {"id":"59486","name":"Presentation - Past-Experience MOSAIC, EU-RESPONSE (Y. Yazdanpanah, I.C. Olsen, P. Olliario (MOSAIC & EU-Solidact)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:27:00Z","last_updated_date":"2023-07-25T13:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-past-experience-mosaic-eu-response-y-yazdanpanah-ic-olsen-p-olliario-mosaic-eu-solidact_en.pdf"},
    {"id":"59487","name":"Presentation - Past-Experience STRIVE (J. Lundgren, University of Copenhagen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:29:00Z","last_updated_date":"2023-07-25T13:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-past-experience-strive-j-lundgren-university-copenhagen_en.pdf"},
    {"id":"59488","name":"Presentation - Current efforts for clinical research in preparedness and during emergencies in the EU (I. Norstedt, DG R&I)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:32:00Z","last_updated_date":"2023-07-25T13:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-efforts-clinical-research-preparedness-and-during-emergencies-eu-i-norstedt-dg-ri_en.pdf"},
    {"id":"59489","name":"Presentation - Current efforts for clinical research in preparedness and during emergencies in the EU (L. Muschel, European Commission)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:33:00Z","last_updated_date":"2023-07-25T13:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-efforts-clinical-research-preparedness-and-during-emergencies-eu-l-muschel-european-commission_en.pdf"},
    {"id":"59490","name":"Presentation - Pandemic Preparedness Partnership (H. Raoul, Be Ready)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:34:00Z","last_updated_date":"2023-07-25T13:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pandemic-preparedness-partnership-h-raoul-be-ready_en.pdf"},
    {"id":"59491","name":"Presentation - Coordination of trials (V. Simensen, J. Arne, NIPH)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:37:00Z","last_updated_date":"2023-07-25T13:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-coordination-trials-v-simensen-j-arne-niph_en.pdf"},
    {"id":"59492","name":"Presentation - JAAM (J. Demotes, ECRIN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:40:00Z","last_updated_date":"2023-07-25T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-jaam-j-demotes-ecrin_en.pdf"},
    {"id":"59493","name":"Presentation - Experience from clinical trials MonkeyVax (L. Binh Luong)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:41:00Z","last_updated_date":"2023-07-25T13:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-clinical-trials-monkeyvax-l-binh-luong_en.pdf"},
    {"id":"59494","name":"Presentation - Experience from clinical trials VACCELERATE (O. Cornely)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:43:00Z","last_updated_date":"2023-07-25T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-clinical-trials-vaccelerate-o-cornely_en.pdf"},
    {"id":"59495","name":"Presentation - Experience from clinical trials EPOXI (M. Ekkelenkamp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:45:00Z","last_updated_date":"2023-07-25T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-clinical-trials-epoxi-m-ekkelenkamp_en.pdf"},
    {"id":"59497","name":"Presentation - European partnership on clinical trials initiative (H. Goossens, Belgian EU presidency)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T13:51:00Z","last_updated_date":"2023-07-25T13:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-partnership-clinical-trials-initiative-h-goossens-belgian-eu-presidency_en.pdf"},
    {"id":"59879","name":"CTIS Bitesize Talk : Part I - only applications and Part II requirements in CTIS - presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T10:48:00Z","last_updated_date":"2023-10-12T16:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/ctis-bitesize-talk-part-i-only-applications-and-part-ii-requirements-ctis-presentation_en.pdf"},
    {"id":"59907","name":"Presentation - GFR slope as a Validated Surrogate Endpoint for CKD in RCT","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-06T12:32:00Z","last_updated_date":"2023-09-06T12:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gfr-slope-validated-surrogate-endpoint-ckd-rct_en.pdf"},
    {"id":"60114","name":"Presentation - Union Product Database - Product grouping and third country product names Webinar for Industry users","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-22T13:48:00Z","last_updated_date":"2023-09-22T13:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-product-database-product-grouping-and-third-country-product-names-webinar-industry-users_en.pdf"},
    {"id":"60124","name":"Presentation -  A new VMP regulation: one year in operation (Eva Zamora Escribano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T11:48:00Z","last_updated_date":"2023-09-25T11:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-vmp-regulation-one-year-operation-eva-zamora-escribano_en.pdf"},
    {"id":"60125","name":"Presentation - EMA role and activities for veterinary medicines (Ivo Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T11:49:00Z","last_updated_date":"2023-09-25T11:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-role-activities-veterinary-medicines-ivo-claassen_en.pdf"},
    {"id":"60126","name":"Presentation - Fostering better veterinary medicines globally through international engagement and connections (Martin Harvey)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T11:53:00Z","last_updated_date":"2023-09-25T11:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fostering-better-veterinary-medicines-globally-through-international-engagement-and-connections-martin-harvey_en.pdf"},
    {"id":"60127","name":"Presentation - Veterinary novel therapies and technologies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T12:10:00Z","last_updated_date":"2023-09-25T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-novel-therapies-and-technologies_en.pdf"},
    {"id":"60128","name":"Presentation - Environmental risk assessment for veterinary medicines (Michael Empl)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T12:13:00Z","last_updated_date":"2023-09-25T12:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-environmental-risk-assessment-veterinary-medicines-michael-empl_en.pdf"},
    {"id":"60129","name":"Presentation - Environmental safety of parasiticidal veterinary medicinal products (VMPs) for cats and dogs in the EU/EEAEMA (Haru Kroneis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T12:15:00Z","last_updated_date":"2023-09-25T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-environmental-safety-parasiticidal-veterinary-medicinal-products-vmps-cats-and-dogs-eu-eeaema-haru-kroneis_en.pdf"},
    {"id":"60130","name":"Presentation - Environmental impact assessment matters (Ivo Roessink)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T12:38:00Z","last_updated_date":"2023-09-25T12:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-environmental-impact-assessment-matters-ivo-roessink_en.pdf"},
    {"id":"60131","name":"Presentation - Impact of animals in society (Nancy De Briyne)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T13:20:00Z","last_updated_date":"2023-09-25T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-animals-society-nancy-de-briyne_en.pdf"},
    {"id":"60140","name":"Presentation - Emergency Task Force (ETF) update - A. Simonds (ERS) and J. Drabwell (IPOPI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:06:00Z","last_updated_date":"2023-09-25T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emergency-task-force-etf-update-simonds-ers-and-j-drabwell-ipopi_en.pdf"},
    {"id":"60141","name":"Presentation - Medicines Shortages Steering Group (MSSG) - C. Roffiaen (EPHA) and P. Polidori (EAHP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:10:00Z","last_updated_date":"2023-09-25T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicines-shortages-steering-group-mssg-c-roffiaen-epha-and-p-polidori-eahp_en.pdf"},
    {"id":"60142","name":"Presentation - Role of EMA in facilitating Clinical Trials in emergencies - M. Mura (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:15:00Z","last_updated_date":"2023-09-25T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-ema-facilitating-clinical-trials-emergencies-m-mura-ema_en.pdf"},
    {"id":"60143","name":"Presentation - Big Data Steering Group update - D. Umuhire (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:17:00Z","last_updated_date":"2023-09-25T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-steering-group-update-d-umuhire-ema_en.pdf"},
    {"id":"60144","name":"Presentation - Feedback from surveys on medicine shortages - I. Abed (EMA) and S. Marschler (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:20:00Z","last_updated_date":"2023-09-25T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-surveys-medicine-shortages-i-abed-ema-and-s-marschler-ema_en.pdf"},
    {"id":"60145","name":"Presentation - EU list of Critical Medicines - J. Ferreira (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:22:00Z","last_updated_date":"2023-09-25T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-list-critical-medicines-j-ferreira-ema_en.pdf"},
    {"id":"60146","name":"Presentation - Update on preparedness activities - E. Matelyte (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:23:00Z","last_updated_date":"2023-09-25T16:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-preparedness-activities-e-matelyte-ema_en.pdf"},
    {"id":"60147","name":"Presentation - An analysis of regulated medicines information for cancer patients - C. Davis (Health Action International)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:26:00Z","last_updated_date":"2023-09-25T16:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-analysis-regulated-medicines-information-cancer-patients-c-davis-health-action-international_en.pdf"},
    {"id":"60148","name":"Presentation - QRD Template revision for package leaflet improvement - M. Buch (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:30:00Z","last_updated_date":"2023-09-25T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qrd-template-revision-package-leaflet-improvement-m-buch-ema_en.pdf"},
    {"id":"60149","name":"Presentation - ICH E21: inclusion of pregnant & breastfeeding individuals in clinical trials - C. de Vries (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:32:00Z","last_updated_date":"2023-09-25T16:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-e21-inclusion-pregnant-breastfeeding-individuals-clinical-trials-c-de-vries-ema_en.pdf"},
    {"id":"60150","name":"Presentation - Proposal for ACT EU MSP Advisory Group - A. Zanoletty (EMA) and M. Filancia (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:33:00Z","last_updated_date":"2023-09-25T16:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposal-act-eu-msp-advisory-group-zanoletty-ema-and-m-filancia-ema_en.pdf"},
    {"id":"60151","name":"Presentation - EMA Social Media Strategy 2023-2025 - C. Enachioiu (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:36:00Z","last_updated_date":"2023-09-25T16:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-social-media-strategy-2023-2025-c-enachioiu-ema_en.pdf"},
    {"id":"60152","name":"Presentation - Addressing mis- and disinformation - S. Labbé (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T16:38:00Z","last_updated_date":"2023-09-25T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-addressing-mis-and-disinformation-s-labbe-ema_en.pdf"},
    {"id":"60157","name":"Presentation - Substance, product, organisation and referential (SPOR) application programming interface (API) - SPOR API Webinar presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-26T15:04:00Z","last_updated_date":"2023-09-26T15:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-product-organisation-and-referential-spor-application-programming-interface-api-spor-api-webinar-presentation_en.pdf"},
    {"id":"60161","name":"Presentation - Substance Management Service (SMS) Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T10:08:00Z","last_updated_date":"2023-09-27T10:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-substance-management-service-sms-webinar_en.pdf"},
    {"id":"60162","name":"Presentation - EMA Account Management Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T10:13:00Z","last_updated_date":"2023-10-11T14:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-account-management-webinar_en.pdf"},
    {"id":"60163","name":"Presentation - Product Management Service (XEVMPD) Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T10:15:00Z","last_updated_date":"2023-10-06T16:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-xevmpd-webinar_en.pdf"},
    {"id":"60164","name":"Presentation : SPOR Data Governance Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T11:12:00Z","last_updated_date":"2023-09-27T11:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-data-governance-webinar_en.pdf"},
    {"id":"60165","name":"Presentation - Referentials Management Service (RMS) Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T11:22:00Z","last_updated_date":"2023-09-27T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-referentials-management-service-rms-webinar_en.pdf"},
    {"id":"60166","name":"Presentation - Organisation Management Service (OMS) Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T11:27:00Z","last_updated_date":"2023-09-27T11:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organisation-management-service-oms-webinar_en.pdf"},
    {"id":"60170","name":"Decentralized Clinical Trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T14:27:00Z","last_updated_date":"2023-09-27T14:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/decentralized-clinical-trials_en.pdf"},
    {"id":"60171","name":"EU Recommendations on Decentralised Elements in Clinical Trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T14:28:00Z","last_updated_date":"2023-09-27T14:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-recommendations-decentralised-elements-clinical-trials_en.pdf"},
    {"id":"60176","name":"Presentation - Recent developments in livestock welfare science (Hans Spoolder)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T17:27:00Z","last_updated_date":"2023-09-27T17:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recent-developments-livestock-welfare-science-hans-spoolder_en.pdf"},
    {"id":"60177","name":"Presentation - Collaboration with academia on regulatory science activities (Ralf Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T17:31:00Z","last_updated_date":"2023-09-27T17:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collaboration-academia-regulatory-science-activities-ralf-herold_en.pdf"},
    {"id":"60178","name":"Presentation - Regulatory science and research in veterinary medicines – an overview of activities (Ana Vidal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T17:32:00Z","last_updated_date":"2023-09-27T17:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-science-research-veterinary-medicines-overview-activities-ana-vidal_en.pdf"},
    {"id":"60179","name":"Presentation - Support and assistance offered by EMA to veterinary (Valentin Nicorescu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T17:35:00Z","last_updated_date":"2023-09-27T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-support-assistance-offered-ema-veterinary-valentin-nicorescu_en.pdf"},
    {"id":"60180","name":"Presentation - CVMP role and responsibilities (Frida Wikstrom)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T17:37:00Z","last_updated_date":"2023-09-27T17:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-role-and-responsibilities-frida-wikstrom_en.pdf"},
    {"id":"60181","name":"Presentation - Perspective of the manufacturers of veterinary medicines (Frederik Schutte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T17:39:00Z","last_updated_date":"2023-09-27T17:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-perspective-manufacturers-veterinary-medicines-frederik-schutte_en.pdf"},
    {"id":"60182","name":"Presentation - EMA and the EU network of veterinary medicines (Jordi Torren)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-27T17:45:00Z","last_updated_date":"2023-09-27T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-eu-network-veterinary-medicines-jordi-torren_en.pdf"},
    {"id":"60232","name":"Presentation - Medical device expert panels (M.Antunes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-03T11:53:00Z","last_updated_date":"2023-10-03T11:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-device-expert-panels-mantunes_en.pdf"},
    {"id":"60233","name":"Presentation - Service Desk for SPOR and XEVMPD webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-03T11:55:00Z","last_updated_date":"2023-10-03T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-service-desk-spor-and-xevmpd-webinar_en.pdf"},
    {"id":"60234","name":"Presentation - Monitoring and mitigating shortages of critical medical devices (P. Ferreira, K. Kruttwig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-03T11:55:00Z","last_updated_date":"2023-10-03T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-mitigating-shortages-critical-medical-devices-p-ferreira-k-kruttwig_en.pdf"},
    {"id":"60235","name":"Presentation - Update on ESMP development progress (P. Pina Ferreira, S. Zastavnik)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-03T12:04:00Z","last_updated_date":"2023-10-03T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-esmp-development-progress-p-pina-ferreira-s-zastavnik_en.pdf"},
    {"id":"60272","name":"Presentation - ISG Update on ACT EU and CTIS (P.Arlett, A. Zanalotty Perez, L.Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-05T15:39:00Z","last_updated_date":"2023-10-05T15:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-isg-update-act-eu-and-ctis-parlett-zanalotty-perez-lpioppo_en.pdf"},
    {"id":"60490","name":"Presentation - AOB update (M. Filancia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-25T17:35:00Z","last_updated_date":"2023-10-25T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-aob-update-m-filancia_en.pdf"},
    {"id":"60556","name":"Presentation - Periodic safety update reports (PSURs) (Irene Rager)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2016-01-25T01:00:00Z","last_updated_date":"2016-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-periodic-safety-update-reports-psurs-irene-rager_en.pdf"},
    {"id":"60590","name":"Presentation - Session 1.06 - Responding to the needs of the 21st century Patient: Addressing challenges and opportunities across the European regulatory framework - View from the industry (Alan Morrison)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2018-11-08T15:55:00Z","last_updated_date":"2018-11-08T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-106-responding-needs-21st-century-patient-addressing-challenges-and-opportunities-across-european-regulatory-framework-view-industry-alan-morrison_en.pdf"},
    {"id":"60658","name":"Presentation - European Commission - Clinical Trial Regulation 536/2014: Objectives, key changes and transitional arrangements (Kristof Bonnarens)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T12:35:00Z","last_updated_date":"2021-11-25T12:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-commission-clinical-trial-regulation-536-2014-objectives-key-changes-and-transitional-arrangements-kristof-bonnarens_en.pdf"},
    {"id":"60659","name":"Presentation - European Organisation for Research and Treatment of Cancer (EORTC): Stakeholders’ experience with the Clinical Trials Regulation No 536/2014 implementation (Stephanie Kromar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T12:42:00Z","last_updated_date":"2021-11-25T12:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-organisation-research-and-treatment-cancer-eortc-stakeholders-experience-clinical-trials-regulation-no-536-2014-implementation-stephanie-kromar_en.pdf"},
    {"id":"60660","name":"Presentation - Medical Faculty and Heidelberg University Hospital: Stakeholders’ experience with the Clinical Trials Regulation No 536/2014 implementation (A. Seidel-Glatzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T12:52:00Z","last_updated_date":"2021-11-25T12:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-faculty-and-heidelberg-university-hospital-stakeholders-experience-clinical-trials-regulation-no-536-2014-implementation-seidel-glatzer_en.pdf"},
    {"id":"60661","name":"Presentation - CTIS explained with user personas and organisation models (Sarah Scales)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T14:01:00Z","last_updated_date":"2021-11-25T14:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-explained-user-personas-and-organisation-models-sarah-scales_en.pdf"},
    {"id":"60662","name":"Presentation - Safety reporting in CTIS (Marianne Lunzer, AGES)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T14:12:00Z","last_updated_date":"2021-11-25T14:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safety-reporting-ctis-marianne-lunzer-ages_en.pdf"},
    {"id":"60663","name":"Presentation - Overview of guidance and training available for sponsors (Fia Westerholm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T14:17:00Z","last_updated_date":"2021-11-25T14:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-guidance-and-training-available-sponsors-fia-westerholm_en.pdf"},
    {"id":"60720","name":"Presentation - Session 2: Panel and audience discussion on CTR (C. Lorck, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T15:20:00Z","last_updated_date":"2023-06-30T15:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-and-audience-discussion-ctr-c-lorck-efpia_en.pdf"},
    {"id":"60741","name":"Presentation - Nitrosamine Implementation Oversight Group (NIOG) – fifth meeting with  pharmaceutical industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-05T12:01:00Z","last_updated_date":"2023-09-05T12:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nitrosamine-implementation-oversight-group-niog-fifth-meeting-pharmaceutical-industry_en.pdf"},
    {"id":"60743","name":"Presentation - Antimicrobial resistance (AMR) initiatives (Zoltan Kunsagi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T11:55:00Z","last_updated_date":"2023-09-25T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antimicrobial-resistance-amr-initiatives-zoltan-kunsagi_en.pdf"}    {"id":"60744","name":"Presentation - Alternatives to veterinary antimicrobials (AVANT) (Luca Guardabassi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T11:57:00Z","last_updated_date":"2023-09-25T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-alternatives-veterinary-antimicrobials-avant-luca-guardabassi_en.pdf"},
    {"id":"60745","name":"Presentation - Availability of VMPs promoting the authorisation of alternatives to antimicrobials (Noemi Garcia del Blanco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T12:12:00Z","last_updated_date":"2023-09-25T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-availability-vmps-promoting-authorisation-alternatives-antimicrobials-noemi-garcia-del-blanco_en.pdf"},
    {"id":"60746","name":"Presentation - The societal impacts of animals (Carel du Marchie Sarvaas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T12:35:00Z","last_updated_date":"2023-09-25T12:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-societal-impacts-animals-carel-du-marchie-sarvaas_en.pdf"},
    {"id":"60747","name":"Presentation - Consumer safety and maximum residue limits (MRLs) (Sebastien Girault)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T13:24:00Z","last_updated_date":"2023-09-25T13:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-consumer-safety-maximum-residue-limits-mrls-sebastien-girault_en.pdf"},
    {"id":"60748","name":"Presentation - Advancing acceptance of 3Rs testing approaches for regulatory testing of medicinal products in the EUThe EMA 3Rs Working Party (Sonja Beken)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T13:34:00Z","last_updated_date":"2023-09-25T13:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advancing-acceptance-3rs-testing-approaches-regulatory-testing-medicinal-products-euthe-ema-3rs-working-party-sonja-beken_en.pdf"},
    {"id":"60749","name":"Presentation - 3RsWP working topics related to veterinary medicinal products (Sarah Adler-Flindt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T13:38:00Z","last_updated_date":"2023-09-25T13:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-3rswp-working-topics-related-veterinary-medicinal-products-sarah-adler-flindt_en.pdf"},
    {"id":"60750","name":"Informative Webinar on Regulatory Procedure Management  for Product Lifecycle Management 1st roll-out on IRIS","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-09-26T11:21:00Z","last_updated_date":"2023-09-26T11:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/informative-webinar-regulatory-procedure-management-product-lifecycle-management-1st-roll-out-iris_en.pdf"},
    {"id":"60753","name":"Presentation - Agile Transformation (M.Castagna, J.Wiemer, T.AIjo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-03T11:50:00Z","last_updated_date":"2023-10-03T11:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agile-transformation-mcastagna-jwiemer-taijo_en.pdf"},
    {"id":"60754","name":"Presentation - EU list of critical medicines (J.Ferreira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-03T11:52:00Z","last_updated_date":"2023-10-03T11:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-list-critical-medicines-jferreira_en.pdf"},
    {"id":"60755","name":"Presentation - Regulatory Research Science Needs (P.Moscariello)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-03T12:01:00Z","last_updated_date":"2023-10-03T12:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-research-science-needs-pmoscariello_en.pdf"},
    {"id":"60757","name":"Presentation - CTIS bitesize talk - Transition trials - 21 Jun 2023","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-03T12:28:00Z","last_updated_date":"2023-10-03T12:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-bitesize-talk-transition-trials-21-jun-2023_en.pdf"},
    {"id":"60780","name":"Presentation - Emergency Task Force (ETF):ETF implementation update including preparedness activities (Marco Cavaleri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-06T20:22:00Z","last_updated_date":"2023-11-06T20:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emergency-task-force-etfetf-implementation-update-including-preparedness-activities-marco-cavaleri_en.pdf"},
    {"id":"60793","name":"Presentation - European Cancer League June 2023","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-07T17:22:00Z","last_updated_date":"2023-11-07T17:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-cancer-league-june-2023_en.pdf"},
    {"id":"60794","name":"Presentation - EHA multiple myeloma CMF June 2023","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-07T17:25:00Z","last_updated_date":"2023-11-07T17:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eha-multiple-myeloma-cmf-june-2023_en.pdf"},
    {"id":"60795","name":"Presentation - EMA proposals to optimise treatment within current procedures CMF june 2023","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-07T17:27:00Z","last_updated_date":"2023-11-07T17:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-proposals-optimise-treatment-within-current-procedures-cmf-june-2023_en.pdf"},
    {"id":"60866","name":"Presentation - Update on human variations web-based electronic application form implementation on product lifecycle management portal","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T14:00:00Z","last_updated_date":"2023-11-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-human-variations-web-based-electronic-application-form-implementation-product-lifecycle-management-portal_en.pdf"},
    {"id":"61016","name":"Presentation - Update on digitalization: eAF & IRIS Focus (K. Puusaari, F. Penaranda, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:19:15Z","last_updated_date":"2023-11-28T15:19:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-digitalization-eaf-iris-focus-k-puusaari-f-penaranda-ema_en.pdf"},
    {"id":"61017","name":"Presentation - submission predictability (F. Day, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:23:43Z","last_updated_date":"2023-11-28T15:23:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-submission-predictability-f-day-ema_en.pdf"},
    {"id":"61018","name":"Presentation - Patient experience data (R. Gonzalez Quevedo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:27:49Z","last_updated_date":"2023-11-28T15:27:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-experience-data-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"61019","name":"Presentation - Working parties and new ways of working (S. da Rocha, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:32:11Z","last_updated_date":"2023-11-28T15:32:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-parties-and-new-ways-working-s-da-rocha-ema_en.pdf"},
    {"id":"61020","name":"Presentation - Update on issues raised during Validation of Type IB and Type II Variations (E. Merken, S. Pulido Sanchez, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:34:48Z","last_updated_date":"2023-11-28T15:34:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-issues-raised-during-validation-type-ib-and-type-ii-variations-e-merken-s-pulido-sanchez-ema_en.pdf"},
    {"id":"61021","name":"Presentation - Windsor protocol implementation aspects (T. Girard, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:37:35Z","last_updated_date":"2023-11-28T15:37:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-windsor-protocol-implementation-aspects-t-girard-ema_en.pdf"},
    {"id":"61022","name":"Presentation - Revised Variation Framework (K. Semm, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:40:48Z","last_updated_date":"2023-11-28T15:40:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revised-variation-framework-k-semm-ec_en.pdf"},
    {"id":"61023","name":"Presentation - New in 2024: opportunity to submit SEND data (C. de Vries, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:43:35Z","last_updated_date":"2023-11-28T15:43:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-2024-opportunity-submit-send-data-c-de-vries-ema_en.pdf"},
    {"id":"61266","name":"Presentation - The EU EU health policy Pharmaceutical  Reform - Lilia Luchianov (DG SANTE, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T11:02:06Z","last_updated_date":"2023-12-06T11:02:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-eu-health-policy-pharmaceutical-reform-lilia-luchianov-dg-sante-ec_en.pdf"},
    {"id":"61269","name":"Presentation - Product Lifecycle Management (PLM) Value Stream Deep-Dive Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T13:40:49Z","last_updated_date":"2023-12-06T13:40:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-lifecycle-management-plm-value-stream-deep-dive-webinar_en.pdf"},
    {"id":"61273","name":"Presentation - Union list of Critical Medicines update (J. Ferreira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T15:41:41Z","last_updated_date":"2023-12-06T15:41:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-list-critical-medicines-update-j-ferreira_en.pdf"},
    {"id":"61274","name":"Presentation - MSSG toolkit on recommendations on tackling shortages of medicinal products (M. Alcarez, Z. Sebris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T15:46:52Z","last_updated_date":"2023-12-06T15:46:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mssg-toolkit-recommendations-tackling-shortages-medicinal-products-m-alcarez-z-sebris_en.pdf"},
    {"id":"61276","name":"Presentation - Update on ESMP development progress status (P. Oliveira, S. Zastavnik)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T15:49:02Z","last_updated_date":"2023-12-06T15:49:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-esmp-development-progress-status-p-oliveira-s-zastavnik_en.pdf"},
    {"id":"61277","name":"Presentation - Monitoring and mitigating shortages of critical medical devices in the context of a public health emergency (P. Oliveira, K. Kruttwig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T15:51:25Z","last_updated_date":"2023-12-06T15:51:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-mitigating-shortages-critical-medical-devices-context-public-health-emergency-p-oliveira-k-kruttwig_en.pdf"},
    {"id":"61278","name":"Presentation - ICMRA PQKMS-update on activities (E. Korakianiti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T15:53:13Z","last_updated_date":"2023-12-06T15:53:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-icmra-pqkms-update-activities-e-korakianiti_en.pdf"},
    {"id":"61279","name":"Presentation - Update on reliance and other collaborative pathways (M. Harvey Allchurch, R. Cherif)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T15:54:57Z","last_updated_date":"2023-12-06T15:54:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-reliance-and-other-collaborative-pathways-m-harvey-allchurch-r-cherif_en.pdf"},
    {"id":"61280","name":"Presentation - EMA/FDA Collaboration in Oncology (A. Marcal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T15:56:50Z","last_updated_date":"2023-12-06T15:56:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-fda-collaboration-oncology-marcal_en.pdf"},
    {"id":"61281","name":"Presentation - Quality Innovation Group (E. Korakianiti, D. Hernan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T15:58:22Z","last_updated_date":"2023-12-06T15:58:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-innovation-group-e-korakianiti-d-hernan_en.pdf"},
    {"id":"61282","name":"Presentation - Call for ISG Topics for 2024 ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-06T16:00:12Z","last_updated_date":"2023-12-06T16:00:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-call-isg-topics-2024_en.pdf"},
    {"id":"61297","name":"Presentation - Strengthening the regulatory/HTA interface: Update on the support to the HTA Regulation implementation - M. Berntgen, F. Cerreta (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T13:59:19Z","last_updated_date":"2023-12-07T13:59:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strengthening-regulatory-hta-interface-update-support-hta-regulation-implementation-m-berntgen-f-cerreta-ema_en.pdf"},
    {"id":"61298","name":"Presentation - HTA Stakeholder Network - B. Dajka, V. Barbuto (EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T14:08:07Z","last_updated_date":"2023-12-07T14:08:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hta-stakeholder-network-b-dajka-v-barbuto-ec_en.pdf"},
    {"id":"61299","name":"Presentation - Update on preparedness activities - E. Matelyte (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T14:10:22Z","last_updated_date":"2023-12-07T14:10:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-preparedness-activities-e-matelyte-ema_en.pdf-0"},
    {"id":"61300","name":"Presentation - Union list of Critical Medicines - J. Ferreira, I. Abed (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T14:12:09Z","last_updated_date":"2023-12-07T14:12:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-list-critical-medicines-j-ferreira-i-abed-ema_en.pdf"},
    {"id":"61301","name":"Presentation - ECHA proposal to ban PFAS – potential impact on availability of medicines - M. Alcaraz (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T14:13:45Z","last_updated_date":"2023-12-07T14:13:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-echa-proposal-ban-pfas-potential-impact-availability-medicines-m-alcaraz-ema_en.pdf"},
    {"id":"61302","name":"Presentation - Update on EU repurposing pilot - C. Bouygues (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T14:15:14Z","last_updated_date":"2023-12-07T14:15:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-eu-repurposing-pilot-c-bouygues-ema_en.pdf"},
    {"id":"61303","name":"Presentation - EMA Workshop on generating clinical evidence for treatment and prevention options for Long-COVID/Post-acute sequelae condition (PASC) - S. Buchholz (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T14:16:49Z","last_updated_date":"2023-12-07T14:16:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-workshop-generating-clinical-evidence-treatment-and-prevention-options-long-covid-post-acute-sequelae-condition-pasc-s-buchholz-ema_en.pdf"},
    {"id":"61304","name":"Presentation - Skills Training for Young Patient Advocates (STYPA) 2023 - C. Louati (EPF)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T14:21:35Z","last_updated_date":"2023-12-07T14:21:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-skills-training-young-patient-advocates-stypa-2023-c-louati-epf_en.pdf"},
    {"id":"61305","name":"Presentation - Next-generation health guidelines - I. Agache (EAACI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T14:24:03Z","last_updated_date":"2023-12-07T14:24:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-next-generation-health-guidelines-i-agache-eaaci_en.pdf"},
    {"id":"61306","name":"Presentation - Highlights 2023 - I. Silva, M. Mavris (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:16:52Z","last_updated_date":"2023-12-07T15:16:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-highlights-2023-i-silva-m-mavris-ema_en.pdf"},
    {"id":"61307","name":"Presentation - COMP Feedback - M. Cavaller, E. Rook, T. Leest","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:19:17Z","last_updated_date":"2023-12-07T15:19:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comp-feedback-m-cavaller-e-rook-t-leest_en.pdf"},
    {"id":"61308","name":"Presentation - Patient Experience Data pilot project – M. Cavaller","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:21:44Z","last_updated_date":"2023-12-07T15:21:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-experience-data-pilot-project-m-cavaller_en.pdf"},
    {"id":"61309","name":"Presentation - Highlights on the Committee for Advanced Therapies - M. de Lemus","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:23:58Z","last_updated_date":"2023-12-07T15:23:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-highlights-committee-advanced-therapies-m-de-lemus_en.pdf"},
    {"id":"61310","name":"Presentation - CHMP feedback - C. Prieto, F. Ventura","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:27:08Z","last_updated_date":"2023-12-07T15:27:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chmp-feedback-c-prieto-f-ventura_en.pdf"},
    {"id":"61311","name":"Presentation - PDCO update - J. Taminiau","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:29:07Z","last_updated_date":"2023-12-07T15:29:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-update-j-taminiau_en.pdf"},
    {"id":"61313","name":"Presentation - Update on Patient Experience Data - R. Gonzalez-Quevedo (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:30:40Z","last_updated_date":"2023-12-07T15:30:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-patient-experience-data-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"61314","name":"Presentation - Big Data Steering Group Workplan - D. Umuhire (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:33:12Z","last_updated_date":"2023-12-07T15:33:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-steering-group-workplan-d-umuhire-ema_en.pdf"},
    {"id":"61315","name":"Presentation - DARWIN EU - A. Segec (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:34:56Z","last_updated_date":"2023-12-07T15:34:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-darwin-eu-segec-ema_en.pdf"},
    {"id":"61316","name":"Presentation - Delivering on stakeholders’ requirements for AI - L. Pinheiro (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:36:34Z","last_updated_date":"2023-12-07T15:36:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-delivering-stakeholders-requirements-ai-l-pinheiro-ema_en.pdf"},
    {"id":"61317","name":"Presentation - Facilitating innovation in regulatory science: research needs and multi-stakeholder collaboration - R. Herold (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:39:43Z","last_updated_date":"2023-12-07T15:39:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-facilitating-innovation-regulatory-science-research-needs-and-multi-stakeholder-collaboration-r-herold-ema_en.pdf"},
    {"id":"61318","name":"Presentation - Improving understanding of biosimilars: Toolkit for Member States - B. Duggan (HMA), R. Gonzalez-Quevedo (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:42:31Z","last_updated_date":"2023-12-07T15:42:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-improving-understanding-biosimilars-toolkit-member-states-b-duggan-hma-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"61319","name":"Presentation - EMA's corporate website and accessibility - C. Gadd (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:46:26Z","last_updated_date":"2023-12-07T15:46:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-corporate-website-and-accessibility-c-gadd-ema_en.pdf"},
    {"id":"61320","name":"Presentation - Collaboration with eligible organisations in the implementation of the social media strategy - L. Herold, G. Gabrielli, C. Enachioiu (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:49:36Z","last_updated_date":"2023-12-07T15:49:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collaboration-eligible-organisations-implementation-social-media-strategy-l-herold-g-gabrielli-c-enachioiu-ema_en.pdf"},
    {"id":"61321","name":"Presentation - Goal Attainment Scaling - F. Houÿez (EURORDIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:51:39Z","last_updated_date":"2023-12-07T15:51:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-goal-attainment-scaling-f-houyez-eurordis_en.pdf"},
    {"id":"61322","name":"Presentation - Antimicrobial stewardship and public awareness - M. Rodzinka-Verhelle (CPME)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T15:56:16Z","last_updated_date":"2023-12-07T15:56:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antimicrobial-stewardship-and-public-awareness-m-rodzinka-verhelle-cpme_en.pdf"},
    {"id":"61349","name":"Presentation - Progress update and report at EU-level - EMA/HMA Big Data Steering Group - J. Kjaer","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-11T14:18:57Z","last_updated_date":"2023-12-11T14:18:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-progress-update-and-report-eu-level-ema-hma-big-data-steering-group-j-kjaer_en.pdf"},
    {"id":"61350","name":"Presentation - AI / ML initiatives that were developed and are applied at Swissmedic - M. Renaudin","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-11T14:23:22Z","last_updated_date":"2023-12-11T14:23:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ai-ml-initiatives-were-developed-and-are-applied-swissmedic-m-renaudin_en.pdf"},
    {"id":"61351","name":"Presentation - Big data to support innovation and regulatory decision making - C. Stirling","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-11T14:26:03Z","last_updated_date":"2023-12-11T14:26:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-support-innovation-and-regulatory-decision-making-c-stirling_en.pdf"},
    {"id":"61352","name":"Presentation - Big Data in Veterinary Medicines Regulation - J. Verstegen","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-11T14:27:52Z","last_updated_date":"2023-12-11T14:27:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-veterinary-medicines-regulation-j-verstegen_en.pdf"},
    {"id":"61353","name":"Presentation - Cross-agency cooperation view - environmental and veterinary big data for One Health collaboration - D. Piselli","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-11T14:30:00Z","last_updated_date":"2023-12-11T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cross-agency-cooperation-view-environmental-and-veterinary-big-data-one-health-collaboration-d-piselli_en.pdf"},
    {"id":"61354","name":"Presentation - Veterinary Big Data Work Plan 2022-2025 - S. Bertulat","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-11T14:32:39Z","last_updated_date":"2023-12-11T14:32:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-big-data-work-plan-2022-2025-s-bertulat_en.pdf"},
    {"id":"61373","name":"Presentation - Session 2: Veterinary medicinal products specificities and challenges","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T11:59:37Z","last_updated_date":"2023-12-12T11:59:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-veterinary-medicinal-products-specificities-and-challenges_en.pdf"},
    {"id":"61374","name":"Presentation - Session 3: Engagement with Stakeholders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T12:00:55Z","last_updated_date":"2023-12-12T12:00:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-engagement-stakeholders_en.pdf"},
    {"id":"61375","name":"Presentation - Session 4.1: Engagement with Academia ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T12:01:43Z","last_updated_date":"2023-12-12T12:01:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-41-engagement-academia_en.pdf"},
    {"id":"61376","name":"Presentation - Session 4.2: Programmes catered to academic developers PRIME, Orphan drugs, Paediatric drugs, Advanced Therapies, Repurposing ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T12:02:41Z","last_updated_date":"2023-12-12T12:02:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-42-programmes-catered-academic-developers-prime-orphan-drugs-paediatric-drugs-advanced-therapies-repurposing_en.pdf"},
    {"id":"61377","name":"Presentation - Session 4.3: Innovation in medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T12:03:40Z","last_updated_date":"2023-12-12T12:03:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-43-innovation-medicines_en.pdf"},
    {"id":"61379","name":"Presentation - Session 5.2: EMA career opportunities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T12:05:42Z","last_updated_date":"2023-12-12T12:05:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-52-ema-career-opportunities_en.pdf"},
    {"id":"61386","name":"Presentation - CTIS Bitesize talk - November 2023 ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T15:48:12Z","last_updated_date":"2023-12-12T15:48:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-bitesize-talk-november-2023_en.pptx"},
    {"id":"61399","name":"Presentation - Enpr-EMA annual report 2022-2023 (P. Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T14:39:18Z","last_updated_date":"2023-12-13T14:39:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-annual-report-2022-2023-p-lepola_en.pdf"},
    {"id":"61400","name":"Presentation - Update from Enpr-EMA off-label working group (S. de Wildt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T14:48:58Z","last_updated_date":"2023-12-13T14:48:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-enpr-ema-label-working-group-s-de-wildt_en.pdf"},
    {"id":"61401","name":"Presentation - Update from Enpr-EMA working group on international collaborations (T. Lacaze)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T14:51:07Z","last_updated_date":"2023-12-13T14:51:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-enpr-ema-working-group-international-collaborations-t-lacaze_en.pdf"},
    {"id":"61402","name":"Presentation - Update from Enpr-EMA paediatric research nurse working group (P. Dicks)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T14:55:05Z","last_updated_date":"2023-12-13T14:55:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-enpr-ema-paediatric-research-nurse-working-group-p-dicks_en.pdf"},
    {"id":"61403","name":"Presentation - Update from Enpr-EMA paediatric clinical trial site standards working group (R. Fernandes, S. Corriol-Rohou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T14:57:52Z","last_updated_date":"2023-12-13T14:57:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-enpr-ema-paediatric-clinical-trial-site-standards-working-group-r-fernandes-s-corriol-rohou_en.pdf"},
    {"id":"61404","name":"Presentation - Update from Enpr-EMA working group mapping/defining existing quality criteria/standards for sites (P. Skovby)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T15:01:03Z","last_updated_date":"2023-12-13T15:01:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-enpr-ema-working-group-mapping-defining-existing-quality-criteria-standards-sites-p-skovby_en.pdf"},
    {"id":"61405","name":"Presentation - Update from Enpr-EMA working group on language discrimination and cross-border access to paediatric clinical trials (B. Nafria)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T15:10:13Z","last_updated_date":"2023-12-13T15:10:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-enpr-ema-working-group-language-discrimination-and-cross-border-access-paediatric-clinical-trials-b-nafria_en.pdf"},
    {"id":"61406","name":"Presentation - EU recommendations on decentralised elements in clinical trials (M. Al)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T15:16:29Z","last_updated_date":"2023-12-13T15:16:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-recommendations-decentralised-elements-clinical-trials-m-al_en.pdf"},
    {"id":"61407","name":"Presentation - Paediatric considerations on decentralized trials (T. Lacaze)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T15:18:22Z","last_updated_date":"2023-12-13T15:18:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-considerations-decentralized-trials-t-lacaze_en.pdf"},
    {"id":"61408","name":"Presentation - Good clinical practice - ICH E6(R3) update from ACT EU (PA4) (K. Pietsch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T15:21:51Z","last_updated_date":"2023-12-13T15:21:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-good-clinical-practice-ich-e6r3-update-act-eu-pa4-k-pietsch_en.pdf"},
    {"id":"61409","name":"Presentation - ACT EU action plan to support non-commercial Multinational CTs (G. Capone)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T15:27:20Z","last_updated_date":"2023-12-13T15:27:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-action-plan-support-non-commercial-multinational-cts-g-capone_en.pdf"},
    {"id":"61410","name":"Presentation - Reform of the EU pharmaceutical legislation and its impact on paediatric medicines and orphan medicine development (F. D'Atri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T15:31:07Z","last_updated_date":"2023-12-13T15:31:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reform-eu-pharmaceutical-legislation-and-its-impact-paediatric-medicines-and-orphan-medicine-development-f-datri_en.pdf"},
    {"id":"61411","name":"Presentation - Highlights from Enpr-EMA networks : paediatric clinical trials need paediatric clinical trial budgets (S. Koulizakos, J. Kindblom)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T15:34:08Z","last_updated_date":"2023-12-13T15:34:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-highlights-enpr-ema-networks-paediatric-clinical-trials-need-paediatric-clinical-trial-budgets-s-koulizakos-j-kindblom_en.pdf"},
    {"id":"61412","name":"Presentation - Highlights from Enpr-EMA networks : The conect4children journey (M. Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T15:37:08Z","last_updated_date":"2023-12-13T15:37:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-highlights-enpr-ema-networks-conect4children-journey-m-turner_en.pdf"},
    {"id":"61413","name":"Presentation - Enpr-EMA workplan 2023-2024 (P. Lepola, G. Egger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T16:04:57Z","last_updated_date":"2023-12-13T16:04:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-workplan-2023-2024-p-lepola-g-egger_en.pdf"},
    {"id":"61414","name":"Presentation - Patients recruitment and retention : practices to improve patient recruitment from a network's perspective (M. Migdal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T16:09:04Z","last_updated_date":"2023-12-13T16:09:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-recruitment-and-retention-practices-improve-patient-recruitment-networks-perspective-m-migdal_en.pdf"},
    {"id":"61415","name":"Presentation - Benefits of involving patients and young people in paediatric clinical research (B. Nafria)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T16:11:31Z","last_updated_date":"2023-12-13T16:11:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-benefits-involving-patients-and-young-people-paediatric-clinical-research-b-nafria_en.pdf"},
    {"id":"61416","name":"Presentation - Improve paediatric health, medicine research, and innovation by sharing children's voices with iCAN (D. Bonifazi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-13T16:14:15Z","last_updated_date":"2023-12-13T16:14:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-improve-paediatric-health-medicine-research-and-innovation-sharing-childrens-voices-ican-d-bonifazi_en.pdf"},
    {"id":"61446","name":"Presentation - Complex clinical trials, enabling innovative designs (breakout session A), EFSPI perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:25:38Z","last_updated_date":"2023-12-15T15:25:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-complex-clinical-trials-enabling-innovative-designs-breakout-session-efspi-perspective_en.pdf"},
    {"id":"61447","name":"Presentation - Paediatric clinical trials - Ethics perspective (breakout session B)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:26:50Z","last_updated_date":"2023-12-15T15:26:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-clinical-trials-ethics-perspective-breakout-session-b_en.pdf"},
    {"id":"61448","name":"Presentation - Paediatric clinical trials - Industry perspective (breakout session B)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:28:04Z","last_updated_date":"2023-12-15T15:28:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-clinical-trials-industry-perspective-breakout-session-b_en.pdf"},
    {"id":"61450","name":"Presentation - Paediatric clinical trials - Patients perspective (breakout session B)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:29:11Z","last_updated_date":"2023-12-15T15:29:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-clinical-trials-patients-perspective-breakout-session-b_en.pdf"},
    {"id":"61451","name":"Presentation - Paediatric clinical trials - Regulatory perspective (breakout session B)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:30:47Z","last_updated_date":"2023-12-15T15:30:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-clinical-trials-regulatory-perspective-breakout-session-b_en.pdf"},
    {"id":"61452","name":"Presentation - Paediatric clinical trials - Setting the scene (breakout session B)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:31:27Z","last_updated_date":"2023-12-15T15:31:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-clinical-trials-setting-scene-breakout-session-b_en.pdf"},
    {"id":"61453","name":"Presentation - Validation of digital endpoints - Academic perspective (breakout session D)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:32:11Z","last_updated_date":"2023-12-15T15:32:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-validation-digital-endpoints-academic-perspective-breakout-session-d_en.pdf"},
    {"id":"61454","name":"\tPresentation - Validation of digital endpoints - Industry perspective (breakout session D)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:33:31Z","last_updated_date":"2023-12-15T15:33:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-validation-digital-endpoints-industry-perspective-breakout-session-d_en.pdf"},
    {"id":"61455","name":"Presentation - Beyond Randomised Clinical Trials - Academic perspective (breakout session E)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:34:04Z","last_updated_date":"2023-12-15T15:34:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-beyond-randomised-clinical-trials-academic-perspective-breakout-session-e_en.pdf"}    {"id":"61456","name":"Presentation - Beyond Randomised Clinical Trials - Ethical perspective (breakout session E)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:34:52Z","last_updated_date":"2023-12-15T15:34:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-beyond-randomised-clinical-trials-ethical-perspective-breakout-session-e_en.pdf"},
    {"id":"61457","name":"Presentation - Beyond Randomised Clinical Trials - HTA perspective (breakout session E)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:35:20Z","last_updated_date":"2023-12-15T15:35:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-beyond-randomised-clinical-trials-hta-perspective-breakout-session-e_en.pdf"},
    {"id":"61458","name":"Presentation - Beyond Randomised Clinical Trials - Industry perspective (breakout session E)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:35:53Z","last_updated_date":"2023-12-15T15:35:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-beyond-randomised-clinical-trials-industry-perspective-breakout-session-e_en.pdf"},
    {"id":"61459","name":"Presentation - Patient centricity, inclusion and representativeness in clinical trials - Ethical and academic perspective (breakout session F)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:36:43Z","last_updated_date":"2023-12-15T15:36:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-centricity-inclusion-and-representativeness-clinical-trials-ethical-and-academic-perspective-breakout-session-f_en.pdf"},
    {"id":"61460","name":"Presentation - Patient centricity, inclusion and representativeness in clinical trials - Industry perspective (breakout session F)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:37:37Z","last_updated_date":"2023-12-15T15:37:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-centricity-inclusion-and-representativeness-clinical-trials-industry-perspective-breakout-session-f_en.pdf"},
    {"id":"61461","name":"Presentation - Patient centricity, inclusion and representativeness in clinical trials - Patients perspective (breakout session F)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:38:05Z","last_updated_date":"2023-12-15T15:38:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-centricity-inclusion-and-representativeness-clinical-trials-patients-perspective-breakout-session-f_en.pdf"},
    {"id":"61462","name":"Presentation - Patient centricity, inclusion and representativeness in clinical trials - Setting the scene (breakout session F)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:38:33Z","last_updated_date":"2023-12-15T15:38:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-centricity-inclusion-and-representativeness-clinical-trials-setting-scene-breakout-session-f_en.pdf"},
    {"id":"61463","name":"Presentation - Decentralised clinical trials - Data analysis perspective (breakout session G)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:39:10Z","last_updated_date":"2023-12-15T15:39:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-decentralised-clinical-trials-data-analysis-perspective-breakout-session-g_en.pdf"},
    {"id":"61464","name":"Presentation - Decentralised clinical trials - Industry perspective (breakout session G)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:40:06Z","last_updated_date":"2023-12-15T15:40:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-decentralised-clinical-trials-industry-perspective-breakout-session-g_en.pdf"},
    {"id":"61465","name":"Presentation - Decentralised clinical trials - Patients perspective (breakout session G)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:40:37Z","last_updated_date":"2023-12-15T15:40:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-decentralised-clinical-trials-patients-perspective-breakout-session-g_en.pdf"},
    {"id":"61466","name":"Presentation - Complex clinical trials - Academic perspective (breakout session H)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:41:08Z","last_updated_date":"2023-12-15T15:41:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-complex-clinical-trials-academic-perspective-breakout-session-h_en.pdf"},
    {"id":"61467","name":"Presentation - Complex clinical trials - HTA perspective (breakout session H)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:41:55Z","last_updated_date":"2023-12-15T15:41:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-complex-clinical-trials-hta-perspective-breakout-session-h_en.pdf"},
    {"id":"61468","name":"Presentation - Complex clinical trials - Setting the scene (breakout session H)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:42:18Z","last_updated_date":"2023-12-15T15:42:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-complex-clinical-trials-setting-scene-breakout-session-h_en.pdf"},
    {"id":"61500","name":"Presentation - National regulatory supports for Innovation (Larry O’Dwyer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T14:54:55Z","last_updated_date":"2023-12-19T14:54:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-national-regulatory-supports-innovation-larry-odwyer_en.pdf"},
    {"id":"61502","name":"Presentation - EMA support to innovative developers (Oriane Blanquie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T14:58:45Z","last_updated_date":"2023-12-19T14:58:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-support-innovative-developers-oriane-blanquie_en.pdf"},
    {"id":"61503","name":"Presentation - Strengthening life sciences innovation across Europe (Dr. Deana Mohr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T15:00:24Z","last_updated_date":"2023-12-19T15:00:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strengthening-life-sciences-innovation-across-europe-dr-deana-mohr_en.pdf"},
    {"id":"61504","name":"Presentation - Strengthening life sciences innovation across Europe (Paul Sarret)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T15:04:54Z","last_updated_date":"2023-12-19T15:04:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strengthening-life-sciences-innovation-across-europe-paul-sarret_en.pdf"},
    {"id":"61509","name":"Presentation - Eurasante (Dorothee Gueras)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T15:11:44Z","last_updated_date":"2023-12-19T15:11:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eurasante-dorothee-gueras_en.pdf"},
    {"id":"61510","name":"Presentation - Translating discovery into innovation (Lourdes Núñez Müller)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T15:17:58Z","last_updated_date":"2023-12-19T15:17:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-translating-discovery-innovation-lourdes-nunez-muller_en.pdf"},
    {"id":"61511","name":"Presentation - Biocatalyst foundation (Andrii Shekhirev)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T15:31:58Z","last_updated_date":"2023-12-19T15:31:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-biocatalyst-foundation-andrii-shekhirev_en.pdf"},
    {"id":"61512","name":"Presentation - Successfully scaling in Europe (Menno Kok)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T15:35:05Z","last_updated_date":"2023-12-19T15:35:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-successfully-scaling-europe-menno-kok_en.pdf"},
    {"id":"61513","name":"Presentation - Bio 4 dreams (Luigi Azzarone)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T15:39:28Z","last_updated_date":"2023-12-19T15:39:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bio-4-dreams-luigi-azzarone_en.pdf"},
    {"id":"61514","name":"Presentation - Flanders irf, connecting the ecosystem dots (Dominic De Groote)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T15:41:07Z","last_updated_date":"2023-12-19T15:41:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-flanders-irf-connecting-ecosystem-dots-dominic-de-groote_en.pdf"},
    {"id":"61522","name":"Presentation - Update on AI in pharmacovigilance at EMA (J. Durand, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T16:13:53Z","last_updated_date":"2023-12-19T16:13:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ai-pharmacovigilance-ema-j-durand-ema_en.pdf"},
    {"id":"61523","name":"Presentation - Update on Good Pharmacovigilance Practices (EU-GVP) (P. Bahri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T16:21:14Z","last_updated_date":"2023-12-19T16:21:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-good-pharmacovigilance-practices-eu-gvp-p-bahri-ema_en.pdf"},
    {"id":"61524","name":"Presentation - RMP publication and Specific adverse reaction Follow-up questionnaires guideline (E. Cochino, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T16:23:40Z","last_updated_date":"2023-12-19T16:23:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rmp-publication-and-specific-adverse-reaction-follow-questionnaires-guideline-e-cochino-ema_en.pdf"},
    {"id":"61525","name":"Presentation - EMA/HMA catalogue of non-interventional studies (EU PAS Register) - new functionality (A. Cochino, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T16:26:39Z","last_updated_date":"2023-12-19T16:26:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-hma-catalogue-non-interventional-studies-eu-pas-register-new-functionality-cochino-ema_en.pdf"},
    {"id":"61526","name":"Presentation - GVP Module VIII - Post-authorisation safety studies (C. Jonker, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T16:29:00Z","last_updated_date":"2023-12-19T16:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gvp-module-viii-post-authorisation-safety-studies-c-jonker-ema_en.pdf"},
    {"id":"61532","name":"Presentation - Paediatric Clinical Trial Site Standards Work Group 1 - Defining what quality of paediatric sites means (R. Fernandes and S. Corriol-Rohou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T09:23:33Z","last_updated_date":"2023-12-20T09:23:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-clinical-trial-site-standards-work-group-1-defining-what-quality-paediatric-sites-means-r-fernandes-and-s-corriol-rohou_en.pdf"},
    {"id":"61533","name":"Presentation - Paediatric Clinical Trial Site Standards Work Group 2 - Defining existing quality criteria/standards for sites (P. Skovby)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T09:29:59Z","last_updated_date":"2023-12-20T09:29:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-clinical-trial-site-standards-work-group-2-defining-existing-quality-criteria-standards-sites-p-skovby_en.pdf"},
    {"id":"61534","name":"Presentation - Young people advisory groups - Patient and public involvement in paediatric research within (S. Gaillard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T09:33:39Z","last_updated_date":"2023-12-20T09:33:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-young-people-advisory-groups-patient-and-public-involvement-paediatric-research-within-s-gaillard_en.pdf"},
    {"id":"61535","name":"Presentation - Young people advisory groups - Promoting children participation in decision making process (D. Bonifazi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T09:44:09Z","last_updated_date":"2023-12-20T09:44:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-young-people-advisory-groups-promoting-children-participation-decision-making-process-d-bonifazi_en.pdf"},
    {"id":"61536","name":"Presentation - The European network of paediatric research at the EMA (Enpr-EMA) - Discussion on simplification of membership criteria (G. Egger and P. Lepola))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T09:59:35Z","last_updated_date":"2023-12-20T09:59:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-paediatric-research-ema-enpr-ema-discussion-simplification-membership-criteria-g-egger-and-p-lepola_en.pdf"},
    {"id":"61537","name":"Presentation - The European network of paediatric research at the EMA (Enpr-EMA) work plan 2023-2024 (G. Egger and P. Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T10:05:10Z","last_updated_date":"2023-12-20T10:05:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-paediatric-research-ema-enpr-ema-work-plan-2023-2024-g-egger-and-p-lepola_en.pdf"},
    {"id":"61538","name":"Presentation - Networks’ practical experiences regarding trial conduct - Early dialogue: essential for better trials (B. Sandner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T10:08:10Z","last_updated_date":"2023-12-20T10:08:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-networks-practical-experiences-regarding-trial-conduct-early-dialogue-essential-better-trials-b-sandner_en.pdf"},
    {"id":"61539","name":"Presentation - Networks’ practical experiences regarding trial conduct_ Supporting paediatric trials - Learnings and insights from conect4children (R. Fernandes","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T10:12:10Z","last_updated_date":"2023-12-20T10:12:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-networks-practical-experiences-regarding-trial-conduct_-supporting-paediatric-trials-learnings-and-insights-conect4children-r-fernandes_en.pdf"},
    {"id":"61634","name":"Presentation: Clinical Trials Information System (CTIS) bitesize talk - How to submit a transitional trial in CTIS","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-10-02T16:59:37Z","last_updated_date":"2023-10-02T16:59:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-how-submit-transitional-trial-ctis_en.pdf"},
    {"id":"61635","name":"Presentation - CTIS Bitesize Talk - IMPD-Q-only Submission","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-06-07T17:05:24Z","last_updated_date":"2023-06-07T17:05:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-bitesize-talk-impd-q-only-submission_en.pdf"},
    {"id":"61636","name":"Presentation - Analysis on common issues raised during Validation of Type IB and Type II Variations (E. Merken, S. Pulido Sanchez, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T17:23:09Z","last_updated_date":"2023-11-28T17:23:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-analysis-common-issues-raised-during-validation-type-ib-and-type-ii-variations-e-merken-s-pulido-sanchez-ema_en.pdf"},
    {"id":"61644","name":"Presentation - Complex clinical trials - Enabling innovative designs - Patients' journey studies (breakout session A)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T16:45:53Z","last_updated_date":"2024-01-05T16:45:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-complex-clinical-trials-enabling-innovative-designs-patients-journey-studies-breakout-session_en.pdf"},
    {"id":"61645","name":"\tPresentation - Complex clinical trials - Enabling innovative designs - Setting the scene (breakout session A)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T16:51:34Z","last_updated_date":"2024-01-05T16:51:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-complex-clinical-trials-enabling-innovative-designs-setting-scene-breakout-session_en.pdf"},
    {"id":"61646","name":"\tPresentation - Complex clinical trials - Enabling innovative designs - The experience of the DRUP trial (breakout session A)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T16:53:14Z","last_updated_date":"2024-01-05T16:53:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-complex-clinical-trials-enabling-innovative-designs-experience-drup-trial-breakout-session_en.pdf"},
    {"id":"61647","name":"Presentation - Pragmatic trials, definition and usefulness - Academic perspective (EORTC) Complex clinical trials - Enabling innovative designs - Patients' journey studies (breakout session C)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T16:54:50Z","last_updated_date":"2024-01-05T16:54:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pragmatic-trials-definition-and-usefulness-academic-perspective-eortc-complex-clinical-trials-enabling-innovative-designs-patients-journey-studies-breakout-session-c_en.pdf"},
    {"id":"61648","name":"Presentation - Pragmatic trials, definition and usefulness - Academic perspective (EORTC) Complex clinical trials - Enabling innovative designs - Ethical perspective (breakout session C)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T16:58:53Z","last_updated_date":"2024-01-05T16:58:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pragmatic-trials-definition-and-usefulness-academic-perspective-eortc-complex-clinical-trials-enabling-innovative-designs-ethical-perspective-breakout-session-c_en.pdf"},
    {"id":"61649","name":"\tPresentation - Pragmatic trials, definition and usefulness - Academic perspective (EORTC) Complex clinical trials - Enabling innovative designs - HTA perspective (breakout session C)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T17:00:04Z","last_updated_date":"2024-01-05T17:00:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pragmatic-trials-definition-and-usefulness-academic-perspective-eortc-complex-clinical-trials-enabling-innovative-designs-hta-perspective-breakout-session-c_en.pdf"},
    {"id":"61650","name":"\tPresentation - Pragmatic trials, definition and usefulness - Academic perspective (EORTC) Complex clinical trials - Enabling innovative designs - Industry perspective (breakout session C)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T17:01:07Z","last_updated_date":"2024-01-05T17:01:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pragmatic-trials-definition-and-usefulness-academic-perspective-eortc-complex-clinical-trials-enabling-innovative-designs-industry-perspective-breakout-session-c_en.pdf"},
    {"id":"61651","name":"Presentation - Validation of digital endpoints - Setting the scene (breakout session D)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T17:04:46Z","last_updated_date":"2024-01-05T17:04:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-validation-digital-endpoints-setting-scene-breakout-session-d_en.pdf"},
    {"id":"61652","name":"Presentation - Patient centricity diversity and representativeness in clinical trials - Industry perspective (breakout session F)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T17:06:16Z","last_updated_date":"2024-01-05T17:06:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-centricity-diversity-and-representativeness-clinical-trials-industry-perspective-breakout-session-f_en.pdf"},
    {"id":"61653","name":"Presentation - Decentralised clinical trials, new directions - Academic perspective (breakout session G)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T17:08:42Z","last_updated_date":"2024-01-05T17:08:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-decentralised-clinical-trials-new-directions-academic-perspective-breakout-session-g_en.pdf"},
    {"id":"61654","name":"Presentation - Complex clinical trials, focus on platform trials - Industry perspective (breakout session H)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-05T17:10:14Z","last_updated_date":"2024-01-05T17:10:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-complex-clinical-trials-focus-platform-trials-industry-perspective-breakout-session-h_en.pdf"},
    {"id":"61669","name":"Presentation - Insight from EMA on recent scientific advice developments (I. Gravanis and K. Cunningham)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-09T13:17:41Z","last_updated_date":"2024-01-09T13:17:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-insight-ema-recent-scientific-advice-developments-i-gravanis-and-k-cunningham_en.pdf"},
    {"id":"61670","name":"Presentation - EMA multistakeholder workshop on Qualification of Novel Methodologies (QoNM) – Outcome report and Recommendations (I. Gravanis, and T.Vetter, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-09T13:20:09Z","last_updated_date":"2024-01-09T13:20:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-multistakeholder-workshop-qualification-novel-methodologies-qonm-outcome-report-and-recommendations-i-gravanis-and-tvetter-ema_en.pdf"},
    {"id":"61672","name":"Presentation - Recent and upcoming developments of the IRIS platform for R&D processes (T. Toufexi and A. Gross, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-09T13:22:55Z","last_updated_date":"2024-01-09T13:22:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recent-and-upcoming-developments-iris-platform-rd-processes-t-toufexi-and-gross-ema_en.pdf"},
    {"id":"61673","name":"Presentation - the Stepwise Paediatric Investigation Plan (sPIP) (C. Pallidis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-09T13:24:39Z","last_updated_date":"2024-01-09T13:24:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stepwise-paediatric-investigation-plan-spip-c-pallidis-ema_en.pdf"},
    {"id":"61674","name":"Presentation - Feedback from the latest discussions of the Focus group-agreed actions and next steps (S. Aarum, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-09T13:26:26Z","last_updated_date":"2024-01-09T13:26:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-latest-discussions-focus-group-agreed-actions-and-next-steps-s-aarum-ema_en.pdf"},
    {"id":"61684","name":"Presentation - Session 1 :  Report on implementation of the HMA-EMA Big Data Task Force priority recommendations - 4th year into our journey to data driven regulation (P. Arlett, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T12:39:01Z","last_updated_date":"2024-01-11T12:39:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-report-implementation-hma-ema-big-data-task-force-priority-recommendations-4th-year-our-journey-data-driven-regulation-p-arlett-ema_en.pdf"},
    {"id":"61685","name":"Presentation - Session 2 : Changing the discoverability and data quality of EU data ecosystem (S. Perez-Gutthann, ENCePP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T12:43:32Z","last_updated_date":"2024-01-11T12:43:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-changing-discoverability-and-data-quality-eu-data-ecosystem-s-perez-gutthann-encepp_en.pdf"},
    {"id":"61686","name":"Presentation - Session 2 : Enabling the use and establishing the value of Real-World Evidence – EHDS2 Pilot first insights (D. Umuhire, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T12:46:40Z","last_updated_date":"2024-01-11T12:46:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-enabling-use-and-establishing-value-real-world-evidence-ehds2-pilot-first-insights-d-umuhire-ema_en.pdf"},
    {"id":"61687","name":"Presentation - Session 2 : How are RWE transforming the EU regulatory network (K. Roes, CBG-MEB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T12:48:59Z","last_updated_date":"2024-01-11T12:48:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-how-are-rwe-transforming-eu-regulatory-network-k-roes-cbg-meb_en.pdf"},
    {"id":"61688","name":"Presentation - Session 2 : Using RWE. Pilots from DARWIN-EU (W. Goettsch, HTA ZIN)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T12:50:54Z","last_updated_date":"2024-01-11T12:50:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-using-rwe-pilots-darwin-eu-w-goettsch-hta-zin_en.pdf"},
    {"id":"61689","name":"Presentation - Session 2 : Progress on convergence with international partners on Real World Data (M. Kampman, Health Canada)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T12:58:01Z","last_updated_date":"2024-01-11T12:58:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-progress-convergence-international-partners-real-world-data-m-kampman-health-canada_en.pdf"},
    {"id":"61693","name":"Presentation - Session 3 : Realising the potential of PED in EU medicine regulation - BDSG workplan opportunities to enhance use of PED for regulatory decision making (G. Paliouras, NCSR “Demokritos”; DDF)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T13:36:27Z","last_updated_date":"2024-01-11T13:36:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-realising-potential-ped-eu-medicine-regulation-bdsg-workplan-opportunities-enhance-use-ped-regulatory-decision-making-g-paliouras-ncsr-demokritos-ddf_en.pdf"},
    {"id":"61694","name":"Presentation - Session 3 : Patient engagement in research area at Barcelona Children’s Hospital (B. Nafria, Saint  Joan de Deus Children’s Hospital)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T13:43:23Z","last_updated_date":"2024-01-11T13:43:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-patient-engagement-research-area-barcelona-childrens-hospital-b-nafria-saint-joan-de-deus-childrens-hospital_en.pdf"},
    {"id":"61695","name":"Presentation - Session 3 : The role of healthcare professionals (D. Makridaki, EAHP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T13:49:57Z","last_updated_date":"2024-01-11T13:49:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-role-healthcare-professionals-d-makridaki-eahp_en.pdf"},
    {"id":"61696","name":"Presentation - Session 3 : Real World Evidence: The PROFILES registry (L. van de Poll-Franse, NCI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T13:53:00Z","last_updated_date":"2024-01-11T13:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-real-world-evidence-profiles-registry-l-van-de-poll-franse-nci_en.pdf"},
    {"id":"61697","name":"Presentation - Session 3 : Patient Experience Data (PED) - Realising the potential of PED in EU medicine regulation (M. Cavaller Bellaubi, EURORDIS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T13:55:47Z","last_updated_date":"2024-01-11T13:55:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-patient-experience-data-ped-realising-potential-ped-eu-medicine-regulation-m-cavaller-bellaubi-eurordis_en.pdf"},
    {"id":"61698","name":"Presentation - Session 3 : State of play and ongoing regulatory initiatives (R. Gonzalez-Quevedo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T13:58:33Z","last_updated_date":"2024-01-11T13:58:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-state-play-and-ongoing-regulatory-initiatives-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"61699","name":"Presentation - Session 3 : What is needed by regulators (B. Sepodes, CHMP, INFARMED and S. Straus, PRAC, MEB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T14:01:48Z","last_updated_date":"2024-01-11T14:01:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-what-needed-regulators-b-sepodes-chmp-infarmed-and-s-straus-prac-meb_en.pdf"},
    {"id":"61702","name":"Presentation - Session 4 : Advances in digital technologies to enable collection of Patient Experience Data (J. Isla, DSEF)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T15:41:21Z","last_updated_date":"2024-01-11T15:41:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-advances-digital-technologies-enable-collection-patient-experience-data-j-isla-dsef_en.pdf"},
    {"id":"61703","name":"Presentation - Session 4 : Quantum computing: a game-changing approach for drug development (A. H. Werner, University of Copenhagen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T15:44:41Z","last_updated_date":"2024-01-11T15:44:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-quantum-computing-game-changing-approach-drug-development-h-werner-university-copenhagen_en.pdf"},
    {"id":"61704","name":"Presentation - Session 4 : Regulatory preparedness on Artificial Intelligence: AI workplan (G. Westman, MPA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T15:46:57Z","last_updated_date":"2024-01-11T15:46:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-regulatory-preparedness-artificial-intelligence-ai-workplan-g-westman-mpa_en.pdf"},
    {"id":"61705","name":"Presentation - Session 4 : Use of external data to accelerate evidence generation - digital twins and external controls (H. Fröhlich, Fraunhofer SCAI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T15:48:34Z","last_updated_date":"2024-01-11T15:48:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-use-external-data-accelerate-evidence-generation-digital-twins-and-external-controls-h-frohlich-fraunhofer-scai_en.pdf"},
    {"id":"61706","name":"Presentation - Session 5 : Data, not dogma: How data analysis can supercharge evidence-based decision making (A. Aerts, The Novartis Foundation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T15:52:06Z","last_updated_date":"2024-01-11T15:52:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-data-not-dogma-how-data-analysis-can-supercharge-evidence-based-decision-making-aerts-novartis-foundation_en.pdf"},
    {"id":"61707","name":"Presentation - Session 5 : How data can be used for a better-informed society (S. J. Piatek, LSHTM)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-11T15:55:41Z","last_updated_date":"2024-01-11T15:55:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-how-data-can-be-used-better-informed-society-s-j-piatek-lshtm_en.pdf"},
    {"id":"61794","name":"Presentation - Regulatory Procedure Management for PLM overview for Network stakeholders ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-17T13:25:09Z","last_updated_date":"2024-02-02T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-procedure-management-plm-overview-network-stakeholders_en.pdf"},
    {"id":"61821","name":"Presentation - Introduction of the EMA and EORTC multi-stakeholder workshop on soft tissue and bone sarcoma by the chair (P. Demolis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T13:54:54Z","last_updated_date":"2024-01-22T13:54:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-ema-and-eortc-multi-stakeholder-workshop-soft-tissue-and-bone-sarcoma-chair-p-demolis_en.pdf"},
    {"id":"61822","name":"\tPresentation - Introduction of the EMA and EORTC multi-stakeholder workshop on soft tissue and bone sarcoma by the chair (S. Stacchiotti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T13:58:35Z","last_updated_date":"2024-01-22T13:58:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-ema-and-eortc-multi-stakeholder-workshop-soft-tissue-and-bone-sarcoma-chair-s-stacchiotti_en.pdf"},
    {"id":"61824","name":"Presentation - EMA regulatory framework for rare disease (R. Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:00:34Z","last_updated_date":"2024-01-22T14:00:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-framework-rare-disease-r-herold_en.pdf"},
    {"id":"61825","name":"Presentation - Ultra-rare Sarcoma major challenges and opportunities (H. Leonard and J. Summer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:09:20Z","last_updated_date":"2024-01-22T14:09:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ultra-rare-sarcoma-major-challenges-and-opportunities-h-leonard-and-j-summer_en.pdf"},
    {"id":"61826","name":"Presentation - Generating the right data (K. Roes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:21:03Z","last_updated_date":"2024-01-22T14:21:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-generating-right-data-k-roes_en.pdf"},
    {"id":"61827","name":"Presentation - Lessons learned from the compassionate use program (T. De Rojas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:23:54Z","last_updated_date":"2024-01-22T14:23:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lessons-learned-compassionate-use-program-t-de-rojas_en.pdf"},
    {"id":"61828","name":"Presentation - How to collect retrospective data (A. Frezza, J. Bovee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:26:41Z","last_updated_date":"2024-01-22T14:26:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-collect-retrospective-data-frezza-j-bovee_en.pdf"},
    {"id":"61829","name":"Presentation - Repurposing of old drugs in new ultra-rare indication example of Sirolimus in EHE (P. Pantziarka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:31:32Z","last_updated_date":"2024-01-22T14:31:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-repurposing-old-drugs-new-ultra-rare-indication-example-sirolimus-ehe-p-pantziarka_en.pdf"},
    {"id":"61830","name":"Presentation - Ultra-rare tumours major challenges and opportunities: the EORTC perspective (D. Lacombe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:18:18Z","last_updated_date":"2024-01-22T14:18:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ultra-rare-tumours-major-challenges-and-opportunities-eortc-perspective-d-lacombe_en.pdf"},
    {"id":"61831","name":"Presentation - Prospective studies - nab-sirolimus (A. Wagner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:35:15Z","last_updated_date":"2024-01-22T14:35:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prospective-studies-nab-sirolimus-wagner_en.pdf"},
    {"id":"61832","name":"Presentation - Prospective registries (A. Trama)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:36:58Z","last_updated_date":"2024-01-22T14:36:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prospective-registries-trama_en.pdf"},
    {"id":"61833","name":"Presentation - A prospective master protocol and platform to conduct international SATs (L. D'Ambrosio, G. Bouche, R. Miceli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:39:16Z","last_updated_date":"2024-01-22T14:39:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-prospective-master-protocol-and-platform-conduct-international-sats-l-dambrosio-g-bouche-r-miceli_en.pdf"},
    {"id":"61834","name":"Presentation - NCI childhood cancer data initiatives (B. Widemann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:47:02Z","last_updated_date":"2024-01-22T14:47:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nci-childhood-cancer-data-initiatives-b-widemann_en.pdf"},
    {"id":"61835","name":"Presentation - Perspectives on rare cancer development (C. Tydings)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-22T14:48:36Z","last_updated_date":"2024-01-22T14:48:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-perspectives-rare-cancer-development-c-tydings_en.pdf"},
    {"id":"61938","name":"Presentation - Nitrosamines survey results implementation of nitrosamines guidance throughout EU MSs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-29T14:43:18Z","last_updated_date":"2024-01-29T14:43:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nitrosamines-survey-results-implementation-nitrosamines-guidance-throughout-eu-mss_en.pdf"},
    {"id":"61939","name":"Presentation - Update on new developments for nitrosamines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-01-29T14:46:21Z","last_updated_date":"2024-01-29T14:46:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-new-developments-nitrosamines_en.pdf"},
    {"id":"61983","name":"Presentation - ACT EU Clinical Trials Analytics Workshop - January 2024","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-02T10:44:08Z","last_updated_date":"2024-02-02T10:44:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-clinical-trials-analytics-workshop-january-2024_en.pdf"},
    {"id":"62182","name":"Presentation - Delivering a research agenda and identifying relevant data sources (I. den Rooijen, EMA; F. Grell Nørgaard, DKMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T13:44:52Z","last_updated_date":"2024-02-15T13:44:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-delivering-research-agenda-identifying-relevant-data-sources-i-den-rooijen-ema-f-grell-norgaard-dkma_en.pdf"},
    {"id":"62183","name":"Presentation - Clinical trial data on CTIS: Potential and challenges (T. Bruckner, TranspariMED)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T13:51:03Z","last_updated_date":"2024-02-15T13:51:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trial-data-ctis-potential-challenges-t-bruckner-transparimed_en.pdf"},
    {"id":"62185","name":"Presentation - Representation in Clinical Trials: data use-case from REPACT project at DKMA (J. Wested, DKMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T13:54:28Z","last_updated_date":"2024-02-15T13:54:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-representation-clinical-trials-data-use-case-repact-project-dkma-j-wested-dkma_en.pdf"},
    {"id":"62187","name":"Presentation - Use case: Finding clinical trials on DMD/BMD (G. Paliouras, Duchenne Data Foundation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T13:58:04Z","last_updated_date":"2024-02-15T13:58:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-case-finding-clinical-trials-dmd-bmd-g-paliouras-duchenne-data-foundation_en.pdf"},
    {"id":"62188","name":"Presentation - ACT EU Clinical Trials Analytics Workshop (M. O'Kane, Novartis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T14:02:36Z","last_updated_date":"2024-02-15T14:02:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-clinical-trials-analytics-workshop-m-okane-novartis_en.pdf"},
    {"id":"62189","name":"Presentation - Clinical Trials Data Present and Future Use case from ethics perspective (M. Zwaan, NVMETC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T14:03:55Z","last_updated_date":"2024-02-15T14:03:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-data-present-future-use-case-ethics-perspective-m-zwaan-nvmetc_en.pdf"},
    {"id":"62190","name":"Presentation - Clinical Data Neutrality: its Role in Transforming Data into Solutions (S. Chin Ma, Critical Path Institute)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T14:05:48Z","last_updated_date":"2024-02-15T14:05:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-data-neutrality-its-role-transforming-data-solutions-s-chin-ma-critical-path-institute_en.pdf"},
    {"id":"62191","name":"Presentation - Clinical electronic Structured Harmonised Protocol (CeSHarP) (M. Sultani, N. Manent, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T14:07:16Z","last_updated_date":"2024-02-15T14:07:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-electronic-structured-harmonised-protocol-cesharp-m-sultani-n-manent-ema_en.pdf"}    {"id":"62192","name":"Presentation - European Clinical Trial Register: challenges from an academic perspective (B. Speich, University Hospital Basel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T14:09:11Z","last_updated_date":"2024-02-15T14:09:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-clinical-trial-register-challenges-academic-perspective-b-speich-university-hospital-basel_en.pdf"},
    {"id":"62193","name":"Presentation - Clinical trial data and B/R assessment of medicines (H. Hillege, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-15T14:11:25Z","last_updated_date":"2024-02-15T14:11:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trial-data-b-r-assessment-medicines-h-hillege-ema_en.pdf"},
    {"id":"62210","name":"Presentation - Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-19T15:05:11Z","last_updated_date":"2024-02-19T15:05:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-webinar-regulatory-procedure-management-product-lifecycle-management-iris_en.pdf"},
    {"id":"62211","name":"Presentation - Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-19T15:06:42Z","last_updated_date":"2024-02-19T15:06:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-webinar-regulatory-procedure-management-product-lifecycle-management-iris_en.pdf-0"},
    {"id":"62290","name":"Presentation - Veterinary medicines information website (Catarina Ferreira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T16:35:00Z","last_updated_date":"2024-02-23T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-medicines-information-website-catarina-ferreira_en.pdf"},
    {"id":"62317","name":"Presentation - Main lessons learnt so far on the qualification of registries (J. Hillert, L. Nährlich)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:37:14Z","last_updated_date":"2024-02-28T09:37:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-main-lessons-learnt-so-far-qualification-registries-j-hillert-l-nahrlich_en.pdf"},
    {"id":"62318","name":"Presentation - Qualification of disease registries & PRAC (S. Straus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:43:12Z","last_updated_date":"2024-02-28T09:43:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qualification-disease-registries-prac-s-straus_en.pdf"},
    {"id":"62319","name":"Presentation - Outcomes of EFPIA survey on registries and qualification performed in February 2024 (G. Crane)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:44:09Z","last_updated_date":"2024-02-28T09:44:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcomes-efpia-survey-registries-qualification-performed-february-2024-g-crane_en.pdf"},
    {"id":"62320","name":"Presentation - An agency of the European Union Scene setting on the EMA Qualification of novel methodologies (QoNM) for medicine development (A. Nolte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:47:54Z","last_updated_date":"2024-02-28T09:47:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agency-european-union-scene-setting-ema-qualification-novel-methodologies-qonm-medicine-development-nolte_en.pdf"},
    {"id":"62321","name":"Presentation - Use case highlighting opportunities and challenges of registries for regulatory decision-making (S. Bennett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:48:48Z","last_updated_date":"2024-02-28T09:48:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-case-highlighting-opportunities-challenges-registries-regulatory-decision-making-s-bennett_en.pdf"},
    {"id":"62322","name":"Presentation - Investing to shape our future (C. Kyriakopoulou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:50:48Z","last_updated_date":"2024-02-28T09:50:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-investing-shape-our-future-c-kyriakopoulou_en.pdf"},
    {"id":"62323","name":"Presentation - Opportunities for integration of the European Platform on Rare Disease Registration (EU RD Platform) with HMA/EMA catalogues (S. Martin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:52:33Z","last_updated_date":"2024-02-28T09:52:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-integration-european-platform-rare-disease-registration-eu-rd-platform-hma-ema-catalogues-s-martin_en.pdf"},
    {"id":"62324","name":"Presentation - EMA-funded registry-based study on spinal muscular atrophy disease (SMA) (K. Breen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:53:51Z","last_updated_date":"2024-02-28T09:53:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-funded-registry-based-study-spinal-muscular-atrophy-disease-sma-k-breen_en.pdf"},
    {"id":"62325","name":"Presentation - HMA-EMA Catalogues of real-world data sources and studies (A. Cochino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:56:25Z","last_updated_date":"2024-02-28T09:56:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hma-ema-catalogues-real-world-data-sources-studies-cochino_en.pdf"},
    {"id":"62326","name":"Presentation - Onboarding to EMA catalogue for RWD sources and studies: A user experience (F. Schaefer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:57:35Z","last_updated_date":"2024-02-28T09:57:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-onboarding-ema-catalogue-rwd-sources-studies-user-experience-f-schaefer_en.pdf"},
    {"id":"62327","name":"Presentation - An agency of the European Union Fit for purpose and Data Quality Framework (K. Roes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T09:59:53Z","last_updated_date":"2024-02-28T09:59:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agency-european-union-fit-purpose-data-quality-framework-k-roes_en.pdf"},
    {"id":"62328","name":"Presentation - Interoperability between registries and other data sources: the HARMONY Big Data Platform (J. María Hernández Rivas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T10:00:55Z","last_updated_date":"2024-02-28T10:00:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interoperability-between-registries-other-data-sources-harmony-big-data-platform-j-maria-hernandez-rivas_en.pdf"},
    {"id":"62329","name":"Presentation - What are the regulatory needs in terms of registry data? (B. Sepodes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T10:02:07Z","last_updated_date":"2024-02-28T10:02:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-are-regulatory-needs-terms-registry-data-b-sepodes_en.pdf"},
    {"id":"62347","name":"Presentation - proposals to optimise treatment within current procedures (Caroline Voltz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-28T15:27:45Z","last_updated_date":"2024-02-28T15:27:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposals-optimise-treatment-within-current-procedures-caroline-voltz_en.pdf"},
    {"id":"62364","name":"Presentation - Useful links and info when creating/transitioning trials in CTIS (Ornela Ademi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T15:56:08Z","last_updated_date":"2024-02-29T15:56:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-useful-links-info-when-creating-transitioning-trials-ctis-ornela-ademi_en.pdf"},
    {"id":"62370","name":"Presentation - ACT EU Training on transition trials for non-commercial sponsors (Lene Grejs Petersen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:01:48Z","last_updated_date":"2024-02-29T16:01:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-training-transition-trials-non-commercial-sponsors-lene-grejs-petersen_en.pdf"},
    {"id":"62371","name":"Presentation - Transition of clinical trials (Elena Garcia Mendez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:04:11Z","last_updated_date":"2024-02-29T16:04:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transition-clinical-trials-elena-garcia-mendez_en.pdf"},
    {"id":"62373","name":"Presentation - Organisation Management Services (OMS) (Débora Martins Braga)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:11:40Z","last_updated_date":"2024-02-29T16:11:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organisation-management-services-oms-debora-martins-braga_en.pdf"},
    {"id":"62374","name":"Presentation - Introduction to the eXtendedEudraVigilance Medicinal Product Dictionary (XEVMPD) (Veronika Baker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:14:55Z","last_updated_date":"2024-02-29T16:14:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-extendedeudravigilance-medicinal-product-dictionary-xevmpd-veronika-baker_en.pdf"},
    {"id":"62375","name":"Presentation - Product Management Services (PMS) Deep-Dive Webinar (22 February 2024)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:16:14Z","last_updated_date":"2024-02-29T16:16:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-services-pms-deep-dive-webinar-22-february-2024_en.pdf"},
    {"id":"62376","name":"Presentation - Technical Webinar: Regulatory Procedure Management for PLM in IRIS for Network Users","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:24:35Z","last_updated_date":"2024-02-29T16:24:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-technical-webinar-regulatory-procedure-management-plm-iris-network-users_en.pdf"},
    {"id":"62424","name":"Presentation - Orphan medicinal product designation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-04T14:00:58Z","last_updated_date":"2024-03-04T14:00:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orphan-medicinal-product-designation_en.pdf"},
    {"id":"62425","name":"Presentation - Rare disease development and patient engagement","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-04T14:04:30Z","last_updated_date":"2024-03-04T14:04:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rare-disease-development-patient-engagement_en.pdf"},
    {"id":"62473","name":"Presentation - Multi-stakeholder webinar on the HMA-EMA Catalogues of real-world data sources and studies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T15:08:40Z","last_updated_date":"2024-03-07T15:08:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multi-stakeholder-webinar-hma-ema-catalogues-real-world-data-sources-studies_en.pdf"},
    {"id":"62503","name":"Presentation - PCWP-HCPWP workplan 2022-2025 Mid-point implementation report - Ivana Silva","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:16:56Z","last_updated_date":"2024-03-08T16:16:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pcwp-hcpwp-workplan-2022-2025-mid-point-implementation-report-ivana-silva_en.pdf"},
    {"id":"62504","name":"Presentation - Overview of 2022-2023 Stakeholder Engagement biennial report - Maria Filancia","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:24:38Z","last_updated_date":"2024-03-08T16:24:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-2022-2023-stakeholder-engagement-biennial-report-maria-filancia_en.pdf"},
    {"id":"62505","name":"Presentation - Revamp of the Human Medicines Highlights newsletter - Kaisa Immonen","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:26:04Z","last_updated_date":"2024-03-08T16:26:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revamp-human-medicines-highlights-newsletter-kaisa-immonen_en.pdf"},
    {"id":"62506","name":"Presentation - Third party interventions for WP - Fabrizio Boccacci","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:27:16Z","last_updated_date":"2024-03-08T16:27:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-third-party-interventions-wp-fabrizio-boccacci_en.pdf"},
    {"id":"62507","name":"Presentation - Cancer Medicines as pathfinder - Francesco Pignatti","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:28:17Z","last_updated_date":"2024-03-08T16:28:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-pathfinder-francesco-pignatti_en.pdf"},
    {"id":"62508","name":"Presentation - Conversations on cancer - Caroline Voltz","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:29:22Z","last_updated_date":"2024-03-08T16:29:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-conversations-cancer-caroline-voltz_en.pdf"},
    {"id":"62509","name":"Presentation - Patient experience data reflection paper - Rosa Gonzalez-Quevedo","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:30:19Z","last_updated_date":"2024-03-08T16:30:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-experience-data-reflection-paper-rosa-gonzalez-quevedo_en.pdf"},
    {"id":"62510","name":"Presentation - Patient experience data and therapeutic areas - Survey - Rosa Gonzalez-Quevedo","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:31:16Z","last_updated_date":"2024-03-08T16:31:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-experience-data-therapeutic-areas-survey-rosa-gonzalez-quevedo_en.pdf"},
    {"id":"62511","name":"Presentation - Update on EU Network Training Centre - Esther Martinez","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:32:10Z","last_updated_date":"2024-03-08T16:32:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-eu-network-training-centre-esther-martinez_en.pdf"},
    {"id":"62512","name":"Presentation - Preparation of amendments to EC Implementing Regulation 5202012 on the performance of pharmacovigilance activities - Izabela Taborska","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:33:01Z","last_updated_date":"2024-03-08T16:33:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparation-amendments-ec-implementing-regulation-5202012-performance-pharmacovigilance-activities-izabela-taborska_en.pdf"},
    {"id":"62513","name":"Presentation - Risk minimisation for patient safety – update on policies and practices - Priya Bahri","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:33:50Z","last_updated_date":"2024-03-08T16:33:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-minimisation-patient-safety-update-policies-practices-priya-bahri_en.pdf"},
    {"id":"62514","name":"Presentation - European Network of Paediatric Research at EMA - Gunter Egger","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:34:53Z","last_updated_date":"2024-03-08T16:34:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-network-paediatric-research-ema-gunter-egger_en.pdf"},
    {"id":"62515","name":"Presentation - PL improvement - Monica Buch","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:35:56Z","last_updated_date":"2024-03-08T16:35:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pl-improvement-monica-buch_en.pdf"},
    {"id":"62516","name":"Presentation - Feedback from stakeholders of the subgroup - Courtney Davis","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:36:53Z","last_updated_date":"2024-03-08T16:36:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-stakeholders-subgroup-courtney-davis_en.pdf"},
    {"id":"62517","name":"Presentation - Debriefing EMA workshop on Long COVID - Stephanie Buchhol","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:37:50Z","last_updated_date":"2024-03-08T16:37:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-debriefing-ema-workshop-long-covid-stephanie-buchhol_en.pdf"},
    {"id":"62518","name":"Presentation - Input Long COVID Europe on Long Covid Trials - Chantal Britt","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:38:45Z","last_updated_date":"2024-03-08T16:38:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-input-long-covid-europe-long-covid-trials-chantal-britt_en.pdf"},
    {"id":"62519","name":"Presentation - ACT EU update - Ana Zanoletty","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:40:24Z","last_updated_date":"2024-03-08T16:40:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-update-ana-zanoletty_en.pdf"},
    {"id":"62520","name":"Presentation - Data discoverability HMA-EMA Catalogues of Real-World Data sources and studies - Ana Cochino","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:41:05Z","last_updated_date":"2024-03-08T16:41:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-discoverability-hma-ema-catalogues-real-world-data-sources-studies-ana-cochino_en.pdf"},
    {"id":"62521","name":"Presentation - EU list of critical medicines_launch of Phase 2 - Joao Francisco Ferreira","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:42:00Z","last_updated_date":"2024-03-08T16:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-list-critical-medicines_launch-phase-2-joao-francisco-ferreira_en.pdf"},
    {"id":"62522","name":"Glucagon-like Peptide-1 (GLP1) Receptor Agonists - Klaus Kruttwig, Romana Micovcakova","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T16:42:50Z","last_updated_date":"2024-03-08T16:42:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/glucagon-peptide-1-glp1-receptor-agonists-klaus-kruttwig-romana-micovcakova_en.pdf"},
    {"id":"62533","name":"Presentation - Patients’ Involvement, what Does that Mean? Variability between diseases and patients (P. Demolis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T14:41:08Z","last_updated_date":"2024-03-11T14:41:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-involvement-what-does-mean-variability-between-diseases-patients-p-demolis_en.pdf"},
    {"id":"62534","name":"Presentation - Evaluating cancer treatments based on overall survival and quality of life (W. van der Graaf)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T14:48:04Z","last_updated_date":"2024-03-11T14:48:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evaluating-cancer-treatments-based-overall-survival-quality-life-w-van-der-graaf_en.pdf"},
    {"id":"62535","name":"Presentation - The tale of two trials: Improving the use of PROs and HRQoLin cancer clinical research (J. Reijneveld)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T14:50:02Z","last_updated_date":"2024-03-11T14:50:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-tale-two-trials-improving-use-pros-hrqolin-cancer-clinical-research-j-reijneveld_en.pdf"},
    {"id":"62536","name":"Presentation - EMA current and future activities on Patient Experience Data (PED), including PROs and HRQoL in medicines’ development and evaluation (J. Garcia Burgos, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T14:51:22Z","last_updated_date":"2024-03-11T14:51:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-current-future-activities-patient-experience-data-ped-including-pros-hrqol-medicines-development-evaluation-j-garcia-burgos-ema_en.pdf"},
    {"id":"62537","name":"Presentation - Learnings from a review of patient reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020 (C. Torre)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T14:53:07Z","last_updated_date":"2024-03-11T14:53:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-learnings-review-patient-reported-outcomes-used-regulatory-approval-oncology-medicinal-products-european-union-between-2017-2020-c-torre_en.pdf"},
    {"id":"62538","name":"Presentation - Patient-Reported Outcomes in Oncology Trials (V. Bhatnagar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T14:56:05Z","last_updated_date":"2024-03-11T14:56:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-reported-outcomes-oncology-trials-v-bhatnagar_en.pdf"},
    {"id":"62539","name":"Presentation - Application and importance of HRQoL/PRO assessment from the HTA perspective (B. Wieseler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T14:57:02Z","last_updated_date":"2024-03-11T14:57:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-application-importance-hrqol-pro-assessment-hta-perspective-b-wieseler_en.pdf"},
    {"id":"62540","name":"Presentation - Enhancing Benefit Risk Assessment: Integrating Survival Data and Longitudinal Patient reported Outcome Data (D. Postmus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T14:58:18Z","last_updated_date":"2024-03-11T14:58:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enhancing-benefit-risk-assessment-integrating-survival-data-longitudinal-patient-reported-outcome-data-d-postmus_en.pdf"},
    {"id":"62541","name":"Presentation - EORTC’s strategy on the development and implementation of PRO and HRQoLmeasures for cancer clinical research (M. Groenvold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T14:59:05Z","last_updated_date":"2024-03-11T14:59:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eortcs-strategy-development-implementation-pro-hrqolmeasures-cancer-clinical-research-m-groenvold_en.pdf"},
    {"id":"62542","name":"Presentation - Measuring HRQOL core outcomesand disease-specific symptoms (Classified as public by the European Medicines Agency (J. M. Giesinger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T15:00:01Z","last_updated_date":"2024-03-11T15:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-measuring-hrqol-core-outcomesand-disease-specific-symptoms-classified-public-european-medicines-agency-j-m-giesinger_en.pdf"},
    {"id":"62543","name":"Presentation - Measuring treatment-specific side effects from the patient perspective: Trial-specific item lists from PRO item libraries (A. Gilbert, C. Piccinin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T15:01:01Z","last_updated_date":"2024-03-11T15:01:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-measuring-treatment-specific-side-effects-patient-perspective-trial-specific-item-lists-pro-item-libraries-gilbert-c-piccinin_en.pdf"},
    {"id":"62544","name":"Presentation - Use of static and flexible PRO measures in global cancer trials: Challenges and opportunities (J. Shaw)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T15:02:13Z","last_updated_date":"2024-03-11T15:02:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-static-flexible-pro-measures-global-cancer-trials-challenges-opportunities-j-shaw_en.pdf"},
    {"id":"62570","name":"Presentation - Opening remarks (Anja van Haren)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:11:58Z","last_updated_date":"2024-03-12T17:11:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-remarks-anja-van-haren_en.pdf"},
    {"id":"62571","name":"Presentation - Opening remarks (James Mount)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:13:18Z","last_updated_date":"2024-03-12T17:13:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-remarks-james-mount_en.pdf"},
    {"id":"62572","name":"Presentation - Opening remarks (Elke Stahl)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:14:16Z","last_updated_date":"2024-03-12T17:14:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-remarks-elke-stahl_en.pdf"},
    {"id":"62573","name":"Presentation - Data Quality Framework overview (Ana Cochino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:15:07Z","last_updated_date":"2024-03-12T17:15:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-quality-framework-overview-ana-cochino_en.pdf"},
    {"id":"62574","name":"Presentation - Guidance, standards, EMA Data Quality activities and uses of ADR data human & veterinary (Tom Paternoster)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:16:11Z","last_updated_date":"2024-03-12T17:16:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-guidance-standards-ema-data-quality-activities-uses-adr-data-human-veterinary-tom-paternoster_en.pdf"},
    {"id":"62575","name":"Presentation - Human NCA Data Quality activities and uses of ADR data (Elena Rodionova)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:17:20Z","last_updated_date":"2024-03-12T17:17:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-human-nca-data-quality-activities-uses-adr-data-elena-rodionova_en.pdf"},
    {"id":"62576","name":"Presentation – Veterinary NCA Data Quality activities and uses of ADR data (Kathrin Schirmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:18:09Z","last_updated_date":"2024-03-12T17:18:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-nca-data-quality-activities-uses-adr-data-kathrin-schirmann_en.pdf"},
    {"id":"62577","name":"Presentation - Stakeholder ADR data quality activities in Europe -Human MAH (Jim Nickas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:18:48Z","last_updated_date":"2024-03-12T17:18:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stakeholder-adr-data-quality-activities-europe-human-mah-jim-nickas_en.pdf"},
    {"id":"62578","name":"Presentation - Stakeholder ADR data quality activities in Europe - CRO (Zurab Koberidze)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:20:27Z","last_updated_date":"2024-03-12T17:20:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stakeholder-adr-data-quality-activities-europe-cro-zurab-koberidze_en.pdf"},
    {"id":"62579","name":"Presentation - Stakeholder ADR data quality activities in Europe - Veterinary MAH (Magali Quetin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:21:31Z","last_updated_date":"2024-03-12T17:21:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stakeholder-adr-data-quality-activities-europe-veterinary-mah-magali-quetin_en.pdf"},
    {"id":"62580","name":"Presentation - Stakeholder ADR data quality activities in Europe - Non-commercial Sponsor (Tuula Ikonen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:22:39Z","last_updated_date":"2024-03-12T17:22:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stakeholder-adr-data-quality-activities-europe-non-commercial-sponsor-tuula-ikonen_en.pdf"},
    {"id":"62581","name":"Presentation - Panel discussion on high–quality ADR data (Tom Paternoster)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T17:24:12Z","last_updated_date":"2024-03-12T17:24:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-panel-discussion-high-quality-adr-data-tom-paternoster_en.pdf"},
    {"id":"62731","name":"Presentation - Implementation of regulation (EU) 2019/6 (Alfonso Las Heras)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T09:29:38Z","last_updated_date":"2024-03-26T09:29:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-regulation-eu-2019-6-alfonso-las-heras_en.pdf"},
    {"id":"62732","name":"Presentation - Implementation of pharmacovigilance requirements (James Mount)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T09:45:45Z","last_updated_date":"2024-03-26T09:45:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-pharmacovigilance-requirements-james-mount_en.pdf"},
    {"id":"62734","name":"Presentation - Industry perspective on pharmacovigilance (Sonja Schwab, Andreas Richter) ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T09:52:34Z","last_updated_date":"2024-03-26T09:52:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-pharmacovigilance-sonja-schwab-andreas-richter_en.pdf"},
    {"id":"62735","name":"Presentation - CVMP workplan for 2024 and beyond (Johan Schefferlie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T10:05:32Z","last_updated_date":"2024-03-26T10:05:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-workplan-2024-beyond-johan-schefferlie_en.pdf"},
    {"id":"62739","name":"Presentation - Veterinary international conference on harmonization (Nick Jarrett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T11:45:32Z","last_updated_date":"2024-03-26T11:45:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-international-conference-harmonization-nick-jarrett_en.pdf"},
    {"id":"62740","name":"Presentation - Regulatory and procedural developments (Emily Drury)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T11:47:29Z","last_updated_date":"2024-03-26T11:47:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-procedural-developments-emily-drury_en.pdf"},
    {"id":"62741","name":"Presentation - Update from the CVMP Efficacy Working Party (EWP-V) (Cristina Muñoz Madero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T11:48:40Z","last_updated_date":"2024-03-26T11:48:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-cvmp-efficacy-working-party-ewp-v-cristina-munoz-madero_en.pdf"},
    {"id":"62742","name":"Presentation - Overview on available guidance for antiparasitic veterinary medicines (Valentin Nicorescu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T11:51:16Z","last_updated_date":"2024-03-26T11:51:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-available-guidance-antiparasitic-veterinary-medicines-valentin-nicorescu_en.pdf"},
    {"id":"62743","name":"Presentation - Latest scientific guidance (Klaus Hellmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T14:48:00Z","last_updated_date":"2024-03-26T14:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-latest-scientific-guidance-klaus-hellmann_en.pdf"},
    {"id":"62744","name":"Presentation - Veterinary novel therapies and technologies (Jaqueline Poot)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T14:50:15Z","last_updated_date":"2024-03-26T14:50:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-novel-therapies-technologies-jaqueline-poot_en.pdf"},
    {"id":"62745","name":"Presentation - Focus on veterinary vaccine availability and emerging diseases (Javier Pozo Gonzalez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T14:52:55Z","last_updated_date":"2024-03-26T14:52:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-veterinary-vaccine-availability-emerging-diseases-javier-pozo-gonzalez_en.pdf"},
    {"id":"62746","name":"Presentation - Focus on innovation: industry perspective (Emmanuelle Royer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-03-26T14:55:22Z","last_updated_date":"2024-03-26T14:55:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-innovation-industry-perspective-emmanuelle-royer_en.pdf"},
    {"id":"62876","name":"Presentation - Pharmacovigilance regulatory update ( J. Olaerts)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-09T15:16:44Z","last_updated_date":"2024-04-09T15:16:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-regulatory-update-j-olaerts_en.pdf"},
    {"id":"62877","name":"Presentation - Update from EMA on highly pathogenic avian influenza (HPAI) (E. Bastino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-09T15:19:35Z","last_updated_date":"2024-04-09T15:19:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ema-highly-pathogenic-avian-influenza-hpai-e-bastino_en.pdf"},
    {"id":"62890","name":"Presentation - Cancer Medicines Forum - rationale and achievements (D. Lacombe, EORTC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T08:49:08Z","last_updated_date":"2024-04-11T08:49:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-rationale-achievements-d-lacombe-eortc_en.pdf"},
    {"id":"62891","name":"Presentation - Cancer Medicines Forum - de-escalating immunotherapy: the example of MOIO phase III French clinical trial (I. Korakis, IUCT-Oncoploe Toulouse & G. Gravis, Institut Paoli-Calmettes Marseille)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T08:52:33Z","last_updated_date":"2024-04-11T08:52:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-de-escalating-immunotherapy-example-moio-phase-iii-french-clinical-trial-i-korakis-iuct-oncoploe-toulouse-g-gravis-institut-paoli-calmettes-marseille_en.pdf"},
    {"id":"62892","name":"Presentation - Cancer Medicines Forum - EORTC, Unicancer, GETUG, CTI consortium trial (B. Tombal, EORTC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T08:56:24Z","last_updated_date":"2024-04-11T08:56:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-eortc-unicancer-getug-cti-consortium-trial-b-tombal-eortc_en.pdf"},
    {"id":"62893","name":"Presentation - Cancer Medicines Forum - examples of drug development and optimisation in haematology (M. Kaiser, EHA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T09:04:29Z","last_updated_date":"2024-04-11T09:04:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-examples-drug-development-optimisation-haematology-m-kaiser-eha_en.pdf"},
    {"id":"62894","name":"Presentation - Cancer Medicines Forum - policy context (R. Sullivan, Institute of Cancer Policy, King's College London) ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T09:07:09Z","last_updated_date":"2024-04-11T09:07:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-policy-context-r-sullivan-institute-cancer-policy-kings-college-london_en.pdf"},
    {"id":"62895","name":"Presentation - Cancer Medicines Forum - treatment optimisation framework (C. Voltz-Girolt, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T09:12:06Z","last_updated_date":"2024-04-11T09:12:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-treatment-optimisation-framework-c-voltz-girolt-ema_en.pdf"},
    {"id":"62896","name":"Presentation - Cancer Medicines Forum - cancer drug development - as a public health matter? (C. Booth, Queen's University, Kingston, Canada)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T09:15:53Z","last_updated_date":"2024-04-11T09:15:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-cancer-drug-development-public-health-matter-c-booth-queens-university-kingston-canada_en.pdf"},
    {"id":"62897","name":"Presentation - Cancer Medicines Forum - the global challenges of post-market optimization research (D. Goldstein, Tel Aviv University)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T09:23:24Z","last_updated_date":"2024-04-11T09:23:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-global-challenges-post-market-optimization-research-d-goldstein-tel-aviv-university_en.pdf"},
    {"id":"62898","name":"Presentation - Cancer Medicines Forum - innovative evidence generation: OCE project Pragmatica (D. R. Rivera, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T09:26:25Z","last_updated_date":"2024-04-11T09:26:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-innovative-evidence-generation-oce-project-pragmatica-d-r-rivera-fda_en.pdf"},
    {"id":"62899","name":"Presentation - Cancer Medicines Forum - the added value of treatment optimization: how does it apply to other fields of medicine? (G. Brusselle, Ghent University Hospital, Belgium)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T09:29:29Z","last_updated_date":"2024-04-11T09:29:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-added-value-treatment-optimization-how-does-it-apply-other-fields-medicine-g-brusselle-ghent-university-hospital-belgium_en.pdf"},
    {"id":"62902","name":"Presentation - Union list of critical medicines update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T12:08:51Z","last_updated_date":"2024-04-11T12:08:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-list-critical-medicines-update_en.pdf"},
    {"id":"62903","name":"Presentation - Update on ESMP development progress status ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T12:10:11Z","last_updated_date":"2024-04-11T12:10:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-esmp-development-progress-status_en.pdf"},
    {"id":"62904","name":"Presentation - Expert Panels on Medical Devices and in vitro Diagnostics - State of Play ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T12:11:25Z","last_updated_date":"2024-04-11T12:11:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-expert-panels-medical-devices-vitro-diagnostics-state-play_en.pdf"}    {"id":"62905","name":"Presentation - Update on the implementation of New Fee Regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T12:12:08Z","last_updated_date":"2024-04-11T12:12:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-implementation-new-fee-regulation_en.pdf"},
    {"id":"62906","name":"Presentation - COVID19 lessons learnt update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T12:12:51Z","last_updated_date":"2024-04-11T12:12:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-covid19-lessons-learnt-update_en.pdf"},
    {"id":"62907","name":"Presentation - European Medicines Agencies Network Strategy update to 2028","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T12:13:39Z","last_updated_date":"2024-04-11T12:13:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agencies-network-strategy-update-2028_en.pdf"},
    {"id":"62908","name":"Presentation - Supporting the African Medicines Agency","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T12:14:15Z","last_updated_date":"2024-04-11T12:14:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supporting-african-medicines-agency_en.pdf"},
    {"id":"62909","name":"Presentation - Update on Opening Procedures at EMA to Non-EU authorities (OPEN) framework","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T12:14:52Z","last_updated_date":"2024-04-11T12:14:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-opening-procedures-ema-non-eu-authorities-open-framework_en.pdf"},
    {"id":"62911","name":"Presentation - EU enlargement –EMA support to candidate and potential candidate countries","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T12:16:03Z","last_updated_date":"2024-04-11T12:16:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-enlargement-ema-support-candidate-potential-candidate-countries_en.pdf"},
    {"id":"62914","name":"Presentation - update on latest developments on substances for use in aquaculture under the cascade (S. Girault, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T13:59:06Z","last_updated_date":"2024-04-11T13:59:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-latest-developments-substances-use-aquaculture-under-cascade-s-girault-ema_en.pdf"},
    {"id":"62915","name":"Presentation - personal perspectives from aquaculture specialists on pharmacovigilance challenges","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T14:02:30Z","last_updated_date":"2024-04-11T14:02:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-personal-perspectives-aquaculture-specialists-pharmacovigilance-challenges_en.pdf"},
    {"id":"62916","name":"Presentation - regulatory environment: pharmacovigilance update (J. Olaerts, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-11T14:04:58Z","last_updated_date":"2024-04-11T14:04:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-environment-pharmacovigilance-update-j-olaerts-ema_en.pdf"},
    {"id":"62968","name":"Presentation - Session 1 CTIS webinar Transition Trials (Linda Abdellal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T11:59:24Z","last_updated_date":"2024-04-16T11:59:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-ctis-webinar-transition-trials-linda-abdellal_en.pdf"},
    {"id":"62970","name":"Presentation - Session 1 CTIS Webinar last year of transition (Monique Al)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T12:13:37Z","last_updated_date":"2024-04-16T12:13:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-ctis-webinar-last-year-transition-monique-al_en.pdf"},
    {"id":"62971","name":"Presentation - Session 1 Presentation CTIS metrics & looking forward (Noemie Manent)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T12:15:32Z","last_updated_date":"2024-04-16T12:15:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-presentation-ctis-metrics-looking-forward-noemie-manent_en.pdf"},
    {"id":"62972","name":"Presentation - Session 2 - CTIS Transition (Barbara Lanthaler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T12:17:12Z","last_updated_date":"2024-04-16T12:17:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-ctis-transition-barbara-lanthaler_en.pdf"},
    {"id":"62973","name":"Presentation - Session 2 - CTIS Last year of transition (Lene Grejs Petersen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T12:18:46Z","last_updated_date":"2024-04-16T12:18:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-ctis-last-year-transition-lene-grejs-petersen_en.pdf"},
    {"id":"62974","name":"Presentation - Session 2 CTIS Webinar Last Year of Transition (Martin OKane)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T12:21:06Z","last_updated_date":"2024-04-16T12:21:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-ctis-webinar-last-year-transition-martin-okane_en.pdf"},
    {"id":"62975","name":"Presentation - Session 2 Experience in Transitional Trials​ Member States perspective (Stefan Strasser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T12:23:00Z","last_updated_date":"2024-04-16T12:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-experience-transitional-trials-member-states-perspective-stefan-strasser_en.pdf"},
    {"id":"62977","name":"Presentation - Clinical electronic Structured Harmonised Protocol (V.A. Perkins, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-16T14:10:17Z","last_updated_date":"2024-04-16T14:10:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-electronic-structured-harmonised-protocol-va-perkins-efpia_en.pdf"},
    {"id":"63010","name":"Enpr-EMA facts on one slide","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T13:58:40Z","last_updated_date":"2024-04-19T13:58:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/enpr-ema-facts-one-slide_en.ppt"},
    {"id":"63013","name":"Presentation - European regulatory perspective of psychedelic drugs in psychiatry (M. Haberkamp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:37:04Z","last_updated_date":"2024-04-19T14:37:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-regulatory-perspective-psychedelic-drugs-psychiatry-m-haberkamp_en.pdf"},
    {"id":"63014","name":"Presentation - Australian regulatory perspective of psychedelic drugs in psychiatry (R Langham)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:38:48Z","last_updated_date":"2024-04-19T14:38:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-australian-regulatory-perspective-psychedelic-drugs-psychiatry-r-langham_en.pdf"},
    {"id":"63015","name":"Presentation - American regulatory perspective of psychedelic drugs in psychiatry (M. Sokolowska)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:40:28Z","last_updated_date":"2024-04-19T14:40:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-american-regulatory-perspective-psychedelic-drugs-psychiatry-m-sokolowska_en.pdf"},
    {"id":"63016","name":"Presentation - Legal status of psychedelics and impact in research and development (T. Hawrot)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:41:42Z","last_updated_date":"2024-04-19T14:41:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-legal-status-psychedelics-impact-research-development-t-hawrot_en.pdf"},
    {"id":"63017","name":"Presentation - Challenges with Health technology assessment after approval (C. Martín Saborido)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:42:56Z","last_updated_date":"2024-04-19T14:42:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-health-technology-assessment-after-approval-c-martin-saborido_en.pdf"},
    {"id":"63018","name":"Presentation - National experience with medical use of psychedelics (J. Horacek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:44:07Z","last_updated_date":"2024-04-19T14:44:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-national-experience-medical-use-psychedelics-j-horacek_en.pdf"},
    {"id":"63019","name":"Presentation - Identification of methodological issues and how to overcome them (G. Knudsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:45:18Z","last_updated_date":"2024-04-19T14:45:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-identification-methodological-issues-how-overcome-them-g-knudsen_en.pdf"},
    {"id":"63020","name":"Presentation - Drawing from ongoing trials and existing clinical experience  (E. Bałkowiec-Iskra)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:47:14Z","last_updated_date":"2024-04-19T14:47:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-drawing-ongoing-trials-existing-clinical-experience-e-balkowiec-iskra_en.pdf"},
    {"id":"63021","name":"Presentation - Set and setting research potential implications for future approval (M. Beckman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:48:31Z","last_updated_date":"2024-04-19T14:48:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-set-setting-research-potential-implications-future-approval-m-beckman_en.pdf"},
    {"id":"63022","name":"Presentation -  Psychedelic treatments; questions from research and clinical implementation (R. Schoevers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:49:30Z","last_updated_date":"2024-04-19T14:49:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-psychedelic-treatments-questions-research-clinical-implementation-r-schoevers_en.pdf"},
    {"id":"63023","name":"Presentation - Clinical experience learned from approved esketamine and potential implications for psychedelics (P. Gorwood)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:50:52Z","last_updated_date":"2024-04-19T14:50:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-experience-learned-approved-esketamine-potential-implications-psychedelics-p-gorwood_en.pdf"},
    {"id":"63024","name":"Presentation -  What can patient and public involvement in research contribute to safe and effective use (I. Dziobek)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T14:51:59Z","last_updated_date":"2024-04-19T14:51:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-can-patient-public-involvement-research-contribute-safe-effective-use-i-dziobek_en.pdf"},
    {"id":"63026","name":"Presentation - Product Management Service (PMS) Info-Day","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T15:26:17Z","last_updated_date":"2024-04-19T15:26:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-pms-info-day_en.pdf"},
    {"id":"63035","name":"Presentation - Clinical Trial Information System (CTIS) - Bitesize talk - How to submit a transitional trial in CTIS","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-04-22T12:26:05Z","last_updated_date":"2024-04-22T12:26:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trial-information-system-ctis-bitesize-talk-how-submit-transitional-trial-ctis_en.pdf"},
    {"id":"63210","name":"Presentation - Information and Q&A session on updated CAPs in web-based eAF","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-05-14T14:33:00Z","last_updated_date":"2024-05-14T14:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-qa-session-updated-caps-web-based-eaf_en.pdf"},
    {"id":"63226","name":"Presentation - Clinical development of psychedelics for psychiatric disorders (N. Hefting, G. Goodwin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T11:45:11Z","last_updated_date":"2024-05-16T11:45:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-development-psychedelics-psychiatric-disorders-n-hefting-g-goodwin_en.pdf"},
    {"id":"63332","name":"Presentation - List of antimicrobials reserved for the treatment of humans (Rory Breathnach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T11:20:00Z","last_updated_date":"2024-05-28T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-list-antimicrobials-reserved-treatment-humans-rory-breathnach_en.pdf"},
    {"id":"63333","name":"Presentation - WHO Medically Important Antimicrobial list (Andreas Palzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-05-28T11:22:00Z","last_updated_date":"2024-05-28T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-who-medically-important-antimicrobial-list-andreas-palzer_en.pdf"},
    {"id":"63363","name":"EU 4 AMA: leveraging European expertise for medicines regulation in Africa","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-05-29T12:05:00Z","last_updated_date":"2024-05-29T12:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/eu-4-ama-leveraging-european-expertise-medicines-regulation-africa_en.pdf"},
    {"id":"63474","name":"Presentation - Product Management Service (PMS) Product UI Training (Access & Navigation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-04T13:41:00Z","last_updated_date":"2024-06-04T13:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-pms-product-ui-training-access-navigation_en.pdf"},
    {"id":"63518","name":"Presentation - Summary of last workshop and objectives (Pan Pantziarka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T15:27:09Z","last_updated_date":"2024-06-06T15:27:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-summary-last-workshop-objectives-pan-pantziarka_en.pdf"},
    {"id":"63521","name":"Presentation - Ultra-rare sarcoma: Accessing patientsHospital cohorts and mobilizing the patient community (Hugh Leonard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T15:52:04Z","last_updated_date":"2024-06-06T15:52:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ultra-rare-sarcoma-accessing-patientshospital-cohorts-mobilizing-patient-community-hugh-leonard_en.pdf"},
    {"id":"63523","name":"Presentation - Identifying new drugs in ultra-rare indications and off label use (Robin L Jones)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T15:53:35Z","last_updated_date":"2024-06-06T15:53:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-identifying-new-drugs-ultra-rare-indications-label-use-robin-l-jones_en.pdf"},
    {"id":"63524","name":"Presentation - Case example from PUSH: LGFMS/SEF and immunotherapy (Andrew J. Wagner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T15:55:40Z","last_updated_date":"2024-06-06T15:55:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-example-push-lgfms-sef-immunotherapy-andrew-j-wagner_en.pdf"},
    {"id":"63525","name":"Presentation - What could the development of medicines in ultra-rare indications look like (Pierre Démolis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T15:57:11Z","last_updated_date":"2024-06-06T15:57:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-could-development-medicines-ultra-rare-indications-look-pierre-demolis_en.pdf"},
    {"id":"63526","name":"Presentation - What is important for patients in addition to RECIST and overall survival (Gerard van Oortmerssen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T16:00:03Z","last_updated_date":"2024-06-06T16:00:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-important-patients-addition-recist-overall-survival-gerard-van-oortmerssen_en.pdf"},
    {"id":"63527","name":"Presentation - Use of Real Word Data to Complement Prospective Studies: Case Example in Alveolar Soft Parts Sarcoma and Epithelioid Sarcoma (William Tap)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T16:01:07Z","last_updated_date":"2024-06-06T16:01:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-real-word-data-complement-prospective-studies-case-example-alveolar-soft-parts-sarcoma-epithelioid-sarcoma-william-tap_en.pdf"},
    {"id":"63528","name":"Presentation - Developing new criteria for response assessment: Case example of epithelioid haemangioendothelioma (Lorenzo D’Ambrosio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T16:02:46Z","last_updated_date":"2024-06-06T16:02:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-developing-new-criteria-response-assessment-case-example-epithelioid-haemangioendothelioma-lorenzo-dambrosio_en.pdf"},
    {"id":"63529","name":"Presentation - Repurposing: case example of sirolimus in epithelioid hemangioendothelioma (Denise Robinson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T16:04:36Z","last_updated_date":"2024-06-06T16:04:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-repurposing-case-example-sirolimus-epithelioid-hemangioendothelioma-denise-robinson_en.pdf"},
    {"id":"63530","name":"Presentation - Engaging companies in academic trials of ultra-rare (UR) tumours (Gauthier Bouche)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-06T16:05:49Z","last_updated_date":"2024-06-06T16:05:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-engaging-companies-academic-trials-ultra-rare-ur-tumours-gauthier-bouche_en.pdf"},
    {"id":"63673","name":"Presentation - Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS 13 June 2024","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T15:31:24Z","last_updated_date":"2024-06-18T15:31:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-webinar-regulatory-procedure-management-product-lifecycle-management-iris-13-june-2024_en.pdf"},
    {"id":"63700","name":"Presentation - Update on EMA progress on Patient Experience Data (J. Garcia Burgos, R. Gonzalez-Quevedo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T09:47:00Z","last_updated_date":"2024-06-21T09:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ema-progress-patient-experience-data-j-garcia-burgos-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"63701","name":"Presentation - Industry Stakeholder Platform meeting on the Centralised Procedure (I. Chicharo, J. Wiemer, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T09:30:00Z","last_updated_date":"2024-06-21T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-stakeholder-platform-meeting-centralised-procedure-i-chicharo-j-wiemer-ema_en.pdf"},
    {"id":"63702","name":"Presentation - Update on IRIS Product Life Cycle Management roll-out -12th Industry Stakeholder Platform (F. Penaranda, M. Duta-Mare, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T09:30:00Z","last_updated_date":"2024-06-21T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-iris-product-life-cycle-management-roll-out-12th-industry-stakeholder-platform-f-penaranda-m-duta-mare-ema_en.pdf"},
    {"id":"63703","name":"Presentation - Lifecycle management of combination products at post-authorisation (M. Bonafonte, V. Rojo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T09:30:00Z","last_updated_date":"2024-06-21T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lifecycle-management-combination-products-post-authorisation-m-bonafonte-v-rojo-ema_en.pdf"},
    {"id":"63704","name":"Presentation - EMA corporate website (M-A Heine, C. Gadd, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T09:30:00Z","last_updated_date":"2024-06-21T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-corporate-website-m-heine-c-gadd-ema_en.pdf"},
    {"id":"63705","name":"Presentation - GMP Inspections MAA submission preparedness (A. Spinei, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T09:30:00Z","last_updated_date":"2024-06-21T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gmp-inspections-maa-submission-preparedness-spinei-ema_en.pdf"},
    {"id":"63706","name":"Presentation - Assuring the Network’s Sustainability (F. Day, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T09:30:00Z","last_updated_date":"2024-06-21T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-assuring-networks-sustainability-f-day-ema_en.pdf"},
    {"id":"63813","name":"Presentation - Quarterly System Demo Q2 2024","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T11:11:01Z","last_updated_date":"2024-06-28T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quarterly-system-demo-q2-2024_en.pdf"},
    {"id":"63855","name":"Presentation - Patients and clinical perspectives and management of Thalassemia (Ali Taher)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T11:20:00Z","last_updated_date":"2024-07-03T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-clinical-perspectives-management-thalassemia-ali-taher_en.pdf"},
    {"id":"63857","name":"Presentation - Management of, and unmet needs in, Sickle Cell disorders (John Porter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T11:25:00Z","last_updated_date":"2024-07-03T11:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-management-unmet-needs-sickle-cell-disorders-john-porter_en.pdf"},
    {"id":"63858","name":"Presentation - Challenges in treatment/drug development from a clinicians’ perspective with regards to study design and endpoints used in clinical trials for management of paediatric Sickle Cell disease (Raffaella Colombatti, Mariane De Montalembert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T11:31:00Z","last_updated_date":"2024-07-03T11:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-treatment-drug-development-clinicians-perspective-regards-study-design-endpoints-used-clinical-trials-management-paediatric-sickle-cell-disease-raffaella-colombatti-mariane-de_en.pdf"},
    {"id":"63859","name":"Presentation - EMA workshop on the challenges in drug development, regulation and clinical practice in hemoglobinopathies (A Loris Brunetta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T11:34:00Z","last_updated_date":"2024-07-03T11:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-workshop-challenges-drug-development-regulation-clinical-practice-hemoglobinopathies-loris-brunetta_en.pdf"},
    {"id":"63860","name":"Presentation - Approved medicines in Sickle Cell Disease and Thalassemia diseases and regulatory considerations by FDA CDER (Patricia Ann Oneal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T11:38:00Z","last_updated_date":"2024-07-03T11:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-approved-medicines-sickle-cell-disease-thalassemia-diseases-regulatory-considerations-fda-cder-patricia-ann-oneal_en.pdf"},
    {"id":"63861","name":"Presentation - Regulatory considerations CBER (Megha Kaushal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T11:43:00Z","last_updated_date":"2024-07-03T11:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-considerations-cber-megha-kaushal_en.pdf"},
    {"id":"63862","name":"Presentation - Authorised medicines and regulatory considerations by EMA (Johanna Lähteenvuo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T11:45:00Z","last_updated_date":"2024-11-07T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-authorised-medicines-regulatory-considerations-ema-johanna-lahteenvuo_en.pdf"},
    {"id":"63863","name":"Presentation - OPEN and other collaborative procedures (Radhouane Cherif)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T11:58:00Z","last_updated_date":"2024-07-03T11:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-open-other-collaborative-procedures-radhouane-cherif_en.pdf"},
    {"id":"63864","name":"Presentations - Bioethics considerations on gene editing (Laurence Lwoff)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T13:50:00Z","last_updated_date":"2024-07-03T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentations-bioethics-considerations-gene-editing-laurence-lwoff_en.pdf"},
    {"id":"63865","name":"Presentation - Hemoglobinopathies HTA challenges (Anja Schiel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T14:22:00Z","last_updated_date":"2024-07-03T14:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hemoglobinopathies-hta-challenges-anja-schiel_en.pdf"},
    {"id":"63866","name":"Presentation - Experience from registries (María del Mar Mañú Pereira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T14:29:00Z","last_updated_date":"2024-07-03T14:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-experience-registries-maria-del-mar-manu-pereira_en.pdf"},
    {"id":"63867","name":"Presention - Challenges in drug development for haemoglobinopathies (Antonella Isgrò)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T14:34:00Z","last_updated_date":"2024-07-03T14:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presention-challenges-drug-development-haemoglobinopathies-antonella-isgro_en.pdf"},
    {"id":"63895","name":"Presentation - Session 1 : Clinical impact of shortages (E. Woodward)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T12:48:00Z","last_updated_date":"2024-07-05T12:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-clinical-impact-shortages-e-woodward_en.pdf"},
    {"id":"63896","name":"Presentation - Session 1 : Clinical impact of shortages (F. Giorgino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T12:53:00Z","last_updated_date":"2024-07-05T12:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-clinical-impact-shortages-f-giorgino_en.pdf"},
    {"id":"63897","name":"Presentation - Session 1 : Overview of the supply situation of GLP-1 RAs (K. Kruttwig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T12:55:00Z","last_updated_date":"2024-07-05T12:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-overview-supply-situation-glp-1-ras-k-kruttwig_en.pdf"},
    {"id":"63898","name":"Presentation - Session 2 : Mitigation measures recommended by EMA/MSSG (K. Kruttwig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T12:58:00Z","last_updated_date":"2024-07-05T12:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-mitigation-measures-recommended-ema-mssg-k-kruttwig_en.pdf"},
    {"id":"63899","name":"Presentation - Session 2 : Sharing of good practice  - examples from a non-EU regulator (R. Kosko)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T13:00:00Z","last_updated_date":"2024-07-05T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-sharing-good-practice-examples-non-eu-regulator-r-kosko_en.pdf"},
    {"id":"63901","name":"Presentation - Session 2 : Sharing of good practice - examples from EUEEA countries (D. di Giorgio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T13:44:00Z","last_updated_date":"2024-07-05T13:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-sharing-good-practice-examples-eueea-countries-d-di-giorgio_en.pdf"},
    {"id":"63902","name":"Presentation - Session 2 : Sharing of good practice - examples from EUEEA countries (G. Wilhelmsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T13:46:00Z","last_updated_date":"2024-07-05T13:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-sharing-good-practice-examples-eueea-countries-g-wilhelmsen_en.pdf"},
    {"id":"63903","name":"Presentation - Session 2 : Sharing of good practice - examples from EUEEA countries (J. Velik)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T13:48:00Z","last_updated_date":"2024-07-05T13:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-sharing-good-practice-examples-eueea-countries-j-velik_en.pdf"},
    {"id":"63904","name":"Presentation - Session 2 : Sharing of good practice - examples from EUEEA countries (S. Schotte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T13:49:00Z","last_updated_date":"2024-07-05T13:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-sharing-good-practice-examples-eueea-countries-s-schotte_en.pdf"},
    {"id":"63905","name":"Presentation - Session 2 : Prevention and mitigation measures taken by companies (E. Mashaki Ceyhan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T13:54:00Z","last_updated_date":"2024-07-05T13:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-prevention-mitigation-measures-taken-companies-e-mashaki-ceyhan_en.pdf"},
    {"id":"63907","name":"Presentation - Session 2 : Prevention and mitigation measures taken by companies (E. Pegg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:04:00Z","last_updated_date":"2024-07-05T14:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-prevention-mitigation-measures-taken-companies-e-pegg_en.pdf"},
    {"id":"63908","name":"Presentation - Session 2 : Prevention and mitigation measures taken by companies (J. Westerbacka)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:07:00Z","last_updated_date":"2024-07-05T14:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-prevention-mitigation-measures-taken-companies-j-westerbacka_en.pdf"},
    {"id":"63909","name":"Presentation - Session 3 : Communication activities by EMAMSSG on shortages of GLP-1 RAs (J. Garcia Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:19:00Z","last_updated_date":"2024-07-05T14:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-communication-activities-emamssg-shortages-glp-1-ras-j-garcia-burgos_en.pdf"},
    {"id":"63910","name":"Presentation - Session 3 : Role of patients and consumers’ / healthcare professional organisations in supporting communication activities (J. Bowman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:23:00Z","last_updated_date":"2024-07-05T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-role-patients-consumers-healthcare-professional-organisations-supporting-communication-activities-j-bowman_en.pdf"},
    {"id":"63911","name":"Presentation - Session 3 : Role of patients and consumers’ healthcare professional organisations in supporting communication activities (E. Dupont)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:25:00Z","last_updated_date":"2024-07-05T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-role-patients-consumers-healthcare-professional-organisations-supporting-communication-activities-e-dupont_en.pdf"},
    {"id":"63912","name":"Presentation - Session 3 : Role of patients and consumers’ / healthcare professional organisations in supporting communication activities (F. Giorgino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:29:00Z","last_updated_date":"2024-07-05T14:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-role-patients-consumers-healthcare-professional-organisations-supporting-communication-activities-f-giorgino_en.pdf"},
    {"id":"63913","name":"Presentation - Session 3 : Sharing of good practice - examples on communication from a non-EU regulator (A. Lostracco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:34:00Z","last_updated_date":"2024-07-05T14:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-sharing-good-practice-examples-communication-non-eu-regulator-lostracco_en.pdf"},
    {"id":"63914","name":"Presentation - Session 3 : The role of social media in shortages of GLP-1 RAs (A. Santos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:35:00Z","last_updated_date":"2024-07-05T14:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-role-social-media-shortages-glp-1-ras-santos_en.pdf"},
    {"id":"63917","name":"Presentation - Session 3 : Sharing of good practice - examples on communication from member states (Y. Knudsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:40:00Z","last_updated_date":"2024-07-05T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-sharing-good-practice-examples-communication-member-states-y-knudsen_en.pdf"},
    {"id":"63918","name":"Presentation - Session 3 : Sharing of good practice - examples on communication from member states (D. Pernas Cabo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-05T14:44:00Z","last_updated_date":"2024-07-05T14:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-sharing-good-practice-examples-communication-member-states-d-pernas-cabo_en.pdf"},
    {"id":"63950","name":"Presentation - Updates from EMA on scientific advice, PRIME and Joint Scientific Consultations with HTA bodies (I.Gravanis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T08:50:20Z","last_updated_date":"2024-07-09T08:50:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-ema-scientific-advice-prime-joint-scientific-consultations-hta-bodies-igravanis-ema_en.pdf"},
    {"id":"63951","name":"Presentation - Consolidated advice pilots - ACT EU Priority Action on consolidated advice (M.Lunzer, M.Sarra, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T08:51:12Z","last_updated_date":"2024-07-09T08:51:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-consolidated-advice-pilots-act-eu-priority-action-consolidated-advice-mlunzer-msarra-ema_en.pdf"},
    {"id":"63952","name":"Presentation - New Fee Regulation: upcoming changes foreseen for R&D Procedures","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T08:52:12Z","last_updated_date":"2024-07-09T08:52:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-fee-regulation-upcoming-changes-foreseen-rd-procedures_en.pdf"},
    {"id":"63953","name":"Presentation - Recent and upcoming developments of the IRIS platform for R&D processes (T.Toufexi, A.Labejof, G.Lesa, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T08:53:09Z","last_updated_date":"2024-07-09T08:53:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recent-upcoming-developments-iris-platform-rd-processes-ttoufexi-alabejof-glesa-ema_en.pdf"},
    {"id":"63954","name":"Presentation - Ad-hoc focus group on RWD & RWE (P.Verpillat, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T09:05:38Z","last_updated_date":"2024-07-09T09:05:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ad-hoc-focus-group-rwd-rwe-pverpillat-ema_en.pdf"},
    {"id":"63955","name":"Presentation - Update on the scientific publication (S.Aarum, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T09:06:55Z","last_updated_date":"2024-07-09T09:06:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-scientific-publication-saarum-ema_en.pdf"},
    {"id":"63960","name":"Presentation - Current practices for communication and uptake of risk minimisation measures by healthcare professionals (O. Clément, ESR)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T13:50:29Z","last_updated_date":"2024-07-09T13:50:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-practices-communication-uptake-risk-minimisation-measures-healthcare-professionals-o-clement-esr_en.pdf"},
    {"id":"63970","name":"Presentation - Update on HCP POG drafting groups (I. Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T14:23:00Z","last_updated_date":"2024-07-09T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-hcp-pog-drafting-groups-i-silva-ema_en.pdf"},
    {"id":"63971","name":"Presentation - CHMP early dialogue with healthcare professional organisations (C. Henrot, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T14:57:00Z","last_updated_date":"2024-07-09T14:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chmp-early-dialogue-healthcare-professional-organisations-c-henrot-ema_en.pdf"},
    {"id":"64000","name":"Presentation - Product Management Service (PMS) Application Programming Interface (API) Training","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T16:53:00Z","last_updated_date":"2024-07-10T16:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-pms-application-programming-interface-api-training_en.pdf"},
    {"id":"64002","name":"Presentation - European Shortages Monitoring Platform (ESMP) essentials and industry reporting requirements webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T17:02:00Z","last_updated_date":"2024-07-10T17:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-shortages-monitoring-platform-esmp-essentials-industry-reporting-requirements-webinar_en.pdf"}    {"id":"64031","name":"Presentation - Industry Standing Group (ISG) mandate update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-11T14:25:00Z","last_updated_date":"2024-07-11T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-standing-group-isg-mandate-update_en.pdf"},
    {"id":"64032","name":"Presentation - Medicine Shortages Steering Group (MSSG) recommendations to strengthen supply chains of critical medicinal products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-11T14:25:00Z","last_updated_date":"2024-07-11T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicine-shortages-steering-group-mssg-recommendations-strengthen-supply-chains-critical-medicinal-products_en.pdf"},
    {"id":"64033","name":"Presentation - Update on the development of the European Shortages Monitoring Platform (ESMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-11T14:25:00Z","last_updated_date":"2024-07-11T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-development-european-shortages-monitoring-platform-esmp_en.pdf"},
    {"id":"64034","name":"Presentation - Regulatory / HTA interface under the HTA Regulation (HTAR)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-11T14:25:00Z","last_updated_date":"2024-07-11T14:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-hta-interface-under-hta-regulation-htar_en.pdf"},
    {"id":"64035","name":"Presentation - European Medicines Agencies Network Strategy update to 2028","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-11T14:30:00Z","last_updated_date":"2024-07-11T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-medicines-agencies-network-strategy-update-2028_en.pdf-0"},
    {"id":"64036","name":"Presentation - Revised CTIS transparency rules and new version of the public portal","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-11T14:30:00Z","last_updated_date":"2024-07-11T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revised-ctis-transparency-rules-new-version-public-portal_en.pdf"},
    {"id":"64037","name":"Presentation - Artificial Intelligence: multi-annual artificial intelligence workplan 2023-2028","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-11T15:15:00Z","last_updated_date":"2024-07-11T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-artificial-intelligence-multi-annual-artificial-intelligence-workplan-2023-2028_en.pdf"},
    {"id":"64038","name":"Presentation - Update on Network Portfolio activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-11T15:17:00Z","last_updated_date":"2024-07-11T15:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-network-portfolio-activities_en.pdf"},
    {"id":"64039","name":"Presentation - International collaboration to facilitate medicines availability global assessment / inspection pathways","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-11T15:19:00Z","last_updated_date":"2024-07-11T15:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-collaboration-facilitate-medicines-availability-global-assessment-inspection-pathways_en.pdf"},
    {"id":"64053","name":"Presentation - Data-driven approaches in health research & innovation (T.Dyląg, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:11:03Z","last_updated_date":"2024-07-12T10:11:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-driven-approaches-health-research-innovation-tdylag-ec_en.pdf"},
    {"id":"64054","name":"Presentation - Introduction to regulatory-grade causal inference (X.Garcia de Albeniz, RTI Health Solutions)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:13:12Z","last_updated_date":"2024-07-12T10:13:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-regulatory-grade-causal-inference-xgarcia-de-albeniz-rti-health-solutions_en.pdf"},
    {"id":"64055","name":"Presentation - RWD-derived external controls in regulatory context (E.Asikanius, FIMEA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:19:48Z","last_updated_date":"2024-07-12T10:19:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rwd-derived-external-controls-regulatory-context-easikanius-fimea_en.pdf"},
    {"id":"64056","name":"Presentation - Use of estimands in target trial emulation (J.Abellan, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:20:54Z","last_updated_date":"2024-07-12T10:20:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-estimands-target-trial-emulation-jabellan-ema_en.pdf"},
    {"id":"64057","name":"Presentation - The use of RWD derived External Control Arm to assess the Benefit of New Therapies (M.Feudjo Tepie, UCB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:22:08Z","last_updated_date":"2024-07-12T10:22:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-rwd-derived-external-control-arm-assess-benefit-new-therapies-mfeudjo-tepie-ucb_en.pdf"},
    {"id":"64059","name":"Presentation - Externally controlled trials in oncology (D.Rivera, US FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:24:49Z","last_updated_date":"2024-07-12T10:24:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-externally-controlled-trials-oncology-drivera-us-fda_en.pdf"},
    {"id":"64060","name":"Presentation - Target trial and estimand in post-market safety studies (R.Izem, Novartis Pharma AG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:25:42Z","last_updated_date":"2024-07-12T10:25:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-target-trial-estimand-post-market-safety-studies-rizem-novartis-pharma-ag_en.pdf"},
    {"id":"64061","name":"Presentation - RWD-derived external controls case study: Abecma (A.Buzzi, T.Framke, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:26:53Z","last_updated_date":"2024-07-12T10:26:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rwd-derived-external-controls-case-study-abecma-abuzzi-tframke-ema_en.pdf"},
    {"id":"64062","name":"Presentation - Use of real-world data in non-interventional studies to generate real-world evidence: Draft reflection paper (X.Kurz, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:31:47Z","last_updated_date":"2024-07-12T10:31:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-real-world-data-non-interventional-studies-generate-real-world-evidence-draft-reflection-paper-xkurz-ema_en.pdf"},
    {"id":"64063","name":"Presentation - Regulatory perspectives on TTE for pharmacovigilance (R.Fitzgerald, HPRA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:32:41Z","last_updated_date":"2024-07-12T10:32:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspectives-tte-pharmacovigilance-rfitzgerald-hpra_en.pdf"},
    {"id":"64064","name":"Presentation - Introduction to the Methodology Working Party (K.Roes, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:34:00Z","last_updated_date":"2024-07-12T10:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-methodology-working-party-kroes-ema_en.pdf"},
    {"id":"64065","name":"Presentation - MWP Roadmap for the development of RWE guidance (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:34:48Z","last_updated_date":"2024-07-12T10:34:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mwp-roadmap-development-rwe-guidance-ema_en.pdf"},
    {"id":"64066","name":"Presentation - The next three years: roadmap for RWE guidance (M.Schoonen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:35:27Z","last_updated_date":"2024-07-12T10:35:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-next-three-years-roadmap-rwe-guidance-mschoonen_en.pdf"},
    {"id":"64067","name":"Presentation - EMA Reflection paper on use of Real-World Data in Non-interventional Studies to Generate Real-World Evidence (A.Spooner, EFPIA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:36:19Z","last_updated_date":"2024-07-12T10:36:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-aspooner-efpia_en.pdf"},
    {"id":"64068","name":"Presentation - Joint HMA/EMA Big Data Steering Group Workshop on RWE methods Harnessing Real-World Data for Regulatory Use (P.Verpillat, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T10:37:26Z","last_updated_date":"2024-07-12T10:37:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-hma-ema-big-data-steering-group-workshop-rwe-methods-harnessing-real-world-data-regulatory-use-pverpillat-ema_en.pdf"},
    {"id":"64092","name":"Presentation - HMA/EMA task force on availability of authorised medicines (I. Abed, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T14:45:00Z","last_updated_date":"2024-07-12T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hma-ema-task-force-availability-authorised-medicines-i-abed-ema_en.pdf"},
    {"id":"64093","name":"Presentation - Joint HMA/EMA big data steering group on real-world evidence (RWE) methods (Klaus Kruttwig, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T14:48:00Z","last_updated_date":"2024-07-12T14:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-hma-ema-big-data-steering-group-real-world-evidence-rwe-methods-klaus-kruttwig-ema_en.pdf"},
    {"id":"64094","name":"Presentation - HMA/EMA task force on availability of authorised medicines (J. Ferreira, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T14:54:00Z","last_updated_date":"2024-07-12T14:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hma-ema-task-force-availability-authorised-medicines-j-ferreira-ema_en.pdf"},
    {"id":"64100","name":"Presentation - EMA’s vaccines outreach strategy (M. Cavaleri, M. Carr, EMA) ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:07:00Z","last_updated_date":"2024-07-12T15:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-vaccines-outreach-strategy-m-cavaleri-m-carr-ema_en.pdf"},
    {"id":"64101","name":"Presentation - European vaccination information portal (EVIP) (N. White, ECDC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:11:00Z","last_updated_date":"2024-07-12T15:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-vaccination-information-portal-evip-n-white-ecdc_en.pdf"},
    {"id":"64102","name":"Presentation - EU vaccine monitoring platform what is it, and how can it inform HCPs, patients, and the public, on the benefit/risk of vaccines (C. Cohet, A. Buoninfante, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T15:20:00Z","last_updated_date":"2024-07-12T15:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-vaccine-monitoring-platform-what-it-how-can-it-inform-hcps-patients-public-benefit-risk-vaccines-c-cohet-buoninfante-ema_en.pdf"},
    {"id":"64118","name":"Presentation - Pack Size Submissions: from XEVMPD to PMS (M.Fernandez Gomez, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-12T16:06:25Z","last_updated_date":"2024-07-12T16:06:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pack-size-submissions-xevmpd-pms-mfernandez-gomez-ema_en.pdf"},
    {"id":"64146","name":"Presentation - Patient engagement in scientific advice (K.Immonen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T11:04:51Z","last_updated_date":"2024-07-15T11:04:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-engagement-scientific-advice-kimmonen-ema_en.pdf"},
    {"id":"64147","name":"Presentation - Activities involving patients/consumers during evaluation phase with CHMP (M.Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T11:07:57Z","last_updated_date":"2024-07-15T11:07:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-activities-involving-patients-consumers-during-evaluation-phase-chmp-mmavris-ema_en.pdf"},
    {"id":"64148","name":"Presentation - EMA and international affairs (M.Hendrix, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T11:11:15Z","last_updated_date":"2024-07-15T11:11:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-international-affairs-mhendrix-ema_en.pdf"},
    {"id":"64149","name":"Presentation - Collaboration with US FDA (M.Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T11:12:06Z","last_updated_date":"2024-07-15T11:12:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collaboration-us-fda-mmavris-ema_en.pdf"},
    {"id":"64150","name":"Presentation - Supporting the African Medicines Agency  (V.Palmi Reig, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T11:12:49Z","last_updated_date":"2024-07-15T11:12:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-supporting-african-medicines-agency-vpalmi-reig-ema_en.pdf"},
    {"id":"64151","name":"Presentation - Outcome of the survey on the joint PCWP-HCPWP workplan actions and discussion on PCWP-specific actions (I.Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T11:13:50Z","last_updated_date":"2024-07-15T11:13:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcome-survey-joint-pcwp-hcpwp-workplan-actions-discussion-pcwp-specific-actions-isilva-ema_en.pdf"},
    {"id":"64159","name":"Presentation - Extension of the EMAN strategy to 2028 (M. Carr, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:24:06Z","last_updated_date":"2024-07-16T13:24:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extension-eman-strategy-2028-m-carr-ema_en.pdf"},
    {"id":"64160","name":"Presentation - HCPO: Roles and Responsibilities of the GP in Prescribing in the Health Care System (M. McCarthy, UEMO)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:32:13Z","last_updated_date":"2024-07-16T13:32:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hcpo-roles-responsibilities-gp-prescribing-health-care-system-m-mccarthy-uemo_en.pdf"},
    {"id":"64161","name":"Presentation - Clinical trials raw data pilot – interim results (F. Pétavy and M. Rückbeil EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:35:30Z","last_updated_date":"2024-07-16T13:35:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-raw-data-pilot-interim-results-f-petavy-m-ruckbeil-ema_en.pdf"},
    {"id":"64162","name":"Presentation - Update on ACT EU and Multistakeholder Platform (Ana Zanoletty, EMA) (Denis Lacombe, EORTC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:39:48Z","last_updated_date":"2024-07-16T13:39:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-act-eu-multistakeholder-platform-ana-zanoletty-ema-denis-lacombe-eortc_en.pdf"},
    {"id":"64163","name":"Presentation - Update of the QRD template of the package leaflet (Monica Buch, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:41:40Z","last_updated_date":"2024-07-16T13:41:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-qrd-template-package-leaflet-monica-buch-ema_en.pdf"},
    {"id":"64164","name":"Presentation - Concept paper on the revision of the Guideline on Risk Assessment of Medicinal Products on Human Reproduction and Lactation: from Data to Labelling (Dinah Duarte, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:42:35Z","last_updated_date":"2024-07-16T13:42:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-concept-paper-revision-guideline-risk-assessment-medicinal-products-human-reproduction-lactation-data-labelling-dinah-duarte-ema_en.pdf"},
    {"id":"64165","name":"Presentation - Re-start of Clinical Data Publication – Update on transparency activities (Silvia GarridoLestache, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:46:03Z","last_updated_date":"2024-07-16T13:46:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-re-start-clinical-data-publication-update-transparency-activities-silvia-garridolestache-ema_en.pdf"},
    {"id":"64166","name":"Presentation -  Revised CTIS transparency rules (Francesca Scotti, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:47:21Z","last_updated_date":"2024-07-16T13:47:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revised-ctis-transparency-rules-francesca-scotti-ema_en.pdf"},
    {"id":"64167","name":"Presentation - Outcome of biosimilars surveys to patients, healthcare professionals, industry and HMA (R. G. Quevedo, EMA - D. de Cock, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T13:48:20Z","last_updated_date":"2024-07-16T13:48:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-outcome-biosimilars-surveys-patients-healthcare-professionals-industry-hma-r-g-quevedo-ema-d-de-cock-ema_en.pdf"},
    {"id":"64177","name":"Presentation - Activities of the European Network Chessmen (N. Simoes, Infarmed) (D. Di Giorgio, AIFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T15:36:47Z","last_updated_date":"2024-07-16T15:36:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-activities-european-network-chessmen-n-simoes-infarmed-d-di-giorgio-aifa_en.pdf"},
    {"id":"64286","name":"Presentation - Info session on web-based electronic Application Form (eAF) add package","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-24T09:38:00Z","last_updated_date":"2025-03-07T14:29:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-info-session-web-based-electronic-application-form-eaf-add-package_en.pdf"},
    {"id":"64298","name":"Presentation - Target trial emulation in a DARWIN EU vaccine effectiveness study (Dani Prieto-Alhambra, DARWIN EU)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-24T11:11:11Z","last_updated_date":"2024-07-24T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-target-trial-emulation-darwin-eu-vaccine-effectiveness-study-dani-prieto-alhambra-darwin-eu_en.pdf"},
    {"id":"64299","name":"Presentation - Externally controlled trials in oncology (Donna Rivera, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-07-24T11:11:01Z","last_updated_date":"2024-07-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-externally-controlled-trials-oncology-donna-rivera-fda_en.pdf"},
    {"id":"64534","name":"Presentation - An agency of the European Union Industry Standing Group (ISG)Mandate update (M. H. Pinheiro, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-08-07T17:15:18Z","last_updated_date":"2024-08-07T17:15:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agency-european-union-industry-standing-group-isgmandate-update-m-h-pinheiro-ema_en.pdf"},
    {"id":"64535","name":"Presentation - MSSG recommendations to strengthen supply chains of critical medicinal products (M. Alcaraz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-08-07T17:17:23Z","last_updated_date":"2024-08-07T17:17:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mssg-recommendations-strengthen-supply-chains-critical-medicinal-products-m-alcaraz_en.pdf"},
    {"id":"64536","name":"Presentation - Medical device expert panels - State of Play (M. Antunes, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-08-07T17:18:31Z","last_updated_date":"2024-08-07T17:18:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-device-expert-panels-state-play-m-antunes-ema_en.pdf"},
    {"id":"64862","name":"Presentation - Session 2: Issue list and proposals for solutions (C.Bahans, E.Stahl, AM.Janson Lang, J.Bryant)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:48:51Z","last_updated_date":"2024-09-16T14:48:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-issue-list-proposals-solutions-cbahans-estahl-amjanson-lang-jbryant_en.pdf"},
    {"id":"64864","name":" Presentation - Session 1: Mapping the landscape (S.Strasser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:50:13Z","last_updated_date":"2024-09-20T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-mapping-landscape-sstrasser_en.pdf"},
    {"id":"64865","name":"Presentation - CTR collaborate project: Setting the scene (M.Lunzer, M.Al)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:50:57Z","last_updated_date":"2024-09-20T22:22:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctr-collaborate-project-setting-scene-mlunzer-mal_en.pdf"},
    {"id":"64866","name":"Presentation - Break-out session 1: Harmonisation in the EU Clinical Trials Framework (C.Bahans)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:52:03Z","last_updated_date":"2024-09-16T14:52:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-break-out-session-1-harmonisation-eu-clinical-trials-framework-cbahans_en.pdf"},
    {"id":"64867","name":"Presentation - Break-out session 2: New strategies for streamlining clinical trial review and approval processes (M.Al)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:53:11Z","last_updated_date":"2024-09-16T14:53:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-break-out-session-2-new-strategies-streamlining-clinical-trial-review-approval-processes-mal_en.pdf"},
    {"id":"64868","name":"Presentation -  Break-out session 3: Fostering innovation in clinical trials (J.Bryant)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:54:20Z","last_updated_date":"2024-09-16T14:54:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-break-out-session-3-fostering-innovation-clinical-trials-jbryant_en.pdf"},
    {"id":"64869","name":"Presentation - Break-out session 4: Enhancing CTIS functionality and operational efficiency (S.Strasser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:55:26Z","last_updated_date":"2024-09-16T14:55:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-break-out-session-4-enhancing-ctis-functionality-operational-efficiency-sstrasser_en.pdf"},
    {"id":"64954","name":"Presentation - Quarterly System Demo - Q3 2024","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T09:33:06Z","last_updated_date":"2024-09-20T09:33:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quarterly-system-demo-q3-2024_en.pdf"},
    {"id":"65034","name":"Presentation - EMA Account Management – What’s new?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-09-25T13:23:00Z","last_updated_date":"2024-09-25T13:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-account-management-whats-new_en.pdf"},
    {"id":"65123","name":"Presentation - SPOR Data Governance Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T11:41:00Z","last_updated_date":"2024-10-03T11:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-data-governance-webinar_en.pdf-0"},
    {"id":"65132","name":"Presentation - Why pharmacogenomics is important for public health (M. Jesús Lamas, AEMPS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:33:00Z","last_updated_date":"2024-10-03T15:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-why-pharmacogenomics-important-public-health-m-jesus-lamas-aemps_en.pdf"},
    {"id":"65133","name":"Presentation - Current state of the art in pharmacogenomics - a regulatory perspective (M. Maliepaard, MEB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:35:00Z","last_updated_date":"2024-10-03T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-current-state-art-pharmacogenomics-regulatory-perspective-m-maliepaard-meb_en.pdf"},
    {"id":"65134","name":"Presentation - Overview of medicinal products with pharmacogenomics information in the SmPC (M. Gordillo-Marañón, AEMPS, UCL)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:38:00Z","last_updated_date":"2024-10-03T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-medicinal-products-pharmacogenomics-information-smpc-m-gordillo-maranon-aemps-ucl_en.pdf"},
    {"id":"65135","name":"Presentation - Pharmacogenetics implementation in Spain (A. Llerena, INUBE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:40:00Z","last_updated_date":"2024-10-03T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenetics-implementation-spain-llerena-inube_en.pdf"},
    {"id":"65136","name":"Presentation - Pharmacogenetics implementation in the UK (M. Pirmohamed, D. Weatherall, University of Liverpool)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:42:00Z","last_updated_date":"2024-10-08T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenetics-implementation-uk-m-pirmohamed-d-weatherall-university-liverpool_en.pdf"},
    {"id":"65137","name":"Presentation - Pharmacogenetic testing in Belgium (KCE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:44:00Z","last_updated_date":"2024-10-03T15:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenetic-testing-belgium-kce_en.pdf"},
    {"id":"65138","name":"Presentation - Pharmacogenomics implementation in Germany (C. Scholl, BfArM)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:47:00Z","last_updated_date":"2024-10-03T15:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenomics-implementation-germany-c-scholl-bfarm_en.pdf"},
    {"id":"65139","name":"Presentation - Pharmacogenomics, an update (M. Ingelman-Sundberg, Karolinska Institutet)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:49:00Z","last_updated_date":"2024-10-03T15:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenomics-update-m-ingelman-sundberg-karolinska-institutet_en.pdf"},
    {"id":"65140","name":"Presentation - Consideration on data sources and data types (S. Reisberg, University of Tartu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:51:00Z","last_updated_date":"2024-10-03T15:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-consideration-data-sources-data-types-s-reisberg-university-tartu_en.pdf"},
    {"id":"65141","name":"Presentation - Pharmacogenomics in real-world data studies (D. Prieto-Alhambra, J. Xie, University of Oxford)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:54:00Z","last_updated_date":"2024-10-03T15:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacogenomics-real-world-data-studies-d-prieto-alhambra-j-xie-university-oxford_en.pdf"},
    {"id":"65142","name":"Presentation - HMA-EMA Catalogues of real-world data sources and studies (S. Simou, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T15:55:00Z","last_updated_date":"2024-10-03T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hma-ema-catalogues-real-world-data-sources-studies-s-simou-ema_en.pdf"},
    {"id":"65146","name":"Presentation - 3RsWP 2024 Workplan","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T17:06:04Z","last_updated_date":"2024-10-03T17:06:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-3rswp-2024-workplan_en.pdf"},
    {"id":"65156","name":"Presentation - Pilot for new Medicine Shortage Communications (MSC) to healthcare professionals ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T12:18:20Z","last_updated_date":"2024-10-04T12:18:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pilot-new-medicine-shortage-communications-msc-healthcare-professionals_en.pdf"},
    {"id":"65157","name":"Presentation - Monitoring VS EuropeanShortagesMonitoringPlatform (ESMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T12:21:24Z","last_updated_date":"2024-10-04T12:21:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-vs-europeanshortagesmonitoringplatform-esmp_en.pdf"},
    {"id":"65158","name":"Presentation - Medical device expert panels –ongoing pilot projects","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T12:23:13Z","last_updated_date":"2024-10-04T12:23:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-device-expert-panels-ongoing-pilot-projects_en.pdf"},
    {"id":"65159","name":"Presentation - Regulatory/HTA interface under the HTA Regulation (HTAR) – Update on implementation activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T12:24:38Z","last_updated_date":"2024-10-04T12:24:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-hta-interface-under-hta-regulation-htar-update-implementation-activities_en.pdf"},
    {"id":"65184","name":"Presentation - SPOR and xEVMPD Stakeholder Engagement Webinars : Referentials Management Service (RMS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T16:51:26Z","last_updated_date":"2024-10-04T16:51:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-xevmpd-stakeholder-engagement-webinars-referentials-management-service-rms_en.pdf"},
    {"id":"65230","name":"Presentation - SPOR and xEVMPD Stakeholder Engagement Webinars : Substance Management Service (SMS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-08T11:19:38Z","last_updated_date":"2024-10-08T11:19:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-xevmpd-stakeholder-engagement-webinars-substance-management-service-sms_en.pdf"},
    {"id":"65231","name":"Presentation - Product Management Service (XEVMPD) for marketing authorisation holders (M. F. Gomez, V. Baker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-08T11:00:00Z","last_updated_date":"2024-10-08T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-xevmpd-marketing-authorisation-holders-m-f-gomez-v-baker_en.pdf"},
    {"id":"65236","name":"Presentation - The ISG Focus Group on Regulatory Science Research Translation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-08T11:56:33Z","last_updated_date":"2024-10-08T11:56:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-isg-focus-group-regulatory-science-research-translation_en.pdf"},
    {"id":"65237","name":"Presentation - Organisation Management Service (OMS) Webinar","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-08T12:26:00Z","last_updated_date":"2024-10-08T12:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-organisation-management-service-oms-webinar_en.pdf-0"},
    {"id":"65260","name":"Presentation - Product Management Service (XEVMPD) for Sponsors","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-09T16:40:07Z","last_updated_date":"2024-10-09T16:40:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-xevmpd-sponsors_en.pdf"},
    {"id":"65291","name":"Presentation - Joint HMA/EMA multi-stakeholder workshop on submission predictability (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-15T09:30:00Z","last_updated_date":"2024-10-15T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-hma-ema-multi-stakeholder-workshop-submission-predictability-ema_en.pdf"},
    {"id":"65292","name":"Presentation - Joint HMA/EMA multi-stakeholder workshop on submission predictability (Member States)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-15T09:31:00Z","last_updated_date":"2024-10-15T09:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-hma-ema-multi-stakeholder-workshop-submission-predictability-member-states_en.pdf"},
    {"id":"65293","name":"Presentation - Update on Rapporteur appointments (A. Ganan Jimenez, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-15T09:33:00Z","last_updated_date":"2024-10-15T09:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-rapporteur-appointments-ganan-jimenez-ema_en.pdf"},
    {"id":"65294","name":"Presentation - Industry representatives’ viewpoints on submission predictability (P. Franco, EuropaBio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-15T09:35:00Z","last_updated_date":"2024-10-15T09:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-representatives-viewpoints-submission-predictability-p-franco-europabio_en.pdf"},
    {"id":"65295","name":"Presentation - Panel discussion","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-15T09:36:00Z","last_updated_date":"2024-10-15T09:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-panel-discussion_en.pdf"},
    {"id":"65337","name":"Presentation - Product Management Service (PMS) Product UI training (access and navigation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T08:43:21Z","last_updated_date":"2024-10-23T15:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-pms-product-ui-training-access-navigation_en.pdf-0"},
    {"id":"65338","name":"Presentation - Training session on Human variations web-based electronic Application Form (eAF) for non-CAPs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T09:16:20Z","last_updated_date":"2025-03-10T16:54:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-training-session-human-variations-web-based-electronic-application-form-eaf-non-caps_en.pdf"},
    {"id":"65374","name":"Presentation - Session 1 - 2024 Veterinary big data strategy update (P. Damien Lynn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-23T00:00:00Z","last_updated_date":"2024-10-23T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-2024-veterinary-big-data-strategy-update-p-damien-lynn_en.pdf"},
    {"id":"65375","name":"Presentation - Session 1 - Big data in veterinary medicines regulation (E. Pacholewicz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-23T11:11:01Z","last_updated_date":"2024-10-23T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-big-data-veterinary-medicines-regulation-e-pacholewicz_en.pdf"},
    {"id":"65376","name":"Presentation - Session 2 - AI in EMA and vet domain (L. Pinheiro and L. Romero)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-23T11:11:01Z","last_updated_date":"2024-10-23T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-ai-ema-vet-domain-l-pinheiro-l-romero_en.pdf"},
    {"id":"65377","name":"Presentation - Session 2 - AI tools in the regulatory domain (E. Lucas Roldan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-23T11:11:01Z","last_updated_date":"2024-10-23T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-ai-tools-regulatory-domain-e-lucas-roldan_en.pdf"},
    {"id":"65378","name":"Presentation - Session 2 - Industry Use cases AI in vet medicines life cycle (C. Stirling)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-23T11:11:01Z","last_updated_date":"2024-10-23T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-industry-use-cases-ai-vet-medicines-life-cycle-c-stirling_en.pdf"},
    {"id":"65385","name":"Presentation - Session 1 - ACT EU update the journey so far (Pioppo, Laura)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-act-eu-update-journey-so-far-pioppo-laura_en.pdf"},
    {"id":"65386","name":"Presentation - Session 1 - Consolidated advice on clinical trials (Al, Monique)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T00:00:00Z","last_updated_date":"2024-10-24T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-consolidated-advice-clinical-trials-al-monique_en.pdf"},
    {"id":"65387","name":"Presentation - Session 1 - Consolidated advice on clinical trials (Oliveira, Laura)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T10:00:00Z","last_updated_date":"2024-10-24T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-consolidated-advice-clinical-trials-oliveira-laura_en.pdf"}    {"id":"65388","name":"Presentation - Session 1 - New CTIS transparency rules - from policy to reality (Dehn, Christine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T10:00:00Z","last_updated_date":"2024-10-24T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-new-ctis-transparency-rules-policy-reality-dehn-christine_en.pdf"},
    {"id":"65389","name":"Presentation - Session 1 - New CTIS transparency rules - from policy to reality (Scotti, Francesca)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-new-ctis-transparency-rules-policy-reality-scotti-francesca_en.pdf"},
    {"id":"65390","name":"Presentation - Session 1 - The MSP AG and stakeholders' feedback (Lacombe, Denis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T00:00:00Z","last_updated_date":"2024-10-24T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-msp-ag-stakeholders-feedback-lacombe-denis_en.pdf"},
    {"id":"65391","name":"Presentation - Session 1 - The MSP AG and stakeholders' feedback (EHA) (El-Galaly, Tarec)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-msp-ag-stakeholders-feedback-eha-el-galaly-tarec_en.pdf"},
    {"id":"65392","name":"Presentation - Session 1 - The MSP Advisory Group and stakeholders' feedback (EURORDIS) (Wheeler, Russell)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-msp-advisory-group-stakeholders-feedback-eurordis-wheeler-russell_en.pdf"},
    {"id":"65393","name":"Presentation - Session 1 - The MSP Advisory Group and stakeholders' feedback (EFPIA) (Leyens, Lada)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-msp-advisory-group-stakeholders-feedback-efpia-leyens-lada_en.pdf"},
    {"id":"65394","name":"Presentation - Session 1 - The MSP Advisory Group and stakeholders' feedback (KWF) (Hovels, Anke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-msp-advisory-group-stakeholders-feedback-kwf-hovels-anke_en.pdf"},
    {"id":"65395","name":"Presentation - Session 2 - What do the numbers tell us (Abdelall, Linda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-what-do-numbers-tell-us-abdelall-linda_en.pdf"},
    {"id":"65396","name":"Presentation - Session 2 - What do the numbers tell us (Nedog, Katarina)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-what-do-numbers-tell-us-nedog-katarina_en.pdf"},
    {"id":"65397","name":"Presentation - Session 2 - Exploring the dynamics of partner collaboration with ACT EU (Zanoletty, Ana)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-24T11:11:01Z","last_updated_date":"2024-11-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-exploring-dynamics-partner-collaboration-act-eu-zanoletty-ana_en.pdf"},
    {"id":"65398","name":"Presentation - Session 2 - CTR Collaborate and CTCG action on patient involvement (Lunzer, Marianne, Al, Monique)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-11-22T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-ctr-collaborate-ctcg-action-patient-involvement-lunzer-marianne-al-monique_en.pdf"},
    {"id":"65399","name":"Presentation - Session 2 - Clinical Trials Coordination and Advisory Group and MedEthicsEU (Abdelall, Linda)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-clinical-trials-coordination-advisory-group-medethicseu-abdelall-linda_en.pdf"},
    {"id":"65400","name":"Presentation - Session 2 - Clinical Trials Coordination and Advisory Group and MedEthicsEU (Al, Monique)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-clinical-trials-coordination-advisory-group-medethicseu-al-monique_en.pdf"},
    {"id":"65401","name":"Presentation - Session 2 - EU COMBINE project overview (Clamou, Isabelle, Tkachenko, Olga)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-eu-combine-project-overview-clamou-isabelle-tkachenko-olga_en.pdf"},
    {"id":"65402","name":"Presentation - Session 2 - Panel discussion (IHI) (Nathalie Seigneuret)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-discussion-ihi-nathalie-seigneuret_en.pdf"},
    {"id":"65403","name":"Presentation - Session 2 - Panel discussion (ECRIN) (Jacques Demotes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-discussion-ecrin-jacques-demotes_en.pdf"},
    {"id":"65404","name":"Presentation - Session 2 - Panel discussion (ACRO) (Leona Fitzgerald)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-panel-discussion-acro-leona-fitzgerald_en.pdf"},
    {"id":"65405","name":"Presentation - Session 3 - The EU's Political drive for clinical trials (Nimmesgern, Elmar, Clamou, Isabelle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-eus-political-drive-clinical-trials-nimmesgern-elmar-clamou-isabelle_en.pdf"},
    {"id":"65406","name":"Presentation - Session 3 - Addressing stakeholder challenges - what’s next (Marianne Lunzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-addressing-stakeholder-challenges-whats-next-marianne-lunzer_en.pdf"},
    {"id":"65407","name":"Presentation - Session 3 - Panel discusion (TEDDY) (Donato Bonifazi) ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-discusion-teddy-donato-bonifazi_en.pdf"},
    {"id":"65408","name":"Presentation - Session 3 - Panel discusion (EHA) (Martin Kaiser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-discusion-eha-martin-kaiser_en.pdf"},
    {"id":"65409","name":"Presentation - Session 3 - Panel discussion (CPE) (Juan Ventura)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-discussion-cpe-juan-ventura_en.pdf"},
    {"id":"65410","name":"Presentation - Session 3 - Panel discussion (EUCOPE) (Sean Byrne)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-panel-discussion-eucope-sean-byrne_en.pdf"},
    {"id":"65411","name":"Presentation - Session 3 - WHO global guidance for more effective and equitable clinical trials (Moorthy, Vasee)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:11:01Z","last_updated_date":"2024-10-24T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-who-global-guidance-more-effective-equitable-clinical-trials-moorthy-vasee_en.pdf"},
    {"id":"65415","name":"Presentation - Session 3 - Successfully embedding clinical research as part of healthcare (Tabernero, Josep)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:22:20Z","last_updated_date":"2024-10-24T11:22:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-successfully-embedding-clinical-research-part-healthcare-tabernero-josep_en.pdf"},
    {"id":"65416","name":"Presentation - Session 3 - Second panel discussion (UMC Utrecht) (Eduard van Beers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:26:03Z","last_updated_date":"2024-10-24T11:26:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-second-panel-discussion-umc-utrecht-eduard-van-beers_en.pdf"},
    {"id":"65417","name":"Presentation - Session 3 - Second panel discussion (CPE) (Juan Ventura)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:29:30Z","last_updated_date":"2024-10-24T11:29:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-second-panel-discussion-cpe-juan-ventura_en.pdf"},
    {"id":"65420","name":"Presentation - Session 3 -  Second panel discussion (ESOP) (Mirjam Crul)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T11:37:16Z","last_updated_date":"2024-10-24T11:37:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-second-panel-discussion-esop-mirjam-crul_en.pdf"},
    {"id":"65421","name":"Presentation - Session 3 - Second panel discussion (EuropaBio) (Maren Koban)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T12:03:36Z","last_updated_date":"2024-10-24T12:03:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-second-panel-discussion-europabio-maren-koban_en.pdf"},
    {"id":"65422","name":"Presentation - Session 3 - From the theory to the practice, how will we measure success (Van Wyk, Jacobus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T12:11:46Z","last_updated_date":"2024-10-24T12:11:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-theory-practice-how-will-we-measure-success-van-wyk-jacobus_en.pdf"},
    {"id":"65428","name":"Presentation - SPOR API (A. Idu, A. Sempere Sanchez) ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T15:00:00Z","last_updated_date":"2024-10-24T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-api-idu-sempere-sanchez_en.pdf"},
    {"id":"65429","name":"Presentation - Session 1 - Towards a dataspace on animal health and welfare (D. Teixeira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T15:09:00Z","last_updated_date":"2024-10-24T15:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-towards-dataspace-animal-health-welfare-d-teixeira_en.pdf"},
    {"id":"65440","name":"Presentation - SME info day - Session 1 Scientific Advice","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T11:26:39Z","last_updated_date":"2024-10-25T11:26:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-info-day-session-1-scientific-advice_en.pdf"},
    {"id":"65441","name":"Presentation - SME info day - Session 2 - Clinical trials in the EU","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T11:29:49Z","last_updated_date":"2024-10-25T11:29:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-info-day-session-2-clinical-trials-eu_en.pdf"},
    {"id":"65442","name":"Presentation - SME info day - Session 3 - Implementation of the new HTA regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T11:32:06Z","last_updated_date":"2024-10-25T11:32:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-info-day-session-3-implementation-new-hta-regulation_en.pdf"},
    {"id":"65443","name":"Presentation - SME info day - Session 3 - HTA CG Joint Clinical Assessment and PICO","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T11:33:55Z","last_updated_date":"2024-10-25T11:33:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-info-day-session-3-hta-cg-joint-clinical-assessment-pico_en.pdf"},
    {"id":"65444","name":"\tPresentation - SME info day - Session 4 - EMA activities on medical devices","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T11:37:34Z","last_updated_date":"2024-11-25T11:20:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-info-day-session-4-ema-activities-medical-devices_en.pdf"},
    {"id":"65445","name":"Presentation - SME info day - Session 5 - New fee regulation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T11:38:57Z","last_updated_date":"2024-10-25T11:38:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-info-day-session-5-new-fee-regulation_en.pdf"},
    {"id":"65446","name":"Presentation - SME info day - Session 6 - Improving the availability of medicines in the EU","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-25T11:40:04Z","last_updated_date":"2024-10-25T11:40:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-info-day-session-6-improving-availability-medicines-eu_en.pdf"},
    {"id":"65458","name":"Presentation - Informative webinar on PMS Product User Interface usage and key actions for Marketing Authorisation Holders (with demo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-28T17:05:00Z","last_updated_date":"2024-10-30T09:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-informative-webinar-pms-product-user-interface-usage-key-actions-marketing-authorisation-holders-demo_en.pdf"},
    {"id":"65479","name":"Presentation - Introduction : The ATMP regulation and the role of the CAT","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T14:48:20Z","last_updated_date":"2024-10-29T14:48:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-atmp-regulation-role-cat_en.pdf"},
    {"id":"65480","name":"Presentation - Patient involvement in the Committee for Advanced Therapies (CAT) (K. Breen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T14:53:05Z","last_updated_date":"2024-10-29T14:53:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-involvement-committee-advanced-therapies-cat-k-breen_en.pdf"},
    {"id":"65481","name":"Presentation - The contribution of CAT to the international development of ATMPs (P. Celis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T14:56:19Z","last_updated_date":"2024-10-29T14:56:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-contribution-cat-international-development-atmps-p-celis_en.pdf"},
    {"id":"65482","name":"Presentation - How did the field of ATMPs evolve over time: The perspectives from the former CAT Chairs (C. K. Schneider)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T14:57:38Z","last_updated_date":"2024-10-29T14:57:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-did-field-atmps-evolve-over-time-perspectives-former-cat-chairs-c-k-schneider_en.pdf"},
    {"id":"65483","name":"Presentation - How have the ATMPs evolved over time? (P. Salmikangas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T14:59:37Z","last_updated_date":"2024-10-29T14:59:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-have-atmps-evolved-over-time-p-salmikangas_en.pdf"},
    {"id":"65484","name":"Presentation - How did the field of ATMPs evolve over time: the perspectives from the former CAT chairs (M. Schuessler-Lenz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T15:01:56Z","last_updated_date":"2024-10-29T15:01:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-did-field-atmps-evolve-over-time-perspectives-former-cat-chairs-m-schuessler-lenz_en.pdf"},
    {"id":"65485","name":"Presentation - What challenges will arise from ATMPs under development? The academia viewpoint (L. Naldini)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T15:04:09Z","last_updated_date":"2024-10-29T15:04:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-challenges-will-arise-atmps-under-development-academia-viewpoint-l-naldini_en.pdf"},
    {"id":"65486","name":"Presentation - What challenges will arise from ATMPs under development? (S. Herzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T15:06:01Z","last_updated_date":"2024-10-29T15:06:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-challenges-will-arise-atmps-under-development-s-herzer_en.pdf"},
    {"id":"65487","name":"Presentation - IRDs: Investing in ATMPs to address a high unmet need - A patient and community perspective (A. Daly)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T15:07:35Z","last_updated_date":"2024-10-29T15:07:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-irds-investing-atmps-address-high-unmet-need-patient-community-perspective-daly_en.pdf"},
    {"id":"65488","name":"Presentation - ATMPs for the next 15 years (J. Awigena-Cook)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T15:09:46Z","last_updated_date":"2024-10-29T15:09:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-atmps-next-15-years-j-awigena-cook_en.pdf"},
    {"id":"65489","name":"Presentation - Key issues for ATMPs for RDs under development","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T15:11:15Z","last_updated_date":"2024-10-29T15:11:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-issues-atmps-rds-under-development_en.pdf"},
    {"id":"65490","name":"Presentation - Challenges in ATMP development: a product quality perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T15:12:57Z","last_updated_date":"2024-10-29T15:12:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-atmp-development-product-quality-perspective_en.pdf"},
    {"id":"65559","name":"Presentation - New fee regulation (H)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-07T11:17:37Z","last_updated_date":"2024-11-07T11:17:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-fee-regulation-h_en.pdf"},
    {"id":"65569","name":"Presentation - New fee Regulation (V)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-08T11:13:44Z","last_updated_date":"2024-11-08T11:13:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-fee-regulation-v_en.pdf"},
    {"id":"65581","name":"Presentation - eAF–Human Variation electronic Application Form (eAF) Training Session and Q&A Clinic for Industry stakeholders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-08T17:02:47Z","last_updated_date":"2025-03-10T17:05:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eaf-human-variation-electronic-application-form-eaf-training-session-qa-clinic-industry-stakeholders_en.pdf"},
    {"id":"65613","name":"Presentation - Training webinar on post-authorisation procedure management in IRIS for Marketing Authorisation Holders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-13T15:56:18Z","last_updated_date":"2024-12-03T09:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-training-webinar-post-authorisation-procedure-management-iris-marketing-authorisation-holders_en.pdf"},
    {"id":"65669","name":"Presentation - EMA - Health Canada collaboration: Review & publication of Clinical Data Packages (R. Popescu, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T11:48:53Z","last_updated_date":"2024-11-15T11:48:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-health-canada-collaboration-review-publication-clinical-data-packages-r-popescu-ema_en.pdf"},
    {"id":"65670","name":"Presentation - Publication of legacy clinical data (D. Fernández López, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T11:53:24Z","last_updated_date":"2024-11-15T11:53:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-publication-legacy-clinical-data-d-fernandez-lopez-ema_en.pdf"},
    {"id":"65671","name":"Presentation - Clinical data publication overview process and timelines (S. Garrido-Lestache, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T11:55:13Z","last_updated_date":"2024-11-15T11:55:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-data-publication-overview-process-timelines-s-garrido-lestache-ema_en.pdf"},
    {"id":"65672","name":"Presentation - Clinical data publication: revised scope and updated toolkit (K. Quigley, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T11:57:13Z","last_updated_date":"2024-11-15T11:57:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-data-publication-revised-scope-updated-toolkit-k-quigley-ema_en.pdf"},
    {"id":"65786","name":"Presentation - ESMP training session on routine shortage reporting for marketing authorisation holders of centrally authorised products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T11:56:53Z","last_updated_date":"2024-11-25T11:56:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esmp-training-session-routine-shortage-reporting-marketing-authorisation-holders-centrally-authorised-products_en.pdf"},
    {"id":"65787","name":"Presentation - Patient and HCP engagement highlights 2024 (M. Carr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T12:02:41Z","last_updated_date":"2024-11-25T12:02:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-hcp-engagement-highlights-2024-m-carr_en.pdf"},
    {"id":"65789","name":"Presentation - Multi-stakeholder platform meeting: Accelerating clinical trials in the EU (ACT EU) initiative (A. Zanoletty, D. Lacombe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:09:14Z","last_updated_date":"2024-11-25T13:09:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multi-stakeholder-platform-meeting-accelerating-clinical-trials-eu-act-eu-initiative-zanoletty-d-lacombe_en.pdf"},
    {"id":"65790","name":"Presentation - The new version of the public portal (F. Scotti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:10:28Z","last_updated_date":"2024-11-25T13:10:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-version-public-portal-f-scotti_en.pdf"},
    {"id":"65791","name":"Presentation - Clinical data publication - next steps (K. Quigley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:11:26Z","last_updated_date":"2024-11-25T13:11:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-data-publication-next-steps-k-quigley_en.pdf"},
    {"id":"65792","name":"Presentation - Overview of EMA activities in the area of medical devices (S. da Rocha Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:12:26Z","last_updated_date":"2024-11-25T13:12:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-ema-activities-area-medical-devices-s-da-rocha-dias_en.pdf"},
    {"id":"65793","name":"Presentation - Expert panels orphan device pilot (M. Vogl)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:16:36Z","last_updated_date":"2024-11-25T13:16:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-expert-panels-orphan-device-pilot-m-vogl_en.pdf"},
    {"id":"65794","name":"Presentation - Big Data Steering Group ongoing activities (F. Domergue, D. Umuhire)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:17:40Z","last_updated_date":"2024-11-25T13:17:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-data-steering-group-ongoing-activities-f-domergue-d-umuhire_en.pdf"},
    {"id":"65795","name":"Presentation - Patient experience data - Reflection paper and upcoming consultation (R. Gonzalez-Quevedo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:19:14Z","last_updated_date":"2024-11-25T13:19:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-experience-data-reflection-paper-upcoming-consultation-r-gonzalez-quevedo_en.pdf"},
    {"id":"65796","name":"Presentation - Multi-annual AI Workplan - Update (L. Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:24:30Z","last_updated_date":"2024-11-25T13:24:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multi-annual-ai-workplan-update-l-pinheiro_en.pdf"},
    {"id":"65797","name":"Presentation - Update on the publication of version 2 of the Union list of critical medicines (ULCM) (J. Ferreira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:26:36Z","last_updated_date":"2024-11-25T13:26:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-publication-version-2-union-list-critical-medicines-ulcm-j-ferreira_en.pdf"},
    {"id":"65798","name":"Presentation - Update on the new Medicine Shortage Communication (MSC) process and template (J. Ferreira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:27:32Z","last_updated_date":"2024-11-25T13:27:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-new-medicine-shortage-communication-msc-process-template-j-ferreira_en.pdf"},
    {"id":"65799","name":"Presentation - Feedback on SPOC Working Party activities on GLP-1 receptor agonists and insulin products shortage management (K. Kruttwig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T13:29:27Z","last_updated_date":"2024-11-25T13:29:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-spoc-working-party-activities-glp-1-receptor-agonists-insulin-products-shortage-management-k-kruttwig_en.pdf"},
    {"id":"65801","name":"Presentation - Communication at EMA (M. Benstetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T14:04:41Z","last_updated_date":"2024-11-25T14:04:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communication-ema-m-benstetter_en.pdf"},
    {"id":"65802","name":"Presentation - Communicating about shortages (G. Gabrielli, L. Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T14:06:06Z","last_updated_date":"2024-11-25T14:06:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communicating-about-shortages-g-gabrielli-l-herold_en.pdf"},
    {"id":"65803","name":"Presentation - Key user group for the EMA corporate website (I. Matos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T14:07:11Z","last_updated_date":"2024-11-25T14:07:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-user-group-ema-corporate-website-i-matos_en.pdf"},
    {"id":"65804","name":"Presentation - Key dates 2025 (J. Garcia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T14:08:36Z","last_updated_date":"2024-11-25T14:08:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-key-dates-2025-j-garcia_en.pdf"},
    {"id":"65808","name":"Presentation - Transitional measures to implement the new variation regulation (T. Girard, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T17:02:11Z","last_updated_date":"2024-11-25T17:02:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transitional-measures-implement-new-variation-regulation-t-girard-ema_en.pdf"},
    {"id":"65809","name":"Presentation - ePI Pilots readout, learnings and next steps (J. Garcia; E. Scanlan, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T17:03:18Z","last_updated_date":"2024-11-25T17:03:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-epi-pilots-readout-learnings-next-steps-j-garcia-e-scanlan-ema_en.pdf"},
    {"id":"65810","name":"Presentation - Focus group on cancer medicines pathfinder regulatory interactions (F.Pignatti, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T17:05:17Z","last_updated_date":"2024-11-25T17:05:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-cancer-medicines-pathfinder-regulatory-interactions-fpignatti-ema_en.pdf"},
    {"id":"65811","name":"Presentation - Ongoing initiatives on the centralised procedure (F. Day, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T17:07:00Z","last_updated_date":"2024-11-25T17:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ongoing-initiatives-centralised-procedure-f-day-ema_en.pdf"},
    {"id":"65812","name":"Presentation - Clinical Study Data Pilot (E. Psarelli, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T17:08:45Z","last_updated_date":"2024-11-25T17:08:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-study-data-pilot-e-psarelli-ema_en.pdf"},
    {"id":"65813","name":"Presentation - Lifecycle management of combination products at post-authorisation (C.Bouygues, C.Vicenzi, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T17:09:41Z","last_updated_date":"2024-11-25T17:09:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lifecycle-management-combination-products-post-authorisation-cbouygues-cvicenzi-ema_en.pdf"},
    {"id":"65814","name":"Presentation - Clinical Data Publication - next steps consultation (K.Quigley, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-25T17:11:56Z","last_updated_date":"2024-11-25T17:11:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-data-publication-next-steps-consultation-kquigley-ema_en.pdf"},
    {"id":"65826","name":"Presentation - Monitoring VS - European Shortages Monitoring Platform (ESMP) (S. Zastavnik, I. Chicharo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T10:30:38Z","last_updated_date":"2024-11-27T10:30:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-vs-european-shortages-monitoring-platform-esmp-s-zastavnik-i-chicharo_en.pdf"},
    {"id":"65827","name":"Presentation - Regulatory/HTA interface under the HTA Regulation (HTAR) – Update on implementation activities (M. Berntgen, J. Ferreira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T10:36:17Z","last_updated_date":"2024-11-27T10:36:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-hta-interface-under-hta-regulation-htar-update-implementation-activities-m-berntgen-j-ferreira_en.pdf"},
    {"id":"65828","name":"Presentation - Draft EMANS to 2028 and plans for stakeholder engagement (M. Carr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T10:46:14Z","last_updated_date":"2024-11-27T10:46:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-draft-emans-2028-plans-stakeholder-engagement-m-carr_en.pdf"},
    {"id":"65830","name":"Presentation - ACT EU workplan 2025/2026 – status update and feedback from the MSP AG","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T10:53:31Z","last_updated_date":"2024-11-27T10:53:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-workplan-2025-2026-status-update-feedback-msp-ag_en.pdf"},
    {"id":"65831","name":"Presentation - Update on Agile governance key dates and Subject Matter Experts status (T. Äijö)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T10:55:38Z","last_updated_date":"2024-11-27T10:55:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-agile-governance-key-dates-subject-matter-experts-status-t-aijo_en.pdf"},
    {"id":"65837","name":"Presentation - Introducing the european platform for regulatory science research (L. Barbier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T15:05:50Z","last_updated_date":"2024-11-27T15:05:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introducing-european-platform-regulatory-science-research-l-barbier_en.pdf"},
    {"id":"65838","name":"Presentation - Bold collaborations. Transforming Health. (N. Blomberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T15:15:15Z","last_updated_date":"2024-11-27T15:15:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bold-collaborations-transforming-health-n-blomberg_en.pdf"},
    {"id":"65839","name":"Presentation - Funding programmes and regulatory science research (T. Dylag)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T15:37:28Z","last_updated_date":"2024-11-27T15:37:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-funding-programmes-regulatory-science-research-t-dylag_en.pdf"},
    {"id":"65843","name":"Presentation - Regulatory science research lifecycle – a strategic approach (R. Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T15:59:58Z","last_updated_date":"2024-11-27T15:59:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-science-research-lifecycle-strategic-approach-r-herold_en.pdf"},
    {"id":"65844","name":"Presentation - The regulatory science research needs 2024 update (P. Moscariello)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T16:05:34Z","last_updated_date":"2024-11-27T16:05:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-science-research-needs-2024-update-p-moscariello_en.pdf"},
    {"id":"65845","name":"Presentation - Evolution of regulatory science in the Netherlands (M. Pasmooij)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-27T16:07:23Z","last_updated_date":"2024-11-27T16:07:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evolution-regulatory-science-netherlands-m-pasmooij_en.pdf"},
    {"id":"65864","name":"Presentation - Introduction to shortages topic (M. Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-11-28T13:02:38Z","last_updated_date":"2024-11-28T13:02:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-shortages-topic-m-dias_en.pdf"},
    {"id":"65897","name":"Presentation - The landscape for ATMPs in Europe 15 years after the initial introduction of the Regulation (K.Breen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:34:18Z","last_updated_date":"2024-12-03T09:34:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-landscape-atmps-europe-15-years-after-initial-introduction-regulation-kbreen-ema_en.pdf"},
    {"id":"65898","name":"Presentation - survey to gather developers' view on challenges and opportunities in ATMP development  (M.Di Marzo, AIFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:37:25Z","last_updated_date":"2024-12-03T09:37:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-survey-gather-developers-view-challenges-opportunities-atmp-development-mdi-marzo-aifa_en.pdf"},
    {"id":"65899","name":"Presentation - Journey of ATMPs from early development to access in EU (F.Locatelli, Bambino Gesu Childrens Hospital)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:38:07Z","last_updated_date":"2024-12-03T09:38:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-journey-atmps-early-development-access-eu-flocatelli-bambino-gesu-childrens-hospital_en.pdf"},
    {"id":"65900","name":"Presentation - (Regulatory) Challenges in the development of a CRISPR/Cas9 edited tacrolimus-resistant regulatory T cell product (L.Amini, BeCAT Therapies)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:39:36Z","last_updated_date":"2024-12-03T09:39:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-challenges-development-crispr-cas9-edited-tacrolimus-resistant-regulatory-t-cell-product-lamini-becat-therapies_en.pdf"}    {"id":"65901","name":"Presentation - The journey of ATMPs from early development to access in EU: challenges and opportunitiesSME perspective (A. Natz, EUCOPE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:40:32Z","last_updated_date":"2024-12-03T09:40:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-journey-atmps-early-development-access-eu-challenges-opportunitiessme-perspective-natz-eucope_en.pdf"},
    {"id":"65902","name":"Presentation - Translating Innovation into Access for ATMPs - Industry Perspective (M.Cattani, Farmindustria)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:41:12Z","last_updated_date":"2024-12-03T09:41:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-translating-innovation-access-atmps-industry-perspective-mcattani-farmindustria_en.pdf"},
    {"id":"65903","name":"Presentation - EMA support to innovation - Translating innovation into access for ATMPs (V.Cordo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:42:14Z","last_updated_date":"2024-12-03T09:42:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-support-innovation-translating-innovation-access-atmps-vcordo-ema_en.pdf"},
    {"id":"65904","name":"Presentation - National Competent Authorities support to innovation - Translating innovationi nto access for ATMPs (E.Agricola, AIFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:43:31Z","last_updated_date":"2024-12-03T09:43:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-national-competent-authorities-support-innovation-translating-innovationi-nto-access-atmps-eagricola-aifa_en.pdf"},
    {"id":"65905","name":"Presentation - HTA Regulation - Joint scientific consultations and joint clinical assessment (P.Rivetti di Val Cervo, AIFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:44:23Z","last_updated_date":"2024-12-03T09:44:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hta-regulation-joint-scientific-consultations-joint-clinical-assessment-privetti-di-val-cervo-aifa_en.pdf"},
    {"id":"65906","name":"Presentation - EU4Health Programme (G.Simone, HaDEA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:45:14Z","last_updated_date":"2024-12-03T09:45:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu4health-programme-gsimone-hadea_en.pdf"},
    {"id":"65907","name":"Presentation - Horizon Europe funding programme - ATMPs (A-P. Papageorgiou, DG Research and Innovation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:46:22Z","last_updated_date":"2024-12-03T09:46:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-horizon-europe-funding-programme-atmps-p-papageorgiou-dg-research-innovation_en.pdf"},
    {"id":"65908","name":"Presentation - Strenghtening the European innovation ecosystem (T.Humphreys)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:47:19Z","last_updated_date":"2024-12-03T09:47:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strenghtening-european-innovation-ecosystem-thumphreys_en.pdf"},
    {"id":"65909","name":"Presentation - The GMO framework (C.Beuneu, FAMHP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:54:39Z","last_updated_date":"2024-12-03T09:54:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gmo-framework-cbeuneu-famhp_en.pdf"},
    {"id":"65910","name":"Presentation - Combined developments CTR, MDR, IVDR (I.Reischl, BASG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:55:34Z","last_updated_date":"2024-12-03T09:55:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-combined-developments-ctr-mdr-ivdr-ireischl-basg_en.pdf"},
    {"id":"65911","name":"Presentation - Hospital Exemption - Non repetitive use of Advanced Therapy Medicines (S.Petraglia, AIFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:56:18Z","last_updated_date":"2024-12-03T09:56:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hospital-exemption-non-repetitive-use-advanced-therapy-medicines-spetraglia-aifa_en.pdf"},
    {"id":"65912","name":"Presentation - Case studies of academic development of ATMP: ARI0001 and ARI0002h (G.Calvo, Hospital Clinic Barcelona)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:57:06Z","last_updated_date":"2024-12-03T09:57:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-studies-academic-development-atmp-ari0001-ari0002h-gcalvo-hospital-clinic-barcelona_en.pdf"},
    {"id":"65924","name":"Presentation - Case study: Fondazione Telethon (C.Scotti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T14:45:50Z","last_updated_date":"2024-12-03T14:45:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-fondazione-telethon-cscotti_en.pdf"},
    {"id":"65925","name":"Presentation - Case study: Holoclar (M.Latella, Holostem)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T14:47:03Z","last_updated_date":"2024-12-03T14:47:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-holoclar-mlatella-holostem_en.pdf"},
    {"id":"65927","name":"Presentation - Round Table discussion: Main factors affecting development and access to ATMPs in the EU","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T14:48:01Z","last_updated_date":"2024-12-03T14:48:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-round-table-discussion-main-factors-affecting-development-access-atmps-eu_en.pdf"},
    {"id":"65928","name":"Presentation - Round Table discussion: Academia no-profit perspective (G.Calvo, Hospital Clinic de Barcelona)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T14:50:00Z","last_updated_date":"2024-12-03T14:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-round-table-discussion-academia-no-profit-perspective-gcalvo-hospital-clinic-de-barcelona_en.pdf"},
    {"id":"65929","name":"Presentation - Round Table discussion: Academia no-profit perspective (A.Biondi, University of Milan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T14:50:59Z","last_updated_date":"2024-12-03T14:50:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-round-table-discussion-academia-no-profit-perspective-abiondi-university-milan_en.pdf"},
    {"id":"65930","name":"Presentation - Round Table discussion: Academia no-profit perspective (A.Aiuti, San Raffaele Telethon Institute for Gene Therapy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T14:51:39Z","last_updated_date":"2024-12-03T14:51:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-round-table-discussion-academia-no-profit-perspective-aaiuti-san-raffaele-telethon-institute-gene-therapy_en.pdf"},
    {"id":"65931","name":"Presentation - Round Table discussion: Industry perspective (R.Ena, Federchimica Assobiotec)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T14:52:41Z","last_updated_date":"2024-12-03T14:52:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-round-table-discussion-industry-perspective-rena-federchimica-assobiotec_en.pdf"},
    {"id":"65957","name":"Presentation - DARWIN EU: How is RWE transforming regulatory decision making? (A. Segec) ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T10:35:08Z","last_updated_date":"2024-12-05T10:35:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-darwin-eu-how-rwe-transforming-regulatory-decision-making-segec_en.pdf"},
    {"id":"65958","name":"Presentation - Agreed approach post section 6 pilot for PSUSA ( M. Escudeiro Dos Santos, B. Pelle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T10:38:13Z","last_updated_date":"2024-12-05T10:38:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agreed-approach-post-section-6-pilot-psusa-m-escudeiro-dos-santos-b-pelle_en.pdf"},
    {"id":"65959","name":"Presentation - An agency of the European Union PSUR frequencies for active substances with DLP 2025 based on a risk-based approach (M. López Fauqued)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T10:43:43Z","last_updated_date":"2024-12-05T10:43:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agency-european-union-psur-frequencies-active-substances-dlp-2025-based-risk-based-approach-m-lopez-fauqued_en.pdf"},
    {"id":"65960","name":"Presentation - Revision of Guideline on Risk assessment of Medicinal Products on Human Reproduction and Lactation: from Data to Labelling (D. Duarte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T10:45:29Z","last_updated_date":"2024-12-05T10:45:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revision-guideline-risk-assessment-medicinal-products-human-reproduction-lactation-data-labelling-d-duarte_en.pdf"},
    {"id":"65962","name":"Presentation - Update on Good Pharmacovigilance Practices (EU-GVP) (P. Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T10:46:57Z","last_updated_date":"2024-12-05T10:46:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-good-pharmacovigilance-practices-eu-gvp-p-bahri_en.pdf"},
    {"id":"65963","name":"Presentation - An agency of the European Union AI in pharmacovigilance –  EMA update ( J. Durand, L. Pinheiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T10:48:15Z","last_updated_date":"2024-12-05T10:48:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-agency-european-union-ai-pharmacovigilance-ema-update-j-durand-l-pinheiro_en.pdf"},
    {"id":"65964","name":"Presentation - EudraVigilance - Masking Policy of Personal Data (R. Postigo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T10:50:18Z","last_updated_date":"2024-12-05T10:50:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eudravigilance-masking-policy-personal-data-r-postigo_en.pdf"},
    {"id":"65965","name":"Presentation - Industry platform meeting -operation of EU pharmacovigilance (M. Rivera Vargas, P. Lopez Fernandez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T10:52:01Z","last_updated_date":"2024-12-05T10:52:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-platform-meeting-operation-eu-pharmacovigilance-m-rivera-vargas-p-lopez-fernandez_en.pdf"},
    {"id":"65974","name":"Presentation - Submission of Manufacturers, Manufacturing Business Operations and structured pack size data to Product Management Service (M. Gomez, V. di Paola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T13:51:52Z","last_updated_date":"2024-12-05T13:51:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-submission-manufacturers-manufacturing-business-operations-structured-pack-size-data-product-management-service-m-gomez-v-di-paola_en.pdf"},
    {"id":"65977","name":"Presentation - Volume of sales data submission: Refresher webinar for the veterinary industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T13:57:52Z","last_updated_date":"2024-12-05T13:57:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-volume-sales-data-submission-refresher-webinar-veterinary-industry_en.pdf"},
    {"id":"65978","name":"Presentation - Quality criteria for paediatric clinical trial sites - an Enpr-EMA initiative (R.Fernandez, P.Skovby)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T14:03:44Z","last_updated_date":"2024-12-05T14:03:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-criteria-paediatric-clinical-trial-sites-enpr-ema-initiative-rfernandez-pskovby_en.pdf"},
    {"id":"65979","name":"Presentation - Language discrimination and cross border access to paediatric clinical trials working group (B.Nafria)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T14:08:47Z","last_updated_date":"2024-12-05T14:08:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-language-discrimination-cross-border-access-paediatric-clinical-trials-working-group-bnafria_en.pdf"},
    {"id":"65980","name":"Presentation - Patient and Public Involvement (PPI) working group (S.Gaillard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T14:11:35Z","last_updated_date":"2024-12-05T14:11:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-public-involvement-ppi-working-group-sgaillard_en.pdf"},
    {"id":"65981","name":"Presentation - Enpr-EMA- Paediatric Research Nurse Working Group (P.Dicks)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T14:12:47Z","last_updated_date":"2024-12-05T14:12:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-paediatric-research-nurse-working-group-pdicks_en.pdf"},
    {"id":"65982","name":"Presentation - Enpr-EMA activities, proposals for 2024-2025 (P.Lepola, G.Egger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T14:13:44Z","last_updated_date":"2024-12-05T14:13:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-activities-proposals-2024-2025-plepola-gegger_en.pdf"},
    {"id":"65983","name":"Presentation - Further development of Enpr-EMA (P.Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T14:23:07Z","last_updated_date":"2024-12-05T14:23:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-further-development-enpr-ema-plepola_en.pdf"},
    {"id":"65984","name":"Presentation - The connect4children paediatric data harmonisation journey (R.Leary)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T14:24:42Z","last_updated_date":"2024-12-05T14:24:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-connect4children-paediatric-data-harmonisation-journey-rleary_en.pdf"},
    {"id":"65986","name":"Presentation - Reflections on the concept of a facilitation framework (D.Karres)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:26:47Z","last_updated_date":"2024-12-05T16:26:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reflections-concept-facilitation-framework-dkarres_en.pdf"},
    {"id":"65987","name":"Presentation - European PaediatricTranslational Research Infrastructure (EPTRI) (D.Bonifazi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:27:45Z","last_updated_date":"2024-12-05T16:27:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-paediatrictranslational-research-infrastructure-eptri-dbonifazi_en.pdf"},
    {"id":"65988","name":"Presentation - OrphaDev4Kids (M.Migdal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:29:14Z","last_updated_date":"2024-12-05T16:29:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-orphadev4kids-mmigdal_en.pdf"},
    {"id":"65989","name":"Presentation - Brief update: Reform of the EU pharmaceutical legislation (G. Egger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:40:14Z","last_updated_date":"2024-12-05T16:40:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-brief-update-reform-eu-pharmaceutical-legislation-g-egger_en.pdf"},
    {"id":"65990","name":"Presentation - The COMBINE project: Interface between medicines and medicinal products (M. Lunzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:43:46Z","last_updated_date":"2024-12-05T16:43:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-combine-project-interface-between-medicines-medicinal-products-m-lunzer_en.pdf"},
    {"id":"65991","name":"Presentation - Update on CTR implementation, including new CTIS transparency rules (F. Scotti, L. Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:45:53Z","last_updated_date":"2024-12-05T16:45:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ctr-implementation-including-new-ctis-transparency-rules-f-scotti-l-pioppo_en.pdf"},
    {"id":"65992","name":"Presentation - 2.5 years of CTR and CTIS: Experiences from Academic Sponsor Institutions in the ITCC network (A. Elsinghorst)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:47:16Z","last_updated_date":"2024-12-05T16:47:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-25-years-ctr-ctis-experiences-academic-sponsor-institutions-itcc-network-elsinghorst_en.pdf"},
    {"id":"65993","name":"PresentatiMechanism of action PIPs: Relevant and expected in oncology (G. Vassal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:49:37Z","last_updated_date":"2024-12-05T16:49:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentatimechanism-action-pips-relevant-expected-oncology-g-vassal_en.pdf"},
    {"id":"65994","name":"Presentation - Non-oncological MoA based PIP – Initial Deliberations from the PDCO working group discussions (S. Scherer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:51:38Z","last_updated_date":"2024-12-05T16:51:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-oncological-moa-based-pip-initial-deliberations-pdco-working-group-discussions-s-scherer_en.pdf"},
    {"id":"65995","name":"Presentation - PDCO update for Enpr-EMA (S. Benchetrit)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:54:27Z","last_updated_date":"2024-12-05T16:54:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-update-enpr-ema-s-benchetrit_en.pdf"},
    {"id":"65996","name":"Presentation - Emerging ethics assessment challenges in paediatric clinical trials and revision of declaration of Helsinki - What will change? (M. A. Ribeiro)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:56:05Z","last_updated_date":"2024-12-05T16:56:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emerging-ethics-assessment-challenges-paediatric-clinical-trials-revision-declaration-helsinki-what-will-change-m-ribeiro_en.pdf"},
    {"id":"65997","name":"Presentation - Enpr-EMA Annual Report 2023-2024 (P. Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T16:58:46Z","last_updated_date":"2024-12-05T16:58:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-annual-report-2023-2024-p-lepola_en.pdf"},
    {"id":"65999","name":"Presentation - Quality criteria for paediatric clinical trial sites – an Enpr-EMA initiative (R. Fernandes, P. Skovby)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T17:00:05Z","last_updated_date":"2024-12-05T17:00:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-criteria-paediatric-clinical-trial-sites-enpr-ema-initiative-r-fernandes-p-skovby_en.pdf"},
    {"id":"66000","name":"Presentation - Language discrimination and cross border access to paediatric clinical trials - working group (B. Nafria)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T17:03:01Z","last_updated_date":"2024-12-05T17:03:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-language-discrimination-cross-border-access-paediatric-clinical-trials-working-group-b-nafria_en.pdf"},
    {"id":"66001","name":"Presentation - Conect4children (c4c) stichting - From IHI initiative to sustainable paediatric research infrastructure (M. Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T17:05:20Z","last_updated_date":"2024-12-05T17:05:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-conect4children-c4c-stichting-ihi-initiative-sustainable-paediatric-research-infrastructure-m-turner_en.pdf"},
    {"id":"66002","name":"Presentation - How can academia build capacity to optimise RWD collection in order to support health technology assessment in paediatrics (D. Umuhire, K. Pleuschke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T17:07:30Z","last_updated_date":"2024-12-05T17:07:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-can-academia-build-capacity-optimise-rwd-collection-order-support-health-technology-assessment-paediatrics-d-umuhire-k-pleuschke_en.pdf"},
    {"id":"66026","name":"Presentation - Portfolio and Technology Meetings (Enrico Tognana)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T15:53:11Z","last_updated_date":"2024-12-09T15:53:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-portfolio-technology-meetings-enrico-tognana_en.pdf"},
    {"id":"66027","name":"Presentation - Updates from EMA on scientific advice and PRIME (Iordanis Gravanis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T15:56:41Z","last_updated_date":"2024-12-09T15:56:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-ema-scientific-advice-prime-iordanis-gravanis_en.pdf"},
    {"id":"66029","name":"Presentation - Stepwise PIP (Chrissi Pallidis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T15:58:20Z","last_updated_date":"2024-12-09T15:58:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-stepwise-pip-chrissi-pallidis_en.pdf"},
    {"id":"66030","name":"Presentation - Focus group on use of RWD and generation of RWE (Patrice Verpillat)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T16:00:15Z","last_updated_date":"2024-12-09T16:00:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-use-rwd-generation-rwe-patrice-verpillat_en.pdf"},
    {"id":"66031","name":"Presentation - NFR impact on RnD processes (Tarita Toufexi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T16:01:43Z","last_updated_date":"2024-12-09T16:01:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-nfr-impact-rnd-processes-tarita-toufexi_en.pdf"},
    {"id":"66051","name":"Presentation - Cancer Medicines Forum: October 2024","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T13:38:12Z","last_updated_date":"2024-12-10T13:38:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cancer-medicines-forum-october-2024_en.pdf"},
    {"id":"66127","name":"Presentation - 5th year into our journey to data driven medicines regulation (P. Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T10:30:08Z","last_updated_date":"2024-12-16T10:30:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-5th-year-our-journey-data-driven-medicines-regulation-p-arlett_en.pdf"},
    {"id":"66128","name":"Presentation - Implementation of the HMA/EMA Big Data Task Force priority recommendations (H. Gardarsdottir)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T10:36:23Z","last_updated_date":"2024-12-16T10:36:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-hma-ema-big-data-task-force-priority-recommendations-h-gardarsdottir_en.pdf"},
    {"id":"66130","name":"Presentation - Implementation of the HMA/EMA Big Data Task Force priority recommendations (C. Thomassin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T10:44:17Z","last_updated_date":"2024-12-16T10:44:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-hma-ema-big-data-task-force-priority-recommendations-c-thomassin_en.pdf"},
    {"id":"66131","name":"Presentation - Reflections on EMA data workplan: learnings and priorities for the future (J. Wang-Silvanto)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T10:46:12Z","last_updated_date":"2024-12-16T10:46:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reflections-ema-data-workplan-learnings-priorities-future-j-wang-silvanto_en.pdf"},
    {"id":"66132","name":"Presentation - Veterinary big data strategy update (P. Damien Lynn, S. Bertulat)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T10:51:50Z","last_updated_date":"2024-12-16T10:51:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-big-data-strategy-update-p-damien-lynn-s-bertulat_en.pdf"},
    {"id":"66133","name":"Presentation - Analysis of real world data to support regulatory decision-making (P. McGettigan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:09:29Z","last_updated_date":"2024-12-16T11:09:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-analysis-real-world-data-support-regulatory-decision-making-p-mcgettigan_en.pdf"},
    {"id":"66134","name":"Presentation - Clinical study data pilot – interim results and learnings (F. Klinglmueller)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:13:18Z","last_updated_date":"2024-12-16T11:13:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-study-data-pilot-interim-results-learnings-f-klinglmueller_en.pdf"},
    {"id":"66136","name":"Presentation - International collaboration progress (M. Kampman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:17:02Z","last_updated_date":"2024-12-16T11:17:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-collaboration-progress-m-kampman_en.pdf"},
    {"id":"66137","name":"Presentation - RWD in the context of clinical trials – from pilots to practice (M. Zuidgeest)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:30:05Z","last_updated_date":"2024-12-16T11:30:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-rwd-context-clinical-trials-pilots-practice-m-zuidgeest_en.pdf"},
    {"id":"66138","name":"Presentation - Evidence generation to advance regulatory excellence, here and now (C. Thomassin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:32:48Z","last_updated_date":"2024-12-16T11:32:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evidence-generation-advance-regulatory-excellence-here-now-c-thomassin_en.pdf"},
    {"id":"66139","name":"Presentation - Multilingual and open Sourced - a new chapter for statistical programming in pharma (J-P. Perttola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:35:46Z","last_updated_date":"2024-12-16T11:35:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multilingual-open-sourced-new-chapter-statistical-programming-pharma-j-p-perttola_en.pdf"},
    {"id":"66140","name":"Presentation - Seeing the totality of evidence generation (B. Sepodes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:37:55Z","last_updated_date":"2024-12-16T11:37:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-seeing-totality-evidence-generation-b-sepodes_en.pdf"},
    {"id":"66141","name":"Presentation - Can social media data be used to support evidence generation? (E. Agricola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:47:37Z","last_updated_date":"2024-12-16T11:47:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-can-social-media-data-be-used-support-evidence-generation-e-agricola_en.pdf"},
    {"id":"66142","name":"Presentation - Harnessing the value of genomic data for evidence generation (J. Mwinyi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:49:18Z","last_updated_date":"2024-12-16T11:49:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-harnessing-value-genomic-data-evidence-generation-j-mwinyi_en.pdf"},
    {"id":"66143","name":"Presentation - Anchoring ethics at all steps (A. Cambon-Thomsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:51:18Z","last_updated_date":"2024-12-16T11:51:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-anchoring-ethics-all-steps-cambon-thomsen_en.pdf"},
    {"id":"66144","name":"Presentation - Evidence generation to advance regulatory excellence, preparing for tomorrow (L. Ishihara)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:55:30Z","last_updated_date":"2024-12-16T11:55:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evidence-generation-advance-regulatory-excellence-preparing-tomorrow-l-ishihara_en.pdf"},
    {"id":"66145","name":"Presentation - Leveraging data through technology & digitalisation (C. Torre)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T11:58:45Z","last_updated_date":"2024-12-16T11:58:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-leveraging-data-through-technology-digitalisation-c-torre_en.pdf"},
    {"id":"66146","name":"Presentation - Unlocking the potential of mHealth data for evidence generation (D. Umuhire)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T12:00:19Z","last_updated_date":"2024-12-16T12:00:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-unlocking-potential-mhealth-data-evidence-generation-d-umuhire_en.pdf"},
    {"id":"66147","name":"Presentation - Network data strategy: analysis of data and use of tools, knowledge and change management (K. Aasen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T12:07:46Z","last_updated_date":"2024-12-16T12:07:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-network-data-strategy-analysis-data-use-tools-knowledge-change-management-k-aasen_en.pdf"},
    {"id":"66148","name":"Presentation - Building a unified Network data strategy for operational excellence (G. Neuwirther)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T12:09:57Z","last_updated_date":"2024-12-16T12:09:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-building-unified-network-data-strategy-operational-excellence-g-neuwirther_en.pdf"},
    {"id":"66149","name":"Presentation - Network data strategy: data governance, data cataloguing and metadata management (H-J Bigalke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T12:12:37Z","last_updated_date":"2024-12-16T12:12:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-network-data-strategy-data-governance-data-cataloguing-metadata-management-h-j-bigalke_en.pdf"},
    {"id":"66150","name":"Presentation - Network data strategy: data quality management & interoperability (I. Chicharo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T12:32:46Z","last_updated_date":"2024-12-16T12:32:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-network-data-strategy-data-quality-management-interoperability-i-chicharo_en.pdf"},
    {"id":"66151","name":"Presentation - Network data strategy interplay with EHDS (D. Asturiol)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T12:34:57Z","last_updated_date":"2024-12-16T12:34:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-network-data-strategy-interplay-ehds-d-asturiol_en.pdf"},
    {"id":"66152","name":"Presentation - Ethical challenges for EMRN network strategy (A. Cambon-Thomsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T12:37:09Z","last_updated_date":"2024-12-16T12:37:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ethical-challenges-emrn-network-strategy-cambon-thomsen_en.pdf"},
    {"id":"66153","name":"Presentation - Value of data: what’s standards contribution? (C. Hay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T12:39:19Z","last_updated_date":"2024-12-16T12:39:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-value-data-whats-standards-contribution-c-hay_en.pdf"},
    {"id":"66176","name":"Presentation - System Demo Q4 2024","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-17T17:01:12Z","last_updated_date":"2024-12-17T17:01:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-system-demo-q4-2024_en.pdf"},
    {"id":"66184","name":"Presentation - Update on Opening Procedures at EMA to Non-EU authorities (OPEN) framework (M.Harvey, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2024-12-18T09:32:27Z","last_updated_date":"2024-12-18T09:32:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-opening-procedures-ema-non-eu-authorities-open-framework-mharvey-ema_en.pdf"},
    {"id":"66320","name":"Presentation - Information on Cross-agency One Health Task Force (A. Vidal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-01-15T15:09:01Z","last_updated_date":"2025-01-15T15:09:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-cross-agency-one-health-task-force-vidal_en.pdf-0"},
    {"id":"66321","name":"Presentation - Update on the publication of version 2 of the Union list of critical medicines (ULCM) (J. Ferreira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-01-15T15:10:39Z","last_updated_date":"2025-01-15T15:10:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-publication-version-2-union-list-critical-medicines-ulcm-j-ferreira_en.pdf-0"},
    {"id":"66356","name":"Presentation - Conditions for using certain antimicrobials under the 'cascade' (R. Breathnach)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-01-17T14:36:00Z","last_updated_date":"2025-01-17T14:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-conditions-using-certain-antimicrobials-under-cascade-r-breathnach_en.pdf"},
    {"id":"66401","name":"Presentation - SPOR & XEVMPD status update webinar - 22 January 2025","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-01-21T16:04:22Z","last_updated_date":"2025-04-23T10:12:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-xevmpd-status-update-webinar-22-january-2025_en.pdf"},
    {"id":"66524","name":"Presentation : Product Management Service (PMS) webinar on Product User Interface (PUI) edit functionalities for industry users (V. Lipucci Di Paola, M. Fernández Gómez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-01-30T11:17:56Z","last_updated_date":"2025-01-30T11:17:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-pms-webinar-product-user-interface-pui-edit-functionalities-industry-users-v-lipucci-di-paola-m-fernandez-gomez_en.pdf"},
    {"id":"66735","name":"Presentation - Regulation (EU) 2024/568: Questions and answers clinic for the Veterinary Industry stakeholders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T13:52:44Z","last_updated_date":"2025-02-13T13:52:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulation-eu-2024-568-questions-answers-clinic-veterinary-industry-stakeholders_en.pdf"},
    {"id":"66736","name":"Presentation - Regulation (EU) 2024/568: Questions and answers clinic for the Human Industry stakeholders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T13:57:18Z","last_updated_date":"2025-02-13T13:57:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulation-eu-2024-568-questions-answers-clinic-human-industry-stakeholders_en.pdf"},
    {"id":"66752","name":"Presentation - Training on human variations web-based electronic application form (eAF) functionalities for non-CAPs variations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T16:10:00Z","last_updated_date":"2025-02-13T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-training-human-variations-web-based-electronic-application-form-eaf-functionalities-non-caps-variations_en.pdf"},
    {"id":"66848","name":"Presentation - Introduction to EMANS to 2028 (Rui Santos Ivo and Michael Lenihan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-18T14:27:59Z","last_updated_date":"2025-02-18T14:27:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-emans-2028-rui-santos-ivo-michael-lenihan_en.pdf"},
    {"id":"66849","name":"Presentation - Accessibility (M. Berntgen) - Theme 1","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-18T14:34:05Z","last_updated_date":"2025-02-18T14:34:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accessibility-m-berntgen-theme-1_en.pdf"},
    {"id":"66850","name":"Presentation - Leveraging data, digitalisation and artificial intelligence (P. Arlett) - Theme 2","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-18T14:35:31Z","last_updated_date":"2025-02-18T14:35:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-leveraging-data-digitalisation-artificial-intelligence-p-arlett-theme-2_en.pdf"},
    {"id":"66851","name":"Presentation - Regulatory science, innovation and competitiveness (Y. Nuevo) - Theme 3","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-18T14:37:10Z","last_updated_date":"2025-02-18T14:37:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-science-innovation-competitiveness-y-nuevo-theme-3_en.pdf"},
    {"id":"66852","name":"Presentation - Antimicrobial resistance and other health threats (T. Haberer) - Theme 4","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-18T14:39:34Z","last_updated_date":"2025-02-18T14:39:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antimicrobial-resistance-other-health-threats-t-haberer-theme-4_en.pdf"},
    {"id":"66853","name":"Presentation - Availability and supply (M. Dias) - Theme 5","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-18T14:40:31Z","last_updated_date":"2025-02-18T14:40:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-availability-supply-m-dias-theme-5_en.pdf"},
    {"id":"66854","name":"Presentation - Sustainability of the European medicines agencies network (S. Kristjansson) - Theme 6","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-18T14:41:40Z","last_updated_date":"2025-02-18T14:41:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sustainability-european-medicines-agencies-network-s-kristjansson-theme-6_en.pdf"}    {"id":"66959","name":"Presentation - Session 1 - Data Governance (Lisbeth Bregnhoj)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:35:37Z","last_updated_date":"2025-02-25T15:35:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-data-governance-lisbeth-bregnhoj_en.pdf"},
    {"id":"66960","name":"Presentation - Session 1 - Sponsor: Main changes (Rebecca Stanbrook)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:36:55Z","last_updated_date":"2025-02-25T15:36:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-sponsor-main-changes-rebecca-stanbrook_en.pdf"},
    {"id":"66961","name":"Presentation - Session 2 - Essential Records for the Conduct of a Clinical Trial (Susanne Norskov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:37:47Z","last_updated_date":"2025-02-25T15:37:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-essential-records-conduct-clinical-trial-susanne-norskov_en.pdf"},
    {"id":"66962","name":"Presentation - Session 2 - Safety Management (Gabriele Schwarz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:39:07Z","last_updated_date":"2025-02-25T15:39:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-safety-management-gabriele-schwarz_en.pdf"},
    {"id":"66963","name":"Presentation - Opening remarks - ACT EU and GCP modernisation (Peter Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:23:22Z","last_updated_date":"2025-02-25T15:23:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-remarks-act-eu-gcp-modernisation-peter-arlett_en.pdf"},
    {"id":"66964","name":"Presentation - Session 1 - ICH guideline development and legal standing of ICH E6 in the EU (Lenita Lindstorm)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:25:40Z","last_updated_date":"2025-02-25T15:25:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-ich-guideline-development-legal-standing-ich-e6-eu-lenita-lindstorm_en.pdf"},
    {"id":"66965","name":"Presentation - Session 1 - Key Concepts of ICH E6 R3 (Gabriele Schwarz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:27:44Z","last_updated_date":"2025-02-25T15:27:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-key-concepts-ich-e6-r3-gabriele-schwarz_en.pdf"},
    {"id":"66966","name":"Presentation - Session 1 - The Overview of ICH E6 renovation (Peter Twomey)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:28:56Z","last_updated_date":"2025-02-25T15:28:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-overview-ich-e6-renovation-peter-twomey_en.pdf"},
    {"id":"66967","name":"Presentation - Session 2 - Informed consent of trial participants (Denis Lacombe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:29:48Z","last_updated_date":"2025-02-25T15:29:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-informed-consent-trial-participants-denis-lacombe_en.pdf"},
    {"id":"66968","name":"Presentation - Session 2 - Informed consent of trial participants (Francois Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:30:41Z","last_updated_date":"2025-02-25T15:30:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-informed-consent-trial-participants-francois-houyez_en.pdf"},
    {"id":"66969","name":"Presentation - Session 2 - Investigator Main Changes (Susanne Norskov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:31:24Z","last_updated_date":"2025-02-25T15:31:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-investigator-main-changes-susanne-norskov_en.pdf"},
    {"id":"66970","name":"Presentation - Session 2 - Informed consent considerations (Gabriele Schwarz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:32:21Z","last_updated_date":"2025-02-25T15:32:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-informed-consent-considerations-gabriele-schwarz_en.pdf"},
    {"id":"66971","name":"Presentation - Session 3 - Good clinical practice - ICH E6 (R3) - Annex II (Andrew Thomson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:33:40Z","last_updated_date":"2025-02-25T15:33:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-good-clinical-practice-ich-e6-r3-annex-ii-andrew-thomson_en.pdf"},
    {"id":"66972","name":"Presentation - Session 4 - Meaningful engagement of patients in the design and conduct of clinical trials​ (Francois Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T15:34:41Z","last_updated_date":"2025-02-25T15:34:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-meaningful-engagement-patients-design-conduct-clinical-trials-francois-houyez_en.pdf"},
    {"id":"66992","name":"Presentation - PMS Project Made Easy: Summary of activities and practical tips for SMEs​ (Marcos Fernandez Gomez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-26T14:07:08Z","last_updated_date":"2025-02-26T14:07:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pms-project-made-easy-summary-activities-practical-tips-smes-marcos-fernandez-gomez_en.pdf"},
    {"id":"67028","name":"Presentation - Webinar for veterinary marketing authorisation holders on an industry dedicated read-only API","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-27T17:31:23Z","last_updated_date":"2025-02-27T17:31:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-webinar-veterinary-marketing-authorisation-holders-industry-dedicated-read-only-api_en.pdf"},
    {"id":"67065","name":"Presentation - Training on human variations web-based electronic application form (eAF) functionalities for CAPs and non-CAPs variations","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T16:51:15Z","last_updated_date":"2025-02-28T16:51:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-training-human-variations-web-based-electronic-application-form-eaf-functionalities-caps-non-caps-variations_en.pdf"},
    {"id":"67066","name":"Presentation - CTIS Bitesize talk: Alternate IMPD-Q and new guidance AxMP","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-03T10:41:43Z","last_updated_date":"2025-03-03T10:41:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-bitesize-talk-alternate-impd-q-new-guidance-axmp_en.pdf"},
    {"id":"67067","name":"Presentation - CTIS Bitesize Talk: Implementation of revised CTIS transparency rules","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-03T10:46:33Z","last_updated_date":"2025-03-03T10:46:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-bitesize-talk-implementation-revised-ctis-transparency-rules_en.pdf"},
    {"id":"67068","name":"Presentation - CTIS Bitesize Talk: End of transition period and notifications including serious breaches","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-03T10:51:30Z","last_updated_date":"2026-05-19T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-bitesize-talk-end-transition-period-notifications-including-serious-breaches_en.pdf"},
    {"id":"67130","name":"Presentation - CTIS Bitesize Talk: Change of sponsor in CTIS 5 March 2025","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-07T10:35:44Z","last_updated_date":"2025-03-07T10:35:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-bitesize-talk-change-sponsor-ctis-5-march-2025_en.pdf"},
    {"id":"67175","name":"Presentation - Q&A Clinic: Non-CAPs in web-based eAF","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-10T17:01:00Z","last_updated_date":"2025-03-10T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qa-clinic-non-caps-web-based-eaf_en.pdf"},
    {"id":"67179","name":"Presentation - Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases: FDA guidance (Mirat Shah)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T11:16:23Z","last_updated_date":"2025-03-11T11:16:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-optimizing-dosage-human-prescription-drugs-biological-products-treatment-oncologic-diseases-fda-guidance-mirat-shah_en.pdf"},
    {"id":"67205","name":"Presentation - Authorised medicines and regulatory considerations by EMA (C. Gramiccioni)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:19:30Z","last_updated_date":"2025-03-11T16:19:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-authorised-medicines-regulatory-considerations-ema-c-gramiccioni_en.pdf"},
    {"id":"67206","name":"Presentation - Clinical considerations on the use of IgG in primary immunodeficiencies (replacement therapy) (M. P. Cicalese)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:22:32Z","last_updated_date":"2025-03-11T16:22:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-considerations-use-igg-primary-immunodeficiencies-replacement-therapy-m-p-cicalese_en.pdf"},
    {"id":"67207","name":"Presentation - Clinical considerations on the use of IgG in secondary immunodeficiencies (P. H Asdahl)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:24:14Z","last_updated_date":"2025-03-11T16:24:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-considerations-use-igg-secondary-immunodeficiencies-p-h-asdahl_en.pdf"},
    {"id":"67208","name":"Presentation - IVIG therapy in immune thrombocytopenia and FNAIT (J. J. Zwaginga, M. de Haas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:25:35Z","last_updated_date":"2025-03-11T16:25:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ivig-therapy-immune-thrombocytopenia-fnait-j-j-zwaginga-m-de-haas_en.pdf"},
    {"id":"67209","name":"Presentation - Clinical considerations on the use of IgG in GBS and CIDP (Y. M. Falzone)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:28:03Z","last_updated_date":"2025-03-11T16:28:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-considerations-use-igg-gbs-cidp-y-m-falzone_en.pdf"},
    {"id":"67210","name":"Presentation - Clinical considerations on the use of IgG in neuropathies (H. C. Lehmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:30:31Z","last_updated_date":"2025-03-11T16:30:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-considerations-use-igg-neuropathies-h-c-lehmann_en.pdf"},
    {"id":"67211","name":"Presentation - PPTA perspective on clinical development and clinical use of immunoglobulins (J. R. Knowles)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:33:03Z","last_updated_date":"2025-03-11T16:33:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ppta-perspective-clinical-development-clinical-use-immunoglobulins-j-r-knowles_en.pdf"},
    {"id":"67212","name":"Presentation - EuropeBio perspectives on clinical development and clinical use of immunoglobulin medicines (V. Katkade)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:34:28Z","last_updated_date":"2025-03-11T16:34:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-europebio-perspectives-clinical-development-clinical-use-immunoglobulin-medicines-v-katkade_en.pdf"},
    {"id":"67213","name":"Presentation - IPFA perspectives on the clinical development and clinical use of Ig (K. Pinachyan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:35:57Z","last_updated_date":"2025-03-11T16:35:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ipfa-perspectives-clinical-development-clinical-use-ig-k-pinachyan_en.pdf"},
    {"id":"67214","name":"Presentation - HTA perspectives on challenges in drug development, regulation and clinical practice for immunoglobulins (A. Schiel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:39:44Z","last_updated_date":"2025-03-11T16:39:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hta-perspectives-challenges-drug-development-regulation-clinical-practice-immunoglobulins-schiel_en.pdf"},
    {"id":"67215","name":"Presentation - Monitoring of supply for immunoglobulins (K. Kruttwig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-11T16:45:05Z","last_updated_date":"2025-03-11T16:45:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-monitoring-supply-immunoglobulins-k-kruttwig_en.pdf"},
    {"id":"67283","name":"Presentation - Webinar on reflection paper on the qualification of non-mutagenic impurities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-14T13:44:17Z","last_updated_date":"2025-03-14T13:44:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-webinar-reflection-paper-qualification-non-mutagenic-impurities_en.pdf"},
    {"id":"67288","name":"Presentation - ESMP training session on crisis and MSSG-led preparedness reporting for marketing authorisation holders (MAHs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-14T15:15:47Z","last_updated_date":"2025-03-14T15:15:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-esmp-training-session-crisis-mssg-led-preparedness-reporting-marketing-authorisation-holders-mahs_en.pdf"},
    {"id":"67297","name":"Presentation - Finding clinical trials with the ACT EU Trial Map","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-17T09:50:09Z","last_updated_date":"2025-03-17T09:50:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-finding-clinical-trials-act-eu-trial-map_en.pdf"},
    {"id":"67329","name":"Presentation - Unlocking Integration – MAH & Software Developers to explore PMS API Machine-to-Machine Connection","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-18T13:52:43Z","last_updated_date":"2025-03-18T13:52:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-unlocking-integration-mah-software-developers-explore-pms-api-machine-machine-connection_en.pdf"},
    {"id":"67381","name":"Presentation: EU-Innovation Network (V. Cordo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T11:26:39Z","last_updated_date":"2025-03-21T11:26:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-innovation-network-v-cordo_en.pdf"},
    {"id":"67382","name":"Presentation: A national competent authority perspective on Innovation (F. Foures)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T11:30:02Z","last_updated_date":"2025-03-21T11:30:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-national-competent-authority-perspective-innovation-f-foures_en.pdf"},
    {"id":"67383","name":"Presentation: Reflections on innovation in veterinary medicines (I. Claassen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T11:33:10Z","last_updated_date":"2025-03-21T11:33:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reflections-innovation-veterinary-medicines-i-claassen_en.pdf"},
    {"id":"67384","name":"Presentation: Novel therapies and technologies working party (J. Poot)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T12:02:29Z","last_updated_date":"2025-03-21T12:02:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-novel-therapies-technologies-working-party-j-poot_en.pdf"},
    {"id":"67385","name":"Presentation: EMA/FDA parallel scientific advice (V. Pucovsky)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T12:04:39Z","last_updated_date":"2025-03-21T12:04:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-fda-parallel-scientific-advice-v-pucovsky_en.pdf"},
    {"id":"67386","name":"Presentation: Support to innovative veterinary medicines (N. Garcia del Blanco)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T12:08:52Z","last_updated_date":"2025-03-21T12:08:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-support-innovative-veterinary-medicines-n-garcia-del-blanco_en.pdf"},
    {"id":"67387","name":"Presentation: Engagement with academic researchers for mutual support (R. Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T12:10:22Z","last_updated_date":"2025-03-21T12:10:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-engagement-academic-researchers-mutual-support-r-herold_en.pdf"},
    {"id":"67388","name":"Presentation: Innovation Task Force briefing meetings (O. Blanquie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T12:15:23Z","last_updated_date":"2025-03-21T12:15:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovation-task-force-briefing-meetings-o-blanquie_en.pdf"},
    {"id":"67389","name":"Presentation: How EMA supports SMEs (T. Ballotti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T12:17:23Z","last_updated_date":"2025-03-21T12:17:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-ema-supports-smes-t-ballotti_en.pdf"},
    {"id":"67390","name":"Presentation: Innovation approaches in vaccine development: Utilising VAMFs and vPTMFs (K. Medendorp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-21T12:18:28Z","last_updated_date":"2025-03-21T12:18:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovation-approaches-vaccine-development-utilising-vamfs-vptmfs-k-medendorp_en.pdf"},
    {"id":"67514","name":"Presentation - European Shortages Monitoring Platform (ESMP) workshop on application programming interface (API) for marketing authorisation holders (MAHs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T09:31:11Z","last_updated_date":"2025-03-28T09:31:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-shortages-monitoring-platform-esmp-workshop-application-programming-interface-api-marketing-authorisation-holders-mahs_en.pdf"},
    {"id":"67515","name":"Presentation - Quarterly System Demo Q1 2025","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T09:34:08Z","last_updated_date":"2025-03-28T09:34:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quarterly-system-demo-q1-2025_en.pdf"},
    {"id":"67652","name":"Presentation - Welcome and introductions - twelfth Industry Standing group (ISG) meeting (M. Filancia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T17:26:03Z","last_updated_date":"2025-04-04T17:26:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-welcome-introductions-twelfth-industry-standing-group-isg-meeting-m-filancia_en.pdf"},
    {"id":"67653","name":"Presentation - Transfer of Task Force on Availability of Authorised Medicines for Human and Veterinary Use activities and The Working Group of the MSSG on the Vulnerability Assessment Methodology (V. Bennett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T17:28:00Z","last_updated_date":"2025-04-04T17:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transfer-task-force-availability-authorised-medicines-human-veterinary-use-activities-working-group-mssg-vulnerability-assessment-methodology-v-bennett_en.pdf"},
    {"id":"67654","name":"Presentation - Medical device expert panels (S. Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T17:29:17Z","last_updated_date":"2025-04-04T17:29:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-device-expert-panels-s-dias_en.pdf"},
    {"id":"67655","name":"Presentation - Update on EMA Emergency Task Force (M. Mura)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T17:30:17Z","last_updated_date":"2025-04-04T17:30:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ema-emergency-task-force-m-mura_en.pdf"},
    {"id":"67656","name":"Presentation - Regulatory/ HTA interface under the HTAR –Update on implementation activities (M. Berntgen and J. Ferreira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T17:31:30Z","last_updated_date":"2025-04-04T17:31:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-hta-interface-under-htar-update-implementation-activities-m-berntgen-j-ferreira_en.pdf"},
    {"id":"67657","name":"Presentation - Update on ePI (E. Scanlan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T17:32:53Z","last_updated_date":"2025-04-04T17:32:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-epi-e-scanlan_en.pdf"},
    {"id":"67658","name":"Presentation - Update on EMANS to 2028 (M. Carr and R. S. Ivo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T17:33:43Z","last_updated_date":"2025-04-04T17:33:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-emans-2028-m-carr-r-s-ivo_en.pdf"},
    {"id":"67659","name":"Presentation - Industry stakeholders’ survey on engagement and or communication activities (M. Filancia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T17:35:06Z","last_updated_date":"2025-04-04T17:35:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-stakeholders-survey-engagement-or-communication-activities-m-filancia_en.pdf"},
    {"id":"67680","name":"Presentation - European Shortages Monitoring Platform (ESMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-08T11:39:35Z","last_updated_date":"2025-04-08T11:39:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-shortages-monitoring-platform-esmp_en.pdf"},
    {"id":"67681","name":"Presentation - SPOR status update webinar 9 April 2025","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-08T11:44:26Z","last_updated_date":"2025-04-08T11:44:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-status-update-webinar-9-april-2025_en.pdf"},
    {"id":"67803","name":"Presentation - EMA's 30th anniversary (E. Cooke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T15:51:14Z","last_updated_date":"2025-04-14T15:51:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-30th-anniversary-e-cooke_en.pdf"},
    {"id":"67804","name":"Presentation - Clinical trials update (P. Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T15:52:19Z","last_updated_date":"2025-04-14T15:52:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-update-p-arlett_en.pdf"},
    {"id":"67805","name":"Presentation - ACT EU workplan 2025-2026 (L. Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T15:53:12Z","last_updated_date":"2025-04-14T15:53:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-workplan-2025-2026-l-pioppo_en.pdf"},
    {"id":"67806","name":"Presentation - Feedback from ACT EU workshop on ICH E6 R3 (P. Twomey, K. Pietsch and F. Houÿez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T15:54:22Z","last_updated_date":"2025-04-14T15:54:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-act-eu-workshop-ich-e6-r3-p-twomey-k-pietsch-f-houyez_en.pdf"},
    {"id":"67807","name":"Presentation - Update on Multistakeholder platform (A. Zanoletty)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T15:56:30Z","last_updated_date":"2025-04-14T15:56:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-multistakeholder-platform-zanoletty_en.pdf"},
    {"id":"67808","name":"Presentation - Risk minimisation in healthcare: updates on policy, practice, research and engagement (P. Bahri)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T15:57:53Z","last_updated_date":"2025-04-14T15:57:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-minimisation-healthcare-updates-policy-practice-research-engagement-p-bahri_en.pdf"},
    {"id":"67809","name":"Presentation - Update on EMA policy on competing interests (policy 0044) (Z. Hanaizi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T15:59:09Z","last_updated_date":"2025-04-14T15:59:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ema-policy-competing-interests-policy-0044-z-hanaizi_en.pdf"},
    {"id":"67810","name":"Presentation - EMANS to 2028 (M. Carr and R. Santos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:00:19Z","last_updated_date":"2025-04-14T16:00:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emans-2028-m-carr-r-santos_en.pdf"},
    {"id":"67811","name":"Presentation - Update of the QRD template: revision of the package leaflet (M. Buch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:01:13Z","last_updated_date":"2025-04-14T16:01:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-qrd-template-revision-package-leaflet-m-buch_en.pdf"},
    {"id":"67812","name":"Presentation - Electronic product information (ePI) pilot and next steps (E. Scanlan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:02:32Z","last_updated_date":"2025-04-14T16:02:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-electronic-product-information-epi-pilot-next-steps-e-scanlan_en.pdf"},
    {"id":"67813","name":"Presentation - European Patients Forum’s statement (S. Jouan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:03:29Z","last_updated_date":"2025-04-14T16:03:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-patients-forums-statement-s-jouan_en.pdf"},
    {"id":"67814","name":"Presentation - Joint statement on ePI (D. Teixeira Pereira)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:10:50Z","last_updated_date":"2025-04-14T16:10:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-joint-statement-epi-d-teixeira-pereira_en.pdf"},
    {"id":"67815","name":"Presentation - Introduction to shortages topic (M. Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:12:57Z","last_updated_date":"2025-04-14T16:12:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-shortages-topic-m-dias_en.pdf-0"},
    {"id":"67816","name":"Presentation - Transfer of Task Force on Availability of Authorised Medicines for Human and Veterinary Use activities (TF-AAM) and The Working Group of the MSSG on the Vulnerability Assessment Methodology (V. Bennett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:13:50Z","last_updated_date":"2025-04-14T16:13:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transfer-task-force-availability-authorised-medicines-human-veterinary-use-activities-tf-aam-working-group-mssg-vulnerability-assessment-methodology-v-bennett_en.pdf"},
    {"id":"67817","name":"Presentation - Ongoing critical shortages (K. Kruttwig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:16:08Z","last_updated_date":"2025-04-14T16:16:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ongoing-critical-shortages-k-kruttwig_en.pdf"},
    {"id":"67818","name":"Presentation - European Shortages Monitoring Platform (ESMP) update (S. Zastavnik)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:17:10Z","last_updated_date":"2025-04-14T16:17:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-shortages-monitoring-platform-esmp-update-s-zastavnik_en.pdf"},
    {"id":"67819","name":"Presentation - CAT committee feedback (K. Sollerbrant)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:18:04Z","last_updated_date":"2025-04-14T16:18:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cat-committee-feedback-k-sollerbrant_en.pdf"},
    {"id":"67820","name":"Presentation - COMP committee feedback (I. Alves and J. Rocha)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:19:24Z","last_updated_date":"2025-04-14T16:19:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-comp-committee-feedback-i-alves-j-rocha_en.pdf"},
    {"id":"67821","name":"Presentation - HMPC committee feedback (An Lê)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:20:56Z","last_updated_date":"2025-04-14T16:20:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hmpc-committee-feedback-le_en.pdf"},
    {"id":"67822","name":"Presentation - PDCO committee feedback (J. Taminiau)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:22:11Z","last_updated_date":"2025-04-14T16:22:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pdco-committee-feedback-j-taminiau_en.pdf"},
    {"id":"67823","name":"Presentation - Data Analysis and Real World Interrogation Network (DARWIN EU): Three years of a journey (A. Segec)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:23:19Z","last_updated_date":"2025-04-14T16:23:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-analysis-real-world-interrogation-network-darwin-eu-three-years-journey-segec_en.pdf"},
    {"id":"67824","name":"Presentation - Update on Patient Experience Data (PED) reflection paper (K. Immonen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:24:49Z","last_updated_date":"2025-04-14T16:24:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-patient-experience-data-ped-reflection-paper-k-immonen_en.pdf"},
    {"id":"67825","name":"Presentation - Call for PCWP and HCPWP mandate 2025-2028 (M. Bonafonte and I. Silva)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:26:11Z","last_updated_date":"2025-04-14T16:26:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-call-pcwp-hcpwp-mandate-2025-2028-m-bonafonte-i-silva_en.pdf"},
    {"id":"67826","name":"Presentation - Information on election of PCWP and HCPWP co-chairs (M. Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:27:34Z","last_updated_date":"2025-04-14T16:27:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-election-pcwp-hcpwp-co-chairs-m-mavris_en.pdf"},
    {"id":"67827","name":"Presentation - Highlights of PCWP HCPWP 2023-2025 mandate (M. Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:28:50Z","last_updated_date":"2025-04-14T16:28:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-highlights-pcwp-hcpwp-2023-2025-mandate-m-mavris_en.pdf"},
    {"id":"67828","name":"Presentation - Information ecosystem management (R. Gonzalez-Quevedo and S. Labbe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T16:45:27Z","last_updated_date":"2025-04-14T16:45:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-ecosystem-management-r-gonzalez-quevedo-s-labbe_en.pdf"},
    {"id":"67829","name":"Presentation - Update on communication campaigns (G. Gabrielli and C. Enachioiu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T17:02:47Z","last_updated_date":"2025-04-14T17:02:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-communication-campaigns-g-gabrielli-c-enachioiu_en.pdf"},
    {"id":"67830","name":"Presentation - Cross-agency One Health Task Force (A. Vidal)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T17:04:08Z","last_updated_date":"2025-04-14T17:04:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cross-agency-one-health-task-force-vidal_en.pdf"},
    {"id":"67831","name":"Presentation - 10 years of experience of patient involvement EMA, opportunities, challenges and learnings for meaningful patient involvement (E. Vroom, D. Athanasiou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T17:05:15Z","last_updated_date":"2025-04-14T17:05:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-10-years-experience-patient-involvement-ema-opportunities-challenges-learnings-meaningful-patient-involvement-e-vroom-d-athanasiou_en.pdf"},
    {"id":"67832","name":"Presentation - Preparing future roles for patients and HCP in EMA committees PRAC-CHMP (F. Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T17:06:39Z","last_updated_date":"2025-04-14T17:06:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-preparing-future-roles-patients-hcp-ema-committees-prac-chmp-f-houyez_en.pdf"},
    {"id":"68238","name":"Presentation - From lab to patients: A fast path from innovation to safe and effective medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T16:16:32Z","last_updated_date":"2025-05-12T16:16:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lab-patients-fast-path-innovation-safe-effective-medicines_en.pdf"},
    {"id":"68239","name":"Presentation - Medicines safety: How we monitor the safety of medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T16:19:05Z","last_updated_date":"2025-05-12T16:19:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicines-safety-how-we-monitor-safety-medicines_en.pdf"},
    {"id":"68240","name":"Presentation - The veterinary division: What we do impacts people's daily lives","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T16:21:47Z","last_updated_date":"2025-05-12T16:21:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-division-what-we-do-impacts-peoples-daily-lives_en.pdf"},
    {"id":"68448","name":"Session 1 presentation - PMS Info-Day","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-05-26T13:54:34Z","last_updated_date":"2025-05-26T13:54:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-1-presentation-pms-info-day_en.pdf"},
    {"id":"68449","name":"PMS Info-Day complete presentation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-05-26T13:57:07Z","last_updated_date":"2025-05-26T13:57:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pms-info-day-complete-presentation_en.pdf"},
    {"id":"68450","name":" Session 3 presentation - PMS Info-Day","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-05-26T13:58:09Z","last_updated_date":"2025-05-26T13:58:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-3-presentation-pms-info-day_en.pdf"},
    {"id":"68451","name":"Session 4 presentation - PMS Info-Day","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-05-26T13:59:01Z","last_updated_date":"2025-05-26T13:59:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-4-presentation-pms-info-day_en.pdf"},
    {"id":"68452","name":"Session 2 presentation - PMS Info-Day","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-05-26T14:03:11Z","last_updated_date":"2025-05-26T14:03:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-2-presentation-pms-info-day_en.pdf"},
    {"id":"68459","name":"Presentation - Dosage review and adjustment of selected veterinary antibiotics (ADRA project) (J. Schefferlie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-05-26T17:09:57Z","last_updated_date":"2025-05-26T17:09:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dosage-review-adjustment-selected-veterinary-antibiotics-adra-project-j-schefferlie_en.pdf"},
    {"id":"68460","name":"Presentation - Dosage review and adjustment of selected veterinary antibiotics (ADRA) - regulatory considerations (A. Azaceta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-05-26T17:11:31Z","last_updated_date":"2025-05-26T17:11:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-dosage-review-adjustment-selected-veterinary-antibiotics-adra-regulatory-considerations-azaceta_en.pdf"}    {"id":"68550","name":"Presentation - Update on CTIS programme - CTIS Info Day May 2025 (M. Sultani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T14:38:12Z","last_updated_date":"2025-06-03T14:38:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ctis-programme-ctis-info-day-may-2025-m-sultani_en.pdf"},
    {"id":"68551","name":"Presentation - CTCG updates - CTIS Info Day May 2025 (M. Lunzer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T14:41:08Z","last_updated_date":"2025-06-03T14:41:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctcg-updates-ctis-info-day-may-2025-m-lunzer_en.pdf"},
    {"id":"68552","name":"Presentation - CTIS cover letter templates - CTIS Info Day May 2025 (J. W. Kleinovink)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T14:42:22Z","last_updated_date":"2025-06-03T14:42:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-cover-letter-templates-ctis-info-day-may-2025-j-w-kleinovink_en.pdf"},
    {"id":"68553","name":"Presentation - CTIS and CTCG/CTAG guidance, CRO perspective - CTIS Info Day May 2025 (P. F. Omnes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T14:43:58Z","last_updated_date":"2025-06-03T14:43:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-ctcg-ctag-guidance-cro-perspective-ctis-info-day-may-2025-p-f-omnes_en.pdf"},
    {"id":"68554","name":"Presentation - CTIS and CTCG/CTAG guidance, industry perspective - CTIS Info Day May 2025 (M. O'Kane)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T14:45:37Z","last_updated_date":"2025-06-03T14:45:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-ctcg-ctag-guidance-industry-perspective-ctis-info-day-may-2025-m-okane_en.pdf"},
    {"id":"68555","name":"Presentation - CTIS and CTCG/CTAG guidance, non-commercial sponsor perspective - CTIS Info Day May 2025 (X. M. Zhou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T14:56:49Z","last_updated_date":"2025-06-03T14:56:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-ctcg-ctag-guidance-non-commercial-sponsor-perspective-ctis-info-day-may-2025-x-m-zhou_en.pdf"},
    {"id":"68556","name":"Presentation - CTIS tips for the users - CTIS Info Day May 2025 (J. Dower)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T14:59:20Z","last_updated_date":"2025-06-03T14:59:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-tips-users-ctis-info-day-may-2025-j-dower_en.pdf"},
    {"id":"68557","name":"Presentation - Simplification taskforce activities - CTIS Info Day May 2025 (O. Bueno)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T15:00:31Z","last_updated_date":"2025-06-03T15:00:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-simplification-taskforce-activities-ctis-info-day-may-2025-o-bueno_en.pdf"},
    {"id":"68558","name":"Presentation - Simplification and redesign of CTR/CTIS training material for Sponsors and Member States - CTIS Info Day May 2025 (F. Scotti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T15:01:51Z","last_updated_date":"2025-06-03T15:01:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-simplification-redesign-ctr-ctis-training-material-sponsors-member-states-ctis-info-day-may-2025-f-scotti_en.pdf"},
    {"id":"68965","name":"Presentation - Variations regulation and guideline implementation (T. Girard, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-25T15:57:34Z","last_updated_date":"2025-06-25T15:57:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-variations-regulation-guideline-implementation-t-girard-ema_en.pdf"},
    {"id":"68966","name":"Presentation - Ongoing initiatives in the centralised procedure - (F. Day, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-25T16:03:09Z","last_updated_date":"2025-06-25T16:03:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ongoing-initiatives-centralised-procedure-f-day-ema_en.pdf-0"},
    {"id":"68967","name":"Presentation - Re-start of F2F oral explanations for in-person Committee meetings – 1 year pilot (S. Ribeiro, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-25T16:04:50Z","last_updated_date":"2026-01-09T15:34:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-re-start-f2f-oral-explanations-person-committee-meetings-1-year-pilot-s-ribeiro-ema_en.pdf"},
    {"id":"68968","name":"Presentation - Submission of clinical study data at EMA – follow up on the clinical study data pilot (E. Psarelli, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-25T16:07:20Z","last_updated_date":"2025-06-25T16:07:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-submission-clinical-study-data-ema-follow-clinical-study-data-pilot-e-psarelli-ema_en.pdf"},
    {"id":"68969","name":"Presentation - ICMRA collaborative assessment pilots : Outcomes and next steps (E. Kotzagiorgis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-25T16:10:41Z","last_updated_date":"2025-06-25T16:10:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-icmra-collaborative-assessment-pilots-outcomes-next-steps-e-kotzagiorgis-ema_en.pdf"},
    {"id":"68970","name":"Presentation - ICMRA Collaborative Hybrid Inspection Pilot (CHIP) (E. Korakianiti, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-25T16:13:05Z","last_updated_date":"2025-06-25T16:13:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-icmra-collaborative-hybrid-inspection-pilot-chip-e-korakianiti-ema_en.pdf"},
    {"id":"68971","name":"Presentation - Information on clock-stops/restarts for processes implemented in IRIS (F. Penaranda, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-25T16:15:30Z","last_updated_date":"2025-06-25T16:15:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-clock-stops-restarts-processes-implemented-iris-f-penaranda-ema_en.pdf"},
    {"id":"68972","name":"Presentation - Combination products (C. Bouygues, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-25T16:18:19Z","last_updated_date":"2025-06-25T16:18:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-combination-products-c-bouygues-ema_en.pdf"},
    {"id":"69031","name":"Presentation - System demo Q2 2025","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T09:58:02Z","last_updated_date":"2025-06-30T09:58:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-system-demo-q2-2025_en.pdf"},
    {"id":"69074","name":"Presentation - European shortages monitoring platform (ESMP): updates and question and answer clinic for marketing authorisation holders","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-01T17:40:00Z","last_updated_date":"2025-07-01T17:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-shortages-monitoring-platform-esmp-updates-question-answer-clinic-marketing-authorisation-holders_en.pdf"},
    {"id":"69089","name":"Presentation - Actions arising from previous meeting and other updates (M. Filancia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-03T14:07:30Z","last_updated_date":"2025-07-03T14:07:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-actions-arising-previous-meeting-other-updates-m-filancia-ema_en.pdf"},
    {"id":"69090","name":"Presentation - Advancing product master data – next steps : strategic recommendations on PMS implementation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-03T14:10:30Z","last_updated_date":"2025-07-03T14:10:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advancing-product-master-data-next-steps-strategic-recommendations-pms-implementation_en.pdf"},
    {"id":"69091","name":"Presentation - Medical device expert panels: support to innovation (M. Antunes, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-03T14:13:08Z","last_updated_date":"2025-07-03T14:13:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-device-expert-panels-support-innovation-m-antunes-ema_en.pdf"},
    {"id":"69092","name":"Presentation - Regulatory/ HTA interface under the HTAR: update on implementation activities (M. Berntgen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-03T14:16:26Z","last_updated_date":"2025-07-03T14:16:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-hta-interface-under-htar-update-implementation-activities-m-berntgen-ema_en.pdf"},
    {"id":"69093","name":"Presentation - Information ecosystem management & building trust on vaccines (S. Labbe and R. Gonzalez-Quevedo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-03T14:23:06Z","last_updated_date":"2025-07-03T14:23:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-ecosystem-management-building-trust-vaccines-s-labbe-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"69094","name":"Presentation - Patient experience data in development programs and regulatory decision-making (R. Gonzalez-Quevedo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-03T14:26:29Z","last_updated_date":"2025-07-03T14:26:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-experience-data-development-programs-regulatory-decision-making-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"69095","name":"Presentation - EMA/HMA European platform for regulatory science research (L. Barbier and R. Herold, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-03T14:28:34Z","last_updated_date":"2025-07-03T14:28:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-hma-european-platform-regulatory-science-research-l-barbier-r-herold-ema_en.pdf"},
    {"id":"69119","name":"Presentation - Training session on Human variations web-based electronic Application Form (eAF) for non-CAPs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-07T11:06:28Z","last_updated_date":"2025-07-07T11:06:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-training-session-human-variations-web-based-electronic-application-form-eaf-non-caps_en.pdf-0"},
    {"id":"69163","name":"Presentation - SPOR and XEVMPD status update (Recent and planned changes and impacts to users)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-08T13:38:17Z","last_updated_date":"2025-07-08T13:38:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-xevmpd-status-update-recent-planned-changes-impacts-users_en.pdf"},
    {"id":"69181","name":"Presentation - Early engagement fostering innovation (M. Filancia, O. Blanquie, E. Tognana, T. Ballotti, G. Lorenti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-09T13:29:11Z","last_updated_date":"2025-07-09T13:29:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-early-engagement-fostering-innovation-m-filancia-o-blanquie-e-tognana-t-ballotti-g-lorenti_en.pdf"},
    {"id":"69182","name":"Presentation - Update on the stepwise PIP pilot (C. Pallidis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-09T13:31:17Z","last_updated_date":"2025-07-09T13:31:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-stepwise-pip-pilot-c-pallidis_en.pdf"},
    {"id":"69183","name":"Presentation - Focus group on use of RWD and generation of RWE (A. Segec)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-09T13:32:46Z","last_updated_date":"2025-07-09T13:32:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-use-rwd-generation-rwe-segec_en.pdf"},
    {"id":"69184","name":"Presentation - Future-proofing Qualification of Novel Methodologies (QoNM) (T. Vetter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-09T13:34:16Z","last_updated_date":"2025-07-09T13:34:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-future-proofing-qualification-novel-methodologies-qonm-t-vetter_en.pdf"},
    {"id":"69185","name":"Presentation - Horizon Scanning activities at EMA (V. Cordo, E. Tognana, F. Ehmann)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-09T13:35:33Z","last_updated_date":"2025-07-09T13:35:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-horizon-scanning-activities-ema-v-cordo-e-tognana-f-ehmann_en.pdf"},
    {"id":"69186","name":"Presentation - Implementation of pilot initiatives based on first 5 years’ experience of PRIME: Analysis (K. Cunningham)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-09T13:36:35Z","last_updated_date":"2025-07-09T13:36:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-pilot-initiatives-based-first-5-years-experience-prime-analysis-k-cunningham_en.pdf"},
    {"id":"69187","name":"Presentation - Reframing the voluntary data submission (S. Ponzano, O. Moriarty)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-09T13:37:56Z","last_updated_date":"2025-07-09T13:37:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reframing-voluntary-data-submission-s-ponzano-o-moriarty_en.pdf"},
    {"id":"69188","name":"Presentation - The EMA Product Development Coordinator (M. Berntgen, I. Gravanis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-09T13:39:01Z","last_updated_date":"2025-07-09T13:39:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-product-development-coordinator-m-berntgen-i-gravanis_en.pdf"},
    {"id":"69189","name":"Presentation - Updates from EMA on scientific advice; 14th Industry stakeholder platform on research and development support (I. Gravanis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-09T13:39:51Z","last_updated_date":"2025-07-09T13:39:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-ema-scientific-advice-14th-industry-stakeholder-platform-research-development-support-i-gravanis_en.pdf"},
    {"id":"69295","name":"Presentation - Welcome and introduction to the strategic approach to regulatory science research","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T14:51:19Z","last_updated_date":"2025-07-15T14:51:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-welcome-introduction-strategic-approach-regulatory-science-research_en.pdf"},
    {"id":"69296","name":"Presentation - Introduction to the Platform and agenda topics","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T14:52:35Z","last_updated_date":"2025-07-15T14:52:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-platform-agenda-topics_en.pdf"},
    {"id":"69297","name":"Presentation - Session 1: Perform studies to develop optimal PK (and PD) designs in children to support extrapolation from adults","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T14:53:13Z","last_updated_date":"2025-07-15T14:53:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-perform-studies-develop-optimal-pk-pd-designs-children-support-extrapolation-adults_en.pdf"},
    {"id":"69298","name":"Presentation - Session 1: Researcher perspective on state, gaps and opportunities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T14:53:51Z","last_updated_date":"2025-07-15T14:53:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-researcher-perspective-state-gaps-opportunities_en.pdf"},
    {"id":"69299","name":"Presentation - Session 2: Session 2 Use of regulatory data in research projects: spotlight on the assessment report","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T14:55:13Z","last_updated_date":"2025-07-15T14:55:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-session-2-use-regulatory-data-research-projects-spotlight-assessment-report_en.pdf"},
    {"id":"69300","name":"Presentation - Session 2: EPAR Search for the CONFIRMS Non-Proportional Hazards Research Project","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T14:55:55Z","last_updated_date":"2025-07-15T14:55:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-epar-search-confirms-non-proportional-hazards-research-project_en.pdf"},
    {"id":"69301","name":"Presentation - Session 2: How can we utilize the large and rich documents that are the EPAR?","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-15T14:57:12Z","last_updated_date":"2025-07-15T14:57:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-how-can-we-utilize-large-rich-documents-are-epar_en.pdf"},
    {"id":"69307","name":"Presentation - Redesign of the CTIS training material for sponsor users - CTIS Bitesize talk 9 July 2025","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-16T11:23:30Z","last_updated_date":"2025-07-16T11:23:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-redesign-ctis-training-material-sponsor-users-ctis-bitesize-talk-9-july-2025_en.pdf"},
    {"id":"69320","name":"Presentation - Introduction to the assessment of medicines in the EU (B. Sepodes, CHMP Chair)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-16T16:37:09Z","last_updated_date":"2025-07-16T16:37:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-assessment-medicines-eu-b-sepodes-chmp-chair_en.pdf"},
    {"id":"69321","name":"Presentation - The clinical assessment (A. Cunney, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-16T16:38:00Z","last_updated_date":"2025-07-16T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-assessment-cunney-ema_en.pdf"},
    {"id":"69322","name":"Presentation - The inspection process (T. Holmberg, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-16T16:38:32Z","last_updated_date":"2025-07-16T16:38:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-inspection-process-t-holmberg-ema_en.pdf"},
    {"id":"69323","name":"Presentation - Opportunities for expert involvement in our core assessment  and related activities (F. Day, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-16T16:39:07Z","last_updated_date":"2025-07-16T16:39:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-expert-involvement-our-core-assessment-related-activities-f-day-ema_en.pdf"},
    {"id":"69326","name":"Presentation - EMA Quality Innovation Group (QIG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-16T16:47:38Z","last_updated_date":"2025-07-16T16:47:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-quality-innovation-group-qig_en.pdf"},
    {"id":"69327","name":"Presentation - ICMRA collaborative assessment pilots","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-16T16:49:42Z","last_updated_date":"2025-07-16T16:49:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-icmra-collaborative-assessment-pilots_en.pdf"},
    {"id":"69332","name":"Presentation - Commission proposal for a Critical Medicines Act","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-17T09:14:35Z","last_updated_date":"2025-07-17T09:14:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-commission-proposal-critical-medicines-act_en.pdf"},
    {"id":"69360","name":"Presentation - Bayesian borrowing in clinical trial test decisions: Frequentist type I error rate and power (A. Kopp-Schneider, DKFZ)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:12:49Z","last_updated_date":"2025-07-18T11:12:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bayesian-borrowing-clinical-trial-test-decisions-frequentist-type-i-error-rate-power-kopp-schneider-dkfz_en.pdf"},
    {"id":"69361","name":"Presentation - Opportunities and challenges of using Bayesian Methods to support regulatory decision making (N. Best, GSK)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:15:40Z","last_updated_date":"2025-07-18T11:15:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-challenges-using-bayesian-methods-support-regulatory-decision-making-n-best-gsk_en.pdf"},
    {"id":"69362","name":"Presentation - EU Concept Paper on the use of Bayesian statistics in clinical development (P.van de Ven, CBG MEB)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:18:50Z","last_updated_date":"2025-07-18T11:18:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-concept-paper-use-bayesian-statistics-clinical-development-pvan-de-ven-cbg-meb_en.pdf"},
    {"id":"69363","name":"Presentation - ICH E20: an industry perspective (U.Bretz, Novartis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:20:54Z","last_updated_date":"2025-07-18T11:20:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-e20-industry-perspective-ubretz-novartis_en.pdf"},
    {"id":"69364","name":"Presentation - ICH E20: a regulatory perspective (F.Petavy, A.Koch, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:23:09Z","last_updated_date":"2025-07-18T11:23:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-e20-regulatory-perspective-fpetavy-akoch-ema_en.pdf"},
    {"id":"69365","name":"Presentation - Bayesian methods without borrowing in ultrarare diseases (N.Muehlemann, J.Priel, Cytel)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:25:49Z","last_updated_date":"2025-07-18T11:25:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bayesian-methods-without-borrowing-ultrarare-diseases-nmuehlemann-jpriel-cytel_en.pdf"},
    {"id":"69366","name":"Presentation - Bayesian Adaptive Design for a Practice-Changing Platform Trial in a Rare Paediatric Cancer: The Glo-BNHL Trial (L.Billingham, University of Birmingham)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:28:00Z","last_updated_date":"2025-07-18T11:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bayesian-adaptive-design-practice-changing-platform-trial-rare-paediatric-cancer-glo-bnhl-trial-lbillingham-university-birmingham_en.pdf"},
    {"id":"69367","name":"Presentation - Bayesian methods to support clinical interpretation of treatment effects, interim decision making and handling of intercurrent events (N.Best, P.Dalvi, GSK)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:29:28Z","last_updated_date":"2025-07-18T11:29:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bayesian-methods-support-clinical-interpretation-treatment-effects-interim-decision-making-handling-intercurrent-events-nbest-pdalvi-gsk_en.pdf"},
    {"id":"69368","name":"Presentation - Bayesian borrowing for paediatric extrapolation: The DINAMO study (M.Sailer, I.Tartakovsky, Boehringer Ingelheim Pharma GmbH & Co. KG)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:30:50Z","last_updated_date":"2025-07-18T11:30:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bayesian-borrowing-paediatric-extrapolation-dinamo-study-msailer-itartakovsky-boehringer-ingelheim-pharma-gmbh-co-kg_en.pdf"},
    {"id":"69369","name":"Presentation - A regulator’s perspective on pediatric Bayesian Methods (J.Travis, US FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:32:15Z","last_updated_date":"2025-07-18T11:32:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulators-perspective-pediatric-bayesian-methods-jtravis-us-fda_en.pdf"},
    {"id":"69370","name":"Presentation - Bayesian shrinkage methods for routine estimation of subgroup treatment effects (B.Bornkamp, Novartis; N.Best, D.Bratton, GSK; M.Jelizarow, UCB; N.Muhlemann, Cytel; J.McMurray, University of Glasgow)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:34:05Z","last_updated_date":"2025-07-18T11:34:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bayesian-shrinkage-methods-routine-estimation-subgroup-treatment-effects-bbornkamp-novartis-nbest-dbratton-gsk-mjelizarow-ucb-nmuhlemann-cytel-jmcmurray-university-glasgow_en.pdf"},
    {"id":"69371","name":"Presentation - ICH-M15 for Bayesian Modelling: A systematic model assessment framework to support design submission and discussion (T.Mielke, Johnson&Johnson)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:36:43Z","last_updated_date":"2025-07-18T11:36:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-m15-bayesian-modelling-systematic-model-assessment-framework-support-design-submission-discussion-tmielke-johnsonjohnson_en.pdf"},
    {"id":"69372","name":"Presentation - Bayesian statistics in regulatory decision-making: Panacea or Pandora’s Box? (K.Karlsson, MWP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T11:38:41Z","last_updated_date":"2025-07-18T11:38:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bayesian-statistics-regulatory-decision-making-panacea-or-pandoras-box-kkarlsson-mwp_en.pdf"},
    {"id":"69505","name":"Presentation - Similarities and differences between SARS-CoV-2 and Influenza (L. Derde, UMC Utrecht)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-similarities-differences-between-sars-cov-2-influenza-l-derde-umc-utrecht_en.pdf"},
    {"id":"69506","name":"Presentation - Regulatory perspective on clinically relevant endpoints for COVID-19 and Influenza (S. Buchholz, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-perspective-clinically-relevant-endpoints-covid-19-influenza-s-buchholz-ema_en.pdf"},
    {"id":"69507","name":"Presentation - Clinically relevant endpoints for COVID-19 and influenza:a clinician perspective (L.Peto, University of Oxford)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinically-relevant-endpoints-covid-19-influenzaa-clinician-perspective-lpeto-university-oxford_en.pdf"},
    {"id":"69508","name":"Presentation - Clinically Relevant Endpoints for Covid-19 and Influenza (R.Chandra, Novartis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinically-relevant-endpoints-covid-19-influenza-rchandra-novartis_en.pdf"},
    {"id":"69509","name":"Presentation - Respiratory virus endpoints (S.Portsmouth, Shionogi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-respiratory-virus-endpoints-sportsmouth-shionogi_en.pdf"},
    {"id":"69510","name":"Presentation - What are clinically relevant study endpoints for COVID-19 and Influenza? Considerations for the immunocompromised host (M.Boeckh, Fred Hutchinson Cancer Center)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-are-clinically-relevant-study-endpoints-covid-19-influenza-considerations-immunocompromised-host-mboeckh-fred-hutchinson-cancer-center_en.pdf"},
    {"id":"69511","name":"Presentation - Antiviral development landscape for COVID-19 & Influenza (Intrepid Alliance)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antiviral-development-landscape-covid-19-influenza-intrepid-alliance_en.pdf"},
    {"id":"69512","name":"Presentation - Efficacy of influenza antivirals in prophylaxis (University of Michigan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-efficacy-influenza-antivirals-prophylaxis-university-michigan_en.pdf"},
    {"id":"69513","name":"Presentation - Antivirals for pre- or post-exposure prophylaxis (C.Wolfe, Duke Medicine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-antivirals-pre-or-post-exposure-prophylaxis-cwolfe-duke-medicine_en.pdf"},
    {"id":"69514","name":"Presentation - Clinical evidence for viral load as surrogate endpoint for antivirals for COVID-19 (M.Hughes, Harvard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-evidence-viral-load-surrogate-endpoint-antivirals-covid-19-mhughes-harvard_en.pdf"},
    {"id":"69515","name":"Presentation - Clinical evidence for viral load as surrogate endpoint for antivirals for COVID-19 (F.Hayden, University of Virginia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-evidence-viral-load-surrogate-endpoint-antivirals-covid-19-fhayden-university-virginia_en.pdf"},
    {"id":"69516","name":"Presentation - Challenges in evidence generation for COVID-19 mAbs: A regulatory experience (F.Josephson, Swedish Medical Products Agency)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-evidence-generation-covid-19-mabs-regulatory-experience-fjosephson-swedish-medical-products-agency_en.pdf"},
    {"id":"69517","name":" Presentation - Challenges in evidence generation for COVID-19 mAbs: A clinician experience (P.Horby, University of Oxford)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-evidence-generation-covid-19-mabs-clinician-experience-phorby-university-oxford_en.pdf"},
    {"id":"69518","name":" Presentation - Challenges in evidence generation for COVID-19 mAbs: Industry experience (AstraZeneca)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-evidence-generation-covid-19-mabs-industry-experience-astrazeneca_en.pdf"},
    {"id":"69519","name":" Presentation - Challenges in evidence generation for COVID-19 mAbs: Industry experience (Leyden Labs)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-evidence-generation-covid-19-mabs-industry-experience-leyden-labs_en.pdf"},
    {"id":"69520","name":"Presentation - Convalescent plasma for treatment of respiratory viruses (D.Focosi, Pisa University Hospital)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-convalescent-plasma-treatment-respiratory-viruses-dfocosi-pisa-university-hospital_en.pdf"},
    {"id":"69521","name":"Presentation - Pandemic Preparedness Session: Importance of pre-approved protocols (I.Olsen, Oslo University Hospital)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pandemic-preparedness-session-importance-pre-approved-protocols-iolsen-oslo-university-hospital_en.pdf"},
    {"id":"69522","name":"Presentation - Pandemic preparedness: Potential clinical study designs for clinical trials intended to be conducted in case of an outbreak (Y.Yazdanpanah, Paris Cite University / I.Olsen, Oslo University Hospital)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pandemic-preparedness-potential-clinical-study-designs-clinical-trials-intended-be-conducted-case-outbreak-yyazdanpanah-paris-cite-university-iolsen-oslo-university-hospital_en.pdf"},
    {"id":"69523","name":"Presentation -  Challenges associated with the (pre-)approval of clinical study protocols: Regulatory perspective (famhp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-associated-pre-approval-clinical-study-protocols-regulatory-perspective-famhp_en.pdf"},
    {"id":"69524","name":"Presentation -  Challenges associated with the (pre-)approval of clinical study protocols: Clinician perspective (K.Lacombe, Sorbonne University)famhp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-associated-pre-approval-clinical-study-protocols-clinician-perspective-klacombe-sorbonne-universityfamhp_en.pdf"},
    {"id":"69525","name":"Presentation -  Remdesivir: The search for an effective treatment for COVID-19 (Y.Murata, Gilead Sciences)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T11:11:11Z","last_updated_date":"2025-07-28T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-remdesivir-search-effective-treatment-covid-19-ymurata-gilead-sciences_en.pdf"},
    {"id":"69686","name":"Presentation - 3Rs Working Party (3RsWP) plenary meeting (April 2025)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-08-08T09:16:25Z","last_updated_date":"2025-08-08T09:16:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-3rs-working-party-3rswp-plenary-meeting-april-2025_en.pdf"},
    {"id":"70215","name":"Presentation - Training session on web-based electronic Application Form  (eAF) for CAPs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-22T15:09:27Z","last_updated_date":"2025-09-22T15:09:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-training-session-web-based-electronic-application-form-eaf-caps_en.pdf"},
    {"id":"70238","name":"Presentation - System Demo Q3 2025","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-23T17:07:06Z","last_updated_date":"2025-09-23T17:07:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-system-demo-q3-2025_en.pdf"},
    {"id":"70304","name":"Presentation - Possibilities for collaboration of ACT EU and Enpr-EMA","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-26T16:18:50Z","last_updated_date":"2025-09-26T16:18:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-possibilities-collaboration-act-eu-enpr-ema_en.pdf"},
    {"id":"70305","name":"Presentation - Strategic aims of Enpr-EMA 2025-2027","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-26T16:20:27Z","last_updated_date":"2025-09-26T16:20:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strategic-aims-enpr-ema-2025-2027_en.pdf"},
    {"id":"70331","name":"Presentation - Introduction to the assessment of medicines in the European Union (B.Sepodes, CHMP, Infarmed)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T17:23:12Z","last_updated_date":"2025-09-30T17:23:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-assessment-medicines-european-union-bsepodes-chmp-infarmed_en.pdf"},
    {"id":"70332","name":"Presentation - Overview of EMA's 30th anniversary scientific conference (S.Thirstrup, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T17:24:17Z","last_updated_date":"2025-09-30T17:24:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-emas-30th-anniversary-scientific-conference-sthirstrup-ema_en.pdf"},
    {"id":"70333","name":"Presentation - Reflection paper on tailored biosimilar development (S.Thirstrup, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T17:25:14Z","last_updated_date":"2025-09-30T17:25:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reflection-paper-tailored-biosimilar-development-sthirstrup-ema_en.pdf"},
    {"id":"70334","name":"Presentation - EMA's first public Open Door Day (M.Mavris, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T17:26:08Z","last_updated_date":"2025-09-30T17:26:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-first-public-open-door-day-mmavris-ema_en.pdf"},
    {"id":"70335","name":"Presentation - Engagement with academic researchers for mutual support (R.Herold, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T17:26:51Z","last_updated_date":"2025-09-30T17:26:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-engagement-academic-researchers-mutual-support-rherold-ema_en.pdf"},
    {"id":"70336","name":"Presentation - Support to Small and Medium Enterprises at EMA (H.Casaert, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T17:27:43Z","last_updated_date":"2025-09-30T17:27:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-support-small-medium-enterprises-ema-hcasaert-ema_en.pdf"},
    {"id":"70337","name":"Presentation - Engagement with industry stakeholders (M.Filancia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T17:28:19Z","last_updated_date":"2025-09-30T17:28:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-engagement-industry-stakeholders-mfilancia-ema_en.pdf"},
    {"id":"70345","name":"Presentation - A newcommunication approach on medicines safety monitoring in the EU (V.Pashova, S.Cohen, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T10:50:57Z","last_updated_date":"2025-09-30T10:50:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-newcommunication-approach-medicines-safety-monitoring-eu-vpashova-scohen-ema_en.pdf"},
    {"id":"70346","name":"Presentation - New EMA webpage on risk minimisation (P.Bahri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T10:51:55Z","last_updated_date":"2025-09-30T10:51:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-ema-webpage-risk-minimisation-pbahri-ema_en.pdf"}    {"id":"70347","name":"Presentation - EMA satisfaction surveys (I.Silva, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T10:52:57Z","last_updated_date":"2025-09-30T10:52:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-satisfaction-surveys-isilva-ema_en.pdf"},
    {"id":"70348","name":"Presentation - New GVP guidance on minimisingembryo-fetal risks of medicines (P.Bahri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T10:53:36Z","last_updated_date":"2025-09-30T10:53:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-gvp-guidance-minimisingembryo-fetal-risks-medicines-pbahri-ema_en.pdf"},
    {"id":"70349","name":"Presentation - CHMP feedback to PCWP and HCPWP (E. Bałkowiec-Iskra, I. Wang, CHMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T10:54:17Z","last_updated_date":"2025-09-30T10:54:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chmp-feedback-pcwp-hcpwp-e-balkowiec-iskra-i-wang-chmp_en.pdf"},
    {"id":"70350","name":"Presentation - CMDhreport to PCWP/HCPWP (N.Malvik, J.Vokrouhlická, CMDh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T10:55:01Z","last_updated_date":"2025-09-30T10:55:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cmdhreport-pcwp-hcpwp-nmalvik-jvokrouhlicka-cmdh_en.pdf"},
    {"id":"70351","name":"Presentation - Update on EMA’s work on Patient Experience Data (R.Gonzales-Quevedo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T10:56:04Z","last_updated_date":"2025-09-30T10:56:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-emas-work-patient-experience-data-rgonzales-quevedo-ema_en.pdf"},
    {"id":"70352","name":"Presentation - AI Research Priorities Survey Invitation (L.Pinheiro, A.Langston, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T10:57:07Z","last_updated_date":"2025-09-30T10:57:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ai-research-priorities-survey-invitation-lpinheiro-alangston-ema_en.pdf"},
    {"id":"70385","name":"Presentation - Actions arising from previous meeting and other updates (M. Filancia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T09:56:23Z","last_updated_date":"2025-10-02T09:56:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-actions-arising-previous-meeting-other-updates-m-filancia-ema_en.pdf-0"},
    {"id":"70386","name":"Presentation - Union list of critical medicines – first annual update (v2.1) (S. McMahon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T09:59:55Z","last_updated_date":"2025-10-02T09:59:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-list-critical-medicines-first-annual-update-v21-s-mcmahon_en.pdf"},
    {"id":"70387","name":"Presentation - MSSG working group on the vulnerability assessment methodology (V.Bennett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T10:01:56Z","last_updated_date":"2025-10-02T10:01:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mssg-working-group-vulnerability-assessment-methodology-vbennett_en.pdf"},
    {"id":"70388","name":"Presentation - Update on shortage prevention and mitigation plans (SPP/SMP) pilot (M. Alcaraz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T10:05:24Z","last_updated_date":"2025-10-02T10:05:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-shortage-prevention-mitigation-plans-spp-smp-pilot-m-alcaraz_en.pdf"},
    {"id":"70391","name":"Presentation - Medical device expert panels: support to innovation (S. da Rocha Dias, M. Antunes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T10:07:40Z","last_updated_date":"2025-10-02T10:07:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medical-device-expert-panels-support-innovation-s-da-rocha-dias-m-antunes_en.pdf"},
    {"id":"70392","name":"Presentation - Regulatory/HTA interface under the HTAR–update on implementation activities (M. Berntgen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T10:09:58Z","last_updated_date":"2025-10-02T10:09:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-hta-interface-under-htar-update-implementation-activities-m-berntgen_en.pdf"},
    {"id":"70393","name":"Presentation - The ISG focus Group on regulatory science research translation (R. Herold, P. Moscariello)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T10:12:22Z","last_updated_date":"2025-10-02T10:12:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-isg-focus-group-regulatory-science-research-translation-r-herold-p-moscariello_en.pdf"},
    {"id":"70394","name":"Presentation - EMA/HMA European platform for regulatory science research-call for expression of interest (L. Barbier, R. Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T10:25:10Z","last_updated_date":"2025-10-02T10:25:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-hma-european-platform-regulatory-science-research-call-expression-interest-l-barbier-r-herold_en.pdf"},
    {"id":"70396","name":"Presentation - Update on EMA’s work on patient experience data (R. Gonzalez-Quevedo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T11:06:25Z","last_updated_date":"2025-10-02T11:06:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-emas-work-patient-experience-data-r-gonzalez-quevedo_en.pdf"},
    {"id":"70397","name":"Presentation - AI research priorities survey invitation (L. Pinheiro, A. Langston, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T11:10:28Z","last_updated_date":"2025-10-02T11:10:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ai-research-priorities-survey-invitation-l-pinheiro-langston-ema_en.pdf"},
    {"id":"70398","name":"Presentation - EMA update on combination products (A. Ganan Jimenez, C. Bouygues)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T11:12:19Z","last_updated_date":"2025-10-02T11:12:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-update-combination-products-ganan-jimenez-c-bouygues_en.pdf"},
    {"id":"70418","name":"Presentation - CAPs and Non-CAPs in web-based electronic application form (eAF)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-06T16:03:40Z","last_updated_date":"2025-10-06T16:03:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-caps-non-caps-web-based-electronic-application-form-eaf_en.pdf"},
    {"id":"70419","name":"Presentation - Refresher training webinar on post-authorisationprocedure management in IRIS for MAHs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-02T16:24:23Z","last_updated_date":"2025-10-02T16:24:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-refresher-training-webinar-post-authorisationprocedure-management-iris-mahs_en.pdf"},
    {"id":"70451","name":"Presentation -  Product data submission & bulk edit made easy (M. Fernández Gómez, V. Lipucci Di Paola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-06T11:27:53Z","last_updated_date":"2025-10-10T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-data-submission-bulk-edit-made-easy-m-fernandez-gomez-v-lipucci-di-paola_en.pdf"},
    {"id":"70480","name":"Presentation - SPOR and XEVMPD status update: recent and planned changes and impacts to users","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-07T16:44:07Z","last_updated_date":"2025-10-07T16:44:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-xevmpd-status-update-recent-planned-changes-impacts-users_en.pdf-0"},
    {"id":"70606","name":"Presentation - Q&A clinic on CAPs and Non-CAPs in web-based eAF","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-16T14:46:53Z","last_updated_date":"2025-10-16T14:46:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-qa-clinic-caps-non-caps-web-based-eaf_en.pdf"},
    {"id":"70661","name":"Presentation : Unlocking PMS API potential: Edit functionality training for MAHs","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-20T11:31:13Z","last_updated_date":"2025-10-20T11:31:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-unlocking-pms-api-potential-edit-functionality-training-mahs_en.pdf"},
    {"id":"70695","name":"Presentation - Introduction: European Platform for Regulatory Science Research meeting September 2025","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:09:15Z","last_updated_date":"2025-10-21T10:09:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-european-platform-regulatory-science-research-meeting-september-2025_en.pdf"},
    {"id":"70696","name":"Presentation - Working on biomarkers - Introduction and topic mapping (M.Pasmooij, Utrecht University)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:10:34Z","last_updated_date":"2025-10-21T10:10:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-biomarkers-introduction-topic-mapping-mpasmooij-utrecht-university_en.pdf"},
    {"id":"70697","name":"Presentation - Working on biomarkers - Researcher perspective (C.Mathieu, KU Leuven)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:11:26Z","last_updated_date":"2025-10-21T10:11:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-working-biomarkers-researcher-perspective-cmathieu-ku-leuven_en.pdf"},
    {"id":"70700","name":"Presentation - Showcasing EMA's clinical data publication (A-S. Henry-Eude, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:13:39Z","last_updated_date":"2025-10-21T10:13:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-showcasing-emas-clinical-data-publication-s-henry-eude-ema_en.pdf"},
    {"id":"70701","name":"Presentation - Showcasing EMA's clinical data publication - Learnings from a researcher (D.Byrne, RCSI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:15:03Z","last_updated_date":"2025-10-21T10:15:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-showcasing-emas-clinical-data-publication-learnings-researcher-dbyrne-rcsi_en.pdf"},
    {"id":"70702","name":"Presentation - Spotlight on funding at EU level - Introduction ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:16:32Z","last_updated_date":"2025-10-21T10:16:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spotlight-funding-eu-level-introduction_en.pdf"},
    {"id":"70703","name":"Presentation - Spotlight on funding at EU level - Funder perspectives and insights (T.Dyląg, European Commission)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:17:21Z","last_updated_date":"2025-10-21T10:17:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spotlight-funding-eu-level-funder-perspectives-insights-tdylag-european-commission_en.pdf"},
    {"id":"70704","name":"Presentation - Spotlight on funding at EU level - Funder perspectives and insights (N.Seigneuret, IHI)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:18:31Z","last_updated_date":"2025-10-21T10:18:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spotlight-funding-eu-level-funder-perspectives-insights-nseigneuret-ihi_en.pdf"},
    {"id":"70705","name":"Presentation - Spotlight on funding at EU level (C.Hasenauer, European Partnership for Personalised Medicine (EP PerMed))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:19:23Z","last_updated_date":"2025-10-21T10:19:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spotlight-funding-eu-level-chasenauer-european-partnership-personalised-medicine-ep-permed_en.pdf"},
    {"id":"70707","name":"Presentation - Enhancing transparency & discoverability - HMA-EMA Catalogues of real-world data (RWD) sources and studies (K-C.Deli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:32:48Z","last_updated_date":"2025-10-21T10:32:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enhancing-transparency-discoverability-hma-ema-catalogues-real-world-data-rwd-sources-studies-k-cdeli_en.pdf"},
    {"id":"70708","name":"Presentation - Session 1: Pharma industry PBPK perspective on the EMA qualification framework (N. Parrott)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:38:09Z","last_updated_date":"2025-10-21T10:38:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-pharma-industry-pbpk-perspective-ema-qualification-framework-n-parrott_en.pdf"},
    {"id":"70709","name":"Presentation - Session 1: Considerations for qualification of Physiologically Based Biopharmaceutics Models - Beyond the EMA framework (X. Pepin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:39:50Z","last_updated_date":"2025-10-21T10:39:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-considerations-qualification-physiologically-based-biopharmaceutics-models-beyond-ema-framework-x-pepin_en.pdf"},
    {"id":"70710","name":"Presentation - Session 1: Harmonization of PBPK platform and model qualification for regulatory assessment (V.Lukacova)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:40:59Z","last_updated_date":"2025-10-21T10:40:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-harmonization-pbpk-platform-model-qualification-regulatory-assessment-vlukacova_en.pdf"},
    {"id":"70711","name":"Presentation - Session 1: Holistic qualification of mechanistic models in drug development (J-F. Schlender)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:41:43Z","last_updated_date":"2025-10-21T10:41:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-holistic-qualification-mechanistic-models-drug-development-j-f-schlender_en.pdf"},
    {"id":"70712","name":"Presentation - Session 1: Introduction EU regulatory paths to acceptance of a mechanistic model (E. Manolis, C. Versantvoort)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:42:34Z","last_updated_date":"2025-10-21T10:42:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-introduction-eu-regulatory-paths-acceptance-mechanistic-model-e-manolis-c-versantvoort_en.pdf"},
    {"id":"70713","name":"Presentation - Session 1: Panel discussion (S. Marshall)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:43:25Z","last_updated_date":"2025-10-21T10:43:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-panel-discussion-s-marshall_en.pdf"},
    {"id":"70714","name":"Presentation - Session 1: Qualification of the Simcyp platform for CYP-mediated drug-drug  interactions - a Certara perspective (R. Yeo Karen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:44:05Z","last_updated_date":"2025-10-21T10:44:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-qualification-simcyp-platform-cyp-mediated-drug-drug-interactions-certara-perspective-r-yeo-karen_en.pdf"},
    {"id":"70715","name":"Presentation - Session 1: Qualification of the Simcyp platform, inter-version qualification bridging (J. Masoud)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:45:11Z","last_updated_date":"2025-10-21T10:45:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-qualification-simcyp-platform-inter-version-qualification-bridging-j-masoud_en.pdf"},
    {"id":"70716","name":"Presentation - Session 1: Risk based assessment of mechanistic models (M.Tshinanu Flora)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:46:12Z","last_updated_date":"2025-10-21T10:46:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-risk-based-assessment-mechanistic-models-mtshinanu-flora_en.pdf"},
    {"id":"70717","name":"Presentation - Session 1: Software Verification, Validation, and Qualification of Open Source M&S Software (S.Schaller)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:46:53Z","last_updated_date":"2025-10-21T10:46:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-software-verification-validation-qualification-open-source-ms-software-sschaller_en.pdf"},
    {"id":"70718","name":"Presentation - Session 2: A regulatory perspective on performance verification of mechanistic models - application to PBPK-based DDI predictions (P. Colin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:47:56Z","last_updated_date":"2025-10-21T10:47:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-regulatory-perspective-performance-verification-mechanistic-models-application-pbpk-based-ddi-predictions-p-colin_en.pdf"},
    {"id":"70719","name":"Presentation - Session 2: Industry experience and discussion from a PBPK working group on the predictive performance of PBPK model for DDI applications (K.Taskar)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:48:40Z","last_updated_date":"2025-10-21T10:48:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-industry-experience-discussion-pbpk-working-group-predictive-performance-pbpk-model-ddi-applications-ktaskar_en.pdf"},
    {"id":"70720","name":"Presentation - Session 2: Uncertainty quantification methods for complex models used in drug development and (or) regulatory approval (A.Hooker)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:49:23Z","last_updated_date":"2025-10-21T10:49:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-uncertainty-quantification-methods-complex-models-used-drug-development-or-regulatory-approval-ahooker_en.pdf"},
    {"id":"70721","name":"Presentation - Session 3: An industry perspective on high impact QSP and QST model applications  in clinical drug development in rare diseases (A.Sher)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:50:48Z","last_updated_date":"2025-10-21T10:50:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-industry-perspective-high-impact-qsp-qst-model-applications-clinical-drug-development-rare-diseases-asher_en.pdf"},
    {"id":"70722","name":"Presentation - Session 3: Experience with software platforms qualification for mechanistic modelsfor agent-based modelling approaches; UISS case (F.Pappalardo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:52:00Z","last_updated_date":"2025-10-21T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-experience-software-platforms-qualification-mechanistic-modelsfor-agent-based-modelling-approaches-uiss-case-fpappalardo_en.pdf"},
    {"id":"70723","name":"Presentation - Session 3: Opportunities for application of PBPK models in special populations and different modalities (L. deZwart)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:52:55Z","last_updated_date":"2025-10-21T10:52:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-opportunities-application-pbpk-models-special-populations-different-modalities-l-dezwart_en.pdf"},
    {"id":"70724","name":"Presentation - Session 3: The landscape of QSP modelling and Virtual Population From current to best practice (A. Kulesza)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:53:41Z","last_updated_date":"2025-10-21T10:53:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-landscape-qsp-modelling-virtual-population-current-best-practice-kulesza_en.pdf"},
    {"id":"70725","name":"Presentation - Session 4: Cross-industry feedback in implementation of regulatory guidance on mechanistic models; case studies, gaps and challenges (P. Sharma)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:54:32Z","last_updated_date":"2025-10-21T10:54:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-cross-industry-feedback-implementation-regulatory-guidance-mechanistic-models-case-studies-gaps-challenges-p-sharma_en.pdf"},
    {"id":"70726","name":"Presentation - Session 4: Guideline on assessment and reporting of mechanistic models used in the context of model informed drug development (F. Musuamba Tshinanu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:55:22Z","last_updated_date":"2025-10-21T10:55:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-guideline-assessment-reporting-mechanistic-models-used-context-model-informed-drug-development-f-musuamba-tshinanu_en.pdf"},
    {"id":"70727","name":"Presentation - Session 4: PBBM Qualification and Guidance - key challenges and emerging opportunities (C. Mackie)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:56:24Z","last_updated_date":"2025-10-21T10:56:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-pbbm-qualification-guidance-key-challenges-emerging-opportunities-c-mackie_en.pdf"},
    {"id":"70728","name":"Presentation - Session 4: Shaping the path forward - advancing mechanistic models for regulatory use (H. Zhu)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-21T10:57:33Z","last_updated_date":"2025-10-21T10:57:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-shaping-path-forward-advancing-mechanistic-models-regulatory-use-h-zhu_en.pdf"},
    {"id":"70806","name":"Presentation - Advancing gene editing medicines from N=1 to N=many : the unique urgency and opportunity of the present moment (F. Urnov, University of California, Berkeley)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T11:56:20Z","last_updated_date":"2025-10-24T11:56:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-advancing-gene-editing-medicines-n1-nmany-unique-urgency-opportunity-present-moment-f-urnov-university-california-berkeley_en.pdf"},
    {"id":"70807","name":"Presentation - Uncovering and mitigating heterogeneity of genome editing outcome at on and off target sites (L. Naldini, SR-Tiget)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T11:59:35Z","last_updated_date":"2025-10-24T11:59:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-uncovering-mitigating-heterogeneity-genome-editing-outcome-target-sites-l-naldini-sr-tiget_en.pdf"},
    {"id":"70809","name":"Presentation - Off-target assessment: how much is too much? (K. Musunuru, University of Pennsylvania)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T12:09:15Z","last_updated_date":"2025-10-24T12:09:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-target-assessment-how-much-too-much-k-musunuru-university-pennsylvania_en.pdf"},
    {"id":"70810","name":"Presentation - A platform genome editing medicinal product for inborn errors of metabolism (K. Musunuru & R. Ahrens-Nicklas, University of Pennsylvania)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T12:12:15Z","last_updated_date":"2025-10-24T12:12:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-platform-genome-editing-medicinal-product-inborn-errors-metabolism-k-musunuru-r-ahrens-nicklas-university-pennsylvania_en.pdf"},
    {"id":"70811","name":"Presentation - Risk-appropriate manufacturing for personalized gene editing: lessons from Baby KJ (V. Almendro & S. Kassim, Danaher Corporation)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T12:15:05Z","last_updated_date":"2025-10-24T12:15:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-appropriate-manufacturing-personalized-gene-editing-lessons-baby-kj-v-almendro-s-kassim-danaher-corporation_en.pdf"},
    {"id":"70812","name":"Presentation - Leveraging data via platform principles in gene editing (M. Lehmicke, Alliance for Regenerative Medicine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T12:18:15Z","last_updated_date":"2025-10-24T12:18:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-leveraging-data-platform-principles-gene-editing-m-lehmicke-alliance-regenerative-medicine_en.pdf"},
    {"id":"70813","name":"Presentation - Challenges in development of in vivo gene editing therapeutics (K. M. Wood, Intellia Therapeutics)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T12:23:06Z","last_updated_date":"2025-10-24T12:23:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-development-vivo-gene-editing-therapeutics-k-m-wood-intellia-therapeutics_en.pdf"},
    {"id":"70814","name":"Presentation - Base editing opportunities for platform development (L. Barrera, Beam Therapeutics)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T12:25:51Z","last_updated_date":"2025-10-24T12:25:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-base-editing-opportunities-platform-development-l-barrera-beam-therapeutics_en.pdf"},
    {"id":"70815","name":"Presentation - Modular platform for in vivo LNP formulated prime editors targeting rare genetic diseases of the liver (A. Anzalone, Prime Medicine)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T12:32:04Z","last_updated_date":"2025-10-24T12:32:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modular-platform-vivo-lnp-formulated-prime-editors-targeting-rare-genetic-diseases-liver-anzalone-prime-medicine_en.pdf"},
    {"id":"70816","name":"Presentation - Arbor biotechnologies challenges in developing gene editing medicines (P. Stetkiewicz, Arbor Biotechnologies)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T12:34:31Z","last_updated_date":"2025-10-24T12:34:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-arbor-biotechnologies-challenges-developing-gene-editing-medicines-p-stetkiewicz-arbor-biotechnologies_en.pdf"},
    {"id":"70903","name":"Presentation - EU support to small and medium-sized enterprises (SMEs) (E.Batta)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T14:53:14Z","last_updated_date":"2025-10-29T14:53:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-support-small-medium-sized-enterprises-smes-ebatta_en.pdf"},
    {"id":"70904","name":"Presentation - The EU Pharmaceutical Reform (O.Solomon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:10:17Z","last_updated_date":"2025-10-29T15:10:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-pharmaceutical-reform-osolomon_en.pdf"},
    {"id":"70905","name":"Presentation - European Investment Bank in life sciences (D.Burduja)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:11:56Z","last_updated_date":"2025-10-29T15:11:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-investment-bank-life-sciences-dburduja_en.pdf"},
    {"id":"70906","name":"Presentation - European Innovation Council (EIC) support for (SME) innovators (O.Symmons)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:13:21Z","last_updated_date":"2025-10-29T15:13:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-innovation-council-eic-support-sme-innovators-osymmons_en.pdf"},
    {"id":"70907","name":"Presentation - Private funding perspectives (S.Slootweg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:15:08Z","last_updated_date":"2025-10-29T15:15:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-private-funding-perspectives-sslootweg_en.pdf"},
    {"id":"70908","name":"Presentation - Life science incubator perspectives (C.Bergstrom)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:15:57Z","last_updated_date":"2025-10-29T15:15:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-life-science-incubator-perspectives-cbergstrom_en.pdf"},
    {"id":"70909","name":"Presentation - Patients' organisation perspectives (V.Hivert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:17:04Z","last_updated_date":"2025-10-29T15:17:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-organisation-perspectives-vhivert_en.pdf"},
    {"id":"70910","name":"Presentation - Achievements of EMA’s SME Regulation (L.Enes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:18:02Z","last_updated_date":"2025-10-29T15:18:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-achievements-emas-sme-regulation-lenes_en.pdf"},
    {"id":"70911","name":"Presentation - SME and Innovation Support in the European Medicines Regulatory Network (L.O'Dwyer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:19:12Z","last_updated_date":"2025-10-29T15:19:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-sme-innovation-support-european-medicines-regulatory-network-lodwyer_en.pdf"},
    {"id":"70912","name":"Presentation - EMA small and medium-sized enterprises (SMEs) survey (T.Ballotti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:20:39Z","last_updated_date":"2025-10-29T15:20:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-small-medium-sized-enterprises-smes-survey-tballotti_en.pdf"},
    {"id":"70913","name":"Presentation - AKIGAI perspective (M.Cameron)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:23:59Z","last_updated_date":"2025-10-29T15:23:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-akigai-perspective-mcameron_en.pdf"},
    {"id":"70914","name":"Presentation - VetHellas perspective (A.Kachrimanidis)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:28:21Z","last_updated_date":"2025-10-29T15:28:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vethellas-perspective-akachrimanidis_en.pdf"},
    {"id":"70915","name":"Presentation - Veterinary Medicines’ perspective (E.Vecino)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:29:16Z","last_updated_date":"2025-10-29T15:29:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-medicines-perspective-evecino_en.pdf"},
    {"id":"70916","name":"Presentation - Human Medicines' perspective (A.Natz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T15:34:51Z","last_updated_date":"2025-10-29T15:34:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-human-medicines-perspective-anatz_en.pdf"},
    {"id":"71055","name":"Presentation - What is a shortage,why do shortages happen,and what is their impact? (J. Garcia Burgos, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T09:27:15Z","last_updated_date":"2025-11-10T09:27:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-shortagewhy-do-shortages-happenand-what-their-impact-j-garcia-burgos-ema_en.pdf"},
    {"id":"71056","name":"Presentation - Addressing shortages: A key priority for the European Commission (L.Geslin, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T09:28:19Z","last_updated_date":"2025-11-10T09:28:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-addressing-shortages-key-priority-european-commission-lgeslin-ec_en.pdf"},
    {"id":"71057","name":"Presentation - What measures do EMA and national authorities take to address shortages? (E.Cormier, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T09:30:00Z","last_updated_date":"2025-11-10T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-what-measures-do-ema-national-authorities-take-address-shortages-ecormier-ema_en.pdf"},
    {"id":"71058","name":"Presentation - Examples of measures taken by EMA and national authorities to tackle shortages (M.Dias, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T09:30:47Z","last_updated_date":"2025-11-10T09:30:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-examples-measures-taken-ema-national-authorities-tackle-shortages-mdias-ema_en.pdf"},
    {"id":"71059","name":"Presentation - Where can patients and healthcare professionals find information on shortages? (I.Abed, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T09:31:39Z","last_updated_date":"2025-11-10T09:31:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-where-can-patients-healthcare-professionals-find-information-shortages-iabed-ema_en.pdf"},
    {"id":"71060","name":"Presentation - Recommendations on shortage management (A.la Santos, BEUC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T09:32:46Z","last_updated_date":"2025-11-10T09:32:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-recommendations-shortage-management-ala-santos-beuc_en.pdf"},
    {"id":"71061","name":"Presentation - Shortages: putting patients first (J.Batista, PharmD PGEU)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T09:33:46Z","last_updated_date":"2025-11-10T09:33:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-shortages-putting-patients-first-jbatista-pharmd-pgeu_en.pdf"},
    {"id":"71062","name":"Presentation - Shortages: Role of patient organisations in supporting/informing patients & EPF recommendations (S.Jouan, EPF)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T09:35:19Z","last_updated_date":"2025-11-10T09:35:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-shortages-role-patient-organisations-supporting-informing-patients-epf-recommendations-sjouan-epf_en.pdf"},
    {"id":"71063","name":"Presentation -The role of patients in preventing and managing medicine shortages (M.Podesta, EFA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T09:36:08Z","last_updated_date":"2025-11-10T09:36:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-role-patients-preventing-managing-medicine-shortages-mpodesta-efa_en.pdf"},
    {"id":"71084","name":"Presentation - Session 1 - Involving patients in clinical trial design - where can we innovate? (A.Hursey)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-11T10:52:37Z","last_updated_date":"2025-11-11T10:52:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-involving-patients-clinical-trial-design-where-can-we-innovate-ahursey_en.pdf"},
    {"id":"71085","name":"Presentation - Session 1 - Update on EMA’s work on patient experience data (PED) (R. Gonzalez-Quevedo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-11T10:57:05Z","last_updated_date":"2025-11-11T10:57:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-update-emas-work-patient-experience-data-ped-r-gonzalez-quevedo_en.pdf"},
    {"id":"71087","name":"Presentation - Session 2 - Concrete examples of trials approved with innovative design(s) (O. Della Pasqua)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-11T11:02:31Z","last_updated_date":"2025-11-11T11:02:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-concrete-examples-trials-approved-innovative-designs-o-della-pasqua_en.pdf"},
    {"id":"71088","name":"Presentation - Session 3 - Digital innovation in healthcare: challenges and possibilities (J. Van Eldere)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-11T11:06:41Z","last_updated_date":"2025-11-11T11:06:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-digital-innovation-healthcare-challenges-possibilities-j-van-eldere_en.pdf"},
    {"id":"71089","name":"Presentation - Session 3 - Opportunities for the European health data space to change clinical trial recruitment (A. Pitcher)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-11T11:11:00Z","last_updated_date":"2025-11-11T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-opportunities-european-health-data-space-change-clinical-trial-recruitment-pitcher_en.pdf"},
    {"id":"71090","name":"Presentation - Session 4 - Safeguarding participants while driving innovation (A. Van Scharen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-11T11:14:43Z","last_updated_date":"2025-11-11T11:14:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-safeguarding-participants-while-driving-innovation-van-scharen_en.pdf"},
    {"id":"71091","name":"Presentation - Session 4 - Informed consent: challenges in complex and novel trials, information of trial subjects (F. Houÿez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-11T11:18:07Z","last_updated_date":"2025-11-11T11:18:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-informed-consent-challenges-complex-novel-trials-information-trial-subjects-f-houyez_en.pdf"},
    {"id":"71118","name":"Presentation - A practical framework for external control trials (H. Ulrich Burger)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:14:56Z","last_updated_date":"2025-11-13T11:14:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-practical-framework-external-control-trials-h-ulrich-burger_en.pdf"},
    {"id":"71120","name":"Presentation - Definition of time-zero for time-to-event data in external arm studies (L. Azoulay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:21:03Z","last_updated_date":"2025-11-13T11:21:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-definition-time-zero-time-event-data-external-arm-studies-l-azoulay_en.pdf"},
    {"id":"71122","name":"Presentation - External control arms driving regulatory decision making: industry examples and learnings (R. Carroll)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:27:22Z","last_updated_date":"2025-11-13T11:27:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-external-control-arms-driving-regulatory-decision-making-industry-examples-learnings-r-carroll_en.pdf"},
    {"id":"71123","name":"Presentation - External controls: emulation half of the target trial (M. Hernán)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:30:18Z","last_updated_date":"2025-11-13T11:30:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-external-controls-emulation-half-target-trial-m-hernan_en.pdf"},
    {"id":"71124","name":"Presentation - External controls in paediatric investigation plans (PIPs) (D. Karres)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:33:46Z","last_updated_date":"2025-11-13T11:33:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-external-controls-paediatric-investigation-plans-pips-d-karres_en.pdf"},
    {"id":"71125","name":"Presentation - Motivation for planned reflection paper and outline of aspects to be addressed (E. Asikanius)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:36:07Z","last_updated_date":"2025-11-13T11:36:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-motivation-planned-reflection-paper-outline-aspects-be-addressed-e-asikanius_en.pdf"}    {"id":"71126","name":"Presentation - Navigating non-randomized comparisons: from pitfalls to practice (R. Izem)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:37:58Z","last_updated_date":"2025-11-13T11:37:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-navigating-non-randomized-comparisons-pitfalls-practice-r-izem_en.pdf"},
    {"id":"71127","name":"Presentation - Non-interventional studies: from data collection to reliable insights (M. Uguen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:40:24Z","last_updated_date":"2025-11-13T11:40:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-interventional-studies-data-collection-reliable-insights-m-uguen_en.pdf"},
    {"id":"71128","name":"Presentation - Overview of the use of external controls in submissions to the European Medicines Agency (J. Lähteenvuo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:42:33Z","last_updated_date":"2025-11-13T11:42:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-use-external-controls-submissions-european-medicines-agency-j-lahteenvuo_en.pdf"},
    {"id":"71129","name":"Presentation - Quantifying and mitigating measurement bias in real-world endpoints when constructing external control arms (B. Ackerman)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:44:38Z","last_updated_date":"2025-11-13T11:44:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quantifying-mitigating-measurement-bias-real-world-endpoints-when-constructing-external-control-arms-b-ackerman_en.pdf"},
    {"id":"71130","name":"Presentation - Strategies to overcome challenges of eligibility criteria for historical data as external control arm source (N. Muehlemann, A. Farjat)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:45:27Z","last_updated_date":"2025-11-13T11:45:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strategies-overcome-challenges-eligibility-criteria-historical-data-external-control-arm-source-n-muehlemann-farjat_en.pdf"},
    {"id":"71135","name":"Presentation - Digital technologies and real-world evidence for the evaluation of medicines (A. Cook)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T14:55:45Z","last_updated_date":"2025-11-13T14:55:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-digital-technologies-real-world-evidence-evaluation-medicines-cook_en.pdf"},
    {"id":"71136","name":"Presentation - Use of RWD in veterinary regulatory applications (R. Bruno)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T14:57:49Z","last_updated_date":"2025-11-13T14:57:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-rwd-veterinary-regulatory-applications-r-bruno_en.pdf"},
    {"id":"71137","name":"Presentation - Veterinary big data strategy and workplan update (P. D. Lynn)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T14:59:15Z","last_updated_date":"2025-11-13T14:59:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-big-data-strategy-workplan-update-p-d-lynn_en.pdf"},
    {"id":"71139","name":"Presentation - Harnessing large language models to improve antimicrobial use monitoring in dairy farming (B. Koppe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:02:04Z","last_updated_date":"2025-11-13T15:02:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-harnessing-large-language-models-improve-antimicrobial-use-monitoring-dairy-farming-b-koppe_en.pdf"},
    {"id":"71140","name":"Presentation - Interoperable big data for veterinary prescription and antimicrobial use (I. Almeida)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:03:25Z","last_updated_date":"2025-11-13T15:03:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-interoperable-big-data-veterinary-prescription-antimicrobial-use-i-almeida_en.pdf"},
    {"id":"71141","name":"Presentation - Use of antimicrobials in companion animals from 133 German veterinary practices (R. Merle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:05:14Z","last_updated_date":"2025-11-13T15:05:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-antimicrobials-companion-animals-133-german-veterinary-practices-r-merle_en.pdf"},
    {"id":"71142","name":"Presentation - A.I. governance in veterinary big data: why pursue it and how to achieve it (P. Harms)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:06:59Z","last_updated_date":"2025-11-13T15:06:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ai-governance-veterinary-big-data-why-pursue-it-how-achieve-it-p-harms_en.pdf"},
    {"id":"71143","name":"Presentation - How company roles are changing with AI (R. Gross)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:08:37Z","last_updated_date":"2025-11-13T15:08:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-company-roles-are-changing-ai-r-gross_en.pdf"},
    {"id":"71144","name":"Presentation - AI@MPA toolbox: AI for medicines regulations (S. Doyle)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:10:34Z","last_updated_date":"2025-11-13T15:10:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-aimpa-toolbox-ai-medicines-regulations-s-doyle_en.pdf"},
    {"id":"71145","name":"Presentation - Leveraging unified big data and AI: insights from VetCompass (N. Kennedy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:11:31Z","last_updated_date":"2025-11-13T15:11:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-leveraging-unified-big-data-ai-insights-vetcompass-n-kennedy_en.pdf"},
    {"id":"71146","name":"Presentation - SPC reader: unlocking veterinary product data (L. Romero Fernández de V.)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:12:54Z","last_updated_date":"2025-11-13T15:12:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spc-reader-unlocking-veterinary-product-data-l-romero-fernandez-de-v_en.pdf"},
    {"id":"71147","name":"Presentation - Introducing the care framework:  development of a data-driven quality improvement project (M. Erwood)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:16:18Z","last_updated_date":"2025-11-13T15:16:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introducing-care-framework-development-data-driven-quality-improvement-project-m-erwood_en.pdf"},
    {"id":"71148","name":"Presentation - Data for environment, climate, and animal health (C. Maia, S. Blesic)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T15:17:58Z","last_updated_date":"2025-11-13T15:17:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-data-environment-climate-animal-health-c-maia-s-blesic_en.pdf"},
    {"id":"71236","name":"Presentation - Balancing innovation and access insights from AIM’s (J. Stokx)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-19T10:25:33Z","last_updated_date":"2025-11-19T10:25:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-balancing-innovation-access-insights-aims-j-stokx_en.pptx"},
    {"id":"71237","name":"Presentation - Collaborative models with academia and research institutions/groups (D. Lacombe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-19T10:29:19Z","last_updated_date":"2025-11-19T10:29:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-collaborative-models-academia-research-institutions-groups-d-lacombe_en.pptx"},
    {"id":"71238","name":"Presentation - Incentives to support post-marketing research (F. Nissen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-19T10:34:48Z","last_updated_date":"2025-11-19T10:34:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-incentives-support-post-marketing-research-f-nissen_en.pptx"},
    {"id":"71240","name":"Presentation - Incentives to support post marketing research - industry view (M. Akimov)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-19T10:36:14Z","last_updated_date":"2025-11-19T10:36:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-incentives-support-post-marketing-research-industry-view-m-akimov_en.pptx"},
    {"id":"71241","name":"Presentation - Industry support for pragmatic trials (N. Kronidou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-19T10:48:36Z","last_updated_date":"2025-11-19T10:48:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-support-pragmatic-trials-n-kronidou_en.pptx"},
    {"id":"71243","name":"Presentation - Innovative reward mechanism (S. van Waalwijk van Doorn-Khosrovani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-19T10:54:55Z","last_updated_date":"2025-11-19T10:54:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovative-reward-mechanism-s-van-waalwijk-van-doorn-khosrovani_en.pdf"},
    {"id":"71244","name":"Presentation - Opportunities in sharing molecular clinical data (J. Bergh)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-19T10:58:30Z","last_updated_date":"2025-11-19T10:58:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opportunities-sharing-molecular-clinical-data-j-bergh_en.pptx"},
    {"id":"71328","name":"Presentation - Should dose finding be concluded pre or post approval? (O. Tenhunen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T11:04:11Z","last_updated_date":"2025-11-25T11:04:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-should-dose-finding-be-concluded-pre-or-post-approval-o-tenhunen_en.pdf"},
    {"id":"71329","name":"Presentation - Context setting on CMF initiatives and industry roles (D. Burcoveanu, M. Zaiac)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T11:05:38Z","last_updated_date":"2025-11-25T11:05:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-context-setting-cmf-initiatives-industry-roles-d-burcoveanu-m-zaiac_en.pdf"},
    {"id":"71393","name":"Presentation - EMA experience with the amended variation regulation (V. Rojo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T14:40:25Z","last_updated_date":"2025-11-28T14:40:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-experience-amended-variation-regulation-v-rojo-ema_en.pdf"},
    {"id":"71394","name":"Presentation - Implementation of the classification guideline on variations (T. Girard, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T14:43:08Z","last_updated_date":"2025-11-28T14:43:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-classification-guideline-variations-t-girard-ema_en.pdf"},
    {"id":"71395","name":"Presentation - Update on IRIS (F. Penaranda, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T14:45:27Z","last_updated_date":"2025-11-28T14:45:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-iris-f-penaranda-ema_en.pdf"},
    {"id":"71396","name":"Presentation - Update on eAFand eCTD v4.0 in the CP (K. Puusaari, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T14:46:35Z","last_updated_date":"2025-11-28T14:46:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-eafand-ectd-v40-cp-k-puusaari-ema_en.pdf"},
    {"id":"71397","name":"Presentation - Update on ongoing initiatives in the centralised procedure (F. Day, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T14:49:54Z","last_updated_date":"2025-11-28T14:49:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-ongoing-initiatives-centralised-procedure-f-day-ema_en.pdf"},
    {"id":"71398","name":"Presentation - EMA’s implementation of IPA programme (K. Rugo; M. Hendrix, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T14:50:47Z","last_updated_date":"2025-11-28T14:50:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emas-implementation-ipa-programme-k-rugo-m-hendrix-ema_en.pdf"},
    {"id":"71399","name":"Presentation - EMA SEND Proof-of-concept study (C. Van Doesum-Wolters, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T14:52:19Z","last_updated_date":"2025-11-28T14:52:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-send-proof-concept-study-c-van-doesum-wolters-ema_en.pdf"},
    {"id":"71400","name":"Presentation - Update on QRD template revision and ‘Key information section’ (KIS) survey (A. Skarlatos, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T14:53:58Z","last_updated_date":"2025-11-28T14:53:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-qrd-template-revision-key-information-section-kis-survey-skarlatos-ema_en.pdf"},
    {"id":"71401","name":"Presentation - Update on Patient Experience Data (PED) (R. Gonzalez-Quevedo, EMA),","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T14:55:16Z","last_updated_date":"2025-11-28T14:55:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-patient-experience-data-ped-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"71418","name":"Presentation - ADR Data Quality Framework - Development, summary and next steps (T.Paternoster-Howe, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T11:51:46Z","last_updated_date":"2025-12-01T11:51:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-adr-data-quality-framework-development-summary-next-steps-tpaternoster-howe-ema_en.pdf"},
    {"id":"71419","name":"Presentation - ICH E2D and ICH E2B updates (A.van Haren, Medicines Evaluation Board; G.Touraille, EMA; T.Paternoster-Howe, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T11:53:08Z","last_updated_date":"2025-12-11T09:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-e2d-ich-e2b-updates-avan-haren-medicines-evaluation-board-gtouraille-ema-tpaternoster-howe-ema_en.pdf"},
    {"id":"71420","name":"Presentation - Impact of the EudraVigilance Signal Detection Pilot termination by MAHs: IR.(EU)2025/1466, amendment of IR (EU)520/2012 (E. Savvaidou, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T11:54:16Z","last_updated_date":"2025-12-11T09:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-impact-eudravigilance-signal-detection-pilot-termination-mahs-ireu2025-1466-amendment-ir-eu520-2012-e-savvaidou-ema_en.pdf"},
    {"id":"71421","name":"Presentation - Industry perspective on signal management (J.Zanetic, Teva;  A.Kubavat, Sandoz; R. Van Eemeren, Amgen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T11:55:12Z","last_updated_date":"2025-12-01T11:55:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-signal-management-jzanetic-teva-akubavat-sandoz-r-van-eemeren-amgen_en.pdf"},
    {"id":"71422","name":"Presentation - Best practice for signal assessment - NCA perspective (B.Mulder, Medicines Evaluation Board)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T11:57:01Z","last_updated_date":"2025-12-11T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-practice-signal-assessment-nca-perspective-bmulder-medicines-evaluation-board_en.pdf"},
    {"id":"71423","name":"Presentation - Achievements and impact of the Medical Literature Monitoring (MLM) service - A retrospective review of the first 10 years (T.Paternoster-Howe, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T11:58:20Z","last_updated_date":"2025-12-01T11:58:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-achievements-impact-medical-literature-monitoring-mlm-service-retrospective-review-first-10-years-tpaternoster-howe-ema_en.pdf"},
    {"id":"71424","name":"Presentation - Automated compliance monitoring based on reporting timelines (R.Nic An Ri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T12:01:42Z","last_updated_date":"2025-12-11T09:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-automated-compliance-monitoring-based-reporting-timelines-rnic-ri-ema_en.pdf"},
    {"id":"71425","name":"Presentation - HMA-EMA catalogues of real-world data (RWD) sources and studies (K-C. Deli, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T12:00:34Z","last_updated_date":"2025-12-01T12:00:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hma-ema-catalogues-real-world-data-rwd-sources-studies-k-c-deli-ema_en.pdf"},
    {"id":"71426","name":"Presentation - Real world evidence update (A. Segec, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T12:03:16Z","last_updated_date":"2025-12-01T12:03:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-real-world-evidence-update-segec-ema_en.pdf"},
    {"id":"71427","name":"Presentation - Update on the EU-good pharmacovigilance practices (EU-GVP) (P. Bahri, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T12:04:50Z","last_updated_date":"2025-12-01T12:04:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-eu-good-pharmacovigilance-practices-eu-gvp-p-bahri-ema_en.pdf"},
    {"id":"71428","name":"Presentation - Termination of the pilot of signal detection in EudraVigilance by marketing authorisation holders (MAHs) (S. Eleni, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T12:06:13Z","last_updated_date":"2025-12-01T12:06:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-termination-pilot-signal-detection-eudravigilance-marketing-authorisation-holders-mahs-s-eleni-ema_en.pdf"},
    {"id":"71429","name":"Presentation - AI in pharmacovigilance – EMA update (L. Pinheiro, J. Durand, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T12:07:17Z","last_updated_date":"2025-12-01T12:07:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ai-pharmacovigilance-ema-update-l-pinheiro-j-durand-ema_en.pdf"},
    {"id":"71431","name":"Presentation - The use of EV data and common inspection findings (Dr.Jahn, Paul-Ehrlich-Institut)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T13:21:09Z","last_updated_date":"2025-12-01T13:21:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-use-ev-data-common-inspection-findings-drjahn-paul-ehrlich-institut_en.pdf"},
    {"id":"71432","name":"Presentation - SMART Methods Working Group: Harnessing collective expertise to strengthen signal detection (C.Zaccaria, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T13:22:42Z","last_updated_date":"2025-12-01T13:22:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-smart-methods-working-group-harnessing-collective-expertise-strengthen-signal-detection-czaccaria-ema_en.pdf"},
    {"id":"71433","name":"Presentation - AI in pharmacovigilane - Industry perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T13:24:06Z","last_updated_date":"2025-12-01T13:24:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ai-pharmacovigilane-industry-perspective_en.pdf"},
    {"id":"71434","name":"Presentation - CIOMS Working Group XIV upcoming report on AI in pharmacovigilance (J.Durand, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T13:25:30Z","last_updated_date":"2025-12-01T13:25:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cioms-working-group-xiv-upcoming-report-ai-pharmacovigilance-jdurand-ema_en.pdf"},
    {"id":"71435","name":"Presentation - Updates on EudraVigilance (J.Caetano, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T13:26:22Z","last_updated_date":"2025-12-01T13:26:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-eudravigilance-jcaetano-ema_en.pdf"},
    {"id":"71436","name":"Presentation - Medicinal product reporting - EU implementation of ISO IDMP: from XEVMPD to PMS (A.van Haren, Medicines Evaluation Board; A.Cochino, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T13:27:01Z","last_updated_date":"2025-12-11T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicinal-product-reporting-eu-implementation-iso-idmp-xevmpd-pms-avan-haren-medicines-evaluation-board-acochino-ema_en.pdf"},
    {"id":"71523","name":"Presentation - Patient and HCP engagement highlights 2025 (M. Carr)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T11:32:27Z","last_updated_date":"2025-12-05T11:32:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-hcp-engagement-highlights-2025-m-carr_en.pdf"},
    {"id":"71525","name":"Presentation - Overview of evolution of patient and healthcare professional engagement in EMA activities (M. Mavris)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T11:34:53Z","last_updated_date":"2025-12-05T11:34:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-evolution-patient-healthcare-professional-engagement-ema-activities-m-mavris_en.pdf"},
    {"id":"71526","name":"Presentation - EMA-led RWE generation (D. Morales)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T11:36:47Z","last_updated_date":"2025-12-05T11:36:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-led-rwe-generation-d-morales_en.pdf"},
    {"id":"71528","name":"Presentation - Updates on Cancer Medicines Forum (C. Voltz-Girolt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T11:38:37Z","last_updated_date":"2025-12-05T11:38:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-cancer-medicines-forum-c-voltz-girolt_en.pdf"},
    {"id":"71536","name":"Presentation - Multi-stakeholder platform 2025 activity (D. Lacombe, F. Houÿez, A. Zanoletty)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:02:47Z","last_updated_date":"2025-12-05T15:02:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-multi-stakeholder-platform-2025-activity-d-lacombe-f-houyez-zanoletty_en.pdf"},
    {"id":"71537","name":"Presentation - Accelerating Clinical Trials in the EU (ACT EU) (L. Pioppo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:05:20Z","last_updated_date":"2025-12-05T15:05:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-accelerating-clinical-trials-eu-act-eu-l-pioppo_en.pdf"},
    {"id":"71538","name":"Presentation - A Patient’s quest to the Magical Land of Clinical Trials: Is there a Yellow Brick Road? (I. Psalti)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:06:37Z","last_updated_date":"2025-12-05T15:06:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patients-quest-magical-land-clinical-trials-there-yellow-brick-road-i-psalti_en.pdf"},
    {"id":"71539","name":"Presentation - Annual training 2026 (K. Immonen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:08:18Z","last_updated_date":"2025-12-05T15:08:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-annual-training-2026-k-immonen_en.pdf"},
    {"id":"71540","name":"Presentation - Training on Scientific Advice (L. Barbier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:09:28Z","last_updated_date":"2025-12-05T15:09:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-training-scientific-advice-l-barbier_en.pdf"},
    {"id":"71541","name":"Presentation - EMA international engagement and activities (M. Harvey)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:10:35Z","last_updated_date":"2025-12-05T15:10:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-international-engagement-activities-m-harvey_en.pdf"},
    {"id":"71542","name":"Presentation - Updates from the Cardiovascular Space (M. Holler)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:12:19Z","last_updated_date":"2025-12-05T15:12:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-cardiovascular-space-m-holler_en.pdf"},
    {"id":"71543","name":"Presentation - Aligning policies with real-world medical needs (M. Romano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:13:43Z","last_updated_date":"2025-12-05T15:13:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-aligning-policies-real-world-medical-needs-m-romano_en.pdf"},
    {"id":"71544","name":"Presentation - Proposed Critical Medicines Act (V. Bennett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:14:57Z","last_updated_date":"2025-12-05T15:14:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-proposed-critical-medicines-act-v-bennett_en.pdf"},
    {"id":"71545","name":"Presentation - Introducing to shortages topic (M. Dias)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:16:21Z","last_updated_date":"2025-12-05T15:16:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introducing-shortages-topic-m-dias_en.pdf"},
    {"id":"71546","name":"Presentation - Union list of critical medicines - first annual update (S. McMahon)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:17:36Z","last_updated_date":"2025-12-05T15:17:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-list-critical-medicines-first-annual-update-s-mcmahon_en.pdf"},
    {"id":"71547","name":"Presentation - Shortage Prevention Plan and Shortage Mitigation Plan pilot (M. Alcaraz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:19:52Z","last_updated_date":"2025-12-05T15:19:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-shortage-prevention-plan-shortage-mitigation-plan-pilot-m-alcaraz_en.pdf"},
    {"id":"71548","name":"Presentation - Ongoing critical shortages and activities (K. Kruttwig)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:21:42Z","last_updated_date":"2025-12-05T15:21:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ongoing-critical-shortages-activities-k-kruttwig_en.pdf"},
    {"id":"71549","name":"Presentation - EAHP Survey on the shortages of medicines and  medical devices (D. Makridaki)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:22:52Z","last_updated_date":"2025-12-05T15:22:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eahp-survey-shortages-medicines-medical-devices-d-makridaki_en.pdf"},
    {"id":"71550","name":"Presentation - EMA-HMA repurposing pilot report (C. Bouygues)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:24:05Z","last_updated_date":"2025-12-05T15:24:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-hma-repurposing-pilot-report-c-bouygues_en.pdf"},
    {"id":"71551","name":"Presentation - Social media campaigns (G. Gabrielli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:25:10Z","last_updated_date":"2025-12-05T15:25:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-social-media-campaigns-g-gabrielli_en.pdf"},
    {"id":"71552","name":"Presentation - Gender equality in women’s health - the forgotten priority (C. de Vries)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:26:41Z","last_updated_date":"2025-12-05T15:26:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-gender-equality-womens-health-forgotten-priority-c-de-vries_en.pdf"},
    {"id":"71553","name":"Presentation - Communications on safety monitoring of medicines in the EU (V. Pashova, S. Cohen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:28:08Z","last_updated_date":"2025-12-05T15:28:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-communications-safety-monitoring-medicines-eu-v-pashova-s-cohen_en.pdf"},
    {"id":"71554","name":"Presentation - Medicine overviews - Feedback from patient and healthcare professional survey (C. Ester)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:29:27Z","last_updated_date":"2025-12-05T15:29:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-medicine-overviews-feedback-patient-healthcare-professional-survey-c-ester_en.pdf"},
    {"id":"71555","name":"Presentation - Update on Human Medicines Highlights (K. Immonen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T15:31:26Z","last_updated_date":"2025-12-05T15:31:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-human-medicines-highlights-k-immonen_en.pdf"},
    {"id":"71602","name":"Presentation - Focus Group on agility in scientific advice (I.Gravanis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T11:13:35Z","last_updated_date":"2025-12-09T11:13:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-focus-group-agility-scientific-advice-igravanis-ema_en.pdf"},
    {"id":"71603","name":"Presentation - HMA/EMA multi-stakeholder workshop on reporting and qualification of mechanistic modelsfor regulatory assessment - Summary report from the meeting and follow-up activities (E.Manolis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T11:14:26Z","last_updated_date":"2025-12-09T11:14:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hma-ema-multi-stakeholder-workshop-reporting-qualification-mechanistic-modelsfor-regulatory-assessment-summary-report-meeting-follow-activities-emanolis-ema_en.pdf"},
    {"id":"71604","name":"Presentation - Streamlining product-specific bioequivalence guidance (C.Versantvoort, D.van den Haak, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T11:15:07Z","last_updated_date":"2025-12-09T11:15:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-streamlining-product-specific-bioequivalence-guidance-cversantvoort-dvan-den-haak-ema_en.pdf"},
    {"id":"71605","name":"Presentation - Future-proofing Qualification of Novel Methodologies (QoNM) - Update on delivery of the action plan  (I.Gravanis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T11:16:02Z","last_updated_date":"2025-12-09T11:16:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-future-proofing-qualification-novel-methodologies-qonm-update-delivery-action-plan-igravanis-ema_en.pdf"},
    {"id":"71606","name":"Presentation - Mechanism of action based PIPs in paediatric oncology (M.Sheean, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T11:19:17Z","last_updated_date":"2025-12-09T11:19:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mechanism-action-based-pips-paediatric-oncology-msheean-ema_en.pdf"},
    {"id":"71607","name":"Presentation - Implementation of pilot initiatives based on first 5 years’ experience of PRIME: Analysis (K.Cunningham, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T11:19:51Z","last_updated_date":"2025-12-09T11:19:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-pilot-initiatives-based-first-5-years-experience-prime-analysis-kcunningham-ema_en.pdf"},
    {"id":"71608","name":"Presentation - Updates from EMA on scientific advice (I.Gravanis, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T11:20:32Z","last_updated_date":"2025-12-09T11:20:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-ema-scientific-advice-igravanis-ema_en.pdf"},
    {"id":"71609","name":"Presentation - Reframing the voluntary data submission to foster regulatory acceptance of NAMs (S.Ponzano, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T11:21:05Z","last_updated_date":"2025-12-09T11:21:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reframing-voluntary-data-submission-foster-regulatory-acceptance-nams-sponzano-ema_en.pdf"},
    {"id":"71650","name":"Presentation - Introducing the Principle of Responsible Inclusion of Children in the Declaration of Helsinki (2024) (D.Sprumont)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:07:47Z","last_updated_date":"2025-12-10T15:07:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introducing-principle-responsible-inclusion-children-declaration-helsinki-2024-dsprumont_en.pdf"},
    {"id":"71651","name":"Presentation - Quality criteria for paediatric clinical trial sites - an Enpr-EMA initiative (P. Skovby, R. Fernandes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:09:13Z","last_updated_date":"2025-12-10T15:09:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-criteria-paediatric-clinical-trial-sites-enpr-ema-initiative-p-skovby-r-fernandes_en.pdf"},
    {"id":"71652","name":"Presentation - Enpr-EMA Annual Report 2024-2025 (P. Lepola, I. Sanchez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:10:11Z","last_updated_date":"2025-12-10T15:10:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-annual-report-2024-2025-p-lepola-i-sanchez_en.pdf"},
    {"id":"71653","name":"Presentation - Case study: Leveraging external data for efficient pediatric study design in multiple sclerosis (D. Hearing, M. Thomas)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:10:47Z","last_updated_date":"2025-12-10T15:10:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-leveraging-external-data-efficient-pediatric-study-design-multiple-sclerosis-d-hearing-m-thomas_en.pdf"},
    {"id":"71655","name":"Presentation - Case Study: Novel Pediatric Trial Design - A study to evaluate the efficacy, safety, and tolerability of Brivaracetam (G. Calarco Smith)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:11:27Z","last_updated_date":"2025-12-10T15:11:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-case-study-novel-pediatric-trial-design-study-evaluate-efficacy-safety-tolerability-brivaracetam-g-calarco-smith_en.pdf"},
    {"id":"71656","name":"Presentation - Translation research from lab to patients - Latest innovations by EPTRI (D. Bonifazi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:12:36Z","last_updated_date":"2025-12-10T15:12:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-translation-research-lab-patients-latest-innovations-eptri-d-bonifazi_en.pdf"},
    {"id":"71657","name":"Presentation - Restoring agility - AI and the future of the paediatric research in Europe (J. Isla)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:13:12Z","last_updated_date":"2025-12-10T15:13:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-restoring-agility-ai-future-paediatric-research-europe-j-isla_en.pdf"},
    {"id":"71658","name":"Presentation - European Health Data Space (D. Morales)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:13:51Z","last_updated_date":"2025-12-10T15:13:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-health-data-space-d-morales_en.pdf"},
    {"id":"71659","name":"Presentation - Putting E11A into practice - Extrapolation from guideline to application (D. Karres)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:14:19Z","last_updated_date":"2025-12-10T15:14:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-putting-e11a-practice-extrapolation-guideline-application-d-karres_en.pdf"},
    {"id":"71660","name":"Presentation - Paediatric clinical trial assessments under the new CTR - from PIP to CTA (L. Fankhauser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:15:00Z","last_updated_date":"2025-12-10T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-clinical-trial-assessments-under-new-ctr-pip-cta-l-fankhauser_en.pdf"},
    {"id":"71661","name":"Presentation - Overview of ICH E6 R3 renovation (P.Twomey)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:15:30Z","last_updated_date":"2025-12-10T15:15:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-ich-e6-r3-renovation-ptwomey_en.pdf"},
    {"id":"71663","name":"Presentation - Quality criteria for paediatric clinical trial sites - an Enpr-EMA initiative (R. Fernandez, P. Skovby)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:01:39Z","last_updated_date":"2025-12-10T15:01:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quality-criteria-paediatric-clinical-trial-sites-enpr-ema-initiative-r-fernandez-p-skovby_en.pdf"},
    {"id":"71664","name":"Presentation - Paediatric cross-border clinical trials: Enpr-EMA Working Group (B. Nafria)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:02:46Z","last_updated_date":"2025-12-10T15:02:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-cross-border-clinical-trials-enpr-ema-working-group-b-nafria_en.pdf"},
    {"id":"71665","name":"Presentation - Enpr-EMA Paediatric research nurse working group (P. Dicks)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:04:23Z","last_updated_date":"2025-12-10T15:04:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-paediatric-research-nurse-working-group-p-dicks_en.pdf"}    {"id":"71666","name":"Presentation - Patient and public involvement (PPI) working group (S. Gaillard)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:05:43Z","last_updated_date":"2025-12-10T15:05:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-public-involvement-ppi-working-group-s-gaillard_en.pdf"},
    {"id":"71667","name":"Presentation - ACT EU: Collaboration with Enpr-EMA (L. Pioppo, M. Al)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:06:45Z","last_updated_date":"2025-12-10T15:06:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-collaboration-enpr-ema-l-pioppo-m-al_en.pdf"},
    {"id":"71668","name":"Presentation - The Lancet Child & Adolescent Health Commission on the future of neonatology (M. Turner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:08:20Z","last_updated_date":"2025-12-10T15:08:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lancet-child-adolescent-health-commission-future-neonatology-m-turner_en.pdf"},
    {"id":"71669","name":"Presentation - Paediatric clinical research: Overcoming challenges and hurdles to foster innovation with Enpr-EMA (A. Siapkara)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:09:01Z","last_updated_date":"2025-12-10T15:09:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-paediatric-clinical-research-overcoming-challenges-hurdles-foster-innovation-enpr-ema-siapkara_en.pdf"},
    {"id":"71670","name":"Presentation - Non-oncological MoA based PIP – Initial deliberations from the PDCO working group discussions (S. Scherer)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:10:21Z","last_updated_date":"2025-12-10T15:10:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-oncological-moa-based-pip-initial-deliberations-pdco-working-group-discussions-s-scherer_en.pdf-0"},
    {"id":"71671","name":"Presentation - Mechanism of action based PIPs in paediatric oncology (M. Sheean)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:11:25Z","last_updated_date":"2025-12-10T15:11:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mechanism-action-based-pips-paediatric-oncology-m-sheean_en.pdf"},
    {"id":"71672","name":"Presentation - Strategic aims of Enpr-EMA 2025-2027 (P. Lepola)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:12:06Z","last_updated_date":"2025-12-10T15:12:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-strategic-aims-enpr-ema-2025-2027-p-lepola_en.pdf"},
    {"id":"71673","name":"Presentation - Enpr-EMA: Modernisation (N. Rodriguez Barcons)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:12:52Z","last_updated_date":"2025-12-10T15:12:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-enpr-ema-modernisation-n-rodriguez-barcons_en.pdf"},
    {"id":"71674","name":"Presentation - Compiance monitoring based on reporting timelines (T. Paternoster-Howe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T15:22:54Z","last_updated_date":"2025-12-10T15:22:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-compiance-monitoring-based-reporting-timelines-t-paternoster-howe_en.pdf"},
    {"id":"71678","name":"Presentation - European Rare Diseases Research Alliance ERDERA (D. Julkowska)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T16:58:36Z","last_updated_date":"2025-12-10T16:58:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-rare-diseases-research-alliance-erdera-d-julkowska_en.pdf"},
    {"id":"71679","name":"Presentation - ACT EU Paediatrics Trials in EU EEA Workshop on the assessment of clinical trials (A. Solli Karlsen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T16:59:19Z","last_updated_date":"2025-12-10T16:59:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-paediatrics-trials-eu-eea-workshop-assessment-clinical-trials-solli-karlsen_en.pdf"},
    {"id":"71734","name":"Presentation - Actions arising from previous meeting and other updates (M. Filancia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T14:35:22Z","last_updated_date":"2025-12-12T14:35:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-actions-arising-previous-meeting-other-updates-m-filancia-ema_en.pdf-1"},
    {"id":"71735","name":"Presentation - New pharmaceutical legislation update : engagement with industry during implementation (M. Carr, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T14:38:15Z","last_updated_date":"2025-12-12T14:38:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmaceutical-legislation-update-engagement-industry-during-implementation-m-carr-ema_en.pdf"},
    {"id":"71736","name":"Presentation - Regulatory / HTA interface under the HTAR – update on implementation activities (N. Manent & D. Karres, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T14:41:16Z","last_updated_date":"2025-12-12T14:41:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-hta-interface-under-htar-update-implementation-activities-n-manent-d-karres-ema_en.pdf"},
    {"id":"71737","name":"Presentation - HTA Regulation (V. Barbuto, EC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T14:43:26Z","last_updated_date":"2025-12-12T14:43:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hta-regulation-v-barbuto-ec_en.pdf"},
    {"id":"71738","name":"Presentation - Publication of information in CVMP agenda and minutes (S. Ribeiro & T. Ferreira, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T14:44:45Z","last_updated_date":"2025-12-12T14:44:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-publication-information-cvmp-agenda-minutes-s-ribeiro-t-ferreira-ema_en.pdf"},
    {"id":"71739","name":"Presentation - OPEN framework (N. Perombelon, H. Cuenca & R. Cherif, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T14:46:04Z","last_updated_date":"2025-12-12T14:46:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-open-framework-n-perombelon-h-cuenca-r-cherif-ema_en.pdf"},
    {"id":"71740","name":"Presentation - Update on Product Management Service (PMS) (H. Hamann & I. Chicharo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T14:48:35Z","last_updated_date":"2025-12-12T14:48:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-product-management-service-pms-h-hamann-i-chicharo-ema_en.pdf"},
    {"id":"71741","name":"Presentation - Industry stakeholders feedback on engagement and communication activities (M. Filancia, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T14:49:53Z","last_updated_date":"2025-12-12T14:49:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-stakeholders-feedback-engagement-communication-activities-m-filancia-ema_en.pdf"},
    {"id":"71823","name":"Presentation - System Demo Q4 2025","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-17T16:09:39Z","last_updated_date":"2025-12-17T16:09:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-system-demo-q4-2025_en.pdf"},
    {"id":"71893","name":"Presentation - Opening remarks from the European Commission: HMA/EMA multi-stakeholder workshop on Patient Registries for Alzheimer's disease (T. Raemaekers)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T09:40:20Z","last_updated_date":"2025-12-22T09:40:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-remarks-european-commission-hma-ema-multi-stakeholder-workshop-patient-registries-alzheimers-disease-t-raemaekers_en.pdf"},
    {"id":"71894","name":"Presentation - Lived experience of Alzheimer’s Disease (European Working Group of People with Dementia) (S. Dougall)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T09:41:58Z","last_updated_date":"2025-12-22T09:41:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lived-experience-alzheimers-disease-european-working-group-people-dementia-s-dougall_en.pdf"},
    {"id":"71895","name":"Presentation - Introduction on Alzheimer’s Disease and current therapies (M. Haberkamp)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T09:42:52Z","last_updated_date":"2025-12-22T09:42:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-alzheimers-disease-current-therapies-m-haberkamp_en.pdf"},
    {"id":"71896","name":"Presentation - Industry perspective on real-world evidence generation: Shaping fit-for-purpose Alzheimer’s Disease registries (E. Grace and P. Dobay)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T09:43:50Z","last_updated_date":"2025-12-22T09:43:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-industry-perspective-real-world-evidence-generation-shaping-fit-purpose-alzheimers-disease-registries-e-grace-p-dobay_en.pdf"},
    {"id":"71897","name":"Presentation - EU Regulator's view on RWD in Alzheimer's disease (P. Mol)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T09:46:37Z","last_updated_date":"2025-12-22T09:46:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-regulators-view-rwd-alzheimers-disease-p-mol_en.pdf"},
    {"id":"71898","name":"Presentation - FDA: Real-world data in Alzheimer's disease (T. Buracchio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T09:49:28Z","last_updated_date":"2025-12-22T09:49:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-real-world-data-alzheimers-disease-t-buracchio_en.pdf"},
    {"id":"71899","name":"Presentation - HTA perspective on real-world evidence generation (N. Hedberg)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T09:53:40Z","last_updated_date":"2025-12-22T09:53:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hta-perspective-real-world-evidence-generation-n-hedberg_en.pdf"},
    {"id":"71900","name":"Presentation - Payer's perspective: Current evidence gaps and potential of real-world data (C. Hernandez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T09:55:05Z","last_updated_date":"2025-12-22T09:55:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-payers-perspective-current-evidence-gaps-potential-real-world-data-c-hernandez_en.pdf"},
    {"id":"71901","name":"Presentation - Healthcare professional perspective on real-world evidence generation (K. Frederiksen)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T09:57:11Z","last_updated_date":"2025-12-22T09:57:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-healthcare-professional-perspective-real-world-evidence-generation-k-frederiksen_en.pdf"},
    {"id":"71902","name":"Presentation - Patient representative perspective: Understanding European perspectives on data sharing (L. Duffner)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T10:01:07Z","last_updated_date":"2025-12-22T10:01:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-representative-perspective-understanding-european-perspectives-data-sharing-l-duffner_en.pdf"},
    {"id":"71903","name":"Presentation - Big MS Network: Multiple sclerosis lessons for Alzheimer’s Disease registries (J. Hillert)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T10:03:09Z","last_updated_date":"2025-12-22T10:03:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-big-ms-network-multiple-sclerosis-lessons-alzheimers-disease-registries-j-hillert_en.pdf"},
    {"id":"71904","name":"Presentation - Swedish registry for cognitive and dementia disorders (SveDem): Registry holder's perspectives on real-world evidence generation (D. Religa)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T10:04:54Z","last_updated_date":"2025-12-22T10:04:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-swedish-registry-cognitive-dementia-disorders-svedem-registry-holders-perspectives-real-world-evidence-generation-d-religa_en.pdf"},
    {"id":"71905","name":"Presentation - International Registry for Alzheimer's Disease and Other Dementias (InRAD): Driving international collaboration for real-world evidence in Alzheimer's disease (R. Perneczky and R. Hyde)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T10:06:41Z","last_updated_date":"2025-12-22T10:06:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-registry-alzheimers-disease-other-dementias-inrad-driving-international-collaboration-real-world-evidence-alzheimers-disease-r-perneczky-r-hyde_en.pdf"},
    {"id":"71928","name":"Presentation - Closing keynote: Healthcare beyond human capabilities (I. Medrano)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T09:58:54Z","last_updated_date":"2026-01-06T09:58:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-closing-keynote-healthcare-beyond-human-capabilities-i-medrano_en.pdf"},
    {"id":"71929","name":"Presentation - Opening remarks: Strengthening the role of patient data in regulatory decisions (M. de Lemus Belmonte)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:00:11Z","last_updated_date":"2026-01-06T10:00:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-remarks-strengthening-role-patient-data-regulatory-decisions-m-de-lemus-belmonte_en.pdf"},
    {"id":"71930","name":"Presentation - Session 1: Progress for a data driven regulatory system (P. Arlett)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:01:17Z","last_updated_date":"2026-01-06T10:01:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-progress-data-driven-regulatory-system-p-arlett_en.pdf"},
    {"id":"71931","name":"Presentation - Session 2: Ethics of data in a digital age (A.Blasimme)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:01:59Z","last_updated_date":"2026-01-06T10:01:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-ethics-data-digital-age-ablasimme_en.pdf"},
    {"id":"71932","name":"Presentation - Session 2: How new EU legislations will transform medicines regulation (J. De Barros and V.Apostolidou)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:02:40Z","last_updated_date":"2026-01-06T10:02:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-how-new-eu-legislations-will-transform-medicines-regulation-j-de-barros-vapostolidou_en.pdf"},
    {"id":"71933","name":"Presentation - Session 3: Medicines master data for smarter regulation (A. Torqui)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:03:33Z","last_updated_date":"2026-01-06T10:03:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-medicines-master-data-smarter-regulation-torqui_en.pdf"},
    {"id":"71934","name":"Presentation - Session 3: The EMRN data strategy (G. Neuwirther)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:04:26Z","last_updated_date":"2026-01-06T10:04:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-3-emrn-data-strategy-g-neuwirther_en.pdf"},
    {"id":"71935","name":"Presentation - Session 4: Patient generated data (F. Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:05:07Z","last_updated_date":"2026-01-06T10:05:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-patient-generated-data-f-houyez_en.pdf"},
    {"id":"71937","name":"Presentation - Session 4: Personalised medicines data, including Omics (M. Pirmohamed)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:05:47Z","last_updated_date":"2026-01-06T10:05:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-personalised-medicines-data-including-omics-m-pirmohamed_en.pdf"},
    {"id":"71938","name":"Presentation - Session 4: AI used in clinical dossier (E. Nikai)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:09:33Z","last_updated_date":"2026-01-06T10:09:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-ai-used-clinical-dossier-e-nikai_en.pdf"},
    {"id":"71939","name":"Presentation - Session 4: Digital health innovation and regulatory opportunities (E. Dashiell-Aje)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:10:17Z","last_updated_date":"2026-01-06T10:10:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-digital-health-innovation-regulatory-opportunities-e-dashiell-aje_en.pdf"},
    {"id":"71940","name":"Presentation - Session 4: Innovative clinical trial design (K. Oude Rengerink)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:21:57Z","last_updated_date":"2026-01-06T10:21:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-innovative-clinical-trial-design-k-oude-rengerink_en.pdf"},
    {"id":"71941","name":"Presentation - Session 4: Modelling and simulation (F. Musuamba)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:23:06Z","last_updated_date":"2026-01-06T10:23:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-4-modelling-simulation-f-musuamba_en.pdf"},
    {"id":"71942","name":"Session 4: Organoids, Digital Twins and Synthetic data (J. Rangarajan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-06T10:24:44Z","last_updated_date":"2026-01-06T10:24:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/session-4-organoids-digital-twins-synthetic-data-j-rangarajan_en.pdf"},
    {"id":"71957","name":"Presentation - Animal models for emerging infectious diseases","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:04:31Z","last_updated_date":"2026-01-07T15:04:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-animal-models-emerging-infectious-diseases_en.pdf"},
    {"id":"71958","name":"Presentation - Challenges in developing medical countermeasures for public health threats","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:06:29Z","last_updated_date":"2026-01-07T15:06:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-challenges-developing-medical-countermeasures-public-health-threats_en.pdf"},
    {"id":"71959","name":"Presentation - EMA regulatory framework","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:07:23Z","last_updated_date":"2026-01-07T15:07:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-regulatory-framework_en.pdf"},
    {"id":"71960","name":" Presentation - FDA regulatory framework","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:10:35Z","last_updated_date":"2026-01-07T15:10:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fda-regulatory-framework_en.pdf"},
    {"id":"71961","name":"Presentation - How to build the right animal model for efficacy demonstration","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:11:45Z","last_updated_date":"2026-01-07T15:11:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-build-right-animal-model-efficacy-demonstration_en.pdf"},
    {"id":"71962","name":"Presentation - Animal models for Ebola vaccines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:12:37Z","last_updated_date":"2026-01-07T15:12:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-animal-models-ebola-vaccines_en.pdf"},
    {"id":"71963","name":"Presentation - Bridging non-clinical models to human vaccine efficacy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:13:15Z","last_updated_date":"2026-01-07T15:13:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-bridging-non-clinical-models-human-vaccine-efficacy_en.pdf"},
    {"id":"71964","name":"Presentation - Chikungunya vaccines: the road to regulatory approval in the EU","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:13:57Z","last_updated_date":"2026-01-07T15:13:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-chikungunya-vaccines-road-regulatory-approval-eu_en.pdf"},
    {"id":"71965","name":"Presentation - Regulatory approval of Zabdeno / Mvabea","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:15:54Z","last_updated_date":"2026-01-07T15:15:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-approval-zabdeno-mvabea_en.pdf"},
    {"id":"71966","name":"Presentation - Modelling and extrapolation to humans - Ebola as a case example","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:16:56Z","last_updated_date":"2026-01-07T15:16:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-modelling-extrapolation-humans-ebola-case-example_en.pdf"},
    {"id":"71967","name":"Presentation - Non-clinical models for orthopoxviruses (mpox)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:17:44Z","last_updated_date":"2026-01-07T15:17:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-clinical-models-orthopoxviruses-mpox_en.pdf"},
    {"id":"71968","name":"Presentation - The regulatory approval of Tecovirimat for orthopoxviruses in the EU","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:18:30Z","last_updated_date":"2026-01-07T15:18:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-approval-tecovirimat-orthopoxviruses-eu_en.pdf"},
    {"id":"71969","name":"Presentation - Which models for anthrax monoclonal antibodies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:19:23Z","last_updated_date":"2026-01-07T15:19:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-which-models-anthrax-monoclonal-antibodies_en.pdf"},
    {"id":"71970","name":"Presentation - Animal models for botulism anti-toxins","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:23:10Z","last_updated_date":"2026-01-07T15:23:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-animal-models-botulism-anti-toxins_en.pdf"},
    {"id":"71971","name":"Presentation - EU authorisation of therapeutics for Acute Radiation Syndrome","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:23:46Z","last_updated_date":"2026-01-07T15:23:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-authorisation-therapeutics-acute-radiation-syndrome_en.pdf"},
    {"id":"71972","name":"Presentation - Non-clinical development of countermeasures for radio-nuclear threats","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:24:27Z","last_updated_date":"2026-01-07T15:24:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-non-clinical-development-countermeasures-radio-nuclear-threats_en.pdf"},
    {"id":"71973","name":"Presentation - Computational methods for efficacy generation_how far are we","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:25:09Z","last_updated_date":"2026-01-07T15:25:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-computational-methods-efficacy-generation_how-far-are-we_en.pdf"},
    {"id":"71974","name":"Presentation - EMA 3R regulatory framework","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:25:48Z","last_updated_date":"2026-01-07T15:25:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ema-3r-regulatory-framework_en.pdf"},
    {"id":"71975","name":"Presentation - From innovation to regulation: Opportunities and limitations of non-animal evidence for efficacy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:26:25Z","last_updated_date":"2026-01-07T15:26:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovation-regulation-opportunities-limitations-non-animal-evidence-efficacy_en.pdf"},
    {"id":"71976","name":"Presentation - Lungs on a chip to test viral infections and medicines efficacy","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:27:35Z","last_updated_date":"2026-01-07T15:27:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-lungs-chip-test-viral-infections-medicines-efficacy_en.pdf"},
    {"id":"71977","name":"Presentation - The mice phrenic nerve hemidiaphragm for botulism antitoxins","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:32:00Z","last_updated_date":"2026-01-07T15:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-mice-phrenic-nerve-hemidiaphragm-botulism-antitoxins_en.pdf"},
    {"id":"71978","name":"Presentation - Post-authorisation efficacy data in humans: Clinical perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:32:42Z","last_updated_date":"2026-01-07T15:32:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-authorisation-efficacy-data-humans-clinical-perspective_en.pdf"},
    {"id":"71979","name":"Presentation - Post-authorisation efficacy data in humans: Regulatory perspective","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T15:33:35Z","last_updated_date":"2026-01-07T15:33:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-post-authorisation-efficacy-data-humans-regulatory-perspective_en.pdf"},
    {"id":"72048","name":"Presentation - New variations guidelines: webinar for marketing authorisation holders (human)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-14T15:41:00Z","last_updated_date":"2026-01-14T15:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-variations-guidelines-webinar-marketing-authorisation-holders-human_en.pdf"},
    {"id":"72072","name":"Presentation - New Variation Classification in eAF - Q&A Clinic","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T15:37:19Z","last_updated_date":"2026-01-15T15:37:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-variation-classification-eaf-qa-clinic_en.pdf"},
    {"id":"72082","name":"Presentation - Decentralized clinical trials (L.Sacks, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:17:12Z","last_updated_date":"2026-01-16T09:17:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-decentralized-clinical-trials-lsacks-fda_en.pdf"},
    {"id":"72083","name":"Presentation - EU recommendations on decentralised elements in clinical trials (M.Wendt, Swedish MPA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:17:56Z","last_updated_date":"2026-01-16T09:17:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eu-recommendations-decentralised-elements-clinical-trials-mwendt-swedish-mpa_en.pdf"},
    {"id":"72086","name":"Presentation - How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions? (C.Voltz, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:22:28Z","last_updated_date":"2026-01-16T09:22:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-can-patient-reported-outcomes-pro-health-related-quality-life-hrqol-data-inform-regulatory-decisions-cvoltz-ema_en.pdf"},
    {"id":"72087","name":"Presentation - Patient reported outcomes and vision related quality of life questionnaires (F.Bocell, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:24:26Z","last_updated_date":"2026-01-16T09:24:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-reported-outcomes-vision-related-quality-life-questionnaires-fbocell-fda_en.pdf"},
    {"id":"72088","name":"Presentation - How shortages are handled int he EU (K.Kruttwig, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:26:36Z","last_updated_date":"2026-01-16T09:26:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-shortages-are-handled-int-he-eu-kkruttwig-ema_en.pdf"},
    {"id":"72089","name":"Presentation - FDA’s drug shortage role and patient resources (R.Kosko, FDA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T09:27:14Z","last_updated_date":"2026-01-16T09:27:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fdas-drug-shortage-role-patient-resources-rkosko-fda_en.pdf"},
    {"id":"72197","name":"Presentation - Update on QRD template revision and ‘Key information section’ (KIS) survey (M. Buch)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T16:00:56Z","last_updated_date":"2026-01-21T16:00:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-qrd-template-revision-key-information-section-kis-survey-m-buch_en.pdf"},
    {"id":"72280","name":"Presentation - SPOR & XEVMPD Status Update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T10:45:25Z","last_updated_date":"2026-02-02T11:17:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-xevmpd-status-update_en.pdf"},
    {"id":"72463","name":"Presentation - A new pharmaceutical framework for Europe and its patients (L. Luchianov and A. Rodiadis (EC))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:15:53Z","last_updated_date":"2026-02-10T10:15:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmaceutical-framework-europe-its-patients-l-luchianov-rodiadis-ec_en.pdf"},
    {"id":"72464","name":"Presentation - New pharma legislation (A.Nolte, M. Carr (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:20:43Z","last_updated_date":"2026-02-10T10:20:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharma-legislation-anolte-m-carr-ema_en.pdf"},
    {"id":"72465","name":"Presentation - From regulatory decision to health technology assessment: the new developments in Europe (M. Berntgen, N. Manent (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:22:39Z","last_updated_date":"2026-02-10T10:22:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-decision-health-technology-assessment-new-developments-europe-m-berntgen-n-manent-ema_en.pdf"},
    {"id":"72466","name":"Presentation - HTA regulation: experience from the first year of implementation (J. Spony (EC))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:24:38Z","last_updated_date":"2026-02-10T10:24:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hta-regulation-experience-first-year-implementation-j-spony-ec_en.pdf"},
    {"id":"72467","name":"Presentation - Next steps in the ECHA assessment of the PFAS universal restriction under REACH (L. Enes and R. Mezzasalma (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:26:06Z","last_updated_date":"2026-02-10T10:26:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-next-steps-echa-assessment-pfas-universal-restriction-under-reach-l-enes-r-mezzasalma-ema_en.pdf"},
    {"id":"72468","name":"Presentation - Shortage mitigation and management at EU level (S. McMahon (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:27:12Z","last_updated_date":"2026-02-10T10:27:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-shortage-mitigation-management-eu-level-s-mcmahon-ema_en.pdf"},
    {"id":"72469","name":"Presentation - Union list of critical medicines: launch of 2026 annual review (S. McMahon (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:28:48Z","last_updated_date":"2026-02-10T10:28:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-list-critical-medicines-launch-2026-annual-review-s-mcmahon-ema_en.pdf"},
    {"id":"72470","name":"Presentation - Candidate countries observing EMA activities (K. Rugo (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:30:12Z","last_updated_date":"2026-02-10T10:30:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-candidate-countries-observing-ema-activities-k-rugo-ema_en.pdf"},
    {"id":"72471","name":"Presentation - ICH E22 guideline on general considerations for patient preference studies (F. Pignatti (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:32:39Z","last_updated_date":"2026-02-10T10:32:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-e22-guideline-general-considerations-patient-preference-studies-f-pignatti-ema_en.pdf"},
    {"id":"72472","name":"Presentation - HMA-EMA Catalogues of real-world data (RWD) sources and studies (K. Deli (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:33:57Z","last_updated_date":"2026-02-10T10:33:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-hma-ema-catalogues-real-world-data-rwd-sources-studies-k-deli-ema_en.pdf"},
    {"id":"72473","name":"Presentation - Emerging topics from PED reflection paper consultation (R. Gonzalez-Quevedo (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:37:10Z","last_updated_date":"2026-02-10T10:37:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emerging-topics-ped-reflection-paper-consultation-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"72474","name":"Presentation - Feedback from surveys in PED priority areas (C. Espinasse, F. Borrelly, F. Wilke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:38:32Z","last_updated_date":"2026-02-10T10:38:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-surveys-ped-priority-areas-c-espinasse-f-borrelly-f-wilke_en.pdf"},
    {"id":"72475","name":"Presentation - Feedback from the HMA-EMA multistakeholder workshop on artificial intelligence (L. Pinheiro (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:39:37Z","last_updated_date":"2026-02-10T10:39:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-feedback-hma-ema-multistakeholder-workshop-artificial-intelligence-l-pinheiro-ema_en.pdf"},
    {"id":"72476","name":"Presentation - Information on workshop for medicines and medical devices in the cardiovascular field (I. Silva (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:40:33Z","last_updated_date":"2026-02-10T10:40:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-information-workshop-medicines-medical-devices-cardiovascular-field-i-silva-ema_en.pdf"},
    {"id":"72477","name":"Presentation - EUNTC training modules","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:42:12Z","last_updated_date":"2026-02-10T10:42:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-euntc-training-modules_en.pdf"},
    {"id":"72478","name":"Presentation - Establishment of an expert group on vaccine confidence – call for volunteers (R. Gonzalez-Quevedo (EMA))","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T10:43:41Z","last_updated_date":"2026-02-10T10:43:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-establishment-expert-group-vaccine-confidence-call-volunteers-r-gonzalez-quevedo-ema_en.pdf"},
    {"id":"72492","name":"Presentation - Overview of the 5-year journey and activities of the Policy Officers Group (POG) (M. Bonafonte, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T14:54:09Z","last_updated_date":"2026-02-10T14:54:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-5-year-journey-activities-policy-officers-group-pog-m-bonafonte-ema_en.pdf"},
    {"id":"72493","name":"Presentation - Selecting outcomes that are relevant to patients and healthcare professionals for trials (A. Mathioudakis, ERS)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T14:55:49Z","last_updated_date":"2026-02-10T14:55:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-selecting-outcomes-are-relevant-patients-healthcare-professionals-trials-mathioudakis-ers_en.pdf"},
    {"id":"72494","name":"Presentation - The Union List of Critical Medicines : current progress and reflections to enhance HCPs consultation (M. Kostrubiec, ESC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T15:00:14Z","last_updated_date":"2026-02-10T15:00:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-list-critical-medicines-current-progress-reflections-enhance-hcps-consultation-m-kostrubiec-esc_en.pdf"},
    {"id":"72501","name":"Presentation - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) e-learning - XEVMPD data submission process (version 1)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-11T09:43:33Z","last_updated_date":"2026-02-11T09:43:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-extended-eudravigilance-medicinal-product-dictionary-xevmpd-e-learning-xevmpd-data-submission-process-version-1_en.pdf"}    {"id":"72502","name":"Presentation - Shortages (A.Mirabile, E. Petelos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-11T10:28:12Z","last_updated_date":"2026-02-11T10:28:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-shortages-amirabile-e-petelos_en.pdf"},
    {"id":"72659","name":"Presentation - 1 year on: HTA in practice (S. Jouan)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-24T10:18:45Z","last_updated_date":"2026-02-24T10:18:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-1-year-hta-practice-s-jouan_en.pdf"},
    {"id":"72660","name":"Presentation - The union list of critical medicines (F. Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-24T10:21:49Z","last_updated_date":"2026-02-24T10:21:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-list-critical-medicines-f-houyez_en.pdf"},
    {"id":"72661","name":"Presentation - Patient preferences studies (F. Houyez)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-24T10:23:32Z","last_updated_date":"2026-02-24T10:23:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-preferences-studies-f-houyez_en.pdf"},
    {"id":"72662","name":"Presentation - Patient experience data in regulatory decision-making (D. Almeida, D. Umuhire, C. Jonker, K. Plueschke, R. Gonzalez-Quevedo, B. Sepodes, C. Torre)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-02-24T10:28:30Z","last_updated_date":"2026-02-24T10:28:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-experience-data-regulatory-decision-making-d-almeida-d-umuhire-c-jonker-k-plueschke-r-gonzalez-quevedo-b-sepodes-c-torre_en.pdf"},
    {"id":"72813","name":"How to apply and benefit from scientific advice - Training for academic medicine developers","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T10:14:15Z","last_updated_date":"2026-03-04T10:14:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/how-apply-benefit-scientific-advice-training-academic-medicine-developers_en.pdf"},
    {"id":"72896","name":"Presentation - Session 1 - Current regulatory routes for individualised therapies (I. Reischl-Kok)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T14:05:49Z","last_updated_date":"2026-03-09T14:05:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-current-regulatory-routes-individualised-therapies-i-reischl-kok_en.pdf"},
    {"id":"72897","name":"Presentaion - Session 1 - Regulatory experience on the use of prior knowledge and platform approaches (EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T14:11:39Z","last_updated_date":"2026-03-09T14:11:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentaion-session-1-regulatory-experience-use-prior-knowledge-platform-approaches-ema_en.pdf"},
    {"id":"72898","name":"Presentation - Session 1 - Provisions of the new EU pharmaceutical legislation on platform approaches (F. Schmidt)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T14:15:42Z","last_updated_date":"2026-03-09T14:15:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-provisions-new-eu-pharmaceutical-legislation-platform-approaches-f-schmidt_en.pdf"},
    {"id":"72899","name":"Presentation - Session 2 case 1 - academia (A. Aartsma-Rus)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T14:19:51Z","last_updated_date":"2026-03-09T14:19:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-case-1-academia-aartsma-rus_en.pdf"},
    {"id":"72900","name":"Presentation - Session 2 case 2 - large pharma (M. Bilanin)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T14:37:32Z","last_updated_date":"2026-03-09T14:37:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-case-2-large-pharma-m-bilanin_en.pdf"},
    {"id":"72901","name":"Presentation - Session 2 case 3 - small and mid-sized enterprises (A. Natz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T14:39:21Z","last_updated_date":"2026-03-09T14:39:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-session-2-case-3-small-mid-sized-enterprises-natz_en.pdf"},
    {"id":"72908","name":"Clinical Trial Information System (CTIS) - Sponsor Frequently Asked Questions (FAQ)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-26T09:14:56Z","last_updated_date":"2026-04-09T13:00:00Z","reference_number":"EXT/40478/2026 v.1.0","document_url":"https://www.ema.europa.eu/en/documents/presentation/clinical-trial-information-system-ctis-frequently-asked-questions_en.pdf"},
    {"id":"73081","name":"Presentation - 3Rs scientific guidelines (S. Adler-Flindt, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:35:13Z","last_updated_date":"2026-03-17T17:35:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-3rs-scientific-guidelines-s-adler-flindt-ema_en.pdf"},
    {"id":"73082","name":"Presentation - 3Rs initiatives - a view from Industry (C.Stirling, Zoetis / Animal Health Europe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:36:06Z","last_updated_date":"2026-03-17T17:36:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-3rs-initiatives-view-industry-cstirling-zoetis-animal-health-europe_en.pdf"},
    {"id":"73083","name":"Presentation - Legislative initiatives with impact on veterinary medicines (C.Philippe, Boehringer Ingelheim / Animal Health Europe)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:37:14Z","last_updated_date":"2026-03-17T17:37:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-legislative-initiatives-impact-veterinary-medicines-cphilippe-boehringer-ingelheim-animal-health-europe_en.pdf"},
    {"id":"73084","name":"Presentation - CVMP workplan for 2026 and beyond (J.Schefferlie, CVMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:38:32Z","last_updated_date":"2026-03-17T17:38:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-cvmp-workplan-2026-beyond-jschefferlie-cvmp_en.pdf"},
    {"id":"73085","name":"Presentation - Innovation and development accelerator (F.Ehmann, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:39:59Z","last_updated_date":"2026-03-17T17:39:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-innovation-development-accelerator-fehmann-ema_en.pdf"},
    {"id":"73086","name":"Presentation - OPEN Framework (M.Harvey-Allchurch, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:40:50Z","last_updated_date":"2026-03-17T17:40:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-open-framework-mharvey-allchurch-ema_en.pdf"},
    {"id":"73087","name":"Presentation - Pharmacovigilance: Industry perspective (S.Schwab, VetVivaRichter)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:41:36Z","last_updated_date":"2026-03-17T17:41:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pharmacovigilance-industry-perspective-sschwab-vetvivarichter_en.pdf"},
    {"id":"73088","name":"Presentation - Implementation status of pharmacovigilance processes (J.Mount, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:42:26Z","last_updated_date":"2026-03-17T17:42:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-status-pharmacovigilance-processes-jmount-ema_en.pdf"},
    {"id":"73089","name":"Presentation - Regulatory and procedural developments (K.Paterson, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:43:10Z","last_updated_date":"2026-03-17T17:43:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-procedural-developments-kpaterson-ema_en.pdf"},
    {"id":"73090","name":"Presentation - Reflection paper providing the current regulatory testing requirements for veterinary medicinal products and opportunities for implementation of the 3Rs (draft 2025) - Industry perspective (J.Soni-Gupta, AVC)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:43:45Z","last_updated_date":"2026-03-17T17:43:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reflection-paper-providing-current-regulatory-testing-requirements-veterinary-medicinal-products-opportunities-implementation-3rs-draft-2025-industry-perspective-jsoni-gupta-avc_en.pdf"},
    {"id":"73091","name":"Presentation - Risk management plan for novel therapy veterinary medicinal products (N.Garcia del Blanco, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:44:50Z","last_updated_date":"2026-03-17T17:44:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-risk-management-plan-novel-therapy-veterinary-medicinal-products-ngarcia-del-blanco-ema_en.pdf"},
    {"id":"73092","name":"Presentation - Update from CHMP/CVMP 3Rs Working Party (S.Beken, 3Rs Working Party)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:45:35Z","last_updated_date":"2026-03-17T17:45:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-chmp-cvmp-3rs-working-party-sbeken-3rs-working-party_en.pdf"},
    {"id":"73093","name":"Pressentation - Update from the CVMP/ADRA temporary working party (tWP) (D.Bouchard, ADRA tWP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:46:19Z","last_updated_date":"2026-03-17T17:46:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/pressentation-update-cvmp-adra-temporary-working-party-twp-dbouchard-adra-twp_en.pdf"},
    {"id":"73094","name":"Presentation - Veterinary medicinal products in the Biotech Act (R.Salvador Roldan, DG SANTE)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T17:48:02Z","last_updated_date":"2026-03-17T17:48:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-veterinary-medicinal-products-biotech-act-rsalvador-roldan-dg-sante_en.pdf"},
    {"id":"73256","name":"Presentation - Quarterly System Demo - Q1 2026","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T17:18:14Z","last_updated_date":"2026-03-27T17:18:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-quarterly-system-demo-q1-2026_en.pdf"},
    {"id":"73296","name":"Presentation - Examining the validity of external controls relative to randomized controls: the essential role of data quality (R. Davi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T13:58:17Z","last_updated_date":"2026-04-01T13:58:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-examining-validity-external-controls-relative-randomized-controls-essential-role-data-quality-r-davi_en.pdf"},
    {"id":"73384","name":"Presentation - Actions arising from previous meeting and other updates (M. Filancia)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-09T15:25:03Z","last_updated_date":"2026-04-09T15:25:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-actions-arising-previous-meeting-other-updates-m-filancia_en.pdf"},
    {"id":"73385","name":"Presentation - A new pharmaceutical framework for Europe","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-09T15:27:18Z","last_updated_date":"2026-04-09T15:27:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharmaceutical-framework-europe_en.pdf"},
    {"id":"73388","name":"Presentation - New pharma legislation","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-09T15:33:24Z","last_updated_date":"2026-06-25T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-pharma-legislation_en.pdf"},
    {"id":"73392","name":"Presentation - Vulnerability assessment of critical medicines","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-09T15:57:01Z","last_updated_date":"2026-04-09T15:57:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-vulnerability-assessment-critical-medicines_en.pdf"},
    {"id":"73393","name":"Presentation - Union list of critical medicines: 2026 annual review","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-09T15:59:49Z","last_updated_date":"2026-04-09T15:59:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-union-list-critical-medicines-2026-annual-review_en.pdf"},
    {"id":"73395","name":"Presentation - European shortages monitoring platform (ESMP)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-09T16:07:20Z","last_updated_date":"2026-04-09T16:07:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-shortages-monitoring-platform-esmp_en.pdf-0"},
    {"id":"73396","name":"Presentation - Regulatory/ HTA interface under the HTAR – Update on implementation activities","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-09T16:10:37Z","last_updated_date":"2026-04-09T16:10:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-regulatory-hta-interface-under-htar-update-implementation-activities_en.pdf"},
    {"id":"73420","name":"Presentation - SPOR & XEVMPD status update","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-10T14:13:00Z","last_updated_date":"2026-04-10T14:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-spor-xevmpd-status-update_en.pdf-0"},
    {"id":"73477","name":"Presentations - ACT EU webinar on draft guidance on the conduct of clinical trials during public health emergencies","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-16T15:55:35Z","last_updated_date":"2026-04-24T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentations-act-eu-webinar-draft-guidance-conduct-clinical-trials-during-public-health-emergencies_en.pdf"},
    {"id":"73497","name":"Presentation - European shortages monitoring platform (ESMP) training on readable IDs and general updates for industry","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-20T15:52:39Z","last_updated_date":"2026-04-20T15:52:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-european-shortages-monitoring-platform-esmp-training-readable-ids-general-updates-industry_en.pdf"},
    {"id":"73567","name":"Presentations - ACT EU webinar on contractual agreements","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-24T11:13:05Z","last_updated_date":"2026-04-24T11:13:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentations-act-eu-webinar-contractual-agreements_en.pdf"},
    {"id":"73584","name":"Presentation - Breakthrough medical devices pilot information session","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-04-30T09:07:57Z","last_updated_date":"2026-04-30T09:07:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-breakthrough-medical-devices-pilot-information-session_en.pdf"},
    {"id":"74001","name":"Presentations - EnprEMA& ACT EU workshop on paediatric clinical trials","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-08T14:08:01Z","last_updated_date":"2026-06-08T14:08:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentations-enprema-act-eu-workshop-paediatric-clinical-trials_en.pdf"},
    {"id":"74017","name":"Presentation - Platform discussion topics and activities in 2026 (L. Barbier)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T15:49:41Z","last_updated_date":"2026-06-09T15:49:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-platform-discussion-topics-activities-2026-l-barbier_en.pdf"},
    {"id":"74018","name":"Presentation - International clinical trials registers & CTIS (J. van Wyk) ","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T15:52:40Z","last_updated_date":"2026-06-09T15:52:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-international-clinical-trials-registers-ctis-j-van-wyk_en.pdf"},
    {"id":"74023","name":"Presentation - Clinical trial registries as research data sources: tips and learnings (T. Machado)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T15:56:49Z","last_updated_date":"2026-06-09T15:56:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trial-registries-research-data-sources-tips-learnings-t-machado_en.pdf"},
    {"id":"74024","name":"Presentation - Using CTIS to track trends in clinical trial activity at regional and national levels (H. Fagerlind)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T15:58:36Z","last_updated_date":"2026-06-09T15:58:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-using-ctis-track-trends-clinical-trial-activity-regional-national-levels-h-fagerlind_en.pdf"},
    {"id":"74025","name":"Presentation - Evidence generation pathway and support at EU level (R. Herold)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T16:23:34Z","last_updated_date":"2026-06-09T16:23:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-evidence-generation-pathway-support-eu-level-r-herold_en.pdf"},
    {"id":"74026","name":"Presentation - New uses landscape and interaction with regulators (M. Pasmooij)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T16:26:48Z","last_updated_date":"2026-06-09T16:26:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-uses-landscape-interaction-regulators-m-pasmooij_en.pdf"},
    {"id":"74027","name":"Presentation - Introduction and demo of data catalogues (K.C. Deli)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T16:28:20Z","last_updated_date":"2026-06-09T16:28:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-introduction-demo-data-catalogues-kc-deli_en.pdf"},
    {"id":"74028","name":"Presentation - Researcher use of the catalogues (H. Gardarsdottir)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T16:50:32Z","last_updated_date":"2026-06-09T16:50:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-researcher-use-catalogues-h-gardarsdottir_en.pdf"},
    {"id":"74033","name":"Presentation - Misinformation framework & vaccine outreach strategy (JG. Burgos)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-10T09:00:38Z","last_updated_date":"2026-06-10T09:00:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-misinformation-framework-vaccine-outreach-strategy-jg-burgos_en.pdf"},
    {"id":"74060","name":"Presentation - Product Management Service (PMS) information day 2026","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-11T15:25:45Z","last_updated_date":"2026-06-11T15:25:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-product-management-service-pms-information-day-2026_en.pdf"},
    {"id":"74127","name":"Presentation - Implementation of the New Pharmaceutical Legislation (NPL) (M. Fanari; M. Vogl; Z. Hanaizi; F. Day; A. Spinei, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T17:01:49Z","last_updated_date":"2026-06-16T17:01:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-implementation-new-pharmaceutical-legislation-npl-m-fanari-m-vogl-z-hanaizi-f-day-spinei-ema_en.pdf"},
    {"id":"74128","name":"Presentation - Submission predictability and revamp pilot (F. Day, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T17:04:23Z","last_updated_date":"2026-06-16T17:04:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-submission-predictability-revamp-pilot-f-day-ema_en.pdf"},
    {"id":"74129","name":"Presentation - Revamp update (C. Pothet, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T17:05:33Z","last_updated_date":"2026-06-16T17:05:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-revamp-update-c-pothet-ema_en.pdf"},
    {"id":"74130","name":"Presentation - Pre-Submission Interactions Group (PreSIG) - Proposal to pilot a revised pre-submission interaction model (T.Castelnovo, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T17:06:25Z","last_updated_date":"2026-06-16T17:06:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-pre-submission-interactions-group-presig-proposal-pilot-revised-pre-submission-interaction-model-tcastelnovo-ema_en.pdf"},
    {"id":"74131","name":"Presentation - ePI update: roadmap and next steps (E.Scanlan, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T17:07:33Z","last_updated_date":"2026-06-16T17:07:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-epi-update-roadmap-next-steps-escanlan-ema_en.pdf"},
    {"id":"74132","name":"Presentation - Using EMA assessments for reliance in post-approval changes (V.Palmi, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T17:08:20Z","last_updated_date":"2026-06-16T17:08:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-using-ema-assessments-reliance-post-approval-changes-vpalmi-ema_en.pdf"},
    {"id":"74133","name":"Presentation - Update on digitalisation initiatives affecting centralised procedure submissions (M. Duta-Mare; K. Puusaari; S. Griniene, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T17:09:37Z","last_updated_date":"2026-06-16T17:09:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-update-digitalisation-initiatives-affecting-centralised-procedure-submissions-m-duta-mare-k-puusaari-s-griniene-ema_en.pdf"},
    {"id":"74165","name":"Presentation - EMRN workshop on Geographic Atrophy endpoints - Opening statement (Bruno Sepodes)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T15:20:53Z","last_updated_date":"2026-06-25T15:20:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emrn-workshop-geographic-atrophy-endpoints-opening-statement-bruno-sepodes_en.pdf"},
    {"id":"74166","name":"Presentation - Potential primary visual functional endpoints for GA pivotal trials (Christine Curcio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T15:28:51Z","last_updated_date":"2026-06-25T15:28:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-potential-primary-visual-functional-endpoints-ga-pivotal-trials-christine-curcio_en.pdf"},
    {"id":"74167","name":"Presentation - Microperimetry as an outcome assessment in Geographic Atrophy (Maximilian Pfau)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T15:38:58Z","last_updated_date":"2026-06-25T15:38:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-microperimetry-outcome-assessment-geographic-atrophy-maximilian-pfau_en.pdf"},
    {"id":"74168","name":"Presentation - Reading performance as an outcome assessment for Geographic Atrophy (Maximilian Pfau)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T16:56:06Z","last_updated_date":"2026-06-25T16:56:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-reading-performance-outcome-assessment-geographic-atrophy-maximilian-pfau_en.pdf"},
    {"id":"74169","name":"Presentation - EMRN workshop on Geographic Atrophy endpoints: Patients perspective (Avril Daly)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T11:11:01Z","last_updated_date":"2026-06-25T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emrn-workshop-geographic-atrophy-endpoints-patients-perspective-avril-daly_en.pdf"},
    {"id":"74170","name":"Presentation - Best corrected visual acuity low luminance visual acuity low luminance deficit (R. Silva, U. Chakravarthy )","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T17:10:20Z","last_updated_date":"2026-06-25T17:10:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-best-corrected-visual-acuity-low-luminance-visual-acuity-low-luminance-deficit-r-silva-u-chakravarthy_en.pdf"},
    {"id":"74171","name":"Presentation - Contrast sensitivity (Karl Csaky)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T17:12:21Z","last_updated_date":"2026-06-25T17:12:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-contrast-sensitivity-karl-csaky_en.pdf"},
    {"id":"74172","name":"Presentation - EMRN workshop on Geographic Atrophy endpoints:  Industry perspective (Fabio Baschiera)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T17:14:30Z","last_updated_date":"2026-06-25T17:14:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emrn-workshop-geographic-atrophy-endpoints-industry-perspective-fabio-baschiera_en.pdf"},
    {"id":"74173","name":"Presentation - A brief outline of principles for validation of a surrogate endpoint-options for qualification advice (Elisabeth Wischnitzki)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-19T17:16:30Z","last_updated_date":"2026-06-19T17:16:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-brief-outline-principles-validation-surrogate-endpoint-options-qualification-advice-elisabeth-wischnitzki_en.pdf"},
    {"id":"74195","name":"Presentation - Updates on CTIS programme (O.Bueno, EMA)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T09:52:56Z","last_updated_date":"2026-06-23T09:52:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-updates-ctis-programme-obueno-ema_en.pdf"},
    {"id":"74196","name":"Presentation - CTIS Progress: Sponsors’ perspective (G.Di Matteo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T09:53:40Z","last_updated_date":"2026-06-23T09:53:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-progress-sponsors-perspective-gdi-matteo_en.pdf"},
    {"id":"74197","name":" Presentation - CTIS Progress: CRO perspective (L.fitzgerald)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T09:54:49Z","last_updated_date":"2026-06-23T09:54:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-progress-cro-perspective-lfitzgerald_en.pdf"},
    {"id":"74198","name":" Presentation - CTIS Progress: Non-commercial sponsor perspective (J.Stans)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T09:55:26Z","last_updated_date":"2026-06-23T09:55:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-progress-non-commercial-sponsor-perspective-jstans_en.pdf"},
    {"id":"74199","name":" Presentation - FAST-EU update (S.Strasser)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T09:56:15Z","last_updated_date":"2026-06-23T09:56:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-fast-eu-update-sstrasser_en.pdf"},
    {"id":"74200","name":" Presentation - COMBINE Project 1 ‘All-in-one’ Coordinated Assessment Pilot update (C.Temple)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T09:56:52Z","last_updated_date":"2026-06-23T09:56:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-combine-project-1-all-one-coordinated-assessment-pilot-update-ctemple_en.pdf"},
    {"id":"74201","name":"Presentation - Clinical Trials Coordination Group (CTCG) FAQ (A.Bonertz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T09:57:37Z","last_updated_date":"2026-06-23T09:57:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-clinical-trials-coordination-group-ctcg-faq-abonertz_en.pdf"},
    {"id":"74202","name":"Presentation - New rules on translations of patient-facing documents; New template on recruitment and informed consent procedure (M.Al)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T09:59:09Z","last_updated_date":"2026-06-23T09:59:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-rules-translations-patient-facing-documents-new-template-recruitment-informed-consent-procedure-mal_en.pdf"},
    {"id":"74203","name":"Presentation - Commission proposal for an European Biotech Act (E.Szepessy)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T10:00:04Z","last_updated_date":"2026-06-23T10:00:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-commission-proposal-european-biotech-act-eszepessy_en.pdf"},
    {"id":"74204","name":"Presentation - ICH M11 - Tools for clinical protocols (N.Manent)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T10:00:37Z","last_updated_date":"2026-06-23T10:00:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ich-m11-tools-clinical-protocols-nmanent_en.pdf"},
    {"id":"74206","name":"Presentation - Safety MVP: Progress update, ASR key changes & upcoming events (M.Sultani)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T10:01:17Z","last_updated_date":"2026-06-23T10:01:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safety-mvp-progress-update-asr-key-changes-upcoming-events-msultani_en.pdf"},
    {"id":"74207","name":"Presentation - CTIS Service Desk and tips for the users reporting issues (G.Varricchio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T10:02:01Z","last_updated_date":"2026-06-23T10:02:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-ctis-service-desk-tips-users-reporting-issues-gvarricchio_en.pdf"},
    {"id":"74208","name":"Presentation - New ways of accessing CTIS training environment (O.Ademi)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T10:02:38Z","last_updated_date":"2026-06-23T10:02:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-new-ways-accessing-ctis-training-environment-oademi_en.pdf"},
    {"id":"74211","name":"Presentation - ACT EU priority action on the support for non-commercial sponsors (G.Capone)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T10:03:17Z","last_updated_date":"2026-06-23T10:03:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-priority-action-support-non-commercial-sponsors-gcapone_en.pdf"},
    {"id":"74212","name":"Presentation - ACT EU Pilots on consolidated advice in clinical trials (M.Sarra)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-23T10:03:55Z","last_updated_date":"2026-06-23T10:03:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-act-eu-pilots-consolidated-advice-clinical-trials-msarra_en.pdf"},
    {"id":"74266","name":"Presentation - A brief outline of principles for validation of a surrogate endpoint-options for qualification advice (Elisabeth Wischnitzki)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T10:37:39Z","last_updated_date":"2026-06-25T10:37:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-brief-outline-principles-validation-surrogate-endpoint-options-qualification-advice-elisabeth-wischnitzki_en.pdf-0"},
    {"id":"74267","name":"Presentation - Imaging in geographic atrophy (GA) (Ursula Schmidt-Erfurth)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T10:44:50Z","last_updated_date":"2026-06-25T10:44:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-imaging-geographic-atrophy-ga-ursula-schmidt-erfurth_en.pdf"},
    {"id":"74268","name":"Presentation - Imaging endpoints, current methods, relationship with histology and retinal function (Christine Curcio)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T10:45:58Z","last_updated_date":"2026-06-25T10:45:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-imaging-endpoints-current-methods-relationship-histology-retinal-function-christine-curcio_en.pdf"},
    {"id":"74269","name":"Presentation - Overview of structure function relationship (Sobha Sivaprasad)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T10:47:38Z","last_updated_date":"2026-06-25T10:47:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-overview-structure-function-relationship-sobha-sivaprasad_en.pdf"},
    {"id":"74270","name":"Presentation - Opening statement: Academic / health care professional perspective (Frank G. Holz)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T10:49:41Z","last_updated_date":"2026-06-25T10:49:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-opening-statement-academic-health-care-professional-perspective-frank-g-holz_en.pdf"},
    {"id":"74273","name":"Presentation - Patient-reported outcomes, quality of life measures, safety outcomes (Jan H. Terheyden)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T13:11:49Z","last_updated_date":"2026-06-25T13:11:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-patient-reported-outcomes-quality-life-measures-safety-outcomes-jan-h-terheyden_en.pdf"},
    {"id":"74274","name":"Presentation - Emerging functional vision endpoints / looking forward (Marion R Munk)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T13:13:19Z","last_updated_date":"2026-06-25T13:13:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-emerging-functional-vision-endpoints-looking-forward-marion-r-munk_en.pdf"},
    {"id":"74307","name":"Presentation - Support for and experiences with researcher evidence generation (D. Lo)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T16:37:33Z","last_updated_date":"2026-06-25T16:37:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-support-experiences-researcher-evidence-generation-d-lo_en.pdf"},
    {"id":"74308","name":"Presentation - Learnings from a researcher case (M. Schuelke)","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-25T16:40:42Z","last_updated_date":"2026-06-25T16:40:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-learnings-researcher-case-m-schuelke_en.pdf"},
    {"id":"74329","name":"Presentation - IRIS roadmap updates &  updates to industry contact management for authorisation products","type":"presentation","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T15:26:48Z","last_updated_date":"2026-06-26T15:26:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-iris-roadmap-updates-updates-industry-contact-management-authorisation-products_en.pdf"},
    {"id":"2390","name":"UCB Pharma withdraws its marketing authorisation application for Lacosamide Pain UCB Pharma","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-26T02:09:21Z","last_updated_date":"2008-09-26T02:09:21Z","reference_number":"EMEA/508780/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/ucb-pharma-withdraws-its-marketing-authorisation-application-lacosamide-pain-ucb-pharma_en.pdf"},
    {"id":"2392","name":"31st meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-01-13T01:00:00Z","last_updated_date":"2003-01-13T01:00:00Z","reference_number":"EMEA/COMP/3194/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/31st-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"2393","name":"3rd meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-06-19T02:00:00Z","last_updated_date":"2000-06-19T02:00:00Z","reference_number":"EMEA/COMP/20/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/3rd-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"2402","name":"Head of Veterinary Medicines Unit to leave European Medicines Agency","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-06-28T02:00:00Z","last_updated_date":"2005-06-28T02:00:00Z","reference_number":"EMEA/207754/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/head-veterinary-medicines-unit-leave-european-medicines-agency_en.pdf"},
    {"id":"2407","name":"Pfizer withdraws its marketing authorisation application for Exulett (dalbavancin)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-10T02:09:21Z","last_updated_date":"2008-09-10T02:09:21Z","reference_number":"EMEA/476868/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/pfizer-withdraws-its-marketing-authorisation-application-exulett-dalbavancin_en.pdf"},
    {"id":"2414","name":"Ninth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-03-06T01:00:00Z","last_updated_date":"1996-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/ninth-meeting-management-board_en.pdf"},
    {"id":"2418","name":"Better surveillance needed to fight spread of antimicrobial resistance in zoonotic infections","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-11-16T00:09:21Z","last_updated_date":"2009-11-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/better-surveillance-needed-fight-spread-antimicrobial-resistance-zoonotic-infections_en.pdf"}    {"id":"2420","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products - Meeting of 17 to 19 September 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-09-19T02:00:00Z","last_updated_date":"2002-09-19T02:00:00Z","reference_number":"EMEA/CPMP/4698/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-17-19-september-2002_en.pdf"},
    {"id":"2423","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the seventy second meeting of the committee for veterinary medicinal products took place in London on 4 - 6 December 2001.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-12-07T12:09:21Z","last_updated_date":"2001-12-07T12:09:21Z","reference_number":"EMEA/CVMP/1121/01-CORRIGENDUM","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-seventy-second-meeting-committee-veterinary-medicinal-products-took-place-london-4-6-december-2001_en.pdf"},
    {"id":"2428","name":"Defect in Herceptin vials identified but supply for patients is maintained","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-11-22T01:00:00Z","last_updated_date":"2006-11-22T01:00:00Z","reference_number":"EMEA/470747/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/defect-herceptin-vials-identified-supply-patients-maintained_en.pdf"},
    {"id":"2440","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products - Meeting of 25 to 27 June 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-06-27T02:00:00Z","last_updated_date":"2002-06-27T02:00:00Z","reference_number":"EMEA/CPMP/3065/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-25-27-june-2002_en.pdf"},
    {"id":"2448","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 10-13 October 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-10-13T02:00:00Z","last_updated_date":"2005-10-13T02:00:00Z","reference_number":"EMEA/341463/2005/Rev1","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-10-13-october-2005_en.pdf"},
    {"id":"2452","name":"Committee for medicinal products for veterinary use: Meeting of 15-17 January 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-01-18T00:09:21Z","last_updated_date":"2008-01-18T00:09:21Z","reference_number":"EMEA/CVMP/7585/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-15-17-january-2008_en.pdf"},
    {"id":"2455","name":"Committee for veterinary medicinal products: Meeting of 16 to 17 September 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-09-18T02:09:21Z","last_updated_date":"2003-09-18T02:09:21Z","reference_number":"EMEA/CVMP/799/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-16-17-september-2003_en.pdf"},
    {"id":"2461","name":"Committee for Proprietary Medicinal Products (CPMP) 57th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-02-21T01:00:00Z","last_updated_date":"2000-02-21T01:00:00Z","reference_number":"CPMP/316/00 corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-57th-plenary-meeting_en.pdf"},
    {"id":"2534","name":"Committee for veterinary medicinal products: 36th meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-10-15T14:09:21Z","last_updated_date":"1998-10-15T14:09:21Z","reference_number":"EMEA/CVMP/520/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-36th-meeting_en.pdf"},
    {"id":"2537","name":"Hexal AG withdraws its marketing authorisation application for Ibandronic acid Hexal (ibandronic acid)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/589738/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/hexal-ag-withdraws-its-marketing-authorisation-application-ibandronic-acid-hexal-ibandronic-acid_en.pdf"},
    {"id":"2555","name":"Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 7-9 June 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-10T02:00:00Z","last_updated_date":"2011-06-10T02:00:00Z","reference_number":"EMA/CVMP/419270/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-7-9-june-2011_en.pdf"},
    {"id":"2578","name":"28th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-10-11T02:09:21Z","last_updated_date":"2002-10-11T02:09:21Z","reference_number":"EMEA/25888/02/corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/28th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"2593","name":"EMA fast-tracks antidote to anticoagulant Pradaxa","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-09-25T14:00:01Z","last_updated_date":"2015-09-25T14:00:01Z","reference_number":"EMA/CHMP/623992/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-fast-tracks-antidote-anticoagulant-pradaxa_en.pdf"},
    {"id":"2617","name":"European Medicines Agency recommends restricting use of tolperisone medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T12:00:00Z","last_updated_date":"2012-06-22T12:00:00Z","reference_number":"EMA/CHMP/406866/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-tolperisone-medicines_en.pdf"},
    {"id":"2621","name":"Twenty-sixth meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-06-09T02:00:00Z","last_updated_date":"2000-06-09T02:00:00Z","reference_number":"EMEA/MB/025/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/twenty-sixth-meeting-management-board_en.pdf"},
    {"id":"2649","name":"European Medicines Agency recommends interim measures for Pandemrix","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/297822/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-interim-measures-pandemrix_en.pdf"},
    {"id":"2665","name":"PRAC considers risk of severe allergic reactions with ambroxol- and bromhexine-containing medicines to be small","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-01-12T11:00:02Z","last_updated_date":"2015-01-12T11:00:02Z","reference_number":"EMA/796499/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-considers-risk-severe-allergic-reactions-ambroxol-and-bromhexine-containing-medicines-be-small_en.pdf"},
    {"id":"2685","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 9-11 October 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-10-12T18:00:00Z","last_updated_date":"2012-10-12T18:00:00Z","reference_number":"EMA/CVMP/639731/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-9-11-october-2012_en.pdf"},
    {"id":"2705","name":"Exploring opportunities for collaboration between regulators and healthcare payers","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-09-27T02:00:00Z","last_updated_date":"2017-09-27T02:00:00Z","reference_number":"EMA/559097/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/exploring-opportunities-collaboration-between-regulators-and-healthcare-payers_en.pdf"},
    {"id":"2724","name":"Committee for Advanced Therapies adopts five-year work programme to foster development of advanced therapies","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/CAT/718256/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-advanced-therapies-adopts-five-year-work-programme-foster-development-advanced-therapies_en.pdf"},
    {"id":"2733","name":"Committee for medicinal products for veterinary use: Meeting of 10-12 November 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-11-13T00:09:21Z","last_updated_date":"2009-11-13T00:09:21Z","reference_number":"EMEA/CVMP/709231/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-10-12-november-2009_en.pdf"},
    {"id":"2763","name":"Committee for Orphan Medicinal Products: February 2005 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-02-07T01:00:00Z","last_updated_date":"2005-02-07T01:00:00Z","reference_number":"EMEA/COMP/44905/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-february-2005-meeting_en.pdf"},
    {"id":"2780","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 9-11 April 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-04-12T19:00:00Z","last_updated_date":"2013-04-12T19:00:00Z","reference_number":"EMA/CVMP/200297/2013 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-9-11-april-2013_en.pdf"},
    {"id":"2792","name":"Key elements* for the summaries of product characteristics of the non-selective NSAIDs piroxicam, ketoprofen and ketorolac adopted by the CHMP","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-09-26T02:00:00Z","last_updated_date":"2006-09-26T02:00:00Z","reference_number":"EMEA/CHMP/381615/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/key-elements-summaries-product-characteristics-non-selective-nsaids-piroxicam-ketoprofen-and-ketorolac-adopted-chmp_en.pdf"},
    {"id":"2806","name":"Antigenics Therapeutics Limited withdraws its marketing authorisation application for Oncophage (vitespen)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-11-25T00:09:21Z","last_updated_date":"2009-12-02T00:00:00Z","reference_number":"EMEA/763056/2009 corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/antigenics-therapeutics-limited-withdraws-its-marketing-authorisation-application-oncophage-vitespen_en.pdf"},
    {"id":"2839","name":"Gardasil 9 offers wider protection against cancers caused by human papillomavirus (HPV)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-03-27T01:00:00Z","reference_number":"EMA/CHMP/202995/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/gardasil-9-offers-wider-protection-against-cancers-caused-human-papillomavirus-hpv_en.pdf"},
    {"id":"2863","name":"Committee for Proprietary Medicinal Products (CPMP) 15th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-04-19T02:00:00Z","last_updated_date":"1996-04-19T02:00:00Z","reference_number":"CPMP/351/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-15th-plenary-meeting_en.pdf"},
    {"id":"2912","name":"EMA concludes safety review of Uptravi","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-04-07T14:00:00Z","last_updated_date":"2017-04-07T14:00:00Z","reference_number":"EMA/224677/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-concludes-safety-review-uptravi_en.pdf"},
    {"id":"2916","name":"Nomination of new Head of the Human Unit","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-07-25T02:00:00Z","last_updated_date":"2000-07-25T02:00:00Z","reference_number":"EMEA/D/20840/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/nomination-new-head-human-unit_en.pdf"},
    {"id":"2928","name":"European Medicines Agency statement on safety of Tamiflu","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-03-23T01:00:00Z","last_updated_date":"2007-03-23T01:00:00Z","reference_number":"EMEA/134566/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-statement-safety-tamiflu_en.pdf"},
    {"id":"2940","name":"Committee on herbal medicinal products (HMPC): Meeting report, 16 - 17 September 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-09-30T02:00:00Z","last_updated_date":"2009-09-30T02:00:00Z","reference_number":"EMEA/HMPC/611604/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-herbal-medicinal-products-hmpc-meeting-report-16-17-september-2009_en.pdf"},
    {"id":"2941","name":"New medicine for rare form of eye allergy in children and teenagers","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/CHMP/459946/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-rare-form-eye-allergy-children-and-teenagers_en.pdf"},
    {"id":"2943","name":"European Medicines Agency recommends extending use of Nexavar to include treatment of differentiated thyroid cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/242564/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-extending-use-nexavar-include-treatment-differentiated-thyroid-cancer_en.pdf"},
    {"id":"2946","name":"Committee for medicinal products for veterinary use: Meeting of 14-15 May 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-05-16T14:09:21Z","last_updated_date":"2007-05-16T14:09:21Z","reference_number":"EMEA/CVMP/194935/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-14-15-may-2007_en.pdf"},
    {"id":"2963","name":"Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 13-15 April 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-04-16T02:00:00Z","last_updated_date":"2010-04-16T02:00:00Z","reference_number":"EMA/CVMP/212502/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-13-15-april-2010_en.pdf"},
    {"id":"2965","name":"Sanofi Aventis withdraws its marketing authorisation application for Sliwens","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-21T01:00:00Z","last_updated_date":"2009-12-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/sanofi-aventis-withdraws-its-marketing-authorisation-application-sliwens_en.pdf"},
    {"id":"2990","name":"European Medicines Agency recommends first switch from prescription-only to non-prescription for a centrally authorised medicine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-10-23T02:09:21Z","last_updated_date":"2008-10-23T02:09:21Z","reference_number":"EMEA/CHMP/493770/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-first-switch-prescription-only-non-prescription-centrally-authorised-medicine_en.pdf"},
    {"id":"3004","name":"Lux Biosciences GmbH withdraws its marketing authorisation application for Luveniq (voclosporin)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T02:00:00Z","reference_number":"EMA/833913/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/lux-biosciences-gmbh-withdraws-its-marketing-authorisation-application-luveniq-voclosporin_en.pdf"},
    {"id":"3015","name":"European Medicines Agency recommends approval of Mekinist for the treatment of melanoma","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/242727/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-mekinist-treatment-melanoma_en.pdf"},
    {"id":"3026","name":"26th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-11-13T19:00:00Z","last_updated_date":"1997-11-13T19:00:00Z","reference_number":"EMEA/CVMP/406/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/26th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3044","name":"19th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-03-14T13:30:00Z","last_updated_date":"1997-03-14T13:30:00Z","reference_number":"EMEA/CVMP/104/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/19th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"3060","name":"Committee for Proprietary Medicinal Products (CPMP) 21st plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-11-20T01:00:00Z","last_updated_date":"1996-11-20T01:00:00Z","reference_number":"CPMP/960/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-21st-plenary-meeting_en.pdf"},
    {"id":"3069","name":"European Medicines Agency launches consultation on its Road Map to 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-01-26T01:00:00Z","last_updated_date":"2010-01-26T01:00:00Z","reference_number":"EMA/54050/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-launches-consultation-its-road-map-2015_en.pdf"},
    {"id":"3083","name":"Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T13:00:01Z","last_updated_date":"2018-03-09T13:00:01Z","reference_number":"EMA/76828/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_en.pdf"},
    {"id":"3193","name":"Reliance GeneMedix Plc. withdraws its marketing authorisation application for Epostim (erythropoietin)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-04-06T11:57:59Z","last_updated_date":"2011-04-06T11:57:59Z","reference_number":"EMA/271900/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/reliance-genemedix-plc-withdraws-its-marketing-authorisation-application-epostim-erythropoietin_en.pdf"},
    {"id":"3209","name":"Committee for veterinary medicinal products: 44th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-18T14:09:21Z","last_updated_date":"2009-06-18T14:09:21Z","reference_number":"EMEA/CVMP/329/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-44th-meeting_en.pdf"},
    {"id":"3221","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n20-23 April 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-04-23T02:09:21Z","last_updated_date":"2009-04-23T02:09:21Z","reference_number":"EMEA/CHMP/249660/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-20-23-april-2009_en.pdf"},
    {"id":"3247","name":"Committee for Orphan Medicinal Products: November 2003 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-11-07T01:00:00Z","last_updated_date":"2003-11-07T01:00:00Z","reference_number":"EMEA/COMP/1552/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-november-2003-meeting_en.pdf"},
    {"id":"3267","name":"Committee for medicinal products for veterinary use: Meeting of 13-15 January 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-01-16T00:09:21Z","last_updated_date":"2009-01-16T00:09:21Z","reference_number":"EMEA/CVMP/2934/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-13-15-january-2009_en.pdf"},
    {"id":"3296","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the seventieth meeting of the committee for veterinary medicinal products took place in London on 9-10 October 2001.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-10-11T14:59:21Z","last_updated_date":"2001-10-11T14:59:21Z","reference_number":"EMEA/CVMP/911/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-seventieth-meeting-committee-veterinary-medicinal-products-took-place-london-9-10-october-2001_en.pdf"},
    {"id":"3345","name":"Committee for medicinal products for veterinary use: Meeting of 8 to 10 February 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-02-11T12:09:21Z","last_updated_date":"2005-02-11T12:09:21Z","reference_number":"EMEA/CVMP/39701/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-8-10-february-2005_en.pdf"},
    {"id":"3370","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 15-18 February 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2010-02-19T01:00:00Z","reference_number":"EMA/CHMP/95106/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-february-2010_en.pdf"},
    {"id":"3391","name":"Visita de las austoridades Iberoamericanas al Ministerio de Sanidad y Consumo de Espaà±a (Madrid) y a la EMEA (Londres) - 18-20 de febrero de 1997","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-02-20T01:00:00Z","last_updated_date":"1997-02-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/visita-de-las-austoridades-iberoamericanas-al-ministerio-de-sanidad-y-consumo-de-espaa-madrid-y-la-emea-londres-18-20-de-febrero-de-1997_en.pdf"},
    {"id":"3439","name":"EMA Management Board: highlights of March 2018 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-03-16T10:15:00Z","last_updated_date":"2018-03-16T10:15:00Z","reference_number":"EMA/162881/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-march-2018-meeting_en.pdf"},
    {"id":"3453","name":"Gendux Molecular Limited withdraws its marketing authorisation application for Advexin (contusugene ladenovec)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-12-19T00:09:21Z","last_updated_date":"2008-12-19T00:09:21Z","reference_number":"EMEA/690558/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/gendux-molecular-limited-withdraws-its-marketing-authorisation-application-advexin-contusugene-ladenovec_en.pdf"},
    {"id":"3464","name":"EMEA recommends a new warning for epoetins for their use in cancer patients","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:09:21Z","last_updated_date":"2008-06-26T02:09:21Z","reference_number":"EMEA/CHMP/333963/2008 –corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-recommends-new-warning-epoetins-their-use-cancer-patients_en.pdf"},
    {"id":"3482","name":"Committee for medicinal products for veterinary use: Meeting of 13-15 October 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-16T02:09:21Z","last_updated_date":"2009-10-16T02:09:21Z","reference_number":"EMEA/CVMP/627024/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-13-15-october-2009_en.pdf"},
    {"id":"3531","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 18 -21 April 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-04-21T02:00:00Z","last_updated_date":"2005-04-21T02:00:00Z","reference_number":"EMEA/138444/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-18-21-april-2005_en.pdf"},
    {"id":"3537","name":"Committee for medicinal products for veterinary use: Meeting of 7 - 9 November 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-11-10T12:09:21Z","last_updated_date":"2006-11-10T12:09:21Z","reference_number":"EMEA/CVMP/430553/2006-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-7-9-november-2006_en.pdf"},
    {"id":"3578","name":"2nd meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-05-16T02:00:00Z","last_updated_date":"2000-05-16T02:00:00Z","reference_number":"EMEA/COMP/9/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/2nd-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"3596","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 19-22 April 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2010-04-23T02:00:00Z","reference_number":"EMA/CHMP/110267/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2010_en.pdf"},
    {"id":"3623","name":"Review of field safety data by the European Medicines Agency finds a goodsafety record for inactivated bluetongue emergency vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-20T01:00:00Z","last_updated_date":"2009-02-20T01:00:00Z","reference_number":"EMEA/56794/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/review-field-safety-data-european-medicines-agency-finds-goodsafety-record-inactivated-bluetongue-emergency-vaccines_en.pdf"},
    {"id":"3642","name":"Towards improving the availability of medicines in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-08-29T14:00:00Z","last_updated_date":"2018-08-29T14:00:00Z","reference_number":"EMA/485874/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/towards-improving-availability-medicines-eu_en.pdf"},
    {"id":"3651","name":"European Medicines Agency Management Board holds its 50th meeting:\n\nAnnual report 2005 shows a reduction in applications for new medicines\n\nbut suggests increases in the years to come","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-03-20T00:09:21Z","last_updated_date":"2006-03-20T00:09:21Z","reference_number":"EMEA/88535/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-management-board-holds-its-50th-meeting-annual-report-2005-shows-reduction-applications-new-medicines-suggests-increases-years-come_en.pdf"},
    {"id":"3707","name":"Bausch & Lomb Ireland withdraws its marketing authorisation application for Retisert","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-23T02:00:00Z","last_updated_date":"2007-07-23T02:00:00Z","reference_number":"EMEA/331932/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/bausch-lomb-ireland-withdraws-its-marketing-authorisation-application-retisert_en.pdf"},
    {"id":"3713","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n21-24 April 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-04-29T02:09:21Z","last_updated_date":"2008-04-29T02:09:21Z","reference_number":"EMEA/CHMP/205947/2008 - corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-21-24-april-2008_en.pdf"},
    {"id":"3715","name":"EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T01:00:00Z","last_updated_date":"2018-03-02T01:00:00Z","reference_number":"EMA/120379/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-urgently-reviewing-multiple-sclerosis-medicine-zinbryta-following-cases-inflammatory-brain-disorders_en.pdf"},
    {"id":"3750","name":"Wyeth Consumer Healthcare withdraws its marketing authorisation application for Ibuprofen/Diphenhydramine Hydrochloride Wyeth","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-01-13T01:00:00Z","last_updated_date":"2010-01-13T01:00:00Z","reference_number":"EMA/23476/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/wyeth-consumer-healthcare-withdraws-its-marketing-authorisation-application-ibuprofendiphenhydramine-hydrochloride-wyeth_en.pdf"},
    {"id":"3751","name":"European Medicines Agency confirms positive benefit-risk balance for Champix","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-21T17:56:27Z","last_updated_date":"2011-07-21T17:56:27Z","reference_number":"EMA/579351/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-positive-benefit-risk-balance-champix_en.pdf"},
    {"id":"3771","name":"European Commission legalisation of EMEA certificates to end","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-10-28T02:00:00Z","last_updated_date":"2005-10-28T02:00:00Z","reference_number":"EMEA/351182/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-commission-legalisation-emea-certificates-end_en.pdf"},
    {"id":"3831","name":"European Medicines Agency and European Commission start reflection process on way forward for the Agency and the network","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-07-08T02:00:00Z","last_updated_date":"2010-07-08T02:00:00Z","reference_number":"EMA/422535/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-european-commission-start-reflection-process-way-forward-agency-and-network_en.pdf"},
    {"id":"3845","name":"Committee for veterinary medicinal products: 52nd meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2000-02-10T00:09:21Z","last_updated_date":"2000-02-10T00:09:21Z","reference_number":"EMEA/CVMP/117/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-52nd-meeting_en.pdf"},
    {"id":"3873","name":"Meeting highlights from the Paediatric Committee: 22 - 24 July 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-07-31T02:00:00Z","last_updated_date":"2009-07-31T02:00:00Z","reference_number":"EMEA/PDCO/449592/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-22-24-july-2009_en.pdf"},
    {"id":"3879","name":"Committee for Orphan Medicinal Products: March 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-03-09T01:00:00Z","last_updated_date":"2006-03-09T01:00:00Z","reference_number":"EMEA/COMP/85385/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-march-2006-meeting_en.pdf"},
    {"id":"3891","name":"EMEA half-year report for 2008 shows activities to be on target, with a marked increase in the provision of scientific advice","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-10-08T02:00:00Z","last_updated_date":"2008-10-08T02:00:00Z","reference_number":"EMEA/MB/521956/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-half-year-report-2008-shows-activities-be-target-marked-increase-provision-scientific-advice_en.pdf"},
    {"id":"3897","name":"Commitee for Orphan Medicinal Products: September 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-09-14T02:00:00Z","last_updated_date":"2004-09-14T02:00:00Z","reference_number":"EMEA/COMP/65396/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-september-2004-meeting_en.pdf"},
    {"id":"3957","name":"Schering-Plough Europe withdraws its marketing authorisation application\n\nfor Garenoxacin mesylate","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-26T02:09:21Z","last_updated_date":"2007-07-26T02:09:21Z","reference_number":"EMEA/341174/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/schering-plough-europe-withdraws-its-marketing-authorisation-application-garenoxacin-mesylate_en.pdf"},
    {"id":"3963","name":"Committee for medicinal products for veterinary use: Meeting of 12 - 14 June 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-15T14:49:21Z","last_updated_date":"2007-06-15T14:49:21Z","reference_number":"EMEA/CVMP/239756/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-12-14-june-2007_en.pdf"},
    {"id":"3974","name":"Otsuka Pharmaceutical Europe Ltd withdraws its application for an extension of indication for Abilify (aripiprazole)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-11-19T00:09:21Z","last_updated_date":"2009-11-19T00:09:21Z","reference_number":"EMEA/749487/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/otsuka-pharmaceutical-europe-ltd-withdraws-its-application-extension-indication-abilify-aripiprazole_en.pdf"},
    {"id":"3995","name":"European Medicines Agency recommends discontinuation of Vimpat 15-mg/ml syrup","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-09-22T19:00:00Z","last_updated_date":"2011-09-22T19:00:00Z","reference_number":"EMA/CHMP/737362/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-discontinuation-vimpat-15-mgml-syrup_en.pdf"},
    {"id":"4016","name":"European Medicines Agency and EUnetHTA agree joint work plan","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-eunethta-agree-joint-work-plan_en.pdf"},
    {"id":"4036","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 6-8 December 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-12-09T17:00:00Z","last_updated_date":"2016-12-09T17:00:00Z","reference_number":"EMA/794393/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-6-8-december-2016_en.pdf"},
    {"id":"4037","name":"Warner Chilcott UK Ltd withdraws its application for an extension of indication for Intrinsa","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-29T02:00:00Z","last_updated_date":"2010-09-29T02:00:00Z","reference_number":"EMA/601877/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/warner-chilcott-uk-ltd-withdraws-its-application-extension-indication-intrinsa_en.pdf"},
    {"id":"4077","name":"Opening up clinical data on new medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T17:00:00Z","last_updated_date":"2016-10-20T17:00:00Z","reference_number":"EMA/650519/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/opening-clinical-data-new-medicines_en.pdf"},
    {"id":"4159","name":"European Medicines Agency starts new review of cardiovascular risks of non-selective NSAIDs","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-10-21T12:07:56Z","last_updated_date":"2011-10-21T12:07:56Z","reference_number":"EMA/CHMP/834463/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-new-review-cardiovascular-risks-non-selective-nsaids_en.pdf"},
    {"id":"4179","name":"EMEA Management Board considers the Agency's road map to 2010 and approves transparency proposal for orphan drugs","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-06-14T02:09:21Z","last_updated_date":"2004-06-14T02:09:21Z","reference_number":"EMEA/16145/04/corr/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-management-board-considers-agencys-road-map-2010-and-approves-transparency-proposal-orphan-drugs_en.pdf"},
    {"id":"4184","name":"Committee for veterinary medicinal products: 41st meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1999-03-18T12:09:21Z","last_updated_date":"1999-03-18T12:09:21Z","reference_number":"EMEA/CVMP/154/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-41st-meeting_en.pdf"},
    {"id":"4213","name":"Committee for Proprietary Medicinal Products (CPMP) 53rd plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-10-25T02:00:00Z","last_updated_date":"1999-10-25T02:00:00Z","reference_number":"CPMP/2769/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-53rd-plenary-meeting_en.pdf"},
    {"id":"4254","name":"Ebola outbreak: EMA to review experimental medicines to support treatment decisions","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/581735/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/ebola-outbreak-ema-review-experimental-medicines-support-treatment-decisions_en.pdf"},
    {"id":"4255","name":"Eli Lilly withdraws its marketing authorisation application for ARXXANT","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-03-15T01:00:00Z","last_updated_date":"2007-03-15T01:00:00Z","reference_number":"EMEA/116976/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/eli-lilly-withdraws-its-marketing-authorisation-application-arxxant_en.pdf"},
    {"id":"4258","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 17-19 April 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-04-20T17:08:00Z","last_updated_date":"2018-05-04T15:03:00Z","reference_number":"EMA/CVMP/225891/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-17-19-april-2018_en.pdf"},
    {"id":"4327","name":"European Medicines Agency reviews hypothesis on\n\nPandemrix and development of narcolepsy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T13:00:00Z","last_updated_date":"2012-10-19T13:00:00Z","reference_number":"EMA/CHMP/676755/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-reviews-hypothesis-pandemrix-and-development-narcolepsy_en.pdf"},
    {"id":"4344","name":"European Medicines Agency recommends lifting of suspension of Octagam","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"EMA/297816/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-lifting-suspension-octagam_en.pdf"},
    {"id":"4383","name":"European Medicines Agency: Committee for Medicinal Products for Human Use, 1-3 June 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-06-04T02:09:21Z","last_updated_date":"2004-06-04T02:09:21Z","reference_number":"EMEA/15358/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-1-3-june-2004_en.pdf"},
    {"id":"4459","name":"European Medicines Agency welcomes new Head of Information and Communications Technology","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T13:00:00Z","last_updated_date":"2012-02-16T13:00:00Z","reference_number":"EMA/119267/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-welcomes-new-head-information-and-communications-technology_en.pdf"},
    {"id":"4461","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n16-18 October 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-10-19T02:09:21Z","last_updated_date":"2006-10-19T02:09:21Z","reference_number":"EMEA/421027/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-16-18-october-2006_en.pdf"},
    {"id":"4481","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 8-10 March 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMA/CVMP/154373/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-march-2011_en.pdf"},
    {"id":"4484","name":"Committee for veterinary medicinal products: 62nd meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-01-11T12:09:21Z","last_updated_date":"2001-01-11T12:09:21Z","reference_number":"EMEA/CVMP/064/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-62nd-meeting_en.pdf"},
    {"id":"4486","name":"EMA Management Board: highlights of June 2015 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-06-12T02:00:00Z","last_updated_date":"2015-06-12T02:00:00Z","reference_number":"EMA/392044/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-june-2015-meeting_en.pdf"},
    {"id":"4496","name":"Management Board finalises its long-term plan and adopts work programme and budget for 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-12-17T00:09:21Z","last_updated_date":"2004-12-17T00:09:21Z","reference_number":"EMEA/204096/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/management-board-finalises-its-long-term-plan-and-adopts-work-programme-and-budget-2005_en.pdf"}    {"id":"4514","name":"Committee for Advanced Therapies (CAT) elects chair and vice-chair","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T01:00:00Z","last_updated_date":"2009-02-16T01:00:00Z","reference_number":"EMEA/85845/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-advanced-therapies-cat-elects-chair-and-vice-chair_en.pdf"},
    {"id":"4526","name":"European Medicines Agency proposes new, faster scientific advice procedure","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-09-22T02:00:00Z","last_updated_date":"2005-09-22T02:00:00Z","reference_number":"EMEA/311762/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-proposes-new-faster-scientific-advice-procedure_en.pdf"},
    {"id":"4531","name":"EU wide recall of Raptiva efalizumab to be initiated","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-08T02:00:00Z","last_updated_date":"2009-06-08T02:00:00Z","reference_number":"EMEA/346255/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-wide-recall-raptiva-efalizumab-be-initiated_en.pdf"},
    {"id":"4624","name":"European Medicines Agency recommends approval of fourth advanced therapy in Europe","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/394057/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-fourth-advanced-therapy-europe_en.pdf"},
    {"id":"4720","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 13-15 December 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-12-16T01:00:00Z","last_updated_date":"2004-12-16T01:00:00Z","reference_number":"EMEA/199703/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-13-15-december-2004_en.pdf"},
    {"id":"4754","name":"SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2017-02-24T01:00:00Z","reference_number":"EMA/118223/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/sglt2-inhibitors-information-potential-risk-toe-amputation-be-included-prescribing-information_en.pdf"},
    {"id":"4762","name":"Meeting of the EMEA working party on herbal medicinal products 13 and 14 March 2001","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-03-23T01:00:00Z","last_updated_date":"2001-03-23T01:00:00Z","reference_number":"EMEA/HMPWP/6/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-emea-working-party-herbal-medicinal-products-13-and-14-march-2001_en.pdf"},
    {"id":"4826","name":"Committee for Proprietary Medicinal Products (CPMP): meeting of 13 to 15 November 2001","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-11-16T00:09:21Z","last_updated_date":"2001-11-16T00:09:21Z","reference_number":"EMEA/CPMP/3658/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-meeting-13-15-november-2001_en.pdf"},
    {"id":"4845","name":"Committee for Orphan Medicinal Products: June 2005 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-06-20T02:00:00Z","last_updated_date":"2005-06-20T02:00:00Z","reference_number":"EMEA/COMP/203574/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-june-2005-meeting_en.pdf"},
    {"id":"4856","name":"EMEA concludes first accelerated assessment for a medicine for human use","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-04-27T02:09:21Z","last_updated_date":"2007-04-27T02:09:21Z","reference_number":"EMEA/184876/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-concludes-first-accelerated-assessment-medicine-human-use_en.pdf"},
    {"id":"4866","name":"European Medicines Agency updates patient and prescriber information for Pradaxa","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-05-25T12:00:00Z","last_updated_date":"2012-05-25T12:00:00Z","reference_number":"EMA/337406/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-patient-and-prescriber-information-pradaxa_en.pdf"},
    {"id":"4885","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the sixty-fourth meeting of the committee for veterinary medicinal products took place in London on 13-15 March 2001.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-03-15T12:29:21Z","last_updated_date":"2001-03-15T12:29:21Z","reference_number":"EMEA/CVMP/287/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-sixty-fourth-meeting-committee-veterinary-medicinal-products-took-place-london-13-15-march-2001_en.pdf"},
    {"id":"4894","name":"First monoclonal antibody in veterinary medicine recommended for marketing authorisation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-02-17T01:00:00Z","last_updated_date":"2017-02-17T01:00:00Z","reference_number":"EMA/CVMP/113787/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-monoclonal-antibody-veterinary-medicine-recommended-marketing-authorisation_en.pdf"},
    {"id":"4948","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 24-27 July 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-07-28T02:09:21Z","last_updated_date":"2006-07-28T02:09:21Z","reference_number":"EMEA/289040/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-24-27-july-2006_en.pdf"},
    {"id":"4995","name":"Twenty-second Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-06-03T02:00:00Z","last_updated_date":"1999-06-03T02:00:00Z","reference_number":"EMEA/MB/040/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/twenty-second-meeting-management-board_en.pdf"},
    {"id":"5006","name":"EMA recommends changes to prescribing information for vancomycin antibiotics","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-05-19T02:00:00Z","reference_number":"EMA/306160/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-changes-prescribing-information-vancomycin-antibiotics_en.pdf"},
    {"id":"5080","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 3-5 October 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-06T02:00:00Z","last_updated_date":"2017-10-06T02:00:00Z","reference_number":"EMA/CVMP/637551/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-3-5-october-2017_en.pdf"},
    {"id":"5091","name":"EMA fast-tracks new oral treatment for non-small cell lung cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T13:00:00Z","last_updated_date":"2015-12-18T13:00:00Z","reference_number":"EMA/CHMP/848525/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-fast-tracks-new-oral-treatment-non-small-cell-lung-cancer_en.pdf"},
    {"id":"5094","name":"EMEA recommends new warnings and contraindications for ergot-derived dopamine agonists","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:09:21Z","last_updated_date":"2008-06-26T02:09:21Z","reference_number":"EMEA/CHMP/322395/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-recommends-new-warnings-and-contraindications-ergot-derived-dopamine-agonists_en.pdf"},
    {"id":"5101","name":"European Medicines Agency recommends the approval of thalidomide\n\nfor the treatment of rare bone-marrow cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/33024/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-thalidomide-treatment-rare-bone-marrow-cancer_en.pdf"},
    {"id":"5135","name":"The bacterial challenge - time to react a call to narrow the gap between multidrug-resistant bacteria in the EU and development of new antibacterial agents","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-09-17T02:00:00Z","last_updated_date":"2009-09-17T02:00:00Z","reference_number":"EMEA/533940/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/bacterial-challenge-time-react-call-narrow-gap-between-multidrug-resistant-bacteria-eu-and-development-new-antibacterial-agents_en.pdf"},
    {"id":"5144","name":"New treatment for rare white blood cell cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/297812/2016 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-rare-white-blood-cell-cancer_en.pdf"},
    {"id":"5158","name":"Further data needed to determine risk of heart attack with abacavir","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-04-02T02:00:00Z","last_updated_date":"2008-04-02T02:00:00Z","reference_number":"EMEA/142888/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/further-data-needed-determine-risk-heart-attack-abacavir_en.pdf"},
    {"id":"5201","name":"GVK Biosciences: European Medicines Agency recommends suspending medicines over flawed studies","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-01-23T13:00:00Z","last_updated_date":"2015-01-23T13:00:00Z","reference_number":"EMA/37763/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/gvk-biosciences-european-medicines-agency-recommends-suspending-medicines-over-flawed-studies_en.pdf"},
    {"id":"5214","name":"PRAC concludes there is no evidence of a change in known risk of neutropenic enterocolitis with docetaxel","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-06-09T16:00:00Z","last_updated_date":"2017-06-09T16:00:00Z","reference_number":"EMA/365357/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-concludes-there-no-evidence-change-known-risk-neutropenic-enterocolitis-docetaxel_en.pdf"},
    {"id":"5287","name":"Ten years of orphan medicines legislation in Europe – European Medicines Agency reviews success and looks ahead","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"EMA/291560/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/ten-years-orphan-medicines-legislation-europe-european-medicines-agency-reviews-success-and-looks-ahead_en.pdf"},
    {"id":"5288","name":"Third Meeting of the Management Board of the European Agency for the Evaluation of Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1994-06-23T02:00:00Z","last_updated_date":"1994-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/third-meeting-management-board-european-agency-evaluation-medicinal-products_en.pdf"},
    {"id":"5312","name":"Twelfth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-12-05T01:00:00Z","last_updated_date":"1996-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/twelfth-meeting-management-board_en.pdf"},
    {"id":"5325","name":"European Medicines Agency recommends first medical treatment for patients with short bowel syndrome","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CHMP/409283/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-first-medical-treatment-patients-short-bowel-syndrome_en.pdf"},
    {"id":"5335","name":"1st EMEA workshop with health professionals and Academia on Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-01-31T00:09:21Z","last_updated_date":"2002-01-31T00:09:21Z","reference_number":"COMP/34/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/1st-emea-workshop-health-professionals-and-academia-orphan-medicinal-products_en.pdf"},
    {"id":"5348","name":"Committee for medicinal products for veterinary use: Meeting of 12-14 February 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-02-15T00:09:21Z","last_updated_date":"2008-02-15T00:09:21Z","reference_number":"EMEA/CVMP/58014/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-12-14-february-2008_en.pdf"},
    {"id":"5368","name":"Further review of Iclusig started","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-06T11:59:00Z","last_updated_date":"2013-12-06T11:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/further-review-iclusig-started_en.pdf"},
    {"id":"5370","name":"Meeting report of the Seventh EMEA/FEDESA joint infoday at the European Agency in London","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-05-22T02:00:00Z","last_updated_date":"2000-05-22T02:00:00Z","reference_number":"EMEA/V/15080/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-report-seventh-emeafedesa-joint-infoday-european-agency-london_en.pdf"},
    {"id":"5375","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 21 to 23 January 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-01-23T01:00:00Z","last_updated_date":"2003-01-23T01:00:00Z","reference_number":"EMEA/CPMP/294/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-21-23-january-2003_en.pdf"},
    {"id":"5376","name":"Vanda Pharmaceuticals Ltd withdraws its marketing-authorisation application for Fanaptum (iloperidone)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-03-14T18:00:00Z","last_updated_date":"2013-03-14T18:00:00Z","reference_number":"EMA/163392/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/vanda-pharmaceuticals-ltd-withdraws-its-marketing-authorisation-application-fanaptum-iloperidone_en.pdf"},
    {"id":"5395","name":"EMA and EUnetHTA finalise joint work plan for 2017-2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T15:30:00Z","last_updated_date":"2017-11-13T15:30:00Z","reference_number":"EMA/699001/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-and-eunethta-finalise-joint-work-plan-2017-2020_en.pdf"},
    {"id":"5403","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 26-28 June 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-06-29T02:09:21Z","last_updated_date":"2006-06-29T02:09:21Z","reference_number":"EMEA/243602/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-26-28-june-2006_en.pdf"},
    {"id":"5416","name":"Alkermes Pharma Ireland Limited withdraws its marketing authorisation application for Megestrol Alkermes (megestrol)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-03-13T12:10:00Z","last_updated_date":"2012-03-13T12:10:00Z","reference_number":"EMA/174944/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/alkermes-pharma-ireland-limited-withdraws-its-marketing-authorisation-application-megestrol-alkermes-megestrol_en.pdf"},
    {"id":"5418","name":"New medicine for rare eye disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T14:00:00Z","last_updated_date":"2017-05-19T14:00:00Z","reference_number":"EMA/CHMP/311622/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-rare-eye-disease_en.pdf"},
    {"id":"5432","name":"EMEA publishes first summaries of opinions for designated orphan medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-03-21T00:09:00Z","last_updated_date":"2002-03-21T00:09:00Z","reference_number":"EMEA/D/7426/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-publishes-first-summaries-opinions-designated-orphan-medicines_en.pdf"},
    {"id":"5438","name":"Meeting highlights from the Paediatric Committee: 21 -  23 November 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-11-27T01:00:00Z","last_updated_date":"2007-11-27T01:00:00Z","reference_number":"EMEA/553291/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-21-23-november-2007_en.pdf"},
    {"id":"5478","name":"European Medicines Agency recommends restricting Trobalt to last-line therapy in partial epilepsy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T12:00:00Z","last_updated_date":"2013-05-31T12:00:00Z","reference_number":"EMA/321395/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-trobalt-last-line-therapy-partial-epilepsy_en.pdf"},
    {"id":"5484","name":"Restrictions in the use of flupirtine-containing medicines - CMDh endorses PRAC recommendation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/384191/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/restrictions-use-flupirtine-containing-medicines-cmdh-endorses-prac-recommendation_en.pdf"},
    {"id":"5486","name":"Committee for medicinal products for veterinary use: Meeting of 14-16 October 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-10-17T02:09:21Z","last_updated_date":"2008-10-17T02:09:21Z","reference_number":"EMEA/CVMP/523644/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-14-16-october-2008_en.pdf"},
    {"id":"5488","name":"Committee for Medicinal Products for Veterinary Use: Meeting of 9-11 March 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-03-12T01:00:00Z","last_updated_date":"2010-03-12T01:00:00Z","reference_number":"EMA/CVMP/122502/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-9-11-march-2010_en.pdf"},
    {"id":"5489","name":"Marvel LifeSciences Ltd withdraws its marketing-authorisation applications for Solumarv, Isomarv medium and Combimarv (human insulin)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-11-27T01:00:00Z","last_updated_date":"2012-11-27T01:00:00Z","reference_number":"EMA/747975/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/marvel-lifesciences-ltd-withdraws-its-marketing-authorisation-applications-solumarv-isomarv-medium-and-combimarv-human-insulin_en.pdf"},
    {"id":"5522","name":"European Medicines Agency is consulting on the reflection paper on the use of\n\nfluoroquinolones in food-producing animals in the European Union: development of resistance and impact on human and animal health","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-02-08T01:00:00Z","last_updated_date":"2006-02-08T01:00:00Z","reference_number":"EMEA/42529/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-consulting-reflection-paper-use-fluoroquinolones-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"5526","name":"Benefits of Diane 35 and generics outweigh risks in specific patient group","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T02:00:00Z","last_updated_date":"2013-05-17T02:00:00Z","reference_number":"EMA/PRAC/284754/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/benefits-diane-35-and-generics-outweigh-risks-specific-patient-group_en.pdf"},
    {"id":"5541","name":"European Medicines Agency and European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) launch electronic Register of Studies (E-Register)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/759118/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-european-network-centres-pharmacoepidemiology-and-pharmacovigilance-encepp-launch-electronic-register-studies-e-register_en.pdf"},
    {"id":"5542","name":"First EU treatment for rare sleep-wake disorder","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/CHMP/260099/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-eu-treatment-rare-sleep-wake-disorder_en.pdf"},
    {"id":"5559","name":"Committee for medicinal products for veterinary use: Meeting of 12 to 14 September 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-09-14T14:09:21Z","last_updated_date":"2006-09-14T14:09:21Z","reference_number":"EMEA/CVMP/323417/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-12-14-september-2006_en.pdf"},
    {"id":"5585","name":"Meeting highlights from the Paediatric Committee: 28 - 30 April 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-05T02:00:00Z","last_updated_date":"2009-05-05T02:00:00Z","reference_number":"EMEA/PDCO/259461/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-28-30-april-2009_en.pdf"},
    {"id":"5654","name":"European Medicines Agency boosts EU transparency with online publication of suspected side effect reports","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-05-31T13:00:00Z","last_updated_date":"2012-05-31T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-boosts-eu-transparency-online-publication-suspected-side-effect-reports_en.pdf"},
    {"id":"5656","name":"Meeting highlights from the Paediatric Committee: 29 - 31 August 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-09-05T02:00:00Z","last_updated_date":"2007-09-05T02:00:00Z","reference_number":"EMEA/294650/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-29-31-august-2007_en.pdf"},
    {"id":"5659","name":"Improving safety of first-in-human clinical trials","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T12:00:00Z","last_updated_date":"2016-05-27T12:00:00Z","reference_number":"EMA/322847/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/improving-safety-first-human-clinical-trials_en.pdf"},
    {"id":"5677","name":"European Medicines Agency recommends approval of pomalidomide for the treatment of multiple myeloma","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-pomalidomide-treatment-multiple-myeloma_en.pdf"},
    {"id":"5678","name":"Better training tools recommended to support patients using adrenaline auto-injectors","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T14:00:00Z","last_updated_date":"2015-06-26T14:00:00Z","reference_number":"EMA/411622/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_en.pdf"},
    {"id":"5692","name":"Committee for medicinal products for veterinary use: Meeting of 13-15 May 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-05-16T02:09:21Z","last_updated_date":"2008-05-16T02:09:21Z","reference_number":"EMEA/CVMP/232903/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-13-15-may-2008_en.pdf"},
    {"id":"5749","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n18-21 February 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2008-02-21T00:09:21Z","reference_number":"EMEA/CHMP/87277/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-18-21-february-2008_en.pdf"},
    {"id":"5762","name":"Meeting highlights from the Paediatric Committee: 1 - 2 August 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-08-06T02:00:00Z","last_updated_date":"2007-08-06T02:00:00Z","reference_number":"EMEA/354317/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-1-2-august-2007_en.pdf"},
    {"id":"5781","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 8-10 October 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"EMA/CVMP/585227/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-october-2013_en.pdf"},
    {"id":"5872","name":"European Medicines Agency reveals new structure","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-09-16T12:00:00Z","last_updated_date":"2013-09-16T12:00:00Z","reference_number":"EMA/549590/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-reveals-new-structure_en.pdf"},
    {"id":"5882","name":"Committee for Proprietary Medicinal Products (CPMP) 32nd plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-11-20T01:00:00Z","last_updated_date":"1997-11-20T01:00:00Z","reference_number":"CPMP/1056/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-32nd-plenary-meeting_en.pdf"},
    {"id":"5905","name":"European Medicines Agency starts review of Protelos / Osseor","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-10-20T17:58:59Z","last_updated_date":"2011-10-20T17:58:59Z","reference_number":"EMA/CHMP/827880/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-review-protelos-osseor_en.pdf"},
    {"id":"5910","name":"Meeting highlights from the Paediatric Committee held by written procedure:19 - 21 August 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-08-25T02:00:00Z","last_updated_date":"2009-08-25T02:00:00Z","reference_number":"EMEA/PDCO/518054/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-held-written-procedure19-21-august-2009_en.pdf"},
    {"id":"5986","name":"European Medicines Agency: Committee for Medicinal Products for Human Use\n\n23-26 May 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-05-25T02:00:00Z","last_updated_date":"2005-05-25T02:00:00Z","reference_number":"EMEA/176508/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-23-26-may-2005_en.pdf"},
    {"id":"6005","name":"Aclasta: further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T13:00:00Z","last_updated_date":"2015-03-27T13:00:00Z","reference_number":"EMA/206916/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/aclasta-further-measures-minimise-risk-osteonecrosis-jaw-bisphosphonate-medicine_en.pdf"},
    {"id":"6008","name":"European Medicines Agency statement on new information on Rotarix oral vaccine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"EMA/189350/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-statement-new-information-rotarix-oral-vaccine_en.pdf"},
    {"id":"6017","name":"European Medicines Agency recommends changes to the use of metoclopramide","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T12:00:00Z","last_updated_date":"2013-07-26T12:00:00Z","reference_number":"EMA/443003/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-changes-use-metoclopramide_en.pdf"},
    {"id":"6094","name":"European Medicines Agency now publishing meeting agendas for all scientific committees","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T13:00:00Z","last_updated_date":"2013-12-17T13:00:00Z","reference_number":"EMA/788618/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-now-publishing-meeting-agendas-all-scientific-committees_en.pdf"},
    {"id":"6099","name":"EMA’s first public hearing: giving EU citizens a voice to help reduce the risk of valproate","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"EMA/630591/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/emas-first-public-hearing-giving-eu-citizens-voice-help-reduce-risk-valproate_en.pdf"},
    {"id":"6120","name":"32nd meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-05-07T14:09:21Z","last_updated_date":"1998-05-07T14:09:21Z","reference_number":"EMEA/CVMP/210/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/32nd-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"6125","name":"Takeda withdraws its marketing authorisation application for Ramelteon","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-25T02:09:21Z","last_updated_date":"2008-09-25T02:09:21Z","reference_number":"EMEA/504716/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/takeda-withdraws-its-marketing-authorisation-application-ramelteon_en.pdf"},
    {"id":"6155","name":"FDA and EMA Agree to Accept a Single Orphan Drug Designation Annual Report","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-02-26T01:00:00Z","last_updated_date":"2010-02-26T01:00:00Z","reference_number":"EMA/121846/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/fda-and-ema-agree-accept-single-orphan-drug-designation-annual-report_en.pdf"},
    {"id":"6247","name":"ISTA Pharma Ltd withdraws its marketing authorisation application for Vitragan","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-04-30T02:09:21Z","last_updated_date":"2007-04-30T02:09:21Z","reference_number":"EMEA/193194/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/ista-pharma-ltd-withdraws-its-marketing-authorisation-application-vitragan_en.pdf"},
    {"id":"6350","name":"European Medicines Agency advises doctors treating patients with nosocomial pneumonia with Doribax","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CHMP/413801/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-advises-doctors-treating-patients-nosocomial-pneumonia-doribax_en.pdf"},
    {"id":"6361","name":"EMEA welcomes new members and observers to its Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-20T02:00:00Z","last_updated_date":"2008-06-20T02:00:00Z","reference_number":"EMEA/319013/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-welcomes-new-members-and-observers-its-management-board_en.pdf"},
    {"id":"6396","name":"European Medicines Agency update on stolen vials of Herceptin","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-17T02:00:00Z","last_updated_date":"2014-08-11T16:00:00Z","reference_number":"EMA/239072/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-update-stolen-vials-herceptin_en.pdf"},
    {"id":"6402","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products 16-17 December 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-12-18T00:09:21Z","last_updated_date":"2003-12-18T00:09:21Z","reference_number":"EMEA/CPMP/6199/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-16-17-december-2003_en.pdf"},
    {"id":"6407","name":"Committee for Proprietary Medicinal Products (CPMP) 56th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-01-24T01:00:00Z","last_updated_date":"2000-01-24T01:00:00Z","reference_number":"CPMP/122/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-56th-plenary-meeting_en.pdf"},
    {"id":"6440","name":"European Medicines Agency gives further interim recommendations on dealing with shortcomings in quality assurance at Ben Venue Laboratories","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-12-09T17:00:00Z","last_updated_date":"2011-12-09T17:00:00Z","reference_number":"EMA/CHMP/954737/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-further-interim-recommendations-dealing-shortcomings-quality-assurance-ben-venue-laboratories_en.pdf"},
    {"id":"6447","name":"Pharmacovigilance Risk Assessment Committee: one year of public health promotion and protection","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T19:00:00Z","last_updated_date":"2013-07-19T19:00:00Z","reference_number":"EMA/445949/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/pharmacovigilance-risk-assessment-committee-one-year-public-health-promotion-and-protection_en.pdf"},
    {"id":"6455","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 17–19 July 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-07-20T16:30:00Z","last_updated_date":"2018-07-20T16:30:00Z","reference_number":"EMA/CVMP/475701/2018 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-17-19-july-2018_en.pdf"},
    {"id":"6478","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 September 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-09-14T18:15:00Z","last_updated_date":"2012-09-14T18:15:00Z","reference_number":"EMA/CVMP/576111/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-11-13-september-2012_en.pdf"},
    {"id":"6493","name":"European Medicines Agency prepares for approval of pandemic vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-04-30T02:00:00Z","last_updated_date":"2009-04-30T02:00:00Z","reference_number":"EMEA/271000/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-prepares-approval-pandemic-vaccines_en.pdf"},
    {"id":"6587","name":"European Medicines Agency finalises review of recent published data on cardiovascular safety of NSAIDs","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T12:00:00Z","last_updated_date":"2012-10-19T12:00:00Z","reference_number":"EMA/CHMP/667707/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-finalises-review-recent-published-data-cardiovascular-safety-nsaids_en.pdf"},
    {"id":"6615","name":"Management Board completes framework for conflicts of interests","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-06-08T14:00:00Z","last_updated_date":"2012-06-08T14:00:00Z","reference_number":"EMA/391894/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/management-board-completes-framework-conflicts-interests_en.pdf"},
    {"id":"6617","name":"European Medicines Agency recommends restricted use of\n\nnimesulide-containing medicinal products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-09-21T02:09:21Z","last_updated_date":"2007-09-21T02:09:21Z","reference_number":"EMEA/432604/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricted-use-nimesulide-containing-medicinal-products_en.pdf"},
    {"id":"6637","name":"Management Board started building approval process of EMA premises in Amsterdam","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T01:00:00Z","last_updated_date":"2018-02-07T01:00:00Z","reference_number":"EMA/72752/2018 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/management-board-started-building-approval-process-ema-premises-amsterdam_en.pdf"},
    {"id":"6642","name":"Proposals to revise guidance on first-in-human clinical trials","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-07-21T14:00:00Z","last_updated_date":"2016-07-21T14:00:00Z","reference_number":"EMA/485860/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/proposals-revise-guidance-first-human-clinical-trials_en.pdf"},
    {"id":"6655","name":"General Court finds no fault in 2011 appointment procedure of EMA Executive Director","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T14:00:00Z","last_updated_date":"2017-10-03T14:00:00Z","reference_number":"EMA/648085/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/general-court-finds-no-fault-2011-appointment-procedure-ema-executive-director_en.pdf"},
    {"id":"6660","name":"First oral treatment for Fabry disease recommended for approval in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/224720/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-oral-treatment-fabry-disease-recommended-approval-eu_en.pdf"},
    {"id":"6672","name":"EMA confirms positive benefit-risk for antidepressant Valdoxan/Thymanax (agomelatine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/577812/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-confirms-positive-benefit-risk-antidepressant-valdoxanthymanax-agomelatine_en.pdf"},
    {"id":"6675","name":"4th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-07-14T02:00:00Z","last_updated_date":"2000-07-14T02:00:00Z","reference_number":"EMEA/COMP/38/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/4th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"6680","name":"EU Clinical Trials Register goes live","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-03-23T00:31:00Z","last_updated_date":"2011-03-23T00:31:00Z","reference_number":"EMA/199558/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-clinical-trials-register-goes-live_en.pdf"},
    {"id":"6704","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 19-21 January 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-01-22T14:50:00Z","last_updated_date":"2016-01-22T14:50:00Z","reference_number":"EMA/CVMP/11490/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-19-21-january-2016_en.pdf"},
    {"id":"6714","name":"European Medicines Agency recommends new anti-malaria treatment for use outside the European Union","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T12:57:21Z","last_updated_date":"2012-02-17T12:57:21Z","reference_number":"EMA/CHMP/114875/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-new-anti-malaria-treatment-use-outside-european-union_en.pdf"},
    {"id":"6716","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP): 14-17 December 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-18T01:00:00Z","last_updated_date":"2010-02-11T01:00:00Z","reference_number":"EMA/CHMP/833104/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-december-2009_en.pdf"},
    {"id":"6733","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 April 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-04-16T02:00:00Z","last_updated_date":"2012-04-16T02:00:00Z","reference_number":"EMA/CVMP/221484/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-11-13-april-2012_en.pdf"},
    {"id":"6736","name":"Press release: Committee for Orphan Medicinal Products January 2007 Meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2007-01-10T00:09:21Z","last_updated_date":"2007-01-10T00:09:21Z","reference_number":"EMEA/COMP/7953/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-committee-orphan-medicinal-products-january-2007-meeting_en.pdf"}    {"id":"6780","name":"Rise in applications for medicines in 2006, concerns over budget situation for 2007 and new transparency measures","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-10-06T02:09:21Z","last_updated_date":"2006-10-06T02:09:21Z","reference_number":"EMEA/388563/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/rise-applications-medicines-2006-concerns-over-budget-situation-2007-and-new-transparency-measures_en.pdf"},
    {"id":"6819","name":"European Medicines Agency and its international partners complete successful inspection pilots","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-08-02T17:54:23Z","last_updated_date":"2011-08-02T17:54:23Z","reference_number":"EMA/612563/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-its-international-partners-complete-successful-inspection-pilots_en.pdf"},
    {"id":"6882","name":"The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-10-23T02:09:21Z","last_updated_date":"2008-10-23T02:09:21Z","reference_number":"EMEA/CHMP/537777/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-marketing-authorisation-acomplia_en.pdf"},
    {"id":"6930","name":"New enzyme replacement therapy to treat rare genetic disorder alpha-mannosidosis in children and adults","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/46083/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-enzyme-replacement-therapy-treat-rare-genetic-disorder-alpha-mannosidosis-children-and-adults_en.pdf"},
    {"id":"7019","name":"European Medicines Agency gives first positive opinions on medicinal products for use outside the European Union","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"EMEA/382477/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-first-positive-opinions-medicinal-products-use-outside-european-union_en.pdf"},
    {"id":"7044","name":"Committee for medicinal products for veterinary use: Meeting of 7 to 9 December 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-12-10T12:29:21Z","last_updated_date":"2004-12-10T12:29:21Z","reference_number":"EMEA/CVMP/1163/04-corrigendum","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-7-9-december-2004_en.pdf"},
    {"id":"7048","name":"Committee for Proprietary Medicinal Products (CPMP) 64th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-10-23T02:00:00Z","last_updated_date":"2000-10-23T02:00:00Z","reference_number":"CPMP/2849/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-64th-plenary-meeting_en.pdf"},
    {"id":"7069","name":"CMDh endorses new advice to minimise risk of next-morning impaired driving ability and mental alertness with zolpidem","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T18:00:00Z","last_updated_date":"2014-04-25T18:00:00Z","reference_number":"EMA/240581/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/cmdh-endorses-new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_en.pdf"},
    {"id":"7101","name":"EMEA statement following withdrawal of Vioxx","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-10-06T02:00:00Z","last_updated_date":"2004-10-06T02:00:00Z","reference_number":"EMEA/97949/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-statement-following-withdrawal-vioxx_en.pdf"},
    {"id":"7106","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 14-16 January 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-01-17T01:00:00Z","last_updated_date":"2014-01-17T01:00:00Z","reference_number":"EMA/CVMP/807518/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-14-16-january-2014_en.pdf"},
    {"id":"7110","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 8-10 January 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"EMA/CVMP/2217/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-january-2013_en.pdf"},
    {"id":"7121","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n21-24 May 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-05-25T02:09:21Z","last_updated_date":"2007-05-25T02:09:21Z","reference_number":"EMEA/231382/2007 - corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-21-24-may-2007_en.pdf"},
    {"id":"7132","name":"Axxonis Pharma AG withdraws its marketing authorisation application for Nenad (lisuride)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-03T00:09:21Z","last_updated_date":"2009-12-03T00:09:21Z","reference_number":"EMEA/775140/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/axxonis-pharma-ag-withdraws-its-marketing-authorisation-application-nenad-lisuride_en.pdf"},
    {"id":"7145","name":"European Medicines Agency recommends revaccination for some travellers in need of protection with Ixiaro","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/CHMP/401327/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-revaccination-some-travellers-need-protection-ixiaro_en.pdf"},
    {"id":"7169","name":"Committee for Proprietary Medicinal Products (CPMP) 31st plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-10-24T02:00:00Z","last_updated_date":"1997-10-24T02:00:00Z","reference_number":"CPMP/921/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-31st-plenary-meeting_en.pdf"},
    {"id":"7176","name":"EMA to further clarify safety profile of human papillomavirus (HPV) vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-07-13T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMA/454979/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-further-clarify-safety-profile-human-papillomavirus-hpv-vaccines_en.pdf"},
    {"id":"7195","name":"European Medicines Agency recommends new advice to surgeons on safer use of fibrin sealants Evicel and Quixil","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2012-11-16T01:00:00Z","reference_number":"EMA/CHMP/734886/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-new-advice-surgeons-safer-use-fibrin-sealants-evicel-and-quixil_en.pdf"},
    {"id":"7207","name":"European Medicines Agency recommends transfer of manufacturing sites for Caelyx and Ceplene","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-03-16T11:00:00Z","last_updated_date":"2012-03-16T11:00:00Z","reference_number":"EMA/CHMP/185096/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-transfer-manufacturing-sites-caelyx-and-ceplene_en.pdf"},
    {"id":"7242","name":"Public hearing on quinolones and fluoroquinolones: 23 speakers from 11 EU countries to share experience","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/378251/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/public-hearing-quinolones-and-fluoroquinolones-23-speakers-11-eu-countries-share-experience_en.pdf"},
    {"id":"7260","name":"Review of Corlentor/Procoralan started","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T02:00:00Z","last_updated_date":"2014-05-08T02:00:00Z","reference_number":"EMA/280865/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/review-corlentorprocoralan-started_en.pdf"},
    {"id":"7282","name":"Thirty-fifth meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-10-04T02:09:21Z","last_updated_date":"2002-10-04T02:09:21Z","reference_number":"EMEA/MB/048/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/thirty-fifth-meeting-management-board_en.pdf"},
    {"id":"7310","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 2-4 June 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-06-05T02:00:00Z","last_updated_date":"2015-06-05T02:00:00Z","reference_number":"EMA/CVMP/338322/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-2-4-june-2015_en.pdf"},
    {"id":"7313","name":"No consistent evidence of an increased risk of heart problems with testosterone medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2014-11-21T01:00:00Z","reference_number":"EMA/706140/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_en.pdf"},
    {"id":"7323","name":"Outcome report on first European collaboration between regulators and HTA organisations: improving the contribution of regulatory assessment reports to health technology assessment","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-06-25T11:00:00Z","last_updated_date":"2014-06-25T11:00:00Z","reference_number":"EMA/295485/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/outcome-report-first-european-collaboration-between-regulators-and-hta-organisations-improving-contribution-regulatory-assessment-reports-health-technology-assessment_en.pdf"},
    {"id":"7338","name":"30th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-03-12T12:39:21Z","last_updated_date":"1998-03-12T12:39:21Z","reference_number":"EMEA/CVMP/095/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/30th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7346","name":"European Medicines Agency recommends first medical treatment for removal of eschar from severe burn wounds","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-09-21T15:00:00Z","last_updated_date":"2012-09-21T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-first-medical-treatment-removal-eschar-severe-burn-wounds_en.pdf"},
    {"id":"7351","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 6-8 March 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-03-09T17:00:00Z","last_updated_date":"2012-03-09T17:00:00Z","reference_number":"EMA/CVMP/137028/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-6-8-march-2012_en.pdf"},
    {"id":"7356","name":"Ipsen Ltd withdraws its application for an extension of indication for NutropinAq","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-01-28T00:09:21Z","last_updated_date":"2008-01-28T00:09:21Z","reference_number":"EMEA/45635/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/ipsen-ltd-withdraws-its-application-extension-indication-nutropinaq_en.pdf"},
    {"id":"7362","name":"European Medicines Agency confirms positive benefit-risk balance of Protelos / Osseor, but recommends new contraindications and revised warnings","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-03-16T11:00:00Z","last_updated_date":"2012-03-16T11:00:00Z","reference_number":"EMA/CHMP/185175/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-positive-benefit-risk-balance-protelos-osseor-recommends-new-contraindications-and-revised-warnings_en.pdf"},
    {"id":"7369","name":"EMEA recommends changes in the product information for Protelos/Osseor due to the risk of severe hypersensitivity reactions","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-11-16T00:09:21Z","last_updated_date":"2007-11-16T00:09:21Z","reference_number":"EMEA/417458/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-recommends-changes-product-information-protelososseor-due-risk-severe-hypersensitivity-reactions_en.pdf"},
    {"id":"7389","name":"15th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1996-10-25T14:39:21Z","last_updated_date":"1996-10-25T14:39:21Z","reference_number":"EMEA/CVMP/233/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/15th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"7398","name":"Committee for Orphan Medicinal Products: April 2005 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-04-12T02:00:00Z","last_updated_date":"2005-04-12T02:00:00Z","reference_number":"EMEA/COMP/127051/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-april-2005-meeting_en.pdf"},
    {"id":"7442","name":"European Medicines Agency adopts first positive opinion for a medicinal product derived from transgenic biotechnology","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-06-02T02:00:00Z","last_updated_date":"2006-06-02T02:00:00Z","reference_number":"EMEA/203163/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-adopts-first-positive-opinion-medicinal-product-derived-transgenic-biotechnology_en.pdf"},
    {"id":"7465","name":"Committee for Proprietary Medicinal Products (CPMP) 29th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-07-25T02:00:00Z","last_updated_date":"1997-07-25T02:00:00Z","reference_number":"CPMP/651/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-29th-plenary-meeting_en.pdf"},
    {"id":"7495","name":"European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"EMEA/CHMP/89523/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-new-contraindication-and-warning-rasilez-and-other-aliskiren-medicines_en.pdf"},
    {"id":"7497","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 17-19 January 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T02:00:00Z","last_updated_date":"2016-10-20T02:00:00Z","reference_number":"EMA/CVMP/9076/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-17-19-january-2017_en.pdf"},
    {"id":"7508","name":"European Medicines Agency recommends first vaccine for foot-and-mouth disease for authorisation at EU level","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T02:00:00Z","last_updated_date":"2013-05-17T02:00:00Z","reference_number":"EMA/296130/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-first-vaccine-foot-and-mouth-disease-authorisation-eu-level_en.pdf"},
    {"id":"7511","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 17-20 May 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-05-21T02:00:00Z","last_updated_date":"2010-05-21T02:00:00Z","reference_number":"EMA/CHMP/163664/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2010_en.pdf"},
    {"id":"7515","name":"European Medicines Agency recommends restricting the use of dexrazoxane-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T14:06:34Z","last_updated_date":"2011-06-24T14:06:34Z","reference_number":"EMA/491205/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-dexrazoxane-containing-medicines_en.pdf"},
    {"id":"7531","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n19-22 February 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-02-23T00:09:21Z","last_updated_date":"2007-02-23T00:09:21Z","reference_number":"EMEA/82856/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-19-22-february-2007_en.pdf"},
    {"id":"7600","name":"Hydroxyethyl starch solutions: CMDh introduces new measures to protect patients","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/422341/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients_en.pdf"},
    {"id":"7610","name":"European Medicines Agency fast-tracks treatment of multiple myeloma for approval in European Union","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T13:00:00Z","last_updated_date":"2016-01-29T13:00:00Z","reference_number":"EMA/CHMP/56735/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-fast-tracks-treatment-multiple-myeloma-approval-european-union_en.pdf"},
    {"id":"7615","name":"Diclofenac use in animals poses a risk to European vultures","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/770700/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/diclofenac-use-animals-poses-risk-european-vultures_en.pdf"},
    {"id":"7620","name":"Seventh Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1995-09-25T01:00:00Z","last_updated_date":"1995-09-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/seventh-meeting-management-board_en.pdf"},
    {"id":"7667","name":"Novartis Europharm Ltd withdraws its marketing-authorisation application for Ruvise (imatinib mesilate)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T15:00:00Z","last_updated_date":"2013-01-24T15:00:00Z","reference_number":"EMA/37093/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/novartis-europharm-ltd-withdraws-its-marketing-authorisation-application-ruvise-imatinib-mesilate_en.pdf"},
    {"id":"7684","name":"First malaria vaccine receives positive scientific opinion from EMA","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T10:42:00Z","last_updated_date":"2015-07-24T10:42:00Z","reference_number":"EMA/CHMP/488348/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-malaria-vaccine-receives-positive-scientific-opinion-ema_en.pdf"},
    {"id":"7691","name":"Meeting of the EMEA working party on herbal medicinal products 3 - 4 November 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-11-14T01:00:00Z","last_updated_date":"2003-11-14T01:00:00Z","reference_number":"EMEA/HMPWP/5516/03 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-emea-working-party-herbal-medicinal-products-3-4-november-2003_en.pdf"},
    {"id":"7767","name":"Committee for veterinary medicinal products: 46th meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1999-08-18T14:39:21Z","last_updated_date":"1999-08-18T14:39:21Z","reference_number":"EMEA/CVMP/537/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-46th-meeting_en.pdf"},
    {"id":"7771","name":"European Medicines Agency recommendations on extension of shelf life for Tamiflu","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-08T02:00:00Z","last_updated_date":"2009-05-08T02:00:00Z","reference_number":"EMEA/284971/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommendations-extension-shelf-life-tamiflu_en.pdf"},
    {"id":"7777","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n19-22 October 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-23T02:09:21Z","last_updated_date":"2009-10-23T02:09:21Z","reference_number":"EMEA/CHMP/671190/2009 corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-19-22-october-2009_en.pdf"},
    {"id":"7791","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 5-7 September 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T17:30:00Z","last_updated_date":"2017-09-08T17:30:00Z","reference_number":"EMA/CVMP/569916/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-5-7-september-2017_en.pdf"},
    {"id":"7795","name":"EMEA launches EudraCT database","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-05-06T02:00:00Z","last_updated_date":"2004-05-06T02:00:00Z","reference_number":"EMEA/12589/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-launches-eudract-database_en.pdf"},
    {"id":"7830","name":"European Medicines Agency reviews treatment recommendations for Fabrazyme","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/CHMP/654389/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-reviews-treatment-recommendations-fabrazyme_en.pdf"},
    {"id":"7848","name":"European Medicines Agency recommends first-in-class medicine for treatment of Duchenne muscular dystrophy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/312458/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-first-class-medicine-treatment-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"7852","name":"Inductos to be suspended in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T14:00:00Z","last_updated_date":"2015-10-23T14:00:00Z","reference_number":"EMA/683814/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/inductos-be-suspended-eu_en.pdf"},
    {"id":"7887","name":"EMEA statement on celecoxib","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-12-17T01:00:00Z","last_updated_date":"2004-12-17T01:00:00Z","reference_number":"EMEA/205831/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-statement-celecoxib_en.pdf"},
    {"id":"7922","name":"Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 14-16 September 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-20T02:00:00Z","last_updated_date":"2010-09-20T02:00:00Z","reference_number":"EMA/CVMP/559704/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-14-16-september-2010_en.pdf"},
    {"id":"7926","name":"New pharmaceutical legislation enters into force on 20 May 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-03T02:00:00Z","last_updated_date":"2009-05-03T02:00:00Z","reference_number":"EMEA/12332/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-pharmaceutical-legislation-enters-force-20-may-2004_en.pdf"},
    {"id":"7953","name":"European Medicines Agency advises on compassionate use of sofosbuvir","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T14:00:00Z","last_updated_date":"2013-10-25T14:00:00Z","reference_number":"EMA/652584/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-advises-compassionate-use-sofosbuvir_en.pdf"},
    {"id":"7960","name":"Supply shortage of Cerezyme – updated treatment recommendations required","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-08-14T02:00:00Z","last_updated_date":"2009-08-14T02:00:00Z","reference_number":"EMEA/512960/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/supply-shortage-cerezyme-updated-treatment-recommendations-required_en.pdf"},
    {"id":"7987","name":"EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/142655/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_en.pdf"},
    {"id":"8021","name":"Committee for Orphan Medicinal Products: September 2005 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-09-14T02:00:00Z","last_updated_date":"2005-09-14T02:00:00Z","reference_number":"EMEA/COMP/299233/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-september-2005-meeting_en.pdf"},
    {"id":"8027","name":"Committee for medicinal products for veterinary use: Meeting of 13 to 15 July 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-07-16T14:39:21Z","last_updated_date":"2004-07-16T14:39:21Z","reference_number":"EMEA/CVMP/713/04/Rev 1","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-13-15-july-2004_en.pdf"},
    {"id":"8134","name":"Review of hydroxyzine-containing medicines started","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T02:00:00Z","last_updated_date":"2014-05-08T02:00:00Z","reference_number":"EMA/268604/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/review-hydroxyzine-containing-medicines-started_en.pdf"},
    {"id":"8148","name":"Committee for Proprietary Medicinal Products (CPMP): meeting of 11 to 13 December 2001","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-12-13T00:09:21Z","last_updated_date":"2001-12-13T00:09:21Z","reference_number":"EMEA/CPMP/4025/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-meeting-11-13-december-2001_en.pdf"},
    {"id":"8181","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 October 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-10-14T02:00:00Z","last_updated_date":"2011-10-14T02:00:00Z","reference_number":"EMA/CVMP/790208/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-11-13-october-2011_en.pdf"},
    {"id":"8252","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 8-10 February2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-02-11T01:00:00Z","last_updated_date":"2011-02-11T01:00:00Z","reference_number":"EMA/CVMP/61158/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-february2011_en.pdf"},
    {"id":"8267","name":"European Medicines Agency recommends suspension of classical swine fever vaccine Porcilis Pesti","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-12-12T01:00:00Z","last_updated_date":"2008-12-12T01:00:00Z","reference_number":"EMEA/493767/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-classical-swine-fever-vaccine-porcilis-pesti_en.pdf"},
    {"id":"8291","name":"Committee for medicinal products for veterinary use: Meeting of 6 to 7 September 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-09-08T14:39:21Z","last_updated_date":"2004-09-08T14:39:21Z","reference_number":"EMEA/CVMP/834/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-6-7-september-2004_en.pdf"},
    {"id":"8311","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n23-26 April 2007","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2007-04-27T02:09:21Z","last_updated_date":"2007-04-27T02:09:21Z","reference_number":"EMEA/186566/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-23-26-april-2007_en.pdf"},
    {"id":"8335","name":"Wyeth Europa Ltd withdraws its marketing authorisation application for Ellefore","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-10-15T02:09:21Z","last_updated_date":"2008-10-15T02:09:21Z","reference_number":"EMEA/542142/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/wyeth-europa-ltd-withdraws-its-marketing-authorisation-application-ellefore_en.pdf"},
    {"id":"8398","name":"Committee for veterinary medicinal products: Meeting of 16 to 18 March 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-03-19T12:49:21Z","last_updated_date":"2004-03-19T12:49:21Z","reference_number":"EMEA/CVMP/317/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-16-18-march-2004_en.pdf"},
    {"id":"8416","name":"Listening to the public’s views on the safety of medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-15T14:00:00Z","last_updated_date":"2016-04-15T14:00:00Z","reference_number":"EMA/262673/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/listening-publics-views-safety-medicines_en.pdf"},
    {"id":"8454","name":"Press release - Management Board meeting - March 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-03-17T14:51:00Z","last_updated_date":"2017-03-17T14:51:00Z","reference_number":"EMA/184615/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-management-board-meeting-march-2017_en.pdf"},
    {"id":"8469","name":"Committee for veterinary medicinal products: under the chairmanship of Mr G. Moulin the seventy sixth meeting of the committee for veterinary medicinal products took place in London on 16 - 18 April 2002.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-04-19T14:09:21Z","last_updated_date":"2002-04-19T14:09:21Z","reference_number":"EMEA/CVMP/417/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-g-moulin-seventy-sixth-meeting-committee-veterinary-medicinal-products-took-place-london-16-18-april-2002_en.pdf"},
    {"id":"8554","name":"Zykadia recommended for approval in advanced non small cell lung cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/133576/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/zykadia-recommended-approval-advanced-non-small-cell-lung-cancer_en.pdf"},
    {"id":"8555","name":"European Medicines Agency recommends suspension of marketing authorisation for sibutramine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-01-21T01:00:00Z","last_updated_date":"2010-01-21T01:00:00Z","reference_number":"EMA/39408/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-marketing-authorisation-sibutramine_en.pdf"},
    {"id":"8575","name":"Invitation to EMEA 10th anniversary celebrations 11 March 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-03-02T00:09:21Z","last_updated_date":"2005-03-02T00:09:21Z","reference_number":"EMEA/50135/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/invitation-emea-10th-anniversary-celebrations-11-march-2005_en.pdf"},
    {"id":"8634","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the sixty-ninth meeting of the committee for veterinary medicinal products took place in London on 11-13 September 2001.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-09-13T14:39:21Z","last_updated_date":"2001-09-13T14:39:21Z","reference_number":"EMEA/CVMP/736/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-sixty-ninth-meeting-committee-veterinary-medicinal-products-took-place-london-11-13-september-2001_en.pdf"},
    {"id":"8697","name":"Thomas Là¶nngren reappointed as Executive Director of the European Medicines Agency","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-12-28T00:09:21Z","last_updated_date":"2005-12-28T00:09:21Z","reference_number":"EMEA/318068/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/thomas-lapnngren-reappointed-executive-director-european-medicines-agency_en.pdf"},
    {"id":"8723","name":"European Medicines Agency adopts first positive opinion for a similar biological medicinal product","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-01-27T00:09:21Z","last_updated_date":"2006-01-27T00:09:21Z","reference_number":"EMEA/31797/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-adopts-first-positive-opinion-similar-biological-medicinal-product_en.pdf"},
    {"id":"8738","name":"Janssen-Cilag International NV withdraws its application for an extension of the indication for Velcade (bortezomib)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-07-03T18:00:00Z","last_updated_date":"2012-07-03T18:00:00Z","reference_number":"EMA/446469/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/janssen-cilag-international-nv-withdraws-its-application-extension-indication-velcade-bortezomib_en.pdf"},
    {"id":"8765","name":"European Medicines Agency notified of recall of swine fever vaccine (Porcilis Pesti) by Intervet International BV","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-05-05T02:00:00Z","last_updated_date":"2008-05-05T02:00:00Z","reference_number":"EMEA/237728/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-notified-recall-swine-fever-vaccine-porcilis-pesti-intervet-international-bv_en.pdf"},
    {"id":"8796","name":"Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-10-25T02:00:00Z","last_updated_date":"2011-10-25T02:00:00Z","reference_number":"EMA/856472/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/xigris-drotrecogin-alfa-activated-be-withdrawn-due-lack-efficacy_en.pdf"},
    {"id":"8819","name":"Astellas withdraws its marketing authorisation application for Vibativ (telavancin)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-10-24T02:09:21Z","last_updated_date":"2008-10-24T02:09:21Z","reference_number":"EMEA/562428/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/astellas-withdraws-its-marketing-authorisation-application-vibativ-telavancin_en.pdf"},
    {"id":"8851","name":"New treatment for advanced form of kidney cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T13:01:00Z","last_updated_date":"2016-02-26T13:01:00Z","reference_number":"EMA/CHMP/147283/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-advanced-form-kidney-cancer_en.pdf"},
    {"id":"8861","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 18 to 20 February 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-02-24T01:00:00Z","last_updated_date":"2003-02-24T01:00:00Z","reference_number":"EMEA/CPMP/890/03/Rev. 1/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-18-20-february-2003_en.pdf"},
    {"id":"8869","name":"Boosting care for newborn babies in low-income countries","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"Umbipro to help prevent umbilical cord infections ","document_url":"https://www.ema.europa.eu/en/documents/press-release/boosting-care-newborn-babies-low-income-countries_en.pdf"},
    {"id":"8887","name":"Pharmaceutics International Inc., US: supply of non-critical medicines to EU to be stopped due to manufacturing failings","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/602744/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-be-stopped-due-manufacturing-failings_en.pdf"},
    {"id":"8900","name":"European and international experts discuss the way forward in stem-cell research and development","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"EMA/274082/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-and-international-experts-discuss-way-forward-stem-cell-research-and-development_en.pdf"},
    {"id":"8960","name":"EMEA Management Board adopts fee implementing rule and looks at the Agency's corporate governance","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-06-09T02:09:21Z","last_updated_date":"2003-06-09T02:09:21Z","reference_number":"EMEA/MB/224/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-management-board-adopts-fee-implementing-rule-and-looks-agencys-corporate-governance_en.pdf"},
    {"id":"8991","name":"Updated temporary treatment recommendations for Cerezyme","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/665112/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/updated-temporary-treatment-recommendations-cerezyme_en.pdf"},
    {"id":"9039","name":"13th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-05-23T02:00:00Z","last_updated_date":"2001-05-23T02:00:00Z","reference_number":"COMP/199/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/13th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"9057","name":"Hydroxyethyl-starch solutions for infusion to be suspended – CMDh endorses PRAC recommendation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T01:00:00Z","last_updated_date":"2018-02-02T01:00:00Z","reference_number":"EMA/35795/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/hydroxyethyl-starch-solutions-infusion-be-suspended-cmdh-endorses-prac-recommendation_en.pdf"},
    {"id":"9058","name":"Committee for Proprietary Medicinal Products (CPMP) 36th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-03-27T00:00:00Z","last_updated_date":"1998-03-27T00:00:00Z","reference_number":"CPMP/438/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-36th-plenary-meeting_en.pdf"},
    {"id":"9105","name":"Construction of new EMA building in Amsterdam on track","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-05-29T02:00:00Z","last_updated_date":"2018-05-29T02:00:00Z","reference_number":"EMA/355745/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/construction-new-ema-building-amsterdam-track_en.pdf"},
    {"id":"9115","name":"Dyax s.a. withdraws its marketing authorisation application for Kalbitor (ecallantide)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-11-15T01:00:00Z","last_updated_date":"2011-11-15T01:00:00Z","reference_number":"EMA/891024/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/dyax-sa-withdraws-its-marketing-authorisation-application-kalbitor-ecallantide_en.pdf"},
    {"id":"9126","name":"GVK Biosciences review: some Member States suspend marketing authorisations for concerned medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T01:00:00Z","last_updated_date":"2014-12-05T01:00:00Z","reference_number":"EMA/763052/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/gvk-biosciences-review-some-member-states-suspend-marketing-authorisations-concerned-medicines_en.pdf"},
    {"id":"9159","name":"Committee for medicinal products for veterinary use: Meeting of 13 - 15 March 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-03-16T12:09:21Z","last_updated_date":"2007-03-16T12:09:21Z","reference_number":"EMEA/CVMP/94094/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-13-15-march-2007_en.pdf"},
    {"id":"9241","name":"European Medicines Agency recommendation on use of angiotensin II receptor antagonists during pregnancy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/206061/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommendation-use-angiotensin-ii-receptor-antagonists-during-pregnancy_en.pdf"}    {"id":"9293","name":"Last meeting of the working party on herbal medicinal products: 3-4 June 2004, EMEA London","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2004-06-24T14:09:21Z","last_updated_date":"2004-06-24T14:09:21Z","reference_number":"EMEA/CHMP/HMPWP/3/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/last-meeting-working-party-herbal-medicinal-products-3-4-june-2004-emea-london_en.pdf"},
    {"id":"9295","name":"European Medicines Agency starts review of aliskiren-containing medicines following termination of ALTITUDE study","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-12-22T17:00:00Z","last_updated_date":"2011-12-22T17:00:00Z","reference_number":"EMA/CHMP/989693/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-review-aliskiren-containing-medicines-following-termination-altitude-study_en.pdf"},
    {"id":"9303","name":"European Medicines Agency confirms positive benefit-risk balance of Rotarix","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/CHMP/462029/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-positive-benefit-risk-balance-rotarix_en.pdf"},
    {"id":"9334","name":"Teva Pharma B.V. withdraws its marketing authorisation application for Clopidogrel Teva Pharma (clopidogrel hydrobromide)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/251627/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/teva-pharma-bv-withdraws-its-marketing-authorisation-application-clopidogrel-teva-pharma-clopidogrel-hydrobromide_en.pdf"},
    {"id":"9336","name":"European Medicines Agency recommends approval of first vaccine for meningitis B","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T13:00:00Z","last_updated_date":"2012-11-16T13:00:00Z","reference_number":"EMA/CHMP/728052/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-first-vaccine-meningitis-b_en.pdf"},
    {"id":"9356","name":"CHMP elects new chair and vice-chair at its first meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/15117/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/chmp-elects-new-chair-and-vice-chair-its-first-meeting_en.pdf"},
    {"id":"9365","name":"Hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients – CMDh endorses PRAC recommendations","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T14:10:13Z","last_updated_date":"2013-10-25T14:10:13Z","reference_number":"EMA/640658/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/hydroxyethyl-starch-solutions-hes-should-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients-cmdh-endorses-prac-recommendations_en.pdf"},
    {"id":"9382","name":"EMA ready to start assessment of Ebola vaccines and treatments as soon as data are made available","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-22T20:55:00Z","last_updated_date":"2014-10-22T20:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-ready-start-assessment-ebola-vaccines-and-treatments-soon-data-are-made-available_en.pdf"},
    {"id":"9410","name":"Ambroxol and bromhexine expectorants: safety information to be updated - Risk of allergy and skin reactions to be included in the product information","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/130676/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ambroxol-and-bromhexine-expectorants-safety-information-be-updated-risk-allergy-and-skin-reactions-be-included-product-information_en.pdf"},
    {"id":"9419","name":"First medicine recommended for approval for hidradenitis suppurativa","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T14:00:00Z","last_updated_date":"2015-06-26T14:00:00Z","reference_number":"EMA/CHMP/424261/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-medicine-recommended-approval-hidradenitis-suppurativa_en.pdf"},
    {"id":"9430","name":"Sixth meeting of the Management Board of the European Agency for the Evaluation of Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1995-04-24T02:00:00Z","last_updated_date":"1995-04-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/sixth-meeting-management-board-european-agency-evaluation-medicinal-products_en.pdf"},
    {"id":"9437","name":"EMA starts new review of hydroxyethyl-starch containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T14:00:00Z","last_updated_date":"2017-10-27T14:00:00Z","reference_number":"EMA/697706/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-starts-new-review-hydroxyethyl-starch-containing-medicines_en.pdf"},
    {"id":"9440","name":"European Medicines Agency recommends approval of first two monoclonal antibody biosimilars","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/390722/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-first-two-monoclonal-antibody-biosimilars_en.pdf"},
    {"id":"9447","name":"20th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-01-28T00:09:21Z","last_updated_date":"2002-01-28T00:09:21Z","reference_number":"EMEA/COMP/38/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/20th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"9458","name":"Novo Nordisk withdraw their application to extend the marketing authorisation for NovoSeven","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-04-06T02:00:00Z","last_updated_date":"2006-04-06T02:00:00Z","reference_number":"EMEA/123938/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/novo-nordisk-withdraw-their-application-extend-marketing-authorisation-novoseven_en.pdf"},
    {"id":"9464","name":"25th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-07-01T02:09:21Z","last_updated_date":"2002-07-01T02:09:21Z","reference_number":"EMEA/15523/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/25th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"9488","name":"Increasing access to reports on adverse reactions to medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/846880/2015 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/increasing-access-reports-adverse-reactions-medicines_en.pdf"},
    {"id":"9547","name":"Committee for veterinary medicinal products: 48th meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1999-10-14T14:39:21Z","last_updated_date":"1999-10-14T14:39:21Z","reference_number":"EMEA/CVMP/726/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-48th-meeting_en.pdf"},
    {"id":"9573","name":"PRAC recommends restricting use of domperidone","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"EMA/129231/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-restricting-use-domperidone_en.pdf"},
    {"id":"9579","name":"Investigation into GLP-1-based diabetes therapies concluded","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/463027/2013 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/investigation-glp-1-based-diabetes-therapies-concluded_en.pdf"},
    {"id":"9641","name":"European Medicines Agency finalises review of Baxter’s dialysis solutions","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/771913/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-finalises-review-baxters-dialysis-solutions_en.pdf"},
    {"id":"9660","name":"European public health agencies evaluate antibiotic resistance of Staphylococcus aureus","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-16T02:00:00Z","last_updated_date":"2009-06-16T02:00:00Z","reference_number":"EMEA/374416/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-public-health-agencies-evaluate-antibiotic-resistance-staphylococcus-aureus_en.pdf"},
    {"id":"9708","name":"Procedural announcements","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-05-07T02:00:00Z","last_updated_date":"2004-05-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/procedural-announcements_en.pdf"},
    {"id":"9768","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the sixty-seventh meeting of the committee for veterinary medicinal products took place in London on 12-13 June 2001.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-06-14T14:39:21Z","last_updated_date":"2001-06-14T14:39:21Z","reference_number":"EMEA/CVMP/568/01 corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-sixty-seventh-meeting-committee-veterinary-medicinal-products-took-place-london-12-13-june-2001_en.pdf"},
    {"id":"9779","name":"European Medicines Agency recommends withdrawal of medicinal products containing veralipride","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-23T02:00:00Z","last_updated_date":"2007-07-23T02:00:00Z","reference_number":"EMEA/299873/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-withdrawal-medicinal-products-containing-veralipride_en.pdf"},
    {"id":"9791","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products extraordinary meeting, 3 September 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-09-04T02:09:21Z","last_updated_date":"2003-09-04T02:09:21Z","reference_number":"EMEA/23230/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-extraordinary-meeting-3-september-2003_en.pdf"},
    {"id":"9813","name":"European Medicines Agency recommends approval of two new treatment options for rare cancers","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-07-25T14:00:00Z","last_updated_date":"2014-07-25T14:00:00Z","reference_number":"EMA/448634/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-two-new-treatment-options-rare-cancers_en.pdf"},
    {"id":"9815","name":"Tripartite Meeting (JPMA/PhRMA/EBC-PC) hosted by EMEA: 'Approving Innovative Medicines in 21st Century'","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-05-30T02:00:00Z","last_updated_date":"2000-05-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/tripartite-meeting-jpmaphrmaebc-pc-hosted-emea-approving-innovative-medicines-21st-century_en.pdf"},
    {"id":"9844","name":"Cooperation on medicines regulation intensified","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-03-14T01:00:00Z","last_updated_date":"2006-03-14T01:00:00Z","reference_number":"EMEA/93090/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/cooperation-medicines-regulation-intensified_en.pdf"},
    {"id":"9907","name":"European Medicines Agency recommends approval of new HIV medicine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/715767/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-new-hiv-medicine_en.pdf"},
    {"id":"9930","name":"Arpida A/S withdraws its marketing authorisation application for Mersarex (iclaprim)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-23T02:00:00Z","last_updated_date":"2009-10-23T02:00:00Z","reference_number":"EMEA/681537/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/arpida-withdraws-its-marketing-authorisation-application-mersarex-iclaprim_en.pdf"},
    {"id":"9962","name":"European Agency for the Evaluation of Medicinal Products: EudraLink Launch meeting 28-29 January 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-02-05T01:00:00Z","last_updated_date":"2003-02-05T01:00:00Z","reference_number":"EMEA/7542/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-eudralink-launch-meeting-28-29-january-2003_en.pdf"},
    {"id":"9963","name":"EudraGMP 2.0 gives public access to information about Good Manufacturing Practice (GMP)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-08-04T02:00:00Z","last_updated_date":"2009-08-04T02:00:00Z","reference_number":"EMEA/494112/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/eudragmp-20-gives-public-access-information-about-good-manufacturing-practice-gmp_en.pdf"},
    {"id":"9968","name":"Joint TAIEX/EMEA Central Eastern European Countries Forum on the regulation of veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1999-06-18T14:09:21Z","last_updated_date":"1999-06-18T14:09:21Z","reference_number":"EMEA/V/PHJ/wjp/18613/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/joint-taiexemea-central-eastern-european-countries-forum-regulation-veterinary-medicinal-products_en.pdf"},
    {"id":"9994","name":"European Medicines Agency recommends precautionary recall of batches of clopidogrel-containing medicines from Acino Pharma GmbH","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-03-25T01:00:00Z","last_updated_date":"2010-03-25T01:00:00Z","reference_number":"EMA/179606/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-precautionary-recall-batches-clopidogrel-containing-medicines-acino-pharma-gmbh_en.pdf"},
    {"id":"10001","name":"EMA reviewing risk of dosing errors with methotrexate","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T02:00:00Z","last_updated_date":"2018-04-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-reviewing-risk-dosing-errors-methotrexate_en.pdf"},
    {"id":"10005","name":"Guerbet withdraws its marketing authorisation application for Sinerem","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T01:00:00Z","last_updated_date":"2007-12-14T01:00:00Z","reference_number":"EMEA/594122/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/guerbet-withdraws-its-marketing-authorisation-application-sinerem_en.pdf"},
    {"id":"10008","name":"Studies from Alkem Laboratories Ltd cannot be used to support medicines approval in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/427636/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_en.pdf"},
    {"id":"10041","name":"Bayer Schering Pharma withdraws its marketing authorisation application for Recothrom (thrombin alfa)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-14T01:00:00Z","last_updated_date":"2009-12-14T01:00:00Z","reference_number":"EMA/812456/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/bayer-schering-pharma-withdraws-its-marketing-authorisation-application-recothrom-thrombin-alfa_en.pdf"},
    {"id":"10098","name":"European Medicines Agency recommends cautious use of Protopic/Protopy and Elidel","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-03-27T02:00:00Z","last_updated_date":"2006-03-27T02:00:00Z","reference_number":"EMEA/98882/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-cautious-use-protopicprotopy-and-elidel_en.pdf"},
    {"id":"10109","name":"European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/706409/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_en.pdf"},
    {"id":"10128","name":"SIAMED 2000: speeding up drug regulation in Europe","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-01-18T00:09:21Z","last_updated_date":"2001-01-18T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/siamed-2000-speeding-drug-regulation-europe_en.pdf"},
    {"id":"10197","name":"European Medicines Agency announces start of process improvement of core business procedures","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-03-18T14:57:32Z","last_updated_date":"2011-03-18T14:57:32Z","reference_number":"EMA/201374/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-announces-start-process-improvement-core-business-procedures_en.pdf"},
    {"id":"10208","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 17-19 May 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-05-20T02:00:00Z","reference_number":"EMA/CVMP/317201/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-17-19-may-2016_en.pdf"},
    {"id":"10258","name":"PRAC reviews known risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T01:00:00Z","last_updated_date":"2016-03-18T01:00:00Z","reference_number":"EMA/197713/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-reviews-known-risk-pneumonia-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_en.pdf"},
    {"id":"10282","name":"European Medicines Agency confirms positive benefit-risk balance of topical formulations of ketoprofen","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/CHMP/465633/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-positive-benefit-risk-balance-topical-formulations-ketoprofen_en.pdf"},
    {"id":"10288","name":"European Medicines Agency and U.S. Food and Drug Administration extend confidentiality arrangements indefinitely","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-15T02:00:00Z","last_updated_date":"2010-09-15T02:00:00Z","reference_number":"EMA/579151/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-us-food-and-drug-administration-extend-confidentiality-arrangements-indefinitely_en.pdf"},
    {"id":"10291","name":"Early dialogue with regulators and HTA bodies","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-03-31T14:00:00Z","last_updated_date":"2016-03-31T14:00:00Z","reference_number":"EMA/187274/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/early-dialogue-regulators-and-hta-bodies_en.pdf"},
    {"id":"10297","name":"Fifteenth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-10-03T02:00:00Z","last_updated_date":"1997-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/fifteenth-meeting-management-board_en.pdf"},
    {"id":"10305","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 14-16 May 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-05-22T10:25:00Z","last_updated_date":"2012-05-22T10:25:00Z","reference_number":"EMA/CVMP/299052/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-14-16-may-2012_en.pdf"},
    {"id":"10366","name":"EMA recommends availability of ellaOne emergency contraceptive without prescription","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2014-11-21T01:00:00Z","reference_number":"EMA/710568/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-availability-ellaone-emergency-contraceptive-without-prescription_en.pdf"},
    {"id":"10431","name":"European Medicines Agency holds first meeting of the Pharmacovigilance Risk Assessment Committee (PRAC)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-07-19T12:10:02Z","last_updated_date":"2012-07-19T12:10:02Z","reference_number":"EMA/487397/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-holds-first-meeting-pharmacovigilance-risk-assessment-committee-prac_en.pdf"},
    {"id":"10433","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 14-16 March 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-03-17T16:00:01Z","last_updated_date":"2017-03-17T16:00:01Z","reference_number":"EMA/CVMP/147249/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-14-16-march-2017_en.pdf"},
    {"id":"10442","name":"PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-04-11T14:00:00Z","reference_number":"EMA/196502/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-against-combined-use-medicines-affecting-renin-angiotensin-ras-system_en.pdf"},
    {"id":"10457","name":"New medicine for rare bone disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T01:00:00Z","last_updated_date":"2017-12-15T01:00:00Z","reference_number":"EMA/CHMP/824779/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-rare-bone-disease_en.pdf"},
    {"id":"10460","name":"European Medicines Agency hosts first workshop on subgroup analysis","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-11-24T17:00:00Z","last_updated_date":"2011-11-24T17:00:00Z","reference_number":"EMA/907825/2011 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-hosts-first-workshop-subgroup-analysis_en.pdf"},
    {"id":"10468","name":"Committee for Proprietary Medicinal Products (CPMP) 35th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-02-27T00:00:00Z","last_updated_date":"1998-02-27T00:00:00Z","reference_number":"CPMP/209/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-35th-plenary-meeting_en.pdf"},
    {"id":"10509","name":"European Medicines Agency recommendations on the use of Linoladiol N and Linoladiol HN estradiol-containing creams","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/247548/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_en.pdf"},
    {"id":"10544","name":"European Medicines Agency recommends restricting use of trimetazidine-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T12:00:00Z","last_updated_date":"2012-06-22T12:00:00Z","reference_number":"EMA/CHMP/417861/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-trimetazidine-containing-medicines_en.pdf"},
    {"id":"10569","name":"Press release: Committee for Orphan Medicinal Products July 2007 Meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-08-06T02:09:21Z","last_updated_date":"2007-08-06T02:09:21Z","reference_number":"EMEA/COMP/328111/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-committee-orphan-medicinal-products-july-2007-meeting_en.pdf"},
    {"id":"10592","name":"Committee for medicinal products for veterinary use: Meeting of 14 to 16 February 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-02-17T12:09:21Z","last_updated_date":"2006-02-17T12:09:21Z","reference_number":"EMEA/CVMP/43330/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-14-16-february-2006_en.pdf"},
    {"id":"10639","name":"Committee for Proprietary Medicinal Products (CPMP) 62nd plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-07-31T02:00:00Z","last_updated_date":"2000-07-31T02:00:00Z","reference_number":"CPMP/1964/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-62nd-plenary-meeting_en.pdf"},
    {"id":"10662","name":"European Medicines Agency recommends limiting long-term use of calcitonin medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T17:00:00Z","last_updated_date":"2012-07-20T17:00:00Z","reference_number":"EMA/CHMP/483874/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-limiting-long-term-use-calcitonin-medicines_en.pdf"},
    {"id":"10739","name":"European Medicines Agency recommends authorisation of novel treatment for type 2 diabetes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-04-20T14:01:12Z","last_updated_date":"2012-04-20T14:01:12Z","reference_number":"EMA/CHMP/257385/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-authorisation-novel-treatment-type-2-diabetes_en.pdf"},
    {"id":"10756","name":"Meeting highlights from the Paediatric Committee:  24 - 26 October 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-10-29T01:00:00Z","last_updated_date":"2007-10-29T01:00:00Z","reference_number":"EMEA/492629/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-24-26-october-2007_en.pdf"},
    {"id":"10775","name":"Committee for Orphan Medicinal Products: May 2007 Meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-01T02:09:21Z","last_updated_date":"2007-06-01T02:09:21Z","reference_number":"EMEA/COMP/244638/07","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-may-2007-meeting_en.pdf"},
    {"id":"10790","name":"European Medicines Agency gives interim recommendations to deal with shortcomings in quality assurance at Ben Venue Laboratories","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-11-22T17:00:00Z","last_updated_date":"2011-11-22T17:00:00Z","reference_number":"EMA/905564/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-interim-recommendations-deal-shortcomings-quality-assurance-ben-venue-laboratories_en.pdf"},
    {"id":"10823","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n23-26 June 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:09:21Z","last_updated_date":"2008-06-26T02:09:21Z","reference_number":"EMEA/CHMP/332645/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-23-26-june-2008_en.pdf"},
    {"id":"10830","name":"EMA restricts use of prostate cancer medicine Xofigo","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/500948/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-restricts-use-prostate-cancer-medicine-xofigo_en.pdf"},
    {"id":"10862","name":"Committee for Proprietary Medicinal Products (CPMP) 54th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-11-22T01:00:00Z","last_updated_date":"1999-11-22T01:00:00Z","reference_number":"CPMP/3091/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-54th-plenary-meeting_en.pdf"},
    {"id":"10915","name":"Extraordinary meeting to finalise review of Anorectic Agents","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-09-09T02:00:00Z","last_updated_date":"1999-09-09T02:00:00Z","reference_number":"CPMP/2335/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/extraordinary-meeting-finalise-review-anorectic-agents_en.pdf"},
    {"id":"10960","name":"EMA Management Board: highlights of October 2014 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-06T14:45:00Z","last_updated_date":"2014-10-06T14:45:00Z","reference_number":"EMA/606176/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-october-2014-meeting_en.pdf"},
    {"id":"11008","name":"Press release - Conditional marketing authorisations give patients access to important new medicines earlier","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T01:00:00Z","last_updated_date":"2017-01-23T01:00:00Z","reference_number":"EMA/16151/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-conditional-marketing-authorisations-give-patients-access-important-new-medicines-earlier_en.pdf"},
    {"id":"11050","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 20-23 March 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-03-24T00:09:21Z","last_updated_date":"2006-03-24T00:09:21Z","reference_number":"EMEA/106554/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-20-23-march-2006_en.pdf"},
    {"id":"11060","name":"EMA Management Board: highlights of June 2016 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T16:30:00Z","last_updated_date":"2016-06-17T16:30:00Z","reference_number":"EMA/415244/2016 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-june-2016-meeting_en.pdf"},
    {"id":"11133","name":"European Medicines Agency recommends lifting suspension of aprotinin","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T11:10:31Z","last_updated_date":"2012-02-17T11:10:31Z","reference_number":"EMA/CHMP/119704/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-lifting-suspension-aprotinin_en.pdf"},
    {"id":"11200","name":"Committee for Proprietary Medicinal Products (CPMP) 39th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-06-29T02:00:00Z","last_updated_date":"1998-06-29T02:00:00Z","reference_number":"CPMP/1150/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-39th-plenary-meeting_en.pdf"},
    {"id":"11222","name":"Committee for Proprietary Medicinal Products (CPMP) 24th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-02-20T01:00:00Z","last_updated_date":"1997-02-20T01:00:00Z","reference_number":"CPMP/182/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-24th-plenary-meeting_en.pdf"},
    {"id":"11231","name":"Numeta G13%E to be suspended and new risk-minimisation measures to be introduced for Numeta G16%E","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/564255/2013  ","document_url":"https://www.ema.europa.eu/en/documents/press-release/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_en.pdf"},
    {"id":"11279","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n16-19 July 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-19T02:09:21Z","last_updated_date":"2007-07-19T02:09:21Z","reference_number":"EMEA/431407/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-16-19-july-2007_en.pdf"},
    {"id":"11291","name":"Committee for veterinary medicinal products: 37th meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-11-12T12:09:21Z","last_updated_date":"1998-11-12T12:09:21Z","reference_number":"EMEA/CVMP/574/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-37th-meeting_en.pdf"},
    {"id":"11295","name":"European Medicines Agency concludes class review of bisphosphonates and atypical fractures","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/292784/2011 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-concludes-class-review-bisphosphonates-and-atypical-fractures_en.pdf"},
    {"id":"11297","name":"Commitee for Orphan Medicinal Products: November 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-11-17T01:00:00Z","last_updated_date":"2004-11-17T01:00:00Z","reference_number":"EMEA/COMP/151881/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-november-2004-meeting_en.pdf"},
    {"id":"11320","name":"Acipimox only to be used as additional or alternative treatment to reduce high triglyceride levels","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/779546/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_en.pdf"},
    {"id":"11353","name":"La Jolla Limited withdraws its marketing authorisation application for Riquent","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-10-13T02:00:00Z","last_updated_date":"2006-10-13T02:00:00Z","reference_number":"EMEA/410861/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/la-jolla-limited-withdraws-its-marketing-authorisation-application-riquent_en.pdf"},
    {"id":"11366","name":"EMA reviewing cancer medicine docetaxel","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T13:00:00Z","last_updated_date":"2017-03-10T13:00:00Z","reference_number":"EMA/156136/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-reviewing-cancer-medicine-docetaxel_en.pdf"},
    {"id":"11428","name":"Targanta Netherlands B.V. withdraws its marketing authorisation application for Ramvocid (oritavancin)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-08-24T02:00:00Z","last_updated_date":"2009-08-24T02:00:00Z","reference_number":"EMEA/535907/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/targanta-netherlands-bv-withdraws-its-marketing-authorisation-application-ramvocid-oritavancin_en.pdf"},
    {"id":"11451","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n15-18 October 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-10-18T02:09:21Z","last_updated_date":"2007-10-18T02:09:21Z","reference_number":"EMEA/479200/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-15-18-october-2007_en.pdf"},
    {"id":"11479","name":"Shaping the future of human and animal health in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/821169/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/shaping-future-human-and-animal-health-eu_en.pdf"},
    {"id":"11494","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 May 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-05-15T14:00:00Z","last_updated_date":"2017-05-15T14:00:00Z","reference_number":"EMA/CVMP/268972/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-10-12-may-2017_en.pdf"},
    {"id":"11596","name":"PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-10T02:00:00Z","last_updated_date":"2014-10-10T02:00:00Z","reference_number":"EMA/615086/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_en.pdf"},
    {"id":"11613","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 9-11 September 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-09-12T02:00:00Z","last_updated_date":"2014-09-12T02:00:00Z","reference_number":"EMA/CVMP/534989/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-9-11-september-2014_en.pdf"},
    {"id":"11660","name":"Dienogest/ethinylestradiol can be used for acne after certain other treatments have failed","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/41643/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_en.pdf"},
    {"id":"11680","name":"European Medicines Agency concludes review of systemic nimesulide-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"EMA/CHMP/486983/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-concludes-review-systemic-nimesulide-containing-medicines_en.pdf"},
    {"id":"11758","name":"21st meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-05-08T14:30:00Z","last_updated_date":"1997-05-08T14:30:00Z","reference_number":"EMEA/CVMP/170/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/21st-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"11788","name":"European Medicines Agency adopts positive opinion for avian influenza vaccines for use in birds","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-07-21T02:00:00Z","last_updated_date":"2009-07-21T02:00:00Z","reference_number":"EMEA/281842/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-adopts-positive-opinion-avian-influenza-vaccines-use-birds_en.pdf"},
    {"id":"11803","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 12-14 June 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T18:15:00Z","last_updated_date":"2012-06-15T18:15:00Z","reference_number":"EMA/CVMP/358270/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-12-14-june-2012_en.pdf"},
    {"id":"11811","name":"EMA to review Inductos","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T14:00:01Z","last_updated_date":"2015-07-24T14:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-review-inductos_en.pdf"},
    {"id":"11824","name":"Meeting highlights from the Paediatric Committee 9 - 11 April 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-04-15T02:00:00Z","last_updated_date":"2008-04-15T02:00:00Z","reference_number":"EMEA/PDCO/190452/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-9-11-april-2008_en.pdf"},
    {"id":"11836","name":"Adaptive pathways: key learnings and next steps","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-08-03T14:00:00Z","last_updated_date":"2016-08-03T14:00:00Z","reference_number":"EMA/484516/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/adaptive-pathways-key-learnings-and-next-steps_en.pdf"}    {"id":"11848","name":"Committee for Proprietary Medicinal Products (CPMP) 27th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-05-16T02:00:00Z","last_updated_date":"1997-05-16T02:00:00Z","reference_number":"CPMP/389/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-27th-plenary-meeting_en.pdf"},
    {"id":"11863","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 9-11 December 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/CVMP/731849/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-9-11-december-2014_en.pdf"},
    {"id":"11864","name":"European Medicines Agency and Heads of Medicines Agencies propose measures to make information in application dossiers more transparent","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-01T17:07:22Z","last_updated_date":"2011-06-01T17:07:22Z","reference_number":"EMA/435707/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-heads-medicines-agencies-propose-measures-make-information-application-dossiers-more-transparent_en.pdf"},
    {"id":"11872","name":"Pharmion Ltd withdraws its marketing authorisation application for\n\nOrplatna (satraplatin)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-08-04T02:00:00Z","last_updated_date":"2008-08-04T02:00:00Z","reference_number":"EMEA/417535/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/pharmion-ltd-withdraws-its-marketing-authorisation-application-orplatna-satraplatin_en.pdf"},
    {"id":"11899","name":"EMA reviewing safety of Uptravi for pulmonary arterial hypertension","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-14T01:00:00Z","reference_number":"EMA/83636/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-reviewing-safety-uptravi-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"11915","name":"EMA recommends suspension of medicines due to unreliable studies from Micro Therapeutic Research Labs","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/188204/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-suspension-medicines-due-unreliable-studies-micro-therapeutic-research-labs_en.pdf"},
    {"id":"11934","name":"First two CAR-T cell medicines recommended for approval in the European Union","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/431116/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-two-car-t-cell-medicines-recommended-approval-european-union_en.pdf"},
    {"id":"11945","name":"EMA to relocate to Amsterdam, the Netherlands","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T19:21:00Z","last_updated_date":"2017-11-20T19:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-relocate-amsterdam-netherlands_en.pdf"},
    {"id":"12019","name":"Sanofi Pharma Bristol-Myers Squibb SNC withdraws its marketing authorisation application for DuoPlavin","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-05-27T02:00:00Z","last_updated_date":"2008-05-27T02:00:00Z","reference_number":"EMEA/CHMP/275182/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/sanofi-pharma-bristol-myers-squibb-snc-withdraws-its-marketing-authorisation-application-duoplavin_en.pdf"},
    {"id":"12083","name":"Committee for medicinal products for veterinary use: Meeting of 15-17 April 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-04-20T02:09:21Z","last_updated_date":"2009-04-20T02:09:21Z","reference_number":"EMEA/CVMP/199749/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-15-17-april-2009_en.pdf"},
    {"id":"12098","name":"CMDh endorses restricted use of bromocriptine for stopping breast milk production","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-08-21T02:00:00Z","last_updated_date":"2014-08-21T02:00:00Z","reference_number":"EMA/441377/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/cmdh-endorses-restricted-use-bromocriptine-stopping-breast-milk-production_en.pdf"},
    {"id":"12148","name":"Meeting highlights from the Paediatric Committee: 27 - 29 May 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-03T02:00:00Z","last_updated_date":"2010-02-11T21:21:54Z","reference_number":"EMEA/PDCO/298970/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-27-29-may-2009_en.pdf"},
    {"id":"12202","name":"Anika Therapeutics S.r.l. withdraws its marketing authorisation application for Hyalograft C autograft","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-02-26T01:00:00Z","last_updated_date":"2013-02-26T01:00:00Z","reference_number":"EMA/30547/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/anika-therapeutics-srl-withdraws-its-marketing-authorisation-application-hyalograft-c-autograft_en.pdf"},
    {"id":"12241","name":"CPMP members","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-01-18T00:09:21Z","last_updated_date":"2001-01-18T00:09:21Z","reference_number":"EMEA/811/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/cpmp-members_en.pdf"},
    {"id":"12319","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n17-20 November 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-11-21T00:09:21Z","last_updated_date":"2008-11-21T00:09:21Z","reference_number":"EMEA/CHMP/606566/2008 corr. 2","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-17-20-november-2008_en.pdf"},
    {"id":"12393","name":"No evidence that Fluad vaccine caused deaths in Italy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-12-03T18:00:00Z","last_updated_date":"2014-12-03T18:00:00Z","reference_number":"EMA/749142/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/no-evidence-fluad-vaccine-caused-deaths-italy_en.pdf"},
    {"id":"12473","name":"Batches of the insulin medicine NovoMix 30 FlexPen and Penfill to be recalled","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T02:00:00Z","last_updated_date":"2013-10-25T02:00:00Z","reference_number":"EMA/657469/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/batches-insulin-medicine-novomix-30-flexpen-and-penfill-be-recalled_en.pdf"},
    {"id":"12497","name":"New treatment for advanced melanoma","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/CHMP/260620/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-advanced-melanoma_en.pdf"},
    {"id":"12553","name":"Closer ties on medicines safety between European and Canadian regulatory authorities","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-01-11T01:00:00Z","last_updated_date":"2008-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/closer-ties-medicines-safety-between-european-and-canadian-regulatory-authorities_en.pdf"},
    {"id":"12578","name":"Pfizer Limited withdraws its application for an extension of the indication for Macugen (pegaptanib sodium)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-19T02:00:00Z","last_updated_date":"2011-07-19T02:00:00Z","reference_number":"EMA/567717/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/pfizer-limited-withdraws-its-application-extension-indication-macugen-pegaptanib-sodium_en.pdf"},
    {"id":"12579","name":"New safety advice for diclofenac – CMDh endorses PRAC recommendation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/380947/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-safety-advice-diclofenac-cmdh-endorses-prac-recommendation_en.pdf"},
    {"id":"12610","name":"First survey on patients’ involvement in the European Medicines Agency’s work reveals high satisfaction levels overall","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-20T02:09:21Z","last_updated_date":"2008-06-20T02:09:21Z","reference_number":"EMEA/319625/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-survey-patients-involvement-european-medicines-agencys-work-reveals-high-satisfaction-levels-overall_en.pdf"},
    {"id":"12615","name":"EMEA strengthens handling of safety concerns for human medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-04-15T02:00:00Z","last_updated_date":"2004-04-15T02:00:00Z","reference_number":"EMEA/9555/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-strengthens-handling-safety-concerns-human-medicines_en.pdf"},
    {"id":"12654","name":"European Medicines Agency’s Management Board nominates Guido Rasi as Executive Director","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-10-01T02:00:00Z","last_updated_date":"2015-10-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-nominates-guido-rasi-executive-director_en.pdf"},
    {"id":"12667","name":"European Medicines Agency recommends revoking authorisations of Caustinerf arsenical and Yranicid arsenical used in dental procedures","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/242277/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-revoking-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures_en.pdf"},
    {"id":"12670","name":"Meeting highlights from the Paediatric Committee:16 -  18 September 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/PDCO/570808/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee16-18-september-2009_en.pdf"},
    {"id":"12671","name":"EMA and heads of national competent authorities discuss consequences of Brexit","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-04-28T02:00:00Z","last_updated_date":"2017-04-28T02:00:00Z","reference_number":"EMA/271635/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-and-heads-national-competent-authorities-discuss-consequences-brexit_en.pdf"},
    {"id":"12683","name":"Two new medicines recommended for the treatment of chronic hepatitis C","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T14:00:00Z","last_updated_date":"2017-06-23T14:00:00Z","reference_number":"EMA/CHMP/392513/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/two-new-medicines-recommended-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"12694","name":"BioPartners GmbH withdraws its application for Biferonex (interferon beta-1a)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/333052/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/biopartners-gmbh-withdraws-its-application-biferonex-interferon-beta-1a_en.pdf"},
    {"id":"12719","name":"Committee for veterinary medicinal products: Meeting of 12 to 14 November 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-11-15T12:09:21Z","last_updated_date":"2002-11-15T12:09:21Z","reference_number":"EMEA/CVMP/1111/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-12-14-november-2002_en.pdf"},
    {"id":"12780","name":"Neurochem withdraws its marketing authorisation application for\n\nKiacta (eprodisate disodium)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-03-17T01:00:00Z","last_updated_date":"2008-03-17T01:00:00Z","reference_number":"EMEA/137989/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/neurochem-withdraws-its-marketing-authorisation-application-kiacta-eprodisate-disodium_en.pdf"},
    {"id":"12784","name":"EMA seeks views of public during its safety review of valproate","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-07-11T14:00:00Z","last_updated_date":"2017-07-11T14:00:00Z","reference_number":"EMA/423957/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-seeks-views-public-during-its-safety-review-valproate_en.pdf"},
    {"id":"12803","name":"Committee for Proprietary Medicinal Products (CPMP) 13th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-02-15T01:00:00Z","last_updated_date":"1996-02-15T01:00:00Z","reference_number":"CPMP/179/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-13th-plenary-meeting_en.pdf"},
    {"id":"12813","name":"European Medicines Agency recommends approval of a locally targeted treatment for ulcerative colitis and Crohn’s disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/169535/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-locally-targeted-treatment-ulcerative-colitis-and-crohns-disease_en.pdf"},
    {"id":"12853","name":"European Medicines Agency confirms positive benefit-risk balance of pholcodine-containing cough medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-11-18T11:00:00Z","last_updated_date":"2011-11-18T11:00:00Z","reference_number":"EMA/CHMP/898043/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-positive-benefit-risk-balance-pholcodine-containing-cough-medicines_en.pdf"},
    {"id":"12854","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/CHMP/723042/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2010_en.pdf"},
    {"id":"12863","name":"European Medicines Agency sees strong level of applications in 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-10-12T02:09:21Z","last_updated_date":"2007-10-12T02:09:21Z","reference_number":"EMEA/454935/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-sees-strong-level-applications-2007_en.pdf"},
    {"id":"12865","name":"Committee for Medicinal Products for Veterinary Use: Meeting of 9-11 February 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-02-12T00:09:21Z","last_updated_date":"2010-02-12T00:09:21Z","reference_number":"EMA/CVMP/54754/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-9-11-february-2010_en.pdf"},
    {"id":"12894","name":"Product Information Management project (\"PIM\")","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-03-26T02:00:00Z","last_updated_date":"2001-03-26T02:00:00Z","reference_number":"EMEA/T/3628/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/product-information-management-project-pim_en.pdf"},
    {"id":"12909","name":"EMEA releases guidelines on development of medicines for Alzheimer’s disease and Parkinson’s disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:09:21Z","last_updated_date":"2008-09-04T02:09:21Z","reference_number":"EMEA/460300/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-releases-guidelines-development-medicines-alzheimers-disease-and-parkinsons-disease_en.pdf"},
    {"id":"12931","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 June 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"EMA/CVMP/330061/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-11-13-june-2013_en.pdf"},
    {"id":"12945","name":"European expert group proposes reduction of use in animals of last resort antibiotic colistin to manage risk of resistance","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-05-26T02:00:00Z","last_updated_date":"2016-05-26T02:00:00Z","reference_number":"EMA/355125/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-expert-group-proposes-reduction-use-animals-last-resort-antibiotic-colistin-manage-risk-resistance_en.pdf"},
    {"id":"12978","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 14-16 June 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"EMA/CVMP/377272/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-14-16-june-2016_en.pdf"},
    {"id":"13026","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 06-08 September 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-09-09T02:00:00Z","last_updated_date":"2016-09-09T02:00:00Z","reference_number":"EMA/CVMP/542033/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-06-08-september-2016_en.pdf"},
    {"id":"13036","name":"Committee for medicinal products for veterinary use: Meeting of 15-17 April 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-04-18T02:09:21Z","last_updated_date":"2008-04-18T02:09:21Z","reference_number":"EMEA/CVMP/166063/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-15-17-april-2008_en.pdf"},
    {"id":"13086","name":"Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2016-10-14T14:00:00Z","reference_number":"EMA/603690/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_en.pdf"},
    {"id":"13095","name":"5th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-09-18T02:00:00Z","last_updated_date":"2000-09-18T02:00:00Z","reference_number":"EMEA/COMP/83/00 rev1","document_url":"https://www.ema.europa.eu/en/documents/press-release/5th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"13158","name":"23rd meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-05-02T02:09:21Z","last_updated_date":"2002-05-02T02:09:21Z","reference_number":"EMEA/COMP/824/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/23rd-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"13169","name":"European Medicines Agency statement following seizure of Avandamet tablets by US Food and Drug Administration","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-03-04T00:09:21Z","last_updated_date":"2005-03-04T00:09:21Z","reference_number":"EMEA/84957/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-statement-following-seizure-avandamet-tablets-us-food-and-drug-administration_en.pdf"},
    {"id":"13178","name":"GVK Biosciences: European Medicines Agency confirms recommendation to suspend medicines over flawed studies","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/324341/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_en.pdf"},
    {"id":"13193","name":"30th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-12-13T00:09:21Z","last_updated_date":"2002-12-13T00:09:21Z","reference_number":"EMEA/COMP/2997/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/30th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"13196","name":"European Antibiotic Awareness Day 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-11-17T01:00:00Z","last_updated_date":"2015-11-18T11:04:00Z","reference_number":"EMA/757302/2015 Corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-antibiotic-awareness-day-2015_en.pdf"},
    {"id":"13204","name":"European Medicines Agency Management Board strengthens conflicts of interest policies and transparency","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-03-26T13:10:00Z","last_updated_date":"2012-03-26T13:10:00Z","reference_number":"EMA/201172/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-management-board-strengthens-conflicts-interest-policies-and-transparency_en.pdf"},
    {"id":"13207","name":"General Court confirms EMA approach to transparency","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-02-06T10:28:00Z","last_updated_date":"2018-02-06T10:28:00Z","reference_number":"EMA/73690/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/general-court-confirms-ema-approach-transparency_en.pdf"},
    {"id":"13227","name":"European Medicines Agency recommends update of product information of Tysabri and risk of progressive multifocal leukoencephalopathy (PML)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-25T02:00:00Z","last_updated_date":"2008-09-25T02:00:00Z","reference_number":"EMEA/CHMP/496612/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-update-product-information-tysabri-and-risk-progressive-multifocal-leukoencephalopathy-pml_en.pdf"},
    {"id":"13242","name":"European Medicines Agency and EUnetHTA review progress of their cooperation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T02:00:00Z","last_updated_date":"2013-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-eunethta-review-progress-their-cooperation_en.pdf"},
    {"id":"13255","name":"European Medicines Agency to grant fee waivers to applications for bluetongue vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-04-01T02:00:00Z","last_updated_date":"2008-04-01T02:00:00Z","reference_number":"EMEA/111979/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-grant-fee-waivers-applications-bluetongue-vaccines_en.pdf"},
    {"id":"13267","name":"33rd meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-03-24T01:00:00Z","last_updated_date":"2003-03-24T01:00:00Z","reference_number":"EMEA/COMP/840/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/33rd-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"13315","name":"Mylan S.A.S. withdraws its marketing authorisation application for Docetaxel Mylan (docetaxel)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-03-15T01:00:00Z","last_updated_date":"2010-03-15T01:00:00Z","reference_number":"EMA/164498/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/mylan-sas-withdraws-its-marketing-authorisation-application-docetaxel-mylan-docetaxel_en.pdf"},
    {"id":"13342","name":"European Medicines Agency concludes review of modified-release oral opioids of the WHO level III scale for the management of pain","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2010-07-23T02:00:00Z","reference_number":"EMA/463702/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-concludes-review-modified-release-oral-opioids-who-level-iii-scale-management-pain_en.pdf"},
    {"id":"13381","name":"2006 EMEA/IFAH-Europe Info Day: Stimulating innovation and managing risk in market access to the veterinary sector","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-11-16T12:09:21Z","last_updated_date":"2006-11-16T12:09:21Z","reference_number":"EMEA/456812/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/2006-emeaifah-europe-info-day-stimulating-innovation-and-managing-risk-market-access-veterinary-sector_en.pdf"},
    {"id":"13383","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 8-10 December 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"EMA/CVMP/790580/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-december-2015_en.pdf"},
    {"id":"13385","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products - Meeting of 19 to 21 March 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-03-21T01:00:00Z","last_updated_date":"2002-03-21T01:00:00Z","reference_number":"EMEA/D/7412/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-19-21-march-2002_en.pdf"},
    {"id":"13391","name":"Committee for veterinary medicinal products: Meeting of 22 to 24 July 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-07-25T14:09:21Z","last_updated_date":"2003-07-25T14:09:21Z","reference_number":"EMEA/CVMP/689/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-22-24-july-2003_en.pdf"},
    {"id":"13410","name":"European Medicines Agency update on review of non-selective NSAIDs","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-09-26T02:00:00Z","last_updated_date":"2006-09-26T02:00:00Z","reference_number":"EMEA/378695/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-update-review-non-selective-nsaids_en.pdf"},
    {"id":"13449","name":"18th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-11-22T00:00:00Z","last_updated_date":"2001-11-22T00:00:00Z","reference_number":"EMEA/COMP/519/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/18th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"13458","name":"European medicines regulators agree a common, Europe-wide approach for the identification of commercially confidential information and personal data","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-03-27T12:15:00Z","last_updated_date":"2012-03-27T12:15:00Z","reference_number":"EMA/211884/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-regulators-agree-common-europe-wide-approach-identification-commercially-confidential-information-and-personal-data_en.pdf"},
    {"id":"13511","name":"EMEA reports strong performance in regulatory and public-health activities in 2007; the outlook for 2008 is even higher application numbers and a focus on advanced-therapy medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-03-10T00:09:21Z","last_updated_date":"2008-03-10T00:09:21Z","reference_number":"EMEA/MB/117248/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-reports-strong-performance-regulatory-and-public-health-activities-2007-outlook-2008-even-higher-application-numbers-and-focus-advanced-therapy-medicines_en.pdf"},
    {"id":"13529","name":"Summary report - EMA hosts workshop on adaptive pathways","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-12-13T01:00:00Z","last_updated_date":"2016-12-13T01:00:00Z","reference_number":"EMA/824492/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/summary-report-ema-hosts-workshop-adaptive-pathways_en.pdf"},
    {"id":"13620","name":"EMEA forecasts modest increase in applications in its 2004 budget and Management Board elects new chairman","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-12-19T00:09:21Z","last_updated_date":"2003-12-19T00:09:21Z","reference_number":"EMEA/MB/73/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-forecasts-modest-increase-applications-its-2004-budget-and-management-board-elects-new-chairman_en.pdf"},
    {"id":"13623","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 06-08 May 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-05-12T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/CVMP/243949/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-06-08-may-2014_en.pdf"},
    {"id":"13633","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 8-10 September 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-09-11T16:00:00Z","last_updated_date":"2015-09-14T16:00:00Z","reference_number":"EMA/CVMP/578106/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-september-2015_en.pdf"},
    {"id":"13654","name":"12th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1996-06-27T14:39:21Z","last_updated_date":"1996-06-27T14:39:21Z","reference_number":"EMEA/CVMP/114/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/12th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"13689","name":"Idea AG withdraws its marketing authorisation application for Diractin (ketoprofen)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/397710/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/idea-ag-withdraws-its-marketing-authorisation-application-diractin-ketoprofen_en.pdf"},
    {"id":"13711","name":"Novartis Europharm Ltd withdraws its marketing authorisation application for Rasival (aliskiren / valsartan)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-17T16:43:38Z","last_updated_date":"2010-09-17T16:43:38Z","reference_number":"EMA/583880/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/novartis-europharm-ltd-withdraws-its-marketing-authorisation-application-rasival-aliskiren-valsartan_en.pdf"},
    {"id":"13745","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19–21 June 2018","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T18:00:00Z","last_updated_date":"2018-06-22T18:00:00Z","reference_number":"EMA/CVMP/404979/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-19-21-june-2018_en.pdf"},
    {"id":"13758","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 14 - 17 March 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-03-17T01:00:00Z","last_updated_date":"2005-03-17T01:00:00Z","reference_number":"EMEA/96995/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-14-17-march-2005_en.pdf"},
    {"id":"13800","name":"European Medicines Agency: Committee for Medicinal Products for Human Use\n\n17-20 January 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2004-01-20T01:00:00Z","last_updated_date":"2004-01-20T01:00:00Z","reference_number":"EMEA/21979/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-17-20-january-2005_en.pdf"},
    {"id":"13816","name":"EMEA statement on the safety of Ketek","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-01-27T01:00:00Z","last_updated_date":"2006-01-27T01:00:00Z","reference_number":"EMEA/29386/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-statement-safety-ketek_en.pdf"},
    {"id":"13833","name":"Committee for medicinal products for veterinary use: Meeting of 6 to 8 September 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-09-09T14:09:21Z","last_updated_date":"2005-09-09T14:09:21Z","reference_number":"EMEA/CVMP/257162/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-6-8-september-2005_en.pdf"},
    {"id":"13865","name":"European Medicines Agency recommends approval of combined advanced-therapy product","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T14:00:02Z","last_updated_date":"2013-04-26T14:00:02Z","reference_number":"EMA/256423/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-combined-advanced-therapy-product_en.pdf"},
    {"id":"13866","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n26-29 May 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:09:21Z","last_updated_date":"2009-05-29T02:09:21Z","reference_number":"EMEA/CHMP/330580/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-26-29-may-2009_en.pdf"},
    {"id":"13867","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 January 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/CHMP/819015/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-january-2011_en.pdf"},
    {"id":"13916","name":"Committee for Orphan Medicinal Products: December 2005 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-12-09T01:00:00Z","last_updated_date":"2005-12-09T01:00:00Z","reference_number":"EMEA/COMP/412637/2005 Corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-december-2005-meeting_en.pdf"},
    {"id":"13926","name":"European Medicines Agency updates on ongoing safety review of sibutramine: Weight-loss medicine assessed over cardiovascular concerns","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-18T01:00:00Z","last_updated_date":"2009-12-18T01:00:00Z","reference_number":"EMA/CHMP/817876/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-ongoing-safety-review-sibutramine-weight-loss-medicine-assessed-over-cardiovascular-concerns_en.pdf"},
    {"id":"13968","name":"EMA recommends approval of new treatment for platinum-resistant ovarian cancer together with companion diagnostic","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/165158/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-approval-new-treatment-platinum-resistant-ovarian-cancer-together-companion-diagnostic_en.pdf"},
    {"id":"13980","name":"Committee for medicinal products for veterinary use: Meeting of 11 to 13 May 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-05-14T14:39:21Z","last_updated_date":"2004-05-14T14:39:21Z","reference_number":"EMEA/CVMP/477/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-11-13-may-2004_en.pdf"},
    {"id":"14015","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n16-19 February 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T00:09:21Z","last_updated_date":"2009-02-19T00:09:21Z","reference_number":"EMEA/CHMP/107282/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-16-19-february-2009_en.pdf"},
    {"id":"14021","name":"7th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-11-23T00:00:00Z","last_updated_date":"2000-11-23T00:00:00Z","reference_number":"EMEA/COMP/249/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/7th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"14044","name":"68th meeting of the Committee for Proprietary Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-03-06T00:09:21Z","last_updated_date":"2001-03-06T00:09:21Z","reference_number":"CPMP/521/01 corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/68th-meeting-committee-proprietary-medicinal-products_en.pdf"},
    {"id":"14105","name":"Committee for medicinal products for veterinary use: Meeting of 14 to 15 June 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-06-16T14:09:21Z","last_updated_date":"2005-06-16T14:09:21Z","reference_number":"EMEA/CVMP/177266/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-14-15-june-2005_en.pdf"},
    {"id":"14116","name":"European Medicines Agency to review third- and fourth-generation combined oral contraceptives","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T17:00:00Z","last_updated_date":"2013-01-28T17:00:00Z","reference_number":"EMA/20410/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-review-third-and-fourth-generation-combined-oral-contraceptives_en.pdf"},
    {"id":"14129","name":"EMEA workshop on homeopathic medicinal products concludes to strengthen harmonisation, but accept different national traditions","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-11-28T00:09:21Z","last_updated_date":"2006-11-28T00:09:21Z","reference_number":"EMEA/460146/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-workshop-homeopathic-medicinal-products-concludes-strengthen-harmonisation-accept-different-national-traditions_en.pdf"},
    {"id":"14147","name":"Committee for veterinary medicinal products: Meeting of 10 to 12 December 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-12-13T12:39:21Z","last_updated_date":"2002-12-13T12:39:21Z","reference_number":"EMEA/CVMP/1222/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-10-12-december-2002_en.pdf"},
    {"id":"14173","name":"European Medicines Agency gives second positive opinion for a paediatric-use marketing authorisation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T13:00:00Z","last_updated_date":"2014-02-21T13:00:00Z","reference_number":"EMA/99224/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-second-positive-opinion-paediatric-use-marketing-authorisation_en.pdf"},
    {"id":"14195","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 16-18 February 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-02-19T15:00:00Z","last_updated_date":"2016-02-19T15:00:00Z","reference_number":"EMA/CVMP/82395/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-16-18-february-2016_en.pdf"},
    {"id":"14212","name":"Supply shortages of Cerezyme and Fabrazyme - priority access for patients most in need of treatment recommended","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/389995/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/supply-shortages-cerezyme-and-fabrazyme-priority-access-patients-most-need-treatment-recommended_en.pdf"},
    {"id":"14222","name":"Committee for Proprietary Medicinal Products (CPMP) 17th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-06-20T02:00:00Z","last_updated_date":"1996-06-20T02:00:00Z","reference_number":"CPMP/513/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-17th-plenary-meeting_en.pdf"},
    {"id":"14237","name":"Sixth EMEA/FEDESA Joint Info Day at the European Agency in London","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-04-21T02:00:00Z","last_updated_date":"1999-04-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/sixth-emeafedesa-joint-info-day-european-agency-london_en.pdf"},
    {"id":"14250","name":"Committee for medicinal products for veterinary use: Meeting of 10-12 February 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-13T00:09:21Z","last_updated_date":"2009-02-13T00:09:21Z","reference_number":"EMEA/CVMP/56807/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-10-12-february-2009_en.pdf"}    {"id":"14267","name":"Message personnel de M. Fernand Sauer, Directeur Exà©cutif de l'EMEA","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-06-28T02:00:00Z","last_updated_date":"2000-06-28T02:00:00Z","reference_number":"EMEA/D/18899/FR","document_url":"https://www.ema.europa.eu/en/documents/press-release/message-personnel-de-m-fernand-sauer-directeur-exaccutif-de-lemea_en.pdf"},
    {"id":"14268","name":"European Medicines Agency recommends conditional approval of Pixuvri (pixantrone) for relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T12:57:06Z","last_updated_date":"2012-02-17T12:57:06Z","reference_number":"EMA/CHMP/121961/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-conditional-approval-pixuvri-pixantrone-relapsed-or-refractory-aggressive-non-hodgkins-b-cell-lymphoma_en.pdf"},
    {"id":"14282","name":"EMA fast-tracks enzyme replacement therapy for lysosomal acid lipase deficiency","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/CHMP/425434/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-fast-tracks-enzyme-replacement-therapy-lysosomal-acid-lipase-deficiency_en.pdf"},
    {"id":"14377","name":"First paediatric medicine to treat rare hormonal disorder","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T01:00:00Z","last_updated_date":"2017-12-15T01:00:00Z","reference_number":"EMA/822961/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-paediatric-medicine-treat-rare-hormonal-disorder_en.pdf"},
    {"id":"14385","name":"Committee for Medicinal Products for Veterinary Use: Meeting of 8-10 December 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-11T01:00:00Z","last_updated_date":"2009-12-11T01:00:00Z","reference_number":"EMA/CVMP/772078/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-8-10-december-2009_en.pdf"},
    {"id":"14410","name":"Meeting highlights from the Paediatric Committee: 26 - 28 September  2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-10-01T02:00:00Z","last_updated_date":"2007-10-01T02:00:00Z","reference_number":"EMEA/440694/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-26-28-september-2007_en.pdf"},
    {"id":"14445","name":"7th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1995-11-16T12:09:21Z","last_updated_date":"1995-11-16T12:09:21Z","reference_number":"EMEA/CVMP/151/95","document_url":"https://www.ema.europa.eu/en/documents/press-release/7th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14488","name":"Committee for veterinary medicinal products: Meeting of 9 to 10 December 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-12-12T12:39:21Z","last_updated_date":"2003-12-12T12:39:21Z","reference_number":"EMEA/CVMP/1129/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-9-10-december-2003_en.pdf"},
    {"id":"14506","name":"Committee for medicinal products for veterinary use: Meeting of 4 to 6 October 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-10-07T14:09:21Z","last_updated_date":"2005-10-07T14:09:21Z","reference_number":"EMEA/CVMP/312958/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-4-6-october-2005_en.pdf"},
    {"id":"14544","name":"Janssen-Cilag International NV withdraws its marketing authorisation application for Comfyde (carisbamate)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-01-20T01:00:00Z","last_updated_date":"2010-01-20T01:00:00Z","reference_number":"EMA/32401/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/janssen-cilag-international-nv-withdraws-its-marketing-authorisation-application-comfyde-carisbamate_en.pdf"},
    {"id":"14599","name":"First medicine for spinal muscular atrophy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/250453/2017  ","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-medicine-spinal-muscular-atrophy_en.pdf"},
    {"id":"14657","name":"17th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-01-16T13:30:00Z","last_updated_date":"1997-01-16T13:30:00Z","reference_number":"EMEA/CVMP/018/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/17th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"14729","name":"European Medicines Agency statement on the suspension of use of Bextra","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-04-07T02:09:21Z","last_updated_date":"2005-04-07T02:09:21Z","reference_number":"EMEA/121637/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-statement-suspension-use-bextra_en.pdf"},
    {"id":"14821","name":"EMEA Workshop on Neonates: Development of medicines for neonates needs multi-disciplinary cooperation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-10-25T02:09:21Z","last_updated_date":"2006-10-25T02:09:21Z","reference_number":"EMEA/416788/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-workshop-neonates-development-medicines-neonates-needs-multi-disciplinary-cooperation_en.pdf"},
    {"id":"14827","name":"European Medicines Agency recommends two new treatment options for tuberculosis","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T13:00:10Z","last_updated_date":"2013-11-22T13:00:10Z","reference_number":"EMA/717915/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-two-new-treatment-options-tuberculosis_en.pdf"},
    {"id":"14877","name":"Committee for Proprietary Medicinal Products (CPMP) 55th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-12-20T01:00:00Z","last_updated_date":"1999-12-20T01:00:00Z","reference_number":"CPMP/3323/99 corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-55th-plenary-meeting_en.pdf"},
    {"id":"14920","name":"Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/603417/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/factor-viii-medicines-no-clear-and-consistent-evidence-difference-risk-inhibitor-development-between-classes_en.pdf"},
    {"id":"14922","name":"European Medicines Agency's Management Board supports plan to publish agendas and minutes of all committees","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-07T02:00:00Z","last_updated_date":"2013-10-07T02:00:00Z","reference_number":"EMA/605248/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-supports-plan-publish-agendas-and-minutes-all-committees_en.pdf"},
    {"id":"15011","name":"EMA Management Board discusses next steps after judgment of EU Civil Service Tribunal","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T01:00:00Z","last_updated_date":"2014-12-01T01:00:00Z","reference_number":"EMA/746361/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-discusses-next-steps-after-judgment-eu-civil-service-tribunal_en.pdf"},
    {"id":"15014","name":"European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-23T02:00:00Z","last_updated_date":"2010-09-23T02:00:00Z","reference_number":"EMA/CHMP/588294/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-review-pandemrix-and-reports-narcolepsy_en.pdf"},
    {"id":"15056","name":"GlaxoSmithKline withdraws its marketing authorisation application for Bosatria","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-07-29T02:00:00Z","last_updated_date":"2009-07-29T02:00:00Z","reference_number":"EMEA/483760/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/glaxosmithkline-withdraws-its-marketing-authorisation-application-bosatria_en.pdf"},
    {"id":"15079","name":"Gendux Molecular Limited withdraws its marketing authorisation application for Contusugene ladenovec Gendux","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/412751/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/gendux-molecular-limited-withdraws-its-marketing-authorisation-application-contusugene-ladenovec-gendux_en.pdf"},
    {"id":"15109","name":"Committee for Proprietary Medicinal Products (CPMP): meeting of 18 to 20 September 2001","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-09-25T02:09:21Z","last_updated_date":"2001-09-25T02:09:21Z","reference_number":"CPMP/2973/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-meeting-18-20-september-2001_en.pdf"},
    {"id":"15149","name":"European Medicines Agency update on combined contraceptives","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T09:00:00Z","last_updated_date":"2013-01-11T09:00:00Z","reference_number":"EMA/19198/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-update-combined-contraceptives_en.pdf"},
    {"id":"15210","name":"European Medicines Agency gives guidance for use of antiviral medicines in case of a novel influenza A/H1N1 pandemic","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-08T02:00:00Z","last_updated_date":"2009-05-08T02:00:00Z","reference_number":"EMEA/285148/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-guidance-use-antiviral-medicines-case-novel-influenza-ah1n1-pandemic_en.pdf"},
    {"id":"15227","name":"European Medicines Agency makes recommendations on the use of\n\nantimicrobials in livestock and companion animals in relation to the risk of\n\nMRSA infection in animals","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-03-27T00:09:21Z","last_updated_date":"2009-03-27T00:09:21Z","reference_number":"EMEA/CVMP/176994/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-makes-recommendations-use-antimicrobials-livestock-and-companion-animals-relation-risk-mrsa-infection-animals_en.pdf"},
    {"id":"15232","name":"European Risk Management Strategy: Progress to date and next steps","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-05-11T02:09:21Z","last_updated_date":"2005-05-11T02:09:21Z","reference_number":"EMEA/136253/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-risk-management-strategy-progress-date-and-next-steps_en.pdf"},
    {"id":"15238","name":"European Medicines Agency recommends continued vaccination with Gardasil","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"EMEA/CHMP/103339/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-continued-vaccination-gardasil_en.pdf"},
    {"id":"15243","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n20-23 July 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-07-24T02:00:00Z","last_updated_date":"2009-07-24T02:00:00Z","reference_number":"EMEA/CHMP/468553/2009 corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-20-23-july-2009_en.pdf"},
    {"id":"15244","name":"European Medicines Agency gives recommendations to deal with sterility assurance concerns for DepoCyte","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-08-24T13:15:00Z","last_updated_date":"2012-08-24T13:15:00Z","reference_number":"EMA/CHMP/555991/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-recommendations-deal-sterility-assurance-concerns-depocyte_en.pdf"},
    {"id":"15317","name":"Committee for Proprietary Medicinal Products (CPMP) 11th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1995-12-21T01:00:00Z","last_updated_date":"1995-12-21T01:00:00Z","reference_number":"CPMP/938/95","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-11th-plenary-meeting_en.pdf"},
    {"id":"15318","name":"Two new medicines for advanced kidney cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/496979/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/two-new-medicines-advanced-kidney-cancer_en.pdf"},
    {"id":"15348","name":"EMEA annual report shows 24 positive reviews for new human medicines in 2003. Agency proposes €108 million budget for 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-03-24T00:09:21Z","last_updated_date":"2004-03-24T00:09:21Z","reference_number":"EMEA/D/8348/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-annual-report-shows-24-positive-reviews-new-human-medicines-2003-agency-proposes-eu108-million-budget-2005_en.pdf"},
    {"id":"15374","name":"Novartis Europharm Ltd. withdraws its application for an extension of indication for Zometa (zoledronic acid)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-15T01:00:00Z","last_updated_date":"2010-12-15T01:00:00Z","reference_number":"EMA/818700/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/novartis-europharm-ltd-withdraws-its-application-extension-indication-zometa-zoledronic-acid_en.pdf"},
    {"id":"15380","name":"European Medicines Agency launches EudraPharm – the European medicines database","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-12-06T01:00:00Z","last_updated_date":"2006-12-06T01:00:00Z","reference_number":"EMEA/456119/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-launches-eudrapharm-european-medicines-database_en.pdf"},
    {"id":"15393","name":"European Medicines Agency gives new temporary treatment recommendations for Fabrazyme","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2010-04-23T02:00:00Z","reference_number":"EMA/257628/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-new-temporary-treatment-recommendations-fabrazyme_en.pdf"},
    {"id":"15460","name":"Committee for Orphan Medicinal Products adopts 100th positive opinion on designation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-03-26T00:09:21Z","last_updated_date":"2002-03-26T00:09:21Z","reference_number":"EMEA/COMP/531/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-adopts-100th-positive-opinion-designation_en.pdf"},
    {"id":"15486","name":"Meeting highlights from the Paediatric Committee: 1 - 3 April 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-04-24T02:00:00Z","last_updated_date":"2009-04-24T02:00:00Z","reference_number":"EMEA/PDCO/201824/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-1-3-april-2009_en.pdf"},
    {"id":"15520","name":"Meeting of the EMEA working party on herbal medicinal products 24 and 25 February 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-03-28T01:00:00Z","last_updated_date":"2003-03-28T01:00:00Z","reference_number":"EMEA/HMPWP/1090/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-emea-working-party-herbal-medicinal-products-24-and-25-february-2003_en.pdf"},
    {"id":"15546","name":"Combined use of medicines affecting the renin-angiotensin system (RAS) to be restricted – CHMP endorses PRAC recommendation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/294911/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/combined-use-medicines-affecting-renin-angiotensin-system-ras-be-restricted-chmp-endorses-prac-recommendation_en.pdf"},
    {"id":"15549","name":"First specific replacement therapy to treat rare bleeding disorder","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T13:00:00Z","last_updated_date":"2016-01-29T13:00:00Z","reference_number":"EMA/CHMP/58757/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-specific-replacement-therapy-treat-rare-bleeding-disorder_en.pdf"},
    {"id":"15560","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 11-13 January 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-01-14T01:00:00Z","last_updated_date":"2011-01-14T01:00:00Z","reference_number":"EMA/CVMP/837941/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-11-13-january-2011_en.pdf"},
    {"id":"15563","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n22-24 January 2007","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2007-01-25T00:09:21Z","last_updated_date":"2007-01-25T00:09:21Z","reference_number":"EMEA/39118/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-22-24-january-2007_en.pdf"},
    {"id":"15568","name":"EMEA/IFAH Infoday: Latest developments in scientific review, legislation and marketing authorisation procedures for veterinary medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-03-18T01:00:00Z","last_updated_date":"2009-03-18T01:00:00Z","reference_number":"EMEA/161593/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/emeaifah-infoday-latest-developments-scientific-review-legislation-and-marketing-authorisation-procedures-veterinary-medicines_en.pdf"},
    {"id":"15601","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 7-9 October 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-10T02:00:00Z","last_updated_date":"2014-10-10T02:00:00Z","reference_number":"EMA/CVMP/590787/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-7-9-october-2014_en.pdf"},
    {"id":"15617","name":"European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/401062/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-withdrawal-dextropropoxyphene-containing-medicines_en.pdf"},
    {"id":"15628","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n15-18 December 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T00:09:21Z","last_updated_date":"2008-12-18T00:09:21Z","reference_number":"EMEA/CHMP/670724/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-15-18-december-2008_en.pdf"},
    {"id":"15654","name":"European Medicines Agency starts infringement procedure to investigate Roche’s alleged non-compliance with pharmacovigilance obligations","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-10-23T14:00:00Z","last_updated_date":"2012-10-23T14:00:00Z","reference_number":"EMA/666493/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-infringement-procedure-investigate-roches-alleged-non-compliance-pharmacovigilance-obligations_en.pdf"},
    {"id":"15668","name":"PRAC confirms that benefits of all combined hormonal contraceptives (CHCs) continue to outweigh risks","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T14:00:00Z","last_updated_date":"2013-10-11T14:00:00Z","reference_number":"EMA/607314/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-confirms-benefits-all-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_en.pdf"},
    {"id":"15677","name":"Updated measures for pregnancy prevention during retinoid use","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T13:00:00Z","last_updated_date":"2018-03-23T13:00:00Z","reference_number":"EMA/165360/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/updated-measures-pregnancy-prevention-during-retinoid-use_en.pdf"},
    {"id":"15690","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 15-17 March 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T01:00:00Z","last_updated_date":"2016-03-18T01:00:00Z","reference_number":"EMA/CVMP/169459/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-15-17-march-2016_en.pdf"},
    {"id":"15720","name":"Committee for medicinal products for veterinary use: Meeting of 11-12 January 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-01-13T12:49:21Z","last_updated_date":"2005-01-13T12:49:21Z","reference_number":"EMEA/CVMP/1947/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-11-12-january-2005_en.pdf"},
    {"id":"15722","name":"European Medicines Agency publishes updated set of mandatory Article 57(2) requirements for marketing authorisation holders","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T13:00:00Z","last_updated_date":"2012-03-05T13:00:00Z","reference_number":"EMA/139333/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-publishes-updated-set-mandatory-article-572-requirements-marketing-authorisation-holders_en.pdf"},
    {"id":"15780","name":"European Medicines Agency implements internal reorganisation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-05T02:00:00Z","last_updated_date":"2009-10-05T02:00:00Z","reference_number":"EMEA/520173/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-implements-internal-reorganisation_en.pdf"},
    {"id":"15792","name":"EMA Management Board: highlights of March 2016 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-03-21T11:28:00Z","last_updated_date":"2016-03-21T11:28:00Z","reference_number":"EMA/205682/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-march-2016-meeting_en.pdf"},
    {"id":"15879","name":"European Medicines Agency welcomes continuation of D:A:D study","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-03T01:00:00Z","last_updated_date":"2009-02-03T01:00:00Z","reference_number":"EMEA/44937/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-welcomes-continuation-dad-study_en.pdf"},
    {"id":"15899","name":"22nd meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-06-13T22:00:00Z","last_updated_date":"1997-06-13T22:00:00Z","reference_number":"EMEA/CVMP/203/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/22nd-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"15911","name":"Protherics withdraws its marketing authorisation application for Voraxaze","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:09:21Z","last_updated_date":"2009-05-29T02:09:21Z","reference_number":"EMEA/235491/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/protherics-withdraws-its-marketing-authorisation-application-voraxaze_en.pdf"},
    {"id":"15945","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 10-12 December 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-13T17:00:00Z","last_updated_date":"2013-12-13T17:00:00Z","reference_number":"EMA/CVMP/735977/20132013","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-10-12-december-2013_en.pdf"},
    {"id":"15989","name":"CHMP meeting on Paroxetine and other SSRIs","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-12-09T01:00:00Z","last_updated_date":"2004-12-09T01:00:00Z","reference_number":"EMEA/192570/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/chmp-meeting-paroxetine-and-other-ssris_en.pdf"},
    {"id":"16017","name":"Committee for medicinal products for veterinary use: Meeting of 17-19 June 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-20T02:09:21Z","last_updated_date":"2008-06-20T02:09:21Z","reference_number":"EMEA/CVMP/276992/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-17-19-june-2008_en.pdf"},
    {"id":"16054","name":"Committee for medicinal products for veterinary use: Meeting of 13-15 February 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-02-19T12:09:21Z","last_updated_date":"2007-02-19T12:09:21Z","reference_number":"EMEA/CVMP/49306/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-13-15-february-2007_en.pdf"},
    {"id":"16082","name":"35th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-09-10T02:09:21Z","last_updated_date":"1998-09-10T02:09:21Z","reference_number":"EMEA/CVMP/392/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/35th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"16121","name":"Infringement procedure against Roche – EMA update","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-07-04T02:00:00Z","last_updated_date":"2016-07-04T02:00:00Z","reference_number":"EMA/453738/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/infringement-procedure-against-roche-ema-update_en.pdf"},
    {"id":"16151","name":"Committee for Proprietary Medicinal Products (CPMP): meeting of 26 to 28 June 2001","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-06-28T02:09:21Z","last_updated_date":"2001-06-28T02:09:21Z","reference_number":"CPMP/1935/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-meeting-26-28-june-2001_en.pdf"},
    {"id":"16211","name":"Committee for Orphan Medicinal Products: September 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-09-07T02:00:00Z","last_updated_date":"2006-09-07T02:00:00Z","reference_number":"EMEA/COMP/357633/2006/Revised","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-september-2006-meeting_en.pdf"},
    {"id":"16215","name":"European Medicines Agency update on the safety of Tamiflu","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"EMEA/385013/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-update-safety-tamiflu_en.pdf"},
    {"id":"16222","name":"European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/652837/2013 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-finalises-review-medicines-concerned-roche-pharmacovigilance-inspection_en.pdf"},
    {"id":"16227","name":"Appeal procedure for Orphan Medicinal Product designation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-02-09T00:00:00Z","last_updated_date":"2001-02-09T00:00:00Z","reference_number":"EMEA/COMP/50/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/appeal-procedure-orphan-medicinal-product-designation_en.pdf"},
    {"id":"16298","name":"European Medicines Agency acts on deficiencies in Roche medicines-safety reporting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-06-21T18:00:05Z","last_updated_date":"2012-06-21T18:00:05Z","reference_number":"EMA/405725/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-acts-deficiencies-roche-medicines-safety-reporting_en.pdf"},
    {"id":"16316","name":"Committee for Proprietary Medicinal Products (CPMP) 16th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-05-23T02:00:00Z","last_updated_date":"1996-05-23T02:00:00Z","reference_number":"CPMP/426/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-16th-plenary-meeting_en.pdf"},
    {"id":"16335","name":"Committee for Proprietary Medicinal Products (CPMP) 65th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-11-21T01:00:00Z","last_updated_date":"2000-11-21T01:00:00Z","reference_number":"CPMP/2901/00 corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-65th-plenary-meeting_en.pdf"},
    {"id":"16379","name":"Management Board prepares groundwork in anticipation of a busy 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-12-20T00:09:21Z","last_updated_date":"2005-12-20T00:09:21Z","reference_number":"EMEA/425026/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/management-board-prepares-groundwork-anticipation-busy-2006_en.pdf"},
    {"id":"16430","name":"Focus group meeting of CVMP experts, interested parties and member states - reflection paper on the use of fluoroquinolones in food-producing animals","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-11-01T00:09:21Z","last_updated_date":"2006-11-01T00:09:21Z","reference_number":"EMEA/425047/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/focus-group-meeting-cvmp-experts-interested-parties-and-member-states-reflection-paper-use-fluoroquinolones-food-producing-animals_en.pdf"},
    {"id":"16438","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 13-15 February 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/CVMP/64908/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-13-15-february-2018_en.pdf"},
    {"id":"16457","name":"Schering-Plough Europe withdraws its marketing authorisation application for Cylatron","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-03-16T01:00:00Z","last_updated_date":"2009-03-16T01:00:00Z","reference_number":"EMEA/158824/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/schering-plough-europe-withdraws-its-marketing-authorisation-application-cylatron_en.pdf"},
    {"id":"16495","name":"European Medicines Agency recommends restricting the use of methysergide-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T13:00:00Z","last_updated_date":"2014-02-21T13:00:00Z","reference_number":"EMA/798712/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-methysergide-containing-medicines_en.pdf"},
    {"id":"16504","name":"Thirteenth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-02-06T01:00:00Z","last_updated_date":"1997-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/thirteenth-meeting-management-board_en.pdf"},
    {"id":"16505","name":"Eric Abadie resigns as chair of the CHMP","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-04-04T22:00:00Z","last_updated_date":"2012-04-04T22:00:00Z","reference_number":"EMA/236168/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/eric-abadie-resigns-chair-chmp_en.pdf"},
    {"id":"16563","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 11-14 April 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/216380/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-april-2011_en.pdf"},
    {"id":"16564","name":"Committee for Proprietary Medicinal Products (CPMP) 48th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-04-26T02:00:00Z","last_updated_date":"1999-04-26T02:00:00Z","reference_number":"CPMP/1150/99 corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-48th-plenary-meeting_en.pdf"},
    {"id":"16575","name":"26th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-07-19T02:09:21Z","last_updated_date":"2002-07-19T02:09:21Z","reference_number":"EMEA/18077/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/26th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"16597","name":"European Medicines Agency update on safety of insulin glargine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-29T02:00:00Z","last_updated_date":"2009-06-29T02:00:00Z","reference_number":"EMEA/408474/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-update-safety-insulin-glargine_en.pdf"},
    {"id":"16602","name":"EMEA celebrates 10th anniversary","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-03-14T00:09:21Z","last_updated_date":"2005-03-14T00:09:21Z","reference_number":"EMEA/95924/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-celebrates-10th-anniversary_en.pdf"},
    {"id":"16630","name":"Visit of IberoAmerican regulatory authorities to the Spanish Ministry of Health and Consumer Affairs (Madrid) and to the EMEA (London) - 18-20 February 1997","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-02-20T01:00:00Z","last_updated_date":"1997-02-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/visit-iberoamerican-regulatory-authorities-spanish-ministry-health-and-consumer-affairs-madrid-and-emea-london-18-20-february-1997_en.pdf"},
    {"id":"16635","name":"New medicine to protect honey bees against Varroa mites","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T16:29:00Z","last_updated_date":"2016-10-07T16:29:00Z","reference_number":"EMA/CVMP/655440/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-protect-honey-bees-against-varroa-mites_en.pdf"},
    {"id":"16647","name":"Committee for medicinal products for veterinary use: Meeting of 9-11 December 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-12-12T00:09:21Z","last_updated_date":"2008-12-12T00:09:21Z","reference_number":"EMEA/CVMP/585012/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-9-11-december-2008_en.pdf"},
    {"id":"16664","name":"Meeting of the EMEA working party on herbal medicinal products 11 and 12 March 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-03-18T01:00:00Z","last_updated_date":"2002-03-18T01:00:00Z","reference_number":"EMEA/HMPWP/227/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-emea-working-party-herbal-medicinal-products-11-and-12-march-2002_en.pdf"},
    {"id":"16716","name":"European Medicines Agency makes first recommendation for use of a medicine in children based on PIP data","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-25T02:09:21Z","last_updated_date":"2008-09-25T02:09:21Z","reference_number":"EMEA/502830/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-makes-first-recommendation-use-medicine-children-based-pip-data_en.pdf"},
    {"id":"16730","name":"Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-10T01:00:00Z","last_updated_date":"2010-12-10T01:00:00Z","reference_number":"EMA/804365/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/thelin-sitaxentan-be-withdrawn-due-cases-unpredictable-serious-liver-injury_en.pdf"},
    {"id":"16748","name":"ChemGenex Europe SAS withdraws its marketing authorisation application for Tekinex (omacetaxine mepesuccinate)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-01-12T01:00:00Z","last_updated_date":"2011-01-12T01:00:00Z","reference_number":"EMA/9192/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/chemgenex-europe-sas-withdraws-its-marketing-authorisation-application-tekinex-omacetaxine-mepesuccinate_en.pdf"},
    {"id":"16771","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products, 20-21 January 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-01-22T00:09:21Z","last_updated_date":"2004-01-22T00:09:21Z","reference_number":"EMEA/CPMP/406/04/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-20-21-january-2004_en.pdf"},
    {"id":"16794","name":"European Medicines Agency reviews further data on narcolepsy and possible association with Pandemrix","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-02-18T01:00:00Z","last_updated_date":"2011-02-18T01:00:00Z","reference_number":"EMA/CHMP/130422/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-reviews-further-data-narcolepsy-and-possible-association-pandemrix_en.pdf"},
    {"id":"16835","name":"European Medicines Agency recommends Acomplia must not be used in patients on antidepressants or with major depression","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/329826/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-acomplia-must-not-be-used-patients-antidepressants-or-major-depression_en.pdf"},
    {"id":"16877","name":"Public statement: Baraclude (entecavir): Occurrence of a resistant HIV variant in a patient co-infected with HIV and HBV","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-03-05T00:09:21Z","last_updated_date":"2007-03-05T00:09:21Z","reference_number":"EMEA/79902/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/public-statement-baraclude-entecavir-occurrence-resistant-hiv-variant-patient-co-infected-hiv-and-hbv_en.pdf"},
    {"id":"16907","name":"EMA Management Board: highlights of December 2016 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T01:00:00Z","last_updated_date":"2016-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-december-2016-meeting_en.pdf"},
    {"id":"16956","name":"PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl starch","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T14:00:00Z","last_updated_date":"2013-06-14T14:00:00Z","reference_number":"EMA/349341/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-suspending-marketing-authorisations-infusion-solutions-containing-hydroxyethyl-starch_en.pdf"},
    {"id":"16985","name":"European Medicines Agency review concludes positive benefit-risk balance for non-selective NSAIDs","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-10-24T02:09:21Z","last_updated_date":"2006-10-24T02:09:21Z","reference_number":"EMEA/413136/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-review-concludes-positive-benefit-risk-balance-non-selective-nsaids_en.pdf"},
    {"id":"17029","name":"European Medicines Agency facilitates interaction between small and medium-sized enterprises (SMEs)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-20T02:00:00Z","last_updated_date":"2010-12-20T02:00:00Z","reference_number":"EMA/784834/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-facilitates-interaction-between-small-and-medium-sized-enterprises-smes_en.pdf"},
    {"id":"17031","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 22 to 24 July 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-07-25T02:09:21Z","last_updated_date":"2003-07-25T02:09:21Z","reference_number":"EMEA/CPMP/3971/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-22-24-july-2003_en.pdf"}    {"id":"17052","name":"Use of antibiotics in animals - European Medicines Agency to give advice to European Commission on public and animal health impact","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-04-16T12:00:00Z","last_updated_date":"2013-04-16T12:00:00Z","reference_number":"EMA/225000/2013 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/use-antibiotics-animals-european-medicines-agency-give-advice-european-commission-public-and-animal-health-impact_en.pdf"},
    {"id":"17112","name":"PRAC recommends restricting the use of codeine when used for pain relief in children","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"EMA/350259/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-restricting-use-codeine-when-used-pain-relief-children_en.pdf"},
    {"id":"17141","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the seventy first meeting of the committee for veterinary medicinal products took place in London on 6 - 8 November 2001.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-11-09T12:39:21Z","last_updated_date":"2001-11-09T12:39:21Z","reference_number":"EMEA/CVMP/1027/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-seventy-first-meeting-committee-veterinary-medicinal-products-took-place-london-6-8-november-2001_en.pdf"},
    {"id":"17178","name":"Janssen-Cilag International N.V. withdraws its application for an extension of indication for Invega (paliperidone)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-12-17T00:09:21Z","last_updated_date":"2008-12-17T00:09:21Z","reference_number":"17 December 2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/janssen-cilag-international-nv-withdraws-its-application-extension-indication-invega-paliperidone_en.pdf"},
    {"id":"17206","name":"European Medicines Agency: Committee for Medicinal Products for Human Use\n\n20-23 June 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-06-27T02:00:00Z","last_updated_date":"2005-06-27T02:00:00Z","reference_number":"EMEA/207407/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-20-23-june-2005_en.pdf"},
    {"id":"17240","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 8-10 November 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-11-11T15:46:00Z","last_updated_date":"2016-11-11T15:46:00Z","reference_number":"EMA/CVMP/713085/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-november-2016_en.pdf"},
    {"id":"17248","name":"Committee for Proprietary Medicinal Products (CPMP) 37th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-04-22T02:00:00Z","last_updated_date":"1998-04-22T02:00:00Z","reference_number":"CPMP/808/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-37th-plenary-meeting_en.pdf"},
    {"id":"17260","name":"Committee for Proprietary Medicinal Products (CPMP) 20th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-10-16T02:00:00Z","last_updated_date":"1996-10-16T02:00:00Z","reference_number":"CPMP/871/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-20th-plenary-meeting_en.pdf"},
    {"id":"17298","name":"69th meeting of the Committee for Proprietary Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-04-03T02:09:21Z","last_updated_date":"2001-04-03T02:09:21Z","reference_number":"CPMP/906/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/69th-meeting-committee-proprietary-medicinal-products_en.pdf"},
    {"id":"17417","name":"WHO declares influenza pandemic – European Medicines Agency initiates crisis -management plan","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-12T02:00:00Z","last_updated_date":"2009-06-12T02:00:00Z","reference_number":"EMEA/367042/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/who-declares-influenza-pandemic-european-medicines-agency-initiates-crisis-management-plan_en.pdf"},
    {"id":"17425","name":"Antimicrobial resistance - European Medicines Agency provides advice on use of colistin and tigecycline in animals","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-07-30T14:00:00Z","last_updated_date":"2013-07-30T14:00:00Z","reference_number":"EMA/443757/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/antimicrobial-resistance-european-medicines-agency-provides-advice-use-colistin-and-tigecycline-animals_en.pdf"},
    {"id":"17443","name":"Committee for medicinal products for veterinary use: Meeting of 11-13 September 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-09-17T14:49:21Z","last_updated_date":"2007-09-17T14:49:21Z","reference_number":"EMEA/CVMP/381994/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-11-13-september-2007_en.pdf"},
    {"id":"17448","name":"PRAC recommends strengthening the restrictions on the use of valproate in women and girls","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-10T02:00:00Z","last_updated_date":"2014-10-10T02:00:00Z","reference_number":"EMA/612389/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-strengthening-restrictions-use-valproate-women-and-girls_en.pdf"},
    {"id":"17455","name":"INFAI withdraws its marketing authorisation application for Gastromotal","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-11-16T00:09:21Z","last_updated_date":"2007-11-16T00:09:21Z","reference_number":"EMEA/521472/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/infai-withdraws-its-marketing-authorisation-application-gastromotal_en.pdf"},
    {"id":"17497","name":"Scenesse recommended for rare disease that causes intolerance to sunlight","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/638997/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/scenesse-recommended-rare-disease-causes-intolerance-sunlight_en.pdf"},
    {"id":"17509","name":"15th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-07-24T02:00:00Z","last_updated_date":"2001-07-24T02:00:00Z","reference_number":"EMEA/COMP/286/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/15th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"17512","name":"Review of flupirtine-containing medicines started","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"EMA/695352/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/review-flupirtine-containing-medicines-started_en.pdf"},
    {"id":"17554","name":"European Medicines Agency’s Management Board endorses work programme 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T11:30:00Z","last_updated_date":"2013-12-17T11:30:00Z","reference_number":"EMA/783177/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-endorses-work-programme-2014_en.pdf"},
    {"id":"17555","name":"8th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-12-21T00:00:00Z","last_updated_date":"2000-12-21T00:00:00Z","reference_number":"EMEA/COMP/271/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/8th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"17608","name":"Update from the European Medicines Agency on COX-2 inhibitors","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-01-20T00:09:21Z","last_updated_date":"2005-01-20T00:09:21Z","reference_number":"EMEA/23547/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-european-medicines-agency-cox-2-inhibitors_en.pdf"},
    {"id":"17630","name":"New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/688187/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-recommendations-minimise-risks-rare-brain-infection-pml-and-type-skin-cancer-gilenya_en.pdf"},
    {"id":"17730","name":"Meeting highlights from the Paediatric Committee: 16 - 18 January 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-01-25T01:00:00Z","last_updated_date":"2008-01-25T01:00:00Z","reference_number":"EMEA/PDCO/33961/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-16-18-january-2008_en.pdf"},
    {"id":"17742","name":"Successful Rijeka conference strengthens EU-Croatian cooperation on medicines regulation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-11-18T00:09:21Z","last_updated_date":"2008-11-18T00:09:21Z","reference_number":"EMEA/605819/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/successful-rijeka-conference-strengthens-eu-croatian-cooperation-medicines-regulation_en.pdf"},
    {"id":"17747","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products -Meeting of 19 to 21 November 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-11-21T01:00:00Z","last_updated_date":"2002-11-21T01:00:00Z","reference_number":"EMEA/CPMP/5802/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-19-21-november-2002_en.pdf"},
    {"id":"17778","name":"Press Release : Entacapone (Comtess, Comtan) - Update of product information","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-11-23T01:00:00Z","last_updated_date":"1998-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-entacapone-comtess-comtan-update-product-information_en.pdf"},
    {"id":"17785","name":"European Medicines Agency concludes that benefit-risk balance of Revlimid remains positive","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T13:00:00Z","last_updated_date":"2011-09-23T13:00:00Z","reference_number":"EMA/CHMP/767843/2011 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-concludes-benefit-risk-balance-revlimid-remains-positive_en.pdf"},
    {"id":"17804","name":"Committee for Proprietary Medicinal Products (CPMP) 41st plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-09-21T02:00:00Z","last_updated_date":"1998-09-21T02:00:00Z","reference_number":"CPMP/2010/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-41st-plenary-meeting_en.pdf"},
    {"id":"17877","name":"European Medicines Agency informs doctors and patients about drug interaction between Victrelis and ritonavir-boosted HIV protease inhibitors","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T17:07:13Z","last_updated_date":"2012-02-16T17:07:13Z","reference_number":"EMA/CHMP/119622/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-informs-doctors-and-patients-about-drug-interaction-between-victrelis-and-ritonavir-boosted-hiv-protease-inhibitors_en.pdf"},
    {"id":"17884","name":"Committee for Proprietary Medical Products: 24-25 april 2001 meeting (summary)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-05-04T02:09:21Z","last_updated_date":"2001-05-04T02:09:21Z","reference_number":"CPMP/1262/01 corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medical-products-24-25-april-2001-meeting-summary_en.pdf"},
    {"id":"17907","name":"Tackling medication errors: European Medicines Agency workshop calls for coordinated EU approach","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-03-01T18:00:00Z","last_updated_date":"2013-03-01T18:00:00Z","reference_number":"EMA/130601/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/tackling-medication-errors-european-medicines-agency-workshop-calls-coordinated-eu-approach_en.pdf"},
    {"id":"17988","name":"EMA restricts use of Keytruda and Tecentriq in bladder cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/364553/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-restricts-use-keytruda-and-tecentriq-bladder-cancer_en.pdf"},
    {"id":"17997","name":"Committee for medicinal products for veterinary use: Meeting of 16-18 September 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-19T02:09:21Z","last_updated_date":"2008-09-19T02:09:21Z","reference_number":"EMEA/CVMP/473629/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-16-18-september-2008_en.pdf"},
    {"id":"18034","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 5–7 December 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"EMA/CVMP/778750/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-5-7-december-2017_en.pdf"},
    {"id":"18039","name":"First EMEA workshop with industry on Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-04-25T02:00:00Z","last_updated_date":"2001-04-25T02:00:00Z","reference_number":"COMP/141/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-emea-workshop-industry-orphan-medicinal-products_en.pdf"},
    {"id":"18042","name":"Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 18-20 May 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-05-21T02:00:00Z","last_updated_date":"2010-05-21T02:00:00Z","reference_number":"EMA/CVMP/286802/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-18-20-may-2010_en.pdf"},
    {"id":"18100","name":"Committee for Orphan Medicinal Products: February 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-02-08T01:00:00Z","last_updated_date":"2006-02-08T01:00:00Z","reference_number":"EMEA/COMP/49248/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-february-2006-meeting_en.pdf"},
    {"id":"18113","name":"Committee for Medicinal Products for Veterinary Use: Meeting of 12-14 January 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-01-15T01:00:00Z","last_updated_date":"2010-01-15T01:00:00Z","reference_number":"EMA/CVMP/6072/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-12-14-january-2010_en.pdf"},
    {"id":"18147","name":"European Medicines Agency receives interim decisions of the General Court of the EU on access to clinical and non-clinical information","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-04-30T02:00:00Z","last_updated_date":"2013-04-30T02:00:00Z","reference_number":"EMA/271410/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-receives-interim-decisions-general-court-eu-access-clinical-and-non-clinical-information_en.pdf"},
    {"id":"18152","name":"Committee for veterinary medicinal products: Meeting of 14 to 16 January 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-01-17T12:49:21Z","last_updated_date":"2003-01-17T12:49:21Z","reference_number":"EMEA/CVMP/071/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-14-16-january-2003_en.pdf"},
    {"id":"18159","name":"European Medicines Agency concludes on use of celecoxib in familial adenomatous polyposis","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/384697/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-concludes-use-celecoxib-familial-adenomatous-polyposis_en.pdf"},
    {"id":"18180","name":"Twenty-fourth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-12-02T01:00:00Z","last_updated_date":"1999-12-02T01:00:00Z","reference_number":"EMEA/MB/075/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/twenty-fourth-meeting-management-board_en.pdf"},
    {"id":"18192","name":"European Medicines Agency statement on Herceptin","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-09-22T02:00:00Z","last_updated_date":"2005-09-22T02:00:00Z","reference_number":"EMEA/312626/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-statement-herceptin_en.pdf"},
    {"id":"18193","name":"EMA recommends suspending the veterinary medicine Velactis used in dairy cows at the time of drying off","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-07-15T02:00:00Z","last_updated_date":"2016-07-15T02:00:00Z","reference_number":"EMA/484068/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-suspending-veterinary-medicine-velactis-used-dairy-cows-time-drying_en.pdf"},
    {"id":"18197","name":"Committee for Proprietary Medicinal Products (CPMP) 28th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-06-20T02:00:00Z","last_updated_date":"1997-06-20T02:00:00Z","reference_number":"CPMP/502/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-28th-plenary-meeting_en.pdf"},
    {"id":"18211","name":"Committee for veterinary medicinal products: 63rd meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-02-15T12:39:21Z","last_updated_date":"2001-02-15T12:39:21Z","reference_number":"EMEA/CVMP/207/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-63rd-meeting_en.pdf"},
    {"id":"18226","name":"Merck Serono Europe Limited withdraws its marketing authorisation application for Movectro (cladribine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-02-17T01:00:00Z","last_updated_date":"2011-02-17T01:00:00Z","reference_number":"EMA/112512/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/merck-serono-europe-limited-withdraws-its-marketing-authorisation-application-movectro-cladribine_en.pdf"},
    {"id":"18227","name":"First treatment recommended for rare bone disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T14:00:00Z","last_updated_date":"2015-06-26T14:00:00Z","reference_number":"EMA/CHMP/422875/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-treatment-recommended-rare-bone-disease_en.pdf"},
    {"id":"18228","name":"24th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-05-23T02:09:21Z","last_updated_date":"2002-05-23T02:09:21Z","reference_number":"COMP/1051/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/24th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"18286","name":"European Medicines Agency recommends new malaria\n\ntreatment for approval","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/496931/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-new-malaria-treatment-approval_en.pdf"},
    {"id":"18303","name":"European Medicines Agency launches EudraGMP - The community GMP database","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-05-01T02:00:00Z","last_updated_date":"2007-05-01T02:00:00Z","reference_number":"EMEA/193640/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-launches-eudragmp-community-gmp-database_en.pdf"},
    {"id":"18307","name":"Committee for Proprietary Medicinal Products (CPMP) 19th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-09-11T02:00:00Z","last_updated_date":"1996-09-11T02:00:00Z","reference_number":"CPMP/741/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-19th-plenary-meeting_en.pdf"},
    {"id":"18329","name":"EMA recommends treatment for rare cancer in children","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/330589/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-treatment-rare-cancer-children_en.pdf"},
    {"id":"18337","name":"Medicines for the treatment of pain in children – EMEA workshop, 28 October 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-11-15T01:00:00Z","last_updated_date":"2004-11-15T01:00:00Z","reference_number":"EMEA/149436/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/medicines-treatment-pain-children-emea-workshop-28-october-2004_en.pdf"},
    {"id":"18343","name":"Committee for Proprietary Medicinal Products (CPMP) 38th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-05-29T02:00:00Z","last_updated_date":"1998-05-29T02:00:00Z","reference_number":"CPMP/975/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-38th-plenary-meeting_en.pdf"},
    {"id":"18352","name":"European Medicines Agency confirms positive benefit-risk balance of orlistat-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T17:00:00Z","last_updated_date":"2012-02-16T17:00:00Z","reference_number":"EMA/CHMP/120218/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-positive-benefit-risk-balance-orlistat-containing-medicines_en.pdf"},
    {"id":"18356","name":"Saxenda recommended for approval in weight management in adults","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-01-23T13:00:00Z","last_updated_date":"2015-01-23T13:00:00Z","reference_number":"EMA/42196/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/saxenda-recommended-approval-weight-management-adults_en.pdf"},
    {"id":"18396","name":"European Medicines Agency recommends the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-11-21T00:09:21Z","last_updated_date":"2008-11-21T00:09:21Z","reference_number":"EMEA/CHMP/613852/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-marketing-authorisation-ionsys-fentanyl-hydrochloride_en.pdf"},
    {"id":"18401","name":"Wyeth Europa Limited withdraws its marketing authorisation application for Brilence","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/342273/201","document_url":"https://www.ema.europa.eu/en/documents/press-release/wyeth-europa-limited-withdraws-its-marketing-authorisation-application-brilence_en.pdf"},
    {"id":"18442","name":"European Medicines Agency publishes a video explaining the concept of medicines under additional monitoring","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-01T12:00:00Z","last_updated_date":"2013-10-01T12:00:00Z","reference_number":"EMA/589330/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-publishes-video-explaining-concept-medicines-under-additional-monitoring_en.pdf"},
    {"id":"18443","name":"Ad hoc working group on herbal medicinal products - executive summary","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-01-28T12:39:21Z","last_updated_date":"1998-01-28T12:39:21Z","reference_number":"EMEA/HMPWG/1120/97 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/press-release/ad-hoc-working-group-herbal-medicinal-products-executive-summary_en.pdf"},
    {"id":"18455","name":"Skye Pharma PLC withdraws its application to extend the marketing\n\nauthorisation for DepoCyte","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-06-30T02:00:00Z","last_updated_date":"2006-06-30T02:00:00Z","reference_number":"EMEA/245584/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/skye-pharma-plc-withdraws-its-application-extend-marketing-authorisation-depocyte_en.pdf"},
    {"id":"18467","name":"Committee for veterinary medicinal products: Meeting of 17 to 19 June 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-06-20T14:49:21Z","last_updated_date":"2003-06-20T14:49:21Z","reference_number":"EMEA/CVMP/595/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-17-19-june-2003_en.pdf"},
    {"id":"18492","name":"European Medicines Agency recommends approval of medicine for reduction of alcohol consumption","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T13:00:00Z","last_updated_date":"2012-12-14T13:00:00Z","reference_number":"EMA/CHMP/786305/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-medicine-reduction-alcohol-consumption_en.pdf"},
    {"id":"18518","name":"Committee for veterinary medicinal products: Meeting of 11 to 13 March 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-03-14T12:39:21Z","last_updated_date":"2003-03-14T12:39:21Z","reference_number":"EMEA/CVMP/272/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-11-13-march-2003_en.pdf"},
    {"id":"18564","name":"New measures to avoid valproate exposure in pregnancy endorsed","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"EMA/145600/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-measures-avoid-valproate-exposure-pregnancy-endorsed_en.pdf"},
    {"id":"18572","name":"European Medicines Agency recommends changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise risk of blood clots","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/716841/20","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-changes-use-leukaemia-medicine-iclusig-ponatinib-order-minimise-risk-blood-clots_en.pdf"},
    {"id":"18596","name":"Novartis withdraws its application to extend the marketing authorisation for Zometa","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-11-20T00:09:21Z","last_updated_date":"2007-11-20T00:09:21Z","reference_number":"EMEA/541192/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/novartis-withdraws-its-application-extend-marketing-authorisation-zometa_en.pdf"},
    {"id":"18620","name":"Sun Pharmaceutical Industries Europe B.V. withdraws its marketing authorisation application for Doxorubicin Sun","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-21T02:00:00Z","last_updated_date":"2011-07-21T02:00:00Z","reference_number":"EMA/587515/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/sun-pharmaceutical-industries-europe-bv-withdraws-its-marketing-authorisation-application-doxorubicin-sun_en.pdf"},
    {"id":"18638","name":"27th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-09-20T02:09:21Z","last_updated_date":"2002-09-20T02:09:21Z","reference_number":"EMEA/23158/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/27th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"18648","name":"European Medicines Agency recommends approval of Gazyvaro for chronic lymphocytic leukaemia","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/307827/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-gazyvaro-chronic-lymphocytic-leukaemia_en.pdf"},
    {"id":"18670","name":"Meeting of the EMEA working party on herbal medicinal products 29 - 30 October 2001","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-11-08T01:00:00Z","last_updated_date":"2001-11-08T01:00:00Z","reference_number":"EMEA/HMPWP/83/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-emea-working-party-herbal-medicinal-products-29-30-october-2001_en.pdf"},
    {"id":"18685","name":"EMA recommends new safety measures for Zydelig","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T13:00:00Z","last_updated_date":"2016-03-18T13:00:00Z","reference_number":"EMA/201814/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-new-safety-measures-zydelig_en.pdf"},
    {"id":"18701","name":"Publication of clinical reports","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2014-10-02T19:00:00Z","reference_number":"EMA/601455/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/publication-clinical-reports_en.pdf"},
    {"id":"18767","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n17-19 March 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-03-20T00:09:21Z","last_updated_date":"2008-03-20T00:09:21Z","reference_number":"EMEA/CHMP/140780/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-17-19-march-2008_en.pdf"},
    {"id":"18783","name":"European Medicines Agency review of pandemic vaccines underway","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-07-24T02:00:00Z","last_updated_date":"2009-07-24T02:00:00Z","reference_number":"EMEA/468568/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-review-pandemic-vaccines-underway_en.pdf"},
    {"id":"18786","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 18-21 January 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-01-28T00:09:21Z","last_updated_date":"2010-01-28T00:09:21Z","reference_number":"EMA/CHMP/32068/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-january-2010_en.pdf"},
    {"id":"18794","name":"PRAC review does not confirm increase in heart problems with testosterone medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-10T02:00:00Z","last_updated_date":"2014-10-10T02:00:00Z","reference_number":"EMA/611318/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-review-does-not-confirm-increase-heart-problems-testosterone-medicines_en.pdf"},
    {"id":"18796","name":"European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T01:00:00Z","last_updated_date":"2013-01-18T16:03:00Z","reference_number":"EMA/CHMP/21862/2013 Rev","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-recommendation-suspend-tredaptive-pelzont-and-trevaclyn_en.pdf"},
    {"id":"18829","name":"PRAC recommends updating advice on use of high-dose ibuprofen","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-04-13T12:00:00Z","last_updated_date":"2015-04-13T12:00:00Z","reference_number":"EMA/217862/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-updating-advice-use-high-dose-ibuprofen_en.pdf"},
    {"id":"18835","name":"Celgene Europe Limited withdraws its marketing authorisation application for Lenalidomide Celgene Europe (lenalidomide)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-04T02:00:00Z","last_updated_date":"2008-06-04T02:00:00Z","reference_number":"EMEA/291600/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/celgene-europe-limited-withdraws-its-marketing-authorisation-application-lenalidomide-celgene-europe-lenalidomide_en.pdf"},
    {"id":"18839","name":"European Medicines Agency starts review of rosiglitazone-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-07-09T02:00:00Z","last_updated_date":"2010-07-09T02:00:00Z","reference_number":"EMA/425166/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-review-rosiglitazone-containing-medicines_en.pdf"},
    {"id":"18853","name":"CIS bio international withdraw their application for Scintimum","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-05-22T02:00:00Z","last_updated_date":"2006-05-22T02:00:00Z","reference_number":"EMEA/183848/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/cis-bio-international-withdraw-their-application-scintimum_en.pdf"},
    {"id":"18911","name":"European Medicines Agency reorganisation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"EMA/277449/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-reorganisation_en.pdf"},
    {"id":"18941","name":"Update on somatropin-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-16T02:00:00Z","last_updated_date":"2010-12-16T02:00:00Z","reference_number":"EMA/CHMP/820649/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-somatropin-containing-medicines_en.pdf"},
    {"id":"18952","name":"18th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-02-12T13:40:00Z","last_updated_date":"1997-02-12T13:40:00Z","reference_number":"EMEA/CVMP/059/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/18th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"18963","name":"14th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-06-13T02:00:00Z","last_updated_date":"2001-06-13T02:00:00Z","reference_number":"COMP/243/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/14th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"18967","name":"European Medicines Agency starts review of ibuprofen medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T17:00:00Z","last_updated_date":"2014-06-13T17:00:00Z","reference_number":"EMA/348597/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-review-ibuprofen-medicines_en.pdf"},
    {"id":"18974","name":"PRAC recommends suspending use of Protelos/Osseor","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-01-10T13:00:00Z","last_updated_date":"2014-01-10T13:00:00Z","reference_number":"EMA/10206/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-suspending-use-protelososseor_en.pdf"},
    {"id":"19083","name":"European Medicines Agency’s Management Board welcomes new civil-society members","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T01:00:00Z","last_updated_date":"2013-03-25T01:00:00Z","reference_number":"EMA/183166/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-welcomes-new-civil-society-members_en.pdf"},
    {"id":"19120","name":"European Medicines Agency recommends lifting of suspension for Viracept","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2007-09-20T02:00:00Z","reference_number":"EMEA/418168/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-lifting-suspension-viracept_en.pdf"},
    {"id":"19137","name":"Committee for medicinal products for veterinary use: Meeting of 10-12 March 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-03-13T00:09:21Z","last_updated_date":"2009-03-13T00:09:21Z","reference_number":"EMEA/CVMP/126568/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-10-12-march-2009_en.pdf"},
    {"id":"19142","name":"European Medicines Agency launches a new version of EudraCT","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"EMA/563462/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-launches-new-version-eudract_en.pdf"},
    {"id":"19165","name":"Committee for Orphan Medicinal Products: November 2005 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-11-11T01:00:00Z","last_updated_date":"2005-11-11T01:00:00Z","reference_number":"EMEA/COMP/ 375618/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-november-2005-meeting_en.pdf"},
    {"id":"19183","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products 23-25 November 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-09-25T02:09:21Z","last_updated_date":"2003-09-25T02:09:21Z","reference_number":"EMEA/CPMP/4817/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-23-25-november-2003_en.pdf"},
    {"id":"19218","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 April 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-04-18T02:00:00Z","last_updated_date":"2017-04-18T02:00:00Z","reference_number":"EMA/CVMP/215817/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-10-12-april-2017_en.pdf"},
    {"id":"19224","name":"CMDh confirms that methylprednisolone injections containing lactose must not be given to patients allergic to cow's milk proteins","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T02:00:00Z","last_updated_date":"2017-08-01T02:00:00Z","reference_number":"EMA/443893/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_en.pdf"},
    {"id":"19225","name":"Twenty-seventh meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-10-23T02:00:00Z","last_updated_date":"2000-10-23T02:00:00Z","reference_number":"EMEA/MB/43/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/twenty-seventh-meeting-management-board_en.pdf"},
    {"id":"19229","name":"European Medicines Agency recommends restricting use of Pandemrix","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-21T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/CHMP/568830/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-pandemrix_en.pdf"},
    {"id":"19237","name":"European Medicines Agency recommends withdrawal of marketing authorisations for cough medicines containing clobutinol","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-10-18T02:00:00Z","last_updated_date":"2007-10-18T02:00:00Z","reference_number":"EMEA/480863/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-withdrawal-marketing-authorisations-cough-medicines-containing-clobutinol_en.pdf"},
    {"id":"19252","name":"New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/377372/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_en.pdf"}    {"id":"19272","name":"28th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-01-15T12:09:21Z","last_updated_date":"1998-01-15T12:09:21Z","reference_number":"EMEA/CVMP/037/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/28th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19282","name":"Committee for Proprietary Medicinal Products (CPMP) 45th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"CPMP/159/1999","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-45th-plenary-meeting_en.pdf"},
    {"id":"19285","name":"European Medicines Agency recommends first-in-class medicine for treatment of cystic fibrosis","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-05-25T14:05:00Z","last_updated_date":"2012-05-25T14:05:00Z","reference_number":"EMA/CHMP/343656/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-first-class-medicine-treatment-cystic-fibrosis_en.pdf"},
    {"id":"19312","name":"Commitee for Orphan Medicinal Products: February 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-02-09T01:00:00Z","last_updated_date":"2004-02-09T01:00:00Z","reference_number":"EMEA/COMP/66/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-february-2004-meeting_en.pdf"},
    {"id":"19353","name":"EMEA holds first meeting of Committee for Advanced Therapies (CAT)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-01-16T00:00:00Z","last_updated_date":"2009-01-16T00:00:00Z","reference_number":"EMEA/7866/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-holds-first-meeting-committee-advanced-therapies-cat_en.pdf"},
    {"id":"19359","name":"Committee for Orphan Medicinal Products: May 2005 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-05-18T02:00:00Z","last_updated_date":"2005-05-18T02:00:00Z","reference_number":"EMEA/COMP/162001/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-may-2005-meeting_en.pdf"},
    {"id":"19370","name":"European Medicines Agency concludes that benefit-risk balance of Invirase remains positive","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-10-21T02:00:00Z","last_updated_date":"2010-10-21T02:00:00Z","reference_number":"EMA/CHMP/648226/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-concludes-benefit-risk-balance-invirase-remains-positive_en.pdf"},
    {"id":"19376","name":"European Medicines Agency recommends restricted use and strengthened warnings for Ketek","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-03-30T02:00:00Z","last_updated_date":"2007-03-30T02:00:00Z","reference_number":"EMEA/129901/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricted-use-and-strengthened-warnings-ketek_en.pdf"},
    {"id":"19382","name":"Amarin Neuroscience Ltd withdraws its marketing authorisation application for Ethyl Eicosapent Soft Capsules (ethyl eicosapent)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-08T01:00:00Z","last_updated_date":"2009-12-08T01:00:00Z","reference_number":"EMA/796337/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/amarin-neuroscience-ltd-withdraws-its-marketing-authorisation-application-ethyl-eicosapent-soft-capsules-ethyl-eicosapent_en.pdf"},
    {"id":"19386","name":"New medicine to treat perianal fistulas in patients with Crohn’s disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T13:00:05Z","last_updated_date":"2017-12-15T13:00:05Z","reference_number":"EMA/827755/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-treat-perianal-fistulas-patients-crohns-disease_en.pdf"},
    {"id":"19432","name":"PRAC recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T14:00:00Z","last_updated_date":"2013-06-14T14:00:00Z","reference_number":"EMA/353084/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-same-cardiovascular-precautions-diclofenac-selective-cox-2-inhibitors_en.pdf"},
    {"id":"19441","name":"Committee for veterinary medicinal products: 55th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-05-18T02:09:21Z","last_updated_date":"2000-05-18T02:09:21Z","reference_number":"EMEA/CVMP/373/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-55th-meeting_en.pdf"},
    {"id":"19455","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 7-9 July 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-07-10T17:00:00Z","last_updated_date":"2015-07-10T17:00:00Z","reference_number":"EMA/CVMP/426922/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-7-9-july-2015_en.pdf"},
    {"id":"19465","name":"EMEA passes milestone of 40th positive opinion for an orphan medicinal product","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-03T02:00:00Z","last_updated_date":"2007-07-03T02:00:00Z","reference_number":"EMEA/290061/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-passes-milestone-40th-positive-opinion-orphan-medicinal-product_en.pdf"},
    {"id":"19475","name":"European Medicines Agency gives first opinion on compassionate use","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-01-22T01:00:00Z","last_updated_date":"2010-01-22T01:00:00Z","reference_number":"EMA/42438/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-first-opinion-compassionate-use_en.pdf"},
    {"id":"19477","name":"12th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-04-17T02:00:00Z","last_updated_date":"2001-04-17T02:00:00Z","reference_number":"COMP/140/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/12th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"19514","name":"European Medicines Agency reaffirms efficacy and safety of H1N1 pandemic vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-11-20T00:09:21Z","last_updated_date":"2009-11-20T00:09:21Z","reference_number":"EMEA/748707/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-reaffirms-efficacy-and-safety-h1n1-pandemic-vaccines_en.pdf"},
    {"id":"19555","name":"New treatment for patients with soft tissue sarcoma","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/CHMP/605971/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-patients-soft-tissue-sarcoma_en.pdf"},
    {"id":"19561","name":"Lynparza recommended for approval in ovarian cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/648393/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/lynparza-recommended-approval-ovarian-cancer_en.pdf"},
    {"id":"19586","name":"European Medicines Agency recommends approval of first radiopharmaceutical for PET imaging of β-amyloid neuritic plaque density","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T14:33:41Z","last_updated_date":"2012-10-19T14:33:41Z","reference_number":"EMA/CHMP/670812/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-first-radiopharmaceutical-pet-imaging-i2-amyloid-neuritic-plaque-density_en.pdf"},
    {"id":"19624","name":"Sanofi-aventis withdraws its marketing authorisation application for Mulsevo (semuloparin sodium)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-07-09T16:09:00Z","last_updated_date":"2012-07-09T16:09:00Z","reference_number":"EMA/450864/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/sanofi-aventis-withdraws-its-marketing-authorisation-application-mulsevo-semuloparin-sodium_en.pdf"},
    {"id":"19682","name":"European Medicines Agency finds no signal for decreased effectiveness of  HBVAXPRO and Procomvax","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-05-08T02:00:00Z","last_updated_date":"2006-05-08T02:00:00Z","reference_number":"EMEA/151041/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-finds-no-signal-decreased-effectiveness-hbvaxpro-and-procomvax_en.pdf"},
    {"id":"19685","name":"First stem-cell therapy recommended for approval in EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-12-19T13:00:00Z","last_updated_date":"2014-12-19T13:00:00Z","reference_number":"EMA/786996/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-stem-cell-therapy-recommended-approval-eu_en.pdf"},
    {"id":"19751","name":"9th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-01-18T00:00:00Z","last_updated_date":"2001-01-18T00:00:00Z","reference_number":"COMP/16/01 corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/9th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"19756","name":"Committee for Proprietary Medicinal Products (CPMP) 66th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-12-18T01:00:00Z","last_updated_date":"2000-12-18T01:00:00Z","reference_number":"CPMP/4305/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-66th-plenary-meeting_en.pdf"},
    {"id":"19763","name":"New restrictions to minimise the risks of effects on heart rhythm with hydroxyzine-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-03-27T01:00:00Z","reference_number":"EMA/149624/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_en.pdf"},
    {"id":"19791","name":"EMEA to review COX-2 inhibitors","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-10-22T02:00:00Z","last_updated_date":"2004-10-22T02:00:00Z","reference_number":"London, 22 October 2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-review-cox-2-inhibitors_en.pdf"},
    {"id":"19816","name":"New treatment for breast cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/CHMP/608772/2016 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-breast-cancer_en.pdf"},
    {"id":"19861","name":"First hormone replacement therapy for parathyroid disorder","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2017-02-24T01:00:00Z","reference_number":"EMA/CHMP/124164/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-hormone-replacement-therapy-parathyroid-disorder_en.pdf"},
    {"id":"19863","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the seventy third meeting of the committee for veterinary medicinal products took place in London on 8 - 10 January 2002.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-01-10T12:29:21Z","last_updated_date":"2002-01-10T12:29:21Z","reference_number":"EMEA/CVMP/065/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-seventy-third-meeting-committee-veterinary-medicinal-products-took-place-london-8-10-january-2002_en.pdf"},
    {"id":"19877","name":"European Medicines Agency’s Management Board nominates Guido Rasi as new Executive Director","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-08T19:41:48Z","last_updated_date":"2011-06-10T19:41:48Z","reference_number":"EMA/348365/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-nominates-guido-rasi-new-executive-director_en.pdf"},
    {"id":"19920","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 September 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-09-13T02:00:00Z","last_updated_date":"2013-09-13T02:00:00Z","reference_number":"EMA/CVMP/494034/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-10-12-september-2013_en.pdf"},
    {"id":"19936","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 12-14 July 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-07-15T17:00:00Z","last_updated_date":"2016-07-15T17:00:00Z","reference_number":"EMA/CVMP/454098/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-12-14-july-2016_en.pdf"},
    {"id":"19937","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 23 to 25 April 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-04-28T02:00:00Z","last_updated_date":"2003-04-28T02:00:00Z","reference_number":"EMEA/CPMP/2376/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-23-25-april-2003_en.pdf"},
    {"id":"19953","name":"Countries should reduce use of colistin in animals to decrease the risk of antimicrobial resistance","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-07-27T13:00:00Z","last_updated_date":"2016-07-27T13:00:00Z","reference_number":"EMA/480583/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/countries-should-reduce-use-colistin-animals-decrease-risk-antimicrobial-resistance_en.pdf"},
    {"id":"19960","name":"Sun Pharmaceutical Industries Europe B.V. withdraws its marketing authorisation application for Repaglinide SUN (repaglinide)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-03-25T01:00:00Z","last_updated_date":"2010-03-25T01:00:00Z","reference_number":"EMA/174503/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/sun-pharmaceutical-industries-europe-bv-withdraws-its-marketing-authorisation-application-repaglinide-sun-repaglinide_en.pdf"},
    {"id":"19968","name":"9th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1996-02-07T12:49:21Z","last_updated_date":"1996-02-07T12:49:21Z","reference_number":"EMEA/CVMP/021/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/9th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"19996","name":"Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/303056/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/sepracor-pharmaceuticals-ltd-withdraws-its-marketing-authorisation-application-lunivia_en.pdf"},
    {"id":"20011","name":"EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"EMA/459276/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity_en.pdf"},
    {"id":"20035","name":"New pharmacovigilance legislation comes into operation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-07-02T14:14:07Z","last_updated_date":"2012-07-02T14:14:07Z","reference_number":"EMA/441425/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-pharmacovigilance-legislation-comes-operation_en.pdf"},
    {"id":"20088","name":"Committee for medicinal products for veterinary use: Meeting of 16-18 June 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:09:21Z","last_updated_date":"2009-06-19T02:09:21Z","reference_number":"EMEA/CVMP/343596/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-16-18-june-2009_en.pdf"},
    {"id":"20102","name":"AstraZeneca withdraws its application for Ximelagatran 36-mg film-coated tablets","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-02-16T00:09:21Z","last_updated_date":"2006-02-16T00:09:21Z","reference_number":"EMEA/57827/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/astrazeneca-withdraws-its-application-ximelagatran-36-mg-film-coated-tablets_en.pdf"},
    {"id":"20157","name":"EMA recommends suspension of medicines over flawed studies at Semler Research Centre","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/489380/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_en.pdf"},
    {"id":"20163","name":"GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa (casopitant mesilate)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-13T02:09:21Z","last_updated_date":"2009-10-13T02:09:21Z","reference_number":"EMEA/639598/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/glaxosmithkline-withdraws-its-marketing-authorisation-application-zunrisa-casopitant-mesilate_en.pdf"},
    {"id":"20190","name":"Committee for Proprietary Medicinal Products (CPMP) 42nd plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-10-26T00:00:00Z","last_updated_date":"1998-10-26T00:00:00Z","reference_number":"CPMP/2244/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-42nd-plenary-meeting_en.pdf"},
    {"id":"20205","name":"European Medicines Agency and Swissmedic agree sharing of information on H1N1 pandemic medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-02-15T01:00:00Z","last_updated_date":"2010-02-15T01:00:00Z","reference_number":"EMA/84887/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-swissmedic-agree-sharing-information-h1n1-pandemic-medicines_en.pdf"},
    {"id":"20221","name":"Committee for Advanced Therapies gives first certification opinion for advanced therapies medicinal product","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-05-26T02:00:00Z","last_updated_date":"2010-05-26T02:00:00Z","reference_number":"EMA/CAT/328191/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-advanced-therapies-gives-first-certification-opinion-advanced-therapies-medicinal-product_en.pdf"},
    {"id":"20225","name":"21st meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-02-27T00:09:21Z","last_updated_date":"2002-02-27T00:09:21Z","reference_number":"EMEA/COMP/201/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/21st-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"20290","name":"13th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1996-07-24T14:09:21Z","last_updated_date":"1996-07-24T14:09:21Z","reference_number":"EMEA/CVMP/161/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/13th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"20442","name":"Statement  on British Biotech Pharmaceuticals Ltd.'s ZACUTEX Application of the 5th May 1998","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-05-05T02:00:00Z","last_updated_date":"1998-05-05T02:00:00Z","reference_number":"EMEA/18846/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/statement-british-biotech-pharmaceuticals-ltds-zacutex-application-5th-may-1998_en.pdf"},
    {"id":"20472","name":"Committee for veterinary medicinal products: 40th meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1999-02-18T12:09:21Z","last_updated_date":"1999-02-18T12:09:21Z","reference_number":"EMEA/CVMP/079/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-40th-meeting_en.pdf"},
    {"id":"20500","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products - Meeting of 23 to 25 April 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-04-26T02:00:00Z","last_updated_date":"2002-04-26T02:00:00Z","reference_number":"EMEA/CPMP/1747/02/en","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-23-25-april-2002_en.pdf"},
    {"id":"20513","name":"Committee for Proprietary Medicinal Products (CPMP) 33rd plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-12-19T01:00:00Z","last_updated_date":"1997-12-19T01:00:00Z","reference_number":"CPMP/1138/97 rev.","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-33rd-plenary-meeting_en.pdf"},
    {"id":"20542","name":"Committee for Proprietary Medicinal Products (CPMP) 59th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-04-17T02:00:00Z","last_updated_date":"2000-04-17T02:00:00Z","reference_number":"CPMP/941/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-59th-plenary-meeting_en.pdf"},
    {"id":"20551","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products -Meeting of 17 and 18 December 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-12-19T01:00:00Z","last_updated_date":"2002-12-19T01:00:00Z","reference_number":"EMEA/CPMP/6589/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-17-and-18-december-2002_en.pdf"},
    {"id":"20557","name":"Press release: Committee for Orphan Medicinal Products March 2007 Meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-03-08T00:09:21Z","last_updated_date":"2007-03-08T00:09:21Z","reference_number":"EMEA/COMP/84536/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-committee-orphan-medicinal-products-march-2007-meeting_en.pdf"},
    {"id":"20569","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n21-24 January 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/CHMP/28614/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-21-24-january-2008_en.pdf"},
    {"id":"20583","name":"Praluent recommended for approval to lower cholesterol","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T14:00:03Z","last_updated_date":"2015-07-24T14:00:03Z","reference_number":"EMA/CHMP/490200/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/praluent-recommended-approval-lower-cholesterol_en.pdf"},
    {"id":"20617","name":"67th meeting of the Committee for Proprietary Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-01-31T00:09:21Z","last_updated_date":"2001-01-31T00:09:21Z","reference_number":"CPMP/250/01 corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/67th-meeting-committee-proprietary-medicinal-products_en.pdf"},
    {"id":"20650","name":"EMEA recommends strengthening warnings and contraindications for etoricoxib-containing medicines used in the treatment of rheumatoid arthritis and ankylosing spondylitis","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:09:21Z","last_updated_date":"2008-06-26T02:09:21Z","reference_number":"EMEA/CHMP/333636/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-recommends-strengthening-warnings-and-contraindications-etoricoxib-containing-medicines-used-treatment-rheumatoid-arthritis-and-ankylosing-spondylitis_en.pdf"},
    {"id":"20655","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 13-16 September 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-09-16T02:00:00Z","last_updated_date":"2004-09-16T02:00:00Z","reference_number":"EMEA/74329/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-13-16-september-2004_en.pdf"},
    {"id":"20661","name":"ADHOC working group meeting on herbal medicinal products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-07-07T02:00:00Z","last_updated_date":"1998-07-07T02:00:00Z","reference_number":"EMEA/HMPC/23812/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/adhoc-working-group-meeting-herbal-medicinal-products_en.pdf"},
    {"id":"20673","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the seventy fourth meeting of the committee for veterinary medicinal products took place in London on 12 - 14 February 2002.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-02-15T12:09:21Z","last_updated_date":"2002-02-15T12:09:21Z","reference_number":"EMEA/CVMP/205/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-seventy-fourth-meeting-committee-veterinary-medicinal-products-took-place-london-12-14-february-2002_en.pdf"},
    {"id":"20710","name":"European Medicines Agency’s Management Board endorses revised EMA code of conduct","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-17T18:15:00Z","last_updated_date":"2013-06-17T18:15:00Z","reference_number":"EMA/366469/2013 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-endorses-revised-ema-code-conduct_en.pdf"},
    {"id":"20720","name":"Twenty-third Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-10-04T02:00:00Z","last_updated_date":"1999-10-04T02:00:00Z","reference_number":"EMEA/MB/056/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/twenty-third-meeting-management-board_en.pdf"},
    {"id":"20744","name":"European Medicines Agency recommends suspension of marketing authorisation of aprotinin-containing medicines for systemic use","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-12-21T00:09:21Z","last_updated_date":"2007-12-21T00:09:21Z","reference_number":"EMEA/534678/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-marketing-authorisation-aprotinin-containing-medicines-systemic-use_en.pdf"},
    {"id":"20764","name":"European Medicines Agency sees no safety concerns with the Rotarix oral vaccine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/CHMP/201923/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-sees-no-safety-concerns-rotarix-oral-vaccine_en.pdf"},
    {"id":"20783","name":"EMEA and EU accession countries meet ahead of enlargement","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-09-23T02:00:00Z","last_updated_date":"2003-09-23T02:00:00Z","reference_number":"EMEA/D/253030/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-and-eu-accession-countries-meet-ahead-enlargement_en.pdf"},
    {"id":"20784","name":"European Medicines Agency and US Food and Drug Administration announce pilot programme for parallel assessment of quality-by-design applications","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-03-16T15:00:13Z","last_updated_date":"2011-03-16T15:00:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-us-food-and-drug-administration-announce-pilot-programme-parallel-assessment-quality-design-applications_en.pdf"},
    {"id":"20818","name":"Fournier Laboratories withdraws its marketing authorisation application for Synordia","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-12-08T01:00:00Z","last_updated_date":"2006-12-08T01:00:00Z","reference_number":"EMEA/495743/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/fournier-laboratories-withdraws-its-marketing-authorisation-application-synordia_en.pdf"},
    {"id":"20832","name":"RepliGen Europe Limited withdraws its marketing authorisation application for SecreFlo (secretin human)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-09-14T12:00:00Z","last_updated_date":"2012-09-14T12:00:00Z","reference_number":"EMA/597126/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/repligen-europe-limited-withdraws-its-marketing-authorisation-application-secreflo-secretin-human_en.pdf"},
    {"id":"20877","name":"Novartis Vaccines and Diagnostics S.r.l. withdraws its application for paediatric use marketing authorisation for Fluad Paediatric (influenza vaccine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T15:00:00Z","last_updated_date":"2012-02-16T15:00:00Z","reference_number":"EMA/112567/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/novartis-vaccines-and-diagnostics-srl-withdraws-its-application-paediatric-use-marketing-authorisation-fluad-paediatric-influenza-vaccine_en.pdf"},
    {"id":"20885","name":"Committee for veterinary medicinal products: 61st meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-12-07T12:49:21Z","last_updated_date":"2000-12-07T12:49:21Z","reference_number":"EMEA/CVMP/967/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-61st-meeting_en.pdf"},
    {"id":"20896","name":"Jinarc recommended for approval in rare kidney disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/CHMP/130684/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/jinarc-recommended-approval-rare-kidney-disease_en.pdf"},
    {"id":"20957","name":"Public statement on Infliximab (Remicade) - Reports of tuberculosis infections","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-12-20T01:00:00Z","last_updated_date":"2000-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/public-statement-infliximab-remicade-reports-tuberculosis-infections_en.pdf"},
    {"id":"20964","name":"European Medicines Agency recommends lifting of supply and treatment restrictions for Neupro","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:09:21Z","last_updated_date":"2009-05-29T02:09:21Z","reference_number":"EMEA/CHMP/322964/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-lifting-supply-and-treatment-restrictions-neupro_en.pdf"},
    {"id":"20991","name":"PRAC recommends further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/169618/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-further-measures-minimise-risk-osteonecrosis-jaw-bisphosphonate-medicine_en.pdf"},
    {"id":"20998","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products - Meeting of 15 to 17 October 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-10-18T02:00:00Z","last_updated_date":"2002-10-18T02:00:00Z","reference_number":"EMEA/CPMP/5203/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-15-17-october-2002_en.pdf"},
    {"id":"21052","name":"PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroids","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-05-18T14:00:00Z","last_updated_date":"2018-05-18T14:00:00Z","reference_number":"EMA/289137/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-new-measures-minimise-risk-rare-serious-liver-injury-esmya-fibroids_en.pdf"},
    {"id":"21054","name":"Commitee for Orphan Medicinal Products: June 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-07-17T02:00:00Z","last_updated_date":"2004-07-17T02:00:00Z","reference_number":"EMEA/COMP/295/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-june-2004-meeting_en.pdf"},
    {"id":"21085","name":"EMEA Creates new Communications and Networking Unit","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-10-18T02:00:00Z","last_updated_date":"2001-10-18T02:00:00Z","reference_number":"EMEA/D/27597/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-creates-new-communications-and-networking-unit_en.pdf"},
    {"id":"21096","name":"EPAR summaries for the public: A further step for the provision of better information about medicines.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-02-02T01:00:00Z","last_updated_date":"2006-02-02T01:00:00Z","reference_number":"EMEA/40317/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/epar-summaries-public-further-step-provision-better-information-about-medicines_en.pdf"},
    {"id":"21104","name":"Towards a robust global framework for conduct and oversight of clinical trials","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-04-16T19:18:01Z","last_updated_date":"2012-04-16T19:18:01Z","reference_number":"EMA/219517/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/towards-robust-global-framework-conduct-and-oversight-clinical-trials_en.pdf"},
    {"id":"21141","name":"Committee for Orphan Medicinal Products: November 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-11-09T01:00:00Z","last_updated_date":"2006-11-09T01:00:00Z","reference_number":"EMEA/COMP/439303/2006 corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-november-2006-meeting_en.pdf"},
    {"id":"21167","name":"European Medicines Agency starts review of orlistat-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-09-22T19:00:00Z","last_updated_date":"2011-09-22T19:00:00Z","reference_number":"EMA/CHMP/771335/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-review-orlistat-containing-medicines_en.pdf"},
    {"id":"21193","name":"European Medicines Agency’s Paediatric Committee: Elects its first chairand vice-chair","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-09-27T02:00:00Z","last_updated_date":"2007-09-27T02:00:00Z","reference_number":"EMEA/441880/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-paediatric-committee-elects-its-first-chairand-vice-chair_en.pdf"},
    {"id":"21258","name":"EMEA recommends information on lung cancer cases to be included in\n\nExubera product information","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-17T02:00:00Z","last_updated_date":"2008-06-17T02:00:00Z","reference_number":"EMEA/306720/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-recommends-information-lung-cancer-cases-be-included-exubera-product-information_en.pdf"},
    {"id":"21290","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 19-21 April 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/CVMP/249719/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-19-21-april-2016_en.pdf"},
    {"id":"21310","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 6-8 October 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-10-09T02:00:00Z","last_updated_date":"2015-10-09T02:00:00Z","reference_number":"EMA/CVMP/646412/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-6-8-october-2015_en.pdf"},
    {"id":"21364","name":"Colour change for insulin injection Fiasp to avoid mix ups with Tresiba","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T13:00:00Z","last_updated_date":"2018-03-23T13:00:00Z","reference_number":"EMA/166410/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/colour-change-insulin-injection-fiasp-avoid-mix-ups-tresiba_en.pdf"},
    {"id":"21367","name":"Restrictions on use of codeine for pain relief in children – CMDh endorses PRAC recommendation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/385716/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_en.pdf"},
    {"id":"21381","name":"EMA review of Zinbryta confirms medicine’s risks outweigh its benefits","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-05-18T14:00:00Z","last_updated_date":"2018-05-18T14:00:00Z","reference_number":"EMA/286850/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_en.pdf"},
    {"id":"21387","name":"EMEA announces composition of its scientific committees","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"EMEA/15150/04/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-announces-composition-its-scientific-committees_en.pdf"},
    {"id":"21393","name":"Pharm Research Associates (UK) Ltd withdraws marketing authorisation application for Surfaxin","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-06-08T02:00:00Z","last_updated_date":"2006-06-08T02:00:00Z","reference_number":"EMEA/211505/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/pharm-research-associates-uk-ltd-withdraws-marketing-authorisation-application-surfaxin_en.pdf"},
    {"id":"21415","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 04-06 October 2016","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:00:00Z","last_updated_date":"2016-10-07T17:00:00Z","reference_number":"EMA/CVMP/626867/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-04-06-october-2016_en.pdf"},
    {"id":"21434","name":"European Medicines Agency recommends new contraindication for Fareston (toremifene)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T00:09:21Z","last_updated_date":"2009-01-23T00:09:21Z","reference_number":"EMEA/27603/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-new-contraindication-fareston-toremifene_en.pdf"},
    {"id":"21512","name":"First EMEA workshop on ethics in clinical trials - Use of placebo in clinical trials","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-12-04T00:09:21Z","last_updated_date":"2001-12-04T00:09:21Z","reference_number":"EMEA/32158/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-emea-workshop-ethics-clinical-trials-use-placebo-clinical-trials_en.pdf"},
    {"id":"21540","name":"European Medicines Agency welcomes publication of the Clinical Trials Regulation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-05-28T02:00:00Z","last_updated_date":"2014-05-28T02:00:00Z","reference_number":"EMA/324129/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-welcomes-publication-clinical-trials-regulation_en.pdf"},
    {"id":"21568","name":"European Medicines Agency concludes review of dose recommendations for anti-tuberculosis medicines used in children","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T12:00:00Z","last_updated_date":"2012-02-17T12:00:00Z","reference_number":"EMA/CHMP/123373/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-concludes-review-dose-recommendations-anti-tuberculosis-medicines-used-children_en.pdf"},
    {"id":"21574","name":"Wyeth Europa Ltd withdraws its marketing authorisation application for\n\nPristiqs (desvenlafaxine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-03-12T01:00:00Z","last_updated_date":"2008-03-12T01:00:00Z","reference_number":"EMEA/128068/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/wyeth-europa-ltd-withdraws-its-marketing-authorisation-application-pristiqs-desvenlafaxine_en.pdf"}    {"id":"21657","name":"European Medicines Agency Management Board adopt new policies on handling of conflicts of interests and on access to documents","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/618958/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-management-board-adopt-new-policies-handling-conflicts-interests-and-access-documents_en.pdf"},
    {"id":"21669","name":"16th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1996-12-13T12:09:21Z","last_updated_date":"1996-12-13T12:09:21Z","reference_number":"EMEA/CVMP/264/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/16th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"21792","name":"European and US regulators agree on mutual recognition of inspections of medicines manufacturers","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T14:00:00Z","last_updated_date":"2017-03-02T14:00:00Z","reference_number":"EMA/34520/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-and-us-regulators-agree-mutual-recognition-inspections-medicines-manufacturers_en.pdf"},
    {"id":"21820","name":"Committee for medicinal products for veterinary use: Meeting of 6 to 8 December 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-12-09T12:09:21Z","last_updated_date":"2006-12-09T12:09:21Z","reference_number":"EMEA/CVMP/401112/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-6-8-december-2005_en.pdf"},
    {"id":"21825","name":"European Medicines Agency recommends authorisation of two vaccines for influenza pandemic (H1N1) 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/602582/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-authorisation-two-vaccines-influenza-pandemic-h1n1-2009_en.pdf"},
    {"id":"21890","name":"Meeting highlights from the Paediatric Committee: 6 - 8 May 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-05-15T02:00:00Z","last_updated_date":"2008-05-15T02:00:00Z","reference_number":"EMEA/PDCO/246860/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-6-8-may-2008_en.pdf"},
    {"id":"21937","name":"European Medicines Agency recommends no changes\n\nfor Tamiflu safety information","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-12-15T00:09:21Z","last_updated_date":"2005-12-15T00:09:21Z","reference_number":"EMEA/420087/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-no-changes-tamiflu-safety-information_en.pdf"},
    {"id":"21952","name":"Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T14:00:02Z","last_updated_date":"2015-10-23T14:00:02Z","reference_number":"EMA/627077/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/updated-recommendations-minimise-risk-rare-brain-infection-pml-tecfidera_en.pdf"},
    {"id":"21964","name":"New restrictions on use of medicines containing ergot derivatives","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/385266/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-restrictions-use-medicines-containing-ergot-derivatives_en.pdf"},
    {"id":"21966","name":"European Medicines Agency and U.S. food and drug administration FDA launch good clinical practice initiative","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-08-03T02:00:00Z","last_updated_date":"2009-08-03T02:00:00Z","reference_number":"EMEA/491083/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-us-food-and-drug-administration-fda-launch-good-clinical-practice-initiative_en.pdf"},
    {"id":"22043","name":"'First-in-man' clinical trials guideline released for public consultation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-03-26T02:00:00Z","last_updated_date":"2007-03-26T02:00:00Z","reference_number":"EMEA/122833/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-man-clinical-trials-guideline-released-public-consultation_en.pdf"},
    {"id":"22046","name":"European Medicines Agency recommends suspension of oral buflomedil-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/394156/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-oral-buflomedil-containing-medicines_en.pdf"},
    {"id":"22057","name":"Schering-Plough Europe withdraws its marketing authorisation application for Zenhale (mometasone furoate/formoterol fumarate)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-11-09T01:00:00Z","last_updated_date":"2010-11-09T01:00:00Z","reference_number":"EMA/700091/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/schering-plough-europe-withdraws-its-marketing-authorisation-application-zenhale-mometasone-furoateformoterol-fumarate_en.pdf"},
    {"id":"22060","name":"33rd meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-06-11T02:09:21Z","last_updated_date":"1998-06-11T02:09:21Z","reference_number":"EMEA/CVMP/257/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/33rd-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22077","name":"Committee for veterinary medicinal products: 43rd meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1999-05-12T14:09:21Z","last_updated_date":"1999-05-12T14:09:21Z","reference_number":"EMEA/CVMP/305/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-43rd-meeting_en.pdf"},
    {"id":"22090","name":"Committee for medicinal products for veterinary use: Meeting of 17 to 18 May 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-05-19T14:09:21Z","last_updated_date":"2005-05-19T14:09:21Z","reference_number":"EMEA/CVMP/153635/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-17-18-may-2005_en.pdf"},
    {"id":"22162","name":"Bristol-Myers Squibb Pharma EEIG withdraws its marketing authorisation\n\napplication for DuoCover","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-05-27T02:00:00Z","last_updated_date":"2008-05-27T02:00:00Z","reference_number":"EMEA/CHMP/275215/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/bristol-myers-squibb-pharma-eeig-withdraws-its-marketing-authorisation-application-duocover_en.pdf"},
    {"id":"22193","name":"Committee for veterinary medicinal products: 42nd meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-04-15T02:09:21Z","last_updated_date":"2009-04-15T02:09:21Z","reference_number":"EMEA/CVMP/217/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-42nd-meeting_en.pdf"},
    {"id":"22206","name":"Two new paediatric-use marketing authorisations recommended by CHMP","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/504263/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/two-new-paediatric-use-marketing-authorisations-recommended-chmp_en.pdf"},
    {"id":"22217","name":"Committee for medicinal products for veterinary use: Meeting of 14-16 July 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-07-17T02:09:21Z","last_updated_date":"2009-07-17T02:09:21Z","reference_number":"EMEA/CVMP/417960/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-14-16-july-2009_en.pdf"},
    {"id":"22346","name":"European Medicines Agency recommends that Protelos/Osseor remain available but with further restrictions","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/84749/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-protelososseor-remain-available-further-restrictions_en.pdf"},
    {"id":"22359","name":"Launch of PRIME – Paving the way for promising medicines for patients","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2016-03-07T12:00:00Z","reference_number":"EMA/89921/2016 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/launch-prime-paving-way-promising-medicines-patients_en.pdf"},
    {"id":"22415","name":"New treatment option for rare inflammatory disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2018-02-23T01:00:00Z","reference_number":"EMA/CHMP/111554/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-option-rare-inflammatory-disease_en.pdf"},
    {"id":"22422","name":"10th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1996-03-22T12:49:21Z","last_updated_date":"1996-03-22T12:49:21Z","reference_number":"EMEA/CVMP/053/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/10th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"22435","name":"European Medicines Agency recommends restricting the use of modafinil","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/459173/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-modafinil_en.pdf"},
    {"id":"22446","name":"Alcon Laboratories (UK) Ltd withdraws its application to extend the marketing authorisation for Opatanol","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-02-23T01:00:00Z","last_updated_date":"2006-02-23T01:00:00Z","reference_number":"EMEA/57801/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/alcon-laboratories-uk-ltd-withdraws-its-application-extend-marketing-authorisation-opatanol_en.pdf"},
    {"id":"22459","name":"European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-07-25T01:31:00Z","last_updated_date":"2008-07-25T01:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-oral-moxifloxacin-containing-medicines_en.pdf"},
    {"id":"22463","name":"Thirty-second meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-12-20T00:09:21Z","last_updated_date":"2001-12-20T00:09:21Z","reference_number":"EMEA/MB/064/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/thirty-second-meeting-management-board_en.pdf"},
    {"id":"22472","name":"European Medicines Agency updates on ongoing benefit-risk review of Multaq","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-21T17:57:09Z","last_updated_date":"2011-07-21T17:57:09Z","reference_number":"EMA/581775/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-ongoing-benefit-risk-review-multaq_en.pdf"},
    {"id":"22504","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 18 to 19 March 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-03-20T01:00:00Z","last_updated_date":"2003-03-20T01:00:00Z","reference_number":"EMEA/CPMP/1611/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-18-19-march-2003_en.pdf"},
    {"id":"22519","name":"Identifying research priorities for the study of drug-related progressive multifocal leukoencephalopathy (PML)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-28T02:00:00Z","last_updated_date":"2011-07-28T02:00:00Z","reference_number":"EMA/612572/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/identifying-research-priorities-study-drug-related-progressive-multifocal-leukoencephalopathy-pml_en.pdf"},
    {"id":"22532","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 13-15 March 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-03-16T01:00:00Z","last_updated_date":"2018-03-16T01:00:00Z","reference_number":"EMA/CVMP/124685/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-13-15-march-2018_en.pdf"},
    {"id":"22678","name":"Press Release : Entacapone (Comtess, Comtan) - Update of product information","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-11-23T01:00:00Z","last_updated_date":"1998-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-entacapone-comtess-comtan-update-product-information_en.pdf-0"},
    {"id":"22709","name":"Euro Nippon Kayaku GmbH withdraws its marketing authorisation\n\napplication for Spanidin (gusperimus)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-19T02:09:21Z","last_updated_date":"2008-06-19T02:09:21Z","reference_number":"EMEA/CHMP/323118/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/euro-nippon-kayaku-gmbh-withdraws-its-marketing-authorisation-application-spanidin-gusperimus_en.pdf"},
    {"id":"22732","name":"Committee for Proprietary Medicinal Products (CPMP) 61st plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-07-04T02:00:00Z","last_updated_date":"2000-07-04T02:00:00Z","reference_number":"CPMP/1586/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-61st-plenary-meeting_en.pdf"},
    {"id":"22743","name":"European Medicines Agency recommends further measures to minimise risk of blood vessel blockage with Iclusig","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-10-24T02:00:00Z","last_updated_date":"2001-10-24T02:00:00Z","reference_number":"EMA/641476/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_en.pdf"},
    {"id":"22772","name":"AD HOC working group on herbal medicinal products meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-11-24T01:00:00Z","last_updated_date":"1997-11-24T01:00:00Z","reference_number":"EMEA/0011/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/ad-hoc-working-group-herbal-medicinal-products-meeting_en.pdf"},
    {"id":"22807","name":"Committee for Proprietary Medicinal Products (CPMP) 30th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-09-25T02:00:00Z","last_updated_date":"1997-09-25T02:00:00Z","reference_number":"CPMP/813/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-30th-plenary-meeting_en.pdf"},
    {"id":"22813","name":"Committee for Orphan Medicinal Products: October 2005 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-10-25T02:00:00Z","last_updated_date":"2005-10-25T02:00:00Z","reference_number":"EMEA/COMP/354440/2005corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-october-2005-meeting_en.pdf"},
    {"id":"22873","name":"European Medicines Agency concludes that benefit-risk balance of angiotensin II receptor antagonists remains positive","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-10-20T19:00:00Z","last_updated_date":"2011-10-20T19:00:00Z","reference_number":"EMA/CHMP/838671/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive_en.pdf"},
    {"id":"22904","name":"EMEA Management Board adopts work programme for a busy year ahead and agrees to move towards greater transparency of its meetings","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-12-17T01:00:00Z","last_updated_date":"2008-12-17T01:00:00Z","reference_number":"EMEA/663348/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-management-board-adopts-work-programme-busy-year-ahead-and-agrees-move-towards-greater-transparency-its-meetings_en.pdf"},
    {"id":"22933","name":"European Medicines Agency update on Diane 35 and generics used in the treatment of acne","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-01-30T22:00:00Z","last_updated_date":"2013-01-31T11:00:00Z","reference_number":"EMA/65929/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-update-diane-35-and-generics-used-treatment-acne_en.pdf"},
    {"id":"22966","name":"32nd meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-02-11T01:00:00Z","last_updated_date":"2003-02-11T01:00:00Z","reference_number":"EMEA/COMP/313/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/32nd-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"23029","name":"Committee for medicinal products for veterinary use: Meeting of 15-17 July 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-07-18T02:09:21Z","last_updated_date":"2008-07-18T02:09:21Z","reference_number":"EMEA/CVMP/355401/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-15-17-july-2008_en.pdf"},
    {"id":"23034","name":"Meeting of the EMEA working party on herbal medicinal products 30 June and 1 July 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-07-09T02:00:00Z","last_updated_date":"2003-07-09T02:00:00Z","reference_number":"EMEA/HMPWP/3520/03 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-emea-working-party-herbal-medicinal-products-30-june-and-1-july-2003_en.pdf"},
    {"id":"23067","name":"Update on seasonal-influenza vaccines produced by Novartis Vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-10-26T20:03:05Z","last_updated_date":"2012-10-26T20:03:05Z","reference_number":"EMA/696434/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-seasonal-influenza-vaccines-produced-novartis-vaccines_en.pdf"},
    {"id":"23178","name":"Review of oral methadone medicines containing povidone started","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"EMA/211946/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/review-oral-methadone-medicines-containing-povidone-started_en.pdf"},
    {"id":"23196","name":"Meeting highlights from the Paediatric Committee: 4 - 6 February 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-13T01:00:00Z","last_updated_date":"2009-02-13T01:00:00Z","reference_number":"http://www.emea.europa.eu/pdfs/human/press/pr/8519","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-4-6-february-2009_en.pdf"},
    {"id":"23203","name":"Committee for Proprietary Medicinal Products (CPMP) 60th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-05-29T02:00:00Z","last_updated_date":"2000-05-29T02:00:00Z","reference_number":"CPMP/1304/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-60th-plenary-meeting_en.pdf"},
    {"id":"23235","name":"Novo Nordisk withdraws its application to extend the marketing authorisations for NovoNorm and Prandin","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-10-13T02:00:00Z","last_updated_date":"2006-10-13T02:00:00Z","reference_number":"EMEA/410100/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/novo-nordisk-withdraws-its-application-extend-marketing-authorisations-novonorm-and-prandin_en.pdf"},
    {"id":"23242","name":"European Medicines Agency completes review of polymyxin-based medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/643444/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-completes-review-polymyxin-based-medicines_en.pdf"},
    {"id":"23251","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 20-23 September 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMA/CHMP/394406/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-september-2010_en.pdf"},
    {"id":"23301","name":"Meeting highlights from the Paediatric Committee:12 - 14 March 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-04-25T02:00:00Z","last_updated_date":"2008-04-25T02:00:00Z","reference_number":"EMEA/PDCO/133735/2008-","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee12-14-march-2008_en.pdf"},
    {"id":"23306","name":"AstraZeneca withdraws its marketing authorisation application for Zactima (vandetanib)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-30T01:00:00Z","last_updated_date":"2009-10-30T01:00:00Z","reference_number":"EMEA/698692/2009 corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/astrazeneca-withdraws-its-marketing-authorisation-application-zactima-vandetanib_en.pdf"},
    {"id":"23338","name":"Committee for veterinary medicinal products: 47th meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1999-09-16T14:49:21Z","last_updated_date":"1999-09-16T14:49:21Z","reference_number":"EMEA/CVMP/623/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-47th-meeting_en.pdf"},
    {"id":"23348","name":"Committee for Proprietary Medicinal Products (CPMP) 58th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-03-20T01:00:00Z","last_updated_date":"2000-03-20T01:00:00Z","reference_number":"CPMP/543/00 corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-58th-plenary-meeting_en.pdf"},
    {"id":"23378","name":"European Medicines Agency recommends withdrawal of benfluorex from the market in European Union","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-18T01:00:00Z","last_updated_date":"2009-12-18T01:00:00Z","reference_number":"EMA/CHMP/815033/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-withdrawal-benfluorex-market-european-union_en.pdf"},
    {"id":"23383","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 February 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-02-18T01:00:00Z","last_updated_date":"2011-02-18T01:00:00Z","reference_number":"EMA/CHMP/818986/2010 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-february-2011_en.pdf"},
    {"id":"23399","name":"European Medicines Agency starts review of Gilenya (fingolimod)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-01-20T10:57:34Z","last_updated_date":"2012-01-20T10:57:34Z","reference_number":"EMA/CHMP/48716/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-review-gilenya-fingolimod_en.pdf"},
    {"id":"23447","name":"Merck Sharp & Dohme (Europe), Inc. withdraws its marketing authorisation application for Janacti (sitagliptin and pioglitazone) and related trade names","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-11-14T01:00:00Z","last_updated_date":"2011-11-14T01:00:00Z","reference_number":"EMA/887576/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/merck-sharp-dohme-europe-inc-withdraws-its-marketing-authorisation-application-janacti-sitagliptin-and-pioglitazone-and-related-trade-names_en.pdf"},
    {"id":"23481","name":"Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 3-5 May 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-05-06T02:00:00Z","last_updated_date":"2011-05-12T02:00:00Z","reference_number":"EMA/CVMP/329812/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-3-5-may-2011_en.pdf"},
    {"id":"23501","name":"Update on review of valsartan medicines due to detection of NDMA","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-08-10T02:00:00Z","last_updated_date":"2018-08-10T02:00:00Z","reference_number":"EMA/543774/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-review-valsartan-medicines-due-detection-ndma_en.pdf"},
    {"id":"23521","name":"European Medicines Agency: Committee for Medicinal Products for Human Use\n\n25-28 July 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"EMEA/246640/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-25-28-july-2005_en.pdf"},
    {"id":"23590","name":"New cell-based therapy to support stem cell transplantation in patients with high-risk blood cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/CHMP/429337/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-cell-based-therapy-support-stem-cell-transplantation-patients-high-risk-blood-cancer_en.pdf"},
    {"id":"23593","name":"Committee for veterinary medicinal products: 39th meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1999-01-14T12:09:21Z","last_updated_date":"1999-01-14T12:09:21Z","reference_number":"EMEA/CVMP/011/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-39th-meeting_en.pdf"},
    {"id":"23609","name":"PRAC recommends new measures to avoid valproate exposure in pregnancy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T01:00:00Z","last_updated_date":"2018-02-09T01:00:00Z","reference_number":"EMA/67672/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-new-measures-avoid-valproate-exposure-pregnancy_en.pdf"},
    {"id":"23688","name":"EU enlargement countries to join EMEA as observers from 1 April 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-03-31T02:00:00Z","last_updated_date":"2003-03-31T02:00:00Z","reference_number":"EMEA/D/8004/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-enlargement-countries-join-emea-observers-1-april-2003_en.pdf"},
    {"id":"23698","name":"Workshop on transparency and access to documents of the EMEA of the 30 October 1997","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-10-31T01:00:00Z","last_updated_date":"1997-10-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/workshop-transparency-and-access-documents-emea-30-october-1997_en.pdf"},
    {"id":"23711","name":"EMEA recommends changes in the storage conditions for Neupro (rotigotine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-04T02:00:00Z","last_updated_date":"2008-06-04T02:00:00Z","reference_number":"EMEA/268751/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-recommends-changes-storage-conditions-neupro-rotigotine_en.pdf"},
    {"id":"23729","name":"European Medicines Agency: Committee for Medicinal Products for Human Use\n\n14-17 November 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"EMEA/384581/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-14-17-november-2005_en.pdf"},
    {"id":"23730","name":"European Medicines Agency updates on safety of Pradaxa","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-11-18T11:06:56Z","last_updated_date":"2011-11-18T11:06:56Z","reference_number":"EMA/CHMP/903767/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-safety-pradaxa_en.pdf"},
    {"id":"23751","name":"European Medicines Agency recommends authorisation of additional vaccine for influenza pandemic (H1N1) 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-02T02:00:00Z","last_updated_date":"2009-10-02T02:00:00Z","reference_number":"EMEA/622908/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-authorisation-additional-vaccine-influenza-pandemic-h1n1-2009_en.pdf"},
    {"id":"23755","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 December 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/CVMP/780667/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-11-13-december-2012_en.pdf"},
    {"id":"23761","name":"Committee for Proprietary Medicinal Products (CPMP) 18th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-07-18T02:00:00Z","last_updated_date":"1996-07-18T02:00:00Z","reference_number":"CPMP/644/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-18th-plenary-meeting_en.pdf"},
    {"id":"23764","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 18-21 October 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/CHMP/591669/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-october-2010_en.pdf"},
    {"id":"23786","name":"New medicine for multiple sclerosis","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"EMA/741144/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-multiple-sclerosis_en.pdf"},
    {"id":"23791","name":"Committee for veterinary medicinal products: 56th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-06-22T14:09:21Z","last_updated_date":"2000-06-22T14:09:21Z","reference_number":"EMEA/CVMP/461/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-56th-meeting_en.pdf"},
    {"id":"23794","name":"EMA Management Board: highlights of October 2015 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"EMA/653178/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-october-2015-meeting_en.pdf"},
    {"id":"23801","name":"European Medicines Agency finalises set of guidelines on similar biological medicines and publishes two more new concept papers","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-03-08T01:00:00Z","last_updated_date":"2006-03-08T01:00:00Z","reference_number":"EMEA/84561/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-finalises-set-guidelines-similar-biological-medicines-and-publishes-two-more-new-concept-papers_en.pdf"},
    {"id":"23811","name":"Committee for Proprietary Medicinal Products (CPMP) 34th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-01-30T00:00:00Z","last_updated_date":"1998-01-30T00:00:00Z","reference_number":"CPMP/069/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-34th-plenary-meeting_en.pdf"},
    {"id":"23826","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 5-7 February 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-02-08T01:00:00Z","last_updated_date":"2013-02-08T01:00:00Z","reference_number":"EMA/CVMP/51283/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-5-7-february-2013_en.pdf"},
    {"id":"23857","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products - Meeting of 23 to 25 July 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-07-25T02:00:00Z","last_updated_date":"2002-07-25T02:00:00Z","reference_number":"EMEA/CPMP/3677/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-23-25-july-2002_en.pdf"},
    {"id":"23874","name":"European Medicines Agency to push ahead in 2014 towards publication and access to clinical trial data","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T01:00:00Z","last_updated_date":"2013-12-17T01:00:00Z","reference_number":"EMA/780089/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-push-ahead-2014-towards-publication-and-access-clinical-trial-data_en.pdf"},
    {"id":"23904","name":"EMEA statement on the safety of Gardasil","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/37479/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-statement-safety-gardasil_en.pdf"},
    {"id":"23961","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP),  14-17 March 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"EMA/CHMP/819291/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-march-2011_en.pdf"},
    {"id":"23963","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 13-15 July 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2010-08-03T02:00:00Z","reference_number":"EMA/CVMP/416930/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-13-15-july-2010_en.pdf"},
    {"id":"23964","name":"Twenty-ninth meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-02-23T00:09:21Z","last_updated_date":"2001-02-23T00:09:21Z","reference_number":"EMEA/MB/011/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/twenty-ninth-meeting-management-board_en.pdf"},
    {"id":"23995","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 6-8 December 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-12-09T18:00:34Z","last_updated_date":"2011-12-09T18:00:34Z","reference_number":"EMA/CVMP/923371/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-6-8-december-2011_en.pdf"},
    {"id":"23999","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n11-14 December 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"EMEA/506977/2006 - corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-11-14-december-2006_en.pdf"},
    {"id":"24057","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the seventy fifth meeting of the committee for veterinary medicinal products took place in London on 12 - 14 March 2002.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-03-15T12:09:21Z","last_updated_date":"2002-03-15T12:09:21Z","reference_number":"EMEA/CVMP/319/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-seventy-fifth-meeting-committee-veterinary-medicinal-products-took-place-london-12-14-march-2002_en.pdf"},
    {"id":"24070","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 8-10 November 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-11-11T17:30:00Z","last_updated_date":"2011-11-11T17:30:00Z","reference_number":"EMA/CVMP/871652/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-november-2011_en.pdf"},
    {"id":"24074","name":"European Medicines Agency concludes new advice to doctors and patients for Champix needed","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T01:00:00Z","last_updated_date":"2007-12-14T01:00:00Z","reference_number":"EMEA/595516/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-concludes-new-advice-doctors-and-patients-champix-needed_en.pdf"},
    {"id":"24104","name":"Committee for veterinary medicinal products: 45th meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1999-07-15T14:39:21Z","last_updated_date":"1999-07-15T14:39:21Z","reference_number":"EMEA/CVMP/442/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-45th-meeting_en.pdf"},
    {"id":"24121","name":"European Medicines Agency recommends precautionary recall of remaining batch of Vistide manufactured at Ben Venue Laboratories","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-12-13T18:00:00Z","last_updated_date":"2011-12-13T18:00:00Z","reference_number":"EMA/CHMP/964006/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-precautionary-recall-remaining-batch-vistide-manufactured-ben-venue-laboratories_en.pdf"},
    {"id":"24147","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 18-21 October 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-10-19T02:00:00Z","last_updated_date":"2004-10-19T02:00:00Z","reference_number":"EMEA/116066/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-18-21-october-2004_en.pdf"},
    {"id":"24152","name":"Regulation of advanced therapy medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-06-03T14:00:00Z","last_updated_date":"2016-06-03T14:00:00Z","reference_number":"EMA/388480/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/regulation-advanced-therapy-medicines_en.pdf"},
    {"id":"24181","name":"Harvoni recommended for the treatment of chronic hepatitis C","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/584056/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/harvoni-recommended-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"24205","name":"Committee for veterinary medicinal products: 80th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-09-06T14:09:21Z","last_updated_date":"2002-09-06T14:09:21Z","reference_number":"EMEA/CVMP/834/02-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-80th-meeting_en.pdf"},
    {"id":"24210","name":"European Medicines Agency advises of risk of fever in young children following vaccination with Pandemrix","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-04T00:09:21Z","last_updated_date":"2009-12-04T00:09:21Z","reference_number":"EMEA/784404/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-advises-risk-fever-young-children-following-vaccination-pandemrix_en.pdf"},
    {"id":"24245","name":"EMEA-coordinated PROTECT project has been accepted for funding bythe Innovative Medicines Initiative Joint Undertaking","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-04-29T02:00:00Z","last_updated_date":"2009-04-29T02:00:00Z","reference_number":"EMEA/230677/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-coordinated-protect-project-has-been-accepted-funding-bythe-innovative-medicines-initiative-joint-undertaking_en.pdf"}    {"id":"24253","name":"New medicine for hereditary rare disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T02:00:00Z","last_updated_date":"2018-06-01T02:00:00Z","reference_number":"EMA/CHMP/366535/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-hereditary-rare-disease_en.pdf"},
    {"id":"24264","name":"Committee for veterinary medicinal products: 57th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-07-20T19:09:21Z","last_updated_date":"2000-07-20T19:09:21Z","reference_number":"EMEA/CVMP/570/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-57th-meeting_en.pdf"},
    {"id":"24294","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products - Meeting of 28 to 30 May 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-05-31T02:00:00Z","last_updated_date":"2002-05-31T02:00:00Z","reference_number":"EMEA/CPMP/2341/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-28-30-may-2002_en.pdf"},
    {"id":"24298","name":"Committee for Proprietary Medicinal Products (CPMP) 44th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-12-21T00:00:00Z","last_updated_date":"1998-12-21T00:00:00Z","reference_number":"CPMP/2866/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-44th-plenary-meeting_en.pdf"},
    {"id":"24344","name":"European Medicines Agency recommends restricting use of Multaq","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-09-22T19:00:00Z","last_updated_date":"2011-09-22T19:00:00Z","reference_number":"EMA/CHMP/718819/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-multaq_en.pdf"},
    {"id":"24345","name":"Fourteenth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-06-06T02:00:00Z","last_updated_date":"1997-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/fourteenth-meeting-management-board_en.pdf"},
    {"id":"24360","name":"Esmya: new measures to minimise risk of rare but serious liver injury","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-08-08T13:00:00Z","last_updated_date":"2018-08-08T13:00:00Z","reference_number":"EMA/482522/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/esmya-new-measures-minimise-risk-rare-serious-liver-injury_en.pdf"},
    {"id":"24368","name":"Thirty-third meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-02-22T00:09:21Z","last_updated_date":"2002-02-22T00:09:21Z","reference_number":"EMEA/MB/018/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/thirty-third-meeting-management-board_en.pdf"},
    {"id":"24419","name":"European Medicines Agency holds international workshop on clinical trials in the context of global medicines development","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-09T02:00:00Z","last_updated_date":"2010-09-09T02:00:00Z","reference_number":"EMA/567306/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-holds-international-workshop-clinical-trials-context-global-medicines-development_en.pdf"},
    {"id":"24460","name":"PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"EMA/707022/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-further-restrictions-multiple-sclerosis-medicine-zinbryta-due-risk-serious-liver-damage_en.pdf"},
    {"id":"24484","name":"First oncolytic immunotherapy medicine recommended for approval","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T14:00:00Z","last_updated_date":"2015-10-23T14:00:00Z","reference_number":"EMA/CHMP/692401/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-oncolytic-immunotherapy-medicine-recommended-approval_en.pdf"},
    {"id":"24503","name":"EMA publishes comments on Member States’ hosting bids","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-03T20:50:00Z","last_updated_date":"2017-10-03T20:50:00Z","reference_number":"EMA/653607/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-publishes-comments-member-states-hosting-bids_en.pdf"},
    {"id":"24509","name":"Committee for Orphan Medicinal Products: October 2003 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-10-16T02:00:00Z","last_updated_date":"2003-10-16T02:00:00Z","reference_number":"EMEA/COMP/1509/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-october-2003-meeting_en.pdf"},
    {"id":"24529","name":"European Medicines Agency recommends approval of first-in-class treatment for metastatic or unresectable melanoma","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-12-16T13:00:00Z","last_updated_date":"2011-12-16T13:00:00Z","reference_number":"EMA/CHMP/975685/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-first-class-treatment-metastatic-or-unresectable-melanoma_en.pdf"},
    {"id":"24545","name":"Update on ongoing European review of pioglitazone–containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-09T02:00:00Z","last_updated_date":"2011-06-09T02:00:00Z","reference_number":"EMA/278128/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-ongoing-european-review-pioglitazone-containing-medicines_en.pdf"},
    {"id":"24598","name":"Committee for medicinal products for veterinary use: Meeting of 6-8 November 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-11-09T12:49:21Z","last_updated_date":"2008-11-09T12:49:21Z","reference_number":"EMEA/CVMP/498760/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-6-8-november-2007_en.pdf"},
    {"id":"24616","name":"Meeting highlights from the Committee for Medicinal Products for Human Use, 18-21 September 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-09-21T02:09:21Z","last_updated_date":"2006-09-21T02:09:21Z","reference_number":"EMEA/376832/2006/corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-18-21-september-2006_en.pdf"},
    {"id":"24633","name":"Committee for Proprietary Medicinal Products (CPMP) 10th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1995-11-29T01:00:00Z","last_updated_date":"1995-11-29T01:00:00Z","reference_number":"CPMP/832/95","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-10th-plenary-meeting_en.pdf"},
    {"id":"24682","name":"European Medicines Agency makes recommendations to minimise risk of nephrogenic systemic fibrosis with gadolinium-containing contrast agents","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-11-20T00:09:21Z","last_updated_date":"2009-11-20T00:09:21Z","reference_number":"EMEA/CHMP/739818/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-makes-recommendations-minimise-risk-nephrogenic-systemic-fibrosis-gadolinium-containing-contrast-agents_en.pdf"},
    {"id":"24696","name":"New medicine to treat heart failure recommended for approval","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-09-25T14:00:00Z","last_updated_date":"2015-09-25T14:00:00Z","reference_number":"EMA/CHMP/628846/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-treat-heart-failure-recommended-approval_en.pdf"},
    {"id":"24700","name":"Committee for Orphan Medicinal Products: July 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-07-14T02:00:00Z","last_updated_date":"2006-07-14T02:00:00Z","reference_number":"EMEA/COMP/271032/2006/Revision","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-july-2006-meeting_en.pdf"},
    {"id":"24716","name":"EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T01:00:00Z","last_updated_date":"2018-03-07T01:00:00Z","reference_number":"EMA/134289/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-immediate-suspension-and-recall-multiple-sclerosis-medicine-zinbryta_en.pdf"},
    {"id":"24724","name":"Meeting of the EMEA working party on herbal medicinal products 2 and 3 February 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-02-18T01:00:00Z","last_updated_date":"2004-02-18T01:00:00Z","reference_number":"EMEA/HMPWP/533/04 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-emea-working-party-herbal-medicinal-products-2-and-3-february-2004_en.pdf"},
    {"id":"24742","name":"Sun Pharmaceutical Industries Europe B.V. withdraws its marketing authorisation application for Topotecan SUN (topotecan)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-02-17T01:00:00Z","last_updated_date":"2011-02-17T01:00:00Z","reference_number":"EMA/134567/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/sun-pharmaceutical-industries-europe-bv-withdraws-its-marketing-authorisation-application-topotecan-sun-topotecan_en.pdf"},
    {"id":"24745","name":"Report from the ADHOC working group meeting on herbal medicinal products: 1997 1998","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-02-10T01:00:00Z","last_updated_date":"1999-02-10T01:00:00Z","reference_number":"EMEA/HMPWG/25/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/report-adhoc-working-group-meeting-herbal-medicinal-products-1997-1998_en.pdf"},
    {"id":"24800","name":"European Medicines Agency updates on development of its policy on publication and access to clinical-trial data","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-13T11:00:00Z","last_updated_date":"2013-11-13T11:00:00Z","reference_number":"EMA/690893/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-development-its-policy-publication-and-access-clinical-trial-data_en.pdf"},
    {"id":"24801","name":"European Medicines Agency, European Commission and Health Canada agree implementation plan for confidentiality arrangement","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-04-08T02:00:00Z","last_updated_date":"2009-04-08T02:00:00Z","reference_number":"EMEA/220316/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-european-commission-and-health-canada-agree-implementation-plan-confidentiality-arrangement_en.pdf"},
    {"id":"24812","name":"European Medicines Agency recommends authorisation of novel antibiotic agent","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/757738/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-authorisation-novel-antibiotic-agent_en.pdf"},
    {"id":"24830","name":"Update on EMA relocation preparedness","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-09-26T02:00:00Z","last_updated_date":"2017-09-26T02:00:00Z","reference_number":"EMA/600204/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-ema-relocation-preparedness_en.pdf"},
    {"id":"24889","name":"European Medicines Agency publishes revised Code of Conduct","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-03-18T00:09:00Z","last_updated_date":"2005-03-18T00:09:00Z","reference_number":"EMEA/98065/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-publishes-revised-code-conduct_en.pdf"},
    {"id":"24919","name":"EMEA Management Board moves for greater transparency","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-06-12T02:09:21Z","last_updated_date":"2006-06-12T02:09:21Z","reference_number":"EMEA/216787/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-management-board-moves-greater-transparency_en.pdf"},
    {"id":"24948","name":"Fourth Meeting of the Management Board of the European Agency for the Evaluation of Medical Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1994-10-28T01:00:00Z","last_updated_date":"1994-10-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/fourth-meeting-management-board-european-agency-evaluation-medical-products_en.pdf"},
    {"id":"24950","name":"Novartis Europharm Ltd withdraws its applications for an extension of the indication for Exelon and Prometax (rivastigmine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-03-15T16:00:00Z","last_updated_date":"2012-03-15T16:00:00Z","reference_number":"EMA/188585/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/novartis-europharm-ltd-withdraws-its-applications-extension-indication-exelon-and-prometax-rivastigmine_en.pdf"},
    {"id":"24964","name":"Press release: Committee for Orphan Medicinal Products September 2007 Meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-09-12T02:09:21Z","last_updated_date":"2007-09-12T02:09:21Z","reference_number":"EMEA/COMP/420207/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-committee-orphan-medicinal-products-september-2007-meeting_en.pdf"},
    {"id":"24992","name":"First Global Animal Health Conference to enhance positive environment for veterinary medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-11-08T12:09:21Z","last_updated_date":"2007-11-08T12:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-global-animal-health-conference-enhance-positive-environment-veterinary-medicines_en.pdf"},
    {"id":"25006","name":"PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-01-12T13:45:00Z","last_updated_date":"2018-01-12T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-suspending-hydroxyethyl-starch-solutions-infusion-market_en.pdf"},
    {"id":"25061","name":"European Medicines Agency’s Management Board formally appoints Guido Rasi as new Executive Director","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-10-07T02:00:00Z","last_updated_date":"2011-10-07T02:00:00Z","reference_number":"EMA/812612/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-formally-appoints-guido-rasi-new-executive-director_en.pdf"},
    {"id":"25082","name":"Patients to discuss benefit-risk evaluation of medicines with the Committee for Medicinal Products for Human Use","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/578072/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/patients-discuss-benefit-risk-evaluation-medicines-committee-medicinal-products-human-use_en.pdf"},
    {"id":"25096","name":"NicOx S.A. withdraws its marketing authorisation application for Beprana (naproxcinod)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-04-20T02:00:00Z","last_updated_date":"2011-04-20T02:00:00Z","reference_number":"EMA/322628/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/nicox-sa-withdraws-its-marketing-authorisation-application-beprana-naproxcinod_en.pdf"},
    {"id":"25097","name":"Committee for medicinal products for veterinary use: Meeting of 12 to 13 July 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-07-15T14:39:21Z","last_updated_date":"2005-07-15T14:39:21Z","reference_number":"EMEA/CVMP/216890/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-12-13-july-2005_en.pdf"},
    {"id":"25103","name":"Committee for veterinary medicinal products: Meeting of 11 to 13 November 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-11-14T12:09:21Z","last_updated_date":"2003-11-14T12:09:21Z","reference_number":"EMEA/CVMP/1042/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-11-13-november-2003_en.pdf"},
    {"id":"25113","name":"CMDh endorses revocation of authorisations for fusafungine sprays used to treat airway infections","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/227560/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_en.pdf"},
    {"id":"25151","name":"Committee for medicinal products for veterinary use: Meeting of 11-13 March 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-03-14T00:09:21Z","last_updated_date":"2008-03-14T00:09:21Z","reference_number":"EMEA/CVMP/96162/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-11-13-march-2008_en.pdf"},
    {"id":"25186","name":"European Medicines Agency strengthens rules on Conflicts of Interests of its scientific experts","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-10-14T17:49:59Z","last_updated_date":"2010-10-14T17:49:59Z","reference_number":"EMA/624730/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-strengthens-rules-conflicts-interests-its-scientific-experts_en.pdf"},
    {"id":"25188","name":"Committee for Orphan Medicinal Products: December 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-12-06T01:00:00Z","last_updated_date":"2006-12-06T01:00:00Z","reference_number":"EMEA/COMP/462996/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-december-2006-meeting_en.pdf"},
    {"id":"25217","name":"Wyeth withdraws its application to extend the marketing authorisation for Tygacil","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:09:21Z","last_updated_date":"2008-04-24T02:09:21Z","reference_number":"EMEA/215870/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/wyeth-withdraws-its-application-extend-marketing-authorisation-tygacil_en.pdf"},
    {"id":"25284","name":"Updated advice on body fat changes and lactic acidosis with HIV medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T14:00:00Z","last_updated_date":"2015-10-23T14:00:00Z","reference_number":"EMA/688896/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/updated-advice-body-fat-changes-and-lactic-acidosis-hiv-medicines_en.pdf"},
    {"id":"25304","name":"PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T14:00:00Z","last_updated_date":"2013-10-11T14:00:00Z","reference_number":"EMA/606303/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-confirms-hydroxyethyl-starch-solutions-hes-should-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_en.pdf"},
    {"id":"25309","name":"Committee for Proprietary Medicinal Products (CPMP) 9th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1995-10-19T01:00:00Z","last_updated_date":"1995-10-19T01:00:00Z","reference_number":"CPMP/656/95","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-9th-plenary-meeting_en.pdf"},
    {"id":"25342","name":"European Medicines Agency recommends first gene therapy for approval","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T14:14:48Z","last_updated_date":"2012-07-20T14:14:48Z","reference_number":"EMA/CHMP/474664/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-first-gene-therapy-approval_en.pdf"},
    {"id":"25343","name":"Commitee for Orphan Medicinal Products: July 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-07-27T02:00:00Z","last_updated_date":"2004-07-27T02:00:00Z","reference_number":"EMEA/COMP/368/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-july-2004-meeting_en.pdf"},
    {"id":"25373","name":"Meeting highlights from the Paediatric Committee: 7 - 9 January 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-01-16T01:00:00Z","last_updated_date":"2009-01-16T01:00:00Z","reference_number":"EMEA/20576/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-7-9-january-2009_en.pdf"},
    {"id":"25392","name":"Meeting highlights from the Paediatric Committee: 2- 4 June 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/PDCO/296494/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-2-4-june-2008_en.pdf"},
    {"id":"25402","name":"PRAC recommends that fusafungine nose and mouth sprays are no longer marketed","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-02-12T13:00:00Z","last_updated_date":"2016-02-12T13:00:00Z","reference_number":"EMA/91073/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-fusafungine-nose-and-mouth-sprays-are-no-longer-marketed_en.pdf"},
    {"id":"25447","name":"News update from veterinary unit 14 April 1997: centralised procedure for authorisation of veterinary medicinal products in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-04-14T14:00:00Z","last_updated_date":"1997-04-14T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/news-update-veterinary-unit-14-april-1997-centralised-procedure-authorisation-veterinary-medicinal-products-eu_en.pdf"},
    {"id":"25477","name":"Novartis withdraws its marketing authorisation application for Joicela (lumiracoxib)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-04-19T02:00:00Z","last_updated_date":"2011-04-19T02:00:00Z","reference_number":"EMA/309990/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/novartis-withdraws-its-marketing-authorisation-application-joicela-lumiracoxib_en.pdf"},
    {"id":"25526","name":"Committee for medicinal products for veterinary use: Meeting of 15 to 17 June 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-06-18T14:39:21Z","last_updated_date":"2004-06-18T14:39:21Z","reference_number":"EMEA/CVMP/621/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-15-17-june-2004_en.pdf"},
    {"id":"25529","name":"Over 1000 SMEs now registered with European Medicines Agency SME office","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-09-18T16:00:00Z","last_updated_date":"2012-09-18T16:00:00Z","reference_number":"EMA/587764/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/over-1000-smes-now-registered-european-medicines-agency-sme-office_en.pdf"},
    {"id":"25532","name":"Closer ties on medicines safety between EU and Japan","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-02-05T01:00:00Z","last_updated_date":"2007-02-05T01:00:00Z","reference_number":"IP/07/135","document_url":"https://www.ema.europa.eu/en/documents/press-release/closer-ties-medicines-safety-between-eu-and-japan_en.pdf"},
    {"id":"25579","name":"Report on EFPIA info day - 22 october 1999","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-10-22T02:00:00Z","last_updated_date":"1999-10-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/report-efpia-info-day-22-october-1999_en.pdf"},
    {"id":"25622","name":"European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-10-18T02:00:00Z","last_updated_date":"2007-10-18T02:00:00Z","reference_number":"EMEA/484277/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-positive-benefit-risk-balance-rosiglitazone-and-pioglitazone_en.pdf"},
    {"id":"25625","name":"Public consultation on application of transparency rules of EU Clinical Trial Regulation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-01-21T13:00:00Z","last_updated_date":"2015-01-21T13:00:00Z","reference_number":"EMA/35075/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/public-consultation-application-transparency-rules-eu-clinical-trial-regulation_en.pdf"},
    {"id":"25640","name":"Update on review of valsartan medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T02:00:00Z","last_updated_date":"2018-09-13T02:00:00Z","reference_number":"EMA/585263/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-review-valsartan-medicines_en.pdf"},
    {"id":"25644","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 11-13 February 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-02-14T01:00:00Z","last_updated_date":"2014-02-14T01:00:00Z","reference_number":"EMA/CVMP/54452/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-11-13-february-2014_en.pdf"},
    {"id":"25671","name":"European Medicines Agency starts review of Pandemrix","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-08-27T02:00:00Z","last_updated_date":"2010-08-27T02:00:00Z","reference_number":"EMA/543435/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-review-pandemrix_en.pdf"},
    {"id":"25702","name":"Meeting highlights from the Committee for Medicinal Products for Human Use, 21-24 July 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-07-25T02:09:21Z","last_updated_date":"2008-07-25T02:09:21Z","reference_number":"EMEA/CHMP/388064/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-21-24-july-2008_en.pdf"},
    {"id":"25708","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the seventy ninth meeting of the committee for veterinary medicinal products took place in London on 9 - 11 July 2002.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-07-12T02:09:21Z","last_updated_date":"2002-07-12T02:09:21Z","reference_number":"EMEA/CVMP/713/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-seventy-ninth-meeting-committee-veterinary-medicinal-products-took-place-london-9-11-july-2002_en.pdf"},
    {"id":"25730","name":"EMEA Management Board adopts the 2007 work programme and budget","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-12-21T00:09:21Z","last_updated_date":"2006-12-21T00:09:21Z","reference_number":"EMEA/517386/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-management-board-adopts-2007-work-programme-and-budget_en.pdf"},
    {"id":"25731","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 March 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/CVMP/134814/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-10-12-march-2015_en.pdf"},
    {"id":"25753","name":"Committee for Proprietary Medicinal Products (CPMP) 12th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-01-18T01:00:00Z","last_updated_date":"1996-01-18T01:00:00Z","reference_number":"CPMP/023/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-12th-plenary-meeting_en.pdf"},
    {"id":"25782","name":"20th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-04-10T17:00:00Z","last_updated_date":"1997-04-10T17:00:00Z","reference_number":"EMEA/CVMP/134/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/20th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25808","name":"European Medicines Agency hears views from stakeholders on its conflicts-of-interests policy for scientific experts","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-09-12T11:30:00Z","last_updated_date":"2013-09-12T11:30:00Z","reference_number":"EMA/552322/2103","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-hears-views-stakeholders-its-conflicts-interests-policy-scientific-experts_en.pdf"},
    {"id":"25831","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 July 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-07-14T16:00:00Z","last_updated_date":"2017-07-14T16:00:00Z","reference_number":"EMA/CVMP/411265/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-11-13-july-2017_en.pdf"},
    {"id":"25833","name":"Pfizer withdraws its application to change the marketing authorisation for Viagra 50 mg (sildenafil) from prescription-only to non-prescription","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T00:09:21Z","last_updated_date":"2008-11-20T00:09:21Z","reference_number":"EMEA/619122/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/pfizer-withdraws-its-application-change-marketing-authorisation-viagra-50-mg-sildenafil-prescription-only-non-prescription_en.pdf"},
    {"id":"25855","name":"European Medicines Agency completes review of protamine-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T13:00:00Z","last_updated_date":"2012-11-16T13:00:00Z","reference_number":"EMA/CHMP/717405/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-completes-review-protamine-containing-medicines_en.pdf"},
    {"id":"25865","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of  5-7 May 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-05-08T18:00:00Z","last_updated_date":"2015-05-08T18:00:00Z","reference_number":"EMA/CVMP/267122/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-5-7-may-2015_en.pdf"},
    {"id":"25876","name":"New treatment for patients with multiple myeloma","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/229074/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-patients-multiple-myeloma_en.pdf"},
    {"id":"25878","name":"EMA takes yet another step in public engagement with its first public hearing","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-05T11:30:00Z","last_updated_date":"2017-10-05T11:30:00Z","reference_number":"EMA/655961/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-takes-yet-another-step-public-engagement-its-first-public-hearing_en.pdf"},
    {"id":"25890","name":"EMA identifies gaps in industry preparedness for Brexit","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-07-10T19:16:00Z","last_updated_date":"2018-07-10T19:16:00Z","reference_number":"EMA/445141/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-identifies-gaps-industry-preparedness-brexit_en.pdf"},
    {"id":"25891","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n27-30 May 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-02T02:09:21Z","last_updated_date":"2008-06-02T02:09:21Z","reference_number":"EMEA/CHMP/278126/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-27-30-may-2008_en.pdf"},
    {"id":"25903","name":"European Medicines Agency recommends suspension of marketing authorisations for meprobamate-containing medicines in the European Union","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-01-20T14:00:00Z","last_updated_date":"2012-01-20T14:00:00Z","reference_number":"EMA/CHMP/49123/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-marketing-authorisations-meprobamate-containing-medicines-european-union_en.pdf"},
    {"id":"25918","name":"Committee for Proprietary Medicinal Products (CPMP) 51st plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-07-30T02:00:00Z","last_updated_date":"1999-07-30T02:00:00Z","reference_number":"CPMP/2137/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-51st-plenary-meeting_en.pdf"},
    {"id":"25924","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products, 20-24 April 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-04-22T02:09:21Z","last_updated_date":"2004-04-22T02:09:21Z","reference_number":"EMEA/D/11206/04/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-20-24-april-2004_en.pdf"},
    {"id":"25931","name":"European Medicines Agency’s Management Board endorses work programme 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-12-16T15:00:00Z","last_updated_date":"2012-01-10T15:45:00Z","reference_number":"EMA/MB/975513/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-endorses-work-programme-2012_en.pdf"},
    {"id":"25958","name":"Committee for Proprietary Medicinal Products (CPMP) 40th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-07-27T02:00:00Z","last_updated_date":"1998-07-27T02:00:00Z","reference_number":"CPMP/1342/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-40th-plenary-meeting_en.pdf"},
    {"id":"25985","name":"29th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-02-12T12:39:21Z","last_updated_date":"1998-02-12T12:39:21Z","reference_number":"EMEA/CVMP/069/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/29th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"25990","name":"Regulatory Cooperation Expanded","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-18T02:00:00Z","last_updated_date":"2007-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/regulatory-cooperation-expanded_en.pdf"},
    {"id":"26015","name":"Committee for veterinary medicinal products: guidelines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-08-15T14:09:21Z","last_updated_date":"2001-08-15T14:09:21Z","reference_number":"EMEA/CVMP/732/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-guidelines_en.pdf"},
    {"id":"26089","name":"Record number of medicines for rare diseases recommended for approval in 2014 - Number of medicines with new active substances continues to increase","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-01-09T01:00:00Z","last_updated_date":"2015-01-09T01:00:00Z","reference_number":"EMA/9834/2015 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/record-number-medicines-rare-diseases-recommended-approval-2014-number-medicines-new-active-substances-continues-increase_en.pdf"},
    {"id":"26092","name":"Only For Children Pharmaceuticals withdraws its marketing-authorisation application for Loulla (mercaptopurine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-12-20T01:00:00Z","last_updated_date":"2012-12-20T01:00:00Z","reference_number":"EMA/820053/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/only-children-pharmaceuticals-withdraws-its-marketing-authorisation-application-loulla-mercaptopurine_en.pdf"},
    {"id":"26161","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 11-13 March 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-03-14T01:00:00Z","last_updated_date":"2014-03-14T01:00:00Z","reference_number":"EMA/CVMP/115994/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-11-13-march-2014_en.pdf"},
    {"id":"26178","name":"Eighth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1995-12-08T01:00:00Z","last_updated_date":"1995-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/eighth-meeting-management-board_en.pdf"},
    {"id":"26185","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 18-21 July 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-25T02:00:00Z","reference_number":"EMA/CHMP/557552/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2011_en.pdf"},
    {"id":"26195","name":"6th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-10-31T00:00:00Z","last_updated_date":"2000-10-31T00:00:00Z","reference_number":"EMEA/COMP/124/00 rev1","document_url":"https://www.ema.europa.eu/en/documents/press-release/6th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"26207","name":"Commitee for Orphan Medicinal Products: May 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-05-17T02:00:00Z","last_updated_date":"2004-05-17T02:00:00Z","reference_number":"EMEA/COMP/178/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-may-2004-meeting_en.pdf"},
    {"id":"26231","name":"European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T00:09:21Z","last_updated_date":"2009-02-19T00:09:21Z","reference_number":"EMEA/CHMP/20857/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-marketing-authorisation-raptiva-efalizumab_en.pdf"},
    {"id":"26236","name":"Committee for Proprietary Medicinal Products (CPMP) 46th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"CPMP/566/1999","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-46th-plenary-meeting_en.pdf"},
    {"id":"26237","name":"European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-04-20T12:00:58Z","last_updated_date":"2012-04-20T12:00:58Z","reference_number":"EMA/263105/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-new-advice-better-manage-risk-adverse-effects-heart-gilenya_en.pdf"},
    {"id":"26325","name":"European Medicines Agency update on safety of insulin glargine - Update","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/470632/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-update-safety-insulin-glargine-update_en.pdf"},
    {"id":"26335","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n22-25 June 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-26T02:09:21Z","last_updated_date":"2009-06-26T02:09:21Z","reference_number":"EMEA/CHMP/397215/2009 corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-22-25-june-2009_en.pdf"}    {"id":"26344","name":"European Medicines Agency confirms positive benefit-risk balance of MabThera","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-05-25T12:00:00Z","last_updated_date":"2012-05-25T12:00:00Z","reference_number":"EMA/CHMP/331339/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-positive-benefit-risk-balance-mabthera_en.pdf"},
    {"id":"26369","name":"European Medicines Agency confirms that presence of unexpected viral DNA in live attenuated vaccines does not raise public health concerns","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/732522/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-presence-unexpected-viral-dna-live-attenuated-vaccines-does-not-raise-public-health-concerns_en.pdf"},
    {"id":"26385","name":"Information on suspected side effects of nationally authorised medicines now available through a single website","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-06T15:00:00Z","last_updated_date":"2014-10-06T15:00:00Z","reference_number":"EMA/540282/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/information-suspected-side-effects-nationally-authorised-medicines-now-available-through-single-website_en.pdf"},
    {"id":"26391","name":"Sanofi-Aventis withdraws marketing authorisation application for MULTAQ","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-09-08T02:00:00Z","last_updated_date":"2009-09-08T02:00:00Z","reference_number":"EMEA/354409/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/sanofi-aventis-withdraws-marketing-authorisation-application-multaq_en.pdf"},
    {"id":"26408","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 5-7 April 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/CVMP/239023/2011 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-5-7-april-2011_en.pdf"},
    {"id":"26433","name":"Twenty-First Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-02-10T01:00:00Z","last_updated_date":"1999-02-10T01:00:00Z","reference_number":"EMEA/MB/015/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/twenty-first-meeting-management-board_en.pdf"},
    {"id":"26536","name":"Committee for Orphan Medicinal Products: January 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-01-12T01:00:00Z","last_updated_date":"2006-01-12T01:00:00Z","reference_number":"EMEA/COMP/11156/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-january-2006-meeting_en.pdf"},
    {"id":"26585","name":"European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T12:00:00Z","last_updated_date":"2013-07-26T12:00:00Z","reference_number":"EMA/458028/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-marketing-authorisations-oral-ketoconazole_en.pdf"},
    {"id":"26606","name":"Meeting highlights from the Paediatric Committee: 24 - 26 June 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2009-07-01T02:00:00Z","reference_number":"EMEA/PDCO/386750/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-24-26-june-2009_en.pdf"},
    {"id":"26611","name":"FGK Representative Service GmbH withdraws its marketing authorisation application for Memantine FGK (memantine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"EMA/18787/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/fgk-representative-service-gmbh-withdraws-its-marketing-authorisation-application-memantine-fgk-memantine_en.pdf"},
    {"id":"26618","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the sixty-sixth meeting of the committee for veterinary medicinal products took place in London on 15-16 May 2001.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-05-17T14:39:21Z","last_updated_date":"2001-05-17T14:39:21Z","reference_number":"EMEA/CVMP/487/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-sixty-sixth-meeting-committee-veterinary-medicinal-products-took-place-london-15-16-may-2001_en.pdf"},
    {"id":"26624","name":"Committee for medicinal products for veterinary use: Meeting of 8 to 10 March 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-03-11T12:49:21Z","last_updated_date":"2005-03-11T12:49:21Z","reference_number":"EMEA/CVMP/80966/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-8-10-march-2005_en.pdf"},
    {"id":"26642","name":"EMA gets ready for relocation decision","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-11-07T14:00:00Z","last_updated_date":"2017-11-07T14:00:00Z","reference_number":"EMA/712386/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-gets-ready-relocation-decision_en.pdf"},
    {"id":"26651","name":"Novagali Pharma S.A. withdraws its marketing authorisation application for Vekacia (ciclosporin)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-11-17T00:09:21Z","last_updated_date":"2008-11-17T00:09:21Z","reference_number":"EMEA/610677/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/novagali-pharma-sa-withdraws-its-marketing-authorisation-application-vekacia-ciclosporin_en.pdf"},
    {"id":"26684","name":"EMA and EUnetHTA step up interaction to align data requirements","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-07-04T11:00:00Z","last_updated_date":"2017-07-04T11:00:00Z","reference_number":"EMA/390765/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-and-eunethta-step-interaction-align-data-requirements_en.pdf"},
    {"id":"26786","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n20-23 October 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-10-24T02:09:21Z","last_updated_date":"2008-10-24T02:09:21Z","reference_number":"EMEA/CHMP/550206/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-20-23-october-2008_en.pdf"},
    {"id":"26803","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 13-15 June 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-06-16T02:00:00Z","last_updated_date":"2017-06-16T02:00:00Z","reference_number":"EMA/CVMP/346237/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-13-15-june-2017_en.pdf"},
    {"id":"26840","name":"CTI Life Sciences Ltd. withdraws its marketing authorisation application for Opaxio (paclitaxel poliglumex)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"EMEA/601200/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/cti-life-sciences-ltd-withdraws-its-marketing-authorisation-application-opaxio-paclitaxel-poliglumex_en.pdf"},
    {"id":"26876","name":"HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/749763/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/hpv-vaccines-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_en.pdf"},
    {"id":"26881","name":"Meeting of the EMEA working party on herbal medicinal products 4 and 5 November 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-12-04T01:00:00Z","last_updated_date":"2002-12-04T01:00:00Z","reference_number":"EMEA/HMPWP/28546/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-emea-working-party-herbal-medicinal-products-4-and-5-november-2002_en.pdf"},
    {"id":"26928","name":"EMEA Management Board considers road map 2010 and welcomes increase in new applications for human medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-10-01T02:09:21Z","last_updated_date":"2004-10-01T02:09:21Z","reference_number":"EMEA/92160/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-management-board-considers-road-map-2010-and-welcomes-increase-new-applications-human-medicines_en.pdf"},
    {"id":"26939","name":"Committee for Proprietary Medicinal Products (CPMP) 26th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-04-18T02:00:00Z","last_updated_date":"1997-04-18T02:00:00Z","reference_number":"CPMP/341/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-26th-plenary-meeting_en.pdf"},
    {"id":"26944","name":"EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/380260/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-recommends-restricted-use-oral-norfloxacin-containing-medicines-urinary-infections_en.pdf"},
    {"id":"27002","name":"“EMA ready to address challenges ahead”","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-12-09T01:00:00Z","last_updated_date":"2015-12-09T01:00:00Z","reference_number":"EMA/824301/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-ready-address-challenges-ahead_en.pdf"},
    {"id":"27026","name":"European Medicines Agency receives second application for human pandemic influenza vaccine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-02-24T01:00:00Z","last_updated_date":"2006-02-24T01:00:00Z","reference_number":"EMEA/35322/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-receives-second-application-human-pandemic-influenza-vaccine_en.pdf"},
    {"id":"27058","name":"New treatment option for patients with rare blood cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-09-25T14:00:00Z","last_updated_date":"2015-09-25T14:00:00Z","reference_number":"EMA/CHMP/628925/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-option-patients-rare-blood-cancer_en.pdf"},
    {"id":"27075","name":"Committee for veterinary medicinal products: Meeting of 8 to 9 April 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-04-11T14:59:21Z","last_updated_date":"2003-04-11T14:59:21Z","reference_number":"EMEA/CVMP/369/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-8-9-april-2003_en.pdf"},
    {"id":"27093","name":"Committee for medicinal products for veterinary use: Meeting of 15-17 September 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-09-18T02:09:21Z","last_updated_date":"2009-09-18T02:09:21Z","reference_number":"EMEA/CVMP/560974/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-15-17-september-2009_en.pdf"},
    {"id":"27101","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 10-12 July 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-07-13T02:00:00Z","last_updated_date":"2012-07-13T02:00:00Z","reference_number":"EMA/CVMP/449083/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-10-12-july-2012_en.pdf"},
    {"id":"27170","name":"European Medicines Agency updates treatment recommendations because of continued Fabrazyme shortage","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-07-06T02:00:00Z","last_updated_date":"2010-07-06T02:00:00Z","reference_number":"EMA/CHMP/428277/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-treatment-recommendations-because-continued-fabrazyme-shortage_en.pdf"},
    {"id":"27171","name":"European Medicines Agency recommends contraindications for suppositories containing terpenic derivatives","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-09-23T13:00:00Z","last_updated_date":"2011-09-23T13:00:00Z","reference_number":"EMA/CHMP/767846/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-contraindications-suppositories-containing-terpenic-derivatives_en.pdf"},
    {"id":"27197","name":"24th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-09-11T14:00:00Z","last_updated_date":"1997-09-11T14:00:00Z","reference_number":"EMEA/CVMP/301/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/24th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"27251","name":"European Medicines Agency starts safety review of Diane 35 and its generics","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-02-08T13:00:00Z","last_updated_date":"2013-02-08T13:00:00Z","reference_number":"EMA/82707/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-safety-review-diane-35-and-its-generics_en.pdf"},
    {"id":"27278","name":"European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2014-11-21T13:00:00Z","reference_number":"EMA/705247/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_en.pdf"},
    {"id":"27311","name":"Committee for medicinal products for veterinary use: Meeting of 12 to 14 October 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-10-15T14:39:21Z","last_updated_date":"2004-10-15T14:39:21Z","reference_number":"EMEA/CVMP/973/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-12-14-october-2004_en.pdf"},
    {"id":"27327","name":"Two new medicines recommended for the treatment of chronic hepatitis C","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2014-11-21T13:00:00Z","reference_number":"EMA/713585/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/two-new-medicines-recommended-treatment-chronic-hepatitis-c_en.pdf-0"},
    {"id":"27367","name":"Ranbaxy, Toansa assessment concluded: no risk to public health","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-06-04T02:00:00Z","last_updated_date":"2014-06-04T02:00:00Z","reference_number":"EMA/326127/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/ranbaxy-toansa-assessment-concluded-no-risk-public-health_en.pdf"},
    {"id":"27421","name":"PRAC recommends restricting the use of flupirtine-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"EMA/362055/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-restricting-use-flupirtine-containing-medicines_en.pdf"},
    {"id":"27447","name":"Mysimba recommended for approval in weight management in adults","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-12-19T13:00:00Z","last_updated_date":"2014-12-19T13:00:00Z","reference_number":"EMA/787060/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/mysimba-recommended-approval-weight-management-adults_en.pdf"},
    {"id":"27481","name":"Review of testosterone-containing medicines started","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:01Z","last_updated_date":"2014-04-11T14:00:01Z","reference_number":"EMA/209962/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/review-testosterone-containing-medicines-started_en.pdf"},
    {"id":"27511","name":"Start of review of ambroxol and bromhexine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-04-11T14:00:00Z","reference_number":"EMA/203011/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/start-review-ambroxol-and-bromhexine_en.pdf"},
    {"id":"27516","name":"EMEA sets out its road map to 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-04-15T02:00:00Z","last_updated_date":"2004-04-15T02:00:00Z","reference_number":"EMEA/9362/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-sets-out-its-road-map-2010_en.pdf"},
    {"id":"27540","name":"Committee for medicinal products for veterinary use: Meeting of 8 to 10 November 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-11-11T12:09:21Z","last_updated_date":"2005-11-11T12:09:21Z","reference_number":"EMEA/CVMP/360925/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-8-10-november-2005_en.pdf"},
    {"id":"27553","name":"CMDh endorses recommendations to restrict the use of diacerein-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"EMA/162540/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/cmdh-endorses-recommendations-restrict-use-diacerein-containing-medicines_en.pdf"},
    {"id":"27650","name":"Early dialogue between regulators and health technology assessment bodies key to medicines development","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-28T01:00:00Z","last_updated_date":"2013-11-28T01:00:00Z","reference_number":"EMA/738272/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/early-dialogue-between-regulators-and-health-technology-assessment-bodies-key-medicines-development_en.pdf"},
    {"id":"27664","name":"European Medicines Agency reviews cardiovascular risk of Multaq","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-11T02:00:00Z","last_updated_date":"2011-07-11T02:00:00Z","reference_number":"EMA/CHMP/542840/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-reviews-cardiovascular-risk-multaq_en.pdf"},
    {"id":"27672","name":"Modified-release paracetamol-containing products to be suspended from EU market","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T01:00:00Z","last_updated_date":"2017-12-15T01:00:00Z","reference_number":"EMA/811872/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/modified-release-paracetamol-containing-products-be-suspended-eu-market_en.pdf"},
    {"id":"27679","name":"CHMP confirms recommendations for use of Zydelig","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/488322/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/chmp-confirms-recommendations-use-zydelig_en.pdf"},
    {"id":"27680","name":"Cerdelga recommended for approval in type 1 Gaucher disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2014-11-21T13:00:00Z","reference_number":"EMA/709331/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/cerdelga-recommended-approval-type-1-gaucher-disease_en.pdf"},
    {"id":"27688","name":"19th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-12-19T00:00:00Z","last_updated_date":"2001-12-19T00:00:00Z","reference_number":"EMEA/COMP/595/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/19th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"27690","name":"Withdrawal of pain medicine flupirtine endorsed","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"EMA/153044/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/withdrawal-pain-medicine-flupirtine-endorsed_en.pdf"},
    {"id":"27735","name":"European Medicines Agency on track to meet core business targets for 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/643695/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-track-meet-core-business-targets-2012_en.pdf"},
    {"id":"27749","name":"Novartis Europharm Ltd withdraws its marketing authorisation application for Joulferon (albinterferon alfa-2b)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-04-19T02:00:00Z","last_updated_date":"2010-04-19T02:00:00Z","reference_number":"EMA/249301/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/novartis-europharm-ltd-withdraws-its-marketing-authorisation-application-joulferon-albinterferon-alfa-2b_en.pdf"},
    {"id":"27754","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n16-19 March 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-03-20T00:09:21Z","last_updated_date":"2009-03-20T00:09:21Z","reference_number":"EMEA/CHMP/172797/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-16-19-march-2009_en.pdf"},
    {"id":"27778","name":"Committee for Proprietary Medicinal Products (CPMP) 22nd plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-12-18T01:00:00Z","last_updated_date":"1996-12-18T01:00:00Z","reference_number":"CPMP/1095/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-22nd-plenary-meeting_en.pdf"},
    {"id":"27783","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 12-14 July 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2011-07-15T02:00:00Z","reference_number":"EMA/CVMP/510960/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-12-14-july-2011_en.pdf"},
    {"id":"27821","name":"European Medicines Agency finalises new procedure for EU pharmaceutical guidelines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-06-30T02:00:00Z","last_updated_date":"2005-06-30T02:00:00Z","reference_number":"EMEA/216832/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-finalises-new-procedure-eu-pharmaceutical-guidelines_en.pdf"},
    {"id":"27844","name":"Alcon Laboratories withdraws its application for RETAANE","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-03-02T01:00:00Z","last_updated_date":"2006-03-02T01:00:00Z","reference_number":"EMEA/76945/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/alcon-laboratories-withdraws-its-application-retaane_en.pdf"},
    {"id":"27863","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 13-15 September 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-09-16T02:00:00Z","last_updated_date":"2011-09-16T02:00:00Z","reference_number":"EMA/CVMP/715220/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-13-15-september-2011_en.pdf"},
    {"id":"27911","name":"Committee for medicinal products for veterinary use: Meeting of 12-14 May 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-15T02:09:21Z","last_updated_date":"2009-05-15T02:09:21Z","reference_number":"EMEA/CVMP/268320/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-12-14-may-2009_en.pdf"},
    {"id":"27914","name":"Eye injuries in people and dogs when using Osurnia ear gel for dogs","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-04-20T02:00:00Z","last_updated_date":"2018-04-20T02:00:00Z","reference_number":"EMA/246469/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/eye-injuries-people-and-dogs-when-using-osurnia-ear-gel-dogs_en.pdf"},
    {"id":"27942","name":"37th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-07-31T02:00:00Z","last_updated_date":"2003-07-31T02:00:00Z","reference_number":"EMEA/COMP/1335/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/37th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"27947","name":"Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks – CHMP endorses PRAC recommendation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/709120/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks-chmp-endorses-prac-recommendation_en.pdf"},
    {"id":"27967","name":"New Paediatric Committee holds its first meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-06T02:00:00Z","last_updated_date":"2007-07-06T02:00:00Z","reference_number":"EMEA/295689/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-paediatric-committee-holds-its-first-meeting_en.pdf"},
    {"id":"28000","name":"Committee for veterinary medicinal products: Meeting of 14 to 16 October 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-10-17T14:39:21Z","last_updated_date":"2003-10-17T14:39:21Z","reference_number":"EMEA/CVMP/943/03/corrigendum","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-14-16-october-2003_en.pdf"},
    {"id":"28048","name":"Supply shortage of Fabrazyme – updated treatment recommendations required for adult male patients","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/602583/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/supply-shortage-fabrazyme-updated-treatment-recommendations-required-adult-male-patients_en.pdf"},
    {"id":"28052","name":"European Medicines Agency and FDA announce launch of generic medicines application inspections initiative","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-18T01:00:00Z","last_updated_date":"2013-12-18T01:00:00Z","reference_number":"EMA/797904/2013 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-fda-announce-launch-generic-medicines-application-inspections-initiative_en.pdf"},
    {"id":"28060","name":"European Medicines Agency’s Management Board endorses work programme 2011 and launches new Road Map to 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/834513/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-endorses-work-programme-2011-and-launches-new-road-map-2015_en.pdf"},
    {"id":"28061","name":"New advanced therapy to repair cartilage defects in the knee","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T14:00:03Z","last_updated_date":"2017-05-19T14:00:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-advanced-therapy-repair-cartilage-defects-knee_en.pdf"},
    {"id":"28064","name":"Commitee for Orphan Medicinal Products: October 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-10-08T02:00:00Z","last_updated_date":"2004-10-08T02:00:00Z","reference_number":"EMEA/COMP/101411/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-october-2004-meeting_en.pdf"},
    {"id":"28105","name":"European Medicines Agency makes recommendations for safer use of Ritalin and other methylphenidate-containing medicines in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T00:09:21Z","last_updated_date":"2009-01-23T00:09:21Z","reference_number":"EMEA/22315/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-makes-recommendations-safer-use-ritalin-and-other-methylphenidate-containing-medicines-eu_en.pdf"},
    {"id":"28116","name":"EMEA launches Eudra Vigilance training programme","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-04-01T02:00:00Z","last_updated_date":"2004-04-01T02:00:00Z","reference_number":"EMEA/9254/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-launches-eudra-vigilance-training-programme_en.pdf"},
    {"id":"28118","name":"Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"EMA/824717/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_en.pdf"},
    {"id":"28141","name":"European Medicines Agency’s Management Board endorses revised policy on handling of declarations of interests","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-03-24T13:00:00Z","last_updated_date":"2014-03-24T13:00:00Z","reference_number":"EMA/170855/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-endorses-revised-policy-handling-declarations-interests_en.pdf"},
    {"id":"28163","name":"Committee for medicinal products for veterinary use: Meeting of 18 to 20 April 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-04-21T14:09:21Z","last_updated_date":"2006-04-21T14:09:21Z","reference_number":"EMEA/CVMP/110786/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-18-20-april-2006_en.pdf"},
    {"id":"28178","name":"European Medicines Agency recommends additional measures to better manage risk of progressive multifocal leukoencephalopathy (PML) with Tysabri","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-01-21T01:00:00Z","last_updated_date":"2010-01-21T01:00:00Z","reference_number":"EMA/37607/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-additional-measures-better-manage-risk-progressive-multifocal-leukoencephalopathy-pml-tysabri_en.pdf"},
    {"id":"28195","name":"European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T13:00:05Z","last_updated_date":"2013-11-22T13:00:05Z","reference_number":"EMA/717004/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-sofosbuvir-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"28199","name":"Committee for medicinal products for veterinary use: Meeting of 18 to 20 July 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-07-21T14:29:21Z","last_updated_date":"2006-07-21T14:29:21Z","reference_number":"EMEA/CVMP/265043/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-18-20-july-2006_en.pdf"},
    {"id":"28218","name":"SGLT2 inhibitors: PRAC makes recommendations to minimise risk of diabetic ketoacidosis","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-02-12T13:00:00Z","last_updated_date":"2016-02-12T13:00:00Z","reference_number":"EMA/100751/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/sglt2-inhibitors-prac-makes-recommendations-minimise-risk-diabetic-ketoacidosis_en.pdf"},
    {"id":"28219","name":"New EMA guidance on development of antibacterials to help in the fight against multidrug-resistant pathogens","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-07T11:35:00Z","last_updated_date":"2013-11-07T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-ema-guidance-development-antibacterials-help-fight-against-multidrug-resistant-pathogens_en.pdf"},
    {"id":"28228","name":"European Medicines Agency appoints senior medical officer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-11-08T01:00:00Z","last_updated_date":"2006-11-08T01:00:00Z","reference_number":"EMEA/405691/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-appoints-senior-medical-officer_en.pdf"},
    {"id":"28248","name":"Sanofi Pasteur withdraws its marketing authorisation application for Emerflu, pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-06T01:00:00Z","last_updated_date":"2010-12-06T01:00:00Z","reference_number":"EMA/776824/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/sanofi-pasteur-withdraws-its-marketing-authorisation-application-emerflu-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_en.pdf"},
    {"id":"28286","name":"31st meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-04-08T14:09:21Z","last_updated_date":"1998-04-08T14:09:21Z","reference_number":"EMEA/CVMP/162/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/31st-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"28455","name":"Oncoscience AG withdraws its application for Theraloc (nimotuzumab)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-12-04T00:09:21Z","last_updated_date":"2008-12-04T00:09:21Z","reference_number":"EMEA/645579/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/oncoscience-ag-withdraws-its-application-theraloc-nimotuzumab_en.pdf"},
    {"id":"28459","name":"Oral almitrine to be withdrawn by EU Member States","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T12:00:00Z","last_updated_date":"2013-05-31T12:00:00Z","reference_number":"EMA/313994/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/oral-almitrine-be-withdrawn-eu-member-states_en.pdf"},
    {"id":"28473","name":"European Medicines Agency recommends authorisation of first generic\n\nmedicine for human use","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/316728/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-authorisation-first-generic-medicine-human-use_en.pdf"},
    {"id":"28479","name":"Animal health experts call for global cooperation to boost animal health product availability and innovation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-11-23T00:09:21Z","last_updated_date":"2007-11-23T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/animal-health-experts-call-global-cooperation-boost-animal-health-product-availability-and-innovation_en.pdf"},
    {"id":"28538","name":"Committee for veterinary medicinal products: Meeting of 1 to 3 October 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-10-04T14:09:21Z","last_updated_date":"2002-10-04T14:09:21Z","reference_number":"EMEA/CVMP/969/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-1-3-october-2002_en.pdf"},
    {"id":"28572","name":"European Medicines Agency to publish information on ongoing medicine evaluations","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T16:11:11Z","last_updated_date":"2012-02-17T16:11:11Z","reference_number":"EMA/123332/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-publish-information-ongoing-medicine-evaluations_en.pdf"},
    {"id":"28585","name":"New gene therapy for the treatment of children with ultra-rare immune disorder recommended for approval","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/230486/2016 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-gene-therapy-treatment-children-ultra-rare-immune-disorder-recommended-approval_en.pdf"},
    {"id":"28627","name":"European Medicines Agency annual report for 2006 shows record numbers of applications; assessment times in core processes significantly reduced","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-03-15T00:09:21Z","last_updated_date":"2007-03-15T00:09:21Z","reference_number":"EMEA/105586/2007-corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-annual-report-2006-shows-record-numbers-applications-assessment-times-core-processes-significantly-reduced_en.pdf"},
    {"id":"28645","name":"Committee for medicinal products for veterinary use: Meeting of 12 to 14 April 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-04-15T14:39:21Z","last_updated_date":"2009-04-15T14:39:21Z","reference_number":"EMEA/CVMP/119411/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-12-14-april-2005_en.pdf"},
    {"id":"28665","name":"Committee for veterinary medicinal products: Meeting of 13 to 15 January 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-01-16T12:39:21Z","last_updated_date":"2004-01-16T12:39:21Z","reference_number":"EMEA/CVMP/081/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-13-15-january-2004_en.pdf"},
    {"id":"28671","name":"Brexit preparedness: EMA to further temporarily scale back and suspend activities","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-08-01T16:00:00Z","last_updated_date":"2018-08-01T16:00:00Z","reference_number":"EMA/483486/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/brexit-preparedness-ema-further-temporarily-scale-back-and-suspend-activities_en.pdf"},
    {"id":"28674","name":"EudraVigilance signal detection methods help detect drug safety issues earlier","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-05-25T02:00:00Z","last_updated_date":"2010-05-25T02:00:00Z","reference_number":"EMA/319375/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/eudravigilance-signal-detection-methods-help-detect-drug-safety-issues-earlier_en.pdf"},
    {"id":"28692","name":"European Medicines Agency recommends use of fibrates as second-line treatment","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/649010/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-use-fibrates-second-line-treatment_en.pdf"},
    {"id":"28707","name":"Pharmacovigilance Risk Assessment Committee (PRAC) elects chair and vice-chair","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-09-07T14:00:00Z","last_updated_date":"2012-09-07T14:00:00Z","reference_number":"EMA/PRAC/580831/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/pharmacovigilance-risk-assessment-committee-prac-elects-chair-and-vice-chair_en.pdf"},
    {"id":"28718","name":"European Medicines Agency agrees to precautionary recall of Advagraf 0.5 mg capsule batches","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-10-20T17:59:08Z","last_updated_date":"2011-10-20T17:59:08Z","reference_number":"EMA/CHMP/840800/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-agrees-precautionary-recall-advagraf-05-mg-capsule-batches_en.pdf"},
    {"id":"28806","name":"Accelerated assessment fast-tracks Lenvima to benefit patients with thyroid cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-03-27T01:00:00Z","reference_number":"EMA/CHMP/200023/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/accelerated-assessment-fast-tracks-lenvima-benefit-patients-thyroid-cancer_en.pdf"},
    {"id":"28823","name":"PRAC recommends using acipimox only as additional or alternative treatment to lower high triglyceride levels","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-08T13:00:01Z","last_updated_date":"2013-11-08T13:00:01Z","reference_number":"EMA/618574/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-using-acipimox-only-additional-or-alternative-treatment-lower-high-triglyceride-levels_en.pdf"}    {"id":"28904","name":"Press Release: Committee for Orphan Medicinal Products April 2007 Meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-04-16T02:09:21Z","last_updated_date":"2007-04-16T02:09:21Z","reference_number":"EMEA/COMP/142534/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-committee-orphan-medicinal-products-april-2007-meeting_en.pdf"},
    {"id":"28906","name":"European Medicines Agency Management Board elects Kent Woods as new chair","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-10T02:00:00Z","last_updated_date":"2011-06-10T02:00:00Z","reference_number":"EMA/451985/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-management-board-elects-kent-woods-new-chair_en.pdf"},
    {"id":"28916","name":"Announcement of seminar on pre-clinical safety evaluation of vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-10-09T02:00:00Z","last_updated_date":"2000-10-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/announcement-seminar-pre-clinical-safety-evaluation-vaccines_en.pdf"},
    {"id":"28950","name":"European Medicines Agency recommends contraindication for Regranex in patients with any pre-existing cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-02-18T01:00:00Z","last_updated_date":"2010-02-18T01:00:00Z","reference_number":"EMA/92326/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-contraindication-regranex-patients-any-pre-existing-cancer_en.pdf"},
    {"id":"28977","name":"European Medicines Agency statement on recent publication on cardiac safety of rosiglitazone (Avandia, Avandamet, Avaglim)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-05-23T02:00:00Z","last_updated_date":"2007-05-23T02:00:00Z","reference_number":"EMEA/230057/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-statement-recent-publication-cardiac-safety-rosiglitazone-avandia-avandamet-avaglim_en.pdf"},
    {"id":"29004","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 14-16 February 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-02-17T01:00:00Z","last_updated_date":"2017-02-17T01:00:00Z","reference_number":"EMA/CVMP/72976/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-14-16-february-2017_en.pdf"},
    {"id":"29087","name":"European Medicines Agency recommends suspension of all buflomedil-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-11-17T16:56:24Z","last_updated_date":"2011-11-17T16:56:24Z","reference_number":"EMA/CHMP/570796/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-all-buflomedil-containing-medicines_en.pdf"},
    {"id":"29099","name":"European and international experts discuss the way forward in developing ophthalmology medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-11-04T13:08:27Z","last_updated_date":"2011-11-04T13:08:27Z","reference_number":"EMA/871844/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-and-international-experts-discuss-way-forward-developing-ophthalmology-medicines_en.pdf"},
    {"id":"29125","name":"25th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-10-16T19:00:00Z","last_updated_date":"1997-10-16T19:00:00Z","reference_number":"EMEA/CVMP/348/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/25th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"29171","name":"Committee for medicinal products for veterinary use: Meeting of 17 to 18 January 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-01-19T12:09:21Z","last_updated_date":"2006-01-19T12:09:21Z","reference_number":"EMEA/CVMP/4720/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-17-18-january-2006_en.pdf"},
    {"id":"29183","name":"Committee for Orphan Medicinal Products: April 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-04-06T02:00:00Z","last_updated_date":"2006-04-06T02:00:00Z","reference_number":"EMEA/COMP/125572/2006Rev1","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-april-2006-meeting_en.pdf"},
    {"id":"29230","name":"2nd EMEA workshop on Orphan Medicinal Products for patients' representatives and learned societies","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-03-18T01:00:00Z","last_updated_date":"2005-03-18T01:00:00Z","reference_number":"EMEA/COMP/85509/2005 corrigendum","document_url":"https://www.ema.europa.eu/en/documents/press-release/2nd-emea-workshop-orphan-medicinal-products-patients-representatives-and-learned-societies_en.pdf"},
    {"id":"29266","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 23-25 May 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-05-28T18:00:00Z","last_updated_date":"2018-05-28T18:00:00Z","reference_number":"EMA/CVMP/296731/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-23-25-may-2018_en.pdf"},
    {"id":"29300","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the seventy seventh meeting of the committee for veterinary medicinal products took place in London on 14 - 16 May 2002.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-05-17T14:09:21Z","last_updated_date":"2002-05-17T14:09:21Z","reference_number":"EMEA/CVMP/511/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-seventy-seventh-meeting-committee-veterinary-medicinal-products-took-place-london-14-16-may-2002_en.pdf"},
    {"id":"29400","name":"Zika virus infection: plasma- and urine-derived medicines safe to use","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-09-21T02:00:00Z","last_updated_date":"2016-09-21T02:00:00Z","reference_number":"EMA/605636/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/zika-virus-infection-plasma-and-urine-derived-medicines-safe-use_en.pdf"},
    {"id":"29491","name":"European Medicines Agency update on progressive multifocal leukoencephalopathy (PML) and Tysabri","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-08-13T02:00:00Z","last_updated_date":"2008-08-13T02:00:00Z","reference_number":"EMEA/CHMP/424554/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-update-progressive-multifocal-leukoencephalopathy-pml-and-tysabri_en.pdf"},
    {"id":"29508","name":"Studies assessed by the EMEA indicate no increased risk of developing cancer for patients who have taken Viracept contaminated with ethyl mesilate","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:09:21Z","last_updated_date":"2008-07-24T02:09:21Z","reference_number":"EMEA/CHMP/382256/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/studies-assessed-emea-indicate-no-increased-risk-developing-cancer-patients-who-have-taken-viracept-contaminated-ethyl-mesilate_en.pdf"},
    {"id":"29513","name":"EMEA and FDA publish implementation plan for confidentiality arrangement","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-10-04T02:00:00Z","last_updated_date":"2004-10-04T02:00:00Z","reference_number":"EMEA/93356/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-and-fda-publish-implementation-plan-confidentiality-arrangement_en.pdf"},
    {"id":"29530","name":"Cooperation between regulators and HTA bodies creates synergies","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-14T13:00:00Z","last_updated_date":"2016-04-14T13:00:00Z","reference_number":"EMA/235891/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/cooperation-between-regulators-and-hta-bodies-creates-synergies_en.pdf"},
    {"id":"29545","name":"CPMP elects new chair and vice-chair at its 100th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-01-20T00:09:21Z","last_updated_date":"2004-01-20T00:09:21Z","reference_number":"EMEA/D/1476/04/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/cpmp-elects-new-chair-and-vice-chair-its-100th-meeting_en.pdf"},
    {"id":"29568","name":"Marvel LifeSciences Ltd withdraws its marketing authorisation applications for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-01-16T00:09:21Z","last_updated_date":"2008-01-16T00:09:21Z","reference_number":"EMEA/2435/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/marvel-lifesciences-ltd-withdraws-its-marketing-authorisation-applications-insulin-human-rapid-marvel-insulin-human-long-marvel-and-insulin-human-3070-mix-marvel_en.pdf"},
    {"id":"29647","name":"Management Board initiates building approval process for EMA premises in Amsterdam","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-02-28T18:00:00Z","last_updated_date":"2018-02-28T18:00:00Z","reference_number":"EMA/114836/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/management-board-initiates-building-approval-process-ema-premises-amsterdam_en.pdf"},
    {"id":"29691","name":"European Medicines Agency recommends suspension of Octagam in all EU Member States","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMA/CHMP/591722/2010 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-octagam-all-eu-member-states_en.pdf"},
    {"id":"29700","name":"Review concludes evidence does not support that HPV vaccines cause CRPS or POTS","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-11-05T01:00:00Z","last_updated_date":"2015-11-05T01:00:00Z","reference_number":"EMA/714950/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/review-concludes-evidence-does-not-support-hpv-vaccines-cause-crps-or-pots_en.pdf"},
    {"id":"29704","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the seventy eighth meeting of the committee for veterinary medicinal products took place in London on 11 - 13 June 2002.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-06-14T14:09:21Z","last_updated_date":"2002-06-14T14:09:21Z","reference_number":"EMEA/CVMP/621/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-seventy-eighth-meeting-committee-veterinary-medicinal-products-took-place-london-11-13-june-2002_en.pdf"},
    {"id":"29773","name":"Meeting highlights from the Paediatric Committee: 18 -  20 December 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-01-10T01:00:00Z","last_updated_date":"2008-01-10T01:00:00Z","reference_number":"EMEA/PDCO/606122/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-18-20-december-2007_en.pdf"},
    {"id":"29782","name":"CHMP confirms PRAC recommendations on Kogenate Bayer/Helixate NexGen","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2013-12-20T13:00:00Z","reference_number":"EMA/781158/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_en.pdf"},
    {"id":"29795","name":"European Medicines Agency publishes first weekly pandemic pharmacovigilance update","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-03T00:09:21Z","last_updated_date":"2009-12-03T00:09:21Z","reference_number":"EMEA/775140/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-publishes-first-weekly-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"29823","name":"European Medicines Agency workshop on first-in-man clinical trials draft guideline","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-18T02:09:21Z","last_updated_date":"2007-06-18T02:09:21Z","reference_number":"EMEA/262385/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-workshop-first-man-clinical-trials-draft-guideline_en.pdf"},
    {"id":"29858","name":"Merck Sharp and Dohme Ltd. withdraws its marketing-authorisation application for Jenzyl (ridaforolimus)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T11:58:37Z","last_updated_date":"2012-11-30T11:58:37Z","reference_number":"EMA/764967/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/merck-sharp-and-dohme-ltd-withdraws-its-marketing-authorisation-application-jenzyl-ridaforolimus_en.pdf"},
    {"id":"29895","name":"Press release: Committee for Orphan Medicinal Products February 2007 Meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2007-02-07T00:09:21Z","last_updated_date":"2007-02-07T00:09:21Z","reference_number":"EMEA/COMP/44996/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-committee-orphan-medicinal-products-february-2007-meeting_en.pdf"},
    {"id":"29911","name":"EMA Management Board: highlights of October 2017 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-06T02:00:00Z","last_updated_date":"2017-10-06T02:00:00Z","reference_number":"EMA/659964/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-october-2017-meeting_en.pdf"},
    {"id":"29930","name":"EMEA recommends new contraindication for Velcade (bortezomib)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-03-20T01:00:00Z","last_updated_date":"2008-03-20T01:00:00Z","reference_number":"EMEA/139443/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-recommends-new-contraindication-velcade-bortezomib_en.pdf"},
    {"id":"29972","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 20 to 22 May 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-05-22T02:09:21Z","last_updated_date":"2003-05-22T02:09:21Z","reference_number":"EMEA/CPMP/2848/03/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-20-22-may-2003_en.pdf"},
    {"id":"29996","name":"EMA Management Board: highlights of October 2016 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:30:00Z","last_updated_date":"2016-10-07T17:30:00Z","reference_number":"EMA/662800/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-october-2016-meeting_en.pdf"},
    {"id":"30051","name":"Meeting highlights from the Paediatric Committee: 17- 19 September 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-24T02:00:00Z","last_updated_date":"2008-09-24T02:00:00Z","reference_number":"EMEA/PDCO/493761/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-17-19-september-2008_en.pdf"},
    {"id":"30060","name":"Sales of antibiotics for animal use decrease by 13% in Europe between 2011 and 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-16T02:00:00Z","last_updated_date":"2017-10-16T02:00:00Z","reference_number":"EMA/658373/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/sales-antibiotics-animal-use-decrease-13-europe-between-2011-and-2015_en.pdf"},
    {"id":"30128","name":"Committee for veterinary medicinal products: 60th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-11-10T12:39:21Z","last_updated_date":"2000-11-10T12:39:21Z","reference_number":"EMEA/CVMP/870/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-60th-meeting_en.pdf"},
    {"id":"30129","name":"Review of emergency contraceptives started","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-01-24T12:59:55Z","last_updated_date":"2014-01-24T12:59:55Z","reference_number":"EMA/36862/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/review-emergency-contraceptives-started_en.pdf"},
    {"id":"30153","name":"European Medicines Agency launches adaptive licensing pilot project","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-03-19T01:00:00Z","last_updated_date":"2014-03-19T01:00:00Z","reference_number":"EMA/430892/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-launches-adaptive-licensing-pilot-project_en.pdf"},
    {"id":"30181","name":"Committee for medicinal products for veterinary use: Meeting of 11-13 November 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T00:29:21Z","last_updated_date":"2008-11-14T00:29:21Z","reference_number":"EMEA/CVMP/585012/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-11-13-november-2008_en.pdf"},
    {"id":"30197","name":"Abbott Laboratories Limited withdraws its marketing authorisation application for Ozespa (briakinumab)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-01-17T01:00:00Z","last_updated_date":"2011-01-17T01:00:00Z","reference_number":"EMA/40297/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/abbott-laboratories-limited-withdraws-its-marketing-authorisation-application-ozespa-briakinumab_en.pdf"},
    {"id":"30206","name":"New medicine to help in the fight against antimicrobial resistance","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T14:00:02Z","last_updated_date":"2016-04-29T14:00:02Z","reference_number":"EMA/CHMP/291057/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-help-fight-against-antimicrobial-resistance_en.pdf"},
    {"id":"30223","name":"European Medicines Agency recommends approval of Tafinlar for the treatment of metastatic melanoma","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/385990/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-tafinlar-treatment-metastatic-melanoma_en.pdf"},
    {"id":"30240","name":"Committee for medicinal products for veterinary use: Meeting of 12 - 14 December 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T12:09:21Z","last_updated_date":"2006-12-15T12:09:21Z","reference_number":"EMEA/CVMP/485281/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-12-14-december-2006_en.pdf"},
    {"id":"30332","name":"European Medicines Agency's conflicts of interests handling recognised in European Court of Auditors report","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-10-11T16:20:00Z","last_updated_date":"2012-10-11T16:20:00Z","reference_number":"EMA/659465/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-conflicts-interests-handling-recognised-european-court-auditors-report_en.pdf"},
    {"id":"30334","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 20-23 February 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-02-24T00:09:21Z","last_updated_date":"2006-02-24T00:09:21Z","reference_number":"EMEA/69276/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-20-23-february-2006_en.pdf"},
    {"id":"30345","name":"European Medicines Agency opens SME Office to support small and medium-sized enterprises","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-12-15T01:00:00Z","last_updated_date":"2005-12-15T01:00:00Z","reference_number":"EMEA/261632/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-opens-sme-office-support-small-and-medium-sized-enterprises_en.pdf"},
    {"id":"30370","name":"Start of review of medicines manufactured at Pharmaceutics International Inc., USA","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/start-review-medicines-manufactured-pharmaceutics-international-inc-usa_en.pdf"},
    {"id":"30373","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 7-9 February 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-10T16:30:00Z","last_updated_date":"2012-04-16T17:30:00Z","reference_number":"EMA/CVMP/69363/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-7-9-february-2012_en.pdf"},
    {"id":"30430","name":"European Medicines Agency tightens conflicts-of-interests policies with immediate effect","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-04-03T21:01:03Z","last_updated_date":"2012-04-03T21:01:03Z","reference_number":"EMA/235722/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-tightens-conflicts-interests-policies-immediate-effect_en.pdf"},
    {"id":"30440","name":"EMA announces final steps for its clinical trial data policy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-08T19:15:00Z","last_updated_date":"2014-04-08T19:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-announces-final-steps-its-clinical-trial-data-policy_en.pdf"},
    {"id":"30465","name":"Conflicts of interests: revised EMA policy reflects more balanced approach","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-11-20T15:00:00Z","last_updated_date":"2014-11-20T15:00:00Z","reference_number":"EMA/709353/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/conflicts-interests-revised-ema-policy-reflects-more-balanced-approach_en.pdf"},
    {"id":"30478","name":"Restrictions on use of short-acting beta-agonists in obstetric indications – CMDh endorses PRAC recommendations","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T14:10:00Z","last_updated_date":"2013-10-25T14:10:00Z","reference_number":"EMA/565019/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_en.pdf"},
    {"id":"30490","name":"Committee for veterinary medicinal products: 53rd meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-03-09T12:49:21Z","last_updated_date":"2000-03-09T12:49:21Z","reference_number":"EMEA/CVMP/189/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-53rd-meeting_en.pdf"},
    {"id":"30512","name":"Management Board re-elects Vice-chair and starts budget discussions for 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-03-10T01:00:00Z","last_updated_date":"2009-03-10T01:00:00Z","reference_number":"EMEA/147842/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/management-board-re-elects-vice-chair-and-starts-budget-discussions-2010_en.pdf"},
    {"id":"30523","name":"Guido Rasi begins as new head of European Medicines Agency","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-11-16T17:20:00Z","last_updated_date":"2011-11-16T17:20:00Z","reference_number":"EMA/901201/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/guido-rasi-begins-new-head-european-medicines-agency_en.pdf"},
    {"id":"30535","name":"Twenty-eighth meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-12-21T01:00:00Z","last_updated_date":"2000-12-21T01:00:00Z","reference_number":"EMEA/MB/056/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/twenty-eighth-meeting-management-board_en.pdf"},
    {"id":"30616","name":"Committee on herbal medicinal products: Elects new chair and vice-chair","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/509881/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-herbal-medicinal-products-elects-new-chair-and-vice-chair_en.pdf"},
    {"id":"30728","name":"Thirty-first meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-10-10T02:09:21Z","last_updated_date":"2001-10-10T02:09:21Z","reference_number":"EMEA/MB/044/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/thirty-first-meeting-management-board_en.pdf"},
    {"id":"30779","name":"Meeting highlights from the Paediatric Committee: 10 - 12 December 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-12-17T01:00:00Z","last_updated_date":"2008-12-17T01:00:00Z","reference_number":"EMEA/PDCO/675823/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-10-12-december-2008_en.pdf"},
    {"id":"30801","name":"EMA recommends avoidance of certain hepatitis C medicines and amiodarone together","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/258577/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-avoidance-certain-hepatitis-c-medicines-and-amiodarone-together_en.pdf"},
    {"id":"30817","name":"European Medicines Agency recommends approval of medicine for treatment of vitreomacular traction","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T01:00:00Z","last_updated_date":"2013-01-18T01:00:00Z","reference_number":"EMA/CHMP/25557/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-medicine-treatment-vitreomacular-traction_en.pdf"},
    {"id":"30829","name":"Narcolepsy treatment recommended for approval","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/764032/2015 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/narcolepsy-treatment-recommended-approval_en.pdf"},
    {"id":"30934","name":"New Management Board elects its chairman and approves composition of new scientific committees","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-05-25T02:09:21Z","last_updated_date":"2004-05-25T02:09:21Z","reference_number":"EMEA/D/14394/04/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-management-board-elects-its-chairman-and-approves-composition-new-scientific-committees_en.pdf"},
    {"id":"30970","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the sixty-eighth meeting of the committee for veterinary medicinal products took place in London on 10-12 July 2001.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-07-12T14:09:21Z","last_updated_date":"2001-07-12T14:09:21Z","reference_number":"EMEA/CVMP/676/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-sixty-eighth-meeting-committee-veterinary-medicinal-products-took-place-london-10-12-july-2001_en.pdf"},
    {"id":"31111","name":"Towards an optimal balance between benefits and risks for\n\nveterinary medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-03-27T00:09:21Z","last_updated_date":"2008-03-27T00:09:21Z","reference_number":"EMEA/161887/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/towards-optimal-balance-between-benefits-and-risks-veterinary-medicines_en.pdf"},
    {"id":"31140","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 6-8 November 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-11-09T16:30:00Z","last_updated_date":"2012-11-09T16:30:00Z","reference_number":"EMA/CVMP/686674/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-6-8-november-2012_en.pdf"},
    {"id":"31158","name":"European Medicines Agency and European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP) launch ‘ENCePP studies’","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-06-11T02:00:00Z","last_updated_date":"2010-06-11T02:00:00Z","reference_number":"EMA/343605/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-european-network-centres-pharmacoepidemiology-pharmacovigilance-encepp-launch-encepp-studies_en.pdf"},
    {"id":"31167","name":"New medicine for hereditary rare disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/510214/2018 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-hereditary-rare-disease_en.pdf-0"},
    {"id":"31171","name":"European Medicines Agency updates on pandemic","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-18T00:09:21Z","last_updated_date":"2009-12-18T00:09:21Z","reference_number":"EMA/816338/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-pandemic_en.pdf"},
    {"id":"31248","name":"Priority access for children during Myozyme supply shortage","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-01-16T00:09:21Z","last_updated_date":"2009-01-16T00:09:21Z","reference_number":"EMEA/13509/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/priority-access-children-during-myozyme-supply-shortage_en.pdf"},
    {"id":"31292","name":"Public statement on the risk of drug interactions with HYPERICUM PERFORATUM (St John's Wort) and antiretroviral medicinal products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-02-28T01:00:00Z","last_updated_date":"2000-02-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/public-statement-risk-drug-interactions-hypericum-perforatum-st-johns-wort-and-antiretroviral-medicinal-products_en.pdf"},
    {"id":"31298","name":"Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 9-11 November 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-11-12T01:00:00Z","last_updated_date":"2010-11-12T01:00:00Z","reference_number":"EMA/CVMP/691376/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-9-11-november-2010_en.pdf"},
    {"id":"31302","name":"8th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1995-12-15T12:09:21Z","last_updated_date":"1995-12-15T12:09:21Z","reference_number":"EMEA/CVMP/168/95","document_url":"https://www.ema.europa.eu/en/documents/press-release/8th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"31314","name":"Seventeenth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-02-20T01:00:00Z","last_updated_date":"1998-02-20T01:00:00Z","reference_number":"EMEA/MB/006/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/seventeenth-meeting-management-board_en.pdf"},
    {"id":"31318","name":"First medicine for rare blood cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/335706/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-medicine-rare-blood-cancer_en.pdf"},
    {"id":"31345","name":"EMA prepares for Brexit","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T02:00:00Z","last_updated_date":"2017-08-01T02:00:00Z","reference_number":"MA/466317/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-prepares-brexit_en.pdf"},
    {"id":"31397","name":"Merck KGaA withdraws its application for an extension of the indication for Erbitux (cetuximab)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-09-19T13:00:00Z","last_updated_date":"2012-09-19T13:00:00Z","reference_number":"EMA/607000/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/merck-kgaa-withdraws-its-application-extension-indication-erbitux-cetuximab_en.pdf"},
    {"id":"31416","name":"Committee for veterinary medicinal products: Meeting of 13 to 14 May 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-05-15T14:49:21Z","last_updated_date":"2003-05-15T14:49:21Z","reference_number":"EMEA/CVMP/484/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-13-14-may-2003_en.pdf"},
    {"id":"31422","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 14-17 February 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-02-17T01:00:00Z","last_updated_date":"2005-02-17T01:00:00Z","reference_number":"EMEA/59424/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-14-17-february-2005_en.pdf"},
    {"id":"31502","name":"CMDh confirms recommendations on restricting use of domperidone-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T17:00:00Z","last_updated_date":"2014-04-25T17:00:00Z","reference_number":"EMA/236452/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/cmdh-confirms-recommendations-restricting-use-domperidone-containing-medicines_en.pdf"},
    {"id":"31531","name":"Recommendation to suspend tetrazepam-containing medicines endorsed by CMDh","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-04-29T14:00:00Z","last_updated_date":"2013-04-29T14:00:00Z","reference_number":"EMA/256383/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/recommendation-suspend-tetrazepam-containing-medicines-endorsed-cmdh_en.pdf"},
    {"id":"31537","name":"European Medicines Agency gives first opinion for a vaccine for use outside the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T14:00:00Z","last_updated_date":"2012-06-22T14:00:00Z","reference_number":"EMA/421125/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-first-opinion-vaccine-use-outside-eu_en.pdf"},
    {"id":"31541","name":"35th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-05-12T02:00:00Z","last_updated_date":"2003-05-12T02:00:00Z","reference_number":"EMEA/COMP/1173/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/35th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"31570","name":"Two new combination therapies against chronic hepatitis C","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T14:00:00Z","last_updated_date":"2016-05-27T14:00:00Z","reference_number":"CHMP/358446/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/two-new-combination-therapies-against-chronic-hepatitis-c_en.pdf"},
    {"id":"31578","name":"PRAC considers benefits of Kogenate Bayer/Helixate NexGen outweigh risks in previously untreated patients","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-06T01:00:00Z","last_updated_date":"2013-12-06T01:00:00Z","reference_number":"EMA/741427/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-considers-benefits-kogenate-bayerhelixate-nexgen-outweigh-risks-previously-untreated-patients_en.pdf"},
    {"id":"31590","name":"70th meeting of the Committee for Proprietary Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-05-02T02:09:21Z","last_updated_date":"2001-05-02T02:09:21Z","reference_number":"CPMP/1252/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/70th-meeting-committee-proprietary-medicinal-products_en.pdf"},
    {"id":"31686","name":"European Medicines Agency publishes final ‘Road map to 2015’","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-01-26T10:58:17Z","last_updated_date":"2011-01-26T10:58:17Z","reference_number":"EMA/61367/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-publishes-final-road-map-2015_en.pdf"},
    {"id":"31693","name":"European Medicines Agency recommends restricted use for piroxicam","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-25T02:00:00Z","last_updated_date":"2007-06-25T02:00:00Z","reference_number":"EMEA/265144/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricted-use-piroxicam_en.pdf"},
    {"id":"31717","name":"Committee for Orphan Medicinal Products: July 2005 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-07-21T02:00:00Z","last_updated_date":"2005-07-21T02:00:00Z","reference_number":"EMEA/COMP/233637/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-july-2005-meeting_en.pdf"},
    {"id":"31719","name":"Benefits of Diane 35 and its generics outweigh risks in certain patient groups - PRAC recommendation endorsed by CMDh","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-05-30T15:00:00Z","last_updated_date":"2013-05-30T15:00:00Z","reference_number":"EMA/318380/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups-prac-recommendation-endorsed-cmdh_en.pdf"},
    {"id":"31774","name":"EMA recommends approval of treatment for attention deficit hyperactivity disorder","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/CHMP/494404/2015 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-approval-treatment-attention-deficit-hyperactivity-disorder_en.pdf"},
    {"id":"31786","name":"European Medicines Agency 2009 mid-year report shows it is still on target, despite influenza pandemic activities","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-26T00:09:21Z","last_updated_date":"2010-02-11T21:21:55Z","reference_number":"EMEA/MB/681032/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-2009-mid-year-report-shows-it-still-target-despite-influenza-pandemic-activities_en.pdf"},
    {"id":"31791","name":"Public hearing on 13 June 2018 - Citizens to be consulted on quinolone and fluoroquinolone antibiotics","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-04-09T02:00:00Z","last_updated_date":"2018-04-09T02:00:00Z","reference_number":"EMA/192201/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/public-hearing-13-june-2018-citizens-be-consulted-quinolone-and-fluoroquinolone-antibiotics_en.pdf"},
    {"id":"31822","name":"Committee for veterinary medicinal products: 38th meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-12-11T00:09:21Z","last_updated_date":"1998-12-11T00:09:21Z","reference_number":"EMEA/CVMP/622/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-38th-meeting_en.pdf"},
    {"id":"31847","name":"GlaxoSmithKline withdraws its application for an extension of the indication for Tyverb (lapatinib)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T15:00:00Z","last_updated_date":"2012-02-16T15:00:00Z","reference_number":"EMA/121832/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/glaxosmithkline-withdraws-its-application-extension-indication-tyverb-lapatinib_en.pdf"},
    {"id":"31866","name":"EMEA announces appointment of new Head of Unit for Human Medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-03-01T01:00:00Z","last_updated_date":"2001-03-01T01:00:00Z","reference_number":"EMEA/D/5796/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-announces-appointment-new-head-unit-human-medicines_en.pdf"},
    {"id":"31882","name":"The European Union and the FDA working together to create Common Application for Orphan Designation for Medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-11-26T01:00:00Z","last_updated_date":"2007-11-26T01:00:00Z","reference_number":"EMEA/557391/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-union-and-fda-working-together-create-common-application-orphan-designation-medicines_en.pdf"},
    {"id":"31914","name":"European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T18:00:00Z","last_updated_date":"2012-02-22T12:20:00Z","reference_number":"EMA/CHMP/119670/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-final-recommendations-12-centrally-authorised-medicines-manufactured-ben-venue-laboratories_en.pdf"}    {"id":"31980","name":"European Medicines Agency maintains recommendation not to grant a marketing authorisation for Glybera","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-04-20T16:11:53Z","last_updated_date":"2012-04-20T16:11:53Z","reference_number":"EMA/CHMP/264472/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-maintains-recommendation-not-grant-marketing-authorisation-glybera_en.pdf"},
    {"id":"32030","name":"Committee for veterinary medicinal products: 58th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-09-14T14:09:21Z","last_updated_date":"2000-09-14T14:09:21Z","reference_number":"EMEA/CVMP/610/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-58th-meeting_en.pdf"},
    {"id":"32055","name":"Committee on Advanced Therapies (CAT) celebrates its first birthday","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-01-27T00:09:21Z","last_updated_date":"2010-01-27T00:09:21Z","reference_number":"EMA/25684/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-advanced-therapies-cat-celebrates-its-first-birthday_en.pdf"},
    {"id":"32097","name":"European Medicines Agency confirms positive benefit-risk balance of somatropin-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-12-15T17:00:00Z","last_updated_date":"2011-12-22T13:15:00Z","reference_number":"EMA/CHMP/965945/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-positive-benefit-risk-balance-somatropin-containing-medicines_en.pdf"},
    {"id":"32157","name":"European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T12:00:00Z","last_updated_date":"2012-02-17T12:00:00Z","reference_number":"EMA/CHMP/112042/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-new-contraindications-and-warnings-aliskiren-containing-medicines_en.pdf"},
    {"id":"32191","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 12-15 September 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-09-15T02:00:00Z","last_updated_date":"2005-09-15T02:00:00Z","reference_number":"EMEA/303099/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-12-15-september-2005_en.pdf"},
    {"id":"32201","name":"European Medicines Agency agrees on action plan following the recall of Viracept and recommends suspension of the Marketing Authorisation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-21T02:00:00Z","last_updated_date":"2007-06-21T02:00:00Z","reference_number":"EMEA/275367/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-agrees-action-plan-following-recall-viracept-and-recommends-suspension-marketing-authorisation_en.pdf"},
    {"id":"32244","name":"EU-US mutual recognition of inspections of medicines manufacturers enters operational phase","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T16:09:00Z","last_updated_date":"2017-10-31T16:09:00Z","reference_number":"EMA/662403/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-us-mutual-recognition-inspections-medicines-manufacturers-enters-operational-phase_en.pdf"},
    {"id":"32272","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 8-10 July 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-07-11T18:00:00Z","last_updated_date":"2014-07-11T18:00:00Z","reference_number":"EMA/CVMP/382972/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-july-2014_en.pdf"},
    {"id":"32281","name":"Committee for Proprietary Medicinal Products (CPMP) 50th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-06-25T02:00:00Z","last_updated_date":"1999-06-25T02:00:00Z","reference_number":"CPMP/1817/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-50th-plenary-meeting_en.pdf"},
    {"id":"32284","name":"Ketoconazole HRA recommended for approval in Cushing's syndrome","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T14:00:04Z","last_updated_date":"2014-09-26T14:00:04Z","reference_number":"EMA/581398/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/ketoconazole-hra-recommended-approval-cushings-syndrome_en.pdf"},
    {"id":"32288","name":"Recommendation to restrict the use of Protelos / Osseor (strontium ranelate)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T14:00:03Z","last_updated_date":"2013-04-26T14:00:03Z","reference_number":"EMA/258269/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/recommendation-restrict-use-protelos-osseor-strontium-ranelate_en.pdf"},
    {"id":"32399","name":"European quality leader of the year 2006 award goes to EMEA staff member","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-06-02T02:00:00Z","last_updated_date":"2006-06-02T02:00:00Z","reference_number":"EMEA/195895/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-quality-leader-year-2006-award-goes-emea-staff-member_en.pdf"},
    {"id":"32414","name":"Committee for Proprietary Medicinal Products (CPMP) 63rd plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-09-25T02:00:00Z","last_updated_date":"2000-09-25T02:00:00Z","reference_number":"CPMP/2522/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-63rd-plenary-meeting_en.pdf"},
    {"id":"32427","name":"Committee for Proprietary Medicinal Products (CPMP) 14th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-03-14T01:00:00Z","last_updated_date":"1996-03-14T01:00:00Z","reference_number":"CPMP/285/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-14th-plenary-meeting_en.pdf"},
    {"id":"32433","name":"Ferrer Internacional, S.A. withdraws its marketing authorisation application for Egrifta (tesamorelin)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-06-26T16:58:00Z","last_updated_date":"2012-06-26T16:58:00Z","reference_number":"EMA/431454/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/ferrer-internacional-sa-withdraws-its-marketing-authorisation-application-egrifta-tesamorelin_en.pdf"},
    {"id":"32443","name":"Updated advice on use of high-dose ibuprofen","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/325007/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/updated-advice-use-high-dose-ibuprofen_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/press-release/updated-advice-use-high-dose-ibuprofen_bg.pdf","es":"https://www.ema.europa.eu/es/documents/press-release/updated-advice-use-high-dose-ibuprofen_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/press-release/updated-advice-use-high-dose-ibuprofen_cs.pdf","da":"https://www.ema.europa.eu/da/documents/press-release/updated-advice-use-high-dose-ibuprofen_da.pdf","de":"https://www.ema.europa.eu/de/documents/press-release/updated-advice-use-high-dose-ibuprofen_de.pdf","et":"https://www.ema.europa.eu/et/documents/press-release/updated-advice-use-high-dose-ibuprofen_et.pdf","el":"https://www.ema.europa.eu/el/documents/press-release/updated-advice-use-high-dose-ibuprofen_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/press-release/updated-advice-use-high-dose-ibuprofen_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/press-release/updated-advice-use-high-dose-ibuprofen_hr.pdf","it":"https://www.ema.europa.eu/it/documents/press-release/updated-advice-use-high-dose-ibuprofen_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/press-release/updated-advice-use-high-dose-ibuprofen_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/press-release/updated-advice-use-high-dose-ibuprofen_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/press-release/updated-advice-use-high-dose-ibuprofen_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/press-release/updated-advice-use-high-dose-ibuprofen_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/press-release/updated-advice-use-high-dose-ibuprofen_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/press-release/updated-advice-use-high-dose-ibuprofen_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/press-release/updated-advice-use-high-dose-ibuprofen_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/press-release/updated-advice-use-high-dose-ibuprofen_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/press-release/updated-advice-use-high-dose-ibuprofen_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/press-release/updated-advice-use-high-dose-ibuprofen_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/press-release/updated-advice-use-high-dose-ibuprofen_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/press-release/updated-advice-use-high-dose-ibuprofen_sv.pdf"}},
    {"id":"32453","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 7-9 November 2017","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T17:00:00Z","last_updated_date":"2017-11-10T17:00:00Z","reference_number":"EMA/CVMP/708873/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-7-9-november-2017_en.pdf"},
    {"id":"32481","name":"European Medicines Agency update on ongoing benefit-risk review of Avandia, Avandamet and Avaglim","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/468928/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-update-ongoing-benefit-risk-review-avandia-avandamet-and-avaglim_en.pdf"},
    {"id":"32508","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 5-7 March 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T18:00:00Z","last_updated_date":"2013-03-08T18:00:00Z","reference_number":"EMA/CVMP/124461/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-5-7-march-2013_en.pdf"},
    {"id":"32544","name":"Committee for medicinal products for veterinary use: Meeting of 11-13 December 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T12:39:21Z","last_updated_date":"2007-12-14T12:39:21Z","reference_number":"EMEA/CVMP/566687/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-11-13-december-2007_en.pdf"},
    {"id":"32545","name":"EMA completes review of inhaled corticosteroids for chronic obstructive pulmonary disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/285392/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_en.pdf"},
    {"id":"32552","name":"Esmya: new measures to minimise risk of rare but serious liver injury","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T02:00:00Z","last_updated_date":"2018-06-01T02:00:00Z","reference_number":"EMA/355940/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/esmya-new-measures-minimise-risk-rare-serious-liver-injury_en.pdf-0"},
    {"id":"32606","name":"Making a difference to human and animal health - European Medicines Agency and Heads of Medicines Agencies consult on common network strategy to 2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-03-31T02:00:00Z","last_updated_date":"2015-03-31T02:00:00Z","reference_number":"EMA/191095/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/making-difference-human-and-animal-health-european-medicines-agency-and-heads-medicines-agencies-consult-common-network-strategy-2020_en.pdf"},
    {"id":"32668","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 16-19 May 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/306703/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2011_en.pdf"},
    {"id":"32704","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 16-19 November 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-11-20T00:09:21Z","last_updated_date":"2009-11-20T00:09:21Z","reference_number":"EMEA/CHMP/752431/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-november-2009_en.pdf"},
    {"id":"32734","name":"Eleventh Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-09-26T02:00:00Z","last_updated_date":"1996-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/eleventh-meeting-management-board_en.pdf"},
    {"id":"32740","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n10-13 December 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-12-14T00:09:21Z","last_updated_date":"2007-12-14T00:09:21Z","reference_number":"EMEA/CHMP/583851/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-10-13-december-2007_en.pdf"},
    {"id":"32759","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 24-27 May 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-06-02T02:09:21Z","last_updated_date":"2006-06-02T02:09:21Z","reference_number":"EMEA/204606/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-24-27-may-2006_en.pdf"},
    {"id":"32856","name":"16th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-09-13T02:00:00Z","last_updated_date":"2001-09-13T02:00:00Z","reference_number":"EMEA/COMP/385/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/16th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"32859","name":"First-in-class medicine to prevent bleeding in haemophilia A patients with inhibitors","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/43074/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-class-medicine-prevent-bleeding-haemophilia-patients-inhibitors_en.pdf"},
    {"id":"32861","name":"European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-21T02:00:00Z","last_updated_date":"2011-07-21T02:00:00Z","reference_number":"EMA/CHMP/568262/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-new-contra-indications-and-warnings-pioglitazone-reduce-small-increased-risk-bladder-cancer_en.pdf"},
    {"id":"32871","name":"Update on review of valsartan medicines following detection of impurity in active substance","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T16:00:00Z","last_updated_date":"2018-07-17T16:00:00Z","reference_number":"EMA/485921/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-review-valsartan-medicines-following-detection-impurity-active-substance_en.pdf"},
    {"id":"32877","name":"New guide on biosimilar medicines for healthcare professionals - Increasing understanding of biosimilar medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-05-05T02:00:00Z","last_updated_date":"2017-05-05T02:00:00Z","reference_number":"EMA/270182/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-guide-biosimilar-medicines-healthcare-professionals-increasing-understanding-biosimilar-medicines_en.pdf"},
    {"id":"32903","name":"European Medicines Agency publishes 2012 annual report","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-04-16T18:00:00Z","last_updated_date":"2013-04-16T18:00:00Z","reference_number":"EMA/235758/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-publishes-2012-annual-report_en.pdf"},
    {"id":"32944","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 24-27 April 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-04-28T02:09:21Z","last_updated_date":"2006-04-28T02:09:21Z","reference_number":"EMEA/152608/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-24-27-april-2006_en.pdf"},
    {"id":"32961","name":"Committee for veterinary medicinal products: under the chairmanship of Mr S. P. Dean the sixty-fifth meeting of the committee for veterinary medicinal products took place in London on 18-19 April 2001.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-04-19T14:49:21Z","last_updated_date":"2001-04-19T14:49:21Z","reference_number":"EMEA/CVMP/365/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-under-chairmanship-mr-s-p-dean-sixty-fifth-meeting-committee-veterinary-medicinal-products-took-place-london-18-19-april-2001_en.pdf"},
    {"id":"33027","name":"PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T13:00:00Z","last_updated_date":"2017-03-10T13:00:00Z","reference_number":"EMA/157486/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-concludes-assessment-gadolinium-agents-used-body-scans-and-recommends-regulatory-actions-including-suspension-some-marketing-authorisations_en.pdf"},
    {"id":"33070","name":"New treatment option for patients with advanced lung cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/329429/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-option-patients-advanced-lung-cancer_en.pdf"},
    {"id":"33079","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 4-6 November 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-11-07T01:00:00Z","last_updated_date":"2014-11-07T01:00:00Z","reference_number":"EMA/CVMP/651488/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-4-6-november-2014_en.pdf"},
    {"id":"33107","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 24 to 26 June 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-06-27T02:09:21Z","last_updated_date":"2003-06-27T02:09:21Z","reference_number":"EMEA/16832/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-24-26-june-2003_en.pdf"},
    {"id":"33116","name":"New medicine for rare inflammatory condition of the oesophagus","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"EMA/734285/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-rare-inflammatory-condition-oesophagus_en.pdf"},
    {"id":"33140","name":"Guido Rasi takes office as head of EMA","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-11-16T01:00:00Z","last_updated_date":"2015-11-16T01:00:00Z","reference_number":"EMA/747097/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/guido-rasi-takes-office-head-ema_en.pdf"},
    {"id":"33148","name":"Update on infringement procedure against Roche Registration Ltd.","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-14T02:00:00Z","last_updated_date":"2014-04-14T02:00:00Z","reference_number":"EMA/211922/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-infringement-procedure-against-roche-registration-ltd_en.pdf"},
    {"id":"33182","name":"Twentieth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-12-03T01:00:00Z","last_updated_date":"1998-12-03T01:00:00Z","reference_number":"EMEA/MB/045/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/twentieth-meeting-management-board_en.pdf"},
    {"id":"33188","name":"European Medicines Agency’s Management Board endorses the work programme 2010 and strengthens the involvement of patients in the work of the Agency","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-17T00:09:21Z","last_updated_date":"2009-12-17T00:09:21Z","reference_number":"EMA/808539/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-endorses-work-programme-2010-and-strengthens-involvement-patients-work-agency_en.pdf"},
    {"id":"33198","name":"Experimental Ebola treatments still at early stage of development","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-12-16T11:00:00Z","last_updated_date":"2014-12-16T11:00:00Z","reference_number":"EMA/733055/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/experimental-ebola-treatments-still-early-stage-development_en.pdf"},
    {"id":"33280","name":"Committee for medicinal products for veterinary use: Meeting of 14 to 16 March 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-03-17T12:29:21Z","last_updated_date":"2006-03-17T12:29:21Z","reference_number":"EMEA/CVMP/66758/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-14-16-march-2006_en.pdf"},
    {"id":"33290","name":"European Medicines Agency recommends approval of a new medicine for multidrug-resistant tuberculosis","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/794261/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-new-medicine-multidrug-resistant-tuberculosis_en.pdf"},
    {"id":"33313","name":"European Medicines Agency announces recall of Viracept","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:00:00Z","last_updated_date":"2007-06-06T02:00:00Z","reference_number":"EMEA/251283/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-announces-recall-viracept_en.pdf"},
    {"id":"33379","name":"European Medicines Agency recommends approval of first treatment for pseudobulbar affect","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T02:00:00Z","last_updated_date":"2013-04-26T02:00:00Z","reference_number":"EMA/177063/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-first-treatment-pseudobulbar-affect_en.pdf"},
    {"id":"33400","name":"European Medicines Agency receives first pandemic influenza vaccine application","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-01-06T01:00:00Z","last_updated_date":"2006-01-06T01:00:00Z","reference_number":"EMEA/425916/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-receives-first-pandemic-influenza-vaccine-application_en.pdf"},
    {"id":"33406","name":"Committee for Proprietary Medicinal Products (CPMP) 52nd plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-09-27T02:00:00Z","last_updated_date":"1999-09-27T02:00:00Z","reference_number":"CPMP/2590/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-52nd-plenary-meeting_en.pdf"},
    {"id":"33491","name":"Committee for Orphan Medicinal Products: June 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-06-26T02:00:00Z","last_updated_date":"2006-06-26T02:00:00Z","reference_number":"EMEA/COMP/227622/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-june-2006-meeting_en.pdf"},
    {"id":"33513","name":"Celgene Europe Limited withdraws its application for an extension of the indication for Revlimid (lenalidomide)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-06-21T02:00:00Z","last_updated_date":"2012-06-21T02:00:00Z","reference_number":"EMA/416782/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/celgene-europe-limited-withdraws-its-application-extension-indication-revlimid-lenalidomide_en.pdf"},
    {"id":"33562","name":"European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-10-21T12:00:00Z","last_updated_date":"2011-10-21T20:00:00Z","reference_number":"EMA/CHMP/847737/2011 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-clarifies-opinion-pioglitazone-and-risk-bladder-cancer_en.pdf"},
    {"id":"33583","name":"Committee for medicinal products for veterinary use: Meeting of 20 to 22 June 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-06-23T14:09:21Z","last_updated_date":"2006-06-23T14:09:21Z","reference_number":"EMEA/CVMP/221740/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-20-22-june-2006_en.pdf"},
    {"id":"33618","name":"The EMEA and the CMD(h) review Europe-wide experience with user consultation in the readability testing of package leaflets","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-11-15T01:00:00Z","last_updated_date":"2006-11-15T01:00:00Z","reference_number":"EMEA/457658/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-and-cmdh-review-europe-wide-experience-user-consultation-readability-testing-package-leaflets_en.pdf"},
    {"id":"33653","name":"14th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1996-09-19T14:09:21Z","last_updated_date":"1996-09-19T14:09:21Z","reference_number":"EMEA/CVMP/202/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/14th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"33706","name":"European Medicines Agency recommends new advice on safer use of fibrin sealant spray applications","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T11:01:00Z","last_updated_date":"2012-12-14T11:01:00Z","reference_number":"EMA/CHMP/772180/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-new-advice-safer-use-fibrin-sealant-spray-applications_en.pdf"},
    {"id":"33760","name":"11th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-03-28T02:00:00Z","last_updated_date":"2001-03-28T02:00:00Z","reference_number":"COMP/90/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/11th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"33793","name":"European Medicines Agency publishes initial list of medicines under additional monitoring","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-04-25T12:00:00Z","last_updated_date":"2013-04-25T12:00:00Z","reference_number":"EMA/251554/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-publishes-initial-list-medicines-under-additional-monitoring_en.pdf"},
    {"id":"33832","name":"Adempas not for use in patients with pulmonary hypertension caused by idiopathic interstitial pneumonia","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/396864/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/adempas-not-use-patients-pulmonary-hypertension-caused-idiopathic-interstitial-pneumonia_en.pdf"},
    {"id":"33845","name":"GlaxoSmithKline Biologicals withdraws its application for a scientific opinion for Globorix","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-10-16T02:09:21Z","last_updated_date":"2007-10-16T02:09:21Z","reference_number":"EMEA/475583/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/glaxosmithkline-biologicals-withdraws-its-application-scientific-opinion-globorix_en.pdf"},
    {"id":"33852","name":"European Medicines Agency’s Scientific Coordination Board starts reflection on best cooperation between scientific committees","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-04-25T18:40:00Z","last_updated_date":"2012-04-25T18:40:00Z","reference_number":"EMA/274306/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-scientific-coordination-board-starts-reflection-best-cooperation-between-scientific-committees_en.pdf"},
    {"id":"33857","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 15-18 November 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2010-11-19T01:00:00Z","reference_number":"EMA/CHMP/734452/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-november-2010_en.pdf"},
    {"id":"33877","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 16-18 July 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T18:30:00Z","last_updated_date":"2013-07-19T18:30:00Z","reference_number":"EMA/CVMP/405417/2013 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-16-18-july-2013_en.pdf"},
    {"id":"33888","name":"European Medicines Agency’s Management Board elects new chair and vice-chair","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-08T02:09:21Z","last_updated_date":"2007-06-08T02:09:21Z","reference_number":"EMEA/252232/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-elects-new-chair-and-vice-chair_en.pdf"},
    {"id":"33906","name":"Orphan drug and paediatric clinical trials - EMEA workshop on metholigical aspects of clinical trials for efficacy evaluation in small populations","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-11-12T00:09:21Z","last_updated_date":"2002-11-12T00:09:21Z","reference_number":"EMEA/28972/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/orphan-drug-and-paediatric-clinical-trials-emea-workshop-metholigical-aspects-clinical-trials-efficacy-evaluation-small-populations_en.pdf"},
    {"id":"33912","name":"European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type 2 diabetes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-03-26T01:00:00Z","last_updated_date":"2013-03-26T01:00:00Z","reference_number":"EMA/178662/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-investigates-findings-pancreatic-risks-glp-1-based-therapies-type-2-diabetes_en.pdf"},
    {"id":"33924","name":"Committee for Medicinal Products for Human Use elects new chair and vice-chair","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-19T02:00:00Z","last_updated_date":"2007-06-19T02:00:00Z","reference_number":"EMEA/271971/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-human-use-elects-new-chair-and-vice-chair_en.pdf"},
    {"id":"33929","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products, 24-26 February 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-02-27T00:09:21Z","last_updated_date":"2004-02-27T00:09:21Z","reference_number":"EMEA/CPMP/857/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-24-26-february-2004_en.pdf"},
    {"id":"33935","name":"ADHOC working group meeting on herbal medicinal products 18 and 19 January","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-01-18T01:00:00Z","last_updated_date":"1999-01-18T01:00:00Z","reference_number":"EMEA/HMPWG/5/99 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/adhoc-working-group-meeting-herbal-medicinal-products-18-and-19-january_en.pdf"},
    {"id":"33953","name":"European Medicines Agency recommends first marketing authorisation for an advanced therapy medicinal product","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-26T02:09:21Z","last_updated_date":"2009-06-26T02:09:21Z","reference_number":"EMEA/CHMP/394741/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-first-marketing-authorisation-advanced-therapy-medicinal-product_en.pdf"},
    {"id":"34002","name":"Commitee for Orphan Medicinal Products: April 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-04-16T02:00:00Z","last_updated_date":"2004-04-16T02:00:00Z","reference_number":"EMEA/COMP/177/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-april-2004-meeting_en.pdf"},
    {"id":"34013","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n22-25 September 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-25T02:09:21Z","last_updated_date":"2008-09-25T02:09:21Z","reference_number":"EMEA/CHMP/503956/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-22-25-september-2008_en.pdf"},
    {"id":"34024","name":"Committee for Proprietary Medicinal Products (CPMP) 23rd plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-01-24T01:00:00Z","last_updated_date":"1997-01-24T01:00:00Z","reference_number":"CPMP/045/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-23rd-plenary-meeting_en.pdf"},
    {"id":"34030","name":"European Medicines Agency recommends suspension of Hexavac","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-09-20T02:00:00Z","last_updated_date":"2005-09-20T02:00:00Z","reference_number":"EMEA/297369/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-hexavac_en.pdf"},
    {"id":"34091","name":"EMEA announces new Head of Unit for Communications and Networking","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-05-02T02:00:00Z","last_updated_date":"2002-05-02T02:00:00Z","reference_number":"EMEA/D/10545/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-announces-new-head-unit-communications-and-networking_en.pdf"},
    {"id":"34103","name":"Committee for medicinal products for veterinary use: Meeting of 10 to 12 October 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-10-12T14:09:21Z","last_updated_date":"2006-10-12T14:09:21Z","reference_number":"EMEA/CVMP/391009/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-10-12-october-2006_en.pdf"},
    {"id":"34112","name":"Press release - It’s time to reduce, replace and re-think the use of antimicrobials in animals","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-01-24T11:00:00Z","last_updated_date":"2017-01-24T11:00:00Z","reference_number":"EMA/CVMP/47873/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-its-time-reduce-replace-and-re-think-use-antimicrobials-animals_en.pdf"},
    {"id":"34122","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n13-16 November 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-11-17T00:09:21Z","last_updated_date":"2006-11-17T00:09:21Z","reference_number":"EMEA/460883/2006 - corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-13-16-november-2006_en.pdf"},
    {"id":"34191","name":"Committee for medicinal products for veterinary use: Meeting of 16 - 18 January 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-01-19T12:19:21Z","last_updated_date":"2007-01-19T12:19:21Z","reference_number":"EMEA/CVMP/1660/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-16-18-january-2007_en.pdf"},
    {"id":"34216","name":"Committee for Orphan Medicinal Products: December 2003 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-12-08T01:00:00Z","last_updated_date":"2003-12-08T01:00:00Z","reference_number":"EMEA/COMP/1603/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-december-2003-meeting_en.pdf"},
    {"id":"34235","name":"EMA advice on use of colistin in animals to be updated","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T01:00:00Z","last_updated_date":"2016-01-11T01:00:00Z","reference_number":"EMA/CVMP/832098/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-advice-use-colistin-animals-be-updated_en.pdf"},
    {"id":"34238","name":"European Medicine Agency: Committee for Medicinal Products for Human Use, 27-29 July 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-07-29T02:00:00Z","last_updated_date":"2004-07-29T02:00:00Z","reference_number":"EMEA/21550/04/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicine-agency-committee-medicinal-products-human-use-27-29-july-2004_en.pdf"},
    {"id":"34274","name":"PRAC recommends new measures to minimise known heart risks of hydroxyzine-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-02-13T13:00:00Z","last_updated_date":"2015-02-13T13:00:00Z","reference_number":"EMA/85678/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-new-measures-minimise-known-heart-risks-hydroxyzine-containing-medicines_en.pdf"},
    {"id":"34292","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 3-5 June 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/CVMP/307034/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-3-5-june-2014_en.pdf"},
    {"id":"34308","name":"Ark Therapeutics withdraws its marketing authorisation application for Cerepro","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-20T02:00:00Z","last_updated_date":"2007-07-20T02:00:00Z","reference_number":"EMEA/331059/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/ark-therapeutics-withdraws-its-marketing-authorisation-application-cerepro_en.pdf"},
    {"id":"34325","name":"Committee for medicinal products for veterinary use: Meeting of 9 to 11 November 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-11-15T12:39:21Z","last_updated_date":"2004-11-15T12:39:21Z","reference_number":"EMEA/CVMP/1076/04-corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-9-11-november-2004_en.pdf"},
    {"id":"34331","name":"Committee for Orphan Medicinal Products: January 2005 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-01-18T01:00:00Z","last_updated_date":"2005-01-18T01:00:00Z","reference_number":"EMEA/COMP/19824/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-january-2005-meeting_en.pdf"},
    {"id":"34338","name":"PRAC updates on the risks of serious vascular occlusive events associated with cancer medicine Iclusig","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-08T12:59:00Z","last_updated_date":"2013-11-08T12:59:00Z","reference_number":"EMA/686491/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-updates-risks-serious-vascular-occlusive-events-associated-cancer-medicine-iclusig_en.pdf"},
    {"id":"34348","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 19-22 July 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2010-07-23T02:00:00Z","reference_number":"EMA/CHMP/310263/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-july-2010_en.pdf"},
    {"id":"34418","name":"Inauguration of the new committee on herbal medicinal products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-01-29T01:00:00Z","last_updated_date":"2004-01-29T01:00:00Z","reference_number":"HMPC/85420/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/inauguration-new-committee-herbal-medicinal-products_en.pdf"},
    {"id":"34438","name":"Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-02-12T13:00:00Z","last_updated_date":"2016-02-12T13:00:00Z","reference_number":"EMA/85655/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/updated-recommendations-minimise-risk-rare-brain-infection-pml-tysabri_en.pdf"},
    {"id":"34440","name":"Mycophenolate: updated recommendations for contraception for men and women","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T01:00:00Z","last_updated_date":"2017-12-15T01:00:00Z","reference_number":"EMA/828208/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/mycophenolate-updated-recommendations-contraception-men-and-women_en.pdf"},
    {"id":"34482","name":"EMEA recommends authorisation of first pre-pandemic influenza vaccine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2008-02-21T00:09:21Z","reference_number":"EMEA/CHMP/90694/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-recommends-authorisation-first-pre-pandemic-influenza-vaccine_en.pdf"},
    {"id":"34489","name":"34th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1998-07-09T14:49:21Z","last_updated_date":"1998-07-09T14:49:21Z","reference_number":"EMEA/CVMP/350/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/34th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"34545","name":"Public statement on Leflunomide 1 (Arava) - Severe and serious hepatic reactions","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-03-12T01:00:00Z","last_updated_date":"2001-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/public-statement-leflunomide-1-arava-severe-and-serious-hepatic-reactions_en.pdf"},
    {"id":"34566","name":"European Medicines Agency adopts first positive opinion for mock-up pandemic influenza vaccine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T00:09:21Z","last_updated_date":"2006-12-15T00:09:21Z","reference_number":"EMEA/502873/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-adopts-first-positive-opinion-mock-pandemic-influenza-vaccine_en.pdf"}    {"id":"34610","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 12-13 October 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-10-15T02:00:00Z","last_updated_date":"2010-10-15T02:00:00Z","reference_number":"EMA/CVMP/609594/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-12-13-october-2010_en.pdf"},
    {"id":"34637","name":"European Medicines Agency recommends measures to manage contamination of heparin-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-05T02:09:21Z","last_updated_date":"2008-06-05T02:09:21Z","reference_number":"EMEA/CHMP/277722/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-measures-manage-contamination-heparin-containing-medicines_en.pdf"},
    {"id":"34645","name":"European Medicines Agency agrees policy on publication of clinical trial data with more user-friendly amendments","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-06-12T02:00:00Z","last_updated_date":"2014-06-12T02:00:00Z","reference_number":"EMA/348985/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-agrees-policy-publication-clinical-trial-data-more-user-friendly-amendments_en.pdf"},
    {"id":"34734","name":"Ark Therapeutics Ltd withdraws its marketing authorisation application for Cerepro (sitimagene ceradenovec)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-03-11T01:00:00Z","last_updated_date":"2010-03-11T01:00:00Z","reference_number":"EMA/151854/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/ark-therapeutics-ltd-withdraws-its-marketing-authorisation-application-cerepro-sitimagene-ceradenovec_en.pdf"},
    {"id":"34748","name":"EMA recommends additional measures to prevent use of mycophenolate in pregnancy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/680077/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-additional-measures-prevent-use-mycophenolate-pregnancy_en.pdf"},
    {"id":"34758","name":"PRAC recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-11-07T01:00:00Z","last_updated_date":"2014-11-07T01:00:00Z","reference_number":"EMA/676096/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_en.pdf"},
    {"id":"34802","name":"European Medicines Agency advises on compassionate use of daclatasvir","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/719859/2013 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-advises-compassionate-use-daclatasvir_en.pdf"},
    {"id":"34814","name":"Committee for Proprietary Medicinal Products (CPMP): meeting of 24 to 26 July 2001","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-07-27T02:09:21Z","last_updated_date":"2001-07-27T02:09:21Z","reference_number":"CPMP/2341/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-meeting-24-26-july-2001_en.pdf"},
    {"id":"34827","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 February 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-02-13T01:00:00Z","last_updated_date":"2015-02-13T01:00:00Z","reference_number":"EMA/CVMP/60802/2015 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-10-12-february-2015_en.pdf"},
    {"id":"34958","name":"EMA Management Board: highlights of December 2015 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/855276/2015 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-december-2015-meeting_en.pdf"},
    {"id":"35042","name":"Committee for Proprietary Medicinal Products (CPMP) 47th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-03-29T02:00:00Z","last_updated_date":"1999-03-29T02:00:00Z","reference_number":"CPMP/841/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-47th-plenary-meeting_en.pdf"},
    {"id":"35053","name":"European Medicines Agency tightens rules on 'revolving door' for committee members and experts","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-05-06T12:00:00Z","last_updated_date":"2015-05-06T12:00:00Z","reference_number":"EMA/282052/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-tightens-rules-revolving-door-committee-members-and-experts_en.pdf"},
    {"id":"35132","name":"EMA Management Board: highlights of June 2017 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-06-16T15:30:00Z","last_updated_date":"2017-06-16T15:30:00Z","reference_number":"EMA/365003/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-june-2017-meeting_en.pdf"},
    {"id":"35140","name":"Committee for veterinary medicinal products: 51st meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2000-01-13T12:49:21Z","last_updated_date":"2000-01-13T12:49:21Z","reference_number":"EMEA/CVMP/049/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-51st-meeting_en.pdf"},
    {"id":"35177","name":"Astellas Pharma Europe B.V. withdraws its application for an extension of the indication for Qutenza (capsaicin)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-03-20T10:15:00Z","last_updated_date":"2012-03-20T10:15:00Z","reference_number":"EMA/197157/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/astellas-pharma-europe-bv-withdraws-its-application-extension-indication-qutenza-capsaicin_en.pdf"},
    {"id":"35209","name":"Committee for veterinary medicinal products: Meeting of 10 to 12 February 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-02-13T12:49:21Z","last_updated_date":"2004-02-13T12:49:21Z","reference_number":"EMEA/CVMP/213/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-10-12-february-2004_en.pdf"},
    {"id":"35214","name":"PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T13:00:00Z","last_updated_date":"2016-12-02T13:00:00Z","reference_number":"EMA/795452/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-warns-risk-hepatitis-b-re-activation-direct-acting-antivirals-hepatitis-c_en.pdf"},
    {"id":"35225","name":"European Medicines Agency introduces new, faster scientific advice procedure","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-05-31T02:00:00Z","last_updated_date":"2009-05-31T02:00:00Z","reference_number":"EMEA/165974/2006 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-introduces-new-faster-scientific-advice-procedure_en.pdf"},
    {"id":"35228","name":"Review of the manufacture of Baxter’s peritoneal dialysis solutions initiated over potential presence of endotoxins in some batches","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/52545/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/review-manufacture-baxters-peritoneal-dialysis-solutions-initiated-over-potential-presence-endotoxins-some-batches_en.pdf"},
    {"id":"35246","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 8-10 April 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-04-13T17:30:00Z","last_updated_date":"2015-04-13T17:30:00Z","reference_number":"EMA/CVMP/205284/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-april-2015_en.pdf"},
    {"id":"35249","name":"New treatment option recommended for patients with advanced melanoma","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/333850/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-option-recommended-patients-advanced-melanoma_en.pdf"},
    {"id":"35326","name":"Orion Corporation withdraws its application for an extension of indication for Stalevo (levodopa/carbidopa/entacapone)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-03-10T01:00:00Z","last_updated_date":"2009-03-10T01:00:00Z","reference_number":"EMEA/147137/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/orion-corporation-withdraws-its-application-extension-indication-stalevo-levodopacarbidopaentacapone_en.pdf"},
    {"id":"35350","name":"Bristol-Myers squibb pharma EEIG withdraws its marketing authorisation application for Ixempra","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-03-19T01:00:00Z","last_updated_date":"2009-03-19T01:00:00Z","reference_number":"EMEA/177056/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/bristol-myers-squibb-pharma-eeig-withdraws-its-marketing-authorisation-application-ixempra_en.pdf"},
    {"id":"35364","name":"Better protection of public health: European Medicines Agency counts down to introduction of new pharmacovigilance legislation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T10:30:00Z","last_updated_date":"2012-02-02T10:30:00Z","reference_number":"EMA/30803/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/better-protection-public-health-european-medicines-agency-counts-down-introduction-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"35394","name":"Sanofi-Aventis Pharma S.A. withdraws its application for an extension of indication for Taxotere and Docetaxel Winthrop (docetaxel)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-11-17T00:09:21Z","last_updated_date":"2008-11-17T00:09:21Z","reference_number":"EMEA/610719/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/sanofi-aventis-pharma-sa-withdraws-its-application-extension-indication-taxotere-and-docetaxel-winthrop-docetaxel_en.pdf"},
    {"id":"35410","name":"34th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-04-16T02:00:00Z","last_updated_date":"2003-04-16T02:00:00Z","reference_number":"EMEA/COMP/1090/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/34th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"35426","name":"European Medicines Agency meets with avian flu vaccine manufacturers","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-03-09T01:00:00Z","last_updated_date":"2006-03-09T01:00:00Z","reference_number":"EMEA/86056/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-meets-avian-flu-vaccine-manufacturers_en.pdf"},
    {"id":"35500","name":"EuroGen Pharmaceuticals withdraws its application for Orathecin","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-01-23T01:00:00Z","last_updated_date":"2006-01-23T01:00:00Z","reference_number":"EMEA/26219/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/eurogen-pharmaceuticals-withdraws-its-application-orathecin_en.pdf"},
    {"id":"35506","name":"EMA reviews cancer medicine Zydelig","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T16:30:00Z","last_updated_date":"2016-03-11T16:30:00Z","reference_number":"EMA/191705/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-reviews-cancer-medicine-zydelig_en.pdf"},
    {"id":"35521","name":"Committee for medicinal products for veterinary use: Meeting of 9-11 October 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-10-15T14:49:21Z","last_updated_date":"2007-10-15T14:49:21Z","reference_number":"EMEA/CVMP/453311/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-9-11-october-2007_en.pdf"},
    {"id":"35552","name":"Personal Message from Mr Fernand Sauer, EMEA Executive Director(29/June/2000)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-06-28T02:00:00Z","last_updated_date":"2000-06-28T02:00:00Z","reference_number":"EMEA/D/18899/EN","document_url":"https://www.ema.europa.eu/en/documents/press-release/personal-message-mr-fernand-sauer-emea-executive-director29june2000_en.pdf"},
    {"id":"35584","name":"Highlights of 100th Management Board meeting: June 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/379969/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/highlights-100th-management-board-meeting-june-2018_en.pdf"},
    {"id":"35586","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products 21-22 November 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-10-23T02:09:21Z","last_updated_date":"2003-10-23T02:09:21Z","reference_number":"EMEA/CPMP/5259/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-21-22-november-2003_en.pdf"},
    {"id":"35632","name":"PRAC concludes review of Zydelig and issues updated recommendations for use","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"EMA/459461/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-concludes-review-zydelig-and-issues-updated-recommendations-use_en.pdf"},
    {"id":"35648","name":"Insmed withdraws its marketing authorisation application for IPLEX","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-03-26T02:00:00Z","last_updated_date":"2007-03-26T02:00:00Z","reference_number":"EMEA/136007/2007-corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/insmed-withdraws-its-marketing-authorisation-application-iplex_en.pdf"},
    {"id":"35653","name":"European Medicines Agency’s Management Board endorses work programme 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-12-18T16:00:00Z","last_updated_date":"2012-12-18T16:00:00Z","reference_number":"EMA/798937/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-endorses-work-programme-2013_en.pdf"},
    {"id":"35713","name":"Unparalleled access to clinical data - one year on","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-10-20T02:00:00Z","last_updated_date":"2017-10-20T02:00:00Z","reference_number":"EMA/682188/2017 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/unparalleled-access-clinical-data-one-year_en.pdf"},
    {"id":"35753","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n21-24 September 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:09:21Z","last_updated_date":"2009-09-25T02:09:21Z","reference_number":"EMEA/CHMP/606274/2009 corr.*","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-21-24-september-2009_en.pdf"},
    {"id":"35765","name":"EMEA launches consultation on the future of EU pharmaceutical guidelines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-09-09T02:00:00Z","last_updated_date":"2004-09-09T02:00:00Z","reference_number":"EMEA/62818/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-launches-consultation-future-eu-pharmaceutical-guidelines_en.pdf"},
    {"id":"35778","name":"EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"EMA/733064/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_en.pdf"},
    {"id":"35792","name":"European Medicines Agency gives first positive opinion for paediatric-use marketing authorisation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/495827/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-first-positive-opinion-paediatric-use-marketing-authorisation_en.pdf"},
    {"id":"35893","name":"Tenth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1996-07-03T02:00:00Z","last_updated_date":"1996-07-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/tenth-meeting-management-board_en.pdf"},
    {"id":"35959","name":"Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-07-24T02:00:00Z","last_updated_date":"2014-07-24T02:00:00Z","reference_number":"EMA/440549/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_en.pdf"},
    {"id":"35968","name":"Update on review of recalled valsartan medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-08-02T02:00:00Z","last_updated_date":"2018-08-02T02:00:00Z","reference_number":"EMA/526031/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-review-recalled-valsartan-medicines_en.pdf"},
    {"id":"36058","name":"First medicine to treat neonatal diabetes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-02-23T13:01:00Z","last_updated_date":"2018-02-23T13:01:00Z","reference_number":"EMA/CHMP/110433/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-medicine-treat-neonatal-diabetes_en.pdf"},
    {"id":"36065","name":"Herbal medicinal products working group executive summary of AD HOC meetings","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-01-28T01:00:00Z","last_updated_date":"1997-01-28T01:00:00Z","reference_number":"EMEA/1120/97 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/herbal-medicinal-products-working-group-executive-summary-ad-hoc-meetings_en.pdf"},
    {"id":"36109","name":"17th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-11-05T00:00:00Z","last_updated_date":"2001-11-05T00:00:00Z","reference_number":"EMEA/COMP/498/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/17th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"36224","name":"Actelion withdraws its application for an extension of indication for Zavesca","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-02-25T00:09:21Z","last_updated_date":"2008-02-25T00:09:21Z","reference_number":"EMEA/95140/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/actelion-withdraws-its-application-extension-indication-zavesca_en.pdf"},
    {"id":"36236","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n17-20 September 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-09-21T02:09:21Z","last_updated_date":"2007-09-21T02:09:21Z","reference_number":"EMEA/323703/2007 - corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-17-20-september-2007_en.pdf"},
    {"id":"36272","name":"Meeting highlights from the Paediatric Committee: 2 - 4 July 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/PDCO/355329/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-2-4-july-2008_en.pdf"},
    {"id":"36279","name":"Committee for Proprietary Medicinal Products (CPMP) 43rd plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-11-24T00:00:00Z","last_updated_date":"1998-11-24T00:00:00Z","reference_number":"CPMP/2572/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-43rd-plenary-meeting_en.pdf"},
    {"id":"36326","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n12-15 November 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-11-16T00:09:21Z","last_updated_date":"2007-11-16T00:09:21Z","reference_number":"EMEA/CHMP/522566/2007-corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-12-15-november-2007_en.pdf"},
    {"id":"36344","name":"27th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-12-11T12:09:21Z","last_updated_date":"1997-12-11T12:09:21Z","reference_number":"EMEA/CVMP/425/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/27th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"36374","name":"EMEA recommends new warnings and contraindications for rosiglitazone","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/42232/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-recommends-new-warnings-and-contraindications-rosiglitazone_en.pdf"},
    {"id":"36423","name":"Committee for veterinary medicinal products: 54th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-04-19T14:09:21Z","last_updated_date":"2000-04-19T14:09:21Z","reference_number":"EMEA/CVMP/298/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-54th-meeting_en.pdf"},
    {"id":"36483","name":"First DNA vaccine in the EU recommended for use in salmon","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/CVMP/281226/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-dna-vaccine-eu-recommended-use-salmon_en.pdf"},
    {"id":"36527","name":"Stimulating the development of medicines for children","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-07-23T13:00:00Z","last_updated_date":"2015-07-23T13:00:00Z","reference_number":"EMA/481636/2015 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/stimulating-development-medicines-children_en.pdf"},
    {"id":"36554","name":"Committee for medicinal products for veterinary use: Meeting of 10-12 July 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-13T14:49:21Z","last_updated_date":"2007-07-13T14:49:21Z","reference_number":"EMEA/CVMP/273194/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-10-12-july-2007_en.pdf"},
    {"id":"36579","name":"Meeting highlights from the Paediatric Committee: 13 - 15 February 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-03-27T01:00:00Z","last_updated_date":"2008-03-27T01:00:00Z","reference_number":"EMEA/PDCO/83264/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-13-15-february-2008_en.pdf"},
    {"id":"36607","name":"European Medicines Agency recommends revocation of marketing authorisations for bufexamac","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2010-04-22T02:00:00Z","reference_number":"EMA/246395/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-revocation-marketing-authorisations-bufexamac_en.pdf"},
    {"id":"36709","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 20-23 June 2011","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T14:50:40Z","last_updated_date":"2011-06-24T14:50:40Z","reference_number":"EMA/CHMP/30246/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2011_en.pdf"},
    {"id":"36748","name":"Meeting highlights from the Paediatric Committee: 14 - 16 October 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/PDCO/645737/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-14-16-october-2009_en.pdf"},
    {"id":"36839","name":"European Risk Management Strategy: Achievements to date","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-26T02:00:00Z","last_updated_date":"2007-07-26T02:00:00Z","reference_number":"EMEA/308167/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-risk-management-strategy-achievements-date_en.pdf"},
    {"id":"36857","name":"Commitee for Orphan Medicinal Products: January 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-01-19T01:00:00Z","last_updated_date":"2004-01-19T01:00:00Z","reference_number":"EMEA/COMP/9/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-january-2004-meeting_en.pdf"},
    {"id":"36870","name":"Novartis withdraws its application to extend the marketing authorisation for Glivec","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-10-06T02:00:00Z","last_updated_date":"2006-10-06T02:00:00Z","reference_number":"EMEA/423844/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/novartis-withdraws-its-application-extend-marketing-authorisation-glivec_en.pdf"},
    {"id":"36936","name":"European Medicines Agency recommends authorisation of first medicine specifically for irritable bowel syndrome","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-09-21T14:02:00Z","last_updated_date":"2012-09-21T14:02:00Z","reference_number":"EMA/CHMP/611096/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-authorisation-first-medicine-specifically-irritable-bowel-syndrome_en.pdf"},
    {"id":"36940","name":"European Medicines Agency holds Focus Group meeting on fibrosarcoma occurring at sites of injection of veterinary medicines in cats","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-07-19T14:49:21Z","last_updated_date":"2007-07-19T14:49:21Z","reference_number":"EMEA/CVMP/PhVWP/296279/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-holds-focus-group-meeting-fibrosarcoma-occurring-sites-injection-veterinary-medicines-cats_en.pdf"},
    {"id":"36951","name":"New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-05-18T14:00:00Z","last_updated_date":"2018-05-18T14:00:00Z","reference_number":"EMA/295960/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-study-suggests-risk-birth-defects-babies-born-women-hiv-medicine-dolutegravir_en.pdf"},
    {"id":"36976","name":"European Medicines Agency recommends authorisation of first medicine for Castleman's disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/163651/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-authorisation-first-medicine-castlemans-disease_en.pdf"},
    {"id":"36999","name":"EMA Management Board: highlights of March 2015 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-03-20T01:00:00Z","last_updated_date":"2015-03-20T01:00:00Z","reference_number":"EMA/188328/2015 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-march-2015-meeting_en.pdf"},
    {"id":"37039","name":"Sixteenth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-12-05T01:00:00Z","last_updated_date":"1997-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/sixteenth-meeting-management-board_en.pdf"},
    {"id":"37092","name":"Collaboration with academia to be reinforced","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-04-03T02:00:00Z","last_updated_date":"2017-04-03T02:00:00Z","reference_number":"EMA/201401/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/collaboration-academia-be-reinforced_en.pdf"},
    {"id":"37110","name":"DOR BIOPHARMA UK Ltd withdraws marketing authorisation application for orBec (beclomethasone dipropionate)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-05-23T02:00:00Z","last_updated_date":"2008-05-23T02:00:00Z","reference_number":"EMEA/CHMP/274727/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/dor-biopharma-uk-ltd-withdraws-marketing-authorisation-application-orbec-beclomethasone-dipropionate_en.pdf"},
    {"id":"37149","name":"European Medicines Agency launches new database of European experts","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-09-30T14:15:05Z","last_updated_date":"2011-09-30T14:15:05Z","reference_number":"EMA/794549/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-launches-new-database-european-experts_en.pdf"},
    {"id":"37192","name":"European Medicines Agency alerts EU healthcare professionals after vials of falsified Herceptin identified","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-16T14:00:00Z","last_updated_date":"2014-08-11T16:00:00Z","reference_number":"EMA/231414/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-alerts-eu-healthcare-professionals-after-vials-falsified-herceptin-identified_en.pdf"},
    {"id":"37207","name":"29th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-11-22T00:09:21Z","last_updated_date":"2002-11-22T00:09:21Z","reference_number":"EMEA/COMP/2792/02/corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/29th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"37214","name":"Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T13:00:00Z","last_updated_date":"2018-03-09T13:00:00Z","reference_number":"EMA/146483/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_en.pdf"},
    {"id":"37228","name":"PRAC recommends restrictions on the use of codeine for cough and cold in children","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/163792/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-restrictions-use-codeine-cough-and-cold-children_en.pdf"},
    {"id":"37268","name":"Novartis Vaccines and Diagnostics S.r.l. withdraws its marketing\n\nauthorisation application for the pre-pandemic vaccine Aflunov","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-06-16T02:00:00Z","last_updated_date":"2008-06-16T02:00:00Z","reference_number":"EMEA/306734/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/novartis-vaccines-and-diagnostics-srl-withdraws-its-marketing-authorisation-application-pre-pandemic-vaccine-aflunov_en.pdf"},
    {"id":"37320","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n19-22 January 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T00:09:21Z","last_updated_date":"2009-01-22T00:09:21Z","reference_number":"EMEA/37933/2009 - corr","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-19-22-january-2009_en.pdf"},
    {"id":"37326","name":"Sanofi-aventis withdraws its marketing authorisation application for\n\nAquilda (satavaptan)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-05-28T02:00:00Z","last_updated_date":"2008-05-28T02:00:00Z","reference_number":"EMEA/CHMP/277714/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/sanofi-aventis-withdraws-its-marketing-authorisation-application-aquilda-satavaptan_en.pdf"},
    {"id":"37343","name":"Committee for Proprietary Medicinal Products (CPMP): meeting of 16 to 18 October 2001","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-10-19T02:09:21Z","last_updated_date":"2001-10-19T02:09:21Z","reference_number":"EMEA/CPMP/3297/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-meeting-16-18-october-2001_en.pdf"},
    {"id":"37385","name":"European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products 18-20 November 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-11-20T00:09:21Z","last_updated_date":"2003-11-20T00:09:21Z","reference_number":"EMEA/CPMP/5732/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-18-20-november-2003_en.pdf"},
    {"id":"37413","name":"European Medicines Agency launches public consultation on new transparency policy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:00:00Z","last_updated_date":"2009-06-19T02:00:00Z","reference_number":"EMEA/376923/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-launches-public-consultation-new-transparency-policy_en.pdf"},
    {"id":"37420","name":"Meeting of the EMEA working party on herbal medicinal products 1 - 2 April 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-04-19T02:00:00Z","last_updated_date":"2004-04-19T02:00:00Z","reference_number":"EMEA/HMPWP/1513/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-emea-working-party-herbal-medicinal-products-1-2-april-2004_en.pdf"},
    {"id":"37430","name":"European Risk Management Strategy: 2008-2009 work programme adopted","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-12-20T01:00:00Z","last_updated_date":"2007-12-20T01:00:00Z","reference_number":"EMEA/564868/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-risk-management-strategy-2008-2009-work-programme-adopted_en.pdf"},
    {"id":"37471","name":"European Medicines Agency recommends authorisation of two additional Bluetongue vaccines through the centralised procedure","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-11-27T00:09:21Z","last_updated_date":"2009-11-27T00:09:21Z","reference_number":"EMEA/733596/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-authorisation-two-additional-bluetongue-vaccines-through-centralised-procedure_en.pdf"},
    {"id":"37483","name":"European Medicines Agency holds first scientific workshop on nanomedicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-06T02:00:00Z","last_updated_date":"2010-09-06T02:00:00Z","reference_number":"EMA/559074/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-holds-first-scientific-workshop-nanomedicines_en.pdf"},
    {"id":"37537","name":"European Medicines Agency recommends suspension of marketing authorisations for carisoprodol-containing medicinal products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-11-16T00:09:21Z","last_updated_date":"2007-11-16T00:09:21Z","reference_number":"EMEA/520463/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-marketing-authorisations-carisoprodol-containing-medicinal-products_en.pdf"},
    {"id":"37545","name":"European Medicines Agency recommends restricting use of estradiol-containing creams Linoladiol N and Linoladiol HN","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T15:00:00Z","last_updated_date":"2013-12-20T15:00:00Z","reference_number":"EMA/796289/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-estradiol-containing-creams-linoladiol-n-and-linoladiol-hn_en.pdf"},
    {"id":"37549","name":"EMEA Paediatric Working Party meets for last time ahead of creation of new\n\nPaediatric Committee","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-11T02:00:00Z","last_updated_date":"2007-06-11T02:00:00Z","reference_number":"EMEA/259192/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-paediatric-working-party-meets-last-time-ahead-creation-new-paediatric-committee_en.pdf"},
    {"id":"37555","name":"Updated statement from European Medicines Agency on celecoxib","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-12-22T01:00:00Z","last_updated_date":"2004-12-22T01:00:00Z","reference_number":"EMEA/212271/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/updated-statement-european-medicines-agency-celecoxib_en.pdf"},
    {"id":"37565","name":"EMA Management Board: highlights of December 2017 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T11:30:00Z","last_updated_date":"2017-12-15T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-december-2017-meeting_en.pdf"},
    {"id":"37576","name":"Increasing the availability of veterinary medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T15:00:00Z","last_updated_date":"2015-01-27T15:00:00Z","reference_number":"EMA/31301/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/increasing-availability-veterinary-medicines_en.pdf"},
    {"id":"37630","name":"Committee for veterinary medicinal products: 50th meeting","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1999-12-09T12:09:21Z","last_updated_date":"1999-12-09T12:09:21Z","reference_number":"EMEA/CVMP/858/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-50th-meeting_en.pdf"},
    {"id":"37651","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 4-6 November 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-11-09T01:00:00Z","last_updated_date":"2015-11-09T01:00:00Z","reference_number":"EMA/CVMP/698783/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-4-6-november-2015_en.pdf"},
    {"id":"37692","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 05-07 November 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-08T18:00:00Z","last_updated_date":"2013-11-08T18:00:00Z","reference_number":"EMA/CVMP/651793/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-05-07-november-2013_en.pdf"},
    {"id":"37696","name":"European Medicines Agency widens public access to documents","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-11-30T01:00:00Z","last_updated_date":"2010-11-30T01:00:00Z","reference_number":"EMA/718259/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-widens-public-access-documents_en.pdf"},
    {"id":"37710","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 14-16 May 2013","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T17:00:00Z","last_updated_date":"2013-05-17T17:00:00Z","reference_number":"EMA/CVMP/276523/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-14-16-may-2013_en.pdf"},
    {"id":"37778","name":"Press Release on the cardiovascular safety of non-selective NSAIDs","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-08-02T02:00:00Z","last_updated_date":"2005-08-02T02:00:00Z","reference_number":"EMEA/247323/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-cardiovascular-safety-non-selective-nsaids_en.pdf"}    {"id":"37803","name":"Committee for veterinary medicinal products: Meeting of 11 to 13 February 2003","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-02-14T12:39:21Z","last_updated_date":"2003-02-14T12:39:21Z","reference_number":"EMEA/CVMP/195/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-meeting-11-13-february-2003_en.pdf"},
    {"id":"37826","name":"38th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-09-12T02:00:00Z","last_updated_date":"2003-09-12T02:00:00Z","reference_number":"EMEA/COMP/1439/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/38th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"37874","name":"1st EMEA/CPMP Workshop for Patients’ Organisations – Information and Participation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-06-06T02:00:00Z","last_updated_date":"2002-06-06T02:00:00Z","reference_number":"EMEA/CPMP/2348/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/1st-emeacpmp-workshop-patients-organisations-information-and-participation_en.pdf"},
    {"id":"37995","name":"Committee for Advanced Therapies adopts first classification recommendation for an advanced therapy medicinal product","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-30T02:00:00Z","last_updated_date":"2009-06-30T02:00:00Z","reference_number":"EMEA/CAT/405761/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-advanced-therapies-adopts-first-classification-recommendation-advanced-therapy-medicinal-product_en.pdf"},
    {"id":"38031","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 8-10 April 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T18:00:00Z","last_updated_date":"2014-04-11T18:00:00Z","reference_number":"EMA/177970/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-april-2014_en.pdf"},
    {"id":"38038","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 15-18 March 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"EMA/CHMP/107570/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-march-2010_en.pdf"},
    {"id":"38057","name":"EMEA releases recommendations for better information for patients","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-04-22T02:00:00Z","last_updated_date":"2004-04-22T02:00:00Z","reference_number":"EMEA/H/10720/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-releases-recommendations-better-information-patients_en.pdf"},
    {"id":"38065","name":"CellSeed Europe Ltd. withdraws its marketing-authorisation application for OraNera (autologous oral mucosal epithelial cells)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T16:00:00Z","last_updated_date":"2013-03-20T16:00:00Z","reference_number":"EMA/178195/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/cellseed-europe-ltd-withdraws-its-marketing-authorisation-application-oranera-autologous-oral-mucosal-epithelial-cells_en.pdf"},
    {"id":"38143","name":"New judicial decisions at odds with EMA’s efforts to allow access to documents on medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-09-29T18:00:00Z","last_updated_date":"2016-09-29T18:00:00Z","reference_number":"EMA/526600/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-judicial-decisions-odds-emas-efforts-allow-access-documents-medicines_en.pdf"},
    {"id":"38176","name":"36th meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-06-16T02:00:00Z","last_updated_date":"2003-06-16T02:00:00Z","reference_number":"EMEA/COMP/1254/03","document_url":"https://www.ema.europa.eu/en/documents/press-release/36th-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"38238","name":"European Medicines Agency completes its review of Avastin used in breast cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-16T01:00:00Z","last_updated_date":"2010-12-16T01:00:00Z","reference_number":"EMA/CHMP/815425/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-completes-its-review-avastin-used-breast-cancer_en.pdf"},
    {"id":"38252","name":"Press release: Committee for Orphan Medicinal Products June 2007 Meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-26T02:09:21Z","last_updated_date":"2007-06-26T02:09:21Z","reference_number":"EMEA/COMP/276840/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-committee-orphan-medicinal-products-june-2007-meeting_en.pdf"},
    {"id":"38304","name":"Workshop on access to clinical-trial data and transparency kicks off process towards proactive publication of data","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-11-23T13:44:13Z","last_updated_date":"2012-11-23T13:44:13Z","reference_number":"EMA/754763/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/workshop-access-clinical-trial-data-and-transparency-kicks-process-towards-proactive-publication-data_en.pdf"},
    {"id":"38358","name":"Committee for Orphan Medicinal Products: October 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-10-04T02:00:00Z","last_updated_date":"2006-10-04T02:00:00Z","reference_number":"EMEA/COMP/383989/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-october-2006-meeting_en.pdf"},
    {"id":"38370","name":"Thirtieth meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-06-27T02:09:21Z","last_updated_date":"2001-06-27T02:09:21Z","reference_number":"EMEA/MB/028/01/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/thirtieth-meeting-management-board_en.pdf"},
    {"id":"38388","name":"United Therapeutics Europe Ltd withdraws its marketing authorisation application for Tyvaso","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2010-02-19T01:00:00Z","reference_number":"EMA/107943/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/united-therapeutics-europe-ltd-withdraws-its-marketing-authorisation-application-tyvaso_en.pdf"},
    {"id":"38405","name":"New oral treatment for rheumatoid arthritis","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/CHMP/856232/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-oral-treatment-rheumatoid-arthritis_en.pdf"},
    {"id":"38439","name":"European Medicines Agency Management Board re-elects Pat O'Mahony as chair","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/MB/376103/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-management-board-re-elects-pat-omahony-chair_en.pdf"},
    {"id":"38454","name":"European Medicines Agency updates on pandemic influenza","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2010-02-19T01:00:00Z","reference_number":"EMA/94706/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-pandemic-influenza_en.pdf"},
    {"id":"38522","name":"Meeting highlights from the Paediatric Committee: 4 - 6 March 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-03-13T01:00:00Z","last_updated_date":"2009-03-13T01:00:00Z","reference_number":"EMEA/PDCO/118305/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-4-6-march-2009_en.pdf"},
    {"id":"38529","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products, 23-24 March 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-03-25T00:09:21Z","last_updated_date":"2004-03-25T00:09:21Z","reference_number":"EMEA/CPMP/1303/04/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-23-24-march-2004_en.pdf"},
    {"id":"38545","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 16–18 January 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-01-19T16:00:00Z","last_updated_date":"2018-01-19T16:00:00Z","reference_number":"EMA/CVMP/1360/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-16-18-january-2018_en.pdf"},
    {"id":"38555","name":"First-in-class treatment to lower cholesterol","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/338105/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-class-treatment-lower-cholesterol_en.pdf"},
    {"id":"38595","name":"Activities of former EMA Executive Director Thomas Là¶nngren","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-03-21T01:00:00Z","last_updated_date":"2011-03-21T01:00:00Z","reference_number":"EMA/222199/2011 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/activities-former-ema-executive-director-thomas-lapnngren_en.pdf"},
    {"id":"38600","name":"Krka, d.d., Novo mesto withdraws its marketing authorisation application for Desloratadine Krka (desloratadine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-10-19T02:00:00Z","last_updated_date":"2011-10-19T02:00:00Z","reference_number":"EMA/840073/2011 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/krka-dd-novo-mesto-withdraws-its-marketing-authorisation-application-desloratadine-krka-desloratadine_en.pdf"},
    {"id":"38616","name":"EMEA prepares for entry into force of new legislation on paediatric medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-01-12T01:00:00Z","last_updated_date":"2007-01-12T01:00:00Z","reference_number":"EMEA/9224/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-prepares-entry-force-new-legislation-paediatric-medicines_en.pdf"},
    {"id":"38637","name":"PRAC recommends product information of zolpidem be updated with new advice to minimise the risk of next-morning impaired driving ability and mental alertness","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"EMA/129598/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-product-information-zolpidem-be-updated-new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness_en.pdf"},
    {"id":"38644","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 15-18 November 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-11-18T01:00:00Z","last_updated_date":"2004-11-18T01:00:00Z","reference_number":"EMEA/152989/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-15-18-november-2004_en.pdf"},
    {"id":"38685","name":"Bioenvision Ltd withdraws its application for an extension of indication for Evoltra (clofarabine)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-03-19T01:00:00Z","last_updated_date":"2008-03-19T01:00:00Z","reference_number":"EMEA/145939/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/bioenvision-ltd-withdraws-its-application-extension-indication-evoltra-clofarabine_en.pdf"},
    {"id":"38701","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 15-17 June 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-15-17-june-2010_en.pdf"},
    {"id":"38725","name":"Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 7-9 December 2010","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-10T01:00:00Z","last_updated_date":"2010-12-10T01:00:00Z","reference_number":"EMA/CVMP/760118/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-7-9-december-2010_en.pdf"},
    {"id":"38753","name":"European Medicines Agency recommends restricting use of cilostazol-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-03-22T01:00:00Z","last_updated_date":"2013-03-22T01:00:00Z","reference_number":"EMA/98571/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_en.pdf"},
    {"id":"38804","name":"European Medicines Agency update on non-selective NSAIDs","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-10-17T02:00:00Z","last_updated_date":"2005-10-17T02:00:00Z","reference_number":"EMEA/298964/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-update-non-selective-nsaids_en.pdf"},
    {"id":"38852","name":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 10-12 January 2012","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-01-13T17:00:00Z","last_updated_date":"2012-01-13T17:00:00Z","reference_number":"EMA/CVMP/5471/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-10-12-january-2012_en.pdf"},
    {"id":"38859","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n18-21 June 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-06-22T02:09:21Z","last_updated_date":"2007-06-22T02:09:21Z","reference_number":"EMEA/267556/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-18-21-june-2007_en.pdf"},
    {"id":"38862","name":"European Medicines Agency releases for public consultation its draft policy on the publication and access to clinical-trial data","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-06-24T16:00:00Z","last_updated_date":"2013-06-24T16:00:00Z","reference_number":"EMA/382397/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-releases-public-consultation-its-draft-policy-publication-and-access-clinical-trial-data_en.pdf"},
    {"id":"38888","name":"European Medicines Agency starts review of Tredaptive, Pelzont and Trevaclyn","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-12-21T12:10:00Z","last_updated_date":"2011-12-21T12:10:00Z","reference_number":"EMA/821179/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-starts-review-tredaptive-pelzont-and-trevaclyn_en.pdf"},
    {"id":"38955","name":"European Medicines Agency: Committee for Medicinal Products for Human Use, 22-23 June 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-06-24T02:09:21Z","last_updated_date":"2004-06-24T02:09:21Z","reference_number":"EMEA/17587/04/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-22-23-june-2004_en.pdf"},
    {"id":"38967","name":"European Medicines Agency consulting on a draft guideline on pharmacovigilance for medicines used in children","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-08-12T02:00:00Z","last_updated_date":"2005-08-12T02:00:00Z","reference_number":"EMEA/262135/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-consulting-draft-guideline-pharmacovigilance-medicines-used-children_en.pdf"},
    {"id":"38996","name":"First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/496941/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-medicine-hiv-pre-exposure-prophylaxis-recommended-approval-eu_en.pdf"},
    {"id":"39020","name":"Committee for Veterinary Medicinal Products: 49th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-11-11T12:09:21Z","last_updated_date":"1999-11-11T12:09:21Z","reference_number":"EMEA/CVMP/778/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-49th-meeting_en.pdf"},
    {"id":"39043","name":"Nineteenth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-10-01T02:00:00Z","last_updated_date":"1998-10-01T02:00:00Z","reference_number":"EMEA/MB/027/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/nineteenth-meeting-management-board_en.pdf"},
    {"id":"39054","name":"Meeting highlights from the Committee for Medicinal Products for Human Use,\n\n19-22 March 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-03-23T00:09:21Z","last_updated_date":"2007-03-23T00:09:21Z","reference_number":"EMEA/132706/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-19-22-march-2007_en.pdf"},
    {"id":"39071","name":"European Medicines Agency’s Management Board emphasises the importance of the European medicines network","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/169371/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-emphasises-importance-european-medicines-network_en.pdf"},
    {"id":"39072","name":"European Medicines Agency agrees to recall of Vimpat 15-mg/ml syrup","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/581202/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-agrees-recall-vimpat-15-mgml-syrup_en.pdf"},
    {"id":"39117","name":"Update on the withdrawal of Thelin","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-16T01:00:00Z","last_updated_date":"2010-12-16T01:00:00Z","reference_number":"EMA/CHMP/819948/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-withdrawal-thelin_en.pdf"},
    {"id":"39185","name":"Merck Sharp & Dohme Ltd withdraws its marketing authorisation application for Vorinostat MSD (vorinostat)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-17T01:00:00Z","last_updated_date":"2009-02-17T01:00:00Z","reference_number":"EMEA/90948/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/merck-sharp-dohme-ltd-withdraws-its-marketing-authorisation-application-vorinostat-msd-vorinostat_en.pdf"},
    {"id":"39217","name":"Meeting highlights from the Paediatric Committee: 29 -  31 July 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/PDCO/412084/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-29-31-july-2008_en.pdf"},
    {"id":"39229","name":"European Medicines Agency: Committee for Medicinal Products for Human Use\n\n11-14 December 2005","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2005-12-15T00:09:21Z","last_updated_date":"2005-12-15T00:09:21Z","reference_number":"EMEA/421484/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-11-14-december-2005_en.pdf"},
    {"id":"39427","name":"Committee for Proprietary Medicinal Products (CPMP) 49th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1999-05-25T02:00:00Z","last_updated_date":"1999-05-25T02:00:00Z","reference_number":"CPMP/1434/99","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-49th-plenary-meeting_en.pdf"},
    {"id":"39453","name":"European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-23T02:00:00Z","last_updated_date":"2010-09-23T02:00:00Z","reference_number":"EMA/585784/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-suspension-avandia-avandamet-and-avaglim_en.pdf"},
    {"id":"39482","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products - Meeting of 19 to 21 February 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-02-21T00:09:21Z","last_updated_date":"2002-02-21T00:09:21Z","reference_number":"EMEA/CPMP/561/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-19-21-february-2002_en.pdf"},
    {"id":"39489","name":"Management Board delays formal adoption of EMA publication of clinical trial data policy to October 2014","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-07-09T02:00:00Z","last_updated_date":"2014-07-09T02:00:00Z","reference_number":"EMA/415308/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/management-board-delays-formal-adoption-ema-publication-clinical-trial-data-policy-october-2014_en.pdf"},
    {"id":"39491","name":"Handling competing interests: revised rules for Management Board members","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-01-14T01:00:00Z","last_updated_date":"2016-01-14T01:00:00Z","reference_number":"EMA/6697/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/handling-competing-interests-revised-rules-management-board-members_en.pdf"},
    {"id":"39543","name":"15% decrease in sales of veterinary antibiotics in Europe","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-15T02:00:00Z","last_updated_date":"2014-10-15T02:00:00Z","reference_number":"EMA/619398/2014 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/15-decrease-sales-veterinary-antibiotics-europe_en.pdf"},
    {"id":"39596","name":"23rd meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1997-07-18T14:00:00Z","last_updated_date":"1997-07-18T14:00:00Z","reference_number":"EMEA/CVMP/240/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/23rd-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"39605","name":"European Medicines Agency recommends extending use of Abraxane to include treatment of pancreatic cancer","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/716830/2013 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-extending-use-abraxane-include-treatment-pancreatic-cancer_en.pdf"},
    {"id":"39642","name":"EMEA launches action plan for improvements for human medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-01-14T01:00:00Z","last_updated_date":"2004-01-14T01:00:00Z","reference_number":"EMEA/H/885/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-launches-action-plan-improvements-human-medicines_en.pdf"},
    {"id":"39765","name":"European Medicines Agency updates on pandemic influenza","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-01-22T01:00:00Z","last_updated_date":"2010-01-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-pandemic-influenza_en.pdf-0"},
    {"id":"39783","name":"European Medicines Agency advises on compassionate use of a new combination therapy for chronic hepatitis C","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T13:00:00Z","last_updated_date":"2014-02-21T13:00:00Z","reference_number":"EMA/104898/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-advises-compassionate-use-new-combination-therapy-chronic-hepatitis-c_en.pdf"},
    {"id":"39822","name":"EMEA announces new CPMP chairman and vice-chairman","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-01-23T00:09:21Z","last_updated_date":"2001-01-23T00:09:21Z","reference_number":"EMEA/D/1568/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-announces-new-cpmp-chairman-and-vice-chairman_en.pdf"},
    {"id":"39826","name":"EMEA concludes new advice to doctors and patients for Tysabri (natalizumab) needed","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-03-20T00:09:21Z","last_updated_date":"2008-03-20T00:09:21Z","reference_number":"EMEA/CHMP/139489/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-concludes-new-advice-doctors-and-patients-tysabri-natalizumab-needed_en.pdf"},
    {"id":"39845","name":"Committee for Orphan Medicinal Products: May 2006 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-05-17T02:00:00Z","last_updated_date":"2006-05-17T02:00:00Z","reference_number":"EMEA/COMP/180251/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-orphan-medicinal-products-may-2006-meeting_en.pdf"},
    {"id":"39876","name":"CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2014-11-21T01:00:00Z","reference_number":"EMA/709243/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_bg.pdf","es":"https://www.ema.europa.eu/es/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_cs.pdf","da":"https://www.ema.europa.eu/da/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_da.pdf","de":"https://www.ema.europa.eu/de/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_de.pdf","et":"https://www.ema.europa.eu/et/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_et.pdf","el":"https://www.ema.europa.eu/el/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_hr.pdf","it":"https://www.ema.europa.eu/it/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/press-release/cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_sv.pdf"}},
    {"id":"39917","name":"Meeting highlights from Paediatric Committee : 11 - 13 November 2009","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-11-24T01:00:00Z","last_updated_date":"2009-11-24T01:00:00Z","reference_number":"http://www.emea.europa.eu/pdfs/human/pdco/71641309","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-11-13-november-2009_en.pdf"},
    {"id":"39945","name":"EMA Management Board: highlights of December 2014 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/790130/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-december-2014-meeting_en.pdf"},
    {"id":"39948","name":"European Medicines Agency appoints new Head of Unit for Veterinary\n\nmedicines and inspections","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-11-24T01:00:00Z","last_updated_date":"2005-11-24T01:00:00Z","reference_number":"EMEA/384622/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-appoints-new-head-unit-veterinary-medicines-and-inspections_en.pdf"},
    {"id":"39965","name":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products - Meeting of 15 to 17 January 2002","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2002-01-17T01:00:00Z","last_updated_date":"2002-01-17T01:00:00Z","reference_number":"EMEA/CPMP/4025/02","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-agency-evaluation-medicinal-products-committee-proprietary-medicinal-products-meeting-15-17-january-2002_en.pdf"},
    {"id":"39971","name":"European Medicines Agency to review the safety of somatropin-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-10T01:00:00Z","last_updated_date":"2010-12-10T01:00:00Z","reference_number":"EMA/804468/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-review-safety-somatropin-containing-medicines_en.pdf"},
    {"id":"40107","name":"EU and Japan reinforce their collaboration on inspections of medicine manufacturers","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-07-18T11:30:00Z","last_updated_date":"2018-07-18T11:30:00Z","reference_number":"EMA/252360/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-and-japan-reinforce-their-collaboration-inspections-medicine-manufacturers_en.pdf"},
    {"id":"40108","name":"EMEA brings in new openness measures and acts to encourage development of veterinary medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-10-03T02:09:21Z","last_updated_date":"2003-10-03T02:09:21Z","reference_number":"EMEA/D/26750/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-brings-new-openness-measures-and-acts-encourage-development-veterinary-medicines_en.pdf"},
    {"id":"40113","name":"European Medicines Agency recommends authorisation of first bluetongue vaccine through centralised procedure","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-02-18T01:00:00Z","last_updated_date":"2009-02-18T01:00:00Z","reference_number":"EMEA/103561/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-authorisation-first-bluetongue-vaccine-through-centralised-procedure_en.pdf"},
    {"id":"40141","name":"Entacapone (COMTESS/COMTAN) - Update of product information","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-11-23T01:00:00Z","last_updated_date":"1998-11-23T01:00:00Z","reference_number":"EMEA/39582/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/entacapone-comtesscomtan-update-product-information_en.pdf"},
    {"id":"40148","name":"1st EMEA workshop for patients' organisations on Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-04-05T02:00:00Z","last_updated_date":"2001-04-05T02:00:00Z","reference_number":"COMP/108/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/1st-emea-workshop-patients-organisations-orphan-medicinal-products_en.pdf"},
    {"id":"40186","name":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-07-01T02:00:00Z","reference_number":"EMA/CHMP/272093/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp_en.pdf"},
    {"id":"40194","name":"Committee for medicinal products for veterinary use: Meeting of 17-18 April 2007","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-04-19T14:09:21Z","last_updated_date":"2007-04-19T14:09:21Z","reference_number":"EMEA/CVMP/162220/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-17-18-april-2007_en.pdf"},
    {"id":"40203","name":"New medicine to prevent cytomegalovirus disease in stem cell transplant patients","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/CHMP/672024/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-prevent-cytomegalovirus-disease-stem-cell-transplant-patients_en.pdf"},
    {"id":"40210","name":"European Medicines Agency concludes action on COX-2 inhibitors","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-06-27T02:00:00Z","last_updated_date":"2005-06-27T02:00:00Z","reference_number":"EMEA/207766/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-concludes-action-cox-2-inhibitors_en.pdf"},
    {"id":"40214","name":"First monoclonal antibody therapy for prevention of migraine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/366426/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-monoclonal-antibody-therapy-prevention-migraine_en.pdf"},
    {"id":"40269","name":"PRAC recommends suspension of diacerein-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-11-08T13:00:01Z","last_updated_date":"2013-11-08T13:00:01Z","reference_number":"EMA/679264/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-suspension-diacerein-containing-medicines_en.pdf"},
    {"id":"40270","name":"European Medicines Agency recommends approval of new medicine for Cushing’s disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2012-04-17T13:15:00Z","reference_number":"EMA/CHMP/48737/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-new-medicine-cushings-disease_en.pdf"},
    {"id":"40272","name":"Committee for medicinal products for veterinary use: Meeting of 16 to 18 May 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2006-05-19T14:29:21Z","last_updated_date":"2006-05-19T14:29:21Z","reference_number":"EMEA/CVMP/165988/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-16-18-may-2006_en.pdf"},
    {"id":"40302","name":"EMEA Management Board elects new chairman and sets out proposed work programme for 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2003-02-21T00:09:21Z","last_updated_date":"2003-02-21T00:09:21Z","reference_number":"EMEA/MB/182/03/Final","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-management-board-elects-new-chairman-and-sets-out-proposed-work-programme-2004_en.pdf"},
    {"id":"40314","name":"Start of review of codeine-containing medicines when used for cough and cold in children","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"EMA/209409/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/start-review-codeine-containing-medicines-when-used-cough-and-cold-children_en.pdf"},
    {"id":"40318","name":"Meeting highlights from the Paediatric Committee: 12 - 14 November 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-11-26T01:00:00Z","last_updated_date":"2008-11-26T01:00:00Z","reference_number":"EMEA/610751/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-12-14-november-2008_en.pdf"},
    {"id":"40369","name":"Committee for medicinal products for veterinary use: Meeting of 14 to 15 April 2004","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-04-16T14:39:21Z","last_updated_date":"2004-04-16T14:39:21Z","reference_number":"EMEA/CVMP/409/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-meeting-14-15-april-2004_en.pdf"},
    {"id":"40394","name":"European Medicines Agency: Committee for Medicinal Products for Human Use 23-26 January 2006","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-01-28T00:09:21Z","last_updated_date":"2006-01-28T00:09:21Z","reference_number":"EMEA/32796/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-committee-medicinal-products-human-use-23-26-january-2006_en.pdf"},
    {"id":"40418","name":"European Medicines Agency and EUnetHTA Joint Action start collaboration on European Public Assessment Report (EPAR) contribution to relative effectiveness assessments","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-02-16T00:09:21Z","last_updated_date":"2010-02-16T00:09:21Z","reference_number":"EMA/98431/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-and-eunethta-joint-action-start-collaboration-european-public-assessment-report-epar-contribution-relative-effectiveness-assessments_en.pdf"},
    {"id":"40432","name":"EMA restricts use of multiple sclerosis medicine Zinbryta","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-07-07T14:00:01Z","last_updated_date":"2017-07-07T14:00:01Z","reference_number":"EMA/424159/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-restricts-use-multiple-sclerosis-medicine-zinbryta_en.pdf"},
    {"id":"40451","name":"PRAC re-examines diacerein and recommends that it remain available with restrictions","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T13:00:00Z","last_updated_date":"2014-03-07T13:00:00Z","reference_number":"EMA/133894/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-re-examines-diacerein-and-recommends-it-remain-available-restrictions_en.pdf"},
    {"id":"40469","name":"New medicine for rare, chronic liver disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T14:00:01Z","last_updated_date":"2016-10-14T14:00:01Z","reference_number":"EMA/CHMP/666310/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-rare-chronic-liver-disease_en.pdf"},
    {"id":"40484","name":"European Medicines Agency announces plan to publish committee agendas and minutes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-07-18T20:14:39Z","last_updated_date":"2012-07-18T20:14:39Z","reference_number":"EMA/480386/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-announces-plan-publish-committee-agendas-and-minutes_en.pdf"},
    {"id":"40498","name":"Eighteenth Meeting of the Management Board","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1998-06-03T02:00:00Z","last_updated_date":"1998-06-03T02:00:00Z","reference_number":"EMEA/MB/015/98","document_url":"https://www.ema.europa.eu/en/documents/press-release/eighteenth-meeting-management-board_en.pdf"},
    {"id":"40518","name":"Committee for Proprietary Medicinal Products (CPMP) 25th plenary meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1997-03-21T01:00:00Z","last_updated_date":"1997-03-21T01:00:00Z","reference_number":"CPMP/234/97","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-proprietary-medicinal-products-cpmp-25th-plenary-meeting_en.pdf"},
    {"id":"40591","name":"New EMEA human medicines units announced","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2001-01-15T01:00:00Z","last_updated_date":"2001-01-15T01:00:00Z","reference_number":"EMEA/D/817/01","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-emea-human-medicines-units-announced_en.pdf"},
    {"id":"40625","name":"11th meeting of the committee for veterinary medicinal products","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"1996-04-25T14:49:21Z","last_updated_date":"1996-04-25T14:49:21Z","reference_number":"EMEA/CVMP/081/96","document_url":"https://www.ema.europa.eu/en/documents/press-release/11th-meeting-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"40674","name":"Medicines regulators on both sides of the Atlantic confirm commitment to cooperation on medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2008-10-07T02:09:21Z","last_updated_date":"2008-10-07T02:09:21Z","reference_number":"EMEA/515723/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/medicines-regulators-both-sides-atlantic-confirm-commitment-cooperation-medicines_en.pdf"},
    {"id":"40686","name":"Meeting highlights from the Paediatric Committee: 15 - 17 October 2008","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-10-24T02:00:00Z","last_updated_date":"2009-10-24T02:00:00Z","reference_number":"EMEA/PDCO/552811/2008","document_url":"https://www.ema.europa.eu/en/documents/press-release/meeting-highlights-paediatric-committee-15-17-october-2008_en.pdf"},
    {"id":"40789","name":"Mitigating risks due to the use of antibiotics in animals","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-12-19T15:00:00Z","last_updated_date":"2014-12-19T15:00:00Z","reference_number":"EMA/787672/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/mitigating-risks-due-use-antibiotics-animals_en.pdf"},
    {"id":"40812","name":"Commitee for Orphan Medicinal Products: March 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-03-17T01:00:00Z","last_updated_date":"2004-03-17T01:00:00Z","reference_number":"EMEA/COMP/134/04","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-march-2004-meeting_en.pdf"}    {"id":"40823","name":"European Medicines Agency’s Management Board backs EMEA conflicts of interests policy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-05-27T02:09:21Z","last_updated_date":"2005-05-27T02:09:21Z","reference_number":"EMEA/179731/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agencys-management-board-backs-emea-conflicts-interests-policy_en.pdf"},
    {"id":"40877","name":"CMDh endorses suspension of methadone oral solutions containing high molecular weight povidone","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-07-24T02:00:00Z","last_updated_date":"2014-07-24T02:00:00Z","reference_number":"EMA/444346/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_en.pdf"},
    {"id":"40896","name":"Update on medicines containing valsartan from Zhejiang Tianyu","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-08-20T02:00:00Z","last_updated_date":"2018-08-20T02:00:00Z","reference_number":"EMA/562158/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-medicines-containing-valsartan-zhejiang-tianyu_en.pdf"},
    {"id":"40904","name":"EMEA Conference on Environmental Risk Assessment for Human and Veterinary Medicinal Products - 27-28 October 2005","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-10-28T02:00:00Z","last_updated_date":"2005-10-28T02:00:00Z","reference_number":"EMEA/359945/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-conference-environmental-risk-assessment-human-and-veterinary-medicinal-products-27-28-october-2005_en.pdf"},
    {"id":"40911","name":"European Medicines Agency awards first 'ENCePP study' seal for post-marketing study","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-10-01T02:00:00Z","last_updated_date":"2010-10-01T02:00:00Z","reference_number":"EMA/613458/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-awards-first-encepp-study-seal-post-marketing-study_en.pdf"},
    {"id":"40935","name":"European Medicines Agency recommends action plan to deal with possible presence of endotoxins in Baxter peritoneal dialysis solutions","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/CHMP/825184/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-action-plan-deal-possible-presence-endotoxins-baxter-peritoneal-dialysis-solutions_en.pdf"},
    {"id":"40962","name":"European Medicines Agency sets out next steps on access to clinical-trial data","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-12-05T17:34:03Z","last_updated_date":"2012-12-05T17:34:03Z","reference_number":"EMA/775817/2012","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-sets-out-next-steps-access-clinical-trial-data_en.pdf"},
    {"id":"40965","name":"Menarini International Operations Luxembourg withdraws its marketing authorisation application for Factive","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-06-23T02:00:00Z","last_updated_date":"2009-06-23T02:00:00Z","reference_number":"EMEA/382408/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/menarini-international-operations-luxembourg-withdraws-its-marketing-authorisation-application-factive_en.pdf"},
    {"id":"41085","name":"Committee for veterinary medicinal products: 59th meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-10-12T14:49:21Z","last_updated_date":"2000-10-12T14:49:21Z","reference_number":"EMEA/CVMP/773/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-veterinary-medicinal-products-59th-meeting_en.pdf"},
    {"id":"41097","name":"European Medicines Agency adopts a positive opinion for the use of Prozac in the treatment of children and adolescents suffering from depression","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2006-06-06T02:09:21Z","last_updated_date":"2006-06-06T02:09:21Z","reference_number":"EMEA/202554/2006","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-adopts-positive-opinion-use-prozac-treatment-children-and-adolescents-suffering-depression_en.pdf"},
    {"id":"41123","name":"First stem cell-based veterinary medicine recommended for marketing authorisation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-06-22T02:00:00Z","last_updated_date":"2018-06-22T02:00:00Z","reference_number":"EMA/CVMP/399992/2018 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-stem-cell-based-veterinary-medicine-recommended-marketing-authorisation_en.pdf"},
    {"id":"41128","name":"Commitee for Orphan Medicinal Products: December 2004 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2004-12-10T01:00:00Z","last_updated_date":"2004-12-10T01:00:00Z","reference_number":"EMEA/COMP/192568/2004","document_url":"https://www.ema.europa.eu/en/documents/press-release/commitee-orphan-medicinal-products-december-2004-meeting_en.pdf"},
    {"id":"41155","name":"First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/CHMP/423123/2015 Corr 1","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-hdac-inhibitor-treatment-multiple-myeloma-recommended-approval-eu_en.pdf"},
    {"id":"41207","name":"Second Meeting of the Management Board of the European Agency for the Evaluation of Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"1994-04-13T02:00:00Z","last_updated_date":"1994-04-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/second-meeting-management-board-european-agency-evaluation-medicinal-products_en.pdf"},
    {"id":"41216","name":"European Medicines Agency launches new organisational structure and new visual identity","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2009-12-08T00:09:21Z","last_updated_date":"2009-12-08T00:09:21Z","reference_number":"EMA/704918/2009","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-launches-new-organisational-structure-and-new-visual-identity_en.pdf"},
    {"id":"41239","name":"EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"EMA/381688/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_en.pdf"},
    {"id":"41251","name":"EMEA annual report shows rise in applications for new medicines in 2004,\n\nwith further increases forecast for 2005 and 2006","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2005-03-14T00:09:21Z","last_updated_date":"2005-03-14T00:09:21Z","reference_number":"EMEA/92603/2005","document_url":"https://www.ema.europa.eu/en/documents/press-release/emea-annual-report-shows-rise-applications-new-medicines-2004-further-increases-forecast-2005-and-2006_en.pdf"},
    {"id":"41286","name":"Inaugural meeting of the Committee for Orphan Medicinal Products","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2000-04-19T02:00:00Z","last_updated_date":"2000-04-19T02:00:00Z","reference_number":"EMEA/COMP/5/00","document_url":"https://www.ema.europa.eu/en/documents/press-release/inaugural-meeting-committee-orphan-medicinal-products_en.pdf"},
    {"id":"41326","name":"European Medicines Agency recommends withdrawal of the marketing authorisations for lumiracoxib-containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2007-12-13T01:00:00Z","last_updated_date":"2007-12-13T01:00:00Z","reference_number":"EMEA/CHMP/579301/2007","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-withdrawal-marketing-authorisations-lumiracoxib-containing-medicines_en.pdf"},
    {"id":"41350","name":"EMA confirms recommendations to minimise risk of brain infection PML with Tysabri","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/137488/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_en.pdf"},
    {"id":"41398","name":"European Medicines Agency updates on ongoing benefit-risk review of pioglitazone–containing medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2011-06-23T02:00:00Z","reference_number":"EMA/CHMP/483851/2011","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-updates-ongoing-benefit-risk-review-pioglitazone-containing-medicines_en.pdf"},
    {"id":"41494","name":"EMA advises on development plan for GSK Ebola vaccine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-10-29T01:00:00Z","last_updated_date":"2014-10-29T01:00:00Z","reference_number":"EMA/668741/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-advises-development-plan-gsk-ebola-vaccine_en.pdf"},
    {"id":"41660","name":"European paediatric research network ready to start","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"EMA/273427/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-paediatric-research-network-ready-start_en.pdf"},
    {"id":"41672","name":"European Medicines Agency confirms positive benefit-risk balance of RotaTeq","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2010-09-23T02:00:00Z","last_updated_date":"2010-09-23T02:00:00Z","reference_number":"EMA/CHMP/588332/2010","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-confirms-positive-benefit-risk-balance-rotateq_en.pdf"},
    {"id":"41724","name":"Codeine not to be used in children below 12 years for cough and cold","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/249413/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/codeine-not-be-used-children-below-12-years-cough-and-cold_en.pdf"},
    {"id":"41735","name":"European Medicines Agency gives recommendations on the use of intravenous nicardipine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T02:00:00Z","last_updated_date":"2013-10-25T02:00:00Z","reference_number":"EMA/644174/2013","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_en.pdf"},
    {"id":"41815","name":"EU report provides basis for effective fight against development of resistant bacteria","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-01-30T01:00:00Z","last_updated_date":"2015-01-30T01:00:00Z","reference_number":"EMA/42113/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-report-provides-basis-effective-fight-against-development-resistant-bacteria_en.pdf"},
    {"id":"41856","name":"European Medicines Agency recommends approval of Daklinza in chronic hepatitis C","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/378294/2014","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-daklinza-chronic-hepatitis-c_en.pdf"},
    {"id":"41906","name":"Defect with Buccolam oral syringes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-01-15T17:00:00Z","last_updated_date":"2018-01-15T17:00:00Z","reference_number":"EMA/12612/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/defect-buccolam-oral-syringes_en.pdf"},
    {"id":"41923","name":"EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/457616/2017 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_en.pdf"},
    {"id":"41938","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 13-15 January 2015","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2015-01-16T16:00:00Z","last_updated_date":"2015-01-16T16:00:00Z","reference_number":"EMA/CVMP/601/2015","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-13-15-january-2015_en.pdf"},
    {"id":"41968","name":"New medicine for rare neurodegenerative disorder in children","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/CHMP/250656/2017","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-rare-neurodegenerative-disorder-children_en.pdf"},
    {"id":"42021","name":"Revising the guideline on first-in-human clinical trials","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMA/731614/2016","document_url":"https://www.ema.europa.eu/en/documents/press-release/revising-guideline-first-human-clinical-trials_en.pdf"},
    {"id":"42045","name":"New medicine for the prevention of migraine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-09-21T14:00:00Z","last_updated_date":"2018-09-21T14:00:00Z","reference_number":"EMA/CHMP/639488/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-prevention-migraine_en.pdf"},
    {"id":"42060","name":"Valsartan: review of impurities extended to other sartan medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/641563/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/valsartan-review-impurities-extended-other-sartan-medicines_en.pdf"},
    {"id":"42080","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 September 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-09-14T02:00:00Z","last_updated_date":"2018-09-14T02:00:00Z","reference_number":"EMA/CVMP/596810/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-11-13-september-2018_en.pdf"},
    {"id":"42102","name":"New medicine to treat infections in adults","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/CHMP/640311/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-treat-infections-adults_en.pdf"},
    {"id":"42107","name":"New gene therapy for rare inherited disorder causing vision loss recommended for approval","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/CHMP/635637/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-gene-therapy-rare-inherited-disorder-causing-vision-loss-recommended-approval_en.pdf"},
    {"id":"42149","name":"EU inspection finds Zhejiang Huahai site non-compliant for manufacture of valsartan","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-09-28T17:00:00Z","last_updated_date":"2018-09-28T17:00:00Z","reference_number":"EMA/671501/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-inspection-finds-zhejiang-huahai-site-non-compliant-manufacture-valsartan_en.pdf"},
    {"id":"42205","name":"EMA Management Board: highlights of October 2018 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-05T10:28:00Z","last_updated_date":"2018-10-05T10:28:00Z","reference_number":"EMA/678495/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-october-2018-meeting_en.pdf"},
    {"id":"42206","name":"Fluoroquinolone and quinolone antibiotics: PRAC recommends restrictions on use","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-05T12:13:00Z","last_updated_date":"2018-10-05T12:13:00Z","reference_number":"EMA/668915/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/fluoroquinolone-and-quinolone-antibiotics-prac-recommends-restrictions-use_en.pdf"},
    {"id":"42244","name":"Update on EMA’s Brexit preparedness","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-09T16:18:00Z","last_updated_date":"2018-10-09T16:18:00Z","reference_number":"EMA/689345/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-emas-brexit-preparedness_en.pdf"},
    {"id":"42319","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 9-11 October 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-12T14:42:00Z","last_updated_date":"2018-10-12T14:42:00Z","reference_number":"EMA/CVMP/677247/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-9-11-october-2018_en.pdf"},
    {"id":"42339","name":"EU authorities take further action in ongoing review of sartans","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-15T12:15:00Z","last_updated_date":"2018-10-15T12:15:00Z","reference_number":"EMA/703416/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-authorities-take-further-action-ongoing-review-sartans_en.pdf"},
    {"id":"42340","name":"EU authorities take further action in ongoing review of sartans","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-15T12:15:00Z","last_updated_date":"2018-10-15T12:15:00Z","reference_number":"EMA/703416/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-authorities-take-further-action-ongoing-review-sartans_en.pdf-0"},
    {"id":"42344","name":"Sales of antibiotics for use in food-producing animals drop across the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-15T14:53:00Z","last_updated_date":"2018-10-15T14:53:00Z","reference_number":"EMA/CVMP/683413/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/sales-antibiotics-use-food-producing-animals-drop-across-eu_en.pdf"},
    {"id":"42373","name":"New medicine for hereditary angioedema, a rare disease causing swelling beneath the skin","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T10:36:00Z","last_updated_date":"2018-10-19T10:36:00Z","reference_number":"EMA/CHMP/721397/2018 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-hereditary-angioedema-rare-disease-causing-swelling-beneath-skin_en.pdf"},
    {"id":"42375","name":"First treatment for rare inherited muscle contraction disorders","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T10:48:00Z","last_updated_date":"2018-10-19T10:48:00Z","reference_number":"EMA/CHMP/716161/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-treatment-rare-inherited-muscle-contraction-disorders_en.pdf"},
    {"id":"42387","name":"First vaccine for prevention of dengue","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T15:38:00Z","last_updated_date":"2018-10-19T15:38:00Z","reference_number":"EMA/CHMP/717080/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-vaccine-prevention-dengue_en.pdf"},
    {"id":"42514","name":"Working with stakeholders to improve availability of medicines in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T18:29:00Z","last_updated_date":"2018-10-30T18:29:00Z","reference_number":"EMA/720894/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/working-stakeholders-improve-availability-medicines-eu_en.pdf"},
    {"id":"42615","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 6-8 November 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T16:00:00Z","last_updated_date":"2018-11-09T16:00:00Z","reference_number":"EMA/CVMP/741346/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-6-8-november-2018_en.pdf"},
    {"id":"42706","name":"CHMP recommends first oral-only treatment for sleeping sickness","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T12:42:00Z","last_updated_date":"2018-11-16T12:42:00Z","reference_number":"EMA/CHMP/798734/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/chmp-recommends-first-oral-only-treatment-sleeping-sickness_en.pdf"},
    {"id":"42714","name":"Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T14:22:00Z","last_updated_date":"2018-11-16T14:22:00Z","reference_number":"EMA/795349/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_en.pdf"},
    {"id":"42725","name":"Valsartan from Mylan laboratories in India can no longer be used in EU medicines due to NDEA impurity","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-11-19T17:13:00Z","last_updated_date":"2018-11-19T17:13:00Z","reference_number":"EMA/809509/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/valsartan-mylan-laboratories-india-can-no-longer-be-used-eu-medicines-due-ndea-impurity_en.pdf"},
    {"id":"42730","name":"Towards electronic product information for EU medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-11-21T12:57:00Z","last_updated_date":"2018-11-21T12:57:00Z","reference_number":"EMA/799809/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/towards-electronic-product-information-eu-medicines_en.pdf"},
    {"id":"42964","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 4-6 December 2018","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-12-07T17:02:00Z","last_updated_date":"2018-12-07T17:02:00Z","reference_number":"EMA/CVMP/818968/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-4-6-december-2018_en.pdf"},
    {"id":"43048","name":"Omega-3 fatty acid medicines no longer considered effective in preventing heart disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T18:00:00Z","last_updated_date":"2018-12-14T18:00:00Z","reference_number":"EMA/712678/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/omega-3-fatty-acid-medicines-no-longer-considered-effective-preventing-heart-disease_en.pdf"},
    {"id":"43049","name":"EMA recommends aligning doses of metamizole medicines and their use during pregnancy and breastfeeding","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T18:04:00Z","last_updated_date":"2018-12-14T18:04:00Z","reference_number":"EMA/853069/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_en.pdf"},
    {"id":"43064","name":"EMA Management Board: highlights of December 2018 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T11:09:00Z","last_updated_date":"2018-12-14T11:09:00Z","reference_number":"EMA/873779/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-december-2018-meeting_en.pdf"},
    {"id":"43154","name":"Regulatory Science to 2025 – launch of six-month public consultation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2018-12-19T11:20:00Z","last_updated_date":"2018-12-19T11:20:00Z","reference_number":"EMA/856924/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/regulatory-science-2025-launch-six-month-public-consultation_en.pdf"},
    {"id":"43462","name":"No new patients should start treatment with Lartruvo after study shows cancer medicine does not prolong life","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T12:00:00Z","last_updated_date":"2019-01-23T12:00:00Z","reference_number":"EMA/27962/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/no-new-patients-should-start-treatment-lartruvo-after-study-shows-cancer-medicine-does-not-prolong-life_en.pdf"},
    {"id":"43464","name":"EMA relocation updates","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T14:00:00Z","last_updated_date":"2019-01-23T14:00:00Z","reference_number":"EMA/889797/2018","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-relocation-updates_en.pdf"},
    {"id":"43493","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 22-24 January 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-01-25T16:14:00Z","last_updated_date":"2019-01-25T16:14:00Z","reference_number":"EMA/CVMP/914436/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-22-24-january-2019_en.pdf"},
    {"id":"43563","name":"Public consultation on key principles for the electronic product information of EU medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-01-31T11:07:00Z","last_updated_date":"2019-01-31T11:07:00Z","reference_number":"EMA/35979/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/public-consultation-key-principles-electronic-product-information-eu-medicines_en.pdf"},
    {"id":"43601","name":"First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T11:27:00Z","last_updated_date":"2019-02-01T11:27:00Z","reference_number":"EMA/CHMP/46542/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes_en.pdf"},
    {"id":"43749","name":"Suspension of fenspiride medicines due to potential risk of heart rhythm problems","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T12:30:00Z","last_updated_date":"2019-02-15T12:30:00Z","reference_number":"EMA/114407/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/suspension-fenspiride-medicines-due-potential-risk-heart-rhythm-problems_en.pdf"},
    {"id":"43882","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-02-22T17:00:00Z","last_updated_date":"2019-02-22T17:00:00Z","reference_number":"EMA/CVMP/106690/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-19-21-february-2019_en.pdf"},
    {"id":"43953","name":"Press release - New add-on treatment for patients with severe asthma","type":"press-release","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T11:00:00Z","last_updated_date":"2019-03-01T11:00:00Z","reference_number":"EMA/CHMP/144932/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-new-add-treatment-patients-severe-asthma_en.pdf"},
    {"id":"43954","name":"Press release - First antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-03-01T11:12:00Z","last_updated_date":"2019-03-01T11:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-first-antidote-reversal-anticoagulation-factor-xa-inhibitors-apixaban-and-rivaroxaban_en.pdf"},
    {"id":"43955","name":"Press release - New add-on treatment to insulin for treatment of certain patients with type 1 diabetes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-03-01T11:17:00Z","last_updated_date":"2019-03-01T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-new-add-treatment-insulin-treatment-certain-patients-type-1-diabetes_en.pdf"},
    {"id":"43956","name":"Press release - First treatment for rare disease characterised by high levels of triglycerides in blood","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-03-01T12:00:00Z","last_updated_date":"2019-03-01T12:00:00Z","reference_number":"EMA/CHMP/143524/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-first-treatment-rare-disease-characterised-high-levels-triglycerides-blood_en.pdf"},
    {"id":"43960","name":"Press release - CHMP recommends authorisation of new treatment for phenylketonuria, a rare inherited metabolic disease","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-03-01T12:45:00Z","last_updated_date":"2019-03-01T12:45:00Z","reference_number":"EMA/CHMP/143328/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/press-release-chmp-recommends-authorisation-new-treatment-phenylketonuria-rare-inherited-metabolic-disease_en.pdf"},
    {"id":"44070","name":"Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-03-20T10:02:00Z","last_updated_date":"2019-03-20T10:02:00Z","reference_number":"EMA/180287/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/increased-risk-blood-clots-lungs-and-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis_en.pdf"},
    {"id":"44087","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 March 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-03-22T14:30:00Z","last_updated_date":"2019-03-22T14:30:00Z","reference_number":"EMA/CVMP/164241/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-19-21-march-2019_en.pdf"},
    {"id":"44088","name":"EMA Management Board: highlights of March 2019 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-03-22T14:31:00Z","last_updated_date":"2019-03-22T14:31:00Z","reference_number":"EMA/175734/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-march-2019-meeting_en.pdf"},
    {"id":"44143","name":"EMA confirms omega-3 fatty acid medicines are not effective in preventing further heart problems after a heart attack","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-03-29T12:00:00Z","last_updated_date":"2019-03-29T12:00:00Z","reference_number":"EMA/186168/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_en.pdf"},
    {"id":"44147","name":"New gene therapy to treat rare inherited blood condition","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-03-29T10:56:00Z","last_updated_date":"2019-03-29T10:56:00Z","reference_number":"EMA/196197/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-gene-therapy-treat-rare-inherited-blood-condition_en.pdf"},
    {"id":"44251","name":"Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T12:09:00Z","last_updated_date":"2019-04-12T12:09:00Z","reference_number":"EMA/220110/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing_en.pdf"},
    {"id":"44316","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 15-16 April 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-04-23T10:21:00Z","last_updated_date":"2019-04-23T10:21:00Z","reference_number":"EMA/CVMP/210002/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-15-16-april-2019_en.pdf"},
    {"id":"44360","name":"EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-04-26T14:43:00Z","last_updated_date":"2019-04-30T12:51:00Z","reference_number":"EMA/237662/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_en.pdf"},
    {"id":"44376","name":"Update on nitrosamine impurities: EMA continues to work to prevent impurities in medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-04-26T13:45:00Z","last_updated_date":"2019-04-26T13:45:00Z","reference_number":"EMA/241020/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-nitrosamine-impurities-ema-continues-work-prevent-impurities-medicines_en.pdf"},
    {"id":"44379","name":"New long-lasting implant to treat opioid dependence","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-04-26T14:49:00Z","last_updated_date":"2019-04-26T14:49:00Z","reference_number":"EMA/CHMP/240446/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-long-lasting-implant-treat-opioid-dependence_en.pdf"},
    {"id":"44396","name":"Re-analysis of data on use of breast cancer medicine Tyverb following treatment with trastuzumab","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-04-30T09:01:00Z","last_updated_date":"2019-04-30T09:01:00Z","reference_number":"EMA/243387/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/re-analysis-data-use-breast-cancer-medicine-tyverb-following-treatment-trastuzumab_en.pdf"},
    {"id":"44531","name":"Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-05-17T12:00:00Z","last_updated_date":"2019-05-17T12:00:00Z","reference_number":"EMA/267216/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/restrictions-use-xeljanz-while-ema-reviews-risk-blood-clots-lungs_en.pdf"},
    {"id":"44532","name":"Withdrawal of marketing authorisations for fenspiride medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-05-17T12:03:00Z","last_updated_date":"2019-05-17T12:03:00Z","reference_number":"EMA/264639/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/withdrawal-marketing-authorisations-fenspiride-medicines_en.pdf"},
    {"id":"44592","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 21-22 May 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-05-24T13:58:00Z","last_updated_date":"2019-05-24T13:58:00Z","reference_number":"EMA/CVMP/255467/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-21-22-may-2019_en.pdf"},
    {"id":"44625","name":"Withdrawal of marketing authorisations for fenspiride medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T16:45:00Z","last_updated_date":"2019-05-29T16:45:00Z","reference_number":"EMA/285298/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/withdrawal-marketing-authorisations-fenspiride-medicines_en.pdf-0"},
    {"id":"44669","name":"Strengthening engagement between EMA and general practitioners","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-06-06T14:11:00Z","last_updated_date":"2019-06-06T14:11:00Z","reference_number":"EMA/293373/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/strengthening-engagement-between-ema-and-general-practitioners_en.pdf"},
    {"id":"44724","name":"Highlights of Management Board meeting: June 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-06-17T16:12:00Z","last_updated_date":"2019-06-17T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/highlights-management-board-meeting-june-2019_en.pdf"},
    {"id":"44786","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 18-20 June 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-06-21T14:45:00Z","last_updated_date":"2019-06-21T14:45:00Z","reference_number":"EMA/CVMP/309117/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-18-20-june-2019_en.pdf"},
    {"id":"44929","name":"Bacterial lysate medicines for respiratory conditions to be used only for prevention of recurrent infections","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T09:17:00Z","last_updated_date":"2019-06-28T09:17:00Z","reference_number":"EMA/351772/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_en.pdf"},
    {"id":"44938","name":"New treatment for children with type 2 diabetes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T12:00:00Z","last_updated_date":"2019-06-28T12:00:00Z","reference_number":"EMA/CHMP/357100/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-children-type-2-diabetes_en.pdf"},
    {"id":"44981","name":"Call for all sponsors to publish clinical trial results in EU database","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T13:24:00Z","last_updated_date":"2019-07-03T13:24:00Z","reference_number":"EMA/348041/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/call-all-sponsors-publish-clinical-trial-results-eu-database_en.pdf"},
    {"id":"44989","name":"Medicine shortages: EU network takes steps to improve reporting and communication","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-07-04T14:31:00Z","last_updated_date":"2019-07-04T14:31:00Z","reference_number":"EMA/345932/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/medicine-shortages-eu-network-takes-steps-improve-reporting-and-communication_en.pdf"},
    {"id":"45039","name":"EU and US reach a milestone in mutual recognition of inspections of medicines manufacturers","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T10:45:00Z","last_updated_date":"2019-07-12T10:45:00Z","reference_number":"EMA/392883/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-and-us-reach-milestone-mutual-recognition-inspections-medicines-manufacturers_en.pdf"},
    {"id":"45047","name":"PRAC recommends new measures to avoid dosing errors with methotrexate","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T11:07:00Z","last_updated_date":"2019-07-12T11:07:00Z","reference_number":"EMA/384938/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-recommends-new-measures-avoid-dosing-errors-methotrexate_en.pdf"},
    {"id":"45104","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 16-18 July 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-07-19T15:08:00Z","last_updated_date":"2019-07-19T15:08:00Z","reference_number":"EMA/CVMP/375135/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-16-18-july-2019_en.pdf"},
    {"id":"45129","name":"Updated restrictions for Gilenya: multiple sclerosis medicine not to be used in pregnancy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/410478/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/updated-restrictions-gilenya-multiple-sclerosis-medicine-not-be-used-pregnancy_en.pdf"},
    {"id":"45132","name":"First ‘histology-independent’ treatment for solid tumours with a specific gene mutation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/391684/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-histology-independent-treatment-solid-tumours-specific-gene-mutation_en.pdf"},
    {"id":"45442","name":"EMA to review ranitidine medicines following detection of NDMA","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-09-13T11:00:00Z","last_updated_date":"2019-09-13T11:00:00Z","reference_number":"EMA/503622/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-review-ranitidine-medicines-following-detection-ndma_en.pdf"}    {"id":"45446","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 September 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-09-13T15:30:00Z","last_updated_date":"2019-09-13T15:30:00Z","reference_number":"EMA/CVMP/474767/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-10-12-september-2019_en.pdf"},
    {"id":"45527","name":"EMA advises companies on steps to take to avoid nitrosamines in human medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-09-26T17:21:00Z","last_updated_date":"2019-09-26T17:21:00Z","reference_number":"EMA/511347/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-advises-companies-steps-take-avoid-nitrosamines-human-medicines_en.pdf"},
    {"id":"45568","name":"Four-week limit for use of high-strength estradiol creams","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-10-04T10:52:00Z","last_updated_date":"2019-10-04T10:52:00Z","reference_number":"EMA/531250/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/four-week-limit-use-high-strength-estradiol-creams_en.pdf"},
    {"id":"45570","name":"EMA Management Board: highlights of October 2019 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-10-04T12:53:00Z","last_updated_date":"2019-10-04T12:53:00Z","reference_number":"EMA/526099/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-october-2019-meeting_en.pdf"},
    {"id":"45661","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 8-10 October 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-10-11T15:00:00Z","last_updated_date":"2019-10-11T15:00:00Z","reference_number":"EMA/CVMP/535058/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-8-10-october-2019_en.pdf"},
    {"id":"45703","name":"European countries increase commitment to responsible antibiotic use in animals","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-10-15T14:00:00Z","last_updated_date":"2019-10-15T14:00:00Z","reference_number":"EMA/561051/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-countries-increase-commitment-responsible-antibiotic-use-animals_en.pdf"},
    {"id":"45759","name":"First vaccine to protect against Ebola","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T11:12:00Z","last_updated_date":"2019-10-18T11:12:00Z","reference_number":"EMA/CHMP/565403/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-vaccine-protect-against-ebola_en.pdf"},
    {"id":"45760","name":"First non-injectable treatment for severe low blood sugar levels","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"EMA/CHMP/561957/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-non-injectable-treatment-severe-low-blood-sugar-levels_en.pdf"},
    {"id":"46028","name":"Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T15:59:00Z","last_updated_date":"2019-11-15T15:59:00Z","reference_number":"EMA/609015/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_en.pdf"},
    {"id":"46029","name":"EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T16:09:00Z","last_updated_date":"2019-11-15T16:09:00Z","reference_number":"EMA/608520/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_bg.pdf","es":"https://www.ema.europa.eu/es/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_cs.pdf","da":"https://www.ema.europa.eu/da/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_da.pdf","de":"https://www.ema.europa.eu/de/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_de.pdf","et":"https://www.ema.europa.eu/et/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_et.pdf","el":"https://www.ema.europa.eu/el/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_hr.pdf","it":"https://www.ema.europa.eu/it/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/press-release/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_sv.pdf"}},
    {"id":"46121","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 5-7 November 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-11-08T13:25:00Z","last_updated_date":"2019-11-08T13:25:00Z","reference_number":"EMA/CVMP/579225/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-5-7-november-2019_en.pdf"},
    {"id":"46252","name":"EMA update on metformin diabetes medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-12-06T12:29:00Z","last_updated_date":"2019-12-06T12:29:00Z","reference_number":"EMA/660975/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-update-metformin-diabetes-medicines_en.pdf"},
    {"id":"46254","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 3-5 December 2019","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-12-06T16:00:00Z","last_updated_date":"2019-12-06T16:00:00Z","reference_number":"EMA/CVMP/629092/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-3-5-december-2019_en.pdf"},
    {"id":"46328","name":"4-year overview of pharmacovigilance activities in the EU shows robust and effective medicines safety system","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-12-17T14:00:00Z","last_updated_date":"2019-12-17T14:00:00Z","reference_number":"EMA/675265/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/4-year-overview-pharmacovigilance-activities-eu-shows-robust-and-effective-medicines-safety-system_en.pdf"},
    {"id":"46364","name":"EMA Management Board: highlights of December 2019 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-12-20T11:00:00Z","last_updated_date":"2019-12-20T11:00:00Z","reference_number":"EMA/679328/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-management-board-highlights-december-2019-meeting_en.pdf"},
    {"id":"46444","name":"EMA suspends Picato as a precaution while review of skin cancer risk continues","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-01-17T10:22:00Z","last_updated_date":"2020-01-21T15:08:00Z","reference_number":"EMA/32231/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_en.pdf"},
    {"id":"46447","name":"PRAC confirms four-week limit for use of high-strength estradiol creams","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-01-17T11:10:00Z","last_updated_date":"2020-01-17T11:10:00Z","reference_number":"EMA/20248/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/prac-confirms-four-week-limit-use-high-strength-estradiol-creams_en.pdf"},
    {"id":"46457","name":"Ten recommendations to unlock the potential of big data for public health in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T09:34:00Z","last_updated_date":"2020-01-20T09:34:00Z","reference_number":"EMA/689902/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/ten-recommendations-unlock-potential-big-data-public-health-eu_en.pdf"},
    {"id":"46490","name":"Court of Justice upholds EMA’s approach to transparency","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-01-22T17:39:00Z","last_updated_date":"2020-01-22T17:39:00Z","reference_number":"EMA/36788/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/court-justice-upholds-emas-approach-transparency_en.pdf"},
    {"id":"46522","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 21-23 January 2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-01-24T13:40:00Z","last_updated_date":"2020-02-06T10:42:00Z","reference_number":"EMA/CVMP/687176/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-21-23-january-2020_en.pdf"},
    {"id":"46598","name":"Categorisation of antibiotics used in animals promotes responsible use to protect public and animal health","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-01-28T13:02:00Z","last_updated_date":"2020-01-28T13:02:00Z","reference_number":"EMA/688114/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/categorisation-antibiotics-used-animals-promotes-responsible-use-protect-public-and-animal-health_en.pdf"},
    {"id":"46612","name":"Key principles for the use of electronic product information for EU medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-01-29T15:00:00Z","last_updated_date":"2020-01-29T15:00:00Z","reference_number":"EMA/26061/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/key-principles-use-electronic-product-information-eu-medicines_en.pdf"},
    {"id":"46643","name":"UK withdrawal from the EU on 31 January 2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-01-31T09:34:00Z","last_updated_date":"2020-01-31T09:34:00Z","reference_number":"EMA/40083/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/uk-withdrawal-eu-31-january-2020_en.pdf"},
    {"id":"46647","name":"First treatment for acute hepatic porphyria","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-01-31T10:31:00Z","last_updated_date":"2020-01-31T10:31:00Z","reference_number":"EMA/CHMP/46675/2020 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-treatment-acute-hepatic-porphyria_en.pdf"},
    {"id":"46648","name":"First oral GLP-1 treatment for type 2 diabetes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-01-31T11:32:00Z","last_updated_date":"2020-01-31T11:32:00Z","reference_number":"EMA/CHMP/47090/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-oral-glp-1-treatment-type-2-diabetes_en.pdf"},
    {"id":"46675","name":"EMA to support development of vaccines and treatments for novel coronavirus","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-02-04T16:21:00Z","last_updated_date":"2020-02-04T16:21:00Z","reference_number":"EMA/57041/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-support-development-vaccines-and-treatments-novel-coronavirus_en.pdf"},
    {"id":"46748","name":"Restrictions in use of cyproterone due to meningioma risk","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-02-14T12:00:00Z","last_updated_date":"2020-02-14T12:00:00Z","reference_number":"EMA/70255/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/restrictions-use-cyproterone-due-meningioma-risk_en.pdf"},
    {"id":"46829","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 18-20 February 2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-02-21T14:51:00Z","last_updated_date":"2020-02-21T14:51:00Z","reference_number":"EMA/CVMP/61915/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-18-20-february-2020_en.pdf"},
    {"id":"46930","name":"Update on nitrosamines in EU medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-03T10:12:00Z","last_updated_date":"2020-03-03T10:12:00Z","reference_number":"EMA/105779/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-nitrosamines-eu-medicines_en.pdf"},
    {"id":"47023","name":"Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T09:11:00Z","last_updated_date":"2020-03-13T09:11:00Z","reference_number":"EMA/121879/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/suspension-ulipristal-acetate-uterine-fibroids-during-ongoing-ema-review-liver-injury-risk_en.pdf"},
    {"id":"47040","name":"EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-18T11:08:00Z","last_updated_date":"2020-03-18T11:08:00Z","reference_number":"EMA/136850/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19_en.pdf"},
    {"id":"47047","name":"First regulatory workshop on COVID-19 facilitates global collaboration on vaccine development","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-18T20:02:00Z","last_updated_date":"2020-03-18T20:02:00Z","reference_number":"EMA/144948/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-regulatory-workshop-covid-19-facilitates-global-collaboration-vaccine-development_en.pdf"},
    {"id":"47051","name":"Call to pool research resources into large multi-centre, multi-arm clinical trials to generate sound evidence on COVID-19 treatments","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-19T11:00:00Z","last_updated_date":"2020-03-19T11:00:00Z","reference_number":"EMA/142322/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/call-pool-research-resources-large-multi-centre-multi-arm-clinical-trials-generate-sound-evidence-covid-19-treatments_en.pdf"},
    {"id":"47084","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 17-18 March 2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-20T14:35:00Z","last_updated_date":"2020-03-20T14:35:00Z","reference_number":"EMA/CVMP/120715/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-17-18-march-2020_en.pdf"},
    {"id":"47085","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 17-18 March 2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-20T14:40:00Z","last_updated_date":"2020-03-20T14:40:00Z","reference_number":"EMA/CVMP/120715/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-17-18-march-2020_en.pdf-0"},
    {"id":"47086","name":"Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-20T15:18:00Z","last_updated_date":"2020-03-20T15:18:00Z","reference_number":"EMA/141885/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/guidance-sponsors-how-manage-clinical-trials-during-covid-19-pandemic_en.pdf"},
    {"id":"47104","name":"COVID-19: Beware of falsified medicines from unregistered websites","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-24T13:00:00Z","last_updated_date":"2020-03-24T13:00:00Z","reference_number":"EMA/141955/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/covid-19-beware-falsified-medicines-unregistered-websites_en.pdf"},
    {"id":"47107","name":"Global regulators map out data requirements for phase 1 COVID-19 vaccine trials","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-24T16:30:00Z","last_updated_date":"2020-03-24T16:30:00Z","reference_number":"EMA/151518/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/global-regulators-map-out-data-requirements-phase-1-covid-19-vaccine-trials_en.pdf"},
    {"id":"47170","name":"No change to product information for breast cancer medicine Tyverb following re-assessment of data","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T16:54:00Z","last_updated_date":"2020-03-27T16:54:00Z","reference_number":"EMA/147884/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/no-change-product-information-breast-cancer-medicine-tyverb-following-re-assessment-data_en.pdf"},
    {"id":"47173","name":"Restrictions in use of cyproterone due to meningioma risk","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T18:14:00Z","last_updated_date":"2020-03-27T18:14:00Z","reference_number":"EMA/147755/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/restrictions-use-cyproterone-due-meningioma-risk_en.pdf-0"},
    {"id":"47178","name":"EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T09:46:00Z","last_updated_date":"2020-03-27T09:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-advises-continued-use-medicines-hypertension-heart-or-kidney-disease-during-covid-19-pandemic_en.pdf"},
    {"id":"47184","name":"Benefits of medicines containing combination of methocarbamol and paracetamol continue to outweigh risks","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/146374/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_en.pdf"},
    {"id":"47187","name":"Recommendations to restrict use of fosfomycin antibiotics","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T10:37:00Z","last_updated_date":"2020-03-27T10:37:00Z","reference_number":"EMA/670563/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/recommendations-restrict-use-fosfomycin-antibiotics_en.pdf"},
    {"id":"47190","name":"New gene therapy to treat spinal muscular atrophy","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T11:18:00Z","last_updated_date":"2020-03-31T17:30:00Z","reference_number":"EMA/163207/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-gene-therapy-treat-spinal-muscular-atrophy_en.pdf"},
    {"id":"47248","name":"Update on treatments and vaccines against COVID-19 under development","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-31T16:00:00Z","last_updated_date":"2020-03-31T16:00:00Z","reference_number":"EMA/160083/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-treatments-and-vaccines-against-covid-19-under-development_en.pdf"},
    {"id":"47250","name":"Advancing regulatory science in the EU – new strategy adopted","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-03-31T16:59:00Z","last_updated_date":"2020-03-31T16:59:00Z","reference_number":"EMA/132421/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/advancing-regulatory-science-eu-new-strategy-adopted_en.pdf"},
    {"id":"47268","name":"COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-01T14:30:00Z","last_updated_date":"2020-04-01T14:30:00Z","reference_number":"EMA/170590/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/covid-19-chloroquine-and-hydroxychloroquine-only-be-used-clinical-trials-or-emergency-use-programmes_en.pdf"},
    {"id":"47327","name":"EMA provides recommendations on compassionate use of remdesivir for COVID-19","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-03T13:24:00Z","last_updated_date":"2020-04-03T13:24:00Z","reference_number":"EMA/152575/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-provides-recommendations-compassionate-use-remdesivir-covid-19_en.pdf"},
    {"id":"47334","name":"EU authorities agree new measures to support availability of medicines used in the COVID-19 pandemic","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-06T15:00:00Z","last_updated_date":"2020-04-06T15:00:00Z","reference_number":"EMA/174606/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-authorities-agree-new-measures-support-availability-medicines-used-covid-19-pandemic_en.pdf"},
    {"id":"47395","name":"Global regulators stress need for robust evidence on COVID-19 treatments","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-09T10:00:00Z","last_updated_date":"2020-04-09T10:00:00Z","reference_number":"EMA/194459/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/global-regulators-stress-need-robust-evidence-covid-19-treatments_en.pdf"},
    {"id":"47398","name":"EMA establishes task force to take quick and coordinated regulatory action related to COVID-19 medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-09T12:30:00Z","last_updated_date":"2020-04-09T12:30:00Z","reference_number":"EMA/194582/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-establishes-task-force-take-quick-and-coordinated-regulatory-action-related-covid-19-medicines_en.pdf"},
    {"id":"47399","name":"Update on EU actions to support availability of medicines during COVID-19 pandemic","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-10T15:03:00Z","last_updated_date":"2020-04-10T15:03:00Z","reference_number":"EMA/197274/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/update-eu-actions-support-availability-medicines-during-covid-19-pandemic_en.pdf"},
    {"id":"47432","name":"EMA review of Picato concludes medicine’s risks outweigh its benefits","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-17T14:56:00Z","last_updated_date":"2020-04-17T14:56:00Z","reference_number":"EMA/194393/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-review-picato-concludes-medicines-risks-outweigh-its-benefits_en.pdf"},
    {"id":"47438","name":"EU actions to support availability of medicines during COVID-19 pandemic – update #2","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-20T14:31:00Z","last_updated_date":"2020-04-20T14:31:00Z","reference_number":"EMA/206317/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-actions-support-availability-medicines-during-covid-19-pandemic-update-2_en.pdf"},
    {"id":"47459","name":"COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-23T11:00:00Z","last_updated_date":"2020-04-23T13:58:00Z","reference_number":"EMA/202483/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/press-release/covid-19-reminder-risk-serious-side-effects-chloroquine-and-hydroxychloroquine_en.pdf"},
    {"id":"47486","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 21-23 April 2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-24T13:40:00Z","last_updated_date":"2020-04-24T13:40:00Z","reference_number":"EMA/CVMP/194437/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-21-23-april-2020_en.pdf"},
    {"id":"47487","name":"EU actions to support availability of medicines during COVID-19 pandemic – update #3","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-24T14:51:00Z","last_updated_date":"2020-04-24T14:51:00Z","reference_number":"EMA/223887/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-actions-support-availability-medicines-during-covid-19-pandemic-update-3_en.pdf"},
    {"id":"47532","name":"Risks of Picato for actinic keratosis outweigh benefits","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/228384/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/risks-picato-actinic-keratosis-outweigh-benefits_en.pdf"},
    {"id":"47535","name":"EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T15:43:00Z","last_updated_date":"2020-04-30T15:43:00Z","reference_number":"EMA/229267/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_en.pdf"},
    {"id":"47537","name":"First triple combination therapy for asthma with optional electronic sensor","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T16:07:00Z","last_updated_date":"2020-04-30T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-triple-combination-therapy-asthma-optional-electronic-sensor_en.pdf"},
    {"id":"47547","name":"Suspension of ranitidine medicines in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T16:40:00Z","last_updated_date":"2020-04-30T16:40:00Z","reference_number":"EMA/231394/2020 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/suspension-ranitidine-medicines-eu_en.pdf"},
    {"id":"47550","name":"EU actions to support availability of medicines during COVID-19 pandemic - update #4","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T18:08:00Z","last_updated_date":"2020-04-30T18:08:00Z","reference_number":"EMA/235997/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-actions-support-availability-medicines-during-covid-19-pandemic-update-4_en.pdf"},
    {"id":"47553","name":"EMA starts rolling review of remdesivir for COVID-19","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T20:30:00Z","last_updated_date":"2020-04-30T20:30:00Z","reference_number":"EMA/238504/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-starts-rolling-review-remdesivir-covid-19_en.pdf"},
    {"id":"47560","name":"COVID-19: how EMA fast-tracks development support and approval of medicines and vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-04T16:41:00Z","last_updated_date":"2020-05-04T16:41:00Z","reference_number":"EMA/231636/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/covid-19-how-ema-fast-tracks-development-support-and-approval-medicines-and-vaccines_en.pdf"},
    {"id":"47631","name":"EU actions to support availability of medicines during COVID-19 pandemic - update #5","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-08T15:01:00Z","last_updated_date":"2020-05-08T15:01:00Z","reference_number":"EMA/248989/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-actions-support-availability-medicines-during-covid-19-pandemic-update-5_en.pdf"},
    {"id":"47644","name":"EMA recommends expanding remdesivir compassionate use to patients not on mechanical ventilation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-11T19:35:00Z","last_updated_date":"2020-05-11T19:35:00Z","reference_number":"EMA/257282/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-recommends-expanding-remdesivir-compassionate-use-patients-not-mechanical-ventilation_en.pdf"},
    {"id":"47675","name":"Leuprorelin depot medicines: PRAC recommends new measures to avoid handling errors","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-15T10:44:00Z","last_updated_date":"2020-05-20T15:18:00Z","reference_number":"EMA/250923/2020 Rev. ","document_url":"https://www.ema.europa.eu/en/documents/press-release/leuprorelin-depot-medicines-prac-recommends-new-measures-avoid-handling-errors_en.pdf"},
    {"id":"47677","name":"International coordination needed to encourage conduct of large, decision-relevant COVID-19 clinical trials","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-15T13:41:00Z","last_updated_date":"2020-05-15T13:41:00Z","reference_number":"EMA/263666/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/international-coordination-needed-encourage-conduct-large-decision-relevant-covid-19-clinical-trials_en.pdf"},
    {"id":"47681","name":"EU actions to support availability of medicines during COVID-19 pandemic - update #6","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-15T16:30:00Z","last_updated_date":"2020-05-15T16:30:00Z","reference_number":"EMA/264426/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-actions-support-availability-medicines-during-covid-19-pandemic-update-6_en.pdf"},
    {"id":"47749","name":"Global regulators commit to cooperate on observational research in the context of COVID-19","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T17:40:00Z","last_updated_date":"2020-05-20T17:40:00Z","reference_number":"EMA/275870/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/global-regulators-commit-cooperate-observational-research-context-covid-19_en.pdf"},
    {"id":"47752","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 18-20 May 2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-25T11:45:00Z","last_updated_date":"2020-05-25T11:45:00Z","reference_number":"EMA/CVMP/251876/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-18-20-may-2020_en.pdf"},
    {"id":"47762","name":"EMA calls for high-quality observational research in context of COVID-19","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-26T15:00:00Z","last_updated_date":"2020-05-26T15:00:00Z","reference_number":"EMA/269353/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-calls-high-quality-observational-research-context-covid-19_en.pdf"},
    {"id":"47764","name":"EMA commissions independent research to prepare for real-world monitoring of COVID-19 vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-27T09:48:00Z","last_updated_date":"2020-05-27T09:48:00Z","reference_number":"EMA/276587/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-commissions-independent-research-prepare-real-world-monitoring-covid-19-vaccines_en.pdf"},
    {"id":"47787","name":"European medicines regulatory network fully mobilised in fight against COVID-19","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-28T11:00:00Z","last_updated_date":"2020-05-28T11:00:00Z","reference_number":"EMA/254823/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-regulatory-network-fully-mobilised-fight-against-covid-19_en.pdf"},
    {"id":"47809","name":"Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID-19 – update #3","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-28T17:26:00Z","last_updated_date":"2020-05-28T17:26:00Z","reference_number":"EMA/289945/2020 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/global-regulators-work-towards-alignment-policy-approaches-and-regulatory-flexibility-during-covid-19-update-3_en.pdf"},
    {"id":"47822","name":"New vaccine for prevention of Ebola virus disease recommended for approval in the European Union","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/CHMP/282251/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-vaccine-prevention-ebola-virus-disease-recommended-approval-european-union_en.pdf"},
    {"id":"47826","name":"COVID-19: reminder of the risks of chloroquine and hydroxychloroquine","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T14:17:00Z","last_updated_date":"2020-05-29T14:17:00Z","reference_number":"EMA/282511/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/covid-19-reminder-risks-chloroquine-and-hydroxychloroquine_en.pdf"},
    {"id":"47893","name":"EMA receives application for conditional authorisation of first COVID-19 treatment in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-08T15:08:00Z","last_updated_date":"2020-06-08T15:08:00Z","reference_number":"EMA/304712/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-receives-application-conditional-authorisation-first-covid-19-treatment-eu_en.pdf"},
    {"id":"47896","name":"EU actions to support availability of medicines during COVID-19 pandemic – update #7","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-08T17:30:00Z","last_updated_date":"2020-06-08T17:30:00Z","reference_number":"EMA/302623/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/eu-actions-support-availability-medicines-during-covid-19-pandemic-update-7_en.pdf"},
    {"id":"47922","name":"Latest data support continued use of ACE inhibitors and ARB medicines during COVID-19 pandemic","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-10T10:27:00Z","last_updated_date":"2020-06-10T10:27:00Z","reference_number":"EMA/284513/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/latest-data-support-continued-use-ace-inhibitors-and-arb-medicines-during-covid-19-pandemic_en.pdf"},
    {"id":"47985","name":"Highlights of Management Board: June 2020 meeting","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-12T13:30:00Z","last_updated_date":"2020-06-12T13:30:00Z","reference_number":"EMA/312765/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/highlights-management-board-june-2020-meeting_en.pdf"},
    {"id":"48011","name":"Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID-19 – update #4","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-15T18:10:00Z","last_updated_date":"2020-06-15T18:10:00Z","reference_number":"EMA/323181/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/global-regulators-work-towards-alignment-policy-approaches-and-regulatory-flexibility-during-covid-19-update-4_en.pdf"},
    {"id":"48043","name":"International regulators stress value of safe and effective vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-18T10:22:00Z","last_updated_date":"2020-06-18T10:22:00Z","reference_number":"EMA/328196/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/international-regulators-stress-value-safe-and-effective-vaccines_en.pdf"},
    {"id":"48056","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 16-18 June 2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-19T14:00:00Z","last_updated_date":"2020-06-19T14:00:00Z","reference_number":"EMA/CVMP/302233/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-16-18-june-2020_en.pdf"},
    {"id":"48070","name":"European regulators make recommendations drawing on lessons learnt from presence of nitrosamines in sartan medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"EMA/303870/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-regulators-make-recommendations-drawing-lessons-learnt-presence-nitrosamines-sartan-medicines_en.pdf"},
    {"id":"48076","name":"Presentation - Background on cases of sartanswith N-nitrosamine impurities (A. Spinei)","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/press-release/presentation-background-cases-sartanswith-n-nitrosamine-impurities-spinei_en.pdf"},
    {"id":"48104","name":"Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-24T12:30:00Z","last_updated_date":"2020-06-24T12:30:00Z","reference_number":"EMA/338758/2020 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/global-regulators-discuss-data-requirements-phase-3-trials-covid-19-vaccines_en.pdf"},
    {"id":"48123","name":"First COVID-19 treatment recommended for EU authorisation","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-25T13:36:00Z","last_updated_date":"2020-06-25T13:36:00Z","reference_number":"EMA/264817/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/first-covid-19-treatment-recommended-eu-authorisation_en.pdf"},
    {"id":"48124","name":"Emer Cooke nominated as new EMA Executive Director","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-25T13:48:00Z","last_updated_date":"2020-06-25T13:48:00Z","reference_number":"EMA/343786/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/emer-cooke-nominated-new-ema-executive-director_en.pdf"},
    {"id":"48159","name":"New medicine for cystic fibrosis patients","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/342501/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-medicine-cystic-fibrosis-patients_en.pdf"},
    {"id":"48161","name":"New treatment to enable kidney transplant in highly sensitised patients","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/CHMP/343884/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/new-treatment-enable-kidney-transplant-highly-sensitised-patients_en.pdf"},
    {"id":"48194","name":"International regulators provide guiding principles for COVID-19 clinical trials","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-07-01T14:50:00Z","last_updated_date":"2020-07-01T14:50:00Z","reference_number":"EMA/347443/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/international-regulators-provide-guiding-principles-covid-19-clinical-trials_en.pdf"},
    {"id":"48226","name":"Launch of public consultation on joint network strategy to 2025","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-07-06T14:00:00Z","last_updated_date":"2020-07-06T14:00:00Z","reference_number":"EMA/296792/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/launch-public-consultation-joint-network-strategy-2025_en.pdf"},
    {"id":"48270","name":"EMA finalises opinion on presence of nitrosamines in medicines","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-07-09T14:00:00Z","last_updated_date":"2020-07-09T14:00:00Z","reference_number":"EMA/341963/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/ema-finalises-opinion-presence-nitrosamines-medicines_en.pdf"},
    {"id":"48271","name":"International regulators align positions on phase 3 COVID-19 vaccine trials","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-07-09T15:40:00Z","last_updated_date":"2020-07-09T15:40:00Z","reference_number":"EMA/367602/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/international-regulators-align-positions-phase-3-covid-19-vaccine-trials_en.pdf"},
    {"id":"48324","name":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 14-16 July 2020","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2020-07-17T14:13:00Z","last_updated_date":"2020-07-17T14:13:00Z","reference_number":"EMA/CVMP/355143/2020","document_url":"https://www.ema.europa.eu/en/documents/press-release/committee-medicinal-products-veterinary-use-cvmp-meeting-14-16-july-2020_en.pdf"},
    {"id":"60542","name":"European Medicines Agency recommends approval of first higher-strength insulin for treatment of patients with diabetes mellitus in the EU","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T15:31:00Z","last_updated_date":"2012-10-19T15:31:00Z","reference_number":"EMA/CHMP/675745/2012 ","document_url":"https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-approval-first-higher-strength-insulin-treatment-patients-diabetes-mellitus-eu_en.pdf"},
    {"id":"60595","name":"Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities","type":"press-release","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T18:35:00Z","last_updated_date":"2019-02-01T18:35:00Z","reference_number":"EMA/44960/2019","document_url":"https://www.ema.europa.eu/en/documents/press-release/sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_en.pdf"},
    {"id":"2813","name":"Ex ante publicity of a negotiated procedure – EMA/2016/22/DF – Supply and disposal of catering equipment including appliances","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-08T11:30:00Z","last_updated_date":"2016-08-08T11:30:00Z","reference_number":"EMA/140157/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema201622df-supply-and-disposal-catering-equipment-including-appliances_en.pdf"},
    {"id":"3469","name":"Ex ante publicity of a negotiated procedure: EMA/2017/12/COM – Financial information on companies and legal entities","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2017-04-11T10:44:00Z","last_updated_date":"2017-04-11T10:44:00Z","reference_number":"EMA/215198/2017","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema201712com-financial-information-companies-and-legal-entities_en.pdf"}    {"id":"3502","name":"Technical specifications - Annex IV - Draft concession agreement - Procurement procedure EMA/2014/35/RE","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T15:00:00Z","last_updated_date":"2015-02-23T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-iv-draft-concession-agreement-procurement-procedure-ema201435re_en.pdf"},
    {"id":"3519","name":"Technical specifications - Annex II exclusion criteria declaration: Procurement procedure EMA/2014/48/PH","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2014-11-04T10:00:00Z","last_updated_date":"2014-11-04T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-ii-exclusion-criteria-declaration-procurement-procedure-ema201448ph_en.pdf"},
    {"id":"5333","name":"Annex IV - Service concession: Minimum technical requirements declaration (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:30:00Z","last_updated_date":"2016-08-15T12:30:00Z","reference_number":"EMA/2016/43/RS","document_url":"https://www.ema.europa.eu/en/documents/procurement/annex-iv-service-concession-minimum-technical-requirements-declaration-ema201643rs_en.pdf"},
    {"id":"7640","name":"Technical specifications - Procurement procedure for access to drug pipeline database(s) - EMA/2014/68/COM","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-19T11:30:00Z","last_updated_date":"2015-02-19T11:30:00Z","reference_number":"EMA/734923/2015","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-procurement-procedure-access-drug-pipeline-databases-ema201468com_en.pdf"},
    {"id":"7912","name":"Questions and answers relating to service concession: meeting and training organisation (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-09-15T12:00:00Z","last_updated_date":"2016-09-20T14:00:00Z","reference_number":"EMA/600716/2016 v1.0","document_url":"https://www.ema.europa.eu/en/documents/procurement/questions-and-answers-relating-service-concession-meeting-and-training-organisation-ema201643rs_en.pdf"},
    {"id":"8051","name":"Questions and answers relating to service concession pharmacovigilance training – EMA/2014/35/RE","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-03-09T01:00:00Z","last_updated_date":"2015-04-14T11:55:00Z","reference_number":"EMA/160758/2015","document_url":"https://www.ema.europa.eu/en/documents/procurement/questions-and-answers-relating-service-concession-pharmacovigilance-training-ema201435re_en.pdf"},
    {"id":"10148","name":"Annex VII - Draft concession contract (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:30:00Z","last_updated_date":"2016-08-15T12:30:00Z","reference_number":"EMA/2016/43/RS","document_url":"https://www.ema.europa.eu/en/documents/procurement/annex-vii-draft-concession-contract-ema201643rs_en.pdf"},
    {"id":"10541","name":"Ex ante publicity of a negotiated procedure: exhibition logistics","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T13:10:00Z","last_updated_date":"2016-02-05T13:10:00Z","reference_number":"EMA/70780/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-exhibition-logistics_en.pdf"},
    {"id":"10609","name":"Ex ante publicity of a negotiated procedure: promotional products and  corporate gifts","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-02-15T10:35:00Z","last_updated_date":"2016-02-15T10:35:00Z","reference_number":"EMA/22900/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-promotional-products-and-corporate-gifts_en.pdf"},
    {"id":"10849","name":"Annex II - Concession specification: costing sheet (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:30:00Z","last_updated_date":"2016-09-06T12:30:00Z","reference_number":"EMA/2016/43/RS","document_url":"https://www.ema.europa.eu/en/documents/procurement/annex-ii-concession-specification-costing-sheet-ema201643rs_en.xls"},
    {"id":"11898","name":"Technical specifications - Letter of invitation to tender: Procurement procedure EMA/2014/48/PH","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2014-11-04T10:00:00Z","last_updated_date":"2014-11-04T10:00:00Z","reference_number":"EMA/473914/2014","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-letter-invitation-tender-procurement-procedure-ema201448ph_en.pdf"},
    {"id":"12109","name":"Technical specifications - Annex V Tenderer information form: Procurement procedure EMA/2014/50/RE","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T17:15:00Z","last_updated_date":"2015-01-08T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-v-tenderer-information-form-procurement-procedure-ema201450re_en.pdf"},
    {"id":"12386","name":"Letter of invitation for service concession - Procurement procedure EMA/2014/35/RE","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T15:00:00Z","last_updated_date":"2015-02-23T15:00:00Z","reference_number":"EMA/47128/2015","document_url":"https://www.ema.europa.eu/en/documents/procurement/letter-invitation-service-concession-procurement-procedure-ema201435re_en.pdf"},
    {"id":"13138","name":"Technical specifications - Annex II - Exclusion criteria declaration -  Procurement procedure EMA/2014/35/RE","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T15:00:00Z","last_updated_date":"2015-02-23T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-ii-exclusion-criteria-declaration-procurement-procedure-ema201435re_en.pdf"},
    {"id":"13732","name":"Employee Assistance Programme and helpline","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2017-07-17T15:53:00Z","last_updated_date":"2017-07-17T15:53:00Z","reference_number":"EMA/452490/2017","document_url":"https://www.ema.europa.eu/en/documents/procurement/employee-assistance-programme-and-helpline_en.pdf"},
    {"id":"14866","name":"Technical specifications for service concession: meeting and training organisation (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:30:00Z","last_updated_date":"2016-08-15T12:30:00Z","reference_number":"EMA/303267/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-service-concession-meeting-and-training-organisation-ema201643rs_en.pdf"},
    {"id":"15239","name":"Technical specifications - Annex III - Summary checklist - Procurement procedure EMA/2014/35/RE","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T15:00:00Z","last_updated_date":"2015-02-23T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-iii-summary-checklist-procurement-procedure-ema201435re_en.pdf"},
    {"id":"15415","name":"Ex ante publicity for negotiated procurement procedure: Activiti training for business users - EMA/2016/32/HR","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-03-23T15:00:00Z","last_updated_date":"2016-03-23T15:00:00Z","reference_number":"EMA/215889/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procurement-procedure-activiti-training-business-users-ema201632hr_en.pdf"},
    {"id":"16045","name":"Ex ante publicity of a negotiated procedure – EMA/2016/60/COM – Pharmaceutical eBooks","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-09-15T14:00:00Z","last_updated_date":"2016-09-15T14:00:00Z","reference_number":"EMA/473661/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema201660com-pharmaceutical-ebooks_en.pdf"},
    {"id":"16372","name":"Letter of invitation - Procurement procedure for access to drug pipeline database(s) - EMA/2014/68/COM","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-19T12:30:00Z","last_updated_date":"2015-02-19T12:30:00Z","reference_number":"EMA/67820/2015","document_url":"https://www.ema.europa.eu/en/documents/procurement/letter-invitation-procurement-procedure-access-drug-pipeline-databases-ema201468com_en.pdf"},
    {"id":"17578","name":"Technical specifications for service concession - Procurement procedure EMA/2014/35/RE","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T15:00:00Z","last_updated_date":"2015-03-04T13:56:00Z","reference_number":"EMA/430052/2014","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-service-concession-procurement-procedure-ema201435re_en.pdf"},
    {"id":"17854","name":"Ex ante publicity of a negotiated procedure – EMA/2016/58/COM – Scientific, Technical and Medical eBooks","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-10-10T12:00:00Z","last_updated_date":"2016-10-10T12:00:00Z","reference_number":"EMA/439870/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema201658com-scientific-technical-and-medical-ebooks_en.pdf"},
    {"id":"18759","name":"Technical specifications - Annex VIIA substances and related substance groups: Procurement procedure EMA/2014/48/PH","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2014-11-04T10:00:00Z","last_updated_date":"2014-11-04T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-viia-substances-and-related-substance-groups-procurement-procedure-ema201448ph_en.pdf"},
    {"id":"19461","name":"Ex ante publicity of a negotiated procedure – EMA/2016/51/COM – Evidence-based database","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-09-19T14:00:00Z","last_updated_date":"2016-09-19T14:00:00Z","reference_number":"EMA/406867/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema201651com-evidence-based-database_en.pdf"},
    {"id":"20198","name":"Appendix B - Estimated business requirements (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:30:00Z","last_updated_date":"2016-08-15T12:30:00Z","reference_number":"EMA/2016/43/RS","document_url":"https://www.ema.europa.eu/en/documents/procurement/appendix-b-estimated-business-requirements-ema201643rs_en.pdf"},
    {"id":"22659","name":"Annex VI - Service concession: Checklist of documents which applicant must submit (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:30:00Z","last_updated_date":"2016-08-15T12:30:00Z","reference_number":"EMA/2016/43/RS","document_url":"https://www.ema.europa.eu/en/documents/procurement/annex-vi-service-concession-checklist-documents-which-applicant-must-submit-ema201643rs_en.pdf"},
    {"id":"23282","name":"Technical specifications - Annex I costing sheet: Procurement procedure EMA/2014/49/AUD","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T10:00:00Z","last_updated_date":"2014-12-10T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-i-costing-sheet-procurement-procedure-ema201449aud_en.xls"},
    {"id":"23932","name":"Technical specifications - Annex I - Costing sheet - Procurement procedure EMA/2014/35/RE","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T15:00:00Z","last_updated_date":"2015-02-23T15:00:00Z","reference_number":"EMA/430052/2014","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-i-costing-sheet-procurement-procedure-ema201435re_en.xls"},
    {"id":"25567","name":"Annex I - Concession information sheet and declaration on submission (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:30:00Z","last_updated_date":"2016-08-15T12:30:00Z","reference_number":"EMA/2016/43/RS","document_url":"https://www.ema.europa.eu/en/documents/procurement/annex-i-concession-information-sheet-and-declaration-submission-ema201643rs_en.pdf"},
    {"id":"26241","name":"Technical specifications - Annex I, II, III, IV to be completed by tenderers: procurement procedure for access to drug pipeline database(s) - EMA/2014/68/COM","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-19T12:30:00Z","last_updated_date":"2015-02-19T12:30:00Z","reference_number":"EMA/91682/2015","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-i-ii-iii-iv-be-completed-tenderers-procurement-procedure-access-drug-pipeline-databases-ema201468com_en.doc"},
    {"id":"26892","name":"Technical specifications - Annex VI - Agency Policy 0062 - Procurement procedure EMA/2014/35/RE","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T15:00:00Z","last_updated_date":"2015-02-23T15:00:00Z","reference_number":"EMA/162459/2013","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-vi-agency-policy-0062-procurement-procedure-ema201435re_en.pdf"},
    {"id":"26996","name":"Ex ante publicity of a negotiated procedure: EMA/2016/42/COM – Promotional products","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-05-10T16:30:00Z","last_updated_date":"2016-05-10T16:30:00Z","reference_number":"EMA/269828/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema201642com-promotional-products_en.pdf"},
    {"id":"27120","name":"Invitation to apply for a service concession in the area of meeting and training organisation (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:30:00Z","last_updated_date":"2016-08-15T12:30:00Z","reference_number":"EMA/303203/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/invitation-apply-service-concession-area-meeting-and-training-organisation-ema201643rs_en.pdf"},
    {"id":"27791","name":"Annex V - Service concession: Subcontractors (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:30:00Z","last_updated_date":"2016-08-15T12:30:00Z","reference_number":"EMA/2016/43/RS","document_url":"https://www.ema.europa.eu/en/documents/procurement/annex-v-service-concession-subcontractors-ema201643rs_en.pdf"},
    {"id":"28434","name":"Guidebook for tenderers","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T13:03:00Z","last_updated_date":"2024-05-14T17:15:00Z","reference_number":"EMA/303494/2018","document_url":"https://www.ema.europa.eu/en/documents/procurement/guidebook-tenderers_en.pdf"},
    {"id":"30414","name":"Questions and answers relating to procurement procedure: provision of internal audit services - EMA/2014/49/AUD","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-01-08T17:00:00Z","last_updated_date":"2015-01-20T10:20:00Z","reference_number":"EMA/772990/2014","document_url":"https://www.ema.europa.eu/en/documents/procurement/questions-and-answers-relating-procurement-procedure-provision-internal-audit-services-ema201449aud_en.pdf"},
    {"id":"30653","name":"Ex ante publicity of a negotiated procedure: EMA/2016/13/FI - Physical inventory of fixed assets","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-05-03T12:45:00Z","last_updated_date":"2016-05-03T12:45:00Z","reference_number":"EMA/220134/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema201613fi-physical-inventory-fixed-assets_en.pdf"},
    {"id":"30790","name":"Legal advice in relation to Dutch employment and labour law","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T11:35:00Z","last_updated_date":"2018-06-01T11:35:00Z","reference_number":"EMA/281766/2018","document_url":"https://www.ema.europa.eu/en/documents/procurement/legal-advice-relation-dutch-employment-and-labour-law_en.pdf"},
    {"id":"32350","name":"Technical specifications - Annex X estimation of ICSRs per annum: Procurement procedure EMA/2014/48/PH","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2014-11-04T10:00:00Z","last_updated_date":"2014-11-04T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-x-estimation-icsrs-annum-procurement-procedure-ema201448ph_en.pdf"},
    {"id":"33137","name":"Technical specifications for open invitation to tender: Procurement procedure EMA/2014/49/AUD","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T10:00:00Z","last_updated_date":"2014-12-10T10:00:00Z","reference_number":"EMA/564159/2014","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-open-invitation-tender-procurement-procedure-ema201449aud_en.pdf"},
    {"id":"33329","name":"Ex ante publicity of a negotiated procedure: managed services consultancy","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-02-09T11:00:00Z","last_updated_date":"2016-02-09T11:00:00Z","reference_number":"EMA/59027/2016","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-managed-services-consultancy_en.pdf"},
    {"id":"34491","name":"Technical specifications - Annex IV draft service contract: Procurement procedure EMA/2014/49/AUD","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T10:00:00Z","last_updated_date":"2014-12-10T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-iv-draft-service-contract-procurement-procedure-ema201449aud_en.pdf"},
    {"id":"40275","name":"Technical specifications -Annex III summary checklist of documents, which tenderers must submit: Procurement procedure EMA/2014/48/PH","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2014-11-04T10:00:00Z","last_updated_date":"2014-11-04T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-iii-summary-checklist-documents-which-tenderers-must-submit-procurement-procedure-ema201448ph_en.pdf"},
    {"id":"40416","name":"Questions and answers on access to drug pipeline database(s) -  EMA/2014/68/COM","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-03-11T18:45:00Z","last_updated_date":"2015-03-11T18:45:00Z","reference_number":"EMA/167796/2015","document_url":"https://www.ema.europa.eu/en/documents/procurement/questions-and-answers-access-drug-pipeline-databases-ema201468com_en.pdf"},
    {"id":"41198","name":"Technical specifications - Annex V - Applicant information sheet - Procurement procedure EMA/2014/35/RE","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2015-02-23T15:00:00Z","last_updated_date":"2015-02-23T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/technical-specifications-annex-v-applicant-information-sheet-procurement-procedure-ema201435re_en.pdf"},
    {"id":"41253","name":"Letter of invitation to tender - Procurement procedure EMA/2014/49/AUD","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T10:00:00Z","last_updated_date":"2014-12-10T10:00:00Z","reference_number":"EMA/700115/2014","document_url":"https://www.ema.europa.eu/en/documents/procurement/letter-invitation-tender-procurement-procedure-ema201449aud_en.pdf"},
    {"id":"41459","name":"Annex III - Service concession: Declaration of honour on exclusion criteria and selection criteria  (EMA/2016/43/RS)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:30:00Z","last_updated_date":"2016-08-15T12:30:00Z","reference_number":"EMA/2016/43/RS","document_url":"https://www.ema.europa.eu/en/documents/procurement/annex-iii-service-concession-declaration-honour-exclusion-criteria-and-selection-criteria-ema201643rs_en.pdf"},
    {"id":"42430","name":"EMA/2018/42/LD - Advisory and support services in relation to EU data protection matters (Ex ante publicity of a negotiated procedure)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2018-10-25T12:29:00Z","last_updated_date":"2018-10-25T12:29:00Z","reference_number":"EMA/718038/2018","document_url":"https://www.ema.europa.eu/en/documents/procurement/ema201842ld-advisory-and-support-services-relation-eu-data-protection-matters-ex-ante-publicity-negotiated-procedure_en.pdf"},
    {"id":"42949","name":"Ex ante publicity of a negotiated procedure: bank accounts for the deposit of surplus funds in euro","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2018-12-06T16:40:00Z","last_updated_date":"2018-12-06T16:40:00Z","reference_number":"EMA/733869/2018","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-bank-accounts-deposit-surplus-funds-euro_en.pdf"},
    {"id":"43426","name":"EMA/2018/15/CO – Ex-ante publicity of a negotiated procedure - On demand supply of books","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T10:32:00Z","last_updated_date":"2019-01-22T10:32:00Z","reference_number":"EMA/287281/2018","document_url":"https://www.ema.europa.eu/en/documents/procurement/ema201815co-ex-ante-publicity-negotiated-procedure-demand-supply-books_en.pdf"},
    {"id":"45588","name":"Ex ante publicity of a negotiated procedure : EMA/2019/35/ED – Executive driver services","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2019-10-08T12:16:00Z","last_updated_date":"2019-10-08T12:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema201935ed-executive-driver-services_en.pdf"},
    {"id":"45748","name":"Ex ante publicity of a negotiated procedure : EMA/2019/32/LD – Legal advice in relation to Dutch law on real estate and building maintenance","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2019-10-17T17:45:00Z","last_updated_date":"2019-10-17T17:45:00Z","reference_number":"EMA/567476/2019","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema201932ld-legal-advice-relation-dutch-law-real-estate-and-building-maintenance_en.pdf"},
    {"id":"46051","name":"Ex ante publicity of a negotiated procedure: EMA/2019/40/LD – Legal advice in relation to procurement matters and contracts under EU procurement and Dutch law","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2019-11-18T15:50:00Z","last_updated_date":"2019-11-18T15:50:00Z","reference_number":"EMA/583396/2019","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema201940ld-legal-advice-relation-procurement-matters-and-contracts-under-eu-procurement-and-dutch-law_en.pdf"},
    {"id":"48290","name":"Ex ante publicity of a negotiated procedure : EMA/2020/23/DED – Catering consultancy services - Corrigendum","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2020-07-20T11:32:00Z","last_updated_date":"2020-07-20T11:32:00Z","reference_number":"EMA/388837/2020","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema202023ded-catering-consultancy-services-corrigendum_en.pdf"},
    {"id":"48373","name":"Ex ante publicity of a negotiated procedure : EMA/2020/23/DED – Catering consultancy services","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2020-07-13T12:23:00Z","last_updated_date":"2020-07-13T12:23:00Z","reference_number":"EMA/221453/2020","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema202023ded-catering-consultancy-services_en.pdf"},
    {"id":"48892","name":"Ex ante publicity of a negotiated procedure - Exhibition logistics","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2020-09-25T15:55:00Z","last_updated_date":"2020-09-25T15:55:00Z","reference_number":"EMA/13501/2020","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-exhibition-logistics_en.pdf-0"},
    {"id":"49210","name":"Ex-ante advertisement EMA/2020/30/CO Evidence-based database","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2020-11-11T16:28:00Z","last_updated_date":"2020-11-11T16:28:00Z","reference_number":"EMA/392304/2020","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-advertisement-ema202030co-evidence-based-database_en.pdf"},
    {"id":"50521","name":"Ex ante publicity of a negotiated procedure : EMA/2021/03/CO - Copyright license","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2021-03-11T09:27:00Z","last_updated_date":"2021-03-11T09:27:00Z","reference_number":"EMA/69658/2021","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema202103co-copyright-license_en.pdf"},
    {"id":"52885","name":"Ex ante publicity of a negotiated procedure : EMA/2021/24/SG - Collective leadership development","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2021-10-20T14:58:00Z","last_updated_date":"2021-10-21T10:42:00Z","reference_number":"EMA/595558/2021 Corr.","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema202124sg-collective-leadership-development_en.pdf"},
    {"id":"53365","name":"Ex ante publicity of a negotiated procedure - EMA/2021/19/LD - Legal advice in relation to Dutch employment and labour law","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2021-12-06T12:00:00Z","last_updated_date":"2021-12-06T12:00:00Z","reference_number":"EMA/589295/2021","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema202119ld-legal-advice-relation-dutch-employment-and-labour-law_en.pdf"},
    {"id":"54726","name":"Ex ante publicity of a negotiated procedure - EMA/2022/09/IT - Transfer of registration of 21 public domain names from the current registrar and extension of their registration to 31/12/2024","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2022-04-11T16:51:00Z","last_updated_date":"2022-04-11T16:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema202209it-transfer-registration-21-public-domain-names-current-registrar-and-extension-their-registration-31122024_en.pdf"},
    {"id":"55087","name":"Ex ante publicity of a negotiated procedure: EMA-2022-06-ST - Provision of external meeting and conference facilities","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2022-05-24T16:44:00Z","last_updated_date":"2022-05-24T16:44:00Z","reference_number":"EMA/317912/2022","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema-2022-06-st-provision-external-meeting-and-conference-facilities_en.pdf"},
    {"id":"56708","name":"Ex ante publicity of a negotiated procedure: EMA/2022/15/CO - On demand supply of books (print and digital)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T10:43:00Z","last_updated_date":"2022-11-18T10:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/ex-ante-publicity-negotiated-procedure-ema202215co-demand-supply-books-print-and-digital_en.pdf"},
    {"id":"56721","name":"EMA/2022/18/ST – Ex-ante publicity of a negotiated procedure - Courier services","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2022-11-21T12:06:00Z","last_updated_date":"2022-11-21T12:06:00Z","reference_number":"EMA/672288/2022","document_url":"https://www.ema.europa.eu/en/documents/procurement/ema202218st-ex-ante-publicity-negotiated-procedure-courier-services_en.pdf"},
    {"id":"59149","name":"Annual list of contract modifications 2022","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T09:12:00Z","last_updated_date":"2023-06-30T09:12:00Z","reference_number":"EMA/19987/2022","document_url":"https://www.ema.europa.eu/en/documents/procurement/annual-list-contract-modifications-2022_en.pdf"},
    {"id":"59150","name":"Annual list of contractors 2022 - contract values Euro 15,000 - 140,000","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T09:12:00Z","last_updated_date":"2023-06-30T09:12:00Z","reference_number":"EMA/279731/2023","document_url":"https://www.ema.europa.eu/en/documents/procurement/annual-list-contractors-2022-contract-values-euro-15000-140000_en.pdf"},
    {"id":"59151","name":"Annual list of specific contracts based on framework contracts – 2022","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T09:15:00Z","last_updated_date":"2023-06-30T09:15:00Z","reference_number":"EMA/279732/2023","document_url":"https://www.ema.europa.eu/en/documents/procurement/annual-list-specific-contracts-based-framework-contracts-2022_en.pdf"},
    {"id":"63007","name":"Annex Va to the call for proposals - Draft grant agreement for an action with one beneficiary","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T15:00:00Z","last_updated_date":"2024-04-19T15:00:00Z","reference_number":"EMA/GRANT/2024/02/IA","document_url":"https://www.ema.europa.eu/en/documents/procurement/annex-va-call-proposals-draft-grant-agreement-action-one-beneficiary_en.pdf"},
    {"id":"63008","name":"Annex Vb to the call for proposals - Draft grant agreement for an action with multiple beneficiaries","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T15:00:00Z","last_updated_date":"2024-04-19T15:00:00Z","reference_number":"EMA/GRANT/2024/02/IA","document_url":"https://www.ema.europa.eu/en/documents/procurement/annex-vb-call-proposals-draft-grant-agreement-action-multiple-beneficiaries_en.pdf"},
    {"id":"63009","name":"Annex IV to the draft agreement - Model financial statement","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T15:00:00Z","last_updated_date":"2024-04-19T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/annex-iv-draft-agreement-model-financial-statement_en.xlsx"},
    {"id":"63011","name":"Call for proposals - Grant procedure EMA/GRANT/2024/02/IA “Medicines regulatory systems strengthening in Sub-Saharan Africa”","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T15:00:00Z","last_updated_date":"2024-04-19T15:00:00Z","reference_number":"EMA/145300/2024","document_url":"https://www.ema.europa.eu/en/documents/procurement/call-proposals-grant-procedure-ema-grant-2024-02-ia-medicines-regulatory-systems-strengthening-sub-saharan-africa_en.pdf"},
    {"id":"64537","name":"Presentation - Artificial Intelligence: Multi-annual AI workplan 2023-2028 (P. Arlett, Z. Frias, EMA)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2024-08-07T17:19:55Z","last_updated_date":"2024-08-07T17:19:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/presentation-artificial-intelligence-multi-annual-ai-workplan-2023-2028-p-arlett-z-frias-ema_en.pdf"},
    {"id":"67445","name":"Annual list of grants 2024","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2025-03-25T16:33:49Z","last_updated_date":"2025-03-25T16:33:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/annual-list-grants-2024_en.pdf"},
    {"id":"71119","name":"Presentation - Application of the EMA DQF for feasibility assessment of 10 use cases in the Target EU project (M. Sabaté)","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2025-11-13T11:18:17Z","last_updated_date":"2025-11-13T11:18:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/procurement/presentation-application-ema-dqf-feasibility-assessment-10-use-cases-target-eu-project-m-sabate_en.pdf"},
    {"id":"72391","name":"Tavneos Article-20 procedure: Timetable for the procedure","type":"procurement","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T14:51:43Z","last_updated_date":"2026-03-31T12:48:00Z","reference_number":"EMADOC-1700519818-2855721 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/procurement/tavneos-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"2576","name":"Public statement on Leflunomide Teva: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-03-18T13:00:00Z","last_updated_date":"2014-03-18T13:00:00Z","reference_number":"EMA/143186/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-leflunomide-teva-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"2722","name":"Public statement on BindRen: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-04-01T02:00:00Z","last_updated_date":"2015-04-01T02:00:00Z","reference_number":"EMA/164735/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-bindren-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"2809","name":"Public statement on Doribax: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-10-17T02:00:00Z","last_updated_date":"2014-10-17T02:00:00Z","reference_number":"EMA/421922/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-doribax-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"2883","name":"Hemoprostol: Withdrawal of the Article 58 scientific opinion - Public statement","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-04-26T16:00:00Z","last_updated_date":"2017-04-26T16:00:00Z","reference_number":"EMA/195172/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/hemoprostol-withdrawal-article-58-scientific-opinion-public-statement_en.pdf"},
    {"id":"2978","name":"Public statement on Xigris: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-02-21T15:23:00Z","last_updated_date":"2012-02-21T15:23:00Z","reference_number":"EMA/128419/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-xigris-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"3046","name":"Public statement on Rasilamlo (aliskiren / amlodipine): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-03-21T10:42:00Z","last_updated_date":"2017-03-21T10:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-rasilamlo-aliskiren-amlodipine-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"3340","name":"Public statement on Xapit (parecoxib): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-08-23T02:09:21Z","last_updated_date":"2004-08-23T02:09:21Z","reference_number":"EMEA/20786/04","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-xapit-parecoxib-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"3459","name":"Public statement on Tenecteplase Boehringer Ingelheim Pharma GmbH & co. KG (tenecteplase): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-12-05T12:49:21Z","last_updated_date":"2005-12-05T12:49:21Z","reference_number":"CHMP/343408/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-tenecteplase-boehringer-ingelheim-pharma-gmbh-co-kg-tenecteplase-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"3470","name":"Public Statement on Positive Opinion for Tuberculosis Vaccine","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2006-11-29T00:09:21Z","last_updated_date":"2006-11-29T00:09:21Z","reference_number":"EMEA/71122/2006","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-positive-opinion-tuberculosis-vaccine_en.pdf"},
    {"id":"3692","name":"Public Statement Prevenar - Resumption on Supplies","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2004-08-23T02:09:21Z","last_updated_date":"2004-08-23T02:09:21Z","reference_number":"EMEA/21709/04 - Final","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-prevenar-resumption-supplies_en.pdf"},
    {"id":"3706","name":"Public statement on Revasc: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-07-29T02:00:00Z","last_updated_date":"2014-07-29T02:00:00Z","reference_number":"EMA/447799/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-revasc-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"3931","name":"Draft public statement on Picrorhiza kurroa Royle ex Benth, radix","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2014-07-31 - 2014-10-31","first_published_date":"2014-07-31T16:05:00Z","last_updated_date":"2014-07-31T16:05:00Z","reference_number":"EMA/HMPC/161476/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-picrorhiza-kurroa-royle-ex-benth-radix_en.pdf"},
    {"id":"4193","name":"Public statement on Intanza: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-09-04T13:36:00Z","last_updated_date":"2018-09-04T13:36:00Z","reference_number":"EMA/567363/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-intanza-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"4287","name":"Draft public statement on Uncaria tomentosa (Willd. ex Schult.) DC., cortex","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2015-04-15 - 2015-07-15","first_published_date":"2015-04-15T13:00:00Z","last_updated_date":"2015-04-15T13:00:00Z","reference_number":"EMA/HMPC/588732/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-uncaria-tomentosa-willd-ex-schult-dc-cortex_en.pdf"},
    {"id":"4654","name":"Public statement on Daquiran: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2006-05-23T02:00:00Z","last_updated_date":"2006-05-23T02:00:00Z","reference_number":"EMEA/184565/2006","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-daquiran-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"4659","name":"Public statement on Clopidogrel BMS: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2010-01-27T00:09:21Z","last_updated_date":"2010-01-27T00:09:21Z","reference_number":"EMEA/784110/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-bms-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"5234","name":"Final public statement on Euphrasia officinalis L. and Euphrasia rostkoviana Hayne), herba","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/727465/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-euphrasia-officinalis-l-and-euphrasia-rostkoviana-hayne-herba_en.pdf"},
    {"id":"5241","name":"Final public statement on Viscum album L., herba","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2013-08-01T17:05:00Z","last_updated_date":"2013-08-01T17:05:00Z","reference_number":"EMA/HMPC/57109/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-viscum-album-l-herba_en.pdf"},
    {"id":"5369","name":"Public statement on Euphrasia officinalis L. and Euphrasia rostkoviana Hayne, herba","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2009-11-12 - 2010-05-15","first_published_date":"2010-02-12T01:09:21Z","last_updated_date":"2010-02-12T01:09:21Z","reference_number":"EMA/HMPC/727465/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-euphrasia-officinalis-l-and-euphrasia-rostkoviana-hayne-herba_en.pdf"},
    {"id":"5394","name":"Public statement on Possia: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-04-22T02:00:00Z","last_updated_date":"2013-04-22T02:00:00Z","reference_number":"EMA/212211/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-possia-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"5497","name":"Public statement on ChondroCelect: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-08-04T19:23:00Z","last_updated_date":"2017-01-12T18:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-chondrocelect-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"5579","name":"Meeting of the EMEA working party on herbal medicinal products 30 and 31 October 2000","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-11-10T01:00:00Z","last_updated_date":"2000-11-10T01:00:00Z","reference_number":"EMEA/HMPWP/45/00","document_url":"https://www.ema.europa.eu/en/documents/public-statement/meeting-emea-working-party-herbal-medicinal-products-30-and-31-october-2000_en.pdf"},
    {"id":"5597","name":"Public statement on Vibativ: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-05-16T11:35:00Z","last_updated_date":"2018-05-16T11:35:00Z","reference_number":"EMA/198910/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vibativ-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"5717","name":"Public statement on Daronrix: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-07-02T12:00:00Z","last_updated_date":"2013-07-02T12:00:00Z","reference_number":"EMA/670070/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-daronrix-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"5764","name":"Revised Public Statement on Etanercept (Enbrel) - Serious hematological reactions and demyelination disorders","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-10-03T02:00:00Z","last_updated_date":"2000-10-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/revised-public-statement-etanercept-enbrel-serious-hematological-reactions-and-demyelination-disorders_en.pdf"}    {"id":"5785","name":"Public Statement on Valdyn (valdecoxib) Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-08-23T02:09:21Z","last_updated_date":"2004-08-23T02:09:21Z","reference_number":"EMEA/20783/04","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-valdyn-valdecoxib-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"6502","name":"EMEA public statement on Refludan (Lepirudin) - Fatal anaphylactic reactions","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2002-10-29T01:00:00Z","last_updated_date":"2002-10-29T01:00:00Z","reference_number":"EMEA/H/27717/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-refludan-lepirudin-fatal-anaphylactic-reactions_en.pdf"},
    {"id":"6568","name":"Public statement on Irbesartan BMS (irbesartan) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-11-23T00:09:21Z","last_updated_date":"2009-11-23T00:09:21Z","reference_number":"EMEA/763788/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-irbesartan-bms-irbesartan-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"6574","name":"Public statement on Valdyn (valdecoxib) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-08-11T14:09:21Z","last_updated_date":"2005-08-11T14:09:21Z","reference_number":"EMEA/265602/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-valdyn-valdecoxib-withdrawal-marketing-authorisation-european-union_en.pdf-0"},
    {"id":"6629","name":"Public statement Fluenz: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-12-03T01:00:00Z","last_updated_date":"2014-12-03T01:00:00Z","reference_number":"EMA/622936/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-fluenz-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"6657","name":"Public statement on Filgrastim ratiopharm: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-07-20T02:00:00Z","last_updated_date":"2011-07-20T02:00:00Z","reference_number":"EMA/348290/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-filgrastim-ratiopharm-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"6696","name":"Public statement on the interpretation of therapeutic indications appropriate to traditional herbal medicinal products in Community herbal monographs","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2011-09-29T12:50:00Z","last_updated_date":"2011-09-29T12:50:00Z","reference_number":"EMA/HMPC/473587/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-interpretation-therapeutic-indications-appropriate-traditional-herbal-medicinal-products-community-herbal-monographs_en.pdf"},
    {"id":"6723","name":"Public statement on Somatropin Biopartners: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T17:20:00Z","last_updated_date":"2017-12-01T17:20:00Z","reference_number":"EMA/791271/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-somatropin-biopartners-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"6808","name":"Public statement on Pantecta Control: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T17:41:00Z","last_updated_date":"2016-11-15T17:41:00Z","reference_number":"EMEA/H/C/001099","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pantecta-control-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"6903","name":"Draft public statement on Glycine max (L.) Merr., semen - First version","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2017-02-28 - 2017-05-31","first_published_date":"2017-02-28T10:30:00Z","last_updated_date":"2017-02-28T10:30:00Z","reference_number":"EMA/HMPC/461814/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-glycine-max-l-merr-semen-first-version_en.pdf"},
    {"id":"6976","name":"Public statement on Trevaclyn: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-05-16T02:00:00Z","last_updated_date":"2013-05-16T02:00:00Z","reference_number":"EMA/183315/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-trevaclyn-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"7099","name":"Public statement on Repso: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-07-28T12:42:00Z","last_updated_date":"2017-07-28T12:42:00Z","reference_number":"EMA/477146/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-repso-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"7367","name":"Public statement on Sprimeo HCT: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-07-23T02:00:00Z","last_updated_date":"2012-07-23T02:00:00Z","reference_number":"EMA/328034/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-sprimeo-hct-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"7385","name":"Draft public statement on Viscum album L., herba","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-20T13:30:15Z","last_updated_date":"2011-10-20T13:30:15Z","reference_number":"EMA/HMPC/57109/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-viscum-album-l-herba_en.pdf"},
    {"id":"7444","name":"Public statement on Ipreziv: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/710373/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ipreziv-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"7891","name":"Public statement on Refludan: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-07-27T02:00:00Z","last_updated_date":"2012-07-27T02:00:00Z","reference_number":"EMA/328034/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-refludan-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"7955","name":"Public statement on HumaSPECT (votumumab) - Non-renewal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-02-24T00:09:21Z","last_updated_date":"2004-02-24T00:09:21Z","reference_number":"EMEA/3885/04","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-humaspect-votumumab-non-renewal-marketing-authorisation-european-union_en.pdf"},
    {"id":"8180","name":"Public statement on contamination of herbal medicinal products/traditional herbal medicinal products with pyrrolizidine alkaloids","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2016-06-08T13:45:00Z","last_updated_date":"2016-06-08T13:45:00Z","reference_number":"EMA/HMPC/328782/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-contamination-herbal-medicinal-productstraditional-herbal-medicinal-products-pyrrolizidine-alkaloids_en.pdf"},
    {"id":"8276","name":"Public Statement on Infliximab (Remicade) - Increased incidence of mortality and hospitalisation for worsening Congestive Heart Failure","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-10-24T02:00:00Z","last_updated_date":"2001-10-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-infliximab-remicade-increased-incidence-mortality-and-hospitalisation-worsening-congestive-heart-failure_en.pdf"},
    {"id":"8285","name":"Withdrawal of the marketing authorisation for the medicinal product \"EchoGen - dodecafluoropentane\" EU/1/98/072/001","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-05-22T02:00:00Z","last_updated_date":"2001-05-22T02:00:00Z","reference_number":"EMEA/37043/00","document_url":"https://www.ema.europa.eu/en/documents/public-statement/withdrawal-marketing-authorisation-medicinal-product-echogen-dodecafluoropentane-eu198072001_en.pdf"},
    {"id":"8310","name":"Draft public statement on Sambucus nigra L., fructus","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2013-03-12 - 2013-07-15","first_published_date":"2013-04-19T04:00:00Z","last_updated_date":"2013-04-19T04:00:00Z","reference_number":"EMA/HMPC/32465/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-sambucus-nigra-l-fructus_en.pdf"},
    {"id":"8366","name":"Public statement on Clopidogrel Acino Pharma GmbH: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-07-26T02:00:00Z","last_updated_date":"2012-07-26T02:00:00Z","reference_number":"EMA/328312/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-acino-pharma-gmbh-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"8392","name":"EMEA announcement: To manufacturers, companies and hospitals having advanced therapy medicinal products legally on the Community market in accordance with national or Community legislation","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-07-31T02:00:00Z","last_updated_date":"2008-07-31T02:00:00Z","reference_number":"EMEA/326145/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-announcement-manufacturers-companies-and-hospitals-having-advanced-therapy-medicinal-products-legally-community-market-accordance-national-or-community-legislation_en.pdf"},
    {"id":"8536","name":"Draft public statement on Allium cepa L., bulbus","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2011-08-15 - 2011-11-15","first_published_date":"2011-08-18T04:00:00Z","last_updated_date":"2011-08-18T04:00:00Z","reference_number":"EMA/HMPC/347189/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-allium-cepa-l-bulbus_en.pdf"},
    {"id":"8668","name":"Withdrawal of the marketing authorisation for the medicinal product Primavax - Diphtheria, tetanus and hepatitis B vaccine","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-12-04T01:00:00Z","last_updated_date":"2000-12-04T01:00:00Z","reference_number":"EMEA/H/2681/00/Final","document_url":"https://www.ema.europa.eu/en/documents/public-statement/withdrawal-marketing-authorisation-medicinal-product-primavax-diphtheria-tetanus-and-hepatitis-b-vaccine_en.pdf"},
    {"id":"8744","name":"Public statement on Incivo: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-10-06T02:00:00Z","last_updated_date":"2016-10-06T02:00:00Z","reference_number":"EMA/599647/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-incivo-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"9209","name":"Public statement on Provenge: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T02:00:00Z","last_updated_date":"2015-05-19T02:00:00Z","reference_number":"EMA/303072/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-provenge-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"9318","name":"Public statement on Onduarp: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-04-02T16:00:00Z","last_updated_date":"2014-04-02T16:00:00Z","reference_number":"EMA/133999/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-onduarp-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"9542","name":"Use of antiretroviral treatment in HIV-patients with hepatic impairment\n\nand/or HBV/HCV co-infection","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-08-06T01:31:00Z","last_updated_date":"2005-08-06T01:31:00Z","reference_number":"EMEA/CHMP/249537/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/use-antiretroviral-treatment-hiv-patients-hepatic-impairment-andor-hbvhcv-co-infection_en.pdf"},
    {"id":"9690","name":"Public statement on Levviax (telithromycin): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-01-25T00:09:21Z","last_updated_date":"2008-01-25T00:09:21Z","reference_number":"EMEA/CHMP/26421/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-levviax-telithromycin-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"9728","name":"Draft public statement on Paeonia lactiflora Pall. and Paeonia veitchii Lynch, radix (Paeoniae radix rubra)","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2016-02-16 - 2016-05-15","first_published_date":"2016-02-16T18:40:00Z","last_updated_date":"2016-02-16T18:40:00Z","reference_number":"EMA/HMPC/762952/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-paeonia-lactiflora-pall-and-paeonia-veitchii-lynch-radix-paeoniae-radix-rubra_en.pdf"},
    {"id":"9951","name":"Public statement on the withdrawal of the marketing authorisation in the European Union for Tekturna (aliskiren)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-09-10T02:00:00Z","last_updated_date":"2009-09-10T02:00:00Z","reference_number":"EMEA/575961/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-withdrawal-marketing-authorisation-european-union-tekturna-aliskiren_en.pdf"},
    {"id":"9992","name":"Public Statement: Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2007-10-23T02:09:21Z","last_updated_date":"2007-10-23T02:09:21Z","reference_number":"EMEA/496188/2007","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-epoetins-and-risk-tumour-growth-progression-and-thromboembolic-events-cancer-patients-and-cardiovascular-risks-patients-chronic-kidney-disease_en.pdf"},
    {"id":"10072","name":"Public statement on Enzepi: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-07-28T13:52:00Z","last_updated_date":"2017-07-28T13:52:00Z","reference_number":"EMA/473867/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-enzepi-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"10436","name":"Final public statement on Picrorhiza kurroa Royle ex Benth, radix","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2015-02-18T01:00:00Z","last_updated_date":"2015-02-18T01:00:00Z","reference_number":"EMA/HMPC/161476/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-picrorhiza-kurroa-royle-ex-benth-radix_en.pdf"},
    {"id":"10567","name":"EMEA public statement on infliximab (Remicade): Update on safety concerns","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2002-02-01T01:00:00Z","last_updated_date":"2002-02-01T01:00:00Z","reference_number":"CPMP/32/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-infliximab-remicade-update-safety-concerns_en.pdf"},
    {"id":"10599","name":"Public statement on Enviage: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-05-19T02:00:00Z","last_updated_date":"2011-05-19T02:00:00Z","reference_number":"EMA/231284/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-enviage-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"10728","name":"Public statement on Clopidogrel Hexal: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-07-26T02:00:00Z","last_updated_date":"2012-07-26T02:00:00Z","reference_number":"EMA/328036/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-hexal-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"10782","name":"Public statement on Budesonide/Formoterol Teva: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-01-31T14:43:00Z","last_updated_date":"2017-01-31T14:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-budesonideformoterol-teva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"10850","name":"Public statement on Insulin Human Winthrop: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-04-30T18:45:00Z","last_updated_date":"2018-04-30T18:45:00Z","reference_number":"EMA/138370/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-insulin-human-winthrop-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"10932","name":"Public statement on the recommendation to suspend the marketing authorisation for Orlaam (levacetylmethadol) in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-04-19T02:00:00Z","last_updated_date":"2001-04-19T02:00:00Z","reference_number":"EMEA/8776/01","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-recommendation-suspend-marketing-authorisation-orlaam-levacetylmethadol-european-union_en.pdf"},
    {"id":"10937","name":"EMEA public statement on antimicrobial preservatives in ophthalmic preparations for human use","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2009-12-08T00:09:21Z","last_updated_date":"2009-12-08T00:09:21Z","reference_number":"EMEA/622721/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-antimicrobial-preservatives-ophthalmic-preparations-human-use_en.pdf"},
    {"id":"11116","name":"Routes of administration of vaccines to poultry","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T16:15:00Z","last_updated_date":"2013-11-18T16:15:00Z","reference_number":"EMA/CVMP/IWP/640481/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/routes-administration-vaccines-poultry_en.pdf"},
    {"id":"11143","name":"Public statement on interaction between clopidogrel and proton-pump inhibitors","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2010-03-17T01:00:00Z","last_updated_date":"2010-03-17T01:00:00Z","reference_number":"EMA/174948/2010","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-interaction-between-clopidogrel-and-proton-pump-inhibitors_en.pdf"},
    {"id":"11317","name":"Final public statement on Glycine max (L.) Merr., semen - First version","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2018-07-31T02:00:00Z","last_updated_date":"2018-07-31T02:00:00Z","reference_number":"EMA/HMPC/461814/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-glycine-max-l-merr-semen-first-version_en.pdf"},
    {"id":"11326","name":"Final public statement on Withania somnifera (L.) Dunal, radix - First version","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/HMPC/681519/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-withania-somnifera-l-dunal-radix-first-version_en.pdf"},
    {"id":"11457","name":"Public statement on Nyracta (rosiglitazone): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-04-18T14:09:21Z","last_updated_date":"2005-04-18T14:09:21Z","reference_number":"EMEA/41043/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-nyracta-rosiglitazone-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"11505","name":"CVMP Public Statement on CPMP Public Statement on Lactose prepared using Calf Rennet: Risk Assessment in relation to bovine spongiform encephalophaties (BSE)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2002-05-06T02:09:21Z","last_updated_date":"2002-05-06T02:09:21Z","reference_number":"EMEA/CVMP/556/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/cvmp-public-statement-cpmp-public-statement-lactose-prepared-using-calf-rennet-risk-assessment-relation-bovine-spongiform-encephalophaties-bse_en.pdf"},
    {"id":"11752","name":"Public statement on the suspension of the marketing authorisation for Bextra (Valdecoxib) in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-10-27T02:00:00Z","last_updated_date":"2005-10-27T02:00:00Z","reference_number":"EMEA/358234/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-suspension-marketing-authorisation-bextra-valdecoxib-european-union_en.pdf"},
    {"id":"12176","name":"Public statement on Clopidogrel DURA (clopidogrel): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-07-10T02:00:00Z","last_updated_date":"2015-07-10T02:00:00Z","reference_number":"EMA/301017/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-dura-clopidogrel-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"12263","name":"Public statement on Raptiva (efalizumab): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-08-03T02:00:00Z","last_updated_date":"2009-08-03T02:00:00Z","reference_number":"EMEA/487107/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-raptiva-efalizumab-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"12306","name":"Public statement on Infanrix Penta: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-07-10T17:00:00Z","last_updated_date":"2013-07-10T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-infanrix-penta-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"12520","name":"Public statement on Bondenza: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-05-13T17:04:00Z","last_updated_date":"2013-05-13T17:04:00Z","reference_number":"EMA/276528/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-bondenza-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"12743","name":"Public statement on Imprida: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-05-11T02:00:00Z","last_updated_date":"2017-05-11T02:00:00Z","reference_number":"EMEA/252290/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-imprida-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"12774","name":"Draft public statement on Andrographis paniculata Nees, folium - First version","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2013-01-15 - 2013-04-15","first_published_date":"2013-01-25T02:00:00Z","last_updated_date":"2013-01-25T02:00:00Z","reference_number":"EMA/HMPC/709282/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-andrographis-paniculata-nees-folium-first-version_en.pdf"},
    {"id":"13054","name":"Public statement on Infliximab (Remicade) on the increased incidence of mortality and hospitalisation for worsening Congestive Heart Failure","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-10-24T02:00:00Z","last_updated_date":"2001-10-24T02:00:00Z","reference_number":"CPMP/3257/01","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-infliximab-remicade-increased-incidence-mortality-and-hospitalisation-worsening-congestive-heart-failure_en.pdf-0"},
    {"id":"13279","name":"European Medicines Agency Public Statement on the lifting of the suspension of the marketing authorisation for Tolcapone (Tasmar)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-04-29T02:09:21Z","last_updated_date":"2004-04-29T02:09:21Z","reference_number":"EMEA/11854/04/Final","document_url":"https://www.ema.europa.eu/en/documents/public-statement/european-medicines-agency-public-statement-lifting-suspension-marketing-authorisation-tolcapone-tasmar_en.pdf"},
    {"id":"13337","name":"Public statement on Riprazo HCT: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-09-20T02:00:00Z","last_updated_date":"2012-09-20T02:00:00Z","reference_number":"EMA/328034/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-riprazo-hct-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"13723","name":"Public statement on Pulsaflox oral solution (difloxaxin): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-03-04T00:09:21Z","last_updated_date":"2004-03-04T00:09:21Z","reference_number":"EMEA/CVMP/021/04","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pulsaflox-oral-solution-difloxaxin-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"13738","name":"Public statement on Ariclaim : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-08-07T18:40:00Z","last_updated_date":"2018-08-07T18:40:00Z","reference_number":"EMA/518555/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ariclaim-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"13770","name":"Draft public statement on Centella asiatica (L.) Urban, herba - First version","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-09-17T02:09:21Z","last_updated_date":"2009-09-17T02:09:21Z","reference_number":"EMEA/HMPC/579663/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-centella-asiatica-l-urban-herba-first-version_en.pdf"},
    {"id":"13877","name":"Public statement on Forcaltonin - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-10-31T00:09:21Z","last_updated_date":"2008-11-18T00:09:21Z","reference_number":"EMEA/518348/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-forcaltonin-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"13967","name":"Public statement on Rivastigmine Teva: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-09-27T02:00:00Z","last_updated_date":"2012-09-27T02:00:00Z","reference_number":"EMA/611488/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-rivastigmine-teva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"14002","name":"Public statement on Removab: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-07-12T16:01:00Z","last_updated_date":"2017-07-12T16:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-removab-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"14062","name":"Public statement on Nespo (darbepoetin alfa): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-12-12T00:09:21Z","last_updated_date":"2008-12-12T00:09:21Z","reference_number":"EMEA/674212/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-nespo-darbepoetin-alfa-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"14135","name":"Public statement on Neupopeg (pegfilgrastim): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-12-16T00:09:21Z","last_updated_date":"2008-12-23T00:09:21Z","reference_number":"EMEA/680805/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-neupopeg-pegfilgrastim-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"14234","name":"Public statement on Olansek (olanzapine): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2003-06-12T02:09:21Z","last_updated_date":"2003-06-12T02:09:21Z","reference_number":"EMEA/15115/03","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-olansek-olanzapine-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"14461","name":"Public statement on Dutrebis: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-04-27T16:06:00Z","last_updated_date":"2017-04-27T16:06:00Z","reference_number":"EMA/193882/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dutrebis-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"14624","name":"Public statement on Quixidar (fondaparinux sodium): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-05-16T02:00:00Z","last_updated_date":"2008-05-16T02:00:00Z","reference_number":"EMEA/245310/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-quixidar-fondaparinux-sodium-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"14800","name":"Public statement on Ristempa: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T15:11:00Z","last_updated_date":"2018-03-07T15:11:00Z","reference_number":"EMA/792923/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ristempa-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"14958","name":"Public statement on Clopidogrel Qualimed: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-09-08T02:00:00Z","last_updated_date":"2014-09-08T02:00:00Z","reference_number":"EMA/539040/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-qualimed-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"15026","name":"Public statement on Avandamet: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-06-08T02:00:00Z","last_updated_date":"2016-06-08T02:00:00Z","reference_number":"EMEA/H/C/000522","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-avandamet-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"15097","name":"Public statement on Viraferon (interferon alfa-2b) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T00:09:21Z","last_updated_date":"2008-11-20T00:09:21Z","reference_number":"EMEA/567934/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-viraferon-interferon-alfa-2b-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"15108","name":"Public statement on Intrinsa: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-06-18T18:37:00Z","last_updated_date":"2012-07-16T18:37:00Z","reference_number":"EMA/360944/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-intrinsa-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"15167","name":"Public Statement on Tritanrix HepB: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-01-07T01:00:00Z","last_updated_date":"2014-01-07T01:00:00Z","reference_number":"EMA/748663/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-tritanrix-hepb-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"15272","name":"Withdrawal of the marketing authorisation for the medicinal product Liprolog - insulin lispro EU/1/97/038/001-003","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-02-26T01:00:00Z","last_updated_date":"2001-02-26T01:00:00Z","reference_number":"EMEA/CPMP/571/01","document_url":"https://www.ema.europa.eu/en/documents/public-statement/withdrawal-marketing-authorisation-medicinal-product-liprolog-insulin-lispro-eu197038001-003_en.pdf"},
    {"id":"15482","name":"Final public statement on Uncaria tomentosa (Willd. ex Schult.) DC., cortex","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2016-01-22T01:00:00Z","last_updated_date":"2016-01-22T01:00:00Z","reference_number":"EMA/HMPC/588732/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-uncaria-tomentosa-willd-ex-schult-dc-cortex_en.pdf"},
    {"id":"15553","name":"Public statement on Triacelluvax (combined diptheria, tetanus and acellular pertussis vaccine): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2002-07-03T02:00:00Z","last_updated_date":"2002-07-03T02:00:00Z","reference_number":"EMEA/15519/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-triacelluvax-combined-diptheria-tetanus-and-acellular-pertussis-vaccine-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"15663","name":"Public statement on Clopidogrel/Acetylsalicylic acid Teva: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-04-28T02:00:00Z","last_updated_date":"2017-04-28T02:00:00Z","reference_number":"EMA/252355/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrelacetylsalicylic-acid-teva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"15676","name":"Public statement on Zoledronic acid Teva Generics: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-08-08T02:00:00Z","last_updated_date":"2016-08-08T02:00:00Z","reference_number":"EMA/528126/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zoledronic-acid-teva-generics-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"15706","name":"Public statement on Paglitaz: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-03-10T12:04:00Z","last_updated_date":"2016-03-10T12:04:00Z","reference_number":"EMEA/H/C/002309","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-paglitaz-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"15849","name":"Public statement on Viracept: Non-renewal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-01-25T15:35:00Z","last_updated_date":"2013-01-25T15:35:00Z","reference_number":"EMA/21055/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-viracept-non-renewal-marketing-authorisation-european-union_en.pdf"},
    {"id":"16135","name":"Public Statement on Thiomersal containing medicinal products","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-07-08T02:00:00Z","last_updated_date":"1999-07-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-thiomersal-containing-medicinal-products_en.pdf"},
    {"id":"16143","name":"Public statement on Zontivity: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-09-20T15:57:00Z","last_updated_date":"2017-09-20T15:57:00Z","reference_number":"EMA/411700/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zontivity-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"16153","name":"Public Statement on Benefix (nonacog alfa) - Intensive post-marketing surveillance for all new patients: New clinical trials","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-10-04T02:00:00Z","last_updated_date":"2001-10-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-benefix-nonacog-alfa-intensive-post-marketing-surveillance-all-new-patients-new-clinical-trials_en.pdf"},
    {"id":"16160","name":"Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) - First version","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2014-12-22T11:30:00Z","last_updated_date":"2014-12-22T11:30:00Z","reference_number":"EMA/HMPC/893108/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-first-version_en.pdf"},
    {"id":"16254","name":"Public statement on Hexavac: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-08-16T02:00:00Z","last_updated_date":"2012-08-16T02:00:00Z","reference_number":"EMA/273279/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-hexavac-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"16480","name":"Meeting of the EMEA working party on herbal medicinal products 28 - 29 October 1999","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-11-18T01:00:00Z","last_updated_date":"1999-11-18T01:00:00Z","reference_number":"EMEA/HMPWP/32/99","document_url":"https://www.ema.europa.eu/en/documents/public-statement/meeting-emea-working-party-herbal-medicinal-products-28-29-october-1999_en.pdf"},
    {"id":"16484","name":"Final public statement on Angelica sinensis (Oliv.) Diels, radix - First version","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-11-25T01:00:00Z","last_updated_date":"2013-11-25T01:00:00Z","reference_number":"EMA/HMPC/681574/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-angelica-sinensis-oliv-diels-radix-first-version_en.pdf"},
    {"id":"16623","name":"Public statement on Sonata: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-10-21T02:00:00Z","last_updated_date":"2015-10-21T02:00:00Z","reference_number":"EMEA/H/C/000227","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-sonata-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"16633","name":"Public statement on Optaflu: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-06-27T02:00:00Z","last_updated_date":"2017-06-27T02:00:00Z","reference_number":"EMA/376617/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-optaflu-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"16738","name":"Public Statement on Levacetylmethadol (Orlaam) - Life threatening ventricular rhythm disorders","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-12-19T01:00:00Z","last_updated_date":"2000-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-levacetylmethadol-orlaam-life-threatening-ventricular-rhythm-disorders_en.pdf"},
    {"id":"16829","name":"EMEA completes the review of recombinant factor VIII products and\n\ninhibitor development","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2007-07-31T02:09:21Z","last_updated_date":"2007-07-31T02:09:21Z","reference_number":"EMEA/310225/2007 Corr","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-completes-review-recombinant-factor-viii-products-and-inhibitor-development_en.pdf"},
    {"id":"17146","name":"Public statement Topotecan Eagle: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T01:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/665152/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-topotecan-eagle-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"17161","name":"Metabolic and cardiovascular complications of antiretroviral combination therapy in HIV-infected patients","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2003-04-25T02:09:21Z","last_updated_date":"2003-04-25T02:09:21Z","reference_number":"EMEA/CPMP/2383/03","document_url":"https://www.ema.europa.eu/en/documents/public-statement/metabolic-and-cardiovascular-complications-antiretroviral-combination-therapy-hiv-infected-patients_en.pdf"},
    {"id":"17254","name":"EMEA public statement on Valdecoxib and parecoxib sodium _cardiovascular risks in coronary artery bypass graft surgery and serious adverse skin reactions","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-12-15T01:00:00Z","last_updated_date":"2004-12-15T01:00:00Z","reference_number":"EMEA/204802/2004","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-valdecoxib-and-parecoxib-sodium-_cardiovascular-risks-coronary-artery-bypass-graft-surgery-and-serious-adverse-skin-reactions_en.pdf"},
    {"id":"17265","name":"Public statement on Acomplia: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-01-30T01:00:00Z","last_updated_date":"2009-01-30T01:00:00Z","reference_number":"EMEA/39457/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-acomplia-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"17326","name":"Important new pharmacokinetic data demonstrating that REYATAZ (atazanavir\n\nsulfate) combined with NORVIR (ritonavir) and omeprazole should not be co-administered","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-12-22T00:31:00Z","last_updated_date":"2004-12-22T00:31:00Z","reference_number":"EMEA/202649/2004","document_url":"https://www.ema.europa.eu/en/documents/public-statement/important-new-pharmacokinetic-data-demonstrating-reyataz-atazanavir-sulfate-combined-norvir-ritonavir-and-omeprazole-should-not-be-co-administered_en.pdf"},
    {"id":"17369","name":"Draft public statement on Chelidonium majus L., herba","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2011-01-15 - 2011-04-15","first_published_date":"2011-01-18T02:00:00Z","last_updated_date":"2011-01-18T02:00:00Z","reference_number":"EMA/HMPC/743927/2010","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-chelidonium-majus-l-herba_en.pdf"},
    {"id":"17663","name":"Public statement on Rienso (ferumoxytol): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-07-13T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMA/437901/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-rienso-ferumoxytol-withdrawal-marketing-authorisation-european-union_en.pdf"}    {"id":"17680","name":"Public Statement on Trovan/Trovan IV/Turvel/Turvel IV (Trovafloxacin/Alatrofloxacin): Serious, severe and unpredictable liver injuries","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-05-25T02:00:00Z","last_updated_date":"1999-05-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-trovantrovan-ivturvelturvel-iv-trovafloxacinalatrofloxacin-serious-severe-and-unpredictable-liver-injuries_en.pdf"},
    {"id":"17934","name":"Public statement on Zinbryta: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T12:20:01Z","last_updated_date":"2018-05-02T12:20:01Z","reference_number":"EMA/247897/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zinbryta-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"18255","name":"Public statement on Vylaer Spiromax: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-01-26T01:00:00Z","last_updated_date":"2017-01-26T01:00:00Z","reference_number":"EMEA/H/C/003952","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vylaer-spiromax-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"18471","name":"Public statement on Sifrol, Daquiran, Mirapexin (pramipexole) - Sudden onset of sleep","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-07-19T02:00:00Z","last_updated_date":"1999-07-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-sifrol-daquiran-mirapexin-pramipexole-sudden-onset-sleep_en.pdf"},
    {"id":"18637","name":"Public statement on Tasermity: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-03-27T13:40:00Z","last_updated_date":"2018-03-27T13:40:00Z","reference_number":"EMA/118962/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-tasermity-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"18805","name":"Public Statement on Abacavir (Ziagen) - Important  safety information on hypersensitivity reactions and respiratory symptoms","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-01-24T01:00:00Z","last_updated_date":"2000-01-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-abacavir-ziagen-important-safety-information-hypersensitivity-reactions-and-respiratory-symptoms_en.pdf"},
    {"id":"18813","name":"Public statement on Rayzon (parecoxib) - withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-08-23T14:09:21Z","last_updated_date":"2005-08-23T14:09:21Z","reference_number":"EMEA/265596/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-rayzon-parecoxib-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"18904","name":"Public statement on supply of Norvir hard capsules","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1998-07-28T02:00:00Z","last_updated_date":"1998-07-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-supply-norvir-hard-capsules_en.pdf"},
    {"id":"19003","name":"Final public statement on Paeonia lactiflora Pallas, radix (Paeoniae radix alba)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-04-25T16:47:00Z","last_updated_date":"2017-04-25T16:47:00Z","reference_number":"EMA/HMPC/150787/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-paeonia-lactiflora-pallas-radix-paeoniae-radix-alba_en.pdf"},
    {"id":"19109","name":"Public statement on Prevenar (pneumococcal polysaccharide conjugate vaccine (7-valent, adsorbed)): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2017-11-24T17:03:00Z","last_updated_date":"2017-11-24T17:03:00Z","reference_number":"EMA/751589/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-prevenar-pneumococcal-polysaccharide-conjugate-vaccine-7-valent-adsorbed-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"19160","name":"Public Statement on Trastuzumab (Herceptin)- New pharmacokinetic data","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-06-13T02:00:00Z","last_updated_date":"2001-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-trastuzumab-herceptin-new-pharmacokinetic-data_en.pdf"},
    {"id":"19233","name":"Public statement on Pelzont: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-05-16T02:00:00Z","last_updated_date":"2013-05-16T02:00:00Z","reference_number":"EMA/285239/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pelzont-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"19277","name":"EU (European Commission and EMEA) and FDA extend confidentiality arrangements for five more years","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-11-10T00:09:21Z","last_updated_date":"2005-11-10T00:09:21Z","reference_number":"EMEA/329559/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/eu-european-commission-and-emea-and-fda-extend-confidentiality-arrangements-five-more-years_en.pdf"},
    {"id":"19474","name":"Public statement on Capecitabine SUN: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-12-22T01:00:00Z","last_updated_date":"2016-12-22T01:00:00Z","reference_number":"EMA/762623/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-capecitabine-sun-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"19538","name":"Public statement on Dynepo: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-04-07T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/126669/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dynepo-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"19865","name":"Second draft public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs)","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2013-11-14 - 2014-02-15","first_published_date":"2013-11-14T13:30:00Z","last_updated_date":"2013-11-14T13:30:00Z","reference_number":"EMA/HMPC/893108/2011 2nd draft","document_url":"https://www.ema.europa.eu/en/documents/public-statement/second-draft-public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas_en.pdf"},
    {"id":"20043","name":"Public statement on Ixense (apomorphine hydrochloride): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-11-10T01:09:21Z","last_updated_date":"2004-11-10T01:09:21Z","reference_number":"EMEA/90947/04","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ixense-apomorphine-hydrochloride-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"20192","name":"Draft public statement on Piper methysticum G. Forst., rhizoma","type":"public-statement","status":"unknown","consultation_date":"2016-12-15 - 2017-03-15","first_published_date":"2016-12-15T11:35:00Z","last_updated_date":"2016-12-15T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-piper-methysticum-g-forst-rhizoma_en.pdf"},
    {"id":"20567","name":"Public Statement on Rapilysin (Reteplase) - Incompatibility with Heparin and Precipitation following the Reconstitution - Important New Instructions for Use","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-12-23T01:00:00Z","last_updated_date":"1999-12-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-rapilysin-reteplase-incompatibility-heparin-and-precipitation-following-reconstitution-important-new-instructions-use_en.pdf"},
    {"id":"20638","name":"Public statement on Quintanrix: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-08-29T02:00:00Z","last_updated_date":"2008-08-29T02:00:00Z","reference_number":"EMEA/424484/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-quintanrix-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"20644","name":"European Commission, EMEA and FDA agree on guiding principles for joint FDA EMEA voluntary genomic data submission briefing meetings","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-05-31T02:00:00Z","last_updated_date":"2009-05-31T02:00:00Z","reference_number":"EMEA/191367/2006","document_url":"https://www.ema.europa.eu/en/documents/public-statement/european-commission-emea-and-fda-agree-guiding-principles-joint-fda-emea-voluntary-genomic-data-submission-briefing-meetings_en.pdf"},
    {"id":"20736","name":"Public statement on Thelin: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2011-03-02T01:00:00Z","last_updated_date":"2011-03-02T01:00:00Z","reference_number":"EMA/149536/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-thelin-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"20838","name":"Final public statement on Chelidonium majus L., herba","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/HMPC/743927/2010","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-chelidonium-majus-l-herba_en.pdf"},
    {"id":"20897","name":"Public statement on the expiry and withdrawal of the marketing authorisation in the European Union for Trazec (nateglinide)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-08-14T02:00:00Z","last_updated_date":"2009-08-14T02:00:00Z","reference_number":"EMEA/375461/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-expiry-and-withdrawal-marketing-authorisation-european-union-trazec-nateglinide_en.pdf"},
    {"id":"20987","name":"Public statement: Risk of peripheral neuropathy with Sebivo (telbivudine)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-02-14T00:09:21Z","last_updated_date":"2008-02-14T00:09:21Z","reference_number":"EMEA/60439/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-risk-peripheral-neuropathy-sebivo-telbivudine_en.pdf"},
    {"id":"21009","name":"Public statement on CEA-Scan (arcitumomab) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-11-16T12:09:21Z","last_updated_date":"2005-11-16T12:09:21Z","reference_number":"EMEA/336826/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-cea-scan-arcitumomab-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"21133","name":"Public statement on Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals (prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/VietNam/1194/20...","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-03-21T01:00:00Z","last_updated_date":"2012-03-21T01:00:00Z","reference_number":"EMA/844313/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted_en.pdf"},
    {"id":"21161","name":"Public statement on Libertek: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-02-08T13:00:00Z","last_updated_date":"2018-02-08T13:00:00Z","reference_number":"EMA/58494/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-libertek-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"21307","name":"Public statement on possible interaction between clopidogrel and proton pump inhibitors","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:09:21Z","last_updated_date":"2009-05-29T02:09:21Z","reference_number":"EMEA/328956/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-possible-interaction-between-clopidogrel-and-proton-pump-inhibitors_en.pdf"},
    {"id":"21343","name":"Public Statement on Docetaxel Teva Pharma: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-01-21T01:00:00Z","last_updated_date":"2014-01-21T01:00:00Z","reference_number":"EMA/784577/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-docetaxel-teva-pharma-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"21362","name":"Public statement on Clopidogrel Sandoz: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-10-26T13:45:00Z","last_updated_date":"2011-10-26T13:45:00Z","reference_number":"EMA/812850/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-sandoz-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"21403","name":"Draft public statement on the use of herbal medicinal products containing thujone","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2011-01-27 - 2011-05-15","first_published_date":"2011-02-22T02:00:00Z","last_updated_date":"2011-02-22T02:00:00Z","reference_number":"EMA/HMPC/732886/2010","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-use-herbal-medicinal-products-containing-thujone_en.pdf"},
    {"id":"21505","name":"Final public statement on Tilia tomentosa Moench, flos","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2012-07-09T18:50:00Z","last_updated_date":"2012-07-09T18:50:00Z","reference_number":"EMA/HMPC/510064/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-tilia-tomentosa-moench-flos_en.pdf"},
    {"id":"21569","name":"Public statement on Infanrix HepB: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-08-04T14:49:21Z","last_updated_date":"2005-08-04T14:49:21Z","reference_number":"EMEA/245029/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-infanrix-hepb-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"21709","name":"Public statement on Photobarr: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-05-07T02:00:00Z","last_updated_date":"2012-05-07T02:00:00Z","reference_number":"EMA/284281/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-photobarr-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"22047","name":"Public statement on Rivastigmine 3M Health Care Ltd: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-09-18T02:00:00Z","last_updated_date":"2014-09-18T02:00:00Z","reference_number":"EMEA/H/C/003824","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-rivastigmine-3m-health-care-ltd-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"22084","name":"Public statement on Clopidogrel Acino: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-01-04T01:00:00Z","last_updated_date":"2018-01-04T01:00:00Z","reference_number":"EMA/798079/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-acino-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"22166","name":"Public statement on Livensa (testosterone): withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2012-04-16T02:00:00Z","last_updated_date":"2012-04-16T02:00:00Z","reference_number":"EMA/222193/2012 ","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-livensa-testosterone-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"22256","name":"Public statement on Maci: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"EMA/457300/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-maci-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"22685","name":"Public statement on Clopidogrel Teva Generics B.V.: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T16:00:00Z","last_updated_date":"2014-06-13T16:00:00Z","reference_number":"EMA/280867/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-teva-generics-bv-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"22767","name":"Draft public statement on the use of herbal medicinal products containing pulegone and menthofuran - Revision 1","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2014-12-22 - 2015-03-31","first_published_date":"2014-12-22T12:30:00Z","last_updated_date":"2014-12-22T12:30:00Z","reference_number":"EMA/HMPC/138386/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-use-herbal-medicinal-products-containing-pulegone-and-menthofuran-revision-1_en.pdf"},
    {"id":"22778","name":"Public statement on Exubera (insulin human) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-11-10T00:09:21Z","last_updated_date":"2008-11-10T00:09:21Z","reference_number":"EMEA/557896/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-exubera-insulin-human-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"22946","name":"Public statement on Paxene (paclitaxel): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2010-03-22T01:00:00Z","last_updated_date":"2010-03-22T01:00:00Z","reference_number":"EMA/168057/2010","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-paxene-paclitaxel-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"23012","name":"Public statement on the expiry and withdrawal of the marketing authorisation in the European Union for Posaconazole SP","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-08-03T02:00:00Z","last_updated_date":"2009-08-03T02:00:00Z","reference_number":"EMEA/464490/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-expiry-and-withdrawal-marketing-authorisation-european-union-posaconazole-sp_en.pdf"},
    {"id":"23047","name":"Public statement on Sepioglin: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T15:45:00Z","last_updated_date":"2013-07-18T15:45:00Z","reference_number":"EMA/103518/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-sepioglin-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"23188","name":"Public statement on Olanzapine Cipla: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-07-24T18:00:00Z","last_updated_date":"2014-07-24T18:00:00Z","reference_number":"EMEA/H/C/000793","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-olanzapine-cipla-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"23431","name":"Public statement on Sifrol, Daquiran, Mirapexin (pramipexole) - Recommendation to reinforce the warning of sudden onset of sleep","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-08-03T02:00:00Z","last_updated_date":"1999-08-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-sifrol-daquiran-mirapexin-pramipexole-recommendation-reinforce-warning-sudden-onset-sleep_en.pdf"},
    {"id":"23702","name":"Public statement on Zerene: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-09-27T16:08:00Z","last_updated_date":"2012-09-27T16:08:00Z","reference_number":"EMA/598127/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zerene-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"23740","name":"Public statement on Evarrest: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-04-03T02:00:00Z","last_updated_date":"2018-04-03T02:00:00Z","reference_number":"EMA/24202/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-evarrest-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"23806","name":"Meeting of the EMEA working party on herbal medicinal products 31 May - 1 June 1999","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-06-03T02:00:00Z","last_updated_date":"1999-06-03T02:00:00Z","reference_number":"EMEA/HMPWP/28/99","document_url":"https://www.ema.europa.eu/en/documents/public-statement/meeting-emea-working-party-herbal-medicinal-products-31-may-1-june-1999_en.pdf"},
    {"id":"23831","name":"Public Statement on Leflunomide (Arava) - Pancytopemia and serious skin reactions","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-10-25T02:00:00Z","last_updated_date":"1999-10-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-leflunomide-arava-pancytopemia-and-serious-skin-reactions_en.pdf"},
    {"id":"23847","name":"Public statement on Fablyn: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-06-21T02:00:00Z","last_updated_date":"2012-06-21T02:00:00Z","reference_number":"EMA/296759/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-fablyn-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"23976","name":"Public statement on Procomvax: Non-renewal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/337787/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-procomvax-non-renewal-marketing-authorisation-european-union_en.pdf"},
    {"id":"24187","name":"Public statement on Irbesartan Hydrochlorothiazide BMS (irbesartan / hydrochlorothiazide): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-11-23T00:09:21Z","last_updated_date":"2009-11-23T00:09:21Z","reference_number":"EMEA/763890/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-irbesartan-hydrochlorothiazide-bms-irbesartan-hydrochlorothiazide-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"24209","name":"Public statement on Agenerase: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-06-21T02:00:00Z","last_updated_date":"2011-06-21T02:00:00Z","reference_number":"EMA/427975/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-agenerase-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"24384","name":"Public statement on Budesonide/formoterol Teva Pharma B.V.: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-01-30T15:25:00Z","last_updated_date":"2017-01-30T15:25:00Z","reference_number":"EMEA/H/C/003953","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-budesonideformoterol-teva-pharma-bv-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"24520","name":"Public statement on Glybera: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-10-30T01:00:00Z","last_updated_date":"2017-10-30T01:00:00Z","reference_number":"EMA/713863/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-glybera-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"24679","name":"Public statement on Valtropin: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-08-14T18:45:00Z","last_updated_date":"2012-08-14T18:45:00Z","reference_number":"EMA/356690/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-valtropin-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"24819","name":"Public statement - European Medicines Agency announces regulatory action on COX-2 inhibitors","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-02-17T00:09:21Z","last_updated_date":"2005-02-17T00:09:21Z","reference_number":"EMEA/62838/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-european-medicines-agency-announces-regulatory-action-cox-2-inhibitors_en.pdf"},
    {"id":"24938","name":"Draft public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2012-10-25 - 2013-02-15","first_published_date":"2012-10-25T13:22:00Z","last_updated_date":"2012-10-25T13:22:00Z","reference_number":"EMA/HMPC/893108/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids_en.pdf"},
    {"id":"24984","name":"Draft public statement on Citrus bergamia Risso et Poiteau, aetheroleum","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2011-10-15 - 2012-02-15","first_published_date":"2011-10-19T20:30:10Z","last_updated_date":"2011-10-19T20:30:10Z","reference_number":"EMA/HMPC/528177/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-citrus-bergamia-risso-et-poiteau-aetheroleum_en.pdf"},
    {"id":"25039","name":"Public statement on the use of herbal medicinal products containing estragole","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2014-12-22 - 2015-03-31","first_published_date":"2014-12-22T12:30:00Z","last_updated_date":"2014-12-22T12:30:00Z","reference_number":"EMA/HMPC/137212/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-estragole_en.pdf"},
    {"id":"25321","name":"CVMP Public Statement on CPMP Public statement on Lactose prepared usng calf rennet: risk assessment in relationship to bovine spongiform encephalopathies (BSE)","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2001-02-28T00:09:21Z","last_updated_date":"2001-02-28T00:09:21Z","reference_number":"EMEA/CVMP/556/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/cvmp-public-statement-cpmp-public-statement-lactose-prepared-usng-calf-rennet-risk-assessment-relationship-bovine-spongiform-encephalopathies-bse_en.pdf"},
    {"id":"25347","name":"Draft public statement on Paeonia lactiflora Pallas, radix (Paeoniae radix alba)","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2016-02-16 - 2016-05-15","first_published_date":"2016-02-16T17:10:00Z","last_updated_date":"2016-02-16T17:10:00Z","reference_number":"EMA/HMPC/150787/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-paeonia-lactiflora-pallas-radix-paeoniae-radix-alba_en.pdf"},
    {"id":"25406","name":"Public statement on Syzygium aromaticum (L.) Merill et L.M. Perry, flos","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T09:43:00Z","last_updated_date":"2012-01-20T09:43:00Z","reference_number":"EMA/HMPC/112102/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-syzygium-aromaticum-l-merill-et-lm-perry-flos_en.pdf"},
    {"id":"25410","name":"Public statement on the use of (fluoro)quinolones in food-producing animals in the European Union: development of resistance and impact on human and animal health","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2007-02-15T01:00:00Z","last_updated_date":"2007-02-15T01:00:00Z","reference_number":"EMEA/CVMP/SAGAM/184651/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-fluoroquinolones-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"25455","name":"Public statement on Krystexxa: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/498114/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-krystexxa-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"25599","name":"Public statement on Ionsys: Non-renewal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2011-01-28T01:00:00Z","reference_number":"EMA/16753/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ionsys-non-renewal-marketing-authorisation-european-union_en.pdf"},
    {"id":"25645","name":"Public statement on the suspension of the marketing authorisation for Optison (perflutren) in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-07-16T02:00:00Z","last_updated_date":"2008-07-16T02:00:00Z","reference_number":"EMEA/210293/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-suspension-marketing-authorisation-optison-perflutren-european-union_en.pdf"},
    {"id":"25651","name":"Public statement on Lactose prepared using Calf Rennet: Risk assessment in relationship to Bovine Spongiform Encephalopathies (BSE)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2002-02-27T00:09:21Z","last_updated_date":"2002-02-27T00:09:21Z","reference_number":"EMEA/CPMP/571/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-lactose-prepared-using-calf-rennet-risk-assessment-relationship-bovine-spongiform-encephalopathies-bse_en.pdf"},
    {"id":"25680","name":"Public statement on Tikosyn (dofetilide): Voluntary withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-04-28T02:09:21Z","last_updated_date":"2004-04-28T02:09:21Z","reference_number":"EMEA/CPMP/1504/04","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-tikosyn-dofetilide-voluntary-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"26030","name":"Public statement on Sabervel: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-06-29T02:00:00Z","last_updated_date":"2017-06-29T02:00:00Z","reference_number":"EMA/379169/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-sabervel-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"26175","name":"Draft public statement on Myroxylon balsamum (L.) Harms var. pereirae (Royle) Harms, balsamum","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2015-12-11 - 2016-03-15","first_published_date":"2015-12-11T13:55:01Z","last_updated_date":"2015-12-11T13:55:01Z","reference_number":"EMA/HMPC/712649/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-myroxylon-balsamum-l-harms-var-pereirae-royle-harms-balsamum_en.pdf"},
    {"id":"26190","name":"Public statement on Trovan / Trovan IV / Turvel / Turvel IV: Withdrawal of the marketing authorisations","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-03-21T01:00:00Z","last_updated_date":"2001-03-21T01:00:00Z","reference_number":"EMEA/2335/01","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-trovan-trovan-iv-turvel-turvel-iv-withdrawal-marketing-authorisations_en.pdf"},
    {"id":"26350","name":"Public Statement on Remicade (Infliximab) - Reports of Tuberculosis Infections","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-12-20T01:00:00Z","last_updated_date":"2000-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-remicade-infliximab-reports-tuberculosis-infections_en.pdf"},
    {"id":"26428","name":"Public statement on Vitrasert Implant (ganciclovir): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2002-05-13T02:00:00Z","last_updated_date":"2002-05-13T02:00:00Z","reference_number":"EMEA/7211/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vitrasert-implant-ganciclovir-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"26913","name":"Public statement on Ribavirin BioPartners - Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-05-06T12:40:00Z","last_updated_date":"2013-05-06T12:40:00Z","reference_number":"EMA/223731/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ribavirin-biopartners-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"26927","name":"Public statement on Clopidogrel Teva Pharma B.V.: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-02-03T01:00:00Z","last_updated_date":"2015-02-03T01:00:00Z","reference_number":"EMA/748663/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-teva-pharma-bv-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"27180","name":"Public statement on Avandia: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-06-08T02:00:00Z","last_updated_date":"2016-06-08T02:00:00Z","reference_number":"EMEA/H/C/000268","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-avandia-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"27248","name":"Public statement on Parareg: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-05-14T02:00:00Z","last_updated_date":"2009-05-14T02:00:00Z","reference_number":"EMEA/686673/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-parareg-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"27300","name":"Public statement on Hepacare (triple antigen hepatitis B recombinant vaccine) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2002-12-17T01:00:00Z","last_updated_date":"2002-12-17T01:00:00Z","reference_number":"EMEA/32933/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-hepacare-triple-antigen-hepatitis-b-recombinant-vaccine-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"27333","name":"Public statement on Pumarix: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-03-17T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"EMA/475613/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pumarix-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"27405","name":"Draft public statement on Salvia officinalis L. Aetheroleum","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2009-11-12 - 2010-04-15","first_published_date":"2010-02-03T02:00:00Z","last_updated_date":"2010-02-03T02:00:00Z","reference_number":"EMA/HMPC/41843/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-salvia-officinalis-l-aetheroleum_en.pdf"},
    {"id":"27470","name":"EMEA Public Statement on Viagra and Patrex","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-04-22T02:00:00Z","last_updated_date":"1999-04-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-viagra-and-patrex_en.pdf"},
    {"id":"27548","name":"Final public statement on Citrus bergamia Risso et Poiteau, aetheroleum","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2012-08-28T13:45:00Z","last_updated_date":"2012-08-28T13:45:00Z","reference_number":"EMA/HMPC/528177/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-citrus-bergamia-risso-et-poiteau-aetheroleum_en.pdf"},
    {"id":"27624","name":"Public statement on Pioglitazone Krka: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-01-14T01:00:00Z","last_updated_date":"2015-01-14T01:00:00Z","reference_number":"EMEA/H/C/002453","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pioglitazone-krka-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"27706","name":"Public statement on Rilonacept Regeneron: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-10-30T15:10:00Z","last_updated_date":"2012-10-30T15:10:00Z","reference_number":"EMA/695977/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-rilonacept-regeneron-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"28058","name":"Public statement on authorisation of bluetongue vaccines","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-06-07T18:45:00Z","last_updated_date":"2013-06-07T18:45:00Z","reference_number":"EMA/CVMP/37133/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-authorisation-bluetongue-vaccines_en.pdf"},
    {"id":"28075","name":"Public statement on Ioa: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-08-26T02:00:00Z","last_updated_date":"2014-08-26T02:00:00Z","reference_number":"EMA/477726/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ioa-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"28095","name":"Public statement on Gonazon: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-08-15T12:20:00Z","last_updated_date":"2012-08-15T12:20:00Z","reference_number":"EMA/537200/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-gonazon-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"28192","name":"Public statement on Patrex (sildenafil): Non-renewal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-08-18T14:49:21Z","last_updated_date":"2005-08-18T14:49:21Z","reference_number":"EMEA/209697/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-patrex-sildenafil-non-renewal-marketing-authorisation-european-union_en.pdf"},
    {"id":"28359","name":"Public statement on Regranex: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-08-15T16:50:00Z","last_updated_date":"2012-08-15T16:50:00Z","reference_number":"EMA/495525/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-regranex-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"28371","name":"Public statement on Docefrez: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2012-06-14T02:00:00Z","last_updated_date":"2012-06-14T02:00:00Z","reference_number":"EMA/394526/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-docefrez-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"28407","name":"Public statement on the interpretation of the term 'external use' for use in the field of traditional herbal medicinal products","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2006-05-12T02:00:00Z","last_updated_date":"2006-05-12T02:00:00Z","reference_number":"EMEA/HMPC/31897/2006","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-interpretation-term-external-use-use-field-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"28461","name":"Public statement on Ultratard (insulin human (rDNA)) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2007-08-24T14:39:21Z","last_updated_date":"2007-08-24T14:39:21Z","reference_number":"EMEA/368302/2007","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ultratard-insulin-human-rdna-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"28568","name":"Public statement on Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostic: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T01:00:00Z","last_updated_date":"2016-03-07T01:00:00Z","reference_number":"EMEA/H/C/002269","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostic-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"28633","name":"Public Statement on Trovan / Trovan IV / Turvel / Turvel IV (Trovafloxacin/Alatrofloxacin) recommendation to suspend the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-06-15T02:00:00Z","last_updated_date":"1999-06-15T02:00:00Z","reference_number":"EMEA/18046/99","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-trovan-trovan-iv-turvel-turvel-iv-trovafloxacinalatrofloxacin-recommendation-suspend-marketing-authorisation-european-union_en.pdf"},
    {"id":"28703","name":"Draft public statement on Salvia fruticosa Mill., folium","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2015-12-09 - 2016-03-15","first_published_date":"2015-12-09T10:30:00Z","last_updated_date":"2015-12-09T10:30:00Z","reference_number":"EMA/HMPC/599993/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-salvia-fruticosa-mill-folium_en.pdf"},
    {"id":"29079","name":"Public statement on Trudexa (adalimumab) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2007-07-26T02:09:21Z","last_updated_date":"2007-07-26T02:09:21Z","reference_number":"EMEA/CHMP/285833/2007","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-trudexa-adalimumab-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"29138","name":"Public statement on Myroxylon balsamum (L.) Harms var. pereirae (Royle) Harms, balsamum","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/HMPC/712649/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-myroxylon-balsamum-l-harms-var-pereirae-royle-harms-balsamum_en.pdf"}    {"id":"29188","name":"SONOVUE (sulphur hexafluoride): New contraindication in patients with heart disease. Restriction of use to non-cardiac imaging","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-05-20T01:31:00Z","last_updated_date":"2004-05-20T01:31:00Z","reference_number":"EMEA/CPMP/212_04","document_url":"https://www.ema.europa.eu/en/documents/public-statement/sonovue-sulphur-hexafluoride-new-contraindication-patients-heart-disease-restriction-use-non-cardiac-imaging_en.pdf"},
    {"id":"29361","name":"Public statement on Allex (desloratadine): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-05-19T02:09:21Z","last_updated_date":"2004-05-19T02:09:21Z","reference_number":"EMEA/10089/04","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-allex-desloratadine-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"29438","name":"Withdrawal of the marketing authorisation for the medicinal product Pylori-Chek - 13C-urea","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-07-17T02:00:00Z","last_updated_date":"2000-07-17T02:00:00Z","reference_number":"EMEA/20317/00","document_url":"https://www.ema.europa.eu/en/documents/public-statement/withdrawal-marketing-authorisation-medicinal-product-pylori-chek-13c-urea_en.pdf"},
    {"id":"29727","name":"Public statement on Advasure (classical swine fever virus E2 subunit antigen) - withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-02-13T00:09:21Z","last_updated_date":"2008-02-13T00:09:21Z","reference_number":"EMEA/CVMP/138988/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-advasure-classical-swine-fever-virus-e2-subunit-antigen-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"29779","name":"Public statement on Vitravene (fomivirsen): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2002-08-07T02:00:00Z","last_updated_date":"2002-08-07T02:00:00Z","reference_number":"EMEA/12382/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vitravene-fomivirsen-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"29822","name":"Public statement on Alisade: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-10-18T02:00:00Z","last_updated_date":"2011-10-18T17:23:00Z","reference_number":"EMA/816761/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-alisade-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"29948","name":"Public statement on Zenapax: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-01-16T01:00:00Z","last_updated_date":"2009-02-13T01:00:00Z","reference_number":"EMEA/683765/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zenapax-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"30044","name":"Public statement on efficacy and safety concerns regarding the co-administration of tenofovir disoproxil fumarate (TDF, Viread) and didanosine (ddI, Videx)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-03-03T00:09:21Z","last_updated_date":"2005-03-03T00:09:21Z","reference_number":"EMEA/62331/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-efficacy-and-safety-concerns-regarding-co-administration-tenofovir-disoproxil-fumarate-tdf-viread-and-didanosine-ddi-videx_en.pdf"},
    {"id":"30057","name":"Public statement on Zartra (imiquimod): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2002-07-31T02:00:00Z","last_updated_date":"2002-07-31T02:00:00Z","reference_number":"EMEA/12594/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zartra-imiquimod-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"30257","name":"Public statement on Olysio: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-05-23T13:00:00Z","last_updated_date":"2018-05-23T13:00:00Z","reference_number":"EMA/71113/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-olysio-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"30451","name":"Public statement on Kepivance: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-04-08T02:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"EMA/250017/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-kepivance-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"30483","name":"Public statement on Parecoxib Sodium (Dynastat/Rayzon/Xapit) on the risk of serious hypersensitivity and skin reactions","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2002-10-22T02:00:00Z","last_updated_date":"2002-10-22T02:00:00Z","reference_number":"EMEA/25175/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-parecoxib-sodium-dynastatrayzonxapit-risk-serious-hypersensitivity-and-skin-reactions_en.pdf"},
    {"id":"30564","name":"Committee for medicinal products for veterinary use (CVMP): Cox-2 inhibitors in veterinary medicine","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2006-12-13T12:09:21Z","last_updated_date":"2006-12-13T12:09:21Z","reference_number":"EMEA/CVMP/108858/2005-Rev.2","document_url":"https://www.ema.europa.eu/en/documents/public-statement/committee-medicinal-products-veterinary-use-cvmp-cox-2-inhibitors-veterinary-medicine_en.pdf"},
    {"id":"30707","name":"Public statement on Opgenra: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-07-14T17:00:00Z","last_updated_date":"2016-07-14T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-opgenra-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"30713","name":"Public statement on Ablavar: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-11-14T11:40:00Z","last_updated_date":"2011-11-14T11:40:00Z","reference_number":"EMA/854517/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ablavar-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"30747","name":"Public statement on Vitekta: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-05-29T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vitekta-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"30764","name":"Public statement on Exalief: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-08-07T12:50:00Z","last_updated_date":"2012-08-07T12:50:00Z","reference_number":"EMA/507881/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-exalief-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"30913","name":"Public Statement on Ziagen (Abacavir) - Abacavir hypersensitivity cases following an interruption of therapy","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-08-14T02:00:00Z","last_updated_date":"2000-08-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ziagen-abacavir-abacavir-hypersensitivity-cases-following-interruption-therapy_en.pdf"},
    {"id":"30951","name":"Public Statement on the risk of drug interactions with Hypericum perforatum (St John's Wort) and antiretroviral medicinal products","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-02-28T01:00:00Z","last_updated_date":"2000-02-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-risk-drug-interactions-hypericum-perforatum-st-johns-wort-and-antiretroviral-medicinal-products_en.pdf"},
    {"id":"31018","name":"Public statement on Celvapan: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T01:00:00Z","last_updated_date":"2016-12-21T01:00:00Z","reference_number":"EMA/820174/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-celvapan-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"31077","name":"Public statement on MabCampath (alemtuzumab): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-08-15T12:59:39Z","last_updated_date":"2012-08-15T12:59:39Z","reference_number":"EMA/532364/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-mabcampath-alemtuzumab-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"31100","name":"Public statement on Osigraft: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-07-27T02:00:00Z","last_updated_date":"2016-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-osigraft-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"31113","name":"Public statement on Salvia officinalis L., aetheroleum","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2010-10-19T02:00:00Z","last_updated_date":"2016-02-12T16:17:00Z","reference_number":"EMA/HMPC/41843/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-salvia-officinalis-l-aetheroleum_en.pdf"},
    {"id":"31163","name":"Public statement on Clopidogrel Acino Pharma: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-07-26T02:00:00Z","last_updated_date":"2012-07-26T02:00:00Z","reference_number":"EMA/328233/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-acino-pharma-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"31178","name":"Public statement on Biograstim: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-12-22T01:00:00Z","last_updated_date":"2016-12-22T01:00:00Z","reference_number":"EMEA/H/C/000826","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-biograstim-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"31269","name":"Public statement on Focetria: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-02-11T01:00:00Z","last_updated_date":"2016-02-11T01:00:00Z","reference_number":"EMA/72773/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-focetria-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"31808","name":"Final public statement on Sambucus nigra L., fructus","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-04-29T02:00:00Z","last_updated_date":"2014-04-29T02:00:00Z","reference_number":"EMA/HMPC/32465/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-sambucus-nigra-l-fructus_en.pdf"},
    {"id":"32096","name":"Withdrawal of the marketing authorisation for the medicinal product Ecokinase - reteplase EU/1/96/017/001","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-12-12T01:00:00Z","last_updated_date":"2000-12-12T01:00:00Z","reference_number":"EMEA/H/38570/00","document_url":"https://www.ema.europa.eu/en/documents/public-statement/withdrawal-marketing-authorisation-medicinal-product-ecokinase-reteplase-eu196017001_en.pdf"},
    {"id":"32258","name":"Public Statement: Prevenar - shortage of supply","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2003-03-22T00:09:21Z","last_updated_date":"2003-03-22T00:09:21Z","reference_number":"EMEA/6659/04-Final","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-prevenar-shortage-supply_en.pdf"},
    {"id":"32451","name":"Public statement on ImmunoGam: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-01-26T01:00:00Z","last_updated_date":"2011-01-26T01:00:00Z","reference_number":"EMA//CHMP/70300/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-immunogam-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"32507","name":"Public statement on Optimark: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T10:29:00Z","last_updated_date":"2017-12-11T10:29:00Z","reference_number":"EMA/805958/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-optimark-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"32529","name":"Public statement: European Medicines Agency starts review of the safety of epoetins","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2007-04-28T01:31:00Z","last_updated_date":"2007-04-28T01:31:00Z","reference_number":"EMEA/188068/2007 - corr","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-european-medicines-agency-starts-review-safety-epoetins_en.pdf"},
    {"id":"32546","name":"European Medicines Agency public statement on update on hexavalent vaccines: Hexavac and Infanrix Hexa","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2003-12-01T00:09:21Z","last_updated_date":"2003-12-01T00:09:21Z","reference_number":"EMEA/CPMP/5889/03","document_url":"https://www.ema.europa.eu/en/documents/public-statement/european-medicines-agency-public-statement-update-hexavalent-vaccines-hexavac-and-infanrix-hexa_en.pdf"},
    {"id":"32714","name":"Public statement on Theryttrex (yttrium (90Y) chloride): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2006-03-02T12:09:21Z","last_updated_date":"2006-03-02T12:09:21Z","reference_number":"CHMP/71254/2006","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-theryttrex-yttrium-90y-chloride-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"33160","name":"Public statement on the increased risk of serious infection and neutropenia in patients treated concurrently with Kineret (anakinra) and Enbrel (etanercept)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2003-02-05T01:00:00Z","last_updated_date":"2003-02-05T01:00:00Z","reference_number":"EMEA/31631/02","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-increased-risk-serious-infection-and-neutropenia-patients-treated-concurrently-kineret-anakinra-and-enbrel-etanercept_en.pdf"},
    {"id":"33333","name":"Superseded public statement on Centella asiatica (L.) Urban, herba","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2022-09-02T01:00:00Z","last_updated_date":"2022-09-02T01:00:00Z","reference_number":"EMA/HMPC/579663/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/superseded-public-statement-centella-asiatica-l-urban-herba_en.pdf"},
    {"id":"33692","name":"Public statement on Preotact: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-07-11T16:30:00Z","last_updated_date":"2014-07-11T16:30:00Z","reference_number":"EMA/319773/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-preotact-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"33889","name":"Public statement on concerns over unregulated medicinal products containing stem cells","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2010-04-16T02:00:00Z","last_updated_date":"2010-04-17T02:00:00Z","reference_number":"EMA/763463/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-concerns-over-unregulated-medicinal-products-containing-stem-cells_en.pdf"},
    {"id":"34357","name":"Public statement on Victrelis","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-07-31T02:00:00Z","last_updated_date":"2018-07-31T02:00:00Z","reference_number":"EMA/375478/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-victrelis_en.pdf"},
    {"id":"34400","name":"Public statement on Infergen (interferon alfacon-1): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2006-06-01T02:09:21Z","last_updated_date":"2006-06-01T02:09:21Z","reference_number":"EMEA/CHMP/192804/2006","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-infergen-interferon-alfacon-1-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"34463","name":"Public statement on Imprida HCT: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-10-22T02:00:00Z","last_updated_date":"2012-10-22T02:00:00Z","reference_number":"EMA/670070/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-imprida-hct-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"34477","name":"Public statement on Clopidogrel Teva Pharma: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMEA/H/C/001052","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-teva-pharma-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"34527","name":"Public statement on Arepanrix: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-01-18T01:00:00Z","last_updated_date":"2011-01-18T01:00:00Z","reference_number":"EMA/22596/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-arepanrix-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"34572","name":"EMEA public statement on Refacto (moroctocog alfa): Introduction of a change to Refacto drug product specific activity specification increase of 20% in the amount of Refacto  protein in each vial","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2003-05-27T02:00:00Z","last_updated_date":"2003-05-27T02:00:00Z","reference_number":"CPMP/2337/03","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-refacto-moroctocog-alfa-introduction-change-refacto-drug-product-specific-activity-specification-increase-20-amount-refacto-protein-each-vial_en.pdf"},
    {"id":"34617","name":"Public statement on prioritisation for assessment of herbal substances associated with safety concerns","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2014-11-24T12:10:00Z","last_updated_date":"2015-10-23T12:46:00Z","reference_number":"EMA/HMPC/682247/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-prioritisation-assessment-herbal-substances-associated-safety-concerns_en.pdf"},
    {"id":"35156","name":"Public Statement on Trovan/Trovan IV/Tuirvel/Turvel IV (Trovafloxacin/Alatrofloxacin) - Recommendation to suspend the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-06-15T02:00:00Z","last_updated_date":"1999-06-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-trovantrovan-ivtuirvelturvel-iv-trovafloxacinalatrofloxacin-recommendation-suspend-marketing-authorisation-european-union_en.pdf"},
    {"id":"35215","name":"Draft public statement on Tilia tomentosa Moench, flos","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2011-09-13 - 2012-02-15","first_published_date":"2011-10-20T04:00:00Z","last_updated_date":"2011-10-20T04:00:00Z","reference_number":"EMA/HMPC/510064/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-tilia-tomentosa-moench-flos_en.pdf"},
    {"id":"35237","name":"Public statement on the  cessation of marketing of  exubera  (Insulin human)","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2007-11-20T00:09:21Z","last_updated_date":"2007-11-20T00:09:21Z","reference_number":"EMEA/522741/2007","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-cessation-marketing-exubera-insulin-human_en.pdf"},
    {"id":"35252","name":"Final public statement on Adhatoda vasica Nees, folium - First version","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2013-09-03T02:00:00Z","last_updated_date":"2013-09-03T02:00:00Z","reference_number":"EMA/HMPC/681468/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-adhatoda-vasica-nees-folium-first-version_en.pdf"},
    {"id":"35352","name":"Public statement on Unituxin: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-04-28T02:00:00Z","last_updated_date":"2017-04-28T02:00:00Z","reference_number":"EMEA/H/C/002800","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-unituxin-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"35564","name":"Public statement - EU-US FDA bilateral meeting","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2003-09-12T02:00:00Z","last_updated_date":"2003-09-12T02:00:00Z","reference_number":"EMEA/D/24478/03/Final","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-eu-us-fda-bilateral-meeting_en.pdf"},
    {"id":"35568","name":"EMEA public statement on Replaglinide (NovoNorm/Prandin) contraindication of concomitant use of Replaglinide and Gemfibrozil","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2003-05-21T02:00:00Z","last_updated_date":"2003-05-21T02:00:00Z","reference_number":"EMEA/11700/03","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-replaglinide-novonormprandin-contraindication-concomitant-use-replaglinide-and-gemfibrozil_en.pdf"},
    {"id":"35647","name":"Public statement on Clopidogrel 1A Pharma: Withdrawal of the marketing authorisation","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T01:00:00Z","last_updated_date":"2013-01-18T01:00:00Z","reference_number":"EMA/107362/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-1a-pharma-withdrawal-marketing-authorisation_en.pdf"},
    {"id":"35731","name":"Public statement on Piper methysticum G. Forst., rhizoma","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T02:00:00Z","last_updated_date":"2018-04-13T02:00:00Z","reference_number":"EMA/HMPC/450588/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-piper-methysticum-g-forst-rhizoma_en.pdf"},
    {"id":"35793","name":"Public statement on Clopidogrel ratiopharm: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-12-12T01:00:00Z","last_updated_date":"2013-12-12T01:00:00Z","reference_number":"EMA/753162/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-ratiopharm-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"35877","name":"Draft public statement on Withania somnifera (L.) Dunal, radix - First version","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2012-12-15 - 2013-04-15","first_published_date":"2012-12-10T18:01:00Z","last_updated_date":"2012-12-10T18:01:00Z","reference_number":"EMA/HMPC/681519/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-withania-somnifera-l-dunal-radix-first-version_en.pdf"},
    {"id":"35883","name":"Public statement on Teslascan: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-08-02T16:00:00Z","last_updated_date":"2012-08-02T16:00:00Z","reference_number":"EMA/486286/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-teslascan-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"36155","name":"Public statement on Duloxetine Boehringer Ingelheim (duloxetine): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2010-06-21T02:00:00Z","last_updated_date":"2010-06-21T02:00:00Z","reference_number":"EMA/168057/2010","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-duloxetine-boehringer-ingelheim-duloxetine-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"36176","name":"Public statement on Tamiflu IV - Closure of compassionate-use programme in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-08-30T17:52:00Z","last_updated_date":"2013-08-30T17:52:00Z","reference_number":"EMA/480494/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-tamiflu-iv-closure-compassionate-use-programme-european-union_en.pdf"},
    {"id":"36179","name":"Public statement on Opulis (desloratadine): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-05-19T02:09:21Z","last_updated_date":"2004-05-19T02:09:21Z","reference_number":"EMEA/10091/04","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-opulis-desloratadine-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"36210","name":"Draft public statement on Syzygium aromaticum (L.) Merill et L.M. Perry, flos","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2011-04-15 - 2011-08-15","first_published_date":"2011-04-20T04:00:00Z","last_updated_date":"2011-04-20T04:00:00Z","reference_number":"EMA/HMPC/112102/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-syzygium-aromaticum-l-merill-et-lm-perry-flos_en.pdf"},
    {"id":"36504","name":"Public statement on Docetaxel Mylan: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-03-19T01:00:00Z","last_updated_date":"2015-06-29T20:00:00Z","reference_number":"EMEA/H/C/002317 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-docetaxel-mylan-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"36551","name":"Final public statement on Andrographis paniculata Nees, folium - First version","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2014-06-10T02:00:00Z","last_updated_date":"2014-06-10T02:00:00Z","reference_number":"EMA/HMPC/709282/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-andrographis-paniculata-nees-folium-first-version_en.pdf"},
    {"id":"36747","name":"EMEA Public Statement on review of recombinant Factor VIII (FVIII) products (Advate, Kogenate Bayer/Helixate NexGen, Kogenate/Helixate, Recombinate, ReFacto) and inhibitor development","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-10-18T02:09:21Z","last_updated_date":"2005-10-18T02:09:21Z","reference_number":"EMEA/331316/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-review-recombinant-factor-viii-fviii-products-advate-kogenate-bayerhelixate-nexgen-kogenatehelixate-recombinate-refacto-and-inhibitor-development_en.pdf"},
    {"id":"36881","name":"Public statement on the recommendation to lift the suspension of the marketing authorisation for Optison (perflutren)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-06-29T02:09:21Z","last_updated_date":"2009-06-29T02:09:21Z","reference_number":"EMEA/367523/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-recommendation-lift-suspension-marketing-authorisation-optison-perflutren_en.pdf"},
    {"id":"36911","name":"Public statement on Trovan IV and Turvel IV","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-02-25T01:00:00Z","last_updated_date":"1999-02-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-trovan-iv-and-turvel-iv_en.pdf"},
    {"id":"36913","name":"Final public statement on Allium cepa L., bulbus","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2012-05-29T18:00:00Z","last_updated_date":"2012-05-29T18:00:00Z","reference_number":"EMA/HMPC/347189/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-allium-cepa-l-bulbus_en.pdf"},
    {"id":"36946","name":"Public statement on Fortovase: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2006-08-07T02:00:00Z","last_updated_date":"2006-08-07T02:00:00Z","reference_number":"EMEA/304680/2006","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-fortovase-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"36986","name":"Public statement on Tredaptive: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-05-16T02:00:00Z","last_updated_date":"2013-05-16T02:00:00Z","reference_number":"EMA/290249/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-tredaptive-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"37009","name":"Public Statement on Insuman Infusat 100IU/ml solution for injection in cartridges of 3.15 ml (insulin","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-02-14T01:00:00Z","last_updated_date":"2000-02-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-insuman-infusat-100iuml-solution-injection-cartridges-315-ml-insulin_en.pdf"},
    {"id":"37023","name":"Public statement on Velosulin: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-04-14T02:00:00Z","last_updated_date":"2009-04-17T02:00:00Z","reference_number":"EMEA/86738/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-velosulin-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"37051","name":"EMEA response to ISDB assessment of 9 EPARs","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"1998-12-18T00:09:21Z","last_updated_date":"1998-12-18T00:09:21Z","reference_number":"EMEA/42941/98","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-response-isdb-assessment-9-epars_en.pdf"},
    {"id":"37935","name":"Public statement on IDflu: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T11:00:00Z","last_updated_date":"2018-03-28T11:00:00Z","reference_number":"EMA/809462/2017","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-idflu-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"37950","name":"Public statement on Protopy (tacrolimus): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-10-08T02:09:21Z","last_updated_date":"2008-10-08T02:09:21Z","reference_number":"EMEA/511485/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-protopy-tacrolimus-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"37960","name":"Public statement on Leflunomide (Arava) - Severe and serious hepatic reactions","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-03-12T01:00:00Z","last_updated_date":"2001-03-12T01:00:00Z","reference_number":"EMEA/H/5611/01/en","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-leflunomide-arava-severe-and-serious-hepatic-reactions_en.pdf"},
    {"id":"38158","name":"Public statement: Vasovist and nephrogenic systemic fibrosis (NSF)","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2007-02-07T01:09:27Z","last_updated_date":"2007-02-07T01:09:27Z","reference_number":"EMEA/49741/2007","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vasovist-and-nephrogenic-systemic-fibrosis-nsf_en.pdf"},
    {"id":"38207","name":"Draft public statement on Adhatoda vasica Nees, folium - Revision 1","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2013-01-15 - 2013-04-15","first_published_date":"2013-01-24T02:00:00Z","last_updated_date":"2013-01-24T02:00:00Z","reference_number":"EMA/HMPC/681468/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-adhatoda-vasica-nees-folium-revision-1_en.pdf"},
    {"id":"38248","name":"Public statement on Sprimeo: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2012-07-23T02:00:00Z","last_updated_date":"2012-07-23T02:00:00Z","reference_number":"EMA/328034/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-sprimeo-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"38512","name":"Public statement on the current shortage of radiopharmaceuticals in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-10-01T02:09:21Z","last_updated_date":"2008-10-01T02:09:21Z","reference_number":"EMEA/501698/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-current-shortage-radiopharmaceuticals-european-union_en.pdf"},
    {"id":"38668","name":"Public statement on Taluvian (apomorphine hydrochloride) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2004-11-10T01:09:21Z","last_updated_date":"2004-11-10T01:09:21Z","reference_number":"EMEA/88093/04","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-taluvian-apomorphine-hydrochloride-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"38707","name":"EMEA Public Statement on Viramune (nevirapine) - severe and  life threatening cutaneous and hepatic reactions","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2000-04-12T02:00:00Z","last_updated_date":"2000-04-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-viramune-nevirapine-severe-and-life-threatening-cutaneous-and-hepatic-reactions_en.pdf"},
    {"id":"39007","name":"Public statement on Onsenal (celecoxib) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-04-06T02:00:00Z","last_updated_date":"2011-04-06T02:00:00Z","reference_number":"EMA/232752/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-onsenal-celecoxib-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"39276","name":"Public statement on Bextra (valdecoxib) non-renewal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2008-03-29T00:09:21Z","last_updated_date":"2008-03-29T00:09:21Z","reference_number":"EMEA/136288/2008","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-bextra-valdecoxib-non-renewal-marketing-authorisation-european-union_en.pdf"},
    {"id":"39357","name":"Withdrawal of the marketing authorisation for the medicinal product Rotashield - rotavirus vaccine EU/1/99/105/001","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-06-07T02:00:00Z","last_updated_date":"2001-06-07T02:00:00Z","reference_number":"EMEA/13002/01","document_url":"https://www.ema.europa.eu/en/documents/public-statement/withdrawal-marketing-authorisation-medicinal-product-rotashield-rotavirus-vaccine-eu199105001_en.pdf"},
    {"id":"39369","name":"Public statement on Venvia (rosiglitazone) - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2005-04-18T14:09:21Z","last_updated_date":"2005-04-18T14:09:21Z","reference_number":"EMEA/41035/2005","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-venvia-rosiglitazone-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"39520","name":"Public statement on LeukoScan: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T01:00:00Z","last_updated_date":"2018-02-09T01:00:00Z","reference_number":"EMA/70932/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-leukoscan-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"39654","name":"Public statement on Zimulti: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-01-30T01:00:00Z","last_updated_date":"2009-01-30T01:00:00Z","reference_number":"EMEA/39560/2009","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zimulti-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"39851","name":"EMEA Public statement on herbal medicinal products containing cimicifugae racemosae rhizoma - Serious hepatic reactions","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2006-07-18T02:00:00Z","last_updated_date":"2006-07-18T02:00:00Z","reference_number":"EMEA/269259/2006","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-herbal-medicinal-products-containing-cimicifugae-racemosae-rhizoma-serious-hepatic-reactions_en.pdf"},
    {"id":"39904","name":"Public statement on Monotard (insulin human (rDNA)): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2007-08-24T14:09:21Z","last_updated_date":"2010-02-11T21:21:54Z","reference_number":"EMEA/367921/2007","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-monotard-insulin-human-rdna-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"40049","name":"Public statement on Nivolumab BMS: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-01-14T01:00:00Z","last_updated_date":"2016-01-14T01:00:00Z","reference_number":"EMA/6927/2016","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-nivolumab-bms-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"40185","name":"Final public statement on Paeonia lactiflora Pall. and/or Paeonia veitchii Lynch, radix (Paeoniae radix rubra)","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2017-04-25T13:01:00Z","last_updated_date":"2017-04-25T13:01:00Z","reference_number":"EMA/HMPC/762952/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-paeonia-lactiflora-pall-andor-paeonia-veitchii-lynch-radix-paeoniae-radix-rubra_en.pdf"},
    {"id":"40370","name":"Public Statement on Levacetylmethadol (Orlaam) - Life threatening cardiac rhythm disorders","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"1999-12-15T01:00:00Z","last_updated_date":"1999-12-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-levacetylmethadol-orlaam-life-threatening-cardiac-rhythm-disorders_en.pdf"},
    {"id":"40551","name":"EMEA Public Statement on Metalyse - importance of correct product handling: syringe vial assembly","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2001-11-12T01:00:00Z","last_updated_date":"2001-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/emea-public-statement-metalyse-importance-correct-product-handling-syringe-vial-assembly_en.pdf"},
    {"id":"40588","name":"Public statement on Humenza: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2011-06-30T02:00:00Z","last_updated_date":"2011-06-30T02:00:00Z","reference_number":"EMA/418809/2011","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-humenza-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"40974","name":"Public statement on NeoSpect (depreotide): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-neospect-depreotide-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"40999","name":"Public statement on Riprazo: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2013-03-01T11:35:00Z","last_updated_date":"2013-03-01T11:35:00Z","reference_number":"EMA/103518/2013","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-riprazo-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"41234","name":"Public statement on Uprima: Non-renewal of marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2006-05-29T02:00:00Z","last_updated_date":"2006-05-29T02:00:00Z","reference_number":"EMEA/186645/2006","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-uprima-non-renewal-marketing-authorisation-european-union_en.pdf"},
    {"id":"41389","name":"Draft public statement on Angelica sinensis (Oliv.) Diels, radix - First version","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2012-12-15 - 2013-04-15","first_published_date":"2012-12-10T18:00:00Z","last_updated_date":"2012-12-10T18:00:00Z","reference_number":"EMA/HMPC/681574/2012","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-angelica-sinensis-oliv-diels-radix-first-version_en.pdf"},
    {"id":"41543","name":"Public statement on Salvia fruticosa Mill., folium","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2016-07-01T02:00:00Z","last_updated_date":"2016-07-01T02:00:00Z","reference_number":"EMA/HMPC/599993/2014","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-salvia-fruticosa-mill-folium_en.pdf"},
    {"id":"41849","name":"Public statement on Daliresp: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2018-02-06T01:00:00Z","last_updated_date":"2018-02-06T01:00:00Z","reference_number":"EMA/58489/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-daliresp-withdrawal-marketing-authorisation-european-union_en.pdf"}    {"id":"42003","name":"Public statement on Pandemrix: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-10-27T15:00:00Z","last_updated_date":"2015-10-27T15:00:00Z","reference_number":"EMA/656472/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pandemrix-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"42098","name":"Public statement on Angiox: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-09-14T16:52:00Z","last_updated_date":"2018-09-14T16:52:00Z","reference_number":"EMA/517907/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-angiox-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"42252","name":"Public statement on Imatinib Teva B.V.: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-10-09T19:07:00Z","last_updated_date":"2018-10-09T19:07:00Z","reference_number":"EMA/293981/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-imatinib-teva-bv-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"42254","name":"Public statement on Raplixa: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T11:01:00Z","last_updated_date":"2018-10-10T11:01:00Z","reference_number":"EMA/421791/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-raplixa-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"42269","name":"Public statement on Raplixa: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-10-10T14:08:00Z","last_updated_date":"2018-10-10T14:08:00Z","reference_number":"EMA/421791/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-raplixa-withdrawal-marketing-authorisation-european-union_en.pdf-0"},
    {"id":"42557","name":"Public statement on the withdrawal of the marketing authorisation in the European Union for Ionsys","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-11-06T16:40:00Z","last_updated_date":"2018-11-06T16:40:00Z","reference_number":"EMA/598797/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-withdrawal-marketing-authorisation-european-union-ionsys_en.pdf"},
    {"id":"42681","name":"Public statement on Trobalt: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-11-19T16:24:00Z","last_updated_date":"2018-11-19T16:24:00Z","reference_number":"EMA/759832/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-trobalt-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"42988","name":"Public statement on the evaluation of the compliance of marketing authorisation holders with CVMP Risk Management Strategy with respect to potential presence of RD114 in feline and canine vaccines","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-12-11T16:00:00Z","last_updated_date":"2018-12-11T16:00:00Z","reference_number":"EMA/CVMP/814776/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-evaluation-compliance-marketing-authorisation-holders-cvmp-risk-management-strategy-respect-potential-presence-rd114-feline-and-canine-vaccines_en.pdf"},
    {"id":"43015","name":"Public statement on Zoledronic acid Teva Pharma:  Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T15:36:00Z","last_updated_date":"2018-12-12T15:36:00Z","reference_number":"EMA/817045/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zoledronic-acid-teva-pharma-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"43447","name":"Public statement on Lusduna: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T14:00:00Z","last_updated_date":"2019-01-22T14:00:00Z","reference_number":"EMA/824401/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-lusduna-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"43976","name":"Public statement on Solymbic: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-03-05T12:27:00Z","last_updated_date":"2019-03-05T12:27:00Z","reference_number":"EMA/7897/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-solymbic-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"43978","name":"Public statement on Cyltezo: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-03-06T09:52:00Z","last_updated_date":"2019-03-06T09:52:00Z","reference_number":"EMA/5286/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-cyltezo-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"43984","name":"Public statement on Topotecan Actavis: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2019-03-07T09:29:00Z","last_updated_date":"2019-03-07T09:29:00Z","reference_number":"EMA/161957/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-topotecan-actavis-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"44040","name":"Public statement on Altargo: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-03-15T11:12:00Z","last_updated_date":"2019-03-15T11:12:00Z","reference_number":"EMA/76365/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-altargo-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"44142","name":"Public statement on Silgard: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-04-02T09:32:00Z","last_updated_date":"2019-04-02T09:32:00Z","reference_number":"EMA/149281/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-silgard-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"44158","name":"Public statement on Vantobra: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-03-29T17:52:00Z","last_updated_date":"2019-03-29T17:52:00Z","reference_number":"EMA/154324/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vantobra-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"44472","name":"Public statement on Arzerra: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2019-05-10T10:25:00Z","last_updated_date":"2019-05-10T10:25:00Z","reference_number":"EMA/149805/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-arzerra-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"44760","name":"Public statement on Ketek : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T17:10:00Z","last_updated_date":"2019-06-19T17:10:00Z","reference_number":"EMA/324558/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ketek-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"44906","name":"Public statement on Macugen : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-06-27T11:30:00Z","last_updated_date":"2019-06-27T11:30:00Z","reference_number":"EMA/335559/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-macugen-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"44972","name":"Public statement on Airexar Spiromax: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-07-02T15:35:00Z","last_updated_date":"2019-07-02T15:35:00Z","reference_number":"EMA/284088/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-airexar-spiromax-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"44983","name":"Public statement on ATryn: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-07-03T15:41:00Z","last_updated_date":"2019-07-03T15:41:00Z","reference_number":"EMA/347833/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-atryn-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"45012","name":"Public statement on Rituzena: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-07-08T13:40:00Z","last_updated_date":"2019-07-08T13:40:00Z","reference_number":"EMA/290565/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-rituzena-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"45354","name":"Public statement on Daklinza: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-08-30T09:55:00Z","last_updated_date":"2019-08-30T09:55:00Z","reference_number":"EMA/476687/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-daklinza-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"45576","name":"Public statement on DepoCyte: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-10-07T14:35:00Z","last_updated_date":"2019-10-07T14:35:00Z","reference_number":"EMA/916333/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-depocyte-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"45701","name":"Public statement on Taxespira: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-10-15T11:06:00Z","last_updated_date":"2019-10-15T11:06:00Z","reference_number":"EMA/916348/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-taxespira-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"45726","name":"Public statement on Imatinib medac: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-10-16T16:40:00Z","last_updated_date":"2019-10-16T16:40:00Z","reference_number":"EMA/290150/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-imatinib-medac-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"45786","name":"Public statement on Thorinane: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-10-24T16:13:00Z","last_updated_date":"2019-10-24T16:13:00Z","reference_number":"EMA/553336/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-thorinane-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"46435","name":"Public statement on Aerivio Spiromax: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-01-15T15:54:00Z","last_updated_date":"2020-01-15T15:54:00Z","reference_number":"EMA/692514/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-aerivio-spiromax-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"46674","name":"Public statement on Fexeric: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-02-04T15:45:00Z","last_updated_date":"2020-02-04T15:45:00Z","reference_number":"EMA/4863/2020 ","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-fexeric-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"46757","name":"Public statement on Zalmoxis: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-02-14T11:28:00Z","last_updated_date":"2020-02-14T11:28:00Z","reference_number":"EMA/587151/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zalmoxis-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"46766","name":"Public statement on Lifmior: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-02-17T14:44:00Z","last_updated_date":"2020-02-17T14:44:00Z","reference_number":"EMA/66704/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-lifmior-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"46776","name":"Public statement on Nonafact","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-02-18T10:27:00Z","last_updated_date":"2020-02-18T10:27:00Z","reference_number":"EMA/326040/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-nonafact_en.pdf"},
    {"id":"46791","name":"Public statement on Iblias : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-02-18T14:44:00Z","last_updated_date":"2020-02-18T14:44:00Z","reference_number":"EMA/63357/2020 ","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-iblias-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"46929","name":"Public statement on Xiapex : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-03-02T16:39:00Z","last_updated_date":"2020-03-02T16:39:00Z","reference_number":"EMA/95504/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-xiapex-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"46943","name":"Public statement on Picato: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-03-04T17:34:00Z","last_updated_date":"2020-03-04T17:34:00Z","reference_number":"EMA/91080/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-picato-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"47111","name":"Public statement on Kromeya: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-03-25T11:12:00Z","last_updated_date":"2020-03-25T11:12:00Z","reference_number":"EMA/98452/2020 ","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-kromeya-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"47281","name":"Public statement on Numient : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2020-04-02T09:25:00Z","last_updated_date":"2020-04-02T09:25:00Z","reference_number":"EMEA/H/C/002611 ","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-numient-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"47499","name":"EMA warns against using unproven cell-based therapies","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-04-28T12:17:00Z","last_updated_date":"2020-04-28T12:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/ema-warns-against-using-unproven-cell-based-therapies_en.pdf"},
    {"id":"47680","name":"Public statement on Protelos: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-05-15T16:39:00Z","last_updated_date":"2020-05-15T16:39:00Z","reference_number":"EMA/234092/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-protelos-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"47703","name":"Public statement on Osseor: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T10:07:00Z","last_updated_date":"2020-05-19T10:07:00Z","reference_number":"EMA/234143/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-osseor-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"47805","name":"Public statement on IV Zanamivir - Closure of compassionate-use programme in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-iv-zanamivir-closure-compassionate-use-programme-european-union_en.pdf"},
    {"id":"47840","name":"Public statement on Helixate NexGen: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-06-02T18:06:00Z","last_updated_date":"2020-06-02T18:06:00Z","reference_number":"EMA/171441/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-helixate-nexgen-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"48027","name":"Public statement on Fertavid: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T13:00:00Z","last_updated_date":"2020-06-23T13:00:00Z","reference_number":"EMA/323441/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-fertavid-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"48313","name":"Public statement on Kolbam: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-07-15T16:14:00Z","last_updated_date":"2020-07-15T16:14:00Z","reference_number":"EMA/282033/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-kolbam-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"48454","name":"Public statement on Zurampic: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-07-28T13:10:00Z","last_updated_date":"2020-07-31T11:39:00Z","reference_number":"EMA/CHMP/358247/2020 Corr.","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zurampic-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"48568","name":"Public statement on Duzallo: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-08-06T17:54:00Z","last_updated_date":"2020-08-06T17:54:00Z","reference_number":"EMA/CHMP/358236/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-duzallo-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"48611","name":"Draft public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) including recommendations regarding contamination of herbal medicinal products with pyrrolizidine alkaloids - Revision 1","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2020-08-15 - 2020-11-15","first_published_date":"2020-08-14T12:40:00Z","last_updated_date":"2020-08-14T12:40:00Z","reference_number":"EMA/HMPC/893108/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf"},
    {"id":"48984","name":"Public statement on Qtrilmet: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-10-09T15:31:00Z","last_updated_date":"2020-10-09T15:31:00Z","reference_number":"EMA/486077/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-qtrilmet-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"49003","name":"Public statement on Zerit: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-10-13T14:55:00Z","last_updated_date":"2020-10-13T14:55:00Z","reference_number":"EMA/446125/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zerit-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"49152","name":"Public statement on Vepacel: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-10-28T17:14:00Z","last_updated_date":"2020-10-28T17:14:00Z","reference_number":"EMA/542469/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vepacel-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"49312","name":"Public statement on Ribavirin Mylan: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-11-23T12:00:00Z","last_updated_date":"2020-11-23T12:00:00Z","reference_number":"EMA/533134/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ribavirin-mylan-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"49487","name":"Public statement on Alpivab: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-12-09T12:23:00Z","last_updated_date":"2020-12-09T12:23:00Z","reference_number":"EMA/CHMP/148367/2018","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-alpivab-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"49774","name":"Public statement on Panretin: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-01-11T13:20:00Z","last_updated_date":"2021-01-11T13:20:00Z","reference_number":"EMA/652257/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-panretin-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"49807","name":"Public statement on Sebivo: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-01-14T18:12:00Z","last_updated_date":"2021-01-14T18:12:00Z","reference_number":"EMA/594353/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-sebivo-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"49832","name":"Public statement on Qutavina: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-01-18T17:20:00Z","last_updated_date":"2021-01-18T17:20:00Z","reference_number":"EMA/CHMP/6617/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-qutavina-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"49875","name":"Public statement on ViraferonPeg: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T11:35:00Z","last_updated_date":"2021-01-22T11:35:00Z","reference_number":"EMA/689345/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-viraferonpeg-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"49932","name":"Public statement on Clopidogrel ratiopharm GmbH: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-01-25T12:21:00Z","last_updated_date":"2021-01-25T12:21:00Z","reference_number":"EMA/CHMP/10194/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-clopidogrel-ratiopharm-gmbh-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"49987","name":"Public statement on Halimatoz: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-01-29T12:00:00Z","last_updated_date":"2021-01-29T12:00:00Z","reference_number":"EMA/687749/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-halimatoz-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"50017","name":"Draft public statement on Salvia miltiorrhiza Bunge, radix et rhizoma - First version","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2021-01-29 - 2021-04-30","first_published_date":"2021-02-01T12:30:00Z","last_updated_date":"2021-02-01T12:30:00Z","reference_number":"EMA/HMPC/509927/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-salvia-miltiorrhiza-bunge-radix-et-rhizoma-first-version_en.pdf"},
    {"id":"50171","name":"Public statement on Udenyca: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-02-15T15:30:00Z","last_updated_date":"2021-02-15T15:30:00Z","reference_number":"EMA/561886/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-udenyca-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"50261","name":"Public statement on Prepandrix: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-02-23T18:20:00Z","last_updated_date":"2021-02-23T18:20:00Z","reference_number":"EMEA/H/C/000822","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-prepandrix-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"50268","name":"Public statement on Truberzi: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-02-25T11:11:00Z","last_updated_date":"2021-02-25T11:11:00Z","reference_number":"EMA/670383/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-truberzi-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"51317","name":"Draft public statement on Saccharomyces cerevisiae CBS 5926","type":"public-statement","status":"Draft: consultation closed","consultation_date":"2021-05-31 - 2021-08-31","first_published_date":"2021-05-31T20:00:00Z","last_updated_date":"2021-05-31T20:00:00Z","reference_number":"EMA/HMPC/483588/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/draft-public-statement-saccharomyces-cerevisiae-cbs-5926_en.pdf"},
    {"id":"51354","name":"Public statement on PegIntron: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-06-03T14:50:00Z","last_updated_date":"2021-06-03T14:50:00Z","reference_number":"EMA/282226/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pegintron-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"51545","name":"Public statement on Nodetrip (previously Xeristar) : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2021-06-22T15:39:00Z","last_updated_date":"2021-06-22T15:39:00Z","reference_number":"EMA/319897/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-nodetrip-previously-xeristar-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"51741","name":"Public statement on Ulipristal Acetate Gedeon Richter: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-07-02T12:28:00Z","last_updated_date":"2021-07-02T12:28:00Z","reference_number":"EMA/265520/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ulipristal-acetate-gedeon-richter-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"51789","name":"Lamivudine ViiV: Cessation of manufacture - Public statement","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2015-12-21T16:26:00Z","last_updated_date":"2015-12-21T16:26:00Z","reference_number":"EMA/847375/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/lamivudine-viiv-cessation-manufacture-public-statement_en.pdf"},
    {"id":"51806","name":"Lamivudine/Zidovudine ViiV : Public statement - Cessation of manufacture","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2009-04-28T17:26:00Z","last_updated_date":"2015-12-21T17:27:00Z","reference_number":"EMA/849940/2015","document_url":"https://www.ema.europa.eu/en/documents/public-statement/lamivudinezidovudine-viiv-public-statement-cessation-manufacture_en.pdf"},
    {"id":"51820","name":"Tritanrix HB : Withdrawal of the Article 58 scientific opinion - Public statement","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2019-08-01T18:01:00Z","last_updated_date":"2019-08-01T18:01:00Z","reference_number":"EMA/370562/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/tritanrix-hb-withdrawal-article-58-scientific-opinion-public-statement_en.pdf"},
    {"id":"51838","name":"Hexaxim: Withdrawal of the Article 58 scientific opinion - Public statement","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T14:43:00Z","last_updated_date":"2020-12-17T14:43:00Z","reference_number":"EMA/648121/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/hexaxim-withdrawal-article-58-scientific-opinion-public-statement_en.pdf"},
    {"id":"52098","name":"Public statement on Portrazza : Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2021-07-27T12:15:00Z","last_updated_date":"2021-07-27T12:15:00Z","reference_number":"EMA/CHMP/390656/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-portrazza-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"52122","name":"Public statement on Pemetrexed Pfizer : Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-07-28T13:24:00Z","last_updated_date":"2021-07-28T13:24:00Z","reference_number":"EMA/504956/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pemetrexed-pfizer-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"52199","name":"Public statement on Azacitidine Celgene : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2021-08-04T17:49:00Z","last_updated_date":"2021-08-04T17:49:00Z","reference_number":"EMA/305416/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-azacitidine-celgene-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"52217","name":"Public statement on Lumoxiti : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2021-08-11T16:54:00Z","last_updated_date":"2021-08-11T16:54:00Z","reference_number":"EMA/431204/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-lumoxiti-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"52218","name":"Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) including recommendations regarding contamination of herbal medicinal products with pyrrolizidine alkaloids - Revision 1","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2021-08-16T09:48:00Z","last_updated_date":"2021-08-16T09:48:00Z","reference_number":"EMA/HMPC/893108/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf"},
    {"id":"52225","name":"Public statement on Ritemvia : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2021-08-16T16:28:00Z","last_updated_date":"2021-08-16T16:28:00Z","reference_number":"EMA/379724/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ritemvia-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"52508","name":"Public statement on Telmisartan Teva : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T15:39:00Z","last_updated_date":"2021-09-17T15:39:00Z","reference_number":"EMA/516349/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-telmisartan-teva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"53297","name":"Public statement on Pemetrexed Lilly : Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-11-26T14:17:00Z","last_updated_date":"2021-11-26T14:17:00Z","reference_number":"EMA/650861/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pemetrexed-lilly-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"53486","name":"Public statement on Docetaxel Teva : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T12:36:00Z","last_updated_date":"2021-12-14T12:36:00Z","reference_number":"EMA/632964/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-docetaxel-teva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"53497","name":"Public statement on Lextemy : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T14:10:00Z","last_updated_date":"2021-12-14T14:10:00Z","reference_number":"EMA/379539/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-lextemy-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"53769","name":"Public statement on Ytracis : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T16:45:00Z","last_updated_date":"2022-01-17T16:45:00Z","reference_number":"EMA/19629/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ytracis-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"53813","name":"Public statement on PANTOLOC Control  : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-01-18T12:23:00Z","last_updated_date":"2022-01-18T12:23:00Z","reference_number":"EMA/10922/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pantoloc-control-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"53867","name":"Public statement on Atripla : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-01-21T10:58:00Z","last_updated_date":"2022-01-21T10:58:00Z","reference_number":"EMA/684003/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-atripla-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"54100","name":"Public statement on Staquis : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-02-08T14:44:00Z","last_updated_date":"2022-02-08T14:44:00Z","reference_number":"EMA/78551/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-staquis-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"54225","name":"Public statement on Leganto : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-02-18T15:52:00Z","last_updated_date":"2022-02-18T15:52:00Z","reference_number":"EMA/102067/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-leganto-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"54306","name":"Public statement on Vivanza : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-02-28T12:14:00Z","last_updated_date":"2022-02-28T12:14:00Z","reference_number":"EMA/74969/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vivanza-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"54690","name":"COVID-19: Joint statement from ECDC and EMA on the  administration of a fourth dose of mRNA vaccines","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-04-06T16:31:00Z","last_updated_date":"2022-04-06T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/covid-19-joint-statement-ecdc-and-ema-administration-fourth-dose-mrna-vaccines_en.pdf"},
    {"id":"54696","name":"Public statement on Umbipro : Withdrawal of the scientific opinion under Article 58","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-04-08T09:19:00Z","last_updated_date":"2022-04-08T09:19:00Z","reference_number":"EMA/128682/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-umbipro-withdrawal-scientific-opinion-under-article-58_en.pdf"},
    {"id":"54698","name":"Public statement on Palonosetron Hospira : Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-04-08T10:30:00Z","last_updated_date":"2022-04-08T10:30:00Z","reference_number":"EMA/205776/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-palonosetron-hospira-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"54837","name":"Public statement on Pregabalin Mylan Pharma : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-04-26T17:29:00Z","last_updated_date":"2022-04-26T17:29:00Z","reference_number":"EMA/522684/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pregabalin-mylan-pharma-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"55042","name":"Public statement on Docetaxel Zentiva : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T12:07:00Z","last_updated_date":"2022-05-20T12:07:00Z","reference_number":"EMA/274291/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-docetaxel-zentiva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"55044","name":"Public statement on Rasilez HCT : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T13:13:00Z","last_updated_date":"2022-05-20T13:13:00Z","reference_number":"EMA/266975/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-rasilez-hct-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"55390","name":"Public statement on Starlix : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-06-28T09:36:00Z","last_updated_date":"2022-06-28T09:36:00Z","reference_number":"EMA/215245/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-starlix-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"55392","name":"Possible use of the vaccine Jynneos against infection by monkeypox virus","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-06-28T13:00:00Z","last_updated_date":"2022-06-28T13:00:00Z","reference_number":"EMA/600064/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/possible-use-vaccine-jynneos-against-infection-monkeypox-virus_en.pdf"},
    {"id":"55457","name":"Public statement on Imatinib Actavis : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-07-05T11:47:00Z","last_updated_date":"2022-07-05T11:47:00Z","reference_number":"EMA/578385/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-imatinib-actavis-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"55458","name":"Public statement on Senstend : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-07-05T12:19:00Z","last_updated_date":"2022-07-05T12:19:00Z","reference_number":"EMA/581764/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-senstend-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"55496","name":"Public statement on Zynteglo : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-07-08T12:19:00Z","last_updated_date":"2022-07-08T12:19:00Z","reference_number":"EMA/192892/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zynteglo-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"55512","name":"Public statement on Crixivan : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-07-12T09:14:00Z","last_updated_date":"2022-07-12T09:14:00Z","reference_number":"EMA/636733/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-crixivan-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"55772","name":"Public statement on Salvia miltiorrhiza Bunge, radix et rhizoma","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-08-03T11:44:00Z","last_updated_date":"2022-08-03T11:44:00Z","reference_number":"EMA/HMPC/509931/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-salvia-miltiorrhiza-bunge-radix-et-rhizoma_en.pdf"},
    {"id":"55792","name":"Final public statement on Saccharomyces cerevisiae CBS 5926","type":"public-statement","status":"Adopted","consultation_date":"","first_published_date":"2022-08-08T10:11:00Z","last_updated_date":"2022-08-08T10:11:00Z","reference_number":"EMA/HMPC/483588/2020","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-saccharomyces-cerevisiae-cbs-5926_en.pdf"}    {"id":"55825","name":"Public statement on Zynquista: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-08-16T14:42:00Z","last_updated_date":"2022-08-16T14:42:00Z","reference_number":"EMA/275660/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zynquista-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"55891","name":"Public statement on Zynquista: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-08-30T17:03:00Z","last_updated_date":"2022-08-30T17:03:00Z","reference_number":"EMA/367772/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zynquista-withdrawal-marketing-authorisation-european-union_en.pdf-0"},
    {"id":"55892","name":"Final public statement on Foeniculum vulgare Miller subsp. vulgare var. vulgare, aetheroleum - Revision 1","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-08-31T10:49:00Z","last_updated_date":"2024-07-19T15:33:00Z","reference_number":"EMA/HMPC/522456/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/final-public-statement-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-aetheroleum-revision-1_en.pdf"},
    {"id":"55996","name":"ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-09-06T13:50:00Z","last_updated_date":"2022-09-06T13:50:00Z","reference_number":"EMA/706119/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/ecdc-ema-statement-booster-vaccination-omicron-adapted-bivalent-covid-19-vaccines_en.pdf"},
    {"id":"56135","name":"Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-09-19T10:21:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/627319/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf"},
    {"id":"56196","name":"Public statement on Zalviso : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T10:55:00Z","last_updated_date":"2022-09-27T10:55:00Z","reference_number":"EMA/670718/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zalviso-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"56422","name":"Public statement on Glustin : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-10-17T10:38:00Z","last_updated_date":"2022-10-17T10:38:00Z","reference_number":"EMA/367013/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-glustin-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"56423","name":"Public statement on Glidipion : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-10-17T11:31:00Z","last_updated_date":"2022-10-17T11:31:00Z","reference_number":"EMA/667468/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-glidipion-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"56431","name":"Public statement on Glubrava : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-10-18T16:08:00Z","last_updated_date":"2022-10-18T16:08:00Z","reference_number":"EMA/366895/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-glubrava-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"56673","name":"Public statement on Neurobloc : Cessation of marketing in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-11-16T15:12:00Z","last_updated_date":"2022-11-16T15:12:00Z","reference_number":"EMA/305129/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-neurobloc-cessation-marketing-european-union_en.pdf"},
    {"id":"56777","name":"Public statement on Temybric Ellipta : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-11-24T15:49:00Z","last_updated_date":"2022-11-24T15:49:00Z","reference_number":"EMA/701455/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-temybric-ellipta-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"56856","name":"Public statement on Macugen : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T08:56:00Z","last_updated_date":"2022-12-02T08:56:00Z","reference_number":"EMA/335559/2019","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-macugen-withdrawal-marketing-authorisation-european-union_en.pdf-0"},
    {"id":"56925","name":"ETF statement on the loss of activity of anti-spike protein monoclonal antibodies due to emerging SARS-CoV-2 variants of concern","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-12-09T13:58:00Z","last_updated_date":"2022-12-09T13:58:00Z","reference_number":"EMA/931457/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/etf-statement-loss-activity-anti-spike-protein-monoclonal-antibodies-due-emerging-sars-cov-2-variants-concern_en.pdf"},
    {"id":"57018","name":"Public statement on IntronA : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T16:56:00Z","last_updated_date":"2022-12-14T16:56:00Z","reference_number":"EMA/935216/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-introna-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"57294","name":"Public statement on Trogarzo : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-01-16T11:49:00Z","last_updated_date":"2023-01-16T11:49:00Z","reference_number":"EMA/866352/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-trogarzo-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"57514","name":"Public statement on Darunavir Krka d.d. : Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-02-03T12:08:00Z","last_updated_date":"2023-02-03T12:08:00Z","reference_number":"EMA/660805/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-darunavir-krka-dd-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"57830","name":"Public statement on Temozolomide Hexal (temozolomide) : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-02-27T16:00:00Z","last_updated_date":"2023-02-27T16:00:00Z","reference_number":"EMA/68497/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-temozolomide-hexal-temozolomide-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"57831","name":"Public statement on Temozolomide Sandoz (temozolomide) : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-02-27T16:58:00Z","last_updated_date":"2023-02-27T16:58:00Z","reference_number":"EMA/68498/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-temozolomide-sandoz-temozolomide-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"57848","name":"Public statement on Hepsera (adefovir dipivoxil) : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-03-01T14:59:00Z","last_updated_date":"2023-03-01T14:59:00Z","reference_number":"EMA/867212/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-hepsera-adefovir-dipivoxil-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"57861","name":"Public statement on Kogenate Bayer : Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-03-02T13:15:00Z","last_updated_date":"2023-03-02T13:15:00Z","reference_number":"EMA/9416/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-kogenate-bayer-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"57881","name":"Public statement on Hepsera : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-03-06T10:20:00Z","last_updated_date":"2023-03-06T10:20:00Z","reference_number":"EMA/867212/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-hepsera-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"58068","name":"Public statement on Pregabalin Zentiva k.s. : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-03-20T12:21:00Z","last_updated_date":"2023-03-20T12:21:00Z","reference_number":"EMA/96595/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pregabalin-zentiva-ks-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"58088","name":"Public statement on Nevirapine Teva : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-03-21T12:36:00Z","last_updated_date":"2023-03-21T12:36:00Z","reference_number":"EMA/112293/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-nevirapine-teva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"58090","name":"Public statement on Lamivudine/Zidovudine Teva : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-03-21T14:40:00Z","last_updated_date":"2023-03-21T14:40:00Z","reference_number":"EMA/102784/2003","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-lamivudinezidovudine-teva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"58213","name":"Public statement on Dasatinib Accord : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T11:21:00Z","last_updated_date":"2023-03-30T11:21:00Z","reference_number":"EMA/145383/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dasatinib-accord-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"58216","name":"Public statement on Dasatinib Accordpharma : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T11:58:00Z","last_updated_date":"2023-03-30T11:58:00Z","reference_number":"EMA/145575/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dasatinib-accordpharma-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"58480","name":"Public statement on Inpremzia (insulin human (rDNA)) : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-04-20T12:24:00Z","last_updated_date":"2023-04-20T12:24:00Z","reference_number":"EMA/168697/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-inpremzia-insulin-human-rdna-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"58581","name":"Public statement on Neurobloc : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-05-04T11:09:00Z","last_updated_date":"2023-05-04T11:09:00Z","reference_number":"EMA/CHMP/125064/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-neurobloc-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"58583","name":"Public statement on Pioglitazone Teva : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-05-04T12:12:00Z","last_updated_date":"2023-05-04T12:12:00Z","reference_number":"EMA/173420/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pioglitazone-teva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"58942","name":"Public statement on Nitisinone MDK : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-06-14T14:59:00Z","last_updated_date":"2023-06-14T14:59:00Z","reference_number":"EMA/169031/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-nitisinone-mdk-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"59311","name":"Public statement on Lenalidomide Krka d.d. : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-07-10T15:40:00Z","last_updated_date":"2023-07-10T15:40:00Z","reference_number":"EMA/294651/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-lenalidomide-krka-dd-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"59553","name":"Public statement on Busilvex : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-08-04T13:01:00Z","last_updated_date":"2023-08-04T13:01:00Z","reference_number":"EMA/948441/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-busilvex-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"59957","name":"Public statement on Pandemic Influenza Vaccine H5N1 Baxter : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-09-13T15:04:00Z","last_updated_date":"2023-09-13T15:04:00Z","reference_number":"EMA/386580/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pandemic-influenza-vaccine-h5n1-baxter-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"60132","name":"Public statement on Invirase : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-09-25T13:21:00Z","last_updated_date":"2023-09-25T13:21:00Z","reference_number":"EMA/375031/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-invirase-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"60378","name":"Public statement on Pregabalin Sandoz GmbH : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-10-12T12:33:00Z","last_updated_date":"2023-10-12T12:33:00Z","reference_number":"EMA/450081/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pregabalin-sandoz-gmbh-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"60453","name":"Public statement on Imatinib Koanaa: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-10-19T10:46:00Z","last_updated_date":"2023-10-19T10:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-imatinib-koanaa-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"60650","name":"Public statement on Ribavirin Teva Pharma B.V. : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T12:53:00Z","last_updated_date":"2021-07-09T12:53:00Z","reference_number":"EMA/222647/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ribavirin-teva-pharma-bv-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"60651","name":"Public statement on Ribavirin Teva : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T13:49:00Z","last_updated_date":"2021-07-09T13:49:00Z","reference_number":"EMA/222638/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ribavirin-teva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"60680","name":"ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-07-11T11:27:00Z","last_updated_date":"2022-07-11T11:27:00Z","reference_number":"EMA/706119/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/ecdc-ema-statement-booster-vaccination-omicron-adapted-bivalent-covid-19-vaccines_en.pdf-0"},
    {"id":"60787","name":"Public statement on Rebetol : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-11-07T14:44:00Z","last_updated_date":"2023-11-07T14:44:00Z","reference_number":"EMA/431866/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-rebetol-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"61188","name":"Public statement on COVID-19 Vaccine (inactivated, adjuvanted) Valneva","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T14:47:07Z","last_updated_date":"2023-12-01T14:47:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-covid-19-vaccine-inactivated-adjuvanted-valneva_en.pdf"},
    {"id":"61323","name":"Public statement on Ivozall : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T16:07:30Z","last_updated_date":"2023-12-07T16:07:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ivozall-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"61493","name":"Zynrelef: public statement - Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T09:21:00Z","last_updated_date":"2023-12-19T09:21:00Z","reference_number":"EMA/453895/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/zynrelef-public-statement-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"61541","name":"Public statement on Episalvan: Withdrawal of the marketing authorisation in the European Union ","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2022-07-15T11:28:40Z","last_updated_date":"2022-07-15T11:28:40Z","reference_number":"EMA/366849/2022","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-episalvan-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"61587","name":"Public statement on Dimethyl fumarate Mylan : Revocation of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T11:12:44Z","last_updated_date":"2023-12-22T11:12:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dimethyl-fumarate-mylan-revocation-marketing-authorisation-european-union_en.pdf"},
    {"id":"61589","name":"Public statement on Dimethyl fumarate Mylan : Revocation of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T11:23:32Z","last_updated_date":"2023-12-22T11:23:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dimethyl-fumarate-mylan-revocation-marketing-authorisation-european-union_en.pdf-0"},
    {"id":"61594","name":"Public statement on Dimethyl fumarate Polpharma : Revocation of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T12:11:19Z","last_updated_date":"2023-12-22T12:11:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dimethyl-fumarate-polpharma-revocation-marketing-authorisation-european-union_en.pdf"},
    {"id":"61595","name":"Public statement on Dimethyl fumarate Polpharma : Revocation of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T12:19:41Z","last_updated_date":"2023-12-22T12:19:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dimethyl-fumarate-polpharma-revocation-marketing-authorisation-european-union_en.pdf-0"},
    {"id":"61596","name":"Public statement on Dimethyl fumarate Polpharma : Revocation of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T12:29:35Z","last_updated_date":"2023-12-22T12:29:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dimethyl-fumarate-polpharma-revocation-marketing-authorisation-european-union_en.pdf-1"},
    {"id":"61599","name":"Public statement on Dimethyl fumarate Accord : Revocation of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T13:27:40Z","last_updated_date":"2023-12-22T13:27:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dimethyl-fumarate-accord-revocation-marketing-authorisation-european-union_en.pdf"},
    {"id":"61601","name":"Public statement on Dimethyl fumarate Neuraxpharm : Revocation of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T14:30:01Z","last_updated_date":"2023-12-22T14:30:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dimethyl-fumarate-neuraxpharm-revocation-marketing-authorisation-european-union_en.pdf"},
    {"id":"61602","name":"Public statement on Dimethyl fumarate Teva : Revocation of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T14:58:01Z","last_updated_date":"2023-12-22T14:58:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-dimethyl-fumarate-teva-revocation-marketing-authorisation-european-union_en.pdf"},
    {"id":"62454","name":"Public statement on Apealea : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-03-06T16:30:25Z","last_updated_date":"2024-03-06T16:30:25Z","reference_number":"EMA/79685/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-apealea-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"62546","name":"Public statement on Pramipexole Accord : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-03-11T17:00:52Z","last_updated_date":"2024-03-11T17:00:52Z","reference_number":"EMA/99746/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pramipexole-accord-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"62595","name":"Public statement on Blenrep (belantamab mafodotin): Non-renewal of the conditional marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T12:39:23Z","last_updated_date":"2024-03-13T12:39:23Z","reference_number":"EMA/108999/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-blenrep-belantamab-mafodotin-non-renewal-conditional-marketing-authorisation-european-union_en.pdf"},
    {"id":"62611","name":"Public statement on Sustiva: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-03-14T08:55:48Z","last_updated_date":"2024-03-14T08:55:48Z","reference_number":"EMA/576905/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-sustiva-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"62652","name":"Public statement on VidPrevtyn Beta: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-03-20T13:37:19Z","last_updated_date":"2024-03-20T13:37:19Z","reference_number":"EMA/585020/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vidprevtyn-beta-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"63184","name":"Public statement on Vaxzevria (previously COVID-19 Vaccine AstraZeneca): Withdrawal of the marketing authorisation in the European Union ","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-05-07T11:00:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"EMEA/H/C/005675","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-vaxzevria-previously-covid-19-vaccine-astrazeneca-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"63941","name":"Public statement on Skysona : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-07-08T09:32:00Z","last_updated_date":"2024-07-08T09:32:00Z","reference_number":"EMA/706673/2021","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-skysona-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"63995","name":"Public statement on Zevalin: Cessation of validity of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T14:53:35Z","last_updated_date":"2024-07-10T14:53:35Z","reference_number":"EMA/226889/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-zevalin-cessation-validity-marketing-authorisation-european-union_en.pdf"},
    {"id":"63997","name":"Public statement on Pixuvri: Expiry of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-07-10T16:24:01Z","last_updated_date":"2024-07-10T16:24:01Z","reference_number":"EMA/272680/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pixuvri-expiry-marketing-authorisation-european-union_en.pdf"},
    {"id":"64395","name":"Public statement on Pemetrexed Krka : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-07-30T10:39:45Z","last_updated_date":"2024-07-30T10:39:45Z","reference_number":"EMA/315898/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pemetrexed-krka-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"64474","name":"Public statement on Tizveni : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T11:33:26Z","last_updated_date":"2024-08-01T11:33:26Z","reference_number":"EMA/323458/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-tizveni-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"64483","name":"Public statement on Evicel : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-08-02T11:20:38Z","last_updated_date":"2024-08-02T11:20:38Z","reference_number":"EMA/325504/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-evicel-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"64547","name":"Public statement on Jcovden (previously COVID-19 Vaccine Janssen): Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-08-09T12:00:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"EMA/273861/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-jcovden-previously-covid-19-vaccine-janssen-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"64569","name":"Public statement on Lymphoseek : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-08-14T14:15:02Z","last_updated_date":"2024-08-14T14:15:02Z","reference_number":"EMA/249009/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-lymphoseek-withdrawal-marketing-authorisation-european-union_en.pdf-0"},
    {"id":"64612","name":"Public statement on Tremelimumab AstraZeneca : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-08-22T10:45:10Z","last_updated_date":"2024-08-22T10:45:10Z","reference_number":"EMA/518554/2023","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-tremelimumab-astrazeneca-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"64761","name":"Public statement on Nyxthracis : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T12:23:00Z","last_updated_date":"2024-09-09T12:23:00Z","reference_number":"EMA/385873/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-nyxthracis-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"65071","name":"Public statement on Esmya: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-10-01T13:42:53Z","last_updated_date":"2025-08-21T14:15:00Z","reference_number":"EMA/347164/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-esmya-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"65072","name":"Public statement on Exviera : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-10-01T16:25:00Z","last_updated_date":"2024-10-01T16:25:00Z","reference_number":"EMA/424395/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-exviera-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"65109","name":"Public statement on Viekirax : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-10-02T09:50:00Z","last_updated_date":"2024-10-02T09:50:00Z","reference_number":"EMA/424396/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-viekirax-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"65315","name":"Public statement on Gefitinib Mylan : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T11:22:00Z","last_updated_date":"2024-10-17T11:22:00Z","reference_number":"EMA/465451/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-gefitinib-mylan-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"65335","name":"Public statement on Ciambra : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T17:22:00Z","last_updated_date":"2024-10-17T17:22:00Z","reference_number":"EMA/484982/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-ciambra-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"65372","name":"Public statement on Memantine LEK : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-10-23T12:17:00Z","last_updated_date":"2024-10-23T12:17:00Z","reference_number":"EMA/452923/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-memantine-lek-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"65427","name":"Public statement on Onbevzi: Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T14:46:06Z","last_updated_date":"2024-10-24T14:46:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-onbevzi-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"65555","name":"Public statement on Pemetrexed Sandoz : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2024-11-06T09:38:22Z","last_updated_date":"2024-11-06T09:38:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-pemetrexed-sandoz-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"66294","name":"Public statement on PreHevbri : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2025-01-10T16:41:45Z","last_updated_date":"2025-01-10T16:41:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-prehevbri-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"66367","name":"Public statement on Gavreto : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2025-01-17T16:24:30Z","last_updated_date":"2025-01-17T16:24:30Z","reference_number":"EMA/551500/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-gavreto-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"66395","name":"Public statement on Alofisel : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2025-01-21T12:36:54Z","last_updated_date":"2025-01-21T12:36:54Z","reference_number":"EMA/586714/2024","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-alofisel-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"66612","name":"Public statement on Penbraya : Withdrawal of the marketing authorisation in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2025-02-05T14:38:58Z","last_updated_date":"2025-02-05T14:38:58Z","reference_number":"EMA/39003/2025","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-penbraya-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"67239","name":"Unregulated advanced therapy medicinal products pose serious risks to health","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2025-03-13T12:00:00Z","last_updated_date":"2025-03-13T12:00:00Z","reference_number":"EMA/66537/2025","document_url":"https://www.ema.europa.eu/en/documents/public-statement/unregulated-advanced-therapy-medicinal-products-pose-serious-risks-health_en.pdf"},
    {"id":"72543","name":"Public statement on Palforzia - cessation of marketing in the European Union","type":"public-statement","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T16:50:00Z","last_updated_date":"2026-02-12T16:50:00Z","reference_number":"EMA/CHMP/38464/2025","document_url":"https://www.ema.europa.eu/en/documents/public-statement/public-statement-palforzia-cessation-marketing-european-union_en.pdf"},
    {"id":"4232","name":"Obizur: educational brochure and video to be given to healthcare professionals to ensure it is used correctly","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T18:20:00Z","last_updated_date":"2015-12-15T18:20:00Z","reference_number":"EMA/770206/2015","document_url":"https://www.ema.europa.eu/en/documents/medication-error/obizur-educational-brochure-and-video-be-given-healthcare-professionals-ensure-it-used-correctly_en.pdf"},
    {"id":"8911","name":"Insulins (high-strength): guidance on prevention of medication errors","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2015-11-27T11:00:00Z","last_updated_date":"2015-11-27T11:00:00Z","reference_number":"EMA/134145/2015","document_url":"https://www.ema.europa.eu/en/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/insulins-high-strength-guidance-prevention-medication-errors_sv.pdf"}},
    {"id":"10956","name":"Amglidia: Guide to be given to prescribers to ensure Amglidia is used correctly","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2018-08-29T13:30:00Z","last_updated_date":"2018-08-29T13:30:00Z","reference_number":"EMA/133231/2018","document_url":"https://www.ema.europa.eu/en/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/amglidia-guide-be-given-prescribers-ensure-amglidia-used-correctly_sv.pdf"}},
    {"id":"12563","name":"Exjade: measures to avoid medication errors","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2016-04-22T13:03:00Z","last_updated_date":"2016-04-22T13:03:00Z","reference_number":"EMA/174254/2016","document_url":"https://www.ema.europa.eu/en/documents/medication-error/exjade-measures-avoid-medication-errors_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/exjade-measures-avoid-medication-errors_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/exjade-measures-avoid-medication-errors_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/exjade-measures-avoid-medication-errors_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/exjade-measures-avoid-medication-errors_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/exjade-measures-avoid-medication-errors_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/exjade-measures-avoid-medication-errors_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/exjade-measures-avoid-medication-errors_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/exjade-measures-avoid-medication-errors_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/exjade-measures-avoid-medication-errors_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/exjade-measures-avoid-medication-errors_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/exjade-measures-avoid-medication-errors_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/exjade-measures-avoid-medication-errors_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/exjade-measures-avoid-medication-errors_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/exjade-measures-avoid-medication-errors_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/exjade-measures-avoid-medication-errors_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/exjade-measures-avoid-medication-errors_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/exjade-measures-avoid-medication-errors_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/exjade-measures-avoid-medication-errors_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/exjade-measures-avoid-medication-errors_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/exjade-measures-avoid-medication-errors_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/exjade-measures-avoid-medication-errors_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/exjade-measures-avoid-medication-errors_sv.pdf"}},
    {"id":"13515","name":"Farydak: compliance card to be given to patients to ensure correct use and avoid medication errors","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2015-11-27T11:00:00Z","last_updated_date":"2015-11-27T11:00:00Z","reference_number":"EMA/599292/2015","document_url":"https://www.ema.europa.eu/en/documents/medication-error/farydak-compliance-card-be-given-patients-ensure-correct-use-avoid-medication-errors_en.pdf"},
    {"id":"16757","name":"Jylamvo: healthcare professionals to receive educational guide to ensure medicine is used correctly","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2017-04-19T02:00:00Z","last_updated_date":"2017-04-19T02:00:00Z","reference_number":"EMA/81869/2017","document_url":"https://www.ema.europa.eu/en/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/jylamvo-healthcare-professionals-receive-educational-guide-ensure-medicine-used-correctly_sv.pdf"}},
    {"id":"18262","name":"Ionsys: measures to ensure that it is handled and used correctly","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2015-11-30T18:00:00Z","last_updated_date":"2015-11-30T18:00:00Z","reference_number":"EMA/734228/2015","document_url":"https://www.ema.europa.eu/en/documents/medication-error/ionsys-measures-ensure-it-handled-and-used-correctly_en.pdf"},
    {"id":"18272","name":"Fiasp: colour change for insulin injection Fiasp to avoid mix ups with Tresiba","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T13:00:00Z","last_updated_date":"2018-03-23T13:00:00Z","reference_number":"EMA/166410/2018","document_url":"https://www.ema.europa.eu/en/documents/medication-error/fiasp-colour-change-insulin-injection-fiasp-avoid-mix-ups-tresiba_en.pdf"},
    {"id":"19980","name":"Suliqua: Educational materials for healthcare professionals and patients using the diabetes medicine Suliqua","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T02:00:00Z","last_updated_date":"2017-03-30T02:00:00Z","reference_number":"EMA/747766/2016","document_url":"https://www.ema.europa.eu/en/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/suliqua-educational-materials-healthcare-professionals-and-patients-using-diabetes-medicine-suliqua_sv.pdf"}},
    {"id":"20702","name":"Velcade: questions and answers on recommendations to prevent administration errors","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2012-01-20T13:00:00Z","last_updated_date":"2012-01-20T13:00:00Z","reference_number":"EMA/34910/2012 ","document_url":"https://www.ema.europa.eu/en/documents/medication-error/velcade-questions-answers-recommendations-prevent-administration-errors_en.pdf"},
    {"id":"23476","name":"Noxafil: EMA warns that tablets and oral suspension have different doses and are not interchangeable","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/425762/2016","document_url":"https://www.ema.europa.eu/en/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/noxafil-ema-warns-tablets-and-oral-suspension-have-different-doses-and-are-not-interchangeable_sv.pdf"}},
    {"id":"30292","name":"Myalepta: Educational material for patients and healthcare professionals to ensure Myalepta is used correctly","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2018-08-06T14:30:00Z","last_updated_date":"2018-08-06T14:30:00Z","reference_number":"EMA/512520/2018","document_url":"https://www.ema.europa.eu/en/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/myalepta-educational-material-patients-and-healthcare-professionals-ensure-myalepta-used-correctly_sv.pdf"}},
    {"id":"35992","name":"Keppra: EMA recommends measures to ensure safe use of oral solution","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"EMA/668736/2016","document_url":"https://www.ema.europa.eu/en/documents/medication-error/keppra-ema-recommends-measures-ensure-safe-use-oral-solution_en.pdf"},
    {"id":"36137","name":"Blincyto: measures to avoid medication errors","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2015-12-08T17:00:00Z","last_updated_date":"2015-12-08T17:00:00Z","reference_number":"EMA/677776/2015","document_url":"https://www.ema.europa.eu/en/documents/medication-error/blincyto-measures-avoid-medication-errors_en.pdf"},
    {"id":"36626","name":"Uptravi: educational brochure for healthcare professionals and diary for patients","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T15:40:00Z","last_updated_date":"2016-05-31T15:40:00Z","reference_number":"EMA/89167/2016","document_url":"https://www.ema.europa.eu/en/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/uptravi-educational-brochure-healthcare-professionals-and-diary-patients_sv.pdf"}},
    {"id":"38246","name":"Strensiq: European Medicines Agency recommends measures to ensure safe and effective use","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T14:00:00Z","last_updated_date":"2015-06-26T14:00:00Z","reference_number":"EMA/386551/2015","document_url":"https://www.ema.europa.eu/en/documents/medication-error/strensiq-european-medicines-agency-recommends-measures-ensure-safe-and-effective-use_en.pdf"},
    {"id":"39122","name":"Insulin and a non-insulin active substance: guidance on prevention of medication errors","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2015-11-27T11:00:00Z","last_updated_date":"2015-11-27T11:00:00Z","reference_number":"EMA/134144/2015","document_url":"https://www.ema.europa.eu/en/documents/medication-error/insulin-non-insulin-active-substance-guidance-prevention-medication-errors_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_sv.pdf"}},
    {"id":"44324","name":"Lynparza: warning that new tablets are used at different doses to the capsules","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2019-04-23T17:14:00Z","last_updated_date":"2019-04-23T17:14:00Z","reference_number":"EMA/107399/2018","document_url":"https://www.ema.europa.eu/en/documents/medication-error/lynparza-warning-new-tablets-are-used-different-doses-capsules_en.pdf"}    {"id":"45312","name":"Methotrexate: new measures to avoid potentially fatal dosing errors with methotrexate for inflammatory diseases","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T17:51:00Z","last_updated_date":"2019-08-22T17:51:00Z","reference_number":"EMA/414775/2019","document_url":"https://www.ema.europa.eu/en/documents/medication-error/methotrexate-new-measures-avoid-potentially-fatal-dosing-errors-methotrexate-inflammatory-diseases_en.pdf"},
    {"id":"46319","name":"Trisenox: EMA issues alert on the risk of dosing errors with the cancer medicine Trisenox","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2019-12-13T12:15:00Z","last_updated_date":"2019-12-13T12:15:00Z","reference_number":"EMA/189409/2019","document_url":"https://www.ema.europa.eu/en/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/trisenox-ema-issues-alert-risk-dosing-errors-cancer-medicine-trisenox_sv.pdf"}},
    {"id":"47384","name":"Vaxchora: avoiding errors when making up and using the vaccine","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2020-04-08T14:47:00Z","last_updated_date":"2026-03-11T10:01:00Z","reference_number":"EMA/378492/2025 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/vaxchora-avoiding-errors-when-making-using-vaccine_sv.pdf"}},
    {"id":"48106","name":"Deferasirox Mylan: Measures to avoid medication errors","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2020-06-24T14:25:00Z","last_updated_date":"2020-06-24T14:25:00Z","reference_number":"EMA/64561/2020","document_url":"https://www.ema.europa.eu/en/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/deferasirox-mylan-measures-avoid-medication-errors_sv.pdf"}},
    {"id":"48134","name":"Leuprorelin-containing depot medicinal products: new measures to avoid handling errors with leuprorelin depot medicines","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/330921/2020","document_url":"https://www.ema.europa.eu/en/documents/medication-error/leuprorelin-containing-depot-medicinal-products-new-measures-avoid-handling-errors-leuprorelin-depot-medicines_en.pdf"},
    {"id":"48706","name":"Gencebok: potential for dosing errors","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2020-08-27T11:39:00Z","last_updated_date":"2020-08-27T11:39:00Z","reference_number":"EMA/354319/2020","document_url":"https://www.ema.europa.eu/en/documents/medication-error/gencebok-potential-dosing-errors_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/gencebok-potential-dosing-errors_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/gencebok-potential-dosing-errors_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/gencebok-potential-dosing-errors_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/gencebok-potential-dosing-errors_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/gencebok-potential-dosing-errors_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/gencebok-potential-dosing-errors_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/gencebok-potential-dosing-errors_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/gencebok-potential-dosing-errors_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/gencebok-potential-dosing-errors_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/gencebok-potential-dosing-errors_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/gencebok-potential-dosing-errors_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/gencebok-potential-dosing-errors_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/gencebok-potential-dosing-errors_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/gencebok-potential-dosing-errors_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/gencebok-potential-dosing-errors_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/gencebok-potential-dosing-errors_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/gencebok-potential-dosing-errors_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/gencebok-potential-dosing-errors_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/gencebok-potential-dosing-errors_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/gencebok-potential-dosing-errors_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/gencebok-potential-dosing-errors_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/gencebok-potential-dosing-errors_sv.pdf"}},
    {"id":"48818","name":"Peyona: potential for dosing errors","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2020-09-16T09:27:00Z","last_updated_date":"2020-09-16T09:27:00Z","reference_number":"EMA/480123/2020","document_url":"https://www.ema.europa.eu/en/documents/medication-error/peyona-potential-dosing-errors_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/peyona-potential-dosing-errors_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/peyona-potential-dosing-errors_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/peyona-potential-dosing-errors_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/peyona-potential-dosing-errors_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/peyona-potential-dosing-errors_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/peyona-potential-dosing-errors_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/peyona-potential-dosing-errors_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/peyona-potential-dosing-errors_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/peyona-potential-dosing-errors_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/peyona-potential-dosing-errors_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/peyona-potential-dosing-errors_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/peyona-potential-dosing-errors_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/peyona-potential-dosing-errors_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/peyona-potential-dosing-errors_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/peyona-potential-dosing-errors_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/peyona-potential-dosing-errors_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/peyona-potential-dosing-errors_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/peyona-potential-dosing-errors_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/peyona-potential-dosing-errors_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/peyona-potential-dosing-errors_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/peyona-potential-dosing-errors_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/peyona-potential-dosing-errors_sv.pdf"}},
    {"id":"49148","name":"Cabazitaxel Accord : Letter to healthcare professionals about risk of mix-ups with Jevtana (cabazitaxel)","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2020-10-28T15:19:00Z","last_updated_date":"2020-10-28T15:19:00Z","reference_number":"EMA/243153/2020","document_url":"https://www.ema.europa.eu/en/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_sv.pdf"}},
    {"id":"63457","name":"Awiqli : measures intended to reduce risk of confusion with dosing requirements","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2024-06-03T13:04:00Z","last_updated_date":"2024-06-03T13:04:00Z","reference_number":"EMA/137463/2024","document_url":"https://www.ema.europa.eu/en/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/awiqli-measures-intended-reduce-risk-confusion-dosing-requirements_sv.pdf"}},
    {"id":"69622","name":"Rybelsus: Risk of medication error due to new tablet formulation","type":"medication-error","status":"unknown","consultation_date":"","first_published_date":"2025-08-01T13:21:03Z","last_updated_date":"2025-08-01T13:21:03Z","reference_number":"EMA/141235/2024","document_url":"https://www.ema.europa.eu/en/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_da.pdf","de":"https://www.ema.europa.eu/de/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_de.pdf","et":"https://www.ema.europa.eu/et/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_et.pdf","el":"https://www.ema.europa.eu/el/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_sv.pdf"}},
    {"id":"2429","name":"Opinion following an Article 7(5) referral for Genotropin International Non-Proprietary Name (INN): Somatropin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-06-26T02:08:00Z","last_updated_date":"2003-06-26T02:08:00Z","reference_number":"CPMP/3477/03","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-75-referral-genotropin-international-non-proprietary-name-inn-somatropin-background-information_sv.pdf"}},
    {"id":"2443","name":"Stamaril - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-07-15T01:59:00Z","last_updated_date":"2006-07-15T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/stamaril-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"2445","name":"Zyrtec - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-16T02:08:21Z","last_updated_date":"2008-10-16T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zyrtec-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"2446","name":"Opinion following an Article 33 (4) referral as amended for Solacyl: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-05-02T01:59:00Z","last_updated_date":"2008-05-02T01:59:00Z","reference_number":"EMEA/209536/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-33-4-referral-amended-solacyl-background-information_sv.pdf"}},
    {"id":"2459","name":"Clavudale - Article 33 referral- Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-03T00:00:00Z","last_updated_date":"2012-02-03T00:00:00Z","reference_number":"EMEA/V/A/068","document_url":"https://www.ema.europa.eu/en/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/clavudale-article-33-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"2466","name":"Opinion following an Article 33 referral for  Ecomectin 18.7 mg/g Oral Paste for Horses and its associated names International Non-Proprietary Name (INN): Ivermectin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-02-19T00:59:00Z","last_updated_date":"2008-02-19T00:59:00Z","reference_number":"EMEA/48261/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-33-referral-ecomectin-187-mgg-oral-paste-horses-and-its-associated-names-international-non-proprietary-name-inn-ivermectin-background-information_sv.pdf"}},
    {"id":"2476","name":"Opinion following an Article-31 referral for serotonin-specific reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-08-19T02:08:21Z","last_updated_date":"2005-08-19T02:08:21Z","reference_number":"CHMP/297837/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-31-referral-serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-background-information_sv.pdf"}},
    {"id":"2494","name":"Almitrine Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"EMA/PRAC/747321/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"2495","name":"Opinion following an Article 12 referral for Naftidrofuryl 200mg/10ml infusion International Non-Proprietary Name (INN): Naftidrofuryl: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1997-04-03T02:08:21Z","last_updated_date":"1997-04-03T02:08:21Z","reference_number":"CPMP/578/95","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-12-referral-naftidrofuryl-200mg10ml-infusion-international-non-proprietary-name-inn-naftidrofuryl-background-information_en.pdf"},
    {"id":"2520","name":"PRAC recommends using acipimox only as additional or alternative treatment to lower high triglyceride levels","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-08T01:00:00Z","last_updated_date":"2013-11-08T01:00:00Z","reference_number":"EMA/618574/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-recommends-using-acipimox-only-additional-or-alternative-treatment-lower-high-triglyceride-levels_en.pdf"},
    {"id":"2540","name":"Ibuprofen and dexibuprofen Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-14T02:00:00Z","last_updated_date":"2015-07-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"2563","name":"Loratadine - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-07-14T02:08:21Z","last_updated_date":"2004-07-14T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/loratadine-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"2579","name":"Leflunomide Apotex Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leflunomide-apotex-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"2648","name":"Final opinion of the Committee for proprietary medicinal products in accordance with Article 12 of Directive 75/319/EEC as amended for Anoretics International Non-Proprietary Name (INN): Type II and Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1996-12-10T00:08:21Z","last_updated_date":"1996-12-10T00:08:21Z","reference_number":"CPMP/111-112/96","document_url":"https://www.ema.europa.eu/en/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-ii-and-annex-i_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-ii-and-annex-i_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-ii-and-annex-i_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-ii-and-annex-i_fr.pdf"}},
    {"id":"2667","name":"Lactose of bovine origin Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T13:00:00Z","last_updated_date":"2016-12-02T13:00:00Z","reference_number":"EMA/PRAC/787822/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"2715","name":"Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Agopton and associated names (see Annex I) International Non-Proprietary Name (INN): Lansoprazole: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-12-14T00:08:21Z","last_updated_date":"2006-12-14T00:08:21Z","reference_number":"EMEA/407636/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-agopton-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lansoprazole-background-information_sv.pdf"}},
    {"id":"2717","name":"Targocid Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2014-01-03T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/targocid-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/targocid-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/targocid-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/targocid-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/targocid-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/targocid-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/targocid-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/targocid-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/targocid-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/targocid-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/targocid-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/targocid-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/targocid-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/targocid-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/targocid-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/targocid-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/targocid-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/targocid-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/targocid-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/targocid-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/targocid-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/targocid-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/targocid-article-30-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/targocid-article-30-referral-annex-iii_no.pdf"}},
    {"id":"2718","name":"Cardioxane Article 13 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-07-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cardioxane-article-13-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cardioxane-article-13-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cardioxane-article-13-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cardioxane-article-13-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cardioxane-article-13-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cardioxane-article-13-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cardioxane-article-13-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cardioxane-article-13-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cardioxane-article-13-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cardioxane-article-13-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cardioxane-article-13-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cardioxane-article-13-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cardioxane-article-13-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cardioxane-article-13-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cardioxane-article-13-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cardioxane-article-13-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cardioxane-article-13-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cardioxane-article-13-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cardioxane-article-13-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cardioxane-article-13-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cardioxane-article-13-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cardioxane-article-13-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cardioxane-article-13-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/cardioxane-article-13-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/cardioxane-article-13-referral-annex-iii_no.pdf"}},
    {"id":"2751","name":"Ciprofloxacin Nycomed  - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-02-19T00:08:21Z","last_updated_date":"2008-02-19T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ciprofloxacin-nycomed-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"2767","name":"Opinion following an Article 30 referral for Risperdal and associated names International Non-Proprietary Name (INN): risperidone: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-08T02:08:21Z","last_updated_date":"2008-10-08T02:08:21Z","reference_number":"EMEA/CHMP/384877/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-risperdal-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_sv.pdf"}},
    {"id":"2797","name":"Valproat Ratiopharm Chrono - Article 6(12) - Annex I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-23T02:00:00Z","last_updated_date":"2012-07-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproat-ratiopharm-chrono-article-612-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"2807","name":"Pharmaceutics International Inc. Article-31 referral – Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T01:00:00Z","last_updated_date":"2016-12-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"2826","name":"Priligy - Article 29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-03-28T02:00:00Z","last_updated_date":"2012-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/priligy-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/priligy-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/priligy-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/priligy-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/priligy-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/priligy-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/priligy-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/priligy-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/priligy-article-29-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/priligy-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/priligy-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/priligy-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/priligy-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/priligy-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/priligy-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/priligy-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/priligy-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/priligy-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/priligy-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/priligy-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/priligy-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/priligy-article-29-referral-annex-iii_sv.pdf"}},
    {"id":"2832","name":"Assessment report for Antifibrinolytic medicines (aminocaproic acid)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-06T01:00:00Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-antifibrinolytic-medicines-aminocaproic-acid_en.pdf"},
    {"id":"2840","name":"Nimesulide - Article 107 procedures - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-08T02:00:00Z","last_updated_date":"2010-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-107-procedures-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nimesulide-article-107-procedures-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nimesulide-article-107-procedures-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nimesulide-article-107-procedures-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nimesulide-article-107-procedures-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nimesulide-article-107-procedures-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nimesulide-article-107-procedures-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nimesulide-article-107-procedures-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nimesulide-article-107-procedures-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nimesulide-article-107-procedures-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nimesulide-article-107-procedures-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nimesulide-article-107-procedures-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nimesulide-article-107-procedures-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nimesulide-article-107-procedures-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nimesulide-article-107-procedures-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nimesulide-article-107-procedures-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nimesulide-article-107-procedures-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nimesulide-article-107-procedures-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nimesulide-article-107-procedures-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nimesulide-article-107-procedures-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nimesulide-article-107-procedures-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nimesulide-article-107-procedures-annex-i_sv.pdf"}},
    {"id":"2869","name":"Methysergide Article-31 referral - Restrictions on the use of methysergide-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-05-27T02:00:00Z","last_updated_date":"2014-05-27T02:00:00Z","reference_number":"EMA/276477/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methysergide-article-31-referral-restrictions-use-methysergide-containing-medicines_sv.pdf"}},
    {"id":"2880","name":"Risperdal - Article 30 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-11-13T00:08:21Z","last_updated_date":"2008-11-13T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"2899","name":"Scandonest Article-30 referral - Use of Scandonest and associated names (mepivacaine) to be harmonised","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T02:00:00Z","last_updated_date":"2018-08-07T02:00:00Z","reference_number":"EMA/356909/2018 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/scandonest-article-30-referral-use-scandonest-and-associated-names-mepivacaine-be-harmonised_sv.pdf"}},
    {"id":"2913","name":"Zydelig Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T13:00:00Z","last_updated_date":"2016-03-18T13:00:00Z","reference_number":"EMA/PRAC/197574/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"2944","name":"Antifibrinolytic medicines - Article 31 referral - Annex III (aprotinin)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T11:09:54Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aprotinin_no.pdf"}},
    {"id":"2949","name":"Thiocolchicoside Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-03-06T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"EMA/40340/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/thiocolchicoside-article-31-referral-assessment-report_en.pdf"},
    {"id":"2958","name":"Engerix B - Article 30 referral - Summary of product characteristics","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2000-08-28T02:08:21Z","last_updated_date":"2000-08-28T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/engerix-b-article-30-referral-summary-product-characteristics_sv.pdf"}},
    {"id":"2966","name":"Alcover Article-29(4) referral - Questions and answers on Alcover granules (sodium oxybate 750, 1250 and 1750 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2018-01-12T01:00:00Z","reference_number":"EMA/391578/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750-1250-and-1750-mg_sv.pdf"}},
    {"id":"2984","name":"Rapinyl - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-09-25T02:08:21Z","last_updated_date":"2009-09-25T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rapinyl-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"3005","name":"Compagel azuril - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-10T01:59:00Z","last_updated_date":"2008-10-10T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/compagel-azuril-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"3008","name":"Lopid - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-08-19T01:59:00Z","last_updated_date":"2004-08-19T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lopid-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/lopid-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lopid-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lopid-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lopid-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lopid-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lopid-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lopid-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lopid-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lopid-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lopid-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lopid-article-30-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lopid-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lopid-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lopid-article-30-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lopid-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lopid-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lopid-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lopid-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"3009","name":"Ergot derivatives Article-31 referral - Dihydroergocristine - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iv_sv.pdf"}},
    {"id":"3021","name":"Intravenous iron-containing medicinal products Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-01T02:00:00Z","last_updated_date":"2013-11-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iii_no.pdf"}},
    {"id":"3023","name":"Questions and answers on Vascace and associated names (cilazapril, 0.5, 1, 2.5 and 5 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2010-04-23T02:00:00Z","reference_number":"EMA/238133/2010 rev","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_sv.pdf"}},
    {"id":"3029","name":"Tetrazepam-containing medicines - Article-107i procedure - PRAC list of questions to be addressed by stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T13:00:00Z","last_updated_date":"2013-01-11T13:00:00Z","reference_number":"EMA/PRAC/5086/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-prac-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"3031","name":"Cymevene Article-30 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-06-21T02:00:00Z","last_updated_date":"2016-06-21T02:00:00Z","reference_number":"EMA/CHMP/175628/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/cymevene-article-30-referral-assessment-report_en.pdf"},
    {"id":"3039","name":"Baxter dialysis solutions Article-31 referral - Annex III (3 sites)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-3-sites_sv.pdf"}},
    {"id":"3075","name":"Tazocin - Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tazocin-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tazocin-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tazocin-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tazocin-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tazocin-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tazocin-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tazocin-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tazocin-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tazocin-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tazocin-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tazocin-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tazocin-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tazocin-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tazocin-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tazocin-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tazocin-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tazocin-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tazocin-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tazocin-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tazocin-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tazocin-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tazocin-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/tazocin-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/tazocin-article-30-referral-annex-iii_no.pdf"}},
    {"id":"3081","name":"Assessment report for Antifibrinolytic medicines (tranexamic acid)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-06T01:00:00Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-antifibrinolytic-medicines-tranexamic-acid_en.pdf"},
    {"id":"3111","name":"Tetrazepam-containing medicines - Article-107i procedure - Recommendation to suspend tetrazepam-containing medicines endorsed by CMDh","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-29T02:00:00Z","last_updated_date":"2013-04-29T02:00:00Z","reference_number":"EMA/256383/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-recommendation-suspend-tetrazepam-containing-medicines-endorsed-cmdh_en.pdf"},
    {"id":"3126","name":"HPV vaccines - Article-20 procedure - Review concludes evidence does not support that HPV vaccines cause CRPS or POTS","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-11-05T01:00:00Z","last_updated_date":"2015-11-05T01:00:00Z","reference_number":"EMA/714950/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-review-concludes-evidence-does-not-support-hpv-vaccines-cause-crps-or-pots_en.pdf"},
    {"id":"3135","name":"Questions and answers on the review of Preflucel and associated names (influenza vaccine, purified antigen)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-07-20T17:02:16Z","last_updated_date":"2012-07-20T17:02:16Z","reference_number":"EMEA/H/A-36/1323","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-preflucel-and-associated-names-influenza-vaccine-purified-antigen_en.pdf"},
    {"id":"3141","name":"Opinion following an Article 6(12) referral for Prozac and associated names  International Non-Proprietary Name (INN): Fluoxetine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-08-21T02:08:21Z","last_updated_date":"2006-08-21T02:08:21Z","reference_number":"EMEA/311654/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-612-referral-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background-information_sv.pdf"}},
    {"id":"3156","name":"Bromocriptine, Dihydroergocryptine and Lisuride - Article 31 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-05T02:08:21Z","last_updated_date":"2009-05-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"3158","name":"Questions and answers on the review of Novosis Goserelin, Goserelin Cell Pharm, Novimp and associated names (goserelin, 3.6 mg implant)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMA/CHMP/477156/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-novosis-goserelin-goserelin-cell-pharm-novimp-and-associated-names-goserelin-36-mg-implant_sv.pdf"}},
    {"id":"3182","name":"Dienogest/ethinylestradiol can be used for acne after certain other treatments have failed","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/200686/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dienogestethinylestradiol-can-be-used-acne-after-certain-other-treatments-have-failed_sv.pdf"}},
    {"id":"3201","name":"Assessment report for Leflunomide Actavis","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"EMA/691568/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-leflunomide-actavis_en.pdf"},
    {"id":"3227","name":"Summary information on a referral opinion following an arbitration pursuant to Article 11 of Council Directive 75/319/EEC as amended, for Glucophage/Glucophage Forte/Risidon/Dianben International Non-Proprietary Name (IN...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2001-02-06T23:08:21Z","last_updated_date":"2001-02-06T23:08:21Z","reference_number":"CPMP/4082/00","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-glucophageglucophage-forterisidondianben-international-non-proprietary-name_sv.pdf"}},
    {"id":"3246","name":"Zinnat - Article-30 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T14:00:00Z","last_updated_date":"2013-01-29T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinnat-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinnat-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinnat-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinnat-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinnat-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinnat-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinnat-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinnat-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinnat-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinnat-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinnat-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinnat-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinnat-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinnat-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinnat-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinnat-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinnat-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinnat-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinnat-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinnat-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinnat-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinnat-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/zinnat-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/zinnat-article-30-referral-annex-iii_no.pdf"}},
    {"id":"3272","name":"Valproate Article-31 referral - Timetable","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T01:00:00Z","last_updated_date":"2017-12-07T01:00:00Z","reference_number":"EMA/PRAC/154221/2017 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-timetable_en.pdf"},
    {"id":"3292","name":"Questions and answers on Priorix (measles, mumps and rubella vaccine (live))","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T01:00:00Z","last_updated_date":"2012-06-21T13:01:00Z","reference_number":"EMA/CHMP/178705/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-priorix-measles-mumps-and-rubella-vaccine-live_sv.pdf"}},
    {"id":"3319","name":"Trimetazidine - Article 31 - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-17T02:00:00Z","last_updated_date":"2012-10-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/trimetazidine-article-31-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/trimetazidine-article-31-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/trimetazidine-article-31-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/trimetazidine-article-31-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/trimetazidine-article-31-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/trimetazidine-article-31-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/trimetazidine-article-31-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/trimetazidine-article-31-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/trimetazidine-article-31-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/trimetazidine-article-31-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/trimetazidine-article-31-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/trimetazidine-article-31-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/trimetazidine-article-31-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/trimetazidine-article-31-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/trimetazidine-article-31-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/trimetazidine-article-31-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/trimetazidine-article-31-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/trimetazidine-article-31-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/trimetazidine-article-31-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/trimetazidine-article-31-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/trimetazidine-article-31-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/trimetazidine-article-31-annex-iii_sv.pdf"}},
    {"id":"3332","name":"Questions and answers on the recommendation to withdraw the marketing authorisations for lumiracoxib-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2007-12-13T01:00:00Z","last_updated_date":"2007-12-13T01:00:00Z","reference_number":"EMEA/536363/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-recommendation-withdraw-marketing-authorisations-lumiracoxib-containing-medicines_en.pdf"},
    {"id":"3351","name":"Retinoid Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-08-04T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-annex-i_en.pdf"},
    {"id":"3380","name":"Quinolone and fluoroquinolone Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-13T01:00:00Z","last_updated_date":"2019-03-19T11:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-i_no.pdf"}},
    {"id":"3388","name":"Daivobet - Article 30 referral  - Annexes I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/daivobet-article-30-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"3389","name":"Famvir - Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-03-05T16:35:00Z","last_updated_date":"2014-03-05T16:35:00Z","reference_number":"EMA/CHMP/89970/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/famvir-article-30-referral-assessment-report_en.pdf"},
    {"id":"3414","name":"Testosterone Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-04-11T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-notification_en.pdf"},
    {"id":"3422","name":"Metamizole Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T00:00:00Z","last_updated_date":"2018-09-21T00:00:00Z","reference_number":"EMA/CHMP/274831/2018 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"3444","name":"Questions and answers on Rocephin and associated names (ceftriaxone, 250 mg, 500 mg, 1 g, 2 g, powder for solution for injection or infusion)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-05-19T02:00:00Z","reference_number":"EMA/34577/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-rocephin-and-associated-names-ceftriaxone-250-mg-500-mg-1-g-2-g-powder-solution-injection-or-infusion_sv.pdf"}},
    {"id":"3448","name":"Opinion following an Article 7(5) referral for Laurina and related invented names International Non-Proprietary Name (INN): Desogestrel/ethinlestradiol: Background information and Annexes I, II (English) and Annex III (a...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-02-02T00:08:21Z","last_updated_date":"2004-02-02T00:08:21Z","reference_number":"CPMP/1390/04","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-75-referral-laurina-and-related-invented-names-international-non-proprietary-name-inn-desogestrelethinlestradiol-background-information-and-annexes-i-ii-english-and-annex-iii_sv.pdf"}},
    {"id":"3455","name":"Opinion following an Article 33(4)  referral for Deltanil 10 mg/ml Pour-on Solution for cattle and sheep and Deltanil 100 mg Spot-on Solution for cattle","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"MA/539462/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_sv.pdf"}},
    {"id":"3481","name":"Fibrates Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-03T17:00:00Z","last_updated_date":"2013-04-03T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrates-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrates-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fibrates-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrates-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrates-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrates-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fibrates-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrates-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fibrates-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrates-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrates-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrates-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fibrates-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrates-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrates-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrates-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrates-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrates-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrates-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrates-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fibrates-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrates-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"3509","name":"Questions and answers on Solamocta 697 mg/g Powder for Use in Drinking Water for Chickens, Ducks and Turkeys (amoxicillin trihydrate)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T01:00:00Z","reference_number":"EMA/23095/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-solamocta-697-mgg-powder-use-drinking-water-chickens-ducks-and-turkeys-amoxicillin-trihydrate_sv.pdf"}},
    {"id":"3525","name":"Iclusig Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-06T13:00:00Z","last_updated_date":"2013-12-06T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-notification_en.pdf"},
    {"id":"3568","name":"Nuflor Swine Once Article-33(4) referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nuflor-swine-once-article-334-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"3597","name":"Doxycycline 50% WSP - Article 34 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-08-23T02:00:00Z","last_updated_date":"2011-08-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/doxycycline-50-wsp-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"3604","name":"Sandimmun Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-12-20T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sandimmun-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sandimmun-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sandimmun-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sandimmun-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sandimmun-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sandimmun-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sandimmun-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sandimmun-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sandimmun-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sandimmun-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sandimmun-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sandimmun-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sandimmun-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sandimmun-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sandimmun-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sandimmun-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sandimmun-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sandimmun-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sandimmun-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sandimmun-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sandimmun-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sandimmun-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sandimmun-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sandimmun-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sandimmun-article-30-referral-annex-iii_no.pdf"}},
    {"id":"3629","name":"Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Coversyl and associated names (see Annex I) International Non-Proprietary Name (INN): perindopril: Background information...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-12-05T00:08:21Z","last_updated_date":"2003-12-05T00:08:21Z","reference_number":"CPMP/32703/03","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-coversyl-and-associated-names-see-annex-i-international-non-proprietary-name-inn-perindopril-background-information_en.pdf"},
    {"id":"3632","name":"Pholcodine - Article 31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-03-28T02:00:00Z","last_updated_date":"2012-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pholcodine-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pholcodine-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pholcodine-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pholcodine-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pholcodine-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pholcodine-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pholcodine-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pholcodine-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pholcodine-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pholcodine-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pholcodine-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pholcodine-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pholcodine-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pholcodine-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pholcodine-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pholcodine-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pholcodine-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pholcodine-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pholcodine-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pholcodine-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pholcodine-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"3665","name":"Docetaxel Teva Generics - Article 29 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-07-03T02:00:00Z","last_updated_date":"2012-07-03T02:00:00Z","reference_number":"EMA/586425/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/docetaxel-teva-generics-article-29-referral-assessment-report_en.pdf"},
    {"id":"3691","name":"Canazole - Article 29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-09T01:00:00Z","last_updated_date":"2012-02-09T01:00:00Z","reference_number":"EMEA/H/A-29/1286","document_url":"https://www.ema.europa.eu/en/documents/referral/canazole-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/canazole-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/canazole-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/canazole-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/canazole-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/canazole-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/canazole-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/canazole-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/canazole-article-29-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/canazole-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/canazole-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/canazole-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/canazole-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/canazole-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/canazole-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/canazole-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/canazole-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/canazole-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/canazole-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/canazole-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/canazole-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/canazole-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"3704","name":"Scandonest Article-30 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2018-02-26T12:50:00Z","reference_number":"EMA/CHMP/563882/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/scandonest-article-30-referral-timetable-procedure_en.pdf"},
    {"id":"3784","name":"EMLA cream Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/emla-cream-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/emla-cream-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/emla-cream-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/emla-cream-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/emla-cream-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/emla-cream-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/emla-cream-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/emla-cream-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/emla-cream-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/emla-cream-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/emla-cream-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/emla-cream-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/emla-cream-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/emla-cream-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/emla-cream-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/emla-cream-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/emla-cream-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/emla-cream-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/emla-cream-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/emla-cream-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/emla-cream-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/emla-cream-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/emla-cream-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/emla-cream-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/emla-cream-article-30-referral-annex-iii_no.pdf"}},
    {"id":"3799","name":"Fentanyl-ratiopharm 25/50/75/100 μg/h TTS - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-12-15T00:08:21Z","last_updated_date":"2007-12-15T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fentanyl-ratiopharm-25-50-75-100-mg-h-tts-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"3801","name":"European Medicines Agency recommends that Protelos/Osseor remain available but with further restrictions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/84749/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/european-medicines-agency-recommends-protelososseor-remain-available-further-restrictions_en.pdf"},
    {"id":"3816","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T13:00:00Z","last_updated_date":"2016-03-18T13:00:00Z","reference_number":"EMA/199242/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-review-started_en.pdf"},
    {"id":"3876","name":"Baxter dialysis solutions Article-31 referral - Annex II (US site)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-us-site_sv.pdf"}},
    {"id":"3888","name":"Assessment report for calcitonin containing medicinal products","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T02:00:00Z","last_updated_date":"2013-07-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-calcitonin-containing-medicinal-products_en.pdf"},
    {"id":"3899","name":"Codeine Article-31 referral - Restrictions on use of codeine for pain relief in children – CMDh endorses PRAC recommendation","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-08-02T02:00:00Z","reference_number":"EMA/385716/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/codeine-article-31-referral-restrictions-use-codeine-pain-relief-children-cmdh-endorses-prac-recommendation_sv.pdf"}},
    {"id":"3916","name":"Lovenox Article 30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-22T18:30:00Z","last_updated_date":"2017-03-22T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lovenox-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lovenox-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lovenox-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lovenox-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lovenox-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lovenox-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lovenox-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lovenox-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lovenox-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lovenox-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lovenox-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lovenox-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lovenox-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lovenox-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lovenox-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lovenox-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lovenox-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lovenox-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lovenox-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lovenox-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lovenox-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lovenox-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lovenox-article-30-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/lovenox-article-30-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/lovenox-article-30-referral-annex-ii_no.pdf"}},
    {"id":"3966","name":"Lovenox Article 30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2017-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lovenox-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lovenox-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lovenox-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lovenox-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lovenox-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lovenox-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lovenox-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lovenox-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lovenox-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lovenox-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lovenox-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lovenox-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lovenox-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lovenox-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lovenox-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lovenox-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lovenox-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lovenox-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lovenox-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lovenox-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lovenox-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lovenox-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lovenox-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/lovenox-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/lovenox-article-30-referral-annex-iii_no.pdf"}},
    {"id":"4008","name":"Zinbryta Article-20 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-annex-iii_en.pdf"},
    {"id":"4041","name":"Vascace Plus - Article 30 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-11-09T01:00:00Z","last_updated_date":"2011-11-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vascace-plus-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vascace-plus-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vascace-plus-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vascace-plus-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vascace-plus-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vascace-plus-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vascace-plus-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vascace-plus-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vascace-plus-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vascace-plus-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vascace-plus-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vascace-plus-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vascace-plus-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vascace-plus-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vascace-plus-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vascace-plus-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vascace-plus-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vascace-plus-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vascace-plus-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vascace-plus-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vascace-plus-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vascace-plus-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"4050","name":"Avinew- Article 18 Referral - Summary of product characteristics of the reference member state","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-01-02T00:59:00Z","last_updated_date":"2002-01-02T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/avinew-article-18-referral-summary-product-characteristics-reference-member-state_sv.pdf"}}    {"id":"4071","name":"Semler Article-31 referral – Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-review-started_en.pdf"},
    {"id":"4076","name":"Valproate and related substances Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2014-07-11T19:00:00Z","reference_number":"EMA/PRAC/606970/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"4106","name":"Ergot derivatives Article-31 referral - Dihydroergocryptine - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-ii_sv.pdf"}},
    {"id":"4110","name":"Augmentin - Article 30 - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/augmentin-article-30-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/augmentin-article-30-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/augmentin-article-30-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/augmentin-article-30-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/augmentin-article-30-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/augmentin-article-30-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/augmentin-article-30-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/augmentin-article-30-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/augmentin-article-30-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/augmentin-article-30-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/augmentin-article-30-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/augmentin-article-30-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/augmentin-article-30-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/augmentin-article-30-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/augmentin-article-30-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/augmentin-article-30-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/augmentin-article-30-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/augmentin-article-30-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/augmentin-article-30-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/augmentin-article-30-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/augmentin-article-30-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/augmentin-article-30-annex-iii_sv.pdf"}},
    {"id":"4144","name":"Avelox - Article 6 (12) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-13T02:08:21Z","last_updated_date":"2008-10-13T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/avelox-article-6-12-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"4147","name":"Yvidually Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/yvidually-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/yvidually-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/yvidually-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/yvidually-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/yvidually-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/yvidually-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/yvidually-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/yvidually-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/yvidually-article-294-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/yvidually-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/yvidually-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/yvidually-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/yvidually-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/yvidually-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/yvidually-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/yvidually-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/yvidually-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/yvidually-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/yvidually-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/yvidually-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/yvidually-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/yvidually-article-294-referral-annex-i_sv.pdf"}},
    {"id":"4171","name":"Targocid Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-03T01:00:00Z","last_updated_date":"2014-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/targocid-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/targocid-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/targocid-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/targocid-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/targocid-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/targocid-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/targocid-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/targocid-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/targocid-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/targocid-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/targocid-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/targocid-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/targocid-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/targocid-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/targocid-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/targocid-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/targocid-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/targocid-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/targocid-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/targocid-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/targocid-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/targocid-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/targocid-article-30-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/targocid-article-30-referral-annex-i_no.pdf"}},
    {"id":"4192","name":"Novimp - Article 36 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMEA/H/A-36/1298","document_url":"https://www.ema.europa.eu/en/documents/referral/novimp-article-36-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/novimp-article-36-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/novimp-article-36-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/novimp-article-36-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/novimp-article-36-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/novimp-article-36-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/novimp-article-36-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/novimp-article-36-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/novimp-article-36-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/novimp-article-36-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/novimp-article-36-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/novimp-article-36-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/novimp-article-36-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/novimp-article-36-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/novimp-article-36-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/novimp-article-36-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/novimp-article-36-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/novimp-article-36-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/novimp-article-36-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/novimp-article-36-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/novimp-article-36-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/novimp-article-36-referral-annex-ii_sv.pdf"}},
    {"id":"4201","name":"Questions and answers on the referral for Prokanazol capsules containing itraconazole 100 mg","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:08:21Z","last_updated_date":"2009-07-16T02:08:21Z","reference_number":"EMEA/CHMP/499991/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_sv.pdf"}},
    {"id":"4208","name":"Prograf - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-05-17T01:59:00Z","last_updated_date":"2006-05-17T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/prograf-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/prograf-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/prograf-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/prograf-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/prograf-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/prograf-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/prograf-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/prograf-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/prograf-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/prograf-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/prograf-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/prograf-article-30-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/prograf-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/prograf-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/prograf-article-30-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/prograf-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/prograf-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/prograf-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/prograf-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"4218","name":"Veterinary medicinal products containing tylosin to be administered orally via feed or the drinking water to pigs Article-35 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-05T13:00:00Z","last_updated_date":"2014-09-05T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"4230","name":"Ambroxol and bromhexine Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-04-30T14:00:00Z","reference_number":"EMA/203011/2014 corr. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-review-started_en.pdf"},
    {"id":"4266","name":"Tibocina Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-08T02:00:00Z","last_updated_date":"2014-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tibocina-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tibocina-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tibocina-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tibocina-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tibocina-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tibocina-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tibocina-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tibocina-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tibocina-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tibocina-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tibocina-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tibocina-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tibocina-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tibocina-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tibocina-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tibocina-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tibocina-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tibocina-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tibocina-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tibocina-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tibocina-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tibocina-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tibocina-article-294-referral-annex-i_sv.pdf"}},
    {"id":"4279","name":"Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Lopid and associated names (see Annex I) International Non-Proprietary Name (INN): Gemfibrozil: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-07-30T01:59:00Z","last_updated_date":"2004-07-30T01:59:00Z","reference_number":"EMEA/CHMP/1268/04/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-lopid-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gemfibrozil-background-information_sv.pdf"}},
    {"id":"4294","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T17:00:00Z","last_updated_date":"2013-02-11T17:00:00Z","reference_number":"EMA/84655/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_en.pdf"},
    {"id":"4298","name":"Ketoprofen - Article 107 referral - Annex IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ketoprofen-article-107-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ketoprofen-article-107-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ketoprofen-article-107-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ketoprofen-article-107-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ketoprofen-article-107-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ketoprofen-article-107-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ketoprofen-article-107-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ketoprofen-article-107-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ketoprofen-article-107-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ketoprofen-article-107-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ketoprofen-article-107-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ketoprofen-article-107-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ketoprofen-article-107-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ketoprofen-article-107-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ketoprofen-article-107-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ketoprofen-article-107-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ketoprofen-article-107-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ketoprofen-article-107-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ketoprofen-article-107-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ketoprofen-article-107-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ketoprofen-article-107-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ketoprofen-article-107-referral-annex-iv_sv.pdf"}},
    {"id":"4301","name":"Lincocin Article-34 referral - Questions and answers on Lincocin and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-11-14T16:00:00Z","last_updated_date":"2017-11-14T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lincocin-article-34-referral-questions-and-answers-lincocin-and-its-associated-names_sv.pdf"}},
    {"id":"4303","name":"Opinion following an Article 29(4)  referral for Glucomed and associated names International Non-Proprietary Name (INN): glucosamine hydrochloride: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-12-14T00:08:21Z","last_updated_date":"2006-12-14T00:08:21Z","reference_number":"EMEA/405628/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-glucomed-and-associated-names-international-non-proprietary-name-inn-glucosamine-hydrochloride-background-information_sv.pdf"}},
    {"id":"4317","name":"Porcilis PRRS - Article 6(12) referral - Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-08-18T02:00:00Z","last_updated_date":"2010-08-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/porcilis-prrs-article-612-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"4331","name":"Codeine Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-08-02T02:00:00Z","last_updated_date":"2013-08-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/codeine-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/codeine-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/codeine-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/codeine-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/codeine-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/codeine-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/codeine-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/codeine-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/codeine-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/codeine-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/codeine-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/codeine-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/codeine-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/codeine-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/codeine-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/codeine-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/codeine-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/codeine-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/codeine-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/codeine-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/codeine-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/codeine-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"4337","name":"Hydroxyethyl starch Article-107i procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-review-started_en.pdf"},
    {"id":"4350","name":"Etoricoxib - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-11-21T00:08:21Z","last_updated_date":"2008-11-21T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"4379","name":"Opinion following an Article 29(4) referral for Activelle and associated names\n\nInternational Non-Proprietary Name (INN): estradiol and norethisterone acetate: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-12T02:08:21Z","last_updated_date":"2008-09-12T02:08:21Z","reference_number":"EMEA/CHMP/496102/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-activelle-and-associated-names-international-non-proprietary-name-inn-estradiol-and-norethisterone-acetate-background-information_sv.pdf"}},
    {"id":"4390","name":"Novosis Goserelin - Article 36 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMEA/H/A-36/1295","document_url":"https://www.ema.europa.eu/en/documents/referral/novosis-goserelin-article-36-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/novosis-goserelin-article-36-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/novosis-goserelin-article-36-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/novosis-goserelin-article-36-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/novosis-goserelin-article-36-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/novosis-goserelin-article-36-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/novosis-goserelin-article-36-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/novosis-goserelin-article-36-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/novosis-goserelin-article-36-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/novosis-goserelin-article-36-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/novosis-goserelin-article-36-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/novosis-goserelin-article-36-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/novosis-goserelin-article-36-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/novosis-goserelin-article-36-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/novosis-goserelin-article-36-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/novosis-goserelin-article-36-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/novosis-goserelin-article-36-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/novosis-goserelin-article-36-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/novosis-goserelin-article-36-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/novosis-goserelin-article-36-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/novosis-goserelin-article-36-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/novosis-goserelin-article-36-referral-annex-iii_sv.pdf"}},
    {"id":"4425","name":"Vepesid Article-30 referral -  Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T19:00:00Z","last_updated_date":"2017-07-14T19:00:00Z","reference_number":"EMEA/H/A-30/1425","document_url":"https://www.ema.europa.eu/en/documents/referral/vepesid-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vepesid-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vepesid-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vepesid-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vepesid-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vepesid-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vepesid-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vepesid-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vepesid-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/vepesid-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vepesid-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vepesid-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vepesid-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vepesid-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vepesid-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vepesid-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vepesid-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vepesid-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vepesid-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vepesid-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vepesid-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vepesid-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vepesid-article-30-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/vepesid-article-30-referral-annex-iii_no.pdf"}},
    {"id":"4426","name":"Somatropin - Article 107 referral - Annex IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-23T02:00:00Z","last_updated_date":"2012-04-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/somatropin-article-107-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/somatropin-article-107-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/somatropin-article-107-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/somatropin-article-107-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/somatropin-article-107-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/somatropin-article-107-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/somatropin-article-107-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/somatropin-article-107-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/somatropin-article-107-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/somatropin-article-107-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/somatropin-article-107-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/somatropin-article-107-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/somatropin-article-107-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/somatropin-article-107-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/somatropin-article-107-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/somatropin-article-107-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/somatropin-article-107-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/somatropin-article-107-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/somatropin-article-107-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/somatropin-article-107-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/somatropin-article-107-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/somatropin-article-107-referral-annex-iv_sv.pdf"}},
    {"id":"4433","name":"Bromocriptine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-06T02:00:00Z","last_updated_date":"2013-09-06T02:00:00Z","reference_number":"EMA/541119/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-annex-i_en.pdf"},
    {"id":"4483","name":"Cardioxane Article 13 referral - Questions and answers on Cardioxane (dexrazoxane, powder for solution for injection, 500 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-07-26T02:00:00Z","reference_number":"EMA/184071/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cardioxane-article-13-referral-questions-and-answers-cardioxane-dexrazoxane-powder-solution-injection-500-mg_sv.pdf"}},
    {"id":"4522","name":"Yvidually Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/yvidually-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/yvidually-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/yvidually-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/yvidually-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/yvidually-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/yvidually-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/yvidually-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/yvidually-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/yvidually-article-294-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/yvidually-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/yvidually-article-294-referral-annex-ii_lv.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/yvidually-article-294-referral-annex-ii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/yvidually-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/yvidually-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/yvidually-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/yvidually-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/yvidually-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/yvidually-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/yvidually-article-294-referral-annex-ii_fi.pdf"}},
    {"id":"4574","name":"Maci Article-20 procedure - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-17T01:00:00Z","last_updated_date":"2014-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/maci-article-20-procedure-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/maci-article-20-procedure-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/maci-article-20-procedure-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/maci-article-20-procedure-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/maci-article-20-procedure-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/maci-article-20-procedure-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/maci-article-20-procedure-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/maci-article-20-procedure-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/maci-article-20-procedure-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/maci-article-20-procedure-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/maci-article-20-procedure-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/maci-article-20-procedure-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/maci-article-20-procedure-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/maci-article-20-procedure-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/maci-article-20-procedure-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/maci-article-20-procedure-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/maci-article-20-procedure-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/maci-article-20-procedure-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/maci-article-20-procedure-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/maci-article-20-procedure-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/maci-article-20-procedure-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/maci-article-20-procedure-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/maci-article-20-procedure-annex-ii_sv.pdf"}},
    {"id":"4591","name":"Valproate and related substances Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/valproate-and-related-substances-article-31-referral-annex-iii_no.pdf"}},
    {"id":"4598","name":"Docetaxel Teva Generics - Article 29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-03T02:00:00Z","last_updated_date":"2012-07-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/docetaxel-teva-generics-article-29-referral-annex-iii_sv.pdf"}},
    {"id":"4601","name":"Myoson Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-28T02:00:00Z","last_updated_date":"2015-07-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/myoson-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/myoson-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/myoson-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/myoson-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/myoson-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/myoson-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/myoson-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/myoson-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/myoson-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/myoson-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/myoson-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/myoson-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/myoson-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/myoson-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/myoson-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/myoson-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/myoson-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/myoson-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/myoson-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/myoson-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/myoson-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/myoson-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/myoson-article-294-referral-annex-i_sv.pdf"}},
    {"id":"4613","name":"Renin-angiotensin-system (RAS)-acting agents Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-10-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-ii_no.pdf"}},
    {"id":"4620","name":"Questions and answers on the review of bisphosphonates and atypical stress fractures","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"EMA/288359/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-bisphosphonates-and-atypical-stress-fractures_sv.pdf"}},
    {"id":"4626","name":"Zanil Article-35 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-25T18:30:00Z","last_updated_date":"2017-10-25T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zanil-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zanil-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zanil-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zanil-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zanil-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zanil-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zanil-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zanil-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zanil-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zanil-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zanil-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zanil-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zanil-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zanil-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zanil-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zanil-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zanil-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zanil-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zanil-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zanil-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zanil-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zanil-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zanil-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"4688","name":"Opinion following an Article 33(4) referral for Doxyprex 100mg premix: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T01:59:00Z","last_updated_date":"2008-06-02T01:59:00Z","reference_number":"EMEA/532206/2007- Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-doxyprex-100mg-premix-background-information_sv.pdf"}},
    {"id":"4715","name":"Thiocolchicoside Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-06T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/thiocolchicoside-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/thiocolchicoside-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/thiocolchicoside-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/thiocolchicoside-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/thiocolchicoside-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/thiocolchicoside-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/thiocolchicoside-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/thiocolchicoside-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/thiocolchicoside-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/thiocolchicoside-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/thiocolchicoside-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/thiocolchicoside-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/thiocolchicoside-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/thiocolchicoside-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/thiocolchicoside-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/thiocolchicoside-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/thiocolchicoside-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/thiocolchicoside-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/thiocolchicoside-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/thiocolchicoside-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/thiocolchicoside-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/thiocolchicoside-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/thiocolchicoside-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"4730","name":"Questions and answers on Genotropin and associated names (somatropin injection)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"EMEA/H/A-6(12)/001251","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_lt.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-genotropin-and-associated-names-somatropin-injection_sv.pdf"}},
    {"id":"4737","name":"Questions and answers on Levothyroxine Alapis and associated names (levothyroxine sodium, oral drops, 100 microgram/ml)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2013-02-15T13:30:00Z","reference_number":"EMA/659681/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-levothyroxine-alapis-and-associated-names-levothyroxine-sodium-oral-drops-100-microgramml_sv.pdf"}},
    {"id":"4775","name":"Plendil - Article 30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"EMA/707004/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/plendil-article-30-referral-assessment-report_en.pdf"},
    {"id":"4795","name":"Opinion following an Article 34(1) referral for Baytril 10% oral solution and associated names: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-11-20T10:15:00Z","last_updated_date":"2012-11-20T10:15:00Z","reference_number":"EMA/511421/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-341-referral-baytril-10-oral-solution-and-associated-names-background-information_sv.pdf"}},
    {"id":"4848","name":"Norvasc - Article 30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-03-29T02:00:00Z","last_updated_date":"2012-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/norvasc-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/norvasc-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/norvasc-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/norvasc-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/norvasc-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/norvasc-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/norvasc-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/norvasc-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/norvasc-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/norvasc-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/norvasc-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/norvasc-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/norvasc-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/norvasc-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/norvasc-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/norvasc-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/norvasc-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/norvasc-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/norvasc-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/norvasc-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/norvasc-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/norvasc-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"4862","name":"Bacterial lysate medicines Article 31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/CHMP/346196/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"4888","name":"Retinoid Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/retinoid-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/retinoid-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/retinoid-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/retinoid-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/retinoid-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/retinoid-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/retinoid-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/retinoid-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/retinoid-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/retinoid-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/retinoid-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/retinoid-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/retinoid-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/retinoid-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/retinoid-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/retinoid-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/retinoid-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/retinoid-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/retinoid-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/retinoid-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/retinoid-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/retinoid-article-31-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/retinoid-article-31-referral-annex-i_no.pdf"}},
    {"id":"4889","name":"Hydroxyethyl starch Article-107i procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-06T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_no.pdf"}},
    {"id":"4897","name":"Tetrazepam-containing medicines - Article-107i procedure - Stakeholder's submission form","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T13:00:00Z","last_updated_date":"2013-01-11T13:00:00Z","reference_number":"EMA/639499/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-stakeholders-submission-form_en.pdf"},
    {"id":"4902","name":"Ikorel and Dancor  Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ikorel-and-dancor-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"4918","name":"Opinion following an Article 29 referral Amlovita International Non-Proprietary Name (INN): Amlodipine: Background information and Annex I, II III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-04-26T02:08:21Z","last_updated_date":"2004-04-26T02:08:21Z","reference_number":"EMEA/CPMP/539/04","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-29-referral-amlovita-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_sv.pdf"}},
    {"id":"4929","name":"Opinion following an Article 35 referral for Suramox 15 % LA 2007 and its associated name Stabox 15 % LA: International Non-Proprietary Name (INN): Amoxicillin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-25T01:59:00Z","last_updated_date":"2007-07-25T01:59:00Z","reference_number":"EMEA/301122/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-suramox-15-la-2007-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_sv.pdf"}},
    {"id":"4971","name":"GVK Biosciences Article-31 referral - GVK Biosciences: European Medicines Agency confirms recommendation to suspend medicines over flawed studies","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/324341/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_en.pdf"},
    {"id":"4991","name":"Lipitor - Article 30 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-10T02:00:00Z","last_updated_date":"2012-04-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lipitor-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lipitor-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lipitor-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lipitor-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lipitor-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lipitor-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lipitor-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lipitor-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lipitor-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lipitor-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lipitor-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lipitor-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lipitor-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lipitor-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lipitor-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lipitor-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lipitor-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lipitor-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lipitor-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lipitor-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lipitor-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lipitor-article-30-referral-annex-i_sv.pdf"}},
    {"id":"4998","name":"Zolpidem Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2014-08-04T12:00:00Z","reference_number":"EMA/428277/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/zolpidem-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zolpidem-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zolpidem-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zolpidem-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zolpidem-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zolpidem-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zolpidem-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zolpidem-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zolpidem-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zolpidem-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zolpidem-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zolpidem-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zolpidem-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zolpidem-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zolpidem-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zolpidem-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zolpidem-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zolpidem-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zolpidem-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zolpidem-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zolpidem-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zolpidem-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zolpidem-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/zolpidem-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/zolpidem-article-31-referral-annex-i_no.pdf"}},
    {"id":"5042","name":"Linoladiol N and Linoladiol HN Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-11T02:00:00Z","last_updated_date":"2014-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-i_sv.pdf"}},
    {"id":"5064","name":"Opinion following an Article 30 referral for Remeron and associated names International Non-Proprietary Name (INN): mirtazapine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-16T02:08:21Z","last_updated_date":"2008-09-16T02:08:21Z","reference_number":"EMEA/CHMP/500252/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-remeron-and-associated-names-international-non-proprietary-name-inn-mirtazapine-background-information_sv.pdf"}},
    {"id":"5113","name":"Doramectin - Article-35 referral - Annexes I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-18T02:00:00Z","last_updated_date":"2013-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/doramectin-article-35-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"5140","name":"Paracetamol/ibuprofen 500mg/150mg Article-29(4) referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T02:00:00Z","last_updated_date":"2017-08-18T02:00:00Z","reference_number":"EMA/517503/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-chmp-assessment-report_en.pdf"},
    {"id":"5164","name":"Opinion following an Article 10 referral for Mizollen International Non-Proprietary Name (INN): Mizalostine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-08-03T02:08:21Z","last_updated_date":"1998-08-03T02:08:21Z","reference_number":"CPMP/1500/98 - EN","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-10-referral-mizollen-international-non-proprietary-name-inn-mizalostine-background-information_en.pdf"},
    {"id":"5174","name":"Avalox - Article-29 referrals - Annex I-III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/avalox-article-29-referrals-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/avalox-article-29-referrals-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/avalox-article-29-referrals-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/avalox-article-29-referrals-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/avalox-article-29-referrals-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/avalox-article-29-referrals-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/avalox-article-29-referrals-annex-i-iii_et.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/avalox-article-29-referrals-annex-i-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/avalox-article-29-referrals-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/avalox-article-29-referrals-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/avalox-article-29-referrals-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/avalox-article-29-referrals-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/avalox-article-29-referrals-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/avalox-article-29-referrals-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/avalox-article-29-referrals-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/avalox-article-29-referrals-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/avalox-article-29-referrals-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/avalox-article-29-referrals-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/avalox-article-29-referrals-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/avalox-article-29-referrals-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/avalox-article-29-referrals-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/avalox-article-29-referrals-annex-i-iii_is.pdf"}},
    {"id":"5192","name":"Zydelig Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T13:00:00Z","last_updated_date":"2016-03-18T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-notification_en.pdf"},
    {"id":"5199","name":"Opinion following an Article 34 referral for Methoxasol-t: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-08-02T01:59:00Z","last_updated_date":"2008-08-02T01:59:00Z","reference_number":"EMEA/458933/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-methoxasol-t-background-information_sv.pdf"}},
    {"id":"5218","name":"Opinion following an Article 31 referral for all medicinal products containing Celecoxib, Etoricoxib, Lumiracoxib, Parecoxib, and Valdecoxib International Non-Proprietary Name (INN): Lumiracoxib: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T00:08:21Z","last_updated_date":"2005-11-29T00:08:21Z","reference_number":"EMEA/CHMP/324332/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-lumiracoxib-background_sv.pdf"}},
    {"id":"5224","name":"Opinion following an Article 31 referral for Loratadine International Non-Proprietary Name (INN): loratadine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-04-28T02:08:21Z","last_updated_date":"2004-04-28T02:08:21Z","reference_number":"CPMP/1333/03","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-31-referral-loratadine-international-non-proprietary-name-inn-loratadine-background-information_sv.pdf"}},
    {"id":"5273","name":"Retinoid Article-31 referral - Divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-divergent-position_en.pdf"},
    {"id":"5289","name":"Tredaptive, Pelzont and Trevaclyn suspended across the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-02T01:00:00Z","last_updated_date":"2013-12-02T01:00:00Z","reference_number":"EMA/402540/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tredaptive-pelzont-and-trevaclyn-suspended-across-eu_sv.pdf"}},
    {"id":"5355","name":"Questions and answers on endotoxins in dialysis solutions produced at Baxter manufacturing plant","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"EMA/CHMP/768789/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-endotoxins-dialysis-solutions-produced-baxter-manufacturing-plant_sv.pdf"}},
    {"id":"5387","name":"Myoson Article-29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-28T02:00:00Z","last_updated_date":"2015-07-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/myoson-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/myoson-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/myoson-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/myoson-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/myoson-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/myoson-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/myoson-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/myoson-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/myoson-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/myoson-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/myoson-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/myoson-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/myoson-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/myoson-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/myoson-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/myoson-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/myoson-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/myoson-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/myoson-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/myoson-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/myoson-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/myoson-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/myoson-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"5405","name":"Inhaled corticosteroids Article-31 referral – Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-08T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-notification_en.pdf"},
    {"id":"5437","name":"Seresto Article-13 referral - Questions and answers on Seresto and its associated name Foresto","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-10T02:00:00Z","last_updated_date":"2018-07-10T02:00:00Z","reference_number":"EMA/392857/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seresto-article-13-referral-questions-and-answers-seresto-and-its-associated-name-foresto_sv.pdf"}},
    {"id":"5470","name":"Meronem - Article 30 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2009-12-12T00:59:00Z","last_updated_date":"2009-12-12T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/meronem-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/meronem-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/meronem-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/meronem-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/meronem-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/meronem-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/meronem-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/meronem-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/meronem-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/meronem-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/meronem-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/meronem-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/meronem-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/meronem-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/meronem-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/meronem-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/meronem-article-30-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/meronem-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/meronem-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/meronem-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/meronem-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"5493","name":"Questions and answers on Ethinylestradiol-Drospirenone 24+4 (ethinylestradiol / drospirenone, 0.02 mg/3 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2013-01-11T11:57:00Z","reference_number":"EMA/257547/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-ethinylestradiol-drospirenone-244-ethinylestradiol-drospirenone-002-mg3-mg-tablets_sv.pdf"}},
    {"id":"5496","name":"Emergency contraceptives Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/emergency-contraceptives-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"5505","name":"Esmya Article-20 procedure - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-08-08T02:00:00Z","last_updated_date":"2018-08-08T02:00:00Z","reference_number":"EMA/442745/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-prac-assessment-report_en.pdf"},
    {"id":"5508","name":"Baxter dialysis solutions Article-31 referral - Annex I (US site)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-us-site_sv.pdf"}},
    {"id":"5517","name":"Opinion following an Article 31 referral for Sibutramine International Non-Proprietary Name (INN): Sibutramine: Background information and Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-12-03T00:59:00Z","last_updated_date":"2002-12-03T00:59:00Z","reference_number":"CPMP/4514/02/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-sibutramine-international-non-proprietary-name-inn-sibutramine-background-information-and-annexes-i-ii-iii_en.pdf"},
    {"id":"5532","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-10T15:00:00Z","last_updated_date":"2013-06-10T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iv_sv.pdf"}},
    {"id":"5535","name":"Flupirtine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-12-04T01:00:00Z","reference_number":"EMEA/H/A-31/1458","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-annex-i_en.pdf"},
    {"id":"5537","name":"Tysabri Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-08T14:00:00Z","last_updated_date":"2015-05-08T14:00:00Z","reference_number":"EMA/286215/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/tysabri-article-20-procedure-review-started_en.pdf"},
    {"id":"5565","name":"Retinoid Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2017-12-05T16:35:00Z","reference_number":"EMA/PRAC/461927/2016 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"5581","name":"Oxynal, Targin Article-13 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T17:15:00Z","last_updated_date":"2015-01-27T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/oxynal-targin-article-13-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/oxynal-targin-article-13-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/oxynal-targin-article-13-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/oxynal-targin-article-13-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/oxynal-targin-article-13-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/oxynal-targin-article-13-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/oxynal-targin-article-13-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/oxynal-targin-article-13-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/oxynal-targin-article-13-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/oxynal-targin-article-13-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/oxynal-targin-article-13-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/oxynal-targin-article-13-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/oxynal-targin-article-13-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/oxynal-targin-article-13-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/oxynal-targin-article-13-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/oxynal-targin-article-13-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/oxynal-targin-article-13-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/oxynal-targin-article-13-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/oxynal-targin-article-13-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/oxynal-targin-article-13-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/oxynal-targin-article-13-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/oxynal-targin-article-13-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/oxynal-targin-article-13-referral-annex-ii_sv.pdf"}},
    {"id":"5594","name":"Protium - Article 30 referrals - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2012-01-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/protium-article-30-referrals-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/protium-article-30-referrals-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/protium-article-30-referrals-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/protium-article-30-referrals-annex-iii_cs.pdf","de":"https://www.ema.europa.eu/de/documents/referral/protium-article-30-referrals-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/protium-article-30-referrals-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/protium-article-30-referrals-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/protium-article-30-referrals-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/protium-article-30-referrals-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/protium-article-30-referrals-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/protium-article-30-referrals-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/protium-article-30-referrals-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/protium-article-30-referrals-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/protium-article-30-referrals-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/protium-article-30-referrals-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/protium-article-30-referrals-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/protium-article-30-referrals-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/protium-article-30-referrals-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/protium-article-30-referrals-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/protium-article-30-referrals-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/protium-article-30-referrals-annex-iii_sv.pdf"}},
    {"id":"5599","name":"Calcitonin Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T02:00:00Z","last_updated_date":"2013-07-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/calcitonin-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/calcitonin-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/calcitonin-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/calcitonin-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/calcitonin-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/calcitonin-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/calcitonin-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/calcitonin-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/calcitonin-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/calcitonin-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/calcitonin-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/calcitonin-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/calcitonin-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/calcitonin-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/calcitonin-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/calcitonin-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/calcitonin-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/calcitonin-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/calcitonin-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/calcitonin-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/calcitonin-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/calcitonin-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"5626","name":"Ergot derivatives Article-31 referral - Dihydroergotamine - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-i_no.pdf"}},
    {"id":"5643","name":"Mifepristone Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/mifepristone-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/mifepristone-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/mifepristone-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/mifepristone-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/mifepristone-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/mifepristone-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/mifepristone-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/mifepristone-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/mifepristone-article-294-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/mifepristone-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/mifepristone-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/mifepristone-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/mifepristone-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/mifepristone-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/mifepristone-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/mifepristone-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/mifepristone-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/mifepristone-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/mifepristone-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/mifepristone-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/mifepristone-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/mifepristone-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"5652","name":"Opinion following an Article 33 (4) referral for Poulvac Bursa Plus and associated names: Background information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-10-07T02:00:00Z","last_updated_date":"2010-10-07T02:00:00Z","reference_number":"EMA/698942/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-33-4-referral-poulvac-bursa-plus-and-associated-names-background-information_sv.pdf"}},
    {"id":"5661","name":"Prontax 10 mg/ml solution - Article 33 referral- Annexes I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-05T02:00:00Z","last_updated_date":"2012-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/prontax-10-mgml-solution-article-33-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"5667","name":"Questions and answers on Glimepirida Parke-Davis (glimepiride, tablets, 2, 3 and 4 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T14:00:02Z","last_updated_date":"2012-12-06T13:00:02Z","reference_number":"EMA/480596/2012, Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-glimepirida-parke-davis-glimepiride-tablets-2-3-and-4-mg_sv.pdf"}},
    {"id":"5681","name":"Questions and answers on Fortum and associated names (ceftazidime powder for solution for infusion or injection, 250 mg, 500 mg, 1 g, 2 g, 3 g)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/659330/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-fortum-and-associated-names-ceftazidime-powder-solution-infusion-or-injection-250-mg-500-mg-1-g-2-g-3-g_en.pdf"},
    {"id":"5730","name":"Tazocin - Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tazocin-article-30-referral-assessment-report_en.pdf"},
    {"id":"5744","name":"Summary information on referral opinion pursuant to Article 6(13) of Commission Regulation (EC) No 1084/2003 for Seretide Evohaler and associated names (See Annex I) International Non-Proprietary Name (INN): salmeterol /...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-07-04T02:08:00Z","last_updated_date":"2006-07-04T02:08:00Z","reference_number":"EMEA/306351/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol_sv.pdf"}},
    {"id":"5783","name":"Assessment report for Tienam and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-20T01:00:00Z","last_updated_date":"2012-02-20T01:00:00Z","reference_number":"EMA/513740/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-tienam-and-associated-names_en.pdf"},
    {"id":"5819","name":"HPV vaccines - Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-13T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMA/454979/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-review-started_en.pdf"},
    {"id":"5830","name":"Adrenaline auto-injectors Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"EMA/CHMP/225801/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"5835","name":"Questions and answers on Kantos Master and associated names (beclomethasone dipropionate / formoterol fumarate, inhaler)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T01:00:00Z","last_updated_date":"2013-05-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-kantos-master-and-associated-names-beclomethasone-dipropionate-formoterol-fumarate-inhaler_sv.pdf"}},
    {"id":"5864","name":"Opinion following an Article 31 referral for all medicinal products containing Celecoxib, Etoricoxib, Parecoxib, Rofecoxib or Valdecoxib International Non-Proprietary Name (INN): Rofecoxib: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-04-30T02:08:21Z","last_updated_date":"2004-04-30T02:08:21Z","reference_number":"EMEA/CPMP/1749/04","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-parecoxib-rofecoxib-or-valdecoxib-international-non-proprietary-name-inn-rofecoxib-background-information_en.pdf"},
    {"id":"5885","name":"Strenzen 500/125mg/g Article-33(4) referral - Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-19T02:00:00Z","last_updated_date":"2013-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/strenzen-500125mgg-article-334-referral-annex-i-iii_sv.pdf"}},
    {"id":"5903","name":"Semler Article-31 referral – Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T15:00:00Z","last_updated_date":"2016-11-17T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/semler-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/semler-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/semler-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/semler-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/semler-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/semler-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/semler-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/semler-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/semler-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/semler-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/semler-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/semler-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/semler-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/semler-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/semler-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/semler-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/semler-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/semler-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/semler-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/semler-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/semler-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/semler-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"5922","name":"Opinion following an Article 7(5) referral norditropin International Non-Proprietary Name (INN): Somatropin: Background information and Annexes I, II (English) and Annex III (all languages)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-06-26T02:08:00Z","last_updated_date":"2003-06-26T02:08:00Z","reference_number":"CPMP/3478/03","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-75-referral-norditropin-international-non-proprietary-name-inn-somatropin-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_sv.pdf"}},
    {"id":"5924","name":"Docetaxel Teva Generics - Article 29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-03T02:00:00Z","last_updated_date":"2012-07-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/docetaxel-teva-generics-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"5942","name":"Tavanic - Article 30 referral - Annex III (tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T15:00:00Z","last_updated_date":"2012-09-12T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tavanic-article-30-referral-annex-iii-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tavanic-article-30-referral-annex-iii-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tavanic-article-30-referral-annex-iii-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tavanic-article-30-referral-annex-iii-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tavanic-article-30-referral-annex-iii-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tavanic-article-30-referral-annex-iii-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tavanic-article-30-referral-annex-iii-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tavanic-article-30-referral-annex-iii-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tavanic-article-30-referral-annex-iii-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tavanic-article-30-referral-annex-iii-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tavanic-article-30-referral-annex-iii-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tavanic-article-30-referral-annex-iii-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tavanic-article-30-referral-annex-iii-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tavanic-article-30-referral-annex-iii-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tavanic-article-30-referral-annex-iii-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tavanic-article-30-referral-annex-iii-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tavanic-article-30-referral-annex-iii-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tavanic-article-30-referral-annex-iii-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tavanic-article-30-referral-annex-iii-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tavanic-article-30-referral-annex-iii-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tavanic-article-30-referral-annex-iii-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tavanic-article-30-referral-annex-iii-tablets_sv.pdf"}}    {"id":"5947","name":"Tolperisone Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tolperisone-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tolperisone-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tolperisone-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tolperisone-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tolperisone-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tolperisone-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tolperisone-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tolperisone-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tolperisone-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tolperisone-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tolperisone-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tolperisone-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tolperisone-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tolperisone-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tolperisone-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tolperisone-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tolperisone-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tolperisone-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tolperisone-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tolperisone-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tolperisone-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tolperisone-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"5998","name":"Summary information on referral opinion pursuant to Article 6(13) of Commission Regulation (EC) No 1084/2003 for Viani Evohaler and associated names (See Annex I) International Non-Proprietary Name (INN): salmeterol / fl...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-07-04T00:08:00Z","last_updated_date":"2006-07-04T00:08:00Z","reference_number":"EMEA/306455/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-viani-evohaler-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-fl_sv.pdf"}},
    {"id":"6011","name":"Methadone Article-107i procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-review-started_en.pdf"},
    {"id":"6028","name":"Opinion following an Article 31 referral for Calcitonins containing medicinal products International Non-Proprietary Name (INN): Calcitonin: Background information and Annexes I,II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-02-28T00:08:21Z","last_updated_date":"2004-02-28T00:08:21Z","reference_number":"CPMP/867/04","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-calcitonins-containing-medicinal-products-international-non-proprietary-name-inn-calcitonin-background-information-and-annexes-iii_en.pdf"},
    {"id":"6043","name":"Buflomedil - Article 107 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-13T02:00:00Z","last_updated_date":"2012-06-13T02:00:00Z","reference_number":"EMA/CHMP/83070/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/buflomedil-article-107-referral-assessment-report_en.pdf"},
    {"id":"6088","name":"Linco-Spectin 100 and associated names: Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-04T02:00:00Z","last_updated_date":"2014-09-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/linco-spectin-100-and-associated-names-annex-i-ii-iii_sv.pdf"}},
    {"id":"6110","name":"Opinion following an Article 30 referral for Cozaar and associated names International Non-Proprietary Name (INN): losartan: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-03T02:08:21Z","last_updated_date":"2008-09-03T02:08:21Z","reference_number":"EMEA/CHMP/494721/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-cozaar-and-associated-names-international-non-proprietary-name-inn-losartan-background-information_sv.pdf"}},
    {"id":"6113","name":"Zolpidem Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-12-06T16:45:00Z","reference_number":"EMA/PRAC/418739/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/zolpidem-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"6118","name":"Questions and answers on the review of calcitonin-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T17:00:00Z","last_updated_date":"2012-07-20T17:00:00Z","reference_number":"EMA/476001/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-calcitonin-containing-medicines_en.pdf"},
    {"id":"6119","name":"Corlentor and Procoralan Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-02-16T01:00:00Z","last_updated_date":"2015-02-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/corlentor-and-procoralan-article-20-procedure-annex-iv_sv.pdf"}},
    {"id":"6131","name":"Questions and answers on the review of antifibrinolytic medicines (aprotinin, aminocaproic acid and tranexamic acid)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T11:09:53Z","last_updated_date":"2013-11-06T18:00:00Z","reference_number":"EMA/CHMP/116572/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid_sv.pdf"}},
    {"id":"6132","name":"Paracetamol Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-01T01:00:00Z","last_updated_date":"2018-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paracetamol-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paracetamol-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paracetamol-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paracetamol-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paracetamol-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paracetamol-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paracetamol-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paracetamol-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paracetamol-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paracetamol-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paracetamol-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paracetamol-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paracetamol-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paracetamol-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paracetamol-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paracetamol-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paracetamol-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paracetamol-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paracetamol-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paracetamol-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paracetamol-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paracetamol-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"6143","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Sovaldi Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T01:00:00Z","last_updated_date":"2017-03-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-sovaldi-annex-i-iii_no.pdf"}},
    {"id":"6169","name":"Bromocriptine Article-31 referral - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-09-06T02:00:00Z","last_updated_date":"2013-09-06T02:00:00Z","reference_number":"EMA/PRAC/493207/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"6241","name":"Questions and answers on the review of Piroxicam","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-06-21T02:08:21Z","last_updated_date":"2007-06-21T02:08:21Z","reference_number":"EMEA/264578/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-piroxicam_en.pdf"},
    {"id":"6260","name":"Tolperisone Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tolperisone-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tolperisone-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tolperisone-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tolperisone-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tolperisone-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tolperisone-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tolperisone-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tolperisone-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tolperisone-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tolperisone-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tolperisone-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tolperisone-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tolperisone-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tolperisone-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tolperisone-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tolperisone-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tolperisone-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tolperisone-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tolperisone-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tolperisone-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tolperisone-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tolperisone-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"6261","name":"Iclusig Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-06T13:00:00Z","last_updated_date":"2013-12-06T13:00:00Z","reference_number":"EMA/PRAC/746091/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"6308","name":"Paracetamol Article-31 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-01T01:00:00Z","last_updated_date":"2018-03-01T01:00:00Z","reference_number":"EMA/94286/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"6316","name":"Flupirtine-containing medicines Article-107i procedure - PRAC list of questions to be addressed by the stakeholders","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-08T13:00:00Z","last_updated_date":"2013-03-08T13:00:00Z","reference_number":"EMA/PRAC/144072/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-prac-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"6364","name":"Zydelig Article-20 procedure - EMA recommends new safety measures for Zydelig","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T13:00:00Z","last_updated_date":"2016-03-18T13:00:00Z","reference_number":"EMA/201814/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zydelig-article-20-procedure-ema-recommends-new-safety-measures-zydelig_sv.pdf"}},
    {"id":"6372","name":"Seroquel, Seroquel XR and associated names Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-09T02:00:00Z","last_updated_date":"2014-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"6375","name":"Summary information on referral opinion pursuant to Article 6(13) of Commisssion Regulation (EC) No 1084/2003 for Viani Diskus and associated names (See Annex I) International Non-Proprietary Name (INN): salmeterol / flu...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-07-04T00:08:00Z","last_updated_date":"2006-07-04T00:08:00Z","reference_number":"EMEA/306421/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-613-commisssion-regulation-ec-no-10842003-viani-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-flu_sv.pdf"}},
    {"id":"6377","name":"Cilostazol - Article-31 referral - Product information as approved by the CHMP on 21 March 2013, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-22T01:00:00Z","last_updated_date":"2013-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cilostazol-article-31-referral-product-information-approved-chmp-21-march-2013-pending-endorsement-european-commission_en.pdf"},
    {"id":"6379","name":"CMDh endorses suspension of methadone oral solutions containing high molecular weight povidone","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-07-24T02:00:00Z","last_updated_date":"2014-07-24T02:00:00Z","reference_number":"EMA/444346/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cmdh-endorses-suspension-methadone-oral-solutions-containing-high-molecular-weight-povidone_sv.pdf"}},
    {"id":"6443","name":"Ergot derivatives Article-31 referral - Dihydroergotoxine - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-i_sv.pdf"}},
    {"id":"6459","name":"Questions and answers on Seasonique and associated names (levonorgestrel / ethinylestradiol)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"EMA/383921/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-seasonique-and-associated-names-levonorgestrel-ethinylestradiol_sv.pdf"}},
    {"id":"6465","name":"Substances related to nicotinic acid Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-13T18:00:00Z","last_updated_date":"2014-03-13T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-i_sv.pdf"}},
    {"id":"6468","name":"Fibrates (bezafibrate, ciprofibrate, fenofibrate and gemfibrozil) - Article-31 referral - changes to product information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrates-bezafibrate-ciprofibrate-fenofibrate-and-gemfibrozil-article-31-referral-changes-product-information_en.pdf"},
    {"id":"6473","name":"Questions and answers on Tavanic (levofloxacin; 250 and 500 mg film-coated tablets and 5mg/ml solution for infusion)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T15:00:00Z","last_updated_date":"2012-09-12T15:00:00Z","reference_number":"EMA/332109/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-tavanic-levofloxacin-250-and-500-mg-film-coated-tablets-and-5mgml-solution-infusion_sv.pdf"}},
    {"id":"6480","name":"Questions and answers on Ikorel, Dancor and associated names (nicorandil, 10 and 20 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T14:00:00Z","last_updated_date":"2015-06-30T15:00:00Z","reference_number":"EMA/199003/2015 ","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-ikorel-dancor-and-associated-names-nicorandil-10-and-20-mg-tablets_sv.pdf"}},
    {"id":"6491","name":"Poulvac Bursa Plus - Article 33 (4) referral - Annexes I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-10-07T02:00:00Z","last_updated_date":"2010-10-07T02:00:00Z","reference_number":"EMA/698942/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/poulvac-bursa-plus-article-33-4-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"6503","name":"Almitrine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-10T02:00:00Z","last_updated_date":"2013-06-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-referral-annex-i_en.pdf"},
    {"id":"6511","name":"Codeine Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-18T02:00:00Z","last_updated_date":"2015-05-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/codeine-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/codeine-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/codeine-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/codeine-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/codeine-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/codeine-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/codeine-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/codeine-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/codeine-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/codeine-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/codeine-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/codeine-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/codeine-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/codeine-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/codeine-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/codeine-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/codeine-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/codeine-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/codeine-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/codeine-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/codeine-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/codeine-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"6517","name":"Divergent position on a CVMP opinion on an Article 34(1) referral of Directive 2001/82/EC for Baytril 10% oral solution and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-20T10:15:00Z","last_updated_date":"2012-11-20T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-341-referral-directive-200182ec-baytril-10-oral-solution-and-associated-names_en.pdf"},
    {"id":"6522","name":"Metformin Article-31 referral - Changes to product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-changes-product-information_en.pdf"},
    {"id":"6555","name":"Methylphenidate Hexal Article-29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-05T01:00:00Z","last_updated_date":"2013-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methylphenidate-hexal-article-29-referral-annex-i_sv.pdf"}},
    {"id":"6578","name":"Retinoid Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"EMA/459912/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-review-started_en.pdf"},
    {"id":"6603","name":"Fenofibrato Pensa and Fenofibrato Ranbaxy Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-ii_fi.pdf"}},
    {"id":"6606","name":"Okrido Article-29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-03T01:00:00Z","last_updated_date":"2014-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/okrido-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/okrido-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/okrido-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/okrido-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/okrido-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/okrido-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/okrido-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/okrido-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/okrido-article-29-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/okrido-article-29-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/okrido-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/okrido-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/okrido-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/okrido-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/okrido-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/okrido-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/okrido-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/okrido-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/okrido-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/okrido-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/okrido-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/okrido-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/okrido-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"6621","name":"Kogenate Bayer and Helixate NexGen Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-03-08T01:00:00Z","reference_number":"EMA/136663/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-review-started_en.pdf"},
    {"id":"6624","name":"Intravenous iron-containing medicinal products Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-01T02:00:00Z","last_updated_date":"2013-10-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"6630","name":"Saroten Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"EMA/255467/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/saroten-article-30-referral-assessment-report_en.pdf"},
    {"id":"6631","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Addendum to PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-15T14:00:00Z","last_updated_date":"2016-04-15T14:00:00Z","reference_number":"EMA/PRAC/196081/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-addendum-prac-list-questions_en.pdf"},
    {"id":"6633","name":"European Medicines Agency finalises review of antidepressants in children\n\nand adolescents","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-04-25T02:08:21Z","last_updated_date":"2005-04-25T02:08:21Z","reference_number":"EMEA/CHMP/128918/2005 corr","document_url":"https://www.ema.europa.eu/en/documents/referral/european-medicines-agency-finalises-review-antidepressants-children-and-adolescents_en.pdf"},
    {"id":"6656","name":"Opinion following an Article 6(12) referral for Sortis International Non-Proprietary Name (INN): atorvastatin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-05-22T02:08:21Z","last_updated_date":"2006-05-22T02:08:21Z","reference_number":"CHMP/477258/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-612-referral-sortis-international-non-proprietary-name-inn-atorvastatin-background-information_sv.pdf"}},
    {"id":"6662","name":"Final opinion of the Committee for proprietary medicinal products in accordance with Article 12 of Directive 75/319/EEC as amended for Anoretics International Non-Proprietary Name (INN): Type I and Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1996-12-10T00:08:21Z","last_updated_date":"1996-12-10T00:08:21Z","reference_number":"CPMP/101-109/96","document_url":"https://www.ema.europa.eu/en/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-i-and-annex-i_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-i-and-annex-i_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-i-and-annex-i_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-i-and-annex-i_fr.pdf"}},
    {"id":"6665","name":"Metoclopramide Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metoclopramide-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metoclopramide-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metoclopramide-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metoclopramide-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metoclopramide-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metoclopramide-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metoclopramide-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metoclopramide-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metoclopramide-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metoclopramide-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metoclopramide-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metoclopramide-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metoclopramide-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metoclopramide-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metoclopramide-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metoclopramide-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metoclopramide-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metoclopramide-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metoclopramide-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metoclopramide-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metoclopramide-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metoclopramide-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metoclopramide-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/metoclopramide-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/metoclopramide-article-31-referral-annex-iii_no.pdf"}},
    {"id":"6688","name":"Questions and answers on Lipitor and associated names (atorvastatin, 10, 20, 40 and 80 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2012-04-10T02:00:00Z","reference_number":"EMA/595578/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_sv.pdf"}},
    {"id":"6695","name":"Nanotop Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T17:00:00Z","last_updated_date":"2014-06-16T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nanotop-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nanotop-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nanotop-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nanotop-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nanotop-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nanotop-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nanotop-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nanotop-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nanotop-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nanotop-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nanotop-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nanotop-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nanotop-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nanotop-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nanotop-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nanotop-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nanotop-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nanotop-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nanotop-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nanotop-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nanotop-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nanotop-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nanotop-article-294-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/nanotop-article-294-referral-annex-iii_no.pdf"}},
    {"id":"6719","name":"Diclofenac Article-31 referral - Divergent position to CMDh position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T12:40:00Z","last_updated_date":"2013-11-27T12:40:00Z","reference_number":"EMEA/H/A-31/1344","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-divergent-position-cmdh-position_en.pdf"},
    {"id":"6741","name":"Esmya Article-20 procedure - Esmya: new measures to minimise risk of rare but serious liver injury","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T02:00:00Z","last_updated_date":"2018-06-01T02:00:00Z","reference_number":"EMA/355940/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_en.pdf"},
    {"id":"6743","name":"Sandimmun Neoral Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T12:00:00Z","last_updated_date":"2013-12-20T12:00:00Z","reference_number":"EMEA/H/A-30/1300","document_url":"https://www.ema.europa.eu/en/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sandimmun-neoral-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"6761","name":"Tetrazepam-containing medicines Article-107i procedure - PRAC recommends suspension of tetrazepam-containing medicines: Questions and answers","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-12T14:00:00Z","last_updated_date":"2013-04-12T14:00:00Z","reference_number":"EMA/225675/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-prac-recommends-suspension-tetrazepam-containing-medicines-questions-and-answers_en.pdf"},
    {"id":"6773","name":"Assessment report for Zinnat and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-01-29T01:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"EMA/CHMP/633839/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-zinnat-and-associated-names_en.pdf"},
    {"id":"6792","name":"Opinion of the Committee for proprietary medicinal products pursuant to Article 12 of Council Directive 75/319/EEC as amended for Terfenadine and Pseudoephedrine hydrochloride and Annexes A and B","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-01-22T00:08:21Z","last_updated_date":"1998-01-22T00:08:21Z","reference_number":"CPMP/1001/97-EN","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-and-pseudoephedrine-hydrochloride-and-annexes-and-b_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-and-pseudoephedrine-hydrochloride-and-annexes-and-b_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-and-pseudoephedrine-hydrochloride-and-annexes-and-b_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-and-pseudoephedrine-hydrochloride-and-annexes-and-b_fr.pdf"}},
    {"id":"6803","name":"Diacerein Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-19T02:00:00Z","last_updated_date":"2014-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diacerein-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diacerein-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diacerein-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diacerein-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diacerein-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diacerein-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diacerein-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diacerein-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diacerein-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diacerein-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diacerein-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diacerein-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diacerein-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diacerein-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diacerein-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diacerein-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diacerein-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diacerein-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diacerein-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diacerein-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diacerein-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diacerein-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"6807","name":"Kantos Master Article-13 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-02T12:00:00Z","last_updated_date":"2013-05-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kantos-master-article-13-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/kantos-master-article-13-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/kantos-master-article-13-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/kantos-master-article-13-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/kantos-master-article-13-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/kantos-master-article-13-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/kantos-master-article-13-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/kantos-master-article-13-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/kantos-master-article-13-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/kantos-master-article-13-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/kantos-master-article-13-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/kantos-master-article-13-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/kantos-master-article-13-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/kantos-master-article-13-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/kantos-master-article-13-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/kantos-master-article-13-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/kantos-master-article-13-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/kantos-master-article-13-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/kantos-master-article-13-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/kantos-master-article-13-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/kantos-master-article-13-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/kantos-master-article-13-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/kantos-master-article-13-referral-annex-iii_no.pdf"}},
    {"id":"6824","name":"Valproate Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/198940/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"6827","name":"Bromocriptine Article-31 referral - CMDh endorses restricted use of bromocriptine for stopping breast milk production","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-21T02:00:00Z","last_updated_date":"2014-08-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-cmdh-endorses-restricted-use-bromocriptine-stopping-breast-milk-production_en.pdf"},
    {"id":"6891","name":"Esmya Article-20 procedure - Assessment report on provisional measures","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-02-21T15:05:00Z","last_updated_date":"2018-02-21T15:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-assessment-report-provisional-measures_en.pdf"},
    {"id":"6905","name":"SGLT2 inhibitors Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-12T14:00:00Z","last_updated_date":"2015-06-12T14:00:00Z","reference_number":"EMA/390062/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-review-started_en.pdf"},
    {"id":"6924","name":"Ergot derivatives Article-31 referral - Dihydroergocryptine - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iv_sv.pdf"}},
    {"id":"6934","name":"Flupirtine-containing medicines Article-107i procedure - Restrictions in the use of flupirtine-containing medicines - CMDh endorses PRAC recommendation","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/384191/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines-cmdh-endorses-prac-recommendation_en.pdf"},
    {"id":"6935","name":"Orlistat - Article 31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-21T01:00:00Z","last_updated_date":"2012-12-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/orlistat-article-31-referral-annex-ii_en.pdf"},
    {"id":"6948","name":"Zinbryta Article-20 referral - Summary of provisional measures","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-07T02:00:00Z","last_updated_date":"2017-11-17T01:00:00Z","reference_number":"EMA/424159/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinbryta-article-20-referral-summary-provisional-measures_sv.pdf"}},
    {"id":"6977","name":"Flolan - Article 30 - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-09-14T02:00:00Z","last_updated_date":"2012-09-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flolan-article-30-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flolan-article-30-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flolan-article-30-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flolan-article-30-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flolan-article-30-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flolan-article-30-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flolan-article-30-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flolan-article-30-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flolan-article-30-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flolan-article-30-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flolan-article-30-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flolan-article-30-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flolan-article-30-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flolan-article-30-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flolan-article-30-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flolan-article-30-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flolan-article-30-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flolan-article-30-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flolan-article-30-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flolan-article-30-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flolan-article-30-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flolan-article-30-annex-ii_sv.pdf"}},
    {"id":"6982","name":"Nasonex Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2015-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nasonex-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nasonex-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nasonex-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nasonex-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nasonex-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nasonex-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nasonex-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nasonex-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nasonex-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nasonex-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nasonex-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nasonex-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nasonex-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nasonex-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nasonex-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nasonex-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nasonex-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nasonex-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nasonex-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nasonex-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nasonex-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nasonex-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nasonex-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/nasonex-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/nasonex-article-30-referral-annex-iii_no.pdf"}},
    {"id":"6986","name":"Remeron - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-13T02:08:21Z","last_updated_date":"2008-10-13T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/remeron-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/remeron-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/remeron-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/remeron-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/remeron-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/remeron-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/remeron-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/remeron-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/remeron-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/remeron-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/remeron-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/remeron-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/remeron-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/remeron-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/remeron-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/remeron-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/remeron-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/remeron-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/remeron-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/remeron-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/remeron-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/remeron-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"7000","name":"Almitrine Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"EMA/750601/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-referral-review-started_en.pdf"},
    {"id":"7016","name":"European Medicines Agency gives recommendations on the use of intravenous nicardipine","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-12T13:00:00Z","last_updated_date":"2014-03-12T13:00:00Z","reference_number":"EMA/14811/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_sv.pdf"}},
    {"id":"7041","name":"Opinion following an Article 34 referral for Doxycycline 50% WSP and associated names: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-08-23T02:00:00Z","last_updated_date":"2011-08-23T02:00:00Z","reference_number":"EMA/507899/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-doxycycline-50-wsp-and-associated-names-background-information_sv.pdf"}},
    {"id":"7043","name":"Vascace Plus - Article 30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-10-27T02:00:00Z","last_updated_date":"2011-11-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vascace-plus-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vascace-plus-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vascace-plus-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vascace-plus-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vascace-plus-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vascace-plus-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vascace-plus-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vascace-plus-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vascace-plus-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vascace-plus-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vascace-plus-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vascace-plus-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vascace-plus-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vascace-plus-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vascace-plus-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vascace-plus-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vascace-plus-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vascace-plus-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vascace-plus-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vascace-plus-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vascace-plus-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vascace-plus-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"7058","name":"Fusafungine Article-31 referral - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-09-11T02:00:00Z","last_updated_date":"2015-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"7122","name":"Leflunomide Actavis Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leflunomide-actavis-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leflunomide-actavis-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leflunomide-actavis-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leflunomide-actavis-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leflunomide-actavis-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leflunomide-actavis-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leflunomide-actavis-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leflunomide-actavis-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leflunomide-actavis-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leflunomide-actavis-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leflunomide-actavis-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leflunomide-actavis-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leflunomide-actavis-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leflunomide-actavis-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leflunomide-actavis-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leflunomide-actavis-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leflunomide-actavis-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leflunomide-actavis-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leflunomide-actavis-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leflunomide-actavis-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leflunomide-actavis-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leflunomide-actavis-article-31-referral-annex-i_sv.pdf"}},
    {"id":"7131","name":"Opinion following an Article 34 referral for Tiamutin premix and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-07-21T02:00:00Z","last_updated_date":"2010-07-30T02:00:00Z","reference_number":"EMA/118068/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-tiamutin-premix-and-associated-names_sv.pdf"}},
    {"id":"7136","name":"Furosemide Vitabalans Article-29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-07-30T17:30:00Z","last_updated_date":"2013-07-30T17:30:00Z","reference_number":"EMA/254361/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/furosemide-vitabalans-article-294-referral-assessment-report_en.pdf"},
    {"id":"7204","name":"Questions and answers on the suspension of medicines containing sibutramine","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-01-21T01:00:00Z","last_updated_date":"2010-09-15T02:00:00Z","reference_number":"EMA/808179/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-suspension-medicines-containing-sibutramine_sv.pdf"}},
    {"id":"7214","name":"Protelos and Osseor Article-20 procedure: PRAC List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T14:00:00Z","last_updated_date":"2013-05-17T14:00:00Z","reference_number":"EMA/PRAC/283429/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/protelos-and-osseor-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"7278","name":"CMDh endorses new advice to minimise risk of next-morning impaired driving ability and mental alertness with zolpidem","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T18:00:00Z","last_updated_date":"2014-04-25T18:00:00Z","reference_number":"EMA/240581/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/cmdh-endorses-new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_en.pdf"},
    {"id":"7298","name":"Questions and answers on Haldol and associated names (haloperidol tablets, oral solutions and injectable solution)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T13:00:00Z","last_updated_date":"2017-05-05T19:00:00Z","reference_number":"EMA/122476/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-haldol-and-associated-names-haloperidol-tablets-oral-solutions-and-injectable-solution_sv.pdf"}},
    {"id":"7303","name":"Goserelin Cell Pharm - Article 36 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/goserelin-cell-pharm-article-36-referral-assessment-report_en.pdf"},
    {"id":"7334","name":"Protelos and Osseor Article-20 procedure - Protelos/Osseor to remain available but with further restrictions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-18T02:00:00Z","last_updated_date":"2014-09-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/protelos-and-osseor-article-20-procedure-protelososseor-remain-available-further-restrictions_sv.pdf"}},
    {"id":"7350","name":"Opinion following an Article 29(4) referral for Ciprofloxacin Nycomed and associated names International Non-Proprietary Name (INN): Ciprofloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-01-24T00:08:21Z","last_updated_date":"2008-01-24T00:08:21Z","reference_number":"EMEA/CHMP/350278/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-ciprofloxacin-nycomed-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_sv.pdf"}},
    {"id":"7360","name":"Linoladiol N and Linoladiol HN Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-11T02:00:00Z","last_updated_date":"2014-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"7372","name":"Domperidone Article-31 referral - Restrictions on the use of domperidone-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-11T02:00:00Z","last_updated_date":"2014-09-11T02:00:00Z","reference_number":"EMA/465179/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_sv.pdf"}},
    {"id":"7384","name":"Hydroxyethyl starch Article-107i referral - Rationale for triggering","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-rationale-triggering_en.pdf"},
    {"id":"7404","name":"Renitec - Article 30 referral - Summary of product characteristics","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-12-02T00:08:21Z","last_updated_date":"2003-12-02T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/renitec-article-30-referral-summary-product-characteristics_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/renitec-article-30-referral-summary-product-characteristics_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/renitec-article-30-referral-summary-product-characteristics_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/renitec-article-30-referral-summary-product-characteristics_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/renitec-article-30-referral-summary-product-characteristics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/renitec-article-30-referral-summary-product-characteristics_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/renitec-article-30-referral-summary-product-characteristics_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/renitec-article-30-referral-summary-product-characteristics_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/renitec-article-30-referral-summary-product-characteristics_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/renitec-article-30-referral-summary-product-characteristics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/renitec-article-30-referral-summary-product-characteristics_sv.pdf"}},
    {"id":"7411","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T13:00:00Z","last_updated_date":"2016-03-18T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-notification_en.pdf"},
    {"id":"7457","name":"Flupirtine Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-05-04T02:00:00Z","last_updated_date":"2018-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flupirtine-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flupirtine-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flupirtine-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flupirtine-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flupirtine-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flupirtine-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flupirtine-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flupirtine-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flupirtine-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flupirtine-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flupirtine-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flupirtine-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flupirtine-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flupirtine-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flupirtine-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flupirtine-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flupirtine-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flupirtine-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flupirtine-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flupirtine-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flupirtine-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flupirtine-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"7484","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Stakeholder's submission form","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T17:00:00Z","last_updated_date":"2013-02-11T17:00:00Z","reference_number":"EMA/639499/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-stakeholders-submission-form_en.pdf"},
    {"id":"7504","name":"Esmya Article-20 procedure - Esmya: new measures to minimise risk of rare but serious liver injury","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-08-08T02:00:00Z","last_updated_date":"2018-08-08T02:00:00Z","reference_number":"EMA/482522/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/esmya-article-20-procedure-esmya-new-measures-minimise-risk-rare-serious-liver-injury_sv.pdf"}},
    {"id":"7518","name":"Opinion following an Article 31 referral for Cisapride International Non-Proprietary Name (INN): Cisapride: Background information and Annexes I, II and IV (English) and Annex III (all languages)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-10-08T01:59:00Z","last_updated_date":"2002-10-08T01:59:00Z","reference_number":"EMEA/CPMP/24844/02","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-31-referral-cisapride-international-non-proprietary-name-inn-cisapride-background-information-and-annexes-i-ii-and-iv-english-and-annex-iii-all-languages_sv.pdf"}},
    {"id":"7545","name":"Opinion following an article 33 referral for Orbax","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-11T02:00:00Z","last_updated_date":"2014-08-11T02:00:00Z","reference_number":"EMA/249446/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-orbax_en.pdf"},
    {"id":"7559","name":"Opinion following an Article 35 referral for veterinary medicinal products which contain the active substances trimethoprim and sulfadiazine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-08-02T01:59:00Z","last_updated_date":"2008-08-02T01:59:00Z","reference_number":"EMEA/457286/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-which-contain-active-substances-trimethoprim-and-sulfadiazine-background-information_sv.pdf"}},
    {"id":"7571","name":"Diclofenac Article-29 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-10-10T02:00:00Z","last_updated_date":"2016-10-10T02:00:00Z","reference_number":"EMA/629122/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-29-referral-assessment-report_en.pdf"},
    {"id":"7605","name":"Questions and answers on the review of the marketing authorisations for topical formulations of ketoprofen","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"EMA/465107/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-marketing-authorisations-topical-formulations-ketoprofen_sv.pdf"}},
    {"id":"7628","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T13:00:00Z","last_updated_date":"2016-10-28T14:00:00Z","reference_number":"EMA/PRAC/196120/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"7635","name":"Inhaled corticosteroids Article-31 referral – PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-15T02:00:00Z","last_updated_date":"2016-07-15T02:00:00Z","reference_number":"EMA/330021/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"7654","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP list of questions to be addressed by the API manufacturers for valsartan-containing medicinal products","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T16:34:00Z","last_updated_date":"2018-07-17T16:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-list-questions-be-addressed-api-manufacturers-valsartan-containing-medicinal-products_en.pdf"},
    {"id":"7661","name":"Opinion following an Article-35 referral for all veterinary medicinal products containing active substances belonging to the class of flukicides for which no maximum residue limit has been established in milk and which a...","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T01:00:00Z","last_updated_date":"2013-01-18T01:00:00Z","reference_number":"EMA/759491/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which_sv.pdf"}}    {"id":"7670","name":"Assessment report for ergot derivatives containing medicinal products - dihydroergotoxine","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"EMA/750630/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-ergot-derivatives-containing-medicinal-products-dihydroergotoxine_en.pdf"},
    {"id":"7690","name":"Vokanamet Article-20 procedure - Annex I - III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-18T02:00:00Z","last_updated_date":"2016-05-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vokanamet-article-20-procedure-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vokanamet-article-20-procedure-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vokanamet-article-20-procedure-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vokanamet-article-20-procedure-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vokanamet-article-20-procedure-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vokanamet-article-20-procedure-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vokanamet-article-20-procedure-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vokanamet-article-20-procedure-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vokanamet-article-20-procedure-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/vokanamet-article-20-procedure-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vokanamet-article-20-procedure-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vokanamet-article-20-procedure-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vokanamet-article-20-procedure-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vokanamet-article-20-procedure-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vokanamet-article-20-procedure-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vokanamet-article-20-procedure-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vokanamet-article-20-procedure-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vokanamet-article-20-procedure-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vokanamet-article-20-procedure-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vokanamet-article-20-procedure-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vokanamet-article-20-procedure-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vokanamet-article-20-procedure-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vokanamet-article-20-procedure-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/vokanamet-article-20-procedure-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/vokanamet-article-20-procedure-annex-i-iii_no.pdf"}},
    {"id":"7719","name":"Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T14:00:00Z","last_updated_date":"2012-10-17T14:00:00Z","reference_number":"EMA/412151/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release-tablet-and-20-mgml-oral-solution_sv.pdf"}},
    {"id":"7726","name":"Pharmaceutics International Inc. Article-31 referral – Start of review","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/425451/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/pharmaceutics-international-inc-article-31-referral-start-review_en.pdf"},
    {"id":"7731","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - PRAC concludes that diabetes medicine canagliflozin may contribute to risk of toe amputation","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"EMA/76661/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-prac-concludes-diabetes-medicine-canagliflozin-may-contribute-risk-toe-amputation_en.pdf"},
    {"id":"7732","name":"Lincomycin and spectinomycin Article 35 referral - Divergent_position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lincomycin-and-spectinomycin-article-35-referral-divergent_position_en.pdf"},
    {"id":"7737","name":"Xofigo Article-20 procedure - Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T01:00:00Z","last_updated_date":"2018-04-09T02:00:00Z","reference_number":"EMA/146483/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xofigo-article-20-procedure-prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-and-prednisoneprednisolone_sv.pdf"}},
    {"id":"7757","name":"Fusafungine Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-09-11T02:00:00Z","last_updated_date":"2015-12-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"7769","name":"Novantrone Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/novantrone-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/novantrone-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/novantrone-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/novantrone-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/novantrone-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/novantrone-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/novantrone-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/novantrone-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/novantrone-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/novantrone-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/novantrone-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/novantrone-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/novantrone-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/novantrone-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/novantrone-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/novantrone-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/novantrone-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/novantrone-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/novantrone-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/novantrone-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/novantrone-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/novantrone-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/novantrone-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/novantrone-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/novantrone-article-30-referral-annex-i_no.pdf"}},
    {"id":"7780","name":"Hydroxyethyl starch Article-107i procedure - PRAC list of questions to be addressed by the stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"EMA/PRAC/411967/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-prac-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"7792","name":"Zydelig Article-20 procedure - PRAC concludes review of Zydelig and issues updated recommendations for use","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"EMA/459461/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-prac-concludes-review-zydelig-and-issues-updated-recommendations-use_en.pdf"},
    {"id":"7802","name":"Questions and answers on the review of Vivaglobin (human normal immunoglobulin, solution for injection under the skin)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T13:00:00Z","last_updated_date":"2012-02-17T13:00:00Z","reference_number":"EMA/107736/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-vivaglobin-human-normal-immunoglobulin-solution-injection-under-skin_en.pdf"},
    {"id":"7858","name":"Fusafungine Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-14T02:00:00Z","last_updated_date":"2016-04-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fusafungine-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fusafungine-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fusafungine-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fusafungine-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fusafungine-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fusafungine-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fusafungine-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fusafungine-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fusafungine-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fusafungine-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fusafungine-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fusafungine-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fusafungine-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fusafungine-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fusafungine-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fusafungine-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fusafungine-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fusafungine-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fusafungine-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fusafungine-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fusafungine-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fusafungine-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"7863","name":"Ambroxol and bromhexine Article-31 referral - Divergent opinion (Belgium, Luxembourg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T09:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-divergent-opinion-belgium-luxembourg_en.pdf"},
    {"id":"7878","name":"Opinion following an Article-35 referral for Suanovil 20 and associated names, Captalin and associated names and generic products thereof","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-02-03T16:00:00Z","last_updated_date":"2015-02-03T16:00:00Z","reference_number":"EMA/745255/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-suanovil-20-and-associated-names-captalin-and-associated-names-and-generic-products-thereof_sv.pdf"}},
    {"id":"7898","name":"Paracetamol Article-31 referral - PRAC confirms that modified-release paracetamol should be suspended from market","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T13:00:00Z","last_updated_date":"2017-12-04T11:55:00Z","reference_number":"EMA/786784/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-prac-confirms-modified-release-paracetamol-should-be-suspended-market_en.pdf"},
    {"id":"7908","name":"Iffeza - Article 29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-25T02:00:00Z","last_updated_date":"2012-10-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/iffeza-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/iffeza-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/iffeza-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/iffeza-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/iffeza-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/iffeza-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/iffeza-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/iffeza-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/iffeza-article-29-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/iffeza-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/iffeza-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/iffeza-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/iffeza-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/iffeza-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/iffeza-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/iffeza-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/iffeza-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/iffeza-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/iffeza-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/iffeza-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/iffeza-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/iffeza-article-29-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/iffeza-article-29-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/iffeza-article-29-referral-annex-i_no.pdf"}},
    {"id":"7920","name":"Yasminelle - Article 5(11) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:08:21Z","last_updated_date":"2008-07-03T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/yasminelle-article-511-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"7929","name":"Octagam Article-31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/octagam-article-31-referral-assessment-report_en.pdf"},
    {"id":"7948","name":"Kogenate Bayer and Helixate NexGen Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-03-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-notification_en.pdf"},
    {"id":"7952","name":"Septanest Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2019-06-19T02:00:00Z","reference_number":"EMA/443931/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/septanest-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/septanest-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/septanest-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/septanest-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/septanest-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/septanest-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/septanest-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/septanest-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/septanest-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/septanest-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/septanest-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/septanest-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/septanest-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/septanest-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/septanest-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/septanest-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/septanest-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/septanest-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/septanest-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/septanest-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/septanest-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/septanest-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/septanest-article-30-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/septanest-article-30-referral-annex-i_no.pdf"}},
    {"id":"7984","name":"Helixate NexGen Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2013-12-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/helixate-nexgen-article-20-procedure-annex-iii_en.pdf"},
    {"id":"7989","name":"Flupirtine-containing medicines Article-107i procedure - PRAC recommends restricting the use of flupirtine-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"EMA/362055/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-prac-recommends-restricting-use-flupirtine-containing-medicines_en.pdf"},
    {"id":"8013","name":"Vivaglobin Article-36 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vivaglobin-article-36-referral-annex-iii_en.pdf"},
    {"id":"8074","name":"Questions and answers on the referral for Sabumalin salbutamol, metered dose aerosol inhaler, 100 μg/dose","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-18T00:08:21Z","last_updated_date":"2009-03-18T00:08:21Z","reference_number":"EMEA/CHMP/194784/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-sabumalin-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_sv.pdf"}},
    {"id":"8076","name":"Fortipan Combi D - Article 29 refferal - Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fortipan-combi-d-article-29-refferal-annex-i-iii_sv.pdf"}},
    {"id":"8082","name":"Retinoid Article-31 referral - Updated measures for pregnancy prevention during retinoid use","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"EMA/254364/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_sv.pdf"}},
    {"id":"8095","name":"Scandonest Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T02:00:00Z","last_updated_date":"2018-08-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/scandonest-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/scandonest-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/scandonest-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/scandonest-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/scandonest-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/scandonest-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/scandonest-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/scandonest-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/scandonest-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/scandonest-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/scandonest-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/scandonest-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/scandonest-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/scandonest-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/scandonest-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/scandonest-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/scandonest-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/scandonest-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/scandonest-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/scandonest-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/scandonest-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/scandonest-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/scandonest-article-30-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/scandonest-article-30-referral-annex-iii_no.pdf"}},
    {"id":"8116","name":"Adrenaline auto-injectors Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-08-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iii_no.pdf"}},
    {"id":"8124","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Annex I-III - Forxiga","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-forxiga_no.pdf"}},
    {"id":"8146","name":"Inductos Article-20 procedure - Inductos to be suspended in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-12-07T01:00:00Z","reference_number":"EMA/683814/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/inductos-article-20-procedure-inductos-be-suspended-eu_sv.pdf"}},
    {"id":"8149","name":"Valproate Article-31 referral - Divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-divergent-position_en.pdf"},
    {"id":"8156","name":"Ergot derivatives Article-31 referral - Nicergoline - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iii_no.pdf"}},
    {"id":"8159","name":"Dexrazoxane - Article 31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T01:00:00Z","last_updated_date":"2012-01-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexrazoxane-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexrazoxane-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexrazoxane-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexrazoxane-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexrazoxane-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexrazoxane-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexrazoxane-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexrazoxane-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexrazoxane-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexrazoxane-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexrazoxane-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexrazoxane-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexrazoxane-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexrazoxane-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexrazoxane-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexrazoxane-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexrazoxane-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexrazoxane-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexrazoxane-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexrazoxane-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexrazoxane-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexrazoxane-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"8161","name":"Antifibrinolytic medicines - Article-31 referral - Annex I (tranexamic acid)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-06T01:00:00Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-tranexamic-acid_no.pdf"}},
    {"id":"8205","name":"Assessment report for fenofibrate-, bezafibrate-, ciprofibrate- and gemfibrozil-containing medicinal products","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-04-03T17:00:00Z","last_updated_date":"2013-04-03T17:00:00Z","reference_number":"EMA/CHMP/580013/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-fenofibrate-bezafibrate-ciprofibrate-and-gemfibrozil-containing-medicinal-products_en.pdf"},
    {"id":"8222","name":"Seasonique Article-29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-01-27T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"EMA/CHMP/24607/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/seasonique-article-294-referral-assessment-report_en.pdf"},
    {"id":"8246","name":"Novimp - Article 36 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMEA/H/A-36/1298","document_url":"https://www.ema.europa.eu/en/documents/referral/novimp-article-36-referral-assessment-report_en.pdf"},
    {"id":"8292","name":"Ergot derivatives Article-31 referral - Nicergoline - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-iv_sv.pdf"}},
    {"id":"8316","name":"Questions and answers on the referral for Uman Big Human Hepatitis B Immunoglobulins, 180 IU/ml, solution for injection","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-10T00:08:21Z","last_updated_date":"2009-03-10T00:08:21Z","reference_number":"EMEA/CHMP/173455/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-uman-big-human-hepatitis-b-immunoglobulins-180-iuml-solution-injection_sv.pdf"}},
    {"id":"8323","name":"Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Prozac and associated names International Non-Proprietary Name (INN): fluoxetine: Background inform...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-06-18T02:08:21Z","last_updated_date":"2003-06-18T02:08:21Z","reference_number":"EMEA/CPMP/3263/03","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-prozac-and-associated-names-international-non-proprietary-name-inn-fluoxetine-background_en.pdf"},
    {"id":"8334","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Annex I-III - Edistride","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-edistride_no.pdf"}},
    {"id":"8340","name":"Cardoreg 4 mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-10-11T02:08:21Z","last_updated_date":"2006-10-11T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cardoreg-4-mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"8414","name":"Zolpidem Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"EMA/417529/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/zolpidem-article-31-referral-review-started_en.pdf"},
    {"id":"8419","name":"Esmya Article-20 procedure - Annex I-II-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T01:00:00Z","last_updated_date":"2018-02-20T09:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-annex-i-ii-iii_en.pdf"},
    {"id":"8457","name":"Fentanyl-ratiopharm Matrixpflaster - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-12-15T00:08:21Z","last_updated_date":"2007-12-15T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fentanyl-ratiopharm-matrixpflaster-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"8461","name":"Myderison - Article 29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-06-16T02:00:00Z","last_updated_date":"2011-06-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/myderison-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/myderison-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/myderison-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/myderison-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/myderison-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/myderison-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/myderison-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/myderison-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/myderison-article-29-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/myderison-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/myderison-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/myderison-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/myderison-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/myderison-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/myderison-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/myderison-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/myderison-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/myderison-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/myderison-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/myderison-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/myderison-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/myderison-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"8485","name":"Paracetamol Article-31 referral - Modified-release paracetamol-containing products to be suspended from EU market","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T01:00:00Z","last_updated_date":"2017-12-15T01:00:00Z","reference_number":"EMA/811872/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_en.pdf"},
    {"id":"8534","name":"Divergent position on a CVMP opinion on an Article-13 referral of Directive 2001/82/EC for Soludox 500-mg/g powder for use in drinking water for pigs","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-09-24T02:00:00Z","last_updated_date":"2013-09-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-13-referral-directive-200182ec-soludox-500-mgg-powder-use-drinking-water-pigs_en.pdf"},
    {"id":"8535","name":"Efexor - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-12-19T00:08:21Z","last_updated_date":"2008-12-19T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/efexor-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/efexor-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/efexor-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/efexor-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/efexor-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/efexor-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/efexor-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/efexor-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/efexor-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/efexor-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/efexor-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/efexor-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/efexor-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/efexor-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/efexor-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/efexor-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/efexor-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/efexor-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/efexor-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/efexor-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/efexor-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/efexor-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"8594","name":"Opinion following an article 35 referral for Micotil 300 and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-12T02:00:00Z","last_updated_date":"2014-08-12T02:00:00Z","reference_number":"EMA/250814/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-micotil-300-and-its-associated-names_en.pdf"},
    {"id":"8616","name":"Alcover Article-29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-01-12T01:00:00Z","last_updated_date":"2018-01-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/alcover-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/alcover-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/alcover-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/alcover-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/alcover-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/alcover-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/alcover-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/alcover-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/alcover-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/alcover-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/alcover-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/alcover-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/alcover-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/alcover-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/alcover-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/alcover-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/alcover-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/alcover-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/alcover-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/alcover-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/alcover-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/alcover-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/alcover-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"8629","name":"Combined hormonal contraceptives: Article-31 referral - Review started","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T13:00:00Z","last_updated_date":"2013-02-08T13:00:00Z","reference_number":"EMA/75551/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-review-started_en.pdf"},
    {"id":"8637","name":"Assessment report for Article-5(3) procedure: Polymyxin-based products","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-05-26T18:00:00Z","last_updated_date":"2015-05-26T18:00:00Z","reference_number":"EMA/CHMP/153652/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-article-53-procedure-polymyxin-based-products_en.pdf"},
    {"id":"8728","name":"Nicardipine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-12T13:00:00Z","last_updated_date":"2014-03-12T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nicardipine-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nicardipine-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nicardipine-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nicardipine-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nicardipine-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nicardipine-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nicardipine-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nicardipine-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nicardipine-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nicardipine-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nicardipine-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nicardipine-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nicardipine-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nicardipine-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nicardipine-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nicardipine-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nicardipine-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nicardipine-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nicardipine-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nicardipine-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nicardipine-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nicardipine-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nicardipine-article-31-referral-annex-i_sv.pdf"}},
    {"id":"8770","name":"Methylphenidate Sandoz Article-29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-05T01:00:00Z","last_updated_date":"2013-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/methylphenidate-sandoz-article-29-referral-annex-i_no.pdf"}},
    {"id":"8774","name":"Divergent position on a CVMP opinion on an Article 33.4 referral for\n\nProntax 10 mg/ml solution for injection for sheep, cattle and pigs (EMEA/V/A/073)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-05T02:00:00Z","last_updated_date":"2012-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-334-referral-prontax-10-mg-ml-solution-injection-sheep-cattle-and-pigs-emea-v-073_en.pdf"},
    {"id":"8777","name":"Lansoprazol-ratiopharm 15 mg and 30 mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-02-25T00:08:21Z","last_updated_date":"2006-02-25T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lansoprazol-ratiopharm-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"8779","name":"Questions and answers on Simvastatin Vale and associated names (simvastatin, oral suspension, 20 mg / 5 ml and 40 mg / 5 ml)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-03T02:00:00Z","last_updated_date":"2013-07-22T02:00:00Z","reference_number":"EMA/169486/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-simvastatin-vale-and-associated-names-simvastatin-oral-suspension-20-mg-5-ml-and-40-mg-5-ml_sv.pdf"}},
    {"id":"8808","name":"Zocord - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-06-09T02:08:21Z","last_updated_date":"2004-06-09T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zocord-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/zocord-article-30-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zocord-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zocord-article-30-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zocord-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zocord-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zocord-article-30-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zocord-article-30-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zocord-article-30-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zocord-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zocord-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"8813","name":"Combined hormonal contraceptives Article-31 referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2013-02-08T13:00:00Z","last_updated_date":"2013-03-11T13:35:00Z","reference_number":"EMA/713187/2012 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_en.pdf"},
    {"id":"8823","name":"Cilostazol-containing medicines - Article-31 referral - Annex II (cilostazol)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-ii-cilostazol_sv.pdf"}},
    {"id":"8834","name":"Dienogest / Ethinylestradiol Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"8836","name":"Adrenaline auto-injectors Article-31 referral - CHMP List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/CHMP/225802/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"8870","name":"Etopophos Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etopophos-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/etopophos-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/etopophos-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etopophos-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etopophos-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etopophos-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etopophos-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etopophos-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etopophos-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/etopophos-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etopophos-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etopophos-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etopophos-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etopophos-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/etopophos-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etopophos-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etopophos-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etopophos-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/etopophos-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etopophos-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etopophos-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etopophos-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etopophos-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"8903","name":"Lamictal - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-08T02:08:21Z","last_updated_date":"2008-09-08T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"8908","name":"Omega-3 acid ethyl esters - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-26T19:23:00Z","last_updated_date":"2019-06-13T19:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/omega-3-acid-ethyl-esters-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/omega-3-acid-ethyl-esters-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/omega-3-acid-ethyl-esters-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/omega-3-acid-ethyl-esters-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/omega-3-acid-ethyl-esters-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/omega-3-acid-ethyl-esters-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/omega-3-acid-ethyl-esters-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/omega-3-acid-ethyl-esters-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/omega-3-acid-ethyl-esters-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/omega-3-acid-ethyl-esters-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/omega-3-acid-ethyl-esters-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/omega-3-acid-ethyl-esters-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/omega-3-acid-ethyl-esters-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/omega-3-acid-ethyl-esters-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/omega-3-acid-ethyl-esters-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/omega-3-acid-ethyl-esters-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/omega-3-acid-ethyl-esters-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/omega-3-acid-ethyl-esters-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/omega-3-acid-ethyl-esters-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/omega-3-acid-ethyl-esters-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/omega-3-acid-ethyl-esters-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/omega-3-acid-ethyl-esters-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/omega-3-acid-ethyl-esters-annex-i_sv.pdf"}},
    {"id":"8924","name":"Goserelin Cell Pharm - Article 36 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/goserelin-cell-pharm-article-36-referral-annex-ii_sv.pdf"}},
    {"id":"8928","name":"Questions and answers on Nanotop and associated names (human albumin colloidal particles, kit for radiopharmaceutical preparation)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_cs.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_sv.pdf"}},
    {"id":"8931","name":"Fusafungine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-14T02:00:00Z","last_updated_date":"2016-04-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fusafungine-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fusafungine-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fusafungine-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fusafungine-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fusafungine-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fusafungine-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fusafungine-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fusafungine-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fusafungine-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fusafungine-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fusafungine-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fusafungine-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fusafungine-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fusafungine-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fusafungine-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fusafungine-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fusafungine-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fusafungine-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fusafungine-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fusafungine-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fusafungine-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fusafungine-article-31-referral-annex-i_sv.pdf"}},
    {"id":"8972","name":"Opinion following an Article 29(2) referral for Crestor 5 mg International Non-Proprietary Name (INN): Rosuvastatin calcium: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-08-09T02:08:21Z","last_updated_date":"2005-08-09T02:08:21Z","reference_number":"EMEA/CHMP/145829/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-crestor-5-mg-international-non-proprietary-name-inn-rosuvastatin-calcium-background-information_sv.pdf"}},
    {"id":"8986","name":"Crestor 5 mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-08-09T02:08:21Z","last_updated_date":"2005-08-09T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"8988","name":"Augmentin - Article 30 - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/augmentin-article-30-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/augmentin-article-30-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/augmentin-article-30-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/augmentin-article-30-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/augmentin-article-30-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/augmentin-article-30-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/augmentin-article-30-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/augmentin-article-30-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/augmentin-article-30-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/augmentin-article-30-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/augmentin-article-30-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/augmentin-article-30-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/augmentin-article-30-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/augmentin-article-30-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/augmentin-article-30-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/augmentin-article-30-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/augmentin-article-30-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/augmentin-article-30-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/augmentin-article-30-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/augmentin-article-30-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/augmentin-article-30-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/augmentin-article-30-annex-ii_sv.pdf"}},
    {"id":"9016","name":"Scandonest Article-30 referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-08-07T02:00:00Z","last_updated_date":"2018-08-07T02:00:00Z","reference_number":"EMA/413109/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/scandonest-article-30-referral-chmp-assessment-report_en.pdf"},
    {"id":"9018","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Divergent positions to CMDh position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-13T02:00:00Z","last_updated_date":"2013-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-divergent-positions-cmdh-position_en.pdf"},
    {"id":"9048","name":"Porcimectin solution for injection Article-33 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-13T02:00:00Z","last_updated_date":"2014-08-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/porcimectin-solution-injection-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"9100","name":"Questions and answers on the referral for Loratadine Sandoz 10 loratadine 10 mg tablets","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-29T02:08:21Z","last_updated_date":"2009-05-29T02:08:21Z","reference_number":"EMEA/321803/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets_en.pdf"},
    {"id":"9101","name":"Simvastatin Vale Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T02:00:00Z","last_updated_date":"2013-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/simvastatin-vale-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/simvastatin-vale-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/simvastatin-vale-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/simvastatin-vale-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/simvastatin-vale-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/simvastatin-vale-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/simvastatin-vale-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/simvastatin-vale-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/simvastatin-vale-article-294-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/simvastatin-vale-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/simvastatin-vale-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/simvastatin-vale-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/simvastatin-vale-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/simvastatin-vale-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/simvastatin-vale-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/simvastatin-vale-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/simvastatin-vale-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/simvastatin-vale-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/simvastatin-vale-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/simvastatin-vale-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/simvastatin-vale-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/simvastatin-vale-article-294-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/simvastatin-vale-article-294-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/simvastatin-vale-article-294-referral-annex-i_no.pdf"}},
    {"id":"9138","name":"Numeta Article-107i procedure - Annex V","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-27T15:00:00Z","last_updated_date":"2013-09-27T15:00:00Z","reference_number":"EMEA/H/A-107i/1373","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-annex-v_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/numeta-article-107i-procedure-annex-v_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/numeta-article-107i-procedure-annex-v_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/numeta-article-107i-procedure-annex-v_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/numeta-article-107i-procedure-annex-v_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/numeta-article-107i-procedure-annex-v_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/numeta-article-107i-procedure-annex-v_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/numeta-article-107i-procedure-annex-v_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/numeta-article-107i-procedure-annex-v_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/numeta-article-107i-procedure-annex-v_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/numeta-article-107i-procedure-annex-v_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/numeta-article-107i-procedure-annex-v_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/numeta-article-107i-procedure-annex-v_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/numeta-article-107i-procedure-annex-v_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/numeta-article-107i-procedure-annex-v_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/numeta-article-107i-procedure-annex-v_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/numeta-article-107i-procedure-annex-v_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/numeta-article-107i-procedure-annex-v_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/numeta-article-107i-procedure-annex-v_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/numeta-article-107i-procedure-annex-v_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/numeta-article-107i-procedure-annex-v_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/numeta-article-107i-procedure-annex-v_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/numeta-article-107i-procedure-annex-v_sv.pdf"}},
    {"id":"9210","name":"Nanotop Article-29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T17:00:00Z","last_updated_date":"2014-06-16T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nanotop-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nanotop-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nanotop-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nanotop-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nanotop-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nanotop-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nanotop-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nanotop-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nanotop-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nanotop-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nanotop-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nanotop-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nanotop-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nanotop-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nanotop-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nanotop-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nanotop-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nanotop-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nanotop-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nanotop-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nanotop-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nanotop-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nanotop-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"9246","name":"Norbonex Article-33(4) referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/norbonex-article-334-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"9261","name":"Questions and answers on the withdrawal of the marketing authorisations for medicines containing dextropropoxyphene - re-examination","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:08:21Z","last_updated_date":"2011-04-07T02:08:21Z","reference_number":"EMEA/681374/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_sv.pdf"}},
    {"id":"9277","name":"Sortis-EMEA/H/A-29 PAD/1255: Article 29 Paediatrics referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-27T02:00:00Z","last_updated_date":"2011-04-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"9284","name":"Moxidectin Article-35 referral - Questions and answers on the environmental impact of moxidectin-containing veterinary medicines used in cattle, sheep and horses","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"EMA/587529/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/moxidectin-article-35-referral-questions-and-answers-environmental-impact-moxidectin-containing-veterinary-medicines-used-cattle-sheep-and-horses_sv.pdf"}},
    {"id":"9315","name":"Summary information on a referral opinion following an arbitration pursuant to Article 18 of Council Directive 81/851/EECc as amended for Avinew: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-01-02T00:59:00Z","last_updated_date":"2002-01-02T00:59:00Z","reference_number":"CVMP/1129/01","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-18-council-directive-81851eecc-amended-avinew-background-information_en.pdf"},
    {"id":"9321","name":"Teicoplanin hospira - Article 29 referral - Annex I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-07-27T02:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/teicoplanin-hospira-article-29-referral-annex-i-ii_sv.pdf"}},
    {"id":"9331","name":"Questions and answers on Docetaxel Teva Generics (docetaxel, 20 mg and 80 mg powder and solvent for solution for infusion)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-02-18T01:00:00Z","last_updated_date":"2012-07-03T02:00:00Z","reference_number":"EMEA/H/A-29/1277","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-docetaxel-teva-generics-docetaxel-20-mg-and-80-mg-powder-and-solvent-solution-infusion_sv.pdf"}},
    {"id":"9359","name":"Combined hormonal contraceptives Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"9369","name":"Micro Therapeutic Research Article-31 referral - Medicinal products recommended for maintenance and marketing authorisation applications for which bioequivalence vis-à -vis the EU reference medicinal product has been est...","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-04-19T02:00:00Z","reference_number":"EMA/203429/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-medicinal-products-recommended-maintenance-and-marketing-authorisation-applications-which-bioequivalence-vis-vis-eu-reference-medicinal-product-has-been_en.pdf"},
    {"id":"9413","name":"Flutiform - Article 29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-25T02:00:00Z","last_updated_date":"2012-10-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flutiform-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flutiform-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flutiform-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flutiform-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flutiform-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flutiform-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flutiform-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flutiform-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flutiform-article-29-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flutiform-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flutiform-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flutiform-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flutiform-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flutiform-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flutiform-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flutiform-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flutiform-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flutiform-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flutiform-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flutiform-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flutiform-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flutiform-article-29-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/flutiform-article-29-referral-annex-iii_no.pdf"}},
    {"id":"9415","name":"Combined hormonal contraceptives Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"9490","name":"Bicalutamide - Article 31 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-10-03T02:08:21Z","last_updated_date":"2007-10-03T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bicalutamide-article-31-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"9522","name":"Questions and answers on Seroquel XR and associated names (50, 150, 200, 300 and 400 mg prolonged-release tablets containing quetiapine)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2010-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-seroquel-xr-and-associated-names-50-150-200-300-and-400-mg-prolonged-release-tablets-containing-quetiapine_sv.pdf"}},
    {"id":"9548","name":"Methotrexate Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T02:00:00Z","last_updated_date":"2018-04-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-notification_en.pdf"},
    {"id":"9549","name":"Retinoid Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-notification_en.pdf"},
    {"id":"9582","name":"Summary information on a referral opinion following an arbitration pursuant to Article 29 of Directive 2001/83/EC (formerly Article 10, paragraph 2 of Directive 75/319/EEC of 20 May 1975 as amended) for Dacarbazine Fauld...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-09-19T02:08:21Z","last_updated_date":"2002-09-19T02:08:21Z","reference_number":"CPMP/2020/02","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-directive-200183ec-formerly-article-10-paragraph-2-directive-75319eec-20-may-1975-amended-dacarbazine-fauld_en.pdf"},
    {"id":"9605","name":"Kytril - Article 30 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-12T02:00:00Z","last_updated_date":"2011-09-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kytril-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/kytril-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/kytril-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/kytril-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/kytril-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/kytril-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/kytril-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/kytril-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/kytril-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/kytril-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/kytril-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/kytril-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/kytril-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/kytril-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/kytril-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/kytril-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/kytril-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/kytril-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/kytril-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/kytril-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/kytril-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/kytril-article-30-referral-annex-i_sv.pdf"}},
    {"id":"9632","name":"Thiocolchicoside Article-31 referral - Divergent positions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-06T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/thiocolchicoside-article-31-referral-divergent-positions_en.pdf"},
    {"id":"9650","name":"PRAC recommends restricting use of domperidone","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"EMA/129231/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-recommends-restricting-use-domperidone_en.pdf"},
    {"id":"9665","name":"Loraxin - Article-29(4) referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-02-28T01:00:00Z","last_updated_date":"2013-02-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/loraxin-article-294-referral-annex-i-ii-iii_no.pdf"}}    {"id":"9672","name":"Prokanazol - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-08-06T02:08:21Z","last_updated_date":"2009-08-06T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/prokanazol-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"9687","name":"Bovimectin Injection Article-33 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-13T02:00:00Z","last_updated_date":"2014-08-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bovimectin-injection-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"9696","name":"Opinion following an Article 36(1) referral Gadograf/Gadovist International Non-Proprietary Name (INN): Gadobutrol: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-04-13T02:08:21Z","last_updated_date":"2007-04-13T02:08:21Z","reference_number":"EMEA/508212/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-361-referral-gadografgadovist-international-non-proprietary-name-inn-gadobutrol-background-information_sv.pdf"}},
    {"id":"9705","name":"Ethinylestradiol-Drospirenone 24+4 Article-6(12) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-i_no.pdf"}},
    {"id":"9732","name":"Opinion of the Committee for proprietary medicinal products pursuant to Article 10 of Council Directive 75/319/EEC as amended","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-08-03T02:08:21Z","last_updated_date":"1998-08-03T02:08:21Z","reference_number":"CPMP/1034/96-EN","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-10-council-directive-75319eec-amended_en.pdf"},
    {"id":"9805","name":"Goserelin Cell Pharm - Article 36 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/goserelin-cell-pharm-article-36-referral-annex-iii_sv.pdf"}},
    {"id":"9821","name":"Assessment report for Leflunomide Apotex","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"EMA/691570/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-leflunomide-apotex_en.pdf"},
    {"id":"9823","name":"Bromocriptine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-02T02:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bromocriptine-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bromocriptine-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bromocriptine-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bromocriptine-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bromocriptine-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bromocriptine-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bromocriptine-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bromocriptine-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/bromocriptine-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bromocriptine-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bromocriptine-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bromocriptine-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bromocriptine-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bromocriptine-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bromocriptine-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bromocriptine-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bromocriptine-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bromocriptine-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bromocriptine-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bromocriptine-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bromocriptine-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bromocriptine-article-31-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/bromocriptine-article-31-referral-annex-i_no.pdf"}},
    {"id":"9829","name":"Simvastatin Vale Article-29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T02:00:00Z","last_updated_date":"2013-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/simvastatin-vale-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/simvastatin-vale-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/simvastatin-vale-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/simvastatin-vale-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/simvastatin-vale-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/simvastatin-vale-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/simvastatin-vale-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/simvastatin-vale-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/simvastatin-vale-article-294-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/simvastatin-vale-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/simvastatin-vale-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/simvastatin-vale-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/simvastatin-vale-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/simvastatin-vale-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/simvastatin-vale-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/simvastatin-vale-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/simvastatin-vale-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/simvastatin-vale-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/simvastatin-vale-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/simvastatin-vale-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/simvastatin-vale-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/simvastatin-vale-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"9859","name":"Codeine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-08-02T02:00:00Z","last_updated_date":"2013-08-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/codeine-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/codeine-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/codeine-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/codeine-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/codeine-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/codeine-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/codeine-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/codeine-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/codeine-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/codeine-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/codeine-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/codeine-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/codeine-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/codeine-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/codeine-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/codeine-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/codeine-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/codeine-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/codeine-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/codeine-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/codeine-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/codeine-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/codeine-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/codeine-article-31-referral-annex-i_no.pdf"}},
    {"id":"9871","name":"Ibuprofen and dexibuprofen Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T17:00:00Z","last_updated_date":"2014-06-13T17:00:00Z","reference_number":"EMA/348597/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-review-started_en.pdf"},
    {"id":"9925","name":"Saroten Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/saroten-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/saroten-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/saroten-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/saroten-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/saroten-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/saroten-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/saroten-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/saroten-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/saroten-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/saroten-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/saroten-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/saroten-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/saroten-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/saroten-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/saroten-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/saroten-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/saroten-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/saroten-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/saroten-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/saroten-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/saroten-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/saroten-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/saroten-article-30-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/saroten-article-30-referral-annex-i_no.pdf"}},
    {"id":"9932","name":"Glimepirida Parke Davis - Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-06T01:00:00Z","last_updated_date":"2012-12-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/glimepirida-parke-davis-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"9948","name":"Etopophos Article-30 referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-14T18:00:00Z","last_updated_date":"2017-07-14T18:00:00Z","reference_number":"EMA/409209/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/etopophos-article-30-referral-chmp-assessment-report_en.pdf"},
    {"id":"9961","name":"Ergot derivatives Article-31 referral - Dihydroergotoxine - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-ii_sv.pdf"}},
    {"id":"9970","name":"Vancomycin Article-31 referral - EMA recommends changes to prescribing information for vancomycin antibiotics","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-11-17T01:00:00Z","reference_number":"EMA/645879/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vancomycin-article-31-referral-ema-recommends-changes-prescribing-information-vancomycin-antibiotics_sv.pdf"}},
    {"id":"9975","name":"Questions and answers on Norvasc and associated names (amlodipine, 5 and 10 mg tablets and capsules)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T16:01:52Z","last_updated_date":"2012-03-29T16:01:52Z","reference_number":"EMA/CHMP/583222/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-norvasc-and-associated-names-amlodipine-5-and-10-mg-tablets-and-capsules_sv.pdf"}},
    {"id":"9980","name":"Questions and answers on the referral for Tritace tablet and hard capsules containing ramipril 1.25 mg, 2.5 mg, 5 mg and 10 mg","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-19T00:08:21Z","last_updated_date":"2009-03-19T00:08:21Z","reference_number":"EMEA/CHMP/233264/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-tritace-tablet-and-hard-capsules-containing-ramipril-125-mg-25-mg-5-mg-and-10-mg_sv.pdf"}},
    {"id":"9982","name":"Bovilis BVD/Bovilis BVD-MD - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-16T00:59:00Z","last_updated_date":"2007-11-16T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bovilis-bvdbovilis-bvd-md-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"10032","name":"Fusafungine Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-04-14T02:00:00Z","last_updated_date":"2016-04-14T02:00:00Z","reference_number":"EMA/194153/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-assessment-report_en.pdf"},
    {"id":"10036","name":"Losec - Article 30 referrals - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-01-23T00:59:00Z","last_updated_date":"2011-09-20T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/losec-article-30-referrals-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/losec-article-30-referrals-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/losec-article-30-referrals-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/losec-article-30-referrals-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/losec-article-30-referrals-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/losec-article-30-referrals-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/losec-article-30-referrals-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/losec-article-30-referrals-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/losec-article-30-referrals-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/losec-article-30-referrals-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/losec-article-30-referrals-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/losec-article-30-referrals-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/losec-article-30-referrals-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/losec-article-30-referrals-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/losec-article-30-referrals-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/losec-article-30-referrals-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/losec-article-30-referrals-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/losec-article-30-referrals-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/losec-article-30-referrals-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/losec-article-30-referrals-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/losec-article-30-referrals-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/losec-article-30-referrals-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/losec-article-30-referrals-annex-iii_no.pdf"}},
    {"id":"10037","name":"Girolan Article-34 referral - Divergent position 1","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-15T02:00:00Z","last_updated_date":"2018-06-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/girolan-article-34-referral-divergent-position-1_en.pdf"},
    {"id":"10044","name":"Levonelle Article-13 referral - Questions and answers on Levonelle and associated names (levonorgestrel, 1500 microgram tablets)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-08-09T02:00:00Z","reference_number":"EMA/517526/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levonelle-article-13-referral-questions-and-answers-levonelle-and-associated-names-levonorgestrel-1500-microgram-tablets_sv.pdf"}},
    {"id":"10045","name":"Enrofloxacin Article-35 referral - Opinion following an Article-35 referral for all veterinary medicines containing enrofloxacin to be administered via the drinking water to chickens and/or turkeys","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-10T14:00:00Z","last_updated_date":"2014-04-10T14:00:00Z","reference_number":"EMEA/V/A/089","document_url":"https://www.ema.europa.eu/en/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-and-or-turkeys_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_mt.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/enrofloxacin-article-35-referral-opinion-following-article-35-referral-all-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys_sv.pdf"}},
    {"id":"10047","name":"Doxazosin Retard \"Arrow\" 4 mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-10-11T02:08:21Z","last_updated_date":"2006-10-11T02:08:21Z","reference_number":"CHMP/423796/06","document_url":"https://www.ema.europa.eu/en/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/doxazosin-retard-arrow-4-mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"10085","name":"Femara - Article 30 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-06-12T02:00:00Z","last_updated_date":"2012-06-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/femara-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/femara-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/femara-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/femara-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/femara-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/femara-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/femara-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/femara-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/femara-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/femara-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/femara-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/femara-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/femara-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/femara-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/femara-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/femara-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/femara-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/femara-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/femara-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/femara-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/femara-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/femara-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/femara-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/femara-article-30-referral-annex-i_no.pdf"}},
    {"id":"10092","name":"Doxyprex 100mg Premix - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-16T00:59:00Z","last_updated_date":"2007-11-16T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/doxyprex-100mg-premix-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"10115","name":"Ambroxol and bromhexine Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-04-11T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-notification_en.pdf"},
    {"id":"10119","name":"PRAC recommends that the marketing authorisation of the painkiller flupirtine be withdrawn","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T01:00:00Z","last_updated_date":"2018-02-09T01:00:00Z","reference_number":"EMA/66114/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-recommends-marketing-authorisation-painkiller-flupirtine-be-withdrawn_en.pdf"},
    {"id":"10178","name":"Iffeza - Article 29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-25T02:00:00Z","last_updated_date":"2012-10-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/iffeza-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/iffeza-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/iffeza-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/iffeza-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/iffeza-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/iffeza-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/iffeza-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/iffeza-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/iffeza-article-29-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/iffeza-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/iffeza-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/iffeza-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/iffeza-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/iffeza-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/iffeza-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/iffeza-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/iffeza-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/iffeza-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/iffeza-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/iffeza-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/iffeza-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/iffeza-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"10179","name":"Factor VIII Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2017-12-05T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/factor-viii-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/factor-viii-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/factor-viii-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/factor-viii-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/factor-viii-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/factor-viii-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/factor-viii-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/factor-viii-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/factor-viii-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/factor-viii-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/factor-viii-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/factor-viii-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/factor-viii-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/factor-viii-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/factor-viii-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/factor-viii-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/factor-viii-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/factor-viii-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/factor-viii-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/factor-viii-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/factor-viii-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/factor-viii-article-31-referral-annex-i_sv.pdf"}},
    {"id":"10194","name":"Short-acting beta-agonists Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-07T01:00:00Z","last_updated_date":"2013-11-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/short-acting-beta-agonists-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"10213","name":"Hydroxyethyl starch Article-107i procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-i_en.pdf-0"},
    {"id":"10216","name":"Actira - Article 6 (12) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-13T02:08:21Z","last_updated_date":"2008-10-13T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/actira-article-6-12-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"10246","name":"Merisone and associated names Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-07-28T02:00:00Z","last_updated_date":"2015-07-28T02:00:00Z","reference_number":"EMA/445102/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/merisone-and-associated-names-article-294-referral-assessment-report_en.pdf"},
    {"id":"10286","name":"Viani Evohaler- Article 6 (13) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-09-14T02:08:21Z","last_updated_date":"2007-09-14T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/viani-evohaler-article-6-13-referral-annex-i-ii-iii_fi.pdf"}},
    {"id":"10293","name":"Questions and answers on the review of orlistat-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-16T17:00:00Z","last_updated_date":"2012-12-21T17:00:00Z","reference_number":"EMA/CHMP/113837/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-orlistat-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-orlistat-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-orlistat-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-orlistat-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-orlistat-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-orlistat-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-orlistat-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-orlistat-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-orlistat-containing-medicines_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-orlistat-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-orlistat-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-orlistat-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-orlistat-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-orlistat-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-orlistat-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-orlistat-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-orlistat-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-orlistat-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-orlistat-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-orlistat-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-orlistat-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-orlistat-containing-medicines_sv.pdf"}},
    {"id":"10310","name":"Codeine Article-31 referral - Codeine not to be used in children below 12 years for cough and cold","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/codeine-article-31-referral-codeine-not-be-used-children-below-12-years-cough-and-cold_sv.pdf"}},
    {"id":"10372","name":"Bromocriptine Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-06T02:00:00Z","last_updated_date":"2013-09-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-notification_en.pdf"},
    {"id":"10385","name":"Xofigo Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-annex-iii_en.pdf"},
    {"id":"10395","name":"Flupirtine-containing medicines Article-107i procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-07-18T14:00:00Z","last_updated_date":"2013-07-18T14:00:00Z","reference_number":"EMA/404308/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-prac-assessment-report_en.pdf"},
    {"id":"10397","name":"Questions and answers on the review of antifibrinolytic medicines (aprotinin, aminocaproic acid and tranexamic acid) (re-examination)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T14:00:00Z","last_updated_date":"2012-06-22T14:00:00Z","reference_number":"EMA/422612/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-and-tranexamic-acid-re-examination_en.pdf"},
    {"id":"10424","name":"GVK Biosciences Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-08-04T02:00:00Z","last_updated_date":"2015-08-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gvk-biosciences-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gvk-biosciences-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gvk-biosciences-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gvk-biosciences-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gvk-biosciences-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gvk-biosciences-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gvk-biosciences-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gvk-biosciences-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gvk-biosciences-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gvk-biosciences-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gvk-biosciences-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gvk-biosciences-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gvk-biosciences-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gvk-biosciences-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gvk-biosciences-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gvk-biosciences-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gvk-biosciences-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gvk-biosciences-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gvk-biosciences-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gvk-biosciences-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gvk-biosciences-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gvk-biosciences-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"10451","name":"Esmya Article-20 procedure - PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroids","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-05-18T14:00:00Z","last_updated_date":"2018-05-18T14:00:00Z","reference_number":"EMA/289137/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-prac-recommends-new-measures-minimise-risk-rare-serious-liver-injury-esmya-fibroids_en.pdf"},
    {"id":"10490","name":"Antifibrinolytic medicines - Article-31 referral - Annex I (aminocaproic acid)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-06T01:00:00Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aminocaproic-acid_sv.pdf"}},
    {"id":"10496","name":"Questions and answers on Zinnat and associated names (cefuroxime axetil, 125-, 250- and 500-mg tablets and 125-, 250- and 500-mg granules for oral suspension)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T14:00:00Z","last_updated_date":"2013-01-29T15:11:00Z","reference_number":"EMA/CHMP/339191/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-zinnat-and-associated-names-cefuroxime-axetil-125-250-and-500-mg-tablets-and-125-250-and-500-mg-granules-oral-suspension_sv.pdf"}},
    {"id":"10515","name":"Nicardipine Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-03-12T13:00:00Z","last_updated_date":"2014-03-12T13:00:00Z","reference_number":"EMA/711459/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/nicardipine-article-31-referral-assessment-report_en.pdf"},
    {"id":"10528","name":"Prozac- Article 6 (12) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-09-05T02:08:21Z","last_updated_date":"2006-09-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/prozac-article-6-12-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"10570","name":"Lactose of bovine origin Article-31 referral - PRAC recommends that injectable methylprednisolone products containing lactose must not be given to patients allergic to cow's milk proteins","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-07T02:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMA/416655/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-prac-recommends-injectable-methylprednisolone-products-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_en.pdf"},
    {"id":"10595","name":"Assessment Report for Diovan - EMEA/H/A/-29 PAD/1220","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"EMA/296507/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-diovan-emeaha-29-pad1220_en.pdf"},
    {"id":"10602","name":"Questions and answers on Vepesid and associated names (etoposide, 50 and 100 mg capsules)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T19:00:00Z","last_updated_date":"2017-07-14T19:00:00Z","reference_number":"EMEA/H/A-30/1425","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-vepesid-and-associated-names-etoposide-50-and-100-mg-capsules_sv.pdf"}},
    {"id":"10607","name":"Ambroxol and bromhexine Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-12-05T13:00:00Z","reference_number":"EMA/PRAC/189079/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"10638","name":"Article 107 referral - Assessment report for Octagam 5% and Octagam 10% medicinal products","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/331530/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/article-107-referral-assessment-report-octagam-5-and-octagam-10-medicinal-products_en.pdf"},
    {"id":"10680","name":"HPV vaccines Article-20 procedure - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-11-26T13:00:00Z","last_updated_date":"2015-11-26T13:00:00Z","reference_number":"EMA/762033/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-assessment-report_en.pdf"},
    {"id":"10684","name":"Loratadine and pseudoephedrine - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-07-14T02:08:21Z","last_updated_date":"2004-07-14T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/loratadine-and-pseudoephedrine-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"10707","name":"Opinion following an Article 31 referral for all medicinal products containing Celecoxib, Etoricoxib, Parecoxib, Rofecoxib or Valdecoxib International Non-Proprietary Name (INN): Etoricoxib: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-04-30T02:08:21Z","last_updated_date":"2004-04-30T02:08:21Z","reference_number":"EMEA/CPMP/1748/04","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-parecoxib-rofecoxib-or-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background-information_en.pdf"},
    {"id":"10713","name":"Hydroxyzine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T17:00:00Z","last_updated_date":"2015-06-08T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyzine-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyzine-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyzine-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyzine-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyzine-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyzine-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyzine-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyzine-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyzine-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyzine-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyzine-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyzine-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyzine-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyzine-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyzine-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyzine-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyzine-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyzine-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyzine-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyzine-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyzine-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyzine-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/hydroxyzine-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/hydroxyzine-article-31-referral-annex-i_no.pdf"}},
    {"id":"10718","name":"Questions and answers on the recommendation to suspend the marketing authorisations for carisoprodol-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-15T00:08:21Z","last_updated_date":"2007-11-15T00:08:21Z","reference_number":"EMEA/520140/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-recommendation-suspend-marketing-authorisations-carisoprodol-containing-medicines_en.pdf"},
    {"id":"10730","name":"Opinion following an Article 34 referral for Micotil 300 Injectie and its associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"EMA/539469/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-micotil-300-injectie-and-its-associated-names_sv.pdf"}},
    {"id":"10755","name":"Fibrinogen Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrinogen-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrinogen-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fibrinogen-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrinogen-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrinogen-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrinogen-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fibrinogen-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrinogen-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fibrinogen-article-31-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrinogen-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrinogen-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrinogen-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fibrinogen-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrinogen-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrinogen-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrinogen-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrinogen-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrinogen-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrinogen-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrinogen-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fibrinogen-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrinogen-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"10797","name":"Assessment report for Baxter dialysis solutions (Castlebar site)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"EMA/973411/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-baxter-dialysis-solutions-castlebar-site_en.pdf"},
    {"id":"10805","name":"Celecoxib - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-06-09T02:08:21Z","last_updated_date":"2004-06-09T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/celecoxib-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"10813","name":"Hydroxyethyl starch Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2013-09-02T02:00:00Z","reference_number":"EMA/PRAC/751078/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"10825","name":"Ikorel and Dancor Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ikorel-and-dancor-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"10828","name":"Questions and answers on the referral for Protium and associated names - pantoprazole, 20 or 40 mg gastro-resistant tablets and 40 mg powder for solution for injection","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2012-01-17T01:00:00Z","reference_number":"EMA/CHMP/565104/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_sv.pdf"}},
    {"id":"10832","name":"Invokana Article-20 procedure - Annex I - III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-18T02:00:00Z","last_updated_date":"2016-05-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/invokana-article-20-procedure-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/invokana-article-20-procedure-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/invokana-article-20-procedure-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/invokana-article-20-procedure-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/invokana-article-20-procedure-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/invokana-article-20-procedure-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/invokana-article-20-procedure-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/invokana-article-20-procedure-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/invokana-article-20-procedure-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/invokana-article-20-procedure-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/invokana-article-20-procedure-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/invokana-article-20-procedure-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/invokana-article-20-procedure-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/invokana-article-20-procedure-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/invokana-article-20-procedure-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/invokana-article-20-procedure-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/invokana-article-20-procedure-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/invokana-article-20-procedure-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/invokana-article-20-procedure-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/invokana-article-20-procedure-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/invokana-article-20-procedure-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/invokana-article-20-procedure-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/invokana-article-20-procedure-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/invokana-article-20-procedure-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/invokana-article-20-procedure-annex-i-iii_no.pdf"}},
    {"id":"10878","name":"Tysabri Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-08T14:00:00Z","last_updated_date":"2015-05-08T14:00:00Z","reference_number":"EMA/PRAC/293316/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/tysabri-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"10881","name":"Diacerein Article-31 referral - Restrictions to the use of diacerein-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-19T02:00:00Z","last_updated_date":"2014-09-19T02:00:00Z","reference_number":"EMA/544268/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diacerein-article-31-referral-restrictions-use-diacerein-containing-medicines_sv.pdf"}},
    {"id":"10893","name":"Hydroxyethyl starch Article-107i procedure - Rationale for triggering","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-rationale-triggering_en.pdf"},
    {"id":"10905","name":"Nasonex Article-30 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-02-03T10:40:00Z","last_updated_date":"2015-02-03T10:40:00Z","reference_number":"EMA/37163/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/nasonex-article-30-referral-assessment-report_en.pdf"},
    {"id":"10959","name":"Opinions following an Article 12 referral for Terfenadine International Non-Proprietary Name (INN): Terfenadine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-10-22T02:08:21Z","last_updated_date":"1998-10-22T02:08:21Z","reference_number":"EMEA/34168/98","document_url":"https://www.ema.europa.eu/en/documents/referral/opinions-following-article-12-referral-terfenadine-international-non-proprietary-name-inn-terfenadine-background-information_en.pdf"},
    {"id":"10973","name":"Diacerein Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-annex-iii_en.pdf-0"},
    {"id":"11016","name":"Lansoprazol AbZ Pharma 15 mg and 30 mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-02-25T00:08:21Z","last_updated_date":"2006-02-25T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lansoprazol-abz-pharma-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"11026","name":"Mifepristone Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/mifepristone-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/mifepristone-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/mifepristone-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/mifepristone-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/mifepristone-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/mifepristone-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/mifepristone-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/mifepristone-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/mifepristone-article-294-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/mifepristone-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/mifepristone-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/mifepristone-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/mifepristone-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/mifepristone-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/mifepristone-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/mifepristone-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/mifepristone-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/mifepristone-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/mifepristone-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/mifepristone-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/mifepristone-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/mifepristone-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"11046","name":"Tylosin Article-35 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-31T02:00:00Z","last_updated_date":"2017-07-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tylosin-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"11065","name":"Opinion following an Article 33(4) referral for Tildren 500 mg, lyophilisate for solution for infusion: Background information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-12-14T01:00:00Z","last_updated_date":"2010-12-14T01:00:00Z","reference_number":"EMA/193771/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-tildren-500-mg-lyophilisate-solution-infusion-background-information_sv.pdf"}},
    {"id":"11145","name":"Atacand plus - Article 30 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-20T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/atacand-plus-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/atacand-plus-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/atacand-plus-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/atacand-plus-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/atacand-plus-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/atacand-plus-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/atacand-plus-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/atacand-plus-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/atacand-plus-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/atacand-plus-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/atacand-plus-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/atacand-plus-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/atacand-plus-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/atacand-plus-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/atacand-plus-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/atacand-plus-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/atacand-plus-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/atacand-plus-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/atacand-plus-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/atacand-plus-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/atacand-plus-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/atacand-plus-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"11149","name":"Enro-K - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-07-30T01:59:00Z","last_updated_date":"2009-07-30T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/enro-k-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"11151","name":"Assessment report for Fenofibrato Pensa and Fenofibrato Ranbaxy","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"EMA/20843/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-fenofibrato-pensa-and-fenofibrato-ranbaxy_en.pdf"},
    {"id":"11155","name":"Tysabri Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-12T02:00:00Z","last_updated_date":"2016-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tysabri-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tysabri-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tysabri-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tysabri-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tysabri-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tysabri-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tysabri-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tysabri-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tysabri-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tysabri-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tysabri-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tysabri-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tysabri-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tysabri-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tysabri-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tysabri-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tysabri-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tysabri-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tysabri-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tysabri-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tysabri-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tysabri-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tysabri-article-20-procedure-annex-iv_sv.pdf"}},
    {"id":"11186","name":"PRAC considers benefits of Kogenate Bayer/Helixate NexGen outweigh risks in previously untreated patients","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-06T13:00:00Z","last_updated_date":"2013-12-06T13:00:00Z","reference_number":"EMA/741427/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-considers-benefits-kogenate-bayerhelixate-nexgen-outweigh-risks-previously-untreated-patients_en.pdf"},
    {"id":"11188","name":"Hydroxyethyl starch Article-107i referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-ii_is.pdf"}},
    {"id":"11189","name":"Sibutramine - Article 31 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-12-14T00:59:00Z","last_updated_date":"2002-12-14T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sibutramine-article-31-referral-annex-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/sibutramine-article-31-referral-annex-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sibutramine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sibutramine-article-31-referral-annex-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sibutramine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sibutramine-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sibutramine-article-31-referral-annex-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sibutramine-article-31-referral-annex-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sibutramine-article-31-referral-annex-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sibutramine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sibutramine-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"11202","name":"Durogesic Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T02:00:00Z","last_updated_date":"2016-10-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/durogesic-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/durogesic-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/durogesic-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/durogesic-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/durogesic-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/durogesic-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/durogesic-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/durogesic-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/durogesic-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/durogesic-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/durogesic-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/durogesic-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/durogesic-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/durogesic-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/durogesic-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/durogesic-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/durogesic-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/durogesic-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/durogesic-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/durogesic-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/durogesic-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/durogesic-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/durogesic-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/durogesic-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/durogesic-article-30-referral-annex-i_no.pdf"}},
    {"id":"11208","name":"Gentamicin Article-35 referral - Divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gentamicin-article-35-referral-divergent-position_en.pdf"},
    {"id":"11250","name":"Questions and answers on the referral for Meronem and associated names meropenem powder for solution for injection or infusion 500 mg and 1 g","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:08:21Z","last_updated_date":"2009-07-23T02:08:21Z","reference_number":"EMEA/CHMP/466849/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g_en.pdf"},
    {"id":"11289","name":"Modafinil-H-A-31-1186: Article 31 Referral-Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"EMA/4038/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/modafinil-h-31-1186-article-31-referral-assessment-report_en.pdf"},
    {"id":"11314","name":"Renin-angiotensin-system (RAS)-acting agents Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T02:00:00Z","last_updated_date":"2013-05-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-notification_en.pdf"},
    {"id":"11315","name":"Questions and answers on Novantrone and associated names (mitoxantrone 2 mg/ml concentrate for solution for infusion)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/55368/2016 ","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-novantrone-and-associated-names-mitoxantrone-2-mgml-concentrate-solution-infusion_sv.pdf"}},
    {"id":"11376","name":"Valproate and related substances Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-notification_en.pdf"},
    {"id":"11385","name":"Enrofloxacin Article-35 referral - Questions and answers on use of enrofloxacin-containing veterinary medicines administered via drinking water to chickens and turkeys","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-04-16T02:00:00Z","last_updated_date":"2018-04-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/enrofloxacin-article-35-referral-questions-and-answers-use-enrofloxacin-containing-veterinary-medicines-administered-drinking-water-chickens-and-turkeys_sv.pdf"}},
    {"id":"11409","name":"Tredaptive, Pelzont and Trevaclyn Article-20 procedure - European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T01:00:00Z","last_updated_date":"2013-01-18T01:00:00Z","reference_number":"EMA/CHMP/21862/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/tredaptive-pelzont-and-trevaclyn-article-20-procedure-european-medicines-agency-confirms-recommendation-suspend-tredaptive-pelzont-and-trevaclyn_en.pdf"},
    {"id":"11455","name":"Nasonex Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-02-03T10:40:00Z","last_updated_date":"2015-02-03T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nasonex-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nasonex-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nasonex-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nasonex-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nasonex-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nasonex-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nasonex-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nasonex-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nasonex-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nasonex-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nasonex-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nasonex-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nasonex-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nasonex-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nasonex-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nasonex-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nasonex-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nasonex-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nasonex-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nasonex-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nasonex-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nasonex-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nasonex-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/nasonex-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/nasonex-article-30-referral-annex-i_no.pdf"}},
    {"id":"11460","name":"Assessment report for ergot derivatives containing medicinal products - dihydroergocristine","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"EMA/750624/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-ergot-derivatives-containing-medicinal-products-dihydroergocristine_en.pdf"},
    {"id":"11495","name":"Divergent position on a revised CVMP opinion on an Article-33(4) referral of Directive 2001/82/EC for Nuflor Swine Once 450-mg/ml solution for injection","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-revised-cvmp-opinion-article-334-referral-directive-200182ec-nuflor-swine-once-450-mgml-solution-injection_en.pdf"},
    {"id":"11511","name":"Clobutinol - Article 107 procedures - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-10-19T02:08:21Z","last_updated_date":"2007-10-19T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/clobutinol-article-107-procedures-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/clobutinol-article-107-procedures-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/clobutinol-article-107-procedures-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/clobutinol-article-107-procedures-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/clobutinol-article-107-procedures-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/clobutinol-article-107-procedures-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/clobutinol-article-107-procedures-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/clobutinol-article-107-procedures-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/clobutinol-article-107-procedures-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/clobutinol-article-107-procedures-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/clobutinol-article-107-procedures-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/clobutinol-article-107-procedures-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/clobutinol-article-107-procedures-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/clobutinol-article-107-procedures-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/clobutinol-article-107-procedures-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/clobutinol-article-107-procedures-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/clobutinol-article-107-procedures-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/clobutinol-article-107-procedures-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/clobutinol-article-107-procedures-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/clobutinol-article-107-procedures-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/clobutinol-article-107-procedures-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/clobutinol-article-107-procedures-annex-i_sv.pdf"}},
    {"id":"11542","name":"Almitrine Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-10T02:00:00Z","last_updated_date":"2013-12-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/almitrine-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/almitrine-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/almitrine-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/almitrine-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/almitrine-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/almitrine-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/almitrine-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/almitrine-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/almitrine-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/almitrine-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/almitrine-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/almitrine-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/almitrine-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/almitrine-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/almitrine-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/almitrine-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/almitrine-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/almitrine-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/almitrine-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/almitrine-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/almitrine-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/almitrine-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"11559","name":"GVK Biosciences Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-08-04T02:00:00Z","last_updated_date":"2015-08-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gvk-biosciences-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gvk-biosciences-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gvk-biosciences-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gvk-biosciences-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gvk-biosciences-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gvk-biosciences-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gvk-biosciences-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gvk-biosciences-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gvk-biosciences-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gvk-biosciences-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gvk-biosciences-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gvk-biosciences-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gvk-biosciences-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gvk-biosciences-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gvk-biosciences-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gvk-biosciences-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gvk-biosciences-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gvk-biosciences-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gvk-biosciences-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gvk-biosciences-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gvk-biosciences-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gvk-biosciences-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"11581","name":"Fusafungine Article-31 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-14T02:00:00Z","reference_number":"EMA/227560/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fusafungine-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fusafungine-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fusafungine-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fusafungine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fusafungine-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fusafungine-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fusafungine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fusafungine-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fusafungine-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fusafungine-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fusafungine-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fusafungine-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fusafungine-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fusafungine-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fusafungine-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fusafungine-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fusafungine-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fusafungine-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fusafungine-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fusafungine-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fusafungine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fusafungine-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"11602","name":"Octegra - Article 6 (12) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-13T02:08:21Z","last_updated_date":"2008-10-13T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_pl.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/octegra-article-6-12-referral-annex-i-ii-iii_sv.pdf"}}    {"id":"11611","name":"Clenil Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T01:00:00Z","last_updated_date":"2016-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/clenil-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/clenil-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/clenil-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/clenil-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/clenil-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/clenil-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/clenil-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/clenil-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/clenil-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/clenil-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/clenil-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/clenil-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/clenil-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/clenil-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/clenil-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/clenil-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/clenil-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/clenil-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/clenil-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/clenil-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/clenil-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/clenil-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/clenil-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"11623","name":"Micro Therapeutic Research Article-31 referral - CHMP list of questions to be addressed by the applicants/marketing authorisation holders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"EMA/CHMP/847556/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-chmp-list-questions-be-addressed-applicantsmarketing-authorisation-holders_en.pdf"},
    {"id":"11640","name":"Didanosine Article-29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-10T01:00:00Z","last_updated_date":"2013-12-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/didanosine-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/didanosine-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/didanosine-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/didanosine-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/didanosine-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/didanosine-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/didanosine-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/didanosine-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/didanosine-article-29-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/didanosine-article-29-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/didanosine-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/didanosine-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/didanosine-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/didanosine-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/didanosine-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/didanosine-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/didanosine-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/didanosine-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/didanosine-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/didanosine-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/didanosine-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/didanosine-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/didanosine-article-29-referral-annex-i_sv.pdf"}},
    {"id":"11642","name":"Ecomectin 18.7mg/g Oral Paste for Horses - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T00:59:00Z","last_updated_date":"2008-02-21T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ecomectin-187mgg-oral-paste-horses-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"11670","name":"Plendil - Article 30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/plendil-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/plendil-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/plendil-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/plendil-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/plendil-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/plendil-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/plendil-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/plendil-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/plendil-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/plendil-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/plendil-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/plendil-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/plendil-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/plendil-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/plendil-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/plendil-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/plendil-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/plendil-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/plendil-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/plendil-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/plendil-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/plendil-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/plendil-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/plendil-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/plendil-article-30-referral-annex-i_no.pdf"}},
    {"id":"11692","name":"Diclofenac Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-31T18:00:00Z","last_updated_date":"2013-05-17T11:40:00Z","reference_number":"EMA/PRAC/696496/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"11702","name":"Final opinion of the Committee for proprietary medicinal products in accordance with Article 12 of Directive 75/319/EEC as amended for Anoretics International Non-Proprietary Name (INN): Type III and Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1996-12-10T00:08:21Z","last_updated_date":"1996-12-10T00:08:21Z","reference_number":"CPMP/113-114/96","document_url":"https://www.ema.europa.eu/en/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-iii-and-annex-i_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-iii-and-annex-i_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-iii-and-annex-i_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-anoretics-international-non-proprietary-name-inn-type-iii-and-annex-i_fr.pdf"}},
    {"id":"11711","name":"Dienogest / Ethinylestradiol Article-31 referral - Amended product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dienogest-ethinylestradiol-article-31-referral-amended-product-information_en.pdf"},
    {"id":"11713","name":"Iclusig Article-20 procedure - Product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-product-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/iclusig-article-20-procedure-product-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/iclusig-article-20-procedure-product-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/iclusig-article-20-procedure-product-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/iclusig-article-20-procedure-product-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/iclusig-article-20-procedure-product-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/iclusig-article-20-procedure-product-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/iclusig-article-20-procedure-product-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/iclusig-article-20-procedure-product-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/iclusig-article-20-procedure-product-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/iclusig-article-20-procedure-product-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/iclusig-article-20-procedure-product-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/iclusig-article-20-procedure-product-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/iclusig-article-20-procedure-product-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/iclusig-article-20-procedure-product-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/iclusig-article-20-procedure-product-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/iclusig-article-20-procedure-product-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/iclusig-article-20-procedure-product-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/iclusig-article-20-procedure-product-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/iclusig-article-20-procedure-product-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/iclusig-article-20-procedure-product-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/iclusig-article-20-procedure-product-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/iclusig-article-20-procedure-product-information_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/iclusig-article-20-procedure-product-information_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/iclusig-article-20-procedure-product-information_no.pdf"}},
    {"id":"11729","name":"Ibuprofen and dexibuprofen Article-31 referral - Updated advice on use of high-dose ibuprofen","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/325007/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-updated-advice-use-high-dose-ibuprofen_sv.pdf"}},
    {"id":"11736","name":"Jardiance Article-20 procedure - Annex I - III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-18T02:00:00Z","last_updated_date":"2016-05-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/jardiance-article-20-procedure-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/jardiance-article-20-procedure-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/jardiance-article-20-procedure-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/jardiance-article-20-procedure-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/jardiance-article-20-procedure-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/jardiance-article-20-procedure-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/jardiance-article-20-procedure-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/jardiance-article-20-procedure-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/jardiance-article-20-procedure-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/jardiance-article-20-procedure-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/jardiance-article-20-procedure-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/jardiance-article-20-procedure-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/jardiance-article-20-procedure-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/jardiance-article-20-procedure-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/jardiance-article-20-procedure-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/jardiance-article-20-procedure-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/jardiance-article-20-procedure-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/jardiance-article-20-procedure-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/jardiance-article-20-procedure-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/jardiance-article-20-procedure-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/jardiance-article-20-procedure-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/jardiance-article-20-procedure-annex-i-iii_fi.pdf","is":"https://www.ema.europa.eu/is/documents/referral/jardiance-article-20-procedure-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/jardiance-article-20-procedure-annex-i-iii_no.pdf"}},
    {"id":"11761","name":"Codeine Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-18T02:00:00Z","last_updated_date":"2015-05-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-annex-iv_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/codeine-article-31-referral-annex-iv_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/codeine-article-31-referral-annex-iv_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/codeine-article-31-referral-annex-iv_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/codeine-article-31-referral-annex-iv_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/codeine-article-31-referral-annex-iv_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/codeine-article-31-referral-annex-iv_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/codeine-article-31-referral-annex-iv_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/codeine-article-31-referral-annex-iv_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/referral/codeine-article-31-referral-annex-iv_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/codeine-article-31-referral-annex-iv_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/codeine-article-31-referral-annex-iv_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/codeine-article-31-referral-annex-iv_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/codeine-article-31-referral-annex-iv_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/codeine-article-31-referral-annex-iv_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/codeine-article-31-referral-annex-iv_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/codeine-article-31-referral-annex-iv_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/codeine-article-31-referral-annex-iv_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/codeine-article-31-referral-annex-iv_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/codeine-article-31-referral-annex-iv_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/codeine-article-31-referral-annex-iv_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/codeine-article-31-referral-annex-iv_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/codeine-article-31-referral-annex-iv_sv.pdf-0"}},
    {"id":"11774","name":"Nimesulide - Article 31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"EMA/73856/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-assessment-report_en.pdf"},
    {"id":"11778","name":"Sandimmun Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T17:00:00Z","last_updated_date":"2013-12-20T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sandimmun-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sandimmun-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sandimmun-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sandimmun-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sandimmun-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sandimmun-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sandimmun-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sandimmun-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sandimmun-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sandimmun-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sandimmun-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sandimmun-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sandimmun-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sandimmun-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sandimmun-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sandimmun-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sandimmun-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sandimmun-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sandimmun-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sandimmun-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sandimmun-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sandimmun-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sandimmun-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"11796","name":"Bromocriptine Article-31 referral - Restrictions in use of bromocriptine for stopping breast milk production","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T01:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"EMA/698187/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bromocriptine-article-31-referral-restrictions-use-bromocriptine-stopping-breast-milk-production_sv.pdf"}},
    {"id":"11832","name":"Canazole - Article 29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-09T01:00:00Z","last_updated_date":"2012-02-09T01:00:00Z","reference_number":"EMEA/H/A-29/1286","document_url":"https://www.ema.europa.eu/en/documents/referral/canazole-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/canazole-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/canazole-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/canazole-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/canazole-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/canazole-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/canazole-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/canazole-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/canazole-article-29-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/canazole-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/canazole-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/canazole-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/canazole-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/canazole-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/canazole-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/canazole-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/canazole-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/canazole-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/canazole-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/canazole-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/canazole-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/canazole-article-29-referral-annex-i_sv.pdf"}},
    {"id":"11852","name":"Zinnat - Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T01:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinnat-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinnat-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinnat-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinnat-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinnat-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinnat-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinnat-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinnat-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinnat-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinnat-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinnat-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinnat-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinnat-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinnat-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinnat-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinnat-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinnat-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinnat-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinnat-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinnat-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinnat-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinnat-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/zinnat-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/zinnat-article-30-referral-annex-i_no.pdf"}},
    {"id":"11884","name":"Opinion of the Committee for proprietary medicinal products pursuant to Article 12 of Council Directive 75/319/EEC as amended for Terfenadine 120mg and Annexes A and B","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-01-22T00:08:21Z","last_updated_date":"1998-01-22T00:08:21Z","reference_number":"CPMP/1000/97-EN","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-120mg-and-annexes-and-b_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-120mg-and-annexes-and-b_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-120mg-and-annexes-and-b_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-120mg-and-annexes-and-b_fr.pdf"}},
    {"id":"11895","name":"Implanon - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-02-27T00:08:21Z","last_updated_date":"2008-02-27T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/implanon-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/implanon-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/implanon-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/implanon-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/implanon-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/implanon-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/implanon-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/implanon-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/implanon-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/implanon-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/implanon-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/implanon-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/implanon-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/implanon-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/implanon-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/implanon-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/implanon-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/implanon-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/implanon-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/implanon-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/implanon-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/implanon-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"11906","name":"Fusafungine Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-09-11T02:00:00Z","last_updated_date":"2015-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-review-started_en.pdf"},
    {"id":"11918","name":"Questions and answers on Cymevene and associated names (ganciclovir, 500 mg powder for concentrate for solution for infusion, intravenous)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-06-21T02:00:00Z","reference_number":"EMA/142869/2016 ","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-cymevene-and-associated-names-ganciclovir-500-mg-powder-concentrate-solution-infusion-intravenous_sv.pdf"}},
    {"id":"11924","name":"Fusafungine Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-09-11T02:00:00Z","last_updated_date":"2015-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-notification_en.pdf"},
    {"id":"11936","name":"Opinion following an Article 29(4) referral for Lisonorm and associated names  International Non-Proprietary Name (INN): lisinopril + amlodipine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-11-15T00:08:21Z","last_updated_date":"2008-11-15T00:08:21Z","reference_number":"EMEA/CHMP/633842/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-lisonorm-and-associated-names-international-non-proprietary-name-inn-lisinopril-amlodipine-background-information_sv.pdf"}},
    {"id":"11962","name":"Seasonique Article-29(4) - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/seasonique-article-294-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/seasonique-article-294-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/seasonique-article-294-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seasonique-article-294-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seasonique-article-294-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seasonique-article-294-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seasonique-article-294-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seasonique-article-294-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seasonique-article-294-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/seasonique-article-294-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seasonique-article-294-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seasonique-article-294-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seasonique-article-294-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seasonique-article-294-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/seasonique-article-294-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seasonique-article-294-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seasonique-article-294-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seasonique-article-294-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/seasonique-article-294-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seasonique-article-294-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seasonique-article-294-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seasonique-article-294-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seasonique-article-294-annex-ii_sv.pdf"}},
    {"id":"11975","name":"Modified release oral opioids - Article 31 referral - Annex IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"11993","name":"Symbioflor 2 Article-31 referral - CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-09-07T02:00:00Z","last_updated_date":"2017-09-07T02:00:00Z","reference_number":"EMA/530965/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"12011","name":"Novimp - Article 36 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMEA/H/A-36/1298","document_url":"https://www.ema.europa.eu/en/documents/referral/novimp-article-36-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/novimp-article-36-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/novimp-article-36-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/novimp-article-36-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/novimp-article-36-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/novimp-article-36-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/novimp-article-36-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/novimp-article-36-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/novimp-article-36-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/novimp-article-36-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/novimp-article-36-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/novimp-article-36-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/novimp-article-36-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/novimp-article-36-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/novimp-article-36-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/novimp-article-36-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/novimp-article-36-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/novimp-article-36-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/novimp-article-36-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/novimp-article-36-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/novimp-article-36-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/novimp-article-36-referral-annex-i_sv.pdf"}},
    {"id":"12013","name":"Questions and answers on the referral for Tritazide tablets containing ramipril and hydrochlorothiazide 2.5/12.5 mg, 5/12.5 mg, 5/25 mg","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-19T00:08:21Z","last_updated_date":"2009-03-19T00:08:21Z","reference_number":"EMEA/CHMP/204584/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_sv.pdf"}},
    {"id":"12027","name":"EMLA cream Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/emla-cream-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/emla-cream-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/emla-cream-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/emla-cream-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/emla-cream-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/emla-cream-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/emla-cream-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/emla-cream-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/emla-cream-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/emla-cream-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/emla-cream-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/emla-cream-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/emla-cream-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/emla-cream-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/emla-cream-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/emla-cream-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/emla-cream-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/emla-cream-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/emla-cream-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/emla-cream-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/emla-cream-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/emla-cream-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/emla-cream-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/emla-cream-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/emla-cream-article-30-referral-annex-i_no.pdf"}},
    {"id":"12084","name":"Enurace 50 - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-16T00:59:00Z","last_updated_date":"2007-11-16T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/enurace-50-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"12138","name":"Nasonex Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-02-03T10:40:00Z","last_updated_date":"2015-02-03T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nasonex-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nasonex-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nasonex-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nasonex-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nasonex-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nasonex-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nasonex-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nasonex-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nasonex-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nasonex-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nasonex-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nasonex-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nasonex-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nasonex-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nasonex-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nasonex-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nasonex-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nasonex-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nasonex-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nasonex-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nasonex-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nasonex-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nasonex-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"12144","name":"Diclofenac Article-31 referral - New safety advice for diclofenac","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T01:00:00Z","last_updated_date":"2013-11-27T01:00:00Z","reference_number":"EMEA/H/A-31/1344","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac_sv.pdf"}},
    {"id":"12154","name":"Final opinion of the Committee for proprietary medicinal products pursuant to Article 12 of Council Directive 75/319/EEC as amended for Terfenadine 30mg and Annexes A, B and I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-01-22T00:08:21Z","last_updated_date":"1998-01-22T00:08:21Z","reference_number":"CPMP/256/98-EN","document_url":"https://www.ema.europa.eu/en/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-30mg-and-annexes-b-and-i_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-30mg-and-annexes-b-and-i_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-30mg-and-annexes-b-and-i_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-30mg-and-annexes-b-and-i_fr.pdf"}},
    {"id":"12180","name":"Fibrin sealants Article 31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrin-sealants-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrin-sealants-article-31-referral-annex-iv_bg.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrin-sealants-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrin-sealants-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrin-sealants-article-31-referral-annex-iv_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrin-sealants-article-31-referral-annex-iv_el.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrin-sealants-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrin-sealants-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrin-sealants-article-31-referral-annex-iv_lt.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrin-sealants-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrin-sealants-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrin-sealants-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrin-sealants-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrin-sealants-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrin-sealants-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrin-sealants-article-31-referral-annex-iv_sl.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrin-sealants-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"12194","name":"Zanil Article-35 referral - Questions and answers on Zanil and associated names, and generic products thereof","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-25T18:30:00Z","last_updated_date":"2017-10-25T18:30:00Z","reference_number":"EMA/586006/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zanil-article-35-referral-questions-and-answers-zanil-and-associated-names-and-generic-products-thereof_sv.pdf"}},
    {"id":"12220","name":"Questions and answers on the review of modified-release oral opioid medicines of the WHO level III scale for the management of pain - Initial","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2010-07-23T02:00:00Z","reference_number":"EMA/459105/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-initial_en.pdf"},
    {"id":"12222","name":"Short-acting beta-agonists Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-07T01:00:00Z","last_updated_date":"2013-11-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_no.pdf"}},
    {"id":"12229","name":"Esmya Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T02:00:00Z","last_updated_date":"2018-06-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-annex-iii_en.pdf"},
    {"id":"12233","name":"Diflucan - Article 30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T01:00:00Z","last_updated_date":"2012-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diflucan-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diflucan-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diflucan-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diflucan-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diflucan-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diflucan-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diflucan-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diflucan-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diflucan-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diflucan-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diflucan-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diflucan-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diflucan-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diflucan-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diflucan-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diflucan-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diflucan-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diflucan-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diflucan-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diflucan-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diflucan-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diflucan-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"12244","name":"Pantoprazole Bluefish - Article 29 referral - Annex I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2011-03-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pantoprazole-bluefish-article-29-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"12311","name":"Orlistat - Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-16T17:30:00Z","last_updated_date":"2012-12-21T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/orlistat-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/orlistat-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/orlistat-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/orlistat-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/orlistat-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/orlistat-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/orlistat-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/orlistat-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/orlistat-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/orlistat-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/orlistat-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/orlistat-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/orlistat-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/orlistat-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/orlistat-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/orlistat-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/orlistat-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/orlistat-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/orlistat-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/orlistat-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/orlistat-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/orlistat-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"12315","name":"Lactose of bovine origin Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-04T02:00:00Z","last_updated_date":"2017-09-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lactose-bovine-origin-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"12342","name":"GVK Biosciences Article-31 referral - GVK Biosciences: Final assessment report following the re-examination procedure","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-08-04T02:00:00Z","last_updated_date":"2015-08-04T02:00:00Z","reference_number":"EMA/348074/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-final-assessment-report-following-re-examination-procedure_en.pdf"},
    {"id":"12391","name":"Zinbryta Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T01:00:00Z","last_updated_date":"2018-03-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"12396","name":"Semler Article-31 referral – Annex IA  and IB","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-03T12:00:00Z","last_updated_date":"2016-11-17T15:00:00Z","reference_number":"EMA/314147/2016 Corr. 6","document_url":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-annex-ia-and-ib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/semler-article-31-referral-annex-ia-and-ib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/semler-article-31-referral-annex-ia-and-ib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/semler-article-31-referral-annex-ia-and-ib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/semler-article-31-referral-annex-ia-and-ib_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/semler-article-31-referral-annex-ia-and-ib_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/semler-article-31-referral-annex-ia-and-ib_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/semler-article-31-referral-annex-ia-and-ib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/semler-article-31-referral-annex-ia-and-ib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/semler-article-31-referral-annex-ia-and-ib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/semler-article-31-referral-annex-ia-and-ib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/semler-article-31-referral-annex-ia-and-ib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/semler-article-31-referral-annex-ia-and-ib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/semler-article-31-referral-annex-ia-and-ib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/semler-article-31-referral-annex-ia-and-ib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/semler-article-31-referral-annex-ia-and-ib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/semler-article-31-referral-annex-ia-and-ib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/semler-article-31-referral-annex-ia-and-ib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/semler-article-31-referral-annex-ia-and-ib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/semler-article-31-referral-annex-ia-and-ib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/semler-article-31-referral-annex-ia-and-ib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/semler-article-31-referral-annex-ia-and-ib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/semler-article-31-referral-annex-ia-and-ib_sv.pdf"}},
    {"id":"12416","name":"Bromocriptine, Dihydroergocryptine and Lisuride - Article 31 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-05T02:08:21Z","last_updated_date":"2009-05-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-i_sv.pdf"}},
    {"id":"12422","name":"Zinbryta Article-20 referral - Assessment report on provisional measures","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-07-19T18:23:00Z","last_updated_date":"2017-09-01T16:55:00Z","reference_number":"EMA/453660/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-assessment-report-provisional-measures_en.pdf"},
    {"id":"12450","name":"Opinion following an Article 29(4) referral for Xeomin International Non-Proprietary Name (INN): Clostridium botulinum neurotoxin type A: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-10-25T02:08:21Z","last_updated_date":"2007-10-25T02:08:21Z","reference_number":"EMEA/CHMP/350251/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-xeomin-international-non-proprietary-name-inn-clostridium-botulinum-neurotoxin-type-background-information_sv.pdf"}},
    {"id":"12479","name":"Ergot derivatives Article-31 referral - Dihydroergotamine - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-ii_sv.pdf"}},
    {"id":"12485","name":"Vivaglobin Article-36 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vivaglobin-article-36-referral-annex-ii_en.pdf"},
    {"id":"12504","name":"Zinbryta Article-20 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-01-12T01:00:00Z","last_updated_date":"2018-01-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinbryta-article-20-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinbryta-article-20-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinbryta-article-20-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinbryta-article-20-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinbryta-article-20-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinbryta-article-20-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinbryta-article-20-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinbryta-article-20-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zinbryta-article-20-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinbryta-article-20-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinbryta-article-20-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinbryta-article-20-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinbryta-article-20-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinbryta-article-20-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinbryta-article-20-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinbryta-article-20-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinbryta-article-20-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinbryta-article-20-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinbryta-article-20-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinbryta-article-20-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinbryta-article-20-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinbryta-article-20-referral-annex-iv_sv.pdf"}},
    {"id":"12506","name":"Canazole - Article 29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-09T01:00:00Z","last_updated_date":"2012-02-09T01:00:00Z","reference_number":"EMEA/H/A-29/1286","document_url":"https://www.ema.europa.eu/en/documents/referral/canazole-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/canazole-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/canazole-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/canazole-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/canazole-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/canazole-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/canazole-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/canazole-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/canazole-article-29-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/canazole-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/canazole-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/canazole-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/canazole-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/canazole-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/canazole-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/canazole-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/canazole-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/canazole-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/canazole-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/canazole-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/canazole-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/canazole-article-29-referral-annex-iii_sv.pdf"}},
    {"id":"12507","name":"Calcitugg - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-01-22T00:08:21Z","last_updated_date":"2004-01-22T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/calcitugg-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"12568","name":"Ergot derivatives Article-31 referral - Dihydroergotamine - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iii_no.pdf"}},
    {"id":"12572","name":"Protium - Article 30 referrals - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-01-17T01:00:00Z","last_updated_date":"2012-01-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/protium-article-30-referrals-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/protium-article-30-referrals-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/protium-article-30-referrals-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/protium-article-30-referrals-annex-iv_cs.pdf","de":"https://www.ema.europa.eu/de/documents/referral/protium-article-30-referrals-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/protium-article-30-referrals-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/protium-article-30-referrals-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/protium-article-30-referrals-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/protium-article-30-referrals-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/protium-article-30-referrals-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/protium-article-30-referrals-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/protium-article-30-referrals-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/protium-article-30-referrals-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/protium-article-30-referrals-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/protium-article-30-referrals-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/protium-article-30-referrals-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/protium-article-30-referrals-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/protium-article-30-referrals-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/protium-article-30-referrals-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/protium-article-30-referrals-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/protium-article-30-referrals-annex-iv_sv.pdf"}},
    {"id":"12591","name":"Assessment report for ergot derivatives containing medicinal products - dihydroergocryptine/caffeine","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"EMA/750625/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-ergot-derivatives-containing-medicinal-products-dihydroergocryptinecaffeine_en.pdf"},
    {"id":"12602","name":"Cobactan DC Article-6(13) referral - Annex I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-12T02:00:00Z","last_updated_date":"2014-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cobactan-dc-article-613-referral-annex-i-ii_sv.pdf"}},
    {"id":"12626","name":"Almitrine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"EMA/759665/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-referral-annex-i_en.pdf-0"},
    {"id":"12635","name":"Etopophos Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-14T18:00:00Z","last_updated_date":"2017-07-14T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etopophos-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/etopophos-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/etopophos-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etopophos-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etopophos-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etopophos-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etopophos-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etopophos-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etopophos-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/etopophos-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etopophos-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etopophos-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etopophos-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etopophos-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/etopophos-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etopophos-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etopophos-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etopophos-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/etopophos-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etopophos-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etopophos-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etopophos-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etopophos-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"12639","name":"Codeine Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-08-02T02:00:00Z","last_updated_date":"2013-08-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-annex-ii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/codeine-article-31-referral-annex-ii_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/codeine-article-31-referral-annex-ii_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/codeine-article-31-referral-annex-ii_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/codeine-article-31-referral-annex-ii_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/codeine-article-31-referral-annex-ii_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/codeine-article-31-referral-annex-ii_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/codeine-article-31-referral-annex-ii_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/codeine-article-31-referral-annex-ii_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/referral/codeine-article-31-referral-annex-ii_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/codeine-article-31-referral-annex-ii_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/codeine-article-31-referral-annex-ii_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/codeine-article-31-referral-annex-ii_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/codeine-article-31-referral-annex-ii_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/codeine-article-31-referral-annex-ii_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/codeine-article-31-referral-annex-ii_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/codeine-article-31-referral-annex-ii_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/codeine-article-31-referral-annex-ii_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/codeine-article-31-referral-annex-ii_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/codeine-article-31-referral-annex-ii_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/codeine-article-31-referral-annex-ii_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/codeine-article-31-referral-annex-ii_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/codeine-article-31-referral-annex-ii_sv.pdf-0"}},
    {"id":"12644","name":"Pharmaceutics International Inc. Article-31 referral – Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T01:00:00Z","last_updated_date":"2016-12-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"12682","name":"Gadovist - Article 36 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-09T00:08:21Z","last_updated_date":"2007-11-09T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gadovist-article-36-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"12688","name":"Sanohex - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-30T02:08:21Z","last_updated_date":"2009-03-30T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sanohex-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"12726","name":"Eprinex pour-on - Article-34 - Annex I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-11T02:00:00Z","last_updated_date":"2014-08-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/eprinex-pour-article-34-annex-i-ii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/eprinex-pour-article-34-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/eprinex-pour-article-34-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/eprinex-pour-article-34-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/eprinex-pour-article-34-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/eprinex-pour-article-34-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/eprinex-pour-article-34-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/eprinex-pour-article-34-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/eprinex-pour-article-34-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/eprinex-pour-article-34-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/eprinex-pour-article-34-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/eprinex-pour-article-34-annex-i-ii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/eprinex-pour-article-34-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/eprinex-pour-article-34-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/eprinex-pour-article-34-annex-i-ii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/eprinex-pour-article-34-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/eprinex-pour-article-34-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/eprinex-pour-article-34-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/eprinex-pour-article-34-annex-i-ii_sv.pdf"}},
    {"id":"12756","name":"Clopidogrel Orion - Article 29 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-08T02:00:00Z","last_updated_date":"2011-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/clopidogrel-orion-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"12767","name":"Acipimox only to be used as additional or alternative treatment to reduce high triglyceride levels","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-13T18:00:00Z","last_updated_date":"2014-03-13T18:00:00Z","reference_number":"EMA/108603/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_sv.pdf"}},
    {"id":"12775","name":"Questions and answers on the referral for Pantoprazole Bluefish pantoprazole 20 and 40 mg tablets","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-11-21T00:59:00Z","last_updated_date":"2011-03-09T00:59:00Z","reference_number":"EMEA/CHMP/734816/2009 Rev","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_sv.pdf"}},
    {"id":"12778","name":"Scandonest Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-08-07T02:00:00Z","last_updated_date":"2018-08-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/scandonest-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/scandonest-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/scandonest-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/scandonest-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/scandonest-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/scandonest-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/scandonest-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/scandonest-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/scandonest-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/scandonest-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/scandonest-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/scandonest-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/scandonest-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/scandonest-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/scandonest-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/scandonest-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/scandonest-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/scandonest-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/scandonest-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/scandonest-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/scandonest-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/scandonest-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/scandonest-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"12790","name":"Adrenaline auto-injectors Article-31 referral - CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T02:00:00Z","last_updated_date":"2015-08-26T02:00:00Z","reference_number":"EMA/478468/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"12795","name":"Methadone Article-107i procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-prac-list-questions_en.pdf"},
    {"id":"12819","name":"Tetrazepam-containing medicines - Article-107i procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-08T18:00:00Z","last_updated_date":"2013-05-08T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-iii_sv.pdf"}},
    {"id":"12821","name":"Merisone Article-29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-28T02:00:00Z","last_updated_date":"2015-07-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/merisone-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/merisone-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/merisone-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/merisone-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/merisone-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/merisone-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/merisone-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/merisone-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/merisone-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/merisone-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/merisone-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/merisone-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/merisone-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/merisone-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/merisone-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/merisone-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/merisone-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/merisone-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/merisone-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/merisone-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/merisone-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/merisone-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/merisone-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"12843","name":"Calcitonin Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T02:00:00Z","last_updated_date":"2013-07-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/calcitonin-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/calcitonin-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/calcitonin-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/calcitonin-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/calcitonin-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/calcitonin-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/calcitonin-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/calcitonin-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/calcitonin-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/calcitonin-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/calcitonin-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/calcitonin-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/calcitonin-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/calcitonin-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/calcitonin-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/calcitonin-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/calcitonin-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/calcitonin-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/calcitonin-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/calcitonin-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/calcitonin-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/calcitonin-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/calcitonin-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/calcitonin-article-31-referral-annex-iii_no.pdf"}},
    {"id":"12866","name":"Pholcodine - Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-03-28T02:00:00Z","last_updated_date":"2012-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pholcodine-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pholcodine-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pholcodine-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pholcodine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pholcodine-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pholcodine-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pholcodine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pholcodine-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pholcodine-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pholcodine-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pholcodine-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pholcodine-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pholcodine-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pholcodine-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pholcodine-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pholcodine-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pholcodine-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pholcodine-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pholcodine-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pholcodine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pholcodine-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"12876","name":"Flupirtine Article-31 referral - Withdrawal of pain medicine flupirtine endorsed","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flupirtine-article-31-referral-withdrawal-pain-medicine-flupirtine-endorsed_sv.pdf"}},
    {"id":"12906","name":"Suvaxyn Parvo/E - Article 40 Referral - Annex I, II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-16T00:59:00Z","last_updated_date":"2007-11-16T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/suvaxyn-parvoe-article-40-referral-annex-i-ii_sv.pdf"}},
    {"id":"12918","name":"Nimesulide - Article 107 procedures - Annex V","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-08T02:00:00Z","last_updated_date":"2010-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-107-procedures-annex-v_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nimesulide-article-107-procedures-annex-v_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nimesulide-article-107-procedures-annex-v_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nimesulide-article-107-procedures-annex-v_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nimesulide-article-107-procedures-annex-v_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nimesulide-article-107-procedures-annex-v_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nimesulide-article-107-procedures-annex-v_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nimesulide-article-107-procedures-annex-v_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nimesulide-article-107-procedures-annex-v_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nimesulide-article-107-procedures-annex-v_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nimesulide-article-107-procedures-annex-v_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nimesulide-article-107-procedures-annex-v_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nimesulide-article-107-procedures-annex-v_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nimesulide-article-107-procedures-annex-v_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nimesulide-article-107-procedures-annex-v_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nimesulide-article-107-procedures-annex-v_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nimesulide-article-107-procedures-annex-v_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nimesulide-article-107-procedures-annex-v_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nimesulide-article-107-procedures-annex-v_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nimesulide-article-107-procedures-annex-v_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nimesulide-article-107-procedures-annex-v_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nimesulide-article-107-procedures-annex-v_sv.pdf"}},
    {"id":"12963","name":"Questions and answers on Seroquel, Seroquel XR and associated names (quetiapine)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-09-09T02:00:00Z","reference_number":"EMA/301727/2014 ","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-seroquel-seroquel-xr-and-associated-names-quetiapine_sv.pdf"}},
    {"id":"12982","name":"Paracetamol Article-31 referral - PRAC recommends modified-release paracetamol be removed from market","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-01T17:00:00Z","last_updated_date":"2017-09-29T17:00:00Z","reference_number":"EMA/562720/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-prac-recommends-modified-release-paracetamol-be-removed-market_en.pdf"},
    {"id":"12987","name":"Opinion following an Article 29(4) referral for Oracea International Non-Proprietary Name (INN): doxycycline monohydrate: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-07-23T02:08:21Z","last_updated_date":"2008-07-23T02:08:21Z","reference_number":"EMEA/CHMP/428671/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-oracea-international-non-proprietary-name-inn-doxycycline-monohydrate-background-information_sv.pdf"}},
    {"id":"12992","name":"Bisphosphonates - Article 31 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bisphosphonates-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bisphosphonates-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bisphosphonates-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bisphosphonates-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bisphosphonates-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bisphosphonates-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bisphosphonates-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bisphosphonates-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bisphosphonates-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bisphosphonates-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bisphosphonates-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bisphosphonates-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bisphosphonates-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bisphosphonates-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bisphosphonates-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bisphosphonates-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bisphosphonates-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bisphosphonates-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bisphosphonates-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bisphosphonates-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bisphosphonates-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bisphosphonates-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"13008","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-10T15:00:00Z","last_updated_date":"2013-06-10T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-iii_no.pdf"}},
    {"id":"13041","name":"Fortekor: Article 34 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T01:00:00Z","last_updated_date":"2019-03-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fortekor-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"13052","name":"Hydroxyethyl starch Article-107i referral - Summary of PRAC recommendation","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2018-01-12T13:45:00Z","last_updated_date":"2018-01-12T13:45:00Z","reference_number":"EMA/4068/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-summary-prac-recommendation_en.pdf"},
    {"id":"13053","name":"Hipralona Enro-S Article-35 referral - Annexes I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-02-04T01:00:00Z","last_updated_date":"2013-02-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hipralona-enro-s-article-35-referral-annexes-i-ii_sv.pdf"}},
    {"id":"13057","name":"Opinion following an article 6(12) referral for Vasotop P tablet for dogs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-14T02:00:00Z","last_updated_date":"2014-08-14T02:00:00Z","reference_number":"EMA/183104/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-612-referral-vasotop-p-tablet-dogs_sv.pdf"}},
    {"id":"13062","name":"Gentamicin Article 35 - Opinion following an Article 35  referral for veterinary medicinal products containing gentamicin presented as solutions for injection to be administered to horses: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-04-10T02:00:00Z","last_updated_date":"2015-04-10T02:00:00Z","reference_number":"EMA/106359/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gentamicin-article-35-opinion-following-article-35-referral-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-background-information_sv.pdf"}},
    {"id":"13104","name":"Novantrone and associated names Article-30 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"EMA/CHMP/427120/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/novantrone-and-associated-names-article-30-referral-assessment-report_en.pdf"},
    {"id":"13157","name":"Methadone Article-107i procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-04T02:00:00Z","last_updated_date":"2014-08-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methadone-article-107i-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methadone-article-107i-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methadone-article-107i-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methadone-article-107i-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methadone-article-107i-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methadone-article-107i-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methadone-article-107i-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methadone-article-107i-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methadone-article-107i-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methadone-article-107i-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methadone-article-107i-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methadone-article-107i-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methadone-article-107i-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methadone-article-107i-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methadone-article-107i-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methadone-article-107i-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methadone-article-107i-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methadone-article-107i-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methadone-article-107i-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methadone-article-107i-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methadone-article-107i-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methadone-article-107i-procedure-annex-iv_sv.pdf"}},
    {"id":"13189","name":"Short-acting beta-agonists Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-07T01:00:00Z","last_updated_date":"2013-11-07T01:00:00Z","reference_number":"EMA/664276/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"13258","name":"Cymevene Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T13:00:00Z","last_updated_date":"2016-06-21T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cymevene-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cymevene-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cymevene-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cymevene-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cymevene-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cymevene-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cymevene-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cymevene-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cymevene-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cymevene-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cymevene-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cymevene-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cymevene-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cymevene-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cymevene-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cymevene-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cymevene-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cymevene-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cymevene-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cymevene-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cymevene-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cymevene-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cymevene-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/cymevene-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/cymevene-article-30-referral-annex-iii_no.pdf"}},
    {"id":"13275","name":"Diacerein Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"EMA/764460/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-annex-i_en.pdf"},
    {"id":"13282","name":"Docetaxel Teva Generics - Article 29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-03T02:00:00Z","last_updated_date":"2012-07-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/docetaxel-teva-generics-article-29-referral-annex-i_sv.pdf"}},
    {"id":"13295","name":"Maci Article-20 procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-17T01:00:00Z","last_updated_date":"2014-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/maci-article-20-procedure-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/maci-article-20-procedure-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/maci-article-20-procedure-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/maci-article-20-procedure-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/maci-article-20-procedure-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/maci-article-20-procedure-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/maci-article-20-procedure-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/maci-article-20-procedure-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/maci-article-20-procedure-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/maci-article-20-procedure-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/maci-article-20-procedure-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/maci-article-20-procedure-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/maci-article-20-procedure-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/maci-article-20-procedure-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/maci-article-20-procedure-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/maci-article-20-procedure-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/maci-article-20-procedure-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/maci-article-20-procedure-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/maci-article-20-procedure-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/maci-article-20-procedure-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/maci-article-20-procedure-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/maci-article-20-procedure-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/maci-article-20-procedure-annex-i_sv.pdf"}},
    {"id":"13350","name":"Sortis - Article 6 (12) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-12-09T00:08:21Z","last_updated_date":"2006-12-09T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sortis-article-6-12-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"13386","name":"Metformin Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T01:00:00Z","last_updated_date":"2016-12-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metformin-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metformin-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metformin-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metformin-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metformin-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metformin-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metformin-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metformin-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metformin-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metformin-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metformin-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metformin-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metformin-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metformin-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metformin-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metformin-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metformin-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metformin-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metformin-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metformin-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metformin-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metformin-article-31-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/metformin-article-31-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/metformin-article-31-referral-annex-ii_no.pdf"}},
    {"id":"13393","name":"Bromocriptine Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-02T02:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bromocriptine-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bromocriptine-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bromocriptine-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bromocriptine-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bromocriptine-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bromocriptine-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bromocriptine-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bromocriptine-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/bromocriptine-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bromocriptine-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bromocriptine-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bromocriptine-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bromocriptine-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bromocriptine-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bromocriptine-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bromocriptine-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bromocriptine-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bromocriptine-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bromocriptine-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bromocriptine-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bromocriptine-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bromocriptine-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"13404","name":"Tritazide - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-04-14T02:08:21Z","last_updated_date":"2009-04-14T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tritazide-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"13470","name":"Zinnat - Article 30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T01:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinnat-article-30-referral-annex-ii_en.pdf"},
    {"id":"13488","name":"Symbioflor 2 Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-09-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/symbioflor-2-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/symbioflor-2-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/symbioflor-2-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/symbioflor-2-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/symbioflor-2-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/symbioflor-2-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/symbioflor-2-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/symbioflor-2-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/symbioflor-2-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/symbioflor-2-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/symbioflor-2-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/symbioflor-2-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/symbioflor-2-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/symbioflor-2-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/symbioflor-2-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/symbioflor-2-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/symbioflor-2-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/symbioflor-2-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/symbioflor-2-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/symbioflor-2-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/symbioflor-2-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/symbioflor-2-article-31-referral-annex-iii_sv.pdf"}}    {"id":"13489","name":"Methylphenidate Sandoz Article-29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-05T01:00:00Z","last_updated_date":"2013-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/methylphenidate-sandoz-article-29-referral-annex-iii_no.pdf"}},
    {"id":"13501","name":"Caustinerf arsenical and Yranicid arsenical Article-31 referral - Authorisations of Caustinerf arsenical and Yranicid arsenical used in dental procedures revoked in the European Union","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-06T13:20:00Z","last_updated_date":"2014-08-06T13:20:00Z","reference_number":"EMA/431170/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures-revoked-european-union_sv.pdf"}},
    {"id":"13513","name":"Nicardipine Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T02:00:00Z","last_updated_date":"2014-03-12T13:00:00Z","reference_number":"Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/nicardipine-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nicardipine-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nicardipine-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nicardipine-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nicardipine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nicardipine-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nicardipine-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nicardipine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nicardipine-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nicardipine-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nicardipine-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nicardipine-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nicardipine-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nicardipine-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nicardipine-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nicardipine-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nicardipine-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nicardipine-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nicardipine-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nicardipine-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nicardipine-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nicardipine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nicardipine-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"13521","name":"Opinion following an Article 31 referral for all medicinal products containing Celecoxib, Etoricoxib, Parecoxib, Rofecoxib or Valdecoxib International Non-Proprietary Name (INN): celecoxib: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-04-30T02:08:21Z","last_updated_date":"2004-04-30T02:08:21Z","reference_number":"EMEA/CPMP/1747/04","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-parecoxib-rofecoxib-or-valdecoxib-international-non-proprietary-name-inn-celecoxib-background-information_en.pdf"},
    {"id":"13538","name":"Trimetazidine - Article 31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-10-17T02:00:00Z","last_updated_date":"2012-10-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/trimetazidine-article-31-referral-assessment-report_en.pdf"},
    {"id":"13542","name":"Questions and answers on Okrido (prednisolone sodium phosphate, oral solution, 6 mg/ml)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2014-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-okrido-prednisolone-sodium-phosphate-oral-solution-6-mgml_sv.pdf"}},
    {"id":"13544","name":"Gadolinium Article-31 referral – PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T13:00:00Z","last_updated_date":"2017-04-07T14:00:00Z","reference_number":"EMA/157486/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-prac-concludes-assessment-gadolinium-agents-used-body-scans-and-recommends-regulatory-actions-including-suspension-some-marketing-authorisations_en.pdf"},
    {"id":"13548","name":"Emergency contraceptives Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-06T16:00:00Z","last_updated_date":"2014-08-06T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_en.pdf"},
    {"id":"13554","name":"Factor VIII Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-05T01:00:00Z","last_updated_date":"2017-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/factor-viii-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/factor-viii-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/factor-viii-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/factor-viii-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/factor-viii-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/factor-viii-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/factor-viii-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/factor-viii-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/factor-viii-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/factor-viii-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/factor-viii-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/factor-viii-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/factor-viii-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/factor-viii-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/factor-viii-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/factor-viii-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/factor-viii-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/factor-viii-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/factor-viii-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/factor-viii-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/factor-viii-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/factor-viii-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"13565","name":"Hydroxyethyl starch Article-107i referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"EMA/PRAC/691228/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-prac-list-questions_en.pdf"},
    {"id":"13598","name":"Tazocin - Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tazocin-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tazocin-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tazocin-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tazocin-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tazocin-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tazocin-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tazocin-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tazocin-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tazocin-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tazocin-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tazocin-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tazocin-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tazocin-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tazocin-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tazocin-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tazocin-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tazocin-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tazocin-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tazocin-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tazocin-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tazocin-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tazocin-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"13621","name":"Mifepristone Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/mifepristone-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/mifepristone-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/mifepristone-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/mifepristone-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/mifepristone-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/mifepristone-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/mifepristone-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/mifepristone-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/mifepristone-article-294-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/mifepristone-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/mifepristone-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/mifepristone-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/mifepristone-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/mifepristone-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/mifepristone-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/mifepristone-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/mifepristone-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/mifepristone-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/mifepristone-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/mifepristone-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/mifepristone-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/mifepristone-article-294-referral-annex-i_sv.pdf"}},
    {"id":"13627","name":"Questions and answers on Femara and associated names (letrozole, 2.5 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T01:00:00Z","last_updated_date":"2012-06-12T02:00:00Z","reference_number":"EMA/180824/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-femara-and-associated-names-letrozole-25-mg-tablets_sv.pdf"}},
    {"id":"13629","name":"Dexamed and associated names Article-29(4) referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-02T02:00:00Z","last_updated_date":"2014-09-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iv_sv.pdf"}},
    {"id":"13640","name":"Corlentor and Procoralan Article-20 procedure - PRAC recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-07T13:00:00Z","last_updated_date":"2014-11-07T13:00:00Z","reference_number":"EMA/676096/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/corlentor-and-procoralan-article-20-procedure-prac-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_en.pdf"},
    {"id":"13688","name":"Short-acting beta-agonists Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"EMA/PRAC/744203/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"13724","name":"Gadolinium Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T01:00:00Z","last_updated_date":"2016-04-26T02:00:00Z","reference_number":"EMA/207286/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-annex-i_en.pdf"},
    {"id":"13727","name":"Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/631408/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_sv.pdf"}},
    {"id":"13731","name":"Cilazapril Teva Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cilazapril-teva-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cilazapril-teva-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cilazapril-teva-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cilazapril-teva-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cilazapril-teva-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cilazapril-teva-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cilazapril-teva-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cilazapril-teva-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cilazapril-teva-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cilazapril-teva-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cilazapril-teva-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cilazapril-teva-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cilazapril-teva-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cilazapril-teva-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cilazapril-teva-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cilazapril-teva-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cilazapril-teva-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cilazapril-teva-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cilazapril-teva-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cilazapril-teva-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cilazapril-teva-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cilazapril-teva-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"13746","name":"Questions and answers on Clopidogrel Teva and associated names (clopidogrel 75 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-02-20T00:59:00Z","last_updated_date":"2011-09-09T01:59:00Z","reference_number":"EMA/103806/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_sv.pdf"}},
    {"id":"13765","name":"Lansoprazol HEXAL 15 mg and 30 mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-10-13T02:08:21Z","last_updated_date":"2005-10-13T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lansoprazol-hexal-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"13767","name":"GVK Biosciences Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-23T13:00:00Z","last_updated_date":"2015-08-04T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gvk-biosciences-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gvk-biosciences-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gvk-biosciences-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gvk-biosciences-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gvk-biosciences-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gvk-biosciences-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gvk-biosciences-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gvk-biosciences-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gvk-biosciences-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gvk-biosciences-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gvk-biosciences-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gvk-biosciences-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gvk-biosciences-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gvk-biosciences-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gvk-biosciences-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gvk-biosciences-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gvk-biosciences-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gvk-biosciences-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gvk-biosciences-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gvk-biosciences-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gvk-biosciences-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gvk-biosciences-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/gvk-biosciences-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/gvk-biosciences-article-31-referral-annex-i_no.pdf"}},
    {"id":"13771","name":"Novantrone Article-30 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/novantrone-article-30-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/novantrone-article-30-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/novantrone-article-30-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/novantrone-article-30-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/novantrone-article-30-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/novantrone-article-30-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/novantrone-article-30-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/novantrone-article-30-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/novantrone-article-30-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/novantrone-article-30-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/novantrone-article-30-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/novantrone-article-30-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/novantrone-article-30-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/novantrone-article-30-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/novantrone-article-30-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/novantrone-article-30-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/novantrone-article-30-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/novantrone-article-30-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/novantrone-article-30-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/novantrone-article-30-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/novantrone-article-30-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/novantrone-article-30-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/novantrone-article-30-referral-annex-iv_sv.pdf"}},
    {"id":"13823","name":"Gadolinium Article-31 referral – PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-03-18T01:00:00Z","last_updated_date":"2016-03-18T01:00:00Z","reference_number":"EMA/PRAC/188631/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"13831","name":"Levothyroxine Alapis - Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-02-15T01:00:00Z","last_updated_date":"2013-02-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levothyroxine-alapis-article-294-referral-annex-ii_fi.pdf"}},
    {"id":"13842","name":"Valproate Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"13872","name":"Combined hormonal contraceptives: Article-31 referral - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T13:00:00Z","last_updated_date":"2013-02-13T13:00:00Z","reference_number":"EMA/PRAC/60232/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"13886","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T13:00:00Z","last_updated_date":"2016-12-02T13:00:00Z","reference_number":"EMA/795452/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-prac-warns-risk-hepatitis-b-re-activation-direct-acting-antivirals-hepatitis-c_en.pdf"},
    {"id":"13887","name":"Numeta G13%E to be suspended and new risk-minimisation measures to be introduced for Numeta G16%E","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/564255/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/numeta-g13e-be-suspended-and-new-risk-minimisation-measures-be-introduced-numeta-g16e_sv.pdf"}},
    {"id":"13889","name":"Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Stamaril and associated names (See Annex I) International Non-Proprietary Name (INN): Live attenuated yellow fever virus:...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-07-05T01:59:00Z","last_updated_date":"2006-07-05T01:59:00Z","reference_number":"EMEA/169383/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-stamaril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-live-attenuated-yellow-fever-virus_sv.pdf"}},
    {"id":"13904","name":"Hydroxyzine Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-06-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyzine-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyzine-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyzine-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyzine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyzine-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyzine-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyzine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyzine-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyzine-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyzine-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyzine-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyzine-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyzine-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyzine-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyzine-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyzine-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyzine-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyzine-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyzine-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyzine-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyzine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyzine-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/hydroxyzine-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/hydroxyzine-article-31-referral-annex-iii_no.pdf"}},
    {"id":"13924","name":"Valproate Article-31 referral - New measures to avoid valproate exposure in pregnancy endorsed","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"EMA/145600/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_en.pdf"},
    {"id":"13940","name":"Questions and answers on the referral for Myderison tablets containing tolperisone hydrochloride 50 and 150 mg","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-23T02:08:21Z","last_updated_date":"2011-06-16T02:08:21Z","reference_number":"EMEA/CHMP/675340/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_sv.pdf"}},
    {"id":"13943","name":"Hydroxyethyl starch Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2013-03-04T11:00:00Z","reference_number":"EMA/126737/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-31-referral-annex-i_en.pdf"},
    {"id":"13956","name":"Opinion following an Article 35  referral for Injectable veterinary medicinal products containing ivermectin that are indicated for use in cattle at dose of 200 ug ivermectin per kg bodyweight: International Non-Propriet...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-02T01:59:00Z","last_updated_date":"2009-10-02T01:59:00Z","reference_number":"EMEA/471056/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-injectable-veterinary-medicinal-products-containing-ivermectin-are-indicated-use-cattle-dose-200-ug-ivermectin-kg-bodyweight-international-non-propriet_sv.pdf"}},
    {"id":"13969","name":"Questions and answers on the review of ergot-derived dopamine agonists","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-26T02:08:21Z","last_updated_date":"2008-06-26T02:08:21Z","reference_number":"EMEA/CHMP/319054/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-ergot-derived-dopamine-agonists_sv.pdf"}},
    {"id":"13983","name":"Questions and answers on Tobramycin VVB and associated names (tobramycin, 300 mg/5 ml nebuliser solution)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T13:00:00Z","last_updated_date":"2016-01-29T13:00:00Z","reference_number":"EMA/55653/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_en.pdf"},
    {"id":"13992","name":"Ambroxol and bromhexine Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T09:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"14040","name":"Fibrinogen Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T18:00:00Z","last_updated_date":"2013-04-02T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrinogen-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrinogen-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fibrinogen-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrinogen-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrinogen-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrinogen-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fibrinogen-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrinogen-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fibrinogen-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrinogen-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrinogen-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrinogen-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fibrinogen-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrinogen-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrinogen-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrinogen-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrinogen-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrinogen-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrinogen-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrinogen-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fibrinogen-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrinogen-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"14056","name":"Opinion following an Article 7(5) referral for Salmeterol and Fluticasone Propionate International Non-Proprietary Name (INN): Salmeterol and fluticasone: Background information and Annexes I, II (English) and Annex III ...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-07-07T02:08:21Z","last_updated_date":"2003-07-07T02:08:21Z","reference_number":"CPMP/1327/03","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-75-referral-salmeterol-and-fluticasone-propionate-international-non-proprietary-name-inn-salmeterol-and-fluticasone-background-information-and-annexes-i-ii-english-and-annex_sv.pdf"}},
    {"id":"14083","name":"Opinion following an Article 34 referral for Linco-Spectin 100 and associated names: Background information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-04T02:00:00Z","last_updated_date":"2014-09-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-linco-spectin-100-and-associated-names-background-information_sv.pdf"}},
    {"id":"14111","name":"Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Zestril and associated names (see Annex I) International Non-Proprietary Name (INN): lisinopril: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-01-17T00:59:00Z","last_updated_date":"2004-01-17T00:59:00Z","reference_number":"CPMP/423/04","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zestril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lisinopril-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zestril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lisinopril-background-information_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zestril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lisinopril-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zestril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lisinopril-background-information_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zestril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lisinopril-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zestril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lisinopril-background-information_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zestril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lisinopril-background-information_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zestril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lisinopril-background-information_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zestril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lisinopril-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zestril-and-associated-names-see-annex-i-international-non-proprietary-name-inn-lisinopril-background-information_sv.pdf"}},
    {"id":"14120","name":"Vancomycin Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/224121/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/vancomycin-article-31-referral-notification_en.pdf"},
    {"id":"14134","name":"Zinacef - Article-30 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinacef-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinacef-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinacef-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinacef-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinacef-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinacef-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinacef-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinacef-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinacef-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinacef-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinacef-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinacef-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinacef-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinacef-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinacef-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinacef-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinacef-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinacef-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinacef-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinacef-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinacef-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinacef-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/zinacef-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/zinacef-article-30-referral-annex-iii_no.pdf"}},
    {"id":"14150","name":"Emergency contraceptives Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/emergency-contraceptives-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/emergency-contraceptives-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/emergency-contraceptives-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/emergency-contraceptives-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/emergency-contraceptives-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/emergency-contraceptives-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/emergency-contraceptives-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/emergency-contraceptives-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/emergency-contraceptives-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/emergency-contraceptives-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/emergency-contraceptives-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/emergency-contraceptives-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/emergency-contraceptives-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/emergency-contraceptives-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/emergency-contraceptives-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/emergency-contraceptives-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/emergency-contraceptives-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/emergency-contraceptives-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/emergency-contraceptives-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/emergency-contraceptives-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/emergency-contraceptives-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/emergency-contraceptives-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/emergency-contraceptives-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/emergency-contraceptives-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/emergency-contraceptives-article-31-referral-annex-i_no.pdf"}},
    {"id":"14170","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Timetable for the procedure","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T17:00:00Z","last_updated_date":"2013-03-15T12:51:00Z","reference_number":"EMA/PRAC/69142/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-timetable-procedure_en.pdf"},
    {"id":"14180","name":"Opinion following an Article 33 referral for Enro-k 10% oral solution International Non-Proprietary Name (INN): Enrofloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-06T01:59:00Z","last_updated_date":"2009-05-06T01:59:00Z","reference_number":"EMEA/214378/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-33-referral-enro-k-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_sv.pdf"}},
    {"id":"14207","name":"Pharmaceutics International Inc. Article-31 referral – Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pharmaceutics-international-inc-article-31-referral-notification_en.pdf"},
    {"id":"14208","name":"Avinew Article-33 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-05T02:00:00Z","last_updated_date":"2014-08-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/avinew-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/avinew-article-33-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/avinew-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/avinew-article-33-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/avinew-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/avinew-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/avinew-article-33-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/avinew-article-33-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/avinew-article-33-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/avinew-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/avinew-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"14228","name":"Lederfoline - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-08-14T02:08:21Z","last_updated_date":"2003-08-14T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lederfoline-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"14264","name":"Questions and answers on the withdrawal of medicines containing benfluorex","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2009-12-18T01:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/811097/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-withdrawal-medicines-containing-benfluorex_sv.pdf"}},
    {"id":"14265","name":"Valproate Article-31 referral - PRAC recommends new measures to avoid valproate exposure in pregnancy","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T01:00:00Z","last_updated_date":"2018-02-09T01:00:00Z","reference_number":"EMA/67672/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-prac-recommends-new-measures-avoid-valproate-exposure-pregnancy_en.pdf"},
    {"id":"14272","name":"Antifibrinolytic medicines - Article-31 referral - Annex II (aminocaproic acid)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-06T01:00:00Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aminocaproic-acid_sv.pdf"}},
    {"id":"14284","name":"Methadone Article-107i procedure - Stakeholder's submission form","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-stakeholders-submission-form_en.pdf"},
    {"id":"14295","name":"Substances related to nicotinic acid Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-13T18:00:00Z","last_updated_date":"2014-03-13T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"14323","name":"Inductos Article-20 procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-12-07T01:00:00Z","last_updated_date":"2015-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/inductos-article-20-procedure-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/inductos-article-20-procedure-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/inductos-article-20-procedure-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/inductos-article-20-procedure-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/inductos-article-20-procedure-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/inductos-article-20-procedure-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/inductos-article-20-procedure-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/inductos-article-20-procedure-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/inductos-article-20-procedure-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/inductos-article-20-procedure-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/inductos-article-20-procedure-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/inductos-article-20-procedure-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/inductos-article-20-procedure-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/inductos-article-20-procedure-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/inductos-article-20-procedure-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/inductos-article-20-procedure-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/inductos-article-20-procedure-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/inductos-article-20-procedure-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/inductos-article-20-procedure-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/inductos-article-20-procedure-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/inductos-article-20-procedure-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/inductos-article-20-procedure-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/inductos-article-20-procedure-annex-i_sv.pdf"}},
    {"id":"14357","name":"Opinion following an Article 29(4) referral for Fentanyl-ratiopharm 25/50/75/100 μg/h Matrixpflaster and associated names International Non-Proprietary Name (INN): fentanyl: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-10-23T02:08:21Z","last_updated_date":"2007-10-23T02:08:21Z","reference_number":"EMEA/338591/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-matrixpflaster-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_sv.pdf"}},
    {"id":"14396","name":"Corlentor Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2015-02-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/corlentor-article-20-procedure-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/corlentor-article-20-procedure-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/corlentor-article-20-procedure-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/corlentor-article-20-procedure-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/corlentor-article-20-procedure-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/corlentor-article-20-procedure-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/corlentor-article-20-procedure-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/corlentor-article-20-procedure-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/corlentor-article-20-procedure-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/corlentor-article-20-procedure-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/corlentor-article-20-procedure-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/corlentor-article-20-procedure-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/corlentor-article-20-procedure-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/corlentor-article-20-procedure-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/corlentor-article-20-procedure-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/corlentor-article-20-procedure-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/corlentor-article-20-procedure-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/corlentor-article-20-procedure-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/corlentor-article-20-procedure-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/corlentor-article-20-procedure-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/corlentor-article-20-procedure-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/corlentor-article-20-procedure-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/corlentor-article-20-procedure-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/corlentor-article-20-procedure-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/corlentor-article-20-procedure-annex-iii_no.pdf"}},
    {"id":"14399","name":"Opinion following an Article 29(2) referral for Lansoprazol-ratiopharm 15 mg and 30 mg International Non-Proprietary Name (INN): Lansoprazole: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-02-22T00:08:21Z","last_updated_date":"2006-02-22T00:08:21Z","reference_number":"EMEA/CHMP/373061/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-lansoprazol-ratiopharm-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sv.pdf"}},
    {"id":"14402","name":"Crestor - Article 29 paediatrics referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-01T02:00:00Z","last_updated_date":"2014-08-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/crestor-article-29-paediatrics-referral-annex-ii_no.pdf"}},
    {"id":"14404","name":"Questions and answers on the suspension of the marketing authorisations for Octagam (human normal immunoglobulin 5% and 10%)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/588737/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-suspension-marketing-authorisations-octagam-human-normal-immunoglobulin-5-and-10_sv.pdf"}},
    {"id":"14453","name":"Ikorel and Dancor Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"EMA/238211/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/ikorel-and-dancor-article-30-referral-assessment-report_en.pdf"},
    {"id":"14455","name":"Micro Therapeutic Research Article-31 referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/420215/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"14467","name":"Metamizole Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T02:00:00Z","last_updated_date":"2018-06-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-notification_en.pdf"},
    {"id":"14515","name":"Crestor - Article 29 paediatrics referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-01T02:00:00Z","last_updated_date":"2014-08-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/crestor-article-29-paediatrics-referral-assessment-report_en.pdf"},
    {"id":"14531","name":"Levonelle Article-13 referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-08-09T02:00:00Z","last_updated_date":"2016-08-09T02:00:00Z","reference_number":"EMA/517526/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/levonelle-article-13-referral-chmp-assessment-report_en.pdf"},
    {"id":"14541","name":"Hydroxyethyl starch Article-107i referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"EMA/697706/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-review-started_en.pdf"},
    {"id":"14558","name":"Methadone Article-107i procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-07-24T02:00:00Z","last_updated_date":"2014-07-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methadone-article-107i-procedure-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methadone-article-107i-procedure-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methadone-article-107i-procedure-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methadone-article-107i-procedure-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methadone-article-107i-procedure-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methadone-article-107i-procedure-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methadone-article-107i-procedure-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methadone-article-107i-procedure-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methadone-article-107i-procedure-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methadone-article-107i-procedure-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methadone-article-107i-procedure-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methadone-article-107i-procedure-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methadone-article-107i-procedure-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methadone-article-107i-procedure-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methadone-article-107i-procedure-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methadone-article-107i-procedure-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methadone-article-107i-procedure-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methadone-article-107i-procedure-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methadone-article-107i-procedure-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methadone-article-107i-procedure-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methadone-article-107i-procedure-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methadone-article-107i-procedure-annex-iii_sv.pdf"}},
    {"id":"14575","name":"Protium - Article 30 referrals - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-01-17T01:00:00Z","last_updated_date":"2012-01-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/protium-article-30-referrals-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/protium-article-30-referrals-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/protium-article-30-referrals-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/protium-article-30-referrals-annex-i_cs.pdf","de":"https://www.ema.europa.eu/de/documents/referral/protium-article-30-referrals-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/protium-article-30-referrals-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/protium-article-30-referrals-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/protium-article-30-referrals-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/protium-article-30-referrals-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/protium-article-30-referrals-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/protium-article-30-referrals-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/protium-article-30-referrals-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/protium-article-30-referrals-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/protium-article-30-referrals-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/protium-article-30-referrals-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/protium-article-30-referrals-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/protium-article-30-referrals-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/protium-article-30-referrals-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/protium-article-30-referrals-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/protium-article-30-referrals-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/protium-article-30-referrals-annex-i_sv.pdf"}},
    {"id":"14589","name":"Questions and answers on Closamectin Pour-On Solution and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T20:00:00Z","last_updated_date":"2016-05-31T20:00:00Z","reference_number":"EMA/672999/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-closamectin-pour-solution-and-associated-names_sv.pdf"}},
    {"id":"14595","name":"Flupirtine-containing medicines Article-107i procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T14:00:00Z","last_updated_date":"2013-07-18T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_sv.pdf"}},
    {"id":"14600","name":"Assessment report for Baxter dialysis solutions (3 sites)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"EMA/404194/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-baxter-dialysis-solutions-3-sites_en.pdf"},
    {"id":"14653","name":"Inhaled corticosteroids Article-31 referral – EMA completes review of inhaled corticosteroids for chronic obstructive pulmonary disease","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-15T02:00:00Z","last_updated_date":"2016-07-15T02:00:00Z","reference_number":"EMA/488280/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_sv.pdf"}},
    {"id":"14665","name":"Questions and answers on veterinary medicinal products containing colistin in combination with other antimicrobial substances to be administered orally","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-08-05T02:00:00Z","last_updated_date":"2016-08-05T02:00:00Z","reference_number":"EMA/461505/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-colistin-combination-other-antimicrobial-substances-be-administered-orally_sv.pdf"}},
    {"id":"14711","name":"Ceftriaxone Tyrol Pharma - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-08-30T02:08:21Z","last_updated_date":"2006-08-30T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ceftriaxone-tyrol-pharma-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"14780","name":"Zydelig Article-20 procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-10-03T18:00:00Z","last_updated_date":"2016-10-03T18:00:00Z","reference_number":"EMA/586939/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-prac-assessment-report_en.pdf"},
    {"id":"14849","name":"Summary information on the opinion pursuant to Article 10 of Council Directive 75/319/EEC as amended, for Kà©toprofà¨ne Ethypharm LP  International Non-Proprietary Name (INN): ketoprofen: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2000-12-28T00:08:21Z","last_updated_date":"2000-12-28T00:08:21Z","reference_number":"CPMP/1988/00","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-opinion-pursuant-article-10-council-directive-75319eec-amended-kactoprofane-ethypharm-lp-international-non-proprietary-name-inn-ketoprofen-background-information_en.pdf"},
    {"id":"14856","name":"Numeta Article-107i procedure - Annex VI","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-27T15:00:00Z","last_updated_date":"2013-09-27T15:00:00Z","reference_number":"EMEA/H/A-107i/1373","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-annex-vi_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/numeta-article-107i-procedure-annex-vi_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/numeta-article-107i-procedure-annex-vi_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/numeta-article-107i-procedure-annex-vi_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/numeta-article-107i-procedure-annex-vi_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/numeta-article-107i-procedure-annex-vi_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/numeta-article-107i-procedure-annex-vi_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/numeta-article-107i-procedure-annex-vi_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/numeta-article-107i-procedure-annex-vi_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/numeta-article-107i-procedure-annex-vi_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/numeta-article-107i-procedure-annex-vi_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/numeta-article-107i-procedure-annex-vi_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/numeta-article-107i-procedure-annex-vi_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/numeta-article-107i-procedure-annex-vi_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/numeta-article-107i-procedure-annex-vi_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/numeta-article-107i-procedure-annex-vi_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/numeta-article-107i-procedure-annex-vi_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/numeta-article-107i-procedure-annex-vi_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/numeta-article-107i-procedure-annex-vi_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/numeta-article-107i-procedure-annex-vi_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/numeta-article-107i-procedure-annex-vi_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/numeta-article-107i-procedure-annex-vi_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/numeta-article-107i-procedure-annex-vi_sv.pdf"}},
    {"id":"14865","name":"Opinion following an Article-35 referral for all injectable and pour-on veterinary medicinal products containing doramectin that are intended for use in mammalian food-producing species","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-18T02:00:00Z","last_updated_date":"2013-10-18T02:00:00Z","reference_number":"EMA/372468/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-all-injectable-and-pour-veterinary-medicinal-products-containing-doramectin-are-intended-use-mammalian-food-producing-species_sv.pdf"}},
    {"id":"14909","name":"Caustinerf arsenical and Yranicid arsenical Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-06T14:00:00Z","last_updated_date":"2014-08-06T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-i_sv.pdf"}},
    {"id":"14910","name":"Flupirtine-containing medicines Article-107i procedure - PRAC list of questions to be addressed by the marketing-authorisation holders","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-08T13:00:00Z","last_updated_date":"2013-03-08T13:00:00Z","reference_number":"EMA/PRAC/137417/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-prac-list-questions-be-addressed-marketing-authorisation-holders_en.pdf"},
    {"id":"14934","name":"Helixate NexGen Article-20 procedure - Product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-09T12:00:00Z","last_updated_date":"2014-04-09T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/helixate-nexgen-article-20-procedure-product-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/helixate-nexgen-article-20-procedure-product-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/helixate-nexgen-article-20-procedure-product-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/helixate-nexgen-article-20-procedure-product-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/helixate-nexgen-article-20-procedure-product-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/helixate-nexgen-article-20-procedure-product-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/helixate-nexgen-article-20-procedure-product-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/helixate-nexgen-article-20-procedure-product-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/helixate-nexgen-article-20-procedure-product-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/helixate-nexgen-article-20-procedure-product-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/helixate-nexgen-article-20-procedure-product-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/helixate-nexgen-article-20-procedure-product-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/helixate-nexgen-article-20-procedure-product-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/helixate-nexgen-article-20-procedure-product-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/helixate-nexgen-article-20-procedure-product-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/helixate-nexgen-article-20-procedure-product-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/helixate-nexgen-article-20-procedure-product-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/helixate-nexgen-article-20-procedure-product-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/helixate-nexgen-article-20-procedure-product-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/helixate-nexgen-article-20-procedure-product-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/helixate-nexgen-article-20-procedure-product-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/helixate-nexgen-article-20-procedure-product-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/helixate-nexgen-article-20-procedure-product-information_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/helixate-nexgen-article-20-procedure-product-information_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/helixate-nexgen-article-20-procedure-product-information_no.pdf"}},
    {"id":"14952","name":"Ergot derivatives Article-31 referral - Dihydroergocryptine - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-i_sv.pdf"}},
    {"id":"14967","name":"Codeine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-07T12:55:00Z","last_updated_date":"2013-03-04T11:00:00Z","reference_number":"EMA/713187/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-annex-i_en.pdf-0"},
    {"id":"14974","name":"Opinion following an Article 40 referral for Suvaxyn Parvo/E: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T01:59:00Z","last_updated_date":"2008-06-02T01:59:00Z","reference_number":"EMEA/532267/2007- Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-40-referral-suvaxyn-parvoe-background-information_sv.pdf"}},
    {"id":"15038","name":"Questions and answers on generic escitalopram-containing medicines (tablets containing escitalopram oxalate, 5, 10, 15 and 20 mg)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-02-20T00:59:00Z","last_updated_date":"2010-02-20T00:59:00Z","reference_number":"EMA/89593/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-generic-escitalopram-containing-medicines-tablets-containing-escitalopram-oxalate-5-10-15-and-20-mg_en.pdf"},
    {"id":"15046","name":"Crestor - Article 29 paediatrics referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-01T02:00:00Z","last_updated_date":"2014-08-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/crestor-article-29-paediatrics-referral-annex-iii_no.pdf"}},
    {"id":"15052","name":"Seroquel, Seroquel XR and associated names Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_no.pdf"}},
    {"id":"15070","name":"Valproate and related substances Article-31 referral - CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2014-11-21T01:00:00Z","reference_number":"EMA/709243/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-and-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate-medicines-women-and-girls_sv.pdf"}},
    {"id":"15082","name":"Methadone Article-107i procedure - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-04T02:00:00Z","last_updated_date":"2014-08-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methadone-article-107i-procedure-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methadone-article-107i-procedure-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methadone-article-107i-procedure-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methadone-article-107i-procedure-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methadone-article-107i-procedure-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methadone-article-107i-procedure-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methadone-article-107i-procedure-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methadone-article-107i-procedure-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methadone-article-107i-procedure-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methadone-article-107i-procedure-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methadone-article-107i-procedure-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methadone-article-107i-procedure-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methadone-article-107i-procedure-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methadone-article-107i-procedure-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methadone-article-107i-procedure-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methadone-article-107i-procedure-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methadone-article-107i-procedure-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methadone-article-107i-procedure-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methadone-article-107i-procedure-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methadone-article-107i-procedure-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methadone-article-107i-procedure-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methadone-article-107i-procedure-annex-ii_sv.pdf"}},
    {"id":"15103","name":"Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Motilium and associated names International Non-Proprietary Name (INN): domperidone: Background inf...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-10-17T02:08:21Z","last_updated_date":"2002-10-17T02:08:21Z","reference_number":"EMEA/CPMP/4786/02/en/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-motilium-and-associated-names-international-non-proprietary-name-inn-domperidone-background_en.pdf"},
    {"id":"15107","name":"Numeta Article-107i procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-27T15:00:00Z","last_updated_date":"2013-09-27T15:00:00Z","reference_number":"EMEA/H/A-107i/1373","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/numeta-article-107i-procedure-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/numeta-article-107i-procedure-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/numeta-article-107i-procedure-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/numeta-article-107i-procedure-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/numeta-article-107i-procedure-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/numeta-article-107i-procedure-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/numeta-article-107i-procedure-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/numeta-article-107i-procedure-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/numeta-article-107i-procedure-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/numeta-article-107i-procedure-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/numeta-article-107i-procedure-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/numeta-article-107i-procedure-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/numeta-article-107i-procedure-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/numeta-article-107i-procedure-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/numeta-article-107i-procedure-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/numeta-article-107i-procedure-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/numeta-article-107i-procedure-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/numeta-article-107i-procedure-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/numeta-article-107i-procedure-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/numeta-article-107i-procedure-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/numeta-article-107i-procedure-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/numeta-article-107i-procedure-annex-iii_sv.pdf"}},
    {"id":"15136","name":"Questions and answers on the review of calcitonin-containing medicines - Outcome of a procedure under Article 31 of Directive 2001/83/EC","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T02:00:00Z","last_updated_date":"2013-07-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-procedure-under-article-31-directive-200183ec_sv.pdf"}},
    {"id":"15145","name":"Suramox 15 % LA and its associated name Stabox 15 % LA - Article 35 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-16T01:59:00Z","last_updated_date":"2008-10-16T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/suramox-15-la-and-its-associated-name-stabox-15-la-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"15150","name":"Flupirtine Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"EMEA/H/A-31/1458","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"15161","name":"Orbax Article-33 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-11T02:00:00Z","last_updated_date":"2014-08-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/orbax-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/orbax-article-33-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/orbax-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/orbax-article-33-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/orbax-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/orbax-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/orbax-article-33-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/orbax-article-33-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/orbax-article-33-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/orbax-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/orbax-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"15181","name":"Ambroxol and bromhexine Article-31 referral - Divergent opinion (Croatia)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T09:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-divergent-opinion-croatia_en.pdf"},
    {"id":"15218","name":"Questions and answers on the review of medicines for which studies have been conducted at Texas-based Cetero Research facility","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T13:00:00Z","last_updated_date":"2021-07-09T13:00:00Z","reference_number":"EMA/796016/2012 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-medicines-which-studies-have-been-conducted-texas-based-cetero-research-facility_en.pdf"},
    {"id":"15237","name":"Orlistat - Article 31 referral - Assessment report for orlistat-containing medicinal products","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-12-21T01:00:00Z","last_updated_date":"2012-12-21T01:00:00Z","reference_number":"EMA/276546/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/orlistat-article-31-referral-assessment-report-orlistat-containing-medicinal-products_en.pdf"},
    {"id":"15267","name":"Xeomin - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-02-08T00:08:21Z","last_updated_date":"2008-02-08T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_sv.pdf"}}    {"id":"15281","name":"Tiamutin - Article 34 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-07-21T02:00:00Z","last_updated_date":"2011-03-14T01:00:00Z","reference_number":"V-A-042","document_url":"https://www.ema.europa.eu/en/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tiamutin-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"15299","name":"Questions and answers on the referral for Meronem and associated names meropenem powder for solution for injection or infusion 500 mg and 1 g - Final","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-12-12T00:59:00Z","last_updated_date":"2009-12-12T00:59:00Z","reference_number":"EMEA/CHMP/746085/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_sv.pdf"}},
    {"id":"15355","name":"Factor VIII Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"EMA/472176/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-review-started_en.pdf"},
    {"id":"15384","name":"Opinion following an Article 35 referral for veterinary medicinal products containing colistin to be administered orally","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-04-13T02:00:00Z","last_updated_date":"2015-04-13T02:00:00Z","reference_number":"EMA/160340/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-colistin-be-administered-orally_sv.pdf"}},
    {"id":"15399","name":"Nimesulide - Article 107 procedures - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-08T02:00:00Z","last_updated_date":"2010-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-107-procedures-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nimesulide-article-107-procedures-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nimesulide-article-107-procedures-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nimesulide-article-107-procedures-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nimesulide-article-107-procedures-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nimesulide-article-107-procedures-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nimesulide-article-107-procedures-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nimesulide-article-107-procedures-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nimesulide-article-107-procedures-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nimesulide-article-107-procedures-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nimesulide-article-107-procedures-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nimesulide-article-107-procedures-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nimesulide-article-107-procedures-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nimesulide-article-107-procedures-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nimesulide-article-107-procedures-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nimesulide-article-107-procedures-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nimesulide-article-107-procedures-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nimesulide-article-107-procedures-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nimesulide-article-107-procedures-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nimesulide-article-107-procedures-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nimesulide-article-107-procedures-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nimesulide-article-107-procedures-annex-iii_sv.pdf"}},
    {"id":"15411","name":"Questions and answers on the recommendation to withdraw the marketing authorisations for Clobutinol-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2007-10-18T02:00:00Z","last_updated_date":"2007-10-18T02:00:00Z","reference_number":"EMEA/471052/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-recommendation-withdraw-marketing-authorisations-clobutinol-containing-medicines_en.pdf"},
    {"id":"15416","name":"Topamax - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-12-15T00:08:21Z","last_updated_date":"2009-12-15T00:08:21Z","reference_number":"EMEA/CHMP/660222/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/topamax-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/topamax-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/topamax-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/topamax-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/topamax-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/topamax-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/topamax-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/topamax-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/topamax-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/topamax-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/topamax-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/topamax-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/topamax-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/topamax-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/topamax-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/topamax-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/topamax-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/topamax-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/topamax-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/topamax-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/topamax-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/topamax-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"15419","name":"Opinion following an Article 35 referral for all pre-mixes for medicated feedingstuff containing 40 g, 100 g or 200 g tilmicosin per kg pre-mix and administered to rabbits","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-19T02:00:00Z","last_updated_date":"2012-07-19T02:00:00Z","reference_number":"EMA/294698/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits_sv.pdf"}},
    {"id":"15436","name":"Final opinion of the Committee for proprietary medicinal products in accordance with Article 12 of Directive 75/319/EEC as amended for Naftidrofuryl International Non-Proprietary Name (INN): Naftidrofuryl","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1996-06-26T02:08:21Z","last_updated_date":"1996-06-26T02:08:21Z","reference_number":"CPMP/578/95","document_url":"https://www.ema.europa.eu/en/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-naftidrofuryl-international-non-proprietary-name-inn-naftidrofuryl_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-naftidrofuryl-international-non-proprietary-name-inn-naftidrofuryl_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-naftidrofuryl-international-non-proprietary-name-inn-naftidrofuryl_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-naftidrofuryl-international-non-proprietary-name-inn-naftidrofuryl_fr.pdf"}},
    {"id":"15448","name":"Risperdal Consta - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-22T02:08:21Z","last_updated_date":"2008-10-22T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/risperdal-consta-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"15449","name":"Combined hormonal contraceptives Article-31 referral - CHMP divergent position to PRAC","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-chmp-divergent-position-prac_en.pdf"},
    {"id":"15454","name":"Questions and answers on the referral for Pantoprazole Olinka pantoprazole 20 and 40 mg tablets (EMEA/H/A-29/1170)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-11-21T00:59:00Z","last_updated_date":"2011-03-09T00:59:00Z","reference_number":"EMEA/CHMP/744722/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_sv.pdf"}},
    {"id":"15456","name":"Questions and answers on the review of medicines containing valproate for use in bipolar disorder","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-23T02:00:00Z","last_updated_date":"2012-07-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_sv.pdf"}},
    {"id":"15500","name":"Alkem Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T13:00:00Z","last_updated_date":"2016-10-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/alkem-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/alkem-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/alkem-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/alkem-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/alkem-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/alkem-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/alkem-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/alkem-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/alkem-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/alkem-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/alkem-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/alkem-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/alkem-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/alkem-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/alkem-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/alkem-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/alkem-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/alkem-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/alkem-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/alkem-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/alkem-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/alkem-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"15505","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"EMA/PRAC/637349/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-prac-assessment-report_en.pdf"},
    {"id":"15522","name":"Questions and answers on Valebo and associated names (tablets containing 70 mg alendronic acid and capsules containing 1 microgram alfacalcidol)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2014-03-31T03:00:00Z","reference_number":"EMA/793424/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-valebo-and-associated-names-tablets-containing-70-mg-alendronic-acid-and-capsules-containing-1-microgram-alfacalcidol_sv.pdf"}},
    {"id":"15536","name":"Cabergoline and Pergolide - Article 31 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-05T02:08:21Z","last_updated_date":"2009-05-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-i_sv.pdf"}},
    {"id":"15541","name":"Opinions following an Article 12 referral for Zagam 100mg and 200mg tablets International Non-Proprietary Name (INN): Sparfloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1997-04-03T02:08:21Z","last_updated_date":"1997-04-03T02:08:21Z","reference_number":"CPMP/931/95","document_url":"https://www.ema.europa.eu/en/documents/referral/opinions-following-article-12-referral-zagam-100mg-and-200mg-tablets-international-non-proprietary-name-inn-sparfloxacin-background-information_en.pdf"},
    {"id":"15602","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Annex I-III - Synjardy","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-synjardy_no.pdf"}},
    {"id":"15626","name":"Substances related to nicotinic acid Article-31 referral - Draft Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-08-15T02:00:00Z","reference_number":"EMA/148540/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-draft-annex-i_en.pdf"},
    {"id":"15629","name":"Hydroxyethyl starch Article-107i referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-notification_en.pdf"},
    {"id":"15651","name":"Cilostazol-containing medicines - Article-31 referral - Annex I (cilostazol)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T00:00:00Z","last_updated_date":"2013-09-11T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-i-cilostazol_sv.pdf"}},
    {"id":"15712","name":"Ibuprofen and dexibuprofen Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T17:00:00Z","last_updated_date":"2015-03-16T17:00:00Z","reference_number":"EMA/PRAC/332908/2014 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"15716","name":"Opinion following an Article-33(4) referral for Melosolute 40 mg/ml solution for injection for cattle, pigs and horses","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-15T17:00:00Z","last_updated_date":"2013-03-15T17:00:00Z","reference_number":"EMEA/V/A/084","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-melosolute-40-mgml-solution-injection-cattle-pigs-and-horses_sv.pdf"}},
    {"id":"15735","name":"Saroten Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/saroten-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/saroten-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/saroten-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/saroten-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/saroten-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/saroten-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/saroten-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/saroten-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/saroten-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/saroten-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/saroten-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/saroten-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/saroten-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/saroten-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/saroten-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/saroten-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/saroten-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/saroten-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/saroten-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/saroten-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/saroten-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/saroten-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/saroten-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"15769","name":"Opinion following an Article 29(2) referral for Ceftriaxone Tyrol Pharma and associated names International Non-Proprietary Name (INN): Ceftriaxone: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-08-21T02:08:21Z","last_updated_date":"2006-08-21T02:08:21Z","reference_number":"EMEA/CHMP/212746/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-ceftriaxone-tyrol-pharma-and-associated-names-international-non-proprietary-name-inn-ceftriaxone-background-information_sv.pdf"}},
    {"id":"15784","name":"Durogesic Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-10-13T02:00:00Z","last_updated_date":"2016-10-13T02:00:00Z","reference_number":"EMA/641560/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/durogesic-article-30-referral-assessment-report_en.pdf"},
    {"id":"15830","name":"Flutiform - Article 29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-25T02:00:00Z","last_updated_date":"2012-10-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flutiform-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flutiform-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flutiform-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flutiform-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flutiform-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flutiform-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flutiform-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flutiform-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flutiform-article-29-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flutiform-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flutiform-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flutiform-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flutiform-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flutiform-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flutiform-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flutiform-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flutiform-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flutiform-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flutiform-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flutiform-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flutiform-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flutiform-article-29-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/flutiform-article-29-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/flutiform-article-29-referral-annex-i_no.pdf"}},
    {"id":"15833","name":"Amoxil Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-09-14T02:00:00Z","last_updated_date":"2015-09-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/amoxil-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/amoxil-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/amoxil-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/amoxil-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/amoxil-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/amoxil-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/amoxil-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/amoxil-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/amoxil-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/amoxil-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/amoxil-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/amoxil-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/amoxil-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/amoxil-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/amoxil-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/amoxil-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/amoxil-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/amoxil-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/amoxil-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/amoxil-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/amoxil-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/amoxil-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/amoxil-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/amoxil-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/amoxil-article-30-referral-annex-i_no.pdf"}},
    {"id":"15848","name":"Final opinion of the Committee for proprietary medicinal products in accordance with Article 12 of Directive 75/319/EEC as amended for Zagam 100mg and Annex","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1996-05-06T02:08:21Z","last_updated_date":"1996-05-06T02:08:21Z","reference_number":"CPMP/931/95","document_url":"https://www.ema.europa.eu/en/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-zagam-100mg-and-annex_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-zagam-100mg-and-annex_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-zagam-100mg-and-annex_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-zagam-100mg-and-annex_fr.pdf"}},
    {"id":"15875","name":"Methylphenidate Sandoz Article-29 referral - Questions and answers on Methylphenidate Sandoz (methylphenidate hydrochloride, prolonged-release tablet, 18, 36 and 54 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-12-05T13:00:00Z","reference_number":"EMA/444197/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methylphenidate-sandoz-article-29-referral-questions-and-answers-methylphenidate-sandoz-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg_sv.pdf"}},
    {"id":"15881","name":"Iclusig Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/iclusig-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/iclusig-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/iclusig-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/iclusig-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/iclusig-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/iclusig-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/iclusig-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/iclusig-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/iclusig-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/iclusig-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/iclusig-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/iclusig-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/iclusig-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/iclusig-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/iclusig-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/iclusig-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/iclusig-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/iclusig-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/iclusig-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/iclusig-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/iclusig-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/iclusig-article-20-procedure-annex-iv_sv.pdf"}},
    {"id":"15908","name":"Colistin oral - Article 35 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-04-13T02:00:00Z","last_updated_date":"2015-04-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/colistin-oral-article-35-referral-annex-i-ii-iii_is.pdf"}},
    {"id":"15914","name":"Polymyxin Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-05T01:00:00Z","last_updated_date":"2015-01-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/polymyxin-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/polymyxin-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/polymyxin-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/polymyxin-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/polymyxin-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/polymyxin-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/polymyxin-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/polymyxin-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/polymyxin-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/polymyxin-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/polymyxin-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/polymyxin-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/polymyxin-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/polymyxin-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/polymyxin-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/polymyxin-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/polymyxin-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/polymyxin-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/polymyxin-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/polymyxin-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/polymyxin-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/polymyxin-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/polymyxin-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"15915","name":"Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Ecazide and associated names International Non-Proprietary Name (INN): captopril/hydrochlorothiazid...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-09-19T02:08:21Z","last_updated_date":"2002-09-19T02:08:21Z","reference_number":"EMEA/CPMP/4717/02/en/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-ecazide-and-associated-names-international-non-proprietary-name-inn_en.pdf"},
    {"id":"15919","name":"Adrenaline auto-injectors Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-notification_en.pdf"},
    {"id":"15921","name":"Opinion following an Article 29(2) referral for Lansoprazol CT-Arzneimittel 15 mg and 30 mg International Non-Proprietary Name (INN): Lansoprazole: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-02-22T00:08:21Z","last_updated_date":"2006-02-22T00:08:21Z","reference_number":"EMEA/CHMP/373108/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-lansoprazol-ct-arzneimittel-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sv.pdf"}},
    {"id":"15922","name":"Isotretinoin - Article 29 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2011-07-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/isotretinoin-article-29-referral-assessment-report_en.pdf"},
    {"id":"15932","name":"Questions and answers on the referral for Priligy","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T02:00:00Z","last_updated_date":"2012-03-28T02:00:00Z","reference_number":"EMA/CHMP/842278/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-priligy_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-priligy_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-priligy_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-priligy_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-priligy_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-priligy_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-priligy_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-priligy_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-priligy_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-priligy_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-priligy_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-priligy_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-priligy_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-priligy_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-priligy_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-priligy_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-priligy_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-priligy_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-priligy_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-priligy_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-priligy_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-priligy_sv.pdf"}},
    {"id":"15996","name":"Targocid Article-30 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-03T01:00:00Z","last_updated_date":"2014-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/targocid-article-30-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/targocid-article-30-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/targocid-article-30-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/targocid-article-30-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/targocid-article-30-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/targocid-article-30-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/targocid-article-30-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/targocid-article-30-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/targocid-article-30-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/targocid-article-30-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/targocid-article-30-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/targocid-article-30-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/targocid-article-30-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/targocid-article-30-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/targocid-article-30-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/targocid-article-30-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/targocid-article-30-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/targocid-article-30-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/targocid-article-30-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/targocid-article-30-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/targocid-article-30-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/targocid-article-30-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/targocid-article-30-referral-annex-iv_sv.pdf"}},
    {"id":"16002","name":"Intravenous iron-containing medicinal products Article-31 referral: Product information as approved by the CHMP on 27 June 2013, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-07-30T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-product-information-approved-chmp-27-june-2013-pending-endorsement-european-commission_en.pdf"},
    {"id":"16042","name":"Didanosine Article-29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-10T01:00:00Z","last_updated_date":"2013-12-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/didanosine-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/didanosine-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/didanosine-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/didanosine-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/didanosine-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/didanosine-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/didanosine-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/didanosine-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/didanosine-article-29-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/didanosine-article-29-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/didanosine-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/didanosine-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/didanosine-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/didanosine-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/didanosine-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/didanosine-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/didanosine-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/didanosine-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/didanosine-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/didanosine-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/didanosine-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/didanosine-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/didanosine-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"16090","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Annex I-III - Vokanamet","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-vokanamet_no.pdf"}},
    {"id":"16101","name":"Ergot derivatives Article-31 referral - Dihydroergocristine - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-iii_sv.pdf"}},
    {"id":"16118","name":"Sandostatin - Article 30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T14:00:00Z","last_updated_date":"2014-07-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sandostatin-article-30-referral-annex-iii_en.pdf"},
    {"id":"16122","name":"Pholcodine - Article 31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-03-28T02:00:00Z","last_updated_date":"2012-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-article-31-referral-assessment-report_en.pdf"},
    {"id":"16124","name":"Numeta Article-107i procedure - PRAC recommends suspension and reformulation for Numeta G13%E and risk minimisation measures for Numeta G16%E","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-06T02:00:00Z","last_updated_date":"2013-09-06T02:00:00Z","reference_number":"EMA/531101/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-prac-recommends-suspension-and-reformulation-numeta-g13e-and-risk-minimisation-measures-numeta-g16e_en.pdf"},
    {"id":"16132","name":"Assessment report pursuant to Article 30 of Directive 2001/83/EC - Kytril and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-12T02:00:00Z","last_updated_date":"2011-09-12T02:00:00Z","reference_number":"EMA/708931/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-pursuant-article-30-directive-200183ec-kytril-and-associated-names_en.pdf"},
    {"id":"16158","name":"Questions and answers on the European Medicines Agency recommendation to suspend the marketing authorisations for aprotinin-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-22T00:08:21Z","last_updated_date":"2007-11-22T00:08:21Z","reference_number":"EMEA/533599/2007 corr","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-european-medicines-agency-recommendation-suspend-marketing-authorisations-aprotinin-containing-medicines_en.pdf"},
    {"id":"16161","name":"Tetrazepam-containing medicines - Article-107i procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T13:00:00Z","last_updated_date":"2013-04-29T14:00:00Z","reference_number":"EMA/13608/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_en.pdf"},
    {"id":"16203","name":"Opinion following an Article 35  referral for Dexadreson 2 mg/ml and associated names, and generic products thereof","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-27T01:00:00Z","last_updated_date":"2013-11-27T01:00:00Z","reference_number":"EMA/539466/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-dexadreson-2-mgml-and-associated-names-and-generic-products-thereof_sv.pdf"}},
    {"id":"16240","name":"Esmya Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T13:00:00Z","last_updated_date":"2017-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-notification_en.pdf"},
    {"id":"16259","name":"Domperidone Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2014-09-11T10:55:00Z","reference_number":"EMA/147415/2013 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/domperidone-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/domperidone-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/domperidone-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/domperidone-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/domperidone-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/domperidone-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/domperidone-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/domperidone-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/domperidone-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/domperidone-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/domperidone-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/domperidone-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/domperidone-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/domperidone-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/domperidone-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/domperidone-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/domperidone-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/domperidone-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/domperidone-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/domperidone-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/domperidone-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/domperidone-article-31-referral-annex-i_sv.pdf"}},
    {"id":"16271","name":"Codeine Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-05-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/codeine-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/codeine-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/codeine-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/codeine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/codeine-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/codeine-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/codeine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/codeine-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/codeine-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/codeine-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/codeine-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/codeine-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/codeine-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/codeine-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/codeine-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/codeine-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/codeine-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/codeine-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/codeine-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/codeine-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/codeine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/codeine-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"16286","name":"Divergent position on a CVMP opinion on an Article 33(4) referral of Directive 2001/82/EC for Deltanil 10 mg/ml pour-on solution for cattle and sheep and Deltanil 100 mg spot-on solution for cattle","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-334-referral-directive-200182ec-deltanil-10-mgml-pour-solution-cattle-and-sheep-and-deltanil-100-mg-spot-solution-cattle_en.pdf"},
    {"id":"16294","name":"Protelos and Osseor Article-20 procedure: CHMP scientific conclusions and PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-02-28T16:30:00Z","last_updated_date":"2014-02-28T16:30:00Z","reference_number":"EMA/112925/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/protelos-and-osseor-article-20-procedure-chmp-scientific-conclusions-and-prac-assessment-report_en.pdf"},
    {"id":"16299","name":"Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Hypnovel and associated names International Non-Proprietary Name (INN): midazolam: Background infor...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-09-16T02:08:21Z","last_updated_date":"2002-09-16T02:08:21Z","reference_number":"EMEA/CPMP/4620/02/en/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-hypnovel-and-associated-names-international-non-proprietary-name-inn-midazolam-background_en.pdf"},
    {"id":"16354","name":"Inhaled corticosteroids Article-31 referral – Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-07-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/inhaled-corticosteroids-article-31-referral-annex-iii_no.pdf"}},
    {"id":"16376","name":"Adrenaline auto-injectors Article-31 referral - Better training tools recommended to support patients using adrenaline auto-injectors","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-08-26T02:00:00Z","reference_number":"EMA/465403/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/adrenaline-auto-injectors-article-31-referral-better-training-tools-recommended-support-patients-using-adrenaline-auto-injectors_sv.pdf"}},
    {"id":"16383","name":"Opinion following an Article-13 referral for Soludox 500-mg/g powder for use in drinking water for pigs and chickens and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-24T02:00:00Z","last_updated_date":"2013-09-24T02:00:00Z","reference_number":"EMA/426302/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-13-referral-soludox-500-mgg-powder-use-drinking-water-pigs-and-chickens-and-associated-names_sv.pdf"}},
    {"id":"16405","name":"Linoladiol N and Linoladiol HN Article-31 referral - European Medicines Agency recommends restricting use of estradiol-containing creams Linoladiol N and Linoladiol HN","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2014-04-25T14:00:00Z","reference_number":"EMA/796289/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-european-medicines-agency-recommends-restricting-use-estradiol-containing-creams-linoladiol-n-and-linoladiol-hn_en.pdf"},
    {"id":"16416","name":"Hydroxyethyl starch Article-107i procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-prac-list-questions_en.pdf"},
    {"id":"16443","name":"Opinion of the Committee for proprietary medicinal products pursuant to Article 10 of Council Directive 75/319/EEC as amended, for Fluoxetin NM","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-06-10T02:08:21Z","last_updated_date":"1998-06-10T02:08:21Z","reference_number":"EMEA/H/A/200","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-10-council-directive-75319eec-amended-fluoxetin-nm_en.pdf"},
    {"id":"16448","name":"Linoladiol N and Linoladiol HN Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-11T02:00:00Z","last_updated_date":"2014-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"16482","name":"Opinion following an Article 33 referral for Nisamox Lactating Cow and associated names: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-12-08T01:00:00Z","last_updated_date":"2011-12-08T01:00:00Z","reference_number":"EMEA/V/A/62","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-33-referral-nisamox-lactating-cow-and-associated-names-background-information_sv.pdf"}},
    {"id":"16499","name":"Questions and answers on the review of dexrazoxane-containing medicines, powder for solution for infusion, 500 mg","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T14:06:32Z","last_updated_date":"2012-01-16T13:06:32Z","reference_number":"EMA/CHMP/485343/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-dexrazoxane-containing-medicines-powder-solution-infusion-500-mg_sv.pdf"}},
    {"id":"16550","name":"Micro Therapeutic Research Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/micro-therapeutic-research-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"16579","name":"Arcoxia - Article 6 (12) referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-11-21T00:08:21Z","last_updated_date":"2008-11-21T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/arcoxia-article-6-12-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"16596","name":"Opinion following an Article-78 procedure for Bayovac IBR Marker Vivum and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-05T02:00:00Z","last_updated_date":"2014-08-05T02:00:00Z","reference_number":"EMA/308604/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-78-procedure-bayovac-ibr-marker-vivum-and-its-associated-names_en.pdf"},
    {"id":"16613","name":"Hydroxyethyl starch Article-107i procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-14T16:00:00Z","last_updated_date":"2013-11-14T16:00:00Z","reference_number":"EMA/667553/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-prac-assessment-report_en.pdf"},
    {"id":"16628","name":"All pre-mixes for medicated feedingstuff containing 40 g, 100 g or 200 g tilmicosin per kg pre-mix and administered to rabbits - Article 35 referral - Annexes I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-19T02:00:00Z","last_updated_date":"2012-07-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-and-administered-rabbits-article-35-referral-annexes-i-ii-iii-iv_sv.pdf"}},
    {"id":"16656","name":"Somatropin - Article 107 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-23T02:00:00Z","last_updated_date":"2012-04-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/somatropin-article-107-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/somatropin-article-107-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/somatropin-article-107-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/somatropin-article-107-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/somatropin-article-107-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/somatropin-article-107-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/somatropin-article-107-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/somatropin-article-107-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/somatropin-article-107-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/somatropin-article-107-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/somatropin-article-107-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/somatropin-article-107-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/somatropin-article-107-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/somatropin-article-107-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/somatropin-article-107-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/somatropin-article-107-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/somatropin-article-107-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/somatropin-article-107-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/somatropin-article-107-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/somatropin-article-107-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/somatropin-article-107-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/somatropin-article-107-referral-annex-ii_sv.pdf"}},
    {"id":"16714","name":"Flupirtine Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"EMEA/H/A-31/1458","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-review-started_en.pdf"},
    {"id":"16734","name":"Opinion following an Article 31 referral for Loratadine and pseudoephedrine International Non-Proprietary Name (INN): loratadine and pseudoephedrine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-04-28T02:08:21Z","last_updated_date":"2003-04-28T02:08:21Z","reference_number":"CPMP/4060/03","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-31-referral-loratadine-and-pseudoephedrine-international-non-proprietary-name-inn-loratadine-and-pseudoephedrine-background-information_sv.pdf"}},
    {"id":"16789","name":"Opinion following an Article 30 referral for Singulair and associated names International Non-Proprietary Name (INN): montelukast: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-07-11T02:08:21Z","last_updated_date":"2008-07-11T02:08:21Z","reference_number":"EMEA/CHMP/411086/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-singulair-and-associated-names-international-non-proprietary-name-inn-montelukast-background-information_sv.pdf"}},
    {"id":"16836","name":"Opinion following an article 20 referral for veterinary medicinal products containing benzathine benzylpenicillin intended for administration to food-producing species","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-13T02:00:00Z","last_updated_date":"2016-07-26T14:00:00Z","reference_number":"EMA/308369/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-20-referral-veterinary-medicinal-products-containing-benzathine-benzylpenicillin-intended-administration-food-producing-species_en.pdf"},
    {"id":"16882","name":"Vancomycin Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vancomycin-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vancomycin-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vancomycin-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vancomycin-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vancomycin-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vancomycin-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vancomycin-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vancomycin-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vancomycin-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/vancomycin-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vancomycin-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vancomycin-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vancomycin-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vancomycin-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vancomycin-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vancomycin-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vancomycin-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vancomycin-article-31-referral-annex-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vancomycin-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vancomycin-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vancomycin-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vancomycin-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/vancomycin-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/vancomycin-article-31-referral-annex-iii_no.pdf"}},
    {"id":"16891","name":"Alkem Article-31 referral - Studies from Alkem Laboratories Ltd cannot be used to support medicines approval in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-10-07T13:10:00Z","reference_number":"EMA/427636/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/alkem-article-31-referral-studies-alkem-laboratories-ltd-cannot-be-used-support-medicines-approval-eu_sv.pdf"}},
    {"id":"16906","name":"Modified release oral opioids - Article 31 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/modified-release-oral-opioids-article-31-referral-annex-i_no.pdf"}},
    {"id":"16921","name":"Solacyl - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-05-24T01:59:00Z","last_updated_date":"2008-05-24T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/solacyl-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"17004","name":"Symbioflor 2 Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2017-03-24T18:00:00Z","reference_number":"EMA/CHMP/233611/2016 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"17024","name":"Ambroxol and bromhexine Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-03-10T01:00:00Z","last_updated_date":"2015-12-02T01:00:00Z","reference_number":"EMA/PRAC/133132/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"17032","name":"Femara - Article 30 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T01:00:00Z","last_updated_date":"2012-06-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/femara-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/femara-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/femara-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/femara-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/femara-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/femara-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/femara-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/femara-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/femara-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/femara-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/femara-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/femara-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/femara-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/femara-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/femara-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/femara-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/femara-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/femara-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/femara-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/femara-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/femara-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/femara-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/femara-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/femara-article-30-referral-annex-iii_no.pdf"}},
    {"id":"17041","name":"Kogenate Bayer Article-20 procedure - Product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-09T12:00:00Z","last_updated_date":"2014-04-09T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kogenate-bayer-article-20-procedure-product-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/kogenate-bayer-article-20-procedure-product-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/kogenate-bayer-article-20-procedure-product-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/kogenate-bayer-article-20-procedure-product-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/kogenate-bayer-article-20-procedure-product-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/kogenate-bayer-article-20-procedure-product-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/kogenate-bayer-article-20-procedure-product-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/kogenate-bayer-article-20-procedure-product-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/kogenate-bayer-article-20-procedure-product-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/kogenate-bayer-article-20-procedure-product-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/kogenate-bayer-article-20-procedure-product-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/kogenate-bayer-article-20-procedure-product-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/kogenate-bayer-article-20-procedure-product-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/kogenate-bayer-article-20-procedure-product-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/kogenate-bayer-article-20-procedure-product-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/kogenate-bayer-article-20-procedure-product-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/kogenate-bayer-article-20-procedure-product-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/kogenate-bayer-article-20-procedure-product-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/kogenate-bayer-article-20-procedure-product-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/kogenate-bayer-article-20-procedure-product-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/kogenate-bayer-article-20-procedure-product-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/kogenate-bayer-article-20-procedure-product-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/kogenate-bayer-article-20-procedure-product-information_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/kogenate-bayer-article-20-procedure-product-information_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/kogenate-bayer-article-20-procedure-product-information_no.pdf"}},
    {"id":"17059","name":"Metoclopramide Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metoclopramide-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metoclopramide-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metoclopramide-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metoclopramide-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metoclopramide-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metoclopramide-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metoclopramide-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metoclopramide-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metoclopramide-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metoclopramide-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metoclopramide-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metoclopramide-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metoclopramide-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metoclopramide-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metoclopramide-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metoclopramide-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metoclopramide-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metoclopramide-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metoclopramide-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metoclopramide-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metoclopramide-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metoclopramide-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metoclopramide-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/metoclopramide-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/metoclopramide-article-31-referral-annex-i_no.pdf"}},
    {"id":"17105","name":"Tienam - Article 30 Referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-20T01:00:00Z","last_updated_date":"2012-02-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tienam-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tienam-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tienam-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tienam-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tienam-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tienam-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tienam-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tienam-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tienam-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tienam-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tienam-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tienam-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tienam-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tienam-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tienam-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tienam-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tienam-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tienam-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tienam-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tienam-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tienam-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tienam-article-30-referral-annex-i_sv.pdf"}},
    {"id":"17110","name":"Cilazapril Teva Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cilazapril-teva-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cilazapril-teva-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cilazapril-teva-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cilazapril-teva-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cilazapril-teva-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cilazapril-teva-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cilazapril-teva-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cilazapril-teva-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cilazapril-teva-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cilazapril-teva-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cilazapril-teva-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cilazapril-teva-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cilazapril-teva-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cilazapril-teva-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cilazapril-teva-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cilazapril-teva-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cilazapril-teva-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cilazapril-teva-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cilazapril-teva-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cilazapril-teva-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cilazapril-teva-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cilazapril-teva-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"17111","name":"Moxifloxacin - Article 107 procedures - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-24T02:08:21Z","last_updated_date":"2007-07-24T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/moxifloxacin-article-107-procedures-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/moxifloxacin-article-107-procedures-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/moxifloxacin-article-107-procedures-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/moxifloxacin-article-107-procedures-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/moxifloxacin-article-107-procedures-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/moxifloxacin-article-107-procedures-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/moxifloxacin-article-107-procedures-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/moxifloxacin-article-107-procedures-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/moxifloxacin-article-107-procedures-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/moxifloxacin-article-107-procedures-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/moxifloxacin-article-107-procedures-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/moxifloxacin-article-107-procedures-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/moxifloxacin-article-107-procedures-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/moxifloxacin-article-107-procedures-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/moxifloxacin-article-107-procedures-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/moxifloxacin-article-107-procedures-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/moxifloxacin-article-107-procedures-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/moxifloxacin-article-107-procedures-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/moxifloxacin-article-107-procedures-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/moxifloxacin-article-107-procedures-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/moxifloxacin-article-107-procedures-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/moxifloxacin-article-107-procedures-annex-ii_sv.pdf"}},
    {"id":"17129","name":"Summary information on referral opinion pursuant to Article 6(13) of Commission Regulation (EC) No 1084/2003 for Seretide Diskus and associated names (See Annex I) International Non-Proprietary Name (INN): salmeterol / f...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-07-04T00:08:00Z","last_updated_date":"2006-07-04T00:08:00Z","reference_number":"EMEA/306065/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-613-commission-regulation-ec-no-10842003-seretide-diskus-and-associated-names-see-annex-i-international-non-proprietary-name-inn-salmeterol-f_sv.pdf"}},
    {"id":"17131","name":"Opinion following an Article 78  procedure for veterinary medicinal products containing  Alpha2-adrenoreceptor agonists2 International Non-Proprietary Name (INN): Xylazine, Medetomidine, Detomidine, Romifidine: Backgroun...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-01T01:59:00Z","last_updated_date":"2009-05-01T01:59:00Z","reference_number":"EMEA/681319/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-78-procedure-veterinary-medicinal-products-containing-alpha2-adrenoreceptor-agonists2-international-non-proprietary-name-inn-xylazine-medetomidine-detomidine-romifidine_sv.pdf"}},
    {"id":"17140","name":"Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines Article-31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-12T18:00:00Z","last_updated_date":"2014-03-12T18:00:00Z","reference_number":"EMA/77344/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-assessment-report_en.pdf"},
    {"id":"17156","name":"Tolperisone Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tolperisone-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tolperisone-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tolperisone-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tolperisone-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tolperisone-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tolperisone-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tolperisone-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tolperisone-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tolperisone-article-31-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tolperisone-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tolperisone-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tolperisone-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tolperisone-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tolperisone-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tolperisone-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tolperisone-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tolperisone-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tolperisone-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tolperisone-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tolperisone-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tolperisone-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tolperisone-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"17158","name":"Questions and answers on Methylphenidate Hexal (methylphenidate hydrochloride, prolonged-release tablet, 18, 36 and 54 mg) - Outcome of a procedure under Article 29 of Directive 2001/83/EC","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-12-05T01:00:00Z","reference_number":"EMEA/H/A-29/1360","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-methylphenidate-hexal-methylphenidate-hydrochloride-prolonged-release-tablet-18-36-and-54-mg-outcome-procedure-under-article-29-directive-200183ec_sv.pdf"}},
    {"id":"17163","name":"Calcitonin Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T02:00:00Z","last_updated_date":"2013-07-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/calcitonin-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/calcitonin-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/calcitonin-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/calcitonin-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/calcitonin-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/calcitonin-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/calcitonin-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/calcitonin-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/calcitonin-article-31-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/calcitonin-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/calcitonin-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/calcitonin-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/calcitonin-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/calcitonin-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/calcitonin-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/calcitonin-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/calcitonin-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/calcitonin-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/calcitonin-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/calcitonin-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/calcitonin-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/calcitonin-article-31-referral-annex-iv_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/calcitonin-article-31-referral-annex-iv_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/calcitonin-article-31-referral-annex-iv_no.pdf"}},
    {"id":"17166","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T16:34:00Z","last_updated_date":"2018-12-18T16:34:00Z","reference_number":"EMA/CHMP/466973/2018 rev.2","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"17245","name":"Semler Article-31 referral – CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T15:00:00Z","last_updated_date":"2016-11-17T15:00:00Z","reference_number":"EMA/633696/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"17268","name":"Clenil Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/clenil-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/clenil-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/clenil-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/clenil-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/clenil-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/clenil-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/clenil-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/clenil-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/clenil-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/clenil-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/clenil-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/clenil-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/clenil-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/clenil-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/clenil-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/clenil-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/clenil-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/clenil-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/clenil-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/clenil-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/clenil-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/clenil-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/clenil-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"17295","name":"Zinbryta Article-20 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-01-12T01:00:00Z","last_updated_date":"2018-01-12T01:00:00Z","reference_number":"EMA/779877/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-prac-assessment-report_en.pdf"},
    {"id":"17318","name":"Opinion following an Article 33(4) referral for Clavudale 50 mg tablet for cats and dogs and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-03T01:00:00Z","last_updated_date":"2012-02-03T01:00:00Z","reference_number":"EMEA/V/A/068","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-clavudale-50-mg-tablet-cats-and-dogs-and-associated-names_sv.pdf"}},
    {"id":"17320","name":"Zydelig Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T13:00:00Z","last_updated_date":"2016-06-10T14:00:00Z","reference_number":"EMA/PRAC/196144/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-timetable-procedure_en.pdf"}    {"id":"17324","name":"Didanosine Article-29 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-12-10T01:00:00Z","last_updated_date":"2013-12-10T01:00:00Z","reference_number":"EMA/686289/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/didanosine-article-29-referral-assessment-report_en.pdf"},
    {"id":"17359","name":"Fibrinogen Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T18:00:00Z","last_updated_date":"2013-04-02T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrinogen-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrinogen-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fibrinogen-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrinogen-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrinogen-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrinogen-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fibrinogen-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrinogen-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fibrinogen-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrinogen-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrinogen-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrinogen-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fibrinogen-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrinogen-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrinogen-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrinogen-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrinogen-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrinogen-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrinogen-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrinogen-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fibrinogen-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrinogen-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"17431","name":"Antifibrinolytic medicines - Article-31 referral - Annex IV (aprotinin)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-06T01:00:00Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_sv.pdf"}},
    {"id":"17438","name":"Questions and answers on the recommendation to lift the suspension of Octagam (human normal immunoglobulin 5% and 10%)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/293780/2011 rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-recommendation-lift-suspension-octagam-human-normal-immunoglobulin-5-and-10_sv.pdf"}},
    {"id":"17462","name":"Hydroxyethyl starch Article-107i referral - Stakeholder's submission form","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"EMEA/H/A-107i/1457","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-stakeholders-submission-form_en.pdf"},
    {"id":"17533","name":"Deltanil - Article 33 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/deltanil-article-33-referral-annex-i-ii-iii_is.pdf"}},
    {"id":"17551","name":"Losec - Article 30 referral - Annex IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-19T02:00:00Z","last_updated_date":"2011-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/losec-article-30-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/losec-article-30-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/losec-article-30-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/losec-article-30-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/losec-article-30-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/losec-article-30-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/losec-article-30-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/losec-article-30-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/losec-article-30-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/losec-article-30-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/losec-article-30-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/losec-article-30-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/losec-article-30-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/losec-article-30-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/losec-article-30-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/losec-article-30-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/losec-article-30-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/losec-article-30-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/losec-article-30-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/losec-article-30-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/losec-article-30-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/losec-article-30-referral-annex-iv_sv.pdf"}},
    {"id":"17557","name":"Priorix - Article 30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-19T02:00:00Z","last_updated_date":"2012-06-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/priorix-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/priorix-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/priorix-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/priorix-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/priorix-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/priorix-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/priorix-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/priorix-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/priorix-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/priorix-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/priorix-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/priorix-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/priorix-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/priorix-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/priorix-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/priorix-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/priorix-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/priorix-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/priorix-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/priorix-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/priorix-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/priorix-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"17561","name":"Questions and answers on the referral for Loratadine Sandoz 10 loratadine 10 mg tablets - Final","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-12-12T00:08:21Z","last_updated_date":"2009-12-12T00:08:21Z","reference_number":"EMEA/CHMP/563259/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_sv.pdf"}},
    {"id":"17570","name":"Ambroxol and bromhexine Article-31 referral - Divergent opinion (Portugal, Czech Republic)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T09:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-divergent-opinion-portugal-czech-republic_en.pdf"},
    {"id":"17587","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - PRAC list of questions to be addressed by stakeholders","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T17:00:00Z","last_updated_date":"2013-02-11T17:00:00Z","reference_number":"EMA/PRAC/78185/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-prac-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"17595","name":"Questions and answers on the review of modified-release oral opioid medicines of the WHO level III scale for the management of pain - Re-examination","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2010-11-19T01:00:00Z","reference_number":"EMA/728909/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-modified-release-oral-opioid-medicines-who-level-iii-scale-management-pain-re-examination_sv.pdf"}},
    {"id":"17617","name":"Factor VIII Article-31 referral - PRAC concludes there is no clear and consistent evidence of a difference in inhibitor development between classes of factor VIII medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-05T18:30:00Z","last_updated_date":"2017-06-09T02:00:00Z","reference_number":"EMA/153837/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-prac-concludes-there-no-clear-and-consistent-evidence-difference-inhibitor-development-between-classes-factor-viii-medicines_en.pdf"},
    {"id":"17619","name":"Ivermectin  - Article 35 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-27T00:59:00Z","last_updated_date":"2009-10-27T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ivermectin-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"17621","name":"Codeine Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2015-02-16T16:25:00Z","reference_number":"EMA/PRAC/180087/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"17664","name":"Methysergide Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-27T02:00:00Z","last_updated_date":"2014-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methysergide-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methysergide-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methysergide-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methysergide-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methysergide-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methysergide-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methysergide-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methysergide-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methysergide-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methysergide-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methysergide-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methysergide-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methysergide-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methysergide-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methysergide-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methysergide-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methysergide-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methysergide-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methysergide-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methysergide-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methysergide-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methysergide-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methysergide-article-31-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/methysergide-article-31-referral-annex-i_no.pdf"}},
    {"id":"17667","name":"Opinion following an Article 36 referral for Sertindole International Non-Proprietary Name (INN): Sertindole: Background information and Annexes I, II (English) and Annex III (all languages)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-09-13T02:08:21Z","last_updated_date":"2002-09-13T02:08:21Z","reference_number":"EMEA/CPMP/2852/02","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_sv.pdf"}},
    {"id":"17672","name":"Iodocasein/thiamine-containing medicinal products-Article 107 referral-Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-i_en.pdf"},
    {"id":"17682","name":"Opinion following an Article 78 procedure for Hiprabovis Pneumos emulsion for injection for cattle and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-12-09T10:32:00Z","last_updated_date":"2011-12-09T10:32:00Z","reference_number":"EMA/CVMP/561772/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-78-procedure-hiprabovis-pneumos-emulsion-injection-cattle-and-associated-names_sv.pdf"}},
    {"id":"17699","name":"Priligy - Article 29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-03-28T02:00:00Z","last_updated_date":"2012-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/priligy-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/priligy-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/priligy-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/priligy-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/priligy-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/priligy-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/priligy-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/priligy-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/priligy-article-29-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/priligy-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/priligy-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/priligy-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/priligy-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/priligy-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/priligy-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/priligy-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/priligy-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/priligy-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/priligy-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/priligy-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/priligy-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/priligy-article-29-referral-annex-i_sv.pdf"}},
    {"id":"17702","name":"Valebo and associated names Article-29(4) referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-31T03:00:00Z","last_updated_date":"2014-03-31T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valebo-and-associated-names-article-294-referral-assessment-report_en.pdf"},
    {"id":"17714","name":"Vivaglobin Article-36 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"EMA/289571/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/vivaglobin-article-36-referral-assessment-report_en.pdf"},
    {"id":"17725","name":"Restrictions on use of short-acting beta-agonists in obstetric indications – CMDh endorses PRAC recommendations","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T14:10:00Z","last_updated_date":"2013-10-25T14:10:00Z","reference_number":"EMA/565019/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/restrictions-use-short-acting-beta-agonists-obstetric-indications-cmdh-endorses-prac-recommendations_sv.pdf"}},
    {"id":"17732","name":"Intravenous iron-containing medicinal products Article-31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-01T02:00:00Z","last_updated_date":"2013-10-01T02:00:00Z","reference_number":"EMA/549569/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-assessment-report_en.pdf"},
    {"id":"17813","name":"Questions and answers on the review of suppositories containing terpenic derivatives","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2012-04-13T12:15:00Z","reference_number":"EMA/CHMP/763180/2011 ","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-suppositories-containing-terpenic-derivatives_sv.pdf"}},
    {"id":"17815","name":"Oxynal, Targin Article-13 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T17:15:00Z","last_updated_date":"2015-01-27T17:15:00Z","reference_number":"EMA/707185/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/oxynal-targin-article-13-referral-assessment-report_en.pdf"},
    {"id":"17821","name":"Substances related to nicotinic acid Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-13T18:00:00Z","last_updated_date":"2014-03-13T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"17823","name":"Bacterial lysate medicines Article 31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/351982/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-review-started_en.pdf"},
    {"id":"17833","name":"Assessment report for Simvastatin Vale and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T02:00:00Z","last_updated_date":"2013-07-22T02:00:00Z","reference_number":"EMA/264659/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-simvastatin-vale-and-associated-names_en.pdf"},
    {"id":"17841","name":"Leflunomide Actavis Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leflunomide-actavis-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"17847","name":"Denagard 45% Article-34 referral - Questions and answers on Denagard 45% and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-08-11T19:00:00Z","last_updated_date":"2017-08-11T19:00:00Z","reference_number":"EMA/275123/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/denagard-45-article-34-referral-questions-and-answers-denagard-45-and-its-associated-names_sv.pdf"}},
    {"id":"17851","name":"Testosterone Article-31 referral - Annex V","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-08T01:00:00Z","last_updated_date":"2015-01-08T01:00:00Z","reference_number":"EMEA/H/A-31/1396","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-annex-v_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/testosterone-article-31-referral-annex-v_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/testosterone-article-31-referral-annex-v_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/testosterone-article-31-referral-annex-v_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/testosterone-article-31-referral-annex-v_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/testosterone-article-31-referral-annex-v_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/testosterone-article-31-referral-annex-v_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/testosterone-article-31-referral-annex-v_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/testosterone-article-31-referral-annex-v_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/testosterone-article-31-referral-annex-v_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/testosterone-article-31-referral-annex-v_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/testosterone-article-31-referral-annex-v_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/testosterone-article-31-referral-annex-v_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/testosterone-article-31-referral-annex-v_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/testosterone-article-31-referral-annex-v_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/testosterone-article-31-referral-annex-v_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/testosterone-article-31-referral-annex-v_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/testosterone-article-31-referral-annex-v_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/testosterone-article-31-referral-annex-v_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/testosterone-article-31-referral-annex-v_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/testosterone-article-31-referral-annex-v_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/testosterone-article-31-referral-annex-v_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/testosterone-article-31-referral-annex-v_sv.pdf"}},
    {"id":"17893","name":"Renin-angiotensin-system (RAS)-acting agents Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T02:00:00Z","last_updated_date":"2014-03-07T14:43:00Z","reference_number":"EMA/PRAC/290691/2013 rev. 3","document_url":"https://www.ema.europa.eu/en/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"17910","name":"Xefo - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-09-28T02:08:21Z","last_updated_date":"2007-09-28T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xefo-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xefo-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xefo-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/xefo-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xefo-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xefo-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xefo-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xefo-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xefo-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xefo-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xefo-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xefo-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xefo-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xefo-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xefo-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xefo-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/xefo-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xefo-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xefo-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xefo-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xefo-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xefo-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"17922","name":"Glucomed - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-12-21T00:08:21Z","last_updated_date":"2006-12-21T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/glucomed-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"17930","name":"Ergot derivatives Article-31 referral - Dihydroergotamine - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotamine-annex-iv_sv.pdf"}},
    {"id":"17985","name":"Numeta Article-107i procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-notification_en.pdf"},
    {"id":"18006","name":"Questions and answers on Saroten and associated names (amitriptyline)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2017-06-06T02:00:00Z","reference_number":"EMA/118128/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-saroten-and-associated-names-amitriptyline_sv.pdf"}},
    {"id":"18037","name":"Short-acting beta-agonists Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T14:10:00Z","last_updated_date":"2013-11-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iii_no.pdf"}},
    {"id":"18041","name":"Levact - Article 29 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-08T02:00:00Z","last_updated_date":"2011-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levact-article-29-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"18044","name":"Questions and answers on Merisone and Myoson (tolperisone, 50 and 150 mg tablets)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-28T02:00:00Z","last_updated_date":"2015-07-28T02:00:00Z","reference_number":"EMA/252261/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_sv.pdf"}},
    {"id":"18055","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-10T15:00:00Z","last_updated_date":"2013-06-10T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-i_no.pdf"}},
    {"id":"18073","name":"Opinion following an Article 33(4) referral for Norbonex 5 mg/ml pour-on solution for beef and dairy cattle","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-05-14T02:00:00Z","last_updated_date":"2014-05-14T02:00:00Z","reference_number":"EMA/128538/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-norbonex-5-mgml-pour-solution-beef-and-dairy-cattle_sv.pdf"}},
    {"id":"18129","name":"Questions and answers on the referral for Lescol and associated names Capsules containing 20 mg or 40 mg fluvastatin Prolonged-release tablets containing 80 mg fluvastatin","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-11-21T00:59:00Z","last_updated_date":"2011-09-13T13:47:00Z","reference_number":"EMEA/CHMP/736379/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_sv.pdf"}},
    {"id":"18149","name":"Esmya Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T13:00:00Z","last_updated_date":"2017-12-01T13:00:00Z","reference_number":"EMA/791062/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-review-started_en.pdf"},
    {"id":"18150","name":"Flupirtine-containing medicines Article-107i procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T14:00:00Z","last_updated_date":"2013-07-18T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iv_sv.pdf"}},
    {"id":"18158","name":"Opinion following an Article 31(2) referral for Etoricoxib containing medicinal products International Non-Proprietary Name (INN): etoricoxib: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:08:21Z","last_updated_date":"2008-10-23T02:08:21Z","reference_number":"EMEA/542169/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-312-referral-etoricoxib-containing-medicinal-products-international-non-proprietary-name-inn-etoricoxib-background-information_sv.pdf"}},
    {"id":"18182","name":"Nanotop Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T17:00:00Z","last_updated_date":"2014-06-16T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nanotop-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nanotop-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nanotop-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nanotop-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nanotop-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nanotop-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nanotop-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nanotop-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nanotop-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nanotop-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nanotop-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nanotop-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nanotop-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nanotop-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nanotop-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nanotop-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nanotop-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nanotop-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nanotop-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nanotop-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nanotop-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nanotop-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nanotop-article-294-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/nanotop-article-294-referral-annex-i_no.pdf"}},
    {"id":"18188","name":"Kogenate Bayer and Helixate NexGen Article-20 procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-04-09T12:00:00Z","last_updated_date":"2014-04-09T12:00:00Z","reference_number":"EMA/10430/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-prac-assessment-report_en.pdf"},
    {"id":"18209","name":"Alkem Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T13:00:00Z","last_updated_date":"2016-10-07T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/alkem-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/alkem-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/alkem-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/alkem-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/alkem-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/alkem-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/alkem-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/alkem-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/alkem-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/alkem-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/alkem-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/alkem-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/alkem-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/alkem-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/alkem-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/alkem-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/alkem-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/alkem-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/alkem-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/alkem-article-31-referral-annex-ii_sl.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/alkem-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"18210","name":"Codeine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2015-05-18T02:00:00Z","reference_number":"EMA/713187/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-annex-i_en.pdf-1","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/codeine-article-31-referral-annex-i_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/codeine-article-31-referral-annex-i_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/codeine-article-31-referral-annex-i_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/codeine-article-31-referral-annex-i_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/codeine-article-31-referral-annex-i_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/codeine-article-31-referral-annex-i_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/codeine-article-31-referral-annex-i_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/codeine-article-31-referral-annex-i_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/referral/codeine-article-31-referral-annex-i_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/codeine-article-31-referral-annex-i_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/codeine-article-31-referral-annex-i_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/codeine-article-31-referral-annex-i_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/codeine-article-31-referral-annex-i_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/codeine-article-31-referral-annex-i_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/codeine-article-31-referral-annex-i_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/codeine-article-31-referral-annex-i_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/codeine-article-31-referral-annex-i_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/codeine-article-31-referral-annex-i_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/codeine-article-31-referral-annex-i_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/codeine-article-31-referral-annex-i_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/codeine-article-31-referral-annex-i_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/codeine-article-31-referral-annex-i_sv.pdf-0"}},
    {"id":"18220","name":"Tysabri Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-08T14:00:00Z","last_updated_date":"2015-05-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tysabri-article-20-procedure-notification_en.pdf"},
    {"id":"18221","name":"Flupirtine-containing medicines Article-107i procedure - Timetable for the procedure","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-08T13:00:00Z","last_updated_date":"2013-05-21T02:00:00Z","reference_number":"EMA/PRAC/137732/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-timetable-procedure_en.pdf"},
    {"id":"18235","name":"Hydroxyethyl starch Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-15T15:30:00Z","last_updated_date":"2013-11-15T15:30:00Z","reference_number":"EMA/667674/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"18264","name":"Rocephin Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-19T02:00:00Z","last_updated_date":"2014-05-19T02:00:00Z","reference_number":"EMEA/H/A-30/1302","document_url":"https://www.ema.europa.eu/en/documents/referral/rocephin-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rocephin-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rocephin-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rocephin-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rocephin-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rocephin-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rocephin-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rocephin-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rocephin-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/rocephin-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rocephin-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rocephin-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rocephin-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rocephin-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rocephin-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rocephin-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rocephin-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rocephin-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rocephin-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rocephin-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rocephin-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rocephin-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rocephin-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"18292","name":"Domperidone Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-06-17T17:00:00Z","last_updated_date":"2014-06-17T17:00:00Z","reference_number":"EMA/152501/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"18319","name":"Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Calcichew-D3 mite and associated names International Non-Proprietary Name (INN): Calcium 500mg / ch...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-12-02T00:08:21Z","last_updated_date":"2003-12-02T00:08:21Z","reference_number":"EMEA/CPMP/3258/03/en/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcichew-d3-mite-and-associated-names-international-non-proprietary-name-inn-calcium-500mg-ch_en.pdf"},
    {"id":"18321","name":"Protelos and Osseor Article-20 procedure - Annex I, II and III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/protelos-and-osseor-article-20-procedure-annex-i-ii-and-iii_en.pdf"},
    {"id":"18336","name":"Dexrazoxane-H-A-31-1275: Article 31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T01:00:00Z","last_updated_date":"2012-01-16T01:00:00Z","reference_number":"EMA/775079/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/dexrazoxane-h-31-1275-article-31-referral-assessment-report_en.pdf"},
    {"id":"18342","name":"Dienogest / Ethinylestradiol Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dienogest-ethinylestradiol-article-31-referral-notification_en.pdf"},
    {"id":"18370","name":"Questions and answers on Arimidex (anastrozole, 1 mg tablets)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-arimidex-anastrozole-1-mg-tablets_sv.pdf"}},
    {"id":"18385","name":"SGLT2 inhibitors Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-18T02:00:00Z","last_updated_date":"2016-05-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iv_sv.pdf"}},
    {"id":"18386","name":"Oxynal, Targin Article-13 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T17:15:00Z","last_updated_date":"2015-01-27T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/oxynal-targin-article-13-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/oxynal-targin-article-13-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/oxynal-targin-article-13-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/oxynal-targin-article-13-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/oxynal-targin-article-13-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/oxynal-targin-article-13-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/oxynal-targin-article-13-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/oxynal-targin-article-13-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/oxynal-targin-article-13-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/oxynal-targin-article-13-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/oxynal-targin-article-13-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/oxynal-targin-article-13-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/oxynal-targin-article-13-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/oxynal-targin-article-13-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/oxynal-targin-article-13-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/oxynal-targin-article-13-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/oxynal-targin-article-13-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/oxynal-targin-article-13-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/oxynal-targin-article-13-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/oxynal-targin-article-13-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/oxynal-targin-article-13-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/oxynal-targin-article-13-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/oxynal-targin-article-13-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/oxynal-targin-article-13-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/oxynal-targin-article-13-referral-annex-iii_no.pdf"}},
    {"id":"18392","name":"Methadone Article-107i procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-annex-i_en.pdf"},
    {"id":"18397","name":"SGLT2 inhibitors Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-12T14:00:00Z","last_updated_date":"2015-06-12T14:00:00Z","reference_number":"EMEA/H/A-20/1419","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-notification_en.pdf"},
    {"id":"18435","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Start of review of Diane 35 and other medicines containing cyproterone acetate 2 mg and ethinylestradiol 35 micrograms","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T13:00:00Z","last_updated_date":"2013-02-08T13:00:00Z","reference_number":"EMA/76602/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-start-review-diane-35-and-other-medicines-containing-cyproterone-acetate-2-mg-and-ethinylestradiol-35-micrograms_en.pdf"},
    {"id":"18473","name":"Kogenate Bayer and Helixate NexGen Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-10-29T12:50:00Z","reference_number":"EMA/PRAC/142799/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"18499","name":"Symbioflor 2 Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/233358/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-review-started_en.pdf"},
    {"id":"18509","name":"Bisphosphonates - Article 31 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bisphosphonates-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bisphosphonates-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bisphosphonates-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bisphosphonates-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bisphosphonates-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bisphosphonates-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bisphosphonates-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bisphosphonates-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bisphosphonates-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bisphosphonates-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bisphosphonates-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bisphosphonates-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bisphosphonates-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bisphosphonates-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bisphosphonates-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bisphosphonates-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bisphosphonates-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bisphosphonates-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bisphosphonates-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bisphosphonates-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bisphosphonates-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bisphosphonates-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"18535","name":"Thiocolchicoside Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/thiocolchicoside-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/thiocolchicoside-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/thiocolchicoside-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/thiocolchicoside-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/thiocolchicoside-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/thiocolchicoside-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/thiocolchicoside-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/thiocolchicoside-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/thiocolchicoside-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/thiocolchicoside-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/thiocolchicoside-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/thiocolchicoside-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/thiocolchicoside-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/thiocolchicoside-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/thiocolchicoside-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/thiocolchicoside-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/thiocolchicoside-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/thiocolchicoside-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/thiocolchicoside-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/thiocolchicoside-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/thiocolchicoside-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/thiocolchicoside-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/thiocolchicoside-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"18543","name":"Tredaptive, Pelzont and Trevaclyn Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-21T01:00:00Z","last_updated_date":"2012-12-21T01:00:00Z","reference_number":"EMA/819878/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/tredaptive-pelzont-and-trevaclyn-article-20-procedure-review-started_en.pdf"},
    {"id":"18561","name":"Priorix - Article 30 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T01:00:00Z","last_updated_date":"2012-06-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/priorix-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/priorix-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/priorix-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/priorix-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/priorix-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/priorix-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/priorix-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/priorix-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/priorix-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/priorix-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/priorix-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/priorix-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/priorix-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/priorix-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/priorix-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/priorix-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/priorix-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/priorix-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/priorix-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/priorix-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/priorix-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/priorix-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"18566","name":"Tibocina-Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-08T02:00:00Z","last_updated_date":"2014-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tibocina-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tibocina-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tibocina-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tibocina-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tibocina-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tibocina-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tibocina-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tibocina-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tibocina-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tibocina-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tibocina-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tibocina-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tibocina-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tibocina-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tibocina-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tibocina-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tibocina-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tibocina-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tibocina-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tibocina-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tibocina-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tibocina-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tibocina-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"18613","name":"CMDh confirms recommendations on restricting use of domperidone-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T17:00:00Z","last_updated_date":"2014-04-25T17:00:00Z","reference_number":"EMA/236452/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/cmdh-confirms-recommendations-restricting-use-domperidone-containing-medicines_en.pdf"},
    {"id":"18618","name":"Renin-angiotensin-system (RAS)-acting agents Article-31 referral - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-05-17T02:00:00Z","last_updated_date":"2013-05-17T02:00:00Z","reference_number":"EMA/PRAC/290692/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"18630","name":"Questions and answers on the review of systemic medicines containing nimesulide","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-06-23T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"EMA/382884/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-systemic-medicines-containing-nimesulide_sv.pdf"}},
    {"id":"18644","name":"Summary information on referral opinion pursuant to Article 31 of Council Directive 2001/83/EC, as amended, for Elidel and associated names (see Annex 1) International Non-Proprietary Name (INN): pimecrolimus: Background...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-05-29T02:08:21Z","last_updated_date":"2006-05-29T02:08:21Z","reference_number":"EMEA/262776/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-elidel-and-associated-names-see-annex-1-international-non-proprietary-name-inn-pimecrolimus-background_sv.pdf"}},
    {"id":"18652","name":"Zydelig Article-20 procedure - CHMP confirms recommendations for use of Zydelig","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_en.pdf"},
    {"id":"18667","name":"Article-31 referral - European Medicines Agency recommends restricting use of cilostazol-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"EMA/423411/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_sv.pdf"}},
    {"id":"18672","name":"Cryopterone / ethinylestradiol-containing medicines: Article-107i procedure - Rationale for the triggering of procedure under Article 107i of Directive 2001/83/EC on cyproterone / ethinylestradiol (2 mg / 0.035 mg) prese...","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-02-27T17:00:00Z","last_updated_date":"2013-03-18T12:00:00Z","reference_number":"EMEA/H/A-107i/1357","document_url":"https://www.ema.europa.eu/en/documents/referral/cryopterone-ethinylestradiol-containing-medicines-article-107i-procedure-rationale-triggering-procedure-under-article-107i-directive-200183ec-cyproterone-ethinylestradiol-2-mg-0035-mg-prese_en.pdf"},
    {"id":"18678","name":"Flupirtine-containing medicines Article-107i procedure - Notification","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-08T13:00:00Z","last_updated_date":"2013-03-08T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-notification_en.pdf"},
    {"id":"18690","name":"Girolan Article-34 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-15T02:00:00Z","last_updated_date":"2018-06-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/girolan-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/girolan-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/girolan-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/girolan-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/girolan-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/girolan-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/girolan-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/girolan-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/girolan-article-34-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/girolan-article-34-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/girolan-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/girolan-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/girolan-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/girolan-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/girolan-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/girolan-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/girolan-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/girolan-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/girolan-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/girolan-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/girolan-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/girolan-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/girolan-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"18727","name":"Opinion following an Article 34 referral for Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus and Prazitel Plus and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-23T02:00:00Z","last_updated_date":"2012-07-23T02:00:00Z","reference_number":"EMA/289985/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-and-prazitel-plus-and-associated-names_sv.pdf"}},
    {"id":"18744","name":"Questions and answers on Atacand and associated names (candesartan cilexetil 2, 4, 8, 16 and 32 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-03-20T00:59:00Z","last_updated_date":"2011-03-17T00:59:00Z","reference_number":"EMEA/H/A-30/1150","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_sv.pdf"}},
    {"id":"18746","name":"Committee for proprietary medicinal products opinion following an Article 12 referral for Chlormezanone International Non-Proprietary Name (INN): Chlormezanone: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-09-22T02:08:21Z","last_updated_date":"2007-09-22T02:08:21Z","reference_number":"CPMP/375/97","document_url":"https://www.ema.europa.eu/en/documents/referral/committee-proprietary-medicinal-products-opinion-following-article-12-referral-chlormezanone-international-non-proprietary-name-inn-chlormezanone-background-information_en.pdf"},
    {"id":"18750","name":"Tritace - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-04-24T02:08:21Z","last_updated_date":"2009-04-24T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tritace-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tritace-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tritace-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tritace-article-30-referral-annex-i-ii-iii_cs.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tritace-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tritace-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tritace-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tritace-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tritace-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tritace-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tritace-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tritace-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tritace-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tritace-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tritace-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tritace-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tritace-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tritace-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tritace-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tritace-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tritace-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"18776","name":"Ergot derivatives Article-31 referral - Dihydroergocristine - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-i_sv.pdf"}},
    {"id":"18789","name":"Questions and answers on Yvidually and associated names (ethinylestradiol / drospirenone, 0.02 mg/3 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2012-04-20T02:00:00Z","reference_number":"EMA/265750/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-yvidually-and-associated-names-ethinylestradiol-drospirenone-002-mg3-mg-tablets_sv.pdf"}},
    {"id":"18823","name":"Short-acting beta-agonists Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-07T01:00:00Z","last_updated_date":"2013-11-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/short-acting-beta-agonists-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"18848","name":"Questions and answers on Targocid and associated names (teicoplanin, powder or powder and solvent for solution for injection, infusion or oral solution, 100, 200 and 400 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2014-01-03T13:00:00Z","reference_number":"EMA/319080/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-targocid-and-associated-names-teicoplanin-powder-or-powder-and-solvent-solution-injection-infusion-or-oral-solution-100-200-and-400-mg_sv.pdf"}},
    {"id":"18873","name":"Long-acting formulations for injection containing barium selenate for all food producing species  - Article 35 referral - Annexes I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-27T02:00:00Z","last_updated_date":"2014-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species-article-35-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"18901","name":"Valproate - Article 31 - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-29T02:00:00Z","last_updated_date":"2011-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-article-31-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-article-31-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-article-31-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-article-31-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-article-31-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-article-31-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-article-31-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-article-31-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-article-31-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-article-31-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-article-31-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-article-31-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-article-31-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-article-31-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-article-31-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-article-31-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-article-31-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-article-31-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-article-31-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-article-31-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-article-31-annex-iii_sv.pdf"}},
    {"id":"18937","name":"Terpenic derivatives - Article 31 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-08T01:00:00Z","last_updated_date":"2012-02-08T01:00:00Z","reference_number":"EMEA/H/A-1284","document_url":"https://www.ema.europa.eu/en/documents/referral/terpenic-derivatives-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/terpenic-derivatives-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/terpenic-derivatives-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/terpenic-derivatives-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/terpenic-derivatives-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/terpenic-derivatives-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/terpenic-derivatives-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/terpenic-derivatives-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/terpenic-derivatives-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/terpenic-derivatives-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/terpenic-derivatives-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/terpenic-derivatives-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/terpenic-derivatives-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/terpenic-derivatives-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/terpenic-derivatives-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/terpenic-derivatives-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/terpenic-derivatives-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/terpenic-derivatives-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/terpenic-derivatives-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/terpenic-derivatives-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/terpenic-derivatives-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/terpenic-derivatives-article-31-referral-annex-i_sv.pdf"}},
    {"id":"18976","name":"Durogesic Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T02:00:00Z","last_updated_date":"2016-10-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/durogesic-article-30-referral-annex-iii_en.pdf","translations":{"is":"https://www.ema.europa.eu/is/documents/referral/durogesic-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/durogesic-article-30-referral-annex-iii_no.pdf"}},
    {"id":"18987","name":"Questions and answers on the referral for Fentrix and associated names 25, 50, 70 and 100 microgram/hour fentanyl transdermal patch","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:08:21Z","last_updated_date":"2009-06-25T02:08:21Z","reference_number":"EMEA/CHMP/393579/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_sv.pdf"}},
    {"id":"19015","name":"Quinolone and fluoroquinolone Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2018-07-18T16:25:00Z","reference_number":"EMA/PRAC/38618/2017 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"19025","name":"Paracetamol Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-notification_en.pdf"},
    {"id":"19046","name":"Domperidone Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-11T02:00:00Z","last_updated_date":"2014-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/domperidone-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/domperidone-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/domperidone-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/domperidone-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/domperidone-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/domperidone-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/domperidone-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/domperidone-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/domperidone-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/domperidone-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/domperidone-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/domperidone-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/domperidone-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/domperidone-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/domperidone-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/domperidone-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/domperidone-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/domperidone-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/domperidone-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/domperidone-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/domperidone-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/domperidone-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"19053","name":"Priligy - Article 29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-03-28T02:00:00Z","last_updated_date":"2012-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/priligy-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/priligy-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/priligy-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/priligy-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/priligy-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/priligy-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/priligy-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/priligy-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/priligy-article-29-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/priligy-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/priligy-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/priligy-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/priligy-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/priligy-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/priligy-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/priligy-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/priligy-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/priligy-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/priligy-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/priligy-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/priligy-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/priligy-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"19065","name":"Zinnat - Article 30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T01:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinnat-article-30-referral-annex-i_en.pdf-0"}    {"id":"19069","name":"Dextropropoxyphene and Paracetamol - Solution for Injection - Article 31 - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-10-19T02:00:00Z","last_updated_date":"2010-10-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dextropropoxyphene-and-paracetamol-solution-injection-article-31-annex-i-ii-iii_sv.pdf"}},
    {"id":"19072","name":"Opinion following an Article 31 referral for Norfloxacin containing medicinal products International Non-Proprietary Name (INN): norfloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-01-14T00:08:21Z","last_updated_date":"2009-01-14T00:08:21Z","reference_number":"EMEA/660192/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-31-referral-norfloxacin-containing-medicinal-products-international-non-proprietary-name-inn-norfloxacin-background-information_sv.pdf"}},
    {"id":"19088","name":"Metoclopramide Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metoclopramide-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metoclopramide-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metoclopramide-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metoclopramide-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metoclopramide-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metoclopramide-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metoclopramide-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metoclopramide-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metoclopramide-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metoclopramide-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metoclopramide-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metoclopramide-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metoclopramide-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metoclopramide-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metoclopramide-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metoclopramide-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metoclopramide-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metoclopramide-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metoclopramide-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metoclopramide-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metoclopramide-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metoclopramide-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metoclopramide-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"19101","name":"Flupirtine-containing medicines Article-107i procedure - Stakeholders' submission form","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-08T13:00:00Z","last_updated_date":"2013-03-08T13:00:00Z","reference_number":"EMA/639499/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-stakeholders-submission-form_en.pdf"},
    {"id":"19147","name":"Roaccutane - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-12-02T00:08:21Z","last_updated_date":"2003-12-02T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/roaccutane-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"19179","name":"PRAC recommends product information of zolpidem be updated with new advice to minimise the risk of next-morning impaired driving ability and mental alertness","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-03-07T01:00:00Z","last_updated_date":"2014-03-07T01:00:00Z","reference_number":"EMA/129598/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-recommends-product-information-zolpidem-be-updated-new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness_en.pdf"},
    {"id":"19190","name":"Questions and answers on Oxynal, Targin and associated names (oxycodone hydrochloride / naloxone hydrochloride)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2015-01-27T01:00:00Z","reference_number":"EMA/653836/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-oxynal-targin-and-associated-names-oxycodone-hydrochloride-naloxone-hydrochloride_sv.pdf"}},
    {"id":"19208","name":"Zolpidem Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T18:00:00Z","last_updated_date":"2014-08-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zolpidem-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zolpidem-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zolpidem-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zolpidem-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zolpidem-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zolpidem-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zolpidem-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zolpidem-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zolpidem-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zolpidem-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zolpidem-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zolpidem-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zolpidem-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zolpidem-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zolpidem-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zolpidem-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zolpidem-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zolpidem-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zolpidem-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zolpidem-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zolpidem-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zolpidem-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zolpidem-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"19246","name":"Substances related to nicotinic acid Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-03-08T01:00:00Z","reference_number":"EMA/PRAC/138313/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"19267","name":"Norditropin - Article 13 referral - Assessment Report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"EMA/171189/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/norditropin-article-13-referral-assessment-report_en.pdf"},
    {"id":"19269","name":"Diclofenac Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-27T12:30:00Z","last_updated_date":"2013-11-27T12:30:00Z","reference_number":"EMEA/H/A-31/1344","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"19280","name":"Corlentor and Procoralan Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-14T11:30:00Z","last_updated_date":"2014-05-14T11:30:00Z","reference_number":"EMA/PRAC/281252/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/corlentor-and-procoralan-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"19290","name":"Vepesid Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vepesid-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vepesid-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vepesid-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vepesid-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vepesid-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vepesid-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vepesid-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vepesid-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vepesid-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/vepesid-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vepesid-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vepesid-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vepesid-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vepesid-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vepesid-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vepesid-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vepesid-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vepesid-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vepesid-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vepesid-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vepesid-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vepesid-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vepesid-article-30-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/vepesid-article-30-referral-annex-i_no.pdf"}},
    {"id":"19292","name":"Zolpidem Article-31 referral - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"EMA/PRAC/418738/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/zolpidem-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"19296","name":"Valproate Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T13:00:00Z","last_updated_date":"2017-03-10T13:00:00Z","reference_number":"EMEA/H/A-31/1454","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-notification_en.pdf"},
    {"id":"19317","name":"Methadone Article-107i procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-08-04T02:00:00Z","last_updated_date":"2014-08-04T02:00:00Z","reference_number":"EMA/464317/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-prac-assessment-report_en.pdf"},
    {"id":"19362","name":"Questions and answers on the review of calcitonin-containing medicines - Outcome of re-examination","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T13:00:00Z","last_updated_date":"2012-11-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-calcitonin-containing-medicines-outcome-re-examination_en.pdf"},
    {"id":"19373","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Olysio Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T01:00:00Z","last_updated_date":"2017-03-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-olysio-annex-i-iii_no.pdf"}},
    {"id":"19411","name":"HPV vaccines - Article-20 procedure - Scientific conclusion - Annex","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-01-20T01:00:00Z","last_updated_date":"2016-01-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hpv-vaccines-article-20-procedure-scientific-conclusion-annex_sv.pdf"}},
    {"id":"19469","name":"Octegra Article-29(4) referral - Annex I, II and III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/octegra-article-294-referral-annex-i-ii-and-iii_is.pdf"}},
    {"id":"19493","name":"Sandostatin LAR - Article 30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T14:00:00Z","last_updated_date":"2014-07-02T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sandostatin-lar-article-30-referral-annex-iii_en.pdf"},
    {"id":"19507","name":"Merisone Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-28T02:00:00Z","last_updated_date":"2015-07-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/merisone-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/merisone-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/merisone-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/merisone-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/merisone-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/merisone-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/merisone-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/merisone-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/merisone-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/merisone-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/merisone-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/merisone-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/merisone-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/merisone-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/merisone-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/merisone-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/merisone-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/merisone-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/merisone-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/merisone-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/merisone-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/merisone-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/merisone-article-294-referral-annex-i_sv.pdf"}},
    {"id":"19518","name":"Hydroxyethyl starch Article-107i procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T14:10:00Z","last_updated_date":"2014-03-06T13:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iii_no.pdf"}},
    {"id":"19523","name":"Targocid Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-03T01:00:00Z","last_updated_date":"2014-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/targocid-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/targocid-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/targocid-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/targocid-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/targocid-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/targocid-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/targocid-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/targocid-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/targocid-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/targocid-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/targocid-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/targocid-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/targocid-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/targocid-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/targocid-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/targocid-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/targocid-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/targocid-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/targocid-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/targocid-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/targocid-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/targocid-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/targocid-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"19544","name":"Opinion following an Article 31 referral Nimesulide containing medicinal products International Non-Proprietary Name (INN): Nimesulide: Background information and Annexes I,II,IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-05-07T02:08:21Z","last_updated_date":"2004-05-07T02:08:21Z","reference_number":"CPMP/1724 /04","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-nimesulide-containing-medicinal-products-international-non-proprietary-name-inn-nimesulide-background-information-and-annexes-iiiiv_en.pdf"},
    {"id":"19566","name":"Numeta Article-107i procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-annex-i_en.pdf"},
    {"id":"19568","name":"Loratadine Sandoz 10 - Article 29 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-12-12T00:08:21Z","last_updated_date":"2009-12-12T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/loratadine-sandoz-10-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"19579","name":"Summary information on a referral opinion following an arbitration according to Article 7(5) of Commission Regulation (EC) No 541/95 as amended, for Zofenil/Zopranol/Bifril International Non-Proprietary Name (INN): zofen...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2000-12-16T00:08:21Z","last_updated_date":"2000-12-16T00:08:21Z","reference_number":"CPMP/2011/00","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-according-article-75-commission-regulation-ec-no-54195-amended-zofenilzopranolbifril-international-non-proprietary-name-inn-zofen_en.pdf"},
    {"id":"19604","name":"Isotretinoin - Article 29 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2011-07-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/isotretinoin-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/isotretinoin-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/isotretinoin-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/isotretinoin-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/isotretinoin-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/isotretinoin-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/isotretinoin-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/isotretinoin-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/isotretinoin-article-29-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/isotretinoin-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/isotretinoin-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/isotretinoin-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/isotretinoin-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/isotretinoin-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/isotretinoin-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/isotretinoin-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/isotretinoin-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/isotretinoin-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/isotretinoin-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/isotretinoin-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/isotretinoin-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/isotretinoin-article-29-referral-annex-iii_sv.pdf"}},
    {"id":"19637","name":"Fibrin sealants Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrin-sealants-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrin-sealants-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fibrin-sealants-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrin-sealants-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrin-sealants-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrin-sealants-article-31-referral-annex-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrin-sealants-article-31-referral-annex-iii_el.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrin-sealants-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrin-sealants-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrin-sealants-article-31-referral-annex-iii_lt.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrin-sealants-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrin-sealants-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrin-sealants-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrin-sealants-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrin-sealants-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrin-sealants-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrin-sealants-article-31-referral-annex-iii_sl.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrin-sealants-article-31-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/fibrin-sealants-article-31-referral-annex-iii_no.pdf"}},
    {"id":"19644","name":"Diacerein Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2014-01-17T16:45:00Z","reference_number":"EMA/PRAC/747322/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"19651","name":"Numeta Article-107i procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-prac-list-questions_en.pdf"},
    {"id":"19657","name":"Ketoconazole Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T02:00:00Z","last_updated_date":"2014-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ketoconazole-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ketoconazole-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ketoconazole-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ketoconazole-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ketoconazole-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ketoconazole-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ketoconazole-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ketoconazole-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ketoconazole-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ketoconazole-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ketoconazole-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ketoconazole-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ketoconazole-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ketoconazole-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ketoconazole-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ketoconazole-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ketoconazole-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ketoconazole-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ketoconazole-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ketoconazole-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ketoconazole-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ketoconazole-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ketoconazole-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"19658","name":"Opinion following an Article 29 referral Amlodipin Wà¶rwag International Non-Proprietary Name (INN): Amlodipine: Background information and Annex I II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-04-27T02:08:21Z","last_updated_date":"2004-04-27T02:08:21Z","reference_number":"EMEA/CPMP/538/04","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-29-referral-amlodipin-waprwag-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_sv.pdf"}},
    {"id":"19684","name":"Somatropin - Article 107 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-23T02:00:00Z","last_updated_date":"2012-04-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/somatropin-article-107-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/somatropin-article-107-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/somatropin-article-107-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/somatropin-article-107-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/somatropin-article-107-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/somatropin-article-107-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/somatropin-article-107-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/somatropin-article-107-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/somatropin-article-107-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/somatropin-article-107-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/somatropin-article-107-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/somatropin-article-107-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/somatropin-article-107-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/somatropin-article-107-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/somatropin-article-107-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/somatropin-article-107-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/somatropin-article-107-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/somatropin-article-107-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/somatropin-article-107-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/somatropin-article-107-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/somatropin-article-107-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/somatropin-article-107-referral-annex-i_sv.pdf"}},
    {"id":"19723","name":"Flupirtine Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"EMEA/H/A-31/1458","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"19724","name":"Questions and answers on the suspension of the marketing authorisations for oral meprobamate-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-01-20T14:00:00Z","last_updated_date":"2012-06-08T16:15:00Z","reference_number":"EMA/42783/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-suspension-marketing-authorisations-oral-meprobamate-containing-medicines_sv.pdf"}},
    {"id":"19736","name":"Femara - Article 30 referral - Assessment Report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-06-12T02:00:00Z","last_updated_date":"2012-06-12T02:00:00Z","reference_number":"EMA/267448/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/femara-article-30-referral-assessment-report_en.pdf"},
    {"id":"19775","name":"Opinion following an Article 34 referral for Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names: Background information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T01:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"EMA/538940/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-background-information_sv.pdf"}},
    {"id":"19783","name":"Opinion following an Article 34 referral for Doxyfar 50% and associated names: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-08-23T02:00:00Z","last_updated_date":"2011-08-23T02:00:00Z","reference_number":"EMA/512470/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-doxyfar-50-and-associated-names-background-information_sv.pdf"}},
    {"id":"19787","name":"Micro Therapeutic Research Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-notification_en.pdf"},
    {"id":"19796","name":"Arimidex - Article 30 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/arimidex-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/arimidex-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/arimidex-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/arimidex-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/arimidex-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/arimidex-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/arimidex-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/arimidex-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/arimidex-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/arimidex-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/arimidex-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/arimidex-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/arimidex-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/arimidex-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/arimidex-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/arimidex-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/arimidex-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/arimidex-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/arimidex-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/arimidex-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/arimidex-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/arimidex-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"19829","name":"Zinbryta Article-20 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-06-09T18:00:00Z","last_updated_date":"2017-06-09T18:00:00Z","reference_number":"EMA/PRAC/366034/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-prac-list-questions_en.pdf"},
    {"id":"19835","name":"Methylprednisolone Article-35 referral - Questions and answers on veterinary medicinal products containing methylprednisolone hydrogen succinate presented as solutions for injection for use in the target species cattle","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T12:00:00Z","last_updated_date":"2017-08-04T12:00:00Z","reference_number":"EMA/398380/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methylprednisolone-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-methylprednisolone-hydrogen-succinate-presented-solutions-injection-use-target-species-cattle_sv.pdf"}},
    {"id":"19872","name":"PRAC recommends suspension of diacerein-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-08T01:00:00Z","last_updated_date":"2013-12-06T13:00:00Z","reference_number":"EMA/679264/2013/rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-recommends-suspension-diacerein-containing-medicines_en.pdf"},
    {"id":"19878","name":"Furosemide Vitabalans Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-30T17:30:00Z","last_updated_date":"2013-07-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/furosemide-vitabalans-article-294-referral-annex-i_no.pdf"}},
    {"id":"19893","name":"Micro Therapeutic Research Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"EMA/CHMP/847557/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"19969","name":"Hydroxyzine Article-31 referral - New restrictions to minimise the risks of effects on heart rhythm with hydroxyzine-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-03-27T01:00:00Z","reference_number":"EMA/149624/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyzine-article-31-referral-new-restrictions-minimise-risks-effects-heart-rhythm-hydroxyzine-containing-medicines_sv.pdf"}},
    {"id":"19985","name":"Symbioflor 2 Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-07T02:00:00Z","last_updated_date":"2017-09-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/symbioflor-2-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/symbioflor-2-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/symbioflor-2-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/symbioflor-2-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/symbioflor-2-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/symbioflor-2-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/symbioflor-2-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/symbioflor-2-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/symbioflor-2-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/symbioflor-2-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/symbioflor-2-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/symbioflor-2-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/symbioflor-2-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/symbioflor-2-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/symbioflor-2-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/symbioflor-2-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/symbioflor-2-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/symbioflor-2-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/symbioflor-2-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/symbioflor-2-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/symbioflor-2-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/symbioflor-2-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"19999","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Benefits of Diane 35 and its generics outweigh risks in certain patient groups - PRAC recommendation endorsed by CMDh","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-30T02:00:00Z","last_updated_date":"2013-05-30T02:00:00Z","reference_number":"EMA/318380/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups-prac-recommendation-endorsed-cmdh_en.pdf"},
    {"id":"20027","name":"GVK Biosciences Article-31 referral - CHMP list of questions to all marketing-authorisation holders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-27T01:00:00Z","last_updated_date":"2014-10-27T01:00:00Z","reference_number":"EMA/CHMP/658332/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-chmp-list-questions-all-marketing-authorisation-holders_en.pdf"},
    {"id":"20030","name":"Xalatan - Article 29 paediatrics - Annexes I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-12-08T01:00:00Z","last_updated_date":"2010-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xalatan-article-29-paediatrics-annexes-i-ii-iii_sv.pdf"}},
    {"id":"20037","name":"Botox - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-10-16T02:08:21Z","last_updated_date":"2003-10-16T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/botox-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/botox-article-29-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/botox-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/botox-article-29-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/botox-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/botox-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/botox-article-29-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/botox-article-29-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/botox-article-29-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/botox-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/botox-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"20051","name":"Nanotop Article-29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-06-16T17:00:00Z","last_updated_date":"2014-06-16T17:00:00Z","reference_number":"EMA/37394/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/nanotop-article-294-referral-assessment-report_en.pdf"},
    {"id":"20052","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Harvoni Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T01:00:00Z","last_updated_date":"2017-03-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-harvoni-annex-i-iii_no.pdf"}},
    {"id":"20060","name":"Glimepirida Parke Davis - Article 29(4) referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-06T01:00:00Z","last_updated_date":"2012-12-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/glimepirida-parke-davis-article-294-referral-assessment-report_en.pdf"},
    {"id":"20061","name":"Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Prograf and associated names (see Annex I) International Non-Proprietary Name (INN): Tacrolimus: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-04-11T01:59:00Z","last_updated_date":"2006-04-11T01:59:00Z","reference_number":"EMEA/85997/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-prograf-and-associated-names-see-annex-i-international-non-proprietary-name-inn-tacrolimus-background-information_sv.pdf"}},
    {"id":"20063","name":"Septanest Article-30 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/350884/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/septanest-article-30-referral-review-started_en.pdf"},
    {"id":"20064","name":"Renin-angiotensin-system (RAS)-acting agents Article-31 referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2013-06-14T12:26:00Z","last_updated_date":"2014-07-14T16:13:00Z","reference_number":"EMA/353230/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-annex-i_en.pdf"},
    {"id":"20072","name":"Opinion following an Article 7(5) referral for Lisinopril Biochemie International Non-Proprietary Name (INN): Lisinopril: Background information and Annexes I, II (English) and Annex III (all languages)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-09-01T02:08:21Z","last_updated_date":"2003-09-01T02:08:21Z","reference_number":"CPMP/886/04/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_sv.pdf"}},
    {"id":"20093","name":"Hydroxyzine Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T17:00:00Z","last_updated_date":"2014-11-14T16:20:00Z","reference_number":"EMA/PRAC/261903/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"20100","name":"Opinion following a referral for arbitration according to Article 7(5) of Commission Regulation (EC) No 541/95 as amended, for MultiHance International Non-Proprietary Name (INN): gadobenic acid: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2000-12-16T00:08:21Z","last_updated_date":"2000-12-16T00:08:21Z","reference_number":"CPMP/1361/00","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-referral-arbitration-according-article-75-commission-regulation-ec-no-54195-amended-multihance-international-non-proprietary-name-inn-gadobenic-acid-background-information_en.pdf"},
    {"id":"20105","name":"Methysergide Article-31 referral - European Medicines Agency recommends restricting the use of methysergide-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T13:00:00Z","last_updated_date":"2014-02-21T13:00:00Z","reference_number":"EMA/798712/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/methysergide-article-31-referral-european-medicines-agency-recommends-restricting-use-methysergide-containing-medicines_en.pdf"},
    {"id":"20116","name":"CHMP assessment report for Cozaar and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-01-13T01:00:00Z","last_updated_date":"2012-01-13T01:00:00Z","reference_number":"EMA/356718/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/chmp-assessment-report-cozaar-and-associated-names_en.pdf"},
    {"id":"20117","name":"Sandimmun Neoral Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T12:00:00Z","last_updated_date":"2013-12-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sandimmun-neoral-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sandimmun-neoral-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sandimmun-neoral-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sandimmun-neoral-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sandimmun-neoral-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sandimmun-neoral-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sandimmun-neoral-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sandimmun-neoral-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sandimmun-neoral-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sandimmun-neoral-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sandimmun-neoral-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sandimmun-neoral-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sandimmun-neoral-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sandimmun-neoral-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sandimmun-neoral-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sandimmun-neoral-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sandimmun-neoral-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sandimmun-neoral-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sandimmun-neoral-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sandimmun-neoral-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sandimmun-neoral-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sandimmun-neoral-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sandimmun-neoral-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sandimmun-neoral-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sandimmun-neoral-article-30-referral-annex-i_no.pdf"}},
    {"id":"20125","name":"Hydroxyzine Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-08T02:00:00Z","last_updated_date":"2015-06-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyzine-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyzine-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyzine-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyzine-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyzine-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyzine-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyzine-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyzine-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyzine-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyzine-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyzine-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyzine-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyzine-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyzine-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyzine-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyzine-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyzine-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyzine-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyzine-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyzine-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyzine-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyzine-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"20132","name":"Opinion following an Article 6(12) referral for Arcoxia International Non-Proprietary Name (INN): etoricoxib: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:08:21Z","last_updated_date":"2008-10-23T02:08:21Z","reference_number":"EMEA/438258/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-612-referral-arcoxia-international-non-proprietary-name-inn-etoricoxib-background-information_sv.pdf"}},
    {"id":"20143","name":"Yvidually Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"EMA/552336/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/yvidually-article-294-referral-assessment-report_en.pdf"},
    {"id":"20154","name":"Lovenox Article 30 referral - Questions and answers on Lovenox and associated names (enoxaparin, solution for injection)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2017-03-22T01:00:00Z","reference_number":"EMA/837288/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_sl.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lovenox-article-30-referral-questions-and-answers-lovenox-and-associated-names-enoxaparin-solution-injection_sv.pdf"}},
    {"id":"20156","name":"Questions and answers on Furosemide Vitabalans (tablet, 40 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/CHMP/664574/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-furosemide-vitabalans-tablet-40-mg_en.pdf"},
    {"id":"20169","name":"Sibutramine - Article 107 procedure - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-09-15T02:00:00Z","last_updated_date":"2010-09-15T02:00:00Z","reference_number":"EMEA/H/A-107/1256","document_url":"https://www.ema.europa.eu/en/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_sv.pdf"}},
    {"id":"20173","name":"Opinion following an Article 29 referral Talam International Non-Proprietary Name (INN): Amlodipine: Background information and Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-04-27T02:08:21Z","last_updated_date":"2004-04-27T02:08:21Z","reference_number":"EMEA/CPMP/540/04","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-29-referral-talam-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-iii_sv.pdf"}},
    {"id":"20177","name":"Flupirtine-containing medicines Article-107i procedure - Review started","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-08T13:00:00Z","last_updated_date":"2013-03-08T13:00:00Z","reference_number":"EMA/139661/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-review-started_en.pdf"},
    {"id":"20183","name":"Dexamethasone Alapis - Article 29 referral - Assessment Report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-02T01:00:00Z","last_updated_date":"2012-02-02T01:00:00Z","reference_number":"EMEA/H/A-29/1308","document_url":"https://www.ema.europa.eu/en/documents/referral/dexamethasone-alapis-article-29-referral-assessment-report_en.pdf"},
    {"id":"20189","name":"Tredaptive, Pelzont and Trevaclyn Article-20 procedure - PRAC considers that benefit-risk balance of Tredaptive, Pelzont and Trevaclyn (laropiprant / nicotinic acid) is negative: Questions and answers","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T13:00:00Z","last_updated_date":"2013-01-11T13:00:00Z","reference_number":"EMA/5817/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/tredaptive-pelzont-and-trevaclyn-article-20-procedure-prac-considers-benefit-risk-balance-tredaptive-pelzont-and-trevaclyn-laropiprant-nicotinic-acid-negative-questions-and-answers_en.pdf"},
    {"id":"20222","name":"Durogesic Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-10-19T14:00:00Z","reference_number":"EMEA/H/A-30/1413","document_url":"https://www.ema.europa.eu/en/documents/referral/durogesic-article-30-referral-annex-iii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/durogesic-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/durogesic-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/durogesic-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/durogesic-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/durogesic-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/durogesic-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/durogesic-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/durogesic-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/durogesic-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/durogesic-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/durogesic-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/durogesic-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/durogesic-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/durogesic-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/durogesic-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/durogesic-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/durogesic-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/durogesic-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/durogesic-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/durogesic-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/durogesic-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/durogesic-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/durogesic-article-30-referral-annex-iii_is.pdf-0","no":"https://www.ema.europa.eu/no/documents/referral/durogesic-article-30-referral-annex-iii_no.pdf-0"}},
    {"id":"20292","name":"Assessment report for Antifibrinolytic medicines (aprotinin)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-06T01:00:00Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-antifibrinolytic-medicines-aprotinin_en.pdf"},
    {"id":"20303","name":"Lactose of bovine origin Article-31 referral - CMDh confirms that methylprednisolone injections containing lactose must not be given to patients allergic to cow's milk proteins","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-08-01T02:00:00Z","last_updated_date":"2017-09-04T02:00:00Z","reference_number":"EMA/443893/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lactose-bovine-origin-article-31-referral-cmdh-confirms-methylprednisolone-injections-containing-lactose-must-not-be-given-patients-allergic-cows-milk-proteins_sv.pdf"}},
    {"id":"20312","name":"Esmya Article-20 procedure - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-02-21T15:05:00Z","last_updated_date":"2018-02-21T15:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/esmya-article-20-procedure-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/esmya-article-20-procedure-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/esmya-article-20-procedure-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/esmya-article-20-procedure-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/esmya-article-20-procedure-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/esmya-article-20-procedure-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/esmya-article-20-procedure-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/esmya-article-20-procedure-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/esmya-article-20-procedure-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/esmya-article-20-procedure-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/esmya-article-20-procedure-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/esmya-article-20-procedure-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/esmya-article-20-procedure-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/esmya-article-20-procedure-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/esmya-article-20-procedure-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/esmya-article-20-procedure-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/esmya-article-20-procedure-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/esmya-article-20-procedure-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/esmya-article-20-procedure-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/esmya-article-20-procedure-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/esmya-article-20-procedure-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/esmya-article-20-procedure-scientific-conclusions_sv.pdf"}},
    {"id":"20321","name":"Tysabri Article-20 procedure - Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-05-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tysabri-article-20-procedure-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tysabri-article-20-procedure-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tysabri-article-20-procedure-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tysabri-article-20-procedure-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tysabri-article-20-procedure-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tysabri-article-20-procedure-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tysabri-article-20-procedure-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tysabri-article-20-procedure-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tysabri-article-20-procedure-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tysabri-article-20-procedure-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tysabri-article-20-procedure-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tysabri-article-20-procedure-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tysabri-article-20-procedure-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tysabri-article-20-procedure-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tysabri-article-20-procedure-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tysabri-article-20-procedure-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tysabri-article-20-procedure-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tysabri-article-20-procedure-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tysabri-article-20-procedure-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tysabri-article-20-procedure-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tysabri-article-20-procedure-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tysabri-article-20-procedure-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tysabri-article-20-procedure-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/tysabri-article-20-procedure-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/tysabri-article-20-procedure-annex-i-iii_no.pdf"}},
    {"id":"20348","name":"Gadograf - Article 36 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-09T00:08:21Z","last_updated_date":"2007-11-09T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_bg.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_el.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_lv.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gadograf-article-36-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"20355","name":"Closamectin Article-78 referral - Annex I-IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T20:00:00Z","last_updated_date":"2016-05-31T20:00:00Z","reference_number":"EMEA/V/A/113","document_url":"https://www.ema.europa.eu/en/documents/referral/closamectin-article-78-referral-annex-i-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/closamectin-article-78-referral-annex-i-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/closamectin-article-78-referral-annex-i-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/closamectin-article-78-referral-annex-i-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/closamectin-article-78-referral-annex-i-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/closamectin-article-78-referral-annex-i-iv_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/closamectin-article-78-referral-annex-i-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/closamectin-article-78-referral-annex-i-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/closamectin-article-78-referral-annex-i-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/closamectin-article-78-referral-annex-i-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/closamectin-article-78-referral-annex-i-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/closamectin-article-78-referral-annex-i-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/closamectin-article-78-referral-annex-i-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/closamectin-article-78-referral-annex-i-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/closamectin-article-78-referral-annex-i-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/closamectin-article-78-referral-annex-i-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/closamectin-article-78-referral-annex-i-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/closamectin-article-78-referral-annex-i-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/closamectin-article-78-referral-annex-i-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/closamectin-article-78-referral-annex-i-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/closamectin-article-78-referral-annex-i-iv_fi.pdf"}},
    {"id":"20360","name":"Alcover Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-01-12T01:00:00Z","last_updated_date":"2018-01-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/alcover-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/alcover-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/alcover-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/alcover-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/alcover-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/alcover-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/alcover-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/alcover-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/alcover-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/alcover-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/alcover-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/alcover-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/alcover-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/alcover-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/alcover-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/alcover-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/alcover-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/alcover-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/alcover-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/alcover-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/alcover-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/alcover-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/alcover-article-294-referral-annex-i_sv.pdf"}},
    {"id":"20366","name":"Quinolone and fluoroquinolone Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"EMA/PRAC/38617/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"20383","name":"Novimp - Article 36 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMEA/H/A-36/1298","document_url":"https://www.ema.europa.eu/en/documents/referral/novimp-article-36-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/novimp-article-36-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/novimp-article-36-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/novimp-article-36-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/novimp-article-36-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/novimp-article-36-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/novimp-article-36-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/novimp-article-36-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/novimp-article-36-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/novimp-article-36-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/novimp-article-36-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/novimp-article-36-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/novimp-article-36-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/novimp-article-36-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/novimp-article-36-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/novimp-article-36-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/novimp-article-36-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/novimp-article-36-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/novimp-article-36-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/novimp-article-36-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/novimp-article-36-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/novimp-article-36-referral-annex-iii_sv.pdf"}},
    {"id":"20385","name":"Combined hormonal contraceptives Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-i_no.pdf"}},
    {"id":"20402","name":"Hydroxyzine Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T17:00:00Z","last_updated_date":"2014-05-08T17:00:00Z","reference_number":"EMA/268604/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-review-started_en.pdf"},
    {"id":"20413","name":"Factor VIII Article-31 referral - No clear and consistent evidence of difference in risk of inhibitor development between classes","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-12-05T01:00:00Z","reference_number":"EMA/603417/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-no-clear-and-consistent-evidence-difference-risk-inhibitor-development-between-classes_en.pdf"},
    {"id":"20420","name":"Ambroxol and bromhexine Article-31 referral - PRAC considers risk of severe allergic reactions with ambroxol- and bromhexine-containing medicines to be small","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-12T13:00:00Z","last_updated_date":"2015-01-12T13:00:00Z","reference_number":"EMA/796499/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-prac-considers-risk-severe-allergic-reactions-ambroxol-and-bromhexine-containing-medicines-be-small_en.pdf"},
    {"id":"20424","name":"Bacterial lysate medicines Article 31 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2018-07-04T16:12:00Z","last_updated_date":"2019-09-16T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-i_sv.pdf"}},
    {"id":"20426","name":"Questions and answers on EMLA cream and associated names (lidocaine 25 mg/g and prilocaine 25 mg/g; cream for topical use)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/440595/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-emla-cream-and-associated-names-lidocaine-25-mgg-and-prilocaine-25-mgg-cream-topical-use_sv.pdf"}},
    {"id":"20431","name":"Flupirtine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-05-04T02:00:00Z","last_updated_date":"2018-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flupirtine-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flupirtine-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flupirtine-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flupirtine-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flupirtine-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flupirtine-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flupirtine-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flupirtine-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flupirtine-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flupirtine-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flupirtine-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flupirtine-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flupirtine-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flupirtine-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flupirtine-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flupirtine-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flupirtine-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flupirtine-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flupirtine-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flupirtine-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flupirtine-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flupirtine-article-31-referral-annex-i_sv.pdf"}},
    {"id":"20467","name":"Semler Article-31 referral – EMA recommends suspension of medicines over flawed studies at Semler Research Centre","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-11-17T15:00:00Z","reference_number":"EMA/489380/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/semler-article-31-referral-ema-recommends-suspension-medicines-over-flawed-studies-semler-research-centre_sv.pdf"}},
    {"id":"20469","name":"Flupirtine-containing medicines Article-107i procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T14:00:00Z","last_updated_date":"2013-07-18T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-iii_sv.pdf"}},
    {"id":"20479","name":"Diflucan - Article 30 referral - Assessment Report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-02T01:00:00Z","last_updated_date":"2012-02-02T01:00:00Z","reference_number":"EMEA/H/A-30/1156","document_url":"https://www.ema.europa.eu/en/documents/referral/diflucan-article-30-referral-assessment-report_en.pdf"},
    {"id":"20488","name":"Retinoid Article-31 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"EMA/254364/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"20507","name":"Questions and answers on the referral for Avalox solution for infusion containing moxifloxacin 400 mg/250 ml","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:08:21Z","last_updated_date":"2013-11-19T01:08:21Z","reference_number":"EMEA/CHMP/150446/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_sv.pdf"}},
    {"id":"20528","name":"Targocid Article-30 referral - CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-01-03T01:00:00Z","last_updated_date":"2014-01-03T01:00:00Z","reference_number":"EMEA/CHMP/269452/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/targocid-article-30-referral-chmp-assessment-report_en.pdf"},
    {"id":"20541","name":"Questions and answers on Didanosine and associated names (didanosine, gastro-resistant capsules, 200, 250 and 400 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-12-10T01:00:00Z","reference_number":"EMA/562334/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-didanosine-and-associated-names-didanosine-gastro-resistant-capsules-200-250-and-400-mg_sv.pdf"}},
    {"id":"20588","name":"Codeine Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-notification_en.pdf"}    {"id":"20624","name":"Tibolona-Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-08T02:00:00Z","last_updated_date":"2014-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tibolona-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tibolona-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tibolona-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tibolona-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tibolona-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tibolona-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tibolona-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tibolona-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tibolona-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tibolona-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tibolona-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tibolona-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tibolona-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tibolona-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tibolona-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tibolona-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tibolona-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tibolona-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tibolona-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tibolona-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tibolona-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tibolona-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tibolona-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"20659","name":"Buflomedil - Article 107 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-13T02:00:00Z","last_updated_date":"2012-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/buflomedil-article-107-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/buflomedil-article-107-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/buflomedil-article-107-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/buflomedil-article-107-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/buflomedil-article-107-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/buflomedil-article-107-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/buflomedil-article-107-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/buflomedil-article-107-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/buflomedil-article-107-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/buflomedil-article-107-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/buflomedil-article-107-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/buflomedil-article-107-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/buflomedil-article-107-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/buflomedil-article-107-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/buflomedil-article-107-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/buflomedil-article-107-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/buflomedil-article-107-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/buflomedil-article-107-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/buflomedil-article-107-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/buflomedil-article-107-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/buflomedil-article-107-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/buflomedil-article-107-referral-annex-i_sv.pdf"}},
    {"id":"20680","name":"Zinbryta Article-20 referral - EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2018-01-12T01:00:00Z","reference_number":"EMA/753277/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinbryta-article-20-referral-ema-concludes-review-zinbryta-and-confirms-further-restrictions-reduce-risk-liver-damage_sv.pdf"}},
    {"id":"20693","name":"Valproate Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-article-31-referral-annex-iv_fi.pdf"}},
    {"id":"20696","name":"Sortis-EMEA/H/A-29 PAD/1254: Article 29 Paediatrics referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-27T02:00:00Z","last_updated_date":"2011-04-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"20722","name":"Prevora - Article 29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/prevora-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/prevora-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/prevora-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/prevora-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/prevora-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/prevora-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/prevora-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/prevora-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/prevora-article-29-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/prevora-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/prevora-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/prevora-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/prevora-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/prevora-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/prevora-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/prevora-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/prevora-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/prevora-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/prevora-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/prevora-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/prevora-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/prevora-article-29-referral-annex-iii_sv.pdf"}},
    {"id":"20724","name":"Substances related to nicotinic acid Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-03-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-notification_en.pdf"},
    {"id":"20725","name":"Nifedipine Pharmamatch 30 and 60 mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-05-05T02:08:21Z","last_updated_date":"2006-05-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nifedipine-pharmamatch-30-and-60-mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"20727","name":"Codeine Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-08-02T02:00:00Z","last_updated_date":"2013-08-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-annex-iii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/codeine-article-31-referral-annex-iii_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/codeine-article-31-referral-annex-iii_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/codeine-article-31-referral-annex-iii_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/codeine-article-31-referral-annex-iii_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/codeine-article-31-referral-annex-iii_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/codeine-article-31-referral-annex-iii_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/codeine-article-31-referral-annex-iii_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/codeine-article-31-referral-annex-iii_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/referral/codeine-article-31-referral-annex-iii_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/codeine-article-31-referral-annex-iii_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/codeine-article-31-referral-annex-iii_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/codeine-article-31-referral-annex-iii_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/codeine-article-31-referral-annex-iii_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/codeine-article-31-referral-annex-iii_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/codeine-article-31-referral-annex-iii_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/codeine-article-31-referral-annex-iii_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/codeine-article-31-referral-annex-iii_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/codeine-article-31-referral-annex-iii_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/codeine-article-31-referral-annex-iii_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/codeine-article-31-referral-annex-iii_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/codeine-article-31-referral-annex-iii_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/codeine-article-31-referral-annex-iii_sv.pdf-0","is":"https://www.ema.europa.eu/is/documents/referral/codeine-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/codeine-article-31-referral-annex-iii_no.pdf"}},
    {"id":"20793","name":"Polymyxin Article-31 referral - European Medicines Agency completes review of polymyxin-based medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2015-01-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/polymyxin-article-31-referral-european-medicines-agency-completes-review-polymyxin-based-medicines_sv.pdf"}},
    {"id":"20842","name":"Zoloft - Article 30 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-07T02:08:21Z","last_updated_date":"2009-05-07T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"20863","name":"Ikorel and Dancor Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-30T02:00:00Z","last_updated_date":"2015-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ikorel-and-dancor-article-30-referral-annex-i_sv.pdf"}},
    {"id":"20901","name":"Lovenox Article 30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-22T18:30:00Z","last_updated_date":"2017-03-22T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lovenox-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lovenox-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lovenox-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lovenox-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lovenox-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lovenox-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lovenox-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lovenox-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lovenox-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lovenox-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lovenox-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lovenox-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lovenox-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lovenox-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lovenox-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lovenox-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lovenox-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lovenox-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lovenox-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lovenox-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lovenox-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lovenox-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lovenox-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/lovenox-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/lovenox-article-30-referral-annex-i_no.pdf"}},
    {"id":"20910","name":"Questions and answers on the review of Prozac for use in children and adolescents","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-06-06T02:08:21Z","last_updated_date":"2006-06-06T02:08:21Z","reference_number":"EMEA/198323/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-prozac-use-children-and-adolescents_en.pdf"},
    {"id":"20930","name":"Tildren - Article 33 referral - Annexes I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-12-14T01:00:00Z","last_updated_date":"2010-12-14T01:00:00Z","reference_number":"EMA/193771/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/tildren-article-33-referral-annexes-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tildren-article-33-referral-annexes-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tildren-article-33-referral-annexes-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tildren-article-33-referral-annexes-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tildren-article-33-referral-annexes-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tildren-article-33-referral-annexes-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tildren-article-33-referral-annexes-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tildren-article-33-referral-annexes-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tildren-article-33-referral-annexes-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tildren-article-33-referral-annexes-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tildren-article-33-referral-annexes-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tildren-article-33-referral-annexes-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tildren-article-33-referral-annexes-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tildren-article-33-referral-annexes-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tildren-article-33-referral-annexes-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tildren-article-33-referral-annexes-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tildren-article-33-referral-annexes-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tildren-article-33-referral-annexes-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tildren-article-33-referral-annexes-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tildren-article-33-referral-annexes-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tildren-article-33-referral-annexes-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tildren-article-33-referral-annexes-i-ii_sv.pdf"}},
    {"id":"20931","name":"Metamizole Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T02:00:00Z","last_updated_date":"2019-03-28T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metamizole-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metamizole-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metamizole-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metamizole-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metamizole-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metamizole-article-31-referral-annex-i_et.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metamizole-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metamizole-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metamizole-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metamizole-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metamizole-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metamizole-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metamizole-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metamizole-article-31-referral-annex-i_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metamizole-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metamizole-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metamizole-article-31-referral-annex-i_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metamizole-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metamizole-article-31-referral-annex-i_sv.pdf"}},
    {"id":"20937","name":"Baxter dialysis solutions Article-31 referral - Annex IV (3 sites)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-3-sites_sv.pdf"}},
    {"id":"20945","name":"Modafinil - Annex III - Summary of product characteristics, labeling or package leaflet","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2010-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/modafinil-annex-iii-summary-product-characteristics-labeling-or-package-leaflet_en.pdf"},
    {"id":"20959","name":"Xigduo Article-20 procedure - Annex I - III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-18T02:00:00Z","last_updated_date":"2016-05-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xigduo-article-20-procedure-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xigduo-article-20-procedure-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xigduo-article-20-procedure-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/xigduo-article-20-procedure-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xigduo-article-20-procedure-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xigduo-article-20-procedure-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xigduo-article-20-procedure-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xigduo-article-20-procedure-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xigduo-article-20-procedure-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/xigduo-article-20-procedure-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xigduo-article-20-procedure-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xigduo-article-20-procedure-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xigduo-article-20-procedure-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xigduo-article-20-procedure-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xigduo-article-20-procedure-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xigduo-article-20-procedure-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xigduo-article-20-procedure-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/xigduo-article-20-procedure-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xigduo-article-20-procedure-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xigduo-article-20-procedure-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xigduo-article-20-procedure-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xigduo-article-20-procedure-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xigduo-article-20-procedure-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/xigduo-article-20-procedure-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/xigduo-article-20-procedure-annex-i-iii_no.pdf"}},
    {"id":"20962","name":"Vascace Plus - Article 30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-11-09T01:00:00Z","last_updated_date":"2011-11-09T01:00:00Z","reference_number":"EMA/110390/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/vascace-plus-article-30-referral-assessment-report_en.pdf"},
    {"id":"20973","name":"Testosterone Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2015-01-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/testosterone-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/testosterone-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/testosterone-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/testosterone-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/testosterone-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/testosterone-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/testosterone-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/testosterone-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/testosterone-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/testosterone-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/testosterone-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/testosterone-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/testosterone-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/testosterone-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/testosterone-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/testosterone-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/testosterone-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/testosterone-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/testosterone-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/testosterone-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/testosterone-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/testosterone-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/testosterone-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/testosterone-article-31-referral-annex-iii_no.pdf"}},
    {"id":"20999","name":"Forxiga Article-20 procedure - Annex I - III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-18T02:00:00Z","last_updated_date":"2016-05-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/forxiga-article-20-procedure-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/forxiga-article-20-procedure-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/forxiga-article-20-procedure-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/forxiga-article-20-procedure-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/forxiga-article-20-procedure-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/forxiga-article-20-procedure-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/forxiga-article-20-procedure-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/forxiga-article-20-procedure-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/forxiga-article-20-procedure-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/forxiga-article-20-procedure-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/forxiga-article-20-procedure-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/forxiga-article-20-procedure-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/forxiga-article-20-procedure-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/forxiga-article-20-procedure-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/forxiga-article-20-procedure-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/forxiga-article-20-procedure-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/forxiga-article-20-procedure-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/forxiga-article-20-procedure-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/forxiga-article-20-procedure-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/forxiga-article-20-procedure-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/forxiga-article-20-procedure-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/forxiga-article-20-procedure-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/forxiga-article-20-procedure-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/forxiga-article-20-procedure-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/forxiga-article-20-procedure-annex-i-iii_no.pdf"}},
    {"id":"21037","name":"Questions and answers on the review of the marketing authorisations for medicines containing pholcodine","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T11:00:00Z","last_updated_date":"2011-11-18T11:00:00Z","reference_number":"EMA/890819/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-marketing-authorisations-medicines-containing-pholcodine_sv.pdf"}},
    {"id":"21042","name":"Combined hormonal contraceptives: Article-31 referral - Notification","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T13:00:00Z","last_updated_date":"2013-02-08T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-notification_en.pdf"},
    {"id":"21061","name":"Valproate and related substances Article-31 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-14T14:00:00Z","last_updated_date":"2014-11-14T14:00:00Z","reference_number":"EMA/686022/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"21068","name":"Ibuprofen and dexibuprofen Article-31 referral - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-06-13T17:00:00Z","last_updated_date":"2014-06-13T17:00:00Z","reference_number":"EMA/PRAC/332909/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"21089","name":"Gadolinium Article-31 referral – Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-annex-iii_en.pdf"},
    {"id":"21116","name":"Tolperisone Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tolperisone-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tolperisone-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tolperisone-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tolperisone-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tolperisone-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tolperisone-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tolperisone-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tolperisone-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tolperisone-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tolperisone-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tolperisone-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tolperisone-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tolperisone-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tolperisone-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tolperisone-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tolperisone-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tolperisone-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tolperisone-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tolperisone-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tolperisone-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tolperisone-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tolperisone-article-31-referral-annex-i_sv.pdf"}},
    {"id":"21128","name":"Suanovil 20 / Captalin Article-35 referral - Divergent position on a CVMP opinion on an Article 35 of Directive 2001/82/EC","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-02-03T01:00:00Z","last_updated_date":"2015-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/suanovil-20-captalin-article-35-referral-divergent-position-cvmp-opinion-article-35-directive-200182ec_en.pdf"},
    {"id":"21136","name":"Pulmotil AC - Article 34 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:08:21Z","last_updated_date":"2009-12-23T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pulmotil-ac-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"21164","name":"European Medicines Agency recommends revoking authorisations of Caustinerf arsenical and Yranicid arsenical used in dental procedures","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/242277/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/european-medicines-agency-recommends-revoking-authorisations-caustinerf-arsenical-and-yranicid-arsenical-used-dental-procedures_en.pdf"},
    {"id":"21213","name":"Mifepristone Article 29(4) referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/mifepristone-article-294-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/mifepristone-article-294-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/mifepristone-article-294-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/mifepristone-article-294-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/mifepristone-article-294-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/mifepristone-article-294-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/mifepristone-article-294-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/mifepristone-article-294-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/mifepristone-article-294-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/mifepristone-article-294-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/mifepristone-article-294-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/mifepristone-article-294-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/mifepristone-article-294-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/mifepristone-article-294-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/mifepristone-article-294-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/mifepristone-article-294-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/mifepristone-article-294-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/mifepristone-article-294-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/mifepristone-article-294-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/mifepristone-article-294-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/mifepristone-article-294-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/mifepristone-article-294-referral-annex-iv_sv.pdf"}},
    {"id":"21227","name":"Questions and answers on Dexamethasone Alapis (dexamethasone, oral solution, 0.4 mg/ml)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T03:00:00Z","last_updated_date":"2012-02-02T02:00:00Z","reference_number":"EMA/CHMP/582483/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-dexamethasone-alapis-dexamethasone-oral-solution-04-mgml_sv.pdf"}},
    {"id":"21257","name":"Questions and answers on Diflucan and associated names (fluconazole, 50, 100, 150 and 200 mg capsules, oral solution 5 mg/ml, powder for oral suspension 10 mg/ml or 40 mg/ml, solution for infusion 2 mg/ml)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2012-02-02T01:00:00Z","reference_number":"EMA/CHMP/478970/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-diflucan-and-associated-names-fluconazole-50-100-150-and-200-mg-capsules-oral-solution-5-mgml-powder-oral-suspension-10-mgml-or-40-mgml-solution-infusion-2-mgml_sv.pdf"}},
    {"id":"21263","name":"Flutiform - Article 29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-25T02:00:00Z","last_updated_date":"2012-10-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flutiform-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flutiform-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flutiform-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flutiform-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flutiform-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flutiform-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flutiform-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flutiform-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flutiform-article-29-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flutiform-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flutiform-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flutiform-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flutiform-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flutiform-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flutiform-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flutiform-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flutiform-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flutiform-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flutiform-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flutiform-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flutiform-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flutiform-article-29-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/flutiform-article-29-referral-annex-ii_is.pdf"}},
    {"id":"21266","name":"Inductos Article-20 procedure - Review started","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/491454/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/inductos-article-20-procedure-review-started_en.pdf"},
    {"id":"21270","name":"Carisoprodol - Article 107 procedures - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-15T00:08:21Z","last_updated_date":"2007-11-15T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/carisoprodol-article-107-procedures-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/carisoprodol-article-107-procedures-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/carisoprodol-article-107-procedures-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/carisoprodol-article-107-procedures-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/carisoprodol-article-107-procedures-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/carisoprodol-article-107-procedures-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/carisoprodol-article-107-procedures-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/carisoprodol-article-107-procedures-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/carisoprodol-article-107-procedures-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/carisoprodol-article-107-procedures-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/carisoprodol-article-107-procedures-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/carisoprodol-article-107-procedures-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/carisoprodol-article-107-procedures-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/carisoprodol-article-107-procedures-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/carisoprodol-article-107-procedures-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/carisoprodol-article-107-procedures-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/carisoprodol-article-107-procedures-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/carisoprodol-article-107-procedures-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/carisoprodol-article-107-procedures-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/carisoprodol-article-107-procedures-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/carisoprodol-article-107-procedures-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/carisoprodol-article-107-procedures-annex-iii_sv.pdf"}},
    {"id":"21275","name":"Norsed Combi D - Article 29 referral - Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/norsed-combi-d-article-29-referral-annex-i-iii_sv.pdf"}},
    {"id":"21298","name":"Baxter dialysis solutions Article-31 referral - Annex III (US site)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-us-site_sv.pdf"}},
    {"id":"21325","name":"Equimectin - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-16T00:59:00Z","last_updated_date":"2007-11-16T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/equimectin-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"21380","name":"Tetrazepam-containing medicines - Article-107i procedure - PRAC list of questions to be addressed by the marketing-authorisation holders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T13:00:00Z","last_updated_date":"2013-01-11T13:00:00Z","reference_number":"EMA/PRAC/15160/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-prac-list-questions-be-addressed-marketing-authorisation-holders_en.pdf"},
    {"id":"21414","name":"Flupirtine-containing medicines Article-107i procedure - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T14:00:00Z","last_updated_date":"2013-07-18T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-ii_sv.pdf"}},
    {"id":"21417","name":"Flupirtine Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"EMEA/H/A-31/1458","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-notification_en.pdf"},
    {"id":"21439","name":"SGLT2 inhibitors Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-annex-iii_en.pdf"},
    {"id":"21504","name":"Merisone Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-07-28T14:00:00Z","reference_number":"EMEA/H/A-29/1411, EMEA/H/A-29/1412","document_url":"https://www.ema.europa.eu/en/documents/referral/merisone-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/merisone-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/merisone-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/merisone-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/merisone-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/merisone-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/merisone-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/merisone-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/merisone-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/merisone-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/merisone-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/merisone-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/merisone-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/merisone-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/merisone-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/merisone-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/merisone-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/merisone-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/merisone-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/merisone-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/merisone-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/merisone-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/merisone-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"21514","name":"Paracetamol Article-31 referral - Modified-release paracetamol-containing products to be suspended from EU market","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-01T01:00:00Z","last_updated_date":"2018-03-01T01:00:00Z","reference_number":"EMA/118413/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paracetamol-article-31-referral-modified-release-paracetamol-containing-products-be-suspended-eu-market_sv.pdf"}},
    {"id":"21531","name":"Diovan - EMEA/H/A/-29 PAD/1220 - Artical 29 Paediatrics referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diovan-emeaha-29-pad1220-artical-29-paediatrics-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"21534","name":"Opinion following an Article 33 referral for Combimox Lactating Cow and associated names: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-12-08T01:00:00Z","last_updated_date":"2011-12-08T01:00:00Z","reference_number":"EMEA/V/A/61","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-33-referral-combimox-lactating-cow-and-associated-names-background-information_sv.pdf"}},
    {"id":"21535","name":"Iclusig Article-20 procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-11-10T01:00:00Z","last_updated_date":"2014-11-10T01:00:00Z","reference_number":"EMA/667786/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-prac-assessment-report_en.pdf"},
    {"id":"21562","name":"Cardioxane Article 13 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-26T11:42:00Z","last_updated_date":"2017-07-26T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cardioxane-article-13-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cardioxane-article-13-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cardioxane-article-13-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cardioxane-article-13-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cardioxane-article-13-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cardioxane-article-13-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cardioxane-article-13-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cardioxane-article-13-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cardioxane-article-13-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cardioxane-article-13-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cardioxane-article-13-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cardioxane-article-13-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cardioxane-article-13-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cardioxane-article-13-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cardioxane-article-13-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cardioxane-article-13-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cardioxane-article-13-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cardioxane-article-13-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cardioxane-article-13-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cardioxane-article-13-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cardioxane-article-13-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cardioxane-article-13-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cardioxane-article-13-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/cardioxane-article-13-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/cardioxane-article-13-referral-annex-i_no.pdf"}},
    {"id":"21603","name":"Methylphenidate - Article 31 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-14T02:08:21Z","last_updated_date":"2007-07-14T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methylphenidate-article-31-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"21620","name":"Assessment Report for Diovan - EMEA/H/A/-29 PAD/1219","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-diovan-emeaha-29-pad1219_en.pdf"},
    {"id":"21625","name":"Lactose of bovine origin Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-06T01:00:00Z","last_updated_date":"2017-09-04T02:00:00Z","reference_number":"EMA/818613/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lactose-bovine-origin-article-31-referral-annex-i_sv.pdf"}},
    {"id":"21631","name":"Prontax 5 mg/ml solution - Article 33 Referral - Annexes I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-05T02:00:00Z","last_updated_date":"2012-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/prontax-5-mgml-solution-article-33-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"21675","name":"Gadolinium Article-31 referral – Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T01:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-annex-iii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gadolinium-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gadolinium-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gadolinium-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gadolinium-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gadolinium-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gadolinium-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gadolinium-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gadolinium-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gadolinium-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gadolinium-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gadolinium-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gadolinium-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gadolinium-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gadolinium-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gadolinium-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gadolinium-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gadolinium-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gadolinium-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gadolinium-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gadolinium-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gadolinium-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gadolinium-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/gadolinium-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/gadolinium-article-31-referral-annex-iii_no.pdf"}},
    {"id":"21679","name":"Semler Article-31 referral – Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T15:00:00Z","last_updated_date":"2016-11-17T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/semler-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/semler-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/semler-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/semler-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/semler-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/semler-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/semler-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/semler-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/semler-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/semler-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/semler-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/semler-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/semler-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/semler-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/semler-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/semler-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/semler-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/semler-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/semler-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/semler-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/semler-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/semler-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"21705","name":"Opinion following an Article 35 referral for veterinary medicinal formulations containing colistin at 2 000 000 IU per ml and intended for administration in drinking water to food producing species: Background informatio...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2010-06-24T02:00:00Z","reference_number":"EMA/189829/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-formulations-containing-colistin-2-000-000-iu-ml-and-intended-administration-drinking-water-food-producing-species-background-informatio_sv.pdf"}},
    {"id":"21706","name":"Questions and answers on the referral for Betavert N tablets containing betahistine dihydrochloride (8 or 16 mg)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-04T02:08:21Z","last_updated_date":"2009-06-04T02:08:21Z","reference_number":"EMEA/403687/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-betavert-n-tablets-containing-betahistine-dihydrochloride-8-or-16-mg_sv.pdf"}},
    {"id":"21710","name":"Opinion following an Article-13 referral for Cydectin TriclaMox (5 mg/ml and 200 mg/ml) pour-on solution for cattle","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-18T13:00:00Z","last_updated_date":"2013-10-18T13:00:00Z","reference_number":"EMA/549503/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-13-referral-cydectin-triclamox-5-mgml-and-200-mgml-pour-solution-cattle_sv.pdf"}},
    {"id":"21718","name":"Summary information on a referral opinion following an arbitration pursuant to Article 29 of Directive 2001/83/EC, for Actilyse International Non-Proprietary Name (INN): Alteplase: Background information and Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-11-22T00:08:21Z","last_updated_date":"2002-11-22T00:08:21Z","reference_number":"CPMP/3346/02-EN","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-directive-200183ec-actilyse-international-non-proprietary-name-inn-alteplase-background-information-and-annex-i_en.pdf"},
    {"id":"21746","name":"Summary information on a referral opinion following an arbitration pursuant to Article 11 of Council Directive 75/319/EEC as amended for Engerix B - common Name: recombinant hepatitis B vaccine: Background information an...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2000-08-28T02:08:21Z","last_updated_date":"2000-08-28T02:08:21Z","reference_number":"CPMP/1493/01","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-11-council-directive-75319eec-amended-engerix-b-common-name-recombinant-hepatitis-b-vaccine-background-information_en.pdf"},
    {"id":"21768","name":"Diacerein Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-19T02:00:00Z","last_updated_date":"2014-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diacerein-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diacerein-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diacerein-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diacerein-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diacerein-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diacerein-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diacerein-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diacerein-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diacerein-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diacerein-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diacerein-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diacerein-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diacerein-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diacerein-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diacerein-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diacerein-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diacerein-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diacerein-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diacerein-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diacerein-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diacerein-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diacerein-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"21829","name":"Diacerein Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2013-03-11T14:45:00Z","reference_number":"EMA/PRAC/759123/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"21837","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-06-10T15:00:00Z","last_updated_date":"2013-06-13T02:00:00Z","reference_number":"EMA/339116/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-prac-assessment-report_en.pdf"},
    {"id":"21859","name":"Summary information on referral opinion pursuant to Article 31 of Council Directive 2001/83/EC, as amended for Bicalutamide 150 mg-containing medicinal products (see Annex 1) International Non-Proprietary Name (INN): bic...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-08-16T02:08:21Z","last_updated_date":"2007-08-16T02:08:21Z","reference_number":"EMEA/378451/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-pursuant-article-31-council-directive-200183ec-amended-bicalutamide-150-mg-containing-medicinal-products-see-annex-1-international-non-proprietary-name-inn-bic_sv.pdf"}},
    {"id":"21866","name":"Opinion following an Article 29(2)  referral for Lansoprazol HEXAL 15 mg and 30 mg International Non-Proprietary Name (INN): Lansoprazole: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-09-15T02:08:21Z","last_updated_date":"2005-09-15T02:08:21Z","reference_number":"EMEA/CHMP/230471/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-lansoprazol-hexal-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sv.pdf"}},
    {"id":"21882","name":"Pantoprazole Olinka (EMEA/H/A-29/1169) - Annex I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2011-03-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pantoprazole-olinka-emeaha-291169-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"21892","name":"Emergency contraceptives Article-31 referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/464144/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/emergency-contraceptives-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"21909","name":"Opinion following an Article 31 referral for all medicinal products containing Celecoxib, Etoricoxib, Lumiracoxib, Parecoxib, and Valdecoxib International Non-Proprietary Name (INN): etoricoxib: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T00:08:21Z","last_updated_date":"2005-11-29T00:08:21Z","reference_number":"EMEA/CHMP/324317/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-etoricoxib-background_sv.pdf"}},
    {"id":"21915","name":"Zinbryta Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T01:00:00Z","last_updated_date":"2018-03-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"21940","name":"Assessment report for bisphosphonates containing medicinal products","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"EMA/725125/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-bisphosphonates-containing-medicinal-products_en.pdf"},
    {"id":"21946","name":"Dienogest / Ethinylestradiol Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T12:00:00Z","last_updated_date":"2017-03-24T12:00:00Z","reference_number":"EMEA/H/A-31/1435","document_url":"https://www.ema.europa.eu/en/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-i_no.pdf"}},
    {"id":"21965","name":"Opinion following an Article 6(12) referral for Porcilis PRRS: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-08-18T02:00:00Z","last_updated_date":"2010-08-18T02:00:00Z","reference_number":"EMA/344861/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-612-referral-porcilis-prrs-background-information_sv.pdf"}},
    {"id":"21980","name":"M-M-RVAXPRO: Product information as approved by the CHMP on 13 December 2012, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T13:00:00Z","last_updated_date":"2012-12-14T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/m-m-rvaxpro-product-information-approved-chmp-13-december-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"21984","name":"Lansoprazole - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-12-14T00:08:21Z","last_updated_date":"2007-12-14T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lansoprazole-article-29-referral-annex-i-ii-iii_fi.pdf"}},
    {"id":"22022","name":"Isotretinoin - Article 29 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2011-07-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/isotretinoin-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/isotretinoin-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/isotretinoin-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/isotretinoin-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/isotretinoin-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/isotretinoin-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/isotretinoin-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/isotretinoin-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/isotretinoin-article-29-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/isotretinoin-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/isotretinoin-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/isotretinoin-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/isotretinoin-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/isotretinoin-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/isotretinoin-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/isotretinoin-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/isotretinoin-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/isotretinoin-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/isotretinoin-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/isotretinoin-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/isotretinoin-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/isotretinoin-article-29-referral-annex-i_sv.pdf"}},
    {"id":"22031","name":"Doxastad 4mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-10-11T02:08:21Z","last_updated_date":"2006-10-11T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/doxastad-4mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"22071","name":"Opinion following an Article 30 referral for Risperdal Consta and associated names International Non-Proprietary Name (INN): risperidone: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-08T02:08:21Z","last_updated_date":"2009-10-08T02:08:21Z","reference_number":"EMEA/CHMP/384879/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-risperdal-consta-and-associated-names-international-non-proprietary-name-inn-risperidone-background-information_sv.pdf"}},
    {"id":"22086","name":"Meprobamate - Article 107 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-06-08T16:15:00Z","last_updated_date":"2012-06-08T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/meprobamate-article-107-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/meprobamate-article-107-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/meprobamate-article-107-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/meprobamate-article-107-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/meprobamate-article-107-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/meprobamate-article-107-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/meprobamate-article-107-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/meprobamate-article-107-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/meprobamate-article-107-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/meprobamate-article-107-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/meprobamate-article-107-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/meprobamate-article-107-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/meprobamate-article-107-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/meprobamate-article-107-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/meprobamate-article-107-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/meprobamate-article-107-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/meprobamate-article-107-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/meprobamate-article-107-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/meprobamate-article-107-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/meprobamate-article-107-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/meprobamate-article-107-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/meprobamate-article-107-referral-annex-iii_sv.pdf"}},
    {"id":"22089","name":"Valproate and related substances Article-31 referral - PRAC recommends strengthening the restrictions on the use of valproate in women and girls","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-10T14:00:00Z","last_updated_date":"2014-10-10T14:00:00Z","reference_number":"EMA/612389/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-prac-recommends-strengthening-restrictions-use-valproate-women-and-girls_en.pdf"},
    {"id":"22108","name":"Isotretinoin - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-12-02T00:08:21Z","last_updated_date":"2003-12-02T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/isotretinoin-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"22150","name":"Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Calcitugg and associated names International Non-Proprietary Name (INN): calcium carbonate: Backgro...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-12-02T00:08:21Z","last_updated_date":"2003-12-02T00:08:21Z","reference_number":"EMEA/CPMP/3256/03/en/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcitugg-and-associated-names-international-non-proprietary-name-inn-calcium-carbonate_en.pdf"},
    {"id":"22154","name":"Paracetamol Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-01T01:00:00Z","last_updated_date":"2018-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paracetamol-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paracetamol-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paracetamol-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paracetamol-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paracetamol-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paracetamol-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paracetamol-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paracetamol-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paracetamol-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paracetamol-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paracetamol-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paracetamol-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paracetamol-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paracetamol-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paracetamol-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paracetamol-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paracetamol-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paracetamol-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paracetamol-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paracetamol-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paracetamol-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paracetamol-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"22176","name":"Esmya Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T13:00:00Z","last_updated_date":"2017-12-01T13:00:00Z","reference_number":"EMA/PRAC/791195/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"22184","name":"Melosolute Article-33(4) referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-15T17:00:00Z","last_updated_date":"2013-03-15T17:00:00Z","reference_number":"EMEA/V/A/084","document_url":"https://www.ema.europa.eu/en/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/melosolute-article-334-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"22185","name":"Crestor - Article 29 paediatrics referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-01T02:00:00Z","last_updated_date":"2014-08-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/crestor-article-29-paediatrics-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/crestor-article-29-paediatrics-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/crestor-article-29-paediatrics-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/crestor-article-29-paediatrics-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/crestor-article-29-paediatrics-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/crestor-article-29-paediatrics-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/crestor-article-29-paediatrics-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/crestor-article-29-paediatrics-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/crestor-article-29-paediatrics-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/crestor-article-29-paediatrics-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/crestor-article-29-paediatrics-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/crestor-article-29-paediatrics-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/crestor-article-29-paediatrics-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/crestor-article-29-paediatrics-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/crestor-article-29-paediatrics-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/crestor-article-29-paediatrics-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/crestor-article-29-paediatrics-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/crestor-article-29-paediatrics-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/crestor-article-29-paediatrics-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/crestor-article-29-paediatrics-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/crestor-article-29-paediatrics-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/crestor-article-29-paediatrics-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/crestor-article-29-paediatrics-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/crestor-article-29-paediatrics-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/crestor-article-29-paediatrics-referral-annex-i_no.pdf"}},
    {"id":"22188","name":"Valproate Article-31 referral - New measures to avoid valproate exposure in pregnancy endorsed","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"EMA/375438/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_sv.pdf"}},
    {"id":"22207","name":"Novosis Goserelin - Article 36 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMEA/H/A-36/1295","document_url":"https://www.ema.europa.eu/en/documents/referral/novosis-goserelin-article-36-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/novosis-goserelin-article-36-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/novosis-goserelin-article-36-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/novosis-goserelin-article-36-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/novosis-goserelin-article-36-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/novosis-goserelin-article-36-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/novosis-goserelin-article-36-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/novosis-goserelin-article-36-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/novosis-goserelin-article-36-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/novosis-goserelin-article-36-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/novosis-goserelin-article-36-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/novosis-goserelin-article-36-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/novosis-goserelin-article-36-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/novosis-goserelin-article-36-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/novosis-goserelin-article-36-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/novosis-goserelin-article-36-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/novosis-goserelin-article-36-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/novosis-goserelin-article-36-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/novosis-goserelin-article-36-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/novosis-goserelin-article-36-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/novosis-goserelin-article-36-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/novosis-goserelin-article-36-referral-annex-i_sv.pdf"}},
    {"id":"22214","name":"Sortis-EMEA/H/A-29 PAD/1254: Article 29 Paediatrics referral - Assessment Report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-27T02:00:00Z","last_updated_date":"2011-04-27T02:00:00Z","reference_number":"EMA/511645/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/sortis-emeaha-29-pad1254-article-29-paediatrics-referral-assessment-report_en.pdf"},
    {"id":"22229","name":"Bleomycin - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-31T02:08:21Z","last_updated_date":"2009-03-31T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bleomycin-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"22235","name":"Summary information on a referral opinion following an arbitration pursuant to Article 30 of Directive 2001/83/EC for Roaccutane and associated names (see Annex I) International Non-Proprietary Name (INN): Isotretinoin: ...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-10-17T02:08:21Z","last_updated_date":"2003-10-17T02:08:21Z","reference_number":"CPMP/2846/03","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-directive-200183ec-roaccutane-and-associated-names-see-annex-i-international-non-proprietary-name-inn-isotretinoin_sv.pdf"}},
    {"id":"22264","name":"Suifertil 4-mg/ml Article-33(4) referral - Annex I, II and III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-30T01:00:00Z","last_updated_date":"2013-10-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/suifertil-4-mgml-article-334-referral-annex-i-ii-and-iii_sv.pdf"}},
    {"id":"22274","name":"Nimesulide - Article 31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nimesulide-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nimesulide-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nimesulide-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nimesulide-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nimesulide-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nimesulide-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nimesulide-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nimesulide-article-31-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nimesulide-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nimesulide-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nimesulide-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nimesulide-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nimesulide-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nimesulide-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nimesulide-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nimesulide-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nimesulide-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nimesulide-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nimesulide-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nimesulide-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nimesulide-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"22291","name":"Zydelig Article-20 procedure - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-annex-i-ii-iii_en.pdf"},
    {"id":"22299","name":"Codeine Article-31 referral - PRAC recommends restricting the use of codeine when used for pain relief in children","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"EMA/350259/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-prac-recommends-restricting-use-codeine-when-used-pain-relief-children_en.pdf"},
    {"id":"22313","name":"Solamocta Article-33(4) referral - Divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/solamocta-article-334-referral-divergent-position_en.pdf"},
    {"id":"22326","name":"Summary information on a referral opinion following an arbitration pursant to Article 29 of Council Directive 2001/83/EC for Fluconazol Tiefenbacher 50mg, 100mg 150 mg, 200mg capsules, hard International Non-Proprietery ...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-01-30T00:08:21Z","last_updated_date":"2004-01-30T00:08:21Z","reference_number":"CPMP/6236/04","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-council-directive-200183ec-fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-international-non-proprietery_en.pdf"},
    {"id":"22327","name":"Zolpidem Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zolpidem-article-31-referral-notification_en.pdf"},
    {"id":"22358","name":"Hydroxyzine Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T17:00:00Z","last_updated_date":"2014-05-08T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-notification_en.pdf"},
    {"id":"22370","name":"PRAC confirms that benefits of all combined hormonal contraceptives (CHCs) continue to outweigh risks","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T14:00:00Z","last_updated_date":"2013-10-11T14:00:00Z","reference_number":"EMA/607314/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-confirms-benefits-all-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_en.pdf"}    {"id":"22421","name":"Diclofenac Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-31T18:00:00Z","last_updated_date":"2012-10-31T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-notification_en.pdf"},
    {"id":"22424","name":"Valproate and related substances Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_no.pdf"}},
    {"id":"22437","name":"Iclusig Article-20 procedure - Product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/641476/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-product-information_en.pdf-0"},
    {"id":"22438","name":"Hydroxyethyl starch Article-107i referral - PRAC List of questions to be addressed by the stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T14:00:00Z","last_updated_date":"2017-10-27T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-prac-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"22445","name":"Antifibrinolytic medicines - Article-31 referral - Annex III (tranexamic acid)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T11:09:55Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-tranexamic-acid_no.pdf"}},
    {"id":"22479","name":"Symbioflor 2 Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2017-09-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/symbioflor-2-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/symbioflor-2-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/symbioflor-2-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/symbioflor-2-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/symbioflor-2-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/symbioflor-2-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/symbioflor-2-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/symbioflor-2-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/symbioflor-2-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/symbioflor-2-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/symbioflor-2-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/symbioflor-2-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/symbioflor-2-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/symbioflor-2-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/symbioflor-2-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/symbioflor-2-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/symbioflor-2-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/symbioflor-2-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/symbioflor-2-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/symbioflor-2-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/symbioflor-2-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/symbioflor-2-article-31-referral-annex-i_sv.pdf"}},
    {"id":"22497","name":"Trimetazidine - Article 31 - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-17T02:00:00Z","last_updated_date":"2012-10-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/trimetazidine-article-31-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/trimetazidine-article-31-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/trimetazidine-article-31-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/trimetazidine-article-31-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/trimetazidine-article-31-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/trimetazidine-article-31-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/trimetazidine-article-31-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/trimetazidine-article-31-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/trimetazidine-article-31-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/trimetazidine-article-31-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/trimetazidine-article-31-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/trimetazidine-article-31-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/trimetazidine-article-31-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/trimetazidine-article-31-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/trimetazidine-article-31-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/trimetazidine-article-31-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/trimetazidine-article-31-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/trimetazidine-article-31-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/trimetazidine-article-31-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/trimetazidine-article-31-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/trimetazidine-article-31-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/trimetazidine-article-31-annex-ii_sv.pdf"}},
    {"id":"22544","name":"Bacterial lysate medicines Article 31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/CHMP/346196/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-notification_en.pdf"},
    {"id":"22545","name":"Substances related to nicotinic acid Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-03-13T18:00:00Z","last_updated_date":"2014-03-13T18:00:00Z","reference_number":"EMA/PRAC/18751/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-assessment-report_en.pdf"},
    {"id":"22549","name":"Questions and answers on Tobramycin VVB and associated names (tobramycin, 300 mg/5 ml nebuliser solution)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-tobramycin-vvb-and-associated-names-tobramycin-300-mg5-ml-nebuliser-solution_sv.pdf"}},
    {"id":"22587","name":"Sandimmun Neoral Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-01-30T11:10:00Z","last_updated_date":"2014-01-30T11:10:00Z","reference_number":"EMA/589501/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/sandimmun-neoral-article-30-referral-assessment-report_en.pdf"},
    {"id":"22593","name":"Corlentor and Procoralan Article-20 procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-02-06T16:30:00Z","last_updated_date":"2015-02-06T16:30:00Z","reference_number":"EMA/734305/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/corlentor-and-procoralan-article-20-procedure-prac-assessment-report_en.pdf"},
    {"id":"22594","name":"Opinion following an Article 29(4) referral for Alendronate HEXAL and associated names International Non-Proprietary Name (INN): alendronic acid (as sodium alendronate trihydrate): Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-04-13T02:08:21Z","last_updated_date":"2007-04-13T02:08:21Z","reference_number":"EMEA/CHMP/75285/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-alendronate-hexal-and-associated-names-international-non-proprietary-name-inn-alendronic-acid-sodium-alendronate-trihydrate-background-information_sv.pdf"}},
    {"id":"22631","name":"Iclusig Article-20 procedure - European Medicines Agency recommends further measures to minimise risk of blood vessel blockage with Iclusig","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/641476/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_en.pdf"},
    {"id":"22662","name":"Norvasc - Article 30 referral - Assessment Report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-03-29T02:00:00Z","last_updated_date":"2012-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/norvasc-article-30-referral-assessment-report_en.pdf"},
    {"id":"22673","name":"Isotretinoin - Article 29 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2011-07-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/isotretinoin-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/isotretinoin-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/isotretinoin-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/isotretinoin-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/isotretinoin-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/isotretinoin-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/isotretinoin-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/isotretinoin-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/isotretinoin-article-29-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/isotretinoin-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/isotretinoin-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/isotretinoin-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/isotretinoin-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/isotretinoin-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/isotretinoin-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/isotretinoin-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/isotretinoin-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/isotretinoin-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/isotretinoin-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/isotretinoin-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/isotretinoin-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/isotretinoin-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"22696","name":"Hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients – CMDh endorses PRAC recommendations","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T14:10:00Z","last_updated_date":"2013-10-25T14:10:00Z","reference_number":"EMA/640658/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-solutions-hes-should-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients-cmdh-endorses-prac-recommendations_en.pdf"},
    {"id":"22738","name":"Budesonide Sandoz - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:08:21Z","last_updated_date":"2009-06-25T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/budesonide-sandoz-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"22747","name":"CattleMarker IBR Inactivated Article-33(4) referral - Annex I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-19T02:00:00Z","last_updated_date":"2016-07-19T02:00:00Z","reference_number":"EMEA/V/A/115","document_url":"https://www.ema.europa.eu/en/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"22761","name":"Okrido Article-29 referral - CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-01-03T01:00:00Z","last_updated_date":"2014-01-03T01:00:00Z","reference_number":"EMA/597619/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/okrido-article-29-referral-chmp-assessment-report_en.pdf"},
    {"id":"22773","name":"PRAC re-examines diacerein and recommends that it remain available with restrictions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-07T13:00:00Z","last_updated_date":"2014-03-07T13:00:00Z","reference_number":"EMA/133894/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-re-examines-diacerein-and-recommends-it-remain-available-restrictions_en.pdf"},
    {"id":"22828","name":"Altrenogest - Article 35 referral - Annexes I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-09-08T02:00:00Z","reference_number":"EMEA/V/A/095","document_url":"https://www.ema.europa.eu/en/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/altrenogest-article-35-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"22842","name":"Ciprofloxacin Kabi  - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-02-06T00:08:21Z","last_updated_date":"2007-02-06T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ciprofloxacin-kabi-article-29-referral-annex-i-ii-iii_fi.pdf"}},
    {"id":"22843","name":"Hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients – CMDh endorses PRAC recommendations","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T14:10:00Z","last_updated_date":"2013-10-25T14:10:00Z","reference_number":"EMA/640658/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-solutions-hes-should-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients-cmdh-endorses-prac-recommendations_en.pdf-0"},
    {"id":"22846","name":"Codeine Article-31 referral – Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-05T14:00:00Z","last_updated_date":"2012-10-05T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-notification_en.pdf-0"},
    {"id":"22934","name":"CHMP confirms PRAC recommendations on Kogenate Bayer/Helixate NexGen","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2014-04-09T14:00:00Z","reference_number":"EMA/781158/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/chmp-confirms-prac-recommendations-kogenate-bayerhelixate-nexgen_sv.pdf"}},
    {"id":"22941","name":"Haldol Decanoate Article-30 - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-05-11T02:00:00Z","last_updated_date":"2017-05-11T02:00:00Z","reference_number":"EMA/217985/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/haldol-decanoate-article-30-assessment-report_en.pdf"},
    {"id":"22963","name":"Haldol Decanoate Article-30 - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-11T02:00:00Z","last_updated_date":"2017-05-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/haldol-decanoate-article-30-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/haldol-decanoate-article-30-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/haldol-decanoate-article-30-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/haldol-decanoate-article-30-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/haldol-decanoate-article-30-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/haldol-decanoate-article-30-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/haldol-decanoate-article-30-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/haldol-decanoate-article-30-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/haldol-decanoate-article-30-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/haldol-decanoate-article-30-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/haldol-decanoate-article-30-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/haldol-decanoate-article-30-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/haldol-decanoate-article-30-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/haldol-decanoate-article-30-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/haldol-decanoate-article-30-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/haldol-decanoate-article-30-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/haldol-decanoate-article-30-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/haldol-decanoate-article-30-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/haldol-decanoate-article-30-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/haldol-decanoate-article-30-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/haldol-decanoate-article-30-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/haldol-decanoate-article-30-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/haldol-decanoate-article-30-annex-ii_sv.pdf"}},
    {"id":"22965","name":"Valproate and related substances Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-and-related-substances-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"22972","name":"Cabergoline and Pergolide - Article 31 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-05T02:08:21Z","last_updated_date":"2009-05-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"22974","name":"Metformin Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"EMA/CHMP/50774/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"22990","name":"Adartrel - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-04-21T02:08:21Z","last_updated_date":"2006-04-21T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/adartrel-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"23006","name":"Paracetamol/ibuprofen 500mg/150mg Article-29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T02:00:00Z","last_updated_date":"2017-08-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"23014","name":"Ibuprofen and dexibuprofen Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-07-14T02:00:00Z","last_updated_date":"2015-07-14T02:00:00Z","reference_number":"EMA/348171/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-assessment-report_en.pdf"},
    {"id":"23031","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Review started (updated communication)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-15T14:00:00Z","last_updated_date":"2016-04-15T14:00:00Z","reference_number":"EMA/263596/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-review-started-updated-communication_en.pdf"},
    {"id":"23077","name":"Opinion following an Article 35 referral for Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names, and related veterinary medicinal products: Background information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T01:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"EMA/538947/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-background-information_sv.pdf"}},
    {"id":"23080","name":"Solamocta Article-33(4) referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/solamocta-article-334-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"23099","name":"Antifibrinolytic medicines - Article-31 referral - Annex I (aprotinin)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-06T01:00:00Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-i-aprotinin_no.pdf"}},
    {"id":"23120","name":"Tredaptive, Pelzont and Trevaclyn Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-21T01:00:00Z","last_updated_date":"2012-12-21T01:00:00Z","reference_number":"EMA/PRAC/821171/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/tredaptive-pelzont-and-trevaclyn-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"23177","name":"Questions and answers on the recommendation to withdraw the marketing authorisation of Veralipride","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-23T02:08:21Z","last_updated_date":"2007-07-23T02:08:21Z","reference_number":"EMEA/299468/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-recommendation-withdraw-marketing-authorisation-veralipride_en.pdf"},
    {"id":"23195","name":"Testosterone Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-07-11T19:00:00Z","reference_number":"EMA/PRAC/178709/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"23200","name":"Ergot derivatives Article-31 referral - Restrictions on use of medicines containing ergot derivatives","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-10-25T02:00:00Z","reference_number":"EMA/385266/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_en.pdf"},
    {"id":"23216","name":"Norvasc - Article 30 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T16:01:53Z","last_updated_date":"2012-03-29T16:01:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/norvasc-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/norvasc-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/norvasc-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/norvasc-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/norvasc-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/norvasc-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/norvasc-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/norvasc-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/norvasc-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/norvasc-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/norvasc-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/norvasc-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/norvasc-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/norvasc-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/norvasc-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/norvasc-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/norvasc-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/norvasc-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/norvasc-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/norvasc-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/norvasc-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/norvasc-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"23220","name":"Methadone Article-107i procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-notification_en.pdf"},
    {"id":"23233","name":"Norditropin - Article 13 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/norditropin-article-13-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/norditropin-article-13-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/norditropin-article-13-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/norditropin-article-13-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/norditropin-article-13-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/norditropin-article-13-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/norditropin-article-13-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/norditropin-article-13-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/norditropin-article-13-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/norditropin-article-13-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/norditropin-article-13-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/norditropin-article-13-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/norditropin-article-13-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/norditropin-article-13-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/norditropin-article-13-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/norditropin-article-13-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/norditropin-article-13-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/norditropin-article-13-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/norditropin-article-13-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/norditropin-article-13-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/norditropin-article-13-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/norditropin-article-13-referral-annex-i_sv.pdf"}},
    {"id":"23294","name":"Caustinerf arsenical and Yranicid arsenical Article-31 referral - CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-08-06T14:00:00Z","last_updated_date":"2014-08-06T14:00:00Z","reference_number":"EMA/CHMP/10350/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"23297","name":"Opinion following an Article 35 referral for all authorised veterinary medicinal products containing toltrazuril intended for use in poultry species International Non-Proprietary Name (INN): Toltrazuril: Background infor...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-27T01:59:00Z","last_updated_date":"2008-09-27T01:59:00Z","reference_number":"EMEA/402698/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-all-authorised-veterinary-medicinal-products-containing-toltrazuril-intended-use-poultry-species-international-non-proprietary-name-inn-toltrazuril-background_sv.pdf"}},
    {"id":"23320","name":"PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T14:00:00Z","last_updated_date":"2013-10-11T14:00:00Z","reference_number":"EMA/606303/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-confirms-hydroxyethyl-starch-solutions-hes-should-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_en.pdf"},
    {"id":"23337","name":"Tibolona Aristo and Tibocina and associated names Article-29(4) referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-08T03:00:00Z","last_updated_date":"2014-04-08T03:00:00Z","reference_number":"EMA/41126/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/tibolona-aristo-and-tibocina-and-associated-names-article-294-referral-assessment-report_en.pdf"},
    {"id":"23349","name":"Methadone Article-107i procedure - Annex V","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-04T02:00:00Z","last_updated_date":"2014-08-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-annex-v_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methadone-article-107i-procedure-annex-v_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methadone-article-107i-procedure-annex-v_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methadone-article-107i-procedure-annex-v_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methadone-article-107i-procedure-annex-v_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methadone-article-107i-procedure-annex-v_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methadone-article-107i-procedure-annex-v_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methadone-article-107i-procedure-annex-v_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methadone-article-107i-procedure-annex-v_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methadone-article-107i-procedure-annex-v_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methadone-article-107i-procedure-annex-v_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methadone-article-107i-procedure-annex-v_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methadone-article-107i-procedure-annex-v_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methadone-article-107i-procedure-annex-v_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methadone-article-107i-procedure-annex-v_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methadone-article-107i-procedure-annex-v_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methadone-article-107i-procedure-annex-v_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methadone-article-107i-procedure-annex-v_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methadone-article-107i-procedure-annex-v_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methadone-article-107i-procedure-annex-v_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methadone-article-107i-procedure-annex-v_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methadone-article-107i-procedure-annex-v_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methadone-article-107i-procedure-annex-v_sv.pdf"}},
    {"id":"23354","name":"Cabergoline and Pergolide - Article 31 referral - Annex IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-05T02:08:21Z","last_updated_date":"2009-05-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"23379","name":"Methotrexate Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T02:00:00Z","last_updated_date":"2018-04-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-review-started_en.pdf"},
    {"id":"23380","name":"Protelos and Osseor Article-20 procedure: Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T14:00:00Z","last_updated_date":"2013-05-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/protelos-and-osseor-article-20-procedure-notification_en.pdf"},
    {"id":"23397","name":"Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks – CHMP endorses PRAC recommendation","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/709120/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks-chmp-endorses-prac-recommendation_en.pdf"},
    {"id":"23422","name":"Durogesic Article-30 referral - Questions and answers on Durogesic and associated names (fentanyl transdermal patches)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-10-19T14:00:00Z","reference_number":"EMA/491912/2016 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/durogesic-article-30-referral-questions-and-answers-durogesic-and-associated-names-fentanyl-transdermal-patches_sv.pdf"}},
    {"id":"23458","name":"Bisphosphonates - Article 31 referral - Annex IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bisphosphonates-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bisphosphonates-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bisphosphonates-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bisphosphonates-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bisphosphonates-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bisphosphonates-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bisphosphonates-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bisphosphonates-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bisphosphonates-article-31-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bisphosphonates-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bisphosphonates-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bisphosphonates-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bisphosphonates-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bisphosphonates-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bisphosphonates-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bisphosphonates-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bisphosphonates-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bisphosphonates-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bisphosphonates-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bisphosphonates-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bisphosphonates-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bisphosphonates-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"23461","name":"Methadone Article-107i procedure - PRAC recommends suspension and reformulation of oral methadone solutions containing high molecular weight povidone","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-07-11T14:00:00Z","last_updated_date":"2014-07-11T14:00:00Z","reference_number":"EMA/415507/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-prac-recommends-suspension-and-reformulation-oral-methadone-solutions-containing-high-molecular-weight-povidone_en.pdf"},
    {"id":"23492","name":"Questions and answers on Prevora (chlorhexidine diacetate, 100 mg/ml dental solution)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_sv.pdf"}},
    {"id":"23494","name":"Tysabri Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-08T14:00:00Z","last_updated_date":"2016-01-15T12:59:00Z","reference_number":"EMA/PRAC/293314/2015 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/referral/tysabri-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"23515","name":"Almitrine Article-31 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-10T02:00:00Z","last_updated_date":"2013-06-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"23525","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T16:34:00Z","last_updated_date":"2018-07-17T16:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-notification_en.pdf"},
    {"id":"23532","name":"Calcichew D3 - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-01-22T00:08:21Z","last_updated_date":"2004-01-22T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/calcichew-d3-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"23538","name":"Seretide Evohaler - Article 6 (13) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-14T02:08:21Z","last_updated_date":"2007-07-14T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seretide-evohaler-article-6-13-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"23545","name":"Agopton - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-12-21T00:08:21Z","last_updated_date":"2006-12-21T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/agopton-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/agopton-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/agopton-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/agopton-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/agopton-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/agopton-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/agopton-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/agopton-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/agopton-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/agopton-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/agopton-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/agopton-article-30-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/agopton-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/agopton-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/agopton-article-30-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/agopton-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/agopton-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/agopton-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/agopton-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"23601","name":"Adrenaline auto-injectors Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-08-26T02:00:00Z","last_updated_date":"2015-08-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"23625","name":"Metformin Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/CHMP/50792/2016 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"23635","name":"Hydroxyzine Article-31 referral - PRAC recommends new measures to minimise known heart risks of hydroxyzine-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-02-13T13:00:00Z","last_updated_date":"2015-02-13T13:00:00Z","reference_number":"EMA/85678/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-prac-recommends-new-measures-minimise-known-heart-risks-hydroxyzine-containing-medicines_en.pdf"},
    {"id":"23690","name":"Ethirfin - Article 29 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-29T02:00:00Z","last_updated_date":"2011-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ethirfin-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ethirfin-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ethirfin-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ethirfin-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ethirfin-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ethirfin-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ethirfin-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ethirfin-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ethirfin-article-29-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ethirfin-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ethirfin-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ethirfin-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ethirfin-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ethirfin-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ethirfin-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ethirfin-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ethirfin-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ethirfin-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ethirfin-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ethirfin-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ethirfin-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ethirfin-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"23694","name":"Vivaglobin Article-36 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vivaglobin-article-36-referral-annex-i_en.pdf"},
    {"id":"23737","name":"Opinion following an Article 33 referral for Fenflor 300 mg/ml solution for injection for cattle International Non-Proprietary Name (INN): Florfenicol: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-08-04T01:59:00Z","last_updated_date":"2009-08-04T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-33-referral-fenflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_sv.pdf"}},
    {"id":"23760","name":"Opinion following an Article 33(4) referral for Nuflor-300 mg/ml solution for injection for cattle and sheep","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T02:00:00Z","last_updated_date":"2012-10-19T02:00:00Z","reference_number":"EMA/556747/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-nuflor-300-mgml-solution-injection-cattle-and-sheep_sv.pdf"}},
    {"id":"23767","name":"Opinion following an Article 30 referral for Efexor depot and associated names International Non-Proprietary Name (INN): venlafaxine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-12-03T00:08:21Z","last_updated_date":"2008-12-03T00:08:21Z","reference_number":"EMEA/CHMP/384876/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-efexor-depot-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_sv.pdf"}},
    {"id":"23859","name":"Codeine Article-31 referral – Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-05T14:00:00Z","last_updated_date":"2013-04-12T18:20:00Z","reference_number":"EMA/PRAC/184919/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-timetable-procedure_en.pdf-0"},
    {"id":"23875","name":"Opinion following an Article 7(5) referral for Cardiostad (lisinopril) International Non-Proprietary Name (INN): Lisinopril: Background information and Annexes I, II (English) and Annex III (all languages)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-09-01T02:08:21Z","last_updated_date":"2003-09-01T02:08:21Z","reference_number":"CPMP/869/04/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-75-referral-cardiostad-lisinopril-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_sv.pdf"}},
    {"id":"23882","name":"Ambroxol and bromhexine Article-31 referral - Divergent opinion (France)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T09:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-divergent-opinion-france_en.pdf"},
    {"id":"23897","name":"Corlentor and Procoralan Article-20 procedure - Divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-02-06T16:30:00Z","last_updated_date":"2015-02-06T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/corlentor-and-procoralan-article-20-procedure-divergent-position_en.pdf"},
    {"id":"23920","name":"Zinbryta Article-20 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2018-06-28T02:00:00Z","last_updated_date":"2018-06-28T02:00:00Z","reference_number":"EMA/377140/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-prac-assessment-report_en.pdf-0"},
    {"id":"23928","name":"Opinion following an Article 30 referral for Lamictal and associated names International Non-Proprietary Name (INN): lamotrigine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-07-23T02:08:21Z","last_updated_date":"2008-07-23T02:08:21Z","reference_number":"EMEA/CHMP/212114/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-lamictal-and-associated-names-international-non-proprietary-name-inn-lamotrigine-background-information_sv.pdf"}},
    {"id":"23987","name":"Haldol Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-05T19:00:00Z","last_updated_date":"2017-05-05T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/haldol-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/haldol-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/haldol-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/haldol-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/haldol-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/haldol-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/haldol-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/haldol-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/haldol-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/haldol-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/haldol-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/haldol-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/haldol-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/haldol-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/haldol-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/haldol-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/haldol-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/haldol-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/haldol-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/haldol-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/haldol-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/haldol-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/haldol-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/haldol-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/haldol-article-30-referral-annex-i_no.pdf"}},
    {"id":"23990","name":"Questions and answers on Sandimmun, Sandimmun Neoral and associated names (ciclosporin, 10, 25, 50 and 100 mg capsules, 100 mg/ml oral solution and 50 mg/ml concentrate for solution for infusion)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-12-20T13:00:00Z","reference_number":"EMA/391239/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_sv.pdf"}},
    {"id":"24018","name":"Leflunomide Apotex Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leflunomide-apotex-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leflunomide-apotex-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leflunomide-apotex-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leflunomide-apotex-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leflunomide-apotex-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leflunomide-apotex-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leflunomide-apotex-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leflunomide-apotex-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leflunomide-apotex-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leflunomide-apotex-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leflunomide-apotex-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leflunomide-apotex-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leflunomide-apotex-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leflunomide-apotex-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leflunomide-apotex-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leflunomide-apotex-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leflunomide-apotex-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leflunomide-apotex-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leflunomide-apotex-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leflunomide-apotex-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leflunomide-apotex-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leflunomide-apotex-article-31-referral-annex-i_sv.pdf"}},
    {"id":"24034","name":"Vancomycin Article-31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-11-17T01:00:00Z","last_updated_date":"2017-11-17T01:00:00Z","reference_number":"EMA/645288/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/vancomycin-article-31-referral-assessment-report_en.pdf"},
    {"id":"24041","name":"Nuflor - Article 33 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T02:00:00Z","last_updated_date":"2012-10-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_cs.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nuflor-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"24059","name":"Diclofenac Article-29 referral - Questions and answers on Diclofenac epolamine 50 mg tablets","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-10-10T02:00:00Z","reference_number":"EMA/490203/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-29-referral-questions-and-answers-diclofenac-epolamine-50-mg-tablets_sv.pdf"}},
    {"id":"24062","name":"Questions and answers on the revocation of the marketing authorisations for medicines containing Bufexamac - Outcome of a procedure under Article 107 of Directive 2001/83/EC","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2011-11-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-revocation-marketing-authorisations-medicines-containing-bufexamac-outcome-procedure-under-article-107-directive-200183ec_sv.pdf"}},
    {"id":"24072","name":"Zinbryta Article-20 procedure - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-14T14:46:00Z","last_updated_date":"2018-03-14T14:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinbryta-article-20-procedure-scientific-conclusions_sv.pdf"}},
    {"id":"24088","name":"Esmya Article-20 procedure - Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T01:00:00Z","last_updated_date":"2018-03-09T01:00:00Z","reference_number":"EMA/76828/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/esmya-article-20-procedure-women-taking-esmya-uterine-fibroids-have-regular-liver-tests-while-ema-review-ongoing_sv.pdf"}},
    {"id":"24107","name":"Paracetamol Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2017-12-11T10:35:00Z","reference_number":"EMA/PRAC/460935/2016 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"24117","name":"Seroquel, Seroquel XR and associated names Article-30 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-09T02:00:00Z","last_updated_date":"2014-09-09T02:00:00Z","reference_number":"EMA/CHMP/489245/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-assessment-report_en.pdf"},
    {"id":"24135","name":"Pharmaceutics International Inc. Article-31 referral – Pharmaceutics International Inc, US: supply of non-critical medicines to EU stopped due to manufacturing failings","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-12-14T01:00:00Z","reference_number":"EMA/602744/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pharmaceutics-international-inc-article-31-referral-pharmaceutics-international-inc-us-supply-non-critical-medicines-eu-stopped-due-manufacturing-failings_sv.pdf"}},
    {"id":"24143","name":"Bisphosphonates - Article 31 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bisphosphonates-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bisphosphonates-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bisphosphonates-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bisphosphonates-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bisphosphonates-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bisphosphonates-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bisphosphonates-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bisphosphonates-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bisphosphonates-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bisphosphonates-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bisphosphonates-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bisphosphonates-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bisphosphonates-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bisphosphonates-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bisphosphonates-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bisphosphonates-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bisphosphonates-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bisphosphonates-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bisphosphonates-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bisphosphonates-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bisphosphonates-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bisphosphonates-article-31-referral-annex-i_sv.pdf"}},
    {"id":"24208","name":"GVK Biosciences Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-notification_en.pdf"},
    {"id":"24225","name":"Divergent position on a CVMP opinion on an Article 33(4) referral of Directive 2001/82/EC for Gutal 1000 g/kg premix for medicated feeding stuff for piglets (EMEA/V/A/108)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-11-26T01:00:00Z","last_updated_date":"2015-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-334-referral-directive-200182ec-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-emeava108_en.pdf"},
    {"id":"24229","name":"Questions and answers on the withdrawal of the marketing authorisations for medicines containing dextropropoxyphene - Initial","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:08:21Z","last_updated_date":"2009-06-25T02:08:21Z","reference_number":"EMEA/401061/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-initial_en.pdf"},
    {"id":"24233","name":"Recommendation to suspend marketing authorisations for hydroxyethyl starch solutions to be re-examined","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"EMA/349341/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/recommendation-suspend-marketing-authorisations-hydroxyethyl-starch-solutions-be-re-examined_en.pdf"},
    {"id":"24235","name":"Elidel - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-08-29T02:08:21Z","last_updated_date":"2006-08-29T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/elidel-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/elidel-article-31-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/elidel-article-31-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/elidel-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/elidel-article-31-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/elidel-article-31-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/elidel-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/elidel-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/elidel-article-31-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/elidel-article-31-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/elidel-article-31-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/elidel-article-31-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/elidel-article-31-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/elidel-article-31-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/elidel-article-31-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/elidel-article-31-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/elidel-article-31-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/elidel-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/elidel-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"24250","name":"Fibrates Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-03T17:00:00Z","last_updated_date":"2013-04-03T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrates-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrates-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fibrates-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrates-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrates-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrates-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fibrates-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrates-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fibrates-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrates-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrates-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrates-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fibrates-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrates-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrates-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrates-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrates-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrates-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrates-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrates-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fibrates-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrates-article-31-referral-annex-i_sv.pdf"}},
    {"id":"24329","name":"Assessment report for Baxter dialysis solutions (US site)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"EMA/488426/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-baxter-dialysis-solutions-us-site_en.pdf"},
    {"id":"24353","name":"Haldol Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T13:00:00Z","last_updated_date":"2017-05-05T19:00:00Z","reference_number":"EMA/122476/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/haldol-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/haldol-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/haldol-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/haldol-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/haldol-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/haldol-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/haldol-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/haldol-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/haldol-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/haldol-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/haldol-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/haldol-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/haldol-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/haldol-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/haldol-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/haldol-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/haldol-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/haldol-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/haldol-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/haldol-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/haldol-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/haldol-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/haldol-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/haldol-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/haldol-article-30-referral-annex-iii_no.pdf"}},
    {"id":"24404","name":"Opinion following an Article-33(4) referral for Suifertil 4-mg/ml oral solution for pigs and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-10-30T01:00:00Z","last_updated_date":"2013-10-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-suifertil-4-mgml-oral-solution-pigs-and-associated-names_sv.pdf"}}    {"id":"24415","name":"Kogenate Bayer and Helixate NexGen Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-03-08T01:00:00Z","reference_number":"EMA/PRAC/142800/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"24425","name":"Pharmasin -Article 33 Referral - Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-30T02:00:00Z","last_updated_date":"2010-04-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pharmasin-article-33-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"24440","name":"Diovan Comp - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-11T02:08:21Z","last_updated_date":"2009-06-11T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diovan-comp-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"24450","name":"Questions and answers on Kytril and associated names (granisetron, 1 and 2 mg tablets, 3 mg/ml, 3 mg/5 ml, 1 mg/ml, 3 mg/3 ml solution for injection)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-05-20T14:11:51Z","last_updated_date":"2011-09-12T14:11:51Z","reference_number":"EMA/217176/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-kytril-and-associated-names-granisetron-1-and-2-mg-tablets-3-mgml-3-mg5-ml-1-mgml-3-mg3-ml-solution-injection_sv.pdf"}},
    {"id":"24451","name":"Didanosine Article-29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-10T01:00:00Z","last_updated_date":"2013-12-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/didanosine-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/didanosine-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/didanosine-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/didanosine-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/didanosine-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/didanosine-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/didanosine-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/didanosine-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/didanosine-article-29-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/didanosine-article-29-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/didanosine-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/didanosine-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/didanosine-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/didanosine-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/didanosine-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/didanosine-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/didanosine-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/didanosine-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/didanosine-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/didanosine-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/didanosine-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/didanosine-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/didanosine-article-29-referral-annex-iii_sv.pdf"}},
    {"id":"24478","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Amended notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-amended-notification_en.pdf"},
    {"id":"24482","name":"Singulair - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-08-05T02:08:21Z","last_updated_date":"2008-08-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/singulair-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/singulair-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/singulair-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/singulair-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/singulair-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/singulair-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/singulair-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/singulair-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/singulair-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/singulair-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/singulair-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/singulair-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/singulair-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/singulair-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/singulair-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/singulair-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/singulair-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/singulair-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/singulair-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/singulair-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/singulair-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/singulair-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"24490","name":"Pharmaceutics International Inc. Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-12-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/pharmaceutics-international-inc-article-31-referral-annex-i_no.pdf"}},
    {"id":"24492","name":"Rocephin Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-05-19T02:00:00Z","last_updated_date":"2014-05-19T02:00:00Z","reference_number":"EMEA/H/A-30/1302","document_url":"https://www.ema.europa.eu/en/documents/referral/rocephin-article-30-referral-assessment-report_en.pdf"},
    {"id":"24516","name":"Opinion following an Article 29(2) referral for Doxazosin \"Winthrop\" 4 mg prolonged release tablets and associated names International Non-proprietary Name (INN): Doxazosin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-10-11T02:08:21Z","last_updated_date":"2006-10-11T02:08:21Z","reference_number":"EMEA/CHMP/423591/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-doxazosin-winthrop-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sv.pdf"}},
    {"id":"24528","name":"Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Leponex and associated names International Non-Proprietary Name (INN): clozapine: Background inform...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-11-13T00:08:21Z","last_updated_date":"2002-11-13T00:08:21Z","reference_number":"EMEA/CPMP/6034/02/en/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-leponex-and-associated-names-international-non-proprietary-name-inn-clozapine-background_en.pdf"},
    {"id":"24614","name":"Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-07-24T14:00:00Z","last_updated_date":"2014-07-24T14:00:00Z","reference_number":"EMA/440549/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/levonorgestrel-and-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight_en.pdf-0"},
    {"id":"24637","name":"Ambroxol and bromhexine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2016-02-05T13:00:00Z","reference_number":"EMA/223489/2014 – corr.1","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-i_no.pdf"}},
    {"id":"24654","name":"Hydroxyzine Article-31 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T12:00:00Z","last_updated_date":"2015-04-20T12:00:00Z","reference_number":"EMA/154392/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"24693","name":"Diclofenac Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T01:00:00Z","last_updated_date":"2013-11-27T01:00:00Z","reference_number":"EMEA/H/A-31/1344","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/diclofenac-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/diclofenac-article-31-referral-annex-iii_no.pdf"}},
    {"id":"24702","name":"Tienam - Article 30 Referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-20T01:00:00Z","last_updated_date":"2012-02-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tienam-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tienam-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tienam-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tienam-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tienam-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tienam-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tienam-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tienam-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tienam-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tienam-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tienam-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tienam-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tienam-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tienam-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tienam-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tienam-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tienam-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tienam-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tienam-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tienam-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tienam-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tienam-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"24723","name":"Bayovac IBR Marker Vivum Article-78 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-05T02:00:00Z","last_updated_date":"2014-08-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bayovac-ibr-marker-vivum-article-78-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"24726","name":"Tetrazepam-containing medicines - Article-107i procedure - Review of tetrazepam-containing medicines started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T13:00:00Z","last_updated_date":"2013-01-11T13:00:00Z","reference_number":"EMEA/H/A-107i/1352","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-review-tetrazepam-containing-medicines-started_en.pdf"},
    {"id":"24734","name":"Xofigo Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T13:00:00Z","last_updated_date":"2017-12-01T13:00:00Z","reference_number":"EMA/789952/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-review-started_en.pdf"},
    {"id":"24786","name":"Questions and answers on Norsed Combi D and associated names (risedronate sodium 35 mg tablets / calcium plus colecalciferol 1000 mg/880 IU effervescent granules))","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMEA/H/A-29/1273","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_sv.pdf"}},
    {"id":"24808","name":"Opinion following an Article 29(2) referral for Lansopon 15 mg and 30 mg International Non-Proprietary Name (INN): Lansoprazole: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-09-15T02:08:21Z","last_updated_date":"2005-09-15T02:08:21Z","reference_number":"EMEA/CHMP/230274/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-lansopon-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sv.pdf"}},
    {"id":"24813","name":"Micro Therapeutic Research Article-31 referral - Products for which the marketing authorisations are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation...","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-04-19T02:00:00Z","reference_number":"EMA/203466/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-products-which-marketing-authorisations-are-recommended-suspension-and-marketing-authorisation-applications-which-do-not-satisfy-criteria-authorisation_en.pdf"},
    {"id":"24817","name":"Zinacef - Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T01:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinacef-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinacef-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinacef-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinacef-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinacef-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinacef-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinacef-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinacef-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinacef-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinacef-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinacef-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinacef-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinacef-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinacef-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinacef-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinacef-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinacef-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinacef-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinacef-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinacef-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinacef-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinacef-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/zinacef-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/zinacef-article-30-referral-annex-i_no.pdf"}},
    {"id":"24846","name":"Methadone Article-107i procedure - PRAC list of questions to be addressed by the stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-prac-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"24853","name":"Dexamed and associated names Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-02T02:00:00Z","last_updated_date":"2014-09-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/dexamed-and-associated-names-article-294-referral-annex-i_no.pdf"}},
    {"id":"24869","name":"Linoladiol N and Linoladiol HN Article-31 referral - EMA recommendations on the use of Linoladiol N and Linoladiol HN estradiol-containing creams","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-11T02:00:00Z","last_updated_date":"2014-09-11T02:00:00Z","reference_number":"EMA/515780/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-ema-recommendations-use-linoladiol-n-and-linoladiol-hn-estradiol-containing-creams_sv.pdf"}},
    {"id":"24873","name":"Retinoid Article-31 referral - PRAC recommends updating measures for pregnancy prevention during retinoid use","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T01:00:00Z","last_updated_date":"2018-02-09T01:00:00Z","reference_number":"EMA/69925/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-prac-recommends-updating-measures-pregnancy-prevention-during-retinoid-use_en.pdf"},
    {"id":"24894","name":"Questions and answers on Ethirfin and associated names (morphine sulphate, prolonged-release capsules, 20, 60, 120 and 200 mg)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2011-04-29T02:00:00Z","reference_number":"EMA/468843/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_sv.pdf"}},
    {"id":"24895","name":"Questions and answers on the referral for Zoloft - hard capsules and film coated tablets containing 25 mg, 50 mg or 100 mg sertraline - concentrate for oral solution containing 20 mg/ml sertraline","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-04-07T02:08:21Z","last_updated_date":"2009-04-07T02:08:21Z","reference_number":"EMEA/CHMP/263995/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-zoloft-hard-capsules-and-film-coated-tablets-containing-25-mg-50-mg-or-100-mg-sertraline-concentrate-oral-solution-containing-20-mgml-sertraline_sv.pdf"}},
    {"id":"24910","name":"Zolpidem Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-08-04T12:00:00Z","last_updated_date":"2014-08-04T12:00:00Z","reference_number":"EMA/418370/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/zolpidem-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"24923","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-03-06T01:00:00Z","last_updated_date":"2017-03-06T01:00:00Z","reference_number":"EMA/103226/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-prac-assessment-report_en.pdf"},
    {"id":"24934","name":"Suanovil 20 / Captalin Article-35 referral - Annex I,II,III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-02-03T01:00:00Z","last_updated_date":"2015-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/suanovil-20-captalin-article-35-referral-annex-iiiiii_sv.pdf"}},
    {"id":"24944","name":"Buflomedil - Article 107 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-13T02:00:00Z","last_updated_date":"2012-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/buflomedil-article-107-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/buflomedil-article-107-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/buflomedil-article-107-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/buflomedil-article-107-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/buflomedil-article-107-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/buflomedil-article-107-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/buflomedil-article-107-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/buflomedil-article-107-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/buflomedil-article-107-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/buflomedil-article-107-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/buflomedil-article-107-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/buflomedil-article-107-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/buflomedil-article-107-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/buflomedil-article-107-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/buflomedil-article-107-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/buflomedil-article-107-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/buflomedil-article-107-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/buflomedil-article-107-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/buflomedil-article-107-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/buflomedil-article-107-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/buflomedil-article-107-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/buflomedil-article-107-referral-annex-ii_sv.pdf"}},
    {"id":"24995","name":"Micro Therapeutic Research Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2017-07-10T12:10:00Z","reference_number":"EMA/866024/2016 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/micro-therapeutic-research-article-31-referral-annex-i_sv.pdf"}},
    {"id":"25012","name":"Factor VIII Article-31 referral - PRAC confirms its previous conclusion on risk of inhibitor development with factor VIII medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-01T17:00:00Z","last_updated_date":"2017-09-01T17:00:00Z","reference_number":"EMA/567277/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-prac-confirms-its-previous-conclusion-risk-inhibitor-development-factor-viii-medicines_en.pdf"},
    {"id":"25019","name":"CHMP Assessment Report for Arimidex 1 mg film-coated tablet","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/311974/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/chmp-assessment-report-arimidex-1-mg-film-coated-tablet_en.pdf"},
    {"id":"25020","name":"Tavanic - Article 30 referral - Annex III (solution for infusion)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T15:00:00Z","last_updated_date":"2012-09-12T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tavanic-article-30-referral-annex-iii-solution-infusion_sv.pdf"}},
    {"id":"25033","name":"Questions and answers on the referral for Gluscan 500 solution for injection containing fludeoxyglucose (18F) 500MBq per ml","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-02T02:08:21Z","last_updated_date":"2009-06-02T02:08:21Z","reference_number":"EMEA/CHMP/342694/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-gluscan-500-solution-injection-containing-fludeoxyglucose-18f-500mbq-ml_sv.pdf"}},
    {"id":"25034","name":"Symbioflor 2 Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-04-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-notification_en.pdf"},
    {"id":"25035","name":"Combimox Lactating Cow: Article 33 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-12-08T01:00:00Z","last_updated_date":"2011-12-08T01:00:00Z","reference_number":"EMEA/V/A/61","document_url":"https://www.ema.europa.eu/en/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/combimox-lactating-cow-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"25037","name":"Atacand - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-03-20T00:59:00Z","last_updated_date":"2011-03-17T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/atacand-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/atacand-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/atacand-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/atacand-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/atacand-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/atacand-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/atacand-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/atacand-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/atacand-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/atacand-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/atacand-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/atacand-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/atacand-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/atacand-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/atacand-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/atacand-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/atacand-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/atacand-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/atacand-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/atacand-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/atacand-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/atacand-article-30-referral-annex-i-ii-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/atacand-article-30-referral-annex-i-ii-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/atacand-article-30-referral-annex-i-ii-iii_no.pdf"}},
    {"id":"25091","name":"Dexrazoxane - Article 31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T01:00:00Z","last_updated_date":"2012-01-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexrazoxane-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexrazoxane-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexrazoxane-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexrazoxane-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexrazoxane-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexrazoxane-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexrazoxane-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexrazoxane-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexrazoxane-article-31-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexrazoxane-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexrazoxane-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexrazoxane-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexrazoxane-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexrazoxane-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexrazoxane-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexrazoxane-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexrazoxane-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexrazoxane-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexrazoxane-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexrazoxane-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexrazoxane-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexrazoxane-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"25128","name":"Questions and answers on the referral for Ciclosporin IDL and associated names capsules containing ciclosporin 25 mg, 50 mg and 100 mg - Initial","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:08:21Z","last_updated_date":"2009-04-23T02:08:21Z","reference_number":"EMEA/CHMP/71684/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-initial_en.pdf"},
    {"id":"25178","name":"Diclofenac Article-29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-10T02:00:00Z","last_updated_date":"2016-10-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-29-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-29-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"25215","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Annex I-III - Jardiance","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-jardiance_no.pdf"}},
    {"id":"25267","name":"Ambroxol and bromhexine Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-04-11T14:00:00Z","reference_number":"EMA/PRAC/189078/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"25277","name":"Saroten Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2017-05-16T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/saroten-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/saroten-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/saroten-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/saroten-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/saroten-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/saroten-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/saroten-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/saroten-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/saroten-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/saroten-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/saroten-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/saroten-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/saroten-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/saroten-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/saroten-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/saroten-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/saroten-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/saroten-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/saroten-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/saroten-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/saroten-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/saroten-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/saroten-article-30-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/saroten-article-30-referral-annex-iii_no.pdf"}},
    {"id":"25286","name":"Opinion following an Article 10 referral Amaryl International Non-Proprietary Name (INN): Glimepiride: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-08-03T02:08:21Z","last_updated_date":"1998-08-03T02:08:21Z","reference_number":"CPMP/1416/98","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-10-referral-amaryl-international-non-proprietary-name-inn-glimepiride-background-information_en.pdf"},
    {"id":"25300","name":"Losec - Article 30 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-19T02:00:00Z","last_updated_date":"2011-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/losec-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/losec-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/losec-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/losec-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/losec-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/losec-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/losec-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/losec-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/losec-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/losec-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/losec-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/losec-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/losec-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/losec-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/losec-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/losec-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/losec-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/losec-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/losec-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/losec-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/losec-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/losec-article-30-referral-annex-i_sv.pdf"}},
    {"id":"25370","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Annex I-III - Invokana","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-invokana_no.pdf"}},
    {"id":"25408","name":"Colistin combinations Article 35 referral - Annexes I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-08-05T02:00:00Z","last_updated_date":"2016-08-05T02:00:00Z","reference_number":"EMA/461505/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/colistin-combinations-article-35-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"25417","name":"Opinion following an Article 29(2) referral for Doxagamma 4 mg prolonged release tablets and associated names International Non-Proprietary Name (INN): Doxazosin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-10-11T02:08:21Z","last_updated_date":"2006-10-11T02:08:21Z","reference_number":"EMEA/CHMP/423308/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-doxagamma-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sv.pdf"}},
    {"id":"25418","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Viekirax Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T01:00:00Z","last_updated_date":"2017-03-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-viekirax-annex-i-iii_no.pdf"}},
    {"id":"25426","name":"Paracetamol/ibuprofen 500mg/150mg Article-29(4) referral - Questions and answers on Paracetamol/ibuprofen 500mg/150mg film-coated tablets and associated names (tablets containing 500 mg paracetamol and 150 mg ibuprofen)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-08-18T02:00:00Z","reference_number":"EMA/304852/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-questions-and-answers-paracetamolibuprofen-500mg150mg-film-coated-tablets-and-associated-names-tablets-containing-500-mg-paracetamol-and-150-mg_en.pdf"},
    {"id":"25427","name":"Corlentor and Procoralan Article-20 procedure - European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2015-02-16T13:00:00Z","reference_number":"EMA/35715/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/corlentor-and-procoralan-article-20-procedure-european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan-ivabradine_sv.pdf"}},
    {"id":"25438","name":"Opinion following an Article 33(4)1 referral for Prontax 10 mg/ml solution for injection for cattle, sheep and pigs and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-07-05T02:00:00Z","last_updated_date":"2012-07-05T02:00:00Z","reference_number":"EMA/281970/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-3341-referral-prontax-10-mgml-solution-injection-cattle-sheep-and-pigs-and-associated-names_sv.pdf"}},
    {"id":"25441","name":"Pravachol - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-05-13T02:08:21Z","last_updated_date":"2004-05-13T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pravachol-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"25448","name":"ProQuad: Product information as approved by the CHMP on 13 December 2012, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T13:00:00Z","last_updated_date":"2012-12-14T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/proquad-product-information-approved-chmp-13-december-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"25451","name":"Valproate and related substances Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-11-07T01:00:00Z","reference_number":"EMA/623683/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-annex-i_en.pdf-0"},
    {"id":"25463","name":"Valproate and related substances Article-31 referral - Annex V","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-and-related-substances-article-31-referral-annex-v_sv.pdf"}},
    {"id":"25467","name":"HPV vaccines - Article-20 procedure - EMA confirms evidence does not support that they cause CRPS or POTS","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2016-01-20T01:00:00Z","reference_number":"EMA/749763/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_sv.pdf"}},
    {"id":"25470","name":"Carisoprodol - Article 107 procedures - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-15T00:08:21Z","last_updated_date":"2007-11-15T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/carisoprodol-article-107-procedures-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/carisoprodol-article-107-procedures-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/carisoprodol-article-107-procedures-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/carisoprodol-article-107-procedures-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/carisoprodol-article-107-procedures-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/carisoprodol-article-107-procedures-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/carisoprodol-article-107-procedures-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/carisoprodol-article-107-procedures-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/carisoprodol-article-107-procedures-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/carisoprodol-article-107-procedures-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/carisoprodol-article-107-procedures-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/carisoprodol-article-107-procedures-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/carisoprodol-article-107-procedures-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/carisoprodol-article-107-procedures-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/carisoprodol-article-107-procedures-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/carisoprodol-article-107-procedures-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/carisoprodol-article-107-procedures-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/carisoprodol-article-107-procedures-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/carisoprodol-article-107-procedures-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/carisoprodol-article-107-procedures-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/carisoprodol-article-107-procedures-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/carisoprodol-article-107-procedures-annex-i_sv.pdf"}},
    {"id":"25498","name":"Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Neurontin and associated names (see Annex I) International Non-Proprietary Name (INN): Gabapentin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-08-04T02:08:21Z","last_updated_date":"2006-08-04T02:08:21Z","reference_number":"EMEA/CHMP/142335/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-neurontin-and-associated-names-see-annex-i-international-non-proprietary-name-inn-gabapentin-background-information_fi.pdf"}},
    {"id":"25500","name":"Zinc oxide Article-35 referral - Annex I,II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-08-14T02:00:00Z","last_updated_date":"2017-08-14T02:00:00Z","reference_number":"EMEA/V/A/118","document_url":"https://www.ema.europa.eu/en/documents/referral/zinc-oxide-article-35-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinc-oxide-article-35-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinc-oxide-article-35-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinc-oxide-article-35-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinc-oxide-article-35-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinc-oxide-article-35-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinc-oxide-article-35-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinc-oxide-article-35-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinc-oxide-article-35-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zinc-oxide-article-35-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinc-oxide-article-35-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinc-oxide-article-35-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinc-oxide-article-35-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinc-oxide-article-35-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinc-oxide-article-35-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinc-oxide-article-35-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinc-oxide-article-35-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinc-oxide-article-35-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinc-oxide-article-35-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinc-oxide-article-35-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinc-oxide-article-35-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinc-oxide-article-35-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinc-oxide-article-35-referral-annex-iii_sv.pdf"}},
    {"id":"25555","name":"Diclofenac Article-31 referral - PRAC recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T14:00:00Z","last_updated_date":"2013-06-14T14:00:00Z","reference_number":"EMA/353084/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-prac-recommends-same-cardiovascular-precautions-diclofenac-selective-cox-2-inhibitors_en.pdf"},
    {"id":"25582","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T17:00:00Z","last_updated_date":"2013-02-11T17:00:00Z","reference_number":"EMA/PRAC/69149/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-prac-list-questions_en.pdf"},
    {"id":"25586","name":"Zinc oxide Article-35 referral - Questions and answers on veterinary medicinal products containing zinc oxide to be administered orally to food-producing species","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-08-14T02:00:00Z","last_updated_date":"2017-09-14T02:00:00Z","reference_number":"EMA/394961/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinc-oxide-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-zinc-oxide-be-administered-orally-food-producing-species_sv.pdf"}},
    {"id":"25617","name":"Questions and answers on Valtrex and associated names (valaciclovir, 250, 500 and 1000 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2011-09-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-valtrex-and-associated-names-valaciclovir-250-500-and-1000-mg-tablets_sv.pdf"}},
    {"id":"25652","name":"Hydroxyethyl starch Article-107i referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-12-01T10:54:00Z","reference_number":"EMA/PRAC/691227/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-timetable-procedure_en.pdf"},
    {"id":"25670","name":"Metformin Article-31 referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T01:00:00Z","last_updated_date":"2016-12-21T01:00:00Z","reference_number":"EMA/867221/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"25678","name":"Codeine Article-31 referral – Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-05T14:00:00Z","last_updated_date":"2012-11-05T13:00:00Z","reference_number":"EMA/641530/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-review-started_en.pdf"},
    {"id":"25750","name":"Baxter dialysis solutions Article-31 referral - Annex II (Castlebar site)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-castlebar-site_sv.pdf"}},
    {"id":"25781","name":"Ergot derivatives Article-31 referral - Nicergoline - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-i_no.pdf"}},
    {"id":"25785","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-22T18:00:00Z","last_updated_date":"2016-10-28T17:00:00Z","reference_number":"EMA/PRAC/271123/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"25806","name":"Ethirfin - Article 29 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-29T02:00:00Z","last_updated_date":"2011-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ethirfin-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ethirfin-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ethirfin-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ethirfin-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ethirfin-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ethirfin-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ethirfin-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ethirfin-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ethirfin-article-29-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ethirfin-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ethirfin-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ethirfin-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ethirfin-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ethirfin-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ethirfin-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ethirfin-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ethirfin-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ethirfin-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ethirfin-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ethirfin-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ethirfin-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ethirfin-article-29-referral-annex-i_sv.pdf"}},
    {"id":"25827","name":"Coglapix Article-33(4) referral - Divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-10-02T18:00:00Z","last_updated_date":"2015-10-02T18:00:00Z","reference_number":"EMEA/V/A/109","document_url":"https://www.ema.europa.eu/en/documents/referral/coglapix-article-334-referral-divergent-position_en.pdf"},
    {"id":"25850","name":"Questions and answers on the referral for Diovan Comp and associated names tablets containing valsartan (80, 160 or 320 mg) and hydrochlorothiazide (12.5 or 25 mg)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-28T02:08:21Z","last_updated_date":"2009-05-28T02:08:21Z","reference_number":"EMEA/CHMP/335293/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_sv.pdf"}},
    {"id":"25853","name":"CattleMarker IBR Inactivated Article-33(4) referral - Divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-19T02:00:00Z","last_updated_date":"2016-07-19T02:00:00Z","reference_number":"EMEA/V/A/115","document_url":"https://www.ema.europa.eu/en/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-divergent-position_en.pdf"},
    {"id":"25856","name":"Lumiracoxib - Article 107 procedures - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-12-14T00:08:21Z","last_updated_date":"2007-12-14T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lumiracoxib-article-107-procedures-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lumiracoxib-article-107-procedures-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lumiracoxib-article-107-procedures-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lumiracoxib-article-107-procedures-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lumiracoxib-article-107-procedures-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lumiracoxib-article-107-procedures-annex-ii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lumiracoxib-article-107-procedures-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lumiracoxib-article-107-procedures-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lumiracoxib-article-107-procedures-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lumiracoxib-article-107-procedures-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lumiracoxib-article-107-procedures-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lumiracoxib-article-107-procedures-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lumiracoxib-article-107-procedures-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lumiracoxib-article-107-procedures-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lumiracoxib-article-107-procedures-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lumiracoxib-article-107-procedures-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lumiracoxib-article-107-procedures-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lumiracoxib-article-107-procedures-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lumiracoxib-article-107-procedures-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lumiracoxib-article-107-procedures-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lumiracoxib-article-107-procedures-annex-ii_sv.pdf"}},
    {"id":"25870","name":"Adrenaline auto-injectors Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-08-26T02:00:00Z","last_updated_date":"2015-08-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"25893","name":"Hydroxyethyl starch Article-107i procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-timetable-procedure_en.pdf"},
    {"id":"25911","name":"Benzathine benzylpenicillin Article-35 referral - Annex I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-13T02:00:00Z","last_updated_date":"2014-08-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/benzathine-benzylpenicillin-article-35-referral-annex-i-ii_sv.pdf"}},
    {"id":"25917","name":"Ketoconazole Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T02:00:00Z","last_updated_date":"2014-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ketoconazole-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ketoconazole-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ketoconazole-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ketoconazole-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ketoconazole-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ketoconazole-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ketoconazole-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ketoconazole-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ketoconazole-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ketoconazole-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ketoconazole-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ketoconazole-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ketoconazole-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ketoconazole-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ketoconazole-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ketoconazole-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ketoconazole-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ketoconazole-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ketoconazole-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ketoconazole-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ketoconazole-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ketoconazole-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ketoconazole-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ketoconazole-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ketoconazole-article-31-referral-annex-i_no.pdf"}},
    {"id":"25923","name":"Substances related to nicotinic acid Article-31 referral - CMDh divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-13T18:00:00Z","last_updated_date":"2014-03-13T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-cmdh-divergent-position_en.pdf"},
    {"id":"25945","name":"HPV vaccines - Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-13T02:00:00Z","last_updated_date":"2015-09-24T02:00:00Z","reference_number":"EMA/PRAC/454661/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"25986","name":"Dienogest / Ethinylestradiol Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/144143/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/dienogest-ethinylestradiol-article-31-referral-review-started_en.pdf"},
    {"id":"25999","name":"Opinion following an Article 33(4) referral for Pharmasin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-01-08T01:00:00Z","last_updated_date":"2010-01-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-pharmasin-background-information_sv.pdf"}},
    {"id":"26001","name":"Intravenous iron-containing medicinal products Article-31 referral - New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-10-01T02:00:00Z","last_updated_date":"2013-11-14T01:00:00Z","reference_number":"EMA/579491/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_sv.pdf"}},
    {"id":"26009","name":"Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Calcichew-D3 and associated names International Non-Proprietary Name (INN): Calcium 500mg / choleca...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-12-01T00:08:21Z","last_updated_date":"2003-12-01T00:08:21Z","reference_number":"EMEA/CPMP/3257/03/en/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcichew-d3-and-associated-names-international-non-proprietary-name-inn-calcium-500mg-choleca_en.pdf"},
    {"id":"26024","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iii_en.pdf"},
    {"id":"26048","name":"Opinion following an Article 33(4) referral for Unisol 10% oral solution International Non-Proprietary Name (INN): Enrofloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-06T01:59:00Z","last_updated_date":"2009-05-06T01:59:00Z","reference_number":"EMEA/215198/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-unisol-10-oral-solution-international-non-proprietary-name-inn-enrofloxacin-background-information_sv.pdf"}},
    {"id":"26058","name":"PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T14:00:00Z","last_updated_date":"2013-10-11T14:00:00Z","reference_number":"EMA/606303/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-confirms-hydroxyethyl-starch-solutions-hes-should-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_en.pdf-0"},
    {"id":"26082","name":"Efexor depot - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-12-20T00:08:21Z","last_updated_date":"2008-12-20T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/efexor-depot-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"26100","name":"Opinion following an Article 36 referral for Cerivastatin International Non-Proprietary Name (INN): Cerivastatin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-09-01T02:08:21Z","last_updated_date":"2002-09-01T02:08:21Z","reference_number":"CPMP/3962/02","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-36-referral-cerivastatin-international-non-proprietary-name-inn-cerivastatin-background-information_en.pdf"},
    {"id":"26129","name":"SGLT2 inhibitors Article-20 procedure - EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-05-18T02:00:00Z","reference_number":"EMA/142655/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes_sv.pdf"}},
    {"id":"26137","name":"Hydroxyethyl starch Article-107i procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-notification_en.pdf"},
    {"id":"26154","name":"Questions and answers on the referral for Pantoprazole Olinka pantoprazole 20 and 40 mg tablets (EMA/H/A-29/1169)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-11-21T00:59:00Z","last_updated_date":"2011-03-09T00:59:00Z","reference_number":"EMEA/CHMP/734798/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_sv.pdf"}},
    {"id":"26222","name":"Retinoid Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"EMA/PRAC/461926/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"26223","name":"Methysergide Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T13:00:00Z","last_updated_date":"2014-05-27T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methysergide-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methysergide-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methysergide-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methysergide-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methysergide-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methysergide-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methysergide-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methysergide-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methysergide-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methysergide-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methysergide-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methysergide-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methysergide-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methysergide-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methysergide-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methysergide-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methysergide-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methysergide-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methysergide-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methysergide-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methysergide-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methysergide-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methysergide-article-31-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/methysergide-article-31-referral-annex-iii_no.pdf"}},
    {"id":"26226","name":"Opinion following an Article 6(12)1 referral for Porcilis M Hyo: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-08-18T02:00:00Z","last_updated_date":"2010-08-18T02:00:00Z","reference_number":"EMA/345914/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-6121-referral-porcilis-m-hyo-background-information_sv.pdf"}}    {"id":"26227","name":"Valsartan Article 31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T17:30:00Z","last_updated_date":"2018-07-05T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valsartan-article-31-referral-review-started_en.pdf"},
    {"id":"26235","name":"Caustinerf arsenical and Yranicid arsenical Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-06T02:00:00Z","last_updated_date":"2014-08-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"26257","name":"Factor VIII Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"EMA/PRAC/471535/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"26281","name":"Micro Therapeutic Research Article-31 referral - EMA recommends suspension of medicines due to unreliable studies from Micro Therapeutic Research Labs","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/188204/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-ema-recommends-suspension-medicines-due-unreliable-studies-micro-therapeutic-research-labs_en.pdf"},
    {"id":"26285","name":"Opinion following an Article 29(4) referral for Vantas International Non-Proprietary Name (INN): Histrelin acetate: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-30T02:08:21Z","last_updated_date":"2007-07-30T02:08:21Z","reference_number":"EMEA/CHMP/247760/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-vantas-international-non-proprietary-name-inn-histrelin-acetate-background-information_sv.pdf"}},
    {"id":"26295","name":"Opinion following an Article 35 referral for all veterinary medicinal products containing quinolones including fluoroquinolones intended for use in food-producing species: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2010-07-16T02:00:00Z","reference_number":"EMA/186029/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-quinolones-including-fluoroquinolones-intended-use-food-producing-species-background-information_sv.pdf"}},
    {"id":"26307","name":"Questions and answers on the referral for Implanon subdermal implant etonogestrel 68 mg","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-02-10T00:08:21Z","last_updated_date":"2009-02-10T00:08:21Z","reference_number":"EMEA/124262/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-implanon-subdermal-implant-etonogestrel-68-mg_sv.pdf"}},
    {"id":"26320","name":"Questions and answers on Zinacef and associated names (cefuroxime sodium, 250 mg, 500 mg, 750 mg, 1 g, 1.5 g, 2 g, powder for solution / suspension for injection or infusion)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"EMA/CHMP/339193/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-zinacef-and-associated-names-cefuroxime-sodium-250-mg-500-mg-750-mg-1-g-15-g-2-g-powder-solution-suspension-injection-or-infusion_sv.pdf"}},
    {"id":"26337","name":"CMDh endorses recommendations to restrict the use of diacerein-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"EMA/162540/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/cmdh-endorses-recommendations-restrict-use-diacerein-containing-medicines_en.pdf"},
    {"id":"26340","name":"Clenil Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-11-18T01:00:00Z","last_updated_date":"2016-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/clenil-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/clenil-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/clenil-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/clenil-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/clenil-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/clenil-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/clenil-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/clenil-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/clenil-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/clenil-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/clenil-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/clenil-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/clenil-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/clenil-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/clenil-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/clenil-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/clenil-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/clenil-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/clenil-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/clenil-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/clenil-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/clenil-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/clenil-article-30-referral-annex-i_sv.pdf"}},
    {"id":"26357","name":"Opinion following an Article 33(4) referral for Compagel gel for horses: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-08-02T01:59:00Z","last_updated_date":"2008-08-02T01:59:00Z","reference_number":"EMEA/459391/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-compagel-gel-horses-background-information_sv.pdf"}},
    {"id":"26379","name":"Coversyl - Article 6 (12) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-12-22T00:08:21Z","last_updated_date":"2005-12-22T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/coversyl-article-6-12-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"26397","name":"Questions and answers on Loraxin and associated names (loratadine, 10 mg tablets)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T14:00:00Z","last_updated_date":"2013-02-28T13:00:00Z","reference_number":"EMA/417631/2012 Rev1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-loraxin-and-associated-names-loratadine-10-mg-tablets_sv.pdf"}},
    {"id":"26401","name":"Xofigo Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T13:00:00Z","last_updated_date":"2017-12-01T13:00:00Z","reference_number":"EMA/PRAC/790594/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"26409","name":"Celecoxib, Etoricoxib, Lumiracoxib, Parecoxib, and Valdecoxib - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-12-07T00:08:21Z","last_updated_date":"2005-12-07T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"26442","name":"Dienogest / Ethinylestradiol Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/CHMP/147245/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/dienogest-ethinylestradiol-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"26458","name":"Betavert N - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-07-01T02:08:21Z","last_updated_date":"2009-07-01T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/betavert-n-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"26464","name":"Opinion following an Article 10 referral for Fluoxetin NM International Non-Proprietary Name (INN): Fluoxetine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-06-19T02:08:21Z","last_updated_date":"1998-06-19T02:08:21Z","reference_number":"CPMP/1154/98","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-10-referral-fluoxetin-nm-international-non-proprietary-name-inn-fluoxetine-background-information_en.pdf"},
    {"id":"26483","name":"Pantoprazole Olinka (EMEA/H/A-29/1170) - Annex I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2011-03-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pantoprazole-olinka-emeaha-291170-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"26498","name":"Opinion following an Article 6 (12) referral Perindopril tert-butylamine salt\n\nInternational Non-Proprietary Name (INN): Perindopril: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-11-08T00:08:21Z","last_updated_date":"2005-11-08T00:08:21Z","reference_number":"CHMP/408150/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-6-12-referral-perindopril-tert-butylamine-salt-international-non-proprietary-name-inn-perindopril-background-information_sv.pdf"}},
    {"id":"26501","name":"Zinacef - Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T01:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinacef-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinacef-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinacef-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinacef-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinacef-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinacef-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinacef-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinacef-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinacef-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinacef-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinacef-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinacef-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinacef-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinacef-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinacef-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinacef-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinacef-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinacef-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinacef-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinacef-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinacef-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinacef-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"26507","name":"Zostavax: Product information as approved by the CHMP on 13 December 2012, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T13:00:00Z","last_updated_date":"2025-06-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zostavax-product-information-approved-chmp-13-december-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"26534","name":"Cardioxane Article 13 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-26T11:42:00Z","last_updated_date":"2017-07-26T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cardioxane-article-13-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cardioxane-article-13-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cardioxane-article-13-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cardioxane-article-13-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cardioxane-article-13-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cardioxane-article-13-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cardioxane-article-13-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cardioxane-article-13-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cardioxane-article-13-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cardioxane-article-13-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cardioxane-article-13-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cardioxane-article-13-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cardioxane-article-13-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cardioxane-article-13-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cardioxane-article-13-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cardioxane-article-13-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cardioxane-article-13-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cardioxane-article-13-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cardioxane-article-13-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cardioxane-article-13-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cardioxane-article-13-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cardioxane-article-13-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cardioxane-article-13-referral-annex-ii_sv.pdf"}},
    {"id":"26632","name":"Assessment report for ergot derivatives containing medicinal products - dihydroergotamine","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"EMA/750626/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-ergot-derivatives-containing-medicinal-products-dihydroergotamine_en.pdf"},
    {"id":"26633","name":"Vancomycin Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/222696/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/vancomycin-article-31-referral-review-started_en.pdf"},
    {"id":"26649","name":"Bromocriptine Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-06T02:00:00Z","last_updated_date":"2013-09-06T02:00:00Z","reference_number":"EMA/533713/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-review-started_en.pdf"},
    {"id":"26656","name":"Testosterone Article-31 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T01:00:00Z","last_updated_date":"2014-12-05T01:00:00Z","reference_number":"EMA/CHMP/717942/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"26662","name":"Renin-angiotensin-system (RAS)-acting agents Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T02:00:00Z","last_updated_date":"2013-05-17T02:00:00Z","reference_number":"EMA/291202/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-review-started_en.pdf"},
    {"id":"26675","name":"Polymyxin Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2015-01-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/polymyxin-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/polymyxin-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/polymyxin-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/polymyxin-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/polymyxin-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/polymyxin-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/polymyxin-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/polymyxin-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/polymyxin-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/polymyxin-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/polymyxin-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/polymyxin-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/polymyxin-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/polymyxin-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/polymyxin-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/polymyxin-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/polymyxin-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/polymyxin-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/polymyxin-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/polymyxin-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/polymyxin-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/polymyxin-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/polymyxin-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/polymyxin-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/polymyxin-article-31-referral-annex-iii_no.pdf"}},
    {"id":"26679","name":"Piroxicam - Article 31 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-01-31T00:08:21Z","last_updated_date":"2008-01-31T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/piroxicam-article-31-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"26685","name":"Lumiracoxib - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-12-07T00:08:21Z","last_updated_date":"2005-12-07T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lumiracoxib-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"26737","name":"Paracetamol Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-01T01:00:00Z","last_updated_date":"2018-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paracetamol-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paracetamol-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paracetamol-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paracetamol-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paracetamol-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paracetamol-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paracetamol-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paracetamol-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paracetamol-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paracetamol-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paracetamol-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paracetamol-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paracetamol-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paracetamol-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paracetamol-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paracetamol-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paracetamol-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paracetamol-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paracetamol-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paracetamol-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paracetamol-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paracetamol-article-31-referral-annex-i_sv.pdf"}},
    {"id":"26781","name":"Semler Article-31 referral – Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"26784","name":"Gentamicin Article-35 referral - Questions and answers on veterinary medicinal products containing gentamicin presented as solutions for injection to be administered to cattle and pigs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/144816/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gentamicin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-and-pigs_sv.pdf"}},
    {"id":"26792","name":"Rofecoxib - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-06-09T02:08:21Z","last_updated_date":"2004-06-09T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"26837","name":"Valproate - Article 31 - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-29T02:00:00Z","last_updated_date":"2011-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-article-31-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-article-31-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-article-31-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-article-31-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-article-31-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-article-31-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-article-31-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-article-31-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-article-31-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-article-31-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-article-31-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-article-31-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-article-31-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-article-31-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-article-31-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-article-31-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-article-31-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-article-31-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-article-31-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-article-31-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-article-31-annex-i_sv.pdf"}},
    {"id":"26841","name":"Retinoid Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/retinoid-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/retinoid-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/retinoid-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/retinoid-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/retinoid-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/retinoid-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/retinoid-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/retinoid-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/retinoid-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/retinoid-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/retinoid-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/retinoid-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/retinoid-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/retinoid-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/retinoid-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/retinoid-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/retinoid-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/retinoid-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/retinoid-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/retinoid-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/retinoid-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/retinoid-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"26864","name":"Gutal Article 33(4) referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-11-26T01:00:00Z","last_updated_date":"2015-11-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gutal-article-334-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gutal-article-334-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gutal-article-334-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gutal-article-334-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gutal-article-334-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gutal-article-334-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gutal-article-334-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gutal-article-334-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gutal-article-334-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gutal-article-334-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gutal-article-334-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gutal-article-334-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gutal-article-334-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gutal-article-334-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gutal-article-334-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gutal-article-334-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gutal-article-334-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gutal-article-334-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gutal-article-334-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gutal-article-334-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gutal-article-334-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gutal-article-334-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gutal-article-334-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"26879","name":"Diovan - EMEA/H/A/-29 PAD/1219 - Article 29 Paediatrics referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-05-31T02:00:00Z","last_updated_date":"2010-05-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diovan-emeaha-29-pad1219-article-29-paediatrics-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"26884","name":"Femara - Article 30 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-06-12T02:00:00Z","last_updated_date":"2012-06-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/femara-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/femara-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/femara-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/femara-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/femara-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/femara-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/femara-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/femara-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/femara-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/femara-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/femara-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/femara-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/femara-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/femara-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/femara-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/femara-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/femara-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/femara-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/femara-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/femara-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/femara-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/femara-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"26888","name":"Novantrone Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/novantrone-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/novantrone-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/novantrone-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/novantrone-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/novantrone-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/novantrone-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/novantrone-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/novantrone-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/novantrone-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/novantrone-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/novantrone-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/novantrone-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/novantrone-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/novantrone-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/novantrone-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/novantrone-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/novantrone-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/novantrone-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/novantrone-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/novantrone-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/novantrone-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/novantrone-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/novantrone-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/novantrone-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/novantrone-article-30-referral-annex-iii_no.pdf"}},
    {"id":"26903","name":"Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-12T18:00:00Z","last_updated_date":"2014-03-12T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"26921","name":"Ketoconazole Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T02:00:00Z","last_updated_date":"2014-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ketoconazole-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ketoconazole-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ketoconazole-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ketoconazole-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ketoconazole-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ketoconazole-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ketoconazole-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ketoconazole-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ketoconazole-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ketoconazole-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ketoconazole-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ketoconazole-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ketoconazole-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ketoconazole-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ketoconazole-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ketoconazole-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ketoconazole-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ketoconazole-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ketoconazole-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ketoconazole-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ketoconazole-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ketoconazole-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ketoconazole-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"26955","name":"Diclofenac Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-31T18:00:00Z","last_updated_date":"2012-10-31T18:00:00Z","reference_number":"EMA/693599/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-review-started_en.pdf"},
    {"id":"26959","name":"Famvir - Article 30 Referral - PI","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2010-04-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/famvir-article-30-referral-pi_en.pdf"},
    {"id":"26961","name":"Zinbryta Article-20 referral - PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2017-10-27T02:00:00Z","reference_number":"EMEA/H/A-20/1456/C/003862/0010","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-prac-recommends-further-restrictions-multiple-sclerosis-medicine-zinbryta-due-risk-serious-liver-damage_en.pdf"},
    {"id":"26966","name":"HPV vaccines - Article-20 procedure - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-07-13T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMA/PRAC/454436/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"26968","name":"Lactose of bovine origin Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-08-01T02:00:00Z","last_updated_date":"2017-09-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/lactose-bovine-origin-article-31-referral-annex-iii_no.pdf"}},
    {"id":"26982","name":"Opinion following an article 6(13) referral for Cobactan DC and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-12T02:00:00Z","last_updated_date":"2014-08-12T02:00:00Z","reference_number":"EMA/250892/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-613-referral-cobactan-dc-and-its-associated-names_en.pdf"},
    {"id":"26983","name":"Somatropin - Article 107 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-23T02:00:00Z","last_updated_date":"2012-04-23T02:00:00Z","reference_number":"EMA/110423/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/somatropin-article-107-referral-assessment-report_en.pdf"},
    {"id":"27036","name":"Opinion following an Article 33(4) referral for Dolovet: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T01:59:00Z","last_updated_date":"2008-06-02T01:59:00Z","reference_number":"EMEA/532160/2007 – Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-dolovet-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-dolovet-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-dolovet-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-dolovet-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-dolovet-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-dolovet-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-dolovet-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-dolovet-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-dolovet-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-dolovet-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-dolovet-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-dolovet-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-dolovet-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-dolovet-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-dolovet-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-dolovet-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-dolovet-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-dolovet-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-dolovet-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-dolovet-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-dolovet-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-dolovet-background-information_sv.pdf"}},
    {"id":"27038","name":"Xofigo Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T13:00:00Z","last_updated_date":"2017-12-01T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-notification_en.pdf"},
    {"id":"27071","name":"Assessment report for cilostazol-containing medicinal products","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"EMA/CHMP/428525/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-cilostazol-containing-medicinal-products_en.pdf"},
    {"id":"27132","name":"Gadolinium Article-31 referral – Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T01:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gadolinium-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gadolinium-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gadolinium-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gadolinium-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gadolinium-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gadolinium-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gadolinium-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gadolinium-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gadolinium-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gadolinium-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gadolinium-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gadolinium-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gadolinium-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gadolinium-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gadolinium-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gadolinium-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gadolinium-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gadolinium-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gadolinium-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gadolinium-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gadolinium-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gadolinium-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"27151","name":"Seroquel XR - Article 6(13) referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2010-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"27157","name":"Pulmotil Premix - Article 34 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-12-23T00:08:21Z","last_updated_date":"2009-12-23T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pulmotil-premix-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"27159","name":"Dexamethasone Alapis - Article 29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T01:00:00Z","last_updated_date":"2012-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexamethasone-alapis-article-29-referral-annex-i_sv.pdf"}},
    {"id":"27166","name":"Bromocriptine Article-31 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-02T02:00:00Z","last_updated_date":"2014-09-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"27175","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information (April 2017)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"EMA/118223/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-sglt2-inhibitors-information-potential-risk-toe-amputation-be-included-prescribing-information-april-2017_en.pdf"},
    {"id":"27178","name":"Vasotop P Article-6(12) referral - Annex I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-14T02:00:00Z","last_updated_date":"2014-08-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vasotop-p-article-612-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vasotop-p-article-612-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vasotop-p-article-612-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vasotop-p-article-612-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vasotop-p-article-612-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vasotop-p-article-612-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vasotop-p-article-612-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vasotop-p-article-612-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vasotop-p-article-612-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vasotop-p-article-612-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vasotop-p-article-612-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vasotop-p-article-612-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vasotop-p-article-612-referral-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vasotop-p-article-612-referral-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vasotop-p-article-612-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vasotop-p-article-612-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vasotop-p-article-612-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vasotop-p-article-612-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vasotop-p-article-612-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vasotop-p-article-612-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vasotop-p-article-612-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vasotop-p-article-612-referral-annex-i-ii_sv.pdf"}},
    {"id":"27196","name":"Baxter dialysis solutions Article-31 referral - Annex III (Castlebar site)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iii-castlebar-site_sv.pdf"}},
    {"id":"27201","name":"Fenflor - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-03T01:59:00Z","last_updated_date":"2009-10-03T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fenflor-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"27209","name":"Short-acting beta-agonists Article-31 referral - Annex V","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-07T01:00:00Z","last_updated_date":"2013-11-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/short-acting-beta-agonists-article-31-referral-annex-v_sv.pdf"}},
    {"id":"27216","name":"Kantos Master Article-13 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-05-02T12:00:00Z","last_updated_date":"2013-05-02T12:00:00Z","reference_number":"EMA/210436/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/kantos-master-article-13-referral-assessment-report_en.pdf"},
    {"id":"27221","name":"Domperidone Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T17:00:00Z","last_updated_date":"2014-09-11T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/domperidone-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/domperidone-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/domperidone-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/domperidone-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/domperidone-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/domperidone-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/domperidone-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/domperidone-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/domperidone-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/domperidone-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/domperidone-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/domperidone-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/domperidone-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/domperidone-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/domperidone-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/domperidone-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/domperidone-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/domperidone-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/domperidone-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/domperidone-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/domperidone-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/domperidone-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"27227","name":"Numeta Article-107i procedure - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-27T15:00:00Z","last_updated_date":"2013-09-27T15:00:00Z","reference_number":"EMEA/H/A-107i/1373","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/numeta-article-107i-procedure-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/numeta-article-107i-procedure-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/numeta-article-107i-procedure-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/numeta-article-107i-procedure-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/numeta-article-107i-procedure-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/numeta-article-107i-procedure-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/numeta-article-107i-procedure-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/numeta-article-107i-procedure-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/numeta-article-107i-procedure-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/numeta-article-107i-procedure-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/numeta-article-107i-procedure-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/numeta-article-107i-procedure-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/numeta-article-107i-procedure-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/numeta-article-107i-procedure-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/numeta-article-107i-procedure-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/numeta-article-107i-procedure-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/numeta-article-107i-procedure-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/numeta-article-107i-procedure-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/numeta-article-107i-procedure-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/numeta-article-107i-procedure-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/numeta-article-107i-procedure-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/numeta-article-107i-procedure-annex-ii_sv.pdf"}},
    {"id":"27237","name":"Agreal - Article 31 referral - Annex I, II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-01-07T00:08:21Z","last_updated_date":"2008-01-07T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/agreal-article-31-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/agreal-article-31-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/agreal-article-31-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/agreal-article-31-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/agreal-article-31-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/agreal-article-31-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/agreal-article-31-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/agreal-article-31-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/agreal-article-31-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/agreal-article-31-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/agreal-article-31-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/agreal-article-31-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/agreal-article-31-referral-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/agreal-article-31-referral-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/agreal-article-31-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/agreal-article-31-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/agreal-article-31-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/agreal-article-31-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/agreal-article-31-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/agreal-article-31-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/agreal-article-31-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/agreal-article-31-referral-annex-i-ii_sv.pdf"}},
    {"id":"27268","name":"Questions and answers on Isotretinoin Ranbaxy (UK) Limited (isotretinoin 10 and 20 mg capsules)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2011-07-15T02:00:00Z","reference_number":"EMA/820119/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-isotretinoin-ranbaxy-uk-limited-isotretinoin-10-and-20-mg-capsules_sv.pdf"}},
    {"id":"27273","name":"Dienogest / Ethinylestradiol Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/dienogest-ethinylestradiol-article-31-referral-annex-iii_no.pdf"}},
    {"id":"27297","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Annex I-III - Ebymect","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-ebymect_no.pdf"}},
    {"id":"27334","name":"Xofigo Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T13:00:00Z","last_updated_date":"2018-06-15T14:00:05Z","reference_number":"EMA/PRAC/791811/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"27363","name":"Tibolona-Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-08T02:00:00Z","last_updated_date":"2014-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tibolona-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tibolona-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tibolona-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tibolona-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tibolona-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tibolona-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tibolona-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tibolona-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tibolona-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tibolona-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tibolona-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tibolona-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tibolona-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tibolona-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tibolona-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tibolona-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tibolona-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tibolona-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tibolona-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tibolona-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tibolona-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tibolona-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tibolona-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"27364","name":"Priorix - Article 30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-19T02:00:00Z","last_updated_date":"2012-06-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/priorix-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/priorix-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/priorix-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/priorix-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/priorix-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/priorix-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/priorix-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/priorix-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/priorix-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/priorix-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/priorix-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/priorix-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/priorix-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/priorix-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/priorix-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/priorix-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/priorix-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/priorix-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/priorix-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/priorix-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/priorix-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/priorix-article-30-referral-annex-i_sv.pdf"}},
    {"id":"27368","name":"Opinion following an Article 33(4) referral for CEVAZURIL 50 mg/ml oral suspension for piglets: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-05-05T02:00:00Z","last_updated_date":"2010-05-05T02:00:00Z","reference_number":"EMA/115640/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-cevazuril-50-mgml-oral-suspension-piglets-background-information_sv.pdf"}},
    {"id":"27375","name":"Diacerein Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"EMA/762522/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-review-started_en.pdf"},
    {"id":"27383","name":"Doxycycline hyclate - Article 35 referral - Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2010-07-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/doxycycline-hyclate-article-35-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"27392","name":"Questions and answers on the potential off-label use of celecoxib in patients with familial adenomatous polyposis","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/376406/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-potential-label-use-celecoxib-patients-familial-adenomatous-polyposis_en.pdf"},
    {"id":"27393","name":"Micotil 300 Injectie Article-34 referral - Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/micotil-300-injectie-article-34-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"27418","name":"Synulox Lactating Cow: Article 34 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-11-17T12:03:00Z","last_updated_date":"2011-11-17T12:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/synulox-lactating-cow-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"27430","name":"Nisamox Lactating Cow: Article 33 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-12-08T01:00:00Z","last_updated_date":"2011-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nisamox-lactating-cow-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"27441","name":"European Medicines Agency gives recommendations on the use of intravenous nicardipine","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T02:00:00Z","last_updated_date":"2013-10-25T02:00:00Z","reference_number":"EMA/644174/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/european-medicines-agency-gives-recommendations-use-intravenous-nicardipine_en.pdf-0"},
    {"id":"27458","name":"Opinion following an Article 29(2) referral for Doxazosin Retard \"Arrow\" 4 mg prolonged release tablets and associated names International Non-Proprietary Name (INN): Doxazosin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-10-11T02:08:21Z","last_updated_date":"2006-10-11T02:08:21Z","reference_number":"EMEA/CHMP/423796/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-doxazosin-retard-arrow-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sv.pdf"}},
    {"id":"27479","name":"Semler Article-31 referral – CHMP list of questions to Semler research centre","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-chmp-list-questions-semler-research-centre_en.pdf"},
    {"id":"27492","name":"Quinolones/fluoroquinolones - Article 35 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-06-16T02:00:00Z","last_updated_date":"2010-06-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/quinolonesfluoroquinolones-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"27507","name":"Symbioflor 2 Article-31 referral - EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-09-07T02:00:00Z","reference_number":"EMA/381688/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/symbioflor-2-article-31-referral-ema-recommends-symbioflor-2-can-continue-be-used-irritable-bowel-syndrome_sv.pdf"}},
    {"id":"27604","name":"Domperidone Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-12-10T15:47:00Z","reference_number":"EMA/PRAC/127280/2013 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"27630","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP list of questions to be addressed by the marketing authorisation holders for valsartan-containing medicinal products","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T16:34:00Z","last_updated_date":"2018-07-17T16:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-list-questions-be-addressed-marketing-authorisation-holders-valsartan-containing-medicinal-products_en.pdf"},
    {"id":"27631","name":"PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-04-11T14:00:00Z","reference_number":"EMA/196502/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-recommends-against-combined-use-medicines-affecting-renin-angiotensin-ras-system_en.pdf"},
    {"id":"27640","name":"Ketoprofen - Article 107 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ketoprofen-article-107-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ketoprofen-article-107-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ketoprofen-article-107-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ketoprofen-article-107-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ketoprofen-article-107-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ketoprofen-article-107-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ketoprofen-article-107-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ketoprofen-article-107-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ketoprofen-article-107-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ketoprofen-article-107-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ketoprofen-article-107-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ketoprofen-article-107-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ketoprofen-article-107-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ketoprofen-article-107-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ketoprofen-article-107-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ketoprofen-article-107-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ketoprofen-article-107-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ketoprofen-article-107-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ketoprofen-article-107-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ketoprofen-article-107-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ketoprofen-article-107-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ketoprofen-article-107-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ketoprofen-article-107-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ketoprofen-article-107-referral-annex-iii_no.pdf"}},
    {"id":"27655","name":"Retinoid Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/retinoid-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/retinoid-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/retinoid-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/retinoid-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/retinoid-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/retinoid-article-31-referral-annex-iv_et.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/retinoid-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/retinoid-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/retinoid-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/retinoid-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/retinoid-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/retinoid-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/retinoid-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/retinoid-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/retinoid-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/retinoid-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/retinoid-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/retinoid-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/retinoid-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/retinoid-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/retinoid-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"27660","name":"Lovenox Article 30 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-22T18:30:00Z","last_updated_date":"2017-03-22T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lovenox-article-30-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lovenox-article-30-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lovenox-article-30-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lovenox-article-30-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lovenox-article-30-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lovenox-article-30-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lovenox-article-30-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lovenox-article-30-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lovenox-article-30-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lovenox-article-30-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lovenox-article-30-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lovenox-article-30-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lovenox-article-30-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lovenox-article-30-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lovenox-article-30-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lovenox-article-30-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lovenox-article-30-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lovenox-article-30-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lovenox-article-30-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lovenox-article-30-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lovenox-article-30-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lovenox-article-30-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lovenox-article-30-referral-annex-iv_sv.pdf"}},
    {"id":"27662","name":"Iclusig Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-06T13:00:00Z","last_updated_date":"2014-07-11T19:00:00Z","reference_number":"EMA/PRAC/746118/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"27691","name":"Numeta Article-107i procedure - Rationale for triggering","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-rationale-triggering_en.pdf"},
    {"id":"27717","name":"Mometasone Furoate Sandoz - Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T01:00:00Z","last_updated_date":"2013-01-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"27722","name":"Combined use of medicines affecting the renin-angiotensin system (RAS) to be restricted – CHMP endorses PRAC recommendation","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/294911/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-use-medicines-affecting-renin-angiotensin-system-ras-be-restricted-chmp-endorses-prac-recommendation_en.pdf"},
    {"id":"27726","name":"Suramox 15% LA - Article 35 Referral - Annex I, II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-26T01:59:00Z","last_updated_date":"2007-07-26T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/suramox-15-la-article-35-referral-annex-i-ii_sv.pdf"}},
    {"id":"27727","name":"Rocephin Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-19T02:00:00Z","last_updated_date":"2014-05-19T02:00:00Z","reference_number":"EMEA/H/A-30/1302","document_url":"https://www.ema.europa.eu/en/documents/referral/rocephin-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rocephin-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rocephin-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rocephin-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rocephin-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rocephin-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rocephin-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rocephin-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rocephin-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/rocephin-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rocephin-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rocephin-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rocephin-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rocephin-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rocephin-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rocephin-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rocephin-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rocephin-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rocephin-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rocephin-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rocephin-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rocephin-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rocephin-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/rocephin-article-30-referral-annex-i_is.pdf"}},
    {"id":"27767","name":"Questions and answers on Tibolona Aristo and Tibocina and associated names (tibolone, tablet, 2.5 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2014-04-08T02:00:00Z","reference_number":"EMA/793605/2013 ","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-tibolona-aristo-and-tibocina-and-associated-names-tibolone-tablet-25-mg_sv.pdf"}},
    {"id":"27796","name":"Nicardipine Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-12T13:00:00Z","last_updated_date":"2014-03-12T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nicardipine-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nicardipine-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nicardipine-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nicardipine-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nicardipine-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nicardipine-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nicardipine-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nicardipine-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nicardipine-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nicardipine-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nicardipine-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nicardipine-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nicardipine-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nicardipine-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nicardipine-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nicardipine-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nicardipine-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nicardipine-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nicardipine-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nicardipine-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nicardipine-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nicardipine-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nicardipine-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"27819","name":"Pregsure BVD - Article 78 referral - Annexes I, II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-08-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pregsure-bvd-article-78-referral-annexes-i-ii_sv.pdf"}}    {"id":"27845","name":"Tetrazepam-containing medicines - Article-107i procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-08T18:00:00Z","last_updated_date":"2013-05-08T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-i_sv.pdf"}},
    {"id":"27855","name":"Septanest Article-30 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/443931/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/septanest-article-30-referral-notification_en.pdf"},
    {"id":"27899","name":"Methylphenidate Hexal Article-29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-05T01:00:00Z","last_updated_date":"2013-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methylphenidate-hexal-article-29-referral-annex-iii_sv.pdf"}},
    {"id":"27903","name":"Methoxasol-t - Article 34 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-10T01:59:00Z","last_updated_date":"2008-10-10T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methoxasol-t-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"27934","name":"Antifibrinolytic medicines - Article-31 referral - Annex II (aprotinin)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-06T01:00:00Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-aprotinin_sv.pdf"}},
    {"id":"27959","name":"Tobramycin VVB and associated names Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-i_sv.pdf"}},
    {"id":"27964","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Daklinza Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T01:00:00Z","last_updated_date":"2017-03-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-daklinza-annex-i-iii_no.pdf"}},
    {"id":"27971","name":"Hydroxyethyl starch Article-107i procedure - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-06T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-ii_sv.pdf"}},
    {"id":"27982","name":"Tavanic - Article 30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-09-12T02:00:00Z","last_updated_date":"2012-09-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tavanic-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tavanic-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tavanic-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tavanic-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tavanic-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tavanic-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tavanic-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tavanic-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tavanic-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tavanic-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tavanic-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tavanic-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tavanic-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tavanic-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tavanic-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tavanic-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tavanic-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tavanic-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tavanic-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tavanic-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tavanic-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tavanic-article-30-referral-annex-i_sv.pdf"}},
    {"id":"28032","name":"Opinion following an Article 6(12) referral Avelox and associated names International Non-Proprietary Name (INN): moxifloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-08-14T02:08:21Z","last_updated_date":"2008-08-14T02:08:21Z","reference_number":"EMEA/CHMP/524251/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-612-referral-avelox-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_sv.pdf"}},
    {"id":"28098","name":"Zinbryta Article-20 referral - Annex IV - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-19T18:23:00Z","last_updated_date":"2017-07-19T18:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinbryta-article-20-referral-annex-iv-scientific-conclusions_sv.pdf"}},
    {"id":"28104","name":"Domperidone Article-31 referral - CMDh divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-11T02:00:00Z","last_updated_date":"2014-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-cmdh-divergent-position_en.pdf"},
    {"id":"28112","name":"Almitrine Article-31 - Oral almitrine to be withdrawn by EU Member States","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T12:00:00Z","last_updated_date":"2013-05-31T12:00:00Z","reference_number":"EMA/313994/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/almitrine-article-31-oral-almitrine-be-withdrawn-eu-member-states_sv.pdf"}},
    {"id":"28147","name":"Methylphenidate Hexal Article-29 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-12-05T01:00:00Z","last_updated_date":"2013-12-05T01:00:00Z","reference_number":"EMA/596773/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-hexal-article-29-referral-assessment-report_en.pdf"},
    {"id":"28153","name":"Intravenous iron-containing medicinal products Article-31 referral: New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/377372/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_en.pdf-0"},
    {"id":"28175","name":"Vian Diskus - Article 6 (13) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-14T02:08:21Z","last_updated_date":"2007-07-14T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vian-diskus-article-6-13-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"28278","name":"Meprobamate - Article 107 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-06-08T16:15:00Z","last_updated_date":"2012-06-08T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/meprobamate-article-107-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/meprobamate-article-107-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/meprobamate-article-107-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/meprobamate-article-107-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/meprobamate-article-107-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/meprobamate-article-107-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/meprobamate-article-107-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/meprobamate-article-107-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/meprobamate-article-107-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/meprobamate-article-107-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/meprobamate-article-107-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/meprobamate-article-107-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/meprobamate-article-107-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/meprobamate-article-107-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/meprobamate-article-107-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/meprobamate-article-107-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/meprobamate-article-107-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/meprobamate-article-107-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/meprobamate-article-107-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/meprobamate-article-107-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/meprobamate-article-107-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/meprobamate-article-107-referral-annex-i_sv.pdf"}},
    {"id":"28279","name":"Tetrazepam-containing medicines - Article-107i procedure - Tetrazepam-containing medicines suspended across the EU","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-07-29T13:00:00Z","last_updated_date":"2013-07-29T13:00:00Z","reference_number":"EMA/402567/2013 – Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-tetrazepam-containing-medicines-suspended-across-eu_sv.pdf"}},
    {"id":"28285","name":"Seasonique Article-29(4) - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/seasonique-article-294-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/seasonique-article-294-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/seasonique-article-294-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seasonique-article-294-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seasonique-article-294-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seasonique-article-294-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seasonique-article-294-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seasonique-article-294-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seasonique-article-294-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/seasonique-article-294-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seasonique-article-294-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seasonique-article-294-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seasonique-article-294-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seasonique-article-294-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/seasonique-article-294-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seasonique-article-294-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seasonique-article-294-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seasonique-article-294-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/seasonique-article-294-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seasonique-article-294-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seasonique-article-294-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seasonique-article-294-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seasonique-article-294-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/seasonique-article-294-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/seasonique-article-294-annex-iii_no.pdf"}},
    {"id":"28310","name":"Opinion following a referral for arbitration according to Article 7(5) of Commission Regulation (EC) No 541/95 as amended, for Bifril/Teoula/Zofepril/Zopranol International Non-Proprietary Name (INN): zofenopril: Backgro...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2000-12-16T00:08:21Z","last_updated_date":"2000-12-16T00:08:21Z","reference_number":"CPMP/4362/00","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-referral-arbitration-according-article-75-commission-regulation-ec-no-54195-amended-bifrilteoulazofeprilzopranol-international-non-proprietary-name-inn-zofenopril-backgro_en.pdf"},
    {"id":"28328","name":"Opinion following an Article 29(2) referral for Cardoreg 4 mg prolonged release tablets and associated names International Non-Proprietary Name (INN): Doxazosin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-10-11T02:08:21Z","last_updated_date":"2006-10-11T02:08:21Z","reference_number":"EMEA/CHMP/422351/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-cardoreg-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sv.pdf"}},
    {"id":"28335","name":"Opinion following an Article 29(4) referral for Lansoprazole and associated names International Non-Proprietary Name (INN): lansoprazole: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-09-18T02:08:21Z","last_updated_date":"2007-09-18T02:08:21Z","reference_number":"EMEA/283378/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-lansoprazole-and-associated-names-international-non-proprietary-name-inn-lansoprazole-background-information_sv.pdf"}},
    {"id":"28366","name":"Opinion following an Article 33 referral for Combisyn Lactating Cow and associated names: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-12-08T01:00:00Z","last_updated_date":"2011-12-08T01:00:00Z","reference_number":"EMEA/V/A/063","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-33-referral-combisyn-lactating-cow-and-associated-names-background-information_sv.pdf"}},
    {"id":"28374","name":"Retinoid Article-31 referral - Updated measures for pregnancy prevention during retinoid use","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"EMA/165360/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-updated-measures-pregnancy-prevention-during-retinoid-use_en.pdf-0"},
    {"id":"28379","name":"Divergent position regarding the referral for arbitration under Article 33 of Directive 2001/82/EC submitted for Bovimec B and Porcimec P","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-13T02:00:00Z","last_updated_date":"2014-08-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-regarding-referral-arbitration-under-article-33-directive-200182ec-submitted-bovimec-b-and-porcimec-p_en.pdf"},
    {"id":"28381","name":"Questions and answers on Amoxil and associated names (amoxicillin)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2016-05-19T02:00:00Z","reference_number":"EMA/421017/2015 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-amoxil-and-associated-names-amoxicillin_sv.pdf"}},
    {"id":"28395","name":"Opinion following an Article 30 referral for Gemzar and associated names International Non-Proprietary Name (INN): gemcitabine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-24T02:08:21Z","last_updated_date":"2008-09-24T02:08:21Z","reference_number":"EMEA/CHMP/512295/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-gemzar-and-associated-names-international-non-proprietary-name-inn-gemcitabine-background-information_sv.pdf"}},
    {"id":"28404","name":"Baxter dialysis solutions Article-31 referral - Annex I (3 sites)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-3-sites_sv.pdf"}},
    {"id":"28424","name":"Inhaled corticosteroids Article-31 referral – PRAC reviews known risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T01:00:00Z","last_updated_date":"2016-03-18T01:00:00Z","reference_number":"EMA/197713/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-prac-reviews-known-risk-pneumonia-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_en.pdf"},
    {"id":"28431","name":"Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Pravachol and associated names (See Annex I) International Non-Proprietary Name (INN): Pravastatin: Background informatio...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-03-03T00:08:21Z","last_updated_date":"2004-03-03T00:08:21Z","reference_number":"EMEA/CPMP/6214/03/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-pravachol-and-associated-names-see-annex-i-international-non-proprietary-name-inn-pravastatin-background-informatio_en.pdf"},
    {"id":"28452","name":"Xofigo Article-20 procedure - Annex I-II-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T13:00:00Z","last_updated_date":"2018-03-09T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-annex-i-ii-iii_en.pdf"},
    {"id":"28491","name":"Lansoprazol CT-Arzneimittel 15 mg and 30 mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-02-25T00:08:21Z","last_updated_date":"2006-02-25T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lansoprazol-ct-arzneimittel-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"28492","name":"Priorix - Article 30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-06-19T02:00:00Z","last_updated_date":"2012-06-19T02:00:00Z","reference_number":"EMA/360443/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/priorix-article-30-referral-assessment-report_en.pdf"},
    {"id":"28522","name":"Polymyxin Article-31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-05T01:00:00Z","last_updated_date":"2015-01-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/polymyxin-article-31-referral-assessment-report_en.pdf"},
    {"id":"28549","name":"Vascace - Article 30 Referral - Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2010-04-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vascace-article-30-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"28575","name":"Final opinion of the Committee for proprietary medicinal products pursuant to Article 12 of Council Directive 75/319/EEC as amended for Terfenadine 6mg/ml and Annexes A, B and I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-01-22T00:08:21Z","last_updated_date":"1998-01-22T00:08:21Z","reference_number":"CPMP/257/98-EN","document_url":"https://www.ema.europa.eu/en/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-6mgml-and-annexes-b-and-i_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-6mgml-and-annexes-b-and-i_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-6mgml-and-annexes-b-and-i_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-6mgml-and-annexes-b-and-i_fr.pdf"}},
    {"id":"28608","name":"Opinion following an Article 341 referral for\n\nFortekor and associated names: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-24T01:00:00Z","last_updated_date":"2012-02-24T01:00:00Z","reference_number":"EMA/965903/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-341-referral-fortekor-and-associated-names-background-information_sv.pdf"}},
    {"id":"28625","name":"Protelos and Osseor Article-20 procedure: Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T14:00:00Z","last_updated_date":"2013-05-17T14:00:00Z","reference_number":"EMA/291972/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/protelos-and-osseor-article-20-procedure-review-started_en.pdf"},
    {"id":"28654","name":"Zinbryta Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T01:00:00Z","last_updated_date":"2018-03-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-procedure-notification_en.pdf"},
    {"id":"28658","name":"Divergent position on a revised CVMP opinion on an Article-35 referral for Hipralona Enro-S and its generics indicated for use in rabbits","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-02-04T01:00:00Z","last_updated_date":"2013-02-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-revised-cvmp-opinion-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_en.pdf"},
    {"id":"28699","name":"Questions and answers on the referral for Diovan film coated tablets and hard capsules containing valsartan 40, 80, 160 or 320 mg","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-02-19T00:08:21Z","last_updated_date":"2009-02-19T00:08:21Z","reference_number":"EMEA/CHMP/137577/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_sv.pdf"}},
    {"id":"28706","name":"Codeine Article-31 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-08-02T02:00:00Z","last_updated_date":"2013-08-02T02:00:00Z","reference_number":"EMA/441891/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"28726","name":"Scandonest Article-30 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/scandonest-article-30-referral-notification_en.pdf"},
    {"id":"28742","name":"Sortis-EMEA/H/A-29 PAD/1255: Article 29 Paediatrics referral - Assessment Report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-04-27T02:00:00Z","last_updated_date":"2011-04-27T02:00:00Z","reference_number":"EMA/511890/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/sortis-emeaha-29-pad1255-article-29-paediatrics-referral-assessment-report_en.pdf"},
    {"id":"28763","name":"GVK Biosciences Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/580140/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-review-started_en.pdf"},
    {"id":"28766","name":"Valproate - Article 31 - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-29T02:00:00Z","last_updated_date":"2011-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-article-31-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-article-31-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-article-31-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-article-31-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-article-31-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-article-31-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-article-31-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-article-31-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-article-31-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-article-31-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-article-31-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-article-31-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-article-31-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-article-31-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-article-31-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-article-31-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-article-31-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-article-31-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-article-31-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-article-31-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-article-31-annex-ii_sv.pdf"}},
    {"id":"28783","name":"Opinion following an Article 33(4) referral for Enurace 50: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T01:59:00Z","last_updated_date":"2008-06-02T01:59:00Z","reference_number":"EMEA/532222/2007 – Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-enurace-50-background-information_sv.pdf"}},
    {"id":"28796","name":"Fenofibrato Pensa and Fenofibrato Ranbaxy Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-iii_fi.pdf"}},
    {"id":"28872","name":"Opinion following an Article 33(4) referral for Bovilis BVD/Bovilis BVD-MD: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T01:59:00Z","last_updated_date":"2008-06-02T01:59:00Z","reference_number":"EMEA/532090/2007– Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-bovilis-bvdbovilis-bvd-md-background-information_sv.pdf"}},
    {"id":"28877","name":"Buflomedil - Article 107 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-13T02:00:00Z","last_updated_date":"2012-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/buflomedil-article-107-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/buflomedil-article-107-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/buflomedil-article-107-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/buflomedil-article-107-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/buflomedil-article-107-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/buflomedil-article-107-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/buflomedil-article-107-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/buflomedil-article-107-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/buflomedil-article-107-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/buflomedil-article-107-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/buflomedil-article-107-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/buflomedil-article-107-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/buflomedil-article-107-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/buflomedil-article-107-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/buflomedil-article-107-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/buflomedil-article-107-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/buflomedil-article-107-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/buflomedil-article-107-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/buflomedil-article-107-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/buflomedil-article-107-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/buflomedil-article-107-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/buflomedil-article-107-referral-annex-iii_sv.pdf"}},
    {"id":"28931","name":"Ketoprofen - Article 107 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ketoprofen-article-107-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ketoprofen-article-107-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ketoprofen-article-107-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ketoprofen-article-107-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ketoprofen-article-107-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ketoprofen-article-107-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ketoprofen-article-107-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ketoprofen-article-107-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ketoprofen-article-107-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ketoprofen-article-107-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ketoprofen-article-107-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ketoprofen-article-107-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ketoprofen-article-107-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ketoprofen-article-107-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ketoprofen-article-107-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ketoprofen-article-107-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ketoprofen-article-107-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ketoprofen-article-107-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ketoprofen-article-107-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ketoprofen-article-107-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ketoprofen-article-107-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ketoprofen-article-107-referral-annex-ii_sv.pdf"}},
    {"id":"28939","name":"Sabumalin - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-30T02:08:21Z","last_updated_date":"2009-03-30T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sabumalin-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"28955","name":"Factor VIII Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2017-07-27T19:30:00Z","reference_number":"EMA/PRAC/471536/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"28978","name":"Iffeza - Article 29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-25T02:00:00Z","last_updated_date":"2012-10-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/iffeza-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/iffeza-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/iffeza-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/iffeza-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/iffeza-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/iffeza-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/iffeza-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/iffeza-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/iffeza-article-29-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/iffeza-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/iffeza-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/iffeza-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/iffeza-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/iffeza-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/iffeza-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/iffeza-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/iffeza-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/iffeza-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/iffeza-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/iffeza-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/iffeza-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/iffeza-article-29-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/iffeza-article-29-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/iffeza-article-29-referral-annex-iii_no.pdf"}},
    {"id":"28980","name":"Diacerein Article-31 referral - CMDh divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-19T02:00:00Z","last_updated_date":"2014-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-cmdh-divergent-position_en.pdf"},
    {"id":"28984","name":"Meprobamate - Article 107 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-06-08T16:15:00Z","last_updated_date":"2012-06-08T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/meprobamate-article-107-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/meprobamate-article-107-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/meprobamate-article-107-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/meprobamate-article-107-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/meprobamate-article-107-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/meprobamate-article-107-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/meprobamate-article-107-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/meprobamate-article-107-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/meprobamate-article-107-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/meprobamate-article-107-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/meprobamate-article-107-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/meprobamate-article-107-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/meprobamate-article-107-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/meprobamate-article-107-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/meprobamate-article-107-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/meprobamate-article-107-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/meprobamate-article-107-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/meprobamate-article-107-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/meprobamate-article-107-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/meprobamate-article-107-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/meprobamate-article-107-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/meprobamate-article-107-referral-annex-ii_sv.pdf"}},
    {"id":"29013","name":"Dexrazoxane - Article 31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-01-16T01:00:00Z","last_updated_date":"2012-01-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexrazoxane-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexrazoxane-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexrazoxane-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexrazoxane-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexrazoxane-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexrazoxane-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexrazoxane-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexrazoxane-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexrazoxane-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexrazoxane-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexrazoxane-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexrazoxane-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexrazoxane-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexrazoxane-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexrazoxane-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexrazoxane-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexrazoxane-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexrazoxane-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexrazoxane-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexrazoxane-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexrazoxane-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexrazoxane-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/dexrazoxane-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/dexrazoxane-article-31-referral-annex-i_no.pdf"}},
    {"id":"29019","name":"Fibrin sealants Article 31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrin-sealants-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrin-sealants-article-31-referral-annex-i_bg.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrin-sealants-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrin-sealants-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrin-sealants-article-31-referral-annex-i_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrin-sealants-article-31-referral-annex-i_el.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrin-sealants-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrin-sealants-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrin-sealants-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fibrin-sealants-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrin-sealants-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrin-sealants-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrin-sealants-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrin-sealants-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrin-sealants-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrin-sealants-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrin-sealants-article-31-referral-annex-i_sl.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrin-sealants-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/fibrin-sealants-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/fibrin-sealants-article-31-referral-annex-i_no.pdf"}},
    {"id":"29030","name":"Dolovet Rifen - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-16T00:59:00Z","last_updated_date":"2007-11-16T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dolovet-rifen-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"29048","name":"Opinion following an Article-35 referral for Hipralona Enro-S and its generics indicated for use in rabbits","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-02-04T01:00:00Z","last_updated_date":"2013-02-04T01:00:00Z","reference_number":"EMA/789897/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-hipralona-enro-s-and-its-generics-indicated-use-rabbits_sv.pdf"}},
    {"id":"29057","name":"Opinion following an Article 30 referral for Efexor and associated names International Non-Proprietary Name (INN): venlafaxine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-12-03T00:08:21Z","last_updated_date":"2008-12-03T00:08:21Z","reference_number":"EMEA/CHMP/384875/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-efexor-and-associated-names-international-non-proprietary-name-inn-venlafaxine-background-information_sv.pdf"}},
    {"id":"29059","name":"Leflunomide Apotex Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leflunomide-apotex-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"29110","name":"Hydroxyethyl starch Article-107i referral - CMDh endorses PRAC recommendation","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T01:00:00Z","last_updated_date":"2018-02-02T01:00:00Z","reference_number":"EMA/35795/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-cmdh-endorses-prac-recommendation_en.pdf"},
    {"id":"29164","name":"Etopophos Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-14T18:00:00Z","last_updated_date":"2017-07-14T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etopophos-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/etopophos-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/etopophos-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etopophos-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etopophos-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etopophos-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etopophos-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etopophos-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etopophos-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/etopophos-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etopophos-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etopophos-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etopophos-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etopophos-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/etopophos-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etopophos-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etopophos-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etopophos-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/etopophos-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etopophos-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etopophos-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etopophos-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etopophos-article-30-referral-annex-i_sv.pdf"}},
    {"id":"29167","name":"Protelos Article-20 procedure - Product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-18T02:00:00Z","last_updated_date":"2014-09-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/protelos-article-20-procedure-product-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/protelos-article-20-procedure-product-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/protelos-article-20-procedure-product-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/protelos-article-20-procedure-product-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/protelos-article-20-procedure-product-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/protelos-article-20-procedure-product-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/protelos-article-20-procedure-product-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/protelos-article-20-procedure-product-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/protelos-article-20-procedure-product-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/protelos-article-20-procedure-product-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/protelos-article-20-procedure-product-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/protelos-article-20-procedure-product-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/protelos-article-20-procedure-product-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/protelos-article-20-procedure-product-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/protelos-article-20-procedure-product-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/protelos-article-20-procedure-product-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/protelos-article-20-procedure-product-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/protelos-article-20-procedure-product-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/protelos-article-20-procedure-product-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/protelos-article-20-procedure-product-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/protelos-article-20-procedure-product-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/protelos-article-20-procedure-product-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/protelos-article-20-procedure-product-information_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/protelos-article-20-procedure-product-information_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/protelos-article-20-procedure-product-information_no.pdf"}},
    {"id":"29209","name":"Inductos Article-20 procedure - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-12-07T01:00:00Z","last_updated_date":"2015-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/inductos-article-20-procedure-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/inductos-article-20-procedure-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/inductos-article-20-procedure-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/inductos-article-20-procedure-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/inductos-article-20-procedure-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/inductos-article-20-procedure-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/inductos-article-20-procedure-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/inductos-article-20-procedure-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/inductos-article-20-procedure-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/inductos-article-20-procedure-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/inductos-article-20-procedure-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/inductos-article-20-procedure-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/inductos-article-20-procedure-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/inductos-article-20-procedure-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/inductos-article-20-procedure-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/inductos-article-20-procedure-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/inductos-article-20-procedure-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/inductos-article-20-procedure-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/inductos-article-20-procedure-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/inductos-article-20-procedure-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/inductos-article-20-procedure-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/inductos-article-20-procedure-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/inductos-article-20-procedure-annex-ii_sv.pdf"}},
    {"id":"29223","name":"Extraneal - Article 6(12) referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-02-10T00:59:00Z","last_updated_date":"2010-02-10T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/extraneal-article-612-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"29253","name":"Lescol - Article 30 referrals - Annex I-III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-11-20T01:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lescol-article-30-referrals-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lescol-article-30-referrals-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lescol-article-30-referrals-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lescol-article-30-referrals-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lescol-article-30-referrals-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lescol-article-30-referrals-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lescol-article-30-referrals-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lescol-article-30-referrals-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lescol-article-30-referrals-annex-i-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lescol-article-30-referrals-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lescol-article-30-referrals-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lescol-article-30-referrals-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lescol-article-30-referrals-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lescol-article-30-referrals-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lescol-article-30-referrals-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lescol-article-30-referrals-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lescol-article-30-referrals-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lescol-article-30-referrals-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lescol-article-30-referrals-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lescol-article-30-referrals-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lescol-article-30-referrals-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lescol-article-30-referrals-annex-i-iii_sv.pdf"}},
    {"id":"29285","name":"Diacerein Article-31 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-19T02:00:00Z","last_updated_date":"2014-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"29305","name":"Questions and answers on the suspension of oral buflomedil-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/377431/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-suspension-oral-buflomedil-containing-medicines_en.pdf"},
    {"id":"29362","name":"Methysergide Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-27T02:00:00Z","last_updated_date":"2014-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methysergide-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methysergide-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methysergide-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methysergide-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methysergide-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methysergide-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methysergide-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methysergide-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methysergide-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methysergide-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methysergide-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methysergide-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methysergide-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methysergide-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methysergide-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methysergide-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methysergide-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methysergide-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methysergide-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methysergide-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methysergide-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methysergide-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methysergide-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"29377","name":"Girolan Article-34 referral - Questions and answers on Girolan and its associated name Apralan","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-15T02:00:00Z","last_updated_date":"2018-06-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/girolan-article-34-referral-questions-and-answers-girolan-and-its-associated-name-apralan_sv.pdf"}},
    {"id":"29404","name":"Elements recommended for inclusion in Summaries of Product Characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-07-14T02:08:21Z","last_updated_date":"2009-07-14T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/elements-recommended-inclusion-summaries-product-characteristics-methylphenidate-containing-medicinal-products-authorised-treatment-adhd-children-aged-six-years-and-above-and-adolescents_en.pdf"},
    {"id":"29409","name":"Valproate Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/valproate-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/valproate-article-31-referral-annex-iii_no.pdf"}},
    {"id":"29410","name":"Questions and answers on the referral for Sanohex salbutamol, metered dose aerosol inhaler, 100 μg/dose","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-18T00:08:21Z","last_updated_date":"2009-03-18T00:08:21Z","reference_number":"EMEA/CHMP/194790/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_sv.pdf"}},
    {"id":"29421","name":"Septanest Article-30 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-12-04T11:25:00Z","reference_number":"EMA/CHMP/382271/2018 rev3","document_url":"https://www.ema.europa.eu/en/documents/referral/septanest-article-30-referral-timetable-procedure_en.pdf"},
    {"id":"29425","name":"Plendil - Article 30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-03-30T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/plendil-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/plendil-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/plendil-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/plendil-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/plendil-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/plendil-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/plendil-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/plendil-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/plendil-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/plendil-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/plendil-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/plendil-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/plendil-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/plendil-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/plendil-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/plendil-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/plendil-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/plendil-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/plendil-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/plendil-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/plendil-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/plendil-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/plendil-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"29449","name":"Doxazosin \"Winthrop\" 4mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-11T02:08:21Z","last_updated_date":"2009-10-11T02:08:21Z","reference_number":"CHMP/423591/06","document_url":"https://www.ema.europa.eu/en/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/doxazosin-winthrop-4mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"29465","name":"SGLT2 inhibitors Article-20 procedure - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-03-10T13:00:00Z","last_updated_date":"2016-03-10T13:00:00Z","reference_number":"EMA/PRAC/50218/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-assessment-report_en.pdf"},
    {"id":"29472","name":"Methadone Article-107i procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-04T02:00:00Z","last_updated_date":"2014-08-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methadone-article-107i-procedure-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methadone-article-107i-procedure-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methadone-article-107i-procedure-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methadone-article-107i-procedure-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methadone-article-107i-procedure-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methadone-article-107i-procedure-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methadone-article-107i-procedure-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methadone-article-107i-procedure-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methadone-article-107i-procedure-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methadone-article-107i-procedure-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methadone-article-107i-procedure-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methadone-article-107i-procedure-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methadone-article-107i-procedure-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methadone-article-107i-procedure-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methadone-article-107i-procedure-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methadone-article-107i-procedure-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methadone-article-107i-procedure-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methadone-article-107i-procedure-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methadone-article-107i-procedure-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methadone-article-107i-procedure-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methadone-article-107i-procedure-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methadone-article-107i-procedure-annex-i_sv.pdf"}},
    {"id":"29515","name":"Maci Article-20 procedure - Closure of EU manufacturing site for Maci","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"EMA/562790/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/maci-article-20-procedure-closure-eu-manufacturing-site-maci_sv.pdf"}},
    {"id":"29540","name":"Questions and answers on the referral for Topamax and associated names topiramate tablets and capsules - Final","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-12-15T00:08:21Z","last_updated_date":"2009-12-15T00:08:21Z","reference_number":"EMEA/CHMP/660222/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_sv.pdf"}},
    {"id":"29547","name":"Lipitor - Article 30 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-10T02:00:00Z","last_updated_date":"2012-04-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lipitor-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lipitor-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lipitor-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lipitor-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lipitor-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lipitor-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lipitor-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lipitor-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lipitor-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lipitor-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lipitor-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lipitor-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lipitor-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lipitor-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lipitor-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lipitor-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lipitor-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lipitor-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lipitor-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lipitor-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lipitor-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lipitor-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"29557","name":"Cozaar - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-25T02:08:21Z","last_updated_date":"2008-09-25T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cozaar-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"29566","name":"Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-12T18:00:00Z","last_updated_date":"2014-03-12T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-i_sv.pdf"}},
    {"id":"29570","name":"Quinolone and fluoroquinolone Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-10T01:00:00Z","last_updated_date":"2017-02-10T01:00:00Z","reference_number":"EMA/85325/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-notification_en.pdf"},
    {"id":"29581","name":"Almitrine Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-referral-notification_en.pdf"},
    {"id":"29633","name":"Arimidex - Article 30 referral - Assessment Report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/418072/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/arimidex-article-30-referral-assessment-report_en.pdf"},
    {"id":"29677","name":"Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names: Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T01:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-annex-i-ii-iii_sv.pdf"}},
    {"id":"29725","name":"Levothyroxine Alapis - Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-02-15T01:00:00Z","last_updated_date":"2013-02-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levothyroxine-alapis-article-294-referral-annex-i_sv.pdf"}},
    {"id":"29734","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T16:00:00Z","last_updated_date":"2017-03-09T16:00:00Z","reference_number":"EMA/141732/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_sv.pdf"}},
    {"id":"29794","name":"Valproate Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T13:00:00Z","last_updated_date":"2017-03-10T13:00:00Z","reference_number":"EMA/144306/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-review-started_en.pdf"},
    {"id":"29797","name":"Cymevene Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-06-21T02:00:00Z","last_updated_date":"2016-06-21T02:00:00Z","reference_number":"EMEA/H/A-30/1406","document_url":"https://www.ema.europa.eu/en/documents/referral/cymevene-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cymevene-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cymevene-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cymevene-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cymevene-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cymevene-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cymevene-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cymevene-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cymevene-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cymevene-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cymevene-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cymevene-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cymevene-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cymevene-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cymevene-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cymevene-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cymevene-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cymevene-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cymevene-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cymevene-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cymevene-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cymevene-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cymevene-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/cymevene-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/cymevene-article-30-referral-annex-i_no.pdf"}},
    {"id":"29819","name":"Questions and answers on the review of medicines containing methylphenidate","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-01-23T00:08:21Z","last_updated_date":"2009-01-23T00:08:21Z","reference_number":"EMEA/658285/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-medicines-containing-methylphenidate_en.pdf"},
    {"id":"29825","name":"Renin-angiotensin-system (RAS)-acting agents Article-31 referral - Scientific conclusion - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-08T02:00:00Z","last_updated_date":"2014-10-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-scientific-conclusion-annex-i_sv.pdf"}},
    {"id":"29829","name":"Doxagamma 4 mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-10-11T02:08:21Z","last_updated_date":"2006-10-11T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/doxagamma-4-mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"29848","name":"Questions and answers on the review of oral formulations of medicines containing norfloxacin","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/378867/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-oral-formulations-medicines-containing-norfloxacin_en.pdf"},
    {"id":"29861","name":"Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_sv.pdf"}},
    {"id":"29920","name":"Numeta Article-107i procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-review-started_en.pdf"},
    {"id":"29931","name":"SGLT2 inhibitors Article-20 procedure - PRAC makes recommendations to minimise risk of diabetic ketoacidosis","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-12T01:00:00Z","last_updated_date":"2016-02-12T01:00:00Z","reference_number":"EMA/100751/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-prac-makes-recommendations-minimise-risk-diabetic-ketoacidosis_en.pdf"}    {"id":"29979","name":"Iclusig Article-20 procedure - PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-10T14:00:00Z","last_updated_date":"2014-10-10T14:00:00Z","reference_number":"EMA/615086/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-prac-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_en.pdf"},
    {"id":"30009","name":"Testosterone Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-08T01:00:00Z","last_updated_date":"2015-01-08T01:00:00Z","reference_number":"EMEA/H/A-31/1396","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/testosterone-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/testosterone-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/testosterone-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/testosterone-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/testosterone-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/testosterone-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/testosterone-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/testosterone-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/testosterone-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/testosterone-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/testosterone-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/testosterone-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/testosterone-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/testosterone-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/testosterone-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/testosterone-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/testosterone-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/testosterone-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/testosterone-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/testosterone-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/testosterone-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/testosterone-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"30117","name":"Augmentin - Article 30 - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T01:00:00Z","last_updated_date":"2013-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/augmentin-article-30-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/augmentin-article-30-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/augmentin-article-30-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/augmentin-article-30-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/augmentin-article-30-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/augmentin-article-30-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/augmentin-article-30-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/augmentin-article-30-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/augmentin-article-30-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/augmentin-article-30-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/augmentin-article-30-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/augmentin-article-30-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/augmentin-article-30-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/augmentin-article-30-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/augmentin-article-30-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/augmentin-article-30-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/augmentin-article-30-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/augmentin-article-30-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/augmentin-article-30-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/augmentin-article-30-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/augmentin-article-30-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/augmentin-article-30-annex-i_sv.pdf"}},
    {"id":"30164","name":"Gadolinium Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T01:00:00Z","last_updated_date":"2016-03-18T01:00:00Z","reference_number":"EMA/200364/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-review-started_en.pdf"},
    {"id":"30194","name":"Valproate and related substances Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"EMA/620381/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-review-started_en.pdf"},
    {"id":"30216","name":"Belanette - Article 5(11) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-07-03T02:08:21Z","last_updated_date":"2008-07-03T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/belanette-article-511-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/belanette-article-511-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/belanette-article-511-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/belanette-article-511-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/belanette-article-511-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/belanette-article-511-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/belanette-article-511-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/belanette-article-511-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/belanette-article-511-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/belanette-article-511-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/belanette-article-511-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/belanette-article-511-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/belanette-article-511-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/belanette-article-511-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/belanette-article-511-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/belanette-article-511-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/belanette-article-511-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/belanette-article-511-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/belanette-article-511-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/belanette-article-511-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/belanette-article-511-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/belanette-article-511-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"30229","name":"Hiprabovis Pneumos - Article 78 referral - Divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-12-09T01:00:00Z","last_updated_date":"2011-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hiprabovis-pneumos-article-78-referral-divergent-position_en.pdf"},
    {"id":"30248","name":"Zinnat - Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-29T01:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinnat-article-30-referral-annex-ii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinnat-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinnat-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinnat-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinnat-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinnat-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinnat-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinnat-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinnat-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinnat-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinnat-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinnat-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinnat-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinnat-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinnat-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinnat-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinnat-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinnat-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinnat-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinnat-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinnat-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinnat-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"30252","name":"Summary information on a referral opinion following an arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Lederfoline and associated names (see Annex I) International Non-Proprietary Name (INN): calci...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-06-30T02:08:21Z","last_updated_date":"2003-06-30T02:08:21Z","reference_number":"EMEA/CPMP/3736/03","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-lederfoline-and-associated-names-see-annex-i-international-non-proprietary-name-inn-calci_sv.pdf"}},
    {"id":"30253","name":"SGLT2 inhibitors Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-12T14:00:00Z","last_updated_date":"2015-10-09T13:00:00Z","reference_number":"EMA/PRAC/391289/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"30263","name":"Haldol Decanoate Article-30 - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T13:00:00Z","last_updated_date":"2017-05-11T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/haldol-decanoate-article-30-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/haldol-decanoate-article-30-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/haldol-decanoate-article-30-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/haldol-decanoate-article-30-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/haldol-decanoate-article-30-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/haldol-decanoate-article-30-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/haldol-decanoate-article-30-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/haldol-decanoate-article-30-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/haldol-decanoate-article-30-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/haldol-decanoate-article-30-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/haldol-decanoate-article-30-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/haldol-decanoate-article-30-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/haldol-decanoate-article-30-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/haldol-decanoate-article-30-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/haldol-decanoate-article-30-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/haldol-decanoate-article-30-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/haldol-decanoate-article-30-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/haldol-decanoate-article-30-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/haldol-decanoate-article-30-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/haldol-decanoate-article-30-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/haldol-decanoate-article-30-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/haldol-decanoate-article-30-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/haldol-decanoate-article-30-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/haldol-decanoate-article-30-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/haldol-decanoate-article-30-annex-iii_no.pdf"}},
    {"id":"30286","name":"Gadolinium Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-12-04T16:00:00Z","last_updated_date":"2017-12-04T16:00:00Z","reference_number":"EMA/411650/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-assessment-report_en.pdf"},
    {"id":"30304","name":"Questions and answers on Bicalutamide 150 mg tablets","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-05-24T02:08:21Z","last_updated_date":"2007-05-24T02:08:21Z","reference_number":"EMEA/218760/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-bicalutamide-150-mg-tablets_en.pdf"},
    {"id":"30307","name":"Alpha2-adrenoreceptor agonists - Article 78 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-23T01:59:00Z","last_updated_date":"2009-06-23T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/alpha2-adrenoreceptor-agonists-article-78-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"30321","name":"Canazole - Article 29 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-09T01:00:00Z","last_updated_date":"2012-02-09T01:00:00Z","reference_number":"EMEA/H/A-29/1286","document_url":"https://www.ema.europa.eu/en/documents/referral/canazole-article-29-referral-assessment-report_en.pdf"},
    {"id":"30335","name":"Paracetamol/ibuprofen 500mg/150mg Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-08-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"30337","name":"Tysabri Article-20 procedure - Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-12T01:00:00Z","last_updated_date":"2016-02-12T01:00:00Z","reference_number":"EMA/85655/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/tysabri-article-20-procedure-updated-recommendations-minimise-risk-rare-brain-infection-pml-tysabri_en.pdf"},
    {"id":"30364","name":"Lactose of bovine origin Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-08-08T14:00:00Z","last_updated_date":"2017-08-08T14:00:00Z","reference_number":"EMA/459263/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"30376","name":"Opinion following an Article-35 referral for veterinary medicinal products containing tylosin to be administered orally via feed or the drinking water to pigs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-05T13:00:00Z","last_updated_date":"2014-09-05T13:00:00Z","reference_number":"EMA/492247/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_da.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs_sv.pdf"}},
    {"id":"30392","name":"Etopophos Article-30 referral - Questions and answers on Etopophos and associated names (etoposide, 100 and 1000 mg powder for solution for infusion)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"EMEA/H/A-30/001417","document_url":"https://www.ema.europa.eu/en/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etopophos-article-30-referral-questions-and-answers-etopophos-and-associated-names-etoposide-100-and-1000-mg-powder-solution-infusion_sv.pdf"}},
    {"id":"30400","name":"Linoladiol N and Linoladiol HN Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T15:00:00Z","last_updated_date":"2014-09-11T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"30432","name":"Cozaar Comp - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-25T02:08:21Z","last_updated_date":"2008-09-25T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cozaar-comp-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"30464","name":"Substances related to nicotinic acid Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-08-15T02:00:00Z","reference_number":"EMA/136363/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-review-started_en.pdf"},
    {"id":"30508","name":"Seresto Article-13 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-10T02:00:00Z","last_updated_date":"2018-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/seresto-article-13-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/seresto-article-13-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/seresto-article-13-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seresto-article-13-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seresto-article-13-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seresto-article-13-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seresto-article-13-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seresto-article-13-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seresto-article-13-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/seresto-article-13-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seresto-article-13-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seresto-article-13-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seresto-article-13-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seresto-article-13-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/seresto-article-13-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seresto-article-13-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seresto-article-13-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seresto-article-13-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/seresto-article-13-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seresto-article-13-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seresto-article-13-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seresto-article-13-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seresto-article-13-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"30510","name":"Gadolinium - Article 31 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-09-01T02:00:00Z","last_updated_date":"2010-09-01T02:00:00Z","reference_number":"Doc. Ref. EMEA/727399/2009 Annex","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gadolinium-article-31-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"30544","name":"Short-acting beta-agonists Article-31 referral - PRAC recommends restricted use of short-acting beta-agonists in obstetric indications","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-06T02:00:00Z","last_updated_date":"2013-09-06T02:00:00Z","reference_number":"EMA/533740/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-prac-recommends-restricted-use-short-acting-beta-agonists-obstetric-indications_en.pdf"},
    {"id":"30553","name":"Inductos Article-20 procedure - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-12-07T01:00:00Z","last_updated_date":"2015-12-07T01:00:00Z","reference_number":"EMA/746527/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/inductos-article-20-procedure-assessment-report_en.pdf"},
    {"id":"30573","name":"Dectomax injectable solution Article-34 referral - Annex I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-13T02:00:00Z","last_updated_date":"2014-08-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dectomax-injectable-solution-article-34-referral-annex-i-ii_sv.pdf"}},
    {"id":"30579","name":"Genotropin - Article 6(12) referral - Annex I, II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-26T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/genotropin-article-612-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/genotropin-article-612-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/genotropin-article-612-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/genotropin-article-612-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/genotropin-article-612-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/genotropin-article-612-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/genotropin-article-612-referral-annex-i-ii_et.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/genotropin-article-612-referral-annex-i-ii_fr.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/genotropin-article-612-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/genotropin-article-612-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/genotropin-article-612-referral-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/genotropin-article-612-referral-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/genotropin-article-612-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/genotropin-article-612-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/genotropin-article-612-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/genotropin-article-612-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/genotropin-article-612-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/genotropin-article-612-referral-annex-i-ii_sl.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/genotropin-article-612-referral-annex-i-ii_sv.pdf"}},
    {"id":"30585","name":"Hiprabovis Pneumos emulsion - Article 78 referral - Annex I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-12-09T01:00:00Z","last_updated_date":"2011-12-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hiprabovis-pneumos-emulsion-article-78-referral-annex-i-ii_sv.pdf"}},
    {"id":"30591","name":"Opinion following an Article 33(4)1 referral for Prontax 5 mg/ml pour-on solution for cattle and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-07-05T02:00:00Z","last_updated_date":"2012-07-05T02:00:00Z","reference_number":"EMA/283286/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-3341-referral-prontax-5-mgml-pour-solution-cattle-and-associated-names_sv.pdf"}},
    {"id":"30595","name":"Calcitonin Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-19T02:00:00Z","last_updated_date":"2013-07-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/calcitonin-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/calcitonin-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/calcitonin-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/calcitonin-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/calcitonin-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/calcitonin-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/calcitonin-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/calcitonin-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/calcitonin-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/calcitonin-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/calcitonin-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/calcitonin-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/calcitonin-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/calcitonin-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/calcitonin-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/calcitonin-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/calcitonin-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/calcitonin-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/calcitonin-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/calcitonin-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/calcitonin-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/calcitonin-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/calcitonin-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/calcitonin-article-31-referral-annex-i_no.pdf"}},
    {"id":"30644","name":"Cardioxane Article 13 referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-26T11:42:00Z","last_updated_date":"2017-07-26T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cardioxane-article-13-referral-chmp-assessment-report_en.pdf"},
    {"id":"30649","name":"Modified-release oral opioids - Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/modified-release-oral-opioids-article-31-referral-annex-iii_no.pdf"}},
    {"id":"30652","name":"Opinion following an Article 34 referral for Synulox Lactating Cow and associated names: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-11-17T12:00:00Z","last_updated_date":"2011-11-17T12:00:00Z","reference_number":"EMA/512798/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-synulox-lactating-cow-and-associated-names-background-information_sv.pdf"}},
    {"id":"30669","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - PRAC recommendations on Diane 35: Questions and answers","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T14:00:00Z","last_updated_date":"2013-05-17T14:00:00Z","reference_number":"EMA/280182/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-prac-recommendations-diane-35-questions-and-answers_en.pdf"},
    {"id":"30681","name":"Methadone Article-107i procedure - Rationale for triggering","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-rationale-triggering_en.pdf"},
    {"id":"30704","name":"Calcium Sandoz - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-08-10T01:59:00Z","last_updated_date":"2005-08-10T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/calcium-sandoz-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"30757","name":"Baxter dialysis solutions Article-31 referral - Annex II (3 sites)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-ii-3-sites_sv.pdf"}},
    {"id":"30811","name":"Trimetazidine - Article 31 - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-17T02:00:00Z","last_updated_date":"2012-10-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/trimetazidine-article-31-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/trimetazidine-article-31-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/trimetazidine-article-31-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/trimetazidine-article-31-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/trimetazidine-article-31-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/trimetazidine-article-31-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/trimetazidine-article-31-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/trimetazidine-article-31-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/trimetazidine-article-31-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/trimetazidine-article-31-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/trimetazidine-article-31-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/trimetazidine-article-31-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/trimetazidine-article-31-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/trimetazidine-article-31-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/trimetazidine-article-31-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/trimetazidine-article-31-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/trimetazidine-article-31-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/trimetazidine-article-31-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/trimetazidine-article-31-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/trimetazidine-article-31-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/trimetazidine-article-31-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/trimetazidine-article-31-annex-i_sv.pdf"}},
    {"id":"30828","name":"Seroquel, Seroquel XR and associated names Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-09T02:00:00Z","last_updated_date":"2014-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-i_no.pdf"}},
    {"id":"30839","name":"Divergent position on a CVMP opinion on an Article 35 referral of Directive 2001/82/EC for Baytril 2.5% injectable, Baytril 5% injectable, Baytril 10%\n\ninjectable and associated names, and related veterinary medicinal pr...","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T01:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-35-referral-directive-200182ec-baytril-25-injectable-baytril-5-injectable-baytril-10-injectable-and-associated-names-and-related-veterinary-medicinal-pr_en.pdf"},
    {"id":"30871","name":"Diovan - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-12T00:08:21Z","last_updated_date":"2009-03-12T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diovan-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diovan-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diovan-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diovan-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diovan-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diovan-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diovan-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diovan-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diovan-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diovan-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diovan-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diovan-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diovan-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diovan-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diovan-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diovan-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diovan-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diovan-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diovan-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diovan-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diovan-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diovan-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"30890","name":"Scandonest Article-30 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/599131/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/scandonest-article-30-referral-review-started_en.pdf"},
    {"id":"30923","name":"Myoson and associated names Article-29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-07-28T02:00:00Z","last_updated_date":"2015-07-28T02:00:00Z","reference_number":"EMA/445101/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/myoson-and-associated-names-article-294-referral-assessment-report_en.pdf"},
    {"id":"30961","name":"Methotrexate Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T02:00:00Z","last_updated_date":"2019-05-17T02:00:00Z","reference_number":"EMA/PRAC/199744/2018 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"30998","name":"Cilazapril Teva Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cilazapril-teva-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cilazapril-teva-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cilazapril-teva-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cilazapril-teva-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cilazapril-teva-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cilazapril-teva-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cilazapril-teva-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cilazapril-teva-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cilazapril-teva-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cilazapril-teva-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cilazapril-teva-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cilazapril-teva-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cilazapril-teva-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cilazapril-teva-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cilazapril-teva-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cilazapril-teva-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cilazapril-teva-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cilazapril-teva-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cilazapril-teva-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cilazapril-teva-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cilazapril-teva-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cilazapril-teva-article-31-referral-annex-i_sv.pdf"}},
    {"id":"31002","name":"Procoralan Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2015-02-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/procoralan-article-20-procedure-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/procoralan-article-20-procedure-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/procoralan-article-20-procedure-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/procoralan-article-20-procedure-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/procoralan-article-20-procedure-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/procoralan-article-20-procedure-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/procoralan-article-20-procedure-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/procoralan-article-20-procedure-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/procoralan-article-20-procedure-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/procoralan-article-20-procedure-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/procoralan-article-20-procedure-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/procoralan-article-20-procedure-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/procoralan-article-20-procedure-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/procoralan-article-20-procedure-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/procoralan-article-20-procedure-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/procoralan-article-20-procedure-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/procoralan-article-20-procedure-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/procoralan-article-20-procedure-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/procoralan-article-20-procedure-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/procoralan-article-20-procedure-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/procoralan-article-20-procedure-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/procoralan-article-20-procedure-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/procoralan-article-20-procedure-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/procoralan-article-20-procedure-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/procoralan-article-20-procedure-annex-iii_no.pdf"}},
    {"id":"31010","name":"Myoson Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-28T02:00:00Z","last_updated_date":"2015-07-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/myoson-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/myoson-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/myoson-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/myoson-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/myoson-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/myoson-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/myoson-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/myoson-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/myoson-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/myoson-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/myoson-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/myoson-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/myoson-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/myoson-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/myoson-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/myoson-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/myoson-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/myoson-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/myoson-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/myoson-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/myoson-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/myoson-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/myoson-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"31059","name":"Somatropin - Article 107 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-23T02:00:00Z","last_updated_date":"2012-04-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/somatropin-article-107-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/somatropin-article-107-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/somatropin-article-107-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/somatropin-article-107-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/somatropin-article-107-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/somatropin-article-107-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/somatropin-article-107-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/somatropin-article-107-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/somatropin-article-107-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/somatropin-article-107-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/somatropin-article-107-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/somatropin-article-107-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/somatropin-article-107-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/somatropin-article-107-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/somatropin-article-107-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/somatropin-article-107-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/somatropin-article-107-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/somatropin-article-107-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/somatropin-article-107-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/somatropin-article-107-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/somatropin-article-107-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/somatropin-article-107-referral-annex-iii_sv.pdf"}},
    {"id":"31065","name":"Levonelle Article-13 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-08-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/levonelle-article-13-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levonelle-article-13-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levonelle-article-13-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levonelle-article-13-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levonelle-article-13-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levonelle-article-13-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levonelle-article-13-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levonelle-article-13-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levonelle-article-13-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/levonelle-article-13-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levonelle-article-13-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levonelle-article-13-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levonelle-article-13-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levonelle-article-13-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levonelle-article-13-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levonelle-article-13-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levonelle-article-13-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levonelle-article-13-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levonelle-article-13-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levonelle-article-13-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levonelle-article-13-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levonelle-article-13-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levonelle-article-13-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/levonelle-article-13-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/levonelle-article-13-referral-annex-iii_no.pdf"}},
    {"id":"31085","name":"Maci Article-20 procedure - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-17T01:00:00Z","last_updated_date":"2014-12-17T01:00:00Z","reference_number":"EMA/671958/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/maci-article-20-procedure-assessment-report_en.pdf"},
    {"id":"31105","name":"Flupirtine-containing medicines Article-107i procedure - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-08T13:00:00Z","last_updated_date":"2013-03-08T13:00:00Z","reference_number":"EMA/147828/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-annex-i_en.pdf-0"},
    {"id":"31123","name":"Valproate and related substances Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-29T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-and-related-substances-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"31125","name":"Questions and answers on the referral for Budesonide Sandoz nasal suspension with 32 or 64 microgram per spray","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-03T02:08:21Z","last_updated_date":"2009-06-03T02:08:21Z","reference_number":"EMEA/CHMP/259505/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_sv.pdf"}},
    {"id":"31145","name":"Meprobamate - Article 107 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-06-08T16:15:00Z","last_updated_date":"2012-06-08T16:15:00Z","reference_number":"EMA/212617/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/meprobamate-article-107-referral-assessment-report_en.pdf"},
    {"id":"31146","name":"Etoricoxib, Celecoxib, Lumiracoxib, Parecoxib, and Valdecoxib - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-12-06T01:00:00Z","last_updated_date":"2005-12-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etoricoxib-celecoxib-lumiracoxib-parecoxib-and-valdecoxib-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"31160","name":"Gadolinium Article-31 referral – EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T01:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"EMA/625317/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_sv.pdf"}},
    {"id":"31164","name":"Fortum - Article 30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fortum-article-30-referral-annex-iii_en.pdf"},
    {"id":"31182","name":"Levothyroxine Alapis- Article 29 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-15T01:00:00Z","last_updated_date":"2013-02-15T01:00:00Z","reference_number":"EMA/701628/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/levothyroxine-alapis-article-29-referral-assessment-report_en.pdf"},
    {"id":"31183","name":"Opinion following an Article 5(11) referral for Yasminelle and associated names (see Annex I)  International Non-Proprietary Name (INN): Drospirenone + Ethinylestradiol: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-17T02:08:21Z","last_updated_date":"2008-06-17T02:08:21Z","reference_number":"EMEA/337156/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-511-referral-yasminelle-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_sv.pdf"}},
    {"id":"31258","name":"Pholcodine - Article 31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-03-28T02:00:00Z","last_updated_date":"2012-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pholcodine-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pholcodine-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pholcodine-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pholcodine-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pholcodine-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pholcodine-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pholcodine-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pholcodine-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pholcodine-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pholcodine-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pholcodine-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pholcodine-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pholcodine-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pholcodine-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pholcodine-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pholcodine-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pholcodine-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pholcodine-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pholcodine-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pholcodine-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pholcodine-article-31-referral-annex-i_sv.pdf"}},
    {"id":"31363","name":"Opinion following an Article 6(12) referral for Actira and associated names\n\nInternational Non-Proprietary Name (INN): moxifloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-08-14T02:08:21Z","last_updated_date":"2008-08-14T02:08:21Z","reference_number":"EMEA/CHMP/524135/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-612-referral-actira-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_sv.pdf"}},
    {"id":"31386","name":"Questions and answers on the referral for Extraneal icodextrin 7.5% solution for peritoneal dialysis","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-27T00:08:21Z","last_updated_date":"2010-02-10T00:08:21Z","reference_number":"EMEA/CHMP/683039/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-extraneal-icodextrin-75-solution-peritoneal-dialysis_sv.pdf"}},
    {"id":"31423","name":"Follow-up opinion following an Article 35 referral for Suramox 15 % LA and its associated name Stabox 15 % LA International Non-Proprietary Name (INN): Amoxicillin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-06T01:59:00Z","last_updated_date":"2008-09-06T01:59:00Z","reference_number":"EMEA/344321/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/follow-opinion-following-article-35-referral-suramox-15-la-and-its-associated-name-stabox-15-la-international-non-proprietary-name-inn-amoxicillin-background-information_sv.pdf"}},
    {"id":"31425","name":"Modified release oral opioids - Article 31 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/modified-release-oral-opioids-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"31427","name":"Gadolinium Article-31 referral – EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/457616/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_en.pdf-0"},
    {"id":"31445","name":"Activelle - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-09-25T02:08:21Z","last_updated_date":"2009-09-25T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/activelle-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/activelle-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/activelle-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/activelle-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/activelle-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/activelle-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/activelle-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/activelle-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/activelle-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/activelle-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/activelle-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/activelle-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/activelle-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/activelle-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/activelle-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/activelle-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/activelle-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/activelle-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/activelle-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/activelle-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/activelle-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/activelle-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"31449","name":"Mometasone Furoate Sandoz - Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T01:00:00Z","last_updated_date":"2013-01-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-i_sv.pdf"}},
    {"id":"31453","name":"Osseor Article-20 procedure - Product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-18T02:00:00Z","last_updated_date":"2014-09-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/osseor-article-20-procedure-product-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/osseor-article-20-procedure-product-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/osseor-article-20-procedure-product-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/osseor-article-20-procedure-product-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/osseor-article-20-procedure-product-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/osseor-article-20-procedure-product-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/osseor-article-20-procedure-product-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/osseor-article-20-procedure-product-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/osseor-article-20-procedure-product-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/osseor-article-20-procedure-product-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/osseor-article-20-procedure-product-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/osseor-article-20-procedure-product-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/osseor-article-20-procedure-product-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/osseor-article-20-procedure-product-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/osseor-article-20-procedure-product-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/osseor-article-20-procedure-product-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/osseor-article-20-procedure-product-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/osseor-article-20-procedure-product-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/osseor-article-20-procedure-product-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/osseor-article-20-procedure-product-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/osseor-article-20-procedure-product-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/osseor-article-20-procedure-product-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/osseor-article-20-procedure-product-information_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/osseor-article-20-procedure-product-information_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/osseor-article-20-procedure-product-information_no.pdf"}},
    {"id":"31463","name":"Metamizole Article-31 referral - List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T02:00:00Z","last_updated_date":"2018-06-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-list-questions_en.pdf"},
    {"id":"31514","name":"Kantos Master Article-13 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-02T12:00:00Z","last_updated_date":"2013-05-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kantos-master-article-13-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/kantos-master-article-13-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/kantos-master-article-13-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/kantos-master-article-13-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/kantos-master-article-13-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/kantos-master-article-13-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/kantos-master-article-13-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/kantos-master-article-13-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/kantos-master-article-13-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/kantos-master-article-13-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/kantos-master-article-13-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/kantos-master-article-13-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/kantos-master-article-13-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/kantos-master-article-13-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/kantos-master-article-13-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/kantos-master-article-13-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/kantos-master-article-13-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/kantos-master-article-13-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/kantos-master-article-13-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/kantos-master-article-13-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/kantos-master-article-13-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/kantos-master-article-13-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/kantos-master-article-13-referral-annex-i_no.pdf"}},
    {"id":"31524","name":"Diacerein Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-19T02:00:00Z","last_updated_date":"2014-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diacerein-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diacerein-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diacerein-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diacerein-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diacerein-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diacerein-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diacerein-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diacerein-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diacerein-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diacerein-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diacerein-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diacerein-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diacerein-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diacerein-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diacerein-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diacerein-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diacerein-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diacerein-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diacerein-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diacerein-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diacerein-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diacerein-article-31-referral-annex-i_sv.pdf"}},
    {"id":"31536","name":"Almitrine Article-31 referral - PRAC recommends withdrawal of oral almitrine-containing medicines: Questions and answers","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T14:00:00Z","last_updated_date":"2013-05-17T14:00:00Z","reference_number":"EMA/286565/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-referral-prac-recommends-withdrawal-oral-almitrine-containing-medicines-questions-and-answers_en.pdf"},
    {"id":"31543","name":"Florgane - Article-33 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-10T14:30:00Z","last_updated_date":"2013-07-10T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/florgane-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/florgane-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/florgane-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/florgane-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/florgane-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/florgane-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/florgane-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/florgane-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/florgane-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/florgane-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/florgane-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/florgane-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/florgane-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/florgane-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/florgane-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/florgane-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/florgane-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/florgane-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/florgane-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/florgane-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/florgane-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/florgane-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"31565","name":"Factor VIII Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-12-05T10:30:00Z","last_updated_date":"2017-12-05T10:30:00Z","reference_number":"EMA/763977/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-assessment-report_en.pdf"},
    {"id":"31595","name":"Esmya Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T13:00:00Z","last_updated_date":"2018-04-13T11:53:00Z","reference_number":"EMA/PRAC/791197/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"31608","name":"Final opinion of the Committee for proprietary medicinal products pursuant to Article 12 of Council Directive 75/319/EEC as amended for Chlormezanone and Annex C","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1997-09-22T02:08:21Z","last_updated_date":"1997-09-22T02:08:21Z","reference_number":"CPMP/375/97-EN","document_url":"https://www.ema.europa.eu/en/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-chlormezanone-and-annex-c_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-chlormezanone-and-annex-c_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-chlormezanone-and-annex-c_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/final-opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-chlormezanone-and-annex-c_fr.pdf"}},
    {"id":"31616","name":"Metformin Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-03T01:00:00Z","last_updated_date":"2016-12-21T01:00:00Z","reference_number":"EMA/82128/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metformin-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metformin-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metformin-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metformin-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metformin-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metformin-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metformin-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metformin-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metformin-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metformin-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metformin-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metformin-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metformin-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metformin-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metformin-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metformin-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metformin-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metformin-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metformin-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metformin-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metformin-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metformin-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/metformin-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/metformin-article-31-referral-annex-i_no.pdf"}},
    {"id":"31631","name":"Methylphenidate Hexal Article-29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-05T01:00:00Z","last_updated_date":"2013-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methylphenidate-hexal-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"31637","name":"Glimepirida Parke Davis - Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-06T01:00:00Z","last_updated_date":"2012-12-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/glimepirida-parke-davis-article-294-referral-annex-i_no.pdf"}},
    {"id":"31691","name":"Valsartan Art 31 - list NAPs and CAPs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T18:00:00Z","last_updated_date":"2019-05-17T16:16:00Z","reference_number":"EMA/480845/2018 rev2","document_url":"https://www.ema.europa.eu/en/documents/referral/valsartan-art-31-list-naps-and-caps_en.pdf"},
    {"id":"31702","name":"Assessment report for fibrinogen-containing solutions for sealant authorised for administration by spray application (Tisseel, Tissucol, Artiss, Beriplast P and associated names)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"EMA/96130/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-fibrinogen-containing-solutions-sealant-authorised-administration-spray-application-tisseel-tissucol-artiss-beriplast-p-and-associated-names_en.pdf"},
    {"id":"31741","name":"Opinion following an Article 30 referral for Xefo and associated names International Non-proprietary Name (INN): lornoxicam: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-05-29T02:08:21Z","last_updated_date":"2007-05-29T02:08:21Z","reference_number":"EMEA/144030/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-xefo-and-associated-names-international-non-proprietary-name-inn-lornoxicam-background-information_sv.pdf"}},
    {"id":"31760","name":"Questions and answers on Tazocin and associated names (piperacillin and tazobactam, 2/0.25 g and 4/0.5 g powder for solution for infusion)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"EMA/656918/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-tazocin-and-associated-names-piperacillin-and-tazobactam-2025-g-and-405-g-powder-solution-infusion_sv.pdf"}},
    {"id":"31820","name":"Ergot derivatives Article-31 referral - Dihydroergocryptine - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocryptine-annex-iii_sv.pdf"}},
    {"id":"31832","name":"Metoclopramide Article-31 referral - European Medicines Agency confirms changes to the use of metoclopramide","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T12:00:00Z","last_updated_date":"2014-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_sv.pdf"}},
    {"id":"31839","name":"Ketoconazole Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-06-13T02:00:00Z","last_updated_date":"2014-06-13T02:00:00Z","reference_number":"EMA/CHMP/580489/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/ketoconazole-article-31-referral-assessment-report_en.pdf"},
    {"id":"31845","name":"Oxynal, Targin Article-13 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T17:15:00Z","last_updated_date":"2015-01-27T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/oxynal-targin-article-13-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/oxynal-targin-article-13-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/oxynal-targin-article-13-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/oxynal-targin-article-13-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/oxynal-targin-article-13-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/oxynal-targin-article-13-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/oxynal-targin-article-13-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/oxynal-targin-article-13-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/oxynal-targin-article-13-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/oxynal-targin-article-13-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/oxynal-targin-article-13-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/oxynal-targin-article-13-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/oxynal-targin-article-13-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/oxynal-targin-article-13-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/oxynal-targin-article-13-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/oxynal-targin-article-13-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/oxynal-targin-article-13-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/oxynal-targin-article-13-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/oxynal-targin-article-13-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/oxynal-targin-article-13-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/oxynal-targin-article-13-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/oxynal-targin-article-13-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/oxynal-targin-article-13-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/oxynal-targin-article-13-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/oxynal-targin-article-13-referral-annex-i_no.pdf"}},
    {"id":"31851","name":"Zolpidem Article-31 - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-04T12:00:00Z","last_updated_date":"2014-08-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zolpidem-article-31-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zolpidem-article-31-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zolpidem-article-31-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zolpidem-article-31-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zolpidem-article-31-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zolpidem-article-31-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zolpidem-article-31-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zolpidem-article-31-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zolpidem-article-31-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zolpidem-article-31-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zolpidem-article-31-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zolpidem-article-31-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zolpidem-article-31-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zolpidem-article-31-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zolpidem-article-31-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zolpidem-article-31-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zolpidem-article-31-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zolpidem-article-31-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zolpidem-article-31-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zolpidem-article-31-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zolpidem-article-31-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zolpidem-article-31-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zolpidem-article-31-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/zolpidem-article-31-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/zolpidem-article-31-annex-ii_no.pdf"}},
    {"id":"31852","name":"Modafinil - Article 31 referral - Annex I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"31855","name":"Questions and answers on the referral for Teicoplanin Hospira powder and solvent for injection containing 200 or 400 mg teicoplanin","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-23T02:08:21Z","last_updated_date":"2010-07-27T02:08:21Z","reference_number":"EMA/CHMP/77992/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_sv.pdf"}},
    {"id":"31890","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Amended review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-15T14:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"EMA/267042/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-amended-review-started_en.pdf"},
    {"id":"31922","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-02-08T13:30:00Z","last_updated_date":"2013-02-08T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-notification_en.pdf"},
    {"id":"31928","name":"Norvasc - Article 30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-03-29T02:00:00Z","last_updated_date":"2012-03-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/norvasc-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/norvasc-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/norvasc-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/norvasc-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/norvasc-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/norvasc-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/norvasc-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/norvasc-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/norvasc-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/norvasc-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/norvasc-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/norvasc-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/norvasc-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/norvasc-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/norvasc-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/norvasc-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/norvasc-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/norvasc-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/norvasc-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/norvasc-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/norvasc-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/norvasc-article-30-referral-annex-i_sv.pdf"}},
    {"id":"31942","name":"Opinion following an Article 29(4) referral for Ciprofloxacin Hikma and associated names International Non-Proprietary Name (INN): Ciprofloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-11T02:08:21Z","last_updated_date":"2007-07-11T02:08:21Z","reference_number":"EMEA/CHMP/75066/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-ciprofloxacin-hikma-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_sv.pdf"}},
    {"id":"32016","name":"Tetrazepam-containing medicines - Article-107i procedure - Divergent positions to CMDh position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-08T18:00:00Z","last_updated_date":"2013-05-08T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-divergent-positions-cmdh-position_en.pdf"},
    {"id":"32019","name":"Serotonin-specific reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors Article-31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-11-03T00:08:21Z","last_updated_date":"2005-11-03T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/serotonin-specific-reuptake-inhibitors-and-serotonin-noradrenaline-reuptake-inhibitors-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"32028","name":"Zinbryta Article-20 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-01-12T01:00:00Z","last_updated_date":"2018-01-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinbryta-article-20-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinbryta-article-20-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinbryta-article-20-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinbryta-article-20-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinbryta-article-20-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinbryta-article-20-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinbryta-article-20-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinbryta-article-20-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zinbryta-article-20-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinbryta-article-20-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinbryta-article-20-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinbryta-article-20-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinbryta-article-20-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinbryta-article-20-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinbryta-article-20-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinbryta-article-20-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinbryta-article-20-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinbryta-article-20-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinbryta-article-20-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinbryta-article-20-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinbryta-article-20-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinbryta-article-20-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/zinbryta-article-20-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/zinbryta-article-20-referral-annex-i_no.pdf"}},
    {"id":"32050","name":"Kantos Master Article-13 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-02T12:00:00Z","last_updated_date":"2013-05-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kantos-master-article-13-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/kantos-master-article-13-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/kantos-master-article-13-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/kantos-master-article-13-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/kantos-master-article-13-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/kantos-master-article-13-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/kantos-master-article-13-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/kantos-master-article-13-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/kantos-master-article-13-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/kantos-master-article-13-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/kantos-master-article-13-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/kantos-master-article-13-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/kantos-master-article-13-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/kantos-master-article-13-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/kantos-master-article-13-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/kantos-master-article-13-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/kantos-master-article-13-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/kantos-master-article-13-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/kantos-master-article-13-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/kantos-master-article-13-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/kantos-master-article-13-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/kantos-master-article-13-referral-annex-ii_sv.pdf"}}    {"id":"32067","name":"Questions and answers on the referral for Trimetadizine-ratiopharm trimetazidine 35 mg modified-release tablets","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-01-23T00:59:00Z","last_updated_date":"2009-01-23T00:59:00Z","reference_number":"EMEA/45404/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-trimetadizine-ratiopharm-trimetazidine-35-mg-modified-release-tablets_en.pdf"},
    {"id":"32087","name":"Renin-angiotensin-system (RAS)-acting agents Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-06-05T02:00:00Z","last_updated_date":"2014-06-05T02:00:00Z","reference_number":"EMA/PRAC/294920/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-assessment-report_en.pdf"},
    {"id":"32102","name":"Opinion following an Article 29(4) referral for Rapinyl and associated names International Non-proprietary Name (INN): fentanyl citrate: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-12T02:08:21Z","last_updated_date":"2008-09-12T02:08:21Z","reference_number":"EMEA/CHMP/495857/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_sv.pdf"}},
    {"id":"32107","name":"Equibactin vet. - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-10T01:59:00Z","last_updated_date":"2008-10-10T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/equibactin-vet-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"32121","name":"Questions and answers on the recommendation to restrict the use of oral formulations of moxifloxacin-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-24T02:08:21Z","last_updated_date":"2007-07-24T02:08:21Z","reference_number":"EMEA/380454/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-recommendation-restrict-use-oral-formulations-moxifloxacin-containing-medicines_en.pdf"},
    {"id":"32146","name":"Methylphenidate Sandoz Article-29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-05T01:00:00Z","last_updated_date":"2013-12-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methylphenidate-sandoz-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"32158","name":"Questions and answers on Nasonex and associated names (mometasone furoate, 50 microgram, nasal spray)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2015-02-03T01:00:00Z","reference_number":"EMA/707071/2014 ","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-nasonex-and-associated-names-mometasone-furoate-50-microgram-nasal-spray_sv.pdf"}},
    {"id":"32161","name":"Opinion following an Article 31 referral for all medicinal products containing Celecoxib, Etoricoxib, Lumiracoxib, Parecoxib, and Valdecoxib International Non-Proprietary Name (INN): celecoxib: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-11-29T00:08:21Z","last_updated_date":"2005-11-29T00:08:21Z","reference_number":"EMEA/CHMP/323166/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-31-referral-all-medicinal-products-containing-celecoxib-etoricoxib-lumiracoxib-parecoxib-and-valdecoxib-international-non-proprietary-name-inn-celecoxib-background_sv.pdf"}},
    {"id":"32173","name":"Opinion of the Committee for proprietary medicinal products pursuant to Article 12 of Council Directive 75/319/EEC as amended, for Vigabatrin and Annexes I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-10-12T02:08:21Z","last_updated_date":"1998-10-12T02:08:21Z","reference_number":"CPMP/1357/99-EN","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-vigabatrin-and-annexes-i-ii-iii-iv_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-vigabatrin-and-annexes-i-ii-iii-iv_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-vigabatrin-and-annexes-i-ii-iii-iv_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-vigabatrin-and-annexes-i-ii-iii-iv_fr.pdf"}},
    {"id":"32174","name":"Bufexamac - Article 107 referral - Annex I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-11-10T01:00:00Z","last_updated_date":"2011-11-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bufexamac-article-107-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bufexamac-article-107-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bufexamac-article-107-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bufexamac-article-107-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bufexamac-article-107-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bufexamac-article-107-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bufexamac-article-107-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bufexamac-article-107-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bufexamac-article-107-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bufexamac-article-107-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bufexamac-article-107-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bufexamac-article-107-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bufexamac-article-107-referral-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bufexamac-article-107-referral-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bufexamac-article-107-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bufexamac-article-107-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bufexamac-article-107-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bufexamac-article-107-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bufexamac-article-107-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bufexamac-article-107-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bufexamac-article-107-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bufexamac-article-107-referral-annex-i-ii_sv.pdf"}},
    {"id":"32175","name":"Linoladiol N and Linoladiol HN Article-31 referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-11T02:00:00Z","last_updated_date":"2014-09-11T02:00:00Z","reference_number":"EMA/281995/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"32181","name":"Numeta Article-107i procedure - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-27T15:00:00Z","last_updated_date":"2013-09-27T15:00:00Z","reference_number":"EMEA/H/A-107i/1373","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/numeta-article-107i-procedure-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/numeta-article-107i-procedure-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/numeta-article-107i-procedure-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/numeta-article-107i-procedure-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/numeta-article-107i-procedure-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/numeta-article-107i-procedure-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/numeta-article-107i-procedure-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/numeta-article-107i-procedure-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/numeta-article-107i-procedure-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/numeta-article-107i-procedure-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/numeta-article-107i-procedure-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/numeta-article-107i-procedure-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/numeta-article-107i-procedure-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/numeta-article-107i-procedure-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/numeta-article-107i-procedure-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/numeta-article-107i-procedure-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/numeta-article-107i-procedure-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/numeta-article-107i-procedure-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/numeta-article-107i-procedure-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/numeta-article-107i-procedure-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/numeta-article-107i-procedure-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/numeta-article-107i-procedure-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/numeta-article-107i-procedure-annex-i_no.pdf"}},
    {"id":"32197","name":"Porcilis M Hyo - Article 6(12) referral - Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-08-18T02:00:00Z","last_updated_date":"2010-08-18T02:00:00Z","reference_number":"EMA/345914/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/porcilis-m-hyo-article-612-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"32219","name":"Lipitor - Article 30 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-10T02:00:00Z","last_updated_date":"2012-04-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lipitor-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lipitor-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lipitor-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lipitor-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lipitor-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lipitor-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lipitor-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lipitor-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lipitor-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lipitor-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lipitor-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lipitor-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lipitor-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lipitor-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lipitor-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lipitor-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lipitor-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lipitor-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lipitor-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lipitor-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lipitor-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lipitor-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"32220","name":"Opinion following an Article 29(4) referral for Fentanyl-ratiopharm 25/50/75/100 μg/h TTS and associated names International Non-Proprietary Name (INN): fentanyl: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-10-23T02:08:21Z","last_updated_date":"2007-10-23T02:08:21Z","reference_number":"EMEA/331678/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-fentanyl-ratiopharm-25-50-75-100-mg-h-tts-and-associated-names-international-non-proprietary-name-inn-fentanyl-background-information_sv.pdf"}},
    {"id":"32237","name":"Cabergoline and Pergolide - Article 31 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-05T02:08:21Z","last_updated_date":"2009-05-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cabergoline-and-pergolide-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"32248","name":"Ciprofloxacin Bayer - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:08:21Z","last_updated_date":"2008-10-23T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"32262","name":"Haldol Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-05-05T19:00:00Z","last_updated_date":"2017-05-05T19:00:00Z","reference_number":"EMA/217986/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/haldol-article-30-referral-assessment-report_en.pdf"},
    {"id":"32287","name":"Questions and answers on paroxetine - revised version following the CHMP meeting of 8 December 2004","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-12-10T00:08:21Z","last_updated_date":"2004-12-10T00:08:21Z","reference_number":"EMEA/192942/2004","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-paroxetine-revised-version-following-chmp-meeting-8-december-2004_en.pdf"},
    {"id":"32301","name":"Clopidogrel Teva - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-08T02:00:00Z","last_updated_date":"2011-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/clopidogrel-teva-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"32313","name":"Almitrine Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-10T02:00:00Z","last_updated_date":"2013-12-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/almitrine-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/almitrine-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/almitrine-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/almitrine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/almitrine-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/almitrine-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/almitrine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/almitrine-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/almitrine-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/almitrine-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/almitrine-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/almitrine-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/almitrine-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/almitrine-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/almitrine-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/almitrine-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/almitrine-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/almitrine-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/almitrine-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/almitrine-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/almitrine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/almitrine-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"32332","name":"Alkem Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/186742/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-review-started_en.pdf"},
    {"id":"32337","name":"Cilostazol-containing medicines - Article-31 referral - Annex III (cilostazol)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iii-cilostazol_sv.pdf"}},
    {"id":"32352","name":"Fluconazol Tiefenbacher 50mg, 100mg 150 mg, 200mg capsules, hard - Article 29 referral - Annex I, II (English) and Annex III (All languages)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-02-12T00:08:00Z","last_updated_date":"2004-02-12T00:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fluconazol-tiefenbacher-50mg-100mg-150-mg-200mg-capsules-hard-article-29-referral-annex-i-ii-english-and-annex-iii-all-languages_sv.pdf"}},
    {"id":"32355","name":"Opinion following an Article-33(4) referral for Strenzen 500/125-mg/g powder for use in drinking water for pigs and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-19T02:00:00Z","last_updated_date":"2013-09-19T02:00:00Z","reference_number":"EMA/325274/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-strenzen-500125-mgg-powder-use-drinking-water-pigs-and-associated-names_sv.pdf"}},
    {"id":"32368","name":"Levonelle Article-13 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-08-09T02:00:00Z","last_updated_date":"2016-08-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/levonelle-article-13-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levonelle-article-13-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levonelle-article-13-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levonelle-article-13-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levonelle-article-13-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levonelle-article-13-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levonelle-article-13-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levonelle-article-13-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levonelle-article-13-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/levonelle-article-13-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levonelle-article-13-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levonelle-article-13-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levonelle-article-13-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levonelle-article-13-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levonelle-article-13-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levonelle-article-13-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levonelle-article-13-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levonelle-article-13-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levonelle-article-13-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levonelle-article-13-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levonelle-article-13-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levonelle-article-13-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levonelle-article-13-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/levonelle-article-13-referral-annex-ii_is.pdf"}},
    {"id":"32370","name":"Opinion following an Article 29(2) referral for Nifedipine Pharmamatch 30 and 60 mg International Non-Proprietary Name (INN): Nifedipine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-04-03T02:08:21Z","last_updated_date":"2006-04-03T02:08:21Z","reference_number":"EMEA/CHMP/106563/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-nifedipine-pharmamatch-30-and-60-mg-international-non-proprietary-name-inn-nifedipine-background-information_sv.pdf"}},
    {"id":"32390","name":"Lactose of bovine origin Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-04T02:00:00Z","last_updated_date":"2017-09-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lactose-bovine-origin-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"32391","name":"Bromocriptine Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-06T02:00:00Z","last_updated_date":"2014-09-02T17:00:05Z","reference_number":"EMA/PRAC/493206/2013 rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"32402","name":"Valproate Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-07T02:00:00Z","last_updated_date":"2018-06-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valproate-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/valproate-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/valproate-article-31-referral-annex-i_no.pdf"}},
    {"id":"32403","name":"Baxter dialysis solutions Article-31 referral - Annex IV (US site)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-iv-us-site_sv.pdf"}},
    {"id":"32416","name":"Almitrine Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2013-04-19T18:45:00Z","reference_number":"EMA/PRAC/747322/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/almitrine-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"32418","name":"Questions and answers on Vascace Plus and associated names (cilazapril/hydrochlorothiazide tablets, 5/12.5 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2011-11-09T01:00:00Z","reference_number":"EMA/652293/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-vascace-plus-and-associated-names-cilazaprilhydrochlorothiazide-tablets-5125-mg_sv.pdf"}},
    {"id":"32468","name":"Tredaptive, Pelzont and Trevaclyn Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-21T01:00:00Z","last_updated_date":"2012-12-21T01:00:00Z","reference_number":"EMA/PRAC/821161/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/tredaptive-pelzont-and-trevaclyn-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"32490","name":"Hydroxyethyl starch Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"EMA/PRAC/750422/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"32553","name":"Sodium Salicylate - Article 35 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-11-20T00:59:00Z","last_updated_date":"2008-11-20T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sodium-salicylate-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"32565","name":"Diflucan - Article 30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T01:00:00Z","last_updated_date":"2012-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diflucan-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diflucan-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diflucan-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diflucan-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diflucan-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diflucan-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diflucan-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diflucan-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diflucan-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diflucan-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diflucan-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diflucan-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diflucan-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diflucan-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diflucan-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diflucan-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diflucan-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diflucan-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diflucan-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diflucan-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diflucan-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diflucan-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/diflucan-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/diflucan-article-30-referral-annex-iii_no.pdf"}},
    {"id":"32571","name":"Iffeza - Article 29 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-10-25T02:00:00Z","last_updated_date":"2012-10-25T02:00:00Z","reference_number":"EMA/399722/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/iffeza-article-29-referral-assessment-report_en.pdf"},
    {"id":"32576","name":"Lincocin Article-34 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-11-14T16:00:00Z","last_updated_date":"2017-11-14T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lincocin-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"32580","name":"Moxifloxacin - Article 107 procedures - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:08:21Z","last_updated_date":"2008-07-24T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/moxifloxacin-article-107-procedures-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/moxifloxacin-article-107-procedures-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/moxifloxacin-article-107-procedures-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/moxifloxacin-article-107-procedures-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/moxifloxacin-article-107-procedures-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/moxifloxacin-article-107-procedures-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/moxifloxacin-article-107-procedures-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/moxifloxacin-article-107-procedures-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/moxifloxacin-article-107-procedures-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/moxifloxacin-article-107-procedures-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/moxifloxacin-article-107-procedures-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/moxifloxacin-article-107-procedures-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/moxifloxacin-article-107-procedures-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/moxifloxacin-article-107-procedures-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/moxifloxacin-article-107-procedures-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/moxifloxacin-article-107-procedures-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/moxifloxacin-article-107-procedures-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/moxifloxacin-article-107-procedures-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/moxifloxacin-article-107-procedures-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/moxifloxacin-article-107-procedures-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/moxifloxacin-article-107-procedures-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/moxifloxacin-article-107-procedures-annex-iii_sv.pdf"}},
    {"id":"32590","name":"Domperidone Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-03-08T01:00:00Z","reference_number":"EMA/140423/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-review-started_en.pdf"},
    {"id":"32610","name":"Opinion following an Article 35 referral for Sodium Salicylate: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-02T01:59:00Z","last_updated_date":"2008-09-02T01:59:00Z","reference_number":"EMEA/436209/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-sodium-salicylate-background-information_sv.pdf"}},
    {"id":"32611","name":"Esmya Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-08-08T02:00:00Z","last_updated_date":"2018-08-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/esmya-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/esmya-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/esmya-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/esmya-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/esmya-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/esmya-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/esmya-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/esmya-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/esmya-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/esmya-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/esmya-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/esmya-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/esmya-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/esmya-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/esmya-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/esmya-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/esmya-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/esmya-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/esmya-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/esmya-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/esmya-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/esmya-article-20-procedure-annex-iv_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/esmya-article-20-procedure-annex-iv_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/esmya-article-20-procedure-annex-iv_no.pdf"}},
    {"id":"32619","name":"Assessment report for ergot derivatives containing medicinal products - nicergoline","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"EMA/750632/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-ergot-derivatives-containing-medicinal-products-nicergoline_en.pdf"},
    {"id":"32629","name":"Protelos and Osseor Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-18T02:00:00Z","last_updated_date":"2014-09-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/protelos-and-osseor-article-20-procedure-annex-iv_sv.pdf"}},
    {"id":"32640","name":"Bromocriptine Article-31 referral - CMDh divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-02T02:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-cmdh-divergent-position_en.pdf"},
    {"id":"32648","name":"Vancomycin Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2017-03-03T01:00:00Z","reference_number":"EMA/CHMP/224121/2016 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/vancomycin-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"32653","name":"Bromocriptine Article-31 referral - PRAC recommends restricted use of bromocriptine for stopping breast milk production","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-07-11T14:00:00Z","last_updated_date":"2014-07-11T14:00:00Z","reference_number":"EMA/409529/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-prac-recommends-restricted-use-bromocriptine-stopping-breast-milk-production_en.pdf"},
    {"id":"32677","name":"Gadolinium Article-31 referral – Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T01:00:00Z","last_updated_date":"2017-05-30T10:45:00Z","reference_number":"EMA/PRAC/195601/2016 Rev.7","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"32684","name":"Zinbryta Article-20 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-07T02:00:00Z","last_updated_date":"2017-09-01T16:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-annex-iii_en.pdf-0"},
    {"id":"32754","name":"Opinion following an article 33 referral for Cobactan IV 4.5% powder and solvent for solution for injection and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-12T02:00:00Z","last_updated_date":"2014-08-12T02:00:00Z","reference_number":"EMA/249659/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-cobactan-iv-45-powder-and-solvent-solution-injection-and-its-associated-names_en.pdf"},
    {"id":"32761","name":"Fusafungine Article-31 referral - CMDh endorses revocation of authorisations for fusafungine sprays used to treat airway infections","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/227560/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fusafungine-article-31-referral-cmdh-endorses-revocation-authorisations-fusafungine-sprays-used-treat-airway-infections_sv.pdf"}},
    {"id":"32773","name":"Opinion following an Article 34 referral Pulmotil AC and associated names: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-16T01:08:21Z","last_updated_date":"2009-10-16T01:08:21Z","reference_number":"EMEA/608943/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-pulmotil-ac-and-associated-names-background-information_sv.pdf"}},
    {"id":"32774","name":"Methotrexate Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T02:00:00Z","last_updated_date":"2018-06-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-annex-i_en.pdf"},
    {"id":"32814","name":"Hydroxyethyl starch Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-31-referral-notification_en.pdf"},
    {"id":"32827","name":"Tisseel and associated names: Product information as approved by the CHMP on 13 December 2012, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T11:00:00Z","last_updated_date":"2012-12-14T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tisseel-and-associated-names-product-information-approved-chmp-13-december-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"32841","name":"Ergot derivatives Article-31 referral - Dihydroergocristine - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergocristine-annex-ii_sv.pdf"}},
    {"id":"32855","name":"Benfluorex - Article 107 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/benfluorex-article-107-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/benfluorex-article-107-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/benfluorex-article-107-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/benfluorex-article-107-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/benfluorex-article-107-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/benfluorex-article-107-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/benfluorex-article-107-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/benfluorex-article-107-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/benfluorex-article-107-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/benfluorex-article-107-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/benfluorex-article-107-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/benfluorex-article-107-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/benfluorex-article-107-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/benfluorex-article-107-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/benfluorex-article-107-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/benfluorex-article-107-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/benfluorex-article-107-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/benfluorex-article-107-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/benfluorex-article-107-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/benfluorex-article-107-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/benfluorex-article-107-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/benfluorex-article-107-referral-annex-ii_sv.pdf"}},
    {"id":"32865","name":"Xofigo Article-20 procedure - Assessment report on provisional measures","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-21T11:32:00Z","last_updated_date":"2018-03-21T11:32:00Z","reference_number":"EMA/176752/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-assessment-report-provisional-measures_en.pdf"},
    {"id":"32889","name":"Ketoconazole Article-31 referral - European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/458028/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/ketoconazole-article-31-referral-european-medicines-agency-recommends-suspension-marketing-authorisations-oral-ketoconazole_en.pdf"},
    {"id":"32895","name":"Restriction of combined use of medicines affecting the renin-angiotensin system (RAS)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-08T02:00:00Z","last_updated_date":"2014-10-08T02:00:00Z","reference_number":"EMA/554928/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/restriction-combined-use-medicines-affecting-renin-angiotensin-system-ras_sv.pdf"}},
    {"id":"32943","name":"Cilostazol-containing medicines - Article-31 referral - Annex IV (cilostazol)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-11T02:00:00Z","last_updated_date":"2013-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cilostazol-containing-medicines-article-31-referral-annex-iv-cilostazol_sv.pdf"}},
    {"id":"32977","name":"Tredaptive, Pelzont and Trevaclyn Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-21T01:00:00Z","last_updated_date":"2012-12-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tredaptive-pelzont-and-trevaclyn-article-20-procedure-notification_en.pdf"},
    {"id":"32990","name":"Cymevene Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-06-21T02:00:00Z","last_updated_date":"2016-06-21T02:00:00Z","reference_number":"EMEA/H/A-30/1406","document_url":"https://www.ema.europa.eu/en/documents/referral/cymevene-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cymevene-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cymevene-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cymevene-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cymevene-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cymevene-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cymevene-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cymevene-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cymevene-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cymevene-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cymevene-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cymevene-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cymevene-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cymevene-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cymevene-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cymevene-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cymevene-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cymevene-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cymevene-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cymevene-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cymevene-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cymevene-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cymevene-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"32996","name":"PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T14:00:00Z","last_updated_date":"2013-06-14T14:00:00Z","reference_number":"EMA/349341/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-recommends-suspending-marketing-authorisations-infusion-solutions-containing-hydroxyethyl-starch_en.pdf"},
    {"id":"33023","name":"Questions and answers on the referral for Augmentin (amoxicillin and clavulanic acid)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:08:21Z","last_updated_date":"2013-11-18T01:08:21Z","reference_number":"EMEA/CHMP/97898/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_sv.pdf"}},
    {"id":"33056","name":"Mometasone Furoate Sandoz - Article-29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T01:00:00Z","last_updated_date":"2013-01-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/mometasone-furoate-sandoz-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"33058","name":"Zydelig Article-20 procedure - CHMP confirms recommendations for use of Zydelig","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T18:00:00Z","last_updated_date":"2016-10-03T18:00:00Z","reference_number":"EMA/550185/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_mt.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zydelig-article-20-procedure-chmp-confirms-recommendations-use-zydelig_sv.pdf"}},
    {"id":"33067","name":"Opinion following an Article 12 referral for Vigabatrin International Non-Proprietary Name (INN): Vigabatrin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1999-11-06T00:08:21Z","last_updated_date":"1999-11-06T00:08:21Z","reference_number":"CPMP/1357/99","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-12-referral-vigabatrin-international-non-proprietary-name-inn-vigabatrin-background-information_en.pdf"},
    {"id":"33081","name":"Questions and answers on Mifepristone Linepharma and associated names (mifepristone, 200-mg tablet)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T14:00:00Z","last_updated_date":"2013-01-03T13:00:00Z","reference_number":"EMA/410788/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-mifepristone-linepharma-and-associated-names-mifepristone-200-mg-tablet_sv.pdf"}},
    {"id":"33086","name":"Diclofenac Article-31 referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2012-10-31T18:00:00Z","last_updated_date":"2013-11-27T11:00:00Z","reference_number":"EMA/704684/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/diclofenac-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/diclofenac-article-31-referral-annex-i_no.pdf"}},
    {"id":"33099","name":"Zydelig Article-20 procedure - Assessment report on provisional measures","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-03-23T01:00:00Z","last_updated_date":"2016-03-23T01:00:00Z","reference_number":"EMA/215033/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-assessment-report-provisional-measures_en.pdf"},
    {"id":"33109","name":"Questions and answers on Flolan and associated names (epoprostenol, 0.5 and 1.5 mg powder for solution for infusion)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T14:00:00Z","last_updated_date":"2012-09-14T14:00:00Z","reference_number":"EMA/CHMP/329168/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-flolan-and-associated-names-epoprostenol-05-and-15-mg-powder-solution-infusion_sv.pdf"}},
    {"id":"33110","name":"Omega-3 acid ethyl esters - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T13:00:00Z","last_updated_date":"2019-03-06T14:00:00Z","reference_number":"EMA/CHMP/171344/2018 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/referral/omega-3-acid-ethyl-esters-timetable-procedure_en.pdf"},
    {"id":"33121","name":"Diacerein Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-notification_en.pdf"},
    {"id":"33155","name":"Prevora - Article 29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-09-20T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/prevora-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/prevora-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/prevora-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/prevora-article-29-referral-annex-i_cs.pdf","de":"https://www.ema.europa.eu/de/documents/referral/prevora-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/prevora-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/prevora-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/prevora-article-29-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/prevora-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/prevora-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/prevora-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/prevora-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/prevora-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/prevora-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/prevora-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/prevora-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/prevora-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/prevora-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/prevora-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/prevora-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/prevora-article-29-referral-annex-i_sv.pdf"}},
    {"id":"33164","name":"Paroxetine - Article 31 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-11-22T00:08:21Z","last_updated_date":"2005-11-22T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paroxetine-article-31-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"33173","name":"Flupirtine-containing medicines Article-107i procedure - Divergent positions to CMDh position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-18T14:00:00Z","last_updated_date":"2013-07-18T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-divergent-positions-cmdh-position_en.pdf"},
    {"id":"33177","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T13:00:00Z","last_updated_date":"2017-02-24T13:00:00Z","reference_number":"EMA/118223/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-sglt2-inhibitors-information-potential-risk-toe-amputation-be-included-prescribing-information_en.pdf"},
    {"id":"33204","name":"GVK Biosciences Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2015-04-10T16:19:00Z","reference_number":"EMA/591005/2014 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"33210","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-10T15:00:00Z","last_updated_date":"2013-06-10T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-annex-ii_sv.pdf"}},
    {"id":"33223","name":"Questions and answers on the referral for Mephatrim trimetazidine 35 mg modified-release tablets","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-01-22T00:08:21Z","last_updated_date":"2009-01-22T00:08:21Z","reference_number":"EMEA/45405/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-mephatrim-trimetazidine-35-mg-modified-release-tablets_en.pdf"},
    {"id":"33228","name":"Article-31 referral - European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"EMA/706409/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/article-31-referral-european-medicines-agency-recommends-restricting-use-thiocolchicoside-mouth-or-injection_sv.pdf"}},
    {"id":"33265","name":"Valtrex Article-30 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2011-09-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valtrex-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"33266","name":"Terpenic derivatives - Article 31 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-08T01:00:00Z","last_updated_date":"2012-02-08T01:00:00Z","reference_number":"EMEA/H/A-1284","document_url":"https://www.ema.europa.eu/en/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/terpenic-derivatives-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"33295","name":"Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Zocord and associated names (see Annex I) International Non-Proprietary Name (INN): Simvastatin: Background information\n\n...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-04-28T02:08:21Z","last_updated_date":"2004-04-28T02:08:21Z","reference_number":"EMEA/CPMP/459/04","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-zocord-and-associated-names-see-annex-i-international-non-proprietary-name-inn-simvastatin-background-information_en.pdf"},
    {"id":"33303","name":"Numeta Article-107i procedure - Amendments to relevant sections of the summary of product characteristics and package leaflet","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-amendments-relevant-sections-summary-product-characteristics-and-package-leaflet_en.pdf"},
    {"id":"33310","name":"Codeine Article-31 referral – Notification (revised)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-05T10:39:00Z","last_updated_date":"2012-11-05T10:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-notification-revised_en.pdf"},
    {"id":"33314","name":"Questions and answers on Clopidogrel Orion and associated names (clopidogrel 75 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-02-20T00:59:00Z","last_updated_date":"2011-09-09T01:59:00Z","reference_number":"EMA/106818/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_mt.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_sv.pdf"}},
    {"id":"33316","name":"Arimidex - Article 30 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/arimidex-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/arimidex-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/arimidex-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/arimidex-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/arimidex-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/arimidex-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/arimidex-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/arimidex-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/arimidex-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/arimidex-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/arimidex-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/arimidex-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/arimidex-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/arimidex-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/arimidex-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/arimidex-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/arimidex-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/arimidex-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/arimidex-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/arimidex-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/arimidex-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/arimidex-article-30-referral-annex-i_sv.pdf"}},
    {"id":"33393","name":"Combined hormonal contraceptives Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/combined-hormonal-contraceptives-article-31-referral-annex-iii_no.pdf"}},
    {"id":"33416","name":"Okrido Article-29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-03T01:00:00Z","last_updated_date":"2014-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/okrido-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/okrido-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/okrido-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/okrido-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/okrido-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/okrido-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/okrido-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/okrido-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/okrido-article-29-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/okrido-article-29-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/okrido-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/okrido-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/okrido-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/okrido-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/okrido-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/okrido-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/okrido-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/okrido-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/okrido-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/okrido-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/okrido-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/okrido-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/okrido-article-29-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/okrido-article-29-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/okrido-article-29-referral-annex-iii_no.pdf"}},
    {"id":"33479","name":"Bicaluplex - Article 29 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-02-08T00:08:21Z","last_updated_date":"2008-02-08T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bicaluplex-article-29-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"33482","name":"Iclusig Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-06T13:00:00Z","last_updated_date":"2013-12-06T13:00:00Z","reference_number":"EMA/745969/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-review-started_en.pdf"},
    {"id":"33501","name":"Questions and answers on Fortipan Combi D and associated names (risedronate sodium 35 mg tablets / calcium plus colecalciferol 1000 mg/880 IU effervescent granules)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMEA/H/A-29/1272","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_sv.pdf"}},
    {"id":"33558","name":"Numeta Article-107i procedure - PRAC list of questions to be addressed by the stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T14:00:00Z","last_updated_date":"2013-06-14T14:00:00Z","reference_number":"EMA/PRAC/366917/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-prac-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"33561","name":"Opinion following an Article 10 referral for Aggrastat International Non-Proprietary Name (INN): Tirofiban: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1999-06-18T02:08:21Z","last_updated_date":"1999-06-18T02:08:21Z","reference_number":"CPMP/990/99-EN","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-10-referral-aggrastat-international-non-proprietary-name-inn-tirofiban-background-information_en.pdf"},
    {"id":"33565","name":"Esmya Article-20 procedure - CHMP divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-08-08T02:00:00Z","last_updated_date":"2018-08-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-chmp-divergent-position_en.pdf"},
    {"id":"33582","name":"Opinion following an Article-78 procedure for Closamectin Pour-On\n\nSolution and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T20:00:00Z","last_updated_date":"2016-05-31T20:00:00Z","reference_number":"EMA/CVMP/511375/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-78-procedure-closamectin-pour-solution-and-associated-names_en.pdf"},
    {"id":"33584","name":"Glimepirida Parke Davis - Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-06T01:00:00Z","last_updated_date":"2012-12-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/glimepirida-parke-davis-article-294-referral-annex-iii_no.pdf"}}    {"id":"33590","name":"Loraxin - Article-29(4) referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-02-28T01:00:00Z","last_updated_date":"2013-02-28T01:00:00Z","reference_number":"EMA/29457/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/loraxin-article-294-referral-assessment-report_en.pdf"},
    {"id":"33613","name":"Paracetamol Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-08-09T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-annex-i_en.pdf-0"},
    {"id":"33621","name":"Sandimmun Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T17:00:00Z","last_updated_date":"2013-12-20T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sandimmun-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sandimmun-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sandimmun-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sandimmun-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sandimmun-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sandimmun-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sandimmun-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sandimmun-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sandimmun-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sandimmun-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sandimmun-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sandimmun-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sandimmun-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sandimmun-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sandimmun-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sandimmun-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sandimmun-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sandimmun-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sandimmun-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sandimmun-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sandimmun-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sandimmun-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sandimmun-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sandimmun-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sandimmun-article-30-referral-annex-i_no.pdf"}},
    {"id":"33625","name":"Clenil Article-30 referral - Questions and answers on Clenil and associated names (beclometasone dipropionate, 400 and 800 microgram nebuliser suspension)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-11-18T01:00:00Z","reference_number":"EMA/612121/2016 ","document_url":"https://www.ema.europa.eu/en/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/clenil-article-30-referral-questions-and-answers-clenil-and-associated-names-beclometasone-dipropionate-400-and-800-microgram-nebuliser-suspension_sv.pdf"}},
    {"id":"33628","name":"Factor VIII Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-12-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/factor-viii-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/factor-viii-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/factor-viii-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/factor-viii-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/factor-viii-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/factor-viii-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/factor-viii-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/factor-viii-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/factor-viii-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/factor-viii-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/factor-viii-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/factor-viii-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/factor-viii-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/factor-viii-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/factor-viii-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/factor-viii-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/factor-viii-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/factor-viii-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/factor-viii-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/factor-viii-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/factor-viii-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/factor-viii-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"33631","name":"Paracetamol Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"EMA/457797/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-review-started_en.pdf"},
    {"id":"33633","name":"Diclofenac Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-31T18:00:00Z","last_updated_date":"2012-10-31T18:00:00Z","reference_number":"EMA/PRAC/696495/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"33718","name":"Questions and answers on Flutiform and Iffeza (fluticasone propionate / formoterol fumarate, 50/5, 125/5 and 250/10 micrograms, pressurised inhalation, suspension)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2012-10-25T02:00:00Z","reference_number":"EMA/264710/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_sv.pdf"}},
    {"id":"33729","name":"Yvidually Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/yvidually-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/yvidually-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/yvidually-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/yvidually-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/yvidually-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/yvidually-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/yvidually-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/yvidually-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/yvidually-article-294-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/yvidually-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/yvidually-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/yvidually-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/yvidually-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/yvidually-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/yvidually-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/yvidually-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/yvidually-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/yvidually-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/yvidually-article-294-referral-annex-iii_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/yvidually-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/yvidually-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"33738","name":"Opinion following an Article 29 referral Pidolma International Non-Proprietary Name (INN): Amlodipine: Background information and Annex I, II and III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-04-27T02:08:21Z","last_updated_date":"2004-04-27T02:08:21Z","reference_number":"EMEA/CPMP/3122/04","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-29-referral-pidolma-international-non-proprietary-name-inn-amlodipine-background-information-and-annex-i-ii-and-iii_sv.pdf"}},
    {"id":"33751","name":"Baytril 10% oral solution and associated names: Annex I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-20T10:15:00Z","last_updated_date":"2012-11-20T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baytril-10-oral-solution-and-associated-names-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"33766","name":"Opinion following an Article 29(2) referral for Doxastad 4 mg prolonged release tablets and associated names International Non-Proprietary Name (INN): Doxazosin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-10-11T02:08:21Z","last_updated_date":"2006-10-11T02:08:21Z","reference_number":"EMEA/CHMP/423384/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-doxastad-4-mg-prolonged-release-tablets-and-associated-names-international-non-proprietary-name-inn-doxazosin-background-information_sv.pdf"}},
    {"id":"33789","name":"Questions and answers on the referral for Octegra solution for infusion containing moxifloxacin 400 mg/250 ml","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:08:21Z","last_updated_date":"2009-06-25T02:08:21Z","reference_number":"EMEA/CHMP/150525/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-octegra-solution-infusion-containing-moxifloxacin-400-mg250-ml_sv.pdf"}},
    {"id":"33790","name":"Hydroxyzine Article-31 referral - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-05-08T19:00:00Z","last_updated_date":"2014-05-13T17:20:00Z","reference_number":"EMA/PRAC/261900/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"33807","name":"Inductos Article-20 procedure -  Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/inductos-article-20-procedure-notification_en.pdf"},
    {"id":"33810","name":"Tetrazepam-containing medicines - Article-107i procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T13:00:00Z","last_updated_date":"2013-01-11T13:00:00Z","reference_number":"EMA/PRAC/15074/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-timetable-procedure_en.pdf"},
    {"id":"33836","name":"Norfloxacin - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-08-29T02:08:21Z","last_updated_date":"2006-08-29T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/norfloxacin-article-31-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"33897","name":"Inductos Article-20 procedure - CHMP list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/CHMP/492625/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/inductos-article-20-procedure-chmp-list-questions_en.pdf"},
    {"id":"33917","name":"Ethinylestradiol-Drospirenone 24+4 Article-6(12) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-annex-ii_sv.pdf"}},
    {"id":"33923","name":"Nimesulide - Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nimesulide-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nimesulide-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nimesulide-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nimesulide-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nimesulide-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nimesulide-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nimesulide-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nimesulide-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nimesulide-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nimesulide-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nimesulide-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nimesulide-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nimesulide-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nimesulide-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nimesulide-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nimesulide-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nimesulide-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nimesulide-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nimesulide-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nimesulide-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nimesulide-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"33955","name":"Intravenous iron-containing medicinal products Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-01T02:00:00Z","last_updated_date":"2013-10-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"33960","name":"Questions and answers on Losec and associated names (omeprazole, 10, 20 or 40 mg capsules and tablets, and 40 mg solution for injection and solution for infusion)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-01-23T00:59:00Z","last_updated_date":"2011-09-20T01:59:00Z","reference_number":"EMA/CHMP/565190/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_sv.pdf"}},
    {"id":"33970","name":"Galantamine Stada - Article 29 referral - Annex I-II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-06-08T16:00:00Z","last_updated_date":"2012-06-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/galantamine-stada-article-29-referral-annex-i-ii_sv.pdf"}},
    {"id":"33976","name":"Flolan - Article 30 - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-09-14T02:00:00Z","last_updated_date":"2012-09-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flolan-article-30-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flolan-article-30-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flolan-article-30-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flolan-article-30-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flolan-article-30-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flolan-article-30-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flolan-article-30-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flolan-article-30-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flolan-article-30-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flolan-article-30-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flolan-article-30-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flolan-article-30-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flolan-article-30-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flolan-article-30-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flolan-article-30-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flolan-article-30-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flolan-article-30-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flolan-article-30-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flolan-article-30-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flolan-article-30-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flolan-article-30-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flolan-article-30-annex-i_sv.pdf"}},
    {"id":"33985","name":"Opinions following an Article 12 referral for Anorectics: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1997-04-03T02:08:21Z","last_updated_date":"1997-04-03T02:08:21Z","reference_number":"CPMP/101-109/96","document_url":"https://www.ema.europa.eu/en/documents/referral/opinions-following-article-12-referral-anorectics-background-information_en.pdf"},
    {"id":"33991","name":"Coversyl - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-12-24T00:08:21Z","last_updated_date":"2003-12-24T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/coversyl-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"34008","name":"Questions and answers on Sandostatin LAR and associated names (octreotide, 10, 20 and 30 mg powder and solvent for suspension for injection)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T14:00:00Z","last_updated_date":"2014-06-27T14:00:00Z","reference_number":"EMA/376450/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-sandostatin-lar-and-associated-names-octreotide-10-20-and-30-mg-powder-and-solvent-suspension-injection_en.pdf"},
    {"id":"34068","name":"Myderison - Article 29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-06-16T02:00:00Z","last_updated_date":"2011-06-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/myderison-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/myderison-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/myderison-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/myderison-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/myderison-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/myderison-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/myderison-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/myderison-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/myderison-article-29-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/myderison-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/myderison-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/myderison-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/myderison-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/myderison-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/myderison-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/myderison-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/myderison-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/myderison-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/myderison-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/myderison-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/myderison-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/myderison-article-29-referral-annex-i_sv.pdf"}},
    {"id":"34097","name":"Committee for medicinal products for human use (CHMP) opinion following an Article 31(2) referral for Piroxicam containing medicinal products International Non-Proprietary Name (INN): piroxicam: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T02:08:21Z","last_updated_date":"2007-09-20T02:08:21Z","reference_number":"EMEA/380917/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/committee-medicinal-products-human-use-chmp-opinion-following-article-312-referral-piroxicam-containing-medicinal-products-international-non-proprietary-name-inn-piroxicam-background-information_sv.pdf"}},
    {"id":"34111","name":"Questions and answers on the review of monovalent and multivalent measles, mumps, rubella and / or varicella vaccines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T13:00:00Z","last_updated_date":"2014-03-12T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines_sv.pdf"}},
    {"id":"34121","name":"Opinion following an Article-33 referral for Avinew","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-05T02:00:00Z","last_updated_date":"2014-08-05T02:00:00Z","reference_number":"EMA/310365/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-avinew_en.pdf"},
    {"id":"34153","name":"Zinbryta Article-20 procedure - Multiple sclerosis medicine Zinbryta suspended in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-07T01:00:00Z","last_updated_date":"2018-03-14T01:00:00Z","reference_number":"EMA/134289/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinbryta-article-20-procedure-multiple-sclerosis-medicine-zinbryta-suspended-eu_sv.pdf"}},
    {"id":"34189","name":"Hydroxyethyl starch Article-107i procedure - CMDh divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-06T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-cmdh-divergent-position_en.pdf"},
    {"id":"34193","name":"Gadolinium Article-31 referral – Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T01:00:00Z","last_updated_date":"2016-03-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-notification_en.pdf"},
    {"id":"34200","name":"Gadolinium Article-31 referral – Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T01:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gadolinium-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gadolinium-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gadolinium-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gadolinium-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gadolinium-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gadolinium-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gadolinium-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gadolinium-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gadolinium-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gadolinium-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gadolinium-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gadolinium-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gadolinium-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gadolinium-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gadolinium-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gadolinium-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gadolinium-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gadolinium-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gadolinium-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gadolinium-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gadolinium-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gadolinium-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"34206","name":"Methylprednisolone Article-35 referral - Annexes I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T12:00:00Z","last_updated_date":"2017-08-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methylprednisolone-article-35-referral-annexes-i-ii-iii-iv_sv.pdf"}},
    {"id":"34207","name":"Thiocolchicoside Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-06T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/thiocolchicoside-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/thiocolchicoside-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/thiocolchicoside-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/thiocolchicoside-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/thiocolchicoside-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/thiocolchicoside-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/thiocolchicoside-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/thiocolchicoside-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/thiocolchicoside-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/thiocolchicoside-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/thiocolchicoside-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/thiocolchicoside-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/thiocolchicoside-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/thiocolchicoside-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/thiocolchicoside-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/thiocolchicoside-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/thiocolchicoside-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/thiocolchicoside-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/thiocolchicoside-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/thiocolchicoside-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/thiocolchicoside-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/thiocolchicoside-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/thiocolchicoside-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"34215","name":"Questions and answers on Famvir and associated names (famciclovir, 125, 250, 500 and 750 mg tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-23T17:00:00Z","last_updated_date":"2011-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-famvir-and-associated-names-famciclovir-125-250-500-and-750-mg-tablets_sv.pdf"}},
    {"id":"34226","name":"Opinion following an article 33 referral for Porcimectin solution for injection and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-13T02:00:00Z","last_updated_date":"2014-08-13T02:00:00Z","reference_number":"EMA/249005/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-porcimectin-solution-injection-and-its-associated-names_en.pdf"},
    {"id":"34229","name":"Ibuprofen and dexibuprofen Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-14T02:00:00Z","last_updated_date":"2015-07-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"34230","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Annex I-III - Xigduo","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-i-iii-xigduo_no.pdf"}},
    {"id":"34234","name":"Opinion following an Article 36 referral for Bupropion hydrochloride International Non-Proprietary Name (INN): Bupropion: Background information and Annexes I, II (English) and Annex III (All languages)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-11-29T00:08:21Z","last_updated_date":"2002-11-29T00:08:21Z","reference_number":"CPMP/27610/02","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-36-referral-bupropion-hydrochloride-international-non-proprietary-name-inn-bupropion-background-information-and-annexes-i-ii-english-and-annex-iii-all-languages_sv.pdf"}},
    {"id":"34277","name":"Mifepristone Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"EMA/556309/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/mifepristone-article-294-referral-assessment-report_en.pdf"},
    {"id":"34328","name":"Questions and answers on Mometasone Furoate Sandoz (mometasone furoate nasal spray, 50 microgram/dose)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T14:00:01Z","last_updated_date":"2013-01-24T13:00:01Z","reference_number":"EMA/476365/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-mometasone-furoate-sandoz-mometasone-furoate-nasal-spray-50-microgramdose_sv.pdf"}},
    {"id":"34346","name":"Questions and answers on the review of somatropin-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-12-15T18:00:00Z","last_updated_date":"2012-04-23T19:00:00Z","reference_number":"EMA/966325/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-somatropin-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-somatropin-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-somatropin-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-somatropin-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-somatropin-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-somatropin-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-somatropin-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-somatropin-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-somatropin-containing-medicines_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-somatropin-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-somatropin-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-somatropin-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-somatropin-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-somatropin-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-somatropin-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-somatropin-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-somatropin-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-somatropin-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-somatropin-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-somatropin-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-somatropin-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-somatropin-containing-medicines_sv.pdf"}},
    {"id":"34356","name":"Opinion following an article 33(4)  referral for Fiprex CAT 52.5 mg spot-on solution for cats; Fiprex S 75 mg spot-on solution for dogs, Fiprex M 150 mg spot-on solution for dogs, Fiprex L 300 mg spot-on solution for dog...","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-14T02:00:00Z","last_updated_date":"2014-08-14T02:00:00Z","reference_number":"EMA/415278/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-fiprex-cat-525-mg-spot-solution-cats-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-dogs-fiprex-l-300-mg-spot-solution-dog_sv.pdf"}},
    {"id":"34366","name":"Opinion following an Article 35 referral for all strengths of water soluble powders and oral solutions containing doxycycline hyclate indicated for use in poultry and intended for administration via drinking water","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2010-07-16T02:00:00Z","reference_number":"EMA/190025/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-all-strengths-water-soluble-powders-and-oral-solutions-containing-doxycycline-hyclate-indicated-use-poultry-and-intended-administration-drinking-water_sv.pdf"}},
    {"id":"34388","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T14:00:00Z","last_updated_date":"2017-05-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-annex-iv_no.pdf"}},
    {"id":"34397","name":"Opinion following an article 33 referral for Bovimectin Injection and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-13T02:00:00Z","last_updated_date":"2014-08-13T02:00:00Z","reference_number":"EMA/76071/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-bovimectin-injection-and-its-associated-names_en.pdf"},
    {"id":"34420","name":"Semler Article-31 referral – CHMP list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"34423","name":"Questions and answers on Haldol Decanoate and associated names (solution for injection)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T13:00:00Z","last_updated_date":"2017-05-11T14:00:00Z","reference_number":"EMA/122472/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-haldol-decanoate-and-associated-names-solution-injection_sv.pdf"}},
    {"id":"34437","name":"Questions and answers on Atacand Plus and associated names (candesartan cilexetil/hydrochlorothiazide tablets 8/12.5 mg, 16/12.5 mg, 32/12.5 mg and 32/25 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"EMEA/H/A-30/001152","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_sv.pdf"}},
    {"id":"34448","name":"Nimesulide - Article 31 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-05-13T02:08:21Z","last_updated_date":"2004-05-13T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-annex-iii_en.pdf-0","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/nimesulide-article-31-referral-annex-iii_es.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/nimesulide-article-31-referral-annex-iii_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/nimesulide-article-31-referral-annex-iii_de.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/nimesulide-article-31-referral-annex-iii_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/nimesulide-article-31-referral-annex-iii_fr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/nimesulide-article-31-referral-annex-iii_it.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/nimesulide-article-31-referral-annex-iii_nl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/nimesulide-article-31-referral-annex-iii_pt.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/nimesulide-article-31-referral-annex-iii_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/nimesulide-article-31-referral-annex-iii_sv.pdf-0"}},
    {"id":"34483","name":"Vancomycin Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-11-17T01:00:00Z","last_updated_date":"2017-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vancomycin-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vancomycin-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vancomycin-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vancomycin-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vancomycin-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vancomycin-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vancomycin-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vancomycin-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vancomycin-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/vancomycin-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vancomycin-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vancomycin-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vancomycin-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vancomycin-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vancomycin-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vancomycin-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vancomycin-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vancomycin-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vancomycin-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vancomycin-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vancomycin-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vancomycin-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vancomycin-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"34496","name":"Valproate and related substances Article-31 referral - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"EMA/PRAC/611881/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"34499","name":"Zydelig Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-03T18:00:00Z","last_updated_date":"2016-10-03T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zydelig-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zydelig-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zydelig-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zydelig-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zydelig-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zydelig-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zydelig-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zydelig-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zydelig-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zydelig-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zydelig-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zydelig-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zydelig-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zydelig-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zydelig-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zydelig-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zydelig-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zydelig-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zydelig-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zydelig-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zydelig-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zydelig-article-20-procedure-annex-iv_sv.pdf"}},
    {"id":"34502","name":"Testosterone Article-31 referral - PRAC review does not confirm increase in heart problems with testosterone medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-10T14:00:00Z","last_updated_date":"2014-10-10T14:00:00Z","reference_number":"EMA/611318/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-prac-review-does-not-confirm-increase-heart-problems-testosterone-medicines_en.pdf"},
    {"id":"34508","name":"Valebo and associated names Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-31T03:00:00Z","last_updated_date":"2014-03-31T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valebo-and-associated-names-article-294-referral-annex-i_sv.pdf"}},
    {"id":"34511","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T01:00:00Z","last_updated_date":"2017-03-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-annex-iv_sv.pdf"}},
    {"id":"34529","name":"Hydroxyethyl starch Article-107i referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iv_sv.pdf"}},
    {"id":"34537","name":"Summary information on referral opinion following arbitration pursuant to Article 29 of Council Directive 2001/83/EC for Botox Active substance: Clostridium Botulinum type A neurotoxin complex: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-08-20T02:08:21Z","last_updated_date":"2003-08-20T02:08:21Z","reference_number":"EMEA/CPMP/4260/03/en","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-council-directive-200183ec-botox-active-substance-clostridium-botulinum-type-neurotoxin-complex-background-information_sv.pdf"}},
    {"id":"34556","name":"Antifibrinolytic medicines - Article-31 referral - Annex II (tranexamic acid)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-06T01:00:00Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-ii-tranexamic-acid_sv.pdf"}},
    {"id":"34580","name":"Protelos and Osseor Article-20 procedure: Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-05-17T14:00:00Z","last_updated_date":"2013-09-06T14:34:00Z","reference_number":"EMA/PRAC/283428/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/protelos-and-osseor-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"34594","name":"Losec - Article 30 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-19T02:00:00Z","last_updated_date":"2011-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/losec-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/losec-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/losec-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/losec-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/losec-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/losec-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/losec-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/losec-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/losec-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/losec-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/losec-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/losec-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/losec-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/losec-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/losec-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/losec-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/losec-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/losec-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/losec-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/losec-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/losec-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/losec-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"34600","name":"Questions and answers on Flutiform and Iffeza (fluticasone propionate / formoterol fumarate, 50/5, 125/5 and 250/10 micrograms, pressurised inhalation, suspension)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2012-10-25T02:00:00Z","reference_number":"EMA/264710/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_fr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-flutiform-and-iffeza-fluticasone-propionate-formoterol-fumarate-505-1255-and-25010-micrograms-pressurised-inhalation-suspension_sv.pdf-0"}},
    {"id":"34612","name":"Atacand plus - Article 30 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-20T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/atacand-plus-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/atacand-plus-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/atacand-plus-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/atacand-plus-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/atacand-plus-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/atacand-plus-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/atacand-plus-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/atacand-plus-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/atacand-plus-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/atacand-plus-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/atacand-plus-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/atacand-plus-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/atacand-plus-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/atacand-plus-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/atacand-plus-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/atacand-plus-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/atacand-plus-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/atacand-plus-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/atacand-plus-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/atacand-plus-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/atacand-plus-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/atacand-plus-article-30-referral-annex-i_sv.pdf"}},
    {"id":"34653","name":"Flutiform - Article 29 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-25T02:00:00Z","last_updated_date":"2012-10-25T02:00:00Z","reference_number":"EMA/399193/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/flutiform-article-29-referral-assessment-report_en.pdf"},
    {"id":"34666","name":"Opinion following an Article 10 referral Cyklo-f International Non-Proprietary Name (INN): Tranexamic acid: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2000-07-27T02:08:21Z","last_updated_date":"2000-07-27T02:08:21Z","reference_number":"CPMP/902/00","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-10-referral-cyklo-f-international-non-proprietary-name-inn-tranexamic-acid-background-information_en.pdf"},
    {"id":"34703","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T13:00:00Z","last_updated_date":"2016-03-18T13:00:00Z","reference_number":"EMA/PRAC/188631/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"34717","name":"Gluscan 500 - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-23T02:08:21Z","last_updated_date":"2009-06-23T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gluscan-500-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"34790","name":"Orlistat - Article 31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-21T01:00:00Z","last_updated_date":"2012-12-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/orlistat-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/orlistat-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/orlistat-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/orlistat-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/orlistat-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/orlistat-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/orlistat-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/orlistat-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/orlistat-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/orlistat-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/orlistat-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/orlistat-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/orlistat-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/orlistat-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/orlistat-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/orlistat-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/orlistat-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/orlistat-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/orlistat-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/orlistat-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/orlistat-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/orlistat-article-31-referral-annex-i_sv.pdf"}},
    {"id":"34800","name":"Xalatan - Article 29 paediatrics - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-12-08T01:00:00Z","last_updated_date":"2010-12-08T01:00:00Z","reference_number":"EMA/531707/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/xalatan-article-29-paediatrics-chmp-assessment-report_en.pdf"},
    {"id":"34819","name":"Terpenic derivatives - Article 31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-08T01:00:00Z","last_updated_date":"2012-02-08T01:00:00Z","reference_number":"EMEA/H/A-1284","document_url":"https://www.ema.europa.eu/en/documents/referral/terpenic-derivatives-article-31-referral-assessment-report_en.pdf"},
    {"id":"34834","name":"Calcichew D3 mite - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-01-22T00:08:21Z","last_updated_date":"2004-01-22T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/calcichew-d3-mite-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"34835","name":"Questions and answers on the review of medicines containing valproate for use in bipolar disorder","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-12-19T00:59:00Z","last_updated_date":"2011-04-30T01:59:00Z","reference_number":"EMA/809287/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_fr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_sv.pdf-0"}},
    {"id":"34842","name":"Canagliflozin Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/canagliflozin-article-20-procedure-notification_en.pdf"},
    {"id":"34850","name":"Zolpidem Article-31 referral - CMDh divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-04T12:00:00Z","last_updated_date":"2014-08-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zolpidem-article-31-referral-cmdh-divergent-position_en.pdf"},
    {"id":"34866","name":"Tysabri Article-20 procedure - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-17T12:00:00Z","last_updated_date":"2016-03-17T12:00:00Z","reference_number":"EMA/PRAC/171485/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/tysabri-article-20-procedure-assessment-report_en.pdf"},
    {"id":"34869","name":"Simvastatin Vale Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T02:00:00Z","last_updated_date":"2013-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/simvastatin-vale-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/simvastatin-vale-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/simvastatin-vale-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/simvastatin-vale-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/simvastatin-vale-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/simvastatin-vale-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/simvastatin-vale-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/simvastatin-vale-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/simvastatin-vale-article-294-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/simvastatin-vale-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/simvastatin-vale-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/simvastatin-vale-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/simvastatin-vale-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/simvastatin-vale-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/simvastatin-vale-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/simvastatin-vale-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/simvastatin-vale-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/simvastatin-vale-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/simvastatin-vale-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/simvastatin-vale-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/simvastatin-vale-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/simvastatin-vale-article-294-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/simvastatin-vale-article-294-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/simvastatin-vale-article-294-referral-annex-iii_no.pdf"}},
    {"id":"34883","name":"Menitorix - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-04-18T02:08:21Z","last_updated_date":"2008-04-18T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/menitorix-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"34902","name":"Dexamethasone - Article 29 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T01:00:00Z","last_updated_date":"2012-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexamethasone-article-29-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexamethasone-article-29-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexamethasone-article-29-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexamethasone-article-29-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexamethasone-article-29-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexamethasone-article-29-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexamethasone-article-29-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexamethasone-article-29-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexamethasone-article-29-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexamethasone-article-29-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexamethasone-article-29-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexamethasone-article-29-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexamethasone-article-29-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexamethasone-article-29-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexamethasone-article-29-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexamethasone-article-29-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexamethasone-article-29-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexamethasone-article-29-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexamethasone-article-29-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexamethasone-article-29-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexamethasone-article-29-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexamethasone-article-29-referral-annex-iii_sv.pdf"}},
    {"id":"34908","name":"Questions and answers on the referral for Furosemide Vitabalans (tablet, 40 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-07-30T17:30:00Z","reference_number":"EMA/107842/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-furosemide-vitabalans-tablet-40-mg_sv.pdf"}},
    {"id":"34935","name":"Testosterone Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-08T01:00:00Z","last_updated_date":"2015-01-08T01:00:00Z","reference_number":"EMEA/H/A-31/1396","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/testosterone-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/testosterone-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/testosterone-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/testosterone-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/testosterone-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/testosterone-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/testosterone-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/testosterone-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/testosterone-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/testosterone-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/testosterone-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/testosterone-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/testosterone-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/testosterone-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/testosterone-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/testosterone-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/testosterone-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/testosterone-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/testosterone-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/testosterone-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/testosterone-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/testosterone-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"34948","name":"Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-12T18:00:00Z","last_updated_date":"2014-03-12T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"34951","name":"Amoxil Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-09-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/amoxil-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/amoxil-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/amoxil-article-30-referral-annex-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/amoxil-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/amoxil-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/amoxil-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/amoxil-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/amoxil-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/amoxil-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/amoxil-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/amoxil-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/amoxil-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/amoxil-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/amoxil-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/amoxil-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/amoxil-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/amoxil-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/amoxil-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/amoxil-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/amoxil-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/amoxil-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/amoxil-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/amoxil-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/amoxil-article-30-referral-annex-iii_no.pdf"}},
    {"id":"35019","name":"Cydectin TriclaMox: Article-13 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-18T13:00:00Z","last_updated_date":"2013-10-18T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cydectin-triclamox-article-13-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"35021","name":"Opinion following an Article 29(2) referral for Lansoprazol AbZ-Pharma 15 mg and 30 mg International Non-Proprietary Name (INN): Lansoprazole: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-02-22T00:08:21Z","last_updated_date":"2006-02-22T00:08:21Z","reference_number":"EMEA/CHMP/373083/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-lansoprazol-abz-pharma-15-mg-and-30-mg-international-non-proprietary-name-inn-lansoprazole-background-information_sv.pdf"}},
    {"id":"35089","name":"Alkem Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/228190/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"35118","name":"Corlentor and Procoralan Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T20:00:00Z","last_updated_date":"2014-05-08T20:00:00Z","reference_number":"EMA/280865/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/corlentor-and-procoralan-article-20-procedure-review-started_en.pdf"},
    {"id":"35147","name":"Emergency contraceptives Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/emergency-contraceptives-article-31-referral-annex-iii_no.pdf"}},
    {"id":"35167","name":"Coglapix Article-33(4) referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-10-02T18:00:00Z","last_updated_date":"2015-10-02T18:00:00Z","reference_number":"EMEA/V/A/109","document_url":"https://www.ema.europa.eu/en/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/coglapix-article-334-referral-annex-i-ii-iii_is.pdf"}},
    {"id":"35182","name":"Methylphenidate Sandoz Article-29 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-12-05T01:00:00Z","last_updated_date":"2013-12-05T01:00:00Z","reference_number":"EMA/596774/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-sandoz-article-29-referral-assessment-report_en.pdf"},
    {"id":"35187","name":"Micro Therapeutic Research Article-31 referral - CHMP list of questions\n\nto be addressed by Micro Therapeutic Research Labs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"EMA/CHMP/302887/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-chmp-list-questions-be-addressed-micro-therapeutic-research-labs_en.pdf"},
    {"id":"35190","name":"European Medicines Agency recommends restricting use of cilostazol-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-22T11:00:00Z","last_updated_date":"2013-03-22T11:00:00Z","reference_number":"EMA/98571/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/european-medicines-agency-recommends-restricting-use-cilostazol-containing-medicines_en.pdf"},
    {"id":"35220","name":"SGLT2 inhibitors Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-12T14:00:00Z","last_updated_date":"2015-06-12T14:00:00Z","reference_number":"EMA/PRAC/390892/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"35240","name":"Hydroxyethyl starch Article-107i procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-06T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-article-107i-procedure-annex-iv_sv.pdf"}},
    {"id":"35264","name":"Corlentor and Procoralan Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-14T11:30:00Z","last_updated_date":"2014-07-18T14:10:00Z","reference_number":"EMA/PRAC/281251/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/corlentor-and-procoralan-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"35294","name":"Questions and answers on the review of the fibrin sealants Tisseel, Tissucol, Artiss and Beriplast P (and associated names) given by spray application","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T11:00:00Z","last_updated_date":"2013-04-02T12:00:00Z","reference_number":"EMA/785380/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-fibrin-sealants-tisseel-tissucol-artiss-and-beriplast-p-and-associated-names-given-spray-application_sv.pdf"}},
    {"id":"35296","name":"Questions and answers on veterinary medicinal products containing altrenogest to be administered orally to pigs and horses","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-09-08T02:00:00Z","last_updated_date":"2016-09-08T02:00:00Z","reference_number":"EMA/462829/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-veterinary-medicinal-products-containing-altrenogest-be-administered-orally-pigs-and-horses_en.pdf"},
    {"id":"35304","name":"Valproate Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T13:00:00Z","last_updated_date":"2017-04-11T20:00:00Z","reference_number":"EMEA/H/A-31/1454","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-annex-i_en.pdf-0"}    {"id":"35318","name":"Doxyfar 50% - Article 34 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-08-23T02:00:00Z","last_updated_date":"2011-08-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/doxyfar-50-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"35380","name":"Lactose of bovine origin Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T13:00:00Z","last_updated_date":"2017-06-13T11:04:00Z","reference_number":"EMA/PRAC/787809/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"35389","name":"Questions and answers on the review of etoricoxib-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-26T02:08:21Z","last_updated_date":"2008-06-26T02:08:21Z","reference_number":"EMEA/329177/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-etoricoxib-containing-medicines_en.pdf"},
    {"id":"35390","name":"Ibuprofen and dexibuprofen Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-20T16:30:00Z","last_updated_date":"2014-06-20T16:30:00Z","reference_number":"EMA/373842/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-i_no.pdf"}},
    {"id":"35414","name":"Opinion following an Article-33 referral for Florgane 300-mg/ml suspension for injection for cattle and pigs and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-07-10T14:30:00Z","last_updated_date":"2013-07-10T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-33-referral-florgane-300-mgml-suspension-injection-cattle-and-pigs-and-associated-names_sv.pdf"}},
    {"id":"35456","name":"Valtrex Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-03-25T11:10:00Z","last_updated_date":"2014-03-25T11:10:00Z","reference_number":"EMA/CHMP/79258/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/valtrex-article-30-referral-assessment-report_en.pdf"},
    {"id":"35474","name":"Tazocin - Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-19T01:00:00Z","last_updated_date":"2013-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tazocin-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tazocin-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tazocin-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tazocin-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tazocin-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tazocin-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tazocin-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tazocin-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tazocin-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tazocin-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tazocin-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tazocin-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tazocin-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tazocin-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tazocin-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tazocin-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tazocin-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tazocin-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tazocin-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tazocin-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tazocin-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tazocin-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/tazocin-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/tazocin-article-30-referral-annex-i_no.pdf"}},
    {"id":"35495","name":"Opinion following an Article 31 referral for Paroxetine International Non-Proprietary Name (INN): paroxetine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-03-29T02:08:21Z","last_updated_date":"2005-03-29T02:08:21Z","reference_number":"CHMP/187488/2004","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-31-referral-paroxetine-international-non-proprietary-name-inn-paroxetine-background-information_sv.pdf"}},
    {"id":"35507","name":"Toltrazuril - Article 35 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-11-27T00:59:00Z","last_updated_date":"2008-11-27T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/toltrazuril-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"35509","name":"Tetrazepam-containing medicines - Article-107i procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-05-08T18:00:00Z","last_updated_date":"2013-05-08T18:00:00Z","reference_number":"EMA/279100/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-prac-assessment-report_en.pdf"},
    {"id":"35535","name":"Ketoprofen - Article 107 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ketoprofen-article-107-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ketoprofen-article-107-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ketoprofen-article-107-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ketoprofen-article-107-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ketoprofen-article-107-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ketoprofen-article-107-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ketoprofen-article-107-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ketoprofen-article-107-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ketoprofen-article-107-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ketoprofen-article-107-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ketoprofen-article-107-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ketoprofen-article-107-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ketoprofen-article-107-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ketoprofen-article-107-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ketoprofen-article-107-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ketoprofen-article-107-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ketoprofen-article-107-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ketoprofen-article-107-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ketoprofen-article-107-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ketoprofen-article-107-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ketoprofen-article-107-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ketoprofen-article-107-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ketoprofen-article-107-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ketoprofen-article-107-referral-annex-i_no.pdf"}},
    {"id":"35539","name":"Micotil 300 Article-35 referral - Annex I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-12T02:00:00Z","last_updated_date":"2014-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/micotil-300-article-35-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"35546","name":"Opinion following an Article 33(4) referral for APPM\n\nRespipharm: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-02-20T00:59:00Z","last_updated_date":"2010-02-20T00:59:00Z","reference_number":"EMA/839689/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-appm-respipharm-background-information_sv.pdf"}},
    {"id":"35547","name":"Xofigo Article 20 procedure - PRAC recommends restricting use of prostate cancer medicine Xofigo","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-13T14:00:00Z","last_updated_date":"2018-07-13T14:00:00Z","reference_number":"EMA/176752/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-prac-recommends-restricting-use-prostate-cancer-medicine-xofigo_en.pdf"},
    {"id":"35548","name":"Ethinylestradiol-Drospirenone 24+4 Article-6(12) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"EMA/399943/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-assessment-report_en.pdf"},
    {"id":"35549","name":"Durogesic Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-19T02:00:00Z","last_updated_date":"2016-10-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/durogesic-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/durogesic-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/durogesic-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/durogesic-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/durogesic-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/durogesic-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/durogesic-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/durogesic-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/durogesic-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/durogesic-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/durogesic-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/durogesic-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/durogesic-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/durogesic-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/durogesic-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/durogesic-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/durogesic-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/durogesic-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/durogesic-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/durogesic-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/durogesic-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/durogesic-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/durogesic-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"35581","name":"Rocephin Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rocephin-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rocephin-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rocephin-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rocephin-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rocephin-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rocephin-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rocephin-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rocephin-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rocephin-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/rocephin-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rocephin-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rocephin-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rocephin-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rocephin-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rocephin-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rocephin-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rocephin-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rocephin-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rocephin-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rocephin-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rocephin-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rocephin-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rocephin-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/rocephin-article-30-referral-annex-iii_is.pdf"}},
    {"id":"35593","name":"PRAC recommends suspending use of Protelos/Osseor","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-10T13:00:00Z","last_updated_date":"2014-01-10T13:00:00Z","reference_number":"EMA/10206/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-recommends-suspending-use-protelososseor_en.pdf"},
    {"id":"35597","name":"Unisol - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-07-30T01:59:00Z","last_updated_date":"2009-07-30T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/unisol-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/unisol-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/unisol-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/unisol-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/unisol-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/unisol-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/unisol-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/unisol-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/unisol-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/unisol-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/unisol-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/unisol-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/unisol-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/unisol-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/unisol-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/unisol-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/unisol-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/unisol-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/unisol-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/unisol-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/unisol-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/unisol-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"35612","name":"Fentrix Article-29(4) referral - Annexes I, II and II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fentrix-article-294-referral-annexes-i-ii-and-ii_sv.pdf"}},
    {"id":"35623","name":"Metoclopramide Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-10-25T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metoclopramide-article-31-referral-annex-iii_en.pdf-0"},
    {"id":"35638","name":"Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names, and related veterinary medicinal products: Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T01:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names-and-related-veterinary-medicinal-products-annex-i-ii-iii_sv.pdf"}},
    {"id":"35642","name":"Vepesid Article-30 referral - CHMP assessment Report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"EMA/409248/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/vepesid-article-30-referral-chmp-assessment-report_en.pdf"},
    {"id":"35645","name":"Ergot derivatives Article-31 referral - Nicergoline - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-nicergoline-annex-ii_sv.pdf"}},
    {"id":"35664","name":"Valebo and associated names Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2014-03-31T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valebo-and-associated-names-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"35710","name":"Ciprofloxacin Hikma  - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-09-06T02:08:21Z","last_updated_date":"2007-09-06T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ciprofloxacin-hikma-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"35722","name":"Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Calcium Sandoz and associated names International Non-Proprietary Name (INN): Calcium lactate gluco...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-08-10T01:59:00Z","last_updated_date":"2005-08-10T01:59:00Z","reference_number":"EMEA/CHMP/289490/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-calcium-sandoz-and-associated-names-international-non-proprietary-name-inn-calcium-lactate_sv.pdf"}},
    {"id":"35747","name":"Questions and answers on the referral for Ciclosporin IDL and associated names capsules containing ciclosporin 25 mg, 50 mg and 100 mg - Re-examination","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:08:21Z","last_updated_date":"2013-11-20T00:08:21Z","reference_number":"EMEA/CHMP/466894/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_sv.pdf"}},
    {"id":"35756","name":"Opinion following an Article 78 procedure for Pregsure BVD and associated names: Background information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-08-26T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/434219/2010-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-78-procedure-pregsure-bvd-and-associated-names-background-information_sv.pdf"}},
    {"id":"35776","name":"Enrofloxacin Article-35 referral - Veterinary medicines containing enrofloxacin to be administered via the drinking water to chickens and/or turkeys Article-35 referral - Annexes","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-10T14:00:00Z","last_updated_date":"2014-04-10T14:00:00Z","reference_number":"EMEA/V/A/089","document_url":"https://www.ema.europa.eu/en/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-and-or-turkeys-article-35-referral-annexes_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/enrofloxacin-article-35-referral-veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-andor-turkeys-article-35-referral-annexes_sv.pdf"}},
    {"id":"35804","name":"Nimesulide - Article 31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nimesulide-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nimesulide-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nimesulide-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nimesulide-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nimesulide-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nimesulide-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nimesulide-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nimesulide-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nimesulide-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nimesulide-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nimesulide-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nimesulide-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nimesulide-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nimesulide-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nimesulide-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nimesulide-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nimesulide-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nimesulide-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nimesulide-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nimesulide-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nimesulide-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"35812","name":"Ketoconazole Article-31 referral - Suspension of marketing authorisations for oral ketoconazole","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T02:00:00Z","last_updated_date":"2014-06-13T02:00:00Z","reference_number":"EMA/584237/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ketoconazole-article-31-referral-suspension-marketing-authorisations-oral-ketoconazole_sv.pdf"}},
    {"id":"35815","name":"Questions and answers on Merisone and Myoson (tolperisone, 50 and 150 mg tablets)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-07-28T14:00:00Z","reference_number":"EMA/252261/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-merisone-and-myoson-tolperisone-50-and-150-mg-tablets_sv.pdf-0"}},
    {"id":"35824","name":"Tibolona-Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-08T02:00:00Z","last_updated_date":"2014-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tibolona-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tibolona-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tibolona-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tibolona-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tibolona-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tibolona-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tibolona-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tibolona-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tibolona-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tibolona-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tibolona-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tibolona-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tibolona-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tibolona-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tibolona-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tibolona-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tibolona-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tibolona-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tibolona-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tibolona-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tibolona-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tibolona-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tibolona-article-294-referral-annex-i_sv.pdf"}},
    {"id":"35825","name":"Colistin - Article 35 referral - Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2010-06-24T02:00:00Z","reference_number":"EMA/189829/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/colistin-article-35-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"35834","name":"Opinion following an Article 5(11)  referral for Belanette and associated names (see Annex I) International Non-Proprietary Name (INN): Drospirenone + Ethinylestradiol: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-17T02:08:21Z","last_updated_date":"2008-06-17T02:08:21Z","reference_number":"EMEA/CHMP/332403/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-511-referral-belanette-and-associated-names-see-annex-i-international-non-proprietary-name-inn-drospirenone-ethinylestradiol-background-information_sv.pdf"}},
    {"id":"35891","name":"Opinion following an Article 33(4) referral for Equibactin vet.: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T01:59:00Z","last_updated_date":"2008-06-02T01:59:00Z","reference_number":"EMEA/455918/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-equibactin-vet-background-information_sv.pdf"}},
    {"id":"35917","name":"Lincomycin and spectinomycin Article 35 referral - Questions and answers on veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and/or poultry","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/462762/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lincomycin-and-spectinomycin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-combination-lincomycin-and-spectinomycin-be-administered-orally-pigs-andor-poultry_sv.pdf"}},
    {"id":"35924","name":"Intravenous iron-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-10-01T02:00:00Z","last_updated_date":"2021-07-28T11:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-annex-i_no.pdf"}},
    {"id":"35932","name":"Questions and answers on Tienam and associated names (imipenem/cilastatin for infusion 500 mg/500 mg)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2012-02-20T01:00:00Z","reference_number":"EMEA/H/A-30/001187","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-tienam-and-associated-names-imipenemcilastatin-infusion-500-mg500-mg_sv.pdf"}},
    {"id":"35991","name":"Moxidectin Article-35 referral - Annex I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-24T02:00:00Z","last_updated_date":"2017-10-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/moxidectin-article-35-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"36034","name":"Kogenate Bayer and Helixate NexGen Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-09T12:00:00Z","last_updated_date":"2014-04-09T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/kogenate-bayer-and-helixate-nexgen-article-20-procedure-annex-iv_sv.pdf"}},
    {"id":"36045","name":"Neurontin - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-09-06T02:08:21Z","last_updated_date":"2006-09-06T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"36124","name":"Divergent position on a CVMP opinion on an Article 34 referral for\n\nMilaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus, Prazitel Plus and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-23T02:00:00Z","last_updated_date":"2012-07-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-34-referral-milaxyn-plus-strantel-plus-prazical-plus-voxical-plus-exitel-plus-cazitel-plus-prazitel-plus-and-associated-names_en.pdf"},
    {"id":"36146","name":"Numeta Article-107i procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-09-27T15:00:00Z","last_updated_date":"2013-09-27T15:00:00Z","reference_number":"EMA/587344/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-prac-assessment-report_en.pdf"},
    {"id":"36153","name":"Leflunomide Actavis Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leflunomide-actavis-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"36209","name":"Valproate Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-10T13:00:00Z","last_updated_date":"2017-03-10T13:00:00Z","reference_number":"EMA/PRAC/154222/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"36215","name":"Omega-3 acid ethyl esters - List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T13:00:00Z","last_updated_date":"2018-03-23T13:00:00Z","reference_number":"EMEA/H/A-31/1464","document_url":"https://www.ema.europa.eu/en/documents/referral/omega-3-acid-ethyl-esters-list-questions_en.pdf"},
    {"id":"36226","name":"Questions and answers on Gutal 1000 g/kg premix for medicated feeding stuff for piglets (zinc oxide)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-11-26T01:00:00Z","last_updated_date":"2015-11-26T01:00:00Z","reference_number":"EMA/709250/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-gutal-1000-gkg-premix-medicated-feeding-stuff-piglets-zinc-oxide_sv.pdf"}},
    {"id":"36231","name":"Clobutinol - Article 107 procedures - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-10-19T02:08:21Z","last_updated_date":"2007-10-19T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/clobutinol-article-107-procedures-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/clobutinol-article-107-procedures-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/clobutinol-article-107-procedures-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/clobutinol-article-107-procedures-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/clobutinol-article-107-procedures-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/clobutinol-article-107-procedures-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/clobutinol-article-107-procedures-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/clobutinol-article-107-procedures-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/clobutinol-article-107-procedures-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/clobutinol-article-107-procedures-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/clobutinol-article-107-procedures-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/clobutinol-article-107-procedures-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/clobutinol-article-107-procedures-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/clobutinol-article-107-procedures-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/clobutinol-article-107-procedures-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/clobutinol-article-107-procedures-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/clobutinol-article-107-procedures-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/clobutinol-article-107-procedures-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/clobutinol-article-107-procedures-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/clobutinol-article-107-procedures-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/clobutinol-article-107-procedures-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/clobutinol-article-107-procedures-annex-ii_sv.pdf"}},
    {"id":"36256","name":"Zydelig Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T13:00:00Z","last_updated_date":"2016-03-18T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-annex-iii_en.pdf"},
    {"id":"36258","name":"Vascace Plus - Article 30 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-11-09T01:00:00Z","last_updated_date":"2011-11-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vascace-plus-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vascace-plus-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vascace-plus-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vascace-plus-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vascace-plus-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vascace-plus-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vascace-plus-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vascace-plus-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vascace-plus-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vascace-plus-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vascace-plus-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vascace-plus-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vascace-plus-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vascace-plus-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vascace-plus-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vascace-plus-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vascace-plus-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vascace-plus-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vascace-plus-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vascace-plus-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vascace-plus-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vascace-plus-article-30-referral-annex-i_sv.pdf"}},
    {"id":"36265","name":"APPM Respipharm - Article 33 Referral -  Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-02-25T00:59:00Z","last_updated_date":"2010-02-25T00:59:00Z","reference_number":"EMEA-2009-0319-01-00","document_url":"https://www.ema.europa.eu/en/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/appm-respipharm-article-33-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"36274","name":"Canagliflozin Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-22T18:00:00Z","last_updated_date":"2016-04-22T18:00:00Z","reference_number":"EMA/PRAC/271175/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/canagliflozin-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"36325","name":"Thiocolchicoside Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-06T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/thiocolchicoside-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/thiocolchicoside-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/thiocolchicoside-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/thiocolchicoside-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/thiocolchicoside-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/thiocolchicoside-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/thiocolchicoside-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/thiocolchicoside-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/thiocolchicoside-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/thiocolchicoside-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/thiocolchicoside-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/thiocolchicoside-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/thiocolchicoside-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/thiocolchicoside-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/thiocolchicoside-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/thiocolchicoside-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/thiocolchicoside-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/thiocolchicoside-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/thiocolchicoside-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/thiocolchicoside-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/thiocolchicoside-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/thiocolchicoside-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/thiocolchicoside-article-31-referral-annex-i_sv.pdf"}},
    {"id":"36348","name":"Questions and answers on Plendil and associated names (felodipine 2.5, 5 and 10 mg prolonged release tablets)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"EMA/638615/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-plendil-and-associated-names-felodipine-25-5-and-10-mg-prolonged-release-tablets_sv.pdf"}},
    {"id":"36382","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Amended product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T13:00:00Z","last_updated_date":"2017-02-24T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-amended-product-information_en.pdf"},
    {"id":"36498","name":"Dexamed and associated names Article-29(4) referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-02T02:00:00Z","last_updated_date":"2014-09-02T02:00:00Z","reference_number":"EMA/353952/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/dexamed-and-associated-names-article-294-referral-assessment-report_en.pdf"},
    {"id":"36525","name":"Terpenic derivatives - Article 31 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-08T01:00:00Z","last_updated_date":"2012-02-08T01:00:00Z","reference_number":"EMEA/H/A-1284","document_url":"https://www.ema.europa.eu/en/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/terpenic-derivatives-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"36581","name":"Sandimmun Neoral Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-12-20T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_no.pdf"}},
    {"id":"36590","name":"Metformin Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"EMA/52124/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-review-started_en.pdf"},
    {"id":"36592","name":"Carisoprodol - Article 107 procedures - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-15T00:08:21Z","last_updated_date":"2007-11-15T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/carisoprodol-article-107-procedures-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/carisoprodol-article-107-procedures-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/carisoprodol-article-107-procedures-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/carisoprodol-article-107-procedures-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/carisoprodol-article-107-procedures-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/carisoprodol-article-107-procedures-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/carisoprodol-article-107-procedures-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/carisoprodol-article-107-procedures-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/carisoprodol-article-107-procedures-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/carisoprodol-article-107-procedures-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/carisoprodol-article-107-procedures-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/carisoprodol-article-107-procedures-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/carisoprodol-article-107-procedures-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/carisoprodol-article-107-procedures-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/carisoprodol-article-107-procedures-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/carisoprodol-article-107-procedures-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/carisoprodol-article-107-procedures-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/carisoprodol-article-107-procedures-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/carisoprodol-article-107-procedures-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/carisoprodol-article-107-procedures-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/carisoprodol-article-107-procedures-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/carisoprodol-article-107-procedures-annex-ii_sv.pdf"}},
    {"id":"36595","name":"Suvaxyn Ery - Article 40 Referral - Annex I, II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-16T00:59:00Z","last_updated_date":"2007-11-16T00:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/suvaxyn-ery-article-40-referral-annex-i-ii_sv.pdf"}},
    {"id":"36610","name":"Gemzar - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-06T02:08:21Z","last_updated_date":"2008-10-06T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gemzar-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"36624","name":"Resflor Article-13 referral: Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-09T18:30:00Z","last_updated_date":"2015-01-09T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/resflor-article-13-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/resflor-article-13-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/resflor-article-13-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/resflor-article-13-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/resflor-article-13-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/resflor-article-13-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/resflor-article-13-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/resflor-article-13-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/resflor-article-13-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/resflor-article-13-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/resflor-article-13-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/resflor-article-13-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/resflor-article-13-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/resflor-article-13-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/resflor-article-13-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/resflor-article-13-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/resflor-article-13-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/resflor-article-13-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/resflor-article-13-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/resflor-article-13-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/resflor-article-13-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/resflor-article-13-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/resflor-article-13-referral-annex-i-ii-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/resflor-article-13-referral-annex-i-ii-iii_no.pdf"}},
    {"id":"36647","name":"Norditropin - Article 13 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/norditropin-article-13-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/norditropin-article-13-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/norditropin-article-13-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/norditropin-article-13-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/norditropin-article-13-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/norditropin-article-13-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/norditropin-article-13-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/norditropin-article-13-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/norditropin-article-13-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/norditropin-article-13-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/norditropin-article-13-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/norditropin-article-13-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/norditropin-article-13-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/norditropin-article-13-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/norditropin-article-13-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/norditropin-article-13-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/norditropin-article-13-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/norditropin-article-13-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/norditropin-article-13-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/norditropin-article-13-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/norditropin-article-13-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/norditropin-article-13-referral-annex-ii_sv.pdf"}},
    {"id":"36648","name":"Divergent position on a CVMP opinion on an Article 34 referral of Directive 2001/82/EC for Baytril 2.5% injectable, Baytril 5% injectable and Baytril\n\n10% injectable and their associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-12-10T01:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-34-referral-directive-200182ec-baytril-25-injectable-baytril-5-injectable-and-baytril-10-injectable-and-their-associated-names_en.pdf"},
    {"id":"36653","name":"Sortis-EMEA/H/A-29 PAD/1253: Article 29 Paediatrics referral - Assessment Report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-27T02:00:00Z","last_updated_date":"2011-04-27T02:00:00Z","reference_number":"EMA/511109/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-assessment-report_en.pdf"},
    {"id":"36659","name":"Methysergide Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-05-27T02:00:00Z","last_updated_date":"2014-05-27T02:00:00Z","reference_number":"EMA/276466/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/methysergide-article-31-referral-assessment-report_en.pdf"},
    {"id":"36661","name":"Lumiracoxib - Article 107 procedures - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-12-14T00:08:21Z","last_updated_date":"2007-12-14T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lumiracoxib-article-107-procedures-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lumiracoxib-article-107-procedures-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lumiracoxib-article-107-procedures-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lumiracoxib-article-107-procedures-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lumiracoxib-article-107-procedures-annex-i_da.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lumiracoxib-article-107-procedures-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lumiracoxib-article-107-procedures-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lumiracoxib-article-107-procedures-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lumiracoxib-article-107-procedures-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lumiracoxib-article-107-procedures-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lumiracoxib-article-107-procedures-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lumiracoxib-article-107-procedures-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lumiracoxib-article-107-procedures-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lumiracoxib-article-107-procedures-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lumiracoxib-article-107-procedures-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lumiracoxib-article-107-procedures-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lumiracoxib-article-107-procedures-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lumiracoxib-article-107-procedures-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lumiracoxib-article-107-procedures-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lumiracoxib-article-107-procedures-annex-i_sv.pdf"}},
    {"id":"36675","name":"Valebo and associated names Article-29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-31T03:00:00Z","last_updated_date":"2014-03-31T03:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valebo-and-associated-names-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"36689","name":"Hydroxyethyl starch Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"EMA/757392/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-31-referral-review-started_en.pdf"},
    {"id":"36692","name":"Zydelig Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-03-11T01:00:00Z","last_updated_date":"2016-03-11T01:00:00Z","reference_number":"EMA/191705/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-review-started_en.pdf"},
    {"id":"36706","name":"Sandimmun Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2014-01-30T11:10:00Z","last_updated_date":"2014-01-30T11:10:00Z","reference_number":"EMA/589500/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/sandimmun-article-30-referral-assessment-report_en.pdf"},
    {"id":"36722","name":"Fusafungine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-09-11T02:00:00Z","last_updated_date":"2015-09-11T02:00:00Z","reference_number":"EMA/323030/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-annex-i_en.pdf-0"},
    {"id":"36728","name":"Codeine Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-05-05T17:20:00Z","last_updated_date":"2015-05-05T17:20:00Z","reference_number":"EMA/235820/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-prac-assessment-report_en.pdf-0"},
    {"id":"36734","name":"CattleMarker IBR Inactivated Article-33(4) referral - Questions and answers","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-19T02:00:00Z","last_updated_date":"2016-07-19T02:00:00Z","reference_number":"EMA/290855/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cattlemarker-ibr-inactivated-article-334-referral-questions-and-answers_sv.pdf"}},
    {"id":"36750","name":"Numeta Article-107i procedure - Stakeholders' submission form","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T14:00:00Z","last_updated_date":"2013-06-14T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-stakeholders-submission-form_en.pdf"},
    {"id":"36751","name":"Questions and answers on the referral for Canazole (clotrimazole cream 1%)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2012-02-09T01:00:00Z","reference_number":"EMA/206825/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-canazole-clotrimazole-cream-1_sv.pdf"}},
    {"id":"36752","name":"Lactose of bovine origin Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T13:00:00Z","last_updated_date":"2016-12-02T13:00:00Z","reference_number":"EMA/792358/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-review-started_en.pdf"},
    {"id":"36844","name":"Calcitonins - Article 31 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-03-02T00:08:21Z","last_updated_date":"2004-03-02T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/calcitonins-article-31-referral-annex-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/calcitonins-article-31-referral-annex-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/calcitonins-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/calcitonins-article-31-referral-annex-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/calcitonins-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/calcitonins-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/calcitonins-article-31-referral-annex-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/calcitonins-article-31-referral-annex-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/calcitonins-article-31-referral-annex-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/calcitonins-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/calcitonins-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"36850","name":"Assessment report for Zinacef and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-01-29T01:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"EMA/CHMP/633654/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-zinacef-and-associated-names_en.pdf"},
    {"id":"36856","name":"Short-acting beta-agonists Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2013-01-10T17:00:00Z","reference_number":"EMA/769026/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-annex-i_en.pdf-0"},
    {"id":"36909","name":"Denagard 45% Article-34 referral - Annex I,II,III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-08-11T19:00:00Z","last_updated_date":"2017-08-11T19:00:00Z","reference_number":"EMEA/V/A/114","document_url":"https://www.ema.europa.eu/en/documents/referral/denagard-45-article-34-referral-annex-iiiiii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/denagard-45-article-34-referral-annex-iiiiii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/denagard-45-article-34-referral-annex-iiiiii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/denagard-45-article-34-referral-annex-iiiiii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/denagard-45-article-34-referral-annex-iiiiii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/denagard-45-article-34-referral-annex-iiiiii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/denagard-45-article-34-referral-annex-iiiiii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/denagard-45-article-34-referral-annex-iiiiii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/denagard-45-article-34-referral-annex-iiiiii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/denagard-45-article-34-referral-annex-iiiiii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/denagard-45-article-34-referral-annex-iiiiii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/denagard-45-article-34-referral-annex-iiiiii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/denagard-45-article-34-referral-annex-iiiiii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/denagard-45-article-34-referral-annex-iiiiii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/denagard-45-article-34-referral-annex-iiiiii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/denagard-45-article-34-referral-annex-iiiiii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/denagard-45-article-34-referral-annex-iiiiii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/denagard-45-article-34-referral-annex-iiiiii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/denagard-45-article-34-referral-annex-iiiiii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/denagard-45-article-34-referral-annex-iiiiii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/denagard-45-article-34-referral-annex-iiiiii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/denagard-45-article-34-referral-annex-iiiiii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/denagard-45-article-34-referral-annex-iiiiii_sv.pdf"}},
    {"id":"36932","name":"Opinion following an Article-33(4) referral for Nuflor Swine Once 450-mg/ml solution for injection","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"EMA/324738/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-nuflor-swine-once-450-mgml-solution-injection_sv.pdf"}},
    {"id":"36962","name":"Dexamed and associated names Article-29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-02T02:00:00Z","last_updated_date":"2014-09-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexamed-and-associated-names-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"36969","name":"Ibuprofen and dexibuprofen Article-31 referral - PRAC recommends updating advice on use of high-dose ibuprofen","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-04-13T12:00:00Z","last_updated_date":"2015-04-13T12:00:00Z","reference_number":"EMA/217862/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-prac-recommends-updating-advice-use-high-dose-ibuprofen_en.pdf"},
    {"id":"36988","name":"Opinion following an Article 29(2) referral for Adartrel International Non-Proprietary Name (INN): Ropinirole: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-04-03T02:08:21Z","last_updated_date":"2006-04-03T02:08:21Z","reference_number":"EMEA/CHMP/416317/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-adartrel-international-non-proprietary-name-inn-ropinirole-background-information_sv.pdf"}},
    {"id":"37010","name":"Adrenaline auto-injectors Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2015-08-26T02:00:00Z","reference_number":"EMA/254887/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/adrenaline-auto-injectors-article-31-referral-annex-i_no.pdf"}},
    {"id":"37043","name":"Fibrinogen Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T17:00:00Z","last_updated_date":"2013-04-02T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrinogen-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrinogen-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fibrinogen-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrinogen-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrinogen-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrinogen-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fibrinogen-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrinogen-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fibrinogen-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrinogen-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrinogen-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrinogen-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fibrinogen-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrinogen-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrinogen-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrinogen-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrinogen-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrinogen-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrinogen-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrinogen-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fibrinogen-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrinogen-article-31-referral-annex-i_sv.pdf"}},
    {"id":"37045","name":"Moxifloxacin - Article 107 procedures - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-24T02:08:21Z","last_updated_date":"2007-07-24T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/moxifloxacin-article-107-procedures-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/moxifloxacin-article-107-procedures-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/moxifloxacin-article-107-procedures-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/moxifloxacin-article-107-procedures-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/moxifloxacin-article-107-procedures-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/moxifloxacin-article-107-procedures-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/moxifloxacin-article-107-procedures-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/moxifloxacin-article-107-procedures-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/moxifloxacin-article-107-procedures-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/moxifloxacin-article-107-procedures-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/moxifloxacin-article-107-procedures-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/moxifloxacin-article-107-procedures-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/moxifloxacin-article-107-procedures-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/moxifloxacin-article-107-procedures-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/moxifloxacin-article-107-procedures-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/moxifloxacin-article-107-procedures-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/moxifloxacin-article-107-procedures-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/moxifloxacin-article-107-procedures-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/moxifloxacin-article-107-procedures-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/moxifloxacin-article-107-procedures-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/moxifloxacin-article-107-procedures-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/moxifloxacin-article-107-procedures-annex-i_sv.pdf"}},
    {"id":"37049","name":"Trimetazidine - Article 31 - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-17T02:00:00Z","last_updated_date":"2012-10-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/trimetazidine-article-31-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/trimetazidine-article-31-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/trimetazidine-article-31-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/trimetazidine-article-31-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/trimetazidine-article-31-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/trimetazidine-article-31-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/trimetazidine-article-31-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/trimetazidine-article-31-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/trimetazidine-article-31-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/trimetazidine-article-31-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/trimetazidine-article-31-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/trimetazidine-article-31-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/trimetazidine-article-31-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/trimetazidine-article-31-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/trimetazidine-article-31-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/trimetazidine-article-31-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/trimetazidine-article-31-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/trimetazidine-article-31-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/trimetazidine-article-31-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/trimetazidine-article-31-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/trimetazidine-article-31-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/trimetazidine-article-31-annex-iv_sv.pdf"}},
    {"id":"37058","name":"Vancomycin Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-11T18:45:00Z","last_updated_date":"2017-11-17T17:45:00Z","reference_number":"EMA/258475/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/vancomycin-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vancomycin-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vancomycin-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vancomycin-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vancomycin-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vancomycin-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vancomycin-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vancomycin-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vancomycin-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/vancomycin-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vancomycin-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vancomycin-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vancomycin-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vancomycin-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vancomycin-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vancomycin-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vancomycin-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vancomycin-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vancomycin-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vancomycin-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vancomycin-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vancomycin-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vancomycin-article-31-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/vancomycin-article-31-referral-annex-i_no.pdf"}},
    {"id":"37072","name":"Alcover Article-29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2018-01-12T01:00:00Z","last_updated_date":"2018-01-12T01:00:00Z","reference_number":"EMA/833636/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/alcover-article-294-referral-assessment-report_en.pdf"},
    {"id":"37079","name":"Hydroxyethyl starch Article-107i referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/171888/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-assessment-report_en.pdf"},
    {"id":"37103","name":"Short-acting beta-agonists Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"EMA/PRAC/74483/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"37104","name":"Opinion following an Article 29(4) referral for Alvesco and associated names International Non-Proprietary Name (INN): ciclesonide: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-07-14T02:08:21Z","last_updated_date":"2008-07-14T02:08:21Z","reference_number":"EMEA/CHMP/151554/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-alvesco-and-associated-names-international-non-proprietary-name-inn-ciclesonide-background-information_sv.pdf"}},
    {"id":"37129","name":"Codeine Article-31 referral - PRAC recommends restrictions on the use of codeine for cough and cold in children","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/163792/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-prac-recommends-restrictions-use-codeine-cough-and-cold-children_en.pdf"},
    {"id":"37171","name":"Alkem Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-10-07T02:00:00Z","reference_number":"EMA/239593/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/alkem-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/alkem-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/alkem-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/alkem-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/alkem-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/alkem-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/alkem-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/alkem-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/alkem-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/alkem-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/alkem-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/alkem-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/alkem-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/alkem-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/alkem-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/alkem-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/alkem-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/alkem-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/alkem-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/alkem-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/alkem-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/alkem-article-31-referral-annex-i_sv.pdf"}},
    {"id":"37186","name":"Baxter dialysis solutions Article-31 referral - Annex I (Castlebar site)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/baxter-dialysis-solutions-article-31-referral-annex-i-castlebar-site_sv.pdf"}}    {"id":"37198","name":"Iclusig Article-20 procedure - European Medicines Agency recommends further measures to minimise risk of blood vessel blockage with Iclusig","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T01:00:00Z","last_updated_date":"2015-03-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/iclusig-article-20-procedure-european-medicines-agency-recommends-further-measures-minimise-risk-blood-vessel-blockage-iclusig_sv.pdf"}},
    {"id":"37217","name":"Alkem Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/228189/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"37222","name":"Ergot derivatives Article-31 referral - Dihydroergotoxine - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iv_sv.pdf"}},
    {"id":"37242","name":"Mometasone Furoate Sandoz - Article-29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-01-24T01:00:00Z","last_updated_date":"2013-01-24T01:00:00Z","reference_number":"EMA/CHMP/573035/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/mometasone-furoate-sandoz-article-294-referral-assessment-report_en.pdf"},
    {"id":"37290","name":"Tylosin Article-35 referral - Questions and answers on veterinary medicinal products containing tylosin that are administered parenterally and intended for the treatment of bovine mastitis caused by Mycoplasma spp.","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-31T02:00:00Z","last_updated_date":"2017-07-31T02:00:00Z","reference_number":"EMA/399858/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tylosin-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-tylosin-are-administered-parenterally-and-intended-treatment-bovine-mastitis-caused-mycoplasma-spp_sv.pdf"}},
    {"id":"37295","name":"Opinion following an Article 29(4) referral for Cefuroximaxetil and associated names International Non-Proprietary Name (INN): cefuroxime (as axetil): Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-08-22T02:08:21Z","last_updated_date":"2007-08-22T02:08:21Z","reference_number":"EMEA/CHMP/248862/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-cefuroximaxetil-and-associated-names-international-non-proprietary-name-inn-cefuroxime-axetil-background-information_sv.pdf"}},
    {"id":"37316","name":"Questions and answers on the review of medicines containing fibrates","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2013-04-03T17:00:00Z","reference_number":"EMA/643808/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-medicines-containing-fibrates_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-medicines-containing-fibrates_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-medicines-containing-fibrates_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-medicines-containing-fibrates_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-medicines-containing-fibrates_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-medicines-containing-fibrates_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-medicines-containing-fibrates_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-medicines-containing-fibrates_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-medicines-containing-fibrates_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-medicines-containing-fibrates_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-medicines-containing-fibrates_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-medicines-containing-fibrates_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-medicines-containing-fibrates_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-medicines-containing-fibrates_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-medicines-containing-fibrates_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-medicines-containing-fibrates_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-medicines-containing-fibrates_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-medicines-containing-fibrates_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-medicines-containing-fibrates_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-medicines-containing-fibrates_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-medicines-containing-fibrates_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-medicines-containing-fibrates_sv.pdf"}},
    {"id":"37324","name":"Combined hormonal contraceptives: Article-31 referral - Timetable for the procedure","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T13:00:00Z","last_updated_date":"2013-07-12T17:30:00Z","reference_number":"EMA/PRAC/122032/2013 - Rev 3","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"37328","name":"Arimidex 1 mg film-coated tablet - Artical 29 Paediatrics referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/arimidex-1-mg-film-coated-tablet-artical-29-paediatrics-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"37390","name":"GVK Biosciences Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/590962/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"37441","name":"Questions and answers on COX-2 inhibitors","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-02-18T00:08:21Z","last_updated_date":"2005-02-18T00:08:21Z","reference_number":"EMEA/62978/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-cox-2-inhibitors_en.pdf"},
    {"id":"37446","name":"Fibrin sealants Article 31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrin-sealants-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrin-sealants-article-31-referral-annex-ii_bg.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrin-sealants-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrin-sealants-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrin-sealants-article-31-referral-annex-ii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrin-sealants-article-31-referral-annex-ii_el.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrin-sealants-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrin-sealants-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrin-sealants-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fibrin-sealants-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrin-sealants-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrin-sealants-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrin-sealants-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrin-sealants-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrin-sealants-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrin-sealants-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrin-sealants-article-31-referral-annex-ii_sl.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrin-sealants-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"37525","name":"Alendronate HEXAL- Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-08-20T02:08:21Z","last_updated_date":"2007-08-20T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_da.pdf","et":"https://www.ema.europa.eu/et/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/alendronate-hexal-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"37540","name":"Shotaflor - Article 33 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-03T01:59:00Z","last_updated_date":"2009-10-03T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/shotaflor-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"37554","name":"Yvidually Article 29(4) referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-03T01:00:00Z","last_updated_date":"2013-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/yvidually-article-294-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/yvidually-article-294-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/yvidually-article-294-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/yvidually-article-294-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/yvidually-article-294-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/yvidually-article-294-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/yvidually-article-294-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/yvidually-article-294-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/yvidually-article-294-referral-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/yvidually-article-294-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/yvidually-article-294-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/yvidually-article-294-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/yvidually-article-294-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/yvidually-article-294-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/yvidually-article-294-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/yvidually-article-294-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/yvidually-article-294-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/yvidually-article-294-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/yvidually-article-294-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/yvidually-article-294-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/yvidually-article-294-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/yvidually-article-294-referral-annex-iv_sv.pdf"}},
    {"id":"37574","name":"Iodocasein/thiamine-containing medicinal products-Article 107 referral-Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/iodocaseinthiamine-containing-medicinal-products-article-107-referral-annex-ii_sv.pdf"}},
    {"id":"37581","name":"Questions and answers on the outcome of the review of nimesulide-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-08T02:00:00Z","last_updated_date":"2010-04-08T02:00:00Z","reference_number":"EMEA/263700/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-outcome-review-nimesulide-containing-medicines_sv.pdf"}},
    {"id":"37593","name":"Paracetamol Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"EMA/PRAC/451078/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"37620","name":"Assessment Report for Authorised modified-release oral medicinal products of the WHO level III scale for the management of pain (intense sustained pain resistant to previous medications) (containing morphine, oxycodone, ...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-06-06T02:00:00Z","last_updated_date":"2011-06-06T02:00:00Z","reference_number":"EMA/355008/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-authorised-modified-release-oral-medicinal-products-who-level-iii-scale-management-pain-intense-sustained-pain-resistant-previous-medications-containing-morphine-oxycodone_en.pdf"},
    {"id":"37683","name":"Alvesco - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-08-05T02:08:21Z","last_updated_date":"2008-08-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/alvesco-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"37686","name":"Ergot derivatives Article-31 referral - Dihydroergotoxine - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-dihydroergotoxine-annex-iii_sv.pdf"}},
    {"id":"37705","name":"Hydroxyethyl starch Article-107i referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-iii_no.pdf"}},
    {"id":"37729","name":"Zinbryta Article-20 procedure - EMA review of Zinbryta confirms medicine’s risks outweigh its benefits","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-05-18T14:00:00Z","last_updated_date":"2018-07-11T14:00:00Z","reference_number":"EMA/286850/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_sv.pdf"}},
    {"id":"37734","name":"Hydroxyethyl-starch solutions (HES) no longer to be used in patients with sepsis or burn injuries or in critically ill patients","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-06T13:00:00Z","last_updated_date":"2014-03-06T13:00:00Z","reference_number":"EMA/809470/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_sv.pdf"}},
    {"id":"37757","name":"Questions and answers on the review of medicines for which studies have been conducted at Texas-based Cetero Research facility","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-09-21T16:45:01Z","last_updated_date":"2012-09-21T16:45:01Z","reference_number":"EMEA/H/A-31/001340","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-medicines-which-studies-have-been-conducted-texas-based-cetero-research-facility_en.pdf-0"},
    {"id":"37805","name":"Short-acting beta-agonists Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-notification_en.pdf"},
    {"id":"37817","name":"Cozaar - Article 29 Paediatrics referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-01-13T01:00:00Z","last_updated_date":"2012-01-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cozaar-article-29-paediatrics-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"37825","name":"Vepesid Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-14T02:00:00Z","last_updated_date":"2017-07-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vepesid-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vepesid-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vepesid-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vepesid-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vepesid-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vepesid-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vepesid-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vepesid-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vepesid-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/vepesid-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vepesid-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vepesid-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vepesid-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vepesid-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vepesid-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vepesid-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vepesid-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vepesid-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vepesid-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vepesid-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vepesid-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vepesid-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vepesid-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"37838","name":"Lisonorm - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-12-15T00:08:21Z","last_updated_date":"2008-12-15T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lisonorm-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"37853","name":"Inhaled corticosteroids Article-31 referral – Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-15T02:00:00Z","last_updated_date":"2016-07-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/inhaled-corticosteroids-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"37875","name":"Questions and answers on Galantamine Stada and associated names (galantamine 8, 16 and 24 mg prolonged released tablets)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2012-06-08T16:00:00Z","reference_number":"EMA/594983/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_sv.pdf"}},
    {"id":"37943","name":"Questions and answers on Levact and associated names (bendamustine hydrochloride, 2.5 mg/ml, powder for concentrate for solution for infusion)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-03-20T00:59:00Z","last_updated_date":"2011-09-09T01:59:00Z","reference_number":"EMEA/H/A-29/1238","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_sv.pdf"}},
    {"id":"37948","name":"Novosis Goserelin - Article 36 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMEA/H/A-36/1295","document_url":"https://www.ema.europa.eu/en/documents/referral/novosis-goserelin-article-36-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/novosis-goserelin-article-36-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/novosis-goserelin-article-36-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/novosis-goserelin-article-36-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/novosis-goserelin-article-36-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/novosis-goserelin-article-36-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/novosis-goserelin-article-36-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/novosis-goserelin-article-36-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/novosis-goserelin-article-36-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/novosis-goserelin-article-36-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/novosis-goserelin-article-36-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/novosis-goserelin-article-36-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/novosis-goserelin-article-36-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/novosis-goserelin-article-36-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/novosis-goserelin-article-36-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/novosis-goserelin-article-36-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/novosis-goserelin-article-36-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/novosis-goserelin-article-36-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/novosis-goserelin-article-36-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/novosis-goserelin-article-36-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/novosis-goserelin-article-36-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/novosis-goserelin-article-36-referral-annex-ii_sv.pdf"}},
    {"id":"37989","name":"Inductos Article-20 procedure – Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-09-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/inductos-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"37993","name":"Questions and answers on the suspension of buflomedil-containing medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-11-17T16:56:21Z","last_updated_date":"2012-06-13T17:56:21Z","reference_number":"EMEA/H/A-107/1293","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-suspension-buflomedil-containing-medicines_sv.pdf"}},
    {"id":"38008","name":"Numeta Article-107i procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T02:00:00Z","last_updated_date":"2013-06-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-timetable-procedure_en.pdf"},
    {"id":"38029","name":"Ambroxol and bromhexine Article-31 referral - Divergent opinion (Italy)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T09:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-divergent-opinion-italy_en.pdf"},
    {"id":"38136","name":"Assessment report for tolperisone-containing medicinal products","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T02:00:00Z","last_updated_date":"2013-04-02T02:00:00Z","reference_number":"EMA/753061/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-tolperisone-containing-medicinal-products_en.pdf"},
    {"id":"38164","name":"Opinion following an Article 29(4) referral for Bicaluplex and associated names International Non-Proprietary Name (INN): bicalutamide: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-11-23T00:08:21Z","last_updated_date":"2007-11-23T00:08:21Z","reference_number":"EMEA/433691/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-bicaluplex-and-associated-names-international-non-proprietary-name-inn-bicalutamide-background-information_sv.pdf"}},
    {"id":"38179","name":"Dextropropoxyphene and Paracetamol - Article 31 referral - Annex I, II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-10-19T02:00:00Z","last_updated_date":"2010-10-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dextropropoxyphene-and-paracetamol-article-31-referral-annex-i-ii_sv.pdf"}},
    {"id":"38232","name":"Nimesulide - Article 107 procedures - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-08T02:00:00Z","last_updated_date":"2010-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-107-procedures-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nimesulide-article-107-procedures-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nimesulide-article-107-procedures-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nimesulide-article-107-procedures-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nimesulide-article-107-procedures-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nimesulide-article-107-procedures-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nimesulide-article-107-procedures-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nimesulide-article-107-procedures-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nimesulide-article-107-procedures-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nimesulide-article-107-procedures-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nimesulide-article-107-procedures-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nimesulide-article-107-procedures-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nimesulide-article-107-procedures-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nimesulide-article-107-procedures-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nimesulide-article-107-procedures-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nimesulide-article-107-procedures-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nimesulide-article-107-procedures-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nimesulide-article-107-procedures-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nimesulide-article-107-procedures-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nimesulide-article-107-procedures-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nimesulide-article-107-procedures-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nimesulide-article-107-procedures-annex-ii_sv.pdf"}},
    {"id":"38249","name":"Micro Therapeutic Research Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"EMA/850878/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-review-started_en.pdf"},
    {"id":"38254","name":"Methotrexate Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T02:00:00Z","last_updated_date":"2018-04-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"38265","name":"Opinion following an Article 30 referral for Zyrtec and associated names International Non-Proprietary Name (INN): cetirizine: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-06T02:08:21Z","last_updated_date":"2008-10-06T02:08:21Z","reference_number":"EMEA/CHMP/541853/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-zyrtec-and-associated-names-international-non-proprietary-name-inn-cetirizine-background-information_sv.pdf"}},
    {"id":"38269","name":"Etoricoxib - Article 31 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-06-09T02:08:21Z","last_updated_date":"2004-06-09T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_en.pdf-0","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_es.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_de.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_fr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_it.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_nl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_pt.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/etoricoxib-article-31-referral-annex-i-ii-iii_sv.pdf-0"}},
    {"id":"38272","name":"Girolan Article-34 referral - Divergent position 2","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-15T02:00:00Z","last_updated_date":"2018-06-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/girolan-article-34-referral-divergent-position-2_en.pdf"},
    {"id":"38274","name":"Hydroxyzine Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-06-08T02:00:00Z","last_updated_date":"2015-06-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyzine-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyzine-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyzine-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyzine-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyzine-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyzine-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyzine-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyzine-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyzine-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyzine-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyzine-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyzine-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyzine-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyzine-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyzine-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyzine-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyzine-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyzine-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyzine-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyzine-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyzine-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyzine-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"38278","name":"Ibuprofen and dexibuprofen Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-annex-iii_no.pdf"}},
    {"id":"38286","name":"Assessment report for Cilazapril Teva","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"EMA/691537/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-cilazapril-teva_en.pdf"},
    {"id":"38288","name":"Oracea - Article 29 referral - Annex I, II, III, IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-08-21T02:08:21Z","last_updated_date":"2008-08-21T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/oracea-article-29-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"38311","name":"Questions and answers on the referral for Topamax and associated names topiramate tablets and capsules","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:08:21Z","last_updated_date":"2009-06-25T02:08:21Z","reference_number":"EMEA/CHMP/239500/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules_en.pdf"},
    {"id":"38315","name":"Zinbryta Article-20 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-06-09T18:00:00Z","last_updated_date":"2017-09-04T18:00:00Z","reference_number":"EMA/PRAC/366037/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-timetable-procedure_en.pdf"},
    {"id":"38329","name":"Cobactan IV 4.5% powder and solvent for solution for injection Article-33 referral - Annex I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-12T02:00:00Z","last_updated_date":"2014-08-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cobactan-iv-45-powder-and-solvent-solution-injection-article-33-referral-annex-i-ii_sv.pdf"}},
    {"id":"38337","name":"Opinion following an Article 40 referral for Suvaxyn Ery: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T01:59:00Z","last_updated_date":"2008-06-02T01:59:00Z","reference_number":"EMEA/532233/2007- Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-40-referral-suvaxyn-ery-background-information_sv.pdf"}},
    {"id":"38354","name":"Tetrazepam-containing medicines - Article-107i procedure - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-05-08T18:00:00Z","last_updated_date":"2013-05-08T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-annex-ii_sv.pdf"}},
    {"id":"38363","name":"Sortis-EMEA/H/A-29 PAD/1253: Article 29 Paediatrics referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-27T02:00:00Z","last_updated_date":"2011-04-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/sortis-emeaha-29-pad1253-article-29-paediatrics-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"38379","name":"Inhaled corticosteroids Article-31 referral – Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T02:00:00Z","last_updated_date":"2016-07-15T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/inhaled-corticosteroids-article-31-referral-annex-i_sv.pdf"}},
    {"id":"38415","name":"Flupirtine Article-31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-28T19:04:00Z","last_updated_date":"2018-03-28T19:04:00Z","reference_number":"EMA/166943/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-assessment-report_en.pdf"},
    {"id":"38417","name":"Opinion following an Article 29(4) referral for Ciprofloxacine Kabi and associated names International Non-Proprietary Name (INN): Ciprofloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-01-25T00:08:21Z","last_updated_date":"2007-01-25T00:08:21Z","reference_number":"EMEA/CHMP/515890/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-ciprofloxacine-kabi-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_en.pdf"},
    {"id":"38428","name":"Tobramycin VVB and associated names Article-29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"38435","name":"Novantrone Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-05T02:00:00Z","last_updated_date":"2016-07-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/novantrone-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/novantrone-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/novantrone-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/novantrone-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/novantrone-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/novantrone-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/novantrone-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/novantrone-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/novantrone-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/novantrone-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/novantrone-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/novantrone-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/novantrone-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/novantrone-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/novantrone-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/novantrone-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/novantrone-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/novantrone-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/novantrone-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/novantrone-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/novantrone-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/novantrone-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/novantrone-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"38452","name":"Final opinion of the Committee for proprietary medicinal products in accordance with Article 12 of Directive 75/319/EEC as amended for Zagam 200mg and Annex","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1996-05-06T02:08:21Z","last_updated_date":"1996-05-06T02:08:21Z","reference_number":"CPMP/835/95","document_url":"https://www.ema.europa.eu/en/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-zagam-200mg-and-annex_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-zagam-200mg-and-annex_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-zagam-200mg-and-annex_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/final-opinion-committee-proprietary-medicinal-products-accordance-article-12-directive-75319eec-amended-zagam-200mg-and-annex_fr.pdf"}},
    {"id":"38465","name":"Short-acting beta-agonists Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-30T01:00:00Z","last_updated_date":"2012-11-30T01:00:00Z","reference_number":"EMA/757433/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-review-started_en.pdf"},
    {"id":"38488","name":"Opinion of the Committee for proprietary medicinal products pursuant to Article 12 of Council Directive 75/319/EEC as amended for Terfenadine 60mg and Annexes A and B","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-01-22T00:08:21Z","last_updated_date":"1998-01-22T00:08:21Z","reference_number":"CPMP/255/98-EN","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-60mg-and-annexes-and-b_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-60mg-and-annexes-and-b_es.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-60mg-and-annexes-and-b_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-12-council-directive-75319eec-amended-terfenadine-60mg-and-annexes-and-b_fr.pdf"}},
    {"id":"38492","name":"Annex III: Relevant Sections of the Summary of Product Characteristics and Package Leaflet - Modified-released oral opioids","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2010-07-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/annex-iii-relevant-sections-summary-product-characteristics-and-package-leaflet-modified-released-oral-opioids_en.pdf"},
    {"id":"38509","name":"Factor VIII Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-notification_en.pdf"},
    {"id":"38520","name":"Omega-3 acid ethyl esters - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T13:00:00Z","last_updated_date":"2018-03-23T13:00:00Z","reference_number":"EMEA/H/A-31/1464","document_url":"https://www.ema.europa.eu/en/documents/referral/omega-3-acid-ethyl-esters-notification_en.pdf"},
    {"id":"38540","name":"Questions and answers on the review of medicines containing modafinil - Initial","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-medicines-containing-modafinil-initial_en.pdf"},
    {"id":"38548","name":"Gentamicin Article 35 - Veterinary medicinal products containing gentamicin presented as solutions for injection to be administered to horses: Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-04-10T02:00:00Z","last_updated_date":"2015-04-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/gentamicin-article-35-veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-horses-annex-i-ii-iii_is.pdf"}},
    {"id":"38570","name":"Zinbryta Article-20 procedure - Assessment report on provisional measures","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-14T14:46:00Z","last_updated_date":"2018-03-14T14:46:00Z","reference_number":"EMA/159031/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-procedure-assessment-report-provisional-measures_en.pdf"},
    {"id":"38589","name":"Opinion following an Article 35 referral for all veterinary medicinal products containing systemically administered (parenteral and oral) 3rd and 4th generation cephalosporins intended for use in food producing species","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-02-01T01:00:00Z","last_updated_date":"2012-02-01T01:00:00Z","reference_number":"EMA/967448/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-all-veterinary-medicinal-products-containing-systemically-administered-parenteral-and-oral-3rd-and-4th-generation-cephalosporins-intended-use-food-producing_sv.pdf"}},
    {"id":"38633","name":"Zydelig Article-20 procedure - Annex IV - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-02T12:00:00Z","last_updated_date":"2016-05-02T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zydelig-article-20-procedure-annex-iv-scientific-conclusions_sv.pdf"}},
    {"id":"38645","name":"Pharmaceutics International Inc. Article-31 referral – CHMP list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/CHMP/428621/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/pharmaceutics-international-inc-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"38682","name":"Divergent position on a CVMP opinion on an Article-13(2) of Commission Regulation (EC) No 1234/2008 Resflor solution injectable","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-09T18:30:00Z","last_updated_date":"2015-01-09T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-132-commission-regulation-ec-no-12342008-resflor-solution-injectable_en.pdf"},
    {"id":"38687","name":"Pharmaceutics International Inc. Article-31 referral – Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/428619/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/pharmaceutics-international-inc-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"38721","name":"Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Floxyfral and associated names International Non-Proprietary Name (INN): fluvoxamine: Background in...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-07-25T02:08:21Z","last_updated_date":"2002-07-25T02:08:21Z","reference_number":"EMEA/CPMP/600/02/en/Final","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-floxyfral-and-associated-names-international-non-proprietary-name-inn-fluvoxamine-background_en.pdf"},
    {"id":"38724","name":"Tetrazepam-containing medicines - Article-107i procedure - Rationale for triggering","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-14T16:00:00Z","last_updated_date":"2013-01-14T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-rationale-triggering_en.pdf"},
    {"id":"38732","name":"Cefuroximaxetil - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-09-24T02:08:21Z","last_updated_date":"2007-09-24T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_hu.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cefuroximaxetil-article-29-referral-annex-i-ii-iii_fi.pdf"}},
    {"id":"38741","name":"Questions and answers on Norditropin and associated names (somatropin, 5 mg, 10 mg and 15 mg/1.5 ml solution for injection)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T13:00:00Z","last_updated_date":"2012-04-19T12:42:00Z","reference_number":"EMA/CHMP/966954/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-norditropin-and-associated-names-somatropin-5-mg-10-mg-and-15-mg15-ml-solution-injection_sv.pdf"}},
    {"id":"38744","name":"Vantas - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-09-06T02:08:21Z","last_updated_date":"2007-09-06T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vantas-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vantas-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vantas-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vantas-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vantas-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vantas-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vantas-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vantas-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vantas-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vantas-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vantas-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vantas-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vantas-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vantas-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vantas-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vantas-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vantas-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vantas-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vantas-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vantas-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vantas-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vantas-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"38746","name":"Opinion following an article 34 referral for Eprinex pour-on and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-11T02:00:00Z","last_updated_date":"2014-08-11T02:00:00Z","reference_number":"EMA/249804/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-eprinex-pour-and-its-associated-names_en.pdf"},
    {"id":"38759","name":"Assessment report for Zinnat and associated names","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-01-29T01:00:00Z","last_updated_date":"2013-01-29T01:00:00Z","reference_number":"EMA/CHMP/633839/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-zinnat-and-associated-names_en.pdf-0"},
    {"id":"38773","name":"Gadolinium Article-31 referral – CHMP divergent positions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T01:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-chmp-divergent-positions_en.pdf"},
    {"id":"38793","name":"Protium - Article 30 referrals - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-01-17T01:00:00Z","last_updated_date":"2012-01-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/protium-article-30-referrals-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/protium-article-30-referrals-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/protium-article-30-referrals-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/protium-article-30-referrals-annex-ii_cs.pdf","de":"https://www.ema.europa.eu/de/documents/referral/protium-article-30-referrals-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/protium-article-30-referrals-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/protium-article-30-referrals-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/protium-article-30-referrals-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/protium-article-30-referrals-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/protium-article-30-referrals-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/protium-article-30-referrals-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/protium-article-30-referrals-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/protium-article-30-referrals-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/protium-article-30-referrals-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/protium-article-30-referrals-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/protium-article-30-referrals-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/protium-article-30-referrals-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/protium-article-30-referrals-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/protium-article-30-referrals-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/protium-article-30-referrals-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/protium-article-30-referrals-annex-ii_sv.pdf"}},
    {"id":"38814","name":"Coglapix Article-33(4) referral - Questions and answers","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-10-02T18:00:00Z","last_updated_date":"2015-10-02T18:00:00Z","reference_number":"EMEA/V/A/109","document_url":"https://www.ema.europa.eu/en/documents/referral/coglapix-article-334-referral-questions-and-answers_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/coglapix-article-334-referral-questions-and-answers_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/coglapix-article-334-referral-questions-and-answers_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/coglapix-article-334-referral-questions-and-answers_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/coglapix-article-334-referral-questions-and-answers_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/coglapix-article-334-referral-questions-and-answers_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/coglapix-article-334-referral-questions-and-answers_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/coglapix-article-334-referral-questions-and-answers_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/coglapix-article-334-referral-questions-and-answers_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/coglapix-article-334-referral-questions-and-answers_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/coglapix-article-334-referral-questions-and-answers_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/coglapix-article-334-referral-questions-and-answers_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/coglapix-article-334-referral-questions-and-answers_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/coglapix-article-334-referral-questions-and-answers_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/coglapix-article-334-referral-questions-and-answers_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/coglapix-article-334-referral-questions-and-answers_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/coglapix-article-334-referral-questions-and-answers_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/coglapix-article-334-referral-questions-and-answers_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/coglapix-article-334-referral-questions-and-answers_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/coglapix-article-334-referral-questions-and-answers_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/coglapix-article-334-referral-questions-and-answers_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/coglapix-article-334-referral-questions-and-answers_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/coglapix-article-334-referral-questions-and-answers_sv.pdf"}},
    {"id":"38879","name":"Amoxil Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-09-14T02:00:00Z","last_updated_date":"2015-09-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/amoxil-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/amoxil-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/amoxil-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/amoxil-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/amoxil-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/amoxil-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/amoxil-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/amoxil-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/amoxil-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/amoxil-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/amoxil-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/amoxil-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/amoxil-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/amoxil-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/amoxil-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/amoxil-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/amoxil-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/amoxil-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/amoxil-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/amoxil-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/amoxil-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/amoxil-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/amoxil-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"38935","name":"Dexamed and associated names Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-09-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/dexamed-and-associated-names-article-294-referral-annex-iii_no.pdf"}},
    {"id":"38984","name":"Opinion following an Article 29(4) referral for Menitorix Common Name: Haemophilus influenzae type b polysaccharide (polyribosyl ribitol phosphate) conjugated to tetanus toxoid and Neisseria meningitidis serogroup C (Men...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-04-01T02:08:21Z","last_updated_date":"2008-04-01T02:08:21Z","reference_number":"EMEA/CHMP/180097/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-294-referral-menitorix-common-name-haemophilus-influenzae-type-b-polysaccharide-polyribosyl-ribitol-phosphate-conjugated-tetanus-toxoid-and-neisseria-meningitidis-serogroup-c_sv.pdf"}},
    {"id":"39023","name":"Tribrissen - Article 35 Referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-10T01:59:00Z","last_updated_date":"2008-10-10T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tribrissen-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"39040","name":"Opinion following an article 34 referral for Dectomax injectable solution and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-13T02:00:00Z","last_updated_date":"2014-08-13T02:00:00Z","reference_number":"EMA/249887/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-dectomax-injectable-solution-and-its-associated-names_en.pdf"},
    {"id":"39042","name":"Fenofibrato Pensa and Fenofibrato Ranbaxy Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-12T01:00:00Z","last_updated_date":"2013-03-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fenofibrato-pensa-and-fenofibrato-ranbaxy-article-31-referral-annex-i_fi.pdf"}},
    {"id":"39049","name":"Gadolinium H-A-31-1097: Assessment Report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-12-06T01:00:00Z","last_updated_date":"2010-12-06T01:00:00Z","reference_number":"EMA/740640/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-h-31-1097-assessment-report_en.pdf"},
    {"id":"39058","name":"Tibocina-Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-08T02:00:00Z","last_updated_date":"2014-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tibocina-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tibocina-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tibocina-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tibocina-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tibocina-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tibocina-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tibocina-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tibocina-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tibocina-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tibocina-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tibocina-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tibocina-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tibocina-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tibocina-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tibocina-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tibocina-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tibocina-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tibocina-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tibocina-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tibocina-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tibocina-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tibocina-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tibocina-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"39069","name":"Metformin Article-31 referral - Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-12-21T01:00:00Z","reference_number":"EMA/603690/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/metformin-article-31-referral-use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function_no.pdf"}},
    {"id":"39084","name":"Summary information on a referral opinion following an arbitration pursant to Article 29 of Directive 2001/83/EC, for Isotretinoin, Lurantal, Trivane, Rexidal, Rcheritonin (See Annex I) International Non-Proprietary Name...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-10-17T02:08:21Z","last_updated_date":"2003-10-17T02:08:21Z","reference_number":"CPMP/2811/03","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/summary-information-referral-opinion-following-arbitration-pursant-article-29-directive-200183ec-isotretinoin-lurantal-trivane-rexidal-rcheritonin-see-annex-i-international-non-proprietary-name_sv.pdf"}},
    {"id":"39089","name":"Divergent position regarding the referral for arbitration under Article 33 of Directive 2001/82/EC submitted for Bovimec B and Porcimec P","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-13T02:00:00Z","last_updated_date":"2014-08-13T02:00:00Z","reference_number":"EMA/76071/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-regarding-referral-arbitration-under-article-33-directive-200182ec-submitted-bovimec-b-and-porcimec-p_en.pdf-0"},
    {"id":"39107","name":"Nimesulide - Article 31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-04-19T02:00:00Z","last_updated_date":"2012-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nimesulide-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nimesulide-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nimesulide-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nimesulide-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nimesulide-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nimesulide-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nimesulide-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nimesulide-article-31-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nimesulide-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nimesulide-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nimesulide-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nimesulide-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nimesulide-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nimesulide-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nimesulide-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nimesulide-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nimesulide-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nimesulide-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nimesulide-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nimesulide-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nimesulide-article-31-referral-annex-i_sv.pdf"}},
    {"id":"39121","name":"Gadolinium Article-31 referral – PRAC confirms restrictions on the use of linear gadolinium agents","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-07T02:00:00Z","last_updated_date":"2017-07-07T02:00:00Z","reference_number":"EMA/424715/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-prac-confirms-restrictions-use-linear-gadolinium-agents_en.pdf"},
    {"id":"39150","name":"Numeta Article-107i procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-27T15:00:00Z","last_updated_date":"2013-09-27T15:00:00Z","reference_number":"EMEA/H/A-107i/1373","document_url":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/numeta-article-107i-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/numeta-article-107i-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/numeta-article-107i-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/numeta-article-107i-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/numeta-article-107i-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/numeta-article-107i-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/numeta-article-107i-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/numeta-article-107i-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/numeta-article-107i-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/numeta-article-107i-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/numeta-article-107i-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/numeta-article-107i-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/numeta-article-107i-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/numeta-article-107i-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/numeta-article-107i-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/numeta-article-107i-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/numeta-article-107i-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/numeta-article-107i-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/numeta-article-107i-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/numeta-article-107i-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/numeta-article-107i-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/numeta-article-107i-procedure-annex-iv_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/numeta-article-107i-procedure-annex-iv_no.pdf"}},
    {"id":"39166","name":"Scandonest Article-30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2018-08-07T02:00:00Z","reference_number":"EMA/594289/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/scandonest-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/scandonest-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/scandonest-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/scandonest-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/scandonest-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/scandonest-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/scandonest-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/scandonest-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/scandonest-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/scandonest-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/scandonest-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/scandonest-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/scandonest-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/scandonest-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/scandonest-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/scandonest-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/scandonest-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/scandonest-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/scandonest-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/scandonest-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/scandonest-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/scandonest-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/scandonest-article-30-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/scandonest-article-30-referral-annex-i_no.pdf"}}    {"id":"39219","name":"Ambroxol and bromhexine Article-31 referral - Divergent opinion (Germany, Hungary, Latvia)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T09:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-divergent-opinion-germany-hungary-latvia_en.pdf"},
    {"id":"39240","name":"Codeine Article-31 referral – PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-10-05T14:00:00Z","last_updated_date":"2012-10-08T12:57:00Z","reference_number":"EMA/PRAC/640904/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"39255","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Addendum to notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-15T14:00:00Z","last_updated_date":"2016-04-15T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-addendum-notification_en.pdf"},
    {"id":"39258","name":"Opinion following an Article 30 referral for Cozaar Comp and associated names International Non-Proprietary Name (INN): losartan + hydrochlorothiazide: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-09-03T02:08:21Z","last_updated_date":"2008-09-03T02:08:21Z","reference_number":"EMEA/CHMP/494914/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-cozaar-comp-and-associated-names-international-non-proprietary-name-inn-losartan-hydrochlorothiazide-background-information_sv.pdf"}},
    {"id":"39269","name":"Tavanic - Article 30 referral - Assessment Report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-09-12T02:00:00Z","last_updated_date":"2012-09-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tavanic-article-30-referral-assessment-report_en.pdf"},
    {"id":"39329","name":"Substances related to nicotinic acid Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-10-11T19:00:00Z","reference_number":"EMA/PRAC/138312/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"39365","name":"Kytril - Article 30 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-12T02:00:00Z","last_updated_date":"2011-09-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kytril-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/kytril-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/kytril-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/kytril-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/kytril-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/kytril-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/kytril-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/kytril-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/kytril-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/kytril-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/kytril-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/kytril-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/kytril-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/kytril-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/kytril-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/kytril-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/kytril-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/kytril-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/kytril-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/kytril-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/kytril-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/kytril-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"39384","name":"Fiprex Article-33 referral - Annex I, II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-14T02:00:00Z","last_updated_date":"2014-08-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fiprex-article-33-referral-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fiprex-article-33-referral-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fiprex-article-33-referral-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fiprex-article-33-referral-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fiprex-article-33-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fiprex-article-33-referral-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fiprex-article-33-referral-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fiprex-article-33-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fiprex-article-33-referral-annex-i-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fiprex-article-33-referral-annex-i-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fiprex-article-33-referral-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fiprex-article-33-referral-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fiprex-article-33-referral-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fiprex-article-33-referral-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fiprex-article-33-referral-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fiprex-article-33-referral-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fiprex-article-33-referral-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fiprex-article-33-referral-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fiprex-article-33-referral-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fiprex-article-33-referral-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fiprex-article-33-referral-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fiprex-article-33-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fiprex-article-33-referral-annex-i-ii_sv.pdf"}},
    {"id":"39389","name":"Famvir - Article 30 Referral - Annex I, II and III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2011-09-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/famvir-article-30-referral-annex-i-ii-and-iii_no.pdf"}},
    {"id":"39411","name":"Valproate - Article 31 - Annex IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-04-29T02:00:00Z","last_updated_date":"2011-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valproate-article-31-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valproate-article-31-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valproate-article-31-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valproate-article-31-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valproate-article-31-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valproate-article-31-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valproate-article-31-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valproate-article-31-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valproate-article-31-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valproate-article-31-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valproate-article-31-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valproate-article-31-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valproate-article-31-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valproate-article-31-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valproate-article-31-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valproate-article-31-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valproate-article-31-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valproate-article-31-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valproate-article-31-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valproate-article-31-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valproate-article-31-annex-iv_sv.pdf"}},
    {"id":"39413","name":"Lactose of bovine origin Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-02T13:00:00Z","last_updated_date":"2016-12-02T13:00:00Z","reference_number":"EMEA/H/A-31/1449","document_url":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-notification_en.pdf"},
    {"id":"39454","name":"Retinoid Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-02T02:00:00Z","last_updated_date":"2018-07-02T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/retinoid-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/retinoid-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/retinoid-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/retinoid-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/retinoid-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/retinoid-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/retinoid-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/retinoid-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/retinoid-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/retinoid-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/retinoid-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/retinoid-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/retinoid-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/retinoid-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/retinoid-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/retinoid-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/retinoid-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/retinoid-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/retinoid-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/retinoid-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/retinoid-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/retinoid-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/retinoid-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/retinoid-article-31-referral-annex-iii_no.pdf"}},
    {"id":"39483","name":"Symbioflor 2 Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-09-07T02:00:00Z","last_updated_date":"2017-09-07T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/symbioflor-2-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/symbioflor-2-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/symbioflor-2-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/symbioflor-2-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/symbioflor-2-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/symbioflor-2-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/symbioflor-2-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/symbioflor-2-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/symbioflor-2-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/symbioflor-2-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/symbioflor-2-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/symbioflor-2-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/symbioflor-2-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/symbioflor-2-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/symbioflor-2-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/symbioflor-2-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/symbioflor-2-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/symbioflor-2-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/symbioflor-2-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/symbioflor-2-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/symbioflor-2-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/symbioflor-2-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"39531","name":"Questions and answers on Sandostatin and associated names (octreotide, 0.05 mg/1 ml, 0.1 mg/1 ml, 0.5 mg/1 ml and 1 mg/5 ml, solution for injection or infusion)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T14:00:00Z","last_updated_date":"2014-06-27T14:00:00Z","reference_number":"EMA/376438/2014 ","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-sandostatin-and-associated-names-octreotide-005-mg1-ml-01-mg1-ml-05-mg1-ml-and-1-mg5-ml-solution-injection-or-infusion_en.pdf"},
    {"id":"39547","name":"Domperidone Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-03-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-notification_en.pdf"},
    {"id":"39582","name":"Cyproterone / ethinylestradiol-containing medicines: Article-107i procedure - Benefits of Diane 35 and its generics outweigh risks in certain patient groups","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-08-05T02:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"EMA/318380/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-benefits-diane-35-and-its-generics-outweigh-risks-certain-patient-groups_sv.pdf"}},
    {"id":"39607","name":"Assessment report for fibrinogen-containing solutions for sealant authorised for administration by spray application","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-04-02T17:00:00Z","last_updated_date":"2013-04-02T17:00:00Z","reference_number":"EMA/66729/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-fibrinogen-containing-solutions-sealant-authorised-administration-spray-application_en.pdf"},
    {"id":"39633","name":"Opinion following an Article 29(2) referral Rigevidon International Non-Proprietary Name (INN): levonorgestrel and ethinylestradiol: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-05-10T02:08:21Z","last_updated_date":"2005-05-10T02:08:21Z","reference_number":"EMEA/CHMP/94618/2005","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-292-referral-rigevidon-international-non-proprietary-name-inn-levonorgestrel-and-ethinylestradiol-background-information_sv.pdf"}},
    {"id":"39637","name":"Questions and answers on the review of medicines containing modafinil - Re-examination","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"EMA/725532/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-medicines-containing-modafinil-re-examination_sv.pdf"}},
    {"id":"39643","name":"Testosterone Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-04-11T14:00:00Z","reference_number":"EMA/PRAC/178703/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"39646","name":"Metformin Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"EMEA/H/A-31/1432","document_url":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-notification_en.pdf"},
    {"id":"39713","name":"Tysabri Article-20 procedure - EMA confirms recommendations to minimise risk of brain infection PML with Tysabri","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-05-12T02:00:00Z","reference_number":"EMA/137488/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_sv.pdf"}},
    {"id":"39758","name":"Bromocriptine Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-21T02:00:00Z","last_updated_date":"2014-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bromocriptine-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bromocriptine-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bromocriptine-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bromocriptine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bromocriptine-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bromocriptine-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bromocriptine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bromocriptine-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/bromocriptine-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bromocriptine-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bromocriptine-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bromocriptine-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bromocriptine-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bromocriptine-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bromocriptine-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bromocriptine-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bromocriptine-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bromocriptine-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bromocriptine-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bromocriptine-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bromocriptine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bromocriptine-article-31-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/bromocriptine-article-31-referral-annex-iii_no.pdf"}},
    {"id":"39768","name":"Questions and answers on the review of gadolinium-containing contrast agents","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-11-21T00:59:00Z","last_updated_date":"2010-09-02T01:59:00Z","reference_number":"EMEA/727399/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-gadolinium-containing-contrast-agents_sv.pdf"}},
    {"id":"39797","name":"Assessment report for KETOPROFEN containing medicinal products (topical formulations)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-10-28T02:00:00Z","last_updated_date":"2011-10-28T02:00:00Z","reference_number":"EMA/824183/2011","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-ketoprofen-containing-medicinal-products-topical-formulations_en.pdf"},
    {"id":"39807","name":"Divergent position on a CVMP opinion on an Article-33(4) referral of Directive 2001/82/EC for Fiprex CAT 52.5 mg spot-on solution for cats, and Fiprex S 75 mg spot-on solution for dogs, Fiprex M 150 mg spot-on solution f...","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-14T02:00:00Z","last_updated_date":"2014-08-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-334-referral-directive-200182ec-fiprex-cat-525-mg-spot-solution-cats-and-fiprex-s-75-mg-spot-solution-dogs-fiprex-m-150-mg-spot-solution-f_en.pdf"},
    {"id":"39813","name":"Ambroxol and bromhexine Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2016-02-05T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ambroxol-and-bromhexine-article-31-referral-annex-iii_no.pdf"}},
    {"id":"39814","name":"Prevora - Article 29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-09-20T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/prevora-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/prevora-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/prevora-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/prevora-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/prevora-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/prevora-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/prevora-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/prevora-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/prevora-article-29-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/prevora-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/prevora-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/prevora-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/prevora-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/prevora-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/prevora-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/prevora-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/prevora-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/prevora-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/prevora-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/prevora-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/prevora-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/prevora-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"39827","name":"Furosemide Vitabalans Article-29(4) - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-30T17:30:00Z","last_updated_date":"2013-07-30T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/furosemide-vitabalans-article-294-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/furosemide-vitabalans-article-294-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/furosemide-vitabalans-article-294-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/furosemide-vitabalans-article-294-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/furosemide-vitabalans-article-294-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/furosemide-vitabalans-article-294-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/furosemide-vitabalans-article-294-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/furosemide-vitabalans-article-294-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/furosemide-vitabalans-article-294-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/furosemide-vitabalans-article-294-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/furosemide-vitabalans-article-294-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/furosemide-vitabalans-article-294-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/furosemide-vitabalans-article-294-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/furosemide-vitabalans-article-294-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/furosemide-vitabalans-article-294-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/furosemide-vitabalans-article-294-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/furosemide-vitabalans-article-294-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/furosemide-vitabalans-article-294-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/furosemide-vitabalans-article-294-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/furosemide-vitabalans-article-294-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/furosemide-vitabalans-article-294-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/furosemide-vitabalans-article-294-annex-ii_sv.pdf"}},
    {"id":"39829","name":"Opinion following an Article 34 referral Pulmotil 40 VET Premix, Pulmotil 100 VET Premix, Pulmotil 200 VET Premix and associated names: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-10-16T01:08:21Z","last_updated_date":"2009-10-16T01:08:21Z","reference_number":"EMEA/608931/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-34-referral-pulmotil-40-vet-premix-pulmotil-100-vet-premix-pulmotil-200-vet-premix-and-associated-names-background-information_sv.pdf"}},
    {"id":"39862","name":"Synjardy Article-20 procedure - Annex I - III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-18T02:00:00Z","last_updated_date":"2016-05-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synjardy-article-20-procedure-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/synjardy-article-20-procedure-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/synjardy-article-20-procedure-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/synjardy-article-20-procedure-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/synjardy-article-20-procedure-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/synjardy-article-20-procedure-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/synjardy-article-20-procedure-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/synjardy-article-20-procedure-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/synjardy-article-20-procedure-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/synjardy-article-20-procedure-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/synjardy-article-20-procedure-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/synjardy-article-20-procedure-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/synjardy-article-20-procedure-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/synjardy-article-20-procedure-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/synjardy-article-20-procedure-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/synjardy-article-20-procedure-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/synjardy-article-20-procedure-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/synjardy-article-20-procedure-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/synjardy-article-20-procedure-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/synjardy-article-20-procedure-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/synjardy-article-20-procedure-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/synjardy-article-20-procedure-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/synjardy-article-20-procedure-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/synjardy-article-20-procedure-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/synjardy-article-20-procedure-annex-i-iii_no.pdf"}},
    {"id":"39981","name":"Opinion following an Article 6(12) referral Octegra and associated names International Non-Proprietary Name (INN): moxifloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-08-14T02:08:21Z","last_updated_date":"2008-08-14T02:08:21Z","reference_number":"EMEA/CHMP/524284/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-612-referral-octegra-and-associated-names-international-non-proprietary-name-inn-moxifloxacin-background-information_sv.pdf"}},
    {"id":"39991","name":"Diclofenac Article-31 referral - New safety advice for diclofenac – CMDh endorses PRAC recommendation","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/380947/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-new-safety-advice-diclofenac-cmdh-endorses-prac-recommendation_en.pdf"},
    {"id":"40015","name":"GVK Biosciences Article-31 referral - GVK Biosciences: European Medicines Agency recommends suspending medicines over flawed studies","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-23T13:00:00Z","last_updated_date":"2015-02-27T13:00:00Z","reference_number":"EMA/37763/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-recommends-suspending-medicines-over-flawed-studies_en.pdf"},
    {"id":"40016","name":"Zinbryta Article-20 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-06-09T18:00:00Z","last_updated_date":"2017-06-09T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-notification_en.pdf"},
    {"id":"40027","name":"Divergent position on a revised CVMP opinion on an Article 35 referral of Directive 2001/82/EC for All long acting formulations for injection containing barium selenate for all food producing species","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-27T02:00:00Z","last_updated_date":"2014-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-revised-cvmp-opinion-article-35-referral-directive-200182ec-all-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_en.pdf"},
    {"id":"40029","name":"Opinion of the Committee for proprietary medicinal products pursuant to Article 10 of Directive 75/319/EEC as amended","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"1998-08-03T02:08:21Z","last_updated_date":"1998-08-03T02:08:21Z","reference_number":"CPMP/343/96","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-committee-proprietary-medicinal-products-pursuant-article-10-directive-75319eec-amended_en.pdf"},
    {"id":"40034","name":"Metformin Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-21T01:00:00Z","last_updated_date":"2016-12-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metformin-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metformin-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metformin-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metformin-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metformin-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metformin-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metformin-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metformin-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metformin-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metformin-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metformin-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metformin-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metformin-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metformin-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metformin-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metformin-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metformin-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metformin-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metformin-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metformin-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metformin-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metformin-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/metformin-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/metformin-article-31-referral-annex-iii_no.pdf"}},
    {"id":"40051","name":"Assessment report for metoclopramide-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"EMA/753989/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/assessment-report-metoclopramide-containing-medicines_en.pdf"},
    {"id":"40056","name":"Tetrazepam-containing medicines - Article-107i procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T13:00:00Z","last_updated_date":"2013-01-11T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-notification_en.pdf"},
    {"id":"40104","name":"Inhaled corticosteroids Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-08T02:00:00Z","last_updated_date":"2015-05-08T02:00:00Z","reference_number":"EMA/285361/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-review-started_en.pdf"},
    {"id":"40131","name":"Paracetamol/ibuprofen 500mg/150mg Article-29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T02:00:00Z","last_updated_date":"2017-08-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-annex-i_sv.pdf"}},
    {"id":"40139","name":"Nimesulide - Article 107 procedures - Annex IV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-04-08T02:00:00Z","last_updated_date":"2010-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-107-procedures-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nimesulide-article-107-procedures-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nimesulide-article-107-procedures-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nimesulide-article-107-procedures-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nimesulide-article-107-procedures-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nimesulide-article-107-procedures-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nimesulide-article-107-procedures-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nimesulide-article-107-procedures-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nimesulide-article-107-procedures-annex-iv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nimesulide-article-107-procedures-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nimesulide-article-107-procedures-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nimesulide-article-107-procedures-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nimesulide-article-107-procedures-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nimesulide-article-107-procedures-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nimesulide-article-107-procedures-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nimesulide-article-107-procedures-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nimesulide-article-107-procedures-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nimesulide-article-107-procedures-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nimesulide-article-107-procedures-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nimesulide-article-107-procedures-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nimesulide-article-107-procedures-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nimesulide-article-107-procedures-annex-iv_sv.pdf"}},
    {"id":"40149","name":"Haldol Decanoate Article-30 - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-11T02:00:00Z","last_updated_date":"2017-05-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/haldol-decanoate-article-30-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/haldol-decanoate-article-30-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/haldol-decanoate-article-30-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/haldol-decanoate-article-30-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/haldol-decanoate-article-30-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/haldol-decanoate-article-30-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/haldol-decanoate-article-30-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/haldol-decanoate-article-30-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/haldol-decanoate-article-30-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/haldol-decanoate-article-30-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/haldol-decanoate-article-30-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/haldol-decanoate-article-30-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/haldol-decanoate-article-30-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/haldol-decanoate-article-30-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/haldol-decanoate-article-30-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/haldol-decanoate-article-30-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/haldol-decanoate-article-30-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/haldol-decanoate-article-30-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/haldol-decanoate-article-30-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/haldol-decanoate-article-30-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/haldol-decanoate-article-30-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/haldol-decanoate-article-30-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/haldol-decanoate-article-30-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/haldol-decanoate-article-30-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/haldol-decanoate-article-30-annex-i_no.pdf"}},
    {"id":"40169","name":"Tavanic - Article 30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-09-12T02:00:00Z","last_updated_date":"2012-09-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tavanic-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tavanic-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tavanic-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tavanic-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tavanic-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tavanic-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tavanic-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tavanic-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tavanic-article-30-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tavanic-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tavanic-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tavanic-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tavanic-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tavanic-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tavanic-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tavanic-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tavanic-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tavanic-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tavanic-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tavanic-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tavanic-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tavanic-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"40189","name":"Opinion following an Article 30 referral for Ciprofloxacin Bayer and associated names International Non-Proprietary Name (INN): ciprofloxacin: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-10-07T02:08:21Z","last_updated_date":"2008-10-07T02:08:21Z","reference_number":"EMEA/CHMP/384874/2008","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-30-referral-ciprofloxacin-bayer-and-associated-names-international-non-proprietary-name-inn-ciprofloxacin-background-information_sv.pdf"}},
    {"id":"40200","name":"Priligy - Article 29 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-03-28T02:00:00Z","last_updated_date":"2012-03-28T02:00:00Z","reference_number":"EMA/73530/2012","document_url":"https://www.ema.europa.eu/en/documents/referral/priligy-article-29-referral-assessment-report_en.pdf"},
    {"id":"40217","name":"Questions and answers on Protopic/protopy and Elidel","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2006-03-23T00:08:21Z","last_updated_date":"2006-03-23T00:08:21Z","reference_number":"EMEA/CHMP/80270/2006","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-protopicprotopy-and-elidel_en.pdf"},
    {"id":"40226","name":"Zinbryta Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-02T11:00:00Z","last_updated_date":"2018-03-02T11:00:00Z","reference_number":"EMA/120379/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-procedure-review-started_en.pdf"},
    {"id":"40233","name":"Fibrates Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-04-03T17:00:00Z","last_updated_date":"2013-04-03T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fibrates-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fibrates-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fibrates-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fibrates-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fibrates-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fibrates-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fibrates-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fibrates-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fibrates-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fibrates-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fibrates-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fibrates-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fibrates-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fibrates-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fibrates-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fibrates-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fibrates-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fibrates-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fibrates-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fibrates-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fibrates-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fibrates-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"40256","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/824717/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-direct-acting-antivirals-hepatitis-c-ema-confirms-recommendation-screen-hepatitis-b_en.pdf-0"},
    {"id":"40273","name":"Hydroxyethyl starch Article-107i referral - CMDh divergent positions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-cmdh-divergent-positions_en.pdf"},
    {"id":"40278","name":"Cerivastatin - Article 36 referral - Annex I, II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2002-12-20T00:08:21Z","last_updated_date":"2002-12-20T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cerivastatin-article-36-referral-annex-i-ii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/cerivastatin-article-36-referral-annex-i-ii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cerivastatin-article-36-referral-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cerivastatin-article-36-referral-annex-i-ii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cerivastatin-article-36-referral-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cerivastatin-article-36-referral-annex-i-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cerivastatin-article-36-referral-annex-i-ii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cerivastatin-article-36-referral-annex-i-ii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cerivastatin-article-36-referral-annex-i-ii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cerivastatin-article-36-referral-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cerivastatin-article-36-referral-annex-i-ii_sv.pdf"}},
    {"id":"40328","name":"Summary information on referral opinion pursuant to Article 30 of Council Directive 2001/83/EC for Renitec and associated names (see Annex I) International Non-Proprietary Name (INN): enalapril: Background information an...","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2003-12-04T00:08:21Z","last_updated_date":"2003-12-04T00:08:21Z","reference_number":"CPMP/3175/03","document_url":"https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-pursuant-article-30-council-directive-200183ec-renitec-and-associated-names-see-annex-i-international-non-proprietary-name-inn-enalapril-background-information_en.pdf"},
    {"id":"40332","name":"Alkem Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-notification_en.pdf"},
    {"id":"40366","name":"Combisyn Lactating Cow: Article 33 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-12-08T01:00:00Z","last_updated_date":"2011-12-08T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/combisyn-lactating-cow-article-33-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"40372","name":"Diflucan - Article 30 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2012-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diflucan-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diflucan-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diflucan-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diflucan-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diflucan-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diflucan-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diflucan-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diflucan-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diflucan-article-30-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diflucan-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diflucan-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diflucan-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diflucan-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diflucan-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diflucan-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diflucan-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diflucan-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diflucan-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diflucan-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diflucan-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diflucan-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diflucan-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/diflucan-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/diflucan-article-30-referral-annex-i_no.pdf"}},
    {"id":"40408","name":"Flolan - Article 30 - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T18:47:00Z","last_updated_date":"2012-09-14T18:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flolan-article-30-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flolan-article-30-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flolan-article-30-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flolan-article-30-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flolan-article-30-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flolan-article-30-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flolan-article-30-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flolan-article-30-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flolan-article-30-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flolan-article-30-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flolan-article-30-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flolan-article-30-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flolan-article-30-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flolan-article-30-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flolan-article-30-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flolan-article-30-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flolan-article-30-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flolan-article-30-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flolan-article-30-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flolan-article-30-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flolan-article-30-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flolan-article-30-annex-iii_sv.pdf"}},
    {"id":"40411","name":"Combined hormonal contraceptives Article-31 referral - PRAC assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-31T01:00:00Z","last_updated_date":"2014-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"40421","name":"Hydroxyethyl starch Article-107i referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T02:00:00Z","last_updated_date":"2018-07-27T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/hydroxyethyl-starch-article-107i-referral-annex-i_no.pdf"}},
    {"id":"40428","name":"Testosterone Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2015-01-08T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/testosterone-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/testosterone-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/testosterone-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/testosterone-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/testosterone-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/testosterone-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/testosterone-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/testosterone-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/testosterone-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/testosterone-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/testosterone-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/testosterone-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/testosterone-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/testosterone-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/testosterone-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/testosterone-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/testosterone-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/testosterone-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/testosterone-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/testosterone-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/testosterone-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/testosterone-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/testosterone-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/testosterone-article-31-referral-annex-i_no.pdf"}},
    {"id":"40464","name":"Inhaled corticosteroids Article-31 referral – Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-05-08T02:00:00Z","last_updated_date":"2015-11-10T18:16:00Z","reference_number":"EMA/PRAC/290163/2015 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"40468","name":"Bromocriptine, Dihydroergocryptine and Lisuride - Article 31 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-05-05T02:08:21Z","last_updated_date":"2009-05-05T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bromocriptine-dihydroergocryptine-and-lisuride-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"40470","name":"Methadone Article-107i procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-05-08T19:30:00Z","reference_number":"EMA/PRAC/186319/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-timetable-procedure_en.pdf"},
    {"id":"40480","name":"Uman Big - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-21T00:08:21Z","last_updated_date":"2009-03-21T00:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/uman-big-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"40501","name":"Alkem Article-31 referral - CHMP List of questions to Alkem BE Centre","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/228248/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-chmp-list-questions-alkem-be-centre_en.pdf"},
    {"id":"40504","name":"Domperidone Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-11T02:00:00Z","last_updated_date":"2014-09-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/domperidone-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/domperidone-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/domperidone-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/domperidone-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/domperidone-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/domperidone-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/domperidone-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/domperidone-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/domperidone-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/domperidone-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/domperidone-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/domperidone-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/domperidone-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/domperidone-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/domperidone-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/domperidone-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/domperidone-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/domperidone-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/domperidone-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/domperidone-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/domperidone-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/domperidone-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"40511","name":"Questions and answers on the review of tolperisone-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T14:00:00Z","last_updated_date":"2013-04-02T18:00:00Z","reference_number":"EMA/673365/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-tolperisone-containing-medicines_sv.pdf"}},
    {"id":"40531","name":"Soludox: Article-1 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-09-24T02:00:00Z","last_updated_date":"2013-09-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/soludox-article-1-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/soludox-article-1-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/soludox-article-1-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/soludox-article-1-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/soludox-article-1-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/soludox-article-1-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/soludox-article-1-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/soludox-article-1-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/soludox-article-1-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/soludox-article-1-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/soludox-article-1-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/soludox-article-1-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/soludox-article-1-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/soludox-article-1-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/soludox-article-1-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/soludox-article-1-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/soludox-article-1-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/soludox-article-1-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/soludox-article-1-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/soludox-article-1-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/soludox-article-1-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/soludox-article-1-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/soludox-article-1-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"40547","name":"Domperidone Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-03-08T01:00:00Z","reference_number":"EMA/PRAC/124198/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"40570","name":"Antifibrinolytic medicines - Article 31 referral - Annex III (aminocaproic acid)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-17T11:09:53Z","last_updated_date":"2013-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iii-aminocaproic-acid_sv.pdf"}},
    {"id":"40614","name":"Plendil - Article 30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2015-03-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/plendil-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/plendil-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/plendil-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/plendil-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/plendil-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/plendil-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/plendil-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/plendil-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/plendil-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/plendil-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/plendil-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/plendil-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/plendil-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/plendil-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/plendil-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/plendil-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/plendil-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/plendil-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/plendil-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/plendil-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/plendil-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/plendil-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/plendil-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/plendil-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/plendil-article-30-referral-annex-iii_no.pdf"}},
    {"id":"40624","name":"GVK Biosciences Article-31 referral - GVK Biosciences: European Medicines Agency confirms recommendation to suspend medicines over flawed studies","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-08-04T02:00:00Z","last_updated_date":"2015-08-04T02:00:00Z","reference_number":"EMA/466132/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-european-medicines-agency-confirms-recommendation-suspend-medicines-over-flawed-studies_sv.pdf"}},
    {"id":"40635","name":"Gadolinium Article-31 referral – Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-12-19T01:00:00Z","last_updated_date":"2017-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gadolinium-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gadolinium-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gadolinium-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gadolinium-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gadolinium-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gadolinium-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gadolinium-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gadolinium-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gadolinium-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gadolinium-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gadolinium-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gadolinium-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gadolinium-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gadolinium-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gadolinium-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gadolinium-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gadolinium-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gadolinium-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gadolinium-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gadolinium-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gadolinium-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gadolinium-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/gadolinium-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/gadolinium-article-31-referral-annex-i_no.pdf"}},
    {"id":"40655","name":"Corlentor and Procoralan Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T20:00:00Z","last_updated_date":"2014-05-08T20:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/corlentor-and-procoralan-article-20-procedure-notification_en.pdf"},
    {"id":"40676","name":"Codeine Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"EMA/PRAC/180085/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-prac-list-questions_en.pdf-0"},
    {"id":"40701","name":"Milaxyn Plus: Article 34 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-07-23T02:00:00Z","last_updated_date":"2012-07-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/milaxyn-plus-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"40705","name":"Zestril - Article 30 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2004-08-10T01:59:00Z","last_updated_date":"2004-08-10T01:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zestril-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/zestril-article-30-referral-annex-i-ii-iii_es.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zestril-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zestril-article-30-referral-annex-i-ii-iii_de.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zestril-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zestril-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zestril-article-30-referral-annex-i-ii-iii_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zestril-article-30-referral-annex-i-ii-iii_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zestril-article-30-referral-annex-i-ii-iii_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zestril-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zestril-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"40710","name":"Maci Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/maci-article-20-procedure-notification_en.pdf"},
    {"id":"40715","name":"Ambroxol and bromhexine Article-31 referral - Divergent opinion (Netherlands)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-05T01:00:00Z","last_updated_date":"2016-02-05T09:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-divergent-opinion-netherlands_en.pdf"},
    {"id":"40721","name":"Hydroxyethyl starch Article-107i procedure - Stakeholders' submission form","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-07-12T14:00:00Z","last_updated_date":"2013-07-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-stakeholders-submission-form_en.pdf"},
    {"id":"40746","name":"Acipimox only to be used as additional or alternative treatment to reduce high triglyceride levels","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/779546/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/acipimox-only-be-used-additional-or-alternative-treatment-reduce-high-triglyceride-levels_en.pdf-0"},
    {"id":"40761","name":"Dexamethasone - Article 29 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T01:00:00Z","last_updated_date":"2012-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexamethasone-article-29-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexamethasone-article-29-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexamethasone-article-29-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexamethasone-article-29-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexamethasone-article-29-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexamethasone-article-29-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexamethasone-article-29-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexamethasone-article-29-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexamethasone-article-29-referral-annex-ii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexamethasone-article-29-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexamethasone-article-29-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexamethasone-article-29-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexamethasone-article-29-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexamethasone-article-29-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexamethasone-article-29-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexamethasone-article-29-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexamethasone-article-29-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexamethasone-article-29-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexamethasone-article-29-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexamethasone-article-29-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexamethasone-article-29-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexamethasone-article-29-referral-annex-ii_sv.pdf"}},
    {"id":"40770","name":"Seretide Diskus- Article 6 (13) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-07-14T02:08:21Z","last_updated_date":"2007-07-14T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seretide-diskus-article-6-13-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"40790","name":"Paracetamol Article-31 referral - CMDh divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-01T01:00:00Z","last_updated_date":"2018-03-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-cmdh-divergent-position_en.pdf"},
    {"id":"40793","name":"Tienam - Article 30 Referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2012-02-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tienam-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tienam-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tienam-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tienam-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tienam-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tienam-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tienam-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tienam-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tienam-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tienam-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tienam-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tienam-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tienam-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tienam-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tienam-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tienam-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tienam-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tienam-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tienam-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tienam-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tienam-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tienam-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"40795","name":"EMLA cream Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/emla-cream-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/emla-cream-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/emla-cream-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/emla-cream-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/emla-cream-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/emla-cream-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/emla-cream-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/emla-cream-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/emla-cream-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/emla-cream-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/emla-cream-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/emla-cream-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/emla-cream-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/emla-cream-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/emla-cream-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/emla-cream-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/emla-cream-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/emla-cream-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/emla-cream-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/emla-cream-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/emla-cream-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/emla-cream-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/emla-cream-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"40807","name":"Divergent position on a CVMP opinion on an Article-33 referral of Directive 2001/82/EC for Florgane 300-mg/ml suspension for injection for cattle and pigs","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-07-10T14:30:00Z","last_updated_date":"2013-07-10T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/divergent-position-cvmp-opinion-article-33-referral-directive-200182ec-florgane-300-mgml-suspension-injection-cattle-and-pigs_en.pdf"},
    {"id":"40849","name":"Zinbryta Article-20 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-06-09T17:41:00Z","last_updated_date":"2017-06-09T17:41:00Z","reference_number":"EMA/366148/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-referral-review-started_en.pdf"},
    {"id":"40871","name":"Arimidex - Article 30 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/arimidex-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/arimidex-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/arimidex-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/arimidex-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/arimidex-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/arimidex-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/arimidex-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/arimidex-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/arimidex-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/arimidex-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/arimidex-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/arimidex-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/arimidex-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/arimidex-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/arimidex-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/arimidex-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/arimidex-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/arimidex-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/arimidex-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/arimidex-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/arimidex-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/arimidex-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"40913","name":"Ciclosporin IDL - Article-30 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-20T00:00:00Z","last_updated_date":"2013-11-20T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ciclosporin-idl-article-30-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"40921","name":"Novosis Goserelin - Article 36 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"EMEA/H/A-36/1295","document_url":"https://www.ema.europa.eu/en/documents/referral/novosis-goserelin-article-36-referral-assessment-report_en.pdf"},
    {"id":"40928","name":"Questions and answers on the referral for Bleomycin, powder for solution for injection, 15 U/Vial, from Pharmachemie BV","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-03-18T00:08:21Z","last_updated_date":"2009-03-18T00:08:21Z","reference_number":"EMEA/CHMP/191900/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_sv.pdf"}},
    {"id":"40931","name":"Seasonique Article-29(4) - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/seasonique-article-294-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/seasonique-article-294-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/seasonique-article-294-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/seasonique-article-294-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/seasonique-article-294-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/seasonique-article-294-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/seasonique-article-294-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/seasonique-article-294-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/seasonique-article-294-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/seasonique-article-294-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/seasonique-article-294-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/seasonique-article-294-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/seasonique-article-294-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/seasonique-article-294-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/seasonique-article-294-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/seasonique-article-294-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/seasonique-article-294-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/seasonique-article-294-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/seasonique-article-294-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/seasonique-article-294-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/seasonique-article-294-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/seasonique-article-294-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/seasonique-article-294-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/seasonique-article-294-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/seasonique-article-294-annex-i_no.pdf"}},
    {"id":"40937","name":"SGLT2 inhibitors (previously canagliflozin) Article-20 procedure - Updated PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T17:00:00Z","last_updated_date":"2016-07-08T17:00:00Z","reference_number":"EMA/PRAC/472827/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-updated-prac-list-questions_en.pdf"},
    {"id":"40961","name":"Semler Article-31 referral – Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-notification_en.pdf"},
    {"id":"41012","name":"HPV vaccines - Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-07-13T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-notification_en.pdf"},
    {"id":"41014","name":"Testosterone Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T14:00:00Z","last_updated_date":"2014-04-11T14:00:00Z","reference_number":"EMA/209962/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-review-started_en.pdf"},
    {"id":"41070","name":"Questions and answers on the review of the fibrin sealants Evicel and Quixil given by spray application","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2013-04-02T17:00:00Z","reference_number":"EMEA/H/A-31/1337","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-fibrin-sealants-evicel-and-quixil-given-spray-application_sv.pdf"}},
    {"id":"41072","name":"Dexamed and associated names Article-29(4) referral - Questions and answers","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-09-02T02:00:00Z","reference_number":"EMA/709170/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexamed-and-associated-names-article-294-referral-questions-and-answers_sv.pdf"}}    {"id":"41082","name":"Goserelin Cell Pharm - Article 36 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-02-06T01:00:00Z","last_updated_date":"2012-02-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/goserelin-cell-pharm-article-36-referral-annex-i_sv.pdf"}},
    {"id":"41084","name":"Diacerein Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-09-19T02:00:00Z","last_updated_date":"2014-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diacerein-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diacerein-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diacerein-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diacerein-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diacerein-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diacerein-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diacerein-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diacerein-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diacerein-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diacerein-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diacerein-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diacerein-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diacerein-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diacerein-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diacerein-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diacerein-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diacerein-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diacerein-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diacerein-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diacerein-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diacerein-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diacerein-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"41098","name":"Veterinary medicinal products containing active substances belonging to the class of flukicides for which no maximum residue limit has been established in milk and which are intended for use in ruminants producing milk f...","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T01:00:00Z","last_updated_date":"2013-01-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/veterinary-medicinal-products-containing-active-substances-belonging-class-flukicides-which-no-maximum-residue-limit-has-been-established-milk-and-which-are-intended-use-ruminants-producing-milk-f_sv.pdf"}},
    {"id":"41102","name":"Testosterone Article-31 referral - No consistent evidence of an increased risk of heart problems with testosterone medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2015-01-08T01:00:00Z","reference_number":"EMA/706140/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/testosterone-article-31-referral-no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_sv.pdf"}},
    {"id":"41104","name":"Rigevidon - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-06-08T02:08:21Z","last_updated_date":"2005-06-08T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rigevidon-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"41135","name":"Lansopon 15 mg and 30 mg - Article 29 referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2005-10-13T02:08:21Z","last_updated_date":"2005-10-13T02:08:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lansopon-15-mg-and-30-mg-article-29-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"41151","name":"Dexrazoxane - Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T13:24:27Z","last_updated_date":"2012-01-16T12:24:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexrazoxane-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexrazoxane-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexrazoxane-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexrazoxane-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexrazoxane-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexrazoxane-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexrazoxane-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexrazoxane-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexrazoxane-article-31-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexrazoxane-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexrazoxane-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexrazoxane-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexrazoxane-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexrazoxane-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexrazoxane-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexrazoxane-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexrazoxane-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexrazoxane-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexrazoxane-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexrazoxane-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexrazoxane-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexrazoxane-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/dexrazoxane-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/dexrazoxane-article-31-referral-annex-iii_no.pdf"}},
    {"id":"41168","name":"Diclofenac Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T01:00:00Z","last_updated_date":"2013-11-27T01:00:00Z","reference_number":"EMEA/H/A-31/1344","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"41192","name":"Adrenaline auto-injectors Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-29T02:00:00Z","reference_number":"EMA/242569/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-review-started_en.pdf"},
    {"id":"41196","name":"Symbioflor 2 Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-06T02:00:00Z","last_updated_date":"2016-04-06T02:00:00Z","reference_number":"EMA/CHMP/233295/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"41204","name":"Okrido Article-29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-03T01:00:00Z","last_updated_date":"2014-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/okrido-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/okrido-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/okrido-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/okrido-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/okrido-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/okrido-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/okrido-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/okrido-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/okrido-article-29-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/okrido-article-29-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/okrido-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/okrido-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/okrido-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/okrido-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/okrido-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/okrido-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/okrido-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/okrido-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/okrido-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/okrido-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/okrido-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/okrido-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/okrido-article-29-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/okrido-article-29-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/okrido-article-29-referral-annex-i_no.pdf"}},
    {"id":"41213","name":"Questions and answers on Daivobet and associated names (calcipotriol/betamethasone gel and ointment, 50 micrograms/0.5 mg per g)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2011-04-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_sv.pdf"}},
    {"id":"41220","name":"Lincomycin and spectinomycin Article 35 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/462762/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lincomycin-and-spectinomycin-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"41241","name":"Opinion following an Article 31 referral for Agreal and associated names (see annex I) International Non-Proprietary Name (INN): Veralipride: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2007-10-01T02:08:21Z","last_updated_date":"2007-10-01T02:08:21Z","reference_number":"EMEA/CHMP/432352/2007","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-31-referral-agreal-and-associated-names-see-annex-i-international-non-proprietary-name-inn-veralipride-background-information_sv.pdf"}},
    {"id":"41244","name":"Lovenox Article 30 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-22T18:30:00Z","last_updated_date":"2017-03-22T18:30:00Z","reference_number":"EMA/134171/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/lovenox-article-30-referral-assessment-report_en.pdf"},
    {"id":"41247","name":"Diclofenac Article-29 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-10-10T02:00:00Z","last_updated_date":"2016-10-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-29-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-29-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-29-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-29-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-29-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-29-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-29-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-29-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-29-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-29-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-29-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-29-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-29-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-29-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-29-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-29-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-29-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-29-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-29-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-29-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-29-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-29-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-29-referral-annex-i_sv.pdf"}},
    {"id":"41315","name":"Codeine Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-04-11T02:00:00Z","last_updated_date":"2014-04-11T02:00:00Z","reference_number":"EMA/209409/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-review-started_en.pdf-0"},
    {"id":"41328","name":"Dexadreson - Article-35 referral - Annexes I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-27T01:00:00Z","last_updated_date":"2013-11-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/dexadreson-article-35-referral-annexes-i-ii-iii_is.pdf"}},
    {"id":"41409","name":"Tobramycin VVB and associated names Article-29(4) referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"EMA/139057/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-chmp-assessment-report_en.pdf"},
    {"id":"41424","name":"Calcitonin: Product information as approved by the CHMP on 15 November 2012, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2012-11-16T13:00:00Z","last_updated_date":"2012-11-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/calcitonin-product-information-approved-chmp-15-november-2012-pending-endorsement-european-commission_en.pdf"},
    {"id":"41429","name":"Kytril - Article 30 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2011-09-12T02:00:00Z","last_updated_date":"2011-09-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kytril-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/kytril-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/kytril-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/kytril-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/kytril-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/kytril-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/kytril-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/kytril-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/kytril-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/kytril-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/kytril-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/kytril-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/kytril-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/kytril-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/kytril-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/kytril-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/kytril-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/kytril-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/kytril-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/kytril-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/kytril-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/kytril-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"41453","name":"Flupirtine-containing medicines Article-107i procedure - Rationale for triggering","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2013-03-08T13:00:00Z","last_updated_date":"2013-03-08T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-rationale-triggering_en.pdf"},
    {"id":"41466","name":"EMLA cream Article-30 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-15T01:00:00Z","last_updated_date":"2015-01-15T01:00:00Z","reference_number":"EMA/707790/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/emla-cream-article-30-referral-assessment-report_en.pdf"},
    {"id":"41474","name":"Opinion following an Article-13 referral for Resflor solution injectable and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-09T18:30:00Z","last_updated_date":"2015-01-09T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-13-referral-resflor-solution-injectable-and-associated-names_sv.pdf"}},
    {"id":"41485","name":"Opinion following an Article 33 referral for Shotaflor 300 mg/ml solution for injection for cattle International Non-Proprietary Name (INN): Florfenicol: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2009-08-04T01:59:00Z","last_updated_date":"2009-08-04T01:59:00Z","reference_number":"EMEA/313852/2009","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-33-referral-shotaflor-300-mgml-solution-injection-cattle-international-non-proprietary-name-inn-florfenicol-background-information_sv.pdf"}},
    {"id":"41486","name":"Questions and answers on Sandimmun, Sandimmun Neoral and associated names (ciclosporin, 10-, 25-, 50- and 100-mg capsules, 100-mg/ml oral solution and 50-mg/ml concentrate for solution for infusion)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-12-20T17:00:00Z","reference_number":"EMA/391239/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-sandimmun-sandimmun-neoral-and-associated-names-ciclosporin-10-25-50-and-100-mg-capsules-100-mgml-oral-solution-and-50-mgml-concentrate-solution-infusion_sv.pdf-0"}},
    {"id":"41491","name":"Tobramycin VVB and associated names Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T13:00:00Z","last_updated_date":"2016-01-29T13:00:00Z","reference_number":"EMA/55653/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_en.pdf"},
    {"id":"41498","name":"Opinion following an Article 35 referral for long-acting formulations for injection containing barium selenate for all food producing species","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-05-27T02:00:00Z","last_updated_date":"2014-05-27T02:00:00Z","reference_number":"EMA/197955/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-35-referral-long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species_sv.pdf"}},
    {"id":"41513","name":"Ergot derivatives Article-31 referral - Restrictions on use of medicines containing ergot derivatives","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-02-17T01:00:00Z","last_updated_date":"2014-02-17T01:00:00Z","reference_number":"EMA/27446/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_sv.pdf"}},
    {"id":"41516","name":"Amoxil Article-30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-09-14T02:00:00Z","last_updated_date":"2015-09-14T02:00:00Z","reference_number":"EMA/499802/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/amoxil-article-30-referral-assessment-report_en.pdf"},
    {"id":"41519","name":"Dienogest / Ethinylestradiol Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/174401/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/dienogest-ethinylestradiol-article-31-referral-assessment-report_en.pdf"},
    {"id":"41525","name":"Opinion following an Article 33(4) referral for Equimectin 12mg/g oral gel for horses: Background information","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T01:59:00Z","last_updated_date":"2008-06-02T01:59:00Z","reference_number":"EMEA/532271/2007 – Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/opinion-following-article-334-referral-equimectin-12mgg-oral-gel-horses-background-information_sv.pdf"}},
    {"id":"41535","name":"Bacterial lysate medicines Article 31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2019-03-06T16:27:00Z","reference_number":"EMA/CHMP/349538/2018 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"41566","name":"Flupirtine Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-05-04T02:00:00Z","last_updated_date":"2018-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flupirtine-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flupirtine-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flupirtine-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flupirtine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flupirtine-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flupirtine-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flupirtine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flupirtine-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flupirtine-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flupirtine-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flupirtine-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flupirtine-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flupirtine-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flupirtine-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flupirtine-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flupirtine-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flupirtine-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flupirtine-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flupirtine-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flupirtine-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flupirtine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flupirtine-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"41634","name":"Dienogest / Ethinylestradiol Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"EMA/CHMP/147246/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/dienogest-ethinylestradiol-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"41643","name":"New advice to minimise risk of next-morning impaired driving ability and mental alertness with zolpidem","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-08-04T12:00:00Z","last_updated_date":"2014-08-04T12:00:00Z","reference_number":"EMA/427574/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/new-advice-minimise-risk-next-morning-impaired-driving-ability-and-mental-alertness-zolpidem_sv.pdf"}},
    {"id":"41677","name":"Retinoid Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-annex-iii_en.pdf-0"},
    {"id":"41680","name":"Atacand Plus - Article 30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2011-09-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/atacand-plus-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/atacand-plus-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/atacand-plus-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/atacand-plus-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/atacand-plus-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/atacand-plus-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/atacand-plus-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/atacand-plus-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/atacand-plus-article-30-referral-annex-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/atacand-plus-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/atacand-plus-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/atacand-plus-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/atacand-plus-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/atacand-plus-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/atacand-plus-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/atacand-plus-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/atacand-plus-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/atacand-plus-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/atacand-plus-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/atacand-plus-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/atacand-plus-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/atacand-plus-article-30-referral-annex-iii_sv.pdf"}},
    {"id":"41687","name":"Flupirtine-containing medicines Article-107i procedure - Restrictions in the use of flupirtine-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-11-21T01:00:00Z","last_updated_date":"2013-11-21T01:00:00Z","reference_number":"EMA/563900/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flupirtine-containing-medicines-article-107i-procedure-restrictions-use-flupirtine-containing-medicines_sv.pdf"}},
    {"id":"41688","name":"CEVAZURIL - Article 33 Referral - Annexes I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2010-05-05T02:00:00Z","last_updated_date":"2010-05-05T02:00:00Z","reference_number":"EMA/115640/2010","document_url":"https://www.ema.europa.eu/en/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_fr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cevazuril-article-33-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"41701","name":"Inhaled corticosteroids Article-31 referral - PRAC list of questions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-05-08T02:00:00Z","last_updated_date":"2015-05-19T02:00:00Z","reference_number":"EMA/PRAC/290016/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"41738","name":"Emergency contraceptives Article-31 referral - Review of emergency contraceptives started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-01-24T01:00:00Z","reference_number":"EMA/36862/2014","document_url":"https://www.ema.europa.eu/en/documents/referral/emergency-contraceptives-article-31-referral-review-emergency-contraceptives-started_en.pdf"},
    {"id":"41746","name":"Ambroxol and bromhexine Article-31 referral - Ambroxol and bromhexine expectorants: safety information to be updated","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2016-02-05T01:00:00Z","reference_number":"EMA/130676/2015","document_url":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ambroxol-and-bromhexine-article-31-referral-ambroxol-and-bromhexine-expectorants-safety-information-be-updated_sv.pdf"}},
    {"id":"41771","name":"Gentamicin Article-35 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/144816/2017","document_url":"https://www.ema.europa.eu/en/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gentamicin-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"41787","name":"Levonelle Article-13 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-08-09T02:00:00Z","last_updated_date":"2016-08-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/levonelle-article-13-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levonelle-article-13-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levonelle-article-13-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levonelle-article-13-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levonelle-article-13-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levonelle-article-13-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levonelle-article-13-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levonelle-article-13-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levonelle-article-13-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/levonelle-article-13-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levonelle-article-13-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levonelle-article-13-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levonelle-article-13-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levonelle-article-13-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levonelle-article-13-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levonelle-article-13-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levonelle-article-13-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levonelle-article-13-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levonelle-article-13-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levonelle-article-13-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levonelle-article-13-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levonelle-article-13-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levonelle-article-13-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/levonelle-article-13-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/levonelle-article-13-referral-annex-i_no.pdf"}},
    {"id":"41811","name":"EMA completes review of inhaled corticosteroids for chronic obstructive pulmonary disease","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/285392/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease_en.pdf"},
    {"id":"41833","name":"Ibuprofen and dexibuprofen Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T17:00:00Z","last_updated_date":"2014-06-13T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-notification_en.pdf"},
    {"id":"41865","name":"Hydroxyethyl-starch solutions (HES) no longer to be used in patients with sepsis or burn injuries or in critically ill patients","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2014-03-06T01:00:00Z","last_updated_date":"2014-03-06T01:00:00Z","reference_number":"EMA/809470/2013","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-solutions-hes-no-longer-be-used-patients-sepsis-or-burn-injuries-or-critically-ill-patients_sv.pdf-0"}},
    {"id":"41878","name":"Pharmaceutics International Inc. Article-31 referral – CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-12-14T01:00:00Z","last_updated_date":"2016-12-14T01:00:00Z","reference_number":"EMA/732186/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/pharmaceutics-international-inc-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"41886","name":"Vancomycin Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/224042/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/vancomycin-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"41891","name":"Polymyxin Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2015-01-05T01:00:00Z","last_updated_date":"2015-01-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/polymyxin-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/polymyxin-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/polymyxin-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/polymyxin-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/polymyxin-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/polymyxin-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/polymyxin-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/polymyxin-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/polymyxin-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/polymyxin-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/polymyxin-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/polymyxin-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/polymyxin-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/polymyxin-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/polymyxin-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/polymyxin-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/polymyxin-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/polymyxin-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/polymyxin-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/polymyxin-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/polymyxin-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/polymyxin-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/polymyxin-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/polymyxin-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/polymyxin-article-31-referral-annex-i_no.pdf"}},
    {"id":"41908","name":"Micro Therapeutic Research Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/micro-therapeutic-research-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"41960","name":"Xofigo Article-20 procedure - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-21T11:32:00Z","last_updated_date":"2018-03-21T11:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xofigo-article-20-procedure-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xofigo-article-20-procedure-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/xofigo-article-20-procedure-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xofigo-article-20-procedure-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xofigo-article-20-procedure-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xofigo-article-20-procedure-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xofigo-article-20-procedure-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xofigo-article-20-procedure-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/xofigo-article-20-procedure-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xofigo-article-20-procedure-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xofigo-article-20-procedure-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xofigo-article-20-procedure-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xofigo-article-20-procedure-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xofigo-article-20-procedure-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xofigo-article-20-procedure-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xofigo-article-20-procedure-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/xofigo-article-20-procedure-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xofigo-article-20-procedure-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xofigo-article-20-procedure-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xofigo-article-20-procedure-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xofigo-article-20-procedure-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xofigo-article-20-procedure-scientific-conclusions_sv.pdf"}},
    {"id":"41966","name":"Direct-acting antivirals for hepatitis C Article-20 procedure - Exviera Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T01:00:00Z","last_updated_date":"2017-03-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-exviera-annex-i-iii_no.pdf"}},
    {"id":"41975","name":"Fusafungine Article-31 referral - PRAC recommends that fusafungine nose and mouth sprays are no longer marketed","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-02-12T01:00:00Z","last_updated_date":"2016-02-12T01:00:00Z","reference_number":"EMA/91073/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-prac-recommends-fusafungine-nose-and-mouth-sprays-are-no-longer-marketed_en.pdf"},
    {"id":"41990","name":"Haldol Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2017-05-05T19:00:00Z","last_updated_date":"2017-05-05T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/haldol-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/haldol-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/haldol-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/haldol-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/haldol-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/haldol-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/haldol-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/haldol-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/haldol-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/haldol-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/haldol-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/haldol-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/haldol-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/haldol-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/haldol-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/haldol-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/haldol-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/haldol-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/haldol-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/haldol-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/haldol-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/haldol-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/haldol-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"42034","name":"Tobramycin VVB and associated names Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T02:00:00Z","last_updated_date":"2016-05-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"42040","name":"Clenil Article-30 referral - CHMP Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2016-11-18T01:00:00Z","last_updated_date":"2016-11-18T01:00:00Z","reference_number":"EMA/635512/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/clenil-article-30-referral-chmp-assessment-report_en.pdf"},
    {"id":"42198","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP list of questions to be addressed by the API manufacturers for valsartan-containing medicinal products","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-04T18:28:00Z","last_updated_date":"2018-10-04T18:28:00Z","reference_number":"EMA/CHMP/668548/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-list-questions-be-addressed-api-manufacturers-valsartan-containing-medicinal-products_en.pdf-0"},
    {"id":"42199","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP list of questions to be addressed by the marketing authorisation holders for valsartan-containing medicinal products","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-04T18:30:00Z","last_updated_date":"2018-10-04T18:30:00Z","reference_number":"EMA/CHMP/668547/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-list-questions-be-addressed-marketing-authorisation-holders-valsartan-containing-medicinal-products_en.pdf-0"},
    {"id":"42200","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - Notification (extension of scope)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-04T18:32:00Z","last_updated_date":"2018-10-04T18:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-notification-extension-scope_en.pdf"},
    {"id":"42201","name":"Candesartan Art 31 - list of NAPs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-04T18:34:00Z","last_updated_date":"2019-05-17T16:31:00Z","reference_number":"EMA/662693/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/candesartan-art-31-list-naps_en.pdf"},
    {"id":"42202","name":"Irbesartan Art 31 - list of NAPs and CAPs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-04T18:35:00Z","last_updated_date":"2019-05-17T16:30:00Z","reference_number":"EMA/662946/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/irbesartan-art-31-list-naps-and-caps_en.pdf"},
    {"id":"42203","name":"Losartan Art 31 - list of NAPs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-04T18:36:00Z","last_updated_date":"2019-05-17T16:30:00Z","reference_number":"EMA/662730/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/losartan-art-31-list-naps_en.pdf"},
    {"id":"42204","name":"Olmesartan Art 31 - list of NAPs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-04T18:38:00Z","last_updated_date":"2019-05-17T16:30:00Z","reference_number":"EMA/662763/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/olmesartan-art-31-list-naps_en.pdf"},
    {"id":"42299","name":"Xofigo Article-20 procedure - EMA restricts use of prostate cancer medicine Xofigo","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-11T16:39:00Z","last_updated_date":"2018-10-11T16:39:00Z","reference_number":"EMA/680161/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_sv.pdf"}},
    {"id":"42300","name":"Xofigo Article-20 procedure - EMA restricts use of prostate cancer medicine Xofigo","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T16:37:00Z","last_updated_date":"2018-07-27T16:37:00Z","reference_number":"EMA/500948/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-ema-restricts-use-prostate-cancer-medicine-xofigo_en.pdf-0"},
    {"id":"42301","name":"Xofigo Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-11T16:50:00Z","last_updated_date":"2018-10-11T16:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xofigo-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xofigo-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/xofigo-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xofigo-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xofigo-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xofigo-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xofigo-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xofigo-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/xofigo-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xofigo-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xofigo-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xofigo-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xofigo-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xofigo-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xofigo-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xofigo-article-20-procedure-annex-iv_pl.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xofigo-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xofigo-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xofigo-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xofigo-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xofigo-article-20-procedure-annex-iv_sv.pdf"}},
    {"id":"42302","name":"Xofigo Article-20 procedure - CHMP divergent positions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-11T16:51:00Z","last_updated_date":"2018-10-11T16:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-chmp-divergent-positions_en.pdf"},
    {"id":"42379","name":"Paclitaxel Hetero Article 29(4) referral - EMA recommends refusal of authorisation for Paclitaxel Hetero (paclitaxel, 6 mg/ml concentrate for solution for infusion)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T12:00:00Z","last_updated_date":"2019-01-21T01:00:00Z","reference_number":"EMA/712446/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paclitaxel-hetero-article-294-referral-ema-recommends-refusal-authorisation-paclitaxel-hetero-paclitaxel-6-mgml-concentrate-solution-infusion_sv.pdf"}},
    {"id":"42380","name":"Perlinring Article-29(4) referral  - EMA recommends authorisation of Perlinring (etonogestrel / ethinylestradiol vaginal ring) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T12:43:00Z","last_updated_date":"2019-01-21T15:03:00Z","reference_number":"EMA/720896/2018 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/perlinring-article-294-referral-ema-recommends-authorisation-perlinring-etonogestrel-ethinylestradiol-vaginal-ring-eu_sv.pdf"}},
    {"id":"42702","name":"Diotop Article 29(4) referral - EMA recommends authorisation of Diotop (diclofenac / omeprazole capsules) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T13:00:00Z","last_updated_date":"2019-02-15T17:14:00Z","reference_number":"EMA/790726/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diotop-article-294-referral-ema-recommends-authorisation-diotop-diclofenac-omeprazole-capsules-eu_sv.pdf"}},
    {"id":"42704","name":"Diclofenac Article 29(4) referral - EMA recommends authorisation of Diclofenac Sodium Spray Gel 4% (diclofenac) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T13:00:00Z","last_updated_date":"2019-02-14T11:57:00Z","reference_number":"EMA/631720/2018 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-294-referral-ema-recommends-authorisation-diclofenac-sodium-spray-gel-4-diclofenac-eu_sv.pdf"}},
    {"id":"42705","name":"Diclofenac Article-29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T13:00:00Z","last_updated_date":"2019-02-14T11:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"42709","name":"Quinolone and fluoroquinolone Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-19T12:58:00Z","last_updated_date":"2019-03-19T12:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iii_no.pdf"}},
    {"id":"42715","name":"Quinolone and fluoroquinolone Article-31 referral - PRAC recommends restrictions on use","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-05T17:26:00Z","last_updated_date":"2018-10-05T17:26:00Z","reference_number":"EMA/668915/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-prac-recommends-restrictions-use_en.pdf"},
    {"id":"42726","name":"Quinolone and fluoroquinolone Article-31 referral - Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T12:04:00Z","last_updated_date":"2019-03-19T16:00:00Z","reference_number":"EMA/175398/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_sv.pdf"}},
    {"id":"43042","name":"Metamizole Article-31 referral - EMA recommends aligning doses of metamizole medicines and their use during pregnancy and breastfeeding","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T17:03:00Z","last_updated_date":"2019-04-15T19:20:00Z","reference_number":"EMA/191666/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metamizole-article-31-referral-ema-recommends-aligning-doses-metamizole-medicines-and-their-use-during-pregnancy-and-breastfeeding_sv.pdf"}},
    {"id":"43043","name":"Metamizole Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T17:05:00Z","last_updated_date":"2019-03-28T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metamizole-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metamizole-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metamizole-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metamizole-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metamizole-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metamizole-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metamizole-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metamizole-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metamizole-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metamizole-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metamizole-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metamizole-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metamizole-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metamizole-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metamizole-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metamizole-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metamizole-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metamizole-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metamizole-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metamizole-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metamizole-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metamizole-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"43047","name":"Omega-3 acid ethyl esters - EMA confirms omega-3 fatty acid medicines are not effective in preventing further heart problems after a heart attack","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T17:50:00Z","last_updated_date":"2019-06-13T12:00:00Z","reference_number":"EMA/328211/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/omega-3-acid-ethyl-esters-ema-confirms-omega-3-fatty-acid-medicines-are-not-effective-preventing-further-heart-problems-after-heart-attack_sv.pdf"}},
    {"id":"43058","name":"Fosfomycin Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/858775/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-review-started_en.pdf"},
    {"id":"43059","name":"Fosfomycin Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T10:56:00Z","last_updated_date":"2018-12-14T10:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-notification_en.pdf"},
    {"id":"43060","name":"Fosfomycin Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2019-12-16T16:30:00Z","reference_number":"EMA/CHMP/848532/2018 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"43061","name":"Fosfomycin Article-31 referral - CHMP List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/CHMP/848509/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"43062","name":"Fosfomycin Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2020-07-06T14:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fosfomycin-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fosfomycin-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fosfomycin-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fosfomycin-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fosfomycin-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fosfomycin-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fosfomycin-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fosfomycin-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fosfomycin-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fosfomycin-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fosfomycin-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fosfomycin-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fosfomycin-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fosfomycin-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fosfomycin-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fosfomycin-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fosfomycin-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fosfomycin-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fosfomycin-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fosfomycin-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fosfomycin-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fosfomycin-article-31-referral-annex-i_sv.pdf"}},
    {"id":"43066","name":"Omega-3 acid ethyl esters - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T11:32:00Z","last_updated_date":"2019-06-13T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/omega-3-acid-ethyl-esters-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/omega-3-acid-ethyl-esters-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/omega-3-acid-ethyl-esters-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/omega-3-acid-ethyl-esters-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/omega-3-acid-ethyl-esters-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/omega-3-acid-ethyl-esters-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/omega-3-acid-ethyl-esters-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/omega-3-acid-ethyl-esters-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/omega-3-acid-ethyl-esters-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/omega-3-acid-ethyl-esters-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/omega-3-acid-ethyl-esters-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/omega-3-acid-ethyl-esters-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/omega-3-acid-ethyl-esters-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/omega-3-acid-ethyl-esters-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/omega-3-acid-ethyl-esters-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/omega-3-acid-ethyl-esters-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/omega-3-acid-ethyl-esters-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/omega-3-acid-ethyl-esters-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/omega-3-acid-ethyl-esters-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/omega-3-acid-ethyl-esters-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/omega-3-acid-ethyl-esters-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/omega-3-acid-ethyl-esters-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/omega-3-acid-ethyl-esters-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/omega-3-acid-ethyl-esters-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/omega-3-acid-ethyl-esters-annex-iii_no.pdf"}},
    {"id":"43071","name":"Omega-3 acid ethyl esters - Start of referral","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T13:32:00Z","last_updated_date":"2018-03-23T13:32:00Z","reference_number":"EMA/177123/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/omega-3-acid-ethyl-esters-start-referral_en.pdf"},
    {"id":"43072","name":"Metamizole Article-31 referral - Start of referral","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T13:40:00Z","last_updated_date":"2018-06-01T13:40:00Z","reference_number":"EMA/338589/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-start-referral_en.pdf"},
    {"id":"43417","name":"Paclitaxel Hetero and associated names ARticle 29(4) referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-01-21T14:29:00Z","last_updated_date":"2019-01-21T14:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-i_sv.pdf"}},
    {"id":"43418","name":"Paclitaxel Hetero and associated names ARticle 29(4) referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-01-21T14:31:00Z","last_updated_date":"2019-01-21T14:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"43420","name":"Paclitaxel Hetero and associated names Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-01-21T14:39:00Z","last_updated_date":"2019-01-21T14:39:00Z","reference_number":"EMA/813213/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-assessment-report_en.pdf"},
    {"id":"43421","name":"Perlinring Article-29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-01-21T16:08:00Z","last_updated_date":"2019-01-21T16:08:00Z","reference_number":"EMA/897708/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/perlinring-article-294-referral-assessment-report_en.pdf"},
    {"id":"43422","name":"Perlinring Article-29(4) referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-01-21T16:09:00Z","last_updated_date":"2019-01-21T16:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/perlinring-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/perlinring-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/perlinring-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/perlinring-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/perlinring-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/perlinring-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/perlinring-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/perlinring-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/perlinring-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/perlinring-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/perlinring-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/perlinring-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/perlinring-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/perlinring-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/perlinring-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/perlinring-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/perlinring-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/perlinring-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/perlinring-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/perlinring-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/perlinring-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/perlinring-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/perlinring-article-294-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/perlinring-article-294-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/perlinring-article-294-referral-annex-i_no.pdf"}},
    {"id":"43423","name":"Perlinring Article-29(4) referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-01-21T16:15:00Z","last_updated_date":"2019-01-21T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/perlinring-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/perlinring-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/perlinring-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/perlinring-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/perlinring-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/perlinring-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/perlinring-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/perlinring-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/perlinring-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/perlinring-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/perlinring-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/perlinring-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/perlinring-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/perlinring-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/perlinring-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/perlinring-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/perlinring-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/perlinring-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/perlinring-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/perlinring-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/perlinring-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/perlinring-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/perlinring-article-294-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/perlinring-article-294-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/perlinring-article-294-referral-annex-ii_no.pdf"}},
    {"id":"43424","name":"Perlinring Article-29(4) referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-01-21T16:17:00Z","last_updated_date":"2019-01-21T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/perlinring-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/perlinring-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/perlinring-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/perlinring-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/perlinring-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/perlinring-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/perlinring-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/perlinring-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/perlinring-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/perlinring-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/perlinring-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/perlinring-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/perlinring-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/perlinring-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/perlinring-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/perlinring-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/perlinring-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/perlinring-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/perlinring-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/perlinring-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/perlinring-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/perlinring-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/perlinring-article-294-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/perlinring-article-294-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/perlinring-article-294-referral-annex-iii_no.pdf"}},
    {"id":"43543","name":"Diclofenac Article 29(4) referral - CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-01-29T13:40:00Z","last_updated_date":"2019-01-29T13:40:00Z","reference_number":"EMA/33272/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-294-referral-chmp-assessment-report_en.pdf"},
    {"id":"43594","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - EMA review of impurities in sartan medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-09-21T18:28:00Z","last_updated_date":"2018-09-21T18:28:00Z","reference_number":"EMA/643116/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-ema-review-impurities-sartan-medicines_en.pdf"},
    {"id":"43602","name":"Lartruvo Article 20 referral - Review of cancer medicine Lartruvo started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T11:29:00Z","last_updated_date":"2019-02-01T11:29:00Z","reference_number":"EMA/44343/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lartruvo-article-20-referral-review-cancer-medicine-lartruvo-started_en.pdf"},
    {"id":"43603","name":"Lartruvo Article 20 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T12:00:00Z","last_updated_date":"2019-02-01T12:00:00Z","reference_number":"EMA/CHMP/41311/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lartruvo-article-20-referral-timetable-procedure_en.pdf"},
    {"id":"43605","name":"Lartruvo Article 20 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T12:00:00Z","last_updated_date":"2019-02-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lartruvo-article-20-referral-notification_en.pdf"}    {"id":"43606","name":"Lartruvo Article 20 referral - List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T12:00:00Z","last_updated_date":"2019-02-01T12:00:00Z","reference_number":"EMA/CHMP/41310/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lartruvo-article-20-referral-list-questions_en.pdf"},
    {"id":"43611","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T13:28:00Z","last_updated_date":"2019-05-28T10:29:00Z","reference_number":"EMA/248364/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities_sv.pdf"}},
    {"id":"43709","name":"Diclofenac Article-29(4) referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T10:48:00Z","last_updated_date":"2019-02-14T10:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-294-referral-annex-i_sv.pdf"}},
    {"id":"43710","name":"Diclofenac Article-29(4) referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-02-14T10:50:00Z","last_updated_date":"2019-02-14T10:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diclofenac-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diclofenac-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diclofenac-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diclofenac-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diclofenac-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diclofenac-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diclofenac-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diclofenac-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diclofenac-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diclofenac-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diclofenac-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diclofenac-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diclofenac-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diclofenac-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diclofenac-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diclofenac-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diclofenac-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diclofenac-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diclofenac-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diclofenac-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diclofenac-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diclofenac-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"43711","name":"Diclofenac Article-29(4) referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-14T10:58:00Z","last_updated_date":"2019-02-14T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-294-referral-notification_en.pdf"},
    {"id":"43750","name":"Fenspiride containing medicinal products Article-107i referral - Suspension of fenspiride medicines due to potential risk of heart rhythm problems","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T11:57:00Z","last_updated_date":"2019-02-15T11:57:00Z","reference_number":"EMA/114407/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-suspension-fenspiride-medicines-due-potential-risk-heart-rhythm-problems_en.pdf"},
    {"id":"43751","name":"Fenspiride containing medicinal products Article-107i referral - PRAC List of questions to be addressed by the stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T12:00:00Z","last_updated_date":"2019-02-15T12:00:00Z","reference_number":"EMA/PRAC/100386/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-prac-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"43752","name":"Fenspiride containing medicinal products Article-107i referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T11:52:00Z","last_updated_date":"2019-02-15T11:52:00Z","reference_number":"EMA/PRAC/100392/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-timetable-procedure_en.pdf"},
    {"id":"43753","name":"Fenspiride containing medicinal products Article-107i referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T11:53:00Z","last_updated_date":"2019-02-15T11:53:00Z","reference_number":"EMA/PRAC/100387/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-prac-list-questions_en.pdf"},
    {"id":"43754","name":"Fenspiride containing medicinal products Article-107i referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2019-02-15T11:55:00Z","last_updated_date":"2019-03-20T11:10:00Z","reference_number":"EMA/121740/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_en.pdf"},
    {"id":"43755","name":"Fenspiride containing medicinal products Article-107i referral - Rationale for triggering","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T12:00:00Z","last_updated_date":"2019-02-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-rationale-triggering_en.pdf"},
    {"id":"43756","name":"Fenspiride containing medicinal products Article-107i referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T12:02:00Z","last_updated_date":"2019-02-15T12:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-notification_en.pdf"},
    {"id":"43757","name":"Fenspiride containing medicinal products Article-107i referral - Stakeholders submission form","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T12:40:00Z","last_updated_date":"2019-02-15T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-stakeholders-submission-form_en.pdf"},
    {"id":"43761","name":"Diotop Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T18:05:00Z","last_updated_date":"2019-02-15T18:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diotop-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diotop-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diotop-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diotop-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diotop-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diotop-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diotop-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diotop-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diotop-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diotop-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diotop-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diotop-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diotop-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diotop-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diotop-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diotop-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diotop-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diotop-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diotop-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diotop-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diotop-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diotop-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diotop-article-294-referral-annex-i_sv.pdf"}},
    {"id":"43762","name":"Diotop Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T18:07:00Z","last_updated_date":"2019-02-15T18:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diotop-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diotop-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diotop-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diotop-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diotop-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diotop-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diotop-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diotop-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diotop-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diotop-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diotop-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diotop-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diotop-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diotop-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diotop-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diotop-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diotop-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diotop-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diotop-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diotop-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diotop-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diotop-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diotop-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"43763","name":"Diotop Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T18:09:00Z","last_updated_date":"2019-02-15T18:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/diotop-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/diotop-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/diotop-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/diotop-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/diotop-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/diotop-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/diotop-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/diotop-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/diotop-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/diotop-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/diotop-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/diotop-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/diotop-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/diotop-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/diotop-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/diotop-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/diotop-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/diotop-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/diotop-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/diotop-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/diotop-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/diotop-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/diotop-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"43764","name":"Diotop Article 29(4) referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T18:16:00Z","last_updated_date":"2019-02-15T18:16:00Z","reference_number":"EMA/813519/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/diotop-article-294-referral-assessment-report_en.pdf"},
    {"id":"43958","name":"Syner-Kinase Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-01T12:00:00Z","last_updated_date":"2019-06-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/syner-kinase-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/syner-kinase-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/syner-kinase-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/syner-kinase-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/syner-kinase-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/syner-kinase-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/syner-kinase-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/syner-kinase-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/syner-kinase-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/syner-kinase-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/syner-kinase-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/syner-kinase-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/syner-kinase-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/syner-kinase-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/syner-kinase-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/syner-kinase-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/syner-kinase-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/syner-kinase-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/syner-kinase-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/syner-kinase-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/syner-kinase-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/syner-kinase-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/syner-kinase-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"44042","name":"Fluorouracil and fluorouracil related substances Article 31 referral - EMA starts review on screening patients before treatment with fluorouracil, capecitabine, tegafur and flucytosine","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-15T16:38:00Z","last_updated_date":"2019-03-15T16:38:00Z","reference_number":"EMA/164425/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-starts-review-screening-patients-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_en.pdf"},
    {"id":"44043","name":"Fluorouracil and fluorouracil related substances Article 31 referral - PRAC List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-15T16:41:00Z","last_updated_date":"2019-03-15T16:41:00Z","reference_number":"EMA/PRAC/165648/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"44044","name":"Fluorouracil and fluorouracil related substances Article 31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-15T16:43:00Z","last_updated_date":"2019-12-11T12:41:00Z","reference_number":"EMA/PRAC/165647/2019 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"44045","name":"Fluorouracil and fluorouracil related substances Article 31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-15T16:45:00Z","last_updated_date":"2020-07-21T02:00:00Z","reference_number":"EMA/176877/2019 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_no.pdf"}},
    {"id":"44046","name":"Fluorouracil and fluorouracil related substances Article 31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-15T16:47:00Z","last_updated_date":"2019-03-15T16:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-notification_en.pdf"},
    {"id":"44051","name":"Quinolone and fluoroquinolone Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-03-19T15:22:00Z","last_updated_date":"2019-03-19T15:22:00Z","reference_number":"EMA/818158/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-assessment-report_en.pdf"},
    {"id":"44054","name":"Quinolone and fluoroquinolone Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-19T15:37:00Z","last_updated_date":"2019-03-19T15:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"44056","name":"Quinolone and fluoroquinolone Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-19T15:41:00Z","last_updated_date":"2019-03-19T15:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"44131","name":"Metamizole Article-31 referral - CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-03-28T13:10:00Z","last_updated_date":"2019-03-28T13:10:00Z","reference_number":"EMA/143912/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"44132","name":"Metamizole Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-28T13:24:00Z","last_updated_date":"2019-03-28T13:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metamizole-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metamizole-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metamizole-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metamizole-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metamizole-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metamizole-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metamizole-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metamizole-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metamizole-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metamizole-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metamizole-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metamizole-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metamizole-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metamizole-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metamizole-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metamizole-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metamizole-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metamizole-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metamizole-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metamizole-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metamizole-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metamizole-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"44146","name":"Basiron AC Article-13 referral - Questions and answers on Basiron AC and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-29T12:00:00Z","last_updated_date":"2019-03-29T12:00:00Z","reference_number":"EMA/193962/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/basiron-ac-article-13-referral-questions-and-answers-basiron-ac-and-associated-names_en.pdf"},
    {"id":"44148","name":"Septanest Article-30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-29T11:27:00Z","last_updated_date":"2019-06-19T12:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/septanest-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/septanest-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/septanest-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/septanest-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/septanest-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/septanest-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/septanest-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/septanest-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/septanest-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/septanest-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/septanest-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/septanest-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/septanest-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/septanest-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/septanest-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/septanest-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/septanest-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/septanest-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/septanest-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/septanest-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/septanest-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/septanest-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/septanest-article-30-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/septanest-article-30-referral-annex-iii_no.pdf"}},
    {"id":"44149","name":"Septanest Article-30 referral - Use of Septanest and associated names (articaine / adrenaline solutions for injection) to be harmonised in EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-29T12:00:00Z","last_updated_date":"2019-06-19T12:41:00Z","reference_number":"EMA/186900/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/septanest-article-30-referral-use-septanest-and-associated-names-articaine-adrenaline-solutions-injection-be-harmonised-eu_sv.pdf"}},
    {"id":"44150","name":"Omega-3 fatty acid medicines - Omega-3 fatty acid medicines no longer considered effective in preventing heart disease","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2019-02-01T12:00:00Z","reference_number":"EMA/19056/2019 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/omega-3-fatty-acid-medicines-omega-3-fatty-acid-medicines-no-longer-considered-effective-preventing-heart-disease_en.pdf"},
    {"id":"44232","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - New review of risks with high-strength estradiol-containing creams","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T10:27:00Z","last_updated_date":"2019-04-12T10:27:00Z","reference_number":"EMA/215459/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-new-review-risks-high-strength-estradiol-containing-creams_en.pdf"},
    {"id":"44233","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T10:31:00Z","last_updated_date":"2019-04-12T10:31:00Z","reference_number":"EMA/PRAC/214199/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"44234","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - Timetable (start of re-examination procedure)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T10:39:00Z","last_updated_date":"2019-12-18T09:55:00Z","reference_number":"EMA/PRAC/214200/2019 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-start-re-examination-procedure_en.pdf"},
    {"id":"44235","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T10:41:00Z","last_updated_date":"2020-04-08T12:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-i_sv.pdf"}},
    {"id":"44236","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T10:42:00Z","last_updated_date":"2019-04-12T10:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-notification_en.pdf"},
    {"id":"44237","name":"Lemtrada Article 20 procedure - Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T10:58:00Z","last_updated_date":"2019-04-12T10:58:00Z","reference_number":"EMA/220110/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing_en.pdf"},
    {"id":"44238","name":"Lemtrada Article 20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T11:01:00Z","last_updated_date":"2019-04-12T11:01:00Z","reference_number":"EMA/PRAC/218935/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"44239","name":"Lemtrada Article 20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T11:03:00Z","last_updated_date":"2019-10-09T10:10:00Z","reference_number":"EMA/PRAC/218954/2019 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"44240","name":"Lemtrada Article 20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-04-12T11:04:00Z","last_updated_date":"2019-04-12T11:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-notification_en.pdf"},
    {"id":"44361","name":"Lartruvo Article 20 referral - EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-04-26T15:07:00Z","last_updated_date":"2019-04-30T12:54:00Z","reference_number":"EMA/237662/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_en.pdf"},
    {"id":"44459","name":"Lemtrada Article 20 procedure - Assessment report on provisional measures","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-05-08T10:55:00Z","last_updated_date":"2019-05-08T10:55:00Z","reference_number":"EMA/249094/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-assessment-report-provisional-measures_en.pdf"},
    {"id":"44460","name":"Lemtrada Article 20 procedure - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-08T10:57:00Z","last_updated_date":"2019-05-08T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_sv.pdf"}},
    {"id":"44461","name":"Lemtrada Article 20 procedure - Product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-08T10:59:00Z","last_updated_date":"2019-05-08T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-product-information_en.pdf"},
    {"id":"44527","name":"Xeljanz Article-20 procedure - Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-17T12:00:00Z","last_updated_date":"2019-05-17T12:00:00Z","reference_number":"EMA/267216/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-restrictions-use-xeljanz-while-ema-reviews-risk-blood-clots-lungs_en.pdf"},
    {"id":"44528","name":"Xeljanz Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-17T12:00:00Z","last_updated_date":"2019-05-17T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-notification_en.pdf"},
    {"id":"44529","name":"Xeljanz Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-17T12:00:00Z","last_updated_date":"2019-09-13T14:05:00Z","reference_number":"EMA/PRAC/269913/2019 – Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"44530","name":"Fenspiride containing medicinal products Article-107i referral - Withdrawal of marketing authorisations for fenspiride medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-17T11:51:00Z","last_updated_date":"2019-05-29T16:45:00Z","reference_number":"EMA/285298/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_sv.pdf"}},
    {"id":"44533","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-17T16:40:00Z","last_updated_date":"2019-05-17T16:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii_no.pdf"}},
    {"id":"44534","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-17T10:15:00Z","last_updated_date":"2019-05-17T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i_sv.pdf"}},
    {"id":"44624","name":"Fenspiride containing medicinal products Article-107i referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T16:45:00Z","last_updated_date":"2019-05-29T16:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-iii_sv.pdf"}},
    {"id":"44626","name":"Methocarbamol / paracetamol Article 31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T18:08:00Z","last_updated_date":"2019-05-29T18:08:00Z","reference_number":"EMA/271110/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-review-started_en.pdf"},
    {"id":"44627","name":"Methocarbamol / paracetamol Article 31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T18:15:00Z","last_updated_date":"2019-05-29T18:15:00Z","reference_number":"EMA/CHMP/285881/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"44628","name":"Methocarbamol / paracetamol Article 31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T18:17:00Z","last_updated_date":"2019-12-17T15:55:00Z","reference_number":"EMA/CHMP/285880/2019 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"44629","name":"Methocarbamol / paracetamol Article 31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T18:18:00Z","last_updated_date":"2020-06-17T01:14:00Z","reference_number":"EMA/298855/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-i_sv.pdf"}},
    {"id":"44630","name":"Methocarbamol / paracetamol Article 31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T18:21:00Z","last_updated_date":"2019-05-29T18:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-notification_en.pdf"},
    {"id":"44640","name":"Syner-Kinase Article 29(4) referral - EMA recommends authorisation of Syner-Kinase (urokinase) in the EU","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T16:43:00Z","last_updated_date":"2019-06-03T16:51:00Z","reference_number":"EMA/299749/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/syner-kinase-article-294-referral-ema-recommends-authorisation-syner-kinase-urokinase-eu_sv.pdf"}},
    {"id":"44641","name":"Syner-Kinase Article 29(4) referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-06-03T16:54:00Z","last_updated_date":"2019-06-03T16:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/syner-kinase-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/syner-kinase-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/syner-kinase-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/syner-kinase-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/syner-kinase-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/syner-kinase-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/syner-kinase-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/syner-kinase-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/syner-kinase-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/syner-kinase-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/syner-kinase-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/syner-kinase-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/syner-kinase-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/syner-kinase-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/syner-kinase-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/syner-kinase-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/syner-kinase-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/syner-kinase-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/syner-kinase-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/syner-kinase-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/syner-kinase-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/syner-kinase-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/syner-kinase-article-294-referral-annex-i_sv.pdf"}},
    {"id":"44642","name":"Syner-Kinase Article 29(4) referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-06-03T16:56:00Z","last_updated_date":"2019-06-03T16:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/syner-kinase-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/syner-kinase-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/syner-kinase-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/syner-kinase-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/syner-kinase-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/syner-kinase-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/syner-kinase-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/syner-kinase-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/syner-kinase-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/syner-kinase-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/syner-kinase-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/syner-kinase-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/syner-kinase-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/syner-kinase-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/syner-kinase-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/syner-kinase-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/syner-kinase-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/syner-kinase-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/syner-kinase-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/syner-kinase-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/syner-kinase-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/syner-kinase-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/syner-kinase-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"44643","name":"Syner-Kinase Article 29(4) referral - CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-06-03T16:58:00Z","last_updated_date":"2019-06-03T16:58:00Z","reference_number":"EMA/294785/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/syner-kinase-article-294-referral-chmp-assessment-report_en.pdf"},
    {"id":"44646","name":"Xeljanz Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-04T12:14:00Z","last_updated_date":"2019-06-04T12:14:00Z","reference_number":"EMA/PRAC/269837/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"44647","name":"Septanest Article-30 referral - CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-06-04T13:37:00Z","last_updated_date":"2019-06-04T13:37:00Z","reference_number":"EMA/220146/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/septanest-article-30-referral-chmp-assessment-report_en.pdf"},
    {"id":"44670","name":"Fenspiride containing medicinal products Article-107i referral - Suspension of fenspiride medicines due to potential risk of heart rhythm problems","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-02-15T16:24:00Z","last_updated_date":"2019-02-15T16:24:00Z","reference_number":"EMA/114407/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-suspension-fenspiride-medicines-due-potential-risk-heart-rhythm-problems_en.pdf-0"},
    {"id":"44671","name":"Fenspiride containing medicinal products Article-107i referral - Withdrawal of marketing authorisations for fenspiride medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-05-17T16:27:00Z","last_updated_date":"2019-05-17T16:27:00Z","reference_number":"EMA/264639/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-withdrawal-marketing-authorisations-fenspiride-medicines_en.pdf-0"},
    {"id":"44691","name":"Fenspiride containing medicinal products Article-107i referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-06-12T10:41:00Z","last_updated_date":"2019-06-12T10:41:00Z","reference_number":"EMA/317731/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-assessment-report_en.pdf"},
    {"id":"44697","name":"Omega-3 acid ethyl esters - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-13T17:40:00Z","last_updated_date":"2019-06-13T17:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/omega-3-acid-ethyl-esters-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/omega-3-acid-ethyl-esters-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/omega-3-acid-ethyl-esters-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/omega-3-acid-ethyl-esters-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/omega-3-acid-ethyl-esters-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/omega-3-acid-ethyl-esters-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/omega-3-acid-ethyl-esters-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/omega-3-acid-ethyl-esters-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/omega-3-acid-ethyl-esters-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/omega-3-acid-ethyl-esters-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/omega-3-acid-ethyl-esters-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/omega-3-acid-ethyl-esters-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/omega-3-acid-ethyl-esters-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/omega-3-acid-ethyl-esters-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/omega-3-acid-ethyl-esters-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/omega-3-acid-ethyl-esters-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/omega-3-acid-ethyl-esters-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/omega-3-acid-ethyl-esters-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/omega-3-acid-ethyl-esters-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/omega-3-acid-ethyl-esters-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/omega-3-acid-ethyl-esters-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/omega-3-acid-ethyl-esters-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/omega-3-acid-ethyl-esters-annex-ii_sv.pdf"}},
    {"id":"44698","name":"Omega-3 acid ethyl esters - Assessment report following the re-examination procedure","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-06-13T17:43:00Z","last_updated_date":"2019-06-13T17:43:00Z","reference_number":"EMA/303982/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/omega-3-acid-ethyl-esters-assessment-report-following-re-examination-procedure_en.pdf"},
    {"id":"44708","name":"Leuprorelin-containing depot medicines Article-31 referral - Review of handling errors with depot formulations of leuprorelin medicines started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-14T15:00:00Z","last_updated_date":"2019-06-14T15:00:00Z","reference_number":"EMA/316598/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-review-handling-errors-depot-formulations-leuprorelin-medicines-started_en.pdf"},
    {"id":"44709","name":"Leuprorelin-containing depot medicines Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-14T15:00:00Z","last_updated_date":"2019-06-14T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-notification_en.pdf"},
    {"id":"44711","name":"Leuprorelin-containing depot medicines Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-14T15:00:00Z","last_updated_date":"2020-07-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-i_no.pdf"}},
    {"id":"44712","name":"Leuprorelin-containing depot medicines Article-31 referral - List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-14T15:00:00Z","last_updated_date":"2019-06-14T15:00:00Z","reference_number":"EMA/PRAC/317692/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-list-questions_en.pdf"},
    {"id":"44713","name":"Leuprorelin-containing depot medicines Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-14T15:00:00Z","last_updated_date":"2020-03-16T16:00:00Z","reference_number":"EMA/PRAC/317693/2019 Rev 2","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"44754","name":"Septanest Article-30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-19T12:44:00Z","last_updated_date":"2019-06-19T12:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/septanest-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/septanest-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/septanest-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/septanest-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/septanest-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/septanest-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/septanest-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/septanest-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/septanest-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/septanest-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/septanest-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/septanest-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/septanest-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/septanest-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/septanest-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/septanest-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/septanest-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/septanest-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/septanest-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/septanest-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/septanest-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/septanest-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/septanest-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"44894","name":"Fenspiride containing medicinal products Article-107i referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-26T14:45:00Z","last_updated_date":"2019-06-26T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-ii_sv.pdf"}},
    {"id":"44895","name":"Fenspiride containing medicinal products Article-107i referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-26T14:48:00Z","last_updated_date":"2019-06-26T14:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-annex-i_sv.pdf"}},
    {"id":"44910","name":"Closantel Article-35 referral - Questions and answers on veterinary medicinal products containing 50 mg closantel per ml (as a single active substance) presented as solutions for injection for subcutaneous use in sheep","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-27T14:12:00Z","last_updated_date":"2019-06-27T14:12:00Z","reference_number":"EMA/246018/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/closantel-article-35-referral-questions-and-answers-veterinary-medicinal-products-containing-50-mg-closantel-ml-single-active-substance-presented-solutions-injection-subcutaneous-use-sheep_sv.pdf"}},
    {"id":"44911","name":"Closantel Article-35 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-27T14:15:00Z","last_updated_date":"2019-06-27T14:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/closantel-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/closantel-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/closantel-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/closantel-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/closantel-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/closantel-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/closantel-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/closantel-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/closantel-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/closantel-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/closantel-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/closantel-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/closantel-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/closantel-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/closantel-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/closantel-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/closantel-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/closantel-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/closantel-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/closantel-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/closantel-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/closantel-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/closantel-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"44944","name":"Bacterial lysate medicines Article 31 referral - Bacterial lysate medicines for respiratory conditions to be used only for prevention of recurrent infections","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T16:08:00Z","last_updated_date":"2019-09-16T16:49:00Z","reference_number":"EMA/502527/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bacterial-lysate-medicines-article-31-referral-bacterial-lysate-medicines-respiratory-conditions-be-used-only-prevention-recurrent-infections_sv.pdf"}},
    {"id":"44945","name":"Bacterial lysate medicines Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T10:16:00Z","last_updated_date":"2019-09-16T16:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"44996","name":"Xeljanz Article-20 procedure - PRAC assessment report on provisional measures","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-05T14:10:00Z","last_updated_date":"2019-07-05T14:10:00Z","reference_number":"EMA/309456/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-prac-assessment-report-provisional-measures_en.pdf"},
    {"id":"45040","name":"Cyproterone Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T10:47:00Z","last_updated_date":"2019-07-12T10:47:00Z","reference_number":"EMA/384708/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-review-started_en.pdf"},
    {"id":"45041","name":"Cyproterone Article-31 referral -  Draft Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T10:49:00Z","last_updated_date":"2019-08-06T15:05:00Z","reference_number":"EMA/398686/2019 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-draft-annex-i_en.pdf"},
    {"id":"45042","name":"Cyproterone Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T10:51:00Z","last_updated_date":"2019-07-12T10:51:00Z","reference_number":"EMA/PRAC/371762/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"45043","name":"Cyproterone Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T10:53:00Z","last_updated_date":"2019-11-12T01:00:00Z","reference_number":"EMA/PRAC/371761/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"45044","name":"Cyproterone Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T10:54:00Z","last_updated_date":"2019-07-12T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-notification_en.pdf"},
    {"id":"45048","name":"Methotrexate Article-31 referral - PRAC recommends new measures to avoid dosing errors with methotrexate","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T10:27:00Z","last_updated_date":"2019-07-12T10:27:00Z","reference_number":"EMA/384938/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-prac-recommends-new-measures-avoid-dosing-errors-methotrexate_en.pdf"},
    {"id":"45096","name":"Basiron AC Article-13 referral - Questions and answers on Basiron AC and associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-03-29T13:54:00Z","last_updated_date":"2019-07-19T14:09:00Z","reference_number":"EMA/400057/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/basiron-ac-article-13-referral-questions-and-answers-basiron-ac-and-associated-names_en.pdf-0"},
    {"id":"45097","name":"Basiron AC - Article 13 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-19T13:55:00Z","last_updated_date":"2019-07-19T13:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/basiron-ac-article-13-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/basiron-ac-article-13-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/basiron-ac-article-13-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/basiron-ac-article-13-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/basiron-ac-article-13-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/basiron-ac-article-13-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/basiron-ac-article-13-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/basiron-ac-article-13-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/basiron-ac-article-13-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/basiron-ac-article-13-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/basiron-ac-article-13-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/basiron-ac-article-13-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/basiron-ac-article-13-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/basiron-ac-article-13-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/basiron-ac-article-13-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/basiron-ac-article-13-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/basiron-ac-article-13-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/basiron-ac-article-13-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/basiron-ac-article-13-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/basiron-ac-article-13-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/basiron-ac-article-13-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/basiron-ac-article-13-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/basiron-ac-article-13-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/basiron-ac-article-13-referral-annex-i_no.pdf"}},
    {"id":"45098","name":"Basiron AC - Article 13 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-19T13:57:00Z","last_updated_date":"2019-07-19T13:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/basiron-ac-article-13-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/basiron-ac-article-13-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/basiron-ac-article-13-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/basiron-ac-article-13-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/basiron-ac-article-13-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/basiron-ac-article-13-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/basiron-ac-article-13-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/basiron-ac-article-13-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/basiron-ac-article-13-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/basiron-ac-article-13-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/basiron-ac-article-13-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/basiron-ac-article-13-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/basiron-ac-article-13-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/basiron-ac-article-13-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/basiron-ac-article-13-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/basiron-ac-article-13-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/basiron-ac-article-13-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/basiron-ac-article-13-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/basiron-ac-article-13-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/basiron-ac-article-13-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/basiron-ac-article-13-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/basiron-ac-article-13-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/basiron-ac-article-13-referral-annex-ii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/basiron-ac-article-13-referral-annex-ii_no.pdf"}},
    {"id":"45099","name":"Basiron AC - Article 13 referral - Assessment Report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-19T13:59:00Z","last_updated_date":"2019-07-19T13:59:00Z","reference_number":"EMA/304143/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/basiron-ac-article-13-referral-assessment-report_en.pdf"},
    {"id":"45193","name":"Xeljanz Article-20 procedure - Annex IV (PASS)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T14:50:00Z","last_updated_date":"2020-03-06T14:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xeljanz-article-20-procedure-annex-iv-pass_sv.pdf"}},
    {"id":"45300","name":"Lartruvo Article 20 referral - EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T11:12:00Z","last_updated_date":"2019-08-22T11:12:00Z","reference_number":"EMA/423345/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lartruvo-article-20-referral-ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo_sv.pdf"}},
    {"id":"45301","name":"Lartruvo Article 20 referral - CHMP assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T11:22:00Z","last_updated_date":"2019-08-22T11:22:00Z","reference_number":"EMA/254126/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lartruvo-article-20-referral-chmp-assessment-report_en.pdf"},
    {"id":"45302","name":"Lartruvo Article 20 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-08-22T11:28:00Z","last_updated_date":"2019-08-22T11:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lartruvo-article-20-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lartruvo-article-20-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lartruvo-article-20-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lartruvo-article-20-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lartruvo-article-20-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lartruvo-article-20-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lartruvo-article-20-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lartruvo-article-20-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lartruvo-article-20-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lartruvo-article-20-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lartruvo-article-20-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lartruvo-article-20-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lartruvo-article-20-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lartruvo-article-20-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lartruvo-article-20-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lartruvo-article-20-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lartruvo-article-20-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lartruvo-article-20-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lartruvo-article-20-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lartruvo-article-20-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lartruvo-article-20-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lartruvo-article-20-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lartruvo-article-20-referral-annex-ii_sv.pdf"}},
    {"id":"45313","name":"Methotrexate Article-31 referral - New measures to avoid potentially fatal dosing errors with methotrexate for inflammatory diseases","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-08-23T10:19:00Z","last_updated_date":"2019-08-23T10:19:00Z","reference_number":"EMA/414775/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-new-measures-avoid-potentially-fatal-dosing-errors-methotrexate-inflammatory-diseases_en.pdf"},
    {"id":"45314","name":"Methotrexate Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-08-23T10:21:00Z","last_updated_date":"2019-10-31T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methotrexate-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methotrexate-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methotrexate-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methotrexate-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methotrexate-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methotrexate-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methotrexate-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methotrexate-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methotrexate-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methotrexate-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methotrexate-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methotrexate-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methotrexate-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methotrexate-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methotrexate-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methotrexate-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methotrexate-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methotrexate-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methotrexate-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methotrexate-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methotrexate-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methotrexate-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/methotrexate-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/methotrexate-article-31-referral-annex-iii_no.pdf"}},
    {"id":"45384","name":"Picato Article-20 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-06T12:00:00Z","last_updated_date":"2020-01-09T18:08:00Z","reference_number":"EMA/484093/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-review-started_en.pdf"},
    {"id":"45385","name":"Picato Article-20 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-06T12:07:00Z","last_updated_date":"2019-09-06T12:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-notification_en.pdf"},
    {"id":"45386","name":"Picato Article-20 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-06T12:13:00Z","last_updated_date":"2020-01-17T02:00:00Z","reference_number":"EMA/PRAC/484544/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-timetable-procedure_en.pdf"}    {"id":"45387","name":"Picato Article-20 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-06T12:14:00Z","last_updated_date":"2019-09-06T12:14:00Z","reference_number":"EMA/PRAC/484308/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-prac-list-questions_en.pdf"},
    {"id":"45458","name":"Bacterial lysate medicines Article 31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-16T16:40:00Z","last_updated_date":"2019-09-16T16:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"45459","name":"Bacterial lysate medicines Article 31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-16T16:41:00Z","last_updated_date":"2019-09-16T16:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_cs.pdf","de":"https://www.ema.europa.eu/de/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/bacterial-lysate-medicines-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"45460","name":"Bacterial lysate medicines Article 31 referral - CHMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-09-16T16:45:00Z","last_updated_date":"2019-09-16T16:45:00Z","reference_number":"EMA/457345/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-chmp-assessment-report_en.pdf"},
    {"id":"45484","name":"Ranitidine Article-31 referral - EMA to review ranitidine medicines following detection of NDMA","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-20T16:40:00Z","last_updated_date":"2019-09-20T16:40:00Z","reference_number":"EMA/503622/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-ema-review-ranitidine-medicines-following-detection-ndma_en.pdf"},
    {"id":"45485","name":"Ranitidine Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-20T16:34:00Z","last_updated_date":"2019-09-20T16:34:00Z","reference_number":"EMA/CHMP/506572/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"45486","name":"Ranitidine Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-20T16:36:00Z","last_updated_date":"2020-12-22T11:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ranitidine-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ranitidine-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ranitidine-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ranitidine-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ranitidine-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ranitidine-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ranitidine-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ranitidine-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ranitidine-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ranitidine-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ranitidine-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ranitidine-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ranitidine-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ranitidine-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ranitidine-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ranitidine-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ranitidine-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ranitidine-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ranitidine-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ranitidine-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ranitidine-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ranitidine-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ranitidine-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ranitidine-article-31-referral-annex-i_no.pdf"}},
    {"id":"45487","name":"Ranitidine Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-20T16:37:00Z","last_updated_date":"2020-08-07T11:16:00Z","reference_number":"EMA/CHMP/506572/2019 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"45488","name":"Ranitidine Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-09-20T16:38:00Z","last_updated_date":"2019-09-20T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-notification_en.pdf"},
    {"id":"45567","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - Four-week limit for use of high-strength estradiol creams","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-10-04T10:41:00Z","last_updated_date":"2019-10-31T15:00:00Z","reference_number":"EMA/531250/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams_en.pdf"},
    {"id":"45756","name":"Flurbiprofen Geiser Article 29(4) referral - EMA recommends authorisation of Flurbiprofen Geiser (flurbiprofen, 8.75 mg, oromucosal spray) in the EU","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2020-01-20T16:04:00Z","reference_number":"EMA/631051/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flurbiprofen-geiser-article-294-referral-ema-recommends-authorisation-flurbiprofen-geiser-flurbiprofen-875-mg-oromucosal-spray-eu_sv.pdf"}},
    {"id":"45757","name":"Flurbiprofen Geiser Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flurbiprofen-geiser-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"45865","name":"Lemtrada Article 20 procedure - Lemtrada for multiple sclerosis: measures to minimise risk of serious side effects","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T14:08:00Z","last_updated_date":"2019-10-31T14:08:00Z","reference_number":"EMA/583516/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-lemtrada-multiple-sclerosis-measures-minimise-risk-serious-side-effects_en.pdf"},
    {"id":"45866","name":"Xeljanz Article-20 procedure - Xeljanz to be used with caution for all patients at high risk of blood clots","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T14:32:00Z","last_updated_date":"2019-10-31T14:32:00Z","reference_number":"EMA/584781/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-xeljanz-be-used-caution-all-patients-high-risk-blood-clots_en.pdf"},
    {"id":"45869","name":"Methotrexate Article-31 referral - New measures to avoid potentially fatal dosing errors with methotrexate for inflammatory diseases","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-10-31T16:30:00Z","last_updated_date":"2019-10-31T16:30:00Z","reference_number":"EMA/587673/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-new-measures-avoid-potentially-fatal-dosing-errors-methotrexate-inflammatory-diseases_en.pdf-0"},
    {"id":"45870","name":"Methotrexate Article-31 referral - Public assessment report - EMEA/H/A-31/1463","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T16:36:00Z","last_updated_date":"2019-10-31T16:36:00Z","reference_number":"EMA/521627/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-public-assessment-report-emeaha-311463_en.pdf"},
    {"id":"45871","name":"Methotrexate Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T16:39:00Z","last_updated_date":"2019-10-31T16:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methotrexate-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methotrexate-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methotrexate-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methotrexate-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methotrexate-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methotrexate-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methotrexate-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methotrexate-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methotrexate-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methotrexate-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methotrexate-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methotrexate-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methotrexate-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methotrexate-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methotrexate-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methotrexate-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methotrexate-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methotrexate-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methotrexate-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methotrexate-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methotrexate-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methotrexate-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/methotrexate-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/methotrexate-article-31-referral-annex-i_no.pdf"}},
    {"id":"45872","name":"Methotrexate Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T16:42:00Z","last_updated_date":"2019-10-31T16:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methotrexate-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methotrexate-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methotrexate-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methotrexate-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methotrexate-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methotrexate-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methotrexate-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methotrexate-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methotrexate-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methotrexate-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methotrexate-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methotrexate-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methotrexate-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methotrexate-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methotrexate-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methotrexate-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methotrexate-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methotrexate-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methotrexate-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methotrexate-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methotrexate-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methotrexate-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"45873","name":"Methotrexate Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T16:45:00Z","last_updated_date":"2019-10-31T16:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methotrexate-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methotrexate-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methotrexate-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methotrexate-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methotrexate-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methotrexate-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methotrexate-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methotrexate-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methotrexate-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methotrexate-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methotrexate-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methotrexate-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methotrexate-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methotrexate-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methotrexate-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methotrexate-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methotrexate-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methotrexate-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methotrexate-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methotrexate-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methotrexate-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methotrexate-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"45874","name":"Methotrexate Article-31 referral - Jylamvo : EPAR - Product Information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T16:48:00Z","last_updated_date":"2019-10-31T16:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-jylamvo-epar-product-information_en.pdf"},
    {"id":"46034","name":"Lemtrada Article 20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T12:00:00Z","last_updated_date":"2019-11-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-annex-iii_en.pdf"},
    {"id":"46035","name":"Lemtrada Article 20 procedure - Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T12:00:00Z","last_updated_date":"2019-11-15T12:00:00Z","reference_number":"EMA/609015/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_en.pdf"},
    {"id":"46038","name":"Xeljanz Article-20 procedure - EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-06T11:01:00Z","last_updated_date":"2020-03-06T11:01:00Z","reference_number":"EMA/92517/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_sv.pdf"}},
    {"id":"46039","name":"Xeljanz Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T12:00:00Z","last_updated_date":"2019-11-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-annex-iii_en.pdf"},
    {"id":"46058","name":"Tylosin injectable for sheep Article-35 referral - Questions and answers on withdrawal periods for injectable veterinary medicines containing tylosin when given to sheep","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-11-19T12:29:00Z","last_updated_date":"2019-11-19T12:29:00Z","reference_number":"EMA/510184/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tylosin-injectable-sheep-article-35-referral-questions-and-answers-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-when-given-sheep_sv.pdf"}},
    {"id":"46060","name":"Tylosin injectable for sheep Article-35 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-11-19T13:44:00Z","last_updated_date":"2019-11-19T13:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tylosin-injectable-sheep-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"46075","name":"Paromomycin Article-35 referral: Questions and answers on suspension of marketing authorisations for injectable veterinary medicines containing paromomycin given to pigs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-11-20T14:22:00Z","last_updated_date":"2019-11-20T14:22:00Z","reference_number":"EMA/487471/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paromomycin-article-35-referral-questions-and-answers-suspension-marketing-authorisations-injectable-veterinary-medicines-containing-paromomycin-given-pigs_sv.pdf"}},
    {"id":"46076","name":"Paromomycin Article-35 referral: Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-11-20T14:24:00Z","last_updated_date":"2019-11-20T14:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/paromomycin-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"46111","name":"Valproate - Article 31 - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-11-22T13:58:00Z","last_updated_date":"2019-11-22T13:58:00Z","reference_number":"EMA/568844/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-assessment-report_en.pdf"},
    {"id":"46336","name":"Flurbiprofen Geiser Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2019-12-19T10:58:00Z","last_updated_date":"2019-12-19T10:58:00Z","reference_number":"EMA/589361/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/flurbiprofen-geiser-article-294-referral-assessment-report_en.pdf"},
    {"id":"46448","name":"Picato Article-20 referral - EMA suspends Picato as a precaution while review of skin cancer risk continues","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-01-17T10:04:00Z","last_updated_date":"2020-01-21T15:09:00Z","reference_number":"EMA/32231/2020 ","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_sv.pdf"}},
    {"id":"46449","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - PRAC confirms four-week limit for use of high-strength estradiol creams","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-01-17T11:32:00Z","last_updated_date":"2020-01-17T11:32:00Z","reference_number":"EMA/20248/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-prac-confirms-four-week-limit-use-high-strength-estradiol-creams_en.pdf"},
    {"id":"46465","name":"Flurbiprofen Geiser Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T12:00:00Z","last_updated_date":"2020-01-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flurbiprofen-geiser-article-294-referral-annex-i_sv.pdf"}},
    {"id":"46466","name":"Flurbiprofen Geiser Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T12:00:00Z","last_updated_date":"2020-01-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/flurbiprofen-geiser-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"46473","name":"Picato Article-20 referral - Annex I - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-01-21T15:18:00Z","last_updated_date":"2020-01-21T15:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/picato-article-20-referral-annex-i-scientific-conclusions_sv.pdf"}},
    {"id":"46474","name":"Picato Article-20 referral - Assessment report on provisional measures","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-01-21T15:18:00Z","last_updated_date":"2020-03-04T17:44:00Z","reference_number":"EMA/30347/2020 ","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-assessment-report-provisional-measures_en.pdf"},
    {"id":"46603","name":"Lemtrada Article 20 procedure - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-01-28T16:30:00Z","last_updated_date":"2020-01-28T16:30:00Z","reference_number":"EMA/682560/2019","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-prac-assessment-report_en.pdf"},
    {"id":"46604","name":"Lemtrada Article 20 procedure - CHMP divergent positions","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-01-28T16:34:00Z","last_updated_date":"2020-01-28T16:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-chmp-divergent-positions_en.pdf"},
    {"id":"46632","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - Four-week limit for use of high-strength estradiol creams confirmed","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-01-31T17:18:00Z","last_updated_date":"2020-04-08T12:05:00Z","reference_number":"EMA/48567/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-four-week-limit-use-high-strength-estradiol-creams-confirmed_sv.pdf"}},
    {"id":"46633","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-01-31T17:22:00Z","last_updated_date":"2020-04-08T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"46668","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - Timetable for the implementation of the CMDh position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-04T12:38:00Z","last_updated_date":"2020-04-08T12:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-timetable-implementation-cmdh-position_sv.pdf"}},
    {"id":"46672","name":"Lemtrada Article 20 procedure - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-04T14:58:00Z","last_updated_date":"2020-02-04T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/lemtrada-article-20-procedure-scientific-conclusions_sv.pdf-0"}},
    {"id":"46673","name":"Lemtrada Article 20 procedure - Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-04T15:02:00Z","last_updated_date":"2020-02-04T15:02:00Z","reference_number":"EMA/45853/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_sv.pdf"}},
    {"id":"46688","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-02-10T10:40:00Z","last_updated_date":"2020-02-10T10:40:00Z","reference_number":"EMA/62697/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"46758","name":"Cyproterone Article-31 referral - Restrictions in use of cyproterone due to meningioma risk","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-14T11:40:00Z","last_updated_date":"2020-02-14T11:40:00Z","reference_number":"EMA/70255/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_en.pdf"},
    {"id":"46895","name":"Yondelis Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-02-28T12:00:00Z","reference_number":"EMA/95220/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/yondelis-article-20-procedure-review-started_en.pdf"},
    {"id":"46896","name":"Yondelis Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-02-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/yondelis-article-20-procedure-notification_en.pdf"},
    {"id":"46897","name":"Yondelis Article-20 procedure - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-02-28T12:00:00Z","reference_number":"EMA/CHMP/88965/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/yondelis-article-20-procedure-chmp-list-questions_en.pdf"},
    {"id":"46898","name":"Yondelis Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-06-05T11:32:00Z","reference_number":"EMA/CHMP/89066/2020 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/yondelis-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"46907","name":"Panexcell Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T12:01:00Z","last_updated_date":"2020-02-28T12:01:00Z","reference_number":"EMA/95202/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-review-started_en.pdf"},
    {"id":"46908","name":"Panexcell Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T12:05:00Z","last_updated_date":"2020-02-28T12:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-notification_en.pdf"},
    {"id":"46912","name":"Panexcell Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T15:46:00Z","last_updated_date":"2020-05-29T14:50:00Z","reference_number":"EMA/CHMP/92001/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"46913","name":"Panexcell Article-31 referral - CHMP list of questions to the Clinical Research Organisation (CRO)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T15:48:00Z","last_updated_date":"2020-02-28T15:48:00Z","reference_number":"EMA/CHMP/106145/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-chmp-list-questions-clinical-research-organisation-cro_en.pdf"},
    {"id":"46914","name":"Panexcell Article-31 referral - CHMP list of questions to be addressed by the applicants/marketing authorisation holders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T15:55:00Z","last_updated_date":"2020-02-28T15:55:00Z","reference_number":"EMA/CHMP/91871/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-chmp-list-questions-be-addressed-applicants-marketing-authorisation-holders_en.pdf"},
    {"id":"46947","name":"Panexcell Article-31 referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2020-03-05T15:07:00Z","last_updated_date":"2020-03-05T15:07:00Z","reference_number":"EMA/116598/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-annex-i_en.pdf"},
    {"id":"46969","name":"Xeljanz-H-A-20-1485-C-4214-0017: Assessment report - Article 20","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-03-06T14:10:00Z","last_updated_date":"2020-03-06T14:10:00Z","reference_number":"EMA/631064/2019 ","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-h-20-1485-c-4214-0017-assessment-report-article-20_en.pdf"},
    {"id":"46979","name":"Xeljanz Article-20 procedure - Annex I, II and III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2019-07-05T14:59:00Z","last_updated_date":"2019-07-05T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/xeljanz-article-20-procedure-annex-i-ii-and-iii_no.pdf"}},
    {"id":"47008","name":"Fluorouracil and fluorouracil related substances Article 31 referral - New testing and treatment recommendations for fluorouracil, capecitabine, tegafur and flucytosine","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T12:00:00Z","last_updated_date":"2020-03-13T12:00:00Z","reference_number":"EMA/125891/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-new-testing-and-treatment-recommendations-fluorouracil-capecitabine-tegafur-and-flucytosine_en.pdf"},
    {"id":"47012","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T12:00:00Z","last_updated_date":"2020-03-30T11:19:00Z","reference_number":"EMA/121879/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-review-started_en.pdf"},
    {"id":"47013","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T12:00:00Z","last_updated_date":"2020-07-01T11:12:00Z","reference_number":"EMA/PRAC/121857/2020 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"47014","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - Annexes A and Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T12:00:00Z","last_updated_date":"2020-04-29T12:02:00Z","reference_number":"EMA/134973/2020 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annexes-and-annex-i_en.pdf"},
    {"id":"47015","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T12:00:00Z","last_updated_date":"2020-03-13T12:00:00Z","reference_number":"EMA/PRAC/121855/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"47016","name":"Ifosfamide solutions Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T11:33:00Z","last_updated_date":"2020-03-13T11:33:00Z","reference_number":"EMA/116503/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-review-started_en.pdf"},
    {"id":"47017","name":"Ifosfamide solutions Article-31 referral -  PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T11:36:00Z","last_updated_date":"2020-03-13T11:36:00Z","reference_number":"EMA/PRAC/111337/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"47018","name":"Ifosfamide solutions Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T11:37:00Z","last_updated_date":"2020-11-03T11:06:00Z","reference_number":"EMA/PRAC/111338/2020 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"47019","name":"Ifosfamide solutions Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T11:38:00Z","last_updated_date":"2020-03-13T11:38:00Z","reference_number":"EMA/135187/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_en.pdf"},
    {"id":"47020","name":"Ifosfamide solutions Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T11:40:00Z","last_updated_date":"2020-03-13T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-notification_en.pdf"},
    {"id":"47021","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T12:00:00Z","last_updated_date":"2020-03-13T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-notification_en.pdf"},
    {"id":"47171","name":"Cyproterone Article-31 referral - Restrictions in use of cyproterone due to meningioma risk","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T18:02:00Z","last_updated_date":"2020-05-20T09:46:00Z","reference_number":"EMA/147755/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cyproterone-article-31-referral-restrictions-use-cyproterone-due-meningioma-risk_sv.pdf"}},
    {"id":"47172","name":"Cyproterone Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T18:04:00Z","last_updated_date":"2020-05-20T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cyproterone-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cyproterone-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cyproterone-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cyproterone-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cyproterone-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cyproterone-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cyproterone-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cyproterone-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cyproterone-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cyproterone-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cyproterone-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cyproterone-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cyproterone-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cyproterone-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cyproterone-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cyproterone-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cyproterone-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cyproterone-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cyproterone-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cyproterone-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cyproterone-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cyproterone-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"47181","name":"Methocarbamol / paracetamol Article 31 referral - Benefits of medicines containing combination of methocarbamol and paracetamol continue to outweigh risks","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-06-17T11:18:00Z","reference_number":"EMA/317184/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methocarbamol-paracetamol-article-31-referral-benefits-medicines-containing-combination-methocarbamol-and-paracetamol-continue-outweigh-risks_sv.pdf"}},
    {"id":"47182","name":"Methocarbamol / paracetamol Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-06-17T11:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"47185","name":"Fosfomycin Article-31 referral - Recommendations to restrict use of fosfomycin antibiotics​","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T10:16:00Z","last_updated_date":"2020-06-18T09:54:00Z","reference_number":"EMA/317719/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fosfomycin-article-31-referral-recommendations-restrict-use-fosfomycin-antibiotics_sv.pdf"}},
    {"id":"47193","name":"EMA recommends refusal of authorisation for Budesonide Sun (budesonide, nebuliser suspension) in the EU","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T11:44:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/148006/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/ema-recommends-refusal-authorisation-budesonide-sun-budesonide-nebuliser-suspension-eu_en.pdf"},
    {"id":"47225","name":"Fosfomycin Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-03-31T08:51:00Z","last_updated_date":"2024-09-18T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fosfomycin-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fosfomycin-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fosfomycin-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fosfomycin-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fosfomycin-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fosfomycin-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fosfomycin-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fosfomycin-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fosfomycin-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fosfomycin-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fosfomycin-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fosfomycin-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fosfomycin-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fosfomycin-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fosfomycin-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fosfomycin-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fosfomycin-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fosfomycin-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fosfomycin-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fosfomycin-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fosfomycin-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fosfomycin-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"47254","name":"Cyproterone Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T10:50:00Z","last_updated_date":"2020-04-01T10:50:00Z","reference_number":"EMA/134740/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"47376","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use Article 31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-04-08T12:29:00Z","last_updated_date":"2020-04-08T12:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"47414","name":"Ketabel Article-33(4) referral - Annex I, II, III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-04-16T12:02:00Z","last_updated_date":"2020-04-16T12:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ketabel-article-334-referral-annex-i-ii-iii_no.pdf"}},
    {"id":"47415","name":"Questions and answers on Ketabel 100 mg/ml solution for injection and associated names (ketamine)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-04-16T16:15:00Z","last_updated_date":"2020-04-16T16:15:00Z","reference_number":"EMA/77090/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-ketabel-100-mgml-solution-injection-and-associated-names-ketamine_sv.pdf"}},
    {"id":"47430","name":"Picato Article-20 referral - EMA review of Picato concludes medicine’s risks outweigh its benefits","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-04-17T14:24:00Z","last_updated_date":"2020-04-17T14:24:00Z","reference_number":"EMA/194393/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-ema-review-picato-concludes-medicines-risks-outweigh-its-benefits_en.pdf"},
    {"id":"47530","name":"Picato Article-20 referral - Risks of Picato for actinic keratosis outweigh benefits","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T15:05:00Z","last_updated_date":"2020-11-16T11:38:00Z","reference_number":"EMA/368170/2020/Corr.1","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/picato-article-20-referral-risks-picato-actinic-keratosis-outweigh-benefits_sv.pdf"}},
    {"id":"47540","name":"Fluorouracil and fluorouracil related substances Article 31 referral - EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-10-08T14:48:00Z","reference_number":"EMA/367286/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_sv.pdf"}},
    {"id":"47543","name":"Fluorouracil and fluorouracil related substances Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/CHMP/171789/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_en.pdf"},
    {"id":"47544","name":"Carbamazepin Tillomed Article 29(4) referral - EMA recommends authorisation of Carbamazepin Tillomed (carbamazepine, 200 and 400 mg prolonged release tablets) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T16:31:00Z","last_updated_date":"2020-07-21T11:57:00Z","reference_number":"EMA/388917/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/carbamazepin-tillomed-article-294-referral-ema-recommends-authorisation-carbamazepin-tillomed-carbamazepine-200-and-400-mg-prolonged-release-tablets-eu_sv.pdf"}},
    {"id":"47545","name":"Carbamazepin Tillomed Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T16:35:00Z","last_updated_date":"2020-07-21T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/carbamazepin-tillomed-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"47548","name":"Ranitidine Article-31 referral - Suspension of ranitidine medicines in the EU","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T16:44:00Z","last_updated_date":"2020-06-26T12:38:00Z","reference_number":"EMA/231394/2020. Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-suspension-ranitidine-medicines-eu_en.pdf"},
    {"id":"47552","name":"Budesonide Sun Article 29(4) referral - Timetable of procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-04-30T19:22:00Z","last_updated_date":"2020-04-30T19:22:00Z","reference_number":"EMA/CHMP/544996/2019 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/budesonide-sun-article-294-referral-timetable-procedure_en.pdf"},
    {"id":"47650","name":"Tylosin injectable for pigs Article 35 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-05-13T02:00:00Z","last_updated_date":"2020-05-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/tylosin-injectable-pigs-article-35-referral-annex-i-ii-iii_no.pdf"}},
    {"id":"47651","name":"Tylosin injectable for pigs Article 35 referral - Questions and answers on the review of withdrawal periods for injectable veterinary medicines containing tylosin base when given to pigs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-05-13T10:47:00Z","last_updated_date":"2020-05-13T10:47:00Z","reference_number":"EMA/78778/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tylosin-injectable-pigs-article-35-referral-questions-and-answers-review-withdrawal-periods-injectable-veterinary-medicines-containing-tylosin-base-when-given-pigs_sv.pdf"}},
    {"id":"47652","name":"Tylosin injectable for pigs Article 35 referral - Divergent position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-05-13T01:00:00Z","last_updated_date":"2020-05-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tylosin-injectable-pigs-article-35-referral-divergent-position_en.pdf"},
    {"id":"47674","name":"Leuprorelin-containing depot medicines Article-31 referral - PRAC recommends new measures to avoid handling errors","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-05-15T10:26:00Z","last_updated_date":"2020-05-20T15:34:00Z","reference_number":"EMA/250923/2020 Rev.","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-prac-recommends-new-measures-avoid-handling-errors_en.pdf"},
    {"id":"47733","name":"Cyproterone Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T10:07:00Z","last_updated_date":"2020-05-20T10:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cyproterone-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cyproterone-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cyproterone-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cyproterone-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cyproterone-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cyproterone-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cyproterone-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cyproterone-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cyproterone-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cyproterone-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cyproterone-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cyproterone-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cyproterone-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cyproterone-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cyproterone-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cyproterone-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cyproterone-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cyproterone-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cyproterone-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cyproterone-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cyproterone-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cyproterone-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"47734","name":"Cyproterone Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T10:06:00Z","last_updated_date":"2020-05-20T10:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cyproterone-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cyproterone-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cyproterone-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cyproterone-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cyproterone-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cyproterone-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cyproterone-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cyproterone-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cyproterone-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cyproterone-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cyproterone-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cyproterone-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cyproterone-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cyproterone-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cyproterone-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cyproterone-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cyproterone-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cyproterone-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cyproterone-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cyproterone-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cyproterone-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cyproterone-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"47735","name":"Cyproterone Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T10:09:00Z","last_updated_date":"2020-05-20T10:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/cyproterone-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/cyproterone-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/cyproterone-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/cyproterone-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/cyproterone-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/cyproterone-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/cyproterone-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/cyproterone-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/cyproterone-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/cyproterone-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/cyproterone-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/cyproterone-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/cyproterone-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/cyproterone-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/cyproterone-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/cyproterone-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/cyproterone-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/cyproterone-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/cyproterone-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/cyproterone-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/cyproterone-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/cyproterone-article-31-referral-annex-i_sv.pdf"}},
    {"id":"47966","name":"Methocarbamol / paracetamol Article 31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-06-11T12:00:00Z","last_updated_date":"2020-06-11T12:00:00Z","reference_number":"EMA/223791/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-assessment-report_en.pdf"},
    {"id":"48030","name":"Methocarbamol / paracetamol Article 31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-06-17T10:14:00Z","last_updated_date":"2020-06-17T10:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/methocarbamol-paracetamol-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"48044","name":"Fosfomycin Article-31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-06-18T09:42:00Z","last_updated_date":"2020-06-18T09:42:00Z","reference_number":"EMA/229801/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-assessment-report_en.pdf"},
    {"id":"48131","name":"Leuprorelin-containing depot medicines Article-31 referral - New measures to avoid handling errors with leuprorelin depot medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T15:38:00Z","last_updated_date":"2020-06-26T15:38:00Z","reference_number":"EMA/330921/2020 ","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-new-measures-avoid-handling-errors-leuprorelin-depot-medicines_en.pdf"},
    {"id":"48132","name":"Leuprorelin-containing depot medicines Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T15:42:00Z","last_updated_date":"2020-06-26T15:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iii_no.pdf"}},
    {"id":"48133","name":"Leuprorelin-containing depot medicines Article-31 referral - Timetable for the implementation of the CMDh position (Annex V)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T15:48:00Z","last_updated_date":"2020-06-26T15:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-timetable-implementation-cmdh-position-annex-v_sv.pdf"}}    {"id":"48148","name":"Refusal of marketing authorisation for Budesonide Sun (budesonide, nebuliser suspension)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-08-27T12:00:00Z","last_updated_date":"2020-08-27T12:00:00Z","reference_number":"EMA/444805/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/refusal-marketing-authorisation-budesonide-sun-budesonide-nebuliser-suspension_sv.pdf"}},
    {"id":"48152","name":"Varilrix Article 30 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T11:16:00Z","last_updated_date":"2020-06-26T11:16:00Z","reference_number":"EMA/334587/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/varilrix-article-30-referral-review-started_en.pdf"},
    {"id":"48153","name":"Varilrix Article 30 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T11:24:00Z","last_updated_date":"2020-12-16T11:58:00Z","reference_number":"EMA/CHMP/330865/2020 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/varilrix-article-30-referral-timetable-procedure_en.pdf"},
    {"id":"48154","name":"Varilrix Article 30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T11:26:00Z","last_updated_date":"2021-05-18T17:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/varilrix-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/varilrix-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/varilrix-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/varilrix-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/varilrix-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/varilrix-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/varilrix-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/varilrix-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/varilrix-article-30-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/varilrix-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/varilrix-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/varilrix-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/varilrix-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/varilrix-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/varilrix-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/varilrix-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/varilrix-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/varilrix-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/varilrix-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/varilrix-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/varilrix-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/varilrix-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/varilrix-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/varilrix-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/varilrix-article-30-referral-annex-i_no.pdf"}},
    {"id":"48155","name":"Varilrix Article 30 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T11:28:00Z","last_updated_date":"2020-06-26T11:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/varilrix-article-30-referral-notification_en.pdf"},
    {"id":"48220","name":"Carbamazepin Tillomed Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-07-03T13:55:00Z","last_updated_date":"2020-07-03T13:55:00Z","reference_number":"EMA/352448/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/carbamazepin-tillomed-article-294-referral-assessment-report_en.pdf"},
    {"id":"48233","name":"Fosfomycin Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-06T13:34:00Z","last_updated_date":"2020-07-06T13:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fosfomycin-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fosfomycin-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fosfomycin-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fosfomycin-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fosfomycin-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fosfomycin-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fosfomycin-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fosfomycin-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fosfomycin-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fosfomycin-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fosfomycin-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fosfomycin-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fosfomycin-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fosfomycin-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fosfomycin-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fosfomycin-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fosfomycin-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fosfomycin-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fosfomycin-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fosfomycin-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fosfomycin-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fosfomycin-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"48234","name":"Fosfomycin Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-06T13:36:00Z","last_updated_date":"2020-07-06T13:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fosfomycin-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fosfomycin-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fosfomycin-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fosfomycin-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fosfomycin-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fosfomycin-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fosfomycin-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fosfomycin-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fosfomycin-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fosfomycin-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fosfomycin-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fosfomycin-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fosfomycin-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fosfomycin-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fosfomycin-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fosfomycin-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fosfomycin-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fosfomycin-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fosfomycin-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fosfomycin-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fosfomycin-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fosfomycin-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"48235","name":"Fosfomycin Article-31 referral - Annex V","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-06T13:38:00Z","last_updated_date":"2020-07-06T13:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-annex-v_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fosfomycin-article-31-referral-annex-v_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fosfomycin-article-31-referral-annex-v_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fosfomycin-article-31-referral-annex-v_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fosfomycin-article-31-referral-annex-v_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fosfomycin-article-31-referral-annex-v_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fosfomycin-article-31-referral-annex-v_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fosfomycin-article-31-referral-annex-v_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fosfomycin-article-31-referral-annex-v_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fosfomycin-article-31-referral-annex-v_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fosfomycin-article-31-referral-annex-v_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fosfomycin-article-31-referral-annex-v_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fosfomycin-article-31-referral-annex-v_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fosfomycin-article-31-referral-annex-v_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fosfomycin-article-31-referral-annex-v_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fosfomycin-article-31-referral-annex-v_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fosfomycin-article-31-referral-annex-v_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fosfomycin-article-31-referral-annex-v_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fosfomycin-article-31-referral-annex-v_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fosfomycin-article-31-referral-annex-v_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fosfomycin-article-31-referral-annex-v_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fosfomycin-article-31-referral-annex-v_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fosfomycin-article-31-referral-annex-v_sv.pdf"}},
    {"id":"48256","name":"Picato Article-20 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-07-08T09:36:00Z","last_updated_date":"2020-07-08T09:36:00Z","reference_number":"EMA/248352/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-assessment-report_en.pdf"},
    {"id":"48310","name":"Fluorouracil and fluorouracil related substances Article 31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-07-15T14:48:00Z","last_updated_date":"2020-07-15T14:48:00Z","reference_number":"EMA/274404/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-assessment-report_en.pdf"},
    {"id":"48339","name":"Carbamazepin Tillomed Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-21T10:41:00Z","last_updated_date":"2020-07-21T10:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/carbamazepin-tillomed-article-294-referral-annex-i_sv.pdf"}},
    {"id":"48340","name":"Carbamazepin Tillomed Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-21T10:42:00Z","last_updated_date":"2020-07-21T10:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/carbamazepin-tillomed-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"48380","name":"Fluorouracil and fluorouracil related substances Article 31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-23T16:19:00Z","last_updated_date":"2020-07-23T16:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-ii_no.pdf"}},
    {"id":"48383","name":"Fluorouracil and fluorouracil related substances Article 31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-23T16:24:00Z","last_updated_date":"2020-07-23T16:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_no.pdf"}},
    {"id":"48384","name":"Fluorouracil and fluorouracil related substances Article 31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-23T16:25:00Z","last_updated_date":"2020-07-23T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_bg.pdf-0","es":"https://www.ema.europa.eu/es/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_es.pdf-0","cs":"https://www.ema.europa.eu/cs/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_cs.pdf-0","da":"https://www.ema.europa.eu/da/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_da.pdf-0","de":"https://www.ema.europa.eu/de/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_de.pdf-0","et":"https://www.ema.europa.eu/et/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_et.pdf-0","el":"https://www.ema.europa.eu/el/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_el.pdf-0","fr":"https://www.ema.europa.eu/fr/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_fr.pdf-0","hr":"https://www.ema.europa.eu/hr/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_hr.pdf-0","it":"https://www.ema.europa.eu/it/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_it.pdf-0","lv":"https://www.ema.europa.eu/lv/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_lv.pdf-0","lt":"https://www.ema.europa.eu/lt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_lt.pdf-0","hu":"https://www.ema.europa.eu/hu/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_hu.pdf-0","mt":"https://www.ema.europa.eu/mt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_mt.pdf-0","nl":"https://www.ema.europa.eu/nl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_nl.pdf-0","pl":"https://www.ema.europa.eu/pl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_pl.pdf-0","pt":"https://www.ema.europa.eu/pt/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_pt.pdf-0","ro":"https://www.ema.europa.eu/ro/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_ro.pdf-0","sk":"https://www.ema.europa.eu/sk/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_sk.pdf-0","sl":"https://www.ema.europa.eu/sl/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_sl.pdf-0","fi":"https://www.ema.europa.eu/fi/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_fi.pdf-0","sv":"https://www.ema.europa.eu/sv/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_sv.pdf-0","is":"https://www.ema.europa.eu/is/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_is.pdf-0","no":"https://www.ema.europa.eu/no/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-i_no.pdf-0"}},
    {"id":"48385","name":"Yondelis Article-20 procedure - Authorised uses of cancer medicine Yondelis unchanged following review of new data","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T16:53:00Z","last_updated_date":"2020-07-24T16:53:00Z","reference_number":"EMA/385842/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_en.pdf"},
    {"id":"48386","name":"Yondelis Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T16:55:00Z","last_updated_date":"2020-07-24T16:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/yondelis-article-20-procedure-annex-iii_en.pdf"},
    {"id":"48392","name":"Panexcell Article-31 referral - Panexcell Clinical Laboratories: suspension of medicines over flawed studies","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T10:14:00Z","last_updated_date":"2020-10-22T11:52:00Z","reference_number":"EMA/547814/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/panexcell-article-31-referral-panexcell-clinical-laboratories-suspension-medicines-over-flawed-studies_sv.pdf"}},
    {"id":"48402","name":"Ibuprofen Kabi 400 mg Article 29(4) referral - EMA recommends authorisation of Ibuprofen Kabi (ibuprofen, 400 mg solution for infusion) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T12:29:00Z","last_updated_date":"2020-10-26T16:40:00Z","reference_number":"EMA/564161/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-ema-recommends-authorisation-ibuprofen-kabi-ibuprofen-400-mg-solution-infusion-eu_sv.pdf"}},
    {"id":"48403","name":"Ibuprofen Kabi 400 mg Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T12:30:00Z","last_updated_date":"2020-10-26T16:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"48406","name":"Yondelis Article-20 procedure - Authorised uses of cancer medicine Yondelis unchanged following review of new data","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T13:31:00Z","last_updated_date":"2020-10-09T12:15:00Z","reference_number":"EMA/513030/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/yondelis-article-20-procedure-authorised-uses-cancer-medicine-yondelis-unchanged-following-review-new-data_sv.pdf"}},
    {"id":"48407","name":"Yondelis Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T13:33:00Z","last_updated_date":"2020-07-24T13:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/yondelis-article-20-procedure-annex-iii_en.pdf-0"},
    {"id":"48428","name":"Picato Article-20 referral - Annex - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-27T15:18:00Z","last_updated_date":"2020-07-27T15:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-annex-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/picato-article-20-referral-annex-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/picato-article-20-referral-annex-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/picato-article-20-referral-annex-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/picato-article-20-referral-annex-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/picato-article-20-referral-annex-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/picato-article-20-referral-annex-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/picato-article-20-referral-annex-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/picato-article-20-referral-annex-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/picato-article-20-referral-annex-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/picato-article-20-referral-annex-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/picato-article-20-referral-annex-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/picato-article-20-referral-annex-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/picato-article-20-referral-annex-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/picato-article-20-referral-annex-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/picato-article-20-referral-annex-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/picato-article-20-referral-annex-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/picato-article-20-referral-annex-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/picato-article-20-referral-annex-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/picato-article-20-referral-annex-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/picato-article-20-referral-annex-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/picato-article-20-referral-annex-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/picato-article-20-referral-annex-scientific-conclusions_sv.pdf"}},
    {"id":"48468","name":"Leuprorelin-containing depot medicines Article-31 referral - Public assessment report to PRAC recommendation","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-07-29T10:37:00Z","last_updated_date":"2020-07-29T10:37:00Z","reference_number":"EMA/397961/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-public-assessment-report-prac-recommendation_en.pdf"},
    {"id":"48520","name":"Leuprorelin-containing depot medicines Article-31 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-07-31T13:54:00Z","last_updated_date":"2020-07-31T13:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"48521","name":"Leuprorelin-containing depot medicines Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-07-31T13:58:00Z","last_updated_date":"2020-07-31T13:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"48707","name":"Budesonide Sun Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-08-27T12:14:00Z","last_updated_date":"2020-08-27T12:14:00Z","reference_number":"EMA/442670/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/budesonide-sun-article-294-referral-assessment-report_en.pdf"},
    {"id":"48757","name":"Ulipristal acetate 5mg medicinal products Article-31 referral- PRAC recommends revoking marketing authorisation of ulipristal acetate for uterine fibroids","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-09-04T12:00:00Z","last_updated_date":"2020-09-04T12:00:00Z","reference_number":"EMA/455818/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-prac-recommends-revoking-marketing-authorisation-ulipristal-acetate-uterine-fibroids_en.pdf"},
    {"id":"48759","name":"Xofigo Article-20 procedure - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-10-11T16:05:00Z","last_updated_date":"2018-10-11T16:05:00Z","reference_number":"EMA/540557/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/xofigo-article-20-procedure-assessment-report_en.pdf"},
    {"id":"48824","name":"Budesonide Sun Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-09-16T19:22:00Z","last_updated_date":"2020-09-16T19:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/budesonide-sun-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/budesonide-sun-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/budesonide-sun-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/budesonide-sun-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/budesonide-sun-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/budesonide-sun-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/budesonide-sun-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/budesonide-sun-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/budesonide-sun-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/budesonide-sun-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/budesonide-sun-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/budesonide-sun-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/budesonide-sun-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/budesonide-sun-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/budesonide-sun-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/budesonide-sun-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/budesonide-sun-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/budesonide-sun-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/budesonide-sun-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/budesonide-sun-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/budesonide-sun-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/budesonide-sun-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/budesonide-sun-article-294-referral-annex-i_sv.pdf"}},
    {"id":"48825","name":"Budesonide Sun Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-09-16T19:22:00Z","last_updated_date":"2020-09-16T19:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/budesonide-sun-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/budesonide-sun-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/budesonide-sun-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/budesonide-sun-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/budesonide-sun-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/budesonide-sun-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/budesonide-sun-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/budesonide-sun-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/budesonide-sun-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/budesonide-sun-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/budesonide-sun-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/budesonide-sun-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/budesonide-sun-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/budesonide-sun-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/budesonide-sun-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/budesonide-sun-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/budesonide-sun-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/budesonide-sun-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/budesonide-sun-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/budesonide-sun-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/budesonide-sun-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/budesonide-sun-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/budesonide-sun-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"48858","name":"Ranitidine Article-31 referral - EMA confirms recommendation to suspend all ranitidine medicines in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-09-18T11:08:00Z","last_updated_date":"2020-09-18T11:08:00Z","reference_number":"EMA/666097/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_sv.pdf"}},
    {"id":"48917","name":"Yondelis Article-20 procedure - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-09-30T12:00:00Z","last_updated_date":"2020-09-30T12:00:00Z","reference_number":"EMA/470721/2020 ","document_url":"https://www.ema.europa.eu/en/documents/referral/yondelis-article-20-procedure-assessment-report_en.pdf"},
    {"id":"48950","name":"Panexcell Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-10-06T09:26:00Z","last_updated_date":"2020-10-06T09:26:00Z","reference_number":"EMA/504714/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-assessment-report_en.pdf"},
    {"id":"48951","name":"Dinolytic and generics Article-35 referral - Questions and answers on the review of withdrawal periods for Dinolytic 12.5 mg/ml and 5 mg/ml solutions for injection and associated names, and generic products thereof","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-10-06T09:38:00Z","last_updated_date":"2020-10-06T09:38:00Z","reference_number":"EMA/451685/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dinolytic-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-dinolytic-125-mgml-and-5-mgml-solutions-injection-and-associated-names-and-generic-products-thereof_sv.pdf"}},
    {"id":"48952","name":"Dinolytic and generics Article-35 referral - Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-10-06T09:57:00Z","last_updated_date":"2020-10-06T09:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/dinolytic-and-generics-article-35-referral-annex-i-iii_no.pdf"}},
    {"id":"48979","name":"Yondelis Article-20 procedure - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-10-09T12:15:00Z","last_updated_date":"2020-10-09T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/yondelis-article-20-procedure-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/yondelis-article-20-procedure-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/yondelis-article-20-procedure-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/yondelis-article-20-procedure-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/yondelis-article-20-procedure-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/yondelis-article-20-procedure-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/yondelis-article-20-procedure-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/yondelis-article-20-procedure-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/yondelis-article-20-procedure-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/yondelis-article-20-procedure-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/yondelis-article-20-procedure-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/yondelis-article-20-procedure-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/yondelis-article-20-procedure-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/yondelis-article-20-procedure-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/yondelis-article-20-procedure-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/yondelis-article-20-procedure-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/yondelis-article-20-procedure-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/yondelis-article-20-procedure-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/yondelis-article-20-procedure-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/yondelis-article-20-procedure-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/yondelis-article-20-procedure-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/yondelis-article-20-procedure-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/yondelis-article-20-procedure-annex-iv_sv.pdf"}},
    {"id":"49022","name":"Panexcell Article-31 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-10-22T15:07:00Z","last_updated_date":"2020-10-22T15:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/panexcell-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/panexcell-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/panexcell-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/panexcell-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/panexcell-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/panexcell-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/panexcell-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/panexcell-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/panexcell-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/panexcell-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/panexcell-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/panexcell-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/panexcell-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/panexcell-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/panexcell-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/panexcell-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/panexcell-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/panexcell-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/panexcell-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/panexcell-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/panexcell-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/panexcell-article-31-referral-annex-i_sv.pdf"}},
    {"id":"49062","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - Timetable for the procedure - CHMP Opinion on the impact of the Article 5(3) referral on nitrosamines in human medicinal products on the referral","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-10-20T11:54:00Z","last_updated_date":"2020-10-20T11:54:00Z","reference_number":"EMA/CHMP/525148/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-timetable-procedure-chmp-opinion-impact-article-53-referral-nitrosamines-human-medicinal-products-referral_en.pdf"},
    {"id":"49102","name":"Panexcell Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-10-22T09:40:00Z","last_updated_date":"2020-10-22T09:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/panexcell-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/panexcell-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/panexcell-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/panexcell-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/panexcell-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/panexcell-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/panexcell-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/panexcell-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/panexcell-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/panexcell-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/panexcell-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/panexcell-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/panexcell-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/panexcell-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/panexcell-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/panexcell-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/panexcell-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/panexcell-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/panexcell-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/panexcell-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/panexcell-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/panexcell-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"49103","name":"Panexcell Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-10-22T09:43:00Z","last_updated_date":"2020-10-22T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/panexcell-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/panexcell-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/panexcell-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/panexcell-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/panexcell-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/panexcell-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/panexcell-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/panexcell-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/panexcell-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/panexcell-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/panexcell-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/panexcell-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/panexcell-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/panexcell-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/panexcell-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/panexcell-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/panexcell-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/panexcell-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/panexcell-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/panexcell-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/panexcell-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/panexcell-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"49131","name":"Ibuprofen Kabi 400 mg Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-10-26T16:47:00Z","last_updated_date":"2020-10-26T16:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-i_sv.pdf"}},
    {"id":"49132","name":"Ibuprofen Kabi 400 mg Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-10-26T16:48:00Z","last_updated_date":"2020-10-26T16:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"49133","name":"Ibuprofen Kabi 400 mg Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-10-26T16:57:00Z","last_updated_date":"2020-10-26T16:57:00Z","reference_number":"EMA/516696/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-assessment-report_en.pdf"},
    {"id":"49160","name":"Questions and answers on the review of withdrawal periods for Stresnil 40 mg/ml solution for injection for pigs and associated names, and generic products thereof","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-10-30T08:53:00Z","last_updated_date":"2020-10-30T08:53:00Z","reference_number":"EMA/460836/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-withdrawal-periods-stresnil-40-mgml-solution-injection-pigs-and-associated-names-and-generic-products-thereof_sv.pdf"}},
    {"id":"49161","name":"Stresnil and generics referral Article-35 - Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-10-30T08:56:00Z","last_updated_date":"2020-10-30T08:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/stresnil-and-generics-referral-article-35-annex-i-iii_no.pdf"}},
    {"id":"49231","name":"Betamox LA and generics Article-35 referral - Questions and answers on the review of withdrawal periods for Betamox LA 150 mg/ml suspension for injection and associated names, and generic products thereof","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T12:12:00Z","last_updated_date":"2020-11-12T12:12:00Z","reference_number":"EMA/502239/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/betamox-la-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-betamox-la-150-mgml-suspension-injection-and-associated-names-and-generic-products-thereof_sv.pdf"}},
    {"id":"49232","name":"Betamox LA Article-35 referral - Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T12:18:00Z","last_updated_date":"2020-11-12T12:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/betamox-la-article-35-referral-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/betamox-la-article-35-referral-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/betamox-la-article-35-referral-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/betamox-la-article-35-referral-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/betamox-la-article-35-referral-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/betamox-la-article-35-referral-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/betamox-la-article-35-referral-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/betamox-la-article-35-referral-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/betamox-la-article-35-referral-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/betamox-la-article-35-referral-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/betamox-la-article-35-referral-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/betamox-la-article-35-referral-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/betamox-la-article-35-referral-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/betamox-la-article-35-referral-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/betamox-la-article-35-referral-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/betamox-la-article-35-referral-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/betamox-la-article-35-referral-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/betamox-la-article-35-referral-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/betamox-la-article-35-referral-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/betamox-la-article-35-referral-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/betamox-la-article-35-referral-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/betamox-la-article-35-referral-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/betamox-la-article-35-referral-annex-i-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/betamox-la-article-35-referral-annex-i-iii_no.pdf"}},
    {"id":"49244","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - Nitrosamines: EMA aligns recommendations for sartans with those for other medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T17:29:00Z","last_updated_date":"2020-11-13T17:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_en.pdf"},
    {"id":"49247","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - Ulipristal acetate for uterine fibroids: EMA recommends restricting use","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T08:37:00Z","last_updated_date":"2021-01-14T11:00:00Z","reference_number":"EMA/24778/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids-ema-recommends-restricting-use_sv.pdf"}},
    {"id":"49249","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - Amendments to the relevant sections of the product information (Annex III)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T12:00:00Z","last_updated_date":"2020-11-17T10:00:00Z","reference_number":"Corr.1","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-amendments-relevant-sections-product-information-annex-iii_en.pdf"},
    {"id":"49689","name":"Ranitidine Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-12-22T18:25:00Z","last_updated_date":"2020-12-22T18:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ranitidine-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ranitidine-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ranitidine-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ranitidine-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ranitidine-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ranitidine-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ranitidine-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ranitidine-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ranitidine-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ranitidine-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ranitidine-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ranitidine-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ranitidine-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ranitidine-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ranitidine-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ranitidine-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ranitidine-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ranitidine-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ranitidine-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ranitidine-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ranitidine-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ranitidine-article-31-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ranitidine-article-31-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ranitidine-article-31-referral-annex-ii_no.pdf"}},
    {"id":"49690","name":"Ranitidine Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2020-12-22T18:27:00Z","last_updated_date":"2020-12-22T18:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ranitidine-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ranitidine-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ranitidine-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ranitidine-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ranitidine-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ranitidine-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ranitidine-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ranitidine-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ranitidine-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ranitidine-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ranitidine-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ranitidine-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ranitidine-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ranitidine-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ranitidine-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ranitidine-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ranitidine-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ranitidine-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ranitidine-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ranitidine-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ranitidine-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ranitidine-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ranitidine-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ranitidine-article-31-referral-annex-iii_no.pdf"}},
    {"id":"49691","name":"Ranitidine Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2020-12-22T18:32:00Z","last_updated_date":"2021-02-17T12:04:00Z","reference_number":"EMA/599846/2020 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-assessment-report_en.pdf"},
    {"id":"49806","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - CHMP scientific conclusions and PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2021-01-14T16:01:00Z","last_updated_date":"2021-01-14T16:01:00Z","reference_number":"EMA/524073/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-chmp-scientific-conclusions-and-prac-assessment-report_en.pdf"},
    {"id":"50049","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-03T14:29:00Z","last_updated_date":"2021-02-03T14:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-i_no.pdf"}},
    {"id":"50050","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-03T14:33:00Z","last_updated_date":"2021-02-03T14:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-ii_no.pdf"}},
    {"id":"50051","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-03T14:36:00Z","last_updated_date":"2021-02-03T14:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iii_no.pdf"}},
    {"id":"50052","name":"Ulipristal acetate 5mg medicinal products Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-03T14:41:00Z","last_updated_date":"2021-02-03T14:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-annex-iv_no.pdf"}},
    {"id":"50075","name":"Tiamulin Referral Article-35 - Questions and answers on the review of veterinary medicines containing tiamulin hydrogen fumarate presented as premix for medicated feeding stuff and oral powder for in-feed use given to pigs","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-05T17:48:00Z","last_updated_date":"2021-02-05T17:48:00Z","reference_number":"EMA/649279/2020","document_url":"https://www.ema.europa.eu/en/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tiamulin-referral-article-35-questions-and-answers-review-veterinary-medicines-containing-tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-and-oral-powder-feed-use-given-pigs_sv.pdf"}},
    {"id":"50076","name":"Tiamulin Referral Article-35 - Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-05T17:53:00Z","last_updated_date":"2021-02-05T17:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tiamulin-referral-article-35-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tiamulin-referral-article-35-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tiamulin-referral-article-35-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tiamulin-referral-article-35-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tiamulin-referral-article-35-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tiamulin-referral-article-35-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tiamulin-referral-article-35-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tiamulin-referral-article-35-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tiamulin-referral-article-35-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tiamulin-referral-article-35-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tiamulin-referral-article-35-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tiamulin-referral-article-35-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tiamulin-referral-article-35-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tiamulin-referral-article-35-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tiamulin-referral-article-35-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tiamulin-referral-article-35-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tiamulin-referral-article-35-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tiamulin-referral-article-35-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tiamulin-referral-article-35-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tiamulin-referral-article-35-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tiamulin-referral-article-35-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tiamulin-referral-article-35-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tiamulin-referral-article-35-annex-i-iii_sv.pdf"}},
    {"id":"50147","name":"Amfepramone-containing medicinal products Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-12T12:00:00Z","last_updated_date":"2021-02-12T12:00:00Z","reference_number":"EMA/53585/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-review-started_en.pdf"},
    {"id":"50148","name":"Amfepramone-containing medicinal products Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-12T12:00:00Z","last_updated_date":"2021-02-12T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-notification_en.pdf"},
    {"id":"50149","name":"Amfepramone-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-12T12:00:00Z","last_updated_date":"2021-02-12T12:00:00Z","reference_number":"EMA/91464/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_en.pdf"},
    {"id":"50150","name":"Amfepramone-containing medicinal products Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-12T12:00:00Z","last_updated_date":"2021-02-12T12:00:00Z","reference_number":"EMA/PRAC/51715/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"50151","name":"Amfepramone-containing medicinal products Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-12T12:00:00Z","last_updated_date":"2022-09-02T13:09:00Z","reference_number":"EMA/PRAC/51714/2021 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"50257","name":"Valbazen and generics Article-35 referral - Annex I-III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-22T15:55:00Z","last_updated_date":"2021-02-22T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valbazen-and-generics-article-35-referral-annex-i-iii_sv.pdf"}},
    {"id":"50258","name":"Valbazen and generics Article 35-referral - Questions and answers on the review of withdrawal periods for Valbazen 100 mg/ml Total Spectrum Wormer oral suspension and associated names, including its generic/hybrid products","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-22T16:05:00Z","last_updated_date":"2021-02-22T16:05:00Z","reference_number":"EMA/42905/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/valbazen-and-generics-article-35-referral-questions-and-answers-review-withdrawal-periods-valbazen-100-mgml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generichybrid_sv.pdf"}},
    {"id":"50285","name":"Varilrix Article 30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T12:00:00Z","last_updated_date":"2021-05-18T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/varilrix-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/varilrix-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/varilrix-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/varilrix-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/varilrix-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/varilrix-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/varilrix-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/varilrix-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/varilrix-article-30-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/varilrix-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/varilrix-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/varilrix-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/varilrix-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/varilrix-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/varilrix-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/varilrix-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/varilrix-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/varilrix-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/varilrix-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/varilrix-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/varilrix-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/varilrix-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/varilrix-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/varilrix-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/varilrix-article-30-referral-annex-iii_no.pdf"}},
    {"id":"50290","name":"Varilrix Article 30 referral - Use of Varilrix (live attenuated varicella virus [OKA strain]) to be harmonised in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T12:00:00Z","last_updated_date":"2021-06-09T13:19:00Z","reference_number":"EMA/104511/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/varilrix-article-30-referral-use-varilrix-live-attenuated-varicella-virus-oka-strain-be-harmonised-eu_sv.pdf"}},
    {"id":"50484","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - Questions & answers on implementation - Impact of the Article 5(3) scientific opinion on nitrosamines in human medicinal products","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2021-03-08T17:40:00Z","last_updated_date":"2021-03-08T17:40:00Z","reference_number":"EMA/86733/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-questions-answers-implementation-impact-article-53-scientific-opinion-nitrosamines-human-medicinal-products_en.pdf"},
    {"id":"50531","name":"Ifosfamide solutions Article-31 referral - Benefits of ifosfamide solutions continue to outweigh risks","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T12:00:00Z","last_updated_date":"2021-03-12T12:00:00Z","reference_number":"EMA/140127/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_en.pdf"},
    {"id":"50533","name":"Zynteglo Article-20 referral - Review of thalassaemia medicine Zynteglo started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T12:19:00Z","last_updated_date":"2021-03-12T12:19:00Z","reference_number":"EMA/127031/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-review-thalassaemia-medicine-zynteglo-started_en.pdf"},
    {"id":"50534","name":"Zynteglo Article-20 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T12:23:00Z","last_updated_date":"2021-06-11T15:51:00Z","reference_number":"EMA/PRAC/104559/2021 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-timetable-procedure_en.pdf"},
    {"id":"50535","name":"Zynteglo Article-20 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T12:26:00Z","last_updated_date":"2021-03-12T12:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-notification_en.pdf"},
    {"id":"50544","name":"Zynteglo Article-20 referral - PRAC List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T15:04:00Z","last_updated_date":"2021-03-12T15:04:00Z","reference_number":"EMA/PRAC/104560/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-prac-list-questions_en.pdf"},
    {"id":"50648","name":"Adjusol trimethoprim sulfa liquide Article-34 referral - Questions and answers on Adjusol trimethoprim sulfa liquide and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-03-19T19:00:00Z","last_updated_date":"2021-03-19T19:00:00Z","reference_number":"EMA/822260/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-questions-and-answers-adjusol-trimethoprim-sulfa-liquide-and-its-associated-names_sv.pdf"}},
    {"id":"50649","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral - Nitrosamines: EMA aligns recommendations for sartans with those for other medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-03-19T10:12:00Z","last_updated_date":"2021-03-19T10:12:00Z","reference_number":"EMA/134937/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-nitrosamines-ema-aligns-recommendations-sartans-those-other-medicines_sv.pdf"}},
    {"id":"50650","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral – Annex I – Impact of the Article 5(3) scientific opinion on nitrosamines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-03-19T10:14:00Z","last_updated_date":"2021-03-19T10:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-i-impact-article-53-scientific-opinion-nitrosamines_sv.pdf"}},
    {"id":"50651","name":"Angiotensin-II-receptor antagonists (sartans) Article 31 referral – Annex II – Impact of the Article 5(3) scientific opinion on nitrosamines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-03-19T10:17:00Z","last_updated_date":"2021-03-19T10:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-annex-ii-impact-article-53-scientific-opinion-nitrosamines_no.pdf"}},
    {"id":"50658","name":"Adjusol trimethoprim sulfa liquide Article-34 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-03-19T19:00:00Z","last_updated_date":"2021-03-19T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/adjusol-trimethoprim-sulfa-liquide-article-34-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"50958","name":"Ifosfamide solutions Article-31 referral - Benefits of ifosfamide solutions continue to outweigh risks","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-19T09:40:00Z","last_updated_date":"2021-07-19T09:40:00Z","reference_number":"EMA/219444/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_sv.pdf"}},
    {"id":"50962","name":"Ifosfamide solutions Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-19T11:45:00Z","last_updated_date":"2021-07-19T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ifosfamide-solutions-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"51137","name":"Varilrix Article 30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2021-05-11T14:46:00Z","last_updated_date":"2021-05-11T14:46:00Z","reference_number":"EMA/201470/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/varilrix-article-30-referral-assessment-report_en.pdf"},
    {"id":"51181","name":"Varilrix Article 30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-05-18T17:36:00Z","last_updated_date":"2021-05-18T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/varilrix-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/varilrix-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/varilrix-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/varilrix-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/varilrix-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/varilrix-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/varilrix-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/varilrix-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/varilrix-article-30-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/varilrix-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/varilrix-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/varilrix-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/varilrix-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/varilrix-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/varilrix-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/varilrix-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/varilrix-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/varilrix-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/varilrix-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/varilrix-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/varilrix-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/varilrix-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/varilrix-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"51605","name":"Etifoxine-containing medicinal products Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-06-25T11:52:00Z","last_updated_date":"2021-06-25T11:52:00Z","reference_number":"EMA/351669/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-review-started_en.pdf"},
    {"id":"51606","name":"Etifoxine-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-06-25T14:01:00Z","last_updated_date":"2021-06-25T14:01:00Z","reference_number":"EMA/361673/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_en.pdf"},
    {"id":"51612","name":"Etifoxine-containing medicinal products Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-06-25T14:01:00Z","last_updated_date":"2021-06-25T14:01:00Z","reference_number":"EMA/CHMP/306202/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"51613","name":"Etifoxine-containing medicinal products Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-06-25T14:01:00Z","last_updated_date":"2021-10-18T11:56:00Z","reference_number":"EMA/CHMP/305937/2021 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"51656","name":"Ifosfamide solutions Article-31 referral - Assessment Report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2021-06-29T09:52:00Z","last_updated_date":"2021-06-29T09:52:00Z","reference_number":"EMA/159195/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-assessment-report_en.pdf"},
    {"id":"51936","name":"Zynteglo Article-20 referral - EMA finds no evidence linking viral vector in Zynteglo to blood cancer","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T12:24:00Z","last_updated_date":"2021-07-09T12:24:00Z","reference_number":"EMA/380481/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-ema-finds-no-evidence-linking-viral-vector-zynteglo-blood-cancer_en.pdf"},
    {"id":"51958","name":"Ifosfamide solutions Article-31 PhV - CMDH divergent positions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-19T08:00:00Z","last_updated_date":"2021-07-19T08:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-phv-cmdh-divergent-positions_en.pdf"},
    {"id":"51959","name":"Ifosfamide solutions Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-19T12:19:00Z","last_updated_date":"2021-07-19T12:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"51960","name":"Ifosfamide solutions Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-19T09:00:00Z","last_updated_date":"2021-07-19T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ifosfamide-solutions-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"51962","name":"Ifosfamide solutions Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-19T16:21:00Z","last_updated_date":"2021-07-19T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ifosfamide-solutions-article-31-referral-annex-i_sv.pdf"}},
    {"id":"51963","name":"Ifosfamide solutions Article-31 referral - Benefits of ifosfamide solutions continue to outweigh risks","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-04-23T09:40:00Z","last_updated_date":"2021-04-23T09:40:00Z","reference_number":"EMA/219444/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-benefits-ifosfamide-solutions-continue-outweigh-risks_en.pdf-1"},
    {"id":"52033","name":"Zynteglo Article-20 referral - CHMP endorses review finding no link between viral vector in Zynteglo and blood cancer","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-23T18:47:00Z","last_updated_date":"2021-10-04T14:34:00Z","reference_number":"EMA/546292/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zynteglo-article-20-referral-chmp-endorses-review-finding-no-link-between-viral-vector-zynteglo-and-blood-cancer_sv.pdf"}},
    {"id":"52042","name":"Zynteglo Article-20 referral - Changes to the summary of product characteristics, labelling and package leaflet","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-23T10:40:00Z","last_updated_date":"2021-07-23T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-changes-summary-product-characteristics-labelling-and-package-leaflet_en.pdf"},
    {"id":"52114","name":"Modified live porcine respiratory and reproducti Article-35 referral - Questions and answers on the review of modified live porcine respiratory and reproductive syndrome (PRRS) virus vaccines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-28T10:16:00Z","last_updated_date":"2021-07-28T10:16:00Z","reference_number":"EMA/324090/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-questions-and-answers-review-modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines_sv.pdf"}}    {"id":"52115","name":"Modified live porcine respiratory and reproducti Article-35 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-07-28T10:25:00Z","last_updated_date":"2021-07-28T10:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/modified-live-porcine-respiratory-and-reproducti-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"52561","name":"Etifoxine-containing medicinal products Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-09-22T16:55:00Z","last_updated_date":"2021-09-22T16:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-notification_en.pdf"},
    {"id":"52633","name":"Injectable veterinary medicinal products containing vitamin A for use in food producing species Article-35 referral - Questions and answers on the review of injectable veterinary medicines containing vitamin A for use in food producing species","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T10:12:00Z","last_updated_date":"2021-09-27T10:12:00Z","reference_number":"EMA/279146/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-questions-and-answers-review-injectable-veterinary-medicines-containing-vitamin-use-food_sv.pdf"}},
    {"id":"52634","name":"Injectable veterinary medicinal products containing vitamin A for use in food producing species Article-35 referral - Annex I, II, III, IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T10:25:00Z","last_updated_date":"2021-09-27T10:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species-article-35-referral-annex-i-ii-iii-iv_sv.pdf"}},
    {"id":"52636","name":"Ronaxan and its associated names Article-34 referral - Questions and answers on Ronaxan and its associated names","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T11:11:00Z","last_updated_date":"2021-09-27T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ronaxan-and-its-associated-names-article-34-referral-questions-and-answers-ronaxan-and-its-associated-names_sv.pdf"}},
    {"id":"52637","name":"Ronaxan and its associated names Article-34 referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T11:04:00Z","last_updated_date":"2021-09-27T11:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ronaxan-and-its-associated-names-article-34-referral-annex-i-ii-iii_no.pdf"}},
    {"id":"52692","name":"Nomegestrol and chlormadinone Article-31 referral - EMA starts review of meningioma risk with nomegestrol- and chlormadinone-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T11:19:00Z","last_updated_date":"2021-10-01T11:19:00Z","reference_number":"EMA/538480/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-ema-starts-review-meningioma-risk-nomegestrol-and-chlormadinone-containing-medicines_en.pdf"},
    {"id":"52693","name":"Nomegestrol and chlormadinone Article-31 referral - Annex A and Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2021-10-01T11:23:00Z","last_updated_date":"2021-11-04T17:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-and-annex-i_en.pdf"},
    {"id":"52694","name":"Nomegestrol and chlormadinone Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T11:25:00Z","last_updated_date":"2021-10-01T11:25:00Z","reference_number":"EMA/PRAC/522593/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"52695","name":"Nomegestrol and chlormadinone Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T11:26:00Z","last_updated_date":"2022-05-10T10:06:00Z","reference_number":"EMA/PRAC/522598/2021 – Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"52696","name":"Nomegestrol and chlormadinone Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T11:28:00Z","last_updated_date":"2021-10-01T11:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-notification_en.pdf"},
    {"id":"52716","name":"Zynteglo Article-20 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2021-10-04T15:15:00Z","last_updated_date":"2021-10-04T15:15:00Z","reference_number":"EMA/418200/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-prac-assessment-report_en.pdf"},
    {"id":"52717","name":"Zynteglo Article-20 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-10-04T14:43:00Z","last_updated_date":"2021-10-04T14:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zynteglo-article-20-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zynteglo-article-20-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zynteglo-article-20-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zynteglo-article-20-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zynteglo-article-20-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zynteglo-article-20-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zynteglo-article-20-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zynteglo-article-20-referral-annex-iii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zynteglo-article-20-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zynteglo-article-20-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zynteglo-article-20-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zynteglo-article-20-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zynteglo-article-20-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zynteglo-article-20-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zynteglo-article-20-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zynteglo-article-20-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zynteglo-article-20-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zynteglo-article-20-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zynteglo-article-20-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zynteglo-article-20-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zynteglo-article-20-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zynteglo-article-20-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/zynteglo-article-20-referral-annex-iii_no.pdf"}},
    {"id":"52718","name":"Zynteglo Article-20 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-10-04T14:40:00Z","last_updated_date":"2021-10-04T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/zynteglo-article-20-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/zynteglo-article-20-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/zynteglo-article-20-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/zynteglo-article-20-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/zynteglo-article-20-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/zynteglo-article-20-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/zynteglo-article-20-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/zynteglo-article-20-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/zynteglo-article-20-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/zynteglo-article-20-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/zynteglo-article-20-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/zynteglo-article-20-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/zynteglo-article-20-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/zynteglo-article-20-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/zynteglo-article-20-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/zynteglo-article-20-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/zynteglo-article-20-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/zynteglo-article-20-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/zynteglo-article-20-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/zynteglo-article-20-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/zynteglo-article-20-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/zynteglo-article-20-referral-annex-iv_sv.pdf"}},
    {"id":"52867","name":"Lidocain/Prilocain Idetec Referral Article-29(4) - EMA recommends refusal of authorisation for Lidocain/Prilocain Idetec and associated names (lidocaine/prilocaine cream)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2022-04-21T01:51:00Z","reference_number":"EMA/567301/2021 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lidocainprilocain-idetec-referral-article-294-ema-recommends-refusal-authorisation-lidocainprilocain-idetec-and-associated-names-lidocaineprilocaine-cream_sv.pdf"}},
    {"id":"53135","name":"Alkem Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2021-11-16T14:59:00Z","last_updated_date":"2021-11-16T14:59:00Z","reference_number":"EMA/630996/2016","document_url":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-assessment-report_en.pdf"},
    {"id":"53714","name":"Terlipressin-containing medicinal products Article-31 referral - New recommendations for terlipressin-containing medicines in the treatment of hepatorenal syndrome","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T11:35:00Z","last_updated_date":"2022-09-30T12:28:00Z","reference_number":"EMA/781753/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_en.pdf"},
    {"id":"53718","name":"Terlipressin-containing medicinal products Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T12:15:00Z","last_updated_date":"2022-01-14T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-notification_en.pdf"},
    {"id":"53719","name":"Terlipressin-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T12:17:00Z","last_updated_date":"2022-12-22T14:56:00Z","reference_number":"EMA/10268/2022 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_en.pdf"},
    {"id":"53720","name":"Terlipressin-containing medicinal products Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T12:20:00Z","last_updated_date":"2022-07-08T16:03:00Z","reference_number":"EMA/PRAC/2205/2022 rev3","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"53721","name":"Terlipressin-containing medicinal products Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T12:23:00Z","last_updated_date":"2022-01-14T12:23:00Z","reference_number":"EMA/PRAC/2204/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"53981","name":"Nasolam Article 29(4) referral - EMA recommends authorisation of Nasolam (midazolam, nasal spray) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T09:53:00Z","last_updated_date":"2022-04-29T12:42:00Z","reference_number":"EMA/223719/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_sv.pdf"}},
    {"id":"53985","name":"Synchron Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:24:00Z","last_updated_date":"2022-01-28T10:24:00Z","reference_number":"EMA/38808/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-review-started_en.pdf"},
    {"id":"53986","name":"Synchron Article-31 referral - CHMP list of questions to be addressed by the applicants and marketing authorisation holders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:36:00Z","last_updated_date":"2022-01-28T10:36:00Z","reference_number":"EMA/CHMP/25663/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-chmp-list-questions-be-addressed-applicants-and-marketing-authorisation-holders_en.pdf"},
    {"id":"53987","name":"Synchron Article-31 referral - CHMP list of questions to be addressed by Synchron Research Services located in Ahmedabad","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:38:00Z","last_updated_date":"2022-01-28T10:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-chmp-list-questions-be-addressed-synchron-research-services-located-ahmedabad_en.pdf"},
    {"id":"53988","name":"Synchron Article-31 referral - Timetable for the procedure - rev 1","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:41:00Z","last_updated_date":"2022-07-22T15:21:00Z","reference_number":"EMA/CHMP/25665/2022 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-timetable-procedure-rev-1_en.pdf"},
    {"id":"53989","name":"Synchron Article-31 referral - Notification (Belgium)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:43:00Z","last_updated_date":"2022-01-28T10:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-notification-belgium_en.pdf"},
    {"id":"53992","name":"Synchron Article-31 referral - Notification (Denmark)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:57:00Z","last_updated_date":"2022-01-28T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-notification-denmark_en.pdf"},
    {"id":"53993","name":"Synchron Article-31 referral - Notification (Netherlands)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T10:55:00Z","last_updated_date":"2022-01-28T10:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-notification-netherlands_en.pdf"},
    {"id":"53994","name":"Synchron Article-31 referral - Notification (Finland)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T11:01:00Z","last_updated_date":"2022-01-28T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-notification-finland_en.pdf"},
    {"id":"53995","name":"Synchron Article-31 referral - Notification (Sweden)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T11:04:00Z","last_updated_date":"2022-01-28T11:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-notification-sweden_en.pdf"},
    {"id":"53997","name":"Etifoxine-containing medicinal products Article-31 referral - EMA concludes review of anxiety medicine Stresam (etifoxine)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T11:19:00Z","last_updated_date":"2022-04-21T11:19:00Z","reference_number":"EMA/46972/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-ema-concludes-review-anxiety-medicine-stresam-etifoxine_sv.pdf"}},
    {"id":"54019","name":"Etifoxine-containing medicinal products Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T15:06:00Z","last_updated_date":"2022-01-28T15:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_en.pdf"},
    {"id":"54041","name":"Synchron Article-31 referral - List of medicines concerned by the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-01T10:41:00Z","last_updated_date":"2022-09-16T15:33:00Z","reference_number":"EMA/60766/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-list-medicines-concerned-procedure_en.pdf"},
    {"id":"54135","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-11T12:00:00Z","last_updated_date":"2022-06-13T14:01:00Z","reference_number":"EMA/71746/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-review-started_en.pdf"},
    {"id":"54137","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-11T12:00:00Z","last_updated_date":"2022-02-11T12:00:00Z","reference_number":"EMA/PRAC/68283/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"54138","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-11T12:00:00Z","last_updated_date":"2022-06-13T16:33:00Z","reference_number":"EMA/PRAC/68282/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"54139","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-11T12:00:00Z","last_updated_date":"2022-02-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-notification_en.pdf"},
    {"id":"54245","name":"Procaine benzylpenicillin – Article-82 referral – CVMP List of questions to be addressed by the stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T09:02:00Z","last_updated_date":"2022-02-23T09:02:00Z","reference_number":"EMA/CVMP/104860/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-cvmp-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"54266","name":"Procaine benzylpenicillin Article-82 referral - Start of review","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T15:25:00Z","last_updated_date":"2022-02-23T15:25:00Z","reference_number":"EMA/119698/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-start-review_en.pdf"},
    {"id":"54267","name":"Procaine benzylpenicillin Article-82 referral - Timetable for procedure under Article 82 of Regulation (EU) 2019/6","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T15:31:00Z","last_updated_date":"2023-07-13T12:34:00Z","reference_number":"EMA/CVMP/104861/2022 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-timetable-procedure-under-article-82-regulation-eu-20196_en.pdf"},
    {"id":"54268","name":"Procaine benzylpenicillin Article-82 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T15:33:00Z","last_updated_date":"2022-02-23T15:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-notification_en.pdf"},
    {"id":"54269","name":"Procaine benzylpenicillin Article-82 referral - List of questions to be addressed by the marketing  authorisation holders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T15:34:00Z","last_updated_date":"2022-02-23T15:34:00Z","reference_number":"EMA/CVMP/104859/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-list-questions-be-addressed-marketing-authorisation-holders_en.pdf"},
    {"id":"54270","name":"Procaine benzylpenicillin Article-82 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T15:36:00Z","last_updated_date":"2022-09-08T12:20:00Z","reference_number":"EMA/116259/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-annex-i_en.pdf"},
    {"id":"54271","name":"Procaine benzylpenicillin Article-82 referral - List of questions to stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-02-23T15:43:00Z","last_updated_date":"2022-02-23T15:43:00Z","reference_number":"EMA/CVMP/104860/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-list-questions-stakeholders_en.pdf"},
    {"id":"54272","name":"Procaine benzylpenicillin Article-82 referral - Stakeholder submission form","type":"referral","status":"unknown","consultation_date":"2022-02-23 - 2022-09-09","first_published_date":"2022-02-23T16:44:00Z","last_updated_date":"2022-02-23T16:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-stakeholder-submission-form_en.pdf"},
    {"id":"54644","name":"Etifoxine-containing medicinal products Article-31 referral - Public Assessment Report including divergent positions to CHMP Opinion","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-03-31T16:42:00Z","last_updated_date":"2022-03-31T16:42:00Z","reference_number":"EMA/148255/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-public-assessment-report-including-divergent-positions-chmp-opinion_en.pdf"},
    {"id":"54731","name":"Nasolam and associated names Article 29(4) referral - Public Assessment Report including divergent positions to CHMP Opinion","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2022-04-12T09:16:00Z","last_updated_date":"2022-04-12T09:16:00Z","reference_number":"EMA/190723/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/nasolam-and-associated-names-article-294-referral-public-assessment-report-including-divergent-positions-chmp-opinion_en.pdf"},
    {"id":"54737","name":"Lidocain/Prilocain Idetec Referral Article-29(4) - Public Assessment Report including divergent positions to CHMP Opinion","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2022-04-12T15:27:00Z","last_updated_date":"2022-04-12T15:27:00Z","reference_number":"EMA/CHMP/344182/2021","document_url":"https://www.ema.europa.eu/en/documents/referral/lidocainprilocain-idetec-referral-article-294-public-assessment-report-including-divergent-positions-chmp-opinion_en.pdf"},
    {"id":"54738","name":"Lidocain/Prilocain Idetec Referral Article-29(4) - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-12T15:33:00Z","last_updated_date":"2022-04-12T15:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-i_sv.pdf"}},
    {"id":"54739","name":"Lidocain/Prilocain Idetec Referral Article-29(4) - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-12T15:35:00Z","last_updated_date":"2022-04-12T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lidocainprilocain-idetec-referral-article-294-annex-ii_sv.pdf"}},
    {"id":"54776","name":"Etifoxine-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-21T12:08:00Z","last_updated_date":"2022-04-21T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-i_no.pdf"}},
    {"id":"54777","name":"Etifoxine-containing medicinal products Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-21T12:14:00Z","last_updated_date":"2022-04-21T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"54778","name":"Etifoxine-containing medicinal products Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-21T12:16:00Z","last_updated_date":"2022-04-21T12:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iii_no.pdf"}},
    {"id":"54779","name":"Etifoxine-containing medicinal products Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-21T12:19:00Z","last_updated_date":"2022-04-21T12:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"54813","name":"Rubraca Article-20 referral - EMA recommends restricting use of cancer medicine Rubraca","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T16:55:00Z","last_updated_date":"2022-10-17T12:36:00Z","reference_number":"EMA/785546/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_sv.pdf"}},
    {"id":"54814","name":"Rubraca Article-20 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T16:57:00Z","last_updated_date":"2022-04-22T16:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-notification_en.pdf"},
    {"id":"54815","name":"Rubraca Article-20 referral - CHMP List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T16:57:00Z","last_updated_date":"2022-04-22T16:57:00Z","reference_number":"EMA/CHMP/223740/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-chmp-list-questions_en.pdf"},
    {"id":"54816","name":"Rubraca Article-20 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T16:58:00Z","last_updated_date":"2022-06-24T12:00:00Z","reference_number":"EMA/CHMP/223739/2022 rev1","document_url":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-timetable-procedure_en.pdf"},
    {"id":"54864","name":"Nasolam and associated names Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-29T12:43:00Z","last_updated_date":"2022-04-29T12:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/nasolam-and-associated-names-article-294-referral-annex-i_no.pdf"}},
    {"id":"54865","name":"Nasolam and associated names Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-29T12:46:00Z","last_updated_date":"2022-04-29T12:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nasolam-and-associated-names-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"54866","name":"Nasolam and associated names Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-04-29T12:48:00Z","last_updated_date":"2022-04-29T12:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/nasolam-and-associated-names-article-294-referral-annex-iii_no.pdf"}},
    {"id":"54876","name":"Rubraca Article-20 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-02T16:17:00Z","last_updated_date":"2022-05-02T16:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-annex-iii_en.pdf"},
    {"id":"54891","name":"N-methyl-pyrrolidone - Article-82 referral - CVMP list of questions to be addressed by the stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-18T09:02:00Z","last_updated_date":"2022-05-18T09:02:00Z","reference_number":"EMA/CVMP/232862/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/n-methyl-pyrrolidone-article-82-referral-cvmp-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"54907","name":"Rubraca Article-20 referral - Assessment report on temporary measures","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-06T08:42:00Z","last_updated_date":"2022-05-06T08:42:00Z","reference_number":"EMA/250815/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-assessment-report-temporary-measures_en.pdf"},
    {"id":"54993","name":"N-methyl-pyrrolidone - Article-82 referral - New measures to reduce risks from exposure to the excipient N-methyl pyrrolidone in veterinary medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-18T16:26:00Z","last_updated_date":"2023-04-14T10:03:00Z","reference_number":"EMA/131536/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/n-methyl-pyrrolidone-article-82-referral-new-measures-reduce-risks-exposure-excipient-n-methyl-pyrrolidone-veterinary-medicines_sv.pdf"}},
    {"id":"54994","name":"N-methyl-pyrrolidone - Article-82 referral - Annex A","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-18T16:28:00Z","last_updated_date":"2022-09-14T11:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/n-methyl-pyrrolidone-article-82-referral-annex_en.pdf"},
    {"id":"54995","name":"N-methyl-pyrrolidone - Article-82 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-18T16:30:00Z","last_updated_date":"2022-05-18T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/n-methyl-pyrrolidone-article-82-referral-notification_en.pdf"},
    {"id":"54996","name":"N-methyl-pyrrolidone - Article-82 referral - Timetable for procedure under Article 82 of Regulation (EU) 2019/6","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-18T16:32:00Z","last_updated_date":"2022-05-18T16:32:00Z","reference_number":"EMA/CVMP/154238/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/n-methyl-pyrrolidone-article-82-referral-timetable-procedure-under-article-82-regulation-eu-20196_en.pdf"},
    {"id":"54997","name":"N-methyl-pyrrolidone - Article-82 referral - Stakeholder submission form","type":"referral","status":"unknown","consultation_date":"2022-05-18 - 2022-09-13","first_published_date":"2022-05-18T18:33:00Z","last_updated_date":"2022-05-18T18:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/n-methyl-pyrrolidone-article-82-referral-stakeholder-submission-form_en.pdf"},
    {"id":"55032","name":"Synchron Article-31 referral - Synchron Research Service: suspension of medicines over flawed studies","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T10:18:00Z","last_updated_date":"2022-06-24T12:42:00Z","reference_number":"EMA/266340/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-synchron-research-service-suspension-medicines-over-flawed-studies_en.pdf"},
    {"id":"55034","name":"Daruph and Anafezyn Article 29(4) referral - EMA recommends authorisation of Daruph / Anafezyn (dasatinib anhydrous) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T10:35:00Z","last_updated_date":"2022-05-20T10:35:00Z","reference_number":"EMA/277932/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_en.pdf"},
    {"id":"55035","name":"Daruph and Anafezyn Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T10:43:00Z","last_updated_date":"2022-07-22T14:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_cs.pdf","de":"https://www.ema.europa.eu/de/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_ga.pdf","it":"https://www.ema.europa.eu/it/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_ro.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/daruph-and-anafezyn-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"55060","name":"Rubraca Article-20 referral - Annex IV on temporary measures","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-05-23T13:51:00Z","last_updated_date":"2022-05-23T13:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rubraca-article-20-referral-annex-iv-temporary-measures_sv.pdf"}},
    {"id":"55102","name":"Hydroxyethyl starch Article-107i referral - Hydroxyethyl starch solutions: CMDh introduces new measures to protect patients (revised position)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2018-07-17T14:23:00Z","last_updated_date":"2018-07-17T14:23:00Z","reference_number":"EMA/498908/2018","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_lv.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures-protect-patients-revised-position_sv.pdf"}},
    {"id":"55191","name":"Amfepramone-containing medicinal products Article-31 referral - EMA recommends withdrawal of marketing authorisation for amfepramone medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-06-10T12:00:00Z","last_updated_date":"2022-10-28T12:00:00Z","reference_number":"EMA/844036/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisation-amfepramone-medicines_en.pdf"},
    {"id":"55225","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - Addendum to the notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T16:34:00Z","last_updated_date":"2022-06-13T16:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-addendum-notification_en.pdf"},
    {"id":"55504","name":"Nomegestrol and chlormadinone Article-31 referral - Medicines containing nomegestrol or chlormadinone: PRAC recommends new measures to minimise risk of meningioma","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-07-08T12:12:00Z","last_updated_date":"2022-07-08T12:12:00Z","reference_number":"EMA/621250/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-medicines-containing-nomegestrol-or-chlormadinone-prac-recommends-new-measures-minimise-risk-meningioma_en.pdf"},
    {"id":"55643","name":"Medicinal products - Synchron Research Services - Article-31 referral - Timetable for the procedure - re-examination","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T10:04:00Z","last_updated_date":"2022-07-22T10:04:00Z","reference_number":"EMA/CHMP/25665/2022 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/medicinal-products-synchron-research-services-article-31-referral-timetable-procedure-re-examination_en.pdf"},
    {"id":"55648","name":"Daruph and Anafezyn Art 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T10:36:00Z","last_updated_date":"2022-07-22T10:36:00Z","reference_number":"EMA/594862/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/daruph-and-anafezyn-art-294-referral-assessment-report_en.pdf"},
    {"id":"55649","name":"Daruph and Anafezyn Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T11:39:00Z","last_updated_date":"2022-07-22T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/daruph-and-anafezyn-article-294-referral-annex-i_sv.pdf"}},
    {"id":"55650","name":"Daruph and Anafezyn Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T10:00:00Z","last_updated_date":"2022-07-22T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/daruph-and-anafezyn-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"55798","name":"Daruph and Anafezyn Article 29(4) referral - EMA recommends authorisation of Daruph / Anafezyn (dasatinib anhydrous) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-08-09T09:41:00Z","last_updated_date":"2022-08-09T09:41:00Z","reference_number":"EMA/662970/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/daruph-and-anafezyn-article-294-referral-ema-recommends-authorisation-daruph-anafezyn-dasatinib-anhydrous-eu_sv.pdf"}},
    {"id":"55934","name":"Pholcodine-containing medicinal products Article-107i referral - List of questions to stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T15:43:00Z","last_updated_date":"2022-09-02T15:43:00Z","reference_number":"EMAP/PRAC/709548/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-list-questions-stakeholders_en.pdf"},
    {"id":"55937","name":"New measures to minimise risk of meningioma with medicines containing nomegestrol or chlormadinone","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T17:15:00Z","last_updated_date":"2022-12-14T14:03:00Z","reference_number":"EMA/684243/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/new-measures-minimise-risk-meningioma-medicines-containing-nomegestrol-or-chlormadinone_sv.pdf"}},
    {"id":"55938","name":"Nomegestrol and chlormadinone Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T17:28:00Z","last_updated_date":"2022-09-02T17:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_en.pdf"},
    {"id":"55939","name":"Nomegestrol and chlormadinone Article-31 referral - Annex I (Zoely)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T17:37:00Z","last_updated_date":"2022-09-02T17:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i-zoely_en.pdf"},
    {"id":"55953","name":"Pholcodine-containing medicinal products Article-107i referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2022-09-02T11:35:00Z","last_updated_date":"2022-10-04T15:38:00Z","reference_number":"EMA/722200/2022 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_en.pdf"},
    {"id":"55954","name":"Pholcodine-containing medicinal products Article-107i referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T11:35:00Z","last_updated_date":"2022-09-02T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-notification_en.pdf"},
    {"id":"55955","name":"Pholcodine-containing medicinal products Article-107i referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T11:35:00Z","last_updated_date":"2022-09-02T11:35:00Z","reference_number":"EMA/PRAC/704708/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-prac-list-questions_en.pdf"},
    {"id":"55956","name":"Pholcodine-containing medicinal products Article-107i referral - List of questions to marketing authorisation holder(s)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T15:43:00Z","last_updated_date":"2022-09-02T15:43:00Z","reference_number":"EMA/PRAC/704708/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-list-questions-marketing-authorisation-holders_en.pdf"},
    {"id":"55957","name":"Pholcodine-containing medicinal products Article-107i referral - Rationale for triggering","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T15:43:00Z","last_updated_date":"2022-09-02T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-rationale-triggering_en.pdf"},
    {"id":"55958","name":"Pholcodine-containing medicinal products Article-107i referral - Stakeholders submission form","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T15:43:00Z","last_updated_date":"2022-09-02T15:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-stakeholders-submission-form_en.pdf"},
    {"id":"55959","name":"Pholcodine-containing medicinal products Article-107i referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T15:43:00Z","last_updated_date":"2022-09-02T15:43:00Z","reference_number":"EMA/PRAC/704846/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-timetable-procedure_en.pdf"},
    {"id":"55960","name":"Pholcodine-containing medicinal products Article-107i referral - EMA recommends withdrawal of pholcodine medicines from EU market","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T15:43:00Z","last_updated_date":"2022-12-02T12:06:00Z","reference_number":"EMA/906150/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-ema-recommends-withdrawal-pholcodine-medicines-eu-market_en.pdf"},
    {"id":"55962","name":"Topiramate Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T14:14:00Z","last_updated_date":"2022-09-02T14:14:00Z","reference_number":"EMA/707437/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-review-started_en.pdf"},
    {"id":"55963","name":"Topiramate Article-31 referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2022-09-02T14:20:00Z","last_updated_date":"2023-11-10T17:29:00Z","reference_number":"EMA/722981/2022 rev.1","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/topiramate-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/topiramate-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/topiramate-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/topiramate-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/topiramate-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/topiramate-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/topiramate-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/topiramate-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/topiramate-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/topiramate-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/topiramate-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/topiramate-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/topiramate-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/topiramate-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/topiramate-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/topiramate-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/topiramate-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/topiramate-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/topiramate-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/topiramate-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/topiramate-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/topiramate-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/topiramate-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/topiramate-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/topiramate-article-31-referral-annex-i_no.pdf"}},
    {"id":"55964","name":"Topiramate Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T14:21:00Z","last_updated_date":"2023-06-12T09:52:00Z","reference_number":"EMA/PRAC/702489/2022 rev.4","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"55965","name":"Topiramate Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T14:23:00Z","last_updated_date":"2022-09-02T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-notification_en.pdf"},
    {"id":"55968","name":"Topiramate Article-31 referral - PRAC List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T16:52:00Z","last_updated_date":"2022-09-02T16:52:00Z","reference_number":"EMA/PRAC/702490/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-prac-list-questions_en.pdf"}    {"id":"56128","name":"Synchron Article-31 referral - Re-examination confirms suspension of medicines over flawed studies","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-09-16T12:17:00Z","last_updated_date":"2022-12-16T14:12:00Z","reference_number":"EMA/915838/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/synchron-article-31-referral-re-examination-confirms-suspension-medicines-over-flawed-studies_sv.pdf"}},
    {"id":"56240","name":"Rubraca Article-20 referral - Public assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2022-09-28T17:19:00Z","last_updated_date":"2022-09-28T17:19:00Z","reference_number":"EMA/674344/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-public-assessment-report_en.pdf"},
    {"id":"56426","name":"Rubraca Article-20 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-10-17T14:14:00Z","last_updated_date":"2022-10-17T14:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rubraca-article-20-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rubraca-article-20-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rubraca-article-20-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rubraca-article-20-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rubraca-article-20-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rubraca-article-20-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rubraca-article-20-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rubraca-article-20-referral-annex-iv_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/rubraca-article-20-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rubraca-article-20-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rubraca-article-20-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rubraca-article-20-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rubraca-article-20-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rubraca-article-20-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rubraca-article-20-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rubraca-article-20-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rubraca-article-20-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rubraca-article-20-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rubraca-article-20-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rubraca-article-20-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rubraca-article-20-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rubraca-article-20-referral-annex-iv_sv.pdf"}},
    {"id":"56501","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T11:35:00Z","last_updated_date":"2022-11-03T11:39:00Z","reference_number":"EMA/838958/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_en.pdf"},
    {"id":"56550","name":"Nomegestrol and chlormadinone Article-31 referral - Divergent positions to CHMP opinion","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-11-08T15:00:00Z","last_updated_date":"2022-11-08T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-divergent-positions-chmp-opinion_en.pdf"},
    {"id":"56584","name":"Terlipressin-containing medicinal products Article-31 referral - New recommendations for terlipressin-containing medicines in the treatment of hepatorenal syndrome","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T16:36:00Z","last_updated_date":"2022-12-22T12:25:00Z","reference_number":"EMA/862470/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome_sv.pdf"}},
    {"id":"56585","name":"Amfepramone-containing medicinal products Article-31 referral - Withdrawal of marketing authorisations for amfepramone  medicines within the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T17:40:00Z","last_updated_date":"2023-01-20T12:48:00Z","reference_number":"EMA/867253/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-withdrawal-marketing-authorisations-amfepramone-medicines-within-eu_sv.pdf"}},
    {"id":"56590","name":"Terlipressin-containing medicinal products Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T09:51:00Z","last_updated_date":"2022-12-22T12:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"56591","name":"Terlipressin-containing medicinal products Article-31 referral - Timetable for the implementation of the CMDh position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T09:53:00Z","last_updated_date":"2022-11-11T09:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_en.pdf"},
    {"id":"56598","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T12:27:00Z","last_updated_date":"2023-01-27T12:27:00Z","reference_number":"EMA/27681/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_en.pdf"},
    {"id":"56631","name":"Cibinqo : EPAR - Product information as approved by the CHMP on 23 January 2023, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-11-15T16:38:00Z","last_updated_date":"2023-01-27T12:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/cibinqo-epar-product-information-approved-chmp-23-january-2023-pending-endorsement-european-commission_en.pdf"},
    {"id":"56632","name":"Jyseleca : EPAR - Product information as approved by the CHMP on 23 January 2023, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-11-15T16:38:00Z","last_updated_date":"2023-01-27T12:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/jyseleca-epar-product-information-approved-chmp-23-january-2023-pending-endorsement-european-commission_en.pdf"},
    {"id":"56633","name":"Olumiant : EPAR - Product information as approved by the CHMP on 23 January 2023, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-11-15T16:38:00Z","last_updated_date":"2023-01-27T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/olumiant-epar-product-information-approved-chmp-23-january-2023-pending-endorsement-european-commission_en.pdf"},
    {"id":"56635","name":"Xeljanz : EPAR - Product information as approved by the CHMP on 23 January 2023, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-11-15T16:38:00Z","last_updated_date":"2023-01-27T12:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/xeljanz-epar-product-information-approved-chmp-23-january-2023-pending-endorsement-european-commission_en.pdf"},
    {"id":"56715","name":"Terlipressin-containing medicinal products Article-31 referral - PRAC assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2022-11-18T16:32:00Z","last_updated_date":"2022-11-18T16:32:00Z","reference_number":"EMA/885651/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-prac-assessment-report_en.pdf"},
    {"id":"56860","name":"Synchron Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2022-12-02T12:15:00Z","last_updated_date":"2022-12-02T12:15:00Z","reference_number":"EMA/878177/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-assessment-report_en.pdf"},
    {"id":"57007","name":"Questions and answers on the review of oral veterinary medicines containing toltrazuril for use in chickens","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T13:07:00Z","last_updated_date":"2022-12-14T13:07:00Z","reference_number":"EMA/709204/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/questions-and-answers-review-oral-veterinary-medicines-containing-toltrazuril-use-chickens_sv.pdf"}},
    {"id":"57008","name":"Veterinary medicinal products containing toltrazuril to be administered orally to chickens – Article 35 referral – Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T13:03:00Z","last_updated_date":"2022-12-14T13:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens-article-35-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"57010","name":"Nomegestrol and chlormadinone Article-31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T13:46:00Z","last_updated_date":"2022-12-14T13:46:00Z","reference_number":"EMA/773938/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-assessment-report_en.pdf"},
    {"id":"57019","name":"Nomegestrol and chlormadinone Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T16:41:00Z","last_updated_date":"2022-12-14T16:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-i_sv.pdf"}},
    {"id":"57020","name":"Nomegestrol and chlormadinone Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T16:43:00Z","last_updated_date":"2022-12-14T16:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"57021","name":"Nomegestrol and chlormadinone Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T16:45:00Z","last_updated_date":"2022-12-14T16:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"57022","name":"Nomegestrol and chlormadinone Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T17:04:00Z","last_updated_date":"2022-12-14T17:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-annex-iv_sv.pdf"}},
    {"id":"57044","name":"EMA recommends withdrawal of pholcodine medicines from EU market","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T15:34:00Z","last_updated_date":"2022-12-16T15:34:00Z","reference_number":"EMA/906150/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/ema-recommends-withdrawal-pholcodine-medicines-eu-market_en.pdf"},
    {"id":"57060","name":"Rambis  Article 29(4) referral - EMA recommends authorisation of Rambis (ramipril / bisoprolol) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T18:03:00Z","last_updated_date":"2022-12-16T18:03:00Z","reference_number":"EMA/940509/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_en.pdf"},
    {"id":"57061","name":"Rambis Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T18:06:00Z","last_updated_date":"2022-12-16T18:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rambis-article-294-referral-annex-iii_en.pdf"},
    {"id":"57072","name":"Gelisia Article 29(4) referral - EMA recommends authorisation of Gelisia (timolol, eye gel) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T10:46:00Z","last_updated_date":"2022-12-16T10:46:00Z","reference_number":"EMA/931490/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_en.pdf"},
    {"id":"57088","name":"Synchron Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T14:01:00Z","last_updated_date":"2022-12-16T14:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/synchron-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/synchron-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/synchron-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/synchron-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/synchron-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/synchron-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/synchron-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/synchron-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/synchron-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/synchron-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/synchron-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/synchron-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/synchron-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/synchron-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/synchron-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/synchron-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/synchron-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/synchron-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/synchron-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/synchron-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/synchron-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/synchron-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/synchron-article-31-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/synchron-article-31-referral-annex-i_no.pdf"}},
    {"id":"57089","name":"Synchron Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T14:05:00Z","last_updated_date":"2022-12-16T14:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/synchron-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/synchron-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/synchron-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/synchron-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/synchron-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/synchron-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/synchron-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/synchron-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/synchron-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/synchron-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/synchron-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/synchron-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/synchron-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/synchron-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/synchron-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/synchron-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/synchron-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/synchron-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/synchron-article-31-referral-annex-ii_ro.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/synchron-article-31-referral-annex-ii_fi.pdf","no":"https://www.ema.europa.eu/no/documents/referral/synchron-article-31-referral-annex-ii_no.pdf"}},
    {"id":"57091","name":"Synchron Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T14:08:00Z","last_updated_date":"2022-12-16T14:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/synchron-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/synchron-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/synchron-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/synchron-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/synchron-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/synchron-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/synchron-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/synchron-article-31-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/synchron-article-31-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/synchron-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/synchron-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/synchron-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/synchron-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/synchron-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/synchron-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/synchron-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/synchron-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/synchron-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/synchron-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/synchron-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/synchron-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/synchron-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/synchron-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/synchron-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/synchron-article-31-referral-annex-iii_no.pdf"}},
    {"id":"57136","name":"Terlipressin-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T12:09:00Z","last_updated_date":"2022-12-22T12:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-i_sv.pdf"}},
    {"id":"57137","name":"Terlipressin-containing medicinal products Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T12:11:00Z","last_updated_date":"2022-12-22T12:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"57138","name":"Terlipressin-containing medicinal products Article-31 referral - Annex VI","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-12-22T12:14:00Z","last_updated_date":"2022-12-22T12:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-annex-vi_sv.pdf"}},
    {"id":"57342","name":"Amfepramone-containing medicinal products Article-31 referral - Divergent positions to CMDh position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-01-20T12:18:00Z","last_updated_date":"2023-01-20T12:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-divergent-positions-cmdh-position_en.pdf"},
    {"id":"57343","name":"Amfepramone-containing medicinal products Article-31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-01-20T12:32:00Z","last_updated_date":"2023-01-20T12:32:00Z","reference_number":"EMA/884474/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-assessment-report_en.pdf"},
    {"id":"57415","name":"Adakveo Article-20 procedure - Review of sickle cell disease medicine Adakveo started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T17:22:00Z","last_updated_date":"2023-01-27T17:22:00Z","reference_number":"EMA/38533/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/adakveo-article-20-procedure-review-sickle-cell-disease-medicine-adakveo-started_en.pdf"},
    {"id":"57420","name":"Adakveo Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T09:28:00Z","last_updated_date":"2023-04-26T17:47:00Z","reference_number":"EMA/CHMP/36788/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/adakveo-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"57421","name":"Adakveo Article-20 procedure - CHMP List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T10:14:00Z","last_updated_date":"2023-01-27T10:14:00Z","reference_number":"EMA/CHMP/37456/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/adakveo-article-20-procedure-chmp-list-questions_en.pdf"},
    {"id":"57422","name":"Adakveo Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T10:15:00Z","last_updated_date":"2023-01-27T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/adakveo-article-20-procedure-notification_en.pdf"},
    {"id":"57487","name":"Amfepramone-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T17:17:00Z","last_updated_date":"2023-01-31T17:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-i_sv.pdf"}},
    {"id":"57488","name":"Amfepramone-containing medicinal products Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T14:19:00Z","last_updated_date":"2023-01-31T14:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"57594","name":"PRAC recommends measures to minimise the risk of serious side effects with medicines containing pseudoephedrine","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T12:00:00Z","last_updated_date":"2023-12-01T12:00:00Z","reference_number":"EMA/535476/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/prac-recommends-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_en.pdf"},
    {"id":"57595","name":"Pseudoephedrine-containing medicines Article-31 referral - PRAC List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T11:45:00Z","last_updated_date":"2023-02-10T11:45:00Z","reference_number":"EMA/PRAC/55342/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicines-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"57596","name":"Pseudoephedrine-containing medicines Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T11:47:00Z","last_updated_date":"2023-02-10T11:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicines-article-31-referral-notification_en.pdf"},
    {"id":"57597","name":"Pseudoephedrine-containing medicines Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T11:48:00Z","last_updated_date":"2023-09-29T14:43:00Z","reference_number":"EMA/PRAC/55340/2023 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicines-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"57598","name":"Pseudoephedrine-containing medicines Article-31 referral - Annex A and Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2023-02-10T11:49:00Z","last_updated_date":"2023-05-12T16:00:00Z","reference_number":"EMA/55341/2023 Rev. 1 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicines-article-31-referral-annex-and-annex-i_en.pdf"},
    {"id":"57820","name":"Rambis Article 29(4) referral - EMA recommends authorisation of Rambis (ramipril / bisoprolol) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-02-24T13:44:00Z","last_updated_date":"2023-03-08T11:50:00Z","reference_number":"EMA/75435/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rambis-article-294-referral-ema-recommends-authorisation-rambis-ramipril-bisoprolol-eu_sv.pdf"}},
    {"id":"57821","name":"Rambis Article 29(4) referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-02-24T13:49:00Z","last_updated_date":"2023-02-24T13:49:00Z","reference_number":"EMA/15850/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/rambis-article-294-referral-assessment-report_en.pdf"},
    {"id":"57822","name":"Rambis Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-02-24T13:51:00Z","last_updated_date":"2023-02-24T13:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rambis-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rambis-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rambis-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rambis-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rambis-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rambis-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rambis-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rambis-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rambis-article-294-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/rambis-article-294-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/rambis-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rambis-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rambis-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rambis-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rambis-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rambis-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rambis-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rambis-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rambis-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rambis-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rambis-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rambis-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rambis-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rambis-article-294-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/rambis-article-294-referral-annex-i_no.pdf"}},
    {"id":"57823","name":"Rambis Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-02-24T13:53:00Z","last_updated_date":"2023-02-24T13:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rambis-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rambis-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rambis-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rambis-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rambis-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rambis-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rambis-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rambis-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rambis-article-294-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/rambis-article-294-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/rambis-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rambis-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rambis-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rambis-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rambis-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rambis-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rambis-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rambis-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rambis-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rambis-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rambis-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rambis-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rambis-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rambis-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"57824","name":"Rambis Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-02-24T13:55:00Z","last_updated_date":"2023-02-24T13:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rambis-article-294-referral-annex-iii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/rambis-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/rambis-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/rambis-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/rambis-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/rambis-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/rambis-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/rambis-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/rambis-article-294-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/rambis-article-294-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/rambis-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/rambis-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/rambis-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/rambis-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/rambis-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/rambis-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/rambis-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/rambis-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/rambis-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/rambis-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/rambis-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/rambis-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/rambis-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/rambis-article-294-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/rambis-article-294-referral-annex-iii_no.pdf"}},
    {"id":"57895","name":"Gelisia Article 29(4) referral - EMA recommends authorisation of Gelisia (timolol, eye gel) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T10:36:00Z","last_updated_date":"2023-03-16T10:32:00Z","reference_number":"EMA/101846/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gelisia-article-294-referral-ema-recommends-authorisation-gelisia-timolol-eye-gel-eu_sv.pdf"}},
    {"id":"57896","name":"Gelisia Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2023-03-07T10:41:00Z","last_updated_date":"2023-03-07T10:41:00Z","reference_number":"EMA/1638/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/gelisia-article-294-referral-assessment-report_en.pdf"},
    {"id":"57897","name":"Gelisia Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T10:43:00Z","last_updated_date":"2023-03-07T10:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gelisia-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gelisia-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gelisia-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gelisia-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gelisia-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gelisia-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gelisia-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gelisia-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gelisia-article-294-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/gelisia-article-294-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gelisia-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gelisia-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gelisia-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gelisia-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gelisia-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gelisia-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gelisia-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gelisia-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gelisia-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gelisia-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gelisia-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gelisia-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gelisia-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gelisia-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"57898","name":"Gelisia Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T10:47:00Z","last_updated_date":"2023-03-07T10:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gelisia-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gelisia-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gelisia-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gelisia-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gelisia-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gelisia-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gelisia-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gelisia-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gelisia-article-294-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/gelisia-article-294-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gelisia-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gelisia-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gelisia-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gelisia-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gelisia-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gelisia-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gelisia-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gelisia-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gelisia-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gelisia-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gelisia-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gelisia-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gelisia-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gelisia-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"57899","name":"Gelisia Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-03-07T10:50:00Z","last_updated_date":"2023-03-07T10:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/gelisia-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/gelisia-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/gelisia-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/gelisia-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/gelisia-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/gelisia-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/gelisia-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/gelisia-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/gelisia-article-294-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/gelisia-article-294-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/gelisia-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/gelisia-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/gelisia-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/gelisia-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/gelisia-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/gelisia-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/gelisia-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/gelisia-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/gelisia-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/gelisia-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/gelisia-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/gelisia-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/gelisia-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/gelisia-article-294-referral-annex-i_sv.pdf"}},
    {"id":"57996","name":"Rubraca Article-20 referral - EMA recommends restricting use of cancer medicine Rubraca","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T17:39:00Z","last_updated_date":"2022-07-22T17:39:00Z","reference_number":"EMA/644337/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-ema-recommends-restricting-use-cancer-medicine-rubraca_en.pdf-0"},
    {"id":"58115","name":"Pholcodine-containing medicinal products Article-107i referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2023-03-22T11:01:00Z","last_updated_date":"2023-03-22T11:01:00Z","reference_number":"EMA/950036/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-assessment-report_en.pdf"},
    {"id":"58116","name":"Pholcodine-containing medicinal products Article-107i referral - Divergent positions to CMDh position","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2023-03-22T11:03:00Z","last_updated_date":"2023-03-22T11:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-divergent-positions-cmdh-position_en.pdf"},
    {"id":"58120","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-03-22T13:32:00Z","last_updated_date":"2023-03-22T13:32:00Z","reference_number":"EMA/586384/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-assessment-report_en.pdf"},
    {"id":"58190","name":"Pholcodine medicines withdrawn from EU market","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-03-29T09:01:00Z","last_updated_date":"2023-03-29T09:01:00Z","reference_number":"EMA/126062/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-medicines-withdrawn-eu-market_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pholcodine-medicines-withdrawn-eu-market_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pholcodine-medicines-withdrawn-eu-market_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pholcodine-medicines-withdrawn-eu-market_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pholcodine-medicines-withdrawn-eu-market_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pholcodine-medicines-withdrawn-eu-market_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pholcodine-medicines-withdrawn-eu-market_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pholcodine-medicines-withdrawn-eu-market_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pholcodine-medicines-withdrawn-eu-market_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/pholcodine-medicines-withdrawn-eu-market_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pholcodine-medicines-withdrawn-eu-market_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pholcodine-medicines-withdrawn-eu-market_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pholcodine-medicines-withdrawn-eu-market_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pholcodine-medicines-withdrawn-eu-market_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pholcodine-medicines-withdrawn-eu-market_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pholcodine-medicines-withdrawn-eu-market_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pholcodine-medicines-withdrawn-eu-market_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pholcodine-medicines-withdrawn-eu-market_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pholcodine-medicines-withdrawn-eu-market_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pholcodine-medicines-withdrawn-eu-market_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pholcodine-medicines-withdrawn-eu-market_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pholcodine-medicines-withdrawn-eu-market_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pholcodine-medicines-withdrawn-eu-market_sv.pdf"}},
    {"id":"58191","name":"Pholcodine-containing medicinal products Article-107i referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-03-29T09:19:00Z","last_updated_date":"2023-03-29T09:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-i_sv.pdf"}},
    {"id":"58192","name":"Pholcodine-containing medicinal products Article-107i referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-03-29T09:21:00Z","last_updated_date":"2023-03-29T09:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-annex-ii_sv.pdf"}},
    {"id":"58520","name":"Vey Tosal Article 33(4) referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-04-25T12:18:00Z","last_updated_date":"2023-04-25T12:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/vey-tosal-article-334-referral-annex-i-ii-iii_no.pdf"}},
    {"id":"58527","name":"Catophos Article 33(4) referral - Annex I, II, III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-04-25T17:28:00Z","last_updated_date":"2023-04-25T17:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/catophos-article-334-referral-annex-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/catophos-article-334-referral-annex-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/catophos-article-334-referral-annex-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/catophos-article-334-referral-annex-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/catophos-article-334-referral-annex-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/catophos-article-334-referral-annex-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/catophos-article-334-referral-annex-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/catophos-article-334-referral-annex-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/catophos-article-334-referral-annex-i-ii-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/catophos-article-334-referral-annex-i-ii-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/catophos-article-334-referral-annex-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/catophos-article-334-referral-annex-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/catophos-article-334-referral-annex-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/catophos-article-334-referral-annex-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/catophos-article-334-referral-annex-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/catophos-article-334-referral-annex-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/catophos-article-334-referral-annex-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/catophos-article-334-referral-annex-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/catophos-article-334-referral-annex-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/catophos-article-334-referral-annex-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/catophos-article-334-referral-annex-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/catophos-article-334-referral-annex-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/catophos-article-334-referral-annex-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/catophos-article-334-referral-annex-i-ii-iii_sv.pdf"}},
    {"id":"58658","name":"Hydroxyprogesterone-containing medicinal products Article 31-referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T14:17:00Z","last_updated_date":"2023-05-12T14:17:00Z","reference_number":"EMA/203354/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-review-started_en.pdf"},
    {"id":"58659","name":"Hydroxyprogesterone-containing medicinal products Article 31-referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2023-05-12T14:19:00Z","last_updated_date":"2023-05-12T14:19:00Z","reference_number":"EMA/194533/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_en.pdf"},
    {"id":"58660","name":"Hydroxyprogesterone-containing medicinal products Article 31-referral - PRAC List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T14:21:00Z","last_updated_date":"2023-05-12T14:21:00Z","reference_number":"EMA/PRAC/194264/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"58661","name":"Hydroxyprogesterone-containing medicinal products Article 31-referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T14:22:00Z","last_updated_date":"2024-02-09T13:09:00Z","reference_number":"EMA/PRAC/194263/2023 rev.3","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"58662","name":"Hydroxyprogesterone-containing medicinal products Article 31-referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T14:23:00Z","last_updated_date":"2023-05-12T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-notification_en.pdf"},
    {"id":"58732","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T11:48:00Z","last_updated_date":"2023-05-22T11:48:00Z","reference_number":"EMA/142279/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_sv.pdf"}},
    {"id":"58733","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - Annex - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T11:53:00Z","last_updated_date":"2023-05-22T11:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-annex-scientific-conclusions_no.pdf"}},
    {"id":"58799","name":"Adakveo Article-20 procedure - Revocation of authorisation for sickle cell disease medicine Adakveo","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T12:35:00Z","last_updated_date":"2023-08-29T15:18:00Z","reference_number":"EMA/359200/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/adakveo-article-20-procedure-revocation-authorisation-sickle-cell-disease-medicine-adakveo_sv.pdf"}},
    {"id":"59435","name":"Synapse Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T15:38:00Z","last_updated_date":"2024-02-15T14:31:00Z","reference_number":"EMA/CHMP/304425/2023 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"59436","name":"Synapse Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T15:39:00Z","last_updated_date":"2023-07-21T15:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-notification_en.pdf"},
    {"id":"59437","name":"Synapse Article-31 referral - CHMP list of questions to be addressed by applicants and marketing authorisation holders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T15:39:00Z","last_updated_date":"2023-07-21T15:39:00Z","reference_number":"EMA/CHMP/304426/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-chmp-list-questions-be-addressed-applicants-and-marketing-authorisation-holders_en.pdf"},
    {"id":"59438","name":"Synapse Article-31 referral - CHMP list of questions to be addressed by Synapse Labs located in Kharadi","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T15:41:00Z","last_updated_date":"2023-07-21T15:41:00Z","reference_number":"EMA/CHMP/304427/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-chmp-list-questions-be-addressed-synapse-labs-located-kharadi_en.pdf"},
    {"id":"59439","name":"Synapse Article-31 referral - List of medicines concerned by the procedure (Annex I)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T15:42:00Z","last_updated_date":"2024-05-06T14:12:00Z","reference_number":"EMA/338956/2023 rev. 4 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-list-medicines-concerned-procedure-annex-i_en.pdf"},
    {"id":"59577","name":"Adakveo Article-20 procedure - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-08-09T15:20:00Z","last_updated_date":"2023-08-21T13:49:00Z","reference_number":"EMA/267688/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/adakveo-article-20-procedure-assessment-report_en.pdf"},
    {"id":"59578","name":"Adakveo Article-20 procedure - Annex - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-08-09T15:23:00Z","last_updated_date":"2023-08-21T13:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_sv.pdf"}},
    {"id":"59884","name":"Topiramate Article-31 referral - New measures to avoid topiramate exposure in pregnancy","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T12:18:00Z","last_updated_date":"2023-11-23T17:28:00Z","reference_number":"EMA/455917/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_no.pdf"}},
    {"id":"59986","name":"Havrix - Article 30 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T15:36:00Z","last_updated_date":"2023-09-15T15:36:00Z","reference_number":"EMA/404824/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/havrix-article-30-referral-review-started_en.pdf"},
    {"id":"59987","name":"Havrix - Article 30 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T15:38:00Z","last_updated_date":"2023-09-15T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/havrix-article-30-referral-notification_en.pdf"},
    {"id":"59988","name":"Havrix - Article 30 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T15:39:00Z","last_updated_date":"2024-09-04T14:34:09Z","reference_number":"EMA/415457/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/havrix-article-30-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/havrix-article-30-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/havrix-article-30-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/havrix-article-30-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/havrix-article-30-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/havrix-article-30-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/havrix-article-30-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/havrix-article-30-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/havrix-article-30-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/havrix-article-30-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/havrix-article-30-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/havrix-article-30-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/havrix-article-30-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/havrix-article-30-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/havrix-article-30-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/havrix-article-30-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/havrix-article-30-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/havrix-article-30-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/havrix-article-30-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/havrix-article-30-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/havrix-article-30-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/havrix-article-30-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/havrix-article-30-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/havrix-article-30-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/havrix-article-30-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/havrix-article-30-referral-annex-i_no.pdf"}},
    {"id":"59989","name":"Havrix - Article 30 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T15:40:00Z","last_updated_date":"2024-03-22T11:54:00Z","reference_number":"EMA/CHMP/101583/2023 rev.3","document_url":"https://www.ema.europa.eu/en/documents/referral/havrix-article-30-referral-timetable-procedure_en.pdf"},
    {"id":"60010","name":"Mysimba Article-20 procedure - CHMP List of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T10:14:00Z","last_updated_date":"2024-05-31T12:20:00Z","reference_number":"EMA/CHMP/236208/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/mysimba-article-20-procedure-chmp-list-questions_en.pdf"},
    {"id":"60011","name":"Mysimba Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T10:14:00Z","last_updated_date":"2025-01-06T16:04:04Z","reference_number":"EMA/CHMP/352892/2023 Rev.7 corr.1","document_url":"https://www.ema.europa.eu/en/documents/referral/mysimba-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"60013","name":"Mysimba Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T10:14:00Z","last_updated_date":"2023-09-15T10:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/mysimba-article-20-procedure-notification_en.pdf"},
    {"id":"60014","name":"Mysimba Article-20 procedure - EMA starts review of weight management medicine Mysimba","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T10:14:00Z","last_updated_date":"2023-09-15T10:14:00Z","reference_number":"EMA/406052/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/mysimba-article-20-procedure-ema-starts-review-weight-management-medicine-mysimba_en.pdf"},
    {"id":"60416","name":"Topiramate Article-31 referral - Annex III","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2024-09-03T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/topiramate-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/topiramate-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/topiramate-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/topiramate-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/topiramate-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/topiramate-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/topiramate-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/topiramate-article-31-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/topiramate-article-31-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/topiramate-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/topiramate-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/topiramate-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/topiramate-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/topiramate-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/topiramate-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/topiramate-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/topiramate-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/topiramate-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/topiramate-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/topiramate-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/topiramate-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/topiramate-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/topiramate-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/topiramate-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/topiramate-article-31-referral-annex-iii_no.pdf"}},
    {"id":"60417","name":"Topiramate Article-31 referral - Annex V","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T17:43:00Z","last_updated_date":"2023-11-10T17:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-annex-v_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/topiramate-article-31-referral-annex-v_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/topiramate-article-31-referral-annex-v_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/topiramate-article-31-referral-annex-v_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/topiramate-article-31-referral-annex-v_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/topiramate-article-31-referral-annex-v_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/topiramate-article-31-referral-annex-v_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/topiramate-article-31-referral-annex-v_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/topiramate-article-31-referral-annex-v_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/topiramate-article-31-referral-annex-v_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/topiramate-article-31-referral-annex-v_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/topiramate-article-31-referral-annex-v_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/topiramate-article-31-referral-annex-v_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/topiramate-article-31-referral-annex-v_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/topiramate-article-31-referral-annex-v_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/topiramate-article-31-referral-annex-v_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/topiramate-article-31-referral-annex-v_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/topiramate-article-31-referral-annex-v_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/topiramate-article-31-referral-annex-v_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/topiramate-article-31-referral-annex-v_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/topiramate-article-31-referral-annex-v_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/topiramate-article-31-referral-annex-v_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/topiramate-article-31-referral-annex-v_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/topiramate-article-31-referral-annex-v_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/topiramate-article-31-referral-annex-v_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/topiramate-article-31-referral-annex-v_no.pdf"}},
    {"id":"60418","name":"Ocaliva Article 20 procedure : Review of Ocaliva started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T11:47:00Z","last_updated_date":"2023-10-13T11:47:00Z","reference_number":"EMA/458857/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-review-ocaliva-started_en.pdf"},
    {"id":"60419","name":"Ocaliva Article 20 procedure : CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T11:51:00Z","last_updated_date":"2023-10-13T11:51:00Z","reference_number":"EMA/CHMP/449195/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-chmp-list-questions_en.pdf"},
    {"id":"60420","name":"Ocaliva Article 20 procedure : Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T11:53:00Z","last_updated_date":"2024-06-03T11:14:00Z","reference_number":"EMA/CHMP/448947/2023 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"60421","name":"Ocaliva Article 20 procedure : Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T11:56:00Z","last_updated_date":"2023-10-13T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-notification_en.pdf"},
    {"id":"60451","name":"Topiramate Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2023-10-18T17:04:00Z","last_updated_date":"2023-10-18T17:04:00Z","reference_number":"EMA/443729/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-assessment-report_en.pdf"},
    {"id":"60569","name":"Substances related to nicotinic acid Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-annex-iii_en.pdf-0"},
    {"id":"60570","name":"Kogenate Bayer Article-20 procedure - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2013-12-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kogenate-bayer-article-20-procedure-annex-iii_en.pdf"},
    {"id":"60697","name":"Janus Kinase inhibitors (JAKi) Article-20 procedure - Divergent positions to CHMP Opinion","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-03-22T13:29:00Z","last_updated_date":"2023-06-14T16:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-divergent-positions-chmp-opinion_en.pdf"},
    {"id":"60845","name":"Azithromycin Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2025-03-05T16:00:00Z","reference_number":"EMA/CHMP/488796/2023 - Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-timetable-procedure_en.pdf"}    {"id":"60847","name":"Azithromycin Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T11:53:00Z","last_updated_date":"2023-11-10T11:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"60848","name":"Azithromycin Article-31 referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2024-07-04T14:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-annex-i_en.pdf"},
    {"id":"60849","name":"Azithromycin Article-31 referral - Start of referral","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T11:55:00Z","last_updated_date":"2023-11-10T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-start-referral_en.pdf"},
    {"id":"60872","name":"Topiramate Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T17:36:00Z","last_updated_date":"2023-11-10T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/topiramate-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/topiramate-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/topiramate-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/topiramate-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/topiramate-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/topiramate-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/topiramate-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/topiramate-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/topiramate-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/topiramate-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/topiramate-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/topiramate-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/topiramate-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/topiramate-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/topiramate-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/topiramate-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/topiramate-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/topiramate-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/topiramate-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/topiramate-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/topiramate-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/topiramate-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/topiramate-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"60873","name":"Topiramate Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T17:34:00Z","last_updated_date":"2023-11-10T17:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/topiramate-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/topiramate-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/topiramate-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/topiramate-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/topiramate-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/topiramate-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/topiramate-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/topiramate-article-31-referral-annex-iv_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/topiramate-article-31-referral-annex-iv_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/topiramate-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/topiramate-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/topiramate-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/topiramate-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/topiramate-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/topiramate-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/topiramate-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/topiramate-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/topiramate-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/topiramate-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/topiramate-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/topiramate-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/topiramate-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/topiramate-article-31-referral-annex-iv_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/topiramate-article-31-referral-annex-iv_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/topiramate-article-31-referral-annex-iv_no.pdf"}},
    {"id":"61763","name":"Rambis Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-01-15T14:15:58Z","last_updated_date":"2024-01-15T14:15:58Z","reference_number":"EMA/15850/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/rambis-article-294-referral-assessment-report_en.pdf-0"},
    {"id":"61817","name":"Pseudoephedrine-containing medicines Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T12:00:00Z","last_updated_date":"2023-02-10T12:00:00Z","reference_number":"EMA/56626/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicines-article-31-referral-review-started_en.pdf"},
    {"id":"61907","name":"EMA confirms measures to minimise the risk of serious side effects with medicines containing pseudoephedrine","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T12:00:00Z","last_updated_date":"2024-04-04T15:18:00Z","reference_number":"EMA/535476/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-containing-pseudoephedrine_sv.pdf"}},
    {"id":"61908","name":"Pseudoephedrine-containing medicines Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T12:00:00Z","last_updated_date":"2024-01-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicines-article-31-referral-annex-iii_en.pdf"},
    {"id":"62274","name":"EMA recommends refusal of authorisation for Ibuprofen NVT (ibuprofen, 400 mg, soft capsules)","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T10:04:01Z","last_updated_date":"2024-06-05T16:01:00Z","reference_number":"EMA/231236/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ema-recommends-refusal-authorisation-ibuprofen-nvt-ibuprofen-400-mg-soft-capsules_sv.pdf"}},
    {"id":"62703","name":"Synapse Article-31 referral - Synapse Labs Pvt. Ltd: re-examination confirms suspension of medicines over flawed studies","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T11:34:19Z","last_updated_date":"2024-03-22T11:34:19Z","reference_number":"EMA/117559/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_en.pdf"},
    {"id":"62707","name":"Micrazym Article 29(4) referral - EMA recommends authorisation of Micrazym (porcine pancreas enzymes) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T12:40:31Z","last_updated_date":"2024-06-11T03:00:05Z","reference_number":"EMA/250738/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/micrazym-article-294-referral-ema-recommends-authorisation-micrazym-porcine-pancreas-enzymes-eu_sv.pdf"}},
    {"id":"62819","name":"Pseudoephedrine-containing medicinal products Article-31 referral - Assessment report","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T15:19:57Z","last_updated_date":"2024-04-04T15:19:57Z","reference_number":"EMA/89241/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-assessment-report_en.pdf"},
    {"id":"62820","name":"Pseudoephedrine-containing medicinal products Article-31 referral - Divergent positions to CHMP Opinion","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T15:26:14Z","last_updated_date":"2024-04-04T15:26:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-divergent-positions-chmp-opinion_en.pdf"},
    {"id":"62821","name":"Pseudoephedrine-containing medicinal products Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T15:28:56Z","last_updated_date":"2024-04-04T15:28:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-iii_no.pdf"}},
    {"id":"62823","name":"Pseudoephedrine-containing medicinal products Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T15:31:06Z","last_updated_date":"2024-04-04T15:31:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-ii_no.pdf"}},
    {"id":"62824","name":"Pseudoephedrine-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T15:32:51Z","last_updated_date":"2024-04-04T15:32:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-annex-i_no.pdf"}},
    {"id":"63241","name":"Ibuprofen NVT Article 29(4) referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-05-16T16:28:44Z","last_updated_date":"2024-05-16T16:28:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_hu.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-nvt-article-294-referral-annex-i_fi.pdf"}},
    {"id":"63242","name":"Ibuprofen NVT Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-05-16T16:29:19Z","last_updated_date":"2024-05-16T16:29:19Z","reference_number":"EMA/16944/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-nvt-article-294-referral-assessment-report_en.pdf"},
    {"id":"63243","name":"Ibuprofen NVT Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T16:22:13Z","last_updated_date":"2024-05-16T16:22:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-nvt-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"63244","name":"Ibuprofen NVT Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T16:23:19Z","last_updated_date":"2024-05-16T16:23:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ibuprofen-nvt-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"63247","name":"Hydroxyprogesterone caproate-containing medicinal products Article 31 referral - Hydroxyprogesterone caproate medicines to be suspended from the EU market","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-05-17T10:31:19Z","last_updated_date":"2024-05-17T10:31:19Z","reference_number":"EMA/225201/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-caproate-containing-medicinal-products-article-31-referral-hydroxyprogesterone-caproate-medicines-be-suspended-eu-market_en.pdf"},
    {"id":"63294","name":"Micrazym Article 29(4) referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-05-22T11:12:00Z","last_updated_date":"2024-05-22T11:12:00Z","reference_number":"EMA/151722/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/micrazym-article-294-referral-assessment-report_en.pdf"},
    {"id":"63295","name":"Micrazym Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-05-22T11:15:00Z","last_updated_date":"2024-05-22T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/micrazym-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/micrazym-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/micrazym-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/micrazym-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/micrazym-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/micrazym-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/micrazym-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/micrazym-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/micrazym-article-294-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/micrazym-article-294-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/micrazym-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/micrazym-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/micrazym-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/micrazym-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/micrazym-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/micrazym-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/micrazym-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/micrazym-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/micrazym-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/micrazym-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/micrazym-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/micrazym-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/micrazym-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/micrazym-article-294-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/micrazym-article-294-referral-annex-i_no.pdf"}},
    {"id":"63296","name":"Micrazym Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-05-22T11:18:00Z","last_updated_date":"2024-05-22T11:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/micrazym-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/micrazym-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/micrazym-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/micrazym-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/micrazym-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/micrazym-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/micrazym-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/micrazym-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/micrazym-article-294-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/micrazym-article-294-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/micrazym-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/micrazym-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/micrazym-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/micrazym-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/micrazym-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/micrazym-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/micrazym-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/micrazym-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/micrazym-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/micrazym-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/micrazym-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/micrazym-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/micrazym-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/micrazym-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"63297","name":"Micrazym Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-05-22T11:22:00Z","last_updated_date":"2024-05-22T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/micrazym-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/micrazym-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/micrazym-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/micrazym-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/micrazym-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/micrazym-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/micrazym-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/micrazym-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/micrazym-article-294-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/micrazym-article-294-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/micrazym-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/micrazym-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/micrazym-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/micrazym-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/micrazym-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/micrazym-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/micrazym-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/micrazym-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/micrazym-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/micrazym-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/micrazym-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/micrazym-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/micrazym-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/micrazym-article-294-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/micrazym-article-294-referral-annex-iii_no.pdf"}},
    {"id":"63372","name":"Procaine benzylpenicillin - Article-82 referral - New recommendations for injectable veterinary medicines containing procaine benzylpenicillin","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-05-29T15:57:00Z","last_updated_date":"2024-05-29T15:57:00Z","reference_number":"EMA/68333/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/procaine-benzylpenicillin-article-82-referral-new-recommendations-injectable-veterinary-medicines-containing-procaine-benzylpenicillin_sv.pdf"}},
    {"id":"63373","name":"Procaine benzylpenicillin Article-82 referral - Annexes I, II and III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-05-29T16:00:00Z","last_updated_date":"2024-05-29T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/procaine-benzylpenicillin-article-82-referral-annexes-i-ii-iii_sv.pdf"}},
    {"id":"63374","name":"Procaine benzylpenicillin Article-82 referral - Divergent position 1","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-05-29T16:05:00Z","last_updated_date":"2024-05-29T16:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-divergent-position-1_en.pdf"},
    {"id":"63375","name":"Procaine benzylpenicillin Article-82 referral - Divergent position 2","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-05-29T16:06:00Z","last_updated_date":"2024-05-29T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-divergent-position-2_en.pdf"},
    {"id":"63376","name":"Procaine benzylpenicillin Article-82 referral - Divergent position 3","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-05-29T16:08:00Z","last_updated_date":"2024-05-29T16:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/procaine-benzylpenicillin-article-82-referral-divergent-position-3_en.pdf"},
    {"id":"63397","name":"Kexxtone Article 130(4) procedure - the veterinary medicine Kexxtone suspended across the European Union","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-04T14:11:51Z","last_updated_date":"2024-06-10T14:11:51Z","reference_number":"EMA/246347/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/kexxtone-article-1304-procedure-veterinary-medicine-kexxtone-suspended-across-european-union_sv.pdf"}},
    {"id":"63398","name":"Kexxtone Article 130(4) procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-04T14:16:07Z","last_updated_date":"2024-06-04T14:16:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kexxtone-article-1304-procedure-notification_en.pdf"},
    {"id":"63399","name":"Kexxtone Article 130(4) procedure - CVMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-04T14:20:15Z","last_updated_date":"2024-06-04T14:20:15Z","reference_number":"Kexxtone Article 130(4) procedure","document_url":"https://www.ema.europa.eu/en/documents/referral/kexxtone-article-1304-procedure-cvmp-list-questions_en.pdf"},
    {"id":"63400","name":"Kexxtone Article 130(4) procedure - Annex I-II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-04T14:21:56Z","last_updated_date":"2024-06-04T14:21:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/kexxtone-article-1304-procedure-annex-i-ii_sv.pdf"}},
    {"id":"63488","name":"Synapse Article-31 referral - Synapse Labs Pvt. Ltd: re-examination confirms suspension of medicines over flawed studies","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-05T14:04:00Z","last_updated_date":"2024-06-14T14:04:00Z","reference_number":"EMA/254191/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-re-examination-confirms-suspension-medicines-over-flawed-studies_sv.pdf"}},
    {"id":"63489","name":"Synapse Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-05T14:10:00Z","last_updated_date":"2024-06-05T14:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/synapse-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/synapse-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/synapse-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/synapse-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/synapse-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/synapse-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/synapse-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/synapse-article-31-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/synapse-article-31-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/synapse-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/synapse-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/synapse-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/synapse-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/synapse-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/synapse-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/synapse-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/synapse-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/synapse-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/synapse-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/synapse-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/synapse-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/synapse-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/synapse-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/synapse-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/synapse-article-31-referral-annex-iii_no.pdf"}},
    {"id":"63490","name":"Synapse Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-05T14:12:00Z","last_updated_date":"2024-06-05T14:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/synapse-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/synapse-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/synapse-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/synapse-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/synapse-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/synapse-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/synapse-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/synapse-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/synapse-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/synapse-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/synapse-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/synapse-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/synapse-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/synapse-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/synapse-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/synapse-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/synapse-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/synapse-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/synapse-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/synapse-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/synapse-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/synapse-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/synapse-article-31-referral-annex-ii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/synapse-article-31-referral-annex-ii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/synapse-article-31-referral-annex-ii_no.pdf"}},
    {"id":"63491","name":"Synapse Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-05T14:14:00Z","last_updated_date":"2024-06-05T14:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/synapse-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/synapse-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/synapse-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/synapse-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/synapse-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/synapse-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/synapse-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/synapse-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/synapse-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/synapse-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/synapse-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/synapse-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/synapse-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/synapse-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/synapse-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/synapse-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/synapse-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/synapse-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/synapse-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/synapse-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/synapse-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/synapse-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/synapse-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/synapse-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/synapse-article-31-referral-annex-i_no.pdf"}},
    {"id":"63492","name":"Synapse Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-06-05T14:17:00Z","last_updated_date":"2024-06-05T14:17:00Z","reference_number":"EMA/169298/2004","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-assessment-report_en.pdf"},
    {"id":"63627","name":"Metamizole-containing medicinal products article 107i referral - List of questions to stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-14T15:55:06Z","last_updated_date":"2024-06-14T15:55:06Z","reference_number":"EMA/PRAC/264723/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-list-questions-stakeholders_en.pdf"},
    {"id":"63628","name":"Metamizole-containing medicinal products article 107i referral - Review of painkiller metamizole started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-14T16:02:50Z","last_updated_date":"2024-06-14T16:02:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-review-painkiller-metamizole-started_en.pdf"},
    {"id":"63629","name":"Metamizole-containing medicinal products article 107i referral - List of questions to marketing authorisation holder(s)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-14T16:03:55Z","last_updated_date":"2024-06-14T16:03:55Z","reference_number":"EMA/PRAC/264726/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-list-questions-marketing-authorisation-holders_en.pdf"},
    {"id":"63630","name":"Metamizole-containing medicinal products article 107i referral - Scientific background","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-14T16:05:11Z","last_updated_date":"2024-06-14T16:05:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-scientific-background_en.pdf"},
    {"id":"63631","name":"Metamizole-containing medicinal products article 107i referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-14T16:06:11Z","last_updated_date":"2024-08-23T09:48:00Z","reference_number":"EMA/PRAC/264725/2024 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-timetable-procedure_en.pdf"},
    {"id":"63632","name":"Metamizole-containing medicinal products article 107i referral - Stakeholders submission form","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-14T16:15:15Z","last_updated_date":"2024-06-14T16:15:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-procedure-stakeholders-submission-form_en.pdf"},
    {"id":"63633","name":"Metamizole-containing medicinal products article 107i referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2024-06-14T16:16:00Z","last_updated_date":"2024-12-06T13:31:00Z","reference_number":"EMA/280148/2024 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-i_sv.pdf"}},
    {"id":"63635","name":"Metamizole-containing medicinal products article 107i referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-14T17:01:29Z","last_updated_date":"2024-06-14T17:01:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-notification_en.pdf"},
    {"id":"63745","name":"Synapse Article-31 referral - Synapse Labs Pvt. Ltd: EMA recommends suspension of medicines over flawed studies","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T12:00:00Z","last_updated_date":"2023-12-15T12:00:00Z","reference_number":"EMA/565115/2023","document_url":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-synapse-labs-pvt-ltd-ema-recommends-suspension-medicines-over-flawed-studies_en.pdf"},
    {"id":"63796","name":"Hydroxyprogesterone-containing medicinal products Article 31-referral - Opinion following CMDH position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-08-19T14:15:10Z","reference_number":"EMA/298147/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-opinion-following-cmdh-position_sv.pdf"}},
    {"id":"63797","name":"Hydroxyprogesterone-containing medicinal products Article PhV-referral - Annex IV Timetable for the implementation of the CMDh position","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-08-19T14:16:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-phv-referral-annex-iv-timetable-implementation-cmdh-position_sv.pdf"}},
    {"id":"63805","name":"Lorazepam Macure - Article 13 referral - Control of status epilepticus to be added to product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-10-08T11:11:11Z","reference_number":"EMA/415192/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lorazepam-macure-article-13-referral-control-status-epilepticus-be-added-product-information_sv.pdf"}},
    {"id":"63806","name":"Lorazepam Macure - Article 13 referral - Product Information as approved by the CHMP on 27 June 2024, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T14:00:00Z","last_updated_date":"2024-06-28T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lorazepam-macure-article-13-referral-product-information-approved-chmp-27-june-2024-pending-endorsement-european-commission_en.pdf"},
    {"id":"63815","name":"Havrix - Article 30 referral - Product Information as approved by the CHMP on 27 June 2024, pending endorsement by the European Commission","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T15:00:00Z","last_updated_date":"2024-06-28T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/havrix-article-30-referral-product-information-approved-chmp-27-june-2024-pending-endorsement-european-commission_en.pdf"},
    {"id":"63816","name":"Havrix - Article 30 referral - Use of Havrix (hepatitis A virus (inactivated, adsorbed), suspension for injection) to be harmonised in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T15:00:00Z","last_updated_date":"2024-09-09T11:11:11Z","reference_number":"EMA/293545/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/havrix-article-30-referral-use-havrix-hepatitis-virus-inactivated-adsorbed-suspension-injection-be-harmonised-eu_sv.pdf"}},
    {"id":"63828","name":"Ocaliva Article 20 procedure : EMA recommends revoking conditional marketing authorisation for Ocaliva","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-09-12T16:00:00Z","reference_number":"EMA/294368/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-ema-recommends-revoking-conditional-marketing-authorisation-ocaliva_en.pdf"},
    {"id":"63900","name":"Hydroxyprogesterone-containing medicinal products Article 31-referral - Public assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-07-05T13:36:58Z","last_updated_date":"2024-07-05T13:36:58Z","reference_number":"EMA/263875/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-public-assessment-report_en.pdf"},
    {"id":"64363","name":"Oxbryta Article-20 procedure - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-07-30T12:54:00Z","last_updated_date":"2024-07-30T12:54:00Z","reference_number":"EMA/351008/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-review-started_en.pdf"},
    {"id":"64364","name":"Oxbryta Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-07-30T12:54:18Z","last_updated_date":"2025-09-22T15:20:00Z","reference_number":"EMA/CHMP/348132/2024 rev.6","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"64365","name":"Oxbryta Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-07-30T12:56:14Z","last_updated_date":"2024-07-30T12:56:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-notification_en.pdf"},
    {"id":"64366","name":"Oxbryta Article-20 procedure - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-07-30T12:57:17Z","last_updated_date":"2024-07-30T12:57:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-chmp-list-questions_en.pdf"},
    {"id":"64589","name":"Hydroxyprogesterone-containing medicinal products Article 31-referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-08-19T14:20:57Z","last_updated_date":"2024-08-19T14:24:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-i_sv.pdf"}},
    {"id":"64590","name":"Hydroxyprogesterone-containing medicinal products Article 31-referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-08-19T14:22:08Z","last_updated_date":"2024-08-19T14:24:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"64591","name":"Hydroxyprogesterone-containing medicinal products Article 31-referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-08-19T14:23:06Z","last_updated_date":"2024-08-19T14:24:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-annex-iii_sv.pdf"}},
    {"id":"64693","name":"Havrix - Article 30 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-09-04T14:28:09Z","last_updated_date":"2024-09-04T14:29:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/havrix-article-30-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/havrix-article-30-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/havrix-article-30-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/havrix-article-30-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/havrix-article-30-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/havrix-article-30-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/havrix-article-30-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/havrix-article-30-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/havrix-article-30-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/havrix-article-30-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/havrix-article-30-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/havrix-article-30-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/havrix-article-30-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/havrix-article-30-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/havrix-article-30-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/havrix-article-30-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/havrix-article-30-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/havrix-article-30-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/havrix-article-30-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/havrix-article-30-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/havrix-article-30-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/havrix-article-30-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/havrix-article-30-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/havrix-article-30-referral-annex-ii_sv.pdf"}},
    {"id":"64694","name":"Havrix - Article 30 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-09-04T14:29:31Z","last_updated_date":"2024-09-04T14:30:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/havrix-article-30-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/havrix-article-30-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/havrix-article-30-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/havrix-article-30-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/havrix-article-30-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/havrix-article-30-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/havrix-article-30-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/havrix-article-30-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/havrix-article-30-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/havrix-article-30-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/havrix-article-30-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/havrix-article-30-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/havrix-article-30-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/havrix-article-30-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/havrix-article-30-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/havrix-article-30-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/havrix-article-30-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/havrix-article-30-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/havrix-article-30-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/havrix-article-30-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/havrix-article-30-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/havrix-article-30-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/havrix-article-30-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/havrix-article-30-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/havrix-article-30-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/havrix-article-30-referral-annex-iii_no.pdf"}},
    {"id":"64695","name":"Havrix - Article 30 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-09-04T14:30:58Z","last_updated_date":"2024-09-04T14:30:58Z","reference_number":"EMA/CHMP/58048/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/havrix-article-30-referral-assessment-report_en.pdf"},
    {"id":"64736","name":"Metamizole-containing medicinal products article 107i referral - EMA recommends measures to minimise serious outcomes of known side effect with painkiller metamizole ","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T12:00:00Z","last_updated_date":"2024-09-06T12:00:00Z","reference_number":"EMA/407900/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-ema-recommends-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_en.pdf"},
    {"id":"64745","name":"Lorazepam Macure - Article 13 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-09-06T14:30:01Z","last_updated_date":"2024-09-06T14:30:01Z","reference_number":"EMA/390606/202","document_url":"https://www.ema.europa.eu/en/documents/referral/lorazepam-macure-article-13-referral-assessment-report_en.pdf"},
    {"id":"64746","name":"Lorazepam Macure - Article 13 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T14:31:08Z","last_updated_date":"2024-09-06T14:31:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lorazepam-macure-article-13-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lorazepam-macure-article-13-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lorazepam-macure-article-13-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lorazepam-macure-article-13-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lorazepam-macure-article-13-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lorazepam-macure-article-13-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lorazepam-macure-article-13-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lorazepam-macure-article-13-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lorazepam-macure-article-13-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/lorazepam-macure-article-13-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lorazepam-macure-article-13-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lorazepam-macure-article-13-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lorazepam-macure-article-13-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lorazepam-macure-article-13-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lorazepam-macure-article-13-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lorazepam-macure-article-13-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lorazepam-macure-article-13-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lorazepam-macure-article-13-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lorazepam-macure-article-13-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lorazepam-macure-article-13-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lorazepam-macure-article-13-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lorazepam-macure-article-13-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lorazepam-macure-article-13-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lorazepam-macure-article-13-referral-annex-i_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/lorazepam-macure-article-13-referral-annex-i_no.pdf"}},
    {"id":"64747","name":"Lorazepam Macure - Article 13 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T14:32:26Z","last_updated_date":"2024-09-06T14:32:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lorazepam-macure-article-13-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lorazepam-macure-article-13-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lorazepam-macure-article-13-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lorazepam-macure-article-13-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lorazepam-macure-article-13-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lorazepam-macure-article-13-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lorazepam-macure-article-13-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lorazepam-macure-article-13-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lorazepam-macure-article-13-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/lorazepam-macure-article-13-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lorazepam-macure-article-13-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lorazepam-macure-article-13-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lorazepam-macure-article-13-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lorazepam-macure-article-13-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lorazepam-macure-article-13-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lorazepam-macure-article-13-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lorazepam-macure-article-13-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lorazepam-macure-article-13-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lorazepam-macure-article-13-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lorazepam-macure-article-13-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lorazepam-macure-article-13-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lorazepam-macure-article-13-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lorazepam-macure-article-13-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lorazepam-macure-article-13-referral-annex-ii_sv.pdf"}},
    {"id":"64748","name":"Lorazepam Macure - Article 13 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T14:33:17Z","last_updated_date":"2024-09-06T14:33:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/lorazepam-macure-article-13-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/lorazepam-macure-article-13-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/lorazepam-macure-article-13-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/lorazepam-macure-article-13-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/lorazepam-macure-article-13-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/lorazepam-macure-article-13-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/lorazepam-macure-article-13-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/lorazepam-macure-article-13-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/lorazepam-macure-article-13-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/lorazepam-macure-article-13-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/lorazepam-macure-article-13-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/lorazepam-macure-article-13-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/lorazepam-macure-article-13-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/lorazepam-macure-article-13-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/lorazepam-macure-article-13-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/lorazepam-macure-article-13-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/lorazepam-macure-article-13-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/lorazepam-macure-article-13-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/lorazepam-macure-article-13-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/lorazepam-macure-article-13-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/lorazepam-macure-article-13-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/lorazepam-macure-article-13-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/lorazepam-macure-article-13-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/lorazepam-macure-article-13-referral-annex-iii_sv.pdf","no":"https://www.ema.europa.eu/no/documents/referral/lorazepam-macure-article-13-referral-annex-iii_no.pdf"}},
    {"id":"64951","name":"Metamizole-containing medicinal products article 107i referral - EMA recommends measures to minimise serious outcomes of known side effect with painkiller metamizole","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T12:00:00Z","last_updated_date":"2024-09-20T12:00:00Z","reference_number":"EMA/407900/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-ema-recommends-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_en.pdf-0"},
    {"id":"64952","name":"Metamizole-containing medicinal products article 107i referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T12:11:01Z","last_updated_date":"2024-12-06T16:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-iii_sv.pdf"}},
    {"id":"65048","name":"Oxbryta Article-20 procedure - EMA starts review of sickle cell disease medicine Oxbryta","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-09-26T16:42:00Z","last_updated_date":"2024-09-26T16:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-ema-starts-review-sickle-cell-disease-medicine-oxbryta_en.pdf"},
    {"id":"65057","name":"Oxbryta Article-20 procedure - Suspension of sickle cell disease medicine Oxbryta","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-09-30T11:11:11Z","last_updated_date":"2024-10-17T13:31:00Z","reference_number":"EMA/464087/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/oxbryta-article-20-procedure-suspension-sickle-cell-disease-medicine-oxbryta_no.pdf"}},
    {"id":"65145","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Review started","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T11:11:01Z","last_updated_date":"2024-10-04T11:11:01Z","reference_number":"EMA/452263/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-review-started_en.pdf"},
    {"id":"65151","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T11:11:01Z","last_updated_date":"2024-10-04T11:11:01Z","reference_number":"EMA/PRAC/414467/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"65152","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T11:11:01Z","last_updated_date":"2025-02-18T11:30:00Z","reference_number":"EMA/PRAC/414468/2024 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"65153","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T11:11:01Z","last_updated_date":"2024-10-04T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-notification_en.pdf"},
    {"id":"65187","name":"Draft finasteride- and dutasteride-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2024-10-04T17:12:00Z","last_updated_date":"2024-12-06T09:51:00Z","reference_number":"EMA/454353/2024 rev1","document_url":"https://www.ema.europa.eu/en/documents/referral/draft-finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_en.pdf"},
    {"id":"65239","name":"Oxbryta Article-20 procedure - Assessment report on temporary measures","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-10-08T13:32:00Z","last_updated_date":"2024-10-08T13:32:00Z","reference_number":"EMA/460760/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-assessment-report-temporary-measures_en.pdf"},
    {"id":"65933","name":"Ocaliva Article 20 procedure : Revocation of conditional marketing authorisation for Ocaliva","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T15:33:15Z","last_updated_date":"2025-01-07T15:51:53Z","reference_number":"EMA/556104/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ocaliva-article-20-procedure-revocation-conditional-marketing-authorisation-ocaliva_sv.pdf"}},
    {"id":"66011","name":"Metamizole-containing medicinal products article 107i referral - Divergent positions to CMDh position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-12-06T16:18:01Z","last_updated_date":"2024-12-06T16:18:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-divergent-positions-cmdh-position_en.pdf"},
    {"id":"66012","name":"Metamizole-containing medicinal products article 107i referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-12-06T16:19:23Z","last_updated_date":"2024-12-06T16:19:23Z","reference_number":"EMA/470471/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-assessment-report_en.pdf"},
    {"id":"66013","name":"Metamizole-containing medicinal products article 107i referral - Measures to minimise serious outcomes of known side effect with painkiller metamizole","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-12-06T16:21:53Z","last_updated_date":"2025-01-29T15:10:00Z","reference_number":"EMA/407900/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-measures-minimise-serious-outcomes-known-side-effect-painkiller-metamizole_no.pdf"}},
    {"id":"66014","name":"Metamizole-containing medicinal products article 107i referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-12-06T16:26:53Z","last_updated_date":"2024-12-06T16:26:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-annex-ii_sv.pdf"}},
    {"id":"66022","name":"Ocaliva Article 20 procedure : Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T15:23:15Z","last_updated_date":"2024-12-09T15:23:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ocaliva-article-20-procedure-scientific-conclusions_no.pdf"}},
    {"id":"66023","name":"Ocaliva Article 20 procedure : Public assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2024-12-09T15:24:52Z","last_updated_date":"2024-12-09T15:24:52Z","reference_number":"EMA/364123/2024","document_url":"https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-public-assessment-report_en.pdf"},
    {"id":"67523","name":"Mysimba Article-20 procedure - EMA concludes review of weight management medicine Mysimba","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-06-03T14:20:00Z","reference_number":"EMA/100420/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/mysimba-article-20-procedure-ema-concludes-review-weight-management-medicine-mysimba_no.pdf"}},
    {"id":"67524","name":"Mysimba Article-20 procedure – Product Information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-06-03T12:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/mysimba-article-20-procedure-product-information_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/mysimba-article-20-procedure-product-information_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/mysimba-article-20-procedure-product-information_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/mysimba-article-20-procedure-product-information_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/mysimba-article-20-procedure-product-information_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/mysimba-article-20-procedure-product-information_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/mysimba-article-20-procedure-product-information_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/mysimba-article-20-procedure-product-information_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/mysimba-article-20-procedure-product-information_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/mysimba-article-20-procedure-product-information_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/mysimba-article-20-procedure-product-information_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/mysimba-article-20-procedure-product-information_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/mysimba-article-20-procedure-product-information_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/mysimba-article-20-procedure-product-information_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/mysimba-article-20-procedure-product-information_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/mysimba-article-20-procedure-product-information_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/mysimba-article-20-procedure-product-information_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/mysimba-article-20-procedure-product-information_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/mysimba-article-20-procedure-product-information_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/mysimba-article-20-procedure-product-information_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/mysimba-article-20-procedure-product-information_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/mysimba-article-20-procedure-product-information_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/mysimba-article-20-procedure-product-information_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/mysimba-article-20-procedure-product-information_no.pdf"}},
    {"id":"68145","name":"Ixchiq Article-20 procedure - EMA starts review of Ixchiq (live attenuated chikungunya vaccine)","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-07T14:21:05Z","last_updated_date":"2025-06-03T16:00:00Z","reference_number":"EMA/170564/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ixchiq-article-20-procedure-ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine_sv.pdf"}},
    {"id":"68161","name":"Ixchiq Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T11:03:19Z","last_updated_date":"2025-05-08T11:03:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-notification_en.pdf"},
    {"id":"68162","name":"Ixchiq Article-20 procedure - Temporary measures product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T11:05:58Z","last_updated_date":"2025-05-08T11:05:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-temporary-measures-product-information_en.pdf"},
    {"id":"68171","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-08T14:49:20Z","last_updated_date":"2025-05-08T14:49:20Z","reference_number":"EMA/142716/2025 ","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts-finasteride-dutasteride-medicines_en.pdf"},
    {"id":"68210","name":"Ixchiq Article-20 procedure - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T08:22:06Z","last_updated_date":"2025-05-12T08:22:06Z","reference_number":"EMA/PRAC/158050/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-prac-list-questions_en.pdf"},
    {"id":"68211","name":"Ixchiq Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-12T08:24:46Z","last_updated_date":"2025-05-12T08:24:46Z","reference_number":"EMA/PRAC/157937/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"68354","name":"Ixchiq Article-20 procedure - PRAC assessment report on temporary measures","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-19T16:08:48Z","last_updated_date":"2025-05-19T16:08:48Z","reference_number":"EMA/166857/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-prac-assessment-report-temporary-measures_en.pdf"},
    {"id":"68405","name":"Ipidacrine-containing medicinal products Article 31 referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2025-05-23T10:56:31Z","last_updated_date":"2026-02-23T13:06:00Z","reference_number":"EMADOC-1700519818-2152423 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/ipidacrine-containing-medicinal-products-article-31-referral-annex-i_en.pdf"},
    {"id":"68406","name":"Ipidacrine-containing medicinal products Article 31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T10:58:09Z","last_updated_date":"2025-05-23T10:58:09Z","reference_number":"EMADOC-1700519818-2130356","document_url":"https://www.ema.europa.eu/en/documents/referral/ipidacrine-containing-medicinal-products-article-31-referral-chmp-list-questions_en.pdf"}    {"id":"68407","name":"Ipidacrine-containing medicinal products Article 31 referral - EMA starts review of ipidacrine-containing medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T10:59:19Z","last_updated_date":"2025-05-23T10:59:19Z","reference_number":"EMA/164665/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/ipidacrine-containing-medicinal-products-article-31-referral-ema-starts-review-ipidacrine-containing-medicines_en.pdf"},
    {"id":"68408","name":"Ipidacrine-containing medicinal products Article 31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T11:00:15Z","last_updated_date":"2026-03-30T10:04:00Z","reference_number":"EMADOC-1700519818-2130355 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/referral/ipidacrine-containing-medicinal-products-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"68409","name":"Ipidacrine-containing medicinal products Article 31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T11:01:36Z","last_updated_date":"2025-05-23T11:01:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ipidacrine-containing-medicinal-products-article-31-referral-notification_en.pdf"},
    {"id":"68413","name":"Azithromycin Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T12:42:36Z","last_updated_date":"2025-06-23T16:48:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-annex-iii_en.pdf"},
    {"id":"68414","name":"Azithromycin Article-31 referral - Changes to the use of antibiotic azithromycin","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T12:54:31Z","last_updated_date":"2025-05-23T12:54:31Z","reference_number":"EMA/165709/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_en.pdf"},
    {"id":"68456","name":"Mysimba Article-20 procedure - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2025-05-26T14:22:45Z","last_updated_date":"2025-05-26T14:22:45Z","reference_number":"EMA/101183/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/mysimba-article-20-procedure-assessment-report_en.pdf"},
    {"id":"68543","name":"Mysimba Article-20 procedure : Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T12:53:59Z","last_updated_date":"2025-06-03T12:53:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/mysimba-article-20-procedure-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/mysimba-article-20-procedure-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/mysimba-article-20-procedure-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/mysimba-article-20-procedure-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/mysimba-article-20-procedure-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/mysimba-article-20-procedure-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/mysimba-article-20-procedure-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/mysimba-article-20-procedure-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/mysimba-article-20-procedure-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/mysimba-article-20-procedure-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/mysimba-article-20-procedure-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/mysimba-article-20-procedure-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/mysimba-article-20-procedure-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/mysimba-article-20-procedure-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/mysimba-article-20-procedure-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/mysimba-article-20-procedure-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/mysimba-article-20-procedure-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/mysimba-article-20-procedure-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/mysimba-article-20-procedure-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/mysimba-article-20-procedure-scientific-conclusions_sk.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/mysimba-article-20-procedure-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/mysimba-article-20-procedure-scientific-conclusions_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/mysimba-article-20-procedure-scientific-conclusions_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/mysimba-article-20-procedure-scientific-conclusions_no.pdf"}},
    {"id":"68755","name":"Albendazole - Article 82 referral - Start of review concerning veterinary medicines containing albendazole","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-13T16:09:16Z","last_updated_date":"2025-06-13T16:09:16Z","reference_number":"EMA/201370/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/albendazole-article-82-referral-start-review-concerning-veterinary-medicines-containing-albendazole_en.pdf"},
    {"id":"68756","name":"Albendazole - Article 82 referral - Stakeholder submission form","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-13T16:15:11Z","last_updated_date":"2025-06-13T16:15:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/albendazole-article-82-referral-stakeholder-submission-form_en.pdf"},
    {"id":"68757","name":"Albendazole - Article 82 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-13T16:17:32Z","last_updated_date":"2025-06-13T16:17:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/albendazole-article-82-referral-notification_en.pdf"},
    {"id":"68758","name":"Albendazole - Article 82 referral - CVMP list of questions to be addressed by the marketing authorisation holders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-13T16:25:25Z","last_updated_date":"2025-06-13T16:25:25Z","reference_number":"EMA/CVMP/180970/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/albendazole-article-82-referral-cvmp-list-questions-be-addressed-marketing-authorisation-holders_en.pdf"},
    {"id":"68759","name":"Albendazole - Article 82 referral - CVMP list of questions to be addressed by the stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-13T16:28:40Z","last_updated_date":"2025-06-13T16:28:40Z","reference_number":"EMA/CVMP/180973/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/albendazole-article-82-referral-cvmp-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"68760","name":"Albendazole - Article 82 referral - Annex I","type":"referral","status":"Draft","consultation_date":"","first_published_date":"2025-06-13T16:30:47Z","last_updated_date":"2025-06-13T16:30:47Z","reference_number":"EMA/181435/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/albendazole-article-82-referral-annex-i_en.pdf"},
    {"id":"68762","name":"Albendazole - Article 82 referral - Timetable for the procedure under Article 82 of Regulation (EU) 2019/6","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-13T16:32:21Z","last_updated_date":"2025-07-24T11:45:59Z","reference_number":"EMA/CVMP/173707/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/albendazole-article-82-referral-timetable-procedure-under-article-82-regulation-eu-2019-6_en.pdf"},
    {"id":"68862","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T10:52:54Z","last_updated_date":"2025-06-20T10:52:54Z","reference_number":"EMA/202053/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts-finasteride-dutasteride-medicines_en.pdf-0"},
    {"id":"68865","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-20T12:37:51Z","last_updated_date":"2025-09-19T08:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iii_no.pdf"}},
    {"id":"68876","name":"Sodium oxybate Article-31 referral  - EMA starts review of sodium oxybate in alcohol dependence","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-20T17:28:50Z","last_updated_date":"2025-06-20T17:28:50Z","reference_number":"EMA starts review of sodium oxybate in alcohol dependence","document_url":"https://www.ema.europa.eu/en/documents/referral/sodium-oxybate-article-31-referral-ema-starts-review-sodium-oxybate-alcohol-dependence_en.pdf"},
    {"id":"68877","name":"Sodium oxybate Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-20T17:36:00Z","last_updated_date":"2025-06-20T17:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sodium-oxybate-article-31-referral-annex-i_en.pdf"},
    {"id":"68878","name":"Sodium oxybate Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-20T17:37:07Z","last_updated_date":"2025-06-20T17:37:07Z","reference_number":"EMADOC-1700519818-2230332","document_url":"https://www.ema.europa.eu/en/documents/referral/sodium-oxybate-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"68879","name":"Sodium oxybate Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-20T17:39:25Z","last_updated_date":"2026-03-02T09:40:00Z","reference_number":"EMADOC-1700519818-2230331 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/sodium-oxybate-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"68880","name":"Sodium oxybate Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-06-20T17:42:47Z","last_updated_date":"2025-06-20T17:42:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/sodium-oxybate-article-31-referral-notification_en.pdf"},
    {"id":"69241","name":"Ixchiq Article-20 procedure - Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-07-11T12:24:14Z","last_updated_date":"2025-07-11T12:24:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_en.pdf"},
    {"id":"69376","name":"Quarter-based selective dry cow therapy 141(1)(i) procedure - Start of review","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T13:34:16Z","last_updated_date":"2025-07-18T13:34:16Z","reference_number":"EMA/235687/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/quarter-based-selective-dry-cow-therapy-1411i-procedure-start-review_en.pdf"},
    {"id":"69377","name":"Quarter-based selective dry cow therapy 141(1)(i) procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T13:36:13Z","last_updated_date":"2025-10-13T12:50:00Z","reference_number":"EMA/CVMP/224794/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/quarter-based-selective-dry-cow-therapy-1411i-procedure-timetable-procedure_en.pdf"},
    {"id":"69378","name":"Quarter-based selective dry cow therapy 141(1)(i) procedure -  CVMP list of questions to be addressed by stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T13:37:27Z","last_updated_date":"2025-07-18T13:37:27Z","reference_number":"EMA/CVMP/231325/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/quarter-based-selective-dry-cow-therapy-1411i-procedure-cvmp-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"69379","name":"Quarter-based selective dry cow therapy 141(1)(i) procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T13:39:32Z","last_updated_date":"2025-07-18T13:39:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/quarter-based-selective-dry-cow-therapy-1411i-procedure-notification_en.pdf"},
    {"id":"69459","name":"Tecovirimat SIGA Article-20 procedure - EMA starts review of Tecovirimat SIGA","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T00:00:00Z","last_updated_date":"2025-07-25T00:00:00Z","reference_number":"EMA/239080/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/tecovirimat-siga-article-20-procedure-ema-starts-review-tecovirimat-siga_en.pdf"},
    {"id":"69460","name":"Tecovirimat SIGA Article-20 procedure - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T18:36:15Z","last_updated_date":"2026-02-27T15:59:00Z","reference_number":"EMADOC-1700519818-2313722 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/referral/tecovirimat-siga-article-20-procedure-timetable-procedure_en.pdf"},
    {"id":"69461","name":"Tecovirimat SIGA Article-20 procedure - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T18:37:48Z","last_updated_date":"2025-07-25T18:37:48Z","reference_number":"EMADOC-1700519818-2313948","document_url":"https://www.ema.europa.eu/en/documents/referral/tecovirimat-siga-article-20-procedure-chmp-list-questions_en.pdf"},
    {"id":"69462","name":"Tecovirimat SIGA Article-20 procedure - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T18:39:00Z","last_updated_date":"2025-07-25T18:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tecovirimat-siga-article-20-procedure-notification_en.pdf"},
    {"id":"69483","name":"Ixchiq Article-20 procedure - Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T10:43:19Z","last_updated_date":"2025-09-29T15:00:00Z","reference_number":"EMA/240749/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ixchiq-article-20-procedure-ixchiq-temporary-restriction-vaccinating-people-65-years-older-be-lifted_no.pdf"}},
    {"id":"69484","name":"Ixchiq Article-20 procedure - Product information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T10:46:54Z","last_updated_date":"2025-09-19T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-product-information_en.pdf"},
    {"id":"69913","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2025-09-01T10:13:03Z","last_updated_date":"2025-09-01T10:13:03Z","reference_number":"EMA/225542/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-assessment-report_en.pdf"},
    {"id":"69965","name":"Levamisole-containing medicinal products Article-31 referral - PRAC starts safety review of levamisole, a medicine used to treat parasitic worm infections","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T12:23:29Z","last_updated_date":"2025-09-05T12:23:29Z","reference_number":"EMA/281577/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-prac-starts-safety-review-levamisole-medicine-used-treat-parasitic-worm-infections_en.pdf"},
    {"id":"69986","name":"Levamisole-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T17:44:15Z","last_updated_date":"2025-09-05T17:44:15Z","reference_number":"EMADOC-1700519818-2418899","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_en.pdf"},
    {"id":"69987","name":"Levamisole-containing medicinal products Article-31 referral - PRAC list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T17:46:28Z","last_updated_date":"2025-09-05T17:46:28Z","reference_number":"EMADOC-1700519818-2392926","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-prac-list-questions_en.pdf"},
    {"id":"69988","name":"Levamisole-containing medicinal products Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T17:49:19Z","last_updated_date":"2026-01-16T16:15:00Z","reference_number":"EMADOC-1700519818-2392927 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"69989","name":"Levamisole-containing medicinal products Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T17:51:46Z","last_updated_date":"2025-09-05T17:51:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-notification_en.pdf"},
    {"id":"70164","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Annex I","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T07:58:00Z","last_updated_date":"2025-09-19T08:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-i_no.pdf"}},
    {"id":"70166","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Annex II","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T08:00:00Z","last_updated_date":"2025-09-19T08:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"70173","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Annex IV","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T08:02:11Z","last_updated_date":"2025-09-19T08:02:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-annex-iv_no.pdf"}},
    {"id":"70174","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Measures to minimise risk of suicidal thoughts","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T08:00:00Z","last_updated_date":"2025-09-19T08:00:00Z","reference_number":"EMA/202053/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-measures-minimise-risk-suicidal-thoughts_sv.pdf"}},
    {"id":"70175","name":"Finasteride- and dutasteride-containing medicinal products Article-31 referral - Divergent positions to CMDh position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T08:00:00Z","last_updated_date":"2025-09-19T08:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-divergent-positions-cmdh-position_en.pdf"},
    {"id":"70187","name":"Ixchiq Article-20 procedure - Annex IV - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T15:00:50Z","last_updated_date":"2025-09-19T15:00:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/ixchiq-article-20-procedure-annex-iv-scientific-conclusions_no.pdf"}},
    {"id":"70188","name":"Ixchiq Article-20 procedure - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T15:02:52Z","last_updated_date":"2025-09-19T15:02:52Z","reference_number":"EMADOC-1700519818-2369308","document_url":"https://www.ema.europa.eu/en/documents/referral/ixchiq-article-20-procedure-assessment-report_en.pdf"},
    {"id":"70277","name":"Azithromycin Article-31 referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T15:11:24Z","last_updated_date":"2025-09-25T15:11:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-annex-iii_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/azithromycin-article-31-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/azithromycin-article-31-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/azithromycin-article-31-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/azithromycin-article-31-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/azithromycin-article-31-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/azithromycin-article-31-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/azithromycin-article-31-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/azithromycin-article-31-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/azithromycin-article-31-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/azithromycin-article-31-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/azithromycin-article-31-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/azithromycin-article-31-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/azithromycin-article-31-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/azithromycin-article-31-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/azithromycin-article-31-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/azithromycin-article-31-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/azithromycin-article-31-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/azithromycin-article-31-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/azithromycin-article-31-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/azithromycin-article-31-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/azithromycin-article-31-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/azithromycin-article-31-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/azithromycin-article-31-referral-annex-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/azithromycin-article-31-referral-annex-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/azithromycin-article-31-referral-annex-iii_no.pdf"}},
    {"id":"70278","name":"Azithromycin Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T15:13:43Z","last_updated_date":"2025-09-25T15:13:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-annex-i_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/azithromycin-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/azithromycin-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/azithromycin-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/azithromycin-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/azithromycin-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/azithromycin-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/azithromycin-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/azithromycin-article-31-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/azithromycin-article-31-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/azithromycin-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/azithromycin-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/azithromycin-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/azithromycin-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/azithromycin-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/azithromycin-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/azithromycin-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/azithromycin-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/azithromycin-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/azithromycin-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/azithromycin-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/azithromycin-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/azithromycin-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/azithromycin-article-31-referral-annex-i_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/azithromycin-article-31-referral-annex-i_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/azithromycin-article-31-referral-annex-i_no.pdf"}},
    {"id":"70279","name":"Azithromycin Article-31 referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T15:14:41Z","last_updated_date":"2025-09-25T15:14:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/azithromycin-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/azithromycin-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/azithromycin-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/azithromycin-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/azithromycin-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/azithromycin-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/azithromycin-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/azithromycin-article-31-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/azithromycin-article-31-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/azithromycin-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/azithromycin-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/azithromycin-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/azithromycin-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/azithromycin-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/azithromycin-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/azithromycin-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/azithromycin-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/azithromycin-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/azithromycin-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/azithromycin-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/azithromycin-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/azithromycin-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/azithromycin-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"70280","name":"Azithromycin Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2025-09-25T15:15:59Z","last_updated_date":"2025-09-25T15:15:59Z","reference_number":"EMA/253465/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-assessment-report_en.pdf"},
    {"id":"70281","name":"Azithromycin Article-31 referral - Changes to the use of antibiotic azithromycin","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T15:18:10Z","last_updated_date":"2025-10-21T12:00:00Z","reference_number":"EMA/165709/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/azithromycin-article-31-referral-changes-use-antibiotic-azithromycin_sv.pdf"}},
    {"id":"70630","name":"Oxbryta Article-20 procedure - EMA confirms suspension of sickle cell disease medicine Oxbryta","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-10-17T11:48:30Z","last_updated_date":"2026-01-16T11:30:00Z","reference_number":"EMA/298985/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_no.pdf"}},
    {"id":"71039","name":"Veterinary medicines containing amoxicillin - Article 141(1)(i) referral - Start of review","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-11-06T15:44:35Z","last_updated_date":"2025-11-06T15:44:35Z","reference_number":"EMA/353616/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/veterinary-medicines-containing-amoxicillin-article-1411i-referral-start-review_en.pdf"},
    {"id":"71040","name":" Veterinary medicines containing amoxicillin - Article 141(1)(i) referral - CVMP list of questions to be addressed by stakeholders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-11-06T15:46:54Z","last_updated_date":"2025-11-06T15:46:54Z","reference_number":"EMA/CVMP/324544/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/veterinary-medicines-containing-amoxicillin-article-1411i-referral-cvmp-list-questions-be-addressed-stakeholders_en.pdf"},
    {"id":"71041","name":"Veterinary medicines containing amoxicillin - Article 141(1)(i) referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-11-06T15:47:50Z","last_updated_date":"2025-11-06T15:47:50Z","reference_number":"EMA/CVMP/322603/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/veterinary-medicines-containing-amoxicillin-article-1411i-referral-timetable-procedure_en.pdf"},
    {"id":"71042","name":"Veterinary medicines containing amoxicillin - Article 141(1)(i) referral - CVMP List of questions to be addressed by the marketing authorisation holders","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-11-06T15:48:40Z","last_updated_date":"2025-11-06T15:48:40Z","reference_number":"EMA/CVMP/322656/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/veterinary-medicines-containing-amoxicillin-article-1411i-referral-cvmp-list-questions-be-addressed-marketing-authorisation-holders_en.pdf"},
    {"id":"71043","name":"Veterinary medicines containing amoxicillin - Article 141(1)(i) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-11-06T15:50:37Z","last_updated_date":"2025-11-06T15:50:37Z","reference_number":"EMA/105000/2022","document_url":"https://www.ema.europa.eu/en/documents/referral/veterinary-medicines-containing-amoxicillin-article-1411i-referral-annex-i_en.pdf"},
    {"id":"71704","name":"Melatomed Article 29(4) referral - EMA recommends authorisation of Melatomed (melatonin, prolonged-release tablets) in the EU","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T08:56:21Z","last_updated_date":"2026-03-17T17:00:00Z","reference_number":"EMA/386502/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/melatomed-article-294-referral-ema-recommends-authorisation-melatomed-melatonin-prolonged-release-tablets-eu_sv.pdf"}},
    {"id":"71806","name":"Oxbryta Article-20 procedure - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2025-12-17T14:01:49Z","last_updated_date":"2025-12-17T14:01:49Z","reference_number":"EMA/354175/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-assessment-report_en.pdf"},
    {"id":"72102","name":"Oxbryta Article-20 procedure - Annex I - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T11:34:53Z","last_updated_date":"2026-01-16T11:34:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/oxbryta-article-20-procedure-annex-i-scientific-conclusions_no.pdf"}},
    {"id":"72103","name":"Oxbryta Article-20 procedure  - Annex II - Conditions for lifting the suspension of the marketing authorisation","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T11:33:00Z","last_updated_date":"2026-01-16T11:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_sv.pdf","is":"https://www.ema.europa.eu/is/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_is.pdf","no":"https://www.ema.europa.eu/no/documents/referral/oxbryta-article-20-procedure-annex-ii-conditions-lifting-suspension-marketing-authorisation_no.pdf"}},
    {"id":"72104","name":"Oxbryta Article-20 procedure - EMA confirms suspension of sickle cell disease medicine Oxbryta","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2025-10-17T12:16:52Z","last_updated_date":"2025-10-17T12:16:52Z","reference_number":"EMA/298985/2025","document_url":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta_en.pdf-0"},
    {"id":"72377","name":"Tavneos Article-20 procedure: EMA starts review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA ","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T11:23:52Z","last_updated_date":"2026-01-30T11:23:52Z","reference_number":"EMA/18986/2026","document_url":"https://www.ema.europa.eu/en/documents/referral/tavneos-article-20-procedure-ema-starts-review-tavneos-medicine-rare-autoimmune-diseases-gpa-mpa_en.pdf"},
    {"id":"72392","name":"Tavneos Article-20 procedure: CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T14:53:13Z","last_updated_date":"2026-01-30T14:53:13Z","reference_number":"EMADOC-1700519818-2855720","document_url":"https://www.ema.europa.eu/en/documents/referral/tavneos-article-20-procedure-chmp-list-questions_en.pdf"},
    {"id":"72393","name":"Tavneos Article-20 procedure: Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T14:54:47Z","last_updated_date":"2026-01-30T14:54:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tavneos-article-20-procedure-notification_en.pdf"},
    {"id":"72550","name":"Levamisole-containing medicinal products Article-31 referral - EMA recommends withdrawal of marketing authorisations for levamisole medicines","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2026-02-13T12:00:00Z","last_updated_date":"2026-02-13T12:00:00Z","reference_number":"EMA/31681/2026","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_en.pdf"},
    {"id":"72712","name":"Melatomed Article 29(4) referral - Public assessment report including divergent positions to CHMP opinion","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2026-02-26T10:14:51Z","last_updated_date":"2026-02-26T10:14:51Z","reference_number":"EMADOC-1700519818-2909554","document_url":"https://www.ema.europa.eu/en/documents/referral/melatomed-article-294-referral-public-assessment-report-including-divergent-positions-chmp-opinion_en.pdf"},
    {"id":"73073","name":"Quarter-based selective dry cow therapy 141(1)(i) procedure - CVMP assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2026-03-17T16:02:02Z","last_updated_date":"2026-03-17T16:02:02Z","reference_number":"EMA/CVMP/44249/2026","document_url":"https://www.ema.europa.eu/en/documents/referral/quarter-based-selective-dry-cow-therapy-1411i-procedure-cvmp-assessment-report_en.pdf"},
    {"id":"73074","name":"Quarter-based selective dry cow therapy 141(1)(i) procedure - CVMP scientific advice","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T16:03:50Z","last_updated_date":"2026-03-17T16:03:50Z","reference_number":"EMA/CVMP/44250/2026","document_url":"https://www.ema.europa.eu/en/documents/referral/quarter-based-selective-dry-cow-therapy-1411i-procedure-cvmp-scientific-advice_en.pdf"},
    {"id":"73078","name":"Melatomed Article 29(4) referral - Annex III","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T16:56:09Z","last_updated_date":"2026-03-17T16:56:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/melatomed-article-294-referral-annex-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/melatomed-article-294-referral-annex-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/melatomed-article-294-referral-annex-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/melatomed-article-294-referral-annex-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/melatomed-article-294-referral-annex-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/melatomed-article-294-referral-annex-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/melatomed-article-294-referral-annex-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/melatomed-article-294-referral-annex-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/melatomed-article-294-referral-annex-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/melatomed-article-294-referral-annex-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/melatomed-article-294-referral-annex-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/melatomed-article-294-referral-annex-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/melatomed-article-294-referral-annex-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/melatomed-article-294-referral-annex-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/melatomed-article-294-referral-annex-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/melatomed-article-294-referral-annex-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/melatomed-article-294-referral-annex-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/melatomed-article-294-referral-annex-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/melatomed-article-294-referral-annex-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/melatomed-article-294-referral-annex-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/melatomed-article-294-referral-annex-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/melatomed-article-294-referral-annex-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/melatomed-article-294-referral-annex-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/melatomed-article-294-referral-annex-iii_sv.pdf"}},
    {"id":"73079","name":"Melatomed Article 29(4) referral - Annex II","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T16:57:12Z","last_updated_date":"2026-03-17T16:57:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/melatomed-article-294-referral-annex-ii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/melatomed-article-294-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/melatomed-article-294-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/melatomed-article-294-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/melatomed-article-294-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/melatomed-article-294-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/melatomed-article-294-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/melatomed-article-294-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/melatomed-article-294-referral-annex-ii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/melatomed-article-294-referral-annex-ii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/melatomed-article-294-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/melatomed-article-294-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/melatomed-article-294-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/melatomed-article-294-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/melatomed-article-294-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/melatomed-article-294-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/melatomed-article-294-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/melatomed-article-294-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/melatomed-article-294-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/melatomed-article-294-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/melatomed-article-294-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/melatomed-article-294-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/melatomed-article-294-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/melatomed-article-294-referral-annex-ii_sv.pdf"}},
    {"id":"73080","name":"Melatomed Article 29(4) referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-03-17T16:58:31Z","last_updated_date":"2026-03-17T16:58:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/melatomed-article-294-referral-annex-i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/melatomed-article-294-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/melatomed-article-294-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/melatomed-article-294-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/melatomed-article-294-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/melatomed-article-294-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/melatomed-article-294-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/melatomed-article-294-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/melatomed-article-294-referral-annex-i_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/referral/melatomed-article-294-referral-annex-i_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/melatomed-article-294-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/melatomed-article-294-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/melatomed-article-294-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/melatomed-article-294-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/melatomed-article-294-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/melatomed-article-294-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/melatomed-article-294-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/melatomed-article-294-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/melatomed-article-294-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/melatomed-article-294-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/melatomed-article-294-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/melatomed-article-294-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/melatomed-article-294-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/melatomed-article-294-referral-annex-i_sv.pdf"}},
    {"id":"73159","name":"Quarter-based selective dry cow therapy 141(1)(i) procedure - CVMP concludes review on quarter-based selective antibiotic dry cow therapy","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T11:26:48Z","last_updated_date":"2026-03-24T11:26:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/quarter-based-selective-dry-cow-therapy-1411i-procedure-cvmp-concludes-review-quarter-based-selective-antibiotic-dry-cow-therapy_en.pdf"},
    {"id":"73234","name":"Tecovirimat SIGA Article-20 procedure - EMA recommends restricting use of Tecovirimat SIGA","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T10:01:13Z","last_updated_date":"2026-06-15T13:00:00Z","reference_number":"EMA/59974/2026","document_url":"https://www.ema.europa.eu/en/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tecovirimat-siga-article-20-procedure-ema-recommends-restricting-use-tecovirimat-siga_sv.pdf"}},
    {"id":"73235","name":"Tecovirimat SIGA - Product information as approved by the CHMP on 26 March 2026, pending endorsement by the EC","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T10:04:09Z","last_updated_date":"2026-03-27T10:04:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tecovirimat-siga-product-information-approved-chmp-26-march-2026-pending-endorsement-ec_en.pdf"},
    {"id":"73250","name":"Levamisole-containing medicinal products Article-31 referral - EMA recommends withdrawal of marketing authorisations for levamisole medicines","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T15:35:47Z","last_updated_date":"2026-05-13T15:35:47Z","reference_number":"EMA/31681/2026","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levamisole-containing-medicinal-products-article-31-referral-ema-recommends-withdrawal-marketing-authorisations-levamisole-medicines_sv.pdf"}},
    {"id":"73251","name":"Levamisole-containing medicinal products Article-31 referral - Timetable for the implementation of the CMDh position","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T15:37:10Z","last_updated_date":"2026-05-13T15:37:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levamisole-containing-medicinal-products-article-31-referral-timetable-implementation-cmdh-position_sv.pdf"}},
    {"id":"73349","name":"Levamisole-containing medicinal products Article-31 referral - Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2026-04-08T11:54:32Z","last_updated_date":"2026-04-08T11:54:32Z","reference_number":"EMADOC-1700519818-2908990","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-assessment-report_en.pdf"},
    {"id":"73737","name":"Levamisole-containing medicinal products Article-31 referral - List of medicinal products and presentations","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-05-13T17:17:21Z","last_updated_date":"2026-05-13T17:17:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-list-medicinal-products-presentations_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-i_sv.pdf"}},
    {"id":"73738","name":"Levamisole-containing medicinal products Article-31 referral - Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-05-13T17:19:50Z","last_updated_date":"2026-05-13T17:19:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/levamisole-containing-medicinal-products-article-31-referral-annex-ii_sv.pdf"}},
    {"id":"73929","name":"Tecovirimat SIGA Article-20 procedure : Scientific conclusions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-06-02T12:48:04Z","last_updated_date":"2026-06-02T12:48:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_bg.pdf","es":"https://www.ema.europa.eu/es/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_cs.pdf","da":"https://www.ema.europa.eu/da/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_da.pdf","de":"https://www.ema.europa.eu/de/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_de.pdf","et":"https://www.ema.europa.eu/et/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_et.pdf","el":"https://www.ema.europa.eu/el/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_hr.pdf","it":"https://www.ema.europa.eu/it/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/referral/tecovirimat-siga-article-20-procedure-scientific-conclusions_sv.pdf"}},
    {"id":"73930","name":"Tecovirimat SIGA Article-20 procedure : Assessment report","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2026-06-02T12:53:29Z","last_updated_date":"2026-06-02T12:53:29Z","reference_number":"EMADOC-1700519818-2986900","document_url":"https://www.ema.europa.eu/en/documents/referral/tecovirimat-siga-article-20-procedure-assessment-report_en.pdf"},
    {"id":"73931","name":"Tecovirimat SIGA Article-20 procedure – Product Information","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-06-02T12:30:44Z","last_updated_date":"2026-06-02T12:30:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tecovirimat-siga-article-20-procedure-product-information_en.pdf"},
    {"id":"74299","name":"Rifadin Article-31 referral - EMA starts review of Rifadin oral suspension and syrup, a liquid formulation of the antibiotic rifampicin","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T16:08:08Z","last_updated_date":"2026-06-26T16:08:08Z","reference_number":"EMA/143096/2026","document_url":"https://www.ema.europa.eu/en/documents/referral/rifadin-article-31-referral-ema-starts-review-rifadin-oral-suspension-syrup-liquid-formulation-antibiotic-rifampicin_en.pdf"},
    {"id":"74300","name":"Rifadin Article-31 referral - CHMP list of questions","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T16:11:54Z","last_updated_date":"2026-06-26T16:11:54Z","reference_number":"EMADOC-1700519818-3223083","document_url":"https://www.ema.europa.eu/en/documents/referral/rifadin-article-31-referral-chmp-list-questions_en.pdf"},
    {"id":"74301","name":"Rifadin Article-31 referral - Timetable for the procedure","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T16:15:23Z","last_updated_date":"2026-06-26T16:15:23Z","reference_number":"EMADOC-1700519818-3224382","document_url":"https://www.ema.europa.eu/en/documents/referral/rifadin-article-31-referral-timetable-procedure_en.pdf"},
    {"id":"74302","name":"Rifadin Article-31 referral - Annex I","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1700519818-3232912","document_url":"https://www.ema.europa.eu/en/documents/referral/rifadin-article-31-referral-annex-i_en.pdf"},
    {"id":"74303","name":"Rifadin Article-31 referral - Notification","type":"referral","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T16:18:48Z","last_updated_date":"2026-06-26T16:18:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/rifadin-article-31-referral-notification_en.pdf"},
    {"id":"74322","name":"Tavneos Article-20 procedure: EMA recommends revoking marketing authorisation for Tavneos","type":"referral","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T11:15:04Z","last_updated_date":"2026-06-26T11:15:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/referral/tavneos-article-20-procedure-ema-recommends-revoking-marketing-authorisation-tavneos_en.pdf"},
    {"id":"2404","name":"Addressing the paediatric or incapacitated patient in the package leaflet","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2000-03-10T00:09:21Z","last_updated_date":"2000-03-10T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/addressing-paediatric-or-incapacitated-patient-package-leaflet_en.pdf"},
    {"id":"2436","name":"The linguistic review process of product information in the centralised procedure - veterinary","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-12-18T01:00:00Z","last_updated_date":"2023-09-05T11:17:00Z","reference_number":"EMEA/288844/2009 Rev 5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/linguistic-review-process-product-information-centralised-procedure-veterinary_en.pdf"},
    {"id":"2490","name":"Guidance on format of the risk-management plan in the European Union part VI: Summary of activities in the risk-management plan by product","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2013-08-21T18:35:00Z","reference_number":"EMA/465929/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-vi-summary-activities-risk-management-plan-product_en.pdf"},
    {"id":"2527","name":"Best practice guidance on the common principle for collaboration between CMDh / reference Member States and the European Medicines Agency on generics and hybrids","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-12-04T10:07:00Z","last_updated_date":"2012-12-04T10:07:00Z","reference_number":"EMA/234449/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/best-practice-guidance-common-principle-collaboration-between-cmdh-reference-member-states-and-european-medicines-agency-generics-and-hybrids_en.pdf"},
    {"id":"2634","name":"Day 80 assessment report overview guidance - generics rev.10.16","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-07-08T15:20:00Z","last_updated_date":"2016-11-08T12:05:00Z","reference_number":"Rev. 10.16","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/day-80-assessment-report-overview-guidance-generics-rev1016_en.pdf"},
    {"id":"2641","name":"EMEA post-authorisation guidance on parallel distribution","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2006-07-01 - 2006-08-10","first_published_date":"2006-07-19T04:00:00Z","last_updated_date":"2006-07-19T04:00:00Z","reference_number":"EMEA/Ho/2368/Rev 4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/emea-post-authorisation-guidance-parallel-distribution_en.pdf"},
    {"id":"2827","name":"Draft good practice guide on recording, coding, reporting and assessment of medication errors","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-14 - 2015-06-14","first_published_date":"2015-04-14T18:00:00Z","last_updated_date":"2015-04-14T18:00:00Z","reference_number":"EMA/762563/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-good-practice-guide-recording-coding-reporting-and-assessment-medication-errors_en.pdf"},
    {"id":"2846","name":"European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-08-31T02:00:00Z","last_updated_date":"2026-03-27T13:00:00Z","reference_number":"EMA/24037/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-pre-authorisation-procedural-advice-users-centralised-procedure_en.pdf"},
    {"id":"2882","name":"Summary of transfers of appropriations in the budget 2009","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/MB/617640/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/summary-transfers-appropriations-budget-2009_en.pdf"},
    {"id":"2915","name":"Guidance on format of the risk-management plan in the European Union part III: Pharmacovigilance plan","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2012-11-08T18:00:00Z","reference_number":"EMA/714913/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-iii-pharmacovigilance-plan_en.pdf"},
    {"id":"2919","name":"Note for guidance on the electronic data interchange (EDI) of individual case safety reports (ICSRS)1 and medicinal product reports (MPRS) in pharmacovigilance during the pre-and post-authorisation phase in the European ...","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-05-31T02:00:00Z","last_updated_date":"2016-05-31T02:00:00Z","reference_number":"EMEA/115735/2004","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/note-guidance-electronic-data-interchange-edi-individual-case-safety-reports-icsrs1-and-medicinal-product-reports-mprs-pharmacovigilance-during-pre-and-post-authorisation-phase-european_en.pdf"},
    {"id":"2981","name":"Guidance on format of the risk-management plan in the European Union part II: Module SVIII - Summary of the safety concerns","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2013-08-21T18:35:00Z","reference_number":"EMA/465928/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-sviii-summary-safety-concerns_en.pdf"}    {"id":"3018","name":"Questions and answers on Article 13 veterinary referral procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T18:00:00Z","last_updated_date":"2017-12-20T18:00:00Z","reference_number":"EMA/503274/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-13-veterinary-referral-procedures_en.pdf"},
    {"id":"3032","name":"Standard paediatric investigation plan for non-adjuvanted or adjuvanted pandemic influenza vaccines during a pandemic - obsolete","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-06-26T02:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"EMA/185099/2010 - obsolete","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/standard-paediatric-investigation-plan-non-adjuvanted-or-adjuvanted-pandemic-influenza-vaccines-during-pandemic-obsolete_en.pdf"},
    {"id":"3049","name":"Overview of comments received on draft guideline on safety and efficacy follow-up - risk management of advanced therapy medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T00:00:00Z","last_updated_date":"2008-11-20T00:00:00Z","reference_number":"EMEA/477055/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-draft-guideline-safety-and-efficacy-follow-risk-management-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"3243","name":"Draft qualification opinion total kidney volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic kidney disease (ADPKD)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-22 - 2015-10-02","first_published_date":"2015-07-22T13:00:00Z","last_updated_date":"2015-07-22T13:00:00Z","reference_number":"EMA/CHMP/SAWP/473433/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-total-kidney-volume-tkv-prognostic-biomarker-use-clinical-trials-evaluating-patients-autosomal-dominant-polycystic-kidney-disease-adpkd_en.pdf"},
    {"id":"3347","name":"IRIS guide for applicants - How to create, submit and manage IRIS applications, for industry and individual applicants","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-07-04T14:00:00Z","last_updated_date":"2026-06-15T13:00:00Z","reference_number":"EMA/444925/2018 Version 3.14","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/iris-guide-applicants-how-create-submit-scientific-applications-industry-individual-applicants_en.pdf"},
    {"id":"3436","name":"Procedure for the preparation of a risk-based programme for routine pharmacovigilance inspections of MAHs connected with human Centrally Authorized Products (CAPs)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2014-06-20T02:00:00Z","reference_number":"EMEA/INS/PhV/105504/2008 Superseded","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-preparation-risk-based-programme-routine-pharmacovigilance-inspections-mahs-connected-human-centrally-authorized-products-caps_en.pdf"},
    {"id":"3617","name":"Overview of comments received on reflection paper on publication of withdrawals","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-10-05T02:00:00Z","last_updated_date":"2006-10-05T02:00:00Z","reference_number":"EMEA/148035/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-reflection-paper-publication-withdrawals_en.pdf"},
    {"id":"3631","name":"Guide for rapporteurs and coordinators on the multinational assessment teams","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-08-08T19:00:00Z","last_updated_date":"2025-10-15T15:20:00Z","reference_number":"EMA/486654/2016 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guide-rapporteurs-coordinators-multinational-assessment-teams_en.pdf"},
    {"id":"3712","name":"Initial notices for parallel distribution – November 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T01:00:00Z","last_updated_date":"2014-12-11T01:00:00Z","reference_number":"EMA/754450/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-november-2014_en.pdf"},
    {"id":"3724","name":"Draft EudraVigilance access policy for medicines for human use","type":"regulatory-procedural-guideline","status":"Draft","consultation_date":"","first_published_date":"2008-12-19T00:00:00Z","last_updated_date":"2008-12-19T00:00:00Z","reference_number":"EMEA/187439/2006/Final","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-eudravigilance-access-policy-medicines-human-use_en.pdf"},
    {"id":"3945","name":"Final conclusions on the pilot joint European Medicines Agency / Food and Drug Administration VXDS experience on qualification of nephrotoxicity biomarkers","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/679719/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/final-conclusions-pilot-joint-european-medicines-agency-food-and-drug-administration-vxds-experience-qualification-nephrotoxicity-biomarkers_en.pdf"},
    {"id":"3951","name":"EudraVigilance Expert Working Group: Volume 9A implementation questions and answers - Version 3.2","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-10-21T02:00:00Z","last_updated_date":"2008-10-21T02:00:00Z","reference_number":"EMEA/560457/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-expert-working-group-volume-9a-implementation-questions-and-answers-version-32_en.pdf"},
    {"id":"3958","name":"Draft reflection paper on ethical and good-clinical-practice aspects of clinical trials of medicinal products for human use conducted in third countries and submitted in marketing authorisation applications to the Europe...","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2010-03-23 - 2010-09-30","first_published_date":"2010-05-28T04:00:00Z","last_updated_date":"2010-05-28T04:00:00Z","reference_number":"EMA/712397/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-reflection-paper-ethical-and-good-clinical-practice-aspects-clinical-trials-medicinal-products-human-use-conducted-third-countries-and-submitted-marketing-authorisation-applications-europe_en.pdf"},
    {"id":"3986","name":"Template and recommended format for list of references","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2014-11-17T15:30:00Z","reference_number":"EMEA/HMPC/574496/2008 Rev. 2 Corr.","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/template-and-recommended-format-list-references_en.pdf"},
    {"id":"4240","name":"Draft EudraVigilance access policy for medicines for veterinary use - Revision 1","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2018-04-30 - 2018-06-27","first_published_date":"2018-04-30T15:33:00Z","last_updated_date":"2018-04-30T15:33:00Z","reference_number":"EMA/113700/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-eudravigilance-access-policy-medicines-veterinary-use-revision-1_en.pdf"},
    {"id":"4263","name":"List of substances and products subject to worksharing for signal management","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-10-05T02:00:00Z","last_updated_date":"2025-12-09T15:22:00Z","reference_number":"EMA/563056/2014 Rev. 14","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/list-substances-products-subject-worksharing-signal-management_en.xlsx"},
    {"id":"4306","name":"EMA procedural advice for medicinal products intended exclusively for markets outside the European Union in the context of co-operation with the World Health Organisation (WHO)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-04-01T02:00:00Z","last_updated_date":"2025-12-10T15:00:00Z","reference_number":"EMA/534107/2008 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-procedural-advice-medicinal-products-intended-exclusively-markets-outside-european-union-context-co-operation-world-health-organisation-who_en.pdf"},
    {"id":"4375","name":"Guideline on good pharmacovigilance practices (GVP): Module XVI Addendum I – Educational materials (superseded)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-12-15T12:30:00Z","last_updated_date":"2015-12-15T12:30:00Z","reference_number":"EMA/61341/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-i-educational-materials-superseded_en.pdf"},
    {"id":"4610","name":"Output of the draft EMEA policy on the practical operation of access to EMEA documents in the context of the authorisation and supervision of medicinal products for human and veterinary use","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T00:00:00Z","last_updated_date":"2008-12-18T00:00:00Z","reference_number":"EMEA/659316/2008/Final","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/output-draft-emea-policy-practical-operation-access-emea-documents-context-authorisation-and-supervision-medicinal-products-human-and-veterinary-use_en.pdf"},
    {"id":"4817","name":"Procedural advice on the certification of quality and non-clinical data for small and medium-sized enterprises developing advanced therapy medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-17T02:00:00Z","last_updated_date":"2016-12-07T01:00:00Z","reference_number":"EMEA/CAT/418458/2008/corr.","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-certification-quality-and-non-clinical-data-small-and-medium-sized-enterprises-developing-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"4818","name":"Questions and answers on periodic safety update report single-assessment (PSUSA): Guidance document for assessors","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-04-06T14:00:00Z","last_updated_date":"2026-05-22T16:00:00Z","reference_number":"EMA/518909/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-periodic-safety-update-report-single-assessment-psusa-guidance-document-assessors_en.pdf"},
    {"id":"4850","name":"External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use - Version 1.2","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-04-12T17:00:02Z","last_updated_date":"2017-04-12T17:00:02Z","reference_number":"EMA/90915/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-version-12_en.pdf"},
    {"id":"4861","name":"Criteria to be fulfilled by patient, consumer and healthcare professional organisations involved in European Medicines Agency (EMA) activities","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-02-07T00:00:00Z","last_updated_date":"2018-06-11T18:30:00Z","reference_number":"EMA/MB/24913/2005 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/criteria-be-fulfilled-patient-consumer-and-healthcare-professional-organisations-involved-european-medicines-agency-ema-activities_en.pdf"},
    {"id":"4962","name":"Paediatric investigation plan: Expected key elements and requirements for a new diphtheria-tetanus-acellular-pertussis-containing combination vaccine seeking marketing authorisation","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2014-09-23 - 2014-12-19","first_published_date":"2014-09-23T21:30:00Z","last_updated_date":"2014-09-23T21:30:00Z","reference_number":"EMA/PDCO/71162/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/paediatric-investigation-plan-expected-key-elements-and-requirements-new-diphtheria-tetanus-acellular-pertussis-containing-combination-vaccine-seeking-marketing-authorisation_en.pdf"},
    {"id":"4978","name":"PDCO rules of procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-07-02T02:09:00Z","last_updated_date":"2021-10-15T14:30:00Z","reference_number":"EMEA/348440/2008 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pdco-rules-procedure_en.pdf"},
    {"id":"5073","name":"Points to consider for assessors. New factor VIII and factor IX products: potency determination for labelling and assays for testing post-infusion samples","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-12-07T17:00:00Z","last_updated_date":"2015-12-07T17:00:00Z","reference_number":"EMA/CHMP/BPWP/231587/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/points-consider-assessors-new-factor-viii-and-factor-ix-products-potency-determination-labelling-and-assays-testing-post-infusion-samples_en.pdf"},
    {"id":"5108","name":"Initial notices for parallel distribution – February 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-03-18T15:25:00Z","last_updated_date":"2014-03-18T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-february-2014_en.pdf"},
    {"id":"5141","name":"Guidance on meetings with applicants on the responses to questions received from European Medicines Agency scientific Committees during the evaluation within the centralised procedure","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-02-09T12:10:00Z","last_updated_date":"2015-02-09T12:10:00Z","reference_number":"EMA/636600/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-meetings-applicants-responses-questions-received-european-medicines-agency-scientific-committees-during-evaluation-within-centralised-procedure_en.pdf"},
    {"id":"5336","name":"Initial notices for parallel distribution – December 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-01-12T12:15:00Z","last_updated_date":"2015-01-12T12:15:00Z","reference_number":"EMA/10492/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-december-2014_en.pdf"},
    {"id":"5481","name":"How to register with EudraVigilance and EVDAS - Training module EV-M1","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2018-07-26T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/how-register-eudravigilance-and-evdas-training-module-ev-m1_en.pdf"},
    {"id":"5520","name":"Questions and answers on Article 31 pharmacovigilance referral procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-01-22T13:00:00Z","last_updated_date":"2019-02-04T14:00:00Z","reference_number":"EMA/33617/2014 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-31-pharmacovigilance-referral-procedures_en.pdf"},
    {"id":"5909","name":"Reflection paper on the use of heat treatment to inactivate retrovirus RD114 in live immunological veterinary medicinal products (IVMPs)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2014-12-19 - 2015-03-31","first_published_date":"2014-12-19T15:45:00Z","last_updated_date":"2014-12-19T15:45:00Z","reference_number":"EMA/CVMP/IWP/37924/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-use-heat-treatment-inactivate-retrovirus-rd114-live-immunological-veterinary-medicinal-products-ivmps_en.pdf"},
    {"id":"5938","name":"Development of non-substantially manipulated cell-based advanced therapy medicinal products: flexibility introduced via the application of the risk-based approach","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-07-03T19:36:00Z","last_updated_date":"2017-07-03T19:36:00Z","reference_number":"EMA/CAT/216556/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/development-non-substantially-manipulated-cell-based-advanced-therapy-medicinal-products-flexibility-introduced-application-risk-based-approach_en.pdf"},
    {"id":"6015","name":"D80 assessment report - Non-clinical guidance rev.10.16","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-05-25T12:30:00Z","last_updated_date":"2016-11-18T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/d80-assessment-report-non-clinical-guidance-rev1016_en.pdf"},
    {"id":"6050","name":"Draft EMA recommendation on the procedural aspects and dossier requirements for the consultation to the EMA by a notified body on an ancillary medicinal substance or an ancillary human blood derivate incorporated in a me...","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2010-10-21 - 2011-01-31","first_published_date":"2010-10-22T04:00:00Z","last_updated_date":"2010-10-22T04:00:00Z","reference_number":"EMA/CHMP/578661/2010 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-ema-recommendation-procedural-aspects-and-dossier-requirements-consultation-ema-notified-body-ancillary-medicinal-substance-or-ancillary-human-blood-derivate-incorporated-me_en.pdf"},
    {"id":"6052","name":"Practical_guidelines on the use of the eCTD format for Plasma Master File holders (PMF - H)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-08-01T02:00:00Z","last_updated_date":"2009-08-01T02:00:00Z","reference_number":"EMEA/512725/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/practical_guidelines-use-ectd-format-plasma-master-file-holders-pmf-h_en.pdf"},
    {"id":"6072","name":"Guidance on format of the risk-management plan in the European Union part II: Module SIII - Clinical-trial exposure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2012-11-14T01:00:00Z","reference_number":"EMA/710081/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-siii-clinical-trial-exposure_en.doc"},
    {"id":"6331","name":"Guidance on triggers for inspections of bioequivalence trials: quick scan","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-08-20T11:30:00Z","last_updated_date":"2017-03-02T10:40:00Z","reference_number":"EMA/745861/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-triggers-inspections-bioequivalence-trials-quick-scan_en.pdf"},
    {"id":"6463","name":"Reflection paper on classification of advanced-therapy medicinal products","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2012-04-30 - 2012-07-31","first_published_date":"2012-04-30T22:13:50Z","last_updated_date":"2012-04-30T22:13:50Z","reference_number":"EMA/CAT/600280/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-classification-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"6628","name":"Procedural advice on CHMP/CAT/PRAC Rapporteur/Co-Rapporteur appointment principles, objective criteria and methodology in accordance with Article 62 (1) of Regulation (EC) No 726/2004","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-12T02:00:00Z","last_updated_date":"2025-02-28T10:53:00Z","reference_number":"EMA/151751/2010 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-chmp-cat-prac-rapporteur-co-rapporteur-appointment-principles-objective-criteria-methodology-accordance-article-62-1-regulation-ec-no-726-2004_en.pdf"},
    {"id":"6697","name":"Draft qualification opinion on molecular neuroimaging of the dopamine transporter as biomarker to identify patients with early manifest Parkinsonism in Parkinson’s disease","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2018-01-24 - 2018-03-07","first_published_date":"2018-01-24T18:00:00Z","last_updated_date":"2018-01-24T18:00:00Z","reference_number":"EMA/765041/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-molecular-neuroimaging-dopamine-transporter-biomarker-identify-patients-early-manifest-parkinsonism-parkinsons-disease_en.pdf"},
    {"id":"6825","name":"Guidance on format of the risk-management plan in the European Union part II: Module SII - Non-clinical part of the safety specification","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2013-08-21T02:00:00Z","reference_number":"EMA/465926/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-sii-non-clinical-part-safety-specification_en.doc"},
    {"id":"6828","name":"Scientific aspects and working definitions for the mandatory scope of the centralised procedure","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-12-13T01:00:00Z","last_updated_date":"2007-12-13T01:00:00Z","reference_number":"EMEA/CHMP/121944/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/scientific-aspects-and-working-definitions-mandatory-scope-centralised-procedure_en.pdf"},
    {"id":"6865","name":"Draft guideline on the scientific application and the practical arrangements necessary to implement the procedure for accelerated assessment pursuant to Article 14(9) of Regulation (EC) No 726/2004 (Revision 1)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-27 - 2015-09-30","first_published_date":"2015-07-27T15:00:00Z","last_updated_date":"2015-07-27T15:00:00Z","reference_number":"EMA/CHMP/697051/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-scientific-application-and-practical-arrangements-necessary-implement-procedure-accelerated-assessment-pursuant-article-149-regulation-ec-no-726-2004-revision-1_en.pdf"},
    {"id":"6888","name":"Draft guideline on the conduct of pharmacovigilance for vaccines for pre- and post-exposure prophylaxis against infectious diseases","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-09-25T02:09:21Z","last_updated_date":"2008-09-25T02:09:21Z","reference_number":"EMEA/CHMP/PhVWP/503449/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-conduct-pharmacovigilance-vaccines-pre-and-post-exposure-prophylaxis-against-infectious-diseases_en.pdf"},
    {"id":"6952","name":"Initial notices for parallel distribution – October 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-11-10T13:10:00Z","last_updated_date":"2014-11-10T13:10:00Z","reference_number":"EMA/695965/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-october-2014_en.pdf"},
    {"id":"7089","name":"Questions and answers on the European Union framework for (traditional) herbal medicinal products, including those from a ‘non-European’ tradition","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-05-12T12:40:00Z","last_updated_date":"2024-02-19T14:00:00Z","reference_number":"EMA/HMPC/402684/2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-european-union-framework-traditional-herbal-medicinal-products-including-those-non-european-tradition_en.pdf"},
    {"id":"7153","name":"Union recommendations on the training and experience of inspectors performing pharmacovigilance inspections","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-06-20T12:15:00Z","last_updated_date":"2014-06-20T12:15:00Z","reference_number":"EMA/INS/PhV/192237/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/union-recommendations-training-and-experience-inspectors-performing-pharmacovigilance-inspections_en.pdf"},
    {"id":"7390","name":"European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: document with tracked changes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-02-07T12:30:00Z","last_updated_date":"2026-03-27T13:00:00Z","reference_number":"EMA/24037/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-pre-authorisation-procedural-advice-users-centralised-procedure-document-tracked-changes_en.pdf"},
    {"id":"7544","name":"Qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for the use of cerebrospinal-fluid amyloid beta 1-42 and t-tau and / or positron-emission-tomography amyloid imaging (positive / negative) as ...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-04-04T19:00:00Z","last_updated_date":"2012-04-04T19:00:00Z","reference_number":"EMA/CHMP/SAWP/893622/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-alzheimers-disease-novel-methodologies-biomarkers-use-cerebrospinal-fluid-amyloid-beta-1-42-and-t-tau-and-or-positron-emission-tomography-amyloid-imaging-positive-negative_en.pdf"},
    {"id":"7816","name":"Procedural advice on the consultation of Notified Bodies in accordance with Article 9 of Regulation (EC) No. 1394/2007","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2010-07-16 - 2010-10-29","first_published_date":"2010-07-29T04:00:00Z","last_updated_date":"2010-07-29T04:00:00Z","reference_number":"EMA/354785/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-consultation-notified-bodies-accordance-article-9-regulation-ec-no-1394-2007_en.pdf"},
    {"id":"7877","name":"Questions and answers on Article 30 referral procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-07-06T18:00:00Z","last_updated_date":"2016-07-06T18:00:00Z","reference_number":"EMA/457319/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-30-referral-procedures_en.pdf"},
    {"id":"7949","name":"Substances considered as not falling within the scope of Regulation (EC) No. 470/2009, with regard to residues of veterinary medicinal products in foodstuffs of animal origin","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2025-11-14T09:20:00Z","reference_number":"EMA/CVMP/519714/2009 Rev. 62","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/substances-considered-not-falling-within-scope-regulation-ec-no-470-2009-regard-residues-veterinary-medicinal-products-foodstuffs-animal-origin_en.pdf"},
    {"id":"8035","name":"Rules of procedure on the organisation and conduct of public hearings at the Pharmacovigilance Risk Assessment Committee (PRAC)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-04-15T14:00:00Z","last_updated_date":"2023-02-17T11:25:00Z","reference_number":"EMA/11523/2023 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_bg.pdf","es":"https://www.ema.europa.eu/es/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_cs.pdf","da":"https://www.ema.europa.eu/da/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_da.pdf","de":"https://www.ema.europa.eu/de/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_de.pdf","et":"https://www.ema.europa.eu/et/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_et.pdf","el":"https://www.ema.europa.eu/el/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_hr.pdf","it":"https://www.ema.europa.eu/it/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/regulatory-procedural-guideline/rules-procedure-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_sv.pdf"}},
    {"id":"8057","name":"Qualification opinion on in-vitro hollow-fibre-system model of tuberculosis (HFS-TB)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-02-06T15:30:00Z","last_updated_date":"2015-02-09T15:50:00Z","reference_number":"EMA/CHMP/SAWP/47290/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-vitro-hollow-fibre-system-model-tuberculosis-hfs-tb_en.pdf"},
    {"id":"8247","name":"EudraVigilance - National competent authorities - Adobe connect invitation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2018-02-14T14:00:00Z","reference_number":"EMA/381965/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-national-competent-authorities-adobe-connect-invitation_en.pdf"},
    {"id":"8261","name":"Procedure: 2nd step of the Plasma Master File (PMF) certification procedure for the centrally authorised medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-15T01:00:00Z","last_updated_date":"2009-01-15T01:00:00Z","reference_number":"EMEA/CHMP/BWP/373464/2005/Rev 01","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-2nd-step-plasma-master-file-pmf-certification-procedure-centrally-authorised-medicinal-products_en.pdf"},
    {"id":"8363","name":"Procedure for conducting pharmacovigilance inspections requested by the CHMP","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-12T01:00:00Z","last_updated_date":"2014-06-20T02:00:00Z","reference_number":"EMEA/INS/GCP/218148/2007 Superseded","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-conducting-pharmacovigilance-inspections-requested-chmp_en.pdf"},
    {"id":"8436","name":"Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-03-20T13:30:00Z","last_updated_date":"2012-03-20T13:30:00Z","reference_number":"EMA/INS/GCP/532137/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-laboratories-perform-analysis-or-evaluation-clinical-trial-samples_en.pdf"},
    {"id":"8471","name":"Pre-submission checklist for 5-year renewal applications","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:00:00Z","last_updated_date":"2017-04-06T14:00:00Z","reference_number":"EMA/190616/2016 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pre-submission-checklist-5-year-renewal-applications_en.pdf"},
    {"id":"8493","name":"External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use - First version","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-03-03T11:00:00Z","last_updated_date":"2016-03-03T11:00:00Z","reference_number":"EMA/90915/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-first-version_en.pdf"},
    {"id":"8527","name":"Question and answer on the information contained within section 5.1 of the summary of product characteristics on pharmacodynamic properties for pharmaceutical products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-02-15T15:50:00Z","last_updated_date":"2026-02-20T15:50:00Z","reference_number":"EMA/CVMP/757903/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/question-answer-information-contained-within-section-51-summary-product-characteristics-pharmacodynamic-properties-pharmaceutical-products_en.pdf"},
    {"id":"8826","name":"European Union recommendations for the influenza-vaccine composition for the season 2007 / 2008","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-03-19T00:09:21Z","last_updated_date":"2007-03-19T00:09:21Z","reference_number":"EMEA/CHMP/BWP/108182/07","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-union-recommendations-influenza-vaccine-composition-season-2007-2008_en.pdf"},
    {"id":"8921","name":"EMEA implementation of electronic submissions and eCTD submissions: Statement of intent: Questions and answers relating to strategic and general aspects of the implementation","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-01-22T01:00:00Z","last_updated_date":"2008-01-22T01:00:00Z","reference_number":"EMEA/596870/2007 correction","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/emea-implementation-electronic-submissions-and-ectd-submissions-statement-intent-questions-and-answers-relating-strategic-and-general-aspects-implementation_en.pdf"},
    {"id":"9130","name":"Combined Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products (Excel)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-07-22T02:00:00Z","last_updated_date":"2022-09-15T16:56:00Z","reference_number":"EMA/CVMP/PhVWP/10418/2009 Rev.13 Corr.","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/combined-veterinary-dictionary-drug-regulatory-activities-veddra-list-clinical-terms-reporting-suspected-adverse-reactions-animals-and-humans-veterinary-medicinal-products-excel_en.xls"},
    {"id":"9264","name":"Initial notices for parallel distribution – March 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-04-22T14:30:00Z","last_updated_date":"2014-04-22T14:30:00Z","reference_number":"EMA/227993/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-march-2014_en.pdf"},
    {"id":"9276","name":"Union procedure on the coordination of EU pharmacovigilance inspections","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-06-20T12:15:00Z","last_updated_date":"2014-06-20T12:15:00Z","reference_number":"EMA/INS/PhV/192234/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/union-procedure-coordination-eu-pharmacovigilance-inspections_en.pdf"},
    {"id":"9319","name":"Acetylsalicylic acid statement translation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2011-04-02T01:31:00Z","last_updated_date":"2011-04-02T01:31:00Z","reference_number":"EMA/18570/2003","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/acetylsalicylic-acid-statement-translation_en.pdf"},
    {"id":"9372","name":"Appointment and responsibilities of rapporteur and co-rapporteur for procedures regarding veterinary medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-01-01T01:00:00Z","last_updated_date":"2005-01-01T01:00:00Z","reference_number":"EMEA/CVMP/928/02-Revision FINAL","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/appointment-and-responsibilities-rapporteur-and-co-rapporteur-procedures-regarding-veterinary-medicinal-products_en.pdf"},
    {"id":"9391","name":"Superseded - EMA guidance on the use of medicinal products for the treatment of patients exposed to terrorist attacks with chemical agents","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2003-04-25T02:09:00Z","last_updated_date":"2024-08-12T15:56:00Z","reference_number":"EMEA/CPMP/1255/03","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/superseded-ema-guidance-use-medicinal-products-treatment-patients-exposed-terrorist-attacks-chemical-agents_en.pdf"},
    {"id":"9414","name":"Procedural advice to CHMP members","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-08-06T02:00:00Z","last_updated_date":"2008-08-06T02:00:00Z","reference_number":"EMEA/361945/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-chmp-members_en.pdf"},
    {"id":"9445","name":"Post-Authorisation Procedural Advice: Human Medicinal Products: New Variation Regulation (EC) No 1234/2008","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-01-20T00:09:21Z","last_updated_date":"2010-01-20T00:09:21Z","reference_number":"EMA/40404/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/post-authorisation-procedural-advice-human-medicinal-products-new-variation-regulation-ec-no-12342008_en.pdf"},
    {"id":"9446","name":"Initial notices for parallel distribution – May 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T18:58:00Z","last_updated_date":"2014-06-16T18:58:00Z","reference_number":"EMA/342868/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-may-2014_en.pdf"},
    {"id":"9485","name":"Electronic common technical document v4.0 draft European Union module 1 implementation guide public consultation","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-03-13 - 2015-05-22","first_published_date":"2015-03-16T14:00:00Z","last_updated_date":"2015-03-16T14:00:00Z","reference_number":"EMA/170681/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/electronic-common-technical-document-v40-draft-european-union-module-1-implementation-guide-public-consultation_en.pdf"},
    {"id":"9668","name":"Mock-ups checklist - Guidance for checking mock-ups","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-04-01T20:00:00Z","last_updated_date":"2022-02-02T17:20:00Z","reference_number":"EMA/102667/2014 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/mock-ups-checklist-guidance-checking-mock-ups_en.pdf"},
    {"id":"9709","name":"Qualification opinion - Total Kidney Volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-11-13T17:20:02Z","last_updated_date":"2015-11-13T17:20:02Z","reference_number":"EMA/CHMP/SAWP/473433/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-total-kidney-volume-tkv-prognostic-biomarker-use-clinical-trials-evaluating-patients-autosomal-dominant-polycystic-kidney-disease-adpkd_en.pdf"},
    {"id":"9817","name":"Initial notices for parallel distribution – 2011","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T17:00:00Z","last_updated_date":"2012-10-10T17:00:00Z","reference_number":"EMA/643088/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-2011_en.pdf"},
    {"id":"9856","name":"Time allowed for applicants to respond to questions and issues raised during the assessment of new marketing authorisation applications in the centralised procedure","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-01-06T01:00:00Z","last_updated_date":"2009-01-06T01:00:00Z","reference_number":"EMEA/75401/2006 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/time-allowed-applicants-respond-questions-and-issues-raised-during-assessment-new-marketing-authorisation-applications-centralised-procedure_en.pdf"},
    {"id":"9867","name":"Implementation of the action plan to further progress the european risk management strategy: rolling two-year work programme (mid 2005-mid 2007)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-12-16T00:00:00Z","last_updated_date":"2005-12-16T00:00:00Z","reference_number":"EMEA/372687/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/implementation-action-plan-further-progress-european-risk-management-strategy-rolling-two-year-work-programme-mid-2005-mid-2007_en.pdf"},
    {"id":"9906","name":"General criteria for granting free scientific advice in respect of supporting the research and development of veterinary medicinal products destined for minor use in major species and minor species","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"2004-02-13 - 2004-03-13","first_published_date":"2004-05-12T04:00:00Z","last_updated_date":"2004-05-12T04:00:00Z","reference_number":"EMEA/CVMP/1136/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/general-criteria-granting-free-scientific-advice-respect-supporting-research-and-development-veterinary-medicinal-products-destined-minor-use-major-species-and-minor-species_en.pdf"},
    {"id":"9919","name":"Qualification opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of phase-II dose-finding studies under model uncertainty","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-02-10T10:20:00Z","last_updated_date":"2014-02-10T10:20:00Z","reference_number":"EMA/CHMP/SAWP/757052/2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-mcp-mod-efficient-statistical-methodology-model-based-design-and-analysis-phase-ii-dose-finding-studies-under-model-uncertainty_en.pdf"},
    {"id":"10033","name":"Guidance on format of the risk-management plan in the European Union part IV: Plans for post-authorisation efficacy studies","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2012-11-08T18:00:00Z","reference_number":"EMA/712370/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-iv-plans-post-authorisation-efficacy-studies_en.pdf"},
    {"id":"10199","name":"Qualification opinion ILSI / HESI submission of novel renal biomarkers for toxicity","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-11-26T01:00:00Z","last_updated_date":"2010-11-26T01:00:00Z","reference_number":"EMA/CHMP/SAWP/283298/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-ilsi-hesi-submission-novel-renal-biomarkers-toxicity_en.pdf"},
    {"id":"10456","name":"Overview of comments received on the draft guideline on the use of statistical signal-detection methods in the EudraVigilance data-analysis system","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:09:21Z","last_updated_date":"2017-02-07T15:41:00Z","reference_number":"EMEA/252216/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-draft-guideline-use-statistical-signal-detection-methods-eudravigilance-data-analysis-system_en.pdf"},
    {"id":"10512","name":"European Medicines Agency regulatory tools for early access to medicines","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-07-27T17:00:00Z","last_updated_date":"2015-07-27T17:00:00Z","reference_number":"EMA/480969/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-regulatory-tools-early-access-medicines_en.pdf"},
    {"id":"10557","name":"EMEA implementation of electronic-only submission and eCTD submission: Practical guidelines relating to non-eCTD electronic submissions","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2008-12-01T01:00:00Z","reference_number":"EMEA/633919/2008 v1.0","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/emea-implementation-electronic-only-submission-and-ectd-submission-practical-guidelines-relating-non-ectd-electronic-submissions_en.pdf"},
    {"id":"10580","name":"Guideline on requirements for Vaccine Antigen Mater File (VAMF) certification","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-02-26T01:00:00Z","last_updated_date":"2004-02-26T01:00:00Z","reference_number":"EMEA/CPMP/4548/03/Final","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-requirements-vaccine-antigen-mater-file-vamf-certification_en.pdf"},
    {"id":"10611","name":"European Medicines Agency procedural advice for users of the centralised procedure for generic / hybrid applications","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-07-02T02:00:00Z","last_updated_date":"2024-12-17T14:06:00Z","reference_number":"EMEA/CHMP/225411/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-users-centralised-procedure-generic-hybrid-applications_en.pdf"},
    {"id":"10770","name":"EudraVigilance - EVWEB user manual","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2026-02-24T16:41:00Z","reference_number":"EMA/501718/2018 Version 1.11","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-evweb-user-manual_en.pdf"},
    {"id":"11234","name":"Guideline on clinical investigation of medicinal products for the treatment of venous thromboembolic disease","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-03-23T01:00:00Z","last_updated_date":"2016-03-23T01:00:00Z","reference_number":"EMA/CHMP/41230/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-clinical-investigation-medicinal-products-treatment-venous-thromboembolic-disease_en.pdf"},
    {"id":"11283","name":"Guidance on format of the risk-management plan in the European Union part II: Module SVIII - Summary of the safety concerns","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2013-08-21T02:00:00Z","reference_number":"EMA/465928/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-sviii-summary-safety-concerns_en.doc"},
    {"id":"11354","name":"Draft qualification opinion on Cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2018-06-29 - 2018-08-21","first_published_date":"2018-06-29T15:00:00Z","last_updated_date":"2018-06-29T15:00:00Z","reference_number":"EMA/CHMP/SAWP/423488/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-cellular-therapy-module-european-society-blood-marrow-transplantation-ebmt-registry_en.pdf"},
    {"id":"11356","name":"ICH guideline S10 on photosafety evaluation of pharmaceuticals - Step 5","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-01-31T18:30:00Z","last_updated_date":"2014-07-14T13:50:00Z","reference_number":"EMA/CHMP/ICH/752211/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-s10-photosafety-evaluation-pharmaceuticals-step-5_en.pdf"},
    {"id":"11412","name":"Initial notices for parallel distribution - 2008","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-06-18T02:00:00Z","last_updated_date":"2009-06-18T02:00:00Z","reference_number":"EMEA/383030/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-2008_en.pdf"},
    {"id":"11437","name":"Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products - Revision 1","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-05-13T12:30:00Z","last_updated_date":"2013-05-13T12:30:00Z","reference_number":"EMA/HMPC/71049/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products-revision-1_en.pdf"},
    {"id":"11578","name":"Reflection paper on the replacement of cell lines used for the production of immunological veterinary medicinal products (IVMPs)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2014-12-19 - 2015-03-31","first_published_date":"2014-12-19T15:45:00Z","last_updated_date":"2014-12-19T15:45:00Z","reference_number":"EMA/CVMP/IWP/37620/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-replacement-cell-lines-used-production-immunological-veterinary-medicinal-products-ivmps_en.pdf"},
    {"id":"11648","name":"Questions and answers on Article 13 referral procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-07-06T18:00:00Z","last_updated_date":"2016-07-06T18:00:00Z","reference_number":"EMA/265223/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-13-referral-procedures_en.pdf"},
    {"id":"11717","name":"EMEA implementation of electronic-only submissions and eCTD submissions in the centralised procedure: Statement of intent","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-01-22T01:00:00Z","last_updated_date":"2008-01-22T01:00:00Z","reference_number":"EMEA/563366/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/emea-implementation-electronic-only-submissions-and-ectd-submissions-centralised-procedure-statement-intent_en.pdf"},
    {"id":"11780","name":"Qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for positron-emission-tomography amyloid imaging (positive / negative) as a biomarker for enrichment, for use in regulatory clinical trials in...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-04-04T17:00:00Z","last_updated_date":"2012-04-04T17:00:00Z","reference_number":"EMA/CHMP/SAWP/892998/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-alzheimers-disease-novel-methodologies-biomarkers-positron-emission-tomography-amyloid-imaging-positive-negative-biomarker-enrichment-use-regulatory-clinical-trials_en.pdf"},
    {"id":"11820","name":"Initial notices for parallel distribution – April 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-05-19T17:00:00Z","last_updated_date":"2014-05-19T17:00:00Z","reference_number":"EMA/270666/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-april-2014_en.pdf"}    {"id":"11937","name":"Pre-accession product information linguistic review process (PALC III)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2011-01-31T01:00:00Z","last_updated_date":"2011-08-16T02:00:00Z","reference_number":"EMA/48630/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pre-accession-product-information-linguistic-review-process-palc-iii_en.pdf"},
    {"id":"12135","name":"Overview of comments received on draft guideline on procedural aspects and dossier requirements for the consultation to the emea by a notified body on an ancillary medicinal substance used in a medical device","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-01-21T01:00:00Z","last_updated_date":"2008-01-21T01:00:00Z","reference_number":"EMEA/CHMP/440251/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-draft-guideline-procedural-aspects-dossier-requirements-consultation-emea-notified-body-ancillary-medicinal-substance-used-medical-device_en.pdf"},
    {"id":"12275","name":"Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under document number C(2002) 1344)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-05-15T02:09:21Z","last_updated_date":"2002-05-15T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/commission-decision-7-may-2002-common-technical-specifications-vitro-diagnostic-medical-devices-notified-under-document-number-c2002-1344_en.pdf"},
    {"id":"12404","name":"Practical considerations on the impact of the new pharmaceutical legislation on marketing authorisation applications via the centralised procedure and centrally authorised products for human use","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-05-03T02:00:00Z","last_updated_date":"2006-05-03T02:00:00Z","reference_number":"EMEA/243280/2005 – Rev 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/practical-considerations-impact-new-pharmaceutical-legislation-marketing-authorisation-applications-centralised-procedure-and-centrally-authorised-products-human-use_en.pdf"},
    {"id":"12465","name":"Commission Directive 2005/61/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and ...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-03-29T02:09:21Z","last_updated_date":"2004-03-29T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/commission-directive-200561ec-30-september-2005-implementing-directive-200298ec-european-parliament-and-council-regards-traceability-requirements-and-notification-serious-adverse-reactions-and_en.pdf"},
    {"id":"12511","name":"Guideline on good pharmacovigilance practices (GVP) - Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev. 2)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T14:00:00Z","last_updated_date":"2017-08-02T12:00:00Z","reference_number":"EMA/873138/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf"},
    {"id":"12556","name":"Non-current Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) low level terms (LLT) and codes","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-07-19T02:00:00Z","last_updated_date":"2025-06-27T11:52:00Z","reference_number":"EMA/CVMP/PhVWP/360871/2010 Rev.9","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/non-current-veterinary-dictionary-drug-regulatory-activities-veddra-low-level-terms-llt-codes_en.xlsx"},
    {"id":"12595","name":"Guidelines on good pharmacovigilance practices (GVP) - Introductory cover note, last updated with draft revision 2 of module V on risk management system for public consultation.","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-02-29T13:00:00Z","last_updated_date":"2016-02-29T13:00:00Z","reference_number":"EMA/136477/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-draft-revision-2-module-v-risk-management-system-public-consultation_en.pdf"},
    {"id":"12605","name":"Guidance for the provision of data (excluding paediatric data)\n\nnot yet submitted to the EMEA","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-09-13T02:00:00Z","last_updated_date":"2005-09-13T02:00:00Z","reference_number":"EMEA/52890/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-provision-data-excluding-paediatric-data-not-yet-submitted-emea_en.pdf"},
    {"id":"12792","name":"Questions and answers on the procedure of paediatric-investigation-plan compliance verification at the European Medicines Agency, and paediatric rewards","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-03-08T01:00:00Z","last_updated_date":"2015-01-21T16:15:00Z","reference_number":"EMA/PDCO/179892/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-procedure-paediatric-investigation-plan-compliance-verification-european-medicines-agency-and-paediatric-rewards_en.pdf"},
    {"id":"12869","name":"EudraVigilance user manual -  Individual case safety report form - Version 1.1","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2018-01-22T16:00:00Z","reference_number":"EMA/249220/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-user-manual-individual-case-safety-report-form-version-11_en.pdf"},
    {"id":"12874","name":"European Union recommendations for the influenza-vaccine composition for the season 2004 / 2005","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-21T02:09:21Z","last_updated_date":"2004-07-21T02:09:21Z","reference_number":"EMEA/BWP/1104/04","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-union-recommendations-influenza-vaccine-composition-season-2004-2005_en.pdf"},
    {"id":"13232","name":"Reflection paper on the development of the European medicines web portal","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:30:00Z","last_updated_date":"2016-10-11T17:30:00Z","reference_number":"EMA/585981/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-development-european-medicines-web-portal_en.pdf"},
    {"id":"13274","name":"Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials (superseded)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-08-12T02:00:00Z","last_updated_date":"2010-08-12T02:00:00Z","reference_number":"EMA/INS/GCP/454280/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-expectations-electronic-source-data-and-data-transcribed-electronic-data-collection-tools-clinical-trials-superseded_en.pdf"},
    {"id":"13313","name":"Guidance document on voting in the framework of discussion and adoption of CHMP opinions","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-06-01T02:00:00Z","last_updated_date":"2023-07-26T11:24:00Z","reference_number":"CPMP/3137/01 Rev 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-document-voting-framework-discussion-and-adoption-chmp-opinions_en.pdf"},
    {"id":"13371","name":"Questions and answers on urgent Union procedures (Article 107i of Directive 2001/83/EC)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-12-19T09:45:00Z","last_updated_date":"2019-02-04T14:00:00Z","reference_number":"EMA/720443/2012 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-urgent-union-procedures-article-107i-directive-200183ec_en.pdf"},
    {"id":"13533","name":"Procedure for notifications of parallel distribution of centrally authorised medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2003-04-01T02:00:00Z","last_updated_date":"2003-04-01T02:00:00Z","reference_number":"EMEA-H-30313-98 - Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-notifications-parallel-distribution-centrally-authorised-medicinal-products_en.pdf"},
    {"id":"13549","name":"Procedural advice for orphan medicinal product designation: Guidance for sponsors","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-06-22T19:00:00Z","last_updated_date":"2026-04-16T16:06:00Z","reference_number":"EMA/420706/2018 Rev.19","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-orphan-medicinal-product-designation-guidance-sponsors_en.pdf"},
    {"id":"13717","name":"Final European Union recommendations for the influenza-vaccine composition for the season 2002 / 2003","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-03-21T00:09:21Z","last_updated_date":"2002-03-21T00:09:21Z","reference_number":"CPMP/BWP/852/02","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/final-european-union-recommendations-influenza-vaccine-composition-season-2002-2003_en.pdf"},
    {"id":"13752","name":"Report of the CHMP working group on benefit-risk assessment models and methods","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-01-19T00:09:21Z","last_updated_date":"2007-01-19T00:09:21Z","reference_number":"EMEA/CHMP/15404/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/report-chmp-working-group-benefit-risk-assessment-models-and-methods_en.pdf"},
    {"id":"13805","name":"Procedure for reporting of pharmacovigilance inspections requested by the CVMP","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2014-12-17T16:05:00Z","reference_number":"EMEA/INS/PhV/226163/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-reporting-pharmacovigilance-inspections-requested-cvmp_en.pdf"},
    {"id":"13942","name":"Questions and answers on Article 35 veterinary referral procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T18:00:00Z","last_updated_date":"2023-12-14T11:47:00Z","reference_number":"EMA/503277/2017 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-35-veterinary-referral-procedures_en.pdf"},
    {"id":"14032","name":"EudraVigilance technical support plan for national competent authorities in the EEA","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2017-09-22T16:22:00Z","reference_number":"EMA/288788/2017 v 1.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-technical-support-plan-national-competent-authorities-eea_en.pdf"},
    {"id":"14254","name":"Qualification opinion of low hippocampal volume (atrophy) by magnetic-resonance imaging for use in clinical trials for regulatory purpose in predementia stage of Alzheimer’s disease","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-12-09T11:44:00Z","last_updated_date":"2011-12-09T11:44:00Z","reference_number":"EMA/CHMP/SAWP/809208/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-low-hippocampal-volume-atrophy-magnetic-resonance-imaging-use-clinical-trials-regulatory-purpose-predementia-stage-alzheimers-disease_en.pdf"},
    {"id":"14317","name":"Initial notices for parallel distribution - May 2015","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-06-18T13:00:00Z","last_updated_date":"2015-06-18T13:00:00Z","reference_number":"EMA/392545/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-may-2015_en.pdf"},
    {"id":"14367","name":"European Union recommendation for the seasonal-influenza-vaccine composition for the season 2008 / 2009","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-03-19T00:09:21Z","last_updated_date":"2008-03-19T00:09:21Z","reference_number":"EMEA/CHMP/BWP/133836/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-union-recommendation-seasonal-influenza-vaccine-composition-season-2008-2009_en.pdf"},
    {"id":"14695","name":"QRD guidance on the use of adopted abbreviations and pictograms on the packaging of veterinary medicinal products authorised via the centralised (CP), mutual recognition (MRP), decentralised (DCP), subsequent recognition (SRP) and national procedures","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-11-25T11:00:00Z","last_updated_date":"2025-07-01T15:50:00Z","reference_number":"EMA/776723/2017 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qrd-guidance-use-adopted-abbreviations-pictograms-packaging-veterinary-medicinal-products-authorised-centralised-cp-mutual-recognition-mrp-decentralised-dcp-subsequent-recognition-srp-national_en.pdf"},
    {"id":"14735","name":"European Union recommendations for the influenza-vaccine composition for the season 2006 / 2007","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-05-29T02:09:21Z","last_updated_date":"2006-05-29T02:09:21Z","reference_number":"EMEA/CHMP/BWP/123643/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-union-recommendations-influenza-vaccine-composition-season-2006-2007_en.pdf"},
    {"id":"14999","name":"Draft EMEA policy on the practical operation of access to EMEA documents","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T00:00:00Z","last_updated_date":"2008-12-18T00:00:00Z","reference_number":"EMEA/110196/2006/Final","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-emea-policy-practical-operation-access-emea-documents_en.pdf"},
    {"id":"15198","name":"Overview of comments received on draft guideline on compassionate use of medicinal products, pursuant to Article 83 of Regulation (EC) No 726/2004","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-07-23T02:00:00Z","last_updated_date":"2007-07-23T02:00:00Z","reference_number":"EMEA/333892/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-draft-guideline-compassionate-use-medicinal-products-pursuant-article-83-regulation-ec-no-7262004_en.pdf"},
    {"id":"15234","name":"Guidance on the format of the risk management plan (RMP) in the EU - in integrated format (Rev. 2.0.1)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-30T17:00:00Z","last_updated_date":"2018-11-30T17:15:00Z","reference_number":"EMA/164014/2018 Rev. 2.0.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-rmp-eu-integrated-format-rev-201_en.pdf"},
    {"id":"15273","name":"Guidance on format of the risk-management plan in the European Union (EU) part II: Module SVI - Additional EU requirements for the safety specification","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2012-11-14T01:00:00Z","reference_number":"EMA/714655/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-eu-part-ii-module-svi-additional-eu-requirements-safety-specification_en.doc"},
    {"id":"15347","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline E2C (R2) on periodic benefit-risk evaluation report - Step 5","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-12-31T01:00:00Z","last_updated_date":"2012-12-31T01:00:00Z","reference_number":"EMA/CHMP/ICH/544553/1998","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-guideline-e2c-r2-periodic-benefit-risk-evaluation-report-step-5_en.pdf"},
    {"id":"15478","name":"Initial notices for parallel distribution – July 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-08-11T16:55:00Z","last_updated_date":"2014-09-09T18:45:00Z","reference_number":"EMA/485269/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-july-2014_en.pdf"},
    {"id":"15502","name":"Annex V to procedure for conducting GCP inspections requested by the EMEA: Phase I units","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-23T02:00:00Z","last_updated_date":"2023-09-22T17:31:00Z","reference_number":"EMA/INS/GCP/416131/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/annex-v-procedure-conducting-gcp-inspections-requested-emea-phase-i-units_en.pdf"},
    {"id":"15530","name":"Committee for Advanced Therapies (CAT) rules of procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-03-13T01:00:00Z","last_updated_date":"2026-06-16T10:00:00Z","reference_number":"EMA/CAT/454446/2008 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/committee-advanced-therapies-cat-rules-procedure_en.pdf"},
    {"id":"15557","name":"Status of MRL procedures - MRL assessments in the context of Council Regulation (EEC) No 2377/90","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2009-07-16T02:00:00Z","reference_number":"EMEA/CVMP/765/99-Rev.23","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/status-mrl-procedures-mrl-assessments-context-council-regulation-eec-no-237790_en.pdf"},
    {"id":"15667","name":"Draft procedure on the publication of HMPC public statements when Community herbal monographs on herbal substances, preparations and/or combinations thereof are not established","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2011-02-15 - 2011-05-15","first_published_date":"2011-02-16T02:00:00Z","last_updated_date":"2011-02-16T02:00:00Z","reference_number":"EMA/HMPC/84530/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-procedure-publication-hmpc-public-statements-when-community-herbal-monographs-herbal-substances-preparations-and-or-combinations-thereof-are-not-established_en.pdf"},
    {"id":"15733","name":"Qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for BMS-708163","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2011-02-10 - 2011-03-25","first_published_date":"2011-02-10T02:00:00Z","last_updated_date":"2011-02-10T02:00:00Z","reference_number":"EMA/CHMP/SAWP/102001/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-alzheimers-disease-novel-methodologies-biomarkers-bms-708163_en.pdf"},
    {"id":"15808","name":"Overview of comments received on draft guidance document on qualification of biomarkers","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/380215/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-draft-guidance-document-qualification-biomarkers_en.pdf"},
    {"id":"15990","name":"EudraVigilance registration manual","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-07-26T11:00:00Z","last_updated_date":"2025-05-23T15:02:00Z","reference_number":"EMA/13454/2020 Rev.16","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-registration-manual_en.pdf"},
    {"id":"15998","name":"Procedure on the publication of Committee on Herbal Medicinal Products public statements when Community herbal monographs on herbal substances, preparations and/or combinations thereof are not established","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-07-20T02:00:00Z","last_updated_date":"2014-02-13T11:20:00Z","reference_number":"EMA/HMPC/84530/2010 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-publication-committee-herbal-medicinal-products-public-statements-when-community-herbal-monographs-herbal-substances-preparations-andor-combinations-thereof-are-not-established_en.pdf"},
    {"id":"16044","name":"Draft ICH guideline E2C (R2): Periodic benefit-risk evaluation report (PBRER)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2012-04-16 - 2012-05-21","first_published_date":"2012-04-16T21:38:33Z","last_updated_date":"2012-04-16T21:38:33Z","reference_number":"EMA/CHMP/ICH/544553/1998","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-ich-guideline-e2c-r2-periodic-benefit-risk-evaluation-report-pbrer_en.pdf"},
    {"id":"16474","name":"Names of the European Union / European Economic Area countries","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-07-23T02:09:00Z","last_updated_date":"2026-03-25T11:42:00Z","reference_number":"EMA/123695/2004 Rev.14","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/names-european-union-european-economic-area-countries_en.pdf"},
    {"id":"16486","name":"Guideline on aspects of the application of Article 8(2) of Regulation (EC) No 141/2000: Review of the period of market exclusivity of orphan medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-09-17T02:00:00Z","last_updated_date":"2008-09-17T02:00:00Z","reference_number":"C(2008) 4051 final","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-aspects-application-article-82-regulation-ec-no-1412000-review-period-market-exclusivity-orphan-medicinal-products_en.pdf"},
    {"id":"16496","name":"Draft guideline on the summary of product characteristics (SPC) for veterinary medicinal products containing antimicrobial substances - Revision 1","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2018-04-30 - 2019-08-31","first_published_date":"2018-04-30T15:33:00Z","last_updated_date":"2018-09-21T20:00:00Z","reference_number":"EMA/CVMP/383441/2005-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-summary-product-characteristics-spc-veterinary-medicinal-products-containing-antimicrobial-substances-revision-1_en.pdf"},
    {"id":"16533","name":"The linguistic review process of product information in the centralised procedure - Human","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-10-15T02:00:00Z","last_updated_date":"2025-02-10T09:30:00Z","reference_number":"EMEA/5542/02 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/linguistic-review-process-product-information-centralised-procedure-human_en.pdf"},
    {"id":"16544","name":"Draft qualification opinion of qualification of exacerbations of chronic pulmonary disease tool (EXACT), and EXACT-respiratory symptoms measure (E-RS) for evaluating treatment outcomes in clinical trials in chronic pulmo...","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-13 - 2015-05-25","first_published_date":"2015-04-13T14:40:00Z","last_updated_date":"2015-04-13T14:40:00Z","reference_number":"EMA/CHMP/SAWP/178465/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-qualification-exacerbations-chronic-pulmonary-disease-tool-exact-and-exact-respiratory-symptoms-measure-e-rs-evaluating-treatment-outcomes-clinical-trials-chronic-pulmo_en.pdf"},
    {"id":"16642","name":"EMEA implementation of electronic-only submissions and mandatory eCTD submissions in the centralised procedure: Statement of intent","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2008-12-01T01:00:00Z","reference_number":"EMEA/572459/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/emea-implementation-electronic-only-submissions-and-mandatory-ectd-submissions-centralised-procedure-statement-intent_en.pdf"},
    {"id":"16776","name":"Guideline on legal status for the supply to the patient of centrally authorised medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-26T02:00:00Z","last_updated_date":"2006-07-26T02:00:00Z","reference_number":"EMEA/186279/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-legal-status-supply-patient-centrally-authorised-medicinal-products_en.pdf"},
    {"id":"16799","name":"COMMISSION DIRECTIVE 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2003-06-27T02:00:00Z","last_updated_date":"2003-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/commission-directive-200363ec-25-june-2003-amending-directive-200183ec-european-parliament-and-council-community-code-relating-medicinal-products-human-use_en.pdf"},
    {"id":"16818","name":"Conduct of Pharmacovigilance for centrally authorised products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-04-15T02:00:00Z","last_updated_date":"1997-04-15T02:00:00Z","reference_number":"CPMP/183/97","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/conduct-pharmacovigilance-centrally-authorised-products_en.pdf"},
    {"id":"16821","name":"Qualification opinion on plasma fibrinogen as a prognostic biomarker (drug development tool) for all-cause mortality and COPD exacerbations in COPD subjects","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-05-02T16:00:00Z","last_updated_date":"2018-05-02T16:00:00Z","reference_number":"EMA/CHMP/SAWP/264260/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-plasma-fibrinogen-prognostic-biomarker-drug-development-tool-all-cause-mortality-and-copd-exacerbations-copd-subjects_en.pdf"},
    {"id":"16976","name":"Guideline on the conduct of pharmacovigilance for vaccines for pre- and post-exposure prophylaxis against infectious diseases","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-07-22T02:09:21Z","last_updated_date":"2009-07-22T02:09:21Z","reference_number":"EMEA/CHMP/PhVWP/503449/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-conduct-pharmacovigilance-vaccines-pre-and-post-exposure-prophylaxis-against-infectious-diseases_en.pdf"},
    {"id":"16979","name":"Handling by the CPMP of safety concerns for pre- and post-authorisation applications submitted in accordance with the centralised procedure","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-04-05T02:00:00Z","last_updated_date":"2004-04-05T02:00:00Z","reference_number":"EMEA/CPMP/4285/04/Final","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/handling-cpmp-safety-concerns-pre-and-post-authorisation-applications-submitted-accordance-centralised-procedure_en.pdf"},
    {"id":"17126","name":"EU Individual Case Safety Report (ICSR) implementation guide business rules spreadsheets","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-07-11T14:15:00Z","last_updated_date":"2024-08-29T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-individual-case-safety-report-icsr-implementation-guide-business-rules-spreadsheets_en.zip"},
    {"id":"17200","name":"Guideline on the documentation to be submitted for inclusion into the 'community list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products'","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2007-07-05T02:09:21Z","reference_number":"EMEA/HMPC/107399/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-documentation-be-submitted-inclusion-community-list-herbal-substances-preparations-and-combinations-thereof-use-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"17210","name":"D80 assessment report - Clinical guidance rev.10.16","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-05-25T12:30:00Z","last_updated_date":"2016-11-08T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/d80-assessment-report-clinical-guidance-rev1016_en.pdf"},
    {"id":"17252","name":"Guidance on format of the risk-management plan in the European Union part III: Pharmacovigilance plan","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2012-11-14T01:00:00Z","reference_number":"EMA/714913/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-iii-pharmacovigilance-plan_en.doc"},
    {"id":"17282","name":"Procedural advice on appeal procedure for orphan-medicinal-product designation or review of orphan-designation criteria at the time of marketing authorisation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-05-04T02:00:00Z","last_updated_date":"2020-12-16T14:00:00Z","reference_number":"EMEA/2677/01 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-appeal-procedure-orphan-medicinal-product-designation-or-review-orphan-designation-criteria-time-marketing-authorisation_en.pdf"},
    {"id":"17401","name":"Points to be considered by applicants to the Horizon 2020 topic: New therapies for rare diseases","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T17:50:00Z","last_updated_date":"2016-04-04T17:50:00Z","reference_number":"EMA/819701/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/points-be-considered-applicants-horizon-2020-topic-new-therapies-rare-diseases_en.pdf"},
    {"id":"17615","name":"Draft rules of procedures on the organisation and conduct of public hearings at the Pharmacovigilance Risk Assessment Committee (PRAC)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2014-07-24 - 2014-10-15","first_published_date":"2014-07-24T18:15:00Z","last_updated_date":"2014-07-24T18:15:00Z","reference_number":"EMA/624809/2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-rules-procedures-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac_en.pdf"},
    {"id":"17620","name":"Guideline on procedures for the granting of a marketing authorisation under exceptional circumstances, pursuant to article 14 (8) of Regulation (EC) No 726/2004","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-12-15T01:00:00Z","last_updated_date":"2005-12-15T01:00:00Z","reference_number":"EMEA/357981/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-procedures-granting-marketing-authorisation-under-exceptional-circumstances-pursuant-article-14-8-regulation-ec-no-7262004_en.pdf"},
    {"id":"17868","name":"INS-GCP-3 procedure for conducting GCP inspections requested by the EMEA","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2007-09-20T02:00:00Z","reference_number":"EMEA/INS/GCP/197223/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ins-gcp-3-procedure-conducting-gcp-inspections-requested-emea_en.pdf"},
    {"id":"17878","name":"Draft reflection paper on a proposal to enhance early dialogue to facilitate accelerated assessment of priority medicines (PRIME)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-10-26 - 2015-12-23","first_published_date":"2015-10-26T12:30:00Z","last_updated_date":"2015-10-26T12:30:00Z","reference_number":"EMA/CHMP/57760/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-reflection-paper-proposal-enhance-early-dialogue-facilitate-accelerated-assessment-priority-medicines-prime_en.pdf"},
    {"id":"17986","name":"Rules of involvement of members of patients' and/or consumers' and healthcare professionals' organisations in committee related activities","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-02-13T00:09:21Z","last_updated_date":"2009-02-13T00:09:21Z","reference_number":"EMEA/483439/2008 rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-involvement-members-patients-andor-consumers-and-healthcare-professionals-organisations-committee-related-activities_en.pdf"},
    {"id":"17994","name":"Draft qualification opinion on plasma fibrinogen as a prognostic biomarker (drug development tool) for all-cause mortality and COPD exacerbations in COPD subjects","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2017-03-30 - 2017-05-03","first_published_date":"2017-03-30T18:30:00Z","last_updated_date":"2017-03-30T18:30:00Z","reference_number":"EMA/474186/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-plasma-fibrinogen-prognostic-biomarker-drug-development-tool-all-cause-mortality-and-copd-exacerbations-copd-subjects_en.pdf"},
    {"id":"18020","name":"Guidance for the template for the qualified person’s declaration concerning good manufacturing practice (GMP) compliance of active substance manufacture “The QP declaration template”","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-06-04T12:10:00Z","last_updated_date":"2014-06-04T12:10:00Z","reference_number":"EMA/196292/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-template-qualified-persons-declaration-concerning-good-manufacturing-practice-gmp-compliance-active-substance-manufacture-qp-declaration-template_en.pdf"},
    {"id":"18063","name":"Pre-submission checklist for annual renewal of conditional marketing authorisation applications","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:00:00Z","last_updated_date":"2016-10-07T17:00:00Z","reference_number":"EMA/198337/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pre-submission-checklist-annual-renewal-conditional-marketing-authorisation-applications_en.pdf"},
    {"id":"18099","name":"D80 assessment report - Overview guidance rev.10.17","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-05-25T12:30:00Z","last_updated_date":"2017-12-05T12:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/d80-assessment-report-overview-guidance-rev1017_en.pdf"},
    {"id":"18232","name":"Procedural advice on the re-examination of CHMP opinions","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-02-12T01:00:00Z","last_updated_date":"2009-02-12T01:00:00Z","reference_number":"EMEA/CHMP/50745/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-re-examination-chmp-opinions_en.pdf"},
    {"id":"18257","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with considerations P.II on biological medicinal products finalised post-public consultation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:00:00Z","last_updated_date":"2016-08-15T12:00:00Z","reference_number":"EMA/529641/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-considerations-pii-biological-medicinal-products-finalised-post-public-consultation_en.pdf"},
    {"id":"18360","name":"Draft reflection paper on extrapolation of efficacy and safety in paediatric medicine development - First version","type":"regulatory-procedural-guideline","status":"Draft","consultation_date":"","first_published_date":"2016-04-04T18:00:00Z","last_updated_date":"2016-04-04T18:00:00Z","reference_number":"EMA/199678/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-reflection-paper-extrapolation-efficacy-and-safety-paediatric-medicine-development-first-version_en.pdf"},
    {"id":"18366","name":"EudraVigilance auditable requirement project: EudraVigilance training plan - Version 5","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-04-08T16:00:00Z","last_updated_date":"2017-11-22T10:30:00Z","reference_number":"EMA/835422/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-auditable-requirement-project-eudravigilance-training-plan-version-5_en.pdf"},
    {"id":"18381","name":"Qualification opinion on Proactive in chronic obstructive pulmonary disease (COPD)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-04-19T13:58:00Z","last_updated_date":"2018-04-19T13:58:00Z","reference_number":"EMA/CHMP/SAWP/226829/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-proactive-chronic-obstructive-pulmonary-disease-copd_en.pdf"},
    {"id":"18399","name":"Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) dataload friendly file including deprecated terms","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2025-09-19T10:23:00Z","reference_number":"EMA/158818/2025 Rev.16 Corr.","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/veterinary-dictionary-drug-regulatory-activities-veddra-dataload-friendly-file-including-deprecated-terms_en.xlsx"},
    {"id":"18418","name":"Guidance to applicants / marketing authorisation holders on oral explanations at CVMP","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T17:00:00Z","last_updated_date":"2017-02-24T17:00:00Z","reference_number":"EMA/CVMP/519444/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-applicants-marketing-authorisation-holders-oral-explanations-cvmp_en.pdf"},
    {"id":"18494","name":"Biologics Working Party (BWP) Ad-hoc Influenza Working Group: Amended European Union recommendations for the seasonal influenza vaccine composition for the season 2017/2018","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T11:00:00Z","last_updated_date":"2017-04-12T12:00:00Z","reference_number":"EMA/CHMP/BWP/216216/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/biologics-working-party-bwp-ad-hoc-influenza-working-group-amended-european-union-recommendations-seasonal-influenza-vaccine-composition-season-20172018_en.pdf"},
    {"id":"18593","name":"Draft qualification opinion of a novel data-driven model of disease progression and trial evaluation in mild and moderate Alzheimer’s disease","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2013-07-19 - 2013-08-27","first_published_date":"2013-07-19T16:00:00Z","last_updated_date":"2013-07-19T16:00:00Z","reference_number":"EMA/CHMP/SAWP/420174/2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-novel-data-driven-model-disease-progression-and-trial-evaluation-mild-and-moderate-alzheimers-disease_en.pdf"},
    {"id":"18842","name":"Final European Union recommendation for influenza-vaccine composition for the season 2003 / 2004","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-03-19T00:09:21Z","last_updated_date":"2002-03-19T00:09:21Z","reference_number":"CPMP/BWP/6011/03","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/final-european-union-recommendation-influenza-vaccine-composition-season-2003-2004_en.pdf"},
    {"id":"19084","name":"Quality Review of Documents (QRD) convention to be followed for the European Medicines Agency QRD templates","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-06-01T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/62470/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/quality-review-documents-qrd-convention-be-followed-european-medicines-agency-qrd-templates_en.pdf"},
    {"id":"19139","name":"Draft European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Vision and Strategy 2016-2020","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2016-04-07 - 2016-06-30","first_published_date":"2016-04-07T19:30:00Z","last_updated_date":"2016-04-07T19:30:00Z","reference_number":"EMA/326299/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-european-surveillance-veterinary-antimicrobial-consumption-esvac-vision-and-strategy-2016-2020_en.pdf"},
    {"id":"19338","name":"Draft Quality Review of Documents recommendations on pack design and labelling for centrally authorised non-prescription human medicinal products","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2011-04-01 - 2011-06-30","first_published_date":"2011-04-02T03:31:00Z","last_updated_date":"2011-04-02T03:31:00Z","reference_number":"EMA/275297/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-quality-review-documents-recommendations-pack-design-and-labelling-centrally-authorised-non-prescription-human-medicinal-products_en.pdf"},
    {"id":"19342","name":"COMP members interaction with sponsors of orphan designation applications","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-07-12T02:00:00Z","last_updated_date":"2020-12-16T17:00:00Z","reference_number":"EMEA/COMP/150409/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/comp-members-interaction-sponsors-orphan-designation-applications_en.pdf"},
    {"id":"19351","name":"EU-RMP Annex I manual - Electronic interface for EudraVigilance (Version 5.1 – October 2013)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-07-07T02:00:00Z","last_updated_date":"2016-07-07T02:00:00Z","reference_number":"Version 5.1 – October 2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-rmp-annex-i-manual-electronic-interface-eudravigilance-version-51-october-2013_en.pdf"},
    {"id":"19524","name":"Quick Response (QR) codes in the labelling and/or package leaflet of veterinary medicinal products authorised via the centralised (CP), mutual recognition (MRP), decentralised procedures (DCP) and national procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T11:12:01Z","last_updated_date":"2023-12-11T16:48:00Z","reference_number":"EMA/364980/2017_rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/quick-response-qr-codes-labelling-and-or-package-leaflet-veterinary-medicinal-products-authorised-centralised-cp-mutual-recognition-mrp-decentralised-procedures-dcp-and-national-procedures_en.pdf"},
    {"id":"19541","name":"Standard acute-myeloid-leukaemia paediatric investigation plan","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2013-02-21 - 2013-05-05","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/288890/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/standard-acute-myeloid-leukaemia-paediatric-investigation-plan_en.pdf"},
    {"id":"19617","name":"Draft qualification opinion on in vitro hollow-fibre-system model of tuberculosis (HFS-TB)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2014-11-18 - 2015-01-09","first_published_date":"2014-11-18T16:00:00Z","last_updated_date":"2014-11-18T16:00:00Z","reference_number":"EMA/CHMP/SAWP/381716/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-vitro-hollow-fibre-system-model-tuberculosis-hfs-tb_en.pdf"},
    {"id":"19652","name":"Procedure for worksharing – Quality variations: Outline of procedure and call for nominations","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-06-27T02:09:21Z","last_updated_date":"2006-06-27T02:09:21Z","reference_number":"EMEA/120457/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-worksharing-quality-variations-outline-procedure-and-call-nominations_en.pdf"},
    {"id":"19709","name":"Draft functional specifications for the European Union portal and European Union database to be audited","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2014-10-10 - 2014-10-31","first_published_date":"2014-10-10T19:40:00Z","last_updated_date":"2014-10-10T19:40:00Z","reference_number":"EMA/42176/2014 corr","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-functional-specifications-european-union-portal-and-european-union-database-be-audited_en.pdf"},
    {"id":"19776","name":"Questions and answers on practical transitional measures for the implementation of the pharmacovigilance legislation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-05-23T20:25:36Z","last_updated_date":"2015-11-06T13:00:00Z","reference_number":"EMA/228816/2012 v.3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-practical-transitional-measures-implementation-pharmacovigilance-legislation_en.pdf"},
    {"id":"19804","name":"Draft qualification opinion on the ingestible sensor system for medication adherence as biomarker for measuring patient adherence to medication in clinical trials","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-09-16 - 2015-10-26","first_published_date":"2015-09-16T17:00:00Z","last_updated_date":"2015-09-16T17:00:00Z","reference_number":"EMA/CHMP/SAWP/513571/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-ingestible-sensor-system-medication-adherence-biomarker-measuring-patient-adherence-medication-clinical-trials_en.pdf"},
    {"id":"19806","name":"Procedural advice to applicants/marketing authorisation holders on re-examination of CVMP opinions (according to Regulation (EC) No 726/2004)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T17:30:00Z","last_updated_date":"2020-09-11T12:03:00Z","reference_number":"EMA/CVMP/321528/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-applicantsmarketing-authorisation-holders-re-examination-cvmp-opinions-according-regulation-ec-no-7262004_en.pdf"},
    {"id":"19873","name":"Annex I to procedure for conducting GCP inspections requested by the CHMP: Investigator site","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T13:26:00Z","last_updated_date":"2022-05-05T13:28:00Z","reference_number":"EMA/INS/GCP/143492/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/annex-i-procedure-conducting-gcp-inspections-requested-chmp-investigator-site_en.pdf"},
    {"id":"19894","name":"Policy on combined Summaries of Product Characteristics (SmPCs)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-06-10T17:00:00Z","last_updated_date":"2015-06-10T17:00:00Z","reference_number":"EMA/333423/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/policy-combined-summaries-product-characteristics-smpcs_en.pdf"},
    {"id":"19931","name":"Guideline on compassionate use of medicinal products, pursuant to Article 83 of Regulation (EC) No 726/2004","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/27170/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-compassionate-use-medicinal-products-pursuant-article-83-regulation-ec-no-7262004_en.pdf"},
    {"id":"19974","name":"Concept paper for a guideline on the conduct of pharmacovigilance for vaccines","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-10-11T02:09:21Z","last_updated_date":"2005-10-11T02:09:21Z","reference_number":"EMEA/CHMP/PhVWP/372004/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/concept-paper-guideline-conduct-pharmacovigilance-vaccines_en.pdf"},
    {"id":"20165","name":"Guidance on format of the risk-management plan in the European Union part VII: Annexes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2012-11-08T18:00:00Z","reference_number":"EMA/716217/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-vii-annexes_en.pdf"},
    {"id":"20171","name":"EudraLex – Volume 9A – Questions and answers on implementation - Version 5.4","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2011-03-29T02:00:00Z","reference_number":"EMA/46003/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudralex-volume-9a-questions-and-answers-implementation-version-54_en.pdf"},
    {"id":"20219","name":"Summary of changes to the ‘External guidance on the implementation of the EMA policy on the publication of clinical data for medicinal products for human use’","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T19:00:00Z","last_updated_date":"2016-12-20T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/summary-changes-external-guidance-implementation-ema-policy-publication-clinical-data-medicinal-products-human-use_en.pdf"}    {"id":"20248","name":"EudraVigilance user manual for marketing authorisation holders","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-11-22T10:30:00Z","last_updated_date":"2021-02-22T14:49:00Z","reference_number":"EMA/167839/2016 Version 2.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-user-manual-marketing-authorisation-holders_en.pdf"},
    {"id":"20249","name":"Procedural advice on appointment and responsibilities of the CVMP rapporteur and co-rapporteur (according to Article 62 (1) of Regulation (EC) No 726/2004)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2019-09-20T11:30:00Z","reference_number":"EMA/CVMP/468877/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-appointment-and-responsibilities-cvmp-rapporteur-and-co-rapporteur-according-article-62-1-regulation-ec-no-7262004_en.pdf"},
    {"id":"20306","name":"Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T17:45:00Z","last_updated_date":"2013-08-02T13:30:00Z","reference_number":"EMA/48663/2013 ","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-and-content-final-study-report-non-interventional-post-authorisation-safety-studies_en.doc"},
    {"id":"20374","name":"Initial notices for parallel distribution – January 2015","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-03-04T11:15:00Z","last_updated_date":"2015-03-04T11:15:00Z","reference_number":"EMA/119264/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-january-2015_en.pdf"},
    {"id":"20406","name":"Overview of comments received on structure of the list of herbal substances, preparations and combinations thereof (EMEA/HMPC/100824/2005)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-10-24T02:09:21Z","last_updated_date":"2005-10-24T02:09:21Z","reference_number":"EMEA/HMPC/309366/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-structure-list-herbal-substances-preparations-and-combinations-thereof-emeahmpc1008242005_en.pdf"},
    {"id":"20430","name":"Day 80 assessment report generics quality guidance rev.10.16","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2016-11-08T12:00:00Z","reference_number":"Rev. 3.16","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/day-80-assessment-report-generics-quality-guidance-rev1016_en.pdf"},
    {"id":"20455","name":"Guideline on good pharmacovigilance practices (GVP) - Module VI Addendum I – Duplicate management of suspected adverse reaction reports","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-28T14:00:00Z","last_updated_date":"2017-08-02T12:00:00Z","reference_number":"EMA/405655/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-addendum-i-duplicate-management-suspected-adverse-reaction-reports_en.pdf"},
    {"id":"20532","name":"HMPC statement on environmental risk assessment of herbal medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-04-28T02:00:00Z","last_updated_date":"2010-04-28T02:00:00Z","reference_number":"EMA/HMPC/121934/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/hmpc-statement-environmental-risk-assessment-herbal-medicinal-products_en.pdf"},
    {"id":"20592","name":"Guidance on format of the risk-management plan in the European Union for generics (Rev. 1)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2013-08-21T18:35:00Z","reference_number":"EMA/465933/2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-generics-rev-1_en.pdf"},
    {"id":"20823","name":"Draft guideline on detection and management of duplicate individual cases and individual case safety reports","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2010-06-29 - 2010-09-29","first_published_date":"2010-06-29T04:00:00Z","last_updated_date":"2010-06-29T04:00:00Z","reference_number":"EMA/13432/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-detection-and-management-duplicate-individual-cases-and-individual-case-safety-reports_en.pdf"},
    {"id":"20836","name":"Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-09-10T02:09:21Z","last_updated_date":"2004-09-10T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/directive-200183ec-european-parliament-and-council-6-november-2001-community-code-relating-medicinal-products-human-use_en.pdf"},
    {"id":"20851","name":"Enhanced early dialogue to facilitate accelerated assessment of PRIority MEdicines (PRIME)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2018-05-07T17:30:00Z","reference_number":"EMA/CHMP/57760/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/enhanced-early-dialogue-facilitate-accelerated-assessment-priority-medicines-prime_en.pdf"},
    {"id":"20902","name":"Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-10-05T02:00:00Z","last_updated_date":"2023-06-27T11:48:00Z","reference_number":"EMA/599977/2012 rev.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-publication-information-withdrawals-applications-related-marketing-authorisation-human-medicinal-products_en.pdf"},
    {"id":"20927","name":"Practical information on translations for referral procedures (human)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-12-19T09:45:00Z","last_updated_date":"2013-11-28T10:19:00Z","reference_number":"EMA/583202/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/practical-information-translations-referral-procedures-human_en.pdf"},
    {"id":"20975","name":"Re-examination procedure of paediatric investigation plan and / or waiver opinions by the PDCO","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-01-29T01:00:00Z","last_updated_date":"2015-01-21T16:15:00Z","reference_number":"EMEA/23604/2008 Re. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/re-examination-procedure-paediatric-investigation-plan-and-or-waiver-opinions-pdco_en.pdf"},
    {"id":"21086","name":"ICH guideline S10 - Guidance on photosafety evaluation of pharmaceuticals - Step 3","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2012-12-17 - 2013-03-01","first_published_date":"2012-12-17T15:55:00Z","last_updated_date":"2012-12-17T15:55:00Z","reference_number":"EMA/CHMP/ICH/752211/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-s10-guidance-photosafety-evaluation-pharmaceuticals-step-3_en.pdf"},
    {"id":"21135","name":"Procedure for conducting pharmacovigilance inspections requested by the CVMP","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/INS/PhV/85058/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-conducting-pharmacovigilance-inspections-requested-cvmp_en.pdf"},
    {"id":"21249","name":"How to use the defective product report to notify a quality defect to European Medicines Agency","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T12:00:00Z","last_updated_date":"2018-05-03T12:00:00Z","reference_number":"EMA/INS/GMP/35037/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/how-use-defective-product-report-notify-quality-defect-european-medicines-agency_en.pdf"},
    {"id":"21384","name":"Guidance on format of the risk-management plan in the European Union part II: Module SIV - Populations not studied in clinical trials","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2013-08-21T18:35:00Z","reference_number":"EMA/465927/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-siv-populations-not-studied-clinical-trials_en.pdf"},
    {"id":"21405","name":"Practical guidance for procedures related to Brexit for medicinal products for human and veterinary use within the framework of the centralised procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-11-28T11:00:00Z","last_updated_date":"2020-03-19T14:30:00Z","reference_number":"EMA/478309/2017 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/practical-guidance-procedures-related-brexit-medicinal-products-human-and-veterinary-use-within-framework-centralised-procedure_en.pdf"},
    {"id":"21485","name":"European Medicines Agency procedural advice for users of the centralised procedure for generic / hybrid applications (tracked changes)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-03-09T16:25:00Z","last_updated_date":"2024-12-17T14:06:00Z","reference_number":"EMEA/CHMP/225411/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-users-centralised-procedure-generic-hybrid-applications-tracked-changes_en.pdf"},
    {"id":"21533","name":"Annex VI to procedure for conducting GCP inspections requested by the CHMP: Record keeping and archiving of documents","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2022-05-05T13:30:00Z","reference_number":"EMA/INS/GCP/183077/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/annex-vi-procedure-conducting-gcp-inspections-requested-chmp-record-keeping-and-archiving-documents_en.pdf"},
    {"id":"21617","name":"Overview of comments on 'Draft qualification opinion on plasma fibrinogen as a prognostic biomarker (drug development tool) for all-cause mortality and COPD exacerbations in COPD subjects'","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-05-02T16:00:00Z","last_updated_date":"2018-05-02T16:00:00Z","reference_number":"EMA/264099/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-draft-qualification-opinion-plasma-fibrinogen-prognostic-biomarker-drug-development-tool-all-cause-mortality-and-copd-exacerbations-copd-subjects_en.pdf"},
    {"id":"21701","name":"Overview of comments received on draft revision 2 of the SmPC guideline - Proposal for a revision of the European Commission guideline on summary of product characteristics","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-10-22T02:09:21Z","last_updated_date":"2009-10-22T02:09:21Z","reference_number":"EMEA/CHMP/663087/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-draft-revision-2-smpc-guideline-proposal-revision-european-commission-guideline-summary-product-characteristics_en.pdf"},
    {"id":"21854","name":"European Union recommendations for the influenza-vaccine composition for the season 2005 / 2006","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-03-30T02:09:21Z","last_updated_date":"2005-03-30T02:09:21Z","reference_number":"EMEA/BWP/111233/05","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-union-recommendations-influenza-vaccine-composition-season-2005-2006_en.pdf"},
    {"id":"21897","name":"Involvement of SAGAM in the evaluation of applications for centralised\n\nmarketing authorisations containing antimicrobial substances","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-02-01T01:00:00Z","last_updated_date":"2005-02-01T01:00:00Z","reference_number":"EMEA/CVMP/1136/04","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/involvement-sagam-evaluation-applications-centralised-marketing-authorisations-containing-antimicrobial-substances_en.pdf"},
    {"id":"22013","name":"Procedural advice on the provision of scientific recommendation on classification of advanced therapy medicinal products in accordance with Article 17 of Regulation (EC) No 1394/2007","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-02-23T00:09:00Z","last_updated_date":"2021-11-30T14:55:00Z","reference_number":"EMA/CAT/99623/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-provision-scientific-recommendation-classification-advanced-therapy-medicinal-products-accordance-article-17-regulation-ec-no-13942007_en.pdf"},
    {"id":"22066","name":"Structure of the list of herbal substances, preparations and combinations thereof","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-13T02:00:00Z","last_updated_date":"2006-07-13T02:00:00Z","reference_number":"EMEA/HMPC/100824/2005 Revision 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/structure-list-herbal-substances-preparations-and-combinations-thereof_en.pdf"},
    {"id":"22232","name":"Annex I variation application(s) content for live attenuated influenza vaccines","type":"regulatory-procedural-guideline","status":"Draft","consultation_date":"2010-12-16 - 2011-03-31","first_published_date":"2010-12-15T02:00:00Z","last_updated_date":"2010-12-15T02:00:00Z","reference_number":"EMA/CHMP/BWP/577998/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/annex-i-variation-applications-content-live-attenuated-influenza-vaccines_en.pdf"},
    {"id":"22245","name":"Reporting requirements of individual case safety reports applicable to marketing-authorisation holders during the interim period","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-05-23T20:04:26Z","last_updated_date":"2015-06-30T14:00:00Z","reference_number":"EMA/321386/2012 Rev. 9","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reporting-requirements-individual-case-safety-reports-applicable-marketing-authorisation-holders-during-interim-period_en.pdf"},
    {"id":"22403","name":"EMEA/CHMP working group with Healthcare Professionals' Organisations (HCP WG) - Draft recommendations and proposals for action","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-06-26T02:09:21Z","last_updated_date":"2008-06-26T02:09:21Z","reference_number":"EMEA/185036/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/emeachmp-working-group-healthcare-professionals-organisations-hcp-wg-draft-recommendations-and-proposals-action_en.pdf"},
    {"id":"22441","name":"Electronic submission of applications for orphan designation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2010-01-25T01:00:00Z","last_updated_date":"2010-01-25T01:00:00Z","reference_number":"EMA/22383/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/electronic-submission-applications-orphan-designation_en.pdf"},
    {"id":"22702","name":"European Union recommendation for the emergent-novel-H1N1-influenza-vaccine composition - Revised to include strain IVR-153","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-06-10T02:09:21Z","last_updated_date":"2009-06-10T02:09:21Z","reference_number":"EMEA/CHMP/BWP/340831/2009/Rev 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-union-recommendation-emergent-novel-h1n1-influenza-vaccine-composition-revised-include-strain-ivr-153_en.pdf"},
    {"id":"22865","name":"Pharmacovigilance Inspection policy for centralised procedures - medicinal products for veterinary use","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-11-27T01:00:00Z","last_updated_date":"2009-11-27T01:00:00Z","reference_number":"EMEA/INS/PhV/384646/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pharmacovigilance-inspection-policy-centralised-procedures-medicinal-products-veterinary-use_en.pdf"},
    {"id":"22959","name":"Draft guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products - Revision 2","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-09 - 2015-07-15","first_published_date":"2015-04-09T20:30:00Z","last_updated_date":"2015-04-09T20:30:00Z","reference_number":"EMA/HMPC/71049/2007 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products-revision-2_en.pdf"},
    {"id":"22977","name":"Initial notices for parallel distribution – February 2015","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-03-16T01:00:00Z","last_updated_date":"2015-03-16T01:00:00Z","reference_number":"EMA/160190/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-february-2015_en.pdf"},
    {"id":"23074","name":"Initial notices for parallel distribution - March 2015","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-04-17T12:00:00Z","last_updated_date":"2015-04-17T12:00:00Z","reference_number":"EMA/245546/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-march-2015_en.pdf"},
    {"id":"23130","name":"Draft guideline on the scientific application and the practical arrangements necessary to implement Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling with...","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-27 - 2015-09-30","first_published_date":"2015-07-27T19:00:00Z","last_updated_date":"2015-07-27T19:00:00Z","reference_number":"EMA/CHMP/509951/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-scientific-application-and-practical-arrangements-necessary-implement-regulation-ec-no-507-2006-conditional-marketing-authorisation-medicinal-products-human-use-falling_en.pdf"},
    {"id":"23184","name":"Overview of comments received on draft guideline on procedures for re-examination of CHMP opinions","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-06-26T02:00:00Z","last_updated_date":"2006-06-26T02:00:00Z","reference_number":"EMEA/CHMP/149558/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-draft-guideline-procedures-re-examination-chmp-opinions_en.pdf"},
    {"id":"23210","name":"Guidance on format of the risk-management plan in the European Union part II: Module SVII - Identified and potential risks","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2012-11-14T01:00:00Z","reference_number":"EMA/714754/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-svii-identified-and-potential-risks_en.doc"},
    {"id":"23212","name":"Procedure for review of information on medicinal products by patients' and consumers' organisations","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-11-24T01:00:00Z","last_updated_date":"2010-05-11T02:00:00Z","reference_number":"EMA/174255/2010 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-review-information-medicinal-products-patients-and-consumers-organisations_en.pdf"},
    {"id":"23292","name":"Procedure for the systematic review of European Union herbal monographs and/or European Union list entries and supporting documents","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"2011-07-12 - 2011-11-15","first_published_date":"2011-07-20T04:00:00Z","last_updated_date":"2015-04-20T13:20:00Z","reference_number":"EMA/HMPC/124695/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-systematic-review-european-union-herbal-monographs-and-or-european-union-list-entries-and-supporting-documents_en.pdf"},
    {"id":"23299","name":"Questions and answers on Article 29(4) referral procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-07-06T18:00:00Z","last_updated_date":"2016-07-06T18:00:00Z","reference_number":"EMA/457269/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-294-referral-procedures_en.pdf"},
    {"id":"23343","name":"Procedural advice on publication of information on negative opinions and refusals of marketing authorisation applications for human medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2013-05-06T19:00:00Z","reference_number":"EMA/599941/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-publication-information-negative-opinions-and-refusals-marketing-authorisation-applications-human-medicinal-products_en.pdf"},
    {"id":"23366","name":"Guidance for applicants seeking scientific support and advice on traditional herbal medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"2011-07-12 - 2011-11-15","first_published_date":"2011-07-20T04:00:00Z","last_updated_date":"2024-12-05T13:20:00Z","reference_number":"EMA/HMPC/127670/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-applicants-seeking-scientific-support-advice-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"23427","name":"Tables of non-standard abbreviations to be used in the summary of product characteristics","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-04-01T02:00:00Z","last_updated_date":"2026-03-25T11:41:00Z","reference_number":"EMA/27236/2003 Rev. 15","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/tables-non-standard-abbreviations-be-used-summary-product-characteristics_en.pdf"},
    {"id":"23495","name":"External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use - Version 1.3","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-09-22T15:00:00Z","last_updated_date":"2017-09-22T15:00:00Z","reference_number":"EMA/90915/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-version-13_en.pdf"},
    {"id":"23513","name":"External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use - Version 1.1","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T19:00:00Z","last_updated_date":"2016-12-20T19:00:00Z","reference_number":"EMA/90915/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-version-11_en.pdf"},
    {"id":"23551","name":"Guidance on format of the risk-management plan in the European Union part I: Product overview","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2012-11-08T18:00:00Z","reference_number":"EMA/709671/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-i-product-overview_en.pdf"},
    {"id":"23816","name":"Guidelines on good pharmacovigilance practices (GVP) - Introductory cover note, last updated with draft revision 2 of module VI on management and reporting of adverse reactions and draft revision 1 of module IX on signal...","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-08-08T17:00:00Z","last_updated_date":"2016-08-08T17:00:00Z","reference_number":"EMA/510998/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-draft-revision-2-module-vi-management-and-reporting-adverse-reactions-and-draft-revision-1-module-ix-signal_en.pdf"},
    {"id":"23852","name":"Guidance on format of the risk-management plan in the European Union part II: Module SV - Postauthorisation experience","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2012-11-14T01:00:00Z","reference_number":"EMA/714415/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-sv-postauthorisation-experience_en.doc"},
    {"id":"23933","name":"Recommended submission dates for veterinary medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2026-02-02T11:30:00Z","reference_number":"EMA/7507/2026","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/recommended-submission-dates-veterinary-medicinal-products_en.pdf"},
    {"id":"23939","name":"Guidelines on good pharmacovigilance practices (GVP) - Introductory cover note, last updated with revision 2 of module VI on ICSRs finalised post-public consultation, its new addendum on duplicate management and the cons...","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-08-02T12:00:00Z","last_updated_date":"2017-08-02T12:00:00Z","reference_number":"EMA/213497/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-revision-2-module-vi-icsrs-finalised-post-public-consultation-its-new-addendum-duplicate-management-and-cons_en.pdf"},
    {"id":"23944","name":"Compilation of quality review of documents (QRD) on stylistic matters in product information","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-02-01T01:00:00Z","last_updated_date":"2024-02-29T16:23:00Z","reference_number":"EMA/25090/2002 Rev. 23","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/compilation-quality-review-documents-qrd-stylistic-matters-product-information_en.pdf"},
    {"id":"23986","name":"Implementation plan for the 'Note for guidance - EudraVigilance Human – Processing of safety messages and individual case safety reports (ICSRs)'","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-11-20T01:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMEA/665231/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/implementation-plan-note-guidance-eudravigilance-human-processing-safety-messages-and-individual-case-safety-reports-icsrs_en.pdf"},
    {"id":"24108","name":"Guidance on the content and the format of data to be collected by the Member States on all existing uses of medicinal products in the paediatric population","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-10-01T02:00:00Z","last_updated_date":"2007-10-01T02:00:00Z","reference_number":"EMEA/575696/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-content-format-data-be-collected-member-states-all-existing-uses-medicinal-products-paediatric-population_en.pdf"},
    {"id":"24110","name":"Checking process of mock-ups and specimens of outer / immediate labelling and package leaflets of human medicinal products in the centralised procedure (highlighted)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-04-05T17:10:00Z","last_updated_date":"2013-04-05T17:10:00Z","reference_number":"EMA/213148/2013/Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/checking-process-mock-ups-and-specimens-outer-immediate-labelling-and-package-leaflets-human-medicinal-products-centralised-procedure-highlighted_en.pdf"},
    {"id":"24199","name":"QRD Appendix IV - Terms and abbreviations for batch number and expiry date to be used on the labelling of human medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-07-01T02:00:00Z","last_updated_date":"2021-12-08T11:00:00Z","reference_number":"EMA/286379/2019 Rev.14","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qrd-appendix-iv-terms-and-abbreviations-batch-number-and-expiry-date-be-used-labelling-human-medicinal-products_en.pdf"},
    {"id":"24201","name":"Revised policy for classification and incentives for veterinary medicinal products indicated for minor use minor species (MUMS) / limited market","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-09-16T11:25:00Z","last_updated_date":"2018-12-14T16:30:00Z","reference_number":"EMA/308411/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/revised-policy-classification-and-incentives-veterinary-medicinal-products-indicated-minor-use-minor-species-mums-limited-market_en.pdf"},
    {"id":"24288","name":"ENCePP resource database - Inventory of patient registries","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-02-26T13:00:00Z","last_updated_date":"2018-02-26T13:00:00Z","reference_number":"EMA/526382/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/encepp-resource-database-inventory-patient-registries_en.pdf"},
    {"id":"24290","name":"European Medicines Agency certificates of medicinal products - instructions on how to fill in the application form","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-30T02:00:00Z","last_updated_date":"2023-01-16T15:20:00Z","reference_number":"EMA/193330/2014 Rev.15","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-certificates-medicinal-products-instructions-how-fill-application-form_en.pdf"},
    {"id":"24458","name":"Draft guideline on the use of statistical signal-detection methods in the EudraVigilance data-analysis system","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-11-16T00:09:21Z","last_updated_date":"2017-02-07T15:40:00Z","reference_number":"EMEA/106464/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-use-statistical-signal-detection-methods-eudravigilance-data-analysis-system_en.pdf"},
    {"id":"24475","name":"Appendix 1 to INS-GCP-4 procedure for reporting of GCP inspections requested by the CHMP: GCP inspection report","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-07-29T14:00:00Z","last_updated_date":"2022-07-13T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/appendix-1-ins-gcp-4-procedure-reporting-gcp-inspections-requested-chmp-gcp-inspection-report_en.pdf"},
    {"id":"24522","name":"List of changes to combined Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) list of clinical terms for reporting suspected adverse events in animal and humans to veterinary medicinal products for 2025","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-07-19T02:00:00Z","last_updated_date":"2025-09-05T10:48:00Z","reference_number":"EMA/CVMP/PhVWP/118833/2025 Rev.2 Corr.","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/list-changes-combined-veterinary-dictionary-drug-regulatory-activities-veddra-list-clinical-terms-reporting-suspected-adverse-events-animal-humans-veterinary-medicinal-products-2025_en.pdf"},
    {"id":"24618","name":"Periodic Safety Update Report (PSUR) repository mandatory use: questions and answers","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-06-10T12:00:00Z","last_updated_date":"2016-06-10T12:00:00Z","reference_number":"EMA/395434/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/periodic-safety-update-report-psur-repository-mandatory-use-questions-and-answers_en.pdf"},
    {"id":"24619","name":"Draft best practice guidance for pilot European Medicines Agency health technology assessment parallel scientific advice procedures","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2014-05-08 - 2014-07-14","first_published_date":"2014-05-08T18:00:00Z","last_updated_date":"2014-05-08T18:00:00Z","reference_number":"EMA/109608/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-best-practice-guidance-pilot-european-medicines-agency-health-technology-assessment-parallel-scientific-advice-procedures_en.pdf"},
    {"id":"24621","name":"Initial notices for parallel distribution - 2007","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:00:00Z","last_updated_date":"2008-06-26T02:00:00Z","reference_number":"EMEA/311899/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-2007_en.pdf"},
    {"id":"24806","name":"Remote pharmacovigilance inspections of MAHs during a crisis situation - Points to consider","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-18T12:00:00Z","last_updated_date":"2020-11-18T17:30:00Z","reference_number":"EMA/509041/2020 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/remote-pharmacovigilance-inspections-mahs-during-crisis-situation-points-consider_en.pdf"},
    {"id":"25017","name":"Day 80 assessment report - Non-clinical and clinical guidance","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-11-28T01:00:00Z","last_updated_date":"2013-03-05T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/day-80-assessment-report-non-clinical-and-clinical-guidance_en.pdf"},
    {"id":"25112","name":"European Medicines Agency post-authorisation procedural advice for users of the centralised procedure: document with tracked changes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-12-09T10:30:00Z","last_updated_date":"2026-03-27T13:00:00Z","reference_number":"EMEA-H-19984/03 Rev. 117","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure-document-tracked-changes_en.pdf"},
    {"id":"25124","name":"Initial notices for parallel distribution – August 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-09-09T18:45:00Z","last_updated_date":"2014-09-09T18:45:00Z","reference_number":"EMA/546994/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-august-2014_en.pdf"},
    {"id":"25143","name":"Union procedure on the management of pharmacovigilance inspection findings which may impact the robustness of the benefit-risk profile of the concerned medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-06-20T12:15:00Z","last_updated_date":"2014-06-20T12:15:00Z","reference_number":"EMA/INS/PhV/192231/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/union-procedure-management-pharmacovigilance-inspection-findings-which-may-impact-robustness-benefit-risk-profile-concerned-medicinal-products_en.pdf"},
    {"id":"25235","name":"User guide on how to generate PDF versions of the product information - human","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-04-21T02:00:00Z","last_updated_date":"2018-05-07T15:12:00Z","reference_number":"EMEA/524020/2007 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/user-guide-how-generate-pdf-versions-product-information-human_en.pdf"},
    {"id":"25333","name":"Procedural guidance to scientific committeesꞌ members and experts on completing the European Medicines Agencyꞌs declaration of interests in the Experts Management Tool","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-11-20T15:00:00Z","last_updated_date":"2026-03-10T10:42:00Z","reference_number":"EMA/627294/2014 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-guidance-scientific-committees-members-experts-completing-european-medicines-agencys-declaration-interests-experts-management-tool_en.pdf"},
    {"id":"25429","name":"EudraVigilance Expert Working Group: Volume 9A implementation questions and answers - Version 1.2","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-02-29T00:09:21Z","last_updated_date":"2008-02-29T00:09:21Z","reference_number":"EMEA/111972/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-expert-working-group-volume-9a-implementation-questions-and-answers-version-12_en.pdf"},
    {"id":"25501","name":"Qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for the use of cerebrospinal-fluid amyloid beta 1-42 and t-tau signature and / or positron-emission-tomography amyloid imaging (positive / neg...","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2011-11-17 - 2011-12-22","first_published_date":"2011-12-02T16:30:00Z","last_updated_date":"2011-12-02T16:30:00Z","reference_number":"EMA/CHMP/SAWP/893622/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-alzheimers-disease-novel-methodologies-biomarkers-use-cerebrospinal-fluid-amyloid-beta-1-42-and-t-tau-signature-and-or-positron-emission-tomography-amyloid-imaging-positive-neg_en.pdf"},
    {"id":"25607","name":"Guideline on the acceptability of names for human medicinal products processed through the centralised procedure","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-06-03T19:05:00Z","last_updated_date":"2014-06-03T19:05:00Z","reference_number":"EMA/CHMP/287710/2014  Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-acceptability-names-human-medicinal-products-processed-through-centralised-procedure_en.pdf"},
    {"id":"25646","name":"Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early Parkinsonian symptoms","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-19T17:00:00Z","last_updated_date":"2018-07-19T17:00:00Z","reference_number":"EMA/CHMP/SAWP/765041/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-dopamine-transporter-imaging-enrichment-biomarker-parkinsons-disease-clinical-trials-patients-early-parkinsonian-symptoms_en.pdf"},
    {"id":"25755","name":"Reflection paper on ethical and good-clinical-practice aspects of clinical trials of medicinal products for human use conducted outside of the European Union (EU) / European Economic Area and submitted in marketing-autho...","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-04-16T19:16:00Z","last_updated_date":"2012-04-16T19:16:00Z","reference_number":"EMA/121340/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-ethical-and-good-clinical-practice-aspects-clinical-trials-medicinal-products-human-use-conducted-outside-european-union-eu-european-economic-area-and-submitted-marketing-autho_en.pdf"},
    {"id":"25894","name":"Final paediatric investigation plan: Expected key elements and requirements for a new DTaP-containing combination vaccine for primary and booster vaccination in infants and toddlers","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-11-23T13:30:00Z","last_updated_date":"2015-11-23T13:30:00Z","reference_number":"EMA/82701/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/final-paediatric-investigation-plan-expected-key-elements-and-requirements-new-dtap-containing-combination-vaccine-primary-and-booster-vaccination-infants-and-toddlers_en.pdf"},
    {"id":"25938","name":"Draft concept paper on the revision of chapter 6 of the EU GMP guide quality control","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2010-09-01 - 2011-02-28","first_published_date":"2010-11-23T02:00:00Z","last_updated_date":"2010-11-23T02:00:00Z","reference_number":"EMA/INS/GMP/632654/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-concept-paper-revision-chapter-6-eu-gmp-guide-quality-control_en.pdf"},
    {"id":"25964","name":"EMEA implementation of electronic-only submissions and mandatory eCTD submissions in the centralised procedure: Statement of intent relating to non-eCTD submissions","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2008-12-01T01:00:00Z","reference_number":"EMEA/577842/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/emea-implementation-electronic-only-submissions-and-mandatory-ectd-submissions-centralised-procedure-statement-intent-relating-non-ectd-submissions_en.pdf"},
    {"id":"25998","name":"Questions and answers on Article 31 non-pharmacovigilance referrals","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-07-06T18:00:00Z","last_updated_date":"2018-09-21T16:00:00Z","reference_number":"EMA/457344/2016 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-31-non-pharmacovigilance-referrals_en.pdf"},
    {"id":"26071","name":"Overview of comments received on the reflection paper on publication of CHMP negative opinion and refusal of marketing authorisation applications for human medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"EMEA/482219/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-reflection-paper-publication-chmp-negative-opinion-and-refusal-marketing-authorisation-applications-human-medicinal-products_en.pdf"},
    {"id":"26266","name":"Procedure for handling rapid alerts arising from quality defects","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-05-18T02:00:00Z","last_updated_date":"2009-05-18T02:00:00Z","reference_number":"EMEA/INS/GMP/313510/2006 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-handling-rapid-alerts-arising-quality-defects_en.pdf"},
    {"id":"26271","name":"Initial notices for parallel distribution – January 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-07-10T15:20:00Z","last_updated_date":"2014-07-10T15:20:00Z","reference_number":"EMA/70960/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-january-2014_en.pdf"},
    {"id":"26302","name":"Gaucher disease: A strategic collaborative approach from European Medicines Agency and Food and Drug Administration","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-05-14T16:00:00Z","last_updated_date":"2014-05-14T16:00:00Z","reference_number":"EMA/44410/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/gaucher-disease-strategic-collaborative-approach-european-medicines-agency-and-food-and-drug-administration_en.pdf"},
    {"id":"26332","name":"Guidance on format of the risk-management plan in the European Union part II: Module SI - Epidemiology of the indication(s) and target population","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2012-11-08T18:00:00Z","reference_number":"EMA/709860/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-si-epidemiology-indications-and-target-population_en.pdf"},
    {"id":"26352","name":"Guidance for companies considering the adaptive pathways approach","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-11-20T11:00:00Z","last_updated_date":"2016-08-03T14:00:00Z","reference_number":"EMA/527726/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-companies-considering-adaptive-pathways-approach_en.pdf"},
    {"id":"26459","name":"National-competent-authority and European Medicines Agency requirements for submission of periodic safety update reports during the transitional period","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-05-23T20:04:25Z","last_updated_date":"2014-08-08T13:30:00Z","reference_number":"EMA/413951/2012 Rev. 8","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/national-competent-authority-and-european-medicines-agency-requirements-submission-periodic-safety-update-reports-during-transitional-period_en.pdf"},
    {"id":"26521","name":"Draft concept paper on storage conditions during transport","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2010-09-01 - 2011-02-28","first_published_date":"2010-11-23T02:00:00Z","last_updated_date":"2010-11-23T02:00:00Z","reference_number":"EMA/INS/GMP/638479/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-concept-paper-storage-conditions-during-transport_en.pdf"},
    {"id":"26589","name":"Validation checklist for Type II (non) clinical variations","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-30T16:00:00Z","last_updated_date":"2026-01-30T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/validation-checklist-type-ii-non-clinical-variations_en.docx"},
    {"id":"26590","name":"Substances considered as not falling within the scope of Council Regulation(EEC) No 2377/90","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-05-15T02:00:00Z","last_updated_date":"2009-05-15T02:00:00Z","reference_number":"EMEA/CVMP/046/00-Rev.16","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/substances-considered-not-falling-within-scope-council-regulationeec-no-237790_en.pdf"},
    {"id":"26703","name":"Submission deadlines for 2008-2009 for submitting a request for a modification to an agreed PIP","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-08-15T02:00:00Z","last_updated_date":"2008-08-15T02:00:00Z","reference_number":"MEA/PDCO/437890/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/submission-deadlines-2008-2009-submitting-request-modification-agreed-pip_en.pdf"},
    {"id":"26715","name":"Testing the electronic reporting of ICSRs/SUSARs to EudraVigilance - Training module IT-M2","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2017-06-26T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/testing-electronic-reporting-icsrssusars-eudravigilance-training-module-it-m2_en.pdf"},
    {"id":"26723","name":"Draft good practice guide on risk minimisation and prevention of medication errors","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-14 - 2015-06-14","first_published_date":"2015-04-14T18:00:00Z","last_updated_date":"2015-04-14T18:00:00Z","reference_number":"EMA/606103/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-good-practice-guide-risk-minimisation-and-prevention-medication-errors_en.pdf"},
    {"id":"26747","name":"Compilation of Quality Review of Documents decisions on the use of terms","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-12-01T01:00:00Z","last_updated_date":"2011-03-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/compilation-quality-review-documents-decisions-use-terms_en.pdf"},
    {"id":"26768","name":"Draft comments on user guide for Micro, Small and Medium-sized Enterprises (SMES)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-12-21T01:00:00Z","last_updated_date":"2006-12-21T01:00:00Z","reference_number":"EMEA/206798/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-comments-user-guide-micro-small-and-medium-sized-enterprises-smes_en.pdf"},
    {"id":"26851","name":"Assessment of the quality of medicinal products containing existing/ known active substances","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-07-10T02:09:21Z","last_updated_date":"2007-07-10T02:09:21Z","reference_number":"EMEA/CHMP/CVMP/QWP/450653/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/assessment-quality-medicinal-products-containing-existing-known-active-substances_en.pdf"},
    {"id":"26872","name":"Guidance on format of the risk-management plan in the European Union part I: Product overview","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2012-11-14T01:00:00Z","reference_number":"EMA/709671/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-i-product-overview_en.doc"}    {"id":"26997","name":"Concept paper on the classification of veterinary medicinal products authorised by the community","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-09-18T02:00:00Z","last_updated_date":"2007-09-18T02:00:00Z","reference_number":"EMEA/CVMP/358850/2007-CONS","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/concept-paper-classification-veterinary-medicinal-products-authorised-community_en.pdf"},
    {"id":"27130","name":"Draft guideline on the acceptability of names for human medicinal products processed through the centralised procedure","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2013-06-07 - 2013-08-30","first_published_date":"2013-06-07T15:00:00Z","last_updated_date":"2013-06-07T15:00:00Z","reference_number":"CPMP/328/98 Revision 6","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-acceptability-names-human-medicinal-products-processed-through-centralised-procedure_en.pdf"},
    {"id":"27133","name":"Draft qualification opinion on the paediatric ulcerative colitis activity index (PUCAI)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-09-18 - 2015-10-26","first_published_date":"2015-09-18T16:00:00Z","last_updated_date":"2015-09-18T16:00:00Z","reference_number":"EMA/CHMP/SAWP/485560/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-paediatric-ulcerative-colitis-activity-index-pucai_en.pdf"},
    {"id":"27181","name":"European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Vision and Strategy 2016-2020","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-02-07T15:40:00Z","last_updated_date":"2017-02-07T15:40:00Z","reference_number":"EMA/326299/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-surveillance-veterinary-antimicrobial-consumption-esvac-vision-and-strategy-2016-2020_en.pdf"},
    {"id":"27288","name":"Guidance on format of the risk-management plan in the European Union part VII: Annexes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2012-11-14T01:00:00Z","reference_number":"EMA/716217/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-vii-annexes_en.doc"},
    {"id":"27343","name":"Guideline on influenza vaccines – submission and procedural requirements","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-07-02T16:10:00Z","last_updated_date":"2015-07-02T16:10:00Z","reference_number":"EMA/56793/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-influenza-vaccines-submission-and-procedural-requirements_en.pdf"},
    {"id":"27348","name":"Changes to the provision of final language versions of the product information for medicinal products for veterinary use","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/793982/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/changes-provision-final-language-versions-product-information-medicinal-products-veterinary-use_en.pdf"},
    {"id":"27414","name":"Principles on the involvement of young patients/consumers within EMA activities","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-19T12:00:00Z","last_updated_date":"2017-07-19T12:00:00Z","reference_number":"EMA/494077/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/principles-involvement-young-patientsconsumers-within-ema-activities_en.pdf"},
    {"id":"27434","name":"Overview of comments received on draft guideline on principles to be applied for the deletion of commercially confidential information for the disclosure of EMEA documents","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-04-15T02:00:00Z","last_updated_date":"2007-04-15T02:00:00Z","reference_number":"EMEA/271222/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-draft-guideline-principles-be-applied-deletion-commercially-confidential-information-disclosure-emea-documents_en.pdf"},
    {"id":"27437","name":"Standard rhabdomyosarcoma paediatric investigation plan","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2013-02-21 - 2013-05-05","first_published_date":"2013-02-22T13:00:01Z","last_updated_date":"2013-02-22T13:00:01Z","reference_number":"EMA/555130/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/standard-rhabdomyosarcoma-paediatric-investigation-plan_en.pdf"},
    {"id":"27528","name":"HMPC rules of procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-11-05T01:00:00Z","last_updated_date":"2021-10-15T11:23:00Z","reference_number":"EMA/HMPC/139800/2004 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/hmpc-rules-procedure_en.pdf"},
    {"id":"27545","name":"COMP rules of procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-03-21T01:00:00Z","last_updated_date":"2021-10-12T17:21:00Z","reference_number":"EMA/COMP/8212/00 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/comp-rules-procedure_en.pdf"},
    {"id":"27635","name":"Procedure on the granting of marketing authorisations by new CADREAC (nCADREAC) drug regulatory authorities for medicinal products for human use already authorised in EU member states following the centralised procedure ...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-01-01T01:00:00Z","last_updated_date":"2006-01-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-granting-marketing-authorisations-new-cadreac-ncadreac-drug-regulatory-authorities-medicinal-products-human-use-already-authorised-eu-member-states-following-centralised-procedure_en.pdf"},
    {"id":"27653","name":"EC - Switzerland MRA: Sectoral Annex on GMP medicinal products GMP inspection and batch certification","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2010-01-05T00:09:21Z","last_updated_date":"2010-01-05T00:09:21Z","reference_number":"EMA/825063/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ec-switzerland-mra-sectoral-annex-gmp-medicinal-products-gmp-inspection-and-batch-certification_en.pdf"},
    {"id":"27694","name":"Table A: Materials of animal origin included in the scope of the Note for Guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:09:21Z","last_updated_date":"2009-06-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/table-materials-animal-origin-included-scope-note-guidance-minimising-risk-transmitting-animal-spongiform-encephalopathy-agents-medicinal-products_en.doc"},
    {"id":"27741","name":"Recommendation of the PDCO to the European Commission regarding the symbol","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-12-01T01:00:00Z","last_updated_date":"2007-12-01T01:00:00Z","reference_number":"EMEA/498247/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/recommendation-pdco-european-commission-regarding-symbol_en.pdf"},
    {"id":"27769","name":"Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-01-28T17:45:00Z","last_updated_date":"2013-08-02T13:30:00Z","reference_number":"EMA/48663/2013 ","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-and-content-final-study-report-non-interventional-post-authorisation-safety-studies_en.pdf"},
    {"id":"27880","name":"EudraVigilance release notes v.1.22","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-11-22T10:30:00Z","last_updated_date":"2019-11-04T12:30:00Z","reference_number":"EMA/257535/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-release-notes-v122_en.pdf"},
    {"id":"27904","name":"Principles of providing the world health organization with Pharmacovigilance information","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-01-19T00:00:00Z","last_updated_date":"1998-01-19T00:00:00Z","reference_number":"CPMP/PhVWP/053/98","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/principles-providing-world-health-organization-pharmacovigilance-information_en.pdf"},
    {"id":"27955","name":"Annex VII to procedure for conducting GCP inspections requested by the CHMP: Bioanalytical part, pharmacokinetic and statistical analyses of bioequivalence trials","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-05-28T02:00:00Z","last_updated_date":"2022-05-05T13:31:00Z","reference_number":"EMA/INS/GCP/188326/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/annex-vii-procedure-conducting-gcp-inspections-requested-chmp-bioanalytical-part-pharmacokinetic-and-statistical-analyses-bioequivalence-trials_en.pdf"},
    {"id":"27979","name":"Day 80 assessment report - Overview guidance","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:09:21Z","last_updated_date":"2015-02-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/day-80-assessment-report-overview-guidance_en.pdf"},
    {"id":"27995","name":"Good practice guide on recording, coding, reporting and assessment of medication errors.","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-11-27T11:00:00Z","last_updated_date":"2015-11-27T11:00:00Z","reference_number":"EMA/762563/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practice-guide-recording-coding-reporting-and-assessment-medication-errors_en.pdf"},
    {"id":"28001","name":"Appendix 2 to INS-GCP-4 procedure for reporting of GCP inspections requested by the CHMP: GCP integrated inspection report","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-07-29T14:00:00Z","last_updated_date":"2017-05-15T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/appendix-2-ins-gcp-4-procedure-reporting-gcp-inspections-requested-chmp-gcp-integrated-inspection-report_en.pdf"},
    {"id":"28062","name":"Initial notices for parallel distribution - 2010","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2011-09-26T13:20:00Z","last_updated_date":"2011-09-26T13:20:00Z","reference_number":"EMA/742250/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-2010_en.pdf"},
    {"id":"28410","name":"Union procedure on sharing of pharmacovigilance inspection information","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-06-20T12:15:00Z","last_updated_date":"2014-06-20T12:15:00Z","reference_number":"EMA/INS/PhV/192233/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/union-procedure-sharing-pharmacovigilance-inspection-information_en.pdf"},
    {"id":"28417","name":"Guidance on format of the risk-management plan in the European Union (EU) part II: Module SVI - Additional EU requirements for the safety specification","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2012-11-08T18:00:00Z","reference_number":"EMA/714655/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-eu-part-ii-module-svi-additional-eu-requirements-safety-specification_en.pdf"},
    {"id":"28556","name":"EudraVigilance registration: questions and answers","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T17:00:00Z","last_updated_date":"2017-03-27T16:37:00Z","reference_number":"EMA/353007/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-registration-questions-and-answers_en.pdf"},
    {"id":"28581","name":"Points to consider on the estimation and reporting of the prevalence of a condition for orphan designation","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-03-22T01:00:00Z","last_updated_date":"2019-06-21T10:00:00Z","reference_number":"EMA/COMP/436/01 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/points-consider-estimation-and-reporting-prevalence-condition-orphan-designation_en.pdf"},
    {"id":"28630","name":"Guidance on format of the risk-management plan in the European Union part VI: Summary of activities in the risk-management plan by product","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2013-08-21T17:00:00Z","reference_number":"EMA/465929/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-vi-summary-activities-risk-management-plan-product_en.doc"},
    {"id":"28746","name":"Guidance on format of the risk-management plan in the European Union part II: Module SV - Post-authorisation experience","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2012-11-08T18:00:00Z","reference_number":"EMA/714415/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-sv-post-authorisation-experience_en.pdf"},
    {"id":"28897","name":"Revision of EMEA Financial Regulation as of 1 January 2009","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-01T00:09:21Z","last_updated_date":"2009-06-11T02:00:00Z","reference_number":"EMEA/MB/174828/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/revision-emea-financial-regulation-1-january-2009_en.pdf"},
    {"id":"29096","name":"European Medicines Agency guidance for companies requesting scientific advice (veterinary)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-03-01T01:00:00Z","last_updated_date":"2020-10-19T11:00:00Z","reference_number":"EMA/CVMP/11887/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-guidance-companies-requesting-scientific-advice-veterinary_en.pdf"},
    {"id":"29128","name":"Mobile scanning and other technologies in the labelling and/or package leaflet of centrally authorised medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T12:00:00Z","last_updated_date":"2026-03-25T09:12:00Z","reference_number":"EMA/493897/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/mobile-scanning-other-technologies-labelling-or-package-leaflet-centrally-authorised-medicinal-products_en.pdf"},
    {"id":"29170","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with revision 2 of module V on risk management systems finalised post-public consultation, related revision 2 of module XVI and ...","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:00:00Z","last_updated_date":"2017-03-30T17:00:00Z","reference_number":"EMA/213497/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-revision-2-module-v-risk-management-systems-finalised-post-public-consultation-related-revision-2-module-xvi-and_en.pdf"},
    {"id":"29189","name":"European Medicines Agency / PDCO standard paediatric investigation plan for allergen products for specific immunotherapy","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-11-24T00:09:21Z","last_updated_date":"2015-03-09T14:55:00Z","reference_number":"EMEA/737605/2009 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-pdco-standard-paediatric-investigation-plan-allergen-products-specific-immunotherapy_en.pdf"},
    {"id":"29212","name":"Concept paper on compliance with pharmacovigilance regulatory obligations","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-11-15T01:00:00Z","last_updated_date":"2001-11-15T01:00:00Z","reference_number":"CPMP/PhVWP/1618/01","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/concept-paper-compliance-pharmacovigilance-regulatory-obligations_en.pdf"},
    {"id":"29255","name":"Guidance on format of the risk-management plan in the European Union part II: Module SI - Epidemiology of the indication(s) and target population","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2012-11-14T01:00:00Z","reference_number":"EMA/709860/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-si-epidemiology-indications-and-target-population_en.doc"},
    {"id":"29290","name":"Framework of collaboration between the European Medicines Agency and academia - Annex I – Action plan","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-04-03T14:00:00Z","last_updated_date":"2017-04-03T14:00:00Z","reference_number":"EMA/58661/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/framework-collaboration-between-european-medicines-agency-and-academia-annex-i-action-plan_en.pdf"},
    {"id":"29531","name":"Draft procedural advice on the evaluation of advanced therapy medicinal products in accordance with article 8 of Regulation (EC) No 1394/2007","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-03-31T02:00:00Z","last_updated_date":"2009-03-31T02:00:00Z","reference_number":"EMEA/630043/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-procedural-advice-evaluation-advanced-therapy-medicinal-products-accordance-article-8-regulation-ec-no-13942007_en.pdf"},
    {"id":"29558","name":"Draft procedural advice on the submission of variations for annual update of human influenza-inactivated-vaccine applications in the centralised procedure - Revision 2 - Superseded","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2013-03-22 - 2013-04-05","first_published_date":"2013-03-22T17:00:00Z","last_updated_date":"2013-03-22T17:00:00Z","reference_number":"EMA/CHMP/BWP/99698/2007 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-procedural-advice-submission-variations-annual-update-human-influenza-inactivated-vaccine-applications-centralised-procedure-revision-2-superseded_en.pdf"},
    {"id":"29562","name":"Day 80 assessment report - Non-clinical guidance","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:09:21Z","last_updated_date":"2011-10-13T13:00:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/day-80-assessment-report-non-clinical-guidance_en.pdf"},
    {"id":"29608","name":"Draft detailed guide regarding the monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2014-06-05 - 2014-07-27","first_published_date":"2014-06-05T21:00:00Z","last_updated_date":"2014-06-05T21:00:00Z","reference_number":"EMA/161530/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-detailed-guide-regarding-monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency_en.pdf"},
    {"id":"29653","name":"Questions and answers on Article 34 veterinary referral procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T18:00:00Z","last_updated_date":"2017-12-20T18:00:00Z","reference_number":"EMA/503276/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-34-veterinary-referral-procedures_en.pdf"},
    {"id":"29761","name":"Role and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the paediatric committee","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-27T01:00:00Z","last_updated_date":"2010-09-17T02:00:00Z","reference_number":"EMEA/537415/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/role-and-responsibilities-members-and-alternates-rapporteur-and-peer-reviewers-experts-and-observers-paediatric-committee_en.pdf"},
    {"id":"29816","name":"Qualification opinion of Alzheimer’s disease novel methodologies / biomarkers for positron-emission-tomograpy amyloid imaging (positive / negative) as a biomarker for enrichment for use in predementia Alzheimer's disease...","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2011-11-17 - 2011-12-22","first_published_date":"2011-12-02T16:30:00Z","last_updated_date":"2011-12-02T16:30:00Z","reference_number":"EMA/CHMP/SAWP/892998/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-alzheimers-disease-novel-methodologies-biomarkers-positron-emission-tomograpy-amyloid-imaging-positive-negative-biomarker-enrichment-use-predementia-alzheimers-disease_en.pdf"},
    {"id":"29843","name":"Quality Review of Documents recommendations on the expression of strength in the name of centrally authorised human medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-11-18T01:00:00Z","last_updated_date":"2009-11-18T01:00:00Z","reference_number":"EMA/707229/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/quality-review-documents-recommendations-expression-strength-name-centrally-authorised-human-medicinal-products_en.pdf"},
    {"id":"29869","name":"Public Hearing - Guidance for participants","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-07-11T14:00:00Z","last_updated_date":"2018-04-09T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/public-hearing-guidance-participants_en.pdf"},
    {"id":"29957","name":"INS-GCP-1 procedure for coordinating good-clinical-practice inspections requested by the CHMP","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2014-05-23T18:00:00Z","reference_number":"EMEA/INS/GCP/197225/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ins-gcp-1-procedure-coordinating-good-clinical-practice-inspections-requested-chmp_en.pdf"},
    {"id":"29989","name":"Guideline on the use of statistical signal-detection methods in the EudraVigilance data-analysis system","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-06-26T02:09:21Z","last_updated_date":"2016-12-21T11:32:00Z","reference_number":"EMEA/106464/2006 rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-use-statistical-signal-detection-methods-eudravigilance-data-analysis-system_en.pdf"},
    {"id":"29995","name":"Compassionate use for centralised medicinal products (according to Article 83 of regulation (EC) No 726/2004)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-03-20T01:00:00Z","last_updated_date":"2006-03-20T01:00:00Z","reference_number":"EMEA/CHMP/72144/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/compassionate-use-centralised-medicinal-products-according-article-83-regulation-ec-no-7262004_en.pdf"},
    {"id":"30023","name":"Overview of comments received on reflection paper - EPAR summary for the public","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-01-26T01:00:00Z","last_updated_date":"2006-01-26T01:00:00Z","reference_number":"EMEA/20722/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-reflection-paper-epar-summary-public_en.pdf"},
    {"id":"30031","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/MB/170391/2009/Rev.4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures_en.pdf"},
    {"id":"30228","name":"Pharmacovigilance inspection policy for centralised procedures - medicinal products for human use","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-11-27T01:00:00Z","last_updated_date":"2013-07-24T19:30:00Z","reference_number":"EMA/INS/PhV/163771/2013, Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pharmacovigilance-inspection-policy-centralised-procedures-medicinal-products-human-use_en.pdf"},
    {"id":"30258","name":"Regulation of the European Medicines Agency laying down detailed rules for the implementation of certain provisions of the financial regulation for the agency","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-10T02:00:00Z","last_updated_date":"2004-06-10T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/regulation-european-medicines-agency-laying-down-detailed-rules-implementation-certain-provisions-financial-regulation-agency_en.pdf"},
    {"id":"30454","name":"Checklist for sponsors applying for the transfer of Orphan Medicinal Product (OMP) designation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-15T01:00:00Z","last_updated_date":"2022-06-09T12:18:00Z","reference_number":"EMA/41277/2007 Rev.15","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/checklist-sponsors-applying-transfer-orphan-medicinal-product-omp-designation_en.pdf"},
    {"id":"30695","name":"Guidance on format of the risk-management plan in the European Union part IV: Plans for postauthorisation efficacy studies","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2012-11-14T01:00:00Z","reference_number":"EMA/712370/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-iv-plans-postauthorisation-efficacy-studies_en.doc"},
    {"id":"30697","name":"Product information templates  - human medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-07-28T02:00:00Z","last_updated_date":"2005-07-28T02:00:00Z","reference_number":"EMEA/245309/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/product-information-templates-human-medicinal-products_en.pdf"},
    {"id":"30775","name":"User guide on how to generate PDF versions of the product information - veterinary","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2023-05-12T15:42:00Z","reference_number":"EMA/793983/2010 v.4.01","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/user-guide-how-generate-pdf-versions-product-information-veterinary_en.pdf"},
    {"id":"30804","name":"Guidance on documentation to be provided by member states and applicants/MAHS in support of a simplified registration referral under articles 16c(1)c and 16c(4)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-09-07T02:00:00Z","last_updated_date":"2006-09-07T02:00:00Z","reference_number":"EMEA/HMPC/431129/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-documentation-be-provided-member-states-and-applicantsmahs-support-simplified-registration-referral-under-articles-16c1c-and-16c4_en.pdf"},
    {"id":"30814","name":"Checking process of mock-ups and specimens of outer / immediate labelling and package leaflets of human medicinal products in the centralised procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-01-22T01:00:00Z","last_updated_date":"2022-09-28T00:00:00Z","reference_number":"EMA/305821/2006 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/checking-process-mock-ups-and-specimens-outer-immediate-labelling-and-package-leaflets-human-medicinal-products-centralised-procedure_en.pdf"},
    {"id":"30910","name":"Guideline on the processing of renewals in the centralised procedure","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-08-04T11:00:00Z","last_updated_date":"2016-08-04T11:00:00Z","reference_number":"EMEA/CHMP/2990/00 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-processing-renewals-centralised-procedure_en.pdf"},
    {"id":"30922","name":"Procedure for reporting of pharmacovigilance inspections requested by the CHMP","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-12T01:00:00Z","last_updated_date":"2014-06-20T02:00:00Z","reference_number":"EMEA/INS/GCP/391114/2005 Superseded","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-reporting-pharmacovigilance-inspections-requested-chmp_en.pdf"},
    {"id":"30964","name":"Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products - First version","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-01-10T01:00:00Z","last_updated_date":"2008-01-10T01:00:00Z","reference_number":"EMEA/HMPC/71049/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products-first-version_en.pdf"},
    {"id":"31001","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated on 12 October 2017","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/213497/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-12-october-2017_en.pdf"},
    {"id":"31032","name":"Practical guidance on the extension of Commission decision annexes in the new accession-country language","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-01-31T13:55:46Z","last_updated_date":"2013-07-01T13:10:00Z","reference_number":"EMA/9826/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/practical-guidance-extension-commission-decision-annexes-new-accession-country-language_en.pdf"},
    {"id":"31078","name":"Traditional herbal medicinal products and simplified registrations for homeopathic medicinal products: pharmacovigilance requirements and EudraVigilance access - Note for clarification","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-03-02T11:00:00Z","last_updated_date":"2017-03-02T11:00:00Z","reference_number":"EMA/80556/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/traditional-herbal-medicinal-products-and-simplified-registrations-homeopathic-medicinal-products-pharmacovigilance-requirements-and-eudravigilance-access-note-clarification_en.pdf"},
    {"id":"31115","name":"Annex I: summary of product characteristics","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-07-01T02:00:00Z","last_updated_date":"2005-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/annex-i-summary-product-characteristics_en.pdf"},
    {"id":"31157","name":"Guidance on format of the risk-management plan in the European Union part II: Module SIII - Clinical-trial exposure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2012-11-08T18:00:00Z","reference_number":"EMA/710081/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-siii-clinical-trial-exposure_en.pdf"},
    {"id":"31219","name":"European Medicines Agency procedural advice on recommendations on unforeseen variations according to Article 5 of Commission Regulation (EC) No 1234/2008","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-03-27T01:00:00Z","last_updated_date":"2025-03-25T14:35:00Z","reference_number":"EMA/588416/2008 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-recommendations-unforeseen-variations-according-article-5-commission-regulation-ec-no-1234-2008_en.pdf"},
    {"id":"31319","name":"Initial notices for parallel distribution – June 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-07-09T14:25:00Z","last_updated_date":"2014-07-09T14:25:00Z","reference_number":"EMA/405392/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-june-2014_en.pdf"},
    {"id":"31371","name":"Initial notices for parallel distribution – 2013","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T19:01:00Z","last_updated_date":"2014-06-16T19:01:00Z","reference_number":"EMA/345614/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-2013_en.pdf"},
    {"id":"31555","name":"European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal products applications: document with tracked changes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-10-29T15:30:00Z","last_updated_date":"2025-02-24T11:19:58Z","reference_number":"EMA/940451/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-users-centralised-procedure-similar-biological-medicinal-products-applications-document-tracked-changes_en.pdf"},
    {"id":"31617","name":"Overview of comments received on guidance on time allowed for applicants to respond to questions and issues raised during the assessment of new marketing authorisation applications in the centralised procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-12-09T01:00:00Z","last_updated_date":"2008-12-09T01:00:00Z","reference_number":"EMEA/545180/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-guidance-time-allowed-applicants-respond-questions-and-issues-raised-during-assessment-new-marketing-authorisation-applications-centralised-procedure_en.pdf"},
    {"id":"31634","name":"Reflection paper on collecting and reporting information on off-label use in pharmacovigilance","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2016-04-29 - 2016-07-29","first_published_date":"2016-04-29T13:20:00Z","last_updated_date":"2016-04-29T13:20:00Z","reference_number":"EMA/293194/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-collecting-and-reporting-information-label-use-pharmacovigilance_en.pdf"},
    {"id":"31648","name":"Guideline on the processing of renewals in the centralised procedure","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-10-20T02:00:00Z","last_updated_date":"2012-07-02T02:00:00Z","reference_number":"EMEA/CHMP/2990/00 rev. 4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-processing-renewals-centralised-procedure_en.pdf-0"},
    {"id":"31661","name":"European Medicines Agency recommendation on the procedural aspects and dossier requirements for the consultation to the European Medicines Agency by a notified body on an ancillary medicinal substance or an ancillary hum...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-02-27T16:26:00Z","last_updated_date":"2012-02-27T16:26:00Z","reference_number":"EMA/CHMP/578661/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-recommendation-procedural-aspects-and-dossier-requirements-consultation-european-medicines-agency-notified-body-ancillary-medicinal-substance-or-ancillary-hum_en.pdf"},
    {"id":"31734","name":"Best practice guide on measures improving predictability of submissions/responses and adherence to communicated submission/responses deadlines","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T18:30:00Z","last_updated_date":"2017-12-11T18:30:00Z","reference_number":"EMA/488783/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/best-practice-guide-measures-improving-predictability-submissionsresponses-and-adherence-communicated-submissionresponses-deadlines_en.pdf"},
    {"id":"31830","name":"Draft questions and answers on sodium in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use'","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-06-24 - 2015-09-30","first_published_date":"2015-06-24T14:00:00Z","last_updated_date":"2015-06-24T14:00:00Z","reference_number":"EMA/CHMP/338679/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-questions-and-answers-sodium-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"31849","name":"EudraVigilance stakeholder change management plan","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-10-27T01:00:00Z","last_updated_date":"2017-11-22T10:30:00Z","reference_number":"EMA/325783/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-stakeholder-change-management-plan_en.pdf"},
    {"id":"31876","name":"Overview of comments received on  the guideline - EMEA/CHMP working group with Healthcare Professionals' Organisations (HCP WG) - Final recommendations and proposals for action","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-02-06T00:09:21Z","last_updated_date":"2009-02-06T00:09:21Z","reference_number":"EMEA/536569/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-guideline-emeachmp-working-group-healthcare-professionals-organisations-hcp-wg-final-recommendations-and-proposals-action_en.pdf"},
    {"id":"31956","name":"Qualification opinion - The European Cystic Fibrosis Society Patient Registry (ECFSPR)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2018-02-09 - 2018-04-09","first_published_date":"2018-02-09T11:00:00Z","last_updated_date":"2018-02-09T11:00:00Z","reference_number":"EMA/CHMP/SAWP/802259/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-european-cystic-fibrosis-society-patient-registry-ecfspr_en.pdf"},
    {"id":"32184","name":"Annex IV to procedure for conducting GCP inspections requested by the CHMP: Sponsor and Contract Research Organisations (CRO)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2022-05-05T13:29:00Z","reference_number":"EMA/INS/GCP/155794/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/annex-iv-procedure-conducting-gcp-inspections-requested-chmp-sponsor-and-contract-research-organisations-cro_en.pdf"},
    {"id":"32211","name":"Initial notices for parallel distribution - June 2015","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-07-20T16:35:00Z","last_updated_date":"2015-07-20T16:35:00Z","reference_number":"EMA/461921/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-june-2015_en.pdf"},
    {"id":"32269","name":"Procedure on management of proposals submitted by interested parties for Community list entries or Community herbal monographs - Revision 1","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-11-12T01:00:00Z","last_updated_date":"2009-11-12T01:00:00Z","reference_number":"EMEA/HMPC/328575/2007 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-management-proposals-submitted-interested-parties-community-list-entries-or-community-herbal-monographs-revision-1_en.pdf"},
    {"id":"32356","name":"EudraVigilance - Marketing authorisation holders - Adobe connect invitation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2018-02-14T14:00:00Z","reference_number":"EMA/368353/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-marketing-authorisation-holders-adobe-connect-invitation_en.pdf"},
    {"id":"32389","name":"Reflection paper on nanotechnology-based medicinal products for human use","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-29T02:09:21Z","last_updated_date":"2006-06-29T02:09:21Z","reference_number":"EMEA/CHMP/79769/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-nanotechnology-based-medicinal-products-human-use_en.pdf"},
    {"id":"32480","name":"Deadlines for submission of applications for orphan medicinal product designation to the EMA and corresponding COMP timetable for valid applications - 2022-2023","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-05-04T02:00:00Z","last_updated_date":"2022-04-25T14:00:00Z","reference_number":"EMADOC-628903358-2283","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/deadlines-submission-applications-orphan-medicinal-product-designation-ema-and-corresponding-comp-timetable-valid-applications-2022-2023_en.pdf"},
    {"id":"32564","name":"Framework of collaboration between the European Medicines Agency and academia","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-04-03T14:00:00Z","last_updated_date":"2017-04-03T14:00:00Z","reference_number":"EMA/125511/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/framework-collaboration-between-european-medicines-agency-and-academia_en.pdf"},
    {"id":"32833","name":"Overview of comments received on 'Procedural Advice on the Provision of Scientific Recommendation on Classification of Advanced Therapy Medicinal Products in Accordance with Article 17 of Regulation (EC) No. 1394/2007'","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2010-02-23T00:09:21Z","last_updated_date":"2010-02-23T00:09:21Z","reference_number":"EMA/CAT/106109/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-procedural-advice-provision-scientific-recommendation-classification-advanced-therapy-medicinal-products-accordance-article-17-regulation-ec-no-1394-2007_en.pdf"},
    {"id":"32893","name":"Medical literature monitoring by EMA - Training module EV-M7","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2017-06-26T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/medical-literature-monitoring-ema-training-module-ev-m7_en.pdf"},
    {"id":"32974","name":"Procedure for coordinating pharmacovigilance inspections requested by the CHMP","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-12T01:00:00Z","last_updated_date":"2014-06-20T02:00:00Z","reference_number":"EMEA/INS/GCP/393141/2005 Superseded","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-coordinating-pharmacovigilance-inspections-requested-chmp_en.pdf"},
    {"id":"32993","name":"Day 80 assessment report - Quality guidance rev.12.17","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:09:21Z","last_updated_date":"2017-12-13T17:00:00Z","reference_number":"12.17","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/day-80-assessment-report-quality-guidance-rev1217_en.pdf"},
    {"id":"33005","name":"Concept paper on a revision of the guideline for an assessor preparing assessment reports","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2009-10-01 - 2009-12-31","first_published_date":"2009-10-19T04:00:00Z","last_updated_date":"2009-10-19T04:00:00Z","reference_number":"EMEA/CVMP/626480/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/concept-paper-revision-guideline-assessor-preparing-assessment-reports_en.pdf"},
    {"id":"33161","name":"Form 1: For marketing-authorisation holders when submitting translation to the national competent authority of Croatia","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2011-01-31T01:00:00Z","last_updated_date":"2013-03-15T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/form-1-marketing-authorisation-holders-when-submitting-translation-national-competent-authority-croatia_en.doc"},
    {"id":"33185","name":"Draft risk minimisation strategy for high strength and fixed combination insulin products, addendum to the good practice guide on risk minimisation and prevention of medication errors","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-14 - 2015-06-14","first_published_date":"2015-04-14T18:00:00Z","last_updated_date":"2015-04-14T18:00:00Z","reference_number":"EMA/686009/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-risk-minimisation-strategy-high-strength-and-fixed-combination-insulin-products-addendum-good-practice-guide-risk-minimisation-and-prevention-medication-errors_en.pdf"},
    {"id":"33222","name":"Qualification opinion of a novel data-driven model of disease progression and trial evaluation in mild and moderate Alzheimer’s disease","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-10-03T17:50:00Z","last_updated_date":"2013-10-03T17:50:00Z","reference_number":"EMA/CHMP/SAWP/567188/2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-novel-data-driven-model-disease-progression-and-trial-evaluation-mild-and-moderate-alzheimers-disease_en.pdf"},
    {"id":"33247","name":"European Union recommendations for the seasonal-influenza-vaccine composition for the season 2009 / 2010","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:09:21Z","last_updated_date":"2009-04-23T02:09:21Z","reference_number":"EMEA/CHMP/BWP/133895/2009/Rev 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-union-recommendations-seasonal-influenza-vaccine-composition-season-2009-2010_en.pdf"},
    {"id":"33407","name":"Initial notices for parallel distribution - 2009","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2011-09-26T13:19:00Z","last_updated_date":"2011-09-26T13:19:00Z","reference_number":"EMA/742248/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-2009_en.pdf"},
    {"id":"33600","name":"List of centrally authorised products with safety-related changes to the product information","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-09-19T16:40:00Z","last_updated_date":"2026-05-29T12:45:00Z","reference_number":"EMA/127491/2026","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/list-centrally-authorised-products-safety-related-changes-product-information_en.xlsx"},
    {"id":"33816","name":"Summary of procedures for consultation by the Committee for Medicinal Products for Veterinary Use of scientific advisory groups (SAGs) and ad-hoc expert groups functioning as SAGs in relation to applications for authoris...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-04-07T02:00:00Z","last_updated_date":"2011-04-07T02:00:00Z","reference_number":"EMA/347137/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/summary-procedures-consultation-committee-medicinal-products-veterinary-use-scientific-advisory-groups-sags-and-ad-hoc-expert-groups-functioning-sags-relation-applications-authoris_en.pdf"}    {"id":"33885","name":"Reflection paper criteria for requiring one additional five-year renewal for centrally authorised medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-15T01:00:00Z","last_updated_date":"2007-11-15T01:00:00Z","reference_number":"EMEA/131973/2006","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-criteria-requiring-one-additional-five-year-renewal-centrally-authorised-medicinal-products_en.pdf"},
    {"id":"33886","name":"Day 80 assessment report non-clinical and clinical guidance - generics rev.10.16","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-07-08T15:20:00Z","last_updated_date":"2016-11-08T12:00:00Z","reference_number":"Rev. 10.16","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/day-80-assessment-report-non-clinical-and-clinical-guidance-generics-rev1016_en.pdf"},
    {"id":"33967","name":"European Medicines Agency procedural advice for marketing authorisation holders/applicants concerned by referral procedures (human medicines)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T15:30:00Z","last_updated_date":"2013-12-17T15:30:00Z","reference_number":"EMA/687960/2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-marketing-authorisation-holdersapplicants-concerned-referral-procedures-human-medicines_en.pdf"},
    {"id":"33973","name":"Dossier requirements for submission of marketing authorisation and maximum residue limit (MRL) applications to the European Medicines Agency (EMA) and to members of the Committee for Medicinal Products for Veterinary use (CVMP)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-11-18T01:09:00Z","last_updated_date":"2023-01-31T17:58:00Z","reference_number":"EMA/466102/2007 Rev. 34","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/dossier-requirements-submission-marketing-authorisation-and-maximum-residue-limit-mrl-applications-european-medicines-agency-ema-and-members-committee-medicinal-products-veterinary-use-cvmp_en.pdf"},
    {"id":"33996","name":"EMEA publication policy of CPMP summaries of opinion","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2001-06-08T02:00:00Z","last_updated_date":"2001-06-08T02:00:00Z","reference_number":"CPMP/1635/01","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/emea-publication-policy-cpmp-summaries-opinion_en.pdf"},
    {"id":"34209","name":"User guide for micro, small and medium-sized enterprises","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-12-01T01:00:00Z","last_updated_date":"2025-03-14T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/user-guide-micro-small-medium-sized-enterprises_en.pdf"},
    {"id":"34296","name":"Support for applications on Article 58","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-02-07T12:30:00Z","last_updated_date":"2017-02-07T12:30:00Z","reference_number":"EMA/619778/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/support-applications-article-58_en.pdf"},
    {"id":"34336","name":"Reflection paper on European public assessment report summary for the public","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-01-26T01:00:00Z","last_updated_date":"2006-01-26T01:00:00Z","reference_number":"EMEA/126757/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-european-public-assessment-report-summary-public_en.pdf"},
    {"id":"34495","name":"Procedure for calls for scientific data for use in HMPC assessment work","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-03-13T00:09:21Z","last_updated_date":"2018-05-03T14:12:00Z","reference_number":"EMEA/HMPC/1004/2006 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-calls-scientific-data-use-hmpc-assessment-work_en.pdf"},
    {"id":"34536","name":"CHMP guideline on detection and management of duplicate individual cases and individual case safety reports","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-21T15:30:00Z","last_updated_date":"2012-06-21T15:30:00Z","reference_number":"EMA/13432/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/chmp-guideline-detection-and-management-duplicate-individual-cases-and-individual-case-safety-reports_en.pdf"},
    {"id":"34584","name":"Commission Regulation (EC) No 1085/2003 of 3 June 2003\n\nconcerning the examination of variations to the terms of a marketing authorisation for medicinal products for human use and veterinary medicinal products falling wi...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-06-26T02:09:21Z","last_updated_date":"2003-06-26T02:09:21Z","reference_number":"(EC) No 1085/2003","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/commission-regulation-ec-no-10852003-3-june-2003-concerning-examination-variations-terms-marketing-authorisation-medicinal-products-human-use-and-veterinary-medicinal-products-falling-wi_en.pdf"},
    {"id":"34618","name":"Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-03-29T02:09:21Z","last_updated_date":"2004-03-29T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/commission-directive-200433ec-22-march-2004-implementing-directive-200298ec-european-parliament-and-council-regards-certain-technical-requirements-blood-and-blood-components_en.pdf"},
    {"id":"34682","name":"Draft guideline on safety and efficacy follow-up - risk management of advanced therapy medicinal products","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-05-06T02:00:00Z","last_updated_date":"2008-05-06T02:00:00Z","reference_number":"EMEA/149995/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-safety-and-efficacy-follow-risk-management-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"34799","name":"EudraVigilance checklist for national competent authorities in the EEA","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2017-06-26T14:00:00Z","reference_number":"EMA/172253/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-checklist-national-competent-authorities-eea_en.pdf"},
    {"id":"34873","name":"Procedural advice on the evaluation of combined advanced therapy medicinal products and the consultation of notified bodies in accordance with Article 9 of Regulation (EC) No. 1394/2007","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-03-03T01:00:00Z","last_updated_date":"2011-03-03T01:00:00Z","reference_number":"EMA/354785/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-evaluation-combined-advanced-therapy-medicinal-products-and-consultation-notified-bodies-accordance-article-9-regulation-ec-no-13942007_en.pdf"},
    {"id":"34900","name":"Draft qualification opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of phase-II dose-finding studies under model uncertainty","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2013-10-15 - 2013-11-24","first_published_date":"2013-10-15T21:00:00Z","last_updated_date":"2013-10-15T21:00:00Z","reference_number":"EMA/CHMP/SAWP/592378/2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-mcp-mod-efficient-statistical-methodology-model-based-design-and-analysis-phase-ii-dose-finding-studies-under-model-uncertainty_en.pdf"},
    {"id":"34947","name":"Procedure for the nomination and appointment of co-opted members of the Medicinal Products for Human Use (CHMP), the Committee for Veterinary Medicinal Products (CVMP) and the Committee on Herbal Medicinal Products (HMPC) (effective from 02/05/2022)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-03-01T01:00:00Z","last_updated_date":"2022-04-28T09:37:00Z","reference_number":"EMA/747064/2021 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-nomination-and-appointment-co-opted-members-medicinal-products-human-use-chmp-committee-veterinary-medicinal-products-cvmp-and-committee-herbal-medicinal-products-hmpc-effective-02052022_en.pdf"},
    {"id":"34979","name":"Data protection statement for the public consultation on European Medicines Agency policy on access to documents","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-03-15T13:25:00Z","last_updated_date":"2017-03-15T13:25:00Z","reference_number":"EMA/108062/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/data-protection-statement-public-consultation-european-medicines-agency-policy-access-documents_en.pdf"},
    {"id":"35092","name":"Annex I variation application(s) content for live attenuated influenza vaccines","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-08-08T02:00:00Z","last_updated_date":"2011-08-08T02:00:00Z","reference_number":"EMA/CHMP/BWP/577998/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/annex-i-variation-applications-content-live-attenuated-influenza-vaccines_en.pdf-0"},
    {"id":"35266","name":"Patient Leaflet template concerning advice on the preparation of herbal teas as (traditional) herbal medicinal products by end-users","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-04-10T12:11:00Z","last_updated_date":"2017-04-10T12:11:00Z","reference_number":"EMA/HMPC/30603/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/patient-leaflet-template-concerning-advice-preparation-herbal-teas-traditional-herbal-medicinal-products-end-users_en.pdf"},
    {"id":"35327","name":"Qualification opinion on ingestible sensor system for medication adherence as biomarker for measuring patient adherence to medication in clinical trials","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-02-15T16:40:00Z","last_updated_date":"2016-02-15T16:40:00Z","reference_number":"EMA/CHMP/SAWP/513571/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-ingestible-sensor-system-medication-adherence-biomarker-measuring-patient-adherence-medication-clinical-trials_en.pdf"},
    {"id":"35363","name":"Pre-submission checklist for annual re-assessment of a marketing authorisation under exceptional circumstances application","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:00:00Z","last_updated_date":"2016-10-07T17:00:00Z","reference_number":"EMA/199522/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pre-submission-checklist-annual-re-assessment-marketing-authorisation-under-exceptional-circumstances-application_en.pdf"},
    {"id":"35366","name":"Output of the European Medicines Agency policy on access to documents related to medicinal products for human and veterinary use","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2010-11-30T01:00:00Z","last_updated_date":"2018-11-23T13:00:00Z","reference_number":"EMA/127362/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/output-european-medicines-agency-policy-access-documents-related-medicinal-products-human-and-veterinary-use_en.pdf"},
    {"id":"35398","name":"Guideline on the exposure to medicinal products during pregnancy: Need for post-authorisation data","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-14T00:09:21Z","last_updated_date":"2005-11-14T00:09:21Z","reference_number":"EMEA/CHMP/313666/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf"},
    {"id":"35439","name":"European Medicines Agency post-authorisation procedural advice for users of the centralised procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2026-03-27T13:00:00Z","reference_number":"EMEA-H-19984/03 Rev. 117","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure_en.pdf"},
    {"id":"35469","name":"Draft guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products - Revision 1","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2012-08-08 - 2012-10-15","first_published_date":"2012-08-08T13:10:00Z","last_updated_date":"2012-08-08T13:10:00Z","reference_number":"EMA/HMPC/71049/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products-revision-1_en.pdf"},
    {"id":"35545","name":"Labelling-exemption requests under Article 63 of Directive 2001/83/EC examined by the Quality Review of Documents group","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-08-19T16:30:00Z","last_updated_date":"2020-02-06T08:54:00Z","reference_number":"EMA/828662/2017 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/labelling-exemption-requests-under-article-63-directive-200183ec-examined-quality-review-documents-group_en.pdf"},
    {"id":"35589","name":"European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal products applications","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-04-11T18:30:00Z","last_updated_date":"2025-02-24T11:20:00Z","reference_number":"EMA/940451/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-users-centralised-procedure-similar-biological-medicinal-products-applications_en.pdf"},
    {"id":"35624","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q4B annex 14 to note for evaluation and recommendation of pharmacopoeial texts for use...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-12-17T14:55:00Z","last_updated_date":"2013-05-16T17:00:00Z","reference_number":"EMA/CHMP/ICH/529785/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q4b-annex-14-note-evaluation-and-recommendation-pharmacopoeial-texts-use_en.pdf"},
    {"id":"35853","name":"Commission Directive 2005/62/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards Community standards and specifications relating to a quality system for bloo...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-09-30T02:09:21Z","last_updated_date":"2005-09-30T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/commission-directive-200562ec-30-september-2005-implementing-directive-200298ec-european-parliament-and-council-regards-community-standards-and-specifications-relating-quality-system-bloo_en.pdf"},
    {"id":"35863","name":"Qualification opinion on paediatric ulcerative colitis activity index (PUCAI)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-01-20T17:10:00Z","last_updated_date":"2016-01-20T17:10:00Z","reference_number":"EMA/CHMP/SAWP/801872/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-paediatric-ulcerative-colitis-activity-index-pucai_en.pdf"},
    {"id":"35866","name":"Draft procedural advice on the provision of scientific recommendation of classification of advanced therapy medicinal products in accordance with article 17 of regulation (EC) NO 1394/2007","type":"regulatory-procedural-guideline","status":"Draft","consultation_date":"","first_published_date":"2010-02-05T01:00:00Z","last_updated_date":"2010-02-05T15:11:00Z","reference_number":"EMEA/99623/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-procedural-advice-provision-scientific-recommendation-classification-advanced-therapy-medicinal-products-accordance-article-17-regulation-ec-no-13942007_en.pdf"},
    {"id":"35910","name":"Operational procedure on handling of consultation with target patient groups on package leaflets for centrally authorised products for human use","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-10-20T02:00:00Z","last_updated_date":"2005-10-20T02:00:00Z","reference_number":"EMEA/277378/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/operational-procedure-handling-consultation-target-patient-groups-package-leaflets-centrally-authorised-products-human-use_en.pdf"},
    {"id":"35971","name":"Guidance on format of the risk-management plan in the European Union part II: Module SII - Non-clinical part of the safety specification","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2013-08-21T18:35:00Z","reference_number":"EMA/465926/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-sii-non-clinical-part-safety-specification_en.pdf"},
    {"id":"35987","name":"Annex II to procedure for conducting GCP inspections requested by the CHMP: Clinical laboratories","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2022-05-05T13:27:00Z","reference_number":"EMA/INS/GCP/154768/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/annex-ii-procedure-conducting-gcp-inspections-requested-chmp-clinical-laboratories_en.pdf"},
    {"id":"36024","name":"Quality Review of Documents general principles regarding the summary-of-product-characteristics information for a generic / hybrid / biosimilar product","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-05-24T11:20:00Z","last_updated_date":"2018-06-27T15:31:00Z","reference_number":"EMA/627621/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/quality-review-documents-general-principles-regarding-summary-product-characteristics-information-generic-hybrid-biosimilar-product_en.pdf"},
    {"id":"36029","name":"Rules of engagement and procedures for participating authorities (active pharmaceutical ingredients / active substances)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-07T01:00:00Z","last_updated_date":"2009-01-07T01:00:00Z","reference_number":"EMEA/INS/GMP/414323/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-engagement-and-procedures-participating-authorities-active-pharmaceutical-ingredients-active-substances_en.pdf"},
    {"id":"36081","name":"Qualification of novel methodologies for drug development: guidance to applicants","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2023-10-04T16:58:00Z","reference_number":"EMEA/CHMP/SAWP/72894/2008 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-novel-methodologies-drug-development-guidance-applicants_en.pdf"},
    {"id":"36159","name":"Connection template - EMA ESTRI Gateway using an AS2 compatible product","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2024-03-07T17:10:00Z","reference_number":"EMA/385068/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/connection-template-ema-estri-gateway-using-as2-compatible-product_en.pdf"},
    {"id":"36199","name":"Form 2: For marketing-authorisation holders when submitting corrected translation to the national competent authority of Croatia","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2011-01-31T01:00:00Z","last_updated_date":"2011-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/form-2-marketing-authorisation-holders-when-submitting-corrected-translation-national-competent-authority-croatia_en.doc"},
    {"id":"36242","name":"Dossier requirements for centrally authorised products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-06-26T02:00:00Z","last_updated_date":"2021-01-06T11:00:00Z","reference_number":"EMA/497021/2012 Rev. 26","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/dossier-requirements-centrally-authorised-products_en.pdf"},
    {"id":"36673","name":"Procedure for coordinating pharmacovigilance inspections requested by the CVMP","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/INS/PhV/85059/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-coordinating-pharmacovigilance-inspections-requested-cvmp_en.pdf"},
    {"id":"36968","name":"Questions and answers (Q&As) on the external guidance of Policy 0070 on clinical data publication (CDP)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-04-12T17:00:00Z","last_updated_date":"2025-07-23T15:38:00Z","reference_number":"EMA/14227/2017 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-qas-external-guidance-policy-0070-clinical-data-publication-cdp_en.pdf"},
    {"id":"37172","name":"Procedure for the preparation of a risk-based programme for routine pharmacovigilance inspections of MAHs connected with veterinary Centrally Authorised Products (CAPs)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/INS/PhV/390778/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-preparation-risk-based-programme-routine-pharmacovigilance-inspections-mahs-connected-veterinary-centrally-authorised-products-caps_en.pdf"},
    {"id":"37512","name":"Guidance on format of the risk-management plan in the European Union part II: Module SIV - Populations not studied in clinical trials","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2013-08-21T02:00:00Z","reference_number":"EMA/465927/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-siv-populations-not-studied-clinical-trials_en.doc"},
    {"id":"37553","name":"Questions and answers on Article 33(4) veterinary referral procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-12-20T18:00:00Z","last_updated_date":"2017-12-20T18:00:00Z","reference_number":"EMA/503275/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-334-veterinary-referral-procedures_en.pdf"},
    {"id":"37617","name":"Submission deadlines for 2008-2009 for PIP applications and applications for waivers and answers to the request for modification plan of the application","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-08-15T02:00:00Z","last_updated_date":"2008-08-15T02:00:00Z","reference_number":"EMEA/PDCO/437852/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/submission-deadlines-2008-2009-pip-applications-and-applications-waivers-and-answers-request-modification-plan-application_en.pdf"},
    {"id":"37648","name":"Dossier requirements for nationally authorised products (referral, PASS107, workshare, signal detection procedures) and ancillary medicinal substances in a medical device","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-05-16T18:50:00Z","last_updated_date":"2021-01-28T11:00:00Z","reference_number":"EMA/13015/2014 Rev. 10","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/dossier-requirements-nationally-authorised-products-referral-pass107-workshare-signal-detection-procedures-ancillary-medicinal-substances-medical-device_en.pdf"},
    {"id":"37682","name":"Risk minimisation strategy for high-strength and fixed-combination insulin products, addendum to the good practice guide on risk minimisation and prevention of medication errors","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-11-27T11:00:00Z","last_updated_date":"2015-11-27T11:00:00Z","reference_number":"EMA/686009/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/risk-minimisation-strategy-high-strength-and-fixed-combination-insulin-products-addendum-good-practice-guide-risk-minimisation-and-prevention-medication-errors_en.pdf"},
    {"id":"37810","name":"Guideline on the processing of renewals in the centralised procedure: document with tracked changes","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-28 - 2015-09-14","first_published_date":"2015-07-28T19:00:00Z","last_updated_date":"2016-08-04T13:00:00Z","reference_number":"EMEA/CHMP/2990/00 Rev.5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-processing-renewals-centralised-procedure-document-tracked-changes_en.pdf"},
    {"id":"37852","name":"Procedure for the preparation of an entry to the 'Community list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products'","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-07-05T02:09:21Z","last_updated_date":"2007-07-05T02:09:21Z","reference_number":"EMEA/HMPC/57137/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-preparation-entry-community-list-herbal-substances-preparations-and-combinations-thereof-use-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"37912","name":"Glossary on herbal teas","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2010-04-28T02:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/5829/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/glossary-herbal-teas_en.pdf"},
    {"id":"37934","name":"Initial notices for parallel distribution – September 2014","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-10-14T14:00:00Z","last_updated_date":"2014-10-14T14:00:00Z","reference_number":"EMA/624990/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-september-2014_en.pdf"},
    {"id":"37944","name":"INS-GCP-4 procedure for reporting of good-clinical-practice inspections requested by the CHMP","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2017-05-15T16:19:00Z","reference_number":"EMA/INS/GCP/158549/2016 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ins-gcp-4-procedure-reporting-good-clinical-practice-inspections-requested-chmp_en.pdf"},
    {"id":"37985","name":"Guidance on the format of the risk management plan (RMP) in the EU - in integrated format (Rev. 2.0.1)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-30T17:00:00Z","last_updated_date":"2018-11-30T17:15:00Z","reference_number":"EMA/164014/2018 Rev. 2.0.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-rmp-eu-integrated-format-rev-201_en.doc"},
    {"id":"38016","name":"Superseded - EMA guidance on use of medicinal products for the treatment and prophylaxis of biological agents that might be used as weapons of bioterrorism","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2002-07-25T02:09:00Z","last_updated_date":"2024-08-12T15:51:00Z","reference_number":"CPMP/4048/01 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/superseded-ema-guidance-use-medicinal-products-treatment-prophylaxis-biological-agents-might-be-used-weapons-bioterrorism_en.pdf"},
    {"id":"38022","name":"Member states contact points for translations review","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-04-21T02:00:00Z","last_updated_date":"2026-06-05T15:26:00Z","reference_number":"EMA/102302/2005 v. 7.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/member-states-contact-points-translations-review_en.pdf"},
    {"id":"38074","name":"European Union individual case safety report (ICSR) implementation guide","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"2014-04-30 - 2014-06-30","first_published_date":"2014-04-30T14:15:00Z","last_updated_date":"2021-04-07T13:35:00Z","reference_number":"EMA/51938/2013 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-union-individual-case-safety-report-icsr-implementation-guide_en.pdf"},
    {"id":"38100","name":"Guidance on handling EMA scientific committee, Management Board or other group member’s intention to engage in occupational activities","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-05-06T12:00:00Z","last_updated_date":"2025-11-27T14:20:00Z","reference_number":"EMA/267183/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-handling-ema-scientific-committee-management-board-or-other-group-members-intention-engage-occupational-activities_en.pdf"},
    {"id":"38194","name":"Procedural advice on the accelerated assessment of marketing authorisation applications pursuant to Article 44 (3) of Regulation (EU) No 2019/6","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-07-17T02:00:00Z","last_updated_date":"2024-02-22T10:26:00Z","reference_number":"EMA/CVMP/32995/2006 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-accelerated-assessment-marketing-authorisation-applications-pursuant-article-44-3-regulation-eu-no-2019-6_en.pdf"},
    {"id":"38204","name":"CVMP Risk Management Strategy - Managing the risk of the potential presence of replication competent endogenous retrovirus RD114 in starting materials and final products of feline and canine vaccines","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T17:00:00Z","last_updated_date":"2017-02-24T17:00:00Z","reference_number":"EMA/CVMP/IWP/592652/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/cvmp-risk-management-strategy-managing-risk-potential-presence-replication-competent-endogenous-retrovirus-rd114-starting-materials-and-final-products-feline-and-canine-vaccines_en.pdf"},
    {"id":"38245","name":"Annex III to procedure for conducting good-clinical-practice inspections requested by the EMA: Computer systems","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-28T01:00:00Z","last_updated_date":"2023-09-22T17:30:00Z","reference_number":"EMA/INS/GCP/155774/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/annex-iii-procedure-conducting-good-clinical-practice-inspections-requested-ema-computer-systems_en.pdf"},
    {"id":"38318","name":"Adverse Drug Reaction (ADR) reporting - Patient guideline","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/adverse-drug-reaction-adr-reporting-patient-guideline_en.pdf"},
    {"id":"38525","name":"Guidance on format of the risk-management plan in the European Union part V: Risk-minimisation measures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2012-11-08T18:00:00Z","reference_number":"EMA/715019/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-v-risk-minimisation-measures_en.pdf"},
    {"id":"38576","name":"Guidance on format of the risk-management plan in the European Union – in integrated format (Rev. 1)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2013-08-21T18:35:00Z","reference_number":"EMA/465932/2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-integrated-format-rev-1_en.pdf"},
    {"id":"38621","name":"Triggers for audits of good laboratory practice (GLP) studies","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T14:20:00Z","last_updated_date":"2015-12-21T14:20:00Z","reference_number":"EMA/89741/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/triggers-audits-good-laboratory-practice-glp-studies_en.pdf"},
    {"id":"38641","name":"Initial notices for parallel distribution – 2012","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-07-22T13:11:00Z","last_updated_date":"2013-07-22T13:11:00Z","reference_number":"EMA/402820/2013","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-2012_en.pdf"},
    {"id":"38808","name":"Member states contact points for review of national translations of Quick Response (QR) codes of veterinary medicinal products authorised via the centralised, mutual recognition, decentralised procedures and national procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T11:12:00Z","last_updated_date":"2023-01-05T12:20:00Z","reference_number":"EMA/785529/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/member-states-contact-points-review-national-translations-quick-response-qr-codes-veterinary-medicinal-products-authorised-centralised-mutual-recognition-decentralised-procedures-and-national_en.pdf"},
    {"id":"38848","name":"Quality review of documents (QRD) template ‘Particulars to appear on the immediate package – combined label and package leaflet’ for veterinary medicinal products authorised via the centralised, mutual recognition and de...","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2017-04-03 - 2018-10-31","first_published_date":"2017-04-03T21:20:00Z","last_updated_date":"2017-04-03T21:20:00Z","reference_number":"EMA/195158/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/quality-review-documents-qrd-template-particulars-appear-immediate-package-combined-label-and-package-leaflet-veterinary-medicinal-products-authorised-centralised-mutual-recognition-and-de_en.pdf"},
    {"id":"38853","name":"Overview of comments received on draft guideline on the conduct of pharmacovigilance for vaccines for pre- and post-exposure prophylaxis against infectious diseases (EMEA/CHMP/PHVWP/503449/2007)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-07-22T02:09:21Z","last_updated_date":"2009-07-22T02:09:21Z","reference_number":"EMEA/CHMP/PhVWP/36043/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-draft-guideline-conduct-pharmacovigilance-vaccines-pre-and-post-exposure-prophylaxis-against-infectious-diseases-emeachmpphvwp5034492007_en.pdf"},
    {"id":"38867","name":"Implementation of the action plan to further progress the european risk management strategy: rolling two-year work programme (2008-2009)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-12-04T00:00:00Z","last_updated_date":"2007-12-04T00:00:00Z","reference_number":"EMEA/280089/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/implementation-action-plan-further-progress-european-risk-management-strategy-rolling-two-year-work-programme-2008-2009_en.pdf"},
    {"id":"39031","name":"INS-GCP-2 procedure for preparing GCP inspections requested by the EMEA","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2007-09-20T02:00:00Z","reference_number":"EMEA/INS/GCP/197228/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ins-gcp-2-procedure-preparing-gcp-inspections-requested-emea_en.pdf"},
    {"id":"39036","name":"EMEA implementation of electronic-only submission and eCTD submission: Questions and answers relating to practical and technical aspects of the implementation","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2008-12-01T01:00:00Z","reference_number":"EMEA/596881/2007 v0.5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/emea-implementation-electronic-only-submission-and-ectd-submission-questions-and-answers-relating-practical-and-technical-aspects-implementation_en.pdf"},
    {"id":"39053","name":"Union procedure on the preparation, conduct and reporting of EU pharmacovigilance inspections","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-06-20T12:15:00Z","last_updated_date":"2024-03-27T09:30:00Z","reference_number":"EMA/INS/PhV/192230/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/union-procedure-preparation-conduct-reporting-eu-pharmacovigilance-inspections_en.pdf"},
    {"id":"39214","name":"EudraVigilance XCOMP release - EudraVigilance web application (EVWEB) version 3.0","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2017-11-22T10:30:00Z","reference_number":"EMA/629617/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-xcomp-release-eudravigilance-web-application-evweb-version-30_en.pdf"},
    {"id":"39228","name":"Guidance on format of the risk-management plan in the European Union part II: Module SVII - Identified and potential risks","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-08T18:00:00Z","last_updated_date":"2012-11-08T18:00:00Z","reference_number":"EMA/714754/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-ii-module-svii-identified-and-potential-risks_en.pdf"},
    {"id":"39359","name":"Qualification opinion of novel methodologies in the predementia stage of Alzheimer’s disease: cerebrospinal-fluid-related biomarkers for drugs affecting amyloid burden","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-05-16T02:00:00Z","last_updated_date":"2011-05-16T02:00:00Z","reference_number":"EMA/CHMP/SAWP/102001/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-novel-methodologies-predementia-stage-alzheimers-disease-cerebrospinal-fluid-related-biomarkers-drugs-affecting-amyloid-burden_en.pdf"},
    {"id":"39418","name":"IRIS guide to registration and RPIs","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T17:29:00Z","last_updated_date":"2026-06-15T13:00:00Z","reference_number":"EMA/444925/2018 Version 2.19","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/iris-guide-registration-rpis_en.pdf"},
    {"id":"39490","name":"Procedural advice on the evaluation of advanced therapy medicinal product in accordance with Article 8 of Regulation (EC) No 1394/2007","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-02-01T11:40:00Z","last_updated_date":"2018-02-01T11:40:00Z","reference_number":"EMA/630043/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-evaluation-advanced-therapy-medicinal-product-accordance-article-8-regulation-ec-no-13942007_en.pdf"},
    {"id":"39511","name":"Guidance on format of the risk-management plan in the European Union part V: Risk-minimisation measures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-14T01:00:00Z","last_updated_date":"2012-11-14T01:00:00Z","reference_number":"EMA/715019/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-european-union-part-v-risk-minimisation-measures_en.doc"},
    {"id":"39533","name":"Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood com...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-02-07T00:09:21Z","last_updated_date":"2003-02-07T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/directive-200298ec-european-parliament-and-council-27-january-2003-setting-standards-quality-and-safety-collection-testing-processing-storage-and-distribution-human-blood-and-blood-com_en.pdf"},
    {"id":"39619","name":"An analysis of quality product defects in the centralised procedure","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-01-18T01:00:00Z","last_updated_date":"2007-01-18T01:00:00Z","reference_number":"EMEA/INS/GMP/23020/2007","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/analysis-quality-product-defects-centralised-procedure_en.pdf"},
    {"id":"39841","name":"Example of a template for communicating a Member State's data on all existing uses of medicinal products in the paediatric population to the Agency","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-12-05T00:09:21Z","last_updated_date":"2007-12-05T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/example-template-communicating-member-states-data-all-existing-uses-medicinal-products-paediatric-population-agency_en.pdf"},
    {"id":"39968","name":"Qualification opinion of low hippocampal volume (atrophy) by magnetic-resonance imaging for use in regulatory clinical trials in predementia stage of Alzheimer’s disease","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2011-09-22 - 2011-11-01","first_published_date":"2011-10-12T19:55:38Z","last_updated_date":"2011-10-12T19:55:38Z","reference_number":"EMA/CHMP/SAWP/102001/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-low-hippocampal-volume-atrophy-magnetic-resonance-imaging-use-regulatory-clinical-trials-predementia-stage-alzheimers-disease_en.pdf"},
    {"id":"39986","name":"Guidance on parallel EMA / EUnetHTA 21 Joint Scientific Consultation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-07-04T11:00:00Z","last_updated_date":"2022-10-06T13:04:00Z","reference_number":"EMA/410962/2017 Rev. 7","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-parallel-ema-eunethta-21-joint-scientific-consultation_en.pdf"},
    {"id":"40020","name":"Questions and answers on Article 20 non-pharmacovigilance procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-07-06T18:00:00Z","last_updated_date":"2016-07-06T18:00:00Z","reference_number":"EMA/457260/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-20-non-pharmacovigilance-procedures_en.pdf"},
    {"id":"40178","name":"Procedure to be followed to facilitate communication and\n\ndialogue between the CVMP and the interested parties","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-06T02:00:00Z","last_updated_date":"2006-06-06T02:00:00Z","reference_number":"EMEA/CVMP/329/04-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-be-followed-facilitate-communication-and-dialogue-between-cvmp-and-interested-parties_en.pdf"},
    {"id":"40282","name":"ICH guideline S1 - Regulatory notice on changes to core guideline on rodent carcinogenicity testing of pharmaceuticals","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"2012-12-17 - 2013-04-01","first_published_date":"2012-12-17T15:55:00Z","last_updated_date":"2016-03-02T13:25:00Z","reference_number":"EMA/CHMP/ICH/536328/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-s1-regulatory-notice-changes-core-guideline-rodent-carcinogenicity-testing-pharmaceuticals_en.pdf"},
    {"id":"40376","name":"Submission deadlines for 2008-2009 for request for compliance check","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-08-15T02:00:00Z","last_updated_date":"2008-08-15T02:00:00Z","reference_number":"EMEA/PDCO/419774/2008","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/submission-deadlines-2008-2009-request-compliance-check_en.pdf"},
    {"id":"40500","name":"EudraVigilance checklist and technical support plan for marketing authorisation holders and sponsors of clinical trials in the EEA","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2017-06-26T14:00:00Z","reference_number":"EMA/306740/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-checklist-and-technical-support-plan-marketing-authorisation-holders-and-sponsors-clinical-trials-eea_en.pdf"},
    {"id":"40680","name":"Day 80 assessment report generics overview guidance","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2015-02-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/day-80-assessment-report-generics-overview-guidance_en.pdf"},
    {"id":"40720","name":"Pre-notification check for type IB Variations","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-11-06T13:00:00Z","last_updated_date":"2015-11-06T13:00:00Z","reference_number":"EMA/413829/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pre-notification-check-type-ib-variations_en.pdf"},
    {"id":"40737","name":"Draft guidance on format of the risk management plan (RMP) in the EU – in integrated format","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-29 - 2016-05-31","first_published_date":"2016-02-29T14:00:00Z","last_updated_date":"2016-02-29T14:00:00Z","reference_number":"EMA/PRAC/613102/2015 Rev.2 accompanying GVP Module","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guidance-format-risk-management-plan-rmp-eu-integrated-format_en.doc"},
    {"id":"40862","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with final addendum I to module XVI on educational materials and, for public consultation draft revision 1 of module XV on safet...","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T12:30:00Z","last_updated_date":"2015-12-15T12:30:00Z","reference_number":"EMA/772189/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-final-addendum-i-module-xvi-educational-materials-and-public-consultation-draft-revision-1-module-xv-safet_en.pdf"},
    {"id":"40888","name":"Timetable for sending of translations to Croatia","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2011-01-31T01:00:00Z","last_updated_date":"2011-08-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/timetable-sending-translations-croatia_en.pdf"},
    {"id":"41037","name":"Recommendations for the implementation of the exemptions to the labelling and package-leaflet obligations in the centralised procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-08-19T16:30:00Z","last_updated_date":"2019-06-18T10:16:00Z","reference_number":"EMA/135540/2019 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/recommendations-implementation-exemptions-labelling-and-package-leaflet-obligations-centralised-procedure_en.pdf"},
    {"id":"41045","name":"Day 80 assessment report - Clinical guidance","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:09:21Z","last_updated_date":"2014-05-28T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/day-80-assessment-report-clinical-guidance_en.pdf"},
    {"id":"41091","name":"Guideline on reporting of suspected transmission of any infectious agent via a medicinal product","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2005-06-01 - 2006-03-31","first_published_date":"2006-01-23T01:00:00Z","last_updated_date":"2006-01-23T01:00:00Z","reference_number":"EMEA/CHMP/296412/2005","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-reporting-suspected-transmission-any-infectious-agent-medicinal-product_en.pdf"},
    {"id":"41395","name":"Good practice guide on risk minimisation and prevention of medication errors","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-11-27T11:00:00Z","last_updated_date":"2015-11-27T11:00:00Z","reference_number":"EMA/606103/2014","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practice-guide-risk-minimisation-and-prevention-medication-errors_en.pdf"},
    {"id":"41756","name":"EudraVigilance - European database of suspected adverse reactions related to medicines: user manual for online access via the adrreports.eu portal - Version 2.0","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-11-22T10:30:00Z","last_updated_date":"2017-11-22T10:30:00Z","reference_number":"EMA/754608/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-european-database-suspected-adverse-reactions-related-medicines-user-manual-online-access-adrreportseu-portal-version-20_en.pdf"}    {"id":"41826","name":"Initial notices for parallel distribution - April 2015","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-05-19T13:58:00Z","last_updated_date":"2015-05-19T13:58:00Z","reference_number":"EMA/304193/2015","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/initial-notices-parallel-distribution-april-2015_en.pdf"},
    {"id":"41884","name":"Guidance for applicants for the preparation of the precise scope section of the variation application form","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-30T16:00:00Z","last_updated_date":"2026-02-12T16:00:00Z","reference_number":"EMA/220707/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-applicants-preparation-precise-scope-section-variation-application-form_en.pdf"},
    {"id":"41917","name":"Instruction guide to support the e-learning training module IT-M2 - E2B(R3)/E2B(R2) XML testing - Version 1.0","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2017-06-26T14:00:00Z","reference_number":"EMA/12076/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/instruction-guide-support-e-learning-training-module-it-m2-e2br3e2br2-xml-testing-version-10_en.pdf"},
    {"id":"41970","name":"Comments received from public consultation on good pharmacovigilance practices (GVP) - GVP Module VI – Management and reporting of adverse reactions to medicinal products (EMA/873138/2011 Rev. 2)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-08-02T12:00:00Z","last_updated_date":"2017-08-02T12:00:00Z","reference_number":"EMA/847133/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/comments-received-public-consultation-good-pharmacovigilance-practices-gvp-gvp-module-vi-management-and-reporting-adverse-reactions-medicinal-products-ema8731382011-rev-2_en.pdf"},
    {"id":"42135","name":"Draft qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2018-09-21 - 2018-11-30","first_published_date":"2018-09-21T17:30:00Z","last_updated_date":"2018-09-21T17:30:00Z","reference_number":"EMA/CHMP/SAWP/527447/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-stride-velocity-95th-centile-secondary-endpoint-duchenne-muscular-dystrophy-measured-valid-and-suitable-wearable-device_en.pdf"},
    {"id":"42185","name":"Qualification Opinion on The European Cystic Fibrosis Society Patient Registry (ECFSPR) and CF Pharmaco-epidemiology Studies","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-10-03T13:07:00Z","last_updated_date":"2018-10-03T13:07:00Z","reference_number":"EMA/CHMP/SAWP/622564/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-european-cystic-fibrosis-society-patient-registry-ecfspr-and-cf-pharmaco-epidemiology-studies_en.pdf"},
    {"id":"42449","name":"Quick interactive guide to EudraVigilance registration process","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-10-26T18:07:00Z","last_updated_date":"2018-10-26T18:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/quick-interactive-guide-eudravigilance-registration-process_en.pdf"},
    {"id":"42562","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with chapter P.IV on pharmacovigilance for the paediatric population finalised post-public consultation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-11-07T12:27:00Z","last_updated_date":"2018-11-07T12:27:00Z","reference_number":"EMA/722239/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-chapter-piv-pharmacovigilance-paediatric-population-finalised-post-public-consultation_en.pdf"},
    {"id":"42610","name":"External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use - Version 1.4","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-11-09T12:54:00Z","last_updated_date":"2018-11-09T12:54:00Z","reference_number":"EMA/90915/2016 Version 1.4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-version-14_en.pdf"},
    {"id":"42690","name":"Draft qualification opinion on eSource Direct Data Capture (DDC)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-15 - 2019-03-14","first_published_date":"2018-11-15T13:22:00Z","last_updated_date":"2018-11-15T13:22:00Z","reference_number":"EMA/282576/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-esource-direct-data-capture-ddc_en.pdf"},
    {"id":"42945","name":"EudraVigilance registration frequently asked questions","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-12-06T11:50:00Z","last_updated_date":"2020-03-27T14:47:00Z","reference_number":"EMA/404930/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-registration-frequently-asked-questions_en.pdf"},
    {"id":"43093","name":"EudraVigilance access policy for medicines for veterinary use - Revision 1","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T15:45:00Z","last_updated_date":"2018-12-14T15:45:00Z","reference_number":"EMA/113700/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-access-policy-medicines-veterinary-use-revision-1_en.pdf"},
    {"id":"43153","name":"Draft EMA Regulatory Science to 2025 - Strategic reflection","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-19 - 2019-06-30","first_published_date":"2018-12-19T13:00:00Z","last_updated_date":"2018-12-19T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-ema-regulatory-science-2025-strategic-reflection_en.pdf"},
    {"id":"43352","name":"Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Preliminary risk profiling for new antimicrobials","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2019-01-15 - 2019-03-31","first_published_date":"2019-01-14T16:57:00Z","last_updated_date":"2019-01-14T16:57:00Z","reference_number":"EMA/CVMP/CHMP/682199/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/answer-request-european-commission-updating-scientific-advice-impact-public-health-and-animal-health-use-antibiotics-animals-preliminary-risk-profiling-new-antimicrobials_en.pdf"},
    {"id":"43399","name":"Checklist for the submission of Type IA and Type IB (without linguistic review) product information annexes and Annex A (if applicable) - veterinary","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-01-18T14:24:00Z","last_updated_date":"2019-01-18T14:24:00Z","reference_number":"EMA/801564/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/checklist-submission-type-ia-and-type-ib-without-linguistic-review-product-information-annexes-and-annex-if-applicable-veterinary_en.pdf"},
    {"id":"43555","name":"Draft procedure on management of proposals submitted by Interested Parties for European Union List Entries or European Union herbal monographs - Revision 2","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2019-01-30 - 2019-07-30","first_published_date":"2019-01-30T18:00:00Z","last_updated_date":"2019-01-30T18:00:00Z","reference_number":"EMEA/HMPC/328575/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-procedure-management-proposals-submitted-interested-parties-european-union-list-entries-or-european-union-herbal-monographs-revision-2_en.pdf"},
    {"id":"43559","name":"Electronic product information for human medicines in the European Union – draft key principles","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2019-01-31 - 2019-07-31","first_published_date":"2019-01-31T13:00:00Z","last_updated_date":"2019-01-31T13:00:00Z","reference_number":"EMA/849614/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/electronic-product-information-human-medicines-european-union-draft-key-principles_en.pdf"},
    {"id":"43688","name":"IRIS guide for parallel distribution applicants","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-02-11T11:15:00Z","last_updated_date":"2022-12-13T11:35:00Z","reference_number":"EMA/805961/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/iris-guide-parallel-distribution-applicants_en.pdf"},
    {"id":"43829","name":"Rules of procedure for the Patients and Consumers Working Party (PCWP) and the Healthcare Professionals Working Party (HCPWP)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-02-20T12:09:00Z","last_updated_date":"2025-04-02T10:17:00Z","reference_number":"EMA/109591/2018 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-procedure-patients-consumers-working-party-pcwp-healthcare-professionals-working-party-hcpwp_en.pdf"},
    {"id":"43928","name":"Questions and answers on implementation of the medical devices and in vitro diagnostic medical devices Regulations ((EU) 2017/745 and (EU) 2017/746)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-02-28T12:00:00Z","last_updated_date":"2025-12-02T11:25:00Z","reference_number":"EMA/37991/2019 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu-2017-745-eu-2017-746_en.pdf"},
    {"id":"44097","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures - Revised implementing rules to the Fee Regulation as of 1 April 2019","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-03-22T16:33:00Z","last_updated_date":"2019-03-22T16:33:00Z","reference_number":"EMA/MB/909612/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures-revised-implementing-rules-fee-regulation-1-april-2019_en.pdf"},
    {"id":"44152","name":"Explanatory note on general fees payable to the European Medicines Agency as of 1 April 2019","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-04-01T10:00:00Z","last_updated_date":"2019-04-01T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/explanatory-note-general-fees-payable-european-medicines-agency-1-april-2019_en.pdf"},
    {"id":"44159","name":"Biologics Working Party (BWP) Ad hoc Influenza Working Group - Amended European Union recommendations for the seasonal influenza vaccine composition for the season 2019/2020","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-04-01T14:00:00Z","last_updated_date":"2019-05-20T12:30:00Z","reference_number":"EMA/CHMP/BWP/266098/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/biologics-working-party-bwp-ad-hoc-influenza-working-group-amended-european-union-recommendations-seasonal-influenza-vaccine-composition-season-20192020_en.pdf"},
    {"id":"44667","name":"Strengthening collaboration between EMA and general practitioners / family physicians","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-06-06T12:29:00Z","last_updated_date":"2019-06-06T12:29:00Z","reference_number":"EMA/875796/2016","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/strengthening-collaboration-between-ema-and-general-practitioners-family-physicians_en.pdf"},
    {"id":"44896","name":"Detailed guide regarding the monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - Addendum 1","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-06-26T16:28:00Z","last_updated_date":"2019-06-26T16:28:00Z","reference_number":"EMA/193190/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/detailed-guide-regarding-monitoring-medical-literature-and-entry-relevant-information-eudravigilance-database-european-medicines-agency-addendum-1_en.pdf"},
    {"id":"44987","name":"Good practice guidance for communication to the public on medicines’ availability issues","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-07-04T14:30:00Z","last_updated_date":"2024-12-17T17:49:00Z","reference_number":"EMA/632473/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practice-guidance-communication-public-medicines-availability-issues_en.pdf"},
    {"id":"44988","name":"Guidance on detection and notification of shortages of medicinal products for Marketing Authorisation Holders (MAHs) in the Union (EEA)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-07-04T14:30:00Z","last_updated_date":"2019-07-04T14:30:00Z","reference_number":"EMA/674304/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-detection-and-notification-shortages-medicinal-products-marketing-authorisation-holders-mahs-union-eea_en.pdf"},
    {"id":"45024","name":"Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Preliminary risk profiling for new antimicrobial veterinary medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-07-10T10:29:00Z","last_updated_date":"2019-07-10T10:29:00Z","reference_number":"EMA/CVMP/CHMP/682199/2017","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/answer-request-european-commission-updating-scientific-advice-impact-public-health-and-animal-health-use-antibiotics-animals-preliminary-risk-profiling-new-antimicrobial-veterinary-medicinal-products_en.pdf"},
    {"id":"45025","name":"Overview of comments received on 'Answer to the request from the EC for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals - Preliminary risk profiling for new antimicrobial vet products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-07-10T10:32:00Z","last_updated_date":"2019-07-10T10:32:00Z","reference_number":"EMA/CVMP/CHMP/201533/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-answer-request-ec-updating-scientific-advice-impact-public-health-and-animal-health-use-antibiotics-animals-preliminary-risk-profiling-new-antimicrobial-vet-products_en.pdf"},
    {"id":"45474","name":"Qualification opinion on eSource Direct Data Capture (DDC)","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-09-19T11:14:00Z","last_updated_date":"2019-09-19T11:14:00Z","reference_number":"EMA/CHMP/SAWP/483349/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-esource-direct-data-capture-ddc_en.pdf"},
    {"id":"45501","name":"Advice implementing measures under Article 146(2) of Regulation (EU) 2019/6 on veterinary medicinal products – Scientific recommendation on the revision of Annex II to Regulation (EU) 2019/6 on veterinary medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-09-23T09:28:00Z","last_updated_date":"2019-09-23T09:28:00Z","reference_number":"EMA/CVMP/351417/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-implementing-measures-under-article-1462-regulation-eu-20196-veterinary-medicinal-products-scientific-recommendation-revision-annex-ii-regulation-eu-20196-veterinary-medicinal-products_en.pdf"},
    {"id":"45502","name":"Advice to the European Commission on the Union Product Database","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-09-23T09:32:00Z","last_updated_date":"2019-09-23T09:32:00Z","reference_number":"EMA/392996/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-european-commission-union-product-database_en.pdf"},
    {"id":"45504","name":"Advice on implementing measures under Article 60(1) of Regulation (EU) 2019/6 on veterinary medicinal products - Scientific recommendation on the list of variations not requiring assessment","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-09-23T09:35:00Z","last_updated_date":"2019-09-23T09:35:00Z","reference_number":"EMA/CVMP/263581/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-implementing-measures-under-article-601-regulation-eu-20196-veterinary-medicinal-products-scientific-recommendation-list-variations-not-requiring-assessment_en.pdf"},
    {"id":"45764","name":"Wording of therapeutic indication - A guide for assessors of centralised applications","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-10-21T12:21:00Z","last_updated_date":"2019-10-21T12:21:00Z","reference_number":"EMA/CHMP/483022/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/wording-therapeutic-indication-guide-assessors-centralised-applications_en.pdf"},
    {"id":"45767","name":"Questions and answers on implementation of the medical devices and in vitro diagnostic medical devices Regulations ((EU) 2017/745 and (EU) 2017/746) - tracked changes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-10-22T14:37:00Z","last_updated_date":"2025-12-02T11:25:00Z","reference_number":"EMA/37991/2019 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu-2017-745-eu-2017-746-tracked-changes_en.pdf"},
    {"id":"45864","name":"EudraVigilance registration documents","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T12:00:00Z","last_updated_date":"2025-01-07T15:15:00Z","reference_number":"EMA/503894/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance_registration_documents_en.pdf"},
    {"id":"46124","name":"Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-11-25T13:34:00Z","last_updated_date":"2019-11-25T13:34:00Z","reference_number":"EMA/CVMP/158366/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-implementing-measures-under-article-374-regulation-eu-20196-veterinary-medicinal-products-criteria-designation-antimicrobials-be-reserved-treatment-certain-infections-humans_en.pdf"},
    {"id":"46290","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with chapter P.III on pharmacovigilance for the use of medicines by pregnant and breastfeeding women","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-12-11T09:08:00Z","last_updated_date":"2019-12-11T09:08:00Z","reference_number":"EMA/659929/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-chapter-piii-pharmacovigilance-use-medicines-pregnant-and-breastfeeding-women_en.pdf"},
    {"id":"46467","name":"Superseded - EMA recommendation on the procedural aspects and dossier requirements for the consultation of the EMA by a notified body on an ancillary medicinal substance or an ancillary human blood derivative incorporated in a medical device - Revision 1","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-01-21T12:04:00Z","last_updated_date":"2020-01-21T12:04:00Z","reference_number":"EMA/CHMP/578661/2010 Rev .1 ","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/superseded-ema-recommendation-procedural-aspects-dossier-requirements-consultation-ema-notified-body-ancillary-medicinal-substance-or-ancillary-human-blood-derivative-incorporated-medical-device_en.pdf"},
    {"id":"46585","name":"Electronic product information for human medicines in the European Union - key principles","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-01-29T15:00:00Z","last_updated_date":"2020-01-29T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/electronic-product-information-human-medicines-european-union-key-principles_en.pdf"},
    {"id":"46615","name":"Guidance for applicants on a pilot for Simultaneous National Scientific Advice (SNSA)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-01-29T17:00:00Z","last_updated_date":"2020-04-16T17:16:00Z","reference_number":"Revision 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-applicants-pilot-simultaneous-national-scientific-advice-snsa_en.pdf"},
    {"id":"46689","name":"Products Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 1: Registration requirements for production environments","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-02-11T15:00:00Z","last_updated_date":"2026-06-12T14:41:00Z","reference_number":"EMA/676105/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/products-management-services-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-1-registration-requirements_en.pdf"},
    {"id":"46690","name":"Product Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 2","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-02-11T15:00:00Z","last_updated_date":"2025-08-08T11:20:00Z","reference_number":"EMA/285848/2020 Version 2.4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/product-management-services-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-2_en.pdf"},
    {"id":"46691","name":"Products Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 6","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-02-11T15:00:00Z","last_updated_date":"2020-02-11T15:00:00Z","reference_number":"EMA/676108/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/products-management-services-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-6_en.pdf"},
    {"id":"46692","name":"Products Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 7","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-02-11T15:00:00Z","last_updated_date":"2024-07-02T09:35:00Z","reference_number":"EMA/676106/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/products-management-services-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-7_en.pdf"},
    {"id":"46693","name":"Substances, Products, Organisations, Referentials (SPOR): SPOR API v2 Specification","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-02-11T15:00:00Z","last_updated_date":"2020-02-11T15:00:00Z","reference_number":"EMA/676296/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/substances-products-organisations-referentials-spor-spor-api-v2-specification_en.pdf"},
    {"id":"46703","name":"Products Management Services - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe: Introduction - EU Implementation Guide","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-02-11T15:00:00Z","last_updated_date":"2024-05-14T09:48:00Z","reference_number":"EMA/676106/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/products-management-services-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-introduction-eu-implementation-guide_en.pdf"},
    {"id":"47052","name":"Notice to stakeholders - Withdrawal of the United Kingdom and EU rules for medicinal products for human use and veterinary medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-03-19T14:30:00Z","last_updated_date":"2020-03-19T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/notice-stakeholders-withdrawal-united-kingdom-and-eu-rules-medicinal-products-human-use-and-veterinary-medicinal-products_en.pdf"},
    {"id":"47089","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures - Revised implementing rules to the Fee Regulation as of 1 April 2020","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-03-20T16:33:00Z","last_updated_date":"2020-03-20T16:33:00Z","reference_number":"EMA/MB/332998/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures-revised-implementing-rules-fee-regulation-1-april-2020_en.pdf"},
    {"id":"47247","name":"EMA Regulatory Science to 2025 - Strategic reflection","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T17:00:00Z","last_updated_date":"2020-03-31T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf"},
    {"id":"47251","name":"Explanatory note on general fees payable to the European Medicines Agency as of 1 April 2020","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-04-01T10:30:00Z","last_updated_date":"2020-04-01T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/explanatory-note-general-fees-payable-european-medicines-agency-1-april-2020_en.pdf"},
    {"id":"47252","name":"Commission Regulation (EU) 2020/422 of 19 March 2020 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate with effect from 1 April 2020","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-04-01T10:30:00Z","last_updated_date":"2020-04-01T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/commission-regulation-eu-2020422-19-march-2020-amending-council-regulation-ec-no-29795-regards-adjustment-fees-european-medicines-agency-inflation-rate-effect-1-april-2020_en.pdf"},
    {"id":"47261","name":"Biologics Working Party (BWP) Ad hoc Influenza Working Group - Amended European Union recommendations for the seasonal influenza vaccine composition for the season 2020/2021","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T13:00:00Z","last_updated_date":"2020-05-15T15:45:00Z","reference_number":"EMA/CHMP/BWP/134670/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/biologics-working-party-bwp-ad-hoc-influenza-working-group-amended-european-union-recommendations-seasonal-influenza-vaccine-composition-season-20202021_en.pdf"},
    {"id":"47405","name":"Notice to sponsors on validation and qualification of computerised systems used in clinical trials","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-04-15T09:40:00Z","last_updated_date":"2020-04-15T09:40:00Z","reference_number":"EMA/INS/GCP/467532/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/notice-sponsors-validation-qualification-computerised-systems-used-clinical-trials_en.pdf"},
    {"id":"47407","name":"Procedure on management of proposals submitted by Interested Parties for European Union List Entries or European Union herbal monographs - Revision 2","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-04-15T11:13:00Z","last_updated_date":"2020-04-15T11:13:00Z","reference_number":"EMEA/HMPC/328575/2007 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-management-proposals-submitted-interested-parties-european-union-list-entries-or-european-union-herbal-monographs-revision-2_en.pdf"},
    {"id":"47421","name":"Guidance for applicants on a pilot for Simultaneous National Scientific Advice (SNSA) - tracked changes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-04-16T17:16:00Z","last_updated_date":"2020-04-16T17:16:00Z","reference_number":"Revision 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-applicants-pilot-simultaneous-national-scientific-advice-snsa-tracked-changes_en.pdf"},
    {"id":"47422","name":"European Medicines Agency’s privacy statement for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Resource Database","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-04-16T17:24:00Z","last_updated_date":"2020-04-16T17:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agencys-privacy-statement-european-network-centres-pharmacoepidemiology-and-pharmacovigilance-encepp-resource-database_en.pdf"},
    {"id":"47423","name":"European Medicines Agency’s privacy statement for the European Union electronic Register of Post-Authorisation Studies (EU PAS Register)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-04-16T17:30:00Z","last_updated_date":"2020-04-16T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agencys-privacy-statement-european-union-electronic-register-post-authorisation-studies-eu-pas-register_en.pdf"},
    {"id":"47437","name":"Detailed guidance on ICSRs in the context of COVID-19 - Validity and coding of ICSRs","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-04-20T14:49:00Z","last_updated_date":"2022-04-13T15:20:00Z","reference_number":"EMA/174312/2020 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/detailed-guidance-icsrs-context-covid-19-validity-and-coding-icsrs_en.pdf"},
    {"id":"47440","name":"Information note on the format and validity features of electronic certificates for medicines issued by the European Medicines Agency","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-04-20T16:56:00Z","last_updated_date":"2023-01-16T15:20:00Z","reference_number":"EMA/206719/2020 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/information-note-format-and-validity-features-electronic-certificates-medicines-issued-european-medicines-agency_en.pdf"},
    {"id":"47516","name":"Union procedure on the follow-up of pharmacovigilance inspections","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T10:36:00Z","last_updated_date":"2020-04-30T10:36:00Z","reference_number":"EMA/INS/PhV/327777/2018","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/union-procedure-follow-pharmacovigilance-inspections_en.pdf"},
    {"id":"47718","name":"Checklist for initial notifications for parallel distribution: guidance for industry","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T16:44:00Z","last_updated_date":"2025-01-06T09:15:00Z","reference_number":"EMA/271978/2024 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/checklist-initial-notifications-parallel-distribution-guidance-industry_en.pdf"},
    {"id":"47732","name":"Pharmacovigilance regulatory recommendations for centrally authorised veterinary medicinal products during 2020","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-05-20T08:50:00Z","last_updated_date":"2020-12-15T17:21:00Z","reference_number":"EMA/112926/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pharmacovigilance-regulatory-recommendations-centrally-authorised-veterinary-medicinal-products-during-2020_en.pdf"},
    {"id":"47894","name":"Guidance on remote GCP inspections during the COVID-19 pandemic","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-06-10T11:40:00Z","last_updated_date":"2020-06-10T11:40:00Z","reference_number":"EMA/INS/GCP/162006/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-remote-gcp-inspections-during-covid-19-pandemic_en.pdf"},
    {"id":"48010","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures - Revised implementing rules to the Fee Regulation as of 12 June 2020","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-06-15T16:42:00Z","last_updated_date":"2020-06-15T16:42:00Z","reference_number":"EMA/MB/238467/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures-revised-implementing-rules-fee-regulation-12-june-2020_en.pdf"},
    {"id":"48095","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with revision 3 of Addendum I of Module VIII on requirements and recommendations for the submission of information (2020)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:05:00Z","last_updated_date":"2020-06-23T14:05:00Z","reference_number":"EMA/261052/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-revision-3-addendum-i-module-viii-requirements-and-recommendations-submission-information-2020_en.pdf"},
    {"id":"48257","name":"Advice on implementing measures under Article 95(8) of Regulation (EU) 2019/6 on veterinary medicinal products - Good distribution practices (GDP) for active substances used as starting materials in veterinary medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-07-08T12:03:00Z","last_updated_date":"2020-07-08T12:03:00Z","reference_number":"EMA/87754/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-implementing-measures-under-article-958-regulation-eu-20196-veterinary-medicinal-products-good-distribution-practices-gdp-active-substances-used-starting-materials-veterinary-medicinal-products_en.pdf"},
    {"id":"48258","name":"Advice on implementing measures under Article 99(6) of Regulation (EU) 2019/6 on veterinary medicinal products - Good distribution practices (GDP) for veterinary medicinal products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-07-08T12:03:00Z","last_updated_date":"2020-07-08T12:03:00Z","reference_number":"EMA/567192/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-implementing-measures-under-article-996-regulation-eu-20196-veterinary-medicinal-products-good-distribution-practices-gdp-veterinary-medicinal-products_en.pdf"},
    {"id":"48259","name":"Advice on implementing measures under Article 57(4) of Regulation (EU) 2019/6 on veterinary medicinal products - Report on the format of the data to be collected on antimicrobial medicinal products used in animals","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-07-08T12:03:00Z","last_updated_date":"2020-07-08T12:03:00Z","reference_number":"EMA/CVMP/586518/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-implementing-measures-under-article-574-regulation-eu-20196-veterinary-medicinal-products-report-format-data-be-collected-antimicrobial-medicinal-products-used-animals_en.pdf"},
    {"id":"48325","name":"Draft Union Product Database (UPD) Access Policy - Veterinary Medicinal Products - Policy no 0082","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2020-07-17 - 2020-09-18","first_published_date":"2020-07-17T19:10:00Z","last_updated_date":"2020-07-17T19:10:00Z","reference_number":"EMA/198149/2020 ","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-union-product-database-upd-access-policy-veterinary-medicinal-products-policy-no-0082_en.pdf"},
    {"id":"48333","name":"Concept paper for the development of a reflection paper on criteria for the application of Article 40(5) of Regulation (EU) 2019/6","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2020-07-20 - 2020-09-21","first_published_date":"2020-07-20T17:33:00Z","last_updated_date":"2020-07-20T17:33:00Z","reference_number":"EMA/CVMP/340959/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/concept-paper-development-reflection-paper-criteria-application-article-405-regulation-eu-2019-6_en.pdf"},
    {"id":"48654","name":"European Medicines Agency privacy statement for EnprEMA network database","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-08-20T13:41:00Z","last_updated_date":"2020-08-20T13:41:00Z","reference_number":"EMA/461900/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-privacy-statement-enprema-network-database_en.pdf"},
    {"id":"48821","name":"Advice on implementing measures under Art 106(6) of Reg (EU) 2019/6 on veterinary medicinal products – scientific problem analysis and recommendations to ensure a safe and efficient administration of oral veterinary medicinal products via routes other ...","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-09-16T12:00:00Z","last_updated_date":"2020-09-16T12:00:00Z","reference_number":"EMA/CVMP/508559/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-implementing-measures-under-art-1066-reg-eu-2019-6-veterinary-medicinal-products-scientific-problem-analysis-recommendations-ensure-safe-efficient-administration-oral-veterinary-medicinal_en.pdf"},
    {"id":"48967","name":"Checklist for annual updates for parallel distribution: guidance for industry","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-10-08T11:53:00Z","last_updated_date":"2025-01-06T09:16:00Z","reference_number":"EMA/271966/2024 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/checklist-annual-updates-parallel-distribution-guidance-industry_en.pdf"},
    {"id":"49220","name":"Draft concept paper on the reporting of antimicrobial sales and use in animals at the EU level","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2020-11-12 - 2021-01-31","first_published_date":"2020-11-12T10:00:00Z","last_updated_date":"2020-11-12T10:00:00Z","reference_number":"EMA/222040/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-concept-paper-reporting-antimicrobial-sales-and-use-animals-eu-level_en.pdf"},
    {"id":"49788","name":"Draft EudraVigilance access policy for medicines for veterinary use - Revision 2","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-01-12 - 2021-03-12","first_published_date":"2021-01-12T18:48:00Z","last_updated_date":"2021-01-12T18:48:00Z","reference_number":"EMA/113700/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-eudravigilance-access-policy-medicines-veterinary-use-revision-2_en.pdf"},
    {"id":"49795","name":"Draft guidance - Parallel application for EU-M4all (Article 58) opinion and centralised marketing authorisation procedure","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-01-14 - 2021-02-15","first_published_date":"2021-01-14T10:50:00Z","last_updated_date":"2021-01-14T10:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guidance-parallel-application-eu-m4all-article-58-opinion-and-centralised-marketing-authorisation-procedure_en.pdf"},
    {"id":"49880","name":"EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - obsolete","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-01-21T17:25:00Z","last_updated_date":"2021-05-17T13:48:00Z","reference_number":"EMA/772576/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-obsolete_en.pdf"},
    {"id":"49881","name":"EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 1: Registration and data access requirements for the User Interface (UI) and Application Programming Interface (API) - obsolete","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-01-21T17:24:00Z","last_updated_date":"2021-05-17T13:50:00Z","reference_number":"EMA/772573/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-chapter-1-registration-data-access-requirements-user-interface-ui-application-programming-interface-api-obsolete_en.pdf"},
    {"id":"49882","name":"EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 2: Format for the electronic submission of veterinary medicinal product information","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-01-21T17:23:00Z","last_updated_date":"2025-09-16T16:40:00Z","reference_number":"EMA/772581/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-chapter-2-format-electronic-submission-veterinary-medicinal-product-information_en.pdf"},
    {"id":"49883","name":"EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 3: Process for the initial submission and maintenance of veterinary medicinal products information - obsolete","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-01-21T17:22:00Z","last_updated_date":"2021-05-17T13:52:00Z","reference_number":"EMA/772574/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-chapter-3-process-initial-submission-maintenance-veterinary-medicinal-products-information-obsolete_en.pdf"},
    {"id":"49884","name":"EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 4: Process and format for the submission of legacy data on veterinary medicinal products - obsolete","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-01-21T17:21:00Z","last_updated_date":"2025-09-02T10:53:00Z","reference_number":"EMA/772577/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-chapter-4-process-format-submission-legacy-data-veterinary-medicinal-products-obsolete_en.pdf"},
    {"id":"49885","name":"EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 5: Technical specifications","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-01-21T17:20:00Z","last_updated_date":"2026-03-19T13:19:00Z","reference_number":"EMA/772575/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-chapter-5-technical-specifications_en.pdf"},
    {"id":"50044","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, revision 3 of Module XVI on risk minimisation measures and its Addendum II on methods for their effectiveness evaluation for public consultation (2021)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-02-03T13:14:00Z","last_updated_date":"2021-02-03T13:14:00Z","reference_number":"EMA/54854/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-revision-3-module-xvi-risk-minimisation-measures-and-its-addendum-ii-methods-their-effectiveness-evaluation-public-consultation_en.pdf"},
    {"id":"50045","name":"Draft guideline on good pharmacovigilance practices (GVP): Module XVI - Risk minimisation measures: selection of tools and effectiveness indicators (Rev 3)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-02-03 - 2021-04-28","first_published_date":"2021-02-03T14:20:00Z","last_updated_date":"2021-03-03T12:00:00Z","reference_number":"EMA/204715/2012 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-selection-tools-effectiveness-indicators-rev-3_en.pdf"},
    {"id":"50046","name":"Guideline on good pharmacovigilance practices (GVP): Module XVI Addendum II - Methods for effectiveness evaluation","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-02-03 - 2021-04-28","first_published_date":"2021-02-03T14:20:00Z","last_updated_date":"2021-02-03T14:20:00Z","reference_number":"EMA/419982/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-ii-methods-effectiveness-evaluation_en.pdf"},
    {"id":"50235","name":"Product Management Service (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 8","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-02-22T10:50:00Z","last_updated_date":"2022-07-27T15:55:00Z","reference_number":"EMA/285849/2020 Version 2.1.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/product-management-service-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-8_en.pdf"},
    {"id":"50255","name":"Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2021","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-02-22T14:39:00Z","last_updated_date":"2021-12-17T09:21:00Z","reference_number":"EMA/CVMP/PhVWP/105691/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pharmacovigilance-related-regulatory-recommendations-centrally-authorised-veterinary-medicinal-products-during-2021_en.pdf"},
    {"id":"50274","name":"Reflection paper on classification of a product as intended for a limited market and eligibility for authorisation according to Article 23 (Applications for limited markets)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-02-25 - 2021-05-15","first_published_date":"2021-02-25T15:25:00Z","last_updated_date":"2021-02-25T15:25:00Z","reference_number":"EMA/CVMP/235292/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-classification-product-intended-limited-market-eligibility-authorisation-according-article-23-applications-limited-markets_en.pdf"},
    {"id":"50647","name":"Checklist for the submission of Day 215 product information annexes for a post-opinion linguistic review (Word file)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-03-19T09:10:00Z","last_updated_date":"2026-06-05T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/checklist-submission-day-215-product-information-annexes-post-opinion-linguistic-review-word-file_en.docx"},
    {"id":"50740","name":"Biologics Working Party (BWP) Ad hoc Influenza Working Group - Amended European Union recommendations for the seasonal influenza vaccine composition for the season 2021/2022","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-03-30T12:30:00Z","last_updated_date":"2021-06-28T13:45:00Z","reference_number":"EMA/CHMP/BWP/80561/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/biologics-working-party-bwp-ad-hoc-influenza-working-group-amended-european-union-recommendations-seasonal-influenza-vaccine-composition-season-20212022_en.pdf"},
    {"id":"50769","name":"EU reference instances (EDQM revision)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-04-07T11:35:00Z","last_updated_date":"2026-01-21T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-reference-instances-edqm-revision_en.zip"},
    {"id":"50770","name":"EU E2B (R3) testing files (EDQM revision)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-04-07T11:35:00Z","last_updated_date":"2021-04-07T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-e2b-r3-testing-files-edqm-revision_en.zip"},
    {"id":"50938","name":"Public guidance - Parallel application for EU-M4all (Article 58) opinion and Centralised Marketing Authorisation procedure","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-04-22T12:11:00Z","last_updated_date":"2021-04-22T12:11:00Z","reference_number":"EMA/104275/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/public-guidance-parallel-application-eu-m4all-article-58-opinion-and-centralised-marketing-authorisation-procedure_en.pdf"},
    {"id":"51161","name":"EU Implementation Guide (Vet EU IG) on veterinary medicines product data in the Union Product Database: Explanatory note on the application of Article 3(3) of Commission Implementing Regulation (EU) 2021/16 - obsolete","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-05-17T15:26:00Z","last_updated_date":"2021-05-17T15:26:00Z","reference_number":"EMA/257565/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-implementation-guide-vet-eu-ig-veterinary-medicines-product-data-union-product-database-explanatory-note-application-article-33-commission-implementing-regulation-eu-2021-16-obsolete_en.pdf"},
    {"id":"51201","name":"ICH guideline Q3C (R8) on impurities: guideline for residual solvents - Step 5","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-05-20T10:28:00Z","last_updated_date":"2022-11-28T10:55:00Z","reference_number":"EMA/CHMP/ICH/82260/2006 Corr.","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-q3c-r8-impurities-guideline-residual-solvents-step-5_en.pdf"},
    {"id":"51265","name":"Validation checklist for Type II quality variations","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-05-25T16:49:00Z","last_updated_date":"2026-02-10T08:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/validation-checklist-type-ii-quality-variations_en.docx"},
    {"id":"51362","name":"Draft EU VICH adverse event report implementation guide","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-06-04 - 2021-08-04","first_published_date":"2021-06-04T16:31:00Z","last_updated_date":"2021-06-04T16:31:00Z","reference_number":"EMA/186368/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-eu-vich-adverse-event-report-implementation-guide_en.pdf"},
    {"id":"51366","name":"EU R2 Dosages to EDQM mapping","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-06-04T14:26:00Z","last_updated_date":"2021-06-04T14:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-r2-dosages-edqm-mapping_en.xlsx"},
    {"id":"51374","name":"Draft EU Common Standard for electronic product information for human medicines (ePI)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-06-07 - 2021-07-31","first_published_date":"2021-06-07T17:32:00Z","last_updated_date":"2021-08-11T13:41:00Z","reference_number":"EMA/319183/2021 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-eu-common-standard-electronic-product-information-human-medicines-epi_en.pdf"}    {"id":"51584","name":"ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products - Step 2b","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-06-24 - 2021-10-24","first_published_date":"2021-06-24T16:20:00Z","last_updated_date":"2021-06-24T16:20:00Z","reference_number":"EMA/CHMP/ICH/318372/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-s12-nonclinical-biodistribution-considerations-gene-therapy-products-step-2b_en.pdf"},
    {"id":"51630","name":"Procedural guidance for variant strain(s) update to vaccines intended for protection against human coronavirus","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T11:24:00Z","last_updated_date":"2022-06-23T09:45:00Z","reference_number":"EMA/175959/2021 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-guidance-variant-strains-update-vaccines-intended-protection-against-human-coronavirus_en.pdf"},
    {"id":"51632","name":"Guideline on the summary of product characteristics (SPC) for veterinary medicinal products containing antimicrobial substances - Revision 1","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-06-28T11:39:00Z","last_updated_date":"2023-07-19T17:40:00Z","reference_number":"EMA/CVMP/383441/2005-Rev.1 Corr1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-summary-product-characteristics-spc-veterinary-medicinal-products-containing-antimicrobial-substances-revision-1_en.pdf"},
    {"id":"51772","name":"Draft guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Collection and recording of suspected adverse events for veterinary medicinal products","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-05 - 2021-09-05","first_published_date":"2021-07-05T12:42:00Z","last_updated_date":"2021-07-05T12:42:00Z","reference_number":"EMA/635856/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-collection-and-recording-suspected-adverse-events-veterinary-medicinal-products_en.pdf"},
    {"id":"51773","name":"Draft guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Controls and pharmacovigilance Inspections","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-05 - 2021-09-05","first_published_date":"2021-07-05T12:50:00Z","last_updated_date":"2021-07-05T12:50:00Z","reference_number":"EMA/328998/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-controls-and-pharmacovigilance-inspections_en.pdf"},
    {"id":"51774","name":"Draft guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Glossary","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2021-07-05T10:55:00Z","last_updated_date":"2021-07-05T10:55:00Z","reference_number":"EMA/118227/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-glossary_en.pdf"},
    {"id":"51775","name":"Draft guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Pharmacovigilance systems, their quality management systems and pharmacovigilance system master files","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-05 - 2021-09-05","first_published_date":"2021-07-05T13:17:00Z","last_updated_date":"2021-07-05T13:17:00Z","reference_number":"EMA/257136/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-pharmacovigilance-systems-their-quality-management-systems-and-pharmacovigilance-system-master-files_en.pdf"},
    {"id":"51776","name":"Draft guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Signal Management","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-05 - 2021-09-05","first_published_date":"2021-07-05T13:20:00Z","last_updated_date":"2021-07-05T13:20:00Z","reference_number":"EMA/399713/2020","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-signal-management_en.pdf"},
    {"id":"51777","name":"Draft guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Veterinary pharmacovigilance communication","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-05 - 2021-09-05","first_published_date":"2021-07-05T13:23:00Z","last_updated_date":"2021-07-05T13:23:00Z","reference_number":"EMA/63454/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-veterinary-pharmacovigilance-communication_en.pdf"},
    {"id":"51974","name":"Explanatory note on general fees payable to the European Medicines Agency as of 15 July 2021","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-07-20T16:40:00Z","last_updated_date":"2021-07-20T16:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/explanatory-note-general-fees-payable-european-medicines-agency-15-july-2021_en.pdf"},
    {"id":"51996","name":"EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 6: Examples for submission of legacy data - obsolete","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-07-21T16:44:00Z","last_updated_date":"2025-09-02T10:55:00Z","reference_number":"EMA/772579/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-implementation-guide-ig-veterinary-medicines-product-data-union-product-database-chapter-6-examples-submission-legacy-data-obsolete_en.pdf"},
    {"id":"52323","name":"Guidance for applicants/marketing authorisation holders involved in GMP inspections coordinated by EMA","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-09-02T15:55:00Z","last_updated_date":"2021-09-02T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-applicantsmarketing-authorisation-holders-involved-gmp-inspections-coordinated-ema_en.pdf"},
    {"id":"52442","name":"Pilot programme: European Medicines Agency-Food and Drug Administration parallel scientific advice for hybrid/complex generic products - General principles","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-09-15T13:30:00Z","last_updated_date":"2021-09-15T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pilot-programme-european-medicines-agency-food-and-drug-administration-parallel-scientific-advice-hybridcomplex-generic-products-general-principles_en.pdf"},
    {"id":"52503","name":"Guidance on the details of the classification of variations requiring assessment according to Article 62 of Regulation (EU) 2019/6 for veterinary medicinal products and on the documentation to be submitted pursuant to those variations","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T14:29:00Z","last_updated_date":"2026-05-21T12:00:00Z","reference_number":"EMA/CMDv/7381/2021 Rev.5 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-details-classification-variations-requiring-assessment-according-article-62-regulation-eu-2019-6-veterinary-medicinal-products-documentation-be-submitted-pursuant-those-variations_en.pdf"},
    {"id":"52850","name":"ICH guideline E8 (R1) on general considerations for clinical studies","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-10-14T16:28:00Z","last_updated_date":"2021-10-14T16:28:00Z","reference_number":"EMA/CHMP/ICH/544570/1998","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-e8-r1-general-considerations-clinical-studies_en.pdf"},
    {"id":"52866","name":"Draft qualification opinion on IMI PREFER","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-10-15 - 2021-11-25","first_published_date":"2021-10-15T13:29:00Z","last_updated_date":"2021-10-15T13:29:00Z","reference_number":"EMADOC-1700519818-732587","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-imi-prefer_en.pdf"},
    {"id":"52883","name":"CHMP & EUnetHTA parallel Scientific Advice: Qualification of a Framework & Points to consider for method selection with methods for performing patient preference studies to inform regulatory & HTAbody medical product decision-making: Briefing document","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-10-18T16:27:00Z","last_updated_date":"2021-10-18T16:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/chmp-eunethta-parallel-scientific-advice-qualification-framework-points-consider-method-selection-methods-performing-patient-preference-studies-inform-regulatory-htabody-medical-product-decision_en.pdf"},
    {"id":"52895","name":"Explanatory note on general fees payable to the European Medicines Agency as of 28 January 2022","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-10-25T16:30:00Z","last_updated_date":"2021-10-25T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/explanatory-note-general-fees-payable-european-medicines-agency-28-january-2022_en.pdf"},
    {"id":"52903","name":"PRIME eligibility requests: 2022 deadlines for submission and timetable for assessment","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-10-26T11:29:00Z","last_updated_date":"2021-10-26T11:29:00Z","reference_number":"EMA/461072/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/prime-eligibility-requests-2022-deadlines-submission-and-timetable-assessment_en.pdf"},
    {"id":"52933","name":"Article 57 user interface (UI) installation guide: Installation of Article 57 UI components and initial set up","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-10-28T15:45:00Z","last_updated_date":"2022-06-07T10:22:00Z","reference_number":"EMA/550318/2021 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/article-57-user-interface-ui-installation-guide-installation-article-57-ui-components-and-initial-set_en.pdf"},
    {"id":"52983","name":"Draft qualification opinion of Islet Autoantibodies (AAs) as Enrichment Biomarkers for Type 1 Diabetes (T1D) Prevention Clinical Trials","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-11-03 - 2021-12-14","first_published_date":"2021-11-03T18:04:00Z","last_updated_date":"2021-11-03T18:04:00Z","reference_number":"EMA/580542/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-islet-autoantibodies-aas-enrichment-biomarkers-type-1-diabetes-t1d-prevention-clinical-trials_en.pdf"},
    {"id":"53149","name":"Guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Glossary","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/118227/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-glossary_en.pdf"},
    {"id":"53150","name":"Guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Collection and recording of suspected adverse events for veterinary medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/306663/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-collection-recording-suspected-adverse-events-veterinary-medicinal-products_en.pdf"},
    {"id":"53151","name":"Guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Veterinary pharmacovigilance communication","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/63454/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-veterinary-pharmacovigilance-communication_en.pdf"},
    {"id":"53152","name":"Guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Controls and pharmacovigilance Inspections","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/328998/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-controls-and-pharmacovigilance-inspections_en.pdf"},
    {"id":"53153","name":"Guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Pharmacovigilance systems, their quality management systems and pharmacovigilance system master files","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/595115/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-pharmacovigilance-systems-their-quality-management-systems-and-pharmacovigilance-system-master-files_en.pdf"},
    {"id":"53154","name":"Guideline on veterinary good pharmacovigilance practices (VGVP) - Module: Signal Management","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-11-18T15:30:00Z","last_updated_date":"2021-11-18T15:30:00Z","reference_number":"EMA/522332/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-signal-management_en.pdf"},
    {"id":"53317","name":"Guidance on Irish language derogation ending on 1 January 2022","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T14:47:00Z","last_updated_date":"2025-01-31T16:00:00Z","reference_number":"EMA/699123/2021 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-irish-language-derogation-ending-1-january-2022_en.pdf"},
    {"id":"53581","name":"Draft guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2021-12-20 - 2022-02-20","first_published_date":"2021-12-20T11:27:00Z","last_updated_date":"2021-12-20T11:27:00Z","reference_number":"EMA/747623/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guidance-procedural-aspects-consultation-european-medicines-agency-notified-body-companion-diagnostics_en.pdf"},
    {"id":"53692","name":"CVMP rules of procedure (according to Regulation (EU) 2019/6)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-01-12T08:36:00Z","last_updated_date":"2022-01-12T08:36:00Z","reference_number":"EMA/CVMP/422/04 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/cvmp-rules-procedure-according-regulation-eu-20196_en.pdf"},
    {"id":"53699","name":"Procedural advice to applicants/marketing authorisation holders on re-examination of CVMP opinions (according to Regulation (EU) 2019/6)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-01-12T16:16:00Z","last_updated_date":"2024-02-16T11:25:00Z","reference_number":"EMA/CVMP/321528/2017 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-applicants-marketing-authorisation-holders-re-examination-cvmp-opinions-according-regulation-eu-2019-6_en.pdf"},
    {"id":"53702","name":"Procedural advice on appointment and responsibilities of the CVMP rapporteur and co-rapporteur in accordance with Article 140(6) of Regulation (EU) 2019/6, and peer reviewer","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-01-12T16:23:00Z","last_updated_date":"2025-09-19T09:45:00Z","reference_number":"EMA/CVMP/468877/2009 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-appointment-responsibilities-cvmp-rapporteur-co-rapporteur-accordance-article-1406-regulation-eu-2019-6-peer-reviewer_en.pdf"},
    {"id":"53708","name":"Accelerating clinical trials in the EU (ACT EU) - Delivering an EU clinical trials transformation initiative","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-01-13T14:30:00Z","last_updated_date":"2022-01-13T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/accelerating-clinical-trials-eu-act-eu-delivering-eu-clinical-trials-transformation-initiative_en.pdf"},
    {"id":"54080","name":"Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2022","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-02-04T14:32:00Z","last_updated_date":"2022-12-16T08:46:00Z","reference_number":"EMA/CVMP/PhVWP/48138/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pharmacovigilance-related-regulatory-recommendations-centrally-authorised-veterinary-medicinal-products-during-2022_en.pdf"},
    {"id":"54294","name":"Procedural advice – extended assessment time for initial marketing authorisation applications of 90 days","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-02-25T09:14:00Z","last_updated_date":"2022-02-25T09:14:00Z","reference_number":"EMA/CVMP/612534/2021 ","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-extended-assessment-time-initial-marketing-authorisation-applications-90-days_en.pdf"},
    {"id":"54307","name":"Advice on the designation of antimicrobials or groups of antimicrobials reserved for treatment of certain infections  in humans - in relation to implementing measures under Article 37(5) of Regulation (EU) 2019/6 on veterinary medicinal products","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-03-01T11:59:00Z","last_updated_date":"2022-06-07T12:00:00Z","reference_number":"EMA/CVMP/678496/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-designation-antimicrobials-or-groups-antimicrobials-reserved-treatment-certain-infections-humans-relation-implementing-measures-under-article-375-regulation-eu-20196-veterinary-medicinal_en.pdf"},
    {"id":"54437","name":"Draft guideline on good pharmacovigilance practices (GVP): Module XVI Addendum III (renumbered to Addendum I after finalisation) – Pregnancy prevention programme and other pregnancy-specific risk minimisation measures","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2022-03-14 - 2022-05-31","first_published_date":"2022-03-14T12:27:00Z","last_updated_date":"2022-03-14T12:27:00Z","reference_number":"EMA/608947/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-iii-renumbered-addendum-i-after-finalisation-pregnancy-prevention-programme-other-pregnancy-specific-risk-minimisation-measures_en.pdf"},
    {"id":"54438","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with release of Addendum III of  Module XVI on pregnancy prevention programmes for public consultation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-03-14T11:37:00Z","last_updated_date":"2022-03-14T11:37:00Z","reference_number":"EMA/95595/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-release-addendum-iii-module-xvi-pregnancy-prevention-programmes-public-consultation_en.pdf"},
    {"id":"54607","name":"Amended Biologics Working Party (BWP) Ad hoc Influenza Working Group - EU recommendations for the seasonal influenza vaccine composition for the season 2022/2023","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-03-29T15:05:00Z","last_updated_date":"2022-03-30T12:51:00Z","reference_number":"EMA/CHMP/BWP/116744/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/amended-biologics-working-party-bwp-ad-hoc-influenza-working-group-eu-recommendations-seasonal-influenza-vaccine-composition-season-20222023_en.pdf"},
    {"id":"54631","name":"Qualification Opinion of Islet Autoantibodies (AAs) as Enrichment Biomarkers for Type 1 Diabetes (T1D) Prevention Clinical Trials","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-03-31T09:58:00Z","last_updated_date":"2022-03-31T09:58:00Z","reference_number":"EMA/CHMP/SAWP/186420/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-islet-autoantibodies-aas-enrichment-biomarkers-type-1-diabetes-t1d-prevention-clinical-trials_en.pdf"},
    {"id":"54649","name":"Commission Regulation (EU) 2022/510 of 29 March 2022 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate with effect from 1 April 2022","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-04-01T13:48:00Z","last_updated_date":"2022-04-01T13:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/commission-regulation-eu-2022510-29-march-2022-amending-council-regulation-ec-no-29795-regards-adjustment-fees-european-medicines-agency-inflation-rate-effect-1-april-2022_en.pdf"},
    {"id":"54666","name":"Guidance for applicants/MAHs involved in GMP, GCP and GVP inspections coordinated by EMA","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-04-06T10:04:00Z","last_updated_date":"2022-12-12T16:19:00Z","reference_number":"EMA/274221/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-applicantsmahs-involved-gmp-gcp-and-gvp-inspections-coordinated-ema_en.pdf"},
    {"id":"54805","name":"Procedural advice for veterinary vaccine antigen master  file (VAMF) certification","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T12:00:00Z","last_updated_date":"2026-02-05T14:00:00Z","reference_number":"EMA/CVMP/127488/2021 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-veterinary-vaccine-antigen-master-file-vamf-certification_en.pdf"},
    {"id":"54883","name":"Qualification opinion on IMI PREFER","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-05-03T14:38:00Z","last_updated_date":"2022-05-03T14:38:00Z","reference_number":"EMADOC-1700519818-808373","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-imi-prefer_en.pdf"},
    {"id":"54957","name":"Public consultation concerning the physical attendance and the location of personal residency of the qualified person","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2022-05-13 - 2022-06-13","first_published_date":"2022-05-13T15:34:00Z","last_updated_date":"2022-05-13T15:34:00Z","reference_number":"EMA/INS/169000/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/public-consultation-concerning-physical-attendance-and-location-personal-residency-qualified-person_en.pdf"},
    {"id":"55412","name":"Draft report on the development of a harmonised approach to exposure assessment methodologies for residues from veterinary medicinal products, feed additives and pesticides residues in food of animal origin","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2022-06-30 - 2022-09-13","first_published_date":"2022-06-30T18:00:00Z","last_updated_date":"2022-08-01T15:28:00Z","reference_number":"EMA/CVMP/499555/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-report-development-harmonised-approach-exposure-assessment-methodologies-residues-veterinary-medicinal-products-feed-additives-and-pesticides-residues-food-animal-origin_en.pdf"},
    {"id":"55429","name":"Superseded - Guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-07-01T11:23:00Z","last_updated_date":"2022-07-01T11:23:00Z","reference_number":"EMA/198592/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/superseded-guidance-procedural-aspects-consultation-european-medicines-agency-notified-body-companion-diagnostics_en.pdf"},
    {"id":"55704","name":"Product Management Service (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 8 - tracked changes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-07-27T16:29:00Z","last_updated_date":"2022-07-27T16:29:00Z","reference_number":"EMA/285849/2020 Version 2.1.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/product-management-service-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-8-tracked-changes_en.pdf"},
    {"id":"55706","name":"Product Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 2 - tracked changes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-07-27T16:37:00Z","last_updated_date":"2025-08-08T11:20:01Z","reference_number":"EMA/285848/2020 Version 2.4","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/product-management-services-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-2-tracked-changes_en.pdf"},
    {"id":"55738","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures - Revised implementing rules to the Fee Regulation as of 1 August 2022","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-08-01T09:46:00Z","last_updated_date":"2022-08-01T09:46:00Z","reference_number":"EMA/MB/95162/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures-revised-implementing-rules-fee-regulation-1-august-2022_en.pdf"},
    {"id":"55850","name":"PRIME eligibility requests: 2023 deadlines for submission and timetable for assessment","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-08-22T09:05:00Z","last_updated_date":"2022-08-22T09:05:00Z","reference_number":"EMA/698619/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/prime-eligibility-requests-2023-deadlines-submission-and-timetable-assessment_en.pdf"},
    {"id":"56140","name":"Qualification opinion for Prognostic Covariate Adjustment (PROCOVA™)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-09-20T14:22:00Z","last_updated_date":"2022-09-20T14:22:00Z","reference_number":"EMADOC-1700519818-907465","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-prognostic-covariate-adjustment-procovatm_en.pdf"},
    {"id":"56170","name":"Implementing measures under Article 93(2) of Regulation (EU) 2019/6 as regards the good manufacturing practice for veterinary medicinal products and active substances used as starting materials","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-09-23T10:54:00Z","last_updated_date":"2022-09-23T10:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/implementing-measures-under-article-932-regulation-eu-20196-regards-good-manufacturing-practice-veterinary-medicinal-products-and-active-substances-used-starting-materials_en.pdf"},
    {"id":"56182","name":"Plasma Master File (PMF) requirements - questions and answers for PMF holders","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-09-26T10:07:00Z","last_updated_date":"2026-02-04T09:10:00Z","reference_number":"EMA/CHMP/BWP/153612/2025. Rev 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/plasma-master-file-pmf-requirements-questions-answers-pmf-holders_en.pdf"},
    {"id":"56212","name":"Good practice guide for the use of the HMA-EMA Catalogues of real-world data sources and studies","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2022-09-27 - 2022-11-16","first_published_date":"2022-09-27T19:00:00Z","last_updated_date":"2025-04-08T16:25:23Z","reference_number":"EMA/787647/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practice-guide-use-hma-ema-catalogues-real-world-data-sources-studies_en.pdf"},
    {"id":"56357","name":"Data Quality Framework for EU medicines regulation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"2022-10-10 - 2022-11-18","first_published_date":"2022-10-10T17:00:00Z","last_updated_date":"2023-12-12T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/data-quality-framework-eu-medicines-regulation_en.pdf"},
    {"id":"56421","name":"European Medicines Agency guidance for applicants seeking scientific advice and protocol assistance with track-changes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2025-04-04T11:30:00Z","reference_number":"EMA/4260/2001 Rev. 16","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-guidance-applicants-seeking-scientific-advice-protocol-assistance-track-changes_en.docx"},
    {"id":"56515","name":"European Medicines Agency guidance for applicants seeking scientific advice and protocol assistance","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-01-21T09:51:00Z","last_updated_date":"2025-04-04T11:30:00Z","reference_number":"EMA/4260/2001 Rev. 16","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-guidance-applicants-seeking-scientific-advice-protocol-assistance_en.pdf"},
    {"id":"56534","name":"Guidance on the anonymisation of protected personal data and assessment of commercially confidential information during the preparation of RMPs (main body and annexes 4 and 6)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-11-04T16:17:00Z","last_updated_date":"2025-04-11T16:56:00Z","reference_number":"EMA/63692/2025 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-anonymisation-protected-personal-data-assessment-commercially-confidential-information-during-preparation-rmps-main-body-annexes-4-6_en.pdf"},
    {"id":"56638","name":"Concept Paper on the revision of Annex 11 of the guidelines on Good Manufacturing Practice for medicinal products – Computerised Systems","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2022-11-16 - 2023-01-16","first_published_date":"2022-11-16T10:33:00Z","last_updated_date":"2022-11-16T10:33:00Z","reference_number":"EMA/INS/GMP/778340/2022 ","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/concept-paper-revision-annex-11-guidelines-good-manufacturing-practice-medicinal-products-computerised-systems_en.pdf"},
    {"id":"56788","name":"Union procedure on the preparation, conduct and reporting of EU veterinary pharmacovigilance inspections","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-11-29T11:02:00Z","last_updated_date":"2024-10-16T14:00:00Z","reference_number":"EMA/INS/PhV/604648/2022 Rev 01","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/union-procedure-preparation-conduct-reporting-eu-veterinary-pharmacovigilance-inspections_en.pdf"},
    {"id":"56789","name":"Union guidance on record keeping and archiving of documents obtained or resulting from pharmacovigilance inspections","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-11-29T11:24:00Z","last_updated_date":"2022-11-29T11:24:00Z","reference_number":"EMA/INS/PhV/773932/2022 – Rev 01","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/union-guidance-record-keeping-and-archiving-documents-obtained-or-resulting-pharmacovigilance-inspections_en.pdf"},
    {"id":"57078","name":"Questions and answers on the ‘Guideline on the summary of product characteristics for antiparasitic veterinary medicinal products'","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T12:22:00Z","last_updated_date":"2022-12-16T12:22:00Z","reference_number":"EMA/CVMP/EWP/799840/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-guideline-summary-product-characteristics-antiparasitic-veterinary-medicinal-products_en.pdf"},
    {"id":"57218","name":"Table of decisions of labelling exemption requests falling under article 63 of Directive 2001/83/EC examined by the Quality Review of Documents (QRD) Group","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-01-11T14:13:00Z","last_updated_date":"2025-12-17T13:22:00Z","reference_number":"EMA/934543/2022 Rev.7","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/table-decisions-labelling-exemption-requests-falling-under-article-63-directive-2001-83-ec-examined-quality-review-documents-qrd-group_en.pdf"},
    {"id":"57423","name":"Guideline on the application of Article 34 of Regulation (EU) 2019/6","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T10:19:00Z","last_updated_date":"2023-01-27T10:19:00Z","reference_number":"EMA/CVMP/273040/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-application-article-34-regulation-eu-20196_en.pdf"},
    {"id":"57525","name":"Guidance for stepwise PIPs (sPIPs)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-02-06T13:46:00Z","last_updated_date":"2025-11-28T16:07:00Z","reference_number":"EMA/768685/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-stepwise-pips-spips_en.pdf"},
    {"id":"57673","name":"Questions & Answers regarding Cannabis-derived medicinal products and the scope of EU herbal monographs for herbal medicinal products within the EU medicines legislation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-02-15T10:08:00Z","last_updated_date":"2023-02-15T10:08:00Z","reference_number":"EMA/HMPC/176770/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-regarding-cannabis-derived-medicinal-products-and-scope-eu-herbal-monographs-herbal-medicinal-products-within-eu-medicines-legislation_en.pdf"},
    {"id":"57721","name":"Deadlines for submission of applications for orphan medicinal product designation to the EMA and corresponding COMP timetable for valid applications - 2024-2025","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-02-17T17:17:00Z","last_updated_date":"2025-01-06T15:50:00Z","reference_number":"EMADOC-628903358-40450","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/deadlines-submission-applications-orphan-medicinal-product-designation-ema-corresponding-comp-timetable-valid-applications-2024-2025_en.pdf"},
    {"id":"57853","name":"Draft Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2023-02-28 - 2023-04-10","first_published_date":"2023-03-01T18:18:00Z","last_updated_date":"2023-03-01T18:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-qualification-opinion-stride-velocity-95th-centile-primary-endpoint-studies-ambulatory-duchenne-muscular-dystrophy_en.pdf"},
    {"id":"57985","name":"Guideline on computerised systems and electronic data in clinical trials","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-03-10T09:20:00Z","last_updated_date":"2023-03-10T09:20:00Z","reference_number":"EMA/INS/GCP/112288/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-computerised-systems-and-electronic-data-clinical-trials_en.pdf"},
    {"id":"58252","name":"Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2023","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T14:10:00Z","last_updated_date":"2023-12-15T15:00:00Z","reference_number":"EMA/CVMP/PhVWP/137199/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pharmacovigilance-related-regulatory-recommendations-centrally-authorised-veterinary-medicinal-products-during-2023_en.pdf"},
    {"id":"58261","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures - Revised implementing rules to the Fee Regulation as of 1 April 2023","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T15:17:00Z","last_updated_date":"2023-03-31T15:17:00Z","reference_number":"EMA/MB/622516/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures-revised-implementing-rules-fee-regulation-1-april-2023_en.pdf"},
    {"id":"58268","name":"Amended Biologics Working Party (BWP) Ad hoc Influenza Working Group - EU recommendations for the seasonal influenza vaccine composition for the season 2023/2024","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-04-03T10:24:00Z","last_updated_date":"2023-04-20T09:18:00Z","reference_number":"EMA/CHMP/BWP/126676/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/amended-biologics-working-party-bwp-ad-hoc-influenza-working-group-eu-recommendations-seasonal-influenza-vaccine-composition-season-20232024_en.pdf"},
    {"id":"58347","name":"N-methyl-pyrrolidone - Article-82 referral - Annexes I, II and III","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-04-14T09:43:00Z","last_updated_date":"2024-03-22T13:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_bg.pdf","es":"https://www.ema.europa.eu/es/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_cs.pdf","da":"https://www.ema.europa.eu/da/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_da.pdf","de":"https://www.ema.europa.eu/de/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_de.pdf","et":"https://www.ema.europa.eu/et/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_et.pdf","el":"https://www.ema.europa.eu/el/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_hr.pdf","it":"https://www.ema.europa.eu/it/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_sv.pdf","is":"https://www.ema.europa.eu/is/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_is.pdf","no":"https://www.ema.europa.eu/no/documents/regulatory-procedural-guideline/n-methyl-pyrrolidone-article-82-referral-annexes-i-ii-iii_no.pdf"}},
    {"id":"58468","name":"ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products - Step 5","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-04-20T09:13:00Z","last_updated_date":"2023-09-11T15:57:00Z","reference_number":"EMA/CHMP/ICH/318372/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-s12-nonclinical-biodistribution-considerations-gene-therapy-products-step-5_en.pdf"},
    {"id":"58611","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures - Revised implementing rules to the Fee Regulation as of 1 May 2023","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-05-10T14:36:00Z","last_updated_date":"2023-05-10T14:36:00Z","reference_number":"EMA/MB/118263/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-implementation-council-regulation-ec-no-29795-fees-payable-european-medicines-agency-and-other-measures-revised-implementing-rules-fee-regulation-1-may-2023_en.pdf"},
    {"id":"58715","name":"Good practices for industry for the prevention of human medicinal product shortages","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-05-17T13:01:00Z","last_updated_date":"2023-05-17T13:01:00Z","reference_number":"EMA/760980/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practices-industry-prevention-human-medicinal-product-shortages_en.pdf"},
    {"id":"59005","name":"Scientific advice under Art.107(6) of Reg.(EU)2019/6 for establishment of a list of antimicrobials which shall not be used in accordance with Art. 112, 113 and 114 or which shall only be used in accordance with these articles subject to certain conditions","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-06-20T14:00:00Z","last_updated_date":"2023-06-20T14:00:00Z","reference_number":"EMA/CVMP/151584/2021","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/scientific-advice-under-art1076-regeu2019-6-establishment-list-antimicrobials-which-shall-not-be-used-accordance-art-112-113-114-or-which-shall-only-be-used-accordance-these-articles-subject-certain_en.pdf"},
    {"id":"59186","name":"Guidance on Parallel EMA/HTA body (HTAb) Scientific Advice for the Interim Period","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T11:39:00Z","last_updated_date":"2023-07-03T11:39:00Z","reference_number":"EMA/250551/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-parallel-emahta-body-htab-scientific-advice-interim-period_en.pdf"},
    {"id":"59671","name":"When is it relevant to include a bodyweight limit in the wording of a paediatric indication?","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-08-30T12:46:00Z","last_updated_date":"2023-08-30T12:46:00Z","reference_number":"EMA/268908/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/when-it-relevant-include-bodyweight-limit-wording-paediatric-indication_en.pdf"},
    {"id":"59682","name":"Procedure for the nomination and appointment of coopted members of the CHMP, CVMP and HMPC","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-09-26T11:28:32Z","last_updated_date":"2023-09-26T11:28:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-nomination-and-appointment-coopted-members-chmp-cvmp-and-hmpc_en.pdf"},
    {"id":"59858","name":"Procedural advice on paediatric applications","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-03-24T11:30:00Z","last_updated_date":"2026-04-16T08:52:59Z","reference_number":"EMA/672643/2017 Rev. 15","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-paediatric-applications_en.pdf"},
    {"id":"60548","name":"Guidance to applicants/marketing authorisation holders on oral explanations at European Medicines Agency","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-04-16T13:40:00Z","last_updated_date":"2023-08-08T11:30:00Z","reference_number":"EMA/748003/2014 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-applicants-marketing-authorisation-holders-oral-explanations-european-medicines-agency_en.pdf"},
    {"id":"60577","name":"Questions and answers on Article 20 pharmacovigilance procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-04-29T14:00:00Z","last_updated_date":"2019-02-04T14:00:00Z","reference_number":"EMA/108934/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-and-answers-article-20-pharmacovigilance-procedures_en.pdf"},
    {"id":"60631","name":"Draft guideline on the application of Article 34 of Regulation (EU) 2019/6 - Classification of veterinary medicinal products (prescription status)","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2022-07-22 - 2022-10-31","first_published_date":"2022-07-22T15:41:00Z","last_updated_date":"2022-07-22T15:41:00Z","reference_number":"EMA/CVMP/273040/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-application-article-34-regulation-eu-2019-6-classification-veterinary-medicinal-products-prescription-status_en.pdf"},
    {"id":"61863","name":"Guidance on remote GCP inspections during public health  threats, political conflicts, natural disasters, or other  major disruptions","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-01-24T12:00:00Z","last_updated_date":"2024-01-24T12:00:00Z","reference_number":"EMA/INS/GCP/397876/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-remote-gcp-inspections-during-public-health-threats-political-conflicts-natural-disasters-or-other-major-disruptions_en.pdf"},
    {"id":"62169","name":"Procedure for the preparation of European Union herbal monographs and European Union list entries and appointment of HMPC rapporteurs and peer-reviewers","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-02-15T10:15:00Z","last_updated_date":"2025-01-13T15:40:00Z","reference_number":"EMA/HMPC/887331/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-preparation-european-union-herbal-monographs-european-union-list-entries-appointment-hmpc-rapporteurs-peer-reviewers_en.pdf"},
    {"id":"62281","name":"Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2024","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T12:05:36Z","last_updated_date":"2025-01-10T16:10:00Z","reference_number":"EMA/CVMP/PhVWP/75148/2024","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pharmacovigilance-related-regulatory-recommendations-centrally-authorised-veterinary-medicinal-products-during-2024_en.pdf"},
    {"id":"62736","name":"Amended EU recommendations for the seasonal influenza vaccine composition for the season 2024/2025","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-03-26T11:58:00Z","last_updated_date":"2024-06-03T17:51:00Z","reference_number":"EMA/60123/2024","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/amended-eu-recommendations-seasonal-influenza-vaccine-composition-season-2024-2025_en.pdf"},
    {"id":"62756","name":"Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures - Revised implementing rules to the Fee Regulation as of 1 April 2024 ","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-03-27T11:54:16Z","last_updated_date":"2024-03-27T11:54:16Z","reference_number":"EMA/MB/182939/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/rules-implementation-council-regulation-ec-no-297-95-fees-payable-european-medicines-agency-other-measures-revised-implementing-rules-fee-regulation-1-april-2024_en.pdf"},
    {"id":"63514","name":"Quality systems framework for Good Manufacturing Practice (GMP) inspectorates","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T12:00:00Z","last_updated_date":"2024-08-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/quality-systems-framework-good-manufacturing-practice-gmp-inspectorates_en.pdf"},
    {"id":"64232","name":"EMA guidance on the use of medicinal products for treatment in case of exposure to chemical agents used as weapons of terrorism, crime, or warfare","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-12T15:55:00Z","last_updated_date":"2024-09-10T17:00:00Z","reference_number":"EMA/323692/2024 Corr.","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-guidance-use-medicinal-products-treatment-case-exposure-chemical-agents-used-weapons-terrorism-crime-or-warfare_en.pdf"},
    {"id":"64233","name":"EMA guidance on the use of medicinal products for treatment and prophylaxis in case of exposure to biological agents used as weapons of terrorism, crime or warfare","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-12T15:50:00Z","last_updated_date":"2024-09-10T17:00:00Z","reference_number":"EMA/323691/2024 Corr.","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-guidance-use-medicinal-products-treatment-prophylaxis-case-exposure-biological-agents-used-weapons-terrorism-crime-or-warfare_en.pdf"},
    {"id":"64335","name":"Combined Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) list of clinical terms for reporting suspected adverse events in animals and humans to veterinary medicinal products - Rev.16","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T10:27:37Z","last_updated_date":"2025-07-03T09:15:00Z","reference_number":"EMA/CVMP/PhVWP/10418/2009 Rev.16","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/combined-veterinary-dictionary-drug-regulatory-activities-veddra-list-clinical-terms-reporting-suspected-adverse-events-animals-humans-veterinary-medicinal-products-rev16_en.pdf"},
    {"id":"64336","name":"Guidance notes on the use of Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) terminology for reporting suspected adverse events in animals and humans - Rev.17","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T10:33:50Z","last_updated_date":"2025-07-16T13:55:00Z","reference_number":"EMA/CVMP/PhVWP/288284/2007 Rev.17 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-notes-use-veterinary-dictionary-drug-regulatory-activities-veddra-terminology-reporting-suspected-adverse-events-animals-humans-rev17_en.pdf"},
    {"id":"64411","name":"A model for risk based planning for inspections of pharmaceutical manufacturers","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T12:00:00Z","last_updated_date":"2024-08-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/model-risk-based-planning-inspections-pharmaceutical-manufacturers_en.pdf"},
    {"id":"64412","name":"Conduct of inspections of pharmaceutical manufacturers or importers","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T12:00:00Z","last_updated_date":"2024-08-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/conduct-inspections-pharmaceutical-manufacturers-or-importers_en.pdf"},
    {"id":"64413","name":"Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:39:39Z","last_updated_date":"2024-12-17T13:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/co-ordinating-good-manufacturing-practice-gmp-inspections-centrally-authorised-products_en.pdf"},
    {"id":"64414","name":"EU/EEA programme for maintenance of equivalence in supervision of good manufacturing practice compliance of pharmaceutical companies","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T12:00:00Z","last_updated_date":"2024-08-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eu-eea-programme-maintenance-equivalence-supervision-good-manufacturing-practice-compliance-pharmaceutical-companies_en.pdf"},
    {"id":"64415","name":"Good distribution practice (GDP) inspection procedure","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:43:13Z","last_updated_date":"2024-08-01T13:43:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-distribution-practice-gdp-inspection-procedure_en.pdf"}    {"id":"64416","name":"Guidance on the occasions when it is appropriate for competent authorities to conduct inspections at the premises of manufacturers, importers and distributors of active substances and manufacturers or importers of excipients used as starting materials","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:48:51Z","last_updated_date":"2024-08-01T13:48:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-occasions-when-it-appropriate-competent-authorities-conduct-inspections-premises-manufacturers-importers-distributors-active-substances-manufacturers-or-importers-excipients-used-starting_en.pdf"},
    {"id":"64417","name":"Guideline on training and qualification of inspectors performing inspections of wholesale distributors","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:50:26Z","last_updated_date":"2024-08-01T13:50:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-training-qualification-inspectors-performing-inspections-wholesale-distributors_en.pdf"},
    {"id":"64418","name":"Guideline on training and qualifications of good manufacturing practice (GMP) inspectors","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:51:51Z","last_updated_date":"2024-08-01T13:51:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-training-qualifications-good-manufacturing-practice-gmp-inspectors_en.pdf"},
    {"id":"64419","name":"Management and classification of reports of suspected quality defects in medicinal products and risk-based decision-making","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:54:05Z","last_updated_date":"2026-04-29T09:40:00Z","reference_number":"Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/management-classification-reports-suspected-quality-defects-medicinal-products-risk-based-decision-making_en.pdf"},
    {"id":"64420","name":"Management of rapid alerts arising from quality defects risk assessment","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:55:08Z","last_updated_date":"2024-08-28T14:57:00Z","reference_number":"Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/management-rapid-alerts-arising-quality-defects-risk-assessment_en.pdf"},
    {"id":"64421","name":"Outline of a procedure for co-ordinating the verification of the GMP status of manufacturers in third countries","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:56:10Z","last_updated_date":"2024-08-01T13:56:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/outline-procedure-co-ordinating-verification-gmp-status-manufacturers-third-countries_en.pdf"},
    {"id":"64422","name":"Procedure for compliance management","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:57:02Z","last_updated_date":"2024-08-01T13:57:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-compliance-management_en.pdf"},
    {"id":"64423","name":"Procedure for dealing with serious good manufacturing practice (GMP) non-compliance information originating from third country authorities or international organisations","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:57:55Z","last_updated_date":"2024-08-01T13:57:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-dealing-serious-good-manufacturing-practice-gmp-non-compliance-information-originating-third-country-authorities-or-international-organisations_en.pdf"},
    {"id":"64424","name":"Procedure for dealing with serious good manufacturing practice (GMP) non-compliance requiring co-ordinated measures to protect public or animal health","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T13:59:17Z","last_updated_date":"2024-08-01T13:59:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-dealing-serious-good-manufacturing-practice-gmp-non-compliance-requiring-co-ordinated-measures-protect-public-or-animal-health_en.pdf"},
    {"id":"64425","name":"The issue and update of good distribution practice (GDP) certificates","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T14:00:51Z","last_updated_date":"2024-08-01T14:00:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/issue-update-good-distribution-practice-gdp-certificates_en.pdf"},
    {"id":"64426","name":"The issue and update of good manufacturing practice (GMP) certificates","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T14:02:14Z","last_updated_date":"2024-08-01T14:02:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/issue-update-good-manufacturing-practice-gmp-certificates_en.pdf"},
    {"id":"64429","name":"Interpretation of the Union format for good manufacturing practice (GMP) certificate","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T14:40:12Z","last_updated_date":"2024-08-01T14:40:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/interpretation-union-format-good-manufacturing-practice-gmp-certificate_en.pdf"},
    {"id":"64430","name":"Interpretation of the Union format for manufacturer / importer authorisation","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T14:42:29Z","last_updated_date":"2024-08-01T14:42:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/interpretation-union-format-manufacturer-importer-authorisation_en.pdf"},
    {"id":"64431","name":"Interpretation of the Union format for a wholesale distribution authorisation ","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T15:01:32Z","last_updated_date":"2024-08-01T15:01:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/interpretation-union-format-wholesale-distribution-authorisation_en.pdf"},
    {"id":"64444","name":"History of changes to the compilation of procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T16:05:47Z","last_updated_date":"2024-08-28T14:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/history-changes-compilation-procedures_en.pdf"},
    {"id":"64503","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with new Addendum II to Module VI on masking of personal data in individual case safety reports submitted to EudraVigilance","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-07-24T16:03:00Z","last_updated_date":"2025-07-24T16:03:00Z","reference_number":"EMA/236736/2025","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-new-addendum-ii-module-vi-masking-personal-data-individual-case-safety-reports-submitted-eudravigilance_en.pdf"},
    {"id":"64504","name":"Guideline on good pharmacovigilance practices (GVP) Module XVI – Risk minimisation measures (Rev 3)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T12:00:00Z","last_updated_date":"2024-08-05T12:00:00Z","reference_number":"EMA/204715/2012","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-rev-3_en.pdf"},
    {"id":"64505","name":"Guideline on good pharmacovigilance practices (GVP): Module XVI Addendum II – Methods for evaluating effectiveness of risk minimisation measures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-05T12:00:00Z","last_updated_date":"2024-08-05T12:00:00Z","reference_number":"EMA/419982/2019","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-ii-methods-evaluating-effectiveness-risk-minimisation-measures_en.pdf"},
    {"id":"64510","name":"Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev. 5) with tracked changes","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-05T12:20:00Z","last_updated_date":"2024-08-05T12:20:00Z","reference_number":"EMA/876333/2011","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-annex-i-definitions-rev-5-tracked-changes_en.pdf"},
    {"id":"64538","name":"Scientific advice under Article 115(5) of Regulation (EU) 2019/6 on veterinary medicinal products, regarding the list of substances essential for the treatment of equine species and for which the withdrawal period for equine species shall be six months","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-08T12:35:02Z","last_updated_date":"2025-03-14T15:00:00Z","reference_number":"EMA/CVMP/159047/2023 Corr.2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/scientific-advice-under-article-1155-regulation-eu-2019-6-veterinary-medicinal-products-regarding-list-substances-essential-treatment-equine-species-which-withdrawal-period-equine-species-shall-be-six_en.pdf"},
    {"id":"64679","name":"Note for guidance - EudraVigilance Human - Processing of safety messages and individual case safety reports (ICSRs) - Revision 2","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-10-15T13:44:56Z","last_updated_date":"2010-10-15T13:44:56Z","reference_number":"EMA/H/20665/04/Final Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/note-guidance-eudravigilance-human-processing-safety-messages-individual-case-safety-reports-icsrs-revision-2_en.pdf"},
    {"id":"64808","name":"PRIME eligibility requests: 2025 deadlines for submission and timetable for assessment","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-09-12T11:14:07Z","last_updated_date":"2024-09-12T11:14:07Z","reference_number":"EMA/180538/2024","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/prime-eligibility-requests-2025-deadlines-submission-timetable-assessment_en.pdf"},
    {"id":"65049","name":"Introduction to the Compilation of Union procedures on inspections and exchange of information","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-09-26T16:47:24Z","last_updated_date":"2024-09-26T16:47:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/introduction-compilation-union-procedures-inspections-exchange-information_en.pdf"},
    {"id":"65510","name":"European Medicines Agency post-authorisation procedural advice for users of the centralised procedure - Type IA Variations (in tracked changes)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T16:16:48Z","last_updated_date":"2024-10-31T16:16:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure-type-ia-variations-tracked-changes_en.pdf"},
    {"id":"65511","name":"European Medicines Agency post-authorisation procedural advice for users of the centralised procedure - Grouping of variations (in tracked changes)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T16:22:49Z","last_updated_date":"2024-10-31T16:22:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure-grouping-variations-tracked-changes_en.pdf"},
    {"id":"65512","name":"European Medicines Agency post-authorisation procedural advice for users of the centralised procedure - Worksharing of variations (tracked changes)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T16:24:32Z","last_updated_date":"2024-11-05T15:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure-worksharing-variations-tracked-changes_en.pdf"},
    {"id":"65513","name":"EMA procedural advice on recommendations on unforeseen variations according to Article 5 of Commission Regulation (EC) No 1234/2008 (tracked changes)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T16:26:04Z","last_updated_date":"2024-10-31T16:26:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-procedural-advice-recommendations-unforeseen-variations-according-article-5-commission-regulation-ec-no-1234-2008-tracked-changes_en.pdf"},
    {"id":"65515","name":"Template : Letter of intent for the submission of a worksharing procedure to the European Medicines Agency (tracked changes)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T16:29:43Z","last_updated_date":"2024-10-31T16:29:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/template-letter-intent-submission-worksharing-procedure-european-medicines-agency-tracked-changes_en.docx"},
    {"id":"65546","name":"Questions and answers on Article 82 referral procedures based on Article 129(3)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-11-05T15:15:00Z","last_updated_date":"2024-11-05T15:15:00Z","reference_number":"EMA/199473/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-article-82-referral-procedures-based-article-1293_en.pdf"},
    {"id":"65549","name":"Questions and answers on Article 82 referral procedures","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-11-05T15:15:00Z","last_updated_date":"2024-11-05T15:15:00Z","reference_number":"EMA/214864/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-article-82-referral-procedures_en.pdf"},
    {"id":"65567","name":"Revised list of enabling tools","type":"regulatory-procedural-guideline","status":"Draft: consultation closed","consultation_date":"2024-11-08 - 2024-11-30","first_published_date":"2024-11-08T09:10:34Z","last_updated_date":"2024-11-08T09:10:34Z","reference_number":"EMA/515876/2024","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/revised-list-enabling-tools_en.pdf"},
    {"id":"66049","name":"QRD veterinary v.9.1 – Implementation plan","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T13:19:17Z","last_updated_date":"2024-12-10T13:19:17Z","reference_number":"EMA/472382/2024","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qrd-veterinary-v91-implementation-plan_en.pdf"},
    {"id":"66177","name":"EMA recommendation on the procedural aspects and dossier requirements for the consultation of the EMA by a notified body on an ancillary medicinal substance or an ancillary human blood derivative incorporated in a medical device - Revision 2","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-12-17T17:02:11Z","last_updated_date":"2024-12-17T17:02:11Z","reference_number":"EMA/CHMP/578661/2010","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-recommendation-procedural-aspects-dossier-requirements-consultation-ema-notified-body-ancillary-medicinal-substance-or-ancillary-human-blood-derivative-incorporated-medical-device-revision-2_en.pdf"},
    {"id":"66180","name":"Guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics - Revision 1","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-12-17T17:48:59Z","last_updated_date":"2024-12-17T17:48:59Z","reference_number":"EMA/198592/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-procedural-aspects-consultation-european-medicines-agency-notified-body-companion-diagnostics-revision-1_en.pdf"},
    {"id":"66405","name":"European Medicines Agency Write PMS API implementation Guide","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-01-21T16:49:36Z","last_updated_date":"2025-11-05T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-write-pms-api-implementation-guide_en.pdf"},
    {"id":"66604","name":"ICH guideline Q8, Q9 and Q10 - questions and answers (R5)","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-02-05T10:42:14Z","last_updated_date":"2025-02-05T10:42:14Z","reference_number":"EMA/CHMP/ICH/265145/2009","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-q8-q9-q10-questions-answers-r5_en.pdf"},
    {"id":"66620","name":"Deadlines for submission of applications for orphan medicinal product designation to the EMA and corresponding COMP timetable for valid applications - 2025-2026","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-02-06T10:33:19Z","last_updated_date":"2025-02-06T10:33:19Z","reference_number":"EMADOC-628903358-40450","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/deadlines-submission-applications-orphan-medicinal-product-designation-ema-corresponding-comp-timetable-valid-applications-2025-2026_en.pdf"},
    {"id":"67578","name":"Amended Biologics Working Party Vaccines Quality Operational Expert Group (BV-OEG) Influenza Meeting: EU recommendations for the seasonal influenza vaccine composition for the season 2025/2026","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-04-01T15:12:48Z","last_updated_date":"2025-05-13T15:00:00Z","reference_number":"EMADOC-628903358-119194 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/amended-biologics-working-party-vaccines-quality-operational-expert-group-bv-oeg-influenza-meeting-eu-recommendations-seasonal-influenza-vaccine-composition-season-2025-2026_en.pdf"},
    {"id":"67705","name":"User guide of the HMA-EMA Catalogues of real-world data sources and studies","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-04-08T16:29:25Z","last_updated_date":"2025-06-12T11:07:00Z","reference_number":"EMA/124437/20255","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/user-guide-hma-ema-catalogues-real-world-data-sources-studies_en.pdf"},
    {"id":"68298","name":"External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use - Version 1.5","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-05-15T14:44:00Z","last_updated_date":"2025-05-15T14:44:00Z","reference_number":"EMA/90915/2016 Version 1.5","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-version-15_en.pdf"},
    {"id":"68299","name":"Summary of changes to the ‘External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use’ - Version 1.5","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-05-15T14:45:00Z","last_updated_date":"2025-05-15T14:45:00Z","reference_number":"EMA/327333/2024","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/summary-changes-external-guidance-implementation-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use-version-15_en.pdf"},
    {"id":"68471","name":"Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2025","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-05-27T14:36:42Z","last_updated_date":"2025-12-16T09:52:00Z","reference_number":"EMA/CVMP/PhVWP/101663/2025","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pharmacovigilance-related-regulatory-recommendations-centrally-authorised-veterinary-medicinal-products-during-2025_en.pdf"},
    {"id":"68487","name":"Scientific advice under Article 114(3) of Regulation (EU) 2019/6 on veterinary medicinal products - List of substances used in veterinary medicinal products authorised in the Union for use in food-producing terrestrial animal species or substances contain","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-05-28T12:00:00Z","last_updated_date":"2025-05-28T12:00:00Z","reference_number":"EMA/CVMP/29892/2024","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/scientific-advice-under-article-1143-regulation-eu-2019-6-veterinary-medicinal-products-list-substances-used-veterinary-medicinal-products-authorised-union-use-food-producing-terrestrial-animal_en.pdf"},
    {"id":"69447","name":"Guideline on good pharmacovigilance practices (GVP) - Module VI Addendum II – Masking of personal data in individual case safety reports submitted to EudraVigilance","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-24T15:59:37Z","last_updated_date":"2025-07-24T15:59:37Z","reference_number":"EMA/178902/2025","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-addendum-ii-masking-personal-data-individual-case-safety-reports-submitted-eudravigilance_en.pdf"},
    {"id":"69450","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with final revision 3 of Module XVI on risk minimisation measures and its Addendum II on their effectiveness evaluation, and revision 5 of Annex I on definitions","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-05T16:08:49Z","last_updated_date":"2024-08-05T16:08:49Z","reference_number":"EMA/340669/2024","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-final-revision-3-module-xvi-risk-minimisation-measures-its-addendum-ii-their-effectiveness-evaluation-revision-5_en.pdf"},
    {"id":"70054","name":"PRIME eligibility requests: 2026 deadlines for submission and timetable for assessment","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-09-10T16:33:41Z","last_updated_date":"2025-09-10T16:33:41Z","reference_number":"EMA/213453/2025 ","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/prime-eligibility-requests-2026-deadlines-submission-timetable-assessment_en.pdf"},
    {"id":"70079","name":"STARS common strategy: regulatory support and advice for academia","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-09-15T13:25:00Z","last_updated_date":"2025-09-15T13:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/stars-common-strategy-regulatory-support-advice-academia_en.pdf"},
    {"id":"70449","name":"Scientific advice on MRL classification of chemical-unlike biological substances considered as not requiring an MRL evaluation according to Regulation (EU) 2018/782","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-10-06T10:45:50Z","last_updated_date":"2025-10-06T10:45:50Z","reference_number":"EMA/CVMP/375793/2024","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/scientific-advice-mrl-classification-chemical-unlike-biological-substances-considered-not-requiring-mrl-evaluation-according-regulation-eu-2018-782_en.pdf"},
    {"id":"71756","name":"ICH M11 Guideline on clinical electronic structured harmonised protocol (CeSHarP) step 5","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-12-15T17:16:04Z","last_updated_date":"2025-12-15T17:16:04Z","reference_number":"EMA/CHMP/ICH/778799/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-m11-guideline-clinical-electronic-structured-harmonised-protocol-cesharp-step-5_en.pdf"},
    {"id":"71758","name":"ICH M11 Clinical electronic structured harmonised protocol (CeSHarP) - Technical specification step 5","type":"regulatory-procedural-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-12-15T17:20:28Z","last_updated_date":"2025-12-15T17:20:28Z","reference_number":"EMA/CHMP/ICH/778800/2022","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-m11-clinical-electronic-structured-harmonised-protocol-cesharp-technical-specification-step-5_en.pdf"},
    {"id":"71759","name":"Overview of comments received on ICH M11 technical specification","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-05-24T17:22:34Z","last_updated_date":"2023-05-24T17:22:34Z","reference_number":"EMA/CHMP/ICH/118288/2023","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/overview-comments-received-ich-m11-technical-specification_en.pdf"},
    {"id":"72141","name":"Deadlines for submission of applications for orphan medicinal product designation to the EMA and corresponding COMP timetable for valid applications 2026-2027","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2026-01-19T17:18:34Z","last_updated_date":"2026-01-19T17:18:34Z","reference_number":"EMADOC-628903358-133247","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/deadlines-submission-applications-orphan-medicinal-product-designation-ema-corresponding-comp-timetable-valid-applications-2026-2027_en.pdf"},
    {"id":"72601","name":"Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2026","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2026-02-19T13:24:57Z","last_updated_date":"2026-06-01T09:35:00Z","reference_number":"EMA/CVMP/PhVWP/37249/2026","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/pharmacovigilance-related-regulatory-recommendations-centrally-authorised-veterinary-medicinal-products-during-2026_en.pdf"},
    {"id":"73267","name":"Amended Biologics Working Party Vaccines Quality Operational Expert Group (BV-OEG) Influenza Meeting: EU recommendations for the seasonal influenza vaccine composition for the season 2026/2027","type":"regulatory-procedural-guideline","status":"unknown","consultation_date":"","first_published_date":"2026-03-30T14:39:03Z","last_updated_date":"2026-05-26T13:05:00Z","reference_number":"EMA/CHMP/BWP/62405/2026","document_url":"https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/amended-biologics-working-party-vaccines-quality-operational-expert-group-bv-oeg-influenza-meeting-eu-recommendations-seasonal-influenza-vaccine-composition-season-2026-2027_en.pdf"},
    {"id":"2424","name":"Contract 2007/146-691 Instrument for Pre-accession Assistance transition assistance programme: Third progress report to the European Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-10-15T02:09:21Z","last_updated_date":"2008-10-15T02:09:21Z","reference_number":"EMEA/548032/2008","document_url":"https://www.ema.europa.eu/en/documents/report/contract-2007146-691-instrument-pre-accession-assistance-transition-assistance-programme-third-progress-report-european-commission_en.pdf"},
    {"id":"2590","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) November 2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-11-26T01:00:00Z","last_updated_date":"2010-11-26T01:00:00Z","reference_number":"EMA/CHMP/PhVWP/727975/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-november-2010-plenary-meeting_en.pdf"},
    {"id":"2609","name":"European Medicines Agency expert meeting on human transmissible spongiform encephalopathies and medicinal products derived from human blood and plasma, 1 December 2000: Summary report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2001-03-28T02:09:21Z","last_updated_date":"2001-03-28T02:09:21Z","reference_number":"EMEA/CPMP/BWP/450/01","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-expert-meeting-human-transmissible-spongiform-encephalopathies-and-medicinal-products-derived-human-blood-and-plasma-1-december-2000-summary-report_en.pdf"},
    {"id":"2635","name":"Appendix 2: Agenda and participants - CAR-T cell therapy registries workshop","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-05-22T11:52:00Z","last_updated_date":"2018-05-22T11:52:00Z","reference_number":"EMA/299557/2018","document_url":"https://www.ema.europa.eu/en/documents/report/appendix-2-agenda-and-participants-car-t-cell-therapy-registries-workshop_en.pdf"},
    {"id":"2848","name":"Scientific recommendation on classification of advanced therapy medicinal products: co-culture of keratinocytes and mesenchymal stem cells isolated from human burn eschar and debrided adipose tissue cells,  seeded onto a...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T13:00:00Z","last_updated_date":"2016-04-12T13:00:00Z","reference_number":"EMA/241020/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-co-culture-keratinocytes-and-mesenchymal-stem-cells-isolated-human-burn-eschar-and-debrided-adipose-tissue-cells-seeded_en.pdf"},
    {"id":"2918","name":"2017 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission - reporting period: 1 January to 31 December 2017","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-03-16T13:35:00Z","last_updated_date":"2018-03-16T13:35:00Z","reference_number":"EMA/7552/2018","document_url":"https://www.ema.europa.eu/en/documents/report/2017-annual-report-eudravigilance-european-parliament-council-and-commission-reporting-period-1-january-31-december-2017_en.pdf"},
    {"id":"2938","name":"Report - Workshop on paediatric formulations for assessors in national regulatory agencies","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-paediatric-formulations-assessors-national-regulatory-agencies_en.pdf"},
    {"id":"2951","name":"Report from the small and medium-sized enterprise office on its fifth year of operation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-12-20T02:00:00Z","last_updated_date":"2010-12-20T02:00:00Z","reference_number":"EMA/790295/2010","document_url":"https://www.ema.europa.eu/en/documents/report/report-small-and-medium-sized-enterprise-office-its-fifth-year-operation_en.pdf"},
    {"id":"2987","name":"Applications for new human medicines under evaluation by the CHMP: December 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-12-01T18:00:00Z","last_updated_date":"2017-12-01T18:00:00Z","reference_number":"EMA/789956/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2017_en.pdf"},
    {"id":"2992","name":"Scientific recommendation on classification of advanced therapy medicinal products: allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T15:30:00Z","last_updated_date":"2016-04-19T15:30:00Z","reference_number":"EMA/556256/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-ex-vivo-expanded-placental-mesenchymal-adherent-stromal-cells_en.pdf"},
    {"id":"3025","name":"Outcomes of the workshop - Multi-stakeholder advanced therapy medicinal products (ATMPs) expert meeting: exploring solutions to foster ATMPs’ development and patient access in Europe","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-06-03T14:00:00Z","last_updated_date":"2016-06-03T14:00:00Z","reference_number":"EMA/345874/2016","document_url":"https://www.ema.europa.eu/en/documents/report/outcomes-workshop-multi-stakeholder-advanced-therapy-medicinal-products-atmps-expert-meeting-exploring-solutions-foster-atmps-development-and-patient-access-europe_en.pdf"},
    {"id":"3034","name":"Report to the European Commission on rewards and incentives under the Paediatric Regulation (2010)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-05-10T02:00:00Z","last_updated_date":"2011-05-10T02:00:00Z","reference_number":"EMA/163613/2011","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-commission-rewards-and-incentives-under-paediatric-regulation-2010_en.pdf"},
    {"id":"3068","name":"Results of the sampling and testing programme for the year 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-17T12:25:00Z","last_updated_date":"2012-10-17T12:25:00Z","reference_number":"EMA/INS/S&T/579345/2012","document_url":"https://www.ema.europa.eu/en/documents/report/results-sampling-and-testing-programme-year-2011_en.pdf"},
    {"id":"3085","name":"Scientific recommendation on classification of advanced therapy medicinal products: Living, autologous, melanoma-derived lymphocytes (CD3+)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T19:00:00Z","last_updated_date":"2015-08-26T19:00:00Z","reference_number":"EMA/555336/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-living-autologous-melanoma-derived-lymphocytes-cd3_en.pdf"},
    {"id":"3168","name":"Committee on Medicinal Products for Veterinary Use strategy on antimicrobials 2006-2010 and status report on activities on antimicrobials","type":"report","status":"unknown","consultation_date":"","first_published_date":"2006-03-20T01:00:00Z","last_updated_date":"2006-03-20T01:00:00Z","reference_number":"EMEA/CVMP/353297/2005","document_url":"https://www.ema.europa.eu/en/documents/report/committee-medicinal-products-veterinary-use-strategy-antimicrobials-2006-2010-and-status-report-activities-antimicrobials_en.pdf"},
    {"id":"3187","name":"Report on budgetary and financial management: financial year 2017","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-08-20T18:30:00Z","last_updated_date":"2018-08-20T18:30:00Z","reference_number":"EMA/838683/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2017_en.pdf"},
    {"id":"3251","name":"Applications for new human medicines under evaluation by the CHMP: March 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-03-18T13:30:00Z","last_updated_date":"2014-03-18T13:30:00Z","reference_number":"EMA/145689/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2014_en.pdf"},
    {"id":"3311","name":"Report on the experts' round table on the difficulties related to the use of new medicinal products in children held 18 December 1997","type":"report","status":"unknown","consultation_date":"","first_published_date":"1998-07-30T02:00:00Z","last_updated_date":"2010-02-11T21:21:54Z","reference_number":"EMEA/27164/98 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/report-experts-round-table-difficulties-related-use-new-medicinal-products-children-held-18-december-1997_en.pdf"},
    {"id":"3402","name":"Report on paediatric development and juvenile animal studies assessors meeting","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-12-02T00:09:21Z","last_updated_date":"2009-12-02T00:09:21Z","reference_number":"EMEA/767493/2009","document_url":"https://www.ema.europa.eu/en/documents/report/report-paediatric-development-and-juvenile-animal-studies-assessors-meeting_en.pdf"},
    {"id":"3420","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Ex-vivo expanded autologous skeletal myoblasts","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-12T16:30:00Z","last_updated_date":"2014-02-12T16:30:00Z","reference_number":"EMA/75935/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-ex-vivo-expanded-autologous-skeletal-myoblasts_en.pdf"},
    {"id":"3478","name":"European Medicines Agency report on the implementation of the possibility for waiving the target animal batch safety test for immunological veterinary medicinal products in the European Union","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-01-23T11:15:00Z","last_updated_date":"2012-01-23T11:15:00Z","reference_number":"EMA/675371/2011","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-report-implementation-possibility-waiving-target-animal-batch-safety-test-immunological-veterinary-medicinal-products-european-union_en.pdf"},
    {"id":"3569","name":"Adeno-associated virus serotype 2 based vector containing the human RPE65 gene expression cassette","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T13:00:00Z","last_updated_date":"2016-05-04T13:00:00Z","reference_number":"EMA/291899/2016","document_url":"https://www.ema.europa.eu/en/documents/report/adeno-associated-virus-serotype-2-based-vector-containing-human-rpe65-gene-expression-cassette_en.pdf"},
    {"id":"3660","name":"Scientific recommendation on classification of advanced therapy medicinal products: Nuclease resistant, synthetic double-stranded small interfering RNA (siRNA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-25T18:00:00Z","last_updated_date":"2017-10-25T18:00:00Z","reference_number":"EMA/665133/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-nuclease-resistant-synthetic-double-stranded-small-interfering-rna-sirna_en.pdf"},
    {"id":"3683","name":"Report of meeting held with GIRP - European Association of Pharmaceutical Full-line Wholesalers","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T02:00:00Z","last_updated_date":"2015-10-06T02:00:00Z","reference_number":"EMA/625931/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-meeting-held-girp-european-association-pharmaceutical-full-line-wholesalers_en.pdf"},
    {"id":"3705","name":"Medicinal products for human use: Monthly figures - October 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-12-08T01:00:00Z","last_updated_date":"2010-12-08T01:00:00Z","reference_number":"EMA/777450/2010","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2010_en.pdf"},
    {"id":"3716","name":"Hearing with Kooperation Phytopharmaka during Working Party on Community Monographs and Community List November 2010 meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-03-15T01:00:00Z","last_updated_date":"2011-03-15T01:00:00Z","reference_number":"EMA/HMPC/130727/2011","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-kooperation-phytopharmaka-during-working-party-community-monographs-and-community-list-november-2010-meeting_en.pdf"},
    {"id":"3814","name":"Scientific recommendation on classification of advanced therapy medicinal products: CD1c (BDCA-1)+ myeloid dendritic cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T11:00:00Z","last_updated_date":"2018-02-13T11:00:00Z","reference_number":"EMA/65746/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cd1c-bdca-1-myeloid-dendritic-cells_en.pdf"},
    {"id":"3923","name":"Medicinal products for human use: Monthly figures - November 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-01-10T01:00:00Z","last_updated_date":"2011-01-10T01:00:00Z","reference_number":"EMA/5021/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2010_en.pdf"},
    {"id":"3932","name":"Report - CAR-T cell therapy registries workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-05-22T11:52:00Z","last_updated_date":"2026-01-07T11:52:00Z","reference_number":"EMA/204454/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-car-t-cell-therapy-registries-workshop_en.pdf"},
    {"id":"3989","name":"Applications for new human medicines under evaluation by the CHMP: November 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-11-13T13:00:00Z","last_updated_date":"2012-11-13T13:00:00Z","reference_number":"EMA/712937/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2012_en.pdf"},
    {"id":"4069","name":"European Medicines Agency budget for 2007","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2006-12-19T01:00:00Z","last_updated_date":"2006-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2007_en.pdf"},
    {"id":"4130","name":"Results of the sampling and testing programme for the year 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-12-18T12:40:00Z","last_updated_date":"2013-12-18T12:40:00Z","reference_number":"EMA/INS/S&T/613387/2013","document_url":"https://www.ema.europa.eu/en/documents/report/results-sampling-and-testing-programme-year-2012_en.pdf"},
    {"id":"4229","name":"Medicinal products for human use: monthly figures - July 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-11T18:00:00Z","last_updated_date":"2017-08-11T18:00:00Z","reference_number":"EMA/523482/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2017_en.pdf"},
    {"id":"4391","name":"Scientific recommendation on classification of advanced therapy medicinal products: Cultured human olfactory ensheathing cells and olfactory nerve fibroblasts","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-08-23T17:00:00Z","last_updated_date":"2018-08-23T17:00:00Z","reference_number":"EMA/496382/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cultured-human-olfactory-ensheathing-cells-and-olfactory-nerve-fibroblasts_en.pdf"},
    {"id":"4394","name":"Medicinal products for human use: Monthly figures - December 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-01-20T12:00:00Z","last_updated_date":"2014-01-20T12:00:00Z","reference_number":"EMA/10115/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2013_en.pdf"},
    {"id":"4413","name":"The bacterial challenge: Time to react","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:00:00Z","last_updated_date":"2009-09-01T02:00:00Z","reference_number":"EMEA/576176/2009","document_url":"https://www.ema.europa.eu/en/documents/report/bacterial-challenge-time-react_en.pdf"},
    {"id":"4421","name":"Significant benefit of orphan drugs: concepts and future developments","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2012-07-25T15:35:00Z","last_updated_date":"2012-07-25T15:35:00Z","reference_number":"EMA/326061/2012","document_url":"https://www.ema.europa.eu/en/documents/report/significant-benefit-orphan-drugs-concepts-and-future-developments_en.pdf"},
    {"id":"4460","name":"Biennial report of the joint CVMP/CHMP working group on the application of the 3Rs in regulatory testing of medical products (2016/2017)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-02-26T15:00:00Z","last_updated_date":"2018-02-26T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/biennial-report-joint-cvmpchmp-working-group-application-3rs-regulatory-testing-medical-products-20162017_en.pdf"},
    {"id":"4470","name":"Pandemic report and lessons learned: Outcome of the European Medicines Agency's activities during the 2009 (H1N1) flu pandemic","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-04-29T13:58:38Z","last_updated_date":"2011-04-29T13:58:38Z","reference_number":"EMA/221017/2011","document_url":"https://www.ema.europa.eu/en/documents/report/pandemic-report-and-lessons-learned-outcome-european-medicines-agencys-activities-during-2009-h1n1-flu-pandemic_en.pdf"},
    {"id":"4475","name":"Applications for new human medicines under evaluation by the CHMP: October 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-12T11:34:00Z","last_updated_date":"2012-10-12T11:34:00Z","reference_number":"EMA/648405/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2012_en.pdf"},
    {"id":"4504","name":"Highlights from the European Medicines Agency industry platform meeting held on 21 April 2016 on the operation of the centralised procedure for human medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-09-02T16:00:00Z","last_updated_date":"2016-09-02T16:00:00Z","reference_number":"EMA/526723/2016","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-european-medicines-agency-industry-platform-meeting-held-21-april-2016-operation-centralised-procedure-human-medicinal-products_en.pdf"},
    {"id":"4527","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Ex-vivo expanded autologous human corneal epithelium containing stem cells","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-12T16:30:00Z","last_updated_date":"2014-02-12T16:30:00Z","reference_number":"EMA/74581/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-ex-vivo-expanded-autologous-human-corneal-epithelium-containing-stem-cells_en.pdf"},
    {"id":"4566","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-28T14:45:00Z","last_updated_date":"2017-02-28T14:45:00Z","reference_number":"EMA/127201/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-epstein-barr-virus-cytotoxic-t-lymphocytes_en.pdf"},
    {"id":"4569","name":"Pandemic pharmacovigilance weekly update (status at 27 November 2009)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-12-03T00:09:21Z","last_updated_date":"2009-12-03T00:09:21Z","reference_number":"EMEA/784681/2009","document_url":"https://www.ema.europa.eu/en/documents/report/pandemic-pharmacovigilance-weekly-update-status-27-november-2009_en.pdf"},
    {"id":"4628","name":"CHMP statistics: May 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T14:00:00Z","last_updated_date":"2016-05-27T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-may-2016_en.pdf"},
    {"id":"4670","name":"Conditional marketing authorisation - Report on ten years of experience at the European Medicines Agency","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T16:30:00Z","last_updated_date":"2017-01-23T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/conditional-marketing-authorisation-report-ten-years-experience-european-medicines-agency_en.pdf"}    {"id":"4741","name":"Report from the CAT expert meeting - Scientific and regulatory considerations for adeno-associated viral vector (AAV)-based gene therapy","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-07-19T02:00:00Z","last_updated_date":"2018-07-19T02:00:00Z","reference_number":"EMA/CAT/60852/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-cat-expert-meeting-scientific-and-regulatory-considerations-adeno-associated-viral-vector-aav-based-gene-therapy_en.pdf"},
    {"id":"4745","name":"Applications for new human medicines under evaluation by the CHMP: June 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T12:42:00Z","last_updated_date":"2013-06-14T12:42:00Z","reference_number":"EMA/358707/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2013_en.pdf"},
    {"id":"4884","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Autologous cells of stromal vascular fraction of adipose tissue","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-22T14:15:00Z","last_updated_date":"2012-10-22T14:15:00Z","reference_number":"EMA/500673/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-cells-stromal-vascular-fraction-adipose-tissue_en.pdf"},
    {"id":"4909","name":"Medicinal products for human use: monthly figures - October 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-11-23T16:30:00Z","last_updated_date":"2015-11-23T16:30:00Z","reference_number":"EMA/776803/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2015_en.pdf"},
    {"id":"4916","name":"CHMP statistics: February 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-february-2016_en.pdf"},
    {"id":"5033","name":"European Medicines Agency budget for 2011","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2011-02-18T01:00:00Z","reference_number":"EMA/MB/784261/2010","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2011_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/report/european-medicines-agency-budget-2011_bg.pdf","es":"https://www.ema.europa.eu/es/documents/report/european-medicines-agency-budget-2011_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/report/european-medicines-agency-budget-2011_cs.pdf","da":"https://www.ema.europa.eu/da/documents/report/european-medicines-agency-budget-2011_da.pdf","de":"https://www.ema.europa.eu/de/documents/report/european-medicines-agency-budget-2011_de.pdf","et":"https://www.ema.europa.eu/et/documents/report/european-medicines-agency-budget-2011_et.pdf","el":"https://www.ema.europa.eu/el/documents/report/european-medicines-agency-budget-2011_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/report/european-medicines-agency-budget-2011_fr.pdf","it":"https://www.ema.europa.eu/it/documents/report/european-medicines-agency-budget-2011_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/report/european-medicines-agency-budget-2011_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/report/european-medicines-agency-budget-2011_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/report/european-medicines-agency-budget-2011_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/report/european-medicines-agency-budget-2011_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/report/european-medicines-agency-budget-2011_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/report/european-medicines-agency-budget-2011_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/report/european-medicines-agency-budget-2011_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/report/european-medicines-agency-budget-2011_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/report/european-medicines-agency-budget-2011_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/report/european-medicines-agency-budget-2011_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/report/european-medicines-agency-budget-2011_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/report/european-medicines-agency-budget-2011_sv.pdf"}},
    {"id":"5055","name":"Applications for new human medicines under evaluation by the CHMP: April 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-04-10T18:00:00Z","last_updated_date":"2018-04-10T18:00:00Z","reference_number":"EMA/216799/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2018_en.pdf"},
    {"id":"5079","name":"Scientific recommendation on classification of advanced therapy medicinal products: decellularized porcine dermal matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T13:00:00Z","last_updated_date":"2016-04-12T13:00:00Z","reference_number":"EMA/241024/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-decellularized-porcine-dermal-matrix_en.pdf"},
    {"id":"5134","name":"Scientific recommendation on classification of advanced therapy medicinal products: Bone marrow derived lineage negative heterogenic stem and progenitor cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-02T16:30:00Z","last_updated_date":"2017-02-02T16:30:00Z","reference_number":"EMA/54559/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-bone-marrow-derived-lineage-negative-heterogenic-stem-and-progenitor-cells_en.pdf"},
    {"id":"5150","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) June2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-07-01T02:00:00Z","last_updated_date":"2010-07-01T02:00:00Z","reference_number":"EMA406000/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-june2010-plenary-meeting_en.pdf"},
    {"id":"5175","name":"Ensuring safe and effective medicines for an ageing population: Workshop proceedings","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-08-17T02:00:00Z","last_updated_date":"2012-08-17T02:00:00Z","reference_number":"EMA/425943/2012","document_url":"https://www.ema.europa.eu/en/documents/report/ensuring-safe-and-effective-medicines-ageing-population-workshop-proceedings_en.pdf"},
    {"id":"5183","name":"Annual accounts: Financial year 2012","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-07-04T11:40:00Z","last_updated_date":"2013-07-04T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2012_en.pdf"},
    {"id":"5220","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human foetal neural stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-07-13T15:40:00Z","last_updated_date":"2018-07-13T15:40:00Z","reference_number":"EMA/381068/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-foetal-neural-stem-cells_en.pdf"},
    {"id":"5284","name":"Medicinal products for human use: monthly figures - May 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-15T18:45:00Z","last_updated_date":"2018-06-15T18:45:00Z","reference_number":"EMA/412673/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2018_en.pdf"},
    {"id":"5314","name":"Report on annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), 22-23 March 2012","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-04-11T13:40:00Z","last_updated_date":"2013-04-11T13:40:00Z","reference_number":"EMA/218181/2013","document_url":"https://www.ema.europa.eu/en/documents/report/report-annual-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema-22-23-march-2012_en.pdf"},
    {"id":"5345","name":"Report on annual workshop of the European Network of Paediatric Research at the European Medicines Agency, 27-28 June 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-08-22T13:42:00Z","last_updated_date":"2013-08-22T13:42:00Z","reference_number":"EMA/401244/2013","document_url":"https://www.ema.europa.eu/en/documents/report/report-annual-workshop-european-network-paediatric-research-european-medicines-agency-27-28-june-2013_en.pdf"},
    {"id":"5363","name":"Outcome of the European Medicines Agency (EMA) survey on centralised initial marketing authorisation procedure 2016/2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-03-01T18:30:00Z","last_updated_date":"2018-03-01T18:30:00Z","reference_number":"EMA/338870/2017","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-european-medicines-agency-ema-survey-centralised-initial-marketing-authorisation-procedure-20162017_en.pdf"},
    {"id":"5449","name":"Medicinal products for human use: monthly figures - February 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-03-14T13:16:00Z","last_updated_date":"2018-03-14T13:16:00Z","reference_number":"EMA/159082/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2018_en.pdf"},
    {"id":"5624","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) October 2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-10-28T02:00:00Z","last_updated_date":"2010-10-28T02:00:00Z","reference_number":"EMA/CHMP/PhVWP/652824/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-october-2010-plenary-meeting_en.pdf"},
    {"id":"5675","name":"COMP report to the Commission in relation to Article 10 of Regulation 141/2000 on orphan medicinal products - Annex 1","type":"report","status":"unknown","consultation_date":"","first_published_date":"2005-07-25T02:00:00Z","last_updated_date":"2005-07-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/comp-report-commission-relation-article-10-regulation-1412000-orphan-medicinal-products-annex-1_en.pdf"},
    {"id":"5754","name":"Scientific recommendation on classification of advanced-therapy medicinal products: A mixture of autologous dendritic cells pulsed with a non-structural-3 protein fragment of the hepatitis-C virus and activated T-cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T13:30:00Z","last_updated_date":"2013-03-08T13:30:00Z","reference_number":"EMA/50963/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-mixture-autologous-dendritic-cells-pulsed-non-structural-3-protein-fragment-hepatitis-c-virus-and-activated-t-cells_en.pdf"},
    {"id":"5791","name":"Medicinal products for human use: monthly figures - September 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T15:35:00Z","last_updated_date":"2017-10-12T15:35:00Z","reference_number":"EMA/672142/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2017_en.pdf"},
    {"id":"5797","name":"CHMP statistics: March 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-march-2017_en.pdf"},
    {"id":"5826","name":"Highlights from the 13th EMA Industry Platform meeting on the operation of EU pharmacovigilance legislation – 20 March 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-05-07T15:13:00Z","last_updated_date":"2018-05-07T15:13:00Z","reference_number":"EMA/181781/2018","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-13th-ema-industry-platform-meeting-operation-eu-pharmacovigilance-legislation-20-march-2018_en.pdf"},
    {"id":"5867","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous adipose tissue-derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T16:30:00Z","last_updated_date":"2017-10-23T16:30:00Z","reference_number":"EMA/561787/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-adipose-tissue-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"5952","name":"Update on the implementation of the EU Telematics strategy","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/724730/2009","document_url":"https://www.ema.europa.eu/en/documents/report/update-implementation-eu-telematics-strategy_en.pdf"},
    {"id":"6039","name":"Scientific recommendation on classification of advanced therapy medicinal products: heterologous human adult liver-derived progenitor cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-21T20:00:00Z","last_updated_date":"2016-10-21T20:00:00Z","reference_number":"EMA/680696/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-heterologous-human-adult-liver-derived-progenitor-cells_en.pdf"},
    {"id":"6067","name":"Scientific recommendation on classification of advanced therapy medicinal products: allogeneic (human Wharton’s jelly derived) mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T15:30:00Z","last_updated_date":"2016-04-19T15:30:00Z","reference_number":"EMA/240980/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-human-whartons-jelly-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"6087","name":"European Medicines Agency workshop on viral safety of plasma-derived medicinal products with particular focus on non-enveloped viruses, 13 September 2000: Summary report","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2001-03-28T02:09:21Z","last_updated_date":"2001-03-28T02:09:21Z","reference_number":"CPMP/BWP/BPWG/4080/00","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-workshop-viral-safety-plasma-derived-medicinal-products-particular-focus-non-enveloped-viruses-13-september-2000-summary-report_en.pdf"},
    {"id":"6107","name":"Monthly report - Pharmacovigilance Working Party (PhVWP) July 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"EMA/CHMP/PhVWP/569591/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-july-2011-plenary-meeting_en.pdf"},
    {"id":"6128","name":"Applications for new human medicines under evaluation by the CHMP: December 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-12-11T15:00:00Z","last_updated_date":"2015-12-11T15:00:00Z","reference_number":"EMA/825991/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2015_en.pdf"},
    {"id":"6141","name":"Report from the small and medium-sized enterprise office on its first year of operation","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2006-12-15T01:00:00Z","last_updated_date":"2006-12-15T01:00:00Z","reference_number":"EMEA/498584/2006","document_url":"https://www.ema.europa.eu/en/documents/report/report-small-and-medium-sized-enterprise-office-its-first-year-operation_en.pdf"},
    {"id":"6202","name":"Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus (AAV) pseudotyped with viral capsid from serotype 5 which holds a construct that contains two guide r...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/417253/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-virus-aav-pseudotyped-viral-capsid-serotype-5-which-holds-construct-contains-two-guide-r_en.pdf"},
    {"id":"6278","name":"Report of the ENCePP Scientific Convention \"EU health care databases for pan-EU pharmacoepidemiological research\"","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-12-08T01:00:00Z","last_updated_date":"2008-12-08T01:00:00Z","reference_number":"EMEA/657414/2008","document_url":"https://www.ema.europa.eu/en/documents/report/report-encepp-scientific-convention-eu-health-care-databases-pan-eu-pharmacoepidemiological-research_en.pdf"},
    {"id":"6322","name":"Report of EMEA expert meeting on the revision of the core SPC and note for guidance for human normal immunoglobulin for intravenous administration (IVIg)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/CHMP/BPWP/361857/2006","document_url":"https://www.ema.europa.eu/en/documents/report/report-emea-expert-meeting-revision-core-spc-and-note-guidance-human-normal-immunoglobulin-intravenous-administration-ivig_en.pdf"},
    {"id":"6337","name":"EMA communication perception survey report 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-07-18T13:40:00Z","last_updated_date":"2018-07-18T13:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/ema-communication-perception-survey-report-2017_en.pdf"},
    {"id":"6384","name":"2016 activity report of the modelling and simulation working group (MSWG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T10:00:00Z","last_updated_date":"2017-03-09T10:00:00Z","reference_number":"EMA/800956/2016","document_url":"https://www.ema.europa.eu/en/documents/report/2016-activity-report-modelling-and-simulation-working-group-mswg_en.pdf"},
    {"id":"6451","name":"Medicinal products for human use: Monthly figures - January 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T15:30:00Z","last_updated_date":"2013-03-08T15:30:00Z","reference_number":"EMA/136611/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2013_en.pdf"},
    {"id":"6475","name":"Applications for new human medicines under evaluation by the CHMP: July 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-07-08T12:40:00Z","last_updated_date":"2016-07-08T12:40:00Z","reference_number":"EMA/462942/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2016_en.pdf"},
    {"id":"6530","name":"Report - Expert meeting on neonatal and paediatric sepsis","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/477725/2010","document_url":"https://www.ema.europa.eu/en/documents/report/report-expert-meeting-neonatal-and-paediatric-sepsis_en.pdf"},
    {"id":"6571","name":"Applications for new human medicines under evaluation by the CHMP: May 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-05-14T16:08:00Z","last_updated_date":"2012-05-14T16:08:00Z","reference_number":"EMA/293765/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2012_en.pdf"},
    {"id":"6583","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Pro-inflammatory dendritic cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:59:00Z","last_updated_date":"2018-01-03T14:59:00Z","reference_number":"EMA/699040/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-pro-inflammatory-dendritic-cells_en.pdf"},
    {"id":"6634","name":"Summary report - Workshop on nanomedicines: 2-3 September 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/538503/2010","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-workshop-nanomedicines-2-3-september-2010_en.pdf"},
    {"id":"6751","name":"CHMP statistics: October 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-october-2016_en.pdf"},
    {"id":"6755","name":"Monthly report - Pharmacovigilance Working Party (PhVWP) October 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-10-27T14:05:00Z","last_updated_date":"2011-10-27T14:05:00Z","reference_number":"EMA/CHMP/PhVWP/845939/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-october-2011-plenary-meeting_en.pdf"},
    {"id":"6766","name":"Medicinal products for human use: Monthly figures - January 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-02-20T18:05:00Z","last_updated_date":"2015-02-20T18:05:00Z","reference_number":"EMA/100284/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2015_en.pdf"},
    {"id":"6845","name":"Medicinal products for human use: Monthly figures - September 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T12:00:00Z","last_updated_date":"2014-10-21T12:00:00Z","reference_number":"EMA/637845/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2014_en.pdf"},
    {"id":"6868","name":"Background review for the excipient propylene glycol: In the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’ - Draft report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T18:20:00Z","last_updated_date":"2014-12-01T18:20:00Z","reference_number":"EMA/CHMP/334655/2013","document_url":"https://www.ema.europa.eu/en/documents/report/background-review-excipient-propylene-glycol-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use-draft-report_en.pdf"},
    {"id":"6942","name":"PRIME: a two-year overview","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-05-07T17:30:00Z","last_updated_date":"2018-05-07T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prime-two-year-overview_en.pdf"},
    {"id":"6964","name":"Applications for new human medicines under evaluation by the CHMP: January 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-01-17T17:00:00Z","last_updated_date":"2014-01-17T17:00:00Z","reference_number":"EMA/21080/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2014_en.pdf"},
    {"id":"7011","name":"European Court of Auditors final report on the annual accounts of the European Medicines Agency for the financial year 2012","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T12:15:00Z","last_updated_date":"2014-07-01T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-court-auditors-final-report-annual-accounts-european-medicines-agency-financial-year-2012_en.pdf"},
    {"id":"7013","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Tissue like combination of osteogenic cells and demineralised bone matrix (three-dimensional structure of demineralised bone matrix and ...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T13:30:00Z","last_updated_date":"2013-03-08T13:30:00Z","reference_number":"EMA/90882/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-tissue-combination-osteogenic-cells-and-demineralised-bone-matrix-three-dimensional-structure-demineralised-bone-matrix-and_en.pdf"},
    {"id":"7037","name":"Report from experience acquired from pilot phase participation of patients / consumers representatives in the Pharmacovigilance Working Party (PhVWP) and proposal for participation of patients’ / consumers’ representativ...","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-12-10T00:09:21Z","last_updated_date":"2009-12-10T00:09:21Z","reference_number":"EMA/355206/2009","document_url":"https://www.ema.europa.eu/en/documents/report/report-experience-acquired-pilot-phase-participation-patients-consumers-representatives-pharmacovigilance-working-party-phvwp-and-proposal-participation-patients-consumers-representativ_en.pdf"},
    {"id":"7051","name":"Applications for new human medicines under evaluation by the CHMP: December 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-12-18T11:45:00Z","last_updated_date":"2013-12-18T11:45:00Z","reference_number":"EMA/773850/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2013_en.pdf"},
    {"id":"7112","name":"CHMP/Biologics Working Party report to the CMDh on pancreatin-containing products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-10-04T16:45:00Z","last_updated_date":"2013-10-04T16:45:00Z","reference_number":"EMEA/CHMP/BWP/373049/2013","document_url":"https://www.ema.europa.eu/en/documents/report/chmpbiologics-working-party-report-cmdh-pancreatin-containing-products_en.pdf"},
    {"id":"7152","name":"Medicinal products for human use: monthly figures - May 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T17:09:00Z","last_updated_date":"2017-06-23T17:09:00Z","reference_number":"EMA/397446/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2017_en.pdf"},
    {"id":"7209","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous bone marrow-derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T16:40:00Z","last_updated_date":"2018-06-27T16:40:00Z","reference_number":"EMA/276857/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-bone-marrow-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"7256","name":"Medicinal products for human use: Monthly figures - September 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-10-19T02:00:00Z","last_updated_date":"2010-10-19T02:00:00Z","reference_number":"EMA/646611/2010","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2010_en.pdf"},
    {"id":"7377","name":"Report - Symposium: Raw materials for the production of cell-based and gene therapy products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-11-05T01:00:00Z","last_updated_date":"2013-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-symposium-raw-materials-production-cell-based-and-gene-therapy-products_en.pdf"},
    {"id":"7381","name":"Applications for new human medicines under evaluation by the CHMP: July 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-07-20T16:23:00Z","last_updated_date":"2015-07-20T16:23:00Z","reference_number":"EMA/463668/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2015_en.pdf"},
    {"id":"7424","name":"EMEA's provision of information to the EMEA's stakeholders - Brainstorming meeting - Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-04-18T02:09:21Z","last_updated_date":"2008-04-18T02:09:21Z","reference_number":"EMEA/436248/2007","document_url":"https://www.ema.europa.eu/en/documents/report/emeas-provision-information-emeas-stakeholders-brainstorming-meeting-report_en.pdf"},
    {"id":"7447","name":"Medicinal products for human use: Monthly figures - February 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-04-03T18:15:00Z","last_updated_date":"2013-04-03T18:15:00Z","reference_number":"EMA/190559/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2013_en.pdf"},
    {"id":"7498","name":"Scientific recommendation on classification of advanced-therapy medicinal product: Pseudomonas aeruginosa bacteria genetically modified to secrete oncoproteins of Merkel-cell carcinoma","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-07-01T12:00:00Z","last_updated_date":"2013-07-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-product-pseudomonas-aeruginosa-bacteria-genetically-modified-secrete-oncoproteins-merkel-cell-carcinoma_en.pdf"},
    {"id":"7553","name":"CHMP statistics: April 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-april-2016_en.pdf"},
    {"id":"7612","name":"Clinical data publication (Policy 0070) report Oct 2016-Oct 2017","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-07-16T17:00:00Z","last_updated_date":"2018-07-16T17:00:00Z","reference_number":"EMA/630246/2017","document_url":"https://www.ema.europa.eu/en/documents/report/clinical-data-publication-policy-0070-report-oct-2016-oct-2017_en.pdf"},
    {"id":"7645","name":"Medicinal products for human use: Monthly figures - July 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-08-11T01:31:00Z","last_updated_date":"2010-08-11T01:31:00Z","reference_number":"EMA/502619/2010","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2010_en.pdf"},
    {"id":"7653","name":"Scientific recommendation on classification of advanced therapy medicinal products: Bone marrow-derived autologous non-haematopoietic stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-28T13:00:00Z","last_updated_date":"2016-11-28T13:00:00Z","reference_number":"EMA/758163/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-bone-marrow-derived-autologous-non-haematopoietic-stem-cells_en.pdf"},
    {"id":"7772","name":"Outcome Report on Pilot to involve patients in benefit/risk discussions at CHMP meetings","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T17:21:00Z","last_updated_date":"2017-05-08T17:21:00Z","reference_number":"EMA/191955/2017","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-report-pilot-involve-patients-benefitrisk-discussions-chmp-meetings_en.pdf"},
    {"id":"7801","name":"Scientific recommendation on classification of advanced therapy medicinal products: allogenic mesenchymal stem cells isolated from umbilical cord","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T16:40:00Z","last_updated_date":"2018-06-27T16:40:00Z","reference_number":"EMA/276793/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogenic-mesenchymal-stem-cells-isolated-umbilical-cord_en.pdf"},
    {"id":"7810","name":"EBV-specific T cells in suspension in human albumin","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-07-11T13:00:00Z","last_updated_date":"2014-07-11T13:00:00Z","reference_number":"EMA/413971/2014","document_url":"https://www.ema.europa.eu/en/documents/report/ebv-specific-t-cells-suspension-human-albumin_en.pdf"},
    {"id":"7855","name":"Scientific recommendation on classification of advanced therapy medicinal products: Messenger RNAs (mRNAs) encoding immunostimulatory proteins caTLR4, CD40L and CD70 and tumour associated antigens (TAA) tyrosinase, gp100...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-25T18:00:00Z","last_updated_date":"2017-10-25T18:00:00Z","reference_number":"EMA/665187/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-messenger-rnas-mrnas-encoding-immunostimulatory-proteins-catlr4-cd40l-and-cd70-and-tumour-associated-antigens-taa_en.pdf"},
    {"id":"7963","name":"Boric acid and borate used as excipients - Report published in support of the ‘Questions and answers on boric acid and borates used as excipients in medicinal products for human use’","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/765436/2012","document_url":"https://www.ema.europa.eu/en/documents/report/boric-acid-and-borate-used-excipients-report-published-support-questions-and-answers-boric-acid-and-borates-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"8037","name":"Medicinal products for human use: Monthly figures - March 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T17:40:00Z","last_updated_date":"2014-04-28T17:40:00Z","reference_number":"EMA/247222/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2014_en.pdf"},
    {"id":"8060","name":"Pharmacovigilance Working Party (PhVWP) - Monthly report on safety concerns, guidelines and general matters - May 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-05-31T13:25:00Z","last_updated_date":"2012-05-31T13:25:00Z","reference_number":"EMA/CHMP/PhVWP/339710/2012","document_url":"https://www.ema.europa.eu/en/documents/report/pharmacovigilance-working-party-phvwp-monthly-report-safety-concerns-guidelines-and-general-matters-may-2012_en.pdf"},
    {"id":"8075","name":"Applications for new human medicines under evaluation by the CHMP: March 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-03-16T15:00:00Z","last_updated_date":"2015-03-16T15:00:00Z","reference_number":"EMA/158334/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2015_en.pdf"},
    {"id":"8088","name":"Benefit-risk methodology project: Work package 4 report: Benefit-risk tools and processes","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2012-03-12T19:36:32Z","last_updated_date":"2012-06-13T12:45:00Z","reference_number":"EMA/297405/2012 rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/benefit-risk-methodology-project-work-package-4-report-benefit-risk-tools-and-processes_en.pdf"},
    {"id":"8120","name":"Meeting report from Fate of veterinary medicinal products in manure Focus Group Meeting - London, 23 June 2009","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-10-07T02:09:21Z","last_updated_date":"2009-10-07T02:09:21Z","reference_number":"EMEA/CVMP/ERA/400210/2009","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-fate-veterinary-medicinal-products-manure-focus-group-meeting-london-23-june-2009_en.pdf"},
    {"id":"8158","name":"Seventh pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-01-20T00:09:21Z","last_updated_date":"2010-01-20T00:09:21Z","reference_number":"EMA/39205/2010","document_url":"https://www.ema.europa.eu/en/documents/report/seventh-pandemic-pharmacovigilance-weekly-update_en.pdf"},
    {"id":"8257","name":"Benefit-risk methodology project - Report on risk perception study module","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-02-23T10:35:00Z","last_updated_date":"2012-02-23T10:35:00Z","reference_number":"EMA/662299/2011","document_url":"https://www.ema.europa.eu/en/documents/report/benefit-risk-methodology-project-report-risk-perception-study-module_en.pdf"},
    {"id":"8336","name":"Report on the European Medicines Agency roundtable meeting with stakeholders - 10th anniversary of the SME initiative","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-12-21T12:35:00Z","last_updated_date":"2015-12-21T12:35:00Z","reference_number":"EMA/821368/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-roundtable-meeting-stakeholders-10th-anniversary-sme-initiative_en.pdf"},
    {"id":"8506","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Bone-marrow-derived autologous suspensions of hematopoietic and mesenchymal stem cells depleted from erythrocytes and lymphocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-09-25T16:01:00Z","last_updated_date":"2012-09-25T16:01:00Z","reference_number":"EMA/494706/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-bone-marrow-derived-autologous-suspensions-hematopoietic-and-mesenchymal-stem-cells-depleted-erythrocytes-and-lymphocytes_en.pdf"},
    {"id":"8557","name":"Summary of transfers of appropriations in budget 2016 - Period 29 November 2016 to 13 December 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-03-17T17:00:00Z","last_updated_date":"2017-03-17T17:00:00Z","reference_number":"EMA/124297/2017","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2016-period-29-november-2016-13-december-2016_en.pdf"},
    {"id":"8562","name":"Applications for new human medicines under evaluation by the CHMP: September 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-09-19T17:12:00Z","last_updated_date":"2016-09-19T17:12:00Z","reference_number":"EMA/607298/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2016_en.pdf"},
    {"id":"8591","name":"Medicinal products for human use: monthly figures - August 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-09-26T02:00:00Z","last_updated_date":"2016-09-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2016_en.pdf"},
    {"id":"8639","name":"Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 2/1 vector encoding human β-hexosaminidase alpha and beta subunits","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:41:00Z","last_updated_date":"2018-01-03T14:41:00Z","reference_number":"EMA/751477/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-virus-serotype-21-vector-encoding-human-i2-hexosaminidase-alpha-and-beta-subunits_en.pdf"},
    {"id":"8658","name":"Pharmacovigilance Working Party (PhVWP) - Monthly report on safety concerns, guidelines and general matters - February 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-02-23T13:00:00Z","last_updated_date":"2012-02-23T13:00:00Z","reference_number":"EMA/CHMP/PhVWP/51794/2012","document_url":"https://www.ema.europa.eu/en/documents/report/pharmacovigilance-working-party-phvwp-monthly-report-safety-concerns-guidelines-and-general-matters-february-2012_en.pdf"},
    {"id":"8665","name":"Report from Committee for Advanced Therapies Interested Parties Focus Groups (CATIPs FG) on system to navigate guidelines for advanced-therapy medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CAT/463795/2011","document_url":"https://www.ema.europa.eu/en/documents/report/report-committee-advanced-therapies-interested-parties-focus-groups-catips-fg-system-navigate-guidelines-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"8687","name":"Publication policy for the monthly reports of the CHMP Pharmacovigilance Working Party","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-10-12T02:00:00Z","last_updated_date":"2009-10-12T02:00:00Z","reference_number":"EMEA/CHMP/PhVWP/33965/2009","document_url":"https://www.ema.europa.eu/en/documents/report/publication-policy-monthly-reports-chmp-pharmacovigilance-working-party_en.pdf"},
    {"id":"8690","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human mesenchymal stem cells derived from Wharton’s jelly tissue of umbilical cord (amyotrophic lateral sclerosis)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T12:30:00Z","last_updated_date":"2015-08-26T12:30:00Z","reference_number":"EMA/561345/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-mesenchymal-stem-cells-derived-whartons-jelly-tissue-umbilical-cord-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"8699","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human burn eschar and debrided adipose tissue cells (sheet)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T11:00:00Z","last_updated_date":"2018-02-13T11:00:00Z","reference_number":"EMA/35691/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-burn-eschar-and-debrided-adipose-tissue-cells-sheet_en.pdf"},
    {"id":"8709","name":"The European Medicines Agency road map to 2010:\n\nPreparing the ground for the future","type":"report","status":"unknown","consultation_date":"","first_published_date":"2005-03-04T01:00:00Z","last_updated_date":"2005-03-04T01:00:00Z","reference_number":"EMEA/H/34163/03/Final","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-road-map-2010-preparing-ground-future_en.pdf"},
    {"id":"8724","name":"Stratification of sales data of antimicrobials by species - Data collection protocol 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-07-05T16:30:00Z","last_updated_date":"2018-07-05T16:30:00Z","reference_number":"EMA/284404/2018","document_url":"https://www.ema.europa.eu/en/documents/report/stratification-sales-data-antimicrobials-species-data-collection-protocol-2017_en.pdf"},
    {"id":"8878","name":"EudraVigilance Veterinary – Status update report (October 2011)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2011-10-04T16:00:00Z","last_updated_date":"2011-10-04T16:00:00Z","reference_number":"EMA/MB/744682/2011","document_url":"https://www.ema.europa.eu/en/documents/report/eudravigilance-veterinary-status-update-report-october-2011_en.pdf"},
    {"id":"8897","name":"Medicinal products for human use: Monthly figures - July 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-08-15T18:00:00Z","last_updated_date":"2013-08-15T18:00:00Z","reference_number":"EMA/477963/2013 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2013_en.pdf"},
    {"id":"8938","name":"Report - Information session on antimicrobial resistance on 19 September 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-11-13T11:30:00Z","last_updated_date":"2017-11-14T15:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-information-session-antimicrobial-resistance-19-september-2017_en.pdf"},
    {"id":"8942","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Recombinant herpes simplex virus type 1 (HSV-1) containing the gene encoding human granulocyte macrophage colony-stimulating factor (GM-...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-12-17T16:00:00Z","last_updated_date":"2012-12-17T16:00:00Z","reference_number":"EMA/494706/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-herpes-simplex-virus-type-1-hsv-1-containing-gene-encoding-human-granulocyte-macrophage-colony-stimulating_en.pdf"},
    {"id":"9097","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Retinal pigment epithelium cells derived from human induced pluripotent stem cells","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-12T16:30:00Z","last_updated_date":"2014-02-12T16:30:00Z","reference_number":"EMA/75786/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-retinal-pigment-epithelium-cells-derived-human-induced-pluripotent-stem-cells_en.pdf"},
    {"id":"9203","name":"Benzalkonium chloride used as an excipient - \n\nReport published in support of the ‘Questions and answers on benzalkonium chloride used as an excipient in medicinal products for human use’","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/352187/2012","document_url":"https://www.ema.europa.eu/en/documents/report/benzalkonium-chloride-used-excipient-report-published-support-questions-and-answers-benzalkonium-chloride-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"9214","name":"Annual accounts: Financial year 2007","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-11-24T00:09:21Z","last_updated_date":"2009-11-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2007_en.pdf"},
    {"id":"9215","name":"Scientific recommendation on classification of advanced therapy medicinal products: Adeno-Associated Viral Vectors derived from wild-type AAV2/5. The expression cassettes contain DNA encoding an RNA interference (RNAi) s...","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T12:00:00Z","last_updated_date":"2015-08-26T12:00:00Z","reference_number":"EMA/557237/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adeno-associated-viral-vectors-derived-wild-type-aav25-expression-cassettes-contain-dna-encoding-rna-interference-rnai-s_en.pdf"}    {"id":"9399","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T16:30:00Z","last_updated_date":"2017-10-23T16:30:00Z","reference_number":"EMA/534841/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-autologous-keratinocytes_en.pdf"},
    {"id":"9428","name":"Report on budgetary and financial management: Financial year 2013","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T12:15:00Z","last_updated_date":"2014-07-01T12:15:00Z","reference_number":"EMA/14575/2014","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2013_en.pdf"},
    {"id":"9496","name":"CHMP statistics: September 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-september-2017_en.pdf"},
    {"id":"9528","name":"European Medicines Agency / Food and Drug Administration joint good-manufacturing-practice-inspection pilot programme - Terms of reference and procedures for participating authorities (manufacturers of medicinal products...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-11-15T01:00:00Z","last_updated_date":"2010-11-15T01:00:00Z","reference_number":"EMA/660316/2010","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-food-and-drug-administration-joint-good-manufacturing-practice-inspection-pilot-programme-terms-reference-and-procedures-participating-authorities-manufacturers-medicinal_en.pdf"},
    {"id":"9559","name":"Update on the implementation of the EU Telematics strategy","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/528743/2009","document_url":"https://www.ema.europa.eu/en/documents/report/update-implementation-eu-telematics-strategy_en.pdf-0"},
    {"id":"9572","name":"Scientific recommendation on classification of advanced therapy medicinal products: Hepatocyte-like cells are cryopreserved in the freezing solution, solution for injection","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T12:45:00Z","last_updated_date":"2016-04-12T12:45:00Z","reference_number":"EMA/213701/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-hepatocyte-cells-are-cryopreserved-freezing-solution-solution-injection_en.pdf"},
    {"id":"9578","name":"Applications for new human medicines under evaluation by the CHMP: May 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-13T15:57:00Z","last_updated_date":"2016-05-13T15:57:00Z","reference_number":"EMA/325064/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2016_en.pdf"},
    {"id":"9643","name":"European Union recommendations for the seasonal-influenza-vaccine composition for the season 2010 / 2011","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/CHMP/BWP/107653/2010","document_url":"https://www.ema.europa.eu/en/documents/report/european-union-recommendations-seasonal-influenza-vaccine-composition-season-2010-2011_en.pdf"},
    {"id":"9689","name":"Medicinal products for human use: Monthly figures - March 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-04-13T02:00:00Z","last_updated_date":"2011-04-13T02:00:00Z","reference_number":"EMA/287398/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2011_en.pdf"},
    {"id":"9766","name":"Highlights from the twelfth industry stakeholder platform on the operation of pharmacovigilance in the European Union","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-19T12:35:00Z","last_updated_date":"2018-04-26T13:00:00Z","reference_number":"EMA/790351/2017","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-twelfth-industry-stakeholder-platform-operation-pharmacovigilance-european-union_en.pdf"},
    {"id":"9784","name":"Applications for new human medicines under evaluation by the CHMP: November 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-11-22T13:45:00Z","last_updated_date":"2013-11-22T13:45:00Z","reference_number":"EMA/693057/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2013_en.pdf"},
    {"id":"9857","name":"Workshop on multiplicity issues in clinical trials: Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"EMA/743074/2012","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-multiplicity-issues-clinical-trials-report_en.pdf"},
    {"id":"9878","name":"Scientific recommendation on classification of advanced therapy medicinal products: Cultured autologous adipose derived regenerative mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/4172015/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cultured-autologous-adipose-derived-regenerative-mesenchymal-stem-cells_en.pdf"},
    {"id":"9950","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Adult autologous regenerative cells in autologous cell-enriched matrix for subcutaneous administration","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T18:00:00Z","last_updated_date":"2013-05-03T18:00:00Z","reference_number":"EMA/129099/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adult-autologous-regenerative-cells-autologous-cell-enriched-matrix-subcutaneous-administration_en.pdf"},
    {"id":"9967","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) February 2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-02-25T01:00:00Z","last_updated_date":"2010-02-25T01:00:00Z","reference_number":"EMA/102067/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-february-2010-plenary-meeting_en.pdf"},
    {"id":"10099","name":"Medical literature monitoring service quarterly report August – October 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-11-11T10:30:00Z","last_updated_date":"2015-11-11T10:30:00Z","reference_number":"EMA/741623/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medical-literature-monitoring-service-quarterly-report-august-october-2015_en.pdf"},
    {"id":"10165","name":"Eighth pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-01-27T01:00:00Z","last_updated_date":"2010-01-27T01:00:00Z","reference_number":"EMA/55806/2010","document_url":"https://www.ema.europa.eu/en/documents/report/eighth-pandemic-pharmacovigilance-weekly-update_en.pdf"},
    {"id":"10181","name":"Use of colistin products in animals within the European Union: development of resistance and possible impact on human and animal health (superseded)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-07-30T14:00:00Z","last_updated_date":"2013-07-30T14:00:00Z","reference_number":"EMA/755938/2012","document_url":"https://www.ema.europa.eu/en/documents/report/use-colistin-products-animals-within-european-union-development-resistance-and-possible-impact-human-and-animal-health-superseded_en.pdf"},
    {"id":"10218","name":"Applications for new human medicines under evaluation by the CHMP: February 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-07T15:00:00Z","last_updated_date":"2018-02-07T15:00:00Z","reference_number":"EMA/72847/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2018_en.pdf"},
    {"id":"10238","name":"Applications for new human medicines under evaluation by the CHMP: April 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-04-11T17:08:07Z","last_updated_date":"2012-04-20T19:18:07Z","reference_number":"EMA/208936/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2012_en.pdf"},
    {"id":"10243","name":"Scientific recommendation on classification of advanced therapy medicinal products: allogeneic human neural stem cells derived from foetal central nervous system","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T16:40:00Z","last_updated_date":"2018-06-27T16:40:00Z","reference_number":"EMA/276886/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-human-neural-stem-cells-derived-foetal-central-nervous-system_en.pdf"},
    {"id":"10261","name":"Medicinal products for human use: monthly figures - February 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-03-20T18:00:00Z","last_updated_date":"2017-03-20T18:00:00Z","reference_number":"EMA/184091/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2017_en.pdf"},
    {"id":"10387","name":"Report: Expert workshop on Creutzfeldt-Jakob-disease risk and urine-derived medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:09:21Z","last_updated_date":"2009-07-23T02:09:21Z","reference_number":"EMEA/CHMP/BWP/472717/2009 ","document_url":"https://www.ema.europa.eu/en/documents/report/report-expert-workshop-creutzfeldt-jakob-disease-risk-and-urine-derived-medicinal-products_en.pdf"},
    {"id":"10421","name":"Applications for new human medicines under evaluation by the CHMP: May 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-05-14T17:21:00Z","last_updated_date":"2018-05-14T17:21:00Z","reference_number":"EMA/280696/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2018_en.pdf"},
    {"id":"10450","name":"Monthly Report - Pharmacovigilance Working Party (PHVWP) October 2009 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-10-29T00:00:00Z","last_updated_date":"2009-10-29T00:00:00Z","reference_number":"EMEA/666243/2009","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-october-2009-plenary-meeting_en.pdf"},
    {"id":"10463","name":"Applications for new human medicines under evaluation by the CHMP: August 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-07T12:29:00Z","last_updated_date":"2017-08-07T12:29:00Z","reference_number":"EMA/506776/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2017_en.pdf"},
    {"id":"10508","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Bone-marrow-derived autologous CD34+ cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-06-04T15:58:00Z","last_updated_date":"2012-06-04T15:58:00Z","reference_number":"EMA/349063/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-bone-marrow-derived-autologous-cd34-cells_en.pdf"},
    {"id":"10531","name":"Monthly report - Pharmacovigilance Working Party (PhVWP) November 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-11-24T10:30:00Z","last_updated_date":"2011-11-24T10:30:00Z","reference_number":"EMA/CHMP/PhVWP/909637/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-november-2011-plenary-meeting_en.pdf"},
    {"id":"10547","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic human mesenchymal stem cells derived from Wharton’s jelly tissue of umbilical cord","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/416862/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-human-mesenchymal-stem-cells-derived-whartons-jelly-tissue-umbilical-cord_en.pdf"},
    {"id":"10571","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-08-19T02:00:00Z","last_updated_date":"2011-08-19T02:00:00Z","reference_number":"EMA/681354/2011","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-mesenchymal-stem-cells_en.pdf"},
    {"id":"10587","name":"Sales of veterinary antimicrobial agents in 25 European Union / European Economic Area countries in 2011 - Third European Surveillance of Veterinary Antimicrobial Consumption report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-10-15T16:35:00Z","last_updated_date":"2013-10-15T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-25-european-union-european-economic-area-countries-2011-third-european-surveillance-veterinary-antimicrobial-consumption-report_en.pdf"},
    {"id":"10591","name":"Public hearing on Valproate - First experience and lessons learnt","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-08T02:00:00Z","last_updated_date":"2018-06-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/public-hearing-valproate-first-experience-and-lessons-learnt_en.pdf"},
    {"id":"10617","name":"Scientific recommendation on classification of advanced therapy medicinal products: recombinant adeno-associated viral vector serotype 2 encoding the human aromatic L-amino acid decarboxylase gene","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-21T20:00:00Z","last_updated_date":"2016-10-21T20:00:00Z","reference_number":"EMA/679228/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-viral-vector-serotype-2-encoding-human-aromatic-l-amino-acid-decarboxylase-gene_en.pdf"},
    {"id":"10622","name":"Medicinal products for human use: Monthly figures - March 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-05-14T16:42:00Z","last_updated_date":"2012-05-14T16:42:00Z","reference_number":"EMA/305337/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2012_en.pdf"},
    {"id":"10695","name":"Second report on the progress on the interaction between EMEA\n\nand patients’ and consumers’ organisations (including performance\n\nindicators)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/MB/576691/2009","document_url":"https://www.ema.europa.eu/en/documents/report/second-report-progress-interaction-between-emea-and-patients-and-consumers-organisations-including-performance-indicators_en.pdf"},
    {"id":"10757","name":"Medicinal products for human use: Monthly figures - April 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-05-17T02:00:00Z","last_updated_date":"2010-05-17T02:00:00Z","reference_number":"EMA/307165/2010","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2010_en.pdf"},
    {"id":"10918","name":"COMP report to the Commission in relation to Article 10 of Regulation 141/2000 on orphan medicinal products - Annex 2","type":"report","status":"unknown","consultation_date":"","first_published_date":"2005-07-25T02:00:00Z","last_updated_date":"2005-07-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/comp-report-commission-relation-article-10-regulation-1412000-orphan-medicinal-products-annex-2_en.pdf"},
    {"id":"11054","name":"Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-06-26T15:59:00Z","last_updated_date":"2016-09-21T16:00:00Z","reference_number":"EMA/INS/GMP/733843/2015","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-manufacturing-and-distribution-practice-inspectors-working-group-2015_en.pdf"},
    {"id":"11076","name":"Report – Meeting with stakeholders on monitoring sales of veterinary antimicrobial agents in Europe","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-12-22T13:01:31Z","last_updated_date":"2010-12-22T13:01:31Z","reference_number":"EMA/706703/2010","document_url":"https://www.ema.europa.eu/en/documents/report/report-meeting-stakeholders-monitoring-sales-veterinary-antimicrobial-agents-europe_en.pdf"},
    {"id":"11159","name":"Report from the CAT expert meeting on scientific and regulatory considerations for adeno-associated viral vector (AAV)-based gene therapy","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-14T14:10:00Z","last_updated_date":"2018-06-14T14:10:00Z","reference_number":"EMA/CAT/60852/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-cat-expert-meeting-scientific-and-regulatory-considerations-adeno-associated-viral-vector-aav-based-gene-therapy_en.pdf-0"},
    {"id":"11217","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous adipose tissue derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T15:30:00Z","last_updated_date":"2016-04-19T15:30:00Z","reference_number":"EMA/240982/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-adipose-tissue-derived-mesenchymal-stem-cells_en.pdf-0"},
    {"id":"11239","name":"Monthly report - Pharmacovigilance Working Party (PhVWP) May 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/CHMP/PhVWP/394737/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-may-2011-plenary-meeting_en.pdf"},
    {"id":"11444","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic bone-marrow derived osteoblastic cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-08-12T15:37:46Z","last_updated_date":"2011-08-12T15:37:46Z","reference_number":"EMA/CAT/647468/2011","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-bone-marrow-derived-osteoblastic-cells_en.pdf"},
    {"id":"11509","name":"Scientific recommendation on classification of advanced therapy medicinal products: Suspension of live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin for intravenous infusion","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T12:45:00Z","last_updated_date":"2016-04-12T12:45:00Z","reference_number":"EMA/213686/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-suspension-live-attenuated-double-deleted-listeria-monocytogenes-expressing-human-mesothelin-intravenous-infusion_en.pdf"},
    {"id":"11531","name":"2011 EudraVigilance Human annual report","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-06-19T11:30:00Z","last_updated_date":"2013-06-19T11:30:00Z","reference_number":"EMA/733372/2012","document_url":"https://www.ema.europa.eu/en/documents/report/2011-eudravigilance-human-annual-report_en.pdf"},
    {"id":"11554","name":"ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals - Joint interagency ant...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-01-30T01:00:00Z","last_updated_date":"2015-01-30T01:00:00Z","reference_number":"636088/2013","document_url":"https://www.ema.europa.eu/en/documents/report/ecdcefsaema-first-joint-report-integrated-analysis-consumption-antimicrobial-agents-and-occurrence-antimicrobial-resistance-bacteria-humans-and-food-producing-animals-joint-interagency-ant_en.pdf"},
    {"id":"11562","name":"Applications for new human medicines under evaluation by the CHMP: February 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-02-25T17:29:00Z","last_updated_date":"2013-02-25T17:29:00Z","reference_number":"EMA/100806/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2013_en.pdf"},
    {"id":"11567","name":"Break-out session 4 report - Modelling and simulation to optimise the design of confirmatory trials, to analyse phase 3 data and to characterise risk-benefit and support label claims","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-05-08T11:30:00Z","last_updated_date":"2012-05-08T11:30:00Z","reference_number":"EMA/143476/2012","document_url":"https://www.ema.europa.eu/en/documents/report/break-out-session-4-report-modelling-and-simulation-optimise-design-confirmatory-trials-analyse-phase-3-data-and-characterise-risk-benefit-and-support-label-claims_en.pdf"},
    {"id":"11577","name":"Applications for new human medicines under evaluation by the CHMP: September 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-09-06T15:23:00Z","last_updated_date":"2017-09-06T15:23:00Z","reference_number":"EMA/583158/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2017_en.pdf"},
    {"id":"11599","name":"Report on interactions between the Japanese Ministry of Health, Labour and Welfare / Pharmaceuticals and Medical Devices Agency and the European Medicines Agency","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-07-30T12:33:37Z","last_updated_date":"2012-07-30T12:33:37Z","reference_number":"EMA/436043/2012","document_url":"https://www.ema.europa.eu/en/documents/report/report-interactions-between-japanese-ministry-health-labour-welfare-pharmaceuticals-medical-devices-agency-european-medicines-agency_en.pdf"},
    {"id":"11607","name":"Medicinal products for human use: Monthly figures - January 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-02-25T12:50:00Z","last_updated_date":"2014-02-25T12:50:00Z","reference_number":"EMA/82258/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2014_en.pdf"},
    {"id":"11685","name":"Twentieth pandemic pharmacovigilance update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/395118/2010","document_url":"https://www.ema.europa.eu/en/documents/report/twentieth-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"11738","name":"Report - European Medicines Agency workshop on pharmacogenomics","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-11-21T12:45:00Z","last_updated_date":"2012-11-21T12:45:00Z","reference_number":"EMA/683241/2012","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-workshop-pharmacogenomics_en.pdf"},
    {"id":"11785","name":"Background review for the excipient boric acid: In the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’ - Draft report","type":"report","status":"Draft","consultation_date":"","first_published_date":"2015-08-04T02:00:00Z","last_updated_date":"2015-08-04T02:00:00Z","reference_number":"EMA/CHMP/765436/2012","document_url":"https://www.ema.europa.eu/en/documents/report/background-review-excipient-boric-acid-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use-draft-report_en.pdf"},
    {"id":"11786","name":"Guide on the interpretation of spontaneous case reports of suspected adverse reactions to medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/CHMP/PhVWP/646186/2010","document_url":"https://www.ema.europa.eu/en/documents/report/guide-interpretation-spontaneous-case-reports-suspected-adverse-reactions-medicines_en.pdf"},
    {"id":"11797","name":"Monthly report - Pharmacovigilance Working Party (PhVWP) December 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-01-10T13:00:00Z","last_updated_date":"2012-04-03T16:00:00Z","reference_number":"EMA/CHMP/PhVWP/973945/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-december-2011-plenary-meeting_en.pdf"},
    {"id":"11903","name":"Meeting report - Joint European Medicines Agency / European Directorate for the Quality of Medicines and Healthcare workshop on improved potency assays for inactivated influenza vaccines held on 12 December 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-07-17T02:00:00Z","last_updated_date":"2012-07-17T02:00:00Z","reference_number":"EMA/142333/2012","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-joint-european-medicines-agency-european-directorate-quality-medicines-and-healthcare-workshop-improved-potency-assays-inactivated-influenza-vaccines-held-12-december-2011_en.pdf"},
    {"id":"12007","name":"Status Report on the Implementation of the EMEA Road Map","type":"report","status":"unknown","consultation_date":"","first_published_date":"2006-05-10T02:00:00Z","last_updated_date":"2006-05-10T02:00:00Z","reference_number":"EMEA/171321/2006","document_url":"https://www.ema.europa.eu/en/documents/report/status-report-implementation-emea-road-map_en.pdf"},
    {"id":"12051","name":"Update report on the Agency’s European Union Telematics: Operations report","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-14T16:30:00Z","last_updated_date":"2012-06-14T16:30:00Z","reference_number":"EMA/310155/2012","document_url":"https://www.ema.europa.eu/en/documents/report/update-report-agencys-european-union-telematics-operations-report_en.pdf"},
    {"id":"12065","name":"Scientific recommendation on classification of advanced therapy medicinal products: co-culture of keratinocytes and mesenchymal stem cells isolated from umbilical cord  seeded on acellular amniotic matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T17:00:00Z","last_updated_date":"2016-04-12T17:00:00Z","reference_number":"EMA/241002/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-co-culture-keratinocytes-and-mesenchymal-stem-cells-isolated-umbilical-cord-seeded-acellular-amniotic-matrix_en.pdf"},
    {"id":"12087","name":"Report from Committee for Advanced Therapies-Interested Parties Focus Groups (CATIPs FG) on non-clinical development of advanced-therapy medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-03-18T19:24:28Z","last_updated_date":"2011-03-18T19:24:28Z","reference_number":"EMA/CAT/134694/2011","document_url":"https://www.ema.europa.eu/en/documents/report/report-committee-advanced-therapies-interested-parties-focus-groups-catips-fg-non-clinical-development-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"12117","name":"Medicinal products for human use: Monthly figures - April 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-08-30T02:00:00Z","last_updated_date":"2011-08-30T02:00:00Z","reference_number":"EMA/455819/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2011_en.pdf"},
    {"id":"12123","name":"Scientific recommendation on classification of advanced therapy medicinal products: non-replicating recombinant Adeno associated virus (rAAV8), expressing the human UGT1A1 gene","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"EMA/270583/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-non-replicating-recombinant-adeno-associated-virus-raav8-expressing-human-ugt1a1-gene_en.pdf"},
    {"id":"12172","name":"European Medicines Agency budget for 2008","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-02-09T00:09:21Z","last_updated_date":"2009-02-09T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2008_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/report/european-medicines-agency-budget-2008_bg.pdf","es":"https://www.ema.europa.eu/es/documents/report/european-medicines-agency-budget-2008_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/report/european-medicines-agency-budget-2008_cs.pdf","da":"https://www.ema.europa.eu/da/documents/report/european-medicines-agency-budget-2008_da.pdf","de":"https://www.ema.europa.eu/de/documents/report/european-medicines-agency-budget-2008_de.pdf","et":"https://www.ema.europa.eu/et/documents/report/european-medicines-agency-budget-2008_et.pdf","el":"https://www.ema.europa.eu/el/documents/report/european-medicines-agency-budget-2008_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/report/european-medicines-agency-budget-2008_fr.pdf","it":"https://www.ema.europa.eu/it/documents/report/european-medicines-agency-budget-2008_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/report/european-medicines-agency-budget-2008_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/report/european-medicines-agency-budget-2008_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/report/european-medicines-agency-budget-2008_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/report/european-medicines-agency-budget-2008_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/report/european-medicines-agency-budget-2008_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/report/european-medicines-agency-budget-2008_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/report/european-medicines-agency-budget-2008_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/report/european-medicines-agency-budget-2008_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/report/european-medicines-agency-budget-2008_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/report/european-medicines-agency-budget-2008_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/report/european-medicines-agency-budget-2008_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/report/european-medicines-agency-budget-2008_sv.pdf"}},
    {"id":"12199","name":"Highlights report of the second industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-26T13:30:00Z","last_updated_date":"2018-02-26T13:30:00Z","reference_number":"EMA/759581/2017","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-report-second-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"12289","name":"Highlights from the fourth European Medicines Agency industry platform meeting held on the 3rd of July 2017 on the operation of the centralised procedure for human medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-31T11:00:00Z","last_updated_date":"2017-10-31T11:00:00Z","reference_number":"EMA/424893/2017","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-fourth-european-medicines-agency-industry-platform-meeting-held-3rd-july-2017-operation-centralised-procedure-human-medicinal-products_en.pdf"},
    {"id":"12349","name":"Applications for new human medicines under evaluation by the CHMP: October 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-05T19:00:00Z","last_updated_date":"2017-10-05T19:00:00Z","reference_number":"EMA/661972/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2017_en.pdf"},
    {"id":"12358","name":"Results of the sampling and testing programme for the year 2009","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-08-10T02:00:00Z","last_updated_date":"2010-12-14T01:00:00Z","reference_number":"EMA/INS/S&T/477571/2010","document_url":"https://www.ema.europa.eu/en/documents/report/results-sampling-and-testing-programme-year-2009_en.pdf"},
    {"id":"12383","name":"Report on the implementation of the European Medicines Agency/Committee for Medicinal Products for Human Use think-tank recommendations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-09-28T13:15:00Z","last_updated_date":"2011-09-28T13:15:00Z","reference_number":"EMA/585687/2010","document_url":"https://www.ema.europa.eu/en/documents/report/report-implementation-european-medicines-agencycommittee-medicinal-products-human-use-think-tank-recommendations_en.pdf"},
    {"id":"12590","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Human ciliary neurotrophic factor (CNTF)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-12-17T16:00:00Z","last_updated_date":"2012-12-17T16:00:00Z","reference_number":"EMA/494706/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-ciliary-neurotrophic-factor-cntf_en.pdf"},
    {"id":"12692","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) January 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-01-28T01:00:00Z","last_updated_date":"2011-01-31T01:00:00Z","reference_number":"EMA/CHMP/PhVWP/51040/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-january-2011-plenary-meeting_en.pdf"},
    {"id":"12716","name":"Medicinal products for human use: Monthly figures - January 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-03-09T12:45:00Z","last_updated_date":"2012-03-09T12:45:00Z","reference_number":"EMA/169271/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2012_en.pdf"},
    {"id":"12718","name":"Report of the 2018 annual face-to-face meeting of Enpr-EMA members and the Enpr-EMA Coordinating Group (CG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-09-07T11:15:00Z","last_updated_date":"2018-09-07T11:15:00Z","reference_number":"EMA/482139/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-2018-annual-face-face-meeting-enpr-ema-members-and-enpr-ema-coordinating-group-cg_en.pdf"},
    {"id":"12827","name":"Highlights from the 7th EMA Industry Platform meeting on the operation of EU pharmacovigilance legislation – 4 April 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-23T12:27:00Z","last_updated_date":"2016-05-23T12:27:00Z","reference_number":"EMA/241387/2016","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-7th-ema-industry-platform-meeting-operation-eu-pharmacovigilance-legislation-4-april-2016_en.pdf"},
    {"id":"12867","name":"Medicinal products for human use: Monthly figures - February 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-04-10T14:08:00Z","last_updated_date":"2015-04-10T14:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2015_en.pdf"},
    {"id":"12905","name":"Report of the tenth annual workshop (2018) of the European Network of Paediatric Research at the EMA (Enpr-EMA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-09-07T11:12:59Z","last_updated_date":"2018-09-07T11:12:59Z","reference_number":"EMA/472030/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-tenth-annual-workshop-2018-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"12923","name":"Report of the East African Community (EAC) benchmarking visit to the European Medicines Agency","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-07-26T19:30:00Z","last_updated_date":"2017-07-27T19:05:00Z","reference_number":"EMA/467939/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-east-african-community-eac-benchmarking-visit-european-medicines-agency_en.pdf"},
    {"id":"12925","name":"Summary of Product Characteristics Advisory Group 2010-2015 activity report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-07-07T16:45:00Z","last_updated_date":"2016-07-07T16:45:00Z","reference_number":"EMA/748160/2015","document_url":"https://www.ema.europa.eu/en/documents/report/summary-product-characteristics-advisory-group-2010-2015-activity-report_en.pdf"},
    {"id":"12938","name":"Results of the sampling and testing programme for the year 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-10-27T18:26:00Z","last_updated_date":"2011-10-27T18:26:00Z","reference_number":"EMA/INS/S&T/834055/2011","document_url":"https://www.ema.europa.eu/en/documents/report/results-sampling-and-testing-programme-year-2010_en.pdf"},
    {"id":"12955","name":"Scientific recommendation on classification of advanced therapy medicinal products: adipose derived regenerative cells encapsulated in hyaluronic acid","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T15:30:00Z","last_updated_date":"2016-04-19T15:30:00Z","reference_number":"EMA/240965/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adipose-derived-regenerative-cells-encapsulated-hyaluronic-acid_en.pdf"},
    {"id":"12996","name":"Scientific recommendation on classification of advanced-therapy medicinal product: Autologous expanded CD34+ stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-07-01T12:00:00Z","last_updated_date":"2013-07-01T12:00:00Z","reference_number":"EMA/370710/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-product-autologous-expanded-cd34-stem-cells_en.pdf"},
    {"id":"13035","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Autologous CD34+ haematopoietic stem cells (HSCs) transduced with lentiviral vector LentiGlobin encoding the human βA-T87Q-globin gene","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-09-25T15:21:00Z","last_updated_date":"2012-09-25T15:21:00Z","reference_number":"EMA/505476/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-cd34-haematopoietic-stem-cells-hscs-transduced-lentiviral-vector-lentiglobin-encoding-human-i2a-t87q-globin-gene_en.pdf"},
    {"id":"13159","name":"European Medicines Agency budget for 2018","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-01-18T10:00:00Z","last_updated_date":"2018-01-18T10:00:00Z","reference_number":"EMA/MB/799068/2017","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2018_en.pdf"},
    {"id":"13166","name":"Scientific recommendation on classification of advanced therapy medicinal products: adeno-associated virus vector serotype rh10 encoding human factor IX","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-22T12:00:00Z","last_updated_date":"2016-03-22T12:00:00Z","reference_number":"EMA/205254/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adeno-associated-virus-vector-serotype-rh10-encoding-human-factor-ix_en.pdf"},
    {"id":"13225","name":"2014 activity report of the modelling and simulation working group","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-04-17T12:40:00Z","last_updated_date":"2015-04-17T12:40:00Z","reference_number":"EMA/91752/2015","document_url":"https://www.ema.europa.eu/en/documents/report/2014-activity-report-modelling-and-simulation-working-group_en.pdf"},
    {"id":"13233","name":"Report from the 2nd workshop for the EMEA /CHMP working group with patients organisations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2005-03-17T01:00:00Z","last_updated_date":"2005-03-17T01:00:00Z","reference_number":"EMEA/17857/2005 Final","document_url":"https://www.ema.europa.eu/en/documents/report/report-2nd-workshop-emea-chmp-working-group-patients-organisations_en.pdf"},
    {"id":"13234","name":"Pharmacovigilance Working Party (PhVWP) - Monthly report on safety concerns, guidelines and general matters - March 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-04-03T16:00:00Z","last_updated_date":"2012-04-03T16:00:00Z","reference_number":"EMA/CHMP/PhVWP/183322/2012","document_url":"https://www.ema.europa.eu/en/documents/report/pharmacovigilance-working-party-phvwp-monthly-report-safety-concerns-guidelines-and-general-matters-march-2012_en.pdf"},
    {"id":"13329","name":"Recommendations on eligibility to PRIME scheme  - Adopted at the CHMP meeting of 11-14 December 2017","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2017-12-20T15:00:00Z","last_updated_date":"2017-12-20T15:00:00Z","reference_number":"EMA/668784/2016","document_url":"https://www.ema.europa.eu/en/documents/report/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-11-14-december-2017_en.pdf"},
    {"id":"13448","name":"Medicinal products for human use: Monthly figures - July 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-08-20T18:45:00Z","last_updated_date":"2014-08-20T18:45:00Z","reference_number":"EMA/506564/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2014_en.pdf"},
    {"id":"13463","name":"Report on workshop on the development of an EMEA transparency policy","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"EMEA/665540/2008","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-development-emea-transparency-policy_en.pdf"},
    {"id":"13473","name":"Annual accounts: Financial year 2008","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-11-24T00:09:21Z","last_updated_date":"2009-11-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2008_en.pdf"},
    {"id":"13483","name":"Scientific recommendation on classification of advanced therapy medicinal products: allogeneic human mesenchymal stem cells derived from umbilical cord","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"EMA/270507/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-human-mesenchymal-stem-cells-derived-umbilical-cord_en.pdf"},
    {"id":"13591","name":"Report from the small and medium-sized enterprise office on its second anniversary","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2007-12-20T01:00:00Z","last_updated_date":"2007-12-20T01:00:00Z","reference_number":"EMEA/585038/2007","document_url":"https://www.ema.europa.eu/en/documents/report/report-small-and-medium-sized-enterprise-office-its-second-anniversary_en.pdf"},
    {"id":"13600","name":"CHMP statistics: July 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-july-2018_en.pdf"},
    {"id":"13646","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Allogeneic peripheral blood mononuclear cells induced to an early apoptotic state","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T17:00:00Z","last_updated_date":"2015-03-02T17:00:00Z","reference_number":"EMA/108192/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-peripheral-blood-mononuclear-cells-induced-early-apoptotic-state_en.pdf"},
    {"id":"13684","name":"Medicinal products for human use: monthly figures - March 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-11T17:23:00Z","last_updated_date":"2017-05-11T17:23:00Z","reference_number":"EMA/246408/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2017_en.pdf"},
    {"id":"13750","name":"Medication-errors workshop report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-05-13T12:30:00Z","last_updated_date":"2013-05-13T12:30:00Z","reference_number":"EMA/144458/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medication-errors-workshop-report_en.pdf"},
    {"id":"13806","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic haptenized, stimulated and irradiated non-proliferative colorectal tumour whole cells derived from 3 colorectal cell lines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/416690/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-haptenized-stimulated-and-irradiated-non-proliferative-colorectal-tumour-whole-cells-derived-3-colorectal-cell_en.pdf"},
    {"id":"13830","name":"Summary report - Fifth annual regulatory conference organised by EBE, in collaboration with the European Medicines Agency (EMA) “Optimising the development of ATMPs to meet patient needs”","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-07T11:55:00Z","last_updated_date":"2017-02-07T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-fifth-annual-regulatory-conference-organised-ebe-collaboration-european-medicines-agency-ema-optimising-development-atmps-meet-patient-needs_en.pdf"},
    {"id":"13921","name":"Scientific recommendation on classification of advanced therapy medicinal products: co-culture of keratinocytes and mesenchymal stem cells isolated from umbilical cord  seeded on acellular dermal matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T17:00:00Z","last_updated_date":"2016-04-12T17:00:00Z","reference_number":"EMA/241004/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-co-culture-keratinocytes-and-mesenchymal-stem-cells-isolated-umbilical-cord-seeded-acellular-dermal-matrix_en.pdf"}    {"id":"13984","name":"Report - Workshop on identifying opportunities for ‘big data’ in medicines development and regulatory science","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-22T10:30:00Z","last_updated_date":"2017-02-22T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-identifying-opportunities-big-data-medicines-development-and-regulatory-science_en.pdf"},
    {"id":"13986","name":"Medicinal products for human use: Monthly figures - December 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-01-10T01:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/16598/2011 rev 1","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2010_en.pdf"},
    {"id":"14022","name":"Scientific recommendation on classification of advanced therapy medicinal products: co-culture of keratinocytes and human amniotic membrane mesenchymal stem cells as seeded on acellular dermal matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T13:00:00Z","last_updated_date":"2016-04-12T13:00:00Z","reference_number":"EMA/241017/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-co-culture-keratinocytes-and-human-amniotic-membrane-mesenchymal-stem-cells-seeded-acellular-dermal-matrix_en.pdf"},
    {"id":"14025","name":"Medicinal products for human use: Monthly figures - September 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-10-25T16:26:00Z","last_updated_date":"2011-10-25T16:26:00Z","reference_number":"EMA/852663/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2011_en.pdf"},
    {"id":"14042","name":"COMP report to the Commission in relation to Article 10 of Regulation 141/2000 on orphan medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2005-07-25T02:00:00Z","last_updated_date":"2005-07-25T02:00:00Z","reference_number":"EMEA/35218/2005 Final","document_url":"https://www.ema.europa.eu/en/documents/report/comp-report-commission-relation-article-10-regulation-1412000-orphan-medicinal-products_en.pdf"},
    {"id":"14128","name":"Outcome report on pilot phase for participation of patient representatives in scientific advisory group (SAG) meetings","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2011-12-15T18:00:43Z","last_updated_date":"2011-12-15T18:00:43Z","reference_number":"EMA/850028/2011","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-report-pilot-phase-participation-patient-representatives-scientific-advisory-group-sag-meetings_en.pdf"},
    {"id":"14149","name":"European Medicines Agency’s interaction with industry stakeholders - Annual report 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T16:00:00Z","last_updated_date":"2016-06-17T16:00:00Z","reference_number":"EMA/48651/2016","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agencys-interaction-industry-stakeholders-annual-report-2015_en.pdf"},
    {"id":"14160","name":"Applications for new human medicines under evaluation by the CHMP: January 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-01-16T15:05:00Z","last_updated_date":"2017-01-16T15:05:00Z","reference_number":"EMA/4827/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2017_en.pdf"},
    {"id":"14184","name":"CHMP statistics: July 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-july-2016_en.pdf"},
    {"id":"14194","name":"Report from CAT interested parties focus group on incentives for academia, hospitals and charities","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-12-18T13:15:00Z","last_updated_date":"2012-12-18T13:15:00Z","reference_number":"EMA/CAT/889316/2011","document_url":"https://www.ema.europa.eu/en/documents/report/report-cat-interested-parties-focus-group-incentives-academia-hospitals-and-charities_en.pdf"},
    {"id":"14205","name":"Report - European Medicines Agency roundtable with small and medium-sized enterprise (SME) stakeholder organisations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-12-21T17:38:24Z","last_updated_date":"2011-12-21T17:38:24Z","reference_number":"EMA/810583/2011","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-roundtable-small-and-medium-sized-enterprise-sme-stakeholder-organisations_en.pdf"},
    {"id":"14213","name":"Medicinal products for human use: Monthly figures - May 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-06-18T17:10:00Z","last_updated_date":"2013-06-18T17:10:00Z","reference_number":"EMA/366275/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2013_en.pdf"},
    {"id":"14291","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 gene","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-07-31T15:16:00Z","last_updated_date":"2012-10-18T13:45:00Z","reference_number":"EMA/505392/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-cd34-haematopoietic-stem-cells-transduced-lentiviral-vector-lenti-d-encoding-human-abcd1-gene_en.pdf"},
    {"id":"14294","name":"Eleventh pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-02-17T00:09:21Z","last_updated_date":"2010-02-17T00:09:21Z","reference_number":"EMA/102392/2010","document_url":"https://www.ema.europa.eu/en/documents/report/eleventh-pandemic-pharmacovigilance-weekly-update_en.pdf"},
    {"id":"14301","name":"Medicinal products for human use: Monthly figures - November 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-01-05T13:04:50Z","last_updated_date":"2012-01-05T13:04:50Z","reference_number":"EMA/5567/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2011_en.pdf"},
    {"id":"14316","name":"Outcome of written procedures","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/MB/517930/2009","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-written-procedures_en.pdf"},
    {"id":"14373","name":"Report: Biologics Working Party, Process Analytical Technologies Group and industry","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-07-16T02:00:00Z","last_updated_date":"2007-07-16T02:00:00Z","reference_number":"EMEA/CHMP/BWP/185370/2007","document_url":"https://www.ema.europa.eu/en/documents/report/report-biologics-working-party-process-analytical-technologies-group-and-industry_en.pdf"},
    {"id":"14374","name":"Annual accounts: Financial year 2011","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2012-07-11T14:50:00Z","last_updated_date":"2012-07-11T14:50:00Z","reference_number":"EMA/398739/2012","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2011_en.pdf"},
    {"id":"14487","name":"Benefit-risk methodology project: Work package 3 report: Field tests","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2011-09-15T17:46:45Z","last_updated_date":"2011-09-15T17:46:45Z","reference_number":"EMA/718294/2011","document_url":"https://www.ema.europa.eu/en/documents/report/benefit-risk-methodology-project-work-package-3-report-field-tests_en.pdf"},
    {"id":"14492","name":"Annual activity report 2017","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-07-10T13:41:00Z","last_updated_date":"2018-07-10T13:41:00Z","reference_number":"EMA/26967/2018","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2017_en.pdf"},
    {"id":"14542","name":"Comments received on European Medicines Agency Committee for Medicinal Products for Human Use Working Group with Patients' Organisations: Outcome of discussions: Recommendations and proposals for action","type":"report","status":"unknown","consultation_date":"","first_published_date":"2005-03-18T01:00:00Z","last_updated_date":"2005-03-18T01:00:00Z","reference_number":"EMEA/18153/2005 Final","document_url":"https://www.ema.europa.eu/en/documents/report/comments-received-european-medicines-agency-committee-medicinal-products-human-use-working-group-patients-organisations-outcome-discussions-recommendations-and-proposals-action_en.pdf"},
    {"id":"14551","name":"Medicinal products for human use: Monthly figures - December 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-02-25T18:00:00Z","last_updated_date":"2013-02-25T18:00:00Z","reference_number":"EMA/73657/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2012_en.pdf"},
    {"id":"14563","name":"Applications for new human medicines under evaluation by the CHMP: April 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-04-11T16:35:00Z","last_updated_date":"2013-04-11T16:35:00Z","reference_number":"EMA/224612/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2013_en.pdf"},
    {"id":"14572","name":"Background review for sodium laurilsulfate used as an excipient: In the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’ - Draft report","type":"report","status":"Draft","consultation_date":"","first_published_date":"2015-08-04T02:00:00Z","last_updated_date":"2015-08-04T02:00:00Z","reference_number":"EMA/CHMP/351898/2014","document_url":"https://www.ema.europa.eu/en/documents/report/background-review-sodium-laurilsulfate-used-excipient-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use-draft-report_en.pdf"},
    {"id":"14645","name":"Medicinal products for human use: Monthly figures - February 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-03-24T14:50:00Z","last_updated_date":"2014-03-24T14:50:00Z","reference_number":"EMA/167858/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2014_en.pdf"},
    {"id":"14663","name":"2008 Public status report on the implementation of the european risk\n\nmanagement strategy","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-03-17T00:00:00Z","last_updated_date":"2009-03-17T00:00:00Z","reference_number":"EMEA/43556/2009","document_url":"https://www.ema.europa.eu/en/documents/report/2008-public-status-report-implementation-european-risk-management-strategy_en.pdf"},
    {"id":"14675","name":"Report - Industry stakeholder meeting on Brexit and operation of the centralised procedure for human medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T11:40:00Z","last_updated_date":"2017-10-27T11:40:00Z","reference_number":"EMA/664332/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-industry-stakeholder-meeting-brexit-and-operation-centralised-procedure-human-medicinal-products_en.pdf"},
    {"id":"14743","name":"Pandemic dossier requirements","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-04-29T02:00:00Z","last_updated_date":"2009-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/pandemic-dossier-requirements_en.pdf"},
    {"id":"14777","name":"Annual accounts: Financial year 2016","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2017-07-05T14:00:00Z","last_updated_date":"2017-07-05T14:00:00Z","reference_number":"EMA/301708/2017","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2016_en.pdf"},
    {"id":"14783","name":"Medicinal products for human use: Monthly figures - September 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-10-25T14:06:00Z","last_updated_date":"2013-10-25T14:06:00Z","reference_number":"EMA/644466/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2013_en.pdf"},
    {"id":"14809","name":"Contract 2007/146-691 Instrument for Pre-accession Assistance transition assistance programme: Fourth progress report to the European Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-03-17T00:09:21Z","last_updated_date":"2009-03-17T00:09:21Z","reference_number":"EMEA/459609/2009/Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/contract-2007146-691-instrument-pre-accession-assistance-transition-assistance-programme-fourth-progress-report-european-commission_en.pdf"},
    {"id":"14812","name":"Wheat starch (containing gluten) used as an excipient - Report published in support of the ‘Questions and answers on wheat starch (containing gluten) used as an excipient in medicinal products for human use’","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2018-12-18T14:00:00Z","reference_number":"EMA/CHMP/639441/2013 Corr.2","document_url":"https://www.ema.europa.eu/en/documents/report/wheat-starch-containing-gluten-used-excipient-report-published-support-questions-and-answers-wheat-starch-containing-gluten-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"14828","name":"Fifth pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-01-06T01:00:00Z","last_updated_date":"2010-01-06T01:00:00Z","reference_number":"EMA/4476/2010","document_url":"https://www.ema.europa.eu/en/documents/report/fifth-pandemic-pharmacovigilance-weekly-update_en.pdf"},
    {"id":"14829","name":"Report of expert meeting on Factor VIII products and inhibitor development","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2007-02-22T00:09:21Z","last_updated_date":"2007-02-22T00:09:21Z","reference_number":"EMEA/CHMP/BPWP/123835/2006","document_url":"https://www.ema.europa.eu/en/documents/report/report-expert-meeting-factor-viii-products-and-inhibitor-development_en.pdf"},
    {"id":"14863","name":"Medicinal products for human use: Monthly figures - May 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/535520/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2011_en.pdf"},
    {"id":"14930","name":"Joint scientific report of the European Centre for Disease Prevention and Control, European Food Safety Authority and European Medicines Agency on meticillin-resistant Staphylococcus aureus (MRSA) in livestock, companion animals and food","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-06-16T02:00:00Z","last_updated_date":"2009-06-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/joint-scientific-report-european-centre-disease-prevention-control-european-food-safety-authority-european-medicines-agency-meticillin-resistant-staphylococcus-aureus-mrsa-livestock-companion-animals_en.pdf"},
    {"id":"14963","name":"Applications for new human medicines under evaluation by the CHMP: July 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-07-07T17:30:00Z","last_updated_date":"2017-07-07T17:30:00Z","reference_number":"EMA/430827/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2017_en.pdf"},
    {"id":"14988","name":"Medicinal products for human use: monthly figures - June 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-08-02T16:30:00Z","last_updated_date":"2018-08-02T16:30:00Z","reference_number":"EMA/497487/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2018_en.pdf"},
    {"id":"15013","name":"Scientific recommendation on classification of advanced therapy medicinal products: bone marrow-derived autologous non-hematopoietic stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T12:35:00Z","last_updated_date":"2016-04-19T12:35:00Z","reference_number":"EMA/264500/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-bone-marrow-derived-autologous-non-hematopoietic-stem-cells_en.pdf"},
    {"id":"15119","name":"CHMP statistics: February 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2018-02-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-february-2018_en.pdf"},
    {"id":"15168","name":"Report on budgetary and financial management: financial year 2016","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-08-20T18:30:00Z","last_updated_date":"2018-08-20T18:30:00Z","reference_number":"EMA/875653/2016","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2016_en.pdf"},
    {"id":"15179","name":"ECDC, EFSA and EMA joint scientific opinion on a list of\n\noutcome indicators as regards surveillance of antimicrobial\n\nresistance and antimicrobial consumption in humans and\n\nfood-producing animals","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-26T15:00:00Z","last_updated_date":"2017-10-26T15:00:00Z","reference_number":"doi: 10.2903/j.efsa.2017.5017","document_url":"https://www.ema.europa.eu/en/documents/report/ecdc-efsa-and-ema-joint-scientific-opinion-list-outcome-indicators-regards-surveillance-antimicrobial-resistance-and-antimicrobial-consumption-humans-and-food-producing-animals_en.pdf"},
    {"id":"15226","name":"2013 annual report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T17:29:00Z","last_updated_date":"2014-04-28T17:29:00Z","reference_number":"EMA/145085/2014","document_url":"https://www.ema.europa.eu/en/documents/report/2013-annual-report-eudravigilance-european-parliament-council-and-commission_en.pdf"},
    {"id":"15252","name":"Applications for new human medicines under evaluation by the CHMP: May 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-08T12:04:00Z","last_updated_date":"2017-05-08T12:04:00Z","reference_number":"EMA/283079/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2017_en.pdf"},
    {"id":"15265","name":"Medicinal products for human use: monthly figures - April 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-13T15:57:00Z","last_updated_date":"2016-05-13T15:57:00Z","reference_number":"EMA/332754/2016","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2016_en.pdf"},
    {"id":"15437","name":"Appendix 1: Proposed data elements relating to efficacy and to safety - CAR-T cell therapy registries workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-05-22T11:52:00Z","last_updated_date":"2018-05-22T11:52:00Z","reference_number":"EMA/299528/2018","document_url":"https://www.ema.europa.eu/en/documents/report/appendix-1-proposed-data-elements-relating-efficacy-and-safety-car-t-cell-therapy-registries-workshop_en.pdf"},
    {"id":"15441","name":"Status report on the implementation of the European Parliament and Council Regulation on orphan medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2002-04-08T02:00:00Z","last_updated_date":"2002-04-08T02:00:00Z","reference_number":"EMEA/7381/01","document_url":"https://www.ema.europa.eu/en/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_es.pdf","da":"https://www.ema.europa.eu/da/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_da.pdf","de":"https://www.ema.europa.eu/de/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_de.pdf","el":"https://www.ema.europa.eu/el/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_fr.pdf","it":"https://www.ema.europa.eu/it/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/report/status-report-implementation-european-parliament-and-council-regulation-orphan-medicinal-products_sv.pdf"}},
    {"id":"15467","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Autologous mature dendritic cells pulsed with tumour antigen-derived synthetic peptides","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T17:00:00Z","last_updated_date":"2015-03-02T17:00:00Z","reference_number":"EMA/107987/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-mature-dendritic-cells-pulsed-tumour-antigen-derived-synthetic-peptides_en.pdf"},
    {"id":"15603","name":"Report - Workshop on health-related quality of life in oncology","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-12-06T15:02:00Z","last_updated_date":"2012-12-06T15:02:00Z","reference_number":"EMA/204419/2012","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-health-related-quality-life-oncology_en.pdf"},
    {"id":"15660","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Autologous skeletal muscle-derived-cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T13:30:00Z","last_updated_date":"2013-03-11T13:30:00Z","reference_number":"EMA/51048/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-skeletal-muscle-derived-cells_en.pdf"},
    {"id":"15661","name":"CVMP assessment report: feline endogenous retrovirus RD114 in some live attenuated vaccines commercially available in the EU for use in animals","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-10-14T14:23:59Z","last_updated_date":"2010-10-14T14:23:59Z","reference_number":"EMA/CVMP/300321/2010","document_url":"https://www.ema.europa.eu/en/documents/report/cvmp-assessment-report-feline-endogenous-retrovirus-rd114-some-live-attenuated-vaccines-commercially-available-eu-use-animals_en.pdf"},
    {"id":"15679","name":"Third report on the progress of the interaction with Patients' and Consumers' Organisations during 2009: Management Board meeting 7 October 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/599720/2010","document_url":"https://www.ema.europa.eu/en/documents/report/third-report-progress-interaction-patients-and-consumers-organisations-during-2009-management-board-meeting-7-october-2010_en.pdf"},
    {"id":"15698","name":"Benzyl alcohol and benzoic acid group used as excipients\n\nReport published in support of the ‘Questions and answers on benzyl alcohol used as an excipient in medicinal products for human use’ (EMA/CHMP/508188/2013) and t...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/272866/2013","document_url":"https://www.ema.europa.eu/en/documents/report/benzyl-alcohol-and-benzoic-acid-group-used-excipients-report-published-support-questions-and-answers-benzyl-alcohol-used-excipient-medicinal-products-human-use-emachmp5081882013-and-t_en.pdf"},
    {"id":"15783","name":"2016 and 2017 annual report on independence","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-04-13T16:00:00Z","last_updated_date":"2018-04-13T16:00:00Z","reference_number":"EMA/463632/2017","document_url":"https://www.ema.europa.eu/en/documents/report/2016-and-2017-annual-report-independence_en.pdf"},
    {"id":"15813","name":"First report on the progress of the interaction with patients’ and consumers’ organisations and analysis of the degree of satisfaction of patients and consumers involved in European Medicines Agency activities during 200...","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2008-02-07T01:00:00Z","last_updated_date":"2008-02-07T01:00:00Z","reference_number":"EMEA/478814/2007","document_url":"https://www.ema.europa.eu/en/documents/report/first-report-progress-interaction-patients-and-consumers-organisations-and-analysis-degree-satisfaction-patients-and-consumers-involved-european-medicines-agency-activities-during-200_en.pdf"},
    {"id":"15844","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) September 2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-10-01T02:00:00Z","last_updated_date":"2010-10-01T02:00:00Z","reference_number":"EMA/CHMP/PhVWP/589053/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-september-2010-plenary-meeting_en.pdf"},
    {"id":"15869","name":"Medicinal products for human use: monthly figures - August 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-09-25T16:00:00Z","last_updated_date":"2015-09-25T16:00:00Z","reference_number":"EMA/619830/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2015_en.pdf"},
    {"id":"15888","name":"Medicinal products for human use: Monthly figures - April 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-05-24T11:33:00Z","last_updated_date":"2013-05-24T11:33:00Z","reference_number":"EMA/296817/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2013_en.pdf"},
    {"id":"15895","name":"Applications for new human medicines under evaluation by the CHMP: July 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-07-13T15:30:00Z","last_updated_date":"2018-07-13T15:30:00Z","reference_number":"EMA/482350/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2018_en.pdf"},
    {"id":"15897","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) July 2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/455361/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-july-2010-plenary-meeting_en.pdf"},
    {"id":"15950","name":"Break-out session 2 report - Modelling and simulation in clinical pharmacology and dose finding","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-05-08T11:30:00Z","last_updated_date":"2012-05-08T11:30:00Z","reference_number":"EMA/143475/2012","document_url":"https://www.ema.europa.eu/en/documents/report/break-out-session-2-report-modelling-and-simulation-clinical-pharmacology-and-dose-finding_en.pdf"},
    {"id":"15983","name":"EMEA workshop on the plasma master file - 10-11 October 2001 - Report","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2002-12-18T01:00:00Z","last_updated_date":"2002-12-18T01:00:00Z","reference_number":"EMEA/CPMP/BWP/1737/02","document_url":"https://www.ema.europa.eu/en/documents/report/emea-workshop-plasma-master-file-10-11-october-2001-report_en.pdf"},
    {"id":"16061","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Naturally-occurring allogeneic donor lymphocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T19:15:00Z","last_updated_date":"2013-05-21T19:15:00Z","reference_number":"EMA/277503/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-naturally-occurring-allogeneic-donor-lymphocytes_en.pdf"},
    {"id":"16099","name":"Trends in the sales of veterinary antimicrobial agents in nine European countries","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-09-19T13:30:00Z","last_updated_date":"2011-09-19T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/trends-sales-veterinary-antimicrobial-agents-nine-european-countries_en.pdf"},
    {"id":"16130","name":"Hearing with interested parties during Working Party on Community Monographs and Community List July 2006 meeting","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-05-22T16:00:00Z","last_updated_date":"2013-05-22T16:00:00Z","reference_number":"EMEA/HMPC/222795/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-interested-parties-during-working-party-community-monographs-and-community-list-july-2006-meeting_en.pdf"},
    {"id":"16139","name":"Contract 2006/118-594: Multi-beneficiary programme on participation of Croatia and Turkey in certain Community agencies in 2006 and 2007: First progress report to the European Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2006-12-12T00:09:21Z","last_updated_date":"2006-12-12T00:09:21Z","reference_number":"EMEA/505194/2006 - Rev 1","document_url":"https://www.ema.europa.eu/en/documents/report/contract-2006118-594-multi-beneficiary-programme-participation-croatia-and-turkey-certain-community-agencies-2006-and-2007-first-progress-report-european-commission_en.pdf"},
    {"id":"16144","name":"Interactions between the European Medicines Agency and United States Food and Drug Administration September 2009-September 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-06-23T16:57:46Z","last_updated_date":"2011-06-23T16:57:46Z","reference_number":"EMA/705027/2010","document_url":"https://www.ema.europa.eu/en/documents/report/interactions-between-european-medicines-agency-and-united-states-food-and-drug-administration-september-2009-september-2010_en.pdf"},
    {"id":"16149","name":"Supporting medicines for children in the European Union","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-05-30T15:00:00Z","last_updated_date":"2018-05-30T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/supporting-medicines-children-european-union_en.pdf"},
    {"id":"16154","name":"Scientific recommendation on classification of advanced therapy medicinal products: Double-stranded naked DNA plasmid encoding an inactive human telomerase reverse transcriptase protein fused to ubiquitin","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T17:00:00Z","last_updated_date":"2015-03-02T17:00:00Z","reference_number":"EMA/107887/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-double-stranded-naked-dna-plasmid-encoding-inactive-human-telomerase-reverse-transcriptase-protein-fused-ubiquitin_en.pdf"},
    {"id":"16204","name":"Scientific recommendation on classification of advanced therapy medicinal products: Exosomes carrying recombinant mRNA encoding for the cystic fibrosis transmembrane conductance regulator protein and microRNA-17","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-07-13T15:40:00Z","last_updated_date":"2018-07-13T15:40:00Z","reference_number":"EMA/381068/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-exosomes-carrying-recombinant-mrna-encoding-cystic-fibrosis-transmembrane-conductance-regulator-protein-and-microrna-17_en.pdf"},
    {"id":"16242","name":"Two irradiated allogeneic pancreatic tumour cell lines, genetically engineered to secrete human granulocyte macrophage-colony stimulating factor (GM-CSF)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T13:00:00Z","last_updated_date":"2016-05-04T13:00:00Z","reference_number":"EMA/291905/2016","document_url":"https://www.ema.europa.eu/en/documents/report/two-irradiated-allogeneic-pancreatic-tumour-cell-lines-genetically-engineered-secrete-human-granulocyte-macrophage-colony-stimulating-factor-gm-csf_en.pdf"},
    {"id":"16253","name":"European Medicines Agency / Food and Drug Administration joint good-manufacturing-practice-inspection pilot programme - General principles","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-11-15T01:00:00Z","last_updated_date":"2010-11-15T01:00:00Z","reference_number":"EMA/660312/2010","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-food-and-drug-administration-joint-good-manufacturing-practice-inspection-pilot-programme-general-principles_en.pdf"},
    {"id":"16256","name":"Medicinal products for human use: monthly figures - September 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-10-14T16:25:00Z","last_updated_date":"2015-10-14T16:25:00Z","reference_number":"EMA/671386/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2015_en.pdf"},
    {"id":"16340","name":"Second EMEA Workshop on Neurodegenerative Diseases, 'Focus on Dementia' -Brief Report & Presentations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-03-05T00:09:21Z","last_updated_date":"2008-03-05T00:09:21Z","reference_number":"EMEA/87024/2008","document_url":"https://www.ema.europa.eu/en/documents/report/second-emea-workshop-neurodegenerative-diseases-focus-dementia-brief-report-presentations_en.pdf"},
    {"id":"16356","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic human glial-restricted precursors","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-25T18:00:00Z","last_updated_date":"2017-10-25T18:00:00Z","reference_number":"EMA/664971/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-human-glial-restricted-precursors_en.pdf"},
    {"id":"16365","name":"Scientific recommendation on classification of advanced therapy medicinal products: A recombinant replicating vaccinia viral vector (rilimogene galvacirepvec) and a recombinant non-replicating fowlpox viral vector (rilim...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-28T13:00:00Z","last_updated_date":"2016-11-28T13:00:00Z","reference_number":"EMA/761630/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-replicating-vaccinia-viral-vector-rilimogene-galvacirepvec-and-recombinant-non-replicating-fowlpox-viral-vector_en.pdf"},
    {"id":"16366","name":"Small and medium-sized enterprise (SME) Office annual report 2014","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-02-04T15:30:00Z","last_updated_date":"2015-02-04T15:30:00Z","reference_number":"EMA/699351/2014","document_url":"https://www.ema.europa.eu/en/documents/report/small-and-medium-sized-enterprise-sme-office-annual-report-2014_en.pdf"},
    {"id":"16378","name":"Minor use or minor species (MUMS)/limited market scheme for veterinary medicinal products - 5th annual report (2014)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-03-26T14:10:00Z","last_updated_date":"2015-03-26T14:10:00Z","reference_number":"EMA/47723/2015","document_url":"https://www.ema.europa.eu/en/documents/report/minor-use-or-minor-species-mumslimited-market-scheme-veterinary-medicinal-products-5th-annual-report-2014_en.pdf"},
    {"id":"16388","name":"Status report on the implementation of the provisions of Chapter 2a of Directive 2001/83/EC as amended by Directive 2004/24/EC as regards traditional herbal medicinal products - October 2006","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-08-15T02:00:00Z","last_updated_date":"2007-08-15T02:00:00Z","reference_number":"EMEA/HMPC/187219/2006","document_url":"https://www.ema.europa.eu/en/documents/report/status-report-implementation-provisions-chapter-2a-directive-200183ec-amended-directive-200424ec-regards-traditional-herbal-medicinal-products-october-2006_en.pdf"},
    {"id":"16391","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: DNA plasmid encoding for the extracellular domain of human TNFα p55 receptor linked to the human IgG1 Fc domain","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:59:00Z","last_updated_date":"2018-01-03T14:59:00Z","reference_number":"EMA/699258/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-dna-plasmid-encoding-extracellular-domain-human-tnfi-p55-receptor-linked-human-igg1-fc-domain_en.pdf"},
    {"id":"16397","name":"CHMP statistics: April 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-april-2017_en.pdf"},
    {"id":"16407","name":"Scientific recommendation on classification of advanced therapy medicinal products: Sterile suspension of autologous cells of stromal vascular fraction of adipose tissue in Lactated Ringers solution","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T12:45:00Z","last_updated_date":"2016-04-12T12:45:00Z","reference_number":"EMA/213726/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-sterile-suspension-autologous-cells-stromal-vascular-fraction-adipose-tissue-lactated-ringers-solution_en.pdf"},
    {"id":"16464","name":"Medicinal products for human use: monthly figures - July 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-08-13T11:20:00Z","last_updated_date":"2015-08-13T11:20:00Z","reference_number":"EMA/549097/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2015_en.pdf"},
    {"id":"16512","name":"CHMP statistics: December 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-december-2015_en.pdf"},
    {"id":"16538","name":"Applications for new human medicines under evaluation by the CHMP: August 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-08-10T18:00:00Z","last_updated_date":"2018-08-10T18:00:00Z","reference_number":"EMA/527853/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2018_en.pdf"},
    {"id":"16546","name":"Antibiotic resistance in the European Union associated with therapeutic use of veterinary medicines: Report and qualitative risk assessment by the CVMP - including Annexes 1-4","type":"report","status":"unknown","consultation_date":"","first_published_date":"1999-07-14T02:00:00Z","last_updated_date":"1999-07-14T02:00:00Z","reference_number":"EMEA/CVMP/342/99-Final","document_url":"https://www.ema.europa.eu/en/documents/report/antibiotic-resistance-european-union-associated-therapeutic-use-veterinary-medicines-report-and-qualitative-risk-assessment-cvmp-including-annexes-1-4_en.pdf"},
    {"id":"16569","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic bone marrow derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-01-19T11:30:00Z","last_updated_date":"2017-01-19T11:30:00Z","reference_number":"EMA/864885/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-bone-marrow-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"16571","name":"Sixth pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-01-13T00:09:21Z","last_updated_date":"2010-01-13T00:09:21Z","reference_number":"EMA/21345/2010","document_url":"https://www.ema.europa.eu/en/documents/report/sixth-pandemic-pharmacovigilance-weekly-update_en.pdf"},
    {"id":"16590","name":"Viral solution for injection of HSV-1 derived oncolytic virus","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-07-11T13:00:00Z","last_updated_date":"2014-07-11T13:00:00Z","reference_number":"EMA/414349/2014","document_url":"https://www.ema.europa.eu/en/documents/report/viral-solution-injection-hsv-1-derived-oncolytic-virus_en.pdf"},
    {"id":"16622","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) March 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2011-03-29T02:00:00Z","reference_number":"EMA/CHMP/PhVWP/217595/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-march-2011-plenary-meeting_en.pdf"},
    {"id":"16652","name":"CHMP statistics: February 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2017-02-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-february-2017_en.pdf"},
    {"id":"16679","name":"Adaptive Pathways Workshop - Report on a meeting with stakeholders (8 December 2016)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-23T15:55:00Z","last_updated_date":"2017-02-23T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/adaptive-pathways-workshop-report-meeting-stakeholders-8-december-2016_en.pdf"},
    {"id":"16701","name":"Annual report on European Medicines Agency’s interaction with patients, consumers, healthcare professionals and their organisations (2014)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"EMA/9496/2015","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-european-medicines-agencys-interaction-patients-consumers-healthcare-professionals-and-their-organisations-2014_en.pdf"},
    {"id":"16744","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous bone marrow derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T15:30:00Z","last_updated_date":"2016-04-19T15:30:00Z","reference_number":"EMA/240985/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-bone-marrow-derived-mesenchymal-stem-cells_en.pdf-0"},
    {"id":"16751","name":"Annual report on the use of the special contribution for orphan medicinal products - 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-03-04T16:10:00Z","last_updated_date":"2019-03-04T16:10:00Z","reference_number":"EMA/86146/2019","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-use-special-contribution-orphan-medicinal-products-2018_en.pdf"},
    {"id":"16761","name":"Report on the event ‘Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem’","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-12-12T17:20:00Z","last_updated_date":"2013-12-12T17:20:00Z","reference_number":"EMA/746806/2013","document_url":"https://www.ema.europa.eu/en/documents/report/report-event-best-use-medicines-legislation-bring-new-antibiotics-patients-and-combat-resistance-problem_en.pdf"},
    {"id":"16764","name":"Report to the CPMP on the EMEA seminar on the use of pharmacogenetics in the drug development process","type":"report","status":"unknown","consultation_date":"","first_published_date":"2000-07-27T02:09:21Z","last_updated_date":"2000-07-27T02:09:21Z","reference_number":"EMEA/CPMP/1483/00","document_url":"https://www.ema.europa.eu/en/documents/report/report-cpmp-emea-seminar-use-pharmacogenetics-drug-development-process_en.pdf"},
    {"id":"16840","name":"Scientific recommendation on classification of advanced therapy medicinal products: mRNA sequence encoding the wild type human OX40L protein","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-28T14:45:00Z","last_updated_date":"2017-02-28T14:45:00Z","reference_number":"EMA/126719/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-mrna-sequence-encoding-wild-type-human-ox40l-protein_en.pdf"},
    {"id":"16923","name":"Medicinal products for human use: Monthly figures - May 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T17:10:00Z","last_updated_date":"2012-07-06T17:10:00Z","reference_number":"EMA/448038/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2012_en.pdf"},
    {"id":"16950","name":"Applications for new human medicines under evaluation by the CHMP: June 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T11:22:00Z","last_updated_date":"2014-06-16T11:22:00Z","reference_number":"EMA/349630/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2014_en.pdf"}    {"id":"17010","name":"Scientific recommendation on classification of advanced therapy medicinal products: Recombinant modified vaccinia virus ankara (MVA) containing genetic sequences coding for the human mucin 1 and the human interleukin 2","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-28T13:00:00Z","last_updated_date":"2016-11-28T13:00:00Z","reference_number":"EMA/761529/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-modified-vaccinia-virus-ankara-mva-containing-genetic-sequences-coding-human-mucin-1-and-human-interleukin-2_en.pdf"},
    {"id":"17194","name":"Report of plasma master file epidemiology workshop with industry","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-11-19T00:09:21Z","last_updated_date":"2009-11-19T00:09:21Z","reference_number":"EMEA/CHMP/BWP/233408/2009","document_url":"https://www.ema.europa.eu/en/documents/report/report-plasma-master-file-epidemiology-workshop-industry_en.pdf"},
    {"id":"17216","name":"Fifth ESVAC report: sales of veterinary antimicrobial agents in 26 European Union/European Economic Area countries in 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-10-15T16:25:00Z","last_updated_date":"2015-10-15T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/fifth-esvac-report-sales-veterinary-antimicrobial-agents-26-european-unioneuropean-economic-area-countries-2013_en.pdf"},
    {"id":"17239","name":"European Union regulatory workshop in ophthalmology - Summary and report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-09-06T14:00:00Z","last_updated_date":"2012-09-06T14:00:00Z","reference_number":"EMA/450332/2012","document_url":"https://www.ema.europa.eu/en/documents/report/european-union-regulatory-workshop-ophthalmology-summary-and-report_en.pdf"},
    {"id":"17247","name":"Hearing the Association of the European Self-Medication Industry during the May 2013 Working Party on Community Monographs and Community List meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-07-25T12:12:00Z","last_updated_date":"2013-07-25T12:12:00Z","reference_number":"EMA/HMPC/413550/2013","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-during-may-2013-working-party-community-monographs-and-community-list-meeting_en.pdf"},
    {"id":"17258","name":"Break-out session 3 report - Modelling and simulation as a tool to bridge efficacy and safety data in special populations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-05-08T11:30:00Z","last_updated_date":"2012-05-08T11:30:00Z","reference_number":"EMA/143471/2012","document_url":"https://www.ema.europa.eu/en/documents/report/break-out-session-3-report-modelling-and-simulation-tool-bridge-efficacy-and-safety-data-special-populations_en.pdf"},
    {"id":"17281","name":"Access to clinical-trial data and transparency: Workshop report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-12-05T17:00:00Z","last_updated_date":"2012-12-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/access-clinical-trial-data-and-transparency-workshop-report_en.pdf"},
    {"id":"17348","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Suspension of oncolytic adenovirus","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-06-05T10:48:00Z","last_updated_date":"2012-06-05T10:48:00Z","reference_number":"EMA/348841/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-suspension-oncolytic-adenovirus_en.pdf"},
    {"id":"17423","name":"Report on ESVAC trial for collecting data on consumption of antimicrobial agents in pigs","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-25T12:25:00Z","last_updated_date":"2016-05-25T12:25:00Z","reference_number":"EMA/836856/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-esvac-trial-collecting-data-consumption-antimicrobial-agents-pigs_en.pdf"},
    {"id":"17485","name":"Background review for cyclodextrins used as excipients: In the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’ - Draft report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-12-01T18:20:00Z","last_updated_date":"2014-12-01T18:20:00Z","reference_number":"EMA/CHMP/333892/2013","document_url":"https://www.ema.europa.eu/en/documents/report/background-review-cyclodextrins-used-excipients-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use-draft-report_en.pdf"},
    {"id":"17528","name":"Fifth report on the interaction with patients' and consumers' organisations (2011)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/507517/2012","document_url":"https://www.ema.europa.eu/en/documents/report/fifth-report-interaction-patients-and-consumers-organisations-2011_en.pdf"},
    {"id":"17529","name":"Scientific recommendation on classification of advanced therapy medicinal products: Haematopoietic stem cells genetically modified to express a zinc finger nuclease which disrupts the enhancer of BCL11A expression","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T11:00:00Z","last_updated_date":"2018-02-13T11:00:00Z","reference_number":"EMA/35484/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-haematopoietic-stem-cells-genetically-modified-express-zinc-finger-nuclease-which-disrupts-enhancer-bcl11a-expression_en.pdf"},
    {"id":"17547","name":"Report on the implementation of the European Medicines Agency-European Network for Health Technology Assessment (EUnetHTA) three-year work plan 2012-2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-14T13:00:00Z","last_updated_date":"2016-04-14T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-implementation-european-medicines-agency-european-network-health-technology-assessment-eunethta-three-year-work-plan-2012-2015_en.pdf"},
    {"id":"17665","name":"Report on budgetary and financial management: Financial year 2011","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2012-07-11T14:50:00Z","last_updated_date":"2012-07-11T14:50:00Z","reference_number":"EMA/396250/2011","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2011_en.pdf"},
    {"id":"17696","name":"Finalisation of the European Medicines Agency policy on publication of and access to clinical trial data – Targeted consultation with key stakeholders - Summary report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2014-10-02T19:00:00Z","reference_number":"EMA/292746/2014","document_url":"https://www.ema.europa.eu/en/documents/report/finalisation-european-medicines-agency-policy-publication-and-access-clinical-trial-data-targeted-consultation-key-stakeholders-summary-report_en.pdf"},
    {"id":"17717","name":"2014 annual report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T14:03:00Z","last_updated_date":"2015-05-04T14:03:00Z","reference_number":"EMA/23619/2015","document_url":"https://www.ema.europa.eu/en/documents/report/2014-annual-report-eudravigilance-european-parliament-council-and-commission_en.pdf"},
    {"id":"17783","name":"Medicinal products for human use: Monthly figures - May 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-06-09T02:00:00Z","last_updated_date":"2010-06-09T02:00:00Z","reference_number":"EMA/65642/2010","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2010_en.pdf"},
    {"id":"17788","name":"Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-12-04T11:28:00Z","last_updated_date":"2017-12-04T11:28:00Z","reference_number":"EMA/INS/GMP/131704/2017","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-manufacturing-and-distribution-practice-inspectors-working-group-2016_en.pdf"},
    {"id":"17831","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human monocytes-derived suppressive cells, expanded ex vivo","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T19:00:00Z","last_updated_date":"2016-04-04T19:00:00Z","reference_number":"EMA/557288/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-monocytes-derived-suppressive-cells-expanded-ex-vivo_en.pdf"},
    {"id":"17849","name":"Report from a workshop on the impact of social media on patients, healthcare professionals and regulators","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T01:00:00Z","last_updated_date":"2016-11-17T01:00:00Z","reference_number":"EMA/625077/2016","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-impact-social-media-patients-healthcare-professionals-and-regulators_en.pdf"},
    {"id":"17866","name":"Scientific recommendation on classification of advanced therapy medicinal products: Sterile suspension of autologous cells of stromal vascular fraction of adipose tissue in Lactated Ringers solution","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T12:45:00Z","last_updated_date":"2016-04-12T12:45:00Z","reference_number":"EMA/213724/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-sterile-suspension-autologous-cells-stromal-vascular-fraction-adipose-tissue-lactated-ringers-solution_en.pdf-0"},
    {"id":"17890","name":"Applications for new human medicines under evaluation by the CHMP: May 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T18:45:00Z","last_updated_date":"2015-05-22T18:45:00Z","reference_number":"EMA/315740/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2015_en.pdf"},
    {"id":"18038","name":"Highlights from the second industry stakeholder platform on the operation of the centralised procedure for human medicinal products held on 9 November 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-02-25T16:05:00Z","last_updated_date":"2016-02-25T16:05:00Z","reference_number":"EMA/5702/2016","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-second-industry-stakeholder-platform-operation-centralised-procedure-human-medicinal-products-held-9-november-2015_en.pdf"},
    {"id":"18140","name":"Report on annual workshop of the European network of paediatric research at the  European Medicines Agency (Enpr-EMA) on 28 - 29 May 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-08-05T13:30:00Z","last_updated_date":"2015-08-05T13:30:00Z","reference_number":"EMA/432711/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-annual-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema-28-29-may-2015_en.pdf"},
    {"id":"18157","name":"EU-USA strategic meeting on the future of paediatric medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-12-14T13:30:00Z","last_updated_date":"2016-12-14T13:30:00Z","reference_number":"EMA/662807/2016","document_url":"https://www.ema.europa.eu/en/documents/report/eu-usa-strategic-meeting-future-paediatric-medicines_en.pdf"},
    {"id":"18222","name":"Report from the PDCO on its first anniversary","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-07-11T02:00:00Z","last_updated_date":"2008-07-11T02:00:00Z","reference_number":"EMEA/PDCO/347884/2008","document_url":"https://www.ema.europa.eu/en/documents/report/report-pdco-its-first-anniversary_en.pdf"},
    {"id":"18249","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic bone marrow derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-28T14:45:00Z","last_updated_date":"2017-02-28T14:45:00Z","reference_number":"EMA/126870/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-bone-marrow-derived-mesenchymal-stem-cells_en.pdf-0"},
    {"id":"18298","name":"Outcome of the European Medicines Agency survey on centralised post-authorisation procedures 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-11T11:10:00Z","last_updated_date":"2016-10-11T11:10:00Z","reference_number":"EMA/156890/2016","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-european-medicines-agency-survey-centralised-post-authorisation-procedures-2015_en.pdf"},
    {"id":"18421","name":"Report on the European network of paediatric research-European Medicines Agency workshop on gastrointestinal (GI) outcome measures to evaluate CFTR modulators for the treatment of cystic fibrosis (CF)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-16T17:10:00Z","last_updated_date":"2016-03-16T17:10:00Z","reference_number":"EMA/26775/2016","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-network-paediatric-research-european-medicines-agency-workshop-gastrointestinal-gi-outcome-measures-evaluate-cftr-modulators-treatment-cystic-fibrosis-cf_en.pdf"},
    {"id":"18464","name":"Scientific recommendation on classification of advanced therapy medicinal products: ex-vivo cultured and expanded human cord blood progenitor cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-21T20:00:00Z","last_updated_date":"2016-10-21T20:00:00Z","reference_number":"EMA/679217/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-ex-vivo-cultured-and-expanded-human-cord-blood-progenitor-cells_en.pdf"},
    {"id":"18503","name":"Fourth report on the progress of the interaction with patients' and consumers' organisations (2010) and results / analysis of the degree of satisfaction of patients and consumers involved in European Medicines Agency act...","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2011-10-20T17:46:00Z","last_updated_date":"2011-10-20T18:03:01Z","reference_number":"EMA/MB/632696/2011","document_url":"https://www.ema.europa.eu/en/documents/report/fourth-report-progress-interaction-patients-and-consumers-organisations-2010-and-results-analysis-degree-satisfaction-patients-and-consumers-involved-european-medicines-agency-act_en.pdf"},
    {"id":"18587","name":"Medicinal products for human use: monthly figures - June 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-07-14T19:30:00Z","last_updated_date":"2016-07-14T19:30:00Z","reference_number":"EMA/482832/2016","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2016_en.pdf"},
    {"id":"18592","name":"Joint meeting with all interested parties on a continuity policy for orphan medicinal products in the European Union","type":"report","status":"unknown","consultation_date":"","first_published_date":"2002-12-06T01:00:00Z","last_updated_date":"2002-12-06T01:00:00Z","reference_number":"EMEA/31723/02","document_url":"https://www.ema.europa.eu/en/documents/report/joint-meeting-all-interested-parties-continuity-policy-orphan-medicinal-products-european-union_en.pdf"},
    {"id":"18662","name":"Medicinal products for human use: monthly figures - January 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T10:18:00Z","last_updated_date":"2018-02-09T10:18:00Z","reference_number":"EMA/85286/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2018_en.pdf"},
    {"id":"18671","name":"European Court of Auditors final report on the annual accounts of the European Medicines Agency for the financial year 2015","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2016-12-08T10:10:00Z","last_updated_date":"2016-12-08T10:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-court-auditors-final-report-annual-accounts-european-medicines-agency-financial-year-2015_en.pdf"},
    {"id":"18673","name":"Applications for new human medicines under evaluation by the CHMP: April 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-04-10T12:00:00Z","last_updated_date":"2017-04-10T12:00:00Z","reference_number":"EMA/225209/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2017_en.pdf"},
    {"id":"18740","name":"Biologics Working Party report to the CHMP: Beta-interferons and neutralising antibodies (in multiple sclerosis)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-02-13T00:09:21Z","last_updated_date":"2008-02-13T00:09:21Z","reference_number":"EMEA/CHMP/BWP/580136/2007","document_url":"https://www.ema.europa.eu/en/documents/report/biologics-working-party-report-chmp-beta-interferons-and-neutralising-antibodies-multiple-sclerosis_en.pdf"},
    {"id":"18793","name":"Applications for new human medicines under evaluation by the CHMP: November 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-11-10T12:03:00Z","last_updated_date":"2015-11-10T12:03:00Z","reference_number":"EMA/731936/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2015_en.pdf"},
    {"id":"18816","name":"Scientific recommendation on classification of advanced therapy medicinal products: Full-thickness human skin substitute composed of an epidermal layer of fully-stratified human keratinocytes and a collagen-rich dermal e...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:41:00Z","last_updated_date":"2018-01-03T14:41:00Z","reference_number":"EMA/751554/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-full-thickness-human-skin-substitute-composed-epidermal-layer-fully-stratified-human-keratinocytes-and-collagen-rich-dermal_en.pdf"},
    {"id":"18827","name":"Applications for new human medicines under evaluation by the CHMP: January 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-08T14:59:00Z","last_updated_date":"2018-01-08T14:59:00Z","reference_number":"EMA/3179/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2018_en.pdf"},
    {"id":"18841","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic engineered Chimeric Antigen Receptor (CAR+) T-cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-06-04T19:00:00Z","last_updated_date":"2014-06-04T19:00:00Z","reference_number":"EMA/326383/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-engineered-chimeric-antigen-receptor-car-t-cells_en.pdf"},
    {"id":"18844","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous adipose-derived stem cells seeded on a collagen matrix scaffold","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T11:00:00Z","last_updated_date":"2018-02-13T11:00:00Z","reference_number":"EMA/65631/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-adipose-derived-stem-cells-seeded-collagen-matrix-scaffold_en.pdf"},
    {"id":"18864","name":"Scientific recommendation on classification of advanced therapy medicinal products: human extracellular matrix proteins (mainly Collagen I and glycosaminoglycans) and residual absorbable polymer, supplied as a lyophilize...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-21T17:45:00Z","last_updated_date":"2016-03-21T17:45:00Z","reference_number":"EMA/555388/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-extracellular-matrix-proteins-mainly-collagen-i-and-glycosaminoglycans-and-residual-absorbable-polymer-supplied_en.pdf"},
    {"id":"18900","name":"Medicinal products for human use: monthly figures - July 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-08-19T11:50:00Z","last_updated_date":"2016-08-19T11:50:00Z","reference_number":"EMA/555021/2016","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2016_en.pdf"},
    {"id":"18905","name":"Pharmaceutical forum working group on information to patients: report on pillar II: statutory information on medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2006-10-10T02:00:00Z","last_updated_date":"2006-10-10T02:00:00Z","reference_number":"EMEA/109974/2006","document_url":"https://www.ema.europa.eu/en/documents/report/pharmaceutical-forum-working-group-information-patients-report-pillar-ii-statutory-information-medicines_en.pdf"},
    {"id":"18927","name":"Stakeholder engagement report 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T13:00:00Z","last_updated_date":"2018-06-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2017_en.pdf"},
    {"id":"18970","name":"Applications for new human medicines under evaluation by the CHMP: November 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T09:57:00Z","last_updated_date":"2016-11-15T09:57:00Z","reference_number":"EMA/735168/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2016_en.pdf"},
    {"id":"19000","name":"CHMP statistics: March 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-march-2016_en.pdf"},
    {"id":"19044","name":"Applications for new human medicines under evaluation by the CHMP: April 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-20T17:55:00Z","last_updated_date":"2016-04-20T17:55:00Z","reference_number":"EMA/269096/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2016_en.pdf"},
    {"id":"19104","name":"Applications for new human medicines under evaluation by the CHMP: October 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-10T11:10:00Z","last_updated_date":"2016-10-10T11:10:00Z","reference_number":"EMA/655666/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2016_en.pdf"},
    {"id":"19140","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Aqueous suspension of attenuated Salmonella typhi Ty21a strain transfected with a plasmid vector encoding for the human vascular endothe...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T13:30:00Z","last_updated_date":"2013-03-08T13:30:00Z","reference_number":"EMA/49924/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-aqueous-suspension-attenuated-salmonella-typhi-ty21a-strain-transfected-plasmid-vector-encoding-human-vascular-endothe_en.pdf"},
    {"id":"19333","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous differentiated adipocytes derived from the subcutaneous adipose tissue","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T12:00:00Z","last_updated_date":"2015-08-26T12:00:00Z","reference_number":"EMA/557278/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-differentiated-adipocytes-derived-subcutaneous-adipose-tissue_en.pdf"},
    {"id":"19363","name":"Scientific recommendation on classification of advanced therapy medicinal products: In vitro derived platelets","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T12:00:00Z","last_updated_date":"2015-08-26T12:00:00Z","reference_number":"EMA/556370 /2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vitro-derived-platelets_en.pdf"},
    {"id":"19379","name":"CHMP statistics: November 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-november-2017_en.pdf"},
    {"id":"19414","name":"Report on the development pathways for advanced-therapy medicinal products workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-01-12T11:29:00Z","last_updated_date":"2015-01-12T11:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-development-pathways-advanced-therapy-medicinal-products-workshop_en.pdf"},
    {"id":"19426","name":"Scientific recommendation on classification of advanced therapy medicinal products: Adipose derived mesenchymal stem cells combined with beta-tricalcium phosphate","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-08-06T12:00:00Z","last_updated_date":"2013-08-06T12:00:00Z","reference_number":"EMA/478311/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adipose-derived-mesenchymal-stem-cells-combined-beta-tricalcium-phosphate_en.pdf"},
    {"id":"19577","name":"Applications for new human medicines under evaluation by the CHMP: November 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-11-13T18:05:00Z","last_updated_date":"2014-11-13T18:05:00Z","reference_number":"EMA/682555/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2014_en.pdf"},
    {"id":"19753","name":"Reflection paper on working parties: Committee for Medicinal Products for Human Use/European Medicines Agency group analysis and proposals","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2010-10-25T14:13:14Z","last_updated_date":"2010-10-25T14:13:14Z","reference_number":"EMA/315270/2010","document_url":"https://www.ema.europa.eu/en/documents/report/reflection-paper-working-parties-committee-medicinal-products-human-useeuropean-medicines-agency-group-analysis-and-proposals_en.pdf"},
    {"id":"19755","name":"Hearing with the Association of the European Self-Medication Industry (AESGP) during the April 2016 Working Party on Community Monographs and Community List meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-06-10T02:00:00Z","last_updated_date":"2016-06-10T02:00:00Z","reference_number":"EMA/HMPC/313623/2016","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-aesgp-during-april-2016-working-party-community-monographs-and-community-list-meeting_en.pdf"},
    {"id":"19781","name":"Innovative medicines initiative WEB-RADR workshop report: mobile technologies and social media as new tools in pharmacovigilance","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-14T12:00:00Z","last_updated_date":"2017-02-14T12:00:00Z","reference_number":"EMA/70469/2017","document_url":"https://www.ema.europa.eu/en/documents/report/innovative-medicines-initiative-web-radr-workshop-report-mobile-technologies-and-social-media-new-tools-pharmacovigilance_en.pdf"},
    {"id":"19789","name":"Ninth pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"EMA/71116/2010","document_url":"https://www.ema.europa.eu/en/documents/report/ninth-pandemic-pharmacovigilance-weekly-update_en.pdf"},
    {"id":"19859","name":"Medicinal products for human use: Monthly figures - August 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-09-29T16:50:00Z","last_updated_date":"2014-09-29T16:50:00Z","reference_number":"EMA/573191/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2014_en.pdf"},
    {"id":"19898","name":"Report on EudraVigilance implementation: Veterinary medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-03-05T00:09:21Z","last_updated_date":"2009-03-05T00:09:21Z","reference_number":"EMEA/86607/2009","document_url":"https://www.ema.europa.eu/en/documents/report/report-eudravigilance-implementation-veterinary-medicines_en.pdf"},
    {"id":"20038","name":"Medicinal products for human use: monthly figures - January 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T13:20:00Z","last_updated_date":"2016-04-04T13:20:00Z","reference_number":"EMA/106708/2016","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2016_en.pdf"},
    {"id":"20041","name":"Workshop on collection of data on antimicrobial agents by species and on unit(s) of measurement","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-12-19T17:00:00Z","last_updated_date":"2011-12-19T17:00:00Z","reference_number":"EMA/926004/2011","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-collection-data-antimicrobial-agents-species-and-units-measurement_en.pdf"},
    {"id":"20081","name":"European Medicines Agency budget for 2014","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-12-17T11:30:00Z","last_updated_date":"2013-12-17T11:30:00Z","reference_number":"EMA/MB/686492/2013","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2014_en.pdf"},
    {"id":"20153","name":"Second report on the progress of the interaction with patients' and consumers' organisations and analysis of the degree of satisfaction of patients / consumers involved in European Medicines Agency activities during 2008","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/259449/2009","document_url":"https://www.ema.europa.eu/en/documents/report/second-report-progress-interaction-patients-and-consumers-organisations-and-analysis-degree-satisfaction-patients-consumers-involved-european-medicines-agency-activities-during-2008_en.pdf"},
    {"id":"20211","name":"European Court of Auditors final report on the annual accounts of the European Medicines Agency for the financial year 2011","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-04-22T11:00:00Z","last_updated_date":"2013-04-22T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-court-auditors-final-report-annual-accounts-european-medicines-agency-financial-year-2011_en.pdf"},
    {"id":"20237","name":"Report on EMEA workshop on homeopathic medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-05-23T02:09:21Z","last_updated_date":"2007-05-23T02:09:21Z","reference_number":"EMEA/509019/2006","document_url":"https://www.ema.europa.eu/en/documents/report/report-emea-workshop-homeopathic-medicinal-products_en.pdf"},
    {"id":"20407","name":"Scientific recommendation on classification of advanced therapy medicinal products: Cultured autologous Wharton’s jelly derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/462485/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cultured-autologous-whartons-jelly-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"20523","name":"Medicinal products for human use: monthly figures - October 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-17T16:50:00Z","last_updated_date":"2016-11-17T16:50:00Z","reference_number":"EMA/752329/2016","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2016_en.pdf"},
    {"id":"20556","name":"Medicinal products for human use: Monthly figures - June 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-08-21T13:50:00Z","last_updated_date":"2012-08-21T13:50:00Z","reference_number":"EMA/465466/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2012_en.pdf"},
    {"id":"20582","name":"Use of glycylcyclines in animals in the European Union: development of resistance and possible impact on human and animal health","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-07-30T14:00:00Z","last_updated_date":"2013-07-30T14:00:00Z","reference_number":"EMA/291760/2013","document_url":"https://www.ema.europa.eu/en/documents/report/use-glycylcyclines-animals-european-union-development-resistance-and-possible-impact-human-and-animal-health_en.pdf"},
    {"id":"20665","name":"Medicinal products for human use: Monthly figures - November 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T15:40:00Z","last_updated_date":"2014-12-11T15:40:00Z","reference_number":"EMA/770463/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2014_en.pdf"},
    {"id":"20687","name":"Report - Workshop on measuring the impact of pharmacovigilance activities","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T16:30:00Z","last_updated_date":"2017-03-27T16:30:00Z","reference_number":"EMA/59474/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-measuring-impact-pharmacovigilance-activities_en.pdf"},
    {"id":"20715","name":"Scientific recommendation on classification of advanced therapy medicinal products: bone marrow-derived autologous non-hematopoietic stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T12:35:00Z","last_updated_date":"2016-04-19T12:35:00Z","reference_number":"EMA/264456/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-bone-marrow-derived-autologous-non-hematopoietic-stem-cells_en.pdf-0"},
    {"id":"20733","name":"Report from the European Medicines Agency / health-technology-assessment-body workshop on parallel scientific advice in drug development on 26 November 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-05-08T16:00:00Z","last_updated_date":"2014-05-08T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-health-technology-assessment-body-workshop-parallel-scientific-advice-drug-development-26-november-2013_en.pdf"},
    {"id":"20774","name":"Fourth pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-12-23T00:09:21Z","last_updated_date":"2009-12-23T00:09:21Z","reference_number":"EMA/841003/2009","document_url":"https://www.ema.europa.eu/en/documents/report/fourth-pandemic-pharmacovigilance-weekly-update_en.pdf"},
    {"id":"20776","name":"Viable autologous adipose tissue-derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-07-11T13:00:00Z","last_updated_date":"2014-07-11T13:00:00Z","reference_number":"EMA/414098/2014","document_url":"https://www.ema.europa.eu/en/documents/report/viable-autologous-adipose-tissue-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"20799","name":"Report on the operation of the Steering Group for the Joint EMA/HMA action plan on availability of veterinary vaccines 2016-2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-03-22T16:10:00Z","last_updated_date":"2018-03-22T16:10:00Z","reference_number":"EMA/565300/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-operation-steering-group-joint-emahma-action-plan-availability-veterinary-vaccines-2016-2017_en.pdf"},
    {"id":"20871","name":"Applications for new human medicines under evaluation by the CHMP: November 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-30T11:05:00Z","last_updated_date":"2017-10-30T11:05:00Z","reference_number":"EMA/716196/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2017_en.pdf"},
    {"id":"20895","name":"Report of the 2017 annual workshop of the European network of paediatric research at the European Medicines Agency (Enpr-EMA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-07-24T12:45:00Z","last_updated_date":"2017-07-24T12:45:00Z","reference_number":"EMA/320019/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-2017-annual-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"20994","name":"Autologous T-cells expressing a chimeric NKG2D receptor","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T16:33:00Z","last_updated_date":"2016-11-15T16:33:00Z","reference_number":"EMA/693976/2016","document_url":"https://www.ema.europa.eu/en/documents/report/autologous-t-cells-expressing-chimeric-nkg2d-receptor_en.pdf"},
    {"id":"21019","name":"2013 activity report of the Modelling and Simulation Working Group","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-06-02T14:30:00Z","last_updated_date":"2014-06-02T14:30:00Z","reference_number":"EMA/303848/2014","document_url":"https://www.ema.europa.eu/en/documents/report/2013-activity-report-modelling-and-simulation-working-group_en.pdf"},
    {"id":"21033","name":"Operation of the Clinical Trials Directive (Directive 2001/20/EC) and Perspectives for the Future - A joint conference of the European Commission and the European Medicines Agency - Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-11-30T00:09:21Z","last_updated_date":"2007-11-30T00:09:21Z","reference_number":"EMEA/565466/2007","document_url":"https://www.ema.europa.eu/en/documents/report/operation-clinical-trials-directive-directive-200120ec-and-perspectives-future-joint-conference-european-commission-and-european-medicines-agency-report_en.pdf"},
    {"id":"21076","name":"Medicinal products for human use: monthly figures - November 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T16:41:00Z","last_updated_date":"2016-12-20T16:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2016_en.pdf"},
    {"id":"21101","name":"Report from the joint EMEA(NRG)/Interested Parties Meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2006-11-13T00:09:21Z","last_updated_date":"2006-11-13T00:09:21Z","reference_number":"EMEA/450165/2006","document_url":"https://www.ema.europa.eu/en/documents/report/report-joint-emeanrginterested-parties-meeting_en.pdf"},
    {"id":"21117","name":"Report of the Committee for Advanced Therapies (CAT) meeting with interested parties","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-05-18T11:00:01Z","last_updated_date":"2015-05-18T11:00:01Z","reference_number":"EMA/CAT/23438/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-committee-advanced-therapies-cat-meeting-interested-parties_en.pdf"},
    {"id":"21127","name":"Summary meeting report - EMA workshop with EU pharmaceutical industry associations on the implementation of Article 57(2), second subparagraph of Regulation (EC) No. 726/2004","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-03-05T13:00:00Z","last_updated_date":"2012-03-05T13:00:00Z","reference_number":"EMA/77868/2012","document_url":"https://www.ema.europa.eu/en/documents/report/summary-meeting-report-ema-workshop-eu-pharmaceutical-industry-associations-implementation-article-572-second-subparagraph-regulation-ec-no-7262004_en.pdf"},
    {"id":"21138","name":"Revision of budget structure from financial year 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-06T17:00:00Z","last_updated_date":"2017-10-06T17:00:00Z","reference_number":"EMA/MB/573458/2017","document_url":"https://www.ema.europa.eu/en/documents/report/revision-budget-structure-financial-year-2018_en.pdf"},
    {"id":"21185","name":"Report on annual workshop of the European network of paediatric research at the European Medicines Agency - 26-27 June 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-02-02T15:00:00Z","last_updated_date":"2015-02-02T15:00:00Z","reference_number":"EMA/500467/2014","document_url":"https://www.ema.europa.eu/en/documents/report/report-annual-workshop-european-network-paediatric-research-european-medicines-agency-26-27-june-2014_en.pdf"},
    {"id":"21297","name":"Medicinal products for human use: monthly figures - August 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-09-12T19:39:00Z","last_updated_date":"2017-09-12T19:39:00Z","reference_number":"EMA/605537/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2017_en.pdf"},
    {"id":"21311","name":"Workshop proceedings - Transatlantic workshop on drug-related progressive multifocal leukoencephalopathy (PML)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-09-08T11:50:00Z","last_updated_date":"2011-09-08T17:29:00Z","reference_number":"EMA/674403/2011","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-proceedings-transatlantic-workshop-drug-related-progressive-multifocal-leukoencephalopathy-pml_en.pdf"},
    {"id":"21353","name":"Annual accounts: Financial year 2009","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/401405/2010","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2009_en.pdf"},
    {"id":"21372","name":"Applications for new human medicines under evaluation by the CHMP: March 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-10T17:20:00Z","last_updated_date":"2016-03-10T17:20:00Z","reference_number":"EMA/182466/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2016_en.pdf"},
    {"id":"21388","name":"Report - Industry stakeholder teleconference on Brexit and operation of the centralised procedure for veterinary medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-11-21T11:12:00Z","last_updated_date":"2017-11-21T11:12:00Z","reference_number":"EMA/686513/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-industry-stakeholder-teleconference-brexit-and-operation-centralised-procedure-veterinary-medicinal-products_en.pdf"},
    {"id":"21408","name":"Report from CAT interested parties focus group on non-clinical development of advanced-therapy medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-12-18T13:15:00Z","last_updated_date":"2012-12-18T13:15:00Z","reference_number":"EMA/CAT/716942/2012","document_url":"https://www.ema.europa.eu/en/documents/report/report-cat-interested-parties-focus-group-non-clinical-development-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"21409","name":"Implementation of European Medicines Agency policy on publication of clinical data: status report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"EMA/MB/614812/2015","document_url":"https://www.ema.europa.eu/en/documents/report/implementation-european-medicines-agency-policy-publication-clinical-data-status-report_en.pdf"},
    {"id":"21423","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Viable autologous adipose-derived regenerative cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:59:00Z","last_updated_date":"2018-01-03T14:59:00Z","reference_number":"EMA/699357/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-viable-autologous-adipose-derived-regenerative-cells_en.pdf"},
    {"id":"21425","name":"Medicinal products for human use: Monthly figures - October 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-11-07T01:00:00Z","last_updated_date":"2012-11-07T01:00:00Z","reference_number":"EMA/708878/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2012_en.pdf"}    {"id":"21435","name":"European Medicines Agency’s interaction with patients, consumers, healthcare professionals and their organisations - Annual report 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-06-16T15:30:00Z","last_updated_date":"2017-06-16T15:30:00Z","reference_number":"EMA/260003/2016","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agencys-interaction-patients-consumers-healthcare-professionals-and-their-organisations-annual-report-2016_en.pdf"},
    {"id":"21442","name":"Medicinal products for human use: monthly figures - April  2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-11T17:20:00Z","last_updated_date":"2017-05-11T17:20:00Z","reference_number":"EMA/294960/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2017_en.pdf"},
    {"id":"21451","name":"Scientific recommendation on classification of advanced therapy medicinal products: Suspension of autologous expanded viable chondrocytes embedded in a cross linked hydrogel","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T12:45:00Z","last_updated_date":"2016-04-12T12:45:00Z","reference_number":"EMA/213716/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-suspension-autologous-expanded-viable-chondrocytes-embedded-cross-linked-hydrogel_en.pdf"},
    {"id":"21458","name":"Session Report: Pharmacovigilance","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-11-28T00:09:21Z","last_updated_date":"2008-11-28T00:09:21Z","reference_number":"EMEA/640479/2008","document_url":"https://www.ema.europa.eu/en/documents/report/session-report-pharmacovigilance_en.pdf"},
    {"id":"21487","name":"Scientific recommendation on classification of advanced therapy medicinal products: bone marrow-derived autologous non-hematopoietic stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T12:35:00Z","last_updated_date":"2016-04-19T12:35:00Z","reference_number":"EMA/264542/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-bone-marrow-derived-autologous-non-hematopoietic-stem-cells_en.pdf-1"},
    {"id":"21501","name":"Update report on the Agency’s implementation of EU Telematics strategy","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/MB/739297/2010","document_url":"https://www.ema.europa.eu/en/documents/report/update-report-agencys-implementation-eu-telematics-strategy_en.pdf"},
    {"id":"21509","name":"Medicinal products for human use: Monthly figures - October 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-11-12T13:55:00Z","last_updated_date":"2014-11-12T13:55:00Z","reference_number":"EMA/696699/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2014_en.pdf"},
    {"id":"21572","name":"EudraVigilance veterinary / Signal detection and on-going related veterinary-information technology (IT) projects","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2016-10-07T17:30:00Z","reference_number":"EMA/13787/2009","document_url":"https://www.ema.europa.eu/en/documents/report/eudravigilance-veterinary-signal-detection-and-going-related-veterinary-information-technology-it-projects_en.pdf"},
    {"id":"21579","name":"Summary of transfers of appropriations in budget 2017 - Management Board meeting: 5 October 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-06T17:00:00Z","last_updated_date":"2017-10-06T17:00:00Z","reference_number":"EMA/MB/573435/2017","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2017-management-board-meeting-5-october-2017_en.pdf"},
    {"id":"21586","name":"ECDC/EFSA/EMA second joint report on the integrated\n\nanalysis of the consumption of antimicrobial agents and\n\noccurrence of antimicrobial resistance in bacteria from\n\nhumans and food-producing animals","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-07-27T12:00:00Z","last_updated_date":"2017-07-27T12:00:00Z","reference_number":"10.2903/j.efsa.2017.4872","document_url":"https://www.ema.europa.eu/en/documents/report/ecdcefsaema-second-joint-report-integrated-analysis-consumption-antimicrobial-agents-and-occurrence-antimicrobial-resistance-bacteria-humans-and-food-producing-animals_en.pdf"},
    {"id":"21594","name":"Applications for new human medicines under evaluation by the CHMP: January 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-01-14T10:15:00Z","last_updated_date":"2015-01-14T10:15:00Z","reference_number":"EMA/9499/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2015_en.pdf"},
    {"id":"21605","name":"Small and medium-sized enterprise (SME) Office annual report 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-04-13T17:00:00Z","last_updated_date":"2018-04-13T17:00:00Z","reference_number":"EMA/123438/2018","document_url":"https://www.ema.europa.eu/en/documents/report/small-and-medium-sized-enterprise-sme-office-annual-report-2017_en.pdf"},
    {"id":"21652","name":"Medicinal products for human use: Monthly figures - March 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-04-10T16:45:00Z","last_updated_date":"2015-04-10T16:45:00Z","reference_number":"EMA/237250/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2015_en.pdf"},
    {"id":"21665","name":"Fourteenth pandemic pharmacovigilance update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-03-24T01:00:00Z","last_updated_date":"2010-03-24T01:00:00Z","reference_number":"EMA/190452/2010","document_url":"https://www.ema.europa.eu/en/documents/report/fourteenth-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"21681","name":"Report of the “Progress in the area of Antimicrobial Resistance – Veterinary Medicines” meeting, organised by the EMA and the HMA (veterinary)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-10-11T02:00:00Z","last_updated_date":"2011-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-progress-area-antimicrobial-resistance-veterinary-medicines-meeting-organised-ema-and-hma-veterinary_en.pdf"},
    {"id":"21693","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Autologous collagen derived from human adipose tissue","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-22T14:15:00Z","last_updated_date":"2012-10-22T14:15:00Z","reference_number":"EMA/500730/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-collagen-derived-human-adipose-tissue_en.pdf"},
    {"id":"21756","name":"Medicinal products for human use: Monthly figures - June 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-07-13T19:24:00Z","last_updated_date":"2015-07-13T19:24:00Z","reference_number":"EMA/464956/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2015_en.pdf"},
    {"id":"21782","name":"PRIME - The first 12 months","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-18T19:30:00Z","last_updated_date":"2017-05-18T19:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prime-first-12-months_en.pdf"},
    {"id":"21815","name":"Report - Multi-stakeholder paediatric oncology strategy workshop (cancers with anaplastic lymphoma kinase aberrations)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-06-01T17:50:00Z","last_updated_date":"2017-06-01T17:50:00Z","reference_number":"EMA/210027/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-multi-stakeholder-paediatric-oncology-strategy-workshop-cancers-anaplastic-lymphoma-kinase-aberrations_en.pdf"},
    {"id":"21861","name":"Scientific recommendation on classification of advanced therapy medicinal products: mesenchymal stem cells isolated from umbilical cord seeded onto acellular dermal matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T17:00:00Z","last_updated_date":"2016-04-12T17:00:00Z","reference_number":"EMA/240994/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-mesenchymal-stem-cells-isolated-umbilical-cord-seeded-acellular-dermal-matrix_en.pdf"},
    {"id":"21891","name":"Medicinal products for human use: Monthly figures - June 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2010-07-16T02:00:00Z","reference_number":"EMA/431469/2010","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2010_en.pdf"},
    {"id":"21925","name":"Report from the first European Medicines Agency workshop with healthcare professional organisations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2006-04-20T02:00:00Z","last_updated_date":"2006-04-20T02:00:00Z","reference_number":"EMEA/124808/2006 corr.","document_url":"https://www.ema.europa.eu/en/documents/report/report-first-european-medicines-agency-workshop-healthcare-professional-organisations_en.pdf"},
    {"id":"21942","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Alginate-encapsulated porcine pancreatic islet cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T19:15:00Z","last_updated_date":"2013-05-21T19:15:00Z","reference_number":"EMA/277458/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-alginate-encapsulated-porcine-pancreatic-islet-cells_en.pdf"},
    {"id":"21963","name":"Minor use or minor species (MUMS)/limited market scheme for veterinary medicinal products - 7th annual report (2016)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T17:00:00Z","last_updated_date":"2017-03-17T17:00:00Z","reference_number":"EMA/868034/2016","document_url":"https://www.ema.europa.eu/en/documents/report/minor-use-or-minor-species-mumslimited-market-scheme-veterinary-medicinal-products-7th-annual-report-2016_en.pdf"},
    {"id":"21973","name":"Scientific recommendation on classification of advanced therapy medicinal products: co-culture of keratinocytes and human amniotic membrane  mesenchymal stem cells as seeded on acellular amniotic matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T13:00:00Z","last_updated_date":"2016-04-12T13:00:00Z","reference_number":"EMA/241015/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-co-culture-keratinocytes-and-human-amniotic-membrane-mesenchymal-stem-cells-seeded-acellular-amniotic-matrix_en.pdf"},
    {"id":"22116","name":"Medicinal products for human use: monthly figures - February 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T13:20:00Z","last_updated_date":"2016-04-04T13:20:00Z","reference_number":"EMA/202787/2016","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2016_en.pdf"},
    {"id":"22129","name":"Sales of veterinary antimicrobial agents in 19 European Union / European Economic Area countries in 2010 - Second European Surveillance of Veterinary Antimicrobial Consumption report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-15T16:00:00Z","last_updated_date":"2012-10-15T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-19-european-union-european-economic-area-countries-2010-second-european-surveillance-veterinary-antimicrobial-consumption-report_en.pdf"},
    {"id":"22143","name":"Scientific recommendation on classification of advanced-therapy medicinal product: Human autologous tumour-infiltrating lymphocytes (TIL)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-07-01T12:00:00Z","last_updated_date":"2013-07-01T12:00:00Z","reference_number":"EMA/341778/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-product-human-autologous-tumour-infiltrating-lymphocytes-til_en.pdf"},
    {"id":"22148","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human foetal neural stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-07-13T15:40:00Z","last_updated_date":"2018-07-13T15:40:00Z","reference_number":"EMA/381050/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-foetal-neural-stem-cells_en.pdf-0"},
    {"id":"22240","name":"Report of the paediatric osteoporosis expert meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-09-09T02:00:00Z","last_updated_date":"2014-09-09T02:00:00Z","reference_number":"EMA/247433/2014","document_url":"https://www.ema.europa.eu/en/documents/report/report-paediatric-osteoporosis-expert-meeting_en.pdf"},
    {"id":"22243","name":"Applications for new human medicines under evaluation by the CHMP: June 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-06-12T11:50:00Z","last_updated_date":"2015-06-12T11:50:00Z","reference_number":"EMA/383502/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2015_en.pdf"},
    {"id":"22250","name":"Twenty-second pandemic pharmacovigilance update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-08-19T02:00:00Z","last_updated_date":"2010-08-19T02:00:00Z","reference_number":"EMA/527985/2010","document_url":"https://www.ema.europa.eu/en/documents/report/twenty-second-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"22271","name":"Second Status Report on the Implementation of the EMEA Road Map","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-10-22T02:00:00Z","last_updated_date":"2007-10-22T02:00:00Z","reference_number":"EMEA/359050/2007","document_url":"https://www.ema.europa.eu/en/documents/report/second-status-report-implementation-emea-road-map_en.pdf"},
    {"id":"22336","name":"Scientific recommendation on classification of advanced therapy medicinal products: allogeneic pancreatic islets encapsulated by elastin-like recombinamers","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T16:40:00Z","last_updated_date":"2018-06-27T16:40:00Z","reference_number":"EMA/277069/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-pancreatic-islets-encapsulated-elastin-recombinamers_en.pdf"},
    {"id":"22384","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Autologous stromal vascular fraction","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:59:00Z","last_updated_date":"2018-01-03T14:59:00Z","reference_number":"EMA/699234/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-stromal-vascular-fraction_en.pdf"},
    {"id":"22450","name":"Scientific recommendation on classification of advanced therapy medicinal products: Stromal vascular fraction cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T16:30:00Z","last_updated_date":"2017-10-23T16:30:00Z","reference_number":"EMA/534818/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-stromal-vascular-fraction-cells_en.pdf"},
    {"id":"22458","name":"Medicinal products for human use: Monthly figures - November 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-12-03T11:07:00Z","last_updated_date":"2012-12-03T11:07:00Z","reference_number":"EMA/771073/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2012_en.pdf"},
    {"id":"22464","name":"Medicinal products for human use: Monthly figures - August 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-10-25T16:26:00Z","last_updated_date":"2011-10-25T16:26:00Z","reference_number":"EMA/851725/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2011_en.pdf"},
    {"id":"22535","name":"CAT scientific workshop: Reducing the number of laboratory animals used in tissue-engineering research","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-12-17T17:00:01Z","last_updated_date":"2012-12-17T17:00:01Z","reference_number":"EMA/CAT/708346/2012","document_url":"https://www.ema.europa.eu/en/documents/report/cat-scientific-workshop-reducing-number-laboratory-animals-used-tissue-engineering-research_en.pdf"},
    {"id":"22542","name":"Uptake of the traditional-use registration scheme and implementation of the provisions of Directive 2004/24/EC in European Union Member States","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2017-06-19T12:20:00Z","reference_number":"EMA/322570/2011 Rev. 7","document_url":"https://www.ema.europa.eu/en/documents/report/uptake-traditional-use-registration-scheme-and-implementation-provisions-directive-200424ec-european-union-member-states_en.pdf"},
    {"id":"22581","name":"Annual accounts: Financial year 2013","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-07-01T12:15:00Z","last_updated_date":"2014-07-01T12:15:00Z","reference_number":"EMA/277014/2014","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2013_en.pdf"},
    {"id":"22607","name":"Medicinal products for human use: monthly figures - April 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-05-15T16:18:00Z","last_updated_date":"2018-05-15T16:18:00Z","reference_number":"EMA/287494/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2018_en.pdf"},
    {"id":"22652","name":"European Medicines Agency workshop on the plasma master file, 10-11 October 2001: Summary report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2002-12-18T00:09:21Z","last_updated_date":"2002-12-18T00:09:21Z","reference_number":"EMEA/CPMP/BWP/173/02","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-workshop-plasma-master-file-10-11-october-2001-summary-report_en.pdf"},
    {"id":"22657","name":"Contract 2007/146-691 Instrument for Pre-accession Assistance transition assistance programme: Second progress report to the European Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-07-11T02:09:21Z","last_updated_date":"2008-07-11T02:09:21Z","reference_number":"EMEA/368794/2008","document_url":"https://www.ema.europa.eu/en/documents/report/contract-2007146-691-instrument-pre-accession-assistance-transition-assistance-programme-second-progress-report-european-commission_en.pdf"},
    {"id":"22735","name":"Scientific recommendation on classification of advanced therapy medicinal products: AAV vector carrying an expression cassette for photoactivable enhanced halorhodopsin protein from Natronomonas pharaonis (eNpHR)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T12:00:00Z","last_updated_date":"2015-08-26T12:00:00Z","reference_number":"EMA/556494/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-aav-vector-carrying-expression-cassette-photoactivable-enhanced-halorhodopsin-protein-natronomonas-pharaonis-enphr_en.pdf"},
    {"id":"22741","name":"Human adult allogenic mesodermal progenitor cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T13:00:00Z","last_updated_date":"2016-05-04T13:00:00Z","reference_number":"EMA/291903/2016","document_url":"https://www.ema.europa.eu/en/documents/report/human-adult-allogenic-mesodermal-progenitor-cells_en.pdf"},
    {"id":"22754","name":"Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells suspension extracted from bone (Ilium) marrow and cultivated during 18 days","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-11-08T10:45:00Z","last_updated_date":"2013-11-08T10:45:00Z","reference_number":"EMA/660945/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-mesenchymal-stem-cells-suspension-extracted-bone-ilium-marrow-and-cultivated-during-18-days_en.pdf"},
    {"id":"22758","name":"CHMP statistics: September 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-september-2016_en.pdf"},
    {"id":"22769","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous dental pulp stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:41:00Z","last_updated_date":"2018-01-03T14:41:00Z","reference_number":"EMA/781622/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-dental-pulp-stem-cells_en.pdf"},
    {"id":"22823","name":"Meeting report on the paediatric high-grade glioma medicines expert workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-07-06T02:00:00Z","last_updated_date":"2011-07-06T02:00:00Z","reference_number":"EMA/289125/2011","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-paediatric-high-grade-glioma-medicines-expert-workshop_en.pdf"},
    {"id":"22881","name":"Annual activity report 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-09-02T18:16:00Z","last_updated_date":"2015-09-02T18:16:00Z","reference_number":"EMA/92858/2015","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2014_en.pdf"},
    {"id":"22913","name":"Medicinal products for human use: monthly figures - December 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T13:20:00Z","last_updated_date":"2016-04-04T13:20:00Z","reference_number":"EMA/22777/2016","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2015_en.pdf"},
    {"id":"22984","name":"Report on the EMEA/CHMP Biomarkers Workshop 2005","type":"report","status":"unknown","consultation_date":"","first_published_date":"2006-02-16T00:09:21Z","last_updated_date":"2006-02-16T00:09:21Z","reference_number":"EMEA/427209/2005","document_url":"https://www.ema.europa.eu/en/documents/report/report-emeachmp-biomarkers-workshop-2005_en.pdf"},
    {"id":"23027","name":"Workshop report - Expert workshop on subgroup analysis","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-11-28T11:54:00Z","last_updated_date":"2011-11-28T11:54:00Z","reference_number":"EMA/916257/2011","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-report-expert-workshop-subgroup-analysis_en.pdf"},
    {"id":"23073","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Adult autologous regenerative cells for subcutaneous administration","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T18:00:00Z","last_updated_date":"2013-05-03T18:00:00Z","reference_number":"EMA/129056/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adult-autologous-regenerative-cells-subcutaneous-administration_en.pdf"},
    {"id":"23161","name":"Nineteenth pandemic pharmacovigilance update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-06-03T02:00:00Z","last_updated_date":"2010-06-03T02:00:00Z","reference_number":"EMA/356087/2010","document_url":"https://www.ema.europa.eu/en/documents/report/nineteenth-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"23224","name":"Focus group meeting on user safety guideline report of the meeting held on 13 december 2007","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-03-17T01:00:00Z","last_updated_date":"2008-03-17T01:00:00Z","reference_number":"EMEA/CVMP/27466/2008","document_url":"https://www.ema.europa.eu/en/documents/report/focus-group-meeting-user-safety-guideline-report-meeting-held-13-december-2007_en.pdf"},
    {"id":"23286","name":"International workshop: Meeting report - Draft reflection paper on ethical and good-clinical-practice aspects of clinical trials of medicinal products for human use conducted in third countries and submitted in marketing...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-05-17T18:34:01Z","last_updated_date":"2011-05-17T18:34:01Z","reference_number":"EMA/601825/2010","document_url":"https://www.ema.europa.eu/en/documents/report/international-workshop-meeting-report-draft-reflection-paper-ethical-and-good-clinical-practice-aspects-clinical-trials-medicinal-products-human-use-conducted-third-countries-and-submitted-marketing_en.pdf"},
    {"id":"23313","name":"Scientific recommendation on classification of advanced therapy medicinal products: expanded autologous auricular chondrocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T16:40:00Z","last_updated_date":"2018-06-27T16:40:00Z","reference_number":"EMA/177325/2018 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-expanded-autologous-auricular-chondrocytes_en.pdf"},
    {"id":"23387","name":"Scientific recommendation on classification of advanced therapy medicinal products: Ex vivo expanded human umbilical tissue-derived cells","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T19:00:00Z","last_updated_date":"2015-11-16T15:35:00Z","reference_number":"EMA/556292/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-ex-vivo-expanded-human-umbilical-tissue-derived-cells_en.pdf"},
    {"id":"23388","name":"Emea workshop on application to pharmaceuticals of assays for markers of TSE held on 19-20 January 1999 report to the CPMP from the Biotechnology Working Party","type":"report","status":"unknown","consultation_date":"","first_published_date":"1999-02-24T00:00:00Z","last_updated_date":"1999-02-24T00:00:00Z","reference_number":"CPMP/BWP/257/99","document_url":"https://www.ema.europa.eu/en/documents/report/emea-workshop-application-pharmaceuticals-assays-markers-tse-held-19-20-january-1999-report-cpmp-biotechnology-working-party_en.pdf"},
    {"id":"23421","name":"Report on first workshop on a European Paediatric Research network, 16 February 2009","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-03-03T00:09:21Z","last_updated_date":"2009-03-03T00:09:21Z","reference_number":"EMEA/105690/2009","document_url":"https://www.ema.europa.eu/en/documents/report/report-first-workshop-european-paediatric-research-network-16-february-2009_en.pdf"},
    {"id":"23496","name":"Hearing the Association of the European Self-Medication Industry during the May 2014 Working Party on Community Monographs and Community List meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-10-21T14:00:00Z","last_updated_date":"2014-10-21T14:00:00Z","reference_number":"EMA/HMPC/540095/2014","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-during-may-2014-working-party-community-monographs-and-community-list-meeting_en.pdf"},
    {"id":"23517","name":"Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed (IVT) ribonucleic acid (RNA)-electroporated and cultured autologous mature dendritic cells (DCs)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-11-29T10:15:00Z","last_updated_date":"2011-12-09T13:27:00Z","reference_number":"EMA/921464/2011 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vitro-transcribed-ivt-ribonucleic-acid-rna-electroporated-and-cultured-autologous-mature-dendritic-cells-dcs_en.pdf"},
    {"id":"23534","name":"Applications for new human medicines under evaluation by the CHMP: March 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-03-27T15:30:00Z","last_updated_date":"2013-03-27T15:30:00Z","reference_number":"EMA/192989/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2013_en.pdf"},
    {"id":"23607","name":"Report on budgetary and financial management: financial year 2015","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2016-08-10T18:45:00Z","last_updated_date":"2016-08-10T18:45:00Z","reference_number":"EMA/668580/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2015_en.pdf"},
    {"id":"23633","name":"Medicinal products for human use: Monthly figures - July 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-08-31T13:45:00Z","last_updated_date":"2012-08-31T13:45:00Z","reference_number":"EMA/562827/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2012_en.pdf"},
    {"id":"23686","name":"Scientific recommendation on classification of advanced therapy medicinal products: Cultured dental pulp stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:41:00Z","last_updated_date":"2018-01-03T14:41:00Z","reference_number":"EMA/751645/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cultured-dental-pulp-stem-cells_en.pdf"},
    {"id":"23743","name":"The European Medicines Agency Road Map to 2015: The Agency’s Contribution to Science, Medicines, Health","type":"report","status":"Draft: consultation closed","consultation_date":"2010-01-26 - 2010-04-30","first_published_date":"2010-01-26T02:00:00Z","last_updated_date":"2010-01-26T02:00:00Z","reference_number":"EMA/299895/2009","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-road-map-2015-agencys-contribution-science-medicines-health_en.pdf"},
    {"id":"23744","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Autologous, non-manipulated lipoaspirate-containing adipocytes and stromal vascular fraction","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-22T14:15:00Z","last_updated_date":"2012-10-22T14:15:00Z","reference_number":"EMA/500724/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-non-manipulated-lipoaspirate-containing-adipocytes-and-stromal-vascular-fraction_en.pdf"},
    {"id":"23782","name":"Medicinal products for human use: Monthly figures - May 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-06-17T15:30:00Z","last_updated_date":"2015-06-17T15:30:00Z","reference_number":"EMA/396547/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2015_en.pdf"},
    {"id":"23809","name":"Scientific recommendation on classification of advanced therapy medicinal products: Cultured human retinal pigment epithelial cells genetically modified to express human factor IX protein","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T11:00:00Z","last_updated_date":"2018-02-13T11:00:00Z","reference_number":"EMA/799372/2017 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cultured-human-retinal-pigment-epithelial-cells-genetically-modified-express-human-factor-ix-protein_en.pdf"},
    {"id":"23818","name":"2012 - First annual report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T16:30:00Z","last_updated_date":"2013-07-26T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/2012-first-annual-report-eudravigilance-european-parliament-council-commission_en.pdf"},
    {"id":"23906","name":"2016 annual report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-03-17T17:00:00Z","last_updated_date":"2017-03-17T17:00:00Z","reference_number":"EMA/9942/2017","document_url":"https://www.ema.europa.eu/en/documents/report/2016-annual-report-eudravigilance-european-parliament-council-and-commission_en.pdf"},
    {"id":"23917","name":"Sixteenth pandemic pharmacovigilance update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2010-04-22T02:00:00Z","reference_number":"EMA/255907/2010","document_url":"https://www.ema.europa.eu/en/documents/report/sixteenth-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"23992","name":"Scientific recommendation on classification of advanced therapy medicinal products: Resorbable, viscoelastic matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/462793/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-resorbable-viscoelastic-matrix_en.pdf"},
    {"id":"24017","name":"Scientific recommendation on classification of advanced therapy medicinal products: mesenchymal stem cells isolated from umbilical cord as a sheet","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T17:00:00Z","last_updated_date":"2016-04-12T17:00:00Z","reference_number":"EMA/240988/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-mesenchymal-stem-cells-isolated-umbilical-cord-sheet_en.pdf"},
    {"id":"24022","name":"Report on the European Medicines Agency-European Federation of Pharmaceutical Industries and Associations workshop on adaptive designs in confirmatory clinical trials","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-03-12T00:09:21Z","last_updated_date":"2008-03-12T00:09:21Z","reference_number":"EMEA/106659/2008","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-european-federation-pharmaceutical-industries-and-associations-workshop-adaptive-designs-confirmatory-clinical-trials_en.pdf"},
    {"id":"24087","name":"Report from the conference on the outcome of the evaluation of the European Medicines Agency","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-03-24T01:00:00Z","last_updated_date":"2011-03-24T01:00:00Z","reference_number":"EMA/373239/2010","document_url":"https://www.ema.europa.eu/en/documents/report/report-conference-outcome-evaluation-european-medicines-agency_en.pdf"},
    {"id":"24109","name":"Preliminary meeting report: EMEA workshop on methodological aspects of clinical trials for efficacy evaluation in small populations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2002-11-12T01:00:00Z","last_updated_date":"2002-11-12T01:00:00Z","reference_number":"EMEA/28975/02","document_url":"https://www.ema.europa.eu/en/documents/report/preliminary-meeting-report-emea-workshop-methodological-aspects-clinical-trials-efficacy-evaluation-small-populations_en.pdf"},
    {"id":"24216","name":"Human medicines highlights 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-23T12:00:00Z","last_updated_date":"2018-01-31T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2017_en.pdf"},
    {"id":"24230","name":"European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) report of a meeting held on 25 November 2009 at the European Medicines Agency","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-04-20T02:00:00Z","last_updated_date":"2010-04-20T02:00:00Z","reference_number":"EMA/788319/2009","document_url":"https://www.ema.europa.eu/en/documents/report/european-surveillance-veterinary-antimicrobial-consumption-esvac-report-meeting-held-25-november-2009-european-medicines-agency_en.pdf"},
    {"id":"24282","name":"Annual accounts: Financial year 2017","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-07-23T12:00:00Z","last_updated_date":"2018-07-23T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2017_en.pdf"},
    {"id":"24322","name":"European Medicines Agency/Committee for Medicinal Products for Human Use Working Group with Patients' Organisations - Outcome of discussions: Recommendations and proposals for action","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2005-03-17T01:00:00Z","last_updated_date":"2005-03-17T01:00:00Z","reference_number":"EMEA/149479/2004 Final","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agencycommittee-medicinal-products-human-use-working-group-patients-organisations-outcome-discussions-recommendations-and-proposals-action_en.pdf"},
    {"id":"24367","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) February 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-02-24T01:00:00Z","last_updated_date":"2011-02-24T01:00:00Z","reference_number":"EMA/CHMP/PhVWP/132783/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-february-2011-plenary-meeting_en.pdf"},
    {"id":"24386","name":"Monthly Report - Pharmacovigilance Working Party (PHVWP) September 2009 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-10-09T02:00:00Z","last_updated_date":"2009-10-09T02:00:00Z","reference_number":"EMEA/599450/2009","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-september-2009-plenary-meeting_en.pdf"},
    {"id":"24414","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous enriched CD31+ cell fraction from peripheral blood","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T16:40:00Z","last_updated_date":"2018-06-27T16:40:00Z","reference_number":"EMA/277112/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-enriched-cd31-cell-fraction-peripheral-blood_en.pdf"},
    {"id":"24461","name":"Report of the first European Medicines Agency and the European Generic and Biosimilar Medicines Association (EGA) annual bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-02-19T12:10:00Z","last_updated_date":"2016-02-19T12:10:00Z","reference_number":"EMA/80132/2016","document_url":"https://www.ema.europa.eu/en/documents/report/report-first-european-medicines-agency-and-european-generic-and-biosimilar-medicines-association-ega-annual-bilateral-meeting_en.pdf"},
    {"id":"24464","name":"EMEA Committee for Proprietary Medicinal Products (CPMP): CPMP Public Assessment Report - combined oral contraceptives and venous thromboembolism","type":"report","status":"unknown","consultation_date":"","first_published_date":"2001-09-28T02:00:00Z","last_updated_date":"2001-09-28T02:00:00Z","reference_number":"EMEA/CPMP/2201/01/en/FINAL","document_url":"https://www.ema.europa.eu/en/documents/report/emea-committee-proprietary-medicinal-products-cpmp-cpmp-public-assessment-report-combined-oral-contraceptives-and-venous-thromboembolism_en.pdf"},
    {"id":"24534","name":"Status report on EudraVigilance implementation: Human medicinal products","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/MB/472819/2009","document_url":"https://www.ema.europa.eu/en/documents/report/status-report-eudravigilance-implementation-human-medicinal-products_en.pdf"},
    {"id":"24549","name":"Sixth ESVAC report: sales of veterinary antimicrobial agents in 29 European countries in 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T12:00:00Z","last_updated_date":"2016-10-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/sixth-esvac-report-sales-veterinary-antimicrobial-agents-29-european-countries-2014_en.pdf"},
    {"id":"24642","name":"Final report on the adaptive pathways pilot","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-08-03T14:00:00Z","last_updated_date":"2016-08-03T14:00:00Z","reference_number":"EMA/276376/2016","document_url":"https://www.ema.europa.eu/en/documents/report/final-report-adaptive-pathways-pilot_en.pdf"},
    {"id":"24645","name":"Report of second EMA-EFPIA annual bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-09-18T02:00:00Z","last_updated_date":"2017-09-18T02:00:00Z","reference_number":"EMA/602747/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-second-ema-efpia-annual-bilateral-meeting_en.pdf"},
    {"id":"24671","name":"1st European SME week 2009\n\nEMEA Roundtable with SME stakeholder organisations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-05-08T02:00:00Z","last_updated_date":"2009-05-08T02:00:00Z","reference_number":"EMEA/290264/2009","document_url":"https://www.ema.europa.eu/en/documents/report/1st-european-sme-week-2009-emea-roundtable-sme-stakeholder-organisations_en.pdf"},
    {"id":"24850","name":"Scientific recommendation on classification of advanced therapy medicinal products: mesenchymal stem cells isolated from umbilical cord seeded acellular amniotic matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T17:00:00Z","last_updated_date":"2016-04-12T17:00:00Z","reference_number":"EMA/240992/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-mesenchymal-stem-cells-isolated-umbilical-cord-seeded-acellular-amniotic-matrix_en.pdf"},
    {"id":"24896","name":"Medicinal products for human use: Monthly figures - December 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-02-23T16:30:00Z","last_updated_date":"2012-02-23T16:30:00Z","reference_number":"EMA/106033/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2011_en.pdf"},
    {"id":"24952","name":"CHMP statistics: June 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-june-2017_en.pdf"},
    {"id":"24955","name":"Applications for new human medicines under evaluation by the CHMP: January 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-01-22T18:00:00Z","last_updated_date":"2013-01-22T18:00:00Z","reference_number":"EMA/21316/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2013_en.pdf"},
    {"id":"24965","name":"Report from EMA industry survey on Brexit preparedness","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-07-10T19:13:00Z","last_updated_date":"2018-07-11T17:34:00Z","reference_number":"EMA/450315/2018 Corr. 1*","document_url":"https://www.ema.europa.eu/en/documents/report/report-ema-industry-survey-brexit-preparedness_en.pdf"},
    {"id":"24982","name":"Third pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-12-16T01:00:00Z","last_updated_date":"2009-12-16T01:00:00Z","reference_number":"EMA/821276/2009","document_url":"https://www.ema.europa.eu/en/documents/report/third-pandemic-pharmacovigilance-weekly-update_en.pdf"}    {"id":"25018","name":"Summary report - Stakeholder focus group meeting on availability of Lumpy Skin Disease (LSD) vaccines authorised to EU standards held","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-04-10T17:57:00Z","last_updated_date":"2017-04-10T17:57:00Z","reference_number":"EMA/CVMP/119074/2017","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-stakeholder-focus-group-meeting-availability-lumpy-skin-disease-lsd-vaccines-authorised-eu-standards-held_en.pdf"},
    {"id":"25105","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) April 2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-04-29T02:00:00Z","last_updated_date":"2010-04-29T02:00:00Z","reference_number":"EMA/254350/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-april-2010-plenary-meeting_en.pdf"},
    {"id":"25169","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous bone marrow derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"EMA/270760/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-bone-marrow-derived-mesenchymal-stem-cells_en.pdf-1"},
    {"id":"25199","name":"European Medicines Agency budget for 2017","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2016-12-19T17:30:00Z","last_updated_date":"2016-12-19T17:30:00Z","reference_number":"EMA/MB/740755/2016","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2017_en.pdf"},
    {"id":"25266","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous dendritic cells loaded with autologous irradiated tumour stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-22T12:00:00Z","last_updated_date":"2016-03-22T12:00:00Z","reference_number":"EMA/556316/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-dendritic-cells-loaded-autologous-irradiated-tumour-stem-cells_en.pdf"},
    {"id":"25292","name":"Report on the EMEA/CHMP Biomarkers Workshop 2006","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-03-08T00:09:21Z","last_updated_date":"2007-03-08T00:09:21Z","reference_number":"EMEA/522496/2006","document_url":"https://www.ema.europa.eu/en/documents/report/report-emeachmp-biomarkers-workshop-2006_en.pdf"},
    {"id":"25301","name":"Applications for new human medicines under evaluation by the CHMP: March 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-03-09T15:21:00Z","last_updated_date":"2018-03-09T15:21:00Z","reference_number":"EMA/141345/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2018_en.pdf"},
    {"id":"25328","name":"Medicinal products for human use: Monthly figures - April 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-06-04T16:50:00Z","last_updated_date":"2014-06-04T16:50:00Z","reference_number":"EMA/320967/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2014_en.pdf"},
    {"id":"25489","name":"Report on the pilot European Medicines Agency-Food and Drug Administration good-clinical-practice initiative","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-08-02T17:54:25Z","last_updated_date":"2011-08-02T17:54:25Z","reference_number":"EXT/INS/GCP/56289/2011","document_url":"https://www.ema.europa.eu/en/documents/report/report-pilot-european-medicines-agency-food-and-drug-administration-good-clinical-practice-initiative_en.pdf"},
    {"id":"25543","name":"Medicinal products for human use: Monthly figures - April 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-06-05T12:00:00Z","last_updated_date":"2015-06-05T12:00:00Z","reference_number":"EMA/328897/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2015_en.pdf"},
    {"id":"25545","name":"Scientific recommendation on classification of advanced therapy medicinal products: banked allogenic leukocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"EMA/272795/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-banked-allogenic-leukocytes_en.pdf"},
    {"id":"25669","name":"Minor use or minor species (MUMS)/limited market scheme for veterinary medicinal products - 6th annual report (2015)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-21T17:00:00Z","last_updated_date":"2016-03-21T17:00:00Z","reference_number":"EMA/57157/2016","document_url":"https://www.ema.europa.eu/en/documents/report/minor-use-or-minor-species-mumslimited-market-scheme-veterinary-medicinal-products-6th-annual-report-2015_en.pdf"},
    {"id":"25684","name":"Benfluorex: Summary background on discussions at CPMP (1998), PhVWP (1998-2003) and CHMP (2009)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-05-19T18:58:30Z","last_updated_date":"2011-05-19T18:58:30Z","reference_number":"EMA/394445/2011","document_url":"https://www.ema.europa.eu/en/documents/report/benfluorex-summary-background-discussions-cpmp-1998-phvwp-1998-2003-and-chmp-2009_en.pdf"},
    {"id":"25687","name":"Applications for new human medicines under evaluation by the CHMP: October 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-10-07T17:35:00Z","last_updated_date":"2015-10-07T17:35:00Z","reference_number":"EMA/657412/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2015_en.pdf"},
    {"id":"25733","name":"Scientific recommendation on classification of advanced therapy medicinal products: bone marrow-derived autologous non-hematopoietic stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T12:35:00Z","last_updated_date":"2016-04-19T12:35:00Z","reference_number":"EMA/264468/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-bone-marrow-derived-autologous-non-hematopoietic-stem-cells_en.pdf-2"},
    {"id":"25813","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous tumour-infiltrating lymphocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-03-23T15:35:00Z","last_updated_date":"2017-03-23T15:35:00Z","reference_number":"EMA/159269/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-tumour-infiltrating-lymphocytes_en.pdf"},
    {"id":"25906","name":"Scientific recommendation on classification of advanced therapy medicinal products: Irradiated plasmacytoid dendritic cell line loaded with peptides from tumour antigens","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T19:00:00Z","last_updated_date":"2015-08-26T19:00:00Z","reference_number":"EMA/556392/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-irradiated-plasmacytoid-dendritic-cell-line-loaded-peptides-tumour-antigens_en.pdf"},
    {"id":"25913","name":"Tumour selectively replicating oncolytic adenovirus expressing tumour necrosis factor alpha (TNFα) and interleukin 2 (IL2)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T16:33:00Z","last_updated_date":"2016-11-15T16:33:00Z","reference_number":"EMA/693934/2016","document_url":"https://www.ema.europa.eu/en/documents/report/tumour-selectively-replicating-oncolytic-adenovirus-expressing-tumour-necrosis-factor-alpha-tnfi-and-interleukin-2-il2_en.pdf"},
    {"id":"25963","name":"Scientific recommendation on classification of advanced therapy medicinal products: Wharton jelly derived allogeneic mesenchymal stem cells, cultured in vitro","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-28T13:00:00Z","last_updated_date":"2016-11-28T13:00:00Z","reference_number":"EMA/758391/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-wharton-jelly-derived-allogeneic-mesenchymal-stem-cells-cultured-vitro_en.pdf"},
    {"id":"26172","name":"Contract 2006/118-594: Multi-beneficiary programme on participation of Croatia and Turkey in certain Community agencies in 2006 and 2007: Fourth progress report to the European Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-08-21T02:09:21Z","last_updated_date":"2007-08-21T02:09:21Z","reference_number":"EMEA/386242/2007","document_url":"https://www.ema.europa.eu/en/documents/report/contract-2006118-594-multi-beneficiary-programme-participation-croatia-and-turkey-certain-community-agencies-2006-and-2007-fourth-progress-report-european-commission_en.pdf"},
    {"id":"26209","name":"Benefit-risk methodology project: Work package 1 report: Description of the current practice of benefit-risk assessment for centralised procedure products in the European Union regulatory network","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2011-07-26T02:00:00Z","last_updated_date":"2011-07-26T02:00:00Z","reference_number":"EMA/227124/2011","document_url":"https://www.ema.europa.eu/en/documents/report/benefit-risk-methodology-project-work-package-1-report-description-current-practice-benefit-risk-assessment-centralised-procedure-products-european-union-regulatory-network_en.pdf"},
    {"id":"26217","name":"2009 EudraVigilance-Human Status Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-10-08T02:00:00Z","last_updated_date":"2010-10-08T02:00:00Z","reference_number":"EMA/MB/599720/2010","document_url":"https://www.ema.europa.eu/en/documents/report/2009-eudravigilance-human-status-report_en.pdf"},
    {"id":"26218","name":"Applications for new human medicines under evaluation by the CHMP: February 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-02-13T13:00:00Z","last_updated_date":"2014-02-13T13:00:00Z","reference_number":"EMA/71695/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2014_en.pdf"},
    {"id":"26230","name":"European Medicines Agency mid-year report 2012 from the Executive Director (January–June 2012)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-10T14:00:00Z","last_updated_date":"2012-10-10T14:00:00Z","reference_number":"EMA/MB/526812/2012","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2012-executive-director-january-june-2012_en.pdf"},
    {"id":"26274","name":"European Medicines Agency mid-year report 2016 from the Executive Director","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-14T11:53:00Z","last_updated_date":"2017-02-14T11:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2016-executive-director_en.pdf"},
    {"id":"26314","name":"Monthly report - Pharmacovigilance Working Party (PhVWP) June 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-06-30T02:00:00Z","last_updated_date":"2011-06-30T02:00:00Z","reference_number":"EMA/CHMP/PhVWP/486894/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-june-2011-plenary-meeting_en.pdf"},
    {"id":"26334","name":"Scientific recommendation on classification of advanced therapy medicinal products: Medicinal product composed of living, genetically modified Lactococcus lactis bacteria, containing the gene for anti-human tumor necrosi...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-14T13:00:00Z","last_updated_date":"2016-03-14T13:00:00Z","reference_number":"EMA/190932/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-medicinal-product-composed-living-genetically-modified-lactococcus-lactis-bacteria-containing-gene-anti-human-tumor-necrosi_en.pdf"},
    {"id":"26358","name":"Report of the Vaccines Working Party closed workshop on correlates for the protection and serological assays for influenza vaccines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-06-05T11:15:00Z","last_updated_date":"2013-06-05T11:15:00Z","reference_number":"EMA/CHMP/VWP/751217/2012","document_url":"https://www.ema.europa.eu/en/documents/report/report-vaccines-working-party-closed-workshop-correlates-protection-and-serological-assays-influenza-vaccines_en.pdf"},
    {"id":"26371","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human burn eschar and debrided adipose tissue cells (suspension)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T11:00:00Z","last_updated_date":"2018-02-13T11:00:00Z","reference_number":"EMA/35687/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-burn-eschar-and-debrided-adipose-tissue-cells-suspension_en.pdf"},
    {"id":"26448","name":"Results of the sampling and testing programme for the year 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-08-17T16:30:00Z","last_updated_date":"2015-08-17T16:30:00Z","reference_number":"EMA/INS/S&T/517529/2014","document_url":"https://www.ema.europa.eu/en/documents/report/results-sampling-and-testing-programme-year-2013_en.pdf"},
    {"id":"26486","name":"Hearing AESPG - 10 March 2009: Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-05-14T02:00:00Z","last_updated_date":"2009-05-14T02:00:00Z","reference_number":"EMEA/HMPC/180442/2009","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-aespg-10-march-2009-report_en.pdf"},
    {"id":"26517","name":"Report of the CVMP on the Safety Evaluation of Steroidal Sex Hormones in particular for 17β-Oestradiol, Progesterone, Altrenogest, Flugestone acetate and Norgestomet in the Light of New Data/Information made available b...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2004-12-21T00:09:21Z","last_updated_date":"2004-12-21T00:09:21Z","reference_number":"EMEA/CVMP/885/99","document_url":"https://www.ema.europa.eu/en/documents/report/report-cvmp-safety-evaluation-steroidal-sex-hormones-particular-17i2-oestradiol-progesterone-altrenogest-flugestone-acetate-and-norgestomet-light-new-datainformation-made-available-b_en.pdf"},
    {"id":"26520","name":"Scientific recommendation on classification of advanced therapy medicinal products: bone marrow-derived autologous non-hematopoietic stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T12:35:00Z","last_updated_date":"2016-04-19T12:35:00Z","reference_number":"EMA/264406/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-bone-marrow-derived-autologous-non-hematopoietic-stem-cells_en.pdf-3"},
    {"id":"26552","name":"Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed mRNA sequences encoding six non-small cell lung cancer (NSCLC) associated antigens","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-28T14:45:00Z","last_updated_date":"2017-02-28T14:45:00Z","reference_number":"EMA/126624/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vitro-transcribed-mrna-sequences-encoding-six-non-small-cell-lung-cancer-nsclc-associated-antigens_en.pdf"},
    {"id":"26601","name":"Second Pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-12-10T00:09:21Z","last_updated_date":"2009-12-10T00:09:21Z","reference_number":"EMA/790386/2009","document_url":"https://www.ema.europa.eu/en/documents/report/second-pandemic-pharmacovigilance-weekly-update_en.pdf"},
    {"id":"26631","name":"Scientific recommendation on classification of advanced therapy medicinal products: natural killer cells derived from human induced pluripotent stem cells transduced to express high-affinity non-cleavable CD16 (hnCD16) F...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-06-19T11:15:00Z","last_updated_date":"2017-06-19T11:15:00Z","reference_number":"EMA/351163/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-natural-killer-cells-derived-human-induced-pluripotent-stem-cells-transduced-express-high-affinity-non-cleavable-cd16_en.pdf"},
    {"id":"26673","name":"European Federation of Pharmaceutical Inudustries and Associations-European Medicines Agency modelling and simulation workshop report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-05-08T11:30:00Z","last_updated_date":"2012-05-08T11:30:00Z","reference_number":"EMA/238961/2012","document_url":"https://www.ema.europa.eu/en/documents/report/european-federation-pharmaceutical-inudustries-and-associations-european-medicines-agency-modelling-and-simulation-workshop-report_en.pdf"},
    {"id":"26691","name":"Update on the implementation of the EU Telematics strategy","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-06-11T02:09:21Z","last_updated_date":"2009-06-11T02:09:21Z","reference_number":"EMEA/287743/2009","document_url":"https://www.ema.europa.eu/en/documents/report/update-implementation-eu-telematics-strategy_en.pdf-1"},
    {"id":"26704","name":"Report - Closed workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-06-15T17:10:59Z","last_updated_date":"2012-06-15T17:10:59Z","reference_number":"EMA/97951/2012","document_url":"https://www.ema.europa.eu/en/documents/report/report-closed-workshop-biosimilar-monoclonal-antibodies-and-immunogenicity-monoclonal-antibodies_en.pdf"},
    {"id":"26758","name":"Annual accounts: Financial year 2014","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-07-03T16:30:00Z","last_updated_date":"2015-07-03T16:30:00Z","reference_number":"EMA/335872/2015","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2014_en.pdf"},
    {"id":"26760","name":"Sodium laurilsulfate used as an excipient - Report published in support of the ‘Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use’","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2018-11-19T12:42:00Z","reference_number":"EMA/CHMP/351898/2014 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/report/sodium-laurilsulfate-used-excipient-report-published-support-questions-and-answers-sodium-laurilsulfate-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"26782","name":"Medicinal products for human use: Monthly figures - December 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-01-27T16:30:00Z","last_updated_date":"2015-01-27T16:30:00Z","reference_number":"EMA/22984/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2014_en.pdf"},
    {"id":"26829","name":"Cumulative index of Pharmacovigilance Working Party monthly reports","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T01:00:00Z","last_updated_date":"2012-07-26T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/cumulative-index-pharmacovigilance-working-party-monthly-reports_en.pdf"},
    {"id":"26874","name":"Scientific recommendation on classification of advanced therapy medicinal products: Tracheal scaffold seeded with autologous bone marrow derived mononuclear cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-06-04T19:00:00Z","last_updated_date":"2014-06-04T19:00:00Z","reference_number":"EMA/328354/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-tracheal-scaffold-seeded-autologous-bone-marrow-derived-mononuclear-cells_en.pdf"},
    {"id":"26919","name":"Scientific recommendation on classification of advanced therapy medicinal products: co-culture of keratinocytes and mesenchymal stem cells isolated from human burn eschar and debrided adipose tissue cells, seeded onto ac...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T13:00:00Z","last_updated_date":"2016-04-12T13:00:00Z","reference_number":"EMA/241022/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-co-culture-keratinocytes-and-mesenchymal-stem-cells-isolated-human-burn-eschar-and-debrided-adipose-tissue-cells-seeded-ac_en.pdf"},
    {"id":"26938","name":"Report - Workshop on development of new antibacterial medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-09-25T12:40:00Z","last_updated_date":"2013-09-25T12:40:00Z","reference_number":"EMA/493109/2013","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-development-new-antibacterial-medicines_en.pdf"},
    {"id":"26979","name":"Contract 2006/118-594: Multi-beneficiary programme on participation of Croatia and Turkey in certain Community agencies in 2006 and 2007: Second progress report to the European Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-06-21T02:09:21Z","last_updated_date":"2007-06-21T02:09:21Z","reference_number":"EMEA/279906/2007","document_url":"https://www.ema.europa.eu/en/documents/report/contract-2006118-594-multi-beneficiary-programme-participation-croatia-and-turkey-certain-community-agencies-2006-and-2007-second-progress-report-european-commission_en.pdf"},
    {"id":"26993","name":"Medicinal products for human use: Monthly figures - June 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-07-09T11:35:00Z","last_updated_date":"2013-07-09T11:35:00Z","reference_number":"EMA/413875/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2013_en.pdf"},
    {"id":"27025","name":"Monthly report - Pharmacovigilance Working Party (PhVWP) April 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-04-20T02:00:00Z","last_updated_date":"2011-04-20T02:00:00Z","reference_number":"EMA/CHMP/PhVWP/298094/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-april-2011-plenary-meeting_en.pdf"},
    {"id":"27050","name":"Workshop report - Making Article 58 and other European Medicines Agency outputs more relevant for non-EU regulators","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-04-26T13:45:00Z","last_updated_date":"2017-04-26T13:45:00Z","reference_number":"EMA/184549/2017","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-report-making-article-58-and-other-european-medicines-agency-outputs-more-relevant-non-eu-regulators_en.pdf"},
    {"id":"27139","name":"Scientific recommendation on classification of advanced therapy medicinal products: adult stem cell population, prepared from human skeletal muscle","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-22T11:45:00Z","last_updated_date":"2016-03-22T11:45:00Z","reference_number":"EMA/556344/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adult-stem-cell-population-prepared-human-skeletal-muscle_en.pdf"},
    {"id":"27144","name":"Annex 2 - Detailed information on unsuccessful conditional marketing authorisations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T16:20:00Z","last_updated_date":"2017-02-03T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annex-2-detailed-information-unsuccessful-conditional-marketing-authorisations_en.pdf"},
    {"id":"27161","name":"Report from the small and medium-sized enterprise office on its third year of operation","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/617936/2008","document_url":"https://www.ema.europa.eu/en/documents/report/report-small-and-medium-sized-enterprise-office-its-third-year-operation_en.pdf"},
    {"id":"27406","name":"Applications for new human medicines under evaluation by the CHMP: June 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-06-05T17:43:00Z","last_updated_date":"2012-06-05T17:43:00Z","reference_number":"EMA/362726/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2012_en.pdf"},
    {"id":"27457","name":"Tenth pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-02-10T00:09:21Z","last_updated_date":"2010-02-10T00:09:21Z","reference_number":"EMA/86784/2010","document_url":"https://www.ema.europa.eu/en/documents/report/tenth-pandemic-pharmacovigilance-weekly-update_en.pdf"},
    {"id":"27542","name":"European Union Telematics operations report: 33rd report for period ending 31 December 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-04-02T13:00:00Z","last_updated_date":"2012-04-02T13:00:00Z","reference_number":"EMA/185200/2012","document_url":"https://www.ema.europa.eu/en/documents/report/european-union-telematics-operations-report-33rd-report-period-ending-31-december-2011_en.pdf"},
    {"id":"27557","name":"Medicinal products for human use: monthly figures - June 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-07-25T15:45:00Z","last_updated_date":"2017-07-25T15:45:00Z","reference_number":"EMA/462682/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2017_en.pdf"},
    {"id":"27567","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic suspension of unexpanded and uncultured human amniotic fluid-derived cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/417402/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-suspension-unexpanded-and-uncultured-human-amniotic-fluid-derived-cells_en.pdf"},
    {"id":"27578","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human cultured dermal fibroblasts and human epidermal keratinocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/417460/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-cultured-dermal-fibroblasts-and-human-epidermal-keratinocytes_en.pdf"},
    {"id":"27659","name":"European Medicines Agency Benefit-Risk methodology project - Description of the current practice of benefit-risk assessment for centralised procedure products in the EU regulatory network","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2010-04-22T02:00:00Z","reference_number":"EMA/213482/2010","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-benefit-risk-methodology-project-description-current-practice-benefit-risk-assessment-centralised-procedure-products-eu-regulatory-network_en.pdf"},
    {"id":"27666","name":"Scientific recommendation on classification of advanced therapy medicinal products: viable genetically engineered ARPE-19 cells of human origin secreting glucose-binding fluorescent biosensor protein","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-16T02:00:00Z","last_updated_date":"2017-05-16T02:00:00Z","reference_number":"EMA/272815/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-viable-genetically-engineered-arpe-19-cells-human-origin-secreting-glucose-binding-fluorescent-biosensor-protein_en.pdf"},
    {"id":"27739","name":"Results of the sampling and testing programme for the year 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-07-29T14:40:00Z","last_updated_date":"2016-07-29T14:40:00Z","reference_number":"EMA/788109/2015","document_url":"https://www.ema.europa.eu/en/documents/report/results-sampling-and-testing-programme-year-2014_en.pdf"},
    {"id":"27763","name":"Report from the small and medium-sized enterprise office on its fourth year of operation","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-12-18T01:00:00Z","last_updated_date":"2009-12-18T01:00:00Z","reference_number":"EMA/793223/2009","document_url":"https://www.ema.europa.eu/en/documents/report/report-small-and-medium-sized-enterprise-office-its-fourth-year-operation_en.pdf"},
    {"id":"27906","name":"Benefit/risk communication by the European Medicines Agency: a study of influential stakeholders’ expectations and attitudes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-05-31T14:08:42Z","last_updated_date":"2011-05-31T14:08:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/benefitrisk-communication-european-medicines-agency-study-influential-stakeholders-expectations-and-attitudes_en.pdf"},
    {"id":"27966","name":"Applications for new human medicines under evaluation by the CHMP: February 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-02-10T16:25:00Z","last_updated_date":"2016-02-10T16:25:00Z","reference_number":"EMA/93292/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2016_en.pdf"},
    {"id":"27987","name":"Pharmacovigilance Working Party (PhVWP) - Monthly report on safety concerns, guidelines and general matters - July 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-07-26T14:01:01Z","last_updated_date":"2012-07-26T14:01:01Z","reference_number":"EMA/CHMP/PhVWP/438980/2012","document_url":"https://www.ema.europa.eu/en/documents/report/pharmacovigilance-working-party-phvwp-monthly-report-safety-concerns-guidelines-and-general-matters-july-2012_en.pdf"},
    {"id":"28014","name":"Scientific recommendation on classification of advanced therapy medicinal products: Viable chondrocytes cultured within a 3D hydrogel","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-25T18:00:00Z","last_updated_date":"2017-10-25T18:00:00Z","reference_number":"EMA/665239/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-viable-chondrocytes-cultured-within-3d-hydrogel_en.pdf"},
    {"id":"28063","name":"Report on the European Medicines Agency workshop of pharmacovigilance in the paediatric population","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-08-28T11:35:00Z","last_updated_date":"2014-08-28T11:35:00Z","reference_number":"EMA/288486/2014","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-workshop-pharmacovigilance-paediatric-population_en.pdf"},
    {"id":"28144","name":"Medicinal products for human use: Monthly figures - April 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-05-14T16:42:00Z","last_updated_date":"2012-05-14T16:42:00Z","reference_number":"EMA/305542/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2012_en.pdf"},
    {"id":"28176","name":"Adenovirus serotype 5 expressing the Core protein, the Polymerase protein and selected domains of the Envelope protein of Hepatitis B Virus","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T13:00:00Z","last_updated_date":"2016-05-04T13:00:00Z","reference_number":"EMA/291911/2016","document_url":"https://www.ema.europa.eu/en/documents/report/adenovirus-serotype-5-expressing-core-protein-polymerase-protein-and-selected-domains-envelope-protein-hepatitis-b-virus_en.pdf"},
    {"id":"28201","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous bone marrow aspirate enriched in autologous mesenchymal stromal cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T17:00:00Z","last_updated_date":"2015-03-02T17:00:00Z","reference_number":"EMA/110601/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-bone-marrow-aspirate-enriched-autologous-mesenchymal-stromal-cells_en.pdf"},
    {"id":"28207","name":"Applications for new human medicines under evaluation by the CHMP: August 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-07-31T11:50:00Z","last_updated_date":"2014-07-31T11:50:00Z","reference_number":"EMA/465005/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2014_en.pdf"},
    {"id":"28288","name":"EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-01-24T10:59:01Z","last_updated_date":"2017-01-24T10:59:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/ema-and-efsa-joint-scientific-opinion-measures-reduce-need-use-antimicrobial-agents-animal-husbandry-european-union-and-resulting-impacts-food-safety-ronafa_en.pdf"},
    {"id":"28298","name":"Summary of Product Characteristics Advisory Group (SmPC AG) 6-year activity report (2016)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-03-27T13:59:00Z","last_updated_date":"2017-03-27T13:59:00Z","reference_number":"EMA/151145/2017","document_url":"https://www.ema.europa.eu/en/documents/report/summary-product-characteristics-advisory-group-smpc-ag-6-year-activity-report-2016_en.pdf"},
    {"id":"28302","name":"Analysis and assessment of the 2009 annual activity report of the Executive Director","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/MB/297535/2010","document_url":"https://www.ema.europa.eu/en/documents/report/analysis-and-assessment-2009-annual-activity-report-executive-director_en.pdf"},
    {"id":"28304","name":"European Court of Auditors final report on the annual accounts of the European Medicines Agency for the financial year 2007","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-11-24T00:09:21Z","last_updated_date":"2009-11-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-court-auditors-final-report-annual-accounts-european-medicines-agency-financial-year-2007_en.pdf"},
    {"id":"28315","name":"Medicinal products for human use: monthly figures - January 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-13T15:23:00Z","last_updated_date":"2017-02-13T15:23:00Z","reference_number":"EMA/99900/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2017_en.pdf"},
    {"id":"28426","name":"Medicinal products for human use: monthly figures - August 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-09-13T18:00:00Z","last_updated_date":"2018-09-13T18:00:00Z","reference_number":"EMA/615404/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2018_en.pdf"},
    {"id":"28472","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human mesenchymal stem cells derived from Wharton’s jelly tissue of umbilical cord (graft-versus-host disease)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T12:30:00Z","last_updated_date":"2015-10-30T11:30:00Z","reference_number":"EMA/562243/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-mesenchymal-stem-cells-derived-whartons-jelly-tissue-umbilical-cord-graft-versus-host-disease_en.pdf"},
    {"id":"28496","name":"Scientific recommendation on classification of advanced therapy medicinal products: human amniotic membrane mesenchymal stem cells seeded on acellular amniotic matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T13:00:00Z","last_updated_date":"2016-04-12T13:00:00Z","reference_number":"EMA/241011/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-amniotic-membrane-mesenchymal-stem-cells-seeded-acellular-amniotic-matrix_en.pdf"},
    {"id":"28517","name":"CHMP statistics: July 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-july-2017_en.pdf"},
    {"id":"28523","name":"European Medicines Agency’s interaction with industry stakeholders - Annual report 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-08-03T17:10:00Z","last_updated_date":"2018-08-03T17:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agencys-interaction-industry-stakeholders-annual-report-2017_en.pdf"},
    {"id":"28552","name":"Report - Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-17T12:30:00Z","last_updated_date":"2017-05-17T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-patients-and-consumers-working-party-pcwp-and-healthcare-professionals-working-party-hcpwp-joint-workshop-personalised-medicines_en.pdf"},
    {"id":"28583","name":"Seventh ESVAC report: sales of veterinary antimicrobial agents in 30 European\n\ncountries in 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-16T14:00:00Z","last_updated_date":"2018-01-18T17:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/seventh-esvac-report-sales-veterinary-antimicrobial-agents-30-european-countries-2015_en.pdf"},
    {"id":"28611","name":"Summary of transfers of appropriations in budget 2017 - Management Board meeting: 14-15 June 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-06-16T15:30:00Z","last_updated_date":"2017-06-16T15:30:00Z","reference_number":"EMA/MB/109400/2017","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2017-management-board-meeting-14-15-june-2017_en.pdf"},
    {"id":"28688","name":"Medicinal products for human use: Monthly figures - February 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-05-14T16:42:00Z","last_updated_date":"2012-05-14T16:42:00Z","reference_number":"EMA/206252/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2012_en.pdf"},
    {"id":"28696","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous mononuclear cells derived from human cord blood","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-21T17:55:00Z","last_updated_date":"2016-03-21T17:55:00Z","reference_number":"EMA/556059/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-mononuclear-cells-derived-human-cord-blood_en.pdf"},
    {"id":"28769","name":"Applications for new human medicines under evaluation by the CHMP: December 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-12-11T16:00:00Z","last_updated_date":"2014-12-11T16:00:00Z","reference_number":"EMA/759365/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2014_en.pdf"},
    {"id":"28777","name":"European Medicines Agency budget for 2013","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-01-04T11:00:00Z","last_updated_date":"2013-01-04T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2013_en.pdf"},
    {"id":"28784","name":"Report on withdrawn centralised applications 1995-1998","type":"report","status":"unknown","consultation_date":"","first_published_date":"1999-05-20T02:00:00Z","last_updated_date":"1999-05-20T02:00:00Z","reference_number":"EMEA/H/14994/99","document_url":"https://www.ema.europa.eu/en/documents/report/report-withdrawn-centralised-applications-1995-1998_en.pdf"},
    {"id":"28821","name":"Summary of transfers of appropriations in budget 2018 - Management Board meeting of 6-7 June 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-11T17:00:00Z","last_updated_date":"2018-06-11T17:00:00Z","reference_number":"EMA/MB/173925/2018","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2018-management-board-meeting-6-7-june-2018_en.pdf"},
    {"id":"28873","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous adipose derived mesenchymal stem cells, freshly isolated","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/417057/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-adipose-derived-mesenchymal-stem-cells-freshly-isolated_en.pdf"},
    {"id":"28881","name":"Medicinal products for human use: Monthly figures - August 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-09-19T11:06:00Z","last_updated_date":"2013-09-19T11:06:00Z","reference_number":"EMA/556359/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2013_en.pdf"},
    {"id":"28883","name":"Scientific recommendation on classification of advanced therapy medicinal products: Ex vivo expanded adult human bone-marrow derived pooled allogeneic mesenchymal stromal cells","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T19:00:00Z","last_updated_date":"2015-08-26T19:00:00Z","reference_number":"EMA/567064/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-ex-vivo-expanded-adult-human-bone-marrow-derived-pooled-allogeneic-mesenchymal-stromal-cells_en.pdf"},
    {"id":"28966","name":"Ad hoc CHMP Expert Group Meeting on 'Nanomedicines' - 29th April 2009","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-07-10T02:09:21Z","last_updated_date":"2009-07-10T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/ad-hoc-chmp-expert-group-meeting-nanomedicines-29th-april-2009_en.pdf"},
    {"id":"28992","name":"Summary of the EMA public hearing on quinolone and fluoroquinolone antibiotics","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-20T14:30:00Z","last_updated_date":"2018-07-12T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_bg.pdf","es":"https://www.ema.europa.eu/es/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_cs.pdf","da":"https://www.ema.europa.eu/da/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_da.pdf","de":"https://www.ema.europa.eu/de/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_de.pdf","et":"https://www.ema.europa.eu/et/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_et.pdf","el":"https://www.ema.europa.eu/el/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_hr.pdf","it":"https://www.ema.europa.eu/it/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/report/summary-ema-public-hearing-quinolone-and-fluoroquinolone-antibiotics_sv.pdf"}},
    {"id":"29029","name":"Biologics Working Party report on viral safety of plasma-derived and urine-derived medicinal products with respect to Zika virus","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-09-21T13:00:00Z","last_updated_date":"2016-09-21T13:00:00Z","reference_number":"EMA/CHMP/BWP/596747/2016","document_url":"https://www.ema.europa.eu/en/documents/report/biologics-working-party-report-viral-safety-plasma-derived-and-urine-derived-medicinal-products-respect-zika-virus_en.pdf"},
    {"id":"29093","name":"Scientific recommendation on classification of advanced therapy medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-12-14T15:30:00Z","last_updated_date":"2011-12-14T15:30:00Z","reference_number":"EMA/963488/2011","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"29146","name":"Annexes - Stakeholder engagement annual report 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T13:00:00Z","last_updated_date":"2018-06-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annexes-stakeholder-engagement-annual-report-2017_en.pdf"},
    {"id":"29204","name":"Medicinal products for human use: Monthly figures - May 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-07-09T19:00:00Z","last_updated_date":"2014-07-09T19:00:00Z","reference_number":"EMA/364469/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2014_en.pdf"}    {"id":"29220","name":"The product includes two active substances i.e. two plasmids encoding for synthetic, non-functional consensus E6 and E7 antigens of human papilloma virus types 16 and 18","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T16:33:00Z","last_updated_date":"2016-11-15T16:33:00Z","reference_number":"EMA/706959/2016","document_url":"https://www.ema.europa.eu/en/documents/report/product-includes-two-active-substances-ie-two-plasmids-encoding-synthetic-non-functional-consensus-e6-and-e7-antigens-human-papilloma-virus-types-16-and-18_en.pdf"},
    {"id":"29244","name":"Report of the workshop on endpoints for cystic fibrosis clinical trials","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T01:00:00Z","last_updated_date":"2012-12-11T01:00:00Z","reference_number":"EMA/769571/2012","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-endpoints-cystic-fibrosis-clinical-trials_en.pdf"},
    {"id":"29443","name":"Interim report on the international active-pharmaceutical-ingredient-inspection pilot programme","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-10-01T02:00:00Z","last_updated_date":"2010-10-01T02:00:00Z","reference_number":"EMA/607491/2010","document_url":"https://www.ema.europa.eu/en/documents/report/interim-report-international-active-pharmaceutical-ingredient-inspection-pilot-programme_en.pdf"},
    {"id":"29490","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autoulogous lymphoid effector cells specific against tumour-cells","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-26T12:10:00Z","last_updated_date":"2014-02-26T12:10:00Z","reference_number":"EMA/113071/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autoulogous-lymphoid-effector-cells-specific-against-tumour-cells_en.pdf"},
    {"id":"29535","name":"Twenty-first pandemic pharmacovigilance update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-07-22T02:00:00Z","last_updated_date":"2010-07-22T02:00:00Z","reference_number":"EMA/472001/2010 ","document_url":"https://www.ema.europa.eu/en/documents/report/twenty-first-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"29576","name":"Report of first European Medicines Agency-EuropaBio annual bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-09-18T02:00:00Z","last_updated_date":"2017-09-18T02:00:00Z","reference_number":"EMA/382410/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-first-european-medicines-agency-europabio-annual-bilateral-meeting_en.pdf"},
    {"id":"29651","name":"Applications for new human medicines under evaluation by the CHMP: June 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-06-16T18:02:00Z","last_updated_date":"2016-06-24T16:50:00Z","reference_number":"EMA/403916/2016 Corr","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2016_en.pdf"},
    {"id":"29661","name":"Update on EMEA implementation of EU Telematics strategy","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-03-05T00:09:21Z","last_updated_date":"2009-03-05T00:09:21Z","reference_number":"EMEA/MB/20870/2009","document_url":"https://www.ema.europa.eu/en/documents/report/update-emea-implementation-eu-telematics-strategy_en.pdf"},
    {"id":"29743","name":"European Medicines Agency budget for 2009","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-03-05T10:40:00Z","last_updated_date":"2013-03-05T10:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2009_en.pdf"},
    {"id":"29790","name":"European strategy for influenza A/H1N1 vaccine benefit-risk monitoring","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-10-01T02:00:00Z","last_updated_date":"2009-10-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-strategy-influenza-ah1n1-vaccine-benefit-risk-monitoring_en.pdf"},
    {"id":"29938","name":"Report on budgetary and financial management: Financial year 2012","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-07-04T11:40:00Z","last_updated_date":"2013-07-04T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2012_en.pdf"},
    {"id":"29975","name":"Summary of transfers of appropriations in budget 2016 - Management Board meeting: 14-15 December 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-12-19T17:30:00Z","last_updated_date":"2016-12-19T17:30:00Z","reference_number":"EMA/MB/707314/2016","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2016-management-board-meeting-14-15-december-2016_en.pdf"},
    {"id":"30098","name":"Contract 2006/118-594: Multi-beneficiary programme on participation of Croatia and Turkey in certain Community agencies in 2006 and 2007: Third progress report to the European Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-08-21T02:09:21Z","last_updated_date":"2007-08-21T02:09:21Z","reference_number":"EMEA/386242/2007","document_url":"https://www.ema.europa.eu/en/documents/report/contract-2006118-594-multi-beneficiary-programme-participation-croatia-and-turkey-certain-community-agencies-2006-and-2007-third-progress-report-european-commission_en.pdf"},
    {"id":"30238","name":"European Surveillance of Veterinary Antimicrobial Consumption (ESVAC): Report of a meeting held on 25 November 2009 at the EMEA","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-02-03T01:00:00Z","last_updated_date":"2010-02-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-surveillance-veterinary-antimicrobial-consumption-esvac-report-meeting-held-25-november-2009-emea_en.pdf"},
    {"id":"30294","name":"Report on workshop on the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), 10 & 11 March 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T15:25:48Z","last_updated_date":"2011-05-27T15:25:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema-10-11-march-2011_en.pdf"},
    {"id":"30456","name":"Annual report of the Good Clinical Practice Inspectors Working Group 2016","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2017-08-18T13:47:00Z","last_updated_date":"2017-08-18T13:47:00Z","reference_number":"EMA/INS/GCP/763873/2016","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-clinical-practice-inspectors-working-group-2016_en.pdf"},
    {"id":"30475","name":"Report on the small-and-medium-sized-enterprise initiative 2006-2011","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T14:30:00Z","last_updated_date":"2011-12-22T14:30:00Z","reference_number":"EMA/956503/2011","document_url":"https://www.ema.europa.eu/en/documents/report/report-small-and-medium-sized-enterprise-initiative-2006-2011_en.pdf"},
    {"id":"30494","name":"CVMP assessment report regarding the request for an opinion under Article-30(3) of Regulation (EC) No 726/2004 in relation to the potential risk for the consumer resulting from the use of lidocaine in food producing spec...","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-04-22T14:00:00Z","last_updated_date":"2015-04-22T14:00:00Z","reference_number":"EMA/CVMP/118717/2015","document_url":"https://www.ema.europa.eu/en/documents/report/cvmp-assessment-report-regarding-request-opinion-under-article-303-regulation-ec-no-7262004-relation-potential-risk-consumer-resulting-use-lidocaine-food-producing-spec_en.pdf"},
    {"id":"30517","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Concentrate of autologous bone marrow","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T13:30:00Z","last_updated_date":"2013-03-08T13:30:00Z","reference_number":"EMA/82120/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-concentrate-autologous-bone-marrow_en.pdf"},
    {"id":"30519","name":"Scientific recommendation on classification of advanced therapy medicinal products: co-culture of keratinocytes and mesenchymal stem cells isolated from umbilical cord seeded on acellular amniotic matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T17:00:00Z","last_updated_date":"2016-04-12T17:00:00Z","reference_number":"EMA/240996/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-co-culture-keratinocytes-and-mesenchymal-stem-cells-isolated-umbilical-cord-seeded-acellular-amniotic-matrix_en.pdf-0"},
    {"id":"30560","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) March 2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"EMA/173011/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-march-2010-plenary-meeting_en.pdf"},
    {"id":"30565","name":"Twelfth pandemic pharmacovigilance weekly update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-02-24T01:00:00Z","last_updated_date":"2010-02-24T01:00:00Z","reference_number":"EMA/117826/2010","document_url":"https://www.ema.europa.eu/en/documents/report/twelfth-pandemic-pharmacovigilance-weekly-update_en.pdf"},
    {"id":"30819","name":"Propylene glycol used as an excipient - Report published in support of the ‘Questions and answers on propylene glycol used as an excipient in medicinal products for human use’","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/334655/2013","document_url":"https://www.ema.europa.eu/en/documents/report/propylene-glycol-used-excipient-report-published-support-questions-and-answers-propylene-glycol-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"30836","name":"Summary report on the EMA workshop on stem cellbased therapies","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-07-01T02:00:00Z","last_updated_date":"2010-07-01T02:00:00Z","reference_number":"EMA/319294/2010","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-ema-workshop-stem-cellbased-therapies_en.pdf"},
    {"id":"30842","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous bone-marrow derived CD34+ cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T11:00:00Z","last_updated_date":"2018-02-13T11:00:00Z","reference_number":"EMA/65571/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-bone-marrow-derived-cd34-cells_en.pdf"},
    {"id":"30854","name":"Scientific recommendation on classification of advanced therapy medicinal products: ex vivo fused autologous human bone marrow-derived mesenchymal stem cell with allogenic human myoblast","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T16:40:00Z","last_updated_date":"2018-06-27T16:40:00Z","reference_number":"EMA/277047/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-ex-vivo-fused-autologous-human-bone-marrow-derived-mesenchymal-stem-cell-allogenic-human-myoblast_en.pdf"},
    {"id":"30901","name":"Fifteenth pandemic pharmacovigilance update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-04-08T02:00:00Z","last_updated_date":"2010-04-08T02:00:00Z","reference_number":"EMA/213238/2010","document_url":"https://www.ema.europa.eu/en/documents/report/fifteenth-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"30907","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human burn eschar and debrided adipose tissue cells (on acellular amniotic matrix)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T11:00:00Z","last_updated_date":"2018-02-13T11:00:00Z","reference_number":"EMA/35696/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-burn-eschar-and-debrided-adipose-tissue-cells-acellular-amniotic-matrix_en.pdf"},
    {"id":"30914","name":"Applications for new human medicines under evaluation by the CHMP: September 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-09-07T10:37:00Z","last_updated_date":"2018-10-18T10:37:00Z","reference_number":"EMA/596452/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2018_en.pdf"},
    {"id":"30949","name":"CHMP statistics: January 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-january-2017_en.pdf"},
    {"id":"30950","name":"Medicinal products for human use: Monthly figures - June 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-07-14T12:45:00Z","last_updated_date":"2014-07-14T12:45:00Z","reference_number":"EMA/413101/2014","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2014_en.pdf"},
    {"id":"30988","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogenic adipose-derived stem cells differentiated in vitro towards the cardiovascular lineage","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:41:00Z","last_updated_date":"2018-01-03T14:41:00Z","reference_number":"EMA/751423/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogenic-adipose-derived-stem-cells-differentiated-vitro-towards-cardiovascular-lineage_en.pdf"},
    {"id":"31036","name":"Report - Patient registries workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-17T15:00:00Z","last_updated_date":"2017-02-17T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-patient-registries-workshop_en.pdf"},
    {"id":"31049","name":"Medicinal products for human use: Monthly figures - November 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-12-13T13:05:00Z","last_updated_date":"2013-12-13T13:05:00Z","reference_number":"EMA/782417/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2013_en.pdf"},
    {"id":"31064","name":"Hearing the Association of the European Self-Medication Industry during the May 2012 Working Party on Community Monographs and Community List meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-09T18:00:00Z","last_updated_date":"2012-10-09T18:00:00Z","reference_number":"EMA/HMPC/466421/2012","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-during-may-2012-working-party-community-monographs-and-community-list-meeting_en.pdf"},
    {"id":"31091","name":"Transatlantic Administrative Simplification Action Plan – Final report on implementation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-07-29T17:56:11Z","last_updated_date":"2011-07-29T17:56:11Z","reference_number":"EMA/440869/2011","document_url":"https://www.ema.europa.eu/en/documents/report/transatlantic-administrative-simplification-action-plan-final-report-implementation_en.pdf"},
    {"id":"31114","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous human gamma-delta T lymphocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-22T12:00:00Z","last_updated_date":"2016-03-22T12:00:00Z","reference_number":"EMA/556557/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-human-gamma-delta-t-lymphocytes_en.pdf"},
    {"id":"31147","name":"Applications for new human medicines under evaluation by the CHMP: December 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-12-07T17:20:00Z","last_updated_date":"2016-12-07T17:20:00Z","reference_number":"EMA/810788/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2016_en.pdf"},
    {"id":"31175","name":"Medicinal products for human use: Monthly figures - July 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-08-30T02:00:00Z","last_updated_date":"2011-08-30T02:00:00Z","reference_number":"EMA/691646/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2011_en.pdf"},
    {"id":"31190","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Allogeneic activated leukocytes","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-12T16:30:00Z","last_updated_date":"2014-02-12T16:30:00Z","reference_number":"EMA/75971/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-activated-leukocytes_en.pdf"},
    {"id":"31203","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Autologous ex vivo expanded polyclonal CD4+CD25+CD127lo/-FOXP3+ regulatory T cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:59:00Z","last_updated_date":"2018-01-03T14:59:00Z","reference_number":"EMA/699338/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-ex-vivo-expanded-polyclonal-cd4cd25cd127lo-foxp3-regulatory-t-cells_en.pdf"},
    {"id":"31217","name":"Report on budgetary and financial management: financial year 2014","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-10-14T15:10:00Z","last_updated_date":"2015-10-14T15:10:00Z","reference_number":"EMA/9022/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2014_en.pdf"},
    {"id":"31242","name":"Status Report on the EudraVigilance-Human Project","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-03-05T00:09:21Z","last_updated_date":"2009-03-05T00:09:21Z","reference_number":"EMEA/MB/45112/2009","document_url":"https://www.ema.europa.eu/en/documents/report/status-report-eudravigilance-human-project_en.pdf"},
    {"id":"31282","name":"Applications for new human medicines under evaluation by the CHMP: August 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-08-12T16:45:00Z","last_updated_date":"2015-08-12T16:45:00Z","reference_number":"EMA/541870/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2015_en.pdf"},
    {"id":"31324","name":"CHMP statistics: June 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-june-2016_en.pdf"},
    {"id":"31350","name":"Contract 2007/146-691 Instrument for Pre-accession Assistance transition assistance programme: First progress report to the European Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-04-07T02:09:21Z","last_updated_date":"2008-04-07T02:09:21Z","reference_number":"EMEA/180416/2008","document_url":"https://www.ema.europa.eu/en/documents/report/contract-2007146-691-instrument-pre-accession-assistance-transition-assistance-programme-first-progress-report-european-commission_en.pdf"},
    {"id":"31457","name":"Scientific recommendation on classification of advanced therapy medicinal products: genetically modified oncolytic adenovirus coated with oligopeptide-end modified Poly (β-amino) esters","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-06-19T11:15:00Z","last_updated_date":"2017-06-19T11:15:00Z","reference_number":"EMA/351239/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-genetically-modified-oncolytic-adenovirus-coated-oligopeptide-end-modified-poly-i2-amino-esters_en.pdf"},
    {"id":"31498","name":"Annex 1 - Detailed information on conditional marketing authorisations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-01-23T16:20:00Z","last_updated_date":"2017-02-03T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annex-1-detailed-information-conditional-marketing-authorisations_en.pdf"},
    {"id":"31523","name":"CHMP statistics: June 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-june-2018_en.pdf"},
    {"id":"31558","name":"Report from the 1st EMEA CPMP workshop with patients organisations information and participation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2005-03-17T01:00:00Z","last_updated_date":"2005-03-17T01:00:00Z","reference_number":"EMEA/17857/2005/Final","document_url":"https://www.ema.europa.eu/en/documents/report/report-1st-emea-cpmp-workshop-patients-organisations-information-and-participation_en.pdf"},
    {"id":"31625","name":"Ethical considerations for paediatric trials","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-25T13:55:00Z","last_updated_date":"2012-10-25T13:55:00Z","reference_number":"EMA/146065/2012","document_url":"https://www.ema.europa.eu/en/documents/report/ethical-considerations-paediatric-trials_en.pdf"},
    {"id":"31666","name":"Applications for new human medicines under evaluation by the CHMP: July 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-07-09T13:00:00Z","last_updated_date":"2012-07-09T13:00:00Z","reference_number":"EMA/454567/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2012_en.pdf"},
    {"id":"31707","name":"European Court of Auditors final report on the annual accounts of the European Medicines Agency for the financial year 2014","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-12-11T16:40:00Z","last_updated_date":"2015-12-11T16:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-court-auditors-final-report-annual-accounts-european-medicines-agency-financial-year-2014_en.pdf"},
    {"id":"31712","name":"European Medicines Agency budget for 2015","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-12-22T15:30:00Z","last_updated_date":"2014-12-22T15:30:00Z","reference_number":"EMA/MB/73904/2014","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2015_en.pdf"},
    {"id":"31723","name":"European Medicines Agency budget for 2006","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2005-12-15T01:00:00Z","last_updated_date":"2005-12-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2006_en.pdf"},
    {"id":"31733","name":"Monthly Report - Pharmacovigilance Working Party (PHVWP) December 2009 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-01-07T01:00:00Z","last_updated_date":"2010-01-07T01:00:00Z","reference_number":"EMA/816248/2009","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-december-2009-plenary-meeting_en.pdf"},
    {"id":"31742","name":"Towards optimising risk minimisation measures: report on European Medicines Agency’s workshop on risk minimisation measures","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-12-14T11:00:00Z","last_updated_date":"2015-12-14T11:00:00Z","reference_number":"EMA/628259/2015","document_url":"https://www.ema.europa.eu/en/documents/report/towards-optimising-risk-minimisation-measures-report-european-medicines-agencys-workshop-risk-minimisation-measures_en.pdf"},
    {"id":"31821","name":"CHMP statistics: October 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-october-2017_en.pdf"},
    {"id":"31896","name":"Applications for new human medicines under evaluation by the CHMP: August 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-08-09T13:50:00Z","last_updated_date":"2016-08-09T13:50:00Z","reference_number":"EMA/529158/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2016_en.pdf"},
    {"id":"31899","name":"European Medicines Agency mid-year report 2014 from the Executive Director","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-10-08T15:00:00Z","last_updated_date":"2014-10-08T15:00:00Z","reference_number":"EMA/620653/2014","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2014-executive-director_en.pdf"},
    {"id":"31902","name":"Scientific recommendation on classification of advanced therapy medicinal products: Vials containing allogeneic mesenchymal precursor cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T12:45:00Z","last_updated_date":"2016-04-12T12:45:00Z","reference_number":"EMA/213712/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vials-containing-allogeneic-mesenchymal-precursor-cells_en.pdf"},
    {"id":"31939","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous expanded mesenchymal cells seeded onto an allogeneic human decellularised trachea scaffold","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T12:45:00Z","last_updated_date":"2016-04-12T12:45:00Z","reference_number":"EMA/213708/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-expanded-mesenchymal-cells-seeded-allogeneic-human-decellularised-trachea-scaffold_en.pdf"},
    {"id":"31967","name":"Road map to 2015: The European Medicines Agency’s contribution to science, medicines and health","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2011-01-26T10:58:15Z","last_updated_date":"2011-01-26T10:58:15Z","reference_number":"EMA/299895/2009","document_url":"https://www.ema.europa.eu/en/documents/report/road-map-2015-european-medicines-agencys-contribution-science-medicines-and-health_en.pdf"},
    {"id":"31982","name":"Scientific recommendation on classification of advanced therapy medicinal products: The medicinal product consists of two compounds, both subcutaneously administered at the same implantation site:\n\nӢ Encapsulated alloge...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T12:45:00Z","last_updated_date":"2016-04-12T12:45:00Z","reference_number":"EMA/213689/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-medicinal-product-consists-two-compounds-both-subcutaneously-administered-same-implantation-site-c-encapsulated-alloge_en.pdf"},
    {"id":"32054","name":"Report on the EMEA/EFPIA Pharmacogenetics Workshop on Integrating Pharmacogenetics Early into Drug Development: PK as a working example","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:09:21Z","last_updated_date":"2009-05-29T02:09:21Z","reference_number":"EMEA/151623/2009","document_url":"https://www.ema.europa.eu/en/documents/report/report-emeaefpia-pharmacogenetics-workshop-integrating-pharmacogenetics-early-drug-development-pk-working-example_en.pdf"},
    {"id":"32086","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human islets of Langerhans","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-08-19T02:00:00Z","last_updated_date":"2011-08-19T02:00:00Z","reference_number":"EMA/681445/2011","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-islets-langerhans_en.pdf"},
    {"id":"32131","name":"2015 annual report on independence","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2017-01-31T11:00:00Z","last_updated_date":"2017-01-31T11:00:00Z","reference_number":"EMA/175527/2016","document_url":"https://www.ema.europa.eu/en/documents/report/2015-annual-report-independence_en.pdf"},
    {"id":"32238","name":"Medicinal products for human use: monthly figures - December 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-01-24T17:10:00Z","last_updated_date":"2017-01-24T17:10:00Z","reference_number":"EMA/18823/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2016_en.pdf"},
    {"id":"32296","name":"Applications for new human medicines under evaluation by the CHMP: October 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-10-13T14:30:00Z","last_updated_date":"2014-10-13T14:30:00Z","reference_number":"EMA/614184/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2014_en.pdf"},
    {"id":"32338","name":"European Medicines Agency budget for 2016","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T14:29:00Z","last_updated_date":"2015-12-18T14:29:00Z","reference_number":"EMA/MB/596380/2015","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2016_en.pdf"},
    {"id":"32404","name":"Applications for new human medicines under evaluation by the CHMP: March 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-03-01T20:24:00Z","last_updated_date":"2012-03-02T20:24:00Z","reference_number":"EMA/152848/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2012_en.pdf"},
    {"id":"32473","name":"Report to the European Commission on rewards and incentives under the Paediatric Regulation (2007-2009)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-05-10T02:00:00Z","last_updated_date":"2010-05-10T02:00:00Z","reference_number":"EMA/50813/2009","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-commission-rewards-and-incentives-under-paediatric-regulation-2007-2009_en.pdf"},
    {"id":"32499","name":"Eighteenth pandemic pharmacovigilance update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-05-20T02:00:00Z","last_updated_date":"2010-05-20T02:00:00Z","reference_number":"EMA/326582/2010","document_url":"https://www.ema.europa.eu/en/documents/report/eighteenth-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"32551","name":"Scientific recommendation on classification of advanced therapy medicinal products: peripheral blood monocytes-derived suppressive cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-22T12:00:00Z","last_updated_date":"2016-03-22T12:00:00Z","reference_number":"EMA/557288/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-peripheral-blood-monocytes-derived-suppressive-cells_en.pdf"},
    {"id":"32592","name":"Hearing with the Association of the European Self-Medication Industry (AESGP) during the March 2017 Working Party on Community Monographs and Community List meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-07-07T18:30:00Z","last_updated_date":"2017-07-07T18:30:00Z","reference_number":"EMA/HMPC/384019/2017","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-aesgp-during-march-2017-working-party-community-monographs-and-community-list-meeting_en.pdf"},
    {"id":"32612","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Viable, autologous keratinocytes and melanocytes grown on AS210 matrix. The active component of\n\ntissue engineered dermis consists of v...","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-12T16:30:00Z","last_updated_date":"2014-02-12T16:30:00Z","reference_number":"EMA/76529 /2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-viable-autologous-keratinocytes-and-melanocytes-grown-as210-matrix-active-component-tissue-engineered-dermis-consists-v_en.pdf"},
    {"id":"32624","name":"Scientific recommendation on classification of advanced therapy medicinal products: Sterile suspension on 5.10 viral particles in 0.5ml of A195 buffer","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-08-06T12:00:00Z","last_updated_date":"2013-08-06T12:00:00Z","reference_number":"EMA/479201/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-sterile-suspension-510-viral-particles-05ml-a195-buffer_en.pdf"},
    {"id":"32662","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous bone marrow-derived CD133+ stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-11-29T10:15:00Z","last_updated_date":"2011-11-29T10:15:00Z","reference_number":"EMA/921674/2011","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-bone-marrow-derived-cd133-stem-cells_en.pdf"},
    {"id":"32664","name":"Applications for new human medicines under evaluation by the CHMP: February 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-02-16T16:40:00Z","last_updated_date":"2015-02-16T16:40:00Z","reference_number":"EMA/82478/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2015_en.pdf"},
    {"id":"32724","name":"Autologous antigen-specific regulatory T lymphocytes suspended in a cryopreservation medium","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-07-11T13:00:00Z","last_updated_date":"2014-07-11T13:00:00Z","reference_number":"EMA/421170/2014","document_url":"https://www.ema.europa.eu/en/documents/report/autologous-antigen-specific-regulatory-t-lymphocytes-suspended-cryopreservation-medium_en.pdf"},
    {"id":"32762","name":"Third report on the progress of the interaction with patients' and consumers' organisations during 2009","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2010-11-22T13:13:18Z","last_updated_date":"2010-11-22T13:13:18Z","reference_number":"EMA/MB/117170/2010","document_url":"https://www.ema.europa.eu/en/documents/report/third-report-progress-interaction-patients-and-consumers-organisations-during-2009_en.pdf"},
    {"id":"32828","name":"CHMP highlights November 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-11T01:00:00Z","last_updated_date":"2016-11-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-highlights-november-2016_en.pdf"},
    {"id":"32864","name":"Medicinal products for human use: monthly figures - May 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-06-23T18:20:00Z","last_updated_date":"2016-06-23T18:20:00Z","reference_number":"EMA/425176/2016","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2016_en.pdf"},
    {"id":"32894","name":"2015 annual report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-21T17:00:00Z","last_updated_date":"2016-03-21T17:00:00Z","reference_number":"EMA/34490/2016 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/report/2015-annual-report-eudravigilance-european-parliament-council-and-commission_en.pdf"},
    {"id":"32898","name":"Report on the survey of all paediatric uses of medicinal\n\nproducts in Europe","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-01-21T00:31:00Z","last_updated_date":"2011-01-21T00:31:00Z","reference_number":"EMA/794083/2009","document_url":"https://www.ema.europa.eu/en/documents/report/report-survey-all-paediatric-uses-medicinal-products-europe_en.pdf"},
    {"id":"32935","name":"European Medicines Agency’s interaction with industry stakeholders - Annual report 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-06-16T15:30:00Z","last_updated_date":"2017-06-16T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agencys-interaction-industry-stakeholders-annual-report-2016_en.pdf"},
    {"id":"32966","name":"Medicinal products for human use: Monthly figures - February 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-03-29T02:00:00Z","last_updated_date":"2011-03-29T02:00:00Z","reference_number":"EMA/232558/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2011_en.pdf"},
    {"id":"33030","name":"Hearing the Association of the European Self-Medication Industry during the May 2011 Working Party on Community Monographs and Community List meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-07-20T02:00:00Z","last_updated_date":"2011-07-20T02:00:00Z","reference_number":"EMA/HMPC/407743/2011","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-during-may-2011-working-party-community-monographs-and-community-list-meeting_en.pdf"},
    {"id":"33040","name":"Autologous blood-derived cells filtered to remove other blood components","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T13:00:00Z","last_updated_date":"2016-05-04T13:00:00Z","reference_number":"EMA/291914/2016","document_url":"https://www.ema.europa.eu/en/documents/report/autologous-blood-derived-cells-filtered-remove-other-blood-components_en.pdf"},
    {"id":"33071","name":"Executive Summary report on EMEA meeting with interested parties and research centres on ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-12-18T01:00:00Z","last_updated_date":"2007-12-18T01:00:00Z","reference_number":"EMEA/601107/2007","document_url":"https://www.ema.europa.eu/en/documents/report/executive-summary-report-emea-meeting-interested-parties-and-research-centres-encepp-european-network-centres-pharmacoepidemiology-and-pharmacovigilance_en.pdf"},
    {"id":"33080","name":"CVMP assessment report regarding the request for an opinion under Article 30(3) of Regulation (EC) No. 726/2004 in relation to the potential risk for the consumer resulting from the use of diethanolamine as an excipient ...","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T12:27:00Z","last_updated_date":"2018-07-25T12:27:00Z","reference_number":"EMA/CVMP/468348/2018","document_url":"https://www.ema.europa.eu/en/documents/report/cvmp-assessment-report-regarding-request-opinion-under-article-303-regulation-ec-no-7262004-relation-potential-risk-consumer-resulting-use-diethanolamine-excipient_en.pdf"},
    {"id":"33089","name":"Annual report on European Medicines Agency’s interaction with patients, consumers, healthcare professionals and their organisations (2013)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-10-08T15:00:00Z","last_updated_date":"2014-10-08T15:00:00Z","reference_number":"EMA/103410/2014","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-european-medicines-agencys-interaction-patients-consumers-healthcare-professionals-and-their-organisations-2013_en.pdf"},
    {"id":"33094","name":"Hearing AESGP - 6 May 2008: Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-07-09T02:00:00Z","last_updated_date":"2008-07-09T02:00:00Z","reference_number":"EMEA/HMPC/348341/2008","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-aesgp-6-may-2008-report_en.pdf"},
    {"id":"33183","name":"Report on second workshop of the European Paediatric Research Network (EnprEMA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-05-12T02:00:00Z","last_updated_date":"2010-05-12T02:00:00Z","reference_number":"EMA/205816/2010","document_url":"https://www.ema.europa.eu/en/documents/report/report-second-workshop-european-paediatric-research-network-enprema_en.pdf"},
    {"id":"33195","name":"Pharmacovigilance Working Party (PhVWP) - Monthly report on safety concerns, guidelines and general matters - April 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-04-26T11:30:00Z","last_updated_date":"2012-04-26T11:30:00Z","reference_number":"EMA/CHMP/PhVWP/262424/2012","document_url":"https://www.ema.europa.eu/en/documents/report/pharmacovigilance-working-party-phvwp-monthly-report-safety-concerns-guidelines-and-general-matters-april-2012_en.pdf"},
    {"id":"33203","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous CD34+ cells transduced with a lentiviral vector containing the FANCA gene","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-08-23T17:00:00Z","last_updated_date":"2018-08-23T17:00:00Z","reference_number":"EMA/496459/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-cd34-cells-transduced-lentiviral-vector-containing-fanca-gene_en.pdf"},
    {"id":"33213","name":"Update on revision of chapters 3 and 5 of the good-manufacturing-practice guide: Dedicated facilities","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-12-10T01:00:00Z","last_updated_date":"2009-12-10T01:00:00Z","reference_number":"EMA/INS/GMP/809387/2009","document_url":"https://www.ema.europa.eu/en/documents/report/update-revision-chapters-3-and-5-good-manufacturing-practice-guide-dedicated-facilities_en.pdf"},
    {"id":"33235","name":"Report from the joint EMEA(NRG)/EFPIA workshop on invented names","type":"report","status":"unknown","consultation_date":"","first_published_date":"2006-11-30T00:09:21Z","last_updated_date":"2006-11-30T00:09:21Z","reference_number":"EMEA/487680/2006","document_url":"https://www.ema.europa.eu/en/documents/report/report-joint-emeanrgefpia-workshop-invented-names_en.pdf"},
    {"id":"33244","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous expanded viable chondrocytes combined with a three dimensional structure (biphasic collagen scaffold)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-22T12:00:00Z","last_updated_date":"2016-03-22T12:00:00Z","reference_number":"EMA/556423/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-expanded-viable-chondrocytes-combined-three-dimensional-structure-biphasic-collagen-scaffold_en.pdf"},
    {"id":"33283","name":"Medicinal products for human use: monthly figures - November 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T11:45:00Z","last_updated_date":"2017-12-15T11:45:00Z","reference_number":"EMA/828728/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2017_en.pdf"}    {"id":"33308","name":"Applications for new human medicines under evaluation by the CHMP: April 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T15:16:00Z","last_updated_date":"2014-04-28T15:16:00Z","reference_number":"EMA/237058/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2014_en.pdf"},
    {"id":"33354","name":"Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated viral vector serotype 8 containing the human low-density lipoprotein receptor (LDLR) gene","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:41:00Z","last_updated_date":"2018-01-03T14:41:00Z","reference_number":"EMA/751492/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adeno-associated-viral-vector-serotype-8-containing-human-low-density-lipoprotein-receptor-ldlr-gene_en.pdf"},
    {"id":"33370","name":"Sales of veterinary antimicrobial agents in 26 European Union / European Economic Area countries in 2012: Fourth European Surveillance of Veterinary Antimicrobial Consumption report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-10-15T15:50:00Z","last_updated_date":"2014-10-15T15:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-26-european-union-european-economic-area-countries-2012-fourth-european-surveillance-veterinary-antimicrobial-consumption-report_en.pdf"},
    {"id":"33390","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous adipose cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-07-13T15:40:00Z","last_updated_date":"2018-07-13T15:40:00Z","reference_number":"EMA/381105/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-adipose-cells_en.pdf"},
    {"id":"33401","name":"Minor use or minor species (MUMS)/limited market scheme for veterinary medicinal products - 8th annual report (2017)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-03-16T13:35:00Z","last_updated_date":"2018-03-16T13:35:00Z","reference_number":"EMA/795802/2017","document_url":"https://www.ema.europa.eu/en/documents/report/minor-use-or-minor-species-mumslimited-market-scheme-veterinary-medicinal-products-8th-annual-report-2017_en.pdf"},
    {"id":"33419","name":"Applications for new human medicines under evaluation by the CHMP: December 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-12-03T09:41:00Z","last_updated_date":"2012-12-03T09:41:00Z","reference_number":"EMA/767392/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2012_en.pdf"},
    {"id":"33438","name":"Scientific recommendation on classification of advanced therapy medicinal products: human amniotic membrane mesenchymal stem cells in suspension","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T13:00:00Z","last_updated_date":"2016-04-12T13:00:00Z","reference_number":"EMA/241009/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-amniotic-membrane-mesenchymal-stem-cells-suspension_en.pdf"},
    {"id":"33471","name":"2010 European Medicines Agency/IFAH Europe Info Day summary report: Latest developments in scientific review, legislation and marketing authorisation procedures","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-03-25T01:00:00Z","last_updated_date":"2010-03-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/2010-european-medicines-agencyifah-europe-info-day-summary-report-latest-developments-scientific-review-legislation-and-marketing-authorisation-procedures_en.pdf"},
    {"id":"33522","name":"Applications for new human medicines under evaluation by the CHMP: October 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-10-23T14:45:00Z","last_updated_date":"2013-11-05T10:17:00Z","reference_number":"EMA/641348/2013 Corr","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2013_en.pdf"},
    {"id":"33538","name":"Final report on the pilot joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-07-03T02:09:21Z","last_updated_date":"2008-07-03T02:09:21Z","reference_number":"EMEA/250885/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/report/final-report-pilot-joint-emeafda-vxds-experience-qualification-nephrotoxicity-biomarkers_en.pdf"},
    {"id":"33567","name":"Mid-year report 2009 from the Executive Director (January – June 2009)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-10-01T02:09:21Z","last_updated_date":"2009-10-01T02:09:21Z","reference_number":"EMEA/MB/503751/2009","document_url":"https://www.ema.europa.eu/en/documents/report/mid-year-report-2009-executive-director-january-june-2009_en.pdf"},
    {"id":"33587","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) January 2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-01-28T01:00:00Z","last_updated_date":"2010-01-28T01:00:00Z","reference_number":"EMA/33138/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-january-2010-plenary-meeting_en.pdf"},
    {"id":"33712","name":"Workshop on antibacterials: Report of the workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-04-26T18:05:46Z","last_updated_date":"2011-04-26T18:05:46Z","reference_number":"EMA/257650/2011","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-antibacterials-report-workshop_en.pdf"},
    {"id":"33736","name":"Thirteenth pandemic pharmacovigilance update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-03-10T01:00:00Z","last_updated_date":"2010-03-10T01:00:00Z","reference_number":"EMA/150633/2010","document_url":"https://www.ema.europa.eu/en/documents/report/thirteenth-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"33835","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-28T14:45:00Z","last_updated_date":"2017-02-28T14:45:00Z","reference_number":"EMA/126953/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-cytomegalovirus-specific-cytotoxic-t-lymphocytes_en.pdf"},
    {"id":"33837","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous cell concentrate from bone marrow aspirate","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-11-08T10:45:00Z","last_updated_date":"2013-11-08T10:45:00Z","reference_number":"EMA/661080/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-cell-concentrate-bone-marrow-aspirate_en.pdf"},
    {"id":"33859","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human umbilical cord blood-derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T16:30:00Z","last_updated_date":"2017-10-23T16:30:00Z","reference_number":"EMA/534881/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-umbilical-cord-blood-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"33866","name":"Public summary report - Inhibitor development in previously untreated patients with severe haemophilia A treated with recombinant factor VIII products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-13T17:00:00Z","last_updated_date":"2016-05-13T17:00:00Z","reference_number":"EMA/PRAC/332348/2016","document_url":"https://www.ema.europa.eu/en/documents/report/public-summary-report-inhibitor-development-previously-untreated-patients-severe-haemophilia-treated-recombinant-factor-viii-products_en.pdf"},
    {"id":"33878","name":"Medicinal products for human use: Monthly figures - October 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-12-14T16:00:00Z","last_updated_date":"2011-12-14T16:00:00Z","reference_number":"EMA/950567/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2011_en.pdf"},
    {"id":"33905","name":"Sixth annual report on the interaction with patients' and consumers' organisations (2012)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-12-17T11:30:00Z","last_updated_date":"2013-12-17T11:30:00Z","reference_number":"EMA/272219/2013","document_url":"https://www.ema.europa.eu/en/documents/report/sixth-annual-report-interaction-patients-and-consumers-organisations-2012_en.pdf"},
    {"id":"33946","name":"Scientific recommendation on classification of advanced therapy medicinal products: human hepatoblastoma cells (HepG2) encapsulated in alginate, expanded to competence and maintained in a fluidised bed bioreactor","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T15:30:00Z","last_updated_date":"2016-04-19T15:30:00Z","reference_number":"EMA/265343/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-hepatoblastoma-cells-hepg2-encapsulated-alginate-expanded-competence-and-maintained-fluidised-bed-bioreactor_en.pdf"},
    {"id":"33979","name":"EMEA Workshop on Pharmacovigilance Systems and Inspections for Veterinary Medicinal Products - Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-02-18T00:09:21Z","last_updated_date":"2008-02-18T00:09:21Z","reference_number":"EMEA/575883/2007","document_url":"https://www.ema.europa.eu/en/documents/report/emea-workshop-pharmacovigilance-systems-and-inspections-veterinary-medicinal-products-report_en.pdf"},
    {"id":"33992","name":"Report - Brexit regulatory preparedness for veterinary medicinal products in the centralised procedure","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-05-24T15:30:00Z","last_updated_date":"2018-05-24T15:30:00Z","reference_number":"EMA/271499/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-brexit-regulatory-preparedness-veterinary-medicinal-products-centralised-procedure_en.pdf"},
    {"id":"34023","name":"Medicinal products for human use: monthly figures - December 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-24T13:45:00Z","last_updated_date":"2018-01-24T13:45:00Z","reference_number":"EMA/39932/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2017_en.pdf"},
    {"id":"34043","name":"Scientific recommendation on classification of advanced therapy medicinal products: Concentrate for solution for infusion","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T12:45:00Z","last_updated_date":"2016-04-12T12:45:00Z","reference_number":"EMA/213732/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-concentrate-solution-infusion_en.pdf"},
    {"id":"34090","name":"Benefit-risk methodology project","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2011-07-26T02:00:00Z","last_updated_date":"2011-07-26T02:00:00Z","reference_number":"EMEA/108979/2009","document_url":"https://www.ema.europa.eu/en/documents/report/benefit-risk-methodology-project_en.pdf"},
    {"id":"34278","name":"Analysis and assessment of the 2008 annual activity report of the Executive Director","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-06-11T02:09:21Z","last_updated_date":"2009-06-11T02:09:21Z","reference_number":"EMEA/MB/319028/2009","document_url":"https://www.ema.europa.eu/en/documents/report/analysis-and-assessment-2008-annual-activity-report-executive-director_en.pdf"},
    {"id":"34287","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous bone marrow mononuclear cells (BM-MNC)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-22T12:00:00Z","last_updated_date":"2016-03-22T12:00:00Z","reference_number":"EMA/203997/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-bone-marrow-mononuclear-cells-bm-mnc_en.pdf"},
    {"id":"34322","name":"Veterinary medicines highlights 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T13:15:00Z","last_updated_date":"2018-02-13T13:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/veterinary-medicines-highlights-2017_en.pdf"},
    {"id":"34333","name":"Report - European Medicines Agency and Association of the European Self-Medication Industry (AESGP) annual bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-22T18:20:00Z","last_updated_date":"2017-02-22T18:20:00Z","reference_number":"EMA/52182/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-and-association-european-self-medication-industry-aesgp-annual-bilateral-meeting_en.pdf"},
    {"id":"34340","name":"Applications for new human medicines under evaluation by the CHMP: September 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-09-11T16:00:00Z","last_updated_date":"2012-09-13T16:00:00Z","reference_number":"EMA/584368/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2012_en.pdf"},
    {"id":"34349","name":"European Medicines Agency mid-year report 2015 from the Executive Director","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-10-06T12:00:00Z","last_updated_date":"2015-10-06T12:00:00Z","reference_number":"EMA/506004/2015","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2015-executive-director_en.pdf"},
    {"id":"34379","name":"Survey report - European Medicines Agency (EMA) consultation on the proposal of a collaboration framework with academia","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-20T14:05:00Z","last_updated_date":"2016-10-20T14:05:00Z","reference_number":"EMA/541709/2016","document_url":"https://www.ema.europa.eu/en/documents/report/survey-report-european-medicines-agency-ema-consultation-proposal-collaboration-framework-academia_en.pdf"},
    {"id":"34387","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic human dermal fibroblasts","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-07-30T12:00:00Z","last_updated_date":"2012-07-30T12:00:00Z","reference_number":"EMA/494515/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-human-dermal-fibroblasts_en.pdf"},
    {"id":"34391","name":"Proceedings of the workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-01-07T12:00:00Z","last_updated_date":"2016-01-07T12:00:00Z","reference_number":"EMA/803589/2015","document_url":"https://www.ema.europa.eu/en/documents/report/proceedings-workshop-role-pharmacokinetic-and-pharmacodynamic-measurements-use-direct-oral-anticoagulants_en.pdf"},
    {"id":"34488","name":"Scientific recommendation on classification of advanced therapy medicinal products: Cultured autologous adipose derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/417149/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cultured-autologous-adipose-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"34528","name":"Scientific recommendation on classification of advanced therapy medicinal products: co-culture of keratinocytes and mesenchymal stem cells isolated from umbilical cord  seeded on transgenic porcine acellular dermal matri...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T17:00:00Z","last_updated_date":"2016-04-12T17:00:00Z","reference_number":"EMA/241000/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-co-culture-keratinocytes-and-mesenchymal-stem-cells-isolated-umbilical-cord-seeded-transgenic-porcine-acellular-dermal_en.pdf"},
    {"id":"34534","name":"Scientific recommendation on classification of advanced therapy medicinal products: recombinant adeno-associated viral vector serotype 8 (AAV8) encoding human glucose-6-phosphatase-α (G6Pase or G6PC)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-21T20:00:00Z","last_updated_date":"2016-10-21T20:00:00Z","reference_number":"EMA/679224/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-viral-vector-serotype-8-aav8-encoding-human-glucose-6-phosphatase-i-g6pase-or-g6pc_en.pdf"},
    {"id":"34535","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human burn eschar and debrided adipose tissue cells (on acellular dermal matrix)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-02-13T11:00:00Z","last_updated_date":"2018-02-13T11:00:00Z","reference_number":"EMA/35702/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-burn-eschar-and-debrided-adipose-tissue-cells-acellular-dermal-matrix_en.pdf"},
    {"id":"34571","name":"EudraVigilance Veterinary – Status update report (June 2011)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"EMA/422934/2011","document_url":"https://www.ema.europa.eu/en/documents/report/eudravigilance-veterinary-status-update-report-june-2011_en.pdf"},
    {"id":"34582","name":"Medicinal products for human use: Monthly figures - January 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-03-02T01:00:00Z","last_updated_date":"2011-03-02T01:00:00Z","reference_number":"EMA/148620/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2011_en.pdf"},
    {"id":"34619","name":"Annex - Replies to EFSA/EMA questions on the use of antimicrobials in food-producing animals in EU and possible measures to reduce antimicrobial use","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-01-24T10:59:00Z","last_updated_date":"2017-01-24T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annex-replies-efsaema-questions-use-antimicrobials-food-producing-animals-eu-and-possible-measures-reduce-antimicrobial-use_en.pdf"},
    {"id":"34638","name":"Scientific recommendation on classification of advanced therapy medicinal products: co-culture of keratinocytes and mesenchymal stem cells isolated from umbilical cord  seeded on acellular dermal matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T17:00:00Z","last_updated_date":"2016-04-12T17:00:00Z","reference_number":"EMA/240998/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-co-culture-keratinocytes-and-mesenchymal-stem-cells-isolated-umbilical-cord-seeded-acellular-dermal-matrix_en.pdf-0"},
    {"id":"34736","name":"CVMP assessment report under Article 30(3) of Regulation (EC) No 726/2004 on the risk to vultures and other necrophagous bird populations in the European Union in connection with the use of veterinary medicinal products ...","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T18:30:00Z","last_updated_date":"2014-12-12T18:30:00Z","reference_number":"EMA/CVMP/721170/2014","document_url":"https://www.ema.europa.eu/en/documents/report/cvmp-assessment-report-under-article-303-regulation-ec-no-7262004-risk-vultures-and-other-necrophagous-bird-populations-european-union-connection-use-veterinary-medicinal-products_en.pdf"},
    {"id":"34768","name":"Scientific recommendation on classification of advanced therapy medicinal products: ex vivo expanded adipose-derived stem cell suspension","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-21T17:35:00Z","last_updated_date":"2016-03-21T17:35:00Z","reference_number":"EMA/555245/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-ex-vivo-expanded-adipose-derived-stem-cell-suspension_en.pdf"},
    {"id":"34793","name":"Report on the 10th anniversary of the SME initiative","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-11T12:30:00Z","last_updated_date":"2016-05-11T12:30:00Z","reference_number":"EMA/155560/2016","document_url":"https://www.ema.europa.eu/en/documents/report/report-10th-anniversary-sme-initiative_en.pdf"},
    {"id":"34797","name":"Summary report - European Medicines Agency-EuropaBio information day","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-11-04T01:00:00Z","last_updated_date":"2015-11-04T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-european-medicines-agency-europabio-information-day_en.pdf"},
    {"id":"34841","name":"Medicinal products for human use: Monthly figures - March 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-04-12T02:00:00Z","last_updated_date":"2010-04-12T02:00:00Z","reference_number":"EMA/227831/2010","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2010_en.pdf"},
    {"id":"34894","name":"Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells suspension extracted from Bone (Ilium) marrow and cultivated during 18 days and pretreated by melatonin during 24...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-11-07T15:47:00Z","last_updated_date":"2013-11-07T15:47:00Z","reference_number":"EMA/661006/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-mesenchymal-stem-cells-suspension-extracted-bone-ilium-marrow-and-cultivated-during-18-days-and-pretreated-melatonin-during_en.pdf"},
    {"id":"34962","name":"Medicinal products for human use: monthly figures - November 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T13:00:00Z","last_updated_date":"2015-12-15T13:00:00Z","reference_number":"EMA/845920/2015","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2015_en.pdf"},
    {"id":"35043","name":"Applications for new human medicines under evaluation by the CHMP: May 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-05-15T14:10:00Z","last_updated_date":"2013-05-15T14:10:00Z","reference_number":"EMA/284501/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2013_en.pdf"},
    {"id":"35070","name":"Report from scientific workshop on serology assays and correlates of protection for influenza vaccines: 29-30 June 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-12-22T12:02:11Z","last_updated_date":"2010-12-22T12:02:11Z","reference_number":"EMA/732806/2010","document_url":"https://www.ema.europa.eu/en/documents/report/report-scientific-workshop-serology-assays-and-correlates-protection-influenza-vaccines-29-30-june-2010_en.pdf"},
    {"id":"35243","name":"Report of meeting held with Lif – the Danish Association of the Pharmaceutical Industry","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-10-30T16:00:01Z","last_updated_date":"2015-10-30T16:00:01Z","reference_number":"EMA/706557/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-meeting-held-lif-danish-association-pharmaceutical-industry_en.pdf"},
    {"id":"35340","name":"Scientific recommendation on classification of advanced therapy medicinal products: Replication incompetent adenoviral vector encoding Interleukin 12 with activator ligand","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/416814/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-replication-incompetent-adenoviral-vector-encoding-interleukin-12-activator-ligand_en.pdf"},
    {"id":"35396","name":"Medicinal products for human use: Monthly figures - February 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-03-11T01:00:00Z","last_updated_date":"2010-03-11T01:00:00Z","reference_number":"EMA/137720/2010","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2010_en.pdf"},
    {"id":"35412","name":"Medicinal products for human use: monthly figures - October 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-27T19:13:00Z","last_updated_date":"2017-10-27T19:13:00Z","reference_number":"EMA/719914/2017","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2017_en.pdf"},
    {"id":"35462","name":"Annual report of the Good Clinical Practice Inspectors Working Group 2013","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-06-16T19:20:00Z","last_updated_date":"2014-06-16T19:20:00Z","reference_number":"EMA/INS/GCP/123295/2013","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-clinical-practice-inspectors-working-group-2013_en.pdf"},
    {"id":"35473","name":"Report on the first 3-year mandate of the Committee for Orphan Medicinal Products (COMP) April 2000 - April 2003","type":"report","status":"unknown","consultation_date":"","first_published_date":"2003-07-21T02:00:00Z","last_updated_date":"2003-07-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-first-3-year-mandate-committee-orphan-medicinal-products-comp-april-2000-april-2003_en.pdf"},
    {"id":"35524","name":"Report of the paediatric hepatitis C therapy expert meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-05-04T13:28:00Z","last_updated_date":"2015-05-04T13:28:00Z","reference_number":"EMA/87232/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-paediatric-hepatitis-c-therapy-expert-meeting_en.pdf"},
    {"id":"35616","name":"Report - Workshop on the patient’s voice in the evaluation of medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-10-29T15:30:00Z","last_updated_date":"2013-10-29T15:30:00Z","reference_number":"EMA/607864/2013","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-patients-voice-evaluation-medicines_en.pdf"},
    {"id":"35727","name":"Scientific recommendation on classification of advanced therapy medicinal products: Cultured autologous chondrocytes","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T12:00:00Z","last_updated_date":"2015-08-26T12:00:00Z","reference_number":"EMA/557326/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cultured-autologous-chondrocytes_en.pdf"},
    {"id":"35730","name":"Presentation ESCOP - 16 September 2009: Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-09-28T02:00:00Z","last_updated_date":"2009-09-28T02:00:00Z","reference_number":"EMEA/HMPC/594986/2009","document_url":"https://www.ema.europa.eu/en/documents/report/presentation-escop-16-september-2009-report_en.pdf"},
    {"id":"35748","name":"Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-08-06T14:05:00Z","last_updated_date":"2018-08-06T14:05:00Z","reference_number":"EMA/INS/GMP/19273/2018","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-manufacturing-and-distribution-practice-inspectors-working-group-2017_en.pdf"},
    {"id":"35760","name":"Meeting report - Joint Biologics Working Party / Quality Working Party workshop with stakeholders in relation to prior knowledge and its use in regulatory applications","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-04-04T13:00:00Z","last_updated_date":"2018-04-04T13:00:00Z","reference_number":"EMA/CHMP/BWP/187162/2018","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-joint-biologics-working-party-quality-working-party-workshop-stakeholders-relation-prior-knowledge-and-its-use-regulatory-applications_en.pdf"},
    {"id":"35789","name":"Summary report of the European Medicines Agency-EuropaBio information day - 22 November 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-01-05T10:20:00Z","last_updated_date":"2017-01-05T10:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-european-medicines-agency-europabio-information-day-22-november-2016_en.pdf"},
    {"id":"35806","name":"Applications for new human medicines under evaluation by the CHMP: April 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-04-10T16:45:00Z","last_updated_date":"2015-07-20T17:34:00Z","reference_number":"EMA/227980/2015 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2015_en.pdf"},
    {"id":"35809","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T12:00:00Z","last_updated_date":"2015-08-26T12:00:00Z","reference_number":"EMA/559104/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-cord-blood-cells-ex-vivo-modulated-1616-dimethyl-prostaglandin-e2_en.pdf"},
    {"id":"35892","name":"Scientific recommendation on classification of advanced therapy medicinal products: human amniotic membrane mesenchymal stem cells seeded on acellular dermal matrix","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T13:00:00Z","last_updated_date":"2016-04-12T13:00:00Z","reference_number":"EMA/241013/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-amniotic-membrane-mesenchymal-stem-cells-seeded-acellular-dermal-matrix_en.pdf"},
    {"id":"35903","name":"CHMP statistics: March 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-march-2018_en.pdf"},
    {"id":"35946","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Autologous mesenchymal stromal cells secreting neurotrophic factors","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T13:30:00Z","last_updated_date":"2013-03-08T13:30:00Z","reference_number":"EMA/81707/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-mesenchymal-stromal-cells-secreting-neurotrophic-factors_en.pdf"},
    {"id":"35979","name":"Scientific recommendation on classification of advanced therapy medicinal products: Ex vivo expanded adipose-derived stem cells suspension","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-04T19:15:00Z","last_updated_date":"2016-04-04T19:15:00Z","reference_number":"EMA/555245/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-ex-vivo-expanded-adipose-derived-stem-cells-suspension_en.pdf"},
    {"id":"36061","name":"Scientific recommendation on classification of advanced therapy medicinal products: cryopreserved allogeneic hematopoietic progenitor cells (HPC–CD34+) accompanied by facilitating cells (FC– CD8+/TCR-) and T cells, prepa...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-19T15:30:00Z","last_updated_date":"2016-04-19T15:30:00Z","reference_number":"EMA/263760/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cryopreserved-allogeneic-hematopoietic-progenitor-cells-hpc-cd34-accompanied-facilitating-cells-fc-cd8tcr-and-t-cells-prepa_en.pdf"},
    {"id":"36139","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous bone marrow cell aspirate in autologous plasma","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-06-04T19:00:00Z","last_updated_date":"2014-06-04T19:00:00Z","reference_number":"EMA/326911/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-bone-marrow-cell-aspirate-autologous-plasma_en.pdf"},
    {"id":"36150","name":"Report of the first EMA-EFPIA annual bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-09-30T14:05:00Z","last_updated_date":"2016-09-30T14:05:00Z","reference_number":"EMA/621049/2016","document_url":"https://www.ema.europa.eu/en/documents/report/report-first-ema-efpia-annual-bilateral-meeting_en.pdf"},
    {"id":"36165","name":"Scientific recommendation on classification of advanced therapy medicinal products: Cultured allogenic Wharton’s jelly derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/417124/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cultured-allogenic-whartons-jelly-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"36268","name":"Revision of budget structure from financial year 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-07T17:30:00Z","last_updated_date":"2016-10-07T17:30:00Z","reference_number":"EMA/MB/607820/2016","document_url":"https://www.ema.europa.eu/en/documents/report/revision-budget-structure-financial-year-2017_en.pdf"},
    {"id":"36304","name":"Annual activity report 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-07-12T11:35:00Z","last_updated_date":"2016-07-12T11:35:00Z","reference_number":"EMA/140840/2016","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2015_en.pdf"},
    {"id":"36377","name":"Applications for new human medicines under evaluation by the CHMP: May 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-05-19T16:15:00Z","last_updated_date":"2014-05-19T16:15:00Z","reference_number":"EMA/284861/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2014_en.pdf"},
    {"id":"36510","name":"Scientific recommendation on classification of advanced therapy medicinal products: Killed spores of Bacillus subtilis incorporating a non-toxic antigen of Clostridium difficile","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T17:00:00Z","last_updated_date":"2015-03-02T17:00:00Z","reference_number":"EMA/590710/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-killed-spores-bacillus-subtilis-incorporating-non-toxic-antigen-clostridium-difficile_en.pdf"},
    {"id":"36556","name":"2015 Activity report of the Modelling and simulation working group (MSWG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-20T19:20:00Z","last_updated_date":"2016-04-20T19:20:00Z","reference_number":"EMA/812945/2015","document_url":"https://www.ema.europa.eu/en/documents/report/2015-activity-report-modelling-and-simulation-working-group-mswg_en.pdf"},
    {"id":"36773","name":"Applications for new human medicines under evaluation by the CHMP: July 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-07-05T17:20:00Z","last_updated_date":"2013-07-05T17:20:00Z","reference_number":"EMA/406711/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2013_en.pdf"},
    {"id":"36825","name":"Report on the joint European Medicines Agency / Heads of Medicines Agencies workshop on requirements for the authorisation of vaccines within the European Union","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-07-13T17:00:00Z","last_updated_date":"2015-07-13T17:00:00Z","reference_number":"EMA/258437/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-joint-european-medicines-agency-heads-medicines-agencies-workshop-requirements-authorisation-vaccines-within-european-union_en.pdf"},
    {"id":"36882","name":"European Medicines Agency mid-year report 2010 from the Executive Director (January - June 2010)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-10-15T02:00:00Z","last_updated_date":"2010-10-15T02:00:00Z","reference_number":"EMA/MB/511982/2010","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2010-executive-director-january-june-2010_en.pdf"},
    {"id":"36887","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) December 2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-01-07T01:00:00Z","last_updated_date":"2011-01-07T01:00:00Z","reference_number":"EMA/CHMP/PhVWP/810358/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-december-2010-plenary-meeting_en.pdf"},
    {"id":"36904","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous anti-BCMA CAR-T cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-28T13:00:00Z","last_updated_date":"2016-11-28T13:00:00Z","reference_number":"EMA/758319/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-anti-bcma-car-t-cells_en.pdf"},
    {"id":"36917","name":"Proposal for involvement and participation of patients consumers representatives in the meetings of the Committee for Medicinal Products for Human Use Pharmacovigilance Working Party","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-03-11T01:00:00Z","last_updated_date":"2009-03-11T01:00:00Z","reference_number":"EMEA/261645/2008Endorsed","document_url":"https://www.ema.europa.eu/en/documents/report/proposal-involvement-and-participation-patients-consumers-representatives-meetings-committee-medicinal-products-human-use-pharmacovigilance-working-party_en.pdf"},
    {"id":"36934","name":"Report on workshop on the development of an EMEA transparency policy, 22nd January 2009","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-04-06T02:00:00Z","last_updated_date":"2009-04-06T02:00:00Z","reference_number":"EMEA/91746/2009","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-development-emea-transparency-policy-22nd-january-2009_en.pdf"},
    {"id":"36944","name":"Report analysis of scientific guidelines - European Medicines Agency Geriatric Medicines Strategy","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T17:30:00Z","last_updated_date":"2013-10-17T17:30:00Z","reference_number":"EMA/352591/2013","document_url":"https://www.ema.europa.eu/en/documents/report/report-analysis-scientific-guidelines-european-medicines-agency-geriatric-medicines-strategy_en.pdf"},
    {"id":"36949","name":"Medicinal products for human use: Monthly figures - September 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-18T14:15:00Z","last_updated_date":"2012-10-18T14:15:00Z","reference_number":"EMA/659098/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2012_en.pdf"},
    {"id":"37005","name":"Report on the European Medicines Agency meeting with stakeholders - First anniversary of PRIME","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-07-17T16:00:00Z","last_updated_date":"2017-07-17T16:00:00Z","reference_number":"EMA/379469/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-meeting-stakeholders-first-anniversary-prime_en.pdf"},
    {"id":"37033","name":"Report of the 2016 annual workshop of the European Network of Paediatric Research at EMA (Enpr-EMA), 2-3 June 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-28T13:45:00Z","last_updated_date":"2016-10-28T13:45:00Z","reference_number":"EMA/408587/2016","document_url":"https://www.ema.europa.eu/en/documents/report/report-2016-annual-workshop-european-network-paediatric-research-ema-enpr-ema-2-3-june-2016_en.pdf"},
    {"id":"37046","name":"EMA collaboration with general practitioners/ family physicians (GPs/FPs): Report from a joint EMA workshop with EFPC, UEMO and WONCA-Europe organised on 19 April 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-06-16T17:50:00Z","last_updated_date":"2016-06-16T17:50:00Z","reference_number":"EMA/281593/2016","document_url":"https://www.ema.europa.eu/en/documents/report/ema-collaboration-general-practitioners-family-physicians-gpsfps-report-joint-ema-workshop-efpc-uemo-and-wonca-europe-organised-19-april-2016_en.pdf"},
    {"id":"37060","name":"Scientific recommendation on classification of advanced therapy medicinal product: Adenoviral vector expressing the non-structural region of hepatitis C virus (HCV) in which a mutation has been introduced","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-08-06T12:00:00Z","last_updated_date":"2013-08-06T12:00:00Z","reference_number":"EMA/479938/2013 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-product-adenoviral-vector-expressing-non-structural-region-hepatitis-c-virus-hcv-which-mutation-has-been-introduced_en.pdf"},
    {"id":"37073","name":"Monthly report - Pharmacovigilance Working Party (PhVWP) September 2011 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-09-29T12:30:00Z","last_updated_date":"2011-09-29T12:30:00Z","reference_number":"EMA/CHMP/PhVWP/776580/2011","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-september-2011-plenary-meeting_en.pdf"},
    {"id":"37101","name":"Benefit-risk methodology project: Update on work package 5: Effects table pilot (Phase I)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-02-24T16:40:00Z","last_updated_date":"2014-02-24T16:40:00Z","reference_number":"EMA/74168/2014","document_url":"https://www.ema.europa.eu/en/documents/report/benefit-risk-methodology-project-update-work-package-5-effects-table-pilot-phase-i_en.pdf"},
    {"id":"37139","name":"Report on the international Active Pharmaceutical Ingredient (API) inspection programme 2011-2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-04-12T16:00:00Z","last_updated_date":"2018-04-12T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-international-active-pharmaceutical-ingredient-api-inspection-programme-2011-2016_en.pdf"},
    {"id":"37159","name":"Hearing the Association of the European Self-Medication Industry during the May 2015 Working Party on Community Monographs and Community List meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-08-19T15:34:00Z","last_updated_date":"2015-08-19T15:34:00Z","reference_number":"EMA/HMPC/399737/2015","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-during-may-2015-working-party-community-monographs-and-community-list-meeting_en.pdf"},
    {"id":"37173","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic human glial-restricted precursors","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-25T18:00:00Z","last_updated_date":"2017-10-25T18:00:00Z","reference_number":"EMA/664954/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-human-glial-restricted-precursors_en.pdf-0"},
    {"id":"37238","name":"Regulatory and methodological standards to improve benefit-risk evaluation of medicines - Workshop report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-04-28T02:00:00Z","last_updated_date":"2014-04-28T02:00:00Z","reference_number":"EMA/141854/2014","document_url":"https://www.ema.europa.eu/en/documents/report/regulatory-and-methodological-standards-improve-benefit-risk-evaluation-medicines-workshop-report_en.pdf"},
    {"id":"37300","name":"CVMP assessment report under Article 30(3) of Regulation (EC) No 726/2004\n\nfor dapsone as an impurity in veterinary medicinal products containing sulphamethoxazole or other sulphonamides","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-02-04T01:00:00Z","last_updated_date":"2013-02-04T01:00:00Z","reference_number":"EMA/CVMP/392271/2012","document_url":"https://www.ema.europa.eu/en/documents/report/cvmp-assessment-report-under-article-303-regulation-ec-no-7262004-dapsone-impurity-veterinary-medicinal-products-containing-sulphamethoxazole-or-other-sulphonamides_en.pdf"}    {"id":"37370","name":"Outcome of small and medium-sized enterprise (SME) office survey on the implementation of the SME regulation - Commission Regulation (EC) No 2049/2005","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-12-21T17:38:23Z","last_updated_date":"2011-12-21T17:38:23Z","reference_number":"EMA/733642/2011","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-small-and-medium-sized-enterprise-sme-office-survey-implementation-sme-regulation-commission-regulation-ec-no-20492005_en.pdf"},
    {"id":"37455","name":"Workshop report - Developing a framework of collaboration between the European Medicines Agency (EMA) and academia","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-08-01T15:50:00Z","last_updated_date":"2016-08-01T15:50:00Z","reference_number":"EMA/424858/2016","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-report-developing-framework-collaboration-between-european-medicines-agency-ema-and-academia_en.pdf"},
    {"id":"37457","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous oral mucosa cells seeded onto a membrane","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-07-10T17:15:00Z","last_updated_date":"2012-07-10T17:15:00Z","reference_number":"EMA/401326/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-oral-mucosa-cells-seeded-membrane_en.pdf"},
    {"id":"37493","name":"COMP report to the Commission in relation to Article 10 of Regulation 141/2000 on orphan medicinal products - Annex 3","type":"report","status":"unknown","consultation_date":"","first_published_date":"2005-07-25T02:00:00Z","last_updated_date":"2005-07-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/comp-report-commission-relation-article-10-regulation-1412000-orphan-medicinal-products-annex-3_en.pdf"},
    {"id":"37533","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human retinal pigment epithelial cells derived from human embryotic stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T17:00:00Z","last_updated_date":"2015-03-02T17:00:00Z","reference_number":"EMA/110702/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-retinal-pigment-epithelial-cells-derived-human-embryotic-stem-cells_en.pdf"},
    {"id":"37604","name":"Living, genetically modified Lactobacillus reuteri bacteria, with a plasmid containing the gene for human CXCL12-1a with an inducible promoter; and an activating peptide","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T16:33:00Z","last_updated_date":"2016-11-15T16:33:00Z","reference_number":"EMA/692834/2016","document_url":"https://www.ema.europa.eu/en/documents/report/living-genetically-modified-lactobacillus-reuteri-bacteria-plasmid-containing-gene-human-cxcl12-1a-inducible-promoter-and-activating-peptide_en.pdf"},
    {"id":"37611","name":"How to better apply the paediatric legislation to boost development of medicines for children - Report on a multi-stakeholder workshop held at EMA\n\non Tuesday 20 March 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-05-30T15:00:00Z","last_updated_date":"2018-05-30T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/how-better-apply-paediatric-legislation-boost-development-medicines-children-report-multi-stakeholder-workshop-held-ema-tuesday-20-march-2018_en.pdf"},
    {"id":"37666","name":"Medicinal products for human use: Monthly figures - June 2011","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-07-27T02:00:00Z","last_updated_date":"2011-07-27T02:00:00Z","reference_number":"EMA/535519/2011","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2011_en.pdf"},
    {"id":"37667","name":"Report on the impact of the volcanic ash cloud disruption on EMA activities","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/MB/719548/2010","document_url":"https://www.ema.europa.eu/en/documents/report/report-impact-volcanic-ash-cloud-disruption-ema-activities_en.pdf"},
    {"id":"37669","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous human adipose perivascular stromal cells genetically modified to secrete soluble TRAIL ligand","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/416766/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-human-adipose-perivascular-stromal-cells-genetically-modified-secrete-soluble-trail-ligand_en.pdf"},
    {"id":"37699","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous bone marrow-derived human mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T16:40:00Z","last_updated_date":"2018-06-27T16:40:00Z","reference_number":"EMA/276929/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-bone-marrow-derived-human-mesenchymal-stem-cells_en.pdf"},
    {"id":"37701","name":"European Court of Auditors final report on the annual accounts of the European Medicines Agency for the financial year 2009","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-court-auditors-final-report-annual-accounts-european-medicines-agency-financial-year-2009_en.pdf"},
    {"id":"37703","name":"Report - The workshop on paediatric investigation plans in type-2 diabetes mellitus","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-05-03T02:00:00Z","last_updated_date":"2013-05-03T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-paediatric-investigation-plans-type-2-diabetes-mellitus_en.pdf"},
    {"id":"37712","name":"Medicinal products for human use: monthly figures - July 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-08-15T13:25:00Z","last_updated_date":"2018-08-15T13:25:00Z","reference_number":"EMA/532878/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2018_en.pdf"},
    {"id":"37736","name":"Report on budgetary and financial management: Financial year 2009","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"EMA/381367/2010","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2009_en.pdf"},
    {"id":"37742","name":"Outcome of written procedures during the period from 26 February 2010 to 2 June 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/MB/281850/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-written-procedures-during-period-26-february-2010-2-june-2010_en.pdf"},
    {"id":"37771","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human autologous stromal vascular fraction (SVF)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/462636/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-autologous-stromal-vascular-fraction-svf_en.pdf"},
    {"id":"37809","name":"European Medicines Agency/Committee for Proprietary Medicinal Products Working Group with Patients' Organisations -  Outcome of discussions: Recommendations and proposals for action","type":"report","status":"unknown","consultation_date":"","first_published_date":"2004-04-20T03:00:00Z","last_updated_date":"2004-04-20T03:00:00Z","reference_number":"EMEA/CPMP/5819/04","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agencycommittee-proprietary-medicinal-products-working-group-patients-organisations-outcome-discussions-recommendations-and-proposals-action_en.pdf"},
    {"id":"37851","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human autologous chondrocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-23T16:30:00Z","last_updated_date":"2017-10-23T16:30:00Z","reference_number":"EMA/534865/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-autologous-chondrocytes_en.pdf"},
    {"id":"37898","name":"Meeting report - Developing a proactive approach to the prevention of medicines shortages due to manufacturing and quality problems","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T10:00:00Z","last_updated_date":"2016-01-27T10:00:00Z","reference_number":"EMA/679967/2015","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-developing-proactive-approach-prevention-medicines-shortages-due-manufacturing-and-quality-problems_en.pdf"},
    {"id":"37904","name":"Applications for new human medicines under evaluation by the CHMP: January 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T16:25:00Z","last_updated_date":"2016-01-11T16:25:00Z","reference_number":"EMA/6499/2016","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2016_en.pdf"},
    {"id":"37913","name":"Medicinal products for human use: Monthly figures - August 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-09-17T14:00:00Z","last_updated_date":"2012-09-17T14:00:00Z","reference_number":"EMA/600733/2012","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2012_en.pdf"},
    {"id":"37916","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human mesenchymal stem cells derived from Wharton’s jelly tissue of umbilical cord (cartilage lesions)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T12:30:00Z","last_updated_date":"2015-08-26T12:30:00Z","reference_number":"EMA/561832/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-mesenchymal-stem-cells-derived-whartons-jelly-tissue-umbilical-cord-cartilage-lesions_en.pdf"},
    {"id":"37922","name":"European Court of Auditors final report on the annual accounts of the European Medicines Agency for the financial year 2013","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-01-09T13:30:00Z","last_updated_date":"2015-01-09T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-court-auditors-final-report-annual-accounts-european-medicines-agency-financial-year-2013_en.pdf"},
    {"id":"37929","name":"Applications for new human medicines under evaluation by the CHMP: March 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-03-16T17:30:00Z","last_updated_date":"2017-03-16T17:30:00Z","reference_number":"EMA/169426/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2017_en.pdf"},
    {"id":"38048","name":"Monthly Report - Pharmacovigilance Working Party (PhVWP) May 2010 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/313457/2010","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-may-2010-plenary-meeting_en.pdf"},
    {"id":"38053","name":"Pharmacovigilance Working Party (PhVWP) - Monthly report on safety concerns, guidelines and general matters - June 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-06-29T14:23:00Z","last_updated_date":"2012-06-29T14:23:00Z","reference_number":"EMA/CHMP/PhVWP/427227/2012","document_url":"https://www.ema.europa.eu/en/documents/report/pharmacovigilance-working-party-phvwp-monthly-report-safety-concerns-guidelines-and-general-matters-june-2012_en.pdf"},
    {"id":"38064","name":"Workshop report - Demonstrating significant benefit of orphan medicines: concepts, methodology and impact on access","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-07-25T18:00:00Z","last_updated_date":"2016-07-25T18:00:00Z","reference_number":"EMA/6690/2016","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-report-demonstrating-significant-benefit-orphan-medicines-concepts-methodology-and-impact-access_en.pdf"},
    {"id":"38090","name":"European Medicines Agency budget for 2010","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2010-01-11T01:00:00Z","last_updated_date":"2010-01-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2010_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/report/european-medicines-agency-budget-2010_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/report/european-medicines-agency-budget-2010_cs.pdf","da":"https://www.ema.europa.eu/da/documents/report/european-medicines-agency-budget-2010_da.pdf","de":"https://www.ema.europa.eu/de/documents/report/european-medicines-agency-budget-2010_de.pdf","et":"https://www.ema.europa.eu/et/documents/report/european-medicines-agency-budget-2010_et.pdf","el":"https://www.ema.europa.eu/el/documents/report/european-medicines-agency-budget-2010_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/report/european-medicines-agency-budget-2010_fr.pdf","it":"https://www.ema.europa.eu/it/documents/report/european-medicines-agency-budget-2010_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/report/european-medicines-agency-budget-2010_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/report/european-medicines-agency-budget-2010_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/report/european-medicines-agency-budget-2010_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/report/european-medicines-agency-budget-2010_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/report/european-medicines-agency-budget-2010_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/report/european-medicines-agency-budget-2010_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/report/european-medicines-agency-budget-2010_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/report/european-medicines-agency-budget-2010_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/report/european-medicines-agency-budget-2010_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/report/european-medicines-agency-budget-2010_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/report/european-medicines-agency-budget-2010_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/report/european-medicines-agency-budget-2010_sv.pdf"}},
    {"id":"38111","name":"Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-11-29T10:15:00Z","last_updated_date":"2011-11-29T10:15:00Z","reference_number":"EMA/920913/2011","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-concentrate-autologous-bone-marrow-derived-mononuclear-cells-bm-mnc_en.pdf"},
    {"id":"38159","name":"Workshop report - Benefit-risk communication to medicines users: How can regulators best meet the information needs of patients and healthcare professionals?","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T15:45:00Z","last_updated_date":"2014-12-08T15:45:00Z","reference_number":"EMA/581546/2014","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-report-benefit-risk-communication-medicines-users-how-can-regulators-best-meet-information-needs-patients-and-healthcare-professionals_en.pdf"},
    {"id":"38206","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Allogeneic bone-marrow-derived mesenchymal cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-05-21T19:15:00Z","last_updated_date":"2013-05-21T19:15:00Z","reference_number":"EMA/277400/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-bone-marrow-derived-mesenchymal-cells_en.pdf"},
    {"id":"38300","name":"Applications for new human medicines under evaluation by the CHMP: July 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-07-09T14:15:00Z","last_updated_date":"2014-07-09T14:15:00Z","reference_number":"EMA/411381/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2014_en.pdf"},
    {"id":"38307","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous human adipose mesenchymal stromal cells, expanded in culture","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-28T13:00:00Z","last_updated_date":"2016-11-28T13:00:00Z","reference_number":"EMA/761560/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-human-adipose-mesenchymal-stromal-cells-expanded-culture_en.pdf"},
    {"id":"38346","name":"Report analysis on product information - European Medicines Agency Geriatric Medicines Strategy","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-10-17T17:30:00Z","last_updated_date":"2013-10-17T17:30:00Z","reference_number":"EMA/352652/2013","document_url":"https://www.ema.europa.eu/en/documents/report/report-analysis-product-information-european-medicines-agency-geriatric-medicines-strategy_en.pdf"},
    {"id":"38369","name":"Final report on the international active-pharmaceutical-ingredient-inspection pilot programme","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-08-02T17:54:23Z","last_updated_date":"2011-08-02T17:54:23Z","reference_number":"EMA/453741/2011","document_url":"https://www.ema.europa.eu/en/documents/report/final-report-international-active-pharmaceutical-ingredient-inspection-pilot-programme_en.pdf"},
    {"id":"38372","name":"Report of the regulatory workshop on clinical trials designs in neuromyelitis optica spectrum disorders","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-06-16T18:00:00Z","last_updated_date":"2015-06-16T18:00:00Z","reference_number":"EMA/CHMP/SAWP/712652/2014","document_url":"https://www.ema.europa.eu/en/documents/report/report-regulatory-workshop-clinical-trials-designs-neuromyelitis-optica-spectrum-disorders_en.pdf"},
    {"id":"38401","name":"Break-out session 1 report - Modelling and simulation in early development","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-05-08T11:30:00Z","last_updated_date":"2012-05-08T11:30:00Z","reference_number":"EMA/143473/2012","document_url":"https://www.ema.europa.eu/en/documents/report/break-out-session-1-report-modelling-and-simulation-early-development_en.pdf"},
    {"id":"38495","name":"Medicinal products for human use: Monthly figures - March 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-04-19T11:25:00Z","last_updated_date":"2013-04-19T11:25:00Z","reference_number":"EMA/238737/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2013_en.pdf"},
    {"id":"38524","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Genetically modified adenovirus coding for human granulocyte-macrophage colony stimulating factor\n\n(GM-CSF)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2014-02-12T16:30:00Z","last_updated_date":"2014-02-12T16:30:00Z","reference_number":"EMA/75932/2014","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-genetically-modified-adenovirus-coding-human-granulocyte-macrophage-colony-stimulating-factor-gm-csf_en.pdf"},
    {"id":"38528","name":"Seventeenth pandemic pharmacovigilance update","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-05-05T02:00:00Z","last_updated_date":"2010-05-05T02:00:00Z","reference_number":"EMA/281958/2010","document_url":"https://www.ema.europa.eu/en/documents/report/seventeenth-pandemic-pharmacovigilance-update_en.pdf"},
    {"id":"38575","name":"Latest developments in scientific review, legislation and marketing authorisation procedures - Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-03-16T00:09:21Z","last_updated_date":"2009-03-16T00:09:21Z","reference_number":"EMEA/168568/2009","document_url":"https://www.ema.europa.eu/en/documents/report/latest-developments-scientific-review-legislation-and-marketing-authorisation-procedures-report_en.pdf"},
    {"id":"38594","name":"Applications for new human medicines under evaluation by the CHMP: June 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-08T15:19:00Z","last_updated_date":"2018-06-20T19:39:00Z","reference_number":"EMA/382940/2018 Corr. ","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2018_en.pdf"},
    {"id":"38627","name":"Human autologous stromal vascular fraction (SVF) cells and human autologous adipose-derived mesenchymal stem cells (ADSC) cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T13:00:00Z","last_updated_date":"2018-02-13T10:12:00Z","reference_number":"EMA/298458/2016","document_url":"https://www.ema.europa.eu/en/documents/report/human-autologous-stromal-vascular-fraction-svf-cells-and-human-autologous-adipose-derived-mesenchymal-stem-cells-adsc-cells_en.pdf"},
    {"id":"38632","name":"Medicinal products for human use: Monthly figures - October 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-11-18T15:06:00Z","last_updated_date":"2013-11-18T15:06:00Z","reference_number":"EMA/704411/2013","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2013_en.pdf"},
    {"id":"38716","name":"Scientific recommendation on classification of advanced therapy medicinal products: human amniotic membrane mesenchymal stem cells as a sheet","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T13:00:00Z","last_updated_date":"2016-04-12T13:00:00Z","reference_number":"EMA/241006/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-amniotic-membrane-mesenchymal-stem-cells-sheet_en.pdf"},
    {"id":"38776","name":"Report from the Workshop European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) test of system data collection by species - experiences","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-04-10T02:00:00Z","last_updated_date":"2015-04-10T02:00:00Z","reference_number":"EMA/128656/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-european-surveillance-veterinary-antimicrobial-consumption-esvac-test-system-data-collection-species-experiences_en.pdf"},
    {"id":"38811","name":"Report on the second stakeholder forum on the implementation of the new pharmacovigilance legislation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2011-06-24T22:06:12Z","last_updated_date":"2011-06-24T22:06:12Z","reference_number":"EMA/486912/2011","document_url":"https://www.ema.europa.eu/en/documents/report/report-second-stakeholder-forum-implementation-new-pharmacovigilance-legislation_en.pdf"},
    {"id":"38905","name":"Workshop report - Joint European Medicines Agency / European Directorate for the Quality of Medicines and Healthcare workshop on characterisation of new clotting-factor concentrates (factor VIII and factor IX) with respe...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-07-11T14:30:00Z","last_updated_date":"2014-07-11T14:30:00Z","reference_number":"EMA/135928/2014","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-report-joint-european-medicines-agency-european-directorate-quality-medicines-and-healthcare-workshop-characterisation-new-clotting-factor-concentrates-factor-viii-and-factor-ix-respe_en.pdf"},
    {"id":"38950","name":"Report on ‘Action plan for herbal medicines 2010-2011’","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2012-06-13T18:15:00Z","last_updated_date":"2012-06-13T18:15:00Z","reference_number":"EMA/HMPC/45679/2012","document_url":"https://www.ema.europa.eu/en/documents/report/report-action-plan-herbal-medicines-2010-2011_en.pdf"},
    {"id":"38983","name":"Scientific recommendation on classification of advanced therapy medicinal products: mesenchymal stem cells isolated from umbilical cord suspended in autologous platelet rich plasma","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-12T17:00:00Z","last_updated_date":"2016-04-12T17:00:00Z","reference_number":"EMA/240990/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-mesenchymal-stem-cells-isolated-umbilical-cord-suspended-autologous-platelet-rich-plasma_en.pdf"},
    {"id":"38988","name":"Report of the pilot on parallel regulatory-health technology assessment scientific advice","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-31T14:00:00Z","last_updated_date":"2016-03-31T14:00:00Z","reference_number":"EMA/695874/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-pilot-parallel-regulatory-health-technology-assessment-scientific-advice_en.pdf"},
    {"id":"39078","name":"Extract from the Communication Paper of the Gene Therapy Discussion Group Meeting (GTDG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-02-02T00:09:21Z","last_updated_date":"2008-02-02T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/extract-communication-paper-gene-therapy-discussion-group-meeting-gtdg_en.pdf"},
    {"id":"39234","name":"Report on the expert workshop on setting specifications for biotech products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-03-09T13:00:00Z","last_updated_date":"2012-03-09T13:00:00Z","reference_number":"EMA/CHMP/BWP/30584/2012","document_url":"https://www.ema.europa.eu/en/documents/report/report-expert-workshop-setting-specifications-biotech-products_en.pdf"},
    {"id":"39281","name":"Report Information Session on Anthroposophic Medicine EMEA, London 6 March 2008","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-05-20T02:00:00Z","last_updated_date":"2008-05-20T02:00:00Z","reference_number":"EMEA/147565/2008","document_url":"https://www.ema.europa.eu/en/documents/report/report-information-session-anthroposophic-medicine-emea-london-6-march-2008_en.pdf"},
    {"id":"39377","name":"Applications for new human medicines under evaluation by the CHMP: June  2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-06-08T12:45:00Z","last_updated_date":"2017-06-08T12:45:00Z","reference_number":"EMA/352726/2017","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2017_en.pdf"},
    {"id":"39456","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human mesenchymal stem cells derived from Wharton’s jelly tissue of umbilical cord (cerebral palsy)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2015-08-26T12:30:00Z","last_updated_date":"2015-10-30T11:30:00Z","reference_number":"EMA/561937/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-mesenchymal-stem-cells-derived-whartons-jelly-tissue-umbilical-cord-cerebral-palsy_en.pdf"},
    {"id":"39502","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Autologous human mesenchymal stem cells present in bone marrow cells suspension","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:59:00Z","last_updated_date":"2018-01-03T14:59:00Z","reference_number":"EMA/699041/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-human-mesenchymal-stem-cells-present-bone-marrow-cells-suspension_en.pdf"},
    {"id":"39693","name":"Report on multiple sclerosis registries","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-23T19:10:00Z","reference_number":"EMA/548474/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-multiple-sclerosis-registries_en.pdf"},
    {"id":"39711","name":"Scientific recommendation on classification of advanced\n\ntherapy medicinal products: Allogeneic mesenchymal precursor cells (MPCs)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-03-08T13:30:00Z","last_updated_date":"2013-03-08T13:30:00Z","reference_number":"EMA/91034/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-mesenchymal-precursor-cells-mpcs_en.pdf"},
    {"id":"39718","name":"Report on cystic fibrosis registries","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-23T18:00:00Z","reference_number":"EMA/510601/2017","document_url":"https://www.ema.europa.eu/en/documents/report/report-cystic-fibrosis-registries_en.pdf"},
    {"id":"39756","name":"Monthly Report - Pharmacovigilance Working Party (PHVWP) November 2009 plenary meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-11-26T00:09:21Z","last_updated_date":"2009-11-26T00:09:21Z","reference_number":"EMEA/720256/2009","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-pharmacovigilance-working-party-phvwp-november-2009-plenary-meeting_en.pdf"},
    {"id":"39776","name":"Medicinal products for human use: Monthly figures - January 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-02-08T01:00:00Z","last_updated_date":"2010-02-08T01:00:00Z","reference_number":"EMA/65642/2010","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2010_en.pdf"},
    {"id":"39888","name":"Cyclodextrins used as excipients - Report published in support of the ‘Questions and answers on cyclodextrins used as excipients in medicinal products for human use’","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/333892/2013","document_url":"https://www.ema.europa.eu/en/documents/report/cyclodextrins-used-excipients-report-published-support-questions-and-answers-cyclodextrins-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"39901","name":"Hearing AESGP during MLWP May 2010 meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/HMPC/300059/2010","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-aesgp-during-mlwp-may-2010-meeting_en.pdf"},
    {"id":"39953","name":"Scientific recommendation on classification of advanced therapy medicinal products: autologous engineered anti-CD19 Chimeric Antigen Receptor (CAR+) T-cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-03-22T12:00:00Z","last_updated_date":"2016-03-22T12:00:00Z","reference_number":"EMA/204251/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-engineered-anti-cd19-chimeric-antigen-receptor-car-t-cells_en.pdf"},
    {"id":"39987","name":"Medicinal products for human use: Monthly figures - August 2010","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-09-20T02:00:00Z","last_updated_date":"2010-09-20T02:00:00Z","reference_number":"EMA/555480/2010","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2010_en.pdf"},
    {"id":"40039","name":"Applications for new human medicines under evaluation by the CHMP: September 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-09-06T11:57:00Z","last_updated_date":"2013-09-06T11:57:00Z","reference_number":"EMA/544684/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2013_en.pdf"},
    {"id":"40052","name":"European Court of Auditors final report on the annual accounts of the European Medicines Agency for the financial year 2008","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2009-11-24T00:09:21Z","last_updated_date":"2009-11-24T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-court-auditors-final-report-annual-accounts-european-medicines-agency-financial-year-2008_en.pdf"},
    {"id":"40078","name":"Applications for new human medicines under evaluation by the CHMP: August 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-08-03T16:00:00Z","last_updated_date":"2012-08-03T16:00:00Z","reference_number":"EMA/507407/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2012_en.pdf"},
    {"id":"40111","name":"Scientific recommendation on classification of advanced-therapy medicinal products: Allogenic and autologous haptenised and irradiated cells and corresponding cell lysates derived from the tumour mass of patients diagnos...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-10-22T14:15:00Z","last_updated_date":"2012-10-22T14:15:00Z","reference_number":"EMA/498937/2012","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogenic-and-autologous-haptenised-and-irradiated-cells-and-corresponding-cell-lysates-derived-tumour-mass-patients_en.pdf"},
    {"id":"40120","name":"Benefit-risk methodology project: Work package 2 report: Applicability of current tools and processes for regulatory benefit-risk assessment","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2010-10-13T18:57:29Z","last_updated_date":"2010-10-13T18:57:29Z","reference_number":"EMA/549682/2010","document_url":"https://www.ema.europa.eu/en/documents/report/benefit-risk-methodology-project-work-package-2-report-applicability-current-tools-and-processes-regulatory-benefit-risk-assessment_en.pdf"},
    {"id":"40155","name":"Medicinal products for human use: monthly figures - March 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-04-16T15:31:00Z","last_updated_date":"2018-04-16T15:31:00Z","reference_number":"EMA/229858/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2018_en.pdf"},
    {"id":"40457","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human dermal fibroblasts cultured on bioresorbable polyglactin mesh","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-11-08T10:45:00Z","last_updated_date":"2013-11-08T10:45:00Z","reference_number":"EMA/659840/2013","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-dermal-fibroblasts-cultured-bioresorbable-polyglactin-mesh_en.pdf"},
    {"id":"40556","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human autologous adipose-derived stromal/stem Cells (ADSCs)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-08-18T13:00:00Z","last_updated_date":"2017-08-18T13:00:00Z","reference_number":"EMA/462732/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-autologous-adipose-derived-stromalstem-cells-adscs_en.pdf"},
    {"id":"40886","name":"CVMP strategy on antimicrobials 2011-2015","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2011-07-25T03:00:00Z","last_updated_date":"2011-07-25T03:00:00Z","reference_number":"EMA/CVMP/287420/2010","document_url":"https://www.ema.europa.eu/en/documents/report/cvmp-strategy-antimicrobials-2011-2015_en.pdf"},
    {"id":"40916","name":"Annual accounts: Financial year 2006","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2007-11-01T00:09:21Z","last_updated_date":"2007-11-01T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2006_en.pdf"},
    {"id":"40953","name":"Applications for new human medicines under evaluation by the CHMP: September 2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-09-12T13:00:00Z","last_updated_date":"2014-09-12T13:00:00Z","reference_number":"EMA/545907/2014","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2014_en.pdf"},
    {"id":"40988","name":"Adaptive pathways to patients: report on the initial experience of the pilot project","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-12-22T13:00:00Z","last_updated_date":"2014-12-22T13:00:00Z","reference_number":"EMA/758619/2014","document_url":"https://www.ema.europa.eu/en/documents/report/adaptive-pathways-patients-report-initial-experience-pilot-project_en.pdf"},
    {"id":"40995","name":"Focus group on implementation of CVMP guideline on environmental impact assessment for veterinary medicinal products in support of the VICH guidelines GL6 (Phase I) and GL38 (Phase II) - Summary of the meeting held on 23...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-11-17T01:00:00Z","last_updated_date":"2008-11-17T01:00:00Z","reference_number":"EMEA/CVMP/ERA/106566/2008","document_url":"https://www.ema.europa.eu/en/documents/report/focus-group-implementation-cvmp-guideline-environmental-impact-assessment-veterinary-medicinal-products-support-vich-guidelines-gl6-phase-i-and-gl38-phase-ii-summary-meeting-held-23_en.pdf"},
    {"id":"41067","name":"FP7 and off patent medicines developed for children - Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2007-06-06T02:09:21Z","last_updated_date":"2007-06-06T02:09:21Z","reference_number":"EMEA/254655/2007","document_url":"https://www.ema.europa.eu/en/documents/report/fp7-and-patent-medicines-developed-children-report_en.pdf"},
    {"id":"41111","name":"Report from the European Medicines Agency/European Federation of Pharmaceutical Industries and Associations workshop on the importance of dose finding and dose selection for the successful development, licensing and life...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-04-17T12:00:00Z","last_updated_date":"2015-04-17T12:00:00Z","reference_number":"EMA/117491/2015","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agencyeuropean-federation-pharmaceutical-industries-and-associations-workshop-importance-dose-finding-and-dose-selection-successful-development-licensing-and-life_en.pdf"},
    {"id":"41118","name":"CHMP statistics: May 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T02:00:00Z","last_updated_date":"2018-06-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-may-2018_en.pdf"},
    {"id":"41158","name":"Meeting report from the second ENCePP meeting with Centres at the EMEA (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2008-10-03T02:00:00Z","last_updated_date":"2008-10-03T02:00:00Z","reference_number":"EMEA/299086/2008","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-second-encepp-meeting-centres-emea-european-network-centres-pharmacoepidemiology-and-pharmacovigilance_en.pdf"},
    {"id":"41237","name":"Applications for new human medicines under evaluation by the CHMP: August 2013","type":"report","status":"unknown","consultation_date":"","first_published_date":"2013-08-01T13:30:00Z","last_updated_date":"2013-08-01T13:30:00Z","reference_number":"EMA/472391/2013","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2013_en.pdf"},
    {"id":"41245","name":"Report of the joint HMA/EMEA meeting on promoting prudent and responsible use of antimicrobials in veterinary medicine","type":"report","status":"unknown","consultation_date":"","first_published_date":"2009-05-19T02:09:21Z","last_updated_date":"2009-05-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-joint-hmaemea-meeting-promoting-prudent-and-responsible-use-antimicrobials-veterinary-medicine_en.pdf"},
    {"id":"41320","name":"Ex vivo expanded autologous Epstein-Barr Virus specific T-cells derived from peripheral blood mononuclear cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-05-04T13:00:00Z","last_updated_date":"2016-05-04T13:00:00Z","reference_number":"EMA/291907/2016","document_url":"https://www.ema.europa.eu/en/documents/report/ex-vivo-expanded-autologous-epstein-barr-virus-specific-t-cells-derived-peripheral-blood-mononuclear-cells_en.pdf"},
    {"id":"41341","name":"EudraVigilance status report 2009 (veterinary)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2014-10-08T15:00:00Z","reference_number":"EMA/13787/2009","document_url":"https://www.ema.europa.eu/en/documents/report/eudravigilance-status-report-2009-veterinary_en.pdf"},
    {"id":"41344","name":"Human autologous stromal vascular fraction cells and human autologous adipose-derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-15T16:33:00Z","last_updated_date":"2016-11-15T16:33:00Z","reference_number":"EMA/693827/2016","document_url":"https://www.ema.europa.eu/en/documents/report/human-autologous-stromal-vascular-fraction-cells-and-human-autologous-adipose-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"41434","name":"Pharmacovigilance Working Party (PhVWP) - Monthly report on safety concerns, guidelines and general matters - January 2012","type":"report","status":"unknown","consultation_date":"","first_published_date":"2012-01-26T16:20:00Z","last_updated_date":"2012-01-26T16:20:00Z","reference_number":"EMA/CHMP/PhVWP/51794/2012","document_url":"https://www.ema.europa.eu/en/documents/report/pharmacovigilance-working-party-phvwp-monthly-report-safety-concerns-guidelines-and-general-matters-january-2012_en.pdf"},
    {"id":"41471","name":"CHMP statistics: January 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T01:00:00Z","last_updated_date":"2018-01-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-january-2018_en.pdf"},
    {"id":"41488","name":"CHMP statistics: May 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-05-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-may-2017_en.pdf"},
    {"id":"41603","name":"Applications for new human medicines under evaluation by the CHMP: February 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-13T15:37:00Z","last_updated_date":"2017-02-13T15:37:00Z","reference_number":"WC500221554","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2017_en.pdf"},
    {"id":"41678","name":"Medicinal products for human use: monthly figures - September 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-10-27T13:25:00Z","last_updated_date":"2016-10-27T13:25:00Z","reference_number":"EMA/668414/2016","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2016_en.pdf"},
    {"id":"41790","name":"Annual accounts: Financial year 2015","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2016-06-29T17:42:00Z","last_updated_date":"2016-06-29T17:42:00Z","reference_number":"EMA/281783/2016","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2015_en.pdf"},
    {"id":"41801","name":"CHMP statistics: December 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T01:00:00Z","last_updated_date":"2017-12-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-december-2017_en.pdf"},
    {"id":"41862","name":"Questions and answers on the European Medicines Agency policy on publication of clinical data for medicinal products for human use","type":"report","status":"unknown","consultation_date":"","first_published_date":"2014-10-02T19:00:00Z","last_updated_date":"2019-04-30T10:30:00Z","reference_number":"EMA/357536/2014 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/report/questions-and-answers-european-medicines-agency-policy-publication-clinical-data-medicinal-products-human-use_en.pdf"},
    {"id":"41882","name":"Workshop report - Best expertise vs conflicts of interests: Striking the right balance","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2013-10-02T17:15:00Z","last_updated_date":"2013-10-02T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-report-best-expertise-vs-conflicts-interests-striking-right-balance_en.pdf"},
    {"id":"41900","name":"Scientific recommendation on classification of advanced therapy medicinal products: Genetically engineered AAV8 that lacks all of the viral protein-coding sequences and encodes a human MTM1 complementary DNA","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-02-28T14:45:00Z","last_updated_date":"2017-02-28T14:45:00Z","reference_number":"EMA/126546/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-genetically-engineered-aav8-lacks-all-viral-protein-coding-sequences-and-encodes-human-mtm1-complementary-dna_en.pdf"},
    {"id":"41902","name":"Scientific recommendation on classification of advanced therapy medicinal products: Plasmid encoding a mutation-inactivated E7-E6 fusion protein from Human Papillomavirus 16 linked to the human chemokine hMIP-1a via a di...","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-03-02T17:00:00Z","last_updated_date":"2015-03-02T17:00:00Z","reference_number":"EMA/107652/2015","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-plasmid-encoding-mutation-inactivated-e7-e6-fusion-protein-human-papillomavirus-16-linked-human-chemokine-hmip-1a-di_en.pdf"}    {"id":"41914","name":"Scientific recommendation on classification of advanced therapy medicinal products: Freshly isolated autologous CD34+","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-01-03T14:41:00Z","last_updated_date":"2018-01-03T14:41:00Z","reference_number":"EMA/751584/2017","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-freshly-isolated-autologous-cd34_en.pdf"},
    {"id":"42009","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous skin cell suspension","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-11-28T13:00:00Z","last_updated_date":"2016-11-28T13:00:00Z","reference_number":"EMA/761604/2016","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-skin-cell-suspension_en.pdf"},
    {"id":"42019","name":"Applications for new human medicines under evaluation by the CHMP: September 2015","type":"report","status":"unknown","consultation_date":"","first_published_date":"2015-09-10T17:30:00Z","last_updated_date":"2015-09-10T17:30:00Z","reference_number":"EMA/599965/2015","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2015_en.pdf"},
    {"id":"42022","name":"Annual activity report 2016","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2017-07-03T15:00:00Z","last_updated_date":"2017-07-03T15:00:00Z","reference_number":"EMA/141860/2017","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2016_en.pdf"},
    {"id":"42025","name":"Patients, consumers, healthcare professionals key figures - 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2017-07-05T12:30:00Z","last_updated_date":"2018-04-18T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/patients-consumers-healthcare-professionals-key-figures-2017_en.pdf"},
    {"id":"42030","name":"Medicinal products for human use: monthly figures - March 2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2016-04-27T11:05:00Z","last_updated_date":"2016-04-27T11:05:00Z","reference_number":"EMA/280157/2016","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2016_en.pdf"},
    {"id":"42044","name":"CHMP statistics: September 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-september-2018_en.pdf"},
    {"id":"42164","name":"Report of the EMA expert meeting on genome editing technologies used in medicinal product development","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-10-01T18:26:00Z","last_updated_date":"2018-10-01T18:26:00Z","reference_number":"EMA/47066/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-ema-expert-meeting-genome-editing-technologies-used-medicinal-product-development_en.pdf"},
    {"id":"42168","name":"European Medicines Agency and European Commission (DG Health and Food Safety) action plan on paediatrics","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-10-02T11:18:00Z","last_updated_date":"2020-12-11T15:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-and-european-commission-dg-health-and-food-safety-action-plan-paediatrics_en.pdf"},
    {"id":"42182","name":"Applications for new human medicines under evaluation by the CHMP: October 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-10-03T10:43:00Z","last_updated_date":"2018-10-18T10:43:00Z","reference_number":"EMA/674542/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2018_en.pdf"},
    {"id":"42193","name":"Report on Haemophilia Registries Workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-10-04T14:10:00Z","last_updated_date":"2018-10-04T14:10:00Z","reference_number":"EMA/487643/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-haemophilia-registries-workshop_en.pdf"},
    {"id":"42234","name":"A common data model for Europe - Why? Which? How? - Workshop report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-10-08T17:21:00Z","last_updated_date":"2018-10-08T17:21:00Z","reference_number":"EMA/614680/2018","document_url":"https://www.ema.europa.eu/en/documents/report/common-data-model-europe-why-which-how-workshop-report_en.pdf"},
    {"id":"42342","name":"Sales of veterinary antimicrobial agents in 30 European countries in 2016 - Trends from 2010 to 2016 Eighth ESVAC report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-10-15T14:40:00Z","last_updated_date":"2018-10-15T14:40:00Z","reference_number":"EMA/275982/2018","document_url":"https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-30-european-countries-2016-trends-2010-2016-eighth-esvac-report_en.pdf"},
    {"id":"42366","name":"Summary of transfers of appropriations in budget 2018 - Management Board meeting of 4 October 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-10-18T14:58:00Z","last_updated_date":"2018-10-18T14:58:00Z","reference_number":"EMA/MB/584626/2018","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2018-management-board-meeting-4-october-2018_en.pdf"},
    {"id":"42368","name":"Medicinal products for human use: monthly figures - September 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-10-18T14:32:00Z","last_updated_date":"2018-10-18T14:32:00Z","reference_number":"EMA/710680/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2018_en.pdf"},
    {"id":"42381","name":"CHMP statistics: October 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-10-19T13:45:00Z","last_updated_date":"2018-10-19T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/chmp-statistics-october-2018_en.pdf"},
    {"id":"42613","name":"Applications for new human medicines under evaluation by the CHMP: November 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T14:51:00Z","last_updated_date":"2018-11-09T14:51:00Z","reference_number":"EMA/779134/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2018_en.pdf"},
    {"id":"42616","name":"Report - First EMA workshop on non-animal approaches in support of medicinal product development – challenges and opportunities for use of micro-physiological systems","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-11-09T14:58:00Z","last_updated_date":"2018-11-09T14:58:00Z","reference_number":"EMA/CHMP/SWP/250438/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-first-ema-workshop-non-animal-approaches-support-medicinal-product-development-challenges-and-opportunities-use-micro-physiological-systems_en.pdf"},
    {"id":"42663","name":"Report of Industry Stakeholder meeting on Brexit and operation of the centralised procedure for human medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-11-13T15:49:00Z","last_updated_date":"2018-11-13T15:49:00Z","reference_number":"EMA/694143/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-industry-stakeholder-meeting-brexit-and-operation-centralised-procedure-human-medicinal-products_en.pdf-0"},
    {"id":"42694","name":"Medicinal products for human use: monthly figures - October 2018","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-11-15T15:08:00Z","last_updated_date":"2018-11-15T15:08:00Z","reference_number":"EMA/790034/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2018_en.pdf"},
    {"id":"42847","name":"Annual report of the Good Clinical Practice Inspectors Working Group 2017","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-11-27T18:29:00Z","last_updated_date":"2018-11-27T18:29:00Z","reference_number":"EMA/INS/GCP/779632/2017","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-clinical-practice-inspectors-working-group-2017_en.pdf"},
    {"id":"42919","name":"Report - Data anonymisation: a key enabler for clinical data sharing","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-04T16:12:00Z","last_updated_date":"2018-12-04T16:12:00Z","reference_number":"EMA/796532/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-data-anonymisation-key-enabler-clinical-data-sharing_en.pdf"},
    {"id":"42937","name":"Organ donor derived CD34+ haematopoietic stem cells and a defined dose of donor-derived CD3+ T-cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-05T17:38:00Z","last_updated_date":"2018-12-05T17:38:00Z","reference_number":"EMA/751638/2018","document_url":"https://www.ema.europa.eu/en/documents/report/organ-donor-derived-cd34-haematopoietic-stem-cells-and-defined-dose-donor-derived-cd3-t-cells_en.pdf"},
    {"id":"42938","name":"Recombinant adeno-associated viral vector serotype 9 (AAV9) encoding a short hairpin RNA and a codon-optimised wildtype protein","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-05T17:40:00Z","last_updated_date":"2018-12-05T17:40:00Z","reference_number":"EMA/751348/2018","document_url":"https://www.ema.europa.eu/en/documents/report/recombinant-adeno-associated-viral-vector-serotype-9-aav9-encoding-short-hairpin-rna-and-codon-optimised-wildtype-protein_en.pdf"},
    {"id":"42939","name":"Stromal vascular fraction","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-05T17:44:00Z","last_updated_date":"2018-12-05T17:44:00Z","reference_number":"EMA/751348/2018","document_url":"https://www.ema.europa.eu/en/documents/report/stromal-vascular-fraction_en.pdf"},
    {"id":"42942","name":"Medicinal products for human use: monthly figures - November 2018","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-12-06T11:30:00Z","last_updated_date":"2018-12-06T11:30:00Z","reference_number":"EMA/854701/2018","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2018_en.pdf"},
    {"id":"42948","name":"Applications for new human medicines under evaluation by the CHMP: December 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-06T16:22:00Z","last_updated_date":"2018-12-06T16:22:00Z","reference_number":"EMA/847849/2018","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2018_en.pdf"},
    {"id":"43001","name":"Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated virus (AAV) vector encoding genes from an algae channel rhodopsin","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T11:30:00Z","last_updated_date":"2018-12-12T11:30:00Z","reference_number":"EMA/576002/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adeno-associated-virus-aav-vector-encoding-genes-algae-channel-rhodopsin_en.pdf"},
    {"id":"43002","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous ex vivo expanded regulatory T lymphocytes with the cell marker profile of CD3+, CD4+, CD25high, CD127-, FoxP3+","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T11:17:00Z","last_updated_date":"2018-12-12T11:17:00Z","reference_number":"EMA/576036/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-ex-vivo-expanded-regulatory-t-lymphocytes-cell-marker-profile-cd3-cd4-cd25high-cd127-foxp3_en.pdf"},
    {"id":"43003","name":"Scientific recommendation on classification of advanced therapy medicinal products: Collagenase enzyme from Clostridium histolyticum","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T11:19:00Z","last_updated_date":"2018-12-12T11:19:00Z","reference_number":"EMA/576408/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-collagenase-enzyme-clostridium-histolyticum_en.pdf"},
    {"id":"43004","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous concentrated bone marrow","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T11:21:00Z","last_updated_date":"2018-12-12T11:21:00Z","reference_number":"EMA/576422/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-concentrated-bone-marrow_en.pdf"},
    {"id":"43005","name":"Scientific recommendation on classification of advanced therapy medicinal products: Live attenuated Listeria monocytogenes transfected with plasmids encoding HPV fusion protein","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T11:23:00Z","last_updated_date":"2018-12-12T11:23:00Z","reference_number":"EMA/576477/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-live-attenuated-listeria-monocytogenes-transfected-plasmids-encoding-hpv-fusion-protein_en.pdf"},
    {"id":"43006","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous fibroblasts expanded in vitro","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T11:25:00Z","last_updated_date":"2018-12-12T11:25:00Z","reference_number":"EMA/576506/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-fibroblasts-expanded-vitro_en.pdf"},
    {"id":"43007","name":"Scientific recommendation on classification of advanced therapy medicinal products: Four independent DNA plasmid vectors encoding HBV antigens and human interleukin-12","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T11:27:00Z","last_updated_date":"2018-12-12T11:27:00Z","reference_number":"EMA/576519/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-four-independent-dna-plasmid-vectors-encoding-hbv-antigens-and-human-interleukin-12_en.pdf"},
    {"id":"43023","name":"Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T17:47:00Z","last_updated_date":"2018-12-12T17:47:00Z","reference_number":"EMA/570147/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-homogenate-antlerogenic-stem-cells_en.pdf"},
    {"id":"43024","name":"Scientific recommendation on classification of advanced therapy medicinal products: Non-replicating recombinant adeno-associated virus carrying a fragment of the Channelrhodopsin-2 (ChR2) protein","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T17:49:00Z","last_updated_date":"2018-12-12T17:49:00Z","reference_number":"EMA/608844/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-non-replicating-recombinant-adeno-associated-virus-carrying-fragment-channelrhodopsin-2-chr2-protein_en.pdf"},
    {"id":"43025","name":"Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T17:51:00Z","last_updated_date":"2018-12-12T17:51:00Z","reference_number":"EMA/570248/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-homogenate-antlerogenic-stem-cells_en.pdf-0"},
    {"id":"43026","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T17:52:00Z","last_updated_date":"2018-12-12T17:52:00Z","reference_number":"EMA/570349/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-anti-bcma-b-cell-maturation-antigen-chimeric-antigen-receptor-car-t-cells_en.pdf"},
    {"id":"43027","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous suspension of blood-derived endothelial and hematopoietic stem/progenitor cells","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-12-12T17:54:00Z","last_updated_date":"2018-12-12T17:54:00Z","reference_number":"EMA/608871/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-suspension-blood-derived-endothelial-and-hematopoietic-stemprogenitor-cells_en.pdf"},
    {"id":"43028","name":"Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of defective myoblasts from a Duchenne Muscular Dystrophy patient with normal myoblasts","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T17:55:00Z","last_updated_date":"2018-12-12T17:55:00Z","reference_number":"EMA/570419/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-dystrophin-expressing-chimeric-cells-obtained-ex-vivo-fusion-defective-myoblasts-duchenne-muscular-dystrophy-patient-normal_en.pdf"},
    {"id":"43029","name":"Scientific recommendation on classification of advanced therapy medicinal products: Four in vitro transcribed mRNA molecules each encoding one tumour antigen","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-12-12T17:57:00Z","last_updated_date":"2018-12-12T17:57:00Z","reference_number":"EMA/608907/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-four-vitro-transcribed-mrna-molecules-each-encoding-one-tumour-antigen_en.pdf"},
    {"id":"43030","name":"Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-12-12T18:09:00Z","last_updated_date":"2018-12-12T18:09:00Z","reference_number":"EMA/608944/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vitro-transcribed-patient-specific-mrna-molecule-encoding-neo-epitopes-are-specifically-derived-tumour-tissue_en.pdf"},
    {"id":"43031","name":"Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T18:16:00Z","last_updated_date":"2018-12-12T18:16:00Z","reference_number":"EMA/570450/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-dystrophin-expressing-chimeric-cells-obtained-ex-vivo-fusion-two-normal-allogeneic-human-myoblasts_en.pdf"},
    {"id":"43032","name":"Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T18:17:00Z","last_updated_date":"2018-12-12T18:17:00Z","reference_number":"EMA/570532/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-codon-optimized-human-ornithine-transcarbamylase-messenger-ribonucleic-acid_en.pdf"},
    {"id":"43033","name":"Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T18:19:00Z","last_updated_date":"2018-12-12T18:19:00Z","reference_number":"EMA/570585/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-viral-vector-capsid-containing-human-iduronate-2-sulfatase-hids-expression-cassette_en.pdf"},
    {"id":"43034","name":"Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-12T18:50:00Z","last_updated_date":"2018-12-12T18:50:00Z","reference_number":"EMA/570248/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-homogenate-antlerogenic-stem-cells-tissue-engineered-product_en.pdf"},
    {"id":"43057","name":"Report on the EMA Management Board delegation visit to the future EMA premises","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T11:58:00Z","last_updated_date":"2018-12-14T11:58:00Z","reference_number":"EMA/8050171/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-ema-management-board-delegation-visit-future-ema-premises_en.pdf"},
    {"id":"43092","name":"Final Guideline on Active Substance Master File Procedure - Revision 4","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T16:44:00Z","last_updated_date":"2018-12-14T16:44:00Z","reference_number":"CHMP/QWP/227/02 Rev 4, EMEA/CVMP/134/02 Rev 4 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/final-guideline-active-substance-master-file-procedure-revision-4_en.pdf"},
    {"id":"43096","name":"Summary of transfers of appropriations in budget 2018 - Management Board meeting of 12-13 December 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T16:26:00Z","last_updated_date":"2018-12-14T16:26:00Z","reference_number":"EMA/MB/832177/2018","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2018-management-board-meeting-12-13-december-2018_en.pdf"},
    {"id":"43122","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T14:50:00Z","last_updated_date":"2018-12-18T14:50:00Z","reference_number":"EMA/574929/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogenic-bone-marrow-derived-mesenchymal-stem-cells-expanded-vitro_en.pdf"},
    {"id":"43123","name":"Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T15:01:00Z","last_updated_date":"2018-12-18T15:01:00Z","reference_number":"EMA/575002/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-concentrate-autologous-bone-marrow-derived-mononuclear-cells-bm-mnc_en.pdf-0"},
    {"id":"43124","name":"Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T15:11:00Z","last_updated_date":"2018-12-18T15:11:00Z","reference_number":"EMA/575038/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-live-attenuated-double-deleted-listeria-monocytogenes-expressing-human-mesothelin_en.pdf"},
    {"id":"43126","name":"Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T15:19:00Z","last_updated_date":"2018-12-18T15:19:00Z","reference_number":"EMA/575136/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-live-attenuated-double-deleted-listeria-monocytogenes-expressing-prostate-antigens_en.pdf"},
    {"id":"43127","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T15:25:00Z","last_updated_date":"2018-12-18T15:25:00Z","reference_number":"EMA/575213/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-cultured-fibroblasts_en.pdf"},
    {"id":"43128","name":"Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T15:35:00Z","last_updated_date":"2018-12-18T15:35:00Z","reference_number":"EMA/575232/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-extracellular-matrix-isolated-adipose-tissue_en.pdf"},
    {"id":"43129","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T15:56:00Z","last_updated_date":"2018-12-18T15:56:00Z","reference_number":"EMA/575260/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-cultured-adipose-derived-mesenchymal-stem-cells_en.pdf"},
    {"id":"43135","name":"Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T16:08:00Z","last_updated_date":"2018-12-18T16:08:00Z","reference_number":"EMA/575295/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vitro-cultured-autologous-chondrocytes_en.pdf"},
    {"id":"43136","name":"Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T16:13:00Z","last_updated_date":"2018-12-18T16:13:00Z","reference_number":"EMA/575365/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-viable-human-autologous-skin-fibroblasts_en.pdf"},
    {"id":"43137","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T16:40:00Z","last_updated_date":"2018-12-18T16:40:00Z","reference_number":"EMA/575478/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-autologous-keratinocytes_en.pdf-0"},
    {"id":"43138","name":"Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T16:45:00Z","last_updated_date":"2018-12-18T16:45:00Z","reference_number":"EMA/575590/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vitro-cultured-autologous-muscle-derived-stem-cells_en.pdf"},
    {"id":"43139","name":"Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T16:49:00Z","last_updated_date":"2018-12-18T16:49:00Z","reference_number":"EMA/575769/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vitro-cultured-autologous-melanocytes_en.pdf"},
    {"id":"43140","name":"Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-12-18T16:54:00Z","last_updated_date":"2018-12-18T16:54:00Z","reference_number":"EMA/575867/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-mesenchymal-stem-cells-isolated-autologous-bone-marrow_en.pdf"},
    {"id":"43156","name":"Recommendations on eligibility to PRIME scheme -  Adopted at the CHMP meeting of 10-13 December 2018","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T12:50:00Z","last_updated_date":"2018-12-19T12:50:00Z","reference_number":"EMA/758070/2018","document_url":"https://www.ema.europa.eu/en/documents/report/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-10-13-december-2018_en.pdf"},
    {"id":"43209","name":"Veterinary medicines highlights 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-01-04T12:00:00Z","last_updated_date":"2019-01-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/veterinary-medicines-highlights-2018_en.pdf"},
    {"id":"43210","name":"Human medicines highlights 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-01-04T10:00:00Z","last_updated_date":"2019-01-04T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2018_en.pdf"},
    {"id":"43220","name":"Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T09:46:00Z","last_updated_date":"2019-01-07T09:46:00Z","reference_number":"EMA/814866/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-virus-serotype-9-vector-encoding-soluble-lysosomal-enzyme-tpp1_en.pdf"},
    {"id":"43221","name":"Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T09:46:00Z","last_updated_date":"2019-01-07T09:46:00Z","reference_number":"EMA/814824/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-codon-optimized-mrna-will-be-translated-functional-human-cystic-fibrosis-transmembrane-conductance-regulator-protein-after_en.pdf"},
    {"id":"43222","name":"Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T09:46:00Z","last_updated_date":"2019-01-07T09:46:00Z","reference_number":"EMA/814789/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vitro-cultured-autologous-mesenchymal-stem-cells-isolated-bone-marrow_en.pdf"},
    {"id":"43223","name":"Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T09:46:00Z","last_updated_date":"2019-01-07T09:46:00Z","reference_number":"EMA/814774/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vitro-cultured-autologous-mesenchymal-stem-cells-isolated-bone-marrow_en.pdf-0"},
    {"id":"43224","name":"Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T09:46:00Z","last_updated_date":"2019-01-07T09:46:00Z","reference_number":"EMA/813715/2018","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicines-allogeneic-epstein-barr-virus-specific-cytotoxic-t-lymphocytes_en.pdf"},
    {"id":"43267","name":"European Medicines Agency budget for 2019","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-01-10T09:30:00Z","last_updated_date":"2019-01-10T09:30:00Z","reference_number":"EMA/MB/647697/2018","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2019_en.pdf"},
    {"id":"43349","name":"Applications for new human medicines under evaluation by the CHMP: January 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-01-14T11:17:00Z","last_updated_date":"2019-03-08T14:05:00Z","reference_number":"EMA/909607/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2019_en.pdf"},
    {"id":"43467","name":"Medicinal products for human use: monthly figures - December 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T16:18:00Z","last_updated_date":"2019-01-23T16:18:00Z","reference_number":"EMA/8963/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2018_en.pdf"},
    {"id":"43558","name":"Report - European Medicines Agency (EMA) / Heads of Medicines Agencies (HMA) / European Commission (EC) workshop on electronic product information (ePI)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-01-31T12:08:00Z","last_updated_date":"2019-01-31T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-ema-heads-medicines-agencies-hma-european-commission-ec-workshop-electronic-product-information-epi_en.pdf"},
    {"id":"43628","name":"Highlight report of the fourth industry stakeholder platform on research and development support on 23 November 2018","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-02-05T09:45:00Z","last_updated_date":"2019-02-05T09:45:00Z","reference_number":"EMA/845782/2018","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-fourth-industry-stakeholder-platform-research-and-development-support-23-november-2018_en.pdf"},
    {"id":"43668","name":"Report - Multi-stakeholder workshop with the HMA/EMA task force on availability of authorised medicine","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-02-08T11:00:00Z","last_updated_date":"2019-02-08T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-multi-stakeholder-workshop-hmaema-task-force-availability-authorised-medicine_en.pdf"},
    {"id":"43770","name":"Applications for new human medicines under evaluation by the CHMP: February 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-02-18T10:15:00Z","last_updated_date":"2019-03-08T14:06:00Z","reference_number":"EMA/115443/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2019_en.pdf"},
    {"id":"43883","name":"Hearing with the Association of the European Self-Medication Industry (AESGP) during the HMPC September 2018 meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T08:56:00Z","last_updated_date":"2019-02-25T08:56:00Z","reference_number":"EMA/HMPC/41915/2019","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-aesgp-during-hmpc-september-2018-meeting_en.pdf"},
    {"id":"43909","name":"Medicinal products for human use: monthly figures - January 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-02-26T10:00:00Z","last_updated_date":"2019-02-26T10:00:00Z","reference_number":"EMA/137376/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2019_en.pdf"},
    {"id":"44013","name":"Report on the International Active Pharmaceutical Ingredient Inspection Programme 2011-2016","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-03-12T15:47:00Z","last_updated_date":"2018-03-12T15:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-international-active-pharmaceutical-ingredient-inspection-programme-2011-2016_en.pdf"},
    {"id":"44078","name":"Applications for new human medicines under evaluation by the CHMP: March 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-03-20T15:55:00Z","last_updated_date":"2019-03-20T15:55:00Z","reference_number":"EMA/178810/2019","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2019_en.pdf"},
    {"id":"44094","name":"Minor use or minor species (MUMS)/limited market scheme for veterinary medicinal products - 9th annual report (2018)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-03-22T15:18:00Z","last_updated_date":"2019-03-22T15:18:00Z","reference_number":"EMA/713390/2018","document_url":"https://www.ema.europa.eu/en/documents/report/minor-use-or-minor-species-mumslimited-market-scheme-veterinary-medicinal-products-9th-annual-report-2018_en.pdf"},
    {"id":"44098","name":"Summary of transfers of appropriations in budget 2018 - Management Board meeting of 21 March 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-03-22T16:35:00Z","last_updated_date":"2019-03-22T16:35:00Z","reference_number":"EMA/MB/129665/2019","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2018-management-board-meeting-21-march-2019_en.pdf"},
    {"id":"44115","name":"2018 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission - Reporting period: 1 January to 31 December 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-03-27T10:12:00Z","last_updated_date":"2019-03-27T10:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/2018-annual-report-eudravigilance-european-parliament-council-and-commission-reporting-period-1-january-31-december-2018_en.pdf"},
    {"id":"44124","name":"20 years of sampling and testing of centrally authorised products: 1998 – 2017","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-03-28T10:28:00Z","last_updated_date":"2019-03-28T10:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/20-years-sampling-and-testing-centrally-authorised-products-1998-2017_en.pdf"},
    {"id":"44136","name":"Medicinal products for human use: monthly figures - February 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-03-28T15:45:00Z","last_updated_date":"2019-03-28T15:45:00Z","reference_number":"EMA/188535/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2019_en.pdf"},
    {"id":"44265","name":"Applications for new human medicines under evaluation by the CHMP: April 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-04-15T13:25:00Z","last_updated_date":"2019-04-15T13:25:00Z","reference_number":"EMA/218036/2019","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2019_en.pdf"},
    {"id":"44312","name":"Medicinal products for human use: monthly figures - March 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-04-17T17:33:00Z","last_updated_date":"2019-04-17T17:33:00Z","reference_number":"EMA/233802/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2019_en.pdf"},
    {"id":"44487","name":"Applications for new human medicines under evaluation by the CHMP: May 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-05-13T18:49:00Z","last_updated_date":"2019-05-13T18:49:00Z","reference_number":"EMA/256508/2019","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2019_en.pdf"},
    {"id":"44526","name":"PRAC statistics: May 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-05-17T12:00:00Z","last_updated_date":"2019-05-17T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-may-2019_en.pdf"},
    {"id":"44542","name":"Medicinal products for human use: monthly figures - April 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-05-20T14:08:00Z","last_updated_date":"2019-05-20T14:08:00Z","reference_number":"EMA/277980/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2019_en.pdf"},
    {"id":"44587","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: February 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-05-24T10:04:00Z","last_updated_date":"2019-05-24T10:04:00Z","reference_number":"EMA/199371/2019","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-february-2019_en.pdf"},
    {"id":"44653","name":"Small and medium-sized enterprise (SME) Office annual report 2018","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-06-05T10:19:00Z","last_updated_date":"2020-06-10T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/small-and-medium-sized-enterprise-sme-office-annual-report-2018_en.pdf"},
    {"id":"44706","name":"Applications for new human medicines under evaluation by the CHMP: June 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-06-14T11:11:00Z","last_updated_date":"2019-06-14T11:11:00Z","reference_number":"EMA/313335/2019","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2019_en.pdf"},
    {"id":"44707","name":"PRAC statistics: June 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-06-14T13:53:00Z","last_updated_date":"2019-06-14T13:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-june-2019_en.pdf"},
    {"id":"44710","name":"Final programming document 2019-2021","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-06-14T14:29:00Z","last_updated_date":"2019-06-14T14:29:00Z","reference_number":"EMA/912857/2019","document_url":"https://www.ema.europa.eu/en/documents/report/final-programming-document-2019-2021_en.pdf"},
    {"id":"44780","name":"Report - European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-06-21T09:43:00Z","last_updated_date":"2019-06-21T09:43:00Z","reference_number":"EMA/873574/2019","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-stakeholder-interaction-development-medicinal-products-chronic-non-infectious-liver-diseases-pbc-psc-nash_en.pdf"},
    {"id":"44862","name":"Medicinal products for human use: monthly figures - May 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-06-25T09:48:00Z","last_updated_date":"2019-06-25T09:48:00Z","reference_number":"EMA/353921/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2019_en.pdf"},
    {"id":"44965","name":"Annual accounts: Financial year 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-07-01T10:04:00Z","last_updated_date":"2019-07-01T10:04:00Z","reference_number":"EMA/269015/2019","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2018_en.pdf"},
    {"id":"45050","name":"PRAC statistics: July 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-07-12T12:16:00Z","last_updated_date":"2019-07-12T12:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-july-2019_en.pdf"}    {"id":"45073","name":"Applications for new human medicines under evaluation by the CHMP: July 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-07-17T09:29:00Z","last_updated_date":"2019-07-17T09:29:00Z","reference_number":"EMA/394421/2019","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2019_en.pdf"},
    {"id":"45079","name":"Medicinal products for human use: monthly figures - June 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-07-17T11:41:00Z","last_updated_date":"2019-07-17T11:41:00Z","reference_number":"EMA/401539/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2019_en.pdf"},
    {"id":"45161","name":"Report: Workshop with stakeholders on support to quality development in early access approaches (i.e. PRIME, Breakthrough Therapies)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-07-31T14:00:00Z","last_updated_date":"2019-07-31T14:00:00Z","reference_number":"EMA/CHMP/BWP/812924/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-stakeholders-support-quality-development-early-access-approaches-ie-prime-breakthrough-therapies_en.pdf"},
    {"id":"45247","name":"Applications for new human medicines under evaluation by the CHMP: August 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-08-13T17:37:00Z","last_updated_date":"2019-09-10T13:04:00Z","reference_number":"EMA/450452/2019 corr. ","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2019_en.pdf"},
    {"id":"45260","name":"Medicinal products for human use: monthly figures - July 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-08-16T13:09:00Z","last_updated_date":"2019-08-16T13:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2019_en.pdf"},
    {"id":"45388","name":"PRAC statistics: September 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-09-06T12:00:00Z","last_updated_date":"2019-09-06T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-september-2019_en.pdf"},
    {"id":"45397","name":"Applications for new human medicines under evaluation by the CHMP: September 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-09-09T11:16:00Z","last_updated_date":"2019-09-26T16:05:00Z","reference_number":"EMA/484798/2019 corr. 2","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2019_en.pdf"},
    {"id":"45401","name":"Medicinal products for human use: monthly figures - August 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-09-10T10:20:00Z","last_updated_date":"2019-09-10T10:20:00Z","reference_number":"EMA/493567/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2019_en.pdf"},
    {"id":"45503","name":"Advice on implementing measures under Article 57(3) of Regulation (EU) 2019/6 on veterinary medicinal products - Report on specific requirements for the collection of data on antimicrobial medicinal products used in animals","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-09-23T09:33:00Z","last_updated_date":"2019-09-23T09:33:00Z","reference_number":"EMA/CVMP/131097/2019","document_url":"https://www.ema.europa.eu/en/documents/report/advice-implementing-measures-under-article-573-regulation-eu-20196-veterinary-medicinal-products-report-specific-requirements-collection-data-antimicrobial-medicinal-products-used-animals_en.pdf"},
    {"id":"45569","name":"PRAC statistics: October 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-10-04T11:47:00Z","last_updated_date":"2019-10-04T11:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-october-2019_en.pdf"},
    {"id":"45624","name":"Applications for new human medicines under evaluation by the CHMP: October 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-10-09T13:21:00Z","last_updated_date":"2019-10-09T13:21:00Z","reference_number":"EMA/544989/2019","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2019_en.pdf"},
    {"id":"45648","name":"Sales of veterinary antimicrobial agents in 31 European countries in 2017 - Ninth ESVAC report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-10-15T14:00:00Z","last_updated_date":"2019-10-15T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-31-european-countries-2017-ninth-esvac-report_en.pdf"},
    {"id":"45768","name":"Medicinal products for human use: monthly figures - September 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-10-22T14:50:00Z","last_updated_date":"2019-10-22T14:50:00Z","reference_number":"EMA/573788/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2019_en.pdf"},
    {"id":"45834","name":"Outcome of public consultation on draft guideline on the pharmacokinetic and clinical evaluation of modified-release dosage forms","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-10-29T14:00:00Z","last_updated_date":"2019-10-29T14:00:00Z","reference_number":"EMA/CHMP/536342/2019","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-public-consultation-draft-guideline-pharmacokinetic-and-clinical-evaluation-modified-release-dosage-forms_en.pdf"},
    {"id":"45867","name":"PRAC statistics: November 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-10-31T15:01:00Z","last_updated_date":"2019-10-31T15:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-november-2019_en.pdf"},
    {"id":"45895","name":"Applications for new human medicines under evaluation by the CHMP: November 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-06T11:28:00Z","last_updated_date":"2019-11-06T11:28:00Z","reference_number":"EMA/596608/2019","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2019_en.pdf"},
    {"id":"45966","name":"Annual activity report 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-12T15:47:00Z","last_updated_date":"2019-11-12T15:47:00Z","reference_number":"EMA/112688/2019","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2018_en.pdf"},
    {"id":"46041","name":"European Medicines Agency mid-year report 2019 from the Executive Director","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T11:06:00Z","last_updated_date":"2019-11-15T11:06:00Z","reference_number":"EMA/619659/2019","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2019-executive-director_en.pdf"},
    {"id":"46046","name":"Medicinal products for human use: monthly figures - October 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T16:38:00Z","last_updated_date":"2019-11-15T16:38:00Z","reference_number":"EMA/618072/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2019_en.pdf"},
    {"id":"46090","name":"European Medicines Agency and Member States joint report to the European Commission on the experience with the list of products subject to additional monitoring","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-11-21T11:25:00Z","last_updated_date":"2019-11-21T11:25:00Z","reference_number":"EMA/385597/2019","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-and-member-states-joint-report-european-commission-experience-list-products-subject-additional-monitoring_en.pdf"},
    {"id":"46104","name":"Decision on amending budget No 2-2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-21T16:32:00Z","last_updated_date":"2019-11-21T16:32:00Z","reference_number":"EMA/MB/379538/2019","document_url":"https://www.ema.europa.eu/en/documents/report/decision-amending-budget-no-2-2019_en.pdf"},
    {"id":"46164","name":"Dashboard created for visual representation of the scoring of the included data sources","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-27T15:30:00Z","last_updated_date":"2019-11-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/dashboard-created-visual-representation-scoring-included-data-sources_en.xlsx"},
    {"id":"46165","name":"Inventory of registries","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-27T15:30:00Z","last_updated_date":"2019-11-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/inventory-registries_en.xlsx"},
    {"id":"46175","name":"Bioanalytical Omics - Subgroup report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-27T15:30:00Z","last_updated_date":"2019-11-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/bioanalytical-omics-subgroup-report_en.pdf"},
    {"id":"46176","name":"Clinical Trial and Imaging - Subgroup report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-27T15:30:00Z","last_updated_date":"2019-11-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/clinical-trial-and-imaging-subgroup-report_en.pdf"},
    {"id":"46177","name":"Data Analytics - Subgroup report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-27T15:30:00Z","last_updated_date":"2019-11-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/data-analytics-subgroup-report_en.pdf"},
    {"id":"46178","name":"Genomics, Genetics, Transcriptomics and Epigenetics - Subgroup report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-27T15:30:00Z","last_updated_date":"2019-11-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/genomics-genetics-transcriptomics-and-epigenetics-subgroup-report_en.pdf"},
    {"id":"46179","name":"Observational data (Real World Data) - Subgroup report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-27T15:30:00Z","last_updated_date":"2019-11-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/observational-data-real-world-data-subgroup-report_en.pdf"},
    {"id":"46180","name":"Social Media and M-Health Data - Subgroup report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-27T15:30:00Z","last_updated_date":"2019-12-03T16:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/social-media-and-m-health-data-subgroup-report_en.pdf"},
    {"id":"46181","name":"Spontaneous Adverse Drug Reactions - Subgroup report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-27T15:30:00Z","last_updated_date":"2019-11-27T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/spontaneous-adverse-drug-reactions-subgroup-report_en.pdf"},
    {"id":"46201","name":"PRAC statistics: December 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-11-29T12:08:00Z","last_updated_date":"2019-11-29T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-december-2019_en.pdf"},
    {"id":"46240","name":"Applications for new human medicines under evaluation by the CHMP: December 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-12-05T14:47:00Z","last_updated_date":"2019-12-05T14:47:00Z","reference_number":"EMA/661071/2019","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2019_en.pdf"},
    {"id":"46291","name":"Annual report 2018 on staff engaging in an occupational activity within two years of leaving the service (article 16 of the staff regulations)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-12-11T10:29:00Z","last_updated_date":"2019-12-11T10:29:00Z","reference_number":"EMA/131220/2019","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-2018-staff-engaging-occupational-activity-within-two-years-leaving-service-article-16-staff-regulations_en.pdf"},
    {"id":"46318","name":"Medicinal products for human use: monthly figures - November 2019","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T11:51:00Z","last_updated_date":"2019-12-13T11:51:00Z","reference_number":"EMA/680162/2019","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2019_en.pdf"},
    {"id":"46322","name":"Report on pharmacovigilance tasks from EU Member States and the European Medicines Agency (EMA) 2015-2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-12-17T14:00:00Z","last_updated_date":"2019-12-17T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-pharmacovigilance-tasks-eu-member-states-and-european-medicines-agency-ema-2015-2018_en.pdf"},
    {"id":"46378","name":"Summary of transfers of appropriations and Summary report on implementation of assigned revenue, fund sources R0 & CL, in budget 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2019-12-20T16:11:00Z","last_updated_date":"2019-12-20T16:11:00Z","reference_number":"EMA/MB/582178/2019","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-and-summary-report-implementation-assigned-revenue-fund-sources-r0-cl-budget-2019_en.pdf"},
    {"id":"46402","name":"Human medicines highlights 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-01-09T13:00:00Z","last_updated_date":"2020-01-23T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2019_en.pdf"},
    {"id":"46405","name":"Veterinary medicines highlights 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-01-10T08:37:00Z","last_updated_date":"2020-01-23T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/veterinary-medicines-highlights-2019_en.pdf"},
    {"id":"46451","name":"PRAC statistics: January 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-01-17T13:22:00Z","last_updated_date":"2020-01-17T13:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-january-2020_en.pdf"},
    {"id":"46453","name":"Applications for new human medicines under evaluation by the CHMP: January 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-01-17T14:13:00Z","last_updated_date":"2020-01-17T14:13:00Z","reference_number":"EMA/4760/2020","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2020_en.pdf"},
    {"id":"46489","name":"Medicinal products for human use: monthly figures - December 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-01-22T17:35:00Z","last_updated_date":"2020-01-22T17:35:00Z","reference_number":"EMA/20204/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2019_en.pdf"},
    {"id":"46580","name":"Infographic - Categorisation of antibiotics for use in animals for prudent and responsible use","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-01-28T13:00:00Z","last_updated_date":"2025-09-24T09:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_bg.pdf","es":"https://www.ema.europa.eu/es/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_cs.pdf","da":"https://www.ema.europa.eu/da/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_da.pdf","de":"https://www.ema.europa.eu/de/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_de.pdf","et":"https://www.ema.europa.eu/et/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_et.pdf","el":"https://www.ema.europa.eu/el/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_hr.pdf","it":"https://www.ema.europa.eu/it/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_sv.pdf"}},
    {"id":"46584","name":"Categorisation of antibiotics in the European Union - Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-01-28T13:00:00Z","last_updated_date":"2025-09-24T09:54:00Z","reference_number":"EMA/CVMP/CHMP/682198/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific-advice-impact-public-health-animal-health-use-antibiotics-animals_en.pdf"},
    {"id":"46602","name":"Report on public consultation on the 'Electronic product information for human medicines in the European Union - draft key principles'","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-01-29T15:00:00Z","last_updated_date":"2020-01-29T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-public-consultation-electronic-product-information-human-medicines-european-union-draft-key-principles_en.pdf"},
    {"id":"46663","name":"European Medicines Agency budget for 2020","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-02-03T14:22:00Z","last_updated_date":"2020-03-16T14:23:00Z","reference_number":"EMA/MB/193731/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2020_en.pdf"},
    {"id":"46687","name":"Final programming document 2020-2022","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-02-10T09:50:00Z","last_updated_date":"2020-02-10T09:50:00Z","reference_number":"EMA/9529/2020","document_url":"https://www.ema.europa.eu/en/documents/report/final-programming-document-2020-2022_en.pdf"},
    {"id":"46723","name":"Applications for new human medicines under evaluation by the CHMP: February 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-02-12T11:16:00Z","last_updated_date":"2020-02-19T16:43:00Z","reference_number":"EMA/458209/2012","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2020_en.pdf"},
    {"id":"46747","name":"Information Management Strategy 2020-2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-02-13T15:40:00Z","last_updated_date":"2020-02-13T15:40:00Z","reference_number":"EMA/410709/2019","document_url":"https://www.ema.europa.eu/en/documents/report/information-management-strategy-2020-2022_en.pdf"},
    {"id":"46756","name":"PRAC statistics: February 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-02-14T12:00:00Z","last_updated_date":"2020-02-14T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-february-2020_en.pdf"},
    {"id":"46867","name":"Medicinal products for human use: monthly figures - January 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T09:23:00Z","last_updated_date":"2020-02-25T09:23:00Z","reference_number":"EMA/87768/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2020_en.pdf"},
    {"id":"46925","name":"Annual report on the use of the special contribution for orphan medicinal products - 2019","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-03-02T14:30:00Z","last_updated_date":"2020-03-02T14:30:00Z","reference_number":"EMA/13083/2020","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-use-special-contribution-orphan-medicinal-products-2019_en.pdf"},
    {"id":"47022","name":"PRAC statistics: March 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-03-13T12:16:00Z","last_updated_date":"2020-03-13T12:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-march-2020_en.pdf"},
    {"id":"47025","name":"Applications for new human medicines under evaluation by the CHMP: March 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-03-16T14:10:00Z","last_updated_date":"2020-03-16T14:10:00Z","reference_number":"EMA/131609/2020","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2020_en.pdf"},
    {"id":"47087","name":"2019 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission - Reporting period: 1 January to 31 December 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-03-20T16:23:00Z","last_updated_date":"2020-03-20T16:23:00Z","reference_number":"EMA/640614/2019","document_url":"https://www.ema.europa.eu/en/documents/report/2019-annual-report-eudravigilance-european-parliament-council-and-commission-reporting-period-1-january-31-december-2019_en.pdf"},
    {"id":"47090","name":"Summary of transfers of appropriations in budget 2019 - Issues for consideration - Management Board meeting of 19 March 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-03-20T16:37:00Z","last_updated_date":"2020-03-20T16:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2019-issues-consideration-management-board-meeting-19-march-2020_en.pdf"},
    {"id":"47109","name":"10-year annual report on MUMS/limited market scheme for veterinary medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-03-25T14:03:00Z","last_updated_date":"2020-03-25T14:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/10-year-annual-report-mumslimited-market-scheme-veterinary-medicines_en.pdf"},
    {"id":"47192","name":"Medicinal products for human use: monthly figures - February 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T11:30:00Z","last_updated_date":"2020-03-27T11:30:00Z","reference_number":"EMA/160030/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2020_en.pdf"},
    {"id":"47336","name":"Report of the workshop on the use of registries in the monitoring of cancer therapies based on tumours’ genetic and molecular features - 29 November 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-04-03T16:20:00Z","last_updated_date":"2020-04-03T16:20:00Z","reference_number":"EMA/661159/2019","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-use-registries-monitoring-cancer-therapies-based-tumours-genetic-and-molecular-features-29-november-2019_en.pdf"},
    {"id":"47394","name":"Applications for new human medicines under evaluation by the CHMP: April 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-04-08T18:30:00Z","last_updated_date":"2020-04-08T18:30:00Z","reference_number":"EMA/194527/2020","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2020_en.pdf"},
    {"id":"47431","name":"PRAC statistics: April 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-04-17T14:45:00Z","last_updated_date":"2020-04-17T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-april-2020_en.pdf"},
    {"id":"47477","name":"Medicinal products for human use: monthly figures - March 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-04-24T10:29:00Z","last_updated_date":"2020-04-24T10:29:00Z","reference_number":"EMA/221650/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2020_en.pdf"},
    {"id":"47643","name":"Applications for new human medicines under evaluation by the CHMP: May 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-05-11T16:42:00Z","last_updated_date":"2020-05-11T16:42:00Z","reference_number":"EMA/254841/2020","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2020_en.pdf"},
    {"id":"47676","name":"PRAC statistics: May 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-05-15T12:01:00Z","last_updated_date":"2020-05-15T12:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-may-2020_en.pdf"},
    {"id":"47699","name":"Hearing with the Association of the European Self-Medication Industry (AESGP) during the HMPC November 2019 meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T16:46:00Z","last_updated_date":"2020-05-18T16:46:00Z","reference_number":"EMA/HMPC/690535/2019","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-aesgp-during-hmpc-november-2019-meeting_en.pdf"},
    {"id":"47720","name":"Report - 2019 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA (Enpr-EMA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-05-19T16:54:00Z","last_updated_date":"2020-05-19T16:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-2019-annual-meeting-members-and-coordinating-group-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"47751","name":"Medicinal products for human use: monthly figures - April 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-05-25T11:44:00Z","last_updated_date":"2020-05-25T11:44:00Z","reference_number":"EMA/272842/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2020_en.pdf"},
    {"id":"47943","name":"Small and medium-sized enterprise (SME) Office annual report 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-06-10T16:21:00Z","last_updated_date":"2020-06-10T16:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/small-and-medium-sized-enterprise-sme-office-annual-report-2019_en.pdf"},
    {"id":"47965","name":"Applications for new human medicines under evaluation by the CHMP: June 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-06-11T15:11:00Z","last_updated_date":"2020-06-11T15:11:00Z","reference_number":"EMA/312416/2020","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2020_en.pdf"},
    {"id":"47980","name":"PRAC statistics: June 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-06-12T11:40:00Z","last_updated_date":"2020-06-12T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-june-2020_en.pdf"},
    {"id":"47981","name":"Report on veterinary medicinal products regarding good pharmacovigilance practice","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-06-12T12:30:00Z","last_updated_date":"2020-06-12T12:30:00Z","reference_number":"EMA/CVMP/111028/2020","document_url":"https://www.ema.europa.eu/en/documents/report/report-veterinary-medicinal-products-regarding-good-pharmacovigilance-practice_en.pdf"},
    {"id":"47982","name":"Report on veterinary medicinal products regarding the pharmacovigilance system master file","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-06-12T12:30:00Z","last_updated_date":"2020-06-12T12:30:00Z","reference_number":"EMA/CVMP/123178/2019","document_url":"https://www.ema.europa.eu/en/documents/report/report-veterinary-medicinal-products-regarding-pharmacovigilance-system-master-file_en.pdf"},
    {"id":"48012","name":"Summary of transfers of appropriations in budget 2020 - Issues for consideration - Management Board meeting of 11 June 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-06-16T09:40:00Z","last_updated_date":"2020-06-16T09:40:00Z","reference_number":"EMA/MB/201079/2020","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2020-issues-consideration-management-board-meeting-11-june-2020_en.pdf"},
    {"id":"48071","name":"Lessons learnt from presence of N-nitrosamine impurities in sartan medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T14:00:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"EMA/526934/2019","document_url":"https://www.ema.europa.eu/en/documents/report/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines_en.pdf"},
    {"id":"48087","name":"Medicinal products for human use: monthly figures - May 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-06-23T13:13:00Z","last_updated_date":"2020-06-23T13:13:00Z","reference_number":"EMA/333357/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2020_en.pdf"},
    {"id":"48197","name":"Annual activity report 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-07-01T15:32:00Z","last_updated_date":"2020-07-01T15:32:00Z","reference_number":"EMA/33568/2020","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2019_en.pdf"},
    {"id":"48198","name":"2018-2019 European Medicines Agency annual reports on independence","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-07-01T16:07:00Z","last_updated_date":"2020-07-01T16:07:00Z","reference_number":"EMA/425399/2019","document_url":"https://www.ema.europa.eu/en/documents/report/2018-2019-european-medicines-agency-annual-reports-independence_en.pdf"},
    {"id":"48211","name":"Annual accounts: Financial year 2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-07-03T10:28:00Z","last_updated_date":"2020-07-03T10:28:00Z","reference_number":"EMA/203278/2020","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2019_en.pdf"},
    {"id":"48282","name":"PRAC statistics: July 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-07-10T11:43:00Z","last_updated_date":"2020-07-10T11:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-july-2020_en.pdf"},
    {"id":"48297","name":"Applications for new human medicines under evaluation by the CHMP: July 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-07-13T15:31:00Z","last_updated_date":"2020-07-13T15:31:00Z","reference_number":"EMA/372622/2020","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2020_en.pdf"},
    {"id":"48303","name":"Medicinal products for human use: monthly figures - June 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-07-14T15:28:00Z","last_updated_date":"2020-07-14T15:28:00Z","reference_number":"EMA/367889/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2020_en.pdf"},
    {"id":"48599","name":"Applications for new human medicines under evaluation by the CHMP: August 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-08-13T10:52:00Z","last_updated_date":"2020-08-19T13:51:00Z","reference_number":"EMA/421034/2020 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2020_en.pdf"},
    {"id":"48645","name":"Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated viral vector encoding the human cytochrome P450 21-hydroxylase gene","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/235515/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adeno-associated-viral-vector-encoding-human-cytochrome-p450-21-hydroxylase-gene_en.pdf"},
    {"id":"48646","name":"Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated virus serotype 5 encoding human retinal guanylate cyclase 1 gene","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/234887/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-adeno-associated-virus-serotype-5-encoding-human-retinal-guanylate-cyclase-1-gene_en.pdf"},
    {"id":"48647","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic cultured postnatal thymus tissue-derived product","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/189324/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-cultured-postnatal-thymus-tissue-derived-product_en.pdf"},
    {"id":"48648","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic haematopoietic stem and progenitor cells treated ex vivo with a fusion protein","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/188546/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-haematopoietic-stem-and-progenitor-cells-treated-ex-vivo-fusion-protein_en.pdf"},
    {"id":"48649","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic human Wharton’s jelly-derived mesenchymal stem cells seeded onto decellularized dermal scaffold","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/188455/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-human-whartons-jelly-derived-mesenchymal-stem-cells-seeded-decellularized-dermal-scaffold_en.pdf"},
    {"id":"48650","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic natural killer cells expanded in vitro","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/189175/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-natural-killer-cells-expanded-vitro_en.pdf"},
    {"id":"48651","name":"Scientific recommendation on classification of ATMP: Allogeneic, ex vivo expanded, umbilical cord blood-derived, haematopoietic CD34+ progenitor cells, & allogeneic, non-expanded, umbilical cord blood-derived,haematopoietic mature myeloid & lymphoid cells","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/235526/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-atmp-allogeneic-ex-vivo-expanded-umbilical-cord-blood-derived-haematopoietic-cd34-progenitor-cells-allogeneic-non-expanded-umbilical-cord-blood_en.pdf"},
    {"id":"48652","name":"Scientific recommendation on classification of  advanced therapy medicinal products: Autologous CD34+ cells transduced with a lentiviral vector encoding for the CD18 β-subunit of human β2 Integrin","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/189223/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-cd34-cells-transduced-lentiviral-vector-encoding-cd18-b-subunit-human-b2-integrin_en.pdf"},
    {"id":"48655","name":"Scientific recommendation on classification of advanced therapy medicinal products: Allogeneic, ex vivo expanded, umbilical cord blood-derived, haematopoietic CD34+ progenitor cells, and allogeneic, non-expanded, umbilical cord blood-derived...","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/235526/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-allogeneic-ex-vivo-expanded-umbilical-cord-blood-derived-haematopoietic-cd34-progenitor-cells-and-allogeneic-non-expanded_en.pdf"},
    {"id":"48656","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous CD34+ cells transduced with a lentiviral vector encoding for the CD18 β-subunit of human β2 Integrin","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/189223/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-cd34-cells-transduced-lentiviral-vector-encoding-cd18-b-subunit-human-b2-integrin_en.pdf-0"},
    {"id":"48657","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous CD34+ cells transduced with a lentiviral vector encoding for the CD18 β-subunit of human β2 Integrin","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/234914/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-cd34-cells-transduced-lentiviral-vector-encoding-cd18-b-subunit-human-b2-integrin_en.pdf-1"},
    {"id":"48658","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous skeletal muscle derived cells attached to poly(DL-lactide-co-glycolide) microparticles","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/235524/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-skeletal-muscle-derived-cells-attached-polydl-lactide-co-glycolide-microparticles_en.pdf"},
    {"id":"48659","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous viable adipose-derived regenerative cells extracted from human subcutaneous fat from liposuction aspirates","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/234878/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-viable-adipose-derived-regenerative-cells-extracted-human-subcutaneous-fat-liposuction-aspirates_en.pdf"},
    {"id":"48660","name":"Scientific recommendation on classification of ATMP: Autologous viable adipose-derived regenerative cells extracted from human subcutaneous fat from liposuction aspirates obtained by enzymatic isolation (using a proprietary system from manufacturer 1)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/234880/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-atmp-autologous-viable-adipose-derived-regenerative-cells-extracted-human-subcutaneous-fat-liposuction-aspirates-obtained-enzymatic-isolation-using-proprietary_en.pdf"},
    {"id":"48661","name":"Scientific recommendation on classification of ATMP: Autologous viable adipose-derived regenerative cells extracted from human subcutaneous fat from liposuction aspirates obtained by enzymatic isolation (using a proprietary system from manufacturer 1)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/234872/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-atmp-autologous-viable-adipose-derived-regenerative-cells-extracted-human-subcutaneous-fat-liposuction-aspirates-obtained-enzymatic-isolation-using-proprietary_en.pdf-0"},
    {"id":"48662","name":"Scientific recommendation on classification of ATMP: Autologous viable adipose-derived regenerative cells extracted from human subcutaneous fat from liposuction aspirates obtained by enzymatic isolation (using a proprietary system from manufacturer 2)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T15:30:00Z","last_updated_date":"2020-08-20T15:30:00Z","reference_number":"EMA/234882/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-atmp-autologous-viable-adipose-derived-regenerative-cells-extracted-human-subcutaneous-fat-liposuction-aspirates-obtained-enzymatic-isolation-using-proprietary_en.pdf-1"},
    {"id":"48663","name":"Scientific recommendation on classification of ATMP: Autologous viable adipose-derived regenerative cells extracted from human subcutaneous fat from liposuction aspirates obtained by enzymatic isolation (using a proprietary system from manufacturer 2)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T15:30:00Z","last_updated_date":"2020-08-20T15:30:00Z","reference_number":"EMA/234874/2019","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-atmp-autologous-viable-adipose-derived-regenerative-cells-extracted-human-subcutaneous-fat-liposuction-aspirates-obtained-enzymatic-isolation-using-proprietary_en.pdf-2"},
    {"id":"48664","name":"Scientific recommendation on classification of advanced therapy medicinal products: Autologous viable adipose-derived regenerative cells extracted from human subcutaneous fat from liposuction aspirates","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/234869/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-viable-adipose-derived-regenerative-cells-extracted-human-subcutaneous-fat-liposuction-aspirates_en.pdf-0"},
    {"id":"48665","name":"Scientific recommendation on classification of advanced therapy medicinal products: Cultured autologous adipose-derived stem cells","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/234927/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-cultured-autologous-adipose-derived-stem-cells_en.pdf"}    {"id":"48666","name":"Scientific recommendation on classification of advanced therapy medicinal products: DNA plasmid vector encoding human IL-12","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/235535/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-dna-plasmid-vector-encoding-human-il-12_en.pdf"},
    {"id":"48667","name":"Scientific recommendation on classification of advanced therapy medicinal products: DNA delivery vector with similar structure-function than bacteriophage capsids","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/189107/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-dna-delivery-vector-similar-structure-function-bacteriophage-capsids_en.pdf"},
    {"id":"48668","name":"Scientific recommendation on classification of advanced therapy medicinal products: Ex-vivo expanded allogeneic bone marrow derived mesenchymal stromal cells","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/235539/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-ex-vivo-expanded-allogeneic-bone-marrow-derived-mesenchymal-stromal-cells_en.pdf"},
    {"id":"48669","name":"Scientific recommendation on classification of advanced therapy medicinal products: Human bone marrow derived allogeneic mesenchymal stem cells expressing human alpha-1 antitrypsin","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/188494/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-human-bone-marrow-derived-allogeneic-mesenchymal-stem-cells-expressing-human-alpha-1-antitrypsin_en.pdf"},
    {"id":"48670","name":"Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed messenger RNA molecules encoding IFNα2b, IL-12, IL-15sushi and GM-CSF cytokines","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/235528/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-vitro-transcribed-messenger-rna-molecules-encoding-ifna2b-il-12-il-15sushi-and-gm-csf-cytokines_en.pdf"},
    {"id":"48671","name":"Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector containing a human micro-dystrophin gene","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/235532/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-viral-vector-containing-human-micro-dystrophin-gene_en.pdf"},
    {"id":"48672","name":"Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus (AAV), serotype 1 containing a transgene that encodes a microRNA targeting huntingtin messenger RNA","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/188618/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-virus-aav-serotype-1-containing-transgene-encodes-microrna-targeting-huntingtin-messenger-rna_en.pdf"},
    {"id":"48673","name":"Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 8 containing a codon optimised copy of the cDNA encoding human Retinitis Pigmentosa GTPase Regulator","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/235760/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-virus-serotype-8-containing-codon-optimised-copy-cdna-encoding-human-retinitis-pigmentosa_en.pdf"},
    {"id":"48674","name":"Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 containing a human α-L-iduronidase gene cassette","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/234920/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-virus-serotype-9-containing-human-l-iduronidase-gene-cassette_en.pdf"},
    {"id":"48675","name":"Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus type rh10 containing a transgene that encodes a microRNA targeting SOD1 messenger RNA under the control of an H1 promoter","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-08-20T10:15:00Z","last_updated_date":"2020-08-20T10:15:00Z","reference_number":"EMA/235044/2019 ","document_url":"https://www.ema.europa.eu/en/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-recombinant-adeno-associated-virus-type-rh10-containing-transgene-encodes-microrna-targeting-sod1-messenger-rna-under_en.pdf"},
    {"id":"48682","name":"Meeting report - ICH E6(R3) Good Clinical Practice workshop with PCWP and HCPWP on 3 June 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-08-28T09:00:00Z","last_updated_date":"2020-08-28T09:00:00Z","reference_number":"EMA/309402/2020","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-ich-e6r3-good-clinical-practice-workshop-pcwp-and-hcpwp-3-june-2020_en.pdf"},
    {"id":"48729","name":"Medicinal products for human use: monthly figures - July 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-09-01T08:46:00Z","last_updated_date":"2020-09-01T08:46:00Z","reference_number":"EMA/433077/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2020_en.pdf"},
    {"id":"48758","name":"PRAC statistics: September 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-09-04T11:44:00Z","last_updated_date":"2020-09-04T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-september-2020_en.pdf"},
    {"id":"48768","name":"Applications for new human medicines under evaluation by the CHMP: September 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-09-09T08:51:00Z","last_updated_date":"2020-09-09T08:51:00Z","reference_number":"EMA/468049/2020","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2020_en.pdf"},
    {"id":"48905","name":"Medicinal products for human use: monthly figures - August 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-09-29T09:28:00Z","last_updated_date":"2020-09-29T09:28:00Z","reference_number":"EMA/496245/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2020_en.pdf"},
    {"id":"48940","name":"PRAC statistics: October 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-02T15:31:00Z","last_updated_date":"2020-10-02T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-october-2020_en.pdf"},
    {"id":"48942","name":"European Medicines Agency mid-year report 2020 (January-June 2020)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-05T13:00:00Z","last_updated_date":"2020-10-05T13:00:00Z","reference_number":"EMA/386447/2020","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2020-january-june-2020_en.pdf"},
    {"id":"48943","name":"Outcome of written procedures finalised during the period from 27 May 2020 to 15 September 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-05T13:00:00Z","last_updated_date":"2020-10-05T13:00:00Z","reference_number":"EMA/MB/474257/2020","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-written-procedures-finalised-during-period-27-may-2020-15-september-2020_en.pdf"},
    {"id":"48944","name":"Summary of transfers of appropriations in budget 2020 - Issues for consideration - Management Board meeting of 1 October 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-05T13:00:00Z","last_updated_date":"2020-10-05T13:00:00Z","reference_number":"EMA/MB/447191/2020","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budget-2020-issues-consideration-management-board-meeting-1-october-2020_en.pdf"},
    {"id":"48997","name":"Applications for new human medicines under evaluation by the CHMP: October 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-12T14:55:00Z","last_updated_date":"2020-10-12T14:55:00Z","reference_number":"EMA/535780/2020","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2020_en.pdf"},
    {"id":"49020","name":"Sales of veterinary antimicrobial agents in 31 European countries in 2018 - Trends from 2010 to 2018 - Tenth ESVAC report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:30:00Z","last_updated_date":"2021-11-19T08:45:00Z","reference_number":"EMA/24309/2020 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-31-european-countries-2018-trends-2010-2018-tenth-esvac-report_en.pdf"},
    {"id":"49059","name":"Medicinal products for human use: monthly figures - September 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-20T09:17:00Z","last_updated_date":"2020-10-20T09:17:00Z","reference_number":"EMA/549770/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2020_en.pdf"},
    {"id":"49067","name":"Austria - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/austria-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49068","name":"Belgium - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/belgium-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49069","name":"Bulgaria - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/bulgaria-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49070","name":"Croatia - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/croatia-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49071","name":"Cyprus - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/cyprus-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49072","name":"Czechia- trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/czechia-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49073","name":"Denmark - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/denmark-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49074","name":"Estonia - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/estonia-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49075","name":"Finland - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/finland-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49076","name":"France - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/france-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49077","name":"Germany - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/germany-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49078","name":"Greece - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/greece-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49079","name":"Hungary - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/hungary-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49080","name":"Iceland - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/iceland-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49081","name":"Ireland - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/ireland-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49082","name":"Italy - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/italy-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49083","name":"Latvia - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/latvia-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49084","name":"Lithuania - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/lithuania-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49085","name":"Luxembourg - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/luxembourg-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49086","name":"Malta - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/malta-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49087","name":"Netherlands - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/netherlands-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49088","name":"Norway - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/norway-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49089","name":"Poland - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/poland-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49090","name":"Portugal - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/portugal-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49091","name":"Romania - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/romania-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49092","name":"Slovakia - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/slovakia-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49093","name":"Slovenia - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/slovenia-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49094","name":"Spain - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/spain-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49095","name":"Sweden - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/sweden-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49096","name":"Switzerland - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/switzerland-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49097","name":"United Kingdom - trends in the sales of veterinary antibiotics between 2010 and 2018","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-21T16:00:00Z","last_updated_date":"2020-10-21T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/united-kingdom-trends-sales-veterinary-antibiotics-between-2010-and-2018_en.pdf"},
    {"id":"49119","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-23T15:10:00Z","last_updated_date":"2020-10-23T15:10:00Z","reference_number":"EMA/CAT/547273/2010","document_url":"https://www.ema.europa.eu/en/documents/report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-october-2020_en.pdf"},
    {"id":"49162","name":"PRAC statistics: October-November 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-10-30T12:00:00Z","last_updated_date":"2020-10-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-october-november-2020_en.pdf"},
    {"id":"49236","name":"Report - Workshop on benefit-risk of medicines used during pregnancy and breastfeeding","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T14:35:00Z","last_updated_date":"2020-11-12T14:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-benefit-risk-medicines-used-during-pregnancy-and-breastfeeding_en.pdf"},
    {"id":"49255","name":"Applications for new human medicines under evaluation by the CHMP: November 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T15:34:00Z","last_updated_date":"2020-11-13T15:34:00Z","reference_number":"EMA/590266/2020","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2020_en.pdf"},
    {"id":"49294","name":"Medicinal products for human use: monthly figures - October 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-11-19T17:15:00Z","last_updated_date":"2020-11-19T17:15:00Z","reference_number":"EMA/612108/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2020_en.pdf"},
    {"id":"49393","name":"PRAC statistics: November-December 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-11-27T12:00:00Z","last_updated_date":"2020-11-27T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-november-december-2020_en.pdf"},
    {"id":"49428","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: November 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-02T17:09:00Z","last_updated_date":"2020-12-02T17:09:00Z","reference_number":"EMA/CAT/620214/2010","document_url":"https://www.ema.europa.eu/en/documents/report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-november-2020_en.pdf"},
    {"id":"49446","name":"Report - Workshop on the application of the General Data Protection Regulation (GDPR) in the area of health and Secondary Use of Data for Medicines and Public Health Purposes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-04T15:05:00Z","last_updated_date":"2020-12-04T15:05:00Z","reference_number":"EMA/532436/2020","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-application-general-data-protection-regulation-gdpr-area-health-and-secondary-use-data-medicines-and-public-health-purposes_en.pdf"},
    {"id":"49477","name":"European Union Medicines Agencies Network Strategy to 2025 - Protecting public health at a time of rapid change","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-08T14:00:00Z","last_updated_date":"2020-12-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-union-medicines-agencies-network-strategy-2025-protecting-public-health-time-rapid-change_en.pdf"},
    {"id":"49478","name":"Analysis and summaries of public consultation results - European Medicines Agencies Network Strategy to 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-08T14:00:00Z","last_updated_date":"2020-12-08T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/analysis-and-summaries-public-consultation-results-european-medicines-agencies-network-strategy-2025_en.pdf"},
    {"id":"49479","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: October 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-08T11:49:00Z","last_updated_date":"2020-12-08T11:49:00Z","reference_number":"EMA/587476/2020","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-october-2020_en.pdf"},
    {"id":"49545","name":"Report of industry stakeholders webinar on the UK withdrawal from the European Union - End of transition period","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T15:00:00Z","last_updated_date":"2020-12-11T15:00:00Z","reference_number":"EMA/654054/2020","document_url":"https://www.ema.europa.eu/en/documents/report/report-industry-stakeholders-webinar-uk-withdrawal-european-union-end-transition-period_en.pdf"},
    {"id":"49548","name":"Applications for new human medicines under evaluation by the CHMP: December 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-14T15:06:00Z","last_updated_date":"2020-12-14T15:06:00Z","reference_number":"EMA/656040/2020","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2020_en.pdf"},
    {"id":"49551","name":"Outcome of SME office survey on the implementation of the SME regulation - Commission Regulation (EC) No 2049/2005","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T10:19:00Z","last_updated_date":"2020-12-15T10:19:00Z","reference_number":"EMA/277477/2020","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-sme-office-survey-implementation-sme-regulation-commission-regulation-ec-no-20492005_en.pdf"},
    {"id":"49557","name":"Report on the European Medicines Agency roundtable with stakeholders - 15 years supporting SMEs","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T10:19:00Z","last_updated_date":"2020-12-15T10:19:00Z","reference_number":"EMA/671119/2020","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-roundtable-stakeholders-15-years-supporting-smes_en.pdf"},
    {"id":"49590","name":"Report from the 2020 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA (Enpr-EMA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-16T10:54:00Z","last_updated_date":"2020-12-16T10:54:00Z","reference_number":"EMA/518319/2020","document_url":"https://www.ema.europa.eu/en/documents/report/report-2020-annual-meeting-members-and-coordinating-group-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"49659","name":"Medicinal products for human use: monthly figures - November 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T09:43:00Z","last_updated_date":"2020-12-21T09:43:00Z","reference_number":"EMA/672085/2020","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2020_en.pdf"},
    {"id":"49660","name":"Stakeholder engagement report 2018-2019","type":"report","status":"unknown","consultation_date":"","first_published_date":"2020-12-21T09:56:00Z","last_updated_date":"2020-12-21T09:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2018-2019_en.pdf"},
    {"id":"49770","name":"Applications for new human medicines under evaluation by the CHMP: January 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-01-11T11:45:00Z","last_updated_date":"2021-01-11T11:45:00Z","reference_number":"EMA/1722/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2021_en.pdf"},
    {"id":"49791","name":"Highlight report - Fifth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-01-13T10:15:00Z","last_updated_date":"2021-01-13T10:15:00Z","reference_number":"EMA/652244/2020","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-fifth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"49850","name":"Human medicines highlights 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:00:00Z","last_updated_date":"2025-11-03T11:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2020_en.pdf"},
    {"id":"49851","name":"Veterinary medicines highlights 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:00:00Z","last_updated_date":"2021-01-21T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/veterinary-medicines-highlights-2020_en.pdf"},
    {"id":"49855","name":"Highlight report - Fifth industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-01-21T10:12:00Z","last_updated_date":"2021-01-21T10:12:00Z","reference_number":"EMA/619777/2020","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-fifth-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"49900","name":"European Medicines Agency’s interaction with industry stakeholders - Biennial report 2018-19","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T12:40:00Z","last_updated_date":"2021-01-22T12:40:00Z","reference_number":"EMA/17744/2021","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agencys-interaction-industry-stakeholders-biennial-report-2018-19_en.pdf"},
    {"id":"49909","name":"Summary report - EU big data stakeholder virtual forum","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-01-22T16:33:00Z","last_updated_date":"2021-01-22T16:33:00Z","reference_number":"EMA/10082/2021","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-eu-big-data-stakeholder-virtual-forum_en.pdf"},
    {"id":"49919","name":"European Medicines Agency budget for 2021","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2021-01-25T09:35:00Z","last_updated_date":"2021-01-25T09:35:00Z","reference_number":"EMA/MB/664792/2020","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-budget-2021_en.pdf"},
    {"id":"49933","name":"Medicinal products for human use: monthly figures - December 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-01-25T12:38:00Z","last_updated_date":"2021-01-25T12:38:00Z","reference_number":"EMA/34585/2021 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2020_en.pdf"},
    {"id":"50048","name":"Final programming document 2021-2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-02-03T15:24:00Z","last_updated_date":"2022-01-11T09:00:00Z","reference_number":"EMA/53919/2021","document_url":"https://www.ema.europa.eu/en/documents/report/final-programming-document-2021-2023_en.pdf"},
    {"id":"50118","name":"Applications for new human medicines under evaluation by the CHMP: February 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-02-10T17:26:00Z","last_updated_date":"2021-02-10T17:26:00Z","reference_number":"EMA/75461/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2021_en.xlsx"},
    {"id":"50152","name":"PRAC statistics: February 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-02-12T12:32:00Z","last_updated_date":"2021-02-12T12:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-february-2021_en.pdf"},
    {"id":"50267","name":"Report - Workshop on support for orphan medicines development","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-02-25T09:30:00Z","last_updated_date":"2021-02-25T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-support-orphan-medicines-development_en.pdf"},
    {"id":"50369","name":"Medicinal products for human use: monthly figures - January 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-03-02T17:01:00Z","last_updated_date":"2021-03-02T17:01:00Z","reference_number":"EMA/128798/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2021_en.pdf"},
    {"id":"50378","name":"Annual report on the use of the special contribution for orphan medicinal products - 2020","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2021-03-03T13:29:00Z","last_updated_date":"2021-03-03T13:29:00Z","reference_number":"EMA/30719/2021","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-use-special-contribution-orphan-medicinal-products-2020_en.pdf"},
    {"id":"50532","name":"PRAC statistics: March 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T12:12:00Z","last_updated_date":"2021-03-12T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-march-2021_en.pdf"},
    {"id":"50537","name":"Applications for new human medicines under evaluation by the CHMP: March 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T14:36:00Z","last_updated_date":"2021-03-12T14:36:00Z","reference_number":"EMA/151574/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2021_en.xlsx"},
    {"id":"50538","name":"Minor use or minor species (MUMS)/limited market scheme for veterinary medicinal products - 11th annual report (2020)","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2021-03-12T14:26:00Z","last_updated_date":"2021-03-12T14:26:00Z","reference_number":"EMA/553359/2020","document_url":"https://www.ema.europa.eu/en/documents/report/minor-use-or-minor-species-mumslimited-market-scheme-veterinary-medicinal-products-11th-annual-report-2020_en.pdf"},
    {"id":"50539","name":"2020 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T14:40:00Z","last_updated_date":"2021-03-12T14:40:00Z","reference_number":"EMA/620104/2020","document_url":"https://www.ema.europa.eu/en/documents/report/2020-annual-report-eudravigilance-european-parliament-council-and-commission_en.pdf"},
    {"id":"50540","name":"2020 European Medicines Agency Annual Report on Independence","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T14:44:00Z","last_updated_date":"2021-03-12T14:44:00Z","reference_number":"EMA/34780/2021","document_url":"https://www.ema.europa.eu/en/documents/report/2020-european-medicines-agency-annual-report-independence_en.pdf"},
    {"id":"50541","name":"Big Data Steering Group (BDSG): 2020 report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T14:52:00Z","last_updated_date":"2021-03-12T14:52:00Z","reference_number":"EMA/48625/2021","document_url":"https://www.ema.europa.eu/en/documents/report/big-data-steering-group-bdsg-2020-report_en.pdf"},
    {"id":"50543","name":"Outcome of written procedures finalised during the period from 26 November 2020 to 12 February 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T14:59:00Z","last_updated_date":"2021-03-12T14:59:00Z","reference_number":"EMA/MB/81947/2021","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-written-procedures-finalised-during-period-26-november-2020-12-february-2021_en.pdf"},
    {"id":"50545","name":"Summary of transfers of appropriations in budgets 2020 and 2021 - Issues for consideration - Management Board meeting: 11 March 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-03-12T15:08:00Z","last_updated_date":"2021-03-12T15:08:00Z","reference_number":"EMA/MB/76157/2021","document_url":"https://www.ema.europa.eu/en/documents/report/summary-transfers-appropriations-budgets-2020-and-2021-issues-consideration-management-board-meeting-11-march-2021_en.pdf"},
    {"id":"50636","name":"Medicinal products for human use: monthly figures - February 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-03-18T11:05:00Z","last_updated_date":"2021-03-18T11:05:00Z","reference_number":"EMA/166432/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2021_en.pdf"},
    {"id":"50784","name":"PRAC statistics: April 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-04-09T12:33:00Z","last_updated_date":"2021-04-09T12:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-april-2021_en.pdf"},
    {"id":"50786","name":"Hearing with the Association of the European Self-Medication Industry (AESGP) during the HMPC November 2020 meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-04-09T15:14:00Z","last_updated_date":"2021-04-09T15:14:00Z","reference_number":"EMA/HMPC/661999/2020","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-aesgp-during-hmpc-november-2020-meeting_en.pdf"},
    {"id":"50853","name":"List of withdrawn medicinal products in accordance with Art. 123(4) of the Directive (1 January - 31 December 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-04-15T11:22:00Z","last_updated_date":"2026-03-19T10:10:00Z","reference_number":"EMA/555562/2024","document_url":"https://www.ema.europa.eu/en/documents/report/list-withdrawn-medicinal-products-accordance-art-1234-directive-1-january-31-december-2025_en.xlsx"},
    {"id":"50899","name":"Medicinal products for human use: monthly figures - March 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-04-19T10:48:00Z","last_updated_date":"2021-04-19T10:48:00Z","reference_number":"EMA/213698/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2021_en.pdf"},
    {"id":"50978","name":"Applications for new human medicines under evaluation by the CHMP: April 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-04-26T09:20:00Z","last_updated_date":"2021-04-26T09:20:00Z","reference_number":"EMA/201519/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2021_en.xlsx"}    {"id":"51107","name":"PRAC statistics: May 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-05-07T12:30:00Z","last_updated_date":"2021-05-07T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-may-2021_en.pdf"},
    {"id":"51159","name":"Applications for new human medicines under evaluation by the CHMP: May 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-05-17T14:16:00Z","last_updated_date":"2021-05-17T14:16:00Z","reference_number":"EMA/247078/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2021_en.xlsx"},
    {"id":"51160","name":"Medicinal products for human use: monthly figures - April 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-05-17T14:45:00Z","last_updated_date":"2021-05-17T14:45:00Z","reference_number":"EMA/269656/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2021_en.pdf"},
    {"id":"51293","name":"Report of the joint HMA/EMA workshop on artificial intelligence in medicines regulation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-05-28T15:26:00Z","last_updated_date":"2021-05-28T15:26:00Z","reference_number":"EMA/292319/2021","document_url":"https://www.ema.europa.eu/en/documents/report/report-joint-hmaema-workshop-artificial-intelligence-medicines-regulation_en.pdf"},
    {"id":"51302","name":"Report on the implementation of the EMA-EUnetHTA work plan 2017 - 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-06-01T09:00:00Z","last_updated_date":"2021-06-01T09:00:00Z","reference_number":"EMA/265469/2021","document_url":"https://www.ema.europa.eu/en/documents/report/report-implementation-ema-eunethta-work-plan-2017-2021_en.pdf"},
    {"id":"51359","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: March 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-06-04T09:29:00Z","last_updated_date":"2021-06-04T09:29:00Z","reference_number":"EMA/195931/2021","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-march-2021_en.pdf"},
    {"id":"51373","name":"Applications for new human medicines under evaluation by the CHMP: June 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-06-07T15:28:00Z","last_updated_date":"2021-06-07T15:28:00Z","reference_number":"EMA/316655/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2021_en.xlsx"},
    {"id":"51388","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: April 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-06-10T10:07:00Z","last_updated_date":"2021-06-10T10:07:00Z","reference_number":"EMA/195931/2021","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-april-2021_en.pdf"},
    {"id":"51419","name":"PRAC statistics: June 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-06-11T12:40:00Z","last_updated_date":"2021-06-11T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-june-2021_en.pdf"},
    {"id":"51443","name":"Report on budgetary and financial management: financial year 2018","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2021-06-15T17:52:00Z","last_updated_date":"2021-06-15T17:52:00Z","reference_number":"EMA/871245/2018","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2018_en.pdf"},
    {"id":"51444","name":"Report on budgetary and financial management: financial year 2019","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2021-06-15T17:52:00Z","last_updated_date":"2021-06-15T17:52:00Z","reference_number":"EMA/231523/2019","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2019_en.pdf"},
    {"id":"51445","name":"Report on budgetary and financial management: financial year 2020","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2021-06-15T17:52:00Z","last_updated_date":"2021-06-15T17:52:00Z","reference_number":"EMA/628814/2020","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2020_en.pdf"},
    {"id":"51465","name":"Medicinal products for human use: monthly figures - May 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-06-17T08:42:00Z","last_updated_date":"2021-06-17T08:42:00Z","reference_number":"EMA/339238/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2021_en.pdf"},
    {"id":"51495","name":"Outcome of written procedures finalised during the period from 13 February 2021 to 25 May 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-06-18T16:36:00Z","last_updated_date":"2021-06-18T16:36:00Z","reference_number":"EMA/MB/315817/2021","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-written-procedures-finalised-during-period-13-february-2021-25-may-2021_en.pdf"},
    {"id":"51634","name":"Highlights from the second meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-06-28T11:59:00Z","last_updated_date":"2021-06-28T11:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-second-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf"},
    {"id":"51636","name":"EMA's SME office report 2016-2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-06-28T12:03:00Z","last_updated_date":"2021-06-28T12:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/emas-sme-office-report-2016-2020_en.pdf"},
    {"id":"51674","name":"EMA/ECDC/EFSA third joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals (JIACRA III)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-06-30T11:00:00Z","last_updated_date":"2021-06-30T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/emaecdcefsa-third-joint-report-integrated-analysis-consumption-antimicrobial-agents-and-occurrence-antimicrobial-resistance-bacteria-humans-and-food-producing-animals-jiacra-iii_en.pdf"},
    {"id":"51771","name":"Annual activity report 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-07-05T10:38:00Z","last_updated_date":"2021-07-05T10:38:00Z","reference_number":"EMA/81758/2021","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2020_en.pdf"},
    {"id":"51896","name":"PRAC statistics: July 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T12:38:00Z","last_updated_date":"2021-07-09T12:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-july-2021_en.pdf"},
    {"id":"51900","name":"Applications for new human medicines under evaluation by the CHMP: July 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T14:50:00Z","last_updated_date":"2021-07-09T14:50:00Z","reference_number":"EMA/373584/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2021_en.xlsx"},
    {"id":"51917","name":"Annual accounts: Financial year 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-07-12T17:49:00Z","last_updated_date":"2021-07-12T17:49:00Z","reference_number":"EMA/184920/2021","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2020_en.pdf"},
    {"id":"51939","name":"Medicinal products for human use: monthly figures - June 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-07-15T15:43:00Z","last_updated_date":"2021-07-15T15:43:00Z","reference_number":"EMA/396354/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2021_en.pdf"},
    {"id":"51961","name":"Genome editing EU-IN Horizon Scanning Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-07-19T16:13:00Z","last_updated_date":"2021-07-19T16:13:00Z","reference_number":"EMA/319248/2020","document_url":"https://www.ema.europa.eu/en/documents/report/genome-editing-eu-horizon-scanning-report_en.pdf"},
    {"id":"52141","name":"Meeting report of the joint meeting of the FDA/CTTI Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP) on 1 July 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-07-29T10:11:00Z","last_updated_date":"2021-07-29T10:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-joint-meeting-fdactti-patient-engagement-collaborative-pec-and-ema-patients-and-consumers-working-party-pcwp-1-july-2021_en.pdf"},
    {"id":"52194","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: June 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-08-04T15:18:00Z","last_updated_date":"2021-08-04T15:18:00Z","reference_number":"EMA/376271/2021","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-june-2021_en.pdf"},
    {"id":"52205","name":"Applications for new human medicines under evaluation by the CHMP: August 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-08-09T14:49:00Z","last_updated_date":"2021-08-09T14:49:00Z","reference_number":"EMA/444323/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2021_en.xlsx"},
    {"id":"52212","name":"Medicinal products for human use: monthly figures - July 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-08-11T11:42:00Z","last_updated_date":"2021-08-11T11:42:00Z","reference_number":"EMA/452002/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2021_en.pdf"},
    {"id":"52318","name":"Applications for new human medicines under evaluation by the CHMP: September 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-09-02T09:46:00Z","last_updated_date":"2021-09-02T09:46:00Z","reference_number":"EMA/491283/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2021_en.xlsx"},
    {"id":"52335","name":"PRAC statistics: September 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-09-03T12:33:00Z","last_updated_date":"2021-09-03T12:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-september-2021_en.pdf"},
    {"id":"52509","name":"Medicinal products for human use: monthly figures - August 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T16:03:00Z","last_updated_date":"2021-09-17T16:03:00Z","reference_number":"EMA/526215/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2021_en.pdf"},
    {"id":"52592","name":"Highlight report - Sixth industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-09-23T15:58:00Z","last_updated_date":"2021-09-23T15:58:00Z","reference_number":"EMA/326151/2021","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-sixth-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"52614","name":"Highlight report from the sixth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-09-24T17:16:00Z","last_updated_date":"2021-09-24T17:16:00Z","reference_number":"EMA/381927/2021","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-sixth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"52698","name":"PRAC statistics: October 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-10-01T12:00:00Z","last_updated_date":"2021-10-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-october-2021_en.pdf"},
    {"id":"52713","name":"Highlights from the third meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-10-04T13:52:00Z","last_updated_date":"2021-10-04T13:52:00Z","reference_number":"EMA/INS/512114/2021","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-third-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf"},
    {"id":"52734","name":"Final feedback from European Medicine Agency (EMA) to the EU Commission request to evaluate the impact of the removal of titanium dioxide from the list of authorised food additives on medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-10-08T12:00:00Z","last_updated_date":"2021-10-08T12:00:00Z","reference_number":"EMA/504010/2021","document_url":"https://www.ema.europa.eu/en/documents/report/final-feedback-european-medicine-agency-ema-eu-commission-request-evaluate-impact-removal-titanium-dioxide-list-authorised-food-additives-medicinal-products_en.pdf"},
    {"id":"52776","name":"Applications for new human medicines under evaluation by the CHMP: October 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-10-08T09:23:00Z","last_updated_date":"2021-10-08T09:23:00Z","reference_number":"EMA/569084/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2021_en.xlsx"},
    {"id":"52799","name":"European Medicines Agency mid-year report 2021 (January-June 2021)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-10-11T15:32:00Z","last_updated_date":"2024-02-14T11:00:00Z","reference_number":"EMA/352298/2021","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2021-january-june-2021_en.pdf"},
    {"id":"52801","name":"Outcome of written procedures finalised during the period from 26 May 2021 to 13 September 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-10-11T15:35:00Z","last_updated_date":"2021-10-11T15:35:00Z","reference_number":"EMA/MB/520127/2021","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-written-procedures-finalised-during-period-26-may-2021-13-september-2021_en.pdf"},
    {"id":"52839","name":"Tailored Scientific Advice for biosimilar development: report on the experience from the pilot (2017-2020)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-10-14T10:13:00Z","last_updated_date":"2021-10-14T10:13:00Z","reference_number":"EMA/297462/2021","document_url":"https://www.ema.europa.eu/en/documents/report/tailored-scientific-advice-biosimilar-development-report-experience-pilot-2017-2020_en.pdf"},
    {"id":"52857","name":"Medicinal products for human use: monthly figures - September 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-10-15T09:42:00Z","last_updated_date":"2021-10-15T09:42:00Z","reference_number":"EMA/582623/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2021_en.pdf"},
    {"id":"52945","name":"PRAC statistics: November 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-10-29T11:42:00Z","last_updated_date":"2021-10-29T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-november-2021_en.pdf"},
    {"id":"53011","name":"Applications for new human medicines under evaluation by the CHMP: November 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-08T12:19:00Z","last_updated_date":"2021-11-08T12:19:00Z","reference_number":"EMA/625035/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2021_en.xlsx"},
    {"id":"53024","name":"Report - 2021 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA (Enpr-EMA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-09T09:57:00Z","last_updated_date":"2021-11-09T09:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-2021-annual-meeting-members-and-coordinating-group-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"53118","name":"Medicinal products for human use: monthly figures - October 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-15T12:09:00Z","last_updated_date":"2021-11-15T12:09:00Z","reference_number":"EMA/641328/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2021_en.pdf"},
    {"id":"53202","name":"Sales of veterinary antimicrobial agents in 31 European countries in 2019 and 2020 - Trends from 2010 to 2020 - Eleventh ESVAC report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-12-17T09:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-31-european-countries-2019-and-2020-trends-2010-2020-eleventh-esvac-report_en.pdf"},
    {"id":"53203","name":"Austria - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/464795/2021","document_url":"https://www.ema.europa.eu/en/documents/report/austria-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53204","name":"Belgium - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/466737/2021","document_url":"https://www.ema.europa.eu/en/documents/report/belgium-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53205","name":"Bulgaria - trends in the sales of antimicrobial VMPs for food-producing animals between 2011 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/505125/2021","document_url":"https://www.ema.europa.eu/en/documents/report/bulgaria-trends-sales-antimicrobial-vmps-food-producing-animals-between-2011-and-2020_en.pdf"},
    {"id":"53207","name":"Switzerland - trends in the sales of antimicrobial VMPs for food-producing animals between 2011 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/499787/2021","document_url":"https://www.ema.europa.eu/en/documents/report/switzerland-trends-sales-antimicrobial-vmps-food-producing-animals-between-2011-and-2020_en.pdf"},
    {"id":"53208","name":"Cyprus - trends in the sales of antimicrobial VMPs for food-producing animals between 2011 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/468170/2021","document_url":"https://www.ema.europa.eu/en/documents/report/cyprus-trends-sales-antimicrobial-vmps-food-producing-animals-between-2011-and-2020_en.pdf"},
    {"id":"53209","name":"Czechia - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/476406/2021","document_url":"https://www.ema.europa.eu/en/documents/report/czechia-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53210","name":"Germany - trends in the sales of antimicrobial VMPs for food-producing animals between 2011 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/471515/2021","document_url":"https://www.ema.europa.eu/en/documents/report/germany-trends-sales-antimicrobial-vmps-food-producing-animals-between-2011-and-2020_en.pdf"},
    {"id":"53211","name":"Denmark - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/477462/2021","document_url":"https://www.ema.europa.eu/en/documents/report/denmark-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53212","name":"Estonia - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/469568/2021","document_url":"https://www.ema.europa.eu/en/documents/report/estonia-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53213","name":"Spain - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/510455/2021","document_url":"https://www.ema.europa.eu/en/documents/report/spain-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53215","name":"Finland- trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/471514/2021","document_url":"https://www.ema.europa.eu/en/documents/report/finland-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53216","name":"France - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/477548/2021","document_url":"https://www.ema.europa.eu/en/documents/report/france-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53218","name":"Greece - trends in the sales of antimicrobial VMPs for food-producing animals between 2015 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/471517/2021","document_url":"https://www.ema.europa.eu/en/documents/report/greece-trends-sales-antimicrobial-vmps-food-producing-animals-between-2015-and-2020_en.pdf"},
    {"id":"53219","name":"Croatia - trends in the sales of antimicrobial VMPs for food-producing animals between 2014 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/505600/2021","document_url":"https://www.ema.europa.eu/en/documents/report/croatia-trends-sales-antimicrobial-vmps-food-producing-animals-between-2014-and-2020_en.pdf"},
    {"id":"53220","name":"Hungary - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/503278/2021","document_url":"https://www.ema.europa.eu/en/documents/report/hungary-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53222","name":"Ireland - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/502187/2021","document_url":"https://www.ema.europa.eu/en/documents/report/ireland-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53224","name":"Iceland - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/477687/2021","document_url":"https://www.ema.europa.eu/en/documents/report/iceland-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53225","name":"Italy - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/474608/2021","document_url":"https://www.ema.europa.eu/en/documents/report/italy-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53227","name":"Lithuania - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/511878/2021","document_url":"https://www.ema.europa.eu/en/documents/report/lithuania-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53228","name":"Luxembourg - trends in the sales of antimicrobial VMPs for food-producing animals between 2012 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/502005/2021","document_url":"https://www.ema.europa.eu/en/documents/report/luxembourg-trends-sales-antimicrobial-vmps-food-producing-animals-between-2012-and-2020_en.pdf"},
    {"id":"53229","name":"Latvia - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/507205/2021","document_url":"https://www.ema.europa.eu/en/documents/report/latvia-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53230","name":"Malta - trends in the sales of antimicrobial VMPs for food-producing animals between 2017 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/505636/2021","document_url":"https://www.ema.europa.eu/en/documents/report/malta-trends-sales-antimicrobial-vmps-food-producing-animals-between-2017-and-2020_en.pdf"},
    {"id":"53231","name":"Netherlands - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/500819/2021","document_url":"https://www.ema.europa.eu/en/documents/report/netherlands-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53232","name":"Norway - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/500518/2021","document_url":"https://www.ema.europa.eu/en/documents/report/norway-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53233","name":"Poland - trends in the sales of antimicrobial VMPs for food-producing animals between 2011 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/508279/2021","document_url":"https://www.ema.europa.eu/en/documents/report/poland-trends-sales-antimicrobial-vmps-food-producing-animals-between-2011-and-2020_en.pdf"},
    {"id":"53234","name":"Portugal - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/511548/2021","document_url":"https://www.ema.europa.eu/en/documents/report/portugal-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53235","name":"Romania - trends in the sales of antimicrobial VMPs for food-producing animals between 2014 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/501517/2021","document_url":"https://www.ema.europa.eu/en/documents/report/romania-trends-sales-antimicrobial-vmps-food-producing-animals-between-2014-and-2020_en.pdf"},
    {"id":"53236","name":"Sweden - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/499230/2021","document_url":"https://www.ema.europa.eu/en/documents/report/sweden-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53237","name":"Slovenia - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/507665/2021","document_url":"https://www.ema.europa.eu/en/documents/report/slovenia-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53238","name":"Slovakia - trends in the sales of antimicrobial VMPs for food-producing animals between 2011 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/507685/2021","document_url":"https://www.ema.europa.eu/en/documents/report/slovakia-trends-sales-antimicrobial-vmps-food-producing-animals-between-2011-and-2020_en.pdf"},
    {"id":"53239","name":"United Kingdom - trends in the sales of antimicrobial VMPs for food-producing animals between 2010 and 2020","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-11-23T14:00:00Z","last_updated_date":"2021-11-23T14:00:00Z","reference_number":"EMA/530673/2021","document_url":"https://www.ema.europa.eu/en/documents/report/united-kingdom-trends-sales-antimicrobial-vmps-food-producing-animals-between-2010-and-2020_en.pdf"},
    {"id":"53357","name":"PRAC statistics: December 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-12-03T11:24:00Z","last_updated_date":"2021-12-03T11:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-december-2021_en.pdf"},
    {"id":"53416","name":"Applications for new human medicines under evaluation by the CHMP: January 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-01-07T13:52:00Z","last_updated_date":"2022-01-07T13:52:00Z","reference_number":"EMA/4718/2022","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2022_en.xlsx"},
    {"id":"53568","name":"Heterologous primary and booster COVID-19 vaccination - Evidence based regulatory considerations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-12-16T17:24:00Z","last_updated_date":"2021-12-16T17:24:00Z","reference_number":"EMA/349565/2021","document_url":"https://www.ema.europa.eu/en/documents/report/heterologous-primary-and-booster-covid-19-vaccination-evidence-based-regulatory-considerations_en.pdf"},
    {"id":"53601","name":"Outcome of written procedures finalised during the period from 14 September 2021 to 24 November 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-12-20T10:47:00Z","last_updated_date":"2021-12-20T10:47:00Z","reference_number":"EMA/MB/717729/2021","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-written-procedures-finalised-during-period-14-september-2021-24-november-2021_en.pdf"},
    {"id":"53608","name":"Report - EU Big Data Stakeholder Forum 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-12-20T16:25:00Z","last_updated_date":"2021-12-20T16:25:00Z","reference_number":"EMA/109720/2020","document_url":"https://www.ema.europa.eu/en/documents/report/report-eu-big-data-stakeholder-forum-2021_en.pdf"},
    {"id":"53615","name":"Report - European Medicines Agency-Nuclear Medicines Europe meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-12-21T16:04:00Z","last_updated_date":"2021-12-21T16:04:00Z","reference_number":"EMA/572597/2021","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-agency-nuclear-medicines-europe-meeting_en.pdf"},
    {"id":"53649","name":"Medicinal products for human use: monthly figures - November 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-01-07T12:10:00Z","last_updated_date":"2022-01-07T12:10:00Z","reference_number":"EMA/738337/2021","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2021_en.pdf"},
    {"id":"53651","name":"Applications for new human medicines under evaluation by the CHMP: December 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T12:19:00Z","last_updated_date":"2021-12-08T12:19:00Z","reference_number":"EMA/726376/2021","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2021_en.xlsx"},
    {"id":"53715","name":"PRAC statistics: January 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-01-14T11:42:00Z","last_updated_date":"2022-01-14T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-january-2022_en.pdf"},
    {"id":"53940","name":"Final programming document 2022-2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-01-27T10:15:00Z","last_updated_date":"2022-09-08T08:51:00Z","reference_number":"EMA/32271/2022","document_url":"https://www.ema.europa.eu/en/documents/report/final-programming-document-2022-2024_en.pdf"},
    {"id":"54026","name":"Meeting report - Learnings initiative webinar for optimal use of big data for regulatory purpose","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T16:10:00Z","last_updated_date":"2022-02-03T15:25:00Z","reference_number":"EMA/18271/2022","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-learnings-initiative-webinar-optimal-use-big-data-regulatory-purpose_en.pdf"},
    {"id":"54049","name":"Highlight report from the seventh meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-02-02T07:16:00Z","last_updated_date":"2022-02-02T07:16:00Z","reference_number":"EMA/711421/2021","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-seventh-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"54056","name":"CAT monthly report of application procedures, guidelines and related documents on advanced therapies: December 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-02-03T12:22:00Z","last_updated_date":"2022-02-03T12:22:00Z","reference_number":"EMA/CAT/760977/2021","document_url":"https://www.ema.europa.eu/en/documents/report/cat-monthly-report-application-procedures-guidelines-and-related-documents-advanced-therapies-december-2021_en.pdf"},
    {"id":"54073","name":"Applications for new human medicines under evaluation by the CHMP: February 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-02-04T13:25:00Z","last_updated_date":"2022-03-23T10:19:00Z","reference_number":"EMA/71693/2022 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2022_en.xlsx"},
    {"id":"54131","name":"Annual report of the Good Clinical Practice Inspectors Working Group 2019","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2022-02-10T16:44:00Z","last_updated_date":"2022-02-10T16:44:00Z","reference_number":"EMA/INS/GCP/588463/2020","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-clinical-practice-inspectors-working-group-2019_en.pdf"},
    {"id":"54140","name":"PRAC statistics: February 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-02-11T11:42:00Z","last_updated_date":"2022-02-11T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-february-2022_en.pdf"},
    {"id":"54163","name":"Medicinal products for human use: monthly figures - December 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-02-15T10:29:00Z","last_updated_date":"2022-02-15T10:29:00Z","reference_number":"EMA/14975/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2021_en.pdf"},
    {"id":"54171","name":"Human medicines highlights 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-02-15T13:00:00Z","last_updated_date":"2022-02-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2021_en.pdf"},
    {"id":"54172","name":"Veterinary medicines highlights 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-02-15T13:00:00Z","last_updated_date":"2022-02-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/veterinary-medicines-highlights-2021_en.pdf"},
    {"id":"54203","name":"Monthly report on application procedures, guidelines and related documents for veterinary medicines: December 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-02-17T10:28:00Z","last_updated_date":"2022-02-17T10:28:00Z","reference_number":"EMA/732242/2021","document_url":"https://www.ema.europa.eu/en/documents/report/monthly-report-application-procedures-guidelines-and-related-documents-veterinary-medicines-december-2021_en.pdf"},
    {"id":"54242","name":"Report on public consultation on EU Common Standard for electronic product information (ePI) - Summary of comments received and next steps","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-02-22T12:00:00Z","last_updated_date":"2022-02-22T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-public-consultation-eu-common-standard-electronic-product-information-epi-summary-comments-received-and-next-steps_en.pdf"},
    {"id":"54302","name":"Medicinal products for human use: monthly figures - January 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-02-25T11:36:00Z","last_updated_date":"2022-02-25T11:36:00Z","reference_number":"EMA/107357/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2022_en.pdf"},
    {"id":"54348","name":"PRIME: Analysis of the first 5 years' experience","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-03T16:00:00Z","last_updated_date":"2022-04-05T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prime-analysis-first-5-years-experience_en.pdf"},
    {"id":"54349","name":"PRIME: 5 years' experience","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-03T16:00:00Z","last_updated_date":"2025-06-26T15:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prime-5-years-experience_en.pdf"}    {"id":"54418","name":"Applications for new human medicines under evaluation by the CHMP: March 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-11T09:45:00Z","last_updated_date":"2022-03-23T10:18:00Z","reference_number":"EMA/144373/2022 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2022_en.xlsx"},
    {"id":"54422","name":"PRAC statistics: March 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-11T11:09:00Z","last_updated_date":"2022-03-11T11:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-march-2022_en.pdf"},
    {"id":"54467","name":"Big Data Steering Group (BDSG): 2021 report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-15T09:41:00Z","last_updated_date":"2022-03-15T09:41:00Z","reference_number":"EMA/40400/2022","document_url":"https://www.ema.europa.eu/en/documents/report/big-data-steering-group-bdsg-2021-report_en.pdf"},
    {"id":"54499","name":"Highlight report from the seventh Industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-17T13:39:00Z","last_updated_date":"2022-03-17T13:39:00Z","reference_number":"EMA/714427/2021","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-seventh-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"54520","name":"Minor uses and minor species (MUMS)/limited market scheme for veterinary medicinal products - 12th annual report","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2022-03-18T16:34:00Z","last_updated_date":"2022-03-18T16:34:00Z","reference_number":"EMA/573681/2021","document_url":"https://www.ema.europa.eu/en/documents/report/minor-uses-and-minor-species-mumslimited-market-scheme-veterinary-medicinal-products-12th-annual-report_en.pdf"},
    {"id":"54521","name":"2021 European Medicines Agency annual report on independence","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2022-03-18T16:35:00Z","last_updated_date":"2023-11-06T21:15:00Z","reference_number":"EMA/759921/2021","document_url":"https://www.ema.europa.eu/en/documents/report/2021-european-medicines-agency-annual-report-independence_en.pdf"},
    {"id":"54579","name":"Medicinal products for human use: monthly figures - February 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T10:11:00Z","last_updated_date":"2022-03-25T10:11:00Z","reference_number":"EMA/184105/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2022_en.pdf"},
    {"id":"54599","name":"Highlights from the fifth meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-28T14:09:00Z","last_updated_date":"2022-03-28T14:09:00Z","reference_number":"EMA/27908/2022","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-fifth-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf"},
    {"id":"54600","name":"Highlights from the fifth meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-28T14:09:00Z","last_updated_date":"2022-03-28T14:09:00Z","reference_number":"EMA/27908/2022","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-fifth-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf-0"},
    {"id":"54601","name":"Highlights from the fifth meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-28T14:09:00Z","last_updated_date":"2022-03-28T14:09:00Z","reference_number":"EMA/27908/2022","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-fifth-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf-1"},
    {"id":"54699","name":"Annual report on the use of the special contribution for orphan medicinal products - 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-04-08T10:36:00Z","last_updated_date":"2022-04-08T10:36:00Z","reference_number":"EMA/770190/2021","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-use-special-contribution-orphan-medicinal-products-2021_en.pdf"},
    {"id":"54700","name":"Applications for new human medicines under evaluation by the CHMP: April 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-04-08T11:11:00Z","last_updated_date":"2022-04-08T11:11:00Z","reference_number":"EMA/203848/2022","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2022_en.xlsx"},
    {"id":"54702","name":"PRAC statistics: April 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-04-08T11:42:00Z","last_updated_date":"2022-04-08T11:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-april-2022_en.pdf"},
    {"id":"54703","name":"Report on budgetary and financial management - financial year 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-04-08T12:02:00Z","last_updated_date":"2022-04-08T12:02:00Z","reference_number":"EMA/2152/2022","document_url":"https://www.ema.europa.eu/en/documents/report/report-budgetary-and-financial-management-financial-year-2021_en.pdf"},
    {"id":"54757","name":"EMA / eligible healthcare professional organisations policy officers’ group (HCP POG) pilot: one-year review","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-04-19T10:20:00Z","last_updated_date":"2022-04-19T10:20:00Z","reference_number":"EMA/26892/2022","document_url":"https://www.ema.europa.eu/en/documents/report/ema-eligible-healthcare-professional-organisations-policy-officers-group-hcp-pog-pilot-one-year-review_en.pdf"},
    {"id":"54762","name":"Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2021","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2022-04-20T12:40:00Z","last_updated_date":"2022-04-20T12:40:00Z","reference_number":"EMA/INS/GMP/706144/2021","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-manufacturing-and-distribution-practice-inspectors-working-group-2021_en.pdf"},
    {"id":"54766","name":"2021 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-03-17T15:57:00Z","last_updated_date":"2022-03-17T15:57:00Z","reference_number":"EMA/719826/2021","document_url":"https://www.ema.europa.eu/en/documents/report/2021-annual-report-eudravigilance-european-parliament-council-and-commission_en.pdf"},
    {"id":"54818","name":"Medicinal products for human use: monthly figures - March 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-04-25T09:13:00Z","last_updated_date":"2022-04-25T09:13:00Z","reference_number":"EMA/219911/20222","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2022_en.pdf"},
    {"id":"54873","name":"Stakeholder engagement report 2020-2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-05-02T15:03:00Z","last_updated_date":"2022-05-10T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2020-2021_en.pdf"},
    {"id":"54912","name":"PRAC statistics: May 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-05-06T11:17:00Z","last_updated_date":"2022-05-06T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-may-2022_en.pdf"},
    {"id":"54964","name":"Applications for new human medicines under evaluation by the CHMP: May 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-05-16T14:08:00Z","last_updated_date":"2022-05-16T14:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2022_en.xlsx"},
    {"id":"55040","name":"Medicinal products for human use: monthly figures - April 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T11:23:00Z","last_updated_date":"2022-05-20T11:23:00Z","reference_number":"EMA/274576/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2022_en.pdf"},
    {"id":"55043","name":"Annual Report of the Good Clinical Practice Inspectors' Working Group 2020","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:56:00Z","last_updated_date":"2022-05-20T12:56:00Z","reference_number":"EMA/INS/GCP/271107/2022","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-clinical-practice-inspectors-working-group-2020_en.pdf"},
    {"id":"55152","name":"Applications for new human medicines under evaluation by the CHMP: June 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-06-08T14:34:00Z","last_updated_date":"2022-06-08T14:34:00Z","reference_number":"EMA/564600/2022","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2022_en.xlsx"},
    {"id":"55168","name":"Medicinal products for human use: monthly figures - May 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-06-09T12:38:00Z","last_updated_date":"2022-06-09T12:38:00Z","reference_number":"EMA/567275/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2022_en.pdf"},
    {"id":"55184","name":"Small and medium-sized enterprise (SME) Office annual report 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-06-10T12:26:00Z","last_updated_date":"2022-06-10T12:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/small-and-medium-sized-enterprise-sme-office-annual-report-2021_en.pdf"},
    {"id":"55185","name":"Small and medium-sized enterprise (SME) Office annual report 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-06-10T12:26:00Z","last_updated_date":"2022-06-10T12:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/small-and-medium-sized-enterprise-sme-office-annual-report-2021_en.pdf-0"},
    {"id":"55192","name":"PRAC statistics: June 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-06-10T11:17:00Z","last_updated_date":"2022-06-10T11:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-june-2022_en.pdf"},
    {"id":"55220","name":"Faecal microbiota transplantation EU-IN Horizon Scanning Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T14:19:00Z","last_updated_date":"2025-11-11T17:22:00Z","reference_number":"EMA/204935/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/faecal-microbiota-transplantation-eu-horizon-scanning-report_en.pdf"},
    {"id":"55333","name":"Annual activity report 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-06-23T14:25:00Z","last_updated_date":"2022-06-23T14:25:00Z","reference_number":"EMA/75685/2022","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2021_en.pdf"},
    {"id":"55402","name":"Annual accounts: Financial year 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-06-29T11:37:00Z","last_updated_date":"2023-01-31T11:23:00Z","reference_number":"EMA/133175/2022 Corr 1","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2021_en.pdf"},
    {"id":"55405","name":"Report - Data quality framework for medicines regulation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-06-29T13:21:00Z","last_updated_date":"2022-06-29T13:21:00Z","reference_number":"EMA/615349/2022","document_url":"https://www.ema.europa.eu/en/documents/report/report-data-quality-framework-medicines-regulation_en.pdf"},
    {"id":"55428","name":"European Medicines Agency’s interaction with industry stakeholders - Biennial report 2020-2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-07-01T11:10:00Z","last_updated_date":"2022-07-01T11:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agencys-interaction-industry-stakeholders-biennial-report-2020-2021_en.pdf"},
    {"id":"55491","name":"OPEN Pilot: One-year review and recommendations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-07-07T15:15:00Z","last_updated_date":"2022-07-07T15:15:00Z","reference_number":"EMA/6881/2022","document_url":"https://www.ema.europa.eu/en/documents/report/open-pilot-one-year-review-and-recommendations_en.pdf"},
    {"id":"55503","name":"PRAC statistics: July 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-07-08T11:56:00Z","last_updated_date":"2022-07-08T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-july-2022_en.pdf"},
    {"id":"55508","name":"Applications for new human medicines under evaluation by the CHMP: July 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-07-08T17:07:00Z","last_updated_date":"2022-07-08T17:07:00Z","reference_number":"EMA/623957/2022","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2022_en.xlsx"},
    {"id":"55521","name":"Medicinal products for human use: monthly figures - June 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-07-12T15:09:00Z","last_updated_date":"2022-07-12T15:09:00Z","reference_number":"EMA/626849/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2022_en.pdf"},
    {"id":"55558","name":"Technology Capability Investment Plan to 2028 - Becoming a digital hub for the European medicines regulator network","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-19T10:45:00Z","last_updated_date":"2025-12-19T10:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/technology-capability-investment-plan-2028-becoming-digital-hub-european-medicines-regulator-network_en.pdf"},
    {"id":"55721","name":"Boric acid and borate used as excipients - Report published in support of the ‘Questions and answers on boric acid and borates used as excipients in medicinal products for human use’ - Rev. 1","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-07-28T02:00:00Z","last_updated_date":"2022-07-28T02:00:00Z","reference_number":"EMA/CHMP/765436/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/boric-acid-and-borate-used-excipients-report-published-support-questions-and-answers-boric-acid-and-borates-used-excipients-medicinal-products-human-use-rev-1_en.pdf"},
    {"id":"55810","name":"Applications for new human medicines under evaluation by the CHMP: August 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-08-10T14:39:00Z","last_updated_date":"2022-08-10T14:39:00Z","reference_number":"EMA/685123/2022","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2022_en.xlsx"},
    {"id":"55846","name":"Highlight report from the eighth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-08-19T14:08:00Z","last_updated_date":"2022-08-19T14:08:00Z","reference_number":"EMA/611878/2022","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-eighth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"55849","name":"Medicinal products for human use: monthly figures - July 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-08-22T09:01:00Z","last_updated_date":"2022-08-22T09:01:00Z","reference_number":"EMA/699442/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2022_en.pdf"},
    {"id":"56197","name":"Applications for new human medicines under evaluation by the CHMP: September 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T11:00:00Z","last_updated_date":"2022-09-27T11:00:00Z","reference_number":"EMA/784941/2022","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2022_en.xlsx"},
    {"id":"56251","name":"Meeting report of the Joint Meeting of the CTTI-FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP) on 15 July 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T10:23:00Z","last_updated_date":"2022-09-29T10:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-joint-meeting-ctti-fda-patient-engagement-collaborative-pec-and-ema-patients-and-consumers-working-party-pcwp-15-july-2022_en.pdf"},
    {"id":"56260","name":"Medicinal products for human use: monthly figures - August 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-09-30T10:07:00Z","last_updated_date":"2022-09-30T10:07:00Z","reference_number":"EMA/787835/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2022_en.pdf"},
    {"id":"56265","name":"PRAC statistics: October 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-09-30T11:47:00Z","last_updated_date":"2022-09-30T11:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-october-2022_en.pdf"},
    {"id":"56365","name":"Pilot on early dialogue with patient organisations for orphan marketing authorisation applications: Outcome Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-10-12T12:21:00Z","last_updated_date":"2022-10-12T12:21:00Z","reference_number":"EMA/665019/2022","document_url":"https://www.ema.europa.eu/en/documents/report/pilot-early-dialogue-patient-organisations-orphan-marketing-authorisation-applications-outcome-report_en.pdf"},
    {"id":"56402","name":"Applications for new human medicines under evaluation by the CHMP: October 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-10-13T14:46:00Z","last_updated_date":"2022-10-13T14:46:00Z","reference_number":"EMA/822461/2022","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2022_en.xlsx"},
    {"id":"56403","name":"Medicinal products for human use: monthly figures - September 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-10-13T14:49:00Z","last_updated_date":"2022-10-13T14:49:00Z","reference_number":"EMA/824712/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2022_en.pdf"},
    {"id":"56420","name":"European Medicines Agency mid-year report 2022 (January-June 2022)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-10-14T14:34:00Z","last_updated_date":"2024-02-14T11:10:00Z","reference_number":"EMA/697686/2022","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2022-january-june-2022_en.pdf"},
    {"id":"56425","name":"Hearing with the Association of the European Self-Medication Industry (AESGP) during the HMPC May 2022 meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-10-17T12:49:00Z","last_updated_date":"2022-10-17T12:49:00Z","reference_number":"EMA/HMPC/609605/2022","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-aesgp-during-hmpc-may-2022-meeting_en.pdf"},
    {"id":"56460","name":"Sales of veterinary antimicrobial agents in 31 European countries in 2021 - Trends from 2010 to 2021 - Twelfth ESVAC report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-12-14T12:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-31-european-countries-2021-trends-2010-2021-twelfth-esvac-report_en.pdf"},
    {"id":"56500","name":"PRAC statistics: November 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-10-28T11:47:00Z","last_updated_date":"2022-10-28T11:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-november-2022_en.pdf"},
    {"id":"56518","name":"Applications for new human medicines under evaluation by the CHMP: November 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-03T10:16:00Z","last_updated_date":"2022-11-03T10:16:00Z","reference_number":"EMA/855051/2022","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2022_en.xlsx"},
    {"id":"56522","name":"Medicinal products for human use: monthly figures - October 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-03T13:33:00Z","last_updated_date":"2022-11-03T13:33:00Z","reference_number":"EMA/858308/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2022_en.pdf"},
    {"id":"56573","name":"Meeting highlights - First European Medicines Agency - European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-10T12:52:00Z","last_updated_date":"2022-11-10T12:52:00Z","reference_number":"EMA/775191/2021","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-highlights-first-european-medicines-agency-european-confederation-pharmaceutical-entrepreneurs-eucope-bilateral-meeting_en.pdf"},
    {"id":"56641","name":"Austria - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/austria-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56642","name":"Belgium - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/belgium-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56643","name":"Bulgaria - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/bulgaria-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56644","name":"Croatia - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/croatia-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56645","name":"Cyprus - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/cyprus-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56646","name":"Czechia - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2023-10-05T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/czechia-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56647","name":"Denmark - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/denmark-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56648","name":"Estonia - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/estonia-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56649","name":"Finland - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/finland-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56651","name":"France - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/france-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56652","name":"Germany - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/germany-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56653","name":"Greece - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/greece-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56654","name":"Hungary - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/hungary-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56655","name":"Iceland - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/iceland-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56656","name":"Ireland - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/ireland-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56657","name":"Italy - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/italy-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56658","name":"Latvia - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/latvia-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56659","name":"Lithuania - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/lithuania-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56660","name":"Luxembourg - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/luxembourg-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56661","name":"Malta - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/malta-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56662","name":"Netherlands - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/netherlands-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56663","name":"Norway - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/norway-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56664","name":"Poland - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/poland-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56665","name":"Portugal - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/portugal-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56666","name":"Romania - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/romania-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56667","name":"Slovakia - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/slovakia-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56668","name":"Slovenia - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/slovenia-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56669","name":"Spain - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/spain-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56670","name":"Sweden - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2023-10-05T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/sweden-sales-trends-mg-pcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56671","name":"Switzerland - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/switzerland-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56672","name":"United Kingdom - Sales trends (mg/PCU) of antibiotic veterinary medicinal products for food-producing animals from 2010 to 2021","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T09:00:00Z","last_updated_date":"2022-11-18T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/united-kingdom-sales-trends-mgpcu-antibiotic-veterinary-medicinal-products-food-producing-animals-2010-2021_en.pdf"},
    {"id":"56705","name":"Report - Multistakeholder workshop on EMA’s extended mandate","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-18T10:32:00Z","last_updated_date":"2022-11-18T10:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-multistakeholder-workshop-emas-extended-mandate_en.pdf"},
    {"id":"56728","name":"Annual Report of the Good Clinical Practice Inspectors' Working Group 2021","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2022-11-21T16:10:00Z","last_updated_date":"2022-11-21T16:10:00Z","reference_number":"EMA/INS/GCP/33934/2022","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-clinical-practice-inspectors-working-group-2021_en.pdf"},
    {"id":"56816","name":"Report - EMA - Parenteral Drug Association bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-11-28T13:46:00Z","last_updated_date":"2022-11-28T13:46:00Z","reference_number":"EMA/852563/2022","document_url":"https://www.ema.europa.eu/en/documents/report/report-ema-parenteral-drug-association-bilateral-meeting_en.pdf"},
    {"id":"56859","name":"PRAC statistics: December 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-12-02T11:55:00Z","last_updated_date":"2022-12-02T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-december-2022_en.pdf"},
    {"id":"56884","name":"Workshop outcome - ACT EU multi-stakeholder meeting on decentralised clinical trials","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-12-06T10:53:00Z","last_updated_date":"2022-12-06T10:53:00Z","reference_number":"EMA/921051/2022","document_url":"https://www.ema.europa.eu/en/documents/report/workshop-outcome-act-eu-multi-stakeholder-meeting-decentralised-clinical-trials_en.pdf"},
    {"id":"56936","name":"Applications for new human medicines under evaluation by the CHMP: December 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-12-12T11:25:00Z","last_updated_date":"2022-12-12T11:25:00Z","reference_number":"EMA/932370/2022","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2022_en.xlsx"},
    {"id":"57104","name":"Medicinal products for human use: monthly figures - November 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-12-20T16:50:00Z","last_updated_date":"2022-12-20T16:50:00Z","reference_number":"EMA/944608/2022","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2022_en.pdf"},
    {"id":"57197","name":"Report from the 2022 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA (Enpr-EMA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-01-10T11:55:00Z","last_updated_date":"2023-01-10T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-2022-annual-meeting-members-and-coordinating-group-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"57219","name":"Highlight report - Ninth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-01-11T14:24:00Z","last_updated_date":"2023-01-11T14:24:00Z","reference_number":"EMA/907045/2022","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-ninth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"57270","name":"Applications for new human medicines under evaluation by the CHMP: January 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-01-12T16:31:00Z","last_updated_date":"2023-01-12T16:31:00Z","reference_number":"EMA/13171/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-january-2023_en.xlsx"},
    {"id":"57271","name":"Big Data Steering Group (BDSG): 2022 report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-01-13T08:41:00Z","last_updated_date":"2023-01-18T10:12:00Z","reference_number":"EMA/826814/2022","document_url":"https://www.ema.europa.eu/en/documents/report/big-data-steering-group-bdsg-2022-report_en.pdf"},
    {"id":"57276","name":"PRAC statistics: January 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-01-13T12:53:00Z","last_updated_date":"2023-01-13T12:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-january-2023_en.pdf"},
    {"id":"57325","name":"EMA / EFSA report on development of a harmonised approach to human dietary exposure","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-01-19T13:00:00Z","last_updated_date":"2023-01-19T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/ema-efsa-report-development-harmonised-approach-human-dietary-exposure_en.pdf"}    {"id":"57448","name":"Medicinal products for human use: monthly figures - December 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-01-30T13:27:00Z","last_updated_date":"2023-01-30T13:27:00Z","reference_number":"EMA/28628/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2022_en.pdf"},
    {"id":"57469","name":"Final programming document 2023-2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T09:58:00Z","last_updated_date":"2023-01-31T09:58:00Z","reference_number":"EMA/36710/2023","document_url":"https://www.ema.europa.eu/en/documents/report/final-programming-document-2023-2025_en.pdf"},
    {"id":"57490","name":"Report - EMA/HMA Big Data Stakeholder Forum 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-02-01T10:56:00Z","last_updated_date":"2023-02-01T10:56:00Z","reference_number":"EMA/919710/2022","document_url":"https://www.ema.europa.eu/en/documents/report/report-emahma-big-data-stakeholder-forum-2022_en.pdf"},
    {"id":"57515","name":"Summary report on targeted consultation on the implementation of the Clinical Trials Regulation (EU) No 536/2014","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-02-03T13:00:00Z","last_updated_date":"2023-02-03T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-targeted-consultation-implementation-clinical-trials-regulation-eu-no-5362014_en.pdf"},
    {"id":"57526","name":"Boosting the development of medicines for children: Closing report of the European Medicines Agency and European Commission (DG Health and Food Safety) action plan on paediatrics","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-02-06T10:49:00Z","last_updated_date":"2023-02-06T10:49:00Z","reference_number":"EMA/635567/2022","document_url":"https://www.ema.europa.eu/en/documents/report/boosting-development-medicines-children-closing-report-european-medicines-agency-and-european-commission-dg-health-and-food-safety-action-plan-paediatrics_en.pdf"},
    {"id":"57587","name":"Applications for new human medicines under evaluation by the CHMP: February 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T07:45:00Z","last_updated_date":"2023-02-14T13:36:00Z","reference_number":"EMA/58424/2023 corr","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-february-2023_en.xlsx"},
    {"id":"57600","name":"PRAC statistics: April 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-04-14T12:16:00Z","last_updated_date":"2023-04-14T12:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-april-2023_en.pdf"},
    {"id":"57610","name":"Summary report - Joint EMA-FDA workshop: Efficacy of monoclonal antibodies in the context of rapidly evolving SARS-CoV-2 variants","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T15:48:00Z","last_updated_date":"2023-02-10T15:48:00Z","reference_number":"EMA/67738/2023","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-joint-ema-fda-workshop-efficacy-monoclonal-antibodies-context-rapidly-evolving-sars-cov-2-variants_en.pdf"},
    {"id":"57675","name":"Veterinary Medicines Highlights 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-02-16T10:46:00Z","last_updated_date":"2023-02-16T10:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/veterinary-medicines-highlights-2022_en.pdf"},
    {"id":"57683","name":"Human medicines highlights 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-02-16T10:46:00Z","last_updated_date":"2026-03-03T15:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2022_en.pdf"},
    {"id":"57826","name":"Report - Regulatory and scientific virtual conference on RNA-based medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-02-24T14:29:00Z","last_updated_date":"2023-02-24T14:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-regulatory-and-scientific-virtual-conference-rna-based-medicines_en.pdf"},
    {"id":"57827","name":"Medicinal products for human use: monthly figures - January 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-02-27T10:07:00Z","last_updated_date":"2023-02-27T10:07:00Z","reference_number":"EMA/76000/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2023_en.pdf"},
    {"id":"57950","name":"Results for EU Survey on proposed use cases - Second Veterinary Big Data Stakeholder Forum","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-03-08T13:25:00Z","last_updated_date":"2023-03-08T13:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/results-eu-survey-proposed-use-cases-second-veterinary-big-data-stakeholder-forum_en.pdf"},
    {"id":"57951","name":"Conclusions - Second Veterinary Big Data Stakeholder Forum","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-03-08T13:33:00Z","last_updated_date":"2023-03-08T13:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/conclusions-second-veterinary-big-data-stakeholder-forum_en.pdf"},
    {"id":"57953","name":"Highlight report - Ninth industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-03-08T13:48:00Z","last_updated_date":"2023-03-08T13:48:00Z","reference_number":"EMA/923972/2022","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-ninth-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"57955","name":"Annual report on the use of the special contribution for orphan medicinal products - 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T14:35:00Z","last_updated_date":"2025-02-14T14:35:00Z","reference_number":"EMA/577794/2024","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-use-special-contribution-orphan-medicinal-products-2024_en.pdf"},
    {"id":"57960","name":"Applications for new human medicines under evaluation by the CHMP: March 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-03-09T09:05:00Z","last_updated_date":"2023-03-09T09:05:00Z","reference_number":"EMA/104578/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-march-2023_en.xlsx"},
    {"id":"58017","name":"Implementing measures under Article Art 115(5) of Regulation (EU) 2019/6 as regards the list of substances which are essential for the treatment of equine species and for which the withdrawal period for equine species shall be six months","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-03-14T09:00:00Z","last_updated_date":"2023-03-14T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/implementing-measures-under-article-art-1155-regulation-eu-20196-regards-list-substances-which-are-essential-treatment-equine-species-and-which-withdrawal-period-equine-species-shall-be-six-months_en.pdf"},
    {"id":"58036","name":"Medicinal products for human use: monthly figures - February 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-03-16T09:21:00Z","last_updated_date":"2023-03-16T09:21:00Z","reference_number":"EMA/111560/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2023_en.pdf"},
    {"id":"58099","name":"2022 European Medicines Agency annual report on independence","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2023-03-21T15:35:00Z","last_updated_date":"2023-11-06T21:15:00Z","reference_number":"EMA/2588/2023","document_url":"https://www.ema.europa.eu/en/documents/report/2022-european-medicines-agency-annual-report-independence_en.pdf"},
    {"id":"58101","name":"2022 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-03-21T16:19:00Z","last_updated_date":"2023-03-21T16:19:00Z","reference_number":"EMA/900566/2022","document_url":"https://www.ema.europa.eu/en/documents/report/2022-annual-report-eudravigilance-european-parliament-council-and-commission_en.pdf"},
    {"id":"58110","name":"EMA’s Regulatory Science Strategy to 2025 - Mid-point achievements to end 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-03-22T11:58:00Z","last_updated_date":"2023-03-22T11:58:00Z","reference_number":"EMA/211551/2022","document_url":"https://www.ema.europa.eu/en/documents/report/emas-regulatory-science-strategy-2025-mid-point-achievements-end-2022_en.pdf"},
    {"id":"58169","name":"Highlights - Fifth EMA-EFPIA annual bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-03-27T15:54:00Z","last_updated_date":"2023-03-27T15:54:00Z","reference_number":"EMA/45560/2023","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-fifth-ema-efpia-annual-bilateral-meeting_en.pdf"},
    {"id":"58351","name":"Applications for new human medicines under evaluation by the CHMP: April 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-04-14T11:26:00Z","last_updated_date":"2023-04-14T11:26:00Z","reference_number":"EMA/164278/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-april-2023_en.xlsx"},
    {"id":"58410","name":"Report on divergent opinion between EFSA and EMA on bisphenol-A","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2023-04-19T10:35:00Z","last_updated_date":"2023-04-19T10:35:00Z","reference_number":"EMA/150385/2023","document_url":"https://www.ema.europa.eu/en/documents/report/report-divergent-opinion-between-efsa-and-ema-bisphenol_en.pdf"},
    {"id":"58569","name":"Medicinal products for human use: monthly figures - March 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-05-03T10:58:00Z","last_updated_date":"2023-05-03T10:58:00Z","reference_number":"EMA/182894/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2023_en.pdf"},
    {"id":"58607","name":"Applications for new human medicines under evaluation by the CHMP: May 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-05-10T12:04:00Z","last_updated_date":"2023-05-10T12:04:00Z","reference_number":"EMA/207107/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-may-2023_en.xlsx"},
    {"id":"58663","name":"PRAC statistics: May 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T15:15:00Z","last_updated_date":"2023-05-12T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-may-2023_en.pdf"},
    {"id":"58708","name":"Implementing measures under Article 114(3) of Regulation (EU) 2019/6 as regards substances used in veterinary medicinal products authorised in the Union which may be used in food-producing aquatic species in accordance with Article 114(1)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-05-16T16:00:00Z","last_updated_date":"2023-05-16T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/implementing-measures-under-article-1143-regulation-eu-20196-regards-substances-used-veterinary-medicinal-products-authorised-union-which-may-be-used-food-producing-aquatic-species-accordance-article_en.pdf"},
    {"id":"58714","name":"Report - Listen and learn focus group meeting of the Quality Innovation Group","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-05-17T10:21:00Z","last_updated_date":"2023-05-17T10:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-listen-and-learn-focus-group-meeting-quality-innovation-group_en.pdf"},
    {"id":"58735","name":"Report - 3RsWP Public Session","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-05-22T12:02:00Z","last_updated_date":"2023-05-22T12:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-3rswp-public-session_en.pdf"},
    {"id":"58742","name":"Medicinal products for human use: monthly figures - April 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-05-23T17:16:00Z","last_updated_date":"2023-05-23T17:16:00Z","reference_number":"EMA/228446/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2023_en.pdf"},
    {"id":"58775","name":"Report - Moving together towards better prevention of medicine shortages in the EU","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-05-25T10:22:00Z","last_updated_date":"2023-05-25T10:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-moving-together-towards-better-prevention-medicine-shortages-eu_en.pdf"},
    {"id":"58900","name":"Applications for new human medicines under evaluation by the CHMP: June 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-06-09T11:12:00Z","last_updated_date":"2023-07-07T10:17:00Z","reference_number":"EMA/207108/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-june-2023_en.xlsx"},
    {"id":"58905","name":"PRAC statistics: June 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-06-09T15:15:00Z","last_updated_date":"2023-06-09T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-june-2023_en.pdf"},
    {"id":"58989","name":"Small and medium-sized enterprise (SME) Office annual report 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-06-19T15:22:00Z","last_updated_date":"2023-06-19T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/small-and-medium-sized-enterprise-sme-office-annual-report-2022_en.pdf"},
    {"id":"59027","name":"Report on pharmacovigilance tasks from EU Member States and the European Medicines Agency (EMA) 2019-2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-06-22T11:45:00Z","last_updated_date":"2023-06-22T11:45:00Z","reference_number":"EMA/142695/2023","document_url":"https://www.ema.europa.eu/en/documents/report/report-pharmacovigilance-tasks-eu-member-states-and-european-medicines-agency-ema-2019-2022_en.pdf"},
    {"id":"59041","name":"Real-world evidence framework to support EU regulatory decision-making: Report on the experience gained with regulator-led studies from September 2021 to February 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-06-22T14:32:00Z","last_updated_date":"2023-07-19T14:45:00Z","reference_number":"EMA/289699/2023","document_url":"https://www.ema.europa.eu/en/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-report-experience-gained-regulator-led-studies-september-2021-february-2023_en.pdf"},
    {"id":"59111","name":"Annual activity report 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-06-28T11:46:00Z","last_updated_date":"2024-02-14T11:00:00Z","reference_number":"EMA/137754/2023","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2022_en.pdf"},
    {"id":"59113","name":"Summary report - biannual BDSG and industry stakeholders meeting 26 May 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-06-27T12:06:00Z","last_updated_date":"2023-06-27T12:06:00Z","reference_number":"EMA/245099/2023","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-biannual-bdsg-and-industry-stakeholders-meeting-26-may-2023_en.pdf"},
    {"id":"59146","name":"Medicinal products for human use: monthly figures - May 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-06-29T14:41:00Z","last_updated_date":"2023-06-29T14:41:00Z","reference_number":"EMA/279528/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2023_en.pdf"},
    {"id":"59158","name":"Annual accounts: Financial year 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-06-30T14:12:00Z","last_updated_date":"2023-06-30T14:12:00Z","reference_number":"EMA/121236/2023","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2022_en.pdf"},
    {"id":"59292","name":"PRAC statistics: July 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-07-07T10:57:00Z","last_updated_date":"2023-07-07T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-july-2023_en.pdf"},
    {"id":"59369","name":"Applications for new human medicines under evaluation by the CHMP: July 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-07-17T14:45:00Z","last_updated_date":"2023-07-17T14:45:00Z","reference_number":"EMA/309551/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2023_en.xlsx"},
    {"id":"59371","name":"Medicinal products for human use: monthly figures - June 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-07-17T14:51:00Z","last_updated_date":"2023-07-17T14:51:00Z","reference_number":"EMA/311341/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2023_en.pdf"},
    {"id":"59496","name":"Report of the EMA/ETF workshop on Lessons Learned on Clinical  Trials in Public Health Emergencies","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-07-25T14:00:00Z","last_updated_date":"2023-07-25T14:00:00Z","reference_number":"EMA/340269/2023","document_url":"https://www.ema.europa.eu/en/documents/report/report-emaetf-workshop-lessons-learned-clinical-trials-public-health-emergencies_en.pdf"},
    {"id":"59511","name":"Highlight report 10th Meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-07-27T16:17:00Z","last_updated_date":"2023-07-27T16:17:00Z","reference_number":"EMA/298697/2023","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-10th-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"59550","name":"EMA communication perception survey report 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-08-04T12:15:00Z","last_updated_date":"2023-08-04T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/ema-communication-perception-survey-report-2022_en.pdf"},
    {"id":"59594","name":"Applications for new human medicines under evaluation by the CHMP: August 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-08-14T13:57:00Z","last_updated_date":"2023-08-14T13:57:00Z","reference_number":"EMA/350192/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-august-2023_en.xlsx"},
    {"id":"59657","name":"Medicinal products for human use: monthly figures - July 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-08-29T14:14:00Z","last_updated_date":"2023-08-29T14:14:00Z","reference_number":"EMA/381074/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2023_en.pdf"},
    {"id":"59661","name":"Meeting report - Multi-stakeholder Workshop on ICH E6(R3) - Public Consultation - Day one","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-08-29T17:31:00Z","last_updated_date":"2023-08-29T17:31:00Z","reference_number":"EMA/321989/2023","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-multi-stakeholder-workshop-ich-e6r3-public-consultation-day-one_en.pdf"},
    {"id":"59882","name":"PRAC statistics: September 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T11:58:00Z","last_updated_date":"2023-09-01T11:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-september-2023_en.pdf"},
    {"id":"59916","name":"Applications for new human medicines under evaluation by the CHMP: September 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-09-07T16:34:00Z","last_updated_date":"2023-09-07T16:34:00Z","reference_number":"EMA/401841/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-september-2023_en.xlsx"},
    {"id":"60018","name":"Report on the implementation of the EMA-EUnetHTA 21 work plan 2021 - 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T15:33:00Z","last_updated_date":"2023-09-15T15:33:00Z","reference_number":"EMA/290158/2023","document_url":"https://www.ema.europa.eu/en/documents/report/report-implementation-ema-eunethta-21-work-plan-2021-2023_en.pdf"},
    {"id":"60071","name":"Medicinal products for human use: monthly figures - August 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-09-20T12:00:00Z","last_updated_date":"2023-09-20T12:00:00Z","reference_number":"EMA/416196/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2023_en.pdf"},
    {"id":"60211","name":"Report - Multi-stakeholder workshop on Real World Data (RWD) quality and Real World Evidence (RWE) use","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T11:58:00Z","last_updated_date":"2023-09-29T11:58:00Z","reference_number":"EMA/EMA/392935/2023","document_url":"https://www.ema.europa.eu/en/documents/report/report-multi-stakeholder-workshop-real-world-data-rwd-quality-and-real-world-evidence-rwe-use_en.pdf"},
    {"id":"60212","name":"PRAC statistics: October 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-09-29T12:50:00Z","last_updated_date":"2023-09-29T12:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-october-2023_en.pdf"},
    {"id":"60271","name":"Highlight report - Tenth industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-10-05T15:17:00Z","last_updated_date":"2023-10-05T15:17:00Z","reference_number":"EMA/326290/2023","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-tenth-industry-stakeholder-platform-research-and-development-support_en.pdf"},
    {"id":"60302","name":"Table of all EPARs for human and veterinary medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-06T14:16:47Z","last_updated_date":"2023-11-06T14:16:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/table-all-epars-human-and-veterinary-medicines_en.xlsx"},
    {"id":"60304","name":"Table of all withdrawn applications for human and veterinary medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-06T14:30:31Z","last_updated_date":"2023-11-06T14:30:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/table-all-withdrawn-applications-human-and-veterinary-medicines_en.xlsx"},
    {"id":"60305","name":"Table of opinions and decisions on paediatric investigation plans (PIPs)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-06T14:31:20Z","last_updated_date":"2023-11-06T14:31:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/table-opinions-and-decisions-paediatric-investigation-plans-pips_en.xlsx"},
    {"id":"60306","name":"Table of all orphan designations","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-06T14:32:01Z","last_updated_date":"2023-11-06T14:32:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/table-all-orphan-designations_en.xlsx"},
    {"id":"60307","name":"Table of referrals for human and veterinary medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-06T14:32:51Z","last_updated_date":"2023-11-06T14:32:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/table-referrals-human-and-veterinary-medicines_en.xlsx"},
    {"id":"60308","name":"Table of lists of nationally authorised medicines involved in PSUR single assessments and regulatory outcomes","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-06T14:33:50Z","last_updated_date":"2023-11-06T14:33:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/table-lists-nationally-authorised-medicines-involved-psur-single-assessments-and-regulatory-outcomes_en.xlsx"},
    {"id":"60309","name":"Table of medicine shortages","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-06T14:34:31Z","last_updated_date":"2023-11-06T14:34:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/table-medicine-shortages_en.xlsx"},
    {"id":"60310","name":"Table of herbal medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-06T14:35:10Z","last_updated_date":"2023-11-06T14:35:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/table-herbal-medicines_en.xlsx"},
    {"id":"60311","name":"Table of opinions on medicines for use outside EU","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-06T14:35:56Z","last_updated_date":"2023-11-06T14:35:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/table-opinions-medicines-use-outside-eu_en.xlsx"},
    {"id":"60424","name":"Medicinal products for human use: monthly figures - September 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T14:17:00Z","last_updated_date":"2023-10-13T14:17:00Z","reference_number":"EMA/461657/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2023_en.pdf"},
    {"id":"60503","name":"PRAC statistics: November 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-10-27T12:07:00Z","last_updated_date":"2023-10-27T12:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-november-2023_en.pdf"},
    {"id":"60586","name":"Meeting Report - Workshop on the draft reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development (EMA/CHMP/138502/2017)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2018-10-03T18:24:00Z","last_updated_date":"2018-10-03T18:24:00Z","reference_number":"EMA/CHMP/579441/2018","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-workshop-draft-reflection-paper-statistical-methodology-comparative-assessment-quality-attributes-drug-development-ema-chmp-138502-2017_en.pdf"},
    {"id":"60684","name":"PRAC statistics: September 2022","type":"report","status":"unknown","consultation_date":"","first_published_date":"2022-09-02T11:13:00Z","last_updated_date":"2022-09-02T11:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-september-2022_en.pdf"},
    {"id":"60760","name":"Applications for new human medicines under evaluation by the CHMP: October 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-10-06T14:23:00Z","last_updated_date":"2023-10-06T14:23:00Z","reference_number":"EMA/444135/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2023_en.xlsx"},
    {"id":"60767","name":"European Medicines Agency mid-year report 2023 (January-June 2023)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-10-18T13:56:00Z","last_updated_date":"2023-10-18T13:56:00Z","reference_number":"EMA/343593/2023","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2023-january-june-2023_en.pdf"},
    {"id":"60782","name":"Applications for new human medicines under evaluation by the CHMP: November 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-07T09:56:00Z","last_updated_date":"2023-11-07T09:56:00Z","reference_number":"EMA/989140/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-november-2023_en.xlsx"},
    {"id":"60875","name":"Medicinal products for human use: monthly figures - October 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-13T09:02:00Z","last_updated_date":"2023-11-13T09:02:00Z","reference_number":"EMA/502579/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2023_en.pdf"},
    {"id":"60974","name":"Sales of veterinary antimicrobial agents in 31 European countries in 2022 - Trends from 2010 to 2022, thirteenth ESVAC report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-11-20T13:02:05Z","last_updated_date":"2023-11-20T13:02:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-31-european-countries-2022-trends-2010-2022-thirteenth-esvac-report_en.pdf"},
    {"id":"61219","name":"COVID-19 lessons learned - Joint report on the response to the public health emergency","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T14:00:00Z","last_updated_date":"2023-12-01T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/covid-19-lessons-learned-joint-report-response-public-health-emergency_en.pdf"},
    {"id":"61295","name":"Applications for new human medicines under evaluation by the CHMP: December 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-12-07T12:44:47Z","last_updated_date":"2023-12-07T12:44:47Z","reference_number":"EMA/553110/2023","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-december-2023_en.xlsx"},
    {"id":"61387","name":"Medicinal products for human use: monthly figures - November 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-12-12T16:02:50Z","last_updated_date":"2023-12-12T16:02:50Z","reference_number":"EMA/563599/2023","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2023_en.pdf"},
    {"id":"61470","name":"Report - EMA multi-stakeholder workshop on qualification of novel methodologies","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T16:13:16Z","last_updated_date":"2023-12-15T16:13:16Z","reference_number":"EMA/569008/2023","document_url":"https://www.ema.europa.eu/en/documents/report/report-ema-multi-stakeholder-workshop-qualification-novel-methodologies_en.pdf"},
    {"id":"61544","name":"European medicines  agencies network  strategy to 2025: Mid-point report to Q2 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T16:00:00Z","last_updated_date":"2023-12-20T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agencies-network-strategy-2025-mid-point-report-q2-2023_en.pdf"},
    {"id":"61555","name":"Report - HMA/EMA Big Data Stakeholder Forum 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-12-20T17:38:31Z","last_updated_date":"2023-12-20T17:38:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-hma-ema-big-data-stakeholder-forum-2023_en.pdf"},
    {"id":"61569","name":"Summary report of the biannual Big Data Steering Group and industry stakeholders meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T13:43:06Z","last_updated_date":"2023-12-21T13:43:06Z","reference_number":"EMA/569554/2023","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-biannual-big-data-steering-group-and-industry-stakeholders-meeting_en.pdf"},
    {"id":"61570","name":"Summary report of the biannual Big Data Steering Group and industry stakeholders meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T13:44:58Z","last_updated_date":"2023-12-21T13:44:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-biannual-big-data-steering-group-and-industry-stakeholders-meeting_en.pdf-0"},
    {"id":"61750","name":"PRAC statistics: December 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T12:27:53Z","last_updated_date":"2023-12-01T12:27:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-december-2023_en.pdf"},
    {"id":"61752","name":"Highlight report of the eleventh meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-01-12T15:26:37Z","last_updated_date":"2024-01-12T15:26:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-eleventh-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"61753","name":"PRAC statistics: January 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-01-12T16:54:46Z","last_updated_date":"2024-01-12T16:54:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-january-2024_en.pdf"},
    {"id":"61755","name":"Applications for new human medicines under evaluation: January 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-01-15T08:51:59Z","last_updated_date":"2024-01-26T17:47:00Z","reference_number":"EMA/9538/2024 Corr.","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-january-2024_en.xlsx"},
    {"id":"61770","name":"Big Data Steering Group (BDSG): 2023 report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-01-15T15:52:34Z","last_updated_date":"2024-01-15T15:52:34Z","reference_number":"EMA/569310/2023","document_url":"https://www.ema.europa.eu/en/documents/report/big-data-steering-group-bdsg-2023-report_en.pdf"},
    {"id":"61802","name":"Report from the 2023 annual workshop of the European network of paediatric research at the EMA (Enpr-EMA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-01-17T15:51:11Z","last_updated_date":"2024-01-17T15:51:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-2023-annual-workshop-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"61869","name":"Medicinal products for human use: monthly figures - December 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-01-24T13:24:28Z","last_updated_date":"2024-01-24T13:24:28Z","reference_number":"EMA/27387/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2023_en.pdf"},
    {"id":"61950","name":"Final programming document 2024-2026","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2024-01-30T11:18:29Z","last_updated_date":"2024-01-30T11:18:29Z","reference_number":"EMA/426707/2023","document_url":"https://www.ema.europa.eu/en/documents/report/final-programming-document-2024-2026_en.pdf"},
    {"id":"62059","name":"PRAC statistics: March 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T12:00:00Z","last_updated_date":"2024-03-08T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-march-2024_en.pdf"},
    {"id":"62076","name":"Applications for new human medicines under evaluation: February 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-02-12T15:55:59Z","last_updated_date":"2024-02-12T15:55:59Z","reference_number":"EMA/58689/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-february-2024_en.xlsx"},
    {"id":"62237","name":"EMA/ECDC/EFSA fourth joint report on the integrated analysis of the antimicrobial agent consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU/EEA (JIACRA IV)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T11:55:00Z","last_updated_date":"2024-02-21T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/ema-ecdc-efsa-fourth-joint-report-integrated-analysis-antimicrobial-agent-consumption-occurrence-antimicrobial-resistance-bacteria-humans-food-producing-animals-eu-eea-jiacra-iv_en.pdf"},
    {"id":"62240","name":"Simplified summary - EMA/ECDC/EFSA fourth joint report on the integrated analysis of the antimicrobial agent consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU/EEA (JIACRA IV)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-02-21T14:00:00Z","last_updated_date":"2024-02-21T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/simplified-summary-ema-ecdc-efsa-fourth-joint-report-integrated-analysis-antimicrobial-agent-consumption-occurrence-antimicrobial-resistance-bacteria-humans-food-producing-animals-eu-eea-jiacra-iv_en.pdf"},
    {"id":"62386","name":"Medicinal products for human use: monthly figures - January 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T17:49:25Z","last_updated_date":"2024-02-29T17:49:25Z","reference_number":"EMA/81738/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2024_en.pdf"},
    {"id":"62426","name":"Highlights from the eight Nitrosamine Implementation Oversight Group (NIOG) meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-03-04T14:24:34Z","last_updated_date":"2024-03-04T14:24:34Z","reference_number":"EMA/735626/2022","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-eight-nitrosamine-implementation-oversight-group-niog-meeting_en.pdf"},
    {"id":"62427","name":"Highlights from the fifth Nitrosamine Implementation Oversight Group (NIOG) meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-03-04T14:29:32Z","last_updated_date":"2024-03-04T14:29:32Z","reference_number":"EMA/353298/2023","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-fifth-nitrosamine-implementation-oversight-group-niog-meeting_en.pdf"},
    {"id":"62437","name":"Highlights - Sixth European Medicines Agency (EMA) EFPIA bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-03-05T14:40:24Z","last_updated_date":"2024-03-05T14:40:24Z","reference_number":"EMA/54487/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-sixth-european-medicines-agency-ema-efpia-bilateral-meeting_en.pdf"}    {"id":"62466","name":"Meeting Report of the second Listen and Learn Focus Group (LLFG) meeting of the Quality Innovation Group (QIG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-03-07T12:10:08Z","last_updated_date":"2024-03-07T12:10:08Z","reference_number":"EMA/455426/2023","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-second-listen-learn-focus-group-llfg-meeting-quality-innovation-group-qig_en.pdf"},
    {"id":"62556","name":"Applications for new human medicines under evaluation: March 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T14:54:23Z","last_updated_date":"2024-03-12T14:54:23Z","reference_number":"EMA/97964/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-march-2024_en.xlsx"},
    {"id":"62558","name":"List of withdrawn medicinal products","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-03-12T15:19:52Z","last_updated_date":"2024-03-12T15:19:52Z","reference_number":"EMA/569891/2023","document_url":"https://www.ema.europa.eu/en/documents/report/list-withdrawn-medicinal-products_en.xlsx"},
    {"id":"62663","name":"Highlight report - Eleventh industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-03-21T08:32:53Z","last_updated_date":"2024-03-21T08:32:53Z","reference_number":"EMA/554023/2023","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-eleventh-industry-stakeholder-platform-research-development-support_en.pdf"},
    {"id":"62698","name":"PRAC statistics: February 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T10:18:26Z","last_updated_date":"2024-03-22T10:18:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-february-2024_en.pdf"},
    {"id":"62748","name":"2023 European Medicines Agency annual report on independence","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2024-03-26T15:01:33Z","last_updated_date":"2024-03-26T15:01:33Z","reference_number":"EMA/114673/2023","document_url":"https://www.ema.europa.eu/en/documents/report/2023-european-medicines-agency-annual-report-independence_en.pdf"},
    {"id":"62797","name":"2023 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-04-03T17:08:22Z","last_updated_date":"2024-04-03T17:08:22Z","reference_number":"EMA/554124/2023","document_url":"https://www.ema.europa.eu/en/documents/report/2023-annual-report-eudravigilance-european-parliament-council-commission_en.pdf"},
    {"id":"62874","name":"Medicinal products for human use: monthly figures - February 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-04-09T15:08:29Z","last_updated_date":"2024-04-09T15:08:29Z","reference_number":"EMA/117755/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2024_en.pdf"},
    {"id":"62926","name":"Applications for new human medicines under evaluation: April 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T09:38:44Z","last_updated_date":"2024-04-12T09:38:44Z","reference_number":"EMA/140936/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-april-2024_en.xlsx"},
    {"id":"62933","name":"PRAC statistics: April 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-04-12T12:04:59Z","last_updated_date":"2024-04-12T12:04:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-april-2024_en.pdf"},
    {"id":"62993","name":"Medicinal products for human use: monthly figures - March 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-04-17T18:02:12Z","last_updated_date":"2024-04-17T18:02:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2024_en.pdf"},
    {"id":"63003","name":"Methodology Working Party (MWP) stakeholder interaction meeting report , 7 December 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-04-18T14:14:47Z","last_updated_date":"2024-04-18T14:14:47Z","reference_number":"EMA/89623/2024","document_url":"https://www.ema.europa.eu/en/documents/report/methodology-working-party-mwp-stakeholder-interaction-meeting-report-7-december-2023_en.pdf"},
    {"id":"63040","name":"Stakeholder engagement report 2022-2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-04-24T12:08:26Z","last_updated_date":"2024-04-24T12:08:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2022-2023_en.pdf"},
    {"id":"63052","name":"Small and medium-sized enterprise (SME) office annual report 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-04-26T11:18:00Z","last_updated_date":"2024-07-10T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/small-medium-sized-enterprise-sme-office-annual-report-2023_en.pdf"},
    {"id":"63174","name":"Meeting report - Joint EMA/EORTC Workshop on Soft Tissue and Bone Sarcoma Workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-05-06T14:45:31Z","last_updated_date":"2024-05-06T14:45:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-joint-ema-eortc-workshop-soft-tissue-bone-sarcoma-workshop_en.pdf"},
    {"id":"63187","name":"Applications for new human medicines under evaluation: May 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-05-07T13:21:00Z","last_updated_date":"2024-05-07T13:21:00Z","reference_number":"EMA/2018069/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-may-2024_en.xlsx"},
    {"id":"63229","name":"Medicinal products for human use: monthly figures - April 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-05-16T11:47:51Z","last_updated_date":"2024-05-16T11:47:51Z","reference_number":"EMA/222526/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2024_en.pdf"},
    {"id":"63248","name":"PRAC statistics: May 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-05-17T11:22:22Z","last_updated_date":"2024-05-17T11:22:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-may-2024_en.pdf"},
    {"id":"63321","name":"Report - Cancer Medicines Forum (CMF) – a way forward for treatment optimisation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-05-29T14:45:00Z","last_updated_date":"2024-05-29T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-cancer-medicines-forum-cmf-way-forward-treatment-optimisation_en.pdf"},
    {"id":"63439","name":"Highlights- 8th Industry Standing Group (ISG) meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T15:34:24Z","last_updated_date":"2024-11-15T16:00:00Z","reference_number":"EMA/130028/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-8th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"63496","name":"Meeting summaries of the Immunisation and Vaccine Monitoring Advisory Board (IVMAB)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-06-05T16:04:25Z","last_updated_date":"2026-06-02T11:46:00Z","reference_number":"EXT/261005/2025","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-summaries-immunisation-vaccine-monitoring-advisory-board-ivmab_en.pdf"},
    {"id":"63597","name":"PRAC statistics: June 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-06-14T11:26:50Z","last_updated_date":"2024-06-14T11:26:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-june-2024_en.pdf"},
    {"id":"63613","name":"Applications for new human medicines under evaluation: June 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-06-14T14:00:00Z","last_updated_date":"2024-06-14T14:00:00Z","reference_number":"EMA/273906/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-june-2024_en.xlsx"},
    {"id":"63636","name":"Annual activity report 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-06-14T17:09:00Z","last_updated_date":"2024-07-11T11:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2023_en.pdf"},
    {"id":"63664","name":"Report - Joint HMA/EMA multi-stakeholder workshop on Patient Registries","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-06-18T13:33:03Z","last_updated_date":"2024-06-18T13:33:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-joint-hma-ema-multi-stakeholder-workshop-patient-registries_en.pdf"},
    {"id":"63749","name":"Medicinal products for human use: monthly figures - May 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-06-25T17:41:00Z","last_updated_date":"2024-06-25T17:41:00Z","reference_number":"EMA/287168/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2024_en.pdf"},
    {"id":"63822","name":"Annual accounts: Financial year 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-07-01T13:52:33Z","last_updated_date":"2024-07-01T13:52:33Z","reference_number":"EMA/95305/2024","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2023_en.pdf"},
    {"id":"63830","name":"Outcome of public consultation on ICH Reflection paper on pursuing opportunities for harmonization in using real-world data to generate real-world evidence","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-07-03T10:00:00Z","last_updated_date":"2024-07-03T10:00:00Z","reference_number":"EMA/CHMP/ICH/301589/2024","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-public-consultation-ich-reflection-paper-pursuing-opportunities-harmonization-using-real-world-data-generate-real-world-evidence_en.pdf"},
    {"id":"63870","name":"Focus group on submission predictability: 2024 final report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-07-08T14:20:00Z","last_updated_date":"2024-07-08T14:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/focus-group-submission-predictability-2024-final-report_en.pdf"},
    {"id":"63957","name":"Highlights from the fifth European Medicines Agency (EMA) and the Association of the European Self-Care Industry (AESGP) bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-07-09T09:25:47Z","last_updated_date":"2024-07-09T09:25:47Z","reference_number":"EMA/187499/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-fifth-european-medicines-agency-ema-association-european-self-care-industry-aesgp-bilateral-meeting_en.pdf"},
    {"id":"64153","name":"Applications for new human medicines under evaluation: July 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-07-15T11:29:17Z","last_updated_date":"2024-07-15T11:29:17Z","reference_number":"EMA/320819/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-july-2024_en.xlsx"},
    {"id":"64180","name":"Report - EMA multi-stakeholder workshop on psychedelics","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-07-16T17:03:00Z","last_updated_date":"2024-07-16T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-ema-multi-stakeholder-workshop-psychedelics_en.pdf"},
    {"id":"64231","name":"Medicinal products for human use: monthly figures - June 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T15:02:33Z","last_updated_date":"2024-07-19T15:02:33Z","reference_number":"EMA/332758/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2024_en.pdf"},
    {"id":"64328","name":"Real-world evidence framework to support EU regulatory decision-making: 2nd report on the experience gained with regulator-led studies from February 2023 to February 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T10:55:00Z","last_updated_date":"2024-08-01T10:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-2nd-report-experience-gained-regulator-led-studies-february-2023-february-2024_en.pdf"},
    {"id":"64367","name":"Report from the 2024 annual workshop of the European network of paediatric research at EMA (Enpr-EMA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T11:11:11Z","last_updated_date":"2024-12-10T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-2024-annual-workshop-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"64381","name":"Medicines output dhpc report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T00:00:00Z","last_updated_date":"2024-09-09T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-dhpc-report_en.xlsx"},
    {"id":"64382","name":"Medicines output herbal_medicines report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T00:00:00Z","last_updated_date":"2024-09-09T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-herbal_medicines-report_en.xlsx"},
    {"id":"64383","name":"Medicines output medicines report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T00:00:00Z","last_updated_date":"2024-09-09T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx"},
    {"id":"64384","name":"Medicines output opinions_outside_eu report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T00:00:00Z","last_updated_date":"2024-09-09T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-opinions_outside_eu-report_en.xlsx"},
    {"id":"64385","name":"Medicines output orphan_designations report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T00:00:00Z","last_updated_date":"2024-09-09T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-orphan_designations-report_en.xlsx"},
    {"id":"64386","name":"Medicines output paediatric_investigation_plans report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T00:00:00Z","last_updated_date":"2024-09-09T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-paediatric_investigation_plans-report_en.xlsx"},
    {"id":"64387","name":"Medicines output post_authorisation report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T00:00:00Z","last_updated_date":"2024-09-09T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-post_authorisation-report_en.xlsx"},
    {"id":"64388","name":"Medicines output periodic_safety_update_report_single_assessments report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T00:00:00Z","last_updated_date":"2024-09-09T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-periodic_safety_update_report_single_assessments-report_en.xlsx"},
    {"id":"64389","name":"Medicines output referrals report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T00:00:00Z","last_updated_date":"2024-09-09T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-referrals-report_en.xlsx"},
    {"id":"64390","name":"Medicines output shortages report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-09T00:00:00Z","last_updated_date":"2024-09-09T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-shortages-report_en.xlsx"},
    {"id":"64478","name":"Highlights report -Twelfth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T17:05:08Z","last_updated_date":"2024-08-01T17:05:08Z","reference_number":"EMA/286831/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-report-twelfth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"64511","name":"Report - Follow up EMA and EORTC multi-stakeholder workshop on soft tissue and bone sarcoma","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-05T09:20:11Z","last_updated_date":"2024-08-20T08:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-follow-ema-eortc-multi-stakeholder-workshop-soft-tissue-bone-sarcoma_en.pdf"},
    {"id":"64556","name":"Applications for new human medicines under evaluation: August 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-12T15:32:24Z","last_updated_date":"2024-08-12T15:32:24Z","reference_number":"EMA/368078/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-august-2024_en.xlsx"},
    {"id":"64586","name":"Multi–stakeholder workshop on data quality framework for adverse drug reaction reporting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-16T15:55:17Z","last_updated_date":"2024-08-16T15:55:17Z","reference_number":"EMA/172989/2022","document_url":"https://www.ema.europa.eu/en/documents/report/multi-stakeholder-workshop-data-quality-framework-adverse-drug-reaction-reporting_en.pdf"},
    {"id":"64603","name":"Medicinal products for human use: monthly figures - July 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-20T15:55:33Z","last_updated_date":"2024-08-20T15:55:33Z","reference_number":"EMA/379389/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2024_en.pdf"},
    {"id":"64608","name":"Highlight report from the 12th Industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-21T11:05:43Z","last_updated_date":"2024-08-21T11:05:43Z","reference_number":"EMA/321731/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-12th-industry-stakeholder-platform-research-development-support_en.pdf"},
    {"id":"64609","name":"Highlights - 9th Industry Standing Group (ISG) meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-21T15:34:36Z","last_updated_date":"2024-11-15T17:00:00Z","reference_number":"EMA/299167/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-9th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"64637","name":"Highlights - Seventh  European Medicines Agency - Medicines for Europe annual bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-26T16:59:40Z","last_updated_date":"2024-08-26T16:59:40Z","reference_number":"EMA/253612/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-seventh-european-medicines-agency-medicines-europe-annual-bilateral-meeting_en.pdf"},
    {"id":"64648","name":"Highlights - Third EMA and MedTech Europe bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-28T14:16:46Z","last_updated_date":"2024-08-28T14:16:46Z","reference_number":"EMA/75640/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-third-ema-medtech-europe-bilateral-meeting_en.pdf"},
    {"id":"64650","name":"Highlights - Fourth EMA and Nuclear Medicines Europe bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-08-28T14:21:13Z","last_updated_date":"2024-08-28T14:21:13Z","reference_number":"EMA/275290/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-fourth-ema-nuclear-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"64753","name":"Applications for new human medicines under evaluation: September 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-06T15:40:00Z","last_updated_date":"2024-09-06T15:40:00Z","reference_number":"EMA/414559/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-september-2024_en.xlsx"},
    {"id":"64859","name":"Early dialogue with healthcare professional organisations for marketing authorisation applications: 1-year report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-16T14:41:20Z","last_updated_date":"2024-09-16T14:41:20Z","reference_number":"EMA/225343/2024","document_url":"https://www.ema.europa.eu/en/documents/report/early-dialogue-healthcare-professional-organisations-marketing-authorisation-applications-1-year-report_en.pdf"},
    {"id":"64919","name":"Medicinal products for human use: monthly figures - August 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-09-19T09:22:53Z","last_updated_date":"2024-09-19T09:22:53Z","reference_number":"EMA/422263/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2024_en.pdf"},
    {"id":"65147","name":"Report - 3RsWP Public Session 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-03T17:16:07Z","last_updated_date":"2024-10-03T17:16:07Z","reference_number":"EMA/459663/2024","document_url":"https://www.ema.europa.eu/en/documents/report/report-3rswp-public-session-2024_en.pdf"},
    {"id":"65154","name":"Meeting report: EMA and EORTC workshop: How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions?","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T12:08:09Z","last_updated_date":"2024-10-04T12:08:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-ema-eortc-workshop-how-can-patient-reported-outcomes-pro-health-related-quality-life-hrqol-data-inform-regulatory-decisions_en.pdf"},
    {"id":"65161","name":"PRAC statistics: October 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-04T11:11:01Z","last_updated_date":"2024-10-04T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-october-2024_en.pdf"},
    {"id":"65238","name":"Report - Multistakeholder workshop on shortages of Glucagon-Like Peptide-1 (GLP-1) receptor agonists","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-08T13:27:15Z","last_updated_date":"2024-10-09T14:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-multistakeholder-workshop-shortages-glucagon-peptide-1-glp-1-receptor-agonists_en.pdf"},
    {"id":"65241","name":"Applications for new human medicines under evaluation: October 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-08T16:58:00Z","last_updated_date":"2024-10-08T16:58:00Z","reference_number":"EMA/459172/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-october-2024_en.xlsx"},
    {"id":"65296","name":"Proof-of-concept pilot on using data from clinical studies in medicines evaluation: Interim report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T14:21:00Z","last_updated_date":"2024-10-18T14:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/proof-concept-pilot-using-data-clinical-studies-medicines-evaluation-interim-report_en.pdf"},
    {"id":"65304","name":"EMA workshop report on the future of vaccine effectiveness studies in Europe","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-16T10:45:18Z","last_updated_date":"2024-10-16T10:45:18Z","reference_number":"EMA/483484/2024","document_url":"https://www.ema.europa.eu/en/documents/report/ema-workshop-report-future-vaccine-effectiveness-studies-europe_en.pdf"},
    {"id":"65340","name":"Medicinal products for human use: monthly figures - September 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T09:26:55Z","last_updated_date":"2024-10-18T09:26:55Z","reference_number":"EMA/485723/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2024_en.pdf"},
    {"id":"65367","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-22T16:01:00Z","last_updated_date":"2024-10-22T16:01:00Z","reference_number":"EMA/INS/PhV/471069/2024","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-pharmacovigilance-inspectors-working-group-2023_en.pdf"},
    {"id":"65434","name":"Highlights from the first Expert Panels and Notified Bodies workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T16:58:00Z","last_updated_date":"2024-10-24T16:58:00Z","reference_number":"EMA/492346/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-first-expert-panels-notified-bodies-workshop_en.pdf"},
    {"id":"65457","name":"mHealth data for real world evidence in regulatory decision-making: expert report for HMA-EMA Big Data Steering Group","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T17:16:00Z","last_updated_date":"2024-10-29T17:16:00Z","reference_number":"EMA/346092/2024","document_url":"https://www.ema.europa.eu/en/documents/report/mhealth-data-real-world-evidence-regulatory-decision-making-expert-report-hma-ema-big-data-steering-group_en.pdf"},
    {"id":"65477","name":"Report - Joint HMA/EMA multi-stakeholder workshop on submission predictability","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-29T14:14:04Z","last_updated_date":"2024-10-29T14:14:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-joint-hma-ema-multi-stakeholder-workshop-submission-predictability_en.pdf"},
    {"id":"65506","name":"PRAC statistics: November 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T14:47:07Z","last_updated_date":"2024-10-31T14:47:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-november-2024_en.pdf"},
    {"id":"65565","name":"Applications for new human medicines under evaluation: November 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-11-07T16:54:09Z","last_updated_date":"2024-11-07T16:54:09Z","reference_number":"EMA/512631/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-november-2024_en.xlsx"},
    {"id":"65598","name":"Medicinal products for human use: monthly figures - October 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-11-12T15:23:44Z","last_updated_date":"2024-11-12T15:23:44Z","reference_number":"EMA/520424/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2024_en.pdf"},
    {"id":"65605","name":"Report - 3rd Listen and Learn Focus Group (LLFG) meeting of the Quality Innovation Group (QIG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-11-13T11:17:06Z","last_updated_date":"2024-11-13T11:17:06Z","reference_number":"EMA/384150/2024","document_url":"https://www.ema.europa.eu/en/documents/report/report-3rd-listen-learn-focus-group-llfg-meeting-quality-innovation-group-qig_en.pdf"},
    {"id":"65619","name":"Summary report - Biannual Big Data Steering Group and industry stakeholders meeting - Oct 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-11-13T16:26:55Z","last_updated_date":"2024-11-13T16:26:55Z","reference_number":"EMA/507275/2024","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-biannual-big-data-steering-group-industry-stakeholders-meeting-oct-2024_en.pdf"},
    {"id":"65631","name":"Highlights - Tenth Industry Standing Group (ISG) meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-11-14T12:08:04Z","last_updated_date":"2024-11-14T12:08:04Z","reference_number":"EMA/449820/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-tenth-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"65870","name":"Alzheimer’s disease EU-IN Horizon Scanning Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-11-28T15:10:00Z","last_updated_date":"2025-12-09T11:41:36Z","reference_number":"EMA/540805/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/alzheimers-disease-eu-horizon-scanning-report_en.pdf"},
    {"id":"65884","name":"PRAC statistics: December 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-11-29T11:30:32Z","last_updated_date":"2024-11-29T11:30:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-december-2024_en.pdf"},
    {"id":"65926","name":"Report - EU NTC ten year anniversary event","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T14:47:15Z","last_updated_date":"2024-12-03T14:47:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-eu-ntc-ten-year-anniversary-event_en.pdf"},
    {"id":"65975","name":"Meeting report - Workshop on the challenges in drug development, regulation and clinical practice in haemoglobinopathies","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T13:54:55Z","last_updated_date":"2024-12-05T13:54:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-workshop-challenges-drug-development-regulation-clinical-practice-haemoglobinopathies_en.pdf"},
    {"id":"66021","name":"Applications for new human medicines under evaluation: December 2024","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2024-12-09T15:03:45Z","last_updated_date":"2024-12-09T15:03:45Z","reference_number":"EMA/561462/2024","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-december-2024_en.xlsx"},
    {"id":"66028","name":"Annual report of the Good Clinical Practice Inspectors Working Group 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T15:55:47Z","last_updated_date":"2024-12-09T15:55:47Z","reference_number":"EMA/INS/GCP/164938/2024","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-clinical-practice-inspectors-working-group-2023_en.pdf"},
    {"id":"66032","name":"Highlights from the 19th EMA Industry Platform meeting on the operation of EU pharmacovigilance legislation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T16:14:58Z","last_updated_date":"2024-12-09T16:14:58Z","reference_number":"EMA/538767/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-19th-ema-industry-platform-meeting-operation-eu-pharmacovigilance-legislation_en.pdf"},
    {"id":"66034","name":"European Medicines Agency mid-year report 2024 (January-June 2024)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T16:34:57Z","last_updated_date":"2024-12-09T16:34:57Z","reference_number":"EMA/298094/2024","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2024-january-june-2024_en.pdf"},
    {"id":"66064","name":"EMA communication perception survey report 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-11T12:00:00Z","last_updated_date":"2024-12-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/ema-communication-perception-survey-report-2024_en.pdf"},
    {"id":"66104","name":"Electronic product information (ePI) report: Experience gained from creation of ePI during regulatory procedures for EU human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T14:00:00Z","last_updated_date":"2024-12-16T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/electronic-product-information-epi-report-experience-gained-creation-epi-during-regulatory-procedures-eu-human-medicines_en.pdf"},
    {"id":"66118","name":"Medicinal products for human use: monthly figures - November 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-13T14:15:22Z","last_updated_date":"2024-12-13T14:15:22Z","reference_number":"EMA/576604/2024","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2024_en.pdf"},
    {"id":"66121","name":"Highlight report - Thirteenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-13T15:01:00Z","last_updated_date":"2024-12-13T15:01:00Z","reference_number":"EMA/544205/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-thirteenth-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"66163","name":"Big Data Steering Group (BDSG): 2024 report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T16:26:04Z","last_updated_date":"2024-12-16T16:26:04Z","reference_number":"EMA/471579/2024","document_url":"https://www.ema.europa.eu/en/documents/report/big-data-steering-group-bdsg-2024-report_en.pdf"},
    {"id":"66195","name":"Highlights - Third European Medicines Agency (EMA) and European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-18T11:15:04Z","last_updated_date":"2024-12-18T11:15:04Z","reference_number":"EMA/491658/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-third-european-medicines-agency-ema-european-confederation-pharmaceutical-entrepreneurs-eucope-bilateral-meeting_en.pdf"},
    {"id":"66196","name":"Highlights - Seventh European Medicines Agency (EMA) EFPIA bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2024-12-18T11:25:01Z","last_updated_date":"2024-12-18T11:25:01Z","reference_number":"EMA/555248/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-seventh-european-medicines-agency-ema-efpia-bilateral-meeting_en.pdf"},
    {"id":"66252","name":"Report - Harnessing Real-world data for regulatory use: Report on the joint HMA/EMA Big Data Steering Group workshop on Real-world evidence (RWE) methods","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-01-07T11:47:50Z","last_updated_date":"2025-01-07T11:47:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-harnessing-real-world-data-regulatory-use-report-joint-hma-ema-big-data-steering-group-workshop-real-world-evidence-rwe-methods_en.pdf"},
    {"id":"66315","name":"Report - HMA/EMA Multi–stakeholder workshop on Artificial Intelligence (AI) - enabling the safe and responsible use of AI","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-01-15T13:25:18Z","last_updated_date":"2025-01-15T13:25:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-hma-ema-multi-stakeholder-workshop-artificial-intelligence-ai-enabling-safe-responsible-use-ai_en.pdf"},
    {"id":"66326","name":"Human medicines in 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-01-16T14:30:00Z","last_updated_date":"2025-01-16T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/human-medicines-2024_en.pdf"},
    {"id":"66331","name":"Applications for new human medicines under evaluation: January 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-01-16T14:05:36Z","last_updated_date":"2025-01-16T14:05:36Z","reference_number":"EMA/5196/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-january-2025_en.xlsx"},
    {"id":"66346","name":"PRAC statistics: January 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-01-17T11:25:37Z","last_updated_date":"2025-01-17T11:25:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-january-2025_en.pdf"},
    {"id":"66429","name":"Veterinary medicines in 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-01-23T14:00:00Z","last_updated_date":"2025-01-23T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/veterinary-medicines-2024_en.pdf"},
    {"id":"66431","name":"Highlights - Eleventh Industry Standing Group (ISG) meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-01-23T12:21:17Z","last_updated_date":"2025-01-23T12:21:17Z","reference_number":"EMA/9662/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-eleventh-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"66452","name":"Medicinal products for human use: monthly figures - December 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-01-24T15:36:45Z","last_updated_date":"2025-01-24T15:36:45Z","reference_number":"EMA/10875/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2024_en.pdf"},
    {"id":"66509","name":"Final programming document 2025-27","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2025-01-29T15:30:00Z","last_updated_date":"2025-01-29T15:30:00Z","reference_number":"EMA/30979/2025","document_url":"https://www.ema.europa.eu/en/documents/report/final-programming-document-2025-27_en.pdf"}    {"id":"66578","name":"Nanotechnology-based medicinal products for human use EU-IN Horizon Scanning Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-02-03T16:46:08Z","last_updated_date":"2025-11-11T11:55:29Z","reference_number":"EMA/20989/2025 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/nanotechnology-based-medicinal-products-human-use-eu-horizon-scanning-report_en.pdf"},
    {"id":"66644","name":"Meeting report - ACT EU multi-stakeholder platform annual meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T12:52:17Z","last_updated_date":"2025-03-14T15:32:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-act-eu-multi-stakeholder-platform-annual-meeting_en.pdf"},
    {"id":"66659","name":"Applications for new human medicines under evaluation: February 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T17:00:26Z","last_updated_date":"2025-02-10T17:00:26Z","reference_number":"EMA/51244/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-february-2025_en.xlsx"},
    {"id":"66766","name":"PRAC statistics: February 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-02-14T11:06:39Z","last_updated_date":"2025-02-14T11:06:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-february-2025_en.pdf"},
    {"id":"66830","name":"Report - HMA/EMA Big Data Stakeholder Forum 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-02-17T16:07:03Z","last_updated_date":"2025-02-17T16:07:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-hma-ema-big-data-stakeholder-forum-2024_en.pdf"},
    {"id":"66931","name":"New Approach Methodologies EU-IN Horizon Scanning Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-02-24T15:21:27Z","last_updated_date":"2025-12-09T11:43:50Z","reference_number":"EMA/56850/2025 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/new-approach-methodologies-eu-horizon-scanning-report_en.pdf"},
    {"id":"66974","name":"Medicinal products for human use: monthly figures - January 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-02-25T16:22:10Z","last_updated_date":"2025-02-25T16:22:10Z","reference_number":"EMA/62379/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2025_en.pdf"},
    {"id":"66993","name":"Report - Joint EC/HMA/EMA multi-stakeholder workshop on pharmacogenomics (24 September 2024)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-02-26T14:12:53Z","last_updated_date":"2025-02-26T14:12:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-joint-ec-hma-ema-multi-stakeholder-workshop-pharmacogenomics-24-september-2024_en.pdf"},
    {"id":"67090","name":"Start of procedure: Type II variation - extension of indication under evaluation by the CHMP (31 January - 27 February 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-03-04T11:27:42Z","last_updated_date":"2025-03-04T11:27:42Z","reference_number":"EMA/78066/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-31-january-27-february-2025_en.xlsx"},
    {"id":"67091","name":"Start of procedure: Extension of marketing authorisation (31 January - 27 February 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-03-04T11:29:36Z","last_updated_date":"2025-03-04T11:29:36Z","reference_number":"EMA/78061/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-31-january-27-february-2025_en.xlsx"},
    {"id":"67274","name":"PRAC statistics: March 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-03-14T11:07:55Z","last_updated_date":"2025-03-14T11:07:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-march-2025_en.pdf"},
    {"id":"67287","name":"Applications for new human medicines under evaluation: March 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-03-14T15:03:13Z","last_updated_date":"2025-03-14T15:03:13Z","reference_number":"EMA/83261/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-march-2025_en.xlsx"},
    {"id":"67340","name":"2024 European Medicines Agency annual report on independence","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2025-03-19T10:39:22Z","last_updated_date":"2025-03-19T10:39:22Z","reference_number":"EMA/573980/2024","document_url":"https://www.ema.europa.eu/en/documents/report/2024-european-medicines-agency-annual-report-independence_en.pdf"},
    {"id":"67344","name":"Medicinal products for human use: monthly figures - February 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-03-19T12:10:28Z","last_updated_date":"2025-03-19T12:10:28Z","reference_number":"EMA/96397/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2025_en.pdf"},
    {"id":"67374","name":"2024 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-03-20T16:43:00Z","last_updated_date":"2025-03-20T16:43:00Z","reference_number":"EMA/559856/2024","document_url":"https://www.ema.europa.eu/en/documents/report/2024-annual-report-eudravigilance-european-parliament-council-commission_en.pdf"},
    {"id":"67411","name":"Pilot on advice from expert panels to manufacturers of high-risk medical devices: Interim report on the experience with the pilot from February 2023 to December 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-03-24T10:53:00Z","last_updated_date":"2025-03-24T10:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/pilot-advice-expert-panels-manufacturers-high-risk-medical-devices-interim-report-experience-pilot-february-2023-december-2024_en.pdf"},
    {"id":"67423","name":"Medicines output medicines_json report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-05-20T10:14:43Z","last_updated_date":"2025-05-20T10:14:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json"},
    {"id":"67424","name":"Medicines output post_authorisation_json report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-04-10T16:08:15Z","last_updated_date":"2025-04-10T16:08:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-post_authorisation_json-report_en.json"},
    {"id":"67425","name":"Documents output JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-05-20T10:15:42Z","last_updated_date":"2025-05-20T10:15:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/documents-output-json-report_en.json"},
    {"id":"67541","name":"European sales and use of antimicrobials for veterinary medicine: Annual surveillance report for 2023","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-03-31T23:37:00Z","last_updated_date":"2025-03-31T23:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-sales-use-antimicrobials-veterinary-medicine-annual-surveillance-report-2023_en.pdf"},
    {"id":"67561","name":"Start of procedure: Type II variation - extension of indication under evaluation by the CHMP (28 February 2025 - 27 March 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-04-01T11:58:29Z","last_updated_date":"2025-04-01T11:58:29Z","reference_number":"EMA/112150/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-28-february-2025-27-march-2025_en.xlsx"},
    {"id":"67562","name":"Start of procedure: Extension of marketing authorisation (28 February 2025 - 27 March 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-04-01T12:02:28Z","last_updated_date":"2025-04-01T12:02:28Z","reference_number":"EMA/112158/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-28-february-2025-27-march-2025_en.xlsx"},
    {"id":"67593","name":"Report - Fourth listen-and-learn focus group meeting of the Quality Innovation Group","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-04-02T09:45:09Z","last_updated_date":"2025-04-02T09:45:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-fourth-listen-learn-focus-group-meeting-quality-innovation-group_en.pdf"},
    {"id":"67651","name":"Highlight report - 13th Industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-04-04T17:15:51Z","last_updated_date":"2025-04-04T17:15:51Z","reference_number":"EMA/578907/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-13th-industry-stakeholder-platform-research-development-support_en.pdf"},
    {"id":"67748","name":"PRAC statistics: April 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-04-11T12:09:38Z","last_updated_date":"2025-04-11T12:09:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-april-2025_en.pdf"},
    {"id":"67874","name":"Report - Industry stakeholders and EU network experts surveys on early engagement fostering innovation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-04-16T12:44:21Z","last_updated_date":"2025-04-30T17:07:20Z","reference_number":"EMA/50604/2025","document_url":"https://www.ema.europa.eu/en/documents/report/report-industry-stakeholders-eu-network-experts-surveys-early-engagement-fostering-innovation_en.pdf"},
    {"id":"67875","name":"Applications for new human medicines under evaluation: April 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-04-16T12:51:43Z","last_updated_date":"2025-04-16T12:51:43Z","reference_number":"EMA/124951/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-april-2025_en.xlsx"},
    {"id":"67877","name":"Medicinal products for human use: monthly figures - March 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-04-16T13:28:32Z","last_updated_date":"2025-04-16T13:28:32Z","reference_number":"EMA/128889/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2025_en.pdf"},
    {"id":"68023","name":"Highlights - twelfth Industry Standing Group meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-04-29T11:07:39Z","last_updated_date":"2025-04-29T11:07:39Z","reference_number":"EMA/66624/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-twelfth-industry-standing-group-meeting_en.pdf"},
    {"id":"68048","name":"Small and medium-sized enterprise (SME) office annual report 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-05-02T10:25:50Z","last_updated_date":"2025-05-02T10:25:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/small-medium-sized-enterprise-sme-office-annual-report-2024_en.pdf"},
    {"id":"68254","name":"Applications for new human medicines under evaluation: May 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-05-13T13:25:30Z","last_updated_date":"2025-05-13T13:25:30Z","reference_number":"EMA/153582/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-may-2025_en.xlsx"},
    {"id":"68344","name":"Medicinal products for human use: monthly figures - April 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-05-19T15:07:54Z","last_updated_date":"2025-05-19T15:07:54Z","reference_number":"EMA/167904/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2025_en.pdf"},
    {"id":"68475","name":"Start of procedure: Type II variation - extension of indication (26 April - 22 May 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-05-27T16:00:00Z","last_updated_date":"2025-05-27T16:00:00Z","reference_number":"EMA/179155/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-26-april-22-may-2025_en.xlsx"},
    {"id":"68476","name":"Start of procedure - extension of marketing authorisation (26 April - 22 May 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-05-27T16:01:00Z","last_updated_date":"2025-05-27T16:01:00Z","reference_number":"EMA/179147/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-26-april-22-may-2025_en.xlsx"},
    {"id":"68594","name":"Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) annual activity report 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-06-06T08:46:32Z","last_updated_date":"2025-06-06T08:46:32Z","reference_number":"EMA/39026/2025","document_url":"https://www.ema.europa.eu/en/documents/report/executive-steering-group-shortages-safety-medicinal-products-mssg-annual-activity-report-2024_en.pdf"},
    {"id":"68608","name":"PRAC statistics: June 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-06-06T11:06:34Z","last_updated_date":"2025-06-06T11:06:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-june-2025_en.pdf"},
    {"id":"68709","name":"Applications for new human medicines under evaluation: June 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-06-12T09:35:00Z","last_updated_date":"2025-06-12T09:35:00Z","reference_number":"EMA/187336/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-june-2025_en.xlsx"},
    {"id":"68807","name":"Medicinal products for human use: monthly figures - May 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-06-18T11:36:08Z","last_updated_date":"2025-06-18T11:36:08Z","reference_number":"EMA/206585/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2025_en.pdf"},
    {"id":"69003","name":"Real-world evidence framework to support EU regulatory decision-making: 3rd report on the experience gained with regulator-led studies from February 2024 to February 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T14:05:20Z","last_updated_date":"2025-06-30T14:05:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-3rd-report-experience-gained-regulator-led-studies-february-2024-february-2025_en.pdf"},
    {"id":"69016","name":"Highlights - Second EMA and European Society of Cardiology (ESC) bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-06-27T14:53:01Z","last_updated_date":"2025-11-11T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-second-ema-european-society-cardiology-esc-bilateral-meeting_en.pdf"},
    {"id":"69025","name":"Annual activity report 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-06-30T14:32:52Z","last_updated_date":"2025-06-30T14:32:52Z","reference_number":"EMA/69085/2025","document_url":"https://www.ema.europa.eu/en/documents/report/annual-activity-report-2024_en.pdf"},
    {"id":"69061","name":"Annual accounts: Financial year 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-01T11:28:17Z","last_updated_date":"2025-07-01T11:28:17Z","reference_number":"EMA/77973/2025","document_url":"https://www.ema.europa.eu/en/documents/report/annual-accounts-financial-year-2024_en.pdf"},
    {"id":"69124","name":"Outcome of SME office survey on the implementation of the SME regulation - Commission Regulation (EC) No 2049/2005","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-07T12:00:00Z","last_updated_date":"2025-07-07T12:00:00Z","reference_number":"EMA/218450/2025","document_url":"https://www.ema.europa.eu/en/documents/report/outcome-sme-office-survey-implementation-sme-regulation-commission-regulation-ec-no-2049-2005_en.pdf"},
    {"id":"69205","name":"2024 AI Observatory report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-10T17:16:04Z","last_updated_date":"2025-07-10T17:16:04Z","reference_number":"EMA/76534/2025","document_url":"https://www.ema.europa.eu/en/documents/report/2024-ai-observatory-report_en.pdf"},
    {"id":"69206","name":"2024 AI Observatory report: Compilation of 2024 experience","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-10T17:16:00Z","last_updated_date":"2025-07-10T17:16:00Z","reference_number":"EMA/154528/2025","document_url":"https://www.ema.europa.eu/en/documents/report/2024-ai-observatory-report-compilation-2024-experience_en.pdf"},
    {"id":"69207","name":"Review of artificial intelligence and machine learning applications in medicines lifecycle 2024: Horizon Scanning Short Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-10T17:17:00Z","last_updated_date":"2025-07-10T17:17:00Z","reference_number":"EMA/571739/2024","document_url":"https://www.ema.europa.eu/en/documents/report/review-artificial-intelligence-machine-learning-applications-medicines-lifecycle-2024-horizon-scanning-short-report_en.pdf"},
    {"id":"69240","name":"PRAC statistics: July 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-11T12:00:00Z","last_updated_date":"2025-07-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-july-2025_en.pdf"},
    {"id":"69389","name":"Applications for new human medicines under evaluation: July 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-18T15:50:42Z","last_updated_date":"2025-07-18T15:50:42Z","reference_number":"EMA/134672/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-july-2025_en.xlsx"},
    {"id":"69394","name":"Highlights from the 13th meeting of the Nitrosamine Implementation Oversight Group (NIOG)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-21T14:22:17Z","last_updated_date":"2025-07-21T14:22:17Z","reference_number":"EMA/166991/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-13th-meeting-nitrosamine-implementation-oversight-group-niog_en.pdf"},
    {"id":"69402","name":"Medicinal products for human use: monthly figures - June 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-22T10:41:46Z","last_updated_date":"2025-07-22T10:41:46Z","reference_number":"EMA/231762/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-june-2025_en.pdf"},
    {"id":"69428","name":"EU Repurposing pilot","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-24T13:55:00Z","last_updated_date":"2025-07-24T13:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/eu-repurposing-pilot_en.pdf"},
    {"id":"69552","name":"Start of procedure: Extension of marketing authorisation (20 June 2025 - 24 July 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T16:09:59Z","last_updated_date":"2025-07-28T16:09:59Z","reference_number":"EMA/244908/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-20-june-2025-24-july-2025_en.xlsx"},
    {"id":"69553","name":"Start of procedure: Type II variation - Extension of indication under evaluation by the CHMP (20 June 2025 - 24 July 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T16:12:52Z","last_updated_date":"2025-07-28T16:12:52Z","reference_number":"EMA/244915/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-20-june-2025-24-july-2025_en.xlsx"},
    {"id":"69555","name":"Report: European medicines regulatory network’s response to nitrosamine impurities in human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-29T09:33:40Z","last_updated_date":"2025-07-29T09:33:40Z","reference_number":"EMA/144509/2025","document_url":"https://www.ema.europa.eu/en/documents/report/report-european-medicines-regulatory-networks-response-nitrosamine-impurities-human-medicines_en.pdf"},
    {"id":"69556","name":"Summary of the Medicine Shortages SPOC Working Party meeting on 17 June 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-29T09:47:16Z","last_updated_date":"2025-07-29T09:47:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-medicine-shortages-spoc-working-party-meeting-17-june-2025_en.pdf"},
    {"id":"69598","name":"Highlight report - 14th meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-07-31T15:11:16Z","last_updated_date":"2025-07-31T15:11:16Z","reference_number":"EMA/208192/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-14th-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"69620","name":"Meeting report - Quality Innovation Group (QIG) Listen and Learn Focus Group (LLFG) on personalised medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-08-01T12:39:38Z","last_updated_date":"2025-08-01T12:39:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-quality-innovation-group-qig-listen-learn-focus-group-llfg-personalised-medicines_en.pdf"},
    {"id":"69642","name":"Highlights - 13th Industry Standing Group (ISG) meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-08-04T15:19:25Z","last_updated_date":"2025-08-04T15:19:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-13th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"69667","name":"Feedback from European Medicine Agency (EMA) to the EU Commission request to evaluate the feasibility of alternatives to replace titanium dioxide (TiO2) in medicinal products and its possible impact on medicines’ availability","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-08-06T14:00:00Z","last_updated_date":"2025-08-06T14:00:00Z","reference_number":"EMA/94330/2024","document_url":"https://www.ema.europa.eu/en/documents/report/feedback-european-medicine-agency-ema-eu-commission-request-evaluate-feasibility-alternatives-replace-titanium-dioxide-tio2-medicinal-products-its-possible-impact-medicines-availability_en.pdf"},
    {"id":"69683","name":"Applications for new human medicines under evaluation: August 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-08-07T14:41:17Z","last_updated_date":"2025-08-07T14:41:17Z","reference_number":"EMA/258764/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-august-2025_en.xlsx"},
    {"id":"69685","name":"Report - 3Rs Working Party (3RsWP) plenary meeting (April 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-08-08T09:14:47Z","last_updated_date":"2025-08-08T09:14:47Z","reference_number":"EMA/264889/2025","document_url":"https://www.ema.europa.eu/en/documents/report/report-3rs-working-party-3rswp-plenary-meeting-april-2025_en.pdf"},
    {"id":"69867","name":"Highlight report from the 14th Industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-08-27T14:45:03Z","last_updated_date":"2025-08-27T14:45:03Z","reference_number":"EMA/213884/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-14th-industry-stakeholder-platform-research-development-support_en.pdf"},
    {"id":"69915","name":"Applications for new human medicines under evaluation: September 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-09-01T13:46:56Z","last_updated_date":"2025-09-01T13:46:56Z","reference_number":"EMA/283011/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-september-2025_en.xlsx"},
    {"id":"69963","name":"PRAC statistics: September 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T10:50:15Z","last_updated_date":"2025-09-05T10:50:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-september-2025_en.pdf"},
    {"id":"70000","name":"Start of procedure: Extension of marketing authorisation (25 July - 21 August 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-09-08T16:16:12Z","last_updated_date":"2025-09-08T16:16:12Z","reference_number":"EMA/286995/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-25-july-21-august-2025_en.xlsx"},
    {"id":"70001","name":"\tStart of procedure: Type II variation - Extension of indication under evaluation by the CHMP (25 July - 21 August 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-09-08T16:19:07Z","last_updated_date":"2025-09-08T16:19:07Z","reference_number":"EMA/286994/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-25-july-21-august-2025_en.xlsx"},
    {"id":"70026","name":"Medicinal products for human use: monthly figures - July 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-09-09T15:46:34Z","last_updated_date":"2025-09-09T15:46:34Z","reference_number":"EMA/291075/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-july-2025_en.pdf"},
    {"id":"70027","name":"Medicinal products for human use: monthly figures - August 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-09-09T15:48:08Z","last_updated_date":"2025-09-09T15:48:08Z","reference_number":"EMA/291583/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-august-2025_en.pdf"},
    {"id":"70112","name":"Highlights - First EMA-ACRO bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-09-17T10:55:28Z","last_updated_date":"2025-09-17T10:55:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-first-ema-acro-bilateral-meeting_en.pdf"},
    {"id":"70224","name":"Engineered living materials for in situ production of therapeutics - EU-IN Horizon Scanning Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-09-23T13:41:37Z","last_updated_date":"2025-11-11T11:57:14Z","reference_number":"EMA/291569/2025 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/report/engineered-living-materials-situ-production-therapeutics-eu-horizon-scanning-report_en.pdf"},
    {"id":"70227","name":"Start of procedure: Type II variation - Extension of indication under evaluation by the CHMP (22 August 2025 - 18 September 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-09-23T13:53:22Z","last_updated_date":"2025-09-23T13:53:22Z","reference_number":"EMA/307982/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-22-august-2025-18-september-2025_en.xlsx"},
    {"id":"70382","name":"Shortages output JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:07Z","last_updated_date":"2026-01-20T08:26:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/shortages-output-json-report_en.json"},
    {"id":"70429","name":"PRAC statistics: October 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T09:36:46Z","last_updated_date":"2025-10-03T09:36:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-october-2025_en.pdf"},
    {"id":"70490","name":"European Medicines Agency mid-year report 2025 (January-June 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-10-08T10:54:52Z","last_updated_date":"2025-10-08T10:54:52Z","reference_number":"EMA/283452/2025","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2025-january-june-2025_en.pdf"},
    {"id":"70511","name":"Annual report of the Pharmacovigilance Inspectors Working Group for 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-10-09T14:20:07Z","last_updated_date":"2025-10-09T14:20:07Z","reference_number":"EMA/INS/PhV/122716/2025","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-pharmacovigilance-inspectors-working-group-2024_en.pdf"},
    {"id":"70527","name":"Applications for new human medicines under evaluation: October 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-10-10T14:42:23Z","last_updated_date":"2025-10-10T14:42:23Z","reference_number":"EMA/322049/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-october-2025_en.xlsx"},
    {"id":"70749","name":"Medicinal products for human use: monthly figures - September 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-10-22T10:15:19Z","last_updated_date":"2025-10-22T10:15:19Z","reference_number":"EMA/333353/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-september-2025_en.pdf"},
    {"id":"70764","name":"Start of procedure: Extension of marketing authorisation (19 September - 16 October 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-10-22T15:59:02Z","last_updated_date":"2025-10-22T15:59:02Z","reference_number":"EMA/337105/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-19-september-16-october-2025_en.xlsx"},
    {"id":"70765","name":"Start of procedure: Type II variation - Extension of indication under evaluation by the CHMP (19 September - 16 October 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-10-22T16:02:36Z","last_updated_date":"2025-10-22T16:02:36Z","reference_number":"EMA/337148/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-19-september-16-october-2025_en.xlsx"},
    {"id":"70805","name":"Meeting report - Workshop on a tailored clinical approach in biosimilar Development","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T11:13:58Z","last_updated_date":"2025-10-24T11:13:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-workshop-tailored-clinical-approach-biosimilar-development_en.pdf"},
    {"id":"70824","name":"Highlights - Second EMA/COCIR bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-10-24T17:12:12Z","last_updated_date":"2025-10-24T17:12:12Z","reference_number":"EMA/465345/2024","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-second-ema-cocir-bilateral-meeting_en.pdf"},
    {"id":"70855","name":"Referrals output JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:07Z","last_updated_date":"2026-01-20T08:26:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/referrals-output-json-report_en.json"},
    {"id":"70856","name":"Documents output epar_documents_json report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T09:14:42Z","last_updated_date":"2025-11-25T09:14:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/documents-output-epar_documents_json-report_en.json"},
    {"id":"70857","name":"Documents output non_epar_documents_json report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T09:14:04Z","last_updated_date":"2025-11-25T09:14:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/documents-output-non_epar_documents_json-report_en.json"},
    {"id":"70858","name":"DHPC output JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:07Z","last_updated_date":"2026-01-20T08:26:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/dhpc-output-json-report_en.json"},
    {"id":"70859","name":"Medicines output periodic_safety_update_report_single_assessments output JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:07Z","last_updated_date":"2026-01-20T08:26:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-periodic_safety_update_report_single_assessments-output-json-report_en.json"},
    {"id":"70860","name":"Medicine for use outside EU output JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:07Z","last_updated_date":"2026-01-20T08:26:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicine-use-outside-eu-output-json-report_en.json"},
    {"id":"70861","name":"Medicines output paediatric_investigation_plans output JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:07Z","last_updated_date":"2026-01-20T08:26:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-paediatric_investigation_plans-output-json-report_en.json"},
    {"id":"70862","name":"Medicines output herbal_medicines report output JSON","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:08Z","last_updated_date":"2026-01-20T08:26:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-herbal_medicines-report-output-json_en.json"},
    {"id":"70863","name":"Medicines output orphan_designations JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:08Z","last_updated_date":"2026-01-20T08:26:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-orphan_designations-json-report_en.json"},
    {"id":"70941","name":"PRAC statistics: November 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-10-31T12:00:00Z","last_updated_date":"2025-10-31T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-november-2025_en.pdf"},
    {"id":"71010","name":"Applications for new human medicines under evaluation: November 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-05T14:32:12Z","last_updated_date":"2025-11-05T14:32:12Z","reference_number":"EMA/352289/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-november-2025_en.xlsx"},
    {"id":"71202","name":"Medicinal products for human use: monthly figures - October 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-17T16:19:53Z","last_updated_date":"2025-11-17T16:19:53Z","reference_number":"EMA/363096/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-october-2025_en.pdf"},
    {"id":"71234","name":"Start of procedure: Extension of marketing authorisation (17 October - 13 November 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-18T17:08:57Z","last_updated_date":"2025-11-18T17:08:57Z","reference_number":"EMA/365076/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-17-october-13-november-2025_en.xlsx"},
    {"id":"71235","name":"Start of procedure: Type II variation - Extension of indication under evaluation by the CHMP (17 October - 13 November 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-18T17:16:53Z","last_updated_date":"2025-11-18T17:16:53Z","reference_number":"EMA/365051/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-17-october-13-november-2025_en.xlsx"},
    {"id":"71319","name":"Medicines output maximum_residue_limits report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:08Z","last_updated_date":"2026-01-20T08:26:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-maximum_residue_limits-report_en.xlsx"},
    {"id":"71320","name":"Medicines output maximum_residue_limits JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T09:10:49Z","last_updated_date":"2025-11-25T09:10:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/medicines-output-maximum_residue_limits-json-report_en.json"},
    {"id":"71321","name":"Events report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:08Z","last_updated_date":"2026-01-20T08:26:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/events-report_en.xlsx"},
    {"id":"71322","name":"Events JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T09:11:01Z","last_updated_date":"2025-11-25T09:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/events-json-report_en.json"},
    {"id":"71338","name":"Meeting report - EMA workshop on the challenges in drug development, regulation and clinical practice for immunoglobulins","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T15:46:55Z","last_updated_date":"2025-11-25T15:46:55Z","reference_number":"EMA/88993/2025","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-ema-workshop-challenges-drug-development-regulation-clinical-practice-immunoglobulins_en.pdf"}    {"id":"71375","name":"3Rs working party biennial report 2023-2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T16:13:50Z","last_updated_date":"2025-11-27T16:13:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/3rs-working-party-biennial-report-2023-2024_en.pdf"},
    {"id":"71377","name":"Highlights - 14th Industry Standing Group (ISG) meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-27T16:29:12Z","last_updated_date":"2025-11-27T16:29:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-14th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"71384","name":"PRAC statistics: December 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T12:00:00Z","last_updated_date":"2025-11-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-december-2025_en.pdf"},
    {"id":"71527","name":"Applications for new human medicines under evaluation: December 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-05T11:45:00Z","last_updated_date":"2025-12-05T11:45:00Z","reference_number":"EMA/352289/2025","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-december-2025_en.xlsx"},
    {"id":"71584","name":"European sales and use of antimicrobials for veterinary medicine: Annual surveillance report for 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T12:57:00Z","last_updated_date":"2025-12-09T12:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-sales-use-antimicrobials-veterinary-medicine-annual-surveillance-report-2024_en.pdf"},
    {"id":"71593","name":"Medicinal products for human use: monthly figures - November 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-08T16:21:54Z","last_updated_date":"2025-12-08T16:21:54Z","reference_number":"EMA/382460/2025","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-november-2025_en.pdf"},
    {"id":"71683","name":"Methodology Working Party (MWP) interested parties meeting report, September 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-11T10:47:15Z","last_updated_date":"2025-12-11T10:47:15Z","reference_number":"EMA/389090/2025","document_url":"https://www.ema.europa.eu/en/documents/report/methodology-working-party-mwp-interested-parties-meeting-report-september-2025_en.pdf"},
    {"id":"71703","name":"Highlights - 20th EMA Industry Platform meeting on the operation of EU pharmacovigilance legislation meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-11T16:43:43Z","last_updated_date":"2025-12-11T16:43:43Z","reference_number":"EMA/370879/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-20th-ema-industry-platform-meeting-operation-eu-pharmacovigilance-legislation-meeting_en.pdf"},
    {"id":"71726","name":"Highlights - Fourth European Medicines Agency - MedTech Europe bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T13:25:42Z","last_updated_date":"2025-12-12T13:25:42Z","reference_number":"EMA/369789/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-fourth-european-medicines-agency-medtech-europe-bilateral-meeting_en.pdf"},
    {"id":"71772","name":"Start of procedure: Extension of marketing authorisation (14 November - 11 December 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-16T10:33:58Z","last_updated_date":"2025-12-16T10:33:58Z","reference_number":"EMA/392654/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-14-november-11-december-2025_en.xlsx"},
    {"id":"71773","name":"Start of procedure: Type II variation - Extension of indication under evaluation by the CHMP (14 November - 11 December 2025)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-16T10:36:46Z","last_updated_date":"2025-12-16T10:36:46Z","reference_number":"EMA/392653/2025","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-14-november-11-december-2025_en.xlsx"},
    {"id":"71892","name":"Summary - Joint HMA/EMA multi-stakeholder workshop on Patient Registries for Alzheimer's disease December 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T09:38:32Z","last_updated_date":"2025-12-22T09:38:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-joint-hma-ema-multi-stakeholder-workshop-patient-registries-alzheimers-disease-december-2025_en.pdf"},
    {"id":"71906","name":"Report - EMA roundtable with stakeholders on the 20th anniversary of the SME regulation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T10:27:18Z","last_updated_date":"2025-12-22T10:27:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-ema-roundtable-stakeholders-20th-anniversary-sme-regulation_en.pdf"},
    {"id":"71925","name":"Report - Industry stakeholders' feedback on engagement and communication activities","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-05T14:50:49Z","last_updated_date":"2026-01-07T14:47:00Z","reference_number":"EMA/273178/2025","document_url":"https://www.ema.europa.eu/en/documents/report/report-industry-stakeholders-feedback-engagement-communication-activities_en.pdf"},
    {"id":"71952","name":"Highlight report - Combination Products Operational Group (COMBO) - In Vitro Diagnostics stream - November 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T14:18:24Z","last_updated_date":"2026-01-07T14:18:24Z","reference_number":"EMA/353484/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-combination-products-operational-group-combo-vitro-diagnostics-stream-november-2025_en.pdf"},
    {"id":"71953","name":"Highlight report - Combination Products Operational Group (COMBO) - Medical Devices stream - November 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-07T14:19:50Z","last_updated_date":"2026-01-07T14:19:50Z","reference_number":"EMA/357562/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-combination-products-operational-group-combo-medical-devices-stream-november-2025_en.pdf"},
    {"id":"71999","name":"Highlight report - 15th meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-08T17:01:03Z","last_updated_date":"2026-01-08T17:01:03Z","reference_number":"EMA/377391/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-15th-meeting-industry-stakeholder-platform-operation-centralised-procedure-human-medicines_en.pdf"},
    {"id":"72039","name":"HMA/EMA annual data forum 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-14T10:17:58Z","last_updated_date":"2026-01-14T10:17:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/hma-ema-annual-data-forum-2025_en.pdf"},
    {"id":"72053","name":"Human medicines in 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T13:00:00Z","last_updated_date":"2026-01-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/human-medicines-2025_en.pdf"},
    {"id":"72138","name":"Veterinary medicines in 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-19T17:00:00Z","last_updated_date":"2026-01-19T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/veterinary-medicines-2025_en.pdf"},
    {"id":"72143","name":"Report - HMA/EMA Multi-stakeholder workshop on Artificial Intelligence (AI)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-19T17:29:43Z","last_updated_date":"2026-01-19T17:29:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-hma-ema-multi-stakeholder-workshop-artificial-intelligence-ai_en.pdf"},
    {"id":"72144","name":"General report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:08Z","last_updated_date":"2026-01-20T08:26:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/general-report_en.xlsx"},
    {"id":"72145","name":"General JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:09Z","last_updated_date":"2026-01-20T08:26:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/general-json-report_en.json"},
    {"id":"72146","name":"News report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:09Z","last_updated_date":"2026-01-20T08:26:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/news-report_en.xlsx"},
    {"id":"72147","name":"News JSON report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T08:26:09Z","last_updated_date":"2026-01-20T08:26:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/news-json-report_en.json"},
    {"id":"72152","name":"Applications for new human medicines under evaluation: January 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T10:56:38Z","last_updated_date":"2026-01-20T10:56:38Z","reference_number":"EMA/11494/2026","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-january-2026_en.xlsx"},
    {"id":"72172","name":"Annual report of the Good Clinical Practice Inspectors Working Group 2024","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-20T16:04:08Z","last_updated_date":"2026-01-20T16:04:08Z","reference_number":"EMA/INS/GCP/37608/2025","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-clinical-practice-inspectors-working-group-2024_en.pdf"},
    {"id":"72201","name":"Summary report - First EMA-HMA multi-stakeholder forum on EudraVigilance and signal detection","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-21T17:00:46Z","last_updated_date":"2026-01-26T16:43:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-report-first-ema-hma-multi-stakeholder-forum-eudravigilance-signal-detection_en.pdf"},
    {"id":"72205","name":"Highlights - Eighth European Medicines Agency (EMA) and Medicines for Europe bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-22T14:44:29Z","last_updated_date":"2026-01-22T14:44:29Z","reference_number":"EMA/393054/2025","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-eighth-european-medicines-agency-ema-medicines-europe-bilateral-meeting_en.pdf"},
    {"id":"72302","name":"Medicinal products for human use: monthly figures - December 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-27T16:58:17Z","last_updated_date":"2026-01-27T16:58:17Z","reference_number":"EMA/5869/2026","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-december-2025_en.pdf"},
    {"id":"72325","name":"Report - Highlights of the 15th Industry Standing Group (ISG) meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-28T14:21:11Z","last_updated_date":"2026-03-02T13:40:00Z","reference_number":"EMA/387702/2025","document_url":"https://www.ema.europa.eu/en/documents/report/report-highlights-15th-industry-standing-group-isg-meeting_en.pdf"},
    {"id":"72363","name":"Final programming document 2026-28","type":"report","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T10:04:26Z","last_updated_date":"2026-01-30T10:04:26Z","reference_number":"EMA/10240/2026","document_url":"https://www.ema.europa.eu/en/documents/report/final-programming-document-2026-28_en.pdf"},
    {"id":"72390","name":"Network Data Steering Group (NDSG) 2025 annual report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-01-30T14:53:19Z","last_updated_date":"2026-01-30T14:53:19Z","reference_number":"EXT/345765/2025","document_url":"https://www.ema.europa.eu/en/documents/report/network-data-steering-group-ndsg-2025-annual-report_en.pdf"},
    {"id":"72399","name":"Report - Highlight report from the 15th Industry stakeholder platform on research and development support","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-02T11:30:29Z","last_updated_date":"2026-02-02T11:30:29Z","reference_number":"EMA/373010/2025","document_url":"https://www.ema.europa.eu/en/documents/report/report-highlight-report-15th-industry-stakeholder-platform-research-development-support_en.pdf"},
    {"id":"72415","name":"Hearing the Association of the European Self-Medication Industry (AESGP) during the HMPC November 2025 meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-04T15:29:00Z","last_updated_date":"2026-02-04T15:29:00Z","reference_number":"EMA/HMPC/378565/2025","document_url":"https://www.ema.europa.eu/en/documents/report/hearing-association-european-self-medication-industry-aesgp-during-hmpc-november-2025-meeting_en.pdf"},
    {"id":"72419","name":"Summary from the industry stakeholder webinar on the revised guideline on the environmental risk assessment of medicinal products for human use","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-04T16:59:41Z","last_updated_date":"2026-02-04T16:59:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/summary-industry-stakeholder-webinar-revised-guideline-environmental-risk-assessment-medicinal-products-human-use_en.pdf"},
    {"id":"72420","name":"Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (12 December 2025 - 29 January 2026)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-04T17:10:29Z","last_updated_date":"2026-02-04T17:10:29Z","reference_number":"EMA/27039/2026","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-12-december-2025-29-january-2026_en.xlsx"},
    {"id":"72421","name":"Start of procedure: Extension of marketing authorisation (12 December 2025 - 29 January 2026)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-04T17:11:47Z","last_updated_date":"2026-02-04T17:11:47Z","reference_number":"EMA/27038/2026","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-12-december-2025-29-january-2026_en.xlsx"},
    {"id":"72428","name":"Applications for new human medicines under evaluation: February 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-05T14:37:50Z","last_updated_date":"2026-02-05T14:37:50Z","reference_number":"EMA/EMA/28614/2026","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-february-2026_en.xlsx"},
    {"id":"72480","name":"Report from the 2025 annual meeting of the European network of paediatric research at the EMA (EnprEMA)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T11:15:37Z","last_updated_date":"2026-02-10T11:15:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-2025-annual-meeting-european-network-paediatric-research-ema-enprema_en.pdf"},
    {"id":"72508","name":"Review of the stepwise paediatric investigation plan (sPIP) pilot: Outcomes and future perspectives","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-12T22:36:59Z","last_updated_date":"2026-02-12T22:36:59Z","reference_number":"EMA/357164/2025","document_url":"https://www.ema.europa.eu/en/documents/report/review-stepwise-paediatric-investigation-plan-spip-pilot-outcomes-future-perspectives_en.pdf"},
    {"id":"72517","name":"Meeting summary - Medicine shortages SPOC working party meeting 9 December 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-11T16:49:34Z","last_updated_date":"2026-02-11T16:49:34Z","reference_number":"EMA/13115/2026","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-summary-medicine-shortages-spoc-working-party-meeting-9-december-2025_en.pdf"},
    {"id":"72557","name":"Medicinal products for human use: monthly figures - January 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-13T15:21:47Z","last_updated_date":"2026-02-13T15:21:47Z","reference_number":"EMA/31675/2026","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-january-2026_en.pdf"},
    {"id":"72558","name":"Highlights - 6th EMA-AESGP bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-13T15:25:34Z","last_updated_date":"2026-02-13T15:25:34Z","reference_number":"EMA/5438/2026","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-6th-ema-aesgp-bilateral-meeting_en.pdf"},
    {"id":"72585","name":"Meeting report - ACT EU multi-stakeholder platform annual meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-17T17:00:53Z","last_updated_date":"2026-02-17T17:00:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/meeting-report-act-eu-multi-stakeholder-platform-annual-meeting_en.pdf-0"},
    {"id":"72724","name":"Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) annual activity report 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-02-26T16:31:41Z","last_updated_date":"2026-02-26T16:31:41Z","reference_number":"EMA/127560/2025","document_url":"https://www.ema.europa.eu/en/documents/report/executive-steering-group-shortages-safety-medicinal-products-mssg-annual-activity-report-2025_en.pdf"},
    {"id":"72808","name":"Start of procedure: Extension of marketing authorisation (30 January 2026 - 26 February 2026)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-03T16:33:48Z","last_updated_date":"2026-03-03T16:33:48Z","reference_number":"EMA/50188/2026","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-30-january-2026-26-february-2026_en.xlsx"},
    {"id":"72811","name":"Annual report on the use of the special contribution for orphan medicinal products - 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-03T17:55:08Z","last_updated_date":"2026-03-03T17:55:08Z","reference_number":"EMA/375104/2025","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-use-special-contribution-orphan-medicinal-products-2025_en.pdf"},
    {"id":"72842","name":"Highlights – 3rd EMA-IPFA-PPTA bilateral meeting","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T16:52:15Z","last_updated_date":"2026-03-04T16:52:15Z","reference_number":"EMA/39753/2026","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-3rd-ema-ipfa-ppta-bilateral-meeting_en.pdf"},
    {"id":"72877","name":"Highlight report - Combination Products Operational Group (COMBO) - In Vitro Diagnostics stream - February 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-06T14:01:13Z","last_updated_date":"2026-03-06T14:01:13Z","reference_number":"EMA/32158/2026","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-combination-products-operational-group-combo-vitro-diagnostics-stream-february-2026_en.pdf"},
    {"id":"72878","name":"Highlight report - Combination Products Operational Group (COMBO) - Medical Devices stream - February 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-06T14:04:46Z","last_updated_date":"2026-03-06T14:04:46Z","reference_number":"EMA/32693/2026","document_url":"https://www.ema.europa.eu/en/documents/report/highlight-report-combination-products-operational-group-combo-medical-devices-stream-february-2026_en.pdf"},
    {"id":"72956","name":"Applications for new human medicines under evaluation: March 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-11T17:03:05Z","last_updated_date":"2026-03-11T17:03:05Z","reference_number":"EMA/53995/2026","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-march-2026_en.xlsx"},
    {"id":"72992","name":"PRAC statistics: March 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-13T12:00:00Z","last_updated_date":"2026-03-13T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-march-2026_en.pdf"},
    {"id":"73027","name":"Progressing EMA’s PRIority Medicines scheme through new pilot features","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-18T14:00:00Z","last_updated_date":"2026-03-18T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/progressing-emas-priority-medicines-scheme-through-new-pilot-features_en.pdf"},
    {"id":"73119","name":"2025 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-19T13:34:37Z","last_updated_date":"2026-03-19T13:34:37Z","reference_number":"EMA/371010/2025 ","document_url":"https://www.ema.europa.eu/en/documents/report/2025-annual-report-eudravigilance-european-parliament-council-commission_en.pdf"},
    {"id":"73135","name":"EMA’s biennial report on stakeholder engagement activities 2024-2025 ","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-20T15:00:00Z","last_updated_date":"2026-03-20T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/emas-biennial-report-stakeholder-engagement-activities-2024-2025_en.pdf"},
    {"id":"73149","name":"Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2025","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-23T16:50:42Z","last_updated_date":"2026-03-23T16:50:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/annual-report-good-manufacturing-distribution-practice-inspectors-working-group-2025_en.pdf"},
    {"id":"73160","name":"Medicinal products for human use: monthly figures - February 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T11:39:34Z","last_updated_date":"2026-03-24T11:39:34Z","reference_number":"EMA/65549/2026","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-february-2026_en.pdf"},
    {"id":"73164","name":"Report - Workshop on the use of Bayesian statistics in clinical development","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-24T13:16:52Z","last_updated_date":"2026-03-24T13:16:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-use-bayesian-statistics-clinical-development_en.pdf"},
    {"id":"73186","name":"2025 European Medicines Agency annual report on independence","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-25T09:20:46Z","last_updated_date":"2026-03-25T09:20:46Z","reference_number":"EMA/8063/2026","document_url":"https://www.ema.europa.eu/en/documents/report/2025-european-medicines-agency-annual-report-independence_en.pdf"},
    {"id":"73265","name":"European medicines agencies network strategy (EMANS) to 2025: Final report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-03-31T10:59:00Z","last_updated_date":"2026-03-31T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/european-medicines-agencies-network-strategy-emans-2025-final-report_en.pdf"},
    {"id":"73321","name":"Report - EMA Industry standing group - Focus Group Regulatory Science Research Translation","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T13:29:25Z","last_updated_date":"2026-04-07T13:29:25Z","reference_number":"EMA/63729/2026","document_url":"https://www.ema.europa.eu/en/documents/report/report-ema-industry-standing-group-focus-group-regulatory-science-research-translation_en.pdf"},
    {"id":"73416","name":"PRAC statistics: April 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-04-10T14:00:00Z","last_updated_date":"2026-04-10T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-april-2026_en.pdf"},
    {"id":"73432","name":"Applications for new human medicines under evaluation: April 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-04-14T09:26:44Z","last_updated_date":"2026-04-14T09:26:44Z","reference_number":"EMA/80934/2026","document_url":"https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-april-2026_en.xlsx"},
    {"id":"73451","name":"Radiopharmaceuticals EU-IN Horizon Scanning Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-04-15T14:52:00Z","last_updated_date":"2026-04-15T14:52:00Z","reference_number":"EMA/82413/2026","document_url":"https://www.ema.europa.eu/en/documents/report/radiopharmaceuticals-eu-horizon-scanning-report_en.pdf"},
    {"id":"73493","name":"Focus group on submission predictability: 2025 final report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-04-20T00:05:41Z","last_updated_date":"2026-04-20T00:05:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/focus-group-submission-predictability-2025-final-report_en.pdf"},
    {"id":"73524","name":"Medicinal products for human use: monthly figures - March 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-04-22T16:24:15Z","last_updated_date":"2026-04-22T16:24:15Z","reference_number":"EMA/89464/2026","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2026_en.pdf"},
    {"id":"73587","name":"Revamp pilot report - Experience gained with applicants pre-filling the factual sections of the D80 assessment reports for initial MAAs","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T09:30:00Z","last_updated_date":"2026-05-08T09:30:00Z","reference_number":"EMA/399716/2025","document_url":"https://www.ema.europa.eu/en/documents/report/revamp-pilot-report-experience-gained-applicants-pre-filling-factual-sections-d80-assessment-reports-initial-maas_en.pdf"},
    {"id":"73662","name":"PRAC statistics: May 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T10:45:34Z","last_updated_date":"2026-05-08T10:45:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/prac-statistics-may-2026_en.pdf"},
    {"id":"73747","name":"Highlights from the second expert panels and notified bodies workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-05-18T13:18:52Z","last_updated_date":"2026-05-18T13:18:52Z","reference_number":"EMA/115162/2026","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-second-expert-panels-notified-bodies-workshop_en.pdf"},
    {"id":"73749","name":"Highlights from the third expert panels and notified bodies workshop","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-05-18T15:43:26Z","last_updated_date":"2026-05-18T15:43:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/highlights-third-expert-panels-notified-bodies-workshop_en.pdf"},
    {"id":"73750","name":"Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (30 January 2026 - 26 February 2026)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-05-18T16:42:14Z","last_updated_date":"2026-05-18T16:42:14Z","reference_number":"EMA/98044/2026","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-30-january-2026-26-february-2026_en.xlsx"},
    {"id":"73751","name":"Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (27 February 2026 - 26 March 2026)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-05-18T16:44:43Z","last_updated_date":"2026-05-18T16:44:43Z","reference_number":"EMA/98008/2026","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-27-february-2026-26-march-2026_en.xlsx"},
    {"id":"73769","name":"Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (27 March 2026 - 23 April 2026)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-05-19T16:38:03Z","last_updated_date":"2026-05-19T16:38:03Z","reference_number":"EMA/97504/2026","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-27-march-2026-23-april-2026_en.xlsx"},
    {"id":"73855","name":"Medicinal products for human use: monthly figures - April 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-05-26T16:53:23Z","last_updated_date":"2026-05-26T16:53:23Z","reference_number":"EMA/119444/2026","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2026_en.pdf"},
    {"id":"73886","name":"20 years supporting small and medium enterprises (SMEs) at EMA report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-05-28T15:45:40Z","last_updated_date":"2026-05-28T15:45:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/20-years-supporting-small-medium-enterprises-smes-ema-report_en.pdf"},
    {"id":"73953","name":"Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (24 April 2026 - 21 May 2026)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T12:01:24Z","last_updated_date":"2026-06-03T12:01:24Z","reference_number":"EMA/128005/2026","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-type-ii-variation-extension-indication-under-evaluation-chmp-24-april-2026-21-may-2026_en.xlsx"},
    {"id":"73954","name":"Start of procedure: Extension of marketing authorisation (24 April 2026 - 21 May 2026)","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T12:03:10Z","last_updated_date":"2026-06-03T12:03:10Z","reference_number":"EMA/128004/2026","document_url":"https://www.ema.europa.eu/en/documents/report/start-procedure-extension-marketing-authorisation-24-april-2026-21-may-2026_en.xlsx"},
    {"id":"73962","name":"2025 AI Observatory report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-06-04T12:33:00Z","last_updated_date":"2026-06-04T12:33:00Z","reference_number":"EMA/67888/2026","document_url":"https://www.ema.europa.eu/en/documents/report/2025-ai-observatory-report_en.pdf"},
    {"id":"73985","name":"Real-world evidence framework to support EU regulatory decision-making: 4th report on the experience gained with regulator-led studies from February 2025 to February 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-06-10T11:00:00Z","last_updated_date":"2026-06-10T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-4th-report-experience-gained-regulator-led-studies-february-2025-february-2026_en.pdf"},
    {"id":"73995","name":"Report - HMA/EMA multi-stakeholder workshop on reporting and qualification of mechanistic models for regulatory assessment","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-06-05T16:12:43Z","last_updated_date":"2026-06-05T16:12:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-hma-ema-multi-stakeholder-workshop-reporting-qualification-mechanistic-models-regulatory-assessment_en.pdf"},
    {"id":"74093","name":"Webinar on the use of platform approaches in the non-clinical and clinical domains - Report","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-06-15T11:44:11Z","last_updated_date":"2026-06-15T11:44:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/webinar-use-platform-approaches-non-clinical-clinical-domains-report_en.pdf"},
    {"id":"74115","name":"Report - Joint HMA/EMA multi-stakeholder workshop on Patient Registries for Alzheimer's disease","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-06-16T10:01:07Z","last_updated_date":"2026-06-16T10:01:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/report/report-joint-hma-ema-multi-stakeholder-workshop-patient-registries-alzheimers-disease_en.pdf"},
    {"id":"74144","name":"Medicinal products for human use: monthly figures - May 2026","type":"report","status":"unknown","consultation_date":"","first_published_date":"2026-06-17T16:28:36Z","last_updated_date":"2026-06-17T16:28:36Z","reference_number":"EMA/138334/2026","document_url":"https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-may-2026_en.pdf"},
    {"id":"39416","name":"Decision of the Executive Director on rules governing the traineeship programme at the EMA","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2009-05-13T02:09:00Z","last_updated_date":"2024-03-21T10:26:00Z","reference_number":"EMA/116263/2024","document_url":"https://www.ema.europa.eu/en/documents/recruitment/decision-executive-director-rules-governing-traineeship-programme-ema_en.pdf"},
    {"id":"41351","name":"Careers at European Medicines Agency (EMA) - Guidance on selection and recruitment","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2018-05-15T16:33:00Z","last_updated_date":"2024-02-01T15:51:00Z","reference_number":"EMA/859332/2022","document_url":"https://www.ema.europa.eu/en/documents/recruitment/careers-european-medicines-agency-ema-guidance-selection-recruitment_en.pdf"},
    {"id":"44343","name":"European Medicines Agency's data protection notice for selection and recruitment","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2019-07-04T12:00:00Z","last_updated_date":"2025-05-23T15:25:00Z","reference_number":"EMA/208342/2019","document_url":"https://www.ema.europa.eu/en/documents/recruitment/european-medicines-agencys-data-protection-notice-selection-recruitment_en.pdf"},
    {"id":"46198","name":"Careers at EMA user-guide","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2019-11-28T15:16:00Z","last_updated_date":"2024-05-28T14:06:00Z","reference_number":"EMA/847592/2017","document_url":"https://www.ema.europa.eu/en/documents/recruitment/careers-ema-user-guide_en.pdf"},
    {"id":"47670","name":"Traineeship - Frequently asked questions (FAQs)","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2020-05-14T17:24:00Z","last_updated_date":"2024-04-05T11:58:00Z","reference_number":"EMA/260778/2020","document_url":"https://www.ema.europa.eu/en/documents/recruitment/traineeship-frequently-asked-questions-faqs_en.pdf"},
    {"id":"53894","name":"EMA Competency Framework","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-01-24T15:01:00Z","last_updated_date":"2022-01-24T15:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/ema-competency-framework_en.pdf"},
    {"id":"54248","name":"Head of Service","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-02-22T17:00:00Z","last_updated_date":"2022-02-22T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/head-service_en.pdf"},
    {"id":"54626","name":"Procurement and Contract Management Assistant","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-03-30T17:00:00Z","last_updated_date":"2022-03-30T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/procurement-and-contract-management-assistant_en.pdf"},
    {"id":"54933","name":"Meeting Support Assistant","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-05-11T17:00:00Z","last_updated_date":"2022-05-11T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/meeting-support-assistant_en.pdf"},
    {"id":"54934","name":"Data Science Officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-05-11T17:00:00Z","last_updated_date":"2022-05-11T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/data-science-officer_en.pdf"},
    {"id":"54935","name":"Change Management Officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-05-11T17:00:00Z","last_updated_date":"2022-05-11T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/change-management-officer_en.pdf"},
    {"id":"54960","name":"Change Manager","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-05-24T15:15:00Z","last_updated_date":"2022-05-24T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/change-manager_en.pdf"},
    {"id":"54967","name":"Role description: Head of Workstream - Management - AD10","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-05-16T15:07:00Z","last_updated_date":"2022-05-16T15:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-head-workstream-management-ad10_en.pdf"},
    {"id":"54968","name":"Role description: Customer Portfolio Analyst - Information Technology Management (ITM) - FGIV","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-05-17T10:00:00Z","last_updated_date":"2022-05-17T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-customer-portfolio-analyst-information-technology-management-itm-fgiv_en.pdf"},
    {"id":"54969","name":"Role description: Platform Analyst - Information Technology Management (ITM) - FGIV","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-05-17T10:00:00Z","last_updated_date":"2022-05-17T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-platform-analyst-information-technology-management-itm-fgiv_en.pdf"},
    {"id":"55290","name":"Role description: Meeting support assisstant","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-06-20T15:07:00Z","last_updated_date":"2022-06-20T15:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-meeting-support-assisstant_en.pdf"}    {"id":"55697","name":"Role description: Legal Officer (FG IV)","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-07-27T14:45:00Z","last_updated_date":"2022-07-27T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-legal-officer-fg-iv_en.pdf"},
    {"id":"56053","name":"Role description: Scientific Support Assistant","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-09-09T16:07:00Z","last_updated_date":"2022-09-09T16:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-scientific-support-assistant_en.pdf"},
    {"id":"56138","name":"Role description: Scientific Senior Specialist - AD8","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-09-20T11:31:00Z","last_updated_date":"2022-09-20T11:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-scientific-senior-specialist-ad8_en.pdf"},
    {"id":"56239","name":"Role description: Scientific officer - FGIV","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-09-29T10:00:00Z","last_updated_date":"2022-09-29T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-scientific-officer-fgiv_en.pdf"},
    {"id":"56294","name":"Role description: Platform Senior Architect - AD08","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T09:43:00Z","last_updated_date":"2022-10-04T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-platform-senior-architect-ad08_en.pdf"},
    {"id":"56295","name":"Role description: Platform Lead - AD06","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T09:45:00Z","last_updated_date":"2022-10-04T09:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-platform-lead-ad06_en.pdf"},
    {"id":"56296","name":"Role description: Head of Service/Office/WS","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T09:47:00Z","last_updated_date":"2022-10-04T09:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-head-service-office-ws_en.pdf"},
    {"id":"56743","name":"Role description: Enterprise Content and Records Management Specialist - Information Technology Management (ITM) - AD","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2022-11-22T10:00:00Z","last_updated_date":"2022-11-22T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-enterprise-content-records-management-specialist-information-technology-management-itm-ad_en.pdf"},
    {"id":"57739","name":"Role description: Head of Service / Office / Workstream -  Management - AD06-AD08 / AST10","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-02-20T15:28:00Z","last_updated_date":"2023-02-20T15:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-head-service-office-workstream-management-ad06-ad08-ast10_en.pdf"},
    {"id":"58168","name":"Role description: Security coordinator","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-03-27T09:47:00Z","last_updated_date":"2023-03-27T09:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-security-coordinator_en.pdf"},
    {"id":"58211","name":"Role description: Senior Liaison Specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T09:47:00Z","last_updated_date":"2023-03-30T09:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-senior-liaison-specialist_en.pdf"},
    {"id":"58418","name":"Role description: Scientific Specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-04-19T09:47:00Z","last_updated_date":"2023-04-19T09:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-scientific-specialist_en.pdf"},
    {"id":"58591","name":"Role description: Epidemiology Specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-05-05T15:26:00Z","last_updated_date":"2023-05-05T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-epidemiology-specialist_en.pdf"},
    {"id":"58796","name":"Role description: Biostatistician Specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T15:26:00Z","last_updated_date":"2023-05-26T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-biostatistician-specialist_en.pdf"},
    {"id":"58797","name":"Role description: Data Science Specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T15:26:00Z","last_updated_date":"2023-05-26T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-data-science-specialist_en.pdf"},
    {"id":"59194","name":"Role description: Service Lead - Information Technology Management (ITM) - Enterprise Service Management - AD6","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-07-03T16:13:00Z","last_updated_date":"2023-07-03T16:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-service-lead-information-technology-management-itm-enterprise-service-management-ad6_en.pdf"},
    {"id":"59861","name":"Role description: Senior Translational Sciences Specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-09-01T16:56:00Z","last_updated_date":"2023-09-01T16:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-senior-translational-sciences-specialist_en.pdf"},
    {"id":"59911","name":"Role description: Medicines and Medical Devices Shortages Officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-09-07T12:32:00Z","last_updated_date":"2023-09-07T12:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-medicines-medical-devices-shortages-officer_en.pdf"},
    {"id":"60033","name":"Role description: Legal Specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T16:56:00Z","last_updated_date":"2023-09-15T16:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-legal-specialist_en.pdf"},
    {"id":"60116","name":"Role description: Financial Specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-09-22T16:56:00Z","last_updated_date":"2023-09-22T16:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-financial-specialist_en.pdf"},
    {"id":"60457","name":"Role description: Customer Portfolio Lead","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-10-20T11:04:00Z","last_updated_date":"2023-10-20T11:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-customer-portfolio-lead_en.pdf"},
    {"id":"60510","name":"Role description: Scientific Support Coordinator","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2023-10-30T17:15:00Z","last_updated_date":"2023-10-30T17:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-scientific-support-coordinator_en.pdf"},
    {"id":"62046","name":"Role description: Financial Officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-02-08T12:53:36Z","last_updated_date":"2024-02-08T12:53:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-financial-officer_en.pdf"},
    {"id":"62155","name":"Role description: Head of Department","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T18:03:58Z","last_updated_date":"2024-02-14T18:03:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-head-department_en.pdf"},
    {"id":"62288","name":"Role description: Clinical Data Publication Officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T15:29:24Z","last_updated_date":"2024-02-23T15:29:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-clinical-data-publication-officer_en.pdf"},
    {"id":"62289","name":"Role description: Access to Documents Officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T16:06:02Z","last_updated_date":"2024-02-23T16:06:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-access-documents-officer_en.pdf"},
    {"id":"62660","name":"Role description: Regulatory Affairs Officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-03-20T18:18:31Z","last_updated_date":"2024-03-20T18:18:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-regulatory-affairs-officer_en.pdf"},
    {"id":"62661","name":"Role description: Scientific Committee Officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-03-20T18:19:25Z","last_updated_date":"2024-03-20T18:19:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-scientific-committee-officer_en.pdf"},
    {"id":"62680","name":"Role description: Senior Medicines and Medical Devices Shortages Specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-03-21T15:15:53Z","last_updated_date":"2024-03-21T15:15:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-senior-medicines-medical-devices-shortages-specialist_en.pdf"},
    {"id":"62884","name":"HR Assistant CF-04-01-400","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-04-10T11:12:29Z","last_updated_date":"2024-04-10T11:12:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/hr-assistant-cf-04-01-400_en.pdf"},
    {"id":"63088","name":"Role description: Pharmacovigilance officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-04-26T12:17:59Z","last_updated_date":"2024-04-26T12:17:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-pharmacovigilance-officer_en.pdf"},
    {"id":"63438","name":"Role description: Translational sciences officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T15:21:52Z","last_updated_date":"2024-05-31T15:21:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-translational-sciences-officer_en.pdf"},
    {"id":"64209","name":"EMA Charter on Diversity and Inclusion","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T10:39:04Z","last_updated_date":"2024-07-19T10:39:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/ema-charter-diversity-inclusion_en.pdf"},
    {"id":"64551","name":"Role description: Medicines and Medical Devices Shortages Specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-08-12T10:31:39Z","last_updated_date":"2024-08-12T10:31:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-medicines-medical-devices-shortages-specialist_en.pdf"},
    {"id":"64613","name":"Role description: HR Specialist (TAS – Talent Development – RPP – SMS)","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-08-22T13:14:11Z","last_updated_date":"2024-08-22T13:14:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-hr-specialist-tas-talent-development-rpp-sms_en.pdf"},
    {"id":"66116","name":"Role description: Service lead","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2024-12-13T13:55:54Z","last_updated_date":"2024-12-13T13:55:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-service-lead_en.pdf"},
    {"id":"66374","name":"Role description: Project / Programme Officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2025-01-20T14:10:37Z","last_updated_date":"2025-01-20T14:10:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-project-programme-officer_en.pdf"},
    {"id":"66449","name":"Role description: Platform Architect","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2025-01-24T15:28:40Z","last_updated_date":"2025-01-24T15:28:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-platform-architect_en.pdf"},
    {"id":"66656","name":"Role description: Procurement and contract management specialist ","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T16:22:12Z","last_updated_date":"2025-02-10T16:22:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-procurement-contract-management-specialist_en.docx"},
    {"id":"67293","name":"Role description: Senior enterprise architect","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2025-03-14T16:27:03Z","last_updated_date":"2025-03-14T16:27:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-senior-enterprise-architect_en.pdf"},
    {"id":"67294","name":"Role description: Regulatory and digital development specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2025-03-14T16:28:38Z","last_updated_date":"2025-03-14T16:28:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-regulatory-digital-development-specialist_en.pdf"},
    {"id":"67856","name":"Role description: accounting coordinator","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2025-04-15T14:32:49Z","last_updated_date":"2025-04-15T14:32:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-accounting-coordinator_en.pdf"},
    {"id":"68559","name":"Role description: Internal audit officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2025-06-03T15:15:07Z","last_updated_date":"2025-06-03T15:15:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-internal-audit-officer_en.pdf"},
    {"id":"70282","name":"Role description: Legal specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T16:26:29Z","last_updated_date":"2025-09-25T16:26:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-legal-specialist_en.pdf-0"},
    {"id":"70380","name":"Role description: Change management specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2025-09-30T16:56:15Z","last_updated_date":"2025-09-30T16:56:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-change-management-specialist_en.pdf"},
    {"id":"71907","name":"Role description: Financial Officer - Corporate Functions & Administration - FGIV","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2025-12-22T10:32:31Z","last_updated_date":"2025-12-22T10:32:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-financial-officer-corporate-functions-administration-fgiv_en.pdf"},
    {"id":"73017","name":"Role description:  SME officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-03-16T08:23:24Z","last_updated_date":"2026-03-16T08:23:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-sme-officer_en.pdf"},
    {"id":"73291","name":"Role description: Senior translational sciences specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T11:09:05Z","last_updated_date":"2026-04-01T11:09:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-senior-translational-sciences-specialist_en.pdf-0"},
    {"id":"73292","name":"Role description: Translational sciences specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-04-01T11:09:06Z","last_updated_date":"2026-04-01T11:09:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-translational-sciences-specialist_en.pdf"},
    {"id":"73598","name":"Role description: Legal and compliance officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-04-30T17:04:28Z","last_updated_date":"2026-04-30T17:04:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-legal-compliance-officer_en.pdf"},
    {"id":"73646","name":"Role description: Programme officer","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-05-07T15:08:41Z","last_updated_date":"2026-05-07T15:08:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-programme-officer_en.pdf"},
    {"id":"73919","name":"Role description: Project management specialist","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-06-01T11:38:01Z","last_updated_date":"2026-06-01T11:38:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-project-management-specialist_en.pdf"},
    {"id":"73942","name":"Role description: Access to documents assistant","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T10:13:38Z","last_updated_date":"2026-06-03T10:13:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-access-documents-assistant_en.pdf"},
    {"id":"73943","name":"Role description: Administrative assistant","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T10:13:45Z","last_updated_date":"2026-06-03T10:13:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-administrative-assistant_en.pdf"},
    {"id":"73944","name":"Role description: Clinical data publication assistant","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T10:13:46Z","last_updated_date":"2026-06-03T10:13:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-clinical-data-publication-assistant_en.pdf"},
    {"id":"73945","name":"Role description: Liaison assistant","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T10:13:47Z","last_updated_date":"2026-06-03T10:13:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-liaison-assistant_en.pdf"},
    {"id":"73946","name":"Role description: Scientific support assistant","type":"recruitment","status":"unknown","consultation_date":"","first_published_date":"2026-06-03T10:13:52Z","last_updated_date":"2026-06-03T10:13:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/recruitment/role-description-scientific-support-assistant_en.pdf-0"},
    {"id":"2401","name":"Draft guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2007-03-01 - 2007-11-01","first_published_date":"2007-03-22T02:00:00Z","last_updated_date":"2007-03-22T02:00:00Z","reference_number":"EMEA/CHMP/GTWP/125459/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-non-clinical-studies-required-first-clinical-use-gene-therapy-medicinal-products_en.pdf"},
    {"id":"2406","name":"Investigation of chiral active substances","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1993-10-01T01:00:00Z","last_updated_date":"1993-10-01T01:00:00Z","reference_number":"3CC29A","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/investigation-chiral-active-substances_en.pdf"},
    {"id":"2412","name":"Concept paper on quality of combination herbal medicinal\n\nproducts/traditional herbal medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-06-22T02:00:00Z","last_updated_date":"2006-06-22T02:00:00Z","reference_number":"EMEA/HMPC/CHMP/CVMP/58222/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-quality-combination-herbal-medicinal-productstraditional-herbal-medicinal-products_en.pdf"},
    {"id":"2413","name":"Concept paper on need for revision of (CHMP) note for guidance on clinical investigation of medicinal products in the treatment of lipid disorders","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/CHMP/EWP/255210/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-chmp-note-guidance-clinical-investigation-medicinal-products-treatment-lipid-disorders_en.pdf"},
    {"id":"2415","name":"Guideline on the requirements to the chemical and pharmaceuticalquality documentation concerning investigational medicinal products in clinical trials - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-03-31T02:00:00Z","last_updated_date":"2006-03-31T02:00:00Z","reference_number":"CHMP/QWP/185401/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-chemical-and-pharmaceuticalquality-documentation-concerning-investigational-medicinal-products-clinical-trials-first-version_en.pdf"},
    {"id":"2419","name":"Draft guideline on clinical investigation of medicinal products in the treatment of hypertension","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"CPMP/EWP/238/95 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-hypertension_en.pdf"},
    {"id":"2438","name":"Draft guideline on human cell-based medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-01-11T01:00:00Z","last_updated_date":"2007-01-11T01:00:00Z","reference_number":"EMEA/CHMP/410869/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-human-cell-based-medicinal-products_en.pdf"},
    {"id":"2488","name":"CPMP position statement on non-remunerated and remunerated donors: safety and supply of plasma-derived medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-05-30T02:00:00Z","last_updated_date":"2002-05-30T02:00:00Z","reference_number":"EMEA/CPMP/BWP/1818/02/Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cpmp-position-statement-non-remunerated-and-remunerated-donors-safety-and-supply-plasma-derived-medicinal-products_en.pdf"},
    {"id":"2505","name":"Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-08-10T11:53:00Z","last_updated_date":"2010-08-10T11:53:00Z","reference_number":"EMA/CHMP/VWP/141697/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-and-clinical-aspects-live-recombinant-viral-vectored-vaccines_en.pdf"},
    {"id":"2508","name":"Draft guideline on core summary of product characteristics for human albumin solution","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-07-01 - 2012-08-31","first_published_date":"2012-06-29T13:30:00Z","last_updated_date":"2012-06-29T13:30:00Z","reference_number":"EMA/CHMP/BPWP/494462/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-human-albumin-solution_en.pdf"},
    {"id":"2552","name":"Draft guideline on core SmPC and Package Leaflet for gadopentetate dimeglumine","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-01 - 2016-04-30","first_published_date":"2016-02-01T17:46:00Z","last_updated_date":"2016-02-01T17:46:00Z","reference_number":"EMA/CHMP/39163/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-and-package-leaflet-gadopentetate-dimeglumine_en.pdf"},
    {"id":"2580","name":"Guideline on core Summary of Product Characteristics (SmPC) for human plasma derived and recombinant coagulation factor IX products - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-12-22T16:30:00Z","last_updated_date":"2014-12-22T16:30:00Z","reference_number":"EMA/CHMP/BPWP/1625/1999 rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-summary-product-characteristics-smpc-human-plasma-derived-and-recombinant-coagulation-factor-ix-products-revision-2_en.pdf"},
    {"id":"2597","name":"Concept paper on the development of a Committee for Medicinal Products for Human Use (CHMP) guideline on the in-vitro investigation of mitochondrial toxicity of anti-HIV medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T01:00:00Z","last_updated_date":"2008-01-24T01:00:00Z","reference_number":"EMEA/CHMP/SWP/151915/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-medicinal-products-human-use-chmp-guideline-vitro-investigation-mitochondrial-toxicity-anti-hiv-medicinal-products_en.pdf"},
    {"id":"2603","name":"ICH: Q 1 B: Photostability testing of new active substances and medicinal products - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-01-01T01:00:00Z","last_updated_date":"1998-01-01T01:00:00Z","reference_number":"CPMP/ICH/279/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-b-photostability-testing-new-active-substances-and-medicinal-products-step-5_en.pdf"},
    {"id":"2623","name":"Concept paper on predictive biomarker-based assay development in the context of drug development and lifecycle","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-07-28 - 2017-11-15","first_published_date":"2017-07-28T16:30:00Z","last_updated_date":"2017-07-28T16:30:00Z","reference_number":"EMA/CHMP/800914/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-predictive-biomarker-based-assay-development-context-drug-development-and-lifecycle_en.pdf"},
    {"id":"2627","name":"Core SmSPC for Human Normal Immunoglobulin for Intravenous administration (IVIg) (CPMP/BPWG/859/95 rev.2)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-29T02:00:00Z","last_updated_date":"2004-07-29T02:00:00Z","reference_number":"CPMP/BPWG/859/95 rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/core-smspc-human-normal-immunoglobulin-intravenous-administration-ivig-cpmpbpwg85995-rev2_en.pdf"},
    {"id":"2631","name":"Note for guidance on in-use stability testing of human medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-03-01T01:00:00Z","last_updated_date":"2001-03-01T01:00:00Z","reference_number":"CPMP/QWP/2934/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-stability-testing-human-medicinal-products_en.pdf"},
    {"id":"2664","name":"Guideline on good pharmacovigilance practices: Module II – Pharmacovigilance system master file (Rev.1) (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-04-12T02:00:00Z","last_updated_date":"2013-04-12T02:00:00Z","reference_number":"EMA/213497/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file-rev1-superseded_en.pdf"},
    {"id":"2674","name":"Questions and answers on benzyl alcohol used as an excipient in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/508188/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-benzyl-alcohol-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"2739","name":"Draft guideline on declaration of herbal substances and herbal preparations in herbal medicinal products/traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-01-29T01:00:00Z","last_updated_date":"2009-01-29T01:00:00Z","reference_number":"EMEA/HMPC/CHMP/CVMP/287539/2005 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-declaration-herbal-substances-and-herbal-preparations-herbal-medicinal-productstraditional-herbal-medicinal-products_en.pdf"},
    {"id":"2745","name":"Guideline on stability testing for applications for variations to a marketing authorisation - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-05-19T02:00:00Z","last_updated_date":"2005-05-19T02:00:00Z","reference_number":"CPMP/QWP/576/96 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-applications-variations-marketing-authorisation-revision-1_en.pdf"},
    {"id":"2777","name":"Guideline on clinical investigation of medicinal products indicated for the treatment of panic disorder","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-01-20T01:00:00Z","last_updated_date":"2005-01-20T01:00:00Z","reference_number":"CHMP/EWP/4280/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-panic-disorder_en.pdf"},
    {"id":"2796","name":"VICH GL16: Efficacy of anthelmintics - Specific recommendations for porcines - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-07-30T02:00:00Z","last_updated_date":"2001-07-30T02:00:00Z","reference_number":"CVMP/VICH/834/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl16-efficacy-anthelmintics-specific-recommendations-porcines-step-7_en.pdf"},
    {"id":"2812","name":"Guideline on submission of marketing authorisation applications for pandemic influenza vaccines through the centralised procedure - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-04-05T02:00:00Z","last_updated_date":"2004-04-05T02:00:00Z","reference_number":"EMEA/CPMP/VEG/4986/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-submission-marketing-authorisation-applications-pandemic-influenza-vaccines-through-centralised-procedure-superseded_en.pdf"},
    {"id":"2815","name":"Joint Ministry of Health, Labour and Welfare / European Medicines Agency reflection paper on the development of block-copolymer-micelle medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-01-10T12:10:00Z","last_updated_date":"2014-01-10T12:10:00Z","reference_number":"EMA/CHMP/13099/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/joint-ministry-health-labour-and-welfare-european-medicines-agency-reflection-paper-development-block-copolymer-micelle-medicinal-products_en.pdf"},
    {"id":"2852","name":"Clinical Investigation of Hypnotic Medicinal Products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1991-09-01T02:00:00Z","last_updated_date":"1991-09-01T02:00:00Z","reference_number":"3CC27a","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/clinical-investigation-hypnotic-medicinal-products_en.pdf"},
    {"id":"2902","name":"Erlotinib film-coated tablets 25, 100 and 150 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-04-10T02:00:00Z","last_updated_date":"2015-04-10T02:00:00Z","reference_number":"EMA/CHMP/675840/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/erlotinib-film-coated-tablets-25-100-and-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"2910","name":"E 11: Clinical investigation of medicinal products in the paediatric population - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"CPMP/ICH/2711/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/e-11-clinical-investigation-medicinal-products-paediatric-population-step-5_en.pdf"},
    {"id":"2922","name":"Note for guidance on the use of adjuvanted veterinary vaccines - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-11-01T01:00:00Z","last_updated_date":"1996-11-01T01:00:00Z","reference_number":"CVMP/IWP/043/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-adjuvanted-veterinary-vaccines-first-version_en.pdf"},
    {"id":"2945","name":"Draft guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-11-18 - 2011-05-31","first_published_date":"2010-11-26T02:00:00Z","last_updated_date":"2010-11-26T02:00:00Z","reference_number":"EMA/CHMP/BMWP/86289/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-immunogenicity-assessment-monoclonal-antibodies-intended-vivo-clinical-use_en.pdf"},
    {"id":"3048","name":"Reflection paper on the chemical structure and properties criteria to be considered for the evaluation of new active substance (NAS) status of chemical substances","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-01-19T12:40:00Z","last_updated_date":"2016-01-19T12:40:00Z","reference_number":"EMA/CHMP/QWP/104223/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-chemical-structure-and-properties-criteria-be-considered-evaluation-new-active-substance-nas-status-chemical-substances_en.pdf"},
    {"id":"3055","name":"Guideline on dossier requirements for anticancer medicinal products for dogs and cats","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/CVMP/28510/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-dossier-requirements-anticancer-medicinal-products-dogs-and-cats_en.pdf"},
    {"id":"3070","name":"Guideline on influenza vaccines – Quality module","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-06-02T16:00:00Z","last_updated_date":"2014-06-02T16:00:00Z","reference_number":"EMA/CHMP/BWP/310834/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-influenza-vaccines-quality-module_en.pdf"},
    {"id":"3084","name":"Points to consider on clinical investigation of medicinal products other than nsaids for treatment of rheumatoid arthritis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-12-17T01:00:00Z","last_updated_date":"2003-12-17T01:00:00Z","reference_number":"CPMP/EWP/556/95 rev 1/Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-clinical-investigation-medicinal-products-other-nsaids-treatment-rheumatoid-arthritis_en.pdf"},
    {"id":"3089","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline M7 (R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals ...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-27T12:54:00Z","last_updated_date":"2017-07-27T12:54:00Z","reference_number":"EMA/CHMP/ICH/83812/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-guideline-m7-r1-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals_en.pdf"},
    {"id":"3113","name":"Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to variant Creutzfeldt-Jakob disease risk","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-10-21T02:00:00Z","last_updated_date":"2004-10-21T02:00:00Z","reference_number":"CPMP/BWP/CPMP/5136/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-manufacturing-processes-plasma-derived-medicinal-products-regard-variant-creutzfeldt-jakob-disease-risk_en.pdf"},
    {"id":"3117","name":"Concept paper on the revision of the guideline on the development of medicinal products for the treatment of ulcerative colitis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-11-14 - 2013-02-15","first_published_date":"2012-10-31T19:00:00Z","last_updated_date":"2012-11-14T11:59:00Z","reference_number":"EMA/CHMP/204354/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-development-medicinal-products-treatment-ulcerative-colitis_en.pdf"},
    {"id":"3119","name":"Concept paper on the need to revise the note for guidance on requirements for combined vaccines CVMP/IWP/52/97-FINAL","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2004-01-16T01:00:00Z","last_updated_date":"2004-01-16T01:00:00Z","reference_number":"EMEA/CVMP/018/04-CONS.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revise-note-guidance-requirements-combined-vaccines-cvmpiwp5297-final_en.pdf"},
    {"id":"3120","name":"Guideline on the principles for preparing assessment reports for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T10:00:00Z","last_updated_date":"2015-12-18T10:00:00Z","reference_number":"EMA/CVMP/450781/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-principles-preparing-assessment-reports-veterinary-medicinal-products_en.pdf"},
    {"id":"3203","name":"ICH: S 9: Nonclinical evaluation for anticancer pharmaceuticals: Note for guidance on nonclinical evaluation for anticancer pharmaceutical - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-12-31T01:00:00Z","last_updated_date":"2008-12-31T01:00:00Z","reference_number":"EMEA/CHMP/ICH/646107/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-9-nonclinical-evaluation-anticancer-pharmaceuticals-note-guidance-nonclinical-evaluation-anticancer-pharmaceutical-step-3_en.pdf"},
    {"id":"3254","name":"Guideline on the environmental risk assessment of medicinal products for human use - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2015-01-13T10:00:00Z","reference_number":"EMEA/CHMP/SWP/4447/00 Corr 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-environmental-risk-assessment-medicinal-products-human-use-first-version_en.pdf"},
    {"id":"3328","name":"Draft guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-05-24T02:00:00Z","last_updated_date":"2007-05-24T02:00:00Z","reference_number":"CHMP/EWP/18504/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-development-products-specific-immunotherapy-treatment-allergic-diseases_en.pdf"},
    {"id":"3334","name":"Draft guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"CPMP/EWP/784/97 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-used-treatment-osteoarthritis_en.pdf"}    {"id":"3343","name":"Guideline on good pharmacovigilance practices: Module VI – Management and reporting of adverse reactions to medicinal products with tracked changes (Rev 1)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-09-15T13:00:00Z","last_updated_date":"2014-09-15T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-vi-management-reporting-adverse-reactions-medicinal-products-tracked-changes-rev-1_en.pdf"},
    {"id":"3354","name":"Recommendation on the submission of multistrain-dossier applications for vaccines against avian influenza, bluetongue and foot-and-mouth disease","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/43283/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-submission-multistrain-dossier-applications-vaccines-against-avian-influenza-bluetongue-and-foot-and-mouth-disease_en.pdf"},
    {"id":"3355","name":"Tadalafil film-coated tablets 2.5, 5, 10 and 20 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315234/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/tadalafil-film-coated-tablets-25-5-10-and-20-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"3396","name":"Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues - Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-02-22T01:00:00Z","last_updated_date":"2006-02-22T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/31329/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-guidance-similar-medicinal-products-containing_en.pdf"},
    {"id":"3407","name":"Concept paper on the revision of the CHMP points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-06-08 - 2012-08-31","first_published_date":"2012-06-08T14:20:00Z","last_updated_date":"2012-06-08T14:20:00Z","reference_number":"EMA/CHMP/172616/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-chmp-points-consider-evaluation-medicinal-products-treatment-irritable-bowel-syndrome_en.pdf"},
    {"id":"3419","name":"Concept paper on revising annex 16 of the guide to good manufacturing practice: Certification by a qualified person and batch release","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-10-01 - 2012-01-31","first_published_date":"2011-11-08T13:30:00Z","last_updated_date":"2011-11-08T13:30:00Z","reference_number":"EMA/INS/GMP/844118/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revising-annex-16-guide-good-manufacturing-practice-certification-qualified-person-and-batch-release_en.pdf"},
    {"id":"3442","name":"Recommendation on the need for revision of (CHMP) points to consider on the requirements for clinical documentation for Orally Inhaled Products (OIP) (CPMP/EWP/4151/00)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-02-22T01:00:00Z","last_updated_date":"2007-02-22T01:00:00Z","reference_number":"EMEA/CHMP/EWP/44238/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-need-revision-chmp-points-consider-requirements-clinical-documentation-orally-inhaled-products-oip-cpmpewp415100_en.pdf"},
    {"id":"3445","name":"Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-07-30 - 2019-08-01","first_published_date":"2018-07-09T17:22:00Z","last_updated_date":"2018-07-30T17:22:00Z","reference_number":"EMA/CHMP/171100/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-develop-reflection-paper-development-medicinal-products-prevent-and-treat-acute-kidney-injury_en.pdf"},
    {"id":"3450","name":"Draft VICH GL50: Harmonisation of criteria to waive target animal batch safety testing for inactivated vaccines for veterinary use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-26 - 2016-08-01","first_published_date":"2016-02-26T16:30:00Z","last_updated_date":"2016-02-26T16:30:00Z","reference_number":"EMA/CVMP/VICH/582610/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl50-harmonisation-criteria-waive-target-animal-batch-safety-testing-inactivated-vaccines-veterinary-use_en.pdf"},
    {"id":"3477","name":"Reflection paper on anthelmintic resistance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-04-23 - 2014-07-31","first_published_date":"2014-04-23T13:10:00Z","last_updated_date":"2014-04-23T13:10:00Z","reference_number":"EMA/CVMP/EWP/573536/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-anthelmintic-resistance_en.pdf"},
    {"id":"3499","name":"Concept Paper on the Need for Revision of the Guideline on Stability Testing for Applications for Variations to a Marketing Authorisation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-02-18 - 2010-04-30","first_published_date":"2010-03-03T02:00:00Z","last_updated_date":"2010-03-03T02:00:00Z","reference_number":"EMA/63033/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-stability-testing-applications-variations-marketing-authorisation_en.pdf"},
    {"id":"3534","name":"Draft elvitegravir 85 mg & 150 mg film-coated tablets product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-12-22 - 2017-03-31","first_published_date":"2016-12-22T14:00:00Z","last_updated_date":"2016-12-22T14:00:00Z","reference_number":"EMA/CHMP/805507/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-elvitegravir-85-mg-150-mg-film-coated-tablets-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"3538","name":"Draft concept paper on the revision of the guideline on the development of new medicinal products for the treatment of ulcerative colitis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-10-01 - 2014-12-31","first_published_date":"2014-10-01T18:00:00Z","last_updated_date":"2014-10-01T18:00:00Z","reference_number":"EMA/CHMP/327812/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-revision-guideline-development-new-medicinal-products-treatment-ulcerative-colitis_en.pdf"},
    {"id":"3558","name":"Concept paper on the need for revision of the guideline on excipients in the label and package leaflet of medicinal products for human use (CPMP/463/00) - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-03-07 - 2012-05-31","first_published_date":"2012-03-07T18:30:00Z","last_updated_date":"2012-03-07T18:30:00Z","reference_number":"EMA/CHMP/SWP/888239/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use-cpmp-463-00-first-version_en.pdf"},
    {"id":"3572","name":"Position paper on the regulatory requirements for the authorisation of low-dose modified release asa formulations in the secondary prevention of cardiovascular events","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-07-25T02:00:00Z","last_updated_date":"2002-07-25T02:00:00Z","reference_number":"EMEA/CPMP/EWP/282/02/Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-regulatory-requirements-authorisation-low-dose-modified-release-asa-formulations-secondary-prevention-cardiovascular-events_en.pdf"},
    {"id":"3591","name":"Draft guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-05-31 - 2012-11-30","first_published_date":"2012-05-31T21:08:31Z","last_updated_date":"2012-05-31T21:08:31Z","reference_number":"EMA/CHMP/BWP/247713/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality-issues-revision-1_en.pdf"},
    {"id":"3599","name":"Position paper on terminology in pharmacoGenetics","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-11-21T01:00:00Z","last_updated_date":"2002-11-21T01:00:00Z","reference_number":"EMEA/CPMP/3070/01 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-terminology-pharmacogenetics_en.pdf"},
    {"id":"3611","name":"Submission of comments on Guideline on Similar Biological Medicinal Products containing biotechnology derived products as active substance: non-clinical and clinical issues Annex: recombinant\n\nErythropoietin containing p...","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-03-01T01:00:00Z","last_updated_date":"2006-03-01T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/149141/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/submission-comments-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-products-active-substance-non-clinical-and-clinical-issues-annex-recombinant-erythropoietin_en.pdf"},
    {"id":"3640","name":"Compilation of individual product-specific guidance on demonstration of bioequivalence","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-04-10T15:50:00Z","last_updated_date":"2015-04-10T15:50:00Z","reference_number":"EMA/CHMP/736403/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/compilation-individual-product-specific-guidance-demonstration-bioequivalence_en.pdf"},
    {"id":"3654","name":"Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man - Condition specific guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-10-07T16:30:00Z","last_updated_date":"2015-10-07T16:30:00Z","reference_number":"EMA/CHMP/703715/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-4-guideline-evaluation-anticancer-medicinal-products-man-condition-specific-guidance-revision-1_en.pdf"},
    {"id":"3671","name":"Concept paper on Use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-10-13 - 2012-01-31","first_published_date":"2011-10-25T19:00:00Z","last_updated_date":"2011-10-25T19:00:00Z","reference_number":"EMA/CVMP/SAGAM/435644/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-use-pleuromutilins-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"3735","name":"Questions and answers on benzoic acid and benzoates used as excipients in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/508189/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-benzoic-acid-and-benzoates-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"3742","name":"Veterinary medicinal products controlling varroa jacobsoni and acarapis woodi parasitosis in bees","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1991-09-01T02:00:00Z","last_updated_date":"1991-09-01T02:00:00Z","reference_number":"7AE16a Volume 7","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/veterinary-medicinal-products-controlling-varroa-jacobsoni-and-acarapis-woodi-parasitosis-bees_en.pdf"},
    {"id":"3759","name":"Draft guideline on parametric release","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-03-15T01:00:00Z","last_updated_date":"2006-03-15T01:00:00Z","reference_number":"EMEA/CVMP/QWP/339588/2005-Cons.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-parametric-release_en.pdf"},
    {"id":"3800","name":"Draft guideline on the use of bovine serum in the manufacture of human biological medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-10-01 - 2012-12-31","first_published_date":"2012-10-01T15:25:00Z","last_updated_date":"2012-10-01T15:25:00Z","reference_number":"EMA/CHMP/BWP/457920/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-use-bovine-serum-manufacture-human-biological-medicinal-products_en.pdf"},
    {"id":"3819","name":"Guidelines on good pharmacovigilance practices: Annex I - Definitions (Rev 1) (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T11:00:00Z","last_updated_date":"2012-06-25T11:00:00Z","reference_number":"EMA/876333/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidelines-good-pharmacovigilance-practices-annex-i-definitions-rev-1-superseded_en.pdf"},
    {"id":"3826","name":"Draft guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-01-01 - 2017-03-31","first_published_date":"2016-12-22T12:31:00Z","last_updated_date":"2016-12-22T12:31:00Z","reference_number":"EMA/CHMP/BPWP/94033/2007 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-revision-3_en.pdf"},
    {"id":"3872","name":"Guideline on user safety of topically administered veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-05-07T13:45:00Z","last_updated_date":"2018-05-07T13:45:00Z","reference_number":"EMA/CVMP/SWP/721059/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-user-safety-topically-administered-veterinary-medicinal-products_en.pdf"},
    {"id":"3875","name":"Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) Rev. 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-12-06T01:00:00Z","last_updated_date":"2010-12-06T01:00:00Z","reference_number":"EMA/CHMP/BPWP/94038/2007 rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-3_en.pdf"},
    {"id":"3883","name":"Guideline on injection site residues - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-10-01T02:00:00Z","last_updated_date":"2004-10-01T02:00:00Z","reference_number":"EMEA/CVMP/542/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-injection-site-residues-first-version_en.pdf"},
    {"id":"3904","name":"Concept paper on the need for revision of the CHMP note for guidance on the clinical development of medicinal products in the treatment of Asthma (CPMP/EWP/2922/01)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-10-22 - 2010-01-31","first_published_date":"2009-10-29T14:00:00Z","last_updated_date":"2009-10-29T14:00:00Z","reference_number":"EMEA/CHMP/EWP/10797/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-chmp-note-guidance-clinical-development-medicinal-products-treatment-asthma-cpmp-ewp-2922-01_en.pdf"},
    {"id":"3908","name":"Guideline on core SmPC and Package Leaflet for (68Ge/68Ga) generator - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-09-08T02:00:00Z","last_updated_date":"2017-09-08T02:00:00Z","reference_number":"EMA/CHMP/337681/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-and-package-leaflet-68ge68ga-generator-first-version_en.pdf"},
    {"id":"3914","name":"Concept paper on the development of a Guideline on clinical monitoring and follow-up of patients exposed to gene therapy/gene transfer medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-04-26T02:00:00Z","last_updated_date":"2007-04-26T02:00:00Z","reference_number":"EMEA/CHMP/GTWP/367513/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-clinical-monitoring-and-follow-patients-exposed-gene-therapygene-transfer-medicinal-products_en.pdf"},
    {"id":"3921","name":"Annex II to note for guidance on process validation CHMP/QWP/848/99 and EMEA/CVMP/598/99 non standard processes","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-08-10T02:00:00Z","last_updated_date":"2004-08-10T02:00:00Z","reference_number":"CPMP/QWP/2054/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-ii-note-guidance-process-validation-chmpqwp84899-and-emeacvmp59899-non-standard-processes_en.pdf"},
    {"id":"3927","name":"Draft guideline on the clinical development of medicinal products for the treatment of HIV infection (Rev.2)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-18T02:00:00Z","last_updated_date":"2007-10-18T02:00:00Z","reference_number":"EMEA/CPMP/EWP/633/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-development-medicinal-products-treatment-hiv-infection-rev2_en.pdf"},
    {"id":"3944","name":"Draft asenapine sublingual tablets 5 and 10 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-15 - 2015-11-01","first_published_date":"2015-07-15T14:00:00Z","last_updated_date":"2015-07-15T14:00:00Z","reference_number":"EMA/CHMP/PKWP/269533/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-asenapine-sublingual-tablets-5-and-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"3981","name":"Draft reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer) as new active substance in relation to a reference active substance which is a racemic mixture of enantiomers","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-11-18 - 2011-02-28","first_published_date":"2010-11-23T02:00:00Z","last_updated_date":"2010-11-23T02:00:00Z","reference_number":"EMA/651649/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-considerations-given-designation-single-stereo-isomeric-form-enantiomer-new-active-substance-relation-reference-active-substance-which-racemic-mixture-enantiomers_en.pdf"},
    {"id":"3990","name":"Concept paper on the need for the development of a reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-06-01 - 2017-08-31","first_published_date":"2017-06-01T13:30:00Z","last_updated_date":"2017-06-01T13:30:00Z","reference_number":"EMA/CHMP/197320/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-development-reflection-paper-regulatory-requirements-development-medicinal-products-chronic-non-infectious-liver-diseases-pbc-psc-nash_en.pdf"},
    {"id":"3991","name":"Guideline on Core SPC for Human Plasma Derived and Recombinant Coagulation Factor IX Products - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-06-29T02:00:00Z","last_updated_date":"2000-06-29T02:00:00Z","reference_number":"CPMP/BPWG/1625/99 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-plasma-derived-and-recombinant-coagulation-factor-ix-products-first-version_en.pdf"},
    {"id":"3998","name":"S 2 B: Note for guidance on genotoxicity: A standard battery for genotoxicity testing of pharmaceuticals","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-03-01T01:00:00Z","last_updated_date":"1998-03-01T01:00:00Z","reference_number":"CPMP/ICH/174/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/s-2-b-note-guidance-genotoxicity-standard-battery-genotoxicity-testing-pharmaceuticals_en.pdf"},
    {"id":"4003","name":"Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man - Condition-specific guidance - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-01-11T11:00:00Z","last_updated_date":"2013-01-11T11:00:00Z","reference_number":"EMA/CHMP/703715/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-4-guideline-evaluation-anticancer-medicinal-products-man-condition-specific-guidance-first-version_en.pdf"},
    {"id":"4004","name":"Concept paper on the need for revision of the note for guidance on antiarrhythmics (CPMP/EWP/237/95)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/CHMP/EWP/358487/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-antiarrhythmics-cpmpewp23795_en.pdf"},
    {"id":"4042","name":"Concept paper on the revision of the 'Guideline on the assessment of clinical safety and efficacy in the preparation of Community herbal monographs for well- established and of Community herbal  monographs/entries to the...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-10-16 - 2016-01-31","first_published_date":"2015-10-16T14:00:00Z","last_updated_date":"2015-10-16T14:00:00Z","reference_number":"EMA/HMPC/427510/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-assessment-clinical-safety-and-efficacy-preparation-community-herbal-monographs-well-established-and-community-herbal-monographs-entries_en.pdf"},
    {"id":"4047","name":"VICH GL17: Stability testing of biotechnological/biological veterinary medicinal products - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-06-01T02:00:00Z","last_updated_date":"2000-06-01T02:00:00Z","reference_number":"CVMP/VICH/501/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl17-stability-testing-biotechnologicalbiological-veterinary-medicinal-products-step-7_en.pdf"},
    {"id":"4054","name":"Concept paper on the need for revision of the note for guidance on clinical investigation of medicinal products for the treatment and prevention of bipolar disorder","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-28 - 2016-10-31","first_published_date":"2016-07-28T21:10:00Z","last_updated_date":"2016-07-28T21:10:00Z","reference_number":"EMA/CHMP/318360/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-clinical-investigation-medicinal-products-treatment-and-prevention-bipolar-disorder_en.pdf"},
    {"id":"4084","name":"Concept paper on the revision of the note for guidance on allergen products (CPMP/BWP/243/96) - Production and quality issues (Replaced by CHMP/BWP/304831/07)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-07-20T02:00:00Z","last_updated_date":"2005-07-20T02:00:00Z","reference_number":"CHMP/BWP/229472/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-allergen-products-cpmpbwp24396-production-and-quality-issues-replaced-chmpbwp30483107_en.pdf"},
    {"id":"4108","name":"Guideline on medicinal gases: Pharmaceutical documentation (including recommendation on non-clinical safety requirements for well established medicinal gases) - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-09T02:00:00Z","last_updated_date":"2008-07-09T02:00:00Z","reference_number":"CPMP/QWP/1719/00 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-medicinal-gases-pharmaceutical-documentation-including-recommendation-non-clinical-safety-requirements-well-established-medicinal-gases-revision-1_en.pdf"},
    {"id":"4126","name":"Draft CHMP guideline on clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/CHMP/EWP/356954/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-chmp-guideline-clinical-investigations-medicinal-products-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"4143","name":"Draft questions and answers on sodium laurilsulfate in the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-08-04 - 2015-11-03","first_published_date":"2015-08-04T12:30:00Z","last_updated_date":"2015-08-04T12:30:00Z","reference_number":"EMA/CHMP/606830/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-and-answers-sodium-laurilsulfate-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"4150","name":"Guideline on the clinical assessment of fixed combinations of herbal substances / herbal preparations","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-01-11T01:00:00Z","last_updated_date":"2006-01-11T01:00:00Z","reference_number":"EMEA/HMPC/166326/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-assessment-fixed-combinations-herbal-substances-herbal-preparations_en.pdf"},
    {"id":"4154","name":"Draft voriconazole product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/422408/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-voriconazole-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"4173","name":"Guideline on the development of new medicinal products for the treatment of ulcerative colitis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-01-24T01:00:00Z","last_updated_date":"2008-01-24T01:00:00Z","reference_number":"CHMP/EWP/18463/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-new-medicinal-products-treatment-ulcerative-colitis_en.pdf"},
    {"id":"4178","name":"Guideline on good pharmacovigilance practices (GVP): Module XVI Addendum I – Educational materials with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-12-15T12:30:00Z","last_updated_date":"2015-12-15T12:30:00Z","reference_number":"EMA/61341/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-i-educational-materials-tracked-changes_en.pdf"},
    {"id":"4188","name":"Draft reflection paper on microbiological aspects of herbal medicinal products and traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-02-19 - 2014-06-15","first_published_date":"2014-02-19T13:35:00Z","last_updated_date":"2014-02-19T13:35:00Z","reference_number":"EMA/HMPC/95714/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-microbiological-aspects-herbal-medicinal-products-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"4223","name":"Vemurafenib film-coated tablets 240 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-03T01:00:00Z","last_updated_date":"2017-03-03T01:00:00Z","reference_number":"EMA/CHMP/476248/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vemurafenib-film-coated-tablets-240-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"4244","name":"Revised note for guidance on limitations to the use of ethylene oxide in the manufacture of medicinal products - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-03-10T15:00:00Z","last_updated_date":"2016-03-10T15:00:00Z","reference_number":"EMEA/CVMP/271/01 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/revised-note-guidance-limitations-use-ethylene-oxide-manufacture-medicinal-products-superseded_en.pdf"},
    {"id":"4247","name":"Draft emtricitabine/rilpivirine/tenofovir disoproxil, film-coated tablets, 200 mg/25 mg/245 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-12-22 - 2017-03-31","first_published_date":"2016-12-22T14:00:00Z","last_updated_date":"2016-12-22T14:00:00Z","reference_number":"EMA/CHMP/805532/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-emtricitabine-rilpivirine-tenofovir-disoproxil-film-coated-tablets-200-mg-25-mg-245-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"4274","name":"Guideline on non-clinical local tolerance testing of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-11-27T15:15:00Z","last_updated_date":"2015-11-27T15:15:00Z","reference_number":"EMA/CHMP/SWP/2145/2000 Rev. 1 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-local-tolerance-testing-medicinal-products_en.pdf"},
    {"id":"4289","name":"Draft guideline on Guideline on core summary of product characteristics (SmPC) and package leaflet for iopamidol 300","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-04-26 - 2017-08-31","first_published_date":"2017-04-26T19:30:00Z","last_updated_date":"2017-04-26T19:30:00Z","reference_number":"EMA/CHMP/813269/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-guideline-core-summary-product-characteristics-smpc-and-package-leaflet-iopamidol-300_en.pdf"},
    {"id":"4323","name":"Concept paper on the revision of the note for guidance on quality of modified release oral dosage forms and transdermal dosage forms: Section I (quality) - Superseded","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-06-24 - 2010-10-31","first_published_date":"2010-07-30T04:00:00Z","last_updated_date":"2010-07-30T04:00:00Z","reference_number":"EMA/CHMP/QWP/202350/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-quality-modified-release-oral-dosage-forms-and-transdermal-dosage-forms-section-i-quality-superseded_en.pdf"},
    {"id":"4348","name":"Draft rilpivirine film-coated tablets 25 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-07-28 - 2017-10-31","first_published_date":"2017-07-28T14:30:00Z","last_updated_date":"2017-07-28T14:30:00Z","reference_number":"EMA/CHMP/356878/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-rilpivirine-film-coated-tablets-25-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"4355","name":"VICH GL23: Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing - Revision at step 9, for implementation at step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-11-19T12:50:00Z","last_updated_date":"2014-11-19T12:50:00Z","reference_number":"EMA/CVMP/VICH/526/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl23-studies-evaluate-safety-residues-veterinary-drugs-human-food-genotoxicity-testing-revision-step-9-implementation-step-7_en.pdf"},
    {"id":"4399","name":"Questions & answers on the withdrawal of the “Note for guidance on single dose toxicity”","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-07-19T02:00:00Z","last_updated_date":"2010-07-19T02:00:00Z","reference_number":"EMA/CHMP/SWP/81714/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-withdrawal-note-guidance-single-dose-toxicity_en.pdf"},
    {"id":"4449","name":"Concept paper on the need to revise the guideline on the use of transgenic animals in the manufacture of biological medicinal products for human use (3ab7a of July 1995)","type":"scientific-guideline","status":"unknown","consultation_date":"2009-06-25 - 2009-09-30","first_published_date":"2009-05-20T04:00:00Z","last_updated_date":"2009-05-20T04:00:00Z","reference_number":"EMEA/CHMP/BWP/134153/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revise-guideline-use-transgenic-animals-manufacture-biological-medicinal-products-human-use-3ab7a-july-1995_en.pdf"},
    {"id":"4471","name":"Guideline on data to be provided in support of a request to include a substance in the list of substances considered as not falling within the scope of Regulation (EC) No 470/2009","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/CVMP/516817/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-be-provided-support-request-include-substance-list-substances-considered-not-falling-within-scope-regulation-ec-no-4702009_en.pdf"},
    {"id":"4473","name":"Guidelines for the conduct of pharmacokinetic studies in target animal species","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-03-08T01:00:00Z","last_updated_date":"2000-03-08T01:00:00Z","reference_number":"EMEA/CVMP/133/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidelines-conduct-pharmacokinetic-studies-target-animal-species_en.pdf"},
    {"id":"4520","name":"Specifications and control tests on the finished product","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1991-12-01T01:00:00Z","last_updated_date":"1991-12-01T01:00:00Z","reference_number":"3AQ11A","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/specifications-and-control-tests-finished-product_en.pdf"},
    {"id":"4564","name":"ICH: M 4: Common technical document for the registration of pharmaceuticals for human use - Questions and answers - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"CPMP/ICH/5552/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-4-common-technical-document-registration-pharmaceuticals-human-use-questions-and-answers-step-5_en.pdf"},
    {"id":"4592","name":"Guideline on requirements for the production and control of immunological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-21T11:45:00Z","last_updated_date":"2012-06-21T11:45:00Z","reference_number":"EMA/CVMP/IWP/206555/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-production-and-control-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"4593","name":"Note for guidance on the inclusion of appendices to clinical study reports in marketing authorisation applications","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-23T02:00:00Z","last_updated_date":"2004-06-23T02:00:00Z","reference_number":"CHMP/EWP/2998/03 Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-inclusion-appendices-clinical-study-reports-marketing-authorisation-applications_en.pdf"},
    {"id":"4627","name":"Draft guideline on core summary of product characteristics for plasma-derived fibrin sealant / haemostatic products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-01-01 - 2014-03-31","first_published_date":"2011-09-27T16:17:00Z","last_updated_date":"2013-12-19T15:30:00Z","reference_number":"EMA/CHMP/BPWP/598816/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-plasma-derived-fibrin-sealant-haemostatic-products_en.pdf"},
    {"id":"4724","name":"Reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in food-producing animals in the European Union: development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Draft","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/CVMP/SAGAM/741087/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-macrolides-lincosamides-and-streptogramins-mls-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"4765","name":"Questions and answers on monoclonal antibodies for veterinary use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-12-11T15:00:00Z","last_updated_date":"2017-12-11T15:00:00Z","reference_number":"EMA/CVMP/ADVENT/307606/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-monoclonal-antibodies-veterinary-use_en.pdf"},
    {"id":"4769","name":"ICH M7(R1) Addendum on application of the principles of the ICH M7 guideline to calculation of compound-specific acceptable intakes - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-08-04 - 2016-02-03","first_published_date":"2015-08-04T15:00:00Z","last_updated_date":"2015-08-04T15:00:00Z","reference_number":"EMA/CHMP/ICH/458894/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m7r1-addendum-application-principles-ich-m7-guideline-calculation-compound-specific-acceptable-intakes-step-2b_en.pdf"},
    {"id":"4822","name":"Guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-03-26T17:00:00Z","last_updated_date":"2015-03-26T17:00:00Z","reference_number":"EMA/CHMP/BPWP/143744/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-normal-immunoglobulin-subcutaneous-intramuscular-administration_en.pdf"},
    {"id":"4936","name":"Guideline on development, production, characterisation and specifications for monoclonal antibodies and related products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/CHMP/BWP/157653/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-production-characterisation-and-specifications-monoclonal-antibodies-and-related-products_en.pdf"},
    {"id":"4972","name":"Concept paper on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use.","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-03-19T01:00:00Z","last_updated_date":"2009-03-19T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/114720/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-immunogenicity-assessment-monoclonal-antibodies-intended-vivo-clinical-use_en.pdf"},
    {"id":"4981","name":"ICH: Q 4 B Annex 12: Analytical sieving general chapter: Annex 12 to note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on analytical sieving general chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-11-01 - 2010-02-28","first_published_date":"2009-12-18T02:00:00Z","last_updated_date":"2009-12-18T02:00:00Z","reference_number":"EMEA/CHMP/ICH/730808/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-12-analytical-sieving-general-chapter-annex-12-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-analytical-sieving-general-chapter-step-3_en.pdf"},
    {"id":"4983","name":"ICH: Q 7: Good manufacturing practice for active pharmaceutical ingredients - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-11-01T01:00:00Z","last_updated_date":"2000-11-01T01:00:00Z","reference_number":"CPMP/ICH/4106/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-7-good-manufacturing-practice-active-pharmaceutical-ingredients-step-5_en.pdf"},
    {"id":"5046","name":"Concept paper on the need for revision of the position on the replacement of animal studies by in vitro models","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-03-17 - 2011-06-30","first_published_date":"2011-04-11T04:00:00Z","last_updated_date":"2011-04-11T04:00:00Z","reference_number":"EMA/CHMP/SWP/169839/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-position-replacement-animal-studies-vitro-models_en.pdf"},
    {"id":"5051","name":"Sunitinib hard capsules 12.5, 25, 37.5 and 50 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315233/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/sunitinib-hard-capsules-125-25-375-and-50-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"5062","name":"Draft addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections to address paediatric-specific clinical data requirements - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-04-06 - 2018-10-30","first_published_date":"2018-04-06T17:00:00Z","last_updated_date":"2018-04-06T17:00:00Z","reference_number":"EMA/CHMP/187859/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-address-paediatric-specific-clinical-data-requirements-first-version_en.pdf"},
    {"id":"5068","name":"Draft guideline on quality aspects included in the product information for vaccines for human use - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-02-01 - 2018-07-31","first_published_date":"2018-02-01T12:01:00Z","last_updated_date":"2018-02-01T12:01:00Z","reference_number":"EMA/CHMP/BWP/133540/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-aspects-included-product-information-vaccines-human-use-revision-1_en.pdf"},
    {"id":"5069","name":"Draft concept paper on the need for revision of the addendum on acute cardiac failure of the note for guidance on clinical investigation of medicinal products for the treatment of cardiac failure (CPMP/EWP/2986/03)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-05-20 - 2010-08-31","first_published_date":"2010-06-04T04:00:00Z","last_updated_date":"2010-06-04T04:00:00Z","reference_number":"EMA/CHMP/EWP/215701/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-need-revision-addendum-acute-cardiac-failure-note-guidance-clinical-investigation-medicinal-products-treatment-cardiac-failure-cpmp-ewp-2986-03_en.pdf"},
    {"id":"5088","name":"Concept paper on the revision of the guideline on statistical principles for veterinary clinical trials (EMEA/CVMP/816/00)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-06-22T02:00:00Z","last_updated_date":"2009-06-22T02:00:00Z","reference_number":"EMEA/CVMP/EWP/37388/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-statistical-principles-veterinary-clinical-trials-emeacvmp81600_en.pdf"},
    {"id":"5112","name":"Concept paper on the revision of the guideline for demonstration efficacy of veterinary medicinal product controlling varroa destructor and acarapis woodi parasitosis in honey bees (III/9283/90)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-09-18T02:00:00Z","last_updated_date":"2007-09-18T02:00:00Z","reference_number":"EMEA/CVMP/EWP/36275/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-demonstration-efficacy-veterinary-medicinal-product-controlling-varroa-destructor-and-acarapis-woodi-parasitosis-honey-bees-iii928390_en.pdf"},
    {"id":"5118","name":"Guideline on declaration of herbal substances and herbal preparations  in herbal medicinal products/traditional herbal medicinal products in the SPC","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-07-26T02:00:00Z","last_updated_date":"2010-04-28T02:00:00Z","reference_number":"EMEA/HMPC/CHMP/CVMP/287539/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-declaration-herbal-substances-and-herbal-preparations-herbal-medicinal-productstraditional-herbal-medicinal-products-spc_en.pdf"},
    {"id":"5120","name":"Draft guideline on requirements for the production and control of immunological veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-03-30 - 2011-09-30","first_published_date":"2011-03-30T04:00:00Z","last_updated_date":"2011-03-30T04:00:00Z","reference_number":"EMA/CVMP/IWP/206555/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-production-and-control-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"5124","name":"Appendix 1 - Draft guideline on the requirements for clinical documentation for Orally Inhaled Products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatme...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-03-19T01:00:00Z","last_updated_date":"2008-03-19T01:00:00Z","reference_number":"EMEA/CHMP/EWP/48501/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-1-draft-guideline-requirements-clinical-documentation-orally-inhaled-products-oip-including-requirements-demonstration-therapeutic-equivalence-between-two-inhaled-products-use-treatme_en.pdf"},
    {"id":"5153","name":"Note for guidance: Duration of protection achieved by veterinary vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-10-01T02:00:00Z","last_updated_date":"2000-10-01T02:00:00Z","reference_number":"EMEA/CVMP/682/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-duration-protection-achieved-veterinary-vaccines_en.pdf"},
    {"id":"5166","name":"Draft vortioxetine hydrobromide, 5 mg, 10 mg, 15 mg and 20 mg immediate release tablets, vortioxetine lactate, oral drops solution 20 mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-12-22 - 2017-03-31","first_published_date":"2016-12-22T14:00:00Z","last_updated_date":"2016-12-22T14:00:00Z","reference_number":"EMA/CHMP/474974/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vortioxetine-hydrobromide-5-mg-10-mg-15-mg-and-20-mg-immediate-release-tablets-vortioxetine-lactate-oral-drops-solution-20-mg-ml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"5182","name":"Guideline on development and manufacture of Lentiviral Vectors","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-05-26T02:00:00Z","last_updated_date":"2005-05-26T02:00:00Z","reference_number":"CHMP/BWP/2458/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-and-manufacture-lentiviral-vectors_en.pdf"},
    {"id":"5208","name":"Agomelatine tablet 25 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-08-03T17:00:00Z","last_updated_date":"2018-08-03T17:00:00Z","reference_number":"EMA/CHMP/800802/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/agomelatine-tablet-25-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"5235","name":"Draft guideline on Core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (CPMP/BPWG/859/95 rev. 3)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-02-06T01:00:00Z","last_updated_date":"2009-02-06T01:00:00Z","reference_number":"CPMP/BPWG/859/95 Rev. 3 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-cpmpbpwg85995-rev-3_en.pdf"},
    {"id":"5252","name":"Final VICH GL53: Electronic exchange of documents: electronic file format","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-03-20T16:00:00Z","last_updated_date":"2015-10-01T11:00:00Z","reference_number":"EMA/CVMP/VICH/758781/2013 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/final-vich-gl53-electronic-exchange-documents-electronic-file-format_en.pdf"},
    {"id":"5281","name":"Guideline on control of impurities of pharmacopoeial substances:\n\ncompliance with the european pharmacopoeia general\n\nmonograph \"substances for pharmaceutical use\" and\n\ngeneral chapter \"control of impurities in substance...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-04-22T02:00:00Z","last_updated_date":"2004-04-22T02:00:00Z","reference_number":"CPMP/QWP/1529/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-control-impurities-pharmacopoeial-substances-compliance-european-pharmacopoeia-general-monograph-substances-pharmaceutical-use-and-general-chapter-control-impurities-substance_en.pdf"},
    {"id":"5323","name":"Note for guidance on the establishment of maximum residue limits for minor animal species","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-11-01T01:00:00Z","last_updated_date":"1997-11-01T01:00:00Z","reference_number":"EMEA/CVMP/153a/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-establishment-maximum-residue-limits-minor-animal-species_en.pdf"},
    {"id":"5391","name":"VICH GL27: Guidance on the pre-approval information for registration of new veterinary medicinal products for food producing animals with respect to antimicrobial resistance - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-01-14T01:00:00Z","last_updated_date":"2004-01-14T01:00:00Z","reference_number":"CVMP/VICH/644/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl27-guidance-pre-approval-information-registration-new-veterinary-medicinal-products-food-producing-animals-respect-antimicrobial-resistance-step-7_en.pdf"},
    {"id":"5397","name":"Guideline on similar biological medicinal products containing Biotechnology-derived proteins as active substance: Quality issues","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-02-22T01:00:00Z","last_updated_date":"2006-02-22T01:00:00Z","reference_number":"EMEA/CHMP/BWP/49348/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality-issues_en.pdf"},
    {"id":"5413","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use topic E 2 C (R2): Questions and answers - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-05-28T17:40:00Z","last_updated_date":"2014-05-28T17:40:00Z","reference_number":"EMA/CHMP/ICH/271908/201","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-topic-e-2-c-r2-questions-and-answers-step-5_en.pdf"}    {"id":"5439","name":"Table of extraneous agents to be tested for in relation to the guideline on requirements for the production and control of immunological veterinary medicinal products","type":"scientific-guideline","status":"Draft","consultation_date":"2012-11-15 - 2013-05-31","first_published_date":"2012-11-19T12:30:00Z","last_updated_date":"2012-11-19T12:30:00Z","reference_number":"EMA/CVMP/IWP/105112/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/table-extraneous-agents-be-tested-relation-guideline-requirements-production-and-control-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"5444","name":"VICH GL23: Safety studies for veterinary drug residues in human food: Genotoxicity studies - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-16T02:00:00Z","last_updated_date":"2004-06-16T02:00:00Z","reference_number":"CVMP/VICH/526/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl23-safety-studies-veterinary-drug-residues-human-food-genotoxicity-studies-step-7_en.pdf"},
    {"id":"5456","name":"Draft CHMP/CAT position statement on Creutzfeldt-Jakob disease and advanced therapy medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-06-24 - 2010-09-30","first_published_date":"2010-07-27T04:00:00Z","last_updated_date":"2010-07-27T04:00:00Z","reference_number":"EMA/CHMP/CAT/BWP/353632/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-chmp-cat-position-statement-creutzfeldt-jakob-disease-and-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"5465","name":"VICH GL50: Harmonisation of criteria to waive target animal batch safety testing for inactivated vaccines for veterinary use - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-03-13T16:30:00Z","last_updated_date":"2013-03-13T16:30:00Z","reference_number":"EMA/CVMP/VICH/582610/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl50-harmonisation-criteria-waive-target-animal-batch-safety-testing-inactivated-vaccines-veterinary-use-first-version_en.pdf"},
    {"id":"5507","name":"VICH GL21: Efficacy of anthelmintics - Specific recommendations for poultry - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-07-30T02:00:00Z","last_updated_date":"2001-07-30T02:00:00Z","reference_number":"CVMP/VICH/546/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl21-efficacy-anthelmintics-specific-recommendations-poultry-step-7_en.pdf"},
    {"id":"5515","name":"Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T16:00:00Z","last_updated_date":"2011-11-29T16:00:00Z","reference_number":"EMA/CVMP/IWP/314550/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-design-studies-evaluate-safety-and-efficacy-fish-vaccines_en.pdf"},
    {"id":"5534","name":"Annex to guideline on similar biological medicinal products containing Biotechnology-derived proteins as active substance: Non-clinical and clinical issues \n\nGuidance on similar medicinal products containing recombinant ...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-02-22T01:00:00Z","last_updated_date":"2006-02-22T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/32775/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-guidance-similar-medicinal-products-containing_en.pdf-0"},
    {"id":"5549","name":"Draft guideline on the evaluation of medicinal products for the treatment of chronic constipation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-03-01 - 2014-08-31","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"EMA/CHMP/336243/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-treatment-chronic-constipation_en.pdf"},
    {"id":"5555","name":"Guideline on quality of oral modified-release products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-07-31T17:00:00Z","last_updated_date":"2014-07-31T17:00:00Z","reference_number":"EMA/CHMP/QWP/428693/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-oral-modified-release-products_en.pdf"},
    {"id":"5574","name":"Draft VICH GL50: Testing harmonisation of criteria to waive target animal batch safety testing for inactivated vaccines for veterinary use - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-12-08 - 2012-06-12","first_published_date":"2011-12-20T16:15:00Z","last_updated_date":"2011-12-20T16:15:00Z","reference_number":"EMA/CVMP/VICH/582610/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl50-testing-harmonisation-criteria-waive-target-animal-batch-safety-testing-inactivated-vaccines-veterinary-use-first-version_en.pdf"},
    {"id":"5575","name":"Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular (CPMP/BPWG/283/00)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-07-25T02:00:00Z","last_updated_date":"2002-07-25T02:00:00Z","reference_number":"EMEA/CPMP/BPWG/283/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-human-normal-immunoglobulin-subcutaneous-and-intramuscular-cpmpbpwg28300_en.pdf"},
    {"id":"5598","name":"Concept paper on the need for revision of note for guidance on clinical investigation of medicinal products in the treatment of depression with regard to treatment resistant depression - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-09-24 - 2009-12-31","first_published_date":"2000-10-09T04:00:00Z","last_updated_date":"2000-10-09T04:00:00Z","reference_number":"EMEA/CHMP/EWP/484366/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-clinical-investigation-medicinal-products-treatment-depression-regard-treatment-resistant-depression-revision-2_en.pdf"},
    {"id":"5604","name":"VICH GL31: Safety studies for veterinary drug residues in human food: Repeat-dose (90) toxicity testing - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-16T02:00:00Z","last_updated_date":"2004-06-16T02:00:00Z","reference_number":"CVMP/VICH/484/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl31-safety-studies-veterinary-drug-residues-human-food-repeat-dose-90-toxicity-testing-step-7_en.pdf"},
    {"id":"5639","name":"Guideline on adjuvants in vaccines for human use (see also explanatory note)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-01-20T01:00:00Z","last_updated_date":"2023-02-16T17:25:00Z","reference_number":"EMEA/CHMP/VEG/134716/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-adjuvants-vaccines-human-use-see-also-explanatory-note_en.pdf"},
    {"id":"5641","name":"Concept paper for a guideline on data requirements regarding veterinary medicinal products for the prevention of transmission of canine and feline vector-borne diseases","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-11-18 - 2015-02-28","first_published_date":"2014-11-18T19:11:00Z","last_updated_date":"2014-11-18T19:11:00Z","reference_number":"EMA/CVMP/EWP/309734/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-data-requirements-regarding-veterinary-medicinal-products-prevention-transmission-canine-and-feline-vector-borne-diseases_en.pdf"},
    {"id":"5650","name":"Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-07-23T02:00:00Z","last_updated_date":"2010-02-01T01:00:00Z","reference_number":"CPMP/EWP/784/97 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-used-treatment-osteoarthritis_en.pdf"},
    {"id":"5668","name":"Points to consider on adjustment for baseline covariates","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-05-22T02:00:00Z","last_updated_date":"2003-05-22T02:00:00Z","reference_number":"CPMP/EWP/2863/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-adjustment-baseline-covariates_en.pdf"},
    {"id":"5680","name":"Concept paper on the revision of the note for guidance on plasma-derived medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-12-06T01:00:00Z","last_updated_date":"2006-12-06T01:00:00Z","reference_number":"EMEA/CHMP/BWP/495530/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-plasma-derived-medicinal-products_en.pdf"},
    {"id":"5682","name":"Scientific guidance on post-authorisation efficacy studies - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-12-22T12:00:00Z","last_updated_date":"2016-12-22T12:00:00Z","reference_number":"EMA/PDCO/CAT/CMDh/PRAC/CHMP/261500/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/scientific-guidance-post-authorisation-efficacy-studies-first-version_en.pdf"},
    {"id":"5707","name":"Information for the package leaflet for fragrances containing allergens used as excipients in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/273718/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/information-package-leaflet-fragrances-containing-allergens-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"5735","name":"Draft guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-02-18 - 2010-08-31","first_published_date":"2010-03-11T02:00:00Z","last_updated_date":"2010-03-11T02:00:00Z","reference_number":"EMA/CHMP/BWP/534898/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials-first-version_en.pdf"},
    {"id":"5737","name":"Points to consider on the clinical requirements of modified release products submitted as a line extension of an existing marketing authorisation - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-12-17T01:00:00Z","last_updated_date":"2003-12-17T01:00:00Z","reference_number":"CPMP/EWP/1875/03/Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-clinical-requirements-modified-release-products-submitted-line-extension-existing-marketing-authorisation-superseded_en.pdf"},
    {"id":"5755","name":"Concept paper on guideline on comparability of Biotechnology derived medicinal products after a change in the manufacturing process. Non-clinical and clinical issues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-02-22T01:00:00Z","last_updated_date":"2006-02-22T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/9437/2006/corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-comparability-biotechnology-derived-medicinal-products-after-change-manufacturing-process-non-clinical-clinical-issues_en.pdf"},
    {"id":"5779","name":"ICH: M 5 EWG: Units and measurements controlled vocabulary - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-05-01T02:00:00Z","last_updated_date":"2005-05-01T02:00:00Z","reference_number":"CHMP/ICH/175818/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-5-ewg-units-and-measurements-controlled-vocabulary-step-5_en.pdf"},
    {"id":"5790","name":"CVMP guideline on pharmacovigilance of veterinary medicinal products - Guidance on procedures for marketing authorisation holders","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-07-15T02:00:00Z","last_updated_date":"2007-07-15T02:00:00Z","reference_number":"EMEA/CVMP/183/96 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cvmp-guideline-pharmacovigilance-veterinary-medicinal-products-guidance-procedures-marketing-authorisation-holders_en.pdf"},
    {"id":"5802","name":"ICH: E 2 F: Development safety update report - Step 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-06-01T02:00:00Z","last_updated_date":"2010-10-18T02:00:00Z","reference_number":"EMA/CHMP/ICH/309348/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-2-f-development-safety-update-report-step-3_en.pdf"},
    {"id":"5810","name":"Draft concept paper on extrapolation of efficacy and safety in medicine development","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-06-29 - 2012-09-30","first_published_date":"2012-06-29T14:40:00Z","last_updated_date":"2012-06-29T14:40:00Z","reference_number":"EMA/129698/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-extrapolation-efficacy-and-safety-medicine-development_en.pdf"},
    {"id":"5815","name":"VICH GL24: Guideline on pharmacovigilance of veterinary medicinal products -Management of adverse event reports (AERS)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-03-17T01:00:00Z","last_updated_date":"2013-12-16T19:00:00Z","reference_number":"EMA/CVMP/VICH/547/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl24-guideline-pharmacovigilance-veterinary-medicinal-products-management-adverse-event-reports-aers_en.pdf"},
    {"id":"5825","name":"Concept paper on the revision of the 'Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products' - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-21 - 2016-09-30","first_published_date":"2016-07-21T16:00:00Z","last_updated_date":"2016-07-21T16:00:00Z","reference_number":"EMA/CHMP/446302/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-strategies-identify-and-mitigate-risks-first-human-clinical-trials-investigational-medicinal-products-revision-1_en.pdf"},
    {"id":"5827","name":"Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process. Non-clinical and clinical issues","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/CHMP/BMWP/101695/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-comparability-biotechnology-derived-medicinal-products-after-change-manufacturing-process-non-clinical-and-clinical-issues_en.pdf"},
    {"id":"5832","name":"Concept paper on the revision of the guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells - Superseeding document","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-07-24 - 2017-10-31","first_published_date":"2017-07-24T20:00:00Z","last_updated_date":"2017-07-24T20:00:00Z","reference_number":"EMA/CAT/424191/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-quality-non-clinical-and-clinical-aspects-medicinal-products-containing-genetically-modified-cells-superseeding-document_en.pdf"},
    {"id":"5836","name":"VICH Topic GL49: at step 4: Guidelines for the validation of analytical methods used in residue depletion studies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-12-10 - 2010-05-20","first_published_date":"2009-12-22T02:00:00Z","last_updated_date":"2010-05-10T04:00:00Z","reference_number":"EMEA/CVMP/VICH/463202/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-topic-gl49-step-4-guidelines-validation-analytical-methods-used-residue-depletion-studies_en.pdf"},
    {"id":"5912","name":"Guideline on specifications test procedures and acceptance criteria for herbal substances herbal preparations and herbal medicinal products traditional herbal medicinal products - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-09-28T12:55:00Z","last_updated_date":"2011-09-28T12:55:00Z","reference_number":"EMA/HMPC/162241/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-specifications-test-procedures-and-acceptance-criteria-herbal-substances-herbal-preparations-and-herbal-medicinal-products-traditional-herbal-medicinal-products-revision-2_en.pdf"},
    {"id":"5928","name":"Position paper on viral safety of Oral Poliovirus Vaccine (OPV)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-05-28T02:00:00Z","last_updated_date":"1998-05-28T02:00:00Z","reference_number":"CPMP/BWP/972/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-viral-safety-oral-poliovirus-vaccine-opv_en.pdf"},
    {"id":"5934","name":"CPMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-02-20T01:00:00Z","last_updated_date":"2003-02-20T01:00:00Z","reference_number":"EMEA/CPMP/BWP/2879/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cpmp-position-statement-creutzfeldt-jakob-disease-and-plasma-derived-and-urine-derived-medicinal-products-first-version_en.pdf"},
    {"id":"5941","name":"ICH guideline E16: Genomic biomarkers related to drug response: context, structure and format of qualification submissions - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2013-02-11T01:00:00Z","reference_number":"EMA/CHMP/ICH/380636/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e16-genomic-biomarkers-related-drug-response-context-structure-and-format-qualification-submissions-step-5_en.pdf"},
    {"id":"5974","name":"Reflection paper on viral safety of plasma-derived medicinal products with respect to Hepatitis E virus","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T12:10:00Z","last_updated_date":"2016-06-27T12:10:00Z","reference_number":"EMA/CHMP/BWP/723009/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-viral-safety-plasma-derived-medicinal-products-respect-hepatitis-e-virus_en.pdf"},
    {"id":"6002","name":"Guideline on repeated dose toxicity - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-03-29T02:00:00Z","last_updated_date":"2010-11-05T01:00:00Z","reference_number":"CPMP/SWP/1042/99 Rev 1 Correction","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-repeated-dose-toxicity-revision-1_en.pdf"},
    {"id":"6016","name":"CPMP position statement on new variant CJD and plasma-derived medicinal products - Superseded by CPMP/BWP/2879/02","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"1998-02-25T01:00:00Z","last_updated_date":"1998-02-25T01:00:00Z","reference_number":"CPMP/201/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cpmp-position-statement-new-variant-cjd-and-plasma-derived-medicinal-products-superseded-cpmpbwp287902_en.pdf"},
    {"id":"6019","name":"Draft guideline on clinical evaluation of vaccines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-04-26 - 2018-10-30","first_published_date":"2018-04-26T21:00:00Z","last_updated_date":"2018-04-26T21:00:00Z","reference_number":"EMEA/CHMP/VWP/164653/05 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-vaccines-revision-1_en.pdf"},
    {"id":"6020","name":"Overview of comments received on 'guideline on veterinary medicinal products controlling Varroa destructor parasitosis in bees'","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/324712/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-guideline-veterinary-medicinal-products-controlling-varroa-destructor-parasitosis-bees_en.pdf"},
    {"id":"6053","name":"Draft guideline on clinical investigation of medicinal products in the treatment of hypertension - Revision 4","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-07-31 - 2014-01-31","first_published_date":"2013-07-31T19:00:00Z","last_updated_date":"2013-07-31T19:00:00Z","reference_number":"EMA/CHMP/29947/2013/Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-hypertension-revision-4_en.pdf"},
    {"id":"6059","name":"Concept paper on revision of the addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections to specifically address the clinical development of new agents to tre...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-11-30 - 2015-02-28","first_published_date":"2014-11-28T16:50:00Z","last_updated_date":"2014-11-28T16:50:00Z","reference_number":"EMA/CHMP/644851/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-addendum-note-guidance-evaluation-medicinal-products-indicated-treatment-bacterial-infections-specifically-address-clinical-development-new-agents-tre_en.pdf"},
    {"id":"6062","name":"Draft addendum to the note for guidance on evaluation of medicinal products Indicated for treatment of bacterial infections to specifically address the clinical development of new agents to treat disease due to Mycobacte...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/14377/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-addendum-note-guidance-evaluation-medicinal-products-indicated-treatment-bacterial-infections-specifically-address-clinical-development-new-agents-treat-disease-due-mycobacte_en.pdf"},
    {"id":"6076","name":"Draft guideline on the conduct of efficacy studies for intramammary products for use in cattle - Revision 2 (first verison)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-10-18 - 2014-04-30","first_published_date":"2013-10-18T19:00:00Z","last_updated_date":"2013-10-18T19:00:00Z","reference_number":"EMEA/CVMP/EWP/141272/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-efficacy-studies-intramammary-products-use-cattle-revision-2-first-verison_en.pdf"},
    {"id":"6078","name":"Guideline on clinical investigation of medicinal products for the treatment of chronic heart failure - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-09-20T13:00:00Z","last_updated_date":"2017-09-20T13:00:00Z","reference_number":"CPMP/EWP/235/95 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-heart-failure-revision-2_en.pdf"},
    {"id":"6090","name":"Reflection paper on microbiological aspects of herbal medicinal products and traditional herbal medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-06-05T11:15:00Z","last_updated_date":"2015-06-05T11:15:00Z","reference_number":"EMA/HMPC/95714/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-microbiological-aspects-herbal-medicinal-products-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"6104","name":"Testing for SV40 in poliovirus vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-04-25T02:00:00Z","last_updated_date":"2002-04-25T02:00:00Z","reference_number":"CPMP/BWP/1412/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/testing-sv40-poliovirus-vaccines_en.pdf"},
    {"id":"6124","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-02-22 - 2013-06-30","first_published_date":"2013-02-22T14:30:00Z","last_updated_date":"2013-05-16T19:10:00Z","reference_number":"EMA/CHMP/ICH/83812/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-m7-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals_en.pdf"},
    {"id":"6137","name":"Lapatinib film-coated tablet 250 mg product-specific bioequivalence guidance - First version (1st draft)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-06-27 - 2018-09-30","first_published_date":"2018-06-27T14:30:00Z","last_updated_date":"2018-06-27T14:30:00Z","reference_number":"EMA/CHMP/257298/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/lapatinib-film-coated-tablet-250-mg-product-specific-bioequivalence-guidance-first-version-1st-draft_en.pdf"},
    {"id":"6148","name":"VICH GL48: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: marker residue depletion studies to establish product withdrawal periods","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-04-07T02:00:00Z","last_updated_date":"2015-02-27T17:30:00Z","reference_number":"EMA/CVMP/VICH/463199/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl48-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-animals-marker-residue-depletion-studies-establish-product-withdrawal-periods_en.pdf"},
    {"id":"6193","name":"Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in non-surgical patients","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-11-29T15:40:00Z","last_updated_date":"2016-11-29T15:40:00Z","reference_number":"EMA/CPMP/EWP/6235/04 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-prevention-venous-thromboembolism-vte-non-surgical-patients_en.pdf"},
    {"id":"6194","name":"Performance enhancers (veterinary)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1991-05-01T02:00:00Z","last_updated_date":"1991-05-01T02:00:00Z","reference_number":"7AE6a Volume 7","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/performance-enhancers-veterinary_en.pdf"},
    {"id":"6216","name":"Concept paper on the need of revision of the note for guidance: Harmonisation of requirements for equine influenza vaccines – Specific requirements for substitution or addition of a strain or strains","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-03-16 - 2012-05-31","first_published_date":"2012-03-16T10:30:00Z","last_updated_date":"2012-03-16T10:30:00Z","reference_number":"EMA/CVMP/IWP/4199/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-harmonisation-requirements-equine-influenza-vaccines-specific-requirements-substitution-or-addition-strain-or-strains_en.pdf"},
    {"id":"6235","name":"Draft guideline on dossier requirements for anticancer medicinal products for dogs and cats (consultation)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-01-21T01:00:00Z","last_updated_date":"2008-01-21T01:00:00Z","reference_number":"MEA/CVMP/28510/2008-CONSULTATION","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-dossier-requirements-anticancer-medicinal-products-dogs-and-cats-consultation_en.pdf"},
    {"id":"6237","name":"Questions and answers on additional clarification for inclusion criteria in the guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease revision 2","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-07-06T11:40:00Z","last_updated_date":"2012-07-06T11:40:00Z","reference_number":"EMA/351466/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-additional-clarification-inclusion-criteria-guideline-clinical-investigation-medicinal-products-treatment-parkinsons-disease-revision-2_en.pdf"},
    {"id":"6268","name":"Guideline on clinical investigation of medicinal products in the treatment of hypertension","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-12-21T01:00:00Z","last_updated_date":"2010-12-21T01:00:00Z","reference_number":"EMA/238/1995/Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-hypertension_en.pdf"},
    {"id":"6282","name":"Draft guideline on clinical investigation of medicinal products for the treatment of psoriatic arthritis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-06-23T02:00:00Z","last_updated_date":"2005-06-23T02:00:00Z","reference_number":"CPMP/EWP/438/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-psoriatic-arthritis_en.pdf"},
    {"id":"6311","name":"Guideline on reporting the results of population pharmacokinetic analyses","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-06-21T02:00:00Z","last_updated_date":"2007-06-21T02:00:00Z","reference_number":"CHMP/EWP/185990/06","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-results-population-pharmacokinetic-analyses_en.pdf"},
    {"id":"6328","name":"Draft reflection paper on in-vitro cultured Chondrocyte containing products for cartilage repair of the knee","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-09-11 - 2009-12-31","first_published_date":"2009-09-17T04:00:00Z","last_updated_date":"2009-10-05T04:00:00Z","reference_number":"EMEA/CAT/CPWP/288934/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-vitro-cultured-chondrocyte-containing-products-cartilage-repair-knee_en.pdf"},
    {"id":"6378","name":"Draft guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-10-30 - 2018-01-31","first_published_date":"2017-10-30T14:30:00Z","last_updated_date":"2017-10-30T14:30:00Z","reference_number":"EMA/CHMP/BPWP/1619/1999 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-human-plasma-derived-and-recombinant-coagulation-factor-viii-products-revision-3_en.pdf"},
    {"id":"6412","name":"Concept paper for the revision of the guideline on the summary of product characteristics for anthelmintics","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-12-15 - 2018-03-31","first_published_date":"2017-12-15T17:00:00Z","last_updated_date":"2017-12-15T17:00:00Z","reference_number":"EMA/CVMP/EWP/158889/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-summary-product-characteristics-anthelmintics_en.pdf"},
    {"id":"6426","name":"Consultation on qualification opinion ILSI / HESI submission of novel renal biomarkers for toxicity","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-03-18 - 2010-07-31","first_published_date":"2010-05-11T04:00:00Z","last_updated_date":"2010-06-07T04:00:00Z","reference_number":"EMA/283298/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/consultation-qualification-opinion-ilsi-hesi-submission-novel-renal-biomarkers-toxicity_en.pdf"},
    {"id":"6445","name":"Draft reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-07-21 - 2012-01-31","first_published_date":"2011-07-26T04:00:00Z","last_updated_date":"2011-07-26T04:00:00Z","reference_number":"EMA/CHMP/806058/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-data-requirements-intravenous-liposomal-products-developed-reference-innovator-liposomal-product_en.pdf"},
    {"id":"6448","name":"Concept paper on the preparation of a guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-01-26T01:00:00Z","last_updated_date":"2006-01-26T01:00:00Z","reference_number":"EMEA/CHMP/EWP/18504/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-preparation-guideline-clinical-development-products-specific-immunotherapy-treatment-allergic-diseases_en.pdf"},
    {"id":"6461","name":"ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - Questions and answers - Step 5 - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/CHMP/ICH/320985/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-s3a-note-guidance-toxicokinetics-assessment-systemic-exposure-toxicity-studies-questions-and-answers-step-5-first-version_en.pdf"},
    {"id":"6476","name":"Note for guidance on the establishment of maximum residue limits for Salmonidae and other fin fish","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-01-01T01:00:00Z","last_updated_date":"1998-01-01T01:00:00Z","reference_number":"EMEA/CVMP/153b/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-establishment-maximum-residue-limits-salmonidae-and-other-fin-fish_en.pdf"},
    {"id":"6482","name":"Concept paper on the need for requiring data to demonstrate the influence of maternally derived antibodies on the vaccination of very young animals","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-04-23T02:00:00Z","last_updated_date":"2007-04-23T02:00:00Z","reference_number":"EMEA/CVMP/IWP/501304/2006-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-requiring-data-demonstrate-influence-maternally-derived-antibodies-vaccination-very-young-animals_en.pdf"},
    {"id":"6505","name":"Guideline on the limits of genotoxic impurities","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-28T02:00:00Z","last_updated_date":"2006-06-28T02:00:00Z","reference_number":"EMEA/CHMP/QWP/251344/2006 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-limits-genotoxic-impurities_en.pdf"},
    {"id":"6524","name":"Reflection paper on stem cell-based medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-02-03T01:00:00Z","last_updated_date":"2011-02-03T01:00:00Z","reference_number":"EMA/CAT/571134/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-stem-cell-based-medicinal-products_en.pdf"},
    {"id":"6525","name":"Concept paper on developing a guideline on quality requirements of medicinal products containing a device component for delivery or use of the medicinal product","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-02-16 - 2017-05-16","first_published_date":"2017-02-16T13:16:00Z","last_updated_date":"2017-02-16T13:16:00Z","reference_number":"EMA/CHMP/QWP/BWP/661488/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-developing-guideline-quality-requirements-medicinal-products-containing-device-component-delivery-or-use-medicinal-product_en.pdf"},
    {"id":"6540","name":"Draft guideline on the design of studies to evaluate the safety and efficacy of fish vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-03-30 - 2011-09-30","first_published_date":"2011-03-30T04:00:00Z","last_updated_date":"2011-03-30T04:00:00Z","reference_number":"EMA/CVMP/IWP/314550/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-design-studies-evaluate-safety-and-efficacy-fish-vaccines_en.pdf"},
    {"id":"6561","name":"Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-20T17:28:00Z","last_updated_date":"2018-07-20T17:28:00Z","reference_number":"EMEA/CHMP/BMWP/94528/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf"},
    {"id":"6585","name":"Draft guideline on core summary of product characteristics and package leaflet for sodium fluoride (18F)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-07-31 - 2014-10-31","first_published_date":"2014-07-31T19:50:00Z","last_updated_date":"2014-07-31T19:50:00Z","reference_number":"EMA/CHMP/465616/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-and-package-leaflet-sodium-fluoride-18f_en.pdf"},
    {"id":"6596","name":"Note for guidance on the clinical investigatiom of medicinal products in the treatment of schizophrenia","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-02-26T01:00:00Z","last_updated_date":"1998-02-26T01:00:00Z","reference_number":"CPMP/EWP/595/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigatiom-medicinal-products-treatment-schizophrenia_en.pdf"},
    {"id":"6651","name":"Adopted guideline on setting specifications for related impurities in antibiotics","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-07-13T13:00:00Z","last_updated_date":"2012-07-13T13:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/199250/2009 corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-guideline-setting-specifications-related-impurities-antibiotics_en.pdf"},
    {"id":"6661","name":"Concept paper on a revision of the guideline on the investigation of drug interactions","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-04-07 - 2017-06-30","first_published_date":"2017-04-07T13:10:00Z","last_updated_date":"2017-04-07T13:10:00Z","reference_number":"EMEA/CHMP/694687/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-investigation-drug-interactions_en.pdf"},
    {"id":"6698","name":"Tacrolimus granules for oral suspension 0.2 and 1 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-11-01T17:37:50Z","reference_number":"EMA/CHMP/159744/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/tacrolimus-granules-oral-suspension-02-and-1-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"6702","name":"Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2011-08-11T02:00:00Z","last_updated_date":"2011-08-11T02:00:00Z","reference_number":"EMA/803916/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-interactive-response-technologies-interactive-voiceweb-response-systems-clinical-trials_en.pdf"},
    {"id":"6706","name":"ICH: Q 4 B Annex 6: To note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on uniformity of dosage unites general chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2008-12-01T01:00:00Z","reference_number":"EMEA/CHMP/ICH/645408/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-6-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-uniformity-dosage-unites-general-chapter-step-3_en.pdf"},
    {"id":"6724","name":"Concept paper on the development of a CHMP guideline on the evaluation of non-clinical and clinical data on the medicinal substances contained in drug-eluting (medicinal substance-eluting) coronary stents within the fram...","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-02-23T01:00:00Z","last_updated_date":"2006-02-23T01:00:00Z","reference_number":"EMEA/CHMP/EWP/56477/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-chmp-guideline-evaluation-non-clinical-and-clinical-data-medicinal-substances-contained-drug-eluting-medicinal-substance-eluting-coronary-stents-within-fram_en.pdf"},
    {"id":"6742","name":"Table of extraneous agents to be tested for in relation to the general and species-specific guidelines on production and control of mammalian veterinary vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-09-01T02:00:00Z","last_updated_date":"1994-09-01T02:00:00Z","reference_number":"7BIm10a Volume 7","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/table-extraneous-agents-be-tested-relation-general-and-species-specific-guidelines-production-and-control-mammalian-veterinary-vaccines_en.pdf"},
    {"id":"6748","name":"Guideline on the clinical development of medicinal products for the treatment of allergic rhino-conjunctivitis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-10-21T02:00:00Z","last_updated_date":"2004-10-21T02:00:00Z","reference_number":"CHMP/EWP/2455/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-treatment-allergic-rhino-conjunctivitis_en.pdf"},
    {"id":"6759","name":"Draft guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), bluetongue (BT) and foot and mouth disease (FMD) - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-03-16T01:00:00Z","last_updated_date":"2009-03-16T01:00:00Z","reference_number":"EMEA/CVMP/IWP/105506/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-multi-strain-dossiers-inactivated-vaccines-against-avian-influenza-ai-bluetongue-bt-and-foot-and-mouth-disease-fmd-first-version_en.pdf"},
    {"id":"6771","name":"Pharmacokinetic studies in man","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-02-01T01:00:00Z","last_updated_date":"2015-02-01T01:00:00Z","reference_number":"3CC3a","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/pharmacokinetic-studies-man_en.pdf"},
    {"id":"6786","name":"ICH: Q 4 B Annex 3: To note for evaluation and recommendation of pharmacopoeial texts for use in the ich regions on test for particulate contamination: Sub-visible particles general chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-11-01T01:00:00Z","last_updated_date":"2007-11-01T01:00:00Z","reference_number":"EMEA/CHMP/ICH/561176/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-3-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-test-particulate-contamination-sub-visible-particles-general-chapter-step-3_en.pdf"},
    {"id":"6814","name":"Draft guideline on core SmPC and package leaflet for gadoteric acid","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-06-01 - 2016-09-30","first_published_date":"2016-06-01T18:00:02Z","last_updated_date":"2016-06-01T18:00:02Z","reference_number":"EMA/CHMP/337820/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-and-package-leaflet-gadoteric-acid_en.pdf"},
    {"id":"6840","name":"Note for guidance on antiarrhythmics","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-01T01:00:00Z","last_updated_date":"2005-11-01T01:00:00Z","reference_number":"CPMP/EWP/237/95 final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-antiarrhythmics_en.pdf"},
    {"id":"6858","name":"Volume 3b guidelines: Medicinal products for human use: Safety, environment and information: Excipients in the label and package leaflet of medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-07-01T02:00:00Z","last_updated_date":"2003-07-01T02:00:00Z","reference_number":"3bc7a","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/volume-3b-guidelines-medicinal-products-human-use-safety-environment-and-information-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"6978","name":"Reflection paper on the chemical structure and properties criteria to be considered for the evaluation of new active substance (NAS) status of chemical substances - Veterinary","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-23T12:25:00Z","last_updated_date":"2017-10-23T12:25:00Z","reference_number":"EMA/CVMP/QWP/3629/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-chemical-structure-and-properties-criteria-be-considered-evaluation-new-active-substance-nas-status-chemical-substances-veterinary_en.pdf"},
    {"id":"6979","name":"Note for guidance pharmacovigilance of veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-07-15T02:00:00Z","last_updated_date":"1997-07-15T02:00:00Z","reference_number":"EMEA/CVMP/183/96 Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-pharmacovigilance-veterinary-medicinal-products_en.pdf"},
    {"id":"7024","name":"Guideline on active substance master file procedure - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-07-13T13:00:00Z","last_updated_date":"2013-06-10T12:54:00Z","reference_number":"CHMP/QWP/227/02 Rev.3 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-active-substance-master-file-procedure-revision-3_en.pdf"},
    {"id":"7029","name":"Draft guideline on the conduct of efficacy studies for intramammary products for use in cattle - Revision 2 (second version)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-26 - 2016-05-31","first_published_date":"2016-02-26T16:30:00Z","last_updated_date":"2016-02-26T16:30:00Z","reference_number":"CVMP/344/1999 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-efficacy-studies-intramammary-products-use-cattle-revision-2-second-version_en.pdf"},
    {"id":"7050","name":"Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-08-13T15:00:00Z","last_updated_date":"2018-08-13T15:00:00Z","reference_number":"EMA/CHMP/BPWP/144533/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-viii-products-revision-2_en.pdf"},
    {"id":"7077","name":"Guideline on the chemistry of new active substances (CVMP)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-05-01T02:00:00Z","last_updated_date":"2004-05-01T02:00:00Z","reference_number":"EMEA/CVMP/541/03/Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-chemistry-new-active-substances-cvmp_en.pdf"},
    {"id":"7088","name":"Guideline on requirements for an authorisation under exceptional circumstances for vaccines for emergency use against bluetongue","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-11-17T01:00:00Z","last_updated_date":"2008-11-17T01:00:00Z","reference_number":"EMEA/CVMP/IWP/220193/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-authorisation-under-exceptional-circumstances-vaccines-emergency-use-against-bluetongue_en.pdf"},
    {"id":"7096","name":"Draft guideline on the conduct of bioequivalence studies for veterinary medicinal products - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-07-14 - 2010-10-31","first_published_date":"2009-03-16T02:00:00Z","last_updated_date":"2010-07-19T04:00:00Z","reference_number":"EMEA/CVMP/016/00 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-revision-2_en.pdf"},
    {"id":"7108","name":"Draft repaglinide tablets 0.5, 1 and 2 mg product-specific bioequivalence guidance - Rev.1","type":"scientific-guideline","status":"Draft","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/675842/2014 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-repaglinide-tablets-05-1-2-mg-product-specific-bioequivalence-guidance-rev1_en.pdf"},
    {"id":"7115","name":"Guideline on radiopharmaceuticals - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-11-26T01:00:00Z","last_updated_date":"2008-11-26T01:00:00Z","reference_number":"EMEA/CHMP/QWP/306970/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-radiopharmaceuticals-revision-1_en.pdf"},
    {"id":"7116","name":"Draft guideline on influenza vaccines – quality module","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-03-08 - 2013-08-08","first_published_date":"2013-03-08T12:00:00Z","last_updated_date":"2013-03-08T12:00:00Z","reference_number":"EMA/CHMP/BWP/310834/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-influenza-vaccines-quality-module_en.pdf"}    {"id":"7139","name":"Draft guidance on the assessment of persistent, bioaccumulative and toxic or very persistent and very bioaccumulative substances in veterinary medicine","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-10-27 - 2015-01-27","first_published_date":"2012-07-25T14:40:00Z","last_updated_date":"2014-10-27T10:55:00Z","reference_number":"EMA/CVMP/ERA/52740/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guidance-assessment-persistent-bioaccumulative-and-toxic-or-very-persistent-and-very-bioaccumulative-substances-veterinary-medicine_en.pdf"},
    {"id":"7154","name":"ICH: Q 1 D: Bracketing and matrixing designs for stability testing of drug substances and drug products - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-02-01T01:00:00Z","last_updated_date":"2002-02-01T01:00:00Z","reference_number":"CPMP/ICH/4104/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-d-bracketing-and-matrixing-designs-stability-testing-drug-substances-and-drug-products-step-5_en.pdf"},
    {"id":"7199","name":"Note for guidance on the risk analysis approach for residues of veterinary medicinal products in food of animal origin","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"EMEA/CVMP/187/00 - FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-risk-analysis-approach-residues-veterinary-medicinal-products-food-animal-origin_en.pdf"},
    {"id":"7211","name":"Position paper on the maximum in-use shelf-life for medicated drinking water","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-12-01T01:00:00Z","last_updated_date":"2002-12-01T01:00:00Z","reference_number":"EMEA/CVMP/1090/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-maximum-use-shelf-life-medicated-drinking-water_en.pdf"},
    {"id":"7215","name":"Draft guideline on procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure - Revision 1 - Superseded","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-05-20 - 2010-09-01","first_published_date":"2010-06-02T04:00:00Z","last_updated_date":"2010-06-02T04:00:00Z","reference_number":"EMA/CHMP/BWP/99698/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-procedural-advice-submission-variations-annual-update-human-influenza-inactivated-vaccines-applications-centralised-procedure-revision-1-superseded_en.pdf"},
    {"id":"7252","name":"Guideline on clinical investigation of medicinal products for the treatment of psoriatic arthritis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-12-14T01:00:00Z","last_updated_date":"2006-12-14T01:00:00Z","reference_number":"CHMP/EWP/438/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-psoriatic-arthritis_en.pdf"},
    {"id":"7257","name":"Asenapine sublingual tablets 5 and 10 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-11-01T01:00:00Z","reference_number":"EMA/CHMP/158542/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/asenapine-sublingual-tablets-5-and-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"7275","name":"Draft guideline on similar biological medicinal products containing low-molecular-weight-heparins","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/BMWP/118264/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-similar-biological-medicinal-products-containing-low-molecular-weight-heparins_en.pdf"},
    {"id":"7292","name":"Paliperidone palmitate depot suspension for injection 25 mg, 50 mg, 75 mg, 100 mg and 150 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-03T01:00:00Z","last_updated_date":"2017-03-03T01:00:00Z","reference_number":"EMA/CHMP/474825/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paliperidone-palmitate-depot-suspension-injection-25-mg-50-mg-75-mg-100-mg-and-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"7299","name":"Draft guideline on quality of combination herbal medicinal products/traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-26T02:00:00Z","last_updated_date":"2007-07-26T02:00:00Z","reference_number":"EMEA/HMPC/CHMP/CVMP/214869/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-combination-herbal-medicinal-productstraditional-herbal-medicinal-products_en.pdf"},
    {"id":"7314","name":"Guideline on good pharmacovigilance practices: Module IV – Pharmacovigilance audits (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"2012-07-26 - 2012-09-21","first_published_date":"2012-12-13T18:00:00Z","last_updated_date":"2012-12-13T18:00:00Z","reference_number":"EMA/228028/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-iv-pharmacovigilance-audits-superseded_en.pdf"},
    {"id":"7382","name":"Guideline on the clinical evaluation of medicinal products intended for treatment of Hepatitis B - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-02-23T01:00:00Z","last_updated_date":"2006-02-23T01:00:00Z","reference_number":"CHMP/EWP/6172/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-intended-treatment-hepatitis-b-first-version_en.pdf"},
    {"id":"7420","name":"Draft guideline on reporting the results of population pharmacokinetic analyses","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-06-29T02:00:00Z","last_updated_date":"2006-06-29T02:00:00Z","reference_number":"EMEA/CHMP/EWP/185990/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-reporting-results-population-pharmacokinetic-analyses_en.pdf"},
    {"id":"7429","name":"Status of EMEA scientific guidelines and European pharmacopoeia monographs and chapters in the regulatory framework applicable to medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-09-11T02:00:00Z","last_updated_date":"2008-09-11T02:00:00Z","reference_number":"EMEA/42371/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/status-emea-scientific-guidelines-and-european-pharmacopoeia-monographs-and-chapters-regulatory-framework-applicable-medicinal-products_en.pdf"},
    {"id":"7437","name":"Draft guideline on virus safety evaluation of biotechnological investigational medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-06-28T02:00:00Z","last_updated_date":"2006-06-28T02:00:00Z","reference_number":"EMEA/CHMP/BWP/398498/2005-corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-virus-safety-evaluation-biotechnological-investigational-medicinal-products_en.pdf"},
    {"id":"7477","name":"CVMP concept paper on the revision of the committee for veterinary medicinal products (CVMP) and committee for proprietary medicinal products (CPMP), Note for guidance on plastic primary packing materials","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2003-11-03T01:00:00Z","last_updated_date":"2003-11-03T01:00:00Z","reference_number":"EMEA/CVMP/1028/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cvmp-concept-paper-revision-committee-veterinary-medicinal-products-cvmp-and-committee-proprietary-medicinal-products-cpmp-note-guidance-plastic-primary-packing-materials_en.pdf"},
    {"id":"7482","name":"Guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T11:00:00Z","last_updated_date":"2015-11-20T11:00:00Z","reference_number":"EMA/CHMP/239770/2014 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-juvenile-idiopathic-arthritis-revision-2_en.pdf"},
    {"id":"7491","name":"Questions and answers on cyclodextrins used as excipients in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/495747/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-cyclodextrins-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"7501","name":"Guideline on quality aspects of pharmaceutical veterinary medicines for administration via drinking water","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-04-15T02:00:00Z","last_updated_date":"2005-04-15T02:00:00Z","reference_number":"EMEA/CVMP/540/03 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-aspects-pharmaceutical-veterinary-medicines-administration-drinking-water_en.pdf"},
    {"id":"7532","name":"Draft capecitabine product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/423732/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-capecitabine-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"7536","name":"ICH  E6 (R1) guideline for Good Clinical Practice - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-07-01T02:00:00Z","last_updated_date":"2002-07-01T02:00:00Z","reference_number":"CPMP/ICH/135/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r1-guideline-good-clinical-practice-revision-1_en.pdf"},
    {"id":"7564","name":"Draft guideline on requirements for the production and control of immunological veterinary medicinal products - Rev.1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-17 - 2016-01-31","first_published_date":"2015-07-17T13:15:00Z","last_updated_date":"2015-07-17T13:15:00Z","reference_number":"EMA/CVMP/IWP/206555/2010-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-production-and-control-immunological-veterinary-medicinal-products-rev1_en.pdf"},
    {"id":"7583","name":"Note for guidance on clinical investigation of medicinal products for treatment of nociceptive pain","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-11-21T01:00:00Z","last_updated_date":"2002-11-21T01:00:00Z","reference_number":"CPMP/EWP/612/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-nociceptive-pain_en.pdf"},
    {"id":"7585","name":"Draft guideline on good pharmacovigilance practices: Module VIII - Post-authorisation safety studies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-02-22T14:20:00Z","last_updated_date":"2012-02-22T14:20:00Z","reference_number":"EMA/813938/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-viii-post-authorisation-safety-studies_en.pdf"},
    {"id":"7596","name":"Recommendation for the revision of the points to consider on missing data (CPMP/EWP/1776/99)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-12-13T01:00:00Z","last_updated_date":"2007-12-13T01:00:00Z","reference_number":"EMEA/CHMP/EWP/439980/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-revision-points-consider-missing-data-cpmpewp177699_en.pdf"},
    {"id":"7599","name":"Reflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-10-10T18:15:00Z","last_updated_date":"2017-07-06T02:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/826771/2016 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-requirements-selection-and-justification-starting-materials-manufacture-chemical-active-substances_en.pdf"},
    {"id":"7631","name":"Guideline on the treatment of premenstrual dysphoric disorder (PMDD)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-08-05T02:00:00Z","last_updated_date":"2011-08-05T02:00:00Z","reference_number":"EMA/CHMP/607022/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf"},
    {"id":"7637","name":"ICH: E 12: Principles for clinical evaluation of new antihypertensive drugs - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-06-01T02:00:00Z","last_updated_date":"2000-06-01T02:00:00Z","reference_number":"CPMP/ICH/541/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-12-principles-clinical-evaluation-new-antihypertensive-drugs-step-5_en.pdf"},
    {"id":"7644","name":"Draft reflection paper on the adaptogenic concept","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-05T02:00:00Z","last_updated_date":"2007-07-05T02:00:00Z","reference_number":"EMEA/HMPC/102655/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-adaptogenic-concept_en.pdf"},
    {"id":"7680","name":"Draft guideline on core summary of product characteristics and package leaflet for technetium (99mTc) sestamibi","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-08-23 - 2012-11-30","first_published_date":"2012-08-23T15:00:00Z","last_updated_date":"2012-08-23T15:00:00Z","reference_number":"EMA/CHMP/448591/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-and-package-leaflet-technetium-99mtc-sestamibi_en.pdf"},
    {"id":"7742","name":"Concept paper on fate of veterinary medicinal products in manure","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-02-16T01:00:00Z","last_updated_date":"2009-02-16T01:00:00Z","reference_number":"EMEA/CVMP/ERA/10043/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-fate-veterinary-medicinal-products-manure_en.pdf"},
    {"id":"7807","name":"Concept paper on preparation of a revised guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-06-13 - 2018-09-13","first_published_date":"2018-06-13T19:35:00Z","last_updated_date":"2018-06-13T19:35:00Z","reference_number":"EMA/CHMP/75653/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-preparation-revised-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf"},
    {"id":"7827","name":"Guideline on Allergen products: Production and quality issues","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/CHMP/BWP/304831/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-allergen-products-production-and-quality-issues_en.pdf"},
    {"id":"7849","name":"Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-06-26T15:35:01Z","last_updated_date":"2018-06-26T15:35:01Z","reference_number":"EMA/CHMP/158772/2016/Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/prasugrel-hydrochloride-film-coated-tablets-5-mg-and-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"7871","name":"Concept paper on revision of the current guideline on the summary of product characteristics for antimicrobial products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-25 - 2016-10-31","first_published_date":"2016-07-25T14:29:00Z","last_updated_date":"2016-07-25T14:29:00Z","reference_number":"EMA/CVMP/AWP/161553/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-current-guideline-summary-product-characteristics-antimicrobial-products_en.pdf"},
    {"id":"7897","name":"Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-02-07 - 2011-05-31","first_published_date":"2011-02-22T02:00:00Z","last_updated_date":"2011-02-22T02:00:00Z","reference_number":"EMA/CHMP/BWP/617111/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality-issues_en.pdf"},
    {"id":"7938","name":"Guideline on quality data requirements for veterinary medicinal products intended for minor uses or minor species","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-20T02:00:00Z","last_updated_date":"2006-07-20T02:00:00Z","reference_number":"EMEA/CVMP/QWP/128710/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-data-requirements-veterinary-medicinal-products-intended-minor-uses-or-minor-species_en.pdf"},
    {"id":"7978","name":"Draft guideline on the development medicinal substances contained in drug-eluting (medicinal substance-eluting) coronary stents","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-03-22T01:00:00Z","last_updated_date":"2007-03-22T01:00:00Z","reference_number":"EMEA/CHMP/EWP/110540/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-medicinal-substances-contained-drug-eluting-medicinal-substance-eluting-coronary-stents_en.pdf"},
    {"id":"8033","name":"Points to consider on the reduction, elimination or substitution of Thiomersal in vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-04-26T02:00:00Z","last_updated_date":"2001-04-26T02:00:00Z","reference_number":"CPMP/BWP/2517/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-reduction-elimination-or-substitution-thiomersal-vaccines_en.pdf"},
    {"id":"8056","name":"Draft guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/BPWP/144533/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-viii-products-first-version_en.pdf"},
    {"id":"8063","name":"Guideline on safety and efficacy follow-up - risk management of advanced therapy medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-11-21T00:00:00Z","last_updated_date":"2008-11-21T00:00:00Z","reference_number":"EMEA/149995/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-safety-and-efficacy-follow-risk-management-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"8094","name":"Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle-stimulating hormone (r-hFSH)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-03-06T12:00:03Z","last_updated_date":"2013-03-06T12:00:03Z","reference_number":"EMA/CHMP/BMWP/671292/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-human-follicle-stimulating-hormone-r-hfsh_en.pdf"},
    {"id":"8130","name":"Guideline on good pharmacovigilance practices: Module XV – Safety communication with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T18:00:00Z","last_updated_date":"2013-01-24T18:00:00Z","reference_number":"EMA/35829/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xv-safety-communication-tracked-changes_en.pdf"},
    {"id":"8182","name":"Concept paper on dossier requirements for oncology products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-06-15T02:00:00Z","last_updated_date":"2005-06-15T02:00:00Z","reference_number":"EMEA/CVMP/EWP/79590/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-dossier-requirements-oncology-products_en.pdf"},
    {"id":"8243","name":"VICH GL11: Impurities in new veterinary medicinal products  - Step 7 (after revision at step 9)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-02-19T01:00:00Z","last_updated_date":"2007-02-19T01:00:00Z","reference_number":"EMEA/CVMP/VICH/838/99-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl11-impurities-new-veterinary-medicinal-products-step-7-after-revision-step-9_en.pdf"},
    {"id":"8245","name":"Revised position paper on indications for veterinary vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-06-20T02:09:21Z","last_updated_date":"2003-06-20T02:09:21Z","reference_number":"EMEA/CVMP/042/97-Rev.1-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/revised-position-paper-indications-veterinary-vaccines_en.pdf"},
    {"id":"8250","name":"Draft guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-09-28 - 2016-03-31","first_published_date":"2015-09-28T18:30:00Z","last_updated_date":"2015-09-28T18:30:00Z","reference_number":"EMA/CHMP/594085/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-use-pharmacokinetics-and-pharmacodynamics-development-antibacterial-medicinal-products_en.pdf"},
    {"id":"8254","name":"Guideline on data requirements for changes to the strain composition of authorised equine influenza vaccines in line with World Organisation for Animal Health (OIE) recommendations","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-11-19T12:00:00Z","last_updated_date":"2014-11-19T12:00:00Z","reference_number":"EMA/CVMP/IWP/97961/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-changes-strain-composition-authorised-equine-influenza-vaccines-line-world-organisation-animal-health-oie-recommendations_en.pdf"},
    {"id":"8274","name":"Draft guideline on clinical development of fixed combination medicinal products - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-05-13 - 2015-11-15","first_published_date":"2015-05-13T14:30:00Z","last_updated_date":"2015-05-13T14:30:00Z","reference_number":"EMA/CHMP/281825/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-development-fixed-combination-medicinal-products-revision-2_en.pdf"},
    {"id":"8298","name":"Public Statement on the allergenic potency of herbal medicinal products containing soya or peanut protein","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-01-12T01:00:00Z","last_updated_date":"2006-01-12T01:00:00Z","reference_number":"EMEA/HMPC/138139/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-allergenic-potency-herbal-medicinal-products-containing-soya-or-peanut-protein_en.pdf"},
    {"id":"8349","name":"Reflection paper on the use of starting materials and intermediates collected from different sources in the manufacturing of biological medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-27 - 2012-08-31","first_published_date":"2012-02-27T18:40:00Z","last_updated_date":"2012-02-27T18:40:00Z","reference_number":"EMA/CHMP/BWP/729106/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-starting-materials-and-intermediates-collected-different-sources-manufacturing-biological-medicinal-products_en.pdf"},
    {"id":"8404","name":"Concept paper on the development of a committee for medicinal products for human use (CHMP) note for guidance on the need for regulatory guidance in the evaluation of medicinal products for the secondary cardiovascular p...","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2004-06-23T02:00:00Z","last_updated_date":"2004-06-23T02:00:00Z","reference_number":"CHMP/EWP/1470/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-medicinal-products-human-use-chmp-note-guidance-need-regulatory-guidance-evaluation-medicinal-products-secondary-cardiovascular-p_en.pdf"},
    {"id":"8410","name":"ICH: Q 6 B: Test procedures and acceptance criteria for biotechnological/biological products - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-09-01T02:00:00Z","last_updated_date":"1999-09-01T02:00:00Z","reference_number":"CPMP/ICH/365/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-6-b-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products-step-5_en.pdf"},
    {"id":"8411","name":"Concept paper on revision of note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use (CPMP/BPWG/283/00)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-12-16 - 2011-03-31","first_published_date":"2010-12-17T02:00:00Z","last_updated_date":"2010-12-17T02:00:00Z","reference_number":"EMA/CHMP/BPWP/761007/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-clinical-investigation-human-normal-immunoglobulin-subcutaneous-and-intramuscular-use-cpmp-bpwg-283-00_en.pdf"},
    {"id":"8421","name":"Draft guideline on the treatment of Premenstrual Dysphoric Disorder (PMDD)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-05-20 - 2010-11-30","first_published_date":"2010-05-24T04:00:00Z","last_updated_date":"2010-05-24T04:00:00Z","reference_number":"EMA/CHMP/EWP/607022/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf"},
    {"id":"8429","name":"Draft addendum to the 'guideline on the evaluation of medicinal products indicated for treatment of bacterial infections' to address the clinical development of new agents to treat disease due to Mycobacterium tuberculos...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-01 - 2017-01-31","first_published_date":"2016-08-01T16:00:00Z","last_updated_date":"2016-08-01T16:00:00Z","reference_number":"EMA/CHMP/EWP/14377/2008 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-address-clinical-development-new-agents-treat-disease-due-mycobacterium-tuberculos_en.pdf"},
    {"id":"8435","name":"Draft information in the package leaflet for fragrances containing allergens in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (CPMP/463/...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-04 - 2016-08-03","first_published_date":"2016-05-04T17:00:00Z","last_updated_date":"2016-05-04T17:00:00Z","reference_number":"EMA/CHMP/273718/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-fragrances-containing-allergens-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use-cpmp-463_en.pdf"},
    {"id":"8442","name":"Guideline on influenza vaccines – submission and procedural requirements (Rev.1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-14T11:59:00Z","last_updated_date":"2017-03-14T11:59:00Z","reference_number":"EMA/56793/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-influenza-vaccines-submission-and-procedural-requirements-rev1_en.pdf"},
    {"id":"8494","name":"ICH: M 2: Electronic common technical document (e-CTD) - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-05-01T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"CPMP/ICH/1840/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-2-electronic-common-technical-document-e-ctd-step-5_en.pdf"},
    {"id":"8495","name":"Draft revised guideline on the SPC for antimicrobial products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-01-17T00:09:21Z","last_updated_date":"2007-01-17T00:09:21Z","reference_number":"EMEA/CVMP/SAGAM/383441/2005-CONSULTATION","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-revised-guideline-spc-antimicrobial-products_en.pdf"},
    {"id":"8498","name":"Concept paper on the revision of the guideline on  immunogenicity assessment of biotechnology-derived  therapeutic proteins - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-03-25 - 2014-06-30","first_published_date":"2014-03-25T10:55:00Z","last_updated_date":"2014-03-25T10:55:00Z","reference_number":"EMA/275542/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-revision-1_en.pdf"},
    {"id":"8523","name":"Draft concept paper on similar biological medicinal products containing low molecular weight heparins1 - (non) clinical issues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/496286/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-similar-biological-medicinal-products-containing-low-molecular-weight-heparins1-non-clinical-issues_en.pdf"},
    {"id":"8529","name":"First cases of bovine spongiform encephalopathy in the United States (USA) and Canada: Risk assessment of ruminant materials originating from the USA and Canada","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-21T02:00:00Z","last_updated_date":"2004-07-21T02:00:00Z","reference_number":"EMEA/CHMP/BWP/27/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/first-cases-bovine-spongiform-encephalopathy-united-states-usa-and-canada-risk-assessment-ruminant-materials-originating-usa-and-canada_en.pdf"},
    {"id":"8559","name":"Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T16:45:00Z","last_updated_date":"2015-03-27T16:45:00Z","reference_number":"EMA/CHMP/SWP/620008/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-requirements-intravenous-iron-based-nano-colloidal-products-developed-reference-innovator-medicinal-product_en.pdf"},
    {"id":"8563","name":"Draft VICH GL56 studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: study design recommendations for residue studies in honey for establishing maximum residue limits and...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-02-24 - 2017-07-31","first_published_date":"2017-02-24T18:00:00Z","last_updated_date":"2017-02-24T18:00:00Z","reference_number":"EMA/CVMP/VICH/176637/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl56-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-species-study-design-recommendations-residue-studies-honey-establishing-maximum-residue-limits-and_en.pdf"},
    {"id":"8579","name":"Draft paliperidone prolonged-release tablet 1.5mg, 3mg, 6mg, 9mg and 12mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-02 - 2016-07-31","first_published_date":"2016-05-02T13:00:00Z","last_updated_date":"2016-05-02T13:00:00Z","reference_number":"EMA/CHMP/156358/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-paliperidone-prolonged-release-tablet-15mg-3mg-6mg-9mg-and-12mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"8592","name":"Draft reflection paper on the pharmaceutical development of medicines for use in the older population - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-08-01 - 2018-01-31","first_published_date":"2017-08-01T16:15:00Z","last_updated_date":"2017-08-01T16:15:00Z","reference_number":"EMA/CHMP/QWP/292439/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-pharmaceutical-development-medicines-use-older-population-first-version_en.pdf"},
    {"id":"8606","name":"Position paper on potential medication errors in the context of benefit-risk balance and risk-minimisation measures","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-06-07T16:55:00Z","last_updated_date":"2013-06-07T16:55:00Z","reference_number":"EMA/CHMP/277591/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-potential-medication-errors-context-benefit-risk-balance-and-risk-minimisation-measures_en.pdf"},
    {"id":"8611","name":"Guideline on good pharmacovigilance practices: Module X – Additional monitoring","type":"scientific-guideline","status":"Adopted","consultation_date":"2012-06-27 - 2012-08-24","first_published_date":"2013-04-25T14:00:00Z","last_updated_date":"2013-04-25T14:00:00Z","reference_number":"EMA/169546/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-x-additional-monitoring_en.pdf"},
    {"id":"8691","name":"Guideline on the Core SPC for human Anti-D immunoglobulin for intramuscular use - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T02:09:21Z","last_updated_date":"2007-09-20T02:09:21Z","reference_number":"CPMP/BPWG/574/99 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-anti-d-immunoglobulin-intramuscular-use-revision-1_en.pdf"},
    {"id":"8693","name":"Recommendation on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of Alzheimer's disease (CPMP/EWP/553/95) - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"EMEA/CHMP/EWP/369929/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-need-revision-guideline-clinical-investigation-medicinal-products-treatment-alzheimers-disease-cpmpewp55395-revision-1_en.pdf"},
    {"id":"8701","name":"Guideline on pharmacogenetics briefing meetings","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-04-27T02:00:00Z","last_updated_date":"2006-04-27T02:00:00Z","reference_number":"EMEA/CHMP/PGxWP/20227/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacogenetics-briefing-meetings_en.pdf"},
    {"id":"8718","name":"Approaches on how to consider excipients in the context of Regulation 2377/90","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-11-23T00:09:21Z","last_updated_date":"2005-11-23T00:09:21Z","reference_number":"EMEA/CVMP/223005/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/approaches-how-consider-excipients-context-regulation-237790_en.pdf"},
    {"id":"8732","name":"Radiopharmaceuticals","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1990-12-01T01:00:00Z","last_updated_date":"1990-12-01T01:00:00Z","reference_number":"3AQ20A","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/radiopharmaceuticals_en.pdf"},
    {"id":"8739","name":"Note for guidance: Investigation of chiral active substances","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-06-01T02:00:00Z","last_updated_date":"1997-06-01T02:00:00Z","reference_number":"EMEA/CVMP/128/95-Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-investigation-chiral-active-substances_en.pdf"},
    {"id":"8742","name":"Guideline on good pharmacovigilance practices (GVP): Module VII – Periodic safety update report - Explanatory note","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-04-06T14:00:00Z","last_updated_date":"2026-05-22T15:40:00Z","reference_number":"EMA/670256/2017 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report-explanatory-note_en.pdf"},
    {"id":"8757","name":"Draft appendix 1 to the guideline on the evaluation of anticancer medicinal products in man (CHMP/EWP/205/95 rev. 3), methodological considerations for using Progression-Free Survival (PFS) as primary endpoint in confirm...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-07-27T02:09:21Z","last_updated_date":"2006-07-27T02:09:21Z","reference_number":"EMEA/CHMP/EWP/267575/2006/Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-appendix-1-guideline-evaluation-anticancer-medicinal-products-man-chmpewp20595-rev-3-methodological-considerations-using-progression-free-survival-pfs-primary-endpoint-confirm_en.pdf"},
    {"id":"8786","name":"Public Statement on the use of herbal medicinal products containing methyleugenol","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-23T01:00:00Z","last_updated_date":"2005-11-23T01:00:00Z","reference_number":"EMEA/HMPC/138363/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-use-herbal-medicinal-products-containing-methyleugenol_en.pdf"},
    {"id":"8789","name":"Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-01-15T02:00:00Z","last_updated_date":"2012-01-15T02:00:00Z","reference_number":"CPMP/EWP/558/95 rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-2_en.pdf"},
    {"id":"8792","name":"Draft guideline on lipid lowering agents - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-11-18 - 2011-05-31","first_published_date":"2010-12-21T02:00:00Z","last_updated_date":"2010-12-21T02:00:00Z","reference_number":"EMA/CPMP/3020/2003","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-lipid-lowering-agents-revision-1_en.pdf"},
    {"id":"8818","name":"Public Statement on the use of herbal medicinal products containing pulegone and menthofuran - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-23T01:00:00Z","last_updated_date":"2005-11-23T01:00:00Z","reference_number":"EMEA/HMPC/138386/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-use-herbal-medicinal-products-containing-pulegone-and-menthofuran-first-version_en.pdf"},
    {"id":"8843","name":"Points to consider on missing data","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-11-15T01:00:00Z","last_updated_date":"2001-11-15T01:00:00Z","reference_number":"CPMP/EWP/1776/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-missing-data_en.pdf"},
    {"id":"8866","name":"Guideline for the conduct of efficacy studies for non-steroidal anti-inflammatory drugs","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T14:25:00Z","last_updated_date":"2014-01-24T14:25:00Z","reference_number":"EMA/CVMP/EWP/1061/2001","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-efficacy-studies-non-steroidal-anti-inflammatory-drugs_en.pdf"},
    {"id":"8885","name":"Reflection paper on clinical aspects related to tissue engineered products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-12-11T16:30:00Z","last_updated_date":"2014-12-11T16:30:00Z","reference_number":"EMA/CAT/573420/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-clinical-aspects-related-tissue-engineered-products_en.pdf"},
    {"id":"8912","name":"Reflection paper on the necessity of initiatives to stimulate the conduct of clinical studies with herbal medicinal products in the paediatric population","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-02-28T10:30:00Z","last_updated_date":"2012-02-28T10:30:00Z","reference_number":"EMA/HMPC/833398/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-necessity-initiatives-stimulate-conduct-clinical-studies-herbal-medicinal-products-paediatric-population_en.pdf"},
    {"id":"8913","name":"Concept paper on the need for the guidance on the clinical investigation of medicinal products to slow progression of renal insufficiency","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-07-22 - 2011-01-01","first_published_date":"2010-09-20T04:00:00Z","last_updated_date":"2010-09-20T04:00:00Z","reference_number":"EMA/CHMP/EWP/6054/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guidance-clinical-investigation-medicinal-products-slow-progression-renal-insufficiency_en.pdf"},
    {"id":"8915","name":"ICH: Q 4 B Annex 4B: To note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on microbiological examination of non-sterile products: Tests for specified micro-organisms - General chap...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-06-01T02:00:00Z","last_updated_date":"2008-06-01T02:00:00Z","reference_number":"EMEA/CHMP/ICH/308817/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-4b-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-microbiological-examination-non-sterile-products-tests-specified-micro-organisms-general-chap_en.pdf"},
    {"id":"8926","name":"Draft guideline on multiplicity issues in clinical trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-04-01 - 2017-06-30","first_published_date":"2017-03-31T21:40:00Z","last_updated_date":"2017-03-31T21:40:00Z","reference_number":"EMA/CHMP/44762/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-multiplicity-issues-clinical-trials_en.pdf"},
    {"id":"8940","name":"Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/CHMP/GTWP/125459/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-studies-required-first-clinical-use-gene-therapy-medicinal-products_en.pdf"},
    {"id":"8944","name":"Concept paper on the development of a Committee for Proprietary Medicinal Products (CPMP) guideline on comparability of biotechnology-derived products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"1998-06-24T02:00:00Z","last_updated_date":"1998-06-24T02:00:00Z","reference_number":"CPMP/BWP/113/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-proprietary-medicinal-products-cpmp-guideline-comparability-biotechnology-derived-products_en.pdf"},
    {"id":"8949","name":"Draft guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-06-23T02:00:00Z","last_updated_date":"2005-06-23T02:00:00Z","reference_number":"CPMP/EWP/422/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-juvenile-idiopathic-arthritis-first-version_en.pdf"},
    {"id":"8955","name":"Concept paper for the revision of the CVMP guideline on the conduct of bioequivalence studies for veterinary medicinal products - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-04-29 - 2016-07-31","first_published_date":"2016-04-29T18:25:00Z","last_updated_date":"2016-04-29T18:25:00Z","reference_number":"EMA/CVMP/EWP/707453/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-cvmp-guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-revision-3_en.pdf"},
    {"id":"8973","name":"Superseding version - Draft revised recommendation for the basic surveillance of Eudravigilance Veterinary (EVVet) data for centrally authorised products (CAPs)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-02-24 - 2017-08-31","first_published_date":"2017-02-24T18:00:00Z","last_updated_date":"2017-02-24T18:00:00Z","reference_number":"EMA/CVMP/PhVWP/171122/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/superseding-version-draft-revised-recommendation-basic-surveillance-eudravigilance-veterinary-evvet-data-centrally-authorised-products-caps_en.pdf"},
    {"id":"8981","name":"Guideline on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Step 4","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-09-24T12:40:00Z","last_updated_date":"2014-09-24T12:40:00Z","reference_number":"EMA/CHMP/ICH/83812/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-step-4_en.pdf"},
    {"id":"8984","name":"Draft guideline on core summary of product characteristics for human normal immunoglobulin for intravenous administration (IVIg) - Rev.5","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-01-01 - 2017-03-31","first_published_date":"2016-12-22T12:30:00Z","last_updated_date":"2016-12-22T12:30:00Z","reference_number":"EMA/CHMP/BPWP/94038/2007 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-human-normal-immunoglobulin-intravenous-administration-ivig-rev5_en.pdf"},
    {"id":"8997","name":"Guideline on procedures for competent authorities for pharmacovigilance information for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-04-15T02:00:00Z","last_updated_date":"2004-04-15T02:00:00Z","reference_number":"EMEA/CVMP/345/98-Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-procedures-competent-authorities-pharmacovigilance-information-veterinary-medicinal-products_en.pdf"},
    {"id":"9029","name":"Guideline on good pharmacovigilance practices: Module VII – Periodic safety update report with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-12-12T11:00:00Z","last_updated_date":"2013-12-12T11:00:00Z","reference_number":"EMA/816292/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-vii-periodic-safety-update-report-tracked-changes_en.pdf"},
    {"id":"9037","name":"CHMP Safety Working Party’s response to the PDCO regarding aluminium hydroxide contained in allergen products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-07-12T02:00:00Z","last_updated_date":"2011-07-12T02:00:00Z","reference_number":"EMA/CHMP/381064/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chmp-safety-working-partys-response-pdco-regarding-aluminium-hydroxide-contained-allergen-products_en.pdf"},
    {"id":"9049","name":"Draft guideline on core summary of product characteristics and package leaflet for fludeoxyglucose (18F)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-09-12 - 2011-12-31","first_published_date":"2011-10-03T13:38:00Z","last_updated_date":"2011-10-03T13:38:00Z","reference_number":"EMA/547466/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-and-package-leaflet-fludeoxyglucose-18f_en.pdf"},
    {"id":"9065","name":"VICH GL 45 quality: bracketing and matrixing designs for stability testing of new veterinary drug substances and medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-05-28T02:00:00Z","last_updated_date":"2010-05-28T02:00:00Z","reference_number":"EMA/CVMP/VICH/581467/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl-45-quality-bracketing-and-matrixing-designs-stability-testing-new-veterinary-drug-substances-and-medicinal-products_en.pdf"}    {"id":"9076","name":"Note for guidance: Additional quality requirements for products intended for incorporation into animal feeding-stuffs (medicated pre-mixes)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-12-01T01:00:00Z","last_updated_date":"1996-12-01T01:00:00Z","reference_number":"EMEA/CVMP/080/95-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-additional-quality-requirements-products-intended-incorporation-animal-feeding-stuffs-medicated-pre-mixes_en.pdf"},
    {"id":"9117","name":"Draft dolutegravir film-coated tablets 10 mg, 25 mg and 50 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-07-28 - 2017-10-31","first_published_date":"2017-07-28T14:00:00Z","last_updated_date":"2017-07-28T14:00:00Z","reference_number":"EMA/CHMP/356874/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-dolutegravir-film-coated-tablets-10-mg-25-mg-and-50-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"9119","name":"Draft guideline for the testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestation in dogs and cats - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-03-20 - 2015-09-30","first_published_date":"2015-03-20T17:00:00Z","last_updated_date":"2015-03-20T17:00:00Z","reference_number":"EMEA/CVMP/EWP/005/2000 - Rev.3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-testing-and-evaluation-efficacy-antiparasitic-substances-treatment-and-prevention-tick-and-flea-infestation-dogs-and-cats-revision-3_en.pdf"},
    {"id":"9139","name":"Reflection paper on methodological issues associated with pharmacogenomic biomarkers in relation to clinical development and patient selection","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-06-09 - 2011-11-25","first_published_date":"2011-07-12T05:00:00Z","last_updated_date":"2011-07-12T05:00:00Z","reference_number":"EMA/446337/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-methodological-issues-associated-pharmacogenomic-biomarkers-relation-clinical-development-and-patient-selection_en.pdf"},
    {"id":"9141","name":"Paediatric addendum on the CHMP guideline on clinical investigation of medicinal products for the treatment of acute heart failure","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-11-18T01:00:00Z","last_updated_date":"2016-11-18T01:00:00Z","reference_number":"EMA/CHMP/707532/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paediatric-addendum-chmp-guideline-clinical-investigation-medicinal-products-treatment-acute-heart-failure_en.pdf"},
    {"id":"9156","name":"Concept paper on the need for revision of the points to consider on the clinical investigation of new medicinal products for the treatment of acute coronary syndrome - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-10-15 - 2015-01-15","first_published_date":"2014-10-15T20:49:00Z","last_updated_date":"2014-10-15T20:49:00Z","reference_number":"EMA/CHMP/559636/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-points-consider-clinical-investigation-new-medicinal-products-treatment-acute-coronary-syndrome-first-version_en.pdf"},
    {"id":"9176","name":"Ticagrelor film-coated tablets 90mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-11-01T17:39:13Z","reference_number":"EMA/CHMP/177281/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ticagrelor-film-coated-tablets-90mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"9193","name":"Guideline on good pharmacovigilance practices: Module VIII – Post-authorisation safety studies (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-06-25T04:00:00Z","last_updated_date":"2012-06-25T04:00:00Z","reference_number":"EMA/813938/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-viii-post-authorisation-safety-studies-superseded_en.pdf"},
    {"id":"9232","name":"Draft reflection paper on level of purification of extracts to be considered as herbal preparations","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-11-06T01:00:00Z","last_updated_date":"2008-11-06T01:00:00Z","reference_number":"EMEA/HMPC/186645/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-level-purification-extracts-be-considered-herbal-preparations_en.pdf"},
    {"id":"9235","name":"Draft guideline on data requirements to support in-use stability claims for veterinary vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-03-16T01:00:00Z","last_updated_date":"2009-03-16T01:00:00Z","reference_number":"EMEA/CVMP/IWP/250147/2008-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-support-use-stability-claims-veterinary-vaccines_en.pdf"},
    {"id":"9247","name":"Note for guidance: DNA vaccines non-amplifiable in eukaryotic cells for veterinary use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-03-01T01:00:00Z","last_updated_date":"2000-03-01T01:00:00Z","reference_number":"CVMP/IWP/07/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-dna-vaccines-non-amplifiable-eukaryotic-cells-veterinary-use_en.pdf"},
    {"id":"9308","name":"Draft guideline on Guideline on core summary of product characteristics (SmPC) and package leaflet for iopamidol 370","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-04-26 - 2017-08-31","first_published_date":"2017-04-26T19:30:00Z","last_updated_date":"2017-04-26T19:30:00Z","reference_number":"EMA/CHMP/813144/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-guideline-core-summary-product-characteristics-smpc-and-package-leaflet-iopamidol-370_en.pdf"},
    {"id":"9324","name":"Concept paper on higher tier testing of antiparasitics to dung organisms","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-09-23T02:00:00Z","last_updated_date":"2009-09-23T02:00:00Z","reference_number":"EMEA/CVMP/ERA/12254/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-higher-tier-testing-antiparasitics-dung-organisms_en.pdf"},
    {"id":"9329","name":"Guideline on similar biological medicinal products (Rev.1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-10-29T15:30:00Z","last_updated_date":"2014-10-29T15:30:00Z","reference_number":"CHMP/437/04 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf"},
    {"id":"9344","name":"Guideline on clinical evaluation of new vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-10-18T02:00:00Z","last_updated_date":"2006-10-18T02:00:00Z","reference_number":"EMEA/CHMP/VWP/164653/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-new-vaccines_en.pdf"},
    {"id":"9390","name":"Concept paper on revision of core SPC for human plasma fibrinogen products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-12-15T01:00:00Z","last_updated_date":"2005-12-15T01:00:00Z","reference_number":"EMEA/CHMP/BPWP/371017/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-core-spc-human-plasma-fibrinogen-products_en.pdf"},
    {"id":"9423","name":"ICH: E 8: General considerations for clinical trials - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-03-01T01:00:00Z","last_updated_date":"2022-12-02T14:15:00Z","reference_number":"EMA/CHMP/ICH/544570/1998 Corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-8-general-considerations-clinical-trials-step-5_en.pdf"},
    {"id":"9441","name":"Concept paper on the revision of the guideline on user safety for pharmaceutical veterinary medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-04-21T02:00:00Z","last_updated_date":"2008-04-21T02:00:00Z","reference_number":"EMEA/CVMP/SWP/173804/2008-CONS","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-user-safety-pharmaceutical-veterinary-medicinal-products_en.pdf"},
    {"id":"9481","name":"Draft guideline on the clinical investigation of hepatitis-B immunoglobulins","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-12-03 - 2013-06-03","first_published_date":"2012-12-03T11:24:00Z","last_updated_date":"2012-12-03T11:24:00Z","reference_number":"EMA/CHMP/BPWP/585257/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-hepatitis-b-immunoglobulins_en.pdf"},
    {"id":"9484","name":"Draft vismodegib hard capsule 150 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-01-31 - 2018-04-30","first_published_date":"2018-01-31T14:15:00Z","last_updated_date":"2018-01-31T14:15:00Z","reference_number":"EMA/CHMP/800794/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vismodegib-hard-capsule-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"9495","name":"Note for guidance on non-clinical local tolerance testing of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-03-01T01:00:00Z","last_updated_date":"2001-03-01T01:00:00Z","reference_number":"CPMP/SWP/2145/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-non-clinical-local-tolerance-testing-medicinal-products_en.pdf"},
    {"id":"9500","name":"Reflection paper on risk based quality management in clinical trials - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/269011/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-based-quality-management-clinical-trials-superseded_en.pdf"},
    {"id":"9513","name":"Reflection paper on the use of pharmacogenetics in the pharmacokinetic evaluation of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-05-25T02:00:00Z","last_updated_date":"2007-05-25T02:00:00Z","reference_number":"EMEA/128517/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-pharmacogenetics-pharmacokinetic-evaluation-medicinal-products_en.pdf"},
    {"id":"9555","name":"Ibuprofen oral use immediate release formulations 200 - 800 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-06-26T16:00:00Z","last_updated_date":"2018-06-26T16:00:00Z","reference_number":"EMA/CHMP/356876/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ibuprofen-oral-use-immediate-release-formulations-200-800-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"9570","name":"ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2013-02-11T12:00:00Z","reference_number":"CPMP/ICH/286/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m3r2-non-clinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorisation-pharmaceuticals-step-5_en.pdf"},
    {"id":"9594","name":"Draft 2 guideline on the quality of biological active substances produced by stable transgene expression in higher plants","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-07-19T02:00:00Z","last_updated_date":"2006-07-19T02:00:00Z","reference_number":"EMEA/CHMP/BWP/48316/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-2-guideline-quality-biological-active-substances-produced-stable-transgene-expression-higher-plants_en.pdf"},
    {"id":"9603","name":"Questions and answers on mentioning solvents in the product information of veterinary medicinal products authorised via the centralised procedure","type":"scientific-guideline","status":"Adopted","consultation_date":"2015-12-18 - 2016-03-31","first_published_date":"2015-12-18T11:00:01Z","last_updated_date":"2016-07-25T18:50:00Z","reference_number":"EMA/CVMP/550607/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-mentioning-solvents-product-information-veterinary-medicinal-products-authorised-centralised-procedure_en.pdf"},
    {"id":"9606","name":"Superseded annex to note for guidance on development pharmaceutics: Decision trees for the selection of sterilisation methods","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-04-05T02:00:00Z","last_updated_date":"2000-04-05T02:00:00Z","reference_number":"CPMP/QWP/054/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/superseded-annex-note-guidance-development-pharmaceutics-decision-trees-selection-sterilisation-methods_en.pdf"},
    {"id":"9607","name":"Guideline on good pharmacovigilance practices: Annex I - Definitions (Rev. 4)  (superseded)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T02:00:00Z","last_updated_date":"2017-10-12T12:00:00Z","reference_number":"EMA/876333/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4-superseded_en.pdf"},
    {"id":"9662","name":"Reflection paper on management of clinical risks deriving from insertional mutagenesis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-08-01T16:20:00Z","last_updated_date":"2013-08-01T16:20:00Z","reference_number":"EMA/CAT/190186/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-management-clinical-risks-deriving-insertional-mutagenesis_en.pdf"},
    {"id":"9682","name":"Draft International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q3D (R1) on elemental impurities - Step 2b - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-05-16 - 2018-08-16","first_published_date":"2018-05-16T15:39:00Z","last_updated_date":"2018-05-16T15:39:00Z","reference_number":"EMA/CHMP/ICH/353369/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q3d-r1-elemental-impurities-step-2b-revision-1_en.pdf"},
    {"id":"9720","name":"Note for guidance on the quality, preclinical and clinical aspects of gene transfer of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-04-24T02:00:00Z","last_updated_date":"2001-04-24T02:00:00Z","reference_number":"CPMP/BWP/3088/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-quality-preclinical-and-clinical-aspects-gene-transfer-medicinal-products_en.pdf"},
    {"id":"9763","name":"VICH Topic GL48: at step 4: Guideline on studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: Marker residue depletion studies to establish product withdrawal periods","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-12-10 - 2010-05-20","first_published_date":"2009-12-22T02:00:00Z","last_updated_date":"2010-05-10T04:00:00Z","reference_number":"EMEA/CVMP/VICH/463199/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-topic-gl48-step-4-guideline-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-animals-marker-residue-depletion-studies-establish-product-withdrawal-periods_en.pdf"},
    {"id":"9785","name":"Draft guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process. Non-clinical and clinical issues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/101695/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-comparability-biotechnology-derived-medicinal-products-after-change-manufacturing-process-non-clinical-and-clinical-issues_en.pdf"},
    {"id":"9794","name":"Concept paper on good manufacturing practice and marketing authorisation holders","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-10-01 - 2016-12-31","first_published_date":"2016-10-04T04:00:00Z","last_updated_date":"2016-10-20T21:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-good-manufacturing-practice-marketing-authorisation-holders_en.pdf"},
    {"id":"9863","name":"Guideline on specific efficacy requirements for ectoparasiticides in cattle","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-23T02:00:00Z","last_updated_date":"2004-07-23T02:00:00Z","reference_number":"EMEA/CVMP/625/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-specific-efficacy-requirements-ectoparasiticides-cattle_en.pdf"},
    {"id":"9881","name":"Note for guidance on the investigation of drug interactions","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-12-17T01:00:00Z","last_updated_date":"1997-12-17T01:00:00Z","reference_number":"CPMP/EWP/560/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-investigation-drug-interactions_en.pdf"},
    {"id":"9889","name":"Draft guideline on the investigation of subgroups in confirmatory clinical trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-02-03 - 2014-07-31","first_published_date":"2014-02-03T17:10:00Z","last_updated_date":"2014-02-03T17:10:00Z","reference_number":"EMA/CHMP/539146/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-investigation-subgroups-confirmatory-clinical-trials_en.pdf"},
    {"id":"9905","name":"Draft guideline on the use of near infrared spectroscopy by the pharmaceutical industry and the data requirements for new submissions and variations - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-02-16T01:00:00Z","last_updated_date":"2009-02-16T01:00:00Z","reference_number":"EMEA/CHMP/CVMP/QWP/17760/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-use-near-infrared-spectroscopy-pharmaceutical-industry-and-data-requirements-new-submissions-and-variations-revision-1_en.pdf"},
    {"id":"9911","name":"Draft guideline on the clinical investigation of recombinant and human plasma-derived factor IX products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/BPWP/144552/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-ix-products_en.pdf"},
    {"id":"9921","name":"Guideline on demonstration of target animal safety and efficacy of veterinary medicinal products intended for use in farmed finfish","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-05-17T02:00:00Z","last_updated_date":"2011-05-17T02:00:00Z","reference_number":"EMA/CVMP/EWP/459868/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-demonstration-target-animal-safety-and-efficacy-veterinary-medicinal-products-intended-use-farmed-finfish_en.pdf"},
    {"id":"9998","name":"Guideline on good pharmacovigilance practices: Module VI – Management and reporting of adverse reactions to medicinal products (Rev. 1) (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T02:00:00Z","last_updated_date":"2012-06-25T02:00:00Z","reference_number":"EMA/873138/2011 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-vi-management-and-reporting-adverse-reactions-medicinal-products-rev-1-superseded_en.pdf"},
    {"id":"9999","name":"Draft guideline on the quality aspects of single-dose veterinary spot-on products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-12-20T01:00:00Z","last_updated_date":"2007-12-20T01:00:00Z","reference_number":"EMEA/CVMP/QWP/544461/2007-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-aspects-single-dose-veterinary-spot-products_en.pdf"},
    {"id":"10142","name":"Concept paper on the development of a guideline on quality and equivalence of topical products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-22 - 2015-07-22","first_published_date":"2015-04-22T15:00:00Z","last_updated_date":"2015-04-22T15:00:00Z","reference_number":"EMA/CHMP/QWP/558185/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-quality-and-equivalence-topical-products_en.pdf"},
    {"id":"10145","name":"Guideline on the Core SPC for human normal immunoglobulin for subcutaneous and intramuscular use (CPMP/BPWG/282/00)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-07-25T02:00:00Z","last_updated_date":"2002-07-25T02:00:00Z","reference_number":"CPMP/BPWG/282/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-normal-immunoglobulin-subcutaneous-and-intramuscular-use-cpmpbpwg28200_en.pdf"},
    {"id":"10160","name":"Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-28 - 2016-10-31","first_published_date":"2016-07-28T18:45:00Z","last_updated_date":"2018-02-07T16:45:00Z","reference_number":"EMA/317855/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus_en.pdf"},
    {"id":"10186","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q9 on quality risk management - Step 5 - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-01-19T01:00:00Z","last_updated_date":"2014-05-28T17:30:00Z","reference_number":"EMA/CHMP/ICH/24235/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q9-quality-risk-management-step-5-first-version_en.pdf"},
    {"id":"10215","name":"ICH S9 guideline on nonclinical evaluation for anticancer 4 pharmaceuticals - questions and answers - Step 2b","type":"scientific-guideline","status":"unknown","consultation_date":"2016-07-28 - 2017-01-28","first_published_date":"2016-07-28T19:35:00Z","last_updated_date":"2016-09-22T19:35:00Z","reference_number":"EMA/CHMP/ICH/453684/2016 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s9-guideline-nonclinical-evaluation-anticancer-4-pharmaceuticals-questions-and-answers-step-2b_en.pdf"},
    {"id":"10280","name":"Note for guidance on the quality of modified release dosage forms for veterinary use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-07-01T02:00:00Z","last_updated_date":"2003-07-01T02:00:00Z","reference_number":"EMEA/CVMP/680/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-quality-modified-release-dosage-forms-veterinary-use_en.pdf"},
    {"id":"10301","name":"Draft guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-02-01 - 2018-05-01","first_published_date":"2018-02-01T16:00:00Z","last_updated_date":"2018-02-01T16:00:00Z","reference_number":"EMEA/149995/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-safety-and-efficacy-follow-and-risk-management-advanced-therapy-medicinal-products-revision-1_en.pdf"},
    {"id":"10314","name":"Guideline on clinical trials with haemopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-03-22T00:09:21Z","last_updated_date":"2007-03-22T00:09:21Z","reference_number":"EMEA/CPMP/555/95 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-trials-haemopoietic-growth-factors-prophylaxis-infection-following-myelosuppressive-or-myeloablative-therapy_en.pdf"},
    {"id":"10352","name":"Excipients in the dossier for application for marketing authorisation of a medicinal product","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-02-01T01:00:00Z","last_updated_date":"2004-02-01T01:00:00Z","reference_number":"3AQ9A","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/excipients-dossier-application-marketing-authorisation-medicinal-product_en.pdf"},
    {"id":"10381","name":"Draft note for guidance on guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products amendments to sections 6.2 and 6.3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2004-06-23T02:00:00Z","last_updated_date":"2004-06-23T02:00:00Z","reference_number":"EMEA/410/01/rev.3 draft","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-guidance-minimising-risk-transmitting-animal-spongiform-encephalopathy-agents-human-and-veterinary-medicinal-products-amendments-sections-62-and-63_en.pdf"},
    {"id":"10399","name":"VICH GL10: Impurities in new veterinary drug substances - Step 7 (after revision at step 9)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-02-19T01:00:00Z","last_updated_date":"2007-02-19T01:00:00Z","reference_number":"EMEA/CVMP/VICH/837/99-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl10-impurities-new-veterinary-drug-substances-step-7-after-revision-step-9_en.pdf"},
    {"id":"10418","name":"Concept paper on the need for revision of the guideline on the clinical development of medicinal products for the treatment of cystic fibrosis (CHMP/EWP/9147/2008) - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-01 - 2016-10-31","first_published_date":"2016-08-01T18:30:00Z","last_updated_date":"2016-08-01T18:30:00Z","reference_number":"EMA/CHMP/259918/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-development-medicinal-products-treatment-cystic-fibrosis-chmp-ewp-9147-2008-revision-1_en.pdf"},
    {"id":"10438","name":"Appendix to the note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia - Methodology of clinical trials concerning the development of depot preparations of approved medici...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-02-20T01:00:00Z","last_updated_date":"2003-02-20T01:00:00Z","reference_number":"CPMP/EWP/49/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-note-guidance-clinical-investigation-medicinal-products-treatment-schizophrenia-methodology-clinical-trials-concerning-development-depot-preparations-approved-medici_en.pdf"},
    {"id":"10506","name":"Draft sitagliptin film-coated tablets 25, 50 and 100 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-15 - 2015-11-01","first_published_date":"2015-07-15T14:00:02Z","last_updated_date":"2015-07-15T14:00:02Z","reference_number":"EMA/CHMP/PKWP/36869/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-sitagliptin-film-coated-tablets-25-50-and-100-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"10517","name":"Concept paper on the development of a committee for proprietary medicinal products (CPMP) note for guidance on requirements for the evaluation of new adjuvants in vaccines","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2002-04-25T02:00:00Z","last_updated_date":"2002-04-25T02:00:00Z","reference_number":"CPMP/BWP/6622/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-proprietary-medicinal-products-cpmp-note-guidance-requirements-evaluation-new-adjuvants-vaccines_en.pdf"},
    {"id":"10540","name":"Draft guideline on clinical evaluation of diagnostic agents - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-06-26T02:00:00Z","last_updated_date":"2008-06-26T02:00:00Z","reference_number":"CPMP/EWP/1119/98/Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-diagnostic-agents-revision-1_en.pdf"},
    {"id":"10550","name":"Principles on assignment of defined daily dose for animals and defined course dose for animals - draft","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-03-16 - 2015-05-12","first_published_date":"2015-03-16T14:10:00Z","last_updated_date":"2015-03-16T14:10:00Z","reference_number":"EMA/710019/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/principles-assignment-defined-daily-dose-animals-and-defined-course-dose-animals-draft_en.pdf"},
    {"id":"10563","name":"Note for guidance for the determination of withdrawal periods for milk","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-03-01T01:00:00Z","last_updated_date":"2000-03-01T01:00:00Z","reference_number":"EMEA/CVMP/473/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-determination-withdrawal-periods-milk_en.pdf"},
    {"id":"10641","name":"Guideline on core summary of product characteristics (SmPC)for human fibrinogen products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T10:35:00Z","last_updated_date":"2015-07-24T10:35:00Z","reference_number":"EMA/CHMP/BPWP/691754/2013 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-summary-product-characteristics-smpcfor-human-fibrinogen-products_en.pdf"},
    {"id":"10664","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) M8 electronic common technical document - questions and answers: Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2014-09-24T12:40:00Z","reference_number":"EMA/CHMP/ICH/820/2003","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-m8-electronic-common-technical-document-questions-and-answers-step-5_en.pdf"},
    {"id":"10672","name":"Note for guidance on development pharmaceutics","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-01-28T01:00:00Z","last_updated_date":"1998-01-28T01:00:00Z","reference_number":"CPMP/QWP/155/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-development-pharmaceutics_en.pdf"},
    {"id":"10740","name":"Guideline on the plant testing strategy for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-24T10:00:00Z","last_updated_date":"2026-03-20T14:26:00Z","reference_number":"EMA/CVMP/ERA/689041/2015 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-plant-testing-strategy-veterinary-medicinal-products_en.pdf"},
    {"id":"10754","name":"Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-09-25T14:10:00Z","last_updated_date":"2014-09-25T14:10:00Z","reference_number":"CPMP/EWP/785/97 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-treatment-irritable-bowel-syndrome-revision-1_en.pdf"},
    {"id":"10781","name":"Environmental risk assessment for Human\n\nMedicinal products containing or consisting of GMOS","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-12-04T00:09:21Z","last_updated_date":"1998-12-04T00:09:21Z","reference_number":"3BR1a","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/environmental-risk-assessment-human-medicinal-products-containing-or-consisting-gmos_en.pdf"},
    {"id":"10819","name":"Draft ticagrelor film-coated tablets 90mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-10-01 - 2016-01-01","first_published_date":"2015-10-06T17:00:00Z","last_updated_date":"2015-10-06T17:00:00Z","reference_number":"EMA/CHMP/PKWP/151478/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ticagrelor-film-coated-tablets-90mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"10833","name":"Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-03-11T16:20:00Z","last_updated_date":"2015-03-11T16:20:00Z","reference_number":"EMEA/CHMP/BMWP/32775/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-human-insulin-and-insulin-analogues-revision-1_en.pdf"},
    {"id":"10835","name":"Note for guidance for the determination of withdrawal periods for milk - Updated application software","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2002-05-15T02:00:00Z","last_updated_date":"2002-05-15T02:00:00Z","reference_number":"EMEA/CVMP/231/00/Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-determination-withdrawal-periods-milk-updated-application-software_en.pdf"},
    {"id":"10868","name":"ICH guideline Q4B Annex 4A on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on micro enumeration - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-06-01T02:00:00Z","last_updated_date":"2017-07-13T16:30:00Z","reference_number":"EMEA/CHMP/ICH/308671/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-4a-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-micro-enumeration-step-5_en.pdf"},
    {"id":"10892","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline E2B (R3): Electronic transmission of individual case safety reports (ICSRs) - data elements ...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-09-01T02:00:00Z","last_updated_date":"2013-08-27T13:55:00Z","reference_number":"CHMP/ICH/287/1995","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-guideline-e2b-r3-electronic-transmission-individual-case-safety-reports-icsrs-data-elements_en.pdf"},
    {"id":"10904","name":"Note for guidance on preclinical pharmacological and toxicological testing of vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-12-17T01:00:00Z","last_updated_date":"1997-12-17T01:00:00Z","reference_number":"CPMP/SWP/465/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-preclinical-pharmacological-and-toxicological-testing-vaccines_en.pdf"},
    {"id":"10929","name":"Draft guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances - Revision 1 (first version)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-05-29 - 2013-11-30","first_published_date":"2013-05-29T13:54:00Z","last_updated_date":"2013-05-29T13:54:00Z","reference_number":"EMA/CVMP/261180/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances-revision-1-first-version_en.pdf"},
    {"id":"10966","name":"Questions and answers on allogenic mesenchymal stem cell-based products for veterinary use: specific questions on tumorigenicity","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-11-21T01:00:00Z","last_updated_date":"2017-11-21T01:00:00Z","reference_number":"EMA/CVMP/ADVENT/791465/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-allogenic-mesenchymal-stem-cell-based-products-veterinary-use-specific-questions-tumorigenicity_en.pdf"},
    {"id":"10976","name":"Guideline on good pharmacovigilance practices: Module III – Pharmacovigilance inspections (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"2012-06-27 - 2012-08-24","first_published_date":"2012-12-13T18:00:00Z","last_updated_date":"2012-12-13T18:00:00Z","reference_number":"EMA/119871/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-iii-pharmacovigilance-inspections-superseded_en.pdf"},
    {"id":"10983","name":"Draft guideline on the development of new medicinal products for the treatment of ulcerative colitis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-11-16T01:00:00Z","last_updated_date":"2006-11-16T01:00:00Z","reference_number":"CHMP/EWP/18463/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-new-medicinal-products-treatment-ulcerative-colitis_en.pdf"},
    {"id":"10984","name":"Guideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species (MUMS)/limited market - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T12:30:00Z","last_updated_date":"2017-04-21T12:30:00Z","reference_number":"EMA/CVMP/IWP/123243/2006 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-immunological-veterinary-medicinal-products-intended-minor-use-or-minor-species-mumslimited-market-revision-3_en.pdf"},
    {"id":"10990","name":"Comparability of medicinal products containing biotechnology-derived proteins as active substance - quality issues (Superseded by ICH Q.5.E - CPMP/ICH/5721/03)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-12-11T01:00:00Z","last_updated_date":"2003-12-11T01:00:00Z","reference_number":"CPMP/BWP/3207/00 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/comparability-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality-issues-superseded-ich-q5e-cpmpich572103_en.pdf"},
    {"id":"11013","name":"Concept paper on the revision of annex 1 of the guidelines on good manufacturing practice – manufacture of sterile medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-02-05 - 2015-03-31","first_published_date":"2015-02-05T17:00:00Z","last_updated_date":"2015-02-05T17:00:00Z","reference_number":"EMA/INS/GMP/735037/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-annex-1-guidelines-good-manufacturing-practice-manufacture-sterile-medicinal-products_en.pdf"},
    {"id":"11079","name":"Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-11-24T11:10:00Z","last_updated_date":"2014-11-24T11:10:00Z","reference_number":"EMA/CHMP/CVMP/SWP/169430/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-setting-health-based-exposure-limits-use-risk-identification-manufacture-different-medicinal-products-shared-facilities_en.pdf"},
    {"id":"11105","name":"Specific requirements for the production and control of allergen products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-09-01T02:00:00Z","last_updated_date":"1994-09-01T02:00:00Z","reference_number":"7BIm11a Volume 7","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/specific-requirements-production-and-control-allergen-products_en.pdf"},
    {"id":"11135","name":"Concept paper on the development of a CHMP guideline on the clinical investigation of medicinal products for the treatment of pulmonary hypertension","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T01:00:00Z","last_updated_date":"2008-01-24T01:00:00Z","reference_number":"EMEA/CHMP/EWP/566954/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-chmp-guideline-clinical-investigation-medicinal-products-treatment-pulmonary-hypertension_en.pdf"},
    {"id":"11163","name":"Draft concept paper on the impact of liver immaturity when investigating medicinal products intended for neonatal use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-07-20T02:00:00Z","last_updated_date":"2005-07-20T02:00:00Z","reference_number":"EMEA/CHMP/PEG/194605/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-impact-liver-immaturity-when-investigating-medicinal-products-intended-neonatal-use_en.pdf"},
    {"id":"11175","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline E3: Questions and answers (R1)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-07-24T02:00:00Z","last_updated_date":"2012-07-24T02:00:00Z","reference_number":"EMA/CHMP/ICH/435606/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-e3-questions-and-answers-r1_en.pdf"},
    {"id":"11177","name":"Public report on risk and regulatory assessment of lactose and other products prepared using calf rennet","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-05-22T02:00:00Z","last_updated_date":"2002-05-22T02:00:00Z","reference_number":"EMEA/CPMP/BWP/337/02/Public","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-report-risk-and-regulatory-assessment-lactose-and-other-products-prepared-using-calf-rennet_en.pdf"},
    {"id":"11246","name":"Draft guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-01 - 2016-12-31","first_published_date":"2016-07-01T19:00:00Z","last_updated_date":"2016-07-01T19:00:00Z","reference_number":"EMA/CHMP/BWP/534898/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials-revision-1_en.pdf"},
    {"id":"11273","name":"Note for guidance on start of shelf-life of the finished dosage form\n\n(annex to note for guidance on the manufacture of the finished dosage form)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-05-31T02:00:00Z","last_updated_date":"2001-05-31T02:00:00Z","reference_number":"CPMP/QWP/072/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-start-shelf-life-finished-dosage-form-annex-note-guidance-manufacture-finished-dosage-form_en.pdf"},
    {"id":"11311","name":"Concept paper on use of recovered / recycled solvents in the manufacture of herbal preparations for use in herbal medicinal products / traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-02-15 - 2013-05-15","first_published_date":"2013-03-01T12:00:00Z","last_updated_date":"2013-03-01T12:00:00Z","reference_number":"EMA/HMPC/13658/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-use-recovered-recycled-solvents-manufacture-herbal-preparations-use-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"11328","name":"Draft VICH GL 18 residual solvents in new veterinary medicinal products, active substances and excipients  - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-05-20 - 2010-10-31","first_published_date":"2010-05-28T04:00:00Z","last_updated_date":"2010-05-28T04:00:00Z","reference_number":"EMA/CVMP/VICH/502/1999-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl-18-residual-solvents-new-veterinary-medicinal-products-active-substances-and-excipients-revision-1_en.pdf"},
    {"id":"11380","name":"Compilation of individual product-specific guidance on demonstration of bioequivalence (Revision 3)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-04-07T18:00:00Z","last_updated_date":"2016-04-07T18:00:00Z","reference_number":"EMA/CHMP/736403/2014 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/compilation-individual-product-specific-guidance-demonstration-bioequivalence-revision-3_en.pdf"},
    {"id":"11434","name":"Draft guideline on the acceptability of names for veterinary medicinal products processed through the centralised procedure","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-06-18T02:00:00Z","last_updated_date":"2007-06-18T02:00:00Z","reference_number":"CVMP/328/98-Revision 3-CONS","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-acceptability-names-veterinary-medicinal-products-processed-through-centralised-procedure_en.pdf"},
    {"id":"11462","name":"Guideline on statistical principles for clinical trials for veterinary medicinal products (pharmaceuticals)","type":"scientific-guideline","status":"Adopted","consultation_date":"2012-01-10 - 2012-07-31","first_published_date":"2012-01-23T11:44:00Z","last_updated_date":"2012-01-23T11:44:00Z","reference_number":"EMA/CVMP/EWP/81976/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-statistical-principles-clinical-trials-veterinary-medicinal-products-pharmaceuticals_en.pdf"},
    {"id":"11485","name":"Concept paper on the need for revision of the note of guidance on manufacture of the finished dosage form","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-17 - 2015-10-17","first_published_date":"2015-07-17T18:38:00Z","last_updated_date":"2015-07-17T18:38:00Z","reference_number":"EMA/CVMP/QWP/360463/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-manufacture-finished-dosage-form_en.pdf"},
    {"id":"11493","name":"Draft note for guidance on antiarrhytmics addendum on atrial fibrillation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/352438/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-antiarrhytmics-addendum-atrial-fibrillation_en.pdf"},
    {"id":"11541","name":"Guideline on the evaluation of control samples in nonclinical safety studies:  checking for contamination with the test substance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-03-17T01:00:00Z","last_updated_date":"2005-03-17T01:00:00Z","reference_number":"CPMP/SWP/1094/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-control-samples-nonclinical-safety-studies-checking-contamination-test-substance_en.pdf"},
    {"id":"11574","name":"Guideline on good pharmacovigilance practices: Module III – Pharmacovigilance inspections with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-12-13T17:00:00Z","last_updated_date":"2012-12-13T17:00:00Z","reference_number":"EMA/119871/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-iii-pharmacovigilance-inspections-tracked-changes_en.pdf"},
    {"id":"11582","name":"Draft guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-02-07 - 2018-08-15","first_published_date":"2018-02-07T13:30:00Z","last_updated_date":"2018-02-07T13:30:00Z","reference_number":"CPMP/EWP/1080/00 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus-revision-2_en.pdf"},
    {"id":"11586","name":"Draft guideline on clinical investigation of medicinal products other than non-steroidal anti-inflammatory drugs for treatment of rheumatoid arthritis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-12-05 - 2012-06-05","first_published_date":"2011-12-20T13:45:00Z","last_updated_date":"2011-12-20T13:45:00Z","reference_number":"CPMP/EWP/556/95 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-other-non-steroidal-anti-inflammatory-drugs-treatment-rheumatoid-arthritis_en.pdf"},
    {"id":"11587","name":"Questions and answers: improving the understanding of normal operating range (NOR), proven acceptable range (PAR), design space (DSp) and normal variability of process parameters","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-07-13T17:35:00Z","last_updated_date":"2017-07-13T17:35:00Z","reference_number":"EMA/CHMP/CVMP/QWP/354895/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-improving-understanding-normal-operating-range-nor-proven-acceptable-range-par-design-space-dsp-and-normal-variability-process-parameters_en.pdf"}    {"id":"11589","name":"Annex B - Clinical Development of Medicinal Products for Treatment of HIV Infection","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-02-22T01:00:00Z","last_updated_date":"2007-02-22T01:00:00Z","reference_number":"EMEA/CHMP/EWP/42065/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-b-clinical-development-medicinal-products-treatment-hiv-infection_en.pdf"},
    {"id":"11610","name":"Guideline on requirements for the production and control of immunological veterinary medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-12-19T13:00:00Z","last_updated_date":"2016-12-19T13:00:00Z","reference_number":"EMA/CVMP/IWP/206555/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-production-and-control-immunological-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"11624","name":"Guideline on anticoccidials used for the therapy of coccidiosis in chickens, turkey and geese","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1992-11-01T01:00:00Z","last_updated_date":"1992-11-01T01:00:00Z","reference_number":"7AE15a Volume 7","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-anticoccidials-used-therapy-coccidiosis-chickens-turkey-geese_en.pdf"},
    {"id":"11632","name":"Draft guideline on plasma-derived medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"CPMP/BWP/269/95 rev. 4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-plasma-derived-medicinal-products_en.pdf"},
    {"id":"11666","name":"Draft questions and answers on bovine spongiform encephalopathies (BSE) and vaccines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-02-01 - 2018-07-31","first_published_date":"2018-02-01T11:20:00Z","last_updated_date":"2018-02-01T11:20:00Z","reference_number":"EMA/CHMP/BWP/192228/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-and-answers-bovine-spongiform-encephalopathies-bse-and-vaccines-revision-1_en.pdf"},
    {"id":"11673","name":"Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-11-16T01:00:00Z","last_updated_date":"2006-11-16T01:00:00Z","reference_number":"CPMP/EWP/561/98 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis-revision-1_en.pdf"},
    {"id":"11684","name":"Guideline on data elements for the electronic submission of adverse reaction reports related to veterinary medicinal products authorised in the european economic area (EEA) including message and transmission specificatio...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-02-01T01:00:00Z","last_updated_date":"2016-04-14T14:30:00Z","reference_number":"EMA/CVMP/65/2003 Version 2.2.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-elements-electronic-submission-adverse-reaction-reports-related-veterinary-medicinal-products-authorised-european-economic-area-eea-including-message-and-transmission-specificatio_en.pdf"},
    {"id":"11687","name":"Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-12-15 - 2015-06-30","first_published_date":"2014-12-15T18:00:00Z","last_updated_date":"2014-12-15T18:00:00Z","reference_number":"EMA/629967/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-minimal-residue-disease-endpoint-chronic-lymphocytic-leukaemia-studies_en.pdf"},
    {"id":"11690","name":"Concept paper on the revision of the guideline on epidemiological data on blood transmissible infections (EMEA/CPMP/BWP/125/04)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/CHMP/BWP/505885/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-epidemiological-data-blood-transmissible-infections-emeacpmpbwp12504_en.pdf"},
    {"id":"11707","name":"Points to consider on the manufacture and quality control of human somatic cell therapy medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-05-31T02:00:00Z","last_updated_date":"2001-05-31T02:00:00Z","reference_number":"CPMP/BWP/41450/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-manufacture-and-quality-control-human-somatic-cell-therapy-medicinal-products_en.pdf"},
    {"id":"11712","name":"Draft guideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species/limited markets - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-07-25T02:00:00Z","last_updated_date":"2008-07-25T02:00:00Z","reference_number":"EMEA/CVMP/IWP/123243/2006-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-immunological-veterinary-medicinal-products-intended-minor-use-or-minor-specieslimited-markets-revision-1_en.pdf"},
    {"id":"11723","name":"ICH: Q 4 B Annex 9: Tablet friability general chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-06-01T02:00:00Z","last_updated_date":"2009-06-01T02:00:00Z","reference_number":"EMEA/CHMP/ICH/379801/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-9-tablet-friability-general-chapter-step-3_en.pdf"},
    {"id":"11724","name":"Draft reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-09-15 - 2014-02-28","first_published_date":"2013-09-16T13:21:00Z","last_updated_date":"2013-09-16T13:21:00Z","reference_number":"EMA/CHMP/SWP/620008/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-data-requirements-intravenous-iron-based-nano-colloidal-products-developed-reference-innovator-medicinal-product_en.pdf"},
    {"id":"11769","name":"Public Statement on Capsicum / capsaicin containing herbal medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-23T01:00:00Z","last_updated_date":"2005-11-23T01:00:00Z","reference_number":"EMEA/HMPC/138379/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-capsicum-capsaicin-containing-herbal-medicinal-products_en.pdf"},
    {"id":"11776","name":"Guideline on efficacy and target animal safety data requirements for veterinary medicinal products intended for minor uses or minor species","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-02-01T01:00:00Z","last_updated_date":"2007-02-01T01:00:00Z","reference_number":"EMEA/CVMP/EWP/117899/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-efficacy-and-target-animal-safety-data-requirements-veterinary-medicinal-products-intended-minor-uses-or-minor-species_en.pdf"},
    {"id":"11779","name":"Draft guideline on clinical investigation of medicinal products other than non-steroidal anti-inflammatory drugs (NSAIDs) for treatment of rheumatoid arthritis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-06-04 - 2015-11-29","first_published_date":"2015-06-04T19:30:00Z","last_updated_date":"2015-06-04T19:30:00Z","reference_number":"CPMP/EWP/556/95 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-other-non-steroidal-anti-inflammatory-drugs-nsaids-treatment-rheumatoid-arthritis_en.pdf"},
    {"id":"11790","name":"Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation","type":"scientific-guideline","status":"Adopted","consultation_date":"2014-07-15 - 2014-10-15","first_published_date":"2014-07-16T19:10:00Z","last_updated_date":"2014-07-16T19:10:00Z","reference_number":"EMA/CHMP/341363/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-prevention-stroke-and-systemic-embolic-events-patients-non-valvular-atrial-fibrillation_en.pdf"},
    {"id":"11794","name":"Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for paediatric indications","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-01-24T01:00:00Z","last_updated_date":"2008-01-24T01:00:00Z","reference_number":"EMEA/CHMP/SWP/169215/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-need-non-clinical-testing-juvenile-animals-pharmaceuticals-paediatric-indications_en.pdf"},
    {"id":"11828","name":"Draft guideline on core summary of product characteristics for human normal immunoglobulin for subcutaneous and intramuscular administration","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-07-31 - 2013-01-31","first_published_date":"2012-07-31T15:50:00Z","last_updated_date":"2012-07-31T15:50:00Z","reference_number":"EMA/CHMP/BPWP/143744/2011 rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-human-normal-immunoglobulin-subcutaneous-intramuscular-administration_en.pdf"},
    {"id":"11841","name":"Guideline on virus safety evaluation of biotechnological investigational medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/BWP/398498/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-virus-safety-evaluation-biotechnological-investigational-medicinal-products_en.pdf"},
    {"id":"11878","name":"Note for guidance on clinical investigation of medicinal products in the treatment of hypertension","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-23T02:00:00Z","last_updated_date":"2004-06-23T02:00:00Z","reference_number":"CPMP/EWP/238/95 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-hypertension_en.pdf"},
    {"id":"11900","name":"Draft concept paper on the revision of the guidance on fixed combination medicinal products in the treatment of hypertension","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-10-18T02:00:00Z","last_updated_date":"2006-10-18T02:00:00Z","reference_number":"CHMP/EWP/426093/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-revision-guidance-fixed-combination-medicinal-products-treatment-hypertension_en.pdf"},
    {"id":"11912","name":"Note for guidance on repeated dose toxicity","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-07-27T02:00:00Z","last_updated_date":"2000-07-27T02:00:00Z","reference_number":"CPMP/SWP/1042/99 corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-repeated-dose-toxicity_en.pdf"},
    {"id":"11923","name":"Draft revised guideline on environmental impact assessment for veterinary medicinal products in support of the VICH guidelines GL6 and GL 38","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-06-23T02:00:00Z","last_updated_date":"2008-06-23T02:00:00Z","reference_number":"EMEA/CVMP/ERA/418282/2005-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-revised-guideline-environmental-impact-assessment-veterinary-medicinal-products-support-vich-guidelines-gl6-and-gl-38_en.pdf"},
    {"id":"11933","name":"Guideline on the evaluation of anticancer medicinal products in man - Revision 4","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-01-11T11:00:00Z","last_updated_date":"2013-01-11T11:00:00Z","reference_number":"EMA/CHMP/205/95 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-4_en.pdf"},
    {"id":"11940","name":"Reflection paper on testing strategy and risk assessment for plants","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-12-20T15:15:00Z","last_updated_date":"2011-12-20T15:15:00Z","reference_number":"EMA/CVMP/ERA/147844/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-testing-strategy-and-risk-assessment-plants_en.pdf"},
    {"id":"11956","name":"Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-03-31T15:00:00Z","last_updated_date":"2015-03-31T15:00:00Z","reference_number":"EMA/CHMP/771815/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis-revision-2_en.pdf"},
    {"id":"11960","name":"ICH guideline M4 (R4) on common technical document (CTD) for the registration of pharmaceuticals for human use - organisation of CTD - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-02-01T01:00:00Z","last_updated_date":"2021-03-19T01:00:00Z","reference_number":"CPMP/ICH/2887/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m4-r4-common-technical-document-ctd-registration-pharmaceuticals-human-use-organisation-ctd-step-5_en.pdf"},
    {"id":"11966","name":"Reflection paper on the extrapolation of results from clinical studies conducted outside the European Union (EU) to the EU population","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-11-13T00:09:21Z","last_updated_date":"2009-11-13T00:09:21Z","reference_number":"EMEA/CHMP/EWP/692702/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-extrapolation-results-clinical-studies-conducted-outside-european-union-eu-eu-population_en.pdf"},
    {"id":"11978","name":"VICH GL26: Biologicals: Testing of residual moisture - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-04-30T02:00:00Z","last_updated_date":"2002-04-30T02:00:00Z","reference_number":"CVMP/VICH/096/01-Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl26-biologicals-testing-residual-moisture-step-7_en.pdf"},
    {"id":"11980","name":"Concept paper on the need for a paediatric addendum to the guideline on clinical investigation of medicinal products for the treatment of acute heart failure","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-01-15 - 2013-04-15","first_published_date":"2013-01-16T12:00:00Z","last_updated_date":"2013-01-16T12:00:00Z","reference_number":"EMA/CHMP/778582/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-paediatric-addendum-guideline-clinical-investigation-medicinal-products-treatment-acute-heart-failure_en.pdf"},
    {"id":"11984","name":"Guideline on clinical investigation of medicinal products for the treatment of ankylosing spondylitis - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"CPMP/EWP/4891/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-ankylosing-spondylitis-first-version_en.pdf"},
    {"id":"12002","name":"S 2 A: Note for guidance on genotoxicity: Specific aspects of regulatory genotoxicity tests for pharmaceuticals","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-04-01T02:00:00Z","last_updated_date":"1996-04-01T02:00:00Z","reference_number":"CPMP/ICH/141/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/s-2-note-guidance-genotoxicity-specific-aspects-regulatory-genotoxicity-tests-pharmaceuticals_en.pdf"},
    {"id":"12021","name":"Draft guideline on good pharmacovigilance practices: Module VII - Periodic safety update report","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-02-22T14:20:00Z","last_updated_date":"2012-02-22T14:20:00Z","reference_number":"EMA/816292/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-vii-periodic-safety-update-report_en.pdf"},
    {"id":"12029","name":"Posaconazole gastro-resistant tablet 100 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-08-03T17:00:00Z","last_updated_date":"2018-08-03T17:00:00Z","reference_number":"EMA/CHMP/800785/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/posaconazole-gastro-resistant-tablet-100-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"12033","name":"Draft concept paper on the revision of the guideline on the development of new medicinal products for the treatment of Crohn’s disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-10-01 - 2014-12-31","first_published_date":"2014-10-01T18:00:00Z","last_updated_date":"2014-10-01T18:00:00Z","reference_number":"EMA/CHMP/328077/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-revision-guideline-development-new-medicinal-products-treatment-crohns-disease_en.pdf"},
    {"id":"12060","name":"Note for guidance on evaluation of anticancer medicinal products on man: Addendum on paediatric oncology","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-07-24T02:00:00Z","last_updated_date":"2003-07-24T02:00:00Z","reference_number":"EMEA/CPMP/EWP/569/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-evaluation-anticancer-medicinal-products-man-addendum-paediatric-oncology_en.pdf"},
    {"id":"12076","name":"Concept paper on an addendum on terms and concepts of pharmacogenomic features related to metabolism to the Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products (E...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-07-10 - 2017-10-10","first_published_date":"2017-07-07T19:00:00Z","last_updated_date":"2017-07-07T19:00:00Z","reference_number":"EMA/CHMP/644998/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-addendum-terms-and-concepts-pharmacogenomic-features-related-metabolism-guideline-use-pharmacogenetic-methodologies-pharmacokinetic-evaluation-medicinal-products-e_en.pdf"},
    {"id":"12077","name":"Concept paper on the development of a guideline on the development of new products for the treatment of tobacco and alcohol dependence","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"EMEA/CHMP/EWP/369963/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-development-new-products-treatment-tobacco-and-alcohol-dependence_en.pdf"},
    {"id":"12134","name":"Draft guideline on the clinical  investigation of medicines for the treatment of Alzheimer’s disease and other dementias","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-01 - 2016-07-31","first_published_date":"2016-02-01T16:30:00Z","last_updated_date":"2016-02-01T16:30:00Z","reference_number":"EMA/CHMP/539931/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicines-treatment-alzheimers-disease-and-other-dementias_en.pdf"},
    {"id":"12160","name":"Replacement of animal studies by in vitro models","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-02-19T01:00:00Z","last_updated_date":"1997-02-19T01:00:00Z","reference_number":"CPMP/SWP/728/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/replacement-animal-studies-vitro-models_en.pdf"},
    {"id":"12162","name":"Stem cell-based products for veterinary use: specific questions on sterility to be addressed by ADVENT - draft","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-03-04 - 2016-05-15","first_published_date":"2016-03-04T12:00:00Z","last_updated_date":"2016-03-04T12:00:00Z","reference_number":"EMA/CVMP/ADVENT/226871/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/stem-cell-based-products-veterinary-use-specific-questions-sterility-be-addressed-advent-draft_en.pdf"},
    {"id":"12178","name":"Note for guidance for the assessment of the effect of antimicrobial substances on diary starter cultures","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-03-01T01:00:00Z","last_updated_date":"2000-03-01T01:00:00Z","reference_number":"EMEA/CVMP/276/99 - FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-assessment-effect-antimicrobial-substances-diary-starter-cultures_en.pdf"},
    {"id":"12184","name":"Concept paper on the need for the development of a paediatric addendum to the chmp note for guidance on the clinical investigation of medicinal products in the treatment of lipid disorders","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/CHMP/EWP/7895/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-development-paediatric-addendum-chmp-note-guidance-clinical-investigation-medicinal-products-treatment-lipid-disorders_en.pdf"},
    {"id":"12211","name":"EMEA public statement on thiomersal in vaccines for human use - recent evidence supports safety of thiomersal-containing vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-03-24T01:00:00Z","last_updated_date":"2004-03-24T01:00:00Z","reference_number":"EMEA/CPMP/VEG/1194/04/Adopted","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/emea-public-statement-thiomersal-vaccines-human-use-recent-evidence-supports-safety-thiomersal-containing-vaccines_en.pdf"},
    {"id":"12227","name":"CHMP Safety Working Party's response to the PDCO regarding the use of PEGylated drug products in the paediatric population","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-11-23T17:56:00Z","last_updated_date":"2012-11-23T17:56:00Z","reference_number":"EMA/CHMP/SWP/647258/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chmp-safety-working-partys-response-pdco-regarding-use-pegylated-drug-products-paediatric-population_en.pdf"},
    {"id":"12230","name":"Concept paper on requirements for vaccines for use in birds against avian influenza virus","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-04-21T02:00:00Z","last_updated_date":"2006-04-21T02:00:00Z","reference_number":"EMEA/CVMP/86063/2006-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-requirements-vaccines-use-birds-against-avian-influenza-virus_en.pdf"},
    {"id":"12247","name":"Position paper on batch potency testing of immunological veterinary medicinal product","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"CVMP/IWP/038/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-batch-potency-testing-immunological-veterinary-medicinal-product_en.pdf"},
    {"id":"12257","name":"Concept paper on the need to revise the guideline on production and\n\nQuality control of monoclonal antibodies (3AB4A, Revision December 1994)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2004-10-21T02:00:00Z","last_updated_date":"2004-10-21T02:00:00Z","reference_number":"CHMP/BWP/64/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revise-guideline-production-and-quality-control-monoclonal-antibodies-3ab4a-revision-december-1994_en.pdf"},
    {"id":"12259","name":"Draft guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials: document with tracked changes - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-07-21T02:00:00Z","last_updated_date":"2016-07-21T02:00:00Z","reference_number":"EMA/CHMP/BWP/534898/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials-document-tracked-changes-revision-1_en.pdf"},
    {"id":"12270","name":"Questions and answers on Benzoic acid and Benzoates in the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-02-24 - 2014-05-31","first_published_date":"2014-02-24T12:00:00Z","last_updated_date":"2014-02-24T12:00:00Z","reference_number":"EMA/CHMP/508189/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-benzoic-acid-and-benzoates-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"12271","name":"Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-02-22T17:30:00Z","last_updated_date":"2018-02-22T17:30:00Z","reference_number":"EMA/CHMP/778709/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-physical-frailty-instruments-baseline-characterisation-older-populations-clinical-trials-first-version_en.pdf"},
    {"id":"12415","name":"Guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-01-03T18:27:00Z","last_updated_date":"2017-01-03T18:27:00Z","reference_number":"EMA/CVMP/SWP/66781/2005–Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-safety-and-residue-data-requirements-pharmaceutical-veterinary-medicinal-products-intended-minor-use-or-minor-species-mumslimited-market_en.pdf"},
    {"id":"12427","name":"Concept paper on the development of a CHMP guideline on clinical investigation of immunosuppressants for solid organ transplantation","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"CHMP/EWP/263148/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-chmp-guideline-clinical-investigation-immunosuppressants-solid-organ-transplantation_en.pdf"},
    {"id":"12481","name":"Questions and answers on wheat starch (containing gluten) used as an excipient in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2018-11-19T02:00:00Z","reference_number":"EMA/CHMP/704219/2013 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-wheat-starch-containing-gluten-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"12483","name":"Guideline on the Core SPC for human plasma derived antithrombin","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-01-17T01:00:00Z","last_updated_date":"2002-01-17T01:00:00Z","reference_number":"CPMP/BPWG/3226/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-plasma-derived-antithrombin_en.pdf"},
    {"id":"12501","name":"Guideline for the conduct of post marketing surveillance studies of veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-02-11T01:00:00Z","last_updated_date":"2000-02-11T01:00:00Z","reference_number":"EMEA/CVMP/044/99 Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-post-marketing-surveillance-studies-veterinary-medicinal-products_en.pdf"},
    {"id":"12540","name":"Draft VICH GL58 Stability testing of new veterinary drug substances and medicinal products in climatic zones III and IV - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-07-27 - 2018-12-31","first_published_date":"2018-07-27T20:10:00Z","last_updated_date":"2018-07-27T20:10:00Z","reference_number":"EMA/CVMP/VICH/335918/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl58-stability-testing-new-veterinary-drug-substances-and-medicinal-products-climatic-zones-iii-and-iv-first-version_en.pdf"},
    {"id":"12559","name":"Chemistry of new active substances - Superseded document","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-12-17T01:00:00Z","last_updated_date":"2003-12-17T01:00:00Z","reference_number":"CPMP/QWP/130/96 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chemistry-new-active-substances-superseded-document_en.pdf"},
    {"id":"12570","name":"Points to Consider regarding reporting of suspected Serious Adverse Reaction to Veterinary Medicinal Products: Common EU Reporting Form for Marketing Authorisation Holders","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-02-17T00:09:21Z","last_updated_date":"2003-02-17T00:09:21Z","reference_number":"EMEA/CVMP/601/02-Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-regarding-reporting-suspected-serious-adverse-reaction-veterinary-medicinal-products-common-eu-reporting-form-marketing-authorisation-holders_en.pdf"},
    {"id":"12574","name":"Concept paper on the need to update the current annex guideline on cell culture inactivated influenza vaccines with respect to the derivation of cell-isolated influenza vaccine viruses","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/CHMP/BWP/481473/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-update-current-annex-guideline-cell-culture-inactivated-influenza-vaccines-respect-derivation-cell-isolated-influenza-vaccine-viruses_en.pdf"},
    {"id":"12614","name":"Draft guideline on similar biological medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-05-02 - 2013-10-31","first_published_date":"2013-05-02T15:10:00Z","last_updated_date":"2013-05-02T15:10:00Z","reference_number":"CHMP/437/04 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-similar-biological-medicinal-products_en.pdf"},
    {"id":"12620","name":"Draft concept paper on the establishment of a guideline on the selection of sterilisation processes for drug products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-04-09 - 2014-07-09","first_published_date":"2014-04-09T20:30:00Z","last_updated_date":"2014-04-09T20:30:00Z","reference_number":"EMA/CHMP/CVMP/QWP/128000/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-establishment-guideline-selection-sterilisation-processes-drug-products_en.pdf"},
    {"id":"12630","name":"Draft questions and answers on boric acid in the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-08-04 - 2015-11-03","first_published_date":"2015-08-04T12:30:00Z","last_updated_date":"2015-08-04T12:30:00Z","reference_number":"EMA/CHMP/619104/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-and-answers-boric-acid-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"12646","name":"VICH GL3: Stability testing of new veterinary drug substances and medicinal products - Revision at step 9 for consultation at step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-10-05T02:00:00Z","last_updated_date":"2005-10-05T02:00:00Z","reference_number":"EMEA/CVMP/VICH/899/99-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl3-stability-testing-new-veterinary-drug-substances-and-medicinal-products-revision-step-9-consultation-step-3_en.pdf"},
    {"id":"12676","name":"Position paper on requirements for vaccines against foot-and-mouth disease - Obsolete","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-12-01T01:00:00Z","last_updated_date":"2004-12-01T01:00:00Z","reference_number":"EMEA/CVMP/775/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-requirements-vaccines-against-foot-mouth-disease-obsolete_en.pdf"},
    {"id":"12697","name":"Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T11:40:00Z","last_updated_date":"2015-12-21T11:40:00Z","reference_number":"EMA/531686/2015 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"12701","name":"ICH guideline Q4B Annex 8 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions sterility test - general chapter - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2017-07-13T16:30:00Z","reference_number":"EMA/CHMP/ICH/645592/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-8-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-sterility-test-general-chapter-step-5_en.pdf"},
    {"id":"12717","name":"Draft guideline on good pharmacovigilance practices (GVP) - Module IX – Signal management (Rev. 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-08 - 2016-10-14","first_published_date":"2016-08-08T19:00:00Z","last_updated_date":"2016-08-08T19:00:00Z","reference_number":"EMA/827661/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf"},
    {"id":"12734","name":"Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668) - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-11-22T10:00:00Z","last_updated_date":"2019-11-22T10:00:00Z","reference_number":"EMA/CHMP/302620/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_bg.pdf","es":"https://www.ema.europa.eu/es/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_cs.pdf","da":"https://www.ema.europa.eu/da/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_da.pdf","de":"https://www.ema.europa.eu/de/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_de.pdf","et":"https://www.ema.europa.eu/et/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_et.pdf","el":"https://www.ema.europa.eu/el/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_hr.pdf","it":"https://www.ema.europa.eu/it/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_sv.pdf","is":"https://www.ema.europa.eu/is/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_is.pdf","no":"https://www.ema.europa.eu/no/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-1_no.pdf"}},
    {"id":"12757","name":"Draft guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-06-01 - 2015-07-01","first_published_date":"2015-06-01T19:00:00Z","last_updated_date":"2015-06-01T19:00:00Z","reference_number":"EMA/CHMP/BPWP/144533/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-viii-products-revision-1_en.pdf"},
    {"id":"12766","name":"Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-08-15T19:00:00Z","last_updated_date":"2017-08-15T19:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/336031/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-dissolution-specification-generic-solid-oral-immediate-release-products-systemic-action-first-version_en.pdf"},
    {"id":"12846","name":"Procedure for European Union guidelines and related documents within the pharmaceutical legislative framework","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-03-18T01:00:00Z","last_updated_date":"2009-03-18T01:00:00Z","reference_number":"EMEA/P/24143/2004 Rev. 1 corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/procedure-european-union-guidelines-and-related-documents-within-pharmaceutical-legislative-framework_en.pdf"},
    {"id":"12855","name":"Draft guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-08-01 - 2014-01-31","first_published_date":"2013-08-01T20:30:00Z","last_updated_date":"2013-08-01T20:30:00Z","reference_number":"EMA/CHMP/40105/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"12879","name":"Reflection paper: Minimum data requirements for an authorisation under exceptional circumstances for vaccines for emergency use against bluetongue","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-04-23T02:00:00Z","last_updated_date":"2007-04-23T02:00:00Z","reference_number":"EMEA/CVMP/IWP/105008/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-minimum-data-requirements-authorisation-under-exceptional-circumstances-vaccines-emergency-use-against-bluetongue_en.pdf"},
    {"id":"12897","name":"Concept paper on guidance on the approach on how to demonstrate whether a substance is capable of pharmacological action or not","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-11-21T01:00:00Z","last_updated_date":"2005-11-21T01:00:00Z","reference_number":"EMEA/CVMP/SWP/139646/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guidance-approach-how-demonstrate-whether-substance-capable-pharmacological-action-or-not_en.pdf"},
    {"id":"12920","name":"Concept paper on the need for revision of points to consider on clinical investigation of medicinal products for the treatment of osteoarthritis (CPMP/EWP/784/97)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/141412/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-points-consider-clinical-investigation-medicinal-products-treatment-osteoarthritis-cpmpewp78497_en.pdf"},
    {"id":"12927","name":"Concept paper on the revision of the guideline for the conduct of bioequivalence studies for veterinary medicinal products (EMEA/CVMP/016/00) - Revision 2","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-12-18T01:00:00Z","last_updated_date":"2006-12-18T01:00:00Z","reference_number":"EMEA/CVMP/EWP/295306/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-emeacvmp01600-revision-2_en.pdf"},
    {"id":"12946","name":"Dimethyl fumarate gastro-resistant capsule 120 mg and 240 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-06-26T13:45:00Z","last_updated_date":"2018-06-26T13:45:00Z","reference_number":"EMA/CHMP/421315/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/dimethyl-fumarate-gastro-resistant-capsule-120-mg-and-240-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"12954","name":"Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"CHMP/EWP/18504/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-products-specific-immunotherapy-treatment-allergic-diseases_en.pdf"},
    {"id":"12970","name":"Concept paper on BCS-based biowaiver","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-05-24T02:00:00Z","last_updated_date":"2007-05-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/213035/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-bcs-based-biowaiver_en.pdf"},
    {"id":"12976","name":"Draft guideline on repeated dose toxicity","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2008-02-21 - 2008-05-30","first_published_date":"2008-02-21T02:00:00Z","last_updated_date":"2008-02-21T02:00:00Z","reference_number":"EMEA/CHMP/SWP/488313/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-repeated-dose-toxicity_en.pdf"},
    {"id":"12990","name":"ICH M4E (R2) Common technical document for the registration of pharmaceuticals for human use - efficacy - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-07-28T19:00:00Z","last_updated_date":"2016-07-28T19:00:00Z","reference_number":"EMA/CPMP/ICH/2887/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m4e-r2-common-technical-document-registration-pharmaceuticals-human-use-efficacy-step-5_en.pdf"},
    {"id":"13021","name":"Draft guideline on efficacy and target animal safety data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-03 - 2016-07-31","first_published_date":"2016-02-03T13:00:00Z","last_updated_date":"2016-02-03T13:00:00Z","reference_number":"EMA/CVMP/EWP/117899/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-efficacy-and-target-animal-safety-data-requirements-veterinary-medicinal-products-intended-minor-use-or-minor-species-mums-limited-market-revision-1_en.pdf"},
    {"id":"13029","name":"Paliperidone prolonged-release tablet 1.5 mg, 3 mg, 6 mg, 9 mg and 12 mg product-specific bioequivalence guidance (Rev. 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-06-26T15:50:00Z","last_updated_date":"2018-06-26T15:50:00Z","reference_number":"EMA/CHMP/156358/2016/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paliperidone-prolonged-release-tablet-15-mg-3-mg-6-mg-9-mg-and-12-mg-product-specific-bioequivalence-guidance-rev-1_en.pdf"},
    {"id":"13042","name":"Draft guideline on the assessment of genotoxic constituents in herbal substances/preparations","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/HMPC/107079/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-assessment-genotoxic-constituents-herbal-substancespreparations_en.pdf"},
    {"id":"13059","name":"Concept paper on the development of a committee proprietary products (CPMP) guideline of comparability of Biotechnology-derived products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"1998-06-24T02:00:00Z","last_updated_date":"1998-06-24T02:00:00Z","reference_number":"CPMP/BWP/1113/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-proprietary-products-cpmp-guideline-comparability-biotechnology-derived-products_en.pdf"},
    {"id":"13087","name":"Draft guideline on the compliance of authorised equine influenza vaccines with World Organisation for Animal Health requirements","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-04-11 - 2013-04-30","first_published_date":"2013-04-25T15:30:00Z","last_updated_date":"2013-04-25T15:30:00Z","reference_number":"EMA/CVMP/IWP/97961/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-compliance-authorised-equine-influenza-vaccines-world-organisation-animal-health-requirements_en.pdf"},
    {"id":"13118","name":"Concept paper on the clinical development of medicinal products for the treatment of Hepatitis C infection","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-04-26T02:00:00Z","last_updated_date":"2007-04-26T02:00:00Z","reference_number":"EMEA/CHMP/EWP/156308/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-clinical-development-medicinal-products-treatment-hepatitis-c-infection_en.pdf"},
    {"id":"13140","name":"Final reflection paper on the risks associated with Furocoumarins contained in preparations of Angelica archangelica L.","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"EMEA/HMPC/317913/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/final-reflection-paper-risks-associated-furocoumarins-contained-preparations-angelica-archangelica-l_en.pdf"},
    {"id":"13165","name":"Draft reflection paper on use of aminoglycosides in animals in the European Union: development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-07-25 - 2017-10-31","first_published_date":"2017-07-25T20:35:00Z","last_updated_date":"2017-07-25T20:35:00Z","reference_number":"EMA/CVMP/AWP/721118/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-aminoglycosides-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"13171","name":"Guideline on good pharmacovigilance practices: Module V – Risk management systems with tracked changes (Rev. 1)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T11:30:00Z","last_updated_date":"2014-04-25T11:30:00Z","reference_number":"EMA/838713/2011 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-tracked-changes-rev-1_en.pdf"},
    {"id":"13175","name":"Local tolerance of intramammary preparations in cows","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1992-11-01T01:00:00Z","last_updated_date":"1992-11-01T01:00:00Z","reference_number":"7AE21a Volume 7 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/local-tolerance-intramammary-preparations-cows_en.pdf"},
    {"id":"13176","name":"Guideline on efficacy and target animal safety data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-01-03T18:18:00Z","last_updated_date":"2017-01-03T18:18:00Z","reference_number":"EMA/CVMP/EWP/117899/2004–Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-efficacy-and-target-animal-safety-data-requirements-veterinary-medicinal-products-intended-minor-use-or-minor-species-mumslimited-market-revision-1_en.pdf"},
    {"id":"13199","name":"Joint Committee on Proprietary Medicinal Products / CVMP note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products: Explanatory note for ...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-02-28T01:00:00Z","last_updated_date":"2001-02-28T01:00:00Z","reference_number":"EMEA/CPMP/BWP/498/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/joint-committee-proprietary-medicinal-products-cvmp-note-guidance-minimising-risk-transmitting-animal-spongiform-encephalopathy-agents-human-and-veterinary-medicinal-products-explanatory-note_en.pdf"},
    {"id":"13202","name":"Draft monoclonal antibodies for veterinary use: specific questions to be addressed by ADVENT","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-03-04 - 2016-05-15","first_published_date":"2016-03-04T12:00:00Z","last_updated_date":"2016-03-04T12:00:00Z","reference_number":"EMA/CVMP/ADVENT/276476/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-monoclonal-antibodies-veterinary-use-specific-questions-be-addressed-advent_en.pdf"},
    {"id":"13211","name":"Draft guideline on xenogeneic cell-based medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-02-27T01:00:00Z","last_updated_date":"2009-02-27T01:00:00Z","reference_number":"EMEA/CHMP/CPWP/83508/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-xenogeneic-cell-based-medicinal-products_en.pdf"},
    {"id":"13215","name":"Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-09-20T02:00:00Z","last_updated_date":"2010-09-20T02:00:00Z","reference_number":"EMA/CHMP/EWP/213056/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-guideline-antiarrhythmics-atrial-fibrillation-and-atrial-flutter_en.pdf"},
    {"id":"13235","name":"Draft questions and answers on Data Monitoring Committees issues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-08-01 - 2019-07-31","first_published_date":"2018-08-01T21:00:00Z","last_updated_date":"2018-08-01T21:00:00Z","reference_number":"EMA/492010/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-and-answers-data-monitoring-committees-issues_en.pdf"},
    {"id":"13236","name":"Recommendation to marketing-authorisation holders for veterinary vaccines, highlighting the need to update marketing authorisations to remove the target animal batch safety test (TABST) following removal of the requireme...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-06-17T13:10:00Z","last_updated_date":"2013-06-17T13:10:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/746429/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-marketing-authorisation-holders-veterinary-vaccines-highlighting-need-update-marketing-authorisations-remove-target-animal-batch-safety-test-tabst-following-removal-requireme_en.pdf"}    {"id":"13273","name":"Guideline on specifications: Test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-03-30T02:00:00Z","last_updated_date":"2006-03-30T02:00:00Z","reference_number":"CPMP/QWP/2820/00 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-specifications-test-procedures-and-acceptance-criteria-herbal-substances-herbal-preparations-and-herbal-medicinal-productstraditional-herbal-medicinal-products-revision-1_en.pdf"},
    {"id":"13280","name":"Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections to specifically address the clinical development of new agents to treat disease due to mycobacterium t...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-01-29T01:00:00Z","last_updated_date":"2010-01-29T01:00:00Z","reference_number":"EMA/CHMP/EWP/14377/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-note-guidance-evaluation-medicinal-products-indicated-treatment-bacterial-infections-specifically-address-clinical-development-new-agents-treat-disease-due-mycobacterium-t_en.pdf"},
    {"id":"13290","name":"Draft guideline on the suitability of the graduation of delivery devices for liquid dosage forms","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-02-18T01:00:00Z","last_updated_date":"2005-02-18T01:00:00Z","reference_number":"EMEA/CHMP/QWP/178621/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-suitability-graduation-delivery-devices-liquid-dosage-forms_en.pdf"},
    {"id":"13296","name":"Guideline on risk assessment of medicinal products on human Reproduction and lactation: from data to labelling","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/203927/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-risk-assessment-medicinal-products-human-reproduction-lactation-data-labelling_en.pdf"},
    {"id":"13316","name":"Guideline on the pharmacokinetic and clinical evaluation of modified-release dosage forms","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-11-27T18:00:00Z","last_updated_date":"2014-11-27T18:00:00Z","reference_number":"EMA/CHMP/EWP/280/96 Rev1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-and-clinical-evaluation-modified-release-dosage-forms_en.pdf"},
    {"id":"13319","name":"Draft reflection paper on in vitro investigation of mitochondrial toxicity of anti-HIV nucleoside reverse transcriptase inhibitors","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2007-12-13 - 2008-06-30","first_published_date":"2007-12-13T02:00:00Z","last_updated_date":"2007-12-13T02:00:00Z","reference_number":"EMEA/CHMP/SWP/8212/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-vitro-investigation-mitochondrial-toxicity-anti-hiv-nucleoside-reverse-transcriptase-inhibitors_en.pdf"},
    {"id":"13356","name":"Reflection paper on formulations of choice for the paediatric population","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-28T02:00:00Z","last_updated_date":"2006-07-28T02:00:00Z","reference_number":"EMEA/CHMP/PEG/194810/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-formulations-choice-paediatric-population_en.pdf"},
    {"id":"13398","name":"Draft points to consider on validity and interpretation of meta-analyses, and one pivotal study","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2000-10-19T02:00:00Z","last_updated_date":"2000-10-19T02:00:00Z","reference_number":"CPMP/EWP/2330/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-points-consider-validity-and-interpretation-meta-analyses-and-one-pivotal-study_en.pdf"},
    {"id":"13416","name":"Draft concept paper on the development of a guideline on the non-clinical\n\nStudies prior to clinical use of gene therapy medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"EMEA/CHMP/GTWP/203821/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-guideline-non-clinical-studies-prior-clinical-use-gene-therapy-medicinal-products_en.pdf"},
    {"id":"13446","name":"Draft joint Ministry of Health, Labour and Welfare / European Medicines Agency reflection paper on the development of block-copolymer-micelle medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-02-01 - 2013-07-01","first_published_date":"2013-02-01T17:00:00Z","last_updated_date":"2013-02-01T17:00:00Z","reference_number":"EMA/CHMP/13099/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-joint-ministry-health-labour-and-welfare-european-medicines-agency-reflection-paper-development-block-copolymer-micelle-medicinal-products_en.pdf"},
    {"id":"13459","name":"Draft guideline on evaluation of anticancer medicinal products in man - Revision 5","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-03-15 - 2016-09-15","first_published_date":"2016-03-15T15:20:00Z","last_updated_date":"2016-03-15T15:20:00Z","reference_number":"EMA/CHMP/205/95 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf"},
    {"id":"13492","name":"Guideline on the clinical evaluation of direct acting antiviral agents intended for treatment of chronic Hepatitis C - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/EWP/30039/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-direct-acting-antiviral-agents-intended-treatment-chronic-hepatitis-c-first-version_en.pdf"},
    {"id":"13562","name":"VICH GL28: Studies to evaluate the safety of veterinary drugs in human: Carcinogenicity testing - Step 7 (after revision on step 9)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-05-18T02:00:00Z","last_updated_date":"2005-05-18T02:00:00Z","reference_number":"CVMP/VICH/645/01-Rev.1-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl28-studies-evaluate-safety-veterinary-drugs-human-carcinogenicity-testing-step-7-after-revision-step-9_en.pdf"},
    {"id":"13596","name":"Guideline for the testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestation in dogs and cats - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-12T01:00:00Z","last_updated_date":"2007-11-12T01:00:00Z","reference_number":"EMEA/CVMP/EWP/005/2000 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-testing-and-evaluation-efficacy-antiparasitic-substances-treatment-and-prevention-tick-and-flea-infestation-dogs-and-cats-revision-2_en.pdf"},
    {"id":"13601","name":"Guideline on clinical investigation of medicinal products in the treatment of hypertension - Revision 4","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-07-08T12:50:00Z","last_updated_date":"2016-07-08T12:50:00Z","reference_number":"EMA/CHMP/29947/2013/Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-hypertension-revision-4_en.pdf"},
    {"id":"13608","name":"Draft reflection paper on the use of pharmacogenetics in the pharmacokinetic evaluation of medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-07-01T02:00:00Z","last_updated_date":"2006-07-01T02:00:00Z","reference_number":"EMEA/128517/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-pharmacogenetics-pharmacokinetic-evaluation-medicinal-products_en.pdf"},
    {"id":"13612","name":"Draft elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil film-coated tablets 150 mg/150 mg/200 mg/ 245 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-12-22 - 2017-03-31","first_published_date":"2016-12-22T14:00:00Z","last_updated_date":"2016-12-22T14:00:00Z","reference_number":"EMA/CHMP/805518/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-elvitegravir-cobicistat-emtricitabine-tenofovir-disoproxil-film-coated-tablets-150-mg-150-mg-200-mg-245-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"13643","name":"Draft procedure for the review and revision of European Union  herbal monographs and European Union list entries","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-10-27 - 2018-01-28","first_published_date":"2017-10-27T20:00:00Z","last_updated_date":"2017-10-31T18:00:00Z","reference_number":"EMA/HMPC/124695/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-procedure-review-and-revision-european-union-herbal-monographs-and-european-union-list-entries_en.pdf"},
    {"id":"13649","name":"VICH GL37: Safety of veterinary drugs in human food repeat-dose (Chronic) toxicity testing - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-16T02:00:00Z","last_updated_date":"2004-06-16T02:00:00Z","reference_number":"CVMP/VICH/468/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl37-safety-veterinary-drugs-human-food-repeat-dose-chronic-toxicity-testing-step-7_en.pdf"},
    {"id":"13653","name":"Concept paper on the need to develop an appendix to the guideline on bioequivalence regarding the presentation of biopharmaceutical and bioanalytical data in application dossiers","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-04-22 - 2010-07-31","first_published_date":"2010-04-30T04:00:00Z","last_updated_date":"2010-04-30T04:00:00Z","reference_number":"EMA/CHMP/EWP/82259/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-develop-appendix-guideline-bioequivalence-regarding-presentation-biopharmaceutical-and-bioanalytical-data-application-dossiers_en.pdf"},
    {"id":"13665","name":"Draft guideline on missing data in confirmatory clinical trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-04-13T02:00:00Z","last_updated_date":"2009-04-13T02:00:00Z","reference_number":"CPMP/EWP/1776/99 Rev. 1 Corr*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-missing-data-confirmatory-clinical-trials_en.pdf"},
    {"id":"13693","name":"Guideline on the development of medicinal products for the treatment of alcohol dependence","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-03-01T01:00:00Z","last_updated_date":"2010-03-01T01:00:00Z","reference_number":"EMA/CHMP/EWP/20097/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-medicinal-products-treatment-alcohol-dependence_en.pdf"},
    {"id":"13762","name":"ICH guideline E18 on genomic sampling and management of genomic data - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-06T19:00:00Z","last_updated_date":"2017-10-06T19:00:00Z","reference_number":"EMA/CHMP/ICH/11623/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e18-genomic-sampling-and-management-genomic-data-step-5_en.pdf"},
    {"id":"13773","name":"Draft miglustat product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/422796/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-miglustat-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"13834","name":"Draft guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-04-12 - 2016-10-12","first_published_date":"2016-04-12T12:50:00Z","last_updated_date":"2016-04-12T12:50:00Z","reference_number":"EMA/CHMP/QWP/834816/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-chemical-and-pharmaceutical-quality-documentation-concerning-investigational-medicinal-products-clinical-trials-revision-1_en.pdf"},
    {"id":"13871","name":"Guideline on requirements for Vaccine Antigen Master File (VAMF) certification","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-03-17T01:00:00Z","last_updated_date":"2005-03-17T01:00:00Z","reference_number":"EMEA/CPMP/4548/03/Final/Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-vaccine-antigen-master-file-vamf-certification_en.pdf"},
    {"id":"13920","name":"ICH: Q 4 B Annex 2: To note evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on test for extractable volume of parenteral preparations general chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-11-01T01:00:00Z","last_updated_date":"2007-11-01T01:00:00Z","reference_number":"EMEA/CHMP/ICH/559409/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-2-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-test-extractable-volume-parenteral-preparations-general-chapter-step-3_en.pdf"},
    {"id":"13934","name":"Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-28T02:00:00Z","last_updated_date":"2006-06-28T02:00:00Z","reference_number":"EMEA/CHMP/EWP/147013/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-role-pharmacokinetics-development-medicinal-products-paediatric-population_en.pdf"},
    {"id":"13953","name":"Draft reflection paper on the use of cocrystals and other solid-state forms of active substances in medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-07-31 - 2014-10-31","first_published_date":"2014-07-31T19:00:00Z","last_updated_date":"2014-07-31T19:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/136250/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-cocrystals-and-other-solid-state-forms-active-substances-medicinal-products_en.pdf"},
    {"id":"13974","name":"Concept paper on the need for revision of the note for guidance on modified release oral and transdermal dosage forms: section II (pharmacokinetic and clinical evaluation)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-05-20 - 2010-08-31","first_published_date":"2010-06-08T04:00:00Z","last_updated_date":"2010-06-08T04:00:00Z","reference_number":"EMA/CHMP/1303/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-modified-release-oral-and-transdermal-dosage-forms-section-ii-pharmacokinetic-and-clinical-evaluation_en.pdf"},
    {"id":"13975","name":"VICH GL39: Test procedures and acceptance criteria for new veterinary drug substances and new medicinal products: Chemical substances - At step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-15T01:00:00Z","last_updated_date":"2005-11-15T01:00:00Z","reference_number":"EMEA/CVMP/VICH/810/04-corrig.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl39-test-procedures-and-acceptance-criteria-new-veterinary-drug-substances-and-new-medicinal-products-chemical-substances-step-7_en.pdf"},
    {"id":"14008","name":"Guideline on good pharmacovigilance practices: Module XVI– Risk minimisation measures: selection of tools and effectiveness indicators (Rev. 1) (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T17:00:00Z","last_updated_date":"2014-04-25T17:00:00Z","reference_number":"EMA/204715/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools-and-effectiveness-indicators-rev-1-superseded_en.pdf"},
    {"id":"14058","name":"Concept paper on the need for a reflection paper on quality aspects of medicines for older people - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-04-05 - 2013-06-30","first_published_date":"2013-04-05T15:00:00Z","last_updated_date":"2013-04-05T15:00:00Z","reference_number":"EMA/165974/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-reflection-paper-quality-aspects-medicines-older-people-first-version_en.pdf"},
    {"id":"14080","name":"Note for guidance on production and quality control of animal immunoglobins and immunosera for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-07-24T02:00:00Z","last_updated_date":"2002-07-24T02:00:00Z","reference_number":"CPMP/BWP/3354/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-production-and-quality-control-animal-immunoglobins-and-immunosera-human-use_en.pdf"},
    {"id":"14136","name":"Questions and Answers on allogenic stem cell-based products for veterinary use: Specific questions on extraneous agents","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-24T02:00:00Z","last_updated_date":"2017-07-24T18:29:00Z","reference_number":"EMA/CVMP/ADVENT/803494/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-allogenic-stem-cell-based-products-veterinary-use-specific-questions-extraneous-agents_en.pdf"},
    {"id":"14144","name":"Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-11-24T16:45:00Z","last_updated_date":"2016-11-24T16:45:00Z","reference_number":"EMEA/CHMP/BMWP/118264/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-low-molecular-weight-heparins-revision-1_en.pdf"},
    {"id":"14196","name":"Draft dasatinib product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/423718/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-dasatinib-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"14224","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline M8 on the electronic common technical document (eCTD) – questions and answers","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-08-22T16:00:00Z","last_updated_date":"2013-08-22T16:00:00Z","reference_number":"EMA/CHMP/ICH/820/2003","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-m8-electronic-common-technical-document-ectd-questions-and-answers_en.pdf"},
    {"id":"14255","name":"Revised guideline on requirements and controls applied to bovine serum used in the production of immunological veterinary medicinal products - Obsolete","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-09T01:00:00Z","last_updated_date":"2005-11-09T01:00:00Z","reference_number":"EMEA/CVMP/743/00-Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/revised-guideline-requirements-controls-applied-bovine-serum-used-production-immunological-veterinary-medicinal-products-obsolete_en.pdf"},
    {"id":"14256","name":"Draft reflection paper on classification of advanced-therapy medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-06-30 - 2014-10-31","first_published_date":"2014-06-30T16:30:00Z","last_updated_date":"2014-06-30T16:30:00Z","reference_number":"EMA/CAT/600280/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-classification-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"14260","name":"Guideline on the use of starting materials and intermediates collected from different sources in the manufacturing of non-recombinant biological medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-07-12T12:55:00Z","last_updated_date":"2013-07-12T12:55:00Z","reference_number":"EMA/CHMP/BWP/729106/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-starting-materials-and-intermediates-collected-different-sources-manufacturing-non-recombinant-biological-medicinal-products_en.pdf"},
    {"id":"14262","name":"Concept paper on the revision of the guideline for the efficacy of veterinary medicinal products (pharmaceuticals) for use in farmed aquatic species","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-10-15T02:00:00Z","last_updated_date":"2007-10-15T02:00:00Z","reference_number":"EMEA/CVMP/EWP/85954/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-efficacy-veterinary-medicinal-products-pharmaceuticals-use-farmed-aquatic-species_en.pdf"},
    {"id":"14280","name":"Reflection paper on pharmacogenomic samples, testing and data handling","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-11-15T01:00:00Z","last_updated_date":"2007-11-15T01:00:00Z","reference_number":"EMEA/CHMP/PGxWP/201914/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-pharmacogenomic-samples-testing-and-data-handling_en.pdf"},
    {"id":"14298","name":"ICH: E 15: Establish definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-01T01:00:00Z","last_updated_date":"2007-11-01T01:00:00Z","reference_number":"EMEA/CHMP/ICH/437986/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-15-establish-definitions-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-and-sample-coding-categories-step-5_en.pdf"},
    {"id":"14324","name":"Draft guideline on good pharmacovigilance practices: Module V - Risk management systems","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-02-22T14:20:00Z","last_updated_date":"2012-02-22T14:20:00Z","reference_number":"EMA/838713/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-v-risk-management-systems_en.pdf"},
    {"id":"14328","name":"Draft reflection paper on markers used for quantitative and qualitative analysis of herbal medicinal products and traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-01-10T01:00:00Z","last_updated_date":"2008-01-10T01:00:00Z","reference_number":"EMEA/HMPC/253629/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-markers-used-quantitative-and-qualitative-analysis-herbal-medicinal-products-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"14370","name":"Draft information in the package leaflet for aspartame in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (CPMP/463/00 Rev. 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-04 - 2016-08-03","first_published_date":"2016-05-04T17:00:00Z","last_updated_date":"2016-05-04T17:00:00Z","reference_number":"EMA/CHMP/134648/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-aspartame-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use-cpmp-463-00-rev-1_en.pdf"},
    {"id":"14406","name":"Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T10:35:00Z","last_updated_date":"2015-07-24T10:35:00Z","reference_number":"EMA/CHMP/BPWP/410415/2011 rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-normal-immunoglobulin-subcutaneous-or-intramuscular-administration-scig-imig-revision-1_en.pdf"},
    {"id":"14411","name":"Draft VICH GL34: Biologicals: testing for the detection of mycoplasma contamination","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-12-08 - 2012-03-12","first_published_date":"2011-12-20T16:15:00Z","last_updated_date":"2011-12-20T16:15:00Z","reference_number":"EMA/CVMP/VICH/463/2002","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl34-biologicals-testing-detection-mycoplasma-contamination_en.pdf"},
    {"id":"14440","name":"Concept paper on the need for revision of the guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-06-23 - 2011-09-30","first_published_date":"2011-07-01T04:00:00Z","last_updated_date":"2011-07-01T04:00:00Z","reference_number":"EMA/CHMP/114599/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-prophylaxis-high-intra-and-post-operative-venous-thromboembolic-risk_en.pdf"},
    {"id":"14457","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use considerations: General principles to address the risk of inadvertent germline integration of gene th...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-11-01T01:00:00Z","last_updated_date":"2006-11-01T01:00:00Z","reference_number":"CHMP/ICH/469991/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-considerations-general-principles-address-risk-inadvertent-germline-integration-gene-th_en.pdf"},
    {"id":"14472","name":"Draft reflection paper on the chemical structure and properties criteria to be considered for the evaluation of new active substance (NAS) status of chemical substances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-24 - 2015-07-24","first_published_date":"2015-04-24T18:30:00Z","last_updated_date":"2015-04-24T18:30:00Z","reference_number":"EMA/CHMP/QWP/104223/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-chemical-structure-and-properties-criteria-be-considered-evaluation-new-active-substance-nas-status-chemical-substances_en.pdf"},
    {"id":"14510","name":"Draft guideline on statistical principles for veterinary clinical trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-09-15 - 2011-03-31","first_published_date":"2010-09-27T04:00:00Z","last_updated_date":"2010-09-27T04:00:00Z","reference_number":"EMA/CVMP/EWP/81976/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-statistical-principles-veterinary-clinical-trials_en.pdf"},
    {"id":"14514","name":"Reflection paper on classification of advanced-therapy medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-12-17T17:16:00Z","last_updated_date":"2012-12-17T17:16:00Z","reference_number":"EMA/CAT/600280/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-classification-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"14560","name":"Reflection paper on anthelmintic resistance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-04-29 - 2016-07-31","first_published_date":"2016-04-29T18:25:00Z","last_updated_date":"2016-04-29T18:25:00Z","reference_number":"CVMP/EWP/573536/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-anthelmintic-resistance_en.pdf-0"},
    {"id":"14609","name":"Draft appendix IV of the guideline on the investigation on bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1): Presentation of biopharmaceutical and bioanalytical data in module 2.7.1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-02-17 - 2011-05-31","first_published_date":"2011-03-14T02:00:00Z","last_updated_date":"2011-03-14T02:00:00Z","reference_number":"EMA/CHMP/600958/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-appendix-iv-guideline-investigation-bioequivalence-cpmp-ewp-qwp-1401-98-rev1-presentation-biopharmaceutical-and-bioanalytical-data-module-271_en.pdf"},
    {"id":"14635","name":"Draft reflection paper providing an overview of the current regulatory testing requirements for medicinal products for human use and opportunities for implementation of the 3Rs - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-11-18 - 2017-05-31","first_published_date":"2016-11-18T10:31:00Z","last_updated_date":"2016-11-18T10:31:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/742466/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-providing-overview-current-regulatory-testing-requirements-medicinal-products-human-use-and-opportunities-implementation-3rs-first-version_en.pdf"},
    {"id":"14643","name":"EMEA public statement on thiomersal containing medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-07-08T02:00:00Z","last_updated_date":"1999-07-08T02:00:00Z","reference_number":"EMEA/20962/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/emea-public-statement-thiomersal-containing-medicinal-products_en.pdf"},
    {"id":"14652","name":"ICH guideline M5 on data elements and standards for drug dictionaries","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-05-01T02:00:00Z","last_updated_date":"2014-07-14T02:00:00Z","reference_number":"EMEA/CHMP/ICH/168535/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m5-data-elements-and-standards-drug-dictionaries_en.pdf"},
    {"id":"14703","name":"Second draft guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food-producing animals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-07-27 - 2018-10-31","first_published_date":"2018-07-27T16:46:00Z","last_updated_date":"2018-07-27T16:46:00Z","reference_number":"EMA/CVMP/AWP/706442/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/second-draft-guideline-assessment-risk-public-health-antimicrobial-resistance-due-use-antimicrobial-veterinary-medicinal-product-food-producing-animals_en.pdf"},
    {"id":"14772","name":"VICH GL44: Target animal safety for veterinary live and inactivated vaccines - At step 4","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-09-18T02:00:00Z","last_updated_date":"2007-09-18T02:00:00Z","reference_number":"EMEA/CVMP/VICH/359665/2005-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl44-target-animal-safety-veterinary-live-and-inactivated-vaccines-step-4_en.pdf"},
    {"id":"14826","name":"Concept paper introducing a review and update of existing European Union guidelines on residues studies to bring these into line with the International Cooperation on Harmonisation of Technical Requirements for Registrat...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-15 - 2012-05-31","first_published_date":"2012-02-15T11:00:00Z","last_updated_date":"2012-02-15T11:00:00Z","reference_number":"EMA/CVMP/SWP/878228/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-introducing-review-and-update-existing-european-union-guidelines-residues-studies-bring-these-line-international-cooperation-harmonisation-technical-requirements-registrat_en.pdf"},
    {"id":"14835","name":"Draft Crizotinib hard capsules 200 mg and 250 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-12-22 - 2017-03-31","first_published_date":"2016-12-22T14:00:00Z","last_updated_date":"2016-12-22T14:00:00Z","reference_number":"EMA/CHMP/805479/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-crizotinib-hard-capsules-200-mg-and-250-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"14836","name":"Draft guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for paediatric indications","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2005-10-11 - 2006-04-30","first_published_date":"2005-09-29T04:00:00Z","last_updated_date":"2005-09-29T04:00:00Z","reference_number":"EMEA/CHMP/SWP/169215/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-need-non-clinical-testing-juvenile-animals-pharmaceuticals-paediatric-indications_en.pdf"},
    {"id":"14838","name":"Guideline on good pharmacovigilance practices: Module XVI– Risk minimisation measures - Selection of tools and effectiveness indicators with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T10:30:00Z","last_updated_date":"2014-02-28T10:30:00Z","reference_number":"EMA/204715/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools-and-effectiveness-indicators-tracked-changes_en.pdf"},
    {"id":"14842","name":"Note for guidance on the use of near infrared spectroscopy by the pharmaceutical industry and the data requirements for new submissions and variations","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-02-20T01:00:00Z","last_updated_date":"2003-02-20T01:00:00Z","reference_number":"CPMP/QWP/ 3309/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-near-infrared-spectroscopy-pharmaceutical-industry-and-data-requirements-new-submissions-and-variations_en.pdf"},
    {"id":"14868","name":"Concept paper on the development of a guideline on the quality aspects of single-dose veterinary spot-on products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-12-15T01:00:00Z","last_updated_date":"2006-12-15T01:00:00Z","reference_number":"EMEA/CVMP/QWP/434665/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-quality-aspects-single-dose-veterinary-spot-products_en.pdf"},
    {"id":"14898","name":"Guideline on clinical investigation of medicinal products, including depot preparations, in the treatment of schizophrenia - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-10-09T15:59:00Z","last_updated_date":"2012-10-09T15:59:00Z","reference_number":"EMA/CHMP/40072/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-including-depot-preparations-treatment-schizophrenia-revision-1_en.pdf"},
    {"id":"14914","name":"Draft concept paper on requirements for the production and control of allergen products for use in animals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-09-18 - 2015-12-31","first_published_date":"2015-09-18T12:46:00Z","last_updated_date":"2015-09-18T12:46:00Z","reference_number":"EMA/CVMP/IWP/351882/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-requirements-production-and-control-allergen-products-use-animals_en.pdf"},
    {"id":"14924","name":"Guideline on plastic immediate packaging materials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-05-19T02:00:00Z","last_updated_date":"2005-05-19T02:00:00Z","reference_number":"CPMP/QWP/4359/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-plastic-immediate-packaging-materials_en.pdf"},
    {"id":"14938","name":"CVMP reflection paper on the risks that should be considered prior to the use of unauthorised vaccines in emergency situations","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-09-28T12:00:00Z","last_updated_date":"2016-09-28T12:00:00Z","reference_number":"EMA/CVMP/IWP/49593/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cvmp-reflection-paper-risks-should-be-considered-prior-use-unauthorised-vaccines-emergency-situations_en.pdf"},
    {"id":"14957","name":"Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-08-03T17:00:00Z","last_updated_date":"2018-08-03T17:00:00Z","reference_number":"EMA/CHMP/800789/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ledipasvirsofosbuvir-film-coated-tablet-90-mg400-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"14970","name":"Overview of comments received on guideline on non-clinical studies required before first clinical use of gene therapy medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/CHMP/GTWP/65260/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-guideline-non-clinical-studies-required-first-clinical-use-gene-therapy-medicinal-products_en.pdf"},
    {"id":"14992","name":"Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and package leaflets for plasma-derived medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-12-14T13:05:00Z","last_updated_date":"2011-12-14T13:05:00Z","reference_number":"EMA/CHMP/BWP/360642/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-warning-transmissible-agents-summary-product-characteristics-smpcs-and-package-leaflets-plasma-derived-medicinal-products_en.pdf"},
    {"id":"15016","name":"Note for guidance conduct of pharmacovigilance for veterinary medicinal products authorised through the mutual recognition procedure","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-03-01T01:00:00Z","last_updated_date":"1999-03-01T01:00:00Z","reference_number":"EMEA/CVMP/143/ 99 - Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-conduct-pharmacovigilance-veterinary-medicinal-products-authorised-through-mutual-recognition-procedure_en.pdf"},
    {"id":"15022","name":"ICH: S 1 B: Testing for carcinogenicity of pharmaceuticals - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-09-30T02:00:00Z","last_updated_date":"1997-09-30T02:00:00Z","reference_number":"CPMP/ICH/299/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-1-b-testing-carcinogenicity-pharmaceuticals-step-5_en.pdf"},
    {"id":"15044","name":"ICH: Q 1 C: Stability testing: Requirements for new dosage forms - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-01-01T01:00:00Z","last_updated_date":"1998-01-01T01:00:00Z","reference_number":"CPMP/ICH/280/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-c-stability-testing-requirements-new-dosage-forms-step-5_en.pdf"},
    {"id":"15065","name":"Draft reflection paper on the use of extrapolation in the development of medicines for paediatrics - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-10-13 - 2018-01-14","first_published_date":"2017-10-13T14:34:00Z","last_updated_date":"2017-10-13T14:34:00Z","reference_number":"EMA/199678/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf"},
    {"id":"15067","name":"Draft everolimus tablets 0.25, 0.5, 0.75 and 1mg; 2.5, 5 and 10mg, dispersible tablets 0.1 and 0.25mg; 2, 3 and 5mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-02 - 2016-07-31","first_published_date":"2016-05-02T13:00:00Z","last_updated_date":"2016-05-02T13:00:00Z","reference_number":"EMA/CHMP/154772/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-everolimus-tablets-025-05-075-1mg-25-5-10mg-dispersible-tablets-01-025mg-2-3-5mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"15106","name":"Draft prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-08-03 - 2017-10-31","first_published_date":"2017-08-03T20:35:00Z","last_updated_date":"2017-08-03T20:35:00Z","reference_number":"EMA/CHMP/158772/2016/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-prasugrel-hydrochloride-film-coated-tablets-5-mg-and-10-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"15143","name":"Guideline on core summary of product characteristics and package leaflet for fludeoxyglucose (18F)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-08-14T13:25:00Z","last_updated_date":"2012-08-14T13:25:00Z","reference_number":"EMA/CHMP/448228/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-summary-product-characteristics-and-package-leaflet-fludeoxyglucose-18f_en.pdf"},
    {"id":"15175","name":"Concept paper on the need for revision of the guideline on the clinical development of medicinal products for the treatment of Hepatitis C","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-04-22 - 2010-07-31","first_published_date":"2010-04-30T04:00:00Z","last_updated_date":"2010-04-30T04:00:00Z","reference_number":"EMA/CHMP/EWP/825749/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-development-medicinal-products-treatment-hepatitis-c_en.pdf"},
    {"id":"15204","name":"Position paper on assessment of the risk of transmission of animal spongiform encephalopathy agents by master seed materials used in the production of veterinary vaccines - Obsolete","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2001-02-16T01:00:00Z","last_updated_date":"2001-02-16T01:00:00Z","reference_number":"EMEA/CVMP/019/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-assessment-risk-transmission-animal-spongiform-encephalopathy-agents-master-seed-materials-used-production-veterinary-vaccines-obsolete_en.pdf"},
    {"id":"15214","name":"Note for guidance on summary of requirements for active substances In part ii of the dossier","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-01-28T01:00:00Z","last_updated_date":"1998-01-28T01:00:00Z","reference_number":"CPMP/QWP/297/97","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-summary-requirements-active-substances-part-ii-dossier_en.pdf"},
    {"id":"15221","name":"Draft concept paper on selection of test materials for genotoxicity testing for traditional herbal medicinal products/ herbal medicinal products1\n\n - An annex to Guideline on the Assessment of Genotoxicity of Herbal subs...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-07-15T02:00:00Z","last_updated_date":"2008-07-15T02:00:00Z","reference_number":"EMEA/HMPC/315413/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-selection-test-materials-genotoxicity-testing-traditional-herbal-medicinal-products-herbal-medicinal-products1-annex-guideline-assessment-genotoxicity-herbal-subs_en.pdf"},
    {"id":"15262","name":"Guideline on stability testing: Stability testing of existing active substances and related finished products - Revision 1 (Corr)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-12-17T01:00:00Z","last_updated_date":"2003-12-17T01:00:00Z","reference_number":"CPMP/QWP/ 122/02 Rev. 1 corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products-revision-1-corr_en.pdf"},
    {"id":"15278","name":"Guideline on Core SPC for plasma derived fibrin sealant/haemostatic products (CPMP/BPWG/153/00)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-29T02:00:00Z","last_updated_date":"2004-07-29T02:00:00Z","reference_number":"CPMP/BPWG/153/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-plasma-derived-fibrin-sealanthaemostatic-products-cpmpbpwg15300_en.pdf"},
    {"id":"15288","name":"VICH GL5: Stability testing: Photostability testing of new veterinary drug substances and medicinal products - Step 7 consensus guideline","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-05-25T02:00:00Z","last_updated_date":"2000-05-25T02:00:00Z","reference_number":"CVMP/VICH/901/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl5-stability-testing-photostability-testing-new-veterinary-drug-substances-and-medicinal-products-step-7-consensus-guideline_en.pdf"},
    {"id":"15319","name":"Draft guideline on pharmaceutical development of medicines for paediatric use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-01-04 - 2013-03-31","first_published_date":"2013-01-04T13:21:00Z","last_updated_date":"2013-01-04T13:21:00Z","reference_number":"EMA/CHMP/QWP/805880/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf"},
    {"id":"15323","name":"Reflection paper on consideration of adjuvants and preservatives under council regulation (EEC) No 2377/90 laying down a community procedure for the establishment of maximum residue limits of veterinary medicinal product...","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-12-17T01:00:00Z","last_updated_date":"2007-12-17T01:00:00Z","reference_number":"EMEA/CVMP/339116/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-consideration-adjuvants-and-preservatives-under-council-regulation-eec-no-237790-laying-down-community-procedure-establishment-maximum-residue-limits-veterinary-medicinal-product_en.pdf"},
    {"id":"15326","name":"Vortioxetine hydrobromide immediate release tablets 5 mg, 10 mg, 15 mg, and 20 mg; vortioxetine lactate oral drops solution 20 mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/CHMP/474974/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vortioxetine-hydrobromide-immediate-release-tablets-5-mg-10-mg-15-mg-and-20-mg-vortioxetine-lactate-oral-drops-solution-20-mgml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"15336","name":"Questions and answers on bovine spongiform encephalopathies (BSE) and vaccines - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-04-24T02:00:00Z","last_updated_date":"2001-04-24T02:00:00Z","reference_number":"EMEA/CPMP/BWP/819/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-bovine-spongiform-encephalopathies-bse-and-vaccines-first-version_en.pdf"},
    {"id":"15369","name":"Concept paper on a guideline on the chemical and pharmaceutical quality documentation concerning biological investigational medicinal products in clinical trials","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/CHMP/BWP/466097/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-chemical-and-pharmaceutical-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials_en.pdf"},
    {"id":"15387","name":"ICH guideline Q4B annex 7 (R2) to note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on dissolution test - general chapter - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2013-02-11T12:00:00Z","reference_number":"EMA/CHMP/ICH/645469/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-7-r2-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-dissolution-test-general-chapter-step-5_en.pdf"},
    {"id":"15389","name":"Paediatric addendum to CHMP guideline on clinical investigation of medicinal products in the treatment of lipid disorders","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-10-02T15:54:00Z","last_updated_date":"2012-10-02T15:54:00Z","reference_number":"EMA/CHMP/494506/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paediatric-addendum-chmp-guideline-clinical-investigation-medicinal-products-treatment-lipid-disorders_en.pdf"},
    {"id":"15392","name":"Note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-12-18T01:00:00Z","last_updated_date":"2011-11-23T01:00:00Z","reference_number":"CPMP/EWP/18/01 final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-urinary-incontinence_en.pdf"},
    {"id":"15466","name":"Draft guideline on the requirements for clinical documentation for Orally Inhaled Products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatme...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-18T02:00:00Z","last_updated_date":"2007-10-18T02:00:00Z","reference_number":"CPMP/EWP/4151/00 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-clinical-documentation-orally-inhaled-products-oip-including-requirements-demonstration-therapeutic-equivalence-between-two-inhaled-products-use-treatme_en.pdf"},
    {"id":"15562","name":"Guideline on the clinical investigation of medicinal products to prevent development/slow progression of chronic renal  insufficiency","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-10-20T13:30:00Z","last_updated_date":"2016-10-20T13:30:00Z","reference_number":"EMA/CHMP/500825/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-prevent-developmentslow-progression-chronic-renal-insufficiency_en.pdf"},
    {"id":"15574","name":"Rivaroxaban film-coated tablets 2.5, 10, 15 and 20mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-11-01T17:34:57Z","reference_number":"EMA/CHMP/160650/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/rivaroxaban-film-coated-tablets-25-10-15-and-20mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"15586","name":"Reflection paper on assessment of cardiovascular safety profile of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T11:25:00Z","last_updated_date":"2016-03-29T11:25:00Z","reference_number":"EMA/CHMP/50549/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-assessment-cardiovascular-safety-profile-medicinal-products_en.pdf"}    {"id":"15614","name":"Concept paper on the development of a guideline on viral safety evaluation of biotechnological products to be used in clinical trials","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2004-12-15T01:00:00Z","last_updated_date":"2004-12-15T01:00:00Z","reference_number":"EMEA/CHMP/BWP/124447/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-viral-safety-evaluation-biotechnological-products-be-used-clinical-trials_en.pdf"},
    {"id":"15623","name":"Draft concept paper on viral safety of plasma-derived medicinal products with respect to hepatitis E virus","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-05-02 - 2014-07-31","first_published_date":"2014-05-02T15:40:00Z","last_updated_date":"2014-05-02T15:40:00Z","reference_number":"EMA/CHMP/BWP/78086/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-viral-safety-plasma-derived-medicinal-products-respect-hepatitis-e-virus_en.pdf"},
    {"id":"15632","name":"Draft addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev 2) to address indication-specific clinical data","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-07-04 - 2013-01-31","first_published_date":"2012-07-04T19:25:47Z","last_updated_date":"2012-07-04T19:25:47Z","reference_number":"EMA/CHMP/776609/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-addendum-note-guidance-evaluation-medicinal-products-indicated-treatment-bacterial-infections-cpmp-ewp-558-95-rev-2-address-indication-specific-clinical-data_en.pdf"},
    {"id":"15659","name":"Guideline on the replacement of rabbit pyrogen testing by an alternative test for plasma derived medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/BWP/452081/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-replacement-rabbit-pyrogen-testing-alternative-test-plasma-derived-medicinal-products_en.pdf"},
    {"id":"15680","name":"Advisory notice to veterinary surgeons regarding the development of fibrosarcomas at sites of injection of veterinary medicinal products in cats","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-01-01T01:00:00Z","last_updated_date":"2003-01-01T01:00:00Z","reference_number":"EMEA/CVMP/205/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/advisory-notice-veterinary-surgeons-regarding-development-fibrosarcomas-sites-injection-veterinary-medicinal-products-cats_en.pdf"},
    {"id":"15693","name":"Draft concept paper on revision of the points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products (CHMP/EWP/2655/99) and conversion to a CHMP guideline","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-02-28 - 2014-05-31","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"EMA/CHMP/792679/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-revision-points-consider-pharmacokinetics-and-pharmacodynamics-development-antibacterial-medicinal-products-chmp-ewp-2655-99-and-conversion-chmp-guideline_en.pdf"},
    {"id":"15701","name":"Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-10-30T13:00:00Z","last_updated_date":"2014-11-20T17:50:00Z","reference_number":"EMA/CHMP/539931/2014 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/discussion-paper-clinical-investigation-medicines-treatment-alzheimers-disease-and-other-dementias_en.pdf"},
    {"id":"15703","name":"Guideline on the clinical evaluation of antifungal agents for the treatment and prophylaxis of invasive fungal disease","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-04-30T02:00:00Z","last_updated_date":"2010-04-30T02:00:00Z","reference_number":"CHMP/EWP/1343/01 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-antifungal-agents-treatment-and-prophylaxis-invasive-fungal-disease_en.pdf"},
    {"id":"15718","name":"ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-08-06 - 2019-02-06","first_published_date":"2018-08-06T18:30:00Z","last_updated_date":"2018-08-06T18:30:00Z","reference_number":"EMA/CHMP/ICH/493213/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m9-biopharmaceutics-classification-system-based-biowaivers-step-2b-first-version_en.pdf"},
    {"id":"15732","name":"Draft note for guidance on excipients, antioxidants and antimicrobial preservatives in the dossier for application for marketing authorisation of a medicinal product (Superseded by Nov 2006 version)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2003-02-20T01:00:00Z","last_updated_date":"2003-02-20T01:00:00Z","reference_number":"CPMP/QWP/419/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-excipients-antioxidants-and-antimicrobial-preservatives-dossier-application-marketing-authorisation-medicinal-product-superseded-nov-2006-version_en.pdf"},
    {"id":"15742","name":"Guideline on adjustment for baseline covariates in clinical trials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T17:00:00Z","last_updated_date":"2015-03-27T17:00:00Z","reference_number":"EMA/CHMP/295050/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-adjustment-baseline-covariates-clinical-trials_en.pdf"},
    {"id":"15756","name":"Points to consider on multiplicity issues in clinical trials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-09-19T02:00:00Z","last_updated_date":"2002-09-19T02:00:00Z","reference_number":"CPMP/EWP/908/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-multiplicity-issues-clinical-trials_en.pdf"},
    {"id":"15774","name":"Guideline on epidemiological data on blood transmissible infections - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-03-01T11:13:00Z","last_updated_date":"2016-03-01T11:13:00Z","reference_number":"EMA/CHMP/BWP/548524/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-epidemiological-data-blood-transmissible-infections-revision-1_en.pdf"},
    {"id":"15785","name":"ICH: Q 4 B: Note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2006-06-01T02:00:00Z","reference_number":"EMEA/CHMP/ICH/222007/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-step-3_en.pdf"},
    {"id":"15791","name":"Questions and answers on post approval change management protocols","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-04-13T17:23:00Z","last_updated_date":"2012-04-13T17:23:00Z","reference_number":"EMA/CHMP/CVMP/QWP/586330/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-post-approval-change-management-protocols_en.pdf"},
    {"id":"15821","name":"CHMP SWP reflection paper on the assessment of the genotoxic potential of antisense oligodeoxynucleotides","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-01-20T01:00:00Z","last_updated_date":"2005-01-20T01:00:00Z","reference_number":"EMEA/CHMP/SWP/199726/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chmp-swp-reflection-paper-assessment-genotoxic-potential-antisense-oligodeoxynucleotides_en.pdf"},
    {"id":"15828","name":"Guideline on the quality of biological active substances produced by stable transgene expression in higher plants","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/BWP/48316/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-biological-active-substances-produced-stable-transgene-expression-higher-plants_en.pdf"},
    {"id":"15840","name":"Points to consider on application with 1.meta-analyses, 2.one pivotal study","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-05-31T02:00:00Z","last_updated_date":"2001-05-31T02:00:00Z","reference_number":"CPMP/EWP/2330/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-application-1meta-analyses-2one-pivotal-study_en.pdf"},
    {"id":"15907","name":"Draft guideline on good pharmacovigilance practices (GVP) - Module VIII – Post-authorisation safety studies (Rev. 2)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-08-11 - 2015-10-09","first_published_date":"2015-08-11T13:00:00Z","last_updated_date":"2015-08-11T13:00:00Z","reference_number":"EMA/813938/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-2_en.pdf"},
    {"id":"15917","name":"Draft guideline on the pharmacokinetic and clinical evaluation of modified-release dosage forms","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-03-15 - 2013-09-15","first_published_date":"2013-03-15T13:00:00Z","last_updated_date":"2013-03-15T13:00:00Z","reference_number":"EMA/CHMP/EWP/280/96 Rev1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-pharmacokinetic-and-clinical-evaluation-modified-release-dosage-forms_en.pdf"},
    {"id":"15933","name":"Guideline on the use of porcine trypsin used in the manufacture of human biological medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-02-28T18:30:00Z","last_updated_date":"2014-02-28T18:30:00Z","reference_number":"EMA/CHMP/BWP/814397/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-porcine-trypsin-used-manufacture-human-biological-medicinal-products_en.pdf"},
    {"id":"15944","name":"Guideline on medicinal products for the treatment of insomnia - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-02-26T00:31:00Z","last_updated_date":"2011-02-26T00:31:00Z","reference_number":"EMA/CHMP/16274/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-medicinal-products-treatment-insomnia-revision-1_en.pdf"},
    {"id":"15978","name":"Draft guideline on manufacture of the veterinary finished dosage form","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-04-23 - 2019-08-31","first_published_date":"2018-04-23T13:22:00Z","last_updated_date":"2019-01-07T12:22:00Z","reference_number":"EMA/CVMP/QWP/798401/2015 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-manufacture-veterinary-finished-dosage-form_en.pdf"},
    {"id":"15986","name":"Draft concept paper on need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-10-31 - 2014-01-31","first_published_date":"2013-10-31T12:00:00Z","last_updated_date":"2013-10-31T12:00:00Z","reference_number":"EMA/CHMP/617734/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-need-revision-guideline-medicinal-products-treatment-alzheimers-disease-and-other-dementias-revision-1_en.pdf"},
    {"id":"16006","name":"Guideline on the Core SPC for human plasma derived Hepatitis-B immunoglobulin for intramuscular use (CPMP/BPWG/4222/02)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-04-27T02:00:00Z","last_updated_date":"2007-04-27T02:00:00Z","reference_number":"CPMP/BPWG/4222/02 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-plasma-derived-hepatitis-b-immunoglobulin-intramuscular-use-cpmpbpwg422202_en.pdf"},
    {"id":"16011","name":"VICH GL18: Impurities: Residual solvents - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-06-01T02:00:00Z","last_updated_date":"2000-06-01T02:00:00Z","reference_number":"CVMP/VICH/502/99-Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl18-impurities-residual-solvents-step-7_en.pdf"},
    {"id":"16019","name":"Draft posaconazole product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/423719/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-posaconazole-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"16047","name":"Procedure for the review and revision of European Union herbal monographs and European Union list entries - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-08-14T13:00:00Z","last_updated_date":"2022-11-22T14:43:00Z","reference_number":"EMA/HMPC/124695/2011 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/procedure-review-and-revision-european-union-herbal-monographs-and-european-union-list-entries-revision-3_en.pdf"},
    {"id":"16102","name":"2003 European Commission guideline on 'Excipients in the label and package leaflet of medicinal products for human use'","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-03-01T14:10:00Z","last_updated_date":"2018-03-01T14:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/2003-european-commission-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"16114","name":"Draft guideline on the clinical investigation of medicinal products for the treatment of axial spondyloarthritis - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-01 - 2016-12-31","first_published_date":"2016-07-01T13:30:00Z","last_updated_date":"2016-07-01T13:30:00Z","reference_number":"CPMP/EWP/4891/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-axial-spondyloarthritis-revision-1_en.pdf"},
    {"id":"16115","name":"Concept paper on the need for revision of the guideline on clinical investigation of hypnotic medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/CHMP/EWP/310566/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-hypnotic-medicinal-products_en.pdf"},
    {"id":"16117","name":"ICH: Q 4 B Annex 11: Capillary electrophoresis general chapter: Annex 11 to note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on capillary electrophoresis general chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-11-01 - 2010-02-28","first_published_date":"2009-12-18T02:00:00Z","last_updated_date":"2009-12-18T02:00:00Z","reference_number":"EMEA/CHMP/ICH/730028/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-11-capillary-electrophoresis-general-chapter-annex-11-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-capillary-electrophoresis-general-chapter-step-3_en.pdf"},
    {"id":"16120","name":"Concept paper on the revision of the note for guidance on radiopharmaceuticals","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-03-30T02:00:00Z","last_updated_date":"2006-03-30T02:00:00Z","reference_number":"EMEA/CHMP/92877/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-radiopharmaceuticals_en.pdf"},
    {"id":"16125","name":"Questions and answers on propylene glycol used as an excipient in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/704195/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-propylene-glycol-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"16165","name":"Draft tacrolimus granules for oral suspension 0.2 and 1 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-10-01 - 2016-01-01","first_published_date":"2015-10-06T17:00:00Z","last_updated_date":"2015-10-06T17:00:00Z","reference_number":"EMA/CHMP/PKWP/36648/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-tacrolimus-granules-oral-suspension-02-and-1-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"16170","name":"Guideline on the specification limits for residues of metal catalysts or metal reagents","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/CHMP/SWP/4446/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-specification-limits-residues-metal-catalysts-or-metal-reagents_en.pdf"},
    {"id":"16221","name":"Guideline on clinical evaluation of diagnostic agents - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"CPMP/EWP/1119/98/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-diagnostic-agents-revision-1_en.pdf"},
    {"id":"16236","name":"Draft guideline on approach towards harmonisation of withdrawal periods","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-25 - 2017-01-31","first_published_date":"2016-07-25T18:20:00Z","last_updated_date":"2016-07-25T18:20:00Z","reference_number":"EMA/CVMP/SWP/735325/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-approach-towards-harmonisation-withdrawal-periods_en.pdf"},
    {"id":"16248","name":"Guideline on quality of herbal medicinal products traditional herbal medicinal products - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-09-28T12:55:00Z","last_updated_date":"2011-09-28T12:55:00Z","reference_number":"EMA/HMPC/201116/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-herbal-medicinal-products-traditional-herbal-medicinal-products-revision-2_en.pdf"},
    {"id":"16257","name":"Gelatin for use in pharmaceuticals: explanatory note (13 december 2000) on the manufacture of gelatin in relationship to the CPMP note For guidance on minimising the risk of transmitting Animal Spongiform Encephalopathy ...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-12-13T01:00:00Z","last_updated_date":"2000-12-13T01:00:00Z","reference_number":"EMEA/CPMP/4306/00/v 0.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/gelatin-use-pharmaceuticals-explanatory-note-13-december-2000-manufacture-gelatin-relationship-cpmp-note-guidance-minimising-risk-transmitting-animal-spongiform-encephalopathy_en.pdf"},
    {"id":"16292","name":"Draft guideline on good pharmacovigilance practices: Module VI - Management and reporting of adverse reactions to medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-02-22T14:20:00Z","last_updated_date":"2012-02-22T14:20:00Z","reference_number":"EMA/873138/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-vi-management-and-reporting-adverse-reactions-medicinal-products_en.pdf"},
    {"id":"16314","name":"Overview of comments on 'Points to consider on frailty: Evaluation instruments for baseline characterisation of clinical trial populations' (EMA/CHMP/778709/2015) - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-02-22T17:30:00Z","last_updated_date":"2018-02-22T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-points-consider-frailty-evaluation-instruments-baseline-characterisation-clinical-trial-populations-emachmp7787092015-first-version_en.pdf"},
    {"id":"16347","name":"ICH: M 3 (R2): Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2008-07-01 - 2008-10-01","first_published_date":"2008-07-01T04:00:00Z","last_updated_date":"2008-07-01T04:00:00Z","reference_number":"CPMP/ICH/286/95-draft","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization-pharmaceuticals-step-3_en.pdf"},
    {"id":"16363","name":"Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"CPMP/EWP/563/95 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-parkinsons-disease_en.pdf"},
    {"id":"16396","name":"Note for guidance: Maximum shelf-life for sterile medicinal products after first opening or following reconstitution","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-07-01T02:00:00Z","last_updated_date":"2000-07-01T02:00:00Z","reference_number":"EMEA/CVMP/198/99 - FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-maximum-shelf-life-sterile-medicinal-products-after-first-opening-or-following-reconstitution_en.pdf"},
    {"id":"16410","name":"Draft guideline on good pharmacovigilance practices (GVP) - Module VIII Addendum I – Requirements for transmission of information on non-interventional post-authorisation safety studies (Rev. 2)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-08-11 - 2015-10-09","first_published_date":"2015-08-11T13:00:00Z","last_updated_date":"2015-08-11T13:00:00Z","reference_number":"EMA/395730/2012 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-viii-addendum-i-requirements-transmission-information-non-interventional-post-authorisation-safety-studies-rev-2_en.pdf"},
    {"id":"16468","name":"ICH: Q 4 B Annex 10: Polyacrylamide gel electrophoresis: Annex 10 to note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on polyacrylamide gel electrophoresis general chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-06-01T02:00:00Z","last_updated_date":"2009-06-01T02:00:00Z","reference_number":"EMEA/CHMP/ICH/381133/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-10-polyacrylamide-gel-electrophoresis-annex-10-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-polyacrylamide-gel-electrophoresis-general-chapter-step-3_en.pdf"},
    {"id":"16490","name":"Draft aliskiren film-coated tablet 150 mg and 300 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-06-27 - 2018-09-30","first_published_date":"2018-06-27T14:30:00Z","last_updated_date":"2018-06-27T14:30:00Z","reference_number":"EMA/CHMP/291450/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-aliskiren-film-coated-tablet-150-mg-and-300-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"16492","name":"Explanatory note on immunomodulators for the guideline on adjuvants in vaccines for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-27T02:00:00Z","last_updated_date":"2006-07-27T02:00:00Z","reference_number":"EMEA/CHMP/VWP/244894/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/explanatory-note-immunomodulators-guideline-adjuvants-vaccines-human-use_en.pdf"},
    {"id":"16568","name":"Production and quality control of monoclonal antibodies","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-12-31T01:00:00Z","last_updated_date":"1994-12-31T01:00:00Z","reference_number":"III/5271/94","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/production-and-quality-control-monoclonal-antibodies_en.pdf"},
    {"id":"16608","name":"Annex A - Clinical Development of Medicinal Products for Treatment of HIV Infection","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-02-22T01:00:00Z","last_updated_date":"2007-02-22T01:00:00Z","reference_number":"EMEA/CHMP/EWP/42065/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-clinical-development-medicinal-products-treatment-hiv-infection_en.pdf"},
    {"id":"16625","name":"Draft sunitinib product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-12-03 - 2014-03-03","first_published_date":"2013-12-04T12:05:00Z","last_updated_date":"2013-12-04T12:05:00Z","reference_number":"CHMP/PKWP/EMA/423716/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-sunitinib-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"16665","name":"Draft zonisamide hard capsules 25, 50 and 100 mg, orodispersible tablets 25, 50, 100 and 300 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-15 - 2015-11-01","first_published_date":"2015-07-15T14:00:03Z","last_updated_date":"2015-07-15T14:00:03Z","reference_number":"EMA/CHMP/PKWP/253507/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-zonisamide-hard-capsules-25-50-and-100-mg-orodispersible-tablets-25-50-100-and-300-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"16680","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q4B annex 13 to note for evaluation and recommendation of pharmacopoeial texts for use...","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2013-02-11T12:00:00Z","reference_number":"EMA/CHMP/ICH/405290/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q4b-annex-13-note-evaluation-and-recommendation-pharmacopoeial-texts-use_en.pdf"},
    {"id":"16710","name":"Draft guideline on the clinical development of medicinal products for the treatment of cystic fibrosis - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/CHMP/EWP/9147/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-development-medicinal-products-treatment-cystic-fibrosis-first-version_en.pdf"},
    {"id":"16722","name":"Guideline on the requirements for clinical documentation for Orally Inhaled Products including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in treatment of asthma and chronic obstructive... Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"CPMP/EWP/4151/00 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-clinical-documentation-orally-inhaled-products-including-requirements-demonstration-therapeutic-equivalence-between-two-inhaled-products-use-treatment-asthma-chronic-obstructive_en.pdf"},
    {"id":"16795","name":"Draft concept paper for a guideline on the demonstration of palatability of veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-11-09 - 2011-02-28","first_published_date":"2010-11-18T02:00:00Z","last_updated_date":"2010-11-18T02:00:00Z","reference_number":"EMA/CVMP/EWP/81987/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-guideline-demonstration-palatability-veterinary-medicinal-products_en.pdf"},
    {"id":"16806","name":"Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"CPMP/EWP/553/95 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-medicinal-products-treatment-alzheimers-disease-and-other-dementias-revision-1_en.pdf"},
    {"id":"16810","name":"Draft concept paper on an addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 Rev. 2) to address paediatric-specific clinical data requiremen...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-04-20 - 2016-07-31","first_published_date":"2016-04-20T19:15:00Z","last_updated_date":"2016-04-20T19:15:00Z","reference_number":"EMA/CHMP/213862/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-cpmp-ewp-558-95-rev-2-address-paediatric-specific-clinical-data-requiremen_en.pdf"},
    {"id":"16825","name":"VICH GL10: Impurities in new veterinary drug substances - Revision at step 9 for consultation at step 4","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-06-15T02:00:00Z","last_updated_date":"2005-06-15T02:00:00Z","reference_number":"CVMP/VICH/837/99-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl10-impurities-new-veterinary-drug-substances-revision-step-9-consultation-step-4_en.pdf"},
    {"id":"16831","name":"Reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer), a complex, a derivative, or a different salt or ester as new active substance in relation to the relevant reference a...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-11-21T15:15:00Z","last_updated_date":"2012-11-21T15:15:00Z","reference_number":"EMA/651649/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-considerations-given-designation-single-stereo-isomeric-form-enantiomer-complex-derivative-or-different-salt-or-ester-new-active-substance-relation-relevant-reference_en.pdf"},
    {"id":"16859","name":"Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure - Revision 1 - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-12-01T01:00:00Z","last_updated_date":"2010-12-01T01:00:00Z","reference_number":"EMA/CHMP/BWP/99698/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/procedural-advice-submission-variations-annual-update-human-influenza-inactivated-vaccines-applications-centralised-procedure-revision-1-superseded_en.pdf"},
    {"id":"16871","name":"ICH: Q 6 A: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-05-01T02:00:00Z","last_updated_date":"2000-05-01T02:00:00Z","reference_number":"CPMP/ICH/367/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-6-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products-chemical-substances-step-5_en.pdf"},
    {"id":"16888","name":"Draft guideline of Core SPC for Human Plasma Derived and Recombinant Coagulation Factor IX Products - Revision 1","type":"scientific-guideline","status":"Draft","consultation_date":"","first_published_date":"2007-08-01T02:00:00Z","last_updated_date":"2007-08-01T02:00:00Z","reference_number":"EMEA/CPMP/BPWG/1625/1999–Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-spc-human-plasma-derived-and-recombinant-coagulation-factor-ix-products-revision-1_en.pdf"},
    {"id":"16899","name":"Efficacy of veterinary medicinal products for use in farmed aquatic species","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-09-01T02:00:00Z","last_updated_date":"1994-09-01T02:00:00Z","reference_number":"7AE22a Volume 7 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/efficacy-veterinary-medicinal-products-use-farmed-aquatic-species_en.pdf"},
    {"id":"16911","name":"Draft guideline on requirements for an authorisation under exceptional circumstances for vaccines for emergency use against bluetongue","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-06-23T02:00:00Z","last_updated_date":"2008-06-23T02:00:00Z","reference_number":"EMEA/CVMP/IWP/220193/2008-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-authorisation-under-exceptional-circumstances-vaccines-emergency-use-against-bluetongue_en.pdf"},
    {"id":"16936","name":"Revised position paper on the definition of substances capable of pharmacological action in the context of council directive 2001/82/EC, as amended, with particular reference to excipients and manufacturing materials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-01T02:00:00Z","last_updated_date":"2004-07-01T02:00:00Z","reference_number":"EMEA/CVMP/072/97/Rev1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/revised-position-paper-definition-substances-capable-pharmacological-action-context-council-directive-200182ec-amended-particular-reference-excipients-and-manufacturing-materials_en.pdf"},
    {"id":"16960","name":"Draft guideline on carcinogenicity evaluation of medicinal products for the treatment of HIV infection","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2006-07-27 - 2007-01-31","first_published_date":"2006-07-27T04:00:00Z","last_updated_date":"2006-07-27T04:00:00Z","reference_number":"EMEA/CHMP/SWP/194898/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-carcinogenicity-evaluation-medicinal-products-treatment-hiv-infection_en.pdf"},
    {"id":"16964","name":"Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on live attenuated influenza vaccines - Superseded","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"1999-07-29T02:00:00Z","last_updated_date":"1999-07-29T02:00:00Z","reference_number":"CPMP/BWP/1765/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-proprietary-medicinal-products-cpmp-points-consider-live-attenuated-influenza-vaccines-superseded_en.pdf"},
    {"id":"17014","name":"Draft non-clinical guideline on drug-induced hepatotoxicity","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2008-01-24 - 2008-08-30","first_published_date":"2008-01-24T02:00:00Z","last_updated_date":"2008-01-24T02:00:00Z","reference_number":"EMEA/CHMP/SWP/150115/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-non-clinical-guideline-drug-induced-hepatotoxicity_en.pdf"},
    {"id":"17025","name":"Guideline on clinical investigation of recombinant and human plasma-derived factor IX products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-08-01T02:00:00Z","last_updated_date":"2011-08-01T02:00:00Z","reference_number":"EMA/CHMP/BPWP/144552/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-ix-products_en.pdf"},
    {"id":"17046","name":"Draft guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"EMEA/CHMP/89249/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-pharmacokinetics-therapeutic-proteins_en.pdf"},
    {"id":"17053","name":"Implementation of the note for guidance on the risk analysis approach for residues of veterinary medicinal products in food of animal origin","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2002-01-01T01:00:00Z","last_updated_date":"2002-01-01T01:00:00Z","reference_number":"EMEA/CVMP/069/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/implementation-note-guidance-risk-analysis-approach-residues-veterinary-medicinal-products-food-animal-origin_en.pdf"},
    {"id":"17065","name":"Draft guideline on the demonstration of palatability of veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-11-16 - 2013-05-31","first_published_date":"2012-11-19T12:30:00Z","last_updated_date":"2012-11-19T12:30:00Z","reference_number":"EMA/CVMP/EWP/206024/2011-CONSULTATION","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-demonstration-palatability-veterinary-medicinal-products_en.pdf"},
    {"id":"17076","name":"Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-10-18T02:00:00Z","last_updated_date":"2007-10-18T02:00:00Z","reference_number":"CHMP/EWP/2459/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-methodological-issues-confirmatory-clinical-trials-planned-adaptive-design_en.pdf"},
    {"id":"17094","name":"Points to consider on the evaluation of medicinal products for the treatment of Irritable Bowel Syndrome","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-03-19T01:00:00Z","last_updated_date":"2003-03-19T01:00:00Z","reference_number":"CPMP/EWP/785/97","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-evaluation-medicinal-products-treatment-irritable-bowel-syndrome_en.pdf"},
    {"id":"17106","name":"Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-15T01:00:00Z","last_updated_date":"2007-11-15T01:00:00Z","reference_number":"CPMP/EWP/707/98 Rev.1 corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-prophylaxis-high-intra-and-post-operative-venous-thromboembolic-risk-revision-1_en.pdf"},
    {"id":"17153","name":"Guideline on pharmaceutical aspects of the product information for human vaccines - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-11-26T01:00:00Z","last_updated_date":"2003-11-26T01:00:00Z","reference_number":"EMEA/CPMP/BWP/2758/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-aspects-product-information-human-vaccines-first-version_en.pdf"},
    {"id":"17172","name":"ICH: Q 4 B: Note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-01T01:00:00Z","last_updated_date":"2007-11-01T01:00:00Z","reference_number":"EMEA/CHMP/ICH/222007/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-step-5_en.pdf"},
    {"id":"17212","name":"Draft guideline on veterinary medicinal products controlling varroa destructor parasitosis in bees","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-10-14 - 2010-04-30","first_published_date":"2009-10-19T04:00:00Z","last_updated_date":"2009-10-19T04:00:00Z","reference_number":"EMEA/CVMP/EWP/459883/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-veterinary-medicinal-products-controlling-varroa-destructor-parasitosis-bees_en.pdf"},
    {"id":"17225","name":"Guideline on clinical investigation of medicinal products in the treatment of patients with Acute Respiratory Distress Syndrome - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/CPMP/EWP/504/97 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-patients-acute-respiratory-distress-syndrome-revision-1_en.pdf"},
    {"id":"17237","name":"Guideline on non-clinical documentation for herbal medicinal products in applications for marketing authorization (bibliographical and mixed applications) and in applications for simplified registration - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-09-07T02:00:00Z","last_updated_date":"2006-09-07T02:00:00Z","reference_number":"EMEA/HMPC/32116/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-documentation-herbal-medicinal-products-applications-marketing-authorization-bibliographical-and-mixed-applications-and-applications-simplified-registration-first-version_en.pdf"},
    {"id":"17276","name":"Note for guidance on approach towards harmonisation of withdrawal periods - Updated application software","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2002-05-15T02:00:00Z","last_updated_date":"2002-05-15T02:00:00Z","reference_number":"EMEA/CVMP/563/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-approach-towards-harmonisation-withdrawal-periods-updated-application-software_en.pdf"},
    {"id":"17288","name":"Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-05-30T14:15:00Z","last_updated_date":"2013-05-30T14:15:00Z","reference_number":"EMA/CHMP/325170/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-prevention-venous-thromboembolism-vte-patients-undergoing-high-vte-risk-surgery-revision-2_en.pdf"},
    {"id":"17314","name":"Reflection paper on injection site residues: considerations for risk assessment and residue surveillance","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-06-23T02:00:00Z","last_updated_date":"2008-06-23T02:00:00Z","reference_number":"EMEA/CVMP/520190/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-injection-site-residues-considerations-risk-assessment-and-residue-surveillance_en.pdf"},
    {"id":"17331","name":"Revised recommendation for the basic surveillance of EudraVigilance Veterinary (EVVet) data for centrally authorised products (CAPs)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-06-04T14:00:01Z","last_updated_date":"2018-06-04T14:00:01Z","reference_number":"EMA/CVMP/PhVWP/171122/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/revised-recommendation-basic-surveillance-eudravigilance-veterinary-evvet-data-centrally-authorised-products-caps_en.pdf"},
    {"id":"17364","name":"Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-01-11 - 2011-03-31","first_published_date":"2011-01-12T01:31:00Z","last_updated_date":"2011-01-12T01:31:00Z","reference_number":"EMA/759784/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-need-active-control-therapeutic-areas-where-use-placebo-deemed-ethical-and-one-or-more-established-medicines-are-available_en.pdf"},
    {"id":"17419","name":"Guideline on good pharmacovigilance practices: Module III – Pharmacovigilance inspections","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-12-13T01:00:00Z","last_updated_date":"2014-09-15T13:00:00Z","reference_number":"EMA/119871/2012 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-iii-pharmacovigilance-inspections_en.pdf"},
    {"id":"17420","name":"Draft guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-03-01 - 2013-08-31","first_published_date":"2013-03-01T13:00:00Z","last_updated_date":"2013-03-01T13:00:00Z","reference_number":"EMA/CHMP/236981/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-duchenne-and-becker-muscular-dystrophy_en.pdf"},
    {"id":"17434","name":"Draft guideline on the clinical evaluation of direct acting antivirals for the treatment of chronic hepatitis - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-07 - 2016-12-31","first_published_date":"2016-07-07T16:30:00Z","last_updated_date":"2016-07-07T16:30:00Z","reference_number":"EMEA/CHMP/EWP/30039/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-direct-acting-antivirals-treatment-chronic-hepatitis-revision-1_en.pdf"},
    {"id":"17476","name":"Draft guideline on the development of new medicinal products for the treatment of Crohn’s Disease - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-01 - 2017-01-31","first_published_date":"2016-08-01T13:30:00Z","last_updated_date":"2016-08-01T13:30:00Z","reference_number":"CPMP/EWP/2284/99 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-new-medicinal-products-treatment-crohns-disease-revision-2_en.pdf"},
    {"id":"17477","name":"Reflection paper on quality, non-clinical and clinical issues related to the development of recombinant adeno-associated viral vectors","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-07-08T02:00:00Z","last_updated_date":"2010-07-08T02:00:00Z","reference_number":"EMEA/CHMP/GTWP/587488/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-quality-non-clinical-and-clinical-issues-related-development-recombinant-adeno-associated-viral-vectors_en.pdf"},
    {"id":"17498","name":"Guideline on determining the fate of veterinary medicinal products in manure","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-03-30T02:00:00Z","last_updated_date":"2024-07-26T02:00:00Z","reference_number":"EMA/CVMP/ERA/430327/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-determining-fate-veterinary-medicinal-products-manure_en.pdf"},
    {"id":"17503","name":"Draft guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-03-22T01:00:00Z","last_updated_date":"2007-03-22T01:00:00Z","reference_number":"EMEA/CHMP/SWP/28367/2007 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-first-man-clinical-trials-potential-high-risk-medicinal-products-first-version_en.pdf"},
    {"id":"17515","name":"VICH GL45: Bracketing and matrixing designs for stability testing of new veterinary drug substances and medicinal products - At step 4","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-02-18T01:00:00Z","last_updated_date":"2008-02-18T01:00:00Z","reference_number":"EMEA/CVMP/VICH/581467/2007-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl45-bracketing-and-matrixing-designs-stability-testing-new-veterinary-drug-substances-and-medicinal-products-step-4_en.pdf"},
    {"id":"17521","name":"Note for guidance on inclusion of antioxidants and antimicrobial preservatives in medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-07-08T02:00:00Z","last_updated_date":"1997-07-08T02:00:00Z","reference_number":"CPMP/CVMP/QWP /115/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-inclusion-antioxidants-and-antimicrobial-preservatives-medicinal-products_en.pdf"},
    {"id":"17538","name":"Concept paper on requirements for multi-strain dossiers - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-04-23T02:00:00Z","last_updated_date":"2007-04-23T02:00:00Z","reference_number":"EMEA/CVMP/IWP/90459/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-requirements-multi-strain-dossiers-first-version_en.pdf"},
    {"id":"17552","name":"Draft dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-07-28 - 2017-10-31","first_published_date":"2017-07-28T14:00:00Z","last_updated_date":"2017-07-28T14:00:00Z","reference_number":"EMA/CHMP/356875/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-dronedarone-film-coated-tablets-400-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"17563","name":"Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-29T13:24:56Z","last_updated_date":"2012-06-29T13:24:56Z","reference_number":"CPMP/EWP/1080/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus-revision-1_en.pdf"},
    {"id":"17566","name":"Draft sorafenib product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/423707/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-sorafenib-product-specific-bioequivalence-guidance_en.pdf"}    {"id":"17604","name":"Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-02-02T11:35:00Z","last_updated_date":"2012-02-02T11:35:00Z","reference_number":"EMA/CHMP/37646/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-pharmacogenetic-methodologies-pharmacokinetic-evaluation-medicinal-products_en.pdf"},
    {"id":"17631","name":"Guideline for the conduct of efficacy studies for non steroidal anti inflammatory drugs","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-12-01T01:00:00Z","last_updated_date":"2001-12-01T01:00:00Z","reference_number":"EMEA/CVMP/237/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-efficacy-studies-non-steroidal-anti-inflammatory-drugs_en.pdf-0"},
    {"id":"17637","name":"Guideline on the Core SPC for Human Plasma Coagulation Factor VII Products (CPMP/BPWG/2048/01)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-29T02:00:00Z","last_updated_date":"2004-07-29T02:00:00Z","reference_number":"CPMP/BPWG/2048/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-plasma-coagulation-factor-vii-products-cpmpbpwg204801_en.pdf"},
    {"id":"17658","name":"Draft explanatory note on the withdrawal of the note for guidance on harmonisation of requirements for influenza Vaccines (CPMP/BWP/214/96) and of the core SmPC/PL for inactivated seasonal influenza vaccines (CMDh/128/2003/Rev5 and CMDh/129/2008/Rev3)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-08-01 - 2013-10-31","first_published_date":"2013-08-01T14:00:00Z","last_updated_date":"2013-08-01T14:00:00Z","reference_number":"EMA/CHMP/VWP/232674/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-explanatory-note-withdrawal-note-guidance-harmonisation-requirements-influenza-vaccines-cpmp-bwp-214-96-and-core-smpc-pl-inactivated-seasonal-influenza-vaccines-cmdh-128-2003-rev5-and-cmdh-129_en.pdf"},
    {"id":"17675","name":"Guideline on production and quality control of animal immunoglobulins and immunosera for human use - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-08-05T12:00:00Z","last_updated_date":"2016-08-05T12:00:00Z","reference_number":"EMA/CHMP/BWP/3354/1999 rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-production-and-quality-control-animal-immunoglobulins-and-immunosera-human-use-revision-1_en.pdf"},
    {"id":"17677","name":"Guideline on good pharmacovigilance practices (GVP): Module VII – Periodic safety update report","type":"scientific-guideline","status":"Adopted","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-06-25T04:00:00Z","last_updated_date":"2013-12-12T12:00:00Z","reference_number":"EMA/816292/2011 Rev.1*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report_en.pdf"},
    {"id":"17685","name":"ICH: Q 3 A (R2): Impurities in new drug substances - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-10-01T02:00:00Z","last_updated_date":"2006-10-01T02:00:00Z","reference_number":"CPMP/ICH/2737/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-3-r2-impurities-new-drug-substances-step-5_en.pdf"},
    {"id":"17724","name":"Draft guideline on clinical investigation of medicinal products for the treatment of ankylosing spondylitis - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-06-23T02:00:00Z","last_updated_date":"2005-06-23T02:00:00Z","reference_number":"CPMP/EWP/4891/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-ankylosing-spondylitis-first-version_en.pdf"},
    {"id":"17820","name":"Guideline on clinical investigation of medicinal products for the treatment of Sepsis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2006-06-01T02:00:00Z","reference_number":"CHMP/EWP/4713/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-sepsis_en.pdf"},
    {"id":"17844","name":"Recommendations on the need for revision of the guideline on clinical investigation of medicinal products for prophylaxis of intra- and post- operative venous thromboembolic risk (CPMP/EWP/707/98)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"EMEA/CHMP/340660/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendations-need-revision-guideline-clinical-investigation-medicinal-products-prophylaxis-intra-and-post-operative-venous-thromboembolic-risk-cpmpewp70798_en.pdf"},
    {"id":"17859","name":"Concept paper on the need of the guideline on clinical investigation of medicinal products for the treatment of gout - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-06-14 - 2012-09-30","first_published_date":"2012-06-14T18:40:00Z","last_updated_date":"2012-06-14T18:40:00Z","reference_number":"EMA/CHMP/937321/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-clinical-investigation-medicinal-products-treatment-gout-first-version_en.pdf"},
    {"id":"17874","name":"ICH: M 4 E: Common technical document for the registration of pharmaceuticals for human use - Efficacy - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-07-01T02:00:00Z","last_updated_date":"2003-07-01T02:00:00Z","reference_number":"CPMP/ICH/2887/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-4-e-common-technical-document-registration-pharmaceuticals-human-use-efficacy-step-5_en.pdf"},
    {"id":"17892","name":"Draft qualification opinion on Proactive in chronic obstructive pulmonary disease (COPD)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-12-20 - 2018-01-29","first_published_date":"2017-12-20T14:00:00Z","last_updated_date":"2017-12-20T14:00:00Z","reference_number":"EMA/810227/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-qualification-opinion-proactive-chronic-obstructive-pulmonary-disease-copd_en.pdf"},
    {"id":"17901","name":"Public statement on the use of herbal medicinal products containing thujone - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-02-20T13:00:00Z","last_updated_date":"2012-06-29T14:13:00Z","reference_number":"EMA/HMPC/732886/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-use-herbal-medicinal-products-containing-thujone-revision-1_en.pdf"},
    {"id":"17904","name":"Guideline on scientific requirements for the environmental risk assessment of gene therapy medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-11-01T01:00:00Z","last_updated_date":"2008-11-01T01:00:00Z","reference_number":"EMEA/CHMP/GTWP/125491/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific-requirements-environmental-risk-assessment-gene-therapy-medicinal-products_en.pdf"},
    {"id":"17912","name":"Draft sirolimus product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/422569/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-sirolimus-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"17915","name":"Concept paper for the revision of the guideline on veterinary medicinal products for fluid therapy in case of diarrhoea","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-12-16 - 2017-03-31","first_published_date":"2016-12-16T20:00:00Z","last_updated_date":"2016-12-16T20:00:00Z","reference_number":"EMA/CVMP/EWP/707299/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-veterinary-medicinal-products-fluid-therapy-case-diarrhoea_en.pdf"},
    {"id":"17932","name":"Guideline on core SmPC for human fibrinogen products\n\n(EMEA/CHMP/BPWP/122007/2005)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/CHMP/BPWP/122007/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-fibrinogen-products-emeachmpbpwp1220072005_en.pdf"},
    {"id":"17956","name":"Questions and answers on boric acid and borates used as excipients in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/619104/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-boric-acid-and-borates-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"17962","name":"VICH GL40: Test procedures and acceptance criteria for new biotechnological/ biological veterinary medicinal products - At step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-15T01:00:00Z","last_updated_date":"2005-11-15T01:00:00Z","reference_number":"EMEA/CVMP/VICH/811/04-corrig.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl40-test-procedures-and-acceptance-criteria-new-biotechnological-biological-veterinary-medicinal-products-step-7_en.pdf"},
    {"id":"17982","name":"Guideline on specific efficacy requirements for ectoparasiticides in sheep","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-07-10T02:00:00Z","last_updated_date":"2002-07-10T02:00:00Z","reference_number":"EMEA/CVMP/411/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-specific-efficacy-requirements-ectoparasiticides-sheep_en.pdf"},
    {"id":"18024","name":"Revised European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) reflection paper on collecting data on consumption of antimicrobial agents per animal species, on technical units of measurement and indicator...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-12-18 - 2013-03-15","first_published_date":"2012-12-19T11:41:00Z","last_updated_date":"2013-10-15T18:35:00Z","reference_number":"EMA/286416/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/revised-european-surveillance-veterinary-antimicrobial-consumption-esvac-reflection-paper-collecting-data-consumption-antimicrobial-agents-animal-species-technical-units-measurement-and-indicator_en.pdf"},
    {"id":"18061","name":"Draft guideline on the clinical development of medicinal products for the treatment of human-immunodeficiency-virus (HIV) infection (revision 3)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-09-30 - 2014-03-31","first_published_date":"2013-09-30T18:00:00Z","last_updated_date":"2013-10-07T20:00:00Z","reference_number":"EMEA/CPMP/EWP/633/02 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-development-medicinal-products-treatment-human-immunodeficiency-virus-hiv-infection-revision-3_en.pdf"},
    {"id":"18062","name":"General principles processing joint FDA EMEA Voluntary Genomic Data Submissions (VGDSs) within the framework of the confidentiality arrangement","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-04-01T02:00:00Z","last_updated_date":"2007-04-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/general-principles-processing-joint-fda-emea-voluntary-genomic-data-submissions-vgdss-within-framework-confidentiality-arrangement_en.pdf"},
    {"id":"18093","name":"Draft guideline on the core SmPC for human Anti-D immunoglobulin for intramuscular use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-11 - 2016-04-30","first_published_date":"2016-02-11T11:55:00Z","last_updated_date":"2016-02-11T11:55:00Z","reference_number":"EMA/CHMP/BPWP/29205/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-human-anti-d-immunoglobulin-intramuscular-use_en.pdf"},
    {"id":"18146","name":"Draft guideline on the clinical evaluation of direct acting antiviral agents intended for treatment of chronic Hepatitis C","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/30039/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-direct-acting-antiviral-agents-intended-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"18252","name":"Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-04-07T02:00:00Z","last_updated_date":"2011-04-07T02:00:00Z","reference_number":"EMA/CHMP/SWP/100094/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-non-clinical-studies-generic-nanoparticle-iron-medicinal-product-applications_en.pdf"},
    {"id":"18284","name":"Draft guideline on production and quality control of monoclonal antibodies and related substances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-04-05T02:00:00Z","last_updated_date":"2007-04-05T02:00:00Z","reference_number":"EMEA/CHMP/BWP/157653/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-production-and-quality-control-monoclonal-antibodies-and-related-substances_en.pdf"},
    {"id":"18297","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use considerations: General principles to address virus and vector shedding","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2009-07-01T02:00:00Z","reference_number":"EMEA/CHMP/ICH/449035/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-considerations-general-principles-address-virus-and-vector-shedding_en.pdf"},
    {"id":"18323","name":"Guideline on good pharmacovigilance practices: Module V – Risk management systems (Rev. 2)","type":"scientific-guideline","status":"Adopted","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-06-25T21:18:13Z","last_updated_date":"2017-03-30T19:00:00Z","reference_number":"EMA/838713/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf"},
    {"id":"18332","name":"Procedure for the systematic review of Community herbal monographs and supporting documents - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-01-24T12:00:00Z","last_updated_date":"2012-01-24T12:00:00Z","reference_number":"EMA/HMPC/124695/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/procedure-systematic-review-community-herbal-monographs-and-supporting-documents-first-version_en.pdf"},
    {"id":"18349","name":"Concept paper on the development of a guideline on setting specifications for related impurities in antibiotics","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-07-09T02:00:00Z","last_updated_date":"2008-07-09T02:00:00Z","reference_number":"CHMP/CVMP/QWP/136351/08","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-setting-specifications-related-impurities-antibiotics_en.pdf"},
    {"id":"18357","name":"Draft guideline on process validation - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-03-15 - 2012-10-31","first_published_date":"2012-04-13T15:25:00Z","last_updated_date":"2012-04-13T15:25:00Z","reference_number":"EMA/CHMP/CVMP/QWP/70278/2012-Rev1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-process-validation-revision-1_en.pdf"},
    {"id":"18361","name":"VICH GL20: Efficacy of anthelmintics - Specific recommendations for feline - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-07-20T02:00:00Z","last_updated_date":"2001-07-20T02:00:00Z","reference_number":"CVMP/VICH/545/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl20-efficacy-anthelmintics-specific-recommendations-feline-step-7_en.pdf"},
    {"id":"18384","name":"Draft guideline on the investigation of medicinal products in the term and preterm neonate - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-01T02:00:00Z","last_updated_date":"2007-10-01T02:00:00Z","reference_number":"EMEA/267484/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-investigation-medicinal-products-term-and-preterm-neonate-first-version_en.pdf"},
    {"id":"18389","name":"List of changes for list of species and breeds for 2011","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-07-19T02:00:00Z","last_updated_date":"2011-06-30T02:00:00Z","reference_number":"EMA/CVMP/PhVWP/377827/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/list-changes-list-species-and-breeds-2011_en.pdf"},
    {"id":"18390","name":"Reflection paper on MRSA in food producing and companion animals in the European Union: epidemiology and control options for human and animal health","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-03-26T01:00:00Z","last_updated_date":"2009-03-26T01:00:00Z","reference_number":"EMEA/CVMP/SAGAM/68290/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-mrsa-food-producing-and-companion-animals-european-union-epidemiology-and-control-options-human-and-animal-health_en.pdf"},
    {"id":"18405","name":"Draft reflection paper on the risk of antimicrobial resistance transfer from companion animals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-10-21 - 2014-01-31","first_published_date":"2013-10-21T15:00:00Z","last_updated_date":"2013-10-21T15:00:00Z","reference_number":"EMA/CVMP/AWP/401740/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-risk-antimicrobial-resistance-transfer-companion-animals_en.pdf"},
    {"id":"18437","name":"Position paper on compliance of veterinary vaccines with veterinary vaccine monographs of the European pharmacopoeia - Obsolete","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-06-01T02:00:00Z","last_updated_date":"1999-06-01T02:00:00Z","reference_number":"EMEA/CVMP/140/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-compliance-veterinary-vaccines-veterinary-vaccine-monographs-european-pharmacopoeia-obsolete_en.pdf"},
    {"id":"18462","name":"Note for guidance: Manufacture of the finished dosage form","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1995-12-01T01:00:00Z","last_updated_date":"1995-12-01T01:00:00Z","reference_number":"EMEA/CVMP/126/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-manufacture-finished-dosage-form_en.pdf"},
    {"id":"18477","name":"Reflection paper on the level of purification of extracts to be considered as herbal preparations","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-01-03T01:00:00Z","last_updated_date":"2011-01-03T01:00:00Z","reference_number":"EMA/HMPC/186645/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-level-purification-extracts-be-considered-herbal-preparations_en.pdf"},
    {"id":"18483","name":"VICH GL43: Target animal safety for veterinary pharmaceutical products - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-09-22T02:00:00Z","last_updated_date":"2008-09-22T02:00:00Z","reference_number":"EMEA/CVMP/VICH/393388/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl43-target-animal-safety-veterinary-pharmaceutical-products-step-7_en.pdf"},
    {"id":"18536","name":"ICH: E 7: Studies in support of special populations: Geriatrics - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"1994-03-01T01:00:00Z","last_updated_date":"2010-07-27T02:00:00Z","reference_number":"EMA/CHMP/604661/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-7-studies-support-special-populations-geriatrics-step-5_en.pdf"},
    {"id":"18559","name":"Core SPC for human Tick-borne Encephalitis immunoglobulin for intramuscular use (CPMP/BPWG/3732/02)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"CPMP/BPWG/3732/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/core-spc-human-tick-borne-encephalitis-immunoglobulin-intramuscular-use-cpmpbpwg373202_en.pdf"},
    {"id":"18567","name":"VICH GL18(R): Impurities: Residual solvents in new veterinary medicinal products, active substances and excipients - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-09-26T13:49:00Z","last_updated_date":"2011-09-26T13:49:00Z","reference_number":"EMA/CVMP/VICH/502/99-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl18r-impurities-residual-solvents-new-veterinary-medicinal-products-active-substances-and-excipients-revision-1_en.pdf"},
    {"id":"18571","name":"Reflection paper on assessment of bioavailability of bound residues in food commodities of animal origin in the context of council regulation (EEC) NO 2377/90","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-09-22T02:00:00Z","last_updated_date":"2008-09-22T02:00:00Z","reference_number":"EMEA/CVMP/SWP/95682/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-assessment-bioavailability-bound-residues-food-commodities-animal-origin-context-council-regulation-eec-no-237790_en.pdf"},
    {"id":"18604","name":"Concept paper on proposed revision to the Guideline for the conduct of efficacy studies for NSAIDs","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-05-19 - 2010-11-30","first_published_date":"2010-05-28T04:00:00Z","last_updated_date":"2010-09-28T04:00:00Z","reference_number":"EMA/CVMP/EWP/62867/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-proposed-revision-guideline-conduct-efficacy-studies-nsaids_en.pdf"},
    {"id":"18614","name":"Points to consider on clinical investigation of new medicinal products for the treatment of acute coronary syndrome (ACS) without persistent st-segment elevation - Superseded document","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-02-17T01:00:00Z","last_updated_date":"2000-02-17T01:00:00Z","reference_number":"CPMP/EWP/570/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-clinical-investigation-new-medicinal-products-treatment-acute-coronary-syndrome-acs-without-persistent-st-segment-elevation-superseded-document_en.pdf"},
    {"id":"18650","name":"Draft guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/14327/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-first-version_en.pdf"},
    {"id":"18668","name":"Overview of comments received on 'Guideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species (MUMS)/limited market' (EMA/CVMP/IWP/123243/2006-Rev.3) - Revision ...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T12:30:00Z","last_updated_date":"2017-04-21T12:30:00Z","reference_number":"EMA/CVMP/IWP/506137/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-guideline-data-requirements-immunological-veterinary-medicinal-products-intended-minor-use-or-minor-species-mumslimited-market-emacvmpiwp1232432006-rev3-revision_en.pdf"},
    {"id":"18669","name":"Draft guideline on Real Time Release Testing (formerly Guideline on Parametric Release)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-12-17 - 2010-08-31","first_published_date":"2010-03-03T02:00:00Z","last_updated_date":"2010-03-03T02:00:00Z","reference_number":"EMA/CHMP/QWP/811210/2009 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-real-time-release-testing-formerly-guideline-parametric-release_en.pdf"},
    {"id":"18674","name":"Reflection paper on stability testing of herbal medicinal products and traditional herbal medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-11-12T01:00:00Z","last_updated_date":"2010-11-12T01:00:00Z","reference_number":"EMA/HMPC/3626/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-stability-testing-herbal-medicinal-products-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"18675","name":"Draft guideline on validation of bionanalytical methods","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-11-20 - 2010-05-31","first_published_date":"2009-12-08T01:09:21Z","last_updated_date":"2009-12-08T01:09:21Z","reference_number":"EMEA/CHMP/EWP/192217/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-validation-bionanalytical-methods_en.pdf"},
    {"id":"18743","name":"Guideline on clinical development of fixed combination medicinal products - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-31T13:00:00Z","last_updated_date":"2017-03-31T13:00:00Z","reference_number":"EMA/CHMP/158268/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-fixed-combination-medicinal-products-revision-2_en.pdf"},
    {"id":"18804","name":"Implementation strategy of ICH Q3D guideline","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-08T16:45:00Z","last_updated_date":"2017-03-08T16:45:00Z","reference_number":"EMA/CHMP/QWP/115498/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/implementation-strategy-ich-q3d-guideline_en.pdf"},
    {"id":"18814","name":"Concept paper on the need for revision of the guideline of medical products used in weight control - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-10-01 - 2012-12-31","first_published_date":"2012-10-01T18:30:00Z","last_updated_date":"2012-10-01T18:30:00Z","reference_number":"EMA/CHMP/229823/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-medical-products-used-weight-control-revision-1_en.pdf"},
    {"id":"18821","name":"Guideline on the conduct of efficacy studies for intramammary products for use in cattle - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-01-26T17:20:00Z","last_updated_date":"2017-01-26T17:20:00Z","reference_number":"EMA/CVMP/344/1999-Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-efficacy-studies-intramammary-products-use-cattle-revision-2_en.pdf"},
    {"id":"18847","name":"Reflection paper on water for injection prepared by reverse osmosis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-03-05T01:00:00Z","last_updated_date":"2008-03-05T01:00:00Z","reference_number":"EMEA/CHMP/CVMP/QWP/28271/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-water-injection-prepared-reverse-osmosis_en.pdf"},
    {"id":"18850","name":"Draft tadalafil film-coated tablets 2.5 mg, 5 mg, 10 mg and 20 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-08-03 - 2017-10-31","first_published_date":"2017-08-03T20:35:01Z","last_updated_date":"2017-08-03T20:35:01Z","reference_number":"EMA/CHMP/315234/2014/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-tadalafil-film-coated-tablets-25-mg-5-mg-10-mg-and-20-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"18856","name":"Draft guideline on equivalence studies for the demonstration of therapeutic equivalence for products that are locally applied, locally acting in the gastrointestinal tract as addendum to the guidance CHMP/EWP/239/95 - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-04-04 - 2017-09-30","first_published_date":"2017-04-04T21:15:00Z","last_updated_date":"2017-04-04T21:15:00Z","reference_number":"CPMP/EWP/239/95 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-equivalence-studies-demonstration-therapeutic-equivalence-products-are-locally-applied-locally-acting-gastrointestinal-tract-addendum-guidance-chmp-ewp-239-95-revision-1_en.pdf"},
    {"id":"18878","name":"Position paper on production of Tallow derivatives for use in pharmaceuticals","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-12-17T01:00:00Z","last_updated_date":"1997-12-17T01:00:00Z","reference_number":"CPMP/1163/97","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-production-tallow-derivatives-use-pharmaceuticals_en.pdf"},
    {"id":"18907","name":"Guideline on good pharmacovigilance practices: Module X – Additional monitoring with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-04-25T12:00:00Z","last_updated_date":"2013-04-25T12:00:00Z","reference_number":"EMA/237329/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-x-additional-monitoring-tracked-changes_en.pdf"},
    {"id":"18909","name":"Draft guideline on the adventitious agent safety of urine-derived medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-22 - 2014-05-31","first_published_date":"2013-11-22T15:40:00Z","last_updated_date":"2013-11-22T15:40:00Z","reference_number":"EMA/CHMP/BWP/126802/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-adventitious-agent-safety-urine-derived-medicinal-products_en.pdf"},
    {"id":"18929","name":"CHMP position statement on Creutzfeldt-Jacob disease and plasma-derived and urine-derived medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-23T02:00:00Z","last_updated_date":"2004-06-23T02:00:00Z","reference_number":"EMEA/CPMP/BMP/2879/02/ rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chmp-position-statement-creutzfeldt-jacob-disease-and-plasma-derived-and-urine-derived-medicinal-products-revision-1_en.pdf"},
    {"id":"18943","name":"Concept paper on the need for revision of guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-06-23 - 2011-09-30","first_published_date":"2011-07-08T04:00:00Z","last_updated_date":"2011-07-08T04:00:00Z","reference_number":"EMA/CHMP/CNSWP/257565/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en.pdf"},
    {"id":"18977","name":"Draft guideline on good pharmacovigilance practices: Module I - Pharmacovigilance systems and their quality systems","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-02-22T14:20:00Z","last_updated_date":"2012-02-22T14:20:00Z","reference_number":"EMA/541760/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-i-pharmacovigilance-systems-and-their-quality-systems_en.pdf"},
    {"id":"19001","name":"Draft VICH GL51: Quality: statistical evaluation of stability data","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-12-08 - 2012-06-12","first_published_date":"2011-12-20T16:15:00Z","last_updated_date":"2011-12-20T16:15:00Z","reference_number":"EMA/CVMP/VICH/858875/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl51-quality-statistical-evaluation-stability-data_en.pdf"},
    {"id":"19005","name":"Demonstration of efficacy of ectoparasiticides","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-09-01T02:00:00Z","last_updated_date":"1994-09-01T02:00:00Z","reference_number":"7AE17a Volume 7 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/demonstration-efficacy-ectoparasiticides_en.pdf"},
    {"id":"19036","name":"Concept paper on the revision of the guideline on dossier structure and content for pandemic influenza marketing authorisation application (CPMP/VEG/4717/03) - Superseded","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-05-15T02:00:00Z","last_updated_date":"2007-05-15T02:00:00Z","reference_number":"EMEA/CHMP/166042/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-dossier-structure-and-content-pandemic-influenza-marketing-authorisation-application-cpmpveg471703-superseded_en.pdf"},
    {"id":"19048","name":"Concept paper on the development of a CHMP guideline on extrapolation results in clinical studies to the EU-population","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"EMEA/CHMP/EWP/7799/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-chmp-guideline-extrapolation-results-clinical-studies-eu-population_en.pdf"},
    {"id":"19068","name":"Draft questions and answers on the haemagglutination inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-02-01 - 2018-07-31","first_published_date":"2018-02-01T14:58:00Z","last_updated_date":"2018-02-01T14:58:00Z","reference_number":"EMA/CHMP/BWP/426390/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-and-answers-haemagglutination-inhibition-hi-test-qualification-influenza-vaccine-inactivated-seed-preparations-first-version_en.pdf"},
    {"id":"19102","name":"Draft guideline on the clinical evaluation of antifungal agents for the treatment and prophylaxis of invasive fungal disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"CHMP/EWP/1343/01 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-antifungal-agents-treatment-and-prophylaxis-invasive-fungal-disease_en.pdf"},
    {"id":"19148","name":"Concept paper on the revision of the note for guidance on the quality, pre-clinical and clinical aspects of gene transfer medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-12-17 - 2010-03-31","first_published_date":"2010-01-13T01:09:21Z","last_updated_date":"2010-01-13T01:09:21Z","reference_number":"EMA/CHMP/GTWP/BWP/234523/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-quality-pre-clinical-and-clinical-aspects-gene-transfer-medicinal-products_en.pdf"},
    {"id":"19150","name":"Concept paper on the revision of the guideline for veterinary medicinal products for zootechnical purposes","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-12-16 - 2017-03-31","first_published_date":"2016-12-16T20:00:00Z","last_updated_date":"2016-12-16T20:00:00Z","reference_number":"EMA/CVMP/EWP/707573/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-veterinary-medicinal-products-zootechnical-purposes_en.pdf"},
    {"id":"19153","name":"Guideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species/limited markets - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2010-04-23T02:00:00Z","reference_number":"EMA/CVMP/IWP/123243/2006-Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-immunological-veterinary-medicinal-products-intended-minor-use-or-minor-specieslimited-markets-revision-2_en.pdf"},
    {"id":"19164","name":"Draft CVMP strategy on antimicrobials 2016-2020","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-11-17 - 2016-02-29","first_published_date":"2015-11-17T14:00:00Z","last_updated_date":"2015-11-17T14:00:00Z","reference_number":"EMA/CVMP/209189/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-cvmp-strategy-antimicrobials-2016-2020_en.pdf"},
    {"id":"19177","name":"Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-06-19T02:00:00Z","last_updated_date":"2007-06-19T02:00:00Z","reference_number":"EMEA/CHMP/QWP/396951/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-excipients-dossier-application-marketing-authorisation-medicinal-product-revision-2_en.pdf"},
    {"id":"19181","name":"Volume 3b guidelines: Medicinal products for human use: Safety, environment and information: Excipients in the label and package leaflet of medicinal products for human use","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2018-03-01T01:00:00Z","reference_number":"CPMP/463/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/volume-3b-guidelines-medicinal-products-human-use-safety-environment-and-information-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf-0"},
    {"id":"19205","name":"Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-08-03T13:00:00Z","last_updated_date":"2018-08-03T13:00:00Z","reference_number":"EMA/CHMP/800759/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cholic-acid-capsules-50-mg-250-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"19253","name":"Guideline on good pharmacovigilance practices: Module V – Risk management systems with tracked changes (Rev. 2)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:00:00Z","last_updated_date":"2017-03-30T17:00:00Z","reference_number":"EMA/838713/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-tracked-changes-rev-2_en.pdf"},
    {"id":"19264","name":"Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-06-03T14:30:00Z","last_updated_date":"2014-06-03T14:30:00Z","reference_number":"EMA/CHMP/BWP/247713/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality-issues-revision-1_en.pdf"},
    {"id":"19284","name":"Dolutegravir film-coated tablets 10 mg, 25 mg and 50 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-02-01T13:00:00Z","last_updated_date":"2018-02-01T13:00:00Z","reference_number":"EMA/CHMP/356874/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/dolutegravir-film-coated-tablets-10-mg-25-mg-and-50-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"19325","name":"ICH: E 16: Note for guidance on genomic biomarkers related to drug response: context, structure and format of qualification submissions - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-06-01T02:00:00Z","last_updated_date":"2009-06-01T02:00:00Z","reference_number":"EMEA/CHMP/ICH/380636/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-16-note-guidance-genomic-biomarkers-related-drug-response-context-structure-and-format-qualification-submissions-step-3_en.pdf"},
    {"id":"19331","name":"Reflection paper on the new approach developed by JECFA for exposure and MRL assessment of residues of VMP","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-09-22T02:00:00Z","last_updated_date":"2008-09-22T02:00:00Z","reference_number":"EMEA/CVMP/SWP/138366/2008-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-new-approach-developed-jecfa-exposure-and-mrl-assessment-residues-vmp_en.pdf"},
    {"id":"19336","name":"Draft reflection paper on the extrapolation of results from clinical studies conducted outside Europe to the European Union population","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"EMEA/CHMP/EWP/692702/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-extrapolation-results-clinical-studies-conducted-outside-europe-european-union-population_en.pdf"},
    {"id":"19344","name":"Guideline on good pharmacovigilance practices (GVP) - Module VIII Addendum I – Requirements and recommendations for the submission of information on non-interventional post-authorisation safety studies (Rev. 2)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T19:19:00Z","last_updated_date":"2020-06-23T14:00:00Z","reference_number":"EMA/395730/2012 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-addendum-i-requirements-and-recommendations-submission-information-non-interventional-post-authorisation-safety-studies-rev-2_en.pdf"},
    {"id":"19347","name":"Concept paper on the development of a committee for proprietary medicinal products (CPMP) note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2001-05-21T02:00:00Z","last_updated_date":"2001-05-21T02:00:00Z","reference_number":"CPMP/EWP/512/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-proprietary-medicinal-products-cpmp-note-guidance-evaluation-medicinal-products-treatment-dyslipoproteinaemia_en.pdf"},
    {"id":"19366","name":"Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-08-02T02:00:00Z","last_updated_date":"2010-08-02T02:00:00Z","reference_number":"EMA/CHMP/BPWP/94033/2007 rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-revision-2_en.pdf"},
    {"id":"19387","name":"Concept paper for the revision of the note for guidance on the use of adjuvanted veterinary vaccines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-09-28 - 2016-12-31","first_published_date":"2016-09-28T17:35:00Z","last_updated_date":"2016-09-28T17:35:00Z","reference_number":"EMA/CVMP/IWP/867395/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-use-adjuvanted-veterinary-vaccines-revision-1_en.pdf"},
    {"id":"19404","name":"Information for the package leaflet regarding aspartame and phenylalanine used as excipients in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2018-11-19T12:24:00Z","reference_number":"EMA/CHMP/134648/2015 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/information-package-leaflet-regarding-aspartame-and-phenylalanine-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"19423","name":"Draft guideline on radiopharmaceuticals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-05T02:00:00Z","last_updated_date":"2007-10-05T02:00:00Z","reference_number":"EMEA/CHMP/QWP/306970/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-radiopharmaceuticals_en.pdf"},
    {"id":"19520","name":"ICH guideline Q4B Annex 3 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on test for particulate contamination: sub-visible particles general chapter - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2017-07-13T16:30:00Z","reference_number":"EMEA/CHMP/ICH/561176/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-3-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-test-particulate-contamination-sub-visible-particles-general-chapter-step-5_en.pdf"},
    {"id":"19584","name":"Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-23T11:48:01Z","last_updated_date":"2018-07-23T11:48:01Z","reference_number":"CHMP/EWP/18463/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-new-medicinal-products-treatment-ulcerative-colitis-revision-1_en.pdf"},
    {"id":"19585","name":"Guideline on the Core SPC for human plasma derived and recombinant coagulation factor VIII products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-06-29T02:00:00Z","last_updated_date":"2000-06-29T02:00:00Z","reference_number":"CPMP/BPWG/1619/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-plasma-derived-and-recombinant-coagulation-factor-viii-products_en.pdf"},
    {"id":"19590","name":"Guideline on pharmaceutical fixed combination products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-12-18T01:00:00Z","last_updated_date":"2006-12-18T01:00:00Z","reference_number":"EMEA/CVMP/83804/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-fixed-combination-products_en.pdf"},
    {"id":"19623","name":"Draft emtricitabine/tenofovir disoproxil product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/423726/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-emtricitabine-tenofovir-disoproxil-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"19625","name":"Guideline on potency labelling for insulin analogue containing products with particular reference to the use of international units or units","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-05-24T02:00:00Z","last_updated_date":"2006-05-24T02:00:00Z","reference_number":"EMEA/CHMP/BWP/124446/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-potency-labelling-insulin-analogue-containing-products-particular-reference-use-international-units-or-units_en.pdf"},
    {"id":"19631","name":"Core SPC for human Tetanus immunoglobulin for intramuscular use\n\n(CPMP/BPWG/3730/02)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"CPMP/BPWG/3730/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/core-spc-human-tetanus-immunoglobulin-intramuscular-use-cpmpbpwg373002_en.pdf"},
    {"id":"19636","name":"Points to consider on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-10-19T02:00:00Z","last_updated_date":"2000-10-19T02:00:00Z","reference_number":"CPMP/EWP/565/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"19670","name":"VICH GL7: Efficacy requirements for anthelmintics overall guidelines - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-12-07T01:00:00Z","last_updated_date":"2000-12-07T01:00:00Z","reference_number":"CVMP/VICH/832/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl7-efficacy-requirements-anthelmintics-overall-guidelines-step-7_en.pdf"}    {"id":"19702","name":"Compilation of individual product-specific guidance on demonstration of bioequivalence rev 2","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-07-07T14:15:00Z","last_updated_date":"2015-07-07T14:15:00Z","reference_number":"EMA/CHMP/736403/2014 Rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/compilation-individual-product-specific-guidance-demonstration-bioequivalence-rev-2_en.pdf"},
    {"id":"19713","name":"Draft points to consider on frailty: Evaluation instruments for baseline characterisation of clinical trial populations - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-12-21 - 2016-05-31","first_published_date":"2015-12-21T13:05:00Z","last_updated_date":"2015-12-21T13:05:00Z","reference_number":"EMA/CHMP/778709/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-points-consider-frailty-evaluation-instruments-baseline-characterisation-clinical-trial-populations-first-version_en.pdf"},
    {"id":"19812","name":"Draft guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-01-31 - 2013-07-31","first_published_date":"2013-01-31T19:20:00Z","last_updated_date":"2013-01-31T19:20:00Z","reference_number":"EMEA/CHMP/BMWP/118264/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-low-molecular-weight-heparins_en.pdf"},
    {"id":"19819","name":"Draft guideline on core summary of product characteristics and package leaflet for radiopharmaceuticals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-03-17 - 2011-04-25","first_published_date":"2011-03-30T04:00:00Z","last_updated_date":"2011-03-30T04:00:00Z","reference_number":"EMA/CHMP/167834/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-and-package-leaflet-radiopharmaceuticals_en.pdf"},
    {"id":"19842","name":"Draft guideline on good pharmacovigilance practices: Module II - Pharmacovigilance system master file","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-02-22T14:20:00Z","last_updated_date":"2012-02-22T14:20:00Z","reference_number":"EMA/816573/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file_en.pdf"},
    {"id":"19879","name":"Guideline on the non-clinical development of fixed combinations of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-01-24T01:00:00Z","last_updated_date":"2008-01-24T01:00:00Z","reference_number":"CHMP/EMEA/CHMP/SWP/258498/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-development-fixed-combinations-medicinal-products_en.pdf"},
    {"id":"19905","name":"Draft guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies – Superseded","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-08-06 - 2018-10-31","first_published_date":"2018-08-06T19:13:00Z","last_updated_date":"2018-08-06T19:13:00Z","reference_number":"EMA/CHMP/459559/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-use-minimal-residual-disease-clinical-endpoint-multiple-myeloma-studies-superseded_en.pdf"},
    {"id":"19910","name":"Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"CHMP/EWP/89249/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-pharmacokinetics-therapeutic-proteins_en.pdf"},
    {"id":"20018","name":"Public Statement on the use of herbal medicinal products containing estragole","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-23T01:00:00Z","last_updated_date":"2005-11-23T01:00:00Z","reference_number":"EMEA/HMPC/137212/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-use-herbal-medicinal-products-containing-estragole_en.pdf"},
    {"id":"20025","name":"Draft appendix 2 to the guideline on the evaluation of anticancer medicinal products in man (CPMP/EWP/205/95 REV. 3) on haematological malignancies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-11-20T00:09:21Z","last_updated_date":"2008-11-20T00:09:21Z","reference_number":"EMEA/CHMP/EWP/520088/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-appendix-2-guideline-evaluation-anticancer-medicinal-products-man-cpmpewp20595-rev-3-haematological-malignancies_en.pdf"},
    {"id":"20044","name":"Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products- Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/HMPC/71049/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products-revision-2_en.pdf"},
    {"id":"20055","name":"Note for guidance on the investigation of bioavailability and bioequivalence","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-07-26T02:00:00Z","last_updated_date":"2001-07-26T02:00:00Z","reference_number":"CPMP/EWP/QWP/1401/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-investigation-bioavailability-and-bioequivalence_en.pdf"},
    {"id":"20073","name":"Principles on assignment of defined daily dose for animals (DDDvet) and defined course dose for animals (DCDvet)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-06-30T16:08:00Z","last_updated_date":"2015-06-30T16:08:00Z","reference_number":"EMA/710019/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/principles-assignment-defined-daily-dose-animals-dddvet-and-defined-course-dose-animals-dcdvet_en.pdf"},
    {"id":"20089","name":"ICH guideline for good clinical practice E6(R2) 4 - Step 2b - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-08-04 - 2016-02-03","first_published_date":"2015-08-04T15:00:00Z","last_updated_date":"2015-08-04T15:00:00Z","reference_number":"EMA/CHMP/ICH/135/1995","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-4-step-2b-revision-1_en.pdf"},
    {"id":"20144","name":"Concept paper on the need for the development of a paediatric addendum to the note for guidance on the clinical investigation on medicinal products in the treatment of hypertension","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/CHMP/EWP/545456/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-development-paediatric-addendum-note-guidance-clinical-investigation-medicinal-products-treatment-hypertension_en.pdf"},
    {"id":"20184","name":"Guideline on good pharmacovigilance practices: Module V – Risk management systems (Rev.1) (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/838713/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev1-superseded_en.pdf"},
    {"id":"20197","name":"Paliperidone prolonged-release tablet 1.5 mg, 3 mg, 6 mg, 9 mg and 12 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-01-03T17:14:00Z","last_updated_date":"2017-01-03T17:14:00Z","reference_number":"EMA/CHMP/156358/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paliperidone-prolonged-release-tablet-15-mg-3-mg-6-mg-9-mg-and-12-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"20212","name":"Draft concept paper for a guideline on user safety of topically administered products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-03-24 - 2014-06-30","first_published_date":"2014-03-24T16:00:00Z","last_updated_date":"2014-03-24T16:00:00Z","reference_number":"EMA/CVMP/SWP/92311/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-guideline-user-safety-topically-administered-products_en.pdf"},
    {"id":"20223","name":"Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-05-14T16:22:00Z","last_updated_date":"2012-05-14T16:22:00Z","reference_number":"EMA/CHMP/BWP/534898/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials-first-version_en.pdf"},
    {"id":"20229","name":"Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-03-15T16:30:00Z","last_updated_date":"2012-03-15T16:30:00Z","reference_number":"EMA/CVMP/ERAWP/409328/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-mitigation-measures-related-environmental-risk-assessment-veterinary-medicinal-products_en.pdf"},
    {"id":"20261","name":"Draft note for guidance on plasma derived medicinal products (CPMP/BWP/269/05 rev. 3) - Addendum on the replacement of rabbit pyrogen testing by an alternative test for plasma derived medicinal products (EMEA/CHMP/BWP/45...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-12-05T01:00:00Z","last_updated_date":"2007-12-05T01:00:00Z","reference_number":"EMEA/CHMP/BWP/452081/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-plasma-derived-medicinal-products-cpmpbwp26905-rev-3-addendum-replacement-rabbit-pyrogen-testing-alternative-test-plasma-derived-medicinal-products-emeachmpbwp45_en.pdf"},
    {"id":"20364","name":"Position paper on data requirements for removing the target animal batch safety test for immunological veterinary medicinal products in the European Union","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-01T02:00:00Z","last_updated_date":"2004-07-01T02:00:00Z","reference_number":"EMEA/CVMP/865/03/Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-data-requirements-removing-target-animal-batch-safety-test-immunological-veterinary-medicinal-products-european-union_en.pdf"},
    {"id":"20404","name":"Note for guidance on coordinating investigator signature of clinical study reports","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-10-18T02:00:00Z","last_updated_date":"2001-10-18T02:00:00Z","reference_number":"CPMP/EWP/2747/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-coordinating-investigator-signature-clinical-study-reports_en.pdf"},
    {"id":"20450","name":"Reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in food-producing animals in the European Union development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-11-29T16:00:00Z","last_updated_date":"2011-11-29T16:00:00Z","reference_number":"EMA/CVMP/SAGAM/741087/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-macrolides-lincosamides-streptogramins-mls-food-producing-animals-european-union-development-resistance-impact-human-animal-health_en.pdf"},
    {"id":"20464","name":"Concept paper on qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and analyses","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-06-27 - 2014-09-30","first_published_date":"2014-06-27T20:30:00Z","last_updated_date":"2014-06-27T20:30:00Z","reference_number":"EMA/CHMP/211243/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-qualification-and-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-and-analyses_en.pdf"},
    {"id":"20466","name":"Note for guidance on quality of modified release products: A: oral dosage formsB: transdermal dosage forms section I (quality) - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-07-29T02:00:00Z","last_updated_date":"1999-07-29T02:00:00Z","reference_number":"CPMP/QWP/604/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-quality-modified-release-products-oral-dosage-formsb-transdermal-dosage-forms-section-i-quality-superseded_en.pdf"},
    {"id":"20502","name":"ICH guideline S9 on non-clinical evaluation for anticancer pharmaceuticals - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2013-02-11T12:00:00Z","reference_number":"EMA/CHMP/ICH/646107/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-s9-non-clinical-evaluation-anticancer-pharmaceuticals-step-5_en.pdf"},
    {"id":"20508","name":"Appendix 2 to the Guideline on the evaluation of Anticancer Medicinal Products in Man (CPMP/EWP/205/95 Rev. 3) on Confirmatory studies in Haematological Malignancies","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-03-03T01:09:00Z","last_updated_date":"2010-03-03T01:09:00Z","reference_number":"EMA/CHMP/EWP/520088/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-2-guideline-evaluation-anticancer-medicinal-products-man-cpmpewp20595-rev-3-confirmatory-studies-haematological-malignancies_en.pdf"},
    {"id":"20524","name":"Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:  Non-clinical and clinical issues - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-02-22T01:00:00Z","last_updated_date":"2006-02-22T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/94528/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-first-version_en.pdf"},
    {"id":"20548","name":"Draft guideline on core summary of product characteristics for human plasma derived and recombinant coagulation factor VIII products - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-06-01 - 2015-07-01","first_published_date":"2015-06-01T19:00:00Z","last_updated_date":"2015-06-01T19:00:00Z","reference_number":"EMA/CHMP/BPWP/1619/1999 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-human-plasma-derived-and-recombinant-coagulation-factor-viii-products-revision-2_en.pdf"},
    {"id":"20563","name":"Note for guidance on clinical investigation of medicinal products in the treatment of Diabetes Mellitus","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-05-30T02:00:00Z","last_updated_date":"2002-05-30T02:00:00Z","reference_number":"CPMP/EWP/1080/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-diabetes-mellitus_en.pdf"},
    {"id":"20566","name":"Guideline on Influenza vaccines – Quality module Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-28T14:00:00Z","last_updated_date":"2017-07-28T14:00:00Z","reference_number":"EMA/CHMP/BWP/310834/2012 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-influenza-vaccines-quality-module-revision-1_en.pdf"},
    {"id":"20602","name":"Entecavir film-coated tablets 0.5 and 1 mg, oral solution 0.05mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-11-01T17:30:07Z","reference_number":"EMA/CHMP/160445/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/entecavir-film-coated-tablets-05-and-1-mg-oral-solution-005mgml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"20623","name":"Guideline on radiopharmaceuticals based on monoclonal antibodies","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1991-05-01T02:00:00Z","last_updated_date":"1991-05-01T02:00:00Z","reference_number":"3AQ21A","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-radiopharmaceuticals-based-monoclonal-antibodies_en.pdf"},
    {"id":"20643","name":"Draft guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-07-31 - 2019-07-31","first_published_date":"2018-07-31T18:00:00Z","last_updated_date":"2018-07-31T18:00:00Z","reference_number":"EMA/CAT/GTWP/671639/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-and-clinical-aspects-medicinal-products-containing-genetically-modified-cells-revision-1_en.pdf"},
    {"id":"20663","name":"Concept paper on revision of guidelines on the clinical investigation and core SmPC of recombinant and human plasma-derived factor VIII products (EMA/CHMP/BPWP/144533/2009 rev. 1)  (EMA/CHMP/BPWP/1619/1999 rev. 2)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-01 - 2016-09-30","first_published_date":"2016-08-01T20:00:00Z","last_updated_date":"2016-08-01T20:00:00Z","reference_number":"EMA/CHMP/BPWP/383118/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidelines-clinical-investigation-and-core-smpc-recombinant-and-human-plasma-derived-factor-viii-products-ema-chmp-bpwp-144533-2009-rev-1-ema-chmp-bpwp-1619-1999-rev-2_en.pdf"},
    {"id":"20679","name":"Points to consider on wording of Helicobacter Pylori eradication therapy in selected SPC sections","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-09-23T02:00:00Z","last_updated_date":"1999-09-23T02:00:00Z","reference_number":"CPMP/EWP/863/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-wording-helicobacter-pylori-eradication-therapy-selected-spc-sections_en.pdf"},
    {"id":"20691","name":"CHMP SWP Reflection Paper on PPARs (Peroxisome Proliferator Activated Receptors)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-09-01T02:09:21Z","last_updated_date":"2006-09-01T02:09:21Z","reference_number":"EMEA/341972/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chmp-swp-reflection-paper-ppars-peroxisome-proliferator-activated-receptors_en.pdf"},
    {"id":"20695","name":"Concept paper on the need for a guideline on the development of new medicinal products intended for the management and treatment of cystic fibrosis - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-03-22T01:00:00Z","last_updated_date":"2007-03-22T01:00:00Z","reference_number":"EMEA/CHMP/EWP/81927/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-development-new-medicinal-products-intended-management-and-treatment-cystic-fibrosis-first-version_en.pdf"},
    {"id":"20703","name":"Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T11:10:00Z","last_updated_date":"2016-01-05T11:10:00Z","reference_number":"EMA/CHMP/236981/2011 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-duchenne-and-becker-muscular-dystrophy_en.pdf"},
    {"id":"20714","name":"ICH guideline Q4B Annex 4B on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on Tests for specified micro-organisms - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-06-01T02:00:00Z","last_updated_date":"2017-07-13T16:30:00Z","reference_number":"EMEA/CHMP/ICH/308817/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-tests-specified-micro-organisms-step-5_en.pdf"},
    {"id":"20755","name":"ICH guideline Q2(R1) Validation of analytical procedures: Text and methodology – Step 5 - first version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1995-06-01T02:00:00Z","last_updated_date":"1995-06-01T02:00:00Z","reference_number":"CPMP/ICH/381/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q2r1-validation-analytical-procedures-text-methodology-step-5-first-version_en.pdf"},
    {"id":"20763","name":"Guideline on clinical investigation of recombinant and human plasma-derived factor IX products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-06-01T17:00:00Z","last_updated_date":"2015-06-01T17:00:00Z","reference_number":"EMA/CHMP/BPWP/144552/2009 Rev.1 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-ix-products-revision-1_en.pdf"},
    {"id":"20770","name":"Explanatory note on the withdrawal of the Note for guidance on harmonisation of requirements for influenza Vaccines and of the core SmPC/PL for inactivated seasonal influenza vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-02-07T01:00:00Z","last_updated_date":"2014-02-07T01:00:00Z","reference_number":"EMA/CHMP/VWP/40560/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/explanatory-note-withdrawal-note-guidance-harmonisation-requirements-influenza-vaccines-and-core-smpcpl-inactivated-seasonal-influenza-vaccines_en.pdf"},
    {"id":"20771","name":"Public statement committee for medicinal products for veterinary use meeting of 16-18 May 2006","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-05-19T02:00:00Z","last_updated_date":"2006-05-19T02:00:00Z","reference_number":"EMEA/CVMP/168467/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-committee-medicinal-products-veterinary-use-meeting-16-18-may-2006_en.pdf"},
    {"id":"20868","name":"Draft guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-10-11T02:00:00Z","last_updated_date":"2006-10-11T02:00:00Z","reference_number":"EMEA/CHMP/BWP/271475/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-potency-testing-cell-based-immunotherapy-medicinal-products-treatment-cancer_en.pdf"},
    {"id":"20873","name":"Reflection paper on markers used for quantitative and qualitative\n\nanalysis of herbal medicinal products and traditional herbal\n\nmedicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-15T02:00:00Z","last_updated_date":"2008-07-15T02:00:00Z","reference_number":"EMEA/HMPC/253629/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-markers-used-quantitative-and-qualitative-analysis-herbal-medicinal-products-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"20906","name":"Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-06-24 - 2010-11-30","first_published_date":"2010-07-12T04:00:00Z","last_updated_date":"2010-07-12T04:00:00Z","reference_number":"EMA/CHMP/641298/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-co-development-pharmacogenomic-biomarkers-and-assays-context-drug-development_en.pdf"},
    {"id":"20935","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use topic E 2 D: Postapproval safety data management - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-11-30T01:00:00Z","last_updated_date":"2003-11-30T01:00:00Z","reference_number":"CPMP/ICH/3945/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-topic-e-2-d-postapproval-safety-data-management-step-5_en.pdf"},
    {"id":"20954","name":"Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) - Rev. 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-20T16:45:00Z","last_updated_date":"2018-07-20T16:45:00Z","reference_number":"EMA/CHMP/BPWP/94038/2007 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-5_en.pdf"},
    {"id":"20968","name":"Draft guideline on the use of near infrared spectroscopy by the pharmaceutical industry and the data requirements for new submissions and variations - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-01-12 - 2012-05-31","first_published_date":"2012-02-09T17:10:00Z","last_updated_date":"2012-02-09T17:10:00Z","reference_number":"EMEA/CHMP/CVMP/QWP/17760/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-use-near-infrared-spectroscopy-pharmaceutical-industry-and-data-requirements-new-submissions-and-variations-revision-2_en.pdf"},
    {"id":"21002","name":"Draft guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-01-08 - 2013-06-30","first_published_date":"2013-01-08T14:00:00Z","last_updated_date":"2013-01-08T14:00:00Z","reference_number":"EMA/CHMP/CVMP/SWP/169430/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-setting-health-based-exposure-limits-use-risk-identification-manufacture-different-medicinal-products-shared-facilities_en.pdf"},
    {"id":"21003","name":"VICH GL44: Target animal safety for veterinary live and inactived vaccines - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-09-22T02:00:00Z","last_updated_date":"2008-09-22T02:00:00Z","reference_number":"EMEA/CVMP/VICH/359665/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl44-target-animal-safety-veterinary-live-and-inactived-vaccines-step-7_en.pdf"},
    {"id":"21021","name":"Reflection paper on the adaptogenic concept","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-05-08T02:00:00Z","last_updated_date":"2008-05-08T02:00:00Z","reference_number":"EMEA/HMPC/102655/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-adaptogenic-concept_en.pdf"},
    {"id":"21026","name":"Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-05-03T16:07:00Z","last_updated_date":"2012-05-03T16:07:00Z","reference_number":"EMA/CAT/GTWP/671639/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-and-clinical-aspects-medicinal-products-containing-genetically-modified-cells-first-version_en.pdf"},
    {"id":"21041","name":"Draft guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF) - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-08-15 - 2019-02-15","first_published_date":"2018-08-15T14:20:00Z","last_updated_date":"2018-08-15T14:20:00Z","reference_number":"EMEA/CHMP/BMWP/31329/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-similar-biological-medicinal-products-containing-recombinant-granulocyte-colony-stimulating-factor-rg-csf-revision-1_en.pdf"},
    {"id":"21074","name":"Draft exenatide powder and solvent for prolonged-release suspension for injection, 2 mg, and powder and solvent for prolonged-release suspension for injection in pre-filled pen, 2 mg product-specific bioequivalence guida...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-01 - 2016-10-31","first_published_date":"2016-08-01T17:00:00Z","last_updated_date":"2016-08-01T17:00:00Z","reference_number":"EMA/CHMP/474782/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-exenatide-powder-and-solvent-prolonged-release-suspension-injection-2-mg-and-powder-and-solvent-prolonged-release-suspension-injection-pre-filled-pen-2-mg-product-specific-bioequivalence-guida_en.pdf"},
    {"id":"21079","name":"Guideline on procedural aspects regarding a CHMP scientific opinion in the context of cooperation with the World Health Organization for the evaluation of medicinal products intended exclusively for markets outside the C...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"EMEA/CHMP/5579/04 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-procedural-aspects-regarding-chmp-scientific-opinion-context-cooperation-world-health-organization-evaluation-medicinal-products-intended-exclusively-markets-outside-c_en.pdf"},
    {"id":"21087","name":"Overview of comments on draft Public statement on the use of herbal medicinal products containing pulegone and menthofuran - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-07-27T16:00:00Z","last_updated_date":"2016-07-27T16:00:00Z","reference_number":"EMA/HMPC/258725/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-draft-public-statement-use-herbal-medicinal-products-containing-pulegone-and-menthofuran-revision-1_en.pdf"},
    {"id":"21120","name":"Fingolimod capsules 0.25 and 0.5 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-01-03T16:58:00Z","last_updated_date":"2025-07-29T16:43:00Z","reference_number":"EMA/CHMP/154812/2016 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/fingolimod-capsules-025-05-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"21132","name":"Draft guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-10-30 - 2018-05-01","first_published_date":"2017-10-30T17:00:00Z","last_updated_date":"2017-10-30T17:00:00Z","reference_number":"EMA/CHMP/257022/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-medicinal-products-indicated-prophylaxis-or-treatment-respiratory-syncytial-virus-rsv-disease-first-version_en.pdf"},
    {"id":"21137","name":"Lenalidomide hard gelatine capsules 2.5, 5, 7.5, 10, 15 and 25mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-11-01T17:31:34Z","reference_number":"EMA/CHMP/177335/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/lenalidomide-hard-gelatine-capsules-25-5-75-10-15-and-25mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"21174","name":"Cell culture inactivated influenza vaccines - Annex to note for guidance on harmonisation of requirements for influenza vaccines CPMP/BWP/214/96","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-01-17T01:00:00Z","last_updated_date":"2002-01-17T01:00:00Z","reference_number":"CPMP/BWP/2490/00/Adopted","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cell-culture-inactivated-influenza-vaccines-annex-note-guidance-harmonisation-requirements-influenza-vaccines-cpmpbwp21496_en.pdf"},
    {"id":"21199","name":"ICH: M 4 E: Common technical document for the registration of pharmaceuticals for human use - Efficacy questions and answers - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"CPMP/ICH/5551/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-4-e-common-technical-document-registration-pharmaceuticals-human-use-efficacy-questions-and-answers-step-5_en.pdf"},
    {"id":"21201","name":"Evaluation of the safety of veterinary medicinal products for the target animals","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-09-01T02:00:00Z","last_updated_date":"1994-09-01T02:00:00Z","reference_number":"7AE2a Volume 7","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/evaluation-safety-veterinary-medicinal-products-target-animals_en.pdf"},
    {"id":"21205","name":"Draft International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q3D on elemental impurities - Step 3 - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-08-08 - 2013-12-31","first_published_date":"2013-08-08T20:40:00Z","last_updated_date":"2013-08-08T20:40:00Z","reference_number":"EMA/CHMP/ICH/353369/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q3d-elemental-impurities-step-3-first-version_en.pdf"},
    {"id":"21224","name":"Draft guideline on the clinical investigation of human Anti-D immunoglobulin for intravenous and/or intramuscular use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-04-27T02:00:00Z","last_updated_date":"2007-04-27T02:00:00Z","reference_number":"CPMP/BPWG/575/99 Rev. 1 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-human-anti-d-immunoglobulin-intravenous-andor-intramuscular-use_en.pdf"},
    {"id":"21278","name":"Reflection paper on the use of heat treatment to inactivate endogenous retroviruses in live immunological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-09-17T18:17:00Z","last_updated_date":"2015-09-17T18:17:00Z","reference_number":"EMA/CVMP/IWP/37924/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-heat-treatment-inactivate-endogenous-retroviruses-live-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"21279","name":"Guideline on core SmPC and package leaflet for sodium iodide (131I) for therapeutic use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-03-22T10:35:00Z","last_updated_date":"2018-03-22T10:35:00Z","reference_number":"EMA/CHMP/630248/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-and-package-leaflet-sodium-iodide-131i-therapeutic-use_en.pdf"},
    {"id":"21312","name":"Guideline on clinical investigation of medicinal products used in weight control","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-15T01:00:00Z","last_updated_date":"2007-11-15T01:00:00Z","reference_number":"CPMP/EWP/281/96 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-used-weight-control_en.pdf"},
    {"id":"21337","name":"Concept paper on new guidance for importers of medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-05-29 - 2015-08-29","first_published_date":"2015-05-29T15:10:00Z","last_updated_date":"2015-05-29T15:10:00Z","reference_number":"EMA/238299/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-new-guidance-importers-medicinal-products_en.pdf"},
    {"id":"21345","name":"Note for guidance on clinical investigation of medicinal products for the treatment of venous thromboembolic disease","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-12-16T01:00:00Z","last_updated_date":"1999-12-16T01:00:00Z","reference_number":"CPMP/EWP/563/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-venous-thromboembolic-disease_en.pdf"},
    {"id":"21363","name":"Concept paper on the development of a quality guideline on pharmaceutical development of medicines for paediatric use","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-07-29T02:00:00Z","last_updated_date":"2008-07-29T02:00:00Z","reference_number":"EMEA/138931/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-quality-guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf"},
    {"id":"21375","name":"Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-01-24T16:30:00Z","last_updated_date":"2018-01-24T16:30:00Z","reference_number":"EMA/CHMP/CVMP/3Rs/94436/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidance-individual-laboratories-transfer-quality-control-methods-validated-collaborative-trials-view-implementing-3rs_en.pdf"},
    {"id":"21378","name":"Draft guideline on the assessment of clinical safety and efficacy in the preparation of European Union herbal monographs for well-established and traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-09-01 - 2016-11-30","first_published_date":"2016-09-01T20:00:00Z","last_updated_date":"2016-09-01T20:00:00Z","reference_number":"EMA/HMPC/104613/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-assessment-clinical-safety-and-efficacy-preparation-european-union-herbal-monographs-well-established-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"21404","name":"Reflection paper: Non-clinical and clinical development of similar medicinal products containing recombinant Interferon Alfa","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/BMWP/102046/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-non-clinical-and-clinical-development-similar-medicinal-products-containing-recombinant-interferon-alfa_en.pdf"},
    {"id":"21411","name":"Points to consider on xenogeneic cell therapy medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2003-12-17T01:00:00Z","last_updated_date":"2003-12-17T01:00:00Z","reference_number":"CPMP/1199/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-xenogeneic-cell-therapy-medicinal-products_en.pdf"},
    {"id":"21428","name":"Guideline for the testing and evaluation of the efficacy of antiparastic substances for the treatment and prevention of tick and flea infestation in dogs and cats - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-11-07T01:00:00Z","last_updated_date":"2000-11-07T01:00:00Z","reference_number":"EMEA/CVMP/005/00-Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-testing-and-evaluation-efficacy-antiparastic-substances-treatment-and-prevention-tick-and-flea-infestation-dogs-and-cats-revision-1_en.pdf"},
    {"id":"21456","name":"Guideline on the clinical investigation of medicinal products for the treatment of urinary incontinence","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T13:15:00Z","last_updated_date":"2013-07-19T13:15:00Z","reference_number":"CPMP/EWP/18/01/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-urinary-incontinence_en.pdf"},
    {"id":"21466","name":"Guidance on collection and provision of national data on antimicrobial use by animal species/categories","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-24T17:30:00Z","last_updated_date":"2018-02-23T15:07:00Z","reference_number":"EMA/489035/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidance-collection-and-provision-national-data-antimicrobial-use-animal-speciescategories_en.pdf"},
    {"id":"21472","name":"Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-01-10T12:24:00Z","last_updated_date":"2018-01-10T12:24:00Z","reference_number":"CPMP/EWP/556/95 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-rheumatoid-arthritis_en.pdf"},
    {"id":"21479","name":"Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T11:00:00Z","last_updated_date":"2017-10-11T14:00:00Z","reference_number":"EMA/CHMP/51230/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-systemic-lupus-erythematosus-and-lupus-nephritis_en.pdf"},
    {"id":"21482","name":"Note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-04-25T02:00:00Z","last_updated_date":"2002-04-25T02:00:00Z","reference_number":"CPMP/EWP/714/98 rev1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-peripheral-arterial-occlusive-disease_en.pdf"},
    {"id":"21488","name":"Draft guideline on stability testing: Stability testing of existing active substances and related finished products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-12T02:00:00Z","last_updated_date":"2007-10-12T02:00:00Z","reference_number":"EMEA/CVMP/QWP/846/99-Rev.1 CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products-revision-1_en.pdf"},
    {"id":"21493","name":"Reflection paper on immune-tolerance induction in haemophilia-A patients with inhibitors","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-03-26T13:10:05Z","last_updated_date":"2013-03-26T13:10:05Z","reference_number":"EMA/CHMP/BPWP/153137/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-immune-tolerance-induction-haemophilia-patients-inhibitors_en.pdf"},
    {"id":"21497","name":"Draft guideline on clinical evaluation of medicinal products used in weight control - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-07-31 - 2015-01-31","first_published_date":"2014-07-31T14:00:00Z","last_updated_date":"2014-07-31T14:00:00Z","reference_number":"EMA/CHMP/311805/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-medicinal-products-used-weight-control-revision-1_en.pdf"},
    {"id":"21536","name":"Draft guideline on good pharmacovigilance practices (GVP) - Module VI – Management and reporting of adverse reactions to medicinal products (Rev. 2)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-08 - 2016-10-14","first_published_date":"2016-08-08T19:00:00Z","last_updated_date":"2016-08-08T19:00:00Z","reference_number":"EMA/873138/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-vi-management-and-reporting-adverse-reactions-medicinal-products-rev-2_en.pdf"},
    {"id":"21545","name":"Draft guideline on selection of test materials for genotoxicity testing for traditional herbal medicinal products/ herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-06-08T02:00:00Z","last_updated_date":"2009-06-08T02:00:00Z","reference_number":"EMEA/HMPC/67644/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-selection-test-materials-genotoxicity-testing-traditional-herbal-medicinal-products-herbal-medicinal-products_en.pdf"},
    {"id":"21551","name":"Note for guidance on specification limits for residues of metal catalysts","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2002-12-17T01:00:00Z","last_updated_date":"2002-12-17T01:00:00Z","reference_number":"CPMP/SWP/QWP/4446/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-specification-limits-residues-metal-catalysts_en.pdf"},
    {"id":"21591","name":"Guideline on clinical investigation of steroid contraceptives in women","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"EMEA/CPMP/EWP/519/98 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-steroid-contraceptives-women_en.pdf"},
    {"id":"21660","name":"Note for guidance on clinical investigation of medicinal products for the treatment and prevention of bipolar disorder","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-04-26T02:00:00Z","last_updated_date":"2001-04-26T02:00:00Z","reference_number":"CPMP/EWP/567/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-and-prevention-bipolar-disorder_en.pdf"},
    {"id":"21673","name":"Draft guideline on adjuvants in vaccines","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2004-03-25T00:09:00Z","last_updated_date":"2004-03-25T00:09:00Z","reference_number":"EMEA/CPMP/VEG/17/03/2004v 5/Consultation","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-adjuvants-vaccines_en.pdf"},
    {"id":"21721","name":"Concept paper on the need for revision of the position paper on indications for veterinary vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-10-13 - 2011-12-31","first_published_date":"2011-10-25T19:00:00Z","last_updated_date":"2011-10-25T19:00:00Z","reference_number":"EMA/CVMP/IWP/785621/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-position-paper-indications-veterinary-vaccines_en.pdf"},
    {"id":"21779","name":"Draft guideline on clinical investigation of immunosuppressants for solid organ transplantation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"CHMP/EWP/263148/06","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-immunosuppressants-solid-organ-transplantation_en.pdf"},
    {"id":"21797","name":"Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"EMEA/CHMP/VWP/263499/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-influenza-vaccines-prepared-viruses-potential-cause-pandemic-and-intended-use-outside-core-dossier-context_en.pdf"},
    {"id":"21800","name":"Recommendation to marketing authorisation holders, highlighting the need to ensure compliance with 3Rs methods described in the European Pharmacopoeia","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-07-25T12:40:00Z","last_updated_date":"2012-07-25T12:40:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/252137/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-marketing-authorisation-holders-highlighting-need-ensure-compliance-3rs-methods-described-european-pharmacopoeia_en.pdf"},
    {"id":"21807","name":"Draft guideline on non-clinical local tolerance testing of medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-04-30 - 2014-07-31","first_published_date":"2014-04-30T18:40:00Z","last_updated_date":"2014-04-30T18:40:00Z","reference_number":"EMA/CHMP/SWP/2145/2000 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-non-clinical-local-tolerance-testing-medicinal-products_en.pdf"},
    {"id":"21848","name":"Guideline on the scientific data requirements for a vaccine antigen master file (VAMF)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-12-15T01:00:00Z","last_updated_date":"2003-12-15T01:00:00Z","reference_number":"EMEA/CPMP/BWP/3734/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific-data-requirements-vaccine-antigen-master-file-vamf_en.pdf"},
    {"id":"21858","name":"Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2018-11-19T12:42:00Z","reference_number":"EMA/CHMP/606830/2014 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-sodium-laurilsulfate-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"21872","name":"Note for guidance on the clinical evaluation of vaccines","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-05-17T02:00:00Z","last_updated_date":"2005-05-17T02:00:00Z","reference_number":"CHMP/VWP/164653/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-evaluation-vaccines_en.pdf"}    {"id":"21876","name":"Guideline on good pharmacovigilance practices (GVP) - Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products with tracked changes (Rev. 2) - In tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-08-02T12:00:00Z","last_updated_date":"2017-08-02T12:00:00Z","reference_number":"EMA/873138/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports-suspected-adverse-reactions-medicinal-products-tracked-changes-rev-2-tracked-changes_en.pdf"},
    {"id":"21900","name":"Guideline on immunogenicity assessment of monoclonal antibodies intended for in-vivo clinical use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-15T17:10:50Z","last_updated_date":"2012-06-15T17:10:50Z","reference_number":"EMA/CHMP/BMWP/86289/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-monoclonal-antibodies-intended-vivo-clinical-use_en.pdf"},
    {"id":"21903","name":"VICH GL32: Studies to evaluate the safety of residues of veterinary drugs in human food: Developmental toxicity testing - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-16T02:00:00Z","last_updated_date":"2004-06-16T02:00:00Z","reference_number":"CVMP/VICH/485/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl32-studies-evaluate-safety-residues-veterinary-drugs-human-food-developmental-toxicity-testing-step-7_en.pdf"},
    {"id":"21941","name":"Draft guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2010-03-24T01:00:00Z","last_updated_date":"2010-03-24T01:00:00Z","reference_number":"EMA/CHMP/BPWP/94033/2007 rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-revision-2_en.pdf"},
    {"id":"21971","name":"VICH GL42: Pharmacovigilance: data elements for submission of adverse event reports (AERs)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-14T01:00:00Z","last_updated_date":"2023-05-22T10:53:00Z","reference_number":"EMEA/CVMP/VICH/355996/2005 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl42-pharmacovigilance-data-elements-submission-adverse-event-reports-aers_en.pdf"},
    {"id":"21981","name":"Guideline on the assessment of clinical safety and efficacy in the preparation of EU herbal monographs for well-established and traditional herbal medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-11-28T12:45:00Z","last_updated_date":"2017-11-28T12:45:00Z","reference_number":"EMA/HMPC/104613/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-assessment-clinical-safety-and-efficacy-preparation-eu-herbal-monographs-well-established-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"21996","name":"Guideline on requirements for concurrent administration of immunological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-10-01T02:00:00Z","last_updated_date":"2003-10-01T02:00:00Z","reference_number":"EMEA/CVMP/550/02-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-concurrent-administration-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"22009","name":"Concept paper/recommendations on the need for a (CHMP) guideline on the validation of bioanalytical methods","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/CHMP/EWP/531305/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paperrecommendations-need-chmp-guideline-validation-bioanalytical-methods_en.pdf"},
    {"id":"22028","name":"Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-09-22 - 2011-12-31","first_published_date":"2011-10-03T18:35:00Z","last_updated_date":"2011-10-03T18:35:00Z","reference_number":"EMA/CHMP/BMWP/572828/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues_en.pdf"},
    {"id":"22032","name":"Concept paper on the testing strategy and risk assessment for plants in the Phase II of the environmental risk assessment for veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-06-18 - 2015-09-30","first_published_date":"2015-06-18T19:40:00Z","last_updated_date":"2015-06-18T19:40:00Z","reference_number":"EMA/CVMP/ERA/698394/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-testing-strategy-and-risk-assessment-plants-phase-ii-environmental-risk-assessment-veterinary-medicinal-products_en.pdf"},
    {"id":"22041","name":"ICH S9 guideline on nonclinical evaluation for anticancer pharmaceuticals - questions and answers - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-05-16T13:39:00Z","last_updated_date":"2018-05-16T13:39:00Z","reference_number":"EMA/CHMP/ICH/453684/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s9-guideline-nonclinical-evaluation-anticancer-pharmaceuticals-questions-and-answers-step-5_en.pdf"},
    {"id":"22042","name":"Concept paper on use of aminoglycosides in animals in the European Union: Development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-07-23 - 2014-10-31","first_published_date":"2014-07-23T16:00:00Z","last_updated_date":"2014-07-23T16:00:00Z","reference_number":"EMA/CVMP/AWP/158821/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-use-aminoglycosides-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"22055","name":"Gene therapy product quality aspects In the production of vectors and genetically modified somatic cells","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-12-31T01:00:00Z","last_updated_date":"1994-12-31T01:00:00Z","reference_number":"3ab6a","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/gene-therapy-product-quality-aspects-production-vectors-and-genetically-modified-somatic-cells_en.pdf"},
    {"id":"22078","name":"Draft dabigatran etexilate, hard capsules, 75 mg, 110 mg and 150 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-12-22 - 2017-03-31","first_published_date":"2016-12-22T14:00:00Z","last_updated_date":"2016-12-22T14:00:00Z","reference_number":"EMA/CHMP/805498/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-dabigatran-etexilate-hard-capsules-75-mg-110-mg-and-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"22094","name":"Public consultation concerning the European Union template for good manufacturing practice (GMP) non-compliance statement","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-04-03 - 2018-05-16","first_published_date":"2018-04-03T16:00:00Z","last_updated_date":"2018-04-03T16:00:00Z","reference_number":"EMA/189939/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-consultation-concerning-european-union-template-good-manufacturing-practice-gmp-non-compliance-statement_en.pdf"},
    {"id":"22096","name":"Guideline on requirements for an authorisation under exceptional circumstances for vaccines for use in birds against avian influenza","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-04-23T02:00:00Z","last_updated_date":"2007-04-23T02:00:00Z","reference_number":"EMEA/CVMP/IWP/222624/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-authorisation-under-exceptional-circumstances-vaccines-use-birds-against-avian-influenza_en.pdf"},
    {"id":"22097","name":"Draft guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-05-30 - 2012-11-30","first_published_date":"2012-05-30T15:30:00Z","last_updated_date":"2012-05-30T15:30:00Z","reference_number":"EMA/CHMP/325170/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-prevention-venous-thromboembolism-vte-patients-undergoing-high-vte-risk-surgery-revision-2_en.pdf"},
    {"id":"22102","name":"Revised guideline on user safety for pharmaceutical veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/CVMP/543/03-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/revised-guideline-user-safety-pharmaceutical-veterinary-medicinal-products_en.pdf"},
    {"id":"22105","name":"Draft guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), bluetongue (BT) and foot-and-mouth disease (FMD) - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-09-18 - 2018-03-31","first_published_date":"2017-09-18T16:38:00Z","last_updated_date":"2017-09-18T16:38:00Z","reference_number":"EMA/CVMP/IWP/105506/2007-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-multi-strain-dossiers-inactivated-vaccines-against-avian-influenza-ai-bluetongue-bt-and-foot-and-mouth-disease-fmd-revision-1_en.pdf"},
    {"id":"22114","name":"Questions and answer on guideline title: Clinical investigation of Corticosteroids intended for use on the skin","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-11-16T01:00:00Z","last_updated_date":"2006-11-16T01:00:00Z","reference_number":"CHMP/EWP/21441/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answer-guideline-title-clinical-investigation-corticosteroids-intended-use-skin_en.pdf"},
    {"id":"22167","name":"Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on on cell-derived influenza vaccines","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"1999-07-29T02:00:00Z","last_updated_date":"1999-07-29T02:00:00Z","reference_number":"CPMP/BWP/1764/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-proprietary-medicinal-products-cpmp-points-consider-cell-derived-influenza-vaccines_en.pdf"},
    {"id":"22180","name":"Questions and answers on benzalkonium chloride in the context of the revision of the guideline on excipients in the label and package leaflet of medicinal products for human use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-06-30 - 2014-09-30","first_published_date":"2014-06-30T14:10:00Z","last_updated_date":"2014-06-30T14:10:00Z","reference_number":"EMA/495737/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-benzalkonium-chloride-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"22199","name":"Concept paper/recommendation on the need for revision of (CHMP) note for guidance on the investigation of drug interactions","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/297931/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paperrecommendation-need-revision-chmp-note-guidance-investigation-drug-interactions_en.pdf"},
    {"id":"22260","name":"Questions and answers on gene therapy","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-01-13T00:09:21Z","last_updated_date":"2010-01-13T00:09:21Z","reference_number":"EMA/CHMP/GTWP/212377/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-gene-therapy_en.pdf"},
    {"id":"22348","name":"Guideline on core summary for product characteristics  for human albumin solution - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-08-13T16:30:00Z","last_updated_date":"2018-08-13T16:30:00Z","reference_number":"EMA/CHMP/BPWP/494462/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-summary-product-characteristics-human-albumin-solution-revision-3_en.pdf"},
    {"id":"22351","name":"Draft concept paper on revision of annex 17 of the good-manufacturing-practice guide","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-11-27 - 2013-02-28","first_published_date":"2012-11-27T10:40:00Z","last_updated_date":"2012-11-27T10:40:00Z","reference_number":"EMA/INS/GMP/705479/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-revision-annex-17-good-manufacturing-practice-guide_en.pdf"},
    {"id":"22380","name":"Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision) - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/CPMP/VEG/4717/2003- Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-dossier-structure-and-content-pandemic-influenza-vaccine-marketing-authorisation-application-revision-superseded_en.pdf"},
    {"id":"22388","name":"Concept paper on the revision of the guideline on quality of herbal medicinal products/traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-06-01 - 2015-08-31","first_published_date":"2015-06-01T20:00:00Z","last_updated_date":"2015-06-01T20:00:00Z","reference_number":"EMA/HMPC/217631/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-quality-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"22390","name":"ICH guideline Q4B annex 11 to note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on capillary electrophoresis - general chapter - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2013-02-11T12:00:00Z","reference_number":"EMA/CHMP/ICH/730028/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-11-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-capillary-electrophoresis-general-chapter-step-5_en.pdf"},
    {"id":"22405","name":"Draft Levodopa/Carbidopa/Entacapone film-coated tablet 200mg/50mg/200mg, 175mg/43.75mg/200mg, 150mg/37.5mg/200mg, 125mg/31.25mg/200mg, 100mg/25mg/200mg, 75mg/18.75mg/200mg and 50mg/12.5mg/200mg product-specific bioequiva...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-02 - 2016-07-31","first_published_date":"2016-05-02T13:00:00Z","last_updated_date":"2016-05-02T13:00:00Z","reference_number":"EMA/CHMP/162889/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-levodopa-carbidopa-entacapone-film-coated-tablet-200mg-50mg-200mg-175mg-4375mg-200mg-150mg-375mg-200mg-125mg-3125mg-200mg-100mg-25mg-200mg-75mg-1875mg-200mg-and-50mg-125mg-200mg-product-specific_en.pdf"},
    {"id":"22416","name":"Guidance on the description of composition of pegylated (conjugated) proteins in the SPC","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-05-14T02:00:00Z","last_updated_date":"2003-05-14T02:00:00Z","reference_number":"EMEA/CPMP/BWP/3068/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidance-description-composition-pegylated-conjugated-proteins-spc_en.pdf"},
    {"id":"22431","name":"Paediatric addendum to the Committee for Medicinal Products for Human Use guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-02-07T17:36:00Z","last_updated_date":"2012-02-07T17:36:00Z","reference_number":"EMA/CHMP/213972/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paediatric-addendum-committee-medicinal-products-human-use-guideline-clinical-investigations-medicinal-products-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"22440","name":"Draft guideline on the development of medicinal products for the treatment of nicotine dependence","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"CHMP/EWP/369963/05","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-medicinal-products-treatment-nicotine-dependence_en.pdf"},
    {"id":"22469","name":"VICH GL14: Efficacy of anthelmintics - Specific recommendations for caprines - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-12-10T01:00:00Z","last_updated_date":"1999-12-10T01:00:00Z","reference_number":"CVMP/VICH/841/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl14-efficacy-anthelmintics-specific-recommendations-caprines-step-7_en.pdf"},
    {"id":"22470","name":"Concept paper on the need for a single note for guidance on the chemistry of active substances - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-02-10 - 2014-08-10","first_published_date":"2014-02-10T15:25:00Z","last_updated_date":"2014-02-10T15:25:00Z","reference_number":"EMA/CHMP/QWP/752676/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-single-note-guidance-chemistry-active-substances-first-version_en.pdf"},
    {"id":"22488","name":"Lessons learned from the review of the labelling of centrally authorised pandemic vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"2014-02-20 - 2014-05-20","first_published_date":"2014-02-20T11:00:00Z","last_updated_date":"2016-01-28T18:15:00Z","reference_number":"EMA/467700/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/lessons-learned-review-labelling-centrally-authorised-pandemic-vaccines_en.pdf"},
    {"id":"22502","name":"Draft guideline on safety and residue data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-03 - 2016-07-31","first_published_date":"2016-02-03T13:00:00Z","last_updated_date":"2016-02-03T13:00:00Z","reference_number":"EMA/CVMP/QWP/66781/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-safety-and-residue-data-requirements-veterinary-medicinal-products-intended-minor-use-or-minor-species-mums-limited-market_en.pdf"},
    {"id":"22521","name":"Concept paper on the development of a CVMP for guidance on quality aspects of pharmaceutical veterinary medicines for administration via drinking water","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2002-11-13T01:00:00Z","last_updated_date":"2002-11-13T01:00:00Z","reference_number":"EMEA/CVMP/1055/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-cvmp-guidance-quality-aspects-pharmaceutical-veterinary-medicines-administration-drinking-water_en.pdf"},
    {"id":"22558","name":"Concept paper on the need for revision of the note for guidance on photosafety testing","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2008-01-24 - 2008-05-31","first_published_date":"2008-01-24T02:00:00Z","last_updated_date":"2008-01-24T02:00:00Z","reference_number":"EMEA/CHMP/SWP/534549/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-photosafety-testing_en.pdf"},
    {"id":"22616","name":"Draft guideline on Allergen products: Production and quality issues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2007-09-20T02:00:00Z","reference_number":"EMEA/CHMP/BWP/304831/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-allergen-products-production-and-quality-issues_en.pdf"},
    {"id":"22617","name":"Draft ICH guideline E17 on general principles for planning and design of multi-regional clinical trials - Step 2b - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-28 - 2017-01-28","first_published_date":"2016-07-28T20:00:00Z","last_updated_date":"2016-09-22T20:00:00Z","reference_number":"EMA/CHMP/ICH/453276/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-e17-general-principles-planning-and-design-multi-regional-clinical-trials-step-2b-first-version_en.pdf"},
    {"id":"22626","name":"Concept paper on the revision of the note for guidance on the approach towards harmonisation of withdrawal periods","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-10-18 - 2014-01-31","first_published_date":"2013-10-18T19:00:00Z","last_updated_date":"2013-10-18T19:00:00Z","reference_number":"EMA/CVMP/SWP/285070/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-approach-towards-harmonisation-withdrawal-periods_en.pdf"},
    {"id":"22635","name":"Draft guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"CHMP/EWP/566/98 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-2_en.pdf"},
    {"id":"22643","name":"Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-02-18 - 2010-08-31","first_published_date":"2010-03-25T02:00:00Z","last_updated_date":"2010-03-25T02:00:00Z","reference_number":"CPMP/EWP/558/95 rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-2_en.pdf"},
    {"id":"22672","name":"Draft concept paper on guideline on the clinical investigation of human normal immunoglobulin for intravenous administration and core summary of product characteristics","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-08-01 - 2014-10-31","first_published_date":"2014-08-01T19:30:00Z","last_updated_date":"2014-08-01T19:30:00Z","reference_number":"EMA/CHMP/BPWP/572805/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-and-core-summary-product-characteristics_en.pdf"},
    {"id":"22684","name":"Environmental risk assessments for medicinal products containing, or consisting of, genetically modified organisms (GMOS) (module 1.6.2)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-01-20T01:00:00Z","last_updated_date":"2005-01-20T01:00:00Z","reference_number":"EMEA/CHMP/BWP/135148/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/environmental-risk-assessments-medicinal-products-containing-or-consisting-genetically-modified-organisms-gmos-module-162_en.pdf"},
    {"id":"22707","name":"Draft guideline on good pharmacovigilance practices: Module III – Pharmacovigilance inspections","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-06-27 - 2012-08-24","first_published_date":"2012-06-27T16:57:57Z","last_updated_date":"2012-06-27T16:57:57Z","reference_number":"EMA/119871/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-iii-pharmacovigilance-inspections_en.pdf"},
    {"id":"22730","name":"Draft guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-07-19 - 2014-01-15","first_published_date":"2013-07-19T15:20:00Z","last_updated_date":"2013-07-19T15:20:00Z","reference_number":"CPMP/EWP/785/97 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-treatment-irritable-bowel-syndrome-revision-1_en.pdf"},
    {"id":"22826","name":"Guideline on quality of herbal medicinal products/traditional herbal medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-03-30T02:00:00Z","last_updated_date":"2006-03-30T02:00:00Z","reference_number":"CPMP/QWP/2819/00 Rev 1 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-herbal-medicinal-productstraditional-herbal-medicinal-products-revision-1_en.pdf"},
    {"id":"22833","name":"Reflection paper on control of the active substance in the finished product for immunological veterinary medicinal products (IVMPs)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/CVMP/IWP/582970/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-control-active-substance-finished-product-immunological-veterinary-medicinal-products-ivmps_en.pdf"},
    {"id":"22868","name":"Concept paper on the need for revision of the Note for Guidance on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence\n\n(CPMP/EWP/18/01)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-04-22 - 2010-07-31","first_published_date":"2010-04-30T04:00:00Z","last_updated_date":"2010-05-20T04:00:00Z","reference_number":"EMA/CHMP/EWP/68523/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-clinical-investigation-medicinal-products-treatment-urinary-incontinence-cpmp-ewp-18-01_en.pdf"},
    {"id":"22879","name":"Guideline on bioanalytical method validation","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-08-01T02:00:00Z","last_updated_date":"2015-06-03T18:10:00Z","reference_number":"EMEA/CHMP/EWP/192217/2009 Rev.1 Corr.2**","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf"},
    {"id":"22929","name":"Draft guideline on setting specifications for related impurities in antibiotics","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-06-24 - 2011-01-31","first_published_date":"2010-07-30T04:00:00Z","last_updated_date":"2010-07-30T04:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/199250/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-setting-specifications-related-impurities-antibiotics_en.pdf"},
    {"id":"22950","name":"Draft VICH GL36: Studies to evaluate the safety of residues of veterinary drugs in human food: general approach to establish a microbiological acceptable daily intake - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-03-10 - 2011-09-14","first_published_date":"2011-04-07T04:00:00Z","last_updated_date":"2011-04-07T04:00:00Z","reference_number":"EMA/CVMP/VICH/467/2003-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl36-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach-establish-microbiological-acceptable-daily-intake-revision-1_en.pdf"},
    {"id":"22960","name":"Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-10-25 - 2017-01-31","first_published_date":"2016-10-25T20:45:00Z","last_updated_date":"2016-10-25T20:45:00Z","reference_number":"EMA/CHMP/179692/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-2_en.pdf"},
    {"id":"22961","name":"Concept paper on the development of a guideline on the development of medicinal products for the treatment of post-traumatic stress disorder","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/CHMP/EWP/358650/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-development-medicinal-products-treatment-post-traumatic-stress-disorder_en.pdf"},
    {"id":"22997","name":"Draft guideline on the development of new medicinal products for the treatment of Ulcerative Colitis - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-01 - 2017-01-31","first_published_date":"2016-08-01T13:30:00Z","last_updated_date":"2016-08-01T13:30:00Z","reference_number":"CHMP/EWP/18463/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-new-medicinal-products-treatment-ulcerative-colitis-revision-1_en.pdf"},
    {"id":"22998","name":"Draft guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-08-15 - 2013-02-15","first_published_date":"2012-08-15T14:17:14Z","last_updated_date":"2012-08-15T14:17:14Z","reference_number":"EMA/CHMP/450916/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-prevention-stroke-and-systemic-embolic-events-patients-non-valvular-atrial-fibrillation_en.pdf"},
    {"id":"23023","name":"Guideline for the conduct of bioequivalence studies for veterinary medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-01-09T01:00:00Z","last_updated_date":"2001-01-09T01:00:00Z","reference_number":"EMEA/CVMP/016/00-cor-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"23032","name":"Reflection paper on risk-based quality management in clinical trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-06-15 - 2012-02-15","first_published_date":"2011-08-05T04:00:00Z","last_updated_date":"2011-08-05T04:00:00Z","reference_number":"EMA/INS/GCP/394194/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-based-quality-management-clinical-trials_en.pdf-0"},
    {"id":"23035","name":"Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular emphasis on the handling of expiry dates (superseded)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-12-18T12:35:00Z","last_updated_date":"2022-02-04T12:35:00Z","reference_number":"EMA/INS/GCP/600788/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-interactive-response-technologies-interactive-voiceweb-response-systems-clinical-trials-particular-emphasis-handling-expiry-dates-superseded_en.pdf"},
    {"id":"23038","name":"Draft guideline on the clinical investigation of medicinal products for the treatment of urinary incontinence (revision 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-11-20 - 2012-05-31","first_published_date":"2011-11-23T02:00:00Z","last_updated_date":"2011-12-01T18:46:00Z","reference_number":"CPMP/EWP/18/01/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-urinary-incontinence-revision-1_en.pdf"},
    {"id":"23044","name":"Concept paper on the need for a guideline on the treatment of Duchenne and Becker muscular dystrophy","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-06-23 - 2011-09-30","first_published_date":"2011-07-08T04:00:00Z","last_updated_date":"2011-07-08T04:00:00Z","reference_number":"EMA/CHMP/CNSWP/236981/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-treatment-duchenne-and-becker-muscular-dystrophy_en.pdf"},
    {"id":"23055","name":"Concept paper on non-pharmacopoeial reference standards for herbal substances, herbal preparations and herbal medicinal products / traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-06-27 - 2012-10-15","first_published_date":"2012-06-27T15:30:00Z","last_updated_date":"2012-06-27T15:30:00Z","reference_number":"EMA/HMPC/312890/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-non-pharmacopoeial-reference-standards-herbal-substances-herbal-preparations-and-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"23058","name":"Second draft guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-04-30 - 2014-07-31","first_published_date":"2014-04-30T18:40:00Z","last_updated_date":"2014-04-30T18:40:00Z","reference_number":"EMEA/CHMP/BMWP/32775/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/second-draft-guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-human-insulin-and-insulin-analogues_en.pdf"},
    {"id":"23064","name":"ICH M4Q: Location issues for common technical document for the registration of pharmaceuticals for human use - Quality - questions and answers - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-08-01T02:00:00Z","last_updated_date":"2003-08-01T02:00:00Z","reference_number":"CPMP/ICH/4680/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m4q-location-issues-common-technical-document-registration-pharmaceuticals-human-use-quality-questions-answers-step-5_en.pdf"},
    {"id":"23065","name":"Concept paper on revision of the current guideline on the SPC for antimicrobial products (EMEA/CVMP/612/01-FINAL)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-06-15T02:09:21Z","last_updated_date":"2005-06-15T02:09:21Z","reference_number":"EMEA/CVMP/67951/2005-CONSULTATION","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-current-guideline-spc-antimicrobial-products-emeacvmp61201-final_en.pdf"},
    {"id":"23076","name":"VICH Topic Gl46: at step 4: Guideline on studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: Metabolism study to determine the quantity and identify the nature of residu...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-12-10 - 2010-05-20","first_published_date":"2009-12-22T02:00:00Z","last_updated_date":"2010-05-10T04:00:00Z","reference_number":"EMEA/CVMP/VICH/463072/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-topic-gl46-step-4-guideline-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-animals-metabolism-study-determine-quantity-and-identify-nature-residu_en.pdf"},
    {"id":"23079","name":"Draft guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and package leaflets for plasma-derived medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-02-17 - 2011-04-30","first_published_date":"2011-02-23T02:00:00Z","last_updated_date":"2011-02-23T02:00:00Z","reference_number":"EMA/CHMP/BWP/360642/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-warning-transmissible-agents-summary-product-characteristics-smpcs-and-package-leaflets-plasma-derived-medicinal-products_en.pdf"},
    {"id":"23081","name":"Guideline on stability testing: Stability testing of existing active substances and related finished products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-08-05T02:00:00Z","last_updated_date":"2008-08-05T02:00:00Z","reference_number":"EMEA/CVMP/QWP/846/99-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products-revision-1_en.pdf"},
    {"id":"23091","name":"Concept paper on the revision of the guideline on similar biological medicinal product","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-11-17 - 2012-02-29","first_published_date":"2011-11-24T10:50:00Z","last_updated_date":"2011-11-24T10:50:00Z","reference_number":"EMA/CHMP/BMWP/572643/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-similar-biological-medicinal-product_en.pdf"},
    {"id":"23145","name":"Reflection paper on quality of essential oils as active substances in herbal medicinal products/traditional herbal medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-05-02T14:00:00Z","last_updated_date":"2014-05-02T14:00:00Z","reference_number":"EMA/HMPC/84789/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-quality-essential-oils-active-substances-herbal-medicinal-productstraditional-herbal-medicinal-products_en.pdf"},
    {"id":"23148","name":"Recommendation for revision of the points to consider on the evaluation of diagnostic agents","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-02-22T01:00:00Z","last_updated_date":"2007-02-22T01:00:00Z","reference_number":"EMEA/CHMP/EWP/13062/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-revision-points-consider-evaluation-diagnostic-agents_en.pdf"},
    {"id":"23154","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline Q3C (R6) on impurities: guideline for residual solvents - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-10-26T01:00:00Z","last_updated_date":"2019-10-08T11:10:00Z","reference_number":"EMA/CHMP/ICH/82260/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-guideline-q3c-r6-impurities-guideline-residual-solvents-step-5_en.pdf"},
    {"id":"23162","name":"VICH GL54 studies to evaluate the safety of residues of veterinary drugs in human food: general approach to establish an acute reference dose (ARfD)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-12-19T13:20:00Z","last_updated_date":"2016-12-19T13:20:00Z","reference_number":"EMA/CVMP/VICH/699251/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl54-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach-establish-acute-reference-dose-arfd_en.pdf"},
    {"id":"23185","name":"ICH guideline E17 on general principles for planning and design of multi-regional clinical trials - Step 5 - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-12-18T13:30:00Z","last_updated_date":"2017-12-18T13:30:00Z","reference_number":"EMA/CHMP/ICH/453276/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e17-general-principles-planning-and-design-multi-regional-clinical-trials-step-5-first-version_en.pdf"},
    {"id":"23186","name":"Concept paper on extrapolation of efficacy and safety in medicine development","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-04-23T15:48:00Z","last_updated_date":"2013-04-23T15:48:00Z","reference_number":"EMA/129698/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-extrapolation-efficacy-and-safety-medicine-development_en.pdf"},
    {"id":"23192","name":"Draft guideline on clinical investigation of medicinal products in the treatment of schizophrenia","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-02-22 - 2011-08-31","first_published_date":"2011-02-22T02:00:00Z","last_updated_date":"2011-02-22T02:00:00Z","reference_number":"CHMP/40072/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-schizophrenia_en.pdf"},
    {"id":"23202","name":"Draft ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management - Step 2b - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-12-18 - 2018-12-18","first_published_date":"2017-12-18T18:00:00Z","last_updated_date":"2017-12-18T18:00:00Z","reference_number":"EMA/CHMP/ICH/804273/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-step-2b-first-version_en.pdf"},
    {"id":"23237","name":"Draft guideline on core SmPC and Package Leaflet for sodium iodide (131I) therapy capsule","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-04-26 - 2017-08-31","first_published_date":"2017-04-26T04:00:00Z","last_updated_date":"2017-04-26T04:00:00Z","reference_number":"EMA/CHMP/649301/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-and-package-leaflet-sodium-iodide-131i-therapy-capsule_en.pdf"},
    {"id":"23253","name":"Quality of biotechnological products: stability testing of biotechnological/biological products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1995-12-31T01:00:00Z","last_updated_date":"1995-12-31T01:00:00Z","reference_number":"3AB5a","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/quality-biotechnological-products-stability-testing-biotechnologicalbiological-products_en.pdf"},
    {"id":"23262","name":"Guideline for the conduct of bioequivalence studies for veterinary medicinal products - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-04-20T02:00:00Z","last_updated_date":"2011-04-20T02:00:00Z","reference_number":"EMA/CVMP/016/00 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-revision-2_en.pdf"},
    {"id":"23266","name":"Guideline on potency testing of cell based immunotherapy\n\nmedicinal products for the treatment of cancer","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-10-10T02:00:00Z","last_updated_date":"2007-10-10T02:00:00Z","reference_number":"EMEA/CHMP/BWP/271475/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-potency-testing-cell-based-immunotherapy-medicinal-products-treatment-cancer_en.pdf"},
    {"id":"23270","name":"Draft guideline on the clinical development of medicinal products intended for the treatment of pain","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-05-30 - 2013-11-30","first_published_date":"2013-05-30T17:00:00Z","last_updated_date":"2013-05-30T17:00:00Z","reference_number":"EMA/CHMP/970057/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-development-medicinal-products-intended-treatment-pain_en.pdf"},
    {"id":"23272","name":"VICH GL38: Environmental impact assessments for veterinary medicinal products (VMPs) - Phase II","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-01-01T01:00:00Z","last_updated_date":"2005-01-01T01:00:00Z","reference_number":"CVMP/VICH/790/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl38-environmental-impact-assessments-veterinary-medicinal-products-vmps-phase-ii_en.pdf"},
    {"id":"23283","name":"ICH guideline Q8, Q9 and Q10 - questions and answers volume 4","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-06-01T02:00:00Z","last_updated_date":"2010-12-09T01:00:00Z","reference_number":"EMEA/CHMP/ICH/265145/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q8-q9-and-q10-questions-and-answers-volume-4_en.pdf"},
    {"id":"23284","name":"Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-26T15:45:00Z","last_updated_date":"2018-11-07T17:00:00Z","reference_number":"EMA/CHMP/BWP/534898/2008 Rev. 1 corrigendum","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials-revision-1_en.pdf"},
    {"id":"23296","name":"Guideline on clinical and non-clinical evaluation during the consultation procedure on medicinal substances contained in drug-eluting (medicinal substance-eluting) coronary stents","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/CHMP/EWP/110540/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-and-non-clinical-evaluation-during-consultation-procedure-medicinal-substances-contained-drug-eluting-medicinal-substance-eluting-coronary-stents_en.pdf"},
    {"id":"23300","name":"Draft guideline on regulatory acceptance of 3R (replacement, reduction, refinement) testing approaches","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-10-03 - 2014-12-31","first_published_date":"2014-10-03T20:00:00Z","last_updated_date":"2014-10-03T20:00:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/450091/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-regulatory-acceptance-3r-replacement-reduction-refinement-testing-approaches_en.pdf"},
    {"id":"23314","name":"Draft guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-03-01 - 2014-08-31","first_published_date":"2014-02-28T18:00:00Z","last_updated_date":"2014-02-28T18:00:00Z","reference_number":"EMA/83874/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf"},
    {"id":"23316","name":"Draft guideline on determining the fate of veterinary medicinal products in manure","type":"scientific-guideline","status":"Draft","consultation_date":"","first_published_date":"2010-02-17T01:09:21Z","last_updated_date":"2010-02-17T01:09:21Z","reference_number":"EMA/CVMP/ERA/430327/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-determining-fate-veterinary-medicinal-products-manure_en.pdf"},
    {"id":"23332","name":"Guideline on non-clinical testing for inadvertent germline transmission of gene transfer vectors","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-11-16T01:00:00Z","last_updated_date":"2006-11-16T01:00:00Z","reference_number":"EMEA/273974/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-testing-inadvertent-germline-transmission-gene-transfer-vectors_en.pdf"},
    {"id":"23360","name":"Guideline on the clinical development of medicinal products for the treatment of HIV infection - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-07-11T14:10:00Z","last_updated_date":"2016-07-11T14:10:00Z","reference_number":"EMEA/CPMP/EWP/633/02 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-treatment-hiv-infection-revision-3_en.pdf"},
    {"id":"23372","name":"Guideline on good pharmacovigilance practices (GVP): Annex I - Definitions (Rev. 3) (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/876333/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-annex-i-definitions-rev-3-superseded_en.pdf"},
    {"id":"23376","name":"Note for guidance on modified release oral and transdermal dosage forms: Section II (pharmacokinetic and clinical evaluation) - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-07-28T02:00:00Z","last_updated_date":"1999-07-28T02:00:00Z","reference_number":"CPMP/EWP/280/96/ Corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-modified-release-oral-and-transdermal-dosage-forms-section-ii-pharmacokinetic-and-clinical-evaluation-superseded_en.pdf"},
    {"id":"23382","name":"Position statement on Polysorbate 80","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-10-22T02:00:00Z","last_updated_date":"1998-10-22T02:00:00Z","reference_number":"CPMP/BWP/1952/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-statement-polysorbate-80_en.pdf"},
    {"id":"23417","name":"Draft guideline on quality of biological active substances produced by transgene expression in animals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-05-31 - 2012-11-30","first_published_date":"2012-05-31T15:25:12Z","last_updated_date":"2012-05-31T15:25:12Z","reference_number":"EMA/CHMP/BWP/159188/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-biological-active-substances-produced-transgene-expression-animals_en.pdf"},
    {"id":"23433","name":"Background to the CPMP position paper on possible pre-clinical studies to investigate addiction and dependence/withdrawal related to the use of selective serotonin uptake inhibitors (SSRIs)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-12-14T01:00:00Z","last_updated_date":"2000-12-14T01:00:00Z","reference_number":"CPMP/2278/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/background-cpmp-position-paper-possible-pre-clinical-studies-investigate-addiction-and-dependencewithdrawal-related-use-selective-serotonin-uptake-inhibitors-ssris_en.pdf"},
    {"id":"23445","name":"ICH: Q 1 A (R2): Stability testing of new drug substances and products - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-08-01T02:00:00Z","last_updated_date":"2003-08-01T02:00:00Z","reference_number":"CPMP/ICH/2736/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf"},
    {"id":"23465","name":"CVMP strategy on antimicrobials 2016-2020","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-10-20T14:00:00Z","last_updated_date":"2016-10-20T14:00:00Z","reference_number":"EMA/CVMP/209189/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cvmp-strategy-antimicrobials-2016-2020_en.pdf"}    {"id":"23497","name":"Draft paediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-05-20 - 2010-11-30","first_published_date":"2010-06-04T04:00:00Z","last_updated_date":"2010-06-04T04:00:00Z","reference_number":"EMA/CHMP/EWP/213972/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-paediatric-addendum-chmp-guideline-clinical-investigations-medicinal-products-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"23502","name":"CPMP position statement on the quality of water used in the production of vaccines for parenteral use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-10-20T02:00:00Z","last_updated_date":"2003-10-20T02:00:00Z","reference_number":"EMEA/CPMP/BWP/1571/02/ Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cpmp-position-statement-quality-water-used-production-vaccines-parenteral-use_en.pdf"},
    {"id":"23523","name":"Draft guideline on good pharmacovigilance practices (GVP): P I - Vaccines for prophylaxis against infectious diseases – Definitions for inclusion in GVP annex I","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-04-12 - 2013-06-12","first_published_date":"2013-04-12T19:55:00Z","last_updated_date":"2013-04-12T19:55:00Z","reference_number":"EMA/109434/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-p-i-vaccines-prophylaxis-against-infectious-diseases-definitions-inclusion-gvp-annex-i_en.pdf"},
    {"id":"23566","name":"Guideline on good pharmacovigilance practices: Annex I - Definitions (Rev 2) (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-01-08T01:00:00Z","last_updated_date":"2014-01-08T01:00:00Z","reference_number":"EMA/876333/2011 Rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-2-superseded_en.pdf"},
    {"id":"23588","name":"Draft guideline on clinical investigation of medicinal products in the treatment of depression - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-09-22 - 2012-03-31","first_published_date":"2011-10-11T12:51:00Z","last_updated_date":"2011-10-11T12:51:00Z","reference_number":"EMA/CHMP/185423/2010, Rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-depression-revision-2_en.pdf"},
    {"id":"23612","name":"CHMP SWP conclusions and recommendations on the use of genetically modified animal models for carcinogenicity assessment - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-23T02:00:00Z","last_updated_date":"2004-06-23T02:00:00Z","reference_number":"CPMP/SWP/2592/02 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chmp-swp-conclusions-and-recommendations-use-genetically-modified-animal-models-carcinogenicity-assessment-revision-1_en.pdf"},
    {"id":"23613","name":"Memantine film-coated tablets 5, 10, 15 and 20 mg, oral solution 5 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315243/2014 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/memantine-film-coated-tablets-5-10-15-and-20-mg-oral-solution-5-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"23623","name":"Draft concept paper on development of guideline on the treatment of attentional deficit hyperactivity disorder (ADHD)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-01-24T01:00:00Z","last_updated_date":"2008-01-24T01:00:00Z","reference_number":"EMEA/CHMP/EWP/20119/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-guideline-treatment-attentional-deficit-hyperactivity-disorder-adhd_en.pdf"},
    {"id":"23624","name":"Concept paper on the need for revision of the note for guidance on clinical investigation of medicinal products in the treatment of schizophrenia (CPMP/EWP/559/95)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-04-22 - 2010-07-31","first_published_date":"2010-04-30T04:00:00Z","last_updated_date":"2010-04-30T04:00:00Z","reference_number":"EMA/CHMP/EWP/179360/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-clinical-investigation-medicinal-products-treatment-schizophrenia-cpmp-ewp-559-95_en.pdf"},
    {"id":"23634","name":"Guideline on the clinical investigation of medicinal products indicated for generalised anxiety disorder","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-01-20T01:00:00Z","last_updated_date":"2005-01-20T01:00:00Z","reference_number":"CPMP/EWP/4284/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-generalised-anxiety-disorder_en.pdf"},
    {"id":"23660","name":"Concept paper on the revision of the guidance on similar biological medicinal products containing recombinant Erythropoietins","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/BMWP/170734/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidance-similar-biological-medicinal-products-containing-recombinant-erythropoietins_en.pdf"},
    {"id":"23666","name":"Guideline on EU requirements for batches with maximum and minimum titre or batch potency for developmental safety and efficacy studies - Obsolete","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-06-17T02:00:00Z","last_updated_date":"2002-06-17T02:00:00Z","reference_number":"EMEA/CVMP/552/02-CONS.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-eu-requirements-batches-maximum-minimum-titre-or-batch-potency-developmental-safety-efficacy-studies-obsolete_en.pdf"},
    {"id":"23668","name":"Draft guideline on good pharmacovigilance practices: Module IV – Pharmacovigilance audits","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-07-26 - 2012-09-21","first_published_date":"2012-07-26T20:15:04Z","last_updated_date":"2012-07-26T20:15:04Z","reference_number":"EMA/228028/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-iv-pharmacovigilance-audits_en.pdf"},
    {"id":"23734","name":"Draft agomelatine oral tablet 25 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-01-31 - 2018-04-30","first_published_date":"2018-01-31T14:15:00Z","last_updated_date":"2018-01-31T14:15:00Z","reference_number":"EMA/CHMP/800802/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-agomelatine-oral-tablet-25-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"23768","name":"Concept paper for the revision on the guideline for the conduct of pharmacokinetic studies in target animal species","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-03 - 2016-04-30","first_published_date":"2016-02-03T13:00:00Z","last_updated_date":"2016-02-03T13:00:00Z","reference_number":"EMA/CVMP/EWP/706701/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-conduct-pharmacokinetic-studies-target-animal-species_en.pdf"},
    {"id":"23799","name":"ICH guideline M8 on eCTD – questions and answers - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-08-04T13:00:00Z","last_updated_date":"2015-08-04T13:00:00Z","reference_number":"EMA/CHMP/ICH/820/2003","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m8-ectd-questions-and-answers-step-5_en.pdf"},
    {"id":"23800","name":"Concept paper on the need for revision of the points to consider on the clinical investigation of medicinal products other than nsaids in rheumatoid arthritis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-01-20 - 2010-04-30","first_published_date":"2010-02-01T02:00:00Z","last_updated_date":"2010-02-01T02:00:00Z","reference_number":"EMA/CHMP/EWP/751552/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-points-consider-clinical-investigation-medicinal-products-other-nsaids-rheumatoid-arthritis_en.pdf"},
    {"id":"23836","name":"Overview of comments received on 'Draft reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action' - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-08-15T19:00:00Z","last_updated_date":"2017-08-15T19:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/257305/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-draft-reflection-paper-dissolution-specification-generic-solid-oral-immediate-release-products-systemic-action-first-version_en.pdf"},
    {"id":"23855","name":"ICH guideline Q4B: Annex 13 to Note for Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Bulk Density and Tapped Density of Powders – General Chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-09-24 - 2010-12-01","first_published_date":"2010-09-24T04:00:00Z","last_updated_date":"2010-09-24T04:00:00Z","reference_number":"EMA/CHMP/ICH/405290/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-13-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-bulk-density-and-tapped-density-powders-general-chapter-step-3_en.pdf"},
    {"id":"23868","name":"Draft guideline on core summary of product characteristics for human plasma-derived and recombinant coagulation factor-IX products - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-10-01 - 2014-10-31","first_published_date":"2014-10-01T17:40:00Z","last_updated_date":"2014-10-01T17:40:00Z","reference_number":"EMA/CHMP/BPWP/1625/1999 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-human-plasma-derived-and-recombinant-coagulation-factor-ix-products-revision-2_en.pdf"},
    {"id":"23869","name":"Guideline on quality of combination herbal medicinal products/traditional herbal medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-06-23T02:00:00Z","last_updated_date":"2008-06-23T02:00:00Z","reference_number":"EMEA/HMPC/CHMP/CVMP/214869/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-combination-herbal-medicinal-productstraditional-herbal-medicinal-products_en.pdf"},
    {"id":"23872","name":"Guideline on the evaluation of anticancer medicinal products in man - Revision 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-11-20T11:30:00Z","last_updated_date":"2017-11-20T11:30:00Z","reference_number":"EMA/CHMP/205/95 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf"},
    {"id":"23876","name":"Voriconazole tablets 50, 200 mg and powder for oral suspension 40 mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315236/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/voriconazole-tablets-50-200-mg-and-powder-oral-suspension-40-mgml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"23899","name":"Note for guidance: Environmental risk assessment for immunological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-07-01T02:00:00Z","last_updated_date":"1996-07-01T02:00:00Z","reference_number":"EMEA/CVMP/074/95 FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-environmental-risk-assessment-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"23900","name":"Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections to address the clinical development of new agents to treat pulmonary disease due to Mycobacterium tubercul...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-08-03T16:00:00Z","last_updated_date":"2017-08-03T16:00:00Z","reference_number":"EMA/CHMP/EWP/14377/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-address-clinical-development-new-agents-treat-pulmonary-disease-due-mycobacterium-tubercul_en.pdf"},
    {"id":"23916","name":"Draft guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/CHMP/VWP/141697/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-and-clinical-aspects-live-recombinant-viral-vectored-vaccines_en.pdf"},
    {"id":"23919","name":"Concept paper for the revision of the guideline on anticoccidials used for the therapy of coccidiosis in chickens, turkeys and geese (7AE15a; 1993)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-25 - 2016-10-31","first_published_date":"2016-07-25T14:30:00Z","last_updated_date":"2016-07-25T14:30:00Z","reference_number":"EMA/CVMP/EWP/706095/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-anticoccidials-used-therapy-coccidiosis-chickens-turkeys-geese-7ae15a-1993_en.pdf"},
    {"id":"23970","name":"VICH GL6: Environmental impact assessment (EIAS) for veterinary medicinal products - Phase I - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-06-30T02:00:00Z","last_updated_date":"2000-06-30T02:00:00Z","reference_number":"CVMP/VICH/592/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl6-environmental-impact-assessment-eias-veterinary-medicinal-products-phase-i-step-7_en.pdf"},
    {"id":"23981","name":"Draft guideline on excipients in the dossier for application for marketing authorisation of a medicinal product - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-11-06T01:00:00Z","last_updated_date":"2006-11-06T01:00:00Z","reference_number":"EMEA/CHMP/QWP/396951/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-excipients-dossier-application-marketing-authorisation-medicinal-product-revision-2_en.pdf"},
    {"id":"24002","name":"Reflection paper on use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-12-17 - 2013-06-30","first_published_date":"2012-12-17T18:00:00Z","last_updated_date":"2012-12-17T18:00:00Z","reference_number":"EMA/CVMP/SAGAM/119489/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-pleuromutilins-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"24013","name":"International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products GL34: Biologicals: testing for the detection of Mycoplasma contamination","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-03-13T16:30:00Z","last_updated_date":"2013-03-13T16:30:00Z","reference_number":"EMA/CVMP/VICH/463/2002","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-cooperation-harmonisation-technical-requirements-registration-veterinary-medicinal-products-gl34-biologicals-testing-detection-mycoplasma-contamination_en.pdf"},
    {"id":"24033","name":"Concept paper on the need to update the note for guidance on clinical investigation of medicinal products in the treatment of lipid disorders and the note for guidance on the clinical investigation on hypertension - Revision 4","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/EWP/350495/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-update-note-guidance-clinical-investigation-medicinal-products-treatment-lipid-disorders-and-note-guidance-clinical-investigation-hypertension-revision-4_en.pdf"},
    {"id":"24039","name":"Note for guidance on photosafety testing","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-06-27T02:00:00Z","last_updated_date":"2002-06-27T02:00:00Z","reference_number":"CPMP/SWSP/398/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-photosafety-testing_en.pdf"},
    {"id":"24080","name":"VICH GL15: Efficacy of anthelmintics - Specific recommendations for equines - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-07-30T02:00:00Z","last_updated_date":"2001-07-30T02:00:00Z","reference_number":"CVMP/VICH/833/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl15-efficacy-anthelmintics-specific-recommendations-equines-step-7_en.pdf"},
    {"id":"24086","name":"Draft guideline on the evaluation of medicinal products for cardiovascular disease prevention","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/CHMP/EWP/311890/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-cardiovascular-disease-prevention_en.pdf"},
    {"id":"24094","name":"Guideline on good pharmacovigilance practices (GVP): Module IX Addendum I – Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/209012/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal-detection-spontaneous-reports-suspected-adverse-reactions_en.pdf"},
    {"id":"24125","name":"Note for guidance on the use of bovine serum in the manufacture of human biological medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-06-18T02:00:00Z","last_updated_date":"2003-06-18T02:00:00Z","reference_number":"CPMP/BWP/1793/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-bovine-serum-manufacture-human-biological-medicinal-products_en.pdf"},
    {"id":"24182","name":"Guideline on requirements for Plasma Master File (PMF) Certification","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-02-26T01:00:00Z","last_updated_date":"2004-02-26T01:00:00Z","reference_number":"CPMP/BMP/4663/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-plasma-master-file-pmf-certification_en.pdf"},
    {"id":"24196","name":"Concept paper on the need for an addendum on the clinical investigation of medicinal products intended for treatment of glucocorticoid-induced osteoporosis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-01-20 - 2010-04-30","first_published_date":"2010-01-29T02:00:00Z","last_updated_date":"2010-01-29T02:00:00Z","reference_number":"EMA/CHMP/EWP/15912/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-addendum-clinical-investigation-medicinal-products-intended-treatment-glucocorticoid-induced-osteoporosis_en.pdf"},
    {"id":"24197","name":"Guideline on the risk-based approach according to annex I, part IV of Directive 2001/83/EC applied to advanced-therapy medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-03-08T11:30:00Z","last_updated_date":"2013-03-08T11:30:00Z","reference_number":"EMA/CAT/CPWP/686637/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-risk-based-approach-according-annex-i-part-iv-directive-200183ec-applied-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"24223","name":"VICH GL29: Guideline on pharmacovigilance of veterinary medicinal products -Management of periodic summary update reports - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-20T02:00:00Z","last_updated_date":"2006-07-20T02:00:00Z","reference_number":"EMEA/CVMP/VICH/646/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl29-guideline-pharmacovigilance-veterinary-medicinal-products-management-periodic-summary-update-reports-step-7_en.pdf"},
    {"id":"24315","name":"Draft guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-01-20 - 2010-07-31","first_published_date":"2010-02-10T02:00:00Z","last_updated_date":"2010-02-10T02:00:00Z","reference_number":"CPMP/EWP/1080/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-diabetes-mellitus-revision-1_en.pdf"},
    {"id":"24365","name":"Concept paper on the revision of the guideline on specifications: Test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-06-01 - 2015-08-31","first_published_date":"2015-06-01T20:00:00Z","last_updated_date":"2015-06-01T20:00:00Z","reference_number":"EMA/HMPC/217753/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-specifications-test-procedures-and-acceptance-criteria-herbal-substances-herbal-preparations-and-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"24375","name":"Concept paper on the impact of brain immaturity when investigating\n\nmedicinal products intended for neonatal use","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-06-02T02:00:00Z","last_updated_date":"2006-06-02T02:00:00Z","reference_number":"EMEA/181377/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-impact-brain-immaturity-when-investigating-medicinal-products-intended-neonatal-use_en.pdf"},
    {"id":"24379","name":"Concept paper on the revision of the CVMP guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-04-07 - 2011-07-31","first_published_date":"2011-04-20T04:00:00Z","last_updated_date":"2011-04-20T04:00:00Z","reference_number":"EMA/CVMP/EWP/760764/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-cvmp-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances_en.pdf"},
    {"id":"24405","name":"Draft guideline on efficacy and target animal safety data requirements for veterinary medicinal products intended for minor uses or minor species","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-04-18T02:00:00Z","last_updated_date":"2005-04-18T02:00:00Z","reference_number":"EMEA/CVMP/EWP/117899/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-efficacy-and-target-animal-safety-data-requirements-veterinary-medicinal-products-intended-minor-uses-or-minor-species_en.pdf"},
    {"id":"24421","name":"Guideline on good pharmacovigilance practices: Module VI – Management and reporting of adverse reactions to medicinal products (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-06-25T21:18:12Z","last_updated_date":"2012-06-25T21:18:12Z","reference_number":"EMA/873138/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-vi-management-and-reporting-adverse-reactions-medicinal-products-superseded_en.pdf"},
    {"id":"24446","name":"Guideline on clinical investigation of medicinal products for the treatment of migraine","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"CPMP/EWP/788/01 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-migraine_en.pdf"},
    {"id":"24469","name":"Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-07-27T02:00:00Z","last_updated_date":"2000-07-27T02:00:00Z","reference_number":"CPMP/EWP/2655/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-pharmacokinetics-and-pharmacodynamics-development-antibacterial-medicinal-products_en.pdf"},
    {"id":"24477","name":"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil film-coated tablets 150 mg/150 mg/200 mg/245 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/CHMP/805518/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/elvitegravircobicistatemtricitabinetenofovir-disoproxil-film-coated-tablets-150-mg150-mg200-mg245-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"24479","name":"Guideline on user safety for pharmaceutical veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/CVMP/543/03-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-user-safety-pharmaceutical-veterinary-medicinal-products_en.pdf"},
    {"id":"24504","name":"Guideline for PMS studies for metered dose inhalers with new propellants","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1995-12-30T01:00:00Z","last_updated_date":"1995-12-30T01:00:00Z","reference_number":"CPMP/180/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pms-studies-metered-dose-inhalers-new-propellants_en.pdf"},
    {"id":"24512","name":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-07-26T13:00:00Z","last_updated_date":"2016-07-26T13:00:00Z","reference_number":"EMA/CHMP/594085/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-pharmacokinetics-and-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf"},
    {"id":"24527","name":"Draft guideline on adjustment for baseline covariates","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-06-28 - 2013-12-31","first_published_date":"2013-06-28T18:50:00Z","last_updated_date":"2013-06-28T18:50:00Z","reference_number":"EMA/295050/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-adjustment-baseline-covariates_en.pdf"},
    {"id":"24540","name":"Concept paper on the development of a guideline on the quality,Preclinical and clinical aspects of medicinal products containing genetically modified cells - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-05-24T02:00:00Z","last_updated_date":"2007-05-24T02:00:00Z","reference_number":"EMEA/CHMP/GTWP/405681/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-qualitypreclinical-and-clinical-aspects-medicinal-products-containing-genetically-modified-cells-first-version_en.pdf"},
    {"id":"24589","name":"Questions and answers on Ethanol in the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-02-24 - 2014-05-31","first_published_date":"2014-02-24T12:00:00Z","last_updated_date":"2014-02-24T12:00:00Z","reference_number":"EMA/CHMP/507988/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-ethanol-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"24596","name":"Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-03-28T17:10:00Z","last_updated_date":"2014-03-28T17:10:00Z","reference_number":"EMA/CHMP/153191/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-intended-treatment-chronic-primary-immune-thrombocytopenia_en.pdf"},
    {"id":"24673","name":"Draft guideline on good pharmacovigilance practices: Module VII – Periodic safety update report (Rev 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-04-25 - 2013-06-25","first_published_date":"2013-04-25T14:00:00Z","last_updated_date":"2013-04-25T14:00:00Z","reference_number":"EMA/816292/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-vii-periodic-safety-update-report-rev-1_en.pdf"},
    {"id":"24733","name":"Draft guideline on core SmPC and package leaflet for fluorodopa (18F)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-06-01 - 2016-09-30","first_published_date":"2016-06-01T18:00:01Z","last_updated_date":"2016-06-01T18:00:01Z","reference_number":"EMA/CHMP/337958/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-and-package-leaflet-fluorodopa-18f_en.pdf"},
    {"id":"24755","name":"Revised guideline on the summary of product characteristics for antimicrobial products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-12T00:09:21Z","last_updated_date":"2007-11-12T00:09:21Z","reference_number":"EMEA/CVMP/SAGAM/383441/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/revised-guideline-summary-product-characteristics-antimicrobial-products_en.pdf"},
    {"id":"24809","name":"Draft rivaroxaban film-coated tablets 2.5, 10, 15 and 20mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-10-01 - 2016-01-01","first_published_date":"2015-10-06T17:00:00Z","last_updated_date":"2015-10-06T17:00:00Z","reference_number":"EMA/CHMP/PKWP/151340/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-rivaroxaban-film-coated-tablets-25-10-15-and-20mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"24832","name":"Guideline on clinical investigation of medicinal products for the treatment of obsessive compulsive disorder","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-01-20T01:00:00Z","last_updated_date":"2005-01-20T01:00:00Z","reference_number":"CHMP/EWP/4279/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-obsessive-compulsive-disorder_en.pdf"},
    {"id":"24861","name":"Guideline on the non-clinical investigation of the dependence potential of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-12-13T01:00:00Z","last_updated_date":"2007-12-13T01:00:00Z","reference_number":"EMEA/CHMP/SWP/94227/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-investigation-dependence-potential-medicinal-products_en.pdf"},
    {"id":"24871","name":"ICH: E 3: Structure and content of clinical study reports - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-07-01T02:00:00Z","last_updated_date":"1996-07-01T02:00:00Z","reference_number":"CPMP/ICH/137/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-3-structure-and-content-clinical-study-reports-step-5_en.pdf"},
    {"id":"24900","name":"ICH: Q 5 A (R1): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin - Step 5 - first version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-10-01T02:00:00Z","last_updated_date":"1997-10-01T02:00:00Z","reference_number":"CPMP/ICH/295/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-r1-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin-step-5-first-version_en.pdf"},
    {"id":"24914","name":"Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-12-15 - 2012-05-31","first_published_date":"2011-12-22T12:20:00Z","last_updated_date":"2011-12-22T12:20:00Z","reference_number":"EMA/CHMP/27994/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-1-guideline-evaluation-anticancer-medicinal-products-man_en.pdf"},
    {"id":"24916","name":"Draft concept paper on review and update of European Medicines Agency guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-02-07 - 2014-05-31","first_published_date":"2014-02-07T18:00:00Z","last_updated_date":"2014-02-07T18:00:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/704685/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-review-and-update-european-medicines-agency-guidelines-implement-best-practice-regard-3rs-replacement-reduction-and-refinement-regulatory-testing-medicinal-products_en.pdf"},
    {"id":"24917","name":"Concept paper for the revision of the guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-01-26 - 2018-02-28","first_published_date":"2018-01-26T19:30:00Z","last_updated_date":"2018-01-26T19:30:00Z","reference_number":"EMA/CVMP/SWP/779037/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-safety-and-residue-data-requirements-pharmaceutical-veterinary-medicinal-products-intended-minor-use-or-minor-species-mums-limited-market_en.pdf"},
    {"id":"24953","name":"Draft guideline on fixed combination medicinal products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"CPMP/EWP/240/95 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-fixed-combination-medicinal-products-revision-1_en.pdf"},
    {"id":"25005","name":"Concept paper on the revision of notes for guidance on the clinical investigation of human plasma derived and recombinant factor VIII and IX products and the corresponding Core SPCs - Revision 1 - Superseded","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2004-12-15T01:00:00Z","last_updated_date":"2004-12-15T01:00:00Z","reference_number":"EMEA/CHMP/BPWG/189106/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-notes-guidance-clinical-investigation-human-plasma-derived-and-recombinant-factor-viii-and-ix-products-and-corresponding-core-spcs-revision-1-superseded_en.pdf"},
    {"id":"25016","name":"Concept paper on clinical investigation of medicinal products for the treatment of axial spondyloarthritis - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-01 - 2015-06-30","first_published_date":"2015-04-01T18:33:00Z","last_updated_date":"2015-04-01T18:33:00Z","reference_number":"EMA/CHMP/80184/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-clinical-investigation-medicinal-products-treatment-axial-spondyloarthritis-revision-1_en.pdf"},
    {"id":"25027","name":"Draft guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances - Revision 1 (second version)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-03-04 - 2015-05-31","first_published_date":"2015-03-04T17:00:00Z","last_updated_date":"2015-03-04T17:00:00Z","reference_number":"EMA/CVMP/261180/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances-revision-1-second-version_en.pdf"},
    {"id":"25029","name":"Concept paper on similar biological medicinal products containing recombinant Alpha-Interferon  Annex to the guideline on similar biological medicinal products containing biotechnology derived protiens as active substanc...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-04-26T02:00:00Z","last_updated_date":"2006-04-26T02:00:00Z","reference_number":"CHMP/BMWP/7241/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-similar-biological-medicinal-products-containing-recombinant-alpha-interferon-annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-protiens-active_en.pdf"},
    {"id":"25041","name":"Dasatinib film-coated tablets 20, 50, 70, 80, 100 & 140 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/675838/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/dasatinib-film-coated-tablets-20-50-70-80-100-140-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"25071","name":"Draft guideline on clinical investigation of medicinal products for the treatment of chronic heart failure  - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-11 - 2016-08-31","first_published_date":"2016-02-11T11:40:00Z","last_updated_date":"2016-02-11T11:40:00Z","reference_number":"EMA/CHMP/392958/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-chronic-heart-failure-revision-2_en.pdf"},
    {"id":"25083","name":"Draft concept paper on the need to revise the \"Guideline on the evaluation of anticancer medicinal products in man\" in order to provide guidance on the reporting of safety data from clinical trials - Revision 5","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-05-01 - 2015-07-31","first_published_date":"2015-04-30T15:00:00Z","last_updated_date":"2015-04-30T15:00:00Z","reference_number":"EMA/130525/2015 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-need-revise-guideline-evaluation-anticancer-medicinal-products-man-order-provide-guidance-reporting-safety-data-clinical-trials-revision-5_en.pdf"},
    {"id":"25101","name":"Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of depression - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-11-18 - 2017-02-28","first_published_date":"2016-11-18T10:30:00Z","last_updated_date":"2016-11-18T10:30:00Z","reference_number":"EMA/CHMP/183826/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf"},
    {"id":"25118","name":"Draft concept paper on the need for revision of the guideline on clinical investigation of medicinal products for the treatment of venous thromboembolic disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-06-03 - 2013-09-01","first_published_date":"2013-06-03T14:00:00Z","last_updated_date":"2013-06-03T14:00:00Z","reference_number":"EMA/CHMP/281099/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-venous-thromboembolic-disease_en.pdf"},
    {"id":"25138","name":"Guideline on the scientific application and the practical arrangements necessary to implement the procedure for accelerated assessment pursuant to Article 14(9) of Regulation (EC) No 726/2004","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2016-03-07T12:00:00Z","reference_number":"EMA/CHMP/671361/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific-application-and-practical-arrangements-necessary-implement-procedure-accelerated-assessment-pursuant-article-149-regulation-ec-no-7262004_en.pdf"},
    {"id":"25160","name":"Prasugrel film-coated tablets 5 and 10 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-11-01T17:33:27Z","reference_number":"EMA/CHMP/158772/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/prasugrel-film-coated-tablets-5-and-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"25175","name":"Guideline on the development of new medicinal products for the treatment of Crohn’s disease - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-23T11:44:59Z","last_updated_date":"2018-07-23T11:44:59Z","reference_number":"CPMP/EWP/2284/99 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-new-medicinal-products-treatment-crohns-disease-revision-2_en.pdf"},
    {"id":"25182","name":"ICH: M 4 S: Common technical document for the registration of pharmaceuticals for human use - Safety questions and answers - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-11-01T01:00:00Z","last_updated_date":"2003-11-01T01:00:00Z","reference_number":"CPMP/ICH/5549/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-4-s-common-technical-document-registration-pharmaceuticals-human-use-safety-questions-and-answers-step-5_en.pdf"},
    {"id":"25185","name":"Guideline on plasma-derived medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-07-29T02:00:00Z","last_updated_date":"2011-07-29T02:00:00Z","reference_number":"EMA/CHMP/BWP/706271/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-plasma-derived-medicinal-products_en.pdf"},
    {"id":"25202","name":"Concept paper on the revision of the guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant granulocyte-colony stimulating factor","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-27 - 2015-10-31","first_published_date":"2015-07-27T20:00:00Z","last_updated_date":"2015-07-27T20:00:00Z","reference_number":"EMA/CHMP/BMWP/214262/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-granulocyte-colony-stimulating-factor_en.pdf"},
    {"id":"25221","name":"Draft questions and answers on post approval change management protocols","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-10-14 - 2011-02-28","first_published_date":"2010-11-04T02:00:00Z","last_updated_date":"2010-11-04T02:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/586330/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-and-answers-post-approval-change-management-protocols_en.pdf"},
    {"id":"25232","name":"Guideline on the clinical investigation of medicinal products for the treatment of asthma - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-12-15T13:00:00Z","last_updated_date":"2015-12-15T13:00:00Z","reference_number":"CHMP/EWP/2922/01 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-asthma-revision-1_en.pdf"},
    {"id":"25243","name":"Concept paper on good genomics biomarker practices - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-08-04 - 2014-11-04","first_published_date":"2014-08-04T15:00:00Z","last_updated_date":"2014-08-04T15:00:00Z","reference_number":"EMA/CHMP/PGWP/415990/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-good-genomics-biomarker-practices-first-version_en.pdf"},
    {"id":"25263","name":"Note for guidance on plasma-derived medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-01-25T01:00:00Z","last_updated_date":"2001-01-25T01:00:00Z","reference_number":"CHMP/BWP/269/95/ rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-plasma-derived-medicinal-products_en.pdf"},
    {"id":"25298","name":"Draft guideline on medicinal products for the treatment of insomnia","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-10-22 - 2010-04-30","first_published_date":"2009-11-12T01:09:00Z","last_updated_date":"2009-11-12T01:09:00Z","reference_number":"EMEA/16274/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-medicinal-products-treatment-insomnia_en.pdf"},
    {"id":"25303","name":"Draft  revision on the guideline on epidemiological data on blood transmissible infections (EMEA/CPMP/BWP/125/04. rev 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-05-20T02:00:00Z","last_updated_date":"2009-05-20T02:00:00Z","reference_number":"EMEA/CPMP/BWP/125/04. Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-revision-guideline-epidemiological-data-blood-transmissible-infections-emeacpmpbwp12504-rev-1_en.pdf"},
    {"id":"25338","name":"Guideline on clinical investigation of immunosuppressants for solid organ transplantation","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"CHMP/EWP/263148/06","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-immunosuppressants-solid-organ-transplantation_en.pdf"},
    {"id":"25354","name":"Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-03-26T18:15:00Z","last_updated_date":"2012-03-26T18:15:00Z","reference_number":"EMA/CHMP/60715/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-no-need-revision-guideline-medicinal-products-treatment-alzheimers-disease-and-other-dementias-revision-2_en.pdf"},
    {"id":"25357","name":"ICH : M2: Business Requirements - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-12-18T01:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMEA/CHMP/ICH/792476/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m2-business-requirements-step-5_en.pdf"},
    {"id":"25377","name":"Draft Fingolimod capsules 0.5mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-02 - 2016-07-31","first_published_date":"2016-05-02T13:00:00Z","last_updated_date":"2016-05-02T13:00:00Z","reference_number":"EMA/CHMP/154812/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-fingolimod-capsules-05mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"25397","name":"Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-12-13T01:00:00Z","last_updated_date":"2007-12-13T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/14327/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-first-version_en.pdf"},
    {"id":"25437","name":"Draft guideline on epidemiological data on blood transmissible infections","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-06-01 - 2015-08-31","first_published_date":"2015-06-02T13:00:00Z","last_updated_date":"2015-06-02T13:00:00Z","reference_number":"EMA/CHMP/BWP/548524/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-epidemiological-data-blood-transmissible-infections_en.pdf"},
    {"id":"25439","name":"Second draft guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-01-15","first_published_date":"2013-11-15T11:30:00Z","last_updated_date":"2013-11-15T11:30:00Z","reference_number":"EMA/CHMP/623942/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/second-draft-guideline-clinical-investigation-medicinal-products-prevention-stroke-and-systemic-embolic-events-patients-non-valvular-atrial-fibrillation_en.pdf"},
    {"id":"25450","name":"Guideline on good pharmacovigilance practices (GVP) - Module VIII Addendum I – Requirements and recommendations for the submission of information on non-interventional post-authorisation safety studies with tracked chang...","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-08-08T17:00:00Z","last_updated_date":"2016-08-08T17:00:00Z","reference_number":"EMA/395730/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-addendum-i-requirements-and-recommendations-submission-information-non-interventional-post-authorisation-safety-studies-tracked-chang_en.pdf"},
    {"id":"25462","name":"Guideline on the clinical investigation of human plasma derived Von Willebrand factor products (CPMP/BPWG/220/02)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-17T00:09:21Z","last_updated_date":"2005-11-17T00:09:21Z","reference_number":"CPMP/BPWG/220/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-plasma-derived-von-willebrand-factor-products-cpmpbpwg22002_en.pdf"},
    {"id":"25486","name":"Draft paediatric addendum to the note for guidance on the clinical investigation on medicinal products in the treatment of hypertension","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-09-30 - 2014-03-31","first_published_date":"2013-09-30T13:30:00Z","last_updated_date":"2013-09-30T13:30:00Z","reference_number":"EMA/CHMP/206815/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-paediatric-addendum-note-guidance-clinical-investigation-medicinal-products-treatment-hypertension_en.pdf"}    {"id":"25513","name":"Miglustat hard capsules 100 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/675841/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/miglustat-hard-capsules-100-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"25520","name":"Guideline on the acceptability of names for veterinary medicinal products processed through the centralised procedure","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-01-21T01:00:00Z","last_updated_date":"2013-05-02T12:48:00Z","reference_number":"EMEA/CVMP/328/98 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-acceptability-names-veterinary-medicinal-products-processed-through-centralised-procedure_en.pdf"},
    {"id":"25542","name":"ICH: E 9: Statistical principles for clinical trials - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"CPMP/ICH/363/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf"},
    {"id":"25553","name":"Note for guidance on in-use stability testing of veterinary medicinal products (excluding immunological veterinary medicinal products)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-02-01T01:00:00Z","last_updated_date":"2002-02-01T01:00:00Z","reference_number":"EMEA/CVMP/424/01 - FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-stability-testing-veterinary-medicinal-products-excluding-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"25606","name":"Additional guidance on documents relating to an active substance master file","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-10-02T18:30:00Z","last_updated_date":"2012-10-02T18:30:00Z","reference_number":"EMA/CHMP/CVMP/QWP/549010/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/additional-guidance-documents-relating-active-substance-master-file_en.pdf"},
    {"id":"25619","name":"Draft guideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-01-30 - 2014-07-30","first_published_date":"2014-01-30T16:00:00Z","last_updated_date":"2014-01-30T16:00:00Z","reference_number":"EMA/281371/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-key-aspects-use-pharmacogenomic-methodologies-pharmacovigilance-evaluation-medicinal-products_en.pdf"},
    {"id":"25661","name":"Concept paper on the need for a guideline on the treatment of premenstrual dysphoric disorder (PMDD)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"EMEA/CHMP/EWP/11877/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf"},
    {"id":"25662","name":"Guideline on the procedure to be followed when a batch of a vaccine finished product is suspected to be contaminated with bovine viral diarrhoea virus (Rev.1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-09-17T18:35:00Z","last_updated_date":"2015-09-17T18:35:00Z","reference_number":"EMA/CVMP/IWP/205351/2006-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-procedure-be-followed-when-batch-vaccine-finished-product-suspected-be-contaminated-bovine-viral-diarrhoea-virus-rev1_en.pdf"},
    {"id":"25674","name":"Guideline on clinical investigation of medicinal products for the prophylaxis of venous thromboembolic risk in non-surgical patients","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2006-06-01T02:00:00Z","reference_number":"CPMP/EWP/6235/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-prophylaxis-venous-thromboembolic-risk-non-surgical-patients_en.pdf"},
    {"id":"25712","name":"Draft guideline on the plant testing strategy for veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-27 - 2016-11-30","first_published_date":"2016-05-27T20:00:00Z","last_updated_date":"2016-05-27T20:00:00Z","reference_number":"EMA/CVMP/ERA/689041/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-plant-testing-strategy-veterinary-medicinal-products_en.pdf"},
    {"id":"25729","name":"Guideline on good pharmacovigilance practices: Module II – Pharmacovigilance system master file (Rev. 2)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T19:18:17Z","last_updated_date":"2017-03-30T17:00:00Z","reference_number":"EMA/816573/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file-rev-2_en.pdf"},
    {"id":"25749","name":"Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) - Rev. 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-20T16:45:00Z","last_updated_date":"2018-07-20T16:45:00Z","reference_number":"EMA/CHMP/BPWP/94033/2007 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-rev-3_en.pdf"},
    {"id":"25765","name":"Draft guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) (CPMP/BPWG/388/95 rev. 2)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-02-06T01:00:00Z","last_updated_date":"2009-02-06T01:00:00Z","reference_number":"CPMP/BPWG/388/95 rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-cpmpbpwg38895-rev-2_en.pdf"},
    {"id":"25798","name":"Draft guideline on dossier structure and content of marketing authorisation applications for influenza vaccines with avian strains with a pandemic potential for use outside of the core dossier context","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-07-24T02:00:00Z","last_updated_date":"2006-07-24T02:00:00Z","reference_number":"EMEA/CHMP/VWP/263499/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-dossier-structure-and-content-marketing-authorisation-applications-influenza-vaccines-avian-strains-pandemic-potential-use-outside-core-dossier-context_en.pdf"},
    {"id":"25801","name":"Draft ICH S5 (R3) guideline on reproductive toxicology: detection of toxicity to reproduction for human pharmaceuticals, step 2b - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-08-31 - 2018-02-28","first_published_date":"2017-08-31T13:10:00Z","last_updated_date":"2017-08-31T13:10:00Z","reference_number":"EMA/CHMP/ICH/544278/1998","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-s5-r3-guideline-reproductive-toxicology-detection-toxicity-reproduction-human-pharmaceuticals-step-2b-revision-3_en.pdf"},
    {"id":"25811","name":"Guideline on selection of test materials for genotoxicity testing for Traditional Herbal Medicinal Products/Herbal Medicinal Products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-01-18T01:00:00Z","last_updated_date":"2010-01-18T01:00:00Z","reference_number":"EMEA/HMPC/67644/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-selection-test-materials-genotoxicity-testing-traditional-herbal-medicinal-productsherbal-medicinal-products_en.pdf"},
    {"id":"25818","name":"Draft concept paper on revision of annex 15 of the good-manufacturing-practice guide","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-11-27 - 2013-02-28","first_published_date":"2012-11-27T10:40:00Z","last_updated_date":"2012-11-27T10:40:00Z","reference_number":"EMA/INS/GMP/705397/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-revision-annex-15-good-manufacturing-practice-guide_en.pdf"},
    {"id":"25838","name":"Concept paper on the need for a guideline on the clinical development of thrombopoetin receptor agonists for the treatment of chronic immune (idiopathic) thrombocytopenic purpura","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-05-20 - 2010-08-31","first_published_date":"2010-06-03T04:00:00Z","last_updated_date":"2010-06-03T04:00:00Z","reference_number":"EMA/CHMP/EWP/203111/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-clinical-development-thrombopoetin-receptor-agonists-treatment-chronic-immune-idiopathic-thrombocytopenic-purpura_en.pdf"},
    {"id":"25883","name":"Draft guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-10-09 - 2013-04-09","first_published_date":"2012-10-09T17:59:00Z","last_updated_date":"2012-10-09T17:59:00Z","reference_number":"EMA/CHMP/771815/2011, Rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis-revision-2_en.pdf"},
    {"id":"25925","name":"VICH GL47: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: laboratory animal comparative metabolism studies","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-04-07T02:00:00Z","last_updated_date":"2011-04-07T02:00:00Z","reference_number":"EMA/CVMP/VICH/463104/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl47-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-animals-laboratory-animal-comparative-metabolism-studies_en.pdf"},
    {"id":"25930","name":"Guideline on summary of requirements for active substances in the quality part of the dossier - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-01T02:00:00Z","last_updated_date":"2004-06-01T02:00:00Z","reference_number":"CHMP/QWP/297/97 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-summary-requirements-active-substances-quality-part-dossier-revision-1_en.pdf"},
    {"id":"25956","name":"ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population - Revision 1 (addendum)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-06T19:00:00Z","last_updated_date":"2017-10-06T19:00:00Z","reference_number":"EMA/CPMP/ICH/2711/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-revision-1-addendum_en.pdf"},
    {"id":"25960","name":"Guideline on good pharmacovigilance practices (GVP) - Module VIII – Post-authorisation safety studies (Rev. 3)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T19:18:14Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/813938/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf"},
    {"id":"25975","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use topic E 2 A: Clinical safety data management: Definitions and standards for expedited reporting - Step...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1995-06-01T02:00:00Z","last_updated_date":"1995-06-01T02:00:00Z","reference_number":"CPMP/ICH/377/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-topic-e-2-clinical-safety-data-management-definitions-and-standards-expedited-reporting-step_en.pdf"},
    {"id":"25997","name":"Concept paper on haematological malignancies","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/CHMP/EWP/20808/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-haematological-malignancies_en.pdf"},
    {"id":"26000","name":"Draft guideline on clinical investigation of medicinal products for the treatment of acute heart failure - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-10-15 - 2013-04-15","first_published_date":"2012-10-15T13:15:00Z","last_updated_date":"2012-10-15T13:15:00Z","reference_number":"CHMP/EWP/2986/03 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-acute-heart-failure-revision-1_en.pdf"},
    {"id":"26041","name":"ICH: Q 4 B Annex 4C: To note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on  microbiological examination of non-sterile products: Acceptance criteria for pharmaceutical preparatio...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-06-01T02:00:00Z","last_updated_date":"2008-06-01T02:00:00Z","reference_number":"EMEA/CHMP/ICH/308867/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-4c-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-microbiological-examination-non-sterile-products-acceptance-criteria-pharmaceutical-preparatio_en.pdf"},
    {"id":"26065","name":"Tests on samples of biological origin","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-12-04T00:09:21Z","last_updated_date":"1998-12-04T00:09:21Z","reference_number":"3AB11a","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/tests-samples-biological-origin_en.pdf"},
    {"id":"26091","name":"Draft guideline on clinical investigation of medicinal products in the treatment of Chronic Obstructive Pulmonary Disease (COPD)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-07-22 - 2011-03-01","first_published_date":"2010-09-20T04:00:00Z","last_updated_date":"2010-09-20T04:00:00Z","reference_number":"CPMP/EWP/562/98 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease-copd_en.pdf"},
    {"id":"26126","name":"Guideline on good pharmacovigilance practices (GVP): Module VIII – Post-authorisation safety studies with tracked changes (Rev. 3)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/813938/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-tracked-changes-rev-3_en.pdf"},
    {"id":"26162","name":"Draft guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-11-15 - 2013-01-15","first_published_date":"2011-11-29T17:00:00Z","last_updated_date":"2012-11-19T12:30:00Z","reference_number":"EMA/CVMP/IWP/594618/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-combined-vaccines-and-associations-immunological-veterinary-medicinal-products-ivmps_en.pdf"},
    {"id":"26184","name":"Guideline on validation of immunoassay for the detection of antibody to human immunodeficiency virus (anti-HIV) in plasma pools","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/CHMP/BWP/298388/05","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-validation-immunoassay-detection-antibody-human-immunodeficiency-virus-anti-hiv-plasma-pools_en.pdf"},
    {"id":"26216","name":"Draft vemurafenib film-coated tablets 240 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-01 - 2016-10-31","first_published_date":"2016-08-01T17:00:00Z","last_updated_date":"2016-08-01T17:00:00Z","reference_number":"EMA/CHMP/476248/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vemurafenib-film-coated-tablets-240-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"26233","name":"Public Statement on Chamomilla containing herbal medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-03-08T01:00:00Z","last_updated_date":"2006-03-08T01:00:00Z","reference_number":"EMEA/HMPC/138309/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-chamomilla-containing-herbal-medicinal-products_en.pdf"},
    {"id":"26240","name":"Draft implementation strategy of ICH Q3D guideline","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-12 - 2016-08-12","first_published_date":"2016-07-12T14:35:00Z","last_updated_date":"2016-07-12T14:35:00Z","reference_number":"EMA/404489/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-implementation-strategy-ich-q3d-guideline_en.pdf"},
    {"id":"26276","name":"VICH GL35: Pharmacovigilance: electronic standards for transfer of data","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-03-13T16:30:00Z","last_updated_date":"2023-05-22T10:43:00Z","reference_number":"EMA/CVMP/VICH/123940/2006 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl35-pharmacovigilance-electronic-standards-transfer-data_en.pdf"},
    {"id":"26284","name":"Draft oseltamivir product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/423665/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-oseltamivir-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"26296","name":"Points to consider on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2000-06-29T02:00:00Z","last_updated_date":"2000-06-29T02:00:00Z","reference_number":"CPMP/EWP/707/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-clinical-investigation-medicinal-products-prophylaxis-high-intra-and-post-operative-venous-thromboembolic-risk_en.pdf"},
    {"id":"26318","name":"ICH guideline Q4B Annex 9 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on tablet friability - general chapter - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2017-07-13T16:30:00Z","reference_number":"EMEA/CHMP/ICH/379801/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-9-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-tablet-friability-general-chapter-step-5_en.pdf"},
    {"id":"26331","name":"Reflection paper on the risk of antimicrobial resistance transfer from companion animals","type":"scientific-guideline","status":"Adopted","consultation_date":"2015-01-27 - 2015-04-30","first_published_date":"2015-01-30T02:00:00Z","last_updated_date":"2015-01-30T02:00:00Z","reference_number":"EMA/CVMP/AWP/401740/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-antimicrobial-resistance-transfer-companion-animals_en.pdf"},
    {"id":"26361","name":"Guideline on the evaluation of medicinal products for cardiovascular disease prevention","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-09-25T02:00:00Z","last_updated_date":"2008-09-25T02:00:00Z","reference_number":"EMEA/CHMP/EWP/311890/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-cardiovascular-disease-prevention_en.pdf"},
    {"id":"26445","name":"Note for guidance: Approach towards harmonisation of withdrawal periods","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-04-01T02:00:00Z","last_updated_date":"1996-04-01T02:00:00Z","reference_number":"EMEA/CVMP/036/95 - FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-approach-towards-harmonisation-withdrawal-periods_en.pdf"},
    {"id":"26467","name":"Concept paper on the need to revise the guideline on the evaluation of anticancer medicinal products in man - Revision 4","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-07-22 - 2011-01-01","first_published_date":"2010-09-17T04:00:00Z","last_updated_date":"2010-09-17T04:00:00Z","reference_number":"EMA/CHMP/EWP/433478/2010 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revise-guideline-evaluation-anticancer-medicinal-products-man-revision-4_en.pdf"},
    {"id":"26493","name":"Guideline on the demonstration of palatability of veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-07-23T14:00:00Z","last_updated_date":"2014-07-23T14:00:00Z","reference_number":"EMA/CVMP/EWP/206024/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-demonstration-palatability-veterinary-medicinal-products_en.pdf"},
    {"id":"26495","name":"Concept paper on the guidance on the non-clinical and clinical development of medicinal products for HIV prevention including oral and topical PrEP","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-02-17 - 2011-04-30","first_published_date":"2011-02-24T02:00:00Z","last_updated_date":"2011-02-24T02:00:00Z","reference_number":"EMA/86004/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guidance-non-clinical-and-clinical-development-medicinal-products-hiv-prevention-including-oral-and-topical-prep_en.pdf"},
    {"id":"26504","name":"ICH: M 4 S: Common technical document for the registration of pharmaceuticals for human use - Safety - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-07-01T02:00:00Z","last_updated_date":"2003-07-01T02:00:00Z","reference_number":"CPMP/ICH/2887/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-4-s-common-technical-document-registration-pharmaceuticals-human-use-safety-step-5_en.pdf"},
    {"id":"26518","name":"Draft guideline on quality of oral modified-release products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-09-15 - 2013-03-15","first_published_date":"2012-09-14T14:00:00Z","last_updated_date":"2012-09-14T14:00:00Z","reference_number":"EMA/492713/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-oral-modified-release-products_en.pdf"},
    {"id":"26600","name":"Concept paper on the revision of the guideline on the development of new medicinal products for the treatment of Crohn’s disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-11-14 - 2013-02-15","first_published_date":"2012-10-31T19:00:00Z","last_updated_date":"2012-11-14T11:55:00Z","reference_number":"EMA/CHMP/396984/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-development-new-medicinal-products-treatment-crohns-disease_en.pdf"},
    {"id":"26667","name":"Draft guideline on the investigation of bioequivalence","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"CPMP/EWP/QWP/1401/98 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-investigation-bioequivalence_en.pdf"},
    {"id":"26674","name":"Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-11-30T00:09:00Z","last_updated_date":"2011-05-13T01:09:00Z","reference_number":"EMEA/CHMP/EWP/9147/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-treatment-cystic-fibrosis-first-version_en.pdf"},
    {"id":"26710","name":"Concept paper on the need of a guideline for clinical investigation of medicinal products for the treatment of chronic constipation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-11-14 - 2013-02-15","first_published_date":"2012-11-08T12:00:00Z","last_updated_date":"2012-11-14T11:57:00Z","reference_number":"EMA/CHMP/462198/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-clinical-investigation-medicinal-products-treatment-chronic-constipation_en.pdf"},
    {"id":"26746","name":"Reflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular and metabolic diseases","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-06-12 - 2015-09-30","first_published_date":"2015-06-12T14:00:00Z","last_updated_date":"2015-06-12T14:00:00Z","reference_number":"EMA/CHMP/50549/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-assessment-cardiovascular-risk-medicinal-products-treatment-cardiovascular-and-metabolic-diseases_en.pdf"},
    {"id":"26759","name":"Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-11-07T10:30:00Z","last_updated_date":"2013-11-07T10:30:00Z","reference_number":"EMA/CHMP/351889/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections_en.pdf"},
    {"id":"26764","name":"ICH: S 7 B: The nonclinical evaluation of the potential for delayed Ventricular Repolarization (QT Interval Prolongation) by human pharmaceuticals - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-05-31T02:00:00Z","last_updated_date":"2005-05-31T02:00:00Z","reference_number":"CPMP/ICH/423/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-7-b-nonclinical-evaluation-potential-delayed-ventricular-repolarization-qt-interval-prolongation-human-pharmaceuticals-step-5_en.pdf"},
    {"id":"26776","name":"Oseltamivir hard capsules 30, 45 and 75 mg, powder for oral suspension 6 mg/ml and 12 mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315246/2014 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/oseltamivir-hard-capsules-30-45-and-75-mg-powder-oral-suspension-6-mgml-and-12-mgml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"26783","name":"Draft template for the Qualified Person’s (QP's) declaration concerning good-manufacturing-practice compliance of the active substance used as starting material and verification of its supply chain “the QP declaration te...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-12-16 - 2011-04-30","first_published_date":"2011-01-13T02:00:00Z","last_updated_date":"2011-06-20T04:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/696270/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-template-qualified-persons-qps-declaration-concerning-good-manufacturing-practice-compliance-active-substance-used-starting-material-and-verification-its-supply-chain-qp-declaration-te_en.pdf"},
    {"id":"26804","name":"Guideline on the core SPC for human plasma derived Von Willebrand factor (CPMP/BPWG/278/02)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"CPMP/BPWG/278/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-plasma-derived-von-willebrand-factor-cpmpbpwg27802_en.pdf"},
    {"id":"26809","name":"Tadalafil film-coated tablets 2.5 mg, 5 mg, 10 mg and 20 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-02-01T13:00:00Z","last_updated_date":"2018-02-01T13:00:00Z","reference_number":"EMA/CHMP/315234/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/tadalafil-film-coated-tablets-25-mg-5-mg-10-mg-and-20-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"26887","name":"Clinical investigation of corticosteroids intended for use of the skin","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1987-02-01T01:00:00Z","last_updated_date":"1987-02-01T01:00:00Z","reference_number":"3CC26A ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/clinical-investigation-corticosteroids-intended-use-skin_en.pdf"},
    {"id":"26900","name":"Draft reflection paper on viral safety of plasma-derived medicinal products with respect to hepatitis E virus","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-01 - 2015-09-30","first_published_date":"2015-07-01T13:19:00Z","last_updated_date":"2015-07-01T13:19:00Z","reference_number":"EMA/CHMP/BWP/723009/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-viral-safety-plasma-derived-medicinal-products-respect-hepatitis-e-virus_en.pdf"},
    {"id":"26909","name":"Draft guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food-producing animals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-03-04 - 2015-08-31","first_published_date":"2015-03-04T17:00:00Z","last_updated_date":"2015-03-04T17:00:00Z","reference_number":"EMA/CVMP/AWP/706442/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-assessment-risk-public-health-antimicrobial-resistance-due-use-antimicrobial-veterinary-medicinal-product-food-producing-animals_en.pdf"},
    {"id":"26941","name":"Guideline on the chemistry of active substances for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-01-19T15:20:00Z","last_updated_date":"2018-01-19T15:20:00Z","reference_number":"EMA/CVMP/QWP/707366/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-chemistry-active-substances-veterinary-medicinal-products_en.pdf"},
    {"id":"26960","name":"Core SPC for human Varicella immunoglobulin for intramuscular use\n\n(CPMP/BPWG/3726/02)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"CPMP/BPWG/3726/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/core-spc-human-varicella-immunoglobulin-intramuscular-use-cpmpbpwg372602_en.pdf"},
    {"id":"26965","name":"Guideline on good pharmacovigilance practices: Annex II – Templates: Cover page of periodic safety update report (PSUR)","type":"scientific-guideline","status":"Adopted","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-06-25T04:00:00Z","last_updated_date":"2013-04-25T14:00:00Z","reference_number":"EMA/170043/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-ii-templates-cover-page-periodic-safety-update-report-psur_en.pdf"},
    {"id":"26986","name":"Levodopa/Carbidopa/Entacapone film-coated tablet 200 mg/50 mg/200 mg, 175 mg/43.75 mg/200 mg, 150 mg/37.5 mg/200 mg, 125 mg/31.25 mg/200 mg, 100 mg/25 mg/200 mg, 75 mg/18.75 mg/200 mg and 50 mg/12.5 mg/200 mg product-spe...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-01-03T17:54:00Z","last_updated_date":"2017-01-03T17:54:00Z","reference_number":"EMA/CHMP/805630/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/levodopacarbidopaentacapone-film-coated-tablet-200-mg50-mg200-mg-175-mg4375-mg200-mg-150-mg375-mg200-mg-125-mg3125-mg200-mg-100-mg25-mg200-mg-75-mg1875-mg200-mg-and-50-mg125-mg200-mg-product-spe_en.pdf"},
    {"id":"27001","name":"Draft guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus, cutaneous lupus and lupus nephritis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-03-05 - 2013-09-04","first_published_date":"2013-03-05T19:00:00Z","last_updated_date":"2013-03-05T19:00:00Z","reference_number":"EMA/CHMP/51230/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-systemic-lupus-erythematosus-cutaneous-lupus-and-lupus-nephritis_en.pdf"},
    {"id":"27004","name":"Recommendation to marketing authorisation holders, highlighting recent measures in the veterinary field to promote replacement, reduction, and refinement (3Rs) measures described in the European Pharmacopoeia - Applicabl...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-01-24T16:30:00Z","last_updated_date":"2018-02-16T11:00:00Z","reference_number":"EMA/CHMP/CVMP/3Rs/614768/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-marketing-authorisation-holders-highlighting-recent-measures-veterinary-field-promote-replacement-reduction-and-refinement-3rs-measures-described-european-pharmacopoeia-applicabl_en.pdf"},
    {"id":"27005","name":"Draft guideline on core summary of product characteristics for human fibrinogen products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-03-04 - 2014-06-04","first_published_date":"2014-03-04T14:00:00Z","last_updated_date":"2014-03-04T14:00:00Z","reference_number":"EMA/CHMP/BPWP/691754/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-product-characteristics-human-fibrinogen-products_en.pdf"},
    {"id":"27014","name":"Draft guideline on the evaluation of medicinal products in the treatment of primary osteoporosis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-12-14T01:00:00Z","last_updated_date":"2005-12-14T01:00:00Z","reference_number":"CPMP/EWP/552/95 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-treatment-primary-osteoporosis_en.pdf"},
    {"id":"27015","name":"Draft guideline on the chemistry of active substances (human) - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-24 - 2015-10-24","first_published_date":"2015-04-24T18:45:00Z","last_updated_date":"2015-04-24T18:45:00Z","reference_number":"EMA/CHMP/QWP/96664/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-chemistry-active-substances-human-first-version_en.pdf"},
    {"id":"27082","name":"Public statement on the use of herbal medicinal products containing pulegone and menthofuran - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T16:00:00Z","last_updated_date":"2016-07-27T16:00:00Z","reference_number":"EMA/HMPC/258725/2015 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-use-herbal-medicinal-products-containing-pulegone-and-menthofuran-revision-1_en.pdf"},
    {"id":"27083","name":"Draft reflection paper on injection-site residues: considerations for risk assessment and residue surveillance (revision 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-10-18 - 2014-04-30","first_published_date":"2013-10-18T19:00:00Z","last_updated_date":"2013-10-18T19:00:00Z","reference_number":"EMA/CVMP/520190/2007-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-injection-site-residues-considerations-risk-assessment-and-residue-surveillance-revision-1_en.pdf"},
    {"id":"27090","name":"Guideline on the approach to establish a pharmacological acceptable daily intake","type":"scientific-guideline","status":"Adopted","consultation_date":"2012-01-10 - 2012-07-31","first_published_date":"2012-01-23T12:30:00Z","last_updated_date":"2012-11-19T12:30:00Z","reference_number":"EMA/CVMP/SWP/355689/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-approach-establish-pharmacological-acceptable-daily-intake_en.pdf"},
    {"id":"27113","name":"Concept paper on assessing the toxicological risk to humans and the environment of veterinary pharmaceuticals in groundwater","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-04-19 - 2013-06-30","first_published_date":"2013-04-19T13:31:02Z","last_updated_date":"2013-04-19T13:31:02Z","reference_number":"EMA/CVMP/ERA/718229/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-assessing-toxicological-risk-humans-and-environment-veterinary-pharmaceuticals-groundwater_en.pdf"},
    {"id":"27129","name":"Draft guideline on similar biological medicinal products containing interferon beta","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-12-15 - 2012-05-31","first_published_date":"2012-01-19T11:32:00Z","last_updated_date":"2012-01-19T11:32:00Z","reference_number":"EMA/CHMP/BMWP/652000/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-similar-biological-medicinal-products-containing-interferon-beta_en.pdf"},
    {"id":"27136","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) M2 on electronic common technical document (eCTD) - file format criteria - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-01-12T16:20:00Z","last_updated_date":"2015-01-12T16:20:00Z","reference_number":"EMA/CHMP/ICH/730231/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-m2-electronic-common-technical-document-ectd-file-format-criteria-step-5_en.pdf"},
    {"id":"27143","name":"ICH guideline Q4B annex 2 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on test for extractable volume of parenteral preparations general chapter - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2017-07-13T16:30:00Z","reference_number":"EMEA/CHMP/ICH/559409/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-2-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-test-extractable-volume-parenteral-preparations-general-chapter-step-5_en.pdf"},
    {"id":"27149","name":"Guideline on clinical development of fixed combination medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"CHMP/EWP/240/95 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-fixed-combination-medicinal-products-revision-1_en.pdf"},
    {"id":"27176","name":"Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-02-02T10:10:00Z","last_updated_date":"2016-02-02T10:10:00Z","reference_number":"EMA/CHMP/725881/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf"},
    {"id":"27191","name":"Concept paper on guideline on immunogenicity assessment of therapeutic proteins - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-02-22T01:00:00Z","last_updated_date":"2006-02-22T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/246511/2005 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-immunogenicity-assessment-therapeutic-proteins-first-version_en.pdf"},
    {"id":"27225","name":"Concept paper on revision of note for guidance for the determination of withdrawal periods for milk","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-12-09 - 2011-03-31","first_published_date":"2010-12-15T02:00:00Z","last_updated_date":"2010-12-15T02:00:00Z","reference_number":"EMA/CVMP/SWP/736014/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-determination-withdrawal-periods-milk_en.pdf"},
    {"id":"27276","name":"Concept paper on the revision of the points to consider on xenogeneic cell therapy medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-05-22T02:00:00Z","last_updated_date":"2007-05-22T02:00:00Z","reference_number":"EMEA/CHMP/165085/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-points-consider-xenogeneic-cell-therapy-medicinal-products_en.pdf"},
    {"id":"27282","name":"Guideline on human cell-based medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-05-21T02:00:00Z","last_updated_date":"2008-05-21T02:00:00Z","reference_number":"EMEA/CHMP/410869/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-human-cell-based-medicinal-products_en.pdf"},
    {"id":"27305","name":"Guideline on good pharmacovigilance practices: Module IV – Pharmacovigilance audits with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"2012-07-26 - 2012-09-21","first_published_date":"2012-12-13T18:00:00Z","last_updated_date":"2012-12-13T18:00:00Z","reference_number":"EMA/228028/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-iv-pharmacovigilance-audits-tracked-changes_en.pdf"},
    {"id":"27306","name":"ICH: Q 1 E: Evaluation of stability data - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-08-01T02:00:00Z","last_updated_date":"2003-08-01T02:00:00Z","reference_number":"CPMP/ICH/420/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-e-evaluation-stability-data-step-5_en.pdf"},
    {"id":"27377","name":"Sitagliptin film-coated tablets 25, 50 and 100 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-11-01T17:36:25Z","reference_number":"EMA/CHMP/158934/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/sitagliptin-film-coated-tablets-25-50-and-100-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"27382","name":"Guideline on data requirements for the replacement of established Master Seeds (MS) already used in authorised Immunological Veterinary Medicinal Products (IVMPs) by new master seed of the same origin","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-07-20T02:00:00Z","last_updated_date":"2009-07-20T02:00:00Z","reference_number":"EMEA/CVMP/IWP/105504/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-replacement-established-master-seeds-ms-already-used-authorised-immunological-veterinary-medicinal-products-ivmps-new-master-seed-same-origin_en.pdf"},
    {"id":"27398","name":"ICH Topic Q 5 C Quality of biotechnological products: Stability testing of biotechnological/biological products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-07-01T02:00:00Z","last_updated_date":"1996-07-01T02:00:00Z","reference_number":"CPMP/ICH/138/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-topic-q-5-c-quality-biotechnological-products-stability-testing-biotechnologicalbiological-products_en.pdf"},
    {"id":"27410","name":"Guideline on the development of medicinal products for the treatment of post-traumatic stress disorder (PTSD)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"CHMP/EWP/358650/2006 Corr 2*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-medicinal-products-treatment-post-traumatic-stress-disorder-ptsd_en.pdf"},
    {"id":"27425","name":"Draft guideline on conduct of pharmacokinetic studies in target animal species - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-11-20 - 2018-05-31","first_published_date":"2017-11-21T13:30:00Z","last_updated_date":"2017-11-21T13:30:00Z","reference_number":"EMEA/CVMP/EWP/133/1999 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-pharmacokinetic-studies-target-animal-species-revision-1_en.pdf"},
    {"id":"27436","name":"Draft guideline on core summary of products characteristics (SmPC) and package leaflet for technetium (99mTc) macrosalb","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-01-24 - 2018-03-31","first_published_date":"2018-01-24T18:30:00Z","last_updated_date":"2018-01-24T18:30:00Z","reference_number":"EMA/CHMP/745358/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-products-characteristics-smpc-and-package-leaflet-technetium-99mtc-macrosalb_en.pdf"},
    {"id":"27456","name":"Guideline on the core SmPC for human Anti-D immunoglobulin for intravenous use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-09-29T12:00:00Z","last_updated_date":"2016-09-29T12:00:00Z","reference_number":"EMA/CHMP/BPWP/319619/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-anti-d-immunoglobulin-intravenous-use_en.pdf"},
    {"id":"27484","name":"Draft guideline on the higher-tier testing of veterinary medicinal products to dung fauna","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-25 - 2017-01-31","first_published_date":"2016-07-25T18:45:00Z","last_updated_date":"2016-07-25T18:45:00Z","reference_number":"EMA/CVMP/ERA/409350/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-higher-tier-testing-veterinary-medicinal-products-dung-fauna_en.pdf"},
    {"id":"27485","name":"Note regarding CVMP guidelines on data requirements for veterinary medicinal products intended for minor uses or minor species - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-01T02:00:00Z","last_updated_date":"2006-07-01T02:00:00Z","reference_number":"EMEA/CVMP/133672/2005-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-regarding-cvmp-guidelines-data-requirements-veterinary-medicinal-products-intended-minor-uses-or-minor-species-revision-1_en.pdf"},
    {"id":"27498","name":"Guideline on clinical investigation of medicinal products indicated for the treatment of social anxiety disorder (SAD)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-01-26T01:00:00Z","last_updated_date":"2006-01-26T01:00:00Z","reference_number":"CHMP/EWP/3635/0","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-social-anxiety-disorder-sad_en.pdf"},
    {"id":"27582","name":"Concept paper on further guidance on interpretation of the data from VICH GL27 (Guidance on pre-approval information for registration of new veterinary medicinal products for food producing animals with respect to antimi...","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-03-09T01:00:00Z","last_updated_date":"2005-03-09T01:00:00Z","reference_number":"EMEA/CVMP/1034/04- Consultation","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-further-guidance-interpretation-data-vich-gl27-guidance-pre-approval-information-registration-new-veterinary-medicinal-products-food-producing-animals-respect-antimi_en.pdf"},
    {"id":"27599","name":"Draft guideline on the specification limits for residues of metal catalysts","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-01-01T01:00:00Z","last_updated_date":"2007-01-01T01:00:00Z","reference_number":"CPMP/SWP/QWP/4446/00 corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-specification-limits-residues-metal-catalysts_en.pdf"},
    {"id":"27601","name":"Concept paper on revision of: Note for Guidance on the Clinical Investigation of Human Normal Immunoglobulin for Intravenous Administration (IVIg) and on the Core SPC for Human Normal l Immunoglobulin for Intravenous Administration (IVIg) - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-03-16T01:00:00Z","last_updated_date":"2005-03-16T01:00:00Z","reference_number":"EMEA/CHMP/BPWG/151426/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-and-core-spc-human-normal-l-immunoglobulin-intravenous-administration-ivig_en.pdf"},
    {"id":"27626","name":"Public consultation concerning a request for CVMP opinion under Article 30(3) of Regulation (EC) No 726/2004 on the risk for the consumer resulting from the use of diethanolamine as an excipient in veterinary medicinal p...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-03-16 - 2018-05-14","first_published_date":"2018-03-16T17:30:00Z","last_updated_date":"2018-03-16T17:30:00Z","reference_number":"EMA/CVMP/157690/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-consultation-concerning-request-cvmp-opinion-under-article-303-regulation-ec-no-726-2004-risk-consumer-resulting-use-diethanolamine-excipient-veterinary-medicinal-p_en.pdf"},
    {"id":"27676","name":"Guideline on environmental risk assessments for medicinal products consisting of, or containing, genetically modified organisms (GMOs)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-12-11T01:00:00Z","last_updated_date":"2006-12-11T01:00:00Z","reference_number":"EMEA/CHMP/BWP/473191/2006 - Corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-environmental-risk-assessments-medicinal-products-consisting-or-containing-genetically-modified-organisms-gmos_en.pdf"}    {"id":"27693","name":"Draft guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-03-20 - 2013-08-31","first_published_date":"2013-03-20T18:00:00Z","last_updated_date":"2013-03-20T18:00:00Z","reference_number":"EMA/CHMP/153191/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-development-medicinal-products-intended-treatment-chronic-primary-immune-thrombocytopenia_en.pdf"},
    {"id":"27705","name":"ICH: Q 3 B (R2): Impurities in new drug products - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2006-06-01T02:00:00Z","reference_number":"CPMP/ICH/2738/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-3-b-r2-impurities-new-drug-products-step-5_en.pdf"},
    {"id":"27728","name":"Evaluation of anticancer medicinal products in man - Appendix 4: Condition specific guidance - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-02-15T16:50:00Z","last_updated_date":"2016-02-15T16:50:00Z","reference_number":"EMA/CHMP/703715/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/evaluation-anticancer-medicinal-products-man-appendix-4-condition-specific-guidance-revision-2_en.pdf"},
    {"id":"27738","name":"Guideline on pharmaceutical development of medicines for paediatric use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-07-31T18:15:00Z","last_updated_date":"2013-07-31T18:15:00Z","reference_number":"EMA/CHMP/QWP/805880/2012 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf"},
    {"id":"27746","name":"VICH GL33: Safety studies for veterinary drug residues in human food: General approach to testing - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T02:00:00Z","last_updated_date":"2009-04-20T02:00:00Z","reference_number":"EMEA/CVMP/VICH/486/02-Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl33-safety-studies-veterinary-drug-residues-human-food-general-approach-testing-step-7_en.pdf"},
    {"id":"27765","name":"Concept paper on guidance for DNA vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-16T02:00:00Z","last_updated_date":"2007-07-16T02:00:00Z","reference_number":"EMEA/CHMP/308136/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guidance-dna-vaccines_en.pdf"},
    {"id":"27771","name":"Guideline on the assessment of clinical safety and efficacy in the preparation of community herbal monographs for well-established and of community herbal monographs / entries to the community list for traditional herbal...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-09-07T02:00:00Z","last_updated_date":"2006-09-07T02:00:00Z","reference_number":"EMEA/HMPC/104613/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-assessment-clinical-safety-and-efficacy-preparation-community-herbal-monographs-well-established-and-community-herbal-monographs-entries-community-list-traditional-herbal_en.pdf"},
    {"id":"27794","name":"Note for guidance on limitations to the use of ethylene oxide in the manufacture of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-03-29T02:00:00Z","last_updated_date":"2001-03-29T15:50:00Z","reference_number":"CPMP/QWP/159/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-limitations-use-ethylene-oxide-manufacture-medicinal-products_en.pdf"},
    {"id":"27805","name":"List of species and breeds for electronic reporting of suspected adverse reactions in veterinary pharmacovigilance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-04-15T02:00:00Z","last_updated_date":"2011-06-30T02:00:00Z","reference_number":"EMA/CVMP/553/03 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/list-species-and-breeds-electronic-reporting-suspected-adverse-reactions-veterinary-pharmacovigilance_en.xls"},
    {"id":"27811","name":"Concept paper on minimum data requirements for an authorisation under exceptional circumstances for vaccines for emergency use against bluetongue","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-03-17T01:00:00Z","last_updated_date":"2008-03-17T01:00:00Z","reference_number":"EMEA/CVMP/IWP/37267/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-minimum-data-requirements-authorisation-under-exceptional-circumstances-vaccines-emergency-use-against-bluetongue_en.pdf"},
    {"id":"27812","name":"Guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-07-29T16:00:00Z","last_updated_date":"2013-07-29T16:00:00Z","reference_number":"EMA/CVMP/IWP/594618/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-combined-vaccines-and-associations-immunological-veterinary-medicinal-products-ivmps_en.pdf"},
    {"id":"27813","name":"Guideline on data requirements for multistrain dossiers for inactivated vaccines against avian influenza, bluetongue and foot-and-mouth disease - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/CVMP/IWP/105506/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-multistrain-dossiers-inactivated-vaccines-against-avian-influenza-bluetongue-and-foot-and-mouth-disease-first-version_en.pdf"},
    {"id":"27847","name":"Draft guideline on good pharmacovigilance practices (GVP): Product- or Population-Specific Considerations II: biological medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-02-29","first_published_date":"2015-12-15T13:30:00Z","last_updated_date":"2015-12-15T13:30:00Z","reference_number":"EMA/168402/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-ii-biological-medicinal-products_en.pdf"},
    {"id":"27850","name":"Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-01-28T01:00:00Z","last_updated_date":"2011-06-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/minimising-risk-transmitting-animal-spongiform-encephalopathy-agents-human-and-veterinary-medicinal-products_en.pdf"},
    {"id":"27878","name":"Draft guideline on demonstration of target animal safety and efficacy of veterinary medicinal products intended for use in farmed finfish","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-10-14 - 2010-10-31","first_published_date":"2009-10-19T04:00:00Z","last_updated_date":"2010-07-19T04:00:00Z","reference_number":"EMA/CVMP/EWP/459868/2008-CONSULTATION","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-demonstration-target-animal-safety-and-efficacy-veterinary-medicinal-products-intended-use-farmed-finfish_en.pdf"},
    {"id":"27881","name":"Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations I: Vaccines for prophylaxis against infectious diseases","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-12-12T11:00:00Z","last_updated_date":"2013-12-12T11:00:00Z","reference_number":"EMA/488220/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-i-vaccines-prophylaxis-against-infectious-diseases_en.pdf"},
    {"id":"27898","name":"VICH GL2: Validation of analytical procedures: Methodology - Step 7 consensus guideline","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-12-10T01:00:00Z","last_updated_date":"1998-12-10T01:00:00Z","reference_number":"CVMP/VICH/591/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl2-validation-analytical-procedures-methodology-step-7-consensus-guideline_en.pdf"},
    {"id":"27908","name":"Guideline on good pharmacovigilance practices (GVP): Module IX – Signal management (Rev. 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-25T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/827661/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf"},
    {"id":"27961","name":"Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on stability and traceability requirements for vaccine intermediates","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2001-01-25T01:00:00Z","last_updated_date":"2001-01-25T01:00:00Z","reference_number":"CPMP/BWP/4310/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-proprietary-medicinal-products-cpmp-points-consider-stability-and-traceability-requirements-vaccine-intermediates_en.pdf"},
    {"id":"27996","name":"Draft guideline on the clinical investigation of human plasma derived factor VIII and IX products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"CPMP/BPWG/198/95 rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-human-plasma-derived-factor-viii-and-ix-products_en.pdf"},
    {"id":"28003","name":"Concept paper on the need for revision of the note for guidance on the clinical investigation of medicinal products for the treatment of cardiac failure - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-03-01 - 2013-05-31","first_published_date":"2013-03-01T12:00:00Z","last_updated_date":"2013-03-01T12:00:00Z","reference_number":"EMA/CHMP/87576/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-clinical-investigation-medicinal-products-treatment-cardiac-failure-revision-1_en.pdf"},
    {"id":"28012","name":"Concept paper on the revision of the guideline on nonclinical and clinical development of  similar biological medicinal products containing low-molecular-weight heparins","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-07-21 - 2011-09-30","first_published_date":"2011-07-27T04:00:00Z","last_updated_date":"2011-07-27T04:00:00Z","reference_number":"EMA/CHMP/BMWP/522386/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-nonclinical-and-clinical-development-similar-biological-medicinal-products-containing-low-molecular-weight-heparins_en.pdf"},
    {"id":"28050","name":"Note for guidance on the clinical Investigation of Recombinant Factor VIII and IX Products - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-10-19T02:00:00Z","last_updated_date":"2000-10-19T02:00:00Z","reference_number":"CPMP/BPWG/1561/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-recombinant-factor-viii-and-ix-products-superseded_en.pdf"},
    {"id":"28071","name":"Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-02-11T10:40:00Z","last_updated_date":"2016-02-11T10:40:00Z","reference_number":"EMA/CHMP/BPWP/144533/2009 rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-viii-products-revision-1_en.pdf"},
    {"id":"28072","name":"Draft guideline on risk assessment of medicinal products on human Reproduction and lactation: from data to labelling","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-03-23T01:00:00Z","last_updated_date":"2006-03-23T01:00:00Z","reference_number":"EMEA/CHMP/203927/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-risk-assessment-medicinal-products-human-reproduction-and-lactation-data-labelling_en.pdf"},
    {"id":"28154","name":"Draft guideline on the chemistry of active substances (veterinary)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-02-13 - 2017-08-13","first_published_date":"2017-02-13T17:00:00Z","last_updated_date":"2017-02-13T17:00:00Z","reference_number":"EMA/CVMP/QWP/49477/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-chemistry-active-substances-veterinary_en.pdf"},
    {"id":"28157","name":"Concept paper on a revision of the guideline on pharmaceutical aspects of the product information for human vaccines (EMEA/CPMP/BWP/2758/02) - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-06-17T02:00:00Z","last_updated_date":"2009-06-17T02:00:00Z","reference_number":"EMEA/CHMP/BWP/290688/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-pharmaceutical-aspects-product-information-human-vaccines-emeacpmpbwp275802-revision-1_en.pdf"},
    {"id":"28169","name":"Note for guidance on pharmaceutical and biological aspects of combined vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-07-23T02:00:00Z","last_updated_date":"1998-07-23T02:00:00Z","reference_number":"CPMP/BWP/477/97","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-pharmaceutical-and-biological-aspects-combined-vaccines_en.pdf"},
    {"id":"28211","name":"Reflection paper on the non-clinical and clinical development for oral and topical HIV pre-exposure prophylaxis (PrEP)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-03-15 - 2012-06-30","first_published_date":"2012-03-15T13:54:29Z","last_updated_date":"2012-03-15T13:54:29Z","reference_number":"EMA/171264/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-non-clinical-and-clinical-development-oral-and-topical-hiv-pre-exposure-prophylaxis-prep_en.pdf"},
    {"id":"28222","name":"VICH GL41: Target animal safety: Examination of live veterinary vaccines in target animals for absence of reversion to virulence - At step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-18T02:00:00Z","last_updated_date":"2007-09-18T02:00:00Z","reference_number":"EMEA/CVMP/VICH/1052/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl41-target-animal-safety-examination-live-veterinary-vaccines-target-animals-absence-reversion-virulence-step-7_en.pdf"},
    {"id":"28258","name":"Draft guideline on clinical investigation of recombinant and human plasma-derived factor VIII products - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-10-30 - 2018-01-31","first_published_date":"2017-10-30T14:30:00Z","last_updated_date":"2017-10-30T14:30:00Z","reference_number":"EMA/CHMP/BPWP/144533/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-viii-products-revision-2_en.pdf"},
    {"id":"28271","name":"Points to consider on the development of live attenuated influenza vaccines - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-02-20T01:00:00Z","last_updated_date":"2003-02-20T01:00:00Z","reference_number":"EMEA/CPMP/BWP/2289/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-development-live-attenuated-influenza-vaccines-superseded_en.pdf"},
    {"id":"28287","name":"Guideline on epidemiological data on blood transmissible infections","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-10-12T02:00:00Z","last_updated_date":"2010-10-12T02:00:00Z","reference_number":"EMA/CHMP/BWP/548524/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-epidemiological-data-blood-transmissible-infections_en.pdf"},
    {"id":"28292","name":"Draft guideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species/limited markets - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-03-16T01:00:00Z","last_updated_date":"2009-03-16T01:00:00Z","reference_number":"EMEA/CVMP/IWP/123243/2006-Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-immunological-veterinary-medicinal-products-intended-minor-use-or-minor-specieslimited-markets-revision-2_en.pdf"},
    {"id":"28300","name":"Concept paper on the update of guidance on the clinical development of medicinal products for the treatment of HIV","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-10-20 - 2012-01-31","first_published_date":"2011-11-15T15:00:00Z","last_updated_date":"2011-11-15T15:00:00Z","reference_number":"EMA/802793/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-update-guidance-clinical-development-medicinal-products-treatment-hiv_en.pdf"},
    {"id":"28324","name":"Draft guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus (second and final release for public consultation) - Revision 1 (second release)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-09-16 - 2011-11-18","first_published_date":"2011-10-07T13:13:00Z","last_updated_date":"2011-10-07T13:13:00Z","reference_number":"CPMP/EWP/1080/00 Rev. 1*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-diabetes-mellitus-second-and-final-release-public-consultation-revision-1-second-release_en.pdf"},
    {"id":"28327","name":"VICH GL50: Harmonisation of criteria to waive target animal batch safety testing for inactivated vaccines for veterinary use - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-06-27T18:00:00Z","last_updated_date":"2017-06-27T18:00:00Z","reference_number":"EMA/CVMP/VICH/582610/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl50-harmonisation-criteria-waive-target-animal-batch-safety-testing-inactivated-vaccines-veterinary-use-revision-1_en.pdf"},
    {"id":"28351","name":"Concept paper on the development of guidance on the non-clinical evaluation of radiopharmaceuticals - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-08-01 - 2017-10-31","first_published_date":"2017-08-01T14:00:00Z","last_updated_date":"2018-02-20T12:00:00Z","reference_number":"EMA/CHMP/SWP/545959/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guidance-non-clinical-evaluation-radiopharmaceuticals-first-version_en.pdf"},
    {"id":"28380","name":"Guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-08-13T15:00:00Z","last_updated_date":"2018-08-13T15:00:00Z","reference_number":"EMA/CHMP/BPWP/1619/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-plasma-derived-and-recombinant-coagulation-factor-viii-products-revision-3_en.pdf"},
    {"id":"28389","name":"Concept paper on the need for revision of the points to consider on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-04-01 - 2012-06-30","first_published_date":"2012-03-30T13:00:00Z","last_updated_date":"2012-03-30T13:00:00Z","reference_number":"EMA/CHMP/59352/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-points-consider-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"28406","name":"Guideline on core SmPC and package leaflet for sodium fluoride (18F)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-07-20T16:45:00Z","last_updated_date":"2015-07-20T16:45:00Z","reference_number":"EMA/212874/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-and-package-leaflet-sodium-fluoride-18f_en.pdf"},
    {"id":"28430","name":"Draft M4E(R2) Common technical document for the registration of pharmaceuticals for human use – efficacy - Step 3","type":"scientific-guideline","status":"Adopted","consultation_date":"2015-10-07 - 2015-12-31","first_published_date":"2015-10-07T13:50:00Z","last_updated_date":"2016-07-28T19:00:00Z","reference_number":"EMA/CPMP/ICH/2887/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-m4er2-common-technical-document-registration-pharmaceuticals-human-use-efficacy-step-3_en.pdf"},
    {"id":"28443","name":"Guideline on clinical medicinal products intended for the treatment of neuropathic pain","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"CPMP/EWP/252/03 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-medicinal-products-intended-treatment-neuropathic-pain_en.pdf"},
    {"id":"28448","name":"Capecitabine film-coated tablets 150, 500 mg product-specific bioequivalence guidance - adopted","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315237/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/capecitabine-film-coated-tablets-150-500-mg-product-specific-bioequivalence-guidance-adopted_en.pdf"},
    {"id":"28467","name":"Draft note for guidance on the investigation of bioavailability and bioequivalence","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2000-12-14T01:00:00Z","last_updated_date":"2000-12-14T01:00:00Z","reference_number":"CPMP/EWP/QWP/1401/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-investigation-bioavailability-and-bioequivalence_en.pdf"},
    {"id":"28485","name":"Core SPC for human Rabies immunoglobulin for intramuscular use\n\n(CPMP/BPWG/3728/02)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"CPMP/BPWG/3728/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/core-spc-human-rabies-immunoglobulin-intramuscular-use-cpmpbpwg372802_en.pdf"},
    {"id":"28489","name":"Draft cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-01-31 - 2018-04-30","first_published_date":"2018-01-31T14:15:00Z","last_updated_date":"2018-01-31T14:15:00Z","reference_number":"EMA/CHMP/800759/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-cholic-acid-capsules-50-mg-and-250-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"28506","name":"VICH GL3: Stability testing of new veterinary drug substances and medicinal products - Step 7 (after revision at step 9)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-02-19T01:00:00Z","last_updated_date":"2007-02-19T01:00:00Z","reference_number":"EMEA/CVMP/VICH/899/99-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl3-stability-testing-new-veterinary-drug-substances-and-medicinal-products-step-7-after-revision-step-9_en.pdf"},
    {"id":"28508","name":"Guideline on good pharmacovigilance practices: Module XV – Safety communication (Rev. 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-01-24T18:00:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/118465/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xv-safety-communication-rev-1_en.pdf"},
    {"id":"28530","name":"Draft reflection paper on stability testing of herbal medicinal products and traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-01-07T01:00:00Z","last_updated_date":"2009-01-07T01:00:00Z","reference_number":"EMEA/HMPC/3626/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-stability-testing-herbal-medicinal-products-and-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"28563","name":"Guideline on xenogeneic cell-based medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-12-01T00:09:21Z","last_updated_date":"2009-12-01T00:09:21Z","reference_number":"EMEA/CHMP/CPWP/83508/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-xenogeneic-cell-based-medicinal-products_en.pdf"},
    {"id":"28607","name":"Questions and answers on sodium used as an excipient in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/338679/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-sodium-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"28651","name":"Reflection paper on ethanol content in herbal medicinal products and traditional herbal medicinal products used in children","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-02-01T01:00:00Z","last_updated_date":"2010-02-01T01:00:00Z","reference_number":"EMA/HMPC/85114/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-ethanol-content-herbal-medicinal-products-and-traditional-herbal-medicinal-products-used-children_en.pdf"},
    {"id":"28672","name":"Guideline on process validation for finished products - information and data to be provided in regulatory submissions - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-02-28T17:20:00Z","last_updated_date":"2016-11-21T16:30:00Z","reference_number":"EMA/CHMP/CVMP/QWP/BWP/70278/2012 Rev. 1, Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-process-validation-finished-products-information-and-data-be-provided-regulatory-submissions-revision-1_en.pdf"},
    {"id":"28737","name":"Draft guideline on good pharmacovigilance practices (GVP): Module XV – Safety communication (Rev. 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-02-29","first_published_date":"2015-12-15T13:30:00Z","last_updated_date":"2015-12-15T13:30:00Z","reference_number":"EMA/118465/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-xv-safety-communication-rev-1_en.pdf"},
    {"id":"28745","name":"Guideline on clinical trials in small populations","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-27T02:00:00Z","last_updated_date":"2006-07-27T02:00:00Z","reference_number":"CHMP/EWP/83561/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-trials-small-populations_en.pdf"},
    {"id":"28754","name":"Reflection paper on pharmacogenomics in oncology","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-04-01T02:00:00Z","last_updated_date":"2008-04-01T02:00:00Z","reference_number":"EMEA/CHMP/PGxWP/128435/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-pharmacogenomics-oncology_en.pdf"},
    {"id":"28771","name":"Draft guideline on good pharmacovigilance practices: Module XV – Safety communication","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-07-26 - 2012-09-21","first_published_date":"2012-07-26T20:15:01Z","last_updated_date":"2012-07-26T20:15:01Z","reference_number":"EMA/118465/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-xv-safety-communication_en.pdf"},
    {"id":"28797","name":"Guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-11-28T12:23:00Z","last_updated_date":"2017-11-28T12:23:00Z","reference_number":"EMA/CHMP/QWP/545525/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-chemical-and-pharmaceutical-quality-documentation-concerning-investigational-medicinal-products-clinical-trials-revision-1_en.pdf"},
    {"id":"28816","name":"Concept paper on the revision of the guideline on parametric release","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-11-26T01:00:00Z","last_updated_date":"2008-11-26T01:00:00Z","reference_number":"EMEA/CHMP/QWP/569959/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-parametric-release_en.pdf"},
    {"id":"28845","name":"Position paper on control of impurities of pharmacopoeial substances: Compliance with the European pharmacopoeia general monograph 'Substances for pharmaceutical use' and general chapter 'Control of impurities in substan...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-03-01T01:00:00Z","last_updated_date":"2004-03-01T01:00:00Z","reference_number":"EMEA/CVMP/059/04 -FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-control-impurities-pharmacopoeial-substances-compliance-european-pharmacopoeia-general-monograph-substances-pharmaceutical-use-and-general-chapter-control-impurities-substan_en.pdf"},
    {"id":"28862","name":"Draft note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products annex on non-clinical testing for inadvertent germline transmission of gene transfer vectors","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2005-11-01 - 2006-05-01","first_published_date":"2005-11-17T02:00:00Z","last_updated_date":"2005-11-17T02:00:00Z","reference_number":"EMEA/273974/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-quality-preclinical-and-clinical-aspects-gene-transfer-medicinal-products-annex-non-clinical-testing-inadvertent-germline-transmission-gene-transfer-vectors_en.pdf"},
    {"id":"28875","name":"Guideline on good pharmacovigilance practices (GVP): Module VII – Periodic safety update report (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T12:00:00Z","last_updated_date":"2012-06-25T12:00:00Z","reference_number":"EMA/816292/2011 superseded","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report-superseded_en.pdf"},
    {"id":"28888","name":"Draft guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-05-20 - 2010-11-30","first_published_date":"2010-06-18T04:00:00Z","last_updated_date":"2010-06-18T04:00:00Z","reference_number":"EMA/CHMP/GTWP/671639/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-and-clinical-aspects-medicinal-products-containing-genetically-modified-cells-first-version_en.pdf"},
    {"id":"28895","name":"Guideline on veterinary medicinal products controlling Varroa destructor parasitosis in bees","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/CVMP/EWP/459883/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-veterinary-medicinal-products-controlling-varroa-destructor-parasitosis-bees_en.pdf"},
    {"id":"28903","name":"Draft guideline on quality of herbal medicinal products/traditional herbal medicinal products - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-08-15 - 2018-11-30","first_published_date":"2018-08-15T20:00:00Z","last_updated_date":"2018-08-15T20:00:00Z","reference_number":"EMA/HMPC/201116/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-herbal-medicinal-products-traditional-herbal-medicinal-products-revision-3_en.pdf"},
    {"id":"28913","name":"Draft guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-05-01 - 2014-10-31","first_published_date":"2014-04-30T14:00:00Z","last_updated_date":"2014-04-30T14:00:00Z","reference_number":"EMA/CHMP/BWP/187338/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-process-validation-manufacture-biotechnology-derived-active-substances-and-data-be-provided-regulatory-submission_en.pdf"},
    {"id":"28932","name":"Concept paper on the need to elaborate summary-of-product-characteristics guidance to minimise the development of anthelmintic resistance","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-10-14T02:09:21Z","last_updated_date":"2008-10-14T02:09:21Z","reference_number":"EMEA/CVMP/638/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-elaborate-summary-product-characteristics-guidance-minimise-development-anthelmintic-resistance_en.pdf"},
    {"id":"28935","name":"Draft guideline on ICH Considerations - Oncolytic viruses","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"CHMP/GTWP/607698/08","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-ich-considerations-oncolytic-viruses_en.pdf"},
    {"id":"28936","name":"ICH guideline E18 on genomic sampling and management of genomic data - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-01 - 2016-05-31","first_published_date":"2016-02-01T16:56:00Z","last_updated_date":"2016-02-01T16:56:00Z","reference_number":"EMA/CHMP/ICH/11623/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e18-genomic-sampling-and-management-genomic-data-step-3_en.pdf"},
    {"id":"28951","name":"Questions and answers on wheat starch containing gluten in the context of the revision of the guideline on excipients in the label and package leaflet of medicinal products for human use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-08-01 - 2014-10-31","first_published_date":"2014-08-01T14:00:00Z","last_updated_date":"2014-08-01T14:00:00Z","reference_number":"EMA/CHMP/704219/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-wheat-starch-containing-gluten-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"28971","name":"Draft reflection paper on immune tolerance induction in haemophilia-A patients with inhibitors","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-07-30 - 2012-10-31","first_published_date":"2012-07-31T17:00:00Z","last_updated_date":"2012-07-31T17:00:00Z","reference_number":"EMA/CHMP/BPWP/153137/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-immune-tolerance-induction-haemophilia-patients-inhibitors_en.pdf"},
    {"id":"28988","name":"Guideline on follow-up of patients administered with gene therapy medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-11-13T00:09:21Z","last_updated_date":"2009-11-13T00:09:21Z","reference_number":"EMEA/CHMP/GTWP/60436/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-follow-patients-administered-gene-therapy-medicinal-products_en.pdf"},
    {"id":"28999","name":"Draft reflection paper providing an overview of the current regulatory testing requirements for veterinary medicinal products and opportunities for implementation of the 3Rs","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-04-29 - 2016-10-31","first_published_date":"2016-04-29T18:25:00Z","last_updated_date":"2016-04-29T18:25:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/164002/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-providing-overview-current-regulatory-testing-requirements-veterinary-medicinal-products-and-opportunities-implementation-3rs_en.pdf"},
    {"id":"29008","name":"Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance Non-clinical and clinical issues (Replaced by CHMP/BMWP/101695/06)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-12-17T01:00:00Z","last_updated_date":"2003-12-17T01:00:00Z","reference_number":"EMEA/CPMP/3097/02/Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-comparability-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-replaced-chmpbmwp10169506_en.pdf"},
    {"id":"29021","name":"Guideline on good pharmacovigilance practices: Module V – Risk management systems (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T11:30:00Z","last_updated_date":"2012-06-25T11:30:00Z","reference_number":"EMA/838713/2011 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-superseded_en.pdf"},
    {"id":"29026","name":"Guideline on the clinical investigation of anti-anginal medicinal products in stable angina pectoris","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2006-06-01T02:00:00Z","reference_number":"CPMP/EWP/234/95/rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-anti-anginal-medicinal-products-stable-angina-pectoris_en.pdf"},
    {"id":"29038","name":"Draft guideline on data requirements for the replacement of established Master Seeds (MS) already used in authorised Immunological Veterinary Medicinal Products (IVMPs)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-03-17T01:00:00Z","last_updated_date":"2008-03-17T01:00:00Z","reference_number":"EMEA/CVMP/IWP/105504/2007-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-replacement-established-master-seeds-ms-already-used-authorised-immunological-veterinary-medicinal-products-ivmps_en.pdf"},
    {"id":"29050","name":"Draft memantine product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/423734/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-memantine-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"29081","name":"Concept paper on the revision of guidelines for influenza vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-09-22 - 2011-12-31","first_published_date":"2011-10-03T18:35:00Z","last_updated_date":"2011-10-03T18:35:00Z","reference_number":"EMA/CHMP/VWP/734330/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidelines-influenza-vaccines_en.pdf"},
    {"id":"29082","name":"Recommendation to marketing authorisation holders, highlighting recent updates for reduction, refinement and replacement (3Rs) methods described in the European Pharmacopoeia applicable to human vaccines against hepatiti...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-07-20T13:25:00Z","last_updated_date":"2015-07-20T13:25:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/243112/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-marketing-authorisation-holders-highlighting-recent-updates-reduction-refinement-and-replacement-3rs-methods-described-european-pharmacopoeia-applicable-human-vaccines-against-hepatiti_en.pdf"},
    {"id":"29105","name":"VICH GL51: Quality: statistical evaluation of stability data","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-03-13T16:30:00Z","last_updated_date":"2013-03-13T16:30:00Z","reference_number":"EMA/CVMP/VICH/858875/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl51-quality-statistical-evaluation-stability-data_en.pdf"},
    {"id":"29111","name":"Revised concept paper on the need for revision of the position on the replacement of animal studies by in-vitro models","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-07-25 - 2012-09-28","first_published_date":"2012-07-25T14:40:00Z","last_updated_date":"2012-07-25T14:40:00Z","reference_number":"MA/CHMP/CVMP/JEG-3Rs/169839/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/revised-concept-paper-need-revision-position-replacement-animal-studies-vitro-models_en.pdf"},
    {"id":"29153","name":"ICH: Q 5 D: Derivation and characterisation of cell substrates used for production of biotechnological/biological products - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-03-31T02:00:00Z","last_updated_date":"1998-03-31T02:00:00Z","reference_number":"CPMP/ICH/294/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-d-derivation-and-characterisation-cell-substrates-used-production-biotechnologicalbiological-products-step-5_en.pdf"},
    {"id":"29193","name":"Questions and answers: Positions on specific questions addressed to the Pharmacokinetics Working Party","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2016-03-03T16:03:00Z","reference_number":"EMA/618604/2008 Rev. 13","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-positions-specific-questions-addressed-pharmacokinetics-working-party_en.pdf"},
    {"id":"29201","name":"ICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-08-04T13:00:00Z","last_updated_date":"2015-08-04T13:00:00Z","reference_number":"EMA/CHMP/ICH/82260/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q7-good-manufacturing-practice-active-pharmaceutical-ingredients-questions-and-answers-step-5_en.pdf"},
    {"id":"29236","name":"Draft guideline on the evaluation of drugs for the treatment of gastroesophageal reflux disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-12-17 - 2010-06-30","first_published_date":"2010-01-08T02:00:00Z","last_updated_date":"2010-01-08T02:00:00Z","reference_number":"EMEA/CHMP/EWP/342691/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-drugs-treatment-gastroesophageal-reflux-disease_en.pdf"},
    {"id":"29237","name":"Draft reflection paper on dose optimisation of established veterinary antibiotics in the context of summary of product characteristics (SPC) harmonisation - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-07-27 - 2019-01-31","first_published_date":"2018-07-27T16:47:00Z","last_updated_date":"2018-07-27T16:47:00Z","reference_number":"EMA/CVMP/849775/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-dose-optimisation-established-veterinary-antibiotics-context-summary-product-characteristics-spc-harmonisation-first-version_en.pdf"},
    {"id":"29241","name":"Position paper on re-establishment of working seeds and working cell banks using TSE compliant materials - Obsolete","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2002-09-10T02:00:00Z","last_updated_date":"2002-09-10T02:00:00Z","reference_number":"Ref: EMEA/22314/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-re-establishment-working-seeds-working-cell-banks-using-tse-compliant-materials-obsolete_en.pdf"},
    {"id":"29248","name":"Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/CHMP/SWP/28367/07","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-and-mitigate-risks-first-human-clinical-trials-investigational-medicinal-products-first-version_en.pdf"},
    {"id":"29275","name":"ICH guideline Q4B Annex 4C on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-06-01T02:00:00Z","last_updated_date":"2017-07-13T16:30:00Z","reference_number":"EMEA/CHMP/ICH/308867/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-4c-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-acceptance-criteria-pharmaceutical-preparations-and-substances-pharmaceutical-use-step-5_en.pdf"},
    {"id":"29320","name":"Draft reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-04-01 - 2018-03-31","first_published_date":"2017-03-31T21:15:00Z","last_updated_date":"2017-03-31T21:15:00Z","reference_number":"EMA/CHMP/138502/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-statistical-methodology-comparative-assessment-quality-attributes-drug-development_en.pdf"},
    {"id":"29323","name":"Draft reflection paper on clinical aspects related to tissue-engineered products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-04-17 - 2012-07-31","first_published_date":"2012-04-17T15:47:00Z","last_updated_date":"2012-04-17T15:47:00Z","reference_number":"EMA/CAT/CPWP/573420/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-clinical-aspects-related-tissue-engineered-products_en.pdf"},
    {"id":"29330","name":"Guideline on the Core SPC for human Anti-D immunoglobulin for intravenous use – Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2007-09-20T02:00:00Z","reference_number":"CPMP/BPWG/574/99 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-anti-d-immunoglobulin-intravenous-use-revision-1_en.pdf"},
    {"id":"29334","name":"Draft guideline on influenza vaccines – submission and procedural requirements","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-10-30 - 2015-01-30","first_published_date":"2014-10-30T13:00:00Z","last_updated_date":"2014-10-30T13:00:00Z","reference_number":"EMA/56793/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-influenza-vaccines-submission-and-procedural-requirements_en.pdf"},
    {"id":"29336","name":"ICH: E 7: Studies in support of special populations: Geriatrics: Questions and answers - Step 5","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-10-01 - 2010-01-31","first_published_date":"2009-09-01T04:00:00Z","last_updated_date":"2010-07-27T04:00:00Z","reference_number":"EMEA/CHMP/ICH/604661/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-7-studies-support-special-populations-geriatrics-questions-and-answers-step-5_en.pdf"},
    {"id":"29370","name":"Guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-02-03T12:00:00Z","last_updated_date":"2016-02-03T12:00:00Z","reference_number":"EMA/CVMP/627/2001 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances-revision-1_en.pdf"},
    {"id":"29384","name":"Overview of comments received on ‘Rilpivirine film-coated tablets 25 mg product-specific bioequivalence guidance’ (EMA/CHMP/356878/2017) - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-02-01T13:00:00Z","last_updated_date":"2018-02-01T13:00:00Z","reference_number":"EMA/CHMP/730771/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-rilpivirine-film-coated-tablets-25-mg-product-specific-bioequivalence-guidance-emachmp3568782017-first-version_en.pdf"},
    {"id":"29385","name":"Draft guideline on Core SPC for Human Plasma Derived and Recombinant Coagulation Factor VIII Products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-19T02:09:21Z","last_updated_date":"2007-07-19T02:09:21Z","reference_number":"EMEA/CPMP/BPWG/1619/1999 – Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-spc-human-plasma-derived-and-recombinant-coagulation-factor-viii-products-revision-1_en.pdf"},
    {"id":"29444","name":"Draft guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-11-16T01:00:00Z","last_updated_date":"2006-11-16T01:00:00Z","reference_number":"CPMP/EWP/707/98 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-prophylaxis-high-intra-and-post-operative-venous-thromboembolic-risk-revision-1_en.pdf"}    {"id":"29447","name":"Draft guideline on good pharmacogenomic practice - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-02 - 2016-09-16","first_published_date":"2016-05-02T15:15:00Z","last_updated_date":"2016-05-02T15:15:00Z","reference_number":"EMA/CHMP/268544/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacogenomic-practice-first-version_en.pdf"},
    {"id":"29451","name":"Elvitegravir film-coated tablets 85 mg and 150 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/CHMP/805507/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/elvitegravir-film-coated-tablets-85-mg-and-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"29475","name":"Reflection paper on non-clinical evaluation of drug-induced liver injury (DILI)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-07-19T02:00:00Z","last_updated_date":"2010-07-19T02:00:00Z","reference_number":"EMEA/CHMP/SWP/150115/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-non-clinical-evaluation-drug-induced-liver-injury-dili_en.pdf"},
    {"id":"29489","name":"Guideline on the core SmPC for human Anti-D immunoglobulin for intramuscular use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-09-29T12:00:01Z","last_updated_date":"2016-09-29T12:00:01Z","reference_number":"EMA/CHMP/BPWP/29205/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-anti-d-immunoglobulin-intramuscular-use_en.pdf"},
    {"id":"29494","name":"Questions and Answers on allogenic stem cell-based products for veterinary use: specific questions on sterility","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T17:00:00Z","last_updated_date":"2017-06-23T17:00:00Z","reference_number":"EMA/CVMP/ADVENT/751229/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-allogenic-stem-cell-based-products-veterinary-use-specific-questions-sterility_en.pdf"},
    {"id":"29512","name":"Telithromycin film-coated tablets 400 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315235/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/telithromycin-film-coated-tablets-400-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"29525","name":"Overview of comments received on draft guideline on the conduct of bioequivalence studies for veterinary medicinal products - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2010-11-03T01:00:00Z","last_updated_date":"2010-11-03T01:00:00Z","reference_number":"EMA/CVMP/561927/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-draft-guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"29528","name":"Draft paracetamol oral use, immediate release formulations product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-07-28 - 2017-10-31","first_published_date":"2017-07-28T14:00:00Z","last_updated_date":"2017-07-28T14:00:00Z","reference_number":"EMA/CHMP/356877/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-paracetamol-oral-use-immediate-release-formulations-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"29583","name":"Draft ICH guideline Q4B: Annex 14 to Note for Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Bacterial Endotoxins Tests – General Chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-09-24 - 2010-12-01","first_published_date":"2010-09-24T04:00:00Z","last_updated_date":"2010-09-24T04:00:00Z","reference_number":"EMA/CHMP/ICH/529785/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-q4b-annex-14-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-bacterial-endotoxins-tests-general-chapter-step-3_en.pdf"},
    {"id":"29585","name":"Draft guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-10-01 - 2016-01-31","first_published_date":"2015-10-01T13:50:00Z","last_updated_date":"2015-10-01T13:50:00Z","reference_number":"EMEA/CHMP/BMWP/14327/2006 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-revision-1_en.pdf"},
    {"id":"29586","name":"Guideline on the pharmaceutical quality of inhalation and nasal products - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-21T02:00:00Z","last_updated_date":"2006-06-21T02:00:00Z","reference_number":"EMEA/CHMP/QWP/49313/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-quality-inhalation-nasal-products-first-version_en.pdf"},
    {"id":"29621","name":"Guideline adventitious agent safety of urine-derived medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-05-29T12:00:00Z","last_updated_date":"2015-05-29T12:00:00Z","reference_number":"EMA/CHMP/BWP/126802/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-adventitious-agent-safety-urine-derived-medicinal-products_en.pdf"},
    {"id":"29625","name":"Note for guidance on electronic exchange of pharmacovigilance information for human and veterinary medicinal products in the European Union","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-08-18T02:00:00Z","last_updated_date":"1999-08-18T02:00:00Z","reference_number":"EMEA/CXMP/PhWHP/2056/","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-electronic-exchange-pharmacovigilance-information-human-and-veterinary-medicinal-products-european-union_en.pdf"},
    {"id":"29628","name":"Sirolimus coated tablets 0.5, 1 and 2 mg, oral solution 1 mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315231/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/sirolimus-coated-tablets-05-1-and-2-mg-oral-solution-1-mgml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"29642","name":"Addendum to EMA/CHMP/CVMP/QWP/17760/2009 Rev 3: Defining the Scope of an NIRS Procedure","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-11-10 - 2023-12-22","first_published_date":"2023-11-13T13:00:00Z","last_updated_date":"2023-11-13T13:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/17760/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-ema-chmp-cvmp-qwp-17760-2009-rev-3-defining-scope-nirs-procedure_en.pdf"},
    {"id":"29655","name":"Note for guidance on the development of vaccinia virus based vaccines against smallpox","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-06-24T02:00:00Z","last_updated_date":"2002-06-24T02:00:00Z","reference_number":"CPMP/1100/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-development-vaccinia-virus-based-vaccines-against-smallpox_en.pdf"},
    {"id":"29669","name":"VICH GL36(R): Studies to evaluate the safety of residues of veterinary drugs in human food: general approach to establish a microbiological ADI - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-07-25T12:40:00Z","last_updated_date":"2012-07-25T12:40:00Z","reference_number":"EMA/CVMP/VICH/467/2003","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl36r-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach-establish-microbiological-adi-first-version_en.pdf"},
    {"id":"29733","name":"ICH: S 3 A: Toxicokinetics: A guidance for assessing systemic exposure in toxicology studies - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-11-30T01:00:00Z","last_updated_date":"1994-11-30T01:00:00Z","reference_number":"CPMP/ICH/384/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-3-toxicokinetics-guidance-assessing-systemic-exposure-toxicology-studies-step-5_en.pdf"},
    {"id":"29777","name":"Draft guideline on core SmPC and package leaflet for (68Ge/68Ga) generator - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-06-01 - 2016-09-30","first_published_date":"2016-06-01T18:00:00Z","last_updated_date":"2016-06-01T18:00:00Z","reference_number":"EMA/CHMP/337681/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-and-package-leaflet-68ge-68ga-generator-first-version_en.pdf"},
    {"id":"29787","name":"Guideline on the clinical development of medicinal products intended for the treatment of pain - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-12-22T16:00:00Z","last_updated_date":"2016-12-22T16:00:00Z","reference_number":"EMA/CHMP/970057/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-intended-treatment-pain-first-version_en.pdf"},
    {"id":"29875","name":"Draft guideline on good pharmacovigilance practices: Annex I - Definitions","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-02-22T15:20:00Z","last_updated_date":"2012-02-22T15:20:00Z","reference_number":"EMA/876333/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-annex-i-definitions_en.pdf"},
    {"id":"29890","name":"Concept paper on the development of a guideline on the risk-based approach according to annex I, part IV of directive 2001/83/EC applied to advanced therapy medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-12-17 - 2010-03-31","first_published_date":"2010-01-26T02:00:00Z","last_updated_date":"2010-01-26T02:00:00Z","reference_number":"EMA/CHMP/CPWP/708420/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-risk-based-approach-according-annex-i-part-iv-directive-2001-83-ec-applied-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"29907","name":"Concept paper on the revision of the guideline on radiopharmaceuticals based on monoclonal antibodies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-09-24 - 2010-01-31","first_published_date":"2009-11-03T01:09:21Z","last_updated_date":"2009-11-03T01:09:21Z","reference_number":"EMEA/CHMP/CVMP/362268/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-radiopharmaceuticals-based-monoclonal-antibodies_en.pdf"},
    {"id":"29918","name":"Guideline on the scientific data requirements for a plasma master file (PMF) - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-11-15T01:00:00Z","last_updated_date":"2006-11-15T01:00:00Z","reference_number":"EMEA/CHMP/BWP/3794/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific-data-requirements-plasma-master-file-pmf-revision-1_en.pdf"},
    {"id":"29951","name":"Guideline on missing data in confirmatory clinical trials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-09-20T02:00:00Z","last_updated_date":"2010-09-20T02:00:00Z","reference_number":"EMA/CPMP/EWP/1776/99 Rev. 1 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-missing-data-confirmatory-clinical-trials_en.pdf"},
    {"id":"29965","name":"Exenatide powder and solvent for prolonged-release suspension for injection, 2 mg, and powder and solvent for prolonged-release suspension for injection in pre-filled pen, 2 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-03T01:00:00Z","last_updated_date":"2017-03-03T01:00:00Z","reference_number":"EMA/CHMP/474782/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/exenatide-powder-and-solvent-prolonged-release-suspension-injection-2-mg-and-powder-and-solvent-prolonged-release-suspension-injection-pre-filled-pen-2-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"30000","name":"Guideline on real-time release testing (formerly guideline on parametric release) - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"2012-03-15 - 2012-10-31","first_published_date":"2012-04-13T15:50:00Z","last_updated_date":"2012-04-13T15:50:00Z","reference_number":"EMA/CHMP/QWP/811210/2009-Rev1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-real-time-release-testing-formerly-guideline-parametric-release-revision-1_en.pdf"},
    {"id":"30008","name":"Updated advice on the use of colistin products in animals within the European Union: development of resistance and possible impact on human and animal health","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-26 - 2016-06-26","first_published_date":"2016-05-26T20:00:00Z","last_updated_date":"2016-05-26T20:00:00Z","reference_number":"EMA/231573/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/updated-advice-use-colistin-products-animals-within-european-union-development-resistance-and-possible-impact-human-and-animal-health_en.pdf"},
    {"id":"30030","name":"Guideline on the clinical development of medicinal products for the treatment of Autism Spectrum Disorder (ASD)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-11-21T10:19:00Z","last_updated_date":"2017-11-21T10:19:00Z","reference_number":"EMA/CHMP/598082/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-treatment-autism-spectrum-disorder-asd_en.pdf"},
    {"id":"30034","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use considerations (ICH) guideline Q8 (R2) on pharmaceutical development - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-06-01T02:00:00Z","last_updated_date":"2014-05-28T17:30:00Z","reference_number":"EMA/CHMP/ICH/167068/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-considerations-ich-guideline-q8-r2-pharmaceutical-development-step-5_en.pdf"},
    {"id":"30040","name":"Questions and answers on the guideline on the limits of genotoxic impurities","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-01-14T01:00:00Z","last_updated_date":"2010-10-19T02:00:00Z","reference_number":"EMEA/CHMP/SWP/431994/2007 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-guideline-limits-genotoxic-impurities_en.pdf"},
    {"id":"30045","name":"Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-04-15T18:30:00Z","last_updated_date":"2014-04-15T18:30:00Z","reference_number":"EMA/PRAC/222346/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu_en.pdf"},
    {"id":"30080","name":"Questions and answers on the withdrawal of the guideline on pharmacokinetics and metabolic studies in the safety evaluation of new medicinal products in animals (3BS11A)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-05-13T16:30:00Z","last_updated_date":"2015-02-04T15:30:00Z","reference_number":"EMEA/CHMP/SWP/1991104/2014 corr 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-withdrawal-guideline-pharmacokinetics-and-metabolic-studies-safety-evaluation-new-medicinal-products-animals-3bs11a_en.pdf"},
    {"id":"30124","name":"Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-08-01T02:00:00Z","last_updated_date":"2011-08-01T02:00:00Z","reference_number":"EMA/CHMP/BPWP/144533/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-viii-products-first-version_en.pdf"},
    {"id":"30127","name":"VICH Topic GL47: at step 4: Guideline on studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: Comparative metabolism studies in laboratory animals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-12-10 - 2010-05-20","first_published_date":"2009-12-22T02:00:00Z","last_updated_date":"2010-05-10T04:00:00Z","reference_number":"EMEA/CVMP/VICH/463104/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-topic-gl47-step-4-guideline-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-animals-comparative-metabolism-studies-laboratory-animals_en.pdf"},
    {"id":"30134","name":"Guideline on active substance master file procedure - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-04-15T02:00:00Z","last_updated_date":"2005-04-15T02:00:00Z","reference_number":"CPMP/QWP/227/02 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-active-substance-master-file-procedure-revision-1_en.pdf"},
    {"id":"30145","name":"Guideline on the investigation of medicinal products in the term and preterm neonate - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/536810/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-medicinal-products-term-and-preterm-neonate-first-version_en.pdf"},
    {"id":"30199","name":"Note for guidance: Requirements for combined veterinary vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-03-01T01:00:00Z","last_updated_date":"2000-03-01T01:00:00Z","reference_number":"CVMP/IWP/52/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-requirements-combined-veterinary-vaccines_en.pdf"},
    {"id":"30200","name":"Draft guideline on influenza vaccines: non-clinical and clinical module","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-07-31 - 2015-01-31","first_published_date":"2014-07-31T18:30:00Z","last_updated_date":"2014-07-31T18:30:00Z","reference_number":"EMA/CHMP/VWP/457259/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-influenza-vaccines-non-clinical-and-clinical-module_en.pdf"},
    {"id":"30204","name":"Guideline on the clinical development of medicinal products for the treatment of HIV infection - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/CPMP/EWP/633/02 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-treatment-hiv-infection-revision-2_en.pdf"},
    {"id":"30268","name":"Draft telithromycin product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/422605/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-telithromycin-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"30285","name":"Draft questions and answers on propylene glycol and esters in the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-12-01 - 2015-02-28","first_published_date":"2014-12-01T19:20:00Z","last_updated_date":"2014-12-01T19:20:00Z","reference_number":"EMA/CHMP/704195/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-and-answers-propylene-glycol-and-esters-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"30348","name":"Influenza vaccines - non-clinical and clinical module","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-07-29T12:20:00Z","last_updated_date":"2016-07-29T12:20:00Z","reference_number":"EMA/CHMP/VWP/457259/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non-clinical-and-clinical-module_en.pdf"},
    {"id":"30353","name":"Capecitabine film-coated tablets 150, 500 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-07-07T14:15:00Z","last_updated_date":"2015-07-07T14:15:00Z","reference_number":"CHMP/PKWP/EMA/423732/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/capecitabine-film-coated-tablets-150-500-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"30356","name":"Veterinary medicinal products for fluid therapy in case of diarrhoea","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1992-03-01T01:00:00Z","last_updated_date":"1992-03-01T01:00:00Z","reference_number":"7AE14a Volume 7","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/veterinary-medicinal-products-fluid-therapy-case-diarrhoea_en.pdf"},
    {"id":"30361","name":"Draft guideline on the procedure to be followed when a batch of a vaccine finished product is suspected to be contaminated with Bovine Viral Diarrhoea (BVD) virus","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-04-23T02:00:00Z","last_updated_date":"2007-04-23T02:00:00Z","reference_number":"EMEA/CVMP/IWP/205351/2006-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-procedure-be-followed-when-batch-vaccine-finished-product-suspected-be-contaminated-bovine-viral-diarrhoea-bvd-virus_en.pdf"},
    {"id":"30389","name":"Revised reflection paper on the use of third- and fourth-generation cephalosporins in food-producing animals in the European Union: Development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-03-16T01:00:00Z","last_updated_date":"2009-03-16T01:00:00Z","reference_number":"EMEA/CVMP/SAGAM/81730/2006-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/revised-reflection-paper-use-third-and-fourth-generation-cephalosporins-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"30415","name":"Draft guideline on the scientific application and the practical arrangements necessary to implement commission regulation (EC) no 507/2006 on the conditional marketing authorisation for medicinal products for human use f...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-12-05T01:00:00Z","last_updated_date":"2006-12-05T01:00:00Z","reference_number":"EMEA/509951/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-scientific-application-and-practical-arrangements-necessary-implement-commission-regulation-ec-no-5072006-conditional-marketing-authorisation-medicinal-products-human-use-f_en.pdf"},
    {"id":"30438","name":"VICH GL1: Validation of analytical procedures: Definition and terminology  - Step 7 consensus guideline","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-12-10T01:00:00Z","last_updated_date":"1998-12-10T01:00:00Z","reference_number":"CVMP/VICH/590/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl1-validation-analytical-procedures-definition-and-terminology-step-7-consensus-guideline_en.pdf"},
    {"id":"30450","name":"Concept paper on revision of the guideline on the pharmaceutical quality of inhalation and nasal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-03-22 - 2017-06-22","first_published_date":"2017-03-22T18:15:00Z","last_updated_date":"2017-03-22T18:15:00Z","reference_number":"EMA/CHMP/QWP/115777/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-pharmaceutical-quality-inhalation-and-nasal-products_en.pdf"},
    {"id":"30460","name":"Guideline on the investigation of bioequivalence (Rev.1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-01-29T01:00:00Z","last_updated_date":"2010-03-10T01:00:00Z","reference_number":"CPMP/EWP/QWP/1401/98 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf"},
    {"id":"30466","name":"VICH GL13: Efficacy of anthelmintics - Specific requirements for ovines - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-12-10T01:00:00Z","last_updated_date":"1999-12-10T01:00:00Z","reference_number":"CVMP/VICH/840/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl13-efficacy-anthelmintics-specific-requirements-ovines-step-7_en.pdf"},
    {"id":"30470","name":"Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-08-17T02:00:00Z","last_updated_date":"2011-08-17T02:00:00Z","reference_number":"EMA/CHMP/BWP/368186/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-aspects-isolation-candidate-influenza-vaccine-viruses-cell-culture_en.pdf"},
    {"id":"30501","name":"Note for guidance on clinical evaluation of new vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-05-19T02:00:00Z","last_updated_date":"1999-05-19T02:00:00Z","reference_number":"CPMP/EWP/463/97","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-evaluation-new-vaccines_en.pdf"},
    {"id":"30622","name":"Guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-10-18T02:00:00Z","last_updated_date":"2006-10-18T02:00:00Z","reference_number":"CPMP/EWP/422/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-juvenile-idiopathic-arthritis-first-version_en.pdf"},
    {"id":"30628","name":"VICH GL19: Efficacy of anthelmintics - Specific recommendations for canines - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-07-30T02:00:00Z","last_updated_date":"2001-07-30T02:00:00Z","reference_number":"CVMP/VICH/835/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl19-efficacy-anthelmintics-specific-recommendations-canines-step-7_en.pdf"},
    {"id":"30635","name":"Draft guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-29 - 2017-01-31","first_published_date":"2016-07-29T20:15:00Z","last_updated_date":"2016-07-29T20:15:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/94436/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guidance-individual-laboratories-transfer-quality-control-methods-validated-collaborative-trials-view-implementing-3rs_en.pdf"},
    {"id":"30636","name":"Concept paper on assessment of persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances in veterinary medicine","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-07-15 - 2010-09-01","first_published_date":"2010-07-19T04:00:00Z","last_updated_date":"2010-07-19T04:00:00Z","reference_number":"EMA/CVMP/ERAWP/389867/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-assessment-persistent-bioaccumulative-and-toxic-pbt-or-very-persistent-and-very-bioaccumulative-vpvb-substances-veterinary-medicine_en.pdf"},
    {"id":"30680","name":"Overview of comments received on 'Paracetamol oral use, immediate release formulations product-specific bioequivalence guidance' (EMA/CHMP/356877/2017) - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-02-01T13:00:00Z","last_updated_date":"2018-02-01T13:00:00Z","reference_number":"EMA/CHMP/729976/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-paracetamol-oral-use-immediate-release-formulations-product-specific-bioequivalence-guidance-emachmp3568772017-first-version_en.pdf"},
    {"id":"30688","name":"Reflection paper on the replacement of cell lines used for the production of immunological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-09-17T18:28:00Z","last_updated_date":"2015-09-17T18:28:00Z","reference_number":"EMA/CVMP/IWP/37620/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-replacement-cell-lines-used-production-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"30712","name":"Draft guideline on clinical investigation of medicinal products for prevention of venous thromboembolism in non-surgical patients (formerly CPMP/EWP/6235/04 Rev.1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-11-16 - 2016-05-15","first_published_date":"2016-10-12T14:00:00Z","last_updated_date":"2016-10-12T14:00:00Z","reference_number":"EMA/CHMP/41252/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-prevention-venous-thromboembolism-non-surgical-patients-formerly-cpmp-ewp-6235-04-rev1_en.pdf"},
    {"id":"30725","name":"Draft review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products – report on actions taken","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-29 - 2016-10-31","first_published_date":"2016-07-29T20:15:00Z","last_updated_date":"2016-07-29T20:15:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/677407/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-review-and-update-ema-guidelines-implement-best-practice-regard-3rs-replacement-reduction-and-refinement-regulatory-testing-medicinal-products-report-actions-taken_en.pdf"},
    {"id":"30778","name":"Draft questions and Answers on the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-06-24 - 2010-09-30","first_published_date":"2010-07-19T04:00:00Z","last_updated_date":"2010-07-19T04:00:00Z","reference_number":"EMA/CHMP/SWP/44609/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-and-answers-guideline-environmental-risk-assessment-medicinal-products-human-use-first-version_en.pdf"},
    {"id":"30784","name":"Draft concept paper for the development of a reflection paper on the use of extended-spectrum penicillins in animals in the European Union: development of resistance and impact on human and animal health - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-17 - 2015-10-31","first_published_date":"2015-07-17T13:15:00Z","last_updated_date":"2015-07-17T13:15:00Z","reference_number":"EMA/CVMP/AWP/37203/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-reflection-paper-use-extended-spectrum-penicillins-animals-european-union-development-resistance-and-impact-human-and-animal-health-first-version_en.pdf"},
    {"id":"30826","name":"Draft guideline on pharmaceutical development of medicines for paediatric use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-05-01 - 2011-12-31","first_published_date":"2011-06-23T04:00:00Z","last_updated_date":"2011-06-23T04:00:00Z","reference_number":"EMA/CHMP/QWP/180157/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf-0"},
    {"id":"30865","name":"Guideline on carcinogenicity evaluation of medicinal products for the treatment of HIV infection","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-12-13T01:00:00Z","last_updated_date":"2007-12-13T01:00:00Z","reference_number":"EMEA/CHMP/SWP/194898/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-carcinogenicity-evaluation-medicinal-products-treatment-hiv-infection_en.pdf"},
    {"id":"30877","name":"Draft guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/CHMP/EWP/431734/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-attention-deficit-hyperactivity-disorder-adhd_en.pdf"},
    {"id":"30883","name":"ICH M4Q: Common technical document for the registration of pharmaceuticals for human use - Quality - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-07-01T02:00:00Z","last_updated_date":"2003-07-01T02:00:00Z","reference_number":"CPMP/ICH/2887/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m4q-common-technical-document-registration-pharmaceuticals-human-use-quality-step-5_en.pdf"},
    {"id":"30911","name":"Concept paper on data requirements to support in use stability claims for immunological veterinary medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-07-20T02:00:00Z","last_updated_date":"2006-07-20T02:00:00Z","reference_number":"EMEA/CVMP/IWP/219089/2006-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-data-requirements-support-use-stability-claims-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"30952","name":"Draft guideline on conduct of pharmacovigilance for medicines used by the paediatric population","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"EMEA/CHMP/235910/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-pharmacovigilance-medicines-used-paediatric-population_en.pdf"},
    {"id":"30975","name":"ICH: E 4: Dose response information to support drug registration - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-11-01T01:00:00Z","last_updated_date":"1994-11-01T01:00:00Z","reference_number":"CPMP/ICH/378/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-4-dose-response-information-support-drug-registration-step-5_en.pdf"},
    {"id":"31016","name":"Note for guidance revised rapid alert systems (RAS) and non urgent information system (NUIS) in veterinary pharmacovigilance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-07-01T02:00:00Z","last_updated_date":"1999-07-01T02:00:00Z","reference_number":"EMEA/CVMP/141/98 Rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-revised-rapid-alert-systems-ras-and-non-urgent-information-system-nuis-veterinary-pharmacovigilance_en.pdf"},
    {"id":"31041","name":"ICH: Q 4 B Annex 8: Annex 6 to note for evaluation and recommendation of pharmacopoeial texts for use in the ich regions on sterility test and general chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2008-12-01T01:00:00Z","reference_number":"EMEA/CHMP/ICH/645592/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-8-annex-6-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-sterility-test-and-general-chapter-step-3_en.pdf"},
    {"id":"31044","name":"Concept paper on similar biological product containing recombinant follicle stimulation hormone","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-03-18 - 2010-06-11","first_published_date":"2010-04-06T04:00:00Z","last_updated_date":"2010-04-06T04:00:00Z","reference_number":"EMA/CHMP/BMWP/94899/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-similar-biological-product-containing-recombinant-follicle-stimulation-hormone_en.pdf"},
    {"id":"31060","name":"Dabigatran etexilate hard capsule 75 mg, 110 mg and 150 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-06-26T13:46:01Z","last_updated_date":"2018-06-26T13:46:01Z","reference_number":"EMA/CHMP/805498/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/dabigatran-etexilate-hard-capsule-75-mg-110-mg-and-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"31063","name":"Guideline on the non-clinical documentation for mixed marketing authorisation applications - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-10-13T02:09:00Z","last_updated_date":"2005-10-13T02:09:00Z","reference_number":"CPMP/SWP/799/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-documentation-mixed-marketing-authorisation-applications-first-version_en.pdf"},
    {"id":"31076","name":"Draft guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-05-20 - 2015-08-31","first_published_date":"2015-05-20T22:30:00Z","last_updated_date":"2015-05-20T22:30:00Z","reference_number":"EMA/CAT/80183/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-and-clinical-aspects-gene-therapy-medicinal-products_en.pdf"},
    {"id":"31087","name":"Note for guidance on clinical investigation of medicinal products for the treatment of cardiac failure - Addendum on acute cardiac failure","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-29T02:00:00Z","last_updated_date":"2004-07-29T02:00:00Z","reference_number":"CPMP/EWP/2986/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-cardiac-failure-addendum-acute-cardiac-failure_en.pdf"},
    {"id":"31131","name":"VICH GL8: Stability testing for medicated premixes - Step 7 consensus guideline","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-12-10T01:00:00Z","last_updated_date":"1999-12-10T01:00:00Z","reference_number":"CVMP/VICH/836/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl8-stability-testing-medicated-premixes-step-7-consensus-guideline_en.pdf"},
    {"id":"31133","name":"Draft guideline on the risk-based approach according to Annex I, part IV of Directive 2001/83/EC applied to advanced-therapy medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-01-19 - 2012-06-30","first_published_date":"2012-01-24T13:55:00Z","last_updated_date":"2012-01-24T13:55:00Z","reference_number":"EMA/CAT/CPWP/686637/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-risk-based-approach-according-annex-i-part-iv-directive-2001-83-ec-applied-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"31134","name":"Draft note for guidance on clinical investigation of medicinal products for treatment of asthma - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-07-01 - 2013-12-31","first_published_date":"2013-07-01T20:15:00Z","last_updated_date":"2013-07-01T20:15:00Z","reference_number":"CHMP/EWP/2922/01 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-clinical-investigation-medicinal-products-treatment-asthma-revision-1_en.pdf"},
    {"id":"31153","name":"Guideline on key aspects for the use of pharmacogenomics in the pharmacovigilance of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T11:50:00Z","last_updated_date":"2015-11-20T11:50:00Z","reference_number":"EMA/CHMP/281371/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-key-aspects-use-pharmacogenomics-pharmacovigilance-medicinal-products_en.pdf"},
    {"id":"31156","name":"Draft questions and answers on 'Guideline on the environmental risk assessment of medicinal products for human use' - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-03-31 - 2015-06-30","first_published_date":"2015-03-31T16:00:00Z","last_updated_date":"2015-03-31T16:00:00Z","reference_number":"EMA/CHMP/SWP/44609/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-and-answers-guideline-environmental-risk-assessment-medicinal-products-human-use-revision-1_en.pdf"},
    {"id":"31179","name":"Draft lenalidomide hard gelatine capsules 2.5, 5, 7.5, 10, 15 and 25mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-10-01 - 2016-01-01","first_published_date":"2015-10-06T17:00:00Z","last_updated_date":"2015-10-06T17:00:00Z","reference_number":"EMA/CHMP/PKWP/152216/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-lenalidomide-hard-gelatine-capsules-25-5-75-10-15-and-25mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"31216","name":"ICH: Gender considerations in the Conduct of Clinical Trials - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-01-05T00:09:21Z","last_updated_date":"2005-01-05T00:09:21Z","reference_number":"EMEA/CHMP/3916/2005 - ICH","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-gender-considerations-conduct-clinical-trials-step-5_en.pdf"},
    {"id":"31227","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q3D on elemental impurities - Step 5 - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-01-12T16:20:00Z","last_updated_date":"2016-07-28T17:00:00Z","reference_number":"EMA/CHMP/ICH/353369/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-q3d-elemental-impurities-step-5-first-version_en.pdf"},
    {"id":"31260","name":"Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-02-17T01:00:00Z","last_updated_date":"2005-02-17T01:00:00Z","reference_number":"CPMP/EWP/2339/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf"},
    {"id":"31270","name":"Guideline on good pharmacovigilance practices: Annex V – Abbreviations (Rev. 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-04-25T12:00:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/135814/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-v-abbreviations-rev-1_en.pdf"},
    {"id":"31311","name":"Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-08-08T16:15:00Z","last_updated_date":"2012-11-15T12:00:00Z","reference_number":"EMA/CHMP/483572/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease_en.pdf"},
    {"id":"31326","name":"Position paper on definition of a new biological active substance in terms of active, passive immunity and immunomodulators which then constitute a new active ingredient in the context of part b of the annex to council r...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-02-01T01:00:00Z","last_updated_date":"1998-02-01T01:00:00Z","reference_number":"CVMP/IWP/029/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-definition-new-biological-active-substance-terms-active-passive-immunity-and-immunomodulators-which-then-constitute-new-active-ingredient-context-part-b-annex-council-r_en.pdf"},
    {"id":"31335","name":"ICH guideline E2F on development safety update report - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-09-30T02:00:00Z","last_updated_date":"2010-09-30T02:00:00Z","reference_number":"EMA/CHMP/ICH/309348/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e2f-development-safety-update-report-step-5_en.pdf"},
    {"id":"31378","name":"Draft guideline on the evaluation of anticancer medicinal products in man - Revision 4","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-12-15 - 2012-05-31","first_published_date":"2011-12-22T12:20:00Z","last_updated_date":"2011-12-22T12:20:00Z","reference_number":"EMA/CHMP/205/95 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-anticancer-medicinal-products-man-revision-4_en.pdf"},
    {"id":"31392","name":"Draft guideline on non-clinical and clinical development of medicinal products for the treatment of nausea and vomiting associated with cancer chemotherapy","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-02-17T00:09:21Z","last_updated_date":"2005-02-17T00:09:21Z","reference_number":"CPMP/EWP/4937/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-non-clinical-and-clinical-development-medicinal-products-treatment-nausea-and-vomiting-associated-cancer-chemotherapy_en.pdf"},
    {"id":"31428","name":"Note for guidance: Field trials with veterinary vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-06-01T02:00:00Z","last_updated_date":"2001-06-01T02:00:00Z","reference_number":"EMEA/CVMP/852/99-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-field-trials-veterinary-vaccines_en.pdf"},
    {"id":"31470","name":"Superseded annex to note for guidance on development pharmaceutics for veterinary products: Decision trees for the selection of sterilisation methods","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-02-01T01:00:00Z","last_updated_date":"2000-02-01T01:00:00Z","reference_number":"EMEA/CVMP/065/99 - Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/superseded-annex-note-guidance-development-pharmaceutics-veterinary-products-decision-trees-selection-sterilisation-methods_en.pdf"},
    {"id":"31484","name":"ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2013-02-11T12:00:00Z","reference_number":"EMA/CHMP/ICH/425213/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q11-development-and-manufacture-drug-substances-chemical-entities-and-biotechnologicalbiological-entities_en.pdf"},
    {"id":"31489","name":"Concept paper for the revision of the guideline on the conduct of efficacy studies for intramammary products for use in cattle","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-09-15 - 2010-12-31","first_published_date":"2010-09-27T04:00:00Z","last_updated_date":"2010-09-27T04:00:00Z","reference_number":"EMA/CVMP/EWP/87114/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-conduct-efficacy-studies-intramammary-products-use-cattle_en.pdf"},
    {"id":"31522","name":"Guideline on the assessment of genotoxicity of herbal substances/preparations","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-05-21T02:00:00Z","last_updated_date":"2008-05-21T02:00:00Z","reference_number":"EMEA/HMPC/107079/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-assessment-genotoxicity-herbal-substancespreparations_en.pdf"},
    {"id":"31542","name":"Draft guideline on risk characterisation and assessment of maximum residue limits (MRLs) for biocides","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-12-08 - 2012-06-30","first_published_date":"2011-12-20T16:15:00Z","last_updated_date":"2011-12-20T16:15:00Z","reference_number":"EMA/CVMP/90250/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-risk-characterisation-and-assessment-maximum-residue-limits-mrls-biocides_en.pdf"},
    {"id":"31552","name":"Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-07-05 - 2018-09-30","first_published_date":"2018-06-26T18:20:00Z","last_updated_date":"2018-07-05T15:30:00Z","reference_number":"EMA/CHMP/800775/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-pegylated-liposomal-doxorubicin-hydrochloride-concentrate-solution-2-mg-ml-product-specific-bioequivalence-guidance_en.pdf"}    {"id":"31557","name":"Guideline for the testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestation in dogs and cats - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-07-25T16:10:00Z","last_updated_date":"2016-07-25T16:10:00Z","reference_number":"EMEA/CVMP/EWP/005/2000 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-testing-and-evaluation-efficacy-antiparasitic-substances-treatment-and-prevention-tick-and-flea-infestation-dogs-and-cats-revision-3_en.pdf"},
    {"id":"31568","name":"ICH: E 5 (R1): Ethnic factors in the acceptability of foreign clinical data - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-09-01T02:00:00Z","last_updated_date":"1998-09-01T02:00:00Z","reference_number":"CPMP/ICH/289/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-5-r1-ethnic-factors-acceptability-foreign-clinical-data-step-5_en.pdf"},
    {"id":"31569","name":"Concept paper on the need for a guideline on multiplicity issues in clinical trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-05-30 - 2012-08-30","first_published_date":"2012-05-30T15:30:00Z","last_updated_date":"2012-05-30T15:30:00Z","reference_number":"EMA/286914/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-multiplicity-issues-clinical-trials_en.pdf"},
    {"id":"31581","name":"Public statement on the evaluation of bovine spongiform encephalopathies (BSE) - risk via the use of materials of bovine origin in or during the manufacture of vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-02-28T01:00:00Z","last_updated_date":"2001-02-28T01:00:00Z","reference_number":"EMEA/CPMP/BWP/476/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-evaluation-bovine-spongiform-encephalopathies-bse-risk-use-materials-bovine-origin-or-during-manufacture-vaccines_en.pdf"},
    {"id":"31596","name":"Note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-11-16T01:00:00Z","last_updated_date":"2000-11-16T01:00:00Z","reference_number":"CPMP/EWP/566/98 rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-epileptic-disorders_en.pdf"},
    {"id":"31701","name":"Reflection paper on polycyclic aromatic hydrocarbons in herbal medicinal products/traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-06-29 - 2016-12-15","first_published_date":"2016-06-29T04:00:00Z","last_updated_date":"2016-06-29T04:00:00Z","reference_number":"EMA/HMPC/300551/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-polycyclic-aromatic-hydrocarbons-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"31713","name":"Draft vandetanib film-coated tablets 100 and 300 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-01 - 2016-10-31","first_published_date":"2016-08-01T17:00:00Z","last_updated_date":"2016-08-01T17:00:00Z","reference_number":"EMA/CHMP/474883/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vandetanib-film-coated-tablets-100-and-300-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"31748","name":"Emtricitabine/Tenofovir Disoproxil film-coated tablets 200mg/245 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/675839/2014 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/emtricitabinetenofovir-disoproxil-film-coated-tablets-200mg245-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"31751","name":"Draft guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-05-20 - 2010-09-01","first_published_date":"2010-05-28T04:00:00Z","last_updated_date":"2010-05-28T04:00:00Z","reference_number":"EMA/CHMP/BWP/68803/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-aspects-isolation-candidate-influenza-vaccine-viruses-cell-culture_en.pdf"},
    {"id":"31762","name":"Draft guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone (r-hFSH)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-11-17 - 2012-05-31","first_published_date":"2011-11-24T10:50:00Z","last_updated_date":"2011-11-24T10:50:00Z","reference_number":"EMA/CHMP/BMWP/671292/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-human-follicle-stimulating-hormone-r-hfsh_en.pdf"},
    {"id":"31775","name":"Guideline on parametric release","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-10-16T02:00:00Z","last_updated_date":"2006-10-16T02:00:00Z","reference_number":"EMEA/CVMP/QWP/339588/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-parametric-release_en.pdf"},
    {"id":"31801","name":"Concept paper on the development of a guideline on similar biological medicinal products containing monoclonal antibodies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-10-01 - 2010-01-31","first_published_date":"2009-11-18T01:09:21Z","last_updated_date":"2009-11-18T01:09:21Z","reference_number":"EMEA/632613/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies_en.pdf"},
    {"id":"31816","name":"ICH: E 1: Population exposure: The extent of population exposure to assess clinical safety - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1995-06-01T02:00:00Z","last_updated_date":"1995-06-01T02:00:00Z","reference_number":"CPMP/ICH/375/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-1-population-exposure-extent-population-exposure-assess-clinical-safety-step-5_en.pdf"},
    {"id":"31828","name":"Draft reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-03-16T01:00:00Z","last_updated_date":"2009-03-16T01:00:00Z","reference_number":"EMEA/CVMP/IWP/439467/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-demonstration-possible-impact-maternally-derived-antibodies-vaccine-efficacy-young-animals_en.pdf"},
    {"id":"31880","name":"Guideline on clinical investigation of medicinal products in the treatment of depression - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-05-30T15:00:00Z","last_updated_date":"2013-05-30T15:00:00Z","reference_number":"EMA/CHMP/185423/2010 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-2_en.pdf"},
    {"id":"31923","name":"Guideline on quality of biological active substances produced by transgene expression in animals","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-06-10T17:18:00Z","last_updated_date":"2013-06-10T17:18:00Z","reference_number":"EMA/CHMP/BWP/151897/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-biological-active-substances-produced-transgene-expression-animals_en.pdf"},
    {"id":"31924","name":"Draft guideline on core SPC for human plasma fibrinogen products\n\n(EMEA/CHMP/BPWP/122007/2005)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-01-25T01:00:00Z","last_updated_date":"2007-01-25T01:00:00Z","reference_number":"EMEA/CHMP/BPWP/122007/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-spc-human-plasma-fibrinogen-products-emeachmpbpwp1220072005_en.pdf"},
    {"id":"31977","name":"Position paper on the premixes for medicated feeding stuffs for veterinary use versus powders/granules for oral use or use in drinking water","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-08-01T02:00:00Z","last_updated_date":"1998-08-01T02:00:00Z","reference_number":"EMEA/CVMP/199/97-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-premixes-medicated-feeding-stuffs-veterinary-use-versus-powdersgranules-oral-use-or-use-drinking-water_en.pdf"},
    {"id":"31986","name":"Guideline on the procedure to be followed when a batch of a vaccine finished product is suspected to be contaminated with bovine viral diarrhoea virus","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-01-27 - 2015-04-30","first_published_date":"2015-01-30T02:00:00Z","last_updated_date":"2015-01-30T02:00:00Z","reference_number":"EMA/CVMP/IWP/205351/2006-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-procedure-be-followed-when-batch-vaccine-finished-product-suspected-be-contaminated-bovine-viral-diarrhoea-virus_en.pdf"},
    {"id":"32002","name":"CHMP position paper on thiomersal implementation of the warning statement relating to sensitisation","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-01-11T01:00:00Z","last_updated_date":"2007-01-11T01:00:00Z","reference_number":"EMEA/CHMP/VWP/19541/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chmp-position-paper-thiomersal-implementation-warning-statement-relating-sensitisation_en.pdf"},
    {"id":"32025","name":"Points to consider on clinical investigation of medicinal products for the treatment of acute stroke","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-09-20T02:00:00Z","last_updated_date":"2001-09-20T02:00:00Z","reference_number":"CPMP/EWP/560/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-clinical-investigation-medicinal-products-treatment-acute-stroke_en.pdf"},
    {"id":"32036","name":"Note for guidance on the evaluation of the pharmacokinetics of medical products in patients with impaired renal function","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-23T02:00:00Z","last_updated_date":"2004-06-23T02:00:00Z","reference_number":"CHMP/EWP/225/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-evaluation-pharmacokinetics-medical-products-patients-impaired-renal-function_en.pdf"},
    {"id":"32074","name":"Draft guideline on good pharmacovigilance practices: Module X – Additional monitoring","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-06-27 - 2012-08-24","first_published_date":"2012-06-27T16:57:58Z","last_updated_date":"2012-06-27T16:57:58Z","reference_number":"EMA/169546/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-x-additional-monitoring_en.pdf"},
    {"id":"32082","name":"VICH GL55: Harmonization of criteria to waive target animal batch safety testing for live vaccines for veterinary use - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-06-27T18:00:00Z","last_updated_date":"2017-06-27T18:00:00Z","reference_number":"EMA/CVMP/VICH/313610/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl55-harmonization-criteria-waive-target-animal-batch-safety-testing-live-vaccines-veterinary-use-first-version_en.pdf"},
    {"id":"32085","name":"Note for guidance on clinical investigation of medical products in the treatment of lipid disorders","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-29T02:00:00Z","last_updated_date":"2004-07-29T02:00:00Z","reference_number":"CPMP/EWP/3020/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medical-products-treatment-lipid-disorders_en.pdf"},
    {"id":"32093","name":"Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-13T02:00:00Z","last_updated_date":"2018-07-13T14:54:00Z","reference_number":"EMA/CAT/80183/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-and-clinical-aspects-gene-therapy-medicinal-products_en.pdf"},
    {"id":"32094","name":"Draft guideline on the clinical investigation of medicinal products to prevent development / slow progression of chronic renal insufficiency","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-07-01 - 2015-01-01","first_published_date":"2014-07-01T12:07:00Z","last_updated_date":"2014-07-01T12:07:00Z","reference_number":"EMA/CHMP/355988/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-prevent-development-slow-progression-chronic-renal-insufficiency_en.pdf"},
    {"id":"32106","name":"CVMP reflection paper on methods found suitable within the European Union for demonstrating freedom from extraneous agents of the seeds used for the production of immunological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-12-19T13:05:00Z","last_updated_date":"2016-12-19T13:05:00Z","reference_number":"EMA/CVMP/IWP/251741/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cvmp-reflection-paper-methods-found-suitable-within-european-union-demonstrating-freedom-extraneous-agents-seeds-used-production-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"32125","name":"Concept Paper on the Revision of the Guideline on Process Validation - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-01-14 - 2010-05-31","first_published_date":"2010-03-03T02:00:00Z","last_updated_date":"2010-03-03T02:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/809114/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-process-validation-revision-1_en.pdf"},
    {"id":"32162","name":"Guideline on good pharmacovigilance practices: Module II – Pharmacovigilance system master file (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-06-25T04:00:00Z","last_updated_date":"2012-06-25T04:00:00Z","reference_number":"EMA/816573/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file-superseded_en.pdf"},
    {"id":"32226","name":"Draft reflection paper on methodological issues in confirmatory clinical trials with flexible design and analysis plan","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-03-23T01:00:00Z","last_updated_date":"2006-03-23T01:00:00Z","reference_number":"CHMP/EWP/2459/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-methodological-issues-confirmatory-clinical-trials-flexible-design-and-analysis-plan_en.pdf"},
    {"id":"32232","name":"Concept paper on the development of a guideline on preparation on herbal teas","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-09-04T02:00:00Z","last_updated_date":"2008-09-04T02:00:00Z","reference_number":"EMEA/HMPC/451978/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-preparation-herbal-teas_en.pdf"},
    {"id":"32236","name":"Concept paper for the revision of the guidelines on data requirements for veterinary medicinal products for minor use minor species","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-11-18 - 2015-02-15","first_published_date":"2014-11-18T19:06:00Z","last_updated_date":"2014-11-18T19:06:00Z","reference_number":"EMA/CVMP/505827/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidelines-data-requirements-veterinary-medicinal-products-minor-use-minor-species_en.pdf"},
    {"id":"32245","name":"VICH Topic GL35: Guideline on pharmacovigilance of veterinary medicinal products: electronic standards of data","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-09-16 - 2011-03-15","first_published_date":"2010-09-27T04:00:00Z","last_updated_date":"2010-09-27T04:00:00Z","reference_number":"EMA/CVMP/VICH/123940/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-topic-gl35-guideline-pharmacovigilance-veterinary-medicinal-products-electronic-standards-data_en.pdf"},
    {"id":"32257","name":"Draft guideline on the use of porcine trypsin used in the manufacture of human biological medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-03-01 - 2013-08-31","first_published_date":"2013-03-01T13:30:00Z","last_updated_date":"2013-03-01T13:30:00Z","reference_number":"EMA/CHMP/BWP/814397/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-use-porcine-trypsin-used-manufacture-human-biological-medicinal-products_en.pdf"},
    {"id":"32263","name":"Replacement of chlorofluorocarbons (CFC) in metered dose inhalation products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1993-12-01T01:00:00Z","last_updated_date":"1993-12-01T01:00:00Z","reference_number":"3BR3a","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/replacement-chlorofluorocarbons-cfc-metered-dose-inhalation-products_en.pdf"},
    {"id":"32293","name":"List of species and breeds for electronic reporting of suspected adverse reactions in veterinary pharmacovigilance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-08-22T02:00:00Z","last_updated_date":"2011-06-30T02:00:00Z","reference_number":"EMEA/CVMP/553/03 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/list-species-and-breeds-electronic-reporting-suspected-adverse-reactions-veterinary-pharmacovigilance_en.pdf"},
    {"id":"32305","name":"Guideline on similar biological medicinal products containing \n\nBiotechnology-derived proteins as active substance:  Non-clinical and clinical issues","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-02-22T01:00:00Z","last_updated_date":"2006-02-22T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/42832/2005 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues_en.pdf"},
    {"id":"32323","name":"Points to consider document on the non-clinical assessment of the carcinogenic potential of insulin analogues","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-11-15T01:00:00Z","last_updated_date":"2001-11-15T01:00:00Z","reference_number":"CPMP/SWP/372/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-document-non-clinical-assessment-carcinogenic-potential-insulin-analogues_en.pdf"},
    {"id":"32359","name":"Concept paper on the need to update the CHMP position statement on CJD and plasma-derived and urine-derived medicinal products (EMEA/CPMP/BWP/2879/02 REV. 1)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/BWP/253246/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-update-chmp-position-statement-cjd-and-plasma-derived-and-urine-derived-medicinal-products-emeacpmpbwp287902-rev-1_en.pdf"},
    {"id":"32379","name":"Guideline on core core summary of product characteristics (SmPC) and package leaflet for (99Mo/99mTc) generator","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T16:30:00Z","last_updated_date":"2015-03-06T16:30:00Z","reference_number":"EMA/CHMP/773757/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-core-summary-product-characteristics-smpc-and-package-leaflet-99mo99mtc-generator_en.pdf"},
    {"id":"32382","name":"Guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-12-11T01:00:00Z","last_updated_date":"2002-12-11T01:00:00Z","reference_number":"EMEA/CVMP/627/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances-first-version_en.pdf"},
    {"id":"32419","name":"Draft guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-29 - 2017-01-31","first_published_date":"2016-07-29T20:00:00Z","last_updated_date":"2016-07-29T20:00:00Z","reference_number":"EMA/CHMP/458101/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-qualification-and-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-and-simulation_en.pdf"},
    {"id":"32436","name":"Draft interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-03-07 - 2014-03-28","first_published_date":"2014-03-07T13:40:00Z","last_updated_date":"2014-03-07T13:40:00Z","reference_number":"EMA/PRAC/135943/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu_en.pdf"},
    {"id":"32464","name":"Note of explanation to accompany publication of\n\nreflection paper on formulations of choice for the paediatric population\n\n(EMEA/CHMP/PEG/194810/2005)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-06-23T02:00:00Z","last_updated_date":"2005-06-23T02:00:00Z","reference_number":"EMEA/196218/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-explanation-accompany-publication-reflection-paper-formulations-choice-paediatric-population-emeachmppeg1948102005_en.pdf"},
    {"id":"32467","name":"Questions and answers on 'Guideline on the environmental risk assessment of medicinal products for human use' - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-06-02T11:20:00Z","last_updated_date":"2016-06-02T11:20:00Z","reference_number":"EMA/CHMP/SWP/44609/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-guideline-environmental-risk-assessment-medicinal-products-human-use-revision-1_en.pdf"},
    {"id":"32492","name":"Reflection paper: Minimum data requirements for an authorisation under exceptional circumstances for vaccines for emergency use in birds against H5 and/or H7 highly pathogenic avian influenza virus","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-02-16T01:00:00Z","last_updated_date":"2006-02-16T01:00:00Z","reference_number":"EMEA/CVMP/IWP/46853/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-minimum-data-requirements-authorisation-under-exceptional-circumstances-vaccines-emergency-use-birds-against-h5-andor-h7-highly-pathogenic-avian-influenza-virus_en.pdf"},
    {"id":"32550","name":"Points to consider on the requirements for clinical documentation for Orally Inhaled Products (OIP)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-04-22T02:00:00Z","last_updated_date":"2004-04-22T02:00:00Z","reference_number":"CPMP/EWP/4151/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-requirements-clinical-documentation-orally-inhaled-products-oip_en.pdf"},
    {"id":"32579","name":"Clinical investigation on medicinal products in the treatment of hypertension (Rev.1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-11-19T01:00:00Z","last_updated_date":"2014-09-22T02:00:00Z","reference_number":"CPMP/EWP/238/95 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/clinical-investigation-medicinal-products-treatment-hypertension-rev1_en.pdf"},
    {"id":"32591","name":"ICH guideline Q4B Annex 1 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on residue on ignition/sulphated ash - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-01T01:00:00Z","last_updated_date":"2017-07-13T16:30:00Z","reference_number":"EMEA/CHMP/ICH/222063/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-1-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-residue-ignitionsulphated-ash-step-5_en.pdf"},
    {"id":"32598","name":"Guideline on good pharmacovigilance practices: Module II – Pharmacovigilance system master file tracked changes (Rev. 2)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:00:00Z","last_updated_date":"2017-03-30T17:00:00Z","reference_number":"EMA/816573/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file-tracked-changes-rev-2_en.pdf"},
    {"id":"32604","name":"Draft guideline on the investigation of drug interactions","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-04-22 - 2010-10-31","first_published_date":"2010-04-30T04:00:00Z","last_updated_date":"2010-05-04T04:00:00Z","reference_number":"EMA/CHMP/EWP/125211/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-investigation-drug-interactions_en.pdf"},
    {"id":"32608","name":"Draft reflection paper on quality of essential oils as active substances in herbal medicinal products / traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-02-15 - 2013-05-15","first_published_date":"2013-03-01T12:00:00Z","last_updated_date":"2013-03-01T12:00:00Z","reference_number":"EMA/HMPC/84789/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-quality-essential-oils-active-substances-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"32623","name":"Draft guideline on data requirements for veterinary medicinal products for the prevention of transmission of vector- borne diseases in dogs and cats","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-07-27 - 2019-08-31","first_published_date":"2018-07-27T14:37:00Z","last_updated_date":"2018-07-27T14:37:00Z","reference_number":"EMA/CVMP/EWP/278031/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-veterinary-medicinal-products-prevention-transmission-vector-borne-diseases-dogs-and-cats_en.pdf"},
    {"id":"32627","name":"ICH guideline Q4B Annex 5 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on disintegration test - general chapter - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2017-07-13T16:30:00Z","reference_number":"EMA/CHMP/ICH/308895/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-5-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-disintegration-test-general-chapter-step-5_en.pdf"},
    {"id":"32632","name":"Draft guideline on clinical evaluation of medicinal products for the treatment of chronic hepatitis C","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-01-20 - 2011-08-31","first_published_date":"2011-02-14T02:00:00Z","last_updated_date":"2011-02-14T02:00:00Z","reference_number":"EMEA/CHMP/51240/2011 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-medicinal-products-treatment-chronic-hepatitis-c_en.pdf"},
    {"id":"32682","name":"Guideline on risk characterisation and assessment of maximum residue limits (MRL) for biocides","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-01-30T01:00:00Z","last_updated_date":"2015-01-30T01:00:00Z","reference_number":"EMA/CVMP/SWP/90250/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-risk-characterisation-and-assessment-maximum-residue-limits-mrl-biocides_en.pdf"},
    {"id":"32687","name":"Draft guideline on clinical investigation of medicinal products used in weight control","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2006-06-01T02:00:00Z","reference_number":"CPMP/EWP/281/96 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-used-weight-control_en.pdf"},
    {"id":"32707","name":"Draft reflection paper on the chemical structure and properties criteria to be considered for the evaluation of new active substance (NAS) status of chemical substances - Veterinary","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-11-17 - 2017-02-17","first_published_date":"2016-11-17T02:00:00Z","last_updated_date":"2016-11-17T02:00:00Z","reference_number":"EMA/CVMP/QWP/3629/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-chemical-structure-and-properties-criteria-be-considered-evaluation-new-active-substance-nas-status-chemical-substances-veterinary_en.pdf"},
    {"id":"32716","name":"Concept paper on the involvement of children and young people at the Paediatric Committee (PDCO)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-09-17 - 2012-11-19","first_published_date":"2012-09-17T20:30:00Z","last_updated_date":"2012-09-17T20:30:00Z","reference_number":"EMA/PDCO/388684/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-involvement-children-and-young-people-paediatric-committee-pdco_en.pdf"},
    {"id":"32722","name":"VICH GL12: Efficacy of anthelmintics: specific recommendations for bovines - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-12-10T01:00:00Z","last_updated_date":"1999-12-10T01:00:00Z","reference_number":"CVMP/VICH/839/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl12-efficacy-anthelmintics-specific-recommendations-bovines-step-7_en.pdf"},
    {"id":"32743","name":"Draft concept paper on guidance for the collection of data on antimicrobial consumption by species from national data collection systems","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-07-13 - 2016-09-30","first_published_date":"2016-07-13T21:25:00Z","last_updated_date":"2016-07-13T21:25:00Z","reference_number":"EMA/321085/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-guidance-collection-data-antimicrobial-consumption-species-national-data-collection-systems_en.pdf"},
    {"id":"32786","name":"Abiraterone tablets 250 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-03T01:00:00Z","last_updated_date":"2017-03-03T01:00:00Z","reference_number":"EMA/CHMP/474712/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/abiraterone-tablets-250-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"32802","name":"Draft reflection paper on stem cell-based medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2010-03-30T02:00:00Z","last_updated_date":"2010-03-30T02:00:00Z","reference_number":"EMA/CAT/571134/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-stem-cell-based-medicinal-products_en.pdf"},
    {"id":"32838","name":"Draft guideline on the data to be provided in support of a request to include a substance in the list of substances considered as not falling within the scope of regulation (EC) No 470/2009","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-11-11 - 2009-05-31","first_published_date":"2009-11-17T02:00:00Z","last_updated_date":"2010-05-10T04:00:00Z","reference_number":"EMEA/CVMP/516817/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-be-provided-support-request-include-substance-list-substances-considered-not-falling-within-scope-regulation-ec-no-470-2009_en.pdf"},
    {"id":"32883","name":"Guideline on the evaluation of anticancer medicinal products in man - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-12-14T00:09:00Z","last_updated_date":"2005-12-14T00:09:00Z","reference_number":"CPMP/EWP/205/95/Rev.3/Corr.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-3_en.pdf"},
    {"id":"32891","name":"Draft guideline on clinical medicinal products intended for the treatment of neuropathic pain","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-01-26T01:00:00Z","last_updated_date":"2006-01-26T01:00:00Z","reference_number":"CPMP/EWP/252/03 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-medicinal-products-intended-treatment-neuropathic-pain_en.pdf"},
    {"id":"32900","name":"Gaucher disease: a strategic collaborative approach from the European Medicines Agency and Food and Drug Administration","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-06-30T19:00:00Z","last_updated_date":"2017-06-30T19:00:00Z","reference_number":"EMA/237265/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/gaucher-disease-strategic-collaborative-approach-european-medicines-agency-and-food-and-drug-administration_en.pdf"},
    {"id":"32904","name":"Draft paediatric addendum to CHMP note for guidance on clinical investigation of medicinal products in the treatment of lipid disorders","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-06-24 - 2010-12-31","first_published_date":"2010-07-08T04:00:00Z","last_updated_date":"2010-07-08T04:00:00Z","reference_number":"EMA/CHMP/213057/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-paediatric-addendum-chmp-note-guidance-clinical-investigation-medicinal-products-treatment-lipid-disorders_en.pdf"},
    {"id":"32938","name":"Guideline on clinical investigation of medicinal products indicated for the treatment of Psoriasis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-11-18T01:00:00Z","last_updated_date":"2004-11-18T01:00:00Z","reference_number":"CHMP/EWP/2454/02 corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf"},
    {"id":"32939","name":"Reflection paper on surface coatings: general issues for consideration regarding parenteral administration of coated nanomedicine products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-08-15T16:56:00Z","last_updated_date":"2013-08-15T16:56:00Z","reference_number":"EMA/325027/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-surface-coatings-general-issues-consideration-regarding-parenteral-administration-coated-nanomedicine-products_en.pdf"},
    {"id":"32949","name":"Guideline on the investigation of drug interactions - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-07-06T11:41:00Z","last_updated_date":"2015-06-03T17:48:00Z","reference_number":"CPMP/EWP/560/95/Rev.1 Corr.2**","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf"},
    {"id":"32956","name":"Draft guideline on the development of medicinal products for the treatment of alcohol dependence","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/CHMP/EWP/20097/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-medicinal-products-treatment-alcohol-dependence_en.pdf"},
    {"id":"32980","name":"Paediatric addendum to the note for guidance on the clinical investigation on medicinal products in the treatment of hypertension","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-03-26T17:30:00Z","last_updated_date":"2015-03-26T17:30:00Z","reference_number":"EMA/CHMP/206815/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paediatric-addendum-note-guidance-clinical-investigation-medicinal-products-treatment-hypertension_en.pdf"},
    {"id":"33011","name":"ICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (R3) - questions and answers - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-06-01T02:00:00Z","last_updated_date":"2016-02-01T15:53:00Z","reference_number":"EMEA/CHMP/ICH/310133/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-drugs-r3-questions-and-answers-step-5_en.pdf"},
    {"id":"33014","name":"Concept paper on the revision of the 'Guideline on non-clinical documentation for herbal medicinal products in applications for marketing authorisation (bibliographical and mixed applications) and in applications for sim...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-09-02 - 2016-11-30","first_published_date":"2016-09-02T13:45:00Z","last_updated_date":"2016-09-02T13:45:00Z","reference_number":"EMA/HMPC/353983/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-non-clinical-documentation-herbal-medicinal-products-applications-marketing-authorisation-bibliographical-and-mixed-applications-and-applications-sim_en.pdf"},
    {"id":"33029","name":"Position paper on the establishment of MRLs for milk considering the daily intake by children","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2002-11-01T01:00:00Z","last_updated_date":"2002-11-01T01:00:00Z","reference_number":"EMEA/CVMP/391/02-FINAL-corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-establishment-mrls-milk-considering-daily-intake-children_en.pdf"},
    {"id":"33041","name":"Concept paper on the need for revision of the position paper on compliance of veterinary vaccines with veterinary vaccine monographs of the European pharmacopoeia","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-11-08T01:00:00Z","last_updated_date":"2006-11-08T01:00:00Z","reference_number":"EMEA/CVMP/378570/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-position-paper-compliance-veterinary-vaccines-veterinary-vaccine-monographs-european-pharmacopoeia_en.pdf"},
    {"id":"33049","name":"Concept paper on an addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev 2) to address indication-specific clinical data requirements","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-09-22 - 2011-12-31","first_published_date":"2011-10-06T18:16:00Z","last_updated_date":"2011-10-06T18:16:00Z","reference_number":"EMA/CHMP/EWP/736904/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-addendum-note-guidance-evaluation-medicinal-products-indicated-treatment-bacterial-infections-cpmp-ewp-558-95-rev-2-address-indication-specific-clinical-data-requirements_en.pdf"},
    {"id":"33093","name":"Overview of comments received on guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products-Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-06-27T02:00:00Z","last_updated_date":"2016-06-27T02:00:00Z","reference_number":"EMA/HMPC/669906/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products-revision-2_en.pdf"},
    {"id":"33159","name":"Draft paediatric addendum on the CHMP guideline on clinical investigation of medicinal products for the treatment of acute heart failure","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-06-10 - 2015-11-30","first_published_date":"2015-06-10T15:14:00Z","last_updated_date":"2015-06-10T15:14:00Z","reference_number":"EMA/CHMP/707532/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-paediatric-addendum-chmp-guideline-clinical-investigation-medicinal-products-treatment-acute-heart-failure_en.pdf"},
    {"id":"33176","name":"Guideline on epidemiological data on blood transmissible infections - For inclusion in the Guideline on the Scientific data requirements for a Plasma Master File (EMEA/CPMP/BWP/3794/03)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-01-20T01:00:00Z","last_updated_date":"2005-01-20T01:00:00Z","reference_number":"EMEA/CPMP/BWP/125/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-epidemiological-data-blood-transmissible-infections-inclusion-guideline-scientific-data-requirements-plasma-master-file-emeacpmpbwp379403_en.pdf"},
    {"id":"33181","name":"Concept paper on the need for revision of the guideline on clinical investigation of medicinal product for the treatment of migraine","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-10-21 - 2017-01-31","first_published_date":"2016-10-21T15:00:00Z","last_updated_date":"2016-10-21T15:00:00Z","reference_number":"EMA/CHMP/179671/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-product-treatment-migraine_en.pdf"},
    {"id":"33201","name":"Guideline on similar biological medicinal products containing interferon beta","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-03-06T12:00:02Z","last_updated_date":"2013-03-06T12:00:02Z","reference_number":"EMA/CHMP/BMWP/652000/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-interferon-beta_en.pdf"},
    {"id":"33258","name":"Note for guidance on the clinical investigation of medicinal products in the treatment of Asthma","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-11-21T01:00:00Z","last_updated_date":"2002-11-21T01:00:00Z","reference_number":"CHMP/EWP/2922/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-asthma_en.pdf"},
    {"id":"33338","name":"Guideline on live recombinant vector vaccines for veterinary use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-12-01T01:00:00Z","last_updated_date":"2004-12-01T01:00:00Z","reference_number":"EMEA/CVMP/004/04-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-live-recombinant-vector-vaccines-veterinary-use_en.pdf"},
    {"id":"33343","name":"ICH guideline S2 (R1) on genotoxicity testing and data interpretation for pharmaceuticals intended for human use - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2013-02-11T12:00:00Z","reference_number":"EMA/CHMP/ICH/126642/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-s2-r1-genotoxicity-testing-and-data-interpretation-pharmaceuticals-intended-human-use-step-5_en.pdf"},
    {"id":"33347","name":"Draft guideline on manufacture of the finished dosage form - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-09 - 2016-01-09","first_published_date":"2015-07-09T15:40:00Z","last_updated_date":"2015-07-09T15:40:00Z","reference_number":"EMA/CHMP/QWP/245074/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-manufacture-finished-dosage-form-revision-1_en.pdf"},
    {"id":"33352","name":"Concept paper on the need for a single note for guidance on the chemistry of active substances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-22 - 2015-10-22","first_published_date":"2015-07-22T18:25:00Z","last_updated_date":"2015-07-22T18:25:00Z","reference_number":"EMA/CVMP/QWP/107359/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-single-note-guidance-chemistry-active-substances_en.pdf-0"},
    {"id":"33376","name":"Note for guidance on carcinogenic potential","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-07-25T02:00:00Z","last_updated_date":"2002-07-25T02:00:00Z","reference_number":"CPMP/SWP/2877/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-carcinogenic-potential_en.pdf"},
    {"id":"33381","name":"Draft guideline on medicinal gases: pharmaceutical documentation - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-05T02:00:00Z","last_updated_date":"2007-10-05T02:00:00Z","reference_number":"CPMP/QWP/1719/00 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-medicinal-gases-pharmaceutical-documentation-revision-1_en.pdf"},
    {"id":"33388","name":"Concept paper on the need for a guideline on the evaluation of drugs for the treatment of Gastroesophageal Reflux disease (GERD)","type":"scientific-guideline","status":"unknown","consultation_date":"2009-02-01 - 2009-05-31","first_published_date":"2009-02-19T02:00:00Z","last_updated_date":"2009-02-19T02:00:00Z","reference_number":"EMEA/CHMP/EWP/15839/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-evaluation-drugs-treatment-gastroesophageal-reflux-disease-gerd_en.pdf"},
    {"id":"33412","name":"Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-10-13T02:00:00Z","last_updated_date":"2005-10-13T02:00:00Z","reference_number":"EMEA/CHMP/021/97 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-hormone-replacement-therapy-oestrogen-deficiency-symptoms-postmenopausal-women-revision-1_en.pdf"},
    {"id":"33417","name":"Draft CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-06-24 - 2010-09-30","first_published_date":"2010-07-27T04:00:00Z","last_updated_date":"2010-07-27T04:00:00Z","reference_number":"EMEA/CPMP/BWP/2879/02/rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-chmp-position-statement-creutzfeldt-jakob-disease-and-plasma-derived-and-urine-derived-medicinal-products-revision-2_en.pdf"},
    {"id":"33430","name":"Concept paper on the need for a guideline on the clinical investigation of medicianl products intended for treatment of systematic and cutaneous lupus erythematosus","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2009-11-19 - 2010-02-28","first_published_date":"2009-12-02T01:09:21Z","last_updated_date":"2009-12-02T01:09:21Z","reference_number":"EMEA/CHMP/EWP/604040/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-clinical-investigation-medicianl-products-intended-treatment-systematic-and-cutaneous-lupus-erythematosus_en.pdf"},
    {"id":"33446","name":"Guideline on user safety for immunological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-04-23T02:00:00Z","last_updated_date":"2007-04-23T02:00:00Z","reference_number":"EMEA/CVMP/IWP/54533/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-user-safety-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"33485","name":"ICH: S 3 B: Pharmacokinetics: Guidance for repeated dose tissue distribution studies - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-11-30T01:00:00Z","last_updated_date":"1994-11-30T01:00:00Z","reference_number":"CPMP/ICH/385/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-3-b-pharmacokinetics-guidance-repeated-dose-tissue-distribution-studies-step-5_en.pdf"},
    {"id":"33497","name":"Core SPC for human Prothrombin complex products (CPMP/BPWG/3735/02)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-11-21T01:00:00Z","last_updated_date":"2004-11-21T01:00:00Z","reference_number":"CPMP/BPWG/3735/02 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/core-spc-human-prothrombin-complex-products-cpmpbpwg373502_en.pdf"},
    {"id":"33503","name":"VICH GL22: Safety studies for veterinary drug residues in human food: Reproduction studies - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-06-16T02:00:00Z","last_updated_date":"2004-06-16T02:00:00Z","reference_number":"CVMP/VICH/525/00-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl22-safety-studies-veterinary-drug-residues-human-food-reproduction-studies-step-7_en.pdf"},
    {"id":"33545","name":"Concept paper on the need for revision of the note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/CHMP/EWP/176348/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-clinical-investigation-medicinal-products-treatment-diabetes-mellitus-revision-1_en.pdf"}    {"id":"33560","name":"Package Leaflet for Radiopharmaceuticals","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/CHMP/EWP/430144/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/package-leaflet-radiopharmaceuticals_en.pdf"},
    {"id":"33574","name":"Draft imatinib product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/423733/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-imatinib-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"33577","name":"ICH: Q 5 B: Analysis of the expression construct in cell lines used for production of r-DNA derived protein products - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-07-01T02:00:00Z","last_updated_date":"1996-07-01T02:00:00Z","reference_number":"CPMP/ICH/139/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-b-analysis-expression-construct-cell-lines-used-production-r-dna-derived-protein-products-step-5_en.pdf"},
    {"id":"33580","name":"Draft guideline on good pharmacovigilance practices (GVP) - Product- or population-specific considerations IV: paediatric population","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-08-02 - 2017-10-13","first_published_date":"2017-08-02T14:00:01Z","last_updated_date":"2017-08-02T14:00:01Z","reference_number":"EMA/572054/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-iv-paediatric-population_en.pdf"},
    {"id":"33594","name":"Points to Consider concerning Endpoints in Clinical Studies with Haematopoietic Growth Factors for Mobilisation of Autologous Stem Cells","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-02-01T01:00:00Z","last_updated_date":"2000-02-01T01:00:00Z","reference_number":"CPMP/EWP/197/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-concerning-endpoints-clinical-studies-haematopoietic-growth-factors-mobilisation-autologous-stem-cells_en.pdf"},
    {"id":"33645","name":"Guideline on quality of transdermal patches","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-12-16T18:40:00Z","last_updated_date":"2014-12-16T18:40:00Z","reference_number":"EMA/CHMP/QWP/608924/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-transdermal-patches_en.pdf"},
    {"id":"33647","name":"Production and quality control of medicinal products derived by recombinant dna technology","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1994-12-31T01:00:00Z","last_updated_date":"1994-12-31T01:00:00Z","reference_number":"3ab1aen ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/production-and-quality-control-medicinal-products-derived-recombinant-dna-technology_en.pdf"},
    {"id":"33655","name":"Guideline on good pharmacovigilance practices: Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-02-28T01:00:00Z","last_updated_date":"2014-02-28T01:00:00Z","reference_number":"EMA/204715/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools-and-effectiveness-indicators-superseded_en.pdf"},
    {"id":"33658","name":"Draft guideline on potency labeling for insulin analogue containing products with particular reference to the use of international units or units","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-04-21T02:00:00Z","last_updated_date":"2005-04-21T02:00:00Z","reference_number":"EMEA/CHMP/BWP/124446/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-potency-labeling-insulin-analogue-containing-products-particular-reference-use-international-units-or-units_en.pdf"},
    {"id":"33664","name":"Guideline on the development of medicinal products for the treatment of smoking","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"CHMP/EWP/369963/05","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-medicinal-products-treatment-smoking_en.pdf"},
    {"id":"33683","name":"Draft ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)","type":"scientific-guideline","status":"Draft","consultation_date":"2011-05-01 - 2011-09-16","first_published_date":"2011-06-16T04:00:00Z","last_updated_date":"2012-05-25T17:45:00Z","reference_number":"EMA/CHMP/ICH/425213/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-q11-development-and-manufacture-drug-substances-chemical-entities-and-biotechnological-biological-entities_en.pdf"},
    {"id":"33686","name":"Note for guidance: Development pharmaceutics for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-08-01T02:00:00Z","last_updated_date":"1999-08-01T02:00:00Z","reference_number":"EMEA/CVMP/315/98 - Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-development-pharmaceutics-veterinary-medicinal-products_en.pdf"},
    {"id":"33708","name":"Guideline on good pharmacovigilance practices: Module IX Addendum I – Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/209012/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-ix-addendum-i-methodological-aspects-signal-detection-spontaneous-reports-suspected-adverse-reactions-tracked-changes_en.pdf"},
    {"id":"33721","name":"Recommendation of revision of the note for guidance on clinical investigation of medicinal products in treatment of epileptic disorders (CPMP/EWP/566/98 Rev. 1)  - Revision 2","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-10-18T02:00:00Z","last_updated_date":"2007-10-18T02:00:00Z","reference_number":"EMEA/CHMP/EWP/453780/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-revision-note-guidance-clinical-investigation-medicinal-products-treatment-epileptic-disorders-cpmpewp56698-rev-1-revision-2_en.pdf"},
    {"id":"33726","name":"Draft guideline on active substance master file procedure - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-04-27T02:00:00Z","last_updated_date":"2005-04-27T02:00:00Z","reference_number":"CPMP/QWP/ 227/02 Rev. 2 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-active-substance-master-file-procedure-revision-2_en.pdf"},
    {"id":"33757","name":"Draft concept paper on the revision of the reflection paper on non-clinical and clinical development of similar biological medicinal products containing recombinant interferon alpha or pegylated recombinant interferon al...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-01-04 - 2016-03-31","first_published_date":"2016-01-04T13:00:00Z","last_updated_date":"2016-01-04T13:00:00Z","reference_number":"EMA/CHMP/BMWP/693108/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-revision-reflection-paper-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-interferon-alpha-or-pegylated-recombinant-interferon-al_en.pdf"},
    {"id":"33798","name":"Medicinal products (non-steroidal anti-inflammatory compounds) for the treatment of chronic disorders","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-02-01T01:00:00Z","last_updated_date":"2015-02-01T01:00:00Z","reference_number":"3CC17a","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/medicinal-products-non-steroidal-anti-inflammatory-compounds-treatment-chronic-disorders_en.pdf"},
    {"id":"33801","name":"Draft guideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species (MUMS)/limited market - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-03 - 2016-07-31","first_published_date":"2016-02-03T13:00:00Z","last_updated_date":"2016-02-03T13:00:00Z","reference_number":"EMA/CVMP/IWP/123243/2006 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-immunological-veterinary-medicinal-products-intended-minor-use-or-minor-species-mums-limited-market-revision-3_en.pdf"},
    {"id":"33805","name":"Guideline on the choice of the non-inferiority margin","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"EMEA/CPMP/EWP/2158/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-choice-non-inferiority-margin_en.pdf"},
    {"id":"33808","name":"Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-01-09T18:00:00Z","last_updated_date":"2015-01-09T18:00:00Z","reference_number":"EMEA/CHMP/BMWP/42832/2005 Rev1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf"},
    {"id":"33822","name":"Concept paper on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-15 - 2012-05-15","first_published_date":"2012-02-15T11:00:00Z","last_updated_date":"2012-02-15T11:00:00Z","reference_number":"EMA/CHMP/917570/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-key-aspects-use-pharmacogenomic-methodologies-pharmacovigilance-evaluation-medicinal-products_en.pdf"},
    {"id":"33830","name":"VICH Topic GL36: Safety of veterinary drugs in human food: General approach to establish a microbiological ADI - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-04-30T02:00:00Z","last_updated_date":"2007-04-30T02:00:00Z","reference_number":"CVMP/VICH/467/03-FINAL-corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-topic-gl36-safety-veterinary-drugs-human-food-general-approach-establish-microbiological-adi-step-7_en.pdf"},
    {"id":"33858","name":"Draft concept paper on the development of medicinal products for the treatment of autism spectrum disorder","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-04-04 - 2013-07-04","first_published_date":"2013-04-03T21:30:00Z","last_updated_date":"2013-04-03T21:30:00Z","reference_number":"EMA/CHMP/40896/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-medicinal-products-treatment-autism-spectrum-disorder_en.pdf"},
    {"id":"33865","name":"Concept paper on the second revision of the guideline on the use of the Common Technical Document format in the preparation of a registration application for traditional herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-12-03 - 2014-03-15","first_published_date":"2013-12-03T11:55:00Z","last_updated_date":"2013-12-03T11:55:00Z","reference_number":"EMA/HMPC/555178/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-second-revision-guideline-use-common-technical-document-format-preparation-registration-application-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"33873","name":"Concept paper on the development of toxicological guidance for use in risk identification in the manufacture of different medicinal products in shared facilities","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-10-20 - 2012-01-31","first_published_date":"2011-10-28T17:40:00Z","last_updated_date":"2011-10-28T17:40:00Z","reference_number":"EMA/CHMP/SWP/598303/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-toxicological-guidance-use-risk-identification-manufacture-different-medicinal-products-shared-facilities_en.pdf"},
    {"id":"33875","name":"Question & answers on the note for guidance on photosafety testing","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-06-24 - 2010-09-30","first_published_date":"2010-07-19T04:00:00Z","last_updated_date":"2010-07-19T04:00:00Z","reference_number":"EMA/CHMP/SWP/336670/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/question-answers-note-guidance-photosafety-testing_en.pdf"},
    {"id":"33882","name":"Concept paper on revision of the guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled prod...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-03-22 - 2017-06-30","first_published_date":"2017-03-22T18:16:00Z","last_updated_date":"2017-03-22T18:16:00Z","reference_number":"EMA/CHMP/267194/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-requirements-clinical-documentation-orally-inhaled-products-oip-including-requirements-demonstration-therapeutic-equivalence-between-two-inhaled-prod_en.pdf"},
    {"id":"33918","name":"Draft guideline on follow-up of patients administered with gene therapy Medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/CHMP/GTWP/60436/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-follow-patients-administered-gene-therapy-medicinal-products_en.pdf"},
    {"id":"33938","name":"Guideline on the use of bovine serum in the manufacture of human biological medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-06-04T11:10:00Z","last_updated_date":"2013-06-04T11:10:00Z","reference_number":"EMA/CHMP/BWP/457920/2012 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-bovine-serum-manufacture-human-biological-medicinal-products-revision-1_en.pdf"},
    {"id":"33941","name":"Draft guideline on similar medicinal products containing recombinant interferon alpha","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-10-18T02:00:00Z","last_updated_date":"2007-10-18T02:00:00Z","reference_number":"EMEA/CHMP/BMWP/102046/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-similar-medicinal-products-containing-recombinant-interferon-alpha_en.pdf"},
    {"id":"33943","name":"Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-04-14T02:00:00Z","last_updated_date":"2010-05-07T02:00:00Z","reference_number":"EMEA/CHMP/BMWP/301636/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-erythropoietins-revision_en.pdf"},
    {"id":"33947","name":"VICH GL30 on pharmacovigilance of veterinary medicinal products: controlled list of terms","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-20T02:00:00Z","last_updated_date":"2013-12-16T19:00:00Z","reference_number":"EMA/CVMP/VICH/647/2001","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl30-pharmacovigilance-veterinary-medicinal-products-controlled-list-terms_en.pdf"},
    {"id":"33958","name":"ICH: S 8: Immunotoxicity studies for human pharmaceuticals - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-10-31T01:00:00Z","last_updated_date":"2005-10-31T01:00:00Z","reference_number":"CHMP/167235/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-8-immunotoxicity-studies-human-pharmaceuticals-step-5_en.pdf"},
    {"id":"34053","name":"Guidelines on statistical principles for veterinary clinical trials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-11-09T01:00:00Z","last_updated_date":"2000-11-09T01:00:00Z","reference_number":"EMEA/CVMP/816/00/Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidelines-statistical-principles-veterinary-clinical-trials_en.pdf"},
    {"id":"34067","name":"Draft guideline on the non-clinical development of fixed combinations of medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2005-10-12 - 2006-04-30","first_published_date":"2005-10-13T04:00:00Z","last_updated_date":"2005-10-13T04:00:00Z","reference_number":"CHMP/EMEA/CHMP/SWP/258498/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-non-clinical-development-fixed-combinations-medicinal-products_en.pdf"},
    {"id":"34084","name":"Procedural advice on the submission of variations for annual update of human-influenza-inactivated-vaccine applications in the centralised procedure - Revision 2 - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T11:10:00Z","last_updated_date":"2013-04-30T11:10:00Z","reference_number":"EMA/CHMP/BWP/99698/2007 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/procedural-advice-submission-variations-annual-update-human-influenza-inactivated-vaccine-applications-centralised-procedure-revision-2-superseded_en.pdf"},
    {"id":"34106","name":"Draft guideline on the clinical development of medicinal products for the treatment of Autism Spectrum Disorder (ASD)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-03-04 - 2016-08-31","first_published_date":"2016-03-04T14:00:00Z","last_updated_date":"2016-03-04T14:00:00Z","reference_number":"EMA/CHMP/598082/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-development-medicinal-products-treatment-autism-spectrum-disorder-asd_en.pdf"},
    {"id":"34132","name":"Draft Pazopanib film-coated tablet 200mg and 400mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-02 - 2016-07-31","first_published_date":"2016-05-02T13:00:00Z","last_updated_date":"2016-05-02T13:00:00Z","reference_number":"EMA/CHMP/154805/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-pazopanib-film-coated-tablet-200mg-and-400mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"34133","name":"The use of ionising radiation in the manufacture of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1991-12-01T01:00:00Z","last_updated_date":"1991-12-01T01:00:00Z","reference_number":"3AQ4A","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/use-ionising-radiation-manufacture-medicinal-products_en.pdf"},
    {"id":"34135","name":"Rilpivirine film-coated tablets 25 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-02-01T13:00:00Z","last_updated_date":"2018-02-01T13:00:00Z","reference_number":"EMA/CHMP/356878/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/rilpivirine-film-coated-tablets-25-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"34143","name":"Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-23T11:11:00Z","last_updated_date":"2018-07-23T11:11:00Z","reference_number":"EMEA/CHMP/BMWP/301636/2008 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-erythropoietins-revision-1_en.pdf"},
    {"id":"34154","name":"ICH guideline Q4B annex 12 to note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on analytical sieving - general chapter - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2013-02-11T12:00:00Z","reference_number":"EMA/CHMP/ICH/730808/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-12-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-analytical-sieving-general-chapter-step-5_en.pdf"},
    {"id":"34159","name":"Results of juvenile animal studies (JAS) and impact on anti-cancer medicine development and use in children","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-11-30T12:47:00Z","last_updated_date":"2017-11-30T12:47:00Z","reference_number":"EMA/629174/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/results-juvenile-animal-studies-jas-and-impact-anti-cancer-medicine-development-and-use-children_en.pdf"},
    {"id":"34165","name":"Draft posaconazole gastro-resistant tablet 100 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-01-31 - 2018-04-30","first_published_date":"2018-01-31T14:15:00Z","last_updated_date":"2018-01-31T14:15:00Z","reference_number":"EMA/CHMP/800785/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-posaconazole-gastro-resistant-tablet-100-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"34181","name":"Guideline on good pharmacovigilance practices (GVP) product- or population-specific considerations I: Vaccines for prophylaxis against infectious diseases with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-12-12T16:00:00Z","last_updated_date":"2013-12-12T16:00:00Z","reference_number":"EMA/488220/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-i-vaccines-prophylaxis-against-infectious-diseases-tracked-changes_en.pdf"},
    {"id":"34212","name":"Vandetanib film-coated tablets 100 mg and 300 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-03-03T01:00:00Z","last_updated_date":"2017-03-03T01:00:00Z","reference_number":"EMA/CHMP/474883/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vandetanib-film-coated-tablets-100-mg-and-300-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"34251","name":"Guideline on clinical evaluation of medicinal products used in weight management - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-07-08T12:50:00Z","last_updated_date":"2016-07-08T12:50:00Z","reference_number":"EMA/CHMP/311805/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-used-weight-management-revision-1_en.pdf"},
    {"id":"34254","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human guideline Q10 on pharmaceutical quality system - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-06-01T02:00:00Z","last_updated_date":"2014-05-28T17:30:00Z","reference_number":"EMA/CHMP/ICH/214732/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-guideline-q10-pharmaceutical-quality-system-step-5_en.pdf"},
    {"id":"34261","name":"Reflection paper providing an overview of the current regulatory testing requirements for veterinary medicinal products and opportunities for implementation of the 3Rs","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"EMA/CHMP/CVMP/3Rs/164002/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-providing-overview-current-regulatory-testing-requirements-veterinary-medicinal-products-and-opportunities-implementation-3rs_en.pdf"},
    {"id":"34262","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) on electronic common technical document v4.0 draft ICH implementation guide v2.0 - Step 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-03-03 - 2015-05-22","first_published_date":"2015-03-03T12:00:00Z","last_updated_date":"2015-03-16T12:00:00Z","reference_number":"EMA/CHMP/ICH/143002/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-electronic-common-technical-document-v40-draft-ich-implementation-guide-v20-step-2_en.pdf"},
    {"id":"34286","name":"Draft VICH GL54: Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an acute reference dose (ARfD)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-03-20 - 2015-08-15","first_published_date":"2015-03-20T17:00:00Z","last_updated_date":"2015-03-20T17:00:00Z","reference_number":"EMA/VICH/699251/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl54-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach-establish-acute-reference-dose-arfd_en.pdf"},
    {"id":"34342","name":"Guideline on the development of new medicinal products for the treatment of Crohn's disease - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"CPMP/EWP/2284/99 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-new-medicinal-products-treatment-crohns-disease-revision-1_en.pdf"},
    {"id":"34347","name":"ICH: Q 4 B Annex 5: To note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on disintegration test general chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-06-01T02:00:00Z","last_updated_date":"2008-06-01T02:00:00Z","reference_number":"EMEA/CHMP/ICH/308895/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-5-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-disintegration-test-general-chapter-step-3_en.pdf"},
    {"id":"34359","name":"ICH: E 15: Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories - Step 4","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-01T01:00:00Z","last_updated_date":"2007-11-01T01:00:00Z","reference_number":"EMEA/CHMP/ICH/437986/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-15-definitions-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-and-sample-coding-categories-step-4_en.pdf"},
    {"id":"34392","name":"Concept paper on the need for revision of the guideline on clinical investigation of medicinal products for the prophylaxis of venous thromboembolic risk in non-surgical patients","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-07-15 - 2014-10-15","first_published_date":"2014-07-16T19:10:00Z","last_updated_date":"2014-07-16T19:10:00Z","reference_number":"EMA/CHMP/283524/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-prophylaxis-venous-thromboembolic-risk-non-surgical-patients_en.pdf"},
    {"id":"34405","name":"Draft guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-06-10 - 2013-11-30","first_published_date":"2013-06-10T14:39:00Z","last_updated_date":"2013-06-10T14:39:00Z","reference_number":"EMEA/CHMP/BMWP/42832/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues_en.pdf"},
    {"id":"34408","name":"Draft VICH GL55: Harmonisation of criteria to waive target animal batch safety testing for live vaccines for veterinary use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-26 - 2016-08-01","first_published_date":"2016-02-26T16:30:00Z","last_updated_date":"2016-02-26T16:30:00Z","reference_number":"EMA/CVMP/VICH/313610/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl55-harmonisation-criteria-waive-target-animal-batch-safety-testing-live-vaccines-veterinary-use_en.pdf"},
    {"id":"34424","name":"Note for guidance on harmonisation of requirements for influenza vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-03-12T01:00:00Z","last_updated_date":"1997-03-12T01:00:00Z","reference_number":"CPMP/BWP/214/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-harmonisation-requirements-influenza-vaccines_en.pdf"},
    {"id":"34436","name":"Concept paper on the development of a committee for medicinal\n\nProducts for human use (CHMP) guideline on nonclinical testing for\n\nInadvertent germline transmission of gene transfer vectors","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2004-11-18T01:00:00Z","last_updated_date":"2004-11-18T01:00:00Z","reference_number":"EMEA/CHMP/SWP/110180/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-medicinal-products-human-use-chmp-guideline-nonclinical-testing-inadvertent-germline-transmission-gene-transfer-vectors_en.pdf"},
    {"id":"34441","name":"Draft guideline on the use of phthalates as excipients in human medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-05-08 - 2013-10-31","first_published_date":"2013-05-08T14:00:00Z","last_updated_date":"2013-05-08T14:00:00Z","reference_number":"EMA/CHMP/SWP/362974/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-use-phthalates-excipients-human-medicinal-products_en.pdf"},
    {"id":"34470","name":"VICH GL34: Guideline on testing for the detection of mycoplasma contamination","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-12-09 - 2011-03-31","first_published_date":"2002-04-26T04:00:00Z","last_updated_date":"2010-12-15T02:00:00Z","reference_number":"EMA/CVMP/VICH/463/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl34-guideline-testing-detection-mycoplasma-contamination_en.pdf"},
    {"id":"34481","name":"Concept paper on the revision of the guideline on nonclinical and clinical development of similar biological medicinal products containing recombinant human insulin","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-07-21 - 2011-09-30","first_published_date":"2011-07-27T04:00:00Z","last_updated_date":"2011-07-27T04:00:00Z","reference_number":"EMA/CHMP/BMWP/506470/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-nonclinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-human-insulin_en.pdf"},
    {"id":"34546","name":"Concept paper for the revision of the guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza, blue tongue and foot and mouth disease - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-09-28 - 2016-12-31","first_published_date":"2016-09-28T17:35:00Z","last_updated_date":"2016-09-28T17:35:00Z","reference_number":"EMA/CVMP/IWP/867388/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-data-requirements-multi-strain-dossiers-inactivated-vaccines-against-avian-influenza-blue-tongue-and-foot-and-mouth-disease-revision-1_en.pdf"},
    {"id":"34595","name":"Guideline on clinical investigation of new medicinal products for the treatment of acute coronary syndrome - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-09-20T13:00:00Z","last_updated_date":"2017-09-20T13:00:00Z","reference_number":"EMA/CHMP/760125/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-new-medicinal-products-treatment-acute-coronary-syndrome-first-version_en.pdf"},
    {"id":"34608","name":"Guideline on development, production, characterisation and specification for monoclonal antibodies and related products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-08-05T12:00:00Z","last_updated_date":"2016-08-05T12:00:00Z","reference_number":"EMA/CHMP/BWP/532517/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-production-characterisation-and-specification-monoclonal-antibodies-and-related-products-revision-1_en.pdf"},
    {"id":"34626","name":"Guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-07-06T11:39:00Z","last_updated_date":"2012-07-06T11:39:00Z","reference_number":"EMA/CHMP/330418/2012 rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-parkinsons-disease_en.pdf-0"},
    {"id":"34633","name":"Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations II: Biological medicinal products with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-08-15T12:00:00Z","last_updated_date":"2016-08-15T12:00:00Z","reference_number":"EMA/168402/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-ii-biological-medicinal-products-tracked-changes_en.pdf"},
    {"id":"34647","name":"Concept paper for a guideline on limits for genotoxic impurities","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-01-18 - 2013-04-30","first_published_date":"2013-01-18T11:00:00Z","last_updated_date":"2013-01-18T11:00:00Z","reference_number":"EMA/CVMP/SWP/398880/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-limits-genotoxic-impurities_en.pdf"},
    {"id":"34654","name":"Draft gefitinib film-coated tablet 250 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-06-27 - 2018-09-30","first_published_date":"2018-06-27T14:30:00Z","last_updated_date":"2018-06-27T14:30:00Z","reference_number":"EMA/CHMP/257026/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-gefitinib-film-coated-tablet-250-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"34655","name":"ICH: S 1 A: The need for carcinogenicity studies of pharmaceuticals - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-07-01T02:09:21Z","last_updated_date":"1996-07-01T02:09:21Z","reference_number":"CPMP/ICH/140/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-1-need-carcinogenicity-studies-pharmaceuticals-step-5_en.pdf"},
    {"id":"34661","name":"Use of transgenic animals in the manufacture of biological medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1995-07-01T02:00:00Z","last_updated_date":"1995-07-01T02:00:00Z","reference_number":"III/3612/93","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/use-transgenic-animals-manufacture-biological-medicinal-products-human-use_en.pdf"},
    {"id":"34720","name":"Draft scientific guidance on post-authorisation efficacy studies - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-11-06 - 2016-01-31","first_published_date":"2015-11-06T14:00:00Z","last_updated_date":"2015-11-06T14:00:00Z","reference_number":"EMA/PDCO/CAT/CMDh/PRAC/CHMP/261500/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-scientific-guidance-post-authorisation-efficacy-studies-first-version_en.pdf"},
    {"id":"34739","name":"Reflection paper on meticillin-resistant Staphylococcus pseudintermedius","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-02-10T01:00:00Z","last_updated_date":"2011-02-10T01:00:00Z","reference_number":"EMA/CVMP/SAGAM/736964/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-meticillin-resistant-staphylococcus-pseudintermedius_en.pdf"},
    {"id":"34779","name":"Draft guideline on assessing the toxicological risk to human health and groundwater communities from veterinary pharmaceuticals in groundwater","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-02-24 - 2017-08-31","first_published_date":"2017-02-24T18:00:00Z","last_updated_date":"2017-02-24T18:00:00Z","reference_number":"EMA/CVMP/ERA/103555/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-assessing-toxicological-risk-human-health-and-groundwater-communities-veterinary-pharmaceuticals-groundwater_en.pdf"},
    {"id":"34803","name":"Draft guideline on non-clinical and clinical development of similar Biological medicinal products containing recombinant Erythropoietins (Revision)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/BMWP/301636/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-erythropoietins-revision_en.pdf"},
    {"id":"34805","name":"Guideline on good pharmacovigilance practices: Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators with tracked changes (Rev. 2)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T17:00:00Z","last_updated_date":"2017-03-30T17:00:00Z","reference_number":"EMA/204715/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools-and-effectiveness-indicators-tracked-changes-rev-2_en.pdf"},
    {"id":"34816","name":"Reflection paper on anthelmintic resistance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-04-24T16:51:00Z","last_updated_date":"2017-04-24T16:51:00Z","reference_number":"EMA/CVMP/EWP/573536/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-anthelmintic-resistance_en.pdf-1"},
    {"id":"34820","name":"Note for guidance on clinical investigation of medicinal products for treatment of depression - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-04-25T02:00:00Z","last_updated_date":"2002-04-25T02:00:00Z","reference_number":"CPMP/EWP/518/97, Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-depression-revision-1_en.pdf"},
    {"id":"34867","name":"Concept paper on the need for revision of the guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-10-01 - 2012-12-15","first_published_date":"2012-09-28T15:30:00Z","last_updated_date":"2012-09-28T15:30:00Z","reference_number":"EMA/CHMP/520782/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-juvenile-idiopathic-arthritis_en.pdf"},
    {"id":"34875","name":"Guideline on similar biological medicinal products - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-10-30T02:00:00Z","last_updated_date":"2005-10-30T02:00:00Z","reference_number":"CHMP/437/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-first-version_en.pdf"},
    {"id":"34899","name":"Overview of comments received on 'Tadalafil film-coated tablets 2.5 mg, 5 mg, 10 mg and 20 mg product-specific bioequivalence guidance' (EMA/CHMP/315234/2014/Rev.1) - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-02-01T13:00:00Z","last_updated_date":"2018-02-01T13:00:00Z","reference_number":"EMA/CHMP/644909/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-tadalafil-film-coated-tablets-25-mg-5-mg-10-mg-and-20-mg-product-specific-bioequivalence-guidance-emachmp3152342014rev1-first-version_en.pdf"},
    {"id":"34926","name":"Concept paper on the need for a guideline on process validation of medicinal products containing biotechnology-derived proteins as active substance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-05-19 - 2011-08-31","first_published_date":"2011-06-06T04:00:00Z","last_updated_date":"2011-06-06T04:00:00Z","reference_number":"EMA/CHMP/BWP/25360/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-process-validation-medicinal-products-containing-biotechnology-derived-proteins-active-substance_en.pdf"},
    {"id":"34927","name":"Guideline on assessing the risk for virus transmission - new chapter 6 of the note for guidance on plasma derived medicinal products (CPMP/BWP/269/95)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-04-30T02:00:00Z","last_updated_date":"2005-04-30T02:00:00Z","reference_number":"CPMP/BWP/5180/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-assessing-risk-virus-transmission-new-chapter-6-note-guidance-plasma-derived-medicinal-products-cpmpbwp26995_en.pdf"},
    {"id":"34934","name":"Note for guidance on clinical investigation of medicinal products in the treatment of cardiac failure - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-12-16T01:00:00Z","last_updated_date":"1999-12-16T01:00:00Z","reference_number":"CPMP/EWP/235/95, Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-medicinal-products-treatment-cardiac-failure-revision-1_en.pdf"},
    {"id":"34999","name":"Guideline on core summary of product characteristics for human plasma derived and recombinant coagulation factor VIII products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-21T11:30:00Z","last_updated_date":"2012-06-21T11:30:00Z","reference_number":"EMA/CHMP/BPWP/1619/1999 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-summary-product-characteristics-human-plasma-derived-and-recombinant-coagulation-factor-viii-products-revision-1_en.pdf"},
    {"id":"35026","name":"Concept paper on a guideline on the assessment of pharmacological/pharmacodynamic data to establish a pharmacological ADI draft","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-05-18T02:00:00Z","last_updated_date":"2005-05-18T02:00:00Z","reference_number":"EMEA/CVMP/SWP/122154/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-assessment-pharmacologicalpharmacodynamic-data-establish-pharmacological-adi-draft_en.pdf"},
    {"id":"35048","name":"Concept paper on the development of a guideline on live recombinant vector vaccines","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-07-16T02:00:00Z","last_updated_date":"2007-07-16T02:00:00Z","reference_number":"EMEA/CHMP/308139/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-live-recombinant-vector-vaccines_en.pdf"},
    {"id":"35098","name":"VICH GL56 on studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: study design recommendations for residue studies in honey for establishing MRLs and withdrawal periods -...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T17:30:00Z","last_updated_date":"2018-07-27T17:30:00Z","reference_number":"EMA/CVMP/VICH/176637/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl56-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-species-study-design-recommendations-residue-studies-honey-establishing-mrls-and-withdrawal-periods_en.pdf"},
    {"id":"35144","name":"Draft reflection paper on ethanol content in herbal medicinal products and traditional herbal medicinal products used in children","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2008-11-06 - 2009-03-15","first_published_date":"2008-11-06T02:00:00Z","last_updated_date":"2008-11-06T02:00:00Z","reference_number":"EMA/HMPC/85114/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-ethanol-content-herbal-medicinal-products-and-traditional-herbal-medicinal-products-used-children_en.pdf"},
    {"id":"35169","name":"Guideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T13:00:00Z","last_updated_date":"2017-02-24T13:00:00Z","reference_number":"EMA/CHMP/CVMP/JEG-3Rs/450091/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-principles-regulatory-acceptance-3rs-replacement-reduction-refinement-testing-approaches_en.pdf"},
    {"id":"35171","name":"Background to the CPMP position paper on selective serotonin uptake inhibitors (SSRIs) and dependency/withdrawal reactions","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-04-12T02:00:00Z","last_updated_date":"2000-04-12T02:00:00Z","reference_number":"EMEA/CPMP/2775/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/background-cpmp-position-paper-selective-serotonin-uptake-inhibitors-ssris-and-dependencywithdrawal-reactions_en.pdf"},
    {"id":"35191","name":"Guideline on the procedure to be followed when a batch of a vaccine finished product is suspected to be contaminated with Bovine Viral Diarrhoea (BVD) virus","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-03-17T01:00:00Z","last_updated_date":"2008-03-17T01:00:00Z","reference_number":"EMEA/CVMP/IWP/205351/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-procedure-be-followed-when-batch-vaccine-finished-product-suspected-be-contaminated-bovine-viral-diarrhoea-bvd-virus_en.pdf"},
    {"id":"35202","name":"Concept paper on the revision of the guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-03-31 - 2011-09-15","first_published_date":"2011-06-01T04:00:00Z","last_updated_date":"2011-06-01T04:00:00Z","reference_number":"EMA/HMPC/111298/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-use-ctd-format-preparation-registration-application-traditional-herbal-medicinal-products-revision-1_en.pdf"},
    {"id":"35213","name":"Explanatory note for clarification of the scope of the VICH guideline 17 on 'Stability testing of new biotechnological/biological veterinary medicinal products CVMP/VICH/501/99'","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-06-18T02:00:00Z","last_updated_date":"2008-06-18T02:00:00Z","reference_number":"EMEA/CVMP/IWP/319771/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/explanatory-note-clarification-scope-vich-guideline-17-stability-testing-new-biotechnologicalbiological-veterinary-medicinal-products-cvmpvich50199_en.pdf"},
    {"id":"35267","name":"Guideline on veterinary medicinal products for zootechnical purposes - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1992-03-01T01:00:00Z","last_updated_date":"1992-03-01T01:00:00Z","reference_number":"7AE7a Volume 7","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-veterinary-medicinal-products-zootechnical-purposes-first-version_en.pdf"},
    {"id":"35285","name":"Draft reflection paper on assessment of bioavailability of bound residues in food commodities of animal origin in the context of council regulation (EEC) NO 2377/90","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-05-23T02:00:00Z","last_updated_date":"2007-05-23T02:00:00Z","reference_number":"EMEA/CVMP/SWP/95682/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-assessment-bioavailability-bound-residues-food-commodities-animal-origin-context-council-regulation-eec-no-237790_en.pdf"},
    {"id":"35319","name":"Draft reflection paper on data requirements for swine influenza vaccines against pandemic (H1N1) 2009 influenza - Obsolete","type":"scientific-guideline","status":"Draft","consultation_date":"","first_published_date":"2010-02-17T00:09:21Z","last_updated_date":"2010-02-17T00:09:21Z","reference_number":"EMA/CVMP/IWP/58879/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-data-requirements-swine-influenza-vaccines-against-pandemic-h1n1-2009-influenza-obsolete_en.pdf"},
    {"id":"35335","name":"Concept paper on the need for a guideline on the use of subgroup analyses in randomised controlled trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-04-22 - 2010-07-31","first_published_date":"2010-04-30T04:00:00Z","last_updated_date":"2010-04-30T04:00:00Z","reference_number":"EMA/CHMP/EWP/117211/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-use-subgroup-analyses-randomised-controlled-trials_en.pdf"},
    {"id":"35338","name":"Guideline on clinical evaluation of medicinal products used in weight control - Addendum on weight control in children","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/517497/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-used-weight-control-addendum-weight-control-children_en.pdf"},
    {"id":"35384","name":"VICH GL43: Target animal safety for pharmaceuticals - Step 4","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-11-08T01:00:00Z","last_updated_date":"2006-11-08T01:00:00Z","reference_number":"EMEA/CVMP/VICH/393388/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl43-target-animal-safety-pharmaceuticals-step-4_en.pdf"}    {"id":"35421","name":"Concept paper on the development of a committee for medicinal\n\nproducts for human use (CHMP) guideline on dosing delivery of\n\ninjectable liquids","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2004-06-02T02:00:00Z","last_updated_date":"2004-06-02T02:00:00Z","reference_number":"EMEA/CHMP/QWP/1888/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-medicinal-products-human-use-chmp-guideline-dosing-delivery-injectable-liquids_en.pdf"},
    {"id":"35443","name":"Overview of comments received on draft guideline on data to be provided in support of a request to include a substance in the list of substances considered as not falling within the scope of Regulation (EC) No 470/2009","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/CVMP/SWP/513604/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-draft-guideline-data-be-provided-support-request-include-substance-list-substances-considered-not-falling-within-scope-regulation-ec-no-4702009_en.pdf"},
    {"id":"35448","name":"Draft reflection paper on the pharmaceutical development of intravenous medicinal products containing active substances solubilised in micellar systems (non-polymeric surfactants)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-09-23 - 2010-12-31","first_published_date":"2010-10-13T04:00:00Z","last_updated_date":"2010-10-13T04:00:00Z","reference_number":"EMA/CHMP/QWP/574767/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-pharmaceutical-development-intravenous-medicinal-products-containing-active-substances-solubilised-micellar-systems-non-polymeric-surfactants_en.pdf"},
    {"id":"35449","name":"Matters relating to the replacement of CFCs in medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1993-12-01T01:00:00Z","last_updated_date":"1993-12-01T01:00:00Z","reference_number":"3BR2A ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/matters-relating-replacement-cfcs-medicinal-products_en.pdf"},
    {"id":"35461","name":"Note for guidance on allergen products (Replaced by CHMP/BWP/304831/07)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-03-13T01:00:00Z","last_updated_date":"1996-03-13T01:00:00Z","reference_number":"CPMP/BMP/243/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-allergen-products-replaced-chmpbwp30483107_en.pdf"},
    {"id":"35489","name":"VICH GL9: Good clinical practices - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-07-04T02:00:00Z","last_updated_date":"2000-07-04T02:00:00Z","reference_number":"EMEA/CVMP/VICH/595/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl9-good-clinical-practices-step-7_en.pdf"},
    {"id":"35503","name":"Concept paper on the development of product-specific guidance on demonstration of bioequivalence","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-08-01 - 2013-09-30","first_published_date":"2013-08-01T20:00:00Z","last_updated_date":"2013-08-01T20:00:00Z","reference_number":"EMA/CHMP/423137/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-product-specific-guidance-demonstration-bioequivalence_en.pdf"},
    {"id":"35505","name":"Draft guideline on medicinal products for the treatment of Alzheimer's disease and other dementias - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"CPMP/EWP/553/95 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-medicinal-products-treatment-alzheimers-disease-and-other-dementias-revision-1_en.pdf"},
    {"id":"35527","name":"Application of VICH GL 18 on residual solvents to veterinary medicinal products containing existing active substances - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-05-01T02:00:00Z","last_updated_date":"2001-05-01T02:00:00Z","reference_number":"EMEA/CVMP/423/01-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/application-vich-gl-18-residual-solvents-veterinary-medicinal-products-containing-existing-active-substances-superseded_en.pdf"},
    {"id":"35531","name":"Posaconazole oral suspension 40 mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315247/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/posaconazole-oral-suspension-40-mgml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"35532","name":"Questions and answers on Benzyl alcohol in the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-02-24 - 2014-05-31","first_published_date":"2014-02-24T12:00:00Z","last_updated_date":"2014-02-24T12:00:00Z","reference_number":"EMA/CHMP/508188/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-benzyl-alcohol-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"35569","name":"Note for guidance for stability testing of existing active substances and related finished products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-11-01T01:00:00Z","last_updated_date":"2000-11-01T01:00:00Z","reference_number":"EMEA/CVMP/846/99 - FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-stability-testing-existing-active-substances-and-related-finished-products_en.pdf"},
    {"id":"35572","name":"Concept paper on the need for a guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with atrial fibrillation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-02-17 - 2011-05-31","first_published_date":"2011-04-07T04:00:00Z","last_updated_date":"2011-04-07T04:00:00Z","reference_number":"EMA/CHMP/68875/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-clinical-investigation-medicinal-products-prevention-stroke-and-systemic-embolic-events-patients-atrial-fibrillation_en.pdf"},
    {"id":"35594","name":"Concept paper on the need for revision of the appendix to the note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia – methodology of clinical trials concerning the develo...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T15:35:00Z","last_updated_date":"2011-10-17T15:35:00Z","reference_number":"EMA/CHMP/457223/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-appendix-note-guidance-clinical-investigation-medicinal-products-treatment-schizophrenia-methodology-clinical-trials-concerning-develo_en.pdf"},
    {"id":"35629","name":"Concept paper on vaccines used for vaccination against foot and mouth disease","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2001-06-01T02:00:00Z","last_updated_date":"2001-06-01T02:00:00Z","reference_number":"EMEA/CVMP/518/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-vaccines-used-vaccination-against-foot-and-mouth-disease_en.pdf"},
    {"id":"35631","name":"Guideline on good pharmacovigilance practices (GVP): Module IX – Signal management with tracked changes (Rev. 1)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/827661/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-tracked-changes-rev-1_en.pdf"},
    {"id":"35655","name":"Note for guidance on the warning on transmissible agents in Summary of Product Characteristics (SPCs) and package leaflets for plasma–derived medicinal products (CPMP/BPWG/BWP/561/03)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-10-22T02:00:00Z","last_updated_date":"2003-10-22T02:00:00Z","reference_number":"CPMP/BPWG/BWP/561/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-warning-transmissible-agents-summary-product-characteristics-spcs-and-package-leaflets-plasma-derived-medicinal-products-cpmpbpwgbwp56103_en.pdf"},
    {"id":"35680","name":"Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-03-19T01:00:00Z","last_updated_date":"2009-03-19T01:00:00Z","reference_number":"EMEA/CHMP/BMWP/118264/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-low-molecular-weight-heparins_en.pdf"},
    {"id":"35716","name":"Recommendation on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease (CPMP/EWP/563/95)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"EMEA/CHMP/EWP/369959/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-need-revision-guideline-clinical-investigation-medicinal-products-treatment-parkinsons-disease-cpmpewp56395_en.pdf"},
    {"id":"35725","name":"Reflection paper on the authorisation of veterinary medicinal products containing (potential) persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-05-23T10:57:00Z","last_updated_date":"2017-05-23T10:57:00Z","reference_number":"EMA/CVMP/448211/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-authorisation-veterinary-medicinal-products-containing-potential-persistent-bioaccumulative-and-toxic-pbt-or-very-persistent-and-very-bioaccumulative-vpvb-substances_en.pdf"},
    {"id":"35737","name":"Concept paper on the need to revise appendix 4 (on condition-specific guidance) to the guideline on the evaluation of anticancer medicinal products in man - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-04-01 - 2017-06-30","first_published_date":"2017-03-31T21:11:00Z","last_updated_date":"2017-03-31T21:11:00Z","reference_number":"EMA/102314/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revise-appendix-4-condition-specific-guidance-guideline-evaluation-anticancer-medicinal-products-man-revision-3_en.pdf"},
    {"id":"35741","name":"ICH: E 14: The Clinical Evaluation of QT/QTs Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic drugs - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-01T01:00:00Z","last_updated_date":"2005-11-01T01:00:00Z","reference_number":"CHMP/ICH/2/04","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-14-clinical-evaluation-qtqts-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-drugs-step-5_en.pdf"},
    {"id":"35755","name":"International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) topic GL23(R): Studies to evaluate the safety of residues of veterinary drugs in human food: G...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-01-18 - 2013-03-31","first_published_date":"2013-01-18T11:00:00Z","last_updated_date":"2013-01-18T11:00:00Z","reference_number":"EMA/CVMP/SWP/398880/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-cooperation-harmonisation-technical-requirements-registration-veterinary-medicinal-products-vich-topic-gl23r-studies-evaluate-safety-residues-veterinary-drugs-human-food-g_en.pdf"},
    {"id":"35762","name":"Reflection paper on in-vitro cultured chondrocyte containing products for cartilage repair of the knee","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-05-18T02:00:00Z","last_updated_date":"2010-05-18T02:00:00Z","reference_number":"EMA/CAT/CPWP/568181/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-vitro-cultured-chondrocyte-containing-products-cartilage-repair-knee_en.pdf"},
    {"id":"35767","name":"Paracetamol oral use immediate release formulations product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-02-01T13:00:00Z","last_updated_date":"2018-02-01T13:00:00Z","reference_number":"EMA/CHMP/356877/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paracetamol-oral-use-immediate-release-formulations-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"35771","name":"Guideline on environmental impact assessment for veterinary medicinal products in support of the VICH guidelines GL6 and GL38","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-11-17T01:00:00Z","last_updated_date":"2016-07-05T11:16:00Z","reference_number":"EMEA/CVMP/ERA/418282/2005-Rev.1 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-environmental-impact-assessment-veterinary-medicinal-products-support-vich-guidelines-gl6-and-gl38_en.pdf"},
    {"id":"35803","name":"Draft guideline on clinical investigation of new medicinal products for the treatment of acute coronary syndrome - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-04-27 - 2016-10-31","first_published_date":"2016-04-27T13:05:00Z","last_updated_date":"2016-04-27T13:05:00Z","reference_number":"EMA/CHMP/207892/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-new-medicinal-products-treatment-acute-coronary-syndrome-first-version_en.pdf"},
    {"id":"35841","name":"Concept paper for a guideline on antimicrobial-resistance risk assessment","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-01-18 - 2013-04-30","first_published_date":"2013-01-18T11:00:00Z","last_updated_date":"2013-01-18T11:00:00Z","reference_number":"EMA/CVMP/680258/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-antimicrobial-resistance-risk-assessment_en.pdf"},
    {"id":"35854","name":"Guideline on clinical investigation of medicinal products in the treatment of lipid disorders","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-01-16T16:10:00Z","last_updated_date":"2014-01-16T16:10:00Z","reference_number":"EMA/CHMP/748108/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-lipid-disorders_en.pdf"},
    {"id":"35870","name":"List on additional controlled terminology for electronic submission of reports on adverse reactions to veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-12-08T00:09:21Z","last_updated_date":"2006-09-15T01:09:21Z","reference_number":"EMEA/CVMP/556/04- Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/list-additional-controlled-terminology-electronic-submission-reports-adverse-reactions-veterinary-medicinal-products_en.pdf"},
    {"id":"35873","name":"Draft guideline on the declaration of the quantitative composition / labelling of biological medicinal products that contain modified proteins as active substance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-03-25 - 2013-10-01","first_published_date":"2013-03-25T11:30:00Z","last_updated_date":"2013-03-25T11:30:00Z","reference_number":"EMA/CHMP/BWP/85290/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-declaration-quantitative-composition-labelling-biological-medicinal-products-contain-modified-proteins-active-substance_en.pdf"},
    {"id":"35880","name":"Draft concept paper on guidance on statistical principles for clinical trials for immunological veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-12-18 - 2016-03-31","first_published_date":"2015-12-18T11:00:01Z","last_updated_date":"2016-01-15T16:35:00Z","reference_number":"EMA/CVMP/IWP/309514/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-guidance-statistical-principles-clinical-trials-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"35887","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use considerations: Oncolytic viruses","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-10-21T02:00:00Z","last_updated_date":"2009-10-21T02:00:00Z","reference_number":"EMEA/CHMP/ICH/607698/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-considerations-oncolytic-viruses_en.pdf"},
    {"id":"35906","name":"Draft guideline on good pharmacovigilance practices: Module VI – Management and reporting of adverse reactions to medicinal products (Rev 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-06-07 - 2013-08-05","first_published_date":"2013-06-07T14:30:00Z","last_updated_date":"2013-06-07T14:30:00Z","reference_number":"EMA/873138/2011 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-vi-management-and-reporting-adverse-reactions-medicinal-products-rev-1_en.pdf"},
    {"id":"35911","name":"Draft prasugrel film-coated tablets 5 and 10 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-15 - 2015-11-01","first_published_date":"2015-07-15T14:00:01Z","last_updated_date":"2015-07-15T14:00:01Z","reference_number":"EMA/CHMP/PKWP/36761/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-prasugrel-film-coated-tablets-5-and-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"35921","name":"Concept paper on the revision of the note for guidance on stability testing of existing active substances and related finshed products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-04-23T02:00:00Z","last_updated_date":"2007-04-23T02:00:00Z","reference_number":"EMEA/CVMP/QWP/103377/2007-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-stability-testing-existing-active-substances-and-related-finshed-products_en.pdf"},
    {"id":"35969","name":"Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"EMEA/CHMP/EWP/139391/2004","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-guidance-use-health-related-quality-life-hrql-measures-evaluation-medicinal-products_en.pdf"},
    {"id":"35984","name":"Draft guideline on the SPC for anthelmintics","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-06-26T02:09:21Z","last_updated_date":"2006-06-26T02:09:21Z","reference_number":"EMEA/CVMP/EWP/170208/2005-CONSULTATION","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-spc-anthelmintics_en.pdf"},
    {"id":"36023","name":"ICH: E 2 C (R1): Clinical safety data management: Periodic safety update reports for marketed drugs - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-06-01T02:00:00Z","last_updated_date":"1997-06-01T02:00:00Z","reference_number":"CPMP/ICH/288/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-2-c-r1-clinical-safety-data-management-periodic-safety-update-reports-marketed-drugs-step-5_en.pdf"},
    {"id":"36035","name":"Points to consider regarding efficacy requirements for minor species and minor indications","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2002-02-14T01:00:00Z","last_updated_date":"2002-02-14T01:00:00Z","reference_number":"EMEA/CVMP/610/01-Consultation","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-regarding-efficacy-requirements-minor-species-and-minor-indications_en.pdf"},
    {"id":"36039","name":"Draft guideline on scientific requirements for the environmental risk assessment of gene therapy medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2007-02-01 - 2007-08-01","first_published_date":"2007-02-08T02:00:00Z","last_updated_date":"2007-02-08T02:00:00Z","reference_number":"EMEA/CHMP/GTWP/125491/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-scientific-requirements-environmental-risk-assessment-gene-therapy-medicinal-products_en.pdf"},
    {"id":"36079","name":"Guideline on the evaluation of medicinal products for the treatment of chronic constipation (including opioid induced constipation) and for bowel cleansing","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-09-14T18:20:00Z","last_updated_date":"2015-09-14T18:20:00Z","reference_number":"EMA/CHMP/336243/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-treatment-chronic-constipation-including-opioid-induced-constipation-and-bowel-cleansing_en.pdf"},
    {"id":"36113","name":"Draft concept paper on the need for revision of the guideline on the clinical investigation of plasma-derived fibrin sealant / haemostatic products and the related core summary of product characteristics","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-06-01 - 2014-08-31","first_published_date":"2014-05-28T13:30:00Z","last_updated_date":"2014-05-28T13:30:00Z","reference_number":"EMA/CHMP/BPWP/572810/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-need-revision-guideline-clinical-investigation-plasma-derived-fibrin-sealant-haemostatic-products-and-related-core-summary-product-characteristics_en.pdf"},
    {"id":"36134","name":"Guideline on the Core SPC for human plasma derived Hepatitis-B immunoglobulin for intravenous use (CPMP/BPWG/4027/02)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-04-27T02:00:00Z","last_updated_date":"2006-04-27T02:00:00Z","reference_number":"CPMP/BPWG/4027/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-plasma-derived-hepatitis-b-immunoglobulin-intravenous-use-cpmpbpwg402702_en.pdf"},
    {"id":"36140","name":"Note for guidance: Harmonisation of requirements for equine influenza vaccines: Specific requirements for substitution or addition of a strain or strains","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-11-01T01:00:00Z","last_updated_date":"1998-11-01T01:00:00Z","reference_number":"EMEA/CVMP/112/98-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-harmonisation-requirements-equine-influenza-vaccines-specific-requirements-substitution-or-addition-strain-or-strains_en.pdf"},
    {"id":"36162","name":"ICH: Q 1 F: Stability data package for registration in climatic zones III and IV","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2006-06-01T02:00:00Z","reference_number":"CPMP/ICH/421/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-f-stability-data-package-registration-climatic-zones-iii-and-iv_en.pdf"},
    {"id":"36164","name":"VICH GL46: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: metabolism study to determine the quantity and identify the nature of residues","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-04-07T02:00:00Z","last_updated_date":"2011-04-07T02:00:00Z","reference_number":"EMA/CVMP/VICH/463072/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl46-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-animals-metabolism-study-determine-quantity-and-identify-nature-residues_en.pdf"},
    {"id":"36171","name":"Draft ibuprofen 200 - 800 mg oral use, immediate release formulations product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-08-03 - 2017-10-31","first_published_date":"2017-08-03T18:30:01Z","last_updated_date":"2017-08-03T18:30:01Z","reference_number":"EMA/CHMP/356876/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ibuprofen-200-800-mg-oral-use-immediate-release-formulations-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"36184","name":"Chemistry of active substances - Superseded document","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-10-01T02:00:00Z","last_updated_date":"2015-10-01T02:00:00Z","reference_number":"3AQ5A","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chemistry-active-substances-superseded-document_en.pdf"},
    {"id":"36194","name":"Guideline on clinical investigation of medicinal products for the treatment of acute heart failure - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-06-10T13:30:00Z","last_updated_date":"2015-06-10T13:30:00Z","reference_number":"CPMP/EWP/2986/03 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-acute-heart-failure-revision-1_en.pdf"},
    {"id":"36216","name":"Guideline on core summary of product characteristics for human plasma-derived and recombinant coagulation factor IX products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-21T11:30:00Z","last_updated_date":"2012-06-21T11:30:00Z","reference_number":"EMA/CHMP/BPWP/1625/1999 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-summary-product-characteristics-human-plasma-derived-and-recombinant-coagulation-factor-ix-products-revision-1_en.pdf"},
    {"id":"36282","name":"Guideline on core summary of product characteristics for human normal immunoglobulin for intravenous administration (IVIg) revision 4","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-12-18T10:46:00Z","last_updated_date":"2012-12-18T10:46:00Z","reference_number":"EMA/CHMP/BPWP/94038/2007 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-summary-product-characteristics-human-normal-immunoglobulin-intravenous-administration-ivig-revision-4_en.pdf"},
    {"id":"36293","name":"Guideline on manufacture of the finished dosage form - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-08-14T13:00:00Z","last_updated_date":"2017-08-14T13:00:00Z","reference_number":"EMA/CHMP/QWP/245074/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-manufacture-finished-dosage-form-revision-1_en.pdf"},
    {"id":"36296","name":"Note for guidance: Excipients in the dossier for application for marketing authorisation for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-02-01T01:00:00Z","last_updated_date":"1999-02-01T01:00:00Z","reference_number":"EMEA/CVMP/004/98 - FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-excipients-dossier-application-marketing-authorisation-veterinary-medicinal-products_en.pdf"},
    {"id":"36358","name":"Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations II: Biological  medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-08-15T12:00:00Z","last_updated_date":"2016-08-15T12:00:00Z","reference_number":"EMA/168402/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-ii-biological-medicinal-products_en.pdf"},
    {"id":"36362","name":"Concept paper on the need for revision of the points to consider on clinical investigation of medicinal products in the chronic treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) (CPMP/EWP/562/98)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"EMEA/CHMP/EWP/8197/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-points-consider-clinical-investigation-medicinal-products-chronic-treatment-patients-chronic-obstructive-pulmonary-disease-copd-cpmpewp56298_en.pdf"},
    {"id":"36443","name":"Recommendation to marketing authorisation holders, highlighting recent measures in the veterinary field to promote reduction, refinement and replacement (3Rs) measures described in the European Pharmacopoeia - Applicable...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-01-24T16:30:00Z","last_updated_date":"2018-02-16T11:00:00Z","reference_number":"EMA/CVMP/3Rs/336802/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-marketing-authorisation-holders-highlighting-recent-measures-veterinary-field-promote-reduction-refinement-and-replacement-3rs-measures-described-european-pharmacopoeia-applicable_en.pdf"},
    {"id":"36474","name":"Concept paper on the need for revision of the note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-06-08 - 2012-07-31","first_published_date":"2012-06-08T14:20:00Z","last_updated_date":"2012-06-08T14:20:00Z","reference_number":"EMA/CHMP/203926/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-evaluation-pharmacokinetics-medicinal-products-patients-impaired-renal-function_en.pdf"},
    {"id":"36476","name":"Note for guidance on quality of water for pharmaceutical use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-05-01T02:00:00Z","last_updated_date":"2002-05-01T02:00:00Z","reference_number":"CPMP/QWP/158/01 Revision","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-quality-water-pharmaceutical-use_en.pdf"},
    {"id":"36542","name":"Draft reflection paper on quality, non-clinical and clinical issues relating specifically to recombinant adeno-associated viral vectors","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-03-19T01:00:00Z","last_updated_date":"2009-03-19T01:00:00Z","reference_number":"EMEA/CHMP/GTWP/587488/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-quality-non-clinical-and-clinical-issues-relating-specifically-recombinant-adeno-associated-viral-vectors_en.pdf"},
    {"id":"36544","name":"Imatinib hard capsules 50 and 100 mg, film-coated tablets 100 and 400 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315242/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/imatinib-hard-capsules-50-and-100-mg-film-coated-tablets-100-and-400-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"36571","name":"VICH GL4: Stability testing for new veterinary dosage forms - Step 7 consensus guideline","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-05-25T02:00:00Z","last_updated_date":"2000-05-25T02:00:00Z","reference_number":"CVMP/VICH/900/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl4-stability-testing-new-veterinary-dosage-forms-step-7-consensus-guideline_en.pdf"},
    {"id":"36638","name":"Draft reflection paper on the dissolution specification for generic oral immediate release products - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-13 - 2016-08-13","first_published_date":"2016-05-13T17:44:00Z","last_updated_date":"2016-05-13T17:44:00Z","reference_number":"EMA/CHMP/CVMP/QWP/37330/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-dissolution-specification-generic-oral-immediate-release-products-first-version_en.pdf"},
    {"id":"36667","name":"Position Paper on Plasma-Derived Medicinal Products: Alt Testing \n\n(Corrigendum, Sept. 1999)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-07-29T02:00:00Z","last_updated_date":"1999-07-29T02:00:00Z","reference_number":"CPMP/BWP/385/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-plasma-derived-medicinal-products-alt-testing-corrigendum-sept-1999_en.pdf"},
    {"id":"36686","name":"Draft reflection paper on the authorisation of veterinary medicinal products containing (potential) persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-26 - 2016-05-31","first_published_date":"2016-02-26T16:30:00Z","last_updated_date":"2016-02-26T16:30:00Z","reference_number":"EMA/CVMP/448211/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-authorisation-veterinary-medicinal-products-containing-potential-persistent-bioaccumulative-and-toxic-pbt-or-very-persistent-and-very-bioaccumulative-vpvb-substances_en.pdf"},
    {"id":"36740","name":"Concept paper on a proposal to limit the applicability of the CPMP/CVMP Note for guidance on limitations to the use of ethylene oxide in the manufacture of medicinal products to veterinary medicinal products - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-11-19T15:45:00Z","last_updated_date":"2015-11-19T15:45:00Z","reference_number":"EMA/CHMP/SWP/211900/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-proposal-limit-applicability-cpmpcvmp-note-guidance-limitations-use-ethylene-oxide-manufacture-medicinal-products-veterinary-medicinal-products-superseded_en.pdf"},
    {"id":"36743","name":"Draft guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-11-10 - 2024-01-30","first_published_date":"2023-11-13T02:00:00Z","last_updated_date":"2023-11-13T13:13:00Z","reference_number":"CHMP/EWP/566/98 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-3_en.pdf"},
    {"id":"36760","name":"ICH: S 1 C (R2): Dose selection for carcinogenicity studies of pharmaceuticals - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2008-04-30T02:00:00Z","last_updated_date":"2008-04-30T02:00:00Z","reference_number":"EMEA/CHMP/ICH/383/1995","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-1-c-r2-dose-selection-carcinogenicity-studies-pharmaceuticals-step-5_en.pdf"},
    {"id":"36798","name":"Discussion paper on the impact of renal immaturity when investigating medicinal products intended for paediatric use","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2004-12-16T01:00:00Z","last_updated_date":"2004-12-16T01:00:00Z","reference_number":"CPMP/PEG/35132/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/discussion-paper-impact-renal-immaturity-when-investigating-medicinal-products-intended-paediatric-use_en.pdf"},
    {"id":"36817","name":"Draft International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products GL52 on bioequivalence: blood-level bioequivalence study","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-12-16 - 2014-05-31","first_published_date":"2013-12-16T19:30:00Z","last_updated_date":"2013-12-16T19:30:00Z","reference_number":"EMA/CVMP/VICH/751935/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-international-cooperation-harmonisation-technical-requirements-registration-veterinary-medicinal-products-gl52-bioequivalence-blood-level-bioequivalence-study_en.pdf"},
    {"id":"36837","name":"Carglumic acid dispersible tablets 200 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315238/2014 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/carglumic-acid-dispersible-tablets-200-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"36891","name":"Concept paper on a guideline on the evaluation of medicinal products indicated for treatment of influenza","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-05-04 - 2017-07-31","first_published_date":"2017-05-04T18:29:00Z","last_updated_date":"2017-05-04T18:29:00Z","reference_number":"EMA/CHMP/EWP/808940/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-evaluation-medicinal-products-indicated-treatment-influenza_en.pdf"},
    {"id":"36906","name":"Draft reflection paper on the use of third and fourth generation cephalosporins in food-producing animals in the European Union: Development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-02-18T01:00:00Z","last_updated_date":"2008-02-18T01:00:00Z","reference_number":"EMEA/CVMP/SAGAM/81730/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-third-and-fourth-generation-cephalosporins-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"36957","name":"Points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with st segment elevation acute myocardial infarction (STEMI)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-06-26T02:00:00Z","last_updated_date":"2003-06-26T02:00:00Z","reference_number":"CPMP/EWP/967/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-clinical-development-fibrinolytic-medicinal-products-treatment-patients-st-segment-elevation-acute-myocardial-infarction-stemi_en.pdf"},
    {"id":"36978","name":"Draft guideline on the clinical development of medicinal products intended for the treatment of pain - Second draft","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-12-21 - 2016-03-31","first_published_date":"2015-12-21T13:05:00Z","last_updated_date":"2015-12-21T13:05:00Z","reference_number":"EMA/CHMP/970057/2011 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-development-medicinal-products-intended-treatment-pain-second-draft_en.pdf"},
    {"id":"36980","name":"Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-05-19T02:00:00Z","last_updated_date":"1999-05-19T02:00:00Z","reference_number":"CPMP/EWP/562/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-clinical-investigation-medicinal-products-chronic-treatment-patients-chronic-obstructive-pulmonary-disease-copd_en.pdf"},
    {"id":"36990","name":"Concept paper on potency declaration / labelling for biological medicinal products which contain modified proteins as active substance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-02-17 - 2011-05-17","first_published_date":"2011-03-14T02:00:00Z","last_updated_date":"2011-03-14T02:00:00Z","reference_number":"EMA/CHMP/BWP/776563/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-potency-declaration-labelling-biological-medicinal-products-which-contain-modified-proteins-active-substance_en.pdf"},
    {"id":"37028","name":"ICH: Q 4 B Annex 1: Annex to regulatory acceptance of analytical procedures and/or acceptance criteria (RAAPAC) - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2006-06-01T02:00:00Z","reference_number":"EMEA/CHMP/ICH/222063/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-1-annex-regulatory-acceptance-analytical-procedures-andor-acceptance-criteria-raapac-step-3_en.pdf"},
    {"id":"37034","name":"Guideline on declaration of storage conditions","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-19T01:00:00Z","last_updated_date":"2007-11-19T01:00:00Z","reference_number":"CPMP/QWP/609/96/Rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-declaration-storage-conditions_en.pdf"},
    {"id":"37063","name":"Guideline on good pharmacovigilance practices (GVP) - Module IV – Pharmacovigilance audits (Rev. 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-12-12T11:00:00Z","last_updated_date":"2015-08-11T11:00:00Z","reference_number":"EMA/228028/2012 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-iv-pharmacovigilance-audits-rev-1_en.pdf"},
    {"id":"37080","name":"Development pharmaceutics for biotechnological and biological products (CPMP/BWP/328/99)\n\nAnnex to note for guidance on development pharmaceutics (CPMP/QWP/155/96)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1999-10-21T02:00:00Z","last_updated_date":"1999-10-21T02:00:00Z","reference_number":"CPMP/BWP/328/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/development-pharmaceutics-biotechnological-and-biological-products-cpmpbwp32899-annex-note-guidance-development-pharmaceutics-cpmpqwp15596_en.pdf"},
    {"id":"37119","name":"Final ICH Concept Paper for Topic E16: Pharmacogenomic (PG) biomarker qualification: format and data standards","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-06-16T02:00:00Z","last_updated_date":"2008-06-16T02:00:00Z","reference_number":"EMEA/CHMP/190395/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/final-ich-concept-paper-topic-e16-pharmacogenomic-pg-biomarker-qualification-format-and-data-standards_en.pdf"},
    {"id":"37183","name":"Reflection paper on the publication of the CVMP’s negative opinion and refusal to recommend the granting of a marketing authorisation for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-07-12T02:00:00Z","last_updated_date":"2007-07-12T02:00:00Z","reference_number":"EMEA/CVMP/459912/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-publication-cvmps-negative-opinion-and-refusal-recommend-granting-marketing-authorisation-veterinary-medicinal-products_en.pdf"},
    {"id":"37199","name":"Concept paper for a guideline on the quality of porcine trypsin used in the manufacture of human biological medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-09-22 - 2011-12-31","first_published_date":"2011-10-12T15:35:00Z","last_updated_date":"2011-10-12T15:35:00Z","reference_number":"EMA/CHMP/BWP/367751/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-quality-porcine-trypsin-used-manufacture-human-biological-medicinal-products_en.pdf"},
    {"id":"37247","name":"Reflection paper on poorly extractable and/or non-radiolabelled substances","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-03-29T11:25:00Z","last_updated_date":"2024-07-26T11:25:00Z","reference_number":"EMA/CVMP/ERA/349254/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-poorly-extractable-or-non-radiolabelled-substances_en.pdf"},
    {"id":"37249","name":"Questions and answers on benzalkonium chloride used as an excipient in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/495737/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-benzalkonium-chloride-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"37251","name":"Draft concept paper on the need for revision of the guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-03-30 - 2015-06-30","first_published_date":"2015-03-30T17:00:00Z","last_updated_date":"2015-03-30T17:00:00Z","reference_number":"EMA/CHMP/QWP/126334/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-need-revision-guideline-requirements-chemical-and-pharmaceutical-quality-documentation-concerning-investigational-medicinal-products-clinical-trials-revision-1_en.pdf"},
    {"id":"37269","name":"Concept paper on the development of a guideline on the demonstration of therapeutic equivalence for locally applied and locally acting products in the gastrointestinal tract - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-10-01 - 2013-12-31","first_published_date":"2013-10-01T16:05:00Z","last_updated_date":"2013-10-01T16:05:00Z","reference_number":"EMA/CHMP/558326/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-demonstration-therapeutic-equivalence-locally-applied-and-locally-acting-products-gastrointestinal-tract-revision-1_en.pdf"},
    {"id":"37272","name":"Draft entecavir film-coated tablets 0.5 and 1 mg, oral solution 0.05mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-10-01 - 2016-01-01","first_published_date":"2015-10-06T17:00:00Z","last_updated_date":"2015-10-06T17:00:00Z","reference_number":"EMA/CHMP/PKWP/151748/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-entecavir-film-coated-tablets-05-and-1-mg-oral-solution-005mg-ml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"37283","name":"Guideline on data monitoring committees","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-07-27T02:00:00Z","last_updated_date":"2005-07-27T02:00:00Z","reference_number":"EMEA/CHMP/EWP/5872/03 Corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-monitoring-committees_en.pdf"},
    {"id":"37297","name":"Reflection paper on use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health (Rev.1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-02-20T16:25:00Z","last_updated_date":"2014-02-20T16:25:00Z","reference_number":"EMA/CVMP/AWP/119489/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-pleuromutilins-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health-rev1_en.pdf"},
    {"id":"37302","name":"Draft guideline on the development of new medicinal products for the treatment of Crohn's disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-02-22T01:00:00Z","last_updated_date":"2007-02-22T01:00:00Z","reference_number":"CPMP/EWP/2284/99 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-new-medicinal-products-treatment-crohns-disease_en.pdf"},
    {"id":"37304","name":"Draft concept paper on the need for a reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-06-28 - 2013-09-30","first_published_date":"2013-06-28T18:50:00Z","last_updated_date":"2014-01-16T16:50:01Z","reference_number":"EMA/CHMP/297149/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-need-reflection-paper-statistical-methodology-comparative-assessment-quality-attributes-drug-development_en.pdf"},
    {"id":"37354","name":"Draft guideline on clinical investigation of medicinal products for the treatment of venous thromboembolic disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-01 - 2015-09-30","first_published_date":"2015-04-01T13:25:00Z","last_updated_date":"2015-04-01T13:25:00Z","reference_number":"EMA/CHMP/41230/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-venous-thromboembolic-disease_en.pdf"},
    {"id":"37355","name":"Annex to the guideline on clinical evaluation of new vaccines: summary of product characteristics requirements - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-10-18T02:00:00Z","last_updated_date":"2006-10-18T02:00:00Z","reference_number":"EMEA/CHMP/VWP/382702/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-guideline-clinical-evaluation-new-vaccines-summary-product-characteristics-requirements-superseded_en.pdf"},
    {"id":"37359","name":"Guideline on good pharmacovigilance practices: Module I – Pharmacovigilance systems and their quality systems","type":"scientific-guideline","status":"Adopted","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-06-25T21:18:20Z","last_updated_date":"2012-06-25T21:18:20Z","reference_number":"EMA/541760/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-i-pharmacovigilance-systems-and-their-quality-systems_en.pdf"},
    {"id":"37367","name":"Concept paper on development of a CPMP points to consider on xenogeneic cell therapy","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2000-11-16T01:00:00Z","last_updated_date":"2000-11-16T01:00:00Z","reference_number":"CPMP/BWP/3326/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-cpmp-points-consider-xenogeneic-cell-therapy_en.pdf"},
    {"id":"37391","name":"Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-11-16T01:00:00Z","last_updated_date":"2006-11-16T01:00:00Z","reference_number":"CPMP/EWP/552/95 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-treatment-primary-osteoporosis_en.pdf"},
    {"id":"37426","name":"Vismodegib hard capsule 150 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-08-03T14:00:00Z","last_updated_date":"2018-08-03T14:00:00Z","reference_number":"EMA/CHMP/800794/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vismodegib-hard-capsule-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"37428","name":"Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-06-15T17:10:00Z","last_updated_date":"2012-06-15T17:10:00Z","reference_number":"EMA/CHMP/BMWP/403543/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical-and-clinical-issues_en.pdf"}    {"id":"37436","name":"Draft guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision) - Superseded","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/CPMP/VEG/4717/03- Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-dossier-structure-and-content-pandemic-influenza-vaccine-marketing-authorisation-application-revision-superseded_en.pdf"},
    {"id":"37456","name":"Guideline on good pharmacovigilance practices: Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators (Rev. 2) (superseded)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-02-28T10:30:00Z","last_updated_date":"2017-03-30T17:00:00Z","reference_number":"EMA/204715/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools-effectiveness-indicators-rev-2-superseded_en.pdf"},
    {"id":"37488","name":"Position statement on the use of tumourigenic cells of human origin for the production of biological and biotechnological medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-03-01T01:00:00Z","last_updated_date":"2001-03-01T01:00:00Z","reference_number":"CPMP/BWP/1143/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-statement-use-tumourigenic-cells-human-origin-production-biological-and-biotechnological-medicinal-products_en.pdf"},
    {"id":"37496","name":"Guideline on good pharmacovigilance practices (GVP) - Module VIII Addendum I – Member States' requirements for transmission of information on non-interventional post-authorisation safety studies (Rev. 1) (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-04-25T17:00:00Z","last_updated_date":"2013-04-25T17:00:00Z","reference_number":"EMA/395730/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-addendum-i-member-states-requirements-transmission-information-non-interventional-post-authorisation-safety-studies-rev-1-superseded_en.pdf"},
    {"id":"37504","name":"Overview of comments received on 'Draft Guideline on manufacture of the finished dosage form' (EMA/CHMP/QWP/245074) - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-11-17T18:30:00Z","last_updated_date":"2017-11-17T18:30:00Z","reference_number":"EMA/CHMP/QWP/104223/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-draft-guideline-manufacture-finished-dosage-form-emachmpqwp245074-revision-1_en.pdf"},
    {"id":"37509","name":"Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T14:25:00Z","last_updated_date":"2016-04-29T14:25:00Z","reference_number":"EMA/CHMP/BWP/187338/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-process-validation-manufacture-biotechnology-derived-active-substances-and-data-be-provided-regulatory-submission_en.pdf"},
    {"id":"37539","name":"Concept paper on transferring quality control methods validated in collaborative trials to a product / laboratory specific context","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-07-18 - 2014-10-31","first_published_date":"2014-07-18T15:35:00Z","last_updated_date":"2014-07-18T15:35:00Z","reference_number":"CHMP/CVMP/JEG-3Rs/94304/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-transferring-quality-control-methods-validated-collaborative-trials-product-laboratory-specific-context_en.pdf"},
    {"id":"37543","name":"Draft guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"CPMP/EWP/563/95 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-parkinsons-disease_en.pdf"},
    {"id":"37550","name":"Draft information in the package leaflet for fructose and sorbitol in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (CPMP/463/00 Rev. 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-04 - 2016-08-03","first_published_date":"2016-05-04T17:00:00Z","last_updated_date":"2016-05-04T17:00:00Z","reference_number":"EMA/CHMP/460886/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-fructose-and-sorbitol-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use-cpmp-463-00-rev-1_en.pdf"},
    {"id":"37579","name":"Reflection paper on design modifications of gene therapy medicinal products during development","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-02-09T14:52:00Z","last_updated_date":"2012-02-09T14:52:00Z","reference_number":"EMA/CAT/GTWP/44236/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-design-modifications-gene-therapy-medicinal-products-during-development_en.pdf"},
    {"id":"37625","name":"Draft erlotinib product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/418988/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-erlotinib-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"37671","name":"Note for guidance on manufacture of the finished dosage form - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-04-01T02:00:00Z","last_updated_date":"1996-04-01T02:00:00Z","reference_number":"CPMP/QWP/486/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-manufacture-finished-dosage-form-first-version_en.pdf"},
    {"id":"37676","name":"ICH: S6(R1): Preclinical safety evaluation of biotechnology - derived pharmaceuticals - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-09-30T02:00:00Z","last_updated_date":"2011-07-25T02:00:00Z","reference_number":"CPMP/ICH/302/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s6r1-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals-step-5_en.pdf"},
    {"id":"37717","name":"Emtricitabine/rilpivirine/tenofovir disoproxil film-coated tablets 200 mg/25 mg/245 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/CHMP/805532/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/emtricitabinerilpivirinetenofovir-disoproxil-film-coated-tablets-200-mg25-mg245-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"37718","name":"Public Statement on the risks associated with the use of herbal products containing Aristolochia species","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-23T01:00:00Z","last_updated_date":"2005-11-23T01:00:00Z","reference_number":"EMEA/HMPC/138381/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-risks-associated-use-herbal-products-containing-aristolochia-species_en.pdf"},
    {"id":"37719","name":"Draft concept paper on the impact of lung and heart immaturity when\n\ninvestigating medicinal products intended for neonatal use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-11-18T01:00:00Z","last_updated_date":"2005-11-18T01:00:00Z","reference_number":"EMEA/CHMP/114218/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-impact-lung-and-heart-immaturity-when-investigating-medicinal-products-intended-neonatal-use_en.pdf"},
    {"id":"37737","name":"Guideline on the quality aspects of single-dose veterinary spot-on products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-02-11T01:00:00Z","last_updated_date":"2009-02-11T01:00:00Z","reference_number":"EMEA/CVMP/QWP/ 544461/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-aspects-single-dose-veterinary-spot-products_en.pdf"},
    {"id":"37765","name":"Information for the package leaflet regarding phosphates used as excipients in eye drops","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/632775/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/information-package-leaflet-regarding-phosphates-used-excipients-eye-drops_en.pdf"},
    {"id":"37766","name":"ICH guideline for good clinical practice E6(R2) - Step 5 - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-07-01T02:00:00Z","last_updated_date":"2016-12-15T01:00:00Z","reference_number":"EMA/CHMP/ICH/135/1995","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-step-5-revision-2_en.pdf"},
    {"id":"37794","name":"Guideline on the use of near-infrared spectroscopy by the pharmaceutical industry and the data requirements for new submissions and variations","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-06-05T16:00:00Z","last_updated_date":"2014-06-05T16:00:00Z","reference_number":"EMEA/CHMP/CVMP/QWP/17760/2009 Rev2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-near-infrared-spectroscopy-pharmaceutical-industry-and-data-requirements-new-submissions-and-variations_en.pdf"},
    {"id":"37796","name":"ICH: S 4: Duration of chronic toxicity testing in animals (rodent and non rodent toxicity testing) - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-11-30T01:00:00Z","last_updated_date":"1998-11-30T01:00:00Z","reference_number":"CPMP/ICH/300/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-4-duration-chronic-toxicity-testing-animals-rodent-and-non-rodent-toxicity-testing-step-5_en.pdf"},
    {"id":"37834","name":"Note for guidance on process validation","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-03-01T01:00:00Z","last_updated_date":"2001-03-01T01:00:00Z","reference_number":"CPMP/QWP/848/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-process-validation_en.pdf"},
    {"id":"37840","name":"Guideline on quality data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-01-03T18:21:00Z","last_updated_date":"2017-01-03T18:21:00Z","reference_number":"EMA/CVMP/QWP/128710/2004-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-data-requirements-veterinary-medicinal-products-intended-minor-use-or-minor-species-mumslimited-market_en.pdf"},
    {"id":"37897","name":"Guideline on the declaration of the quantitative composition / potency labelling of biological medicinal products that contain modified proteins as active substance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T17:55:00Z","last_updated_date":"2014-03-21T17:55:00Z","reference_number":"EMA/CHMP/BWP/85290/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-declaration-quantitative-composition-potency-labelling-biological-medicinal-products-contain-modified-proteins-active-substance_en.pdf"},
    {"id":"37920","name":"Recommendation on the need for revision of (CHMP) (note for guidance on the investigation of bioavailability and bioequivalence)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-05-24T02:00:00Z","last_updated_date":"2007-05-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/200943/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/recommendation-need-revision-chmp-note-guidance-investigation-bioavailability-and-bioequivalence_en.pdf"},
    {"id":"37924","name":"Note for guidance on pharmaceutical development","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2010-01-12T01:00:00Z","last_updated_date":"2010-01-12T01:00:00Z","reference_number":"EMEA/CHMP/167068/2004 - ICH","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-pharmaceutical-development_en.pdf"},
    {"id":"37932","name":"Concept paper on the need for a guideline on the clinical investigation of specific immunoglobulins","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/BPWP/161104/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-clinical-investigation-specific-immunoglobulins_en.pdf"},
    {"id":"37936","name":"Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/CVMP/IWP/439467/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-demonstration-possible-impact-maternally-derived-antibodies-vaccine-efficacy-young-animals_en.pdf"},
    {"id":"37939","name":"Draft ICH guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - Questions and answers - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-31 - 2016-08-31","first_published_date":"2016-05-31T13:25:00Z","last_updated_date":"2016-05-31T13:25:00Z","reference_number":"EMA/CHMP/ICH/320985/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-s3a-note-guidance-toxicokinetics-assessment-systemic-exposure-toxicity-studies-questions-and-answers-first-version_en.pdf"},
    {"id":"37992","name":"Guideline on the summary of product characteristics for anthelmintics - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-07-12T02:09:00Z","last_updated_date":"2007-07-12T02:09:00Z","reference_number":"EMEA/CVMP/EWP/170208/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-summary-product-characteristics-anthelmintics-first-version_en.pdf"},
    {"id":"38034","name":"Guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-02-20T01:00:00Z","last_updated_date":"2006-02-20T01:00:00Z","reference_number":"EMEA/HMPC/246816/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-agricultural-collection-practice-gacp-starting-materials-herbal-origin-superseded_en.pdf"},
    {"id":"38035","name":"Guideline on the clinical investigation of hepatitis B immunoglobulins","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T10:35:00Z","last_updated_date":"2015-07-24T10:35:00Z","reference_number":"EMA/CHMP/BPWP/585257/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-hepatitis-b-immunoglobulins_en.pdf"},
    {"id":"38054","name":"Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-08-05T02:00:00Z","last_updated_date":"2010-08-25T02:00:00Z","reference_number":"EMEA/CHMP/EWP/431734/2008 Rev. 2 Corrigendum","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-attention-deficit-hyperactivity-disorder-adhd_en.pdf"},
    {"id":"38061","name":"Guideline on the minimum quality and non-clinical data for certification of advanced therapy medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-06-19T02:00:00Z","last_updated_date":"2010-11-10T01:00:00Z","reference_number":"EMEA/CAT/486831/2008/corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-minimum-quality-and-non-clinical-data-certification-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"38062","name":"Draft guideline on clinical investigation of recombinant and human plasma-derived factor IX products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-01-06 - 2015-02-07","first_published_date":"2015-01-06T18:00:00Z","last_updated_date":"2015-01-06T18:00:00Z","reference_number":"EMA/CHMP/BPWP/144552/2009 rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-ix-products-revision-1_en.pdf"},
    {"id":"38077","name":"ICH: S 7 A: Safety pharmacology studies for human pharmaceuticals - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-11-30T01:00:00Z","last_updated_date":"2000-11-30T01:00:00Z","reference_number":"CPMP/ICH/539/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-7-safety-pharmacology-studies-human-pharmaceuticals-step-5_en.pdf"},
    {"id":"38088","name":"Draft reflection paper on gender differences in cardiovascular diseases","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-12-14T01:00:00Z","last_updated_date":"2006-12-14T01:00:00Z","reference_number":"EMEA/CHMP/EWP/498145/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-gender-differences-cardiovascular-diseases_en.pdf"},
    {"id":"38089","name":"Guideline on core summary of product characteristics and package leaflet for radiopharmaceuticals","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-10-03T11:37:00Z","last_updated_date":"2011-10-03T11:37:00Z","reference_number":"EMA/CHMP/167834/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-summary-product-characteristics-and-package-leaflet-radiopharmaceuticals_en.pdf"},
    {"id":"38112","name":"VICH GL25: Biologicals: Testing of residual formaldehyde - Step 7","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-04-30T02:00:00Z","last_updated_date":"2002-04-30T02:00:00Z","reference_number":"CVMP/VICH/095/01-Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl25-biologicals-testing-residual-formaldehyde-step-7_en.pdf"},
    {"id":"38125","name":"Concept paper on guidance for DNA vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-03-30 - 2012-06-30","first_published_date":"2012-03-30T13:00:00Z","last_updated_date":"2012-03-30T13:00:00Z","reference_number":"EMEA/CHMP/308136/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guidance-dna-vaccines_en.pdf-0"},
    {"id":"38170","name":"Position statement on DNA and host cell proteins (HCP) impurities, routine testing versus validation studies - partly superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1997-06-10T02:00:00Z","last_updated_date":"2023-10-26T09:45:00Z","reference_number":"EMEA/CPMP/BWP/382/97","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-statement-dna-and-host-cell-proteins-hcp-impurities-routine-testing-versus-validation-studies-partly-superseded_en.pdf"},
    {"id":"38226","name":"Concept paper on similar biological product containing recombinant interferon beta","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-03-18 - 2010-06-11","first_published_date":"2010-04-06T04:00:00Z","last_updated_date":"2010-04-06T04:00:00Z","reference_number":"EMA/CHMP/BMWP/86572/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-similar-biological-product-containing-recombinant-interferon-beta_en.pdf"},
    {"id":"38251","name":"Zonisamide hard capsules 25, 50 and 100 mg, orodispersible tablets 25, 50, 100 and 300 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-11-01T17:40:17Z","reference_number":"EMA/CHMP/159882/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/zonisamide-hard-capsules-25-50-and-100-mg-orodispersible-tablets-25-50-100-and-300-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"38264","name":"Note for guidance on the clinical investigation of plasma derived antithrombin products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-01-17T01:00:00Z","last_updated_date":"2002-01-17T01:00:00Z","reference_number":"CPMP/BPWG/2220/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-plasma-derived-antithrombin-products_en.pdf"},
    {"id":"38314","name":"Draft guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-11-15 - 2017-02-28","first_published_date":"2016-11-15T13:00:00Z","last_updated_date":"2016-11-15T13:00:00Z","reference_number":"EMEA/CHMP/SWP/28367/07 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products-revision-1_en.pdf"},
    {"id":"38332","name":"Guideline on good pharmacogenomic practice - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-03-19T15:00:00Z","last_updated_date":"2018-07-13T16:00:00Z","reference_number":"EMA/CHMP/718998/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacogenomic-practice-first-version_en.pdf"},
    {"id":"38339","name":"VICH GL49: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: validation of analytical methods used in residue depletion studies","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-04-07T02:00:00Z","last_updated_date":"2015-02-27T17:30:00Z","reference_number":"EMA/CVMP/VICH/463202/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl49-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-animals-validation-analytical-methods-used-residue-depletion-studies_en.pdf"},
    {"id":"38359","name":"Draft guideline on good pharmacovigilance practices (GVP) - Module V – Risk management systems (Rev 2)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-29 - 2016-05-31","first_published_date":"2016-02-29T13:00:00Z","last_updated_date":"2016-02-29T13:00:00Z","reference_number":"EMA/838713/2011 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-v-risk-management-systems-rev-2_en.pdf"},
    {"id":"38381","name":"Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-05-05 - 2011-08-31","first_published_date":"2011-05-17T04:00:00Z","last_updated_date":"2011-05-17T04:00:00Z","reference_number":"EMA/CVMP/ERAWP/409328/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-mitigation-measures-related-environmental-risk-assessment-veterinary-medicinal-products_en.pdf-0"},
    {"id":"38385","name":"Concept paper on the revision of the 'Guideline on the environmental risk assessment of medicinal products for human use' - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-05-04 - 2016-10-31","first_published_date":"2016-05-04T13:00:00Z","last_updated_date":"2016-05-04T13:00:00Z","reference_number":"EMA/CHMP/SWP/65429/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-environmental-risk-assessment-medicinal-products-human-use-first-version_en.pdf"},
    {"id":"38423","name":"ICH: Q 4 B Annex 7: To note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on dissolution test general chapter - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2008-12-01T01:00:00Z","reference_number":"EMEA/CHMP/ICH/645469/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-7-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-dissolution-test-general-chapter-step-3_en.pdf"},
    {"id":"38444","name":"Guideline on core SmPC and Package Leaflet for nanocolloidal technetium (99mTc) albumin - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-02-03T16:30:00Z","last_updated_date":"2017-02-03T16:30:00Z","reference_number":"EMA/CHMP/39283/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-and-package-leaflet-nanocolloidal-technetium-99mtc-albumin-first-version_en.pdf"},
    {"id":"38516","name":"Annexes to CPMP/ICH/283/95 impurities: Guideline for residual solvents andCVMP/VICH/502/99 guideline on impurities: Residual solvents - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-02-10T01:00:00Z","last_updated_date":"2013-03-12T12:05:00Z","reference_number":"CPMP/QWP/450/03 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annexes-cpmpich28395-impurities-guideline-residual-solvents-andcvmpvich50299-guideline-impurities-residual-solvents-revision-1_en.pdf"},
    {"id":"38541","name":"Core summary of product characteristics for pandemic-influenza vaccines - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/VWP/193031/2004 Rev- 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/core-summary-product-characteristics-pandemic-influenza-vaccines-superseded_en.pdf"},
    {"id":"38554","name":"First draft guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-12-14 - 2013-06-30","first_published_date":"2012-12-14T18:24:00Z","last_updated_date":"2012-12-14T18:24:00Z","reference_number":"EMEA/CHMP/BMWP/32775/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/first-draft-guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-recombinant-human-insulin-and-insulin-analogues_en.pdf"},
    {"id":"38558","name":"Guideline for the conduct of efficacy studies for intramammary products for use in cattle - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-03-08T01:00:00Z","last_updated_date":"2000-03-08T01:00:00Z","reference_number":"EMEA/CVMP/344/99-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-efficacy-studies-intramammary-products-use-cattle-revision-1_en.pdf"},
    {"id":"38564","name":"Reflection paper on the use of fumigants","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-10-26T02:00:00Z","last_updated_date":"2006-10-26T02:00:00Z","reference_number":"EMEA/HMPC/125562/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-fumigants_en.pdf"},
    {"id":"38583","name":"Position paper on potential medication errors in the context of benefit-risk balance and risk minimisation measures","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-06-01 - 2012-11-30","first_published_date":"2012-06-01T19:00:00Z","last_updated_date":"2012-06-01T19:00:00Z","reference_number":"EMA/274183/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-potential-medication-errors-context-benefit-risk-balance-and-risk-minimisation-measures_en.pdf-0"},
    {"id":"38588","name":"Concept paper on the need for the development of a paediatric addendum to the chmp guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/CHMP/EWP/644261/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-development-paediatric-addendum-chmp-guideline-clinical-investigations-medicinal-products-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"38599","name":"Points to consider on the need for assessment of reproductive toxicity of human insulin analogues","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2002-03-01T01:00:00Z","last_updated_date":"2002-03-01T01:00:00Z","reference_number":"CPMP/SWP/2600/01 Final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-need-assessment-reproductive-toxicity-human-insulin-analogues_en.pdf"},
    {"id":"38629","name":"ICH: Q 5 E: Comparability of biotechnological/biological products - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-06-01T02:00:00Z","last_updated_date":"2005-06-01T02:00:00Z","reference_number":"CPMP/ICH/5721/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-e-comparability-biotechnologicalbiological-products-step-5_en.pdf"},
    {"id":"38639","name":"Note for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1998-01-28T01:00:00Z","last_updated_date":"1998-01-28T01:00:00Z","reference_number":"CPMP/QWP/159/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-maximum-shelf-life-sterile-products-human-use-after-first-opening-or-following-reconstitution_en.pdf"},
    {"id":"38728","name":"Draft paliperidone palmitate depot suspension for injection 25, 50, 75, 100 and 150 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-01 - 2016-10-31","first_published_date":"2016-08-01T17:00:00Z","last_updated_date":"2016-08-01T17:00:00Z","reference_number":"EMA/CHMP/474825/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-paliperidone-palmitate-depot-suspension-injection-25-50-75-100-and-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"38738","name":"Guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-12-02T00:09:21Z","last_updated_date":"2009-12-02T00:09:21Z","reference_number":"EMEA/CHMP/EWP/356954/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigations-medicinal-products-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"38775","name":"Concept paper on the need for revision of the guideline on non-clinical local tolerance testing of medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-07-21 - 2011-10-30","first_published_date":"2011-07-26T04:00:00Z","last_updated_date":"2011-07-26T04:00:00Z","reference_number":"EMA/CHMP/SWP/708666/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-non-clinical-local-tolerance-testing-medicinal-products_en.pdf"},
    {"id":"38798","name":"ICH: M 5 EWG: Routes of administration controlled vocabulary - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-05-01T02:00:00Z","last_updated_date":"2005-05-01T02:00:00Z","reference_number":"CHMP/ICH/175860/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-5-ewg-routes-administration-controlled-vocabulary-step-5_en.pdf"},
    {"id":"38799","name":"Reflection paper on the pharmaceutical development of intravenous medicinal products containing active substances solubilised in micellar systems","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2012-03-20T17:00:00Z","last_updated_date":"2012-03-20T17:00:00Z","reference_number":"EMA/CHMP/QWP/799402/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-pharmaceutical-development-intravenous-medicinal-products-containing-active-substances-solubilised-micellar-systems_en.pdf"},
    {"id":"38813","name":"Information for the package leaflet regarding fructose and sorbitol used as excipients in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T02:00:00Z","last_updated_date":"2017-10-09T02:00:00Z","reference_number":"EMA/CHMP/460886/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/information-package-leaflet-regarding-fructose-and-sorbitol-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"38816","name":"Note for guidance on parametric release","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-03-01T01:00:00Z","last_updated_date":"2001-03-01T01:00:00Z","reference_number":"CPMP/QWP/3015/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-parametric-release_en.pdf"},
    {"id":"38840","name":"Draft guideline on good pharmacovigilance practices (GVP): Product-or population-specific considerations I: Vaccines for prophylaxis against infectious diseases","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-04-12 - 2013-06-12","first_published_date":"2013-04-12T19:55:00Z","last_updated_date":"2013-04-12T19:55:00Z","reference_number":"EMA/488220/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-i-vaccines-prophylaxis-against-infectious-diseases_en.pdf"},
    {"id":"38856","name":"Draft guideline on good pharmacovigilance practices (GVP): Module XVI Addendum I – Educational materials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-04-27 - 2015-06-30","first_published_date":"2015-04-27T14:58:00Z","last_updated_date":"2015-04-27T14:58:00Z","reference_number":"EMA/61341/2015 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-i-educational-materials_en.pdf"},
    {"id":"38880","name":"VICH GL11: Impurities in new veterinary medicinal products - Revision at step 9 for consultation at step 4","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-06-15T02:00:00Z","last_updated_date":"2005-06-15T02:00:00Z","reference_number":"CVMP/VICH/838/99-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl11-impurities-new-veterinary-medicinal-products-revision-step-9-consultation-step-4_en.pdf"},
    {"id":"38885","name":"Concept paper on revision of the note for guidance on the use of near infrared spectroscopy by the pharmaceutical industry and the data requirements for new submissions and variations","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-06-27T02:00:00Z","last_updated_date":"2006-06-27T02:00:00Z","reference_number":"EMEA/CHMP/CVMP/QWP/173698/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-note-guidance-use-near-infrared-spectroscopy-pharmaceutical-industry-and-data-requirements-new-submissions-and-variations_en.pdf"},
    {"id":"38899","name":"Appendix 1 to the guideline on clinical evaluation of diagnostic agents (CPMP/EWP/1119/98 REV. 1) on imaging agents","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/EWP/321180/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-1-guideline-clinical-evaluation-diagnostic-agents-cpmpewp111998-rev-1-imaging-agents_en.pdf"},
    {"id":"38904","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use topic E 2 E: Pharmacovigilance planning - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-12-31T01:00:00Z","last_updated_date":"2004-12-31T01:00:00Z","reference_number":"CPMP/ICH/5716/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-topic-e-2-e-pharmacovigilance-planning-step-5_en.pdf"},
    {"id":"38931","name":"Draft guideline on good pharmacovigilance practices (GVP) - Module IX Addendum I – Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-08 - 2016-10-14","first_published_date":"2016-08-08T19:00:00Z","last_updated_date":"2016-08-08T19:00:00Z","reference_number":"EMA/209012/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal-detection-spontaneous-reports-suspected-adverse-reactions_en.pdf"},
    {"id":"38944","name":"Concept paper on the need to revise the points to consider on adjustment for baseline covariates","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-29 - 2012-05-30","first_published_date":"2012-02-29T11:15:00Z","last_updated_date":"2012-02-29T11:15:00Z","reference_number":"EMA/CHMP/965150/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revise-points-consider-adjustment-baseline-covariates_en.pdf"},
    {"id":"38961","name":"Draft guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2005-09-15T02:00:00Z","last_updated_date":"2005-09-15T02:00:00Z","reference_number":"EMEA/CHMP/EWP/561/98 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis-revision-1_en.pdf"},
    {"id":"38986","name":"Draft guideline on the use of pharmacogenetic methodologies in the  pharmacokinetic evaluation of medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-04-22 - 2010-10-31","first_published_date":"2010-05-06T04:00:00Z","last_updated_date":"2010-05-06T04:00:00Z","reference_number":"EMA/CHMP/37646/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-use-pharmacogenetic-methodologies-pharmacokinetic-evaluation-medicinal-products_en.pdf"},
    {"id":"38995","name":"Concept paper on the development of a CHMP guideline on the non-clinical requirements to support early phase I clinical trials with pharmaceutical compounds","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2006-03-23 - 2006-06-30","first_published_date":"2006-03-23T02:00:00Z","last_updated_date":"2006-03-23T02:00:00Z","reference_number":"EMEA/CHMP/SWP/91850/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-chmp-guideline-non-clinical-requirements-support-early-phase-i-clinical-trials-pharmaceutical-compounds_en.pdf"},
    {"id":"39002","name":"Concept paper on the development of a CVMP note for guidance on the stability test data to be submited for variation applications to a marketing authorisation","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2003-12-15T01:00:00Z","last_updated_date":"2003-12-15T01:00:00Z","reference_number":"EMEA/CVMP/1027/03-CONS.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-cvmp-note-guidance-stability-test-data-be-submited-variation-applications-marketing-authorisation_en.pdf"},
    {"id":"39008","name":"Guideline on user safety for pharmaceutical veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-01-17T00:09:21Z","last_updated_date":"2005-01-17T00:09:21Z","reference_number":"EMEA/CVMP/543/03-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-user-safety-pharmaceutical-veterinary-medicinal-products_en.pdf-0"},
    {"id":"39029","name":"Guideline on the use of phthalates as excipients in human medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-11-24T11:10:00Z","last_updated_date":"2014-12-16T17:30:00Z","reference_number":"EMA/CHMP/SWP/362974/2012 Corr 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-phthalates-excipients-human-medicinal-products_en.pdf"},
    {"id":"39057","name":"International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products GL52 on bioequivalence: blood-level bioequivalence study","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-09-17T17:52:00Z","last_updated_date":"2015-09-17T17:52:00Z","reference_number":"EMA/CVMP/VICH/751935/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-cooperation-harmonisation-technical-requirements-registration-veterinary-medicinal-products-gl52-bioequivalence-blood-level-bioequivalence-study_en.pdf"},
    {"id":"39103","name":"Note for guidance on virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1996-02-14T01:00:00Z","last_updated_date":"1996-02-14T01:00:00Z","reference_number":"CPMP/BWP/268/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-virus-validation-studies-design-contribution-and-interpretation-studies-validating-inactivation-and-removal-viruses_en.pdf"},
    {"id":"39131","name":"Concept paper - Recommendation for revision of the guideline on the clinical development of medicinal products for the treatment of HIV infection (CPMP/EWP/633/02 REV. 1)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-02-22T01:00:00Z","last_updated_date":"2007-02-22T01:00:00Z","reference_number":"EMEA/CHMP/EWP/42065/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-recommendation-revision-guideline-clinical-development-medicinal-products-treatment-hiv-infection-cpmpewp63302-rev-1_en.pdf"},
    {"id":"39141","name":"Concept paper on concurrent administration of immunological veterinary medicinal products in view of determining day X to be 14 days and consequent revision of the summary-of-product-characteristics guideline for immunol...","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-04-21T02:09:21Z","last_updated_date":"2006-04-21T02:09:21Z","reference_number":"EMEA/CVMP/123846/2006-CONSULTATION","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-concurrent-administration-immunological-veterinary-medicinal-products-view-determining-day-x-be-14-days-and-consequent-revision-summary-product-characteristics-guideline-immunol_en.pdf"},
    {"id":"39142","name":"Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man - Methodological consideration for using progression-free survival or disease-free survival in confirmatory trials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-01-11T11:00:00Z","last_updated_date":"2013-01-11T11:00:00Z","reference_number":"EMA/CHMP/27994/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-1-guideline-evaluation-anticancer-medicinal-products-man-methodological-consideration-using-progression-free-survival-or-disease-free-survival-confirmatory-trials_en.pdf"},
    {"id":"39143","name":"Note for guidance on the clinical investigation of human plasma-derived factor VIII and IX products - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-10-19T02:00:00Z","last_updated_date":"2000-10-19T02:00:00Z","reference_number":"CPMP/BPWG/198/95 rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-investigation-human-plasma-derived-factor-viii-and-ix-products-superseded_en.pdf"},
    {"id":"39182","name":"Draft guideline on quality data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-03 - 2016-07-31","first_published_date":"2016-02-03T13:00:00Z","last_updated_date":"2016-02-03T13:00:00Z","reference_number":"EMA/CVMP/QWP/128710/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-data-requirements-veterinary-medicinal-products-intended-minor-use-or-minor-species-mums-limited-market_en.pdf"},
    {"id":"39191","name":"Concept paper on the development of a CPMP guideline on comparability of biotechnology-derived products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"1998-06-24T02:00:00Z","last_updated_date":"1998-06-24T02:00:00Z","reference_number":"CPMP/BWP//1113/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-cpmp-guideline-comparability-biotechnology-derived-products_en.pdf"},
    {"id":"39198","name":"ICH: Q 4 B Annex 4A: To note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on microbiological examination of non-sterile products: Microbial enumeration tests  general chapter - Ste...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-06-01T02:09:21Z","last_updated_date":"2008-06-01T02:09:21Z","reference_number":"EMEA/CHMP/ICH/308671/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-4-b-annex-4a-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-microbiological-examination-non-sterile-products-microbial-enumeration-tests-general-chapter-ste_en.pdf"},
    {"id":"39209","name":"Draft reflection paper on poorly extractable and or non-radiolabelled substances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-03-20 - 2015-08-31","first_published_date":"2015-03-20T17:00:00Z","last_updated_date":"2015-03-20T17:00:00Z","reference_number":"EMA/CVMP/ERA/349254/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-poorly-extractable-and-or-non-radiolabelled-substances_en.pdf"},
    {"id":"39216","name":"Draft guideline on good pharmacovigilance practices: Module IX - Signal management","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-02-21 - 2012-04-18","first_published_date":"2012-02-22T14:20:00Z","last_updated_date":"2012-02-22T14:20:00Z","reference_number":"EMA/827661/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-ix-signal-management_en.pdf"},
    {"id":"39268","name":"Draft reflection paper on investigation of pharmacokinetics and pharmacodynamics in the obese population","type":"scientific-guideline","status":"Adopted","consultation_date":"2018-02-01 - 2018-07-31","first_published_date":"2018-02-01T13:45:00Z","last_updated_date":"2018-02-01T13:45:00Z","reference_number":"EMA/CHMP/535116/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-investigation-pharmacokinetics-pharmacodynamics-obese-population_en.pdf"},
    {"id":"39292","name":"Guideline on the chemistry of active substances - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-11-21T16:10:00Z","last_updated_date":"2016-11-21T16:10:00Z","reference_number":"EMA/454576/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-chemistry-active-substances-first-version_en.pdf"},
    {"id":"39299","name":"Draft guideline on the development of medicinal products for the treatment of post-traumatic stress disorder (PTSD)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2007-09-20T02:00:00Z","reference_number":"CHMP/EWP/358650/06","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-medicinal-products-treatment-post-traumatic-stress-disorder-ptsd_en.pdf"},
    {"id":"39304","name":"Draft ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-01-31 - 2018-04-30","first_published_date":"2018-01-31T14:15:00Z","last_updated_date":"2018-01-31T14:15:00Z","reference_number":"EMA/CHMP/800789/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ledipasvir-sofosbuvir-film-coated-tablet-90-mg-400-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"39305","name":"Guideline on the clinical investigation of human Anti-D immunoglobulin for intravenous and/or intramuscular use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-09-20T02:00:00Z","last_updated_date":"2007-09-20T02:00:00Z","reference_number":"CPMP/BPWG/575/99 Rev. 1 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-anti-d-immunoglobulin-intravenous-andor-intramuscular-use_en.pdf"},
    {"id":"39311","name":"Concept paper on the development of a guideline on the use of pharmacogenomic methodologies in the pharmacokinetic evaluation of medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/PGxWP/63270/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-use-pharmacogenomic-methodologies-pharmacokinetic-evaluation-medicinal-products_en.pdf"}    {"id":"39346","name":"Production and quality control of cytokine products derived by biotechnological process","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1990-08-31T02:00:00Z","last_updated_date":"1990-08-31T02:00:00Z","reference_number":"3AB3aen","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/production-and-quality-control-cytokine-products-derived-biotechnological-process_en.pdf"},
    {"id":"39372","name":"Guideline on core SmPC for plasma-derived fibrin sealant / haemostatic products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-06-25T12:00:00Z","last_updated_date":"2015-06-25T12:00:00Z","reference_number":"EMA/CHMP/BPWP/598816/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-plasma-derived-fibrin-sealant-haemostatic-products_en.pdf"},
    {"id":"39391","name":"Draft guideline on user safety of topically administered veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-06-27 - 2016-12-31","first_published_date":"2016-06-27T19:40:00Z","last_updated_date":"2016-06-27T19:40:00Z","reference_number":"EMA/CVMP/SWP/721059/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-user-safety-topically-administered-veterinary-medicinal-products_en.pdf"},
    {"id":"39406","name":"Guideline on implementation of risk assessment requirements to control elemental impurities in veterinary medicinal products - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-12-13T12:45:00Z","last_updated_date":"2017-12-13T12:45:00Z","reference_number":"EMA/CVMP/QWP/631010/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-implementation-risk-assessment-requirements-control-elemental-impurities-veterinary-medicinal-products-first-version_en.pdf"},
    {"id":"39433","name":"Draft guideline on Core SPC for human plasma derived and recombinant coagulation factor IX products – Rev. 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"EMEA/CPMP/BPWG/1625/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-spc-human-plasma-derived-and-recombinant-coagulation-factor-ix-products-rev-1_en.pdf"},
    {"id":"39463","name":"Draft guideline on clinical investigation of medicinal products in the treatment of lipid disorders - Revision 1 and 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-12-15 - 2013-03-15","first_published_date":"2012-12-14T18:30:00Z","last_updated_date":"2013-01-31T16:35:00Z","reference_number":"EMA/CHMP/718840/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-lipid-disorders-revision-1-and-2_en.pdf"},
    {"id":"39477","name":"Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1995-11-01T01:00:00Z","last_updated_date":"1995-11-01T01:00:00Z","reference_number":"CHMP/EWP/239/95 final","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-clinical-requirements-locally-applied-locally-acting-products-containing-known-constituents-first-version_en.pdf"},
    {"id":"39512","name":"Points to consider on the evaluation of diagnostic agents","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-11-15T01:00:00Z","last_updated_date":"2001-11-15T01:00:00Z","reference_number":"CPMP/EWP/1119/98","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-evaluation-diagnostic-agents_en.pdf"},
    {"id":"39522","name":"Reflection paper on the use of cocrystals of active substances in medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-07-16T18:10:02Z","last_updated_date":"2015-07-16T18:10:02Z","reference_number":"EMA/CHMP/CVMP/QWP/284008/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-cocrystals-active-substances-medicinal-products_en.pdf"},
    {"id":"39552","name":"Concept paper on the need to revise the guideline on the clinical development of fixed-dose combinations of medicinal products regarding dossier content requirements - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-03-01 - 2013-05-31","first_published_date":"2013-03-01T12:00:00Z","last_updated_date":"2013-03-01T12:00:00Z","reference_number":"EMA/CHMP/779887/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revise-guideline-clinical-development-fixed-dose-combinations-medicinal-products-regarding-dossier-content-requirements-revision-2_en.pdf"},
    {"id":"39555","name":"Guideline on validation of immunoassay for the detection of hepatitis B virus surface antigen (HBSAG) in plasma pools","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-09-21T02:00:00Z","last_updated_date":"2006-09-21T02:00:00Z","reference_number":"EMEA/CHMP/BWP/298390/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-validation-immunoassay-detection-hepatitis-b-virus-surface-antigen-hbsag-plasma-pools_en.pdf"},
    {"id":"39579","name":"Concept paper on the need for revision of the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 REV 1) - Revision 2","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"EMEA/CHMP/EWP/435635/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-evaluation-medicinal-products-indicated-treatment-bacterial-infections-cpmpewp55895-rev-1-revision-2_en.pdf"},
    {"id":"39606","name":"Guideline on the clinical investigation of medicinal products for the treatment of axial spondyloarthritis - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-31T14:33:00Z","last_updated_date":"2018-07-13T14:35:00Z","reference_number":"EMA/CPMP/EWP/4891/03 Rev.1 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-axial-spondyloarthritis-revision-1_en.pdf"},
    {"id":"39612","name":"Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-25T16:00:00Z","last_updated_date":"2017-07-25T16:00:00Z","reference_number":"EMEA/CHMP/SWP/28367/07 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products-revision-1_en.pdf"},
    {"id":"39638","name":"Guideline on non-clinical and clinical development of medicinal products for the treatment of nausea and vomiting associated with cancer chemotherapy","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-12-14T00:09:21Z","last_updated_date":"2006-12-14T00:09:21Z","reference_number":"CPMP/EWP/4937/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-and-clinical-development-medicinal-products-treatment-nausea-and-vomiting-associated-cancer-chemotherapy_en.pdf"},
    {"id":"39648","name":"Draft guideline on the clinical Investigation of Recombinant Factor VIII and IX Products - Superseded","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-07-19T02:00:00Z","last_updated_date":"2007-07-19T02:00:00Z","reference_number":"CPMP/BPWG/1561/99 rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-recombinant-factor-viii-and-ix-products-superseded_en.pdf"},
    {"id":"39652","name":"Draft guideline on core SmPC and Package Leaflet for nanocolloidal technetium (99mTc) albumin","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-01 - 2016-04-30","first_published_date":"2016-02-01T17:46:01Z","last_updated_date":"2016-02-01T17:46:01Z","reference_number":"EMA/CHMP/39283/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-and-package-leaflet-nanocolloidal-technetium-99mtc-albumin_en.pdf"},
    {"id":"39677","name":"Draft CVMP reflection paper on methods found suitable within the EU for demonstrating freedom from extraneous agents of the seeds used for the production of immunological veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-07-17 - 2016-01-31","first_published_date":"2015-07-17T13:15:00Z","last_updated_date":"2015-07-17T13:15:00Z","reference_number":"EMA/CVMP/IWP/251741/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-cvmp-reflection-paper-methods-found-suitable-within-eu-demonstrating-freedom-extraneous-agents-seeds-used-production-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"39679","name":"Guideline on the evaluation of drugs for the treatment of gastro-oesophageal reflux disease","type":"scientific-guideline","status":"Adopted","consultation_date":"2009-12-17 - 2010-06-30","first_published_date":"2011-03-14T02:00:00Z","last_updated_date":"2011-03-14T02:00:00Z","reference_number":"EMA/CHMP/EWP/342691/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-drugs-treatment-gastro-oesophageal-reflux-disease_en.pdf"},
    {"id":"39686","name":"Draft concept paper on the need for revision of the note for guidance on manufacture of the finished dosage form - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-07-04 - 2013-12-31","first_published_date":"2013-07-04T14:00:00Z","last_updated_date":"2013-07-04T14:00:00Z","reference_number":"EMA/CHMP/QWP/324350/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-need-revision-note-guidance-manufacture-finished-dosage-form-revision-1_en.pdf"},
    {"id":"39691","name":"Draft reflection paper on testing strategy and risk assessment for plants","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-03-09 - 2011-06-30","first_published_date":"2011-03-29T04:00:00Z","last_updated_date":"2011-03-29T04:00:00Z","reference_number":"EMA/CVMP/ERA/147844/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-testing-strategy-and-risk-assessment-plants_en.pdf"},
    {"id":"39706","name":"Draft dimethyl fumarate gastro-resistant capsules 120 mg and 240 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-08-03 - 2017-10-31","first_published_date":"2017-08-03T18:30:00Z","last_updated_date":"2017-08-03T18:30:00Z","reference_number":"EMA/CHMP/421315/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-dimethyl-fumarate-gastro-resistant-capsules-120-mg-and-240-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"39717","name":"Guideline on good pharmacovigilance practices: Module IX – Signal management (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T19:18:16Z","last_updated_date":"2012-06-25T19:18:16Z","reference_number":"EMA/827661/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-ix-signal-management-superseded_en.pdf"},
    {"id":"39729","name":"Guideline on good pharmacovigilance practices (GVP): Module XV – Safety communication (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T01:00:00Z","last_updated_date":"2013-01-24T01:00:00Z","reference_number":"EMA/118465/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xv-safety-communication-superseded_en.pdf"},
    {"id":"39760","name":"Pazopanib film-coated tablet 200 mg and 400 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-01-03T17:39:00Z","last_updated_date":"2017-01-03T17:39:00Z","reference_number":"EMA/CHMP/154805/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/pazopanib-film-coated-tablet-200-mg-and-400-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"39771","name":"Draft guideline on the Core SPC for human Anti-D immunoglobulin for intravenous use – Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-04-27T02:09:21Z","last_updated_date":"2006-04-27T02:09:21Z","reference_number":"CHMP/BPWP/319619/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-spc-human-anti-d-immunoglobulin-intravenous-use-revision-1_en.pdf"},
    {"id":"39774","name":"ICH: S 5 (R2): Detection of toxicity to reproduction for medicinal products & toxicity to male fertility - Step 5 - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"1993-09-30T01:00:00Z","last_updated_date":"1993-09-30T01:00:00Z","reference_number":"CPMP/ICH/386/95","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-5-r2-detection-toxicity-reproduction-medicinal-products-toxicity-male-fertility-step-5-revision-2_en.pdf"},
    {"id":"39785","name":"Reflection paper on the use of genomics in cardiovascular clinical intervention trials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-11-15T01:00:00Z","last_updated_date":"2007-11-15T01:00:00Z","reference_number":"EMEA/CHMP/PGxWP/278789/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-genomics-cardiovascular-clinical-intervention-trials_en.pdf"},
    {"id":"39816","name":"Guideline on the Core SPC for human Albumin solution\n\n(CPMP/PhVWP/BPWG/2231/99 rev.2)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-17T01:00:00Z","last_updated_date":"2005-11-17T01:00:00Z","reference_number":"CPMP/PhVWP/BPWG/2231/99/Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-spc-human-albumin-solution-cpmpphvwpbpwg223199-rev2_en.pdf"},
    {"id":"39828","name":"Concept paper on DNA vaccines non-amplifiable in eukaryotic cells for veterinary use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-04-29 - 2016-07-31","first_published_date":"2016-04-29T18:25:00Z","last_updated_date":"2016-04-29T18:25:00Z","reference_number":"EMA/CVMP/IWP/867401/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-dna-vaccines-non-amplifiable-eukaryotic-cells-veterinary-use_en.pdf"},
    {"id":"39837","name":"Concept paper on the need for revision of the guideline on the evaluation of medicinal products in the treatment of primary osteoporosis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-11-01 - 2013-01-31","first_published_date":"2012-10-31T19:00:00Z","last_updated_date":"2012-10-31T19:00:00Z","reference_number":"EMA/CHMP/520786/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-evaluation-medicinal-products-treatment-primary-osteoporosis_en.pdf"},
    {"id":"39856","name":"Guideline on good pharmacovigilance practices (GVP) - Module VIII – Post-authorisation safety studies with tracked changes (Rev. 2)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-08-08T17:00:00Z","last_updated_date":"2016-08-08T17:00:00Z","reference_number":"EMA/813938/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-tracked-changes-rev-2_en.pdf"},
    {"id":"39873","name":"Appendix IV of the guideline on the investigation on bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1): Presentation of biopharmaceutical and bioanalytical data in module 2.7.1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T16:51:00Z","last_updated_date":"2011-12-08T14:32:00Z","reference_number":"EMA/CHMP/600958/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-iv-guideline-investigation-bioequivalence-cpmpewpqwp140198-rev1-presentation-biopharmaceutical-and-bioanalytical-data-module-271_en.pdf"},
    {"id":"39897","name":"Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-03-13T14:00:00Z","last_updated_date":"2013-03-21T18:00:00Z","reference_number":"EMA/CHMP/806058/2009/Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-requirements-intravenous-liposomal-products-developed-reference-innovator-liposomal-product-revision-2_en.pdf"},
    {"id":"39930","name":"Concept paper for the preparation of a reflection paper on meticillin-resistant Staphylococcus (pseud)intermedius","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-07-20T02:00:00Z","last_updated_date":"2009-07-20T02:00:00Z","reference_number":"EMEA/CVMP/SAGAM/386369/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-preparation-reflection-paper-meticillin-resistant-staphylococcus-pseudintermedius_en.pdf"},
    {"id":"39942","name":"Concept paper on conduct of pharmacovigilance for medicines used children","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2002-10-17T02:00:00Z","last_updated_date":"2002-10-17T02:00:00Z","reference_number":"CPMP/PhVWP/4838/02","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-conduct-pharmacovigilance-medicines-used-children_en.pdf"},
    {"id":"39977","name":"Guideline on clinical investigation of medicinal products in the treatment of lipid disorders - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-07-08T12:50:00Z","last_updated_date":"2016-07-08T12:50:00Z","reference_number":"EMA/CHMP/748108/2013 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-lipid-disorders-revision-3_en.pdf"},
    {"id":"39982","name":"ICH guideline Q4B Annex 10 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on polyacrylamide gel electrophoresis - general chapter - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-02-11T01:00:00Z","last_updated_date":"2017-07-13T16:30:00Z","reference_number":"EMEA/CHMP/ICH/381133/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-10-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-polyacrylamide-gel-electrophoresis-general-chapter-step-5_en.pdf"},
    {"id":"39984","name":"Draft guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and / or intramuscular administration (SCIg / IMIg) - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-12-03 - 2013-06-03","first_published_date":"2012-12-03T11:24:00Z","last_updated_date":"2012-12-03T11:24:00Z","reference_number":"EMA/CHMP/BPWP/410415/2011 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-human-normal-immunoglobulin-subcutaneous-or-intramuscular-administration-scig-imig-revision-1_en.pdf"},
    {"id":"39998","name":"Guideline on good pharmacovigilance practices (GVP): Module XV – Safety communication with tracked changes (Rev. 1)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/118465/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xv-safety-communication-tracked-changes-rev-1_en.pdf"},
    {"id":"40003","name":"Reflection paper on the use of recovered/recycled solvents in the manufacture of herbal preparations for use in herbal medicinal products / traditional herbal medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-12-03T10:55:00Z","last_updated_date":"2013-12-03T10:55:00Z","reference_number":"EMA/HMPC/453258/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-recoveredrecycled-solvents-manufacture-herbal-preparations-use-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"40008","name":"Reflection paper on classification of advanced therapy medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-06-08T16:20:00Z","last_updated_date":"2015-06-08T16:20:00Z","reference_number":"EMA/CAT/600280/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-classification-advanced-therapy-medicinal-products_en.pdf-0"},
    {"id":"40031","name":"Public Statement on CPMP List of Herbal Drugs with serious risks, dated 1992","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-23T01:00:00Z","last_updated_date":"2005-11-23T01:00:00Z","reference_number":"EMEA/HMPC/246736/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-cpmp-list-herbal-drugs-serious-risks-dated-1992_en.pdf"},
    {"id":"40046","name":"Draft guideline on implementation of risk assessment requirements to control elemental impurities in veterinary medicinal products - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-10-16 - 2017-11-17","first_published_date":"2017-10-16T13:28:00Z","last_updated_date":"2017-10-16T13:28:00Z","reference_number":"EMA/CVMP/QWP/631010/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-implementation-risk-assessment-requirements-control-elemental-impurities-veterinary-medicinal-products-first-version_en.pdf"},
    {"id":"40062","name":"Draft guideline on active substance master file procedure - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-01-12 - 2012-03-12","first_published_date":"2012-01-19T17:30:00Z","last_updated_date":"2012-01-19T17:30:00Z","reference_number":"CHMP/QWP/227/02 Rev 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-active-substance-master-file-procedure-revision-3_en.pdf"},
    {"id":"40090","name":"Guideline on data requirements for removing the target animal batch safety test for immunological veterinary medicinal products in the European Union - Obsolete","type":"scientific-guideline","status":"Adopted","consultation_date":"2012-01-10 - 2012-07-31","first_published_date":"2012-01-23T12:15:00Z","last_updated_date":"2012-01-23T12:15:00Z","reference_number":"EMA/CVMP/IWP/810769/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-removing-target-animal-batch-safety-test-immunological-veterinary-medicinal-products-european-union-obsolete_en.pdf"},
    {"id":"40091","name":"Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-08-05T12:00:00Z","last_updated_date":"2016-08-05T12:00:00Z","reference_number":"EMA/CHMP/BWP/271475/2006 rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-potency-testing-cell-based-immunotherapy-medicinal-products-treatment-cancer-revision-1_en.pdf"},
    {"id":"40092","name":"ICH: E 10: Choice of control group in clinical trials - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2001-01-01T01:00:00Z","last_updated_date":"2001-01-01T01:00:00Z","reference_number":"CPMP/ICH/364/96","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-10-choice-control-group-clinical-trials-step-5_en.pdf"},
    {"id":"40105","name":"Draft reflection paper on the use of patient reported outcome (PRO) measures in oncology studies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-06-17 - 2014-11-30","first_published_date":"2014-06-17T18:15:00Z","last_updated_date":"2014-06-17T18:15:00Z","reference_number":"EMA/CHMP/292464/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-patient-reported-outcome-pro-measures-oncology-studies_en.pdf"},
    {"id":"40106","name":"Draft guideline on stability testing for applications for variations to a marketing authorisation - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-07-13 - 2012-01-31","first_published_date":"2011-07-26T04:00:00Z","last_updated_date":"2011-07-26T04:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/441071/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-stability-testing-applications-variations-marketing-authorisation-revision-2_en.pdf"},
    {"id":"40115","name":"Draft guideline on the core SmPC for human Anti-D immunoglobulin for intravenous use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-02-11 - 2016-04-30","first_published_date":"2016-02-11T11:55:00Z","last_updated_date":"2016-02-11T11:55:00Z","reference_number":"EMA/CHMP/BPWP/319619/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-human-anti-d-immunoglobulin-intravenous-use_en.pdf"},
    {"id":"40122","name":"Draft ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population, step 2b - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-10-13 - 2017-04-13","first_published_date":"2016-10-13T19:03:00Z","last_updated_date":"2016-10-13T19:03:00Z","reference_number":"EMA/CPMP/ICH/2711/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-step-2b-revision-1_en.pdf"},
    {"id":"40150","name":"Draft guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-05-15 - 2014-11-15","first_published_date":"2014-05-15T13:50:00Z","last_updated_date":"2014-05-15T13:50:00Z","reference_number":"EMA/CHMP/239770/2014 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-juvenile-idiopathic-arthritis-revision-2_en.pdf"},
    {"id":"40182","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Quality Implementation Working Group: Points to consider for ICH Q8/Q9/Q10 guidelines","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-03-01T01:00:00Z","last_updated_date":"2012-03-01T01:00:00Z","reference_number":"EMA/CHMP/ICH/902964/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-quality-implementation-working-group-points-consider-ich-q8q9q10-guidelines_en.pdf"},
    {"id":"40187","name":"Draft guideline for the conduct of efficacy studies for non-steroidal anti-inflammatory drugs","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-11-16 - 2013-05-31","first_published_date":"2012-11-19T12:30:00Z","last_updated_date":"2012-11-19T12:30:00Z","reference_number":"EMA/CVMP/EWP/1061/2001-CONSULTATION","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-efficacy-studies-non-steroidal-anti-inflammatory-drugs_en.pdf"},
    {"id":"40218","name":"Concept paper on the need for revision of note for guidance on clinical medicinal products for treatment of nociceptive pain and guideline on clinical investigation of products intended for the treatment of neuropathic p...","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2011-09-22 - 2011-12-31","first_published_date":"2011-09-29T17:55:00Z","last_updated_date":"2011-09-29T17:55:00Z","reference_number":"EMA/CHMP/210477/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-clinical-medicinal-products-treatment-nociceptive-pain-and-guideline-clinical-investigation-products-intended-treatment-neuropathic-p_en.pdf"},
    {"id":"40223","name":"Concept paper for use of data in EudraVigilance veterinary","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-06-26T02:00:00Z","last_updated_date":"2006-06-26T02:00:00Z","reference_number":"EMEA/CVMP/68614/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-use-data-eudravigilance-veterinary_en.pdf"},
    {"id":"40228","name":"ICH: E 5 (R1): Questions & answers ethnic factors in the acceptability of foreign clinical data","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-06-01T02:00:00Z","last_updated_date":"2006-06-01T02:00:00Z","reference_number":"CPMP/ICH/5746/03","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-5-r1-questions-answers-ethnic-factors-acceptability-foreign-clinical-data_en.pdf"},
    {"id":"40245","name":"Draft guideline on core SmPC and package leaflet for (99Mo/99mTc) generator","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-01-29 - 2014-04-15","first_published_date":"2014-01-29T02:00:00Z","last_updated_date":"2014-01-29T02:00:00Z","reference_number":"EMA/773757/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-and-package-leaflet-99mo-99mtc-generator_en.pdf"},
    {"id":"40260","name":"Guideline on the clinical investigation of plasma derived fibrin sealant/haemostatic products (CPMP/BPWG/1089/00)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2004-07-29T02:00:00Z","last_updated_date":"2004-07-29T02:00:00Z","reference_number":"CPMP/BPWG/1089/00","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-plasma-derived-fibrin-sealanthaemostatic-products-cpmpbpwg108900_en.pdf"},
    {"id":"40309","name":"Draft carglumic acid product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/422457/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-carglumic-acid-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"40323","name":"Concept paper on the revision of the CHMP points to consider on clinical investigation of medicinal products for the management of Crohn's disease","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-01-26T01:00:00Z","last_updated_date":"2006-01-26T01:00:00Z","reference_number":"CHMP/EWP/18446/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-chmp-points-consider-clinical-investigation-medicinal-products-management-crohns-disease_en.pdf"},
    {"id":"40345","name":"Guideline on data requirements to support in-use stability claims for veterinary vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-03-18T01:00:00Z","last_updated_date":"2010-03-18T01:00:00Z","reference_number":"EMA/CVMP/IWP/250147/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-support-use-stability-claims-veterinary-vaccines_en.pdf"},
    {"id":"40350","name":"Concept paper on the development of a guideline on the assessment of genotoxic constituents in herbal substances/preparations","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-10-26T02:00:00Z","last_updated_date":"2006-10-26T02:00:00Z","reference_number":"EMEA/HMPC/413271/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-assessment-genotoxic-constituents-herbal-substancespreparations_en.pdf"},
    {"id":"40351","name":"Reflection paper on the use of methyl- and propylparaben as excipients in human medicinal products for oral use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-11-19T11:00:00Z","last_updated_date":"2015-11-19T11:00:00Z","reference_number":"EMA/CHMP/SWP/272921/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-methyl-and-propylparaben-excipients-human-medicinal-products-oral-use_en.pdf"},
    {"id":"40373","name":"Draft apixaban film-coated tablet 2.5 and 5 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-06-27 - 2018-09-30","first_published_date":"2018-06-27T14:30:00Z","last_updated_date":"2018-06-27T14:30:00Z","reference_number":"EMA/CHMP/291499/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-apixaban-film-coated-tablet-25-and-5-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"40374","name":"Guideline on good pharmacovigilance practices (GVP) - Module VIII – Post-authorisation safety studies (Rev. 1) (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-04-25T17:00:00Z","last_updated_date":"2013-04-25T17:00:00Z","reference_number":"EMA/813938/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-1-superseded_en.pdf"},
    {"id":"40397","name":"Reflection paper on use of aminoglycosides in animals in the European Union: development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-07-05T02:00:00Z","last_updated_date":"2018-07-05T02:00:00Z","reference_number":"EMA/CVMP/AWP/721118/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-aminoglycosides-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"40409","name":"Draft concept paper on the need for revision of the guideline on the investigation of medicinal products in the term and preterm neonate - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-09-17 - 2018-12-16","first_published_date":"2018-09-17T14:00:00Z","last_updated_date":"2018-09-17T14:00:00Z","reference_number":"EMA/PDCO/362462/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-need-revision-guideline-investigation-medicinal-products-term-and-preterm-neonate-revision-1_en.pdf"},
    {"id":"40438","name":"Guideline on declaration of storage conditions: a) in the product information of pharmaceutical veterinary medicinal products b) for active substances annex to guideline on stability testing of new veterinary drug substa...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2007-12-20T01:00:00Z","last_updated_date":"2007-12-20T01:00:00Z","reference_number":"EMEA/CVMP/422/99/Rev.3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-declaration-storage-conditions-product-information-pharmaceutical-veterinary-medicinal-products-b-active-substances-annex-guideline-stability-testing-new-veterinary-drug-substa_en.pdf"},
    {"id":"40456","name":"Concept paper on the development of a guideline on parametric release","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2005-04-14T02:00:00Z","last_updated_date":"2005-04-14T02:00:00Z","reference_number":"EMEA/CVMP/QWP/114420/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-parametric-release_en.pdf"},
    {"id":"40462","name":"Annexes to guideline on the scientific data requirements for a plasma master file (PMF) Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-11-15T01:00:00Z","last_updated_date":"2006-11-15T01:00:00Z","reference_number":"EMEA/CHMP/BWP/3794/03 Rev1 Ann.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annexes-guideline-scientific-data-requirements-plasma-master-file-pmf-revision-1_en.doc"},
    {"id":"40527","name":"Reflection paper on meticillin-resistant Staphylococcus pseudintermedius","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-09-15 - 2010-11-30","first_published_date":"2010-09-27T04:00:00Z","last_updated_date":"2010-09-27T04:00:00Z","reference_number":"EMA/CVMP/SAGAM/736964/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-meticillin-resistant-staphylococcus-pseudintermedius_en.pdf-0"},
    {"id":"40572","name":"Concept paper on preparation of master seeds to replace established master seeds already used in authorised Immunological Veterinary Medicinal Products (IVMPS)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2006-07-20T02:00:00Z","last_updated_date":"2006-07-20T02:00:00Z","reference_number":"EMEA/CVMP/IWP/205712/2006-CON.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-preparation-master-seeds-replace-established-master-seeds-already-used-authorised-immunological-veterinary-medicinal-products-ivmps_en.pdf"},
    {"id":"40582","name":"Draft guideline on quality of transdermal patches","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2012-09-15 - 2013-03-15","first_published_date":"2012-09-14T14:00:00Z","last_updated_date":"2012-09-14T14:00:00Z","reference_number":"EMA/CHMP/QWP/911254/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-transdermal-patches_en.pdf"},
    {"id":"40585","name":"Concept paper on the use of macrolides, lincosamides and streptogramins in food-producing animals in the European Union: development of resistance and impact on human and animal health","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2009-06-22T02:00:00Z","last_updated_date":"2009-06-22T02:00:00Z","reference_number":"EMEA/CVMP/SAGAM/113420/2009","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-use-macrolides-lincosamides-and-streptogramins-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"40611","name":"Draft octreotide acetate depot powder and solvent for suspension for injection 10 mg, 20 mg or 30 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-06-27 - 2018-09-30","first_published_date":"2018-06-27T14:30:00Z","last_updated_date":"2018-06-27T14:30:00Z","reference_number":"EMA/CHMP/291571/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-octreotide-acetate-depot-powder-and-solvent-suspension-injection-10-mg-20-mg-or-30-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"40658","name":"Draft guideline on the Core SPC for human Anti-D immunoglobulin for intramuscular use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-04-27T02:00:00Z","last_updated_date":"2006-04-27T02:00:00Z","reference_number":"CPMP/BPWG/574/99 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-spc-human-anti-d-immunoglobulin-intramuscular-use_en.pdf"},
    {"id":"40688","name":"Draft guideline on the use of adjuvanted veterinary vaccines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-07-05 - 2019-01-15","first_published_date":"2018-07-05T18:02:00Z","last_updated_date":"2018-07-05T18:02:00Z","reference_number":"EMA/CVMP/IWP/315887/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-use-adjuvanted-veterinary-vaccines-revision-1_en.pdf"},
    {"id":"40716","name":"Concept paper on preparation of an addendum to the guideline on development of antibacterial agents to specifically address the clinical development of new agents to treat tuberculosis","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-04-26T02:00:00Z","last_updated_date":"2007-04-26T02:00:00Z","reference_number":"EMEA/CHMP/EWP/122355/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-preparation-addendum-guideline-development-antibacterial-agents-specifically-address-clinical-development-new-agents-treat-tuberculosis_en.pdf"},
    {"id":"40728","name":"Concept paper on the revision of the guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-05-04 - 2017-07-31","first_published_date":"2017-05-04T13:30:00Z","last_updated_date":"2017-05-04T13:30:00Z","reference_number":"EMA/CHMP/448599/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-role-pharmacokinetics-development-medicinal-products-paediatric-population_en.pdf"},
    {"id":"40763","name":"Guideline on safety and residue data requirements for veterinary medicinal products intended for minor uses or minor species","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2006-07-20T02:00:00Z","last_updated_date":"2006-07-20T02:00:00Z","reference_number":"EMEA/CVMP/SWP/66781/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-safety-and-residue-data-requirements-veterinary-medicinal-products-intended-minor-uses-or-minor-species_en.pdf"},
    {"id":"40765","name":"ICH guideline Q4B annex 6 to note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on uniformity of dosage units - general chapter - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-01-31T18:30:00Z","last_updated_date":"2014-07-14T14:00:00Z","reference_number":"EMA/CHMP/ICH/645408/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q4b-annex-6-note-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-uniformity-dosage-units-general-chapter-step-5_en.pdf"},
    {"id":"40775","name":"Points to consider on the clinical evaluation of new agents for invasive fungal infections","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2003-05-22T02:00:00Z","last_updated_date":"2003-05-22T02:00:00Z","reference_number":"CPMP/EWP/1343/01","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-clinical-evaluation-new-agents-invasive-fungal-infections_en.pdf"},
    {"id":"40788","name":"Concept paper on the harmonisation and update of the clinical aspects in the authorised conditions of use for radiopharmaceuticals and other diagnostic medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/EWP/12052/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-harmonisation-and-update-clinical-aspects-authorised-conditions-use-radiopharmaceuticals-and-other-diagnostic-medicinal-products_en.pdf"},
    {"id":"40829","name":"ICH: S 2 (R1): Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use - Step 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2008-03-01T01:00:00Z","last_updated_date":"2008-03-01T01:00:00Z","reference_number":"EMEA/CHMP/ICH/126642/2008","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-2-r1-guidance-genotoxicity-testing-and-data-interpretation-pharmaceuticals-intended-human-use-step-3_en.pdf"},
    {"id":"40873","name":"Concept paper on the need for revision of note for guidance on quality of water for pharmaceutical use (H+V)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-03-06 - 2017-06-06","first_published_date":"2017-03-06T12:40:00Z","last_updated_date":"2017-03-06T12:40:00Z","reference_number":"EMA/CHMP/CVMP/QWP/BWP/428135/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-quality-water-pharmaceutical-use-hv_en.pdf"},
    {"id":"40887","name":"Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling...","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2016-03-07T12:00:00Z","reference_number":"EMA/CHMP/509951/2006, Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific-application-and-practical-arrangements-necessary-implement-commission-regulation-ec-no-5072006-conditional-marketing-authorisation-medicinal-products-human-use-falling_en.pdf"},
    {"id":"40902","name":"Guideline on immunogenicity assessment of therapeutic proteins - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-06-01T02:00:00Z","last_updated_date":"2017-06-01T02:00:00Z","reference_number":"EMEA/CHMP/BMWP/14327/2006 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf"},
    {"id":"40914","name":"Draft guideline on non-clinical documentation in applications for marketing authorisation/registration of well-established and traditional herbal medicinal products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-08-22 - 2017-11-30","first_published_date":"2017-08-22T20:00:00Z","last_updated_date":"2017-08-22T20:00:00Z","reference_number":"EMEA/HMPC/32116/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-non-clinical-documentation-applications-marketing-authorisation-registration-well-established-and-traditional-herbal-medicinal-products-revision-1_en.pdf"},
    {"id":"40918","name":"Draft abiraterone tablets 250 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-08-01 - 2016-10-31","first_published_date":"2016-08-01T17:00:00Z","last_updated_date":"2016-08-01T17:00:00Z","reference_number":"EMA/CHMP/474712/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-abiraterone-tablets-250-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"40977","name":"Reflection paper on use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-11-18T15:45:00Z","last_updated_date":"2013-11-18T15:45:00Z","reference_number":"EMA/CVMP/AWP/119489/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-pleuromutilins-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf-0"},
    {"id":"40978","name":"Draft guideline on clinical investigation of medicinal products for the treatment of migraine","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-01-26T01:00:00Z","last_updated_date":"2006-01-26T01:00:00Z","reference_number":"CPMP/EWP/788/01 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-migraine_en.pdf"},
    {"id":"41020","name":"Draft guideline on clinical trials with haemopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2006-04-27T02:09:21Z","last_updated_date":"2006-04-27T02:09:21Z","reference_number":"CPMP/EWP/555/95 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-trials-haemopoietic-growth-factors-prophylaxis-infection-following-myelosuppressive-or-myeloablative-therapy_en.pdf"},
    {"id":"41049","name":"Sorafenib film-coated tablets 200 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-05-25T02:00:00Z","last_updated_date":"2016-05-25T02:00:00Z","reference_number":"EMA/CHMP/315232/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/sorafenib-film-coated-tablets-200-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"41054","name":"Draft guideline on good pharmacovigilance practices: Module XVI – Risk-minimisation measures: selection of tools and effectiveness indicators","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-06-07 - 2013-08-05","first_published_date":"2013-06-07T14:30:00Z","last_updated_date":"2013-06-07T14:30:00Z","reference_number":"EMA/204715/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools-and-effectiveness-indicators_en.pdf"},
    {"id":"41068","name":"Concept paper on preparation of a guideline on the evaluation of medicinal products indicated for the treatment and prophylaxis of respiratory syncytial virus (RSV) infection - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-10-26T16:27:00Z","last_updated_date":"2016-10-26T16:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-preparation-guideline-evaluation-medicinal-products-indicated-treatment-and-prophylaxis-respiratory-syncytial-virus-rsv-infection-first-version_en.pdf"},
    {"id":"41129","name":"Draft guideline on the conduct of bioequivalence studies for veterinary medicinal products - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-04-12 - 2017-10-31","first_published_date":"2017-04-24T18:54:00Z","last_updated_date":"2017-04-24T18:54:00Z","reference_number":"EMA/CVMP/EWP/016/00 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-revision-3_en.pdf"},
    {"id":"41138","name":"Draft questions and answers on cyclodextrins in the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use'","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-12-01 - 2015-02-28","first_published_date":"2014-12-01T19:20:00Z","last_updated_date":"2014-12-01T19:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-and-answers-cyclodextrins-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use_en.pdf"},
    {"id":"41163","name":"Concept paper for the revision of the guideline for the testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestations in dogs and cats - Revision 2","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-10-23T02:00:00Z","last_updated_date":"2012-10-23T02:00:00Z","reference_number":"EMA/CVMP/EWP/290691/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-testing-and-evaluation-efficacy-antiparasitic-substances-treatment-and-prevention-tick-and-flea-infestations-dogs-and-cats-revision-2_en.pdf"}    {"id":"41231","name":"Draft guideline on the role of the pathological Complete Response as an endpoint in neoadjuvant breast cancer studies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-04-28 - 2014-07-31","first_published_date":"2014-04-28T14:45:00Z","last_updated_date":"2014-04-28T14:45:00Z","reference_number":"EMA/CHMP/151853/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-role-pathological-complete-response-endpoint-neoadjuvant-breast-cancer-studies_en.pdf"},
    {"id":"41277","name":"Guideline on core summary of product characteristics and package leaflet for technetium (99mTc) sestamibi","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2013-12-17T15:15:00Z","last_updated_date":"2013-12-17T15:15:00Z","reference_number":"EMA/CHMP/617617/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-summary-product-characteristics-and-package-leaflet-technetium-99mtc-sestamibi_en.pdf"},
    {"id":"41292","name":"Draft guideline on clinical evaluation of medicinal products used in weight control - Addendum on weight control in children","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2007-11-15T01:00:00Z","last_updated_date":"2007-11-15T01:00:00Z","reference_number":"EMEA/CHMP/EWP/517497/2007","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-medicinal-products-used-weight-control-addendum-weight-control-children_en.pdf"},
    {"id":"41304","name":"Points to consider on switching between superiority and non-inferiority","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2000-07-27T02:00:00Z","last_updated_date":"2000-07-27T02:00:00Z","reference_number":"CPMP/EWP/482/99","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-switching-between-superiority-and-non-inferiority_en.pdf"},
    {"id":"41372","name":"Compilation of individual product-specific guidance on demonstration of bioequivalence","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T18:35:00Z","last_updated_date":"2014-12-19T18:35:00Z","reference_number":"EMA/CHMP/736403/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/compilation-individual-product-specific-guidance-demonstration-bioequivalence_en.pdf-0"},
    {"id":"41427","name":"Draft reflection paper on off-label use of antimicrobials in veterinary medicine in the European Union - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-07-25 - 2018-01-31","first_published_date":"2017-07-25T20:30:00Z","last_updated_date":"2017-07-25T20:30:00Z","reference_number":"EMA/CVMP/AWP/237294/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-label-use-antimicrobials-veterinary-medicine-european-union-first-version_en.pdf"},
    {"id":"41428","name":"Draft guideline on the sterilisation of the medicinal product, active substance, excipient and primary container","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-04-13 - 2016-10-13","first_published_date":"2016-04-13T16:00:00Z","last_updated_date":"2016-04-13T16:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/BWP/850374/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-sterilisation-medicinal-product-active-substance-excipient-and-primary-container_en.pdf"},
    {"id":"41449","name":"Updated advice on the use of colistin products in animals within the European Union: development of resistance and possible impact on human and animal health","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-07-27T13:00:00Z","last_updated_date":"2016-07-27T13:00:00Z","reference_number":"EMA/CVMP/CHMP/231573/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/updated-advice-use-colistin-products-animals-within-european-union-development-resistance-and-possible-impact-human-and-animal-health_en.pdf-0"},
    {"id":"41456","name":"Draft tadalafil product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/423735/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-tadalafil-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"41462","name":"Draft VICH GL57 on studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: marker residue depletion studies to establish product withdrawal periods in aquatic species","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-01-26 - 2018-06-15","first_published_date":"2018-01-26T19:30:00Z","last_updated_date":"2018-01-26T19:30:00Z","reference_number":"EMA/CVMP/VICH/517152/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl57-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-species-marker-residue-depletion-studies-establish-product-withdrawal-periods-aquatic-species_en.pdf"},
    {"id":"41511","name":"Q3C (R6): Impurities: guideline for residual solvents - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2015-08-04 - 2015-11-03","first_published_date":"2015-08-04T15:00:00Z","last_updated_date":"2015-08-04T15:00:00Z","reference_number":"EMA/CHMP/ICH/82260/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/q3c-r6-impurities-guideline-residual-solvents-step-2b_en.pdf"},
    {"id":"41615","name":"Core summary of product characteristics for Radiopharmaceuticals","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2010-07-29T02:00:00Z","last_updated_date":"2010-07-29T02:00:00Z","reference_number":"EMA/CHMP/EWP/430004/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/core-summary-product-characteristics-radiopharmaceuticals_en.pdf"},
    {"id":"41638","name":"Public Statement on the use of herbal medicinal products containing asarone","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2005-11-23T01:00:00Z","last_updated_date":"2005-11-23T01:00:00Z","reference_number":"EMEA/HMPC/139215/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-use-herbal-medicinal-products-containing-asarone_en.pdf"},
    {"id":"41642","name":"Draft guideline on similar biological medicinal products containing monoclonal antibodies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2010-11-18 - 2011-05-31","first_published_date":"2010-11-26T02:00:00Z","last_updated_date":"2010-11-26T02:00:00Z","reference_number":"EMA/CHMP/BMWP/403543/2010","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies_en.pdf"},
    {"id":"41647","name":"Draft reflection paper on the use of methyl- and propylparaben as excipients in human medicinal products for oral use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-05-08 - 2013-10-31","first_published_date":"2013-05-08T14:00:00Z","last_updated_date":"2013-05-08T14:00:00Z","reference_number":"EMA/CHMP/SWP/272921/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-methyl-and-propylparaben-excipients-human-medicinal-products-oral-use_en.pdf"},
    {"id":"41679","name":"Concept paper on the need to revise condition–specific guidance, appendix 4 to the guideline on the evaluation of anticancer medicinal products in man - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-07-31 - 2013-10-31","first_published_date":"2013-07-31T17:55:00Z","last_updated_date":"2013-07-31T17:55:00Z","reference_number":"EMA/CHMP/432831/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revise-condition-specific-guidance-appendix-4-guideline-evaluation-anticancer-medicinal-products-man-revision-1_en.pdf"},
    {"id":"41733","name":"Draft guideline on specifications: test procedures and acceptance criteria for herbal  substances, herbal  preparations and herbal medicinal products/traditional herbal medicinal products - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-08-15 - 2018-11-30","first_published_date":"2018-08-15T20:00:00Z","last_updated_date":"2018-08-15T20:00:00Z","reference_number":"EMA/HMPC/162241/2005","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-specifications-test-procedures-and-acceptance-criteria-herbal-substances-herbal-preparations-and-herbal-medicinal-products-traditional-herbal-medicinal-products-revision-3_en.pdf"},
    {"id":"41750","name":"Concept paper on the need for a paediatric addendum of the guideline on clinical investigation of medicinal products for the treatment and prophylaxis of venous thromboembolic disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-10-31 - 2018-01-31","first_published_date":"2017-10-31T18:00:00Z","last_updated_date":"2017-10-31T18:00:00Z","reference_number":"EMA/230866/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-paediatric-addendum-guideline-clinical-investigation-medicinal-products-treatment-and-prophylaxis-venous-thromboembolic-disease_en.pdf"},
    {"id":"41763","name":"Stem cell -based products for veterinary use: Specific questions on extraneous agents to be addressed by Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2016-06-27 - 2016-09-30","first_published_date":"2016-06-27T19:40:00Z","last_updated_date":"2016-06-27T19:40:00Z","reference_number":"EMA/CVMP/ADVENT/174610/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/stem-cell-based-products-veterinary-use-specific-questions-extraneous-agents-be-addressed-ad-hoc-expert-group-veterinary-novel-therapies-advent_en.pdf"},
    {"id":"41783","name":"Draft ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials, step 2b - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-08-31 - 2018-02-28","first_published_date":"2017-08-31T13:10:01Z","last_updated_date":"2017-08-31T13:10:01Z","reference_number":"EMA/CHMP/ICH/436221/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-2b-revision-1_en.pdf"},
    {"id":"41810","name":"Guideline on assessing the environmental and human health risks of veterinary medicinal products in groundwater","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-04-30T13:33:00Z","last_updated_date":"2024-12-13T14:22:00Z","reference_number":"EMA/CVMP/ERA/103555/2015 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-assessing-environmental-human-health-risks-veterinary-medicinal-products-groundwater_en.pdf"},
    {"id":"41820","name":"Guideline on the assessment of persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances in veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2015-09-17T18:05:00Z","last_updated_date":"2015-09-17T18:05:00Z","reference_number":"EMA/CVMP/ERA/52740/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-assessment-persistent-bioaccumulative-and-toxic-pbt-or-very-persistent-and-very-bioaccumulative-vpvb-substances-veterinary-medicinal-products_en.pdf"},
    {"id":"41821","name":"Concept paper on revision of guideline on epidemiological data on blood-transmissible infections","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2014-08-01 - 2014-12-31","first_published_date":"2014-08-01T15:00:00Z","last_updated_date":"2014-08-01T15:00:00Z","reference_number":"EMA/CHMP/BWP/295676/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-epidemiological-data-blood-transmissible-infections_en.pdf"},
    {"id":"41834","name":"Draft guideline on assessment and control of DNA reactive, mutagenic impurities in veterinary medicines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-02-24 - 2017-08-31","first_published_date":"2017-02-24T18:00:00Z","last_updated_date":"2017-02-24T18:00:00Z","reference_number":"EMA/CVMP/SWP/377245/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-assessment-and-control-dna-reactive-mutagenic-impurities-veterinary-medicines_en.pdf"},
    {"id":"41840","name":"Dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-02-01T13:00:00Z","last_updated_date":"2018-02-01T13:00:00Z","reference_number":"EMA/CHMP/356875/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/dronedarone-film-coated-tablets-400-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"41870","name":"Crizotinib hard capsules 200 mg and 250 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-10T02:00:00Z","last_updated_date":"2017-07-10T02:00:00Z","reference_number":"EMA/CHMP/805479/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/crizotinib-hard-capsules-200-mg-and-250-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"41879","name":"Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-02-28T13:30:00Z","last_updated_date":"2018-02-28T13:30:00Z","reference_number":"CPMP/EWP/553/95 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf"},
    {"id":"41926","name":"Draft ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management - Step 2b - Annexes - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-12-18 - 2018-12-18","first_published_date":"2017-12-18T18:00:00Z","last_updated_date":"2017-12-18T18:00:00Z","reference_number":"EMA/CHMP/ICH/804273/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-step-2b-annexes-first-version_en.pdf"},
    {"id":"41929","name":"Final guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2016-02-11T10:40:00Z","last_updated_date":"2016-02-11T10:40:00Z","reference_number":"EMA/CHMP/BPWP/1619/1999 rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/final-guideline-core-smpc-human-plasma-derived-and-recombinant-coagulation-factor-viii-products-revision-2_en.pdf"},
    {"id":"41940","name":"Guideline on good pharmacovigilance practices (GVP): Module VIII – Post-authorisation safety studies (Rev. 2) (superseded)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2016-08-04T02:00:00Z","last_updated_date":"2016-08-04T02:00:00Z","reference_number":"EMA/813938/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-2-superseded_en.pdf"},
    {"id":"41941","name":"Draft repaglinide product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2013-11-15 - 2014-02-15","first_published_date":"2013-11-15T16:00:00Z","last_updated_date":"2013-11-15T16:00:00Z","reference_number":"CHMP/PKWP/EMA/422421/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-repaglinide-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"41950","name":"Guideline on stability testing for applications for variations to a marketing authorisation - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-04-09T18:30:00Z","last_updated_date":"2014-04-09T18:30:00Z","reference_number":"EMA/CHMP/CVMP/QWP/441071/2011- Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-applications-variations-marketing-authorisation-revision-2_en.pdf"},
    {"id":"41977","name":"Guidelines on good pharmacovigilance practices (GVP) - Introductory cover note, last updated with revision 1 of module IV on audits and launch of public consultation of module VIII and its addendum I on post-authorisatio...","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2015-08-11T11:00:00Z","last_updated_date":"2015-08-11T11:00:00Z","reference_number":"EMA/501523/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-revision-1-module-iv-audits-and-launch-public-consultation-module-viii-and-its-addendum-i-post-authorisatio_en.pdf"},
    {"id":"42000","name":"Concept paper on the development of a reflection paper on new analytical methods/technologies in the quality control of herbal medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-10-31 - 2018-04-30","first_published_date":"2017-10-31T13:00:00Z","last_updated_date":"2017-10-31T13:00:00Z","reference_number":"EMA/HMPC/541422/2017 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-new-analytical-methods-technologies-quality-control-herbal-medicinal-products_en.pdf"},
    {"id":"42004","name":"Concept paper on revision of the guideline on clinical development of vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2017-06-23 - 2017-09-30","first_published_date":"2017-06-23T20:13:00Z","last_updated_date":"2017-06-23T20:13:00Z","reference_number":"EMA/CHMP/VWP/124350/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-clinical-development-vaccines_en.pdf"},
    {"id":"42077","name":"Guideline on determination of withdrawal periods for edible tissues - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T18:00:00Z","last_updated_date":"2018-09-21T18:00:00Z","reference_number":"EMA/CVMP/SWP/735325/2012","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-determination-withdrawal-periods-edible-tissues-revision-1_en.pdf"},
    {"id":"42091","name":"Draft reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-09-21 - 2018-12-21","first_published_date":"2018-09-21T20:00:00Z","last_updated_date":"2018-09-21T20:00:00Z","reference_number":"EMA/CVMP/AWP/842786/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-aminopenicillins-and-their-beta-lactamase-inhibitor-combinations-animals-european-union-development-resistance-and-impact-human-and-animal-health-first-version_en.pdf"},
    {"id":"42108","name":"Question and answer on the adequacy of the Mahalanobis distance to assess the comparability of drug dissolution profiles","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-09-19T13:30:00Z","last_updated_date":"2018-09-19T13:30:00Z","reference_number":"EMA/810713/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/question-and-answer-adequacy-mahalanobis-distance-assess-comparability-drug-dissolution-profiles_en.pdf"},
    {"id":"42110","name":"Draft Reflection paper on resistance in ectoparasites","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-02-21 - 2019-08-31","first_published_date":"2018-09-21T20:00:00Z","last_updated_date":"2018-09-21T20:00:00Z","reference_number":"EMA/CVMP/EWP/310225/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-resistance-ectoparasites_en.pdf"},
    {"id":"42141","name":"ICH guideline S11 on nonclinical safety testing in support of development of paediatric medicines - Step 2b - Draft guideline","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-09-24 - 2019-03-24","first_published_date":"2018-09-27T13:08:00Z","last_updated_date":"2018-09-27T13:08:00Z","reference_number":"EMA/CHMP/ICH/616110/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-s11-nonclinical-safety-testing-support-development-paediatric-medicines-step-2b-draft-guideline_en.pdf"},
    {"id":"42190","name":"ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T19:32:00Z","last_updated_date":"2018-02-03T00:00:00Z","reference_number":"EMA/CHMP/ICH/83812/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m7r1-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-step-5_en.pdf"},
    {"id":"42435","name":"ICH guideline Q3C (R6) on impurities - support document 1: toxicological data for class 1 solvents - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-10-26T15:05:00Z","last_updated_date":"2019-10-15T11:24:00Z","reference_number":"EMA/CHMP/ICH/735035/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q3c-r6-impurities-support-document-1-toxicological-data-class-1-solvents-step-5_en.pdf"},
    {"id":"42436","name":"ICH guideline Q3C (R6) on impurities - support document 2: toxicological data for class 2 solvents - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-10-26T15:07:00Z","last_updated_date":"2019-10-15T11:26:00Z","reference_number":"EMA/CHMP/ICH/735036/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q3c-r6-impurities-support-document-2-toxicological-data-class-2-solvents-step-5_en.pdf"},
    {"id":"42437","name":"ICH guideline Q3C (R6) on impurities - support document 3: toxicological data for class 3 solvents - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-10-26T15:08:00Z","last_updated_date":"2019-10-15T11:27:00Z","reference_number":"EMA/CHMP/ICH/735038/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q3c-r6-impurities-support-document-3-toxicological-data-class-3-solvents-step-5_en.pdf"},
    {"id":"42512","name":"Adopted reflection paper on the use of extrapolation in the development of medicines for paediatrics - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-10-30T17:31:00Z","last_updated_date":"2018-10-30T17:31:00Z","reference_number":"EMA/189724/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf"},
    {"id":"42513","name":"Overview of comments received on ' Reflection paper on the use of extrapolation in the development of medicines for paediatrics ' (EMA/189724/2018) - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-10-30T17:35:00Z","last_updated_date":"2018-10-30T17:35:00Z","reference_number":"EMA/696705/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-reflection-paper-use-extrapolation-development-medicines-paediatrics-ema1897242018-revision-1_en.pdf"},
    {"id":"42563","name":"Guideline on good pharmacovigilance practices (GVP): Product- or Population-Specific Considerations IV: Paediatric population with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-11-07T12:41:00Z","last_updated_date":"2018-11-07T12:41:00Z","reference_number":"EMA/572054/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-iv-paediatric-population-tracked-changes_en.pdf"},
    {"id":"42565","name":"Guideline on good pharmacovigilance practices (GVP): Product- or Population-Specific Considerations IV: Paediatric population","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-11-07T12:34:00Z","last_updated_date":"2018-11-07T12:34:00Z","reference_number":"EMA/572054/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-iv-paediatric-population_en.pdf"},
    {"id":"42567","name":"Guideline on conduct of pharmacovigilance for medicines used by the paediatric population","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2007-01-25T12:01:00Z","last_updated_date":"2007-01-25T12:01:00Z","reference_number":"EMEA/CHMP/PhVWP/235910/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-pharmacovigilance-medicines-used-paediatric-population_en.pdf"},
    {"id":"42568","name":"Guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-11-07T15:14:00Z","last_updated_date":"2018-11-07T15:14:00Z","reference_number":"EMA/CHMP/257022/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-indicated-prophylaxis-or-treatment-respiratory-syncytial-virus-rsv-disease-first-version_en.pdf"},
    {"id":"42570","name":"Reflection paper providing an overview of the current regulatory testing requirements for medicinal products for human use and opportunities for implementation of the 3Rs - First","type":"scientific-guideline","status":"Draft","consultation_date":"","first_published_date":"2018-11-07T15:51:00Z","last_updated_date":"2018-11-07T15:51:00Z","reference_number":"EMA/CHMP/CVMP/3Rs/742466/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-providing-overview-current-regulatory-testing-requirements-medicinal-products-human-use-and-opportunities-implementation-3rs-first_en.pdf"},
    {"id":"42574","name":"Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-11-07T16:38:00Z","last_updated_date":"2019-04-29T09:58:00Z","reference_number":"CPMP/EWP/239/95 Rev. 1 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-equivalence-studies-demonstration-therapeutic-equivalence-locally-applied-locally-acting-products-gastrointestinal-tract-revision-1_en.pdf"},
    {"id":"42576","name":"Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials with tracked changes - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-11-07T17:00:00Z","last_updated_date":"2018-11-07T17:00:00Z","reference_number":"EMA/CHMP/BWP/534898/2008 rev. 1 corrigendum","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials-tracked-changes-revision-1_en.pdf"},
    {"id":"42577","name":"Guideline on quality aspects included in the product information for vaccines for human use - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-11-07T18:36:00Z","last_updated_date":"2018-11-07T18:36:00Z","reference_number":"EMA/CHMP/BWP/133540/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-aspects-included-product-information-vaccines-human-use-revision-1_en.pdf"},
    {"id":"42580","name":"Questions and answers on the haemagglutination inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-11-08T11:22:00Z","last_updated_date":"2018-11-08T11:22:00Z","reference_number":"EMA/CHMP/BWP/426390/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-haemagglutination-inhibition-hi-test-qualification-influenza-vaccine-inactivated-seed-preparations-first-version_en.pdf"},
    {"id":"42584","name":"Questions and answers on bovine spongiform encephalopathies (BSE) and vaccines - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-11-08T11:33:00Z","last_updated_date":"2018-11-08T11:33:00Z","reference_number":"EMA/CHMP/BWP/192228/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-bovine-spongiform-encephalopathies-bse-and-vaccines-revision-1_en.pdf"},
    {"id":"42691","name":"Concept paper on the need for revision of the Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Peripheral Arterial Occlusive Disease (CHMP/EWP/714/98 rev 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-12 - 2019-06-30","first_published_date":"2018-11-15T15:15:00Z","last_updated_date":"2018-11-15T15:15:00Z","reference_number":"EMA/CHMP/78339/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-clinical-investigation-medicinal-products-treatment-peripheral-arterial-occlusive-disease-chmp-ewp-714-98-rev-1_en.pdf"},
    {"id":"42692","name":"Draft guideline on the quality of water for pharmaceutical use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-15 - 2019-05-15","first_published_date":"2018-11-15T15:44:00Z","last_updated_date":"2018-11-15T15:44:00Z","reference_number":"EMA/CHMP/CVMP/QWP/496873/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-water-pharmaceutical-use_en.pdf"},
    {"id":"42697","name":"Draft CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-10-18 - 2019-10-31","first_published_date":"2018-11-16T11:30:00Z","last_updated_date":"2018-11-16T11:30:00Z","reference_number":"EMA/CHMP/BWP/303353/2010 Rev 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-chmp-position-statement-creutzfeldt-jakob-disease-plasma-derived-urine-derived-medicinal-products-revision-3_en.pdf"},
    {"id":"42716","name":"Draft information for the package leaflet regarding dextrans used as excipients in medicinal products for human use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-19 - 2019-05-31","first_published_date":"2018-11-19T13:01:00Z","last_updated_date":"2018-11-19T13:01:00Z","reference_number":"EMA/CHMP/187129/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-regarding-dextrans-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"42717","name":"Draft information for the package leaflet regarding lactose used as an excipient in medicinal products for human use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-19 - 2019-05-31","first_published_date":"2018-11-19T13:04:00Z","last_updated_date":"2018-11-19T13:04:00Z","reference_number":"EMA/CHMP/186428/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-regarding-lactose-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"42718","name":"Draft information for the package leaflet regarding polysorbates used as excipients in medicinal products for human use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-19 - 2019-05-31","first_published_date":"2018-11-19T13:06:00Z","last_updated_date":"2018-11-19T13:06:00Z","reference_number":"EMA/CHMP/190743/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-regarding-polysorbates-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"42719","name":"Draft information for the package leaflet regarding proline used as an excipient in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"2018-11-19 - 2019-05-31","first_published_date":"2018-11-19T13:07:00Z","last_updated_date":"2018-11-19T13:07:00Z","reference_number":"EMA/CHMP/332530/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-regarding-proline-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"42720","name":"Draft reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-19 - 2019-08-31","first_published_date":"2018-11-19T13:49:00Z","last_updated_date":"2018-12-12T17:22:00Z","reference_number":"EMA/CHMP/299976/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-regulatory-requirements-development-medicinal-products-chronic-non-infectious-liver-diseases-pbc-psc-nash_en.pdf"},
    {"id":"42731","name":"Draft reflection paper on antimicrobial resistance in the environment: considerations for current and future risk assessment of veterinary medicinal products - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-21 - 2019-08-31","first_published_date":"2018-11-21T16:35:00Z","last_updated_date":"2018-11-21T16:35:00Z","reference_number":"EMA/CVMP/ERA/632109/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-antimicrobial-resistance-environment-considerations-current-and-future-risk-assessment-veterinary-medicinal-products-first-version_en.pdf"},
    {"id":"42733","name":"Reflection paper on off-label use of antimicrobials in veterinary medicine in the European Union - First version - Obsolete","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-11-21T16:24:00Z","last_updated_date":"2018-11-21T16:24:00Z","reference_number":"EMA/CVMP/AWP/237294/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-label-use-antimicrobials-veterinary-medicine-european-union-first-version-obsolete_en.pdf"},
    {"id":"42734","name":"Overview of comments received on 'Reflection paper on off-label use of antimicrobials in veterinary medicine in the European Union' (EMA/CVMP/AWP/237294/2017) - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-11-21T16:29:00Z","last_updated_date":"2018-11-21T16:29:00Z","reference_number":"EMA/CVMP/AWP/30098/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-reflection-paper-label-use-antimicrobials-veterinary-medicine-european-union-emacvmpawp2372942017-first-version_en.pdf"},
    {"id":"42742","name":"Draft guideline on the non-clinical requirements for radiopharmaceuticals - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-22 - 2019-06-30","first_published_date":"2018-11-22T13:15:00Z","last_updated_date":"2018-11-22T13:15:00Z","reference_number":"EMA/CHMP/SWP/686140/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-non-clinical-requirements-radiopharmaceuticals-first-version_en.pdf"},
    {"id":"42765","name":"Reflection paper on the qualification of non-genotoxic impurities - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-23 - 2019-09-30","first_published_date":"2018-11-23T16:00:00Z","last_updated_date":"2018-11-23T16:00:00Z","reference_number":"EMA/CHMP/SWP/545588/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-qualification-non-genotoxic-impurities-first-version_en.pdf"},
    {"id":"42766","name":"Paediatric addendum on the guidelines on clinical investigation of medicinal products for the treatment and prophylaxis of venous thromboembolic disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-11-23 - 2019-06-30","first_published_date":"2018-11-23T18:45:00Z","last_updated_date":"2018-11-23T18:45:00Z","reference_number":"EMA/CHMP/763438/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paediatric-addendum-guidelines-clinical-investigation-medicinal-products-treatment-and-prophylaxis-venous-thromboembolic-disease_en.pdf"},
    {"id":"42884","name":"Implementation of risk assessment requirements to control elemental impurities in veterinary medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-11-29T11:00:00Z","last_updated_date":"2018-11-29T11:00:00Z","reference_number":"EMA/CVMP/QWP/631010/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/implementation-risk-assessment-requirements-control-elemental-impurities-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"42889","name":"Draft guideline on clinical investigation of recombinant and human plasma-derived factor IX products - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-03 - 2019-06-30","first_published_date":"2018-11-30T12:12:00Z","last_updated_date":"2018-12-19T16:55:00Z","reference_number":"EMA/CHMP/BPWP/144552/2009 rev. 2 Corr.1 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-recombinant-and-human-plasma-derived-factor-ix-products-revision-2_en.pdf"},
    {"id":"42890","name":"Draft guideline on core SmPC for human plasma derived and recombinant coagulation factor IX products - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-03 - 2019-06-30","first_published_date":"2018-11-30T13:00:00Z","last_updated_date":"2018-11-30T13:00:00Z","reference_number":"EMA/CHMP/BPWP/1625/1999 rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-human-plasma-derived-and-recombinant-coagulation-factor-ix-products-revision-3_en.pdf"},
    {"id":"42891","name":"Draft guideline on the environmental risk assessment of medicinal products for human use - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-01 - 2019-06-30","first_published_date":"2018-11-30T13:23:00Z","last_updated_date":"2018-11-30T13:23:00Z","reference_number":"EMEA/CHMP/SWP/4447/00 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-environmental-risk-assessment-medicinal-products-human-use-revision-1_en.pdf"},
    {"id":"42915","name":"Review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products – report on actions taken","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-12-04T13:26:00Z","last_updated_date":"2018-12-04T13:26:00Z","reference_number":"EMA/CHMP/CVMP/3Rs/677407/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/review-and-update-ema-guidelines-implement-best-practice-regard-3rs-replacement-reduction-and-refinement-regulatory-testing-medicinal-products-report-actions-taken_en.pdf"},
    {"id":"42916","name":"Overview of comments received on ' Draft Review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products – report on actions taken’ (EMA/CHMP/CVMP/JEG-3R","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-12-04T13:33:00Z","last_updated_date":"2018-12-04T13:33:00Z","reference_number":"EMA/CHMP/CVMP/3Rs/731086/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-draft-review-and-update-ema-guidelines-implement-best-practice-regard-3rs-replacement-reduction-and-refinement-regulatory-testing-medicinal-products-report-actions-taken_en.pdf"},
    {"id":"42918","name":"Overview of comments received on draft dimethyl fumarate gastro-resistant capsules 120 mg and 240 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-12-04T15:15:00Z","last_updated_date":"2018-12-04T15:15:00Z","reference_number":"EMA/CHMP/730229/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-draft-dimethyl-fumarate-gastro-resistant-capsules-120-mg-and-240-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"42929","name":"Overview of comments received on Ibuprofen 200 – 800 mg oral use, immediate release formulations product-specific bioequivalence guidance","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2018-12-04T17:38:00Z","last_updated_date":"2018-12-04T17:38:00Z","reference_number":"EMA/CHMP/730723/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-ibuprofen-200-800-mg-oral-use-immediate-release-formulations-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"43036","name":"Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-12-13T12:36:00Z","last_updated_date":"2018-12-13T12:36:00Z","reference_number":"EMA/CHMP/458101/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-and-simulation_en.pdf"},
    {"id":"43051","name":"Aliskiren film-coated tablet 150 mg and 300 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-12-13T18:57:00Z","last_updated_date":"2018-12-13T18:57:00Z","reference_number":"EMA/CHMP/291450/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/aliskiren-film-coated-tablet-150-mg-and-300-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"43053","name":"Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-12-13T19:17:00Z","last_updated_date":"2018-12-13T19:17:00Z","reference_number":"EMA/CHMP/800775/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/pegylated-liposomal-doxorubicin-hydrochloride-concentrate-solution-2-mgml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"43065","name":"Draft guideline on quality and equivalence of topical products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-14 - 2019-06-30","first_published_date":"2018-12-14T12:30:00Z","last_updated_date":"2018-12-14T12:30:00Z","reference_number":"CHMP/QWP/708282/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-and-equivalence-topical-products_en.pdf"},
    {"id":"43097","name":"Draft reflection paper on risk management requirements for elemental impurities in veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-17 - 2019-08-31","first_published_date":"2018-12-17T11:06:00Z","last_updated_date":"2018-12-17T11:06:00Z","reference_number":"EMA/CVMP/QWP/153641/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-risk-management-requirements-elemental-impurities-veterinary-medicinal-products_en.pdf"},
    {"id":"43098","name":"Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-21 - 2019-06-30","first_published_date":"2018-12-17T11:57:00Z","last_updated_date":"2018-12-17T11:57:00Z","reference_number":"EMA/CHMP/802491/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ezetimibe-tablet-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"43099","name":"Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-21 - 2019-06-30","first_published_date":"2018-12-17T13:29:00Z","last_updated_date":"2018-12-17T13:29:00Z","reference_number":"EMA/CHMP/790333/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-cabozantinib-tablet-20-mg-40-mg-and-60-mg-capsule-20-4-mg-and-80-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"43113","name":"Guideline on the content, management and archiving of the clinical trial master file (paper and/or electronic)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-12-18T10:23:00Z","last_updated_date":"2018-12-18T10:23:00Z","reference_number":"EMA/INS/GCP/856758/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-content-management-and-archiving-clinical-trial-master-file-paper-andor-electronic_en.pdf"},
    {"id":"43125","name":"Draft guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-18 - 2019-08-31","first_published_date":"2018-12-18T16:10:00Z","last_updated_date":"2018-12-18T16:10:00Z","reference_number":"EMA/CVMP/SWP/66781/2005 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-safety-and-residue-data-requirements-pharmaceutical-veterinary-medicinal-products-intended-minor-use-or-minor-species-mums-limited-market-revision-2_en.pdf"},
    {"id":"43152","name":"Draft guideline on requirements for the quality (production and control), safety and efficacy of allergen products for use in horses, dogs and cats - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-19 - 2019-08-31","first_published_date":"2018-12-19T11:00:00Z","last_updated_date":"2018-12-19T11:00:00Z","reference_number":"EMA/CVMP/IWP/170689/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-quality-production-and-control-safety-and-efficacy-allergen-products-use-horses-dogs-and-cats-revision-1_en.pdf"},
    {"id":"43165","name":"Guideline on the conduct of bioequivalence studies for veterinary medicinal products - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2018-12-19T16:00:00Z","last_updated_date":"2020-01-24T15:43:00Z","reference_number":"EMA/CVMP/016/2000 Rev. 3 corr. ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-revision-3_en.pdf"},
    {"id":"43172","name":"Draft guideline for the demonstration of efficacy for veterinary medicinal products containing anticoccidial substances - Revision 1 (first version)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-19 - 2019-08-31","first_published_date":"2018-12-19T18:00:00Z","last_updated_date":"2018-12-19T18:00:00Z","reference_number":"EMA/CVMP/EWP/755916/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-anticoccidial-substances-revision-1-first-version_en.pdf"},
    {"id":"43196","name":"Concept paper on a guideline for allergen products development in moderate to low-sized study populations","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2018-12-21 - 2019-06-30","first_published_date":"2018-12-20T13:54:00Z","last_updated_date":"2018-12-20T13:54:00Z","reference_number":"EMA/CHMP/251023/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-allergen-products-development-moderate-low-sized-study-populations_en.pdf"},
    {"id":"43261","name":"Questions and answers on the CVMP guideline on the guideline on veterinary medicinal products controlling Varroa destructor parasitosis in bees (EMA/CVMP/EWP/77872/2018)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-01-09T16:00:00Z","last_updated_date":"2019-01-09T16:00:00Z","reference_number":"EMA/CVMP/EWP/77872/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-cvmp-guideline-guideline-veterinary-medicinal-products-controlling-varroa-destructor-parasitosis-bees-emacvmpewp778722018_en.pdf"},
    {"id":"43262","name":"Guideline on assessment and control of DNA reactive (mutagenic) impurities in veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-01-09T17:00:00Z","last_updated_date":"2019-01-09T17:00:00Z","reference_number":"EMA/CVMP/SWP/377245/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-assessment-and-control-dna-reactive-mutagenic-impurities-veterinary-medicinal-products_en.pdf"},
    {"id":"43264","name":"Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), Bluetongue (BT) and Foot-and-Mouth disease (FMD) - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-01-09T17:00:00Z","last_updated_date":"2019-01-09T17:00:00Z","reference_number":"EMA/CVMP/IWP/105506/2007 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-multi-strain-dossiers-inactivated-vaccines-against-avian-influenza-ai-bluetongue-bt-and-foot-and-mouth-disease-fmd-revision-1_en.pdf"},
    {"id":"43350","name":"Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-01-14 - 2019-07-31","first_published_date":"2019-01-14T12:32:00Z","last_updated_date":"2019-01-14T12:32:00Z","reference_number":"EMA/844951/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf"},
    {"id":"43351","name":"Concept paper on the revision of the guideline on the evaluation of anticancer medicinal products in man","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-01-14 - 2019-04-14","first_published_date":"2019-01-14T16:10:00Z","last_updated_date":"2019-01-14T16:10:00Z","reference_number":"EMA/CHMP/755489/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-evaluation-anticancer-medicinal-products-man_en.pdf"},
    {"id":"43669","name":"Draft guideline on clinical investigation of medicinal products for the treatment of gout - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-02-08 - 2019-08-31","first_published_date":"2019-02-08T09:45:00Z","last_updated_date":"2019-08-07T15:50:00Z","reference_number":"EMA/CHMP/774470/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-gout-first-version_en.pdf"},
    {"id":"43671","name":"Draft alectinib hard capsule 150 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-02-08 - 2019-06-30","first_published_date":"2019-02-08T09:40:00Z","last_updated_date":"2019-02-08T09:40:00Z","reference_number":"EMA/CHMP/790261/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-alectinib-hard-capsule-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"43672","name":"Draft palbociclib hard capsule 75 mg, 100 mg and 125 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-02-08 - 2019-06-30","first_published_date":"2019-02-08T10:00:00Z","last_updated_date":"2019-02-08T10:00:00Z","reference_number":"EMA/CHMP/802679/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-palbociclib-hard-capsule-75-mg-100-mg-and-125-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"43673","name":"Octreotide acetate depot powder and solvent for suspension for injection 10 mg, 20 mg and 30 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-02-08T10:09:00Z","last_updated_date":"2019-02-08T10:09:00Z","reference_number":"EMA/CHMP/291571/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/octreotide-acetate-depot-powder-and-solvent-suspension-injection-10-mg-20-mg-and-30-mg-product-specific-bioequivalence-guidance_en.pdf"}    {"id":"43871","name":"Draft guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-02-21 - 2019-08-01","first_published_date":"2019-02-21T19:40:00Z","last_updated_date":"2019-02-21T19:40:00Z","reference_number":"EMA/CAT/852602/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials-first-version_en.pdf"},
    {"id":"43884","name":"Guideline on non-clinical documentation in applications for marketing authorisation/registration of well-established and traditional herbal medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-02-25T11:12:00Z","last_updated_date":"2019-02-25T11:12:00Z","reference_number":"EMEA/HMPC/32116/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-documentation-applications-marketing-authorisationregistration-well-established-and-traditional-herbal-medicinal-products-revision-1_en.pdf"},
    {"id":"43931","name":"Question and answer on adjustment for cross-over in estimating effects in oncology trials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-02-28T11:29:00Z","last_updated_date":"2019-02-28T11:29:00Z","reference_number":"EMA/845963/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/question-and-answer-adjustment-cross-over-estimating-effects-oncology-trials_en.pdf"},
    {"id":"43937","name":"Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-01-10T15:44:00Z","last_updated_date":"2014-01-10T15:44:00Z","reference_number":"EMA/CHMP/13099/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/joint-mhlwema-reflection-paper-development-block-copolymer-micelle-medicinal-products_en.pdf"},
    {"id":"43943","name":"Qualification opinion on Cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-02-28T18:00:00Z","last_updated_date":"2019-02-28T18:00:00Z","reference_number":"EMA/CHMP/SAWP/792574/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-cellular-therapy-module-european-society-blood-marrow-transplantation-ebmt-registry_en.pdf"},
    {"id":"43998","name":"Draft Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-03-08 - 2019-06-30","first_published_date":"2019-03-08T15:39:00Z","last_updated_date":"2019-03-08T15:39:00Z","reference_number":"EMA/CHMP/35552/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-colchicine-tablet-05-mg-and-1-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"43999","name":"Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-03-08T15:36:00Z","last_updated_date":"2019-03-08T15:36:00Z","reference_number":"EMA/CHMP/CVMP/QWP/850374/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-sterilisation-medicinal-product-active-substance-excipient-and-primary-container_en.pdf"},
    {"id":"44025","name":"Draft ICH guideline M10 on bioanalytical method validation - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-03-14 - 2019-09-01","first_published_date":"2019-03-14T09:06:00Z","last_updated_date":"2019-03-14T09:06:00Z","reference_number":"EMA/CHMP/ICH/172948/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m10-bioanalytical-method-validation-step-2b_en.pdf"},
    {"id":"44039","name":"Guideline on the investigation of subgroups in confirmatory clinical trials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-03-14T17:21:00Z","last_updated_date":"2019-03-14T17:21:00Z","reference_number":"EMA/CHMP/539146/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-subgroups-confirmatory-clinical-trials_en.pdf"},
    {"id":"44116","name":"Draft ICH guideline E19 on optimisation of safety data collection - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-03-29 - 2019-09-29","first_published_date":"2019-03-29T15:00:00Z","last_updated_date":"2019-03-29T15:00:00Z","reference_number":"EMA/CHMP/ICH/173706/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-e19-optimisation-safety-data-collection-step-2b_en.pdf"},
    {"id":"44120","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q3D on elemental impurities - Step 5 - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-03-29T14:00:00Z","last_updated_date":"2019-03-29T14:00:00Z","reference_number":"EMA/CHMP/ICH/353369/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-q3d-elemental-impurities-step-5-revision-1_en.pdf"},
    {"id":"44166","name":"VICH GL57 on Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: marker residue depletion studies to establish product withdrawal periods in aquatic species","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-04-03T14:07:00Z","last_updated_date":"2019-04-03T14:07:00Z","reference_number":"EMA/CVMP/VICH/517152/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl57-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food-producing-species-marker-residue-depletion-studies-establish-product-withdrawal-periods-aquatic-species_en.pdf"},
    {"id":"44167","name":"VICH GL36(R2): Studies to evaluate the safety of residues of veterinary drugs in human food: general approach to establish a microbiological ADI - Revision 2","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-04-03T15:36:00Z","last_updated_date":"2019-04-03T15:36:00Z","reference_number":"EMA/CVMP/VICH/467/2003","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl36r2-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach-establish-microbiological-adi-revision-2_en.pdf"},
    {"id":"44480","name":"Draft ICH guideline E8 (R1) on general considerations for clinical studies - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-05-10 - 2019-09-30","first_published_date":"2019-05-10T17:25:00Z","last_updated_date":"2019-05-10T17:25:00Z","reference_number":"EMA/CHMP/ICH/544570/1998","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-e8-r1-general-considerations-clinical-studies-step-2b_en.pdf"},
    {"id":"44598","name":"Draft etonogestrel and ethinylestradiol vaginal delivery system 0.12mg/0.015mg/day product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-05-27 - 2019-10-28","first_published_date":"2019-05-27T19:19:00Z","last_updated_date":"2019-05-27T19:19:00Z","reference_number":"EMA/CHMP/97470/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-etonogestrel-and-ethinylestradiol-vaginal-delivery-system-012mg-0015mg-day-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"44611","name":"Qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-05-29T11:15:00Z","last_updated_date":"2019-05-29T11:15:00Z","reference_number":"EMA/CHMP/SAWP/178058/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-stride-velocity-95th-centile-secondary-endpoint-duchenne-muscular-dystrophy-measured-valid-and-suitable-wearable-device_en.pdf"},
    {"id":"44637","name":"Draft guideline on the quality requirements for drug-device combinations - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-06-03 - 2019-08-31","first_published_date":"2019-06-03T16:00:00Z","last_updated_date":"2019-06-03T16:00:00Z","reference_number":"EMA/CHMP/QWP/BWP/259165/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-requirements-drug-device-combinations-first-version_en.pdf"},
    {"id":"44752","name":"Draft qualification opinion of Multiple sclerosis clinical outcome assessment (MSCOA)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-06-18 - 2019-09-20","first_published_date":"2019-06-19T12:37:00Z","last_updated_date":"2019-07-02T10:55:00Z","reference_number":"EMA/CHMP/SAWP/336445/2019 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-qualification-opinion-multiple-sclerosis-clinical-outcome-assessment-mscoa_en.pdf"},
    {"id":"44947","name":"Questions and Answers on allogenic stem cell-based products for veterinary use: Specific questions on extraneous agents - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T14:00:00Z","last_updated_date":"2019-06-28T14:00:00Z","reference_number":"EMA/CVMP/ADVENT/803494/2016-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-allogenic-stem-cell-based-products-veterinary-use-specific-questions-extraneous-agents-revision-1_en.pdf"},
    {"id":"44948","name":"Questions and Answers on allogeneic stem cell-based products for veterinary use: specific questions on sterility - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T14:17:00Z","last_updated_date":"2019-06-28T14:17:00Z","reference_number":"EMA/CVMP/ADVENT/751229/2016-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-allogeneic-stem-cell-based-products-veterinary-use-specific-questions-sterility-revision-1_en.pdf"},
    {"id":"44966","name":"Concept paper on the need for revision of the guideline on the investigation of medicinal products in the term and preterm neonate - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-07-01T15:30:00Z","last_updated_date":"2019-07-01T15:30:00Z","reference_number":"EMA/PDCO/362462/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-investigation-medicinal-products-term-and-preterm-neonate-revision-1_en.pdf"},
    {"id":"45707","name":"Alectinib hard capsule 150 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-10-15T14:17:00Z","last_updated_date":"2019-10-15T14:17:00Z","reference_number":"EMA/CHMP/790261/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/alectinib-hard-capsule-150-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"45709","name":"Apixaban film-coated tablet 2.5 and 5 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-10-15T14:27:00Z","last_updated_date":"2019-10-15T14:27:00Z","reference_number":"EMA/CHMP/291499/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/apixaban-film-coated-tablet-25-and-5-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"45710","name":"Cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 mg and 80 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-10-15T14:34:00Z","last_updated_date":"2019-10-15T14:34:00Z","reference_number":"EMA/CHMP/790333/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cabozantinib-tablet-20-mg-40-mg-and-60-mg-capsule-20-mg-and-80-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"45711","name":"Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-10-15T14:36:00Z","last_updated_date":"2019-10-15T14:36:00Z","reference_number":"EMA/CHMP/35552/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/colchicine-tablet-05-mg-and-1-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"45713","name":"Ezetimibe tablet 10 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-10-15T14:41:00Z","last_updated_date":"2019-10-15T14:41:00Z","reference_number":"EMA/CHMP/802491/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ezetimibe-tablet-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"45714","name":"Gefitinib film-coated tablet 250 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-10-15T14:45:00Z","last_updated_date":"2019-10-15T14:45:00Z","reference_number":"EMA/CHMP/257026/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/gefitinib-film-coated-tablet-250-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"45715","name":"Draft palbociclib hard capsule 75 mg, 100 mg and 125 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-10-15T14:50:00Z","last_updated_date":"2019-10-15T14:50:00Z","reference_number":"EMA/CHMP/802679/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-palbociclib-hard-capsule-75-mg-100-mg-and-125-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"45762","name":"Reflection paper on promoting the authorisation of alternatives to antimicrobials in the EU","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-10-18 - 2020-04-30","first_published_date":"2019-10-18T17:10:00Z","last_updated_date":"2019-10-18T17:10:00Z","reference_number":"EMA/CVMP/461776/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-promoting-authorisation-alternatives-antimicrobials-eu_en.pdf"},
    {"id":"46017","name":"Guideline on clinical investigation of medicinal products for the treatment of gout - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-11-14T10:00:00Z","last_updated_date":"2019-11-14T10:00:00Z","reference_number":"EMA/CHMP/774470/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-gout-first-version_en.pdf"},
    {"id":"46050","name":"Draft VICH GL59 Harmonisation of criteria to waive laboratory animal batch safety testing for vaccines for veterinary use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-11-18 - 2020-04-10","first_published_date":"2019-11-18T16:34:00Z","last_updated_date":"2019-11-18T16:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl59-harmonisation-criteria-waive-laboratory-animal-batch-safety-testing-vaccines-veterinary-use_en.pdf"},
    {"id":"46091","name":"Concept paper for the revision of scientific guidelines on limited market for veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-11-21 - 2020-01-31","first_published_date":"2019-11-21T18:00:00Z","last_updated_date":"2019-11-21T18:00:00Z","reference_number":"EMA/CVMP/539861/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-scientific-guidelines-limited-market-veterinary-medicinal-products_en.pdf"},
    {"id":"46106","name":"Information for the package leaflet regarding ethanol used as an excipient in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2019-11-22T09:21:00Z","last_updated_date":"2022-01-31T11:20:00Z","reference_number":"EMA/CHMP/43486/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/information-package-leaflet-regarding-ethanol-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"46107","name":"Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668) - Superseded","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-10-09T10:01:00Z","last_updated_date":"2019-11-22T10:00:00Z","reference_number":"EMA/CHMP/302620/2017 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_bg.pdf","es":"https://www.ema.europa.eu/es/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_cs.pdf","da":"https://www.ema.europa.eu/da/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_da.pdf","de":"https://www.ema.europa.eu/de/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_de.pdf","et":"https://www.ema.europa.eu/et/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_et.pdf","el":"https://www.ema.europa.eu/el/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_hr.pdf","it":"https://www.ema.europa.eu/it/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_sv.pdf","is":"https://www.ema.europa.eu/is/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_is.pdf","no":"https://www.ema.europa.eu/no/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-and-package-leaflet-medicinal-products-human-use-sante-2017-11668-superseded_no.pdf"}},
    {"id":"46289","name":"Draft guideline on good pharmacovigilance practices: Product- or population-specific considerations III: Pregnant and breastfeeding women","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2019-12-11 - 2020-02-28","first_published_date":"2019-12-11T09:52:00Z","last_updated_date":"2019-12-11T09:52:00Z","reference_number":"EMA/653036/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-product-or-population-specific-considerations-iii-pregnant-breastfeeding-women_en.pdf"},
    {"id":"46314","name":"VICH GL58 stability testing of new veterinary drug substances and medicinal products in climatic zones III and IV - First version","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2019-12-13T10:00:00Z","last_updated_date":"2020-12-17T19:00:00Z","reference_number":"EMA/CVMP/VICH/335918/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl58-stability-testing-new-veterinary-drug-substances-and-medicinal-products-climatic-zones-iii-and-iv-first-version_en.pdf"},
    {"id":"46461","name":"Draft reflection paper on good manufacturing practice and marketing authorisation holders","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-01-17 - 2020-07-17","first_published_date":"2020-01-20T14:34:00Z","last_updated_date":"2020-04-29T18:40:00Z","reference_number":"EMA/457570/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-good-manufacturing-practice-and-marketing-authorisation-holders_en.pdf"},
    {"id":"46649","name":"Question and answer document in support of the guideline on the assessment of persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances in veterinary medicinal products (EMA/CVMP/ERA/52740/2012)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-01-31T15:19:00Z","last_updated_date":"2020-01-31T15:19:00Z","reference_number":"EMA/593989/2019 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/question-and-answer-document-support-guideline-assessment-persistent-bioaccumulative-and-toxic-pbt-or-very-persistent-and-very-bioaccumulative-vpvb-substances-veterinary-medicinal-products_en.pdf"},
    {"id":"46704","name":"ICH M9 on biopharmaceutics classification system based biowaivers - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-02-11T14:09:00Z","last_updated_date":"2020-02-11T14:09:00Z","reference_number":"EMA/CHMP/ICH/493213/2018 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m9-biopharmaceutics-classification-system-based-biowaivers-step-5_en.pdf"},
    {"id":"46773","name":"Implementation of risk assessment requirements to control elemental impurities in veterinary medicinal products - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-02-17T17:45:00Z","last_updated_date":"2020-02-17T17:45:00Z","reference_number":"EMA/CVMP/QWP/631010/2017 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/implementation-risk-assessment-requirements-control-elemental-impurities-veterinary-medicinal-products-revision-2_en.pdf"},
    {"id":"46775","name":"Reflection paper on risk management requirements for elemental impurities in veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-02-17T17:41:00Z","last_updated_date":"2020-02-17T17:41:00Z","reference_number":"EMA/CVMP/QWP/153641/2018 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-management-requirements-elemental-impurities-veterinary-medicinal-products_en.pdf"},
    {"id":"46789","name":"ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-02-18T13:52:00Z","last_updated_date":"2020-02-18T13:52:00Z","reference_number":"EMA/CHMP/ICH/436221/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf"},
    {"id":"46790","name":"ICH S5 (R3) guideline on detection of reproductive and developmental toxicity for human pharmaceuticals - step 5 - Revision 4","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-02-18T14:30:00Z","last_updated_date":"2023-05-22T11:15:00Z","reference_number":"EMA/CHMP/ICH/544278/1998","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s5-r3-guideline-detection-reproductive-and-developmental-toxicity-human-pharmaceuticals-step-5-revision-4_en.pdf"},
    {"id":"46933","name":"ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-03-04T09:37:00Z","last_updated_date":"2020-03-04T09:37:00Z","reference_number":"EMA/CHMP/ICH/804273/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-step-5_en.pdf"},
    {"id":"46934","name":"ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management - Step 5 - Annexes","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-03-04T09:30:00Z","last_updated_date":"2020-03-04T09:30:00Z","reference_number":"EMA/CHMP/ICH/831751/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-step-5-annexes_en.pdf"},
    {"id":"46935","name":"Note on EU implementation of ICH Q12 (guideline on technical and regulatory considerations for pharmaceutical product lifecycle management)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-03-04T09:30:00Z","last_updated_date":"2020-03-04T09:30:00Z","reference_number":"EMA/CHMP/ICH/78332/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/note-eu-implementation-ich-q12-guideline-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management_en.pdf"},
    {"id":"47113","name":"Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-03-25 - 2020-04-25","first_published_date":"2020-03-25T16:45:00Z","last_updated_date":"2020-03-25T16:45:00Z","reference_number":"EMA/158330/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-implications-coronavirus-disease-covid-19-methodological-aspects-ongoing-clinical-trials_en.pdf"},
    {"id":"47255","name":"ICH guideline S11 on nonclinical safety testing in support of development of paediatric pharmaceuticals - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T10:47:00Z","last_updated_date":"2020-04-01T10:47:00Z","reference_number":"EMA/CHMP/ICH/616110/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-s11-nonclinical-safety-testing-support-development-paediatric-pharmaceuticals-step-5_en.pdf"},
    {"id":"47276","name":"Etonogestrel and ethinylestradiol vaginal delivery system 0.12 mg/0.015 mg/day product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-04-01T14:52:00Z","last_updated_date":"2020-04-01T14:52:00Z","reference_number":"EMA/CHMP/97470/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/etonogestrel-and-ethinylestradiol-vaginal-delivery-system-012-mg0015-mgday-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"47557","name":"Q3C (R8) Step 2b - impurities guideline for residual solvents - Pde for 2-methyltetrahydrofuran, cyclopentyl methyl ether, and tertiary-butyl alcohol","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-05-04 - 2020-07-30","first_published_date":"2020-05-04T17:13:00Z","last_updated_date":"2020-05-04T17:13:00Z","reference_number":"EMA/CHMP/ICH/213867/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/q3c-r8-step-2b-impurities-guideline-residual-solvents-pde-2-methyltetrahydrofuran-cyclopentyl-methyl-ether-and-tertiary-butyl-alcohol_en.pdf"},
    {"id":"47571","name":"Draft dasatinib film-coated tablets 20, 50, 70, 80, 100 & 140 mg and suspension 10 mg/ml product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-05-04 - 2020-08-31","first_published_date":"2020-05-06T11:10:00Z","last_updated_date":"2020-05-06T11:10:00Z","reference_number":"EMA/CHMP/675838/2014/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-dasatinib-film-coated-tablets-20-50-70-80-100-140-mg-and-suspension-10-mg-ml-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"47584","name":"Concept paper for the development of a reflection paper on the environmental risk assessment for parasiticide veterinary medicinal products used in companion animals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-05-07 - 2020-10-31","first_published_date":"2020-05-07T12:08:00Z","last_updated_date":"2020-05-07T12:08:00Z","reference_number":"EMA/CVMP/ERA/55512/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-environmental-risk-assessment-parasiticide-veterinary-medicinal-products-used-companion-animals_en.pdf"},
    {"id":"47709","name":"Superseded note for guidance: Environmental risk assessment for veterinary medicinal products other than GMO-containing and immunological products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-05-19T11:27:00Z","last_updated_date":"2020-05-19T11:27:00Z","reference_number":"EMEA/CVMP/055/96-FINAL","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/superseded-note-guidance-environmental-risk-assessment-veterinary-medicinal-products-other-gmo-containing-and-immunological-products_en.pdf"},
    {"id":"48007","name":"Draft Levothyroxine tablets 12.5 mcg, 25 mcg, 50 mcg, 75 mcg, 100 mcg (and additional strengths) and 200 mcg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-06-15 - 2020-09-30","first_published_date":"2020-06-15T13:30:00Z","last_updated_date":"2020-06-15T13:30:00Z","reference_number":"EMA/CHMP/176098/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-levothyroxine-tablets-125-mcg-25-mcg-50-mcg-75-mcg-100-mcg-and-additional-strengths-and-200-mcg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"48009","name":"Draft abiraterone tablets 250 mg and 500 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-06-15 - 2020-09-30","first_published_date":"2020-06-15T16:41:00Z","last_updated_date":"2020-06-15T16:41:00Z","reference_number":"EMA/CHMP/474712/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-abiraterone-tablets-250-mg-and-500-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"48096","name":"Guideline on good pharmacovigilance practices (GVP): Module VIII Addendum I - Requirements and recommendations for the submission of information on non-interventional post-authorisation safety studies (Rev. 3)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-06-23T14:17:00Z","last_updated_date":"2020-06-23T14:17:00Z","reference_number":"EMA/395730/2012 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-addendum-i-requirements-and-recommendations-submission-information-non-interventional-post-authorisation-safety-studies-rev-3_en.pdf"},
    {"id":"48170","name":"Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-06-29T13:45:00Z","last_updated_date":"2020-06-29T13:45:00Z","reference_number":"EMA/158330/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-implications-coronavirus-disease-covid-19-methodological-aspects-ongoing-clinical-trials-revision-1_en.pdf"},
    {"id":"48193","name":"Draft CVMP strategy on antimicrobials 2021-2025","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-07-01 - 2020-09-30","first_published_date":"2020-07-01T12:25:00Z","last_updated_date":"2020-07-01T12:25:00Z","reference_number":"EMA/CVMP/179874/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-cvmp-strategy-antimicrobials-2021-2025_en.pdf"},
    {"id":"48221","name":"Lapatinib film-coated tablet 250 mg product-specific bioequivalence guidance - First version (2nd draft)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-07-06 - 2021-01-31","first_published_date":"2020-07-03T16:58:00Z","last_updated_date":"2020-11-17T10:30:00Z","reference_number":"EMA/CHMP/257298/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/lapatinib-film-coated-tablet-250-mg-product-specific-bioequivalence-guidance-first-version-2nd-draft_en.pdf"},
    {"id":"48225","name":"Questions and answers - ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-07-03 - 2020-10-02","first_published_date":"2020-07-03T18:11:00Z","last_updated_date":"2020-07-03T18:11:00Z","reference_number":"EMA/CHMP/ICH/321999/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-ich-guideline-m7-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-step-2b_en.pdf"},
    {"id":"48335","name":"Guideline on the quality of water for pharmaceutical use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-07-20T17:20:00Z","last_updated_date":"2020-07-20T17:20:00Z","reference_number":"EMA/CHMP/CVMP/QWP/496873/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-water-pharmaceutical-use_en.pdf"},
    {"id":"48720","name":"ICH guideline E14/S7B on clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential - questions and answers - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-08-28 - 2020-11-28","first_published_date":"2020-08-28T14:58:00Z","last_updated_date":"2020-08-28T14:58:00Z","reference_number":"EMA/CHMP/ICH/415588/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e14-s7b-clinical-and-nonclinical-evaluation-qt-qtc-interval-prolongation-and-proarrhythmic-potential-questions-and-answers-step-2b_en.pdf"},
    {"id":"48864","name":"Draft ICH guideline Q3D (R2) on elemental impurities - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-09-18 - 2020-12-25","first_published_date":"2020-09-18T16:39:00Z","last_updated_date":"2020-10-01T13:12:00Z","reference_number":"EMA/CHMP/ICH/353369/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-q3d-r2-elemental-impurities-step-2b_en.pdf"},
    {"id":"48885","name":"Draft guideline on registry-based studies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-09-24 - 2020-12-31","first_published_date":"2020-09-24T14:00:00Z","last_updated_date":"2020-09-24T14:00:00Z","reference_number":"EMA/502388/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-registry-based-studies_en.pdf"},
    {"id":"48968","name":"Questions and answers on Data Monitoring Committees issues","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-10-08T15:49:00Z","last_updated_date":"2020-10-08T15:49:00Z","reference_number":"EMA/CHMP/470185/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-data-monitoring-committees-issues_en.pdf"},
    {"id":"48999","name":"Draft guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) - Rev. 4","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-10-13 - 2021-01-13","first_published_date":"2020-10-13T15:11:00Z","last_updated_date":"2020-10-13T15:11:00Z","reference_number":"EMA/CHMP/BPWP/94033/2007 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-rev-4_en.pdf"},
    {"id":"49000","name":"Draft guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) - Rev. 6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-10-13 - 2021-01-13","first_published_date":"2020-10-13T15:14:00Z","last_updated_date":"2020-10-13T15:14:00Z","reference_number":"EMA/CHMP/BPWP/94038/2007 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-6_en.pdf"},
    {"id":"49107","name":"Reflection paper on the pharmaceutical development of medicines for use in the older population - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-10-22T14:35:00Z","last_updated_date":"2020-10-22T14:35:00Z","reference_number":"EMA/CHMP/QWP/292439/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-pharmaceutical-development-medicines-use-older-population-first-version_en.pdf"},
    {"id":"49195","name":"Dasatinib film-coated tablets 20, 50, 70, 80, 100 & 140 mg and suspension 10 mg/ml product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-11-09T09:08:00Z","last_updated_date":"2020-11-09T09:08:00Z","reference_number":"EMA/CHMP/675838/2014/Rev.1*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/dasatinib-film-coated-tablets-20-50-70-80-100-140-mg-and-suspension-10-mgml-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"49196","name":"Draft acenocoumarol, tablet, 1 mg and 4 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-11-09 - 2021-02-28","first_published_date":"2020-11-09T10:35:00Z","last_updated_date":"2020-11-09T10:35:00Z","reference_number":"EMA/CHMP/512475/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-acenocoumarol-tablet-1-mg-and-4-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"49257","name":"Draft guideline on the evaluation of anticancer medicinal products in man - Revision 6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-11-13 - 2021-02-15","first_published_date":"2020-11-16T09:58:00Z","last_updated_date":"2020-11-16T09:58:00Z","reference_number":"EMA/CHMP/205/95 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-anticancer-medicinal-products-man-revision-6_en.pdf"},
    {"id":"49314","name":"Abiraterone acetate tablets 250 mg and 500 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-11-23T13:32:00Z","last_updated_date":"2020-11-23T13:32:00Z","reference_number":"EMA/CHMP/474712/2016 Rev. 1 Corr 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/abiraterone-acetate-tablets-250-mg-and-500-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"49315","name":"Guidance related to GMP/GDP and PMF distant assessments","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2020-11-23T13:47:00Z","last_updated_date":"2024-08-20T15:53:00Z","reference_number":"EMA/335293/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidance-related-gmp-gdp-pmf-distant-assessments_en.pdf"},
    {"id":"49317","name":"Draft palbociclib hard capsule 75 mg, 100 mg and 125 mg and film-coated tablet 75 mg, 100 mg and 125 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-11-23 - 2021-02-28","first_published_date":"2020-11-23T16:24:00Z","last_updated_date":"2020-11-23T16:24:00Z","reference_number":"EMA/CHMP/802679/2018 Rev. 1 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-palbociclib-hard-capsule-75-mg-100-mg-and-125-mg-and-film-coated-tablet-75-mg-100-mg-and-125-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"49500","name":"ICH reflection paper on proposed ICH guideline work to advance patient focused drug development","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-12-10 - 2021-03-07","first_published_date":"2020-12-10T10:30:00Z","last_updated_date":"2020-12-10T10:30:00Z","reference_number":"EMA/CHMP/ICH/415588/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-reflection-paper-proposed-ich-guideline-work-advance-patient-focused-drug-development_en.pdf"},
    {"id":"49591","name":"Levothyroxine tablets 12.5 mcg, 25 mcg, 50 mcg, 75 mcg, 100 mcg and 200 mcg (and additional strengths within the range) product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-12-16T12:54:00Z","last_updated_date":"2020-12-16T12:54:00Z","reference_number":"EMA/CHMP/176098/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/levothyroxine-tablets-125-mcg-25-mcg-50-mcg-75-mcg-100-mcg-and-200-mcg-and-additional-strengths-within-range-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"49606","name":"Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-12-17T13:24:00Z","last_updated_date":"2021-04-28T01:05:00Z","reference_number":"EMA/CAT/GTWP/671639/2008 Rev. 1 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-and-clinical-aspects-medicinal-products-containing-genetically-modified-cells-revision-1_en.pdf"},
    {"id":"49622","name":"Draft deferasirox, dispersible tablets (125 mg, 250 mg and 500 mg), film-coated tablets (90 mg, 180 mg, and 360 mg), and granules (90 mg, 180 mg and 360 mg) product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2020-12-18 - 2021-03-31","first_published_date":"2020-12-18T12:22:00Z","last_updated_date":"2020-12-18T12:22:00Z","reference_number":"EMA/CHMP/472383/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-deferasirox-dispersible-tablets-125-mg-250-mg-500-mg-film-coated-tablets-90-mg-180-mg-360-mg-granules-90-mg-180-mg-360-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"49684","name":"VICH GL59 Harmonisation of criteria to waive laboratory animal batch safety testing for vaccines for veterinary use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2020-12-22T14:35:00Z","last_updated_date":"2020-12-22T14:35:00Z","reference_number":"EMA/CVMP/VICH/677723/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl59-harmonisation-criteria-waive-laboratory-animal-batch-safety-testing-vaccines-veterinary-use_en.pdf"},
    {"id":"49792","name":"Reflection paper on dose review and adjustment of established veterinary antibiotics in the context of SPC harmonisation - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-01-13T10:28:00Z","last_updated_date":"2021-01-13T10:28:00Z","reference_number":"EMA/CVMP/849775/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-dose-review-and-adjustment-established-veterinary-antibiotics-context-spc-harmonisation-first-version_en.pdf"},
    {"id":"49977","name":"Draft concept paper for the development of a guideline on data requirements for authorisation of immunological veterinary medicinal products under exceptional circumstances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-01-29 - 2021-03-31","first_published_date":"2021-01-29T15:00:00Z","last_updated_date":"2021-01-29T15:00:00Z","reference_number":"EMA/CVMP/IWP/630533/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-guideline-data-requirements-authorisation-immunological-veterinary-medicinal-products-under-exceptional-circumstances_en.pdf"},
    {"id":"49978","name":"Draft concept paper for the revision of the guideline on data requirements for multi-strain dossiers for inactivated vaccines against Avian Influenza (AI), Blue Tongue (BT) and Foot and Mouth Disease (FMD) - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-01-29 - 2021-03-31","first_published_date":"2021-01-29T15:04:00Z","last_updated_date":"2021-01-29T15:04:00Z","reference_number":"EMA/CVMP/IWP/600275/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-revision-guideline-data-requirements-multi-strain-dossiers-inactivated-vaccines-against-avian-influenza-ai-blue-tongue-bt-and-foot-and-mouth-disease-fmd-revision-2_en.pdf"},
    {"id":"49979","name":"Draft concept paper for the development of a guideline on data requirements for vaccine antigen master files (VAMF)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-01-29 - 2021-03-31","first_published_date":"2021-01-29T15:01:00Z","last_updated_date":"2021-01-29T15:01:00Z","reference_number":"EMA/CVMP/IWP/674640/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-guideline-data-requirements-vaccine-antigen-master-files-vamf_en.pdf"},
    {"id":"49980","name":"Draft concept paper for the development of a guideline on data requirements for vaccine platform technology master files (PTMF)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-01-29 - 2021-03-31","first_published_date":"2021-01-29T15:03:00Z","last_updated_date":"2021-01-29T15:03:00Z","reference_number":"EMA/CVMP/IWP/582191/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-guideline-data-requirements-vaccine-platform-technology-master-files-ptmf_en.pdf"},
    {"id":"49981","name":"Draft concept paper on the provision of field efficacy studies in support of marketing authorisation applications for immunological veterinary medicinal products and on indications for veterinary vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-01-29 - 2021-03-31","first_published_date":"2021-01-29T15:06:00Z","last_updated_date":"2021-01-29T15:06:00Z","reference_number":"EMA/CVMP/IWP/671155/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-provision-field-efficacy-studies-support-marketing-authorisation-applications-immunological-veterinary-medicinal-products-and-indications-veterinary-vaccines_en.pdf"},
    {"id":"50019","name":"CVMP strategy on antimicrobials 2021-2025","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-02-02T09:45:00Z","last_updated_date":"2021-02-02T09:45:00Z","reference_number":"EMA/CVMP/179874/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cvmp-strategy-antimicrobials-2021-2025_en.pdf"},
    {"id":"50029","name":"Draft toolbox guidance on scientific elements and regulatory tools to support quality data packages for PRIME marketing authorisation applications","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-02-02 - 2021-07-31","first_published_date":"2021-02-02T16:30:00Z","last_updated_date":"2021-02-02T16:30:00Z","reference_number":"EMA/CHMP/BWP/QWP/IWG/694114/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-toolbox-guidance-scientific-elements-and-regulatory-tools-support-quality-data-packages-prime-marketing-authorisation-applications_en.pdf"},
    {"id":"50072","name":"Sorafenib film-coated tablets 200 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-02-05T02:00:00Z","last_updated_date":"2021-02-05T02:00:00Z","reference_number":"EMA/CHMP/315232/2014 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/sorafenib-film-coated-tablets-200-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"50269","name":"Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-02-25T13:58:00Z","last_updated_date":"2021-02-25T13:58:00Z","reference_number":"EMA/117973/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-vaccines-intended-provide-protection-against-variant-strains-sars-cov-2_en.pdf"},
    {"id":"50275","name":"Draft guideline on efficacy and target animal safety data requirements for applications for non-immunological veterinary medicinal products intended for limited markets submitted under Article 23 of the Regulation (EU) 2019/6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-02-25 - 2021-05-15","first_published_date":"2021-02-25T15:43:00Z","last_updated_date":"2021-02-25T15:43:00Z","reference_number":"EMA/CVMP/52665/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-efficacy-and-target-animal-safety-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-2019_en.pdf"},
    {"id":"50276","name":"Draft guideline on data requirements for applications for immunological veterinary medicinal products intended for limited markets submitted under Article 23 of the Regulation (EU) 2019/6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-02-25 - 2021-05-15","first_published_date":"2021-02-25T15:47:00Z","last_updated_date":"2021-02-25T15:47:00Z","reference_number":"EMA/CVMP/59531/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-applications-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-2019-6_en.pdf"},
    {"id":"50277","name":"Draft guideline on safety and residue data requirements for applications for non-immunological veterinary medicinal products intended for limited markets submitted under Article 23 of the Regulation (EU) 2019/6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-02-25 - 2021-05-15","first_published_date":"2021-02-25T15:52:00Z","last_updated_date":"2021-02-25T15:52:00Z","reference_number":"EMA/CVMP/345237/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-safety-and-residue-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-2019-6_en.pdf"},
    {"id":"50278","name":"Draft guideline on safety and residue data requirements for the establishment of Maximum Residue Limits in minor species","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-02-25 - 2021-05-15","first_published_date":"2021-02-25T15:56:00Z","last_updated_date":"2021-02-25T15:56:00Z","reference_number":"EMA/CVMP/345236/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-safety-and-residue-data-requirements-establishment-maximum-residue-limits-minor-species_en.pdf"},
    {"id":"50327","name":"Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-03-01T15:21:00Z","last_updated_date":"2021-03-01T15:21:00Z","reference_number":"EMA/CVMP/AWP/842786/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-aminopenicillins-and-their-beta-lactamase-inhibitor-combinations-animals-european-union-development-resistance-and-impact-human-and-animal-health-first-version_en.pdf"},
    {"id":"50332","name":"Reflection paper on antimicrobial resistance in the environment: considerations for current and future risk assessment of veterinary medicinal products - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-03-01T16:39:00Z","last_updated_date":"2021-03-01T16:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-antimicrobial-resistance-environment-considerations-current-and-future-risk-assessment-veterinary-medicinal-products-first-version_en.pdf"},
    {"id":"50595","name":"CHMP Safety Working Party’s response to CMDh questions on chlorobutanol","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-03-17T09:03:00Z","last_updated_date":"2021-07-26T15:09:00Z","reference_number":" EMA/CHMP/SWP/482438/2020 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chmp-safety-working-partys-response-cmdh-questions-chlorobutanol_en.pdf"},
    {"id":"50979","name":"Concept paper for the revision of the guideline on the summary of product characteristics for anthelmintics","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-04-22 - 2021-05-31","first_published_date":"2021-04-26T11:33:00Z","last_updated_date":"2021-04-26T11:33:00Z","reference_number":"EMA/CVMP/EWP/165592/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-summary-product-characteristics-anthelmintics_en.pdf-0"},
    {"id":"51202","name":"Addendum to the ICH guideline S1B on testing for carcinogenicity of pharmaceuticals - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-04-22 - 2021-10-22","first_published_date":"2021-05-20T13:05:00Z","last_updated_date":"2021-05-20T13:05:00Z","reference_number":"EMA/CHMP/ICH/272147/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-ich-guideline-s1b-testing-carcinogenicity-pharmaceuticals-step-2b_en.pdf"},
    {"id":"51254","name":"Draft reflection paper on methods found suitable within the EU for demonstrating freedom from extraneous agents of the seeds used for the production of immunological veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-05-21 - 2021-07-23","first_published_date":"2021-05-25T15:50:00Z","last_updated_date":"2021-05-25T15:50:00Z","reference_number":"EMA/CVMP/IWP/251741/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-methods-found-suitable-within-eu-demonstrating-freedom-extraneous-agents-seeds-used-production-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"51424","name":"Deferasirox, dispersible tablets (125 mg, 250 mg and 500 mg), film-coated tablets (90 mg, 180 mg, and 360 mg), and granules (90 mg, 180 mg and 360 mg) product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-06-14T10:41:00Z","last_updated_date":"2021-06-14T10:41:00Z","reference_number":"EMA/CHMP/472383/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/deferasirox-dispersible-tablets-125-mg-250-mg-and-500-mg-film-coated-tablets-90-mg-180-mg-and-360-mg-and-granules-90-mg-180-mg-and-360-mg-product-specific-bioequivalence-guidance_en.pdf-0"}    {"id":"51490","name":"EudraVigilance access policy for medicines for veterinary use - Revision 2.1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T16:30:00Z","last_updated_date":"2022-06-01T09:17:00Z","reference_number":"EMA/113700/2008 Rev. 2.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/eudravigilance-access-policy-medicines-veterinary-use-revision-21_en.pdf"},
    {"id":"51574","name":"Draft ICH guideline E6 on good clinical practice - Revision 2","type":"scientific-guideline","status":"Draft","consultation_date":"","first_published_date":"2021-06-24T10:56:00Z","last_updated_date":"2021-06-24T10:56:00Z","reference_number":"EMA/CHMP/ICH/337843/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-e6-good-clinical-practice-revision-2_en.pdf"},
    {"id":"51575","name":"ICH reflection paper - proposed ICH guideline work to advance Patient Focused Drug Development (PFDD)","type":"scientific-guideline","status":"Draft","consultation_date":"","first_published_date":"2021-06-24T11:03:00Z","last_updated_date":"2021-06-24T11:03:00Z","reference_number":"EMA/CHMP/ICH/338534/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-reflection-paper-proposed-ich-guideline-work-advance-patient-focused-drug-development-pfdd_en.pdf"},
    {"id":"51576","name":"Outcome of public consultation on ICH reflection paper on proposed ICH guideline work to advance patient focused drug development (PFDD)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-06-24T11:07:00Z","last_updated_date":"2021-06-24T11:07:00Z","reference_number":"EMA/CHMP/ICH/338535/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/outcome-public-consultation-ich-reflection-paper-proposed-ich-guideline-work-advance-patient-focused-drug-development-pfdd_en.pdf"},
    {"id":"51611","name":"Draft guideline on data requirements for multi-strain dossiers for inactivated veterinary vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-06-25 - 2021-09-30","first_published_date":"2021-06-25T16:03:00Z","last_updated_date":"2021-06-25T16:03:00Z","reference_number":"EMA/CVMP/IWP/105506/2007 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-multi-strain-dossiers-inactivated-veterinary-vaccines_en.pdf"},
    {"id":"51614","name":"Concept paper for the revision of the guideline on requirements for production and control of immunological veterinary medicinal products - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-06-25 - 2021-09-30","first_published_date":"2021-06-25T16:12:00Z","last_updated_date":"2021-06-25T16:12:00Z","reference_number":"EMA/CVMP/IWP/284316/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-requirements-production-and-control-immunological-veterinary-medicinal-products-revision-2_en.pdf"},
    {"id":"51615","name":"Concept paper for the revision of residues guidelines to align with the definitions for withdrawal periods provided in Regulation (EU) 2019/6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-06-25 - 2021-07-31","first_published_date":"2021-06-25T16:19:00Z","last_updated_date":"2021-06-25T16:19:00Z","reference_number":"EMA/CVMP/SWP/265238/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-residues-guidelines-align-definitions-withdrawal-periods-provided-regulation-eu-2019-6_en.pdf"},
    {"id":"51616","name":"Draft guideline on data requirements for vaccine antigen master files (VAMF)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-06-25 - 2021-09-30","first_published_date":"2021-06-25T16:32:00Z","last_updated_date":"2021-06-25T16:32:00Z","reference_number":"EMA/CVMP/IWP/258755/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-vaccine-antigen-master-files-vamf_en.pdf"},
    {"id":"51704","name":"Draft guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-01 - 2021-08-31","first_published_date":"2021-07-01T10:40:00Z","last_updated_date":"2021-07-01T10:40:00Z","reference_number":"EMA/CHMP/BWP/534898/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials-revision-2_en.pdf"},
    {"id":"51705","name":"Draft guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-01 - 2021-08-31","first_published_date":"2021-07-01T10:46:00Z","last_updated_date":"2021-07-01T10:46:00Z","reference_number":"EMA/CHMP/QWP/545525/2017 Rev. 2 *Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-chemical-and-pharmaceutical-quality-documentation-concerning-investigational-medicinal-products-clinical-trials-revision-2_en.pdf"},
    {"id":"51895","name":"Consideration on core requirements for PSURs of COVID-19 vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-09T11:10:00Z","last_updated_date":"2021-07-09T11:10:00Z","reference_number":"EMA/362988/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/consideration-core-requirements-psurs-covid-19-vaccines_en.pdf"},
    {"id":"51972","name":"Concept paper on the development of a guideline on determination of the need for an MRL evaluation for biological substances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-23 - 2021-09-30","first_published_date":"2021-07-23T18:26:00Z","last_updated_date":"2021-07-23T18:26:00Z","reference_number":"EMA/CVMP/SWP/207500/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-determination-need-mrl-evaluation-biological-substances_en.pdf"},
    {"id":"52027","name":"Guideline on data requirements for adjuvants in vaccines for veterinary use - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T13:51:00Z","last_updated_date":"2021-07-23T13:51:00Z","reference_number":"EMA/CVMP/IWP/315887/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-adjuvants-vaccines-veterinary-use-revision-1_en.pdf"},
    {"id":"52030","name":"Draft guideline on data requirements for authorisation of immunological veterinary medicinal products under exceptional circumstances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-23 - 2021-10-29","first_published_date":"2021-07-23T11:26:00Z","last_updated_date":"2021-07-23T11:26:00Z","reference_number":"EMA/CVMP/IWP/299554/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-authorisation-immunological-veterinary-medicinal-products-under-exceptional-circumstances_en.pdf"},
    {"id":"52031","name":"Draft guideline on clinical trials with immunological veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-23 - 2021-10-29","first_published_date":"2021-07-23T14:30:00Z","last_updated_date":"2021-07-23T14:30:00Z","reference_number":"EMA/CVMP/IWP/260956/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-trials-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"52037","name":"Guideline on Manufacture of the veterinary finished dosage form","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T16:40:00Z","last_updated_date":"2021-07-23T16:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-manufacture-veterinary-finished-dosage-form_en.pdf"},
    {"id":"52039","name":"Draft guideline on data requirements for vaccine platform technology master files (vPTMF)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-23 - 2021-10-29","first_published_date":"2021-07-23T10:44:00Z","last_updated_date":"2021-07-23T10:44:00Z","reference_number":"EMA/CVMP/IWP/286631","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-vaccine-platform-technology-master-files-vptmf_en.pdf"},
    {"id":"52047","name":"Guideline on quality documentation for medicinal products when used with a medical device - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:12:00Z","last_updated_date":"2021-07-23T12:12:00Z","reference_number":"EMA/CHMP/QWP/BWP/259165/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-documentation-medicinal-products-when-used-medical-device-first-version_en.pdf"},
    {"id":"52055","name":"Draft guideline on the summary of product characteristics for antiparasitic veterinary medicinal products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-23 - 2021-09-30","first_published_date":"2021-07-23T15:10:00Z","last_updated_date":"2021-07-23T15:10:00Z","reference_number":"EMA/CVMP/EWP/170208/2005 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-summary-product-characteristics-antiparasitic-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"52068","name":"Concept paper on the development of a guideline on the environmental risk assessment of veterinary medicinal products intended to be used in aquaculture","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-23 - 2021-10-31","first_published_date":"2021-07-23T18:21:00Z","last_updated_date":"2021-07-23T18:21:00Z","reference_number":"EMA/CVMP/ERA/173026/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-environmental-risk-assessment-veterinary-medicinal-products-intended-be-used-aquaculture_en.pdf"},
    {"id":"52071","name":"Guideline on safety and residue data requirements for applications for non-immunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T17:06:00Z","last_updated_date":"2021-07-23T17:06:00Z","reference_number":"EMA/CVMP/345237/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-safety-and-residue-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-20196_en.pdf"},
    {"id":"52072","name":"Guideline on efficacy and target animal safety data requirements for applications for non-immunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T17:16:00Z","last_updated_date":"2021-07-23T17:16:00Z","reference_number":"EMA/CVMP/52665/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-efficacy-and-target-animal-safety-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-20196_en.pdf"},
    {"id":"52073","name":"Guideline on data requirements for applications for immunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T17:24:00Z","last_updated_date":"2021-07-23T17:24:00Z","reference_number":"EMA/CVMP/59531/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-applications-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-20196_en.pdf"},
    {"id":"52074","name":"Guideline for the conduct of efficacy studies for non-steroidal anti-inflammatory drugs - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T10:58:00Z","last_updated_date":"2021-07-26T10:58:00Z","reference_number":"EMA/CVMP/EWP/1061/2001 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-efficacy-studies-non-steroidal-anti-inflammatory-drugs-revision-1_en.pdf"},
    {"id":"52075","name":"Guideline on the conduct of bioequivalence studies for veterinary medicinal products - Revision 4","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T11:14:00Z","last_updated_date":"2021-07-26T11:14:00Z","reference_number":"EMA/CVMP/016/2000 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-revision-4_en.pdf"},
    {"id":"52076","name":"Guideline on statistical principles for clinical trials for veterinary medicinal products (pharmaceuticals) - Rev. 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T11:45:00Z","last_updated_date":"2021-07-26T11:45:00Z","reference_number":"EMA/CVMP/EWP/81976/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-statistical-principles-clinical-trials-veterinary-medicinal-products-pharmaceuticals-rev-1_en.pdf"},
    {"id":"52077","name":"Reflection paper on promoting the authorisation of alternatives to antimicrobial veterinary medicinal products in the EU","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T14:02:00Z","last_updated_date":"2021-07-26T14:02:00Z","reference_number":"EMA/CVMP/143258/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-promoting-authorisation-alternatives-antimicrobial-veterinary-medicinal-products-eu_en.pdf"},
    {"id":"52079","name":"Guideline on the demonstration of palatability of veterinary medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T14:17:00Z","last_updated_date":"2021-07-26T14:17:00Z","reference_number":"EMA/CVMP/EWP/206024/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-demonstration-palatability-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"52080","name":"Guideline on demonstration of target animal safety and efficacy of veterinary medicinal products intended for use in farmed finfish - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T14:43:00Z","last_updated_date":"2021-07-26T14:43:00Z","reference_number":"EMA/CVMP/EWP/459868/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-demonstration-target-animal-safety-and-efficacy-veterinary-medicinal-products-intended-use-farmed-finfish-revision-1_en.pdf"},
    {"id":"52081","name":"Guideline on dossier requirements for anticancer medicinal products for dogs and cats - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T14:51:00Z","last_updated_date":"2021-07-26T14:51:00Z","reference_number":"EMA/CVMP/28510/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-dossier-requirements-anticancer-medicinal-products-dogs-and-cats-revision-1_en.pdf"},
    {"id":"52082","name":"Guideline on veterinary medicinal products controlling Varroa destructor parasitosis in bees - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T15:00:00Z","last_updated_date":"2021-07-26T15:00:00Z","reference_number":"EMA/CVMP/EWP/459883/2008 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-veterinary-medicinal-products-controlling-varroa-destructor-parasitosis-bees-revision-1_en.pdf"},
    {"id":"52083","name":"Guidelines on specific efficacy requirements for ectoparasiticides in cattle - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T15:15:00Z","last_updated_date":"2021-07-26T15:15:00Z","reference_number":"EMA/CVMP/625/03-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidelines-specific-efficacy-requirements-ectoparasiticides-cattle-revision-1_en.pdf"},
    {"id":"52084","name":"Guidelines on specific efficacy requirements for ectoparasiticides in sheep - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T15:28:00Z","last_updated_date":"2021-07-26T15:28:00Z","reference_number":"EMA/CVMP/411/01-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidelines-specific-efficacy-requirements-ectoparasiticides-sheep-revision-1_en.pdf"},
    {"id":"52085","name":"Guidelines on specific efficacy requirements for ectoparasiticides in sheep - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T15:28:00Z","last_updated_date":"2021-07-26T15:28:00Z","reference_number":"EMA/CVMP/411/01-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidelines-specific-efficacy-requirements-ectoparasiticides-sheep-revision-1_en.pdf-0"},
    {"id":"52086","name":"Guideline for the testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestation in dogs and cats - Revision 4","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-07-26T16:50:00Z","last_updated_date":"2021-07-26T16:50:00Z","reference_number":"EMEA/CVMP/EWP/005/2000 Rev.4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-testing-and-evaluation-efficacy-antiparasitic-substances-treatment-and-prevention-tick-and-flea-infestation-dogs-and-cats-revision-4_en.pdf"},
    {"id":"52087","name":"Guideline on pharmaceutical fixed combination products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-26T16:52:00Z","last_updated_date":"2021-07-26T16:52:00Z","reference_number":"EMA/CVMP/83804/2005-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-fixed-combination-products-revision-1_en.pdf"},
    {"id":"52096","name":"Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-27T11:08:00Z","last_updated_date":"2021-07-27T11:08:00Z","reference_number":"EMA/CHMP/138502/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-statistical-methodology-comparative-assessment-quality-attributes-drug-development_en.pdf"},
    {"id":"52144","name":"Draft guideline on core SmPC, labelling and package leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-30 - 2021-10-31","first_published_date":"2021-07-30T11:00:00Z","last_updated_date":"2021-07-30T11:00:00Z","reference_number":"EMA/CAT/CHMP/158266/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-labelling-and-package-leaflet-advanced-therapy-medicinal-products-atmps-containing-genetically-modified-cells_en.pdf"},
    {"id":"52148","name":"Draft ICH guideline Q13 on continuous manufacturing of drug substances and drug products - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-29 - 2021-12-20","first_published_date":"2021-07-29T16:39:00Z","last_updated_date":"2021-07-29T16:39:00Z","reference_number":"EMA/CHMP/ICH/427817/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-q13-continuous-manufacturing-drug-substances-and-drug-products-step-2b_en.pdf"},
    {"id":"52149","name":"Reflection paper on good manufacturing practice and marketing authorisation holders","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-07-29T14:58:00Z","last_updated_date":"2022-01-14T11:46:00Z","reference_number":"EMA/419571/2021 Version 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-good-manufacturing-practice-marketing-authorisation-holders_en.pdf"},
    {"id":"52428","name":"Palbociclib hard capsule 75 mg, 100 mg and 125 mg and film-coated tablet 75 mg, 100 mg and 125 mg productspecific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-09-13T13:59:00Z","last_updated_date":"2021-09-13T13:59:00Z","reference_number":"EMA/CHMP/802679/2018 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/palbociclib-hard-capsule-75-mg-100-mg-and-125-mg-and-film-coated-tablet-75-mg-100-mg-and-125-mg-productspecific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"52429","name":"Palbociclib hard capsule 75 mg, 100 mg and 125 mg and film-coated tablet 75 mg, 100 mg and 125 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-09-13T14:11:00Z","last_updated_date":"2021-09-22T11:00:00Z","reference_number":"EMA/CHMP/802679/2018 Rev.1 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/palbociclib-hard-capsule-75-mg-100-mg-and-125-mg-and-film-coated-tablet-75-mg-100-mg-and-125-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"52430","name":"Lapatinib film-coated tablet 250 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-09-13T14:18:00Z","last_updated_date":"2021-09-22T11:01:00Z","reference_number":"EMA/CHMP/257298/2018 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/lapatinib-film-coated-tablet-250-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"52432","name":"Acenocoumarol, tablet, 1 mg and 4 mg product-specific bioequivalence guidance - First version","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-09-13T14:41:00Z","last_updated_date":"2021-09-22T11:57:00Z","reference_number":"EMA/CHMP/512475/2020 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/acenocoumarol-tablet-1-mg-and-4-mg-product-specific-bioequivalence-guidance-first-version_en.pdf"},
    {"id":"52504","name":"Draft reflection paper on the interpretation of Article 18(7) of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-09-17 - 2021-12-17","first_published_date":"2021-09-17T16:45:00Z","last_updated_date":"2021-09-17T16:45:00Z","reference_number":"EMA/CVMP/ERA/622045/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-interpretation-article-187-regulation-eu-2019-6_en.pdf"},
    {"id":"52505","name":"Reflection paper on higher tier testing to investigate the effects of parasiticidal veterinary medicinal products on dung fauna","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T14:56:00Z","last_updated_date":"2021-09-17T14:56:00Z","reference_number":"EMA/CVMP/ERA/87473/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-higher-tier-testing-investigate-effects-parasiticidal-veterinary-medicinal-products-dung-fauna_en.pdf"},
    {"id":"52506","name":"Reflection paper on methods found suitable within the EU for demonstrating freedom from extraneous agents of the seeds used for the production of immunological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T15:05:00Z","last_updated_date":"2021-09-17T15:05:00Z","reference_number":"EMA/CVMP/IWP/251741/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-methods-found-suitable-within-eu-demonstrating-freedom-extraneous-agents-seeds-used-production-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"52777","name":"Draft ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Addendum - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-10-08 - 2021-12-08","first_published_date":"2021-10-08T11:27:00Z","last_updated_date":"2021-10-08T11:27:00Z","reference_number":"EMA/CHMP/ICH/502766/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m7-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-addendum-step-2b_en.pdf"},
    {"id":"52856","name":"Draft reflection paper on the interpretation of Article 72 of Regulation (EU) 2019/6 - Environmental safety documentation and environmental risk assessment of certain veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-10-15 - 2022-01-31","first_published_date":"2021-10-15T11:22:00Z","last_updated_date":"2021-10-15T11:22:00Z","reference_number":"EMA/CVMP/ERA/245311/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-interpretation-article-72-regulation-eu-2019-6-environmental-safety-documentation-and-environmental-risk-assessment-certain-veterinary-medicinal-products_en.pdf"},
    {"id":"52870","name":"Concept paper on scientific guidelines for limited market products deemed not eligible for authorisation under Article 23 of Regulation 2019/6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-10-15 - 2021-12-15","first_published_date":"2021-10-15T13:45:00Z","last_updated_date":"2021-10-15T13:45:00Z","reference_number":"EMA/CVMP/435071/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-scientific-guidelines-limited-market-products-deemed-not-eligible-authorisation-under-article-23-regulation-2019-6_en.pdf"},
    {"id":"52871","name":"Concept paper on an update to the CVMP’s reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in food-producing animals in the European Union: development of resistance and impact on human and animal health","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-10-15 - 2022-01-31","first_published_date":"2021-10-15T15:15:00Z","last_updated_date":"2021-10-15T15:15:00Z","reference_number":"EMA/CVMP/AWP/266787/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-update-cvmps-reflection-paper-use-macrolides-lincosamides-and-streptogramins-mls-food-producing-animals-european-union-development-resistance-and-impact-human-and-animal-health_en.pdf"},
    {"id":"52872","name":"Draft guideline on determination of withdrawal periods for edible tissues - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-10-15 - 2021-12-17","first_published_date":"2021-10-15T16:22:00Z","last_updated_date":"2021-10-15T16:22:00Z","reference_number":"EMA/CVMP/SWP/735325/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-determination-withdrawal-periods-edible-tissues-revision-2_en.pdf"},
    {"id":"52873","name":"Draft guideline on determination of withdrawal periods for milk - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-10-15 - 2021-12-17","first_published_date":"2021-10-15T16:28:00Z","last_updated_date":"2021-10-15T16:28:00Z","reference_number":"EMA/CVMP/SWP/735418/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-determination-withdrawal-periods-milk-revision-1_en.pdf"},
    {"id":"52874","name":"Draft guideline on injection site residue - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-10-15 - 2021-12-17","first_published_date":"2021-10-15T16:35:00Z","last_updated_date":"2021-10-15T16:35:00Z","reference_number":"EMA/CVMP/SWP/185470/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-injection-site-residue-revision-1_en.pdf"},
    {"id":"52897","name":"Guideline on registry-based studies","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-10-26T10:00:00Z","last_updated_date":"2021-10-26T10:00:00Z","reference_number":"EMA/426390/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies_en.pdf"},
    {"id":"53040","name":"Concept paper on the revision of annex 4 of the guidelines on good manufacturing practice – manufacture of veterinary medicinal products other than immunologicals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-11-09 - 2022-01-09","first_published_date":"2021-11-09T16:48:00Z","last_updated_date":"2021-11-09T16:48:00Z","reference_number":"EMA/628488/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-annex-4-guidelines-good-manufacturing-practice-manufacture-veterinary-medicinal-products-other-immunologicals_en.pdf"},
    {"id":"53041","name":"Concept paper on the revision of annex 5 of the guidelines on good manufacturing practice for medicinal products – manufacture of immunological veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-11-09 - 2022-01-09","first_published_date":"2021-11-09T16:52:00Z","last_updated_date":"2021-11-09T16:52:00Z","reference_number":"EMA/628491/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-annex-5-guidelines-good-manufacturing-practice-medicinal-products-manufacture-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"53101","name":"Procedural advice for veterinary vaccine antigen master file (VAMF) certification - draft","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-11-12 - 2022-01-12","first_published_date":"2021-11-12T10:32:00Z","last_updated_date":"2021-11-12T10:32:00Z","reference_number":"EMA/127488/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/procedural-advice-veterinary-vaccine-antigen-master-file-vamf-certification-draft_en.pdf"},
    {"id":"53103","name":"Concept paper on the revision of the CVMP Recommendation on the evaluation of the benefit-risk balance of veterinary medicinal products (EMEA/CVMP/248499/2007)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-11-12 - 2022-02-28","first_published_date":"2021-11-12T10:48:00Z","last_updated_date":"2021-11-12T10:48:00Z","reference_number":"EMA/CVMP/299406/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-cvmp-recommendation-evaluation-benefit-risk-balance-veterinary-medicinal-products-emea-cvmp-248499-2007_en.pdf"},
    {"id":"53245","name":"EU VICH adverse event report implementation guide","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-11-23T15:41:00Z","last_updated_date":"2021-11-23T15:41:00Z","reference_number":"EMA/186368/202","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/eu-vich-adverse-event-report-implementation-guide_en.pdf"},
    {"id":"53436","name":"Draft International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q9 (R1) on quality risk management - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-12-16 - 2022-03-15","first_published_date":"2021-12-16T10:20:00Z","last_updated_date":"2021-12-16T10:20:00Z","reference_number":"EMA/CHMP/ICH/24235/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q9-r1-quality-risk-management-step-2b_en.pdf"},
    {"id":"53464","name":"Draft guideline on the acceptability of names for human medicinal products processed through the centralised procedure","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-12-16 - 2022-03-16","first_published_date":"2021-12-16T11:10:00Z","last_updated_date":"2021-12-16T11:10:00Z","reference_number":"EMA/CHMP/287710/2014 Rev. 7","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-acceptability-names-human-medicinal-products-processed-through-centralised-procedure_en.pdf"},
    {"id":"53499","name":"Draft ibrutinib hard capsules 140 mg and film-coated tablets 140, 280, 420 & 560 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-12-16 - 2022-03-31","first_published_date":"2021-12-16T10:30:00Z","last_updated_date":"2021-12-16T10:30:00Z","reference_number":"EMA/CHMP/371445/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ibrutinib-hard-capsules-140-mg-and-film-coated-tablets-140-280-420-560-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"53500","name":"Draft liposomal amphotericin B powder for dispersion for infusion 50 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-12-17 - 2022-03-31","first_published_date":"2021-12-17T10:20:00Z","last_updated_date":"2021-12-17T10:20:00Z","reference_number":"EMA/CHMP/559889/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-liposomal-amphotericin-b-powder-dispersion-infusion-50-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"53501","name":"Draft ursodeoxycholic acid capsule 250 mg, film-coated tablet 150 mg, 300 mg, 450 mg, 500 mg, 600 mg and suspension 50 mg/ml (250 mg/5 ml) product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-12-17 - 2022-03-31","first_published_date":"2021-12-17T10:20:00Z","last_updated_date":"2021-12-17T10:20:00Z","reference_number":"EMA/CHMP/559890/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ursodeoxycholic-acid-capsule-250-mg-film-coated-tablet-150-mg-300-mg-450-mg-500-mg-600-mg-and-suspension-50-mg-ml-250-mg-5-ml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"53502","name":"Draft olaparib 100 mg & 150 mg film-coated tablets product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-12-16 - 2022-03-31","first_published_date":"2021-12-16T10:30:00Z","last_updated_date":"2021-12-16T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-olaparib-100-mg-150-mg-film-coated-tablets-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"53503","name":"Draft enzalutamide soft capsule 40 mg and film-coated tablet 40 mg & 80 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-12-15 - 2022-03-31","first_published_date":"2021-12-15T11:00:00Z","last_updated_date":"2021-12-15T11:00:00Z","reference_number":"EMA/CHMP/371467/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-enzalutamide-soft-capsule-40-mg-and-film-coated-tablet-40-mg-80-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"53542","name":"Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) - Rev. 6","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-12-16T10:12:00Z","last_updated_date":"2022-02-03T14:02:00Z","reference_number":"EMA/CHMP/BPWP/94038/2007 Rev. 6 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-6_en.pdf"},
    {"id":"53569","name":"Guideline on the clinical investigation of human normal  immunoglobulin for intravenous administration (IVIg) - rev. 4","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-12-16T17:33:00Z","last_updated_date":"2021-12-16T17:33:00Z","reference_number":"EMA/CHMP/BPWP/94033/2007 rev. 4","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-rev-4_en.pdf"},
    {"id":"53570","name":"Guideline on the summary of product characteristics for antiparasitic veterinary medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-12-16T17:35:00Z","last_updated_date":"2023-07-19T17:42:00Z","reference_number":"EMA/CVMP/EWP/170208/2005 Rev.1 Corr1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-summary-product-characteristics-antiparasitic-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"53573","name":"Question and answer document on requirements for pre-clinical studies submitted in support of a marketing authorisation application for a veterinary medicinal product","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2021-12-16T18:03:00Z","last_updated_date":"2022-01-28T10:00:00Z","reference_number":"EMA/CVMP/565615/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/question-and-answer-document-requirements-pre-clinical-studies-submitted-support-marketing-authorisation-application-veterinary-medicinal-product_en.pdf"},
    {"id":"53574","name":"Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T09:30:00Z","last_updated_date":"2023-07-04T09:36:00Z","reference_number":"EMA/698382/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-notification-serious-breaches-regulation-eu-no-5362014-or-clinical-trial-protocol_en.pdf"},
    {"id":"53963","name":"Guideline on data requirements for multi-strain dossiers for inactivated veterinary vaccines - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T15:00:00Z","last_updated_date":"2022-01-28T15:00:00Z","reference_number":"EMA/CVMP/IWP/105506/2007 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-multi-strain-dossiers-inactivated-veterinary-vaccines-revision-2_en.pdf"},
    {"id":"53965","name":"Draft guideline on determination of the need for an MRL evaluation for biological substances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-01-28 - 2022-04-29","first_published_date":"2022-01-28T10:00:00Z","last_updated_date":"2022-01-28T10:00:00Z","reference_number":"EMA/CVMP/SWP/591282/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-determination-need-mrl-evaluation-biological-substances_en.pdf"},
    {"id":"53966","name":"Draft guideline on requirements for the production and control of immunological veterinary medicinal products - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-01-19 - 2022-03-28","first_published_date":"2022-01-28T16:05:00Z","last_updated_date":"2022-01-28T16:05:00Z","reference_number":"EMA/CVMP/IWP/206555/2010-Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-production-and-control-immunological-veterinary-medicinal-products-revision-2_en.pdf"},
    {"id":"53967","name":"Guideline on data requirements for vaccine platform technology master files (vPTMF)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T15:10:00Z","last_updated_date":"2022-01-28T15:10:00Z","reference_number":"EMA/CVMP/IWP/286631/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-vaccine-platform-technology-master-files-vptmf_en.pdf"},
    {"id":"53969","name":"Guideline on data requirements for vaccine antigen master files (VAMF)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T15:06:00Z","last_updated_date":"2022-01-28T15:06:00Z","reference_number":"EMA/CVMP/IWP/258755/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-vaccine-antigen-master-files-vamf_en.pdf"},
    {"id":"53976","name":"Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T16:00:00Z","last_updated_date":"2022-01-28T16:00:00Z","reference_number":"EMA/CHMP/QWP/545525/2017 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-chemical-and-pharmaceutical-quality-documentation-concerning-investigational-medicinal-products-clinical-trials-revision-2_en.pdf"},
    {"id":"53983","name":"Guideline on clinical trials with immunological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T10:12:00Z","last_updated_date":"2022-01-28T10:12:00Z","reference_number":"EMA/CVMP/IWP/260956/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-trials-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"53998","name":"Draft guideline on clinical trials with immunological veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2021-07-23 - 2021-10-29","first_published_date":"2021-07-23T13:26:00Z","last_updated_date":"2021-07-23T13:26:00Z","reference_number":"EMA/CVMP/IWP/260956/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-trials-immunological-veterinary-medicinal-products_en.pdf-0"},
    {"id":"54008","name":"Guideline on data requirements for authorisation of immunological veterinary medicinal products in exceptional circumstances","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T13:56:00Z","last_updated_date":"2022-01-28T13:56:00Z","reference_number":"EMA/CVMP/IWP/251947/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-authorisation-immunological-veterinary-medicinal-products-exceptional-circumstances_en.pdf"},
    {"id":"54017","name":"Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T14:46:00Z","last_updated_date":"2022-01-28T14:46:00Z","reference_number":"EMA/CHMP/BWP/534898/2008 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical-trials-revision-2_en.pdf"},
    {"id":"54020","name":"Concept paper on the development and data requirements of potency tests for cell-based therapy products and the relation to clinical efficacy","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-01-28 - 2022-04-29","first_published_date":"2022-01-28T16:35:00Z","last_updated_date":"2022-01-28T16:35:00Z","reference_number":"EMA/CVMP/NTWP/470741/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-and-data-requirements-potency-tests-cell-based-therapy-products-and-relation-clinical-efficacy_en.pdf"},
    {"id":"54022","name":"Concept paper on quality, safety and efficacy of bacteriophages as veterinary medicines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-01-28 - 2022-04-29","first_published_date":"2022-01-28T16:45:00Z","last_updated_date":"2022-01-28T16:45:00Z","reference_number":"EMA/CVMP/NTWP/438290/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-quality-safety-and-efficacy-bacteriophages-veterinary-medicines_en.pdf"},
    {"id":"54040","name":"Draft VICH GL18 (R2) Impurities: residual solvents in new veterinary medicinal products, active substances and excipients - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-01-31 - 2022-06-10","first_published_date":"2022-01-31T14:56:00Z","last_updated_date":"2022-01-31T14:56:00Z","reference_number":"EMA/CVMP/VICH/502/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl18-r2-impurities-residual-solvents-new-veterinary-medicinal-products-active-substances-and-excipients-revision-2_en.pdf"},
    {"id":"54081","name":"Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular emphasis on the handling of expiry dates","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-02-04T15:57:00Z","last_updated_date":"2023-04-05T14:16:00Z","reference_number":"EMA/151704/2023 (replacing EMA/803916/2022 for the first page disclaimer only) ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-interactive-response-technologies-interactive-voiceweb-response-systems-clinical-trials-particular-emphasis-handling-expiry-dates_en.pdf"},
    {"id":"54253","name":"Draft qualification opinion for the use of Enroll-HD (a Huntington’s disease patient registry) as a data source and infrastructure support for post-authorisation monitoring of medical products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-02-23 - 2022-04-11","first_published_date":"2022-02-23T10:18:00Z","last_updated_date":"2022-02-23T10:18:00Z","reference_number":"EMA/SA/0000056662","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-qualification-opinion-use-enroll-hd-huntingtons-disease-patient-registry-data-source-and-infrastructure-support-post-authorisation-monitoring-medical-products_en.pdf"},
    {"id":"54295","name":"Draft reflection paper on criteria for determining that an active substance is essential when considered in the context of Article 37(2)(j) of Regulation 2019/6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-02-25 - 2022-05-31","first_published_date":"2022-02-25T10:23:00Z","last_updated_date":"2022-02-25T10:23:00Z","reference_number":"EMA/CVMP/116512/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-criteria-determining-active-substance-essential-when-considered-context-article-372j-regulation-2019-6_en.pdf"},
    {"id":"54298","name":"Reflection paper on the interpretation of Article 18(7) of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T09:44:00Z","last_updated_date":"2022-02-25T09:44:00Z","reference_number":"EMA/CVMP/ERA/622045/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-interpretation-article-187-regulation-eu-20196_en.pdf"},
    {"id":"54309","name":"Public Statement on the use of herbal medicinal products containing estragole","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-03-01T14:12:00Z","last_updated_date":"2022-03-01T14:12:00Z","reference_number":"EMA/HMPC/137212/2005 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/public-statement-use-herbal-medicinal-products-containing-estragole_en.pdf-0"},
    {"id":"54311","name":"Concept paper on the revision of the guideline on good agricultural and collection practice for starting materials of herbal origin - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-03-01 - 2022-06-01","first_published_date":"2022-03-01T15:33:00Z","last_updated_date":"2022-03-01T15:33:00Z","reference_number":"EMA/HMPC/398706/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-good-agricultural-collection-practice-starting-materials-herbal-origin-revision-1_en.pdf"},
    {"id":"54408","name":"Best practice guide on measures improving predictability of submissions and adherence to communicated deadlines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-03-10T10:11:00Z","last_updated_date":"2022-03-10T10:11:00Z","reference_number":"EMA/488783/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/best-practice-guide-measures-improving-predictability-submissions-and-adherence-communicated-deadlines_en.pdf"},
    {"id":"54555","name":"ICH guideline E14/S7B: clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential - questions and answers - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-03-24T15:35:00Z","last_updated_date":"2022-03-29T12:00:00Z","reference_number":"EMA/CHMP/ICH/415588/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e14s7b-clinical-and-nonclinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-questions-and-answers-step-5_en.pdf"},
    {"id":"54565","name":"Adopted reflection paper on the interpretation of Article 72 of Regulation (EU) 2019/6 - Environmental safety documentation and environmental risk assessment of certain veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T07:58:00Z","last_updated_date":"2022-03-25T07:58:00Z","reference_number":"EMA/CVMP/ERA/245311/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-reflection-paper-interpretation-article-72-regulation-eu-20196-environmental-safety-documentation-and-environmental-risk-assessment-certain-veterinary-medicinal-products_en.pdf"},
    {"id":"54567","name":"Concept paper on the elaboration of guidance for the application of Article 34 of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-03-25 - 2022-04-30","first_published_date":"2022-03-25T10:20:00Z","last_updated_date":"2022-03-25T10:20:00Z","reference_number":"EMA/CVMP/65618/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-elaboration-guidance-application-article-34-regulation-eu-2019-6_en.pdf"},
    {"id":"54569","name":"Adopted guideline on safety and residue data requirements for the establishment of Maximum Residue Limits in minor species","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T10:15:00Z","last_updated_date":"2022-03-25T10:15:00Z","reference_number":"EMA/CVMP/345236/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-guideline-safety-and-residue-data-requirements-establishment-maximum-residue-limits-minor-species_en.pdf"},
    {"id":"54572","name":"Adopted guideline on injection site residues - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T08:53:00Z","last_updated_date":"2022-03-25T08:53:00Z","reference_number":"EMA/CVMP/SWP/185470/2004 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-guideline-injection-site-residues-revision-1_en.pdf"},
    {"id":"54573","name":"Adopted guideline on determination of withdrawal periods for milk - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T09:56:00Z","last_updated_date":"2022-03-25T09:56:00Z","reference_number":"EMA/CVMP/SWP/735418/2012 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-guideline-determination-withdrawal-periods-milk-revision-1_en.pdf"},
    {"id":"54575","name":"Adopted guideline on determination of withdrawal periods for edible tissues - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T08:59:00Z","last_updated_date":"2022-03-25T08:59:00Z","reference_number":"EMA/CVMP/SWP/735325/2012 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-guideline-determination-withdrawal-periods-edible-tissues-revision-2_en.pdf"},
    {"id":"54646","name":"ICH guideline Q2(R2) on validation of analytical procedures - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-03-31 - 2022-07-31","first_published_date":"2022-04-01T11:17:00Z","last_updated_date":"2022-04-01T11:17:00Z","reference_number":"EMA/CHMP/ICH/82072/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q2r2-validation-analytical-procedures-step-2b_en.pdf"}    {"id":"54647","name":"ICH guideline Q14 on analytical procedure development - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-03-31 - 2022-07-31","first_published_date":"2022-04-01T11:29:00Z","last_updated_date":"2022-04-01T11:29:00Z","reference_number":"EMA/CHMP/ICH/195040/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q14-analytical-procedure-development-step-2b_en.pdf"},
    {"id":"54659","name":"Draft paracetamol oral use immediate release formulations product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-04-04 - 2022-07-31","first_published_date":"2022-04-04T12:12:00Z","last_updated_date":"2022-04-04T12:12:00Z","reference_number":"EMA/CHMP/356877/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-paracetamol-oral-use-immediate-release-formulations-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"54660","name":"Draft tadalafil film-coated tablets 2.5 mg, 5 mg, 10 mg and 20 mg product-specific bioequivalence guidance - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-04-04 - 2022-07-31","first_published_date":"2022-04-04T12:27:00Z","last_updated_date":"2022-04-04T12:27:00Z","reference_number":"EMA/CHMP/315234/2014 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-tadalafil-film-coated-tablets-25-mg-5-mg-10-mg-and-20-mg-product-specific-bioequivalence-guidance-revision-2_en.pdf"},
    {"id":"54663","name":"Draft ibuprofen oral use immediate release formulations 200 – 800 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-04-04 - 2022-07-31","first_published_date":"2022-04-04T14:26:00Z","last_updated_date":"2022-04-04T14:26:00Z","reference_number":"EMA/CHMP/356876/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ibuprofen-oral-use-immediate-release-formulations-200-800-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"54686","name":"Draft ICH guideline E11A on pediatric extrapolation Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-04-06 - 2022-08-06","first_published_date":"2022-04-06T16:07:00Z","last_updated_date":"2022-04-06T16:07:00Z","reference_number":"EMA/CHMP/ICH/205218/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-e11a-pediatric-extrapolation-step-2b_en.pdf"},
    {"id":"54753","name":"Points to consider on the impact of the war in Ukraine on methodological aspects of ongoing clinical trials","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-04-13T16:48:00Z","last_updated_date":"2022-04-13T16:48:00Z","reference_number":"EMA/214249/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-impact-war-ukraine-methodological-aspects-ongoing-clinical-trials_en.pdf"},
    {"id":"54811","name":"Toolbox guidance on scientific elements and regulatory tools to support quality data packages for PRIME and certain marketing authorisation applications targeting an unmet medical need","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T16:03:00Z","last_updated_date":"2022-04-22T16:03:00Z","reference_number":"EMA/CHMP/BWP/QWP/IWG/694114/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/toolbox-guidance-scientific-elements-and-regulatory-tools-support-quality-data-packages-prime-and-certain-marketing-authorisation-applications-targeting-unmet-medical-need_en.pdf"},
    {"id":"54882","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q3D on elemental impurities - Step 5 - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-05-03T14:15:00Z","last_updated_date":"2022-05-03T14:15:00Z","reference_number":"EMA/CHMP/ICH/353369/2013 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-q3d-elemental-impurities-step-5-revision-2_en.pdf"},
    {"id":"54954","name":"Final guideline on quality of herbal medicinal products/traditional herbal medicinal products - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-05-12T15:59:00Z","last_updated_date":"2022-05-12T15:59:00Z","reference_number":"EMA/HMPC/CHMP/CVMP/201116/20051 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/final-guideline-quality-herbal-medicinal-productstraditional-herbal-medicinal-products-revision-3_en.pdf"},
    {"id":"54955","name":"Guideline on specifications: test procedures and acceptance criteria for herbal  substances, herbal  preparations and herbal medicinal products/traditional herbal medicinal products - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-05-12T16:18:00Z","last_updated_date":"2022-05-12T16:18:00Z","reference_number":"EMA/HMPC/CHMP/CVMP/162241/2005 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-specifications-test-procedures-and-acceptance-criteria-herbal-substances-herbal-preparations-and-herbal-medicinal-productstraditional-herbal-medicinal-products-revision-3_en.pdf"},
    {"id":"54970","name":"Draft lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-05-17 - 2022-08-31","first_published_date":"2022-05-17T12:00:00Z","last_updated_date":"2022-05-17T12:00:00Z","reference_number":"EMA/CHMP/559891/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-lanreotide-acetate-prolonged-release-solution-injection-prefilled-syringe-60-90-and-120-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"55025","name":"Reflection paper on data required in confirmatory studies of medicinal products for the treatment of type 2 diabetes - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-05-20 - 2022-08-31","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/240473/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-required-confirmatory-studies-medicinal-products-treatment-type-2-diabetes-revision-2_en.pdf"},
    {"id":"55033","name":"Draft procedural advice for vaccine platform technology master file (vPTMF) certification","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-05-20 - 2022-07-20","first_published_date":"2022-05-20T12:47:00Z","last_updated_date":"2022-05-20T12:47:00Z","reference_number":"EMA/CVMP/184591/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-procedural-advice-vaccine-platform-technology-master-file-vptmf-certification_en.pdf"},
    {"id":"55037","name":"Questions and Answers on data requirements for multi-strain dossiers for inactivated veterinary vaccines","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T11:02:00Z","last_updated_date":"2022-05-20T11:02:00Z","reference_number":"EMA/CVMP/IWP/466888/2017-Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-data-requirements-multi-strain-dossiers-inactivated-veterinary-vaccines_en.pdf"},
    {"id":"55056","name":"Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-05-24T09:55:00Z","last_updated_date":"2022-05-24T09:55:00Z","reference_number":"CPMP/EWP/558/95 Rev 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf"},
    {"id":"55058","name":"Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections to address paediatric-specific clinical data requirements","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-05-24T11:26:00Z","last_updated_date":"2022-05-24T11:26:00Z","reference_number":"EMA/CHMP/187859/2017","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-address-paediatric-specific-clinical-data-requirements_en.pdf"},
    {"id":"55320","name":"Ibrutinib hard capsules 140 mg and film-coated tablets 140, 280, 420 & 560 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-06-27T09:51:00Z","last_updated_date":"2022-06-27T09:51:00Z","reference_number":"EMA/CHMP/371445/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ibrutinib-hard-capsules-140-mg-and-film-coated-tablets-140-280-420-560-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"55321","name":"Enzalutamide soft capsule 40 mg and film-coated tablet 40 mg & 80 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-06-27T09:50:00Z","last_updated_date":"2022-06-27T09:50:00Z","reference_number":"EMA/CHMP/371467/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/enzalutamide-soft-capsule-40-mg-and-film-coated-tablet-40-mg-80-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"55350","name":"Guideline on requirements for the production and control of immunological veterinary medicinal products - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T09:05:00Z","last_updated_date":"2022-06-24T09:05:00Z","reference_number":"EMA/CVMP/IWP/206555/2010-Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-production-and-control-immunological-veterinary-medicinal-products-revision-2_en.pdf"},
    {"id":"55354","name":"Guideline on data requirements for veterinary medicinal products intended to reduce the risk of transmission of vector-borne pathogens in dogs and cats","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T10:16:00Z","last_updated_date":"2022-06-24T10:16:00Z","reference_number":"EMA/CVMP/EWP/278031/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-veterinary-medicinal-products-intended-reduce-risk-transmission-vector-borne-pathogens-dogs-and-cats_en.pdf"},
    {"id":"55356","name":"VICH GL7 Efficacy of anthelmintics: general requirements - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-06-24 - 2022-11-01","first_published_date":"2022-06-24T12:24:00Z","last_updated_date":"2022-06-24T12:24:00Z","reference_number":"EMA/CVMP/VICH/832/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl7-efficacy-anthelmintics-general-requirements-revision-1_en.pdf"},
    {"id":"55357","name":"VICH GL21: Efficacy of anthelmintics: specific recommendations for chickens – gallus gallus  - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-06-24 - 2022-11-01","first_published_date":"2022-06-24T12:30:00Z","last_updated_date":"2022-06-24T12:30:00Z","reference_number":"EMA/CVMP/VICH/546/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl21-efficacy-anthelmintics-specific-recommendations-chickens-gallus-gallus-revision-1_en.pdf"},
    {"id":"55358","name":"VICH GL20: Efficacy of anthelmintics: specific recommendations for felines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-06-24 - 2022-11-01","first_published_date":"2022-06-24T12:30:00Z","last_updated_date":"2022-06-24T12:30:00Z","reference_number":"EMA/CVMP/VICH/545/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl20-efficacy-anthelmintics-specific-recommendations-felines-revision-1_en.pdf"},
    {"id":"55359","name":"VICH GL19: Efficacy of anthelmintics: specific recommendations for canines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-06-24 - 2022-11-01","first_published_date":"2022-06-24T12:30:00Z","last_updated_date":"2022-06-24T12:30:00Z","reference_number":"EMA/CVMP/VICH/835/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl19-efficacy-anthelmintics-specific-recommendations-canines-revision-1_en.pdf"},
    {"id":"55360","name":"VICH GL16: Efficacy of anthelmintics: specific recommendations for porcines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-06-24 - 2022-11-01","first_published_date":"2022-06-24T12:30:00Z","last_updated_date":"2022-06-24T12:30:00Z","reference_number":"EMA/CVMP/VICH/834/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl16-efficacy-anthelmintics-specific-recommendations-porcines-revision-1_en.pdf"},
    {"id":"55362","name":"VICH GL15: Efficacy of anthelmintics: specific recommendations for equines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-06-24 - 2022-11-01","first_published_date":"2022-06-24T12:30:00Z","last_updated_date":"2022-06-24T12:30:00Z","reference_number":"EMA/CVMP/VICH/833/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl15-efficacy-anthelmintics-specific-recommendations-equines-revision-1_en.pdf"},
    {"id":"55363","name":"VICH GL14: Efficacy of anthelmintics: specific recommendations for caprines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-06-24 - 2022-11-01","first_published_date":"2022-06-24T12:30:00Z","last_updated_date":"2022-06-24T12:30:00Z","reference_number":"EMA/CVMP/VICH/841/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl14-efficacy-anthelmintics-specific-recommendations-caprines-revision-1_en.pdf"},
    {"id":"55364","name":"VICH GL13: Efficacy of anthelmintics: specific recommendations for ovines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-06-24 - 2022-11-01","first_published_date":"2022-06-24T12:30:00Z","last_updated_date":"2022-06-24T12:30:00Z","reference_number":"EMA/CVMP/VICH/840/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl13-efficacy-anthelmintics-specific-recommendations-ovines-revision-1_en.pdf"},
    {"id":"55365","name":"VICH GL12: Efficacy of anthelmintics: specific recommendations for bovines - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-06-24 - 2022-11-01","first_published_date":"2022-06-24T12:30:00Z","last_updated_date":"2022-06-24T12:30:00Z","reference_number":"EMA/CVMP/VICH/839/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl12-efficacy-anthelmintics-specific-recommendations-bovines-revision-1_en.pdf"},
    {"id":"55385","name":"Ursodeoxycholic acid capsule 250 mg, film-coated tablet 150 mg, 300 mg, 450 mg, 500 mg, 600 mg and suspension 50 mg/ml (250 mg/5 ml) product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-06-27T15:16:00Z","last_updated_date":"2022-06-27T15:16:00Z","reference_number":"EMA/CHMP/559890/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ursodeoxycholic-acid-capsule-250-mg-film-coated-tablet-150-mg-300-mg-450-mg-500-mg-600-mg-and-suspension-50-mgml-250-mg5-ml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"55387","name":"Olaparib 100 mg & 150 mg film-coated tablets product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-06-27T15:22:00Z","last_updated_date":"2022-06-27T15:22:00Z","reference_number":"EMA/CHMP/371470/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/olaparib-100-mg-150-mg-film-coated-tablets-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"55522","name":"Reflection paper on the use of measurable residual disease as a clinical endpoint in multiple myeloma studies","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-07-12T15:16:00Z","last_updated_date":"2022-07-12T15:16:00Z","reference_number":"EMA/49401/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-measurable-residual-disease-clinical-endpoint-multiple-myeloma-studies_en.pdf"},
    {"id":"55611","name":"Draft ICH guideline M12 on drug interaction studies - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-07-21 - 2022-11-21","first_published_date":"2022-07-21T13:40:00Z","last_updated_date":"2022-07-21T13:40:00Z","reference_number":"EMA/CHMP/ICH/652460/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m12-drug-interaction-studies-step-2b_en.pdf"},
    {"id":"55644","name":"Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668) - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T10:00:00Z","last_updated_date":"2022-07-22T10:00:00Z","reference_number":"EMA/CHMP/302620/2017 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-2_en.pdf"},
    {"id":"55645","name":"All languages - Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668) - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-03-04T12:00:00Z","last_updated_date":"2024-03-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/all-languages-annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-3_en.xlsx"},
    {"id":"55663","name":"Concept paper on the revision of the guideline for veterinary medicinal products for zootechnical purposes - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-07-22 - 2022-10-31","first_published_date":"2022-07-22T16:31:00Z","last_updated_date":"2022-07-22T16:31:00Z","reference_number":"EMA/CVMP/EWP/222080/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-veterinary-medicinal-products-zootechnical-purposes-revision-1_en.pdf"},
    {"id":"55687","name":"Concept paper on the revision of the guideline on the chemistry of active substances - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-07-26 - 2022-10-31","first_published_date":"2022-07-26T17:11:00Z","last_updated_date":"2022-07-26T17:11:00Z","reference_number":"EMA/CHMP/600383/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-chemistry-active-substances-revision-1_en.pdf"},
    {"id":"55689","name":"ICH guideline M10 on bioanalytical method validation - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-07-27T10:00:00Z","last_updated_date":"2022-07-27T10:00:00Z","reference_number":"EMA/CHMP/ICH/172948/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf"},
    {"id":"55690","name":"ICH guideline M10 on bioanalytical method validation and study sample analysis – Frequently Asked Questions (FAQ)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-07-27T10:27:00Z","last_updated_date":"2023-01-13T11:40:00Z","reference_number":"EMA/CHMP/ICH/660315/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m10-bioanalytical-method-validation-and-study-sample-analysis-frequently-asked-questions-faq_en.pdf"},
    {"id":"55692","name":"Qualification opinion of the use of Enroll-HD (a Huntington’s disease patient registry) as a data source and infrastructure support for post-authorisation monitoring of medical products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-07-28T11:04:00Z","last_updated_date":"2022-07-28T11:04:00Z","reference_number":"EMADOC-1700519818-828910","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-use-enroll-hd-huntingtons-disease-patient-registry-data-source-and-infrastructure-support-post-authorisation-monitoring-medical-products_en.pdf"},
    {"id":"55722","name":"Questions and answers on boric acid and borates used as excipients in medicinal products for human use - Rev.1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-07-28T02:00:00Z","last_updated_date":"2022-07-28T02:00:00Z","reference_number":"EMA/CHMP/619104/2013 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-boric-acid-and-borates-used-excipients-medicinal-products-human-use-rev1_en.pdf"},
    {"id":"55779","name":"Draft - Guideline on epidemiological data on blood transmissible infections - Rev 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2013-03-25T17:49:00Z","last_updated_date":"2013-03-25T17:49:00Z","reference_number":"EMEA/CPMP/BWP/125/04. Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-epidemiological-data-blood-transmissible-infections-rev-1_en.pdf"},
    {"id":"56098","name":"Concept paper on the establishment of a guideline on the development and manufacture of synthetic oligonucleotides","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-09-20 - 2022-12-20","first_published_date":"2022-09-20T12:52:00Z","last_updated_date":"2022-09-20T12:52:00Z","reference_number":"EMA/CHMP/QWP/735423/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-establishment-guideline-development-and-manufacture-synthetic-oligonucleotides_en.pdf"},
    {"id":"56099","name":"Concept paper on the establishment of a guideline on the development and manufacture of synthetic peptides","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-09-20 - 2022-12-20","first_published_date":"2022-09-20T12:53:00Z","last_updated_date":"2022-09-20T12:53:00Z","reference_number":"EMA/CHMP/QWP/735422/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-establishment-guideline-development-and-manufacture-synthetic-peptides_en.pdf"},
    {"id":"56118","name":"Concept paper on a guideline on data requirements for post-authorisation studies for antimicrobial veterinary medicinal products under Article 36(2) of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-09-16 - 2023-01-31","first_published_date":"2022-09-16T11:16:00Z","last_updated_date":"2022-09-16T11:16:00Z","reference_number":"EMA/CVMP/AWP/201064/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-data-requirements-post-authorisation-studies-antimicrobial-veterinary-medicinal-products-under-article-362-regulation-eu-2019-6_en.pdf"},
    {"id":"56191","name":"Overview of comments received on ICH guideline E11A on pediatric extrapolation Step 2bEMA/CHMP/ICH/205218/2022","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-09-26T17:36:00Z","last_updated_date":"2022-12-01T10:25:00Z","reference_number":"EMA/CHMP/ICH/205218/2022 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-ich-guideline-e11a-pediatric-extrapolation-step-2bemachmpich2052182022_en.pdf"},
    {"id":"56233","name":"Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-10-26T12:18:00Z","last_updated_date":"2022-10-26T12:18:00Z","reference_number":"EMA/CAT/CHMP/158266/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-labelling-and-package-leaflet-advanced-therapy-medicinal-products-atmps-containing-genetically-modified-cells_en.pdf"},
    {"id":"56332","name":"ICH guideline E19 on a selective approach to safety data collection in specific late-stage pre-approval or post-approval clinical trials - Step5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-10-06T12:20:00Z","last_updated_date":"2022-10-06T12:20:00Z","reference_number":"EMA/782210/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e19-selective-approach-safety-data-collection-specific-late-stage-pre-approval-or-post-approval-clinical-trials-step5_en.pdf"},
    {"id":"56339","name":"DRAFT Qualification opinion for the iBox Scoring System as a secondary efficacy endpoint in clinical trials investigating novel immunosuppressive medicines in kidney transplant patients","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-10-06T16:18:00Z","last_updated_date":"2022-10-06T16:18:00Z","reference_number":"EMADOC-1700519818-946771","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-qualification-opinion-ibox-scoring-system-secondary-efficacy-endpoint-clinical-trials-investigating-novel-immunosuppressive-medicines-kidney-transplant-patients_en.pdf"},
    {"id":"56340","name":"Qualification opinion - Appendix for Final Draft Qualification Opinion","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-10-06T16:23:00Z","last_updated_date":"2022-10-06T16:23:00Z","reference_number":"EMADOC-360526170-1156137","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-appendix-final-draft-qualification-opinion_en.pdf"},
    {"id":"56341","name":"Qualification opinion - C-PATH response to iBox Scoring System (Composite Biomarker Panel) - Second List of Issues","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-10-06T16:28:00Z","last_updated_date":"2022-10-06T16:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-c-path-response-ibox-scoring-system-composite-biomarker-panel-second-list-issues_en.pdf"},
    {"id":"56342","name":"Qualification opinion - C-PATH response to iBox Scoring System (Composite Biomarker Panel) - List of Issues","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-10-06T16:31:00Z","last_updated_date":"2022-10-06T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-c-path-response-ibox-scoring-system-composite-biomarker-panel-list-issues_en.pdf"},
    {"id":"56343","name":"Qualification opinion - Applicant revised briefing book for iBox Scoring System (Composite Biomarker Panel)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-10-06T16:34:00Z","last_updated_date":"2022-10-06T16:34:00Z","reference_number":"EMADOC-1700519818-946771","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-applicant-revised-briefing-book-ibox-scoring-system-composite-biomarker-panel_en.pdf"},
    {"id":"56351","name":"ICH: Q 5 A (R2): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-10-10 - 2023-02-10","first_published_date":"2022-10-10T11:45:00Z","last_updated_date":"2022-10-10T11:45:00Z","reference_number":"EMA/CHMP/ICH/804363/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-r2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin-step-2b_en.pdf"},
    {"id":"56352","name":"ICH S1B(R1) Guideline on testing for carcinogenicity of pharmaceuticals Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-10-10T09:50:00Z","last_updated_date":"2022-10-10T09:50:00Z","reference_number":"EMA/774371/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s1br1-guideline-testing-carcinogenicity-pharmaceuticals-step-5_en.pdf"},
    {"id":"56399","name":"Reflection paper on criteria for determining that an active substance is essential when considered in the context of Article 37(2)(j) of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T09:31:00Z","last_updated_date":"2022-10-14T09:31:00Z","reference_number":"EMA/CVMP/116512/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-criteria-determining-active-substance-essential-when-considered-context-article-372j-regulation-eu-20196_en.pdf"},
    {"id":"56481","name":"ICH M11 Guideline Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-10-26 - 2023-02-26","first_published_date":"2022-10-26T13:13:00Z","last_updated_date":"2022-10-26T13:13:00Z","reference_number":"EMA/CHMP/ICH/778799/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m11-guideline-step-2b_en.pdf"},
    {"id":"56482","name":"ICH M11 technical specification - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-10-26 - 2023-02-26","first_published_date":"2022-10-26T13:15:00Z","last_updated_date":"2022-10-26T13:15:00Z","reference_number":"EMA/CHMP/ICH/778800/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m11-technical-specification-step-2b_en.pdf"},
    {"id":"56483","name":"ICH M11 template - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-10-26 - 2023-02-26","first_published_date":"2022-10-26T13:13:00Z","last_updated_date":"2022-10-26T13:13:00Z","reference_number":"EMA/CHMP/ICH/778801/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m11-template-step-2b_en.pdf"},
    {"id":"56512","name":"Concept paper on the revision of the guideline on the assessment of genotoxicity of herbal substances/preparations (EMEA/HMPC/107079/2007)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-10-31 - 2023-01-31","first_published_date":"2022-10-31T11:26:00Z","last_updated_date":"2022-10-31T11:26:00Z","reference_number":"EMA/HMPC/41456/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-assessment-genotoxicity-herbal-substances-preparations-emea-hmpc-107079-2007_en.pdf"},
    {"id":"56581","name":"Concept paper on platform trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-11-11 - 2023-01-31","first_published_date":"2022-11-11T11:00:00Z","last_updated_date":"2022-11-11T11:00:00Z","reference_number":"EMA/CHMP/840036/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-platform-trials_en.pdf"},
    {"id":"56707","name":"Reflection paper on the criteria to be considered for the evaluation of new active substance (NAS) status of biological substances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-11-18 - 2023-05-31","first_published_date":"2022-11-18T11:45:00Z","last_updated_date":"2022-11-18T11:45:00Z","reference_number":"EMA/CHMP/CMDh/CAT/BWP/828612/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-criteria-be-considered-evaluation-new-active-substance-nas-status-biological-substances_en.pdf"},
    {"id":"56711","name":"Draft guideline on the development and data requirements of potency tests for cell-based therapy products and the relation to clinical efficacy","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-11-18 - 2023-02-28","first_published_date":"2022-11-18T14:27:00Z","last_updated_date":"2022-11-18T14:27:00Z","reference_number":"EMA/CVMP/NTWP/179287/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-and-data-requirements-potency-tests-cell-based-therapy-products-and-relation-clinical-efficacy_en.pdf"},
    {"id":"56764","name":"Draft reflection paper on the application of Article 40(5) of Regulation (EU) 2019/6 for certain categories of variations","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-11-24 - 2023-02-28","first_published_date":"2022-11-24T09:30:00Z","last_updated_date":"2022-11-24T09:30:00Z","reference_number":"EMA/CVMP/64911/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-application-article-405-regulation-eu-2019-6-certain-categories-variations_en.pdf"},
    {"id":"56939","name":"Overview of comments received on ICH Harmonized Guideline Drug Interactions M12 (EMA/CHMP/ICH/652460/2022)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-12-12T16:25:00Z","last_updated_date":"2022-12-12T16:25:00Z","reference_number":"EMA/CHMP/ICH/652460/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-ich-harmonized-guideline-drug-interactions-m12-emachmpich6524602022_en.pdf"},
    {"id":"56987","name":"Liposomal amphotericin B powder for dispersion for infusion 50 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T10:00:00Z","last_updated_date":"2022-12-16T10:00:00Z","reference_number":"EMA/CHMP/559889/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/liposomal-amphotericin-b-powder-dispersion-infusion-50-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"56988","name":"Lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg productspecific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T10:00:00Z","last_updated_date":"2022-12-16T10:00:00Z","reference_number":"EMA/CHMP/559891/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/lanreotide-acetate-prolonged-release-solution-injection-prefilled-syringe-60-90-and-120-mg-productspecific-bioequivalence-guidance_en.pdf"},
    {"id":"57080","name":"Qualification opinion for the iBox Scoring System as a secondary efficacy endpoint in clinical trials investigating novel immunosuppressive medicines in kidney transplant patients","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T12:58:00Z","last_updated_date":"2022-12-16T12:58:00Z","reference_number":"EMADOC-1700519818-946771","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-ibox-scoring-system-secondary-efficacy-endpoint-clinical-trials-investigating-novel-immunosuppressive-medicines-kidney-transplant-patients_en.pdf"},
    {"id":"57081","name":"Reflection paper on the environmental risk assessment of ectoparasiticidal veterinary medicinal products used in cats and dogs","type":"scientific-guideline","status":"Adopted","consultation_date":"2022-12-16 - 2023-03-31","first_published_date":"2022-12-16T13:59:00Z","last_updated_date":"2023-11-21T11:11:11Z","reference_number":"EMA/CVMP/ERA/31905/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-environmental-risk-assessment-ectoparasiticidal-veterinary-medicinal-products-used-cats-and-dogs_en.pdf"},
    {"id":"57096","name":"Concept paper on a guideline on risk management requirements for elemental impurities in veterinary medicinal products, including immunological veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-12-19 - 2023-03-31","first_published_date":"2022-12-19T11:12:00Z","last_updated_date":"2022-12-19T11:12:00Z","reference_number":"EMA/CVMP/637041/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-risk-management-requirements-elemental-impurities-veterinary-medicinal-products-including-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"57172","name":"ICH guideline Q13 on continuous manufacturing of drug substances and drug products - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-01-06T15:04:00Z","last_updated_date":"2023-01-06T15:04:00Z","reference_number":"EMA/CHMP/ICH/427817/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q13-continuous-manufacturing-drug-substances-and-drug-products-step-5_en.pdf"},
    {"id":"57429","name":"Procedural advice for vaccine platform technology master file (vPTMF) certification","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T11:20:00Z","last_updated_date":"2026-02-05T14:00:00Z","reference_number":"EMA/CVMP/184591/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/procedural-advice-vaccine-platform-technology-master-file-vptmf-certification_en.pdf"},
    {"id":"57431","name":"Reflection paper on resistance in ectoparasites","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T11:39:00Z","last_updated_date":"2023-01-27T11:39:00Z","reference_number":"EMA/CVMP/EWP/310225/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-resistance-ectoparasites_en.pdf"},
    {"id":"57433","name":"Guideline on clinical evaluation of vaccines - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-01T17:44:00Z","last_updated_date":"2023-02-01T17:44:00Z","reference_number":"EMEA/CHMP/VWP/164653/05 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-vaccines-revision-1_en.pdf"},
    {"id":"57435","name":"Guideline on quality, safety and efficacy of veterinary medicinal products specifically designed for phage therapy","type":"scientific-guideline","status":"Adopted","consultation_date":"2023-01-27 - 2023-05-31","first_published_date":"2023-01-27T12:52:00Z","last_updated_date":"2023-10-13T17:25:00Z","reference_number":"EMA/CVMP/NTWP/32862/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-safety-and-efficacy-veterinary-medicinal-products-specifically-designed-phage-therapy_en.pdf"},
    {"id":"57501","name":"Priority Action 3 concept paper: an EU multi-stakeholder platform for improving clinical trials - Accelerating Clinical Trials in the European Union (ACT EU)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-02-03T13:10:00Z","last_updated_date":"2023-02-03T13:10:00Z","reference_number":"EMA/41656/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/priority-action-3-concept-paper-eu-multi-stakeholder-platform-improving-clinical-trials-accelerating-clinical-trials-european-union-act-eu_en.pdf"},
    {"id":"57527","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q9 (R1) on quality risk management - Step 5 - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-06T10:54:00Z","last_updated_date":"2023-02-06T10:54:00Z","reference_number":"EMA/CHMP/ICH/24235/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q9-r1-quality-risk-management-step-5-revision-1_en.pdf"},
    {"id":"57552","name":"ICH Guideline M13A on bioequivalence for immediate-release solid oral dosage forms - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-01-26 - 2023-05-26","first_published_date":"2023-02-07T18:23:00Z","last_updated_date":"2023-02-07T18:23:00Z","reference_number":"EMA/CHMP/ICH953493/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m13a-bioequivalence-immediate-release-solid-oral-dosage-forms-step-2b_en.pdf"},
    {"id":"57592","name":"Paediatric Addendum on the guidelines on clinical investigation of medicinal products for the treatment and prophylaxis of venous thromboembolic disease","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T10:43:00Z","last_updated_date":"2023-02-10T10:43:00Z","reference_number":"EMA/CHMP/20507/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paediatric-addendum-guidelines-clinical-investigation-medicinal-products-treatment-and-prophylaxis-venous-thromboembolic-disease_en.pdf-0"},
    {"id":"57593","name":"Overview of comments received on draft Paediatric Addendum on the guidelines on clinical investigation of medicinal products for the treatment and prophylaxis of venous thromboembolic disease (EMA/CHMP/763438/2017)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-02-10T10:47:00Z","last_updated_date":"2023-02-10T10:47:00Z","reference_number":"EMA/CHMP/20512/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-draft-paediatric-addendum-guidelines-clinical-investigation-medicinal-products-treatment-and-prophylaxis-venous-thromboembolic-disease-emachmp7634382017_en.pdf"},
    {"id":"57654","name":"Concept paper on revision of the ‘Guideline on declaration of herbal substances and herbal preparations in herbal medicinal products / traditional herbal medicinal products’","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-03-01 - 2023-05-31","first_published_date":"2023-02-14T17:18:00Z","last_updated_date":"2023-02-14T17:18:00Z","reference_number":"EMA/HMPC/888811/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-declaration-herbal-substances-and-herbal-preparations-herbal-medicinal-products-traditional-herbal-medicinal-products_en.pdf"},
    {"id":"57702","name":"Guideline on development pharmaceutics for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T11:10:00Z","last_updated_date":"2023-02-17T11:10:00Z","reference_number":"EMA/CVMP/QWP/684556/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-pharmaceutics-veterinary-medicinal-products_en.pdf"},
    {"id":"57703","name":"Guideline on the chemistry of active substances for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T11:33:00Z","last_updated_date":"2023-02-17T11:33:00Z","reference_number":"EMA/CVMP/QWP/707366/2017-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-chemistry-active-substances-veterinary-medicinal-products_en.pdf-0"},
    {"id":"57704","name":"Reflection paper on the chemical structure and properties criteria to be considered for the evaluation of New Active Substance (NAS) status of chemical substances for veterinary medical products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T11:57:00Z","last_updated_date":"2023-02-17T11:57:00Z","reference_number":"EMA/CVMP/QWP/3629/2016-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-chemical-structure-and-properties-criteria-be-considered-evaluation-new-active-substance-nas-status-chemical-substances-veterinary-medical-products_en.pdf"},
    {"id":"57705","name":"Guideline on control of impurities of pharmacopoeial substances: compliance with the European Pharmacopoeia general monograph “substances for pharmaceutical use” and general chapter “control of impurities in substances for pharmaceutical use”","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T12:35:00Z","last_updated_date":"2023-02-17T12:35:00Z","reference_number":"EMA/CVMP/QWP/907965/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-control-impurities-pharmacopoeial-substances-compliance-european-pharmacopoeia-general-monograph-substances-pharmaceutical-use-and-general-chapter-control-impurities-substances_en.pdf"},
    {"id":"57706","name":"Guideline on Parametric release","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T12:42:00Z","last_updated_date":"2023-02-17T12:42:00Z","reference_number":"EMA/CVMP/QWP/339588/2005 – Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-parametric-release_en.pdf-0"},
    {"id":"57726","name":"Guideline on declaration of storage conditions: A) in the product information of pharmaceutical veterinary medicinal products B) for active substances","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T10:28:00Z","last_updated_date":"2023-02-20T10:28:00Z","reference_number":"EMA/CVMP/QWP/857608/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-declaration-storage-conditions-product-information-pharmaceutical-veterinary-medicinal-products-b-active-substances_en.pdf"},
    {"id":"57727","name":"Guideline on Stability Testing: Stability testing of existing active substances and related finished products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T10:55:00Z","last_updated_date":"2023-07-21T13:30:00Z","reference_number":"EMA/CVMP/QWP/709423/2022,Corr.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products_en.pdf"},
    {"id":"57728","name":"Guideline on additional Quality requirements for products intended for incorporation into animal feed","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T11:03:00Z","last_updated_date":"2023-02-20T11:03:00Z","reference_number":"EMA/CVMP/QWP/711629/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-additional-quality-requirements-products-intended-incorporation-animal-feed_en.pdf"},
    {"id":"57729","name":"Guideline on the quality aspects of single-dose veterinary spot-on products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T11:16:00Z","last_updated_date":"2023-02-20T11:16:00Z","reference_number":"EMA/CVMP/QWP/544461/2007-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-aspects-single-dose-veterinary-spot-products_en.pdf-0"},
    {"id":"57731","name":"Guideline on the quality of modified release dosage forms for veterinary use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-02-20T11:45:00Z","last_updated_date":"2023-02-20T11:45:00Z","reference_number":"EMA/CVMP/QWP/908160/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-modified-release-dosage-forms-veterinary-use_en.pdf"},
    {"id":"57819","name":"Draft guideline on plasmid DNA vaccines for veterinary use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-02-24 - 2023-06-23","first_published_date":"2023-02-24T14:12:00Z","last_updated_date":"2023-02-24T14:12:00Z","reference_number":"EMA/CVMP/IWP/365817/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-plasmid-dna-vaccines-veterinary-use_en.pdf"},
    {"id":"58260","name":"Guideline on Quality Aspects of Pharmaceutical Veterinary Medicines for administration via drinking water - Draft Annex on compatibility studies between veterinary medicinal products and biocidal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-04-01 - 2023-06-30","first_published_date":"2023-03-31T18:31:00Z","last_updated_date":"2023-03-31T18:31:00Z","reference_number":"EMA/CVMP/QWP/592906/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-aspects-pharmaceutical-veterinary-medicines-administration-drinking-water-draft-annex-compatibility-studies-between-veterinary-medicinal-products-and-biocidal-products_en.pdf"},
    {"id":"58269","name":"Guideline on influenza vaccines – submission and procedural requirements (Rev.2)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-04-03T10:38:00Z","last_updated_date":"2023-04-03T10:38:00Z","reference_number":"EMA/56793/2014 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-influenza-vaccines-submission-and-procedural-requirements-rev2_en.pdf"},
    {"id":"58282","name":"Questions and answers on data requirements when transitioning to low global warming potential (LGWP) propellants in oral pressurised metered dose inhalers","type":"scientific-guideline","status":"Adopted","consultation_date":"2023-04-05 - 2023-05-31","first_published_date":"2023-04-05T11:36:00Z","last_updated_date":"2024-10-03T16:02:00Z","reference_number":"EMA/477469/2023 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-data-requirements-when-transitioning-low-global-warming-potential-lgwp-propellants-oral-pressurised-metered-dose-inhalers_en.pdf"},
    {"id":"58490","name":"Draft reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-04-21 - 2023-09-30","first_published_date":"2023-04-21T15:48:00Z","last_updated_date":"2023-04-21T15:48:00Z","reference_number":"EMA/CHMP/564424/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-establishing-efficacy-based-single-arm-trials-submitted-pivotal-evidence-marketing-authorisation_en.pdf"},
    {"id":"58588","name":"Concept paper on revision of the Guideline on clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-05-04 - 2023-07-31","first_published_date":"2023-05-04T19:21:00Z","last_updated_date":"2023-05-04T19:21:00Z","reference_number":"EMA/CHMP/175067/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-clinical-investigation-medicinal-products-treatment-patients-acute-respiratory-distress-syndrome_en.pdf"},
    {"id":"58782","name":"Draft ICH E6 (R3) Guideline on good clinical practice (GCP) - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-05-26 - 2023-09-26","first_published_date":"2023-05-26T15:44:00Z","last_updated_date":"2023-05-26T15:44:00Z","reference_number":"EMA/CHMP/ICH/135/1995","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-e6-r3-guideline-good-clinical-practice-gcp-step-2b_en.pdf"},
    {"id":"59043","name":"Bosutinib film-coated tablets 100, 400 and 500 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-06-22 - 2023-09-30","first_published_date":"2023-06-22T16:40:00Z","last_updated_date":"2023-06-22T16:40:00Z","reference_number":"EMA/CHMP/590937/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/bosutinib-film-coated-tablets-100-400-and-500-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"59044","name":"Fampridine prolonged-release tablet 10 mg product specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-06-22 - 2023-09-30","first_published_date":"2023-06-22T16:58:00Z","last_updated_date":"2023-06-22T16:58:00Z","reference_number":"EMA/CHMP/39346/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/fampridine-prolonged-release-tablet-10-mg-product-specific-bioequivalence-guidance_en.pdf"}    {"id":"59046","name":"Lurasidone film-coated tablets 18.5, 37 and 74 mg 4 product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-06-22 - 2023-09-30","first_published_date":"2023-06-22T17:10:00Z","last_updated_date":"2023-06-22T17:10:00Z","reference_number":"EMA/CHMP/39336/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/lurasidone-film-coated-tablets-185-37-and-74-mg-4-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"59048","name":"Draft metformin immediate-release film-coated tablets 500, 850 and 1000 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-06-22 - 2023-09-30","first_published_date":"2023-06-22T17:17:00Z","last_updated_date":"2023-06-22T17:17:00Z","reference_number":"EMA/CHMP/591346/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-metformin-immediate-release-film-coated-tablets-500-850-1000-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"59053","name":"Pirfenidone film-coated tablets 267, 537 and 801 mg, and hard capsules 267 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-06-22 - 2023-09-30","first_published_date":"2023-06-22T17:44:00Z","last_updated_date":"2023-06-22T17:44:00Z","reference_number":"EMA/CHMP/901584/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/pirfenidone-film-coated-tablets-267-537-and-801-mg-and-hard-capsules-267-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"59056","name":"Paracetamol oral use immediate release formulations product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-06-22T16:13:00Z","last_updated_date":"2023-06-22T16:13:00Z","reference_number":"EMA/CHMP/356877/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paracetamol-oral-use-immediate-release-formulations-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"59060","name":"Tadalafil film-coated tablets 2.5 mg, 5 mg, 10 mg and 20 mg product-specific bioequivalence guidance - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-06-22T16:42:00Z","last_updated_date":"2023-06-22T16:42:00Z","reference_number":"EMA/CHMP/315234/2014 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/tadalafil-film-coated-tablets-25-mg-5-mg-10-mg-and-20-mg-product-specific-bioequivalence-guidance-revision-2_en.pdf"},
    {"id":"59062","name":"Ibuprofen oral use immediate release formulations 200 - 800 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-06-22T17:01:00Z","last_updated_date":"2023-06-22T17:01:00Z","reference_number":"EMA/CHMP/356876/2017 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ibuprofen-oral-use-immediate-release-formulations-200-800-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"59064","name":"Concept paper for the revision of the guideline on live recombinant vector vaccines for veterinary use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-06-23 - 2023-09-22","first_published_date":"2023-06-23T12:20:00Z","last_updated_date":"2023-06-23T12:20:00Z","reference_number":"EMA/CVMP/IWP/161133/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-live-recombinant-vector-vaccines-veterinary-use_en.pdf"},
    {"id":"59065","name":"Guideline on the development and data requirements of potency tests for veterinary cell-based therapy products and the relation to clinical efficacy","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T10:26:00Z","last_updated_date":"2023-06-23T10:26:00Z","reference_number":"EMA/CVMP/NTWP/179287/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-and-data-requirements-potency-tests-veterinary-cell-based-therapy-products-and-relation-clinical-efficacy_en.pdf"},
    {"id":"59070","name":"Guideline on the reporting of antimicrobial sales and use in animals at the EU level – denominators and indicators","type":"scientific-guideline","status":"Adopted","consultation_date":"2023-06-23 - 2023-07-31","first_published_date":"2023-06-23T13:24:00Z","last_updated_date":"2023-10-13T18:07:00Z","reference_number":"EMA/CVMP/882931/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-antimicrobial-sales-and-use-animals-eu-level-denominators-and-indicators_en.pdf"},
    {"id":"59074","name":"Concept paper on the development of a guideline on the quality aspects of mRNA vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-06-23 - 2023-09-30","first_published_date":"2023-06-23T14:17:00Z","last_updated_date":"2023-06-23T14:17:00Z","reference_number":"EMA/CHMP/BWP/211968/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-quality-aspects-mrna-vaccines_en.pdf"},
    {"id":"59118","name":"Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-06-28T11:08:00Z","last_updated_date":"2023-06-28T11:08:00Z","reference_number":"CPMP/EWP/1080/00 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus-revision-2_en.pdf"},
    {"id":"59119","name":"Overview of comments received on the draft guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus - Revision 2","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-06-28T11:12:00Z","last_updated_date":"2023-06-28T11:12:00Z","reference_number":"EMA/279883/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-diabetes-mellitus-revision-2_en.pdf"},
    {"id":"59121","name":"VICH GL18(R2) impurities: residual solvents in new veterinary medicinal products, active substances and excipients - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-06-28T13:46:00Z","last_updated_date":"2023-06-28T13:46:00Z","reference_number":"EMA/CVMP/VICH/502/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl18r2-impurities-residual-solvents-new-veterinary-medicinal-products-active-substances-and-excipients-revision-2_en.pdf"},
    {"id":"59272","name":"ICH reflection paper on proposed international harmonisation of real-world evidence terminology and convergence of general principles regarding planning and reporting of studies using real-world data, with a focus on effectiveness of medicines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-06-30 - 2023-09-30","first_published_date":"2023-07-06T12:10:00Z","last_updated_date":"2023-07-06T12:10:00Z","reference_number":"EMA/CHMP/ICH/295401/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-reflection-paper-proposed-international-harmonisation-real-world-evidence-terminology-and-convergence-general-principles-regarding-planning-and-reporting-studies-using-real-world-data-focus_en.pdf"},
    {"id":"59308","name":"Concept paper on the need for revision of the Paediatric addendum to the guideline on clinical investigation of medicinal products for the treatment of pulmonary arterial hypertension","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-07-07T17:35:00Z","last_updated_date":"2023-07-07T17:35:00Z","reference_number":"EMA/CHMP/264860/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-paediatric-addendum-guideline-clinical-investigation-medicinal-products-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"59368","name":"Draft reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-07-19 - 2023-12-31","first_published_date":"2023-07-19T13:00:00Z","last_updated_date":"2023-07-19T13:00:00Z","reference_number":"EMA/CHMP/CVMP/83833/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf"},
    {"id":"59403","name":"ICH M7(R2) Addendum on application of the principles of the ICH M7 guideline to calculation of compound-specific acceptable intakes - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-07-19T17:00:00Z","last_updated_date":"2023-07-19T17:00:00Z","reference_number":"EMA/CHMP/ICH/502766/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m7r2-addendum-application-principles-ich-m7-guideline-calculation-compound-specific-acceptable-intakes-step-5_en.pdf"},
    {"id":"59411","name":"ICH M7(R2) Guideline on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-07-19T16:53:00Z","last_updated_date":"2023-07-19T16:53:00Z","reference_number":"EMA/CHMP/ICH/83812/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m7r2-guideline-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-step-5_en.pdf"},
    {"id":"59453","name":"Guideline on excipients in the dossier for application for marketing authorisation for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T13:34:00Z","last_updated_date":"2023-07-21T13:34:00Z","reference_number":"EMA/CVMP/QWP/307647/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-excipients-dossier-application-marketing-authorisation-veterinary-medicinal-products_en.pdf"},
    {"id":"59454","name":"Concept paper for the development of a reflection paper on the availability and characteristics of diagnostic tests to improve the responsible use of antibiotics in animals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-07-21 - 2023-10-31","first_published_date":"2023-07-21T17:28:00Z","last_updated_date":"2023-07-21T17:28:00Z","reference_number":"EMA/CVMP/AWP/933451/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-availability-and-characteristics-diagnostic-tests-improve-responsible-use-antibiotics-animals_en.pdf"},
    {"id":"59455","name":"Concept paper on the revision of the 'Guideline on Radiopharmaceuticals - Revision 1'","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-07-21 - 2023-10-31","first_published_date":"2023-07-21T17:44:00Z","last_updated_date":"2023-07-21T17:44:00Z","reference_number":"EMA/CHMP/QWP/298182/2023 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-radiopharmaceuticals-revision-1_en.pdf"},
    {"id":"59456","name":"Concept paper on the revision of the guideline on 'Guideline on Radiopharmaceuticals based on monoclonal antibodies'","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-07-21 - 2023-10-31","first_published_date":"2023-07-21T17:51:00Z","last_updated_date":"2023-07-21T17:51:00Z","reference_number":"EMA/CHMP/BWP/245588/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-guideline-radiopharmaceuticals-based-monoclonal-antibodies_en.pdf"},
    {"id":"59458","name":"Guideline on quality data requirements for applications for veterinary medicinal products other than biologicals intended for limited markets","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-07-21 - 2024-01-31","first_published_date":"2023-07-21T18:14:00Z","last_updated_date":"2024-10-18T15:36:00Z","reference_number":"EMA/CVMP/QWP/47285/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-data-requirements-applications-veterinary-medicinal-products-other-biologicals-intended-limited-markets_en.pdf"},
    {"id":"59459","name":"Guideline on requirements for the quality (production and control), safety and efficacy of allergen products for use in horses, dogs and cats","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T16:33:00Z","last_updated_date":"2023-07-21T16:33:00Z","reference_number":"EMA/CVMP/IWP/170689/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-quality-production-and-control-safety-and-efficacy-allergen-products-use-horses-dogs-and-cats_en.pdf"},
    {"id":"59460","name":"Overview of comments received on 'Draft guideline on requirements for the quality (production and control), safety and efficacy of allergen products for use in horses, dogs and cats'","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T16:37:00Z","last_updated_date":"2023-07-21T16:37:00Z","reference_number":"EMA/CVMP/IWP/530940/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-draft-guideline-requirements-quality-production-and-control-safety-and-efficacy-allergen-products-use-horses-dogs-and-cats_en.pdf"},
    {"id":"59461","name":"Concept paper on the revision of the guideline for the demonstration of efficacy of ectoparasiticides","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-07-21 - 2023-10-31","first_published_date":"2023-07-21T18:46:00Z","last_updated_date":"2023-07-21T18:46:00Z","reference_number":"EMA/CVMP/EWP/56030/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-demonstration-efficacy-ectoparasiticides_en.pdf"},
    {"id":"59463","name":"Guideline on efficacy and target animal safety data requirements for applications for non-immunological veterinary medicinal products intended for limited markets but not eligible for authorisation under Article 23 of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Adopted","consultation_date":"2023-07-21 - 2024-01-31","first_published_date":"2023-07-21T19:02:00Z","last_updated_date":"2024-10-18T15:20:00Z","reference_number":"EMA/CVMP/EWP/231668/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-efficacy-target-animal-safety-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-not-eligible-authorisation-under-article-23-regulation_en.pdf"},
    {"id":"59528","name":"Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy studies","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-07-31T12:29:00Z","last_updated_date":"2023-07-31T12:29:00Z","reference_number":"EMADOC-1700519818-1127132","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-stride-velocity-95th-centile-primary-endpoint-studies-ambulatory-duchenne-muscular-dystrophy-studies_en.pdf"},
    {"id":"59604","name":"Concept paper on the development of a reflection paper on modern manufacturing techniques used for herbal preparations","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-08-15 - 2023-11-15","first_published_date":"2023-08-17T15:41:00Z","last_updated_date":"2023-08-17T15:41:00Z","reference_number":"EMA/HMPC/885124/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-modern-manufacturing-techniques-used-herbal-preparations_en.pdf"},
    {"id":"59904","name":"DRAFT qualification opinion for GFR slope as a Surrogate Endpoint in RCT for CKD","type":"scientific-guideline","status":"Draft","consultation_date":"","first_published_date":"2023-09-06T11:49:00Z","last_updated_date":"2023-09-06T11:49:00Z","reference_number":"EMA/SA/00000104642","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-qualification-opinion-gfr-slope-surrogate-endpoint-rct-ckd_en.pdf"},
    {"id":"59915","name":"Draft guideline on clinical investigation of medicinal products in the treatment of depression - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-09-15 - 2024-03-31","first_published_date":"2023-09-07T16:20:00Z","last_updated_date":"2023-09-15T11:35:00Z","reference_number":"EMA/CHMP/185423/2010 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf"},
    {"id":"60019","name":"Guideline on safety and residue data requirements for applications for non-immunological veterinary medicinal products intended for limited markets but not eligible for authorisation under Article 23 of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T14:00:00Z","last_updated_date":"2024-10-18T15:00:00Z","reference_number":"EMA/CVMP/SWP/32027/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-safety-residue-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-not-eligible-authorisation-under-article-23-regulation-eu-2019-6_en.pdf"},
    {"id":"60022","name":"Guideline on safety and efficacy data requirements for applications for immunological veterinary medicinal products intended for limited markets but not eligible for authorisation under Article 23 of Regulation (EU) 2019/6","type":"scientific-guideline","status":"Adopted","consultation_date":"2023-09-15 - 2024-01-31","first_published_date":"2023-09-15T14:00:00Z","last_updated_date":"2024-10-18T14:40:00Z","reference_number":"EMA/CVMP/IWP/224724/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-safety-efficacy-data-requirements-applications-immunological-veterinary-medicinal-products-intended-limited-markets-not-eligible-authorisation-under-article-23-regulation-eu-2019-6_en.pdf"},
    {"id":"60026","name":"Guideline on quality data requirements for applications for biological veterinary medicinal products intended for limited markets","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-09-07 - 2024-01-31","first_published_date":"2023-09-15T14:00:00Z","last_updated_date":"2024-10-18T16:10:00Z","reference_number":"EMA/CVMP/IWP/228730/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-data-requirements-applications-biological-veterinary-medicinal-products-intended-limited-markets_en.pdf"},
    {"id":"60028","name":"Concept paper on the revision of the Guideline on user safety of topically administered veterinary medicinal products (EMA/CVMP/SWP/721059/2014)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-09-15 - 2023-11-30","first_published_date":"2023-09-15T14:22:00Z","last_updated_date":"2023-09-15T14:22:00Z","reference_number":"EMA/CVMP/SWP/104211/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-user-safety-topically-administered-veterinary-medicinal-products-ema-cvmp-swp-721059-2014_en.pdf"},
    {"id":"60425","name":"Draft guideline on the calculation of dose factor to be submitted to the Union Product Database (UPD)","type":"scientific-guideline","status":"Draft","consultation_date":"2023-10-13 - 2023-11-13","first_published_date":"2023-10-13T11:00:00Z","last_updated_date":"2023-10-13T11:00:00Z","reference_number":"EMA/CVMP/PhVWPV/399363/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-calculation-dose-factor-be-submitted-union-product-database-upd_en.pdf"},
    {"id":"60439","name":"Concept paper on a guideline on stability testing for applications for variations to a marketing authorisation for veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-10-13 - 2024-01-05","first_published_date":"2023-10-13T19:38:00Z","last_updated_date":"2023-10-13T19:38:00Z","reference_number":"EMA/CVMP/QWP/348098/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-stability-testing-applications-variations-marketing-authorisation-veterinary-medicinal-products_en.pdf"},
    {"id":"60449","name":"Draft guideline on the development and manufacture of synthetic peptides","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-10-18 - 2024-04-30","first_published_date":"2023-10-18T17:08:00Z","last_updated_date":"2023-10-18T17:08:00Z","reference_number":"EMA/CHMP/CVMP/QWP/387541/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-manufacture-synthetic-peptides_en.pdf"},
    {"id":"60517","name":"Concept paper on the revision of the Non-clinical and Clinical Module of the influenza vaccines guideline","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-11-01 - 2024-01-30","first_published_date":"2023-10-31T18:28:00Z","last_updated_date":"2023-10-31T18:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-non-clinical-clinical-module-influenza-vaccines-guideline_en.pdf"},
    {"id":"60518","name":"Draft guideline on the clinical requirements for non replacement therapy in haemophilia A and B","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-11-01 - 2024-04-30","first_published_date":"2023-10-31T18:48:00Z","last_updated_date":"2023-10-31T18:48:00Z","reference_number":"EMA/CHMP/453562/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-requirements-non-replacement-therapy-haemophilia-b_en.pdf"},
    {"id":"60521","name":"Concept paper on the development of an addendum to the Guideline on clinical development of vaccines on clinical trials for vaccines for immunocompromised individuals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-11-01 - 2024-01-01","first_published_date":"2023-11-03T17:00:00Z","last_updated_date":"2023-11-03T17:00:00Z","reference_number":"EMA/CHMP/453562/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-addendum-guideline-clinical-development-vaccines-clinical-trials-vaccines-immunocompromised-individuals_en.pdf"},
    {"id":"60535","name":"Everolimus tablets 0.25 mg, 0.5 mg, 0.75 mg and 1 mg; 2.5 mg, 5 mg and 10 mg, dispersible tablets 0.1 mg and 0.25 mg; 2 mg, 3 mg and 5 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-01-03T16:42:00Z","last_updated_date":"2017-01-03T16:42:00Z","reference_number":"EMA/CHMP/151597/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/everolimus-tablets-025-mg-05-mg-075-mg-and-1-mg-25-mg-5-mg-and-10-mg-dispersible-tablets-01-mg-and-025-mg-2-mg-3-mg-and-5-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"60630","name":"Concept paper on the need for amendment of Guideline on Quality Aspects of Pharmaceutical Veterinary Medicines for administration via drinking water - Annex on the concomitant use of Veterinary Medicinal Products and biocides.","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2022-01-28 - 2022-04-30","first_published_date":"2022-01-28T15:15:00Z","last_updated_date":"2022-01-28T15:15:00Z","reference_number":"EMA/CVMP/QWP/697426/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-amendment-guideline-quality-aspects-pharmaceutical-veterinary-medicines-administration-drinking-water-annex-concomitant-use-veterinary-medicinal-products-and-biocides_en.pdf"},
    {"id":"60695","name":"Implementation strategy of ICH Guideline M10 on bioanalytical method validation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-11-10 - 2024-01-31","first_published_date":"2023-11-13T12:36:00Z","last_updated_date":"2024-05-03T10:39:00Z","reference_number":"EMA/449486/20233","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/implementation-strategy-ich-guideline-m10-bioanalytical-method-validation_en.pdf"},
    {"id":"60728","name":"ICH M7(R2) Questions and Answers on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-07-19T16:56:00Z","last_updated_date":"2023-07-19T16:56:00Z","reference_number":"EMA/CHMP/ICH/321999/2020","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m7r2-questions-and-answers-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-step-5_en.pdf"},
    {"id":"60792","name":"Draft guideline on VICH GL60 Good manufacturing practice for active ingredients used in veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-10-06 - 2024-03-25","first_published_date":"2023-11-07T16:41:00Z","last_updated_date":"2023-11-07T16:41:00Z","reference_number":"EMA/CVMP/196216/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-vich-gl60-good-manufacturing-practice-active-ingredients-used-veterinary-medicinal-products_en.pdf"},
    {"id":"60964","name":"Concept paper on the revision of the guideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-11-20 - 2024-02-28","first_published_date":"2023-11-23T14:42:34Z","last_updated_date":"2023-11-23T14:42:34Z","reference_number":"EMA/CHMP/CVMP/452614/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-principles-regulatory-acceptance-3rs-replacement-reduction-refinement-testing-approaches_en.pdf"},
    {"id":"60992","name":"Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2010-01-29T14:45:21Z","last_updated_date":"2010-08-25T14:44:33Z","reference_number":"CHMP/EWP/566/98 Rev.2/Corr","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-2_en.pdf"},
    {"id":"61070","name":"Bosutinib film-coated tablets 100, 400 and 500 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-11-28T14:17:09Z","last_updated_date":"2023-11-28T14:17:09Z","reference_number":"EMA/CHMP/590937/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/bosutinib-film-coated-tablets-100-400-and-500-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"61073","name":"Fampridine prolonged-release tablet 10 mg product specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-11-28T14:49:16Z","last_updated_date":"2023-11-28T14:49:16Z","reference_number":"EMA/CHMP/39346/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/fampridine-prolonged-release-tablet-10-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"61074","name":"Lurasidone film-coated tablets 18.5, 37 and 74 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-11-28T14:56:28Z","last_updated_date":"2023-11-28T14:56:28Z","reference_number":"EMA/CHMP/39336/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/lurasidone-film-coated-tablets-185-37-and-74-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"61075","name":"Lurasidone film-coated tablets 18.5, 37 and 74 mg 4 product-specific bioequivalence guidance","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-11-28T15:04:12Z","last_updated_date":"2023-11-28T15:04:12Z","reference_number":"EMA/CHMP/39336/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/lurasidone-film-coated-tablets-185-37-and-74-mg-4-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"61076","name":"Metformin immediate-release film-coated tablets 500, 850 and 1000 mg product-specific bioequivalence guidance ","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-11-28T15:13:13Z","last_updated_date":"2023-11-28T15:13:13Z","reference_number":"EMA/CHMP/591346/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/metformin-immediate-release-film-coated-tablets-500-850-and-1000-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"61078","name":"Pirfenidone film-coated tablets 267, 537 and 801 mg, and hard capsules 267 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-11-28T15:17:09Z","last_updated_date":"2023-11-28T15:17:09Z","reference_number":"EMA/CHMP/901584/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/pirfenidone-film-coated-tablets-267-537-and-801-mg-and-hard-capsules-267-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"61254","name":"Structured guidance on the use of extrapolation","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2022-04-04T15:32:54Z","last_updated_date":"2022-04-04T15:32:54Z","reference_number":"EMA/CHMP/13622/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/structured-guidance-use-extrapolation_en.pdf"},
    {"id":"61342","name":"Draft reflection paper on the environmental risk assessment of ectoparasiticidal veterinary medicinal products used in cats and dogs","type":"scientific-guideline","status":"unknown","consultation_date":"2022-12-16 - 2023-03-31","first_published_date":"2022-12-16T16:03:33Z","last_updated_date":"2022-12-16T16:03:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-environmental-risk-assessment-ectoparasiticidal-veterinary-medicinal-products-used-cats-and-dogs_en.pdf"},
    {"id":"61442","name":"Guideline on the acceptability of names for human medicinal products processed through the centralised procedure - revision 7","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T14:18:48Z","last_updated_date":"2023-12-15T14:18:48Z","reference_number":"EMA/CHMP/287710/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-acceptability-names-human-medicinal-products-processed-through-centralised-procedure-revision-7_en.pdf"},
    {"id":"61449","name":"Guideline on the calculation of dose factor to be submitted to the Union Product Database (UPD)","type":"scientific-guideline","status":"Adopted","consultation_date":"2023-10-13 - 2023-11-13","first_published_date":"2023-12-15T15:28:17Z","last_updated_date":"2023-12-15T15:28:17Z","reference_number":"EMA/CVMP/PhVWPV/399363/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-calculation-dose-factor-be-submitted-union-product-database-upd_en.pdf"},
    {"id":"61471","name":"Guideline on the conduct of pharmacokinetic studies in target animal species - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T16:33:58Z","last_updated_date":"2023-12-15T16:33:58Z","reference_number":"EMA/CVMP/EWP/133/1999-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-pharmacokinetic-studies-target-animal-species-revision-1_en.pdf"},
    {"id":"61472","name":"Overview of comments received on Guideline on the conduct of pharmacokinetic studies in target animal species (EMEA/CVMP/EWP/133/1999-Rev.1)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T16:43:01Z","last_updated_date":"2023-12-15T16:43:01Z","reference_number":"EMA/CVMP/EWP/326568/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-guideline-conduct-pharmacokinetic-studies-target-animal-species-emea-cvmp-ewp-133-1999-rev1_en.pdf"},
    {"id":"61479","name":"Draft Assessment of SmPC section 5.1: A Guide for Assessors of Centralised Applications","type":"scientific-guideline","status":"unknown","consultation_date":"2023-12-15 - 2024-03-04","first_published_date":"2023-12-18T10:54:26Z","last_updated_date":"2023-12-18T10:54:26Z","reference_number":"EMA/CHMP/566497/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-assessment-smpc-section-51-guide-assessors-centralised-applications_en.pdf"},
    {"id":"61485","name":"Reflection paper on regulatory requirements for the development of medicinal products for Acute Kidney Injury (AKI)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-12-18T14:44:45Z","last_updated_date":"2023-12-18T14:44:45Z","reference_number":"EMA/CHMP/536854/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-acute-kidney-injury-aki_en.pdf"},
    {"id":"61489","name":"Guideline on the evaluation of the benefit-risk balance of veterinary medicinal products","type":"scientific-guideline","status":"unknown","consultation_date":"2023-12-15 - 2024-06-30","first_published_date":"2023-12-18T17:20:50Z","last_updated_date":"2024-11-15T13:44:00Z","reference_number":"EMA/CVMP/248499/2007 – Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-benefit-risk-balance-veterinary-medicinal-products_en.pdf"},
    {"id":"61521","name":"Reflection paper on regulatory requirements for the development of medicinal products for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-12-19T15:56:39Z","last_updated_date":"2023-12-19T15:56:39Z","reference_number":"EMA/CHMP/299976/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-primary-biliary-cholangitis-pbc-primary-sclerosing-cholangitis-psc_en.pdf"},
    {"id":"61603","name":"Concept paper on the establishment of a guideline on the development and manufacture of human medicinal products specifically designed for phage therapy","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2023-12-22 - 2024-03-31","first_published_date":"2023-12-22T15:16:45Z","last_updated_date":"2023-12-22T15:16:45Z","reference_number":"EMA/CHMP/BWP/486838/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-establishment-guideline-development-manufacture-human-medicinal-products-specifically-designed-phage-therapy_en.pdf"},
    {"id":"61604","name":"ICH Q2(R2) guideline on validation of analytical procedures - Step 5 - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2023-12-22T15:35:27Z","last_updated_date":"2026-02-20T11:11:11Z","reference_number":"EMA/CHMP/ICH/82072/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q2r2-guideline-validation-analytical-procedures-step-5-revision-2_en.pdf"},
    {"id":"61622","name":"ICH Q5A(R2) Guideline on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-01-03T14:48:14Z","last_updated_date":"2024-01-03T14:48:14Z","reference_number":"EMA/CHMP/ICH/804363/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q5ar2-guideline-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin-step-5_en.pdf"},
    {"id":"61766","name":"Draft azacitidine powder for suspension for injection 25 mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-01-15 - 2024-04-30","first_published_date":"2024-01-15T14:26:58Z","last_updated_date":"2024-01-15T14:26:58Z","reference_number":"EMA/CHMP/172895/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-azacitidine-powder-suspension-injection-25-mg-ml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"61767","name":"Draft paliperidone palmitate depot suspension for injection (every 3 months) 175, 263, 350 and 525 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft","consultation_date":"2024-01-15 - 2024-04-30","first_published_date":"2024-01-15T14:37:14Z","last_updated_date":"2024-01-15T14:37:14Z","reference_number":"EMA/CHMP/890768/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-paliperidone-palmitate-depot-suspension-injection-every-3-months-175-263-350-525-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"61842","name":"Guideline on the clinical evaluation of anticancer medicinal products - Revision 6","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-01-23T13:37:16Z","last_updated_date":"2024-01-23T13:37:16Z","reference_number":"EMA/CHMP/205/95 Rev.6","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-anticancer-medicinal-products-revision-6_en.pdf"},
    {"id":"61891","name":"Concept paper on the revision of the guideline on the clinical evaluation of medicinal products intended for the treatment of Hepatitis B - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-01-26 - 2024-04-30","first_published_date":"2024-01-26T13:53:07Z","last_updated_date":"2024-01-26T13:53:07Z","reference_number":"EMA/CHMP/28391/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-clinical-evaluation-medicinal-products-intended-treatment-hepatitis-b-revision-1_en.pdf"},
    {"id":"61898","name":"Draft guideline on data requirements for veterinary medicinal products for zootechnical purposes - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-01-26 - 2024-05-31","first_published_date":"2024-01-26T09:40:05Z","last_updated_date":"2024-01-26T09:40:05Z","reference_number":"EMA/CVMP/EWP/37280/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-data-requirements-veterinary-medicinal-products-zootechnical-purposes-revision-1_en.pdf"},
    {"id":"61913","name":"Guideline on plasmid DNA vaccines for veterinary use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-01-26T14:11:45Z","last_updated_date":"2024-01-26T14:11:45Z","reference_number":"EMA/CVMP/IWP/365817/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-plasmid-dna-vaccines-veterinary-use_en.pdf"},
    {"id":"61915","name":"Draft guideline on live recombinant vector vaccines for veterinary use - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-01-26 - 2024-05-31","first_published_date":"2024-01-26T14:23:20Z","last_updated_date":"2024-01-26T14:23:20Z","reference_number":"EMA/CVMP/IWP/390313/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-live-recombinant-vector-vaccines-veterinary-use-revision-1_en.pdf"},
    {"id":"61917","name":"Guideline on determination of the need for an MRL evaluation for chemical-unlike biological substances","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-01-26T14:55:12Z","last_updated_date":"2024-01-26T14:55:12Z","reference_number":"EMA/CVMP/SWP/591282/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-determination-need-mrl-evaluation-chemical-unlike-biological-substances_en.pdf"},
    {"id":"61925","name":"ICH Q14 Guideline on analytical procedure development - Step 5 - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-01-26T16:18:41Z","last_updated_date":"2026-02-24T11:40:00Z","reference_number":"EMA/CHMP/ICH/195040/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q14-guideline-analytical-procedure-development-step-5-revision-1_en.pdf"},
    {"id":"62097","name":"Questions and answers on how to use a CEP in the context of a Marketing Authorisation Application (MAA) or a Marketing Authorisation Variation (MAV)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-02-13T11:45:56Z","last_updated_date":"2026-01-28T16:01:00Z","reference_number":"EMA/CHMP/CVMP/QWP/5/2024 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-how-use-cep-context-marketing-authorisation-application-maa-or-marketing-authorisation-variation-mav_en.pdf"},
    {"id":"62137","name":"Reflection paper on investigation of pharmacokinetics in the obese population - Scientific guideline","type":"scientific-guideline","status":"Adopted","consultation_date":"2018-02-01 - 2018-07-31","first_published_date":"2024-02-14T15:27:37Z","last_updated_date":"2024-02-14T15:27:37Z","reference_number":"EMA/CHMP/535116/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-investigation-pharmacokinetics-obese-population-scientific-guideline_en.pdf"},
    {"id":"62202","name":"Concept Paper for the Development of a Guideline on Non-Inferiority and Equivalence Comparisons in Clinical Trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-02-16 - 2024-05-31","first_published_date":"2024-02-16T12:49:35Z","last_updated_date":"2024-02-16T12:49:35Z","reference_number":"EMA/65012/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-non-inferiority-equivalence-comparisons-clinical-trials_en.pdf"},
    {"id":"62252","name":"Concept paper on the development of a guideline on the non-clinical and clinical evaluation of antiviral medicinal products and monoclonal antibodies for the prevention and treatment of COVID-19","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-02-22 - 2024-04-30","first_published_date":"2024-02-22T11:57:00Z","last_updated_date":"2024-02-22T11:57:00Z","reference_number":"EMA/CHMP/70203/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-non-clinical-clinical-evaluation-antiviral-medicinal-products-monoclonal-antibodies-prevention-treatment-covid-19_en.pdf"},
    {"id":"62291","name":"Draft guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-02-28 - 2024-05-31","first_published_date":"2024-02-23T16:44:32Z","last_updated_date":"2024-02-23T16:44:32Z","reference_number":"EMA/CHMP/72790/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-allergen-products-development-immunotherapy-allergy-diagnosis-moderate-low-sized-study-populations_en.pdf"},
    {"id":"62381","name":"Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells highlighted","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T17:01:03Z","last_updated_date":"2024-02-29T17:01:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-labelling-package-leaflet-advanced-therapy-medicinal-products-atmps-containing-genetically-modified-cells-highlighted_en.pdf"},
    {"id":"62382","name":"Preliminary QIG Considerations regarding Pharmaceutical Process Models","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-02-29 - 2024-03-29","first_published_date":"2024-02-29T17:07:47Z","last_updated_date":"2024-02-29T17:07:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/preliminary-qig-considerations-regarding-pharmaceutical-process-models_en.pdf"},
    {"id":"62396","name":"VICH GL22(R) - Studies to evaluate the safety of residues of veterinary drugs in human food reproduction testing (Revision 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-07-31","first_published_date":"2024-03-01T12:29:37Z","last_updated_date":"2024-03-01T12:29:37Z","reference_number":"EMA/CVMP/VICH/525/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl22r-studies-evaluate-safety-residues-veterinary-drugs-human-food-reproduction-testing-revision-1_en.pdf"},
    {"id":"62411","name":"ICH E2D(R1) Guideline on post-approval safety data Step 2b - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-02-22 - 2024-06-22","first_published_date":"2024-03-01T16:36:07Z","last_updated_date":"2024-03-01T16:36:07Z","reference_number":"EMA/CHMP/ICH/59123/20241","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e2dr1-guideline-post-approval-safety-data-step-2b-revision-1_en.pdf"},
    {"id":"62472","name":"Information for the package leaflet regarding proline used as an excipient in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-03-07T14:18:38Z","last_updated_date":"2024-03-07T14:18:38Z","reference_number":"EMA/CHMP/332530/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/information-package-leaflet-regarding-proline-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"62491","name":"Overview of comments received on 'Guideline on Quality Aspects of Pharmaceutical Veterinary Medicines for administration via drinking water - Annex on compatibility studies between veterinary medicinal products and biocidal products","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-03-08T10:24:36Z","last_updated_date":"2024-03-08T10:24:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-guideline-quality-aspects-pharmaceutical-veterinary-medicines-administration-drinking-water-annex-compatibility-studies-between-veterinary-medicinal-products-biocidal_en.pdf"},
    {"id":"62492","name":"Guideline on Quality Aspects of Pharmaceutical Veterinary Medicines for administration via drinking water - Annex on compatibility studies between veterinary medicinal products and biocidal products.","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-03-08T10:28:00Z","last_updated_date":"2024-03-08T10:28:00Z","reference_number":"EMA/CVMP/QWP/592906/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-aspects-pharmaceutical-veterinary-medicines-administration-drinking-water-annex-compatibility-studies-between-veterinary-medicinal-products-biocidal-products_en.pdf"},
    {"id":"62528","name":"Draft dabrafenib hard capsule 50 and 75 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-03-11 - 2024-06-30","first_published_date":"2024-03-11T11:23:22Z","last_updated_date":"2024-03-11T11:23:22Z","reference_number":"EMA/CHMP/39771/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-dabrafenib-hard-capsule-50-75-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"62529","name":"Trametinib film-coated tablet 0.5 and 2mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-03-11 - 2024-06-30","first_published_date":"2024-03-11T11:25:45Z","last_updated_date":"2024-03-11T11:25:45Z","reference_number":"EMA/CHMP/41624/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/trametinib-film-coated-tablet-05-2mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"62602","name":"Overview of comments received on 'Information for the package leaflet regarding proline used as an excipient in medicinal products for human use'","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-03-13T14:59:53Z","last_updated_date":"2024-03-13T14:59:53Z","reference_number":"EMA/CHMP/426533/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-information-package-leaflet-regarding-proline-used-excipient-medicinal-products-human-use_en.pdf"},
    {"id":"62687","name":"Guideline on the environmental risk assessment of medicinal products for human use - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-03-21T16:45:32Z","last_updated_date":"2024-08-23T13:47:00Z","reference_number":"EMEA/CHMP/SWP/4447/00 Rev. 1 - Corr. ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-environmental-risk-assessment-medicinal-products-human-use-revision-1_en.pdf"},
    {"id":"62724","name":"Draft guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials - Second version","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-03-25 - 2024-05-31","first_published_date":"2024-03-25T14:55:35Z","last_updated_date":"2024-03-25T14:55:35Z","reference_number":"EMA/CAT/123573/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials-second-version_en.pdf"},
    {"id":"62798","name":"Overview of comments received on 'Reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)’(EMA/CHMP/299976/2018)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-04-04T09:43:45Z","last_updated_date":"2024-04-04T09:43:45Z","reference_number":"EMA/CHMP/111546/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-reflection-paper-regulatory-requirements-development-medicinal-products-chronic-non-infectious-liver-diseases-pbc-psc-nashema-chmp-299976-2018_en.pdf"},
    {"id":"62799","name":"Reflection paper on regulatory requirements for the development of medicinal products for non-alcoholic steatohepatitis (NASH)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-04-04T09:48:43Z","last_updated_date":"2024-04-04T09:48:43Z","reference_number":"EMA/CHMP/111529/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-non-alcoholic-steatohepatitis-nash_en.pdf"},
    {"id":"62924","name":"Draft guideline on the requirements for demonstrating therapeutic equivalence between orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease (COPD)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-04-12 - 2024-10-30","first_published_date":"2024-04-12T09:12:50Z","last_updated_date":"2024-04-12T09:12:50Z","reference_number":"EMA/CHMP/101453/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-demonstrating-therapeutic-equivalence-between-orally-inhaled-products-oip-asthma-chronic-obstructive-pulmonary-disease-copd_en.pdf"},
    {"id":"62927","name":"Draft guideline on the pharmaceutical quality of inhalation and nasal medicinal products - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-04-12 - 2024-10-31","first_published_date":"2024-04-12T10:03:09Z","last_updated_date":"2024-04-12T10:03:09Z","reference_number":"EMA/CHMP/20607/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-pharmaceutical-quality-inhalation-nasal-medicinal-products-revision-1_en.pdf"},
    {"id":"62983","name":"Information for the package leaflet regarding polysorbates used as excipients in medicinal products for human use","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-04-17T09:54:26Z","last_updated_date":"2024-04-17T09:54:26Z","reference_number":"EMA/CHMP/190743/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/information-package-leaflet-regarding-polysorbates-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"62985","name":"Guideline on VICH GL61 Pharmaceutical Development","type":"scientific-guideline","status":"Draft","consultation_date":"2024-03-15 - 2024-08-15","first_published_date":"2024-04-17T12:35:18Z","last_updated_date":"2024-04-17T12:35:18Z","reference_number":"EMA/CVMP/841162/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-vich-gl61-pharmaceutical-development_en.pdf"},
    {"id":"63001","name":"Draft guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-04-15 - 2024-07-15","first_published_date":"2024-04-18T11:31:51Z","last_updated_date":"2024-04-18T11:31:51Z","reference_number":"EMEA/HMPC/246816/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-agricultural-collection-practice-gacp-starting-materials-herbal-origin-revision-1_en.pdf"}    {"id":"63093","name":"Concept paper for the development of a guideline on the safety of nanoparticles – in the context of the establishment of maximum residue limits and veterinary marketing authorisations","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-04-26 - 2024-07-31","first_published_date":"2024-04-26T14:30:00Z","last_updated_date":"2024-04-26T14:30:00Z","reference_number":"EMA/CVMP/NTWP/143787/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-safety-nanoparticles-context-establishment-maximum-residue-limits-veterinary-marketing-authorisations_en.pdf"},
    {"id":"63102","name":"Concept paper on the revision of the 'Guideline on epidemiological data on blood transmissible infections' - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-04-30 - 2024-06-28","first_published_date":"2024-04-30T11:30:00Z","last_updated_date":"2024-04-30T11:30:00Z","reference_number":"EMA/CHMP/BWP/4/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-epidemiological-data-blood-transmissible-infections-revision-2_en.pdf"},
    {"id":"63104","name":"ICH Q3C (R9) Guideline on impurities guideline for residual solvents - Step 5","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-04-29T16:49:48Z","last_updated_date":"2024-04-29T16:49:48Z","reference_number":"EMA/CHMP/ICH/82260/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q3c-r9-guideline-impurities-guideline-residual-solvents-step-5_en.pdf"},
    {"id":"63114","name":"Draft reflection paper on use of real-world data in non-interventional studies to generate real-world evidence","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-05-03 - 2024-08-31","first_published_date":"2024-05-03T09:50:00Z","last_updated_date":"2024-05-03T09:50:00Z","reference_number":"EMA/CHMP/150527/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence_en.pdf"},
    {"id":"63117","name":"Addendum to EMA/CHMP/CVMP/QWP/17760/2009 Rev 2: Defining the Scope of an NIRS Procedure","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2014-06-05T16:41:16Z","last_updated_date":"2014-06-05T16:41:16Z","reference_number":"EMA/CHMP/CVMP/QWP/63699/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-ema-chmp-cvmp-qwp-17760-2009-rev-2-defining-scope-nirs-procedure_en.pdf"},
    {"id":"63127","name":"Overview of comments received on Addendum to EMA/CHMP/CVMP/QWP/17760/2009 Rev 3: Defining the Scope of an NIRS Procedure","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-05-02T08:38:36Z","last_updated_date":"2024-05-02T08:38:36Z","reference_number":"EMA/101673/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-addendum-ema-chmp-cvmp-qwp-17760-2009-rev-3-defining-scope-nirs-procedure_en.pdf"},
    {"id":"63132","name":"Concept paper on revision of the Guideline on Risk Assessment of Medicinal Products on Human Reproduction and Lactation: from Data to Labelling","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-05-02 - 2024-09-13","first_published_date":"2024-05-02T09:10:57Z","last_updated_date":"2024-09-03T11:56:00Z","reference_number":"EMA/CHMP/170670/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-risk-assessment-medicinal-products-human-reproduction-lactation-data-labelling_en.pdf"},
    {"id":"63133","name":"Draft guideline on stability testing for applications for variations to a marketing authorisation for veterinary medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-05-02 - 2024-08-31","first_published_date":"2024-05-02T09:25:30Z","last_updated_date":"2024-05-02T09:25:30Z","reference_number":"EMA/CVMP/QWP/515653/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-stability-testing-applications-variations-marketing-authorisation-veterinary-medicinal-products_en.pdf"},
    {"id":"63148","name":"Addendum to EMA/CHMP/CVMP/QWP/17760/2009 Rev 3: Defining the Scope of an NIRS Procedure","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2024-05-02T14:50:47Z","last_updated_date":"2024-06-07T10:00:00Z","reference_number":"EMA/CHMP/CVMP/QWP/17760/2009 Rev 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-ema-chmp-cvmp-qwp-17760-2009-rev-3-defining-scope-nirs-procedure_en.pdf-0"},
    {"id":"63151","name":"Overview of comments received on Implementation strategy of ICH Guideline M10 on bioanalytical method validation EMA/449486/20233","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-05-03T10:41:43Z","last_updated_date":"2024-05-03T10:41:43Z","reference_number":"EMA/144393/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-implementation-strategy-ich-guideline-m10-bioanalytical-method-validation-ema-449486-20233_en.pdf"},
    {"id":"63377","name":"ICH M14 guideline on general principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-05-30 - 2024-08-30","first_published_date":"2024-05-30T09:13:00Z","last_updated_date":"2024-05-30T09:13:00Z","reference_number":"EMA/CHMP/ICH/155061/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines-step-2b_en.pdf"},
    {"id":"63433","name":"CHMP reflection paper on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/BWP/303353/2010 Rev 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/chmp-reflection-paper-creutzfeldt-jakob-disease-plasma-derived-urine-derived-medicinal-products-revision-3_en.pdf"},
    {"id":"63711","name":"ICH M12 Guideline on drug interaction studies - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-06-21T09:47:03Z","last_updated_date":"2024-06-21T09:47:03Z","reference_number":"EMA/CHMP/ICH/652460/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m12-guideline-drug-interaction-studies-step-5_en.pdf"},
    {"id":"63712","name":"Question and answers ICH M12 Guideline on drug interaction studies","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-06-21T09:55:34Z","last_updated_date":"2024-06-21T09:55:34Z","reference_number":"EMA/CHMP/ICH/227930/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/question-answers-ich-m12-guideline-drug-interaction-studies_en.pdf"},
    {"id":"63730","name":"Budesonide, prolonged release tablets, 9 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-06-25 - 2024-09-30","first_published_date":"2024-06-25T08:00:00Z","last_updated_date":"2024-06-25T08:00:00Z","reference_number":"EMA/CHMP/219378/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/budesonide-prolonged-release-tablets-9-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"63731","name":"Budesonide, gastro-resistant hard capsules, 3 mg, gastro-resistant granules, 9 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-06-25 - 2024-09-30","first_published_date":"2024-06-25T08:00:00Z","last_updated_date":"2024-06-25T08:00:00Z","reference_number":"EMA/CHMP/219288/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/budesonide-gastro-resistant-hard-capsules-3-mg-gastro-resistant-granules-9-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"63732","name":"Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-06-25 - 2024-09-30","first_published_date":"2024-06-25T08:00:00Z","last_updated_date":"2024-06-25T08:00:00Z","reference_number":"EMA/CHMP/219393/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/budesonide-gastro-resistant-hard-capsules-prolonged-release-properties-3-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"63733","name":"Methylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-06-25 - 2024-09-30","first_published_date":"2024-06-25T15:03:13Z","last_updated_date":"2025-02-10T14:40:00Z","reference_number":"EMA/94136/2024 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/methylphenidate-prolonged-release-tablet-18-mg-27-mg-36-mg-54-mg-modified-release-capsule-5-mg-10-mg-20-mg-30-mg-40-mg-50-mg-60-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"63734","name":"Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-06-25 - 2024-09-30","first_published_date":"2024-06-25T15:05:36Z","last_updated_date":"2024-06-25T15:05:36Z","reference_number":"EMA/CHMP/518671/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/nilotinib-hard-capsules-50-150-200-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"63748","name":"Concept paper on the revision of the COVID-19 vaccines guidance documents","type":"scientific-guideline","status":"unknown","consultation_date":"2024-07-01 - 2024-09-30","first_published_date":"2024-07-01T09:42:00Z","last_updated_date":"2024-07-01T09:42:00Z","reference_number":"EMA/CHMP/276798/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-covid-19-vaccines-guidance-documents_en.pdf"},
    {"id":"63794","name":"Guideline on the conduct of efficacy studies for intramammary products for use in cattle - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"2024-06-28 - 2024-10-31","first_published_date":"2024-06-28T13:00:00Z","last_updated_date":"2025-02-21T11:24:00Z","reference_number":"EMA/CVMP/344/1999 Rev.3*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-efficacy-studies-intramammary-products-use-cattle-revision-3_en.pdf"},
    {"id":"63800","name":"Guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"2024-06-28 - 2024-10-31","first_published_date":"2024-06-28T11:11:01Z","last_updated_date":"2025-02-21T10:30:00Z","reference_number":"EMA/CVMP/627/2001 Rev.2*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances-revision-2_en.pdf"},
    {"id":"63807","name":"Guideline on the clinical investigation of recombinant and human plasma-derived factor IX products - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T14:00:00Z","last_updated_date":"2024-06-28T14:00:00Z","reference_number":"EMA/CHMP/BPWP/144552/2009 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-recombinant-human-plasma-derived-factor-ix-products-revision-2_en.pdf"},
    {"id":"63810","name":"Guideline on core SmPC for human plasma derived and recombinant coagulation factor IX products - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T14:40:00Z","last_updated_date":"2024-06-28T14:40:00Z","reference_number":"EMA/CHMP/BPWP/277622/2024 rev. 3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-plasma-derived-recombinant-coagulation-factor-ix-products-revision-3_en.pdf"},
    {"id":"63814","name":"Concept paper on the need for revision of the guideline on clinical investigation of medicinal products for the treatment of psoriatic arthritis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-07-01 - 2024-09-30","first_published_date":"2024-07-01T08:00:00Z","last_updated_date":"2024-07-01T08:00:00Z","reference_number":"EMA/CHMP/96250/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-psoriatic-arthritis_en.pdf"},
    {"id":"63886","name":"Draft VICH GL23 Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-06-21 - 2024-11-30","first_published_date":"2024-07-05T09:17:56Z","last_updated_date":"2024-07-05T09:17:56Z","reference_number":"EMA/CVMP/VICH/526/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-vich-gl23-studies-evaluate-safety-residues-veterinary-drugs-human-food-genotoxicity-testing-revision-2_en.pdf"},
    {"id":"64210","name":"Addendum to the Guideline on clinical development of vaccines to address clinical trials in immunocompromised individuals","type":"scientific-guideline","status":"Adopted","consultation_date":"2024-07-19 - 2024-10-31","first_published_date":"2024-07-19T10:38:00Z","last_updated_date":"2025-02-26T10:16:40Z","reference_number":"EMA/52912/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-guideline-clinical-development-vaccines-address-clinical-trials-immunocompromised-individuals_en.pdf"},
    {"id":"64268","name":"Draft guideline on the development and manufacture of oligonucleotides","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-07-22 - 2025-01-31","first_published_date":"2024-07-22T13:08:00Z","last_updated_date":"2024-07-22T13:08:00Z","reference_number":"EMA/CHMP/CVMP/QWP/262313/202424","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-manufacture-oligonucleotides_en.pdf"},
    {"id":"64308","name":"Draft guideline on the chemistry of active substances - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-07-25 - 2025-01-31","first_published_date":"2024-07-25T13:05:51Z","last_updated_date":"2024-07-25T13:05:51Z","reference_number":"EMA/321776/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-chemistry-active-substances-revision-1_en.pdf"},
    {"id":"64315","name":"Concept paper for the development of a guideline on the demonstration of therapeutic equivalence for nasal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-07-25 - 2025-01-31","first_published_date":"2024-07-25T16:00:00Z","last_updated_date":"2024-11-22T14:31:51Z","reference_number":"EMA/CHMP/315603/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-demonstration-therapeutic-equivalence-nasal-products_en.pdf"},
    {"id":"64338","name":"Tolvaptan tablets with the dose range 7.5, 15 and 30 mg and tolvaptan tablets with the dose range 15, 30, 45, 60 and 90 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-07-26 - 2024-10-31","first_published_date":"2024-07-26T11:10:44Z","last_updated_date":"2024-07-26T11:10:44Z","reference_number":"EMA/CHMP/254395/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/tolvaptan-tablets-dose-range-75-15-30-mg-tolvaptan-tablets-dose-range-15-30-45-60-90-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"64340","name":"Concept paper on the revision of the guideline on user safety for pharmaceutical veterinary medicinal products (EMA/CVMP/543/03-Rev.1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-07-26 - 2024-10-31","first_published_date":"2024-07-26T11:20:50Z","last_updated_date":"2024-07-26T11:20:50Z","reference_number":"EMA/CVMP/SWP/564774/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-user-safety-pharmaceutical-veterinary-medicinal-products-ema-cvmp-543-03-rev1_en.pdf"},
    {"id":"64342","name":"Concept paper for the revision of the guideline on the conduct of bioequivalence studies for veterinary medicinal products (EMA/CVMP/016/2000-Rev.4)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-07-26 - 2024-10-31","first_published_date":"2024-07-26T11:29:34Z","last_updated_date":"2024-07-26T11:29:34Z","reference_number":"EMA/CVMP/256158/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-ema-cvmp-016-2000-rev4_en.pdf"},
    {"id":"64344","name":"Concept paper on the revision of the guideline on veterinary medicinal products controlling Varroa destructor parasitosis in bees","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-07-26 - 2024-10-31","first_published_date":"2024-07-26T13:47:03Z","last_updated_date":"2024-07-26T13:47:03Z","reference_number":"EMA/CVMP/EWP/247519/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-veterinary-medicinal-products-controlling-varroa-destructor-parasitosis-bees_en.pdf"},
    {"id":"64346","name":"Paliperidone palmitate depot suspension for injection (every 3 months) 175, 263, 350 and 525 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T14:03:05Z","last_updated_date":"2024-07-26T14:03:05Z","reference_number":"EMA/CHMP/890768/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paliperidone-palmitate-depot-suspension-injection-every-3-months-175-263-350-525-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"64349","name":"Concept paper on the revision of the guideline on dossier requirements for anticancer medicinal products for dogs and cats","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-07-26 - 2024-10-31","first_published_date":"2024-07-26T15:10:54Z","last_updated_date":"2024-07-26T15:10:54Z","reference_number":"EMA/CVMP/EWP/259765/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-dossier-requirements-anticancer-medicinal-products-dogs-cats_en.pdf"},
    {"id":"64450","name":"Concept paper on the need for a reflection paper on assessment of cardiovascular safety of oncology medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-08-01 - 2024-10-31","first_published_date":"2024-07-31T16:44:24Z","last_updated_date":"2024-07-31T16:44:24Z","reference_number":"EMA/CHMP/322756/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-reflection-paper-assessment-cardiovascular-safety-oncology-medicinal-products_en.pdf"},
    {"id":"64485","name":"ICH M13A Guideline on bioequivalence for immediaterelease solid oral dosage forms - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-08-02T11:31:33Z","last_updated_date":"2024-08-02T11:31:33Z","reference_number":"EMA/CHMP/ICH/953493/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m13a-guideline-bioequivalence-immediaterelease-solid-oral-dosage-forms-step-5_en.pdf"},
    {"id":"64491","name":"ICH M13A Guideline on bioequivalence for immediate-release solid oral dosage forms - Questions and answers","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-02T12:43:20Z","last_updated_date":"2024-08-02T12:43:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m13a-guideline-bioequivalence-immediate-release-solid-oral-dosage-forms-questions-answers_en.pdf"},
    {"id":"64494","name":"ICH reflection paper on pursuing opportunities for harmonisation in using real-world data to generate realworld evidence, with a focus on effectiveness of medicines","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-08-02T13:40:56Z","last_updated_date":"2024-08-02T13:40:56Z","reference_number":"EMA/CHMP/ICH/295401/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-reflection-paper-pursuing-opportunities-harmonisation-using-real-world-data-generate-realworld-evidence-focus-effectiveness-medicines_en.pdf"},
    {"id":"64514","name":"Draft Guideline on good pharmacovigilance practices (GVP): Module XVI Addendum II – Methods for effectiveness evaluation","type":"scientific-guideline","status":"unknown","consultation_date":"2021-02-03 - 2021-04-28","first_published_date":"2021-02-03T12:42:20Z","last_updated_date":"2024-02-03T12:47:00Z","reference_number":"EMA/419982/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-ii-methods-effectiveness-evaluation_en.pdf"},
    {"id":"64516","name":"Guideline on good pharmacovigilance practices: Annex I - Definitions (Rev. 5)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T17:38:00Z","last_updated_date":"2024-08-05T19:20:00Z","reference_number":"EMA/876333/2011","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-5_en.pdf"},
    {"id":"64629","name":"ICH guideline E11A on pediatric extrapolation Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-08-27T09:57:43Z","last_updated_date":"2024-09-03T14:03:00Z","reference_number":"EMA/CHMP/ICH/205218/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e11a-pediatric-extrapolation-step-5_en.pdf"},
    {"id":"64757","name":"Draft guideline on clinical development of medicinal products for the treatment and prevention of bipolar disorder - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-09-09 - 2025-03-31","first_published_date":"2024-09-09T09:40:47Z","last_updated_date":"2024-09-09T09:40:47Z","reference_number":"EMA/CHMP/406037/2024 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-development-medicinal-products-treatment-prevention-bipolar-disorder-revision-1_en.pdf"},
    {"id":"64793","name":"Draft questions and answers regarding co-processed excipients used in solid oral dosage forms (H & V)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-09-11 - 2024-12-31","first_published_date":"2024-09-11T13:47:05Z","last_updated_date":"2024-09-11T13:47:05Z","reference_number":"EMA/CHMP/CVMP/QWP/422493/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-questions-answers-regarding-co-processed-excipients-used-solid-oral-dosage-forms-h-v_en.pdf"},
    {"id":"64874","name":"Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation application","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-09-16T16:33:09Z","last_updated_date":"2024-09-16T16:33:09Z","reference_number":"EMA/CHMP/430688/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-establishing-efficacy-based-single-arm-trials-submitted-pivotal-evidence-marketing-authorisation-application_en.pdf"},
    {"id":"64899","name":"Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-09-30T13:57:44Z","last_updated_date":"2024-09-30T13:57:44Z","reference_number":"EMA/CHMP/CVMP/83833/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf"},
    {"id":"64974","name":"Guideline on safety and residue data requirements for applications for non-immunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation (EU) 2019/6 - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:11:01Z","last_updated_date":"2024-09-20T11:11:01Z","reference_number":"EMA/CVMP/345237/2020 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-safety-residue-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-2019-6-revision-1_en.pdf"},
    {"id":"64979","name":"Guideline on data requirements for applications for immunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation (EU) 2019/6 - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:11:01Z","last_updated_date":"2024-09-20T11:11:01Z","reference_number":"EMA/CVMP/59531/2020 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-applications-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-2019-6-revision-1_en.pdf"},
    {"id":"64981","name":"Guideline on efficacy and target animal safety data requirements for applications for non-immunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation (EU) 2019/6 - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:11:01Z","last_updated_date":"2024-09-20T11:11:01Z","reference_number":"EMA/CVMP/52665/2020 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-efficacy-target-animal-safety-data-requirements-applications-non-immunological-veterinary-medicinal-products-intended-limited-markets-submitted-under-article-23-regulation-eu-2019-6-revision_en.pdf"},
    {"id":"65069","name":"Draft guideline on risk management requirements for elemental impurities in veterinary medicinal products - Revision 3","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-10-01 - 2025-01-31","first_published_date":"2024-10-01T13:58:00Z","last_updated_date":"2024-10-01T13:58:00Z","reference_number":"EMA/CVMP/426245/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-risk-management-requirements-elemental-impurities-veterinary-medicinal-products-revision-3_en.pdf"},
    {"id":"65074","name":"Guideline on quality and equivalence of locally applied, locally acting cutaneous products","type":"scientific-guideline","status":"Adopted","consultation_date":"2018-12-14 - 2019-06-30","first_published_date":"2024-10-01T16:34:18Z","last_updated_date":"2024-10-01T16:34:18Z","reference_number":"EMA/CHMP/QWP/708282/2018","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-equivalence-locally-applied-locally-acting-cutaneous-products_en.pdf"},
    {"id":"65281","name":"Concept paper on clinical evaluation of therapeutic radiopharmaceuticals in oncology","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-10-11 - 2025-01-31","first_published_date":"2024-10-11T14:40:39Z","last_updated_date":"2024-10-11T14:40:39Z","reference_number":"EMA/CHMP/451705/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-clinical-evaluation-therapeutic-radiopharmaceuticals-oncology_en.pdf"},
    {"id":"65498","name":"Draft guideline on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease of the lower extremities - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-10-31 - 2025-04-30","first_published_date":"2024-10-31T09:00:00Z","last_updated_date":"2024-10-31T09:00:00Z","reference_number":"EMA/CHMP/464798/2024 Rev. 2 (previously EMA/CHMP/464798/2024 Rev. 1)","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-peripheral-arterial-occlusive-disease-lower-extremities-revision-2_en.pdf"},
    {"id":"65690","name":"VICH GL7 Efficacy of anthelmintics: general requirements - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-11-18T13:28:02Z","last_updated_date":"2024-11-18T13:28:02Z","reference_number":"EMA/CVMP/VICH/832/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl7-efficacy-anthelmintics-general-requirements-revision-1_en.pdf-0"},
    {"id":"65691","name":"VICH GL12: Efficacy of anthelmintics: specific recommendations for bovines (Revision 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-11-18T13:48:47Z","last_updated_date":"2024-11-18T13:48:47Z","reference_number":"EMA/CVMP/VICH/839/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl12-efficacy-anthelmintics-specific-recommendations-bovines-revision-1_en.pdf-0"},
    {"id":"65692","name":"VICH GL13 Efficacy of anthelmintics: specific recommendations for ovines (Revision 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-11-18T14:00:47Z","last_updated_date":"2024-11-18T14:00:47Z","reference_number":"EMA/CVMP/VICH/840/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl13-efficacy-anthelmintics-specific-recommendations-ovines-revision-1_en.pdf-0"},
    {"id":"65693","name":"VICH GL14 Efficacy of anthelmintics: specific recommendations for caprines (Revision 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-11-18T14:08:46Z","last_updated_date":"2024-11-18T14:08:46Z","reference_number":"EMA/CVMP/VICH/841/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl14-efficacy-anthelmintics-specific-recommendations-caprines-revision-1_en.pdf-0"},
    {"id":"65694","name":"VICH GL15 Efficacy of anthelmintics: specific recommendations for equines (Revision 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-11-18T14:13:12Z","last_updated_date":"2024-11-18T14:13:12Z","reference_number":"EMA/CVMP/VICH/833/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl15-efficacy-anthelmintics-specific-recommendations-equines-revision-1_en.pdf-0"},
    {"id":"65695","name":"VICH GL16 Efficacy of anthelmintics: specific recommendations for porcines (Revision 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-11-18T14:15:50Z","last_updated_date":"2024-11-18T14:15:50Z","reference_number":"EMA/CVMP/VICH/834/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl16-efficacy-anthelmintics-specific-recommendations-porcines-revision-1_en.pdf-0"},
    {"id":"65696","name":"VICH GL19 Efficacy of anthelmintics: specific recommendations for canines (Revision 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-11-18T14:30:24Z","last_updated_date":"2024-11-18T14:30:24Z","reference_number":"EMA/CVMP/VICH/835/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl19-efficacy-anthelmintics-specific-recommendations-canines-revision-1_en.pdf-0"},
    {"id":"65697","name":"VICH GL20 Efficacy of anthelmintics: specific recommendations for felines (Revision 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-11-18T14:33:58Z","last_updated_date":"2024-11-18T14:33:58Z","reference_number":"EMA/CVMP/VICH/545/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl20-efficacy-anthelmintics-specific-recommendations-felines-revision-1_en.pdf-0"},
    {"id":"65698","name":"VICH GL21 Efficacy of anthelmintics: specific recommendations for chickens – gallus gallus (Revision 1)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-11-18T14:38:20Z","last_updated_date":"2024-11-18T14:38:20Z","reference_number":"EMA/CVMP/VICH/546/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl21-efficacy-anthelmintics-specific-recommendations-chickens-gallus-gallus-revision-1_en.pdf-0"},
    {"id":"65753","name":"Draft guideline for the demonstration of efficacy for veterinary medicinal products containing anticoccidial substances - Revision 1 (second version)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-10-18 - 2025-02-28","first_published_date":"2024-10-18T09:09:36Z","last_updated_date":"2024-10-18T09:09:36Z","reference_number":"EMA/CVMP/EWP/755916/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-anticoccidial-substances-revision-1-second-version_en.pdf"},
    {"id":"65805","name":"Guideline on stability testing for applications for variations to a marketing authorisation for veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-11-25T14:25:43Z","last_updated_date":"2024-11-25T14:25:43Z","reference_number":"EMA/CVMP/QWP/515653/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-applications-variations-marketing-authorisation-veterinary-medicinal-products_en.pdf"},
    {"id":"65875","name":"Draft ICH M15 Guideline on general principles for model-informed drug development - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-11-29 - 2025-02-28","first_published_date":"2024-11-29T10:30:07Z","last_updated_date":"2024-11-29T10:30:07Z","reference_number":"EMA/CHMP/ICH/496426/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-m15-guideline-general-principles-model-informed-drug-development-step-2b_en.pdf"},
    {"id":"65881","name":"Draft ICH E6(R3) guideline for good clinical practice – Annex 2 - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-11-29 - 2025-02-28","first_published_date":"2024-11-29T10:57:07Z","last_updated_date":"2024-11-29T10:57:07Z","reference_number":"EMA/CHMP/ICH/495903/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-e6r3-guideline-good-clinical-practice-annex-2-step-2b_en.pdf"},
    {"id":"65922","name":"Concept paper on the need for revision of the addendum on weight control in children to the guideline on clinical evaluation of medicinal products used in weight control ","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-12-02 - 2025-02-28","first_published_date":"2024-12-03T13:23:12Z","last_updated_date":"2024-12-03T13:23:12Z","reference_number":"EMA/501950/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-addendum-weight-control-children-guideline-clinical-evaluation-medicinal-products-used-weight-control_en.pdf"},
    {"id":"65939","name":"Guideline on the clinical requirements for non-replacement therapy in haemophilia A and B","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-12-04T11:33:10Z","last_updated_date":"2024-12-04T11:33:10Z","reference_number":"EMA/CHMP/BPWP/518080/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-requirements-non-replacement-therapy-haemophilia-b_en.pdf"},
    {"id":"65976","name":"Draft guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-12-05 - 2025-06-13","first_published_date":"2024-12-05T13:50:18Z","last_updated_date":"2025-06-04T11:53:22Z","reference_number":"EMA/CHMP/BPWP/496692/2023 rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-human-normal-immunoglobulin-subcutaneous-or-intramuscular-administration-scig-imig-revision-2_en.pdf"},
    {"id":"66006","name":"Draft guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration (SCIg/IMIg) - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-12-05 - 2025-06-13","first_published_date":"2024-12-05T14:25:46Z","last_updated_date":"2025-06-04T14:23:18Z","reference_number":"EMA/CHMP/BPWP/143744/2011 rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-human-normal-immunoglobulin-subcutaneous-intramuscular-administration-scig-imig-revision-2_en.pdf"},
    {"id":"66122","name":"Concept paper for the revision of the Guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-12-13 - 2025-03-13","first_published_date":"2024-12-13T15:55:59Z","last_updated_date":"2024-12-13T15:55:59Z","reference_number":"EMA/CVMP/IWP/188413/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-requirements-combined-vaccines-associations-immunological-veterinary-medicinal-products-ivmps_en.pdf"},
    {"id":"66123","name":"Overview of comments received on Guideline on live recombinant vector vaccines for veterinary use - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2024-12-13T16:12:12Z","last_updated_date":"2024-12-13T16:12:12Z","reference_number":"EMA/260063/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-guideline-live-recombinant-vector-vaccines-veterinary-use-revision-1_en.pdf"},
    {"id":"66124","name":"Guideline on live recombinant vector vaccines for veterinary use - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T16:13:31Z","last_updated_date":"2024-12-13T16:13:31Z","reference_number":"EMA/CVMP/IWP/390313/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-live-recombinant-vector-vaccines-veterinary-use-revision-1_en.pdf"},
    {"id":"66157","name":"Draft guideline on VICH GL8(R) Stability testing for medicated premixes","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-12-06 - 2025-05-31","first_published_date":"2024-12-16T15:37:06Z","last_updated_date":"2024-12-16T15:37:06Z","reference_number":"EMA/CVMP/VICH/836/1999","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-vich-gl8r-stability-testing-medicated-premixes_en.pdf"},
    {"id":"66182","name":"ICH Q4B(R1) Guideline on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-12-18T09:16:06Z","last_updated_date":"2024-12-18T09:16:06Z","reference_number":"EMA/CHMP/ICH/222007/2006","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q4br1-guideline-evaluation-recommendation-pharmacopoeial-texts-use-ich-regions-step-5_en.pdf"},
    {"id":"66226","name":"Trametinib film-coated tablet 0.5 and 2mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2024-12-19T14:02:13Z","last_updated_date":"2024-12-19T14:02:13Z","reference_number":"EMA/41624/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/trametinib-film-coated-tablet-05-2mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"66266","name":"Draft concept paper for the development of a guideline on quality aspects of mRNA vaccines for veterinary use","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-01-08 - 2025-04-08","first_published_date":"2025-01-08T10:38:12Z","last_updated_date":"2025-01-08T10:38:12Z","reference_number":"EMA/CVMP/IWP/189026/2024 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-guideline-quality-aspects-mrna-vaccines-veterinary-use_en.pdf"},
    {"id":"66410","name":"Guideline on specific adverse reaction follow-up questionnaires (Specific AR FUQ)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-01-22T10:23:51Z","last_updated_date":"2025-01-22T10:23:51Z","reference_number":"EMA/PRAC/490455/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-specific-adverse-reaction-follow-questionnaires-specific-ar-fuq_en.pdf-0"},
    {"id":"66450","name":"Final guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food- producing animal species","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-01-24T15:33:36Z","last_updated_date":"2025-01-24T15:33:36Z","reference_number":"EMA/CVMP/AWP/706442/2013","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/final-guideline-assessment-risk-public-health-antimicrobial-resistance-due-use-antimicrobial-veterinary-medicinal-product-food-producing-animal-species_en.pdf"},
    {"id":"66453","name":"Guideline on data requirements for veterinary medicinal products for zootechnical purposes","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-01-24T15:41:16Z","last_updated_date":"2025-01-24T15:41:16Z","reference_number":"EMA/CVMP/EWP/37280/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-veterinary-medicinal-products-zootechnical-purposes_en.pdf"},
    {"id":"66474","name":"ICH E6 (R3) Guideline for good clinical practice (GCP) - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-01-27T15:15:33Z","last_updated_date":"2025-01-27T15:15:33Z","reference_number":"EMA/CHMP/ICH/135/1995","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r3-guideline-good-clinical-practice-gcp-step-5_en.pdf"},
    {"id":"66530","name":"Draft reflection paper on the qualification of non-mutagenic impurities ","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-01-30 - 2025-04-30","first_published_date":"2025-01-30T13:43:41Z","last_updated_date":"2025-01-30T13:43:41Z","reference_number":"EMA/CHMP/543397/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-qualification-non-mutagenic-impurities_en.pdf"},
    {"id":"66544","name":"Draft aprepitant, hard capsules, 80mg, 125mg, 80+125mg and powder for oral suspension 125mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-01-31 - 2025-04-30","first_published_date":"2025-01-31T10:19:29Z","last_updated_date":"2025-01-31T10:19:29Z","reference_number":"EMA/13174/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-aprepitant-hard-capsules-80mg-125mg-80125mg-powder-oral-suspension-125mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"66545","name":"Draft Paclitaxel (nanoparticle albumin-bound) powder for suspension for infusion, 5mg/ml","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-01-31 - 2025-04-30","first_published_date":"2025-01-31T10:23:35Z","last_updated_date":"2025-01-31T10:23:35Z","reference_number":"EMA/418520/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-paclitaxel-nanoparticle-albumin-bound-powder-suspension-infusion-5mg-ml_en.pdf"},
    {"id":"66554","name":"Draft reflection paper on the use of information in European Union herbal monographs and assessment reports for borderline issues","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-02-01 - 2025-05-01","first_published_date":"2025-01-31T13:26:19Z","last_updated_date":"2025-01-31T13:26:19Z","reference_number":"EMA/HMPC/224438/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-information-european-union-herbal-monographs-assessment-reports-borderline-issues_en.pdf"},
    {"id":"66563","name":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q9 (R1) on quality risk management - Step 5 - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T16:00:12Z","last_updated_date":"2025-01-31T16:00:12Z","reference_number":"EMA/CHMP/ICH/24235/2006 Corr.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q9-r1-quality-risk-management-step-5-revision-2_en.pdf"},
    {"id":"66623","name":"Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-02-06T13:05:02Z","last_updated_date":"2025-02-06T13:05:02Z","reference_number":"EMA/CAT/22473/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials_en.pdf"},
    {"id":"66689","name":"Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-02-12T09:25:14Z","last_updated_date":"2025-02-12T09:25:14Z","reference_number":"EMA/CHMP/518671/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/nilotinib-hard-capsules-50-150-200-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"66690","name":"Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-02-12T09:24:18Z","last_updated_date":"2025-02-12T09:24:18Z","reference_number":"EMA/CHMP/219393/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/budesonide-gastro-resistant-hard-capsules-prolonged-release-properties-3-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"66709","name":"Budesonide, gastro-resistant hard capsules, 3 mg, gastro- resistant granules, 9 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-02-12T16:03:20Z","last_updated_date":"2025-02-12T16:03:20Z","reference_number":"EMA/CHMP/219288/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/budesonide-gastro-resistant-hard-capsules-3-mg-gastro-resistant-granules-9-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"66710","name":"Budesonide, prolonged release tablets, 9 mg product- specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-02-12T16:18:04Z","last_updated_date":"2025-02-12T16:18:04Z","reference_number":"EMA/CHMP/219378/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/budesonide-prolonged-release-tablets-9-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"66714","name":"Implementation strategy of ICH Guideline M12 on drug interaction studies","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-02-13T09:44:22Z","last_updated_date":"2025-02-13T09:44:22Z","reference_number":"EMA/460496/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/implementation-strategy-ich-guideline-m12-drug-interaction-studies_en.pdf"},
    {"id":"66744","name":"Draft reflection paper on the current regulatory testing requirements for medicinal products for human use and opportunities for implementation of the 3Rs - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-02-13 - 2025-06-30","first_published_date":"2025-02-13T15:02:32Z","last_updated_date":"2025-02-13T15:02:32Z","reference_number":"EMA/CHMP/CVMP/3Rs/742466/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-current-regulatory-testing-requirements-medicinal-products-human-use-opportunities-implementation-3rs-revision-1_en.pdf"},
    {"id":"66745","name":"Draft reflection paper on the current regulatory testing requirements for veterinary medicinal products and opportunities for implementation of the 3Rs - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-02-13 - 2025-06-30","first_published_date":"2025-02-13T15:07:33Z","last_updated_date":"2025-02-13T15:07:33Z","reference_number":"EMA/CHMP/CVMP/3Rs/164002/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-current-regulatory-testing-requirements-veterinary-medicinal-products-opportunities-implementation-3rs-revision-1_en.pdf"},
    {"id":"66764","name":"Concept paper on the development of a Guideline on assessment and reporting of mechanistic models used in the context of model informed drug development","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-02-14 - 2025-05-31","first_published_date":"2025-02-14T09:38:17Z","last_updated_date":"2025-02-14T09:38:17Z","reference_number":"EMA/5875/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-assessment-reporting-mechanistic-models-used-context-model-informed-drug-development_en.pdf"},
    {"id":"66985","name":"Considerations regarding the implementation of ICH M13A on bioequivalence for immediate-release solid oral dosage forms","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-02-26T12:57:35Z","last_updated_date":"2025-02-26T12:57:35Z","reference_number":"EMA/531548/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/considerations-regarding-implementation-ich-m13a-bioequivalence-immediate-release-solid-oral-dosage-forms_en.pdf"},
    {"id":"67006","name":"Draft guideline on the clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-02-28 - 2025-05-31","first_published_date":"2025-02-28T08:00:59Z","last_updated_date":"2025-02-28T08:00:59Z","reference_number":"EMA/67201/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-patients-acute-respiratory-distress-syndrome-revision-2_en.pdf"},
    {"id":"67176","name":"Draft guideline on the conduct of efficacy studies for intramammary products for use in cattle","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2024-06-28T09:30:57Z","last_updated_date":"2024-06-28T09:30:57Z","reference_number":"EMA/CVMP/344/1999-Rev.3*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-efficacy-studies-intramammary-products-use-cattle_en.pdf"},
    {"id":"67177","name":"Draft guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2024-06-28T09:34:55Z","last_updated_date":"2024-06-28T09:34:55Z","reference_number":"EMA/CVMP/627/2001-Rev.2*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-demonstration-efficacy-veterinary-medicinal-products-containing-antimicrobial-substances_en.pdf-0"}    {"id":"67221","name":"Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-03-12T10:39:42Z","last_updated_date":"2025-03-12T10:39:42Z","reference_number":"CHMP/EWP/566/98 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-3_en.pdf"},
    {"id":"67222","name":"Guideline on clinical investigation of medicinal products in the treatment of depression - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-03-12T10:43:42Z","last_updated_date":"2025-03-12T10:43:42Z","reference_number":"EMA/CHMP/185423/2010 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf"},
    {"id":"67319","name":"ICH M11 Technical Specification - Updated step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-03-18 - 2025-04-22","first_published_date":"2025-03-18T14:02:26Z","last_updated_date":"2025-03-18T14:02:26Z","reference_number":"EMA/CHMP/ICH/778800/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m11-technical-specification-updated-step-2b_en.pdf"},
    {"id":"67347","name":"Guideline on clinical evaluation of medicinal products used in weight management","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2014-07-31T13:20:12Z","last_updated_date":"2014-07-31T13:20:12Z","reference_number":"EMA/CHMP/311805/2014","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-used-weight-management_en.pdf"},
    {"id":"67554","name":"Draft guideline on the quality aspects of mRNA vaccines","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-03-31 - 2025-09-30","first_published_date":"2025-03-31T16:26:36Z","last_updated_date":"2025-03-31T16:26:36Z","reference_number":"EMA/CHMP/BWP/82416/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-aspects-mrna-vaccines_en.pdf"},
    {"id":"67557","name":"Concept paper on the revision of the guideline on the Scientific Data Requirements for a Plasma Master File (PMF) Revision 1 and Annexes","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-03-31 - 2025-06-30","first_published_date":"2025-03-31T16:37:39Z","last_updated_date":"2025-03-31T16:37:39Z","reference_number":"EMA/CHMP/BWP/91140/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-scientific-data-requirements-plasma-master-file-pmf-revision-1-annexes_en.pdf"},
    {"id":"67594","name":"Tolvaptan tablets with the dose range 7.5, 15 and 30 mg and tolvaptan tablets with the dose range 15, 30, 45, 60 and 90 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-04-02T10:48:02Z","last_updated_date":"2025-04-02T10:48:02Z","reference_number":"EMA/CHMP/254395/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/tolvaptan-tablets-dose-range-75-15-30-mg-tolvaptan-tablets-dose-range-15-30-45-60-90-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"67707","name":"ICH Guideline M13B on bioequivalence for immediate release solid oral dosage forms - additional strengths - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-04-09 - 2025-07-09","first_published_date":"2025-04-09T10:35:27Z","last_updated_date":"2025-04-09T10:35:27Z","reference_number":"EMA/CHMP/ICH/85092/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m13b-bioequivalence-immediate-release-solid-oral-dosage-forms-additional-strengths-step-2b_en.pdf"},
    {"id":"67864","name":"Concept paper for the development of a reflection paper on the assessment of public health risks related to antimicrobial resistance acquired via the environment, resulting from the use of a veterinary medicinal product","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-04-16 - 2025-10-31","first_published_date":"2025-04-16T09:21:49Z","last_updated_date":"2025-04-16T09:21:49Z","reference_number":"EMA/CVMP/ERA/75412/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-assessment-public-health-risks-related-antimicrobial-resistance-acquired-environment-resulting-use-veterinary-medicinal-product_en.pdf"},
    {"id":"67876","name":"Overview of comments received on ICH M15 Guideline on general principles for model informed drug development (EMA/CHMP/ICH/496426/2024)","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-04-16T12:56:15Z","last_updated_date":"2025-04-16T12:56:15Z","reference_number":"EMA/91404/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-ich-m15-guideline-general-principles-model-informed-drug-development-ema-chmp-ich-496426-2024_en.pdf"},
    {"id":"68040","name":"Draft ICH Q1 guideline on stability testing of drug substances and drug products - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-04-30 - 2025-07-30","first_published_date":"2025-04-30T15:21:10Z","last_updated_date":"2025-04-30T15:21:10Z","reference_number":"EMA/CHMP/ICH/130561/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-q1-guideline-stability-testing-drug-substances-drug-products-step-2b_en.pdf"},
    {"id":"68047","name":"Concept paper on the revision of the guideline on the evaluation of anticancer medicinal products and appendices - Revision 7","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-04-30 - 2025-07-31","first_published_date":"2025-04-30T16:45:01Z","last_updated_date":"2025-04-30T16:45:01Z","reference_number":"EMA/122980/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-evaluation-anticancer-medicinal-products-appendices-revision-7_en.pdf"},
    {"id":"68167","name":"Concept paper on the revision of Part IV guidelines on good manufacturing practice specific to advanced therapy medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-05-08 - 2025-07-08","first_published_date":"2025-05-08T12:20:38Z","last_updated_date":"2025-05-08T12:20:38Z","reference_number":"EMA/INS/GMP/48771/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-part-iv-guidelines-good-manufacturing-practice-specific-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"68415","name":"Concept paper on the development of a guideline on consumer safety of active substances of immunological veterinary medicinal products acting against endogenous targets","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-05-23 - 2025-08-31","first_published_date":"2025-05-23T13:44:20Z","last_updated_date":"2025-05-23T13:44:20Z","reference_number":"EMA/CVMP/SWP/564861/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-consumer-safety-active-substances-immunological-veterinary-medicinal-products-acting-against-endogenous-targets_en.pdf"},
    {"id":"68418","name":"Concept paper on a guideline on investigation of drug interactions in the gastrointestinal tract","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T14:26:22Z","last_updated_date":"2025-05-23T14:26:22Z","reference_number":"EMA/124631/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-investigation-drug-interactions-gastrointestinal-tract_en.pdf"},
    {"id":"68506","name":"Draft reflection paper on data recommendations for herbal medicinal products and traditional herbal medicinal products used in children and adolescents","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-06-01 - 2025-08-31","first_published_date":"2025-06-02T08:54:43Z","last_updated_date":"2025-06-02T08:54:43Z","reference_number":"EMA/HMPC/71333/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-data-recommendations-herbal-medicinal-products-traditional-herbal-medicinal-products-used-children-adolescents_en.pdf"},
    {"id":"68514","name":"Reflection paper on the application of Article 40(5) of Regulation (EU) 2019/6 for certain categories of variations","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-02T10:45:26Z","last_updated_date":"2025-06-02T10:45:26Z","reference_number":"EMA/CVMP/55240/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-application-article-405-regulation-eu-2019-6-certain-categories-variations_en.pdf"},
    {"id":"68778","name":"Guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to lowsized study populations","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-16T15:54:36Z","last_updated_date":"2025-06-16T15:54:36Z","reference_number":"EMA/161669/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-allergen-products-development-immunotherapy-allergy-diagnosis-moderate-lowsized-study-populations_en.pdf"},
    {"id":"68812","name":"Concept paper on the new reflection paper on the clinical investigation of medicinal products for the treatment of systemic sclerosis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-06-30 - 2025-09-30","first_published_date":"2025-06-18T15:55:00Z","last_updated_date":"2025-06-18T15:55:00Z","reference_number":"EMA/179449/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-new-reflection-paper-clinical-investigation-medicinal-products-treatment-systemic-sclerosis_en.pdf"},
    {"id":"68825","name":"Draft chapter 9 of guideline on epidemiological data on blood transmissible infections","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-06-18 - 2025-08-31","first_published_date":"2025-06-19T09:44:42Z","last_updated_date":"2025-06-19T09:44:42Z","reference_number":"EMA/CHMP/BWP/548524/2008 rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-chapter-9-guideline-epidemiological-data-blood-transmissible-infections_en.pdf"},
    {"id":"68849","name":"Concept paper for the development of a guideline on the methodology of environmental risk assessment for ectoparasiticidal VMPs for cats and dogs","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-06-20 - 2025-10-31","first_published_date":"2025-06-20T08:40:35Z","last_updated_date":"2025-06-20T08:40:35Z","reference_number":"EMA/CVMP/ERA/499198/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-methodology-environmental-risk-assessment-ectoparasiticidal-vmps-cats-dogs_en.pdf"},
    {"id":"68850","name":"Concept paper on the need for revision of note for guidance on quality aspects of pharmaceutical veterinary medicines for administration via drinking water","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-06-20 - 2025-10-31","first_published_date":"2025-06-20T09:22:11Z","last_updated_date":"2025-06-20T09:22:11Z","reference_number":"EMA/CVMP/QWP/85848/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-note-guidance-quality-aspects-pharmaceutical-veterinary-medicines-administration-drinking-water_en.pdf"},
    {"id":"68960","name":"ICH M4Q(R2) : Guideline on the Common Technical Document for the registration of pharmaceuticals for human use - Quality - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-06-25 - 2025-10-24","first_published_date":"2025-06-25T13:00:18Z","last_updated_date":"2025-06-25T13:00:18Z","reference_number":"EMA/CHMP/ICH/178042/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m4qr2-guideline-common-technical-document-registration-pharmaceuticals-human-use-quality-step-2b_en.pdf"},
    {"id":"69033","name":"Repaglinide tablets 0.5, 1 and 2 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T10:21:45Z","last_updated_date":"2025-06-30T10:21:45Z","reference_number":"CHMP/PKWP/EMA/123579/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/repaglinide-tablets-05-1-2-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69034","name":"Tadalafil film-coated tablets 2.5 mg, 5 mg, 10 mg and 20 mg product-specific bioequivalence guidance - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T10:31:34Z","last_updated_date":"2025-06-30T10:31:34Z","reference_number":"EMA/CHMP/315234/2014 Rev.3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/tadalafil-film-coated-tablets-25-mg-5-mg-10-mg-20-mg-product-specific-bioequivalence-guidance-revision-3_en.pdf"},
    {"id":"69036","name":"Voriconazole tablets 50, 200 mg and powder for oral suspension 40 mg/ml product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T10:49:06Z","last_updated_date":"2025-06-30T10:49:06Z","reference_number":"EMA/123572/2025 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/voriconazole-tablets-50-200-mg-powder-oral-suspension-40-mg-ml-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69041","name":"Acenocoumarol, tablet, 1 mg and 4 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T11:14:33Z","last_updated_date":"2025-06-30T11:14:33Z","reference_number":"EMA/CHMP/512475/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/acenocoumarol-tablet-1-mg-4-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69042","name":"Apixaban film-coated tablet 2.5 and 5 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T11:42:37Z","last_updated_date":"2025-06-30T11:42:37Z","reference_number":"EMA/151689/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/apixaban-film-coated-tablet-25-5-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69043","name":"Reflection paper on lessons learned from the COVID-19 pandemic: Scientific considerations on non-clinical aspects","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-06-30 - 2025-09-30","first_published_date":"2025-06-30T11:28:13Z","last_updated_date":"2025-06-30T11:28:13Z","reference_number":"EMA/CHMP/55697/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-lessons-learned-covid-19-pandemic-scientific-considerations-non-clinical-aspects_en.pdf"},
    {"id":"69044","name":"ICH E20 guideline on adaptive designs for clinical trials - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-06-30 - 2025-11-30","first_published_date":"2025-06-30T12:32:45Z","last_updated_date":"2025-06-30T12:32:45Z","reference_number":"EMA/CHMP/ICH/206586/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e20-guideline-adaptive-designs-clinical-trials-step-2b_en.pdf"},
    {"id":"69047","name":"Posaconazole oral suspension 40 mg/ml product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T13:30:18Z","last_updated_date":"2025-06-30T13:30:18Z","reference_number":"EMA/123564/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/posaconazole-oral-suspension-40-mg-ml-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69048","name":"Memantine film-coated tablets 5, 10, 15 and 20 mg, oral solution 5 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T14:09:09Z","last_updated_date":"2025-06-30T14:09:09Z","reference_number":"EMA/123562/2025 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/memantine-film-coated-tablets-5-10-15-20-mg-oral-solution-5-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69051","name":"Dabigatran etexilate hard capsule 75 mg, 110 mg and 150 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T14:52:52Z","last_updated_date":"2025-06-30T14:52:52Z","reference_number":"EMA/151692/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/dabigatran-etexilate-hard-capsule-75-mg-110-mg-150-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69052","name":"Metformin immediate-release film-coated tablets 500, 850 and 1000 mg and 1000 mg/5ml oral solution product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T14:56:34Z","last_updated_date":"2025-06-30T14:56:34Z","reference_number":"EMA/CHMP/591346/2022 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/metformin-immediate-release-film-coated-tablets-500-850-1000-mg-1000-mg-5ml-oral-solution-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69053","name":"Paracetamol oral use immediate release formulations product-specific bioequivalence guidance - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T15:07:00Z","last_updated_date":"2025-06-30T15:07:00Z","reference_number":"EMA/CHMP/356877/2017 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paracetamol-oral-use-immediate-release-formulations-product-specific-bioequivalence-guidance-revision-2_en.pdf"},
    {"id":"69054","name":"Oseltamivir hard capsules 30, 45 and 75 mg, powder for oral suspension 6 mg/ml and 12 mg/ml product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T15:05:24Z","last_updated_date":"2025-06-30T15:05:24Z","reference_number":"EMA/151698/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/oseltamivir-hard-capsules-30-45-75-mg-powder-oral-suspension-6-mg-ml-12-mg-ml-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69055","name":"Prasugrel film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T15:10:13Z","last_updated_date":"2025-06-30T15:10:13Z","reference_number":"EMA/151699/2025 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/prasugrel-film-coated-tablets-5-mg-10-mg-product-specific-bioequivalence-guidance-revision-2_en.pdf"},
    {"id":"69056","name":"Ursodeoxycholic acid capsule 250 mg, film-coated tablet 150 mg, 300 mg, 450 mg, 500 mg, 600 mg and suspension 50mg/ml (250mg/5ml) product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T15:14:37Z","last_updated_date":"2025-06-30T15:14:37Z","reference_number":"EMA/CHMP/559890/202 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ursodeoxycholic-acid-capsule-250-mg-film-coated-tablet-150-mg-300-mg-450-mg-500-mg-600-mg-suspension-50mg-ml-250mg-5ml-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69059","name":"Lurasidone film-coated tablets 18.5, 37 and 74 mg 4 product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-06-30T17:12:50Z","last_updated_date":"2025-06-30T17:12:50Z","reference_number":"EMA/CHMP/39336/2023 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/lurasidone-film-coated-tablets-185-37-74-mg-4-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69060","name":"Carglumic acid dispersible tablets 200 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-01T09:34:20Z","last_updated_date":"2025-07-01T09:34:20Z","reference_number":"EMA/151691/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/carglumic-acid-dispersible-tablets-200-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"69067","name":"Asenapine sublingual tablets 5 and 10 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-01T12:30:00Z","last_updated_date":"2025-07-01T12:30:00Z","reference_number":"EMA/151690/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/asenapine-sublingual-tablets-5-10-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"69071","name":"Levothyroxine tablets 12.5 mcg, 25 mcg, 50 mcg, 75 mcg, 100 mcg and 200 mcg (and additional strengths within the range) product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-01T16:24:23Z","last_updated_date":"2025-07-01T16:24:23Z","reference_number":"EMA/123366/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/levothyroxine-tablets-125-mcg-25-mcg-50-mcg-75-mcg-100-mcg-200-mcg-additional-strengths-within-range-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69072","name":"Dolutegravir film-coated tablets 10 mg, 25 mg and 50 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-01T16:28:23Z","last_updated_date":"2025-07-01T16:28:23Z","reference_number":"EMA/226629/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/dolutegravir-film-coated-tablets-10-mg-25-mg-50-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69073","name":"Ibuprofen oral use immediate release formulations 200 - 800 mg product-specific bioequivalence guidance - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-01T16:31:08Z","last_updated_date":"2025-07-01T16:31:08Z","reference_number":"EMA/122751/2025 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ibuprofen-oral-use-immediate-release-formulations-200-800-mg-product-specific-bioequivalence-guidance-revision-2_en.pdf"},
    {"id":"69174","name":"Draft sirolimus coated tablets 0.5, 1 and 2 mg, oral solution 1 mg/ml product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-07-10 - 2025-10-31","first_published_date":"2025-07-08T17:19:17Z","last_updated_date":"2025-07-08T17:19:17Z","reference_number":"EMA/151700/2025 Rev. 1*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-sirolimus-coated-tablets-05-1-2-mg-oral-solution-1-mg-ml-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69217","name":"Draft aliskiren film-coated tablet 150 mg and 300 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-07-10 - 2025-10-31","first_published_date":"2025-07-10T09:27:57Z","last_updated_date":"2025-07-10T09:27:57Z","reference_number":"EMA/151687/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-aliskiren-film-coated-tablet-150-mg-300-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69218","name":"Draft ledipasvir/sofosbuvir film-coated tablet 45 mg/200 mg and 90 mg/400 mg, coated granules 33.75mg/150mg and 45mg/200mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-07-10 - 2025-10-31","first_published_date":"2025-07-10T09:55:40Z","last_updated_date":"2025-07-10T09:55:40Z","reference_number":"EMA/151702/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ledipasvir-sofosbuvir-film-coated-tablet-45-mg-200-mg-90-mg-400-mg-coated-granules-3375mg-150mg-45mg-200mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69219","name":"Draft dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-07-10 - 2025-10-31","first_published_date":"2025-07-10T10:12:09Z","last_updated_date":"2025-07-10T10:12:09Z","reference_number":"EMA/151695/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-dronedarone-film-coated-tablets-400-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69397","name":"Guideline on the pharmaceutical quality of inhalation and nasal medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-21T16:05:17Z","last_updated_date":"2025-07-24T13:45:00Z","reference_number":"EMEA/CHMP/QWP/49313/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-quality-inhalation-nasal-medicinal-products-revision-1_en.pdf"},
    {"id":"69399","name":"Guideline on the requirements for demonstrating therapeutic equivalence between orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease (COPD) - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-21T16:14:57Z","last_updated_date":"2025-07-21T16:14:57Z","reference_number":"CPMP/EWP/4151/00 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-demonstrating-therapeutic-equivalence-between-orally-inhaled-products-oip-asthma-chronic-obstructive-pulmonary-disease-copd-revision-2_en.pdf"},
    {"id":"69434","name":"Draft concept paper on the development of a reflection paper on the use of external controls for evidence generation in regulatory decision-making","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-07-25 - 2025-10-31","first_published_date":"2025-07-25T10:00:00Z","last_updated_date":"2025-07-25T10:00:00Z","reference_number":"EMA/CHMP/225255/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-reflection-paper-use-external-controls-evidence-generation-regulatory-decision-making_en.pdf"},
    {"id":"69437","name":"Guideline for the demonstration of efficacy for veterinary medicinal products containing anticoccidial substances - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T10:00:00Z","last_updated_date":"2025-07-25T10:00:00Z","reference_number":"EMA/CVMP/EWP/755916/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-demonstration-efficacy-veterinary-medicinal-products-containing-anticoccidial-substances-revision-1_en.pdf"},
    {"id":"69560","name":"Entecavir film-coated tablets 0.5 and 1 mg, oral solution 0.05 mg/ml product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-29T13:06:40Z","last_updated_date":"2025-07-29T13:06:40Z","reference_number":"EMA/188373/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/entecavir-film-coated-tablets-05-1-mg-oral-solution-005-mg-ml-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69567","name":"Fingolimod capsules 0.25 and 0.5 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2017-01-03T10:31:53Z","last_updated_date":"2019-08-09T10:30:00Z","reference_number":"EMA/CHMP/154812/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/fingolimod-capsules-025-05-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"69568","name":"Tacrolimus granules for oral suspension 0.2 and 1 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T10:47:29Z","last_updated_date":"2025-07-30T10:47:29Z","reference_number":"EMA/188385/2025/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/tacrolimus-granules-oral-suspension-02-1-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69569","name":"Sitagliptin film-coated tablets 25, 50 and 100 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T10:53:49Z","last_updated_date":"2025-07-30T10:53:49Z","reference_number":"EMA/188381/2025/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/sitagliptin-film-coated-tablets-25-50-100-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69570","name":"Rivaroxaban film-coated tablets 2.5, 10, 15 and 20mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T10:57:19Z","last_updated_date":"2025-07-30T10:57:19Z","reference_number":"EMA/188384/2025/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/rivaroxaban-film-coated-tablets-25-10-15-20mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69571","name":"Rilpivirine film-coated tablets 25 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T11:00:19Z","last_updated_date":"2025-07-30T11:00:19Z","reference_number":"EMA/188380/2025/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/rilpivirine-film-coated-tablets-25-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69572","name":"Ticagrelor film-coated tablets 60 mg and 90 mg productspecific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T11:05:55Z","last_updated_date":"2025-07-30T11:05:55Z","reference_number":"EMA/188392/2025/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ticagrelor-film-coated-tablets-60-mg-90-mg-productspecific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69573","name":"Emtricitabine/rilpivirine/tenofovir disoproxil film-coated tablets 200 mg/25 mg/245 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T11:13:55Z","last_updated_date":"2025-07-30T11:13:55Z","reference_number":"EMA/188363/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/emtricitabine-rilpivirine-tenofovir-disoproxil-film-coated-tablets-200-mg-25-mg-245-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69574","name":"Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T11:19:18Z","last_updated_date":"2025-07-30T11:19:18Z","reference_number":"EMA/188361/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/colchicine-tablet-05-mg-1-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69575","name":"Emtricitabine/Tenofovir Disoproxil film-coated tablets 200mg/245 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T11:23:14Z","last_updated_date":"2025-07-30T11:23:14Z","reference_number":"EMA/188370/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/emtricitabine-tenofovir-disoproxil-film-coated-tablets-200mg-245-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69576","name":"Paclitaxel (nanoparticle albumin-bound) powder for suspension for infusion, 5mg/ml","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T11:27:12Z","last_updated_date":"2025-07-30T11:27:12Z","reference_number":"EMA/418520/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paclitaxel-nanoparticle-albumin-bound-powder-suspension-infusion-5mg-ml_en.pdf-0"},
    {"id":"69578","name":"Zonisamide hard capsules 25, 50 and 100 mg, orodispersible tablets 25, 50, 100 and 300 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T12:09:15Z","last_updated_date":"2025-07-30T12:09:15Z","reference_number":"EMA/188397/2025/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/zonisamide-hard-capsules-25-50-100-mg-orodispersible-tablets-25-50-100-300-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69579","name":"Vortioxetine hydrobromide immediate release tablets 5 mg, 10 mg, 15 mg, and 20 mg; vortioxetine lactate oral drops solution 20 mg/ml product-specific bioequivalence - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T12:14:28Z","last_updated_date":"2025-07-30T12:14:28Z","reference_number":"EMA/188396/2025/Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vortioxetine-hydrobromide-immediate-release-tablets-5-mg-10-mg-15-mg-20-mg-vortioxetine-lactate-oral-drops-solution-20-mg-ml-product-specific-bioequivalence-revision-1_en.pdf"},
    {"id":"69580","name":"Aprepitant, hard capsules, 80mg, 125mg, 80+125mg and powder for oral suspension 125mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T12:42:18Z","last_updated_date":"2025-07-30T12:42:18Z","reference_number":"EMA/13174/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/aprepitant-hard-capsules-80mg-125mg-80125mg-powder-oral-suspension-125mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"69582","name":"Azacitidine powder for suspension for injection 25 mg/ml product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T14:09:29Z","last_updated_date":"2025-07-30T14:09:29Z","reference_number":"EMA/CHMP/172895/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/azacitidine-powder-suspension-injection-25-mg-ml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"69583","name":"Overview of comments received on ‘Draft azacitidine powder for suspension for injection 25 mg/ml product-specific bioequivalence guidance’","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-07-30T14:14:38Z","last_updated_date":"2025-07-30T14:14:38Z","reference_number":"EMA/188720/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-draft-azacitidine-powder-suspension-injection-25-mg-ml-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"69588","name":"Dabrafenib hard capsule 50 and 75 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T16:38:01Z","last_updated_date":"2025-07-30T16:38:01Z","reference_number":"EMA/39771/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/dabrafenib-hard-capsule-50-75-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"69590","name":"Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-07-30T16:46:43Z","last_updated_date":"2025-07-30T16:46:43Z","reference_number":"EMA/188360/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/cholic-acid-capsules-50-mg-250-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69677","name":"Concept paper on the need for revision of the guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-08-06 - 2026-02-28","first_published_date":"2025-08-06T12:57:17Z","last_updated_date":"2025-08-06T12:57:17Z","reference_number":"EMA/231314/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicines-treatment-alzheimers-disease_en.pdf"},
    {"id":"69690","name":"Overview of comments received on ICH Q1 Guideline on stability testing","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-08-08T14:23:05Z","last_updated_date":"2025-08-08T14:23:05Z","reference_number":"EMA/240075/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/overview-comments-received-ich-q1-guideline-stability-testing_en.pdf"},
    {"id":"69713","name":"Guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-08-12T16:50:59Z","last_updated_date":"2025-08-12T16:50:59Z","reference_number":"EMA/HMPC/246816/2005 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-agricultural-collection-practice-gacp-starting-materials-herbal-origin-revision-1_en.pdf"},
    {"id":"69735","name":"Pirfenidone film-coated tablets 267, 537 and 801 mg, and hard capsules 267 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-08-14T09:59:25Z","last_updated_date":"2025-08-14T09:59:25Z","reference_number":"EMA/CHMP/901584/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/pirfenidone-film-coated-tablets-267-537-801-mg-hard-capsules-267-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"69736","name":"Deferasirox film-coated tablets 90 mg, 180 mg and 360mg, granules 90 mg, 180 mg and 360 mg productspecific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-08-14T10:54:40Z","last_updated_date":"2025-08-14T10:54:40Z","reference_number":"EMA/CHMP/472383/2020 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/deferasirox-film-coated-tablets-90-mg-180-mg-360mg-granules-90-mg-180-mg-360-mg-productspecific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"69738","name":"Everolimus tablets 0.25 mg, 0.5 mg, 0.75 mg and 1 mg; 2.5 mg, 5 mg and 10 mg, dispersible tablets 0.1 mg and 0.25 mg; 2 mg, 3 mg and 5 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-08-14T11:02:42Z","last_updated_date":"2025-08-14T11:02:42Z","reference_number":"EMA/CHMP/151597/2015","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/everolimus-tablets-025-mg-05-mg-075-mg-1-mg-25-mg-5-mg-10-mg-dispersible-tablets-01-mg-025-mg-2-mg-3-mg-5-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"69753","name":"Draft ICH Q3E guideline for extractables and leachables","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-08-18 - 2025-12-18","first_published_date":"2025-08-18T09:42:59Z","last_updated_date":"2025-08-18T09:42:59Z","reference_number":"EMA/CHMP/ICH/236669/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-q3e-guideline-extractables-leachables_en.pdf"},
    {"id":"69754","name":"Draft ICH Q3E guideline for extractables and leachables - supporting documentation: class 3 leachable monographs","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-08-18 - 2025-12-18","first_published_date":"2025-08-18T10:31:08Z","last_updated_date":"2025-08-18T10:31:08Z","reference_number":"EMA/CHMP/ICH/236668/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-q3e-guideline-extractables-leachables-supporting-documentation-class-3-leachable-monographs_en.pdf"},
    {"id":"69891","name":"Guideline on good pharmacovigilance practices (GVP) - Module XVI Addendum I – Risk minimisation measures for medicinal products with embryo-fetal risks","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-08-28T15:24:48Z","last_updated_date":"2025-08-28T15:24:48Z","reference_number":"EMA/608947/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-i-risk-minimisation-measures-medicinal-products-embryo-fetal-risks_en.pdf"},
    {"id":"69892","name":"Guideline on good pharmacovigilance practices (GVP): Module XVI Addendum I – Risk minimisation measures for medicinal products with embryo-fetal risks with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-08-28T15:41:30Z","last_updated_date":"2025-08-28T15:41:30Z","reference_number":"EMA/608947/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-i-risk-minimisation-measures-medicinal-products-embryo-fetal-risks-tracked-changes_en.pdf"},
    {"id":"69894","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with final Addendum I to Module XVI on minimising embryo-fetal risks of medicines","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2025-08-28T15:58:17Z","last_updated_date":"2025-08-28T15:58:17Z","reference_number":"EMA/269111/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-final-addendum-i-module-xvi-minimising-embryo-fetal-risks-medicines_en.pdf"},
    {"id":"70182","name":"Guideline on duration of immunity achieved by veterinary vaccines","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T09:50:19Z","last_updated_date":"2025-09-19T09:50:19Z","reference_number":"EMA/CVMP/IWP/224985/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-duration-immunity-achieved-veterinary-vaccines_en.pdf"},
    {"id":"70183","name":"Guideline on the procedure to be followed when a batch of a vaccine finished product is suspected to be contaminated with bovine viral diarrhoea virus - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T09:55:46Z","last_updated_date":"2025-09-19T09:55:46Z","reference_number":"EMA/CVMP/IWP/205351/2006 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-procedure-be-followed-when-batch-vaccine-finished-product-suspected-be-contaminated-bovine-viral-diarrhoea-virus-revision-2_en.pdf"},
    {"id":"70255","name":"Reflection paper on patient experience data","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-09-29 - 2026-01-31","first_published_date":"2025-09-29T12:00:00Z","last_updated_date":"2025-09-29T12:00:00Z","reference_number":"EMA/CHMP/PRAC/148869/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-patient-experience-data_en.pdf"},
    {"id":"70257","name":"Draft melatonin prolonged release tablets 2 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-09-25 - 2025-12-31","first_published_date":"2025-09-25T09:27:17Z","last_updated_date":"2025-09-25T09:27:17Z","reference_number":"EMA/226444/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-melatonin-prolonged-release-tablets-2-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"70258","name":"Draft eltrombopag film-coated tablets 12.5 mg, 25 mg, 50 mg, 75 mg and powder for oral suspension 25 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-09-25 - 2025-12-31","first_published_date":"2025-09-25T09:30:52Z","last_updated_date":"2025-09-25T09:30:52Z","reference_number":"EMA/226445/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-eltrombopag-film-coated-tablets-125-mg-25-mg-50-mg-75-mg-powder-oral-suspension-25-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"70343","name":"Concept paper on new guidance on the clinical investigation of medicinal products for the treatment of idiopathic pulmonary fibrosis (IPF)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-09-30 - 2025-12-31","first_published_date":"2025-09-30T10:40:57Z","last_updated_date":"2025-11-13T15:40:00Z","reference_number":"EMA/CHMP/290364/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-new-guidance-clinical-investigation-medicinal-products-treatment-idiopathic-pulmonary-fibrosis-ipf_en.pdf"},
    {"id":"70353","name":"Draft guideline on clinical investigation of medicinal products for the treatment of psoriatic arthritis - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-09-30 - 2026-03-31","first_published_date":"2025-09-30T11:09:30Z","last_updated_date":"2025-09-30T11:09:30Z","reference_number":"CHMP/EWP/438/04 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-psoriatic-arthritis-revision-1_en.pdf"},
    {"id":"70356","name":"Draft guideline on the clinical evaluation of medicinal products intended for the treatment of chronic hepatitis B (CHB) - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-09-30 - 2026-03-31","first_published_date":"2025-09-30T11:28:34Z","last_updated_date":"2025-09-30T11:28:34Z","reference_number":"EMA/283093/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-medicinal-products-intended-treatment-chronic-hepatitis-b-chb-revision-1_en.pdf"},
    {"id":"70383","name":"Guideline on in-use stability testing of veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-10-01T09:33:35Z","last_updated_date":"2025-10-01T09:33:35Z","reference_number":"EMA/CVMP/QWP/59158/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-stability-testing-veterinary-medicinal-products_en.pdf"},
    {"id":"70408","name":"VICH GL22(R) - Studies to evaluate the safety of residues of veterinary drugs in human food reproduction testing (Revision 1)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2024-02-15 - 2024-07-31","first_published_date":"2025-10-02T15:40:00Z","last_updated_date":"2025-10-02T15:40:00Z","reference_number":"EMA/CVMP/VICH/525/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl22r-studies-evaluate-safety-residues-veterinary-drugs-human-food-reproduction-testing-revision-1_en.pdf-0"},
    {"id":"70410","name":"VICH GL23 Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing (revision 2)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"","first_published_date":"2025-10-02T15:50:00Z","last_updated_date":"2025-10-02T15:50:00Z","reference_number":"EMA/CVMP/VICH/526/2000","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl23-studies-evaluate-safety-residues-veterinary-drugs-human-food-genotoxicity-testing-revision-2_en.pdf"},
    {"id":"70421","name":"VICH GL62 on target animal safety of veterinary monoclonal antibody products (VMAPs)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-09-15 - 2026-02-15","first_published_date":"2025-09-15T16:42:10Z","last_updated_date":"2025-09-15T16:42:10Z","reference_number":"EMA/CVMP/VICH/250843/2021","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl62-target-animal-safety-veterinary-monoclonal-antibody-products-vmaps_en.pdf"},
    {"id":"70515","name":"ICH E2D(R1) Guideline on post-approval safety data: definitions and standards for management and reporting of individual case safety reports - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"2024-02-22 - 2024-06-22","first_published_date":"2025-10-09T15:59:50Z","last_updated_date":"2025-10-09T15:59:50Z","reference_number":"EMA/CHMP/ICH/59123/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e2dr1-guideline-post-approval-safety-data-definitions-standards-management-reporting-individual-case-safety-reports-step-5_en.pdf"},
    {"id":"70523","name":"ICH M14 guideline on general principles on planning, designing, analysing, and reporting of non-interventional studies that utilise real-world data for safety assessment of medicines Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-10-10T08:30:49Z","last_updated_date":"2025-10-10T08:30:49Z","reference_number":"EMA/CHMP/ICH/155061/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m14-guideline-general-principles-planning-designing-analysing-reporting-non-interventional-studies-utilise-real-world-data-safety-assessment-medicines-step-5_en.pdf"},
    {"id":"70543","name":"Reflection paper on non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-10-23 - 2026-01-31","first_published_date":"2025-10-23T15:32:59Z","last_updated_date":"2025-10-23T15:32:59Z","reference_number":"EMA/CHMP/55697/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-non-human-primates-safety-testing-human-medicinal-products-opportunities-3rs-implementation_en.pdf"},
    {"id":"70747","name":"Concept paper on a paediatric update on the guideline on the development of new medicinal products for the treatment of Ulcerative Colitis","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-10-31 - 2026-01-31","first_published_date":"2025-10-22T09:11:41Z","last_updated_date":"2025-11-13T15:26:00Z","reference_number":"EMA/CHMP/312843/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-paediatric-update-guideline-development-new-medicinal-products-treatment-ulcerative-colitis_en.pdf"},
    {"id":"70752","name":"Concept paper on a paediatric update of the guideline on clinical investigation of medicinal products for the management of Crohn’s disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-10-22 - 2026-01-31","first_published_date":"2025-10-22T10:30:43Z","last_updated_date":"2025-11-13T15:30:00Z","reference_number":"EMA/CHMP/312837/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-paediatric-update-guideline-clinical-investigation-medicinal-products-management-crohns-disease_en.pdf"},
    {"id":"70799","name":"Draft guideline on quality aspects of phage therapy medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-10-23 - 2026-04-30","first_published_date":"2025-10-24T08:56:58Z","last_updated_date":"2025-10-24T08:56:58Z","reference_number":"EMA/CHMP/BWP/1/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-aspects-phage-therapy-medicinal-products_en.pdf"},
    {"id":"71105","name":"Draft guideline on non-inferiority and equivalence comparisons in clinical trials","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-11-13 - 2026-05-31","first_published_date":"2025-11-13T10:19:50Z","last_updated_date":"2025-11-13T10:19:50Z","reference_number":"EMA/301654/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-non-inferiority-equivalence-comparisons-clinical-trials_en.pdf"}    {"id":"71160","name":"Questions and answers on classification of a product as intended for a limited market according to Article 4(29) and/or eligibility for authorisation according to Article 23 (Applications for limited markets)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T09:39:00Z","last_updated_date":"2025-11-14T09:39:00Z","reference_number":"EMA/CVMP/33689/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-classification-product-intended-limited-market-according-article-429-or-eligibility-authorisation-according-article-23-applications-limited-markets_en.pdf"},
    {"id":"71162","name":"Concept paper for the development of a guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in non-food-producing animal species","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-11-14 - 2026-05-31","first_published_date":"2025-11-14T09:48:09Z","last_updated_date":"2025-11-14T09:48:09Z","reference_number":"EMA/CVMP/AWP/109142/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-assessment-risk-public-health-antimicrobial-resistance-due-use-antimicrobial-veterinary-medicinal-product-non-food-producing-animal-species_en.pdf"},
    {"id":"71411","name":"Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-11-30 - 2026-03-31","first_published_date":"2025-12-01T10:34:59Z","last_updated_date":"2025-12-01T10:34:59Z","reference_number":"EMA/322471/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-parkinsons-disease_en.pdf"},
    {"id":"71511","name":"Explanatory note on the withdrawal of the interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-12-04T17:00:54Z","last_updated_date":"2025-12-04T17:00:54Z","reference_number":"EMA/175359/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/explanatory-note-withdrawal-interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu_en.pdf"},
    {"id":"71524","name":"All languages - Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668) - Revision 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T11:39:00Z","last_updated_date":"2025-12-05T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/all-languages-annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use-sante-2017-11668-revision-5_en.xlsx"},
    {"id":"71563","name":"Concept paper on the guideline revision on good pharmacogenomic practice","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-12-09 - 2026-03-31","first_published_date":"2025-12-08T09:44:23Z","last_updated_date":"2025-12-09T15:57:00Z","reference_number":"EMA/282050/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-guideline-revision-good-pharmacogenomic-practice_en.pdf"},
    {"id":"71611","name":"Guideline on the development and manufacture of synthetic peptides","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T11:27:01Z","last_updated_date":"2025-12-09T11:27:01Z","reference_number":"EMA/CHMP/CVMP/QWP/367182/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-manufacture-synthetic-peptides_en.pdf"},
    {"id":"71624","name":"Information for the package leaflet regarding dextrans used as excipients in medicinal products for human use","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-12-09T15:07:33Z","last_updated_date":"2025-12-09T15:07:33Z","reference_number":"EMA/CHMP/187129/2016","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/information-package-leaflet-regarding-dextrans-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"71676","name":"Draft guideline on quality of radiopharmaceuticals - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-12-10 - 2026-04-30","first_published_date":"2025-12-10T15:26:32Z","last_updated_date":"2025-12-10T15:26:32Z","reference_number":"EMA/CHMP/QWP/363827/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-radiopharmaceuticals-revision-2_en.pdf"},
    {"id":"71682","name":"Questions and answers on post approval change management protocols (PACMP) - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-12-11T08:57:14Z","last_updated_date":"2025-12-11T08:57:14Z","reference_number":"EMA/CHMP/QWP/586330/2010 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-post-approval-change-management-protocols-pacmp-revision-1_en.pdf"},
    {"id":"71705","name":"Guideline on stability testing for applications for variations to a marketing authorisation - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T09:17:37Z","last_updated_date":"2025-12-12T09:17:37Z","reference_number":"EMA/CHMP/QWP/441071/2011- Rev.3","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-applications-variations-marketing-authorisation-revision-3_en.pdf"},
    {"id":"71720","name":"ICH E22 Guideline on general considerations for patient preference studies - Step 2b","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-12-12 - 2026-04-12","first_published_date":"2025-12-12T11:00:00Z","last_updated_date":"2025-12-12T11:00:00Z","reference_number":"EMA/CHMP/ICH/371537/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e22-guideline-general-considerations-patient-preference-studies-step-2b_en.pdf"},
    {"id":"71725","name":"Guideline on the clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T13:06:10Z","last_updated_date":"2025-12-12T13:06:10Z","reference_number":"EMA/58320/2025 rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-patients-acute-respiratory-distress-syndrome-revision-2_en.pdf"},
    {"id":"71755","name":"Concept Paper on the revision of Annex 3 of the guidelines on Good Manufacturing Practice for Radiopharmaceuticals","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2025-12-15 - 2026-02-15","first_published_date":"2025-12-15T11:41:06Z","last_updated_date":"2025-12-17T16:16:23Z","reference_number":"EMA/INS/GMP/389655/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-annex-3-guidelines-good-manufacturing-practice-radiopharmaceuticals_en.pdf"},
    {"id":"72056","name":"Guideline on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease of the lower extremities","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-01-15T10:33:48Z","last_updated_date":"2026-01-15T10:33:48Z","reference_number":"EMA/369563/2025 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-peripheral-arterial-occlusive-disease-lower-extremities_en.pdf"},
    {"id":"72208","name":"Reflection paper on investigation and assessment of cardiovascular safety of anticancer medicinal products","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-01-22 - 2026-07-31","first_published_date":"2026-01-23T08:30:26Z","last_updated_date":"2026-01-23T08:30:26Z","reference_number":"EMA/8699/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-investigation-assessment-cardiovascular-safety-anticancer-medicinal-products_en.pdf"},
    {"id":"72212","name":"Draft guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs) - Revision 1","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-01-14 - 2026-05-22","first_published_date":"2026-01-23T09:50:12Z","last_updated_date":"2026-01-23T09:50:12Z","reference_number":"EMA/CVMP/IWP/365787/2025-Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-combined-vaccines-associations-immunological-veterinary-medicinal-products-ivmps-revision-1_en.pdf"},
    {"id":"72216","name":"Guideline on user safety for immunological veterinary medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-01-23T09:50:55Z","last_updated_date":"2026-01-23T09:50:55Z","reference_number":"EMA/CVMP/IWP/54533/2006 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-user-safety-immunological-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"72217","name":"Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-01-23T09:53:53Z","last_updated_date":"2026-01-23T09:53:53Z","reference_number":"EMA/CVMP/IWP/314550/2010 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-design-studies-evaluate-safety-efficacy-fish-vaccines-revision-1_en.pdf"},
    {"id":"72218","name":"Guideline on environmental risk assessment for immunological veterinary medicinal products - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-01-23T09:56:11Z","last_updated_date":"2026-01-23T09:56:11Z","reference_number":"EMEA/CVMP/074/95 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-environmental-risk-assessment-immunological-veterinary-medicinal-products-revision-1_en.pdf"},
    {"id":"72219","name":"Draft guideline for the evaluation of efficacy of ectoparasiticides - general requirements","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-01-23 - 2026-05-31","first_published_date":"2026-01-23T10:31:55Z","last_updated_date":"2026-01-23T10:31:55Z","reference_number":"EMA/CVMP/EWP/507106/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-efficacy-ectoparasiticides-general-requirements_en.pdf"},
    {"id":"72220","name":"Draft guideline on veterinary medicinal products controlling Varroa destructor parasitosis in bees - Revision 2","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-01-23 - 2026-05-31","first_published_date":"2026-01-23T10:32:44Z","last_updated_date":"2026-01-23T10:32:44Z","reference_number":"EMA/CVMP/EWP/459883/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-veterinary-medicinal-products-controlling-varroa-destructor-parasitosis-bees-revision-2_en.pdf"},
    {"id":"72222","name":"Concept paper on the development of a guideline for using owner assessment as efficacy parameter","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-01-23 - 2026-04-30","first_published_date":"2026-01-23T11:11:48Z","last_updated_date":"2026-01-23T11:11:48Z","reference_number":"EMA/CVMP/EWP/364649/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-using-owner-assessment-efficacy-parameter_en.pdf"},
    {"id":"72242","name":"Questions and answers on the use of Product Lifecycle Management (PLCM) document","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-01-26T09:39:23Z","last_updated_date":"2026-01-26T09:39:23Z","reference_number":"EMA/CHMP/QWP/7093/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-use-product-lifecycle-management-plcm-document_en.pdf"},
    {"id":"72322","name":"Questions and answers regarding co-processed excipients used in solid oral dosage forms (H & V)","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-01-28T13:57:34Z","last_updated_date":"2026-01-28T13:57:34Z","reference_number":"EMA/CHMP/CVMP/QWP/422493/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-regarding-co-processed-excipients-used-solid-oral-dosage-forms-h-v_en.pdf-0"},
    {"id":"72394","name":"Concept paper on the revision of the guideline on clinical evaluation of diagnostic agents and its appendix 1 on imaging agents","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-01-30 - 2026-04-30","first_published_date":"2026-01-30T15:31:49Z","last_updated_date":"2026-01-30T15:31:49Z","reference_number":"EMA/4366/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-clinical-evaluation-diagnostic-agents-its-appendix-1-imaging-agents_en.pdf"},
    {"id":"72395","name":"Concept paper for the development of a reflection paper on the use of Bayesian methods in clinical development","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-01-30 - 2026-04-30","first_published_date":"2026-01-30T15:39:43Z","last_updated_date":"2026-01-30T15:39:43Z","reference_number":"EMA/CHMP/1813/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-use-bayesian-methods-clinical-development_en.pdf"},
    {"id":"72402","name":"Reflection paper on the qualification of non-mutagenic impurities","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-02-02T16:32:54Z","last_updated_date":"2026-03-13T16:19:00Z","reference_number":"EMA/CHMP/4299/2026 Corr.","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-qualification-non-mutagenic-impurities_en.pdf"},
    {"id":"72411","name":"Guideline on epidemiological data on blood transmissible infections - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-02-04T09:37:26Z","last_updated_date":"2026-02-04T09:37:26Z","reference_number":"EMA/CHMP/BWP/548524/2008 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-epidemiological-data-blood-transmissible-infections-revision-2_en.pdf"},
    {"id":"72434","name":"Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with final considerations on pregnant and breastfeeding women and their children exposed in utero or via breastmilk","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2026-02-06T17:12:13Z","last_updated_date":"2026-02-06T17:12:13Z","reference_number":"EMA/358327/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-final-considerations-pregnant-breastfeeding-women-their-children-exposed-utero-or-breastmilk_en.pdf"},
    {"id":"72436","name":"Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations III: Pregnant and breastfeeding women and their children exposed in utero or via breastmilk","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-02-06T17:12:01Z","last_updated_date":"2026-02-06T17:12:01Z","reference_number":"EMA/653036/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-iii-pregnant-breastfeeding-women-their-children-exposed-utero-or-breastmilk_en.pdf"},
    {"id":"72438","name":"Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations III: Pregnant and breastfeeding women and their children exposed in utero or via breastmilk - with tracked changes","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2026-02-06T17:12:52Z","last_updated_date":"2026-02-06T17:12:52Z","reference_number":"EMA/653036/2019","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-iii-pregnant-breastfeeding-women-their-children-exposed-utero-or-breastmilk-tracked-changes_en.pdf"},
    {"id":"72452","name":"Concept paper on the revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 15 - Qualification and validation","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-02-09 - 2026-04-09","first_published_date":"2026-02-09T10:00:28Z","last_updated_date":"2026-02-09T10:00:28Z","reference_number":"EMA/INS/GMP/20217/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidelines-good-manufacturing-practice-medicinal-products-annex-15-qualification-validation_en.pdf"},
    {"id":"72479","name":"Ledipasvir/sofosbuvir film-coated tablet 45 mg/200 mg and 90 mg/400 mg, coated granules 33.75mg/150mg and 45mg/200mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-02-10T10:56:04Z","last_updated_date":"2026-02-10T10:56:04Z","reference_number":"EMA/151702/2025 Rev. 1*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ledipasvir-sofosbuvir-film-coated-tablet-45-mg-200-mg-90-mg-400-mg-coated-granules-3375mg-150mg-45mg-200mg-product-specific-bioequivalence-guidance-revision-1_en.pdf-0"},
    {"id":"72482","name":"Dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-02-10T11:28:58Z","last_updated_date":"2026-02-10T11:28:58Z","reference_number":"EMA/151695/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/dronedarone-film-coated-tablets-400-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf"},
    {"id":"72486","name":"Sirolimus coated tablets 0.5, 1 and 2 mg, oral solution 1 mg/ml product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-02-10T13:50:15Z","last_updated_date":"2026-02-10T13:50:15Z","reference_number":"EMA/151700/2025 Rev. 1*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/sirolimus-coated-tablets-05-1-2-mg-oral-solution-1-mg-ml-product-specific-bioequivalence-guidance-revision-1_en.pdf-0"},
    {"id":"72495","name":"Aliskiren film-coated tablet 150 mg and 300 mg product-specific bioequivalence guidance - Revision 1","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2026-02-10T15:41:51Z","last_updated_date":"2026-02-10T15:41:51Z","reference_number":"EMA/151687/2025 Rev. 1*","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/aliskiren-film-coated-tablet-150-mg-300-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf-0"},
    {"id":"72499","name":"ICH M15 Guideline on general principles for model-informed drug development - Step 5","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-02-11T09:10:55Z","last_updated_date":"2026-02-11T09:10:55Z","reference_number":"EMA/CHMP/ICH/496426/2024","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m15-guideline-general-principles-model-informed-drug-development-step-5_en.pdf"},
    {"id":"72500","name":"Concept paper on revision of the guidelines on good manufacturing practice for medicinal products - annex 6 manufacture of medicinal gases","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-02-11 - 2026-04-11","first_published_date":"2026-02-11T09:24:34Z","last_updated_date":"2026-02-11T09:24:34Z","reference_number":"EMA/INS/GMP/371598/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidelines-good-manufacturing-practice-medicinal-products-annex-6-manufacture-medicinal-gases_en.pdf"},
    {"id":"72545","name":"Concept paper on the need of a guideline on clinical investigation of medicinal products in the treatment of Myasthenia Gravis","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-02-13 - 2026-08-30","first_published_date":"2026-02-13T10:07:29Z","last_updated_date":"2026-02-13T10:07:29Z","reference_number":"EMA/9533/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-clinical-investigation-medicinal-products-treatment-myasthenia-gravis_en.pdf"},
    {"id":"72554","name":"Concept paper for the revision of the guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal Management (EMA/522332/2021)","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-02-13 - 2026-03-15","first_published_date":"2026-02-13T15:57:12Z","last_updated_date":"2026-02-13T15:57:12Z","reference_number":"EMA/CVMP/PhVWP/31941/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-veterinary-good-pharmacovigilance-practices-vgvp-module-signal-management-ema-522332-2021_en.pdf"},
    {"id":"72614","name":"Draft guideline on quality aspects of mRNA vaccines for veterinary use","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-02-20 - 2026-08-31","first_published_date":"2026-02-20T13:00:00Z","last_updated_date":"2026-02-20T13:00:00Z","reference_number":"EMA/CVMP/IWP/128476/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-aspects-mrna-vaccines-veterinary-use_en.pdf"},
    {"id":"72616","name":"Guideline on risk management requirements for elemental impurities in veterinary medicinal products - Revision 3","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-02-20T09:20:17Z","last_updated_date":"2026-02-20T09:20:17Z","reference_number":"EMA/CVMP/426245/2023","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-risk-management-requirements-elemental-impurities-veterinary-medicinal-products-revision-3_en.pdf"},
    {"id":"72617","name":"Implementation of submission of risk assessments to control elemental impurities required by the European Pharmacopeia in immunological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-02-20T09:22:12Z","last_updated_date":"2026-02-20T09:22:12Z","reference_number":"EMA/CVMP/366323/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/implementation-submission-risk-assessments-control-elemental-impurities-required-european-pharmacopeia-immunological-veterinary-medicinal-products_en.pdf"},
    {"id":"72772","name":"Guideline on the clinical investigation of medicinal products for the treatment of cystic fibrosis","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-03-01 - 2026-08-31","first_published_date":"2026-03-02T10:59:25Z","last_updated_date":"2026-03-02T10:59:25Z","reference_number":"EMA/21378/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-cystic-fibrosis_en.pdf"},
    {"id":"72775","name":"Draft concept paper on the development of a reflection paper on the non-clinical development and evaluation of microbiome-based medicinal products","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-03-02 - 2026-04-30","first_published_date":"2026-03-02T13:19:37Z","last_updated_date":"2026-03-02T13:19:37Z","reference_number":"EMA/CHMP/30023/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-reflection-paper-non-clinical-development-evaluation-microbiome-based-medicinal-products_en.pdf"},
    {"id":"72825","name":"Draft guidance on the conduct of clinical trials during public health emergencies","type":"scientific-guideline","status":"Draft: consultation closed","consultation_date":"2026-03-04 - 2026-04-30","first_published_date":"2026-03-04T13:19:18Z","last_updated_date":"2026-03-04T13:19:18Z","reference_number":"EMA/44884/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guidance-conduct-clinical-trials-during-public-health-emergencies_en.pdf"},
    {"id":"72870","name":"EU implementation strategy of ICH E2D(R1) Guideline - Post-approval safety data: Definitions and standards for management and reporting of individual case safety reports","type":"scientific-guideline","status":"unknown","consultation_date":"","first_published_date":"2026-03-06T15:02:57Z","last_updated_date":"2026-03-27T15:40:00Z","reference_number":"EMA/11141/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/eu-implementation-strategy-ich-e2dr1-guideline-post-approval-safety-data-definitions-standards-management-reporting-individual-case-safety-reports_en.pdf"},
    {"id":"72974","name":"Concept paper on the development of a reflection paper on proof-of-concept data to support the development of anti-cancer medicinal products in paediatric patients","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-03-13 - 2026-06-30","first_published_date":"2026-03-13T08:00:00Z","last_updated_date":"2026-03-13T08:00:00Z","reference_number":"EMA/32831/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-proof-concept-data-support-development-anti-cancer-medicinal-products-paediatric-patients_en.pdf"},
    {"id":"73133","name":"Guideline on the chemistry of active substances ","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-03-20T13:52:17Z","last_updated_date":"2026-03-20T13:52:17Z","reference_number":"EMA/CHMP/QWP/49484/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-chemistry-active-substances_en.pdf"},
    {"id":"73134","name":"Guidance and template on the risk management plan (RMP) for novel therapy veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-03-20T14:15:55Z","last_updated_date":"2026-03-20T14:15:55Z","reference_number":"EMA/CVMP/NTWP/201952/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guidance-template-risk-management-plan-rmp-novel-therapy-veterinary-medicinal-products_en.pdf"},
    {"id":"73205","name":"Eltrombopag film-coated tablets 12.5 mg, 25 mg, 50 mg, 75 mg and powder for oral suspension 25 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-03-25T15:26:00Z","last_updated_date":"2026-03-25T15:26:00Z","reference_number":"EMA/226445/2025 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/eltrombopag-film-coated-tablets-125-mg-25-mg-50-mg-75-mg-powder-oral-suspension-25-mg-product-specific-bioequivalence-guidance_en.pdf-0"},
    {"id":"73229","name":"Melatonin prolonged release tablets 2 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T08:11:48Z","last_updated_date":"2026-03-27T08:11:48Z","reference_number":"EMA/226444/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/melatonin-prolonged-release-tablets-2-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"73286","name":"Concept paper on the need for revision of the guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-03-31 - 2026-09-30","first_published_date":"2026-03-31T17:52:50Z","last_updated_date":"2026-03-31T17:52:50Z","reference_number":"EMA/61447/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf"},
    {"id":"73287","name":"Paediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-03-31 - 2026-09-30","first_published_date":"2026-03-31T17:53:43Z","last_updated_date":"2026-03-31T17:53:43Z","reference_number":"EMA/CHMP/60723/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/paediatric-addendum-chmp-guideline-clinical-investigations-medicinal-products-treatment-pulmonary-arterial-hypertension_en.pdf"},
    {"id":"73308","name":"Draft ‘Guideline on declaration of herbal substances and herbal preparations in herbal medicinal products / traditional herbal medicinal products’ - Revision 2","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-04-01 - 2026-06-30","first_published_date":"2026-04-01T16:37:05Z","last_updated_date":"2026-04-01T16:37:05Z","reference_number":"EMA/HMPC/CHMP/CVMP/287539/2005 Rev. 2 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-declaration-herbal-substances-herbal-preparations-herbal-medicinal-products-traditional-herbal-medicinal-products-revision-2_en.pdf"},
    {"id":"73310","name":"Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-04-01T16:51:03Z","last_updated_date":"2026-04-01T16:51:03Z","reference_number":"EMA/CHMP/BPWP/59529/2026 rev 2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-normal-immunoglobulin-subcutaneous-or-intramuscular-administration-scig-imig-revision-2_en.pdf"},
    {"id":"73311","name":"Guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration (SCIg/IMIg) - Revision 2","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-04-01T16:59:43Z","last_updated_date":"2026-04-01T16:59:43Z","reference_number":"EMA/CHMP/BPWP/143744/2011 Rev.2 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-normal-immunoglobulin-subcutaneous-intramuscular-administration-scig-imig-revision-2_en.pdf"},
    {"id":"73559","name":"Draft reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Revision 1","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-04-24 - 2026-08-31","first_published_date":"2026-04-24T10:15:56Z","last_updated_date":"2026-04-24T10:15:56Z","reference_number":"EMA/CVMP/AWP/741087/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-macrolides-lincosamides-streptogramins-mls-animals-european-union-development-resistance-impact-public-animal-health-revision-1_en.pdf"},
    {"id":"73570","name":"Concept paper on the development for guidance on demonstration of biosimilarity of biological veterinary medicinal products","type":"scientific-guideline","status":"Adopted","consultation_date":"2026-04-24 - 2026-07-31","first_published_date":"2026-04-24T11:44:06Z","last_updated_date":"2026-04-24T11:44:06Z","reference_number":"EMA/CVMP/121133/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guidance-demonstration-biosimilarity-biological-veterinary-medicinal-products_en.pdf"},
    {"id":"73583","name":"Annexes to ICH Q3C guideline on impurities: guideline for residual solvents (EMA/CHMP/ICH/82260/2006) and VICH GL18 Impurities: residual solvents in new veterinary medicinal products, active substances and excipients (EMA/CVMP/VICH/502/1999) - Revision 2","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-04-29 - 2026-06-30","first_published_date":"2026-04-29T13:27:24Z","last_updated_date":"2026-04-29T13:27:24Z","reference_number":"CPMP/QWP/450/03 Rev.2; EMEA/CVMP/511/03 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/annexes-ich-q3c-guideline-impurities-guideline-residual-solvents-ema-chmp-ich-82260-2006-vich-gl18-impurities-residual-solvents-new-veterinary-medicinal-products-active-substances-excipients-ema-cvmp_en.pdf"},
    {"id":"73589","name":"Liraglutide 6 mg/mL solution for injection in a prefilled pen product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-04-30 - 2026-07-31","first_published_date":"2026-04-30T11:53:38Z","last_updated_date":"2026-04-30T11:53:38Z","reference_number":"EMA/65789/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/liraglutide-6-mg-ml-solution-injection-prefilled-pen-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"73590","name":"Tafamidis soft gelatin capsules 20 mg and 61 mg product-specific bioequivalence guidance","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-04-30 - 2026-07-31","first_published_date":"2026-04-30T12:21:34Z","last_updated_date":"2026-04-30T12:21:34Z","reference_number":"EMA/85747/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/tafamidis-soft-gelatin-capsules-20-mg-61-mg-product-specific-bioequivalence-guidance_en.pdf"},
    {"id":"73892","name":"Guideline on VICH GL61 Pharmaceutical Development","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-05-29T10:23:54Z","last_updated_date":"2026-05-29T10:23:54Z","reference_number":"EMA/CVMP/841162/2022","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-vich-gl61-pharmaceutical-development_en.pdf-0"},
    {"id":"73893","name":"Concept paper on the need for revision of the guideline on the development of medicinal products for the treatment of smoking","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-05-29 - 2026-08-30","first_published_date":"2026-05-29T10:34:25Z","last_updated_date":"2026-05-29T10:34:25Z","reference_number":"EMA/112569/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-development-medicinal-products-treatment-smoking_en.pdf"},
    {"id":"73909","name":"Guideline on determination of the need for an MRL evaluation for chemical-unlike biological substances - Revision 1","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-05-29T13:48:00Z","last_updated_date":"2026-05-29T13:48:00Z","reference_number":"EMA/CVMP/SWP/591282/2021 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-determination-need-mrl-evaluation-chemical-unlike-biological-substances-revision-1_en.pdf"},
    {"id":"73961","name":"Concept paper on the development of a reflection paper on the use of External controls for evidence generation in regulatory decision-making","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-06-03T15:42:19Z","last_updated_date":"2026-06-03T15:42:19Z","reference_number":"EMA/125200/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-use-external-controls-evidence-generation-regulatory-decision-making_en.pdf"},
    {"id":"74124","name":"Reflection paper on data recommendations for herbal medicinal products and traditional herbal medicinal products used in paediatric patients","type":"scientific-guideline","status":"Adopted","consultation_date":"","first_published_date":"2026-06-16T16:32:04Z","last_updated_date":"2026-06-16T16:32:04Z","reference_number":"EMA/HMPC/71333/2023 ","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-recommendations-herbal-medicinal-products-traditional-herbal-medicinal-products-used-paediatric-patients_en.pdf"},
    {"id":"74258","name":"Guideline on the clinical evaluation of medicinal products for weight management - Addendum on weight control in children","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-06-24 - 2026-10-31","first_published_date":"2026-06-25T09:22:53Z","last_updated_date":"2026-06-25T09:22:53Z","reference_number":"EMA/126591/2026","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-weight-management-addendum-weight-control-children_en.pdf"},
    {"id":"74330","name":"Concept paper on the revision of the Guideline on data requirements for the replacement of established master seeds (MS) already used in authorised immunological veterinary medicinal products (IVMPs) by new MS of the same origin","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-06-26 - 2026-09-30","first_published_date":"2026-06-26T16:05:26Z","last_updated_date":"2026-06-26T16:05:26Z","reference_number":"EMA/CVMP/IWP/385637/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-data-requirements-replacement-established-master-seeds-ms-already-used-authorised-immunological-veterinary-medicinal-products-ivmps-new-ms-same-origin_en.pdf"},
    {"id":"74331","name":"Concept paper on the revision of the Guideline on data requirements for authorisation of immunological veterinary medicinal products in exceptional circumstances (EMA/CVMP/IWP/251947/2021)","type":"scientific-guideline","status":"Draft: consultation open","consultation_date":"2026-06-26 - 2026-09-30","first_published_date":"2026-06-26T16:12:51Z","last_updated_date":"2026-06-26T16:12:51Z","reference_number":"EMA/CVMP/IWP/385629/2025","document_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-data-requirements-authorisation-immunological-veterinary-medicinal-products-exceptional-circumstances-ema-cvmp-iwp-251947-2021_en.pdf"},
    {"id":"2400","name":"Standard Operating Procedure for Management of 15-day Suspected Adverse Reaction (SAR) reports to a centrally authorised veterinary medicinal product","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2005-12-09T01:00:00Z","last_updated_date":"2005-12-09T01:00:00Z","reference_number":"CVMP/SOP/693/99-Rev.2","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-management-15-day-suspected-adverse-reaction-sar-reports-centrally-authorised-veterinary-medicinal-product_en.pdf"},
    {"id":"3283","name":"Standard operating procedure for consultation of environmental competent authorities on genetically modified organisms with respect to environmental risk assessment in product evaluation (human use)","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2009-10-07T02:00:00Z","last_updated_date":"2020-01-22T12:30:00Z","reference_number":"SOP/H/3191","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-consultation-environmental-competent-authorities-genetically-modified-organisms-respect-environmental-risk-assessment-product-evaluation-human-use_en.pdf"},
    {"id":"3476","name":"Standard operating procedure for preparation of question-and-answer documents for withdrawals of marketing authorisation applications by the Medical Information Sector","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-11-28T01:00:00Z","last_updated_date":"2012-03-22T11:00:00Z","reference_number":"SOP/H/3137","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-preparation-question-and-answer-documents-withdrawals-marketing-authorisation-applications-medical-information-sector_en.pdf"},
    {"id":"3488","name":"Standard Operating Procedure for translation workflow of EMA documents","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2010-10-25T02:00:00Z","last_updated_date":"2010-10-25T02:00:00Z","reference_number":"SOP/PDM/1400","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-translation-workflow-ema-documents_en.pdf"},
    {"id":"3983","name":"Standard operating procedure for European Pharmacovigilance Issues Tracking Tool user registration and management","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2016-10-20T19:05:00Z","reference_number":"SOP/H/3341","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-european-pharmacovigilance-issues-tracking-tool-user-registration-and-management_en.pdf"},
    {"id":"4096","name":"Standard operating procedure for CHMP / CAT / PRAC rapporteur / co-rapporteur / peer-reviewer appointment in the centralised procedure","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-06-18T02:00:00Z","last_updated_date":"2017-04-11T19:10:00Z","reference_number":"SOP/H/3143","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-chmp-cat-prac-rapporteur-co-rapporteur-peer-reviewer-appointment-centralised-procedure_en.pdf"},
    {"id":"5379","name":"Standard operating procedure for type IB variations to centralised marketing authorisations (medicines for veterinary use)","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-05-16T02:00:00Z","last_updated_date":"2016-05-13T17:00:00Z","reference_number":"SOP/V/4011","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-type-ib-variations-centralised-marketing-authorisations-medicines-veterinary-use_en.pdf"},
    {"id":"5420","name":"Standard operating procedure for checking of mock-ups and specimens for all post-authorisation procedures other than new applications, line extensions, renewals and transfers","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-06-10T02:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"SOP/H/3219","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-checking-mock-ups-and-specimens-all-post-authorisation-procedures-other-new-applications-line-extensions-renewals-and-transfers_en.pdf"},
    {"id":"6816","name":"Standard Operating Procedure for marketing status reporting and sunset clause monitoring (Human Medicine)","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-04-25T02:00:00Z","last_updated_date":"2008-04-25T02:00:00Z","reference_number":"SOP/H/3128","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-marketing-status-reporting-and-sunset-clause-monitoring-human-medicine_en.pdf"},
    {"id":"6923","name":"Standard operating procedure for evaluation of conflicts of interests of experts for involvement in Agency activities","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2006-08-22T02:00:00Z","last_updated_date":"2024-07-11T10:54:00Z","reference_number":"EMA/52293/2006","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-evaluation-conflicts-interests-experts-involvement-agency-activities_en.pdf"},
    {"id":"7815","name":"Standard operating procedure for processing of requests for fee reduction falling under paragraph 1 of Article 9 of Council Regulation (EC) No 297/95","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-03-17T01:00:00Z","last_updated_date":"2020-07-30T10:30:00Z","reference_number":"SOP/EMA/0028","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-processing-requests-fee-reduction-falling-under-paragraph-1-article-9-council-regulation-ec-no-29795_en.pdf"},
    {"id":"7881","name":"Standard Operating Procedure for Requests for advice from CMD(v) to CVMP","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-01-16T01:00:00Z","last_updated_date":"2008-01-16T01:00:00Z","reference_number":"SOP/V/4036","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-requests-advice-cmdv-cvmp_en.pdf"},
    {"id":"8080","name":"Standard Operating Procedure for Creating the SAFE Print","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-06-07T02:00:00Z","last_updated_date":"2007-06-07T02:00:00Z","reference_number":"SOP/H/3026","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-creating-safe-print_en.pdf"},
    {"id":"8330","name":"Standard operating procedure on handling of European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) study seal applications","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"SOP/H/3362","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-european-network-centres-pharmacoepidemiology-and-pharmacovigilance-encepp-study-seal-applications_en.pdf"},
    {"id":"10198","name":"Standard Operating Procedure for Checklist of mandatory input to annual management review","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2006-03-06T01:00:00Z","last_updated_date":"2006-03-06T01:00:00Z","reference_number":"EMEA/6310/2006","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-checklist-mandatory-input-annual-management-review_en.pdf"},
    {"id":"10222","name":"Standard operating procedure for assignment of micro-, small- or medium-sized-enterprise status","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2009-11-03T00:00:00Z","last_updated_date":"2025-05-06T16:20:00Z","reference_number":"SOP/EMEA/0039","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-assignment-micro-small-or-medium-sized-enterprise-status_en.pdf"},
    {"id":"10227","name":"Standard operating procedure for preparation of a European public assessment report for a human medicinal product following positive or negative opinion","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-12-05T01:00:00Z","last_updated_date":"2012-09-13T17:25:00Z","reference_number":"SOP/H/3003","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-preparation-european-public-assessment-report-human-medicinal-product-following-positive-or-negative-opinion_en.pdf"},
    {"id":"10259","name":"Standard operating procedure for organisation and management of ENCePP plenary meetings","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"SOP/H/3358","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-organisation-and-management-encepp-plenary-meetings_en.pdf"},
    {"id":"10678","name":"Standard Operating Procedure for handling of a request for accelerated assessment of initial marketing authorisation applications (human use)","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2009-01-05T01:00:00Z","last_updated_date":"2009-01-05T01:00:00Z","reference_number":"SOP/H/3182","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-request-accelerated-assessment-initial-marketing-authorisation-applications-human-use_en.pdf"},
    {"id":"11213","name":"Standard operating procedure for preparation of ‘lines-to-take’ documents for use within the European Union regulatory network to answer external queries in a consistent manner","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"SOP/H/3347","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-preparation-lines-take-documents-use-within-european-union-regulatory-network-answer-external-queries-consistent-manner_en.pdf"},
    {"id":"11302","name":"Standard operating procedure for preparation and updates of European public assessment report summaries by Product-related Information to the Network Service","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2014-05-14T15:50:00Z","reference_number":"SOP/H/3131","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-preparation-and-updates-european-public-assessment-report-summaries-product-related-information-network-service_en.pdf"},
    {"id":"11358","name":"Standard Operating Procedure for Summary of the roles of the different parties in the event of a potential quality defect","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-02-09T01:00:00Z","last_updated_date":"2007-02-09T01:00:00Z","reference_number":"EMEA/INS/GMP/75467/2007","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-summary-roles-different-parties-event-potential-quality-defect_en.pdf"},
    {"id":"11418","name":"Standard Operating Procedure for SIAMED-related data validation of new veterinary centralised procedures","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-02-16T01:00:00Z","last_updated_date":"2010-04-27T02:00:00Z","reference_number":"SOP/V/4033","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-siamed-related-data-validation-new-veterinary-centralised-procedures_en.pdf"},
    {"id":"11463","name":"Standard operating procedure for referral procedures in accordance with the provisions of Articles 33(4), 34 and 35 of Directive 2001/82/EC, and Article 13 of Commission Regulation (EC) No 1234/2008, related to veterinar...","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-04-15T02:00:00Z","last_updated_date":"2016-01-14T19:00:00Z","reference_number":"SOP/V/4024","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-referral-procedures-accordance-provisions-articles-334-34-and-35-directive-200182ec-and-article-13-commission-regulation-ec-no-12342008-related-veterinar_en.pdf"},
    {"id":"11812","name":"Standard operating procedure for review and approval of VICH guidelines by CVMP and its working parties","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2009-08-24T02:00:00Z","last_updated_date":"2015-09-02T16:50:00Z","reference_number":"SOP/V/4047","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-review-and-approval-vich-guidelines-cvmp-and-its-working-parties_en.pdf"},
    {"id":"12107","name":"Standard operating procedure for annual review of VeDDRA  list to be used in EudraVigilance Veterinary","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2015-05-26T02:00:00Z","last_updated_date":"2026-02-26T13:58:00Z","reference_number":"SOP/V/4019","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-annual-review-veddra-list-be-used-eudravigilance-veterinary_en.pdf"},
    {"id":"12124","name":"Standard operating procedure for checking of mock-ups and specimens for transfer of marketing authorisation","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-06-10T02:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"SOP/H/3218","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-checking-mock-ups-and-specimens-transfer-marketing-authorisation_en.pdf"},
    {"id":"12374","name":"Standard Operating Procedure for MRL Procedure: Submission of Dossiers to the Members of the Committee for Veterinary Medicinal Products","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-12-10T01:00:00Z","last_updated_date":"2007-12-10T01:00:00Z","reference_number":"EMEA/CVMP/819/99-Annex 1","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-mrl-procedure-submission-dossiers-members-committee-veterinary-medicinal-products_en.pdf"},
    {"id":"12851","name":"Standard Operating Procedure for Suspected Defective Product Report","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-02-09T01:00:00Z","last_updated_date":"2007-02-09T01:00:00Z","reference_number":"EMEA/INS/GMP/75464/2007","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-suspected-defective-product-report_en.pdf"}    {"id":"13476","name":"Standard operating procedure for evaluation procedure for eligibility of patients', consumers' and healthcare professionals’ organisations","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2013-02-04T11:20:00Z","last_updated_date":"2015-03-17T11:10:00Z","reference_number":"SOP/H/3390","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-evaluation-procedure-eligibility-patients-consumers-and-healthcare-professionals-organisations_en.pdf"},
    {"id":"13895","name":"Standard operating procedure for provision of scientific recommendation on classification of advanced-therapy medicinal products","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2011-11-07T12:40:00Z","last_updated_date":"2016-06-10T14:48:00Z","reference_number":"SOP/H/3309","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-provision-scientific-recommendation-classification-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"13901","name":"Standard operating procedure for co-ordination of good-laboratory-practice inspections","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-27T18:30:00Z","last_updated_date":"2012-09-27T18:30:00Z","reference_number":"SOP/INSP/2049","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-co-ordination-good-laboratory-practice-inspections_en.pdf"},
    {"id":"13910","name":"Standard operating procedure on data analysis of EudraVigilance","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T02:00:00Z","last_updated_date":"2019-01-07T09:35:00Z","reference_number":"SOP/H/3289","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-data-analysis-eudravigilance_en.pdf"},
    {"id":"14286","name":"Standard operating procedure for Product Information Quality / Quality Review of Documents pre-opinion review of product information for initial applications and annex-II applications","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-08T02:00:00Z","last_updated_date":"2010-12-15T01:00:00Z","reference_number":"SOP/EMA/0009","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-product-information-quality-quality-review-documents-pre-opinion-review-product-information-initial-applications-and-annex-ii-applications_en.pdf"},
    {"id":"14770","name":"Standard operating procedure for renewal of micro-, small- or medium-sized-enterprise status","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-22T15:00:00Z","last_updated_date":"2025-05-06T16:20:00Z","reference_number":"SOP/EMA/0124","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-renewal-micro-small-or-medium-sized-enterprise-status_en.pdf"},
    {"id":"15042","name":"Standard operating procedure on annual re-assessment of centrally authorised veterinary medicinal products under exceptional circumstances","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-24T11:26:00Z","last_updated_date":"2016-05-13T17:00:00Z","reference_number":"SOP/V/4006","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-annual-re-assessment-centrally-authorised-veterinary-medicinal-products-under-exceptional-circumstances_en.pdf"},
    {"id":"15137","name":"Standard operating procedure for evaluation and certification of quality and non-clinical data relating to advanced therapy medicinal products","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T10:02:00Z","last_updated_date":"2012-03-01T10:02:00Z","reference_number":"SOP/H/3334","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-evaluation-and-certification-quality-and-non-clinical-data-relating-advanced-therapy-medicinal-products_en.pdf"},
    {"id":"15293","name":"Standard operating procedure for preparation and publication of Committee for Orphan Medicinal Products monthly report","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-10-15T02:00:00Z","last_updated_date":"2011-12-19T13:00:00Z","reference_number":"SOP/H/3018","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-preparation-and-publication-committee-orphan-medicinal-products-monthly-report_en.pdf"},
    {"id":"15861","name":"Standard operating procedure for cover during out of Agency office hours for a potentially serious problem with a centrally authorised product","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-06-18T02:00:00Z","last_updated_date":"2010-12-08T01:00:00Z","reference_number":"SOP/EMA/0087","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-cover-during-out-agency-office-hours-potentially-serious-problem-centrally-authorised-product_en.pdf"},
    {"id":"16088","name":"Standard operating procedure for processing of type II variations for medicinal products for veterinary use","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-05-16T02:00:00Z","last_updated_date":"2016-01-14T19:00:00Z","reference_number":"SOP/V/4004","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-processing-type-ii-variations-medicinal-products-veterinary-use_en.pdf"},
    {"id":"16138","name":"Standard operating procedure on Article 29 procedures according to the Paediatric Regulation No 1901/2006","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-06-28T18:30:00Z","last_updated_date":"2012-06-28T18:30:00Z","reference_number":"SOP/H/3249","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-article-29-procedures-according-paediatric-regulation-no-19012006_en.pdf"},
    {"id":"16456","name":"Standard operating procedure for evaluation procedure for applications and requests for the establishment or review of Maximum Residue Limits (MRLs)","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2017-05-10T19:10:00Z","last_updated_date":"2017-05-10T19:10:00Z","reference_number":"SOP/V/4150","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-evaluation-procedure-applications-and-requests-establishment-or-review-maximum-residue-limits-mrls_en.pdf"},
    {"id":"17270","name":"Standard operating procedure for handling of requests for information","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-10-17T02:00:00Z","last_updated_date":"2019-11-18T17:00:00Z","reference_number":"SOP/EMA/0019","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-requests-information_en.pdf"},
    {"id":"17309","name":"Standard operating procedure for involvement of the CVMP Antimicrobials Working Party in the evaluation of applications for centralised marketing authorisations for veterinary medicinal products containing antimicrobial substances","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-12-19T01:00:00Z","last_updated_date":"2015-07-03T17:46:00Z","reference_number":"SOP/V/4042","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-involvement-cvmp-antimicrobials-working-party-evaluation-applications-centralised-marketing-authorisations-veterinary-medicinal-products-containing-antimicrobial_en.pdf"},
    {"id":"17339","name":"Standard operating procedure for procedure to be followed when the incident management plan for medicines for veterinary use is triggered","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-20T16:30:00Z","last_updated_date":"2026-01-20T14:05:00Z","reference_number":"SOP/V/4003","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-procedure-be-followed-when-incident-management-plan-medicines-veterinary-use-triggered_en.pdf"},
    {"id":"17991","name":"Standard operating procedure for Management Board consultation on new nominations to the CHMP and the CVMP","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-10-02T02:00:00Z","last_updated_date":"2013-01-30T12:15:00Z","reference_number":"SOP/EMEA/0076","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-management-board-consultation-new-nominations-chmp-and-cvmp_en.pdf"},
    {"id":"19159","name":"Standard operating procedure for type IA variations (single and grouped) to centralised marketing authorisations (medicines for veterinary use)","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-05-16T02:00:00Z","last_updated_date":"2016-06-28T10:45:00Z","reference_number":"SOP/V/4010","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-type-ia-variations-single-and-grouped-centralised-marketing-authorisations-medicines-veterinary-use_en.pdf"},
    {"id":"19243","name":"Standard Operating Procedure for Template for Assessment Report","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-02-08T01:00:00Z","last_updated_date":"2007-02-08T01:00:00Z","reference_number":"EMEA/INS/GMP/75469/2007","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-template-assessment-report_en.doc"},
    {"id":"20707","name":"Standard operating procedure for early notification system: procedure for advanced notification of emerging safety issues to European Union regulatory network and international partners","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"SOP/H/3346","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-early-notification-system-procedure-advanced-notification-emerging-safety-issues-european-union-regulatory-network-and-international-partners_en.pdf"},
    {"id":"20813","name":"Standard Operating Procedure for EMEA Inspections Sector Contact Details Template","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-02-09T01:00:00Z","last_updated_date":"2007-02-09T01:00:00Z","reference_number":"EMEA/INS/GMP/75466/2007","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-emea-inspections-sector-contact-details-template_en.pdf"},
    {"id":"21110","name":"Standard operating procedure for handling invoice payment within deadline of 30 days (rapporteurs' and inspectors' payments)","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2013-01-03T17:00:00Z","last_updated_date":"2014-07-02T16:20:00Z","reference_number":"SOP/EMA/0134","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-invoice-payment-within-deadline-30-days-rapporteurs-and-inspectors-payments_en.pdf"},
    {"id":"21888","name":"Standard operating procedure for procedures in accordance with Article 78 of Directive 2001/82/EC, related to pharmacovigilance measures for veterinary medicinal products authorised in the European Union","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-04-19T17:07:00Z","last_updated_date":"2016-02-11T15:45:00Z","reference_number":"SOP/V/4025","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-procedures-accordance-article-78-directive-200182ec-related-pharmacovigilance-measures-veterinary-medicinal-products-authorised-european-union_en.pdf"},
    {"id":"22339","name":"Standard operating procedure for coordination of good-manufacturing-practice and good-distribution-practice inspections","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-27T18:30:00Z","last_updated_date":"2012-09-27T18:30:00Z","reference_number":"SOP/INSP/2048","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-coordination-good-manufacturing-practice-and-good-distribution-practice-inspections_en.pdf"},
    {"id":"23094","name":"Standard Operating Procedure for Checklist of non-mandatory input to annual management review","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2006-03-06T01:00:00Z","last_updated_date":"2006-03-06T01:00:00Z","reference_number":"EMEA/6322/2006","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-checklist-non-mandatory-input-annual-management-review_en.pdf"},
    {"id":"23493","name":"Standard operating procedure for procedure for liaising between the European Medicines Agency, the Committee for Medicinal Products for Human Use (CHMP) and the Clinical Trials Facilitation Group on the potential CHMP ne...","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-03-01T12:16:00Z","last_updated_date":"2012-03-01T12:16:00Z","reference_number":"SOP/INSP/2033","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-procedure-liaising-between-european-medicines-agency-committee-medicinal-products-human-use-chmp-and-clinical-trials-facilitation-group-potential-chmp-ne_en.pdf"},
    {"id":"23587","name":"Standard operating procedure for the organisation of European Medicines Agency Human Scientific Committees’ Working Party meetings with Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals’ Organisa...","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-12-05T01:00:00Z","last_updated_date":"2015-02-18T16:10:00Z","reference_number":"SOP/H/3130","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-organisation-european-medicines-agency-human-scientific-committees-working-party-meetings-patients-and-consumers-organisations-pcwp-and-healthcare-professionals-organisa_en.pdf"},
    {"id":"23746","name":"Standard operating procedure for scientific and administrative support to working groups and working party under the Compliance and Inspection Sector's responsibility","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-07-15T02:00:00Z","last_updated_date":"2012-04-23T12:15:00Z","reference_number":"SOP/INSP/2015","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-scientific-and-administrative-support-working-groups-and-working-party-under-compliance-and-inspection-sectors-responsibility_en.pdf"},
    {"id":"23896","name":"Standard operating procedure for handling of external requests for access to information from patients, healthcare professionals, academia and the general public","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2011-02-25T01:00:00Z","last_updated_date":"2016-11-24T16:55:00Z","reference_number":"SOP/H/3386","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-external-requests-access-information-patients-healthcare-professionals-academia-and-general-public_en.pdf"},
    {"id":"24740","name":"Standard operating procedure for rapporteur / co-rapporteur appointment for re-examination of a CHMP opinion","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-12-05T01:00:00Z","last_updated_date":"2012-09-26T18:35:15Z","reference_number":"SOP/H/3175","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-rapporteur-co-rapporteur-appointment-re-examination-chmp-opinion_en.pdf"},
    {"id":"24835","name":"Standard operating procedure for handling of requests for confirmation of applicability of a European Medicines Agency decision on class waivers","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2011-07-25T02:00:00Z","last_updated_date":"2011-07-25T02:00:00Z","reference_number":"SOP/H/3259","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-requests-confirmation-applicability-european-medicines-agency-decision-class-waivers_en.pdf"},
    {"id":"25824","name":"Standard operating procedure for coordination of site visits in the context of the certification of quality and non-clinical data submitted by small and medium-sized enterprises developing advanced-therapy medicinal prod...","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-28T12:30:00Z","last_updated_date":"2012-09-28T12:30:00Z","reference_number":"SOP/INSP/2001","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-coordination-site-visits-context-certification-quality-and-non-clinical-data-submitted-small-and-medium-sized-enterprises-developing-advanced-therapy-medicinal-prod_en.pdf"},
    {"id":"25980","name":"Standard Operating Procedure for Reports of Defective Centrally Authorised Products","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-02-09T01:00:00Z","last_updated_date":"2007-02-09T01:00:00Z","reference_number":"EMEA/INS/GMP/75465/2007","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-reports-defective-centrally-authorised-products_en.pdf"},
    {"id":"26124","name":"Standard operating procedure for handling and validation of EU-RMP annex 1","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"SOP/H/3291","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-and-validation-eu-rmp-annex-1_en.pdf"},
    {"id":"26592","name":"Standard operating procedure for micro, small and medium-sized enterprises (SME) conditional fee exemptions","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2016-07-07T19:00:00Z","last_updated_date":"2016-07-07T19:00:00Z","reference_number":"SOP/EMA/0038","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-micro-small-and-medium-sized-enterprises-sme-conditional-fee-exemptions_en.pdf"},
    {"id":"26714","name":"Standard Operating Procedure for updating of the European Public Assessment Report for a veterinary medicinal product","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-10-01T02:00:00Z","last_updated_date":"2016-01-14T19:00:00Z","reference_number":"SOP/V/4038","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-updating-european-public-assessment-report-veterinary-medicinal-product_en.pdf"},
    {"id":"28296","name":"Standard operating procedure for Processing of parallel distribution initial notifications","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-07-19T13:00:00Z","last_updated_date":"2012-07-19T13:00:00Z","reference_number":"SOP/INSP/2014","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-processing-parallel-distribution-initial-notifications_en.pdf"},
    {"id":"28411","name":"Standard operating procedure for handling of requests for ADR-related EudraVigilance data","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T10:53:00Z","last_updated_date":"2019-01-07T10:53:00Z","reference_number":"SOP/H/3326","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-requests-adr-related-eudravigilance-data_en.pdf"},
    {"id":"29016","name":"Standard operating procedure for evaluation procedure for CVMP MUMS/limited market classification requests","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T15:02:00Z","last_updated_date":"2018-01-26T15:02:00Z","reference_number":"SOP/V/4111","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-evaluation-procedure-cvmp-mumslimited-market-classification-requests_en.pdf"},
    {"id":"31367","name":"Standard operating procedure for certificates of medicinal products","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-04-04T12:00:00Z","last_updated_date":"2012-04-04T12:00:00Z","reference_number":"SOP/INSP/2000","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-certificates-medicinal-products_en.pdf"},
    {"id":"31592","name":"Standard operating procedure for handling of financial procedure for parallel distribution","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2011-10-17T10:40:00Z","last_updated_date":"2011-10-17T10:40:00Z","reference_number":"SOP/INSP/2013","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-financial-procedure-parallel-distribution_en.pdf"},
    {"id":"31729","name":"Standard Operating Procedure for Check of expert for product evaluation","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2005-09-21T02:00:00Z","last_updated_date":"2005-09-21T02:00:00Z","reference_number":"SOP/H/3022","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-check-expert-product-evaluation_en.pdf"},
    {"id":"32282","name":"Standard operating procedure for preparation, dissemination and publication of safety-related European Medicines Agency press releases and question-and-answer documents","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"SOP/EMA/0111","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-preparation-dissemination-and-publication-safety-related-european-medicines-agency-press-releases-and-question-and-answer-documents_en.pdf"},
    {"id":"32364","name":"Standard Operating Procedure for Submission and evaluation procedure for an application for the establishment of Maximum Residue Limits (MRLs)","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2006-03-01T01:00:00Z","last_updated_date":"2006-03-01T01:00:00Z","reference_number":"EMEA/CVMP/819/99-Rev.5","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-submission-and-evaluation-procedure-application-establishment-maximum-residue-limits-mrls_en.pdf"},
    {"id":"32409","name":"Standard operation procedure for handling of requests from a national competent authority to the CMDh for a recommendation on the classification of an unforeseen variation under Article 5 of Commission Regulation (EC) No...","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2013-03-14T11:00:00Z","last_updated_date":"2017-03-02T11:00:00Z","reference_number":"SOP/H/3375","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operation-procedure-handling-requests-national-competent-authority-cmdh-recommendation-classification-unforeseen-variation-under-article-5-commission-regulation-ec-no_en.pdf"},
    {"id":"32999","name":"Standard operating procedure for checking of mock-ups and specimens for new applications and extensions","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-10-21T02:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"SOP/H/3013","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-checking-mock-ups-and-specimens-new-applications-and-extensions_en.pdf"},
    {"id":"33170","name":"Standard operating procedure for co-ordination of GCP inspections","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-05-16T02:00:00Z","last_updated_date":"2012-09-27T02:00:00Z","reference_number":"SOP/INSP/2020","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-co-ordination-gcp-inspections_en.pdf"},
    {"id":"33224","name":"Standard operating procedure for handover file","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-22T14:30:00Z","last_updated_date":"2013-03-26T18:00:00Z","reference_number":"SOP/EMA/0127","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handover-file_en.pdf"},
    {"id":"33732","name":"Standard operating procedure for checking of mock-ups and specimens for renewals","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2008-06-10T02:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"SOP/H/3217","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-checking-mock-ups-and-specimens-renewals_en.pdf"},
    {"id":"34530","name":"Standard operating procedure on handling of external requests on the European Union Clinical Trials Register and EudraCT","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-06T11:40:00Z","last_updated_date":"2012-09-06T11:40:00Z","reference_number":"SOP/INSP/2044","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-external-requests-european-union-clinical-trials-register-and-eudract_en.pdf"},
    {"id":"35072","name":"Standard Operating Procedure for Template for recording top management decisions","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2006-03-06T01:00:00Z","last_updated_date":"2006-03-06T01:00:00Z","reference_number":"EMEA/245906/2005","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-template-recording-top-management-decisions_en.pdf"},
    {"id":"35336","name":"Standard operating procedure for rectifying errors in PDCO opinions and European Medicines Agency decisions","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-07-27T16:05:00Z","last_updated_date":"2017-12-01T15:00:00Z","reference_number":"SOP/H/3458","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-rectifying-errors-pdco-opinions-and-european-medicines-agency-decisions_en.pdf"},
    {"id":"35607","name":"Standard operating procedure for eligibility to the centralised procedure for medicinal products for human use","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-10T16:00:00Z","last_updated_date":"2016-02-10T16:00:00Z","reference_number":"SOP/H/3462","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-eligibility-centralised-procedure-medicinal-products-human-use_en.pdf"},
    {"id":"35644","name":"Standard operating procedure for conducting checks for conflicts of interest of the European Medicines Agency employees assigned duties relating to medicinal products for human or veterinary use","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2009-11-30T10:25:00Z","last_updated_date":"2023-06-27T12:17:00Z","reference_number":"SOP/EMEA/0101","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-conducting-checks-conflicts-interest-european-medicines-agency-employees-assigned-duties-relating-medicinal-products-human-or-veterinary-use_en.pdf"},
    {"id":"35810","name":"Standard operating procedure for evaluation procedure for CVMP scientific advice requests","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2018-01-16T11:30:00Z","last_updated_date":"2018-01-16T11:30:00Z","reference_number":"SOP/V/4112","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-evaluation-procedure-cvmp-scientific-advice-requests_en.pdf"},
    {"id":"36413","name":"Standard Operating Procedure for European group for product defects","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-02-09T01:00:00Z","last_updated_date":"2007-02-09T01:00:00Z","reference_number":"EMEA/INS/GMP/75468/2007","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-european-group-product-defects_en.pdf"},
    {"id":"36497","name":"Standard operating procedure for re-evaluation and financial re-assessment procedures for eligible patients', consumers' and healthcare professionals’ organisations","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2013-02-04T11:20:00Z","last_updated_date":"2015-03-17T11:10:00Z","reference_number":"SOP/H/3417","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-re-evaluation-and-financial-re-assessment-procedures-eligible-patients-consumers-and-healthcare-professionals-organisations_en.pdf"},
    {"id":"36809","name":"Standard operating procedure for arrangements for handling of conflicts of interests for European Medicines Agency scientific meetings","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-10-08T17:40:00Z","last_updated_date":"2024-07-11T10:48:00Z","reference_number":"EMA/508581/2012","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-arrangements-handling-conflicts-interests-european-medicines-agency-scientific-meetings_en.pdf"},
    {"id":"37422","name":"Standard operating procedure for handling invoice payment within deadline of 30 days (standard payments)","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2013-01-03T17:00:01Z","last_updated_date":"2015-02-17T14:00:00Z","reference_number":"SOP/EMA/0135","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-invoice-payment-within-deadline-30-days-standard-payments_en.pdf"},
    {"id":"37781","name":"Standard operating procedure on Article 30 referrals triggered by the European Commission or a Member State","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-06T11:40:00Z","last_updated_date":"2012-09-06T11:40:00Z","reference_number":"SOP/H/3215","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-article-30-referrals-triggered-european-commission-or-member-state_en.pdf"},
    {"id":"37828","name":"Standard operating procedure for processing of parallel distribution notifications of a change","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-28T12:00:00Z","last_updated_date":"2012-09-28T12:00:00Z","reference_number":"SOP/INSP/2039","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-processing-parallel-distribution-notifications-change_en.pdf"},
    {"id":"38750","name":"Standard operating procedure for preparation of an initial European Public Assessment Report (EPAR) for a veterinary medicinal product following positive or negative opinion","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-10-01T02:00:00Z","last_updated_date":"2015-06-17T13:15:00Z","reference_number":"SOP/V/4037","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-preparation-initial-european-public-assessment-report-epar-veterinary-medicinal-product-following-positive-or-negative-opinion_en.pdf"},
    {"id":"39545","name":"Standard operating procedure for processing of annual update notifications for parallel distribution","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2015-05-08T18:20:00Z","last_updated_date":"2015-05-08T18:20:00Z","reference_number":"SOP/INS/2058","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-processing-annual-update-notifications-parallel-distribution_en.pdf"},
    {"id":"39694","name":"Standard operating procedure for evaluation of veterinary medicinal products containing or consisting of genetically modified organisms","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2007-05-16T02:00:00Z","last_updated_date":"2015-05-07T13:10:00Z","reference_number":"SOP/V/4012","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-evaluation-veterinary-medicinal-products-containing-or-consisting-genetically-modified-organisms_en.pdf"},
    {"id":"39855","name":"Standard operating procedure for co-ordination of pharmacovigilance inspections","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-28T12:00:00Z","last_updated_date":"2012-09-28T12:00:00Z","reference_number":"SOP/INSP/2045","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-co-ordination-pharmacovigilance-inspections_en.pdf"},
    {"id":"40391","name":"Standard operating procedure for tracking and handling in SIAMED of SDA post-authorisation measures for centrally authorised products","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2017-04-11T19:10:00Z","last_updated_date":"2017-04-11T19:10:00Z","reference_number":"SOP/H/3441","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-tracking-and-handling-siamed-sda-post-authorisation-measures-centrally-authorised-products_en.pdf"},
    {"id":"40856","name":"Standard operating procedure on the organisation of Name Review Group meetings","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2011-04-18T02:00:00Z","last_updated_date":"2011-04-18T02:00:00Z","reference_number":"SOP/H/3213","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-organisation-name-review-group-meetings_en.pdf"},
    {"id":"41165","name":"Standard operating procedure for CHMP rapporteur / co-rapporteur appointment for Community procedures","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2009-02-11T01:00:00Z","last_updated_date":"2012-09-26T18:36:00Z","reference_number":"SOP/H/3176","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-chmp-rapporteur-co-rapporteur-appointment-community-procedures_en.pdf"},
    {"id":"41332","name":"Standard operating procedure for handling of information from external sources disclosing alleged improprieties concerning EMA activities on the authorisation, supervision and maintenance of medicinal products for human ...","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2017-07-17T14:00:00Z","last_updated_date":"2017-07-17T14:00:00Z","reference_number":"SOP/EMA/0129","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-handling-information-external-sources-disclosing-alleged-improprieties-concerning-ema-activities-authorisation-supervision-and-maintenance-medicinal-products-human_en.pdf"},
    {"id":"60559","name":"Standard operating procedure for evaluation procedure for veterinary medicines initial marketing authorisation procedures and extensions","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2018-01-19T12:58:00Z","last_updated_date":"2018-10-01T10:58:00Z","reference_number":"SOP/V/4110","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-evaluation-procedure-veterinary-medicines-initial-marketing-authorisation-procedures-and-extensions_en.pdf"},
    {"id":"66171","name":"Standard operating procedure for processing of requests for fee reduction falling under paragraph 5 of Article 6 of Regulation (EU) 2024/568","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2024-12-18T15:48:00Z","last_updated_date":"2026-03-17T17:29:00Z","reference_number":"SOP/EMA/0028","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-processing-requests-fee-reduction-falling-under-paragraph-5-article-6-regulation-eu-2024-568_en.pdf"},
    {"id":"68353","name":"Standard operating procedure for validation, publication, and maintenance of real-world data sources and studies in the HMA-EMA RWD Catalogues","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2025-05-19T16:02:44Z","last_updated_date":"2025-05-19T16:02:44Z","reference_number":"EMA/467789/2024","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-validation-publication-maintenance-real-world-data-sources-studies-hma-ema-rwd-catalogues_en.pdf"},
    {"id":"73972","name":"Standard operating procedure for the contribution to the 3-yearly JIACRA reports","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-04T11:20:18Z","last_updated_date":"2026-06-04T11:20:18Z","reference_number":"SOP/V/4161","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-contribution-3-yearly-jiacra-reports_en.pdf"},
    {"id":"73992","name":"Standard operating procedure for the preparation of ESUAvet annual reports","type":"sop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-05T14:56:43Z","last_updated_date":"2026-06-05T14:56:43Z","reference_number":"SOP/V/4160","document_url":"https://www.ema.europa.eu/en/documents/sop/standard-operating-procedure-preparation-esuavet-annual-reports_en.pdf"},
    {"id":"2439","name":"CVMP post-authorisation summary of positive opinion for Zolvix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-12-10T01:00:00Z","last_updated_date":"2010-12-10T01:00:00Z","reference_number":"EMA/CVMP/509583/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-zolvix_en.pdf"},
    {"id":"2513","name":"CHMP post-authorisation summary of positive opinion for Revlimid","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-01-29T00:00:00Z","last_updated_date":"2016-01-29T00:00:00Z","reference_number":"EMA/CHMP/37179/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revlimid_en.pdf"},
    {"id":"2599","name":"CHMP post-authorisation summary of positive opinion for ProQuad","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T13:00:00Z","last_updated_date":"2012-03-16T13:00:00Z","reference_number":"EMA/CHMP/168236/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-proquad_en.pdf"},
    {"id":"2697","name":"CHMP post-authorisation summary of positive opinion for Xyrem","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-03-24T01:00:00Z","last_updated_date":"2011-03-24T01:00:00Z","reference_number":"EMA/217136/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xyrem_en.pdf"},
    {"id":"2737","name":"CHMP post authorisation summary of positive opinion for Xeristar on 22 October 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-06-26T02:00:00Z","last_updated_date":"2008-06-26T02:00:00Z","reference_number":"EMEA/CHMP/676041/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xeristar-22-october-2009_en.pdf"},
    {"id":"2814","name":"CHMP post-authorisation summary of positive opinion for Ilaris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-01-18T13:00:00Z","reference_number":"EMA/CHMP/8612/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ilaris_en.pdf"},
    {"id":"2888","name":"Committee for medicinal products for human use  post-authorisation summary of positive opinion for Revatio on 29 May 2009","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2005-05-29T02:00:00Z","last_updated_date":"2005-05-29T02:00:00Z","reference_number":"EMEA/CHMP/323291/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-revatio-29-may-2009_en.pdf"},
    {"id":"2909","name":"CHMP post-authorisation summary of positive opinion for Retacrit","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/484149/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-retacrit_en.pdf"},
    {"id":"2914","name":"CHMP post-authorisation summary of positive opinion for Gardasil on 30 May 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"EMEA/CHMP/280871/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gardasil-30-may-2008_en.pdf"},
    {"id":"3019","name":"CHMP post-authorisation summary of positive opinion for Revolade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"EMA/CHMP/722540/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revolade_en.pdf"},
    {"id":"3063","name":"CHMP post-authorisation summary of positive opinion for Harvoni","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"EMA/384974/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-harvoni_en.pdf"},
    {"id":"3088","name":"CHMP post-authorisation summary of positive opinion for Sprycel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/CHMP/646979/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sprycel_en.pdf"},
    {"id":"3151","name":"CVMP post-authorisation summary of positive opinion for Porcilis PCV","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-12-11T01:09:21Z","last_updated_date":"2009-12-11T01:09:21Z","reference_number":"EMA/CVMP/802298/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-porcilis-pcv_en.pdf"},
    {"id":"3161","name":"CHMP post-authorisation summary of positive opinion for Stelara","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/CHMP/435265/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stelara_en.pdf"},
    {"id":"3165","name":"CHMP post-authorisation summary of positive opinion for Sprycel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T14:00:00Z","last_updated_date":"2018-04-27T14:00:00Z","reference_number":"EMA/CHMP/243108/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sprycel_en.pdf-0"},
    {"id":"3202","name":"CHMP post-authorisation summary of positive opinion for Resolor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/CHMP/234861/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-resolor_en.pdf"},
    {"id":"3244","name":"CHMP post-authorisation summary of positive opinion for Edarbi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/569644/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-edarbi_en.pdf"},
    {"id":"3280","name":"CHMP post-authorisation summary of positive opinion for Eylea","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/284732/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eylea_en.pdf"},
    {"id":"3310","name":"CVMP post-authorisation summary of positive opinion for Convenia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-12-11T01:09:21Z","last_updated_date":"2009-12-11T01:09:21Z","reference_number":"EMA/CVMP/734100/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-convenia_en.pdf"},
    {"id":"3313","name":"CHMP post-authorisation summary of positive opinion for Prolia (II-68)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T14:00:00Z","last_updated_date":"2018-04-27T14:00:00Z","reference_number":"EMA/CHMP/256922/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prolia-ii-68_en.pdf"},
    {"id":"3322","name":"CHMP post-authorisation summary of positive opinion for Humira on 24 July 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-07-28T02:00:00Z","last_updated_date":"2008-07-28T02:00:00Z","reference_number":"EMEA/CHMP/384125/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira-24-july-2008_en.pdf"},
    {"id":"3375","name":"CHMP post-authorisation summary of positive opinion for Synflorix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/497733/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-synflorix_en.pdf"},
    {"id":"3493","name":"Committee for medicinal products for veterinary use summary of opinion: Aivlosin 42.5 mg/g oral powder for pigs: International Non-proprietary Names (INN): Tylvalosin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-10-16T03:09:21Z","last_updated_date":"2009-10-16T03:09:21Z","reference_number":"EMEA/CVMP/632577/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-veterinary-use-summary-opinion-aivlosin-425-mgg-oral-powder-pigs-international-non-proprietary-names-inn-tylvalosin_en.pdf"},
    {"id":"3505","name":"CHMP post-authorisation summary of positive opinion for Sutent","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/655737/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sutent_en.pdf"},
    {"id":"3513","name":"CVMP post-authorisation summary of positive opinion for Metacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-02-13T01:00:00Z","last_updated_date":"2015-02-13T01:00:00Z","reference_number":"EMA/CVMP/736376/2014 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-metacam_en.pdf"},
    {"id":"3542","name":"CHMP post-authorisation summary of positive opinion for Alli on 23 October 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:09:21Z","last_updated_date":"2008-10-23T02:09:21Z","reference_number":"EMEA/CHMP/506083/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-alli-23-october-2008_en.pdf"}    {"id":"3626","name":"CHMP post-authorisation summary of positive opinion for Vectibix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/494254/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vectibix_en.pdf"},
    {"id":"3630","name":"CVMP post-authorisation summary of positive opinion for Poulvac E. coli","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-19T01:00:00Z","last_updated_date":"2016-02-19T01:00:00Z","reference_number":"EMA/CVMP/45330/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-poulvac-e-coli_en.pdf"},
    {"id":"3641","name":"CHMP post-authorisation summary of positive opinion for Volibris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/CHMP/605508/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-volibris_en.pdf"},
    {"id":"3695","name":"CHMP post-authorisation summary of positive opinion for Vidaza-II-30","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/631451/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vidaza-ii-30_en.pdf"},
    {"id":"3740","name":"CHMP post-authorisation summary of positive opinion for Mabthera on 23 July 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/455429/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera-23-july-2009_en.pdf"},
    {"id":"3828","name":"CVMP post-authorisation summary of positive opinion for Aivlosin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/CVMP/231759/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-aivlosin_en.pdf"},
    {"id":"3970","name":"CHMP post-authorisation summary of positive opinion for Soliris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/CHMP/94647/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-soliris_en.pdf"},
    {"id":"4059","name":"CVMP post-authorisation summary of positive opinion for Contacera","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-12-13T17:00:00Z","last_updated_date":"2013-12-13T17:00:00Z","reference_number":"EMA/CVMP/694589/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-contacera_en.pdf"},
    {"id":"4079","name":"CHMP post-authorisation summary of positive opinion for Kineret","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2018-02-23T01:00:00Z","reference_number":"EMA/84249/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kineret_en.pdf"},
    {"id":"4086","name":"CHMP post-authorisation summary of positive opinion for Tesavel of 23 April 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/240352/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tesavel-23-april-2009_en.pdf"},
    {"id":"4102","name":"Questions and answers on the recommendation for the refusal of a change to the marketing authorisation for Avastin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/CHMP/746208/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-avastin_sv.pdf"}},
    {"id":"4207","name":"CHMP post-authorisation summary of positive opinion for Invega","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-10-01T02:00:00Z","last_updated_date":"2010-10-01T02:00:00Z","reference_number":"EMA/CHMP/444944/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-invega_en.pdf"},
    {"id":"4224","name":"CHMP summary of positive opinion for Lenvima","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-03-27T01:00:00Z","reference_number":"EMA/CHMP/156546/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-lenvima_en.pdf"},
    {"id":"4238","name":"CHMP post-authorisation summary of positive opinion for Mabthera on 22 January 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-01-23T01:00:00Z","last_updated_date":"2009-01-23T01:00:00Z","reference_number":"EMEA/CHMP/48585/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera-22-january-2009_en.pdf"},
    {"id":"4248","name":"CHMP post-authorisation summary of positive opinion for Inductos","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2017-06-15T14:00:00Z","reference_number":"EMA/CHMP/696168/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-inductos_en.pdf"},
    {"id":"4411","name":"Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Avaglim on 24 January 2008","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2008-01-24T00:09:21Z","reference_number":"EMEA/CHMP/42762/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-avaglim-24-january-2008_en.pdf"},
    {"id":"4465","name":"CHMP post-authorisation summary of positive opinion for Pradaxa","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/804086/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pradaxa_en.pdf"},
    {"id":"4513","name":"CHMP post-authorisation positive summary of opinion for Pradaxa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"EMA/337034/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-positive-summary-opinion-pradaxa_en.pdf"},
    {"id":"4630","name":"CHMP post-authorisation summary of positive opinion for Vepacel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T02:00:00Z","last_updated_date":"2013-10-25T02:00:00Z","reference_number":"EMA/CHMP/648050/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vepacel_en.pdf"},
    {"id":"4652","name":"CHMP post-authorisation summary of positive opinion for Erbitux","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/702774/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-erbitux_en.pdf"},
    {"id":"4658","name":"CVMP post-authorisation summary of negative opinion for Draxxin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-05-20T02:00:00Z","last_updated_date":"2016-05-20T02:00:00Z","reference_number":"EMA/CVMP/289817/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-negative-opinion-draxxin_en.pdf"},
    {"id":"4703","name":"CHMP post-authorisation summary of positive opinion for Tygacil","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/CHMP/262234/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tygacil_en.pdf"},
    {"id":"4881","name":"CVMP post-authorisation summary of positive opinion for Circovac","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-10-15T02:00:00Z","last_updated_date":"2010-10-15T02:00:00Z","reference_number":"EMA/CVMP/223810/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-circovac_en.pdf"},
    {"id":"4883","name":"CHMP post-authorisation summary of positive opinion for Kalydeco","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/365663/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco_en.pdf"},
    {"id":"5032","name":"CHMP post-authorisation summary of positive opinion for Victoza","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/270952/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-victoza_en.pdf"},
    {"id":"5039","name":"CHMP post-authorisation summary of positive opinion for Orencia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-05-21T02:00:00Z","last_updated_date":"2010-05-21T02:00:00Z","reference_number":"EMA/CHMP/316572/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-orencia_en.pdf"},
    {"id":"5105","name":"CHMP post-authorisation summary of positive opinion for Erbitux on 30 May 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-05-30T02:09:21Z","last_updated_date":"2008-05-30T02:09:21Z","reference_number":"EMEA/CHMP/280402/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-erbitux-30-may-2008_en.pdf"},
    {"id":"5114","name":"CHMP post-authorisation summary of positive opinion for Cervarix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/CHMP/101703/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cervarix_en.pdf"},
    {"id":"5139","name":"CHMP post-authorisation summary of positive opinion for Rebetol","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2023-11-07T02:00:00Z","reference_number":"EMEA/CHMP/609356/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rebetol_en.pdf"},
    {"id":"5243","name":"CHMP post-authorisation summary of positive opinion for Translarna (II-37)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2025-04-16T14:00:00Z","reference_number":"EMA/304289/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-translarna-ii-37_en.pdf"},
    {"id":"5499","name":"CVMP post-authorisation summary of positive opinion for Equioxx","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-10-16T02:09:00Z","last_updated_date":"2009-10-16T02:09:00Z","reference_number":"EMEA/CVMP/612607/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-equioxx_en.pdf"},
    {"id":"5676","name":"CHMP Post-authorisation summary of positive opinion for Trajenta (CHMP)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T10:38:00Z","last_updated_date":"2016-12-16T10:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trajenta-chmp_en.pdf"},
    {"id":"5794","name":"CHMP post-authorisation summary of positive opinion for Neoclarityn on 21 February 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/CHMP/86517/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-neoclarityn-21-february-2008_en.pdf"},
    {"id":"5814","name":"CHMP post-authorisation summary of positive opinion for Mimpara (X-55-G)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T14:00:00Z","last_updated_date":"2026-05-20T14:00:00Z","reference_number":"EMA/CHMP/379833/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mimpara-x-55-g_en.pdf"},
    {"id":"5840","name":"CHMP post-authorisation summary of positive opinion for Erbitux","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T11:14:00Z","last_updated_date":"2011-11-18T11:14:00Z","reference_number":"EMA/882977/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-erbitux_en.pdf-0"},
    {"id":"5936","name":"CVMP post-authorisation summary of positive opinion for Improvac","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2011-07-15T02:00:00Z","reference_number":"EMA/CVMP/559849/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-improvac_en.pdf"},
    {"id":"5944","name":"CHMP post-authorisation summary of positive opinion for Opdivo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/231518/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo_en.pdf"},
    {"id":"5976","name":"CHMP post-authorisation summary of positive opinion for Kinzalkomb","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/CHMP/261191/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kinzalkomb_en.pdf"},
    {"id":"5990","name":"CVMP post-authorisation summary of positive opinion for Procox","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-09T16:30:00Z","last_updated_date":"2012-11-09T16:30:00Z","reference_number":"EMA/CVMP/584720/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-procox_en.pdf"},
    {"id":"6014","name":"CHMP post-authorisation summary of positive opinion for Janumet of 23 April 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/240520/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-janumet-23-april-2009_en.pdf"},
    {"id":"6038","name":"CHMP post-authorisation summary of positive opinion for Abilify on 24 April 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/156983/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abilify-24-april-2008_en.pdf"},
    {"id":"6127","name":"CVMP post-authorisation summary of positive opinion for Metacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/CVMP/158720/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-metacam_en.pdf-0"},
    {"id":"6161","name":"CHMP post-authorisation summary of positive opinion for Benlysta (X-46-G)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/CHMP/601079/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-benlysta-x-46-g_en.pdf"},
    {"id":"6173","name":"CHMP post-authorisation summary of positive opinion for Forsteo on 21 February 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/86990/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-forsteo-21-february-2008_en.pdf"},
    {"id":"6227","name":"CHMP post-authorisation summary of positive opinion for Efficib of 23 April 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/240565/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-efficib-23-april-2009_en.pdf"},
    {"id":"6262","name":"CHMP post-authorisation summary of positive opinion for Cymbalta on 22 October 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/CHMP/656849/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cymbalta-22-october-2009_en.pdf"},
    {"id":"6273","name":"CHMP post-authorisation summary of positive opinion for Busilvex","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2023-08-04T12:53:00Z","reference_number":"EMA/CHMP/450097/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-busilvex_en.pdf"},
    {"id":"6356","name":"CHMP post-authorisation summary of positive opinion for Yervoy (II-55)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T14:00:00Z","last_updated_date":"2018-04-27T14:00:00Z","reference_number":"EMA/CHMP/201590/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yervoy-ii-55_en.pdf"},
    {"id":"6401","name":"CHMP post-authorisation summary of positive opinion for Rebif","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T11:21:00Z","last_updated_date":"2011-11-18T11:21:00Z","reference_number":"EMA/900110/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rebif_en.pdf"},
    {"id":"6450","name":"CHMP post-authorisation summary of positive opinion for Tarceva","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tarceva_en.pdf"},
    {"id":"6458","name":"CHMP post-authorisation summary of positive opinion for Avastin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/190702/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avastin_en.pdf"},
    {"id":"6464","name":"CHMP post-authorisation summary of positive opinion for Nimenrix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2016-11-11T13:00:00Z","reference_number":"EMA/CHMP/512584/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nimenrix_en.pdf"},
    {"id":"6500","name":"CHMP post-authorisation summary of positive opinion for RotaTeq","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/CHMP/49745/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rotateq_en.pdf"},
    {"id":"6546","name":"CHMP post-authorisation summary of positive opinion for Osseor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/311245/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-osseor_en.pdf"},
    {"id":"6548","name":"CHMP post-authorisation summary of positive opinion for Truvada","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T11:00:00Z","last_updated_date":"2017-02-24T11:00:00Z","reference_number":"EMA/CHMP/103160/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-truvada_en.pdf"},
    {"id":"6564","name":"CHMP post-authorisation summary of positive opinion for Herceptin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/822467/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-herceptin_en.pdf"},
    {"id":"6581","name":"CHMP summary of positive opinion for Tasigna","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMA/CHMP/462567/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-tasigna_en.pdf"},
    {"id":"6589","name":"CVMP post-authorisation summary of positive opinion for Credelio","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-04-20T17:08:00Z","last_updated_date":"2018-04-20T17:08:00Z","reference_number":"EMA/CVMP/175952/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-credelio_en.pdf"},
    {"id":"6608","name":"CHMP post-authorisation summary of positive opinion for Truvada","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/488317/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-truvada_en.pdf-0"},
    {"id":"6640","name":"CHMP post-authorisation summary of positive opinion for Arcalyst","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:09:21Z","last_updated_date":"2009-07-23T02:09:21Z","reference_number":"EMEA/CHMP/346815/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-arcalyst_en.pdf"},
    {"id":"6895","name":"CHMP post-authorisation summary of positive opinion for MicardisPlus","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/CHMP/261191/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-micardisplus_en.pdf"},
    {"id":"7030","name":"CHMP post-authorisation summary of positive opinion for Xiliarx","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T01:00:00Z","last_updated_date":"2011-12-16T01:00:00Z","reference_number":"EMA/CHMP/975250/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xiliarx_en.pdf"},
    {"id":"7166","name":"CHMP post-authorisation summary of positive opinion for Adenuric","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/CHMP/79455/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adenuric_en.pdf"},
    {"id":"7297","name":"Committee for medicinal products for human use, post-authorisation summary of positive opinion for Mabthera on 13 December 2007","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2007-12-20T01:00:00Z","last_updated_date":"2007-12-20T01:00:00Z","reference_number":"EMEA/CHMP/572100/2007","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-mabthera-13-december-2007_en.pdf"},
    {"id":"7300","name":"CHMP post-authorisation summary of positive opinion for Trisenox","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-10-13T14:00:00Z","last_updated_date":"2016-10-13T14:00:00Z","reference_number":"EMA/CHMP/625736/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trisenox_en.pdf"},
    {"id":"7365","name":"Questions and answers on the recommendation for the refusal of a change to the marketing authorisation for Taxotere / Docetaxel Winthrop","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:09:21Z","last_updated_date":"2008-07-24T02:09:21Z","reference_number":"EMEA/384759/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-taxotere-docetaxel-winthrop_en.pdf"},
    {"id":"7406","name":"CVMP post-authorisation summary of positive opinion for Metacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"EMA/CVMP/371866/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-metacam_en.pdf-1"},
    {"id":"7428","name":"CVMP post-authorisation summary of positive opinion for Zactran","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"EMA/CVMP/749682/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-zactran_en.pdf"},
    {"id":"7665","name":"CHMP post-authorisation summary of positive opinion for Edurant","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/CHMP/679659/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-edurant_en.pdf"},
    {"id":"7693","name":"CHMP post-authorisation summary of positive opinion for Torisel on 23 July 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/464665/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-torisel-23-july-2009_en.pdf"},
    {"id":"7896","name":"CHMP post-authorisation summary of positive opinion for Enbrel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/366512/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enbrel_en.pdf"},
    {"id":"7919","name":"CHMP post-authorisation summary of positive opinion for HyQvia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/37597/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-hyqvia_en.pdf"},
    {"id":"8058","name":"CHMP post-authorisation summary of positive opinion for Telzir","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2026-01-05T01:00:00Z","reference_number":"EMA/156121/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-telzir_en.pdf"},
    {"id":"8190","name":"CHMP post-authorisation summary of positive opinion for Isentress","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2018-03-06T12:07:00Z","reference_number":"EMA/CHMP/87645/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-isentress_en.pdf"},
    {"id":"8192","name":"CHMP post-authorisation summary of positive opinion for Baraclude","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/CHMP/56057/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-baraclude_en.pdf"},
    {"id":"8321","name":"CHMP post-authorisation summary of positive opinion for Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/CHMP/332974/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals_en.pdf"},
    {"id":"8368","name":"CHMP post-authorisation summary of positive opinion for Micardis on 22 October 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/CHMP/676934/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-micardis-22-october-2009_en.pdf"},
    {"id":"8386","name":"CVMP post authorisation positive summary of opinion for Meloxidyl","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2010-06-18T02:00:00Z","reference_number":"EMA/CVMP/342846/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-positive-summary-opinion-meloxidyl_en.pdf"},
    {"id":"8393","name":"CVMP post-authorisation summary of positive opinion for Rheumocam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-11-12T01:00:00Z","last_updated_date":"2010-11-12T01:00:00Z","reference_number":"EMA/CVMP/147814/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-rheumocam_en.pdf"},
    {"id":"8396","name":"CHMP post-authorisation summary of positive opinion for ellaOne","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2014-11-21T01:00:00Z","reference_number":"EMA/CHMP/717569/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ellaone_en.pdf"},
    {"id":"8405","name":"CHMP post-authorisation summary of positive opinion for Apidra on 24 April 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-04-24T02:09:21Z","last_updated_date":"2008-04-24T02:09:21Z","reference_number":"EMEA/CHMP/174791/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-apidra-24-april-2008_en.pdf"},
    {"id":"8445","name":"CHMP post-authorisation summary of positive opinion for Halaven","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/CHMP/312178/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-halaven_en.pdf"},
    {"id":"8503","name":"CHMP post-authorisation summary of positive opinion for Xgeva (II-55)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T13:00:00Z","last_updated_date":"2018-02-23T13:00:00Z","reference_number":"EMA/86370/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xgeva-ii-55_en.pdf"},
    {"id":"8630","name":"CHMP post-authorisation summary of positive opinion for Tresiba","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/CHMP/745432/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tresiba_en.pdf"},
    {"id":"8655","name":"CHMP post-authorisation summary of positive opinion for TachoSil on 18 December 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2005-12-18T01:00:00Z","last_updated_date":"2005-12-18T01:00:00Z","reference_number":"EMEA/677195/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tachosil-18-december-2008_en.pdf"},
    {"id":"8711","name":"CHMP post-authorisation summary of positive opinion for Darzalex (II-11)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/CHMP/501485/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-darzalex-ii-11_en.pdf"},
    {"id":"8737","name":"CHMP post authorisation summary of positive opinion for ViraferonPeg on 24 September 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2021-01-22T02:00:00Z","reference_number":"EMEA/CHMP/612232/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viraferonpeg-24-september-2009_en.pdf"},
    {"id":"8750","name":"CVMP post-authorisation summary of positive opinion for Rheumocam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-14T02:00:00Z","last_updated_date":"2012-09-14T02:00:00Z","reference_number":"EMA/CVMP/396534/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-rheumocam_en.pdf-0"},
    {"id":"8763","name":"CHMP post-authorisation summary of positive opinion for Galvus","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/600948/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-galvus_en.pdf"},
    {"id":"8767","name":"CHMP post-authorisation summary of positive opinion for Alimta on 29 May 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-05-29T02:09:21Z","last_updated_date":"2009-05-29T02:09:21Z","reference_number":"EMEA/CHMP/331827/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-alimta-29-may-2009_en.pdf"},
    {"id":"8822","name":"CHMP post-authorisation summary of positive opinion for Binocrit","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/499769/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-binocrit_en.pdf"},
    {"id":"8905","name":"CHMP post-authorisation summary of positive opinion for Opdivo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/606649/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo_en.pdf-0"},
    {"id":"9067","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/228011/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf"},
    {"id":"9091","name":"CHMP post-authorisation summary of positive opinion for Voncento","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T14:00:00Z","last_updated_date":"2015-06-26T14:00:00Z","reference_number":"EMA/CHMP/420571/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-voncento_en.pdf"},
    {"id":"9098","name":"CHMP post-authorisation summary of positive opinion for Votubia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/609118/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-votubia_en.pdf"},
    {"id":"9168","name":"CHMP post-authorisation summary of positive opinion for Ozurdex","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-07-25T02:00:00Z","reference_number":"EMA/CHMP/430193/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ozurdex_en.pdf"},
    {"id":"9289","name":"CHMP post-authorisation summary of positive opinion for Optisulin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2012-04-20T02:00:00Z","reference_number":"EMA/CHMP/184676/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-optisulin_en.pdf"},
    {"id":"9347","name":"CHMP post-authorisation summary of positive opinion for Evicel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2024-08-02T14:00:00Z","reference_number":"EMA/CHMP/393917/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-evicel_en.pdf"},
    {"id":"9514","name":"CHMP post-authorisation summary of positive opinion for Imbruvica","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/493040/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imbruvica_en.pdf"},
    {"id":"9553","name":"CHMP post-authorisation summary of positive opinion for Thyrogen","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/CHMP/745393/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-thyrogen_en.pdf"}    {"id":"9635","name":"CHMP post-authorisation summary of positive opinion for Protelos","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/313022/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-protelos_en.pdf"},
    {"id":"9655","name":"CHMP post-authorisation summary of positive opinion for Viread","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2010-07-23T02:00:00Z","reference_number":"EMA/CHMP/473630/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viread_en.pdf"},
    {"id":"9679","name":"CVMP post-authorisation summary of positive opinion for Suprelorin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-04-16T02:00:00Z","last_updated_date":"2010-04-16T02:00:00Z","reference_number":"EMA/CVMP/149474/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-suprelorin_en.pdf"},
    {"id":"9683","name":"CHMP post-authorisation summary of positive opinion for Avastin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/295853/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avastin_en.pdf-0"},
    {"id":"9711","name":"CHMP post-authorisation summary of positive opinion for Velmetia of 23 April 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/240552/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velmetia-23-april-2009_en.pdf"},
    {"id":"9787","name":"CHMP post-authorisation summary of positive opinion for Remicade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T11:00:00Z","last_updated_date":"2012-01-20T11:00:00Z","reference_number":"EMA/CHMP/31386/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-remicade_en.pdf"},
    {"id":"9828","name":"CHMP post-authorisation summary of positive opinion for Simponi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/295989/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-simponi_en.pdf"},
    {"id":"9833","name":"Questions and answers on recommendation for the refusal of a change to the marketing authorisation for Cymbalta / Xeristar","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:00:00Z","last_updated_date":"2021-06-22T14:29:00Z","reference_number":"EMEA/551181/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_sv.pdf"}},
    {"id":"9908","name":"CVMP post-authorisation summary of positive opinion for ZactranIII","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"EMA/CVMP/763148/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-zactraniii_en.pdf"},
    {"id":"9927","name":"CHMP post-authorisation summary of positive opinion for Rebetol","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2023-11-07T01:00:00Z","reference_number":"EMA/CHMP/114050/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rebetol_en.pdf-0"},
    {"id":"10127","name":"CVMP post-authorisation summary of positive opinion for Draxxin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/CVMP/233183/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-draxxin_en.pdf"},
    {"id":"10129","name":"CVMP post-authorisation summary of positive opinion for BTVPUR AlSap 1-8","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-19T01:00:00Z","last_updated_date":"2016-02-19T01:00:00Z","reference_number":"EMEA/CVMP/66986/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-btvpur-alsap-1-8_en.pdf"},
    {"id":"10169","name":"CVMP post-authorisation summary of positive opinion for Cerenia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T18:00:00Z","last_updated_date":"2013-07-19T18:00:00Z","reference_number":"EMA/CVMP/322884/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-cerenia_en.pdf"},
    {"id":"10188","name":"CHMP post-authorisation summary of positive opinion for Xiapex","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2020-03-02T01:00:00Z","reference_number":"EMA/CHMP/747440/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xiapex_en.pdf"},
    {"id":"10195","name":"CVMP post-authorisation summary of positive opinion for Panacur AquaSol (II/0015)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-01-19T01:00:00Z","last_updated_date":"2018-01-19T01:00:00Z","reference_number":"EMA/CVMP/834159/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-panacur-aquasol-ii0015_en.pdf"},
    {"id":"10307","name":"CHMP summary of positive opinion for Isentress (X-59)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T18:35:00Z","last_updated_date":"2017-05-19T18:35:00Z","reference_number":"EMA/301751/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-isentress-x-59_en.pdf"},
    {"id":"10340","name":"CVMP post-authorisation summary of positive opinion for Equilis Prequenza Te","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T17:00:00Z","last_updated_date":"2013-02-08T17:00:00Z","reference_number":"EMA/CVMP/35976/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-equilis-prequenza-te_en.pdf"},
    {"id":"10351","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Bronchitol","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/474477/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-recommendation-refusal-marketing-authorisation-bronchitol_en.pdf"},
    {"id":"10357","name":"CVMP post-authorisation summary of positive opinion for Inflacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-06-15T02:00:00Z","last_updated_date":"2012-06-15T02:00:00Z","reference_number":"EMA/CVMP/310571/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-inflacam_en.pdf"},
    {"id":"10376","name":"CHMP post-authorisation summary of positive opinion for Esmya","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/CHMP/245897/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-esmya_en.pdf"},
    {"id":"10386","name":"CHMP post-authorisation summary of positive opinion for Pradaxa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-06-04T02:00:00Z","reference_number":"EMA/337053/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pradaxa_en.pdf-0"},
    {"id":"10453","name":"CHMP post authorisation summary of positive opinion for  Zavesca on 18 December 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/CHMP/335965/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zavesca-18-december-2008_en.pdf"},
    {"id":"10473","name":"CVMP post-authorisation summary of positive opinion for Econor","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T17:00:00Z","last_updated_date":"2025-09-04T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-econor_en.pdf"},
    {"id":"10482","name":"CHMP post-authorisation summary of positive opinion for Votubia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/CHMP/734936/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-votubia_en.pdf-0"},
    {"id":"10497","name":"CHMP post-authorisation summary of positive opinion for Jakavi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"EMA/CHMP/42526/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jakavi_en.pdf"},
    {"id":"10572","name":"CHMP post-authorisation summary of positive opinion for Revestive","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/178344/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revestive_en.pdf"},
    {"id":"10589","name":"CHMP post-authorisation summary of positive opinion for Telzir on 19 February 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2026-01-05T01:00:00Z","reference_number":"EMEA/109046/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-telzir-19-february-2009_en.pdf"},
    {"id":"10620","name":"CHMP post-authorisation summary of positive opinion for Revlimid (II-89G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/CHMP/35623/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revlimid-ii-89g_en.pdf"},
    {"id":"10643","name":"CHMP post-authorisation summary of positive opinion for Bondenza","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T00:09:21Z","last_updated_date":"2013-05-13T19:00:00Z","reference_number":"EMA/821569/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bondenza_en.pdf"},
    {"id":"10655","name":"CHMP post-authorisation summary of positive opinion for Tresiba","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"EMA/CHMP/164154/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tresiba_en.pdf-0"},
    {"id":"10826","name":"CHMP post-authorisation summary of positive opinion for Byetta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/CHMP/113061/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-byetta_en.pdf"},
    {"id":"10876","name":"CHMP post-authorisation summary of positive opinion for Januvia on 25 June 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/368573/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-januvia-25-june-2009_en.pdf"},
    {"id":"11021","name":"CVMP post-authorisation summary of positive opinion for Loxicom","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2011-07-15T02:00:00Z","reference_number":"EMA/CVMP/63405/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-loxicom_en.pdf"},
    {"id":"11055","name":"CHMP post-authorisation summary of positive opinion for Jalra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/600945/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jalra_en.pdf"},
    {"id":"11139","name":"CHMP post-authorisation summary of positive opinion for Pritor","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T02:00:00Z","last_updated_date":"2013-04-26T02:00:00Z","reference_number":"EMA/CHMP/261191/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pritor_en.pdf"},
    {"id":"11210","name":"CHMP post-authorisation summary of positive opinion for Gilenya","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/243755/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gilenya_en.pdf"},
    {"id":"11221","name":"CHMP post authorisation summary of positive opinion for PegIntron on 24 September 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2021-06-03T02:00:00Z","reference_number":"EMEA/CHMP/609368/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pegintron-24-september-2009_en.pdf"},
    {"id":"11241","name":"CVMP post-authorisation summary of positive opinion for Advocate (II/0039/G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-01-19T01:00:00Z","last_updated_date":"2018-01-19T01:00:00Z","reference_number":"EMA/CVMP/825952/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-advocate-ii0039g_en.pdf"},
    {"id":"11271","name":"CHMP post-authorisation summary of positive opinion for Pradaxa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/304146/2011  ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pradaxa_en.pdf-1"},
    {"id":"11329","name":"CHMP post-authorisation summary of positive opinion for Ameluz","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/CHMP/813686/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ameluz_en.pdf"},
    {"id":"11393","name":"CHMP post-authorisation summary of positive opinion for Kalydeco","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/619312/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco_en.pdf-0"},
    {"id":"11420","name":"CHMP post-authorisation summary of positive opinion for Soliris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/CHMP/179438/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-soliris_en.pdf-0"},
    {"id":"11440","name":"CHMP post-authorisation summary of positive opinion for Orencia","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T14:00:00Z","last_updated_date":"2017-06-23T14:00:00Z","reference_number":"EMA/CHMP/368672/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-orencia_en.pdf-0"},
    {"id":"11469","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/CHMP/120503/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-0"},
    {"id":"11470","name":"CHMP post-authorisation summary of positive opinion for Adcetris (II-48)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/CHMP/706305/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adcetris-ii-48_en.pdf"},
    {"id":"11544","name":"CHMP post-authorisation summary of positive opinion for Xarelto (II-58)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/515065/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xarelto-ii-58_en.pdf"},
    {"id":"11647","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/CHMP/82703/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-1"},
    {"id":"11784","name":"CHMP post-authorisation summary of positive opinion for Irbesartan Zentiva","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/388301/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-irbesartan-zentiva_en.pdf"},
    {"id":"11789","name":"CHMP post-authorisation summary of positive opinion for Epoetin alfa Hexal","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/503858/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-epoetin-alfa-hexal_en.pdf"},
    {"id":"11818","name":"CHMP post-authorisation summary of positive opinion for Zontivity (II/0005)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2017-09-20T02:00:00Z","reference_number":"EMA/CHMP/420912/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zontivity-ii0005_en.pdf"},
    {"id":"11842","name":"CHMP post-authorisation summary of positive opinion for Opdivo (II/0002)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/CHMP/148121/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ii0002_en.pdf"},
    {"id":"11950","name":"CVMP post-authorisation summary of positive opinion for Rheumocam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/CVMP/106521/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-rheumocam_en.pdf-1"},
    {"id":"11971","name":"Questions and answers on the outcome of an application an application to extend use of Abilify in schizophrenia to 13 and 14 year olds","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2016-10-13T18:04:00Z","last_updated_date":"2016-10-13T18:04:00Z","reference_number":"EMA/616984/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_fi.pdf","is":"https://www.ema.europa.eu/is/documents/smop/questions-and-answers-outcome-application-application-extend-use-abilify-schizophrenia-13-and-14-year-olds_is.pdf"}},
    {"id":"12008","name":"CHMP post authorisation summary of positive opinion for Xeristar on 26 June 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-06-26T02:00:00Z","last_updated_date":"2021-06-22T14:32:00Z","reference_number":"EMEA/CHMP/335994/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xeristar-26-june-2008_en.pdf"},
    {"id":"12026","name":"CVMP post-authorisation summary of negative opinion for Masivet","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-04-16T02:00:00Z","last_updated_date":"2010-07-16T02:00:00Z","reference_number":"EMA/CVMP/177595/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-negative-opinion-masivet_en.pdf"},
    {"id":"12137","name":"CVMP post-authorisation summary of positive opinion for Loxicom","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-02-12T00:09:21Z","last_updated_date":"2010-02-12T00:09:21Z","reference_number":"EMA/CVMP/95049/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-loxicom_en.pdf-0"},
    {"id":"12147","name":"CHMP post-authorisation summary of positive opinion for Victoza (II-42)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T14:00:00Z","last_updated_date":"2017-06-23T14:00:00Z","reference_number":"EMA/CHMP/378657/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-victoza-ii-42_en.pdf"},
    {"id":"12179","name":"Committee for medicinal products for human use, post-authorisation summary of positive opinion for Neupro on 24 April 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2011-05-26T16:30:00Z","reference_number":"EMEA/CHMP/174788/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-neupro-24-april-2008_en.pdf"},
    {"id":"12246","name":"CHMP post-authorisation summary of positive opinion for Tyverb","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/CHMP/364588/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tyverb_en.pdf"},
    {"id":"12274","name":"CHMP post-authorisation summary of positive opinion for RoActemra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/288328/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-roactemra_en.pdf"},
    {"id":"12299","name":"CVMP post-authorisation summary of positive opinion for Panacur AquaSol","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/CVMP/732988/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-panacur-aquasol_en.pdf"},
    {"id":"12405","name":"CHMP post-authorisation summary of positive opinion for Stelara","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-01-24T01:00:00Z","reference_number":"EMA/CHMP/20129/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stelara_en.pdf-0"},
    {"id":"12412","name":"CHMP post-authorisation summary of positive opinion for Thyrogen","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/CHMP/667825/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-thyrogen_en.pdf-0"},
    {"id":"12437","name":"CHMP summary of positive opinion for NovoRapid","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/CHMP/606776/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-novorapid_en.pdf"},
    {"id":"12440","name":"CHMP post-authorisation summary of positive opinion for Nplate","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/CHMP/738145/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nplate_en.pdf"},
    {"id":"12552","name":"CHMP post-authorisation summary of positive opinion for Tivicay","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/CHMP/816690/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tivicay_en.pdf"},
    {"id":"12613","name":"CHMP post-authorisation summary of positive opinion for Imprida","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2017-05-11T14:00:00Z","reference_number":"EMA/CHMP/397194/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imprida_en.pdf"},
    {"id":"12645","name":"CHMP post-authorisation summary of positive opinion for Janumet of 24 September 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/544393/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-janumet-24-september-2009_en.pdf"},
    {"id":"12650","name":"Questions and answers on the outcome of extension of indication application for Victoza (liraglutide)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/770558/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-outcome-extension-indication-application-victoza-liraglutide_en.pdf"},
    {"id":"12693","name":"CHMP post-authorisation summary of positive opinion for Onglyza","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T02:00:00Z","last_updated_date":"2011-10-21T02:00:00Z","reference_number":"EMA/CHMP/834742/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-onglyza_en.pdf"},
    {"id":"12732","name":"CHMP post-authorisation summary of positive opinion for Synflorix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T14:00:00Z","last_updated_date":"2013-10-25T14:00:00Z","reference_number":"EMA/CHMP/389824/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-synflorix_en.pdf-0"},
    {"id":"12860","name":"CHMP post-authorisation summary of positive opinion for Orencia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/811199/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-orencia_en.pdf-1"},
    {"id":"12862","name":"CHMP post-authorisation summary of positive opinion for Xultophy II/23","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"EMA/CHMP/250993/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xultophy-ii23_en.pdf"},
    {"id":"12888","name":"CVMP post-authorisation summary of positive opinion for Econor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-10-15T02:00:00Z","last_updated_date":"2025-09-09T02:00:00Z","reference_number":"EMA/CVMP/480091/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-econor_en.pdf-0"},
    {"id":"12962","name":"CHMP post-authorisation summary of positive opinion for Levemir","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/775779/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-levemir_en.pdf"},
    {"id":"13046","name":"CHMP post-authorisation summary of positive opinion for Sevelamer carbonate Zentiva (WS/965)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-05-22T17:11:00Z","last_updated_date":"2017-05-22T17:11:00Z","reference_number":"EMA/CHMP/310511/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sevelamer-carbonate-zentiva-ws-965_en.pdf"},
    {"id":"13056","name":"CHMP post-authorisation summary of positive opinion for Zutectra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/729343/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zutectra_en.pdf"},
    {"id":"13067","name":"CHMP post-authorisation summary of positive opinion for Onglyza","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/383947/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-onglyza_en.pdf-0"},
    {"id":"13071","name":"CHMP post-authorisation summary of positive opinion for Perjeta (II-0034)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T14:00:00Z","last_updated_date":"2018-04-27T14:00:00Z","reference_number":"EMA/258941/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-perjeta-ii-0034_en.pdf"},
    {"id":"13103","name":"CVMP post-authorisation summary of positive opinion for Cerenia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-03-09T01:00:00Z","last_updated_date":"2012-03-09T01:00:00Z","reference_number":"EMA/CVMP/129854/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-cerenia_en.pdf-0"},
    {"id":"13106","name":"CHMP post-authorisation summary of positive opinion for Avastin (II/0092)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/CHMP/247926/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avastin-ii0092_en.pdf"},
    {"id":"13115","name":"CHMP post-authorisation summary of positive opinion for Vectibix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/371571/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vectibix_en.pdf-0"},
    {"id":"13139","name":"CHMP post-authorisation summary of positive opinion for Carbaglu","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/306613/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-carbaglu_en.pdf"},
    {"id":"13146","name":"CHMP post-authorisation summary of positive opinion for Trevicta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/237035/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trevicta_en.pdf"},
    {"id":"13184","name":"CHMP post-authorisation summary of positive opinion for NovoThirteen","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T13:00:00Z","last_updated_date":"2014-01-24T13:00:00Z","reference_number":"EMA/CHMP/21116/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-novothirteen_en.pdf"},
    {"id":"13203","name":"CHMP post-authorisation summary of positive opinion for Kinzalmono on 22 October 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/CHMP/681835/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kinzalmono-22-october-2009_en.pdf"},
    {"id":"13220","name":"CHMP post-authorisation summary of positive opinion for Prezista on 23 October 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:00:00Z","last_updated_date":"2008-10-23T02:00:00Z","reference_number":"EMEA/CHMP/552332/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prezista-23-october-2008_en.pdf"},
    {"id":"13247","name":"CHMP post-authorisation summary of positive opinion for Copalia HCT","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/CHMP/397231/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-copalia-hct_en.pdf"},
    {"id":"13294","name":"CHMP post-authorisation summary of positive opinion for Giotrif","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/CHMP/100611/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-giotrif_en.pdf"},
    {"id":"13348","name":"CHMP post-authorisation summary of positive opinion for Alimta on 21 February 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2008-02-21T00:09:21Z","reference_number":"EMEA/CHMP/92929/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-alimta-21-february-2008_en.pdf"},
    {"id":"13357","name":"CHMP post-authorisation summary of positive opinion for Relistor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/CHMP/249216/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-relistor_en.pdf"},
    {"id":"13370","name":"CHMP post-authorisation summary of positive opinion for Revestive","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/178344/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revestive_en.pdf-0"},
    {"id":"13490","name":"CHMP post-authorisation summary of positive opinion for Xalkori","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/488316/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xalkori_en.pdf"},
    {"id":"13557","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/CHMP/674619/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-2"},
    {"id":"13659","name":"CHMP post authorisation summary of positive opinion for Abilify on 27 July 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-27T02:00:00Z","last_updated_date":"2009-07-27T02:00:00Z","reference_number":"EMEA/483040/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abilify-27-july-2009_en.pdf"},
    {"id":"13749","name":"CHMP post-authorisation summary of positive opinion for Lucentis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"EMA/CHMP/221398/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lucentis_en.pdf"},
    {"id":"13795","name":"CVMP post-authorisation summary of positive opinion for Loxicom","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2013-01-11T01:00:00Z","last_updated_date":"2013-01-11T01:00:00Z","reference_number":"EMA/CVMP/749848/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-loxicom_en.pdf-1"},
    {"id":"13809","name":"CVMP post-authorisation summary of positive opinion for Panacur AquaSol","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-01-17T01:00:00Z","last_updated_date":"2014-01-17T01:00:00Z","reference_number":"EMA/CVMP/735220/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-panacur-aquasol_en.pdf-0"},
    {"id":"13861","name":"CVMP post-authorisation summary of positive opinion for Metacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-04-16T02:00:00Z","last_updated_date":"2010-04-16T02:00:00Z","reference_number":"EMA/CVMP/140057/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-metacam_en.pdf-2"},
    {"id":"13883","name":"CHMP post-authorisation summary of positive opinion for Firazyr (II-34-G)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/CHMP/590603/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-firazyr-ii-34-g_en.pdf"}    {"id":"13892","name":"CHMP post-authorisation summary of positive opinion for Velcade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/CHMP/782879/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velcade_en.pdf"},
    {"id":"13989","name":"CHMP post-authorisation summary of positive opinion for Kinzalmono","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/CHMP/261191/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kinzalmono_en.pdf"},
    {"id":"14017","name":"CHMP post-authorisation summary of positive opinion for Xolair","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-01-24T01:00:00Z","reference_number":"EMA/CHMP/20684/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xolair_en.pdf"},
    {"id":"14020","name":"CHMP post-authorisation summary of positive opinion for RoActemra (II-66)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/CHMP/431293/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-roactemra-ii-66_en.pdf"},
    {"id":"14047","name":"CVMP post-authorisation summary of positive opinion for Zuprevo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-02-13T01:00:00Z","last_updated_date":"2015-02-13T01:00:00Z","reference_number":"EMA/CVMP/102337/2014 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-zuprevo_en.pdf"},
    {"id":"14110","name":"CHMP post-authorisation summary of positive opinion for Herceptin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"EMA/CHMP/207702/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-herceptin_en.pdf-0"},
    {"id":"14157","name":"CHMP post-authorisation summary of positive opinion for Prezista on 20 November 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/CHMP/618601/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prezista-20-november-2008_en.pdf"},
    {"id":"14330","name":"CVMP post-authorisation summary of negative opinion for Naxcel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-09T16:30:00Z","last_updated_date":"2012-11-09T16:30:00Z","reference_number":"EMA/CVMP/283906/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-negative-opinion-naxcel_en.pdf"},
    {"id":"14392","name":"CHMP post-authorisation summary of positive opinion for Cervarix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T02:00:00Z","last_updated_date":"2011-10-21T02:00:00Z","reference_number":"EMA/CHMP/847218/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cervarix_en.pdf-0"},
    {"id":"14466","name":"CHMP post-authorisation summary of positive opinion for Tysabri","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/181854/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tysabri_en.pdf"},
    {"id":"14480","name":"CHMP post-authorisation summary of positive opinion for Victoza","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T01:00:00Z","last_updated_date":"2014-03-21T01:00:00Z","reference_number":"EMA/CHMP/164151/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-victoza_en.pdf-0"},
    {"id":"14522","name":"Committee for medicinal products for veterinary use post-authorisation summary of opinion: Rabigen SAG2","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-03-14T01:09:21Z","last_updated_date":"2008-03-14T01:09:21Z","reference_number":"EMEA/CVMP/124204/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-veterinary-use-post-authorisation-summary-opinion-rabigen-sag2_en.pdf"},
    {"id":"14568","name":"CHMP post-authorisation summary of positive opinion for Jinarc","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/CHMP/411942/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jinarc_en.pdf"},
    {"id":"14591","name":"CVMP post-authorisation summary of positive opinion for Metacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-04-16T02:00:00Z","last_updated_date":"2010-04-16T02:00:00Z","reference_number":"EMA/CVMP/184259/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-metacam_en.pdf-3"},
    {"id":"14641","name":"CHMP post-authorisation summary of positive opinion for Prezista","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/CHMP/67919/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prezista_en.pdf"},
    {"id":"14685","name":"CHMP post-authorisation summary of positive opinion for Exforge HCT","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/388293/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-exforge-hct_en.pdf"},
    {"id":"14689","name":"CHMP post-authorisation summary of positive opinion for Ryzodeg","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/CHMP/399756/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ryzodeg_en.pdf"},
    {"id":"14794","name":"CHMP post-authorisation summary of positive opinion for Stivarga (II-20)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T14:00:00Z","last_updated_date":"2017-06-23T14:00:00Z","reference_number":"EMA/CHMP/386334/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stivarga-ii-20_en.pdf"},
    {"id":"14803","name":"CHMP post-authorisation summary of positive opinion for Privigen","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/CHMP/108789/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-privigen_en.pdf"},
    {"id":"14831","name":"CHMP post-authorisation summary of positive opinion for Prezista","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2015-02-09T16:20:00Z","reference_number":"EMA/CHMP/580195/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prezista_en.pdf-0"},
    {"id":"14935","name":"CHMP post-authorisation summary of positive opinion for Taxotere","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-05-21T02:00:00Z","last_updated_date":"2010-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-taxotere_en.pdf"},
    {"id":"15002","name":"CHMP summary of positive opinion for Prevenar 13","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/763049/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-prevenar-13_en.pdf"},
    {"id":"15131","name":"CHMP post-authorisation summary of positive opinion for Dafiro","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/397193/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dafiro_en.pdf"},
    {"id":"15185","name":"CHMP post-authorisation summary of positive opinion for Signifor (X-30-G)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/CHMP/431002/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-signifor-x-30-g_en.pdf"},
    {"id":"15219","name":"CHMP post-authorisation summary of positive opinion for Prezista","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/CHMP/51975/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prezista_en.pdf-1"},
    {"id":"15242","name":"CHMP post-authorisation summary of positive opinion for Glivec on 19 March 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-03-20T01:00:00Z","last_updated_date":"2009-03-20T01:00:00Z","reference_number":"EMEA/CHMP/659495/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-glivec-19-march-2009_en.pdf"},
    {"id":"15247","name":"CHMP post-authorisation summary of positive opinion for Tyverb","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2010-02-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tyverb_en.pdf-0"},
    {"id":"15340","name":"CVMP post-authorisation summary of negative opinion for Masivet","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-12-10T01:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/CVMP/198376/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-negative-opinion-masivet_en.pdf-0"},
    {"id":"15385","name":"CHMP post-authorisation summary of positive opinion for Arzerra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2016-11-11T13:00:00Z","reference_number":"EMA/CHMP/693024/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-arzerra_en.pdf"},
    {"id":"15407","name":"CHMP post-authorisation summary of positive opinion for Cialis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/293550/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cialis_en.pdf"},
    {"id":"15440","name":"CHMP post-authorisation summary of positive opinion for Simponi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/339032/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-simponi_en.pdf-0"},
    {"id":"15503","name":"CHMP post-authorisation summary of positive opinion for Revlimid","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2015-02-18T01:00:00Z","reference_number":"EMA/CHMP/790008/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revlimid_en.pdf-0"},
    {"id":"15793","name":"CHMP post-authorisation summary of positive opinion for Angiox  22 October 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:09:21Z","last_updated_date":"2018-09-14T02:09:21Z","reference_number":"EMEA/CHMP/671740/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-angiox-22-october-2009_en.pdf"},
    {"id":"15797","name":"CHMP post-authorisation summary of positive opinion for Invega","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/CHMP/245423/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-invega_en.pdf-0"},
    {"id":"15819","name":"CHMP post-authorisation summary of positive opinion for Cayston","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CHMP/410842/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cayston_en.pdf"},
    {"id":"15823","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-42;II-43)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/481048/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-42ii-43_en.pdf"},
    {"id":"15859","name":"CHMP post-authorisation summary of positive opinion for Uptravi (II-07)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-05-19T02:00:00Z","reference_number":"EMA/CHMP/315335/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-uptravi-ii-07_en.pdf"},
    {"id":"15934","name":"CHMP post-authorisation summary of positive opinion for Docetaxel Winthrop","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2022-05-20T01:00:00Z","reference_number":"EMEA/CHMP/752754/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-docetaxel-winthrop_en.pdf"},
    {"id":"16049","name":"CHMP post-authorisation summary of positive opinion for Zytiga","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2012-11-16T01:00:00Z","reference_number":"EMA/CHMP/697344/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zytiga_en.pdf"},
    {"id":"16073","name":"Committee for medicinal products for human use  post authorisation summary of positive opinion for  Xelivia on 15 November 2007","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2007-12-20T01:00:00Z","last_updated_date":"2007-12-20T01:00:00Z","reference_number":"EMEA/CHMP/536624/2007","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-xelivia-15-november-2007_en.pdf"},
    {"id":"16156","name":"CHMP post-authorisation summary of positive opinion for Taltz (II-09)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/CHMP/811414/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-taltz-ii-09_en.pdf"},
    {"id":"16173","name":"CHMP post-authorisation summary of positive opinion for Menveo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T13:00:00Z","last_updated_date":"2012-03-16T13:00:00Z","reference_number":"EMA/CHMP/187861/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-menveo_en.pdf"},
    {"id":"16184","name":"CHMP post-authorisation summary of positive opinion for Corlentor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/CHMP/712657/2013 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-corlentor_en.pdf"},
    {"id":"16313","name":"CHMP post-authorisation summary of positive opinion for Revolade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/CHMP/371721/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revolade_en.pdf-0"},
    {"id":"16386","name":"CHMP post-authorisation summary of positive opinion for Afinitor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/591153/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-afinitor_en.pdf"},
    {"id":"16413","name":"CHMP post-authorisation summary of positive opinion for Velcade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/CHMP/384262/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velcade_en.pdf-0"},
    {"id":"16436","name":"CHMP post-authorisation summary of positive opinion for Tesavel of 25 June 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/369191/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tesavel-25-june-2009_en.pdf"},
    {"id":"16465","name":"CHMP post-authorisation summary of positive opinion for Revatio","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"EMA/CHMP/207927/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revatio_en.pdf"},
    {"id":"16561","name":"CHMP post-authorisation summary of positive opinion for Toujeo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/CHMP/124102/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-toujeo_en.pdf"},
    {"id":"16671","name":"CHMP post-authorisation summary of positive opinion for Ecalta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-07-25T02:00:00Z","reference_number":"EMA/CHMP/430755/2014 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ecalta_en.pdf"},
    {"id":"16745","name":"CHMP post-authorisation summary of positive opinion for Opdivo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-28T02:00:00Z","last_updated_date":"2018-06-28T02:00:00Z","reference_number":"EMA/CHMP/442334/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo_en.pdf-1"},
    {"id":"16784","name":"CHMP post-authorisation summary of positive opinion for Pradaxa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/CHMP/804118/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pradaxa_en.pdf-2"},
    {"id":"16803","name":"CHMP post-authorisation summary of positive opinion for Lucentis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-10-13T14:00:00Z","last_updated_date":"2016-10-13T14:00:00Z","reference_number":"EMA/CHMP/647568/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lucentis_en.pdf-0"},
    {"id":"16935","name":"CHMP post-authorisation summary of positive opinion for Exjade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2012-11-16T01:00:00Z","reference_number":"EMA/CHMP/698691/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-exjade_en.pdf"},
    {"id":"16994","name":"Questions and answers on refusal of a change to the marketing authorisation for Javlor (vinflunine)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-12-10T01:00:00Z","reference_number":"EMA/587197/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-javlor-vinflunine_sv.pdf"}},
    {"id":"17218","name":"CHMP post-authorisation summary of positive opinion for Tafinlar","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2017-02-24T01:00:00Z","reference_number":"EMA/CHMP/120396/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tafinlar_en.pdf"},
    {"id":"17333","name":"CHMP post-authorisation summary of positive opinion for Aptivus on 23 April 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:09:21Z","last_updated_date":"2009-04-23T02:09:21Z","reference_number":"EMEA/CHMP/232607/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aptivus-23-april-2009_en.pdf"},
    {"id":"17379","name":"CHMP post-authorisation summary of positive opinion for Alecensa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"EMA/CHMP/660204/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-alecensa_en.pdf"},
    {"id":"17418","name":"CHMP post-authorisation summary of positive opinion for Perjeta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T14:00:00Z","last_updated_date":"2015-06-26T14:00:00Z","reference_number":"EMA/CHMP/334570/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-perjeta_en.pdf"},
    {"id":"17469","name":"CHMP post authorisation summary of positive opinion for Pegintron","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2021-06-03T01:00:00Z","reference_number":"EMA/CHMP/114051/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pegintron_en.pdf"},
    {"id":"17539","name":"CVMP post authorisation positive summary of opinion for Advocate","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2010-07-16T02:00:00Z","reference_number":"EMEA/CVMP/401633/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-positive-summary-opinion-advocate_en.pdf"},
    {"id":"17588","name":"CHMP post-authorisation summary of positive opinion for TachoSil","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/147980/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tachosil_en.pdf"},
    {"id":"17589","name":"CHMP post-authorisation summary of positive opinion for Komboglyze","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T14:00:00Z","last_updated_date":"2017-05-19T14:00:00Z","reference_number":"EMA/CHMP/301707/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-komboglyze_en.pdf"},
    {"id":"17614","name":"CVMP post-authorisation summary of positive opinion for Meloxidyl","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-01-15T00:09:21Z","last_updated_date":"2010-01-15T00:09:21Z","reference_number":"EMA/CVMP/826131/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-meloxidyl_en.pdf"},
    {"id":"17640","name":"CHMP post-authorisation summary of positive opinion for Imbruvica","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/284604/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imbruvica_en.pdf-0"},
    {"id":"17671","name":"CHMP post-authorisation summary of positive opinion for Soliris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"EMA/CHMP/377462/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-soliris_en.pdf-1"},
    {"id":"17782","name":"CHMP post-authorisation summary of positive opinion for Faslodex","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"EMA/675100/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-faslodex_en.pdf"},
    {"id":"17816","name":"CHMP post-authorisation summary of positive opinion for Xeljanz (X-05-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/CHMP/366645/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xeljanz-x-05-g_en.pdf"},
    {"id":"17896","name":"CHMP post-authorisation summary of positive opinion for Eylea","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/568489/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eylea_en.pdf-0"},
    {"id":"17971","name":"CHMP post-authorisation summary of positive opinion for Nevanac","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T11:19:00Z","last_updated_date":"2011-11-18T11:19:00Z","reference_number":"EMA/CHMP/651318/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nevanac_en.pdf"},
    {"id":"18005","name":"Committee for medicinal products for veterinary use summary of opinion: Meloxidyl: International Non-proprietary Name (INN): Meloxicam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-17T03:09:21Z","last_updated_date":"2009-07-17T03:09:21Z","reference_number":"EMEA/CVMP/409781/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-veterinary-use-summary-opinion-meloxidyl-international-non-proprietary-name-inn-meloxicam_en.pdf"},
    {"id":"18050","name":"CHMP post-authorisation summary of positive opinion for Cyramza","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T13:00:00Z","last_updated_date":"2015-12-18T13:00:00Z","reference_number":"EMA/CHMP/550291/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cyramza_en.pdf"},
    {"id":"18175","name":"CHMP post-authorisation summary of positive opinion for Silgard","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2019-04-02T02:00:00Z","reference_number":"EMA/CHMP/243055/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-silgard_en.pdf"},
    {"id":"18229","name":"CHMP post-authorisation summary of positive opinion for Abraxane","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"EMA/CHMP/42494/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abraxane_en.pdf"},
    {"id":"18258","name":"CVMP post-authorisation summary of positive opinion for Dexdomitor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-06-15T02:00:00Z","last_updated_date":"2012-06-15T02:00:00Z","reference_number":"EMA/CVMP/345725/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-dexdomitor_en.pdf"},
    {"id":"18302","name":"CHMP post-authorisation summary of positive opinion for Xgeva","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-07-25T02:00:00Z","reference_number":"EMA/CHMP/445632/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xgeva_en.pdf"},
    {"id":"18432","name":"CHMP post-authorisation summary of positive opinion for Fycompa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/324690/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fycompa_en.pdf"},
    {"id":"18436","name":"CHMP post-authorisation summary of positive opinion for Travatan","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2014-11-21T13:00:00Z","reference_number":"EMA/CHMP/697464/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-travatan_en.pdf"},
    {"id":"18448","name":"CHMP post-authorisation positive summary of opinion for Procoralan","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T01:00:00Z","last_updated_date":"2011-12-16T01:00:00Z","reference_number":"EMA/CHMP/963751/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-positive-summary-opinion-procoralan_en.pdf"},
    {"id":"18487","name":"CHMP post-authorisation summary of positive opinion for Stelara","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/333057/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stelara_en.pdf-1"},
    {"id":"18502","name":"CVMP summary of opinion: Aivlosin 625 mg/g granules for use in drinking water for pheasants","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-10-16T03:09:00Z","last_updated_date":"2009-10-16T03:09:00Z","reference_number":"EMEA/CVMP/627079/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-summary-opinion-aivlosin-625-mgg-granules-use-drinking-water-pheasants_en.pdf"},
    {"id":"18558","name":"CHMP post-authorisation summary of positive opinion for Vimpat (II-65-G)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/CHMP/433563/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vimpat-ii-65-g_en.pdf"},
    {"id":"18626","name":"CHMP post-authorisation summary of positive opinion for Izba","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T14:00:00Z","last_updated_date":"2017-05-19T14:00:00Z","reference_number":"EMA/CHMP/269250/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-izba_en.pdf"},
    {"id":"18677","name":"CHMP post-authorisation summary of positive opinion for Ilaris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/CHMP/433406/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ilaris_en.pdf-0"},
    {"id":"18868","name":"CHMP post-authorisation summary of opinion for Rapamune","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/CHMP/229070/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-rapamune_en.pdf"},
    {"id":"18874","name":"CHMP post-authorisation summary of positive opinion for Cimzia (II-65)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T14:00:00Z","last_updated_date":"2018-04-27T14:00:00Z","reference_number":"EMA/CHMP/153785/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cimzia-ii-65_en.pdf"},
    {"id":"18933","name":"CHMP post-authorisation summary of positive opinion for Abseamed","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/503859/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abseamed_en.pdf"},
    {"id":"19073","name":"CHMP post-authorisation summary of positive opinion for Zebinix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/CHMP/824232/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zebinix_en.pdf"},
    {"id":"19133","name":"CHMP post-authorisation summary of positive opinion for Keppra on 23 July 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-24T02:00:00Z","last_updated_date":"2009-07-24T02:00:00Z","reference_number":"EMEA/CHMP/417760/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keppra-23-july-2009_en.pdf"},
    {"id":"19216","name":"CHMP post authorisation summary of positive opinion for  Zevalin on 19 March 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-03-30T01:00:00Z","last_updated_date":"2008-03-30T01:00:00Z","reference_number":"EMEA/CHMP/144112/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zevalin-19-march-2008_en.pdf"},
    {"id":"19222","name":"Committee for medicinal products for veterinary use summary of opinion: Naxcel: International Non-proprietary Name (INN): Ceftiofur","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-17T03:09:21Z","last_updated_date":"2009-07-17T03:09:21Z","reference_number":"EMEA/CVMP/405655/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-veterinary-use-summary-opinion-naxcel-international-non-proprietary-name-inn-ceftiofur_en.pdf"},
    {"id":"19236","name":"CHMP post-authorisation summary of positive opinion for Votrient","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/CHMP/225896/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-votrient_en.pdf"},
    {"id":"19245","name":"CHMP post-authorisation summary of positive opinion for Lucentis","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/CHMP/320328/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lucentis_en.pdf-1"},
    {"id":"19279","name":"CHMP post-authorisation summary of positive opinion for Pradaxa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/CHMP/261823/2013  ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pradaxa_en.pdf-3"},
    {"id":"19437","name":"CVMP post-authorisation summary of positive opinion for Inflacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-10-09T02:00:00Z","last_updated_date":"2015-10-09T02:00:00Z","reference_number":"EMA/CVMP/596354/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-inflacam_en.pdf-0"},
    {"id":"19449","name":"CHMP post-authorisation summary of positive opinion for Vimpat","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T01:00:00Z","last_updated_date":"2016-11-11T01:00:00Z","reference_number":"EMA/CHMP/581734/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vimpat_en.pdf"},
    {"id":"19466","name":"CHMP post-authorisation summary of positive opinion for Enbrel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/557917/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enbrel_en.pdf-0"},
    {"id":"19482","name":"CHMP post-authorisation summary of positive opinion for Enbrel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/557933/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enbrel_en.pdf-1"},
    {"id":"19533","name":"CHMP post-authorisation summary of positive opinion for Tracleer on 26 June 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-06-26T02:00:00Z","last_updated_date":"2008-06-26T02:00:00Z","reference_number":"EMEA/CHMP/210276/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tracleer-26-june-2008_en.pdf"},
    {"id":"19699","name":"CHMP post-authorisation summary of positive opinion for Jentadueto","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T10:38:00Z","last_updated_date":"2016-12-16T10:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jentadueto_en.pdf"}    {"id":"19739","name":"CHMP post-authorisation summary of positive opinion for RoActemra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-07-25T02:00:00Z","reference_number":"EMA/CHMP/437831/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-roactemra_en.pdf-0"},
    {"id":"19743","name":"CHMP post-authorisation summary of positive opinion for Cimzia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/752205/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cimzia_en.pdf"},
    {"id":"19921","name":"CVMP post-authorisation summary of positive opinion for Loxicom","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-05-06T02:00:00Z","last_updated_date":"2011-05-06T02:00:00Z","reference_number":"EMA/CVMP/62249/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-loxicom_en.pdf-2"},
    {"id":"19977","name":"CHMP post-authorisation summary of positive opinion for Levemir","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-06-25T14:00:00Z","last_updated_date":"2015-06-25T14:00:00Z","reference_number":"EMA/CHMP/393290/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-levemir_en.pdf-0"},
    {"id":"19989","name":"CHMP post-authorisation summary of positive opinion for Avastin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:09:21Z","last_updated_date":"2009-06-25T02:09:21Z","reference_number":"EMEA/CHMP/400280/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avastin_en.pdf-1"},
    {"id":"20016","name":"CVMP post-authorisation summary of positive opinion for Porcilis PCV M Hyo","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2018-05-28T18:00:00Z","last_updated_date":"2018-05-28T18:00:00Z","reference_number":"EMA/CVMP/281117/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-porcilis-pcv-m-hyo_en.pdf"},
    {"id":"20057","name":"CVMP post-authorisation summary of positive opinion for Activyl Tick Plus","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-04-18T02:00:00Z","last_updated_date":"2022-10-04T09:29:00Z","reference_number":"EMA/CVMP/62199/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-activyl-tick-plus_en.pdf"},
    {"id":"20103","name":"CHMP post-authorisation summary of positive opinion for Kaletra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"EMA/CHMP/377673/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kaletra_en.pdf"},
    {"id":"20176","name":"CVMP post-authorisation summary of positive opinion for Melovem","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T18:00:00Z","last_updated_date":"2013-07-19T18:00:00Z","reference_number":"EMA/CVMP/384391/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-melovem_en.pdf"},
    {"id":"20195","name":"CHMP post-authorisation summary of positive opinion for Avastin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/569545/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avastin_en.pdf-2"},
    {"id":"20230","name":"CHMP post-authorisation summary of positive opinion for Insuman","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/CHMP/435143/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-insuman_en.pdf"},
    {"id":"20325","name":"CHMP post-authorisation summary of positive opinion for Prolia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/CHMP/208646/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prolia_en.pdf"},
    {"id":"20337","name":"CVMP post-authorisation summary of positive opinion for Trifexis (II-0008)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T01:00:00Z","last_updated_date":"2018-10-08T01:00:00Z","reference_number":"EMA/CVMP/713330/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-trifexis-ii-0008_en.pdf"},
    {"id":"20458","name":"CHMP post-authorisation summary of positive opinion for Simponi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T14:00:00Z","last_updated_date":"2015-05-22T14:00:00Z","reference_number":"EMA/CHMP/308417/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-simponi_en.pdf-1"},
    {"id":"20568","name":"CHMP post-authorisation summary of positive opinion for Abilify","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/800447/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abilify_en.pdf"},
    {"id":"20627","name":"CHMP post-authorisation summary of positive opinion for Gazyvaro (II-16)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T13:03:00Z","last_updated_date":"2017-07-21T13:03:00Z","reference_number":"EMA/CHMP/296989/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gazyvaro-ii-16_en.pdf"},
    {"id":"20630","name":"CHMP post-authorisation summary of positive opinion for Jentadueto","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/CHMP/798869/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jentadueto_en.pdf-0"},
    {"id":"20653","name":"CHMP post-authorisation summary of positive opinion for Enbrel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CHMP/408365/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enbrel_en.pdf-2"},
    {"id":"20800","name":"CHMP post-authorisation summary of positive opinion for Revolade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/CHMP/467044/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revolade_en.pdf-1"},
    {"id":"20884","name":"CHMP post-authorisation summary of positive opinion for Exforge","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/388283/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-exforge_en.pdf"},
    {"id":"20917","name":"CHMP post-authorisation summary of positive opinion for Tafinlar","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T14:00:00Z","last_updated_date":"2015-07-24T14:00:00Z","reference_number":"EMA/CHMP/444359/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tafinlar_en.pdf-0"},
    {"id":"20976","name":"CHMP post authorisation summary of positive opinion for Xelivia on 25 June 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/369153/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xelivia-25-june-2009_en.pdf"},
    {"id":"20977","name":"CHMP post-authorisation summary of positive opinion for Brilique","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/CHMP/730883/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-brilique_en.pdf"},
    {"id":"20984","name":"CHMP post-authorisation summary of positive opinion for Komboglyze","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/450949/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-komboglyze_en.pdf-0"},
    {"id":"21111","name":"CHMP post-authorisation summary of positive opinion for Ilaris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T14:00:00Z","last_updated_date":"2016-06-24T14:00:00Z","reference_number":"EMA/CHMP/421628/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ilaris_en.pdf-1"},
    {"id":"21165","name":"CHMP post-authorisation summary of positive opinion for Parareg on 24 April 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/206494/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-parareg-24-april-2008_en.pdf"},
    {"id":"21265","name":"CHMP post-authorisation summary of positive opinion for Reyataz","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2010-04-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-reyataz_en.pdf"},
    {"id":"21308","name":"CHMP authorisation positive summary of opinion for Arixtra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2010-07-23T02:00:00Z","reference_number":"EMA/CHMP/429539/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-authorisation-positive-summary-opinion-arixtra_en.pdf"},
    {"id":"21406","name":"CVMP post-authorisation summary of positive opinion for Metacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-12-11T00:09:21Z","last_updated_date":"2009-12-11T00:09:21Z","reference_number":"EMA/CVMP/802307/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-metacam_en.pdf-4"},
    {"id":"21446","name":"CHMP post authorisation positive summary of opinion for Kepivance","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2016-04-08T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-positive-summary-opinion-kepivance_en.pdf"},
    {"id":"21588","name":"CHMP post-authorisation summary of positive opinion for Pegasys","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/CHMP/166776/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pegasys_en.pdf"},
    {"id":"21611","name":"CHMP post-authorisation summary of positive opinion for Xeljanz","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T13:24:00Z","last_updated_date":"2018-04-27T13:24:00Z","reference_number":"EMA/CHMP/244920/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xeljanz_en.pdf"},
    {"id":"21735","name":"CHMP post-authorisation summary of positive opinion for Pritor on 22 October 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/CHMP/681834/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pritor-22-october-2009_en.pdf"},
    {"id":"21744","name":"CHMP post-authorisation summary of positive opinion for TachoSil (II-0041)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T13:00:00Z","last_updated_date":"2012-11-16T13:00:00Z","reference_number":"EMA/CHMP/724928/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tachosil-ii-0041_en.pdf"},
    {"id":"21771","name":"CHMP post-authorisation summary of positive opinion for Ozurdex","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"EMA/CHMP/271228/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ozurdex_en.pdf-0"},
    {"id":"21798","name":"CVMP post-authorisation summary of positive opinion for Nobivac LeuFel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T02:00:00Z","last_updated_date":"2018-06-22T02:00:00Z","reference_number":"EMA/CVMP/113131/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nobivac-leufel_en.pdf"},
    {"id":"22015","name":"CHMP post-authorisation summary of positive opinion for Opdivo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2016-10-14T14:00:00Z","reference_number":"EMA/CHMP/671272/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo_en.pdf-2"},
    {"id":"22045","name":"CHMP post-authorisation summary of positive opinion for INOmax","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/CHMP/733047/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-inomax_en.pdf"},
    {"id":"22068","name":"CHMP post-authorisation summary of positive opinion for Silgard","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2019-04-02T02:00:00Z","reference_number":"EMEA/CHMP/280938/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-silgard_en.pdf-0"},
    {"id":"22145","name":"CHMP post-authorisation summary of positive opinion for Januvia on 23 April 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/240299/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-januvia-23-april-2009_en.pdf"},
    {"id":"22146","name":"CHMP post-authorisation summary of positive opinion for Rebetol","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2023-11-07T02:00:00Z","reference_number":"EMA/CHMP/408137/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rebetol_en.pdf-1"},
    {"id":"22225","name":"CVMP post-authorisation summary of positive opinion for Porcilis PCV ID","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/CVMP/59625/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-porcilis-pcv-id_en.pdf"},
    {"id":"22263","name":"CHMP post-authorisation summary of positive opinion for Xarelto","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/753436/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xarelto_en.pdf"},
    {"id":"22330","name":"CHMP post-authorisation summary of positive opinion for Sovaldi","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/CHMP/428252/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sovaldi_en.pdf"},
    {"id":"22340","name":"CVMP post-authorisation summary of positive opinion for Cerenia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-04-13T17:30:00Z","last_updated_date":"2015-04-13T17:30:00Z","reference_number":"EMA/CVMP/180883/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-cerenia_en.pdf-1"},
    {"id":"22361","name":"CHMP post-authorisation summary of positive opinion for Keytruda","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/CHMP/428392/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda_en.pdf"},
    {"id":"22406","name":"CVMP post-authorisation summary of positive opinion for Advocate","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T18:00:00Z","last_updated_date":"2013-07-19T18:00:00Z","reference_number":"EMA/CVMP/428221/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-advocate_en.pdf"},
    {"id":"22408","name":"CHMP post-authorisation summary of positive opinion for Briviact","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T15:33:00Z","last_updated_date":"2018-06-01T15:33:00Z","reference_number":"EMA/CHMP/327758/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-briviact_en.pdf"},
    {"id":"22585","name":"Questions and answers on the recommendation for the refusal of a change to the marketing authorisation for Erbitux","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-11-20T00:09:21Z","last_updated_date":"2009-11-20T00:09:21Z","reference_number":"EMEA/CHMP/748861/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-erbitux_sv.pdf"}},
    {"id":"22651","name":"CVMP post-authorisation summary  of opinion for Equioxx","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2016-12-09T16:04:00Z","last_updated_date":"2016-12-09T16:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-opinion-equioxx_en.pdf"},
    {"id":"22720","name":"CHMP post-authorisation summary of positive opinion for Votrient","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/CHMP/121263/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-votrient_en.pdf-0"},
    {"id":"22728","name":"CHMP post-authorisation summary of positive opinion for Mekinist","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2017-02-24T01:00:00Z","reference_number":"EMA/CHMP/120396/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mekinist_en.pdf"},
    {"id":"22750","name":"Questions and answers on the refusal of a change to the marketing authorisation for Raxone (idebenone)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/613204/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-raxone-idebenone_en.pdf"},
    {"id":"22781","name":"CHMP post-authorisation summary of positive opinion for Jardiance","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/398392/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jardiance_en.pdf"},
    {"id":"22885","name":"Questions and answers on the refusal of a change to the marketing authorisation for Ariclaim, Cymbalta and Xeristar","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2018-08-07T02:00:00Z","reference_number":"EMA/CHMP/580268/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_sv.pdf"}},
    {"id":"22938","name":"CHMP post-authorisation summary of positive opinion for PritorPlus","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/CHMP/261191/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pritorplus_en.pdf"},
    {"id":"22958","name":"Committee for medicinal products for human use post-authorisation summary of positive opinion for Avandia on 24 January 2008","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2016-06-09T01:09:21Z","reference_number":"EMEA/CHMP/42712/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-avandia-24-january-2008_en.pdf"},
    {"id":"22991","name":"CHMP post-authorisation summary of positive opinion for Xultophy","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/332827/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xultophy_en.pdf"},
    {"id":"23089","name":"CHMP post-authorisation summary of positive opinion for Aerius on 21 February 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/CHMP/86516/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aerius-21-february-2008_en.pdf"},
    {"id":"23097","name":"CHMP post-authorisation summary of positive opinion for Onglyza (WS/1078)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T14:00:00Z","last_updated_date":"2017-05-19T14:00:00Z","reference_number":"EMA/CHMP/304199/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-onglyza-ws1078_en.pdf"},
    {"id":"23102","name":"CVMP post-authorisation summary of positive opinion for Onsior","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-07-13T16:01:00Z","last_updated_date":"2012-07-13T16:01:00Z","reference_number":"EMA/461234/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-onsior_en.pdf"},
    {"id":"23250","name":"CHMP post-authorisation summary of positive opinion for Trajenta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/591330/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trajenta_en.pdf"},
    {"id":"23361","name":"CHMP post-authorisation summary of positive opinion for Humira (II-163)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/CHMP/402059/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira-ii-163_en.pdf"},
    {"id":"23423","name":"CHMP post-authorisation summary of positive opinion for ViraferonPeg","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2021-01-22T01:00:00Z","reference_number":"EMA/CHMP/114049/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viraferonpeg_en.pdf"},
    {"id":"23510","name":"CHMP post-authorisation summary of positive opinion for Reyataz on 24 April 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/129961/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-reyataz-24-april-2008_en.pdf"},
    {"id":"23511","name":"CHMP post-authorisation summary of positive opinion for Avastin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/569554/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avastin_en.pdf-3"},
    {"id":"23535","name":"CHMP post-authorisation summary of positive opinion for Nexavar","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/CHMP/236261/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nexavar_en.pdf"},
    {"id":"23783","name":"CVMP post-authorisation summary of positive opinion for Equilis Prequenza","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T17:00:00Z","last_updated_date":"2013-02-08T17:00:00Z","reference_number":"EMA/CVMP/36013/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-equilis-prequenza_en.pdf"},
    {"id":"23798","name":"CHMP post-authorisation summary of positive opinion for Celsentri (X-46-G)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T17:00:00Z","last_updated_date":"2017-04-21T17:00:00Z","reference_number":"EMA/CHMP/219462/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-celsentri-x-46-g_en.pdf"},
    {"id":"23808","name":"CHMP post-authorisation summary of positive opinion for Clopidogrel Winthrop","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2010-11-19T01:00:00Z","reference_number":"EMA/CHMP/740478/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-clopidogrel-winthrop_en.pdf"},
    {"id":"23931","name":"CHMP post-authorisation summary of positive opinion for Zinforo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/265582/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zinforo_en.pdf"},
    {"id":"23991","name":"CHMP post-authorisation summary of positive opinion for MabThera","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMA/598746/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera_en.pdf"},
    {"id":"24111","name":"CVMP post-authorisation summary of positive opinion for Zactran (X/0034)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/CVMP/129619/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-zactran-x0034_en.pdf"},
    {"id":"24120","name":"CHMP post-authorisation summary of positive opinion for Iscover","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2010-11-19T01:00:00Z","reference_number":"EMA/CHMP/740477/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-iscover_en.pdf"},
    {"id":"24220","name":"CHMP post-authorisation summary of positive opinion for Aprovel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/388259/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aprovel_en.pdf"},
    {"id":"24221","name":"CHMP post-authorisation summary of positive opinion for Zomarist","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/600946/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zomarist_en.pdf"},
    {"id":"24232","name":"Questions and answers on the refusal of a change to the marketing authorisations for Ariclaim, Cymbalta and Xeristar (duloxetine) - Outcome of re-examination","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T01:00:00Z","last_updated_date":"2021-06-22T16:00:00Z","reference_number":"EMA/901723/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_sv.pdf"}},
    {"id":"24320","name":"CVMP post-authorisation summary of positive opinion for Suprelorin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-09-16T02:00:00Z","last_updated_date":"2011-09-16T02:00:00Z","reference_number":"EMA/CVMP/407323/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-suprelorin_en.pdf-0"},
    {"id":"24357","name":"Questions and answers on recommendation for the refusal of a change to the marketing authorisation for NutropinAq","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2007-09-21T02:09:21Z","last_updated_date":"2007-09-21T02:09:21Z","reference_number":"EMEA/423515/2007","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-nutropinaq_en.pdf"},
    {"id":"24381","name":"CHMP post-authorisation summary of positive opinion for Qutenza","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/CHMP/442672/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-qutenza_en.pdf"},
    {"id":"24391","name":"CHMP post-authorisation positive summary of opinion for Corlentor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T01:00:00Z","last_updated_date":"2011-12-16T01:00:00Z","reference_number":"EMA/CHMP/963758/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-positive-summary-opinion-corlentor_en.pdf"},
    {"id":"24471","name":"CVMP post-authorisation summary of positive opinion for Eravac","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/CVMP/21684/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-eravac_en.pdf"},
    {"id":"24514","name":"CHMP post-authorisation summary of positive opinion for Zykadia (II-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T14:18:00Z","last_updated_date":"2017-05-19T14:18:00Z","reference_number":"EMA/CHMP/313473/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zykadia-ii-12_en.pdf"},
    {"id":"24777","name":"CVMP post-authorisation summary of positive opinion for Activyl Tick Plus","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-03-16T01:00:00Z","last_updated_date":"2022-10-04T09:31:00Z","reference_number":"EMA/CVMP/121944/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-activyl-tick-plus_en.pdf-0"},
    {"id":"24840","name":"CHMP post-authorisation summary of positive opinion for Adcirca","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/CHMP/669325/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adcirca_en.pdf"},
    {"id":"24967","name":"CHMP post-authorisation summary of positive opinion for Cholestagel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2010-02-19T01:00:00Z","reference_number":"EMA/CHMP/103005/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cholestagel_en.pdf"},
    {"id":"25064","name":"Committee for Medicinal Products for Veterinary use Post authorisation summary of opinion: Previcox International Non-proprietary Name (INN): Firocoxib","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-09-19T02:09:21Z","last_updated_date":"2008-09-19T02:09:21Z","reference_number":"EMEA/CVMP/461247/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-veterinary-use-post-authorisation-summary-opinion-previcox-international-non-proprietary-name-inn-firocoxib_en.pdf"},
    {"id":"25150","name":"CHMP summary of positive opinion for Omnitrop","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2003-06-26T02:00:00Z","last_updated_date":"2003-06-26T02:00:00Z","reference_number":"CPMP/3184/03","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-omnitrop_en.pdf"},
    {"id":"25153","name":"CHMP post-authorisation summary of positive opinion for Bosulif","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2018-02-23T01:00:00Z","reference_number":"EMA/CHMP/85019/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bosulif_en.pdf"},
    {"id":"25154","name":"CVMP post-authorisation summary of positive opinion for Broadline","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/CVMP/128685/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-broadline_en.pdf"},
    {"id":"25323","name":"CHMP post-authorisation summary of positive opinion for Xolair on 25 June 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/CHMP/384861/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xolair-25-june-2009_en.pdf"},
    {"id":"25430","name":"CHMP post-authorisation summary of positive opinion for Adcetris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/207100/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adcetris_en.pdf"},
    {"id":"25488","name":"CHMP post-authorisation summary of positive opinion for Zytiga","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"EMA/CHMP/666739/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zytiga_en.pdf-0"},
    {"id":"25595","name":"CHMP post-authorisation summary of positive opinion for Sustiva","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2024-03-14T01:00:00Z","reference_number":"EMA/CHMP/104007/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sustiva_en.pdf"},
    {"id":"25623","name":"CHMP post-authorisation summary of positive opinion for Lucentis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-10-21T02:00:00Z","last_updated_date":"2010-10-21T02:00:00Z","reference_number":"EMA/CHMP/640157/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lucentis_en.pdf-2"},
    {"id":"25701","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"EMA/CHMP/487292/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-3"},
    {"id":"25703","name":"CHMP post-authorisation summary of positive opinion for Lenvima","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T14:00:00Z","last_updated_date":"2018-06-29T14:00:00Z","reference_number":"EMA/CHMP/426631/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lenvima_en.pdf"},
    {"id":"25928","name":"CHMP post-authorisation summary of positive opinion for Avastin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-02-19T00:09:21Z","last_updated_date":"2009-02-19T00:09:21Z","reference_number":"EMEA/CHMP/121120/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avastin_en.pdf-4"},
    {"id":"25968","name":"CHMP post-authorisation summary of positive opinion for Dexdor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/CHMP/430649/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dexdor_en.pdf"},
    {"id":"26029","name":"CHMP post-authorisation summary of positive opinion for Pandemic influenza vaccine H5N1 Baxter","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T14:00:00Z","last_updated_date":"2023-09-13T14:00:00Z","reference_number":"EMA/CHMP/648055/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pandemic-influenza-vaccine-h5n1-baxter_en.pdf"}    {"id":"26119","name":"CHMP post-authorisation summary of positive opinion for Prezista","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2015-02-09T16:20:00Z","reference_number":"EMA/CHMP/580222/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prezista_en.pdf-2"},
    {"id":"26210","name":"CHMP post-authorisation summary of positive opinion for Gazyvaro","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/265542/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gazyvaro_en.pdf"},
    {"id":"26264","name":"CVMP post-authorisation summary of positive opinion for Leucofeligen FeLV/RCP","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T18:00:00Z","last_updated_date":"2018-06-22T18:00:00Z","reference_number":"EMA/CVMP/113131/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-leucofeligen-felv-rcp_en.pdf"},
    {"id":"26300","name":"CVMP post-authorisation summary of positive opinion for Bravecto","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-03-18T01:00:00Z","last_updated_date":"2016-03-18T01:00:00Z","reference_number":"EMA/CVMP/186144/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bravecto_en.pdf"},
    {"id":"26532","name":"CHMP post-authorisation summary of positive opinion for Avandamet on 24 January 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-01-24T00:09:21Z","last_updated_date":"2016-06-09T01:09:21Z","reference_number":"EMEA/CHMP/42782/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avandamet-24-january-2008_en.pdf"},
    {"id":"26583","name":"CHMP post-authorisation summary of positive opinion for Cinryze","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T10:00:00Z","last_updated_date":"2016-12-16T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cinryze_en.pdf"},
    {"id":"26700","name":"CHMP post-authorisation summary of positive opinion for CoAprovel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/388266/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-coaprovel_en.pdf"},
    {"id":"27011","name":"CVMP post-authorisation summary of positive opinion for Draxxin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-03-13T01:00:00Z","last_updated_date":"2015-03-13T01:00:00Z","reference_number":"EMA/CVMP/156049/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-draxxin_en.pdf-0"},
    {"id":"27031","name":"CHMP post-authorisation summary of positive opinion for Alimta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/776909/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-alimta_en.pdf"},
    {"id":"27041","name":"CHMP post-authorisation summary of positive opinion for Irbesartan Hydrochlorothiazide Zentiva","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/388295/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-irbesartan-hydrochlorothiazide-zentiva_en.pdf"},
    {"id":"27088","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-07-25T02:00:00Z","reference_number":"EMA/CHMP/438693/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-4"},
    {"id":"27096","name":"CVMP post-authorisation summary of positive opinion for Draxxin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-19T01:00:00Z","last_updated_date":"2016-02-19T01:00:00Z","reference_number":"EMEA/CVMP/65204/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-draxxin_en.pdf-1"},
    {"id":"27147","name":"CHMP post-authorisation summary of positive opinion for Eliquis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/608476/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eliquis_en.pdf"},
    {"id":"27271","name":"CHMP post-authorisation summary of positive opinion for Isentress","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/CHMP/652316/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-isentress_en.pdf-0"},
    {"id":"27354","name":"CHMP post-authorisation summary of positive opinion for Ilaris","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/CHMP/789757/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ilaris_en.pdf-2"},
    {"id":"27428","name":"CHMP post-authorisation summary of positive opinion for Isentress","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/373399/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-isentress_en.pdf-1"},
    {"id":"27537","name":"CHMP post-authorisation summary of positive opinion for Azomyr on 21 February 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2008-02-21T00:09:21Z","reference_number":"EMEA/CHMP/86315/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-azomyr-21-february-2008_en.pdf"},
    {"id":"27555","name":"CVMP post-authorisation summary of positive opinion for Porcilis AR-T DF","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2010-07-16T02:00:00Z","reference_number":"EMA/CVMP/374456/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-porcilis-ar-t-df_en.pdf"},
    {"id":"27560","name":"CHMP post-authorisation summary of positive opinion for Ozurdex","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/295989/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ozurdex_en.pdf-1"},
    {"id":"27562","name":"CHMP post-authorisation summary of positive opinion for Synjardy","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T10:00:00Z","last_updated_date":"2017-01-27T10:00:00Z","reference_number":"EMA/CHMP/44144/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-synjardy_en.pdf"},
    {"id":"27583","name":"CHMP post-authorisation summary of positive opinion for Velcade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/711216/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velcade_en.pdf-1"},
    {"id":"27625","name":"CHMP post-authorisation summary of positive opinion for Bondronat","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T00:09:21Z","last_updated_date":"2009-12-17T00:09:21Z","reference_number":"EMA/824754/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bondronat_en.pdf"},
    {"id":"27645","name":"CHMP post-authorisation summary of positive opinion for Multaq","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/603654/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-multaq_en.pdf"},
    {"id":"27649","name":"CHMP post authorisation summary of positive opinion for Xelivia on 24 September 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/546145/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xelivia-24-september-2009_en.pdf"},
    {"id":"27711","name":"CHMP post-authorisation summary of positive opinion for Orencia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/486928/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-orencia_en.pdf-2"},
    {"id":"27740","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Luveniq","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/474336/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-recommendation-refusal-marketing-authorisation-luveniq_en.pdf"},
    {"id":"27798","name":"CHMP post-authorisation summary of positive opinion for Bonviva","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T00:09:21Z","last_updated_date":"2009-12-17T00:09:21Z","reference_number":"EMA/CHMP/818349/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bonviva_en.pdf"},
    {"id":"27905","name":"CHMP post-authorisation summary of positive opinion for Cimzia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMEA/CHMP/569182/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cimzia_en.pdf-0"},
    {"id":"27940","name":"CHMP post-authorisation summary of positive opinion for Eylea","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"EMA/CHMP/25641/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eylea_en.pdf-1"},
    {"id":"27954","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/CHMP/148113/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-5"},
    {"id":"28011","name":"CHMP post-authorisation summary of positive opinion for Nevanac","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T14:00:00Z","last_updated_date":"2016-06-24T14:00:00Z","reference_number":"EMA/CHMP/421658/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nevanac_en.pdf-0"},
    {"id":"28053","name":"CHMP post-authorisation summary of positive opinion for RoActemra (II/57)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/CHMP/420471/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-roactemra-ii57_en.pdf"},
    {"id":"28093","name":"CHMP post-authorisation summary of positive opinion for Baraclude","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-07-25T02:00:00Z","reference_number":"EMA/CHMP/425704/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-baraclude_en.pdf-0"},
    {"id":"28161","name":"CHMP post-authorisation summary of positive opinion for Prepandrix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/CHMP/62736/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prepandrix_en.pdf"},
    {"id":"28239","name":"CHMP post-authorisation summary of positive opinion for Relvar Ellipta (WS-1208)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T10:12:00Z","last_updated_date":"2018-01-26T10:12:00Z","reference_number":"EMA/CHMP/12287/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-relvar-ellipta-ws-1208_en.pdf"},
    {"id":"28253","name":"CHMP post-authorisation summary of positive opinion for Zonegran","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/336696/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zonegran_en.pdf"},
    {"id":"28261","name":"Committee for medicinal products for human use, post-authorisation summary of positive opinion for Januvia on 15 November 2007","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2007-12-20T01:00:00Z","last_updated_date":"2007-12-20T01:00:00Z","reference_number":"EMEA/CHMP/531209/2007","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-januvia-15-november-2007_en.pdf"},
    {"id":"28307","name":"CHMP post-authorisation summary of positive opinion for Tamiflu","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-03-27T01:00:00Z","reference_number":"EMA/186701/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tamiflu_en.pdf"},
    {"id":"28332","name":"CHMP post-authorisation summary of positive opinion for Eliquis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T14:00:00Z","last_updated_date":"2014-06-27T14:00:00Z","reference_number":"EMA/CHMP/360384/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eliquis_en.pdf-0"},
    {"id":"28447","name":"CVMP post-authorisation summary of positive opinion for Novem (X/0018)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/CVMP/140608/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-novem-x0018_en.pdf"},
    {"id":"28529","name":"CVMP post-authorisation summary of positive opinion for Semintra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-03-16T01:00:00Z","last_updated_date":"2018-03-16T01:00:00Z","reference_number":"EMA/CVMP/25787/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-semintra_en.pdf"},
    {"id":"28560","name":"CVMP post-authorisation summary of positive opinion for Metacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-05-06T02:00:00Z","last_updated_date":"2011-05-06T02:00:00Z","reference_number":"EMA/CVMP/62249/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-metacam_en.pdf-5"},
    {"id":"28580","name":"CHMP post-authorisation summary of positive opinion for Mirapexin on 25 June 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-13T02:00:00Z","last_updated_date":"2009-07-13T02:00:00Z","reference_number":"EMEA/CHMP/395371/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mirapexin-25-june-2009_en.pdf"},
    {"id":"28612","name":"CHMP post-authorisation summary of positive opinion for Glivec","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/CHMP/332285/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-glivec_en.pdf"},
    {"id":"28626","name":"CHMP post-authorisation summary of positive opinion for Zydelig","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/108191/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zydelig_en.pdf"},
    {"id":"28753","name":"CVMP post-authorisation summary of positive opinion for Aivlosin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"EMA/CVMP/585227/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-aivlosin_en.pdf-0"},
    {"id":"28889","name":"CHMP post-authorisation summary of positive opinion for Jalra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T01:00:00Z","last_updated_date":"2011-12-16T01:00:00Z","reference_number":"EMA/CHMP/975250/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jalra_en.pdf-0"},
    {"id":"28893","name":"CHMP post-authorisation summary of positive opinion for Ipreziv","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/CHMP/569645/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ipreziv_en.pdf"},
    {"id":"28898","name":"CVMP post-authorisation summary of opinion for Nexgard Spectra (II/0008)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/CVMP/159285/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-opinion-nexgard-spectra-ii0008_en.pdf"},
    {"id":"29039","name":"CVMP post-authorisation summary of positive opinion for Equip WNV","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-09-13T18:00:00Z","last_updated_date":"2013-09-13T18:00:00Z","reference_number":"EMA/CVMP/524600/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-equip-wnv_en.pdf"},
    {"id":"29071","name":"CHMP post-authorisation summary of positive opinion for Byetta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-byetta_en.pdf-0"},
    {"id":"29118","name":"CHMP post-authorisation summary of positive opinion for Gilenya","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T14:00:00Z","last_updated_date":"2015-09-25T14:00:00Z","reference_number":"EMA/CHMP/627232/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gilenya_en.pdf-0"},
    {"id":"29225","name":"CHMP post-authorisation summary of positive opinion for Bydureon","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/CHMP/405393/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bydureon_en.pdf"},
    {"id":"29313","name":"CHMP post-authorisation summary of positive opinion for Protopic on 22 January 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/40340/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-protopic-22-january-2009_en.pdf"},
    {"id":"29364","name":"CHMP post-authorisation summary of positive opinion for Icandra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/600950/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-icandra_en.pdf"},
    {"id":"29432","name":"CHMP post authorisation summary of positive opinion for Yondelis on 24 September 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/CHMP/608550/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yondelis-24-september-2009_en.pdf"},
    {"id":"29440","name":"CHMP post-authorisation summary of positive opinion for Genvoya (II-26)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T15:06:00Z","last_updated_date":"2017-11-10T15:06:00Z","reference_number":"EMA/CHMP/452568/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-genvoya-ii-26_en.pdf"},
    {"id":"29470","name":"CHMP post-authorisation summary of positive opinion for Prevenar 13","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2012-11-16T01:00:00Z","reference_number":"EMA/CHMP/717080/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prevenar-13_en.pdf"},
    {"id":"29483","name":"CHMP post-authorisation summary of positive opinion for Kyprolis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/340832/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kyprolis_en.pdf"},
    {"id":"29511","name":"CHMP post-authorisation summary of positive opinion for Feraccru","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2018-02-23T01:00:00Z","reference_number":"EMA/84262/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-feraccru_en.pdf"},
    {"id":"29572","name":"CHMP post-authorisation summary of positive opinion for Vfend","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/CHMP/306835/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vfend_en.pdf"},
    {"id":"29645","name":"CHMP post-authorisation summary of positive opinion for Caprelsa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T01:00:00Z","last_updated_date":"2016-11-11T01:00:00Z","reference_number":"EMA/CHMP/200154/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-caprelsa_en.pdf"},
    {"id":"29729","name":"CHMP post-authorisation summary of positive opinion for Dafiro HCT","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/CHMP/397292/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dafiro-hct_en.pdf"},
    {"id":"29738","name":"CHMP post-authorisation summary of positive opinion for Binocrit on 23 October 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:09:21Z","last_updated_date":"2008-10-23T02:09:21Z","reference_number":"EMEA/CHMP/567061/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-binocrit-23-october-2008_en.pdf"},
    {"id":"29839","name":"CHMP post-authorisation summary of positive opinion for Keytruda","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/CHMP/849400/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda_en.pdf-0"},
    {"id":"29845","name":"CHMP post-authorisation summary of positive opinion for Nplate","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/CHMP/849254/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nplate_en.pdf-0"},
    {"id":"30017","name":"CHMP post-authorisation summary of positive opinion for Pegasys (II-91)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-10-13T14:00:00Z","last_updated_date":"2017-10-13T14:00:00Z","reference_number":"EMA/CHMP/634272/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pegasys-ii-91_en.pdf"},
    {"id":"30137","name":"CHMP post-authorisation summary of positive opinion for  Stelara","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T14:00:00Z","last_updated_date":"2016-09-16T14:00:00Z","reference_number":"EMA/CHMP/582037/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stelara_en.pdf-2"},
    {"id":"30201","name":"CVMP post-authorisation summary of positive opinion for Advocate","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-07-10T17:00:00Z","last_updated_date":"2015-07-10T17:00:00Z","reference_number":"EMA/CVMP/467847/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-advocate_en.pdf-0"},
    {"id":"30273","name":"CHMP post-authorisation summary of positive opinion for Karvezide","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/388323/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-karvezide_en.pdf"},
    {"id":"30301","name":"CHMP post-authorisation summary of positive opinion for Tamiflu","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2005-12-14T00:09:21Z","last_updated_date":"2005-12-14T00:09:21Z","reference_number":"EMEA/CHMP/418336/2005","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tamiflu_en.pdf-0"},
    {"id":"30457","name":"CHMP post-authorisation summary of positive opinion for Halaven","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/223997/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-halaven_en.pdf-0"},
    {"id":"30689","name":"CHMP post-authorisation summary of positive opinion for Intelence","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T13:00:00Z","last_updated_date":"2012-11-16T13:00:00Z","reference_number":"EMA/CHMP/723089/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-intelence_en.pdf"},
    {"id":"30800","name":"CVMP post-authorisation summary of opinion for Advocate","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-20T03:09:21Z","last_updated_date":"2009-04-20T03:09:21Z","reference_number":"EMEA/CVMP/205582/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-opinion-advocate_en.pdf"},
    {"id":"30948","name":"CHMP post-authorisation summary of positive opinion for RoActemra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T02:00:00Z","last_updated_date":"2013-04-26T02:00:00Z","reference_number":"EMA/CHMP/236919/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-roactemra_en.pdf-1"},
    {"id":"31122","name":"CHMP post-authorisation summary of positive opinion for Afinitor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/269366/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-afinitor_en.pdf-0"},
    {"id":"31130","name":"CVMP post-authorisation summary of positive opinion for Onsior","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-03-16T01:00:00Z","last_updated_date":"2018-03-16T01:00:00Z","reference_number":"EMA/CVMP/843508/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-onsior_en.pdf-0"},
    {"id":"31135","name":"CHMP post-authorisation summary of positive opinion for Reyataz","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/265549/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-reyataz_en.pdf-0"},
    {"id":"31188","name":"CVMP post-authorisation summary of positive opinion for Inflacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-14T02:00:00Z","last_updated_date":"2012-09-14T02:00:00Z","reference_number":"EMA/CVMP/396530/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-inflacam_en.pdf-1"},
    {"id":"31222","name":"CHMP post-authorisation summary of positive opinion for Stivarga","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/365741/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stivarga_en.pdf"},
    {"id":"31338","name":"CHMP post-authorisation summary of positive opinion for Gardasil","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/CHMP/243054/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gardasil_en.pdf"},
    {"id":"31539","name":"CHMP post-authorisation summary of positive opinion for Keytruda","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/CHMP/406390/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda_en.pdf-1"},
    {"id":"31599","name":"CVMP post-authorisation summary of negative opinion for Suvaxyn PCV","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T18:00:00Z","last_updated_date":"2020-04-15T18:00:00Z","reference_number":"EMA/CVMP/404045/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-negative-opinion-suvaxyn-pcv_en.pdf"},
    {"id":"31601","name":"CHMP post-authorisation summary of positive opinion for Blincyto (II-18)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T16:34:00Z","last_updated_date":"2018-07-27T16:34:00Z","reference_number":"EMA/CHMP/518362/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-blincyto-ii-18_en.pdf"},
    {"id":"31603","name":"CHMP post-authorisation summary of positive opinion for Kiovig","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/495548/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kiovig_en.pdf"},
    {"id":"31672","name":"CHMP post-authorisation summary of positive opinion for Revlimid","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T02:00:00Z","last_updated_date":"2013-04-26T02:00:00Z","reference_number":"EMA/CHMP/244652/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revlimid_en.pdf-1"},
    {"id":"31690","name":"Questions and answers on the recommendation for the refusal of a change to the marketing authorisation for Vectibix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"EMA/213981/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-vectibix_en.pdf"},
    {"id":"31781","name":"CHMP post-authorisation summary of positive opinion for Ilaris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/CHMP/827091/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ilaris_en.pdf-3"},
    {"id":"31842","name":"CHMP post-authorisation summary of positive opinion for Galvus","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T16:43:00Z","last_updated_date":"2011-12-16T16:43:00Z","reference_number":"EMA/CHMP/966346/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-galvus_en.pdf-0"},
    {"id":"32006","name":"CHMP post-authorisation summary of positive opinion for Kuvan","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/324747/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kuvan_en.pdf"},
    {"id":"32007","name":"CHMP post-authorisation summary of positive opinion for Januvia on 24 September 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/545425/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-januvia-24-september-2009_en.pdf"},
    {"id":"32095","name":"CHMP post authorisation positive summary of opinion for M-M-RVaxPro","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2010-07-23T02:00:00Z","reference_number":"EMA/CHMP/477330/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-positive-summary-opinion-m-m-rvaxpro_en.pdf"},
    {"id":"32247","name":"CVMP post-authorisation summary of positive opinion for Aftovaxpur DOE","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-03-14T01:00:00Z","last_updated_date":"2023-07-04T01:00:00Z","reference_number":"EMA/CVMP/109591/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-aftovaxpur-doe_en.pdf"},
    {"id":"32325","name":"CHMP post-authorisation summary of positive opinion for Aclasta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T16:43:00Z","last_updated_date":"2011-12-16T16:43:00Z","reference_number":"EMA/CHMP/966950/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aclasta_en.pdf"},
    {"id":"32408","name":"CVMP post-authorisation summary of positive opinion for Pexion","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2018-05-28T18:00:00Z","last_updated_date":"2018-05-28T18:00:00Z","reference_number":"EMA/CVMP/293399/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-pexion_en.pdf"},
    {"id":"32501","name":"CVMP post-authorisation summary of positive opinion for Simparica","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T17:30:00Z","last_updated_date":"2017-09-08T17:30:00Z","reference_number":"EMA/CVMP/557544/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-simparica_en.pdf"},
    {"id":"32515","name":"CHMP post-authorisation summary of positive opinion for Emend","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/CHMP/697606/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-emend_en.pdf"},
    {"id":"32547","name":"CHMP post-authorisation summary of positive opinion for Pegasys","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-01-18T13:00:00Z","reference_number":"EMA/CHMP/29025/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pegasys_en.pdf-0"},
    {"id":"32618","name":"CHMP post-authorisation summary of positive opinion for Cosentyx","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/CHMP/670627/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx_en.pdf"},
    {"id":"32645","name":"CHMP post-authorisation summary of positive opinion for RoActemra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2010-04-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-roactemra_en.pdf-2"}    {"id":"32693","name":"CVMP post-authorisation summary of positive opinion for Naxcel","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-05-06T02:00:00Z","last_updated_date":"2011-05-06T02:00:00Z","reference_number":"EMA/CVMP/62249/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-naxcel_en.pdf"},
    {"id":"32711","name":"CHMP post-authorisation summary of positive opinion for Simponi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/CHMP/793256/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-simponi_en.pdf-2"},
    {"id":"32757","name":"CHMP post-authorisation summary of positive opinion for Cabometyx (II-03)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T15:46:00Z","last_updated_date":"2018-03-23T15:46:00Z","reference_number":"EMA/CHMP/175713/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cabometyx-ii-03_en.pdf"},
    {"id":"32785","name":"CHMP post-authorisation summary of positive opinion for Isentress on 23 July 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/471151/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-isentress-23-july-2009_en.pdf"},
    {"id":"32817","name":"CHMP post-authorisation summary of positive opinion for Cimzia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T14:00:00Z","last_updated_date":"2013-10-25T14:00:00Z","reference_number":"EMA/CHMP/617166/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cimzia_en.pdf-1"},
    {"id":"32848","name":"CHMP post-authorisation summary of positive opinion for Inovelon","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T14:00:00Z","last_updated_date":"2018-06-29T14:00:00Z","reference_number":"EMA/CHMP/414679/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-inovelon_en.pdf"},
    {"id":"32947","name":"CHMP post-authorisation summary of positive opinion for Bydureon","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-10-13T02:00:00Z","last_updated_date":"2017-10-13T02:00:00Z","reference_number":"EMA/659394/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bydureon_en.pdf-0"},
    {"id":"32970","name":"CVMP post-authorisation summary of positive opinion for DraxxinII","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-09-09T02:00:00Z","last_updated_date":"2016-09-09T02:00:00Z","reference_number":"EMA/CVMP/586537/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-draxxinii_en.pdf"},
    {"id":"32989","name":"CHMP post-authorisation summary of positive opinion for Soliris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/771662/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-soliris_en.pdf-2"},
    {"id":"33020","name":"CHMP post-authorisation summary of positive opinion for Repatha II-17-G","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T13:00:00Z","last_updated_date":"2018-03-23T13:00:00Z","reference_number":"EMA/CHMP/799799/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-repatha-ii-17-g_en.pdf"},
    {"id":"33125","name":"CHMP post-authorisation summary of positive opinion for Prevenar 13","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-05-30T02:00:00Z","last_updated_date":"2013-05-30T02:00:00Z","reference_number":"EMA/CHMP/327906/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prevenar-13_en.pdf-0"},
    {"id":"33294","name":"CHMP post-authorisation summary of positive opinion for Opdivo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T19:00:00Z","last_updated_date":"2017-04-21T19:00:00Z","reference_number":"EMA/CHMP/251204/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo_en.pdf-3"},
    {"id":"33312","name":"CHMP post-authorisation summary of positive opinion for Hizentra (II-0087)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/48689/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-hizentra-ii-0087_en.pdf"},
    {"id":"33442","name":"CVMP post-authorisation summary of positive opinion for Comfortis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-09T16:30:00Z","last_updated_date":"2023-06-26T16:30:00Z","reference_number":"EMA/CVMP/676652/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-comfortis_en.pdf"},
    {"id":"33549","name":"CHMP post-authorisation summary of positive opinion for Stribild","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/CHMP/603432/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stribild_en.pdf"},
    {"id":"33591","name":"CVMP post-authorisation summary of positive opinion for Melovem","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T18:00:00Z","last_updated_date":"2013-07-19T18:00:00Z","reference_number":"EMA/CVMP/384390/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-melovem_en.pdf-0"},
    {"id":"33596","name":"CHMP post-authorisation summary of positive opinion for Viread","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/CHMP/161713/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viread_en.pdf-0"},
    {"id":"33650","name":"CHMP post-authorisation summary of positive opinion for Invega","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/243851/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-invega_en.pdf-1"},
    {"id":"33676","name":"CVMP post-authorisation summary of positive opinion for Profender","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2016-03-18T01:00:00Z","last_updated_date":"2016-03-18T01:00:00Z","reference_number":"EMA/CVMP/159748/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-profender_en.pdf-0"},
    {"id":"33682","name":"CHMP post-authorisation summary of positive opinion for Velcade on 24 July 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/382041/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velcade-24-july-2008_en.pdf"},
    {"id":"33723","name":"CHMP post-authorisation summary of positive opinion for Karvea","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/388307/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-karvea_en.pdf"},
    {"id":"33777","name":"CHMP post-authorisation summary of positive opinion for Nucala","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/CHMP/489705/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nucala_en.pdf"},
    {"id":"33871","name":"CHMP post-authorisation summary of positive opinion for Zonegran","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/CHMP/416989/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zonegran_en.pdf-0"},
    {"id":"34015","name":"CHMP post-authorisation summary of positive opinion for Cancidas on 25 September 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-09-25T02:09:21Z","last_updated_date":"2008-09-25T02:09:21Z","reference_number":"EMEA/CHMP/505041/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cancidas-25-september-2008_en.pdf"},
    {"id":"34025","name":"CHMP post-authorisation summary of positive opinion for Ferriprox","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/284564/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ferriprox_en.pdf"},
    {"id":"34046","name":"CHMP post-authorisation summary of positive opinion for Abilify on 21 February 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/CHMP/69701/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abilify-21-february-2008_en.pdf"},
    {"id":"34056","name":"CHMP post-authorisation summary of positive opinion for Remicade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"EMA/CHMP/221507/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-remicade_en.pdf-0"},
    {"id":"34107","name":"CVMP post-authorisation summary of opinion for Broadline (II/0013)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-05-15T02:00:00Z","last_updated_date":"2017-05-15T02:00:00Z","reference_number":"EMA/CVMP/259214/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-opinion-broadline-ii0013_en.pdf"},
    {"id":"34170","name":"CHMP post-authorisation positive summary of opinion for Teysuno","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T12:50:00Z","last_updated_date":"2011-12-16T12:50:00Z","reference_number":"EMA/796457/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-positive-summary-opinion-teysuno_en.pdf"},
    {"id":"34220","name":"CHMP post-authorisation summary of positive opinion for Sifrol on 25 June 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/391474/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sifrol-25-june-2009_en.pdf"},
    {"id":"34773","name":"CHMP post-authorisation summary of positive opinion for Viekirax (WS-1348)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2024-10-02T14:00:00Z","reference_number":"EMA/CHMP/500340/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viekirax-ws-1348_en.pdf"},
    {"id":"34852","name":"CHMP post-authorisation summary of positive opinion for Abseamed on 23 October 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:00:00Z","last_updated_date":"2008-10-23T02:00:00Z","reference_number":"EMEA/CHMP/567083/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abseamed-23-october-2008_en.pdf"},
    {"id":"34955","name":"CVMP post-authorisation summary of positive opinion for SevoFlo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-10-06T02:00:00Z","last_updated_date":"2017-10-06T02:00:00Z","reference_number":"EMA/CVMP/628411/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-sevoflo_en.pdf"},
    {"id":"34974","name":"CVMP post-authorisation summary of positive opinion for Novem","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-09T16:30:00Z","last_updated_date":"2012-11-09T16:30:00Z","reference_number":"EMA/CVMP/722500/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-novem_en.pdf"},
    {"id":"35007","name":"CHMP post-authorisation summary of positive opinion for Arzerra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/CHMP/312178/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-arzerra_en.pdf-0"},
    {"id":"35009","name":"Questions and answers on recommendation for the refusal of a change to the marketing authorisation for Zavesca","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2007-10-18T02:09:21Z","last_updated_date":"2007-10-18T02:09:21Z","reference_number":"EMEA/461135/2007","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-zavesca_en.pdf"},
    {"id":"35027","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-02-18T01:00:00Z","last_updated_date":"2011-02-18T01:00:00Z","reference_number":"CHMP post-authorisation summary of positive opinio","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-6"},
    {"id":"35077","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-10-11T14:00:00Z","last_updated_date":"2016-10-11T14:00:00Z","reference_number":"EMA/CHMP/691443/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-7"},
    {"id":"35165","name":"CHMP post-authorisation summary of positive opinion for Xarelto","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"MA/CHMP/183242/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xarelto_en.pdf-0"},
    {"id":"35221","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-01-18T13:00:00Z","reference_number":"EMA/CHMP/30243/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-8"},
    {"id":"35333","name":"CHMP post-authorisation summary of positive opinion for Xalkori","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T14:00:00Z","last_updated_date":"2015-10-23T14:00:00Z","reference_number":"EMA/CHMP/489271/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xalkori_en.pdf-0"},
    {"id":"35438","name":"CHMP post-authorisation summary of positive opinion for Zeffix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-05-21T02:00:00Z","last_updated_date":"2010-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zeffix_en.pdf"},
    {"id":"35481","name":"CHMP post-authorisation summary of positive opinion for Tasigna","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T12:21:00Z","last_updated_date":"2017-09-15T12:21:00Z","reference_number":"EMA/CHMP/595185/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tasigna_en.pdf"},
    {"id":"35537","name":"CHMP post-authorisation summary of positive opinion for Ruconest","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T01:00:00Z","last_updated_date":"2016-11-11T01:00:00Z","reference_number":"EMA/CHMP/732641/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ruconest_en.pdf"},
    {"id":"35590","name":"CHMP post-authorisation summary of positive opinion for Tagrisso II/0019","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"EMA/CHMP/254059/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tagrisso-ii0019_en.pdf"},
    {"id":"35686","name":"CHMP post-authorisation summary of positive opinion for Volibris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMEA/CHMP/423444/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-volibris_en.pdf-0"},
    {"id":"35711","name":"CHMP post-authorisation summary of positive opinion for Taxotere","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-taxotere_en.pdf-0"},
    {"id":"35849","name":"CHMP post-authorisation summary of positive opinion for Cervarix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/CHMP/389753/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cervarix_en.pdf-1"},
    {"id":"35860","name":"CHMP post-authorisation summary of positive opinion for Velcade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/CHMP/252977/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velcade_en.pdf-2"},
    {"id":"35965","name":"CHMP post-authorisation summary of positive opinion for Pradaxa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/252976/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pradaxa_en.pdf-4"},
    {"id":"36163","name":"CHMP post-authorisation summary of positive opinion for Eylea","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/CHMP/185823/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eylea_en.pdf-2"},
    {"id":"36187","name":"CHMP post-authorisation summary of positive opinion for Procoralan","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/CHMP/712673/2013  ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-procoralan_en.pdf"},
    {"id":"36192","name":"CHMP post-authorisation summary of positive opinion for Eucreas","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/600949/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eucreas_en.pdf"},
    {"id":"36193","name":"CVMP post-authorisation summary of positive opinion for Stronghold","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2015-01-16T01:00:00Z","reference_number":"EMA/737305/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-stronghold_en.pdf"},
    {"id":"36355","name":"CHMP post-authorisation summary of positive opinion for Micardis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/CHMP/261191/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-micardis_en.pdf"},
    {"id":"36463","name":"CHMP post-authorisation summary of positive opinion for Aclasta on 24 July 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/391587/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aclasta-24-july-2008_en.pdf"},
    {"id":"36519","name":"CHMP post-authorisation summary of positive opinion for SonoVue","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T17:53:00Z","last_updated_date":"2017-06-23T17:53:00Z","reference_number":"EMA/CHMP/347620/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sonovue_en.pdf"},
    {"id":"36564","name":"CHMP post-authorisation summary of positive opinion for Herceptin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T11:16:00Z","last_updated_date":"2011-11-18T11:16:00Z","reference_number":"EMA/CHMP/897580/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-herceptin_en.pdf-1"},
    {"id":"36570","name":"CHMP post-authorisation summary of positive opinion for Afinitor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CHMP/402772/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-afinitor_en.pdf-1"},
    {"id":"36641","name":"CVMP post-authorisation summary of positive opinion for Rheumocam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-11-11T01:00:00Z","last_updated_date":"2011-11-11T01:00:00Z","reference_number":"EMA/CVMP/765011/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-rheumocam_en.pdf-2"},
    {"id":"36707","name":"CHMP post-authorisation summary of positive opinion for Enbrel on 20 November 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-11-20T00:09:21Z","last_updated_date":"2008-11-20T00:09:21Z","reference_number":"EMEA/CHMP/594954/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enbrel-20-november-2008_en.pdf"},
    {"id":"36710","name":"CHMP post-authorisation summary of positive opinion for Mekinist","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T14:00:00Z","last_updated_date":"2015-07-24T14:00:00Z","reference_number":"EMA/CHMP/444362/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mekinist_en.pdf-0"},
    {"id":"36718","name":"CHMP post-authorisation summary of positive opinion for Azopt on 24 April 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-04-24T02:09:21Z","last_updated_date":"2008-04-24T02:09:21Z","reference_number":"EMEA/CHMP/216404/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-azopt-24-april-2008_en.pdf"},
    {"id":"36733","name":"CHMP post-authorisation summary of positive opinion for Xarelto","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/CHMP/676157/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xarelto_en.pdf-1"},
    {"id":"36753","name":"CVMP post authorisation positive summary of opinion for Tyverb","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2010-02-19T01:00:00Z","reference_number":"EMA/CHMP/85718/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-positive-summary-opinion-tyverb_en.pdf"},
    {"id":"36801","name":"Questions and answers on refusal of a change to the marketing authorisation for Sutent (sunitinib)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"EMA/113242/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-sutent-sunitinib_en.pdf"},
    {"id":"36838","name":"CHMP post-authorisation summary of positive opinion for Erbitux","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-06-09T02:00:00Z","last_updated_date":"2011-06-09T02:00:00Z","reference_number":"EMA/CHMP/398312/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-erbitux_en.pdf-1"},
    {"id":"36849","name":"CHMP post-authorisation summary of positive opinion for Revolade","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T13:00:00Z","last_updated_date":"2015-12-18T13:00:00Z","reference_number":"EMA/CHMP/671604/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revolade_en.pdf-2"},
    {"id":"36896","name":"CHMP post-authorisation summary of positive opinion for Signifor","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/524720/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-signifor_en.pdf"},
    {"id":"36919","name":"CHMP post-authorisation summary of positive opinion for Lantus","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2012-04-20T02:00:00Z","reference_number":"EMA/CHMP/184674/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lantus_en.pdf"},
    {"id":"36972","name":"CHMP post-authorisation summary of positive opinion for Onglyza","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T01:00:00Z","last_updated_date":"2013-01-18T01:00:00Z","reference_number":"EMA/CHMP/35984/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-onglyza_en.pdf-1"},
    {"id":"37029","name":"CHMP post-authorisation summary of positive opinion for Vectibix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T13:00:00Z","last_updated_date":"2015-02-27T13:00:00Z","reference_number":"EMA/CHMP/119269/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vectibix_en.pdf-1"},
    {"id":"37087","name":"Questions and answers on refusal of a change to the marketing authorisation for Arzerra (ofatumumab)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/433595/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-arzerra-ofatumumab_en.pdf"},
    {"id":"37107","name":"CHMP summary of positive opinion for Akynzeo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-03-27T01:00:00Z","reference_number":"EMA/CHMP/169908/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-akynzeo_en.pdf"},
    {"id":"37111","name":"CHMP post-authorisation summary of positive opinion for Gardasil","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gardasil_en.pdf-0"},
    {"id":"37122","name":"CHMP post authorisation summary of positive opinion for Velmetia of 24 September 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/CHMP/544764/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velmetia-24-september-2009_en.pdf"},
    {"id":"37148","name":"CHMP post-authorisation summary of positive opinion for Ameluz","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/485818/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ameluz_en.pdf-0"},
    {"id":"37175","name":"CHMP post-authorisation summary of positive opinion for Xtandi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/647461/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xtandi_en.pdf"},
    {"id":"37275","name":"CHMP post-authorisation summary of positive opinion for Votubia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/543900/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-votubia_en.pdf-1"},
    {"id":"37381","name":"CHMP post-authorisation summary of positive opinion for Xiliarx","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/600947/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xiliarx_en.pdf-0"},
    {"id":"37382","name":"CHMP post-authorisation summary of positive opinion for Tesavel of 24 September 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/546109/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tesavel-24-september-2009_en.pdf"},
    {"id":"37454","name":"CHMP post authorisation summary of positive opinion for Efficib of 24 September 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/CHMP/544759/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-efficib-24-september-2009_en.pdf"},
    {"id":"37462","name":"CVMP post-authorisation summary of positive opinion for Comfortis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-09-13T18:00:00Z","last_updated_date":"2023-06-26T18:00:00Z","reference_number":"EMA/CVMP/490575/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-comfortis_en.pdf-0"},
    {"id":"37547","name":"CHMP post-authorisation summary of positive opinion for Renvela (WS/965)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-05-22T17:11:00Z","last_updated_date":"2017-05-22T17:11:00Z","reference_number":"EMA/CHMP/314225/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-renvela-ws965_en.pdf"},
    {"id":"37568","name":"CHMP post-authorisation summary of positive opinion for Tarceva","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/585446/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tarceva_en.pdf-0"},
    {"id":"37681","name":"CHMP post-authorisation summary of positive opinion for Cubicin (II-61)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-10-13T14:00:00Z","last_updated_date":"2017-10-13T14:00:00Z","reference_number":"EMA/CHMP/664609/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cubicin-ii-61_en.pdf"},
    {"id":"37839","name":"CHMP post-authorisation summary of positive opinion for Pegasys on 23 October 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:00:00Z","last_updated_date":"2008-10-23T02:00:00Z","reference_number":"EMEA/CHMP/561136/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pegasys-23-october-2008_en.pdf"},
    {"id":"38150","name":"CVMP post-authorisation summary of positive opinion for Metacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-04-16T02:00:00Z","last_updated_date":"2010-04-16T02:00:00Z","reference_number":"EMA/CVMP/139659/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-metacam_en.pdf-6"},
    {"id":"38172","name":"CVMP post-authorisation summary of positive opinion for Onsior","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-09T16:30:00Z","last_updated_date":"2012-11-09T16:30:00Z","reference_number":"EMA/CVMP/683698/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-onsior_en.pdf-1"},
    {"id":"38199","name":"CHMP post-authorisation summary of positive opinion for Avastin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/365686/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avastin_en.pdf-5"},
    {"id":"38209","name":"CHMP post-authorisation summary of positive opinion for Truvada (II-135)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/CHMP/804062/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-truvada-ii-135_en.pdf"},
    {"id":"38270","name":"CHMP post-authorisation summary of positive opinion for Aptivus on 23 April 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:09:21Z","last_updated_date":"2009-04-23T02:09:21Z","reference_number":"EMEA/CHMP/232469/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aptivus-23-april-2009_en.pdf-0"},
    {"id":"38283","name":"CVMP summary of opinion for Aivlosin 625 mg/g granules for use in drinking water for pigs","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-03-13T00:09:00Z","last_updated_date":"2009-03-13T00:09:00Z","reference_number":"EMEA/CVMP/106523/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-summary-opinion-aivlosin-625-mgg-granules-use-drinking-water-pigs_en.pdf"},
    {"id":"38399","name":"CHMP post-authorisation summary of positive opinion for Repatha","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-repatha_en.pdf"},
    {"id":"38473","name":"CHMP post-authorisation summary of positive opinion for Kalydeco (II-63-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/506642/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-ii-63-g_en.pdf"},
    {"id":"38500","name":"Committee for medicinal products for human use, post-authorisation summary of positive opinion for Tarceva on 14 December 2006","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2008-01-09T01:00:00Z","last_updated_date":"2008-01-09T01:00:00Z","reference_number":"EMEA/CHMP/511166/2006","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-tarceva-14-december-2006_en.pdf"},
    {"id":"38609","name":"Committee for medicinal products for veterinary use post-authoriastion summary of opinion: Flexicam: International Non-proprietary Name (INN): Meloxicam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-10-17T03:09:21Z","last_updated_date":"2014-05-20T03:09:21Z","reference_number":"EMEA/CVMP/512816/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/committee-medicinal-products-veterinary-use-post-authoriastion-summary-opinion-flexicam-international-non-proprietary-name-inn-meloxicam_en.pdf"},
    {"id":"38700","name":"CHMP post-authorisation summary of positive opinion for Ventavis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T13:00:00Z","last_updated_date":"2012-03-16T13:00:00Z","reference_number":"EMA/CHMP/191421/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ventavis_en.pdf"},
    {"id":"38743","name":"CHMP post-authorisation summary of positive opinion for Ivemend","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"EMA/CHMP/171802/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ivemend_en.pdf"},
    {"id":"38843","name":"CHMP post-authorisation summary of positive opinion for Docetaxel Winthrop","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-05-21T02:00:00Z","last_updated_date":"2022-05-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-docetaxel-winthrop_en.pdf-0"}    {"id":"38957","name":"CHMP post-authorisation summary of positive opinion for Yervoy","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/547838/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yervoy_en.pdf"},
    {"id":"38991","name":"CVMP summary of opinion: Aivlosin (previously: acetylisovaleryltylosin)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-03-14T01:09:00Z","last_updated_date":"2008-03-14T01:09:00Z","reference_number":"EMEA/CVMP/91929/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-summary-opinion-aivlosin-previously-acetylisovaleryltylosin_en.pdf"},
    {"id":"39076","name":"CHMP post-authorisation summary of positive opinion for Simponi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/CHMP/365481/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-simponi_en.pdf-3"},
    {"id":"39135","name":"CHMP post-authorisation summary of positive opinion for Plavix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2010-11-19T01:00:00Z","reference_number":"EMA/CHMP/740480/2010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-plavix_en.pdf"},
    {"id":"39156","name":"CHMP post-authorisation summary of positive opinion for Thymanax","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2023-08-08T02:00:00Z","reference_number":"EMA/CHMP/578213/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-thymanax_en.pdf"},
    {"id":"39187","name":"CHMP post-authorisation summary of positive opinion for Ixiaro","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/CHMP/800917/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ixiaro_en.pdf"},
    {"id":"39326","name":"CHMP post-authorisation summary of positive opinion for Abraxane","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/627632/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abraxane_en.pdf-0"},
    {"id":"39508","name":"CHMP post-authorisation summary of positive opinion for Faslodex","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T14:00:00Z","last_updated_date":"2017-06-23T14:00:00Z","reference_number":"EMA/CHMP/398319/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-faslodex_en.pdf-0"},
    {"id":"39671","name":"CVMP post-authorisation summary of negative opinion for Bravecto","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"EMA/CVMP/750172/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-negative-opinion-bravecto_en.pdf"},
    {"id":"39792","name":"CVMP post-authorisation summary of positive opinion for Metacam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-11-09T16:30:00Z","last_updated_date":"2012-11-09T16:30:00Z","reference_number":"EMA/CVMP/585201/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-metacam_en.pdf-7"},
    {"id":"39849","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CHMP/422860/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-9"},
    {"id":"39907","name":"CHMP post-authorisation summary of positive opinion for Epoetin alfa Hexal on 23 October 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:09:21Z","last_updated_date":"2008-10-23T02:09:21Z","reference_number":"EMEA/CHMP/567074/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-epoetin-alfa-hexal-23-october-2008_en.pdf"},
    {"id":"39918","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-0014)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T13:00:00Z","last_updated_date":"2017-03-24T13:00:00Z","reference_number":"EMA/CHMP/162113/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-0014_en.pdf"},
    {"id":"39941","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/CHMP/365477/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-10"},
    {"id":"39956","name":"CHMP post-authorisation summary of positive opinion for Twynsta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T02:00:00Z","last_updated_date":"2013-04-26T02:00:00Z","reference_number":"EMA/CHMP/261191/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-twynsta_en.pdf"},
    {"id":"39961","name":"CHMP post-authorisation summary of positive opinion for Adenuric on 21 February 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/CHMP/80751/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adenuric-21-february-2008_en.pdf"},
    {"id":"40018","name":"CHMP post-authorisation summary of positive opinion for Sebivo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2021-01-14T01:00:00Z","reference_number":"EMA/CHMP/123824/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sebivo_en.pdf"},
    {"id":"40088","name":"CHMP post authorisation summary of positive opinion for Xelivia on 23 April 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/240341/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xelivia-23-april-2009_en.pdf"},
    {"id":"40152","name":"CHMP post-authorisation summary of positive opinion for Viread","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/609388/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viread_en.pdf-1"},
    {"id":"40171","name":"CHMP post-authorisation summary of positive opinion for Imbruvica","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T14:00:00Z","last_updated_date":"2015-05-22T14:00:00Z","reference_number":"EMA/CHMP/281931/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imbruvica_en.pdf-1"},
    {"id":"40209","name":"CHMP post-authorisation summary of positive opinion for Orkambi (X-20)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/738556/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-orkambi-x-20_en.pdf"},
    {"id":"40319","name":"CHMP post-authorisation summary of positive opinion for Tysabri","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/321062/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tysabri_en.pdf-0"},
    {"id":"40377","name":"CHMP post-authorisation summary of positive opinion for Prevenar 13","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"EMA/CHMP/39942/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prevenar-13_en.pdf-1"},
    {"id":"40381","name":"CHMP post-authorisation summary of positive opinion for Prezista on 23 April 2009","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/237260/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prezista-23-april-2009_en.pdf"},
    {"id":"40538","name":"CHMP post-authorisation summary of positive opinion for RoActemra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/CHMP/419360/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-roactemra_en.pdf-3"},
    {"id":"40548","name":"CHMP post-authorisation summary of positive opinion for Zebinix","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2016-10-14T14:00:00Z","reference_number":"EMA/CHMP/643479/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zebinix_en.pdf-0"},
    {"id":"40586","name":"CHMP post-authorisation summary of positive opinion for Mimpara on 24 April 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2026-05-20T02:00:00Z","reference_number":"EMEA/CHMP/206457/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mimpara-24-april-2008_en.pdf"},
    {"id":"40641","name":"CHMP post-authorisation summary of positive opinion for Onduarp","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2014-04-02T14:00:00Z","reference_number":"EMA/CHMP/261191/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-onduarp_en.pdf"},
    {"id":"40735","name":"CHMP post-authorisation summary of positive opinion for Opdivo","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T13:00:00Z","last_updated_date":"2017-03-24T13:00:00Z","reference_number":"EMA/CHMP/193182/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo_en.pdf-4"},
    {"id":"40802","name":"CHMP post-authorisation summary of positive opinion for Darzalex","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2017-02-24T01:00:00Z","reference_number":"EMA/CHMP/126505/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-darzalex_en.pdf"},
    {"id":"40815","name":"CHMP post-authorisation summary of positive opinion for MabThera","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/CHMP/166944/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera_en.pdf-0"},
    {"id":"40851","name":"CHMP post-authorisation summary of positive opinion for Komboglyze","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T01:00:00Z","last_updated_date":"2013-01-18T01:00:00Z","reference_number":"EMA/CHMP/35983/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-komboglyze_en.pdf-1"},
    {"id":"40908","name":"CHMP post-authorisation summary of positive opinion for Revinty Ellipta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/53722/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revinty-ellipta_en.pdf"},
    {"id":"40956","name":"CHMP post-authorisation summary of positive opinion for Brivaness","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-02-18T01:00:00Z","last_updated_date":"2011-02-18T01:00:00Z","reference_number":"EMA/CHMP/131489/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-brivaness_en.pdf"},
    {"id":"41027","name":"CVMP post-authorisation summary of positive opinion for Rheumocam","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMA/CVMP/9999/2011","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-rheumocam_en.pdf-3"},
    {"id":"41256","name":"CHMP post-authorisation summary of positive opinion for Prezista","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"EMA/CHMP/487381/2012","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prezista_en.pdf-3"},
    {"id":"41287","name":"CHMP post-authorisation summary of positive opinion for Cymbalta on 26 June 2008","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-06-26T02:00:00Z","last_updated_date":"2008-06-26T02:00:00Z","reference_number":"EMEA/CHMP/335965/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cymbalta-26-june-2008_en.pdf"},
    {"id":"41324","name":"CVMP post-authorisation summary of opinion for Profender","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2008-06-20T03:09:21Z","last_updated_date":"2008-06-20T03:09:21Z","reference_number":"EMEA/CVMP/314204/2008","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-opinion-profender_en.pdf"},
    {"id":"41403","name":"CVMP post-authorisation summary of negative opinion for Suvaxyn PCV","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-11-08T18:00:00Z","last_updated_date":"2020-04-15T18:00:00Z","reference_number":"EMA/CVMP/686504/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-negative-opinion-suvaxyn-pcv_en.pdf-0"},
    {"id":"41422","name":"CHMP post-authorisation summary of positive opinion for Mekinist (WS/1274)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/297226/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mekinist-ws1274_en.pdf"},
    {"id":"41468","name":"CHMP post-authorisation summary of positive opinion for Zydelig","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/500725/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zydelig_en.pdf-0"},
    {"id":"41506","name":"CHMP post-authorisation summary of positive opinion for Valdoxan","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/577714/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-valdoxan_en.pdf"},
    {"id":"41540","name":"CHMP post-authorisation summary of positive opinion for Pradaxa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/CHMP/719108/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pradaxa_en.pdf-5"},
    {"id":"41582","name":"CHMP post-authorisation summary of positive opinion for Ruconest","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/CHMP/137174/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ruconest_en.pdf-0"},
    {"id":"41609","name":"Questions and answers on recommendation for the refusal of a change to the marketing authorisation for Lyrica","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2009-07-24T02:00:00Z","last_updated_date":"2009-07-24T02:00:00Z","reference_number":"EMEA/464033/2009","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-lyrica_sv.pdf"}},
    {"id":"41611","name":"CHMP post-authorisation summary of positive opinion for Yervoy (II-44)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/CHMP/807424/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yervoy-ii-44_en.pdf"},
    {"id":"41629","name":"CVMP post-authorisation summary of positive opinion for Vectormune ND (II/0007)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-01-19T01:00:00Z","last_updated_date":"2018-01-19T01:00:00Z","reference_number":"EMA/CVMP/739766/2017","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-vectormune-nd-ii0007_en.pdf"},
    {"id":"41740","name":"CHMP post-authorisation summary of positive opinion for Humira","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/329583/2016","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira_en.pdf-11"},
    {"id":"41778","name":"CHMP post-authorisation summary of positive opinion for Cubicin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/CHMP/670705/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cubicin_en.pdf"},
    {"id":"41792","name":"CHMP post-authorisation summary of positive opinion for Tafinlar (WS-1274)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/457561/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tafinlar-ws-1274_en.pdf"},
    {"id":"41805","name":"CHMP post-authorisation summary of positive opinion for Levemir","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/CHMP/272298/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-levemir_en.pdf-1"},
    {"id":"41874","name":"CHMP post-authorisation summary of positive opinion for Copalia","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-06-26T14:00:00Z","last_updated_date":"2013-06-26T14:00:00Z","reference_number":"EMA/CHMP/397192/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-copalia_en.pdf"},
    {"id":"41885","name":"CHMP post-authorisation summary of positive opinion for Kineret","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/569575/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kineret_en.pdf-0"},
    {"id":"41888","name":"CHMP post-authorisation summary of positive opinion for Avastin","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/CHMP/43975/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avastin_en.pdf-6"},
    {"id":"41925","name":"CHMP post-authorisation summary of positive opinion for Aloxi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"EMA/CHMP/39940/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aloxi_en.pdf"},
    {"id":"41934","name":"CVMP post-authorisation summary of positive opinion for Leucogen","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T18:00:00Z","last_updated_date":"2018-06-22T18:00:00Z","reference_number":"EMA/CVMP/113131/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-leucogen_en.pdf"},
    {"id":"41947","name":"Questions and answers on the refusal of a change to the marketing authorisation for Avastin (bevacizumab)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-11-18T13:00:00Z","reference_number":"EMA/577647/2014","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_sv.pdf"}},
    {"id":"41958","name":"CHMP post-authorisation summary of positive opinion for Eviplera","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T02:00:00Z","last_updated_date":"2013-10-25T02:00:00Z","reference_number":"EMA/CHMP/656293/2013","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eviplera_en.pdf"},
    {"id":"42007","name":"CHMP post-authorisation summary of positive opinion for Tarceva","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T13:00:00Z","last_updated_date":"2015-12-18T13:00:00Z","reference_number":"EMA/CHMP/816956/2015","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tarceva_en.pdf-1"},
    {"id":"42047","name":"CHMP summary of positive opinion for Venclyxto (II/08)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/CHMP/599359/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-venclyxto-ii08_en.pdf"},
    {"id":"42051","name":"CVMP post-authorisation summary of positive opinion for Inflacam (X-0015)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-14T02:00:00Z","last_updated_date":"2018-09-14T02:00:00Z","reference_number":"EMA/CVMP/543202/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-inflacam-x-0015_en.pdf"},
    {"id":"42052","name":"CVMP post-authorisation summary of positive opinion for RESPIPORC FLUpan H1N1","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-14T02:00:00Z","last_updated_date":"2018-09-14T02:00:00Z","reference_number":"EMA/CVMP/562184/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-respiporc-flupan-h1n1_en.pdf"},
    {"id":"42059","name":"CHMP post-authorisation summary of positive opinion for Gilenya (X/44/G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/CHMP/612718/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gilenya-x44g_en.pdf"},
    {"id":"42069","name":"CHMP post-authorisation summary of positive opinion for RoActemra II-76","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T14:00:00Z","last_updated_date":"2018-09-21T14:00:00Z","reference_number":"EMA/CHMP/517697/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-roactemra-ii-76_en.pdf"},
    {"id":"42070","name":"CVMP post-authorisation summary of positive opinion for Versican Plus DHPPi/L4R","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-14T02:00:00Z","last_updated_date":"2018-09-14T02:00:00Z","reference_number":"EMA/CVMP/574869/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-versican-plus-dhppil4r_en.pdf"},
    {"id":"42073","name":"CVMP post-authorisation summary of positive opinion for Versican Plus Pi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-14T02:00:00Z","last_updated_date":"2018-09-14T02:00:00Z","reference_number":"EMA/CVMP/574869/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-versican-plus-pi_en.pdf"},
    {"id":"42074","name":"CVMP post-authorisation summary of positive opinion for NexGard (WS1338_G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-14T02:00:00Z","last_updated_date":"2018-09-14T02:00:00Z","reference_number":"EMA/CVMP/525858/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-ws1338_g_en.pdf"},
    {"id":"42075","name":"CHMP post-authorisation summary of positive opinion for Cabometyx","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T14:00:00Z","last_updated_date":"2018-09-21T14:00:00Z","reference_number":"EMA/CHMP/616909/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cabometyx_en.pdf"},
    {"id":"42079","name":"CVMP post-authorisation summary of positive opinion for Nexgard Spectra","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-14T02:00:00Z","last_updated_date":"2018-09-14T02:00:00Z","reference_number":"EMA/CVMP/525858/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-spectra_en.pdf"},
    {"id":"42092","name":"CHMP post-authorisation summary of positive opinion for Xtandi II-39-G","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-20T02:00:00Z","last_updated_date":"2018-09-20T02:00:00Z","reference_number":"EMA/CHMP/638103/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xtandi-ii-39-g_en.pdf"},
    {"id":"42105","name":"CVMP post-authorisation summary of positive opinion for Versican Plus L4","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-14T02:00:00Z","last_updated_date":"2018-09-14T02:00:00Z","reference_number":"EMA/CVMP/574869/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-versican-plus-l4_en.pdf"},
    {"id":"42115","name":"CVMP post-authorisation summary of positive opinion for Rheumocam (X-0022)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-14T02:00:00Z","last_updated_date":"2018-09-14T02:00:00Z","reference_number":"EMA/CVMP/529543/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-rheumocam-x-0022_en.pdf"},
    {"id":"42120","name":"CVMP post-authorisation summary of positive opinion for Versican Plus DHPPi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-14T02:00:00Z","last_updated_date":"2018-09-14T02:00:00Z","reference_number":"EMA/CVMP/574869/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-versican-plus-dhppi_en.pdf"},
    {"id":"42129","name":"CHMP post-authorisation summary of positive opinion for Trelegy Ellipta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/CHMP/652421/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trelegy-ellipta_en.pdf"},
    {"id":"42134","name":"CHMP post-authorisation summary of positive opinion for Elebrato Ellipta","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/CHMP/622586/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-elebrato-ellipta_en.pdf"},
    {"id":"42369","name":"CHMP post-authorisation summary of positive opinion for NovoSeven","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T12:00:00Z","last_updated_date":"2018-10-19T12:00:00Z","reference_number":"EMA/CHMP/701490/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-novoseven_en.pdf"},
    {"id":"42372","name":"CHMP post-authorisation summary of positive opinion for Kalydeco (II-69)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T12:00:00Z","last_updated_date":"2018-10-19T12:00:00Z","reference_number":"EMA/CHMP/727925/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-ii-69_en.pdf"},
    {"id":"42378","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-47)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T12:26:00Z","last_updated_date":"2018-10-31T17:00:00Z","reference_number":"EMA/CHMP/706955/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-47_en.pdf"},
    {"id":"42619","name":"CVMP post-authorisation summary of positive opinion for Aftovaxpur DOE","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-11-09T16:30:00Z","last_updated_date":"2018-11-09T16:30:00Z","reference_number":"EMA/CVMP/722013/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-aftovaxpur-doe_en.pdf-0"},
    {"id":"42674","name":"CHMP post-authorisation summary of positive opinion for Ravicti (II-19)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T14:56:00Z","last_updated_date":"2018-11-16T14:56:00Z","reference_number":"EMA/CHMP/801110/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ravicti-ii-19_en.pdf"},
    {"id":"42676","name":"CHMP post-authorisation summary of positive opinion for Kisqali (II-04)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T13:00:00Z","last_updated_date":"2018-11-16T13:00:00Z","reference_number":"EMA/CHMP/795769/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kisqali-ii-04_en.pdf"},
    {"id":"42682","name":"CHMP post-authorisation summary of positive opinion for Orkambi (X-34-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T13:00:00Z","last_updated_date":"2018-11-16T13:00:00Z","reference_number":"EMA/774653/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-orkambi-x-34-g_en.pdf"},
    {"id":"42698","name":"CHMP post-authorisation summary of positive opinion for MabThera (II-149)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T13:00:00Z","last_updated_date":"2018-11-16T13:00:00Z","reference_number":"EMA/CHMP/790642/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera-ii-149_en.pdf"},
    {"id":"42707","name":"CHMP post-authorisation summary of positive opinion for Blincyto (II-0011)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T13:00:00Z","last_updated_date":"2018-11-16T13:00:00Z","reference_number":"EMA/CHMP/799482/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-blincyto-ii-0011_en.pdf"},
    {"id":"42711","name":"CHMP post-authorisation summary of positive opinion for Opdivo (WS-1278)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T13:11:00Z","last_updated_date":"2018-11-16T13:11:00Z","reference_number":"EMA/CHMP/788598/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ws-1278_en.pdf"},
    {"id":"42712","name":"Questions and answers on positive opinion on the change to the marketing authorisation for Opdivo (nivolumab) and Yervoy (ipilimumab)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T13:13:00Z","last_updated_date":"2018-11-16T13:13:00Z","reference_number":"EMA/799169/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-and-yervoy-ipilimumab_sv.pdf"}},
    {"id":"42713","name":"CHMP post-authorisation summary of positive opinion for Yervoy (WS-1278)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T13:10:00Z","last_updated_date":"2018-11-16T13:10:00Z","reference_number":"EMA/795695/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yervoy-ws-1278_en.pdf"},
    {"id":"42961","name":"CVMP post-authorisation summary of positive opinion for Zulvac BTV Ovis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-12-07T16:42:00Z","last_updated_date":"2018-12-07T16:42:00Z","reference_number":"EMA/CVMP/808341/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-zulvac-btv-ovis_en.pdf"},
    {"id":"43038","name":"CHMP post-authorisation summary of positive opinion for Trimbow (II-02)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/598794/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trimbow-ii-02_en.pdf"},
    {"id":"43039","name":"CHMP post-authorisation summary of positive opinion for Sprycel (II-59)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T15:46:00Z","last_updated_date":"2018-12-14T15:46:00Z","reference_number":"EMA/CHMP/840868/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sprycel-ii-59_en.pdf"},
    {"id":"43040","name":"CHMP post-authorisation summary of positive opinion for Simponi (X-83-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T16:50:00Z","last_updated_date":"2018-12-14T16:50:00Z","reference_number":"EMA/CHMP/833171/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-simponi-x-83-g_en.pdf"},
    {"id":"43046","name":"CHMP post-authorisation summary of positive opinion for Rapiscan (II-27)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/CHMP/831008/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rapiscan-ii-27_en.pdf"},
    {"id":"43056","name":"CHMP post-authorisation summary of positive opinion for Rubraca (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/CHMP/830894/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rubraca-ii-01_en.pdf"},
    {"id":"43073","name":"CHMP post-authorisation summary of positive opinion for Adcetris (II-55)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T14:49:00Z","last_updated_date":"2018-12-14T14:49:00Z","reference_number":"EMA/CHMP/621289/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adcetris-ii-55_en.pdf"},
    {"id":"43256","name":"Questions and answers on the refusal of a change to the marketing authorisations for Opdivo (nivolumab) and Yervoy (ipilimumab)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:06:00Z","last_updated_date":"2018-07-27T14:06:00Z","reference_number":"EMA/568014/2018 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-opdivo-nivolumab-and-yervoy-ipilimumab_en.pdf"},
    {"id":"43257","name":"Questions and answers on the refusal of a change to the marketing authorisation for Blincyto","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:10:00Z","last_updated_date":"2018-07-27T14:10:00Z","reference_number":"EMA/622207/2018 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-blincyto_en.pdf"},
    {"id":"43574","name":"CHMP post-authorisation summary of positive opinion for Tecentriq (II-07-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T12:06:00Z","last_updated_date":"2019-02-01T12:06:00Z","reference_number":"EMA/CHMP/904817/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tecentriq-ii-07-g_en.pdf"},
    {"id":"43575","name":"CHMP post-authorisation summary of positive opinion for Orencia (X-117-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T15:58:00Z","last_updated_date":"2019-02-01T15:58:00Z","reference_number":"EMA/CHMP/917551/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-orencia-x-117-g_en.pdf"},
    {"id":"43587","name":"CHMP post-authorisation summary of positive opinion for Hemlibra (II-02)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T12:00:00Z","last_updated_date":"2019-02-01T12:00:00Z","reference_number":"EMA/CHMP/848842/2018","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-hemlibra-ii-02_en.pdf"},
    {"id":"43588","name":"CHMP post-authorisation summary of positive opinion for Maviret (II-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T12:00:00Z","last_updated_date":"2019-02-01T12:00:00Z","reference_number":"EMA/CHMP/901868/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-maviret-ii-12_en.pdf"}    {"id":"43590","name":"CHMP post-authorisation summary of positive opinion for MabThera (II-150)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T12:00:00Z","last_updated_date":"2019-02-01T12:00:00Z","reference_number":"EMA/CHMP/47828/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera-ii-150_en.pdf"},
    {"id":"43591","name":"CHMP post-authorisation summary of positive opinion for Praluent (II-42)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T12:00:00Z","last_updated_date":"2019-02-01T12:00:00Z","reference_number":"EMA/CHMP/44606/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-praluent-ii-42_en.pdf"},
    {"id":"43599","name":"CHMP post-authorisation summary of positive opinion for Edistride (WS-1344)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T10:48:00Z","last_updated_date":"2019-02-01T10:48:00Z","reference_number":"EMA/62945/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-edistride-ws-1344_en.pdf"},
    {"id":"43600","name":"CHMP post-authorisation summary of positive opinion for Forxiga (WS-1344)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T10:53:00Z","last_updated_date":"2019-02-01T10:53:00Z","reference_number":"EMA/56302/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-forxiga-ws-1344_en.pdf"},
    {"id":"43612","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-60)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T14:47:00Z","last_updated_date":"2019-02-01T14:47:00Z","reference_number":"EMA/CHMP/75264/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-60_en.pdf"},
    {"id":"43933","name":"CHMP post-authorisation summary of positive opinion for Riarify","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T13:56:00Z","last_updated_date":"2025-03-18T12:18:00Z","reference_number":"EMA/CHMP/136909/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-riarify_en.pdf"},
    {"id":"43934","name":"CHMP post-authorisation summary of positive opinion for Trydonis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T13:58:00Z","last_updated_date":"2019-03-01T13:58:00Z","reference_number":"EMA/CHMP/136916/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trydonis_en.pdf"},
    {"id":"43935","name":"CHMP post-authorisation summary of positive opinion for Viread (II-191)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T12:00:00Z","last_updated_date":"2019-03-01T12:00:00Z","reference_number":"EMA/CHMP/129761/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-viread-ii-191_en.pdf"},
    {"id":"43947","name":"CHMP post-authorisation summary of positive opinion for Lynparza (II-20)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T09:52:00Z","last_updated_date":"2019-03-01T09:52:00Z","reference_number":"EMA/CHMP/146940/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-20_en.pdf"},
    {"id":"43961","name":"CHMP post-authorisation summary of positive opinion for Dupixent (X-0004-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T12:00:00Z","last_updated_date":"2019-03-01T12:00:00Z","reference_number":"EMA/CHMP/41336/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-x-0004-g_en.pdf"},
    {"id":"44091","name":"CVMP post-authorisation summary of positive opinion for Innovax-ND-IBD (X-001)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-22T15:42:00Z","last_updated_date":"2019-03-22T15:42:00Z","reference_number":"EMA/CVMP/153784/201","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-innovax-nd-ibd-x-001_en.pdf"},
    {"id":"44092","name":"CVMP post-authorisation summary of positive opinion for ProZinc (II-0015)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-22T15:47:00Z","last_updated_date":"2019-03-22T15:47:00Z","reference_number":"EMA/CVMP/147691/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-prozinc-ii-0015_en.pdf"},
    {"id":"44093","name":"CVMP post-authorisation summary of positive opinion for Vectra 3D (II-0011)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-22T15:51:00Z","last_updated_date":"2019-03-22T15:51:00Z","reference_number":"EMA/CVMP/164096/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-vectra-3d-ii-0011_en.pdf"},
    {"id":"44133","name":"CHMP post-authorisation summary of positive opinion for Revlimid (II-102-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-29T12:07:00Z","last_updated_date":"2019-03-29T12:07:00Z","reference_number":"EMA/CHMP/195079/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revlimid-ii-102-g_en.pdf"},
    {"id":"44135","name":"CHMP post-authorisation summary of positive opinion for Imnovid (II-31-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-29T14:35:00Z","last_updated_date":"2019-03-29T14:35:00Z","reference_number":"EMA/CHMP/177804/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imnovid-ii-31-g_en.pdf"},
    {"id":"44137","name":"CHMP post-authorisation summary of positive opinion for Mozobil (II-34)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-03-29T15:49:00Z","last_updated_date":"2019-03-29T15:49:00Z","reference_number":"EMA/CHMP/198032/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mozobil-ii-34_en.pdf"},
    {"id":"44315","name":"CVMP post-authorisation summary of positive opinion for Suvaxyn PRRS MLV","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-04-23T09:44:00Z","last_updated_date":"2019-04-23T09:44:00Z","reference_number":"EMA/CVMP/199498/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-suvaxyn-prrs-mlv_en.pdf"},
    {"id":"44359","name":"CHMP post-authorisation summary of positive opinion for Lynparza (II-23)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T12:15:00Z","last_updated_date":"2019-04-26T12:15:00Z","reference_number":"EMA/CHMP/232262/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-23_en.pdf"},
    {"id":"44589","name":"CVMP post-authorisation summary of positive opinion for Bravecto Plus","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-05-24T14:00:00Z","last_updated_date":"2019-05-24T14:00:00Z","reference_number":"EMA/CVMP/256330/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bravecto-plus_en.pdf"},
    {"id":"44785","name":"CVMP post-authorisation summary of positive opinion for Advocate (II-0041-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-21T14:50:00Z","last_updated_date":"2019-06-21T14:50:00Z","reference_number":"EMA/CVMP/319271/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-advocate-ii-0041-g_en.pdf"},
    {"id":"44918","name":"CHMP post-authorisation summary of positive opinion for Ebymect (WS1539/0035)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T16:08:00Z","last_updated_date":"2019-06-28T16:08:00Z","reference_number":"EMA/CHMP/365312/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ebymect-ws15390035_en.pdf"},
    {"id":"44919","name":"CHMP post-authorisation summary of positive opinion for Edistride (WS1539/0029)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T16:22:00Z","last_updated_date":"2019-06-28T16:22:00Z","reference_number":"EMA/CHMP/365313/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-edistride-ws15390029_en.pdf"},
    {"id":"44920","name":"CHMP post-authorisation summary of positive opinion for Forxiga (WS1539/0048)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T16:26:00Z","last_updated_date":"2019-06-28T16:26:00Z","reference_number":"EMA/CHMP/354402/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-forxiga-ws15390048_en.pdf"},
    {"id":"44921","name":"CHMP post-authorisation summary of positive opinion for Zinforo (II-41, II-43)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T16:29:00Z","last_updated_date":"2019-06-28T16:29:00Z","reference_number":"EMA/CHMP/354371/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zinforo-ii-41-ii-43_en.pdf"},
    {"id":"44922","name":"CHMP post-authorisation summary of positive opinion for Xigduo (WS1539/0046)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T16:31:00Z","last_updated_date":"2019-06-28T16:31:00Z","reference_number":"EMA/CHMP/354402/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xigduo-ws15390046_en.pdf"},
    {"id":"44923","name":"CHMP post-authorisation summary of positive opinion for Victoza (II-49)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T11:42:00Z","last_updated_date":"2019-06-28T11:42:00Z","reference_number":"EMA/CHMP/339781/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-victoza-ii-49_en.pdf"},
    {"id":"44924","name":"CHMP post-authorisation summary of positive opinion for Fiasp (II/0010)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T12:00:00Z","last_updated_date":"2019-06-28T12:00:00Z","reference_number":"EMA/CHMP/354045/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fiasp-ii0010_en.pdf"},
    {"id":"44925","name":"CHMP post-authorisation summary of positive opinion for Imbruvica (II-46, II-47)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T17:09:00Z","last_updated_date":"2019-06-28T17:09:00Z","reference_number":"EMA/CHMP/366056/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imbruvica-ii-46-ii-47_en.pdf"},
    {"id":"44926","name":"CHMP post-authorisation summary of positive opinion for Dupixent (II-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T17:46:00Z","last_updated_date":"2019-06-28T17:46:00Z","reference_number":"EMA/CHMP/345816/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-ii-12_en.pdf"},
    {"id":"44927","name":"CHMP post-authorisation summary of positive opinion for Flebogamma DIF (II-59-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T18:02:00Z","last_updated_date":"2019-06-28T18:02:00Z","reference_number":"EMA/CHMP/365308/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-flebogamma-dif-ii-59-g_en.pdf"},
    {"id":"44936","name":"CHMP post-authorisation summary of positive opinion for Tecentriq (X-17-II-22)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T12:22:00Z","last_updated_date":"2019-06-28T12:22:00Z","reference_number":"EMA/366637/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tecentriq-x-17-ii-22_en.pdf"},
    {"id":"44937","name":"CHMP post-authorisation summary of positive opinion for Cyramza (II-27)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T10:35:00Z","last_updated_date":"2019-06-28T10:35:00Z","reference_number":"EMA/CHMP/360998/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cyramza-ii-27_en.pdf"},
    {"id":"44942","name":"Questions and answers on the refusal of a change to the marketing authorisation for Translarna (ataluren)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T11:55:00Z","last_updated_date":"2025-04-16T12:00:00Z","reference_number":"EMA/565599/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_sv.pdf"}},
    {"id":"44943","name":"Questions and answers on the refusal of a change to the marketing authorisation for Revolade (eltrombopag)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T11:57:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"EMA/559880/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-revolade-eltrombopag_sv.pdf"}},
    {"id":"45100","name":"CVMP post-authorisation summary of positive opinion for Broadline (II-0024)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-19T14:12:00Z","last_updated_date":"2019-07-19T14:12:00Z","reference_number":"EMA/CVMP/370703/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-broadline-ii-0024_en.pdf"},
    {"id":"45101","name":"CVMP post-authorisation summary of positive opinion for Nexgard Spectra (II-0019)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-19T14:15:00Z","last_updated_date":"2019-07-19T14:15:00Z","reference_number":"EMA/CVMP/369202/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-spectra-ii-0019_en.pdf"},
    {"id":"45103","name":"CVMP post-authorisation summary of positive opinion for NexGard Spectra ; NexGard","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-19T14:50:00Z","last_updated_date":"2019-07-19T14:50:00Z","reference_number":"EMA/CVMP/369028/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-spectra-nexgard_en.pdf"},
    {"id":"45120","name":"CHMP post-authorisation summary of positive opinion for Stelara - II/0071","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T09:18:00Z","last_updated_date":"2019-07-26T09:18:00Z","reference_number":"EMA/CHMP/408535/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stelara-ii0071_en.pdf"},
    {"id":"45121","name":"CHMP post-authorisation summary of positive opinion for Empliciti (II-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/399458/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-empliciti-ii-12_en.pdf"},
    {"id":"45123","name":"CHMP post-authorisation summary of positive opinion for Tecentriq - II/0019","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/416072/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tecentriq-ii0019_en.pdf"},
    {"id":"45126","name":"CHMP post-authorisation summary of positive opinion for Zerbaxa - II/0020","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/409666/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zerbaxa-ii0020_en.pdf"},
    {"id":"45127","name":"CHMP post-authorisation summary of positive opinion for Lonsurf - II/0012","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/416776/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lonsurf-ii0012_en.pdf"},
    {"id":"45130","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-69)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/346038/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-69_en.pdf"},
    {"id":"45131","name":"CHMP post-authorisation summary of positive opinion for Soliris (II-105)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/410407/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-soliris-ii-105_en.pdf"},
    {"id":"45134","name":"CHMP post-authorisation summary of positive opinion for Lucentis - II/0074/G","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/422841/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lucentis-ii0074g_en.pdf"},
    {"id":"45449","name":"CVMP post-authorisation summary of positive opinion for Bravecto (II/0033/G, II/0036)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-13T15:30:00Z","last_updated_date":"2019-09-13T15:30:00Z","reference_number":"EMA/CVMP/465180/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bravecto-ii0033g-ii0036_en.pdf"},
    {"id":"45450","name":"CVMP post-authorisation summary of positive opinion Vectra Felis (II/0009)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-13T15:30:00Z","last_updated_date":"2019-09-13T15:30:00Z","reference_number":"EMA/CVMP/450607/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-vectra-felis-ii0009_en.pdf"},
    {"id":"45451","name":"CVMP post-authorisation summary of negative opinion for Velactis (II/0004)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-13T15:30:00Z","last_updated_date":"2019-12-06T16:00:00Z","reference_number":"EMA/CVMP/633397/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-negative-opinion-velactis-ii0004_en.pdf"},
    {"id":"45468","name":"CHMP post-authorisation summary of positive opinion for Lucentis (II-76)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:00:00Z","last_updated_date":"2019-09-20T12:00:00Z","reference_number":"EMA/CHMP/503493/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lucentis-ii-76_en.pdf"},
    {"id":"45471","name":"CHMP post-authorisation summary of positive opinion for Trulicity (II-40)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:00:00Z","last_updated_date":"2019-09-20T12:00:00Z","reference_number":"EMA/504760/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trulicity-ii-40_en.pdf"},
    {"id":"45477","name":"CHMP post-authorisation summary of positive opinion for Benlysta (II/0062)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:01:00Z","last_updated_date":"2019-09-20T12:01:00Z","reference_number":"EMA/CHMP/349325/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-benlysta-ii0062_en.pdf"},
    {"id":"45478","name":"CHMP post-authorisation summary of positive opinion for Remsima (X-62)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:11:00Z","last_updated_date":"2019-09-20T12:11:00Z","reference_number":"EMA/CHMP/476189/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-remsima-x-62_en.pdf"},
    {"id":"45489","name":"CHMP post-authorisation summary of positive opinion for Taxotere (WS-1550)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:00:00Z","last_updated_date":"2019-09-20T12:00:00Z","reference_number":"EMA/CHMP/510409/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-taxotere-ws-1550_en.pdf"},
    {"id":"45490","name":"CHMP post-authorisation summary of positive opinion for Docetaxel Zentiva (WS-1550)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:00:00Z","last_updated_date":"2022-05-20T11:50:00Z","reference_number":"EMA/CHMP/510410/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-docetaxel-zentiva-ws-1550_en.pdf"},
    {"id":"45492","name":"CHMP post-authorisation summary of positive opinion for Dupixent (II-17)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:03:00Z","last_updated_date":"2019-09-20T12:03:00Z","reference_number":"EMA/CHMP/506821/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-ii-17_en.pdf"},
    {"id":"45493","name":"CHMP post-authorisation summary of positive opinion for Bavencio (II-09)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:00:00Z","last_updated_date":"2019-09-20T12:00:00Z","reference_number":"EMA/CHMP/473440/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bavencio-ii-09_en.pdf"},
    {"id":"45741","name":"CHMP post-authorisation summary of positive opinion for Kalydeco (X-75-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"EMA/567043/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-x-75-g_en.pdf"},
    {"id":"45742","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-65)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"EMA/CHMP/473502/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-65_en.pdf"},
    {"id":"45743","name":"CHMP post-authorisation summary of positive opinion for Darzalex (II-29)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"EMA/CHMP/530492/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-darzalex-ii-29_en.pdf"},
    {"id":"45753","name":"CHMP post-authorisation summary of positive opinion for Evotaz (II-30)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T09:37:00Z","last_updated_date":"2019-10-18T09:37:00Z","reference_number":"EMA/563896/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-evotaz-ii-30_en.pdf"},
    {"id":"45761","name":"CHMP post-authorisation summary of positive opinion for Toujeo (II-108)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T12:26:00Z","last_updated_date":"2019-10-18T12:26:00Z","reference_number":"EMA/CHMP/571247/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-toujeo-ii-108_en.pdf"},
    {"id":"45942","name":"CVMP post-authorisation summary of positive opinion Bravecto Plus (II-0006)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T12:00:00Z","last_updated_date":"2019-11-08T12:00:00Z","reference_number":"EMA/CVMP/599149/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bravecto-plus-ii-0006_en.pdf"},
    {"id":"46037","name":"CHMP post-authorisation summary of positive opinion for Revlimid (II-107)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T10:08:00Z","last_updated_date":"2019-11-15T10:08:00Z","reference_number":"EMA/CHMP/581784/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revlimid-ii-107_en.pdf"},
    {"id":"46040","name":"CHMP post-authorisation summary of positive opinion for Kadcyla (II/45)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T12:00:00Z","last_updated_date":"2019-11-15T12:00:00Z","reference_number":"EMA/CHMP/615141/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kadcyla-ii45_en.pdf"},
    {"id":"46255","name":"CVMP post-authorisation summary of positive opinion for Eravac (II-0005-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-12-06T16:00:00Z","last_updated_date":"2019-12-06T16:00:00Z","reference_number":"EMA/CVMP/640568/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-eravac-ii-0005-g_en.pdf"},
    {"id":"46256","name":"CVMP post-authorisation summary of positive opinion for Onsior (II-0024-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-12-06T16:00:00Z","last_updated_date":"2019-12-06T16:00:00Z","reference_number":"EMA/CVMP/622008/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-onsior-ii-0024-g_en.pdf"},
    {"id":"46292","name":"CHMP post-authorisation summary of positive opinion for Erleada (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T12:00:00Z","last_updated_date":"2019-12-13T12:00:00Z","reference_number":"EMA/CHMP/672735/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-erleada-ii-01_en.pdf"},
    {"id":"46298","name":"CHMP post-authorisation summary of positive opinion for Stelara (II-73)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T12:00:00Z","last_updated_date":"2019-12-13T12:00:00Z","reference_number":"EMA/CHMP/645416/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stelara-ii-73_en.pdf"},
    {"id":"46300","name":"CHMP post-authorisation summary of positive opinion for Darzalex (II-30)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T12:52:00Z","last_updated_date":"2019-12-13T12:52:00Z","reference_number":"EMA/CHMP/598973/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-darzalex-ii-30_en.pdf"},
    {"id":"46301","name":"CHMP post-authorisation summary of positive opinion for Sirturo (II-33-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T12:00:00Z","last_updated_date":"2019-12-13T12:00:00Z","reference_number":"EMA/CHMP/542462/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sirturo-ii-33-g_en.pdf"},
    {"id":"46303","name":"CHMP post-authorisation summary of positive opinion for Dificlir (X-34)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T14:27:00Z","last_updated_date":"2019-12-13T14:27:00Z","reference_number":"EMA/CHMP/515208/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dificlir-x-34_en.pdf"},
    {"id":"46312","name":"CHMP post-authorisation summary of positive opinion for Cyramza (II-33)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T09:45:00Z","last_updated_date":"2019-12-13T09:45:00Z","reference_number":"EMA/CHMP/676031/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cyramza-ii-33_en.pdf"},
    {"id":"46313","name":"CHMP post-authorisation summary of positive opinion for Akynzeo","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T09:53:00Z","last_updated_date":"2019-12-13T09:53:00Z","reference_number":"EMA/CHMP/670824/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-akynzeo_en.pdf"},
    {"id":"46317","name":"CHMP post-authorisation summary of positive opinion for Vyndaqel (X-49-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T12:00:00Z","last_updated_date":"2019-12-13T12:00:00Z","reference_number":"EMA/CHMP/649350/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vyndaqel-x-49-g_en.pdf"},
    {"id":"46523","name":"CVMP post-authorisation summary of positive opinion for Rabitec (II-0002)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-01-24T13:40:00Z","last_updated_date":"2020-01-24T13:40:00Z","reference_number":"EMA/CVMP/691934/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-rabitec-ii-0002_en.pdf"},
    {"id":"46619","name":"CHMP post-authorisation summary of positive opinion for Suliqua (II-11)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T11:46:00Z","last_updated_date":"2020-01-31T11:46:00Z","reference_number":"EMA/CHMP/41157/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-suliqua-ii-11_en.pdf"},
    {"id":"46623","name":"CHMP post-authorisation summary of positive opinion for Rezolsta (II-33)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T14:40:00Z","last_updated_date":"2020-01-31T14:40:00Z","reference_number":"EMA/CHMP/36079/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rezolsta-ii-33_en.pdf"},
    {"id":"46626","name":"CHMP post-authorisation summary of positive opinion for Ameluz (II-39-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T16:35:00Z","last_updated_date":"2020-01-31T16:35:00Z","reference_number":"EMA/CHMP/34417/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ameluz-ii-39-g_en.pdf"},
    {"id":"46636","name":"CHMP post-authorisation summary of positive opinion for MabThera (II-162)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T12:00:00Z","last_updated_date":"2020-01-31T12:00:00Z","reference_number":"EMA/CHMP/55667/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mabthera-ii-162_en.pdf"},
    {"id":"46639","name":"CHMP post-authorisation summary of positive opinion for Tybost (II-51)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T18:04:00Z","last_updated_date":"2020-01-31T18:04:00Z","reference_number":"EMA/CHMP/541245/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tybost-ii-51_en.pdf"},
    {"id":"46640","name":"CHMP post-authorisation summary of positive opinion for Venclyxto (II-23-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T18:11:00Z","last_updated_date":"2020-01-31T18:11:00Z","reference_number":"EMA/CHMP/43686/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-venclyxto-ii-23-g_en.pdf"},
    {"id":"46834","name":"CVMP post-authorisation summary of positive opinion for Clynav","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-02-21T15:41:00Z","last_updated_date":"2020-02-21T15:41:00Z","reference_number":"EMA/CVMP/624348/2019","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-clynav_en.pdf"},
    {"id":"46892","name":"CHMP post-authorisation summary of positive opinion for Entyvio","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-02-28T12:00:00Z","reference_number":"EMA/85157/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-entyvio_en.pdf"},
    {"id":"46893","name":"CHMP post-authorisation summary of positive opinion for Ofev (II-26)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-02-28T12:00:00Z","reference_number":"EMA/CHMP/102818/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ofev-ii-26_en.pdf"},
    {"id":"46894","name":"Questions and answers on the refusal of a change to the marketing authorisation for Emgality (galcanezumab)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-06-12T09:50:00Z","reference_number":"EMA/95744/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_sv.pdf"}},
    {"id":"46904","name":"CHMP post-authorisation summary of positive opinion for Alunbrig (II-03)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-02-28T12:00:00Z","reference_number":"EMA/CHMP/99918/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-alunbrig-ii-03_en.pdf"},
    {"id":"46906","name":"CHMP post-authorisation summary of positive opinion for Otezla (II-29)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-02-28T11:22:00Z","last_updated_date":"2020-02-28T11:22:00Z","reference_number":"EMA/CHMP/89174/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-otezla-ii-29_en.pdf"},
    {"id":"47160","name":"CHMP post-authorisation summary of positive opinion for Cosentyx (II-53-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/CHMP/110280/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-ii-53-g_en.pdf"},
    {"id":"47167","name":"CHMP summary of positive opinion for Ruconest (II-53)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/CHMP/133160/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-ruconest-ii-53_en.pdf"},
    {"id":"47169","name":"CHMP post-authorisation summary of positive opinion for Intelence (II-58)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/CHMP/142909/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-intelence-ii-58_en.pdf"},
    {"id":"47179","name":"CHMP post-authorisation summary of positive opinion for Kineret (II-70)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/CHMP/114338/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kineret-ii-70_en.pdf"},
    {"id":"47188","name":"CHMP post-authorisation summary of positive opinion for Jorveza (X-07-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/CHMP/117524/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jorveza-x-07-g_en.pdf"},
    {"id":"47189","name":"CHMP post-authorisation summary of positive opinion for Adcetris (II-70)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/CHMP/158590/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adcetris-ii-70_en.pdf"},
    {"id":"47519","name":"CHMP post-authorisation summary of positive opinion for Darzalex (X-32)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T17:28:00Z","last_updated_date":"2020-04-30T17:28:00Z","reference_number":"EMA/CHMP/233457/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-darzalex-x-32_en.pdf"},
    {"id":"47525","name":"CHMP post-authorisation summary of positive opinion for Ecalta (II-40)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T13:49:00Z","last_updated_date":"2020-04-30T13:49:00Z","reference_number":"EMA/CHMP/213950/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ecalta-ii-40_en.pdf"},
    {"id":"47526","name":"CHMP post-authorisation summary of positive opinion for Suboxone (X-42)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T13:57:00Z","last_updated_date":"2020-04-30T13:57:00Z","reference_number":"EMA/CHMP/219873/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-suboxone-x-42_en.pdf"},
    {"id":"47528","name":"CHMP post-authorisation summary of positive opinion for Ultomiris (II-02)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T14:10:00Z","last_updated_date":"2020-04-30T14:10:00Z","reference_number":"EMA/CHMP/142111/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ultomiris-ii-02_en.pdf"},
    {"id":"47529","name":"CHMP post-authorisation summary of positive opinion for Sovaldi (X-59-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T14:10:00Z","last_updated_date":"2020-04-30T14:10:00Z","reference_number":"EMA/CHMP/54432/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sovaldi-x-59-g_en.pdf"},
    {"id":"47531","name":"CHMP post-authorisation summary of positive opinion for Braftovi (WS-1695)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T14:10:00Z","last_updated_date":"2020-04-30T14:10:00Z","reference_number":"EMA/CHMP/217942/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-braftovi-ws-1695_en.pdf"},
    {"id":"47533","name":"CHMP post-authorisation summary of positive opinion for Harvoni (X-81)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/CHMP/54435/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-harvoni-x-81_en.pdf"}    {"id":"47534","name":"CHMP post-authorisation summary of positive opinion for Taltz (II-30)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T15:32:00Z","last_updated_date":"2020-04-30T15:32:00Z","reference_number":"EMA/178688/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-taltz-ii-30_en.pdf"},
    {"id":"47536","name":"CHMP post-authorisation summary of positive opinion for Kalydeco (II-82)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/207923/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-ii-82_en.pdf"},
    {"id":"47538","name":"CHMP post-authorisation summary of positive opinion for Carmustine Obvius (II-02)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/CHMP/212192/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-carmustine-obvius-ii-02_en.pdf"},
    {"id":"47546","name":"CHMP post-authorisation summary of positive opinion for Cablivi (II-21)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/CHMP/227535/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cablivi-ii-21_en.pdf"},
    {"id":"47755","name":"CVMP post-authorisation summary of positive opinion for Zulvac BTV (II-0004)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-05-25T12:36:00Z","last_updated_date":"2020-05-25T12:36:00Z","reference_number":"EMA/CVMP/235910/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-zulvac-btv-ii-0004_en.pdf"},
    {"id":"47756","name":"CVMP post-authorisation summary of positive opinion for Leucofeligen FeLV/RCP (II-0012)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-05-25T12:51:00Z","last_updated_date":"2020-05-25T12:51:00Z","reference_number":"EMA/CVMP/242131/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-leucofeligen-felv-rcp-ii-0012_en.pdf"},
    {"id":"47757","name":"CVMP post-authorisation summary of positive opinion for Aivlosin (II-0078)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-05-25T12:56:00Z","last_updated_date":"2020-05-25T12:56:00Z","reference_number":"EMA/CVMP/238731/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-aivlosin-ii-0078_en.pdf"},
    {"id":"47794","name":"CHMP post-authorisation summary of positive opinion for Invokana (II-46)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/CHMP/229700/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-invokana-ii-46_en.pdf"},
    {"id":"47799","name":"CHMP post-authorisation summary of positive opinion for Taltz (II-31)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T16:17:00Z","last_updated_date":"2020-05-29T16:17:00Z","reference_number":"EMA/178694/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-taltz-ii-31_en.pdf"},
    {"id":"47801","name":"CHMP post-authorisation summary of positive opinion for Ofev (II-27)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T16:35:00Z","last_updated_date":"2020-05-29T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ofev-ii-27_en.pdf"},
    {"id":"47808","name":"CHMP post-authorisation summary of positive opinion for Lynparza (II-33)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/CHMP/282935/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-33_en.pdf"},
    {"id":"47812","name":"CHMP post-authorisation summary of positive opinion for Sivextro (II-35)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/CHMP/269339/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sivextro-ii-35_en.pdf"},
    {"id":"48058","name":"CVMP post-authorisation summary of positive opinion for Bluevac BTV","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-06-19T14:00:00Z","last_updated_date":"2020-06-19T14:00:00Z","reference_number":"EMA/CVMP/307513/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bluevac-btv_en.pdf"},
    {"id":"48102","name":"CHMP post-authorisation summary of positive opinion for Zavicefta (II-19)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T09:46:00Z","last_updated_date":"2020-06-26T09:46:00Z","reference_number":"EMA/CHMP/312635/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zavicefta-ii-19_en.pdf"},
    {"id":"48128","name":"CHMP post-authorisation summary of positive opinion for Cosentyx (II-57)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T15:18:00Z","last_updated_date":"2020-06-26T15:18:00Z","reference_number":"EMA/CHMP/171152/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-ii-57_en.pdf"},
    {"id":"48137","name":"CHMP post-authorisation summary of positive opinion for Xolair (II-101)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T16:23:00Z","last_updated_date":"2020-06-26T16:23:00Z","reference_number":"EMA/339453/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xolair-ii-101_en.pdf"},
    {"id":"48138","name":"CHMP post-authorisation summary of positive opinion for Epclusa (X-43-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T16:29:00Z","last_updated_date":"2020-06-26T16:29:00Z","reference_number":"EMA/CHMP/285838/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-epclusa-x-43-g_en.pdf"},
    {"id":"48143","name":"CHMP post-authorisation summary of positive opinion for Remsima (II/82)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T08:37:00Z","last_updated_date":"2020-06-26T08:37:00Z","reference_number":"EMA/322223/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-remsima-ii82_en.pdf"},
    {"id":"48361","name":"CHMP post-authorisation summary of positive opinion for NovoThirteen (II-26-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2020-07-24T12:00:00Z","reference_number":"EMA/CHMP/385004/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-novothirteen-ii-26-g_en.pdf"},
    {"id":"48362","name":"CHMP post-authorisation summary of positive opinion for Latuda (II-29)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2020-07-24T12:00:00Z","reference_number":"EMA/CHMP/386251/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-latuda-ii-29_en.pdf"},
    {"id":"48375","name":"CHMP post-authorisation summary of positive opinion for Fortacin (II-30)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T14:21:00Z","last_updated_date":"2020-07-24T14:21:00Z","reference_number":"EMA/CHMP/112785/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fortacin-ii-30_en.pdf"},
    {"id":"48377","name":"CHMP post-authorisation summary of positive opinion for Reyataz (II-129-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-23T14:54:00Z","last_updated_date":"2020-07-23T14:54:00Z","reference_number":"EMA/CHMP/278510/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-reyataz-ii-129-g_en.pdf"},
    {"id":"48378","name":"CHMP post-authorisation summary of positive opinion for Shingrix (II-22)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T15:19:00Z","last_updated_date":"2020-07-24T15:19:00Z","reference_number":"EMA/CHMP/383838/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-shingrix-ii-22_en.pdf"},
    {"id":"48379","name":"CHMP post-authorisation summary of positive opinion for Crysvita (II-10-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T15:28:00Z","last_updated_date":"2020-07-24T15:28:00Z","reference_number":"EMA/381090/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-crysvita-ii-10-g_en.pdf"},
    {"id":"48387","name":"CHMP post-authorisation summary of positive opinion for Kalydeco (II-85)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T17:44:00Z","last_updated_date":"2020-07-24T17:44:00Z","reference_number":"EMA/393019/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-ii-85_en.pdf"},
    {"id":"48393","name":"CHMP post-authorisation summary of positive opinion for Imbruvica (II-59)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T10:15:00Z","last_updated_date":"2020-07-24T10:15:00Z","reference_number":"EMA/CHMP/377740/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imbruvica-ii-59_en.pdf"},
    {"id":"48395","name":"CHMP post-authorisation summary of positive opinion for Imfinzi (II-14-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2020-07-24T12:00:00Z","reference_number":"EMA/CHMP/393807/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imfinzi-ii-14-g_en.pdf"},
    {"id":"48396","name":"CHMP post-authorisation summary of positive opinion for Prezista (II-107)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2020-07-24T12:00:00Z","reference_number":"EMA/CHMP/382827/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prezista-ii-107_en.pdf"},
    {"id":"48398","name":"CHMP post-authorisation summary of positive opinion for HyQvia (II-56)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2020-07-24T12:00:00Z","reference_number":"EMA/CHMP/358726/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-hyqvia-ii-56_en.pdf"},
    {"id":"48797","name":"CVMP post-authorisation summary of positive opinion for Cytopoint (II-0009)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-11T15:00:00Z","last_updated_date":"2020-09-11T15:00:00Z","reference_number":"EMA/CVMP/446877/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-cytopoint-ii-0009_en.pdf"},
    {"id":"48836","name":"CHMP post-authorisation summary of positive opinion for Flucelvax Tetra (II-13)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T11:36:00Z","last_updated_date":"2026-02-27T08:00:00Z","reference_number":"EMA/CHMP/316963/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-flucelvax-tetra-ii-13_en.pdf"},
    {"id":"48837","name":"CHMP post-authorisation summary of positive opinion for Velphoro (X-20-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T11:57:00Z","last_updated_date":"2020-09-18T11:57:00Z","reference_number":"EMA/CHMP/471709/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-velphoro-x-20-g_en.pdf"},
    {"id":"48838","name":"CHMP post-authorisation summary of positive opinion for Fycompa (II-47)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T12:01:00Z","last_updated_date":"2020-09-18T12:01:00Z","reference_number":"EMA/CHMP/471522/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fycompa-ii-47_en.pdf"},
    {"id":"48841","name":"CHMP post-authorisation summary of positive opinion for Zavicefta (II-15)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T14:58:00Z","last_updated_date":"2020-09-18T14:58:00Z","reference_number":"EMA/CHMP/380902/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zavicefta-ii-15_en.pdf"},
    {"id":"48842","name":"CHMP post-authorisation summary of positive opinion for Symkevi (X-15-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T15:09:00Z","last_updated_date":"2020-09-18T15:09:00Z","reference_number":"EMA/487752/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-symkevi-x-15-g_en.pdf"},
    {"id":"48844","name":"CHMP post-authorisation summary of positive opinion for Olumiant (II-16)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T16:07:00Z","last_updated_date":"2020-09-18T16:07:00Z","reference_number":"EMA/CHMP/267941/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-olumiant-ii-16_en.pdf"},
    {"id":"48848","name":"CHMP post-authorisation summary of positive opinion for Zejula (II-19)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T12:00:00Z","last_updated_date":"2020-09-18T12:00:00Z","reference_number":"EMA/CHMP/491345/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zejula-ii-19_en.pdf"},
    {"id":"48849","name":"CHMP post-authorisation summary of positive opinion for Orfadin (II-71)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T12:00:00Z","last_updated_date":"2020-09-18T12:00:00Z","reference_number":"EMA/CHMP/487691/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-orfadin-ii-71_en.pdf"},
    {"id":"48852","name":"CHMP post-authorisation summary of positive opinion for Tecentriq (II-39)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T10:04:00Z","last_updated_date":"2020-09-18T10:04:00Z","reference_number":"EMA/CHMP/488242/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tecentriq-ii-39_en.pdf"},
    {"id":"48853","name":"CHMP post-authorisation summary of positive opinion for Opdivo (WS-1783)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T10:37:00Z","last_updated_date":"2020-09-18T10:37:00Z","reference_number":"EMA/CHMP/451053/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ws-1783_en.pdf"},
    {"id":"48854","name":"CHMP post-authorisation summary of positive opinion for Kalydeco (X-83-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T10:38:00Z","last_updated_date":"2020-09-18T10:38:00Z","reference_number":"EMA/CHMP/481882/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-x-83-g_en.pdf"},
    {"id":"48855","name":"CHMP post-authorisation summary of positive opinion for Kalydeco (II-86)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T10:46:00Z","last_updated_date":"2020-09-18T10:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-ii-86_en.pdf"},
    {"id":"48856","name":"CHMP post-authorisation summary of positive opinion for Lynparza (II-35; II-36))","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T10:56:00Z","last_updated_date":"2020-09-18T10:56:00Z","reference_number":"EMA/CHMP/490929/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-35-ii-36_en.pdf"},
    {"id":"48857","name":"CHMP post-authorisation summary of positive opinion for Deltyba (II-40)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T11:06:00Z","last_updated_date":"2020-09-18T11:06:00Z","reference_number":"EMA/CHMP/316556/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-deltyba-ii-40_en.pdf"},
    {"id":"48859","name":"CHMP summary of positive opinion for Phelinun","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T11:21:00Z","last_updated_date":"2020-09-18T11:21:00Z","reference_number":"EMA/CHMP/449146/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-phelinun_en.pdf"},
    {"id":"48862","name":"CHMP post-authorisation summary of positive opinion for Yervoy (WS-1783)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T12:57:00Z","last_updated_date":"2020-09-18T12:57:00Z","reference_number":"EMA/CHMP/451052/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yervoy-ws-1783_en.pdf"},
    {"id":"48977","name":"CVMP post-authorisation summary of positive opinion for Innovax-ND-IBD (II/0004)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-09T13:00:00Z","last_updated_date":"2020-10-09T13:00:00Z","reference_number":"EMA/CVMP/507630/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-innovax-nd-ibd-ii0004_en.pdf"},
    {"id":"49008","name":"CHMP post-authorisation summary of positive opinion for Dupixent (II-27)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/535576/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-ii-27_en.pdf"},
    {"id":"49009","name":"CHMP post-authorisation summary of positive opinion for Tremfya (II-17)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/535466/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tremfya-ii-17_en.pdf"},
    {"id":"49010","name":"CHMP post-authorisation summary of positive opinion for Plegridy (X-56)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/521586/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-plegridy-x-56_en.pdf"},
    {"id":"49014","name":"CHMP post-authorisation summary of positive opinion for Recarbrio (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T10:15:00Z","last_updated_date":"2020-10-16T10:15:00Z","reference_number":"EMA/CHMP/537033/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-recarbrio-ii-01_en.pdf"},
    {"id":"49023","name":"CHMP post-authorisation summary of positive opinion for Forxiga (WS-1737)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/535224/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-forxiga-ws-1737_en.pdf"},
    {"id":"49024","name":"CHMP post-authorisation summary of positive opinion for Edistride (WS-1737)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/551424/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-edistride-ws-1737_en.pdf"},
    {"id":"49025","name":"CHMP post-authorisation summary of positive opinion for Blincyto (II-30)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/509424/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-blincyto-ii-30_en.pdf"},
    {"id":"49028","name":"CHMP post-authorisation summary of positive opinion for Opdivo (II-80)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T17:16:00Z","last_updated_date":"2020-10-16T17:16:00Z","reference_number":"EMA/CHMP/550956/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ii-80_en.pdf"},
    {"id":"49029","name":"CHMP post-authorisation summary of positive opinion for Desloratadine ratiopharm (II-23-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/114257/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-desloratadine-ratiopharm-ii-23-g_en.pdf"},
    {"id":"49032","name":"CHMP post-authorisation summary of positive opinion for Humira (II-198)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/522809/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-humira-ii-198_en.pdf"},
    {"id":"49035","name":"CHMP post-authorisation summary of positive opinion for Lacosamide UCB (WS/1782)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/544469/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lacosamide-ucb-ws1782_en.pdf"},
    {"id":"49036","name":"CHMP post-authorisation summary of positive opinion for Vimpat (WS/1782)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/544470/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vimpat-ws1782_en.pdf"},
    {"id":"49211","name":"CHMP post-authorisation summary of positive opinion for Xarelto(X-74-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T17:04:00Z","last_updated_date":"2020-11-13T17:04:00Z","reference_number":"EMA/CHMP/592368/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xareltox-74-g_en.pdf"},
    {"id":"49219","name":"CHMP post-authorisation summary of positive opinion for Kyprolis (II-45)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T18:00:00Z","last_updated_date":"2020-11-13T18:00:00Z","reference_number":"EMA/CHMP/593624/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kyprolis-ii-45_en.pdf"},
    {"id":"49235","name":"CHMP post-authorisation summary of positive opinion for Xyrem (II-76)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T12:00:00Z","last_updated_date":"2020-11-13T12:00:00Z","reference_number":"EMA/CHMP/602260/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xyrem-ii-76_en.pdf"},
    {"id":"49242","name":"CHMP post-authorisation summary of positive opinion for Pradaxa (X-122-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T12:00:00Z","last_updated_date":"2020-11-13T12:00:00Z","reference_number":"EMA/CHMP/585170/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pradaxa-x-122-g_en.pdf"},
    {"id":"49245","name":"CHMP post-authorisation summary of positive opinion for Trimbow (X-08-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T18:02:00Z","last_updated_date":"2020-11-13T18:02:00Z","reference_number":"EMA/599401/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trimbow-x-08-g_en.pdf"},
    {"id":"49251","name":"CHMP post-authorisation summary of positive opinion for Tivicay (X-58-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T13:00:00Z","last_updated_date":"2020-11-13T13:00:00Z","reference_number":"EMA/CHMP/540606/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tivicay-x-58-g_en.pdf"},
    {"id":"49501","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-91)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T09:52:00Z","last_updated_date":"2020-12-11T09:52:00Z","reference_number":"EMA/CHMP/646079/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-91_en.pdf"},
    {"id":"49502","name":"CHMP post-authorisation summary of positive opinion for Spravato (II-0001-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T10:11:00Z","last_updated_date":"2020-12-11T10:11:00Z","reference_number":"EMA/CHMP/654550/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-spravato-ii-0001-g_en.pdf"},
    {"id":"49509","name":"CHMP post-authorisation summary of positive opinion for Rinvoq (II-04,II-05)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T11:44:00Z","last_updated_date":"2020-12-11T11:44:00Z","reference_number":"EMA/CHMP/662294/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rinvoq-ii-04ii-05_en.pdf"},
    {"id":"49514","name":"CHMP post-authorisation summary of positive opinion for Nordimet (II-16)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/658053/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nordimet-ii-16_en.pdf"},
    {"id":"49518","name":"CHMP post-authorisation summary of positive opinion for Bavencio (II-18)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/627792/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bavencio-ii-18_en.pdf"},
    {"id":"49521","name":"CHMP post-authorisation summary of positive opinion for Nplate (II-77)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/655636/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nplate-ii-77_en.pdf"},
    {"id":"49522","name":"CHMP post-authorisation summary of positive opinion for Iscover (WS-1769)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/660100/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-iscover-ws-1769_en.pdf"},
    {"id":"49523","name":"CHMP post-authorisation summary of positive opinion for Plavix (WS-1769)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/668777/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-plavix-ws-1769_en.pdf"},
    {"id":"49530","name":"CHMP post-authorisation summary of positive opinion for Doptelet (II-04-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/659983/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-doptelet-ii-04-g_en.pdf"},
    {"id":"49540","name":"CHMP post-authorisation summary of positive opinion for Veklury (II-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T11:20:00Z","last_updated_date":"2020-12-11T11:20:00Z","reference_number":"EMA/669235/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veklury-ii-12_en.pdf"},
    {"id":"49990","name":"CHMP post-authorisation summary of positive opinion for Tysabri (X-116)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T15:25:00Z","last_updated_date":"2021-02-01T15:25:00Z","reference_number":"EMA/CHMP/50871/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tysabri-x-116_en.pdf"},
    {"id":"49991","name":"CHMP post-authorisation summary of positive opinion for Sirturo (X-36-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T15:38:00Z","last_updated_date":"2021-02-01T15:38:00Z","reference_number":"EMA/CHMP/607909/2020","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sirturo-x-36-g_en.pdf"},
    {"id":"49995","name":"CHMP post-authorisation summary of positive opinion for Vaxchora (II-03-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T17:10:00Z","last_updated_date":"2021-02-01T17:10:00Z","reference_number":"EMA/CHMP/46810/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vaxchora-ii-03-g_en.pdf"},
    {"id":"49996","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-90)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T17:31:00Z","last_updated_date":"2021-02-01T17:31:00Z","reference_number":"EMA/CHMP/39064/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-90_en.pdf"},
    {"id":"50244","name":"CVMP post-authorisation summary of positive opinion for Emdocam (X-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-19T12:59:00Z","last_updated_date":"2021-02-19T12:59:00Z","reference_number":"EMA/CVMP/92879/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-emdocam-x-12_en.pdf"},
    {"id":"50245","name":"CVMP post-authorisation summary of positive opinion for Emdocam (X-13)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-19T14:00:00Z","last_updated_date":"2021-02-19T14:00:00Z","reference_number":"EMA/CVMP/92881/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-emdocam-x-13_en.pdf"},
    {"id":"50264","name":"CHMP post-authorisation summary of positive opinion for Cabometyx (II-17)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T12:00:00Z","last_updated_date":"2021-02-26T12:00:00Z","reference_number":"EMA/102980/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cabometyx-ii-17_en.pdf"},
    {"id":"50265","name":"CHMP post-authorisation summary of positive opinion for Cabometyx (II-17)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-25T12:00:00Z","last_updated_date":"2021-02-25T12:00:00Z","reference_number":"EMA/102980/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cabometyx-ii-17_en.pdf-0"},
    {"id":"50270","name":"CHMP post-authorisation summary of positive opinion for Quofenix (II-03)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T13:57:00Z","last_updated_date":"2021-02-26T13:57:00Z","reference_number":"EMA/CHMP/99783/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-quofenix-ii-03_en.pdf"},
    {"id":"50273","name":"CHMP post-authorisation summary of positive opinion for Epidyolex (II-05)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T14:16:00Z","last_updated_date":"2021-02-26T14:16:00Z","reference_number":"EMA/CHMP/51910/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-epidyolex-ii-05_en.pdf"},
    {"id":"50283","name":"CHMP post-authorisation summary of positive opinion for Sarclisa (II-03)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T16:51:00Z","last_updated_date":"2021-02-26T16:51:00Z","reference_number":"EMA/CHMP/111163/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sarclisa-ii-03_en.pdf"},
    {"id":"50284","name":"CHMP post-authorisation summary of positive opinion for Opdivo (II-92)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T12:22:00Z","last_updated_date":"2021-02-26T12:22:00Z","reference_number":"EMA/CHMP/84465/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ii-92_en.pdf"},
    {"id":"50291","name":"Questions and answers on the refusal of a change to the marketing authorisation for Elebrato Ellipta (fluticasone furoate / umeclidinium / vilanterol)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T11:55:00Z","last_updated_date":"2021-02-26T11:55:00Z","reference_number":"EMA/126141/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-elebrato-ellipta-fluticasone-furoate-umeclidinium-vilanterol_en.pdf"},
    {"id":"50292","name":"Questions and answers on the refusal of a change to the marketing authorisation for Temybric Ellipta (fluticasone furoate / umeclidinium / vilanterol)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T12:00:00Z","last_updated_date":"2022-11-24T15:37:00Z","reference_number":"EMA/126142/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-temybric-ellipta-fluticasone-furoate-umeclidinium-vilanterol_en.pdf"},
    {"id":"50293","name":"Questions and answers on the refusal of a change to the marketing authorisation for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T12:23:00Z","last_updated_date":"2021-02-26T12:23:00Z","reference_number":"EMA/123532/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-trelegy-ellipta-fluticasone-furoate-umeclidinium-vilanterol_en.pdf"},
    {"id":"50652","name":"CVMP post-authorisation summary of positive opinion for Cortavance","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-03-19T13:00:00Z","last_updated_date":"2021-03-19T13:00:00Z","reference_number":"EMA/CVMP/144750/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-cortavance_en.pdf"},
    {"id":"50701","name":"CHMP post-authorisation summary of positive opinion for Benlysta (II-80)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T12:00:00Z","last_updated_date":"2021-03-26T12:00:00Z","reference_number":"EMA/CHMP/170073/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-benlysta-ii-80_en.pdf"},
    {"id":"50704","name":"CHMP post-authorisation summary of positive opinion for Xtandi (II-47-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T12:00:00Z","last_updated_date":"2021-03-26T12:00:00Z","reference_number":"EMA/CHMP/169064/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xtandi-ii-47-g_en.pdf"},
    {"id":"50716","name":"CHMP post-authorisation summary of positive opinion for Saxenda (II-26)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T12:00:00Z","last_updated_date":"2021-03-26T12:00:00Z","reference_number":"EMA/CHMP/172820/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-saxenda-ii-26_en.pdf"},
    {"id":"50717","name":"CHMP post-authorisation summary of positive opinion for Kaftrio (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T12:00:00Z","last_updated_date":"2021-03-26T12:00:00Z","reference_number":"EMA/CHMP/153342/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kaftrio-ii-01_en.pdf"},
    {"id":"50720","name":"CHMP post-authorisation summary of positive opinion for Tecentriq (II-33)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T12:00:00Z","last_updated_date":"2021-03-26T12:00:00Z","reference_number":"EMA/CHMP/171659/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tecentriq-ii-33_en.pdf"},
    {"id":"50724","name":"CHMP post-authorisation summary of positive opinion for Kalydeco (II-89)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T12:00:00Z","last_updated_date":"2021-03-26T12:00:00Z","reference_number":"EMA/177576/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-ii-89_en.pdf"},
    {"id":"50944","name":"CHMP post-authorisation summary of positive opinion for DuoResp Spiromax (II-33-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/216237/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-duoresp-spiromax-ii-33-g_en.pdf"},
    {"id":"50946","name":"CHMP post-authorisation summary of positive opinion for Aubagio (X-31)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/213204/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aubagio-x-31_en.pdf"},
    {"id":"50947","name":"CHMP post-authorisation summary of positive opinion for Nulojix (II-70)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/179746/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nulojix-ii-70_en.pdf"}    {"id":"50948","name":"CHMP post-authorisation summary of positive opinion for BiResp Spiromax (II-33-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/218046/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-biresp-spiromax-ii-33-g_en.pdf"},
    {"id":"50949","name":"CHMP post-authorisation summary of positive opinion for Opdivo (WS-1881)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/210870/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ws-1881_en.pdf"},
    {"id":"50950","name":"CHMP post-authorisation summary of positive opinion for Yervoy (WS-1881)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/210871/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yervoy-ws-1881_en.pdf"},
    {"id":"50963","name":"CHMP post-authorisation summary of positive opinion for Tagrisso (II-39-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/230979/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tagrisso-ii-39-g_en.pdf"},
    {"id":"50965","name":"CHMP post-authorisation summary of positive opinion for Venclyxto (II-30)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/206516/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-venclyxto-ii-30_en.pdf"},
    {"id":"50980","name":"CHMP post-authorisation summary of positive opinion for Maviret (X-33-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-04-26T09:36:00Z","last_updated_date":"2021-04-26T09:36:00Z","reference_number":"EMA/CHMP/212239/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-maviret-x-33-g_en.pdf"},
    {"id":"51208","name":"CHMP post-authorisation summary of positive opinion for Spherox (II-20)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T15:19:00Z","last_updated_date":"2021-05-21T15:19:00Z","reference_number":"EMA/CHMP/273246/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-spherox-ii-20_en.pdf"},
    {"id":"51209","name":"CHMP post-authorisation summary of positive opinion for Opdivo (WS-1840)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T15:52:00Z","last_updated_date":"2021-05-21T15:52:00Z","reference_number":"EMA/CHMP/264429/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ws-1840_en.pdf"},
    {"id":"51210","name":"CHMP post-authorisation summary of positive opinion for Yervoy (WS-1840)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T16:00:00Z","last_updated_date":"2021-05-21T16:00:00Z","reference_number":"EMA/CHMP/264433/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yervoy-ws-1840_en.pdf"},
    {"id":"51211","name":"CHMP post-authorisation summary of positive opinion for Blincyto (II-38)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T12:00:00Z","last_updated_date":"2021-05-21T12:00:00Z","reference_number":"EMA/CHMP/241760/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-blincyto-ii-38_en.pdf"},
    {"id":"51212","name":"CHMP post-authorisation summary of positive opinion for Galvus (WS-1938-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T02:00:00Z","last_updated_date":"2021-05-21T02:00:00Z","reference_number":"EMA/283685/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-galvus-ws-1938-g_en.pdf"},
    {"id":"51214","name":"CHMP post-authorisation summary of positive opinion for Jalra (WS-1938-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T02:00:00Z","last_updated_date":"2021-05-21T02:00:00Z","reference_number":"EMA/283685/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jalra-ws-1938-g_en.pdf"},
    {"id":"51215","name":"CHMP post-authorisation summary of positive opinion for Xiliarx (WS-1938-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T02:00:00Z","last_updated_date":"2021-05-21T02:00:00Z","reference_number":"EMA/283685/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xiliarx-ws-1938-g_en.pdf"},
    {"id":"51216","name":"CHMP post-authorisation summary of positive opinion for Zomarist (WS-1937-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T17:19:00Z","last_updated_date":"2021-05-21T17:19:00Z","reference_number":"EMA/283696/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zomarist-ws-1937-g_en.pdf"},
    {"id":"51217","name":"CHMP post-authorisation summary of positive opinion for Icandra (WS-1937-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T12:00:00Z","last_updated_date":"2021-05-21T12:00:00Z","reference_number":"EMA/283696/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-icandra-ws-1937-g_en.pdf"},
    {"id":"51218","name":"CHMP post-authorisation summary of positive opinion for Eucreas (WS-1937-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T17:32:00Z","last_updated_date":"2021-05-21T17:32:00Z","reference_number":"EMA/283696/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eucreas-ws-1937-g_en.pdf"},
    {"id":"51222","name":"CHMP post-authorisation summary of positive opinion for Jardiance (II-55)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T01:00:00Z","last_updated_date":"2021-05-21T01:00:00Z","reference_number":"EMA/CHMP/275069/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jardiance-ii-55_en.pdf"},
    {"id":"51225","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-97)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T12:00:00Z","last_updated_date":"2021-05-21T12:00:00Z","reference_number":"EMA/262267/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-97_en.pdf"},
    {"id":"51226","name":"CHMP post-authorisation summary of positive opinion for Darzalex (II-43, II-44)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T12:15:00Z","last_updated_date":"2021-05-21T12:15:00Z","reference_number":"EMA/CHMP/278065/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-darzalex-ii-43-ii-44_en.pdf"},
    {"id":"51229","name":"CHMP post-authorisation summary of positive opinion for Evotaz (II-38)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T15:36:00Z","last_updated_date":"2021-05-21T15:36:00Z","reference_number":"EMA/289551/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-evotaz-ii-38_en.pdf"},
    {"id":"51294","name":"CHMP post-authorisation summary of positive opinion for Comirnaty (II-30)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-05-28T17:14:00Z","last_updated_date":"2021-05-28T17:14:00Z","reference_number":"EMA/303424/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-comirnaty-ii-30_en.pdf"},
    {"id":"51562","name":"CHMP post-authorisation summary of positive opinion for Galafold (II-29)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T15:52:00Z","last_updated_date":"2021-06-25T15:52:00Z","reference_number":"EMA/CHMP/302791/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-galafold-ii-29_en.pdf"},
    {"id":"51563","name":"CHMP summary of positive opinion for Fingolimod Mylan","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T16:16:00Z","last_updated_date":"2021-06-25T16:16:00Z","reference_number":"EMA/CHMP/325945/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-fingolimod-mylan_en.pdf"},
    {"id":"51578","name":"CHMP post-authorisation summary of positive opinion for Rinvoq (X-06-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T12:01:00Z","last_updated_date":"2021-06-25T12:01:00Z","reference_number":"EMA/CHMP/189397/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rinvoq-x-06-g_en.pdf"},
    {"id":"51579","name":"CHMP post-authorisation summary of positive opinion for Xeljanz (X-24-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T12:05:00Z","last_updated_date":"2021-06-25T12:05:00Z","reference_number":"EMA/CHMP/337119/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xeljanz-x-24-g_en.pdf"},
    {"id":"51589","name":"CHMP post-authorisation summary of positive opinion for Opdivo (II-95)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T16:16:00Z","last_updated_date":"2021-06-25T16:16:00Z","reference_number":"EMA/CHMP/341080/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ii-95_en.pdf"},
    {"id":"51598","name":"CHMP post-authorisation summary of positive opinion for Edistride (WS-1941)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T12:00:00Z","last_updated_date":"2021-06-25T12:00:00Z","reference_number":"EMA/CHMP/347889/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-edistride-ws-1941_en.pdf"},
    {"id":"51599","name":"CHMP post-authorisation summary of positive opinion for Forxiga (WS-1941)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T10:46:00Z","last_updated_date":"2021-06-25T10:46:00Z","reference_number":"EMA/CHMP/347888/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-forxiga-ws-1941_en.pdf"},
    {"id":"51948","name":"CVMP post-authorisation summary of positive opinion for Suvaxyn CSF Marker (II-0009)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-07-16T14:00:00Z","last_updated_date":"2025-09-02T11:11:11Z","reference_number":"EMA/CVMP/395141/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-suvaxyn-csf-marker-ii-0009_en.pdf"},
    {"id":"52015","name":"CHMP post-authorisation summary of positive opinion for Volibris (X-61-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:11:00Z","last_updated_date":"2021-07-23T12:11:00Z","reference_number":"EMA/CHMP/398036/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-volibris-x-61-g_en.pdf"},
    {"id":"52034","name":"CHMP post-authorisation summary of positive opinion for Vosevi (X-45-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T19:04:00Z","last_updated_date":"2021-07-23T19:04:00Z","reference_number":"EMA/CHMP/229665/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vosevi-x-45-g_en.pdf"},
    {"id":"52035","name":"CHMP post-authorisation summary of positive opinion for Deltyba (X-46-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T19:11:00Z","last_updated_date":"2021-07-23T19:11:00Z","reference_number":"EMA/CHMP/266703/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-deltyba-x-46-g_en.pdf"},
    {"id":"52040","name":"CHMP post-authorisation summary of positive opinion for Ultomiris (II-10)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:00:00Z","last_updated_date":"2021-07-23T12:00:00Z","reference_number":"EMA/CHMP/408323/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ultomiris-ii-10_en.pdf"},
    {"id":"52045","name":"Questions and answers on the outcome of assessment on use of Siklos in the treatment of severe chronic anaemia in sickle cell syndrome","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T11:37:00Z","last_updated_date":"2021-07-23T11:37:00Z","reference_number":"EMA/412082/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-outcome-assessment-use-siklos-treatment-severe-chronic-anaemia-sickle-cell-syndrome_en.pdf"},
    {"id":"52046","name":"CHMP post-authorisation summary of positive opinion for Spikevax (II-21)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:01:00Z","last_updated_date":"2021-07-23T12:01:00Z","reference_number":"EMA/CHMP/325680/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-spikevax-ii-21_en.pdf"},
    {"id":"52421","name":"CVMP post-authorisation summary of positive opinion for Frontpro","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-10T11:05:00Z","last_updated_date":"2021-09-10T11:05:00Z","reference_number":"EMA/CVMP/483593/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-frontpro_en.pdf"},
    {"id":"52451","name":"CHMP post-authorisation summary of positive opinion for Noxafil (II-62)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T13:41:00Z","last_updated_date":"2021-09-17T13:41:00Z","reference_number":"EMA/CHMP/508764/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-noxafil-ii-62_en.pdf"},
    {"id":"52461","name":"CHMP post-authorisation summary of positive opinion for Zepatier (II-29)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T13:06:00Z","last_updated_date":"2021-09-17T13:06:00Z","reference_number":"EMA/CHMP/505022/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zepatier-ii-29_en.pdf"},
    {"id":"52465","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-99)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T15:00:00Z","last_updated_date":"2021-09-17T15:00:00Z","reference_number":"EMA/CHMP/510671/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-99_en.pdf"},
    {"id":"52468","name":"CHMP post-authorisation summary of positive opinion for Firmagon (II-39-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/498649/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-firmagon-ii-39-g_en.pdf"},
    {"id":"52471","name":"CHMP post-authorisation summary of positive opinion for Opdivo (II-96)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/470881/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ii-96_en.pdf"},
    {"id":"52474","name":"CHMP post-authorisation summary of positive opinion for Jyseleca (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/501847/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jyseleca-ii-01_en.pdf"},
    {"id":"52480","name":"CHMP post-authorisation summary of positive opinion for Nucala (II-35, II-36, II-37)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/2165/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nucala-ii-35-ii-36-ii-37_en.pdf"},
    {"id":"52484","name":"CHMP post-authorisation summary of positive opinion for Adempas (II-32-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/508328/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adempas-ii-32-g_en.pdf"},
    {"id":"52492","name":"CHMP post-authorisation summary of positive opinion for Segluromet (WS-1953)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/526207/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-segluromet-ws-1953_en.pdf"},
    {"id":"52493","name":"CHMP post-authorisation summary of positive opinion for Steglatro (WS-1953)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T11:36:00Z","last_updated_date":"2021-09-30T15:02:00Z","reference_number":"EMA/CHMP/513781/2021 Corr.","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-steglatro-ws-1953_en.pdf"},
    {"id":"52496","name":"CHMP post-authorisation summary of positive opinion for Byannli (X-02-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/504133/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-byannli-x-02-g_en.pdf"},
    {"id":"52789","name":"CVMP post-authorisation summary of positive opinion for Apoquel (II-0019)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T14:56:00Z","last_updated_date":"2021-10-08T14:56:00Z","reference_number":"EMA/CVMP/523501/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-apoquel-ii-0019_en.pdf"},
    {"id":"52791","name":"CVMP post-authorisation summary of positive opinion for NexGard Combo (II-0002-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T15:04:00Z","last_updated_date":"2021-10-08T15:04:00Z","reference_number":"EMA/CVMP/521675/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-combo-ii-0002-g_en.pdf"},
    {"id":"52836","name":"CHMP post-authorisation summary of positive opinion for Kisplyx (II-45)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/CHMP/551957/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kisplyx-ii-45_en.pdf"},
    {"id":"52837","name":"CHMP post-authorisation summary of positive opinion for Xeljanz (II-35)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/CHMP/561838/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xeljanz-ii-35_en.pdf"},
    {"id":"52838","name":"CHMP post-authorisation summary of positive opinion for Zeposia (II-0002-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/578657/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zeposia-ii-0002-g_en.pdf"},
    {"id":"52848","name":"CHMP post-authorisation summary of opinion for Hizentra (II-29)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/CHMP/490034/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-hizentra-ii-29_en.pdf"},
    {"id":"52852","name":"CHMP post-authorisation summary of opinion for Repatha (II-49-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-14T16:42:00Z","last_updated_date":"2021-10-14T16:42:00Z","reference_number":"EMA/CHMP/584205/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-repatha-ii-49-g_en.pdf"},
    {"id":"52854","name":"CHMP post-authorisation summary of positive opinion for Lenvima (II-42)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-14T17:38:00Z","last_updated_date":"2021-10-14T17:38:00Z","reference_number":"EMA/CHMP/565583/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lenvima-ii-42_en.pdf"},
    {"id":"52862","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-104, II-105)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/CHMP/552097/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-104-ii-105_en.pdf"},
    {"id":"52868","name":"CHMP post-authorisation summary of positive opinion for Edistride (WS-1952)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/CHMP/589418/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-edistride-ws-1952_en.pdf"},
    {"id":"52869","name":"CHMP post-authorisation summary of positive opinion for Forxiga (WS-1952)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/CHMP/589419/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-forxiga-ws-1952_en.pdf"},
    {"id":"53065","name":"CHMP post-authorisation summary of positive opinion for Noxafil (X-63-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/CHMP/598957/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-noxafil-x-63-g_en.pdf"},
    {"id":"53072","name":"CHMP post-authorisation summary of positive opinion for Epclusa (X-56-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/CHMP/603118/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-epclusa-x-56-g_en.pdf"},
    {"id":"53075","name":"CHMP post-authorisation summary of positive opinion for Dengvaxia (II-11;II-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T14:48:00Z","last_updated_date":"2025-12-04T12:00:00Z","reference_number":"EMA/CHMP/618604/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dengvaxia-ii-11ii-12_en.pdf"},
    {"id":"53076","name":"CHMP post-authorisation summary of positive opinion for Rapiscan (II-38)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T14:52:00Z","last_updated_date":"2021-11-12T14:52:00Z","reference_number":"EMA/CHMP606839/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rapiscan-ii-38_en.pdf"},
    {"id":"53082","name":"CHMP post-authorisation summary of positive opinion for Kaftrio (X-08-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/CHMP/560959/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kaftrio-x-08-g_en.pdf"},
    {"id":"53088","name":"CHMP post-authorisation summary of opinion for Kalydeco (II-96)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/590546/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-kalydeco-ii-96_en.pdf"},
    {"id":"53372","name":"CHMP post-authorisation summary of positive opinion for RoActemra (II-101)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-12-06T14:59:00Z","last_updated_date":"2021-12-06T14:59:00Z","reference_number":"EMA/CHMP/683450/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-roactemra-ii-101_en.pdf"},
    {"id":"53440","name":"CVMP post-authorisation summary of positive opinion for Bravecto (II-0051)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-12-10T15:33:00Z","last_updated_date":"2021-12-10T15:33:00Z","reference_number":"EMA/CVMP/696735/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bravecto-ii-0051_en.pdf"},
    {"id":"53441","name":"CVMP post-authorisation summary of positive opinion for Improvac (II-0036)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-12-10T15:42:00Z","last_updated_date":"2021-12-10T15:42:00Z","reference_number":"EMA/CVMP/714359/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-improvac-ii-0036_en.pdf"},
    {"id":"53549","name":"CHMP post-authorisation summary of positive opinion for Teysuno (II-45)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T12:30:00Z","last_updated_date":"2021-12-17T12:30:00Z","reference_number":"EMA/CHMP/714788/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-teysuno-ii-45_en.pdf"},
    {"id":"53551","name":"CHMP post-authorisation summary of opinion for Kineret (II-86)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-12-16T14:12:00Z","last_updated_date":"2021-12-16T14:12:00Z","reference_number":"EMA/CHMP/697130/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-kineret-ii-86_en.pdf"},
    {"id":"53553","name":"CHMP post-authorisation summary of positive opinion for Entyvio (II-61)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T14:31:00Z","last_updated_date":"2021-12-17T14:31:00Z","reference_number":"EMA/CHMP/748916/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-entyvio-ii-61_en.pdf"},
    {"id":"53555","name":"CHMP post-authorisation summary of positive opinion for Keytruda  (II-108)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T14:41:00Z","last_updated_date":"2021-12-17T14:41:00Z","reference_number":"EMA/702822/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-108_en.pdf"},
    {"id":"53560","name":"CHMP post-authorisation summary of opinion for Lorviqua (II-15)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T12:00:00Z","last_updated_date":"2021-12-17T12:00:00Z","reference_number":"EMA/CHMP/684399/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-lorviqua-ii-15_en.pdf"},
    {"id":"53561","name":"CHMP post-authorisation summary of positive opinion for Veklury (II-16)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T12:00:00Z","last_updated_date":"2021-12-17T12:00:00Z","reference_number":"EMA/CHMP/727702/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veklury-ii-16_en.pdf"},
    {"id":"53870","name":"CVMP post-authorisation summary of positive opinion for Credelio (II-0019)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-01-21T12:20:00Z","last_updated_date":"2022-01-21T12:20:00Z","reference_number":"EMA/CVMP/11507/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-credelio-ii-0019_en.pdf"},
    {"id":"53915","name":"CHMP post-authorisation summary of positive opinion for Tecfidera (II-0073)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T12:20:00Z","last_updated_date":"2022-04-22T10:11:00Z","reference_number":"EMA/CHMP/691024/2021 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tecfidera-ii-0073_en.pdf"},
    {"id":"53920","name":"CHMP post-authorisation summary of opinion for Briviact (II-32-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T12:00:00Z","last_updated_date":"2022-01-28T12:00:00Z","reference_number":"EMA/CHMP/37228/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-briviact-ii-32-g_en.pdf"},
    {"id":"53923","name":"CHMP post-authorisation summary of positive opinion for Vimpat (WS-2049-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T12:00:00Z","last_updated_date":"2022-01-28T12:00:00Z","reference_number":"EMA/CHMP/37453/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vimpat-ws-2049-g_en.pdf"},
    {"id":"53927","name":"CHMP post-authorisation summary of opinion for Lacosamide UCB (WS-2049-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T12:00:00Z","last_updated_date":"2022-01-28T12:00:00Z","reference_number":"EMA/CHMP/37452/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-lacosamide-ucb-ws-2049-g_en.pdf"},
    {"id":"53945","name":"CHMP post-authorisation summary of positive opinion for Ayvakyt (X-04-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T15:33:00Z","last_updated_date":"2022-01-28T15:33:00Z","reference_number":"EMA/CHMP/40668/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ayvakyt-x-04-g_en.pdf"},
    {"id":"53946","name":"CHMP post-authorisation summary of positive opinion for Jardiance (II-0060)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T11:55:00Z","last_updated_date":"2022-01-28T11:55:00Z","reference_number":"EMA/CHMP/36445/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jardiance-ii-0060_en.pdf"},
    {"id":"53961","name":"CHMP post-authorisation summary of positive opinion for Senshio (II-0041)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T11:55:00Z","last_updated_date":"2022-01-28T11:55:00Z","reference_number":"EMA/CHMP/22550/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-senshio-ii-0041_en.pdf"},
    {"id":"53996","name":"CHMP summary of opinion for Dupixent (X-45-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T12:00:00Z","last_updated_date":"2022-01-28T12:00:00Z","reference_number":"EMA/CHMP/39058/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-opinion-dupixent-x-45-g_en.pdf"},
    {"id":"54254","name":"CHMP post-authorisation summary of positive opinion for Delstrigo (WS-2065)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T18:01:00Z","last_updated_date":"2022-02-25T18:01:00Z","reference_number":"EMA/CHMP/107210/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-delstrigo-ws-2065_en.pdf"},
    {"id":"54255","name":"CHMP post-authorisation summary of positive opinion for Pifeltro (WS-2065)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T18:07:00Z","last_updated_date":"2022-02-25T18:07:00Z","reference_number":"EMA/CHMP/107190/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pifeltro-ws-2065_en.pdf"},
    {"id":"54276","name":"CHMP summary of positive opinion for Quviviq","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2022-02-25T12:00:00Z","reference_number":"EMA/CHMP/72381/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-quviviq_en.pdf"},
    {"id":"54279","name":"CHMP post-authorisation summary of opinion for Spikevax (II-41)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-02-24T15:35:00Z","last_updated_date":"2022-02-24T15:35:00Z","reference_number":"EMA/CHMP/70705/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-spikevax-ii-41_en.pdf"},
    {"id":"54281","name":"CHMP summary of positive opinion for Opdivo (II-100_II-107_WS-2113)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2022-02-25T12:00:00Z","reference_number":"EMA/CHMP/66144/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-opdivo-ii-100_ii-107_ws-2113_en.pdf"},
    {"id":"54283","name":"CHMP summary of positive opinion for Yervoy (WS-2113)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T16:20:00Z","last_updated_date":"2022-02-25T16:20:00Z","reference_number":"EMA/CHMP/101990/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-yervoy-ws-2113_en.pdf"},
    {"id":"54299","name":"CHMP post-authorisation summary of opinion for Verzenios (II-13)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2022-02-25T12:00:00Z","reference_number":"EMA/CHMP/116347/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-verzenios-ii-13_en.pdf"},
    {"id":"54300","name":"CHMP post-authorisation summary of opinion for Beovu (II-10)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2022-02-25T12:00:00Z","reference_number":"EMA/CHMP/123447/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-beovu-ii-10_en.pdf"},
    {"id":"54518","name":"CVMP post-authorisation summary of positive opinion for Advocate (II-0046)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-03-18T14:00:00Z","last_updated_date":"2022-03-18T14:00:00Z","reference_number":"EMA/CVMP/126530/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-advocate-ii-0046_en.pdf"},
    {"id":"54558","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-109; II-117)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:43:00Z","last_updated_date":"2022-03-25T12:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-109-ii-117_en.pdf"},
    {"id":"54561","name":"CHMP post-authorisation summary of opinion for Cabometyx (II-23)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:00:00Z","last_updated_date":"2022-03-25T12:00:00Z","reference_number":"EMA/CHMP/170076/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-cabometyx-ii-23_en.pdf"},
    {"id":"54563","name":"CHMP post-authorisation summary of opinion for Jakavi (II-53)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:00:00Z","last_updated_date":"2022-03-25T12:00:00Z","reference_number":"EMA/CHMP/119529/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-jakavi-ii-53_en.pdf"},
    {"id":"54564","name":"CHMP post-authorisation summary of opinion for Kymriah (II-44)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:00:00Z","last_updated_date":"2022-03-25T12:00:00Z","reference_number":"EMA/CHMP/167689/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-kymriah-ii-44_en.pdf"},
    {"id":"54591","name":"CHMP post-authorisation summary of positive opinion for Polivy (II-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T11:56:00Z","last_updated_date":"2022-03-25T11:56:00Z","reference_number":"EMA/CHMP/172750/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-polivy-ii-12_en.pdf"},
    {"id":"54781","name":"CHMP post-authorisation summary of opinion for NovoSeven (II-116)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/213286/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-novoseven-ii-116_en.pdf"},
    {"id":"54787","name":"CHMP post-authorisation summary of opinion for Keytruda (II-110)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/203854/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-keytruda-ii-110_en.pdf"},
    {"id":"54792","name":"CHMP post-authorisation summary of opinion for Yescarta (II-42)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/222176/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-yescarta-ii-42_en.pdf"},
    {"id":"54796","name":"CHMP post-authorisation summary of opinion for Elonva (II-61)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/223560/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-elonva-ii-61_en.pdf"}    {"id":"54797","name":"CHMP post-authorisation summary of opinion for Bydureon (II-73)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/224384/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-bydureon-ii-73_en.pdf"},
    {"id":"54809","name":"CHMP post-authorisation summary of opinion for Tecentriq (II-64)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/219365/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-tecentriq-ii-64_en.pdf"},
    {"id":"54810","name":"CHMP post-authorisation summary of opinion for Retsevmo (II-11)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:05:00Z","last_updated_date":"2022-04-22T14:05:00Z","reference_number":"EMA/CHMP/219292/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-retsevmo-ii-11_en.pdf"},
    {"id":"54958","name":"CVMP post-authorisation summary of positive opinion for Suprelorin (II-0032-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-05-13T15:23:00Z","last_updated_date":"2022-05-13T15:23:00Z","reference_number":"EMA/CVMP/250532/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-suprelorin-ii-0032-g_en.pdf"},
    {"id":"55009","name":"CHMP post-authorisation summary of opinion for Keytruda (II-111)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/CHMP/237136/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-keytruda-ii-111_en.pdf"},
    {"id":"55010","name":"CHMP post-authorisation summary of positive opinion for Cosentyx (II-79)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T14:08:00Z","last_updated_date":"2022-05-20T14:08:00Z","reference_number":"EMA/CHMP/260147/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-ii-79_en.pdf"},
    {"id":"55014","name":"CHMP post-authorisation summary of positive opinion for Olumiant (II-29-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T15:06:00Z","last_updated_date":"2022-05-20T15:06:00Z","reference_number":"EMA/CHMP/260143/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-olumiant-ii-29-g_en.pdf"},
    {"id":"55020","name":"CHMP post-authorisation summary of opinion for Nexpovio (II-01-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/CHMP/266096/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-nexpovio-ii-01-g_en.pdf"},
    {"id":"55029","name":"CHMP post-authorisation summary of opinion for Xeljanz","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/CHMP/262700/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-xeljanz_en.pdf"},
    {"id":"55031","name":"CHMP post-authorisation summary of opinion for Rinvoq (X-12-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/CHMP/260144/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-rinvoq-x-12-g_en.pdf"},
    {"id":"55269","name":"CVMP post-authorisation summary of positive opinion for Bravecto (II-0054-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-06-17T14:23:00Z","last_updated_date":"2022-06-17T14:23:00Z","reference_number":"EMA/CVMP/294601/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bravecto-ii-0054-g_en.pdf"},
    {"id":"55327","name":"CHMP post-authorisation summary of positive opinion for Enhertu (II-14)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T13:12:00Z","last_updated_date":"2022-06-24T13:12:00Z","reference_number":"EMA/CHMP/594646/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enhertu-ii-14_en.pdf"},
    {"id":"55336","name":"CHMP post-authorisation summary of positive opinion for Crysvita (II-23)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-06-23T15:21:00Z","last_updated_date":"2022-06-23T15:21:00Z","reference_number":"EMA/CHMP/596303/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-crysvita-ii-23_en.pdf"},
    {"id":"55338","name":"CHMP post-authorisation summary of positive opinion for Imbruvica (II-70)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T15:36:00Z","last_updated_date":"2022-06-24T15:36:00Z","reference_number":"EMA/CHMP/595994/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imbruvica-ii-70_en.pdf"},
    {"id":"55341","name":"CHMP post-authorisation summary of positive opinion for Lonquex (II-58-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T15:52:00Z","last_updated_date":"2022-06-24T15:52:00Z","reference_number":"EMA/CHMP/576014/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lonquex-ii-58-g_en.pdf"},
    {"id":"55342","name":"CHMP post-authorisation summary of positive opinion for Nuvaxovid (II-0009)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-06-23T16:00:00Z","last_updated_date":"2022-06-23T16:00:00Z","reference_number":"EMA/604944/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nuvaxovid-ii-0009_en.pdf"},
    {"id":"55345","name":"CHMP post-authorisation summary of positive opinion for Zerbaxa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T12:00:00Z","last_updated_date":"2022-06-24T12:00:00Z","reference_number":"EMA/CHMP/595935/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zerbaxa_en.pdf"},
    {"id":"55361","name":"CHMP post-authorisation summary of positive opinion for Lynparza (II-51-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T10:35:00Z","last_updated_date":"2022-06-24T10:35:00Z","reference_number":"EMA/CHMP/602696/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-51-g_en.pdf"},
    {"id":"55462","name":"Questions and answers on the refusal of a change to the marketing authorisation for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2022-07-05T14:41:00Z","last_updated_date":"2022-07-05T14:41:00Z","reference_number":"EMA/123532/2021","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-trelegy-ellipta-fluticasone-furoate-umeclidinium-vilanterol_en.pdf-0"},
    {"id":"55623","name":"CHMP post-authorisation summary of positive opinion for Imvanex (II-76)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T12:00:00Z","last_updated_date":"2022-07-22T12:00:00Z","reference_number":"EMA/CHMP/642836/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imvanex-ii-76_en.pdf"},
    {"id":"55625","name":"CHMP post-authorisation summary of positive opinion for Tecartus (II-08-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T12:00:00Z","last_updated_date":"2022-07-22T12:00:00Z","reference_number":"EMA/CHMP/653247/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tecartus-ii-08-g_en.pdf"},
    {"id":"55632","name":"CHMP post-authorisation summary of positive opinion for Imcivree (II-02-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T16:41:00Z","last_updated_date":"2022-07-22T16:41:00Z","reference_number":"EMA/639016/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imcivree-ii-02-g_en.pdf"},
    {"id":"55641","name":"CHMP post-authorisation summary of positive opinion for Retsevmo (II-0014-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T08:52:00Z","last_updated_date":"2022-07-22T08:52:00Z","reference_number":"EMA/CHMP/654924/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-retsevmo-ii-0014-g_en.pdf"},
    {"id":"55642","name":"CHMP post-authorisation summary of positive opinion for Ultomiris (II-0026)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T09:50:00Z","last_updated_date":"2022-07-22T09:50:00Z","reference_number":"EMA/CHMP/637630/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ultomiris-ii-0026_en.pdf"},
    {"id":"55658","name":"CHMP post-authorisation summary of positive opinion for Genvoya (X-79-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-07-25T09:47:00Z","last_updated_date":"2022-07-25T09:47:00Z","reference_number":"EMA/CHMP/126645/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-genvoya-x-79-g_en.pdf"},
    {"id":"56052","name":"CVMP post-authorisation summary of positive opinion for Improvac (VRA-0039-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-09T16:55:00Z","last_updated_date":"2022-09-09T16:55:00Z","reference_number":"EMA/CVMP/721187/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-improvac-vra-0039-g_en.pdf"},
    {"id":"56097","name":"CHMP post-authorisation summary of opinion for Exparel liposomal","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T02:00:00Z","last_updated_date":"2022-09-16T02:00:00Z","reference_number":"EMA/CHMP/762558/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-exparel-liposomal_en.pdf"},
    {"id":"56100","name":"CHMP post-authorisation summary of positive opinion for Adtralza (II-0002)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T10:38:00Z","last_updated_date":"2022-09-16T10:38:00Z","reference_number":"EMA/CHMP/742227/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adtralza-ii-0002_en.pdf"},
    {"id":"56106","name":"CHMP post-authorisation summary of positive opinion for Vaxneuvance (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T13:40:00Z","last_updated_date":"2022-09-16T13:40:00Z","reference_number":"EMA/CHMP/762289/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vaxneuvance-ii-01_en.pdf"},
    {"id":"56107","name":"CHMP post-authorisation summary of positive opinion for Yescarta (II-46)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T13:44:00Z","last_updated_date":"2022-09-16T13:44:00Z","reference_number":"EMA/CHMP/760015/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yescarta-ii-46_en.pdf"},
    {"id":"56108","name":"CHMP post-authorisation summary of positive opinion for Skyrizi (X-20-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T13:49:00Z","last_updated_date":"2022-09-16T13:49:00Z","reference_number":"EMA/CHMP/727463/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-skyrizi-x-20-g_en.pdf"},
    {"id":"56110","name":"CHMP post-authorisation summary of positive opinion for Biktarvy (X-40-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T14:26:00Z","last_updated_date":"2022-09-16T14:26:00Z","reference_number":"EMA/CHMP/765087/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-biktarvy-x-40-g_en.pdf"},
    {"id":"56112","name":"CHMP post-authorisation summary of positive opinion for Revolade (II-68)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T16:13:00Z","last_updated_date":"2022-09-16T16:13:00Z","reference_number":"EMA/CHMP/721208/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-revolade-ii-68_en.pdf"},
    {"id":"56114","name":"CHMP post-authorisation summary of positive opinion for Evusheld (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T16:54:00Z","last_updated_date":"2025-10-14T12:22:22Z","reference_number":"EMA/759875/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-evusheld-ii-01_en.pdf"},
    {"id":"56115","name":"CHMP post-authorisation summary of positive opinion for Veklury (II-35-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T17:03:00Z","last_updated_date":"2022-09-16T17:03:00Z","reference_number":"EMA/CHMP/722554/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veklury-ii-35-g_en.pdf"},
    {"id":"56116","name":"CHMP post-authorisation summary of positive opinion for Xalkori (II-0072)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T09:03:00Z","last_updated_date":"2022-09-16T09:03:00Z","reference_number":"EMA/CHMP/757723/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xalkori-ii-0072_en.pdf"},
    {"id":"56127","name":"CHMP post-authorisation summary of positive opinion for Brukinsa (II-02)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T11:49:00Z","last_updated_date":"2022-09-16T11:49:00Z","reference_number":"EMA/CHMP/767634/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-brukinsa-ii-02_en.pdf"},
    {"id":"56347","name":"CVMP post-authorisation summary of positive opinion for Simparica (WS)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-10-07T13:37:00Z","last_updated_date":"2022-10-07T13:37:00Z","reference_number":"EMA/CVMP/780812/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-simparica-ws_en.pdf"},
    {"id":"56348","name":"CVMP post-authorisation summary of positive opinion for MiPet Easecto","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-10-07T13:40:00Z","last_updated_date":"2022-10-07T13:40:00Z","reference_number":"EMA/CVMP/780812/2022  ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-mipet-easecto_en.pdf"},
    {"id":"56349","name":"CVMP post-authorisation summary of positive opinion for Meloxoral","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-10-07T13:42:00Z","last_updated_date":"2022-10-07T13:42:00Z","reference_number":"EMA/CVMP/785090/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-meloxoral_en.pdf"},
    {"id":"56387","name":"CHMP post-authorisation summary of positive opinion for Xydalba (II-43)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/787460/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xydalba-ii-43_en.pdf"},
    {"id":"56401","name":"CHMP post-authorisation summary of positive opinion for Libtayo (II-26)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/CHMP/820786/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-libtayo-ii-26_en.pdf"},
    {"id":"56406","name":"CHMP post-authorisation summary of positive opinion for Lyumjev (II-14)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T17:08:00Z","last_updated_date":"2022-10-14T17:08:00Z","reference_number":"EMA/CHMP/805193/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lyumjev-ii-14_en.pdf"},
    {"id":"56411","name":"CHMP post-authorisation summary of positive opinion for Brukinsa (II-03)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/815806/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-brukinsa-ii-03_en.pdf"},
    {"id":"56436","name":"CHMP post-authorisation summary of positive opinion for Comirnaty (X-0138)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-10-19T12:00:00Z","last_updated_date":"2022-10-19T12:00:00Z","reference_number":"EMA/838787/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-comirnaty-x-0138_en.pdf"},
    {"id":"56545","name":"CHMP post-authorisation summary of positive opinion for Eylea (II-77-G)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T12:00:00Z","last_updated_date":"2022-11-11T12:00:00Z","reference_number":"EMA/CHMP/869021/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eylea-ii-77-g_en.pdf"},
    {"id":"56546","name":"CHMP post-authorisation summary of positive opinion for Xofluza (X-08-G)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T12:00:00Z","last_updated_date":"2022-11-11T12:00:00Z","reference_number":"EMA/CHMP/862821/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xofluza-x-08-g_en.pdf"},
    {"id":"56568","name":"CHMP post-authorisation summary of positive opinion for Enhertu (II-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-11-11T17:12:00Z","last_updated_date":"2022-11-11T17:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enhertu-ii-12_en.pdf"},
    {"id":"56571","name":"CHMP post-authorisation summary of positive opinion for Dupixent (II-63)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T12:00:00Z","last_updated_date":"2022-11-11T12:00:00Z","reference_number":"EMA/CHMP/859363/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-ii-63_en.pdf"},
    {"id":"56574","name":"CHMP post-authorisation summary of positive opinion for DuoPlavin (WS-2150)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-11-11T14:29:00Z","last_updated_date":"2022-11-11T14:29:00Z","reference_number":"EMA/862229/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-duoplavin-ws-2150_en.pdf"},
    {"id":"56575","name":"CHMP post-authorisation summary of positive opinion for Iscover (WS-2150)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-11-11T14:29:00Z","last_updated_date":"2022-11-11T14:29:00Z","reference_number":"EMA/862230/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-iscover-ws-2150_en.pdf"},
    {"id":"56576","name":"CHMP post-authorisation summary of positive opinion for Plavix (WS-2150)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-11-11T14:29:00Z","last_updated_date":"2022-11-11T14:29:00Z","reference_number":"EMA/862231/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-plavix-ws-2150_en.pdf"},
    {"id":"56582","name":"CHMP post-authorisation summary of positive opinion for Comirnaty (X-147)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-11-11T16:29:00Z","last_updated_date":"2022-11-11T16:29:00Z","reference_number":"EMA/873797/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-comirnaty-x-147_en.pdf"},
    {"id":"56588","name":"CHMP post-authorisation summary of positive opinion for Imfinzi (II-46)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T12:00:00Z","last_updated_date":"2022-11-11T12:00:00Z","reference_number":"EMA/858595/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imfinzi-ii-46_en.pdf"},
    {"id":"56594","name":"CHMP post-authorisation summary of positive opinion for Ceprotin (II-127)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T12:00:00Z","last_updated_date":"2022-11-11T12:00:00Z","reference_number":"EMA/858603/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ceprotin-ii-127_en.pdf"},
    {"id":"56595","name":"CHMP post-authorisation summary of positive opinion for Lynparza (II-53)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T12:00:00Z","last_updated_date":"2022-11-11T12:00:00Z","reference_number":"EMA/CHMP/822269/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-53_en.pdf"},
    {"id":"56927","name":"CVMP post-authorisation summary of positive opinion for Credelio Plus","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-09T15:33:00Z","last_updated_date":"2022-12-09T15:33:00Z","reference_number":"EMA/CVMP/903852/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-credelio-plus_en.pdf"},
    {"id":"56928","name":"CVMP post-authorisation summary of positive opinion for Simparica Trio","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-09T15:00:00Z","last_updated_date":"2022-12-09T15:00:00Z","reference_number":"EMA/CVMP/904196/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-simparica-trio_en.pdf"},
    {"id":"56929","name":"CVMP post-authorisation summary of positive opinion for Nexgard Spectra (WS)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-09T14:48:00Z","last_updated_date":"2022-12-09T14:48:00Z","reference_number":"EMA/CVMP/924541/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-spectra-ws_en.pdf"},
    {"id":"56930","name":"CVMP post-authorisation summary of positive opinion for NexGard (WS)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-09T14:50:00Z","last_updated_date":"2022-12-09T14:50:00Z","reference_number":"EMA/CVMP/924541/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-ws_en.pdf"},
    {"id":"57023","name":"CHMP post-authorisation summary of positive opinion for Enhertu (II-22)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/932509/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enhertu-ii-22_en.pdf"},
    {"id":"57038","name":"CHMP post-authorisation summary of opinion for Fintepla (II-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/917134/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-fintepla-ii-12_en.pdf"},
    {"id":"57039","name":"CHMP post-authorisation summary of opinion for Triumeq (X-101-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/916000/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-triumeq-x-101-g_en.pdf"},
    {"id":"57040","name":"CHMP post-authorisation summary of opinion for Hemlibra (II-27)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/931343/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-hemlibra-ii-27_en.pdf"},
    {"id":"57042","name":"CHMP post-authorisation summary of positive opinion for Kerendia (II-01-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T14:34:00Z","last_updated_date":"2022-12-16T14:34:00Z","reference_number":"EMA/CHMP/904661/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kerendia-ii-01-g_en.pdf"},
    {"id":"57062","name":"CHMP post-authorisation summary of opinion for Forxiga (WS-2299)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/938370/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-forxiga-ws-2299_en.pdf"},
    {"id":"57064","name":"CHMP post-authorisation summary of positive opinion for Dupixent (II-62)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/917915/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-ii-62_en.pdf"},
    {"id":"57067","name":"CHMP post-authorisation summary of positive opinion for Imfinzi (II-41)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T10:22:00Z","last_updated_date":"2022-12-16T10:22:00Z","reference_number":"EMA/CHMP/925959/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imfinzi-ii-41_en.pdf"},
    {"id":"57069","name":"CHMP post-authorisation summary of positive opinion for Imfinzi (II-45)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/925960/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imfinzi-ii-45_en.pdf"},
    {"id":"57071","name":"CHMP post-authorisation summary of positive opinion for Adcirca (II-58-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T10:35:00Z","last_updated_date":"2022-12-16T10:35:00Z","reference_number":"EMA/CHMP/929228/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adcirca-ii-58-g_en.pdf"},
    {"id":"57077","name":"CHMP post-authorisation summary of opinion for Spikevax (II-83-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/931797/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-spikevax-ii-83-g_en.pdf"},
    {"id":"57381","name":"CHMP post-authorisation summary of opinion for Wakix (II-30)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/CHMP/7134/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-wakix-ii-30_en.pdf"},
    {"id":"57391","name":"CHMP post-authorisation summary of positive opinion for Dupixent (II-60)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/CHMP/14158/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-ii-60_en.pdf"},
    {"id":"57398","name":"CHMP post-authorisation summary of positive opinion for Trecondi (II-14)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/CHMP/31201/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trecondi-ii-14_en.pdf"},
    {"id":"57408","name":"CHMP post-authorisation summary of opinion for Byfavo (X-02)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/CHMP/27760/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-byfavo-x-02_en.pdf"},
    {"id":"57411","name":"CHMP post-authorisation summary of opinion for Trulicity (II-65)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/CHMP/26443/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-trulicity-ii-65_en.pdf"},
    {"id":"57417","name":"CHMP post-authorisation summary of opinion for Reblozyl (II-09)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/CHMP/25569/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-reblozyl-ii-09_en.pdf"},
    {"id":"57425","name":"CHMP post-authorisation summary of opinion for Nubeqa (II-09)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/33048/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-nubeqa-ii-09_en.pdf"},
    {"id":"57708","name":"CVMP post-authorisation summary of positive opinion for Bravecto Plus (VRA)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T13:11:00Z","last_updated_date":"2023-02-17T13:11:00Z","reference_number":"EMA/CVMP/51467/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bravecto-plus-vra_en.pdf"},
    {"id":"57709","name":"CVMP post-authorisation summary of positive opinion for Coxevac (X)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T13:17:00Z","last_updated_date":"2023-02-17T13:17:00Z","reference_number":"EMA/CVMP/46528/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-coxevac-x_en.pdf"},
    {"id":"57712","name":"CVMP post-authorisation summary of positive opinion for Lotilaner Elanco","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T13:33:00Z","last_updated_date":"2023-02-17T13:33:00Z","reference_number":"EMA/CVMP/42347/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-lotilaner-elanco_en.pdf"},
    {"id":"57714","name":"CVMP post-authorisation summary of positive opinion for Suvaxyn PRRS MLV","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T13:43:00Z","last_updated_date":"2023-02-17T13:43:00Z","reference_number":"EMA/CVMP/40684/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-suvaxyn-prrs-mlv_en.pdf-0"},
    {"id":"57715","name":"CVMP post-authorisation summary of positive opinion for Zeleris","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T13:47:00Z","last_updated_date":"2023-02-17T13:47:00Z","reference_number":"EMA/CVMP/39823/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-zeleris_en.pdf"},
    {"id":"57797","name":"CHMP post-authorisation summary of positive opinion for TachoSil (II-0117)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T13:00:00Z","last_updated_date":"2023-02-24T13:00:00Z","reference_number":"EMA/CHMP/64876/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tachosil-ii-0117_en.pdf"},
    {"id":"57802","name":"CHMP post-authorisation summary of positive opinion for Esbriet (II-74)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T14:46:00Z","last_updated_date":"2023-02-24T14:46:00Z","reference_number":"EMA/CHMP/64403/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-esbriet-ii-74_en.pdf"},
    {"id":"57803","name":"CHMP post-authorisation summary of positive opinion for Rinvoq (II-27)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T12:00:00Z","last_updated_date":"2023-02-24T12:00:00Z","reference_number":"EMA/CHMP/67344/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rinvoq-ii-27_en.pdf"},
    {"id":"57807","name":"CHMP post-authorisation summary of positive opinion for Libtayo (II-28)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T12:00:00Z","last_updated_date":"2023-02-24T12:00:00Z","reference_number":"EMA/CHMP/608399/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-libtayo-ii-28_en.pdf"},
    {"id":"58205","name":"CHMP post-authorisation summary of positive opinion for Ultomiris  (II-32)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T16:14:00Z","last_updated_date":"2023-03-31T16:14:00Z","reference_number":"EMA/CHMP/101113/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ultomiris-ii-32_en.pdf"},
    {"id":"58215","name":"CHMP post-authorisation summary of positive opinion for Ultomiris (X-27-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T11:58:00Z","last_updated_date":"2023-07-19T15:35:00Z","reference_number":"EMA/CHMP/111122/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ultomiris-x-27-g_en.pdf"},
    {"id":"58226","name":"CHMP post-authorisation summary of positive opinion for Tenkasi (II-37)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/CHMP/150406/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tenkasi-ii-37_en.pdf"},
    {"id":"58234","name":"CHMP post-authorisation summary of opinion for Wegovy (II-09)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/141466/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-wegovy-ii-09_en.pdf"},
    {"id":"58236","name":"CHMP post-authorisation summary of positive opinion for Breyanzi (II-05)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/CHMP/137148/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-breyanzi-ii-05_en.pdf"},
    {"id":"58242","name":"CHMP post-authorisation summary of positive opinion for Entresto (X-44-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T10:38:00Z","last_updated_date":"2023-03-31T10:38:00Z","reference_number":"EMA/CHMP/127997/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-entresto-x-44-g_en.pdf"},
    {"id":"58246","name":"CHMP post-authorisation summary of positive opinion for Neparvis (X-42-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T10:51:00Z","last_updated_date":"2023-03-31T10:51:00Z","reference_number":"EMA/CHMP/130048/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-neparvis-x-42-g_en.pdf"},
    {"id":"58492","name":"CVMP post-authorisation summary of positive opinion for Gumbohatch (VRA-0009)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-21T15:04:00Z","last_updated_date":"2023-04-21T15:04:00Z","reference_number":"EMA/CVMP/163699/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-gumbohatch-vra-0009_en.pdf"},
    {"id":"58493","name":"CVMP post-authorisation summary of positive opinion for Melovem (VRA-0015)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-21T15:11:00Z","last_updated_date":"2023-04-21T15:11:00Z","reference_number":"EMA/CVMP/80399/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-melovem-vra-0015_en.pdf"},
    {"id":"58494","name":"CVMP post-authorisation summary of positive opinion for Proteq West Nile (VRA-0018-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-21T15:16:00Z","last_updated_date":"2023-04-21T15:16:00Z","reference_number":"EMA/CVMP/168333/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-proteq-west-nile-vra-0018-g_en.pdf"},
    {"id":"58517","name":"CHMP post-authorisation summary of positive opinion for Vemlidy (II-40)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/155745/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vemlidy-ii-40_en.pdf"},
    {"id":"58518","name":"CHMP post-authorisation summary of positive opinion for Cosentyx (II-90)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/106197/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-ii-90_en.pdf"},
    {"id":"58521","name":"CHMP post-authorisation summary of positive opinion for Ronapreve (II-02)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2026-01-23T04:44:04Z","reference_number":"EMA/CHMP/80241/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ronapreve-ii-02_en.pdf"}    {"id":"58523","name":"CHMP post-authorisation summary of positive opinion for Spikevax (II-97-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/181335/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-spikevax-ii-97-g_en.pdf"},
    {"id":"58530","name":"CHMP post-authorisation summary of positive opinion for Adempas (II-37)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/169143/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adempas-ii-37_en.pdf"},
    {"id":"58532","name":"CHMP post-authorisation summary of positive opinion for Bimzelx (II-10)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/168258/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bimzelx-ii-10_en.pdf"},
    {"id":"58533","name":"CHMP post-authorisation summary of positive opinion for Bimzelx (II-11)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/168469/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bimzelx-ii-11_en.pdf"},
    {"id":"58536","name":"CHMP post-authorisation summary of positive opinion for Opdivo (II-125/G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/167454/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ii-125g_en.pdf"},
    {"id":"58539","name":"CHMP post-authorisation summary of opinion for Orkambi (X-78-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/177745/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-orkambi-x-78-g_en.pdf"},
    {"id":"58541","name":"CHMP post-authorisation summary of opinion for Revestive (II-54-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/177909/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-revestive-ii-54-g_en.pdf"},
    {"id":"58544","name":"CHMP post-authorisation summary of positive opinion for Yervoy (II-100)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/167320/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yervoy-ii-100_en.pdf"},
    {"id":"58789","name":"CHMP post-authorisation summary of positive opinion for Opdivo (II-117)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-05-26T12:00:00Z","last_updated_date":"2023-05-26T12:00:00Z","reference_number":"EMA/CHMP/213546/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ii-117_en.pdf"},
    {"id":"58792","name":"CHMP post-authorisation summary of positive opinion for Sogroya (X-06-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-05-26T13:46:00Z","last_updated_date":"2023-05-26T13:46:00Z","reference_number":"EMA/CHMP/221367/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sogroya-x-06-g_en.pdf"},
    {"id":"59036","name":"CHMP post-authorisation summary of positive opinion for Lonsurf (II-26)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T12:00:00Z","last_updated_date":"2023-06-23T12:00:00Z","reference_number":"EMA/CHMP/263819/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lonsurf-ii-26_en.pdf"},
    {"id":"59037","name":"CHMP post-authorisation summary of positive opinion for Jardiance (II-74)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T12:00:00Z","last_updated_date":"2023-06-23T12:00:00Z","reference_number":"EMA/281506/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jardiance-ii-74_en.pdf"},
    {"id":"59039","name":"CHMP post-authorisation summary of positive opinion for Soliris (II-126)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T12:00:00Z","last_updated_date":"2023-06-23T12:00:00Z","reference_number":"EMA/266855/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-soliris-ii-126_en.pdf"},
    {"id":"59045","name":"CHMP post-authorisation summary of positive opinion for Imjudo (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T14:52:00Z","last_updated_date":"2023-06-23T14:52:00Z","reference_number":"EMA/CHMP/285608/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imjudo-ii-01_en.pdf"},
    {"id":"59047","name":"CHMP post-authorisation summary of positive opinion for Refixia (II-32)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T12:00:00Z","last_updated_date":"2023-06-23T12:00:00Z","reference_number":"EMA/265277/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-refixia-ii-32_en.pdf"},
    {"id":"59051","name":"CHMP post-authorisation summary of positive opinion for Mircera (II-92)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T15:39:00Z","last_updated_date":"2023-06-23T15:39:00Z","reference_number":"EMA/286712/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mircera-ii-92_en.pdf"},
    {"id":"59052","name":"CHMP post-authorisation summary of positive opinion for Trodelvy (II-20)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T12:00:00Z","last_updated_date":"2023-06-23T12:00:00Z","reference_number":"EMA/279923/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trodelvy-ii-20_en.pdf"},
    {"id":"59094","name":"CHMP post-authorisation summary of positive opinion for Comirnaty (I-177-G-X-176)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-06-26T14:46:00Z","last_updated_date":"2023-06-26T14:46:00Z","reference_number":"EMA/CHMP/284978/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-comirnaty-i-177-g-x-176_en.pdf"},
    {"id":"59356","name":"CVMP post-authorisation summary of positive opinion for Nexgard Combo (VRA-0007-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-07-14T02:00:00Z","last_updated_date":"2023-07-14T02:00:00Z","reference_number":"EMA/CVMP/300547/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-combo-vra-0007-g_en.pdf"},
    {"id":"59410","name":"CHMP post-authorisation summary of positive opinion for Ervebo (II-25)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T16:40:00Z","last_updated_date":"2023-07-21T16:40:00Z","reference_number":"EMA/CHMP/189667/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ervebo-ii-25_en.pdf"},
    {"id":"59415","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-133)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T09:24:00Z","last_updated_date":"2023-07-21T09:24:00Z","reference_number":"EMA/CHMP/287639/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-133_en.pdf"},
    {"id":"59426","name":"CHMP post-authorisation summary of positive opinion for Opdivo (II-130)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-21T12:00:00Z","reference_number":"EMA/CHMP/292683/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ii-130_en.pdf"},
    {"id":"59441","name":"CHMP post-authorisation summary of positive opinion for Bylvay (II-11 )","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T16:40:00Z","last_updated_date":"2023-07-21T16:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bylvay-ii-11_en.pdf"},
    {"id":"59442","name":"CHMP post-authorisation summary of opinion for Olumiant (X-35-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-21T12:00:00Z","reference_number":"EMA/CHMP/311719/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-olumiant-x-35-g_en.pdf"},
    {"id":"59449","name":"CHMP post-authorisation summary of positive opinion for Evrysdi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T10:40:00Z","last_updated_date":"2023-07-21T10:40:00Z","reference_number":"EMA/CHMP/807714/2022","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-evrysdi_en.pdf"},
    {"id":"59452","name":"CHMP post-authorisation summary of positive opinion for Spikevax (II-104-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:51:00Z","last_updated_date":"2023-07-21T12:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-spikevax-ii-104-g_en.pdf"},
    {"id":"59943","name":"CHMP post-authorisation summary of positive opinion for Kaftrio (X-33)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T10:52:00Z","last_updated_date":"2023-09-15T10:52:00Z","reference_number":"EMA/344229/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kaftrio-x-33_en.pdf"},
    {"id":"59947","name":"CHMP post-authorisation summary of positive opinion for Kalydeco (X-114-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T11:23:00Z","last_updated_date":"2023-09-15T11:23:00Z","reference_number":"EMA/405326/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-x-114-g_en.pdf"},
    {"id":"59948","name":"CHMP post-authorisation summary of positive opinion for Nordimet (II-27)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T11:23:00Z","last_updated_date":"2023-09-15T11:23:00Z","reference_number":"EMA/CHMP/354618/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nordimet-ii-27_en.pdf"},
    {"id":"59974","name":"CHMP post-authorisation summary of positive opinion for Voxzogo (II-06)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T10:52:00Z","last_updated_date":"2023-09-15T10:52:00Z","reference_number":"EMA/410364/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-voxzogo-ii-06_en.pdf"},
    {"id":"59975","name":"CHMP post-authorisation summary of positive opinion for Ryeqo (II-13-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T14:03:00Z","last_updated_date":"2023-09-15T14:03:00Z","reference_number":"EMA/CHMP/402803/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ryeqo-ii-13-g_en.pdf"},
    {"id":"59981","name":"CHMP post-authorisation summary of positive opinion for Takhzyro (X-0032-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T12:00:00Z","last_updated_date":"2023-09-15T12:00:00Z","reference_number":"EMA/CHMP/400511/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-takhzyro-x-0032-g_en.pdf"},
    {"id":"59982","name":"CHMP post-authorisation summary of positive opinion for Olumiant (II-37)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T15:14:00Z","last_updated_date":"2023-09-14T15:14:00Z","reference_number":"EMA/CHMP/343776/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-olumiant-ii-37_en.pdf"},
    {"id":"60012","name":"CHMP post-authorisation summary of positive opinion for Pepaxti (II-02)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T12:00:00Z","last_updated_date":"2023-09-15T12:00:00Z","reference_number":"EMA/CHMP/405889/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pepaxti-ii-02_en.pdf"},
    {"id":"60015","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-121)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T12:00:00Z","last_updated_date":"2023-09-15T12:00:00Z","reference_number":"EMA/CHMP/377073/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-121_en.pdf"},
    {"id":"60025","name":"CHMP post-authorisation summary of positive opinion for Adcetris (II-107)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T11:08:00Z","last_updated_date":"2023-09-15T11:08:00Z","reference_number":"EMA/CHMP/403313/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adcetris-ii-107_en.pdf"},
    {"id":"60029","name":"CHMP post-authorisation summary of opinion for Enhertu (II-27)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T12:00:00Z","last_updated_date":"2023-09-15T12:00:00Z","reference_number":"EMA/CHMP/400602/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-enhertu-ii-27_en.pdf"},
    {"id":"60282","name":"CVMP post-authorisation summary of positive opinion for Suiseng Diff/A","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-06T14:39:00Z","last_updated_date":"2023-10-06T14:39:00Z","reference_number":"EMA/CVMP/436655/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-suiseng-diff_en.pdf"},
    {"id":"60283","name":"CVMP post-authorisation summary of positive opinion for Porcilis PCV ID","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-06T14:40:00Z","last_updated_date":"2023-10-06T14:40:00Z","reference_number":"EMA/CVMP/437066/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-porcilis-pcv-id_en.pdf-0"},
    {"id":"60288","name":"CVMP post-authorisation summary of positive for CircoMax","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-06T14:41:00Z","last_updated_date":"2023-10-06T14:41:00Z","reference_number":"EMA/CVMP/452706/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-circomax_en.pdf"},
    {"id":"60289","name":"CVMP post-authorisation summary of positive opinion for CircoMax Myco","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-06T14:41:00Z","last_updated_date":"2023-10-06T14:41:00Z","reference_number":"EMA/CVMP/452705/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-circomax-myco_en.pdf"},
    {"id":"60296","name":"CHMP post-authorisation summary of opinion for Jemperli (II-23)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/CHMP/445059/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-jemperli-ii-23_en.pdf"},
    {"id":"60377","name":"CHMP post-authorisation summary of positive opinion for Praluent (II-78)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/CHMP/435644/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-praluent-ii-78_en.pdf"},
    {"id":"60381","name":"CHMP post-authorisation summary of opinion for Keytruda (II-36)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/CHMP/345447/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-keytruda-ii-36_en.pdf"},
    {"id":"60384","name":"CHMP post-authorisation summary of positive opinion for Rubraca (II-36)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/CHMP/445199/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rubraca-ii-36_en.pdf"},
    {"id":"60393","name":"CHMP post-authorisation summary of positive opinion for Veyvondi (II-30)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/448949/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veyvondi-ii-30_en.pdf"},
    {"id":"60414","name":"CHMP post-authorisation summary of positive opinion for Imfinzi (II-57)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/272025/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imfinzi-ii-57_en.pdf"},
    {"id":"60438","name":"CHMP post-authorisation positive summary of opinion on Brukinsa","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T17:21:00Z","last_updated_date":"2023-10-13T17:21:00Z","reference_number":"EMA/CHMP/440550/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-positive-summary-opinion-brukinsa_en.pdf"},
    {"id":"60765","name":"CHMP summary of positive opinion for Prevymis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/454102/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-prevymis_en.pdf"},
    {"id":"60816","name":"CHMP post-authorisation summary of positive opinion for Jardiance (II-76)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/483404/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jardiance-ii-76_en.pdf"},
    {"id":"60817","name":"CHMP post-authorisation summary of positive opinion for Talzenna (X-15-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/488483/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-talzenna-x-15-g_en.pdf"},
    {"id":"60818","name":"CHMP post-authorisation summary of positive opinion for NexoBrid (II-58)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/480164/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nexobrid-ii-58_en.pdf"},
    {"id":"60822","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-138)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/492420/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-138_en.pdf"},
    {"id":"60824","name":"CHMP post-authorisation summary of positive opinion for Veltassa (X-31-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/331542/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veltassa-x-31-g_en.pdf"},
    {"id":"60836","name":"CHMP post-authorisation summary of positive opinion for Mounjaro (II-07)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/488959/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mounjaro-ii-07_en.pdf"},
    {"id":"60837","name":"CHMP post-authorisation summary of positive opinion for Evkeeza (II-11)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/489254/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-evkeeza-ii-11_en.pdf"},
    {"id":"60838","name":"CHMP summary of positive opinion for Fluad Tetra (II-43)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T09:45:00Z","last_updated_date":"2026-02-26T12:00:00Z","reference_number":"EMA/CHMP/492465/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-fluad-tetra-ii-43_en.pdf"},
    {"id":"60840","name":"CHMP summary of positive opinion for Ayvakyt (II-23)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/495432/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-ayvakyt-ii-23_en.pdf"},
    {"id":"60855","name":"CHMP post-authorisation summary of positive opinion for Pradaxa (II-147-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/498446/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pradaxa-ii-147-g_en.pdf"},
    {"id":"61341","name":"CVMP summary of positive opinion for Frontpro (previously known as Afoxolaner Merial) ","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2023-12-08T16:00:23Z","last_updated_date":"2023-12-08T16:00:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-summary-positive-opinion-frontpro-previously-known-afoxolaner-merial_en.pdf"},
    {"id":"61365","name":"CVMP post-authorisation summary of positive opinion for Bravecto (VRA-0059)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2023-12-11T17:41:50Z","last_updated_date":"2023-12-11T17:41:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bravecto-vra-0059_en.pdf"},
    {"id":"61421","name":"CHMP post-authorisation summary of positive opinion for Metalyse (II-70-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T12:26:40Z","last_updated_date":"2024-11-07T09:54:00Z","reference_number":"EMA/CHMP/562322/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-metalyse-ii-70-g_en.pdf"},
    {"id":"61428","name":"CHMP post-authorisation summary of positive opinion for Zinplava (II-37)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T12:00:00Z","last_updated_date":"2023-12-15T12:00:00Z","reference_number":"EMA/CHMP/534898/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zinplava-ii-37_en.pdf"},
    {"id":"61429","name":"CHMP post-authorisation summary of positive opinion for VeraSeal (II-27)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T12:00:00Z","last_updated_date":"2023-12-15T12:00:00Z","reference_number":"EMA/539247/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veraseal-ii-27_en.pdf"},
    {"id":"61431","name":"CHMP post-authorisation summary of positive opinion for HyQvia (II-87)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T12:00:00Z","last_updated_date":"2023-12-15T12:00:00Z","reference_number":"EMA/516097/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-hyqvia-ii-87_en.pdf"},
    {"id":"61806","name":"CHMP post-authorisation summary of positive opinion for Prevymis","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-01-18T09:59:58Z","last_updated_date":"2024-01-18T09:59:58Z","reference_number":"EMA/454102/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prevymis_en.pdf"},
    {"id":"61811","name":"CVMP post-authorisation summary of positive opinion for Metacam (VRA-0151-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-01-19T12:07:28Z","last_updated_date":"2024-01-19T12:07:28Z","reference_number":"EMA/CVMP/10551/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-metacam-vra-0151-g_en.pdf"},
    {"id":"61882","name":"CHMP post-authorisation summary of positive opinion for Abecma (II-31)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T12:00:00Z","last_updated_date":"2024-01-26T12:00:00Z","reference_number":"EMA/CHMP/20859/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abecma-ii-31_en.pdf"},
    {"id":"61890","name":"CHMP post-authorisation summary of positive opinion for Retsevmo (II-21)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-01-26T13:53:48Z","last_updated_date":"2024-01-26T13:53:48Z","reference_number":"EMA/CHMP/22212/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-retsevmo-ii-21_en.pdf"},
    {"id":"61900","name":"CHMP summary of positive opinion for Aspaveli","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-01-26T12:00:00Z","last_updated_date":"2024-01-26T12:00:00Z","reference_number":"EMA/12438/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-positive-opinion-aspaveli_en.pdf"},
    {"id":"61906","name":"CHMP post-authorisation summary of positive opinion for Prevenar 20 (previously Apexxnar) (II-12)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-01-26T11:22:19Z","last_updated_date":"2024-01-26T11:22:19Z","reference_number":"EMA/CHMP/33149/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prevenar-20-previously-apexxnar-ii-12_en.pdf"},
    {"id":"62253","name":"CHMP post-authorisation summary of positive opinion for Kalydeco (X-0115-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/CHMP/65752/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-x-0115-g_en.pdf"},
    {"id":"62254","name":"CHMP post-authorisation summary of positive opinion for Carvykti (II-21)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/CHMP/58610/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-carvykti-ii-21_en.pdf"},
    {"id":"62263","name":"CHMP post-authorisation summary of positive opinion for Xromi (II-19)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/CHMP/56243/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xromi-ii-19_en.pdf"},
    {"id":"62264","name":"CHMP post-authorisation summary of positive opinion for Cibinqo (II-0010)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/CHMP/50/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cibinqo-ii-0010_en.pdf"},
    {"id":"62272","name":"CHMP post-authorisation summary of positive opinion for Reblozyl (II-21)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/65369/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-reblozyl-ii-21_en.pdf"},
    {"id":"62276","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-134)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/CHMP/58279/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-134_en.pdf"},
    {"id":"62635","name":"CVMP post-authorisation summary of positive opinion for Prevexxion RN+HVT+IBD","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-03-18T14:48:01Z","last_updated_date":"2024-03-18T14:48:01Z","reference_number":"EMA/114981/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-prevexxion-rnhvtibd_en.pdf"},
    {"id":"62656","name":"CHMP post-authorisation summary of positive opinion for Onivyde pegylated liposomal (previously known as Onivyde) (II-34)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T15:09:06Z","last_updated_date":"2024-03-22T15:09:06Z","reference_number":"EMA/CHMP/87106/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-onivyde-pegylated-liposomal-previously-known-onivyde-ii-34_en.pdf"},
    {"id":"62662","name":"CHMP post-authorisation summary of positive opinion for Bimzelx (II-20)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T18:04:20Z","last_updated_date":"2024-03-22T18:04:20Z","reference_number":"EMA/CHMP/8354/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bimzelx-ii-20_en.pdf"},
    {"id":"62685","name":"CHMP post-authorisation summary of positive opinion for Retsevmo (II-22)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T16:01:30Z","last_updated_date":"2024-03-22T16:01:30Z","reference_number":"EMA/297074/2023","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-retsevmo-ii-22_en.pdf"},
    {"id":"62694","name":"CHMP post-authorisation summary of positive opinion for Nustendi (II-35)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/115796/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nustendi-ii-35_en.pdf"},
    {"id":"62695","name":"CHMP post-authorisation summary of positive opinion for Nilemdo (II-31)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/115783/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nilemdo-ii-31_en.pdf"},
    {"id":"62696","name":"CHMP post-authorisation summary of positive opinion for Xtandi (II-63)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/87028/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xtandi-ii-63_en.pdf"},
    {"id":"63056","name":"CHMP post-authorisation summary of positive opinion for Triumeq (II-116)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T17:41:28Z","last_updated_date":"2024-04-26T17:41:28Z","reference_number":"EMA/CHMP/136295/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-triumeq-ii-116_en.pdf"},
    {"id":"63071","name":"CHMP post-authorisation summary of positive opinion for Reyataz (II-139)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T15:30:03Z","last_updated_date":"2024-04-26T15:30:03Z","reference_number":"EMA/CHMP/178127/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-reyataz-ii-139_en.pdf"},
    {"id":"63075","name":"CHMP post-authorisation summary of positive opinion for Opdivo (II-137)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/CHMP/172162/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ii-137_en.pdf"},
    {"id":"63077","name":"CHMP post-authorisation summary of positive opinion for Rozlytrek (X-17-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/CHMP/169495/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rozlytrek-x-17-g_en.pdf"},
    {"id":"63078","name":"CHMP post-authorisation summary of positive opinion for Sirturo (II-56)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/160345/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sirturo-ii-56_en.pdf"},
    {"id":"63082","name":"CHMP summary of post-authorisation positive opinion for Alecensa (II-47)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/CHMP/164804/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-post-authorisation-positive-opinion-alecensa-ii-47_en.pdf"},
    {"id":"63084","name":"CHMP post-summary of positive opinon for Rybrevant (II-10)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:29:38Z","last_updated_date":"2024-04-26T12:29:38Z","reference_number":"EMA/CHMP/174588/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-summary-positive-opinon-rybrevant-ii-10_en.pdf"},
    {"id":"63312","name":"CVMP post-authorisation summary of positive opinion for Bluevac BTV (VRA-0012-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-05-24T12:00:00Z","last_updated_date":"2024-05-24T12:00:00Z","reference_number":"EMA/CVMP/183632/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bluevac-btv-vra-0012-g_en.pdf"},
    {"id":"63402","name":"CHMP post-authorisation summary of positive opinion for Kinpeygo (II-08)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:47:22Z","last_updated_date":"2024-05-31T12:47:22Z","reference_number":"EMA/233577/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kinpeygo-ii-08_en.pdf"},
    {"id":"63412","name":"CHMP post-authorisation summary of positive opinion for Tevimbra (II-08)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/245593/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tevimbra-ii-08_en.pdf"},
    {"id":"63413","name":"CHMP post-authorisation summary of positive opinion for LIVMARLI (II-03-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/250300/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-livmarli-ii-03-g_en.pdf"},
    {"id":"63415","name":"CHMP post-authorisation summary of positive opinion for Tagrisso (II-53)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-05-30T15:38:53Z","last_updated_date":"2024-05-30T15:38:53Z","reference_number":"EMA/CHMP/240704/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tagrisso-ii-53_en.pdf"},
    {"id":"63421","name":"CHMP post-authorisation summary of positive opinion for Eliquis (X-89-G)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/247780/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eliquis-x-89-g_en.pdf"},
    {"id":"63427","name":"CHMP post-authorisation summary of positive opinion for Skyrizi (X-43-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/237901/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-skyrizi-x-43-g_en.pdf"},
    {"id":"63432","name":"CHMP post-authorisation summary of positive opinion for Dupixent (II-79)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T13:00:00Z","last_updated_date":"2024-05-31T13:00:00Z","reference_number":"EMA/CHMP/146624/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-ii-79_en.pdf"},
    {"id":"63714","name":"CVMP post-authorisation summary of positive opinion for Daxocox (VRA-0003-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-21T12:21:50Z","last_updated_date":"2024-06-21T12:21:50Z","reference_number":"EMA/CVMP/273005/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-daxocox-vra-0003-g_en.pdf"}    {"id":"63717","name":"CVMP post-authorisation summary of positive opinion for Suvaxyn PRRS MLV (VRA-0011-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-21T14:37:24Z","last_updated_date":"2024-06-21T14:37:24Z","reference_number":"EMA/CVMP/265921/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-suvaxyn-prrs-mlv-vra-0011-g_en.pdf"},
    {"id":"63718","name":"CVMP post-authorisation summary of positive opinion for Rabitec (VRA-0011)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-21T14:13:40Z","last_updated_date":"2024-06-21T14:13:40Z","reference_number":"EMA/CVMP/95671/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-rabitec-vra-0011_en.pdf"},
    {"id":"63719","name":"CVMP post-authorisation summary of positive opinion for Stronghold Plus (VRA-0000174657)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-21T14:37:40Z","last_updated_date":"2024-06-21T14:37:40Z","reference_number":"EMADOC1700519818-148159 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-stronghold-plus-vra-0000174657_en.pdf"},
    {"id":"63753","name":"CHMP post-authorisation summary of positive opinion for Pegasys (II-0119-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/145669/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pegasys-ii-0119-g_en.pdf"},
    {"id":"63764","name":"CHMP post-authorisation summary of positive opinion for Infanrix Hexa (II-340-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/291491/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-infanrix-hexa-ii-340-g_en.pdf"},
    {"id":"63765","name":"CHMP post-authorisation summary of positive opinion for Beyfortus (II-05)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:30Z","last_updated_date":"2024-06-28T12:00:30Z","reference_number":"EMA/CHMP/37430/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-beyfortus-ii-05_en.pdf"},
    {"id":"63769","name":"CHMP post-authorisation summary of positive opinion for Betmiga (X-39-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T14:46:53Z","last_updated_date":"2024-06-28T14:46:53Z","reference_number":"EMA/CHMP/30239/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-betmiga-x-39-g_en.pdf"},
    {"id":"63772","name":"CHMP post-authorisation summary of positive opinion for Xalkori (X-80-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T15:13:30Z","last_updated_date":"2024-06-28T15:13:30Z","reference_number":"EMA/CHMP/293420/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xalkori-x-80-g_en.pdf"},
    {"id":"63774","name":"CHMP post-authorisation summary of positive opinion for Tepkinly (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:03:57Z","last_updated_date":"2024-06-28T12:03:57Z","reference_number":"EMA/CHMP/293400/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tepkinly-ii-01_en.pdf"},
    {"id":"63779","name":"CHMP post-authorisation summary of positive opinion for Vabysmo (II-05)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T17:07:57Z","last_updated_date":"2024-06-28T17:07:57Z","reference_number":"EMA/CHMP/254404/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vabysmo-ii-05_en.pdf"},
    {"id":"63789","name":"CHMP post-authorisation summary of positive opinion for Imcivree (II-18)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:03:55Z","last_updated_date":"2024-06-28T12:03:55Z","reference_number":"EMA/CHMP/277218/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imcivree-ii-18_en.pdf"},
    {"id":"63803","name":"CHMP post-authorisation summary of positive opinion for Imfinzi","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/291945/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imfinzi_en.pdf"},
    {"id":"63804","name":"CHMP post-authorisation summary of positive opinion for Lynparza","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/291952/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza_en.pdf-0"},
    {"id":"63809","name":"CHMP post-authorisation summary of positive opinion for Cresemba (X-42-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T14:41:00Z","last_updated_date":"2024-06-28T14:41:00Z","reference_number":"EMA/298353/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cresemba-x-42-g_en.pdf"},
    {"id":"64307","name":"CHMP post-authorisation summary of positive opinion for Rybrevant (II-11)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:13:06Z","last_updated_date":"2024-07-26T12:13:06Z","reference_number":"EMA/CHMP/335044/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rybrevant-ii-11_en.pdf"},
    {"id":"64309","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-150)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T13:07:54Z","last_updated_date":"2024-07-26T13:07:54Z","reference_number":"EMA/CHMP/310413/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-150_en.pdf"},
    {"id":"64310","name":"CHMP post-authorisation summary of positive opinion for Padcev (II-13)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T13:15:56Z","last_updated_date":"2024-07-26T13:15:56Z","reference_number":"EMA/CHMP/310402/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-padcev-ii-13_en.pdf"},
    {"id":"64319","name":"CHMP post-authorisation summary of positive opinion for Edurant (X-42-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T15:27:14Z","last_updated_date":"2024-07-26T15:27:14Z","reference_number":"EMA/CHMP/326801/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-edurant-x-42-g_en.pdf"},
    {"id":"64320","name":"CHMP post-authorisation summary of positive opinion for Braftovi (WS-2538)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T15:48:26Z","last_updated_date":"2024-07-26T15:48:26Z","reference_number":"EMA/CHMP/323249/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-braftovi-ws-2538_en.pdf"},
    {"id":"64321","name":"CHMP post-authorisation summary of positive opinion for Mektovi (WS-2538)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T16:20:18Z","last_updated_date":"2024-07-26T16:20:18Z","reference_number":"EMA/CHMP/323250/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mektovi-ws-2538_en.pdf"},
    {"id":"64323","name":"CHMP post-authorisation summary of positive opinion for Slenyto (II-25)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T16:55:20Z","last_updated_date":"2024-07-26T16:55:20Z","reference_number":"EMA/CHMP/321012/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-slenyto-ii-25_en.pdf"},
    {"id":"64333","name":"CHMP post-authorisation summary of opinion for Spevigo (X-06-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:00:00Z","last_updated_date":"2024-07-26T12:00:00Z","reference_number":"EMA/331897/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-spevigo-x-06-g_en.pdf"},
    {"id":"64339","name":"CHMP post-authorisation summary of opinion for Tecentriq (II-82)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:00:00Z","last_updated_date":"2024-07-26T12:00:00Z","reference_number":"EMA/CHMP/324648/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-tecentriq-ii-82_en.pdf"},
    {"id":"64341","name":"CHMP post-authorisation summary of positive opinion for Opsumit (X-51-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T11:21:39Z","last_updated_date":"2024-07-26T11:21:39Z","reference_number":"EMA/CHMP/326580/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opsumit-x-51-g_en.pdf"},
    {"id":"64343","name":"CHMP post-authorisation summary of opinion for Arexvy (II-08)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:53:02Z","last_updated_date":"2024-07-26T12:53:02Z","reference_number":"EMA/CHMP/304362/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-arexvy-ii-08_en.pdf"},
    {"id":"64902","name":"CHMP post-authorisation summary of positive opinion for Imvanex (II-108)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-19T14:28:55Z","last_updated_date":"2024-09-19T14:28:55Z","reference_number":"EMA/418293/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imvanex-ii-108_en.pdf"},
    {"id":"64904","name":"CHMP post-authorisation summary of positive opinion for Dupixent (II-81)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T15:12:44Z","last_updated_date":"2024-09-20T15:12:44Z","reference_number":"EMA/CHMP/247127/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-ii-81_en.pdf"},
    {"id":"64925","name":"CHMP post-authorisation summary of positive opinion for Aflunov (II-86)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T10:41:56Z","last_updated_date":"2024-09-20T10:41:56Z","reference_number":"EMA/CHMP/435295/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aflunov-ii-86_en.pdf"},
    {"id":"64927","name":"CHMP post-authorisation summary of positive opinion for Darzalex (II-72)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T10:47:53Z","last_updated_date":"2024-09-20T10:47:53Z","reference_number":"EMA/CHMP/410979/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-darzalex-ii-72_en.pdf"},
    {"id":"64929","name":"CHMP post-authorisation summary of positive opinion for Otezla (II-44-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T10:51:28Z","last_updated_date":"2024-09-20T10:51:28Z","reference_number":"EMA/CHMP/416713/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-otezla-ii-44-g_en.pdf"},
    {"id":"64940","name":"CHMP post-authorisation summary of positive opinion for Fasenra (II-52)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T14:54:21Z","last_updated_date":"2024-09-20T14:54:21Z","reference_number":"EMA/422937/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fasenra-ii-52_en.pdf"},
    {"id":"64949","name":"CHMP post-authorisation summary of positive opinion for Buccolam (II-61)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T17:55:43Z","last_updated_date":"2024-09-20T17:55:43Z","reference_number":"EMA/CHMP/427451/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-buccolam-ii-61_en.pdf"},
    {"id":"64950","name":"CHMP post-authorisation summary of positive opinion for Esperoct (II-23)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T12:06:29Z","last_updated_date":"2024-09-20T12:06:29Z","reference_number":"EMA/423647/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-esperoct-ii-23_en.pdf"},
    {"id":"64965","name":"CHMP post-authorisation summary of positive opinion for Synjardy  (II-78)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:04:01Z","last_updated_date":"2024-09-20T11:04:01Z","reference_number":"EMA/CHMP/423614/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-synjardy-ii-78_en.pdf"},
    {"id":"64966","name":"CHMP post-authorisation summary of positive opinion for Pravafenix (II-37)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:08:07Z","last_updated_date":"2024-09-20T11:08:07Z","reference_number":"EMA/CHMP/423595/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pravafenix-ii-37_en.pdf"},
    {"id":"64969","name":"CHMP post-authorisation summary of positive opinion for Zavicefta (II-35)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:58:35Z","last_updated_date":"2024-09-20T11:58:35Z","reference_number":"EMA/CHMP/429747/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zavicefta-ii-35_en.pdf"},
    {"id":"64972","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-145)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T13:00:00Z","last_updated_date":"2024-09-20T13:00:00Z","reference_number":"EMA/CHMP/417252/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-145_en.pdf"},
    {"id":"64973","name":"CVMP post-authorisation summary of positive opinion for Yurvac  (VRA-0001)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T12:13:55Z","last_updated_date":"2024-09-20T12:13:55Z","reference_number":"EMA/CVMP/433078/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-yurvac-vra-0001_en.pdf"},
    {"id":"64983","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-153)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T15:20:00Z","last_updated_date":"2024-09-20T15:20:00Z","reference_number":"EMA/CHMP/413921/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-153_en.pdf"},
    {"id":"65277","name":"CVMP post-authorisation summary of positive opinion for Eluracat (VRA-0002-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-10-11T12:00:00Z","last_updated_date":"2024-10-11T12:00:00Z","reference_number":"EMA/CVMP/446484/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-eluracat-vra-0002-g_en.pdf"},
    {"id":"65313","name":"CHMP post-authorisation summary of positive opinion for Tevimbra (II-06)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/435989/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tevimbra-ii-06_en.pdf"},
    {"id":"65314","name":"CHMP post-authorisation summary of positive opinion for Tevimbra (II-03)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/368205/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tevimbra-ii-03_en.pdf"},
    {"id":"65319","name":"CHMP post-authorisation summary of positive opinion for Hepcludex (II-31)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/447783/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-hepcludex-ii-31_en.pdf"},
    {"id":"65324","name":"CHMP post-authorisation summary of positive opinion for Cerdelga (X-36-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/477910/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cerdelga-x-36-g_en.pdf"},
    {"id":"65326","name":"CHMP post-authorisation summary of positive opinion for Kevzara (II-44)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/453178/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kevzara-ii-44_en.pdf"},
    {"id":"65343","name":"CHMP post-authorisation summary of positive opinion for Yselty (II-13)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T09:59:44Z","last_updated_date":"2024-10-18T09:59:44Z","reference_number":"EMA/473427/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yselty-ii-13_en.pdf"},
    {"id":"65346","name":"CHMP post-authorisation summary of positive opinion for Kisqali (II-45)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/472365/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kisqali-ii-45_en.pdf"},
    {"id":"65578","name":"CVMP post-authorisation summary of opinion for Simparica Trio","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-08T12:50:10Z","last_updated_date":"2024-11-08T12:50:10Z","reference_number":"EMADOC-1700519818-1721693","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-opinion-simparica-trio_en.pdf"},
    {"id":"65621","name":"CHMP post-authorisation summary of positive opinion for Kevzara (X-43-G)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/506746/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kevzara-x-43-g_en.pdf"},
    {"id":"65634","name":"CHMP post-authorisation summary of positive opinion for Tagrisso (II-56)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/519859/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tagrisso-ii-56_en.pdf"},
    {"id":"65638","name":"CHMP post-authorisation summary of positive opinion for Sarclisa (II-30)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/508897/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sarclisa-ii-30_en.pdf"},
    {"id":"65639","name":"CHMP post-authorisation summary of positive opinion for Jakavi (X-70-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/518145/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jakavi-x-70-g_en.pdf"},
    {"id":"65644","name":"CHMP post-authorisation summary of positive opinion for Opdivo (WS-2672)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/515560/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ws-2672_en.pdf"},
    {"id":"65645","name":"CHMP post-authorisation summary of positive opinion for Yervoy (WS-2672)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/515561/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yervoy-ws-2672_en.pdf"},
    {"id":"65649","name":"CHMP post-authorisation summary of positive opinion for Keytruda (II-154)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-20T11:11:01Z","reference_number":"EMA/CHMP/526175/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-154_en.pdf"},
    {"id":"65653","name":"CHMP post-authorisation summary of positive opinion for CellCept (II-170-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T16:42:53Z","last_updated_date":"2024-11-15T16:42:53Z","reference_number":"EMA/178674/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cellcept-ii-170-g_en.pdf"},
    {"id":"65656","name":"CHMP post-authorisation summary of positive opinion for Palforzia (II-14-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/397782/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-palforzia-ii-14-g_en.pdf"},
    {"id":"65661","name":"CHMP post-authorisation summary of positive opinion for Rybrevant (II-13)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/525856/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rybrevant-ii-13_en.pdf"},
    {"id":"65663","name":"CHMP post-authorisation summary of positive opinion for Evkeeza (II-15)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T10:10:39Z","last_updated_date":"2024-11-15T10:10:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-evkeeza-ii-15_en.pdf"},
    {"id":"66053","name":"CHMP post-authorisation summary of positive opinion for Ofev (X-57-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T14:44:43Z","last_updated_date":"2024-12-13T14:44:43Z","reference_number":"EMA/CHMP/512578/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ofev-x-57-g_en.pdf"},
    {"id":"66055","name":"CHMP post-authorisation summary of positive opinion for Flucelvax Tetra (II-47)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T15:39:50Z","last_updated_date":"2026-02-27T08:00:00Z","reference_number":"EMA/CHMP/559432/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-flucelvax-tetra-ii-47_en.pdf"},
    {"id":"66076","name":"CHMP post-authorisation summary of positive opinion for Omvoh (X-06-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/CHMP/548700/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-omvoh-x-06-g_en.pdf"},
    {"id":"66082","name":"CHMP post-authorisation summary of positive opinion for Rekambys  (II-22)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2024-12-13T12:16:29Z","last_updated_date":"2024-12-13T12:16:29Z","reference_number":"EMA/CHMP/559420/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rekambys-ii-22_en.pdf"},
    {"id":"66083","name":"CHMP post-authorisation summary of positive opinion for Bridion (II-47)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:25:15Z","last_updated_date":"2024-12-13T12:25:15Z","reference_number":"EMA/CHMP/567626/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bridion-ii-47_en.pdf"},
    {"id":"66094","name":"CHMP post-authorisation summary of positive opinion for Jemperli (II-32)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/CHMP/547387/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jemperli-ii-32_en.pdf"},
    {"id":"66101","name":"CHMP post-authorisation summary of positive opinion for Blincyto (II-56)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T09:42:44Z","last_updated_date":"2024-12-13T09:42:44Z","reference_number":"EMA/570665/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-blincyto-ii-56_en.pdf"},
    {"id":"66109","name":"CHMP post-authorisation summary of positive opinion for Vocabria (II-22)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/559372/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vocabria-ii-22_en.pdf"},
    {"id":"66508","name":"CHMP post-authorisation summary of positive opinion for Ronapreve (II-17)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2026-01-23T05:55:55Z","reference_number":"EMA/516539/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ronapreve-ii-17_en.pdf"},
    {"id":"66518","name":"CHMP post-authorisation summary of positive opinion for Slenyto (II-28)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/35017/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-slenyto-ii-28_en.pdf"},
    {"id":"66525","name":"CHMP post-authorisation summary of positive opinion for Rxulti (II-15)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/13690/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rxulti-ii-15_en.pdf"},
    {"id":"66526","name":"CHMP post-authorisation summary of positive opinion for Sivextro (II-54)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/31360/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sivextro-ii-54_en.pdf"},
    {"id":"66529","name":"CHMP post-authorisation summary of positive opinion for Breyanzi (II-43-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/34922/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-breyanzi-ii-43-g_en.pdf"},
    {"id":"66541","name":"CHMP post-authorisation summary of positive opinion for Imfinzi (II-69)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/27692/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imfinzi-ii-69_en.pdf"},
    {"id":"66542","name":"CHMP post-authorisation summary of positive opinion for Yervoy (WS-2717)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/15257/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yervoy-ws-2717_en.pdf"},
    {"id":"66543","name":"CHMP post-authorisation summary of positive opinion for Opdivo (WS-2717)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/15252/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ws-2717_en.pdf"},
    {"id":"66779","name":"CVMP post-authorisation summary of positive opinion for Porcilis ColiClos (VRA-0018-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-14T13:38:36Z","last_updated_date":"2025-02-14T13:38:36Z","reference_number":"EMA/CVMP/34688/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-porcilis-coliclos-vra-0018-g_en.pdf"},
    {"id":"66782","name":"CVMP post-authorisation summary of positive opinion for Simparica Trio","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-14T15:00:00Z","last_updated_date":"2025-02-14T15:00:00Z","reference_number":"EMADOC-1700519818-1896425","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-simparica-trio_en.pdf-0"},
    {"id":"66989","name":"CHMP post-authorisation summary of positive opinion for Abrysvo II-07","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/564741/2024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abrysvo-ii-07_en.pdf"},
    {"id":"67015","name":"CHMP post-authorisation summary of positive opinion for Darzalex (II-76)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/50155/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-darzalex-ii-76_en.pdf"},
    {"id":"67016","name":"CHMP post-authorisation summary of positive opinion for Jaypirca (II-02)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/50600/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jaypirca-ii-02_en.pdf"},
    {"id":"67019","name":"CHMP post-authorisation summary of positive opinion for Calquence (II-26)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/50186/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-calquence-ii-26_en.pdf"},
    {"id":"67020","name":"CHMP post-authorisation summary of positive opinion for Ixchiq (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/62534/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ixchiq-ii-01_en.pdf"},
    {"id":"67025","name":"CHMP post-authorisation summary of positive opinion for Supemtek Tetra II-21-G","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/56849/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-supemtek-tetra-ii-21-g_en.pdf"},
    {"id":"67026","name":"CHMP post-authorisation summary of positive opinion for Prevymis X-37-G","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/65082/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prevymis-x-37-g_en.pdf"},
    {"id":"67033","name":"CHMP post-authorisation summary of positive opinion for Enhertu (II-48)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/67229/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enhertu-ii-48_en.pdf"},
    {"id":"67034","name":"CHMP post-authorisation summary of positive opinion for Fabhalta (II-01)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/327/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fabhalta-ii-01_en.pdf"},
    {"id":"67040","name":"CHMP post-authorisation summary of positive opinion for Keytruda","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/60149/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda_en.pdf-2"},
    {"id":"67041","name":"CHMP post-authorisation summary of positive opinion for Rinvoq (II-56)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/55472/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rinvoq-ii-56_en.pdf"},
    {"id":"67042","name":"CHMP post-authorisation summary of positive opinion for Tremfya (X-43-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T10:36:11Z","last_updated_date":"2025-02-28T10:36:11Z","reference_number":"EMA/CHMP/54843/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tremfya-x-43-g_en.pdf"},
    {"id":"67043","name":"CHMP post-authorisation summary of positive opinion for Stelara II-108","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/57839/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stelara-ii-108_en.pdf"},
    {"id":"67044","name":"CHMP post-authorisation summary of positive opinion for Imfinzi (II-64)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/63977/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imfinzi-ii-64_en.pdf"},
    {"id":"67046","name":"CHMP post-authorisation summary of positive opinion for Kaftrio WS-2551","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/62074/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kaftrio-ws-2551_en.pdf"},
    {"id":"67047","name":"CHMP post-authorisation summary of positive opinion for Kalydeco WS-2551","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/64893/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kalydeco-ws-2551_en.pdf"},
    {"id":"67052","name":"CHMP post-authorisation summary of positive opinion for Columvi (II-05)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/54323/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-columvi-ii-05_en.pdf"},
    {"id":"67278","name":"CVMP post-authorisation summary of positive opinion for Rheumocam (VRA-I-0038)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T11:39:56Z","last_updated_date":"2025-03-14T11:39:56Z","reference_number":" EMA/CVMP/81597/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-rheumocam-vra-i-0038_en.pdf"},
    {"id":"67475","name":"CHMP post-authorisation summary of positive opinion for Opdivo (II-140)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"EMA/CHMP/94575/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-ii-140_en.pdf"},
    {"id":"67476","name":"CHMP post-authorisation summary of positive opinion for Opdivo (X-144)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"EMA/CHMP/108241/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-x-144_en.pdf"},
    {"id":"67480","name":"CHMP post-authorisation summary of positive opinion for Calquence (II-25)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"EMA/CHMP/103398/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-calquence-ii-25_en.pdf"},
    {"id":"67512","name":"CHMP post-authorisation summary of positive opinion for Tevimbra (II-16)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"EMA/CHMP/98542/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tevimbra-ii-16_en.pdf"},
    {"id":"67518","name":"Questions and answers on the refusal of a change to the marketing authorisation for Pemazyre (pemigatinib) (II-15)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"EMA/103752/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-answers-refusal-change-marketing-authorisation-pemazyre-pemigatinib-ii-15_en.pdf"}    {"id":"67522","name":"CHMP post-authorisation summary of positive opinion for Bosulif (X-58-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"EMA/CHMP/86912/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bosulif-x-58-g_en.pdf"},
    {"id":"67935","name":"CHMP post-authorisation summary of positive opinion for Veklury (II-53-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-28T09:48:47Z","reference_number":"EMA/CHMP/118124/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veklury-ii-53-g_en.pdf"},
    {"id":"67938","name":"CHMP post-authorisation summary of positive opinion for Calquence (II-28)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/125193/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-calquence-ii-28_en.pdf"},
    {"id":"67952","name":"CHMP post-authorisation summary of positive opinion for Vyvgart (II-20)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/135941/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vyvgart-ii-20_en.pdf"},
    {"id":"67961","name":"CHMP post-authorisation summary of positive opinion for Zoonotic Influenza Vaccine Seqirus (VR0000249071)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMADOC-1700519818-2059670","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zoonotic-influenza-vaccine-seqirus-vr0000249071_en.pdf"},
    {"id":"67972","name":"CHMP post-authorisation summary of positive opinion for Adcetris (II-111)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/125287/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adcetris-ii-111_en.pdf"},
    {"id":"67975","name":"CHMP post-authorisation summary of positive opinion for Jivi (II-34)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/123587/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jivi-ii-34_en.pdf"},
    {"id":"67980","name":"CHMP post-authorisation summary of positive opinion for Cystadrops (II-32)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/135105/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cystadrops-ii-32_en.pdf"},
    {"id":"67983","name":"CHMP post-authorisation summary of positive opinion for Amvuttra (II-15)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/137435/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-amvuttra-ii-15_en.pdf"},
    {"id":"67990","name":"CHMP post-authorisation summary of positive opinion for Adempas (X-41)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T14:15:12Z","last_updated_date":"2025-04-25T14:15:12Z","reference_number":"EMA/CHMP/131389/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adempas-x-41_en.pdf"},
    {"id":"68002","name":" CHMP post-authorisation summary of positive opinion for Xofluza (II-21)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2025-04-28T09:04:27Z","last_updated_date":"2025-04-28T09:04:27Z","reference_number":"EMA/136484/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xofluza-ii-21_en.pdf"},
    {"id":"68327","name":"CVMP post-authoirsation summary of positive opinion for Bluevac BTV ","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-05-16T14:47:59Z","last_updated_date":"2025-05-16T14:47:59Z","reference_number":"EMAVRA0000255727","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authoirsation-summary-positive-opinion-bluevac-btv_en.pdf"},
    {"id":"68334","name":"CVMP post-authorisation summary of positive opinion for NexGard Combo (VRA-0012-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-05-16T15:07:09Z","last_updated_date":"2025-05-16T15:07:09Z","reference_number":"EMA/CVMP/82901/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-combo-vra-0012-g_en.pdf"},
    {"id":"68335","name":"CVMP post-authorisation summary of positive opinion for Stronghold Plus (VRA-0000243880)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-05-16T15:05:53Z","last_updated_date":"2025-05-16T15:05:53Z","reference_number":"EMADOC-1700519818-2108863","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-stronghold-plus-vra-0000243880_en.pdf"},
    {"id":"68379","name":"CHMP post-authorisation summary of positive opinion for Tevimbra (II-17)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/CHMP/145452/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tevimbra-ii-17_en.pdf"},
    {"id":"68388","name":"CHMP post-authorisation summary of positive opinion for Rezolsta (X-54-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/CHMP/162393/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rezolsta-x-54-g_en.pdf"},
    {"id":"68402","name":"CHMP post-authorisation summary of positive opinion for Imfinzi (II-73)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/162386/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imfinzi-ii-73_en.pdf"},
    {"id":"68410","name":"CHMP post-authorisation summary of positive opinion for Saxenda (II-42)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/158218/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-saxenda-ii-42_en.pdf"},
    {"id":"68744","name":"CVMP post-authorisation summary of positive opinion for Daxocox (VRA0000246340)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T13:29:09Z","last_updated_date":"2025-06-13T13:29:09Z","reference_number":"EMADOC-1700519818-2194512","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-daxocox-vra0000246340_en.pdf"},
    {"id":"68751","name":"CVMP post-authorisation summary of positive opinion for NexGard Spectra (VRA0000245082)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T15:27:17Z","last_updated_date":"2025-06-13T15:27:17Z","reference_number":"EMADOC-1700519818-2201538","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-spectra-vra0000245082_en.pdf"},
    {"id":"68752","name":"CVMP post-authorisation summary of positive opinion for NexGard (VRA0000245082)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T15:28:48Z","last_updated_date":"2025-06-13T15:28:48Z","reference_number":"EMADOC-1700519818-2201538","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nexgard-vra0000245082_en.pdf"},
    {"id":"68754","name":"CVMP post-authorisation summary of positive opinion for Nobivac L4 and Nobivac LoVo L4 (VRA0000184065)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T15:35:17Z","last_updated_date":"2025-07-18T00:00:00Z","reference_number":"EMADOC-1700519818-2188844","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-nobivac-l4-nobivac-lovo-l4-vra0000184065_en.pdf"},
    {"id":"68820","name":"CHMP post-authorisation summary of positive opinion for Darzalex (II-77)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T12:00:00Z","last_updated_date":"2025-06-20T12:00:00Z","reference_number":"EMA/CHMP/144721/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-darzalex-ii-77_en.pdf"},
    {"id":"68833","name":"CHMP post-authorisation summary of positive opinion for Benlysta (II-133)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T13:30:46Z","last_updated_date":"2025-06-20T13:30:46Z","reference_number":"EMA/CHMP/177699/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-benlysta-ii-133_en.pdf"},
    {"id":"68838","name":"CHMP post-authorisation summary of positive opinion for Sarclisa (II-35)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T13:58:48Z","last_updated_date":"2025-06-20T13:58:48Z","reference_number":"EMA/CHMP/186923/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sarclisa-ii-35_en.pdf"},
    {"id":"68843","name":"CHMP post-authorisation summary of positive opinion for Imbruvica (II-92)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T16:58:33Z","last_updated_date":"2025-06-20T16:58:33Z","reference_number":"EMA/CHMP/200830/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imbruvica-ii-92_en.pdf"},
    {"id":"68844","name":"CHMP post-authorisation summary of positive opinion for Cabometyx (II-40)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T12:00:00Z","last_updated_date":"2025-06-20T12:00:00Z","reference_number":"EMA/CHMP/201774/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cabometyx-ii-40_en.pdf"},
    {"id":"68856","name":"CHMP post-authorisation summary of positive opinion for Nubeqa (II-24)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T09:57:57Z","last_updated_date":"2025-06-20T09:57:57Z","reference_number":"EMA/CHMP/141494/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nubeqa-ii-24_en.pdf"},
    {"id":"69375","name":"CVMP post-authorisation summary of positive opinion for Syvazul BTV 3 (VRA-I -EMAVRA0000269481)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-07-18T12:38:18Z","last_updated_date":"2025-07-18T12:38:18Z","reference_number":"EMADOC-1700519818-2241723","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-syvazul-btv-3-vra-i-emavra0000269481_en.pdf"},
    {"id":"69418","name":"CHMP post-authorisation summary of positive opinion for Tevimbra (II-18)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T14:10:29Z","last_updated_date":"2025-07-25T14:10:29Z","reference_number":"EMA/CHMP/212907/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tevimbra-ii-18_en.pdf"},
    {"id":"69419","name":"CHMP post-authorisation summary of positive opinion for Clopidogrel Zentiva (II-92)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T14:17:22Z","last_updated_date":"2025-07-25T14:17:22Z","reference_number":"EMA/CHMP/222151/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-clopidogrel-zentiva-ii-92_en.pdf"},
    {"id":"69420","name":"CHMP post-authorisation summary of positive opinion for Sirturo (EMAVR0000249065)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T14:23:18Z","last_updated_date":"2025-07-25T14:23:18Z","reference_number":"EMADOC-1700519818-2301684","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sirturo-emavr0000249065_en.pdf"},
    {"id":"69429","name":"CHMP post-authorisation summary of positive opinion for Alhemo (EMAVR0000244862)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T12:00:00Z","last_updated_date":"2025-07-25T12:00:00Z","reference_number":"EMADOC-1700519818-2288040","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-alhemo-emavr0000244862_en.pdf"},
    {"id":"69432","name":"CHMP post-authorisation summary of positive opinion for mResvia (VR-0000248175)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T13:18:23Z","last_updated_date":"2025-07-25T13:18:23Z","reference_number":"EMADOC-1700519818-2313919","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mresvia-vr-0000248175_en.pdf"},
    {"id":"69444","name":"CHMP post-authorisation summary of positive opinion for Taltz (II-53)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T15:37:14Z","last_updated_date":"2025-07-25T15:37:14Z","reference_number":"EMA/226344/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-taltz-ii-53_en.pdf"},
    {"id":"69453","name":"CHMP post-authorisation summary of positive opinion for Invokana (II-69)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T12:00:00Z","last_updated_date":"2025-07-25T12:00:00Z","reference_number":"EMA/CHMP/237364/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-invokana-ii-69_en.pdf"},
    {"id":"69494","name":"CHMP post-authorisation summary of positive opinion for Baqsimi (EMAVR0000244909)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T11:55:58Z","last_updated_date":"2025-07-25T11:55:58Z","reference_number":"EMADOC-1700519818-2288212","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-baqsimi-emavr0000244909_en.pdf"},
    {"id":"70072","name":"CVMP post-authorisation summary of positive opinion for Bravecto TriUNO (EMAVRA0000263135)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-12T13:55:50Z","last_updated_date":"2025-09-12T13:55:50Z","reference_number":"EMADOC-1700519818-2407766","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bravecto-triuno-emavra0000263135_en.pdf"},
    {"id":"70092","name":"CHMP post-authorisation summary of positive opinion for Tezspire","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2025-09-19T12:00:00Z","reference_number":"EMADOC-1700519818-2094000","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tezspire_en.pdf"},
    {"id":"70138","name":"CHMP post-authorisation summary of positive opinion for Keytruda (EMAX0000248795)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T10:41:16Z","last_updated_date":"2025-09-19T10:41:16Z","reference_number":"EMADOC-1700519818-2436470","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-emax0000248795_en.pdf"},
    {"id":"70139","name":"CHMP post-authorisation summary of positive opinion for Keytruda (EMAVR0000245108)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T10:43:13Z","last_updated_date":"2025-09-19T10:43:13Z","reference_number":"EMADOC-1700519818-2436387","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-emavr0000245108_en.pdf"},
    {"id":"70147","name":"CHMP post-authorisation summary of positive opinion for Norvir (EMAVR0000249795)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T14:06:00Z","last_updated_date":"2025-09-19T14:06:00Z","reference_number":"EMADOC-1700519818-2433357","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-norvir-emavr0000249795_en.pdf"},
    {"id":"70148","name":"CHMP post-authorisation summary of positive opinion for Uplizna","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2025-09-19T12:00:00Z","reference_number":"EMA/CHMP/290671/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-uplizna_en.pdf"},
    {"id":"70149","name":"CHMP post-authorisation summary of positive opinion for Bimervax (EMAVR0000257408)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T14:37:07Z","last_updated_date":"2025-10-21T10:30:00Z","reference_number":"EMADOC-1700519818-2450542 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bimervax-emavr0000257408_en.pdf"},
    {"id":"70151","name":"CHMP post-authorisation summary of positive opinion for Koselugo (EMAVR0000245231)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T14:49:20Z","last_updated_date":"2025-09-19T14:49:20Z","reference_number":"EMADOC-1700519818-2413725","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-koselugo-emavr0000245231_en.pdf"},
    {"id":"70159","name":"CHMP post-authorisation summary of positive opinion for Dupixent (EMA/VR/0000257461)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T16:46:07Z","last_updated_date":"2025-09-19T16:46:07Z","reference_number":"EMADOC-1700519818-2222939","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-ema-vr-0000257461_en.pdf"},
    {"id":"70170","name":"CHMP post-authorisation summary of positive opinion for Lunsumio (X-15)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2025-09-19T12:00:00Z","reference_number":"EMA/CHMP/289787/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lunsumio-x-15_en.pdf"},
    {"id":"70344","name":"CHMP post-authorisation summary of positive opinion for Remsima (X-149)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-09-30T10:39:38Z","last_updated_date":"2025-09-30T10:39:38Z","reference_number":"EMA/314083/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-remsima-x-149_en.pdf"},
    {"id":"70607","name":"CHMP post-authorisation summary of positive opinion for Paxlovid (II-61-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T15:17:58Z","last_updated_date":"2025-10-17T15:17:58Z","reference_number":"EMA/CHMP/308348/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-paxlovid-ii-61-g_en.pdf"},
    {"id":"70608","name":"CHMP post-authorisation summary of positive opinion for Libtayo (EMAVR0000264999)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2025-10-17T16:17:35Z","last_updated_date":"2025-10-17T16:17:35Z","reference_number":"EMADOC-1700519818-2492915","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-libtayo-emavr0000264999_en.pdf"},
    {"id":"70610","name":"CHMP post-authorisation summary of positive opinion for Breyanzi (II-EMAVR0000265024)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T16:30:53Z","last_updated_date":"2025-10-17T16:30:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-breyanzi-ii-emavr0000265024_en.pdf"},
    {"id":"70611","name":"CHMP post-authorisation summary of positive opinion for Scemblix (II-EMAVR0000265010)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T16:40:33Z","last_updated_date":"2025-10-17T16:40:33Z","reference_number":"EMADOC-1700519818-2475296","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-scemblix-ii-emavr0000265010_en.pdf"},
    {"id":"70612","name":"CHMP post-authorisation summary of positive opinion for Gazyvaro (EMAVR0000244907)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T16:47:59Z","last_updated_date":"2025-10-17T16:47:59Z","reference_number":"EMADOC-1700519818-2492302","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gazyvaro-emavr0000244907_en.pdf"},
    {"id":"70614","name":"CHMP post-authorisation summary of positive opinion for Cejemly (EMAVR0000261157)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T17:05:09Z","last_updated_date":"2025-10-17T17:05:09Z","reference_number":"EMADOC-1700519818-2464690","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cejemly-emavr0000261157_en.pdf"},
    {"id":"70615","name":"CHMP post-authorisation summary of positive opinion for Tremfya (EMAX0000248626)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-10-16T17:17:40Z","last_updated_date":"2025-10-16T17:17:40Z","reference_number":"EMADOC-1700519818-2494685","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tremfya-emax0000248626_en.pdf"},
    {"id":"70616","name":"CHMP post-authorisation summary of positive opinion for Pyrukynd (X-10-G)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T12:00:00Z","last_updated_date":"2025-10-17T12:00:00Z","reference_number":"EMA/329333/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pyrukynd-x-10-g_en.pdf"},
    {"id":"71052","name":"CVMP post-authorisation summary of positive opinion for Credelio, Lotimax, Credelio Plus","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-11-07T15:00:00Z","last_updated_date":"2025-11-07T15:00:00Z","reference_number":"EMADOC-1700519818-2563727","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-credelio-lotimax-credelio-plus_en.pdf"},
    {"id":"71053","name":"CVMP post-authorisation summary of positive opinion for Frontpro","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-11-07T15:00:00Z","last_updated_date":"2025-11-07T15:00:00Z","reference_number":"  EMADOC-1700519818-2578983","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-frontpro_en.pdf-0"},
    {"id":"71054","name":"CVMP post-authorisation summary of positive opinion for Mhyosphere PCV ID","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-11-07T15:00:00Z","last_updated_date":"2025-11-07T15:00:00Z","reference_number":"EMADOC-1700519818-2563533","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-mhyosphere-pcv-id_en.pdf"},
    {"id":"71099","name":"CHMP post-authorisation summary of positive opinion for Minjuvi (EMAVR0000255975)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMADOC-1700519818-2579167","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-minjuvi-emavr0000255975_en.pdf"},
    {"id":"71131","name":"CHMP post-authorisation summary of positive opinion for Veyvondi (EMAVR0000264863)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMADOC-1700519818-2554896","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veyvondi-emavr0000264863_en.pdf"},
    {"id":"71158","name":"CHMP post-authorisation summary of positive opinion for Koselugo X-18-G","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMA/CHMP/348586/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-koselugo-x-18-g_en.pdf"},
    {"id":"71173","name":"CHMP post-authorisation summary of positive opinion for Xerava (EMAVR0000265697)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T11:08:10Z","last_updated_date":"2025-11-14T11:08:10Z","reference_number":"EMADOC-1700519818-2615480","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xerava-emavr0000265697_en.pdf"},
    {"id":"71177","name":"Questions and answers on the refusal of a change to the marketing authorisation for Hetlioz (tasimelteon) (II-40)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T11:50:47Z","last_updated_date":"2026-06-02T16:45:00Z","reference_number":"EMEA/H/C/003870/II/0040","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-ii-40_sv.pdf"}},
    {"id":"71533","name":"CVMP post-authorisation summary of positive opinion for Dexdomitor (EMA/VRA/0000257740)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T14:00:00Z","last_updated_date":"2025-12-05T14:00:00Z","reference_number":"EMADOC-1700519818-2668331","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-dexdomitor-ema-vra-0000257740_en.pdf"},
    {"id":"71645","name":"CHMP post-authorisation summary of positive opinion for Recarbrio (EMA/VR/0000265089)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:30:09Z","last_updated_date":"2025-12-12T14:30:09Z","reference_number":"EMADOC-1700519818-2608675","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-recarbrio-ema-vr-0000265089_en.pdf"},
    {"id":"71687","name":"CHMP post-authorisation summary of positive opinion for Aspaveli (EMA/VR/0000248937)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T13:46:14Z","last_updated_date":"2025-12-12T13:46:14Z","reference_number":"EMADOC-1700519818-2607912","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aspaveli-ema-vr-0000248937_en.pdf"},
    {"id":"71688","name":"CHMP post-authorisation summary of positive opinion for Simponi (II-121)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T13:49:58Z","last_updated_date":"2025-12-12T13:49:58Z","reference_number":"EMA/CHMP/378614/2025","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-simponi-ii-121_en.pdf"},
    {"id":"71689","name":"CHMP post-authorisation summary of positive opinion for Vfend (EMA/VR/0000284468)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:07:02Z","last_updated_date":"2025-12-12T14:07:02Z","reference_number":"EMADOC-1700519818-2658010","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vfend-ema-vr-0000284468_en.pdf"},
    {"id":"71691","name":"CHMP post-authorisation summary of positive opinion for Arexvy (EMA/VR/0000276225)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-11T15:07:39Z","last_updated_date":"2025-12-11T15:07:39Z","reference_number":"EMADOC-1700519818-2676032","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-arexvy-ema-vr-0000276225_en.pdf"},
    {"id":"71694","name":"CHMP post-authorisation summary of positive opinion for Winrevair (EMA/VR/0000278021)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T15:25:04Z","last_updated_date":"2025-12-12T15:25:04Z","reference_number":"EMADOC-1700519818-2692693","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-winrevair-ema-vr-0000278021_en.pdf"},
    {"id":"71706","name":"CHMP post-authorisation summary of positive opinion for Dovprela (VR-0000258124)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMADOC-1700519818-2699355","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dovprela-vr-0000258124_en.pdf"},
    {"id":"71707","name":"CHMP post-authorisation summary of positive opinion for Eylea (EMA/VR/0000264981)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T10:02:36Z","last_updated_date":"2025-12-12T10:02:36Z","reference_number":"EMADOC-1700519818-2706651","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eylea-ema-vr-0000264981_en.pdf"},
    {"id":"71709","name":"CHMP post-authorisation summary of positive opinion for Elucirem (EMAVR0000249008)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMADOC-1700519818-2671019","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-elucirem-emavr0000249008_en.pdf"},
    {"id":"71710","name":"CHMP post-authorisation summary of positive opinion for Vueway (EMAVR0000249008)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMADOC-1700519818-2707211","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vueway-emavr0000249008_en.pdf"},
    {"id":"71718","name":"CHMP post-authorisation summary of positive opinion for Nucala (EMAVR0000257645)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMADOC-1700519818-2707697","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nucala-emavr0000257645_en.pdf"},
    {"id":"71721","name":"Questions and answers on the refusal of a change to the marketing authorisation for Hetlioz (tasimelteon) (X-39)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2026-03-17T16:46:00Z","reference_number":"EMEA/H/C/003870/X/0039","document_url":"https://www.ema.europa.eu/en/documents/smop/questions-answers-refusal-change-marketing-authorisation-hetlioz-tasimelteon-x-39_en.pdf"},
    {"id":"71723","name":"CHMP post-authorisation summary of positive opinion for Mounjaro (EMAVR0000281937)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMADOC-1700519818-2705294","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mounjaro-emavr0000281937_en.pdf"},
    {"id":"71724","name":"CHMP post-authorisation summary of positive opinion for Uplizna (EMAVR0000257358)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMADOC-1700519818-2662446","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-uplizna-emavr0000257358_en.pdf"},
    {"id":"72328","name":"CHMP post-authorisation summary of positive opinion for Noxafil (EMA/VR/0000263360)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T12:00:00Z","last_updated_date":"2026-01-30T12:00:00Z","reference_number":"EMADOC-1700519818-2632880","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-noxafil-ema-vr-0000263360_en.pdf"},
    {"id":"72358","name":"CHMP post-authorisation summary of positive opinion for Kerendia (EMA/X/0000248026)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T16:40:40Z","last_updated_date":"2026-01-30T16:40:40Z","reference_number":"EMADOC-1700519818-2833585","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kerendia-ema-x-0000248026_en.pdf"},
    {"id":"72361","name":"CHMP post-authorisation summary of positive opinion for Eurneffy (EMA/X/0000248440)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T12:00:00Z","last_updated_date":"2026-01-30T12:00:00Z","reference_number":"EMADOC-1700519818-2852304","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-eurneffy-ema-x-0000248440_en.pdf"},
    {"id":"72366","name":"CHMP post-authorisation summary of positive opinion for Iclusig (EMA/VR/0000263550)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T10:20:22Z","last_updated_date":"2026-01-30T10:20:22Z","reference_number":"EMADOC-1700519818-2832341","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-iclusig-ema-vr-0000263550_en.pdf"},
    {"id":"72368","name":"CHMP post-authorisation summary of positive opinion for Opdivo (EMAVR0000282199)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T10:28:18Z","last_updated_date":"2026-01-30T10:28:18Z","reference_number":"EMADOC-1700519818-2843485","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-emavr0000282199_en.pdf"},
    {"id":"72370","name":"CHMP post-authorisation summary of positive opinion for Zynyz (EMAVR0000247788)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T10:33:29Z","last_updated_date":"2026-01-30T10:33:29Z","reference_number":"EMADOC-1700519818-2841651","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zynyz-emavr0000247788_en.pdf"},
    {"id":"72371","name":"CHMP post-authorisation summary of positive opinion for Efmody (EMA/VR/0000282500)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T10:33:51Z","last_updated_date":"2026-01-30T10:33:51Z","reference_number":"EMADOC-1700519818-2850511","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-efmody-ema-vr-0000282500_en.pdf"},
    {"id":"72373","name":"CHMP post-authorisation summary of positive opinion for Akeega (EMAVR0000282377)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T10:59:06Z","last_updated_date":"2026-01-30T10:59:06Z","reference_number":"EMADOC-1700519818-2853904","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-akeega-emavr0000282377_en.pdf"},
    {"id":"72379","name":"CHMP post-authorisation summary of positive opinion for Imfinzi (EMA/VR/0000282058)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T12:00:00Z","last_updated_date":"2026-01-30T12:00:00Z","reference_number":"EMADOC-1700519818-2861543","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imfinzi-ema-vr-0000282058_en.pdf"},
    {"id":"72552","name":"CVMP post-authorisation summary of opinion for Suvaxyn PRRS MLV (EMA/VRA/0000269293)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-02-13T12:30:26Z","last_updated_date":"2026-02-13T12:30:26Z","reference_number":"EMADOC-1700519818-2885543","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-opinion-suvaxyn-prrs-mlv-ema-vra-0000269293_en.pdf"},
    {"id":"72553","name":"CVMP post-authorisation summary of positive opinion for Bluevac BTV (EMA/VRA/0000293372)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-02-13T12:46:32Z","last_updated_date":"2026-02-13T12:46:32Z","reference_number":"EMADOC-1700519818-2907706","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-bluevac-btv-ema-vra-0000293372_en.pdf"},
    {"id":"72701","name":"CHMP post-authorisation summary of positive opinion for Jorveza (X/0000257468)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T14:47:40Z","last_updated_date":"2026-02-27T14:47:40Z","reference_number":"EMADOC-1700519818-2896158","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jorveza-x-0000257468_en.pdf"},
    {"id":"72703","name":"CHMP post-authorisation summary of positive opinion for Dupixent (VR/0000282164)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T15:14:46Z","last_updated_date":"2026-02-27T15:14:46Z","reference_number":"EMADOC-1700519818-2492665","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-vr-0000282164_en.pdf"},
    {"id":"72706","name":"CHMP post-authorisation summary of positive opinion for Olumiant (VR/0000288098)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T16:41:50Z","last_updated_date":"2026-02-27T16:41:50Z","reference_number":"EMADOC-1700519818-2937601","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-olumiant-vr-0000288098_en.pdf"},
    {"id":"72715","name":"CHMP post-authorisation summary of positive opinion for Stelara (VR/0000290099)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T10:23:20Z","last_updated_date":"2026-02-27T10:23:20Z","reference_number":"EMADOC-1700519818-2938344","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stelara-vr-0000290099_en.pdf"},
    {"id":"72716","name":"CHMP post-authorisation summary of positive opinion for Scemblix (X/0000256688)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T10:56:48Z","last_updated_date":"2026-02-27T10:56:48Z","reference_number":"EMADOC-1700519818-2935903","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-scemblix-x-0000256688_en.pdf"},
    {"id":"72734","name":"CHMP post-authorisation summary of positive opinion for Keytruda (VR-0000293815)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T12:00:00Z","last_updated_date":"2026-02-27T12:00:00Z","reference_number":"EMADOC-1700519818-2908250","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-vr-0000293815_en.pdf"},
    {"id":"73217","name":"CHMP post-authorisation summary of positive opinion for Hympavzi (VR/0000304590)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-2999788","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-hympavzi-vr-0000304590_en.pdf"},
    {"id":"73219","name":"CHMP post-authorisation summary of positive opinion for Feraccru (VR/0000268118)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-2994500","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-feraccru-vr-0000268118_en.pdf"},
    {"id":"73220","name":"CHMP post-authorisation summary of positive opinion for Capvaxive (VR/0000294070)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-3006977","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-capvaxive-vr-0000294070_en.pdf"},
    {"id":"73222","name":"CHMP post-authorisation summary of positive opinion for Besponsa (VR/0000257310)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-2985043","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-besponsa-vr-0000257310_en.pdf"}    {"id":"73223","name":"CHMP post-authorisation summary of positive opinion for Hetronifly (VR/0000282407)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-2975996","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-hetronifly-vr-0000282407_en.pdf"},
    {"id":"73224","name":"CHMP post-authorisation summary of positive opinion for Hetronifly (VR/0000284402) ","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-3000971","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-hetronifly-vr-0000284402_en.pdf"},
    {"id":"73225","name":"CHMP post-authorisation summary of positive opinion for Retsevmo (VR/0000282012)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-2992694","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-retsevmo-vr-0000282012_en.pdf"},
    {"id":"73226","name":"CHMP post-authorisation summary of positive opinion for Namuscla (X/0000258210)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-3015439","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-namuscla-x-0000258210_en.pdf"},
    {"id":"73228","name":"CHMP post-authorisation summary of positive opinion for Sotyktu (VR/0000282554)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-2802747","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sotyktu-vr-0000282554_en.pdf"},
    {"id":"73236","name":"CHMP post-authorisation summary of positive opinion for Sarclisa (X/0000281242)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-3026808","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sarclisa-x-0000281242_en.pdf"},
    {"id":"73239","name":"CHMP post-authorisation summary of positive opinion for Lojuxta (X/0000258068)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-3013044 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lojuxta-x-0000258068_en.pdf"},
    {"id":"73240","name":"CHMP post-authorisation summary of positive opinion for Imcivree (VR/0000288021)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-3024392","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imcivree-vr-0000288021_en.pdf"},
    {"id":"73241","name":"CHMP post-authorisation summary of positive opinion for Mekinist (VR0000278305)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T13:00:00Z","last_updated_date":"2026-03-27T13:00:00Z","reference_number":"EMADOC-1700519818-2971643","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mekinist-vr0000278305_en.pdf"},
    {"id":"73242","name":"CHMP post-authorisation summary of positive opinion for mResvia (VR0000312911)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T13:00:00Z","last_updated_date":"2026-03-27T13:00:00Z","reference_number":"EMADOC-1700519818-3003233","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mresvia-vr0000312911_en.pdf"},
    {"id":"73243","name":"CHMP post-authorisation summary of positive opinion for Tafinlar (VR0000271728)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-3002663","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tafinlar-vr0000271728_en.pdf"},
    {"id":"73244","name":"CHMP post-authorisation summary of positive opinion for Mekinist (VR0000271728)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMADOC-1700519818-3002663","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-mekinist-vr0000271728_en.pdf"},
    {"id":"73245","name":"CHMP post-authorisation summary of positive opinion for Tafinlar (VR0000278305)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T13:00:00Z","last_updated_date":"2026-03-27T13:00:00Z","reference_number":"EMADOC-1700519818-2971643","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tafinlar-vr0000278305_en.pdf"},
    {"id":"73248","name":"Outcome of the public consultation on the Data Quality Framework for EU Medicines Regulation: application to Real-World Data","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T14:22:04Z","last_updated_date":"2026-03-27T14:22:04Z","reference_number":"EMA/63520/2026","document_url":"https://www.ema.europa.eu/en/documents/smop/outcome-public-consultation-data-quality-framework-eu-medicines-regulation-application-real-world-data_en.pdf"},
    {"id":"73488","name":"CVMP post-authorisation summary of opinion for Startvac (EMA-VRA-0000288186)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-04-17T15:00:00Z","last_updated_date":"2026-04-17T15:00:00Z","reference_number":"EMADOC-1700519818-3056849","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-opinion-startvac-ema-vra-0000288186_en.pdf"},
    {"id":"73508","name":"CHMP post-authorisation summary of positive opinion for Agamree (VR-0000293535)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T16:36:07Z","last_updated_date":"2026-04-24T16:36:07Z","reference_number":"EMADOC-1700519818-3082428","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-agamree-vr-0000293535_en.pdf"},
    {"id":"73509","name":"CHMP post-authorisation summary of positive opinion for Aquipta (VR-0000310717)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T16:49:54Z","last_updated_date":"2026-04-24T16:49:54Z","reference_number":"EMADOC-1700519818-3082414","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aquipta-vr-0000310717_en.pdf"},
    {"id":"73531","name":"CHMP post-authorisation summary of positive opinion for Privigen (VR-0000304719)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-04-24T12:00:00Z","reference_number":"EMADOC-1700519818-3028574","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-privigen-vr-0000304719_en.pdf"},
    {"id":"73532","name":"CHMP post-authorisation summary of positive opinion for Inaqovi (VR-0000304730)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-04-24T12:00:00Z","reference_number":"EMADOC-1700519818-3050557 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-inaqovi-vr-0000304730_en.pdf"},
    {"id":"73540","name":"CHMP post-authorisation summary of positive opinion for Venclyxto (VR-0000322237)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T13:35:41Z","last_updated_date":"2026-04-24T13:35:41Z","reference_number":"EMADOC-1700519818-3010835","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-venclyxto-vr-0000322237_en.pdf"},
    {"id":"73541","name":"CHMP post-authorisation summary of positive opinion for Venclyxto (VR-0000322240)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T13:40:33Z","last_updated_date":"2026-04-24T13:40:33Z","reference_number":"EMADOC-1700519818-3013050","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-venclyxto-vr-0000322240_en.pdf"},
    {"id":"73547","name":"CHMP post-authorisation summary of positive opinion for Skyrizi (X-0000296763)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T15:39:10Z","last_updated_date":"2026-04-24T15:39:10Z","reference_number":"EMADOC-1700519818-3075007","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-skyrizi-x-0000296763_en.pdf"},
    {"id":"73549","name":"CHMP post-authorisation summary of positive opinion for Opdivo (VR-0000304938)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-04-24T12:00:00Z","reference_number":"EMADOC-1700519818-3055572","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opdivo-vr-0000304938_en.pdf"},
    {"id":"73555","name":"CHMP post-authorisation summary of positive opinion for Crysvita (VR-0000263400)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-04-24T12:00:00Z","reference_number":"EMADOC-1700519818-3044024","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-crysvita-vr-0000263400_en.pdf"},
    {"id":"73556","name":"CHMP post-authorisation summary of positive opinion for Comirnaty (VR-0000320534)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-04-24T12:00:00Z","reference_number":"EMADOC-1700519818-3080442","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-comirnaty-vr-0000320534_en.pdf"},
    {"id":"73790","name":"CHMP post-authorisation summary of positive opinion for Trodelvy (VR-0000312649)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:00:00Z","last_updated_date":"2026-05-22T12:00:00Z","reference_number":"EMADOC-1700519818-3129523","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trodelvy-vr-0000312649_en.pdf"},
    {"id":"73792","name":"CHMP post-authorisation summary of positive opinion for Enhertu (VR-0000293327)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:00:00Z","last_updated_date":"2026-05-22T12:00:00Z","reference_number":"EMADOC-1700519818-3166834","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enhertu-vr-0000293327_en.pdf"},
    {"id":"73795","name":"CHMP post-authorisation summary of positive opinion for Hetronifly (VR/0000290021)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T14:39:03Z","last_updated_date":"2026-05-22T14:39:03Z","reference_number":"EMADOC-1700519818-3134638","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-hetronifly-vr-0000290021_en.pdf"},
    {"id":"73797","name":"CHMP post-authorisation summary of positive opinion for Padcev (VR-0000312495)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:00:00Z","last_updated_date":"2026-05-22T12:00:00Z","reference_number":"EMADOC-1700519818-3134776","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-padcev-vr-0000312495_en.pdf"},
    {"id":"73800","name":"CHMP post-authorisation summary of positive opinion for Maviret (VR/0000316551)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T14:56:16Z","last_updated_date":"2026-05-22T14:56:16Z","reference_number":"EMADOC-1700519818-3140849","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-maviret-vr-0000316551_en.pdf"},
    {"id":"73802","name":"CHMP post-authorisation summary of positive opinion for Iclusig (X/0000296489)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-21T14:53:14Z","last_updated_date":"2026-05-21T14:53:14Z","reference_number":"EMADOC-1700519818-3162552","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-iclusig-x-0000296489_en.pdf"},
    {"id":"73803","name":"CHMP post-authorisation summary of positive opinion for Tepkinly (VR/0000311043)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:00:00Z","last_updated_date":"2026-05-22T12:00:00Z","reference_number":"EMADOC-1700519818-3169911","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tepkinly-vr-0000311043_en.pdf"},
    {"id":"73810","name":"CHMP post-authorisation summary of positive opinion for Braftovi (VR/0000304994)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:00:00Z","last_updated_date":"2026-05-22T12:00:00Z","reference_number":"EMADOC-1700519818-2963478","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-braftovi-vr-0000304994_en.pdf"},
    {"id":"73811","name":"CHMP summary of post-authorisation positive opinion for Keytruda (VR/0000316576)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T16:13:33Z","last_updated_date":"2026-05-22T16:13:33Z","reference_number":"EMADOC-1700519818-3170644","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-summary-post-authorisation-positive-opinion-keytruda-vr-0000316576_en.pdf"},
    {"id":"73812","name":"CHMP post-authorisation summary of positive opinion for Sogroya (VR-0000264734)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T08:35:48Z","last_updated_date":"2026-06-26T00:00:00Z","reference_number":"EMADOC-1700519818-3170422","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sogroya-vr-0000264734_en.pdf"},
    {"id":"73813","name":"CHMP post-authorisation summary of positive opinion for Keytruda (VR-0000312515)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:00:00Z","last_updated_date":"2026-05-22T12:00:00Z","reference_number":"EMADOC-1700519818-3169949","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-vr-0000312515_en.pdf"},
    {"id":"73814","name":"CHMP post-authorisation summary of positive opinion for Palynziq (VR/0000302032)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T08:46:08Z","last_updated_date":"2026-05-22T08:46:08Z","reference_number":"EMADOC-1700519818-3182005","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-palynziq-vr-0000302032_en.pdf"},
    {"id":"73822","name":"CHMP post-authorisation summary of positive opinion for Fasenra (VR/0000288520)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T09:50:40Z","last_updated_date":"2026-05-22T09:50:40Z","reference_number":"EMADOC-1700519818-3115823","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fasenra-vr-0000288520_en.pdf"},
    {"id":"73824","name":"CHMP post-authorisation summary of positive opinion for Wegovy (X/0000296344)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T10:04:04Z","last_updated_date":"2026-05-22T10:04:04Z","reference_number":"EMADOC-1700519818-2790091","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-wegovy-x-0000296344_en.pdf"},
    {"id":"73825","name":"CHMP post-authorisation summary of positive opinion for Erbitux (VR/0000326978)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T10:25:13Z","last_updated_date":"2026-05-22T10:25:13Z","reference_number":"VR/0000326978","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-erbitux-vr-0000326978_en.pdf"},
    {"id":"73826","name":"CHMP post-authorisation summary of positive opinion for Erbitux (VR/0000327014)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T10:37:45Z","last_updated_date":"2026-05-22T10:37:45Z","reference_number":"EMADOC-1700519818-2963496","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-erbitux-vr-0000327014_en.pdf"},
    {"id":"73837","name":"CVMP post-authorisation summary of positive opinion for BTVPUR (VRA/0000322270)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T13:28:17Z","last_updated_date":"2026-05-22T13:28:17Z","reference_number":"EMADOC-1700519818-3149659","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-btvpur-vra-0000322270_en.pdf"},
    {"id":"73842","name":"CVMP post-authorisation summary of positive opinion for Respivac aMPV (VRA/0000309778)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T15:07:11Z","last_updated_date":"2026-05-22T15:07:11Z","reference_number":"EMADOC-1700519818-3136867","document_url":"https://www.ema.europa.eu/en/documents/smop/cvmp-post-authorisation-summary-positive-opinion-respivac-ampv-vra-0000309778_en.pdf"},
    {"id":"74279","name":"CHMP post-authorisation summary of positive opinion for Stelara (VR-0000316205)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1700519818-3138737","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-stelara-vr-0000316205_en.pdf"},
    {"id":"74282","name":"CHMP post-authorisation summary of positive opinion for Leqvio (VR-0000293324)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1700519818-3253464","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-leqvio-vr-0000293324_en.pdf"},
    {"id":"74286","name":"CHMP post-authorisation summary of positive opinion for Datroway (VR-0000316654)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1700519818-3269360","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-datroway-vr-0000316654_en.pdf"},
    {"id":"74287","name":"CHMP post-authoirsation summary of positive opinion for Jaypirca (VR-0000316267)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1700519818-3256196 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authoirsation-summary-positive-opinion-jaypirca-vr-0000316267_en.pdf"},
    {"id":"74288","name":"CHMP post-authoirsation summary of positive opinion for Orladeyo (X-0000268892)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1700519818-3024086","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authoirsation-summary-positive-opinion-orladeyo-x-0000268892_en.pdf"},
    {"id":"74289","name":"CHMP post-authorisation summary of positive opinion for Opzelura (VR-0000313318)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T15:02:28Z","last_updated_date":"2026-06-26T15:02:28Z","reference_number":"EMADOC-1700519818-3086715","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-opzelura-vr-0000313318_en.pdf"},
    {"id":"74294","name":"CHMP post-authorisation summary of positive opinion for Vyndaqel (X-0000287968)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":" EMADOC-1700519818-3264389","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vyndaqel-x-0000287968_en.pdf"},
    {"id":"74295","name":"CHMP post-authoirsation summary of positive opinion for MenQuadfi (VR-0000281377)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T15:46:22Z","last_updated_date":"2026-06-26T15:46:22Z","reference_number":"EMADOC-1700519818-3191549","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authoirsation-summary-positive-opinion-menquadfi-vr-0000281377_en.pdf"},
    {"id":"74296","name":"CHMP post-authorisation summary of positive opinion for Rinvoq (VR-0000312506)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1700519818-3215454 ","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rinvoq-vr-0000312506_en.pdf"},
    {"id":"74297","name":"CHMP post-authorisation summary of positive opinion for Rinvoq (VR-0000325958)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1700519818-3194723","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rinvoq-vr-0000325958_en.pdf"},
    {"id":"74298","name":"CHMP post-authorisation summary of positive opinion for Imvanex (VR-0000337204)","type":"smop","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"Imvanex","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imvanex-vr-0000337204_en.pdf"},
    {"id":"74316","name":"CHMP post-authorisation summary of positive opinion for Rezolsta (X-0000268372)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T09:28:29Z","last_updated_date":"2026-06-26T09:28:29Z","reference_number":"EMADOC-1700519818-3224353","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rezolsta-x-0000268372_en.pdf"},
    {"id":"74318","name":"CHMP post-authorisation summary of positive opinion for Tecvayli (VR-0000322279)","type":"smop","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T09:59:09Z","last_updated_date":"2026-06-26T09:59:09Z","reference_number":"EMADOC-1700519818-3256178","document_url":"https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tecvayli-vr-0000322279_en.pdf"},
    {"id":"2469","name":"CHMP summary of positive opinion for Aflunov","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMA/CHMP/487326/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aflunov_en.pdf"},
    {"id":"2561","name":"CHMP summary of positive opinion for Orphacol","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/CHMP/790588/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-orphacol_en.pdf"},
    {"id":"2570","name":"CHMP summary of positive opinion for Somatropin Biopartners","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/CHMP/229455/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-somatropin-biopartners_en.pdf"},
    {"id":"2614","name":"CHMP summary of positive opinion for Oxervate","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T12:00:00Z","last_updated_date":"2017-05-19T12:00:00Z","reference_number":"EMA/CHMP/297602/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-oxervate_en.pdf"},
    {"id":"2624","name":"CHMP summary of positive opinion for Levetiracetam Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/354114/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-levetiracetam-teva_en.pdf"},
    {"id":"2734","name":"CHMP summary of positive opinion for Vargatef","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/534352/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vargatef_en.pdf"},
    {"id":"2743","name":"CHMP summary of positive opinion for Clopidogrel 1A Pharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2011-02-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-clopidogrel-1a-pharma_en.pdf"},
    {"id":"2790","name":"CVMP summary of positive opinion for Halagon","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-07T17:00:00Z","last_updated_date":"2016-10-07T17:00:00Z","reference_number":"EMA/CVMP/585411/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-halagon_en.pdf"},
    {"id":"2794","name":"Committee for medicinal products for human use summary of positive opinion for Filgrastim Hexal","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T00:09:21Z","last_updated_date":"2008-11-20T00:09:21Z","reference_number":"EMEA/CHMP/619105/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-filgrastim-hexal_en.pdf"},
    {"id":"2853","name":"CHMP summary of positive opinion for Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/446644/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals_en.pdf"},
    {"id":"2893","name":"CHMP summary of positive opinion for Steglatro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/12820/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-steglatro_en.pdf"},
    {"id":"2924","name":"CHMP summary of opinion for Atazanavir Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T14:00:00Z","last_updated_date":"2016-06-24T14:00:00Z","reference_number":"EMA/CHMP/258309/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-atazanavir-mylan_en.pdf"},
    {"id":"3057","name":"CVMP summary of positive opinion for Veraflox","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2011-02-11T01:00:00Z","reference_number":"EMA/CVMP/411755/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-veraflox_en.pdf"},
    {"id":"3139","name":"CHMP summary of positive opinion for Libertek","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2018-02-08T01:00:00Z","reference_number":"EMA/CHMP/775689/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-libertek_en.pdf"},
    {"id":"3140","name":"CHMP summary of positive opinion for Jorveza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/CHMP/733678/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jorveza_en.pdf"},
    {"id":"3146","name":"CHMP summary of positive opinion for Spherox","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T11:23:00Z","last_updated_date":"2017-05-19T11:23:00Z","reference_number":"EMA/CHMP/304021/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-spherox_en.pdf"},
    {"id":"3154","name":"CHMP summary of positive opinion for Pregabalin Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/CHMP/357351/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-accord_en.pdf"},
    {"id":"3214","name":"CHMP summary of positive opinion for Dexdor","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/549755/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dexdor_en.pdf"},
    {"id":"3228","name":"CHMP summary of positive opinion for Mekinist","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"EMA/CHMP/197424/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mekinist_en.pdf"},
    {"id":"3242","name":"CVMP summary of negative opinion for Horse Allo 20","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T18:00:00Z","last_updated_date":"2018-06-22T18:00:00Z","reference_number":"EMA/CVMP/371385/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-negative-opinion-horse-allo-20_en.pdf"},
    {"id":"3287","name":"CHMP summary of positive opinion for Mepact","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/CHMP/668423/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mepact_en.pdf"},
    {"id":"3303","name":"CHMP summary of positive opinion for Lonquex","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/CHMP/274489/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lonquex_en.pdf"},
    {"id":"3327","name":"CHMP summary of positive opinion for Imprida HCT","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/471451/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imprida-hct_en.pdf"},
    {"id":"3353","name":"CHMP summary of positive opinion for Tadalafil Lilly","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/CHMP/38153/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tadalafil-lilly_en.pdf"},
    {"id":"3358","name":"Questions and answers on the recommendation for the refusal of the marketing authorization for Valdoxan/Thymanax","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2006-11-18T01:00:00Z","last_updated_date":"2006-11-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_sv.pdf"}},
    {"id":"3363","name":"CHMP summary of positive opinion for Zoledronic acid Actavis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2026-05-12T01:00:00Z","reference_number":"EMA/CHMP/995075/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zoledronic-acid-actavis_en.pdf"},
    {"id":"3368","name":"CHMP summary of positive opinion for Blitzima","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-05-19T02:00:00Z","reference_number":"EMA/CHMP/307669/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-blitzima_en.pdf"},
    {"id":"3386","name":"CHMP summary of positive opinion for Fasenra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/727638/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fasenra_en.pdf"},
    {"id":"3393","name":"CHMP summary of positive opinion for Zevtera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/CHMP/552347/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zevtera_en.pdf"},
    {"id":"3433","name":"CHMP summary of opinion for Kolbam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2020-07-15T14:00:00Z","reference_number":"EMA/627629/2015 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-kolbam_en.pdf"},
    {"id":"3460","name":"CHMP summary of positive opinion for Temozolomide Sandoz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/810097/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-temozolomide-sandoz_en.pdf"},
    {"id":"3484","name":"CHMP summary of positive opinion for Nimvastid","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-03-19T01:00:00Z","last_updated_date":"2009-03-19T01:00:00Z","reference_number":"EMEA/CHMP/153867/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nimvastid_en.pdf"},
    {"id":"3544","name":"CHMP summary of positive opinion for Ikervis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"EMA/CHMP/14288/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ikervis_en.pdf"},
    {"id":"3580","name":"CHMP summary of positive opinion for Revinty Ellipta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/CHMP/137719/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-revinty-ellipta_en.pdf"},
    {"id":"3602","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel Qualimed","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2014-09-08T02:00:00Z","reference_number":"EMEA/CHMP/379506/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-qualimed_en.pdf"},
    {"id":"3688","name":"CVMP summary of positive opinion for Versican Plus Pi/L4R","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/CVMP/301696/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-versican-plus-pil4r_en.pdf"},
    {"id":"3699","name":"Committee for medicinal products for human use, summary of positive opinion for Pandemrix","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2015-10-27T01:00:00Z","reference_number":"EMEA/CHMP/65954/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-pandemrix_en.pdf"},
    {"id":"3810","name":"CHMP summary of positive opinion for Lonsurf","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/CHMP/130102/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lonsurf_en.pdf"},
    {"id":"3822","name":"CHMP summary of opinion for Pandemic influenza vaccine H5N1 MedImmune","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/170789/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-pandemic-influenza-vaccine-h5n1-medimmune_en.pdf"},
    {"id":"3838","name":"CHMP summary of positive opinion for Suliqua","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2016-11-11T13:00:00Z","reference_number":"EMA/CHMP/715538/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-suliqua_en.pdf"},
    {"id":"3925","name":"CHMP summary of positive opinion for Capecitabine Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/CHMP/106716/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-capecitabine-krka_en.pdf"},
    {"id":"4044","name":"CVMP summary of positive opinion for Clevor","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-02-16T01:00:00Z","last_updated_date":"2018-02-16T01:00:00Z","reference_number":"EMA/CVMP/679647/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-clevor_en.pdf"},
    {"id":"4117","name":"CHMP summary of positive opinion for Pioglitazone Actavis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/CHMP/508725/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-actavis_en.pdf"},
    {"id":"4127","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Milnacipran Pierre Fabre Médicament / Impulsor","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-11-20T01:00:00Z","last_updated_date":"2009-11-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-milnacipran-pierre-fabre-medicament-impulsor_sv.pdf"}}    {"id":"4134","name":"CHMP summary of positive opinion for Kymriah","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T14:00:00Z","last_updated_date":"2018-06-29T14:00:00Z","reference_number":"EMA/CHMP/289459/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kymriah_en.pdf"},
    {"id":"4148","name":"CHMP summary of positive opinion for Clopidogrel ratiopharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/CHMP/476872/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-clopidogrel-ratiopharm_en.pdf"},
    {"id":"4152","name":"Committee for medicinal products for human use summary of positive opinion for Filgrastim ratiopharm","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T00:09:21Z","last_updated_date":"2008-02-21T00:09:21Z","reference_number":"EMEA/CHMP/67399/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-filgrastim-ratiopharm_en.pdf"},
    {"id":"4176","name":"CHMP summary of positive opinion for Novothirteen","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/CHMP/246097/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-novothirteen_en.pdf"},
    {"id":"4196","name":"CHMP summary of opinion for Enzepi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/291219/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-enzepi_en.pdf"},
    {"id":"4205","name":"Questions and answers on refusal of the marketing authorisation for EnCyzix (enclomifene)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T01:00:00Z","last_updated_date":"2018-04-20T02:00:00Z","reference_number":"EMA/CHMP/54473/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_sv.pdf"}},
    {"id":"4212","name":"CHMP summary of positive opinion for Saxenda","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"EMA/CHMP/27724/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-saxenda_en.pdf"},
    {"id":"4228","name":"CHMP summary of positive opinion for Actelsar HCT","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-01-18T13:00:00Z","reference_number":"EMA/CHMP/774027/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-actelsar-hct_en.pdf"},
    {"id":"4431","name":"CHMP summary of positive opinion for Hizentra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-02-18T01:00:00Z","last_updated_date":"2011-02-18T01:00:00Z","reference_number":"EMA/CHMP/110226/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hizentra_en.pdf"},
    {"id":"4434","name":"CHMP summary of positive opinion for Rivastigmine 1 A Pharma","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rivastigmine-1-pharma_en.pdf"},
    {"id":"4454","name":"CHMP summary of positive opinion for Zoledronic acid Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T13:00:00Z","last_updated_date":"2012-03-16T13:00:00Z","reference_number":"EMA/186863/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zoledronic-acid-teva_en.pdf"},
    {"id":"4497","name":"CHMP summary of positive opinion for Vitekta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2017-05-29T02:00:00Z","reference_number":"EMA/CHMP/5643227/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vitekta_en.pdf"},
    {"id":"4507","name":"CHMP summary of positive opinion for Ibandronic acid Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/513131/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ibandronic-acid-accord_en.pdf"},
    {"id":"4541","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for Lenalidomide Celgene Europe","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T02:00:00Z","last_updated_date":"2008-06-02T02:00:00Z","reference_number":"EMEA/CHMP/271288/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-lenalidomide-celgene-europe_en.pdf"},
    {"id":"4648","name":"CHMP summary of positive opinion for Mepsevii","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T14:00:00Z","last_updated_date":"2018-06-29T14:00:00Z","reference_number":"EMA/CHMP/383566/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mepsevii_en.pdf"},
    {"id":"4699","name":"Committee for medicinal products for human use, summary of positive opinion for Olanzapine Mylan","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/376249/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-olanzapine-mylan_en.pdf"},
    {"id":"4701","name":"CHMP summary of positive opinion for Dacogen","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"EMA/461407/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dacogen_en.pdf"},
    {"id":"4812","name":"CHMP summary of positive opinion for Dupixent ","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T17:29:00Z","last_updated_date":"2017-07-21T17:29:00Z","reference_number":"EMA/CHMP/453766/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dupixent_en.pdf"},
    {"id":"4844","name":"CHMP summary of opinion for Flixabi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/793732/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-flixabi_en.pdf"},
    {"id":"4899","name":"Committee for medicinal products for human use, summary of positive opinion for Tredaptive","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/196951/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-tredaptive_en.pdf"},
    {"id":"4937","name":"CHMP summary of positive opinion for Vepacel","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T01:00:00Z","last_updated_date":"2011-12-16T01:00:00Z","reference_number":"EMA/CHMP/932537/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vepacel_en.pdf"},
    {"id":"4976","name":"CVMP summary of positive opinion for Vepured","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-06-16T02:00:00Z","last_updated_date":"2017-06-16T02:00:00Z","reference_number":"EMA/CVMP/292749/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-vepured_en.pdf"},
    {"id":"5026","name":"CHMP summary of opinion for Zurampic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/CHMP/824058/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-zurampic_en.pdf"},
    {"id":"5048","name":"CHMP summary of positive opinion for Harvoni","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/572137/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-harvoni_en.pdf"},
    {"id":"5090","name":"CHMP summary of positive opinion for Sepioglin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2013-07-18T02:00:00Z","reference_number":"EMA/CHMP/644013/2011 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sepioglin_en.pdf"},
    {"id":"5103","name":"CVMP summary of positive opinion for Prevomax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-18T02:00:00Z","last_updated_date":"2017-04-18T02:00:00Z","reference_number":"EMA/CVMP/192928/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-prevomax_en.pdf"},
    {"id":"5189","name":"CHMP summary of positive opinion for Xadago","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/CHMP/741610/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xadago_en.pdf"},
    {"id":"5222","name":"Questions and answers on refusal of a change to the marketing authorisation for Lympreva (dasiprotimut-T)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/249530/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-lympreva-dasiprotimut-t_sv.pdf"}},
    {"id":"5238","name":"CHMP summary of positive opinion for Nuedexta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/CHMP/132029/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nuedexta_en.pdf"},
    {"id":"5255","name":"CHMP summary of positive opinion for Farydak","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/CHMP/304387/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-farydak_en.pdf"},
    {"id":"5295","name":"CHMP summary of positive opinion for Neocepri","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/CHMP/139150/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-neocepri_en.pdf"},
    {"id":"5315","name":"CHMP summary of positive opinion for Verzenios","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/420258/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-verzenios_en.pdf"},
    {"id":"5328","name":"CHMP summary of opinion for Bortezomib Hospira","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2026-04-15T02:00:00Z","reference_number":"EMA/CHMP/327595/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-bortezomib-hospira_en.pdf"},
    {"id":"5332","name":"Committee for medicinal products for human use, summary of positive opinion for Iressa","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/200756/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-iressa_en.pdf"},
    {"id":"5460","name":"CHMP summary of positive opinion for Brintellix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T15:00:00Z","last_updated_date":"2013-10-25T15:00:00Z","reference_number":"EMA/CHMP/630715/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-brintellix_en.pdf"},
    {"id":"5477","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Rhucin","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2007-12-13T01:00:00Z","last_updated_date":"2007-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-rhucin_en.pdf"},
    {"id":"5504","name":"CHMP summary of positive opinion for Odomzo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/CHMP/400811/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-odomzo_en.pdf"},
    {"id":"5610","name":"CHMP summary of positive opinion for Trelegy Ellipta","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T17:39:00Z","last_updated_date":"2017-09-15T17:39:00Z","reference_number":"EMA/CHMP/244744/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trelegy-ellipta_en.pdf"},
    {"id":"5708","name":"CHMP summary of positive opinion for Bexsero","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T13:00:00Z","last_updated_date":"2012-11-16T13:00:00Z","reference_number":"EMA/CHMP/669278/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bexsero_en.pdf"},
    {"id":"5729","name":"Committee for medicinal products for human use, summary of positive opinion for Topotecan Actavis","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/CHMP/291093/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-topotecan-actavis_en.pdf"},
    {"id":"5750","name":"CHMP summary of positive opinion for Intrarosa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"EMA/CHMP/724429/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-intrarosa_en.pdf"},
    {"id":"5772","name":"Questions and answers on refusal of the marketing authorisation for Xeljanz","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T02:00:00Z","last_updated_date":"2013-04-26T02:00:00Z","reference_number":"EMA/248755/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz_en.pdf"},
    {"id":"5774","name":"CHMP summary of positive opinion for Daptomycin Hospira","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T13:00:00Z","last_updated_date":"2017-01-27T13:00:00Z","reference_number":"EMA/CHMP/37961/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-daptomycin-hospira_en.pdf"},
    {"id":"5777","name":"CHMP summary of positive opinion for Ciambra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T14:00:00Z","last_updated_date":"2024-10-17T14:00:00Z","reference_number":"EMA/CHMP/572488/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ciambra_en.pdf"},
    {"id":"5793","name":"CHMP summary of positive opinion for Stribild","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/CHMP/158160/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-stribild_en.pdf"},
    {"id":"5824","name":"CHMP summary of positive opinion for Prolia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/776168/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-prolia_en.pdf"},
    {"id":"5857","name":"Committee for medicinal products for human use, summary of positive opinion for Nymusa","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/212696/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-nymusa_en.pdf"},
    {"id":"5900","name":"CHMP summary of positive opinion for Jakavi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2012-04-20T02:00:00Z","reference_number":"EMA/CHMP/231626/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jakavi_en.pdf"},
    {"id":"5945","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for Biferonex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-02-20T00:09:00Z","last_updated_date":"2009-02-20T00:09:00Z","reference_number":"EMEA/91120/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-biferonex_en.pdf"},
    {"id":"5968","name":"CHMP summary of opinion for Odefsey","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/267024/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-odefsey_en.pdf"},
    {"id":"5984","name":"CHMP summary of positive opinion for Biktarvy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"EMA/CHMP/228562/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-biktarvy_en.pdf"},
    {"id":"6018","name":"CHMP summary of positive opinion for Xalkori","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"EMA/CHMP/453868/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xalkori_en.pdf"},
    {"id":"6054","name":"CHMP summary of positive opinion for Docetaxel Kabi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T01:00:00Z","last_updated_date":"2012-03-16T01:00:00Z","reference_number":"EMA/CHMP/56643/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-docetaxel-kabi_en.pdf"},
    {"id":"6073","name":"CHMP summary of positive opinion for Hemlibra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/785115/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hemlibra_en.pdf"},
    {"id":"6086","name":"CHMP summary of positive opinion for Symtuza","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/411074/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-symtuza_en.pdf"},
    {"id":"6096","name":"Committee for medicinal products for human use, summary of positive opinion for Instanyl","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/65031/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-instanyl_en.pdf"},
    {"id":"6108","name":"Committee for medicinal products for human use, summary of positive opinion for  Velmetia","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-04-30T02:00:00Z","last_updated_date":"2008-04-30T02:00:00Z","reference_number":"EMEA/CHMP/216688/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-velmetia_en.pdf"},
    {"id":"6134","name":"CHMP summary of positive opinion for Somac Control","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-02-18T01:00:00Z","last_updated_date":"2009-02-18T01:00:00Z","reference_number":"EMEA/CHMP/108577/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-somac-control_en.pdf"},
    {"id":"6146","name":"CHMP summary of opinion for Oncaspar","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/734982/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-oncaspar_en.pdf"},
    {"id":"6181","name":"CHMP summary of positive opinion for Rivastigmine 3M Health Care Ltd","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-09-18T02:00:00Z","reference_number":"EMA/CHMP/25190/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rivastigmine-3m-health-care-ltd_en.pdf"},
    {"id":"6214","name":"CHMP summary of positive opinion for Prevymis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T12:59:00Z","last_updated_date":"2017-11-10T12:59:00Z","reference_number":"EMA/CHMP/737340/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-prevymis_en.pdf"},
    {"id":"6265","name":"CVMP summary of positive opinion for Credelio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-02-17T01:00:00Z","last_updated_date":"2017-02-17T01:00:00Z","reference_number":"EMA/CVMP/49053/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-credelio_en.pdf"},
    {"id":"6280","name":"CHMP summary of positive opinion for Mercaptopurine Nova Laboratories","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/470877/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mercaptopurine-nova-laboratories_en.pdf"},
    {"id":"6295","name":"CHMP summary of positive opinion for Ritonavir Mylan","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/CHMP/541227/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ritonavir-mylan_en.pdf"},
    {"id":"6310","name":"CHMP summary of positive opinion for Zyclara","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CHMP/423167/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zyclara_en.pdf"},
    {"id":"6395","name":"CHMP summary of positive opinion for  Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T14:00:00Z","last_updated_date":"2017-05-19T14:00:00Z","reference_number":"EMA/CHMP/308697/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-efavirenzemtricitabinetenofovir-disoproxil-zentiva_en.pdf"},
    {"id":"6433","name":"CHMP summary of positive opinion for Xermelo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xermelo_en.pdf"},
    {"id":"6485","name":"CHMP summary of positive opinion for Hemangiol","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/CHMP/95120/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hemangiol_en.pdf"},
    {"id":"6547","name":"CHMP summary of positive opinion for Myfenax","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-01-14T01:00:00Z","last_updated_date":"2008-01-14T01:00:00Z","reference_number":"EMEA/CHMP/562878/2007, corr.","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-myfenax_en.pdf"},
    {"id":"6594","name":"CHMP summary of positive opinion for Colobreathe","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-29T16:00:00Z","last_updated_date":"2011-09-29T16:00:00Z","reference_number":"EMA/CHMP/754272/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-colobreathe_en.pdf"},
    {"id":"6623","name":"Committee for medicinal products for human use, summary of positive opinion for Repaglinide Krka","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-repaglinide-krka_en.pdf"},
    {"id":"6673","name":"CHMP summary of positive opinion for Zejula","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/CHMP/574018/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zejula_en.pdf"},
    {"id":"6676","name":"CHMP summary of positive opinion for Ifirmacombi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/646092/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ifirmacombi_en.pdf"},
    {"id":"6850","name":"CHMP summary of positive opinion for Lifmior","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T15:02:00Z","last_updated_date":"2020-02-20T15:02:00Z","reference_number":"EMA/CHMP/764586/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lifmior_en.pdf"},
    {"id":"6853","name":"CVMP summary of positive opinion for Purevax Rabies","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-10T01:00:00Z","last_updated_date":"2010-12-10T01:00:00Z","reference_number":"EMA/CVMP/144109/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-purevax-rabies_en.pdf"},
    {"id":"6879","name":"CHMP summary of positive opinion for Clopidogrel Acino Pharma GmbH","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:09:21Z","last_updated_date":"2009-06-25T02:09:21Z","reference_number":"EMEA/CHMP/376524/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-clopidogrel-acino-pharma-gmbh_en.pdf"},
    {"id":"6899","name":"CHMP summary of opinion for Amlodipine-Valsartan Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"EMA/CHMP/18049/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-amlodipine-valsartan-mylan_en.pdf"},
    {"id":"6929","name":"CHMP summary of opinion for Tagrisso","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/776644/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-tagrisso_en.pdf"},
    {"id":"6939","name":"CVMP summary of positive opinion for Aftovaxpur DOE","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-05-17T02:00:00Z","last_updated_date":"2023-07-04T02:00:00Z","reference_number":"EMA/CVMP/257822/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-aftovaxpur-doe_en.pdf"},
    {"id":"6960","name":"CVMP summary of positive opinion for Nobivac LeuFel","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T17:30:00Z","last_updated_date":"2017-09-08T17:30:00Z","reference_number":"EMA/CVMP/518494/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-leufel_en.pdf"},
    {"id":"7018","name":"CHMP summary of positive opinion for Kalydeco","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/CHMP/311973/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kalydeco_en.pdf"},
    {"id":"7065","name":"CHMP summary of opinion for Zonisamide Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"EMA/CHMP/15884/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-zonisamide-mylan_en.pdf"},
    {"id":"7329","name":"CHMP summary of positive opinion for Nexium Control","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/328140/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nexium-control_en.pdf"},
    {"id":"7358","name":"CHMP summary of positive opinion for Efficib","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-04-29T02:00:00Z","last_updated_date":"2008-04-29T02:00:00Z","reference_number":"EMEA/CHMP/216662/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-efficib_en.pdf"},
    {"id":"7370","name":"CHMP summary of positive opinion for Yargesa","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T10:00:00Z","last_updated_date":"2017-01-27T10:00:00Z","reference_number":"EMA/CHMP/22018/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yargesa_en.pdf"},
    {"id":"7421","name":"Committee for medicinal products for human use, summary of positive opinion for Synflorix","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T01:00:00Z","last_updated_date":"2009-01-22T01:00:00Z","reference_number":"EMEA/CHMP/13120/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-synflorix_en.pdf"},
    {"id":"7446","name":"CHMP summary of opinion for Sialanar","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/CHMP/487260/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-sialanar_en.pdf"},
    {"id":"7466","name":"CVMP summary of positive opinion for Equilis West Nile","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2013-04-12T19:00:00Z","last_updated_date":"2013-04-12T19:00:00Z","reference_number":"EMA/CVMP/161880/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-equilis-west-nile_en.pdf"},
    {"id":"7492","name":"CVMP summary of positive opinion for Bravecto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-12-13T17:00:00Z","last_updated_date":"2013-12-13T17:00:00Z","reference_number":"EMA/CVMP/627638/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bravecto_en.pdf"},
    {"id":"7539","name":"CHMP summary of positive opinion for Exviera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2024-10-01T13:00:00Z","reference_number":"EMA/CHMP/688227/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-exviera_en.pdf"},
    {"id":"7541","name":"CHMP summary of positive opinion for Halaven","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/27541/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-halaven_en.pdf"},
    {"id":"7592","name":"CHMP summary of opinion for EndolucinBeta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/230649/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-endolucinbeta_en.pdf"},
    {"id":"7625","name":"CVMP summary of positive opinion for Pexion","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/CVMP/734633/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-pexion_en.pdf"},
    {"id":"7729","name":"Questions and answers on the recommendation for the refusal of the marketing authorization for Mycograb","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2007-03-21T01:00:00Z","last_updated_date":"2007-03-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mycograb_sv.pdf"}},
    {"id":"7746","name":"CHMP summary of positive opinion for Ketoconazole HRA","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/568353/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ketoconazole-hra_en.pdf"},
    {"id":"7796","name":"CVMP summary of positive opinion for Emdocam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-10T02:00:00Z","last_updated_date":"2011-06-10T02:00:00Z","reference_number":"EMA/CVMP/295707/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-emdocam_en.pdf"},
    {"id":"7814","name":"CHMP summary of positive opinion for Carmustine Obvius","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"EMA/88410/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-carmustine-obvius_en.pdf"},
    {"id":"7846","name":"CHMP summary of positive opinion for Tevagrastim","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-07-25T02:00:00Z","last_updated_date":"2008-07-25T02:00:00Z","reference_number":"EMEA/CHMP/360673/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tevagrastim_en.pdf"},
    {"id":"7866","name":"CHMP summary of positive opinion for DuoResp Spiromax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/CHMP/68037/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duoresp-spiromax_en.pdf"},
    {"id":"7895","name":"CHMP summary of opinion for Episalvan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2022-07-15T14:00:00Z","reference_number":"EMA/765144/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-episalvan_en.pdf"}    {"id":"7956","name":"CHMP summary of positive opinion for Ratioepo","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ratioepo_en.pdf"},
    {"id":"7966","name":"CHMP summary of positive opinion for Fycompa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/CHMP/242764/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fycompa_en.pdf"},
    {"id":"8101","name":"CHMP summary of positive opinion for Imraldi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"EMA/358372/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imraldi_en.pdf"},
    {"id":"8109","name":"CHMP summary of positive opinion for Cabometyx","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/498981/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cabometyx_en.pdf"},
    {"id":"8234","name":"CVMP summary of positive opinion for RevitaCAM","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-12-09T01:00:00Z","last_updated_date":"2016-05-30T02:00:00Z","reference_number":"EMA/CVMP/77474/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-revitacam_en.pdf"},
    {"id":"8440","name":"CHMP summary of positive opinion for Silodyx","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/CHMP/752757/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-silodyx_en.pdf"},
    {"id":"8449","name":"CHMP summary of positive opinion for Betmiga","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/CHMP/551730/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-betmiga_en.pdf"},
    {"id":"8462","name":"CHMP summary of positive opinion for Eperzan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2019-02-20T01:00:00Z","reference_number":"EMA/CHMP/20616/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eperzan_en.pdf"},
    {"id":"8472","name":"CHMP summary of positive opinion for Semglee","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T01:00:00Z","last_updated_date":"2018-01-26T01:00:00Z","reference_number":"EMA/CHMP/13698/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-semglee_en.pdf"},
    {"id":"8481","name":"CVMP summary of positive opinion for Comfortis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-10T01:00:00Z","last_updated_date":"2023-06-26T01:00:00Z","reference_number":"EMA/CVMP/499406/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-comfortis_en.pdf"},
    {"id":"8620","name":"CHMP summary of positive opinion for Removab","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-02-18T01:00:00Z","last_updated_date":"2017-07-12T02:00:00Z","reference_number":"EMEA/CHMP/100097/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-removab_en.pdf"},
    {"id":"8653","name":"CHMP summary of positive opinion for Memantine Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/428241/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-memantine-accord_en.pdf"},
    {"id":"8664","name":"CHMP summary of positive opinion for Xofigo","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/411215/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xofigo_en.pdf"},
    {"id":"8696","name":"CHMP summary of positive opinion for Unituxin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2017-04-28T02:00:00Z","reference_number":"EMA/CHMP/303761/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-unituxin_en.pdf"},
    {"id":"8702","name":"Questions and answers on refusal of the marketing authorisation for Masiviera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-23T01:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/298222/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masiviera_sv.pdf"}},
    {"id":"8749","name":"Committee for medicinal products for human use, summary of positive opinion for Pantecta Control","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-02-18T01:00:00Z","last_updated_date":"2016-11-15T01:00:00Z","reference_number":"EMEA/CHMP/108580/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-pantecta-control_en.pdf"},
    {"id":"8835","name":"CVMP summary of positive opinion for Bovilis BTV8","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2022-07-27T11:23:00Z","reference_number":"EMA/CVMP/115976/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bovilis-btv8_en.pdf"},
    {"id":"8839","name":"CHMP summary of positive opinion for Darunavir Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2016-11-11T13:00:00Z","reference_number":"EMA/CHMP/573531/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-darunavir-mylan_en.pdf"},
    {"id":"8879","name":"CHMP summary of positive opinion for Egranli","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/453326/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-egranli_en.pdf"},
    {"id":"8893","name":"CHMP summary of positive opinion for Ongentys","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/268284/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ongentys_en.pdf"},
    {"id":"8947","name":"CHMP summary of positive opinion for Pheburane","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/CHMP/633855/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pheburane_en.pdf"},
    {"id":"8948","name":"CHMP summary of opinion for Eptifibatide Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/721224/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-eptifibatide-accord_en.pdf"},
    {"id":"8956","name":"CHMP summary of positive opinion for Pelgraz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/456066/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pelgraz_en.pdf"},
    {"id":"8958","name":"CHMP summary of positive opinion for Zaltrap","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2012-11-16T01:00:00Z","reference_number":"EMA/CHMP/697268/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zaltrap_en.pdf"},
    {"id":"8996","name":"CHMP summary of positive opinion for Pioglitazone Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/423166/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-krka_en.pdf"},
    {"id":"9024","name":"CHMP summary of positive opinion for Bemfola","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-01-24T01:00:00Z","reference_number":"EMA/CHMP/41421/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bemfola_en.pdf"},
    {"id":"9030","name":"Committee for medicinal products for human use  summary of positive opinion  for Xarelto","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/357818/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-xarelto_en.pdf"},
    {"id":"9050","name":"CVMP summary of positive opinion for Letifend","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-02-19T01:00:00Z","last_updated_date":"2016-02-19T01:00:00Z","reference_number":"EMA/CVMP/4233/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-letifend_en.pdf"},
    {"id":"9052","name":"CHMP summary of positive opinion for Fluenz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2014-12-03T01:00:00Z","reference_number":"EMA/CHMP/503333/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fluenz_en.pdf"},
    {"id":"9060","name":"CHMP summary of positive opinion for Grastofil","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/CHMP/304525/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-grastofil_en.pdf"},
    {"id":"9125","name":"Committee for medicinal products for human use, summary of positive opinion for  Vedrop","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/CHMP/282149/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-vedrop_en.pdf"},
    {"id":"9147","name":"CHMP summary of positive opinion for Segluromet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/12790/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-segluromet_en.pdf"},
    {"id":"9153","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Alpheon","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2007-10-22T02:09:00Z","last_updated_date":"2007-10-22T02:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_sv.pdf"}},
    {"id":"9190","name":"CHMP summary of positive opinion for Ristfor","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMEA/CHMP/771707/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ristfor_en.pdf"},
    {"id":"9204","name":"CHMP summary of positive opinion for Imvanex","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/CHMP/256704/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imvanex_en.pdf"},
    {"id":"9220","name":"Committee for medicinal products for human use summary of positive opinion for Firmagon","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T00:09:21Z","last_updated_date":"2008-12-18T00:09:21Z","reference_number":"EMEA/CHMP/667162/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-firmagon_en.pdf"},
    {"id":"9242","name":"CHMP summary of positive opinion for Paglitaz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/CHMP/423153/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-paglitaz_en.pdf"},
    {"id":"9285","name":"Committee for medicinal products for veterinary use summary of opinion: Suvaxyn PCV: International Non-proprietary Names (INN): Gamithromycin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T03:09:00Z","last_updated_date":"2020-04-15T03:09:00Z","reference_number":"EMEA/CVMP/257211/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-suvaxyn-pcv-international-non-proprietary-names-inn-gamithromycin_en.pdf"},
    {"id":"9298","name":"CHMP summary of positive opinion for Granpidam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/592404/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-granpidam_en.pdf"},
    {"id":"9302","name":"CHMP summary of positive opinion for Varuby","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T11:00:00Z","last_updated_date":"2020-03-02T11:00:00Z","reference_number":"EMA/CHMP/97358/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-varuby_en.pdf"},
    {"id":"9313","name":"CHMP summary of positive opinion for Sprimeo HCT","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-02-17T01:00:00Z","last_updated_date":"2012-08-28T02:00:00Z","reference_number":"EMA/124454/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sprimeo-hct_en.pdf"},
    {"id":"9351","name":"CHMP summary of opinion for Epclusa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T14:00:00Z","last_updated_date":"2016-05-27T14:00:00Z","reference_number":"EMA/CHMP/323098/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-epclusa_en.pdf"},
    {"id":"9529","name":"CHMP summary of positive opinion for Imatinib Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/CHMP/597641/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imatinib-teva_en.pdf"},
    {"id":"9533","name":"CVMP summary of positive opinion for MiPet Easecto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-10-06T02:00:00Z","last_updated_date":"2017-10-06T02:00:00Z","reference_number":"EMA/CVMP/618926/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-mipet-easecto_en.pdf"},
    {"id":"9577","name":"CVMP summary of positive opinion for BTVPUR AlSap 2-4","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2018-11-13T02:00:00Z","reference_number":"EMA/CVMP/256124/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-btvpur-alsap-2-4_en.pdf"},
    {"id":"9614","name":"Questions and answers on refusal of the marketing authorisation for Nerventra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-05-23T14:00:00Z","reference_number":"EMA/311892/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerventra_sv.pdf"}},
    {"id":"9627","name":"CHMP summary of positive opinion for Entecavir Mylan","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/CHMP/275743/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-entecavir-mylan_en.pdf"},
    {"id":"9664","name":"CVMP summary of positive opinion for Zeleris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/CVMP/69359/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zeleris_en.pdf"},
    {"id":"9721","name":"CVMP summary of positive opinion for Imrestor","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-10-09T02:00:00Z","last_updated_date":"2015-10-09T02:00:00Z","reference_number":"EMA/CVMP/484431/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-imrestor_en.pdf"},
    {"id":"9723","name":"CHMP summary of positive opinion for Temozolomide Sun","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/354114/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-temozolomide-sun_en.pdf"},
    {"id":"9734","name":"Questions and answers on the recommendation for the refusal of the marketing authorization for Cimzia","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-03-20T01:00:00Z","last_updated_date":"2008-03-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-cimzia_sv.pdf"}},
    {"id":"9801","name":"CHMP summary of positive opinion for Taltz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T13:05:00Z","last_updated_date":"2016-02-26T13:05:00Z","reference_number":"EMA/CHMP/78341/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-taltz_en.pdf"},
    {"id":"9808","name":"CVMP summary of positive opinion for Suvaxyn Circo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-12-08T01:00:00Z","last_updated_date":"2017-12-08T01:00:00Z","reference_number":"EMA/CVMP/757567/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-suvaxyn-circo_en.pdf"},
    {"id":"9836","name":"CHMP summary of positive opinion for Tecentriq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/CHMP/372183/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tecentriq_en.pdf"},
    {"id":"9858","name":"CHMP summary of positive opinion for Repso","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/CHMP/605155/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-repso_en.pdf"},
    {"id":"9885","name":"CHMP summary of positive opinion for Pioglitazone Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2023-05-04T01:00:00Z","reference_number":"EMA/CHMP/756122/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-teva_en.pdf"},
    {"id":"9900","name":"CVMP summary of opinion for Acticam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-10-17T03:09:00Z","last_updated_date":"2021-03-24T03:09:00Z","reference_number":"EMEA/CVMP/512781/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-opinion-acticam_en.pdf"},
    {"id":"9915","name":"CVMP summary of positive opinion for Recuvyra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-05-06T02:00:00Z","last_updated_date":"2017-07-12T02:00:00Z","reference_number":"EMA/CVMP/62249/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-recuvyra_en.pdf"},
    {"id":"10012","name":"CHMP summary of positive opinion for Brilique","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMA/536945/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-brilique_en.pdf"},
    {"id":"10015","name":"CHMP summary of positive opinion for Ibandronic Acid Sandoz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-02-18T01:00:00Z","last_updated_date":"2011-02-18T01:00:00Z","reference_number":"EMA/112994/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ibandronic-acid-sandoz_en.pdf"},
    {"id":"10087","name":"CHMP summary of positive opinion for Telmisartan Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/CHMP/267262/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-telmisartan-teva_en.pdf"},
    {"id":"10125","name":"CHMP summary of positive opinion for Bavencio","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/CHMP/426201/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bavencio_en.pdf"},
    {"id":"10183","name":"CHMP summary of positive opinion for Dinutuximab beta Apeiron","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/CHMP/153871/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dinutuximab-beta-apeiron_en.pdf"},
    {"id":"10212","name":"CHMP summary of positive opinion for Juluca","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T13:00:00Z","last_updated_date":"2018-03-23T13:00:00Z","reference_number":"EMA/CHMP/37238/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-juluca_en.pdf"},
    {"id":"10242","name":"Committee for medicinal products for human use summary of positive opinion for Cayston","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:09:21Z","last_updated_date":"2009-06-25T02:09:21Z","reference_number":"EMEA/CHMP/391766/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-cayston_en.pdf"},
    {"id":"10287","name":"Questions and answers on the refusal of the marketing authorisation for Glybera - Outcome of re-examination","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T02:00:00Z","last_updated_date":"2011-10-21T02:00:00Z","reference_number":"EMA/CHMP/474562/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-glybera-outcome-re-examination_en.pdf"},
    {"id":"10362","name":"CVMP summary of positive opinion for Porcilis ColiClos","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-04-16T02:00:00Z","last_updated_date":"2012-04-16T02:00:00Z","reference_number":"EMA/CVMP/135528/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-porcilis-coliclos_en.pdf"},
    {"id":"10373","name":"CHMP summary of positive opinion for Azarga","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-09-25T02:09:21Z","last_updated_date":"2008-09-25T02:09:21Z","reference_number":"EMEA/CHMP/472224/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-azarga_en.pdf"},
    {"id":"10413","name":"Committee for medicinal products for veterinary use summary of opinion: Porcilis PCV","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-11-14T01:09:21Z","last_updated_date":"2008-11-14T01:09:21Z","reference_number":"EMEA/CVMP/573498/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-porcilis-pcv_en.pdf"},
    {"id":"10488","name":"CHMP summary of positive opinion for Truxima","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"EMA/CHMP/813387/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-truxima_en.pdf"},
    {"id":"10502","name":"CHMP summary of positive opinion for Jentadueto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/CHMP/321580/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jentadueto_en.pdf"},
    {"id":"10503","name":"CHMP summary of positive opinion for Budesonide / Formoterol Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T15:40:00Z","last_updated_date":"2017-01-31T14:40:00Z","reference_number":"EMA/CHMP/436479/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-budesonide-formoterol-teva_en.pdf"},
    {"id":"10649","name":"CHMP summary of positive opinion for Qutenza","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-03-19T01:00:00Z","last_updated_date":"2009-03-19T01:00:00Z","reference_number":"EMEA/CHMP/162956/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-qutenza_en.pdf"},
    {"id":"10741","name":"CHMP summary of opinion for Zepatier","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/342247/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-zepatier_en.pdf"},
    {"id":"10789","name":"CHMP summary of opinion for Darzalex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/174469/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-darzalex_en.pdf"},
    {"id":"10791","name":"CHMP summary of positive opinion for Ozurdex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-05-21T02:00:00Z","last_updated_date":"2010-05-21T02:00:00Z","reference_number":"EMA/CHMP/316582/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ozurdex_en.pdf"},
    {"id":"10895","name":"Questions and answers on the refusal of the marketing authorisation for Qsiva (phentermine / topiramate)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/109958/2013 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_sv.pdf"}},
    {"id":"10917","name":"CHMP summary of positive opinion for Sirturo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/CHMP/771324/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sirturo_en.pdf"},
    {"id":"10922","name":"CHMP summary of positive opinion for Omidria","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/289526/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-omidria_en.pdf"},
    {"id":"10923","name":"CHMP summary of positive opinion for Velphoro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/204589/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-velphoro_en.pdf"},
    {"id":"10931","name":"CHMP summary of positive opinion for Leganto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2022-02-18T02:00:00Z","reference_number":"EMA/259223/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-leganto_en.pdf"},
    {"id":"10951","name":"Questions and answers on refusal of the marketing authorisation for Heparesc (human heterologous liver cells)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/413158/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-heparesc-human-heterologous-liver-cells_sv.pdf"}},
    {"id":"10994","name":"CHMP summary of positive opinion Kyprolis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/627858/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kyprolis_en.pdf"},
    {"id":"11006","name":"CHMP summary of positive opinion for Praxbind","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T14:00:00Z","last_updated_date":"2015-09-25T14:00:00Z","reference_number":"EMA/CHMP/575990/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-praxbind_en.pdf"},
    {"id":"11031","name":"Questions and answers on the refusal of the marketing authorisation for  Balaxur","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2013-03-11T13:30:00Z","reference_number":"EMA/CHMP/667674/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-balaxur_sv.pdf"}},
    {"id":"11047","name":"CHMP summary of positive opinion for Controloc Control","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"EMEA/CHMP/108578/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-controloc-control_en.pdf"},
    {"id":"11048","name":"CHMP summary of positive opinion for Nivolumab BMS","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2016-01-14T01:00:00Z","reference_number":"EMA/CHMP/310230/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nivolumab-bms_en.pdf"},
    {"id":"11070","name":"CHMP summary of positive opinion for Pumarix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2015-03-17T01:00:00Z","reference_number":"EMA/CHMP/692469/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pumarix_en.pdf"},
    {"id":"11080","name":"CHMP summary of positive opinion for Tremfya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/CHMP/556833/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tremfya_en.pdf"},
    {"id":"11154","name":"Committee for medicinal products for human use  summary of positive opinion  for Zyllt","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-24T02:00:00Z","last_updated_date":"2009-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zyllt_en.pdf"},
    {"id":"11182","name":"CHMP summary of positive opinion for Crysvita","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/CHMP/813650/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-crysvita_en.pdf"},
    {"id":"11215","name":"CVMP summary of positive opinion for Canileish","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-14T01:00:00Z","last_updated_date":"2023-10-24T13:11:00Z","reference_number":"EMA/CVMP/296014/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-canileish_en.pdf"},
    {"id":"11225","name":"CHMP summary of positive opinion for Cometriq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/CHMP/539526/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cometriq_en.pdf"},
    {"id":"11248","name":"CHMP summary of positive opinion for Fampyra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/396600/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fampyra_en.pdf"},
    {"id":"11268","name":"CHMP summary of opinion for Zalmoxis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/CHMP/380467/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-zalmoxis_en.pdf"},
    {"id":"11310","name":"CHMP summary of positive opinion for Temozolomide Hospira","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/810712/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-temozolomide-hospira_en.pdf"},
    {"id":"11365","name":"CHMP summary of positive opinion for Rasilez HCT","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2022-05-20T01:00:00Z","reference_number":"EMEA/CHMP/599453/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rasilez-hct_en.pdf"},
    {"id":"11397","name":"CHMP summary of positive opinion for Aimovig","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/CHMP/283640/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aimovig_en.pdf"},
    {"id":"11482","name":"CVMP summary of positive opinion for Versican Plus Pi/L4","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/CVMP/301775/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-versican-plus-pil4_en.pdf"},
    {"id":"11490","name":"CHMP summary of positive opinion for Entacapone Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-11-26T01:00:00Z","last_updated_date":"2010-11-26T01:00:00Z","reference_number":"EMA/CHMP/659548/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-entacapone-teva_en.pdf"}    {"id":"11508","name":"CHMP summary of positive opinion for Ucedane","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/CHMP/253159/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ucedane_en.pdf"},
    {"id":"11516","name":"CHMP summary of positive opinion for Victrelis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2018-07-31T02:00:00Z","reference_number":"EMA/CHMP/354114/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-victrelis_en.pdf"},
    {"id":"11549","name":"Committee for medicinal products for human use, summary of positive opinion for Vidaza","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-10-24T02:00:00Z","last_updated_date":"2008-10-24T02:00:00Z","reference_number":"EMEA/CHMP/528772/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-vidaza_en.pdf"},
    {"id":"11571","name":"CHMP summary of positive opinion for Cholib","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/380955/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cholib_en.pdf"},
    {"id":"11590","name":"CHMP summary of positive opinion for Mysimba","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-12-22T01:00:00Z","last_updated_date":"2014-12-22T01:00:00Z","reference_number":"EMA/CHMP/756988/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mysimba_en.pdf"},
    {"id":"11627","name":"CHMP summary of positive opinion for Ryzodeg","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/CHMP/582765/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ryzodeg_en.pdf"},
    {"id":"11630","name":"CHMP summary of positive opinion for Raplixa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2018-10-10T01:00:00Z","reference_number":"EMA/CHMP/197/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-raplixa_en.pdf"},
    {"id":"11700","name":"CHMP summary of positive opinion for Mirvaso","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/CHMP/684313/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mirvaso_en.pdf"},
    {"id":"11705","name":"CHMP summary of opinion for Caspofungin Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/CHMP/843681/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-caspofungin-accord_en.pdf"},
    {"id":"11744","name":"CHMP summary of positive opinion for Buccolam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/438483/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-buccolam_en.pdf"},
    {"id":"11792","name":"CHMP summary of opinion for Kovaltry","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/CHMP/774664/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-kovaltry_en.pdf"},
    {"id":"11891","name":"Questions and answers on refusal of the marketing authorisation for Delamanid","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/446276/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-delamanid_en.pdf"},
    {"id":"11902","name":"CHMP summary of positive opinion for Zykadia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/140022/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zykadia_en.pdf"},
    {"id":"11967","name":"CHMP summary of positive opinion for Revolade","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/344171/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-revolade_en.pdf"},
    {"id":"12012","name":"CHMP summary of positive opinion Aripiprazole Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/569870/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aripiprazole-accord_en.pdf"},
    {"id":"12047","name":"CVMP post-authorisation summary of negative opinion for Respiporc FLUpan H1N1","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2016-12-09T17:00:00Z","last_updated_date":"2016-12-09T17:00:00Z","reference_number":"EMA/CVMP/748641/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-post-authorisation-summary-negative-opinion-respiporc-flupan-h1n1_en.pdf"},
    {"id":"12106","name":"CHMP summary of positive opinion for Esmya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T01:00:00Z","last_updated_date":"2011-12-16T01:00:00Z","reference_number":"EMA/679632/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-esmya_en.pdf"},
    {"id":"12145","name":"CHMP summary of positive opinion for Pramipexole Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2024-03-11T02:00:00Z","reference_number":"EMA/CHMP/507521/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pramipexole-accord_en.pdf"},
    {"id":"12205","name":"CHMP summary of positive opinion for Roteas","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2017-02-24T01:00:00Z","reference_number":"EMA/CHMP/103918/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-roteas_en.pdf"},
    {"id":"12225","name":"CHMP summary of positive opinion for Trazimera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/CHMP/284157/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trazimera_en.pdf"},
    {"id":"12228","name":"CHMP summary of positive opinion for Imbruvica","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-07-25T02:00:00Z","reference_number":"EMA/CHMP/414325/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imbruvica_en.pdf"},
    {"id":"12290","name":"Committee for medicinal products for human use, summary of positive opinion for Pelzont","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/197000/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-pelzont_en.pdf"},
    {"id":"12318","name":"Committee for medicinal products for human use, summary of positive opinion for Nplate","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/CHMP/571877/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-nplate_en.pdf"},
    {"id":"12370","name":"CVMP summary of positive opinion for Zulvac 1+8 Ovis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-14T01:00:00Z","last_updated_date":"2011-01-14T01:00:00Z","reference_number":"EMA/CVMP/295355/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zulvac-18-ovis_en.pdf"},
    {"id":"12382","name":"Questions and answers on the recommendation for refusal of a marketing authorisation application for Veraflox","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2007-01-24T01:00:00Z","last_updated_date":"2007-01-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-veraflox_sv.pdf"}},
    {"id":"12397","name":"CHMP summary of positive opinion for Amglidia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2018-02-23T01:00:00Z","reference_number":"EMA/102426/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-amglidia_en.pdf"},
    {"id":"12429","name":"CHMP summary of positive opinion for Memantine ratiopharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/CHMP/157191/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-memantine-ratiopharm_en.pdf"},
    {"id":"12453","name":"CHMP summary of positive opinion for Busulfan Fresenius Kabi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-07-25T02:00:00Z","reference_number":"EMA/CHMP/388260/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-busulfan-fresenius-kabi_en.pdf"},
    {"id":"12529","name":"CVMP summary of positive opinion for Nobivac Myxo-RHD","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2023-09-12T13:31:00Z","reference_number":"MA/CVMP/504724/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-myxo-rhd_en.pdf"},
    {"id":"12584","name":"CHMP summary of positive opinion for Cuprymina","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/66275/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cuprymina_en.pdf"},
    {"id":"12632","name":"CVMP summary of positive opinion for Certifect","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CVMP/531077/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-certifect_en.pdf"},
    {"id":"12740","name":"CHMP summary of positive opinion for Vyndaqel","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/546201/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vyndaqel_en.pdf"},
    {"id":"12750","name":"CHMP summary of positive opinion for Voriconazole Hospira","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-03-27T01:00:00Z","reference_number":"EMA/CHMP/189813/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-voriconazole-hospira_en.pdf"},
    {"id":"12760","name":"CHMP summary of positive opinion for Evarrest","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2018-04-03T14:00:00Z","reference_number":"EMA/CHMP/385035/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-evarrest_en.pdf"},
    {"id":"12771","name":"CHMP summary of positive opinion Kolbam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2020-07-15T02:00:00Z","reference_number":"EMA/627629/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kolbam_en.pdf"},
    {"id":"12781","name":"CHMP summary of positive opinion for Nimenrix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/CHMP/70728/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nimenrix_en.pdf"},
    {"id":"12802","name":"CHMP summary of opinion for Neparvis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/204025/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-neparvis_en.pdf"},
    {"id":"12815","name":"CVMP summary of positive opinion for Zycortal","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-11T16:00:00Z","last_updated_date":"2015-09-11T16:00:00Z","reference_number":"EMA/CVMP/478464/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zycortal_en.pdf"},
    {"id":"12859","name":"CVMP summary of positive opinion for Bluevac BTV8","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-02-11T01:00:00Z","last_updated_date":"2011-02-11T01:00:00Z","reference_number":"EMA/CVMP/343772/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bluevac-btv8_en.pdf"},
    {"id":"12919","name":"CVMP summary of positive opinion for Bovela","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-10-10T02:00:00Z","last_updated_date":"2014-10-10T02:00:00Z","reference_number":"EMA/CVMP/575913/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bovela_en.pdf"},
    {"id":"12953","name":"CHMP summary of positive opinion for Repaglinide Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-04-27T02:00:00Z","last_updated_date":"2009-04-27T02:00:00Z","reference_number":"EMEA/CHMP/245770/2009 corr","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-repaglinide-teva_en.pdf"},
    {"id":"13003","name":"CHMP summary of positive opinion for Respreeza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/CHMP/76738/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-respreeza_en.pdf"},
    {"id":"13063","name":"CHMP summary of positive opinion for Yervoy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/384358/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yervoy_en.pdf"},
    {"id":"13088","name":"CHMP summary of positive opinion for Maviret","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"EMA/364961/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-maviret_en.pdf"},
    {"id":"13125","name":"CHMP summary of positive opinion for Pioglitazone ratio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/589801/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-ratio_en.pdf"},
    {"id":"13147","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for  Kiacta","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2007-12-13T00:09:00Z","last_updated_date":"2007-12-13T00:09:00Z","reference_number":"EMEA/566159/2007","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-kiacta_en.pdf"},
    {"id":"13177","name":"CHMP summary of positive opinion for Paliperidone Janssen","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/CHMP/605917/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-paliperidone-janssen_en.pdf"},
    {"id":"13218","name":"CVMP summary of positive opinion for Osurnia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/CVMP/290192/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-osurnia_en.pdf"},
    {"id":"13387","name":"CHMP summary of positive opinion for HyQvia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/CHMP/38042/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hyqvia_en.pdf"},
    {"id":"13394","name":"CHMP summary of positive opinion for Levodopa/Carbidopa/Entacapone Orion","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/456787/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-levodopacarbidopaentacapone-orion_en.pdf"},
    {"id":"13414","name":"CHMP summary of positive opinion for Irbesartan Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/456015/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-irbesartan-teva_en.pdf"},
    {"id":"13426","name":"CHMP summary of positive opinion for Nerlynx","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T14:00:00Z","last_updated_date":"2018-06-29T14:00:00Z","reference_number":"EMA/CHMP/433871/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nerlynx_en.pdf"},
    {"id":"13450","name":"CHMP summary of positive opinion for Prasugrel_Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"EMA/CHMP/50933/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-prasugrel_mylan_en.pdf"},
    {"id":"13479","name":"CHMP summary of positive opinion for Glyxambi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T14:00:00Z","last_updated_date":"2016-09-16T14:00:00Z","reference_number":"EMA/CHMP/595813/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-glyxambi_en.pdf"},
    {"id":"13481","name":"Committee for medicinal products for veterinary use summary of opinion: Leucofeligen FELV/RCP","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-03-13T00:09:21Z","last_updated_date":"2009-03-13T00:09:21Z","reference_number":"EMEA/CVMP/112548/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-leucofeligen-felv-rcp_en.pdf"},
    {"id":"13526","name":"CVMP summary of positive opinion for Equisolon","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-17T01:00:00Z","last_updated_date":"2014-01-17T01:00:00Z","reference_number":"EMA/CVMP/570503/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-equisolon_en.pdf"},
    {"id":"13528","name":"Committee for medicinal products for human use, summary of positive opinion for  Tadalafil Lilly","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/304729/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-tadalafil-lilly_en.pdf"},
    {"id":"13543","name":"CHMP summary of positive opinion for Imatinib Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/250071/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imatinib-accord_en.pdf"},
    {"id":"13561","name":"CHMP summary of positive opinion for Ristempa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2018-03-07T01:00:00Z","reference_number":"EMA/CHMP/83846/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ristempa_en.pdf"},
    {"id":"13570","name":"Committee for medicinal products for human use summary of positive opinion for Bridion","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:09:21Z","last_updated_date":"2008-05-30T02:09:21Z","reference_number":"EMEA/CHMP/246405/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-bridion_en.pdf"},
    {"id":"13607","name":"CVMP summary of positive opinion for Coliprotec F4/F18","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T01:00:00Z","last_updated_date":"2016-11-11T01:00:00Z","reference_number":"EMA/CVMP/700160/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-coliprotec-f4f18_en.pdf"},
    {"id":"13610","name":"CHMP summary of positive opinion for Atosiban SUN","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/CHMP/314586/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-atosiban-sun_en.pdf"},
    {"id":"13616","name":"CHMP summary of positive opinion for Holoclar","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/CHMP/737422/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-holoclar_en.pdf"},
    {"id":"13707","name":"CVMP summary of positive opinion for Cytopoint","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-02-17T01:00:00Z","last_updated_date":"2017-02-17T01:00:00Z","reference_number":"EMA/CVMP/44548/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-cytopoint_en.pdf"},
    {"id":"13708","name":"CHMP summary of positive opinion for Tasermity","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2018-03-27T02:00:00Z","reference_number":"EMA/CHMP/761518/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tasermity_en.pdf"},
    {"id":"13719","name":"Questions and answers on refusal of the marketing authorisation for Labazenit","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T01:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/177112/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit_en.pdf"},
    {"id":"13748","name":"CHMP summary of positive opinion for Venclyxto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2016-10-14T14:00:00Z","reference_number":"EMA/CHMP/561089/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-venclyxto_en.pdf"},
    {"id":"13761","name":"CHMP summary of positive opinion for Tadalafil Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/476904/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tadalafil-mylan_en.pdf"},
    {"id":"13785","name":"CHMP summary of positive opinion for Gazyvaro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/CHMP/280012/2014 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-gazyvaro_en.pdf"},
    {"id":"13839","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel Winthrop","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-05-06T02:00:00Z","last_updated_date":"2008-05-06T02:00:00Z","reference_number":"EMEA/CHMP/216044/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-winthrop_en.pdf"},
    {"id":"13846","name":"CHMP summary of positive opinion for Veyvondi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/CHMP/324506/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-veyvondi_en.pdf"},
    {"id":"13874","name":"Questions and answers on refusal of the marketing authorisation for Solumarv (insulin human)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/765377/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_sv.pdf"}},
    {"id":"13879","name":"Committee for medicinal products for human use summary of positive opinion for Ceplene","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:09:21Z","last_updated_date":"2008-07-24T02:09:21Z","reference_number":"EMEA/CHMP/398691/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-ceplene_en.pdf"},
    {"id":"13919","name":"CVMP summary of positive opinion for Ecoporc Shiga","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T01:00:00Z","last_updated_date":"2013-02-08T01:00:00Z","reference_number":"EMA/CVMP/15924/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-ecoporc-shiga_en.pdf"},
    {"id":"13939","name":"Committee for medicinal products for human use, summary of positive opinion for Rivastigmine Hexal","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/582930/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-rivastigmine-hexal_en.pdf"},
    {"id":"13999","name":"CVMP summary of opinion for Easotic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-09-19T03:09:00Z","last_updated_date":"2008-09-19T03:09:00Z","reference_number":"EMEA/CVMP/405937/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-opinion-easotic_en.pdf"},
    {"id":"14007","name":"Questions and answers on the refusal of the marketing authorisation for  Acrescent","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2013-03-11T13:30:00Z","reference_number":"EMA/CHMP/816079/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-acrescent_sv.pdf"}},
    {"id":"14037","name":"Committee for medicinal products for human use summary of positive opinion for Biopoin","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:09:21Z","last_updated_date":"2009-07-23T02:09:21Z","reference_number":"EMEA/CHMP/468645/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-biopoin_en.pdf"},
    {"id":"14079","name":"CHMP positive summary of opinion for Twynsta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2010-07-23T02:00:00Z","reference_number":"EMA/CHMP/423682/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-twynsta_en.pdf"},
    {"id":"14108","name":"CHMP summary of positive opinion for Voncento","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/CHMP/301621/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-voncento_en.pdf"},
    {"id":"14132","name":"Committee for medicinal products for human use summary of positive opinion for Biograstim","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-07-25T02:09:21Z","last_updated_date":"2017-01-19T01:09:21Z","reference_number":"EMEA/CHMP/371648/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-biograstim_en.pdf"},
    {"id":"14142","name":"CHMP summary of positive opinion for Erelzi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/236014/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-erelzi_en.pdf"},
    {"id":"14155","name":"CVMP summary of positive opinion for Canigen L4","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-05-08T18:00:00Z","last_updated_date":"2015-05-08T18:00:00Z","reference_number":"EMA/CVMP/259133/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-canigen-l4_en.pdf"},
    {"id":"14172","name":"CHMP summary of positive opinion for Aripiprazole Pharmathen","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/CHMP/227409/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aripiprazole-pharmathen_en.pdf"},
    {"id":"14186","name":"Committee for medicinal products for human use  summary of positive opinion  for Zypadhera","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-09-25T02:00:00Z","last_updated_date":"2008-09-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zypadhera_en.pdf"},
    {"id":"14220","name":"CHMP summary of positive opinion for Obizur","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/CHMP/471356/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-obizur_en.pdf"},
    {"id":"14240","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel DURA","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:09:21Z","last_updated_date":"2015-07-10T02:09:21Z","reference_number":"EMEA/CHMP/379512/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-dura_en.pdf"},
    {"id":"14257","name":"CHMP summary of positive opinion for Parsabiv","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T14:00:00Z","last_updated_date":"2016-09-16T14:00:00Z","reference_number":"EMA/CHMP/587633/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-parsabiv_en.pdf"},
    {"id":"14283","name":"CHMP summary of positive opinion for Clopidogrel Mylan Pharma","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/455323/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-clopidogrel-mylan-pharma_en.pdf"},
    {"id":"14342","name":"CVMP summary of positive opinion for Cimalgex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-10T01:00:00Z","last_updated_date":"2010-12-10T01:00:00Z","reference_number":"EMA/CVMP/498811/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-cimalgex_en.pdf"},
    {"id":"14437","name":"CHMP summary of positive opinion for Rolufta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"EMA/CHMP/39488/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rolufta_en.pdf"},
    {"id":"14532","name":"CHMP summary of positive opinion for Opsumit","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T14:00:00Z","last_updated_date":"2013-10-25T14:00:00Z","reference_number":"EMA/CHMP/590387/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-opsumit_en.pdf"},
    {"id":"14543","name":"CHMP summary of opinion for Qtern","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/271065/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-qtern_en.pdf"},
    {"id":"14569","name":"CHMP summary of positive opinion for Cinryze","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"EMA/CHMP/217963/201","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cinryze_en.pdf"},
    {"id":"14573","name":"CHMP positive summary of opinion for Nivestim","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"EMA/CHMP/117846/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-nivestim_en.pdf"},
    {"id":"14633","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Cerepro (sitimagene ceradenovec)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/828428/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-cerepro-sitimagene-ceradenovec_en.pdf"},
    {"id":"14761","name":"CHMP summary of positive opinion for Stelara","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/CHMP/582270/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-stelara_en.pdf"},
    {"id":"14832","name":"CVMP summary of positive opinion for Exzolt","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-06-16T02:00:00Z","last_updated_date":"2017-06-16T02:00:00Z","reference_number":"EMA/CVMP/268590/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-exzolt_en.pdf"},
    {"id":"14940","name":"CVMP summary of positive opinion for Versican Plus DHPPi/L4R","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-14T01:00:00Z","last_updated_date":"2014-03-14T01:00:00Z","reference_number":"EMA/CVMP/92024/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-versican-plus-dhppil4r_en.pdf"},
    {"id":"14965","name":"CHMP summary of positive opinion for Scenesse","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/CHMP/601448/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-scenesse_en.pdf"}    {"id":"14997","name":"CHMP summary of negative opinion for Yondelis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2003-11-20T01:00:00Z","last_updated_date":"2003-11-20T01:00:00Z","reference_number":"CPMP/5706/03","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-negative-opinion-yondelis_en.pdf"},
    {"id":"15018","name":"CHMP summary of positive opinion for Imatinib Teva B.V.","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2018-10-09T14:00:00Z","reference_number":"EMA/CHMP/600427/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imatinib-teva-bv_en.pdf"},
    {"id":"15021","name":"CHMP summary of positive opinion for Leflunomide Ratiopharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMA/CHMP/571131/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-leflunomide-ratiopharm_en.pdf"},
    {"id":"15034","name":"CHMP summary of positive opinion for Gardasil 9","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T13:00:00Z","last_updated_date":"2015-03-27T13:00:00Z","reference_number":"EMA/CHMP/76588/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-gardasil-9_en.pdf"},
    {"id":"15072","name":"CHMP summary of positive opinion for Methylthioninium chloride Proveblue","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-02-18T01:00:00Z","last_updated_date":"2011-02-18T01:00:00Z","reference_number":"EMA/CHMP/82326/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-methylthioninium-chloride-proveblue_en.pdf"},
    {"id":"15132","name":"CHMP summary of positive opinion for Brineura","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/CHMP/208415/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-brineura_en.pdf"},
    {"id":"15144","name":"CHMP summary of positive opinion for Axumin","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T13:00:00Z","last_updated_date":"2017-03-24T13:00:00Z","reference_number":"EMA/CHMP/144418/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-axumin_en.pdf"},
    {"id":"15199","name":"Committee for Medicinal Products for Human Use positive summary of opinion for Raloxifene Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2010-02-19T01:00:00Z","reference_number":"EMA/CHMP/74631/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-positive-summary-opinion-raloxifene-teva_en.pdf"},
    {"id":"15260","name":"CHMP summary of opinion for Coagadex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"EMA/CHMP/15062/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-coagadex_en.pdf"},
    {"id":"15263","name":"CHMP summary of positive opinion for Onpattro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T15:28:00Z","last_updated_date":"2018-07-27T15:28:00Z","reference_number":"EMA/CHMP/482444/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-onpattro_en.pdf"},
    {"id":"15290","name":"CVMP summary of positive opinion for Suvaxyn CSF Marker","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/CVMP/699011/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-suvaxyn-csf-marker_en.pdf"},
    {"id":"15295","name":"Questions and answers on refusal of the marketing authorisation for Glybera (alipogene tiparvovec)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T16:11:52Z","last_updated_date":"2012-04-20T16:11:52Z","reference_number":"EMA/261507/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-glybera-alipogene-tiparvovec_en.pdf"},
    {"id":"15300","name":"CHMP summary of positive opinion for Ibrance","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/CHMP/597497/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ibrance_en.pdf"},
    {"id":"15371","name":"CHMP summary of positive opinion for Pioglitazone Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/CHMP/559141/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-accord_en.pdf"},
    {"id":"15397","name":"CHMP summary of positive opinion for Afstyla","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2016-11-11T13:00:00Z","reference_number":"EMA/699392/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-afstyla_en.pdf"},
    {"id":"15426","name":"CHMP summary of positive opinion for Onduarp","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-24T00:00:00Z","last_updated_date":"2014-04-03T00:00:00Z","reference_number":"EMA/CHMP/690726/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-onduarp_en.pdf"},
    {"id":"15463","name":"CHMP summary of positive opinion for Descovy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-02-25T01:00:00Z","last_updated_date":"2016-02-25T01:00:00Z","reference_number":"EMA/CHMP/155866/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-descovy_en.pdf"},
    {"id":"15483","name":"CVMP summary of opinion for Respiporc Flu3","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-13T01:09:21Z","last_updated_date":"2009-11-13T01:09:21Z","reference_number":"EMEA/CVMP/661116/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-opinion-respiporc-flu3_en.pdf"},
    {"id":"15492","name":"CHMP summary of positive opinion for VeraSeal","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/CHMP/586635/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-veraseal_en.pdf"},
    {"id":"15544","name":"CHMP summary of positive opinion for Plenadren","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/553960/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-plenadren_en.pdf"},
    {"id":"15559","name":"CHMP summary of positive opinion for Skilarence","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T17:00:00Z","last_updated_date":"2017-04-21T17:00:00Z","reference_number":"EMA/CHMP/244798/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-skilarence_en.pdf"},
    {"id":"15575","name":"CHMP summary of positive opinion for Darunavir Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"EMA/CHMP/719729/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-darunavir-krka_en.pdf"},
    {"id":"15582","name":"CHMP summary of positive opinion for Amgevita","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T13:00:00Z","last_updated_date":"2017-01-27T13:00:00Z","reference_number":"EMA/CHMP/39045/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-amgevita_en.pdf"},
    {"id":"15619","name":"CHMP summary of positive opinion for Envarsus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/CHMP/277292/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-envarsus_en.pdf"},
    {"id":"15658","name":"CHMP summary of positive opinion for Vemlidy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T01:00:00Z","last_updated_date":"2016-11-11T01:00:00Z","reference_number":"EMA/704543/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vemlidy_en.pdf"},
    {"id":"15691","name":"Questions and answers on the recommendation for the refusal of a marketing authorisation application for Movectro: Outcome of re-examination","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/CHMP/51402/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-movectro-outcome-re-examination_en.pdf"},
    {"id":"15730","name":"Questions and answers on refusal of marketing authorisation for Translarna","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/36356/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-translarna_en.pdf"},
    {"id":"15782","name":"Committee for medicinal products for human use, summary of positive opinion for Lamivudine Teva Pharma B.V.","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/582879/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-lamivudine-teva-pharma-bv_en.pdf"},
    {"id":"15798","name":"Questions and answers on the refusal of the marketing authorisation for Folotyn","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/CHMP/32841/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn_en.pdf"},
    {"id":"15887","name":"CHMP summary of positive opinion for Forxiga","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2012-04-20T02:00:00Z","reference_number":"EMA/CHMP/259852/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-forxiga_en.pdf"},
    {"id":"15894","name":"CHMP summary of positive opinion for Enurev Breezhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T14:00:00Z","last_updated_date":"2012-08-07T13:25:00Z","reference_number":"EMA/CHMP/422796/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-enurev-breezhaler_en.pdf"},
    {"id":"15940","name":"Committee for medicinal products for human use, summary of positive opinion for  RoActemra","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/CHMP/580914/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-roactemra_en.pdf"},
    {"id":"16009","name":"Committee for medicinal products for human use summary of positive opinion for Exalief","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T00:09:21Z","last_updated_date":"2009-02-19T00:09:21Z","reference_number":"EMEA/CHMP/98344/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-exalief_en.pdf"},
    {"id":"16010","name":"CHMP summary of positive opinion for Duloxetine Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/CHMP/238545/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duloxetine-mylan_en.pdf"},
    {"id":"16060","name":"CHMP summary of positive opinion for Entecavir Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/CHMP/367264/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-entecavir-accord_en.pdf"},
    {"id":"16087","name":"CHMP summary of positive opinion for Desloratadine ratiopharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T01:00:00Z","last_updated_date":"2011-11-18T01:00:00Z","reference_number":"EMA/CHMP/614374/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-desloratadine-ratiopharm_en.pdf"},
    {"id":"16111","name":"CHMP summary of positive opinion for Levetiracetam Actavis Group","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/508585/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-levetiracetam-actavis-group_en.pdf"},
    {"id":"16174","name":"CVMP summary of positive opinion for Coxevac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2010-07-16T02:00:00Z","reference_number":"EMA/401721/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-coxevac_en.pdf"},
    {"id":"16332","name":"CHMP summary of positive opinion for Keytruda","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/298313/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-keytruda_en.pdf"},
    {"id":"16342","name":"CHMP summary of positive opinion for Sivextro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"EMA/CHMP/46218/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sivextro_en.pdf"},
    {"id":"16358","name":"CVMP summary of positive opinion for Recocam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-15T02:00:00Z","last_updated_date":"2011-07-15T02:00:00Z","reference_number":"EMA/CVMP/534720/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-recocam_en.pdf"},
    {"id":"16506","name":"Committee for medicinal products for veterinary use summary of opinion: Onisor: International Non-proprietary Name (INN): Robenacoxib","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-10-17T03:09:21Z","last_updated_date":"2008-10-17T03:09:21Z","reference_number":"EMEA/CVMP/508377/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-onisor-international-non-proprietary-name-inn-robenacoxib_en.pdf"},
    {"id":"16572","name":"CHMP summary of opinion for Rasagiline Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"EMA/CHMP/23731/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-rasagiline-mylan_en.pdf"},
    {"id":"16585","name":"CHMP summary of positive opinion for Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T17:37:00Z","last_updated_date":"2017-06-23T17:37:00Z","reference_number":"EMA/CHMP/387395/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-efavirenzemtricitabinetenofovir-disoproxil-mylan_en.pdf"},
    {"id":"16618","name":"CHMP summary of positive opinion for Pravafenix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/37551/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pravafenix_en.pdf"},
    {"id":"16678","name":"CHMP summary of positive opinion for Terrosa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2016-11-11T13:00:00Z","reference_number":"EMA/CHMP/714649/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-terrosa_en.pdf"},
    {"id":"16692","name":"CVMP summary of positive opinion for Kexxtone","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-11-09T16:30:00Z","last_updated_date":"2012-11-09T16:30:00Z","reference_number":"EMA/670976/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-kexxtone_en.pdf"},
    {"id":"16695","name":"CHMP summary of positive opinion for Ivabradine JensonR","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2018-12-20T02:00:00Z","reference_number":"EMA/CHMP/605096/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ivabradine-jensonr_en.pdf"},
    {"id":"16723","name":"CHMP summary of positive opinion for Benlysta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/296249/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-benlysta_en.pdf"},
    {"id":"16739","name":"CHMP summary of positive opinion for Gefitinib Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2024-10-17T14:00:00Z","reference_number":"EMA/489607/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-gefitinib-mylan_en.pdf"},
    {"id":"16750","name":"CHMP summary of positive opinion for Pemetrexed Sandoz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T14:00:00Z","last_updated_date":"2024-11-06T14:00:00Z","reference_number":"EMA/CHMP/470192/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pemetrexed-sandoz_en.pdf"},
    {"id":"16762","name":"CHMP summary of opinion for Alprolix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/CHMP/83216/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-alprolix_en.pdf"},
    {"id":"16788","name":"CHMP summary of positive opinion for Privigen","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/CHMP/97213/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-privigen_en.pdf"},
    {"id":"16928","name":"CVMP summary of positive opinion for BTVPUR AlSap 1","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-10-15T02:00:00Z","last_updated_date":"2018-05-17T02:00:00Z","reference_number":"EMA/CVMP/343642/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-btvpur-alsap-1_en.pdf"},
    {"id":"17035","name":"CHMP summary of positive opinion for Deltyba","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T13:00:00Z","last_updated_date":"2013-11-22T13:00:00Z","reference_number":"EMA/CHMP/713909/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-deltyba_en.pdf"},
    {"id":"17042","name":"CHMP summary of positive opinion for Jetrea","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2025-06-19T13:00:00Z","reference_number":"EMA/CHMP/5734/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jetrea_en.pdf"},
    {"id":"17068","name":"Committee for medicinal products for human use,  summary of positive opinion  for Viread","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-03-20T01:00:00Z","last_updated_date":"2008-03-20T01:00:00Z","reference_number":"EMEA/CHMP/146782/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-viread_en.pdf"},
    {"id":"17081","name":"CVMP summary of positive opinion for Versican Plus DHPPi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/CVMP/229798/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-versican-plus-dhppi_en.pdf"},
    {"id":"17092","name":"CHMP summary of positive opinion for Pantozol Control","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-02-18T01:00:00Z","last_updated_date":"2009-02-18T01:00:00Z","reference_number":"EMEA/CHMP/23494/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pantozol-control_en.pdf"},
    {"id":"17098","name":"CHMP positive summary of opinion for Ribavirin Three Rivers","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"EMA/CHMP/143985/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-ribavirin-three-rivers_en.pdf"},
    {"id":"17099","name":"CHMP summary of positive opinion for Dutrebis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2017-04-27T02:00:00Z","reference_number":"EMA/CHMP/38006/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dutrebis_en.pdf"},
    {"id":"17175","name":"CHMP summary of positive opinion for Jinarc","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-02-27T01:00:00Z","last_updated_date":"2015-02-27T01:00:00Z","reference_number":"EMA/CHMP/115318/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jinarc_en.pdf"},
    {"id":"17181","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Gemesis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-20T01:00:00Z","last_updated_date":"2009-11-20T01:00:00Z","reference_number":"EMEA/CHMP/730064/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-gemesis_sv.pdf"}},
    {"id":"17184","name":"CVMP summary of negative opinion for Longrange","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T18:00:00Z","last_updated_date":"2018-10-12T16:00:00Z","reference_number":"EMA/CVMP/686486/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-negative-opinion-longrange_en.pdf"},
    {"id":"17267","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel BMS","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-05-06T02:09:21Z","last_updated_date":"2008-05-06T02:09:21Z","reference_number":"EMEA/CHMP/191695/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-bms_en.pdf"},
    {"id":"17280","name":"CHMP summary of opinion for Tenofovir disoproxil Zentiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/CHMP/438736/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-tenofovir-disoproxil-zentiva_en.pdf"},
    {"id":"17327","name":"CHMP summary of positive opinion for Pregabalin Mylan Pharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2022-04-26T14:00:00Z","reference_number":"EMA/CHMP/236014/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-mylan-pharma_en.pdf"},
    {"id":"17349","name":"CHMP summary of positive opinion for Riximyo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/CHMP/76823/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-riximyo_en.pdf"},
    {"id":"17380","name":"CHMP summary of positive opinion Edistride","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/524152/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-edistride_en.pdf"},
    {"id":"17389","name":"CVMP summary of positive opinion for Zulvac SBV","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-12-12T01:00:00Z","last_updated_date":"2014-12-12T01:00:00Z","reference_number":"EMA/CVMP/699002/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zulvac-sbv_en.pdf"},
    {"id":"17391","name":"CHMP summary of positive opinion for Jylamvo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-02-01T01:00:00Z","reference_number":"EMA/CHMP/15894/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jylamvo_en.pdf"},
    {"id":"17403","name":"CHMP summary of positive opinion for Anagrelide Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/818102/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-anagrelide-mylan_en.pdf"},
    {"id":"17414","name":"CHMP summary of positive opinion for Rasilamlo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-02-17T12:10:00Z","last_updated_date":"2017-03-28T13:10:00Z","reference_number":"EMA/CHMP/124404/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rasilamlo_en.pdf"},
    {"id":"17435","name":"CHMP summary of positive opinion for Xiapex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2020-03-02T01:00:00Z","reference_number":"EMA/CHMP/773322/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xiapex_en.pdf"},
    {"id":"17513","name":"CVMP summary of positive opinion for Nexgard Spectra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-07T01:00:00Z","last_updated_date":"2014-11-07T01:00:00Z","reference_number":"EMA/CVMP/641766/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nexgard-spectra_en.pdf"},
    {"id":"17549","name":"CHMP summary of positive opinion for Latuda","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T13:00:00Z","last_updated_date":"2014-01-24T13:00:00Z","reference_number":"EMA/CHMP/26583/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-latuda_en.pdf"},
    {"id":"17582","name":"CHMP summary of positive opinion for Benepali","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/693863/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-benepali_en.pdf"},
    {"id":"17706","name":"CVMP summary of positive opinion for Semintra","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/CVMP/734548/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-semintra_en.pdf"},
    {"id":"17765","name":"CHMP summary of positive opinion for Lutathera","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/CHMP/437314/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lutathera_en.pdf"},
    {"id":"17789","name":"CHMP positive summary of opinion for Ruconest","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-06-25T02:00:00Z","reference_number":"EMA/CHMP/380794/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-ruconest_en.pdf"},
    {"id":"17835","name":"CHMP summary of positive opinion for Kanjinti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T10:33:00Z","last_updated_date":"2018-03-23T10:33:00Z","reference_number":"EMA/CHMP/22098/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kanjinti_en.pdf"},
    {"id":"17863","name":"CHMP summary of positive opinion for Aubagio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/379992/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aubagio_en.pdf"},
    {"id":"17952","name":"CHMP summary of positive opinion for Kadcyla","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/572965/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kadcyla_en.pdf"},
    {"id":"17960","name":"CHMP summary of positive opinion for Opdivo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/CHMP/76686/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-opdivo_en.pdf"},
    {"id":"18053","name":"CHMP summary of positive opinion for Bydureon","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/103509/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bydureon_en.pdf"},
    {"id":"18089","name":"Committee for medicinal products for human use, summary of positive opinion for Rivastigmine Sandoz","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/593097/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-rivastigmine-sandoz_en.pdf"},
    {"id":"18130","name":"CHMP summary of positive opinion for Capecitabine Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/CHMP/106696/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-capecitabine-accord_en.pdf"},
    {"id":"18133","name":"CHMP summary of positive opinion for Zydelig","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T14:00:00Z","last_updated_date":"2014-07-25T14:00:00Z","reference_number":"EMA/CHMP/338526/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zydelig_en.pdf"},
    {"id":"18194","name":"CHMP summary of positive opinion for Levetiracetam Hospira","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-10-25T14:00:00Z","last_updated_date":"2013-10-25T14:00:00Z","reference_number":"EMA/443446/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-levetiracetam-hospira_en.pdf"},
    {"id":"18260","name":"Committee for medicinal products for human use  summary of positive opinion  for Zopya","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-24T02:00:00Z","last_updated_date":"2009-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zopya_en.pdf"},
    {"id":"18305","name":"CHMP summary of opinion for Feraccru","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/765141/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-feraccru_en.pdf"},
    {"id":"18315","name":"CHMP summary of positive opinion for Vylaer Spiromax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/436529/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vylaer-spiromax_en.pdf"},
    {"id":"18322","name":"Committee for medicinal products for human use summary of positive opinion for Fertavid","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-01-22T00:09:00Z","last_updated_date":"2020-06-23T00:09:00Z","reference_number":"EMEA/CHMP/16455/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-fertavid_en.pdf"},
    {"id":"18351","name":"CHMP summary of positive opinion for Hyrimoz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/CHMP/241901/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hyrimoz_en.pdf"},
    {"id":"18353","name":"CHMP summary of positive opinion for Duoplavin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/831262/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duoplavin_en.pdf"},
    {"id":"18393","name":"CHMP summary of positive opinion for Xtandi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T02:00:00Z","last_updated_date":"2013-04-26T02:00:00Z","reference_number":"EMA/CHMP/231975/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xtandi_en.pdf"},
    {"id":"18444","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel ratiopharm","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/375222/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-ratiopharm_en.pdf"},
    {"id":"18480","name":"CHMP summary of positive opinion for Incivo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2016-10-06T02:00:00Z","reference_number":"EMA/CHMP/554705/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-incivo_en.pdf"},
    {"id":"18491","name":"CHMP summary of positive opinion for Viekirax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2024-10-02T13:00:00Z","reference_number":"EMA/CHMP/688255/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-viekirax_en.pdf"},
    {"id":"18498","name":"CHMP summary of positive opinion for Pioglitazone ratiopharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/573613/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-ratiopharm_en.pdf"}    {"id":"18523","name":"CHMP summary of positive opinion for Lenalidomide Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/CHMP/475938/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lenalidomide-accord_en.pdf"},
    {"id":"18545","name":"CVMP summary of positive opinion for Porcilis PCV ID","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-10T17:00:00Z","last_updated_date":"2015-07-10T17:00:00Z","reference_number":"EMA/CVMP/354782/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-porcilis-pcv-id_en.pdf"},
    {"id":"18588","name":"CHMP summary of positive opinion for Remsima","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/CHMP/363689/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-remsima_en.pdf"},
    {"id":"18595","name":"Questions and answers on the refusal of the marketing authorisation for Fanaptum (iloperidone)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"EMA/729957/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum-iloperidone_sv.pdf"}},
    {"id":"18598","name":"CHMP summary of positive opinion for Extavia","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-03-20T00:09:00Z","last_updated_date":"2025-04-30T00:09:00Z","reference_number":"EMEA/CHMP/138637/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-extavia_en.pdf"},
    {"id":"18619","name":"Questions and answers on the recommendation for the refusal of the marketing authorization for Genasense","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2007-10-31T01:00:00Z","last_updated_date":"2007-10-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-genasense_sv.pdf"}},
    {"id":"18651","name":"CHMP summary of positive opinion for Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMA/CHMP/597536/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics_en.pdf"},
    {"id":"18663","name":"Committee for medicinal products for human use summary of positive opinion for Duloxetine Boehringer Ingelheim","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/333730/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-duloxetine-boehringer-ingelheim_en.pdf"},
    {"id":"18666","name":"CHMP summary of positive opinion for Genvoya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T14:00:00Z","last_updated_date":"2015-09-25T14:00:00Z","reference_number":"EMA/628515/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-genvoya_en.pdf"},
    {"id":"18731","name":"CVMP summary of positive opinion for UBAC","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2018-05-28T18:00:00Z","last_updated_date":"2018-05-28T18:00:00Z","reference_number":"EMA/CVMP/273331/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-ubac_en.pdf"},
    {"id":"18861","name":"CHMP summary of positive opinion for Sovaldi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T13:00:00Z","last_updated_date":"2013-11-22T13:00:00Z","reference_number":"EMA/CHMP/687741/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sovaldi_en.pdf"},
    {"id":"18959","name":"CHMP summary of positive opinion for Elonva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/CHMP/362887/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-elonva_en.pdf"},
    {"id":"18962","name":"CHMP summary of positive opinion for Vibativ","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-05-19T13:00:00Z","last_updated_date":"2018-05-16T13:00:00Z","reference_number":"EMA/CHMP/399709/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vibativ_en.pdf"},
    {"id":"19006","name":"CHMP summary of positive opinion for Dasselta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/614045/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dasselta_en.pdf"},
    {"id":"19014","name":"Committee for medicinal products for human use summary of positive opinion for Copalia HCT","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/471503/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-copalia-hct_en.pdf"},
    {"id":"19033","name":"Committee for medicinal products for human use, summary of positive opinion for Intanza","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2018-09-04T02:00:00Z","reference_number":"EMEA/CHMP/642748/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-intanza_en.pdf"},
    {"id":"19071","name":"CHMP summary of positive opinion for Repaglinide Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T02:00:00Z","last_updated_date":"2011-10-21T02:00:00Z","reference_number":"EMA/CHMP/812168/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-repaglinide-accord_en.pdf"},
    {"id":"19100","name":"CVMP summary of positive opinion for Versican Plus DHPPi/L4","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-14T01:00:00Z","last_updated_date":"2014-03-14T01:00:00Z","reference_number":"EMA/CVMP/92026/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-versican-plus-dhppil4_en.pdf"},
    {"id":"19121","name":"CHMP summary of positive opinion for Nitisinone MendeliKABS","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2023-06-14T02:00:00Z","reference_number":"EMA/CHMP/368249/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nitisinone-mendelikabs_en.pdf"},
    {"id":"19127","name":"CVMP positive summary of opinion for Meloxoral","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-09-14T02:00:00Z","last_updated_date":"2010-09-14T02:00:00Z","reference_number":"EMA/CVMP/140266/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-positive-summary-opinion-meloxoral_en.pdf"},
    {"id":"19149","name":"CHMP summary of positive opinion for Entyvio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/CHMP/134524/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-entyvio_en.pdf"},
    {"id":"19234","name":"CHMP summary of positive opinion for Lunivia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-10-23T02:09:21Z","last_updated_date":"2008-10-23T02:09:21Z","reference_number":"EMEA/CHMP/546022/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lunivia_en.pdf"},
    {"id":"19260","name":"CHMP summary of positive opinion for Esbriet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/CHMP/820343/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-esbriet_en.pdf"},
    {"id":"19328","name":"CHMP positive summary of opinion for Clopidogrel Teva Generics B.V.","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/CHMP/455692/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-clopidogrel-teva-generics-bv_en.pdf"},
    {"id":"19425","name":"Questions and answers on the refusal of the marketing authorisation for Raxone","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-01-18T13:00:00Z","reference_number":"EMA/22262/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raxone_en.pdf"},
    {"id":"19442","name":"CHMP summary of positive opinion for Pioglitazone Actavis Group","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2022-10-17T01:00:00Z","reference_number":"EMA/CHMP/511503/2011 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-actavis-group_en.pdf"},
    {"id":"19451","name":"CHMP summary of positive opinion for Senshio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2014-11-21T13:00:00Z","reference_number":"EMA/CHMP/702486/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-senshio_en.pdf"},
    {"id":"19452","name":"CVMP summary of positive opinion for BTVPUR AlSap 1-8","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-10-15T02:00:00Z","last_updated_date":"2010-10-15T02:00:00Z","reference_number":"EMA/CVMP/343726/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-btvpur-alsap-1-8_en.pdf"},
    {"id":"19464","name":"CHMP summary of positive opinion for Cyramza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/552028/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cyramza_en.pdf"},
    {"id":"19528","name":"CHMP summary of positive opinion for Zinforo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CHMP/405738/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zinforo_en.pdf"},
    {"id":"19656","name":"CHMP summary of positive opinion for Alpivab","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2020-12-09T01:00:00Z","reference_number":"EMA/CHMP/97060/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-alpivab_en.pdf"},
    {"id":"19698","name":"Committee for medicinal products for human use, summary of positive opinion for Oprymea","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:00:00Z","last_updated_date":"2008-06-26T02:00:00Z","reference_number":"EMEA/CHMP/313494/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-oprymea_en.pdf"},
    {"id":"19710","name":"Committee for medicinal products for human use summary of positive opinion for Ellaone","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-03-20T00:09:21Z","last_updated_date":"2009-03-20T00:09:21Z","reference_number":"EMEA/CHMP/167750/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-ellaone_en.pdf"},
    {"id":"19802","name":"CHMP summary of positive opinion for Stayveer","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/CHMP/160010/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-stayveer_en.pdf"},
    {"id":"19858","name":"CHMP summary of positive opinion for Cotellic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T14:00:00Z","last_updated_date":"2015-09-25T14:00:00Z","reference_number":"EMA/CHMP/571584/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cotellic_en.pdf"},
    {"id":"19897","name":"CHMP summary of positive opinion for Glybera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"EMA/CHMP/472167/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-glybera_en.pdf"},
    {"id":"19997","name":"CHMP summary of positive opinion for Kevzara","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T19:00:00Z","last_updated_date":"2017-04-21T19:00:00Z","reference_number":"EMA/243800/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kevzara_en.pdf"},
    {"id":"20003","name":"CHMP summary of opinion for Ninlaro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/CHMP/603622/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-ninlaro_en.pdf"},
    {"id":"20012","name":"Committee for medicinal products for veterinary use summary of opinion: Loxicom: International Non-proprietary Name (INN): Meloxicam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-11-14T01:09:21Z","last_updated_date":"2008-11-14T01:09:21Z","reference_number":"EMEA/CVMP/573465/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-loxicom-international-non-proprietary-name-inn-meloxicam_en.pdf"},
    {"id":"20045","name":"CHMP summary of positive opinion for Trydonis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T13:00:00Z","last_updated_date":"2018-02-23T13:00:00Z","reference_number":"EMA/CHMP/59240/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trydonis_en.pdf"},
    {"id":"20133","name":"CHMP summary of positive opinion for Ipreziv","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/CHMP/737200/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ipreziv_en.pdf"},
    {"id":"20253","name":"Questions and answers on the refusal of the marketing authorisation for Sumatriptan Galpharm 50 mg tablets - Outcome of re-examination","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T01:00:00Z","last_updated_date":"2011-11-18T01:00:00Z","reference_number":"EMA/CHMP/896315/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sumatriptan-galpharm-50-mg-tablets-outcome-re-examination_sv.pdf"}},
    {"id":"20283","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:09:21Z","last_updated_date":"2009-05-29T02:09:21Z","reference_number":"EMEA/CHMP/305809/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-teva_en.pdf"},
    {"id":"20313","name":"Questions and answers on refusal of the marketing authorisation for Reasanz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-09-01T02:00:00Z","reference_number":"EMA/299385/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-reasanz_sv.pdf"}},
    {"id":"20317","name":"CVMP summary of positive opinion for Oncept IL-2","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-08T01:00:00Z","last_updated_date":"2013-03-08T01:00:00Z","reference_number":"EMA/CVMP/100985/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-oncept-il-2_en.pdf"},
    {"id":"20389","name":"CHMP summary of positive opinion for Dzuveo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-04-27T02:00:00Z","last_updated_date":"2018-04-27T02:00:00Z","reference_number":"EMA/CHMP/199029/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dzuveo_en.pdf"},
    {"id":"20423","name":"CHMP summary of positive opinion for Arepanrix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-01-22T01:00:00Z","last_updated_date":"2010-01-22T01:00:00Z","reference_number":"EMA/CHMP/30965/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-arepanrix_en.pdf"},
    {"id":"20444","name":"CHMP summary of positive opinion for Repatha","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/291871/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-repatha_en.pdf"},
    {"id":"20445","name":"CVMP summary of positive opinion for ProZinc","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-05-17T17:00:00Z","last_updated_date":"2013-05-17T17:00:00Z","reference_number":"EMA/CVMP/250455/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-prozinc_en.pdf"},
    {"id":"20459","name":"CHMP positive summary of opinion for Brinavess","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-06-25T02:00:00Z","reference_number":"EMA/392565/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-brinavess_en.pdf"},
    {"id":"20539","name":"CHMP summary of positive opinion for Capecitabine Medac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/502040/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-capecitabine-medac_en.pdf"},
    {"id":"20574","name":"CHMP summary of positive opinion for Rienso","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2015-07-13T02:00:00Z","reference_number":"EMA/CHMP/262205/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rienso_en.pdf"},
    {"id":"20587","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Zelnorm","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2007-10-23T01:09:00Z","last_updated_date":"2007-10-23T01:09:00Z","reference_number":"EMEA/CHMP/109088/2006","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_hu.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_sv.pdf"}},
    {"id":"20604","name":"CHMP summary of positive opinion for Voriconazole Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/151315/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-voriconazole-accord_en.pdf"},
    {"id":"20622","name":"CHMP summary of positive opinion for Mylotarg","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T13:00:00Z","last_updated_date":"2018-02-23T13:00:00Z","reference_number":"EMA/CHMP/85476/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mylotarg_en.pdf"},
    {"id":"20681","name":"CHMP summary of positive opinion for Ionsys","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T14:00:00Z","last_updated_date":"2018-11-06T14:00:00Z","reference_number":"EMA/CHMP/588247/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ionsys_en.pdf"},
    {"id":"20694","name":"Committee for medicinal products for human use,  summary of positive opinion  for Vimpat","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:00:00Z","last_updated_date":"2008-06-26T02:00:00Z","reference_number":"EMEA/CHMP/209605/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-vimpat_en.pdf"},
    {"id":"20732","name":"CHMP summary of opinion for Uptravi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/826224/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-uptravi_en.pdf"},
    {"id":"20742","name":"Committee for medicinal products for human use, summary of positive opinion for Opgenra","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-10-23T02:00:00Z","last_updated_date":"2016-07-14T02:00:00Z","reference_number":"EMEA/CHMP/558609/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-opgenra_en.pdf"},
    {"id":"20745","name":"CHMP summary of positive opinion for Xgeva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/383964/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xgeva_en.pdf"},
    {"id":"20772","name":"CHMP summary of positive opinion for Edarbi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/736839/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-edarbi_en.pdf"},
    {"id":"20780","name":"Questions and answers on the recommendation for the refusal of the marketing authorization for Rhucin","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-03-19T01:00:00Z","last_updated_date":"2008-03-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-rhucin_sv.pdf"}},
    {"id":"20788","name":"Questions and answers on refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-11-30T01:00:00Z","reference_number":"EMA/599030/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_sv.pdf"}},
    {"id":"20828","name":"Questions and answers on refusal of the marketing authorisation for Alsitek (masitinib)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-04-20T13:45:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/207380/2018 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-alsitek-masitinib_sv.pdf"}},
    {"id":"20915","name":"Questions and answers on the refusal of the marketing authorisation for Kynamro - Outcome of re-examination","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T01:00:00Z","last_updated_date":"2013-03-22T01:00:00Z","reference_number":"EMA/177547/2013  ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-outcome-re-examination_sv.pdf"}},
    {"id":"20936","name":"CHMP summary of positive opinion for Lamivudine/Zidovudine Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-11-19T01:00:00Z","last_updated_date":"2023-03-21T01:00:00Z","reference_number":"EMA/725978/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lamivudinezidovudine-teva_en.pdf"},
    {"id":"20946","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for  Cimzia  International non-proprietary name (INN): certolizumab pegol","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-03-20T00:09:00Z","last_updated_date":"2008-03-20T00:09:00Z","reference_number":"EMEA/CHMP/145497/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-cimzia-international-non-proprietary-name-inn-certolizumab-pegol_en.pdf"},
    {"id":"21016","name":"Committee for medicinal products for human use summary of positive opinion for Efient","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T00:09:21Z","last_updated_date":"2008-12-18T00:09:21Z","reference_number":"EMEA/CHMP/591490/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-efient_en.pdf"},
    {"id":"21029","name":"CHMP summary of positive opinion for Zinplava","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-23T01:00:00Z","last_updated_date":"2016-11-23T01:00:00Z","reference_number":"EMA/CHMP/714398/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zinplava_en.pdf"},
    {"id":"21046","name":"CHMP summary of positive opinion for Teysuno","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/CHMP/806039/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-teysuno_en.pdf"},
    {"id":"21063","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel HCS","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:09:21Z","last_updated_date":"2009-06-25T02:09:21Z","reference_number":"EMEA/CHMP/379509/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-hcs_en.pdf"},
    {"id":"21077","name":"Committee for medicinal products for human use summary of positive opinion for Eporatio","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:09:21Z","last_updated_date":"2009-07-23T02:09:21Z","reference_number":"EMEA/CHMP/469178/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-eporatio_en.pdf"},
    {"id":"21105","name":"CHMP summary of opinion for Iblias","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/CHMP/774757/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-iblias_en.pdf"},
    {"id":"21106","name":"CHMP summary of positive opinion for ImmunoGam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/831707/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-immunogam_en.pdf"},
    {"id":"21115","name":"CHMP summary of positive opinion for Invokana","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/564958/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-invokana_en.pdf"},
    {"id":"21171","name":"Committee for medicinal products for human use summary of positive opinion for Dafiro HCT","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/471511/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-dafiro-hct_en.pdf"},
    {"id":"21179","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for Cayston: International non-proprietary name (INN): aztreonam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-03-20T00:09:21Z","last_updated_date":"2009-03-20T00:09:21Z","reference_number":"EMEA/154142/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-cayston-international-non-proprietary-name-inn-aztreonam_en.pdf"},
    {"id":"21180","name":"CHMP summary of positive opinion for Vokanamet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T13:00:00Z","last_updated_date":"2014-04-02T12:10:00Z","reference_number":"EMA/CHMP/90545/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vokanamet_en.pdf"},
    {"id":"21184","name":"CHMP summary of positive opinion for Movymia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2016-11-11T13:00:00Z","reference_number":"EMA/CHMP/737990/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-movymia_en.pdf"},
    {"id":"21208","name":"CVMP summary of positive opinion for Suvaxyn Circo + MH RTU","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-11T16:00:00Z","last_updated_date":"2015-09-11T16:00:00Z","reference_number":"EMA/CVMP/511548/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-suvaxyn-circo-mh-rtu_en.pdf"},
    {"id":"21232","name":"CHMP summary of positive opinion for Mycamine","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/CHMP/366318/2007","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mycamine_en.pdf"},
    {"id":"21277","name":"CHMP summary of positive opinion for Jevtana","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/26276/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jevtana_en.pdf"},
    {"id":"21283","name":"CHMP summary of positive opinion for Emtricitabine/Tenofovir disoproxil Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"EMA/CHMP/659472/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-emtricitabinetenofovir-disoproxil-mylan_en.pdf"},
    {"id":"21420","name":"CHMP summary of opinion for Kanuma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/CHMP/359213/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-kanuma_en.pdf"},
    {"id":"21476","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for Ramelteon","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-06-02T02:09:21Z","last_updated_date":"2008-06-02T02:09:21Z","reference_number":"EMEA/CHMP/268216/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-ramelteon_en.pdf"},
    {"id":"21541","name":"CVMP summary of positive opinion for Zulvac 1+8 Bovis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-13T01:00:00Z","last_updated_date":"2011-01-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zulvac-18-bovis_en.pdf"},
    {"id":"21566","name":"CHMP summary of positive opinion for Emtricitabine/Tenofovir disoproxil Krka d.d.","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2017-02-24T01:00:00Z","reference_number":"EMA/CHMP/75449/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-emtricitabinetenofovir-disoproxil-krka-dd_en.pdf"},
    {"id":"21614","name":"CHMP positive summary of opinion for Clopidogrel HCS","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2010-07-23T02:00:00Z","reference_number":"EMA/CHMP/442453/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-clopidogrel-hcs_en.pdf"},
    {"id":"21653","name":"CHMP summary of opinion for Aerivio Spiromax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2020-01-15T02:00:00Z","reference_number":"EMA/CHMP/431214/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-aerivio-spiromax_en.pdf"},
    {"id":"21683","name":"CVMP summary of opinion for Zulvac 8 Ovis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-13T01:09:21Z","last_updated_date":"2009-11-13T01:09:21Z","reference_number":"EMEA/CVMP/665795/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-opinion-zulvac-8-ovis_en.pdf"},
    {"id":"21755","name":"Questions and answers on the refusal of the marketing authorisation for Fanaptum","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/793402/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-fanaptum_en.pdf"},
    {"id":"21781","name":"CHMP summary of positive opinion for Menveo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/796967/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-menveo_en.pdf"},
    {"id":"21789","name":"CVMP summary of positive opinion for Procox","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-02-11T01:00:00Z","last_updated_date":"2011-02-11T01:00:00Z","reference_number":"EMA/CVMP/533373/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-procox_en.pdf"},
    {"id":"21811","name":"CHMP summary of positive opinion for Eylea","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/299413/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eylea_en.pdf"},
    {"id":"21898","name":"CHMP summary of positive opinion for Simbrinza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/CHMP/276487/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-simbrinza_en.pdf"},
    {"id":"21916","name":"CVMP summary of positive opinion for Eryseng Parvo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/CVMP/158893/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-eryseng-parvo_en.pdf"},
    {"id":"21920","name":"Questions and answers on refusal of the marketing authorisation for Eladynos (abaloparatide)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/504599/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_sv.pdf"}},
    {"id":"21935","name":"CHMP summary of positive opinion for Neuraceq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/CHMP/772521/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-neuraceq_en.pdf"},
    {"id":"21983","name":"CHMP summary of positive opinion for Xigduo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T13:00:00Z","last_updated_date":"2013-11-22T13:00:00Z","reference_number":"EMA/CHMP/703245/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xigduo_en.pdf"},
    {"id":"22005","name":"CHMP summary of positive opinion for Ozempic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/CHMP/726991/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ozempic_en.pdf"}    {"id":"22019","name":"CVMP summary of opinion for Equioxx","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-05-16T03:09:00Z","last_updated_date":"2008-05-16T03:09:00Z","reference_number":"EMEA/CVMP/218393/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-opinion-equioxx_en.pdf"},
    {"id":"22026","name":"CHMP summary of positive opinion Numient","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/519889/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-numient_en.pdf"},
    {"id":"22131","name":"CHMP summary of positive opinion for Tivicay","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2013-11-22T01:00:00Z","reference_number":"EMA/CHMP/636968/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tivicay_en.pdf"},
    {"id":"22134","name":"CHMP summary of positive opinion for Strensiq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-25T14:00:00Z","last_updated_date":"2015-06-25T14:00:00Z","reference_number":"EMA/CHMP/383497/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-strensiq_en.pdf"},
    {"id":"22165","name":"CHMP summary of positive opinion for Nyxoid","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/CHMP/594248/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nyxoid_en.pdf"},
    {"id":"22177","name":"CVMP summary of positive opinion for Eravac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-07-15T17:00:00Z","last_updated_date":"2016-07-15T17:00:00Z","reference_number":"EMA/CVMP/410201/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-eravac_en.pdf"},
    {"id":"22328","name":"Questions and answers on the refusal of the marketing authorisation for Istodax (romidepsin)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"EMA/475603/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin_en.pdf"},
    {"id":"22375","name":"CVMP summary of positive opinion for Zulvac 1 Bovis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-10T02:00:00Z","last_updated_date":"2020-03-30T02:00:00Z","reference_number":"EMA/CVMP/506555/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zulvac-1-bovis_en.pdf"},
    {"id":"22383","name":"CHMP summary of opinion for Wakix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T13:00:00Z","last_updated_date":"2015-11-20T13:00:00Z","reference_number":"EMA/CHMP/759419/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-wakix_en.pdf"},
    {"id":"22436","name":"CHMP summary of positive opinion for Ocaliva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2025-01-20T14:00:00Z","reference_number":"EMA/CHMP/651446/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ocaliva_en.pdf"},
    {"id":"22531","name":"CHMP summary of positive opinion for Bronchitol","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T02:00:00Z","last_updated_date":"2011-10-21T02:00:00Z","reference_number":"EMA/CHMP/837842/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bronchitol_en.pdf"},
    {"id":"22547","name":"CHMP summary of positive opinion for Topotecan Hospira","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"EMA/CHMP/43325/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-topotecan-hospira_en.pdf"},
    {"id":"22555","name":"CHMP summary of opinion for Palonosetron Hospira","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2022-04-08T01:00:00Z","reference_number":"EMA/CHMP/131135/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-palonosetron-hospira_en.pdf"},
    {"id":"22589","name":"CHMP summary of positive opinion for Zoledronic acid Teva Pharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T13:00:00Z","last_updated_date":"2018-12-12T13:00:00Z","reference_number":"EMA/176371/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zoledronic-acid-teva-pharma_en.pdf"},
    {"id":"22700","name":"CVMP summary of positive opinion for Activyl","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-10T01:00:00Z","last_updated_date":"2024-06-17T01:00:00Z","reference_number":"EMA/CVMP/528765/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-activyl_en.pdf"},
    {"id":"22839","name":"CHMP summary of positive opinion for Ristaben","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/771751/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ristaben_en.pdf"},
    {"id":"22841","name":"CHMP summary of positive opinion for Sabervel","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/CHMP/101946/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sabervel_en.pdf"},
    {"id":"22874","name":"Committee for medicinal products for human use summary of positive opinion for Effentora","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T01:00:00Z","last_updated_date":"2008-01-24T01:00:00Z","reference_number":"EMEA/34716/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-effentora_en.pdf"},
    {"id":"22923","name":"Committee for Medicinal Products for Human Use positive summary of opinion for Humenza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2011-06-30T02:00:00Z","reference_number":"EMA/CHMP/31616/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-positive-summary-opinion-humenza_en.pdf"},
    {"id":"22927","name":"CHMP summary of positive opinion for Duavive","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T14:00:00Z","last_updated_date":"2014-10-24T14:00:00Z","reference_number":"EMA/CHMP/654571/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duavive_en.pdf"},
    {"id":"23000","name":"CVMP summary of positive opinion for RESPIPORC FLUpan H1N1","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/CVMP/154135/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-respiporc-flupan-h1n1_en.pdf"},
    {"id":"23013","name":"CHMP summary of positive opinion for Cerdelga","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2014-11-21T01:00:00Z","reference_number":"EMA/CHMP/687220/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cerdelga_en.pdf"},
    {"id":"23049","name":"CHMP summary of positive opinion for Levetiracetam ratiopharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-05-20T02:00:00Z","last_updated_date":"2011-05-20T02:00:00Z","reference_number":"EMA/CHMP/373851/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-levetiracetam-ratiopharm_en.pdf"},
    {"id":"23149","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Glybera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/474562/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-glybera_en.pdf"},
    {"id":"23197","name":"CHMP summary of positive opinion for Febuxostat Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/221561/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-febuxostat-mylan_en.pdf"},
    {"id":"23261","name":"CHMP summary of positive opinion for Shingrix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/811150/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-shingrix_en.pdf"},
    {"id":"23281","name":"CHMP summary of positive opinion for Pregabalin Sandoz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/CHMP/242142/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-sandoz_en.pdf"},
    {"id":"23328","name":"CHMP summary of positive opinion for Levetiracetam Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/551332/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-levetiracetam-accord_en.pdf"},
    {"id":"23352","name":"Committee for medicinal products for human use, summary of positive opinion for Mozobil","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/CHMP/307173/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-mozobil_en.pdf"},
    {"id":"23368","name":"Questions and answers on the recommendation for the refusal of the  marketing authorisation for Nenad","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/CHMP/726734/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-nenad_en.pdf"},
    {"id":"23418","name":"CHMP summary of positive opinion for Oslif Breezhaler","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/592262/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-oslif-breezhaler_en.pdf"},
    {"id":"23453","name":"CHMP summary of positive opinion for Ioa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2014-08-28T02:00:00Z","reference_number":"EMA/CHMP/195954/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ioa_en.pdf"},
    {"id":"23462","name":"CHMP summary of positive opinion for Ontruzant","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/CHMP/532508/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ontruzant_en.pdf"},
    {"id":"23512","name":"CHMP summary of opinion for Vaxelis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-12-17T01:00:00Z","last_updated_date":"2015-12-17T01:00:00Z","reference_number":"EMA/CHMP/777080/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-vaxelis_en.pdf"},
    {"id":"23561","name":"CHMP summary of positive opinion for Vyxeos","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T14:00:00Z","last_updated_date":"2018-06-29T14:00:00Z","reference_number":"EMA/CHMP/239619/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vyxeos_en.pdf"},
    {"id":"23736","name":"CHMP summary of positive opinion for Erivedge","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/CHMP/263262/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-erivedge_en.pdf"},
    {"id":"23749","name":"CHMP summary of positive opinion for Triumeq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/373218/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-triumeq_en.pdf"},
    {"id":"23810","name":"CHMP summary of opinion for Galafold","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/220589/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-galafold_en.pdf"},
    {"id":"23814","name":"Committee for medicinal products for veterinary use summary of opinion: Leucogen","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-03-13T00:09:21Z","last_updated_date":"2009-03-13T00:09:21Z","reference_number":"EMEA/CVMP/112551/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-leucogen_en.pdf"},
    {"id":"23861","name":"CHMP summary of positive opinion for Valdoxan","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-valdoxan_en.pdf"},
    {"id":"23864","name":"CHMP summary of positive opinion Pemetrexed Hospira","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/574156/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pemetrexed-hospira_en.pdf"},
    {"id":"23885","name":"Committee for medicinal products for human use, summary of positive opinion for Topotecan Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/383983/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-topotecan-teva_en.pdf"},
    {"id":"23888","name":"CHMP summary of positive opinion for Lusduna","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2019-01-22T13:00:00Z","reference_number":"EMA/CHMP/706807/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lusduna_en.pdf"},
    {"id":"23901","name":"CHMP summary of positive opinion for Levetiracetam Actavis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/508445/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-levetiracetam-actavis_en.pdf"},
    {"id":"23914","name":"CVMP summary of positive opinion for Bravecto Plus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-03-16T01:00:00Z","last_updated_date":"2018-03-16T01:00:00Z","reference_number":"EMA/CVMP/35302/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bravecto-plus_en.pdf"},
    {"id":"23980","name":"CHMP summary of positive opinion for Grepid","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/CHMP/310253/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-grepid_en.pdf"},
    {"id":"23983","name":"CHMP summary of positive opinion for Selincro","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-17T15:05:00Z","reference_number":"EMEA/CHMP/805882/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-selincro_en.pdf"},
    {"id":"24050","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel Krka","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:09:21Z","last_updated_date":"2009-06-25T02:09:21Z","reference_number":"EMEA/CHMP/372866/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-krka_en.pdf"},
    {"id":"24134","name":"CHMP summary of positive opinion for Quinsair","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/CHMP/676678/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-quinsair_en.pdf"},
    {"id":"24271","name":"CHMP summary of positive opinion for Hulio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/CHMP/481798/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hulio_en.pdf"},
    {"id":"24297","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for Ceplene","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-03-19T01:00:00Z","last_updated_date":"2008-03-19T01:00:00Z","reference_number":"EMEA/CHMP/125792/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-ceplene_en.pdf"},
    {"id":"24299","name":"CVMP summary of positive opinion for Coliprotec F4","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2015-01-16T01:00:00Z","reference_number":"EMA/CVMP/742823/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-coliprotec-f4_en.pdf"},
    {"id":"24300","name":"CHMP summary of positive opinion for Ivabradine Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/CHMP/146036/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ivabradine-accord_en.pdf"},
    {"id":"24305","name":"CHMP summary of positive opinion for Xoterna Breezhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/CHMP/457182/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xoterna-breezhaler_en.pdf"},
    {"id":"24459","name":"Committee for medicinal products for human use, summary of positive opinion for Sildenafil Actavis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/440521/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-sildenafil-actavis_en.pdf"},
    {"id":"24515","name":"CHMP summary of positive opinion for Giotrif","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/CHMP/447957/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-giotrif_en.pdf"},
    {"id":"24523","name":"CHMP summary of positive opinion for Rasitrio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/746483/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rasitrio_en.pdf"},
    {"id":"24623","name":"Committee for medicinal products for human use, summary of positive opinion for Pramipexole Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-10-23T02:00:00Z","last_updated_date":"2008-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-pramipexole-teva_en.pdf"},
    {"id":"24628","name":"CHMP summary of positive opinion for Alecensa","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-alecensa_en.pdf"},
    {"id":"24629","name":"CHMP summary of positive opinion for Trobalt","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2018-11-19T02:00:00Z","reference_number":"EMA/31145/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trobalt_en.pdf"},
    {"id":"24636","name":"CHMP summary of positive opinion for Zalviso","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T14:00:00Z","last_updated_date":"2022-09-27T11:28:00Z","reference_number":"EMA/CHMP/471000/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zalviso_en.pdf"},
    {"id":"24847","name":"Committee for medicinal products for human use summary of positive opinion for Conbriza","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"EMEA/CHMP/661136/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-conbriza_en.pdf"},
    {"id":"24915","name":"CHMP summary of positive opinion for Onivyde","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/478619/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-onivyde_en.pdf"},
    {"id":"24922","name":"CHMP summary of positive opinion for Laventair","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/CHMP/89644/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-laventair_en.pdf"},
    {"id":"25032","name":"CHMP summary of positive opinion for Vizamyl","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/326770/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vizamyl_en.pdf"},
    {"id":"25076","name":"CHMP summary of positive opinion for Lojuxta","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/327261/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lojuxta_en.pdf"},
    {"id":"25129","name":"CHMP summary of positive opinion for Trimbow","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-05-23T02:00:00Z","reference_number":"EMA/CHMP/290028/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trimbow_en.pdf"},
    {"id":"25183","name":"CHMP summary of positive opinion for Izba","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T01:00:00Z","last_updated_date":"2013-12-20T01:00:00Z","reference_number":"EMA/CHMP/592024/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-izba_en.pdf"},
    {"id":"25211","name":"CHMP summary of positive opinion for Yellox","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"EMA/CHMP/87152/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yellox_en.pdf"},
    {"id":"25213","name":"CHMP summary of positive opinion for Tybost","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/CHMP/413499/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tybost_en.pdf"},
    {"id":"25218","name":"CVMP summary of positive opinion for Meloxidolor","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-02-08T01:00:00Z","last_updated_date":"2013-02-08T01:00:00Z","reference_number":"EMA/CVMP/33458/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-meloxidolor_en.pdf"},
    {"id":"25353","name":"CHMP summary of positive opinion for Rixathon","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T19:00:00Z","last_updated_date":"2017-04-21T19:00:00Z","reference_number":"EMA/CHMP/76832/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rixathon_en.pdf"},
    {"id":"25384","name":"CHMP summary of positive opinion for Adcetris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"EMA/CHMP/471107/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-adcetris_en.pdf"},
    {"id":"25398","name":"CHMP summary of positive opinion for Tafinlar","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/CHMP/339899/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tafinlar_en.pdf"},
    {"id":"25407","name":"CHMP summary of positive opinion for Deferiprone Lipomed","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-25T17:16:00Z","last_updated_date":"2018-07-25T17:16:00Z","reference_number":"EMA/CHMP/432508/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-deferiprone-lipomed_en.pdf"},
    {"id":"25414","name":"CHMP summary of positive opinion for Bortezomib Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T14:00:00Z","last_updated_date":"2015-05-22T14:00:00Z","reference_number":"EMA/CHMP/288307/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bortezomib-accord_en.pdf"},
    {"id":"25465","name":"CHMP summary of positive opinion for Miglustat Gen.Orph","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/CHMP/537471/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-miglustat-genorph_en.pdf"},
    {"id":"25483","name":"CHMP summary of positive opinion for Docetaxel Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T01:00:00Z","last_updated_date":"2015-03-12T01:00:00Z","reference_number":"EMA/CHMP/858298/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-docetaxel-mylan_en.pdf"},
    {"id":"25494","name":"CHMP summary of positive opinion for Reagila","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T18:56:00Z","last_updated_date":"2017-05-19T18:56:00Z","reference_number":"EMA/309096/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-reagila_en.pdf"},
    {"id":"25554","name":"CHMP summary of positive opinion for Tenofovir disoproxil Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"EMA/CHMP/659525/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tenofovir-disoproxil-mylan_en.pdf"},
    {"id":"25584","name":"CHMP summary of opinion for Neofordex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2015-12-18T01:00:00Z","reference_number":"EMA/CHMP/558150/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-neofordex_en.pdf"},
    {"id":"25596","name":"CVMP summary of positive opinion for Simparica","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-11T16:00:00Z","last_updated_date":"2015-09-15T18:20:00Z","reference_number":"EMA/CVMP/478463/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-simparica_en.pdf"},
    {"id":"25659","name":"CVMP summary of positive opinion for Posatex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-04-18T03:09:21Z","last_updated_date":"2008-04-18T03:09:21Z","reference_number":"EMEA/CVMP/163193/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-posatex_en.pdf"},
    {"id":"25668","name":"CVMP summary of positive opinion for Broadline","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"EMA/CVMP/575422/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-broadline_en.pdf"},
    {"id":"25762","name":"CHMP summary of positive opinion for Synjardy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-03-27T13:00:00Z","last_updated_date":"2015-03-27T13:00:00Z","reference_number":"EMA/CHMP/190945/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-synjardy_en.pdf"},
    {"id":"25797","name":"CHMP summary of positive opinion for Temozolomide Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/CHMP/567027/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-temozolomide-teva_en.pdf"},
    {"id":"25847","name":"CHMP summary of opinion for Zavicefta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/CHMP/266959/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-zavicefta_en.pdf"},
    {"id":"25887","name":"CVMP summary of positive opinion for Sileo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-13T17:30:00Z","last_updated_date":"2015-04-13T17:30:00Z","reference_number":"EMA/CVMP/123810/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-sileo_en.pdf"},
    {"id":"25962","name":"CHMP summary of positive opinion for Mvasi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"EMA/708111/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mvasi_en.pdf"},
    {"id":"25981","name":"Committee for medicinal products for veterinary use summary of opinion: Duvaxyn WNV: International Non-proprietary Name (INN): Vaccine to aid in prevention of West Nile virus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-09-19T03:09:21Z","last_updated_date":"2008-09-19T03:09:21Z","reference_number":"EMEA/CVMP/425966/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-duvaxyn-wnv-international-non-proprietary-name-inn-vaccine-aid-prevention-west-nile-virus_en.pdf"},
    {"id":"26010","name":"CHMP summary of positive opinion for Lixiana","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/CHMP/239353/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lixiana_en.pdf"},
    {"id":"26033","name":"Committee for Medicinal products for Human use positive summary of opinion for Docefrez","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2012-06-14T02:00:00Z","reference_number":"EMA/CHMP/54045/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-positive-summary-opinion-docefrez_en.pdf"},
    {"id":"26105","name":"Committee for medicinal products for veterinary use summary of opinion: Palladia: International Non-proprietary Names (INN): Toceranib","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-06-19T03:09:21Z","last_updated_date":"2009-06-19T03:09:21Z","reference_number":"EMEA/CVMP/319738/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-palladia-international-non-proprietary-names-inn-toceranib_en.pdf"},
    {"id":"26107","name":"CVMP summary of positive opinion for NexGard","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-12-13T17:00:00Z","last_updated_date":"2013-12-13T17:00:00Z","reference_number":"EMA/CVMP/700673/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nexgard_en.pdf"},
    {"id":"26244","name":"CHMP summary of positive opinion for Docetaxel Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2021-12-14T01:00:00Z","reference_number":"EMEA/CHMP/726960/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-docetaxel-teva_en.pdf"},
    {"id":"26441","name":"CHMP summary of positive opinion for Capecitabine SUN","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T02:00:00Z","last_updated_date":"2016-12-22T01:00:00Z","reference_number":"EMA/CHMP/138360/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-capecitabine-sun_en.pdf"},
    {"id":"26457","name":"CHMP summary of positive opinion for Xultophy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-07-25T02:00:00Z","reference_number":"EMA/CHMP/424921/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xultophy_en.pdf"},
    {"id":"26472","name":"CHMP summary of positive opinion for Docetaxel Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-03-16T01:00:00Z","last_updated_date":"2012-03-16T01:00:00Z","reference_number":"EMA/CHMP/134774/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-docetaxel-accord_en.pdf"},
    {"id":"26487","name":"CHMP summary of positive opinion for Besponsa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/CHMP/245560/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-besponsa_en.pdf"},
    {"id":"26515","name":"CHMP summary of positive opinion for Clopidogrel TAD","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/379482/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-clopidogrel-tad_en.pdf"}    {"id":"26522","name":"CVMP summary of positive opinion for Arti-Cell Forte","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T18:00:00Z","last_updated_date":"2018-06-22T18:00:00Z","reference_number":"EMA/CVMP/332343/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-arti-cell-forte_en.pdf"},
    {"id":"26680","name":"CHMP summary of positive opinion for Votubia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/477609/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-votubia_en.pdf"},
    {"id":"26770","name":"CVMP summary of positive opinion for Apoquel","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T02:00:00Z","last_updated_date":"2013-07-19T02:00:00Z","reference_number":"EMA/CVMP/322909/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-apoquel_en.pdf"},
    {"id":"26773","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for  Rhucin","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2007-12-13T01:00:00Z","last_updated_date":"2007-12-13T01:00:00Z","reference_number":"EMEA/567761/2007","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-rhucin_en.pdf-0"},
    {"id":"26824","name":"CHMP positive summary of opinion for Myclausen","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2010-07-23T02:00:00Z","reference_number":"EMA/CHMP/439259/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-myclausen_en.pdf"},
    {"id":"26865","name":"CHMP summary of positive opinion for Veltassa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T19:14:00Z","last_updated_date":"2017-05-19T19:14:00Z","reference_number":"EMA/CHMP/293038/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-veltassa_en.pdf"},
    {"id":"26898","name":"Committee for medicinal products for human use, summary of positive opinion for Intelence","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-06-26T02:00:00Z","last_updated_date":"2008-06-26T02:00:00Z","reference_number":"EMEA/CHMP/44000/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-intelence_en.pdf"},
    {"id":"26924","name":"CVMP summary of positive opinion for Oxybee","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T17:30:00Z","last_updated_date":"2017-09-08T17:30:00Z","reference_number":"EMA/CVMP/499119/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-oxybee_en.pdf"},
    {"id":"26952","name":"CHMP positive summary of opinion for Olanzapine Apotex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"EMA/148993/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-olanzapine-apotex_en.pdf"},
    {"id":"26964","name":"Committee for medicinal products for veterinary use summary of opinion: Gripovac 3: International Non-proprietary Names (INN): Inactivated vaccine against swine influenza in pigs","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-13T01:09:21Z","last_updated_date":"2018-09-04T16:30:00Z","reference_number":"EMEA/CVMP/661084/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-gripovac-3-international-non-proprietary-names-inn-inactivated-vaccine-against-swine-influenza-pigs_en.pdf"},
    {"id":"26998","name":"CHMP summary of positive opinion for Fotivda","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T14:00:00Z","last_updated_date":"2017-06-23T14:00:00Z","reference_number":"EMA/CHMP/333095/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fotivda_en.pdf"},
    {"id":"27084","name":"CHMP summary of positive opinion for Tovanor Breezhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T14:00:00Z","last_updated_date":"2012-08-07T13:25:00Z","reference_number":"EMA/CHMP/422793/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tovanor-breezhaler_en.pdf"},
    {"id":"27127","name":"CHMP summary of positive opinion for Cinqaero","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/403687/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cinqaero_en.pdf"},
    {"id":"27148","name":"CHMP summary of positive opinion for Lemtrada","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2013-06-28T14:00:00Z","reference_number":"EMA/377379/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lemtrada_en.pdf"},
    {"id":"27177","name":"CHMP summary of positive opinion for Nemdatine","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/CHMP/82387/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nemdatine_en.pdf"},
    {"id":"27234","name":"CHMP summary of positive opinion for Trumenba","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T13:00:00Z","last_updated_date":"2017-03-24T13:00:00Z","reference_number":"EMA/152667/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trumenba_en.pdf"},
    {"id":"27289","name":"CHMP summary of positive opinion for Ultibro Breezhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/CHMP/347765/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ultibro-breezhaler_en.pdf"},
    {"id":"27298","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel Mylan","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/379519/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-mylan_en.pdf"},
    {"id":"27568","name":"CHMP summary of positive opinion for Clopidogrel Sandoz","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/376597/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-clopidogrel-sandoz_en.pdf"},
    {"id":"27570","name":"CHMP summary of positive opinion for Praluent","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/CHMP/392428/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-praluent_en.pdf"},
    {"id":"27581","name":"CHMP summary of positive opinion for Zelboraf","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-12-16T01:00:00Z","last_updated_date":"2011-12-16T01:00:00Z","reference_number":"EMA/CHMP/926998/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zelboraf_en.pdf"},
    {"id":"27591","name":"CHMP summary of positive opinion for Riarify","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T13:00:00Z","last_updated_date":"2025-03-18T11:18:00Z","reference_number":"EMA/CHMP/109090/2018 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-riarify_en.pdf"},
    {"id":"27637","name":"Committee for medicinal products for human use summary of positive opinion  for Afinitor","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/CHMP/269077/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-afinitor_en.pdf"},
    {"id":"27638","name":"CHMP summary of positive opinion for Pregabalin Sandoz GmbH","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2023-10-12T02:00:00Z","reference_number":"EMA/CHMP/244649/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-sandoz-gmbh_en.pdf"},
    {"id":"27747","name":"CHMP summary of positive opinion for Revestive","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CHMP/390445/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-revestive_en.pdf"},
    {"id":"27757","name":"CHMP summary of positive opinion for Ledaga","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ledaga_en.pdf"},
    {"id":"27768","name":"CHMP summary of positive opinion for Ivabradine Zentiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/CHMP/603734/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ivabradine-zentiva_en.pdf"},
    {"id":"27797","name":"CVMP summary of positive opinion for Clynav","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/CVMP/223807/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-clynav_en.pdf"},
    {"id":"27826","name":"CVMP summary of positive opinion for Innovax-ND-IBD","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-06-16T02:00:00Z","last_updated_date":"2017-06-16T02:00:00Z","reference_number":"EMA/CVMP/290079/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-innovax-nd-ibd_en.pdf"},
    {"id":"27831","name":"CVMP summary of positive opinion for TruScient","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-10-14T17:00:00Z","last_updated_date":"2015-02-03T17:00:00Z","reference_number":"EMA/CVMP/648569/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-truscient_en.pdf"},
    {"id":"27864","name":"CHMP summary of positive opinion for Rezolsta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/578742/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rezolsta_en.pdf"},
    {"id":"27960","name":"CHMP summary of positive opinion for Ofev","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2014-11-21T13:00:00Z","reference_number":"EMA/CHMP/683189/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ofev_en.pdf"},
    {"id":"28091","name":"Committee for medicinal products for human use summary of positive opinion for Exforge HCT","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:09:21Z","last_updated_date":"2009-07-23T02:09:21Z","reference_number":"EMEA/CHMP/450701/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-exforge-hct_en.pdf"},
    {"id":"28101","name":"CHMP summary of positive opinion for Signifor","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-01-20T01:00:00Z","last_updated_date":"2012-01-20T01:00:00Z","reference_number":"EMA/34679/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-signifor_en.pdf"},
    {"id":"28121","name":"CHMP summary of positive opinion for Duloxetine Zentiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T14:00:00Z","last_updated_date":"2015-06-26T14:00:00Z","reference_number":"EMA/CHMP/431635/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duloxetine-zentiva_en.pdf"},
    {"id":"28129","name":"CHMP summary of positive opinion for Lidocaine/Prilocaine Plethora","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/488493/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lidocaineprilocaine-plethora_en.pdf"},
    {"id":"28155","name":"CHMP summary of positive opinion for Modigraf","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-03-19T01:00:00Z","last_updated_date":"2009-03-19T01:00:00Z","reference_number":"EMEA/CHMP/127261/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-modigraf_en.pdf"},
    {"id":"28181","name":"CVMP summary of positive opinion for Poulvac E. coli","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-04-16T02:00:00Z","last_updated_date":"2012-04-16T02:00:00Z","reference_number":"EMA/CVMP/184381/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-poulvac-e-coli_en.pdf"},
    {"id":"28184","name":"CHMP positive summary of opinion for Clopidogrel Teva Pharma B.V.","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-07-23T02:00:00Z","last_updated_date":"2015-02-03T01:00:00Z","reference_number":"EMA/CHMP/289096/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-clopidogrel-teva-pharma-bv_en.pdf"},
    {"id":"28194","name":"CHMP summary of positive opinion for Pregabalin Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-05-29T14:00:00Z","reference_number":"EMA/CHMP/238445/2015 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-mylan_en.pdf"},
    {"id":"28206","name":"CVMP summary of positive opinion for Evalon","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-02-19T01:00:00Z","last_updated_date":"2016-02-19T01:00:00Z","reference_number":"EMA/CVMP/864727/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-evalon_en.pdf"},
    {"id":"28220","name":"CHMP summary of positive opinion for Slenyto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/491031/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-slenyto_en.pdf"},
    {"id":"28238","name":"Committee for medicinal products for human use, summary of positive opinion for Mycophenolate","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-01-14T01:00:00Z","last_updated_date":"2008-01-14T01:00:00Z","reference_number":"EMEA/CHMP/563031/2007, corr","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-mycophenolate_en.pdf"},
    {"id":"28255","name":"Questions and answers on the positive opinion on the marketing authorisation for Defitelio (defibrotide) - Outcome of re-examination","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/457737/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-positive-opinion-marketing-authorisation-defitelio-defibrotide-outcome-re-examination_en.pdf"},
    {"id":"28264","name":"CVMP summary of positive opinion for Dany's BienenWohl","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-04-20T17:08:00Z","last_updated_date":"2018-04-20T17:08:00Z","reference_number":"EMA/CVMP/178553/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-danys-bienenwohl_en.pdf"},
    {"id":"28361","name":"CHMP summary of positive opinion for Vizarsin","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-24T02:00:00Z","last_updated_date":"2009-06-24T02:00:00Z","reference_number":"EMEA/CHMP/372528/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vizarsin_en.pdf"},
    {"id":"28369","name":"CHMP summary of opinion for Docetaxel Hospira UK Limited","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2019-10-15T02:00:00Z","reference_number":"EMA/CHMP/289487/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-docetaxel-hospira-uk-limited_en.pdf"},
    {"id":"28402","name":"Committee for medicinal products for human use, summary of positive opinion for Renvela","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-03-19T01:00:00Z","last_updated_date":"2009-03-19T01:00:00Z","reference_number":"EMEA/CHMP/175954/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-renvela_en.pdf"},
    {"id":"28510","name":"CHMP summary of positive opinion for Olysio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2018-05-23T14:00:00Z","reference_number":"EMA/CHMP/137969/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-olysio_en.pdf"},
    {"id":"28528","name":"CHMP summary of positive opinion for BiResp Spiromax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/CHMP/68061/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-biresp-spiromax_en.pdf"},
    {"id":"28534","name":"CHMP summary of positive opinion for Lacosamide Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/CHMP/370634/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lacosamide-accord_en.pdf"},
    {"id":"28594","name":"CHMP summary of positive opinion for Abasria","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/340931/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-abasria_en.pdf"},
    {"id":"28782","name":"CHMP summary of positive opinion for Seebri Breezhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T14:00:00Z","last_updated_date":"2012-08-07T13:25:00Z","reference_number":"EMA/CHMP/422050/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-seebri-breezhaler_en.pdf"},
    {"id":"28943","name":"CHMP summary of positive opinion for Trajenta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/450821/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trajenta_en.pdf"},
    {"id":"28945","name":"CHMP summary of positive opinion for Otezla","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2014-11-21T13:00:00Z","reference_number":"EMA/CHMP/490023/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-otezla_en.pdf"},
    {"id":"28962","name":"CHMP summary of positive opinion for Lumark","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2026-02-11T02:00:00Z","reference_number":"EMA/247591/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lumark_en.pdf"},
    {"id":"29027","name":"CHMP summary of positive opinion for Stivarga","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/358125/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-stivarga_en.pdf"},
    {"id":"29072","name":"CHMP summary of opinion for Fluenz Tetra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2025-08-14T02:00:00Z","reference_number":"EMA/CHMP/547873/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-fluenz-tetra_en.pdf"},
    {"id":"29083","name":"Committee for medicinal products for human use, summary of positive opinion for Resolor","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/449050/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-resolor_en.pdf"},
    {"id":"29109","name":"CHMP summary of positive opinion for Sylvant","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/CHMP/142794/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sylvant_en.pdf"},
    {"id":"29116","name":"CHMP summary of positive opinion for Hexyon","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/CHMP/113913/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hexyon_en.pdf"},
    {"id":"29142","name":"Committee for medicinal products for human use  summary of positive opinion  for Zomarist","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-09-25T02:00:00Z","last_updated_date":"2008-09-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zomarist_en.pdf"},
    {"id":"29144","name":"CVMP summary of positive opinion for Contacera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-10-12T18:00:00Z","last_updated_date":"2012-10-12T18:00:00Z","reference_number":"EMA/CVMP/486534/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-contacera_en.pdf"},
    {"id":"29197","name":"CHMP summary of positive opinion for Mermatine Merz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/589593/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mermatine-merz_en.pdf"},
    {"id":"29213","name":"Questions and answers on refusal of the marketing authorisation for Masipro (masitinib)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2018-04-04T02:00:00Z","reference_number":"EMA/599464/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masipro-masitinib_sv.pdf"}},
    {"id":"29226","name":"CVMP summary of positive opinion for Novaquin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-10T17:00:00Z","last_updated_date":"2015-07-10T17:00:00Z","reference_number":"EMA/CVMP/389241/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-novaquin_en.pdf"},
    {"id":"29234","name":"CHMP summary of positive opinion for Elocta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T14:00:00Z","last_updated_date":"2015-09-25T14:00:00Z","reference_number":"EMA/CHMP/557976/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-elocta_en.pdf"},
    {"id":"29279","name":"CHMP summary of positive opinion for Jardiance","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-04-02T12:10:00Z","reference_number":"EMA/CHMP/157961/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jardiance_en.pdf"},
    {"id":"29303","name":"CHMP summary of positive opinion for Cyltezo","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/CHMP/532447/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cyltezo_en.pdf"},
    {"id":"29337","name":"CVMP summary of positive opinion for Bovilis Blue-8","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-08T17:30:00Z","last_updated_date":"2024-06-17T17:30:00Z","reference_number":"EMA/CVMP/506378/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bovilis-blue-8_en.pdf"},
    {"id":"29406","name":"CHMP summary of positive opinion for Inhixa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2016-07-22T14:00:00Z","reference_number":"EMA/CHMP/482423/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-inhixa_en.pdf"},
    {"id":"29414","name":"Committee for medicinal products for human use, summary of positive opinion for Ilaris","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-24T02:00:00Z","last_updated_date":"2009-07-24T02:00:00Z","reference_number":"EMEA/CHMP/447829/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-ilaris_en.pdf"},
    {"id":"29456","name":"Committee for medicinal products for human use summary of positive opinion for Evicel","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:09:21Z","last_updated_date":"2024-08-02T02:09:21Z","reference_number":"EMEA/CHMP/399406/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-evicel_en.pdf"},
    {"id":"29556","name":"CHMP summary of positive opinion for Duzallo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T14:00:00Z","last_updated_date":"2020-08-06T14:00:00Z","reference_number":"EMA/CHMP/374196/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duzallo_en.pdf"},
    {"id":"29676","name":"CHMP summary of positive opinion for Rekovelle","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"EMA/CHMP/635107/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rekovelle_en.pdf"},
    {"id":"29697","name":"Committee for medicinal products for veterinary use summary of opinion: BTVPUR Alsap 8: International Non-proprietary Names (INN): inactivated bluetongue virus Serotype 8","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-02-13T01:09:21Z","last_updated_date":"2018-05-16T02:09:21Z","reference_number":"EMEA/CVMP/685571/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-btvpur-alsap-8-international-non-proprietary-names-inn-inactivated-bluetongue-virus-serotype-8_en.pdf"},
    {"id":"29741","name":"CHMP summary of positive opinion for Zoledronic Acid Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T13:00:00Z","last_updated_date":"2013-11-22T13:00:00Z","reference_number":"EMA/CHMP/523516/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zoledronic-acid-accord_en.pdf"},
    {"id":"29770","name":"CHMP summary of positive opinion for Procysbi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/CHMP/355942/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-procysbi_en.pdf"},
    {"id":"29791","name":"CHMP summary of opinion for Lopinavir / Ritonavir Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T13:00:00Z","last_updated_date":"2015-11-20T13:00:00Z","reference_number":"EMA/CHMP/772058/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-lopinavir-ritonavir-mylan_en.pdf"},
    {"id":"29873","name":"CHMP summary of positive opinion for Daliresp","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2018-02-06T01:00:00Z","reference_number":"EMA/CHMP/825394/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-daliresp_en.pdf"},
    {"id":"29904","name":"CHMP summary of positive opinion for Pomalidomide Celgene","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T14:00:00Z","last_updated_date":"2013-05-31T14:00:00Z","reference_number":"EMA/306855/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pomalidomide-celgene_en.pdf"},
    {"id":"29914","name":"CHMP summary of positive opinion for Cosentyx","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2014-11-21T13:00:00Z","reference_number":"EMA/CHMP/489954/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cosentyx_en.pdf"},
    {"id":"29922","name":"Committee for medicinal products for human use post-authorisation summary of positive opinion for Corlentor/Procorolan on 24 September 2009","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/CHMP/608839/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-corlentorprocorolan-24-september-2009_en.pdf"},
    {"id":"29935","name":"CVMP summary of positive opinion for Suvaxyn PRRS MLV","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-06-16T02:00:00Z","last_updated_date":"2017-06-16T02:00:00Z","reference_number":"EMA/CVMP/327193/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-suvaxyn-prrs-mlv_en.pdf"},
    {"id":"30077","name":"CHMP summary of positive opinion for Rivastigmine Actavis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/98238/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rivastigmine-actavis_en.pdf"},
    {"id":"30113","name":"CHMP summary of opinion for Blincyto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/571712/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-blincyto_en.pdf"},
    {"id":"30142","name":"CHMP positive summary of opinion for Zoledronic acid medac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2026-05-19T02:00:00Z","reference_number":"EMA/CHMP/271157/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-zoledronic-acid-medac_en.pdf"},
    {"id":"30165","name":"CVMP summary of positive opinion for Parvoduk","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-14T01:00:00Z","last_updated_date":"2019-04-15T01:00:00Z","reference_number":"EMA/CVMP/60159/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-parvoduk_en.pdf"},
    {"id":"30247","name":"Questions and answers on refusal of the marketing authorisation for Sialanar (glycopyrronium bromide)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/500080/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sialanar-glycopyrronium-bromide_en.pdf"},
    {"id":"30279","name":"CVMP summary of positive opinion for Nobilis IB Primo QX","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-07-11T18:00:00Z","last_updated_date":"2014-07-11T18:00:00Z","reference_number":"EMA/CVMP/345403/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobilis-ib-primo-qx_en.pdf"},
    {"id":"30344","name":"CHMP summary of positive opinion for Riluzole Zentiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/109002/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-riluzole-zentiva_en.pdf"},
    {"id":"30403","name":"CHMP summary of positive opinion for Perjeta","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/CHMP/803313/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-perjeta_en.pdf"},
    {"id":"30437","name":"CHMP summary of positive opinion for Folcepri","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/CHMP/139146/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-folcepri_en.pdf"},
    {"id":"30452","name":"CVMP summary of positive opinion for Cardalis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-05-21T02:00:00Z","last_updated_date":"2012-05-21T02:00:00Z","reference_number":"EMA/CVMP/273464/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-cardalis_en.pdf"},
    {"id":"30473","name":"Committee for medicinal products for human use, summary of positive opinion for Tyverb","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/382675/2007","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-tyverb_en.pdf"},
    {"id":"30500","name":"Summary of opinion for Portrazza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T13:00:00Z","last_updated_date":"2021-07-27T13:52:00Z","reference_number":"EMA/CHMP/756429/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/summary-opinion-portrazza_en.pdf"},
    {"id":"30509","name":"CHMP summary of positive opinion for Budesonide / Formoterol Teva Pharma B.V.","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T16:18:00Z","last_updated_date":"2017-01-30T15:18:00Z","reference_number":"EMA/CHMP/443986/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-budesonide-formoterol-teva-pharma-bv_en.pdf"},
    {"id":"30590","name":"CHMP summary of positive opinion for Pregabalin Pfizer","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/87173/2014 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-pfizer_en.pdf"},
    {"id":"30596","name":"CHMP summary of positive opinion for Ivabradine Anpharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/CHMP/461869/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ivabradine-anpharm_en.pdf"},
    {"id":"30612","name":"CVMP summary of opinion for Zolvix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-07-17T03:09:00Z","last_updated_date":"2009-07-17T03:09:00Z","reference_number":"EMEA/CVMP/398294/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-opinion-zolvix_en.pdf"}    {"id":"30640","name":"CHMP positive summary of opinion for Bretaris Genuair","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-06-28T02:00:00Z","reference_number":"EMA/CHMP/304281/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-bretaris-genuair_en.pdf"},
    {"id":"30641","name":"CHMP summary of opinion for Airexar Spiromax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/CHMP/431246/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-airexar-spiromax_en.pdf"},
    {"id":"30643","name":"CHMP summary of positive opinion for Vpriv","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-06-25T02:00:00Z","reference_number":"EMA/CHMP/384050/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vpriv_en.pdf"},
    {"id":"30662","name":"CHMP summary of positive opinion for Symkevi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/CHMP/413708/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-symkevi_en.pdf"},
    {"id":"30701","name":"CHMP summary of positive opinion for Desloratadine Actavis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T01:00:00Z","last_updated_date":"2011-11-18T01:00:00Z","reference_number":"EMA/CHMP/796881/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-desloratadine-actavis_en.pdf"},
    {"id":"30730","name":"CHMP summary of positive opinion for Evotaz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/277547/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-evotaz_en.pdf"},
    {"id":"30739","name":"CVMP summary of positive opinion for Eryseng","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/CVMP/158588/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-eryseng_en.pdf"},
    {"id":"30744","name":"CHMP summary of positive opinion for Pantoloc Control","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-02-18T01:00:00Z","last_updated_date":"2022-01-18T01:00:00Z","reference_number":"EMEA/CHMP/108579/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pantoloc-control_en.pdf"},
    {"id":"30808","name":"CHMP summary of opinion for Empliciti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"EMA/CHMP/15592/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-empliciti_en.pdf"},
    {"id":"30843","name":"CHMP summary of positive opinion for Tobi Podhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMA/CHMP/571131/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tobi-podhaler_en.pdf"},
    {"id":"30918","name":"Questions and answers on the refusal of the marketing authorisation for Qsiva (phentermine / topiramate)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/666052/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-qsiva-phentermine-topiramate_en.pdf-0"},
    {"id":"30930","name":"CHMP summary of positive opinion for Capecitabine Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/CHMP/99418/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-capecitabine-teva_en.pdf"},
    {"id":"30945","name":"CHMP summary of positive opinion for DuoCover","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/765467/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duocover_en.pdf"},
    {"id":"31026","name":"CHMP summary of positive opinion for Trevaclyn","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/196882/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trevaclyn_en.pdf"},
    {"id":"31040","name":"CHMP summary of positive opinion for Maci","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2018-07-05T14:00:00Z","reference_number":"EMA/54023/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-maci_en.pdf"},
    {"id":"31061","name":"CHMP summary of positive opinion for Xydalba","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-12-19T01:00:00Z","last_updated_date":"2014-12-19T01:00:00Z","reference_number":"EMA/CHMP/757915/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xydalba_en.pdf"},
    {"id":"31082","name":"CHMP summary of positive opinion for Tadalafil Generics","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T13:00:00Z","last_updated_date":"2016-11-11T13:00:00Z","reference_number":"EMA/CHMP/697437/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tadalafil-generics_en.pdf"},
    {"id":"31118","name":"CHMP summary of positive opinion for Steglujan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/12848/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-steglujan_en.pdf"},
    {"id":"31312","name":"CHMP summary of positive opinion for Raxone","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/CHMP/368035/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-raxone_en.pdf"},
    {"id":"31330","name":"CHMP summary of positive opinion for Intuniv","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/CHMP/450088/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-intuniv_en.pdf"},
    {"id":"31383","name":"CHMP summary of positive opinion for Provenge","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T14:00:00Z","last_updated_date":"2015-05-19T14:00:00Z","reference_number":"EMA/CHMP/363851/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-provenge_en.pdf"},
    {"id":"31387","name":"CHMP positive summary of opinion for PecFent","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-06-24T02:00:00Z","last_updated_date":"2010-06-24T02:00:00Z","reference_number":"EMA/CHMP/344109/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-pecfent_en.pdf"},
    {"id":"31403","name":"CHMP summary of positive opinion for Entacapone Orion","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/456583/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-entacapone-orion_en.pdf"},
    {"id":"31501","name":"Committee for medicinal products for human use, summary of positive opinion for  Simponi","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/362870/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-simponi_en.pdf"},
    {"id":"31627","name":"Committee for medicinal products for human use, summary of positive opinion for Javlor","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/370895/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-javlor_en.pdf"},
    {"id":"31660","name":"CHMP summary of positive opinion for Rydapt","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"EMA/CHMP/263985/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rydapt_en.pdf"},
    {"id":"31674","name":"Committee for medicinal products for human use summary of positive opinion for Fablyn","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T00:09:21Z","last_updated_date":"2008-12-18T00:09:21Z","reference_number":"EMEA/CHMP/609979/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-fablyn_en.pdf"},
    {"id":"31708","name":"CHMP summary of positive opinion for Zoledronic acid Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-06-22T02:00:00Z","reference_number":"EMA/CHMP/417185/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zoledronic-acid-mylan_en.pdf"},
    {"id":"31710","name":"CHMP summary of positive opinion for Rxulti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/344772/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rxulti_en.pdf"},
    {"id":"31757","name":"CHMP summary of positive opinion for Tookad","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/CHMP/449509/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tookad_en.pdf"},
    {"id":"31784","name":"CHMP summary of positive opinion for Zontivity","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2017-09-20T02:00:00Z","reference_number":"EMA/CHMP/666694/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zontivity_en.pdf"},
    {"id":"31823","name":"CHMP summary of positive opinion for Matever","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/555635/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-matever_en.pdf"},
    {"id":"31945","name":"CVMP summary of positive opinion for Zuprevo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-03-11T01:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMA/CVMP/91406/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zuprevo_en.pdf"},
    {"id":"31988","name":"CHMP summary of positive opinion for Cinacalcet Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T14:00:00Z","last_updated_date":"2015-09-25T14:00:00Z","reference_number":"EMA/CHMP/596066/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cinacalcet-mylan_en.pdf"},
    {"id":"32004","name":"CHMP summary of positive opinion for Clopidogrel / Acetylsalicylic acid Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2017-04-28T02:00:00Z","reference_number":"EMA/CHMP/369651/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-clopidogrel-acetylsalicylic-acid-teva_en.pdf"},
    {"id":"32010","name":"Questions and answers on refusal of the marketing authorisation for Defitelio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/167992/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-defitelio_en.pdf"},
    {"id":"32038","name":"CHMP summary of positive opinion for Pixuvri","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/CHMP/102366/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pixuvri_en.pdf"},
    {"id":"32059","name":"CHMP summary of positive opinion for Hetlioz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T02:00:00Z","last_updated_date":"2015-04-24T02:00:00Z","reference_number":"EMA/CHMP/239154/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hetlioz_en.pdf"},
    {"id":"32116","name":"CHMP summary of positive opinion for Incresync","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/CHMP/229752/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-incresync_en.pdf"},
    {"id":"32128","name":"CHMP summary of positive opinion for Para-aminosalicylic acid Lucane","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T01:00:00Z","last_updated_date":"2026-01-05T01:00:00Z","reference_number":"EMA/CHMP/709518/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-para-aminosalicylic-acid-lucane_en.pdf"},
    {"id":"32183","name":"CHMP summary of positive opinion for Iasibon","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/643636/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-iasibon_en.pdf"},
    {"id":"32192","name":"CHMP summary of positive opinion for Refixia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/CHMP/193129/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-refixia_en.pdf"},
    {"id":"32204","name":"Committee for medicinal products for human use, summary of positive opinion for Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:00:00Z","last_updated_date":"2008-07-24T02:00:00Z","reference_number":"EMEA/CHMP/366446/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals_en.pdf"},
    {"id":"32206","name":"CHMP summary of opinion for Pemetrexed Actavis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/675005/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-pemetrexed-actavis_en.pdf"},
    {"id":"32241","name":"CHMP summary of positive opinion for Adempas","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-01-24T01:00:00Z","reference_number":"EMA/CHMP/807324/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-adempas_en.pdf"},
    {"id":"32264","name":"CHMP summary of positive opinion for Zoely","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"EMA/CHMP/195947/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zoely_en.pdf"},
    {"id":"32280","name":"CHMP summary of positive opinion for Zessly","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"EMA/CHMP/58481/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zessly_en.pdf"},
    {"id":"32357","name":"Committee for medicinal products for human use summary of positive opinion for Enyglid","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:09:21Z","last_updated_date":"2009-07-23T02:09:21Z","reference_number":"EMEA/CHMP/441193/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-enyglid_en.pdf"},
    {"id":"32358","name":"CHMP summary of positive opinion for Efavirenz Tenz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T02:00:00Z","last_updated_date":"2011-10-21T02:00:00Z","reference_number":"EMA/CHMP/613927/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-efavirenz-tenz_en.pdf"},
    {"id":"32386","name":"CHMP summary of positive opinion for Kengrexal","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"EMA/CHMP/45332/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kengrexal_en.pdf"},
    {"id":"32479","name":"Questions and answers on refusal of the marketing authorisation for Ninlaro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T14:00:00Z","last_updated_date":"2016-06-28T12:52:00Z","reference_number":"EMA/358656/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ninlaro_en.pdf"},
    {"id":"32522","name":"CVMP summary of positive opinion for UpCard","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-05T02:00:00Z","last_updated_date":"2015-06-05T02:00:00Z","reference_number":"EMA/CVMP/292500/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-upcard_en.pdf"},
    {"id":"32617","name":"CHMP summary of positive opinion for  Samsca","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/CHMP/285157/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-samsca_en.pdf"},
    {"id":"32631","name":"CHMP summary of positive opinion for Chenodeoxycholic acid sigma-tau","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/CHMP/542534/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-chenodeoxycholic-acid-sigma-tau_en.pdf"},
    {"id":"32649","name":"CVMP summary of positive opinion for Ingelvac PCV FLEX","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-03-17T01:00:00Z","last_updated_date":"2017-03-17T01:00:00Z","reference_number":"EMA/CVMP/132641/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-ingelvac-pcv-flex_en.pdf"},
    {"id":"32652","name":"CHMP summary of positive opinion for Spectrila","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/730109/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-spectrila_en.pdf"},
    {"id":"32678","name":"CHMP summary of positive opinion for Pemetrexed Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2024-07-30T01:00:00Z","reference_number":"EMA/CHMP/10762/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pemetrexed-krka_en.pdf"},
    {"id":"32683","name":"CHMP summary of opinion for Zinbryta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T02:00:00Z","last_updated_date":"2018-05-02T02:00:00Z","reference_number":"EMA/CHMP/268320/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-zinbryta_en.pdf"},
    {"id":"32700","name":"Questions and answers on refusal of the marketing authorisation for Xeljanz - Outcome of re-examination","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/460814/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xeljanz-outcome-re-examination_sv.pdf"}},
    {"id":"32770","name":"Questions and answers on recommendation for the refusal of the marketing authorisation  for Genasense","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2007-04-26T02:09:00Z","last_updated_date":"2007-04-26T02:09:00Z","reference_number":"EMEA/171749/2007","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-genasense_en.pdf"},
    {"id":"32792","name":"CHMP summary of positive opinion for Nulojix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-04-15T02:00:00Z","last_updated_date":"2011-04-15T02:00:00Z","reference_number":"EMA/CHMP/273603/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nulojix_en.pdf"},
    {"id":"32793","name":"CHMP summary of positive opinion for Tacforius","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-10-13T14:00:00Z","last_updated_date":"2017-10-13T14:00:00Z","reference_number":"EMA/CHMP/661981/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tacforius_en.pdf"},
    {"id":"32854","name":"Committee for medicinal products for human use, summary of positive opinion for Kuvan","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-09-25T02:00:00Z","last_updated_date":"2008-09-25T02:00:00Z","reference_number":"EMEA/CHMP/434814/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-kuvan_en.pdf"},
    {"id":"32887","name":"CHMP summary of positive opinion for Fulvestrant Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/CHMP/734315/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fulvestrant-mylan_en.pdf"},
    {"id":"32915","name":"CVMP summary of positive opinion for MS-H vaccine","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-04-08T02:00:00Z","last_updated_date":"2011-04-08T02:00:00Z","reference_number":"EMA/CVMP/232001/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-ms-h-vaccine_en.pdf"},
    {"id":"32917","name":"CHMP summary of positive opinion for Alkindi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/CHMP/817958/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-alkindi_en.pdf"},
    {"id":"32919","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Oncophage","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-20T00:09:00Z","last_updated_date":"2009-11-20T00:09:00Z","reference_number":"EMEA/CHMP/729781/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-oncophage_en.pdf"},
    {"id":"33179","name":"CHMP summary of positive opinion for Inflectra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/CHMP/364710/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-inflectra_en.pdf"},
    {"id":"33180","name":"CHMP summary of positive opinion for Pioglitazone Teva Pharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2022-08-30T17:10:00Z","reference_number":"EMA/CHMP/756105/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-teva-pharma_en.pdf"},
    {"id":"33292","name":"Committee for medicinal products for human use  summary of positive opinion  for Zylagren","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-24T02:00:00Z","last_updated_date":"2009-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zylagren_en.pdf"},
    {"id":"33293","name":"CHMP summary of positive opinion for Topotecan Eagle","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T02:00:00Z","last_updated_date":"2014-11-14T01:00:00Z","reference_number":"EMA/CHMP/795162/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-topotecan-eagle_en.pdf"},
    {"id":"33349","name":"CHMP summary of positive opinion for Telmisartan Teva Pharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/522766/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-telmisartan-teva-pharma_en.pdf"},
    {"id":"33396","name":"CHMP summary of positive opinion for Tuxella","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T14:00:00Z","last_updated_date":"2017-05-19T14:00:00Z","reference_number":"EMA/CHMP/307683/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tuxella_en.pdf"},
    {"id":"33444","name":"CHMP summary of positive opinion for Briviact","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/742520/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-briviact_en.pdf"},
    {"id":"33495","name":"Questions and answers on the recommendation for the refusal of the marketing authorization for Mylotarg","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-01-24T01:00:00Z","last_updated_date":"2008-01-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_sv.pdf"}},
    {"id":"33502","name":"CHMP summary of positive opinion for Hexacima","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/CHMP/113895/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hexacima_en.pdf"},
    {"id":"33505","name":"CHMP summary of positive opinion for Kigabeq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/395605/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kigabeq_en.pdf"},
    {"id":"33547","name":"CHMP summary of positive opinion for Eviplera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/736674/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eviplera_en.pdf"},
    {"id":"33570","name":"CHMP summary of positive opinion for SomaKit TOC","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2016-10-14T14:00:00Z","reference_number":"EMA/603784/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-somakit-toc_en.pdf"},
    {"id":"33586","name":"CHMP summary of positive opinion for Tegsedi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/CHMP/288734/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tegsedi_en.pdf"},
    {"id":"33588","name":"CVMP summary of positive opinion for Stronghold Plus","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2016-12-09T15:46:00Z","last_updated_date":"2016-12-09T15:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-stronghold-plus_en.pdf"},
    {"id":"33609","name":"Questions and answers on the refusal of the marketing authorisation for Lodipressin (amlodipine besilate)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-01-16T01:00:00Z","last_updated_date":"2016-04-29T02:00:00Z","reference_number":"EMA/55773/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lodipressin-amlodipine-besilate_sv.pdf"}},
    {"id":"33624","name":"CHMP summary of positive opinion for Nevirapine Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2023-03-21T02:00:00Z","reference_number":"EMEA/CHMP/578510/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nevirapine-teva_en.pdf"},
    {"id":"33667","name":"CHMP summary of positive opinion for Zytiga","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/587645/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zytiga_en.pdf"},
    {"id":"33685","name":"CHMP summary of positive opinion for Incruse","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/CHMP/68182/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-incruse_en.pdf"},
    {"id":"33716","name":"CHMP summary of positive opinion for Pregabalin Zentiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"EMA/CHMP/295412/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-zentiva_en.pdf"},
    {"id":"33737","name":"CHMP summary of positive opinion for Lamzede","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-01-26T13:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/811505/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lamzede_en.pdf"},
    {"id":"33771","name":"CHMP summary of positive opinion for Halimatoz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2021-01-29T12:18:00Z","reference_number":"EMA/CHMP/241919/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-halimatoz_en.pdf"},
    {"id":"33833","name":"Committee for medicinal products for human use, summary of positive opinion for Relistor","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-04-24T02:00:00Z","last_updated_date":"2008-04-24T02:00:00Z","reference_number":"EMEA/CHMP/198599/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-relistor_en.pdf"},
    {"id":"33853","name":"CHMP summary of positive opinion Ocrevus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"EMA/CHMP/643958/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ocrevus_en.pdf"},
    {"id":"33864","name":"CHMP summary of positive opinion for Insulin lispro Sanofi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-05-19T02:00:00Z","reference_number":"EMA/CHMP/269671/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-insulin-lispro-sanofi_en.pdf"},
    {"id":"33908","name":"CHMP summary of positive opinion for Hirobriz Breezhaler","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/592257/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hirobriz-breezhaler_en.pdf"},
    {"id":"33933","name":"CHMP summary of positive opinion for Xerava","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/CHMP/447907/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xerava_en.pdf"},
    {"id":"34032","name":"CVMP summary of positive opinion for Inflacam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-10-14T17:00:00Z","last_updated_date":"2011-10-14T18:00:00Z","reference_number":"EMA/CVMP/778856/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-inflacam_en.pdf"},
    {"id":"34044","name":"Questions and answers on refusal of the marketing authorisation for Elelyso","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2012-06-22T02:00:00Z","last_updated_date":"2012-11-23T01:00:00Z","reference_number":"EMA/756393/2012/rev. 3","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-elelyso_en.pdf"},
    {"id":"34075","name":"CHMP summary of positive opinion for Ulunar Breezhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/65875/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ulunar-breezhaler_en.pdf"},
    {"id":"34088","name":"CHMP summary of positive opinion for Cablivi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/CHMP/419463/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cablivi_en.pdf"},
    {"id":"34108","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Zeftera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-02-19T01:00:00Z","last_updated_date":"2010-02-19T01:00:00Z","reference_number":"EMA/83783/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-recommendation-refusal-marketing-authorisation-zeftera_en.pdf-0"},
    {"id":"34114","name":"Committee for medicinal products for human use, summary of positive opinion for Ribavirin Teva Pharma BV","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2021-07-09T02:00:00Z","reference_number":"EMEA/CHMP/228100/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-ribavirin-teva-pharma-bv_en.pdf"},
    {"id":"34141","name":"CHMP summary of positive opinion for Levetiracetam Sun","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T02:00:00Z","last_updated_date":"2011-10-21T02:00:00Z","reference_number":"EMA/CHMP/752234/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-levetiracetam-sun_en.pdf"}    {"id":"34268","name":"CHMP summary of positive opinion for Vipidia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T02:00:00Z","last_updated_date":"2013-07-26T02:00:00Z","reference_number":"EMA/CHMP/229786/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vipidia_en.pdf"},
    {"id":"34290","name":"CHMP summary of positive opinion for Udenyca","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/490650/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-udenyca_en.pdf"},
    {"id":"34304","name":"CHMP summary of positive opinion for Ameluz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-10-21T02:00:00Z","last_updated_date":"2011-10-21T02:00:00Z","reference_number":"EMA/CHMP/486900/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ameluz_en.pdf"},
    {"id":"34307","name":"Committee for medicinal products for human use, summary of positive opinion  for Volibris","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-02-21T01:00:00Z","last_updated_date":"2008-02-21T01:00:00Z","reference_number":"EMEA/CHMP/31425/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-volibris_en.pdf"},
    {"id":"34396","name":"CVMP summary of positive opinion for Innovax-ILT","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-05-08T18:00:00Z","last_updated_date":"2015-05-08T18:00:00Z","reference_number":"EMA/235978/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-innovax-ilt_en.pdf"},
    {"id":"34407","name":"CHMP summary of positive opinion for Prevenar 13","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/CHMP/546417/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-prevenar-13_en.pdf"},
    {"id":"34413","name":"CHMP positive summary of opinion for Telmisartan Actavis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-06-25T02:00:00Z","reference_number":"EMA/CHMP/372629/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-telmisartan-actavis_en.pdf"},
    {"id":"34487","name":"CVMP summary of positive opinion for Vectormune ND","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-10T17:00:00Z","last_updated_date":"2015-07-10T17:00:00Z","reference_number":"EMA/CVMP/354791/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-vectormune-nd_en.pdf"},
    {"id":"34504","name":"CHMP summary of positive opinion for Desloratadine Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/749646/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-desloratadine-teva_en.pdf"},
    {"id":"34533","name":"Committee for medicinal products for human use  summary of positive opinion  for Zebinix","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-02-19T01:00:00Z","last_updated_date":"2009-02-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zebinix_en.pdf"},
    {"id":"34635","name":"CVMP summary of positive opinion for Vectra Felis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-04-11T18:00:00Z","last_updated_date":"2014-04-11T18:00:00Z","reference_number":"EMA/CVMP/158566/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-vectra-felis_en.pdf"},
    {"id":"34649","name":"CHMP summary of positive opinion for Myalepta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/352612/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-myalepta_en.pdf"},
    {"id":"34652","name":"Committee for medicinal products for human use, summary of positive opinion for Ixiaro","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2008-12-18T01:00:00Z","reference_number":"EMEA/CHMP/662316/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-ixiaro_en.pdf"},
    {"id":"34660","name":"Questions and answers on the recommendation for the refusal of a marketing authorisation application for Sumitriptan Galpharm 50 mg tablets","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-07-22T02:00:00Z","last_updated_date":"2011-07-22T02:00:00Z","reference_number":"EMA/CHMP/423166/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-sumitriptan-galpharm-50-mg-tablets_en.pdf"},
    {"id":"34701","name":"CHMP summary of positive opinion for Kyntheum","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-05-19T02:00:00Z","reference_number":"EMA/CHMP/714138/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kyntheum_en.pdf"},
    {"id":"34766","name":"CHMP summary of positive opinion for Verkazia","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T14:00:00Z","last_updated_date":"2017-07-21T14:00:00Z","reference_number":"EMA/CHMP/372110/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-verkazia_en.pdf"},
    {"id":"34801","name":"CHMP summary of positive opinion for Memantine Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2013-02-22T13:00:00Z","reference_number":"EMA/CHMP/74594/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-memantine-mylan_en.pdf"},
    {"id":"34887","name":"CHMP summary of positive opinion for Ribavirin BioPartners","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-01-22T01:00:00Z","last_updated_date":"2013-05-06T12:00:00Z","reference_number":"EMA/CHMP/40892/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ribavirin-biopartners_en.pdf"},
    {"id":"34943","name":"CHMP summary of positive opinion for Cuprior","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T19:00:00Z","last_updated_date":"2017-04-21T19:00:00Z","reference_number":"EMA/CHMP/665612/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cuprior_en.pdf"},
    {"id":"34956","name":"Committee for medicinal products for veterinary use summary of opinion: Startvac: International Non-proprietary Names (INN): Inactivated vaccine for cattle","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-12-12T01:09:21Z","last_updated_date":"2008-12-12T01:09:21Z","reference_number":"EMEA/586213/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-startvac-international-non-proprietary-names-inn-inactivated-vaccine-cattle_en.pdf"},
    {"id":"34991","name":"CHMP summary of positive opinion for Imfinzi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/CHMP/458931/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imfinzi_en.pdf"},
    {"id":"35032","name":"CHMP summary of positive opinion for Darunavir Krka d.d.","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2023-02-03T01:00:00Z","reference_number":"EMA/CHMP/729969/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-darunavir-krka-dd_en.pdf"},
    {"id":"35064","name":"CHMP summary of positive opinion for Prepandrix","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"EMEA/CHMP/334055/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-prepandrix_en.pdf"},
    {"id":"35136","name":"CVMP summary of positive opinion for Versican Plus Pi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-05-12T02:00:00Z","last_updated_date":"2014-05-12T02:00:00Z","reference_number":"EMA/CVMP/229790/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-versican-plus-pi_en.pdf"},
    {"id":"35189","name":"CVMP summary of positive opinion for Sevocalm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-22T02:00:00Z","last_updated_date":"2016-04-22T02:00:00Z","reference_number":"EMA/CVMP/213655/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-sevocalm_en.pdf"},
    {"id":"35301","name":"CHMP summary of positive opinion for Ribavirin Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-01-21T01:00:00Z","last_updated_date":"2021-07-09T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ribavirin-teva_en.pdf"},
    {"id":"35342","name":"CVMP summary of positive opinion for Panacur AquaSol","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-10-14T17:00:00Z","last_updated_date":"2011-10-14T17:00:00Z","reference_number":"EMA/CVMP/760936/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-panacur-aquasol_en.pdf"},
    {"id":"35343","name":"CHMP summary of positive opinion for Brimica Genuair","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/593246/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-brimica-genuair_en.pdf"},
    {"id":"35388","name":"CVMP summary of positive opinion for Rabitec","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-10-06T02:00:00Z","last_updated_date":"2017-10-06T02:00:00Z","reference_number":"EMA/CVMP/601163/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-rabitec_en.pdf"},
    {"id":"35401","name":"CHMP summary of positive opinion for Vipdomet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/CHMP/223982/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vipdomet_en.pdf"},
    {"id":"35423","name":"CHMP summary of positive opinion for Edurant","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/724496/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-edurant_en.pdf"},
    {"id":"35459","name":"CHMP summary of positive opinion for Emtricitabine/Tenofovir disoproxil Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2016-10-14T14:00:00Z","reference_number":"EMA/CHMP/651530/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-emtricitabinetenofovir-disoproxil-krka_en.pdf"},
    {"id":"35491","name":"CHMP summary of positive opinion for Trulicity","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/524609/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trulicity_en.pdf"},
    {"id":"35523","name":"Questions and answers on the recommendation for the refusal of a marketing authorisation application for Fampyra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/24587/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-application-fampyra_en.pdf"},
    {"id":"35543","name":"CHMP summary of positive opinion for Truberzi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2021-02-25T14:00:00Z","reference_number":"EMA/CHMP/467320/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-truberzi_en.pdf"},
    {"id":"35641","name":"CHMP summary of positive opinion for Imatinib Actavis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-02-22T13:00:00Z","last_updated_date":"2022-07-05T13:00:00Z","reference_number":"EMA/CHMP/82403/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imatinib-actavis_en.pdf"},
    {"id":"35734","name":"Committee for medicinal products for human use, summary of positive opinion for Jalra","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-09-25T02:00:00Z","last_updated_date":"2008-09-25T02:00:00Z","reference_number":"EMEA/CHMP/472051/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-jalra_en.pdf"},
    {"id":"35743","name":"CHMP summary of positive opinion for Maruxa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-01-18T13:00:00Z","reference_number":"EMA/CHMP/6584/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-maruxa_en.pdf"},
    {"id":"35781","name":"CHMP summary of positive opinion for Zerbaxa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMEA/CHMP/448694/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zerbaxa_en.pdf"},
    {"id":"35797","name":"Questions and answers on the recommendation for the refusal of the marketing authorization for Sovrima","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-11-21T01:00:00Z","last_updated_date":"2008-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_el.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-sovrima_sv.pdf"}},
    {"id":"35823","name":"CHMP summary of positive opinion for Bosulif","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-01-18T13:00:00Z","reference_number":"EMA/CHMP/4601/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bosulif_en.pdf"},
    {"id":"35831","name":"CVMP summary of opinion for Melovem","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-05-15T03:09:21Z","last_updated_date":"2009-05-15T03:09:21Z","reference_number":"EMEA/CVMP/247920/2009 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-opinion-melovem_en.pdf"},
    {"id":"35934","name":"CHMP summary of positive opinion for Picato","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2020-03-04T02:00:00Z","reference_number":"EMA/CHMP/553672/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-picato_en.pdf"},
    {"id":"35938","name":"CHMP summary of positive opinion for Temozolomide Hexal","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2023-02-27T15:53:00Z","reference_number":"EMA/CHMP/810041/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-temozolomide-hexal_en.pdf"},
    {"id":"35962","name":"Committee for medicinal products for human use, summary of positive opinion for IDflu","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T01:00:00Z","last_updated_date":"2018-03-28T02:00:00Z","reference_number":"EMEA/CHMP/642949/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-idflu_en.pdf"},
    {"id":"36009","name":"CVMP summary of positive opinion for Galliprant","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/CVMP/673968/017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-galliprant_en.pdf"},
    {"id":"36021","name":"CHMP summary of positive opinion for Hefiya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/CHMP/241971/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hefiya_en.pdf"},
    {"id":"36032","name":"CHMP summary of positive opinion for Olumiant","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-olumiant_en.pdf"},
    {"id":"36033","name":"Committee for medicinal products for veterinary use summary of opinion: Zactran: International Non-proprietary Names (INN): Gamithromycin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-05-16T03:09:21Z","last_updated_date":"2008-05-16T03:09:21Z","reference_number":"EMEA/CVMP/220772/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-zactran-international-non-proprietary-names-inn-gamithromycin_en.pdf"},
    {"id":"36037","name":"CHMP summary of positive opinion for Mektovi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/476013/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mektovi_en.pdf"},
    {"id":"36085","name":"CHMP summary of positive opinion for Rubraca","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T13:00:00Z","last_updated_date":"2018-03-23T13:00:00Z","reference_number":"EMA/CHMP/723380/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rubraca_en.pdf"},
    {"id":"36120","name":"CHMP summary of positive opinion for Rapiscan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-06-25T02:00:00Z","reference_number":"EMA/CHMP/392715/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rapiscan_en.pdf"},
    {"id":"36125","name":"CHMP summary of positive opinion for Duloxetine Lilly","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/CHMP/605915/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duloxetine-lilly_en.pdf"},
    {"id":"36190","name":"CHMP summary of positive opinion for Idelvion","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-02-26T01:00:00Z","last_updated_date":"2016-02-26T01:00:00Z","reference_number":"EMA/CHMP/79845/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-idelvion_en.pdf"},
    {"id":"36232","name":"CVMP summary of positive opinion for Cepedex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-07T17:00:00Z","last_updated_date":"2016-10-07T17:00:00Z","reference_number":"EMA/CVMP/623365/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-cepedex_en.pdf"},
    {"id":"36257","name":"CHMP summary of positive opinion for Spinraza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-04-21T02:00:00Z","last_updated_date":"2017-04-21T02:00:00Z","reference_number":"EMA/181654/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-spinraza_en.pdf"},
    {"id":"36271","name":"CHMP summary of positive opinion for Urorec","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/CHMP/597059/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-urorec_en.pdf"},
    {"id":"36319","name":"CHMP summary of positive opinion for Zoledronic acid Teva Generics","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T01:00:00Z","last_updated_date":"2014-01-24T01:00:00Z","reference_number":"EMA/CHMP/25433/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zoledronic-acid-teva-generics_en.pdf"},
    {"id":"36323","name":"CVMP summary of positive opinion for Zulvac BTV Ovis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-02-17T01:00:00Z","last_updated_date":"2017-02-17T01:00:00Z","reference_number":"EMA/CVMP/50456/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zulvac-btv-ovis_en.pdf"},
    {"id":"36328","name":"CHMP summary of positive opinion for Arzerra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-01-22T01:00:00Z","last_updated_date":"2010-01-22T01:00:00Z","reference_number":"EMA/CHMP/21426/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-arzerra_en.pdf"},
    {"id":"36427","name":"CHMP summary of positive opinion for Komboglyze","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/755839/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-komboglyze_en.pdf"},
    {"id":"36437","name":"CHMP summary of positive opinion for Nuwiq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/CHMP/279317/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nuwiq_en.pdf"},
    {"id":"36546","name":"CHMP summary of positive opinion for Zoledronic acid Hospira","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2026-05-12T02:00:00Z","reference_number":"EMA/CHMP/604898/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zoledronic-acid-hospira_en.pdf"},
    {"id":"36557","name":"CHMP summary of positive opinion for Orbactiv","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-29T01:00:00Z","reference_number":"EMA/CHMP/803701/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-orbactiv_en.pdf"},
    {"id":"36558","name":"CHMP summary of positive opinion for BindRen","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2012-10-02T01:31:00Z","last_updated_date":"2015-04-02T01:31:00Z","reference_number":"EMA/555461/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bindren_en.pdf"},
    {"id":"36602","name":"CHMP summary of positive opinion Orkambi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/617813/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-orkambi_en.pdf"},
    {"id":"36603","name":"CHMP summary of positive opinion for Lokelma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2018-01-26T13:00:00Z","reference_number":"EMA/CHMP/24825/2018 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lokelma_en.pdf"},
    {"id":"36652","name":"CVMP summary of positive opinion for Cortacare","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-22T16:43:00Z","last_updated_date":"2018-06-22T16:43:00Z","reference_number":"EMA/CVMP/357032/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-cortacare_en.pdf"},
    {"id":"36690","name":"CHMP positive summary of opinion for Tolura","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"EMA/CHMP/143991/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-tolura_en.pdf"},
    {"id":"36696","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel Acino Pharma","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:09:21Z","last_updated_date":"2009-06-25T02:09:21Z","reference_number":"EMEA/CHMP/369869/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-acino-pharma_en.pdf"},
    {"id":"36774","name":"CHMP summary of positive opinion for Braftovi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T02:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/CHMP/476007/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-braftovi_en.pdf"},
    {"id":"36776","name":"Committee for medicinal products for human use summary of positive opinion for Celvapan","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-12-18T00:09:21Z","last_updated_date":"2016-12-22T00:09:21Z","reference_number":"EMEA/CHMP/657005/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-celvapan_en.pdf"},
    {"id":"36812","name":"Questions and answers on refusal of the marketing authorisation for Winfuran","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T13:00:00Z","last_updated_date":"2013-12-20T13:00:00Z","reference_number":"EMA/790619/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-winfuran_en.pdf"},
    {"id":"36820","name":"CHMP summary of positive opinion for Aripiprazole Zentiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"EMA/CHMP/232372/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aripiprazole-zentiva_en.pdf"},
    {"id":"36841","name":"CHMP summary of positive opinion for Vimizim","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/92845/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vimizim_en.pdf"},
    {"id":"36845","name":"CVMP summary of positive opinion for Zulvac 1 Ovis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-10T02:00:00Z","last_updated_date":"2020-04-01T02:00:00Z","reference_number":"EMA/CVMP/291025/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zulvac-1-ovis_en.pdf"},
    {"id":"36895","name":"CHMP summary of positive opinion for Krystexxa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2016-07-22T14:30:00Z","reference_number":"EMA/CHMP/672303/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-krystexxa_en.pdf"},
    {"id":"36956","name":"CHMP summary of positive opinion for Relvar Ellipta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/476694/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-relvar-ellipta_en.pdf"},
    {"id":"36979","name":"CHMP summary of positive opinion for Iclusig","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T01:00:00Z","last_updated_date":"2013-03-22T01:00:00Z","reference_number":"EMA/CHMP/178415/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-iclusig_en.pdf"},
    {"id":"37027","name":"Questions and answers on refusal of the marketing authorisation for Dropcys (mercaptamine hydrochloride)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-12-18T01:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/227275/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dropcys-mercaptamine-hydrochloride_sv.pdf"}},
    {"id":"37083","name":"Questions and answers on the refusal of the marketing authorisation for Folotyn (pralatrexate)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-04-20T02:00:00Z","last_updated_date":"2012-07-11T02:00:00Z","reference_number":"EMA/CHMP/255106/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-folotyn-pralatrexate_sv.pdf"}},
    {"id":"37131","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for Ixempra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-11-21T01:09:00Z","last_updated_date":"2008-11-21T01:09:00Z","reference_number":"EMEA/602569/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-ixempra_en.pdf"},
    {"id":"37153","name":"Committee for medicinal products for veterinary use summary of opinion: Netvax: Clostridium perfringens type A toxoid","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-02-13T01:09:21Z","last_updated_date":"2014-06-11T02:09:21Z","reference_number":"EMEA/CVMP/685574/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-netvax-clostridium-perfringens-type-toxoid_en.pdf"},
    {"id":"37154","name":"CHMP summary of opinion for Emtricitabine/Tenofovir disoproxil Zentiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"EMA/CHMP/596525/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-emtricitabinetenofovir-disoproxil-zentiva_en.pdf"},
    {"id":"37210","name":"CHMP summary of positive opinion for Lymphoseek","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2024-08-14T14:18:00Z","reference_number":"EMA/CHMP/525445/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lymphoseek_en.pdf"},
    {"id":"37387","name":"CHMP summary of positive opinion for Eurartesim","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-24T02:00:00Z","last_updated_date":"2011-06-24T02:00:00Z","reference_number":"EMA/CHMP/207988/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eurartesim_en.pdf"},
    {"id":"37421","name":"CHMP summary of positive opinion for Mysildecard","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-08-03T02:00:00Z","last_updated_date":"2016-08-03T02:00:00Z","reference_number":"EMA/485582/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mysildecard_en.pdf"},
    {"id":"37437","name":"CHMP summary of positive opinion for Translarna","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2025-04-16T02:00:00Z","reference_number":"EMEA/CHMP/310130/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-translarna_en.pdf"},
    {"id":"37445","name":"CHMP summary of positive opinion for Adynovi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-11-10T01:00:00Z","last_updated_date":"2017-11-10T01:00:00Z","reference_number":"EMA/CHMP/708455/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-adynovi_en.pdf"},
    {"id":"37485","name":"CHMP summary of positive opinion Ebymect","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/523224/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ebymect_en.pdf"},
    {"id":"37524","name":"CVMP summary of positive opinion for Proteq West Nile","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-06-10T02:00:00Z","last_updated_date":"2011-06-10T02:00:00Z","reference_number":"EMA/CVMP/396064/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-proteq-west-nile_en.pdf"},
    {"id":"37585","name":"CHMP summary of positive opinion for Aubagio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-03-22T13:00:00Z","reference_number":"EMA/167896/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aubagio_en.pdf-0"},
    {"id":"37643","name":"Committee for medicinal products for human use, summary of positive opinion for  Victoza","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-04-23T02:00:00Z","last_updated_date":"2009-04-23T02:00:00Z","reference_number":"EMEA/CHMP/141689/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-victoza_en.pdf"},
    {"id":"37685","name":"Committee for medicinal products for veterinary use summary of opinion: Zulvac 8 Bovis: International Non-proprietary Names (INN): inactivated Bluetongue Virus (BTV) Serotype 8","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-13T01:09:00Z","last_updated_date":"2009-11-13T01:09:00Z","reference_number":"EMEA/CVMP/665815/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-zulvac-8-bovis-international-non-proprietary-names-inn-inactivated-bluetongue-virus-btv-serotype-8_en.pdf"},
    {"id":"37690","name":"CVMP summary of positive opinion for Activyl Tick Plus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-11-11T01:00:00Z","last_updated_date":"2022-10-04T09:38:00Z","reference_number":"EMA/CVMP/825805/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-activyl-tick-plus_en.pdf"},
    {"id":"37707","name":"CVMP summary of positive opinion for  Melosus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-10T01:00:00Z","last_updated_date":"2010-12-10T01:00:00Z","reference_number":"EMA/CVMP/144729/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-melosus_en.pdf"},
    {"id":"37752","name":"CHMP summary of positive opinion for Moventig","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/496850/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-moventig_en.pdf"},
    {"id":"37822","name":"CVMP summary of positive opinion for Sedadex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"EMA/CVMP/371866/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-sedadex_en.pdf"},
    {"id":"37827","name":"Committee for medicinal products for human use, summary of positive opinion for Rivastigmine Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-02-18T01:00:00Z","last_updated_date":"2009-02-18T01:00:00Z","reference_number":"EMEA/CHMP/100894/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-rivastigmine-teva_en.pdf"},
    {"id":"37857","name":"Committee for medicinal products for human use, summary of positive opinion for Onglyza","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:00:00Z","last_updated_date":"2009-06-25T02:00:00Z","reference_number":"EMEA/CHMP/369490/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-onglyza_en.pdf"}    {"id":"37975","name":"CHMP summary of positive opinion for Amyvid","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/CHMP/545417/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-amyvid_en.pdf"},
    {"id":"38007","name":"CHMP summary of positive opinion for Eliquis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-03-18T01:00:00Z","last_updated_date":"2011-03-18T01:00:00Z","reference_number":"EMA/CHMP/87152/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eliquis_en.pdf"},
    {"id":"38017","name":"CHMP summary of positive opinion for Rixubis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/CHMP/631607/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rixubis_en.pdf"},
    {"id":"38027","name":"Committee for medicinal products for human use, summary of positive opinion for Sildenafil Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/CHMP/433047/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-sildenafil-teva_en.pdf"},
    {"id":"38109","name":"CHMP summary of positive opinion for Nityr","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"EMA/CHMP/230825/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nityr_en.pdf"},
    {"id":"38137","name":"CHMP summary of opinion for Pemetrexed medac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/596263/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-pemetrexed-medac_en.pdf"},
    {"id":"38144","name":"Committee for medicinal products for veterinary use summary of opinion: Trocoxil: International Non-proprietary Names (INN): Mavacoxib","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-07-18T03:09:21Z","last_updated_date":"2008-07-18T03:09:21Z","reference_number":"EMEA/CVMP/333587/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-trocoxil-international-non-proprietary-names-inn-mavacoxib_en.pdf"},
    {"id":"38146","name":"CVMP summary of positive opinion for Nobivac L4","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-05-21T02:00:00Z","last_updated_date":"2012-05-21T02:00:00Z","reference_number":"EMA/CVMP/282463/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-l4_en.pdf"},
    {"id":"38153","name":"CHMP summary of positive opinion for Duaklir Genuair","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-26T02:00:00Z","last_updated_date":"2014-09-26T02:00:00Z","reference_number":"EMA/CHMP/490903/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duaklir-genuair_en.pdf"},
    {"id":"38217","name":"CVMP summary of positive opinion for Versican Plus L4","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-06T02:00:00Z","last_updated_date":"2014-06-06T02:00:00Z","reference_number":"EMA/CVMP/301792/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-versican-plus-l4_en.pdf"},
    {"id":"38234","name":"CHMP summary of opinion for Palonosetron Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/220588/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-palonosetron-accord_en.pdf"},
    {"id":"38239","name":"Questions and answers on the refusal of the marketing authorisation for Onzeald (etirinotecan pegol)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"EMA/736863/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_pl.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-onzeald-etirinotecan-pegol_fi.pdf"}},
    {"id":"38244","name":"Summary of positive opinion for Clopidogrel Ratiopharm GmbH","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:00:00Z","last_updated_date":"2009-05-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/summary-positive-opinion-clopidogrel-ratiopharm-gmbh_en.pdf"},
    {"id":"38255","name":"CHMP summary of positive opinion for Constella","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-09-21T02:00:00Z","last_updated_date":"2012-09-21T02:00:00Z","reference_number":"EMA/CHMP/604998/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-constella_en.pdf"},
    {"id":"38261","name":"CHMP summary of positive opinion for Elebrato Ellipta","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"EMA/CHMP/587955/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-elebrato-ellipta_en.pdf"},
    {"id":"38277","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel Acino","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:09:21Z","last_updated_date":"2009-05-29T02:09:21Z","reference_number":"EMEA/CHMP/326464/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-acino_en.pdf"},
    {"id":"38349","name":"CHMP summary of positive opinion for Riprazo HCT","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/35671/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-riprazo-hct_en.pdf"},
    {"id":"38361","name":"CHMP summary of positive opinion for Possia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-09-24T02:00:00Z","last_updated_date":"2010-09-24T02:00:00Z","reference_number":"EMA/538872/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-possia_en.pdf"},
    {"id":"38430","name":"Questions and answers on the refusal of the marketing authorisation for Istodax (romidepsin) - Outcome of re-examination","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T13:00:00Z","last_updated_date":"2012-11-16T13:00:00Z","reference_number":"EMA/725439/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-istodax-romidepsin-outcome-re-examination_sv.pdf"}},
    {"id":"38466","name":"CHMP summary of positive opinion for Temomedac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-11-19T01:00:00Z","last_updated_date":"2009-11-19T01:00:00Z","reference_number":"EMEA/CHMP/567028/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-temomedac_en.pdf"},
    {"id":"38471","name":"CHMP summary of positive opinion for Caprelsa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T10:45:00Z","last_updated_date":"2011-11-18T10:45:00Z","reference_number":"EMA/CHMP/817228/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-caprelsa_en.pdf"},
    {"id":"38549","name":"CVMP summary of positive opinion for VarroMed","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-07T17:00:00Z","last_updated_date":"2016-10-07T17:00:00Z","reference_number":"EMA/CVMP/618897/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-varromed_en.pdf"},
    {"id":"38580","name":"CHMP summary of positive opinion for Docetaxel Teva Pharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/CHMP/630633/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-docetaxel-teva-pharma_en.pdf"},
    {"id":"38607","name":"CHMP summary of positive opinion for Adasuve","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/778608/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-adasuve_en.pdf"},
    {"id":"38689","name":"CHMP summary of positive opinion for Inlyta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-05-25T02:00:00Z","reference_number":"EMA/293828/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-inlyta_en.pdf"},
    {"id":"38704","name":"CHMP summary of opinion for Bortezomib Sun","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/170461/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-bortezomib-sun_en.pdf"},
    {"id":"38782","name":"CHMP summary of opinion for Nordimet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"EMA/CHMP/403945/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-nordimet_en.pdf"},
    {"id":"38795","name":"Questions and answers on the recommendation for the refusal of the marketing authorisation for Zeftera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-09-22T02:00:00Z","reference_number":"EMA/404483/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-recommendation-refusal-marketing-authorisation-zeftera_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zeftera_sv.pdf"}},
    {"id":"38818","name":"Committee for medicinal products for human use summary of positive opinion for Doribax","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2014-10-17T02:00:00Z","reference_number":"EMEA/CHMP/185915/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-doribax_en.pdf"},
    {"id":"38836","name":"CHMP summary of positive opinion for Pemetrexed Hospira UK Limited","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-02-24T01:00:00Z","last_updated_date":"2021-07-29T01:00:00Z","reference_number":"EMA/CHMP/96855/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pemetrexed-hospira-uk-limited_en.pdf"},
    {"id":"38839","name":"CHMP summary of positive opinion for Abilify Maintena","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/489804/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-abilify-maintena_en.pdf"},
    {"id":"38874","name":"CHMP summary of positive opinion for Daklinza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"EMA/CHMP/372924/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-daklinza_en.pdf"},
    {"id":"38934","name":"Committee for medicinal products for veterinary use summary of opinion: Improvac: Gonadotropin releasing factor (GNRF) analogue-protein conjugate","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-03-13T01:09:21Z","last_updated_date":"2009-03-13T01:09:21Z","reference_number":"EMEA/CVMP/18480/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-improvac-gonadotropin-releasing-factor-gnrf-analogue-protein-conjugate_en.pdf"},
    {"id":"38946","name":"CVMP summary of positive opinion for Ratiogratim","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-07-25T02:00:00Z","last_updated_date":"2008-07-25T02:00:00Z","reference_number":"EMEA/CHMP/374682/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-ratiogratim_en.pdf"},
    {"id":"38963","name":"CVMP summary of positive opinion for Porcilis PCV M Hyo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-09-12T02:00:00Z","last_updated_date":"2014-09-12T02:00:00Z","reference_number":"EMA/CVMP/450050/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-porcilis-pcv-m-hyo_en.pdf"},
    {"id":"39087","name":"CHMP summary of positive opinion Entresto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/616915/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-entresto_en.pdf"},
    {"id":"39094","name":"CVMP summary of opinion for Rheumocam","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-07-17T03:09:21Z","last_updated_date":"2009-07-17T03:09:21Z","reference_number":"EMEA/CVMP/398949/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-opinion-rheumocam_en.pdf"},
    {"id":"39104","name":"CHMP summary of positive opinion for Alofisel","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2025-01-21T13:00:00Z","reference_number":"EMA/CHMP/815767/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-alofisel_en.pdf"},
    {"id":"39109","name":"CHMP summary of positive opinion for Yescarta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T14:00:00Z","last_updated_date":"2018-06-29T14:00:00Z","reference_number":"EMA/CHMP/396710/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yescarta_en.pdf"},
    {"id":"39177","name":"CHMP positive summary of opinion for Ibandronic Acid Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-06-25T02:00:00Z","reference_number":"EMA/CHMP/390850/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-ibandronic-acid-teva_en.pdf"},
    {"id":"39195","name":"Committee for medicinal products for human use summary of positive opinion for Foclivia","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/446601/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-foclivia_en.pdf"},
    {"id":"39206","name":"Committee for medicinal products for human use, summary of positive opinion for Lamivudine Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2023-09-25T02:00:00Z","reference_number":"EMEA/CHMP/436960/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-lamivudine-teva_en.pdf"},
    {"id":"39247","name":"CHMP positive summary of opinion for Eklira Genuair","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-05-25T02:00:00Z","last_updated_date":"2012-06-28T02:00:00Z","reference_number":"EMA/CHMP/304272/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-eklira-genuair_en.pdf"},
    {"id":"39271","name":"CHMP summary of positive opinion for Defitelio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-26T14:00:00Z","last_updated_date":"2013-07-26T14:00:00Z","reference_number":"EMA/CHMP/455080/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-defitelio_en.pdf"},
    {"id":"39298","name":"CHMP summary of positive opinion for Ravicti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/628694/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ravicti_en.pdf"},
    {"id":"39302","name":"CHMP summary of positive opinion for Tresiba","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-10-19T14:30:00Z","last_updated_date":"2012-10-19T14:30:00Z","reference_number":"EMA/CHMP/582803/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tresiba_en.pdf"},
    {"id":"39310","name":"CHMP summary of positive opinion for Efavirenz/Emtricitabine/Tenofovir disoproxil Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T13:00:00Z","last_updated_date":"2017-12-15T13:00:00Z","reference_number":"EMA/CHMP/812280/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-efavirenzemtricitabinetenofovir-disoproxil-krka_en.pdf"},
    {"id":"39349","name":"Committee for medicinal products for human use summary of positive opinion for Clopidogrel Hexal","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-05-29T02:09:21Z","last_updated_date":"2009-05-29T02:09:21Z","reference_number":"EMEA/CHMP/227915/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-clopidogrel-hexal_en.pdf"},
    {"id":"39364","name":"Questions and answers on refusal of the marketing authorisation for Dexxience (betrixaban)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-07-27T02:00:00Z","reference_number":"EMA/164390/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban_en.pdf"},
    {"id":"39378","name":"CHMP summary of opinion for Kisplyx","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"EMA/CHMP/480541/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-kisplyx_en.pdf"},
    {"id":"39386","name":"Questions and answers on recommendation for the refusal of the marketing authorisation for Emerflu","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-03-20T00:09:21Z","last_updated_date":"2009-03-20T00:09:21Z","reference_number":"EMEA/CHMP/154410/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-emerflu_en.pdf"},
    {"id":"39408","name":"CHMP summary of positive opinion for Levodopa/Carbidopa/Entacapone Sandoz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/364817/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-levodopa-carbidopa-entacapone-sandoz_en.pdf"},
    {"id":"39420","name":"CHMP summary of positive opinion for Accofil","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-07-25T14:00:00Z","last_updated_date":"2014-07-25T14:00:00Z","reference_number":"EMA/CHMP/403328/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-accofil_en.pdf"},
    {"id":"39444","name":"CHMP summary of positive opinion for Sevelamer carbonate Zentiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2014-11-21T01:00:00Z","reference_number":"EMA/CHMP/703681/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sevelamer-carbonate-zentiva_en.pdf"},
    {"id":"39458","name":"CHMP summary of positive opinion  for Alendronate sodium and colecalciferol, MSD","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2009-07-23T02:00:00Z","reference_number":"EMEA/CHMP/374221/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-alendronate-sodium-colecalciferol-msd_en.pdf"},
    {"id":"39460","name":"CHMP summary of positive opinion for Elmiron","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"EMA/158291/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-elmiron_en.pdf"},
    {"id":"39536","name":"CHMP summary of positive opinion for Lyxumia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-11-16T01:00:00Z","last_updated_date":"2026-02-05T01:00:00Z","reference_number":"EMA/CHMP/706420/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lyxumia_en.pdf"},
    {"id":"39554","name":"Committee for medicinal products for human use, summary of positive opinion for Pandemic Influenza Vaccine H5N1 Baxter","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-07-23T02:00:00Z","last_updated_date":"2023-09-13T02:00:00Z","reference_number":"EMEA/CHMP/446619/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-pandemic-influenza-vaccine-h5n1-baxter_en.pdf"},
    {"id":"39564","name":"Questions and answers on refusal of the marketing authorisation for Human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/310037/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-human-igg1-monoclonal-antibody-specific-human-interleukin-1-alpha-xbiotech_sv.pdf"}},
    {"id":"39585","name":"CHMP summary of positive opinion for Pregabalin Zentiva k.s.","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2023-03-20T01:00:00Z","reference_number":"EMA/CHMP/643488/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-zentiva-ks_en.pdf"},
    {"id":"39667","name":"CHMP summary of positive opinion for Onbrez Breezhaler","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/541231/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-onbrez-breezhaler_en.pdf"},
    {"id":"39781","name":"CHMP summary of positive opinion for Tepadina","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2009-12-17T01:00:00Z","reference_number":"EMA/CHMP/720221/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tepadina_en.pdf"},
    {"id":"39799","name":"CHMP summary of positive opinion for Zubsolv","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"EMA/CHMP/535541/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zubsolv_en.pdf"},
    {"id":"39852","name":"CHMP summary of positive opinion for Lynparza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-10-24T02:00:00Z","last_updated_date":"2014-10-24T02:00:00Z","reference_number":"EMA/CHMP/632090/2014 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lynparza_en.pdf"},
    {"id":"39880","name":"CHMP summary of opinion for Pemetrexed Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T01:00:00Z","last_updated_date":"2015-11-20T01:00:00Z","reference_number":"EMA/CHMP/729989/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-pemetrexed-accord_en.pdf"},
    {"id":"39959","name":"CHMP summary of positive opinion for Cresemba","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T02:00:00Z","last_updated_date":"2015-07-24T02:00:00Z","reference_number":"EMA/CHMP/470149/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cresemba_en.pdf"},
    {"id":"39963","name":"CHMP summary of positive opinion for Rasagiline ratiopharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2014-11-21T01:00:00Z","reference_number":"EMA/CHMP/693590/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rasagiline-ratiopharm_en.pdf"},
    {"id":"39969","name":"CHMP summary of positive opinion for Vynfinit","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/CHMP/138539/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vynfinit_en.pdf"},
    {"id":"39985","name":"Questions and answers on refusal of the marketing authorisation for Masican","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-11-22T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/167920/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-masican_sv.pdf"}},
    {"id":"40026","name":"CHMP summary of opinion for Strimvelis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-01T02:00:00Z","last_updated_date":"2016-04-01T02:00:00Z","reference_number":"EMA/CHMP/160482/2016 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-strimvelis_en.pdf"},
    {"id":"40036","name":"CHMP summary of positive opinion for Memantine LEK","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-02-25T10:15:00Z","last_updated_date":"2024-10-23T10:15:00Z","reference_number":"EMA/CHMP/82409/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-memantine-lek_en.pdf"},
    {"id":"40043","name":"CVMP summary of positive opinion for Hiprabovis IBR Marker Live","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-11-12T01:00:00Z","last_updated_date":"2010-11-12T01:00:00Z","reference_number":"EMA/CVMP/257022/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-hiprabovis-ibr-marker-live_en.pdf"},
    {"id":"40059","name":"CHMP summary of positive opinion for Ulipristal Acetate Gedeon Richter","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"EMA/CHMP/417636/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ulipristal-acetate-gedeon-richter_en.pdf"},
    {"id":"40060","name":"CHMP positive summary of opinion for Sycrest","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-06-25T02:00:00Z","last_updated_date":"2010-06-25T02:00:00Z","reference_number":"EMA/CHMP/397789/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-sycrest_en.pdf"},
    {"id":"40067","name":"CHMP summary of positive opinion for Potactasol","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"EMA/643392/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-potactasol_en.pdf"},
    {"id":"40137","name":"CHMP summary of positive opinion for Solymbic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T13:00:00Z","last_updated_date":"2017-01-27T13:00:00Z","reference_number":"EMA/CHMP/41575/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-solymbic_en.pdf"},
    {"id":"40199","name":"Questions and answers on the recommendation for the refusal of the marketing authorization for Natalizumab Elan Pharma","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-01-25T01:00:00Z","last_updated_date":"2008-01-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_fr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-natalizumab-elan-pharma_sv.pdf"}},
    {"id":"40246","name":"CHMP summary of positive opinion for Tecfidera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-03-22T13:00:00Z","last_updated_date":"2013-11-27T17:00:00Z","reference_number":"EMA/167897/2013/Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tecfidera_en.pdf"},
    {"id":"40262","name":"CHMP summary of positive opinion for Kisqali","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"EMA/CHMP/383155/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kisqali_en.pdf"},
    {"id":"40281","name":"CVMP summary of positive opinion for Vectra 3D","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-10-11T02:00:00Z","last_updated_date":"2013-10-11T02:00:00Z","reference_number":"EMA/CVMP/569374/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-vectra-3d_en.pdf"},
    {"id":"40292","name":"Questions and answers on the refusal of the marketing authorisation for Labazenit - Outcome of re-examination","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"EMA/391542/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-labazenit-outcome-re-examination_sv.pdf"}},
    {"id":"40306","name":"Committee for Medicinal Products for Human use Summary of positive opinion for Scintimun","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-10-22T02:00:00Z","last_updated_date":"2009-10-22T02:00:00Z","reference_number":"EMEA/CHMP/649306/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-scintimun_en.pdf-0"},
    {"id":"40308","name":"CHMP summary of positive opinion for Cystadrops","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-10-14T14:00:00Z","last_updated_date":"2016-10-14T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cystadrops_en.pdf"},
    {"id":"40315","name":"CHMP summary of positive opinion for Ritemvia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-05-19T02:00:00Z","last_updated_date":"2021-08-16T02:00:00Z","reference_number":"EMA/CHMP/307703/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ritemvia_en.pdf"},
    {"id":"40317","name":"Committee for Medicinal Products for Veterinary Use positive summary of opinion for Rhiniseng","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-07-16T02:00:00Z","last_updated_date":"2010-07-16T02:00:00Z","reference_number":"EMA/403480/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-positive-summary-opinion-rhiniseng_en.pdf"},
    {"id":"40365","name":"CHMP summary of positive opinion for Vantobra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-06-03T02:00:00Z","last_updated_date":"2019-03-29T01:00:00Z","reference_number":"EMA/CHMP/780275/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vantobra_en.pdf"},
    {"id":"40384","name":"Questions and answers on refusal of the marketing authorisation for Kynamro (mipomersen)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"EMA/792736/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-mipomersen_en.pdf"},
    {"id":"40494","name":"CHMP summary of positive opinion for Vosevi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"EMA/CHMP/347210/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vosevi_en.pdf"},
    {"id":"40497","name":"Committee for medicinal products for human use, summary of positive opinion for Multaq","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/CHMP/376839/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-multaq_en.pdf"},
    {"id":"40509","name":"Committee for Medicinal Products for Human use Summary of positive opinion for Zutectra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2009-09-24T02:00:00Z","last_updated_date":"2009-09-24T02:00:00Z","reference_number":"EMEA/CHMP/603846/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zutectra_en.pdf"},
    {"id":"40583","name":"CHMP summary of positive opinion for NovoEight","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-09-20T02:00:00Z","last_updated_date":"2013-09-20T02:00:00Z","reference_number":"EMA/CHMP/471074/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-novoeight_en.pdf"},
    {"id":"40858","name":"CHMP summary of positive opinion for Imatinib medac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-08-05T02:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"Imatinib medac","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imatinib-medac_en.pdf"},
    {"id":"40878","name":"CHMP summary of positive opinion for Gilenya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-01-21T01:00:00Z","last_updated_date":"2011-01-21T01:00:00Z","reference_number":"EMA/26661/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-gilenya_en.pdf"},
    {"id":"40895","name":"CHMP summary of positive opinion for Xeplion","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/777632/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xeplion_en.pdf"},
    {"id":"40905","name":"CHMP summary of positive opinion for Aripiprazole Sandoz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-06-26T02:00:00Z","last_updated_date":"2015-06-26T02:00:00Z","reference_number":"EMA/CHMP/387290/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aripiprazole-sandoz_en.pdf"},
    {"id":"40923","name":"CHMP summary of positive opinion for Leflunomide medac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-05-21T02:00:00Z","last_updated_date":"2010-05-21T02:00:00Z","reference_number":"EMA/CHMP/291554/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-leflunomide-medac_en.pdf"},
    {"id":"40952","name":"CHMP summary of positive opinion for Votrient","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-02-18T01:00:00Z","last_updated_date":"2010-04-23T02:00:00Z","reference_number":"EMA/CHMP/104905/2010 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-votrient_en.pdf"},
    {"id":"40963","name":"CHMP summary of positive opinion for Herzuma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-12-15T01:00:00Z","last_updated_date":"2017-12-15T01:00:00Z","reference_number":"EMA/CHMP/774782/2017 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-herzuma_en.pdf"},
    {"id":"41000","name":"CHMP summary of positive opinion for Plegridy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-05-23T02:00:00Z","last_updated_date":"2014-05-23T02:00:00Z","reference_number":"EMA/CHMP/276483/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-plegridy_en.pdf"},
    {"id":"41009","name":"Committee for medicinal products for human use summary of positive opinion for Firazyr","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-04-28T02:09:21Z","last_updated_date":"2008-04-28T02:09:21Z","reference_number":"EMEA/CHMP/197104/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-firazyr_en.pdf"}    {"id":"41025","name":"CVMP summary of positive opinion for Fungitraxx","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-17T01:00:00Z","last_updated_date":"2014-01-17T01:00:00Z","reference_number":"EMA/CVMP/715528/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-fungitraxx_en.pdf"},
    {"id":"41055","name":"CHMP summary of opinion for Pemetrexed Fresenius Kabi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"EMA/CHMP/337417/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-pemetrexed-fresenius-kabi_en.pdf"},
    {"id":"41109","name":"CHMP summary of positive opinion for Sancuso","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T01:00:00Z","last_updated_date":"2012-02-17T01:00:00Z","reference_number":"EMA/CHMP/56995/2012","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sancuso_en.pdf"},
    {"id":"41130","name":"CHMP summary of opinion for Imlygic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"EMA/690530/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-imlygic_en.pdf"},
    {"id":"41144","name":"CHMP summary of positive opinion for Anoro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-02-21T01:00:00Z","last_updated_date":"2014-02-21T01:00:00Z","reference_number":"EMA/CHMP/55884/2014","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-anoro_en.pdf"},
    {"id":"41164","name":"CHMP positive summary of opinion for Daxas","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-04-23T02:00:00Z","last_updated_date":"2010-04-23T02:00:00Z","reference_number":"EMA/CHMP/159861/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-daxas_en.pdf"},
    {"id":"41185","name":"CHMP summary of positive opinion for Xeljanz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2017-01-27T13:00:00Z","last_updated_date":"2017-01-27T13:00:00Z","reference_number":"EMA/CHMP/32752/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xeljanz_en.pdf"},
    {"id":"41235","name":"CHMP summary of positive opinion for Dificlir","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2011-09-23T02:00:00Z","last_updated_date":"2011-09-23T02:00:00Z","reference_number":"EMA/CHMP/724015/2011","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dificlir_en.pdf"},
    {"id":"41248","name":"Committee for medicinal products for human use summary of positive opinion for ChondroCelect","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-06-25T02:09:21Z","last_updated_date":"2017-01-12T18:22:00Z","reference_number":"EMEA/CHMP/383366/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-chondrocelect_en.pdf"},
    {"id":"41254","name":"CHMP summary of positive opinion for Janumet","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-04-30T02:00:00Z","last_updated_date":"2008-04-30T02:00:00Z","reference_number":"EMEA/CHMP/132748/2008-corr","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-janumet_en.pdf"},
    {"id":"41267","name":"CHMP summary of positive opinion for Fexeric","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T14:00:00Z","last_updated_date":"2015-07-24T14:00:00Z","reference_number":"EMA/CHMP/453873/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fexeric_en.pdf"},
    {"id":"41273","name":"CHMP summary of positive opinion for Mavenclad","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T14:00:00Z","last_updated_date":"2017-06-23T14:00:00Z","reference_number":"EMA/CHMP/364898/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mavenclad_en.pdf"},
    {"id":"41348","name":"CVMP summary of opinion for Reconcile","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-04-18T03:09:21Z","last_updated_date":"2008-04-18T03:09:21Z","reference_number":"EMEA/CVMP/168454/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-opinion-reconcile_en.pdf"},
    {"id":"41358","name":"CHMP summary of positive opinion for Spedra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-04-26T14:00:00Z","last_updated_date":"2013-04-26T14:00:00Z","reference_number":"EMA/CHMP/61591/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-spedra_en.pdf"},
    {"id":"41363","name":"CHMP summary of positive opinion for Tolucombi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-01-18T13:00:00Z","reference_number":"EMA/CHMP/6036/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tolucombi_en.pdf"},
    {"id":"41452","name":"CHMP summary of positive opinion for Natpar","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2017-02-24T11:00:00Z","last_updated_date":"2017-02-24T11:00:00Z","reference_number":"EMA/CHMP/99882/2017","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-natpar_en.pdf"},
    {"id":"41469","name":"Committee for medicinal products for veterinary use summary of opinion: Masivet: International Non-proprietary Name (INN): Masitinib mesylate","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2008-09-19T03:09:21Z","last_updated_date":"2008-09-19T03:09:21Z","reference_number":"EMEA/CVMP/488287/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-veterinary-use-summary-opinion-masivet-international-non-proprietary-name-inn-masitinib-mesylate_en.pdf"},
    {"id":"41476","name":"CHMP summary of positive opinion for Lartruvo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2019-09-02T11:00:00Z","reference_number":"EMA/CHMP/589981/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lartruvo_en.pdf"},
    {"id":"41478","name":"CHMP summary of positive opinion for Ebilfumin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-03-21T13:00:00Z","last_updated_date":"2014-03-21T13:00:00Z","reference_number":"EMA/CHMP/66668/2014 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ebilfumin_en.pdf"},
    {"id":"41518","name":"CHMP summary of positive opinion for Leflunomide Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2014-03-18T01:00:00Z","reference_number":"EMA/CHMP/605159/2010","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-leflunomide-teva_en.pdf"},
    {"id":"41601","name":"Committee for medicinal products for human use, summary of positive opinion for Irbesartan/Hydrochlorothiazide Teva","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2009-09-25T02:00:00Z","last_updated_date":"2009-09-25T02:00:00Z","reference_number":"EMEA/592212/2009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-irbesartanhydrochlorothiazide-teva_en.pdf"},
    {"id":"41721","name":"Committee for medicinal products for human use  summary of positive opinion  for Zarzio","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T01:00:00Z","last_updated_date":"2008-11-20T01:00:00Z","reference_number":"EMEA/CHMP/574426/2008","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zarzio_en.pdf"},
    {"id":"41749","name":"CVMP summary of positive opinion for Trifexis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-07-19T02:00:00Z","last_updated_date":"2018-10-08T02:00:00Z","reference_number":"EMA/CVMP/374777/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-trifexis_en.pdf"},
    {"id":"41759","name":"CHMP summary of positive opinion for Vihuma","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T10:00:00Z","last_updated_date":"2016-12-16T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vihuma_en.pdf"},
    {"id":"41793","name":"CVMP summary of positive opinion for Velactis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-10-09T02:00:00Z","last_updated_date":"2021-01-25T02:00:00Z","reference_number":"EMA/CVMP/484406/2015 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-velactis_en.pdf"},
    {"id":"41871","name":"CHMP summary of positive opinion for Ovaleap","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-08-01T18:00:00Z","last_updated_date":"2013-08-01T18:00:00Z","reference_number":"EMA/422789/2013","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ovaleap_en.pdf"},
    {"id":"41937","name":"Questions and answers on the positive opinion on the marketing authorisation for Nerlynx (neratinib)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2018-06-29T14:00:00Z","reference_number":"EMA/105037/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-positive-opinion-marketing-authorisation-nerlynx-neratinib_en.pdf"},
    {"id":"41967","name":"CVMP summary of positive opinion for Fortekor Plus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-10T17:00:00Z","last_updated_date":"2015-07-10T17:00:00Z","reference_number":"EMA/CVMP/274376/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-fortekor-plus_en.pdf"},
    {"id":"41974","name":"CHMP summary of positive opinion for Ilumetri","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"EMA/CHMP/464222/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ilumetri_en.pdf"},
    {"id":"41989","name":"CHMP summary of positive opinion Nucala","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-09-25T02:00:00Z","last_updated_date":"2015-09-25T02:00:00Z","reference_number":"EMA/CHMP/519805/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nucala_en.pdf"},
    {"id":"41999","name":"CHMP summary of positive opinion for Thorinane","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-07-22T14:00:00Z","last_updated_date":"2019-10-24T14:00:00Z","reference_number":"EMA/CHMP/482415/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-thorinane_en.pdf"},
    {"id":"42023","name":"CHMP summary of positive opinion for Fiasp","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-11-11T01:00:00Z","last_updated_date":"2016-11-11T01:00:00Z","reference_number":"EMA/CHMP/702450/2016","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fiasp_en.pdf"},
    {"id":"42048","name":"CHMP summary of positive opinion for Pifeltro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T14:00:00Z","last_updated_date":"2018-09-21T14:00:00Z","reference_number":"EMA/CHMP/619927/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pifeltro_en.pdf"},
    {"id":"42062","name":"CHMP summary of positive opinion for Pelmeg","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/CHMP/557733/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pelmeg_en.pdf"},
    {"id":"42081","name":"CHMP summary of positive opinion for Delstrigo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T18:48:00Z","last_updated_date":"2018-09-21T18:48:00Z","reference_number":"EMA/CHMP/619909/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-delstrigo_en.pdf"},
    {"id":"42084","name":"CHMP summary of positive opinion for Alunbrig","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T14:00:00Z","last_updated_date":"2018-09-21T14:00:00Z","reference_number":"EMA/CHMP/583486/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-alunbrig_en.pdf"},
    {"id":"42095","name":"CHMP summary of positive opinion for Ziextenzo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/612888/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ziextenzo_en.pdf"},
    {"id":"42111","name":"CHMP summary of positive opinion for Apealea","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2024-03-06T16:22:00Z","reference_number":"EMA/CHMP/474774/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-apealea_en.pdf"},
    {"id":"42116","name":"Summary of opinion for Vabomere","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T14:00:00Z","last_updated_date":"2018-09-21T14:00:00Z","reference_number":"EMA/CHMP/635393/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/summary-opinion-vabomere_en.pdf"},
    {"id":"42127","name":"CHMP summary of positive opinion for Jivi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/CHMP/637902/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jivi_en.pdf"},
    {"id":"42128","name":"Summary of opinion for Emgality","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T14:00:00Z","last_updated_date":"2018-09-21T14:00:00Z","reference_number":"EMA/CHMP/621470/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/summary-opinion-emgality_en.pdf"},
    {"id":"42130","name":"CHMP summary of positive opinion for Fulphila","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"EMA/CHMP/572713/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fulphila_en.pdf"},
    {"id":"42132","name":"Summary of opinion for Buvidal","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T14:00:00Z","last_updated_date":"2018-09-21T14:00:00Z","reference_number":"EMA/618608/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/summary-opinion-buvidal_en.pdf"},
    {"id":"42136","name":"CHMP summary of positive opinion for Poteligeo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-09-21T14:00:00Z","last_updated_date":"2018-09-21T14:00:00Z","reference_number":"EMA/CHMP/598685/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-poteligeo_en.pdf"},
    {"id":"42176","name":"Questions and answers on refusal of the marketing authorisation for Exondys (eteplirsen) - Outcome of re-examination","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2018-07-01T23:16:00Z","last_updated_date":"2018-09-21T11:11:00Z","reference_number":"EMA/621972/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-exondys-eteplirsen-outcome-re-examination_sv.pdf"}},
    {"id":"42241","name":"Questions and answers on refusal of the marketing authorisation for Dexxience (betrixaban) - Outcome of re-examination","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T15:31:00Z","last_updated_date":"2018-10-09T11:17:00Z","reference_number":"EMA/501901/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-dexxience-betrixaban-outcome-re-examination_sv.pdf"}},
    {"id":"42326","name":"CVMP summary of negative opinion for HorStem","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-10-12T15:27:00Z","last_updated_date":"2018-10-12T15:27:00Z","reference_number":"EMA/CVMP/197495/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-negative-opinion-horstem_en.pdf"},
    {"id":"42354","name":"CHMP summary of positive opinion for Flucelvax Tetra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T14:58:00Z","last_updated_date":"2026-02-27T08:00:00Z","reference_number":"EMA/CHMP/641495/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-flucelvax-tetra_en.pdf"},
    {"id":"42355","name":"CHMP summary of positive opinion for Dengvaxia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T15:03:00Z","last_updated_date":"2025-12-04T12:00:00Z","reference_number":"EMA/CHMP/666423/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dengvaxia_en.pdf"},
    {"id":"42360","name":"CHMP summary of positive opinion for Takhzyro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T12:00:00Z","last_updated_date":"2018-10-19T12:00:00Z","reference_number":"EMA/700432/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-takhzyro_en.pdf"},
    {"id":"42364","name":"CHMP summary of positive opinion for Ogivri","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T12:00:00Z","last_updated_date":"2018-10-19T12:00:00Z","reference_number":"EMA/CHMP/688548/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ogivri_en.pdf"},
    {"id":"42374","name":"CHMP summary of positive opinion for Bevespi Aerosphere","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T12:00:00Z","last_updated_date":"2018-10-19T12:00:00Z","reference_number":"EMA/CHMP/70534/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bevespi-aerosphere_en.pdf"},
    {"id":"42377","name":"CHMP summary of positive opinion for Namuscla","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-10-19T11:01:00Z","last_updated_date":"2018-10-19T11:01:00Z","reference_number":"EMA/CHMP/650838/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-namuscla_en.pdf"},
    {"id":"42617","name":"CVMP summary of positive opinion for Isemid","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-11-09T15:35:00Z","last_updated_date":"2018-11-09T15:35:00Z","reference_number":"EMA/CVMP/719848/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-isemid_en.pdf"},
    {"id":"42618","name":"CVMP summary of opinion for Syvazul BTV","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-11-09T15:54:00Z","last_updated_date":"2018-11-09T15:54:00Z","reference_number":"EMA/CVMP/735427/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-opinion-syvazul-btv_en.pdf"},
    {"id":"42673","name":"CHMP summary of positive opinion for Silodosin Recordati","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T14:50:00Z","last_updated_date":"2018-11-16T14:50:00Z","reference_number":"EMA/766073/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-silodosin-recordati_en.pdf"},
    {"id":"42679","name":"CHMP summary of positive opinion for Macimorelin Aeterna Zentaris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T15:58:00Z","last_updated_date":"2018-11-16T15:58:00Z","reference_number":"EMA/CHMP/777751/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-macimorelin-aeterna-zentaris_en.pdf"},
    {"id":"42696","name":"CHMP summary of positive opinion for Erleada","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T13:00:00Z","last_updated_date":"2018-11-16T13:00:00Z","reference_number":"EMA/CHMP/784876/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-erleada_en.pdf"},
    {"id":"42699","name":"CHMP summary of opinion for Fexinidazole Winthrop","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T10:49:00Z","last_updated_date":"2018-11-16T10:49:00Z","reference_number":"EMA/791484/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-fexinidazole-winthrop_en.pdf"},
    {"id":"42962","name":"CVMP summary of positive opinion for Kriptazen","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-12-07T16:48:00Z","last_updated_date":"2018-12-07T16:48:00Z","reference_number":"EMA/CVMP/788664/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-kriptazen_en.pdf"},
    {"id":"43037","name":"CHMP summary of positive opinion for Rizmoic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/845509/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rizmoic_en.pdf"},
    {"id":"43044","name":"CHMP summary of positive opinion for Tobramycin PARI","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/CHMP/862388/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tobramycin-pari_en.pdf"},
    {"id":"43045","name":"CHMP summary of positive opinion for Miglustat Dipharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/CHMP/825267/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-miglustat-dipharma_en.pdf"},
    {"id":"43050","name":"CHMP summary of positive opinion for Lusutrombopag Shionogi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"EMA/CHMP/862586/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lusutrombopag-shionogi_en.pdf"},
    {"id":"43067","name":"CHMP summary of positive opinion for Zirabev","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T11:53:00Z","last_updated_date":"2018-12-14T11:53:00Z","reference_number":"EMA/CHMP/852740/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zirabev_en.pdf"},
    {"id":"43070","name":"CHMP summary of positive opinion for Besremi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T12:06:00Z","last_updated_date":"2018-12-14T12:06:00Z","reference_number":"EMA/CHMP/867687/2018 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-besremi_en.pdf"},
    {"id":"43074","name":"CHMP summary of positive opinion for Trecondi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-12-14T14:00:00Z","last_updated_date":"2019-01-17T16:56:00Z","reference_number":"EMA/CHMP/848829/2018 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trecondi_en.pdf"},
    {"id":"43567","name":"CHMP summary of positive opinion for Ajovy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T14:13:00Z","last_updated_date":"2019-02-01T14:13:00Z","reference_number":"EMA/CHMP/808036/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ajovy_en.pdf"},
    {"id":"43572","name":"CHMP summary of positive opinion for Febuxostat Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T15:42:00Z","last_updated_date":"2019-02-01T15:42:00Z","reference_number":"EMA/CHMP/849632/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-febuxostat-krka_en.pdf"},
    {"id":"43592","name":"CHMP summary of positive opinion for Atazanavir Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T12:00:00Z","last_updated_date":"2026-03-27T11:30:00Z","reference_number":"EMA/CHMP/17181/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-atazanavir-krka_en.pdf"},
    {"id":"43593","name":"CHMP summary of positive opinion for Kromeya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-01-31T18:26:00Z","last_updated_date":"2019-01-31T18:26:00Z","reference_number":"EMA/CHMP/45722/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kromeya_en.pdf"},
    {"id":"43596","name":"CHMP summary of positive opinion for Idacio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T10:08:00Z","last_updated_date":"2019-02-01T10:08:00Z","reference_number":"EMA/CHMP/41190/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-idacio_en.pdf"},
    {"id":"43598","name":"CHMP summary of positive opinion for Vizimpro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T10:22:00Z","last_updated_date":"2019-02-01T10:22:00Z","reference_number":"EMA/CHMP/34937/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vizimpro_en.pdf"},
    {"id":"43610","name":"Questions and answers on the refusal of the marketing authorisation for Doxolipad (doxorubicin)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-01T13:19:00Z","last_updated_date":"2019-08-26T11:30:00Z","reference_number":"EMA/295022/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-doxolipad-doxorubicin_sv.pdf"}},
    {"id":"43877","name":"CVMP summary of positive opinion for ReproCyc ParvoFLEX","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-22T16:08:00Z","last_updated_date":"2019-02-22T16:08:00Z","reference_number":"EMA/CVMP/56532/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-reprocyc-parvoflex_en.pdf"},
    {"id":"43878","name":"CVMP summary of positive opinion for HorStem","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-22T16:24:00Z","last_updated_date":"2019-02-22T16:24:00Z","reference_number":"EMA/CVMP/131410/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-horstem_en.pdf"},
    {"id":"43879","name":"CVMP summary of positive opinion for Forceris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-22T16:33:00Z","last_updated_date":"2019-02-22T16:33:00Z","reference_number":"EMA/CVMP/64773/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-forceris_en.pdf"},
    {"id":"43880","name":"CVMP summary of positive opinion for Felisecto Plus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-22T16:37:00Z","last_updated_date":"2019-02-22T16:37:00Z","reference_number":"EMA/CVMP/112858/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-felisecto-plus_en.pdf"},
    {"id":"43881","name":"CVMP summary of positive opinion for Chanhold","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-02-22T16:44:00Z","last_updated_date":"2019-02-22T16:44:00Z","reference_number":"EMA/CVMP/64944/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-chanhold_en.pdf"},
    {"id":"43926","name":"CHMP summary of positive opinion for Dectova","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T10:22:00Z","last_updated_date":"2019-03-01T10:22:00Z","reference_number":"EMA/CHMP/851518/2018","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dectova_en.pdf"},
    {"id":"43927","name":"CHMP summary of positive opinion for Skyrizi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T10:43:00Z","last_updated_date":"2019-03-01T10:43:00Z","reference_number":"EMA/CHMP/132686/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-skyrizi_en.pdf"},
    {"id":"43932","name":"CHMP summary of positive opinion for Palynziq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T13:55:00Z","last_updated_date":"2019-03-01T13:55:00Z","reference_number":"EMA/CHMP/139000/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-palynziq_en.pdf"},
    {"id":"43939","name":"CHMP summary of positive opinion for Zynquista","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T12:00:00Z","last_updated_date":"2022-08-16T15:30:00Z","reference_number":"EMA/CHMP/138211/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zynquista_en.pdf"},
    {"id":"43940","name":"CHMP summary of positive opinion for Ondexxya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T12:00:00Z","last_updated_date":"2019-03-01T12:00:00Z","reference_number":"EMA/CHMP/40684/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ondexxya_en.pdf"},
    {"id":"43942","name":"CHMP summary of positive opinion for Waylivra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T12:00:00Z","last_updated_date":"2019-03-01T12:00:00Z","reference_number":"EMA/CHMP/130311/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-waylivra_en.pdf"},
    {"id":"43946","name":"CHMP summary of positive opinion for Lorviqua","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T09:48:00Z","last_updated_date":"2019-03-01T09:48:00Z","reference_number":"EMA/CHMP/34031/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lorviqua_en.pdf"},
    {"id":"43948","name":"CHMP summary of positive opinion for Pazenir","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-01T09:55:00Z","last_updated_date":"2019-03-01T09:55:00Z","reference_number":"EMA/CHMP/147314/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pazenir_en.pdf"},
    {"id":"44081","name":"Questions and answers on the refusal of the marketing authorisation for Longrange","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2019-03-21T09:36:00Z","last_updated_date":"2019-03-21T09:36:00Z","reference_number":"EMA/778491/201","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-longrange_sv.pdf"}},
    {"id":"44089","name":"CVMP summary of positive opinion for Afoxolaner Merial","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-22T15:31:00Z","last_updated_date":"2019-03-22T15:31:00Z","reference_number":"EMA/CVMP/149492/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-afoxolaner-merial_en.pdf"},
    {"id":"44090","name":"CVMP summary of positive opinion for Baycox Iron","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-22T15:37:00Z","last_updated_date":"2019-03-22T15:37:00Z","reference_number":"EMA/CVMP/98703/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-baycox-iron_en.pdf"},
    {"id":"44134","name":"CHMP summary of positive opinion for Zynteglo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-03-29T14:30:00Z","last_updated_date":"2019-03-29T14:30:00Z","reference_number":"EMA/CHMP/166977/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zynteglo_en.pdf"},
    {"id":"44353","name":"CHMP summary of opinion for Sixmo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T15:00:00Z","last_updated_date":"2025-08-14T18:07:33Z","reference_number":"EMA/CHMP/215656/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-sixmo_en.pdf"},
    {"id":"44355","name":"CHMP summary of positive opinion for Grasustek","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T15:03:00Z","last_updated_date":"2019-04-26T15:03:00Z","reference_number":"EMA/CHMP/209662/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-grasustek_en.pdf"},
    {"id":"44356","name":"CHMP summary of positive opinion for Xromi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T15:11:00Z","last_updated_date":"2019-04-26T15:11:00Z","reference_number":"EMA/CHMP/223395/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xromi_en.pdf"},
    {"id":"44357","name":"CHMP summary of positive opinion for Esperoct","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T09:34:00Z","last_updated_date":"2019-04-26T09:34:00Z","reference_number":"EMA/CHMP/170114/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-esperoct_en.pdf"},
    {"id":"44358","name":"CHMP summary of positive opinion for Striascan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T12:04:00Z","last_updated_date":"2019-04-26T12:04:00Z","reference_number":"EMA/CHMP/225317/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-striascan_en.pdf"},
    {"id":"44362","name":"CHMP summary of positive opinion for Doptelet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T15:00:00Z","last_updated_date":"2019-04-26T15:00:00Z","reference_number":"EMA/CHMP/208938/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-doptelet_en.pdf"},
    {"id":"44363","name":"CHMP summary of positive opinion for Ultomiris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T15:00:00Z","last_updated_date":"2019-04-26T15:00:00Z","reference_number":"EMA/CHMP/223053/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ultomiris_en.pdf"},
    {"id":"44370","name":"CHMP summary of positive opinion for Ambrisentan Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T15:30:00Z","last_updated_date":"2019-04-26T15:30:00Z","reference_number":"EMA/231400/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ambrisentan-mylan_en.pdf"},
    {"id":"44377","name":"CHMP summary of positive opinion for Talzenna","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T14:38:00Z","last_updated_date":"2019-04-26T14:38:00Z","reference_number":"EMA/CHMP/232257/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-talzenna_en.pdf"}    {"id":"44378","name":"CHMP summary of positive opinion for Nuceiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T14:43:00Z","last_updated_date":"2019-04-26T14:43:00Z","reference_number":"EMA/CHMP/184075/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nuceiva_en.pdf"},
    {"id":"44380","name":"CHMP summary of positive opinion for Libtayo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T15:00:00Z","last_updated_date":"2019-04-26T15:00:00Z","reference_number":"EMA/CHMP/213223/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-libtayo_en.pdf"},
    {"id":"44383","name":"CHMP summary of positive opinion for Temybric Ellipta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T17:41:00Z","last_updated_date":"2022-11-24T15:34:00Z","reference_number":"EMA/CHMP/228757/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-temybric-ellipta_en.pdf"},
    {"id":"44384","name":"Questions and answers on the refusal of the marketing authorisation for Cabazitaxel Teva (cabazitaxel)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-26T17:48:00Z","last_updated_date":"2019-07-24T16:10:00Z","reference_number":"EMA/280533/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-cabazitaxel-teva-cabazitaxel_sv.pdf"}},
    {"id":"44385","name":"CHMP summary of positive opinion for Dovato","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-04-29T09:08:00Z","last_updated_date":"2019-04-29T09:08:00Z","reference_number":"EMA/CHMP/213099/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dovato_en.pdf"},
    {"id":"44590","name":"CVMP summary of positive opinion for Evicto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-05-24T13:46:00Z","last_updated_date":"2019-05-24T13:46:00Z","reference_number":"EMA/CVMP/263560/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-evicto_en.pdf"},
    {"id":"44591","name":"CVMP summary of positive opinion for Nasym","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-05-24T13:51:00Z","last_updated_date":"2019-05-24T13:51:00Z","reference_number":"EMA/CVMP/252872/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nasym_en.pdf"},
    {"id":"44603","name":"CHMP summary of positive opinion for Posaconazole Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-05-29T19:52:00Z","last_updated_date":"2019-05-29T19:52:00Z","reference_number":"EMA/CHMP/275407/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-posaconazole-accord_en.pdf"},
    {"id":"44604","name":"CHMP summary of positive opinion for Posaconazole AHCL","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-05-29T19:00:00Z","last_updated_date":"2019-05-29T19:00:00Z","reference_number":"EMA/CHMP/275501/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-posaconazole-ahcl_en.pdf"},
    {"id":"44607","name":"CHMP summary of positive opinion for Cufence","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-05-29T10:32:00Z","last_updated_date":"2019-05-29T10:32:00Z","reference_number":"EMA/290870/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cufence_en.pdf"},
    {"id":"44620","name":"CHMP summary of positive opinion for LysaKare","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-05-29T14:39:00Z","last_updated_date":"2019-05-29T14:39:00Z","reference_number":"EMA/CHMP/276812/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lysakare_en.pdf"},
    {"id":"44623","name":"Questions and answers on the refusal of the marketing authorisation for Xyndari (glutamine)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-05-29T19:00:00Z","last_updated_date":"2019-06-28T12:03:00Z","reference_number":"EMA/290531/2019 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-xyndari-glutamine_en.pdf"},
    {"id":"44677","name":"Questions and answers on refusal of the marketing authorisation for Nerlynx (neratinib)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-02-23T16:30:00Z","last_updated_date":"2018-02-23T16:30:00Z","reference_number":"EMA/105037/2018 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nerlynx-neratinib_en.pdf"},
    {"id":"44903","name":"CHMP summary of positive opinion for Azacitidine Celgene","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T12:00:00Z","last_updated_date":"2021-08-04T16:54:00Z","reference_number":"EMA/CHMP/332005/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-azacitidine-celgene_en.pdf"},
    {"id":"44905","name":"CHMP summary of positive opinion for Giapreza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T11:06:00Z","last_updated_date":"2019-06-28T11:06:00Z","reference_number":"EMA/CHMP/287624/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-giapreza_en.pdf"},
    {"id":"44940","name":"CHMP summary of positive opinion for Lacosamide UCB","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T11:29:00Z","last_updated_date":"2019-06-28T11:29:00Z","reference_number":"EMA/CHMP/343641/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lacosamide-ucb_en.pdf"},
    {"id":"45102","name":"CVMP summary of positive opinion for Simparica Trio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-07-19T14:16:00Z","last_updated_date":"2019-07-19T14:16:00Z","reference_number":"EMA/CVMP/364931/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-simparica-trio_en.pdf"},
    {"id":"45124","name":"CHMP summary of positive opinion for Vitrakvi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/413258/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vitrakvi_en.pdf"},
    {"id":"45125","name":"CHMP summary of positive opinion for Inbrija","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/394791/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-inbrija_en.pdf"},
    {"id":"45128","name":"CHMP summary of positive opinion for Deferasirox Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:15:00Z","last_updated_date":"2019-07-26T12:15:00Z","reference_number":"EMA/CHMP/376612/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-deferasirox-mylan_en.pdf"},
    {"id":"45133","name":"CHMP summary of positive opinion for Epidyolex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2019-07-26T12:00:00Z","reference_number":"EMA/CHMP/417900/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-epidyolex_en.pdf"},
    {"id":"45137","name":"CHMP summary of positive opinion for Trogarzo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-07-26T12:00:00Z","last_updated_date":"2023-01-16T11:29:00Z","reference_number":"EMA/CHMP/85932/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trogarzo_en.pdf"},
    {"id":"45426","name":"Questions and answers on the refusal of the marketing authorisation for Horse Allo 20","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2019-09-12T14:08:00Z","last_updated_date":"2019-09-12T14:08:00Z","reference_number":"EMA/390978/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-horse-allo-20_sv.pdf"}},
    {"id":"45447","name":"CHMP summary of positive opinion for Gumbohatch","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-09-13T13:34:00Z","last_updated_date":"2019-09-13T13:34:00Z","reference_number":"EMA/CVMP/472052/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-gumbohatch_en.pdf"},
    {"id":"45448","name":"CHMP summary of positive opinion for Nobivac Myxo-RHD Plus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-09-13T13:48:00Z","last_updated_date":"2019-09-13T13:48:00Z","reference_number":"EMA/CVMP/473135/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nobivac-myxo-rhd-plus_en.pdf"},
    {"id":"45466","name":"CHMP summary of positive opinion for Bortezomib Fresenius Kabi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T16:09:00Z","last_updated_date":"2019-09-20T16:09:00Z","reference_number":"EMA/CHMP/496127/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bortezomib-fresenius-kabi_en.pdf"},
    {"id":"45467","name":"CHMP summary of positive opinion for Ivozall","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T16:22:00Z","last_updated_date":"2023-12-07T15:52:00Z","reference_number":"EMA/CHMP/494372/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ivozall_en.pdf"},
    {"id":"45475","name":"CHMP summary of positive opinion for Rhokiinsa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T11:51:00Z","last_updated_date":"2019-09-20T11:51:00Z","reference_number":"EMA/505213/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rhokiinsa_en.pdf"},
    {"id":"45476","name":"CHMP summary of positive opinion for Arsenic trioxide Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T11:58:00Z","last_updated_date":"2019-09-20T11:58:00Z","reference_number":"EMA/CHMP/498421/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-arsenic-trioxide-accord_en.pdf"},
    {"id":"45482","name":"CHMP summary of positive opinion for Qtrilmet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T14:58:00Z","last_updated_date":"2019-09-20T14:58:00Z","reference_number":"EMA/CHMP/478963/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-qtrilmet_en.pdf"},
    {"id":"45483","name":"CHMP summary of positive opinion for Xospata","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:13:00Z","last_updated_date":"2019-09-20T12:13:00Z","reference_number":"EMA/CHMP/501445/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xospata_en.pdf"},
    {"id":"45491","name":"CHMP summary of positive opinion for Senstend","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-09-20T12:00:00Z","last_updated_date":"2022-07-05T12:16:00Z","reference_number":"EMA/CHMP/382383/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-senstend_en.pdf"},
    {"id":"45664","name":"CVMP summary of positive opinion for Mirataz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-11T15:00:00Z","last_updated_date":"2019-10-11T15:00:00Z","reference_number":"EMA/CVMP/515319/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-mirataz_en.pdf"},
    {"id":"45665","name":"CVMP summary of positive opinion for Neptra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-11T15:00:00Z","last_updated_date":"2019-10-11T15:00:00Z","reference_number":"EMA/CVMP/513917/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-neptra_en.pdf"},
    {"id":"45728","name":"CHMP  summary of positive opinion for Ervebo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T09:16:00Z","last_updated_date":"2019-10-18T09:16:00Z","reference_number":"EMA/CHMP/557387/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ervebo_en.pdf"},
    {"id":"45732","name":"CHMP summary of positive opinion for Rinvoq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"EMA/CHMP/521392/2019 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rinvoq_en.pdf"},
    {"id":"45738","name":"CHMP  summary of positive opinion for Baqsimi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T14:38:00Z","last_updated_date":"2019-10-18T14:38:00Z","reference_number":"EMA/CHMP/542297/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-baqsimi_en.pdf"},
    {"id":"45746","name":"CHMP summary of positive opinion for Evenity","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-06-28T16:48:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"EMA/546072/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-evenity_en.pdf"},
    {"id":"45747","name":"CHMP  summary of positive opinion for Spravato","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T17:35:00Z","last_updated_date":"2019-10-18T17:35:00Z","reference_number":"EMA/557804/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-spravato_en.pdf"},
    {"id":"45750","name":"Questions and answers on the refusal of the marketing authorisation for Vanflyta (quizartinib)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T18:04:00Z","last_updated_date":"2020-01-06T15:22:00Z","reference_number":"EMA/559309/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-vanflyta-quizartinib_sv.pdf"}},
    {"id":"45751","name":"CHMP  summary of positive opinion for Quofenix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T12:00:00Z","last_updated_date":"2019-10-18T12:00:00Z","reference_number":"EMA/CHMP/471384/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-quofenix_en.pdf"},
    {"id":"45754","name":"CHMP summary of positive opinion for Pegfilgrastim Mundipharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T09:44:00Z","last_updated_date":"2019-10-18T09:44:00Z","reference_number":"EMA/CHMP/553662/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pegfilgrastim-mundipharma_en.pdf"},
    {"id":"45940","name":"CVMP summary of positive opinion for Aservo EquiHaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T11:48:00Z","last_updated_date":"2019-11-08T11:48:00Z","reference_number":"EMA/CVMP/573530/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-aservo-equihaler_en.pdf"},
    {"id":"45941","name":"CVMP summary of positive opinion for Stelfonta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-11-08T11:55:00Z","last_updated_date":"2019-11-08T11:55:00Z","reference_number":"EMA/CVMP/560649/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-stelfonta_en.pdf"},
    {"id":"45990","name":"CHMP  summary of positive opinion for Clopidogrel / Acetylsalicylic acid Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T11:18:00Z","last_updated_date":"2019-11-15T11:18:00Z","reference_number":"EMA/419889/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-clopidogrel-acetylsalicylic-acid-mylan_en.pdf"},
    {"id":"46021","name":"CHMP summary of positive opinion for Tavlesse","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T13:47:00Z","last_updated_date":"2019-11-15T13:47:00Z","reference_number":"EMA/CHMP/536390/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tavlesse_en.pdf"},
    {"id":"46024","name":"CHMP  summary of positive opinion for Isturisa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T15:10:00Z","last_updated_date":"2019-11-15T15:10:00Z","reference_number":"EMA/545160/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-isturisa_en.pdf"},
    {"id":"46025","name":"CHMP  summary of positive opinion for Mayzent","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T15:25:00Z","last_updated_date":"2019-11-15T15:25:00Z","reference_number":"EMA/CHMP/596356/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mayzent_en.pdf"},
    {"id":"46026","name":"CHMP summary of positive opinion for Sunosi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T15:30:00Z","last_updated_date":"2019-11-15T15:30:00Z","reference_number":"EMA/CHMP/569229/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sunosi_en.pdf"},
    {"id":"46027","name":"CHMP summary of positive opinion for Deferasirox Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T15:33:00Z","last_updated_date":"2019-11-15T15:33:00Z","reference_number":"EMA/CHMP/590490/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-deferasirox-accord_en.pdf"},
    {"id":"46042","name":"CHMP summary of positive opinion for Polivy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T12:00:00Z","last_updated_date":"2019-11-15T12:00:00Z","reference_number":"EMA/CHMP/402512/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-polivy_en.pdf"},
    {"id":"46283","name":"CHMP summary of positive opinion for Beovu","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T16:12:00Z","last_updated_date":"2019-12-13T16:12:00Z","reference_number":"EMA/CHMP/656078/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-beovu_en.pdf"},
    {"id":"46299","name":"CHMP summary of positive opinion for Amsparity","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T12:46:00Z","last_updated_date":"2019-12-13T12:46:00Z","reference_number":"EMA/CHMP/642336/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-amsparity_en.pdf"},
    {"id":"46302","name":"CHMP summary of positive opinion for Recarbrio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T12:00:00Z","last_updated_date":"2019-12-13T12:00:00Z","reference_number":"EMA/CHMP/662007/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-recarbrio_en.pdf"},
    {"id":"46304","name":"CHMP summary of positive opinion for Dexmedetomidine Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T15:54:00Z","last_updated_date":"2019-12-13T15:54:00Z","reference_number":"EMA/CHMP/655997/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dexmedetomidine-accord_en.pdf"},
    {"id":"46315","name":"CHMP summary of positive opinion for Azacitidine Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-12-13T12:00:00Z","last_updated_date":"2019-12-13T12:00:00Z","reference_number":"EMA/CHMP/595680/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-azacitidine-accord_en.pdf"},
    {"id":"46348","name":"CHMP summary of positive opinion for Spravato","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T15:52:00Z","last_updated_date":"2019-10-18T15:52:00Z","reference_number":"EMA/557804/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-spravato_en.pdf-0"},
    {"id":"46373","name":"CHMP summary of positive opinion for Quofenix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-10-18T14:19:00Z","last_updated_date":"2019-10-18T14:19:00Z","reference_number":"EMA/CHMP/471384/2019 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-quofenix_en.pdf-0"},
    {"id":"46512","name":"CHMP summary of positive opinion for Mayzent","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2019-11-15T16:03:00Z","last_updated_date":"2019-11-15T16:03:00Z","reference_number":"EMA/CHMP/596356/2019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mayzent_en.pdf-0"},
    {"id":"46620","name":"CHMP summary of positive opinion for Nustendi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T12:07:00Z","last_updated_date":"2020-01-31T12:07:00Z","reference_number":"EMA/CHMP/44979/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nustendi_en.pdf"},
    {"id":"46621","name":"CHMP summary of positive opinion for Nilemdo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T12:21:00Z","last_updated_date":"2020-01-31T12:21:00Z","reference_number":"EMA/CHMP/44961/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nilemdo_en.pdf"},
    {"id":"46622","name":"CHMP summary of positive opinion for Vaxchora","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T12:00:00Z","last_updated_date":"2020-01-31T12:00:00Z","reference_number":"EMA/CHMP/33389/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vaxchora_en.pdf"},
    {"id":"46625","name":"CHMP summary of positive opinion for Rybelsus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T16:22:00Z","last_updated_date":"2020-01-31T16:22:00Z","reference_number":"EMA/43724/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rybelsus_en.pdf"},
    {"id":"46627","name":"CHMP summary of positive opinion for Staquis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T16:40:00Z","last_updated_date":"2022-02-08T14:12:00Z","reference_number":"EMA/CHMP/35206/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-staquis_en.pdf"},
    {"id":"46628","name":"CHMP summary of positive opinion for Arsenic trioxide Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T16:44:00Z","last_updated_date":"2025-05-06T11:22:00Z","reference_number":"EMA/CHMP/28370/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-arsenic-trioxide-mylan_en.pdf"},
    {"id":"46629","name":"CHMP summary of positive opinion for Cinacalcet Accordpharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T12:00:00Z","last_updated_date":"2020-01-31T12:00:00Z","reference_number":"EMA/43762/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cinacalcet-accordpharma_en.pdf"},
    {"id":"46630","name":"CHMP summary of positive opinion for Givlaari","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T16:58:00Z","last_updated_date":"2020-01-31T16:58:00Z","reference_number":"EMA/CHMP/38428/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-givlaari_en.pdf"},
    {"id":"46631","name":"CHMP summary of positive opinion for Nubeqa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T12:00:00Z","last_updated_date":"2020-01-31T12:00:00Z","reference_number":"EMA/32437/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nubeqa_en.pdf"},
    {"id":"46634","name":"CHMP summary of positive opinion for Trepulmix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T17:33:00Z","last_updated_date":"2020-01-31T17:33:00Z","reference_number":"EMA/CHMP/665088/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trepulmix_en.pdf"},
    {"id":"46635","name":"CHMP summary of positive opinion for Azacitidine Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T12:00:00Z","last_updated_date":"2020-02-04T15:39:00Z","reference_number":"EMA/CHMP/36892/2020 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-azacitidine-mylan_en.pdf"},
    {"id":"46637","name":"CHMP summary of positive opinion for Budesonide / Formoterol Teva Pharma B.V.","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T17:53:00Z","last_updated_date":"2020-01-31T17:53:00Z","reference_number":"EMA/CHMP/44189/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-budesonide-formoterol-teva-pharma-bv_en.pdf-0"},
    {"id":"46638","name":"CHMP summary of positive opinion for Liumjev","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T12:00:00Z","last_updated_date":"2020-01-31T12:00:00Z","reference_number":"EMA/CHMP/15190/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-liumjev_en.pdf"},
    {"id":"46644","name":"CHMP summary of positive opinion for Azacitidine betapharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T12:00:00Z","last_updated_date":"2020-01-31T12:00:00Z","reference_number":"EMA/CHMP/649228/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-azacitidine-betapharm_en.pdf"},
    {"id":"46646","name":"CHMP summary of positive opinion for Ruxience","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-01-31T10:11:00Z","last_updated_date":"2020-01-31T10:11:00Z","reference_number":"EMA/CHMP/28049/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ruxience_en.pdf"},
    {"id":"46831","name":"CVMP summary of positive opinion for Vectormune FP ILT + AE","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-02-21T15:06:00Z","last_updated_date":"2020-02-21T15:06:00Z","reference_number":"EMA/CVMP/62052/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-vectormune-fp-ilt-ae_en.pdf"},
    {"id":"46832","name":"CVMP summary of positive opinion for Tulissin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-02-21T15:21:00Z","last_updated_date":"2020-02-21T15:21:00Z","reference_number":"EMA/CVMP/50662/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-tulissin_en.pdf"},
    {"id":"46833","name":"CVMP summary of positive opinion for Tulaven","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-02-21T15:32:00Z","last_updated_date":"2020-02-21T15:32:00Z","reference_number":"EMA/CVMP/50678/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-tulaven_en.pdf"},
    {"id":"46891","name":"CHMP summary of positive opinion for Fetcroja","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-02-28T12:00:00Z","last_updated_date":"2020-02-28T12:00:00Z","reference_number":"EMA/CHMP/73102/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fetcroja_en.pdf"},
    {"id":"46905","name":"CHMP summary of positive opinion for Tigecycline Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-02-28T11:19:00Z","last_updated_date":"2020-02-28T11:19:00Z","reference_number":"EMA/CHMP/73022/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tigecycline-accord_en.pdf"},
    {"id":"47065","name":"CVMP summary of positive opinion for Lydaxx","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-03-20T15:00:00Z","last_updated_date":"2020-03-20T15:00:00Z","reference_number":"EMA/CVMP/110264/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-lydaxx_en.pdf"},
    {"id":"47115","name":"CHMP summary of positive opinion for Fluad Tetra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T13:33:00Z","last_updated_date":"2026-02-26T16:00:00Z","reference_number":"EMA/CHMP/132960/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fluad-tetra_en.pdf"},
    {"id":"47165","name":"CHMP summary of positive opinion for Sarclisa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T10:56:00Z","last_updated_date":"2020-03-27T10:56:00Z","reference_number":"EMA/CHMP/105780/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sarclisa_en.pdf"},
    {"id":"47168","name":"CHMP summary of positive opinion for Zolgensma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T16:11:00Z","last_updated_date":"2020-03-27T16:11:00Z","reference_number":"EMA/106773/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zolgensma_en.pdf"},
    {"id":"47176","name":"CHMP summary of positive opinion for Pretomanid FGK","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/CHMP/116569/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pretomanid-fgk_en.pdf"},
    {"id":"47177","name":"CHMP summary of positive opinion for Nepexto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/CHMP/114945/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nepexto_en.pdf"},
    {"id":"47186","name":"CHMP summary of positive opinion for Zeposia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-03-27T13:25:00Z","last_updated_date":"2020-03-27T13:25:00Z","reference_number":"EMA/CHMP/136468/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zeposia_en.pdf"},
    {"id":"47194","name":"CHMP summary of positive opinion for Atectura Breezhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T16:02:00Z","last_updated_date":"2020-04-03T17:20:00Z","reference_number":"EMA/CHMP/74496/2020 Rev. ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-atectura-breezhaler_en.pdf"},
    {"id":"47196","name":"CHMP summary of positive opinion for Bemrist Breezhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-03-31T16:08:00Z","last_updated_date":"2020-04-03T17:20:00Z","reference_number":"EMA/CHMP/138090/2020 Rev.","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bemrist-breezhaler_en.pdf"},
    {"id":"47512","name":"CHMP summary of positive opinion for Cabazitaxel Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/CHMP/200669/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cabazitaxel-accord_en.pdf"},
    {"id":"47517","name":"CHMP summary of positive opinion for Insulin aspart Sanofi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T16:15:00Z","last_updated_date":"2020-04-30T16:15:00Z","reference_number":"EMA/CHMP/207078/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-insulin-aspart-sanofi_en.pdf"},
    {"id":"47522","name":"CHMP summary of positive opinion for Daurismo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/CHMP/222209/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-daurismo_en.pdf"},
    {"id":"47523","name":"CHMP summary of positive opinion for Enerzair Breezhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T12:01:00Z","last_updated_date":"2020-04-30T12:01:00Z","reference_number":"EMA/CHMP/64858/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-enerzair-breezhaler_en.pdf"},
    {"id":"47524","name":"CHMP summary of positive opinion for Paliperidone Janssen-Cilag International","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T18:06:00Z","last_updated_date":"2020-04-30T18:06:00Z","reference_number":"EMA/CHMP/230829/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-paliperidone-janssen-cilag-international_en.pdf"},
    {"id":"47527","name":"CHMP summary of positive opinion for Zimbus Breezhaler","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T14:07:00Z","last_updated_date":"2020-04-30T14:07:00Z","reference_number":"EMA/CHMP/138288/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zimbus-breezhaler_en.pdf"},
    {"id":"47539","name":"CHMP summary of positive opinion for Reblozyl","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/CHMP/221210/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-reblozyl_en.pdf"},
    {"id":"47542","name":"CHMP summary of positive opinion for Fingolimod Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-04-30T18:00:00Z","last_updated_date":"2020-04-30T18:00:00Z","reference_number":"EMA/CHMP/213580/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fingolimod-accord_en.pdf"},
    {"id":"47753","name":"CVMP summary of positive opinion for Prevexxion RN","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-05-25T12:21:00Z","last_updated_date":"2020-05-25T12:21:00Z","reference_number":"EMA/CVMP/240890/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-prevexxion-rn_en.pdf"},
    {"id":"47754","name":"CVMP summary of positive opinion for Prevexxion RN+HVT+IBD","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-05-25T12:30:00Z","last_updated_date":"2020-05-25T12:30:00Z","reference_number":"EMA/CVMP/240518/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-prevexxion-rnhvtibd_en.pdf"},
    {"id":"47791","name":"CHMP summary of positive opinion for Apixaban Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/270403/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-apixaban-accord_en.pdf"},
    {"id":"47800","name":"CHMP summary of positive opinion for Rozlytrek","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T16:25:00Z","last_updated_date":"2020-05-29T16:25:00Z","reference_number":"EMA/CHMP/279960/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rozlytrek_en.pdf"}    {"id":"47807","name":"CHMP summary of positive opinion for Piqray","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/CHMP/266002/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-piqray_en.pdf"},
    {"id":"47810","name":"CHMP summary of positive opinion for Zercepac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T17:40:00Z","last_updated_date":"2020-05-29T17:40:00Z","reference_number":"EMA/CHMP/251510/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zercepac_en.pdf"},
    {"id":"47813","name":"CHMP summary of positive opinion for Mvabea","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/CHMP/138136/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mvabea_en.pdf"},
    {"id":"47814","name":"CHMP summary of positive opinion for Zabdeno","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"EMA/CHMP/138172/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zabdeno_en.pdf"},
    {"id":"47821","name":"CHMP summary of positive opinion for Xenleta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T11:38:00Z","last_updated_date":"2020-05-29T11:38:00Z","reference_number":"EMA/CHMP/265461/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xenleta_en.pdf"},
    {"id":"47823","name":"CHMP summary of positive opinion for Hepcludex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-05-29T11:43:00Z","last_updated_date":"2020-05-29T11:43:00Z","reference_number":"EMA/CHMP/270357/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hepcludex_en.pdf"},
    {"id":"48122","name":"CHMP summary of positive opinion for Veklury","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-06-25T14:00:00Z","last_updated_date":"2020-06-25T14:00:00Z","reference_number":"EMA/CHMP/311506/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-veklury_en.pdf"},
    {"id":"48126","name":"CHMP summary of positive opinion for Methylthioninium chloride Cosmo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/CHMP/313588/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-methylthioninium-chloride-cosmo_en.pdf"},
    {"id":"48135","name":"CHMP summary of positive opinion for Aybintio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T16:09:00Z","last_updated_date":"2020-06-26T16:09:00Z","reference_number":"EMA/CHMP/266464/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aybintio_en.pdf"},
    {"id":"48136","name":"CHMP summary of positive opinion for Idefirix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/178706/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-idefirix_en.pdf"},
    {"id":"48139","name":"CHMP summary of positive opinion for Gencebok","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/339403/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-gencebok_en.pdf"},
    {"id":"48140","name":"Questions and answers on the refusal of the marketing authorisation for Turalio (pexidartinib)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/336104/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-turalio-pexidartinib_sv.pdf"}},
    {"id":"48149","name":"CHMP summary of positive opinion for Livogiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/CHMP/295899/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-livogiva_en.pdf"},
    {"id":"48150","name":"CHMP summary of positive opinion for Qutavina","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"EMA/CHMP/341130/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-qutavina_en.pdf"},
    {"id":"48167","name":"CHMP summary of positive opinion for Kaftrio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-06-26T12:36:00Z","last_updated_date":"2020-06-26T12:36:00Z","reference_number":"EMA/CHMP/308597/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kaftrio_en.pdf"},
    {"id":"48326","name":"CVMP summary of positive opinion for Increxxa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-17T15:20:00Z","last_updated_date":"2020-07-17T15:20:00Z","reference_number":"EMA/CVMP/304165/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-increxxa_en.pdf"},
    {"id":"48327","name":"CVMP summary of positive opinion for Mhyosphere PCV ID","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-17T15:23:00Z","last_updated_date":"2020-07-17T15:23:00Z","reference_number":"EMA/CVMP/349868/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-mhyosphere-pcv-id_en.pdf"},
    {"id":"48328","name":"CVMP summary of positive opinion for Innovax-ND-ILT","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-17T15:25:00Z","last_updated_date":"2020-07-17T15:25:00Z","reference_number":"EMA/CVMP/350609/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-innovax-nd-ilt_en.pdf"},
    {"id":"48329","name":"CVMP summary of positive opinion for Tulinovet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-17T15:42:00Z","last_updated_date":"2020-07-17T15:42:00Z","reference_number":"EMA/CVMP/305738/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-tulinovet_en.pdf"},
    {"id":"48353","name":"CHMP summary of positive opinion for Adakveo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2023-08-21T14:05:00Z","reference_number":"EMA/373250/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-adakveo_en.pdf"},
    {"id":"48354","name":"CHMP summary of positive opinion for Ayvakyt","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2020-07-24T12:00:00Z","reference_number":"EMA/CHMP/392892/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ayvakyt_en.pdf"},
    {"id":"48368","name":"CHMP summary of positive opinion for Blenrep","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:56:00Z","last_updated_date":"2020-07-24T12:56:00Z","reference_number":"EMA/383350/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-blenrep_en.pdf"},
    {"id":"48369","name":"CHMP summary of positive opinion for Equidacent","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T11:49:00Z","last_updated_date":"2021-11-25T16:45:00Z","reference_number":"EMA/CHMP/358607/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-equidacent_en.pdf"},
    {"id":"48370","name":"CHMP summary of positive opinion for Fampridine Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T11:56:00Z","last_updated_date":"2020-07-24T11:56:00Z","reference_number":"EMA/CHMP/377211/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fampridine-accord_en.pdf"},
    {"id":"48374","name":"CHMP summary of positive opinion for Arsenic trioxide medac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T14:17:00Z","last_updated_date":"2020-07-24T14:17:00Z","reference_number":"EMA/CHMP/383424/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-arsenic-trioxide-medac_en.pdf"},
    {"id":"48376","name":"CHMP summary of positive opinion for Zynrelef","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2023-11-22T12:00:00Z","reference_number":"EMA/CHMP/367342/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zynrelef_en.pdf"},
    {"id":"48391","name":"CHMP summary of positive opinion for Calquence","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T10:02:00Z","last_updated_date":"2020-07-24T10:02:00Z","reference_number":"EMA/CHMP/374568/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-calquence_en.pdf"},
    {"id":"48394","name":"CHMP summary of positive opinion for Arikayce liposomal","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2020-07-28T11:56:00Z","reference_number":"EMA/CHMP/257409/2020 Corr.","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-arikayce-liposomal_en.pdf"},
    {"id":"48401","name":"Questions and answers on the approval of the marketing authorisation for Elzonris (tagraxofusp)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T11:31:00Z","last_updated_date":"2020-11-13T11:31:00Z","reference_number":"EMA/601698/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-approval-marketing-authorisation-elzonris-tagraxofusp_en.pdf"},
    {"id":"48408","name":"CHMP summary of positive opinion for Jyseleca","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T14:06:00Z","last_updated_date":"2020-07-24T14:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jyseleca_en.pdf"},
    {"id":"48409","name":"Questions and answers on the refusal of the marketing authorisation for Gamifant (emapalumab)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T14:33:00Z","last_updated_date":"2021-03-19T02:00:00Z","reference_number":"EMA/601716/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-gamifant-emapalumab_sv.pdf"}},
    {"id":"48795","name":"CVMP summary of positive opinion for Librela","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-09-11T15:00:00Z","last_updated_date":"2020-09-11T15:00:00Z","reference_number":"EMA/CVMP/438128/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-librela_en.pdf"},
    {"id":"48796","name":"CVMP summary of positive opinion for OvuGel","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-09-11T15:00:00Z","last_updated_date":"2020-09-11T15:00:00Z","reference_number":"EMA/CVMP/430527/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-ovugel_en.pdf"},
    {"id":"48835","name":"CHMP summary of positive opinion for Rivaroxaban Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T10:34:00Z","last_updated_date":"2020-09-18T10:34:00Z","reference_number":"EMA/CHMP/484813/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rivaroxaban-accord_en.pdf"},
    {"id":"48839","name":"CHMP summary of positive opinion for MenQuadfi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T12:06:00Z","last_updated_date":"2020-09-18T12:06:00Z","reference_number":"EMA/CHMP/452678/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-menquadfi_en.pdf"},
    {"id":"48840","name":"CHMP summary of positive opinion for Obiltoxaximab SFL","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T12:09:00Z","last_updated_date":"2024-09-09T12:10:00Z","reference_number":"EMA/CHMP/460994/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-obiltoxaximab-sfl_en.pdf"},
    {"id":"48843","name":"CHMP summary of positive opinion for Supemtek","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T15:52:00Z","last_updated_date":"2020-09-18T15:52:00Z","reference_number":"EMA/CHMP/355381/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-supemtek_en.pdf"},
    {"id":"48845","name":"CHMP summary of positive opinion for Exparel","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T16:23:00Z","last_updated_date":"2020-09-18T16:23:00Z","reference_number":"EMA/CHMP/476199/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-exparel_en.pdf"},
    {"id":"48850","name":"CHMP summary of positive opinion for Nyvepria","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-09-18T12:00:00Z","last_updated_date":"2020-09-18T12:00:00Z","reference_number":"EMA/CHMP/447855/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nyvepria_en.pdf"},
    {"id":"48972","name":"CVMP summary of positive opinion for CircoMax Myco","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-09T13:00:00Z","last_updated_date":"2020-10-09T13:00:00Z","reference_number":"EMA/CVMP/495892/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-circomax-myco_en.pdf"},
    {"id":"48973","name":"CVMP summary of positive opinion for Enteroporc Coli AC","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-09T13:00:00Z","last_updated_date":"2020-10-09T13:00:00Z","reference_number":"EMA/CVMP/489228/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-enteroporc-coli-ac_en.pdf"},
    {"id":"48975","name":"CVMP summary of positive opinion for Nobivac DP Plus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-09T13:00:00Z","last_updated_date":"2020-10-09T13:00:00Z","reference_number":"EMA/CVMP/500514/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-dp-plus_en.pdf"},
    {"id":"48976","name":"CVMP summary of positive opinion for Rexxolide","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-09T13:00:00Z","last_updated_date":"2020-10-09T13:00:00Z","reference_number":"EMA/CVMP/496850/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-rexxolide_en.pdf"},
    {"id":"48982","name":"CVMP summary of positive opinion for Vectormune FP ILT","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-09T13:00:00Z","last_updated_date":"2020-10-09T13:00:00Z","reference_number":"EMA/CVMP/505185/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-vectormune-fp-ilt_en.pdf"},
    {"id":"49011","name":"CHMP summary of positive opinion for Oxlumo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T09:38:00Z","last_updated_date":"2020-10-16T09:38:00Z","reference_number":"EMA/CHMP/529305/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-oxlumo_en.pdf"},
    {"id":"49013","name":"CHMP summary of positive opinion for Fintepla","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T10:05:00Z","last_updated_date":"2020-10-16T10:05:00Z","reference_number":"EMA/CHMP/510338/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fintepla_en.pdf"},
    {"id":"49019","name":"CHMP summary of positive opinion for Libmeldy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T11:13:00Z","last_updated_date":"2020-10-16T11:13:00Z","reference_number":"EMA/CHMP/527975/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-libmeldy_en.pdf"},
    {"id":"49026","name":"CHMP summary of positive opinion for Lenalidomide Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T17:06:00Z","last_updated_date":"2020-10-16T17:06:00Z","reference_number":"EMA/CHMP/509778/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lenalidomide-mylan_en.pdf"},
    {"id":"49027","name":"CHMP summary of positive opinion for Leqvio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/520993/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-leqvio_en.pdf"},
    {"id":"49030","name":"CHMP summary of positive opinion for Tecartus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/538747/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tecartus_en.pdf"},
    {"id":"49031","name":"CHMP summary of positive opinion for Palforzia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/498161/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-palforzia_en.pdf"},
    {"id":"49039","name":"CHMP summary of positive opinion for Trixeo Aerosphere","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T12:00:00Z","last_updated_date":"2020-10-16T12:00:00Z","reference_number":"EMA/CHMP/64785/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trixeo-aerosphere_en.pdf"},
    {"id":"49041","name":"CHMP summary of positive opinion for Vocabria","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T16:25:00Z","last_updated_date":"2020-10-16T16:25:00Z","reference_number":"EMA/CHMP/447977/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vocabria_en.pdf"},
    {"id":"49042","name":"CHMP summary of positive opinion for Rekambys","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-10-16T16:15:00Z","last_updated_date":"2020-10-16T16:15:00Z","reference_number":"EMA/CHMP/455296/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rekambys_en.pdf"},
    {"id":"49186","name":"CVMP summary of positive opinion for Enteroporc Coli","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-11-06T12:31:00Z","last_updated_date":"2024-05-31T15:00:00Z","reference_number":"EMA/CVMP/551905/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-enteroporc-coli_en.pdf"},
    {"id":"49187","name":"CVMP summary of positive opinion for NexGard Combo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-11-06T14:18:00Z","last_updated_date":"2020-11-06T14:18:00Z","reference_number":"EMA/CVMP/535061/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nexgard-combo_en.pdf"},
    {"id":"49218","name":"CHMP summary of positive opinion for Phesgo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T17:50:00Z","last_updated_date":"2020-11-13T17:50:00Z","reference_number":"EMA/CHMP/540000/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-phesgo_en.pdf"},
    {"id":"49237","name":"CHMP summary of positive opinion for Xofluza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T14:34:00Z","last_updated_date":"2020-11-13T14:34:00Z","reference_number":"EMA/CHMP/537072/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xofluza_en.pdf"},
    {"id":"49243","name":"CHMP summary of positive opinion for Roclanda","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T16:26:00Z","last_updated_date":"2020-11-13T16:26:00Z","reference_number":"EMA/CHMP/593876/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-roclanda_en.pdf"},
    {"id":"49246","name":"CHMP summary of positive opinion for Onbevzi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T18:31:00Z","last_updated_date":"2024-10-24T14:41:00Z","reference_number":"EMA/CHMP/576998/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-onbevzi_en.pdf"},
    {"id":"49250","name":"CHMP summary of positive opinion for Elzonris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-11-13T12:02:00Z","last_updated_date":"2020-11-13T12:02:00Z","reference_number":"EMA/CHMP/597095/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-elzonris_en.pdf"},
    {"id":"49503","name":"CHMP summary of positive opinion for Sunitinib Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T10:23:00Z","last_updated_date":"2020-12-11T10:23:00Z","reference_number":"EMA/CHMP/635286/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sunitinib-accord_en.pdf"},
    {"id":"49505","name":"CHMP summary of positive opinion for Heplisav B","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/601178/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-heplisav-b_en.pdf"},
    {"id":"49506","name":"CHMP summary of positive opinion for Kixelle","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/623370/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kixelle_en.pdf"},
    {"id":"49510","name":"CHMP summary of positive opinion for Lumoxiti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T11:52:00Z","last_updated_date":"2021-08-11T16:32:00Z","reference_number":"EMA/CHMP/652159/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lumoxiti_en.pdf"},
    {"id":"49513","name":"CHMP summary of positive opinion for Yuflyma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:49:00Z","last_updated_date":"2020-12-11T12:49:00Z","reference_number":"EMA/CHMP/639447/2020 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yuflyma_en.pdf"},
    {"id":"49515","name":"CHMP summary of positive opinion for Lenalidomide Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/651078/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lenalidomide-krka_en.pdf"},
    {"id":"49516","name":"CHMP summary of positive opinion for Lenalidomide Krka d.d.","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2023-07-10T15:17:00Z","reference_number":"EMA/CHMP/651085/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lenalidomide-krka-dd_en.pdf"},
    {"id":"49517","name":"CHMP summary of positive opinion for Lenalidomide Krka d.d. Novo mesto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/650983/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lenalidomide-krka-dd-novo-mesto_en.pdf"},
    {"id":"49519","name":"CHMP summary of positive opinion for Tukysa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T15:15:00Z","last_updated_date":"2020-12-11T15:15:00Z","reference_number":"EMA/CHMP/646289/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tukysa_en.pdf"},
    {"id":"49520","name":"CHMP summary of positive opinion for Inrebic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/636661/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-inrebic_en.pdf"},
    {"id":"49524","name":"CHMP summary of positive opinion for Sibnayal","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/650319/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sibnayal_en.pdf"},
    {"id":"49531","name":"CHMP summary of positive opinion for Ogluo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/650408/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ogluo_en.pdf"},
    {"id":"49532","name":"CHMP summary of positive opinion for Enhertu","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T18:34:00Z","last_updated_date":"2020-12-11T18:34:00Z","reference_number":"EMA/CHMP/631955/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-enhertu_en.pdf"},
    {"id":"49535","name":"CHMP summary of positive opinion for Rukobia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA/CHMP/613669/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rukobia_en.pdf"},
    {"id":"49538","name":"CVMP summary of positive opinion for Solensia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T14:00:00Z","last_updated_date":"2020-12-11T14:00:00Z","reference_number":"EMA/631469/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-solensia_en.pdf"},
    {"id":"49539","name":"CHMP summary of positive opinion for Retsevmo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"EMA//CHMP/664344/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-retsevmo_en.pdf"},
    {"id":"49671","name":"CHMP summary of positive opinion for Comirnaty","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-12-21T14:51:00Z","last_updated_date":"2020-12-21T14:51:00Z","reference_number":"EMA/660602/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-comirnaty_en.pdf"},
    {"id":"49734","name":"CHMP summary of positive opinion for COVID-19 Vaccine Moderna","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-01-06T13:30:00Z","last_updated_date":"2021-01-06T13:30:00Z","reference_number":"EMA/704372/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-covid-19-vaccine-moderna_en.pdf"},
    {"id":"49970","name":"CHMP summary of positive opinion for COVID-19 Vaccine AstraZeneca","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-01-29T17:10:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"EMA/57617/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-covid-19-vaccine-astrazeneca_en.pdf"},
    {"id":"49993","name":"CHMP summary of positive opinion for Ontozry","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T11:49:00Z","last_updated_date":"2021-02-01T11:49:00Z","reference_number":"EMA/CHMP/12859/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ontozry_en.pdf"},
    {"id":"49994","name":"CHMP summary of positive opinion for Nexpovio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T11:48:00Z","last_updated_date":"2021-02-01T11:48:00Z","reference_number":"EMA/636723/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nexpovio_en.pdf"},
    {"id":"49997","name":"CHMP summary of positive opinion for Byfavo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T17:44:00Z","last_updated_date":"2021-02-01T17:44:00Z","reference_number":"EMA/CHMP/622868/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-byfavo_en.pdf"},
    {"id":"49998","name":"CHMP summary of positive opinion for Vazkepa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T17:55:00Z","last_updated_date":"2021-02-01T17:55:00Z","reference_number":"EMA/CHMP/646053/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vazkepa_en.pdf"},
    {"id":"49999","name":"CHMP summary of positive opinion for Sogroya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T18:06:00Z","last_updated_date":"2021-02-01T18:06:00Z","reference_number":"EMA/CHMP/593869/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sogroya_en.pdf"},
    {"id":"50000","name":"CHMP summary of positive opinion for Pemazyre","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T18:15:00Z","last_updated_date":"2021-02-26T11:09:00Z","reference_number":"EMA/35501/2021 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pemazyre_en.pdf"},
    {"id":"50001","name":"CHMP summary of positive opinion for BroPair Spiromax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T11:40:00Z","last_updated_date":"2025-06-30T16:08:00Z","reference_number":"EMA/CHMP/52922/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bropair-spiromax_en.pdf"},
    {"id":"50002","name":"CHMP summary of positive opinion for Seffalair Spiromax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T11:40:00Z","last_updated_date":"2021-02-01T11:40:00Z","reference_number":"EMA/52882/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-seffalair-spiromax_en.pdf"},
    {"id":"50003","name":"CHMP summary of positive opinion for Kesimpta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T11:40:00Z","last_updated_date":"2021-02-01T11:40:00Z","reference_number":"EMA/CHMP/17719/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kesimpta_en.pdf"},
    {"id":"50004","name":"CHMP summary of positive opinion for Thiotepa Riemser","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T11:40:00Z","last_updated_date":"2021-02-01T11:40:00Z","reference_number":"EMA/CHMP/60776/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-thiotepa-riemser_en.pdf"},
    {"id":"50005","name":"CHMP summary of positive opinion for Alymsys","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T09:39:00Z","last_updated_date":"2021-02-01T09:39:00Z","reference_number":"EMA/CHMP/27294/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-alymsys_en.pdf"},
    {"id":"50006","name":"CHMP summary of positive opinion for Oyavas","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-01T09:45:00Z","last_updated_date":"2021-02-01T09:45:00Z","reference_number":"EMA/CHMP/27606/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-oyavas_en.pdf"},
    {"id":"50246","name":"CVMP summary of positive opinion for Credelio Plus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-19T14:00:00Z","last_updated_date":"2021-02-19T14:00:00Z","reference_number":"EMA/CVMP/65055/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-credelio-plus_en.pdf"},
    {"id":"50247","name":"CVMP summary of positive opinion for Daxocox","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-19T14:00:00Z","last_updated_date":"2021-02-19T14:00:00Z","reference_number":"EMA/CVMP/65023/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-daxocox_en.pdf"},
    {"id":"50248","name":"CVMP summary of positive opinion for Ultifend ND IBD","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-19T14:00:00Z","last_updated_date":"2021-02-19T14:00:00Z","reference_number":"EMA/CVMP/74964/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-ultifend-nd-ibd_en.pdf"},
    {"id":"50266","name":"CHMP summary of positive opinion for Abiraterone Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T12:00:00Z","last_updated_date":"2021-02-26T12:00:00Z","reference_number":"EMA/CHMP/101446/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-abiraterone-accord_en.pdf"},
    {"id":"50271","name":"CHMP summary of positive opinion for Orladeyo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T14:08:00Z","last_updated_date":"2021-02-26T14:08:00Z","reference_number":"EMA/CHMP/86405/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-orladeyo_en.pdf"},
    {"id":"50279","name":"CHMP summary of positive opinion for Evrysdi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T12:00:00Z","last_updated_date":"2021-02-26T12:00:00Z","reference_number":"EMA/CHMP/19316/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-evrysdi_en.pdf"},
    {"id":"50282","name":"CHMP summary of positive opinion for Jemperli","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T16:41:00Z","last_updated_date":"2021-05-03T11:28:00Z","reference_number":"EMA/CHMP/53909/2021 Corr.","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jemperli_en.pdf"},
    {"id":"50287","name":"CHMP summary of positive opinion for Abevmy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T12:00:00Z","last_updated_date":"2021-02-26T12:00:00Z","reference_number":"EMA/CHMP/87659/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-abevmy_en.pdf"}    {"id":"50288","name":"CHMP summary of positive opinion for Lextemy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-02-26T12:00:00Z","last_updated_date":"2021-02-26T12:00:00Z","reference_number":"EMA/CHMP/87640/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lextemy_en.pdf"},
    {"id":"50524","name":"CHMP summary of positive opinion for COVID-19 Vaccine Janssen","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-03-11T14:05:00Z","last_updated_date":"2024-08-09T12:05:00Z","reference_number":"EMA/146391/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-covid-19-vaccine-janssen_en.pdf"},
    {"id":"50696","name":"CHMP summary of positive opinion for Ponvory","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-01-26T12:00:00Z","last_updated_date":"2021-01-26T12:00:00Z","reference_number":"EMA/CHMP/164792/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ponvory_en.pdf"},
    {"id":"50697","name":"CHMP summary of positive opinion for Efmody","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T10:24:00Z","last_updated_date":"2021-03-26T10:24:00Z","reference_number":"EMA/CHMP/176520/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-efmody_en.pdf"},
    {"id":"50708","name":"CHMP summary of positive opinion for Drovelis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T15:52:00Z","last_updated_date":"2021-03-26T15:52:00Z","reference_number":"EMA/CHMP/156143/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-drovelis_en.pdf"},
    {"id":"50710","name":"CHMP summary of positive opinion for Lydisilka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T16:04:00Z","last_updated_date":"2021-03-26T16:04:00Z","reference_number":"EMA/CHMP/156178/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lydisilka_en.pdf"},
    {"id":"50722","name":"CHMP summary of positive opinion for Copiktra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T12:00:00Z","last_updated_date":"2026-04-09T11:14:00Z","reference_number":"EMA/CHMP/84697/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-copiktra_en.pdf"},
    {"id":"50940","name":"CHMP summary of positive opinion for Enspryng","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/215160/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-enspryng_en.pdf"},
    {"id":"50941","name":"CHMP summary of positive opinion for Jayempi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/213654/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jayempi_en.pdf"},
    {"id":"50945","name":"CHMP summary of positive opinion for Celsunax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/218686/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-celsunax_en.pdf"},
    {"id":"50959","name":"CHMP summary of positive opinion for Adtralza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/202204/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-adtralza_en.pdf"},
    {"id":"50960","name":"CHMP summary of positive opinion for Evkeeza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T09:49:00Z","last_updated_date":"2021-04-23T09:49:00Z","reference_number":"EMA/CHMP/164775/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-evkeeza_en.pdf"},
    {"id":"50964","name":"CHMP summary of positive opinion for Abiraterone Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/211070/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-abiraterone-krka_en.pdf"},
    {"id":"50966","name":"CHMP summary of positive opinion for Onureg","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/211128/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-onureg_en.pdf"},
    {"id":"50967","name":"CHMP summary of positive opinion for Koselugo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T12:00:00Z","last_updated_date":"2021-04-23T12:00:00Z","reference_number":"EMA/CHMP/210566/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-koselugo_en.pdf"},
    {"id":"51158","name":"CVMP summary of positive opinion for Bonqat","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-05-17T12:30:00Z","last_updated_date":"2021-05-17T12:30:00Z","reference_number":"EMA/CVMP/241883/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bonqat_en.pdf"},
    {"id":"51192","name":"CHMP summary of positive opinion for Bylvay","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T15:03:00Z","last_updated_date":"2021-05-21T15:03:00Z","reference_number":"EMA/CHMP/273563/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bylvay_en.pdf"},
    {"id":"51205","name":"CHMP summary of positive opinion for Verquvo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T15:03:00Z","last_updated_date":"2021-05-21T15:03:00Z","reference_number":"EMA/CHMP/259029/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-verquvo_en.pdf"},
    {"id":"51206","name":"CHMP summary of positive opinion for Ryeqo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T15:03:00Z","last_updated_date":"2021-05-21T15:03:00Z","reference_number":"EMA/CHMP/126766/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ryeqo_en.pdf"},
    {"id":"51207","name":"CHMP summary of positive opinion for Icatibant Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T15:00:00Z","last_updated_date":"2021-05-21T15:00:00Z","reference_number":"EMA/CHMP/244588/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-icatibant-accord_en.pdf"},
    {"id":"51213","name":"CHMP summary of positive opinion for Ozawade","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T12:00:00Z","last_updated_date":"2021-05-21T12:00:00Z","reference_number":"EMA/CHMP/153636/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ozawade_en.pdf"},
    {"id":"51219","name":"CHMP summary of positive opinion for Skysona","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T12:00:00Z","last_updated_date":"2022-04-04T12:52:00Z","reference_number":"EMA/CHMP/273940/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-skysona_en.pdf"},
    {"id":"51220","name":"CHMP summary of positive opinion for Klisyri","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T12:00:00Z","last_updated_date":"2021-05-21T12:00:00Z","reference_number":"EMA/CHMP/212648/2021 Corr","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-klisyri_en.pdf"},
    {"id":"51223","name":"CHMP summary of positive opinion for Imcivree","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T12:00:00Z","last_updated_date":"2021-05-21T12:00:00Z","reference_number":"EMA/CHMP/270677/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imcivree_en.pdf"},
    {"id":"51227","name":"CHMP summary of positive opinion for Libtayo (II-11, II-12)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T15:00:00Z","last_updated_date":"2021-05-21T15:00:00Z","reference_number":"EMA/259161/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-libtayo-ii-11-ii-12_en.pdf"},
    {"id":"51493","name":"CVMP summary of positive opinion for Fatrovax RHD","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T14:23:00Z","last_updated_date":"2021-06-18T14:23:00Z","reference_number":"EMA/CVMP/306191/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-fatrovax-rhd_en.pdf"},
    {"id":"51494","name":"CVMP summary of positive opinion for Tessie","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T15:01:00Z","last_updated_date":"2021-06-18T15:01:00Z","reference_number":"EMA/CVMP/306774/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-tessie_en.pdf"},
    {"id":"51498","name":"CVMP summary of positive opinion for Strangvac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T14:46:00Z","last_updated_date":"2021-06-18T14:46:00Z","reference_number":"EMA/CVMP/308991/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-strangvac_en.pdf"},
    {"id":"51569","name":"CHMP summary of positive opinion for Evrenzo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T09:45:00Z","last_updated_date":"2021-06-25T09:45:00Z","reference_number":"EMA/CHMP/341057/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-evrenzo_en.pdf"},
    {"id":"51583","name":"CHMP summary of positive opinion for Abiraterone Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T14:13:00Z","last_updated_date":"2021-06-25T14:13:00Z","reference_number":"EMA/CHMP/313865/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-abiraterone-mylan_en.pdf"},
    {"id":"51585","name":"CHMP summary of positive opinion for Voxzogo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T14:50:00Z","last_updated_date":"2021-06-25T14:50:00Z","reference_number":"EMA/CHMP/337860/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-voxzogo_en.pdf"},
    {"id":"51587","name":"CHMP summary of positive opinion for Minjuvi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T16:06:00Z","last_updated_date":"2021-06-25T16:06:00Z","reference_number":"EMA/CHMP/314017/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-minjuvi_en.pdf"},
    {"id":"51593","name":"CHMP summary of positive opinion for Byooviz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T16:42:00Z","last_updated_date":"2021-06-25T16:42:00Z","reference_number":"EMA/CHMP/321116/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-byooviz_en.pdf"},
    {"id":"51594","name":"CHMP summary of positive opinion for Bimzelx","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T16:57:00Z","last_updated_date":"2021-06-25T16:57:00Z","reference_number":"EMA/CHMP/336023/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bimzelx_en.pdf"},
    {"id":"51604","name":"CHMP summary of positive opinion for Abecma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-06-25T11:38:00Z","last_updated_date":"2021-06-25T11:38:00Z","reference_number":"EMA/CHMP/348641/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-abecma_en.pdf"},
    {"id":"52016","name":"CHMP summary of positive opinion for Imatinib Koanaa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:16:00Z","last_updated_date":"2023-10-19T10:42:00Z","reference_number":"EMA/338599/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imatinib-koanaa_en.pdf"},
    {"id":"52029","name":"Questions and answers on the refusal of the marketing authorisation for Nouryant (istradefylline)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2021-07-23T12:07:00Z","last_updated_date":"2022-01-19T15:35:00Z","reference_number":"EMA/713010/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-nouryant-istradefylline_sv.pdf"}},
    {"id":"52048","name":"CHMP summary of positive opinion for Nexviadyme","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-07-23T12:18:00Z","last_updated_date":"2021-11-12T01:34:00Z","reference_number":"EMA/CHMP/631749/2021 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nexviadyme_en.pdf"},
    {"id":"52419","name":"CVMP summary of positive opinion for Felpreva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-10T11:00:00Z","last_updated_date":"2021-09-10T11:00:00Z","reference_number":"EMA/CVMP/494159/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-felpreva_en.pdf"},
    {"id":"52449","name":"CHMP summary of positive opinion for Artesunate Amivas","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:20:00Z","last_updated_date":"2021-09-17T12:20:00Z","reference_number":"EMA/CHMP/438991/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-artesunate-amivas_en.pdf"},
    {"id":"52454","name":"CHMP summary of positive opinion for Sugammadex Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:39:00Z","last_updated_date":"2021-09-17T12:39:00Z","reference_number":"EMA/CHMP/493758/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sugammadex-mylan_en.pdf"},
    {"id":"52455","name":"CHMP summary of positive opinion for Vumerity","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T14:48:00Z","last_updated_date":"2021-09-17T14:48:00Z","reference_number":"EMA/CHMP/500803/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vumerity_en.pdf"},
    {"id":"52470","name":"CHMP summary of positive opinion for Rivaroxaban Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/513776/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rivaroxaban-mylan_en.pdf"},
    {"id":"52475","name":"CHMP summary of positive opinion for Qinlock","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/338054/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-qinlock_en.pdf"},
    {"id":"52476","name":"CHMP summary of positive opinion for Libmyris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/513885/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-libmyris_en.pdf"},
    {"id":"52477","name":"CHMP summary of positive opinion for Hukyndra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/414368/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hukyndra_en.pdf"},
    {"id":"52483","name":"CHMP summary of positive opinion for Brukinsa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"EMA/CHMP/352390/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-brukinsa_en.pdf"},
    {"id":"52487","name":"Questions and answers on the refusal of the marketing authorisation for Raylumis (tanezumab)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T10:44:00Z","last_updated_date":"2021-09-17T10:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_en.pdf"},
    {"id":"52489","name":"CHMP summary of positive opinion for Gavreto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2025-01-17T16:20:50Z","reference_number":"Gavreto","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-gavreto_en.pdf"},
    {"id":"52790","name":"CVMP summary of positive opinion for Imoxat","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T15:00:00Z","last_updated_date":"2021-10-08T15:00:00Z","reference_number":"EMA/CVMP/523600/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-imoxat_en.pdf"},
    {"id":"52792","name":"CVMP summary of positive opinion for Suiseng Diff/A","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T15:07:00Z","last_updated_date":"2021-10-08T15:07:00Z","reference_number":"EMA/CVMP/522701/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-suiseng-diffa_en.pdf"},
    {"id":"52793","name":"CVMP summary of positive opinion for Zenalpha","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-10-08T15:13:00Z","last_updated_date":"2021-10-08T15:13:00Z","reference_number":"EMA/CVMP/544339/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zenalpha_en.pdf"},
    {"id":"52835","name":"CHMP summary of positive opinion for Vaxneuvance","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/CHMP/539313/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vaxneuvance_en.pdf"},
    {"id":"52847","name":"CHMP post-authorisation summary of opinion for Skyrizi (II-14)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/537752/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-post-authorisation-summary-opinion-skyrizi-ii-14_en.pdf"},
    {"id":"52851","name":"CHMP summary of opinion for Aspaveli","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/CHMP/555115/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-aspaveli_en.pdf"},
    {"id":"52853","name":"CHMP summary of opinion for Sitagliptin SUN","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-10-14T17:05:00Z","last_updated_date":"2021-10-14T17:05:00Z","reference_number":"EMA/CHMP/570740/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-sitagliptin-sun_en.pdf"},
    {"id":"52859","name":"CHMP summary of positive opinion for Trodelvy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/411659/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trodelvy_en.pdf"},
    {"id":"52860","name":"CHMP summary of positive opinion for Rybrevant","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T10:12:00Z","last_updated_date":"2021-10-15T10:12:00Z","reference_number":"EMA/CHMP/572279/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rybrevant_en.pdf"},
    {"id":"52861","name":"CHMP summary of opinion for Cibinqo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-10-15T12:00:00Z","last_updated_date":"2021-10-15T12:00:00Z","reference_number":"EMA/CHMP/555194/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-cibinqo_en.pdf"},
    {"id":"53012","name":"CVMP summary of positive opinion for CircoMax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-08T12:31:00Z","last_updated_date":"2021-11-08T12:31:00Z","reference_number":"EMA/CVMP/617167/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-circomax_en.pdf"},
    {"id":"53066","name":"CHMP summary of opinion for Tecovirimat SIGA","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/CHMP/606390/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-tecovirimat-siga_en.pdf"},
    {"id":"53067","name":"CHMP summary of opinion for Riltrava Aerosphere","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/CHMP/627233/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-riltrava-aerosphere_en.pdf"},
    {"id":"53077","name":"CHMP summary of opinion for Regkirona","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-11T16:00:00Z","last_updated_date":"2025-04-24T12:04:00Z","reference_number":"EMA/CHMP/629422/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-regkirona_en.pdf"},
    {"id":"53079","name":"CHMP summary of positive opinion for Vyepti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T15:31:00Z","last_updated_date":"2021-11-12T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vyepti_en.pdf"},
    {"id":"53083","name":"CHMP summary of opinion for Lumykras","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/624008/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-lumykras_en.pdf"},
    {"id":"53085","name":"CHMP summary of positive opinion for Ronapreve","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-11T17:39:00Z","last_updated_date":"2026-01-23T17:40:00Z","reference_number":"EMA/CHMP/629963/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ronapreve_en.pdf"},
    {"id":"53086","name":"CHMP summary of positive opinion for Voraxaze","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/CHMP/505741/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-voraxaze_en.pdf"},
    {"id":"53087","name":"CHMP summary of positive opinion for Wegovy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T18:21:00Z","last_updated_date":"2021-11-12T18:21:00Z","reference_number":"EMA/CHMP/639299/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-wegovy_en.pdf"},
    {"id":"53089","name":"CHMP summary of positive opinion for Uplizna","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/625434/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-uplizna_en.pdf"},
    {"id":"53090","name":"CHMP summary of positive opinion for Tavneos","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/CHMP/624375/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tavneos_en.pdf"},
    {"id":"53106","name":"CHMP summary of opinion for Lonapegsomatropin Ascendis Pharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-11-12T12:00:00Z","last_updated_date":"2021-11-12T12:00:00Z","reference_number":"EMA/CHMP/615593/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-lonapegsomatropin-ascendis-pharma_en.pdf"},
    {"id":"53498","name":"CHMP summary of positive opinion for Lextemy","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2021-12-14T14:18:00Z","last_updated_date":"2021-12-14T14:18:00Z","reference_number":"EMA/CHMP/87640/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lextemy_en.pdf-0"},
    {"id":"53532","name":"CHMP summary of positive opinion for Sapropterin Dipharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T17:30:00Z","last_updated_date":"2021-12-17T17:30:00Z","reference_number":"EMA/CHMP/732482/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sapropterin-dipharma_en.pdf"},
    {"id":"53533","name":"CHMP summary of positive opinion for Apexxnar","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T17:35:00Z","last_updated_date":"2021-12-17T17:35:00Z","reference_number":"EMA/CHMP/689575/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-apexxnar_en.pdf"},
    {"id":"53534","name":"CHMP summary of positive opinion for Okedi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T17:52:00Z","last_updated_date":"2021-12-17T17:52:00Z","reference_number":"EMA/CHMP/726160/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-okedi_en.pdf"},
    {"id":"53535","name":"CHMP summary of positive opinion for Sitagliptin / Metformin hydrochloride Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T18:04:00Z","last_updated_date":"2021-12-17T18:04:00Z","reference_number":"EMA/CHMP/732596/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sitagliptin-metformin-hydrochloride-mylan_en.pdf"},
    {"id":"53539","name":"CHMP summary of positive opinion for Xevudy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-16T09:56:00Z","last_updated_date":"2026-03-04T11:00:00Z","reference_number":"EMA/CHMP/694182/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xevudy_en.pdf"},
    {"id":"53550","name":"CHMP summary of positive opinion for Saphnelo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T13:37:00Z","last_updated_date":"2021-12-17T13:37:00Z","reference_number":"EMA/CHMP/683625/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-saphnelo_en.pdf"},
    {"id":"53552","name":"CHMP summary of positive opinion for Ngenla","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T14:20:00Z","last_updated_date":"2021-12-17T14:20:00Z","reference_number":"EMA/CHMP/685662/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ngenla_en.pdf"},
    {"id":"53554","name":"CHMP summary of positive opinion for Padcev","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T14:36:00Z","last_updated_date":"2022-02-25T12:04:00Z","reference_number":"EMA/CHMP/119530/2022 Rev 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-padcev_en.pdf"},
    {"id":"53562","name":"CHMP summary of opinion for Ontilyv","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T12:00:00Z","last_updated_date":"2025-03-28T15:55:00Z","reference_number":"EMA/CHMP/679312/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-ontilyv_en.pdf"},
    {"id":"53565","name":"CHMP summary of opinion for Yselty","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T12:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/712969/2021 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-yselty_en.pdf"},
    {"id":"53566","name":"CHMP summary of opinion for Kerendia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T12:00:00Z","last_updated_date":"2021-12-17T12:00:00Z","reference_number":"EMA/CHMP/610605/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-kerendia_en.pdf"},
    {"id":"53578","name":"CHMP summary of opinion for Oxbryta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T12:00:00Z","last_updated_date":"2021-12-17T12:00:00Z","reference_number":"EMA/CHMP/622322/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-oxbryta_en.pdf"},
    {"id":"53579","name":"CHMP summary of positive opinion for Tepmetko","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-17T11:14:00Z","last_updated_date":"2021-12-17T11:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tepmetko_en.pdf"},
    {"id":"53607","name":"CHMP summary of opinion for Nuvaxovid","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2021-12-20T14:37:00Z","last_updated_date":"2021-12-20T14:37:00Z","reference_number":"EMEA/H/C/005808","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-nuvaxovid_en.pdf"},
    {"id":"53925","name":"CHMP summary of positive opinion for Vildagliptin/Metformin hydrochloride Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T15:33:00Z","last_updated_date":"2022-01-28T15:33:00Z","reference_number":"EMA/CHMP/687405/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vildagliptinmetformin-hydrochloride-accord_en.pdf"},
    {"id":"53947","name":"CHMP summary of positive opinion for Paxlovid","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-01-27T15:00:00Z","last_updated_date":"2022-01-27T15:00:00Z","reference_number":"EMA/CHMP/18383/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-paxlovid_en.pdf"},
    {"id":"53951","name":"CHMP summary of opinion for Dasatinib Accordpharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T12:00:00Z","last_updated_date":"2023-03-30T11:54:00Z","reference_number":"EMA/CHMP/10901/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-dasatinib-accordpharma_en.pdf"},
    {"id":"53952","name":"CHMP summary of opinion for Dasatinib Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T12:00:00Z","last_updated_date":"2023-03-30T11:19:00Z","reference_number":"EMA/CHMP/10836/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-dasatinib-accord_en.pdf"},
    {"id":"53962","name":"CHMP summary of positive opinion for Stimufend","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T11:55:00Z","last_updated_date":"2022-01-28T11:55:00Z","reference_number":"EMA/CHMP/18376/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-stimufend_en.pdf"},
    {"id":"53984","name":"CHMP summary of opinion for Breyanzi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T10:43:00Z","last_updated_date":"2022-01-28T10:43:00Z","reference_number":"EMA/CHMP/45656/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-breyanzi_en.pdf"},
    {"id":"53990","name":"CHMP summary of opinion for Sondelbay","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-01-28T12:00:00Z","last_updated_date":"2022-01-28T12:00:00Z","reference_number":"EMA/CHMP/40683/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-sondelbay_en.pdf"},
    {"id":"54180","name":"Questions and answers on the refusal of the marketing authorisation for Raylumis (tanezumab)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2022-02-15T15:01:00Z","last_updated_date":"2022-02-15T15:01:00Z","reference_number":"EMA/512898/2021","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_en.pdf-0","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-raylumis-tanezumab_sv.pdf"}},
    {"id":"54232","name":"CVMP summary of positive opinion for RenuTend","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-21T13:50:00Z","last_updated_date":"2022-02-21T13:50:00Z","reference_number":"EMA/CVMP/73401/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-renutend_en.pdf"},
    {"id":"54233","name":"CVMP summary of positive opinion for Chanaxin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-21T14:08:00Z","last_updated_date":"2022-02-21T14:08:00Z","reference_number":"EMA/CVMP/570131/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-chanaxin_en.pdf"},
    {"id":"54275","name":"CHMP summary of positive opinion for Kapruvia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T14:48:00Z","last_updated_date":"2022-02-25T14:48:00Z","reference_number":"EMA/CHMP/107869/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kapruvia_en.pdf"},
    {"id":"54277","name":"CHMP summary of positive opinion for Vydura","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T14:56:00Z","last_updated_date":"2022-02-25T14:56:00Z","reference_number":"EMA/CHMP/106030/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vydura_en.pdf"},
    {"id":"54280","name":"CHMP summary of positive opinion for Truvelog Mix 30","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2026-05-07T12:44:00Z","reference_number":"EMA/CHMP/83437/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-truvelog-mix-30_en.pdf"},
    {"id":"54284","name":"CHMP summary of positive opinion for Inpremzia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T16:40:00Z","last_updated_date":"2023-04-20T12:21:00Z","reference_number":"EMA/CHMP/113249/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-inpremzia_en.pdf"}    {"id":"54285","name":"CHMP summary of positive opinion for Orgovyx","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2022-02-25T12:00:00Z","reference_number":"EMA/111169/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-orgovyx_en.pdf"},
    {"id":"54286","name":"CHMP summary of opinion for Kimmtrak","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2022-02-25T12:00:00Z","reference_number":"EMA/CHMP/116411/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-kimmtrak_en.pdf"},
    {"id":"54287","name":"CHMP summary of opinion for Sitagliptin Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2022-02-25T12:00:00Z","reference_number":"EMA/CHMP/105005/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-sitagliptin-accord_en.pdf"},
    {"id":"54288","name":"CHMP summary of opinion for Amversio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2022-02-25T12:00:00Z","reference_number":"EMA/CHMP/83287/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-amversio_en.pdf"},
    {"id":"54289","name":"CHMP summary of opinion for Dimethyl fumarate Mylan","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-12-22T10:58:00Z","last_updated_date":"2023-12-22T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-dimethyl-fumarate-mylan_en.pdf"},
    {"id":"54290","name":"CHMP summary of opinion for Dimethyl fumarate Polpharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-12-22T12:03:00Z","last_updated_date":"2023-12-22T12:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-dimethyl-fumarate-polpharma_en.pdf"},
    {"id":"54291","name":"CHMP summary of positive opinion for Dimethyl fumarate Neuraxpharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T18:11:00Z","last_updated_date":"2023-12-22T14:22:02Z","reference_number":"EMA/CHMP/102451/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dimethyl-fumarate-neuraxpharm_en.pdf"},
    {"id":"54296","name":"CHMP summary of opinion for PreHevbri","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-02-25T12:00:00Z","last_updated_date":"2025-01-10T17:18:00Z","reference_number":"EMA/CHMP/87383/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-prehevbri_en.pdf"},
    {"id":"54550","name":"CHMP summary of opinion for Zolsketil pegylated liposomal","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:00:00Z","last_updated_date":"2022-03-25T12:00:00Z","reference_number":"EMA/CHMP/169456/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-zolsketil-pegylated-liposomal_en.pdf"},
    {"id":"54551","name":"CHMP summary of positive opinion for Carvykti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:00:00Z","last_updated_date":"2022-03-25T12:00:00Z","reference_number":"EMA/CHMP/168651/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-carvykti_en.pdf"},
    {"id":"54560","name":"CHMP summary of opinion for Camcevi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:00:00Z","last_updated_date":"2022-03-25T12:00:00Z","reference_number":"EMA/CHMP/138725/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-camcevi_en.pdf"},
    {"id":"54583","name":"CHMP summary of opinion for Evusheld","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:00:00Z","last_updated_date":"2025-10-14T12:22:22Z","reference_number":"EMA/184295/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-evusheld_en.pdf"},
    {"id":"54593","name":"CHMP summary of positive opinion for Amifampridine SERB","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-03-25T12:35:00Z","last_updated_date":"2022-03-25T12:35:00Z","reference_number":"EMA/CHMP/122713/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-amifampridine-serb_en.pdf"},
    {"id":"54784","name":"CHMP summary of positive opinion for Pirfenidone AET","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/215096/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pirfenidone-aet_en.pdf"},
    {"id":"54788","name":"CHMP summary of positive opinion for Filsuvez","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/188166/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-filsuvez_en.pdf"},
    {"id":"54793","name":"CHMP summary of positive opinion for Insulatard","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T12:00:00Z","last_updated_date":"2022-04-22T12:00:00Z","reference_number":"EMA/CHMP/223184/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-insulatard_en.pdf"},
    {"id":"54807","name":"CHMP summary of positive opinion for Lunsumio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T13:03:00Z","last_updated_date":"2022-04-22T13:03:00Z","reference_number":"EMA/CHMP/158054/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lunsumio_en.pdf"},
    {"id":"54808","name":"CHMP summary of positive opinion for Tabrecta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T14:00:00Z","last_updated_date":"2022-04-22T14:00:00Z","reference_number":"EMA/CHMP/164312/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tabrecta_en.pdf"},
    {"id":"54983","name":"CHMP summary of positive opinion for Ganirelix Gedeon Richter","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ganirelix-gedeon-richter_en.pdf"},
    {"id":"55004","name":"CHMP summary of positive opinion for Upstaza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T10:36:00Z","last_updated_date":"2022-05-20T10:36:00Z","reference_number":"EMA/CHMP/274542/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-upstaza_en.pdf"},
    {"id":"55011","name":"CHMP summary of positive opinion for Cevenfacta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/CHMP/262927/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cevenfacta_en.pdf"},
    {"id":"55013","name":"CHMP summary of positive opinion for Sitagliptin / Metformin hydrochloride Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T15:00:00Z","last_updated_date":"2025-11-13T09:45:00Z","reference_number":"EMA/264071/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sitagliptin-metformin-hydrochloride-accord_en.pdf"},
    {"id":"55015","name":"CHMP summary of positive opinion for Xenpozyme","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/260811/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xenpozyme_en.pdf"},
    {"id":"55016","name":"Questions and answers on the refusal of a change to the marketing authorisation for Tuznue (trastuzumab)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T15:37:00Z","last_updated_date":"2022-06-24T12:41:00Z","reference_number":"EMA/267893/2022 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-tuznue-trastuzumab_en.pdf"},
    {"id":"55017","name":"Questions and answers on the refusal of the marketing authorisation for Hervelous (trastuzumab)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T15:41:00Z","last_updated_date":"2022-06-24T12:00:00Z","reference_number":"EMA/373753/2022 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-hervelous-trastuzumab_en.pdf"},
    {"id":"55018","name":"CHMP summary of positive opinion for Zokinvy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/CHMP/264223/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zokinvy_en.pdf"},
    {"id":"55019","name":"CHMP summary of positive opinion for Sugammadex Fresenius Kabi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T15:48:00Z","last_updated_date":"2022-05-20T15:48:00Z","reference_number":"EMA/CHMP/266795/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sugammadex-fresenius-kabi_en.pdf"},
    {"id":"55024","name":"CHMP summary of positive opinion for Ertapenem SUN","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T16:45:00Z","last_updated_date":"2022-05-20T16:45:00Z","reference_number":"EMA/CHMP/266696/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ertapenem-sun_en.pdf"},
    {"id":"55028","name":"CHMP summary of positive opinion for Kinpeygo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"EMA/253572/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kinpeygo_en.pdf"},
    {"id":"55063","name":"Questions and answers on the refusal of the marketing authorisation for Ipique (bevacizumab)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2022-11-12T12:07:00Z","last_updated_date":"2022-11-12T12:07:00Z","reference_number":"EMA/120074/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-ipique-bevacizumab_sv.pdf"}},
    {"id":"55271","name":"CVMP summary of positive opinion for Cortaderm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-17T14:00:00Z","last_updated_date":"2022-06-17T14:00:00Z","reference_number":"EMA/CVMP/579025/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-cortaderm_en.pdf"},
    {"id":"55272","name":"CVMP summary of positive opinion for Coxatab","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-17T14:00:00Z","last_updated_date":"2022-06-17T14:00:00Z","reference_number":"EMA/CVMP/563847/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-coxatab_en.pdf"},
    {"id":"55273","name":"CVMP summary of positive opinion for Evanovo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-17T14:00:00Z","last_updated_date":"2022-06-17T14:00:00Z","reference_number":"EMA/CVMP/560050/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-evanovo_en.pdf"},
    {"id":"55276","name":"CVMP summary of positive opinion for DogStem","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-17T14:00:00Z","last_updated_date":"2022-06-17T14:00:00Z","reference_number":"EMA/CVMP/576246/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-dogstem_en.pdf"},
    {"id":"55312","name":"CHMP summary of positive opinion for Vegzelma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T15:07:00Z","last_updated_date":"2022-06-24T15:07:00Z","reference_number":"EMA/CHMP/595241/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vegzelma_en.pdf"},
    {"id":"55324","name":"CHMP summary of positive opinion for Ranivisio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T17:10:00Z","last_updated_date":"2022-06-24T17:10:00Z","reference_number":"EMA/593501/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ranivisio_en.pdf"},
    {"id":"55325","name":"CHMP summary of positive opinion for Scemblix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T11:03:00Z","last_updated_date":"2022-06-24T11:03:00Z","reference_number":"EMA/CHMP/587767/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-scemblix_en.pdf"},
    {"id":"55335","name":"CHMP summary of positive opinion for Rayvow","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T12:00:00Z","last_updated_date":"2022-06-24T12:00:00Z","reference_number":"EMA/CHMP/473504/2021 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rayvow_en.pdf"},
    {"id":"55339","name":"CHMP summary of positive opinion for COVID-19 Vaccine (inactivated, adjuvanted) Valneva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-23T16:00:00Z","last_updated_date":"2023-12-01T12:00:00Z","reference_number":"EMEA/H/C/006019","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-covid-19-vaccine-inactivated-adjuvanted-valneva_en.pdf"},
    {"id":"55344","name":"CHMP summary of positive opinion for Roctavian","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T17:40:00Z","last_updated_date":"2022-06-24T17:40:00Z","reference_number":"EMA/CHMP/584501/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-roctavian_en.pdf"},
    {"id":"55346","name":"CHMP summary of positive opinion for Sunlenca","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T12:00:00Z","last_updated_date":"2022-06-24T12:00:00Z","reference_number":"EMA/CHMP/562259/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sunlenca_en.pdf"},
    {"id":"55347","name":"CHMP summary of positive opinion for Pepaxti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T12:00:00Z","last_updated_date":"2022-06-24T12:00:00Z","reference_number":"EMA/CHMP/585580/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pepaxti_en.pdf"},
    {"id":"55366","name":"CHMP summary of positive opinion for Vyvgart","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-06-24T12:00:00Z","last_updated_date":"2022-06-24T12:00:00Z","reference_number":"EMA/373753/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vyvgart_en.pdf"},
    {"id":"55559","name":"CVMP summary of positive opinion for Lotilaner Elanco","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-15T13:46:00Z","last_updated_date":"2022-07-15T13:46:00Z","reference_number":"EMA/CVMP/623416/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-lotilaner-elanco_en.pdf"},
    {"id":"55621","name":"CHMP summary of opinion for Thalidomide Lipomed","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T15:32:00Z","last_updated_date":"2022-07-22T15:32:00Z","reference_number":"EMA/CHMP/625361/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-thalidomide-lipomed_en.pdf"},
    {"id":"55622","name":"CHMP summary of positive opinion for Opdualag","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T15:42:00Z","last_updated_date":"2022-07-22T15:42:00Z","reference_number":"EMA/CHMP/617724/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-opdualag_en.pdf"},
    {"id":"55627","name":"CHMP summary of positive opinion for Illuzyce","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T12:00:00Z","last_updated_date":"2022-07-22T12:00:00Z","reference_number":"EMA/CHMP/617852/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-illuzyce_en.pdf"},
    {"id":"55629","name":"CHMP summary of positive opinion for Tecvayli","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T12:00:00Z","last_updated_date":"2022-07-22T12:00:00Z","reference_number":"EMA/CHMP/644929/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tecvayli_en.pdf"},
    {"id":"55630","name":"CHMP summary of positive opinion for Amvuttra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T16:17:00Z","last_updated_date":"2022-07-22T16:17:00Z","reference_number":"EMA/CHMP/637065/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-amvuttra_en.pdf"},
    {"id":"55631","name":"CHMP summary of positive opinion for Lupkynis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T12:00:00Z","last_updated_date":"2022-07-22T12:00:00Z","reference_number":"EMA/CHMP/623061/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lupkynis_en.pdf"},
    {"id":"55633","name":"CHMP summary of positive opinion for Tezspire","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T16:45:00Z","last_updated_date":"2022-07-22T16:45:00Z","reference_number":"EMA/CHMP/620586/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tezspire_en.pdf"},
    {"id":"55640","name":"CHMP summary of positive opinion for Mounjaro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T08:45:00Z","last_updated_date":"2022-07-22T08:45:00Z","reference_number":"EMA/CHMP/648485/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mounjaro_en.pdf"},
    {"id":"55647","name":"CHMP summary of positive opinion for Vabysmo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T12:00:00Z","last_updated_date":"2022-07-22T12:00:00Z","reference_number":"EMA/CHMP/644170/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vabysmo_en.pdf"},
    {"id":"55653","name":"CHMP summary of positive opinion for Nulibry","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T11:57:00Z","last_updated_date":"2022-07-22T11:57:00Z","reference_number":"EMA/647175/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nulibry_en.pdf"},
    {"id":"55655","name":"CHMP summary of positive opinion for Celdoxome pegylated liposomal","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T12:00:00Z","last_updated_date":"2025-11-27T09:36:00Z","reference_number":"EMA/CHMP/655859/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-celdoxome-pegylated-liposomal_en.pdf"},
    {"id":"55809","name":"Dapivirine Vaginal Ring 25 mg - Summary of opinion","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2020-07-24T10:57:00Z","last_updated_date":"2020-07-24T10:57:00Z","reference_number":"EMA/CHMP/330850/2020","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/dapivirine-vaginal-ring-25-mg-summary-opinion_en.pdf"},
    {"id":"56096","name":"CHMP summary of opinion for Livtencity","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T12:00:00Z","last_updated_date":"2022-09-16T12:00:00Z","reference_number":"EMA/CHMP/248091/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-livtencity_en.pdf"},
    {"id":"56101","name":"CHMP summary of positive opinion for Teriflunomide Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T10:45:00Z","last_updated_date":"2022-09-16T10:45:00Z","reference_number":"EMA/CHMP/748820/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-teriflunomide-accord_en.pdf"},
    {"id":"56102","name":"CHMP summary of positive opinion for Enjaymo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T11:17:00Z","last_updated_date":"2022-09-16T11:17:00Z","reference_number":"EMA/CHMP/723511/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-enjaymo_en.pdf"},
    {"id":"56103","name":"CHMP summary of positive opinion for Pyrukynd","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T12:00:00Z","last_updated_date":"2022-09-16T12:00:00Z","reference_number":"EMA/CHMP/734156/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pyrukynd_en.pdf"},
    {"id":"56104","name":"CHMP summary of positive opinion for Zynlonta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T13:07:00Z","last_updated_date":"2022-09-19T11:54:00Z","reference_number":"EMA/CHMP/722012/2022 Corr.","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zynlonta_en.pdf"},
    {"id":"56105","name":"CHMP summary of positive opinion for Teriparatide Sun","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T13:34:00Z","last_updated_date":"2022-09-16T13:34:00Z","reference_number":"EMA/CHMP/734147/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-teriparatide-sun_en.pdf"},
    {"id":"56109","name":"CHMP summary of positive opinion for Ximluci","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T13:56:00Z","last_updated_date":"2022-09-16T13:56:00Z","reference_number":"EMA/CHMP/733467/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ximluci_en.pdf"},
    {"id":"56111","name":"CHMP summary of positive opinion for Melatonin Neurim","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T12:00:00Z","last_updated_date":"2022-09-16T12:00:00Z","reference_number":"EMA/CHMP/734993/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-melatonin-neurim_en.pdf"},
    {"id":"56113","name":"CHMP summary of positive opinion for Beyfortus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T16:26:00Z","last_updated_date":"2022-09-16T16:26:00Z","reference_number":"EMA/CHMP/647784/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-beyfortus_en.pdf"},
    {"id":"56125","name":"CHMP summary of positive opinion for Mycapssa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T10:41:00Z","last_updated_date":"2025-03-21T10:42:00Z","reference_number":"EMA/721412/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mycapssa_en.pdf"},
    {"id":"56126","name":"CHMP summary of positive opinion for Sorafenib Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T11:39:00Z","last_updated_date":"2022-09-16T11:39:00Z","reference_number":"EMA/CHMP/758392/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sorafenib-accord_en.pdf"},
    {"id":"56129","name":"CHMP summary of positive opinion for Teriflunomide Mylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-09-16T15:36:00Z","last_updated_date":"2022-09-16T15:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-teriflunomide-mylan_en.pdf"},
    {"id":"56345","name":"CVMP summary of positive opinion for Mometamax Ultra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-07T14:00:00Z","last_updated_date":"2022-10-07T14:00:00Z","reference_number":"EMA/CVMP/793345/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-mometamax-ultra_en.pdf"},
    {"id":"56381","name":"CHMP summary of positive opinion for Dimethyl fumarate Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T11:08:00Z","last_updated_date":"2023-12-22T14:56:00Z","reference_number":"EMA/CHMP/790837/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dimethyl-fumarate-teva_en.pdf"},
    {"id":"56397","name":"CHMP summary of positive opinion for Pluvicto","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/CHMP/793918/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pluvicto_en.pdf"},
    {"id":"56400","name":"CHMP summary of positive opinion for Locametz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/CHMP/742076/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-locametz_en.pdf"},
    {"id":"56404","name":"CHMP summary of positive opinion for Ebvallo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/CHMP/791184/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ebvallo_en.pdf"},
    {"id":"56405","name":"CHMP summary of positive opinion for Eladynos","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-13T17:00:00Z","last_updated_date":"2022-10-13T17:00:00Z","reference_number":"EMA/806878/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eladynos_en.pdf"},
    {"id":"56408","name":"CHMP summary of positive opinion for Spevigo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/CHMP/804058/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-spevigo_en.pdf"},
    {"id":"56409","name":"CHMP summary of positive opinion for Livmarli","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/CHMP/803191/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-livmarli_en.pdf"},
    {"id":"56412","name":"CHMP summary of positive opinion for Pemetrexed Baxter","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/CHMP/808787/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pemetrexed-baxter_en.pdf"},
    {"id":"56415","name":"CHMP summary of positive opinion for Qdenga","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:00:00Z","last_updated_date":"2022-10-14T12:00:00Z","reference_number":"EMA/CHMP/781052/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-qdenga_en.pdf"},
    {"id":"56427","name":"CHMP summary of positive opinion for Plerixafor Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-10-18T09:14:00Z","last_updated_date":"2022-10-18T09:14:00Z","reference_number":"EMA/CHMP/830349/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-plerixafor-accord_en.pdf"},
    {"id":"56547","name":"CHMP summary of positive opinion for Sugammadex Amomed","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T12:00:00Z","last_updated_date":"2022-11-11T12:00:00Z","reference_number":"EMA/CHMP/855683/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sugammadex-amomed_en.pdf"},
    {"id":"56577","name":"CHMP summary of positive opinion for VidPrevtyn Beta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-11-10T14:41:00Z","last_updated_date":"2024-03-20T13:20:00Z","reference_number":"EMA/867425/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vidprevtyn-beta_en.pdf"},
    {"id":"56586","name":"CHMP summary of positive opinion for Kauliv","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T12:00:00Z","last_updated_date":"2022-11-11T12:00:00Z","reference_number":"EMA/CHMP/863898/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kauliv_en.pdf"},
    {"id":"56597","name":"CHMP summary of positive opinion for Pirfenidone Viatris","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T12:00:00Z","last_updated_date":"2022-11-11T12:00:00Z","reference_number":"EMA/CHMP/846957/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pirfenidone-viatris_en.pdf"},
    {"id":"56599","name":"CVMP summary of positive opinion for Neoleish","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-11-11T14:11:00Z","last_updated_date":"2022-11-11T14:11:00Z","reference_number":"EMA/CVMP/858971/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-neoleish_en.pdf"},
    {"id":"56926","name":"CVMP summary of positive opinion for Brucellin Aquilon","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-12-09T15:00:00Z","last_updated_date":"2022-12-09T15:00:00Z","reference_number":"EMA/CVMP/889858/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-brucellin-aquilon_en.pdf"},
    {"id":"56993","name":"CHMP summary of positive opinion for Dimethyl fumarate Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T11:11:00Z","last_updated_date":"2023-12-22T12:50:00Z","reference_number":"EMA/CHMP/922592/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dimethyl-fumarate-accord_en.pdf"},
    {"id":"57035","name":"CHMP summary of positive opinion for Hemgenix","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/916178/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hemgenix_en.pdf"},
    {"id":"57043","name":"CHMP summary of positive opinion for Imjudo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T14:48:00Z","last_updated_date":"2022-12-16T14:48:00Z","reference_number":"EMA/904398/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imjudo_en.pdf"},
    {"id":"57058","name":"Questions and answers on the refusal of a change to the marketing authorisation for Omblastys (omburtamab (131I))","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T17:15:00Z","last_updated_date":"2023-06-14T12:18:00Z","reference_number":"EMA/900390/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-change-marketing-authorisation-omblastys-omburtamab-131i_sv.pdf"}},
    {"id":"57059","name":"CHMP post-authorisation summary of opinion for Edistride (WS-2299)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/938371/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-post-authorisation-summary-opinion-edistride-ws-2299_en.pdf"},
    {"id":"57063","name":"CHMP summary of positive opinion for Tremelimumab AstraZeneca","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2024-08-22T10:44:00Z","reference_number":"EMA/CHMP/925958/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tremelimumab-astrazeneca_en.pdf"},
    {"id":"57065","name":"CHMP summary of positive opinion for Pombiliti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"EMA/CHMP/794393/2022 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pombiliti_en.pdf"},
    {"id":"57406","name":"CHMP summary of positive opinion for Sitagliptin / Metformin hydrochloride Sun","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/CHMP/30966/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sitagliptin-metformin-hydrochloride-sun_en.pdf"},
    {"id":"57409","name":"Questions and answers on the refusal of the marketing authorisation for Sohonos (palovarotene)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-07-27T13:40:00Z","reference_number":"EMA/230889/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_sv.pdf"}},
    {"id":"57410","name":"CHMP summary of positive opinion for Tolvaptan Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/CHMP/30821/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tolvaptan-accord_en.pdf"},
    {"id":"57412","name":"CHMP summary of positive opinion for Sotyktu","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"EMA/CHMP/898000/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sotyktu_en.pdf"},
    {"id":"57416","name":"CHMP summary of positive opinion for Dapagliflozin Viatris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-01-27T17:44:00Z","last_updated_date":"2023-01-27T17:44:00Z","reference_number":"EMA/CHMP/30826/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dapagliflozin-viatris_en.pdf"},
    {"id":"57707","name":"CVMP summary of positive opinion for Bovilis Nasalgen-C","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T13:05:00Z","last_updated_date":"2023-02-17T13:05:00Z","reference_number":"EMA/CVMP/42050/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bovilis-nasalgen-c_en.pdf"},
    {"id":"57710","name":"CVMP summary of positive opinion for Eurican L4","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T13:23:00Z","last_updated_date":"2023-02-17T13:23:00Z","reference_number":"EMA/CVMP/54218/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-eurican-l4_en.pdf"},
    {"id":"57711","name":"CVMP summary of positive opinion for Innovax-ILT-IBD","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T13:29:00Z","last_updated_date":"2023-02-17T13:29:00Z","reference_number":"EMA/CVMP/45112/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-innovax-ilt-ibd_en.pdf"}    {"id":"57713","name":"CVMP summary of positive opinion for Prolevare","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-17T13:38:00Z","last_updated_date":"2023-02-17T13:38:00Z","reference_number":"EMA/CVMP/66932/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-prolevare_en.pdf"},
    {"id":"57798","name":"CHMP summary of positive opinion for Elfabrio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T14:16:00Z","last_updated_date":"2023-02-24T14:16:00Z","reference_number":"EMA/CHMP/60808/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-elfabrio_en.pdf"},
    {"id":"57800","name":"CHMP summary of positive opinion for Bekemv","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T14:22:00Z","last_updated_date":"2023-02-24T14:22:00Z","reference_number":"EMA/CHMP/72305/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bekemv_en.pdf"},
    {"id":"57801","name":"CHMP summary of positive opinion for Opzelura","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T14:35:00Z","last_updated_date":"2023-02-24T14:35:00Z","reference_number":"EMA/CHMP/27927/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-opzelura_en.pdf"},
    {"id":"57806","name":"CHMP summary of positive opinion for Tibsovo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T12:00:00Z","last_updated_date":"2023-02-24T12:00:00Z","reference_number":"EMA/CHMP/76153/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tibsovo_en.pdf"},
    {"id":"57808","name":"CHMP summary of positive opinion for Tidhesco","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T12:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/180261/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tidhesco_en.pdf"},
    {"id":"57810","name":"CHMP summary of positive opinion for Vafseo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T12:00:00Z","last_updated_date":"2023-02-24T12:00:00Z","reference_number":"EMA/CHMP/64870/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vafseo_en.pdf"},
    {"id":"57811","name":"CHMP summary of positive opinion for Akeega","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T10:21:00Z","last_updated_date":"2023-02-24T10:21:00Z","reference_number":"EMA/CHMP/55463/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-akeega_en.pdf"},
    {"id":"57812","name":"CHMP summary of positive opinion for Hyftor","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T10:21:00Z","last_updated_date":"2023-02-24T10:21:00Z","reference_number":"EMA/CHMP/55479/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hyftor_en.pdf"},
    {"id":"57817","name":"Questions and answers on the refusal of the marketing authorisation for Lagevrio (molnupiravir)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-02-24T12:00:00Z","last_updated_date":"2023-03-13T14:30:00Z","reference_number":"EMA/82948/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-lagevrio-molnupiravir_en.pdf"},
    {"id":"58160","name":"CVMP summary of positive opinion for Newflend ND H9","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-03-24T15:51:00Z","last_updated_date":"2023-03-24T15:51:00Z","reference_number":"EMA/CVMP/116044/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-newflend-nd-h9_en.pdf"},
    {"id":"58189","name":"CHMP summary of positive opinion for Briumvi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T17:38:00Z","last_updated_date":"2023-03-31T17:38:00Z","reference_number":"EMA/CHMP/122125/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-briumvi_en.pdf"},
    {"id":"58194","name":"CHMP summary of positive opinion for Omvoh","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/CHMP/138535/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-omvoh_en.pdf"},
    {"id":"58203","name":"CHMP summary of positive opinion for Epysqli","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/CHMP/113220/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-epysqli_en.pdf"},
    {"id":"58204","name":"CHMP summary of positive opinion for Pedmarqsi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/CHMP/130783/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pedmarqsi_en.pdf"},
    {"id":"58227","name":"CHMP summary of positive opinion for Bimervax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-03-30T15:19:00Z","last_updated_date":"2023-03-30T15:19:00Z","reference_number":"EMA/141306/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bimervax_en.pdf"},
    {"id":"58229","name":"CHMP summary of positive opinion for Sugammadex Adroiq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/CHMP/130386/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sugammadex-adroiq_en.pdf"},
    {"id":"58230","name":"CHMP summary of positive opinion for Qaialdo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/CHMP/141137/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-qaialdo_en.pdf"},
    {"id":"58233","name":"CHMP summary of positive opinion for Lacosamide Adroiq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/CHMP/126756/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lacosamide-adroiq_en.pdf"},
    {"id":"58235","name":"CHMP summary of positive opinion for Dabigatran etexilate Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-03-31T12:00:00Z","last_updated_date":"2023-03-31T12:00:00Z","reference_number":"EMA/CHMP/583559/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dabigatran-etexilate-accord_en.pdf"},
    {"id":"58524","name":"CHMP summary of positive opinion for Camzyos","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/918256/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-camzyos_en.pdf"},
    {"id":"58528","name":"CHMP summary of positive opinion for Sugammadex Piramal","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/178271/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sugammadex-piramal_en.pdf"},
    {"id":"58529","name":"CHMP summary of positive opinion for Opfolda","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/794403/2022","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-opfolda_en.pdf"},
    {"id":"58531","name":"CHMP summary of positive opinion for Jaypirca","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/167799/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jaypirca_en.pdf"},
    {"id":"58534","name":"CHMP summary of opinion for Arexvy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/141401/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-arexvy_en.pdf"},
    {"id":"58537","name":"CHMP summary of positive opinion for Columvi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/166656/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-columvi_en.pdf"},
    {"id":"58538","name":"CHMP summary of opinion for Lytgobi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-04-26T18:00:00Z","last_updated_date":"2023-04-26T18:00:00Z","reference_number":"EMA/CHMP/169349/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-lytgobi_en.pdf"},
    {"id":"58736","name":"CVMP summary of positive opinion for Eluracat","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-05-22T14:38:00Z","last_updated_date":"2023-05-22T14:38:00Z","reference_number":"EMA/CVMP/194243/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-eluracat_en.pdf"},
    {"id":"58790","name":"CHMP summary of positive opinion for Pylclari","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-05-26T12:00:00Z","last_updated_date":"2023-05-26T12:00:00Z","reference_number":"EMA/CHMP/235199/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pylclari_en.pdf"},
    {"id":"58793","name":"CHMP summary of positive opinion for Ztalmy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-05-26T13:46:00Z","last_updated_date":"2023-05-26T13:46:00Z","reference_number":"EMA/CHMP/207481/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ztalmy_en.pdf"},
    {"id":"59049","name":"CHMP summary of positive opinion for Aquipta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T12:00:00Z","last_updated_date":"2023-06-23T12:00:00Z","reference_number":"EMA/CHMP/257716/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aquipta_en.pdf"},
    {"id":"59050","name":"CHMP summary of positive opinion for Jesduvroq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-06-23T15:34:00Z","last_updated_date":"2023-07-21T12:53:00Z","reference_number":"EMA/269186/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jesduvroq_en.pdf"},
    {"id":"59068","name":"Questions and answers on the refusal of the marketing authorisation for Albrioza (sodium phenylbutyrate / ursodoxicoltaurine)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T12:00:00Z","last_updated_date":"2024-02-01T15:08:00Z","reference_number":"EMA/471411/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-albrioza-sodium-phenylbutyrate-ursodoxicoltaurine_sv.pdf"}},
    {"id":"59355","name":"CVMP summary of positive opinion for YURVAC RHD","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-14T14:38:00Z","last_updated_date":"2023-07-14T14:38:00Z","reference_number":"EMA/CVMP/311987/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-yurvac-rhd_en.pdf"},
    {"id":"59405","name":"CHMP summary of positive opinion for Lyfnua","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T16:07:00Z","last_updated_date":"2023-07-21T16:07:00Z","reference_number":"EMA/CHMP/322106/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lyfnua_en.pdf"},
    {"id":"59406","name":"CHMP summary of positive opinion for Tyruko","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T16:06:00Z","last_updated_date":"2023-07-21T16:06:00Z","reference_number":"EMA/CHMP/268353/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tyruko_en.pdf"},
    {"id":"59407","name":"CHMP summary of positive opinion for Orserdu","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T16:21:00Z","last_updated_date":"2023-07-21T16:21:00Z","reference_number":"EMA/CHMP/325146/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-orserdu_en.pdf"},
    {"id":"59409","name":"CHMP summary of positive opinion for Litfulo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-21T12:00:00Z","reference_number":"EMA/CHMP/328223/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-litfulo_en.pdf"},
    {"id":"59417","name":"CHMP summary of positive opinion for Abrysvo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-21T12:00:00Z","reference_number":"EMA/CHMP/327338/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-abrysvo_en.pdf"},
    {"id":"59427","name":"CHMP summary of positive opinion for Inaqovi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T11:51:00Z","last_updated_date":"2023-07-21T11:51:00Z","reference_number":"EMA/324132/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-inaqovi_en.pdf"},
    {"id":"59428","name":"CHMP summary of positive opinion for Yesafili","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T11:56:00Z","last_updated_date":"2023-07-21T11:56:00Z","reference_number":"EMA/CHMP/299233/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yesafili_en.pdf"},
    {"id":"59429","name":"CHMP summary of positive opinion for Apretude","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:01:00Z","last_updated_date":"2023-07-21T12:01:00Z","reference_number":"EMA/327881/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-apretude_en.pdf"},
    {"id":"59430","name":"Questions and answers on the refusal of the marketing authorisation for Krazati (adagrasib)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-28T17:06:00Z","reference_number":"EMA/333057/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-krazati-adagrasib_en.pdf"},
    {"id":"59432","name":"CHMP summary of positive opinion for Talvey","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-20T14:59:00Z","last_updated_date":"2023-07-20T14:59:00Z","reference_number":"EMA/323969/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-talvey_en.pdf"},
    {"id":"59433","name":"CHMP summary of positive opinion for Enrylaze","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T15:04:00Z","last_updated_date":"2023-07-21T15:04:00Z","reference_number":"EMA/323951/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-enrylaze_en.pdf"},
    {"id":"59440","name":"CHMP summary of opinion for Tevimbra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-21T12:00:00Z","reference_number":"EMA/CHMP/321765/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-tevimbra_en.pdf"},
    {"id":"59444","name":"CHMP summary of positive opinion for Tepkinly","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T17:16:00Z","last_updated_date":"2023-07-21T17:16:00Z","reference_number":"EMA/CHMP/324066/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tepkinly_en.pdf"},
    {"id":"59445","name":"CHMP summary of positive opinion for Tyenne","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-21T12:00:00Z","reference_number":"EMA/245419/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tyenne_en.pdf"},
    {"id":"59919","name":"CVMP summary of positive opinion for Loxitab","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-08T12:00:00Z","last_updated_date":"2023-09-08T12:00:00Z","reference_number":"EMA/CVMP/386093/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-loxitab_en.pdf"},
    {"id":"59920","name":"CVMP summary of positive opinion for Oxmax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-08T12:54:00Z","last_updated_date":"2023-09-08T12:54:00Z","reference_number":"EMA/CVMP/374571/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-oxmax_en.pdf"},
    {"id":"59921","name":"CVMP summary of positive opinion for Poulvac Procerta HVT-IBD","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-08T12:00:00Z","last_updated_date":"2023-09-08T12:00:00Z","reference_number":"EMA/CVMP/379398/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-poulvac-procerta-hvt-ibd_en.pdf"},
    {"id":"59922","name":"CVMP summary of positive opinion for Prevexxion RN+HVT","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-08T13:05:00Z","last_updated_date":"2023-09-08T13:05:00Z","reference_number":"EMA/CVMP/398578/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-prevexxion-rnhvt_en.pdf"},
    {"id":"59976","name":"CHMP summary of positive opinion for Herwenda","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T12:00:00Z","last_updated_date":"2023-09-15T12:00:00Z","reference_number":"EMA/CHMP/400511/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-herwenda_en.pdf"},
    {"id":"59980","name":"CHMP summary of positive opinion for Ebglyss","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T15:09:00Z","last_updated_date":"2023-09-15T15:09:00Z","reference_number":"EMA/CHMP/343777/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ebglyss_en.pdf"},
    {"id":"59992","name":"CHMP summary of positive opinion for Vanflyta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T16:06:00Z","last_updated_date":"2023-09-15T16:06:00Z","reference_number":"EMA/CHMP/378674/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vanflyta_en.pdf"},
    {"id":"59993","name":"CHMP summary of positive opinion for Aqumeldi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-14T16:18:00Z","last_updated_date":"2023-09-14T16:18:00Z","reference_number":"EMA/CHMP/209632/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aqumeldi_en.pdf"},
    {"id":"59994","name":"CHMP summary of positive opinion for Zoonotic Influenza Vaccine Seqirus","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T16:23:00Z","last_updated_date":"2023-09-15T16:23:00Z","reference_number":"EMA/CHMP/387186/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zoonotic-influenza-vaccine-seqirus_en.pdf"},
    {"id":"59997","name":"CHMP summary of positive opinion for Finlee","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T12:00:00Z","last_updated_date":"2023-09-15T12:00:00Z","reference_number":"EMA/CHMP/402638/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-finlee_en.pdf"},
    {"id":"60008","name":"CHMP summary of positive for Yorvipath","type":"smop-initial","status":"Draft","consultation_date":"","first_published_date":"2023-09-15T12:00:00Z","last_updated_date":"2023-09-15T12:00:00Z","reference_number":"EMA/CHMP/405555/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-yorvipath_en.pdf"},
    {"id":"60027","name":"CHMP summary of positive opinion for Catiolanze","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T12:20:00Z","last_updated_date":"2023-09-15T12:20:00Z","reference_number":"EMA/CHMP/402547/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-catiolanze_en.pdf"},
    {"id":"60031","name":"CHMP summary of positive opinion for Zilbrysq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-09-15T14:29:00Z","last_updated_date":"2023-09-15T14:29:00Z","reference_number":"EMA/CHMP/404478/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zilbrysq_en.pdf"},
    {"id":"60281","name":"CVMP summary of positive opinion for Bovilis Cryptium","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-10-06T12:57:00Z","last_updated_date":"2023-10-06T12:57:00Z","reference_number":"EMA/CVMP/416566/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bovilis-cryptium_en.pdf"},
    {"id":"60286","name":"CVMP summary of positive opinion for Nobivac LoVo L4","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-10-06T13:20:00Z","last_updated_date":"2023-10-06T13:20:00Z","reference_number":"EMA/CVMP/424834/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-lovo-l4_en.pdf"},
    {"id":"60287","name":"CVMP summary of positive opinion for Senvelgo","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-10-06T14:20:00Z","last_updated_date":"2023-10-06T14:20:00Z","reference_number":"EMA/CVMP/432172/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-senvelgo_en.pdf"},
    {"id":"60364","name":"CHMP summary of positive opinion for Elucirem","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/CHMP/448539/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-elucirem_en.pdf"},
    {"id":"60365","name":"CHMP summary of positive opinion for Vueway","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/CHMP/448534/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vueway_en.pdf"},
    {"id":"60366","name":"CHMP summary of positive opinion for Elrexfio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T15:18:00Z","last_updated_date":"2023-10-13T15:18:00Z","reference_number":"EMA/CHMP/436072/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-elrexfio_en.pdf"},
    {"id":"60374","name":"CHMP summary of positive opinion for Rezzayo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/448724/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rezzayo_en.pdf"},
    {"id":"60379","name":"CHMP summary of positive opinion for Loargys","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/CHMP/450010/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-loargys_en.pdf"},
    {"id":"60382","name":"CHMP summary of positive opinion for Veoza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/CHMP/440243/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-veoza_en.pdf"},
    {"id":"60565","name":"CHMP summary of positive opinion for Pemetrexed Lilly","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T14:00:00Z","last_updated_date":"2021-11-26T14:00:00Z","reference_number":"EMA/CHMP/448340/2015","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pemetrexed-lilly_en.pdf"},
    {"id":"60729","name":"CHMP summary of positive opinion for Degarelix Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-21T12:00:00Z","reference_number":"EMA/CHMP/325725/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-degarelix-accord_en.pdf"},
    {"id":"60766","name":"CHMP summary of positive opinion for Agamree","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"EMA/CHMP/458203/2023EMA/CHMP/458203/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-agamree_en.pdf"},
    {"id":"60825","name":"CHMP summary of positive opinion for Krazati","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/492226/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-krazati_en.pdf"},
    {"id":"60834","name":"CHMP summary of positive opinion for Naveruclif","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/481586/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-naveruclif_en.pdf"},
    {"id":"60839","name":"CHMP summary of positive opinion for Uzpruvo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-uzpruvo_en.pdf"},
    {"id":"60841","name":"Questions and answers on the approval of the marketing authorisation for Krazati (adagrasib) - outcome of re-examination","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/497823/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-approval-marketing-authorisation-krazati-adagrasib-outcome-re-examination_en.pdf"},
    {"id":"60842","name":"CHMP summary of positive opinion for Omjjara","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T11:22:00Z","last_updated_date":"2023-11-10T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-omjjara_en.pdf"},
    {"id":"60856","name":"CHMP summary of positive opinion for Rimmyrah","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T12:47:00Z","last_updated_date":"2023-11-10T12:47:00Z","reference_number":"EMA/CHMP/482871/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rimmyrah_en.pdf"},
    {"id":"60857","name":"CHMP summary of positive opinion for Rystiggo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-11-10T13:01:00Z","last_updated_date":"2023-11-10T13:01:00Z","reference_number":"EMA/CHMP/488847/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rystiggo_en.pdf"},
    {"id":"60983","name":"CHMP summary of positive opinion for Spexotras","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-11-24T15:05:52Z","last_updated_date":"2023-11-24T15:05:52Z","reference_number":"EMA/CHMP/483504/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-spexotras_en.pdf"},
    {"id":"61424","name":"CHMP summary of positive opinion for Pomalidomide Viatris","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T15:57:22Z","last_updated_date":"2023-12-15T15:57:22Z","reference_number":"EMA/CHMP/554066/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pomalidomide-viatris_en.pdf"},
    {"id":"61426","name":"CHMP summary of positive opinion for Velsipity","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T12:00:00Z","last_updated_date":"2023-12-15T12:00:00Z","reference_number":"EMA/CHMP/552342/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-velsipity_en.pdf"},
    {"id":"61427","name":"CHMP summary of positive opinion for Mevlyq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T12:00:00Z","last_updated_date":"2023-12-15T12:00:00Z","reference_number":"EMA/CHMP/543409/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mevlyq_en.pdf"},
    {"id":"61432","name":"CHMP initial authorisation summary of positive opinion for Dabigatran Etexilate Leon Farma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T12:00:00Z","last_updated_date":"2023-12-15T12:00:00Z","reference_number":"EMA/CHMP/556286/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-initial-authorisation-summary-positive-opinion-dabigatran-etexilate-leon-farma_en.pdf"},
    {"id":"61433","name":"CHMP initial authorisation summary of positive opinion for Ibuprofen Gen.Orph","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T12:00:00Z","last_updated_date":"2023-12-15T12:00:00Z","reference_number":"EMA/CHMP/562650/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-initial-authorisation-summary-positive-opinion-ibuprofen-genorph_en.pdf"},
    {"id":"61436","name":"CHMP summary of positive opinion for Casgevy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T12:00:00Z","last_updated_date":"2023-12-15T12:00:00Z","reference_number":"EMA/CHMP/506425/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-casgevy_en.pdf"},
    {"id":"61437","name":"CHMP summary of positive opinion for Skyclarys","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-12-15T12:30:07Z","last_updated_date":"2023-12-15T12:30:07Z","reference_number":"EMA/CHMP/535984/2023 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-skyclarys_en.pdf"},
    {"id":"61879","name":"CHMP summary of positive opinion for Ryzneuta","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T12:00:00Z","last_updated_date":"2024-01-26T12:00:00Z","reference_number":"EMA/CHMP/31327/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ryzneuta_en.pdf"},
    {"id":"61902","name":"CHMP summary of positive opinion for Exblifep","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-01-26T12:00:00Z","last_updated_date":"2024-01-26T12:00:00Z","reference_number":"EMA/CHMP/15483/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-exblifep_en.pdf"},
    {"id":"61903","name":"Questions and answers on the refusal of the marketing authorisation for Nezglyal (leriglitazone)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T12:00:00Z","last_updated_date":"2024-11-20T11:53:00Z","reference_number":"EMA/251627/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nezglyal-leriglitazone_sv.pdf"}},
    {"id":"61905","name":"CHMP summary of positive opinion for Niapelf","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-01-26T10:46:16Z","last_updated_date":"2024-01-26T10:46:16Z","reference_number":"EMA/CHMP/18799/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-niapelf_en.pdf"},
    {"id":"62203","name":"CVMP summary of positive opinion for Divence Penta","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-02-16T16:42:46Z","last_updated_date":"2024-02-16T16:42:46Z","reference_number":"EMA/CVMP/43998/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-divence-penta_en.pdf"},
    {"id":"62204","name":"CVMP summary of positive opinion for Alcort","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-02-16T16:48:43Z","last_updated_date":"2024-02-16T16:48:43Z","reference_number":"EMA/CVMP/44401/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-alcort_en.pdf"},
    {"id":"62205","name":"CVMP summary of positive opinion for Lexylan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-02-16T16:59:50Z","last_updated_date":"2024-02-16T16:59:50Z","reference_number":"EMA/CVMP/49162/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-lexylan_en.pdf"},
    {"id":"62255","name":"CHMP summary of positive opinion for Filspari","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-03-05T17:30:00Z","reference_number":"EMA/518075/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-filspari_en.pdf"},
    {"id":"62256","name":"CHMP summary of positive opinion for Pyzchiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/56536/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pyzchiva_en.pdf"},
    {"id":"62262","name":"CHMP summary of positive opinion for Azacitidine Kabi","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T12:00:00Z","last_updated_date":"2023-11-10T12:00:00Z","reference_number":"EMA/CHMP/481607/2023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-azacitidine-kabi_en.pdf"},
    {"id":"62265","name":"CHMP summary of positive opinion for Qalsody","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/CHMP/50520/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-qalsody_en.pdf"},
    {"id":"62266","name":"CHMP summary of positive opinion for Zynyz","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/CHMP/60465/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zynyz_en.pdf"}    {"id":"62267","name":"CHMP summary of positive opinion for Celldemic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T15:48:39Z","last_updated_date":"2024-02-23T15:48:39Z","reference_number":"EMA/71755/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-celldemic_en.pdf"},
    {"id":"62268","name":"CHMP summary of positive opinion for Voydeya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/CHMP/63838/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-voydeya_en.pdf"},
    {"id":"62269","name":"CHMP summary of positive opinion for Apremilast Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/CHMP/28290/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-apremilast-accord_en.pdf"},
    {"id":"62270","name":"CHMP summary of positive opinion for Nintedanib Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-02-23T12:00:00Z","reference_number":"EMA/CHMP/34939/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nintedanib-accord_en.pdf"},
    {"id":"62271","name":"CHMP summary of positive opinion for Incellipan","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T16:22:26Z","last_updated_date":"2024-02-23T16:22:26Z","reference_number":"EMA/71759/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-incellipan_en.pdf"},
    {"id":"62280","name":"CHMP summary of positive opinion for Tizveni","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-02-23T12:00:00Z","last_updated_date":"2024-08-02T15:58:50Z","reference_number":"EMA/CHMP/59203/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tizveni_en.pdf"},
    {"id":"62630","name":"CVMP summary of positive opinion for Divence Tetra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-18T13:06:28Z","last_updated_date":"2024-03-18T13:06:28Z","reference_number":"EMA/CVMP/98737/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-divence-tetra_en.pdf"},
    {"id":"62631","name":"CVMP summary of positive opinion for Lotimax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-18T13:40:14Z","last_updated_date":"2024-03-18T13:40:14Z","reference_number":" EMA/CVMP/99608/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-lotimax_en.pdf"},
    {"id":"62632","name":"CVMP summary of positive opinion for Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-18T13:49:36Z","last_updated_date":"2024-03-18T13:49:36Z","reference_number":"EMA/CVMP/90386/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobilis-multriva-rtibmndgmreomeds_en.pdf"},
    {"id":"62633","name":"CVMP summary of positive opinion for Trilocur","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-18T14:31:29Z","last_updated_date":"2024-03-18T14:31:29Z","reference_number":"EMA/CVMP/105711/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-trilocur_en.pdf"},
    {"id":"62634","name":"CVMP summary of positive opinion for Trilorale","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-18T14:41:48Z","last_updated_date":"2024-03-18T14:41:48Z","reference_number":"EMA/CVMP/105714/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-trilorale_en.pdf"},
    {"id":"62665","name":"CHMP summary of positive opinion for Fabhalta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/54481/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fabhalta_en.pdf"},
    {"id":"62667","name":"CHMP summary of positive opinion for Awiqli","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/107168/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-awiqli_en.pdf"},
    {"id":"62668","name":"CHMP summary of positive opinion for Jubbonti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/99825/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jubbonti_en.pdf"},
    {"id":"62669","name":"CHMP summary of positive opinion for Emblaveo","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T11:11:04Z","last_updated_date":"2024-03-22T11:11:04Z","reference_number":"EMA/CHMP/80600/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-emblaveo_en.pdf"},
    {"id":"62670","name":"CHMP summary of positive opinion for Wyost","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/99814/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-wyost_en.pdf"},
    {"id":"62675","name":"CHMP summary of positive opinion for Dimethyl fumarate Neuraxpharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/104444/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dimethyl-fumarate-neuraxpharm_en.pdf-0"},
    {"id":"62683","name":"CHMP summary of positive opinion for Neoatricon","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/61250/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-neoatricon_en.pdf"},
    {"id":"62688","name":"CHMP summary of positive opinion for Agilus","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T17:20:54Z","last_updated_date":"2024-03-22T17:20:54Z","reference_number":"EMA/CHMP/68942/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-agilus_en.pdf"},
    {"id":"62689","name":"CHMP summary of positive opinion for Omlyclo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/117126/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-omlyclo_en.pdf"},
    {"id":"62690","name":"CHMP summary of positive opinion for Dimethyl fumarate Mylan","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T17:33:00Z","last_updated_date":"2024-03-22T17:33:00Z","reference_number":"EMA/CHMP/107054/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dimethyl-fumarate-mylan_en.pdf"},
    {"id":"62693","name":"CHMP summary of positive opinion for Dimethyl fumarate Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/107040/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dimethyl-fumarate-accord_en.pdf-0"},
    {"id":"62701","name":"CHMP summary of positive opinion for Lytenava","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-03-22T12:00:00Z","last_updated_date":"2024-03-22T12:00:00Z","reference_number":"EMA/CHMP/101744/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lytenava_en.pdf"},
    {"id":"63025","name":"CVMP summary of positive opinion for Respivac TRT","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-04-19T15:26:23Z","last_updated_date":"2024-04-19T15:26:23Z","reference_number":"EMA/CVMP/136137/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-respivac-trt_en.pdf"},
    {"id":"63059","name":"CHMP summary of positive opinion for Eribulin Baxter","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:55Z","last_updated_date":"2024-04-26T12:00:55Z","reference_number":"EMA/132945/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eribulin-baxter_en.pdf"},
    {"id":"63063","name":"CHMP summary of positive opinion for Wezenla","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/153422/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-wezenla_en.pdf"},
    {"id":"63066","name":"CHMP summary of positive opinion for Jeraygo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/CHMP/148449/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jeraygo_en.pdf"},
    {"id":"63068","name":"CHMP summary of positive opinion for Altuvoct","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/167452/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-altuvoct_en.pdf"},
    {"id":"63073","name":"CVMP summary of positive opinion for Innovax-ND-H5","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-04-25T17:00:00Z","last_updated_date":"2024-04-25T17:00:00Z","reference_number":"EMA/CVMP/165069/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-innovax-nd-h5_en.pdf"},
    {"id":"63074","name":"CHMP summary of positive opinion for Obgemsa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/CHMP/159701/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-obgemsa_en.pdf"},
    {"id":"63079","name":"CHMP summary of positive opinion for Tofidence","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/CHMP/134201/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tofidence_en.pdf"},
    {"id":"63083","name":"CHMP summary of positive opinion for Truqap","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/151857/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-truqap_en.pdf"},
    {"id":"63085","name":"CHMP summary of positive opinion for Fruzaqla","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"EMA/CHMP/168563/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fruzaqla_en.pdf"},
    {"id":"63313","name":"CVMP summary of positive opinion for Nobilis Multriva RT+IBm+ND+EDS","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-24T12:00:00Z","last_updated_date":"2024-05-24T12:00:00Z","reference_number":"EMA/CVMP/189378/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobilis-multriva-rtibmndeds_en.pdf"},
    {"id":"63315","name":"CVMP summary of positive opinion for Nobilis Multriva RT+IBm+ND+Gm+REOm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-24T12:00:00Z","last_updated_date":"2024-05-24T12:00:00Z","reference_number":"EMA/CVMP/187085/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobilis-multriva-rtibmndgmreom_en.pdf"},
    {"id":"63396","name":"CHMP summary of positive opinion for Pomalidomide Krka","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T13:00:00Z","last_updated_date":"2024-05-31T13:00:00Z","reference_number":"EMA/CHMP/227643/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pomalidomide-krka_en.pdf"},
    {"id":"63401","name":"CHMP summary of positive opinion for Fluenz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/228604/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fluenz_en.pdf-0"},
    {"id":"63404","name":"CHMP summary of positive opinion for Ixchiq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/40091/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ixchiq_en.pdf"},
    {"id":"63405","name":"CHMP summary of positive opinion for Pomalidomide Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/227529/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pomalidomide-accord_en.pdf"},
    {"id":"63408","name":"CHMP summary of positive opinion for Pomalidomide Zentiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/227782/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pomalidomide-zentiva_en.pdf"},
    {"id":"63410","name":"CHMP summary of positive opinion for Avzivi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/226533/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-avzivi_en.pdf"},
    {"id":"63411","name":"CHMP summary of positive opinion for Apexelsin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMEA/250328/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-apexelsin_en.pdf"},
    {"id":"63416","name":"CHMP summary of positive opinion for Cejemly","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/224098/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cejemly_en.pdf"},
    {"id":"63417","name":"CHMP summary of positive opinion for Adzynma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/237295/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-adzynma_en.pdf"},
    {"id":"63418","name":"CHMP summary of positive opinion for GalliaPharm","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/149530/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-galliapharm_en.pdf"},
    {"id":"63423","name":"CHMP summary of positive opinion for Akantior","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-05-31T08:50:50Z","last_updated_date":"2024-05-31T08:50:50Z","reference_number":"EMA/248910/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-akantior_en.pdf"},
    {"id":"63425","name":"CHMP summary of positive opinion for Durveqtix","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2025-06-04T11:44:00Z","reference_number":"EMA/CHMP/232716/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-durveqtix_en.pdf"},
    {"id":"63426","name":"CHMP summary of positive opinion for Zegalogue","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/222106/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zegalogue_en.pdf"},
    {"id":"63431","name":"CHMP summary of positive opinion for Dasatinib Accord Healthcare","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T12:00:00Z","last_updated_date":"2024-05-31T12:00:00Z","reference_number":"EMA/CHMP/233375/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dasatinib-accord-healthcare_en.pdf"},
    {"id":"63716","name":"CVMP summary of positive opinion for Divence IBR Marker Live","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-21T12:00:00Z","last_updated_date":"2024-06-21T12:00:00Z","reference_number":"EMA/CVMP/252070/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-divence-ibr-marker-live_en.pdf"},
    {"id":"63760","name":"CHMP initial authorisation summary of positive opinion for Eurneffy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/281399/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-initial-authorisation-summary-positive-opinion-eurneffy_en.pdf"},
    {"id":"63771","name":"CHMP summary of positive opinion for Piasky","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-27T15:09:07Z","last_updated_date":"2024-06-27T15:09:07Z","reference_number":"EMA/290325/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-piasky_en.pdf"},
    {"id":"63773","name":"CHMP summary of positive opinion for Winrevair","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/289588/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-winrevair_en.pdf"},
    {"id":"63777","name":"CHMP summary of positive opinion for Balversa ","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/267474/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-balversa_en.pdf"},
    {"id":"63778","name":"CHMP summary of positive opinion for Nilotinib Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/281252/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nilotinib-accord_en.pdf"},
    {"id":"63782","name":"Questions and answers on the refusal of the marketing authorisation for Masitinib AB Science (masitinib mesilate)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-06-28T09:22:07Z","last_updated_date":"2025-01-22T14:07:00Z","reference_number":"EMA/472277/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-masitinib-ab-science-masitinib-mesilate_sv.pdf"}},
    {"id":"63783","name":"Questions and answers on the refusal of the marketing authorisation for Syfovre","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-09-19T11:11:01Z","reference_number":"EMA/432931/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-syfovre_en.pdf"},
    {"id":"63785","name":"CHMP summary of positive opinion for Ordspono","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/276689/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ordspono_en.pdf"},
    {"id":"63786","name":"CHMP summary of positive opinion for mResvia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/285703/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mresvia_en.pdf"},
    {"id":"63787","name":"CHMP summary of positive opinion for Steqeyma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/275388/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-steqeyma_en.pdf"},
    {"id":"63791","name":"CHMP summary of positive opinion for Tauvid","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/CHMP/287484/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tauvid_en.pdf"},
    {"id":"63798","name":"CHMP summary of positive opinion for Enzalutamide Viatris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"EMA/270183/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-enzalutamide-viatris_en.pdf"},
    {"id":"64222","name":"CVMP summary of positive opinion for Cepeloron","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-19T12:23:04Z","last_updated_date":"2024-07-19T12:23:04Z","reference_number":"EMA/CVMP/313134/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-cepeloron_en.pdf"},
    {"id":"64223","name":"CVMP summary of positive opinion for Porcilis PCV M Hyo ID","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-19T12:23:03Z","last_updated_date":"2024-07-19T12:23:03Z","reference_number":"EMA/CVMP/303620/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-porcilis-pcv-m-hyo-id_en.pdf"},
    {"id":"64225","name":"CVMP summary of positive opinion for Cevac Salmune ETI K","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-19T00:00:00Z","last_updated_date":"2024-07-19T00:00:00Z","reference_number":"EMA/CVMP/301999/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-cevac-salmune-eti-k_en.pdf"},
    {"id":"64279","name":"CHMP summary of positive opinion for Ranibizumab Midas","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T10:22:02Z","last_updated_date":"2024-07-26T10:22:02Z","reference_number":"EMA/CHMP/332433/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ranibizumab-midas_en.pdf"},
    {"id":"64283","name":"CHMP summary of positive opinion for Yuvanci","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T11:11:01Z","last_updated_date":"2024-07-26T11:11:01Z","reference_number":"EMA/CHMP/338583/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yuvanci_en.pdf"},
    {"id":"64294","name":"CHMP summary of positive opinion for Ituxredi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:00:00Z","last_updated_date":"2024-07-26T12:00:00Z","reference_number":"EMA/CHMP/333263/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ituxredi_en.pdf"},
    {"id":"64305","name":"CHMP summary of positive opinion for Kayfanda","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T11:11:01Z","last_updated_date":"2024-07-26T11:11:01Z","reference_number":"EMA/CHMP/314863/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kayfanda_en.pdf"},
    {"id":"64306","name":"CHMP summary of positive opinion for Anzupgo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:00:00Z","last_updated_date":"2024-07-26T12:00:00Z","reference_number":"EMA/CHMP/239042/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-anzupgo_en.pdf"},
    {"id":"64312","name":"CHMP summary of positive opinion for Iqirvo","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-07-26T11:11:01Z","last_updated_date":"2024-07-26T11:11:01Z","reference_number":"EMA/CHMP/327112/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-iqirvo_en.pdf"},
    {"id":"64313","name":"CHMP summary of positive opinion for Eksunbi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T11:11:01Z","last_updated_date":"2025-09-08T15:58:00Z","reference_number":"EMA/CHMP/322195/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eksunbi_en.pdf"},
    {"id":"64318","name":"CHMP summary of positive opinion for Loqtorzi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T11:11:01Z","last_updated_date":"2024-07-26T11:11:01Z","reference_number":"EMA/CHMP/305308/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-loqtorzi_en.pdf"},
    {"id":"64324","name":"CHMP summary of positive opinion for Otulfi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:00:00Z","last_updated_date":"2024-07-26T12:00:00Z","reference_number":"EMA/CHMP/294331/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-otulfi_en.pdf"},
    {"id":"64325","name":"CHMP summary of positive opinion for Fymskina","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:22:02Z","last_updated_date":"2024-07-26T12:22:02Z","reference_number":"EMA/CHMP/294338/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fymskina_en.pdf"},
    {"id":"64326","name":"CHMP summary of positive opinion for Tuznue","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:00:00Z","last_updated_date":"2024-07-26T12:00:00Z","reference_number":"EMA/CHMP/340490/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tuznue_en.pdf"},
    {"id":"64327","name":"CHMP summary of positive opinion for Vyloy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:00:00Z","last_updated_date":"2024-07-26T12:00:00Z","reference_number":"EMA/CHMP/318981/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vyloy_en.pdf"},
    {"id":"64331","name":"CHMP summary of positive opinion for Vevizye","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:00:00Z","last_updated_date":"2024-07-26T12:00:00Z","reference_number":"EMA/CHMP/320011/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vevizye_en.pdf"},
    {"id":"64332","name":"CHMP summary of positive opinion for Axitinib Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-07-26T12:00:00Z","last_updated_date":"2024-07-26T12:00:00Z","reference_number":"EMA/284159/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-axitinib-accord_en.pdf"},
    {"id":"64846","name":"CVMP summary of positive opinion for Cirbloc M Hyo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-09-13T13:00:00Z","last_updated_date":"2024-09-13T13:00:00Z","reference_number":"EMA/CVMP/413939/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-cirbloc-m-hyo_en.pdf"},
    {"id":"64847","name":"CVMP summary of positive opinion for ArthriCox","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-09-13T13:00:00Z","last_updated_date":"2024-09-13T13:00:00Z","reference_number":"EMA/CVMP/417587/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-arthricox_en.pdf"},
    {"id":"64895","name":"CHMP summary of positive opinion for Afqlir","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:36:06Z","last_updated_date":"2024-09-20T11:36:06Z","reference_number":"EMA/CHMP/379153/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-afqlir_en.pdf"},
    {"id":"64896","name":"CHMP summary of positive opinion for Opuviz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:43:20Z","last_updated_date":"2024-09-20T11:43:20Z","reference_number":"EMA/364707/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-opuviz_en.pdf"},
    {"id":"64907","name":"CHMP summary of positive opinion for Elahere","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:11:01Z","last_updated_date":"2024-09-20T11:11:01Z","reference_number":"EMA/CHMP/415249/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-elahere_en.pdf"},
    {"id":"64909","name":"CHMP summary of positive opinion for Theralugand","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:11:01Z","last_updated_date":"2024-09-20T11:11:01Z","reference_number":"EMA/CHMP/417097/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-theralugand_en.pdf"},
    {"id":"64930","name":"CHMP summary of opinion for Pomalidomide Teva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T10:56:26Z","last_updated_date":"2024-09-20T10:56:26Z","reference_number":"EMA/CHMP/377627/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-pomalidomide-teva_en.pdf"},
    {"id":"64964","name":"CHMP summary of positive opinion for Penbraya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T13:00:00Z","last_updated_date":"2025-02-05T12:45:00Z","reference_number":"EMA/424272/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-penbraya_en.pdf"},
    {"id":"64980","name":"CHMP summary of positive opinion for Hympavzi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T11:11:01Z","last_updated_date":"2024-09-20T11:11:01Z","reference_number":"EMA/423564/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hympavzi_en.pdf"},
    {"id":"64982","name":"CHMP summary of positive opinion for Hetronifly","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-09-20T13:40:00Z","last_updated_date":"2024-09-20T13:40:00Z","reference_number":"EMA/CHMP/424207/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hetronifly_en.pdf"},
    {"id":"65278","name":"CVMP summary of positive opinion for Duotic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-11T13:17:00Z","last_updated_date":"2024-10-11T13:17:00Z","reference_number":"EMA/CVMP/446917/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-duotic_en.pdf"},
    {"id":"65279","name":"CVMP summary of positive opinion for Bravecto TriUNO","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-11T12:00:00Z","last_updated_date":"2024-10-11T12:00:00Z","reference_number":"EMA/CVMP/443870/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bravecto-triuno_en.pdf"},
    {"id":"65280","name":"CVMP summary of positive opinion for Vaxxon ND Clone","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-11T12:00:00Z","last_updated_date":"2024-10-11T12:00:00Z","reference_number":"EMA/CVMP/446894/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-vaxxon-nd-clone_en.pdf"},
    {"id":"65308","name":"CHMP summary of positive opinion for Eltrombopag Viatris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T11:46:00Z","last_updated_date":"2024-10-18T11:46:00Z","reference_number":"EMA/CHMP/398947/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eltrombopag-viatris_en.pdf"},
    {"id":"65309","name":"CHMP summary of positive opinion for Wainzua","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/474509/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-wainzua_en.pdf"},
    {"id":"65310","name":"CHMP summary of positive opinion for Korjuny","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T11:47:00Z","last_updated_date":"2024-10-18T11:47:00Z","reference_number":"EMA/CHMP/444199/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-korjuny_en.pdf"},
    {"id":"65316","name":"CHMP summary of positive opinion for Buprenorphine Neuraxpharm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/112129/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-buprenorphine-neuraxpharm_en.pdf"},
    {"id":"65325","name":"CHMP summary of positive opinion for Absimky","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2025-12-18T12:06:00Z","reference_number":"EMA/CHMP/448121/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-absimky_en.pdf"},
    {"id":"65327","name":"CHMP summary of positive opinion for Imuldosa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/448102/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imuldosa_en.pdf"},
    {"id":"65336","name":"CHMP summary of positive opinion for Alhemo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-30T16:39:00Z","reference_number":"EMA/470073/2024 Corr.","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-alhemo_en.pdf"},
    {"id":"65339","name":"CHMP summary of positive opinion for Siiltibcy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/265104/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-siiltibcy_en.pdf"}    {"id":"65342","name":"CHMP summary of positive opinion for Flucelvax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"EMA/CHMP/452597/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-flucelvax_en.pdf"},
    {"id":"65347","name":"CHMP summary of positive opinion for Fluad","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-10-18T11:11:01Z","last_updated_date":"2024-10-18T11:11:01Z","reference_number":"EMA/CHMP/452577/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fluad_en.pdf"},
    {"id":"65577","name":"CVMP summary of positive opinion for Carprofen Orion","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-11-08T12:45:18Z","last_updated_date":"2024-11-08T12:45:18Z","reference_number":"EMA/CVMP/490426/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-carprofen-orion_en.pdf"},
    {"id":"65623","name":"CHMP summary of positive opinion for Gohibic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"Gohibic","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-gohibic_en.pdf"},
    {"id":"65625","name":"CHMP summary of positive opinion for Ahzantive","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/515216/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ahzantive_en.pdf"},
    {"id":"65632","name":"CHMP summary of positive opinion for Augtyro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/490671/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-augtyro_en.pdf"},
    {"id":"65643","name":"CHMP summary of positive opinion for Baiama","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T15:29:38Z","last_updated_date":"2024-11-15T15:29:38Z","reference_number":"EMA/CHMP/514475/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-baiama_en.pdf"},
    {"id":"65650","name":"CHMP summary of positive opinion for Lazcluze","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/515529/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lazcluze_en.pdf"},
    {"id":"65651","name":"CHMP summary of positive opinion for Leqembi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-11-14T16:44:43Z","last_updated_date":"2025-02-28T13:52:00Z","reference_number":"EMA/CHMP/530551/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-leqembi_en.pdf"},
    {"id":"65657","name":"CHMP summary of positive opinion for Obodence","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/515514/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-obodence_en.pdf"},
    {"id":"65658","name":"CHMP summary of positive opinion for Xbryk","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"EMA/CHMP/515564/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xbryk_en.pdf"},
    {"id":"65664","name":"Questions and answers on the refusal of the marketing authorisation for Cinainu (extracts from Allium cepa (onion) fresh bulb and Citrus limon (lemon) fresh fruit, Paullinia cupana (guarana) seed, and Theobroma cacao (cocoa) seed) ","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-27T13:22:00Z","reference_number":"EMA/529369/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-cinainu-extracts-allium-cepa-onion-fresh-bulb-citrus-limon-lemon-fresh-fruit-paullinia-cupana-guarana-seed-theobroma-cacao-cocoa-seed_en.pdf"},
    {"id":"66007","name":"CVMP summary of positive opinion for Icthiovac ERM","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-06T12:11:04Z","last_updated_date":"2024-12-06T12:11:04Z","reference_number":"EMA/CVMP/536281/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-icthiovac-erm_en.pdf"},
    {"id":"66008","name":"CVMP summary of positive opinion for Tolfenamic acid VMD","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-06T12:14:45Z","last_updated_date":"2024-12-06T12:14:45Z","reference_number":"EMA/CVMP/543175/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-tolfenamic-acid-vmd_en.pdf"},
    {"id":"66009","name":"CVMP summary of positive opinion for Poulvac Procerta HVT-IBD-ND","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-06T12:16:34Z","last_updated_date":"2024-12-06T12:16:34Z","reference_number":"EMA/CVMP/442900/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-poulvac-procerta-hvt-ibd-nd_en.pdf"},
    {"id":"66062","name":"CHMP summary of positive opinion for Eydenzelt","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/CHMP/561046/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eydenzelt_en.pdf"},
    {"id":"66073","name":"CHMP summary of positive opinion for Rytelo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/CHMP/561782/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rytelo_en.pdf"},
    {"id":"66084","name":"CHMP summary of positive opinion for Tuzulby","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/CHMP/574129/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tuzulby_en.pdf"},
    {"id":"66086","name":"CHMP summary of positive opinion for Yesintek ","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T13:33:02Z","last_updated_date":"2025-01-31T12:30:00Z","reference_number":"EMA/CHMP/530301/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yesintek_en.pdf"},
    {"id":"66087","name":"CHMP summary of positive opinion for Kostaive","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T13:35:51Z","last_updated_date":"2024-12-13T13:35:51Z","reference_number":"EMA/392588/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kostaive_en.pdf"},
    {"id":"66088","name":"CHMP summary of positive opinion for Kavigale","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T13:44:21Z","last_updated_date":"2024-12-13T13:44:21Z","reference_number":"EMA/CHMP/562567/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kavigale_en.pdf"},
    {"id":"66091","name":"CHMP summary of positive opinion for Nemluvio","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/CHMP/561246/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nemluvio_en.pdf"},
    {"id":"66095","name":"CHMP summary of positive opinion for Avtozma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T15:21:11Z","last_updated_date":"2024-12-13T15:21:11Z","reference_number":"EMA/CHMP/546116/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-avtozma_en.pdf"},
    {"id":"66097","name":"CHMP summary of positive opinion for Stoboclo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T17:07:37Z","last_updated_date":"2024-12-13T17:07:37Z","reference_number":"EMA/CHMP/568713/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-stoboclo_en.pdf"},
    {"id":"66098","name":"CHMP summary of positive opinion for Seladelpar Gilead","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T09:14:21Z","last_updated_date":"2024-12-13T16:47:14Z","reference_number":"EMA/CHMP/548691/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-seladelpar-gilead_en.pdf"},
    {"id":"66100","name":"CHMP summary of positive opinion for Osenvelt","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/CHMP/566643/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-osenvelt_en.pdf"},
    {"id":"66102","name":"CHMP summary of positive opinion for Paxneury","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/CHMP/575645/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-paxneury_en.pdf"},
    {"id":"66103","name":"CHMP summary of positive opinion for Zefylti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T09:56:26Z","last_updated_date":"2024-12-13T09:56:26Z","reference_number":"EMA/557861/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zefylti_en.pdf"},
    {"id":"66105","name":"CHMP summary of positive opinion for Emcitate","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T10:37:34Z","last_updated_date":"2025-03-11T11:22:00Z","reference_number":"EMA/49758/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-emcitate_en.pdf"},
    {"id":"66107","name":"CHMP summary of positive opinion for Welireg","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T10:56:24Z","last_updated_date":"2024-12-13T10:56:24Z","reference_number":"EMA/CHMP/563904/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-welireg_en.pdf"},
    {"id":"66108","name":"CHMP summary of positive opinion for Beyonttra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/CHMP/546392/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-beyonttra_en.pdf"},
    {"id":"66110","name":"CHMP summary of positive opinion for Andembry","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"EMA/CHMP/511066/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-andembry_en.pdf"},
    {"id":"66350","name":"CVMP summary of positive opinion for Bluevac-3","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-01-17T13:38:36Z","last_updated_date":"2025-01-17T13:38:36Z","reference_number":"EMA/CVMP/584037/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bluevac-3_en.pdf"},
    {"id":"66351","name":"CVMP summary of positive opinion for Syvazul BTV 3","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2025-01-17T13:45:11Z","last_updated_date":"2025-01-17T13:45:11Z","reference_number":"EMA/596315/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-syvazul-btv-3_en.pdf"},
    {"id":"66352","name":"CVMP summary of positive opinion for Nobilis Multriva REOm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-01-17T13:49:44Z","last_updated_date":"2025-01-17T13:49:44Z","reference_number":"EMA/CVMP/592483/2024 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobilis-multriva-reom_en.pdf"},
    {"id":"66510","name":"CHMP summary of positive opinion for Pavblu","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/15089/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pavblu_en.pdf"},
    {"id":"66511","name":"CHMP summary of positive opinion for Skojoy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-03-13T09:22:00Z","reference_number":"EMA/CHMP/15109/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-skojoy_en.pdf"},
    {"id":"66531","name":"CHMP summary of positive opinion for Eltrombopag Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/563278/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eltrombopag-accord_en.pdf"},
    {"id":"66534","name":"CHMP summary of positive opinion for Capvaxive","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/24781/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-capvaxive_en.pdf"},
    {"id":"66535","name":"CHMP summary of positive opinion for Datroway","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-02-07T11:25:00Z","reference_number":"EMA/CHMP/28954/2025 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-datroway_en.pdf"},
    {"id":"66540","name":"CHMP summary of positive opinion for Dyrupeg","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/24523/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dyrupeg_en.pdf"},
    {"id":"66546","name":"CHMP summary of positive opinion for Vimkunya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/552510/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vimkunya_en.pdf"},
    {"id":"66547","name":"CHMP summary of positive opinion for Tivdak","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/3463/202","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tivdak_en.pdf"},
    {"id":"66770","name":"CVMP summary of positive opinion for Elmaro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-02-14T15:00:00Z","last_updated_date":"2025-02-14T15:00:00Z","reference_number":"EMA/CVMP/43175/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-elmaro_en.pdf"},
    {"id":"66777","name":"CVMP summary of positive opinion for Omeprazole TriviumVet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-02-14T15:00:00Z","last_updated_date":"2025-02-14T15:00:00Z","reference_number":"EMA/27689/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-omeprazole-triviumvet_en.pdf"},
    {"id":"66778","name":"CVMP summary of positive opinion for Vectormune HVT-AIV","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-02-14T15:00:00Z","last_updated_date":"2025-02-14T15:00:00Z","reference_number":"EMA/CVMP/28067/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-vectormune-hvt-aiv_en.pdf"},
    {"id":"67021","name":"CHMP summary of positive opinion for Lynozyfic","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T15:02:12Z","last_updated_date":"2025-02-28T15:02:12Z","reference_number":"EMA/CHMP/48992/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lynozyfic_en.pdf"},
    {"id":"67022","name":"CHMP summary of positive opinion for Vyjuvek","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/CHMP/52904/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vyjuvek_en.pdf"},
    {"id":"67024","name":"CHMP summary of positive opinion for Deqsiga","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-02-28T12:00:00Z","reference_number":"EMA/2527/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-deqsiga_en.pdf"},
    {"id":"67036","name":"CHMP summary of positive opinion for Trabectedin Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-02-28T09:39:51Z","last_updated_date":"2025-02-28T09:39:51Z","reference_number":"EMA/CHMP/559896/2024","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-trabectedin-accord_en.pdf"},
    {"id":"67045","name":"Questions and answers on the refusal of the marketing authorisation for Kizfizo (temozolomide)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMA/77307/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kizfizo-temozolomide_sv.pdf"}},
    {"id":"67276","name":"CVMP summary of positive opinion for Hepizovac","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T12:00:00Z","last_updated_date":"2025-03-14T12:00:00Z","reference_number":"EMA/CVMP/82379/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-hepizovac_en.pdf"},
    {"id":"67277","name":"CVMP summary of positive opinion for Nobilis Multriva IBm+ND+EDS","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T12:00:00Z","last_updated_date":"2025-03-14T12:00:00Z","reference_number":"EMA/CVMP/74106/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobilis-multriva-ibmndeds_en.pdf"},
    {"id":"67279","name":"CVMP summary of positive opinion for Prevestrus vet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T11:45:38Z","last_updated_date":"2025-03-14T11:45:38Z","reference_number":"EMA/CVMP/67541/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-prevestrus-vet_en.pdf"},
    {"id":"67280","name":"CVMP summary of positive opinion for Prazivetin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-03-14T11:50:18Z","last_updated_date":"2025-03-14T11:50:18Z","reference_number":"EMA/CVMP/83482/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-prazivetin_en.pdf"},
    {"id":"67455","name":"CHMP summary of positive opinion for Xoanacyl","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"EMA/CHMP/82632/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xoanacyl_en.pdf"},
    {"id":"67487","name":"CHMP summary of positive opinion for Ryjunea","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T12:03:55Z","last_updated_date":"2025-04-03T10:38:20Z","reference_number":"EMA/CHMP/103734/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ryjunea_en.pdf"},
    {"id":"67503","name":"CHMP summary of positive opinion for Jubereq","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"EMA/75347/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jubereq_en.pdf"},
    {"id":"67504","name":"CHMP summary of positive opinion for Osvyrti","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"EMA/75348/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-osvyrti_en.pdf"},
    {"id":"67513","name":"CHMP summary of positive opinion for Qoyvolma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"EMA/89444/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-qoyvolma_en.pdf"},
    {"id":"67521","name":"Questions and answers on the refusal of the marketing authorisation for Kisunla (donanemab)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-03-28T10:22:36Z","last_updated_date":"2025-07-25T12:40:00Z","reference_number":"EMA/98483/2025 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kisunla-donanemab_en.pdf"},
    {"id":"67749","name":"CVMP summary of positive opinion for Nobilis Multriva Gm+REOm","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-11T15:00:00Z","last_updated_date":"2025-04-11T15:00:00Z","reference_number":"EMA/CVMP/113812/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobilis-multriva-gmreom_en.pdf"},
    {"id":"67751","name":"CVMP summary of positive opinion for Nobilis Multriva IBm+ND","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-11T15:00:00Z","last_updated_date":"2025-04-11T15:00:00Z","reference_number":"EMA/CVMP/98876/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobilis-multriva-ibmnd_en.pdf"},
    {"id":"67757","name":"CVMP summary of positive opinion for Emevet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-11T15:00:00Z","last_updated_date":"2025-04-11T15:00:00Z","reference_number":"EMA/CVMP/102998/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-emevet_en.pdf"},
    {"id":"67937","name":"CHMP summary of positive opinion for Duvyzat","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/90149/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duvyzat_en.pdf"},
    {"id":"67966","name":"CHMP summary of positive opinion for Enwylma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/132987/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-enwylma_en.pdf"},
    {"id":"67967","name":"CHMP summary of positive opinion for Vevzuo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/133517/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vevzuo_en.pdf"},
    {"id":"67968","name":"CHMP summary of positive opinion for Denosumab BBL","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/133533/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-denosumab-bbl_en.pdf"},
    {"id":"67971","name":"CHMP summary of positive opinion for Junod","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T10:55:27Z","last_updated_date":"2025-04-25T10:55:27Z","reference_number":"EMA/118084/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-junod_en.pdf"},
    {"id":"67973","name":"CHMP summary of positive opinion for Alyftrek","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/131190/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-alyftrek_en.pdf"},
    {"id":"67974","name":"CHMP summary of positive opinion for Denbrayce","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T11:28:25Z","last_updated_date":"2025-04-25T11:28:25Z","reference_number":"EMA/123568/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-denbrayce_en.pdf"},
    {"id":"67976","name":"CHMP summary of positive opinion for Ziihera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/124079/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ziihera_en.pdf"},
    {"id":"67977","name":"CHMP summary of positive opinion for Izamby","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T12:05:15Z","last_updated_date":"2025-04-25T12:05:15Z","reference_number":"EMA/123736/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-izamby_en.pdf"},
    {"id":"67979","name":"CHMP summary of positive opinion for Yaxwer","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T12:08:37Z","last_updated_date":"2025-04-25T12:08:37Z","reference_number":"EMA/122126/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yaxwer_en.pdf"},
    {"id":"67981","name":"CHMP summary of positive opinion for Zadenvi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:11:19Z","last_updated_date":"2025-04-25T16:11:19Z","reference_number":"EMA/127794/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zadenvi_en.pdf"},
    {"id":"67984","name":"CHMP summary of positive opinion for Attrogy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/134824/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-attrogy_en.pdf"},
    {"id":"67985","name":"CHMP summary of positive opinion for Oczyesa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T16:00:00Z","last_updated_date":"2025-04-25T16:00:00Z","reference_number":"EMA/CHMP/132414/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-oczyesa_en.pdf"},
    {"id":"67986","name":"CHMP summary of positive opinion for Sephience","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T13:26:35Z","last_updated_date":"2025-04-25T13:26:35Z","reference_number":"EMA/CHMP/132388/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sephience_en.pdf"},
    {"id":"67987","name":"CHMP summary of positive opinion for Tepezza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-25T13:30:33Z","last_updated_date":"2025-04-25T13:30:33Z","reference_number":"EMA/CHMP/126704/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tepezza_en.pdf"},
    {"id":"68003","name":"CHMP summary of positive opinion for Dazublys","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-28T09:53:12Z","last_updated_date":"2025-04-28T09:53:12Z","reference_number":"EMA/CHMP/126052/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dazublys_en.pdf"},
    {"id":"68030","name":"Questions and answers on the refusal of the marketing authorisation for Winlevi (clascoterone)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-04-30T10:00:00Z","last_updated_date":"2025-05-15T10:41:50Z","reference_number":"EMA/140610/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-winlevi-clascoterone_en.pdf"},
    {"id":"68328","name":"CVMP summary of positive opinion for Fluralaner Intervet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-16T14:52:16Z","last_updated_date":"2025-05-16T14:52:16Z","reference_number":"EMA/CVMP/149237/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-fluralaner-intervet_en.pdf"},
    {"id":"68330","name":"CVMP summary of positive opinion for Nobilis Multriva IBm+ND+Gm+REOm+EDS","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-16T14:52:43Z","last_updated_date":"2025-05-16T14:52:43Z","reference_number":"EMA/CVMP/116551/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobilis-multriva-ibmndgmreomeds_en.pdf"},
    {"id":"68331","name":"CVMP summary of positive opinion for Innovax-ND-IBD-ILT","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-16T14:58:17Z","last_updated_date":"2025-05-16T14:58:17Z","reference_number":"EMA/155368/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-innovax-nd-ibd-ilt_en.pdf"},
    {"id":"68382","name":"CHMP summary of positive opinion for Riulvy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-22T11:11:14Z","last_updated_date":"2025-05-22T11:11:14Z","reference_number":"EMA/CHMP/144927/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-riulvy_en.pdf"},
    {"id":"68384","name":"CHMP summary of positive opinion for Itovebi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/CHMP/134194/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-itovebi_en.pdf"},
    {"id":"68385","name":"CHMP summary of positive opinion for Aucatzyl","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/CHMP/165911/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aucatzyl_en.pdf"},
    {"id":"68386","name":"CHMP summary of positive opinion for Emtricitabine / Tenofovir alafenamide Viatris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/CHMP/161057/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-emtricitabine-tenofovir-alafenamide-viatris_en.pdf"},
    {"id":"68387","name":"CHMP summary of positive opinion for Blenrep","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/CHMP/152727/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-blenrep_en.pdf-0"},
    {"id":"68396","name":"CHMP summary of positive opinion for Rolcya","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/CHMP/174489/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rolcya_en.pdf"},
    {"id":"68400","name":"CHMP summary of positive opinion for Maapliv","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T10:17:58Z","last_updated_date":"2025-05-23T10:17:58Z","reference_number":"EMA/CHMP/164305/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-maapliv_en.pdf"},
    {"id":"68403","name":"CHMP summary of positive opinion for Bomyntra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/CHMP/161295/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bomyntra_en.pdf"},
    {"id":"68404","name":"CHMP summary of positive opinion for Conexxence","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T12:00:00Z","last_updated_date":"2025-05-23T12:00:00Z","reference_number":"EMA/CHMP/161299/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-conexxence_en.pdf"},
    {"id":"68412","name":"CHMP summary of positive opinion for Ezmekly","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-23T11:35:09Z","last_updated_date":"2025-05-23T11:35:09Z","reference_number":"EMA/CHMP/160270/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ezmekly_en.pdf"},
    {"id":"68425","name":"Questions and answers on the refusal of the marketing authorisation for Aplidin (plitidepsin)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T15:39:44Z","last_updated_date":"2025-05-23T15:39:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-aplidin-plitidepsin_en.pdf"},
    {"id":"68461","name":"Questions and answers on the refusal of the marketing authorisation for Kinselby (resminostat)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-05-27T09:00:00Z","last_updated_date":"2025-05-27T09:00:00Z","reference_number":"EMA/176131/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-kinselby-resminostat_en.pdf"},
    {"id":"68741","name":"CVMP summary of positive opinion for Biobhyo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T13:25:55Z","last_updated_date":"2025-06-13T13:25:55Z","reference_number":"EMA/CVMP/184015/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-biobhyo_en.pdf"},
    {"id":"68742","name":"CVMP summary of positive opinion for Numelvi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T13:26:51Z","last_updated_date":"2025-06-13T13:26:51Z","reference_number":"EMA/CVMP/179581/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-numelvi_en.pdf"},
    {"id":"68743","name":"CVMP summary of positive opinion for Zenrelia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T13:28:01Z","last_updated_date":"2025-06-13T13:28:01Z","reference_number":"EMA/CVMP/179106/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-zenrelia_en.pdf"},
    {"id":"68745","name":"CVMP post-authorisation summary of negative opinion for Poulvac E. coli (VRA0000243824)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T13:31:53Z","last_updated_date":"2025-06-13T13:31:53Z","reference_number":"EMADOC-1700519818-2191067","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-post-authorisation-summary-negative-opinion-poulvac-e-coli-vra0000243824_en.pdf"}    {"id":"68746","name":"CVMP summary of positive opinion for Bravecto CombiUNO","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-13T14:33:08Z","last_updated_date":"2025-06-13T14:33:08Z","reference_number":"EMA/CVMP/187220/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-bravecto-combiuno_en.pdf"},
    {"id":"68789","name":"CHMP summary of positive opinion for Nintedanib Viatris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T12:00:00Z","last_updated_date":"2025-06-20T12:00:00Z","reference_number":"EMA/CHMP/156564/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nintedanib-viatris_en.pdf"},
    {"id":"68790","name":"CHMP summary of positive opinion for Eiyzey","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T12:00:00Z","last_updated_date":"2025-06-20T12:00:00Z","reference_number":"EMA/CHMP/201926/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eiyzey_en.pdf"},
    {"id":"68792","name":"CHMP summary of positive opinion for Vgenfli","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T12:00:00Z","last_updated_date":"2025-06-20T12:00:00Z","reference_number":"EMA/CHMP/193205/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vgenfli_en.pdf"},
    {"id":"68809","name":"CHMP summary of positive opinion for Usymro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T12:00:00Z","last_updated_date":"2025-06-20T12:00:00Z","reference_number":"EMA/CHMP/138479/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-usymro_en.pdf"},
    {"id":"68822","name":"CHMP summary of positive opinion for Austedo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T12:00:00Z","last_updated_date":"2025-10-17T09:55:00Z","reference_number":"EMA/CHMP/170298/2025 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-austedo_en.pdf"},
    {"id":"68827","name":"CHMP summary of positive opinion for Zemcelpro","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T12:00:00Z","last_updated_date":"2025-06-20T12:00:00Z","reference_number":"EMA/CHMP/189609/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zemcelpro_en.pdf"},
    {"id":"68834","name":"CHMP summary of positive opinion for Mynzepli","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T12:00:00Z","last_updated_date":"2025-06-20T12:00:00Z","reference_number":"EMA/202775/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mynzepli_en.pdf"},
    {"id":"68835","name":"CHMP summary of positive opinion for Afiveg","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T13:40:14Z","last_updated_date":"2025-06-20T13:40:14Z","reference_number":"EMA/CHMP/201985/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-afiveg_en.pdf"},
    {"id":"68841","name":"CHMP summary of positive opinion for Rezdiffra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T14:52:54Z","last_updated_date":"2025-06-20T14:52:54Z","reference_number":"EMA/193903/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rezdiffra_en.pdf"},
    {"id":"68846","name":"CHMP summary of positive opinion for Ogsiveo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T12:00:00Z","last_updated_date":"2025-06-20T12:00:00Z","reference_number":"EMA/124078/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ogsiveo_en.pdf"},
    {"id":"68857","name":"CHMP summary of positive opinion for Imreplys","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T09:59:21Z","last_updated_date":"2025-06-20T09:59:21Z","reference_number":"EMA/CHMP/82619/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imreplys_en.pdf"},
    {"id":"68863","name":"CHMP summary of positive opinion for Vivlipeg","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T11:10:22Z","last_updated_date":"2025-06-20T11:10:22Z","reference_number":"EMA/CHMP/200894/2025 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vivlipeg_en.pdf"},
    {"id":"68864","name":"CHMP summary of positive opinion for Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-06-20T11:31:12Z","last_updated_date":"2025-06-20T11:31:12Z","reference_number":"EMA/CHMP/200894/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-emtricitabine-rilpivirine-tenofovir-alafenamide-viatris_en.pdf"},
    {"id":"69373","name":"CVMP summary of positive opinion for Cevac Reomune","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-18T12:19:50Z","last_updated_date":"2025-07-18T12:19:50Z","reference_number":"EMA/CVMP/31091/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-cevac-reomune_en.pdf"},
    {"id":"69374","name":"CVMP summary of positive opinion for Hemosyvet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-18T12:33:20Z","last_updated_date":"2025-07-18T12:33:20Z","reference_number":"EMA/CVMP/223195/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-hemosyvet_en.pdf"},
    {"id":"69421","name":"CHMP summary of positive opinion for Ekterly","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T14:33:37Z","last_updated_date":"2025-07-25T14:33:37Z","reference_number":"EMA/CHMP/172918/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ekterly_en.pdf"},
    {"id":"69425","name":"CHMP summary of positive opinion for Eyluxvi","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T18:05:48Z","last_updated_date":"2025-07-25T18:05:48Z","reference_number":"EMA/222568/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eyluxvi_en.pdf"},
    {"id":"69446","name":"CHMP summary of positive opinion for Usrenty","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T10:00:00Z","last_updated_date":"2025-07-25T10:00:00Z","reference_number":"EMA/CHMP/241636/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-usrenty_en.pdf"},
    {"id":"69451","name":"Questions and answers on the refusal of the marketing authorisation for Nurzigma (pridopidine)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T10:00:00Z","last_updated_date":"2025-08-12T15:59:36Z","reference_number":"EMA/232635/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-nurzigma-pridopidine_en.pdf"},
    {"id":"69457","name":"CHMP summary of positive opinion for Macitentan Accord","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T10:00:00Z","last_updated_date":"2025-07-25T10:00:00Z","reference_number":"EMA/CHMP/225526/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-macitentan-accord_en.pdf"},
    {"id":"69458","name":"CHMP summary of positive opinion for Macitentan AccordPharma","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T18:26:55Z","last_updated_date":"2025-07-25T18:26:55Z","reference_number":"EMA/CHMP/225527/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-macitentan-accordpharma_en.pdf"},
    {"id":"69470","name":"Questions and answers on the refusal of the marketing authorisation for Jelrix (cartilage-forming cells, autologous)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T09:12:28Z","last_updated_date":"2025-08-12T14:26:55Z","reference_number":"EMA/237508/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-jelrix-cartilage-forming-cells-autologous_en.pdf"},
    {"id":"69471","name":"CHMP summary of positive opinion for Zurzuvae","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T09:25:26Z","last_updated_date":"2025-07-25T09:25:26Z","reference_number":"EMADOC-628903358-125643","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zurzuvae_en.pdf"},
    {"id":"69472","name":"CHMP summary of positive opinion for Voranigo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T09:30:04Z","last_updated_date":"2025-07-25T09:30:04Z","reference_number":"EMA/CHMP/227935/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-voranigo_en.pdf"},
    {"id":"69475","name":"CHMP summary of positive opinion for Tryngolza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T09:35:38Z","last_updated_date":"2025-07-25T09:35:38Z","reference_number":"EMA/CHMP/225521/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tryngolza_en.pdf"},
    {"id":"69476","name":"CHMP summary of positive opinion for Romvimza","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T09:54:58Z","last_updated_date":"2025-07-25T09:54:58Z","reference_number":"EMA/214551/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-romvimza_en.pdf"},
    {"id":"69477","name":"CHMP summary of positive opinion for Aqneursa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T10:23:08Z","last_updated_date":"2025-11-14T12:35:57Z","reference_number":"EMA/114031/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aqneursa_en.pdf"},
    {"id":"69478","name":"CHMP summary of positive opinion for Bildyos","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T10:30:46Z","last_updated_date":"2025-07-25T10:30:46Z","reference_number":"EMA/CHMP/228095/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bildyos_en.pdf"},
    {"id":"69479","name":"CHMP summary of positive opinion for Bilprevda","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T10:32:57Z","last_updated_date":"2025-07-25T10:32:57Z","reference_number":"EMA/CHMP/228070/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bilprevda_en.pdf"},
    {"id":"69487","name":"CHMP summary of positive opinion for Kisunla","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T10:55:35Z","last_updated_date":"2025-07-25T10:55:35Z","reference_number":"EMADOC-628903358-125940","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kisunla_en.pdf"},
    {"id":"69491","name":"CHMP summary of positive opinion for Yeytuo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T11:25:24Z","last_updated_date":"2025-07-25T11:25:24Z","reference_number":"EMA/CHMP/243442/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-yeytuo_en.pdf"},
    {"id":"69857","name":"CHMP summary of positive opinion for Winlevi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-08-26T14:00:00Z","last_updated_date":"2025-08-26T14:00:00Z","reference_number":"EMA/CHMP/244647/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-winlevi_en.pdf"},
    {"id":"70074","name":"CVMP summary of positive opinion for Portela","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-12T13:46:35Z","last_updated_date":"2025-09-12T13:46:35Z","reference_number":"EMA/CVMP/285092/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-portela_en.pdf"},
    {"id":"70115","name":"CHMP summary of positive opinion for Kyinsu","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-17T11:26:19Z","last_updated_date":"2025-09-17T11:26:19Z","reference_number":"EMA/CHMP/297654/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kyinsu_en.pdf"},
    {"id":"70136","name":"CHMP summary of positive opinion for Enflonsia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T10:06:31Z","last_updated_date":"2025-09-19T10:06:31Z","reference_number":"EMA/CHMP/274513/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-enflonsia_en.pdf"},
    {"id":"70137","name":"CHMP summary of positive opinion for Imaavy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T10:20:35Z","last_updated_date":"2025-09-19T10:20:35Z","reference_number":"EMA/CHMP/292567/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imaavy_en.pdf"},
    {"id":"70150","name":"CHMP summary of positive opinion for Gobivaz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2025-09-19T12:00:00Z","reference_number":"EMA/CHMP/290609/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-gobivaz_en.pdf"},
    {"id":"70154","name":"CHMP summary of positive opinion for Zvogra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2025-09-19T12:00:00Z","reference_number":"EMA/274493/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zvogra_en.pdf"},
    {"id":"70156","name":"CHMP summary of positive opinion for Xbonzy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2025-09-19T12:00:00Z","reference_number":"EMA/273823/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xbonzy_en.pdf"},
    {"id":"70158","name":"CHMP summary of positive opinion for Lynkuet","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2025-09-19T12:00:00Z","reference_number":"EMA/CHMP/299126/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-lynkuet_en.pdf"},
    {"id":"70161","name":"CHMP summary of positive opinion for Usgena","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2025-09-19T12:00:00Z","reference_number":"EMA/292179/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-usgena_en.pdf"},
    {"id":"70162","name":"CHMP summary of positive opinion for Rivaroxaban Koanaa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2025-09-19T12:00:00Z","reference_number":"EMA/CHMP/297836/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rivaroxaban-koanaa_en.pdf"},
    {"id":"70167","name":"Questions and answers on the refusal of the marketing authorisation for Atropine sulfate FGK (atropine sulfate)","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T17:06:12Z","last_updated_date":"2025-11-28T09:45:00Z","reference_number":"EMEA/H/C/006385","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-atropine-sulfate-fgk-atropine-sulfate_sv.pdf"}},
    {"id":"70172","name":"CHMP summary of positive opinion for Denosumab Intas","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T12:00:00Z","last_updated_date":"2026-04-24T15:20:00Z","reference_number":"EMA/CHMP/297735/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/chmp-summary-positive-opinion-denosumab-intas_sv.pdf"}},
    {"id":"70176","name":"CHMP summary of positive opinion for Degevma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T08:39:35Z","last_updated_date":"2025-09-19T08:39:35Z","reference_number":"EMA/CHMP/273622/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-degevma_en.pdf"},
    {"id":"70179","name":"CHMP summary of positive opinion for Acvybra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T09:03:43Z","last_updated_date":"2025-09-19T09:03:43Z","reference_number":"EMA/CHMP/274464/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-acvybra_en.pdf"},
    {"id":"70180","name":"CHMP summary of positive opinion for Kefdensis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T09:05:46Z","last_updated_date":"2025-09-19T09:05:46Z","reference_number":"EMA/CHMP/273906/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kefdensis_en.pdf"},
    {"id":"70185","name":"CHMP summary of positive opinion for Ponlimsi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-09-19T10:28:49Z","last_updated_date":"2025-09-19T10:28:49Z","reference_number":"EMA/CHMP/273625/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ponlimsi_en.pdf"},
    {"id":"70524","name":"CVMP summary of positive opinion for Vaxxitek HVT+IBD+H5","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-10-10T14:00:00Z","last_updated_date":"2025-10-10T14:00:00Z","reference_number":"EMA/CVMP/307532/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-vaxxitek-hvtibdh5_en.pdf"},
    {"id":"70525","name":"CVMP summary of positive opinion for Lenivia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-10-10T14:00:00Z","last_updated_date":"2025-10-10T14:00:00Z","reference_number":"EMA/CVMP/308157/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-lenivia_en.pdf"},
    {"id":"70613","name":"CHMP summary of positive opinion for Brinsupri","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T12:00:00Z","last_updated_date":"2025-10-17T12:00:00Z","reference_number":"EMA/CHMP/310418/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-brinsupri_en.pdf"},
    {"id":"70617","name":"CHMP summary of positive opinion for Wayrilz","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T17:37:52Z","last_updated_date":"2025-10-17T17:37:52Z","reference_number":"EMA/CHMP/228349/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-wayrilz_en.pdf"},
    {"id":"70619","name":"Questions and answers on the refusal of the marketing authorisation for Rezurock (belumosudil)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-10-17T09:54:53Z","last_updated_date":"2025-11-14T15:29:16Z","reference_number":"EMA/335553/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-rezurock-belumosudil_en.pdf"},
    {"id":"71050","name":"CVMP summary of positive opinion for Vaxxinact H5","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-07T15:00:00Z","last_updated_date":"2025-11-07T15:00:00Z","reference_number":"EMA/CVMP/341546/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-vaxxinact-h5_en.pdf"},
    {"id":"71051","name":"CVMP summary of positive opinion for Ecovaxxin MS","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-07T15:00:00Z","last_updated_date":"2025-11-07T15:00:00Z","reference_number":"EMA/CVMP/347145/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-ecovaxxin-ms_en.pdf"},
    {"id":"71098","name":"CHMP summary of positive opinion for Ondibta","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMA/337755/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ondibta_en.pdf"},
    {"id":"71114","name":"CHMP summary of positive opinion for Dawnzera","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMA/CHMP/303939/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dawnzera_en.pdf"},
    {"id":"71116","name":"CHMP summary of positive opinion for Enzalutamide Accordpharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMA/245975/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-enzalutamide-accordpharma_en.pdf"},
    {"id":"71117","name":"CHMP summary of positive opinion for Inluriyo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMA/CHMP/354855/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-inluriyo_en.pdf"},
    {"id":"71134","name":"CHMP summary of positive opinion for Teduglutide Viatris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMA/358510/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-teduglutide-viatris_en.pdf"},
    {"id":"71150","name":"CHMP summary of positive opinion for Teizeild","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T15:43:19Z","last_updated_date":"2025-11-20T11:11:01Z","reference_number":"EMADOC-1829012207-34306","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-teizeild_en.pdf"},
    {"id":"71157","name":"CHMP summary of positive opinion for VacPertagen","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T17:15:43Z","last_updated_date":"2025-11-14T17:15:43Z","reference_number":"EMA/CHMP/354843/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vacpertagen_en.pdf"},
    {"id":"71159","name":"CHMP summary of positive opinion for Osqay","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2025-11-14T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMA/CHMP/355239/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-osqay_en.pdf"},
    {"id":"71172","name":"CHMP summary of positive opinion for GalenVita","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T12:00:00Z","last_updated_date":"2025-11-14T12:00:00Z","reference_number":"EMA/354268/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-galenvita_en.pdf"},
    {"id":"71175","name":"CHMP summary of positive opinion for Waskyra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-11-14T11:36:52Z","last_updated_date":"2025-11-14T11:36:52Z","reference_number":"EMA/343921/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-waskyra_en.pdf"},
    {"id":"71530","name":"CVMP summary of positive opinion for Epizootic haemorrhagic disease vaccine (recombinant protein) Laboratorios Syva S.A.","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T14:00:00Z","last_updated_date":"2025-12-05T14:00:00Z","reference_number":"EMA/CVMP/368551/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-epizootic-haemorrhagic-disease-vaccine-recombinant-protein-laboratorios-syva-sa_en.pdf"},
    {"id":"71531","name":"CVMP summary of positive opinion for Firocoxib CP-Pharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T14:00:00Z","last_updated_date":"2025-12-05T14:00:00Z","reference_number":"EMA/CVMP/367445/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-firocoxib-cp-pharma_en.pdf"},
    {"id":"71532","name":"CVMP summary of positive opinion for Varenzin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-05T14:00:00Z","last_updated_date":"2025-12-05T14:00:00Z","reference_number":"EMA/CVMP/367341/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-varenzin_en.pdf"},
    {"id":"71699","name":"CHMP summary of positive opinion for Myqorzo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T16:15:02Z","last_updated_date":"2025-12-12T16:15:02Z","reference_number":"EMA/376438/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-myqorzo_en.pdf"},
    {"id":"71708","name":"CHMP summary of positive opinion for Ranluspec","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMADOC-1829012207-37184","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ranluspec_en.pdf"},
    {"id":"71711","name":"CHMP summary of positive opinion for mNexspike","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMA/CHMP/381880/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mnexspike_en.pdf"},
    {"id":"71712","name":"CHMP summary of positive opinion for Gotenfia","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMADOC-1829012207-36858","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-gotenfia_en.pdf"},
    {"id":"71714","name":"CHMP summary of positive opinion for Anktiva","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMADOC-1829012207-35903","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-anktiva_en.pdf"},
    {"id":"71719","name":"CHMP summary of positive opinion for Exdensur","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMADOC-1829012207-35814","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-exdensur_en.pdf"},
    {"id":"71722","name":"CHMP summary of positive opinion for Aumseqa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-12T14:00:00Z","reference_number":"EMA/CHMP/369595/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aumseqa_en.pdf"},
    {"id":"71733","name":"Questions and answers on the refusal of the marketing authorisation for Blarcamesine Anavex","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T14:00:00Z","last_updated_date":"2025-12-18T13:25:00Z","reference_number":"EMA/385732/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-blarcamesine-anavex_en.pdf"},
    {"id":"72109","name":"CVMP summary of positive opinion for Lotilaner / Milbemycin Elanco","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-01-16T13:33:50Z","last_updated_date":"2026-01-16T13:33:50Z","reference_number":"EMA/CVMP/1734/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-lotilaner-milbemycin-elanco_en.pdf"},
    {"id":"72329","name":"CHMP summary of positive opinion for Ilumira","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T12:00:00Z","last_updated_date":"2026-01-30T12:00:00Z","reference_number":"EMADOC-1829012207-40538","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ilumira_en.pdf"},
    {"id":"72362","name":"CHMP summary of positive opinion for Supemtek","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T12:00:00Z","last_updated_date":"2026-01-30T12:00:00Z","reference_number":"EMADOC-1829012207-40387","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-supemtek_en.pdf-0"},
    {"id":"72367","name":"CHMP summary of positive opinion for Fylrevy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T10:24:58Z","last_updated_date":"2026-01-30T10:24:58Z","reference_number":"EMA/CHMP/24373/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fylrevy_en.pdf"},
    {"id":"72372","name":"CHMP summary of positive opinion for Kygevvi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T10:43:40Z","last_updated_date":"2026-01-30T10:43:40Z","reference_number":"EMA/CHMP/384297/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kygevvi_en.pdf"},
    {"id":"72376","name":"CHMP summary of positive opinion for Kayshild","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T12:00:00Z","last_updated_date":"2026-01-30T12:00:00Z","reference_number":"EMA/CHMP/17332/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kayshild_en.pdf"},
    {"id":"72551","name":"CVMP summary of positive opinion for Emepax","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2026-02-13T12:16:42Z","last_updated_date":"2026-02-13T12:16:42Z","reference_number":"EMA/CVMP/25902/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-emepax_en.pdf"},
    {"id":"72702","name":"CHMP summary of positive opinion for Onerji","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T15:08:04Z","last_updated_date":"2026-02-27T15:08:04Z","reference_number":"EMA/CHMP/370118/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-onerji_en.pdf"},
    {"id":"72704","name":"CHMP summary of positive opinion for Tuyory","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T15:25:55Z","last_updated_date":"2026-02-27T15:25:55Z","reference_number":"EMADOC-1829012207-42079","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-tuyory_en.pdf"},
    {"id":"72708","name":"CHMP summary of positive opinion for Rhapsido","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T17:10:46Z","last_updated_date":"2026-02-27T17:10:46Z","reference_number":"EMADOC-1829012207-42073","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-rhapsido_en.pdf"},
    {"id":"72713","name":"CHMP summary of positive opinion for Xolremdi","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-26T10:23:18Z","last_updated_date":"2026-02-26T10:23:18Z","reference_number":"EMADOC-1829012207-42285","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-xolremdi_en.pdf"},
    {"id":"72714","name":"CHMP summary of positive opinion for Fubelv","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T12:00:00Z","last_updated_date":"2026-02-27T12:00:00Z","reference_number":"EMADOC-1829012207-42793","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fubelv_en.pdf"},
    {"id":"72720","name":"CHMP summary of positive opinion for mCombriax","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T14:00:24Z","last_updated_date":"2026-02-27T14:00:24Z","reference_number":"EMADOC-1829012207-43023","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-mcombriax_en.pdf"},
    {"id":"72722","name":"CHMP summary of positive opinion for Poherdy","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T14:33:27Z","last_updated_date":"2026-02-27T14:33:27Z","reference_number":"EMA/CHMP/371627/2025","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-poherdy_en.pdf"},
    {"id":"72728","name":"Questions and answers on the refusal of the marketing authorisation for Iloperidone Vanda Pharmaceuticals (iloperidone)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T12:00:00Z","last_updated_date":"2026-05-20T16:25:00Z","reference_number":"EMA/41634/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_bg.pdf","es":"https://www.ema.europa.eu/es/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_cs.pdf","da":"https://www.ema.europa.eu/da/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_da.pdf","de":"https://www.ema.europa.eu/de/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_de.pdf","et":"https://www.ema.europa.eu/et/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_et.pdf","el":"https://www.ema.europa.eu/el/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_hr.pdf","it":"https://www.ema.europa.eu/it/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/smop-initial/questions-answers-refusal-marketing-authorisation-iloperidone-vanda-pharmaceuticals-iloperidone_sv.pdf"}},
    {"id":"72729","name":"CHMP summary of positive opinion for Palsonify","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T12:00:00Z","last_updated_date":"2026-02-27T12:00:00Z","reference_number":"EMA/22216/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-palsonify_en.pdf"},
    {"id":"72730","name":"CHMP summary of positive opinion for Dazparda","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T12:00:00Z","last_updated_date":"2026-02-27T12:00:00Z","reference_number":"EMA/CHMP/37389/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-dazparda_en.pdf"},
    {"id":"72731","name":"CHMP summary of positive opinion for Bysumlog","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T12:00:00Z","last_updated_date":"2026-02-27T12:00:00Z","reference_number":"EMA/CHMP/38012/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bysumlog_en.pdf"},
    {"id":"72736","name":"CHMP summary of positive opinion for Zandoriah","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T10:42:37Z","last_updated_date":"2026-02-27T10:42:37Z","reference_number":"EMA/CHMP/48966/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zandoriah_en.pdf"},
    {"id":"72739","name":"CHMP summary of positive opinion for Ojemda","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T12:00:00Z","last_updated_date":"2026-02-27T12:00:00Z","reference_number":"EMA/CHMP/43372/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ojemda_en.pdf"},
    {"id":"73004","name":"CVMP summary of positive opinion for AviGate S. Infantis","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-03-13T14:15:00Z","last_updated_date":"2026-03-13T14:15:00Z","reference_number":"EMA/CVMP/37522/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-avigate-s-infantis_en.pdf"},
    {"id":"73006","name":"CVMP summary of positive opinion for VeroBlue-3","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-03-13T14:15:00Z","last_updated_date":"2026-03-13T14:15:00Z","reference_number":"EMA/CVMP/4011/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-veroblue-3_en.pdf"},
    {"id":"73213","name":"CHMP summary of positive opinion for Joenja","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMA/CHMP/28350/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-joenja_en.pdf"}    {"id":"73214","name":"CHMP summary of positive opinion for Bopediat","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMA/CHMP/73735/2026 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-bopediat_en.pdf"},
    {"id":"73215","name":"CHMP summary of positive opinion for Zepzelca","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMA/56282/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zepzelca_en.pdf"},
    {"id":"73218","name":"CHMP summary of positive opinion for Imdylltra","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMA/CHMP/62536/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imdylltra_en.pdf"},
    {"id":"73221","name":"CHMP summary of positive opinion for Adstiladrin","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-03-27T12:00:00Z","last_updated_date":"2026-03-27T12:00:00Z","reference_number":"EMA/CHMP/66758/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-adstiladrin_en.pdf"},
    {"id":"73487","name":"CVMP summary of positive opinion for Nobivac NXT HCPChFeLV","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-04-17T15:00:00Z","last_updated_date":"2026-06-19T15:30:00Z","reference_number":"EMA/CVMP/75635/2026 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-nxt-hcpchfelv_en.pdf"},
    {"id":"73510","name":"CHMP summary of positive opinion for Itvisma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T17:07:32Z","last_updated_date":"2026-04-24T17:07:32Z","reference_number":"EMADOC-1829012207-48071","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-itvisma_en.pdf"},
    {"id":"73511","name":"CHMP summary of positive for Rexatilux","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-04-24T12:00:00Z","reference_number":"EMA/CHMP/91490/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-rexatilux_en.pdf"},
    {"id":"73512","name":"CHMP summary of positive opinion for Palbociclib Viatris","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T08:52:37Z","last_updated_date":"2026-04-24T08:52:37Z","reference_number":"EMA/84334/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-palbociclib-viatris_en.pdf"},
    {"id":"73539","name":"CHMP summary of positive opinion for Cenrifki","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T13:19:46Z","last_updated_date":"2026-04-24T13:19:46Z","reference_number":"EMADOC-1829012207-47809","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-cenrifki_en.pdf"},
    {"id":"73562","name":"CHMP summary of positive opinion for Redemplo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-04-24T10:43:50Z","last_updated_date":"2026-04-24T10:43:50Z","reference_number":"EMA/CHMP/94677/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-redemplo_en.pdf"},
    {"id":"73768","name":"CHMP summary of positive opinion for Jascayd","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T12:00:00Z","last_updated_date":"2026-05-22T12:00:00Z","reference_number":"EMADOC-1829012207-48872","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jascayd_en.pdf"},
    {"id":"73793","name":"CHMP summary of positive opinion for Boey","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:00:00Z","last_updated_date":"2026-05-22T12:00:00Z","reference_number":"EMADOC-1829012207-51979","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-boey_en.pdf"},
    {"id":"73796","name":"CHMP summary of positive opinion for Colchicine Agepha Pharma","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:00:00Z","last_updated_date":"2026-05-22T12:00:00Z","reference_number":"EMA/CHMP/97816/202","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-colchicine-agepha-pharma_en.pdf"},
    {"id":"73798","name":"CHMP summary of positive opinion for Etcamah","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T14:51:47Z","last_updated_date":"2026-05-22T14:51:47Z","reference_number":"EMA/114517/2026 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-etcamah_en.pdf"},
    {"id":"73799","name":"Questions and answers on the refusal of the marketing authorisation for Deqtynet (copper (64Cu) oxodotreotide)","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T14:51:50Z","last_updated_date":"2026-05-22T14:51:50Z","reference_number":"EMEA/H/C/006608","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-deqtynet-copper-64cu-oxodotreotide_en.pdf"},
    {"id":"73809","name":"CHMP summary of positive opinion for Vislyfa","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T15:44:56Z","last_updated_date":"2026-05-22T15:44:56Z","reference_number":"EMADOC-1829012207-52030","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vislyfa_en.pdf"},
    {"id":"73815","name":"CHMP summary of positive opinion for Vijoice","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T08:51:05Z","last_updated_date":"2026-05-22T08:51:05Z","reference_number":"EMADOC-1829012207-50265","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vijoice_en.pdf"},
    {"id":"73831","name":"CHMP summary of positive opinion for Ablymico","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:13:48Z","last_updated_date":"2026-05-22T12:13:48Z","reference_number":"EMADOC-1829012207-51236 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-ablymico_en.pdf"},
    {"id":"73832","name":"CHMP summary of positive opinion for Liraglutide Stada","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T12:14:54Z","last_updated_date":"2026-05-22T12:14:54Z","reference_number":"EMADOC-1829012207-51237","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-liraglutide-stada_en.pdf"},
    {"id":"73838","name":"CVMP summary of positive opinion for Nobivac NXT HC","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T13:34:02Z","last_updated_date":"2026-05-22T13:34:02Z","reference_number":"EMA/CVMP/104787/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-nxt-hc_en.pdf"},
    {"id":"73839","name":"CVMP summary of positive opinion for Nobivac NXT HCP","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T13:58:43Z","last_updated_date":"2026-05-22T13:58:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-nxt-hcp_en.pdf"},
    {"id":"73840","name":"CVMP summary of positive opinion for Nobivac NXT HCPCh","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-05-22T14:10:05Z","last_updated_date":"2026-05-22T14:10:05Z","reference_number":"EMA/CVMP/106114/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-nxt-hcpch_en.pdf"},
    {"id":"73841","name":"CVMP summary of positive opinion for Poulvac Procerta HVT-ND","type":"smop-initial","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T15:00:00Z","last_updated_date":"2026-05-22T15:00:00Z","reference_number":"EMA/CVMP/107543/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-poulvac-procerta-hvt-nd_en.pdf"},
    {"id":"74162","name":"CVMP summary of positive opinion for Nobivac NXT FeLV","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-19T13:25:40Z","last_updated_date":"2026-06-19T13:25:40Z","reference_number":"EMA/CVMP/107685/2026 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-nxt-felv_en.pdf"},
    {"id":"74163","name":"CVMP summary of positive opinion for Nobivac NXT HCPFeLV","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-19T14:13:54Z","last_updated_date":"2026-06-19T14:13:54Z","reference_number":"EMA/CVMP/105182/2026 ","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-nobivac-nxt-hcpfelv_en.pdf"},
    {"id":"74290","name":"CHMP summary of positive opinion for Hopledo","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T15:11:39Z","last_updated_date":"2026-06-26T15:11:39Z","reference_number":"EMADOC-1829012207-54127","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hopledo_en.pdf"},
    {"id":"74291","name":"Questions and answers on the refusal of the marketing authorisation for Yartemlea","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMA/143535/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-yartemlea_en.pdf"},
    {"id":"74309","name":"Questions and answers on the refusal of the marketing authorisation for Xervyteg","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T16:45:50Z","last_updated_date":"2026-06-26T16:45:50Z","reference_number":"EMA/143268/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-xervyteg_en.pdf"},
    {"id":"74311","name":"CHMP summary of positive opinion for Nylaspeg","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1829012207-56685","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-nylaspeg_en.pdf"},
    {"id":"74312","name":"Questions and answer on the refusal of the marketing authorisation for Tacquell","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T16:53:55Z","last_updated_date":"2026-06-26T16:53:55Z","reference_number":"EMA/127401/2026","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/questions-answer-refusal-marketing-authorisation-tacquell_en.pdf"},
    {"id":"74315","name":"CHMP summary of positive opinion for Denosumab Ascend","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1829012207-56670","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-denosumab-ascend_en.pdf"},
    {"id":"74321","name":"CHMP summary of positive opinion for Daybu","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1829012207-57009","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-daybu_en.pdf"},
    {"id":"74324","name":"CHMP summary of positive opinion for Onswik","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1829012207-54438","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-onswik_en.pdf"},
    {"id":"74325","name":"CHMP summary of positive opinion for Aujemflu","type":"smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-06-26T12:00:00Z","last_updated_date":"2026-06-26T12:00:00Z","reference_number":"EMADOC-1829012207-56091","document_url":"https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-aujemflu_en.pdf"},
    {"id":"4","name":"Template for submission of comments on scientific guidelines","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T12:28:55Z","last_updated_date":"2023-01-27T12:28:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/form-submission-comments-scientific-guidelines_en.doc"},
    {"id":"2546","name":"Informed consent application in accordance with Article 10c of Directive 2001/83/EC - Rev. 05. 21","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-05-05T02:00:00Z","last_updated_date":"2021-06-25T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/informed-consent-application-accordance-article-10c-directive-200183ec-rev-05-21_en.docx"},
    {"id":"2604","name":"Application form for the involvement of industry stakeholder organisations in the activities of the European Medicines Agency (EMA)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-09-12T16:40:00Z","last_updated_date":"2019-03-05T09:30:00Z","reference_number":"EMA/379033/2016","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-involvement-industry-stakeholder-organisations-activities-european-medicines-agency-ema_en.pdf"},
    {"id":"2756","name":"Transfer of MA templates Attachment 6.4 (Superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-06-28T10:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-ma-templates-attachment-64-superseded_en.doc"},
    {"id":"3027","name":"European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) population correction unit template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-10-15T16:35:00Z","last_updated_date":"2013-10-15T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/european-surveillance-veterinary-antimicrobial-consumption-esvac-population-correction-unit-template_en.xls"},
    {"id":"3097","name":"Transfer of MA templates Attachment 6.2 (Superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-06-28T10:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-ma-templates-attachment-62-superseded_en.doc"},
    {"id":"3329","name":"QRD annex IV conditional positive template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-10-08T13:00:00Z","last_updated_date":"2019-06-28T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-annex-iv-conditional-positive-template_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-annex-iv-conditional-positive-template_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-annex-iv-conditional-positive-template_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-annex-iv-conditional-positive-template_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-annex-iv-conditional-positive-template_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-annex-iv-conditional-positive-template_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-annex-iv-conditional-positive-template_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-annex-iv-conditional-positive-template_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-annex-iv-conditional-positive-template_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-annex-iv-conditional-positive-template_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-annex-iv-conditional-positive-template_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-annex-iv-conditional-positive-template_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-annex-iv-conditional-positive-template_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-annex-iv-conditional-positive-template_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-annex-iv-conditional-positive-template_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-annex-iv-conditional-positive-template_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-annex-iv-conditional-positive-template_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-annex-iv-conditional-positive-template_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-annex-iv-conditional-positive-template_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-annex-iv-conditional-positive-template_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-annex-iv-conditional-positive-template_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-annex-iv-conditional-positive-template_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-annex-iv-conditional-positive-template_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-annex-iv-conditional-positive-template_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-annex-iv-conditional-positive-template_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-annex-iv-conditional-positive-template_no.docx"}},
    {"id":"3421","name":"Draft guideline on good pharmacovigilance practices (GVP): Annex II – Templates: Direct Healthcare Professional Communication (DHPC) (Rev. 1)","type":"template-form","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-02-29","first_published_date":"2015-12-15T13:30:00Z","last_updated_date":"2015-12-15T13:30:00Z","reference_number":"EMA/36988/2013 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/template-form/draft-guideline-good-pharmacovigilance-practices-gvp-annex-ii-templates-direct-healthcare-professional-communication-dhpc-rev-1_en.pdf"},
    {"id":"3512","name":"Administrative information Application form for a Scientific Opinion according to Article 58 of Regulation (EC) 726/2004","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2009-04-01T02:00:00Z","last_updated_date":"2017-09-04T02:00:00Z","reference_number":"EMEA/210134/2008","document_url":"https://www.ema.europa.eu/en/documents/template-form/administrative-information-application-form-scientific-opinion-according-article-58-regulation-ec-7262004_en.doc"},
    {"id":"3663","name":"Day 120 draft list of questions template (Word) - September 2009","type":"template-form","status":"Draft","consultation_date":"","first_published_date":"2009-09-01T02:09:21Z","last_updated_date":"2009-09-01T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-120-draft-list-questions-template-word-september-2009_en.doc"},
    {"id":"3765","name":"Template letter for applicant - waiving right for a re-examination request","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:21Z","last_updated_date":"2013-08-07T16:22:00Z","reference_number":"n/a","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-letter-applicant-waiving-right-re-examination-request_en.doc"},
    {"id":"3884","name":"Architect/Building engineer - Exclusion criteria declaration form - EMA/CEI/2018-2","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-09-10T12:30:00Z","last_updated_date":"2018-09-10T12:30:00Z","reference_number":"EMA/CEI/2018-2","document_url":"https://www.ema.europa.eu/en/documents/template-form/architectbuilding-engineer-exclusion-criteria-declaration-form-emacei2018-2_en.docx"},
    {"id":"3939","name":"Questionnaire for the PDCO members on involvement of children, adolescents, their parents, carers or legal representatives and members representing patients' organisations in the activities of the PDCO","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-05-11T16:00:00Z","last_updated_date":"2015-05-11T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/questionnaire-pdco-members-involvement-children-adolescents-their-parents-carers-or-legal-representatives-and-members-representing-patients-organisations-activities-pdco_en.pdf"},
    {"id":"3941","name":"Application form for European Medicines Agency certificates of medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:00:00Z","last_updated_date":"2024-06-05T09:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-european-medicines-agency-certificates-medicinal-products_en.pdf"},
    {"id":"4022","name":"Examples on how to fill in the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) data collection form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-04-20T02:00:00Z","last_updated_date":"2012-03-29T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/examples-how-fill-european-surveillance-veterinary-antimicrobial-consumption-esvac-data-collection-form_en.xls"},
    {"id":"4451","name":"EudraVigilance Form B","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2023-01-20T09:15:00Z","reference_number":"EMA/99667/2016","document_url":"https://www.ema.europa.eu/en/documents/template-form/eudravigilance-form-b_en.docx"},
    {"id":"4553","name":"Registration form: First anniversary of PRIME: experience so far","type":"template-form","status":"Draft","consultation_date":"","first_published_date":"2017-03-22T15:00:00Z","last_updated_date":"2017-03-22T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-first-anniversary-prime-experience-so-far_en.pdf"},
    {"id":"4843","name":"Mutual-recognition, decentralised and referral product-information template version 4.2","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-08-30T02:00:00Z","last_updated_date":"2024-02-29T16:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-version-42_no.docx"}},
    {"id":"4973","name":"Transfer of MA templates Attachment 6.1.1 (No longer valid)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-06-28T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-ma-templates-attachment-611-no-longer-valid_en.doc"},
    {"id":"5007","name":"Registration form for Workshop: In vitro Cytokine release assays; To predict Cytokine release syndrome: The current state-of-the-science","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-07-24T02:09:21Z","last_updated_date":"2009-07-24T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-workshop-vitro-cytokine-release-assays-predict-cytokine-release-syndrome-current-state-science_en.pdf"},
    {"id":"5013","name":"Registration form - Workshop on site and histology - Independent indications in oncology","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-11-20T19:30:00Z","last_updated_date":"2017-11-20T19:30:00Z","reference_number":"EMA/743635/2017","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-workshop-site-and-histology-independent-indications-oncology_en.pdf"},
    {"id":"5170","name":"Annex 1 - Active substance master file (ASMF) assessment report template - Applicant's part rev. 07.18","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-07-03T13:00:00Z","last_updated_date":"2018-07-26T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-1-active-substance-master-file-asmf-assessment-report-template-applicants-part-rev-0718_en.docx"},
    {"id":"5433","name":"Submission of comments on good pharmacovigilance practices: Annex I – Definitions (EMA/876333/2011)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T13:20:00Z","last_updated_date":"2012-02-22T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-annex-i-definitions-ema8763332011_en.doc"},
    {"id":"5551","name":"Template for letter from marketing-authorisation holder (MAH) permitting the Agency to send certificates elsewhere than to MAH address","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2009-09-01T02:00:00Z","last_updated_date":"2024-09-25T14:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-letter-marketing-authorisation-holder-mah-permitting-agency-send-certificates-elsewhere-mah-address_en.doc"},
    {"id":"5564","name":"PRAC advice template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:00:00Z","last_updated_date":"2024-12-13T14:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/prac-advice-template_en.doc"},
    {"id":"5713","name":"Annex 1 - Active substance master file (ASMF) assessment report template - Restricted part rev. 06.17","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-07-03T16:30:04Z","last_updated_date":"2017-07-03T16:30:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-1-active-substance-master-file-asmf-assessment-report-template-restricted-part-rev-0617_en.docx"},
    {"id":"5817","name":"EnprEMA self-assessment form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-03-21T17:45:00Z","last_updated_date":"2014-03-21T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/enprema-self-assessment-form_en.pdf"},
    {"id":"5995","name":"Transfer of marketing authorisation template - attachment 3","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2026-03-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-marketing-authorisation-template-attachment-3_en.docx"},
    {"id":"6252","name":"PSUSA nationally authorised products template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-09-15T16:23:00Z","last_updated_date":"2024-01-24T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/psusa-nationally-authorised-products-template_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/psusa-nationally-authorised-products-template_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/psusa-nationally-authorised-products-template_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/psusa-nationally-authorised-products-template_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/psusa-nationally-authorised-products-template_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/psusa-nationally-authorised-products-template_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/psusa-nationally-authorised-products-template_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/psusa-nationally-authorised-products-template_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/psusa-nationally-authorised-products-template_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/psusa-nationally-authorised-products-template_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/psusa-nationally-authorised-products-template_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/psusa-nationally-authorised-products-template_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/psusa-nationally-authorised-products-template_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/psusa-nationally-authorised-products-template_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/psusa-nationally-authorised-products-template_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/psusa-nationally-authorised-products-template_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/psusa-nationally-authorised-products-template_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/psusa-nationally-authorised-products-template_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/psusa-nationally-authorised-products-template_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/psusa-nationally-authorised-products-template_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/psusa-nationally-authorised-products-template_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/psusa-nationally-authorised-products-template_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/psusa-nationally-authorised-products-template_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/psusa-nationally-authorised-products-template_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/psusa-nationally-authorised-products-template_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/psusa-nationally-authorised-products-template_no.docx"}},
    {"id":"6324","name":"Connecting to the Agency ESTRI Gateway using an AS2 compatible product","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-06-26T14:00:00Z","last_updated_date":"2024-03-07T17:00:00Z","reference_number":"EMA/385007/2017","document_url":"https://www.ema.europa.eu/en/documents/template-form/connecting-agency-estri-gateway-using-as2-compatible-product_en.docx"},
    {"id":"6339","name":"European Veterinary Pharmacovigilance reporting form for MAHs","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T01:00:00Z","last_updated_date":"2008-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/european-veterinary-pharmacovigilance-reporting-form-mahs_en.doc"},
    {"id":"6341","name":"QRD annex A template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:00:00Z","last_updated_date":"2019-06-28T10:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-annex-template_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-annex-template_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-annex-template_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-annex-template_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-annex-template_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-annex-template_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-annex-template_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-annex-template_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-annex-template_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-annex-template_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-annex-template_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-annex-template_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-annex-template_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-annex-template_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-annex-template_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-annex-template_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-annex-template_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-annex-template_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-annex-template_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-annex-template_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-annex-template_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-annex-template_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-annex-template_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-annex-template_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-annex-template_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-annex-template_no.docx"}},
    {"id":"6444","name":"Submission of comments on the EMEA Transparency Policy draft for Public Consultation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-17T02:09:21Z","last_updated_date":"2009-06-17T02:09:21Z","reference_number":"EMEA/380503/2009","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-emea-transparency-policy-draft-public-consultation_en.doc"},
    {"id":"6496","name":"Request for confirmation of the applicability of the Agency’s decision on class waivers","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-03-03T01:09:21Z","last_updated_date":"2010-03-03T01:09:21Z","reference_number":"EMA/72240/2008","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-confirmation-applicability-agencys-decision-class-waivers_en.pdf"},
    {"id":"7068","name":"Non-imposed post-authorisation safety study (PASS) final results assessment report sub-template for type II variations","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:00:00Z","last_updated_date":"2018-09-18T17:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/non-imposed-post-authorisation-safety-study-pass-final-results-assessment-report-sub-template-type-ii-variations_en.docx"},
    {"id":"7619","name":"Ancillary - CHMP Day 120 LoQ rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:15:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-chmp-day-120-loq-rev1016_en.doc"},
    {"id":"7950","name":"QRD veterinary annex A template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:00:00Z","last_updated_date":"2019-06-28T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-veterinary-annex-template_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-veterinary-annex-template_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-veterinary-annex-template_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-veterinary-annex-template_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-veterinary-annex-template_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-veterinary-annex-template_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-veterinary-annex-template_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-veterinary-annex-template_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-veterinary-annex-template_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-veterinary-annex-template_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-veterinary-annex-template_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-veterinary-annex-template_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-veterinary-annex-template_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-veterinary-annex-template_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-veterinary-annex-template_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-veterinary-annex-template_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-veterinary-annex-template_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-veterinary-annex-template_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-veterinary-annex-template_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-veterinary-annex-template_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-veterinary-annex-template_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-veterinary-annex-template_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-veterinary-annex-template_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-veterinary-annex-template_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-veterinary-annex-template_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-veterinary-annex-template_no.docx"}},
    {"id":"8015","name":"Annex C Response Questionnaire","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-11-12T01:00:00Z","last_updated_date":"2009-11-12T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-c-response-questionnaire_en.xls"},
    {"id":"8104","name":"Annex H: Standard expenses form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-07-01T02:00:00Z","last_updated_date":"2008-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-h-standard-expenses-form_en.pdf"},
    {"id":"8378","name":"Ancillary - Day 150 JAR Non-clinical and clinical template rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:18:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-day-150-jar-non-clinical-and-clinical-template-rev1016_en.doc"},
    {"id":"8686","name":"Annual re-assessment assessment report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:00:00Z","last_updated_date":"2017-08-04T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annual-re-assessment-assessment-report-template_en.docx"},
    {"id":"8936","name":"Application form: Call for expressions of interest for drug safety studies","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-04-13T02:00:00Z","last_updated_date":"2014-07-28T18:25:00Z","reference_number":"EMA/988338/2011 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-call-expressions-interest-drug-safety-studies_en.pdf"},
    {"id":"9223","name":"Application form for the establishment of maximum-residue-limits for an active substance to be used in veterinary medicinal products in accordance with Regulation (EC) No. 470/2009","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-04-26T15:25:00Z","last_updated_date":"2018-08-31T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-establishment-maximum-residue-limits-active-substance-be-used-veterinary-medicinal-products-accordance-regulation-ec-no-4702009_en.pdf"},
    {"id":"9253","name":"Day 180 list of outstanding issues template rev. 10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:09:21Z","last_updated_date":"2016-11-08T17:25:00Z","reference_number":"Rev. 3.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-180-list-outstanding-issues-template-rev-1016_en.doc"},
    {"id":"9421","name":"QRD veterinary product-information template version 8.2","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-04-08T02:00:00Z","last_updated_date":"2020-12-31T16:42:00Z","reference_number":"Version 8.2","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-veterinary-product-information-template-version-82_en.doc","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-veterinary-product-information-template-version-82_bg.doc","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-veterinary-product-information-template-version-82_es.doc","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-veterinary-product-information-template-version-82_cs.doc","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-veterinary-product-information-template-version-82_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-veterinary-product-information-template-version-82_de.doc","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-veterinary-product-information-template-version-82_et.doc","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-veterinary-product-information-template-version-82_el.doc","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-veterinary-product-information-template-version-82_fr.doc","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-veterinary-product-information-template-version-82_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-veterinary-product-information-template-version-82_hr.doc","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-veterinary-product-information-template-version-82_it.doc","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-veterinary-product-information-template-version-82_lv.doc","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-veterinary-product-information-template-version-82_lt.doc","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-veterinary-product-information-template-version-82_hu.doc","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-veterinary-product-information-template-version-82_mt.doc","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-veterinary-product-information-template-version-82_nl.doc","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-veterinary-product-information-template-version-82_pl.doc","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-veterinary-product-information-template-version-82_pt.doc","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-veterinary-product-information-template-version-82_ro.doc","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-veterinary-product-information-template-version-82_sk.doc","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-veterinary-product-information-template-version-82_sl.doc","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-veterinary-product-information-template-version-82_fi.doc","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-veterinary-product-information-template-version-82_sv.doc","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-veterinary-product-information-template-version-82_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-veterinary-product-information-template-version-82_no.doc"}},
    {"id":"9575","name":"Transfer of MA templates Attachment 9 (Superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-06-28T10:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-ma-templates-attachment-9-superseded_en.doc"},
    {"id":"9576","name":"QRD product-information annotated template (English) version 10.4","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"1997-12-03T01:00:00Z","last_updated_date":"2024-02-29T15:52:00Z","reference_number":"10.4","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-product-information-annotated-template-english-version-104_en.pdf"},
    {"id":"9640","name":"Registration form - European Medicines Agency veterinary medicines info day","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-12-20T12:00:00Z","last_updated_date":"2016-12-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-european-medicines-agency-veterinary-medicines-info-day_en.doc"},
    {"id":"9776","name":"Annual report on a designated orphan medicinal product","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-11-24T17:30:00Z","last_updated_date":"2011-12-09T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annual-report-designated-orphan-medicinal-product_en.doc"},
    {"id":"9812","name":"Day 80 assessment report - Non-clinical template with guidance - Rev 06.25 Revamp ","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-05-21T12:00:00Z","last_updated_date":"2025-06-10T11:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-non-clinical-template-guidance-rev-0625-revamp_en.docx"},
    {"id":"10114","name":"Day 180 list of outstanding issues generics template rev. 10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T12:15:00Z","reference_number":"Rev. 10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-180-list-outstanding-issues-generics-template-rev-1016_en.doc"},
    {"id":"10149","name":"Transfer of MA templates Attachment 6.1 (Superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-ma-templates-attachment-61-superseded_en.doc"},
    {"id":"10325","name":"Registration form - EMEA workshop - Medicines for bees - What the EMEA can do to increase availability","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-10-16T02:09:21Z","last_updated_date":"2009-10-16T02:09:21Z","reference_number":"EMEA/627827/2009","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-emea-workshop-medicines-bees-what-emea-can-do-increase-availability_en.pdf"},
    {"id":"10575","name":"Day 150 or Day 195 joint response assessment report - Non-clinical template - Rev. 05. 21","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2006-09-01T02:09:00Z","last_updated_date":"2021-06-25T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-150-or-day-195-joint-response-assessment-report-non-clinical-template-rev-05-21_en.docx"},
    {"id":"10646","name":"Ancillary - Day 80 Quality template rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:25:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-day-80-quality-template-rev1016_en.doc"},
    {"id":"10831","name":"Submission of comments on good pharmacovigilance practices: Module VI – Management and reporting of adverse reactions to medicinal products (EMA/873138/2011)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T13:20:00Z","last_updated_date":"2012-02-22T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-vi-management-and-reporting-adverse-reactions-medicinal-products-ema8731382011_en.doc"},
    {"id":"10975","name":"Day 80 assessment report - Overview and D120 LOQ template with guidance - Rev. 10.23","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-05-21T12:00:00Z","last_updated_date":"2023-10-20T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-overview-and-d120-loq-template-guidance-rev-1023_en.docx"},
    {"id":"11071","name":"Request/declaration form for the provision of information via mobile scanning and other technologies in the centralised procedure","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-07-24T12:00:00Z","last_updated_date":"2026-03-25T09:11:58Z","reference_number":"EMA/493921/2015 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-declaration-form-provision-information-mobile-scanning-other-technologies-centralised-procedure_en.docx"},
    {"id":"11305","name":"Submission of comments on 'European Network of Paediatric Research - Recognition criteria for self-assessment'","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-02-12T00:09:21Z","last_updated_date":"2010-02-12T00:09:21Z","reference_number":"EMA/89566/2010","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-european-network-paediatric-research-recognition-criteria-self-assessment_en.doc"},
    {"id":"11335","name":"(Co) Rapporteur (joint) assessment report of the grounds for the re-examination procedure - Rev. 05.21","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-07-03T16:30:00Z","last_updated_date":"2021-06-25T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/co-rapporteur-joint-assessment-report-grounds-re-examination-procedure-rev-0521_en.docx"},
    {"id":"11389","name":"Template for comments to answer to Questions 3 and 4 - Public consultation regarding the request to the European Medicines Agency from the European Commission for scientific advice on the impact on public health and anim...","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T16:15:00Z","last_updated_date":"2013-12-17T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-comments-answer-questions-3-and-4-public-consultation-regarding-request-european-medicines-agency-european-commission-scientific-advice-impact-public-health-and-anim_en.doc"},
    {"id":"11446","name":"Template to report an allegation concerning an impropriety in an area of EMA’s responsibility (authorisation, supervision and maintenance of human and veterinary medicinal products)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-11-28T18:21:00Z","last_updated_date":"2020-01-10T09:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-report-allegation-concerning-impropriety-area-emas-responsibility-authorisation-supervision-and-maintenance-human-and-veterinary-medicinal-products_en.doc"},
    {"id":"11456","name":"Ancillary - Day 150 JAR Quality template rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:25:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-day-150-jar-quality-template-rev1016_en.doc"},
    {"id":"11472","name":"CHMP rapporteurs' assessment report for paediatric studies submitted in accordance with Article 46","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-05-28T13:00:00Z","last_updated_date":"2024-03-05T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/chmp-rapporteurs-assessment-report-paediatric-studies-submitted-accordance-article-46_en.docx"},
    {"id":"11486","name":"Annex 02  Response Questionnaire - EMA-2012-09-IF","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"EMA/687077/2011","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-02-response-questionnaire-ema-2012-09-if_en.xls"},
    {"id":"11517","name":"QRD Appendix II - Medical Dictionary for Regulatory Activities terminology to be used in section 4.8 'undesirable effects' of the summary of product characteristics","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2026-03-25T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics_no.docx"}}    {"id":"11547","name":"Registration form: Second Veterinary E-Submission Workshop","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-11-18T00:09:21Z","last_updated_date":"2009-11-18T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-second-veterinary-e-submission-workshop_en.pdf"},
    {"id":"11686","name":"Application form for consultation by a notified body on an ancillary medicinal substance/ancillary human blood or plasma derivative used in a medical device ","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T16:25:00Z","last_updated_date":"2021-03-30T17:20:00Z","reference_number":"EMA/75225/2020 ","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-consultation-notified-body-ancillary-medicinal-substance-ancillary-human-blood-or-plasma-derivative-used-medical-device_en.doc"},
    {"id":"11694","name":"Registration form - Annual workshop of the European network of paediatric research at the European Medicines Agency","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-04-08T17:00:00Z","last_updated_date":"2015-04-08T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-annual-workshop-european-network-paediatric-research-european-medicines-agency_en.pdf"},
    {"id":"11696","name":"Template for a European Union list entry","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2008-03-07T00:09:00Z","last_updated_date":"2020-07-29T15:30:00Z","reference_number":"EMA/HMPC/439705/2006 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-european-union-list-entry_en.doc"},
    {"id":"11798","name":"Request for confirmation of the applicability of the Agency's decision on class waivers","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-03-12T01:00:00Z","last_updated_date":"2019-03-20T09:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-confirmation-applicability-agencys-decision-class-waivers_en.docx"},
    {"id":"12032","name":"Statement of quantitative composition","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2009-09-01T02:00:00Z","last_updated_date":"2023-03-07T11:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/statement-quantitative-composition_en.docx"},
    {"id":"12125","name":"Letter of intent for the submission of a work sharing procedure to the European Medicines Agency according to Article 20 of Commission Regulation (EC) No 1234/2008 - Veterinary applications","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2019-05-24T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/letter-intent-submission-work-sharing-procedure-european-medicines-agency-according-article-20-commission-regulation-ec-no-12342008-veterinary-applications_en.doc"},
    {"id":"12207","name":"Day 80 Assessment report - Non-clinical template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:09:21Z","last_updated_date":"2010-10-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-non-clinical-template_en.doc"},
    {"id":"12454","name":"QRD annex related to the Article-127a template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-10-08T13:00:00Z","last_updated_date":"2019-06-28T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-annex-related-article-127a-template_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-annex-related-article-127a-template_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-annex-related-article-127a-template_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-annex-related-article-127a-template_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-annex-related-article-127a-template_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-annex-related-article-127a-template_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-annex-related-article-127a-template_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-annex-related-article-127a-template_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-annex-related-article-127a-template_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-annex-related-article-127a-template_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-annex-related-article-127a-template_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-annex-related-article-127a-template_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-annex-related-article-127a-template_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-annex-related-article-127a-template_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-annex-related-article-127a-template_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-annex-related-article-127a-template_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-annex-related-article-127a-template_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-annex-related-article-127a-template_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-annex-related-article-127a-template_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-annex-related-article-127a-template_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-annex-related-article-127a-template_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-annex-related-article-127a-template_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-annex-related-article-127a-template_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-annex-related-article-127a-template_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-annex-related-article-127a-template_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-annex-related-article-127a-template_no.docx"}},
    {"id":"12619","name":"Application form for the involvement of healthcare professionals’ organisations in the activities of the European Medicines Agency","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-29T17:29:00Z","last_updated_date":"2026-05-19T11:21:00Z","reference_number":"EMA/101582/2012 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-involvement-healthcare-professionals-organisations-activities-european-medicines-agency_en.docx"},
    {"id":"12806","name":"QRD Appendix II - Medical Dictionary for Regulatory Activities terminology to be used in section 4.8 'undesirable effects' of the summary of product characteristics (Cover page)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-06-27T15:36:00Z","last_updated_date":"2026-03-25T11:45:00Z","reference_number":"EMA/295934/2018 v.7","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-appendix-ii-medical-dictionary-regulatory-activities-terminology-be-used-section-48-undesirable-effects-summary-product-characteristics-cover-page_en.docx"},
    {"id":"12832","name":"Template of the request to the CVMP to (re)classify a veterinary medicinal product as minor use minor species (MUMS) / intended for use in a limited market","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-10-30T14:40:00Z","last_updated_date":"2020-12-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-request-cvmp-reclassify-veterinary-medicinal-product-minor-use-minor-species-mums-intended-use-limited-market_en.docx"},
    {"id":"12838","name":"PRAC rapporteur risk-management-plan assessment report - report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-05-13T19:00:00Z","last_updated_date":"2013-07-03T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/prac-rapporteur-risk-management-plan-assessment-report-report-template_en.doc"},
    {"id":"13010","name":"Template for a public statement when no European Union herbal monograph is established","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-07-20T02:00:00Z","last_updated_date":"2020-07-29T15:32:00Z","reference_number":"EMA/HMPC/75972/2010 Rev. 1 Corr.  1","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-public-statement-when-no-european-union-herbal-monograph-established_en.doc"},
    {"id":"13113","name":"Day 80 assessment report - Overview template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:09:21Z","last_updated_date":"2015-02-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-overview-template_en.doc"},
    {"id":"13248","name":"Template - Standard statements for change of applicant due to Brexit","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-06-19T16:00:00Z","last_updated_date":"2018-06-19T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-standard-statements-change-applicant-due-brexit_en.doc"},
    {"id":"13421","name":"Template for overview of comments received on on draft European Union herbal monograph or European Union list entry","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2009-04-03T02:09:21Z","last_updated_date":"2014-11-17T15:30:00Z","reference_number":"EMEA/HMPC/411398/2006 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-overview-comments-received-draft-european-union-herbal-monograph-or-european-union-list-entry_en.doc"},
    {"id":"13504","name":"Questionnaire on criteria to be fulfilled by patients’ and consumers’ organisations prior to involvement in the EMEA activities in PDF format","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-07-09T02:00:00Z","last_updated_date":"2008-07-09T02:00:00Z","reference_number":"EMEA/333929/2005","document_url":"https://www.ema.europa.eu/en/documents/template-form/questionnaire-criteria-be-fulfilled-patients-and-consumers-organisations-prior-involvement-emea-activities-pdf-format_en.pdf"},
    {"id":"13690","name":"PRAC rapporteur PASS protocol amendment assessment report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-11-30T14:34:00Z","last_updated_date":"2017-11-30T14:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/prac-rapporteur-pass-protocol-amendment-assessment-report-template_en.doc"},
    {"id":"13815","name":"CHMP and rapporteurs' joint assessment report on derogation applicable to similar orphan products - Rev. 03.23","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-05-28T13:00:00Z","last_updated_date":"2023-03-14T09:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/chmp-rapporteurs-joint-assessment-report-derogation-applicable-similar-orphan-products-rev-0323_en.docx"},
    {"id":"13860","name":"QRD annex IV exceptional circumstances positive template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-10-08T13:00:00Z","last_updated_date":"2019-06-28T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-annex-iv-exceptional-circumstances-positive-template_no.docx"}},
    {"id":"13902","name":"Proposed invented name(s) request form for veterinary medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:09:21Z","last_updated_date":"2023-12-06T08:53:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/proposed-invented-names-request-form-veterinary-medicinal-products_en.docx"},
    {"id":"14013","name":"Day 80 assessment report - New active substance status template - Rev. 03. 23","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-10-13T13:00:00Z","last_updated_date":"2023-03-14T09:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-new-active-substance-status-template-rev-03-23_en.docx"},
    {"id":"14425","name":"Marketing authorisation status - product template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-05-15T12:35:00Z","last_updated_date":"2017-05-15T12:35:00Z","reference_number":"EMA/217698/2017","document_url":"https://www.ema.europa.eu/en/documents/template-form/marketing-authorisation-status-product-template_en.doc"},
    {"id":"14640","name":"Exclusion criteria declaration form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-07-10T12:00:00Z","last_updated_date":"2019-02-25T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/exclusion-criteria-declaration-form_en.docx"},
    {"id":"14651","name":"Assessment report for post-authorisation measures (PAMs)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-05-28T13:00:00Z","last_updated_date":"2024-03-05T16:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/assessment-report-post-authorisation-measures-pams_en.docx"},
    {"id":"14679","name":"Guidance for usage of application form related to Article 16 of the Staff Regulations","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-06-12T12:00:00Z","last_updated_date":"2022-06-15T15:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/guidance-usage-application-form-related-article-16-staff-regulations_en.pdf"},
    {"id":"14727","name":"CHMP protocol assistance scientific advice briefing document template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2023-06-21T15:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/chmp-protocol-assistance-scientific-advice-briefing-document-template_en.docx"},
    {"id":"14906","name":"Day 80 assessment report - Generic clinical and non-clinical template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-26T00:09:21Z","last_updated_date":"2013-03-05T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-generic-clinical-and-non-clinical-template_en.doc"},
    {"id":"14916","name":"European Union regulatory workshop in ophthalmology - Expression of interest form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-07-04T02:00:00Z","last_updated_date":"2011-07-04T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/european-union-regulatory-workshop-ophthalmology-expression-interest-form_en.pdf"},
    {"id":"14946","name":"Electronic form for paediatric-investigation-plan application and request for waiver - (PED1) certified","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-05-28T02:00:00Z","last_updated_date":"2021-10-11T10:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/electronic-form-paediatric-investigation-plan-application-and-request-waiver-ped1-certified_en.pdf"},
    {"id":"15001","name":"QRD Appendix III to the Quality Review of Documents templates for human medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-02-09T01:00:00Z","last_updated_date":"2026-03-25T11:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products_no.docx"}},
    {"id":"15053","name":"One year extension of data protection for legal status switch assessment report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:00:00Z","last_updated_date":"2018-09-18T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/one-year-extension-data-protection-legal-status-switch-assessment-report-template_en.docx"},
    {"id":"15057","name":"Annex B PDF template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-12-21T00:09:21Z","last_updated_date":"2013-08-02T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-b-pdf-template_en.pdf"},
    {"id":"15125","name":"Template for scientific document for paediatric investigation plan or product-specific waiver","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-02-15T12:10:00Z","last_updated_date":"2026-04-16T08:52:56Z","reference_number":"EMA/257294/2024 Version 4","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-scientific-document-paediatric-investigation-plan-or-product-specific-waiver_en.docx"},
    {"id":"15320","name":"Checklist for requesting new EU sub-numbers (type IAIN and Type IB lead procedures only)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T18:30:00Z","last_updated_date":"2017-12-11T18:30:00Z","reference_number":"EMA/441692/2017","document_url":"https://www.ema.europa.eu/en/documents/template-form/checklist-requesting-new-eu-sub-numbers-type-iain-and-type-ib-lead-procedures-only_en.doc"},
    {"id":"15444","name":"Appendix 1 - Pharmacovigilance inspection report template (Human)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-07-27T02:00:00Z","last_updated_date":"2016-04-04T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-1-pharmacovigilance-inspection-report-template-human_en.doc"},
    {"id":"15558","name":"Registration form - Sixth workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-05-15T13:45:00Z","last_updated_date":"2014-05-15T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-sixth-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"15657","name":"Peer review of the certification procedure","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-12-17T15:50:00Z","last_updated_date":"2014-12-17T15:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/peer-review-certification-procedure_en.doc"},
    {"id":"15776","name":"Financial identification form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-06-30T02:00:00Z","last_updated_date":"2010-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/financial-identification-form_en.xls"},
    {"id":"15982","name":"Draft guideline on good pharmacovigilance practices (GVP): Annex II – Templates: Communication Plan for Direct Healthcare Professional Communication (CP DHPC)","type":"template-form","status":"Draft: consultation closed","consultation_date":"2015-12-15 - 2016-02-29","first_published_date":"2015-12-15T13:30:00Z","last_updated_date":"2015-12-15T13:30:00Z","reference_number":"EMA/334164/2015","document_url":"https://www.ema.europa.eu/en/documents/template-form/draft-guideline-good-pharmacovigilance-practices-gvp-annex-ii-templates-communication-plan-direct-healthcare-professional-communication-cp-dhpc_en.pdf"},
    {"id":"16287","name":"Request for confirmation of the applicability of the EMEA decision on class waivers","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-07-21T02:00:00Z","last_updated_date":"2008-07-21T02:00:00Z","reference_number":"n/a","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-confirmation-applicability-emea-decision-class-waivers_en.doc"},
    {"id":"16429","name":"Transfer of marketing authorisation templates - attachment 1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2026-03-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-marketing-authorisation-templates-attachment-1_en.doc"},
    {"id":"16507","name":"Guideline on good pharmacovigilance practices (GVP): Annex II – Templates: Communication Plan for Direct Healthcare Professional Communication (CP DHPC)","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2017-10-12T12:30:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/334164/2015","document_url":"https://www.ema.europa.eu/en/documents/template-form/guideline-good-pharmacovigilance-practices-gvp-annex-ii-templates-communication-plan-direct-healthcare-professional-communication-cp-dhpc_en.pdf"},
    {"id":"16527","name":"QRD Form 1: For Member States' product information check","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:00:00Z","last_updated_date":"2025-02-10T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-form-1-member-states-product-information-check_en.docx"},
    {"id":"16599","name":"Post-authorisation efficacy studies (PAES) assessment report sub-template for type II variations","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:00:00Z","last_updated_date":"2018-09-18T17:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/post-authorisation-efficacy-studies-paes-assessment-report-sub-template-type-ii-variations_en.docx"},
    {"id":"16787","name":"Registration form - 2012 European Medicines Agency/International Federation for Animal Health Europe info day","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-2012-european-medicines-agencyinternational-federation-animal-health-europe-info-day_en.doc"},
    {"id":"16801","name":"Template - Request for compliance check on an agreed paediatric investigation plan (PIP)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-06-14T02:00:00Z","last_updated_date":"2026-05-04T17:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-request-compliance-check-agreed-paediatric-investigation-plan-pip_en.docx"},
    {"id":"16841","name":"Day 150 or Day 195 joint assessment report - Quality template - Rev. 05. 21","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2006-09-01T02:09:00Z","last_updated_date":"2021-06-25T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-150-or-day-195-joint-assessment-report-quality-template-rev-05-21_en.docx"},
    {"id":"16984","name":"Notification of annual update to the parallel distribution of a centrally authorised medicinal product","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T12:00:00Z","last_updated_date":"2015-02-04T14:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/notification-annual-update-parallel-distribution-centrally-authorised-medicinal-product_en.pdf"},
    {"id":"16986","name":"GLP compliance: Non-clinical studies GLP compliance (annex to the cover letter)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-09-17T14:29:00Z","last_updated_date":"2024-06-21T13:30:00Z","reference_number":"Revision 1.1","document_url":"https://www.ema.europa.eu/en/documents/template-form/glp-compliance-non-clinical-studies-glp-compliance-annex-cover-letter_en.docx"},
    {"id":"17160","name":"Public hearing application form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-07-11T14:00:00Z","last_updated_date":"2017-07-11T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/public-hearing-application-form_en.pdf"},
    {"id":"17382","name":"Annex B Word template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-12-21T00:09:21Z","last_updated_date":"2017-04-06T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-b-word-template_en.doc"},
    {"id":"17399","name":"European Medicines Agency/European Federation of Pharmaceutical Industries and Associations second workshop on adaptive design in confirmatory trials - Registration form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-04-02T02:09:21Z","last_updated_date":"2009-04-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/european-medicines-agencyeuropean-federation-pharmaceutical-industries-and-associations-second-workshop-adaptive-design-confirmatory-trials-registration-form_en.pdf"},
    {"id":"17484","name":"Day 80 assessment report generics overview template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-26T00:09:21Z","last_updated_date":"2015-02-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-generics-overview-template_en.doc"},
    {"id":"17500","name":"Application for marketing authorisation form – from transferrer to transferee","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-11-30T01:00:00Z","last_updated_date":"2017-11-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-marketing-authorisation-form-transferrer-transferee_en.docx"},
    {"id":"17592","name":"Ancillary - Day 150 JAR Overview template rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:25:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-day-150-jar-overview-template-rev1016_en.doc"},
    {"id":"17625","name":"Template - Translations required with the submission of  an application for transfer of orphan medicinal product designation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:00Z","last_updated_date":"2022-10-06T13:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-translations-required-submission-application-transfer-orphan-medicinal-product-designation_en.doc"},
    {"id":"17649","name":"Table B: Materials from animals other than those included in the scope of the Note for Guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:09:21Z","last_updated_date":"2009-06-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/table-b-materials-animals-other-those-included-scope-note-guidance-minimising-risk-transmitting-animal-spongiform-encephalopathy-agents-medicinal-products_en.doc"},
    {"id":"17802","name":"Registration form - European Medicines Agency/International Federation for Animal Health Europe info day 2016","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-12-21T01:00:00Z","last_updated_date":"2015-12-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-european-medicines-agencyinternational-federation-animal-health-europe-info-day-2016_en.doc"},
    {"id":"17822","name":"Template to change applicant name or details","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-01-04T01:00:00Z","last_updated_date":"2017-03-21T12:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-change-applicant-name-or-details_en.doc"},
    {"id":"17972","name":"Justification table templates","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-03-03T11:00:00Z","last_updated_date":"2025-05-13T11:00:00Z","reference_number":"EMA/152360/2016 rev.1","document_url":"https://www.ema.europa.eu/en/documents/template-form/justification-table-templates_en.docx"},
    {"id":"18002","name":"European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) web based data collection form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-06-12T11:15:00Z","last_updated_date":"2023-02-13T15:45:00Z","reference_number":"EMA/307386/2020 Rev. 4","document_url":"https://www.ema.europa.eu/en/documents/template-form/european-surveillance-veterinary-antimicrobial-consumption-esvac-web-based-data-collection-form_en.zip"},
    {"id":"18028","name":"Template for the Cover Letter to submit data on Post-Authorisation Commitments","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-07-29T02:09:21Z","last_updated_date":"2009-07-29T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-cover-letter-submit-data-post-authorisation-commitments_en.doc"},
    {"id":"18065","name":"Template - Active substance-master-file procedure","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-07-13T13:03:00Z","last_updated_date":"2021-03-23T12:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-active-substance-master-file-procedure_en.doc"},
    {"id":"18204","name":"Template for the Letter of Undertaking (commitments undertaken by the Applicant/MAH)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-05-12T02:09:21Z","last_updated_date":"2009-05-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-letter-undertaking-commitments-undertaken-applicantmah_en.doc"},
    {"id":"18301","name":"Subject disposition for clinical study","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-12-11T18:30:00Z","last_updated_date":"2017-12-11T18:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/subject-disposition-clinical-study_en.doc"},
    {"id":"18317","name":"Annex 4 Required skills per profile - EMA-2012-09-IF","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"EMA/687438/2011","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-4-required-skills-profile-ema-2012-09-if_en.xls"},
    {"id":"18341","name":"Pre-qualification questionnaire for a restricted tender procedure organised by EMA - Business Continuity Consultancy; EMA/2012/02/IS","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-02T01:00:00Z","last_updated_date":"2012-02-02T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/pre-qualification-questionnaire-restricted-tender-procedure-organised-ema-business-continuity-consultancy-ema201202is_en.doc"},
    {"id":"18354","name":"Generics - Hybrids - Day 80 assessment report overview and Day 120 list of outstanding issues template with guidance - Rev. 05. 21","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-07-08T15:20:00Z","last_updated_date":"2021-06-25T03:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/generics-hybrids-day-80-assessment-report-overview-day-120-list-outstanding-issues-template-guidance-rev-05-21_en.docx"},
    {"id":"18516","name":"Submission of comments on 'Draft rules of procedures on the organisation and conduct of public hearings at the Pharmacovigilance Risk Assessment Committee (PRAC)' (EMA/624809/2013)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-07-24T16:15:00Z","last_updated_date":"2014-07-24T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-draft-rules-procedures-organisation-and-conduct-public-hearings-pharmacovigilance-risk-assessment-committee-prac-ema6248092013_en.doc"},
    {"id":"18660","name":"Day 150 or Day 195 joint response assessment report - Clinical template - Rev. 05. 21","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2006-09-01T02:09:00Z","last_updated_date":"2021-06-25T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-150-or-day-195-joint-response-assessment-report-clinical-template-rev-05-21_en.docx"},
    {"id":"18720","name":"Transfer of MA templates Attachment 6.3 (Superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-06-28T10:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-ma-templates-attachment-63-superseded_en.doc"},
    {"id":"18762","name":"Ancillary - Day 80 Non-clinical and clinical template rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:30:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-day-80-non-clinical-and-clinical-template-rev1016_en.doc"},
    {"id":"18824","name":"Addendum to public declaration of interests and confidentiality undertaking of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) members relating to research interests","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-24T18:48:50Z","last_updated_date":"2012-02-24T18:48:50Z","reference_number":"EMA/807846/2011","document_url":"https://www.ema.europa.eu/en/documents/template-form/addendum-public-declaration-interests-and-confidentiality-undertaking-european-network-paediatric-research-european-medicines-agency-enpr-ema-members-relating-research-interests_en.doc"},
    {"id":"19378","name":"Request form - Expression of interest to participate in the information sharing pilot for the evaluation of generic drug applications involving the centralised procedure of the European Union","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-01-19T15:00:00Z","last_updated_date":"2015-01-19T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-form-expression-interest-participate-information-sharing-pilot-evaluation-generic-drug-applications-involving-centralised-procedure-european-union_en.docx"},
    {"id":"19406","name":"Proposed invented name(s) justification form for veterinary medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:09:00Z","last_updated_date":"2024-03-06T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/proposed-invented-names-justification-form-veterinary-medicinal-products_en.docx"},
    {"id":"19609","name":"Ancillary - Day 180 JAR Non-clinical and clinical template rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:25:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-day-180-jar-non-clinical-and-clinical-template-rev1016_en.doc"},
    {"id":"19711","name":"One year of additional market protection for new indication assessment report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:00:00Z","last_updated_date":"2018-09-18T17:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/one-year-additional-market-protection-new-indication-assessment-report-template_en.docx"},
    {"id":"19767","name":"Nomination form for European experts","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-27T00:09:21Z","last_updated_date":"2014-12-05T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/nomination-form-european-experts_en.pdf"},
    {"id":"19807","name":"Letter of recommendations - Template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-11-03T16:35:00Z","last_updated_date":"2021-03-19T11:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/letter-recommendations-template_en.doc"},
    {"id":"19866","name":"QRD Appendix V - Adverse-drug-reaction reporting details","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-03-15T17:00:00Z","last_updated_date":"2026-03-25T11:48:00Z","reference_number":"EMA/67830/2013 Version 35","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-appendix-v-adverse-drug-reaction-reporting-details_en.docx"},
    {"id":"19946","name":"Declaration on the qualification of an enterprise as a micro, small or medium-sized enterprise (SME)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-12-06T14:57:00Z","last_updated_date":"2025-07-01T11:18:00Z","reference_number":"Version 1.6","document_url":"https://www.ema.europa.eu/en/documents/template-form/declaration-qualification-enterprise-micro-small-or-medium-sized-enterprise-sme_en.pdf"},
    {"id":"19979","name":"Template for submission of a request for scientific support and advice on a traditional herbal medicinal product","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2005-10-24T02:00:00Z","last_updated_date":"2014-11-17T16:30:00Z","reference_number":"EMEA/HMPC/119889/2005 Rev. 1 Corr.","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-request-scientific-support-and-advice-traditional-herbal-medicinal-product_en.doc"},
    {"id":"20059","name":"Pre-submission request form for a EMA procedure prior to the submission of a marketing authorisation application or Article 58 Application","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-02-05T02:00:00Z","last_updated_date":"2025-09-08T14:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/pre-submission-request-form-ema-procedure-prior-submission-marketing-authorisation-application-or-article-58-application_en.pdf"},
    {"id":"20155","name":"Day 120 list of questions generics template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-10-12T02:09:21Z","last_updated_date":"2015-02-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-120-list-questions-generics-template_en.doc"},
    {"id":"20174","name":"Quick Response (QR) code","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-01-18T01:00:00Z","last_updated_date":"2016-01-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/quick-response-qr-code_en.doc"},
    {"id":"20250","name":"European network of paediatric research (EnprEMA) - Recognition criteria for self-assessment","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-02-12T00:09:21Z","last_updated_date":"2012-05-31T14:09:00Z","reference_number":"EMA/89565/2010","document_url":"https://www.ema.europa.eu/en/documents/template-form/european-network-paediatric-research-enprema-recognition-criteria-self-assessment_en.doc"},
    {"id":"20293","name":"Submission of comments on good pharmacovigilance practices: Module I – Pharmacovigilance systems and their quality systems (EMA/541760/2011)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T13:20:00Z","last_updated_date":"2012-02-22T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-i-pharmacovigilance-systems-and-their-quality-systems-ema5417602011_en.doc"},
    {"id":"20881","name":"Mock-ups and specimens: Response form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-04-05T17:10:00Z","last_updated_date":"2013-04-05T17:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/mock-ups-and-specimens-response-form_en.doc"},
    {"id":"21027","name":"Template for submission of comments on draft European Union herbal monograph or draft  European Union list entry","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-04-03T02:09:00Z","last_updated_date":"2020-07-29T15:10:00Z","reference_number":"EMA/HMPC/384286/2006","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-comments-draft-european-union-herbal-monograph-or-draft-european-union-list-entry_en.doc"},
    {"id":"21217","name":"(Superseded) European Surveillance of Veterinary Antimicrobial Consumption  (ESVAC) data collection form (template)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-04-20T02:00:00Z","last_updated_date":"2013-04-18T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/superseded-european-surveillance-veterinary-antimicrobial-consumption-esvac-data-collection-form-template_en.xlsx"},
    {"id":"21220","name":"Public declaration of interests and confidentiality undertaking of European\n\nMedicines Agency (EMA) Management Board members, scientific committee\n\nmembers and experts","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-07-18T02:00:00Z","last_updated_date":"2010-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/public-declaration-interests-and-confidentiality-undertaking-european-medicines-agency-ema-management-board-members-scientific-committee-members-and-experts_en.pdf"},
    {"id":"21457","name":"Registration form - 2016 annual workshop of the European network of paediatric research at the EMA (Enpr-EMA)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-04-14T02:00:00Z","last_updated_date":"2016-04-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-2016-annual-workshop-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"21961","name":"Letter of intent to submit an application to fulfil the conditions set out in Regulation 1901/2006","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-10-31T01:00:00Z","last_updated_date":"2008-10-31T01:00:00Z","reference_number":"n/a","document_url":"https://www.ema.europa.eu/en/documents/template-form/letter-intent-submit-application-fulfil-conditions-set-out-regulation-19012006_en.doc"},
    {"id":"22080","name":"Template for information exchange for the preparation of the assessment report supporting the establishment of European Union monographs and European Union list entries - Revision 1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-07-20T02:00:00Z","last_updated_date":"2014-11-17T16:45:00Z","reference_number":"EMEA/HMPC/137093/2006 Rev. 1 Corr.","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-information-exchange-preparation-assessment-report-supporting-establishment-european-union-monographs-and-european-union-list-entries-revision-1_en.doc"},
    {"id":"22295","name":"Template for sections A to E for the scientific part of the application for orphan designation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-10-14T12:25:00Z","last_updated_date":"2023-04-20T09:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-sections-e-scientific-part-application-orphan-designation_en.docx"},
    {"id":"22349","name":"Financial identification form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-12-10T00:09:21Z","last_updated_date":"2009-12-10T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/financial-identification-form_en.xls-0"},
    {"id":"22508","name":"Request for modification of an agreed paediatric investigation plan","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-05-28T02:00:00Z","last_updated_date":"2025-11-26T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-modification-agreed-paediatric-investigation-plan_en.docx"},
    {"id":"22692","name":"Peer reviewers comments at day 100","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-07-03T16:30:00Z","last_updated_date":"2017-07-03T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/peer-reviewers-comments-day-100_en.docx"}    {"id":"22793","name":"Registration form - 2017 Annual workshop of the European network of paediatric research at the EMA (Enpr-EMA)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-02-09T15:00:00Z","last_updated_date":"2017-02-09T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-2017-annual-workshop-european-network-paediatric-research-ema-enpr-ema_en.pdf"},
    {"id":"22853","name":"Day 120 list of questions template rev. 10.17","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-05-21T12:00:00Z","last_updated_date":"2017-12-01T17:28:00Z","reference_number":"D120 list of questions rev. 10.17","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-120-list-questions-template-rev-1017_en.docx"},
    {"id":"23416","name":"Confidentiality undertaking for observers","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2006-09-28T02:09:00Z","last_updated_date":"2025-05-16T09:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/confidentiality-undertaking-observers_en.pdf"},
    {"id":"23460","name":"Notification of a change for parallel distribution of a centrally authorised medicinal product","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-04-06T02:00:00Z","last_updated_date":"2013-07-09T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/notification-change-parallel-distribution-centrally-authorised-medicinal-product_en.doc"},
    {"id":"23548","name":"QRD Form  2: For applicants when submitting revised translations to the European Medicines Agency","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T12:00:00Z","last_updated_date":"2013-08-05T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-form-2-applicants-when-submitting-revised-translations-european-medicines-agency_en.doc"},
    {"id":"23596","name":"EudraVigilance delegation declaration - registration process delegation form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2016-06-17T02:00:00Z","reference_number":"EMA/99668/2016","document_url":"https://www.ema.europa.eu/en/documents/template-form/eudravigilance-delegation-declaration-registration-process-delegation-form_en.doc"},
    {"id":"23616","name":"Submission of comments on good pharmacovigilance practices: Module V – Risk management systems (EMA/838713/2011)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T13:20:00Z","last_updated_date":"2012-02-22T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-v-risk-management-systems-ema8387132011_en.doc"},
    {"id":"23651","name":"Template for submission of comments for the Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) standard list for EudraVigilance Veterinary (EVVet)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-07-06T14:00:00Z","last_updated_date":"2025-09-03T09:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-comments-veterinary-dictionary-drug-regulatory-activities-veddra-standard-list-eudravigilance-veterinary-evvet_en.xlsx"},
    {"id":"23757","name":"Declaration of Interests Assessment Group rules of procedure","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2006-07-01T02:00:00Z","last_updated_date":"2006-07-01T02:00:00Z","reference_number":"EMEA/26628/2006","document_url":"https://www.ema.europa.eu/en/documents/template-form/declaration-interests-assessment-group-rules-procedure_en.pdf"},
    {"id":"23777","name":"Annex II: Expression of interest form - Donation of EMA assets no. EMA/2014/28/IS","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-07-30T12:00:00Z","last_updated_date":"2014-07-30T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-ii-expression-interest-form-donation-ema-assets-no-ema201428is_en.doc"},
    {"id":"23823","name":"Table C: Albumin and other human tissue derived materials","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:09:21Z","last_updated_date":"2009-06-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/table-c-albumin-and-other-human-tissue-derived-materials_en.doc"},
    {"id":"23894","name":"PRIME eligibility request: applicant’s justification template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T12:00:00Z","last_updated_date":"2022-04-06T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/prime-eligibility-request-applicants-justification-template_en.doc"},
    {"id":"23967","name":"Transfer of marketing authorisation template - attachment 2","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-03-27T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-marketing-authorisation-template-attachment-2_en.doc"},
    {"id":"24323","name":"Public declaration of interests and confidentiality undertaking of European Medicines Agency scientific committees' members and experts - prefilled sample form (version 4)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-12-08T11:20:00Z","last_updated_date":"2021-02-02T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/public-declaration-interests-and-confidentiality-undertaking-european-medicines-agency-scientific-committees-members-and-experts-prefilled-sample-form-version-4_en.pdf"},
    {"id":"24342","name":"Registration form - Workshop on veterinary regulatory support for micro, small and medium-sized enterprises (SMEs)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-10-09T13:00:00Z","last_updated_date":"2013-10-09T13:00:00Z","reference_number":"EMA/563985/2013","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-workshop-veterinary-regulatory-support-micro-small-and-medium-sized-enterprises-smes_en.pdf"},
    {"id":"24487","name":"Appendix 3 - PhV inspection outcome sharing template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-07-27T02:00:00Z","last_updated_date":"2024-03-21T10:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-3-phv-inspection-outcome-sharing-template_en.doc"},
    {"id":"24556","name":"Renewal assessment report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:00:00Z","last_updated_date":"2017-08-04T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/renewal-assessment-report-template_en.docx"},
    {"id":"24583","name":"Day 80 assessment report - Clinical template with guidance - Rev. 07.25 - Revamp","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-05-21T12:00:00Z","last_updated_date":"2025-08-01T12:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-clinical-template-guidance-rev-0725-revamp_en.docx"},
    {"id":"24757","name":"Registration form - European Medicines Agency/European Federation of Pharmaceutical Industries and Associations (EFPIA) workshop on the importance of dose finding and dose selection for the successful development, licens...","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-06-23T02:00:00Z","last_updated_date":"2014-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-european-medicines-agencyeuropean-federation-pharmaceutical-industries-and-associations-efpia-workshop-importance-dose-finding-and-dose-selection-successful-development-licens_en.pdf"},
    {"id":"24825","name":"Expression of interest form - European Medicines Agency / health-technology-assessment-body workshop on parallel scientific advice in drug development","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-06-14T17:42:00Z","last_updated_date":"2013-06-14T17:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/expression-interest-form-european-medicines-agency-health-technology-assessment-body-workshop-parallel-scientific-advice-drug-development_en.pdf"},
    {"id":"24826","name":"Marketing status reporting","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:09:00Z","last_updated_date":"2021-01-13T09:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/marketing-status-reporting_en.xlsx"},
    {"id":"24930","name":"Day 80 assessment report - Clinical template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:09:21Z","last_updated_date":"2014-05-28T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-clinical-template_en.doc"},
    {"id":"25080","name":"Public Declaration of Interests and Confidentiality Undertaking of European\n\nMedicines Agency (EMA) Management Board members, Scientific Committee\n\nmembers and experts","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-06-30T02:00:00Z","last_updated_date":"2010-06-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/public-declaration-interests-and-confidentiality-undertaking-european-medicines-agency-ema-management-board-members-scientific-committee-members-and-experts_en.pdf-0"},
    {"id":"25246","name":"EMEA Workshop on Pharmacovigilance Systems and Inspections for Veterinary Medicinal Products - Announcement and registration form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2007-11-22T00:09:21Z","last_updated_date":"2007-11-22T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/emea-workshop-pharmacovigilance-systems-and-inspections-veterinary-medicinal-products-announcement-and-registration-form_en.pdf"},
    {"id":"25356","name":"National experts on secondment application form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-08-06T12:25:00Z","last_updated_date":"2014-11-21T14:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/national-experts-secondment-application-form_en.pdf"},
    {"id":"25379","name":"Request to consult declarations of interests of European experts","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-19T00:09:21Z","last_updated_date":"2008-11-19T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-consult-declarations-interests-european-experts_en.pdf"},
    {"id":"25400","name":"Submission of comments on good pharmacovigilance practices: Module IX – Signal management (EMA/827661/2011)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T13:20:00Z","last_updated_date":"2012-02-22T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-ix-signal-management-ema8276612011_en.doc"},
    {"id":"25559","name":"Request to CMDh / European Medicines Agency for a recommendation on the classification of an unforeseen variation under Article 5 of Commission Regulation (EC) No 1234/2008","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-03-01T01:00:00Z","last_updated_date":"2022-06-08T14:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-cmdh-european-medicines-agency-recommendation-classification-unforeseen-variation-under-article-5-commission-regulation-ec-no-12342008_en.doc"},
    {"id":"25735","name":"Template for submission by Committee on Herbal Medicinal Products (HMPC) members or national competent authorities of questions for discussion by the HMPC","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-07-20T02:00:00Z","last_updated_date":"2014-11-17T15:00:00Z","reference_number":"EMA/HMPC/463090/2011 Corr","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-committee-herbal-medicinal-products-hmpc-members-or-national-competent-authorities-questions-discussion-hmpc_en.pdf"},
    {"id":"26051","name":"QRD annex IV standard positive template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-10-08T13:00:00Z","last_updated_date":"2019-06-28T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-annex-iv-standard-positive-template_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-annex-iv-standard-positive-template_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-annex-iv-standard-positive-template_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-annex-iv-standard-positive-template_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-annex-iv-standard-positive-template_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-annex-iv-standard-positive-template_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-annex-iv-standard-positive-template_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-annex-iv-standard-positive-template_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-annex-iv-standard-positive-template_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-annex-iv-standard-positive-template_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-annex-iv-standard-positive-template_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-annex-iv-standard-positive-template_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-annex-iv-standard-positive-template_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-annex-iv-standard-positive-template_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-annex-iv-standard-positive-template_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-annex-iv-standard-positive-template_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-annex-iv-standard-positive-template_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-annex-iv-standard-positive-template_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-annex-iv-standard-positive-template_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-annex-iv-standard-positive-template_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-annex-iv-standard-positive-template_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-annex-iv-standard-positive-template_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-annex-iv-standard-positive-template_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-annex-iv-standard-positive-template_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-annex-iv-standard-positive-template_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-annex-iv-standard-positive-template_no.docx"}},
    {"id":"26128","name":"Transfer of MA templates Attachment 4 (Superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-06-28T10:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-ma-templates-attachment-4-superseded_en.doc"},
    {"id":"26197","name":"Name Review Group form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T12:10:00Z","last_updated_date":"2015-09-25T16:05:00Z","reference_number":"Version 1.0.4","document_url":"https://www.ema.europa.eu/en/documents/template-form/name-review-group-form_en.pdf"},
    {"id":"26362","name":"Registration form 2011 European Medicines Agency/IFAH-Europe Info Day","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-02-17T01:00:00Z","last_updated_date":"2011-02-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-2011-european-medicines-agencyifah-europe-info-day_en.doc"},
    {"id":"26402","name":"Registration form - European Medicines Agency/International Federation for Animal Health Europe info day 2014","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-02-06T18:10:00Z","last_updated_date":"2014-02-06T18:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-european-medicines-agencyinternational-federation-animal-health-europe-info-day-2014_en.pdf"},
    {"id":"26415","name":"QRD product-information template version 10.4","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"1997-12-03T01:00:00Z","last_updated_date":"2024-02-29T15:59:00Z","reference_number":"10.4","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-product-information-template-version-104_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-product-information-template-version-104_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-product-information-template-version-104_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-product-information-template-version-104_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-product-information-template-version-104_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-product-information-template-version-104_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-product-information-template-version-104_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-product-information-template-version-104_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-product-information-template-version-104_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-product-information-template-version-104_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-product-information-template-version-104_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-product-information-template-version-104_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-product-information-template-version-104_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-product-information-template-version-104_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-product-information-template-version-104_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-product-information-template-version-104_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-product-information-template-version-104_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-product-information-template-version-104_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-product-information-template-version-104_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-product-information-template-version-104_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-product-information-template-version-104_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-product-information-template-version-104_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-product-information-template-version-104_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-product-information-template-version-104_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-product-information-template-version-104_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-product-information-template-version-104_no.docx"}},
    {"id":"26513","name":"Submission of comments template - EU Medicines Agencies Network Strategy to 2020 - Working together to improve health","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-03-31T12:00:00Z","last_updated_date":"2015-03-31T12:00:00Z","reference_number":"EMA/201512/2015","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-template-eu-medicines-agencies-network-strategy-2020-working-together-improve-health_en.doc"},
    {"id":"26608","name":"EudraVigilance user declaration for qualified person for pharmacovigilance/responsible person for EudraVigilance","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2024-08-13T15:55:00Z","reference_number":"EMA/204890/2017","document_url":"https://www.ema.europa.eu/en/documents/template-form/eudravigilance-user-declaration-qualified-person-pharmacovigilance-responsible-person-eudravigilance_en.pdf"},
    {"id":"26634","name":"Submission of comments on good pharmacovigilance practices: Module VII – Periodic safety update report (EMA/816292/2011)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T13:20:00Z","last_updated_date":"2012-02-22T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-vii-periodic-safety-update-report-ema8162922011_en.doc"},
    {"id":"26950","name":"Parallel consultation: briefing document template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-03-31T14:00:00Z","last_updated_date":"2022-10-06T13:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/parallel-consultation-briefing-document-template_en.docx"},
    {"id":"27124","name":"Template for comments to answer to Question 2 - Public consultation regarding the request to the European Medicines Agency from the European Commission for scientific advice on the impact on public health and animal heal...","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-12-17T16:15:00Z","last_updated_date":"2013-12-17T16:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-comments-answer-question-2-public-consultation-regarding-request-european-medicines-agency-european-commission-scientific-advice-impact-public-health-and-animal-heal_en.doc"},
    {"id":"27359","name":"Template letter for applicant - waiving right for a re-examination request","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-04-05T12:15:00Z","last_updated_date":"2019-03-20T09:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-letter-applicant-waiving-right-re-examination-request_en.doc-0"},
    {"id":"27471","name":"European Union list of planned and conducted pharmacovigilance inspections","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-02-03T11:00:00Z","last_updated_date":"2015-02-03T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/european-union-list-planned-and-conducted-pharmacovigilance-inspections_en.xlsx"},
    {"id":"27474","name":"Specimen submission form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:00Z","last_updated_date":"2022-09-28T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/specimen-submission-form_en.docx"},
    {"id":"27503","name":"Day 120 list of questions template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:09:21Z","last_updated_date":"2015-02-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-120-list-questions-template_en.doc"},
    {"id":"27584","name":"Template cover letter for worksharing procedures including centrally authorised products and nationally authorised products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-06-18T02:00:00Z","last_updated_date":"2013-08-02T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-cover-letter-worksharing-procedures-including-centrally-authorised-products-and-nationally-authorised-products_en.doc"},
    {"id":"27682","name":"Annual report on deferral granted in the paediatric investigation plan - (PED6) certified","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2000-06-19T02:00:00Z","last_updated_date":"2017-05-22T17:20:00Z","reference_number":"Version 1.0.6","document_url":"https://www.ema.europa.eu/en/documents/template-form/annual-report-deferral-granted-paediatric-investigation-plan-ped6-certified_en.pdf"},
    {"id":"27715","name":"Request to consult information on the areas of expertise of European experts","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-12-05T11:15:00Z","last_updated_date":"2014-12-05T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-consult-information-areas-expertise-european-experts_en.doc"},
    {"id":"27936","name":"Template for submission of a request for scientific support and advice on a traditional herbal medicinal product","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2005-10-24T02:00:00Z","last_updated_date":"2014-11-17T16:30:00Z","reference_number":"EMEA/HMPC/119889/2005 Rev. 1 Corr","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-request-scientific-support-and-advice-traditional-herbal-medicinal-product_en.pdf"},
    {"id":"27946","name":"Appendix for a 2nd step Notification (EMA)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-10-08T02:09:21Z","last_updated_date":"2009-10-08T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-2nd-step-notification-ema_en.doc"},
    {"id":"27975","name":"Registration form - Stakeholder focus group meeting on availability of lumpy skin disease (LSD) vaccines authorised to European Union (EU) standards","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-01-03T01:00:00Z","last_updated_date":"2017-01-03T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-stakeholder-focus-group-meeting-availability-lumpy-skin-disease-lsd-vaccines-authorised-european-union-eu-standards_en.doc"},
    {"id":"28036","name":"Good-manufacturing-practice inspection report - Community format","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2006-09-20T02:00:00Z","last_updated_date":"2011-03-11T01:00:00Z","reference_number":"EMEA/INS/GMP/313539/2006","document_url":"https://www.ema.europa.eu/en/documents/template-form/good-manufacturing-practice-inspection-report-community-format_en.doc"},
    {"id":"28077","name":"Day 120 list of questions - generics template rev. 10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-07-08T15:20:00Z","last_updated_date":"2016-10-03T13:30:00Z","reference_number":"Rev. 3.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-120-list-questions-generics-template-rev-1016_en.doc"},
    {"id":"28247","name":"Registration form - 2013 European Medicines Agency / International Federation for Animal Health Europe info day","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T16:00:01Z","last_updated_date":"2013-01-24T16:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-2013-european-medicines-agency-international-federation-animal-health-europe-info-day_en.doc"},
    {"id":"28393","name":"Generics - Hybrids - PRAC D94 Rapporteur RMP assessment report template rev. 01.23","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-05-21T12:00:00Z","last_updated_date":"2023-01-20T16:34:00Z","reference_number":"Rev. 01.23","document_url":"https://www.ema.europa.eu/en/documents/template-form/generics-hybrids-prac-d94-rapporteur-rmp-assessment-report-template-rev-0123_en.docx"},
    {"id":"28647","name":"Notification of parallel distribution of a centrally authorised medicinal product","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-04-01T02:00:00Z","last_updated_date":"2013-07-09T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/notification-parallel-distribution-centrally-authorised-medicinal-product_en.pdf"},
    {"id":"28902","name":"Registration form - Workshop on immunogenicity assessment of biotechnology derived-therapeutic proteins with interested parties","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-01-27T13:30:00Z","last_updated_date":"2016-01-27T13:30:00Z","reference_number":"EMA/55161/2016","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-workshop-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-interested-parties_en.doc"},
    {"id":"29113","name":"Applicant / marketing authorisation holder change of contact person for product invented name / product number template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:09:00Z","last_updated_date":"2025-06-02T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/applicant-marketing-authorisation-holder-change-contact-person-product-invented-name-product-number-template_en.doc"},
    {"id":"29194","name":"Generics - Hybrids - Day 80 assessment report - Non-clinical and clinical template with guidance - Rev. 05. 21","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-07-08T15:20:00Z","last_updated_date":"2021-06-25T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/generics-hybrids-day-80-assessment-report-non-clinical-and-clinical-template-guidance-rev-05-21_en.docx"},
    {"id":"29233","name":"Template for submission by Committee on Herbal Medicinal Products (HMPC) members or national competent authorities of questions for discussion by the HMPC","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-07-20T02:00:00Z","last_updated_date":"2014-11-17T15:00:00Z","reference_number":"EMA/HMPC/463090/2011 Corr.","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-committee-herbal-medicinal-products-hmpc-members-or-national-competent-authorities-questions-discussion-hmpc_en.doc"},
    {"id":"29296","name":"Template for requesting orphan industry user admin role","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-07-13T15:58:00Z","last_updated_date":"2018-07-13T15:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-requesting-orphan-industry-user-admin-role_en.doc"},
    {"id":"29372","name":"Template PRAC assessment report of an non-interventional imposed PASS final study report","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-02-10T17:45:00Z","last_updated_date":"2017-11-30T12:55:00Z","reference_number":"EMA/699686/2015","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-prac-assessment-report-non-interventional-imposed-pass-final-study-report_en.pdf"},
    {"id":"29446","name":"PRAC rapporteur post-authorisation-safety-study-protocol assessment-report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-12-11T17:00:00Z","last_updated_date":"2026-02-04T14:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/prac-rapporteur-post-authorisation-safety-study-protocol-assessment-report-template_en.docx"},
    {"id":"29476","name":"Submission of comments on 'good pharmacovigilance practices module X – Additional monitoring' (EMA/169546/2012)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-06-27T14:57:59Z","last_updated_date":"2012-06-27T14:57:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-x-additional-monitoring-ema1695462012_en.doc"},
    {"id":"29529","name":"2009 EMEA/IFAH-Europe Info Day London, 12-13 March 2009 - Registration form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-02-02T00:09:21Z","last_updated_date":"2009-02-02T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/2009-emeaifah-europe-info-day-london-12-13-march-2009-registration-form_en.pdf"},
    {"id":"29724","name":"EudraVigilance human - Sponsor registration form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-06-17T02:00:00Z","last_updated_date":"2025-01-07T15:18:00Z","reference_number":"EMA/99666/2016","document_url":"https://www.ema.europa.eu/en/documents/template-form/eudravigilance-human-sponsor-registration-form_en.docx"},
    {"id":"29910","name":"Guideline on good pharmacovigilance practices: Annex II – Templates: Direct Healthcare Professional Communication (DHPC) (Rev. 1)","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2013-01-24T18:00:00Z","last_updated_date":"2017-10-12T12:30:00Z","reference_number":"EMA/36988/2013","document_url":"https://www.ema.europa.eu/en/documents/template-form/guideline-good-pharmacovigilance-practices-annex-ii-templates-direct-healthcare-professional-communication-dhpc-rev-1_en.pdf"},
    {"id":"30015","name":"Template letter of intent for request of scientific advice - veterinary","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T13:24:00Z","last_updated_date":"2017-03-30T14:24:00Z","reference_number":"EMA/279341/2012","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-letter-intent-request-scientific-advice-veterinary_en.doc"},
    {"id":"30191","name":"Questionnaire on eligibility to become an interested party to Committee for Advanced Therapies (CAT)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-23T02:09:21Z","last_updated_date":"2009-06-23T02:09:21Z","reference_number":"EMEA/CAT/393507/2009","document_url":"https://www.ema.europa.eu/en/documents/template-form/questionnaire-eligibility-become-interested-party-committee-advanced-therapies-cat_en.doc"},
    {"id":"30497","name":"Template for registering new active substance on EUTCT","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-07-13T15:58:00Z","last_updated_date":"2023-01-10T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-registering-new-active-substance-eutct_en.xlsx"},
    {"id":"30691","name":"Request for the CVMP to classify a veterinary medicinal product as intended for use in minor uses minor species / limited market","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-07-24T02:09:21Z","last_updated_date":"2013-08-02T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-cvmp-classify-veterinary-medicinal-product-intended-use-minor-uses-minor-species-limited-market_en.pdf"},
    {"id":"30787","name":"Template for a public statement when no Community herbal monograph is established","type":"template-form","status":"unknown","consultation_date":"2011-02-15 - 2011-05-15","first_published_date":"2011-02-16T02:00:00Z","last_updated_date":"2020-07-29T17:33:00Z","reference_number":"EMA/HMPC/75972/2010 Rev. 1 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-public-statement-when-no-community-herbal-monograph-established_en.pdf"},
    {"id":"30807","name":"Standalone signal notification form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-01-09T11:55:00Z","last_updated_date":"2020-02-27T10:01:00Z","reference_number":"EMA/150823/2017 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/template-form/standalone-signal-notification-form_en.doc"},
    {"id":"30853","name":"Generics - Hybrids - Day 80 assessment report - Quality template with guidance - Rev. 05. 21","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:00Z","last_updated_date":"2021-06-25T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/generics-hybrids-day-80-assessment-report-quality-template-guidance-rev-05-21_en.docx"},
    {"id":"31137","name":"Proposed invented name(s) request form for human medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2006-07-01T02:00:00Z","last_updated_date":"2024-08-05T16:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/proposed-invented-names-request-form-human-medicinal-products_en.pdf"},
    {"id":"31327","name":"Submission of comments during the pilot phase for the QRD template ‘Particulars to appear on the immediate package – combined label and package leaflet’","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-04-03T19:20:00Z","last_updated_date":"2017-04-03T19:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-during-pilot-phase-qrd-template-particulars-appear-immediate-package-combined-label-and-package-leaflet_en.doc"},
    {"id":"31395","name":"European Medicines Agency active-substance-master-file-number request form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-08-14T11:47:00Z","last_updated_date":"2020-10-23T15:10:00Z","reference_number":"EMA/501697/2020","document_url":"https://www.ema.europa.eu/en/documents/template-form/european-medicines-agency-active-substance-master-file-number-request-form_en.docx"},
    {"id":"31464","name":"Template - Translations required with the submission of an application for orphan medicinal product designation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-12-10T00:09:00Z","last_updated_date":"2022-10-06T13:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-translations-required-submission-application-orphan-medicinal-product-designation_en.doc"},
    {"id":"31546","name":"Request form for the provision of information via Quick Response (QR) codes in the labelling and/or package leaflet of veterinary medicinal products authorised via the centralised (CP), mutual recognition (MRP), decentra...","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-02-09T11:10:00Z","last_updated_date":"2023-12-11T16:50:00Z","reference_number":"EMA/818103/2017, rev. 1","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-form-provision-information-quick-response-qr-codes-labelling-and-or-package-leaflet-veterinary-medicinal-products-authorised-centralised-cp-mutual-recognition-mrp-decentra_en.pdf"},
    {"id":"31676","name":"Product-information-quality form: For applicants when submitting revised English product information to the European Medicines Agency - Day 121","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:09:21Z","last_updated_date":"2010-05-06T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/product-information-quality-form-applicants-when-submitting-revised-english-product-information-european-medicines-agency-day-121_en.doc"},
    {"id":"31700","name":"Template for European Union risk-management plan (superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2006-09-27T02:00:00Z","last_updated_date":"2006-09-27T02:00:00Z","reference_number":"EMEA/192632/2006","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-european-union-risk-management-plan-superseded_en.pdf"},
    {"id":"31761","name":"Signal assessment report - template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-10-29T10:00:00Z","last_updated_date":"2022-10-21T09:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/signal-assessment-report-template_en.docx"},
    {"id":"31798","name":"Transfer of MA templates Attachment 8 (Superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-06-28T10:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-ma-templates-attachment-8-superseded_en.doc"},
    {"id":"31840","name":"Template for a European Union list entry","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2008-03-07T00:09:00Z","last_updated_date":"2020-07-29T15:30:00Z","reference_number":"EMA/HMPC/439705/2006 Rev. 5","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-european-union-list-entry_en.pdf"},
    {"id":"31875","name":"Template - Framework for a correlation table (notice to applicants: Common Technical Document (CTD)) for active-substance master files / part 2 in CTD format for dossiers for veterinary medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-22T15:30:00Z","last_updated_date":"2012-05-22T15:30:00Z","reference_number":"EMA/115282/2012","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-framework-correlation-table-notice-applicants-common-technical-document-ctd-active-substance-master-files-part-2-ctd-format-dossiers-veterinary-medicinal-products_en.pdf"},
    {"id":"31881","name":"Annex 3 Response Questionnaire - Financial - EMA-2012-09-IF","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"EMA/687094/2011","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-3-response-questionnaire-financial-ema-2012-09-if_en.xls"},
    {"id":"31889","name":"Risk management plan  (RMP) assessment report sub-template for type II variations and  periodic safety update reports (PSURs)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:00:00Z","last_updated_date":"2018-09-18T17:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/risk-management-plan-rmp-assessment-report-sub-template-type-ii-variations-and-periodic-safety-update-reports-psurs_en.docx"},
    {"id":"32045","name":"Template to be used to notify the European Medicines Agency and concerned Member States of 'withdrawn products'","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-10-31T15:00:00Z","last_updated_date":"2022-03-21T08:41:00Z","reference_number":"EMA/445787/2013 Rev.4 Corr.","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-be-used-notify-european-medicines-agency-and-concerned-member-states-withdrawn-products_en.xlsx"},
    {"id":"32062","name":"Ancillary - Day 180 JAR Quality template rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:26:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-day-180-jar-quality-template-rev1016_en.doc"},
    {"id":"32083","name":"Eudralink account request form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-10-22T02:00:00Z","last_updated_date":"2010-10-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/eudralink-account-request-form_en.doc"},
    {"id":"32089","name":"Submission of comments on The European Medicines Agency Road Map to 2015: The Agency’s Contribution to Science, Medicines, Health","type":"template-form","status":"unknown","consultation_date":"2010-01-26 - 2010-04-30","first_published_date":"2010-01-26T02:00:00Z","last_updated_date":"2010-01-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-european-medicines-agency-road-map-2015-agencys-contribution-science-medicines-health_en.doc"},
    {"id":"32266","name":"Checklist for the submission of product information annexes and Annex A (if applicable) for minor procedures without linguistic review - human","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-12-16T01:00:00Z","last_updated_date":"2025-07-15T16:30:00Z","reference_number":"EMA/749945/2015 Rev.7","document_url":"https://www.ema.europa.eu/en/documents/template-form/checklist-submission-product-information-annexes-annex-if-applicable-minor-procedures-without-linguistic-review-human_en.doc"},
    {"id":"32307","name":"Notification of discontinuation of an agreed PIP decision","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-04-02T11:09:00Z","last_updated_date":"2023-12-19T11:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/notification-discontinuation-agreed-pip-decision_en.doc"},
    {"id":"32863","name":"QRD PSUR annex IV template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-03-19T17:45:00Z","last_updated_date":"2025-08-18T16:45:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-psur-annex-iv-template_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-psur-annex-iv-template_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-psur-annex-iv-template_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-psur-annex-iv-template_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-psur-annex-iv-template_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-psur-annex-iv-template_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-psur-annex-iv-template_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-psur-annex-iv-template_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-psur-annex-iv-template_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-psur-annex-iv-template_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-psur-annex-iv-template_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-psur-annex-iv-template_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-psur-annex-iv-template_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-psur-annex-iv-template_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-psur-annex-iv-template_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-psur-annex-iv-template_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-psur-annex-iv-template_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-psur-annex-iv-template_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-psur-annex-iv-template_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-psur-annex-iv-template_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-psur-annex-iv-template_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-psur-annex-iv-template_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-psur-annex-iv-template_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-psur-annex-iv-template_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-psur-annex-iv-template_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-psur-annex-iv-template_no.docx"}},
    {"id":"32925","name":"Appendix - checklist for the transfer of PMF to a new Holder","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-10-07T02:09:21Z","last_updated_date":"2009-10-07T02:09:21Z","reference_number":"EMEA/63698/2007","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-checklist-transfer-pmf-new-holder_en.doc"},
    {"id":"32972","name":"Pre qualification questionnaire - excel format","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-04-28T02:00:00Z","last_updated_date":"2008-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/pre-qualification-questionnaire-excel-format_en.xls"},
    {"id":"33076","name":"Registration form - Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-08-16T19:00:00Z","last_updated_date":"2016-08-16T19:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-committee-advanced-therapies-cat-workshop-scientific-and-regulatory-challenges-genetically-modified-cell-based-cancer-immunotherapy-products_en.docx"},
    {"id":"33230","name":"Transfer of MA templates - Attachment 5 (Superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-06-28T10:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-ma-templates-attachment-5-superseded_en.doc"},
    {"id":"33254","name":"Scientific recommendation on classification of advanced therapy medicinal products: Request form and briefing information Article 17 - Regulation (EC) No 1394/2007","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-05-26T03:00:00Z","last_updated_date":"2011-03-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/scientific-recommendation-classification-advanced-therapy-medicinal-products-request-form-and-briefing-information-article-17-regulation-ec-no-13942007_en.doc"},
    {"id":"33384","name":"Template - Business pipeline - Rapporteur update on type II variations and line extensions - United Kingdom","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-03-15T01:00:00Z","last_updated_date":"2018-03-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-business-pipeline-rapporteur-update-type-ii-variations-and-line-extensions-united-kingdom_en.xlsx"},
    {"id":"33690","name":"Scientific advice request template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-04-05T16:38:00Z","last_updated_date":"2020-10-19T11:00:00Z","reference_number":"EMA/CVMP/SAWP/11888/2020","document_url":"https://www.ema.europa.eu/en/documents/template-form/scientific-advice-request-template_en.docx"}    {"id":"33694","name":"Transfer of MA templates Attachment 7 (Superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-09-21T02:00:00Z","last_updated_date":"2024-06-28T10:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/transfer-ma-templates-attachment-7-superseded_en.doc"},
    {"id":"33982","name":"Submission of comments on 'good pharmacovigilance practices module IV – Pharmacovigilance audits' (EMA/228028/2012)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-07-26T18:15:02Z","last_updated_date":"2012-07-26T18:15:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-iv-pharmacovigilance-audits-ema2280282012_en.doc"},
    {"id":"34201","name":"Request for accelerated assessment pursuant to Article 14(9) of Regulation (EC) No 726/2004' to be replaced by 'Briefing Note and Recommendations on a Request for Accelerated Assessment Pursuant to Article 14 (9) of Regulation (EC) No 726/2004 - Template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-11-03T16:35:00Z","last_updated_date":"2021-02-17T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-accelerated-assessment-pursuant-article-149-regulation-ec-no-7262004-be-replaced-briefing-note-and-recommendations-request-accelerated-assessment-pursuant-article-14-9-regulation-ec-no-7262004_en.docx"},
    {"id":"34316","name":"Annexes to the application form for certification of quality and non-clinical data for Advanced Therapy Medicinal Products developed by Small and Medium-sized Enterprises (SME)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-02-15T01:00:00Z","last_updated_date":"2010-02-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annexes-application-form-certification-quality-and-non-clinical-data-advanced-therapy-medicinal-products-developed-small-and-medium-sized-enterprises-sme_en.doc"},
    {"id":"34428","name":"Template for comments - Public consultation regarding the request to the European Medicines Agency from the European Commission for a scientific opinion regarding the risks to vultures and other necrophagous bird populat...","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-09-12T19:30:00Z","last_updated_date":"2014-09-12T19:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-comments-public-consultation-regarding-request-european-medicines-agency-european-commission-scientific-opinion-regarding-risks-vultures-and-other-necrophagous-bird-populat_en.doc"},
    {"id":"34454","name":"CHMP and rapporteurs' joint assessment report template and assessment on similarity rev. 07.18","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-05-28T13:00:00Z","last_updated_date":"2018-07-26T11:30:00Z","reference_number":"Rev. 07.18","document_url":"https://www.ema.europa.eu/en/documents/template-form/chmp-and-rapporteurs-joint-assessment-report-template-and-assessment-similarity-rev-0718_en.doc"},
    {"id":"34461","name":"QRD Appendix III to the Quality Review of Documents templates for human medicinal products (Cover page)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-07-31T02:00:00Z","last_updated_date":"2026-03-25T11:37:00Z","reference_number":"EMEA/29277/2003 v.6","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-appendix-iii-quality-review-documents-templates-human-medicinal-products-cover-page_en.docx"},
    {"id":"34596","name":"Registration form - MUMS/Limited Markets - Info Day","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-08-25T02:09:21Z","last_updated_date":"2009-08-25T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-mumslimited-markets-info-day_en.pdf"},
    {"id":"34826","name":"Annex . Line listing of all the studies included in the development program","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-03-30T02:09:21Z","last_updated_date":"2009-03-30T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-line-listing-all-studies-included-development-program_en.doc"},
    {"id":"34879","name":"Pre-qualification questionnaire - Building maintenance - EMA/2012/28/IS","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-10-18T12:40:00Z","last_updated_date":"2012-10-18T12:40:00Z","reference_number":"EMA/223694/2012","document_url":"https://www.ema.europa.eu/en/documents/template-form/pre-qualification-questionnaire-building-maintenance-ema201228is_en.doc"},
    {"id":"34896","name":"Ancillary - CHMP Day 180 LoQ rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:30:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-chmp-day-180-loq-rev1016_en.doc"},
    {"id":"34901","name":"Plasma master file timetable: 30-day - Period 2024-2026","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-03-04T00:09:00Z","last_updated_date":"2024-08-20T14:38:00Z","reference_number":"EMA/378805/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/plasma-master-file-timetable-30-day-period-2024-2026_en.doc"},
    {"id":"34980","name":"Evaluation of conflicts of interests form (in relation to specific European Medicines Agency activity)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2006-09-25T02:09:21Z","last_updated_date":"2011-07-11T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/evaluation-conflicts-interests-form-relation-specific-european-medicines-agency-activity_en.pdf"},
    {"id":"35033","name":"Submission of comments on good pharmacovigilance practices: Module VIII – Post-authorisation safety studies (EMA/813938/2011)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T13:20:00Z","last_updated_date":"2012-02-22T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-viii-post-authorisation-safety-studies-ema8139382011_en.doc"},
    {"id":"35044","name":"Statement of expenses for candidate reimbursement","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-08-10T15:09:00Z","last_updated_date":"2018-08-10T15:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/statement-expenses-candidate-reimbursement_en.xlsm"},
    {"id":"35106","name":"PRAC periodic-safety-update-report assessment report template NAP only","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-01-11T16:45:00Z","last_updated_date":"2016-12-19T17:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/prac-periodic-safety-update-report-assessment-report-template-nap-only_en.docx"},
    {"id":"35538","name":"Application form for the involvement of patients’ and consumers’ organisations in the activities of the European Medicines Agency","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-07-09T02:00:00Z","last_updated_date":"2021-01-15T09:46:00Z","reference_number":"EMA/520442/2010 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-involvement-patients-and-consumers-organisations-activities-european-medicines-agency_en.doc"},
    {"id":"35738","name":"Pre-qualification questionnaire - Security consultancy services - EMA/2012/19/IS","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-10-12T10:59:00Z","last_updated_date":"2012-10-12T10:59:00Z","reference_number":"EMA/2012/19/IS","document_url":"https://www.ema.europa.eu/en/documents/template-form/pre-qualification-questionnaire-security-consultancy-services-ema201219is_en.doc"},
    {"id":"35759","name":"Generics - Hybrids - Day 150 or Day 195 joint report assessment report - Overview and D180 list of outstanding issues template with guidance - Rev. 05. 21","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-25T00:09:00Z","last_updated_date":"2021-06-25T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/generics-hybrids-day-150-or-day-195-joint-report-assessment-report-overview-and-d180-list-outstanding-issues-template-guidance-rev-05-21_en.docx"},
    {"id":"35929","name":"Cover letter template for notification of \"withdrawn products\" by marketing authorisation holders","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-10-31T15:00:00Z","last_updated_date":"2013-10-31T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/cover-letter-template-notification-withdrawn-products-marketing-authorisation-holders_en.doc"},
    {"id":"35983","name":"Ancillary - Day 80 Overview template rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:30:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-day-80-overview-template-rev1016_en.doc"},
    {"id":"36012","name":"Annex 11 Financial identification form - EMA-2012-09-IF","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T11:00:00Z","last_updated_date":"2012-02-27T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-11-financial-identification-form-ema-2012-09-if_en.xls"},
    {"id":"36044","name":"Template for submission of comments for standard lists for EudraVigilance Veterinary (EVVet)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-07-19T02:00:00Z","last_updated_date":"2013-06-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-comments-standard-lists-eudravigilance-veterinary-evvet_en.doc"},
    {"id":"36066","name":"Submission of comments on 'good pharmacovigilance practices module XV – Safety communication' (EMA/118465/2012)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-07-26T18:15:00Z","last_updated_date":"2012-07-26T18:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-xv-safety-communication-ema1184652012_en.doc"},
    {"id":"36104","name":"Day 150 or Day 195 joint response assessment report with guidance - Overview and list of outstanding issues template - Rev. 10.23","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-09-01T02:09:00Z","last_updated_date":"2023-10-20T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-150-or-day-195-joint-response-assessment-report-guidance-overview-list-outstanding-issues-template-rev-1023_en.docx"},
    {"id":"36151","name":"Veterinary Scientific Advice Workshop - Registration form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-05-07T02:09:21Z","last_updated_date":"2008-05-07T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/veterinary-scientific-advice-workshop-registration-form_en.pdf"},
    {"id":"36480","name":"Certification evaluation report","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-12-17T15:50:00Z","last_updated_date":"2014-12-17T15:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/certification-evaluation-report_en.doc"},
    {"id":"36578","name":"Guideline on good pharmacovigilance practices (GVP): Annex II – Templates: Direct Healthcare Professional Communication (DHPC) (superseded)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T01:00:00Z","last_updated_date":"2013-01-24T01:00:00Z","reference_number":"EMA/36988/2013","document_url":"https://www.ema.europa.eu/en/documents/template-form/guideline-good-pharmacovigilance-practices-gvp-annex-ii-templates-direct-healthcare-professional-communication-dhpc-superseded_en.pdf"},
    {"id":"36984","name":"Submission of comments on good pharmacovigilance practices: Module II – Pharmacovigilance system master file (EMA/816573/2011)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T13:20:00Z","last_updated_date":"2012-02-22T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file-ema8165732011_en.doc"},
    {"id":"37075","name":"Second EMEA - EGA Info Day; Generic and Biosimilar Medicines in the Centralised Procedure - Registration form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-07-24T02:09:21Z","last_updated_date":"2008-07-24T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/second-emea-ega-info-day-generic-and-biosimilar-medicines-centralised-procedure-registration-form_en.pdf"},
    {"id":"37146","name":"Submission form for comments on Policy 70: Publication and access to clinical-trial data","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2013-06-24T16:00:00Z","last_updated_date":"2013-06-24T16:00:00Z","reference_number":"EMA/240810/2013","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-form-comments-policy-70-publication-and-access-clinical-trial-data_en.doc"},
    {"id":"37166","name":"Formatting check list for the product information (annexes) in PDF format - veterinary","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-02-07T01:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"EMA/793981/2010 v.1.0","document_url":"https://www.ema.europa.eu/en/documents/template-form/formatting-check-list-product-information-annexes-pdf-format-veterinary_en.doc"},
    {"id":"37200","name":"Applicant’s consent to share assessment and inspection documents with non-European Union (EU) regulatory authorities template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2016-03-30T18:30:00Z","last_updated_date":"2016-03-30T18:30:00Z","reference_number":"EMA/801202/2015","document_url":"https://www.ema.europa.eu/en/documents/template-form/applicants-consent-share-assessment-and-inspection-documents-non-european-union-eu-regulatory-authorities-template_en.doc"},
    {"id":"37267","name":"Ancillary - Day 180 JAR Overview template rev.10.16","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-05-10T12:00:00Z","last_updated_date":"2016-11-08T11:26:00Z","reference_number":"rev.10.16","document_url":"https://www.ema.europa.eu/en/documents/template-form/ancillary-day-180-jar-overview-template-rev1016_en.doc"},
    {"id":"37323","name":"Registration form - European Medicines Agency/International Federation for Animal Health-Europe info day 2015","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-01-22T17:00:00Z","last_updated_date":"2015-01-22T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-european-medicines-agencyinternational-federation-animal-health-europe-info-day-2015_en.doc"},
    {"id":"37566","name":"QRD Appendix I - Statements for use in section 4.6 'pregnancy and lactation' of the summary of product characteristics","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-07-01T02:00:00Z","last_updated_date":"2026-03-25T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics_no.docx"}},
    {"id":"37570","name":"Appendix 1 - Pharmacovigilance inspection report template (Vet)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-02-02T16:55:00Z","last_updated_date":"2016-04-04T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-1-pharmacovigilance-inspection-report-template-vet_en.doc"},
    {"id":"37586","name":"Flyer and registration form for the annual European Medicines Agency review of the year and outlook for 2011 and beyond","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-10-26T02:00:00Z","last_updated_date":"2010-10-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/flyer-and-registration-form-annual-european-medicines-agency-review-year-and-outlook-2011-and-beyond_en.pdf"},
    {"id":"37815","name":"Template letter of intent work sharing procedure","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-12-17T01:00:00Z","last_updated_date":"2020-10-14T10:30:00Z","reference_number":"EMA/293212/2017","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-letter-intent-work-sharing-procedure_en.docx"},
    {"id":"37927","name":"Registration form - Regulatory workshop on clinical trials designs in neuromyelitis optica and spectrum disorders","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-07-07T16:00:00Z","last_updated_date":"2014-07-07T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-regulatory-workshop-clinical-trials-designs-neuromyelitis-optica-and-spectrum-disorders_en.pdf"},
    {"id":"37976","name":"Enpr-EMA networks funding sources form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-11-09T16:55:00Z","last_updated_date":"2021-03-12T14:54:00Z","reference_number":"EMA/571898/2015","document_url":"https://www.ema.europa.eu/en/documents/template-form/enpr-ema-networks-funding-sources-form_en.doc"},
    {"id":"38030","name":"Submission of comments on 'good pharmacovigilance practices module III – Pharmacovigilance inspections' (EMA/119871/2012)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-06-27T14:57:56Z","last_updated_date":"2012-06-27T14:57:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-good-pharmacovigilance-practices-module-iii-pharmacovigilance-inspections-ema1198712012_en.doc"},
    {"id":"38661","name":"CHMP-CAT-PRAC member comments on rapporteur’s reports","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-07-03T16:30:00Z","last_updated_date":"2021-07-12T17:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/chmp-cat-prac-member-comments-rapporteurs-reports_en.docx"},
    {"id":"38887","name":"Appendix 2 - Pharmacovigilance inspection overview template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-02-02T16:55:00Z","last_updated_date":"2015-02-02T16:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-2-pharmacovigilance-inspection-overview-template_en.doc"},
    {"id":"39004","name":"Annex 1 -  Report template for the review of a European Union herbal monograph","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-08-20T12:00:00Z","last_updated_date":"2022-11-22T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-1-report-template-review-european-union-herbal-monograph_en.docx"},
    {"id":"39110","name":"Application form - User guide for the electronic application form for a marketing authorisation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-07-13T14:00:00Z","last_updated_date":"2023-10-02T17:00:00Z","reference_number":"CMDh/332/2017/Rev.4","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-user-guide-electronic-application-form-marketing-authorisation_en.pdf"},
    {"id":"39368","name":"Application form for variation to Article 58 CHMP scientific opinion","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-02-07T10:05:00Z","last_updated_date":"2017-09-04T18:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-variation-article-58-chmp-scientific-opinion_en.doc"},
    {"id":"39500","name":"EMEA template for the cover letter submission of PSURs data","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2009-06-19T02:09:21Z","last_updated_date":"2009-06-19T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/emea-template-cover-letter-submission-psurs-data_en.doc"},
    {"id":"39588","name":"Appendix 2 - PhV inspection overview template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-07-27T02:00:00Z","last_updated_date":"2014-07-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-2-phv-inspection-overview-template_en.doc"},
    {"id":"39620","name":"QRD product-information annotated template (English) version 10.4 - highlighted","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"1997-12-03T01:09:00Z","last_updated_date":"2024-02-29T12:40:00Z","reference_number":"10.4","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-product-information-annotated-template-english-version-104-highlighted_en.pdf"},
    {"id":"39708","name":"Proposed invented name(s) justification form for human medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2006-07-01T02:00:00Z","last_updated_date":"2006-07-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/proposed-invented-names-justification-form-human-medicinal-products_en.doc"},
    {"id":"39724","name":"Application form for a post-consultation procedure on an ancillary medicinal substance in a medical device","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-27T16:25:00Z","last_updated_date":"2021-03-30T17:20:00Z","reference_number":"EMA/75252/2020 ","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-post-consultation-procedure-ancillary-medicinal-substance-medical-device_en.doc"},
    {"id":"39738","name":"Application form: Call for expression of interest - EMA/2012/59/PD \"Provision of access to databases / electronic resources\"","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-12-17T01:00:00Z","last_updated_date":"2015-07-14T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-call-expression-interest-ema201259pd-provision-access-databases-electronic-resources_en.pdf"},
    {"id":"39801","name":"Summary of quality differences form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-01-19T15:00:00Z","last_updated_date":"2015-01-19T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/summary-quality-differences-form_en.docx"},
    {"id":"39819","name":"Submission of general comments on good pharmacovigilance practices","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-02-22T13:20:00Z","last_updated_date":"2012-02-22T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-general-comments-good-pharmacovigilance-practices_en.doc"},
    {"id":"39980","name":"Fraud reporting process and reporting template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-03-22T10:58:00Z","last_updated_date":"2017-03-22T10:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/fraud-reporting-process-and-reporting-template_en.pdf"},
    {"id":"40065","name":"Marketing authorisation holder electronic reaction monitoring report example","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-02T18:10:00Z","last_updated_date":"2017-09-25T12:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/marketing-authorisation-holder-electronic-reaction-monitoring-report-example_en.xlsx"},
    {"id":"40257","name":"Quality Review of Documents (QRD) form for submission and assessment of user testing bridging proposals","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-12-22T10:45:00Z","last_updated_date":"2015-07-09T12:40:00Z","reference_number":"EMA/355722/2014  Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/template-form/quality-review-documents-qrd-form-submission-and-assessment-user-testing-bridging-proposals_en.doc"},
    {"id":"40386","name":"GCP inspections template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-09-17T14:29:00Z","last_updated_date":"2015-09-17T14:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/gcp-inspections-template_en.doc"},
    {"id":"40692","name":"Application form for orphan-medicinal-product designation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2011-11-24T01:00:00Z","last_updated_date":"2017-09-26T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-orphan-medicinal-product-designation_en.pdf"},
    {"id":"40695","name":"Registration form - 2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-04-25T16:00:00Z","last_updated_date":"2018-04-25T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/registration-form-2018-annual-workshop-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf"},
    {"id":"40769","name":"Pre-submission interaction letter of intent form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-01-04T01:00:00Z","last_updated_date":"2018-10-04T16:15:00Z","reference_number":"Version 1.0.4","document_url":"https://www.ema.europa.eu/en/documents/template-form/pre-submission-interaction-letter-intent-form_en.pdf"},
    {"id":"40867","name":"One year extension of data protection for new indication of well-established use product assessment report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:00:00Z","last_updated_date":"2018-09-18T17:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/one-year-extension-data-protection-new-indication-well-established-use-product-assessment-report-template_en.docx"},
    {"id":"41110","name":"Template and recommended format for list of references","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2009-07-16T02:00:00Z","last_updated_date":"2014-11-17T15:30:00Z","reference_number":"EMEA/HMPC/574496/2008 Rev. 2 Corr.","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-and-recommended-format-list-references_en.doc"},
    {"id":"41174","name":"Qualified Person’s declaration concerning good manufacturing practice (GMP) compliance of the active substance manufacture “The QP declaration template”","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-06-04T12:10:00Z","last_updated_date":"2014-06-04T12:10:00Z","reference_number":"EMA/334808/2014","document_url":"https://www.ema.europa.eu/en/documents/template-form/qualified-persons-declaration-concerning-good-manufacturing-practice-gmp-compliance-active-substance-manufacture-qp-declaration-template_en.doc"},
    {"id":"41229","name":"Product information templates: Veterinary medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2005-08-11T02:00:00Z","last_updated_date":"2005-08-11T02:00:00Z","reference_number":"EMEA/265568/2005","document_url":"https://www.ema.europa.eu/en/documents/template-form/product-information-templates-veterinary-medicinal-products_en.pdf"},
    {"id":"41246","name":"Template for a request for amendments of or addition of active substances or combinations of active substances to the European Union reference-date list","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2012-10-01T14:45:00Z","last_updated_date":"2026-03-17T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-request-amendments-or-addition-active-substances-or-combinations-active-substances-european-union-reference-date-list_en.docx"},
    {"id":"41440","name":"Template PRAC assessment report of an non-interventional imposed PASS final study report","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-02-10T17:45:00Z","last_updated_date":"2026-02-04T14:22:00Z","reference_number":"EMA/699686/2015 ","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-prac-assessment-report-non-interventional-imposed-pass-final-study-report_en.docx"},
    {"id":"41741","name":"Appendix 3 - Pharmacovigilance inspection information collection template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-02-02T16:55:00Z","last_updated_date":"2015-02-02T16:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-3-pharmacovigilance-inspection-information-collection-template_en.doc"},
    {"id":"41803","name":"Sponsor's report on the maintenance of the designation criteria at the time of marketing authorisation for a designated orphan-medicinal-product","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-02-03T13:15:00Z","last_updated_date":"2024-09-04T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/sponsors-report-maintenance-designation-criteria-time-marketing-authorisation-designated-orphan-medicinal-product_en.doc"},
    {"id":"41812","name":"Common European Medicines Agency / Food and Drug Administration application form for orphan-medicinal-product-designation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2008-11-24T01:00:00Z","last_updated_date":"2017-09-26T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/common-european-medicines-agency-food-and-drug-administration-application-form-orphan-medicinal-product-designation_en.pdf"},
    {"id":"41866","name":"Statement of expenses for candidates","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-08-04T11:00:00Z","last_updated_date":"2018-06-06T12:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/statement-expenses-candidates_en.doc"},
    {"id":"41910","name":"EMA fees query form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2015-04-20T13:50:00Z","last_updated_date":"2015-05-18T12:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/ema-fees-query-form_en.pdf"},
    {"id":"42018","name":"Annual renewal assessment report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-08-04T15:00:00Z","last_updated_date":"2017-08-04T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annual-renewal-assessment-report-template_en.docx"},
    {"id":"42145","name":"Change of applicant - Cover letter standard text (human)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-09-28T16:00:00Z","last_updated_date":"2018-09-28T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/change-applicant-cover-letter-standard-text-human_en.docx"},
    {"id":"42159","name":"Marketing authorisation application (MAA) - pre-submission interactions form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-10-01T16:30:00Z","last_updated_date":"2025-08-06T11:20:05Z","reference_number":"EMA/193818/2025","document_url":"https://www.ema.europa.eu/en/documents/template-form/marketing-authorisation-application-maa-pre-submission-interactions-form_en.docx"},
    {"id":"42161","name":"Change of applicant checklist - pre-submission guidance (human)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-10-02T17:13:00Z","last_updated_date":"2020-07-20T10:21:00Z","reference_number":"EMA/639036/2018 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/template-form/change-applicant-checklist-pre-submission-guidance-human_en.xlsx"},
    {"id":"42165","name":"Change of applicant checklist - pre-submission guidance (veterinary)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-10-01T18:33:00Z","last_updated_date":"2022-05-03T13:48:00Z","reference_number":"EMA/603587/2018","document_url":"https://www.ema.europa.eu/en/documents/template-form/change-applicant-checklist-pre-submission-guidance-veterinary_en.pdf"},
    {"id":"42166","name":"Change of applicant - Cover letter standard text (veterinary)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-10-01T18:38:00Z","last_updated_date":"2022-05-03T13:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/change-applicant-cover-letter-standard-text-veterinary_en.docx"},
    {"id":"42175","name":"Plasma master file timetable: 90-day – Period 2024-2026","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-10-02T18:21:00Z","last_updated_date":"2024-08-20T14:41:00Z","reference_number":"EMA/378893/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/plasma-master-file-timetable-90-day-period-2024-2026_en.doc"},
    {"id":"43379","name":"Guidance on the format of the risk management plan (RMP) in the EU - in integrated format (Rev. 2)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2017-03-30T10:30:00Z","last_updated_date":"2019-01-17T09:33:00Z","reference_number":"EMA/PRAC/613102/2015 Rev.2 accompanying GVP Module V Rev.2","document_url":"https://www.ema.europa.eu/en/documents/template-form/guidance-format-risk-management-plan-rmp-eu-integrated-format-rev-2_en.pdf"},
    {"id":"43595","name":"Parallel distribution user admin affiliation template letter","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T08:30:00Z","last_updated_date":"2019-02-01T08:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/parallel-distribution-user-admin-affiliation-template-letter_en.doc"},
    {"id":"43655","name":"Explanatory note - Letter of representation for procedure under Article 5(3) of Regulation No. 726/20","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-02-07T10:59:00Z","last_updated_date":"2019-02-07T10:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/explanatory-note-letter-representation-procedure-under-article-53-regulation-no-72620_en.docx"},
    {"id":"43679","name":"(Suspected) falsified medicinal product report","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-02-08T11:30:00Z","last_updated_date":"2019-02-08T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/suspected-falsified-medicinal-product-report_en.pdf"},
    {"id":"43680","name":"How to use the (suspected) falsified medicinal product report template to report a case of (suspected) falsified medicinal product to European Medicines Agency","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-02-08T11:16:00Z","last_updated_date":"2019-02-08T11:16:00Z","reference_number":"EMA/538719/2018","document_url":"https://www.ema.europa.eu/en/documents/template-form/how-use-suspected-falsified-medicinal-product-report-template-report-case-suspected-falsified-medicinal-product-european-medicines-agency_en.pdf"},
    {"id":"43681","name":"Dossier administrative validation checklist for initial marketing authorisation applications by applicants","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-02-08T17:00:00Z","last_updated_date":"2025-09-08T15:13:00Z","reference_number":" EMA/573531/2018 Rev 5","document_url":"https://www.ema.europa.eu/en/documents/template-form/dossier-admin-validation-checklist-initial_en.zip"},
    {"id":"43707","name":"Information required for identification of a need for pre-authorisation GCP inspections","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-02-13T17:11:00Z","last_updated_date":"2022-06-20T11:30:00Z","reference_number":"Revision 1.4","document_url":"https://www.ema.europa.eu/en/documents/template-form/information-required-identification-need-pre-authorisation-gcp-inspections_en.doc"},
    {"id":"43727","name":"Delegate financial identification form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-02-14T14:44:00Z","last_updated_date":"2019-02-27T15:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/delegate-financial-identification-form_en.pdf"},
    {"id":"43874","name":"Joint audit programme for EEA GMP inspectorates: Follow-up on CAPA implementation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-02-22T11:30:00Z","last_updated_date":"2019-02-22T11:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/joint-audit-programme-eea-gmp-inspectorates-follow-capa-implementation_en.docx"},
    {"id":"43885","name":"Template for information exchange for the preparation of the assessment report supporting the establishment of European Union monographs and European Union list entries - Revision 2","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-02-25T10:33:00Z","last_updated_date":"2019-02-25T10:33:00Z","reference_number":"EMA/HMPC/137093/2006 Rev.2 ","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-information-exchange-preparation-assessment-report-supporting-establishment-european-union-monographs-and-european-union-list-entries-revision-2_en.doc"},
    {"id":"43974","name":"Template - Notification of request for a time-limited exemption to continue batch control testing in the United Kingdom (UK) after UK’s withdrawal from the Union for a centrally authorised medicinal product","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-03-04T17:03:00Z","last_updated_date":"2019-03-04T17:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-notification-request-time-limited-exemption-continue-batch-control-testing-united-kingdom-uk-after-uks-withdrawal-union-centrally-authorised-medicinal-product_en.docx"},
    {"id":"44055","name":"Template for information exchange for the preparation of the assessment report supporting the establishment of European Union monographs and European Union list entries - Revision 2 (PDF)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-03-19T15:34:00Z","last_updated_date":"2019-03-19T15:34:00Z","reference_number":"EMA/HMPC/137093/2006 Rev. 2","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-information-exchange-preparation-assessment-report-supporting-establishment-european-union-monographs-and-european-union-list-entries-revision-2-pdf_en.pdf"},
    {"id":"44908","name":"QRD product-information template version 10.4 - highlighted","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T10:43:00Z","last_updated_date":"2024-02-29T16:00:01Z","reference_number":"10.4","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-product-information-template-version-104-highlighted_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-product-information-template-version-104-highlighted_bg.pdf","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-product-information-template-version-104-highlighted_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-product-information-template-version-104-highlighted_cs.pdf","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-product-information-template-version-104-highlighted_da.pdf","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-product-information-template-version-104-highlighted_de.pdf","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-product-information-template-version-104-highlighted_et.pdf","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-product-information-template-version-104-highlighted_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-product-information-template-version-104-highlighted_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-product-information-template-version-104-highlighted_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-product-information-template-version-104-highlighted_hr.pdf","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-product-information-template-version-104-highlighted_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-product-information-template-version-104-highlighted_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-product-information-template-version-104-highlighted_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-product-information-template-version-104-highlighted_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-product-information-template-version-104-highlighted_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-product-information-template-version-104-highlighted_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-product-information-template-version-104-highlighted_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-product-information-template-version-104-highlighted_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-product-information-template-version-104-highlighted_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-product-information-template-version-104-highlighted_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-product-information-template-version-104-highlighted_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-product-information-template-version-104-highlighted_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-product-information-template-version-104-highlighted_sv.pdf","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-product-information-template-version-104-highlighted_is.pdf","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-product-information-template-version-104-highlighted_no.pdf"}},
    {"id":"45804","name":"Step 1 - No risk identified response template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-10-28T10:00:00Z","last_updated_date":"2021-02-01T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/step-1-no-risk-identified-response-template_en.docx"},
    {"id":"45805","name":"Step 1 - Risk identified response template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-10-28T10:00:00Z","last_updated_date":"2021-02-01T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/step-1-risk-identified-response-template_en.docx"},
    {"id":"45806","name":"Step 1 - Risk identified response template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-10-28T10:00:00Z","last_updated_date":"2019-10-28T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/step-1-risk-identified-response-template_en.xlsx"},
    {"id":"45807","name":"Step 2 - No nitrosamine detected response template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-10-28T10:00:00Z","last_updated_date":"2022-08-09T10:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/step-2-no-nitrosamine-detected-response-template_en.docx"},
    {"id":"45808","name":"Step 2 - Nitrosamine detected above acceptable intake or new nitrosamine detected response template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-10-28T10:00:00Z","last_updated_date":"2021-07-02T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/step-2-nitrosamine-detected-above-acceptable-intake-or-new-nitrosamine-detected-response-template_en.xlsx"},
    {"id":"45809","name":"Step 2 - Nitrosamine detected response template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-10-28T10:00:00Z","last_updated_date":"2023-07-28T10:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/step-2-nitrosamine-detected-response-template_en.docx"},
    {"id":"46249","name":"Open call for data on use of antimicrobials  in animals - questionaire","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2019-12-05T18:08:00Z","last_updated_date":"2019-12-05T18:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/open-call-data-use-antimicrobials-animals-questionaire_en.xlsx"}    {"id":"46420","name":"HMA-EMA Joint Big Data Taskforce Phase II report: Annex III - Blank assessment fiche","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T10:30:00Z","last_updated_date":"2020-01-20T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/hma-ema-joint-big-data-taskforce-phase-ii-report-annex-iii-blank-assessment-fiche_en.docx"},
    {"id":"46422","name":"HMA-EMA Joint Big Data Taskforce Phase II report: Annex IV - Assessment fiches","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-01-20T10:30:00Z","last_updated_date":"2020-01-20T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/hma-ema-joint-big-data-taskforce-phase-ii-report-annex-iv-assessment-fiches_en.docx"},
    {"id":"46794","name":"Plasma master file timetable: 60-day - Period 2024-2026","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-02-18T15:39:00Z","last_updated_date":"2024-08-20T14:40:00Z","reference_number":"EMA/378899/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/plasma-master-file-timetable-60-day-period-2024-2026_en.doc"},
    {"id":"47501","name":"Template for pharmacovigilance inspection information sharing","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-04-28T12:57:00Z","last_updated_date":"2020-04-28T12:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-pharmacovigilance-inspection-information-sharing_en.doc"},
    {"id":"47502","name":"Template for pharmacovigilance assessment information sharing","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-04-28T13:00:00Z","last_updated_date":"2024-03-21T10:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-pharmacovigilance-assessment-information-sharing_en.doc"},
    {"id":"47687","name":"Innovation Task Force (ITF) briefing meeting request form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-05-18T12:35:00Z","last_updated_date":"2026-03-19T13:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/innovation-task-force-itf-briefing-meeting-request-form_en.docx"},
    {"id":"48016","name":"CHMP and Rapporteurs' assessment report template on Similarity Rev. 01.25","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2014-05-28T10:28:00Z","last_updated_date":"2025-01-22T14:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/chmp-rapporteurs-assessment-report-template-similarity-rev-0125_en.docx"},
    {"id":"48210","name":"Template for submission of a notification for a Covid-19 exceptional change management process (ECMP) ","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-07-03T12:00:00Z","last_updated_date":"2020-07-03T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-notification-covid-19-exceptional-change-management-process-ecmp_en.docx"},
    {"id":"48886","name":"Submission of comments on ‘Guideline on registry-based studies’ (EMA/484811/2020)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-09-24T12:00:00Z","last_updated_date":"2020-09-24T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-guideline-registry-based-studies-ema4848112020_en.doc"},
    {"id":"49170","name":"Form: Notification of change for paediatric procedures","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-11-03T17:33:00Z","last_updated_date":"2020-11-03T17:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/form-notification-change-paediatric-procedures_en.pdf"},
    {"id":"49413","name":"Declaration of intention to engage in an occupational activity after leaving the European Medicines Agency","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-12-01T13:45:00Z","last_updated_date":"2021-02-16T15:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/declaration-intention-engage-occupational-activity-after-leaving-european-medicines-agency_en.docx"},
    {"id":"49619","name":"ATMP classification - administrative information sheet","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-12-17T17:27:00Z","last_updated_date":"2020-12-17T17:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/atmp-classification-administrative-information-sheet_en.xlsx"},
    {"id":"49771","name":"Summary of main efficacy results - Module 5.3.5 of the dossier administrative validation checklist for initial marketing authorisation applications by applicants","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-01-11T11:59:00Z","last_updated_date":"2021-01-13T09:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/summary-main-efficacy-results-module-535-dossier-administrative-validation-checklist-initial-marketing-authorisation-applications-applicants_en.docx"},
    {"id":"49789","name":"Submission of comments on ‘Public Guidance on Parallel application for EU-M4all (Article 58) opinion and Centralised Marketing Authorisation procedure’","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-01-13T10:04:00Z","last_updated_date":"2021-01-13T10:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-public-guidance-parallel-application-eu-m4all-article-58-opinion-and-centralised-marketing-authorisation-procedure_en.doc"},
    {"id":"50114","name":"QRD product-information annotated template (Swedish) version 10.2 Rev.1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"1997-12-03T01:00:00Z","last_updated_date":"2021-02-09T11:13:00Z","reference_number":"10.2 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-product-information-annotated-template-swedish-version-102-rev1_en.pdf"},
    {"id":"50115","name":"QRD product-information annotated template (Finnish) version 10.2 Rev.1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"1997-12-03T01:00:00Z","last_updated_date":"2021-02-09T11:13:00Z","reference_number":"10.2 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-product-information-annotated-template-finnish-version-102-rev1_en.pdf"},
    {"id":"50660","name":"Pre-submission request form to the European Medicines Agency for veterinary medicinal product in accordance with Regulation (EU) 2019/6","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-03-22T09:55:00Z","last_updated_date":"2024-12-13T14:22:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/pre-submission-request-form-european-medicines-agency-veterinary-medicinal-product-accordance-regulation-eu-2019-6_en.docx"},
    {"id":"50999","name":"Mutual-recognition decentralised referral product information template (English) version 4.2 - highlighted","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-04-28T17:13:00Z","last_updated_date":"2021-04-28T17:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/mutual-recognition-decentralised-referral-product-information-template-english-version-42-highlighted_en.pdf"},
    {"id":"51068","name":"Declaration of interests form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-05-05T15:04:00Z","last_updated_date":"2021-05-05T15:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/declaration-interests-form_en.pdf"},
    {"id":"51897","name":"Programme and registration form - eXtended EudraVigilance Medicinal Product Dictionary training courses - September, October, November 2021","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-07-09T14:25:00Z","last_updated_date":"2021-07-09T14:25:00Z","reference_number":"Courses: #21583; #21584; #21585","document_url":"https://www.ema.europa.eu/en/documents/template-form/programme-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-training-courses-september-october-november-2021_en.pdf"},
    {"id":"51953","name":"QRD veterinary product-information annotated template (English) version 8.2","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2010-04-08T15:45:00Z","last_updated_date":"2020-12-21T15:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-veterinary-product-information-annotated-template-english-version-82_en.pdf"},
    {"id":"51987","name":"Download Market Report Current Status- Template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-07-23T11:36:00Z","last_updated_date":"2021-07-23T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/download-market-report-current-status-template_en.xlsx"},
    {"id":"52118","name":"Clinical Trial Information System (CTIS) structured data form - Initial application, additional Member State Concerned, (Multi trial) substantial modification, non-substantial modification, and Request for information (RFI)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-07-29T10:40:00Z","last_updated_date":"2025-11-07T15:51:00Z","reference_number":"EMA/343883/2021","document_url":"https://www.ema.europa.eu/en/documents/template-form/clinical-trial-information-system-ctis-structured-data-form-initial-application-additional-member-state-concerned-substantial-modification-non-substantial-modification_en.xlsx"},
    {"id":"52120","name":"Clinical Trial Information System (CTIS) structured data form - Notifications, Annual Safety Report (ASR) and results","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-07-29T10:40:00Z","last_updated_date":"2025-10-23T16:27:00Z","reference_number":"EMA/297654/2021","document_url":"https://www.ema.europa.eu/en/documents/template-form/clinical-trial-information-system-ctis-structured-data-form-notifications-results_en.xlsx"},
    {"id":"52145","name":"Submission of comments on 'Guideline on core SmPC, labelling and package leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells'","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-07-30T10:00:00Z","last_updated_date":"2021-07-30T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-guideline-core-smpc-labelling-and-package-leaflet-advanced-therapy-medicinal-products-atmps-containing-genetically-modified-cells_en.doc"},
    {"id":"52229","name":"Simplified salary calculator - Contract Agents","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-08-17T10:41:00Z","last_updated_date":"2026-01-20T15:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/simplified-salary-calculator-contract-agents_en.xlsx"},
    {"id":"52230","name":"Simplified salary calculator - Temporary Agents","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-08-17T10:41:00Z","last_updated_date":"2026-01-20T15:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/simplified-salary-calculator-temporary-agents_en.xlsx"},
    {"id":"52321","name":"Request to the CVMP for classification of a veterinary medicinal product as intended for a limited market according to Article 4(29) and for eligibility for authorisation according to Article 23 (Applications for limited markets)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-09-02T14:35:00Z","last_updated_date":"2025-09-23T13:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-cvmp-classification-veterinary-medicinal-product-intended-limited-market-according-article-429-eligibility-authorisation-according-article-23-applications-limited-markets_en.docx"},
    {"id":"52657","name":"Veterinary pre-submission meeting request form - in accordance with Regulation (EU) No 2019/6","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-09-29T09:48:00Z","last_updated_date":"2026-03-03T10:00:00Z","reference_number":"EMA/340680/2021","document_url":"https://www.ema.europa.eu/en/documents/template-form/veterinary-pre-submission-meeting-request-form-accordance-regulation-eu-no-2019-6_en.doc"},
    {"id":"52719","name":"Request form - Request for a recommendation on the classification of a not already listed variation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-10-04T15:20:00Z","last_updated_date":"2021-10-04T15:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-form-request-recommendation-classification-not-already-listed-variation_en.doc"},
    {"id":"52929","name":"Submission form - Repurposing pilot project for authorised medicines","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-10-28T12:45:00Z","last_updated_date":"2022-01-20T14:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-form-repurposing-pilot-project-authorised-medicines_en.docx"},
    {"id":"53115","name":"Rapid alert notification of a quality defect / recall","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-11-15T09:33:00Z","last_updated_date":"2024-09-04T13:53:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/rapid-alert-notification-quality-defect-recall_en.pdf"},
    {"id":"53116","name":"Follow-up and non-urgent information for quality defects","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-11-15T09:33:00Z","last_updated_date":"2024-09-04T13:51:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/follow-non-urgent-information-quality-defects_en.pdf"},
    {"id":"53314","name":"Irish language waiver request template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-11-29T14:30:00Z","last_updated_date":"2021-11-29T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/irish-language-waiver-request-template_en.docx"},
    {"id":"53368","name":"Programme and registration form - eXtended EudraVigilance Medicinal Product Dictionary live virtual training course for sponsors - May, June 2022","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-12-08T14:25:00Z","last_updated_date":"2022-03-28T15:33:00Z","reference_number":"Courses: #22587; #22588","document_url":"https://www.ema.europa.eu/en/documents/template-form/programme-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-live-virtual-training-course-sponsors-may-june-2022_en.pdf"},
    {"id":"53369","name":"Programme and registration form - eXtended EudraVigilance Medicinal Product Dictionary training courses - February, May, June 2022","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-12-06T14:25:00Z","last_updated_date":"2021-12-06T14:25:00Z","reference_number":"Courses: #22580; #22581; #22582","document_url":"https://www.ema.europa.eu/en/documents/template-form/programme-and-registration-form-extended-eudravigilance-medicinal-product-dictionary-training-courses-february-may-june-2022_en.pdf"},
    {"id":"53463","name":"Template for the submission of comments for the draft guideline on the acceptability of names for human medicinal products processed through the centralised procedure","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-12-16T10:00:00Z","last_updated_date":"2021-12-16T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-comments-draft-guideline-acceptability-names-human-medicinal-products-processed-through-centralised-procedure_en.docx"},
    {"id":"53557","name":"Clinical Trial Information System (CTIS) list values","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-12-16T15:05:00Z","last_updated_date":"2021-12-16T15:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/clinical-trial-information-system-ctis-list-values_en.xlsx"},
    {"id":"53575","name":"Appendix III b – Information to be submitted with a notification of a serious breach - Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-12-17T09:30:00Z","last_updated_date":"2023-07-04T09:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-iii-b-information-be-submitted-notification-serious-breach-guideline-notification-serious-breaches-regulation-eu-no-5362014-or-clinical-trial-protocol_en.doc"},
    {"id":"53582","name":"Application form for initial consultation by a notified body on a companion diagnostic","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-12-20T10:26:00Z","last_updated_date":"2022-07-01T11:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-initial-consultation-notified-body-companion-diagnostic_en.docx"},
    {"id":"53583","name":"Consultation on companion diagnostic - Assessment report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-12-20T10:25:00Z","last_updated_date":"2022-07-01T11:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/consultation-companion-diagnostic-assessment-report-template_en.docx"},
    {"id":"53815","name":"Letter of intent for the submission of a worksharing procedure to the European Medicines Agency according to Article 65 of Regulation (EU) 2019/6","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-01-20T16:00:00Z","last_updated_date":"2025-09-17T17:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/letter-intent-submission-worksharing-procedure-european-medicines-agency-according-article-65-regulation-eu-2019-6_en.docx"},
    {"id":"54581","name":"Template - Innovation Task Force briefing document","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T10:25:00Z","last_updated_date":"2023-02-17T12:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-innovation-task-force-briefing-document_en.docx"},
    {"id":"54582","name":"Template - Innovation Task Force briefing meeting report","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-03-25T10:26:00Z","last_updated_date":"2022-03-25T10:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-innovation-task-force-briefing-meeting-report_en.docx"},
    {"id":"54602","name":"Veterinary signal assessment report for marketing authorisation holders","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-03-29T10:00:00Z","last_updated_date":"2025-12-04T14:29:55Z","reference_number":"EMA/464566/2021 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/template-form/veterinary-signal-assessment-report-marketing-authorisation-holders_en.docx"},
    {"id":"54977","name":"Application for an EMA certificate for a Plasma Master File (PMF)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-05-17T16:35:00Z","last_updated_date":"2022-05-17T16:35:00Z","reference_number":"EMA/176679/2020","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-ema-certificate-plasma-master-file-pmf_en.doc"},
    {"id":"54978","name":"Plasma Master File (PMF) variation - Annex","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-05-17T16:36:00Z","last_updated_date":"2022-05-17T16:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/plasma-master-file-pmf-variation-annex_en.doc"},
    {"id":"55323","name":"Information required for early identification of a need for pre-authorisation GMP inspections","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-06-22T15:24:00Z","last_updated_date":"2022-06-22T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/information-required-early-identification-need-pre-authorisation-gmp-inspections_en.doc"},
    {"id":"55431","name":"Application form for follow-up consultation procedure by a notified body on a companion diagnostic","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-07-01T11:34:00Z","last_updated_date":"2022-07-01T11:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-follow-consultation-procedure-notified-body-companion-diagnostic_en.docx"},
    {"id":"55506","name":"Letter of intent for the submission of a consultation to the European Medicines Agency by a notified body on a companion diagnostic in accordance with Regulation (EU) 2017/746","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-07-08T13:56:00Z","last_updated_date":"2023-07-31T14:41:00Z","reference_number":"EMA/781233/2021","document_url":"https://www.ema.europa.eu/en/documents/template-form/letter-intent-submission-consultation-european-medicines-agency-notified-body-companion-diagnostic-accordance-regulation-eu-2017746_en.docx"},
    {"id":"56014","name":"QRD veterinary Appendix I - Adverse event (PhV) MSs reporting details","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-09-07T13:54:00Z","last_updated_date":"2026-03-19T13:51:00Z","reference_number":"EMA/437396/2023, version 5","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-veterinary-appendix-i-adverse-event-phv-mss-reporting-details_en.pdf"},
    {"id":"56211","name":"Form for submission of comments on “Good Practice Guide for the use of the Metadata Catalogue of Real-World Data Sources” (EMA/226421/2022)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-09-27T16:14:00Z","last_updated_date":"2022-09-27T16:14:00Z","reference_number":"EMA/226421/2022","document_url":"https://www.ema.europa.eu/en/documents/template-form/form-submission-comments-good-practice-guide-use-metadata-catalogue-real-world-data-sources-ema2264212022_en.doc"},
    {"id":"56234","name":"ATMP product information template version 1.1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T12:19:00Z","last_updated_date":"2024-02-29T16:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/atmp-product-information-template-version-11_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/scientific-guideline/atmp-product-information-template-version-11_bg.docx","es":"https://www.ema.europa.eu/es/documents/scientific-guideline/atmp-product-information-template-version-11_es.docx","cs":"https://www.ema.europa.eu/cs/documents/scientific-guideline/atmp-product-information-template-version-11_cs.docx","da":"https://www.ema.europa.eu/da/documents/scientific-guideline/atmp-product-information-template-version-11_da.docx","de":"https://www.ema.europa.eu/de/documents/scientific-guideline/atmp-product-information-template-version-11_de.docx","et":"https://www.ema.europa.eu/et/documents/scientific-guideline/atmp-product-information-template-version-11_et.docx","el":"https://www.ema.europa.eu/el/documents/scientific-guideline/atmp-product-information-template-version-11_el.docx","fr":"https://www.ema.europa.eu/fr/documents/scientific-guideline/atmp-product-information-template-version-11_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/scientific-guideline/atmp-product-information-template-version-11_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/scientific-guideline/atmp-product-information-template-version-11_hr.docx","it":"https://www.ema.europa.eu/it/documents/scientific-guideline/atmp-product-information-template-version-11_it.docx","lv":"https://www.ema.europa.eu/lv/documents/scientific-guideline/atmp-product-information-template-version-11_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/scientific-guideline/atmp-product-information-template-version-11_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/scientific-guideline/atmp-product-information-template-version-11_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/scientific-guideline/atmp-product-information-template-version-11_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/scientific-guideline/atmp-product-information-template-version-11_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/scientific-guideline/atmp-product-information-template-version-11_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/scientific-guideline/atmp-product-information-template-version-11_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/scientific-guideline/atmp-product-information-template-version-11_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/scientific-guideline/atmp-product-information-template-version-11_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/scientific-guideline/atmp-product-information-template-version-11_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/scientific-guideline/atmp-product-information-template-version-11_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/scientific-guideline/atmp-product-information-template-version-11_sv.docx","is":"https://www.ema.europa.eu/is/documents/scientific-guideline/atmp-product-information-template-version-11_is.docx","no":"https://www.ema.europa.eu/no/documents/scientific-guideline/atmp-product-information-template-version-11_no.docx"}},
    {"id":"56354","name":"Submission of comments on “Data Quality Framework for EU medicines regulation” (EMA/798293/2022)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-10-10T11:22:00Z","last_updated_date":"2022-10-10T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-data-quality-framework-eu-medicines-regulation-ema7982932022_en.doc"},
    {"id":"56484","name":"CTIS MAH Admin - affiliation template letter","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-10-26T11:27:00Z","last_updated_date":"2022-10-26T11:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/ctis-mah-admin-affiliation-template-letter_en.docx"},
    {"id":"56791","name":"Appendix 1 - Pharmacovigilance Inspection Report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-11-29T11:36:00Z","last_updated_date":"2022-11-29T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-1-pharmacovigilance-inspection-report-template_en.doc"},
    {"id":"56792","name":"Appendix 2 - Template for collecting information on Pharmacovigilance issues for the attention of the inspectors and assessors","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2022-11-29T11:43:00Z","last_updated_date":"2022-11-29T11:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/appendix-2-template-collecting-information-pharmacovigilance-issues-attention-inspectors-and-assessors_en.doc"},
    {"id":"57184","name":"Antimicrobial Sales and Use (ASU) - Use data template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T15:11:00Z","last_updated_date":"2024-01-29T12:20:00Z","reference_number":"EMA/27834/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/antimicrobial-sales-and-use-asu-use-data-template_en.xlsx"},
    {"id":"57186","name":"Antimicrobial Sales and Use (ASU) - Sales data template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-01-09T15:10:00Z","last_updated_date":"2024-01-29T12:15:00Z","reference_number":"EMA/27836/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/antimicrobial-sales-and-use-asu-sales-data-template_en.xlsx"},
    {"id":"57394","name":"Application form - ATMP academic development support pilot","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-01-26T10:46:00Z","last_updated_date":"2024-02-08T15:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-atmp-academic-development-support-pilot_en.docx"},
    {"id":"57535","name":"Letter of interest template for online application - Information session on the pilot for expert panels’ scientific advice to manufacturers of certain high-risk medical devices","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-02-06T15:25:00Z","last_updated_date":"2023-02-06T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/letter-interest-template-online-application-information-session-pilot-expert-panels-scientific-advice-manufacturers-certain-high-risk-medical-devices_en.pdf"},
    {"id":"57685","name":"Template for submission of comments on ICH guidelines","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-02-15T17:29:00Z","last_updated_date":"2023-02-15T17:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-comments-ich-guidelines_en.xlsx"},
    {"id":"58257","name":"PRIME regulatory roadmap and product development tracker","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T15:55:00Z","last_updated_date":"2023-03-31T15:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/prime-regulatory-roadmap-and-product-development-tracker_en.docx"},
    {"id":"58309","name":"Template for response to list of questions/list of outstanding issues: Quality / Non-clinical / Clinical","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T12:30:00Z","last_updated_date":"2026-05-12T09:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-response-list-questions-list-outstanding-issues-quality-non-clinical-clinical_en.docx"},
    {"id":"58666","name":"List of questions and scientific overview (biologicals)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:09:00Z","last_updated_date":"2023-05-12T16:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/list-questions-and-scientific-overview-biologicals_en.docx"},
    {"id":"58667","name":"List of questions and scientific overview (non-biologicals)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:09:00Z","last_updated_date":"2023-05-12T16:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/list-questions-and-scientific-overview-non-biologicals_en.docx"},
    {"id":"58669","name":"List of questions and scientific overview (immunologicals)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-05-12T16:09:00Z","last_updated_date":"2023-05-12T16:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/list-questions-and-scientific-overview-immunologicals_en.docx"},
    {"id":"58902","name":"Paediatric investigation plan (PIP) - Key elements form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-06-09T11:09:00Z","last_updated_date":"2026-04-16T08:51:55Z","reference_number":"EMA/283362/2012 Version 9","document_url":"https://www.ema.europa.eu/en/documents/template-form/paediatric-investigation-plan-pip-key-elements-form_en.docx"},
    {"id":"59082","name":"QRD Appendix I - Statements for use in section 4.6 'pregnancy and lactation' of the summary of product characteristics (Cover page)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T14:45:00Z","last_updated_date":"2023-06-23T14:45:00Z","reference_number":"EMA/215345/2023","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-appendix-i-statements-use-section-46-pregnancy-lactation-summary-product-characteristics-cover-page_en.docx"},
    {"id":"59646","name":"Template: Declaration for the risk management plan (RMP) publication","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-08-28T11:34:00Z","last_updated_date":"2023-09-29T12:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-declaration-risk-management-plan-rmp-publication_en.docx"},
    {"id":"59894","name":"QRD Form 1 - veterinary","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-09-05T11:18:00Z","last_updated_date":"2023-09-05T11:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-form-1-veterinary_en.docx"},
    {"id":"59895","name":"QRD Form 2 and checklist for the submission of day +25 files - veterinary","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-09-05T11:19:00Z","last_updated_date":"2025-11-04T12:31:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-form-2-checklist-submission-day-25-files-veterinary_en.docx"},
    {"id":"59896","name":"Checklist for the submission of day +5 translations for a post-opinion linguistic review - veterinary","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-09-05T11:20:00Z","last_updated_date":"2025-12-12T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/checklist-submission-day-5-translations-post-opinion-linguistic-review-veterinary_en.docx"},
    {"id":"60533","name":"Defective product report form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2018-05-03T12:00:00Z","last_updated_date":"2018-05-03T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/defective-product-report-form_en.pdf"},
    {"id":"60603","name":"Standard operating procedure for consultation of environmental competent authorities on genetically modified organisms with respect to environmental risk assessment in product evaluation (human use) - Forms 1-7","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2020-01-22T12:29:00Z","last_updated_date":"2020-01-22T12:29:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/standard-operating-procedure-consultation-environmental-competent-authorities-genetically-modified-organisms-respect-environmental-risk-assessment-product-evaluation-human-use-forms-1-7_en.zip"},
    {"id":"60656","name":"PRAC rapporteurs' assessment report for non-imposed non-interventional PASS protocol","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2021-09-27T09:35:00Z","last_updated_date":"2021-09-27T09:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/prac-rapporteurs-assessment-report-non-imposed-non-interventional-pass-protocol_en.doc"},
    {"id":"61480","name":"Annex to Letter of Intent (pre-submission request form)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-12-18T13:19:08Z","last_updated_date":"2023-12-18T13:19:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-letter-intent-pre-submission-request-form_en.docx"},
    {"id":"61499","name":"Request a change of the applicant for an ongoing marketing authorisation application","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T14:48:33Z","last_updated_date":"2023-12-19T14:48:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-change-applicant-ongoing-marketing-authorisation-application_en.pdf"},
    {"id":"61932","name":"Antimicrobial Sales and Use (ASU) - Animal population data template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-01-29T13:11:00Z","last_updated_date":"2024-01-29T13:11:00Z","reference_number":"EMA/27835/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/antimicrobial-sales-and-use-asu-animal-population-data-template_en.xlsx"},
    {"id":"62379","name":"ATMP product information template version 1.1 - highlighted","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-02-29T16:52:08Z","last_updated_date":"2024-02-29T16:52:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/atmp-product-information-template-version-11-highlighted_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/other/atmp-product-information-template-version-11-highlighted_bg.pdf","es":"https://www.ema.europa.eu/es/documents/other/atmp-product-information-template-version-11-highlighted_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/other/atmp-product-information-template-version-11-highlighted_cs.pdf","da":"https://www.ema.europa.eu/da/documents/other/atmp-product-information-template-version-11-highlighted_da.pdf","de":"https://www.ema.europa.eu/de/documents/other/atmp-product-information-template-version-11-highlighted_de.pdf","et":"https://www.ema.europa.eu/et/documents/other/atmp-product-information-template-version-11-highlighted_et.pdf","el":"https://www.ema.europa.eu/el/documents/other/atmp-product-information-template-version-11-highlighted_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/other/atmp-product-information-template-version-11-highlighted_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/other/atmp-product-information-template-version-11-highlighted_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/other/atmp-product-information-template-version-11-highlighted_hr.pdf","it":"https://www.ema.europa.eu/it/documents/other/atmp-product-information-template-version-11-highlighted_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/other/atmp-product-information-template-version-11-highlighted_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/other/atmp-product-information-template-version-11-highlighted_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/other/atmp-product-information-template-version-11-highlighted_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/other/atmp-product-information-template-version-11-highlighted_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/other/atmp-product-information-template-version-11-highlighted_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/other/atmp-product-information-template-version-11-highlighted_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/other/atmp-product-information-template-version-11-highlighted_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/other/atmp-product-information-template-version-11-highlighted_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/other/atmp-product-information-template-version-11-highlighted_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/other/atmp-product-information-template-version-11-highlighted_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/other/atmp-product-information-template-version-11-highlighted_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/other/atmp-product-information-template-version-11-highlighted_sv.pdf","is":"https://www.ema.europa.eu/is/documents/other/atmp-product-information-template-version-11-highlighted_is.pdf","no":"https://www.ema.europa.eu/no/documents/other/atmp-product-information-template-version-11-highlighted_no.pdf"}},
    {"id":"62636","name":"Template - Application for transfer of marketing authorisation from transferor to transferee, attachment 1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-03-19T15:40:00Z","last_updated_date":"2024-03-19T15:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-application-transfer-marketing-authorisation-transferor-transferee-attachment-1_en.docx"},
    {"id":"62639","name":"Template - Application for transfer of marketing authorisation from transferor to transferee, attachment 2","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-03-18T15:52:00Z","last_updated_date":"2024-03-18T15:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-application-transfer-marketing-authorisation-transferor-transferee-attachment-2_en.doc"},
    {"id":"62640","name":"Template - Application for transfer of marketing authorisation from transferor to transferee, attachment 3","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-03-18T16:00:00Z","last_updated_date":"2024-03-18T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-application-transfer-marketing-authorisation-transferor-transferee-attachment-3_en.docx"},
    {"id":"62642","name":"Template - Application for transfer of marketing authorisation from transferor to transferee, cover letter (veterinary)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-03-18T16:06:00Z","last_updated_date":"2024-04-15T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-application-transfer-marketing-authorisation-transferor-transferee-cover-letter-veterinary_en.pdf"},
    {"id":"62758","name":"Template for request of clock-stop extension","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-03-27T12:04:26Z","last_updated_date":"2024-03-27T12:04:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-request-clock-stop-extension_en.docx"},
    {"id":"63006","name":"Annex II to the call for proposals - Vendor financial identification form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-04-19T15:00:00Z","last_updated_date":"2024-04-19T15:00:00Z","reference_number":"EMA/59469/2022","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-ii-call-proposals-vendor-financial-identification-form_en.docx"},
    {"id":"63214","name":"Template - Application for transfer of marketing authorisation from transferor to transferee - cover letter (human)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-05-15T13:47:00Z","last_updated_date":"2026-03-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-application-transfer-marketing-authorisation-transferor-transferee-cover-letter-human_en.docx"},
    {"id":"63319","name":"Anonymisation report form template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-05-24T14:33:02Z","last_updated_date":"2024-05-24T14:33:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/anonymisation-report-form-template_en.pdf"},
    {"id":"63464","name":"Feedback questionnaire for applicants on the Simultaneous National Scientific Advice (SNSA) pilot procedure","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-06-03T17:00:00Z","last_updated_date":"2024-06-03T17:00:00Z","reference_number":"EMA/255759/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/feedback-questionnaire-applicants-simultaneous-national-scientific-advice-snsa-pilot-procedure_en.docx"},
    {"id":"63465","name":"SNSA meeting minutes template for applicants","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-06-03T17:00:00Z","last_updated_date":"2024-06-03T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/snsa-meeting-minutes-template-applicants_en.doc"},
    {"id":"63466","name":"SNSA final advice report template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-06-03T17:00:00Z","last_updated_date":"2024-06-03T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/snsa-final-advice-report-template_en.doc"},
    {"id":"63478","name":"Application form to request  Simultaneous National Scientific Advice (SNSA) or a pre-CTA Advice","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-06-04T12:00:00Z","last_updated_date":"2024-06-04T12:00:00Z","reference_number":"EMA/255386/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/application-form-request-simultaneous-national-scientific-advice-snsa-or-pre-cta-advice_en.docx"},
    {"id":"63698","name":"Cover letter - Article 61(3) Notification","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-06-21T12:05:27Z","last_updated_date":"2025-08-06T14:59:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/cover-letter-article-613-notification_en.docx"},
    {"id":"64371","name":"European Shortages Monitoring Platform (ESMP): Marketing authorisation holder reporting templates","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-07-31T16:55:00Z","last_updated_date":"2025-05-13T00:00:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/european-shortages-monitoring-platform-esmp-marketing-authorisation-holder-reporting-templates_en.xlsx"},
    {"id":"64373","name":"European Shortages Monitoring Platform (ESMP): National competent authority reporting templates","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-07-29T16:55:00Z","last_updated_date":"2025-05-13T00:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/european-shortages-monitoring-platform-esmp-national-competent-authority-reporting-templates_en.xlsx"},
    {"id":"64432","name":"Good manufacturing practice (GMP) inspection report - Union format","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T15:21:00Z","last_updated_date":"2024-08-28T14:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/good-manufacturing-practice-gmp-inspection-report-union-format_en.docx"},
    {"id":"64433","name":"Union format for manufacturer’s authorisation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T15:22:55Z","last_updated_date":"2024-08-01T15:22:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/union-format-manufacturers-authorisation_en.pdf"},
    {"id":"64434","name":"Union format for a good distribution practice (GDP) certificate","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T15:25:54Z","last_updated_date":"2024-08-01T15:25:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/union-format-good-distribution-practice-gdp-certificate_en.pdf"},
    {"id":"64435","name":"Statement of non-compliance with good manufacturing practice (GMP)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T15:28:52Z","last_updated_date":"2024-08-01T15:28:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/statement-non-compliance-good-manufacturing-practice-gmp_en.pdf"},
    {"id":"64436","name":"Notification of serious good manufacturing practice (GMP) non-compliance information originating from third country authorities or international organisations","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T15:36:30Z","last_updated_date":"2024-08-01T15:36:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/notification-serious-good-manufacturing-practice-gmp-non-compliance-information-originating-third-country-authorities-or-international-organisations_en.pdf"}    {"id":"64437","name":"Union format for a wholesale distribution authorisation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T15:39:22Z","last_updated_date":"2024-08-01T15:39:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/union-format-wholesale-distribution-authorisation_en.pdf"},
    {"id":"64438","name":"Union format for a good distribution practice (GDP) certificate for active substances to be used as starting materials in medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T15:41:01Z","last_updated_date":"2024-08-01T15:41:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/union-format-good-distribution-practice-gdp-certificate-active-substances-be-used-starting-materials-medicinal-products_en.pdf"},
    {"id":"64439","name":"Good distribution practice (GDP) inspection report – Union format","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T15:54:14Z","last_updated_date":"2024-08-01T15:54:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/good-distribution-practice-gdp-inspection-report-union-format_en.pdf"},
    {"id":"64440","name":"Statement of non-compliance with good distribution practice","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T15:59:20Z","last_updated_date":"2024-08-01T15:59:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/statement-non-compliance-good-distribution-practice_en.pdf"},
    {"id":"64441","name":"Statement of non-compliance with good distribution practice of a distributor of active substances for use as starting materials in medicinal products","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T16:01:45Z","last_updated_date":"2024-08-01T16:01:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/statement-non-compliance-good-distribution-practice-distributor-active-substances-use-starting-materials-medicinal-products_en.pdf"},
    {"id":"64442","name":"Request form for the exchange of information on marketing authorisation holders or manufacturing authorisation holders between the competent authorities in the EEA","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T16:03:12Z","last_updated_date":"2024-08-01T16:03:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-form-exchange-information-marketing-authorisation-holders-or-manufacturing-authorisation-holders-between-competent-authorities-eea_en.pdf"},
    {"id":"64443","name":"Union format for registration of manufacturer, importer or distributor of active substance","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T16:04:07Z","last_updated_date":"2024-08-01T16:04:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/union-format-registration-manufacturer-importer-or-distributor-active-substance_en.pdf"},
    {"id":"64445","name":"Union format for a good manufacturing practice (GMP) certificate","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-01T16:26:20Z","last_updated_date":"2024-08-01T16:26:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/union-format-good-manufacturing-practice-gmp-certificate_en.pdf"},
    {"id":"64578","name":"Annex I and IV to call for proposals ","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-08-14T16:38:00Z","last_updated_date":"2024-08-14T16:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/annex-i-iv-call-proposals_en.docx"},
    {"id":"65431","name":"Request for veterinary medicinal product classification","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T15:40:00Z","last_updated_date":"2025-10-15T16:51:32Z","reference_number":"EMA/345968/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/request-veterinary-medicinal-product-classification_en.docx"},
    {"id":"65514","name":"Template : Letter of intent for the submission of a worksharing procedure to the European Medicines Agency ","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-10-31T16:28:38Z","last_updated_date":"2024-10-31T16:28:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-letter-intent-submission-worksharing-procedure-european-medicines-agency_en.docx"},
    {"id":"65592","name":"Declaration of interests and confidentiality undertaking form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-11-12T14:00:00Z","last_updated_date":"2024-11-12T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/declaration-interests-confidentiality-undertaking-form_en.pdf"},
    {"id":"65724","name":"Template - Request for advice on the orphan device status pursuant to Article 61(2) of Regulation (EU) 2017/745 and MDCG 2024-10","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-11-20T12:59:21Z","last_updated_date":"2025-04-01T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-request-advice-orphan-device-status-pursuant-article-612-regulation-eu-2017-745-mdcg-2024-10_en.pdf"},
    {"id":"65725","name":"Template - Request for advice on the clinical development strategy or clinical data required for the clinical evaluation pursuant to Article 61(2) or Article 106(11) of Regulation (EU) 2017/745 and MDCG 2024-10 on <device name> from the Expert Panels","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-11-20T13:01:41Z","last_updated_date":"2025-04-01T12:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-request-advice-clinical-development-strategy-or-clinical-data-required-clinical-evaluation-pursuant-article-612-or-article-10611-regulation-eu-2017-745-mdcg-2024-10-expert-panels_en.pdf"},
    {"id":"65878","name":"Submission of comments template for ICH E6(R3) Annex 2","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-11-29T16:59:44Z","last_updated_date":"2024-11-29T16:59:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-template-ich-e6r3-annex-2_en.xlsx"},
    {"id":"65955","name":"Template to report an allegation concerning breaches in an area of EMA’s responsibility (authorisation, supervision and maintenance of human and veterinary medicinal products)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T10:08:38Z","last_updated_date":"2024-12-05T10:08:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-report-allegation-concerning-breaches-area-emas-responsibility-authorisation-supervision-maintenance-human-veterinary-medicinal-products_en.docx"},
    {"id":"66043","name":"QRD veterinary product-information annotated template (English) version 9.1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T12:13:31Z","last_updated_date":"2024-12-10T12:13:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-veterinary-product-information-annotated-template-english-version-91_en.pdf"},
    {"id":"66044","name":"QRD veterinary product-information annotated template (English) version 9.1 highlighted","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T12:15:43Z","last_updated_date":"2024-12-10T12:15:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-veterinary-product-information-annotated-template-english-version-91-highlighted_en.pdf"},
    {"id":"66045","name":"QRD veterinary combined label-leaflet template v.9.1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T13:07:53Z","last_updated_date":"2026-05-05T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_fr.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-veterinary-combined-label-leaflet-template-v91_no.docx"}},
    {"id":"66046","name":"QRD veterinary combined label-leaflet annotated template (English) v.9.1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T13:10:53Z","last_updated_date":"2024-12-10T13:10:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-veterinary-combined-label-leaflet-annotated-template-english-v91_en.docx"},
    {"id":"66047","name":"QRD veterinary product-information highlighted template version 9.1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T13:03:33Z","last_updated_date":"2025-06-05T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_bg.pdf","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_cs.pdf","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_da.pdf","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_de.pdf","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_et.pdf","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_fr.pdf","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_ga.pdf","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_hr.pdf","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_sv.pdf","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_is.pdf","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-veterinary-product-information-highlighted-template-version-91_no.pdf"}},
    {"id":"66048","name":"QRD veterinary product-information template version 9.1","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T13:05:33Z","last_updated_date":"2025-06-05T11:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-veterinary-product-information-template-version-91_en.docx","translations":{"bg":"https://www.ema.europa.eu/bg/documents/template-form/qrd-veterinary-product-information-template-version-91_bg.docx","es":"https://www.ema.europa.eu/es/documents/template-form/qrd-veterinary-product-information-template-version-91_es.docx","cs":"https://www.ema.europa.eu/cs/documents/template-form/qrd-veterinary-product-information-template-version-91_cs.docx","da":"https://www.ema.europa.eu/da/documents/template-form/qrd-veterinary-product-information-template-version-91_da.docx","de":"https://www.ema.europa.eu/de/documents/template-form/qrd-veterinary-product-information-template-version-91_de.docx","et":"https://www.ema.europa.eu/et/documents/template-form/qrd-veterinary-product-information-template-version-91_et.docx","el":"https://www.ema.europa.eu/el/documents/template-form/qrd-veterinary-product-information-template-version-91_el.docx","fr":"https://www.ema.europa.eu/fr/documents/template-form/qrd-veterinary-product-information-template-version-91_fr.docx","ga":"https://www.ema.europa.eu/ga/documents/template-form/qrd-veterinary-product-information-template-version-91_ga.docx","hr":"https://www.ema.europa.eu/hr/documents/template-form/qrd-veterinary-product-information-template-version-91_hr.docx","it":"https://www.ema.europa.eu/it/documents/template-form/qrd-veterinary-product-information-template-version-91_it.docx","lv":"https://www.ema.europa.eu/lv/documents/template-form/qrd-veterinary-product-information-template-version-91_lv.docx","lt":"https://www.ema.europa.eu/lt/documents/template-form/qrd-veterinary-product-information-template-version-91_lt.docx","hu":"https://www.ema.europa.eu/hu/documents/template-form/qrd-veterinary-product-information-template-version-91_hu.docx","mt":"https://www.ema.europa.eu/mt/documents/template-form/qrd-veterinary-product-information-template-version-91_mt.docx","nl":"https://www.ema.europa.eu/nl/documents/template-form/qrd-veterinary-product-information-template-version-91_nl.docx","pl":"https://www.ema.europa.eu/pl/documents/template-form/qrd-veterinary-product-information-template-version-91_pl.docx","pt":"https://www.ema.europa.eu/pt/documents/template-form/qrd-veterinary-product-information-template-version-91_pt.docx","ro":"https://www.ema.europa.eu/ro/documents/template-form/qrd-veterinary-product-information-template-version-91_ro.docx","sk":"https://www.ema.europa.eu/sk/documents/template-form/qrd-veterinary-product-information-template-version-91_sk.docx","sl":"https://www.ema.europa.eu/sl/documents/template-form/qrd-veterinary-product-information-template-version-91_sl.docx","fi":"https://www.ema.europa.eu/fi/documents/template-form/qrd-veterinary-product-information-template-version-91_fi.docx","sv":"https://www.ema.europa.eu/sv/documents/template-form/qrd-veterinary-product-information-template-version-91_sv.docx","is":"https://www.ema.europa.eu/is/documents/template-form/qrd-veterinary-product-information-template-version-91_is.docx","no":"https://www.ema.europa.eu/no/documents/template-form/qrd-veterinary-product-information-template-version-91_no.docx"}},
    {"id":"66189","name":"Call for expression of interest for Academia to participate in the European Platform for Regulatory Science Research ","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-12-18T10:21:09Z","last_updated_date":"2024-12-18T10:21:09Z","reference_number":"EMA/593410/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/call-expression-interest-academia-participate-european-platform-regulatory-science-research_en.docx"},
    {"id":"66215","name":"Template - CVMP member comments on rapporteur’s reports","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2024-12-18T15:09:49Z","last_updated_date":"2024-12-18T15:09:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-cvmp-member-comments-rapporteurs-reports_en.docx"},
    {"id":"66409","name":"Tracked product information annexes statement translation for cover page","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T09:53:35Z","last_updated_date":"2025-04-15T14:59:17Z","reference_number":"EMA/38725/2025 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/template-form/tracked-product-information-annexes-statement-translation-cover-page_en.docx"},
    {"id":"66465","name":"QRD Form 2 and checklist for the submission of day +25 files - human","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-02-10T10:53:07Z","last_updated_date":"2025-11-04T12:31:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/qrd-form-2-checklist-submission-day-25-files-human_en.docx"},
    {"id":"66833","name":"Template for Assessment report for the development of European Union herbal monographs and European Union list entries","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2025-02-17T17:54:30Z","last_updated_date":"2025-02-17T17:54:30Z","reference_number":"EMA/HMPC/418902/2005 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-assessment-report-development-european-union-herbal-monographs-european-union-list-entries_en.pdf"},
    {"id":"66834","name":"Template for Assessment report for the development of European Union herbal monographs and European Union list entries","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2025-02-17T17:56:10Z","last_updated_date":"2025-02-17T17:56:10Z","reference_number":"EMA/HMPC/418902/2005 Rev. 6","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-assessment-report-development-european-union-herbal-monographs-european-union-list-entries_en.docx"},
    {"id":"66835","name":"Template for a European Union herbal monograph","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2025-02-17T18:01:22Z","last_updated_date":"2025-02-17T18:01:22Z","reference_number":"EMA/HMPC/107436/2005 Rev. 8","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-european-union-herbal-monograph_en.pdf-1"},
    {"id":"66836","name":"Template for a European Union herbal monograph","type":"template-form","status":"Adopted","consultation_date":"","first_published_date":"2025-02-17T18:02:32Z","last_updated_date":"2025-02-17T18:02:32Z","reference_number":"EMA/HMPC/107436/2005 Rev. 8 ","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-european-union-herbal-monograph_en.docx"},
    {"id":"66870","name":"List of contacts for procedure ","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-02-19T11:28:08Z","last_updated_date":"2025-02-19T11:28:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/list-contacts-procedure_en.docx"},
    {"id":"66917","name":"Veterinary medicines – variations requiring assessment (VRAs) in accordance with regulation (EU) 2019/6 - pre-submission meeting request form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-02-21T14:34:12Z","last_updated_date":"2025-02-21T14:34:12Z","reference_number":"EMA/261953/2024","document_url":"https://www.ema.europa.eu/en/documents/template-form/veterinary-medicines-variations-requiring-assessment-vras-accordance-regulation-eu-2019-6-pre-submission-meeting-request-form_en.docx"},
    {"id":"67291","name":"Template for late submission of ICSRs to EV","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-03-14T15:49:06Z","last_updated_date":"2025-04-22T15:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-late-submission-icsrs-ev_en.xlsx"},
    {"id":"67299","name":"Day 80 assessment report - Quality template with guidance (Biologics) Rev. 03.25 - Revamp","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-03-17T10:54:29Z","last_updated_date":"2025-03-17T10:54:29Z","reference_number":"rev 03.25 - Revamp","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-quality-template-guidance-biologics-rev-0325-revamp_en.docx"},
    {"id":"67300","name":"Day 80 assessment report - Quality template with guidance (Chemicals) Rev. 03.25 - Revamp","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-03-17T10:57:29Z","last_updated_date":"2025-03-17T10:57:29Z","reference_number":"rev 03.25 - Revamp","document_url":"https://www.ema.europa.eu/en/documents/template-form/day-80-assessment-report-quality-template-guidance-chemicals-rev-0325-revamp_en.docx"},
    {"id":"67362","name":"Portfolio and technology meeting briefing document ","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-03-20T09:44:25Z","last_updated_date":"2026-03-10T11:00:00Z","reference_number":"EMA/571070/2023","document_url":"https://www.ema.europa.eu/en/documents/template-form/portfolio-technology-meeting-briefing-document_en.docx"},
    {"id":"67363","name":"Portfolio and technology meeting report","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-03-20T09:46:55Z","last_updated_date":"2025-03-20T09:46:55Z","reference_number":"EMA/247780/2023","document_url":"https://www.ema.europa.eu/en/documents/template-form/portfolio-technology-meeting-report_en.docx"},
    {"id":"67745","name":"CHMP-CAT - D80-210 Overview to final EPAR - Rev 07.25 Revamp","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T09:34:46Z","last_updated_date":"2025-08-05T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/chmp-cat-d80-210-overview-final-epar-rev-0725-revamp_en.docx"},
    {"id":"67785","name":"Quality Review of Documents (QRD) annotated template v11: Draft for public consultation","type":"template-form","status":"Draft: consultation closed","consultation_date":"2025-04-14 - 2025-08-31","first_published_date":"2025-04-14T15:38:00Z","last_updated_date":"2025-04-14T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/quality-review-documents-qrd-annotated-template-v11-draft-public-consultation_en.pdf"},
    {"id":"67787","name":"Quality Review of Documents (QRD) annotated template v11: Draft for public consultation - tracked changes","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T15:37:00Z","last_updated_date":"2025-04-14T15:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/quality-review-documents-qrd-annotated-template-v11-draft-public-consultation-tracked-changes_en.pdf"},
    {"id":"67788","name":"Quality Review of Documents (QRD) annotated template v11: Form for submission of comments to public consultation","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T15:38:00Z","last_updated_date":"2025-04-14T15:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/quality-review-documents-qrd-annotated-template-v11-form-submission-comments-public-consultation_en.docx"},
    {"id":"69454","name":"Innovation Task Force (ITF) briefing meeting report","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-07-24T17:02:46Z","last_updated_date":"2026-03-20T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/innovation-task-force-itf-briefing-meeting-report_en.docx"},
    {"id":"69533","name":"Response to Paediatric Committee request for supplementary information and modification of proposed PIP (RSI) - Re-submission following clock-stop","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T13:40:05Z","last_updated_date":"2025-07-28T13:40:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/response-paediatric-committee-request-supplementary-information-modification-proposed-pip-rsi-re-submission-following-clock-stop_en.docx"},
    {"id":"69534","name":"Additional information - Applicant’s clarifications following Paediatric Committee (PDCO) discussions or re-discussions","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-07-28T13:40:07Z","last_updated_date":"2025-07-28T13:40:07Z","reference_number":"EMA/241572/2025","document_url":"https://www.ema.europa.eu/en/documents/template-form/additional-information-applicants-clarifications-following-paediatric-committee-pdco-discussions-or-re-discussions_en.docx"},
    {"id":"70256","name":"Submission of comments on Reflection paper on patient experience data (EMA/CHMP/PRAC/268899/2025)","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-09-29T12:00:00Z","last_updated_date":"2025-09-29T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/submission-comments-reflection-paper-patient-experience-data-ema-chmp-prac-268899-2025_en.xlsx"},
    {"id":"70283","name":"Template for submission of comments on reflection paper on patient experience data","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T16:28:42Z","last_updated_date":"2025-09-25T16:28:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-comments-reflection-paper-patient-experience-data_en.xlsx"},
    {"id":"70825","name":"Template for sharing EMA documents by Industry to support reliance","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-10-28T14:29:05Z","last_updated_date":"2026-04-09T13:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-sharing-ema-documents-industry-support-reliance_en.xlsx"},
    {"id":"71189","name":"Severe cutaneous adverse reactions - standard template wording for product information","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-11-17T10:53:52Z","last_updated_date":"2025-11-17T10:53:52Z","reference_number":"EMA/358383/2025","document_url":"https://www.ema.europa.eu/en/documents/template-form/severe-cutaneous-adverse-reactions-standard-template-wording-product-information_en.pdf"},
    {"id":"71407","name":"Vaccine platform technology master file (vPTMF) submission letter template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T16:40:05Z","last_updated_date":"2025-11-28T16:40:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/vaccine-platform-technology-master-file-vptmf-submission-letter-template_en.docx"},
    {"id":"71408","name":"Vaccine antigen master file (VAMF) submission letter template","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-11-28T16:40:22Z","last_updated_date":"2025-11-28T16:40:22Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/vaccine-antigen-master-file-vamf-submission-letter-template_en.docx"},
    {"id":"71760","name":"ICH M11 Clinical electronic structured harmonised protocol (CeSHarP) - Template step 5","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2025-12-15T17:32:15Z","last_updated_date":"2025-12-15T17:32:15Z","reference_number":"EMA/CHMP/ICH/778801/2022","document_url":"https://www.ema.europa.eu/en/documents/template-form/ich-m11-clinical-electronic-structured-harmonised-protocol-cesharp-template-step-5_en.pdf"},
    {"id":"72079","name":"Briefing Document for Quality Innovation Group (QIG) 1-to-1 meeting","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2026-01-15T18:12:31Z","last_updated_date":"2026-01-15T18:12:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/briefing-document-quality-innovation-group-qig-1-1-meeting_en.docx"},
    {"id":"72817","name":"Template for submission of comments - Draft guidance on the conduct of clinical trials during public health emergencies","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2026-03-04T11:20:00Z","last_updated_date":"2026-03-04T11:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/template-submission-comments-draft-guidance-conduct-clinical-trials-during-public-health-emergencies_en.xlsx"},
    {"id":"73211","name":"Pharmaceutical quality system (PQS) effectiveness pilot project application form","type":"template-form","status":"unknown","consultation_date":"","first_published_date":"2026-03-26T10:40:13Z","last_updated_date":"2026-03-26T10:40:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/template-form/pharmaceutical-quality-system-pqs-effectiveness-pilot-project-application-form_en.docx"},
    {"id":"2499","name":"Withdrawal letter : orBec","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-05-23T02:00:00Z","last_updated_date":"2008-05-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-orbec_en.pdf"},
    {"id":"2639","name":"Withdrawal letter : Emerflu","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/792246/2010","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-emerflu_en.pdf"},
    {"id":"2980","name":"Withdrawal letter : Docetaxel Mylan","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-03-26T01:00:00Z","last_updated_date":"2010-03-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-docetaxel-mylan_en.pdf"},
    {"id":"3316","name":"Withdrawal letter : Orplatna","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-08-01T02:00:00Z","last_updated_date":"2008-08-01T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-orplatna_en.pdf"},
    {"id":"3530","name":"Movectro: Withdrawal letter","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/movectro-withdrawal-letter_en.pdf"},
    {"id":"3887","name":"Withdrawal letter : Diractin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-07-23T02:00:00Z","last_updated_date":"2008-07-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-diractin_en.pdf"},
    {"id":"4250","name":"Withdrawal letter : Xegafri","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-xegafri_en.pdf"},
    {"id":"4479","name":"Withdrawal letter: Omontys","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-omontys_en.pdf"},
    {"id":"4557","name":"Withdrawal letter: Megestrol Alkermes (megestrol)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-03-19T01:00:00Z","last_updated_date":"2012-03-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-megestrol-alkermes-megestrol_en.pdf"},
    {"id":"4823","name":"Withdrawal letter : Riquent","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2006-10-11T02:00:00Z","last_updated_date":"2006-10-11T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-riquent_en.pdf"},
    {"id":"5519","name":"Withdrawal letter: Qtern","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T11:33:00Z","last_updated_date":"2018-04-27T11:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-qtern_en.pdf"},
    {"id":"5572","name":"Withdrawal letter: Neofordex","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-07-25T02:00:00Z","last_updated_date":"2014-07-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-neofordex_en.pdf"},
    {"id":"6366","name":"Withdrawal letter: Belviq","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-05-31T12:00:00Z","last_updated_date":"2013-05-31T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-belviq_en.pdf"},
    {"id":"6532","name":"Withdrawal letter: Blectifor","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-blectifor_en.pdf"},
    {"id":"6575","name":"Withdrawal letter : Lacosamide Pain UCB Pharma","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-09-25T02:00:00Z","last_updated_date":"2008-09-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-lacosamide-pain-ucb-pharma_en.pdf"},
    {"id":"6645","name":"Withdrawal letter: Beprana","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"EMA/364651/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-beprana_en.pdf"},
    {"id":"7008","name":"Withdrawal letter : Vekacia","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-11-14T01:00:00Z","last_updated_date":"2008-11-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-vekacia_en.pdf"},
    {"id":"7307","name":"Withdrawal letter : Vitragan","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2007-08-25T02:00:00Z","last_updated_date":"2007-08-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-vitragan_en.pdf"},
    {"id":"7574","name":"Withdrawal letter: Egrifta (tesamorelin)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-07-18T02:00:00Z","last_updated_date":"2012-07-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-egrifta-tesamorelin_en.pdf"},
    {"id":"7707","name":"Withdrawal letter: Doxorubicin SUN","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-09-13T02:00:00Z","last_updated_date":"2011-09-13T02:00:00Z","reference_number":"EMA/CHMP/647763/2011","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-doxorubicin-sun_en.pdf"},
    {"id":"7812","name":"Withdrawal letter : Arxxant","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2007-03-13T01:00:00Z","last_updated_date":"2007-03-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-arxxant_en.pdf"},
    {"id":"7879","name":"Withdrawal  letter: Janacti","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-11-22T01:00:00Z","last_updated_date":"2011-11-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-janacti_en.pdf"},
    {"id":"7880","name":"Withdrawal  letter: Qizenday","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-12-15T01:00:00Z","last_updated_date":"2017-12-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-qizenday_en.pdf"},
    {"id":"8096","name":"Withdrawal letter : Docetaxel Sun","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-docetaxel-sun_en.pdf"},
    {"id":"8155","name":"Withdrawal letter: Somnena","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-09-14T02:00:00Z","last_updated_date":"2017-09-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-somnena_en.pdf"},
    {"id":"8703","name":"Withdrawal letter: Aripiprazole Mylan","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aripiprazole-mylan_en.pdf"},
    {"id":"8809","name":"Withdrawal letter: Cavoley","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-cavoley_en.pdf"},
    {"id":"9103","name":"Withdrawal letter: Kyndrisa","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-06-22T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-kyndrisa_en.pdf"},
    {"id":"9540","name":"Withdrawal letter: Pioglitazone ratio","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T02:00:00Z","last_updated_date":"2012-04-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-pioglitazone-ratio_en.pdf"},
    {"id":"10071","name":"Withdrawal letter:  Ibuprofen/Diphenhydramine Hydrochloride Wyeth","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-01-28T01:00:00Z","last_updated_date":"2010-01-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ibuprofen-diphenhydramine-hydrochloride-wyeth_en.pdf"},
    {"id":"10444","name":"Withdrawal letter: Restaysis","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-06-01T14:00:00Z","last_updated_date":"2018-06-01T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-restaysis_en.pdf"},
    {"id":"10461","name":"Withdrawal letter: Neocepri","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-06-17T02:00:00Z","last_updated_date":"2014-06-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-neocepri_en.pdf"},
    {"id":"10769","name":"Withdrawal letter : Gallimune Flu H5N9(i)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-11-16T01:00:00Z","last_updated_date":"2010-11-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-gallimune-flu-h5n9i_en.pdf"},
    {"id":"11106","name":"Withdrawal letter : Retaane","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2006-02-28T01:00:00Z","last_updated_date":"2006-02-28T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-retaane_en.pdf"},
    {"id":"11196","name":"Withdrawal letter: Aripiprazole Mylan","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aripiprazole-mylan_en.pdf-0"},
    {"id":"11243","name":"Withdrawal letter : Bosatria","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-07-28T02:00:00Z","last_updated_date":"2009-07-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-bosatria_en.pdf"},
    {"id":"11781","name":"Withdrawal letter : Lunivia","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-05-13T02:00:00Z","last_updated_date":"2009-05-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-lunivia_en.pdf"},
    {"id":"11897","name":"Withdrawal letter :  Factive","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-06-17T02:00:00Z","last_updated_date":"2009-06-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-factive_en.pdf"},
    {"id":"12053","name":"Withdrawal letter: Efgratin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-efgratin_en.pdf"},
    {"id":"12267","name":"Withdrawal letter: Pioglitazone ratiopharm GmbH","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-04-30T13:21:00Z","last_updated_date":"2012-04-30T13:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-pioglitazone-ratiopharm-gmbh_en.pdf"},
    {"id":"12418","name":"Withdrawal letter: Paccal Vet","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-04-25T02:00:00Z","last_updated_date":"2012-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-paccal-vet_en.pdf"},
    {"id":"12841","name":"Withdrawal letter: Ruvise","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T15:15:00Z","last_updated_date":"2013-01-24T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ruvise_en.pdf"},
    {"id":"13779","name":"Withdrawal letter: Teysuno","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2015-01-23T01:00:00Z","last_updated_date":"2015-01-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-teysuno_en.pdf"},
    {"id":"13786","name":"Withdrawal letter : Aflunov","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-06-13T02:00:00Z","last_updated_date":"2008-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aflunov_en.pdf"},
    {"id":"14433","name":"Withdrawal letter : Synordia","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2006-12-07T01:00:00Z","last_updated_date":"2006-12-07T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-synordia_en.pdf"},
    {"id":"14516","name":"Withdrawal letter - Ratioepo","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-03-22T01:00:00Z","last_updated_date":"2010-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ratioepo_en.pdf"}    {"id":"14807","name":"Withdrawal letter: Cerepro","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-cerepro_en.pdf-0"},
    {"id":"14857","name":"Withdrawal letter : Kiacta","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-03-13T01:00:00Z","last_updated_date":"2008-03-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-kiacta_en.pdf"},
    {"id":"14980","name":"Withdrawal letter : Comfyde","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-01-27T00:09:21Z","last_updated_date":"2010-01-27T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-comfyde_en.pdf"},
    {"id":"15152","name":"Withdrawal letter : Retisert","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2007-07-16T02:00:00Z","last_updated_date":"2007-07-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-retisert_en.pdf"},
    {"id":"15191","name":"Withdrawal letter: Balimek","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T01:00:00Z","last_updated_date":"2018-01-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-balimek_en.pdf"},
    {"id":"15523","name":"Withdrawal letter: Enpaxiq","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-enpaxiq_en.pdf"},
    {"id":"15666","name":"Withdrawal letter : Multaq","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2006-09-06T02:00:00Z","last_updated_date":"2006-09-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-multaq_en.pdf"},
    {"id":"15873","name":"Withdrawal letter: SecreFlo (secretin human)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-09-24T02:00:00Z","last_updated_date":"2012-09-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-secreflo-secretin-human_en.pdf"},
    {"id":"16041","name":"Withdrawal letter: Opdivo (II-30)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T01:00:00Z","last_updated_date":"2018-01-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-opdivo-ii-30_en.pdf"},
    {"id":"16069","name":"Withdrawal letter: Luveniq","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-10-24T02:00:00Z","last_updated_date":"2011-10-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-luveniq_en.pdf"},
    {"id":"16157","name":"Withdrawal letter : Advexin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-12-17T01:00:00Z","last_updated_date":"2008-12-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-advexin_en.pdf"},
    {"id":"16785","name":"Withdrawal letter: Qinprezo","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-06-09T18:51:00Z","last_updated_date":"2017-06-09T18:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-qinprezo_en.pdf"},
    {"id":"16804","name":"Withdrawal letter: Elmisol","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-elmisol_en.pdf"},
    {"id":"16912","name":"Withdrawal letter: Loulla","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T13:00:00Z","last_updated_date":"2013-01-18T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-loulla_en.pdf"},
    {"id":"17355","name":"Withdrawal letter : Keytruda","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-keytruda_en.pdf"},
    {"id":"17737","name":"Withdrawal letter : Zactima","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-10-27T01:00:00Z","last_updated_date":"2009-10-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zactima_en.pdf"},
    {"id":"18018","name":"Withdrawal letter: Joicela","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-05-27T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-joicela_en.pdf"},
    {"id":"18419","name":"Withdrawal letter : Spanidin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-06-17T02:00:00Z","last_updated_date":"2008-06-17T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-spanidin_en.pdf"},
    {"id":"18434","name":"Withdrawal letter: Prohippur","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-04-27T11:33:00Z","last_updated_date":"2018-04-27T11:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-prohippur_en.pdf"},
    {"id":"18457","name":"Withdrawal letter: Plivensia","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-plivensia_en.pdf"},
    {"id":"19371","name":"Withdrawal letter: Folcepri","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-06-13T02:00:00Z","last_updated_date":"2014-06-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-folcepri_en.pdf"},
    {"id":"19563","name":"Withdrawal letter : Contusugene ladenovec gendux","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-06-12T02:00:00Z","last_updated_date":"2009-06-12T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-contusugene-ladenovec-gendux_en.pdf"},
    {"id":"19801","name":"Withdrawal letter: Ogivri","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ogivri_en.pdf"},
    {"id":"20067","name":"Withdrawal letter: Ertapenem Hospira","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ertapenem-hospira_en.pdf"},
    {"id":"20362","name":"Withdrawal letter : Zunrisa","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-10-25T02:00:00Z","last_updated_date":"2009-10-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zunrisa_en.pdf"},
    {"id":"20396","name":"Withdrawal letter: Faldaprevir Boehringer Ingelheim","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-06-27T02:00:00Z","last_updated_date":"2014-06-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-faldaprevir-boehringer-ingelheim_en.pdf"},
    {"id":"20447","name":"Withdrawal letter : Scintimun","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2006-05-17T02:00:00Z","last_updated_date":"2010-03-15T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-scintimun_en.pdf"},
    {"id":"20646","name":"Withdrawal letter : Sliwens","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-12-18T01:00:00Z","last_updated_date":"2009-12-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sliwens_en.pdf"},
    {"id":"21032","name":"Withdrawal letter: Aivlosin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-07-21T18:00:00Z","last_updated_date":"2014-07-21T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aivlosin_en.pdf"},
    {"id":"21389","name":"Withdrawal letter : DuoCover","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-05-22T02:00:00Z","last_updated_date":"2008-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-duocover_en.pdf"},
    {"id":"21459","name":"Withdrawal letter : Voraxaze","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2007-05-21T02:00:00Z","last_updated_date":"2007-05-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-voraxaze_en.pdf"},
    {"id":"21484","name":"Withdrawal letter: Raligize","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-raligize_en.pdf"},
    {"id":"21918","name":"Withdrawal letter: Joulferon","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-04-29T02:00:00Z","last_updated_date":"2010-04-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-joulferon_en.pdf"},
    {"id":"22017","name":"Withdrawal letter: Kyomarc","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-11-10T13:00:00Z","last_updated_date":"2017-11-10T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-kyomarc_en.pdf"},
    {"id":"22087","name":"Withdrawal letter : Nenad","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-11-30T01:00:00Z","last_updated_date":"2009-11-30T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-nenad_en.pdf"},
    {"id":"22625","name":"Withdrawal letter : Pristiqs","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-03-10T01:00:00Z","last_updated_date":"2008-03-10T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-pristiqs_en.pdf"},
    {"id":"23051","name":"Withdrawal letter: Zenhale","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-11-25T01:00:00Z","last_updated_date":"2010-11-25T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zenhale_en.pdf"},
    {"id":"23092","name":"Withdrawal letter: Opsiria","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-05-27T02:00:00Z","last_updated_date":"2016-05-27T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-opsiria_en.pdf"},
    {"id":"23336","name":"Withdrawal letter: Corluxin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2015-05-22T02:00:00Z","last_updated_date":"2015-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-corluxin_en.pdf"},
    {"id":"23459","name":"Withdrawal letter: VeraSeal","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2015-10-23T02:00:00Z","last_updated_date":"2015-10-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-veraseal_en.pdf"},
    {"id":"24097","name":"Withdrawal letter : Vorinostat MSD","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-02-13T01:00:00Z","last_updated_date":"2009-02-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-vorinostat-msd_en.pdf"},
    {"id":"24139","name":"Withdrawal letter: Sutent","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T11:32:00Z","last_updated_date":"2018-07-27T11:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sutent_en.pdf"},
    {"id":"24497","name":"Withdrawal letter : Sinerem","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2007-12-13T01:00:00Z","last_updated_date":"2007-12-13T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sinerem_en.pdf"},
    {"id":"24719","name":"Withdrawal letter : Insulin Human Rapid Marvel, Insulin Human Long Marvel, Insulin Human 30/70 Mix Marvel","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2007-12-20T01:00:00Z","last_updated_date":"2007-12-20T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-insulin-human-rapid-marvel-insulin-human-long-marvel-insulin-human-30-70-mix-marvel_en.pdf"},
    {"id":"24822","name":"Withdrawal letter : Garenoxacin mesylate","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2007-07-25T02:00:00Z","last_updated_date":"2007-07-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-garenoxacin-mesylate_en.pdf"},
    {"id":"24876","name":"Withdrawal letter : Mersarex","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-10-21T02:00:00Z","last_updated_date":"2009-10-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-mersarex_en.pdf"},
    {"id":"25001","name":"Withdrawal letter : Repaglinide Sun","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-04-28T02:00:00Z","last_updated_date":"2010-04-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-repaglinide-sun_en.pdf"},
    {"id":"25236","name":"Withdrawal letter: Raxone","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-04-26T02:00:00Z","last_updated_date":"2013-04-26T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-raxone_en.pdf"},
    {"id":"25618","name":"Topotecan SUN: Withdrawal letter","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-02-23T01:00:00Z","last_updated_date":"2011-02-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/topotecan-sun-withdrawal-letter_en.pdf"},
    {"id":"25740","name":"Withdrawal letter: Arikayce","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-arikayce_en.pdf"},
    {"id":"25771","name":"Withdrawal letter: Fulphila","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-fulphila_en.pdf"},
    {"id":"25895","name":"Withdrawal letter: Mulsevo (semuloparin sodium)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-07-20T02:00:00Z","last_updated_date":"2012-07-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-mulsevo-semuloparin-sodium_en.pdf"},
    {"id":"25927","name":"Withdrawal letter: Graspa","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-06-29T02:00:00Z","last_updated_date":"2018-06-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-graspa_en.pdf"},
    {"id":"26122","name":"Withdrawal letter : Oncophage","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-12-17T00:09:21Z","last_updated_date":"2009-12-17T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-oncophage_en.pdf"},
    {"id":"26525","name":"Withdrawal letter: Egranli","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T01:00:00Z","last_updated_date":"2014-11-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-egranli_en.pdf"},
    {"id":"26603","name":"Withdrawal letter: Zemfirza","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zemfirza_en.pdf"},
    {"id":"26728","name":"Withdrawal letter: OraNera","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-03-20T16:00:00Z","last_updated_date":"2013-03-20T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-oranera_en.pdf"},
    {"id":"26753","name":"Withdrawal letter for Oncept Melanoma","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2015-02-24T11:00:00Z","last_updated_date":"2015-02-24T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-oncept-melanoma_en.pdf"},
    {"id":"26929","name":"Withdrawal letter : Ramelteon","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-09-19T02:00:00Z","last_updated_date":"2008-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ramelteon_en.pdf"},
    {"id":"27145","name":"Withdrawal letter : Clopidogrel Teva Pharma","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-04-22T02:00:00Z","last_updated_date":"2009-04-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-clopidogrel-teva-pharma_en.pdf"},
    {"id":"27205","name":"Withdrawal letter : Cerepro","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2007-07-16T02:00:00Z","last_updated_date":"2007-07-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-cerepro_en.pdf"},
    {"id":"27541","name":"Withdrawal letter: Issarlos","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-issarlos_en.pdf"},
    {"id":"27689","name":"Withdrawal letter : Ixempra","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-03-18T01:00:00Z","last_updated_date":"2009-03-18T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ixempra_en.pdf"},
    {"id":"27714","name":"Withdrawal letter: Zydelig","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-02-23T01:00:00Z","last_updated_date":"2018-02-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zydelig_en.pdf"},
    {"id":"27852","name":"Withdrawal letter: Cokiera","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-cokiera_en.pdf"},
    {"id":"28620","name":"Withdrawal letter: Pemetrexed ditromethamine Hospira","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-10-14T02:00:00Z","last_updated_date":"2016-10-14T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-pemetrexed-ditromethamine-hospira_en.pdf"},
    {"id":"28668","name":"Withdrawal letter : Surfaxin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2006-06-06T02:00:00Z","last_updated_date":"2006-06-06T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-surfaxin_en.pdf"},
    {"id":"28756","name":"Withdrawal letter: Duloxetine Sandoz","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2015-04-24T14:00:00Z","last_updated_date":"2015-04-24T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-duloxetine-sandoz_en.pdf"},
    {"id":"29161","name":"Withdrawal letter Rienso","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2015-02-27T13:00:00Z","last_updated_date":"2015-02-27T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-rienso_en.pdf"},
    {"id":"29200","name":"Withdrawal letter : Lenalidomide Celgene Europe","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:00:00Z","last_updated_date":"2008-05-30T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-lenalidomide-celgene-europe_en.pdf"},
    {"id":"29461","name":"Withdrawal letter: Brilence","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-06-29T02:00:00Z","last_updated_date":"2010-06-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-brilence_en.pdf"},
    {"id":"29793","name":"Withdrawal letter: Ditelos","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-04-25T02:00:00Z","last_updated_date":"2014-04-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ditelos_en.pdf"},
    {"id":"30116","name":"Withdrawal letter : Cylatron","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-03-11T01:00:00Z","last_updated_date":"2009-03-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-cylatron_en.pdf"},
    {"id":"30133","name":"Withdrawal letter: Opdivo (II/0039)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-07-27T14:00:00Z","last_updated_date":"2018-07-27T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-opdivo-ii0039_en.pdf"},
    {"id":"30147","name":"Withdrawal letter: Winfuran","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-01-24T01:00:00Z","last_updated_date":"2013-01-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-winfuran_en.pdf"},
    {"id":"30366","name":"Withdrawal letter: Ceprotin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-11-21T13:00:00Z","last_updated_date":"2014-11-21T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ceprotin_en.pdf"},
    {"id":"30368","name":"Withdrawal letter: Tyvaso","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-03-23T01:00:00Z","last_updated_date":"2010-03-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tyvaso_en.pdf"},
    {"id":"30515","name":"Withdrawal letter: Imagify","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-08-28T02:00:00Z","last_updated_date":"2014-08-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-imagify_en.pdf"},
    {"id":"30520","name":"Withdrawal letter: Xgeva","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-xgeva_en.pdf"},
    {"id":"30618","name":"Withdrawal letter: Vynfinit","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-06-16T02:00:00Z","last_updated_date":"2014-06-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-vynfinit_en.pdf"},
    {"id":"30986","name":"Withdrawal letter: Aripiprazole Mylan","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-01-29T01:00:00Z","last_updated_date":"2016-01-29T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aripiprazole-mylan_en.pdf-1"},
    {"id":"31279","name":"Withdrawal letter: Rotigotine Mylan","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-01-26T01:00:00Z","last_updated_date":"2018-01-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-rotigotine-mylan_en.pdf"},
    {"id":"31389","name":"Withdrawal letter Ketoconazole AID- SCFM","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2015-03-27T01:00:00Z","last_updated_date":"2015-03-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ketoconazole-aid-scfm_en.pdf"},
    {"id":"31493","name":"Withdrawal letter: Zafiride","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-06-23T02:00:00Z","last_updated_date":"2017-06-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zafiride_en.pdf"},
    {"id":"31765","name":"Withdrawal letter: Begedina","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-07-22T02:00:00Z","last_updated_date":"2016-07-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-begedina_en.pdf"},
    {"id":"31901","name":"Withdrawal letter: Tigecycline Accord","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T14:00:00Z","last_updated_date":"2017-09-15T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tigecycline-accord_en.pdf"},
    {"id":"31949","name":"Withdrawal letter : Opaxio","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-09-21T02:00:00Z","last_updated_date":"2009-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-opaxio_en.pdf"},
    {"id":"31972","name":"Withdrawal letter : Exulett","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-09-09T02:00:00Z","last_updated_date":"2008-09-09T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-exulett_en.pdf"},
    {"id":"32071","name":"Withdrawal letter : Aquilda","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-05-23T02:00:00Z","last_updated_date":"2008-05-23T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aquilda_en.pdf"},
    {"id":"32100","name":"Withdrawal letter: Cheristin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-09-29T02:00:00Z","last_updated_date":"2017-09-29T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-cheristin_en.pdf"},
    {"id":"32118","name":"Withdrawal letter: Opdivo","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-09-15T02:00:00Z","last_updated_date":"2017-09-15T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-opdivo_en.pdf-0"},
    {"id":"32119","name":"Withdrawal letter : Theraloc","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-12-01T01:00:00Z","last_updated_date":"2008-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-theraloc_en.pdf"},
    {"id":"32459","name":"Withdrawal letter: Aranesp","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-03-23T01:00:00Z","last_updated_date":"2018-03-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aranesp_en.pdf"},
    {"id":"32747","name":"Withdrawal letter : DuoPlavin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-05-22T02:00:00Z","last_updated_date":"2008-05-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-duoplavin_en.pdf"},
    {"id":"33367","name":"Withdrawal letter: Desloratadine Krka","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-11-17T01:00:00Z","last_updated_date":"2011-11-17T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-desloratadine-krka_en.pdf"},
    {"id":"33646","name":"Withdrawal letter: Solithromycin Triskel EU Services","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-04-21T12:00:00Z","last_updated_date":"2017-04-21T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-solithromycin-triskel-eu-services_en.pdf"},
    {"id":"33959","name":"Withdrawal letter: Hyalograft C autograft","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-02-26T01:00:00Z","last_updated_date":"2013-02-26T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-hyalograft-c-autograft_en.pdf"},
    {"id":"33977","name":"Withdrawal letter: Somavert","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-09-19T02:00:00Z","last_updated_date":"2014-09-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-somavert_en.pdf"},
    {"id":"33978","name":"Withdrawal letter : Iplex","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2007-03-22T01:00:00Z","last_updated_date":"2007-03-22T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-iplex_en.pdf"},
    {"id":"34184","name":"Withdrawal letter: Combimarv, Isomarv, Solumarv","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-combimarv-isomarv-solumarv_en.pdf"}    {"id":"34825","name":"Withdrawal letter: Kalbitor","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-11-23T01:00:00Z","last_updated_date":"2011-11-23T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-kalbitor_en.pdf"},
    {"id":"35081","name":"Withdrawal letter: Translarna","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-03-24T01:00:00Z","last_updated_date":"2017-03-24T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-translarna_en.pdf"},
    {"id":"35536","name":"Withdrawal letter: Zioxtenzo","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-01-27T01:00:00Z","last_updated_date":"2017-01-27T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zioxtenzo_en.pdf"},
    {"id":"35591","name":"Ozespa: Withdrawal letter","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-01-31T01:00:00Z","last_updated_date":"2011-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/ozespa-withdrawal-letter_en.pdf"},
    {"id":"35619","name":"Withdrawal letter: Alendronic Acid/Colecalciferol Mylan","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-06-24T02:00:00Z","last_updated_date":"2016-06-24T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-alendronic-acidcolecalciferol-mylan_en.pdf"},
    {"id":"35676","name":"Heplisav withdrawal letter","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-02-21T13:00:00Z","last_updated_date":"2014-02-21T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/heplisav-withdrawal-letter_en.pdf"},
    {"id":"35796","name":"Withdrawal letter - Oxapex","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2015-07-29T14:00:00Z","last_updated_date":"2015-07-29T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-oxapex_en.pdf"},
    {"id":"35949","name":"Withdrawal letter : Orathecin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2006-01-19T01:00:00Z","last_updated_date":"2006-01-19T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-orathecin_en.pdf"},
    {"id":"36100","name":"Withdrawal letter : Ethyl Eicosapent","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-12-01T01:00:00Z","last_updated_date":"2009-12-01T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ethyl-eicosapent_en.pdf"},
    {"id":"36390","name":"Withdrawal letter: Enthryv","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2014-11-06T01:00:00Z","last_updated_date":"2014-11-06T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-enthryv_en.pdf"},
    {"id":"36410","name":"Withdrawal letter : Recothrom","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-12-11T01:00:00Z","last_updated_date":"2009-12-11T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-recothrom_en.pdf"},
    {"id":"36583","name":"Withdrawal letter : Biferonex","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-05-28T02:00:00Z","last_updated_date":"2009-05-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-biferonex_en.pdf"},
    {"id":"36617","name":"Withdrawal letter: Jenzyl (ridaforolimus)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-12-14T01:00:00Z","last_updated_date":"2012-12-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-jenzyl-ridaforolimus_en.pdf"},
    {"id":"36971","name":"Withdrawal letter : Rasival","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2010-09-28T02:00:00Z","last_updated_date":"2010-09-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-rasival_en.pdf"},
    {"id":"37336","name":"Withdrawal letter: Fanaptum","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-03-14T18:00:00Z","last_updated_date":"2013-03-14T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-fanaptum_en.pdf"},
    {"id":"37773","name":"Withdrawal letter : Ximelagatran 36 mg film coated tablets","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2006-02-14T01:00:00Z","last_updated_date":"2006-02-14T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ximelagatran-36-mg-film-coated-tablets_en.pdf"},
    {"id":"38041","name":"Withdrawal letter: Memantine FGK","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T01:00:00Z","last_updated_date":"2013-01-25T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-memantine-fgk_en.pdf"},
    {"id":"38108","name":"Withdrawal letter : Vibativ","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-10-20T02:00:00Z","last_updated_date":"2008-10-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-vibativ_en.pdf"},
    {"id":"39189","name":"Tekinex: Withdrawal letter","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-01-31T01:00:00Z","last_updated_date":"2011-01-31T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/tekinex-withdrawal-letter_en.pdf"},
    {"id":"39205","name":"Withdrawal letter - Oxapex","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-06-25T02:00:00Z","last_updated_date":"2012-06-25T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-oxapex_en.pdf-0"},
    {"id":"39263","name":"Withdrawal letter : Epostim","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-04-19T02:00:00Z","last_updated_date":"2011-04-19T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-epostim_en.pdf"},
    {"id":"39702","name":"Withdrawal letter : Fluad Paediatric","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2012-02-21T01:00:00Z","last_updated_date":"2012-02-21T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-fluad-paediatric_en.pdf"},
    {"id":"39866","name":"Withdrawal letter : Ellefore","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2008-10-13T02:00:00Z","last_updated_date":"2008-10-13T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ellefore_en.pdf"},
    {"id":"39936","name":"Withdrawal letter : Gastromotal","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2007-11-05T01:00:00Z","last_updated_date":"2007-11-05T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-gastromotal_en.pdf"},
    {"id":"40055","name":"Withdrawal letter: Kepnetic","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-kepnetic_en.pdf"},
    {"id":"40212","name":"Withdrawal letter: Ibandronic Acid Hexal","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2011-08-22T02:00:00Z","last_updated_date":"2011-08-22T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ibandronic-acid-hexal_en.pdf"},
    {"id":"40452","name":"Withdrawal letter: Arzerra","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T13:00:00Z","last_updated_date":"2016-12-16T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-arzerra_en.pdf"},
    {"id":"41608","name":"Withdrawal letter: IXinity","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2013-06-28T02:00:00Z","last_updated_date":"2013-06-28T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ixinity_en.pdf"},
    {"id":"41645","name":"Withdrawal letter : Ramvocid","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2009-08-20T02:00:00Z","last_updated_date":"2009-08-20T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ramvocid_en.pdf"},
    {"id":"41939","name":"Withdrawal letter: Graspa","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-12-16T01:00:00Z","last_updated_date":"2016-12-16T01:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-graspa_en.pdf-0"},
    {"id":"41949","name":"Withdrawal letter: Infinia","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2017-07-21T02:00:00Z","last_updated_date":"2017-07-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-infinia_en.pdf"},
    {"id":"41954","name":"Withdrawal letter Adempas","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2016-09-16T02:00:00Z","last_updated_date":"2016-09-16T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-adempas_en.pdf"},
    {"id":"42114","name":"Withdrawal letter: Treprostinil SciPharm Sarl","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-09-21T02:00:00Z","last_updated_date":"2018-09-21T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-treprostinil-scipharm-sarl_en.pdf"},
    {"id":"42700","name":"Withdrawal letter: Tecentriq","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-11-16T11:21:00Z","last_updated_date":"2018-11-19T17:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tecentriq_en.pdf"},
    {"id":"42798","name":"Withdrawal letter: HopGuard Gold","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-11-26T16:41:00Z","last_updated_date":"2018-11-26T16:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-hopguard-gold_en.pdf"},
    {"id":"42912","name":"Withdrawal letter : Zydax","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-12-03T18:09:00Z","last_updated_date":"2018-12-03T18:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zydax_en.pdf"},
    {"id":"43016","name":"Withdrawal letter: Fyzoclad","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-fyzoclad_en.pdf"},
    {"id":"43018","name":"Withdrawal letter: Canakinumab Novartis","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-12-14T12:00:00Z","last_updated_date":"2018-12-14T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-canakinumab-novartis_en.pdf"},
    {"id":"43578","name":"Withdrawal letter : Cavoley","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T16:25:00Z","last_updated_date":"2019-02-01T16:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-cavoley_en.pdf-0"},
    {"id":"43580","name":"Withdrawal letter : Efgratin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T16:41:00Z","last_updated_date":"2019-02-01T16:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-efgratin_en.pdf-0"},
    {"id":"43609","name":"Withdrawal letter : Vynpenta","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T12:57:00Z","last_updated_date":"2019-02-01T12:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-vynpenta_en.pdf"},
    {"id":"43938","name":"Withdrawal letter : Epjevy","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-03-01T15:52:00Z","last_updated_date":"2019-03-01T15:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-epjevy_en.pdf"},
    {"id":"44163","name":"Withdrawal letter : Equitend","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-04-01T18:40:00Z","last_updated_date":"2019-04-01T18:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-equitend_en.pdf"},
    {"id":"44567","name":"Withdrawal letter: Ambrisentan Zentiva","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T14:34:00Z","last_updated_date":"2019-05-29T14:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ambrisentan-zentiva_en.pdf"},
    {"id":"44619","name":"Withdrawal letter: Radicava","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-05-29T19:05:00Z","last_updated_date":"2019-05-29T19:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-radicava_en.pdf"},
    {"id":"44941","name":"Withdrawal letter: ABP 710","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-06-28T11:32:00Z","last_updated_date":"2019-06-28T11:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-abp-710_en.pdf"},
    {"id":"45465","name":"Withdrawal letter: Coliprotec F4/F18","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-09-18T11:23:00Z","last_updated_date":"2019-09-18T11:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-coliprotec-f4f18_en.pdf"},
    {"id":"45718","name":"Withdrawal letter: Xyndari","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T02:00:00Z","last_updated_date":"2019-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-xyndari_en.pdf"},
    {"id":"45719","name":"Withdrawal letter: Nuzyra","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T02:00:00Z","last_updated_date":"2019-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-nuzyra_en.pdf"},
    {"id":"45720","name":"Withdrawal letter: Ekesivy","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-10-18T02:00:00Z","last_updated_date":"2019-10-18T02:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ekesivy_en.pdf"},
    {"id":"45967","name":"Withdrawal letter: Luxceptar","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T16:06:00Z","last_updated_date":"2019-11-15T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-luxceptar_en.pdf"},
    {"id":"45968","name":"Withdrawal letter: Linhaliq","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T16:10:00Z","last_updated_date":"2019-11-15T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-linhaliq_en.pdf"},
    {"id":"45969","name":"Withdrawal letter: Opsumit (II-0029)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2019-11-15T16:12:00Z","last_updated_date":"2019-11-15T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-opsumit-ii-0029_en.pdf"},
    {"id":"46596","name":"Withdrawal letter : Keytruda (II-72)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-01-31T16:06:00Z","last_updated_date":"2020-01-31T16:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-keytruda-ii-72_en.pdf"},
    {"id":"46617","name":"Withdrawal letter: Idhifa","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-01-31T12:00:00Z","last_updated_date":"2020-01-31T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-idhifa_en.pdf"},
    {"id":"46901","name":"Withdrawal letter: Opdivo and Yervoy (WS/1372)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T11:06:00Z","last_updated_date":"2020-02-28T11:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-opdivo-and-yervoy-ws1372_en.pdf"},
    {"id":"46903","name":"Withdrawal letter: Axumin (II-11)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-02-28T11:14:00Z","last_updated_date":"2020-02-28T11:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-axumin-ii-11_en.pdf"},
    {"id":"46928","name":"Public statement on Varuby: Withdrawal of the marketing authorisation in the European Union","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-03-02T15:44:00Z","last_updated_date":"2020-03-02T15:44:00Z","reference_number":"EMA/100421/2020","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/public-statement-varuby-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"47101","name":"Withdrawal letter: Doxorubicin Hydrochloride Tillomed","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-doxorubicin-hydrochloride-tillomed_en.pdf"},
    {"id":"47183","name":"Rituximab Mabion: Withdrawal letter","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-03-30T15:00:00Z","last_updated_date":"2020-03-30T15:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/rituximab-mabion-withdrawal-letter_en.pdf"},
    {"id":"47758","name":"Withdrawal letter: Erlotinib Accord","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-erlotinib-accord_en.pdf"},
    {"id":"47759","name":"Withdrawal letter: Fingolimod Mylan","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-fingolimod-mylan_en.pdf"},
    {"id":"47804","name":"Withdrawal letter: Fingolimod Mylan","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-05-29T12:00:00Z","last_updated_date":"2020-05-29T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-fingolimod-mylan_en.pdf-0"},
    {"id":"48127","name":"Withdrawal letter: Zemdri","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zemdri_en.pdf"},
    {"id":"48130","name":"Withdrawal letter: Sondelbay","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sondelbay_en.pdf"},
    {"id":"48145","name":"Withdrawal letter: Xiidra","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-06-26T12:00:00Z","last_updated_date":"2020-06-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-xiidra_en.pdf"},
    {"id":"48382","name":"Withdrawal letter:  Rayoqta","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T12:00:00Z","last_updated_date":"2020-07-24T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-rayoqta_en.pdf"},
    {"id":"48390","name":"Withdrawal letter: Abilify Mycite","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T09:26:00Z","last_updated_date":"2020-07-24T09:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-abilify-mycite_en.pdf"},
    {"id":"48551","name":"Withdrawal letter: Tulatrixx","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-08-04T17:11:00Z","last_updated_date":"2020-08-04T17:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tulatrixx_en.pdf"},
    {"id":"48828","name":"Withdrawal letter: Upkanz","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-09-18T12:00:00Z","last_updated_date":"2020-09-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-upkanz_en.pdf"},
    {"id":"49234","name":"Withdrawal letter: Puldysa","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T14:11:00Z","last_updated_date":"2020-11-12T14:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-puldysa_en.pdf"},
    {"id":"49238","name":"Withdrawal letter: Roctavian","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T14:44:00Z","last_updated_date":"2020-11-13T14:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-roctavian_en.pdf"},
    {"id":"49241","name":"Withdrawal letter: Tibsovo","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-11-13T15:02:00Z","last_updated_date":"2020-11-13T15:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tibsovo_en.pdf"},
    {"id":"49474","name":"Withdrawal letter: Artobend","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2020-12-11T12:00:00Z","last_updated_date":"2020-12-11T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-artobend_en.pdf"},
    {"id":"49957","name":"Withdrawal letter: Tecentriq (II-42)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-02-01T12:00:00Z","last_updated_date":"2021-02-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tecentriq-ii-42_en.pdf"},
    {"id":"49958","name":"Withdrawal letter: Dexamethasone Taw","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-01-29T12:00:00Z","last_updated_date":"2021-01-29T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-dexamethasone-taw_en.pdf"},
    {"id":"50719","name":"Withdrawal letter: Brilique","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-03-26T17:00:00Z","last_updated_date":"2021-03-26T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-brilique_en.pdf"},
    {"id":"51573","name":"Withdrawal letter: Esbriet (II-69)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-06-25T15:02:00Z","last_updated_date":"2021-06-25T15:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-esbriet-ii-69_en.pdf"},
    {"id":"52020","name":"Withdrawal letter: Tecentriq (II-52)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-07-23T12:27:00Z","last_updated_date":"2021-07-23T12:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tecentriq-ii-52_en.pdf"},
    {"id":"52463","name":"Withdrawal letter: Livmarli","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T13:16:00Z","last_updated_date":"2021-09-17T13:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-livmarli_en.pdf"},
    {"id":"52467","name":"Withdrawal letter: Oportuzumab monatox DLRC Pharma Services","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T12:00:00Z","last_updated_date":"2021-09-17T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-oportuzumab-monatox-dlrc-pharma-services_en.pdf"},
    {"id":"52473","name":"Withdrawal letter: Teriparatide Cinnagen","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T16:18:00Z","last_updated_date":"2021-09-17T16:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-teriparatide-cinnagen_en.pdf"},
    {"id":"52479","name":"Withdrawal letter: Sildenafil FGK","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-09-17T16:58:00Z","last_updated_date":"2021-09-17T16:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sildenafil-fgk_en.pdf"},
    {"id":"52811","name":"Withdrawal letter: Zynyz","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-10-15T13:43:00Z","last_updated_date":"2021-10-15T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zynyz_en.pdf"},
    {"id":"52970","name":"Withdrawal letter: Bamlanivimab and etesevimab","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-11-02T15:05:00Z","last_updated_date":"2021-11-02T15:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-bamlanivimab-and-etesevimab_en.pdf"},
    {"id":"53046","name":"Withdrawal letter: Flynpovi","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T13:43:00Z","last_updated_date":"2021-11-12T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-flynpovi_en.pdf"},
    {"id":"53048","name":"Withdrawal letter: Cervarix","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-11-12T13:43:00Z","last_updated_date":"2021-11-12T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-cervarix_en.pdf"},
    {"id":"53277","name":"Public statement on Equidacent : Withdrawal of the marketing authorisation in the European Union","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-11-25T16:53:00Z","last_updated_date":"2021-11-25T16:53:00Z","reference_number":"EMA/584437/2021","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/public-statement-equidacent-withdrawal-marketing-authorisation-european-union_en.pdf"},
    {"id":"53389","name":"Withdrawal letter: Aivlosin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-12-07T13:43:00Z","last_updated_date":"2021-12-07T13:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aivlosin_en.pdf-0"},
    {"id":"53491","name":"Withdrawal letter: Zektayos-Hepjuvo","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2021-12-17T13:12:00Z","last_updated_date":"2021-12-17T13:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zektayos-hepjuvo_en.pdf"},
    {"id":"53890","name":"Withdrawal letter: Aliqopa","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T13:12:00Z","last_updated_date":"2022-01-28T13:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aliqopa_en.pdf"},
    {"id":"53954","name":"Withdrawal letter: Tookad (II-13)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T14:24:00Z","last_updated_date":"2022-01-28T14:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tookad-ii-13_en.pdf"},
    {"id":"53959","name":"Withdrawal letter: Brilique (II-49)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T15:15:00Z","last_updated_date":"2022-01-28T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-brilique-ii-49_en.pdf"},
    {"id":"53974","name":"Withdrawal letter:  Abylqis","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T19:19:00Z","last_updated_date":"2022-01-28T19:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-abylqis_en.pdf"},
    {"id":"54586","name":"Withdrawal letter: Dimherity","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-03-29T10:43:00Z","last_updated_date":"2022-03-29T10:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-dimherity_en.pdf"},
    {"id":"54611","name":"Withdrawal letter : Bravecto","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-03-29T15:12:00Z","last_updated_date":"2022-03-29T15:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-bravecto_en.pdf"},
    {"id":"54773","name":"Withdrawal letter: Aduhelm","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T13:12:00Z","last_updated_date":"2022-04-22T13:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aduhelm_en.pdf"},
    {"id":"54785","name":"Withdrawal letter: Miplyffa","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T13:12:00Z","last_updated_date":"2022-04-22T13:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-miplyffa_en.pdf"},
    {"id":"54794","name":"Withdrawal letter: Neffy","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-04-22T13:12:00Z","last_updated_date":"2022-04-22T13:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-neffy_en.pdf"},
    {"id":"55023","name":"Withdrawal letter: HemAryo","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T12:00:00Z","last_updated_date":"2022-05-20T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-hemaryo_en.pdf"}    {"id":"55041","name":"Withdrawal letter: Sitoiganap","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-05-20T11:34:00Z","last_updated_date":"2022-05-20T11:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sitoiganap_en.pdf"},
    {"id":"55612","name":"Withdrawal letter: Parsaclisib Incyte Biosciences Distribution B.V.","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T13:36:00Z","last_updated_date":"2022-07-22T13:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-parsaclisib-incyte-biosciences-distribution-bv_en.pdf"},
    {"id":"55626","name":"Withdrawal letter: Imcivree","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-07-21T16:01:00Z","last_updated_date":"2022-07-21T16:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-imcivree_en.pdf"},
    {"id":"55840","name":"Withdrawal letter: Sevsury","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-08-19T16:01:00Z","last_updated_date":"2022-08-19T16:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sevsury_en.pdf"},
    {"id":"55843","name":"Withdrawal letter: Exkivity","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-08-19T09:35:00Z","last_updated_date":"2022-08-19T09:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-exkivity_en.pdf"},
    {"id":"56414","name":"Withdrawal letter: Hervelous","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-10-14T11:46:00Z","last_updated_date":"2022-10-14T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-hervelous_en.pdf"},
    {"id":"56417","name":"Withdrawal letter: Tuznue","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-10-14T11:57:00Z","last_updated_date":"2022-10-14T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tuznue_en.pdf"},
    {"id":"56559","name":"Withdrawal letter: Ilaris","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T11:46:00Z","last_updated_date":"2022-11-11T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ilaris_en.pdf"},
    {"id":"56560","name":"Withdrawal letter: Febseltiq","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T11:46:00Z","last_updated_date":"2022-11-11T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-febseltiq_en.pdf"},
    {"id":"56561","name":"Withdrawal letter: Orepaxam","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T11:46:00Z","last_updated_date":"2022-11-11T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-orepaxam_en.pdf"},
    {"id":"56570","name":"Withdrawal letter: Gavreto","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-11-11T11:46:00Z","last_updated_date":"2022-11-11T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-gavreto_en.pdf"},
    {"id":"56995","name":"Withdrawal letter: Imbarkyd","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T11:36:00Z","last_updated_date":"2022-12-16T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-imbarkyd_en.pdf"},
    {"id":"57033","name":"Withdrawal letter : Olumiant (II-0028)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2022-12-16T12:00:00Z","last_updated_date":"2022-12-16T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-olumiant-ii-0028_en.pdf"},
    {"id":"57380","name":"Withdrawal letter : Imbruvica (II-73)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T12:00:00Z","last_updated_date":"2023-01-27T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-imbruvica-ii-73_en.pdf"},
    {"id":"57387","name":"Withdrawal letter : Versiguard SARS CoV2","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-01-25T14:05:00Z","last_updated_date":"2023-01-25T14:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-versiguard-sars-cov2_en.pdf"},
    {"id":"57738","name":"Withdrawal letter : Buvidal (II-17)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-02-24T12:00:00Z","last_updated_date":"2023-02-24T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-buvidal-ii-17_en.pdf"},
    {"id":"57843","name":"Withdrawal letter: Garsun (artesunate)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-03-01T11:56:00Z","last_updated_date":"2023-03-01T11:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-garsun-artesunate_en.pdf"},
    {"id":"57849","name":"Withdrawal letter: Hepsera (adefovir dipivoxil)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-03-01T15:03:00Z","last_updated_date":"2023-03-01T15:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-hepsera-adefovir-dipivoxil_en.pdf"},
    {"id":"58174","name":"Withdrawal letter: Feraheme","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T11:57:00Z","last_updated_date":"2023-03-31T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-feraheme_en.pdf"},
    {"id":"58175","name":"Withdrawal letter: Raltegravir Viatris","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-03-31T11:57:00Z","last_updated_date":"2023-03-31T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-raltegravir-viatris_en.pdf"},
    {"id":"58543","name":"Withdrawal letter: Lumevoq","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-04-26T16:28:00Z","last_updated_date":"2023-04-26T16:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-lumevoq_en.pdf"},
    {"id":"58769","name":"Withdrawal letter: Asimtufii","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T12:00:00Z","last_updated_date":"2023-05-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-asimtufii_en.pdf"},
    {"id":"58770","name":"Withdrawal letter: Susvimo","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-05-26T16:28:00Z","last_updated_date":"2023-05-26T16:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-susvimo_en.pdf"},
    {"id":"59010","name":"Withdrawal letter : Tidhesco","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-06-21T14:01:00Z","last_updated_date":"2023-06-21T14:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tidhesco_en.pdf"},
    {"id":"59055","name":"Withdrawal letter: Zefylti","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T16:09:00Z","last_updated_date":"2023-06-23T16:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zefylti_en.pdf"},
    {"id":"59059","name":"Withdrawal letter: Dyrupeg","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-06-23T12:00:00Z","last_updated_date":"2023-06-23T12:00:00Z","reference_number":"EMA/274951/2023","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-dyrupeg_en.pdf"},
    {"id":"59117","name":"Withdrawal letter: Lagevrio","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-06-27T13:49:00Z","last_updated_date":"2023-06-27T13:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-lagevrio_en.pdf"},
    {"id":"59373","name":"Withdrawal letter: Gazyvaro (II-0052)","type":"withdrawal-letter","status":"Adopted","consultation_date":"","first_published_date":"2023-07-21T17:26:00Z","last_updated_date":"2023-07-21T17:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-gazyvaro-ii-0052_en.pdf"},
    {"id":"59398","name":"Withdrawal letter: Jesduvroq","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T12:00:00Z","last_updated_date":"2023-07-21T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-jesduvroq_en.pdf"},
    {"id":"59413","name":"Withdrawal letter: Gefzuris","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-07-21T18:03:00Z","last_updated_date":"2023-07-21T18:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-gefzuris_en.pdf"},
    {"id":"59602","name":"Withdrawal letter: Lutholaz (pegfilgrastim)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-08-17T10:56:00Z","last_updated_date":"2023-08-17T10:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-lutholaz-pegfilgrastim_en.pdf"},
    {"id":"59941","name":"Withdrawal letter: Skycovion","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T09:27:00Z","last_updated_date":"2023-09-15T09:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-skycovion_en.pdf"},
    {"id":"59942","name":"Withdrawal letter: Vivjoa","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-09-15T09:33:00Z","last_updated_date":"2023-09-15T09:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-vivjoa_en.pdf"},
    {"id":"60358","name":"Withdrawal letter: Jivadco","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T12:00:00Z","last_updated_date":"2023-10-13T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-jivadco_en.pdf"},
    {"id":"60359","name":"Withdrawal letter: Sugammadex Lorien","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-10-13T17:46:00Z","last_updated_date":"2023-10-13T17:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sugammadex-lorien_en.pdf"},
    {"id":"60360","name":"Withdrawal letter: RoActemra (II-114)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-10-10T17:51:00Z","last_updated_date":"2023-10-10T17:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-roactemra-ii-114_en.pdf"},
    {"id":"60583","name":"Withdrawal letter: Entolimod TMC","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2018-09-25T17:43:00Z","last_updated_date":"2018-09-25T17:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-entolimod-tmc_en.pdf"},
    {"id":"60810","name":"Withdrawal letter: Vijoice","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T12:04:00Z","last_updated_date":"2023-11-10T12:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-vijoice_en.pdf"},
    {"id":"61026","name":"Withdrawal letter: Bylvay (II-11)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2023-11-10T17:24:01Z","last_updated_date":"2023-11-10T17:24:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-bylvay-ii-11_en.pdf-0"},
    {"id":"62692","name":"Withdrawal letter: Orencia (II-152)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T17:42:54Z","last_updated_date":"2024-03-22T17:42:54Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-orencia-ii-152_en.pdf"},
    {"id":"62700","name":"Withdrawal letter: Adcetris (II-109)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T10:39:35Z","last_updated_date":"2024-03-22T10:39:35Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-adcetris-ii-109_en.pdf"},
    {"id":"62706","name":"Withdrawal letter: Ongentys (WS2552-60)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T12:33:04Z","last_updated_date":"2024-03-22T12:33:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ongentys-ws2552-60_en.pdf"},
    {"id":"62712","name":"Withdrawal letter: Ontilyv (WS-2552)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-03-22T14:26:59Z","last_updated_date":"2024-03-22T14:26:59Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ontilyv-ws-2552_en.pdf"},
    {"id":"63091","name":"Withdrawal letter: GeGant","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-04-26T12:00:00Z","last_updated_date":"2024-04-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-gegant_en.pdf"},
    {"id":"63420","name":"Withdrawal letter: Kinharto (omecamtiv mecarbil)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T13:00:00Z","last_updated_date":"2024-05-31T13:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-kinharto_en.pdf"},
    {"id":"63429","name":"Withdrawal letter: Scenesse","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-05-31T10:40:13Z","last_updated_date":"2024-05-31T10:40:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-scenesse_en.pdf"},
    {"id":"63793","name":"Withdrawal letter dabigatran etexilate teva","type":"withdrawal-letter","status":"Adopted","consultation_date":"","first_published_date":"2024-06-28T12:00:00Z","last_updated_date":"2024-06-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-dabigatran-etexilate-teva_en.pdf"},
    {"id":"64400","name":"Withdrawal letter : Upstelda","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-07-30T12:44:14Z","last_updated_date":"2024-07-30T12:44:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-upstelda_en.pdf"},
    {"id":"64957","name":"Withdrawal letter: Durysta","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T11:11:01Z","last_updated_date":"2024-09-20T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-durysta_en.pdf"},
    {"id":"64959","name":"Withdrawal letter: Sialanar (II-29)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T09:59:31Z","last_updated_date":"2024-09-20T09:59:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sialanar-ii-29_en.pdf"},
    {"id":"64961","name":"Withdrawal letter: Tecentriq (II-81)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-09-20T10:00:05Z","last_updated_date":"2024-09-20T10:00:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tecentriq-ii-81_en.pdf"},
    {"id":"65318","name":"Withdrawal letter: Apremilast Viatris","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T11:11:01Z","last_updated_date":"2024-10-18T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-apremilast-viatris_en.pdf"},
    {"id":"65345","name":"Withdrawal letter: Epixram","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-10-18T12:00:00Z","last_updated_date":"2024-10-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-epixram_en.pdf"},
    {"id":"65660","name":"Withdrawal letter: Izelvay","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-izelvay_en.pdf"},
    {"id":"65668","name":"Withdrawal letter: Inaqovi (II-0002 - myelodysplastic syndromes)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-11-15T12:00:00Z","last_updated_date":"2024-11-15T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-inaqovi-ii-0002-myelodysplastic-syndromes_en.pdf"},
    {"id":"65720","name":"Withdrawal letter: Inaqovi (II-0002 -CMML)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-11-20T10:55:41Z","last_updated_date":"2024-11-20T10:55:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-inaqovi-ii-0002-cmml_en.pdf"},
    {"id":"66114","name":"Withdrawal letter : Alofisel (II-51-G)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2024-12-13T12:00:00Z","last_updated_date":"2024-12-13T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-alofisel-ii-51-g_en.pdf"},
    {"id":"66549","name":"Withdrawal letter: Nugalviq","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-nugalviq_en.pdf"},
    {"id":"66551","name":"Withdrawal letter: Datopotamab deruxtecan Daiichi Sankyo","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-datopotamab-deruxtecan-daiichi-sankyo_en.pdf"},
    {"id":"67031","name":"Withdrawal letter: Rilonacept FGK Representative Service GmbH","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T12:00:13Z","last_updated_date":"2025-02-28T12:00:13Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-rilonacept-fgk-representative-service-gmbh_en.pdf"},
    {"id":"67038","name":"Withdrawal letter: Pelgraz Paediatric","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T10:15:31Z","last_updated_date":"2025-02-28T10:15:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-pelgraz-paediatric_en.pdf"},
    {"id":"67049","name":"Withdrawal letter: Bimervax (II-0016)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T11:49:56Z","last_updated_date":"2025-02-28T11:49:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-bimervax-ii-0016_en.pdf"},
    {"id":"67051","name":"Withdrawal letter: Dupixent (II-0083)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-02-28T11:52:14Z","last_updated_date":"2025-02-28T11:52:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-dupixent-ii-0083_en.pdf"},
    {"id":"67500","name":"Withdrawal letter: Cinainu","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T14:09:37Z","last_updated_date":"2025-03-28T14:09:37Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-cinainu_en.pdf"},
    {"id":"67520","name":"Withdrawal letter: Amyvid (II-0046)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T12:00:00Z","last_updated_date":"2025-03-28T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-amyvid-ii-0046_en.pdf"},
    {"id":"67526","name":"Withdrawal letter: Insulin Human Rechon","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-03-28T11:08:15Z","last_updated_date":"2025-03-28T11:08:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-insulin-human-rechon_en.pdf"},
    {"id":"67774","name":"Withdrawal letter: Skojoy","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-04-14T11:42:24Z","last_updated_date":"2025-04-14T11:42:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-skojoy_en.pdf"},
    {"id":"67953","name":"Withdrawal letter: Dazluma","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-04-25T14:08:44Z","last_updated_date":"2025-04-25T14:08:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-dazluma_en.pdf"},
    {"id":"67988","name":"Withdrawal letter: Ngenla (II-16)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-04-25T14:05:52Z","last_updated_date":"2025-04-25T14:05:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ngenla-ii-16_en.pdf"},
    {"id":"68380","name":"Withdrawal letter: Lutathera (II-52)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T10:38:40Z","last_updated_date":"2025-05-23T10:38:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-lutathera-ii-52_en.pdf"},
    {"id":"68381","name":"Withdrawal letter: Teriparatide Ascend","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-05-23T10:44:25Z","last_updated_date":"2025-05-23T10:44:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-teriparatide-ascend_en.pdf"},
    {"id":"69449","name":"Withdrawal letter: Nidlegy","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T12:00:00Z","last_updated_date":"2025-07-25T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-nidlegy_en.pdf"},
    {"id":"69474","name":"Withdrawal letter: Aplidin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T09:29:48Z","last_updated_date":"2025-07-25T09:29:48Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-aplidin_en.pdf"},
    {"id":"69502","name":"Withdrawal letter: Ifinwil","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-07-25T15:04:57Z","last_updated_date":"2025-07-25T15:04:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ifinwil_en.pdf"},
    {"id":"69845","name":"Withdrawal letter: Amtagvi","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-08-22T12:14:25Z","last_updated_date":"2025-08-22T12:14:25Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-amtagvi_en.pdf"},
    {"id":"69846","name":"Withdrawal letter: Fanskya","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-08-22T12:16:31Z","last_updated_date":"2025-08-22T12:16:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-fanskya_en.pdf"},
    {"id":"70152","name":"Withdrawal letter: Omforro","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T14:57:27Z","last_updated_date":"2025-09-19T14:57:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-omforro_en.pdf"},
    {"id":"70153","name":"Withdrawal letter: Tuzodi","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T15:00:57Z","last_updated_date":"2025-09-19T15:00:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-tuzodi_en.pdf"},
    {"id":"70274","name":"Withdrawal letter: Equilis EHV 1+4","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-09-25T14:27:16Z","last_updated_date":"2025-09-25T14:27:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-equilis-ehv-14_en.pdf"},
    {"id":"70440","name":"Withdrawal letter: Sileo (II-22)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-10-03T14:22:14Z","last_updated_date":"2025-10-03T14:22:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sileo-ii-22_en.pdf"},
    {"id":"70601","name":"Withdrawal letter: Hydrocortisone Aguettant","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-10-17T14:14:32Z","last_updated_date":"2025-10-17T14:14:32Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-hydrocortisone-aguettant_en.pdf"},
    {"id":"71138","name":"Withdrawal letter: Nurzigma","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-11-14T15:00:04Z","last_updated_date":"2025-11-14T15:00:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-nurzigma_en.pdf"},
    {"id":"71169","name":"Withdrawal letter: Ohtuvayre","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-11-14T12:48:18Z","last_updated_date":"2025-11-14T12:48:18Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-ohtuvayre_en.pdf"},
    {"id":"71176","name":"Withdrawal letter: Insulin Aspart Injection","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-11-14T11:51:26Z","last_updated_date":"2025-11-14T11:51:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-insulin-aspart-injection_en.pdf"},
    {"id":"71336","name":"Withdrawal letter : Vectra 3D (VRA/0026/G)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-11-25T15:18:52Z","last_updated_date":"2025-11-25T15:18:52Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-vectra-3d-vra-0026-g_en.pdf"},
    {"id":"71649","name":"Withdrawal letter : Sirolimus TriviumVet","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2025-12-10T14:53:55Z","last_updated_date":"2025-12-10T14:53:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-sirolimus-triviumvet_en.pdf"},
    {"id":"72685","name":"Withdrawal letter: Zumrad","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2026-02-27T12:00:00Z","last_updated_date":"2026-02-27T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-zumrad_en.pdf"},
    {"id":"73140","name":"Withdrawal letter: Cunitraxx","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2026-03-20T16:28:27Z","last_updated_date":"2026-03-20T16:28:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-cunitraxx_en.pdf"},
    {"id":"73232","name":"Withdrawal letter: Blarcamesine Anavex","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2026-03-27T08:49:08Z","last_updated_date":"2026-03-27T08:49:08Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-blarcamesine-anavex_en.pdf"},
    {"id":"73418","name":"Withdrawal letter : Equidormin","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2026-04-10T13:38:58Z","last_updated_date":"2026-04-10T13:38:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-equidormin_en.pdf"},
    {"id":"73561","name":"Withdrawal letter: Pluvicto (VR-0000288073)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-04-24T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-pluvicto-vr-0000288073_en.pdf"},
    {"id":"73564","name":"Withdrawal letter: Viokat","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2026-04-24T12:00:00Z","last_updated_date":"2026-04-24T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-viokat_en.pdf"},
    {"id":"73806","name":"Withdrawal letter: Orblid","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T15:20:56Z","last_updated_date":"2026-05-22T15:20:56Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-orblid_en.pdf"},
    {"id":"73827","name":"Withdrawal letter: Veblocema","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2026-05-22T10:56:30Z","last_updated_date":"2026-05-22T10:56:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-veblocema_en.pdf"},
    {"id":"74333","name":"Withdrawal letter: BiResp Spiromax (WS-2806-G)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T16:19:17Z","last_updated_date":"2026-06-26T16:19:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-biresp-spiromax-ws-2806-g_en.pdf"},
    {"id":"74335","name":"Withdrawal letter: DuoResp Spiromax (WS-2806-G)","type":"withdrawal-letter","status":"unknown","consultation_date":"","first_published_date":"2026-06-26T16:27:28Z","last_updated_date":"2026-06-26T16:27:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-duoresp-spiromax-ws-2806-g_en.pdf"},
    {"id":"3585","name":"Work instructions for handling of paediatric Article 45 work-sharing procedures by the Co-ordination Group for Mutual Recognition and Decentralised Procedure – Human (CMDh) secretariat","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2014-03-21T16:30:00Z","reference_number":"WIN/H/3374","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-handling-paediatric-article-45-work-sharing-procedures-co-ordination-group-mutual-recognition-and-decentralised-procedure-human-cmdh-secretariat_en.pdf"},
    {"id":"3861","name":"Work instructions for organising a EudraVigilance reporting review meeting with stakeholders","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2009-06-26T02:00:00Z","last_updated_date":"2011-05-27T02:00:00Z","reference_number":"WIN/H/3209","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-organising-eudravigilance-reporting-review-meeting-stakeholders_en.pdf"},
    {"id":"3948","name":"Work instructions for organisation of paediatric expert group meetings","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2012-11-29T11:26:00Z","last_updated_date":"2012-11-29T11:26:00Z","reference_number":"WIN/H/3412","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-organisation-paediatric-expert-group-meetings_en.pdf"},
    {"id":"4655","name":"Work instructions for preparing notices for publication in Official Journal of the European Union (OJEU)","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2013-04-18T11:30:00Z","last_updated_date":"2013-04-18T11:30:00Z","reference_number":"WIN/EMA/0133","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-preparing-notices-publication-official-journal-european-union-ojeu_en.pdf"}    {"id":"4860","name":"Work instructions for recording, validation and production of certificates of medicinal products","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2012-04-04T12:00:00Z","last_updated_date":"2012-04-04T12:00:00Z","reference_number":"WIN/INSP/2029","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-recording-validation-and-production-certificates-medicinal-products_en.pdf"},
    {"id":"5828","name":"Work instructions for using the Agency's Twitter channel","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2014-02-28T10:45:00Z","reference_number":"WIN/EMA/0123","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-using-agencys-twitter-channel_en.pdf"},
    {"id":"6436","name":"Work instructions for product information for parallel distributors","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2013-07-10T02:00:00Z","last_updated_date":"2013-07-10T02:00:00Z","reference_number":"WIN/INS/2035","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-product-information-parallel-distributors_en.pdf"},
    {"id":"6479","name":"Work Instructions for design of an analysis of EudraVigilance data","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2019-01-07T02:00:00Z","last_updated_date":"2019-01-07T09:30:00Z","reference_number":"WIN/H/3290","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-design-analysis-eudravigilance-data_en.pdf"},
    {"id":"8682","name":"Work instructions on documentation of external requests for access to information and their responses","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2011-02-25T01:00:00Z","last_updated_date":"2011-02-25T01:00:00Z","reference_number":"WIN/H/3320","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-documentation-external-requests-access-information-and-their-responses_en.pdf"},
    {"id":"8707","name":"Work instructions for managing EudraCT alerts","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2014-10-13T19:30:00Z","last_updated_date":"2014-10-13T19:30:00Z","reference_number":"WIN/INS/2053","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-managing-eudract-alerts_en.pdf"},
    {"id":"9431","name":"Work instructions for handling of paediatric Article 46 work-sharing procedures by the Co-ordination Group for Mutual Recognition and Decentralised Procedure – Human (CMDh) secretariat","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2011-06-27T02:00:00Z","last_updated_date":"2011-06-27T02:00:00Z","reference_number":"WIN/H/3376","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-handling-paediatric-article-46-work-sharing-procedures-co-ordination-group-mutual-recognition-and-decentralised-procedure-human-cmdh-secretariat_en.pdf"},
    {"id":"9717","name":"Work Instructions for new standard term requests to EDQM","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2010-02-18T01:00:00Z","last_updated_date":"2010-02-18T01:00:00Z","reference_number":"WIN/EMA/0108","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-new-standard-term-requests-edqm_en.pdf"},
    {"id":"11445","name":"Work instructions for publication of the monthly and annual overview of parallel distribution notices issued by the European Medicines Agency","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2009-07-20T02:00:00Z","last_updated_date":"2012-07-11T17:30:02Z","reference_number":"WIN/H/2037","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-publication-monthly-and-annual-overview-parallel-distribution-notices-issued-european-medicines-agency_en.pdf"},
    {"id":"13655","name":"Work instructions for European Pharmacovigilance Issues Tracking Tool (EPITT) user registration and management – Assessment of eligibility for an EPITT account","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2016-10-27T16:05:00Z","reference_number":"WIN/H/3367","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-european-pharmacovigilance-issues-tracking-tool-epitt-user-registration-and-management-assessment-eligibility-epitt-account_en.pdf"},
    {"id":"14523","name":"Work instructions for Processing requests for inclusion in the list of substances not falling within the scope of Regulation EC 470/2009 (out of scope)","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2017-05-10T19:10:00Z","last_updated_date":"2017-05-10T19:10:00Z","reference_number":"WIN/V/4151","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-processing-requests-inclusion-list-substances-not-falling-within-scope-regulation-ec-4702009-out-scope_en.pdf"},
    {"id":"14797","name":"Work instructions for sending of lines to take and safety-related information to the European Union regulatory network and international partners","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2011-04-14T02:00:00Z","reference_number":"WIN/H/3210","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-sending-lines-take-and-safety-related-information-european-union-regulatory-network-and-international-partners_en.pdf"},
    {"id":"15729","name":"Work instructions for marketing status and sunset clause monitoring for centrally authorised veterinary medicinal products","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2017-05-12T15:45:00Z","last_updated_date":"2017-05-12T15:45:00Z","reference_number":"WIN/V/4125","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-marketing-status-and-sunset-clause-monitoring-centrally-authorised-veterinary-medicinal-products_en.pdf"},
    {"id":"16094","name":"Work instructions for non-removal of the European public assessment report following withdrawal / expiry of the marketing authorisation","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2007-09-14T02:00:00Z","last_updated_date":"2012-09-13T17:23:00Z","reference_number":"WIN/H/3202","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-non-removal-european-public-assessment-report-following-withdrawal-expiry-marketing-authorisation_en.pdf"},
    {"id":"18300","name":"Work instructions for inspection of quality control facilities located in third countries","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2012-01-09T12:40:00Z","last_updated_date":"2017-04-18T11:08:00Z","reference_number":"WIN/INSP/2047","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-inspection-quality-control-facilities-located-third-countries_en.pdf"},
    {"id":"18552","name":"Work instructions for non-removal of the European public assessment report following suspension of the marketing authorisation","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2008-07-01T02:00:00Z","last_updated_date":"2012-09-13T17:21:00Z","reference_number":"WIN/H/3216","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-non-removal-european-public-assessment-report-following-suspension-marketing-authorisation_en.pdf"},
    {"id":"18894","name":"Work instructions for management of the procedure for assessment of the final report of Post-Authorisation Safety Studies (PASS) for veterinary medicines","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2016-04-04T14:15:00Z","last_updated_date":"2016-04-04T14:15:00Z","reference_number":"WIN/V/4028","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-management-procedure-assessment-final-report-post-authorisation-safety-studies-pass-veterinary-medicines_en.pdf"},
    {"id":"19718","name":"Work instructions for Regulatory check of initial notifications of parallel distribution","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2012-07-19T13:00:00Z","last_updated_date":"2012-07-19T13:00:00Z","reference_number":"WIN/INSP/2031","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-regulatory-check-initial-notifications-parallel-distribution_en.pdf"},
    {"id":"19891","name":"Work instructions for transparency of outcome of resubmission in previously published refusals or withdrawal European public assessment reports","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2008-06-18T02:00:00Z","last_updated_date":"2012-09-13T17:20:00Z","reference_number":"WIN/H/3242","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-transparency-outcome-resubmission-previously-published-refusals-or-withdrawal-european-public-assessment-reports_en.pdf"},
    {"id":"19922","name":"Work instructions for publication of web content on www.ema.europa.eu","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2009-03-18T01:00:00Z","last_updated_date":"2016-07-07T19:00:00Z","reference_number":"WIN/EMA/0099","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-publication-web-content-wwwemaeuropaeu_en.pdf"},
    {"id":"23214","name":"Work Instructions for QRD co-ordination of post-opinion linguistic reviews of Initial Applications and Annex II applications","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2010-02-18T01:00:00Z","last_updated_date":"2010-02-18T01:00:00Z","reference_number":"WIN/EMA/0106","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-qrd-co-ordination-post-opinion-linguistic-reviews-initial-applications-and-annex-ii-applications_en.pdf"},
    {"id":"23779","name":"Work Instructions for Connect to e-Submission trading community","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2009-06-24T02:00:00Z","last_updated_date":"2009-06-24T02:00:00Z","reference_number":"WIN/IT/5030","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-connect-e-submission-trading-community_en.pdf"},
    {"id":"24782","name":"Work instructions for handling of Article 29(1) referrrals to the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) (60-day procedure) by the CMDh secretariat (including Article 13 re...","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2011-08-31T02:00:00Z","last_updated_date":"2011-08-31T02:00:00Z","reference_number":"WIN/H/3339","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-handling-article-291-referrrals-co-ordination-group-mutual-recognition-and-decentralised-procedures-human-cmdh-60-day-procedure-cmdh-secretariat-including-article-13-re_en.pdf"},
    {"id":"24924","name":"Work instructions for data entry in Corporate GxP for good-clinical-practice and pharmacovigilance inspections","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2013-03-26T13:30:00Z","last_updated_date":"2013-03-26T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-data-entry-corporate-gxp-good-clinical-practice-and-pharmacovigilance-inspections_en.pdf"},
    {"id":"27374","name":"Work instructions for organisation of CVMP Working Party meetings","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2017-01-05T15:10:00Z","last_updated_date":"2017-01-05T15:10:00Z","reference_number":"WIN/V/4029","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-organisation-cvmp-working-party-meetings_en.pdf"},
    {"id":"27497","name":"Work Instructions for preparation of CxMP overviews of procedures requiring Member States linguistic review","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2010-02-18T01:00:00Z","last_updated_date":"2010-02-18T01:00:00Z","reference_number":"WIN/EMA/0105","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-preparation-cxmp-overviews-procedures-requiring-member-states-linguistic-review_en.pdf"},
    {"id":"27673","name":"Work instructions for handling of renewals for centrally authorised veterinary medicinal products","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2016-07-20T16:30:00Z","last_updated_date":"2016-07-20T16:30:00Z","reference_number":"WIN/V/4030","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-handling-renewals-centrally-authorised-veterinary-medicinal-products_en.pdf"},
    {"id":"28210","name":"Work Instructions for EudraVigilance medicinal product dictionary: population with approved substances - type vaccines","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2009-07-10T02:00:00Z","last_updated_date":"2010-10-01T02:00:00Z","reference_number":"WIN/H/3302","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-eudravigilance-medicinal-product-dictionary-population-approved-substances-type-vaccines_en.pdf"},
    {"id":"28536","name":"Work instructions for user registration and management - Maintenance of the European Pharmacovigilance Issues Tracking Tool (EPITT) accounts and provision of trainings to users","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2011-04-14T02:00:00Z","last_updated_date":"2016-10-20T19:05:00Z","reference_number":"WIN/H/3369","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-user-registration-and-management-maintenance-european-pharmacovigilance-issues-tracking-tool-epitt-accounts-and-provision-trainings-users_en.pdf"},
    {"id":"29032","name":"Work instructions for QRD forms 2 (former linguistic check forms)","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2009-05-05T02:00:00Z","last_updated_date":"2010-12-15T01:00:00Z","reference_number":"WIN/EMA/0098","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-qrd-forms-2-former-linguistic-check-forms_en.pdf"},
    {"id":"29497","name":"Work instructions for EU-RMP annex 1: validation","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2009-07-01T02:00:00Z","last_updated_date":"2011-02-07T01:00:00Z","reference_number":"WIN/H/3292","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-eu-rmp-annex-1-validation_en.pdf"},
    {"id":"29675","name":"Work instructions for preparation of the annual good-manufacturing-practice re-inspection programme","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2012-09-28T12:00:00Z","last_updated_date":"2012-09-28T12:00:00Z","reference_number":"WIN/INSP/2046","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-preparation-annual-good-manufacturing-practice-re-inspection-programme_en.pdf"},
    {"id":"29966","name":"Work instructions for how to create reports from scientific memory database (SMD)","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2011-11-18T12:30:00Z","last_updated_date":"2011-11-18T12:30:00Z","reference_number":"WIN/INSP/2040","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-how-create-reports-scientific-memory-database-smd_en.pdf"},
    {"id":"30683","name":"Work instructions for good-manufacturing-practice validation of initial marketing-authorisation applications, line extensions and variations","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2013-04-30T11:40:00Z","last_updated_date":"2013-04-30T11:40:00Z","reference_number":"WIN/INS/2041","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-good-manufacturing-practice-validation-initial-marketing-authorisation-applications-line-extensions-and-variations_en.pdf"},
    {"id":"34365","name":"Work instructions for maintenance of rapid-alert/non-urgent-information (RA/NUI) contact points list and fax machine for RA/NUI use","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2008-12-05T01:00:00Z","last_updated_date":"2011-08-01T02:00:00Z","reference_number":"WIN/H/3150","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-maintenance-rapid-alertnon-urgent-information-ranui-contact-points-list-and-fax-machine-ranui-use_en.pdf"},
    {"id":"36346","name":"Work instructions for handling of veterinary e-submissions","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2016-07-20T16:30:00Z","last_updated_date":"2016-07-20T16:30:00Z","reference_number":"WIN/V/4062","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-handling-veterinary-e-submissions_en.pdf"},
    {"id":"36655","name":"Work instructions for checking licences for parallel distribution","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2009-06-23T02:00:00Z","last_updated_date":"2012-07-24T18:00:00Z","reference_number":"WIN/INSP/2038","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-checking-licences-parallel-distribution_en.pdf"},
    {"id":"36889","name":"Work instructions for checklist for the co-ordination of training organised by the Section for Clinical and Non-Clinical Compliance","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2011-10-04T11:16:00Z","last_updated_date":"2011-10-04T11:16:00Z","reference_number":"WIN/INSP/2034","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-checklist-co-ordination-training-organised-section-clinical-and-non-clinical-compliance_en.pdf"},
    {"id":"37311","name":"Work instructions for handling of withdrawals of applications for marketing authorisation of veterinary medicines","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2014-05-08T14:00:00Z","last_updated_date":"2014-05-08T14:00:00Z","reference_number":"WIN/V/4031","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-handling-withdrawals-applications-marketing-authorisation-veterinary-medicines_en.pdf"},
    {"id":"37964","name":"Work instructions for secretarial tasks for initial preparation and update of veterinary European public assessment reports (EPARs)","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2015-05-07T13:10:00Z","last_updated_date":"2016-02-10T15:55:00Z","reference_number":"WIN/V/4035","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-secretarial-tasks-initial-preparation-and-update-veterinary-european-public-assessment-reports-epars_en.pdf"},
    {"id":"40195","name":"Work instructions for how to create and revise the pharmacovigilance inspections programme","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2013-01-15T18:00:00Z","last_updated_date":"2013-01-15T18:00:00Z","reference_number":"WIN/INSP/2042","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-how-create-and-revise-pharmacovigilance-inspections-programme_en.pdf"},
    {"id":"40968","name":"Work instructions for workflow of data entry to scientific-memory database","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2013-02-12T16:00:00Z","last_updated_date":"2013-02-12T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-workflow-data-entry-scientific-memory-database_en.pdf"},
    {"id":"41311","name":"Work instructions for announcement of good-clinical-practice / pharmacovigilance inspection to reporting inspectorate, applicant and third-country inspectorate prepared by the Section for Clinical and Non-clinical Compli...","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2012-09-28T12:00:00Z","last_updated_date":"2012-09-28T12:00:00Z","reference_number":"WIN/INSP/2025","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-announcement-good-clinical-practice-pharmacovigilance-inspection-reporting-inspectorate-applicant-and-third-country-inspectorate-prepared-section-clinical-and-non-clinical-compli_en.pdf"},
    {"id":"41591","name":"Work instructions for checking of MRL status of constituents of veterinary medicinal products subject to a marketing authorisation application to the EMA","type":"win","status":"Adopted","consultation_date":"","first_published_date":"2015-05-28T13:10:00Z","last_updated_date":"2015-05-28T13:10:00Z","reference_number":"WIN/V/4046","document_url":"https://www.ema.europa.eu/en/documents/win/work-instructions-checking-mrl-status-constituents-veterinary-medicinal-products-subject-marketing-authorisation-application-ema_en.pdf"},
    {"id":"3067","name":"Pharmacovigilance Risk Assessment Committee (PRAC) work plan 2015","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2015-07-07T13:05:00Z","last_updated_date":"2015-07-07T13:05:00Z","reference_number":"EMA/PRAC/794108/2013","document_url":"https://www.ema.europa.eu/en/documents/work-programme/pharmacovigilance-risk-assessment-committee-prac-work-plan-2015_en.pdf"},
    {"id":"3492","name":"Pharmacovigilance Risk Assessment Committee (PRAC): Work Plan 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2018-03-16T17:30:00Z","last_updated_date":"2018-03-16T17:30:00Z","reference_number":"EMA/PRAC/139104/2018","document_url":"https://www.ema.europa.eu/en/documents/work-programme/pharmacovigilance-risk-assessment-committee-prac-work-plan-2018_en.pdf"},
    {"id":"3621","name":"Work programme for the European Agency for the Evaluation of Medicinal Products 2003","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2003-06-12T02:09:21Z","last_updated_date":"2003-06-12T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_es.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_de.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2003_sv.pdf"}},
    {"id":"3909","name":"European Medicines Agency modelling and simulation working group plan 2015","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2015-04-17T12:05:00Z","last_updated_date":"2016-04-20T19:00:00Z","reference_number":"EMA/811070/2015","document_url":"https://www.ema.europa.eu/en/documents/work-programme/european-medicines-agency-modelling-and-simulation-working-group-plan-2015_en.pdf"},
    {"id":"4441","name":"Multiannual work programme 2018-2020","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2018-03-19T11:30:00Z","last_updated_date":"2018-03-19T11:30:00Z","reference_number":"EMA/73199/2018","document_url":"https://www.ema.europa.eu/en/documents/work-programme/multiannual-work-programme-2018-2020_en.pdf"},
    {"id":"4452","name":"Work plan of the CHMP Blood Products Working Party for 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2016-03-08T11:00:00Z","last_updated_date":"2018-01-18T16:37:00Z","reference_number":"EMA/CHMP/BPWP/399637/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-chmp-blood-products-working-party-2018_en.pdf"},
    {"id":"4632","name":"CPMP Working Party on Herbal Medicinal Products (HMPWP) work programme 2004-2005","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2003-11-27T12:09:21Z","last_updated_date":"2003-11-27T12:09:21Z","reference_number":"EMEA/CPMP/HMPWP/5885/03","document_url":"https://www.ema.europa.eu/en/documents/work-programme/cpmp-working-party-herbal-medicinal-products-hmpwp-work-programme-2004-2005_en.pdf"},
    {"id":"4651","name":"Work plan for the joint CHMP/ CVMP Quality Working Party for 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-01-26T17:40:00Z","last_updated_date":"2017-12-21T11:30:00Z","reference_number":"EMA/CHMP/CVMP/QWP/504882/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-joint-chmp-cvmp-quality-working-party-2018_en.pdf"},
    {"id":"4943","name":"Work plan for Good Clinical Practice Inspectors Working Group 2013","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2013-01-29T09:35:00Z","last_updated_date":"2013-01-29T09:35:00Z","reference_number":"EMA/569405/2012","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-good-clinical-practice-inspectors-working-group-2013_en.pdf"},
    {"id":"5168","name":"Summary of the work programme for the European Medicines Agency 2007","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2007-01-30T00:09:21Z","last_updated_date":"2007-01-30T00:09:21Z","reference_number":"EMEA/MB/442095/2006","document_url":"https://www.ema.europa.eu/en/documents/work-programme/summary-work-programme-european-medicines-agency-2007_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/work-programme/summary-work-programme-european-medicines-agency-2007_bg.pdf","es":"https://www.ema.europa.eu/es/documents/work-programme/summary-work-programme-european-medicines-agency-2007_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/summary-work-programme-european-medicines-agency-2007_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/summary-work-programme-european-medicines-agency-2007_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/summary-work-programme-european-medicines-agency-2007_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/summary-work-programme-european-medicines-agency-2007_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/summary-work-programme-european-medicines-agency-2007_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/summary-work-programme-european-medicines-agency-2007_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/summary-work-programme-european-medicines-agency-2007_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/summary-work-programme-european-medicines-agency-2007_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/summary-work-programme-european-medicines-agency-2007_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/summary-work-programme-european-medicines-agency-2007_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/summary-work-programme-european-medicines-agency-2007_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/summary-work-programme-european-medicines-agency-2007_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/summary-work-programme-european-medicines-agency-2007_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/summary-work-programme-european-medicines-agency-2007_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/work-programme/summary-work-programme-european-medicines-agency-2007_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/work-programme/summary-work-programme-european-medicines-agency-2007_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/summary-work-programme-european-medicines-agency-2007_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/summary-work-programme-european-medicines-agency-2007_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/summary-work-programme-european-medicines-agency-2007_sv.pdf"}},
    {"id":"5482","name":"CHMP Workplan 2008-2010 “Specialised Experts and SAGs: Optimisation of Consultation process from CHMP”","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2010-04-09T02:00:00Z","last_updated_date":"2010-04-09T02:00:00Z","reference_number":"Ref. EMA/312354/2009","document_url":"https://www.ema.europa.eu/en/documents/work-programme/chmp-workplan-2008-2010-specialised-experts-and-sags-optimisation-consultation-process-chmp_en.pdf"},
    {"id":"6854","name":"Work programme of the European Medicines Agency 2012","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T15:20:00Z","last_updated_date":"2012-02-17T15:20:00Z","reference_number":"EMA/MB/554514/2011","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2012_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/work-programme/work-programme-european-medicines-agency-2012_bg.pdf","es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-medicines-agency-2012_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/work-programme-european-medicines-agency-2012_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-medicines-agency-2012_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-medicines-agency-2012_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/work-programme-european-medicines-agency-2012_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-medicines-agency-2012_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-medicines-agency-2012_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-medicines-agency-2012_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/work-programme-european-medicines-agency-2012_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/work-programme-european-medicines-agency-2012_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/work-programme-european-medicines-agency-2012_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/work-programme-european-medicines-agency-2012_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-medicines-agency-2012_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/work-programme-european-medicines-agency-2012_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-medicines-agency-2012_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/work-programme/work-programme-european-medicines-agency-2012_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/work-programme/work-programme-european-medicines-agency-2012_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/work-programme-european-medicines-agency-2012_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-medicines-agency-2012_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-medicines-agency-2012_sv.pdf"}},
    {"id":"6974","name":"Work programme for the European Medicines Agency 2010","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2010-03-19T01:00:00Z","last_updated_date":"2010-03-19T01:00:00Z","reference_number":"EMA/MB/203131/2009","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2010_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/work-programme/work-programme-european-medicines-agency-2010_bg.pdf","es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-medicines-agency-2010_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/work-programme-european-medicines-agency-2010_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-medicines-agency-2010_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-medicines-agency-2010_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/work-programme-european-medicines-agency-2010_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-medicines-agency-2010_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-medicines-agency-2010_fr.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/work-programme-european-medicines-agency-2010_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/work-programme-european-medicines-agency-2010_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/work-programme-european-medicines-agency-2010_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/work-programme-european-medicines-agency-2010_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-medicines-agency-2010_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/work-programme-european-medicines-agency-2010_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-medicines-agency-2010_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/work-programme/work-programme-european-medicines-agency-2010_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/work-programme/work-programme-european-medicines-agency-2010_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/work-programme-european-medicines-agency-2010_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-medicines-agency-2010_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-medicines-agency-2010_sv.pdf"}},
    {"id":"7188","name":"Work plan for the Cardiovascular Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2018-01-05T17:00:00Z","last_updated_date":"2018-01-08T17:00:00Z","reference_number":"EMA/CHMP/365586/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-cardiovascular-working-party-2018_en.pdf"},
    {"id":"8463","name":"Work plan for the CVMP Safety Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-19T15:30:00Z","last_updated_date":"2017-12-19T15:30:00Z","reference_number":"EMA/CVMP/SWP/278493/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-cvmp-safety-working-party-2018_en.pdf"},
    {"id":"9300","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2014","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2014-05-22T16:55:00Z","last_updated_date":"2014-05-22T16:55:00Z","reference_number":"EMA/INS/PhV/555137/2013","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2014_en.pdf"},
    {"id":"10946","name":"Work plan 2018 for the joint CVMP/CHMP working group on the application of the 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products (J3RsWG)","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-19T15:30:00Z","last_updated_date":"2017-12-19T15:30:00Z","reference_number":"EMA/CHMP/CVMP/3Rs/479556/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-2018-joint-cvmpchmp-working-group-application-3rs-replacement-reduction-and-refinement-regulatory-testing-medicinal-products-j3rswg_en.pdf"},
    {"id":"11087","name":"Mandate, objectives and rules of procedure for HMPC temporary working parties and drafting groups","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2009-12-16T01:00:00Z","last_updated_date":"2017-06-29T12:20:00Z","reference_number":"EMEA/HMPC/644241/2009 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/work-programme/mandate-objectives-and-rules-procedure-hmpc-temporary-working-parties-and-drafting-groups_en.pdf"},
    {"id":"11270","name":"Work programme until 2025 of the HMA/EMA task force on availability of authorised medicines for human and veterinary use","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2018-08-29T14:00:00Z","last_updated_date":"2023-05-17T15:35:00Z","reference_number":"EMA/724592/2022 Rev.2","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-until-2025-hmaema-task-force-availability-authorised-medicines-human-and-veterinary-use_en.pdf"},
    {"id":"11322","name":"PDCO work plan 2019","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2019-03-06T11:45:00Z","last_updated_date":"2019-03-06T11:45:00Z","reference_number":"EMA/PDCO/598684/2018","document_url":"https://www.ema.europa.eu/en/documents/work-programme/pdco-work-plan-2019_en.pdf"},
    {"id":"11834","name":"Work programme for the European Agency for the Evaluation of Medicinal Products 2000-2001","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2001-02-16T00:09:21Z","last_updated_date":"2001-02-16T00:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2000-2001_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2000-2001_es.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2000-2001_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2000-2001_fr.pdf"}},
    {"id":"11875","name":"Work programme for the European Medicines Agency 2005","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2005-02-16T00:09:21Z","last_updated_date":"2005-02-16T00:09:21Z","reference_number":"EMEA/MB/138351/2004/en/Final","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2005_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-medicines-agency-2005_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/work-programme-european-medicines-agency-2005_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-medicines-agency-2005_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-medicines-agency-2005_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/work-programme-european-medicines-agency-2005_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-medicines-agency-2005_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-medicines-agency-2005_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-medicines-agency-2005_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/work-programme-european-medicines-agency-2005_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/work-programme-european-medicines-agency-2005_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/work-programme-european-medicines-agency-2005_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/work-programme-european-medicines-agency-2005_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-medicines-agency-2005_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/work-programme-european-medicines-agency-2005_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-medicines-agency-2005_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/work-programme/work-programme-european-medicines-agency-2005_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/work-programme-european-medicines-agency-2005_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-medicines-agency-2005_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-medicines-agency-2005_sv.pdf"}},
    {"id":"12056","name":"Work plan for Good Clinical Practice Inspectors Working Group 2015","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2015-03-06T15:40:00Z","last_updated_date":"2015-03-06T15:40:00Z","reference_number":"EMA/INS/GCP/434364/2014","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-good-clinical-practice-inspectors-working-group-2015_en.pdf"},
    {"id":"12150","name":"Work plan for the Pharmacokinetics Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2018-01-05T15:00:00Z","last_updated_date":"2018-01-05T15:00:00Z","reference_number":"EMA/CHMP/643117/2016","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacokinetics-working-party-2018_en.pdf"},
    {"id":"12221","name":"HMPC work programme for 2012-2015","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2011-12-22T10:45:00Z","last_updated_date":"2011-12-22T10:45:00Z","reference_number":"EMA/HMPC/501139/2011","document_url":"https://www.ema.europa.eu/en/documents/work-programme/hmpc-work-programme-2012-2015_en.pdf"},
    {"id":"12575","name":"Work programme of the European Medicines Agency 2016","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2016-03-07T13:00:00Z","last_updated_date":"2016-07-11T13:40:00Z","reference_number":"EMA/92499/2016 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2016_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/work-programme/work-programme-european-medicines-agency-2016_bg.pdf","es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-medicines-agency-2016_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/work-programme-european-medicines-agency-2016_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-medicines-agency-2016_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-medicines-agency-2016_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/work-programme-european-medicines-agency-2016_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-medicines-agency-2016_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-medicines-agency-2016_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/work-programme/work-programme-european-medicines-agency-2016_hr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-medicines-agency-2016_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/work-programme-european-medicines-agency-2016_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/work-programme-european-medicines-agency-2016_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/work-programme-european-medicines-agency-2016_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/work-programme-european-medicines-agency-2016_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-medicines-agency-2016_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/work-programme-european-medicines-agency-2016_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-medicines-agency-2016_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/work-programme/work-programme-european-medicines-agency-2016_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/work-programme/work-programme-european-medicines-agency-2016_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/work-programme-european-medicines-agency-2016_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-medicines-agency-2016_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-medicines-agency-2016_sv.pdf"}},
    {"id":"12983","name":"Work plan for the CHMP Respiratory Drafting Group for 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2011-12-21T17:15:00Z","last_updated_date":"2018-01-18T15:32:00Z","reference_number":"EMA/CHMP/383892/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-chmp-respiratory-drafting-group-2018_en.pdf"},
    {"id":"12988","name":"Work plan for the Modelling and Simulation Working Group for 2018","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2018-02-26T13:45:00Z","last_updated_date":"2018-02-26T13:45:00Z","reference_number":"EMA/710355/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-modelling-and-simulation-working-group-2018_en.pdf"},
    {"id":"13932","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2015","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2015-05-04T13:37:00Z","last_updated_date":"2015-05-04T13:37:00Z","reference_number":"EMA/INS/PhV/574749/2014","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2015_en.pdf"},
    {"id":"14781","name":"Work plan for the HMPC Quality Drafting Group (Q DG) 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-02-27T18:15:00Z","last_updated_date":"2018-03-21T13:00:00Z","reference_number":"EMA/HMPC/114746/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-hmpc-quality-drafting-group-q-dg-2018_en.pdf"},
    {"id":"15695","name":"Pharmacovigilance Risk Assessment Committee (PRAC) work plan 2016","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2016-02-24T16:30:00Z","last_updated_date":"2016-02-24T16:30:00Z","reference_number":"EMA/148594/2016","document_url":"https://www.ema.europa.eu/en/documents/work-programme/pharmacovigilance-risk-assessment-committee-prac-work-plan-2016_en.pdf"},
    {"id":"16031","name":"Work plan for Biostatistics Working Party (BSWP) 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2012-12-18T01:00:00Z","last_updated_date":"2018-02-08T18:30:00Z","reference_number":"EMA/CHMP/333668/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-biostatistics-working-party-bswp-2018_en.pdf"},
    {"id":"16594","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2016","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2016-06-28T13:30:00Z","last_updated_date":"2016-06-28T13:30:00Z","reference_number":"EMA/INS/PhV/618590/2015","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2016_en.pdf"},
    {"id":"17970","name":"Committee for Advanced Therapies (CAT) work programme 2010 - 2015","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/CAT/235374/2010","document_url":"https://www.ema.europa.eu/en/documents/work-programme/committee-advanced-therapies-cat-work-programme-2010-2015_en.pdf"},
    {"id":"18072","name":"Work programme for the European Medicines Agency 2008","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2008-04-07T02:09:21Z","last_updated_date":"2008-04-07T02:09:21Z","reference_number":"EMEA/MB/487174/2007 Adopted","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2008_en.pdf"},
    {"id":"18154","name":"Work programme for the European Medicines Agency 2007","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2007-03-13T00:09:21Z","last_updated_date":"2007-03-13T00:09:21Z","reference_number":"EMEA/MB/428793/2006/EN/FINAL","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2007_en.pdf"},
    {"id":"18702","name":"Work plan for Good Clinical Practice (GCP) Inspectors Working Group for 2017","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-02-21T18:00:00Z","last_updated_date":"2017-02-21T18:00:00Z","reference_number":"EMA/INS/GCP/13279/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-good-clinical-practice-gcp-inspectors-working-group-2017_en.pdf"},
    {"id":"19170","name":"Work program 2011 of the EMA/CAT and Medical Devices’ Notified Body (EMA/CAT-NG) Collaboration Group","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2010-12-06T01:00:00Z","last_updated_date":"2010-12-06T01:00:00Z","reference_number":"EMA/328081/2010","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-program-2011-ema-cat-medical-devices-notified-body-ema-cat-ng-collaboration-group_en.pdf"},
    {"id":"19618","name":"European Medicines Agency modelling and simulation working group plan 2017","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2017-03-09T09:55:00Z","last_updated_date":"2017-03-09T09:55:00Z","reference_number":"EMA/799154/2016","document_url":"https://www.ema.europa.eu/en/documents/work-programme/european-medicines-agency-modelling-and-simulation-working-group-plan-2017_en.pdf"},
    {"id":"19933","name":"Work programme for the European Agency for the Evaluation of Medicinal Products 1997-1998","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"1997-02-11T00:09:21Z","last_updated_date":"1997-02-11T00:09:21Z","reference_number":"EMEA/MB/002/97.final","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1997-1998_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1997-1998_es.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1997-1998_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1997-1998_fr.pdf"}},
    {"id":"20322","name":"Work plan for the Gastroenterology Drafting Group 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2018-01-10T11:00:00Z","last_updated_date":"2018-01-10T11:00:00Z","reference_number":"EMA/CHMP/350919/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-gastroenterology-drafting-group-2018_en.pdf"},
    {"id":"20375","name":"Work programme for the European Medicines Agency 2006","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2007-03-13T00:09:21Z","last_updated_date":"2007-03-13T00:09:21Z","reference_number":"EMEA/MB/374230/2005","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2006_en.pdf"},
    {"id":"20870","name":"Work programme for the European Agency for the Evaluation of Medicinal Products 1998-1999","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"1998-10-13T02:09:21Z","last_updated_date":"1998-10-13T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1998-1999_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1998-1999_es.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1998-1999_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1998-1999_fr.pdf"}},
    {"id":"21119","name":"Work plan for the Working Party on European Union Monographs and List (MLWP) 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-02-27T18:15:00Z","last_updated_date":"2018-03-09T16:00:00Z","reference_number":"EMA/HMPC/142826/2018","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-working-party-european-union-monographs-and-list-mlwp-2018_en.pdf"},
    {"id":"21400","name":"Summary of the work programme for the European Medicines Agency 2008","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2008-03-28T00:09:21Z","last_updated_date":"2008-03-28T00:09:21Z","reference_number":"EMEA/MB/556125/2007","document_url":"https://www.ema.europa.eu/en/documents/work-programme/summary-work-programme-european-medicines-agency-2008_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/work-programme/summary-work-programme-european-medicines-agency-2008_bg.pdf","es":"https://www.ema.europa.eu/es/documents/work-programme/summary-work-programme-european-medicines-agency-2008_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/summary-work-programme-european-medicines-agency-2008_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/summary-work-programme-european-medicines-agency-2008_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/summary-work-programme-european-medicines-agency-2008_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/summary-work-programme-european-medicines-agency-2008_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/summary-work-programme-european-medicines-agency-2008_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/summary-work-programme-european-medicines-agency-2008_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/summary-work-programme-european-medicines-agency-2008_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/summary-work-programme-european-medicines-agency-2008_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/summary-work-programme-european-medicines-agency-2008_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/summary-work-programme-european-medicines-agency-2008_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/summary-work-programme-european-medicines-agency-2008_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/summary-work-programme-european-medicines-agency-2008_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/summary-work-programme-european-medicines-agency-2008_pl.pdf","ro":"https://www.ema.europa.eu/ro/documents/work-programme/summary-work-programme-european-medicines-agency-2008_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/work-programme/summary-work-programme-european-medicines-agency-2008_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/summary-work-programme-european-medicines-agency-2008_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/summary-work-programme-european-medicines-agency-2008_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/summary-work-programme-european-medicines-agency-2008_sv.pdf"}},
    {"id":"21552","name":"Work plan for the CVMP Ad Hoc Group on Veterinary Novel Therapies 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-19T15:30:00Z","last_updated_date":"2017-12-19T15:30:00Z","reference_number":"EMA/CVMP/ADVENT/573725/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-cvmp-ad-hoc-group-veterinary-novel-therapies-2018_en.pdf"},
    {"id":"21845","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2010","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2010-04-22T02:00:00Z","last_updated_date":"2010-04-22T02:00:00Z","reference_number":"EMA/INS/PhV/786484/2009","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2010_en.pdf"},
    {"id":"21878","name":"Work plan for the CVMP Efficacy Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-19T13:30:00Z","last_updated_date":"2017-12-19T13:30:00Z","reference_number":"EMA/CVMP/EWP/222886/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-cvmp-efficacy-working-party-2018_en.pdf"},
    {"id":"22787","name":"Work plan for Good Clinical Practice Inspectors Working Group 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2018-03-22T14:00:00Z","last_updated_date":"2018-03-22T14:00:00Z","reference_number":"EMA/87812 /2018","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-good-clinical-practice-inspectors-working-group-2018_en.pdf"},
    {"id":"23322","name":"Work plan for the Cell-based Products Working Party 2012","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2011-01-20T01:00:00Z","last_updated_date":"2012-01-23T09:47:00Z","reference_number":"EMA/CAT/CPWP/669140/2011","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-cell-based-products-working-party-2012_en.pdf"},
    {"id":"23542","name":"Draft Work plan for the European Medicines Agency Human Scientific Committees’ Working Party with Patients’ and Consumers’ Organisations (PCWP) 2016","type":"work-programme","status":"Draft","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"EMA/501464/2015","document_url":"https://www.ema.europa.eu/en/documents/work-programme/draft-work-plan-european-medicines-agency-human-scientific-committees-working-party-patients-and-consumers-organisations-pcwp-2016_en.pdf"},
    {"id":"23604","name":"Summary of the work programme for the European Medicines Agency 2006","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2007-03-09T00:09:21Z","last_updated_date":"2007-03-09T00:09:21Z","reference_number":"EMEA/62913/2006","document_url":"https://www.ema.europa.eu/en/documents/work-programme/summary-work-programme-european-medicines-agency-2006_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/work-programme/summary-work-programme-european-medicines-agency-2006_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/summary-work-programme-european-medicines-agency-2006_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/summary-work-programme-european-medicines-agency-2006_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/summary-work-programme-european-medicines-agency-2006_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/summary-work-programme-european-medicines-agency-2006_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/summary-work-programme-european-medicines-agency-2006_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/summary-work-programme-european-medicines-agency-2006_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/summary-work-programme-european-medicines-agency-2006_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/summary-work-programme-european-medicines-agency-2006_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/summary-work-programme-european-medicines-agency-2006_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/summary-work-programme-european-medicines-agency-2006_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/summary-work-programme-european-medicines-agency-2006_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/summary-work-programme-european-medicines-agency-2006_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/summary-work-programme-european-medicines-agency-2006_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/summary-work-programme-european-medicines-agency-2006_pt.pdf","sk":"https://www.ema.europa.eu/sk/documents/work-programme/summary-work-programme-european-medicines-agency-2006_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/summary-work-programme-european-medicines-agency-2006_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/summary-work-programme-european-medicines-agency-2006_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/summary-work-programme-european-medicines-agency-2006_sv.pdf"}},
    {"id":"23738","name":"Work programme of the European Medicines Agency 2014","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2014-03-19T11:45:00Z","last_updated_date":"2014-03-19T11:45:00Z","reference_number":"EMA/695772/2013","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2014_en.pdf"},
    {"id":"24177","name":"Work plan for the CHMP Biologics Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-21T12:10:00Z","last_updated_date":"2017-12-21T12:10:00Z","reference_number":"EMA/CHMP/BWP/400117/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-chmp-biologics-working-party-2018_en.pdf"},
    {"id":"24428","name":"Work plan for the European Medicines Agency CHMP Pharmacovigilance Working Party (PhVWP) 2012","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2012-01-30T01:00:00Z","last_updated_date":"2012-01-30T10:26:00Z","reference_number":"EMEA/CHMP/PhVWP/295724/2009","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-european-medicines-agency-chmp-pharmacovigilance-working-party-phvwp-2012_en.pdf"},
    {"id":"24431","name":"Work programme for the European Agency for the Evaluation of Medicinal Products 1999-2000","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"1999-06-02T02:09:21Z","last_updated_date":"1999-06-02T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1999-2000_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1999-2000_es.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1999-2000_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1999-2000_de.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1999-2000_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1999-2000_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1999-2000_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1999-2000_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1999-2000_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-1999-2000_sv.pdf"}}    {"id":"24829","name":"Work plan for the Radiopharmaceuticals Drafting Group 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-01-20T10:40:00Z","last_updated_date":"2018-01-25T11:00:00Z","reference_number":"EMA/CHMP/519446/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-radiopharmaceuticals-drafting-group-2018_en.pdf"},
    {"id":"25255","name":"Work programme of the European Medicines Agency 2015","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2015-03-02T10:45:00Z","last_updated_date":"2015-08-26T17:50:00Z","reference_number":"EMA/773839/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2015_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/work-programme/work-programme-european-medicines-agency-2015_bg.pdf","es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-medicines-agency-2015_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/work-programme-european-medicines-agency-2015_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-medicines-agency-2015_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-medicines-agency-2015_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/work-programme-european-medicines-agency-2015_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-medicines-agency-2015_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-medicines-agency-2015_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/work-programme/work-programme-european-medicines-agency-2015_hr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-medicines-agency-2015_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/work-programme-european-medicines-agency-2015_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/work-programme-european-medicines-agency-2015_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/work-programme-european-medicines-agency-2015_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/work-programme-european-medicines-agency-2015_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-medicines-agency-2015_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/work-programme-european-medicines-agency-2015_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-medicines-agency-2015_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/work-programme/work-programme-european-medicines-agency-2015_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/work-programme/work-programme-european-medicines-agency-2015_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/work-programme-european-medicines-agency-2015_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-medicines-agency-2015_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-medicines-agency-2015_sv.pdf"}},
    {"id":"25276","name":"Work programme of the European Medicines Agency 2011","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2011-02-11T01:00:00Z","last_updated_date":"2011-02-11T01:00:00Z","reference_number":"EMA/MB/482208/2010","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2011_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/work-programme/work-programme-european-medicines-agency-2011_bg.pdf","es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-medicines-agency-2011_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/work-programme-european-medicines-agency-2011_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-medicines-agency-2011_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-medicines-agency-2011_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/work-programme-european-medicines-agency-2011_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-medicines-agency-2011_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-medicines-agency-2011_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-medicines-agency-2011_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/work-programme-european-medicines-agency-2011_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/work-programme-european-medicines-agency-2011_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/work-programme-european-medicines-agency-2011_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/work-programme-european-medicines-agency-2011_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-medicines-agency-2011_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/work-programme-european-medicines-agency-2011_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-medicines-agency-2011_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/work-programme/work-programme-european-medicines-agency-2011_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/work-programme/work-programme-european-medicines-agency-2011_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/work-programme-european-medicines-agency-2011_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-medicines-agency-2011_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-medicines-agency-2011_sv.pdf"}},
    {"id":"25293","name":"Work plan for the Pharmacogenomics Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2018-01-10T11:00:00Z","last_updated_date":"2018-01-10T11:00:00Z","reference_number":"EMA/CHMP/370931/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacogenomics-working-party-2018_en.pdf"},
    {"id":"25723","name":"Work plan for the Central Nervous System Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2018-01-05T15:00:00Z","last_updated_date":"2018-01-05T15:00:00Z","reference_number":"EMA/CHMP/625937/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-central-nervous-system-working-party-2018_en.pdf"},
    {"id":"27440","name":"Work plan for the Committee for Medicinal Products for Veterinary Use (CVMP) Scientific Advice Working Party (SAWP-V) for 2021","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-19T15:30:00Z","last_updated_date":"2020-12-17T14:42:00Z","reference_number":"EMA/CVMP/SAWP/564965/2020","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-medicinal-products-veterinary-use-cvmp-scientific-advice-working-party-sawp-v-2021_en.pdf"},
    {"id":"28126","name":"Work programme for the European Agency for the Evaluation of Medicinal Products 2002","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2002-04-02T02:09:21Z","last_updated_date":"2002-04-02T02:09:21Z","reference_number":"EMEA/MB/049/01-EN-Final","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_es.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_de.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2002_sv.pdf"}},
    {"id":"28200","name":"Draft Work plan for the European Medicines Agency Human Scientific Committees’ Working Party with Healthcare Professionals’ Organisations (HCPWP) 2016","type":"work-programme","status":"Draft","consultation_date":"","first_published_date":"2015-12-11T01:00:00Z","last_updated_date":"2015-12-11T01:00:00Z","reference_number":"EMA/505963/2015","document_url":"https://www.ema.europa.eu/en/documents/work-programme/draft-work-plan-european-medicines-agency-human-scientific-committees-working-party-healthcare-professionals-organisations-hcpwp-2016_en.pdf"},
    {"id":"28272","name":"Paediatric Committee (PDCO) workplan 2016","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2015-07-06T20:40:00Z","last_updated_date":"2015-07-06T20:40:00Z","reference_number":"EMA/PDCO/605931/2016","document_url":"https://www.ema.europa.eu/en/documents/work-programme/paediatric-committee-pdco-workplan-2016_en.pdf"},
    {"id":"28498","name":"Work plan for the Vaccine Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-21T17:20:00Z","last_updated_date":"2017-12-21T17:20:00Z","reference_number":"EMA/CHMP/VWP/515395/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-vaccine-working-party-2018_en.pdf"},
    {"id":"28629","name":"Committee for Advanced Therapies (CAT) - Work Plan 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2018-02-13T14:14:00Z","last_updated_date":"2018-02-13T14:14:00Z","reference_number":"EMA/CAT/614550/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/committee-advanced-therapies-cat-work-plan-2018_en.pdf"},
    {"id":"29342","name":"Work plan for the CVMP Environmental Risk Assessment Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-19T13:30:00Z","last_updated_date":"2017-12-19T13:30:00Z","reference_number":"EMA/CVMP/ERA/289769/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-cvmp-environmental-risk-assessment-working-party-2018_en.pdf"},
    {"id":"30862","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2012","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2012-07-13T02:00:00Z","last_updated_date":"2012-07-13T02:00:00Z","reference_number":"EMA/INS/PhV/313103/2012","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2012_en.pdf"},
    {"id":"31126","name":"Work programme for the European Agency for the Evaluation of Medicinal Products 2001-2002","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2001-06-05T02:09:21Z","last_updated_date":"2001-06-05T02:09:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_es.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_de.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2001-2002_sv.pdf"}},
    {"id":"31556","name":"Work programme for the European Agency for the Evaluation of Medicinal Products 2004","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2004-02-06T00:09:21Z","last_updated_date":"2004-02-06T00:09:21Z","reference_number":"EMEA/MB/58/03/en/FINAL","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_en.pdf","translations":{"es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_es.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_de.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_it.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_nl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_pt.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-agency-evaluation-medicinal-products-2004_sv.pdf"}},
    {"id":"31831","name":"Work plan for the Gene Therapy Working Party 2012","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2010-12-02T00:09:21Z","last_updated_date":"2012-01-23T12:11:00Z","reference_number":"EMA/CAT/GTWP/574590/2010","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-gene-therapy-working-party-2012_en.pdf"},
    {"id":"32962","name":"Work programme for the European Medicines Agency 2009","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2009-02-26T00:09:21Z","last_updated_date":"2009-02-26T00:09:21Z","reference_number":"EMEA/87375/2009 Adopted","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2009_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/work-programme/work-programme-european-medicines-agency-2009_bg.pdf","es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-medicines-agency-2009_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/work-programme-european-medicines-agency-2009_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-medicines-agency-2009_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-medicines-agency-2009_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/work-programme-european-medicines-agency-2009_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-medicines-agency-2009_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-medicines-agency-2009_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-medicines-agency-2009_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/work-programme-european-medicines-agency-2009_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/work-programme-european-medicines-agency-2009_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/work-programme-european-medicines-agency-2009_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/work-programme-european-medicines-agency-2009_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-medicines-agency-2009_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/work-programme-european-medicines-agency-2009_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-medicines-agency-2009_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/work-programme/work-programme-european-medicines-agency-2009_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/work-programme/work-programme-european-medicines-agency-2009_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/work-programme-european-medicines-agency-2009_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-medicines-agency-2009_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-medicines-agency-2009_sv.pdf"}},
    {"id":"34449","name":"Work plan for Good Clinical Practice Inspectors Working Group 2016","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2016-02-26T16:35:00Z","last_updated_date":"2016-02-26T16:35:00Z","reference_number":"EMA/INS/GCP/752886/2015","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-good-clinical-practice-inspectors-working-group-2016_en.pdf"},
    {"id":"35201","name":"Multiannual work programme to 2020","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2016-06-30T16:05:00Z","last_updated_date":"2016-06-30T16:05:00Z","reference_number":"EMA/319713/2016","document_url":"https://www.ema.europa.eu/en/documents/work-programme/multiannual-work-programme-2020_en.pdf"},
    {"id":"35782","name":"Work plan for the Organisational Matters Drafting Group (ORGAM DG) 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-02-27T18:15:00Z","last_updated_date":"2018-03-09T16:00:00Z","reference_number":"EMA/HMPC/547742/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-organisational-matters-drafting-group-orgam-dg-2018_en.pdf"},
    {"id":"35881","name":"Work plan for the Biosimilar Medicinal Products Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T16:00:00Z","last_updated_date":"2018-01-18T16:30:00Z","reference_number":"EMA/CHMP/BMWP/420509/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-biosimilar-medicinal-products-working-party-2018_en.pdf"},
    {"id":"36055","name":"COMP work plan 2020","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2020-03-09T16:30:00Z","last_updated_date":"2020-03-09T16:30:00Z","reference_number":"EMA/COMP/478696/2019","document_url":"https://www.ema.europa.eu/en/documents/work-programme/comp-work-plan-2020_en.pdf"},
    {"id":"37143","name":"Work programme of the European Medicines Agency 2013","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2013-03-13T11:17:00Z","last_updated_date":"2013-03-13T11:17:00Z","reference_number":"EMA/MB/945561/2011","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2013_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/work-programme/work-programme-european-medicines-agency-2013_bg.pdf","es":"https://www.ema.europa.eu/es/documents/work-programme/work-programme-european-medicines-agency-2013_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/work-programme/work-programme-european-medicines-agency-2013_cs.pdf","da":"https://www.ema.europa.eu/da/documents/work-programme/work-programme-european-medicines-agency-2013_da.pdf","de":"https://www.ema.europa.eu/de/documents/work-programme/work-programme-european-medicines-agency-2013_de.pdf","et":"https://www.ema.europa.eu/et/documents/work-programme/work-programme-european-medicines-agency-2013_et.pdf","el":"https://www.ema.europa.eu/el/documents/work-programme/work-programme-european-medicines-agency-2013_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/work-programme/work-programme-european-medicines-agency-2013_fr.pdf","it":"https://www.ema.europa.eu/it/documents/work-programme/work-programme-european-medicines-agency-2013_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/work-programme/work-programme-european-medicines-agency-2013_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/work-programme/work-programme-european-medicines-agency-2013_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/work-programme/work-programme-european-medicines-agency-2013_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/work-programme/work-programme-european-medicines-agency-2013_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/work-programme/work-programme-european-medicines-agency-2013_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/work-programme/work-programme-european-medicines-agency-2013_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/work-programme/work-programme-european-medicines-agency-2013_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/work-programme/work-programme-european-medicines-agency-2013_ro.pdf","sl":"https://www.ema.europa.eu/sl/documents/work-programme/work-programme-european-medicines-agency-2013_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/work-programme/work-programme-european-medicines-agency-2013_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/work-programme/work-programme-european-medicines-agency-2013_sv.pdf"}},
    {"id":"38083","name":"Work plan for the CHMP Oncology Working Party for 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2018-01-10T11:00:00Z","last_updated_date":"2018-01-10T11:00:00Z","reference_number":"EMA/CHMP/413341/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-chmp-oncology-working-party-2018_en.pdf"},
    {"id":"38126","name":"CHMP work plan 2025","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-01-10T14:24:00Z","last_updated_date":"2025-01-23T11:39:13Z","reference_number":"EMA/CHMP/546022/2024 Corr.1","document_url":"https://www.ema.europa.eu/en/documents/work-programme/chmp-work-plan-2025_en.pdf"},
    {"id":"38658","name":"Work plan for Good Clinical Practice Inspectors Working Group 2014","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2014-02-25T16:50:00Z","last_updated_date":"2014-02-25T16:50:00Z","reference_number":"EMA/INS/GCP/554674/2013","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-good-clinical-practice-inspectors-working-group-2014_en.pdf"},
    {"id":"39010","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2017","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-05-17T13:22:00Z","last_updated_date":"2017-05-17T13:22:00Z","reference_number":"EMA/IN EMA/INS/PhV/128277/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2017_en.pdf"},
    {"id":"39032","name":"Work plan for the Infectious Diseases Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2015-12-21T16:00:00Z","last_updated_date":"2018-01-18T16:00:00Z","reference_number":"EMA/CHMP/517878/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-infectious-diseases-working-party-2018_en.pdf"},
    {"id":"39284","name":"Work plan for the Pharmacovigilance Inspectors Working\n\nGroup for 2013","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2013-03-14T12:30:00Z","last_updated_date":"2013-03-14T12:30:00Z","reference_number":"EMA/INS/PhV/697759/2012","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2013_en.pdf"},
    {"id":"39288","name":"Work plan for the Efficacy Working Party (EWP) 2010","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2009-12-17T00:09:21Z","last_updated_date":"2009-12-17T00:09:21Z","reference_number":"EMA/CHMP/EWP/248088/2009 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-efficacy-working-party-ewp-2010_en.pdf"},
    {"id":"40041","name":"Work plan for the CVMP Immunologicals Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-19T15:30:00Z","last_updated_date":"2018-04-30T13:47:00Z","reference_number":"EMA/CVMP/IWP/347865/2017 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-cvmp-immunologicals-working-party-2018_en.pdf"},
    {"id":"40562","name":"EudraVigilance Expert Working Group (EV-EWG) work programme 2025-2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2023-03-09T14:02:00Z","last_updated_date":"2025-04-28T09:32:00Z","reference_number":"EMA/31031/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/eudravigilance-expert-working-group-ev-ewg-work-programme-2025-2026_en.pdf"},
    {"id":"40581","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2018-05-23T12:23:00Z","last_updated_date":"2018-05-23T12:23:00Z","reference_number":"EMA/INS/PhV/138699/2018","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2018_en.pdf"},
    {"id":"40932","name":"Work programme of the European Medicines Agency 2017","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2017-02-14T11:50:00Z","last_updated_date":"2017-10-12T17:30:00Z","reference_number":"EMA/583016/2016 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-programme-european-medicines-agency-2017_en.pdf"},
    {"id":"41250","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2011","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2011-06-16T02:00:00Z","last_updated_date":"2011-06-16T02:00:00Z","reference_number":"EMA/INS/PhV/835137/2010","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2011_en.pdf"},
    {"id":"41393","name":"Work plan for the CVMP Antimicrobials Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-19T13:30:00Z","last_updated_date":"2017-12-19T13:30:00Z","reference_number":"EMA/CVMP/AWP/484533/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-cvmp-antimicrobials-working-party-2018_en.pdf"},
    {"id":"43463","name":"EMA activities, other than the highest priority activities (category 1 activities), that will continue in 2019 - Annex 1","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2019-01-23T14:02:00Z","last_updated_date":"2019-06-17T17:00:00Z","reference_number":"EMA/30394/2019","document_url":"https://www.ema.europa.eu/en/documents/work-programme/ema-activities-other-highest-priority-activities-category-1-activities-will-continue-2019-annex-1_en.pdf"},
    {"id":"44102","name":"PRAC work plan 2020","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2020-03-11T15:30:00Z","last_updated_date":"2020-03-11T15:30:00Z","reference_number":"EMA/PRAC/131664/2020 ","document_url":"https://www.ema.europa.eu/en/documents/work-programme/prac-work-plan-2020_en.pdf"},
    {"id":"47026","name":"PDCO work plan 2022","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2022-02-21T15:29:00Z","last_updated_date":"2022-02-21T15:29:00Z","reference_number":"EMA/PDCO/517591/2021","document_url":"https://www.ema.europa.eu/en/documents/work-programme/pdco-work-plan-2022_en.pdf"},
    {"id":"47403","name":"HMPC work plan 2023","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-03-01T17:34:00Z","last_updated_date":"2023-03-01T17:34:00Z","reference_number":"EMA/HMPC/855550/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/hmpc-work-plan-2023_en.pdf"},
    {"id":"47649","name":"Work Plan 2020 of the Good Clinical Practice Inspectors' Working Group","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2020-05-12T15:18:00Z","last_updated_date":"2020-05-12T15:18:00Z","reference_number":"EMA/INS/GCP/637644 /2019","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-2020-good-clinical-practice-inspectors-working-group_en.pdf"},
    {"id":"48219","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2020","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2020-07-03T11:57:00Z","last_updated_date":"2020-07-03T11:57:00Z","reference_number":"EMA/INS/PhV/359174/2020","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2020_en.pdf"},
    {"id":"48782","name":"Workplan 2020: HMA-EMA joint Big Data Steering Group","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2020-09-14T10:40:00Z","last_updated_date":"2020-09-30T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/workplan-2020-hma-ema-joint-big-data-steering-group_en.pdf"},
    {"id":"50103","name":"COMP work plan 2021","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2021-02-08T17:03:00Z","last_updated_date":"2021-02-08T17:03:00Z","reference_number":"EMA/COMP/559551/2021","document_url":"https://www.ema.europa.eu/en/documents/work-programme/comp-work-plan-2021_en.pdf"},
    {"id":"50790","name":"Nitrosamine Implementation Oversight Group Terms of Reference","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2021-04-12T16:16:00Z","last_updated_date":"2021-04-12T16:16:00Z","reference_number":"EMA/34730/2021","document_url":"https://www.ema.europa.eu/en/documents/work-programme/nitrosamine-implementation-oversight-group-terms-reference_en.pdf"},
    {"id":"52249","name":"PRAC work plan 2022","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2021-08-23T09:22:00Z","last_updated_date":"2022-03-16T15:34:00Z","reference_number":"EMA/PRAC/576527/2021","document_url":"https://www.ema.europa.eu/en/documents/work-programme/prac-work-plan-2022_en.pdf"},
    {"id":"52290","name":"Workplan 2021-2023: HMA-EMA joint Big Data Steering Group","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2021-08-27T11:11:00Z","last_updated_date":"2021-08-27T11:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/workplan-2021-2023-hma-ema-joint-big-data-steering-group_en.pdf"},
    {"id":"53572","name":"CVMP work plan 2025","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2024-12-11T17:13:00Z","last_updated_date":"2024-12-11T17:13:00Z","reference_number":"EMA/CVMP/456565/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/cvmp-work-plan-2025_en.pdf"},
    {"id":"54013","name":"Work plan for the Committee for Veterinary Medicinal Products (CVMP) Environmental Risk Assessment Working Party (ERAWP) 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T09:38:00Z","last_updated_date":"2025-12-12T09:38:00Z","reference_number":"EMA/CVMP/ERA/291857/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-veterinary-medicinal-products-cvmp-environmental-risk-assessment-working-party-erawp-2026_en.pdf"},
    {"id":"54014","name":"Work plan for the Committee for Veterinary Medicinal  Products (CVMP) Antimicrobials Working Party (AWP) 2022","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2022-01-28T14:32:00Z","last_updated_date":"2022-01-28T14:32:00Z","reference_number":"EMA/CVMP/AWP/605507/2021 ","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-veterinary-medicinal-products-cvmp-antimicrobials-working-party-awp-2022_en.pdf"},
    {"id":"54015","name":"Work plan for the Committee for Veterinary Medicinal Products (CVMP) Efficacy Working Party (EWP-V) 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T09:40:00Z","last_updated_date":"2025-12-12T09:40:00Z","reference_number":"EMA/CVMP/EWP/230324/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-veterinary-medicinal-products-cvmp-efficacy-working-party-ewp-v-2026_en.pdf"},
    {"id":"54123","name":"Work Plan 2021-2023 of the Good Clinical Practice Inspectors Working Group (GCP IWG)","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2022-02-10T10:38:00Z","last_updated_date":"2022-02-10T10:38:00Z","reference_number":"EMA/INS/GCP/452875/2020","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-2021-2023-good-clinical-practice-inspectors-working-group-gcp-iwg_en.pdf"},
    {"id":"54369","name":"COMP work plan 2022","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2022-03-07T17:29:00Z","last_updated_date":"2022-03-07T17:29:00Z","reference_number":"EMA/COMP/29342/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/comp-work-plan-2022_en.pdf"},
    {"id":"54730","name":"European collaboration between regulators and health technology assessment bodies - Joint work plan (2021-2023) between EMA and European HTA bodies facilitated through EUnetHTA21","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2022-04-12T14:00:00Z","last_updated_date":"2023-07-24T13:53:00Z","reference_number":"EMA/188201/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/european-collaboration-between-regulators-and-health-technology-assessment-bodies-joint-work-plan-2021-2023-between-ema-and-european-hta-bodies-facilitated-through-eunethta21_en.pdf"},
    {"id":"54764","name":"Work plan for the Pharmacovigilance Inspectors Working Group for 2021-2024","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2022-04-20T12:52:00Z","last_updated_date":"2022-04-20T12:52:00Z","reference_number":"EMA/213692/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-pharmacovigilance-inspectors-working-group-2021-2024_en.pdf"},
    {"id":"55714","name":"Workplan 2022-2025: HMA-EMA joint Big Data Steering Group","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2022-07-28T10:11:00Z","last_updated_date":"2022-07-28T10:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/workplan-2022-2025-hma-ema-joint-big-data-steering-group_en.pdf"},
    {"id":"56173","name":"2025-2028 Work plan for the Patients’ and Consumers’  Working Party (PCWP) and the Healthcare Professionals’  Working Party (HCPWP)","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2026-06-09T14:10:00Z","last_updated_date":"2026-06-09T14:10:00Z","reference_number":"EMA/336787/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/2025-2028-work-plan-patients-consumers-working-party-pcwp-healthcare-professionals-working-party-hcpwp_en.pdf"},
    {"id":"56538","name":"Cardiovascular Working Party (CVSWP) work plan 2022-2024","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2022-11-07T11:52:00Z","last_updated_date":"2024-02-14T16:09:00Z","reference_number":"EMA/467818/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/cardiovascular-working-party-cvswp-work-plan-2022-2024_en.pdf"},
    {"id":"56915","name":"Oncology Working Party (ONCWP) work plan 2022-2024","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2022-12-08T17:07:00Z","last_updated_date":"2023-06-16T15:27:00Z","reference_number":"EMA/CHMP/277603/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/oncology-working-party-oncwp-work-plan-2022-2024_en.pdf"},
    {"id":"56947","name":"Haematology Working Party (HWP) work plan 2022-2024","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T09:38:00Z","last_updated_date":"2024-02-14T16:10:00Z","reference_number":"EMA/535136/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/haematology-working-party-hwp-work-plan-2022-2024_en.pdf"},
    {"id":"56986","name":"Central Nervous System Working Party (CNSWP) work plan 2022-2024","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2022-12-13T16:56:00Z","last_updated_date":"2024-02-14T16:07:00Z","reference_number":"EMA/CHMP/919105/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/central-nervous-system-working-party-cnswp-work-plan-2022-2024_en.pdf"},
    {"id":"57073","name":"Work plan for the Committee for Veterinary Medicinal Products (CVMP) Scientific Advice Working Party (SAWP-V) for 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T09:24:00Z","last_updated_date":"2025-12-12T09:24:00Z","reference_number":"EMA/CVMP/SAWP/302107/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-veterinary-medicinal-products-cvmp-scientific-advice-working-party-sawp-v-2026_en.pdf"},
    {"id":"57074","name":"Work plan for the Committee for Veterinary Medicinal Products (CVMP) Antimicrobials Working Party (AWP) 2024","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2024-01-26T15:30:00Z","last_updated_date":"2024-01-26T15:30:00Z","reference_number":"EMA/CVMP/AWP/381708/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-veterinary-medicinal-products-cvmp-antimicrobials-working-party-awp-2024_en.pdf"},
    {"id":"57090","name":"Work plan for the CVMP Novel Therapies & Technologies Working Party (NTWP) 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T09:36:00Z","last_updated_date":"2025-12-12T09:36:00Z","reference_number":"EMA/CVMP/NTWP/228977/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-cvmp-novel-therapies-technologies-working-party-ntwp-2026_en.pdf"},
    {"id":"57169","name":"Consolidated 3-year work plan for the Rheumatology and Immunology Working Party (RIWP)","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-01-05T15:38:00Z","last_updated_date":"2023-01-05T15:38:00Z","reference_number":"EMA/CHMP/946000/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/consolidated-3-year-work-plan-rheumatology-and-immunology-working-party-riwp_en.pdf"},
    {"id":"57339","name":"PDCO work plan 2023","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2023-01-20T10:41:00Z","last_updated_date":"2023-01-20T10:41:00Z","reference_number":"EMA/PDCO/867297/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/pdco-work-plan-2023_en.pdf"},
    {"id":"57426","name":"Work plan for the Committee for Veterinary Medicinal Products (CVMP) Immunologicals Working Party (IWP) 2026","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T09:27:00Z","last_updated_date":"2025-12-12T09:27:00Z","reference_number":"EMA/CVMP/IWP/298213/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-veterinary-medicinal-products-cvmp-immunologicals-working-party-iwp-2026_en.pdf"},
    {"id":"57437","name":"PRAC work plan 2023","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-01-27T13:11:00Z","last_updated_date":"2023-01-27T13:11:00Z","reference_number":"EMA/PRAC/45172/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/prac-work-plan-2023_en.pdf"},
    {"id":"57472","name":"Work plan for the joint CHMP/ CVMP Quality Working Party (QWP) for 2023","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T11:48:00Z","last_updated_date":"2023-01-31T11:48:00Z","reference_number":"EMA/CHMP/CVMP/QWP/822156/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-joint-chmp-cvmp-quality-working-party-qwp-2023_en.pdf"},
    {"id":"57522","name":"Consolidated 3-year work plan for the Methodology Working Party (MWP)","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-02-06T10:10:00Z","last_updated_date":"2023-02-06T10:10:00Z","reference_number":"EMA/CHMP/58124/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/consolidated-3-year-work-plan-methodology-working-party-mwp_en.pdf"},
    {"id":"57542","name":"COMP work plan 2023","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2023-02-07T15:31:00Z","last_updated_date":"2023-02-07T15:31:00Z","reference_number":"EMA/COMP/48038/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/comp-work-plan-2023_en.pdf"},
    {"id":"57655","name":"Consolidated 3-year work plan for the Infectious Disease Working Party (IDWP)","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-02-13T16:31:00Z","last_updated_date":"2024-02-14T16:12:00Z","reference_number":"EMA/534753/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/consolidated-3-year-work-plan-infectious-disease-working-party-idwp_en.pdf"},
    {"id":"57684","name":"Work plan for the Biologics Working Party (BWP) for 2023","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-02-15T16:20:00Z","last_updated_date":"2023-02-15T16:20:00Z","reference_number":"EMA/CHMP/BWP/860809/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-biologics-working-party-bwp-2023_en.pdf"},
    {"id":"57833","name":"2023 work plan for the Quality Innovation Group (QIG)","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-02-28T12:04:00Z","last_updated_date":"2023-02-28T12:04:00Z","reference_number":"EMA/824798/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/2023-work-plan-quality-innovation-group-qig_en.pdf"},
    {"id":"59447","name":"Work plan for the European Sales and Use of Antimicrobials in veterinary medicine Working Group (ESUAvet WG) 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T09:32:00Z","last_updated_date":"2025-12-12T09:32:00Z","reference_number":"EMA/CVMP/ESUAVET/290391/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-european-sales-use-antimicrobials-veterinary-medicine-working-group-esuavet-wg-2026_en.pdf"},
    {"id":"59500","name":"Consolidated 3-year work plan for the Emergency Task Force (ETF)","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-07-27T10:10:00Z","last_updated_date":"2025-12-11T09:05:00Z","reference_number":"EMA/388410/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/consolidated-3-year-work-plan-emergency-task-force-etf_en.pdf"},
    {"id":"59519","name":"Workplan 2023-2025: HMA-EMA joint Big Data Steering Group","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-07-28T16:00:00Z","last_updated_date":"2024-06-20T15:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/workplan-2023-2025-hma-ema-joint-big-data-steering-group_en.pdf"},
    {"id":"59729","name":"Work plan for the Respiratory Drafting Group (RDG) for 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2023-10-04T12:54:37Z","last_updated_date":"2023-10-04T12:54:37Z","reference_number":"EMA/CHMP/383892/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-respiratory-drafting-group-rdg-2018_en.pdf"},
    {"id":"59731","name":"Work plan for the Safety Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2023-10-04T13:46:13Z","last_updated_date":"2023-10-04T13:46:13Z","reference_number":"EMA/CHMP/SWP/420217/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-safety-working-party-2018_en.pdf"},
    {"id":"59831","name":"Work plan for the Committee for Veterinary Medicinal Products (CVMP) Pharmacovigilance Working Party (PhVWP-V) 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T09:34:00Z","last_updated_date":"2025-12-12T09:34:00Z","reference_number":"EMA/CVMP/PhVWP/189306/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-veterinary-medicinal-products-cvmp-pharmacovigilance-working-party-phvwp-v-2026_en.pdf"},
    {"id":"59832","name":"Work plan for the joint CHMP/ CVMP Quality Working Party (QWP) for 2023","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-10-23T16:39:47Z","last_updated_date":"2023-10-23T16:39:47Z","reference_number":"EMA/CHMP/CVMP/QWP/822156/2022","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-joint-chmp-cvmp-quality-working-party-qwp-2023_en.pdf-0"},
    {"id":"60514","name":"Revised consolidated 3-year work plan for the Methodology Working Party (MWP)","type":"work-programme","status":"Draft: consultation closed","consultation_date":"2023-11-01 - 2023-11-30","first_published_date":"2023-10-31T15:22:00Z","last_updated_date":"2024-02-14T16:12:00Z","reference_number":"EMA/CHMP/478317/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/revised-consolidated-3-year-work-plan-methodology-working-party-mwp_en.pdf"},
    {"id":"60545","name":"Work plan for the Safety Working Party 2018","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2017-12-21T12:10:00Z","last_updated_date":"2017-12-21T12:10:00Z","reference_number":"EMA/CHMP/SWP/420217/2017","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-safety-working-party-2018_en.pdf-0"},
    {"id":"61476","name":"Multi-annual artificial intelligence workplan 2023-2028: HMA-EMA joint Big Data Steering Group","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-12-18T13:55:00Z","last_updated_date":"2024-01-25T13:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/multi-annual-artificial-intelligence-workplan-2023-2028-hma-ema-joint-big-data-steering-group_en.pdf"},
    {"id":"61575","name":"2024-2026 Work Plan of the Good Clinical Practice Inspectors Working Group (GCP IWG)","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2023-12-21T15:44:18Z","last_updated_date":"2025-03-17T16:03:00Z","reference_number":"EMA/INS/GCP/329215/2023 Rev.1","document_url":"https://www.ema.europa.eu/en/documents/work-programme/2024-2026-work-plan-good-clinical-practice-inspectors-working-group-gcp-iwg_en.pdf"},
    {"id":"61623","name":"PDCO work plan 2024","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2024-01-03T15:43:38Z","last_updated_date":"2024-01-03T15:43:38Z","reference_number":"EMA/PDCO/480409/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/pdco-work-plan-2024_en.pdf"},
    {"id":"61946","name":"PRAC work plan 2024","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2024-01-29T16:51:30Z","last_updated_date":"2024-01-29T16:51:30Z","reference_number":"EMA/PRAC/43499/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/prac-work-plan-2024_en.pdf"},
    {"id":"61969","name":"COMP work plan 2024","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2024-01-31T16:32:59Z","last_updated_date":"2024-01-31T16:32:59Z","reference_number":"EMA/COMP/31131/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/comp-work-plan-2024_en.pdf"},
    {"id":"62141","name":"Three-year work plan for the Quality Innovation Group (QIG) 2024-2026","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2024-02-14T16:20:06Z","last_updated_date":"2024-02-14T16:20:06Z","reference_number":"EMA/477650/2023","document_url":"https://www.ema.europa.eu/en/documents/work-programme/three-year-work-plan-quality-innovation-group-qig-2024-2026_en.pdf"},
    {"id":"62998","name":"Work plan for the Good Manufacturing Practice / Good Distribution Practice Inspectors Working Group 2024-2026","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2024-04-18T10:51:56Z","last_updated_date":"2024-04-18T10:51:56Z","reference_number":"EMA/INS/GMP/61300/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-good-manufacturing-practice-good-distribution-practice-inspectors-working-group-2024-2026_en.pdf"},
    {"id":"64354","name":"Draft Central Nervous System Working Party (CNSWP) consolidated 3-year rolling work plan 2025-2027","type":"work-programme","status":"Draft: consultation closed","consultation_date":"2024-07-29 - 2024-09-30","first_published_date":"2024-07-29T16:00:00Z","last_updated_date":"2024-07-29T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/draft-central-nervous-system-working-party-cnswp-consolidated-3-year-rolling-work-plan-2025-2027_en.pdf"},
    {"id":"64355","name":"Draft Cardiovascular Working Party (CVSWP) consolidated 3-year rolling work plan 2025-2027","type":"work-programme","status":"Draft: consultation closed","consultation_date":"2024-07-29 - 2024-09-15","first_published_date":"2024-07-29T16:00:00Z","last_updated_date":"2024-07-29T16:00:00Z","reference_number":"EMA/248684/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/draft-cardiovascular-working-party-cvswp-consolidated-3-year-rolling-work-plan-2025-2027_en.pdf"},
    {"id":"64356","name":"Infectious Diseases Working Party (IDWP) consolidated 3-year rolling work plan 2025-2027","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2024-07-29T16:00:00Z","last_updated_date":"2025-02-28T17:20:00Z","reference_number":"EMA/CHMP/307418/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/infectious-diseases-working-party-idwp-consolidated-3-year-rolling-work-plan-2025-2027_en.pdf"},
    {"id":"64782","name":"Draft 3-year rolling work plan for the Rheumatology and Immunology Working Party (RIWP) : 2025-2027","type":"work-programme","status":"Draft: consultation closed","consultation_date":"2024-09-10 - 2024-10-10","first_published_date":"2024-09-10T16:34:24Z","last_updated_date":"2024-09-10T16:34:24Z","reference_number":"EMA/400811/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/draft-3-year-rolling-work-plan-rheumatology-immunology-working-party-riwp-2025-2027_en.pdf"},
    {"id":"64783","name":"Consolidated 3-year rolling work plan for the Oncology Working Party : January 2025 - December 2027","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2024-09-10T16:38:46Z","last_updated_date":"2025-02-21T15:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/consolidated-3-year-rolling-work-plan-oncology-working-party-january-2025-december-2027_en.pdf"},
    {"id":"64784","name":"Consolidated 3-year rolling work plan for the Haematology Working Party (HAEMWP) : January 2025 - December 2027","type":"work-programme","status":"Draft: consultation closed","consultation_date":"2024-09-10 - 2024-10-10","first_published_date":"2024-09-10T16:43:33Z","last_updated_date":"2024-09-10T16:43:33Z","reference_number":"EMA/CHMP/BPWP/320406/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/consolidated-3-year-rolling-work-plan-haematology-working-party-haemwp-january-2025-december-2027_en.pdf"},
    {"id":"65359","name":"Three-year work plan for the Quality Drafting Group (QDG) of the Committee on Herbal Medicinal Products (HMPC)","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2024-10-21T09:22:19Z","last_updated_date":"2026-02-03T13:30:00Z","reference_number":"EMA/HMPC/358650/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/three-year-work-plan-quality-drafting-group-qdg-committee-herbal-medicinal-products-hmpc_en.pdf"},
    {"id":"65548","name":"Draft consolidated 3-year rolling work plan for the Vaccine Working Party (VWP) - 2025-2027","type":"work-programme","status":"Draft: consultation closed","consultation_date":"2024-11-05 - 2024-12-06","first_published_date":"2024-11-05T14:15:04Z","last_updated_date":"2024-11-05T14:15:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/work-programme/draft-consolidated-3-year-rolling-work-plan-vaccine-working-party-vwp-2025-2027_en.pdf"},
    {"id":"66054","name":"Three-year rolling work plan for the Quality Innovation Group (QIG) 2025-2027","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2024-12-10T15:09:37Z","last_updated_date":"2024-12-10T15:09:37Z","reference_number":"EMA/373754/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/three-year-rolling-work-plan-quality-innovation-group-qig-2025-2027_en.pdf"},
    {"id":"66117","name":"Work plan for the Committee for Veterinary Medicinal  Products (CVMP) Safety Working Party (SWP-V) 2025","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2025-12-12T09:30:00Z","last_updated_date":"2025-12-12T09:30:00Z","reference_number":"EMA/CVMP/SWP/192449/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-veterinary-medicinal-products-cvmp-safety-working-party-swp-v-2025_en.pdf"}    {"id":"66120","name":"Work plan for the Committee for Veterinary Medicinal Products (CVMP) Antimicrobials Working Party (AWP) 2025","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2024-12-13T14:45:00Z","last_updated_date":"2024-12-13T14:45:00Z","reference_number":"EMA/CVMP/AWP/341740/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-veterinary-medicinal-products-cvmp-antimicrobials-working-party-awp-2025_en.pdf"},
    {"id":"66328","name":"PRAC work plan 2025","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-01-16T13:44:07Z","last_updated_date":"2025-01-16T13:44:07Z","reference_number":"EMA/PRAC/583868/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/prac-work-plan-2025_en.pdf"},
    {"id":"66402","name":"PDCO work plan 2025","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2025-01-21T16:30:06Z","last_updated_date":"2025-01-21T16:30:06Z","reference_number":"EMA/PDCO/488895/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/pdco-work-plan-2025_en.pdf"},
    {"id":"66523","name":"Committee on Herbal Medicinal Products (HMPC): Work Plan 2025","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-01-30T11:02:51Z","last_updated_date":"2025-01-30T11:02:51Z","reference_number":"EMA/HMPC/422040/2024","document_url":"https://www.ema.europa.eu/en/documents/work-programme/committee-herbal-medicinal-products-hmpc-work-plan-2025_en.pdf"},
    {"id":"66532","name":"COMP work plan 2025","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-01-30T15:44:40Z","last_updated_date":"2025-01-30T15:44:40Z","reference_number":"EMA/COMP/31017/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/comp-work-plan-2025_en.pdf"},
    {"id":"66576","name":"Committee for Advanced Therapies (CAT): Work Plan 2025","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-02-03T15:22:36Z","last_updated_date":"2025-02-03T15:22:36Z","reference_number":"EMA/CAT/42540/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/committee-advanced-therapies-cat-work-plan-2025_en.pdf"},
    {"id":"67489","name":"Three year work plan for the Good Manufacturing Practice / Good Distribution Practice Inspectors Working Group 2025-2027","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2025-03-27T13:15:28Z","last_updated_date":"2025-03-27T13:15:28Z","reference_number":"EMA/INS/GMP/50356/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/three-year-work-plan-good-manufacturing-practice-good-distribution-practice-inspectors-working-group-2025-2027_en.pdf"},
    {"id":"71715","name":"CVMP work plan 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T10:30:35Z","last_updated_date":"2025-12-12T10:30:35Z","reference_number":"EMA/CVMP/210842/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/cvmp-work-plan-2026_en.pdf"},
    {"id":"71746","name":"Work plan for the Committee for Veterinary Medicinal Products (CVMP) Antimicrobials Working Party (AWP) 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2025-12-12T16:43:30Z","last_updated_date":"2025-12-12T16:43:30Z","reference_number":"EMA/CVMP/AWP/289168/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/work-plan-committee-veterinary-medicinal-products-cvmp-antimicrobials-working-party-awp-2026_en.pdf"},
    {"id":"72230","name":"PDCO work plan 2026","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2026-01-23T15:54:17Z","last_updated_date":"2026-01-23T15:54:17Z","reference_number":"EMA/PDCO/348308/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/pdco-work-plan-2026_en.pdf"},
    {"id":"72237","name":"PRAC work plan 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2026-01-23T16:56:48Z","last_updated_date":"2026-01-23T16:56:48Z","reference_number":"EMA/PRAC/352294/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/prac-work-plan-2026_en.pdf"},
    {"id":"72383","name":"Committee on Herbal Medicinal Products (HMPC): Work Plan 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2026-01-30T12:25:00Z","last_updated_date":"2026-01-30T12:25:00Z","reference_number":"EMA/HMPC/351681/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/committee-herbal-medicinal-products-hmpc-work-plan-2026_en.pdf"},
    {"id":"72403","name":" COMP work plan 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2026-02-02T16:55:04Z","last_updated_date":"2026-02-02T16:55:04Z","reference_number":"EMA/COMP/17759/2026","document_url":"https://www.ema.europa.eu/en/documents/work-programme/comp-work-plan-2026_en.pdf"},
    {"id":"72405","name":"CHMP work plan 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2026-02-03T10:51:53Z","last_updated_date":"2026-02-03T10:51:53Z","reference_number":"EMA/CHMP/348308/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/chmp-work-plan-2026_en.pdf"},
    {"id":"72416","name":"Committee for Advanced Therapies (CAT): Work Plan 2026","type":"work-programme","status":"Adopted","consultation_date":"","first_published_date":"2026-02-04T15:34:46Z","last_updated_date":"2026-02-04T15:34:46Z","reference_number":"EMA/CAT/353549/2025","document_url":"https://www.ema.europa.eu/en/documents/work-programme/committee-advanced-therapies-cat-work-plan-2026_en.pdf"},
    {"id":"72810","name":"Consolidated 3-year work plan for the clinical domain","type":"work-programme","status":"unknown","consultation_date":"","first_published_date":"2026-03-03T17:19:52Z","last_updated_date":"2026-03-03T17:19:52Z","reference_number":"EXT/31963/2026","document_url":"https://www.ema.europa.eu/en/documents/work-programme/consolidated-3-year-work-plan-clinical-domain_en.pdf"},
    {"id":"46753","name":"Direct healthcare professional communication (DHPC): Picato (ingenol mebutate): Suspension of the marketing authorisation due to risk of skin malignancy","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-02-14T09:26:00Z","last_updated_date":"2020-02-14T09:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-picato-ingenol-mebutate-suspension-marketing-authorisation-due-risk-skin-malignancy_en.pdf"},
    {"id":"46754","name":"Direct healthcare professional communication (DHPC): Ecalta 100mg powder for concentrate for solution for infusion (anidulafungin) - Solution for infusion must no longer be frozen","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-02-14T09:51:00Z","last_updated_date":"2020-02-14T09:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ecalta-100mg-powder-concentrate-solution-infusion-anidulafungin-solution-infusion-must-no-longer-be-frozen_en.pdf"},
    {"id":"46812","name":"Direct healthcare professional communication (DHPC): Risks associated with systemic exposure to estradiol creams","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-02-20T15:20:00Z","last_updated_date":"2020-02-20T15:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-risks-associated-systemic-exposure-estradiol-creams_en.pdf"},
    {"id":"46873","name":"Direct healthcare professional communication (DHPC): Mepact 4mg (mifamurtide): Potential for filter leakage or malfunction","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-02-25T13:35:00Z","last_updated_date":"2020-02-25T13:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-mepact-4mg-mifamurtide-potential-filter-leakage-or-malfunction_en.pdf"},
    {"id":"47097","name":"Direct healthcare professional communication (DHPC): Ulipristal acetate 5 mg for uterine fibroids not to be used during ongoing review of liver injury risk","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-03-23T14:46:00Z","last_updated_date":"2020-03-23T14:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ulipristal-acetate-5-mg-uterine-fibroids-not-be-used-during-ongoing-review-liver-injury-risk_en.pdf"},
    {"id":"47507","name":"Direct healthcare professional communication (DHPC): Restrictions in use of cyproterone acetate due to risk of meningioma","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-04-29T11:52:00Z","last_updated_date":"2020-04-29T11:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-restrictions-use-cyproterone-acetate-due-risk-meningioma_en.pdf"},
    {"id":"47556","name":"Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin) 140 mg powder for concentrate for solution for injection: Important information on plastic vial flip-off cap colour","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-05-04T14:51:00Z","last_updated_date":"2020-05-04T14:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-polivy-polatuzumab-vedotin-140-mg-powder-concentrate-solution-injection-important-information-plastic-vial-flip-cap-colour_en.pdf"},
    {"id":"47647","name":"Direct healthcare professional communication (DHPC): Brivudine: potentially fatal toxicity of fluoropyrimidines if administered shortly before or at the same time with brivudine or used within 4 weeks after the end of treatment with brivudine","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-05-12T11:52:00Z","last_updated_date":"2020-05-12T11:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-brivudine-potentially-fatal-toxicity-fluoropyrimidines-if-administered-shortly-or-same-time-brivudine-or-used-within-4-weeks-after-end-treatment_en.pdf"},
    {"id":"47838","name":"Direct healthcare professional communication (DHPC): Tepadina (thiotepa) 100 mg: possible risk of defective vials in batches n°1709192/1, n°1709192/2 and n°1709192/3 presenting a crimp seal not properly fixed on the vial","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-06-02T12:02:00Z","last_updated_date":"2020-06-02T12:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-tepadina-thiotepa-100-mg-possible-risk-defective-vials-batches-ndeg17091921-ndeg17091922-and-ndeg17091923-presenting-crimp-seal-not-properly-fixed_en.pdf"},
    {"id":"47868","name":"Direct healthcare professional communication (DHPC): 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T16:37:00Z","last_updated_date":"2020-06-04T16:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-5-fluorouracil-iv-capecitabine-and-tegafur-containing-products-pre-treatment-testing-identify-dpd-deficient-patients-increased-risk-severe-toxicity_en.pdf"},
    {"id":"47870","name":"Direct healthcare professional communication (DHPC): Flucytosine: Updated recommendations for the use in patients with dihydropyrimidine dehydrogenase (DPD) deficiency","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-06-04T16:56:00Z","last_updated_date":"2020-06-04T16:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-flucytosine-updated-recommendations-use-patients-dihydropyrimidine-dehydrogenase-dpd-deficiency_en.pdf"},
    {"id":"48035","name":"Direct healthcare professional communication (DHPC): Ondexxya (andexanet alfa): commercial anti-FXa activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-06-17T11:58:00Z","last_updated_date":"2020-06-17T11:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ondexxya-andexanet-alfa-commercial-anti-fxa-activity-assays-are-unsuitable-measuring-anti-fxa-activity-following-administration-andexanet-alfa_en.pdf"},
    {"id":"48046","name":"Direct healthcare professional communication (DHPC): Suboxone sublingual tablets (buprenorphine / naloxone): inaccurate Braille information on the carton for HU/CZ/SK pack","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-06-18T10:30:00Z","last_updated_date":"2020-06-18T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-suboxone-sublingual-tablets-buprenorphine-naloxone-inaccurate-braille-information-carton-huczsk-pack_en.pdf"},
    {"id":"48047","name":"Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 5.8mg vial: inconsistency in the Spanish language package leaflet","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-06-18T11:00:00Z","last_updated_date":"2020-06-18T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-myalepta-metreleptin-58mg-vial-inconsistency-spanish-language-package-leaflet_en.pdf"},
    {"id":"48048","name":"Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 5.8 mg vial: inconsistency in the Portuguese-language package leaflet","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-06-18T11:03:00Z","last_updated_date":"2020-06-18T11:03:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-myalepta-metreleptin-58-mg-vial-inconsistency-portuguese-language-package-leaflet_en.pdf"},
    {"id":"48049","name":"Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 3 mg vial: inconsistency in the Portuguese-language package leaflet","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-06-18T11:04:00Z","last_updated_date":"2020-06-18T11:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-myalepta-metreleptin-3-mg-vial-inconsistency-portuguese-language-package-leaflet_en.pdf"},
    {"id":"48050","name":"Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 3 mg vial: inconsistency in the Spanish language package leaflet (PL)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-06-18T11:05:00Z","last_updated_date":"2020-06-18T11:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-myalepta-metreleptin-3-mg-vial-inconsistency-spanish-language-package-leaflet-pl_en.pdf"},
    {"id":"48051","name":"Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 5.8 mg vial: inconsistency in the English-language package leaflet (PL)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-06-18T11:06:00Z","last_updated_date":"2020-06-18T11:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-myalepta-metreleptin-58-mg-vial-inconsistency-english-language-package-leaflet-pl_en.pdf"},
    {"id":"48337","name":"Direct healthcare professional communication (DHPC): Insuman Implantable 400 IU/ml insulin solution for infusion: no new patients should be started due to discontinuation of MiniMed Implantable Pump","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-07-21T10:21:00Z","last_updated_date":"2020-07-21T10:21:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-insuman-implantable-400-iuml-insulin-solution-infusion-no-new-patients-should-be-started-due-discontinuation-minimed-implantable-pump_en.pdf"},
    {"id":"48794","name":"Direct healthcare professional communication (DHPC): Prevymis (letermovir) concentrate for solution for infusion - Essential to administer through sterile 0.2 micron or 0.22 micron polyethersulfone (PES) in-line filter","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-09-11T12:45:00Z","last_updated_date":"2020-09-11T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-prevymis-letermovir-concentrate-solution-infusion-essential-administer-through-sterile-02-micron-or-022-micron-polyethersulfone-pes-line-filter_en.pdf"},
    {"id":"48881","name":"Direct healthcare professional communication (DHPC): Nulojix (belatacept): Extension of the temporary restriction in supply up until 4Q 2021 (initiated in March 2017)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-09-23T12:27:00Z","last_updated_date":"2020-09-23T12:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-nulojix-belatacept-extension-temporary-restriction-supply-until-4q-2021-initiated-march-2017_en.pdf"},
    {"id":"48939","name":"Direct healthcare professional communication (DHPC): Leuprorelin-containing depot products: need to strictly follow instructions for reconstitution and administration to reduce the risk of handling errors that may result in lack of efficacy","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-10-02T15:04:00Z","last_updated_date":"2020-10-02T15:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-leuprorelin-containing-depot-products-need-strictly-follow-instructions-reconstitution-and-administration-reduce-risk-handling-errors-may-result-lack_en.pdf"},
    {"id":"49149","name":"Direct healthcare professional communication (DHPC): Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: Risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-10-28T15:22:00Z","last_updated_date":"2020-10-28T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-cabazitaxel-accord-20-mgml-concentrate-solution-infusion-risk-medication-errors-and-mix-jevtana-60-mg15-ml-concentrate-and-solvent-solution-infusion_en.pdf"},
    {"id":"49153","name":"Direct healthcare professional communication (DHPC): Systemic and inhaled fluoroquinolones: risk of heart valve regurgitation/incompetence","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-10-29T15:22:00Z","last_updated_date":"2020-10-29T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-systemic-and-inhaled-fluoroquinolones-risk-heart-valve-regurgitationincompetence_en.pdf"},
    {"id":"49155","name":"Direct healthcare professional communication (DHPC): Esbriet (pirfenidone): Important safety update and new recommendations to prevent Drug-Induced Liver Injury (DILI)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-10-29T11:15:00Z","last_updated_date":"2020-10-29T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-esbriet-pirfenidone-important-safety-update-and-new-recommendations-prevent-drug-induced-liver-injury-dili_en.pdf"},
    {"id":"49172","name":"Direct healthcare professional communication (DHPC): Ondexxya (andexanet alfa): Avoid use of andexanet prior to heparinization","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-11-04T09:04:00Z","last_updated_date":"2020-11-04T09:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ondexxya-andexanet-alfa-avoid-use-andexanet-prior-heparinization_en.pdf"},
    {"id":"49202","name":"Direct healthcare professional communication (DHPC): Gilenya (fingolimod): Updated recommendations to minimise the risk of drug-induced liver injury (DILI)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-11-10T10:45:00Z","last_updated_date":"2020-11-10T10:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-gilenya-fingolimod-updated-recommendations-minimise-risk-drug-induced-liver-injury-dili_en.pdf"},
    {"id":"49230","name":"Direct healthcare professional communication (DHPC): Tecfidera (dimethyl fumarate): Updated recommendations in the light of cases of progressive multifocal leukoencephalopathy (PML) in the setting of mild lymphopenia","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-11-12T11:15:00Z","last_updated_date":"2020-11-12T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-tecfidera-dimethyl-fumarate-updated-recommendations-light-cases-progressive-multifocal-leukoencephalopathy-pml-setting-mild-lymphopenia_en.pdf"},
    {"id":"49417","name":"Direct healthcare professional communication (DHPC): Important information on Gliolan (5-aminolevulinic acid, 5-ALA): What to do in case of delayed surgery and information on fluorescence in non high-grade glioma","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-12-01T16:12:00Z","last_updated_date":"2020-12-01T16:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-important-information-gliolan-5-aminolevulinic-acid-5-ala-what-do-case-delayed-surgery-and-information-fluorescence-non-high-grade-glioma_en.pdf"},
    {"id":"49569","name":"Direct healthcare professional communication (DHPC): Metamizole: Risk of drug-induced liver injury","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-12-15T12:45:00Z","last_updated_date":"2020-12-15T12:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-metamizole-risk-drug-induced-liver-injury_en.pdf"},
    {"id":"49687","name":"Direct healthcare professional communication (DHPC): GLOBAL RECALL: Zerbaxa (ceftolozane / tazobactam) 1 g/0.5 g powder for concentrate for solution for infusion","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2020-12-22T16:45:00Z","last_updated_date":"2020-12-22T16:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-global-recall-zerbaxa-ceftolozane-tazobactam-1-g05-g-powder-concentrate-solution-infusion_en.pdf"},
    {"id":"49700","name":"Direct healthcare professional communication (DHPC): Kaletra (lopinavir/ritonavir) oral solution, 2 bottle pack containing 2-ml oral dosing syringes: Presence of amide particles in 2-ml oral dosing syringes","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-01-04T12:27:00Z","last_updated_date":"2021-01-04T12:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-kaletra-lopinavirritonavir-oral-solution-2-bottle-pack-containing-2-ml-oral-dosing-syringes-presence-amide-particles-2-ml-oral-dosing-syringes_en.pdf"},
    {"id":"49953","name":"Direct healthcare professional communication (DHPC): Shortage of Nucala (mepolizumab) Pre-Filled Pen (EU/1/15/1043/003, EU/1/15/1043/004)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-01-27T15:53:00Z","last_updated_date":"2021-01-27T15:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-shortage-nucala-mepolizumab-pre-filled-pen-eu1151043003-eu1151043004_en.pdf"},
    {"id":"50066","name":"Direct healthcare professional communication (DHPC): Risk of acute adrenal insufficiency when switching from crushed or compounded oral hydrocortisone formulations to Alkindi (hydrocortisone granules in capsules for opening)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-02-04T12:15:00Z","last_updated_date":"2021-02-04T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-risk-acute-adrenal-insufficiency-when-switching-crushed-or-compounded-oral-hydrocortisone-formulations-alkindi-hydrocortisone-granules-capsules_en.pdf"},
    {"id":"50153","name":"Direct healthcare professional communication (DHPC): Respreeza (human alpha-1-proteinase inhibitor): batch-specific product recall","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-02-12T14:14:00Z","last_updated_date":"2021-02-12T14:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-respreeza-human-alpha-1-proteinase-inhibitor-batch-specific-product-recall_en.pdf"},
    {"id":"50201","name":"Direct healthcare professional communication (DHPC): Reminder to monitor the liver function of patients treated with Lojuxta and to avoid use in pregnancy","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-02-17T12:41:00Z","last_updated_date":"2021-02-17T12:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-reminder-monitor-liver-function-patients-treated-lojuxta-and-avoid-use-pregnancy_en.pdf"},
    {"id":"50640","name":"Direct healthcare professional communication (DHPC): Zolgensma (onasemnogene abeparvovec): risk for thrombotic microangiopathy","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-03-18T12:36:00Z","last_updated_date":"2021-03-18T12:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-zolgensma-onasemnogene-abeparvovec-risk-thrombotic-microangiopathy_en.pdf"},
    {"id":"50666","name":"Direct healthcare professional communication (DHPC): Strimvelis: first case of lymphoid T cell leukaemia after insertional oncogenesis","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-03-22T12:12:00Z","last_updated_date":"2021-03-22T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-strimvelis-first-case-lymphoid-t-cell-leukaemia-after-insertional-oncogenesis_en.pdf"},
    {"id":"50687","name":"Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): Risk of thrombocytopenia and coagulation disorders","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-03-24T10:00:00Z","last_updated_date":"2021-03-24T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca-risk-thrombocytopenia-and-coagulation-disorders_en.pdf"},
    {"id":"50690","name":"Direct healthcare professional communication (DHPC): Xeljanz (tofacitinib): Initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF— alpha inhibitors","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-03-24T12:23:00Z","last_updated_date":"2021-03-24T12:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-xeljanz-tofacitinib-initial-clinical-trial-results-increased-risk-major-adverse-cardiovascular-events-and-malignancies-excluding-nmsc-use-tofacitinib_en.pdf"},
    {"id":"50698","name":"Direct healthcare professional communication (DHPC): Tecentriq (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-03-25T11:10:00Z","last_updated_date":"2021-03-25T11:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-tecentriq-atezolizumab-risk-severe-cutaneous-adverse-reactions-scars_en.pdf"},
    {"id":"50721","name":"Direct healthcare professional communication (DHPC): Respreeza (human alpha-1-proteinase inhibitor): Sterility issue with the infusion device co-packed with Respreeza 4.000 mg and 5.000 mg","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-03-26T11:10:00Z","last_updated_date":"2021-03-26T11:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-respreeza-human-alpha-1-proteinase-inhibitor-sterility-issue-infusion-device-co-packed-respreeza-4000-mg-and-5000-mg_en.pdf"},
    {"id":"50795","name":"Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-04-13T09:53:00Z","last_updated_date":"2021-04-13T09:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca-link-between-vaccine-and-occurrence-thrombosis-combination-thrombocytopenia_en.pdf"},
    {"id":"50855","name":"Direct healthcare professional communication (DHPC): Eylea 40 mg/mL (aflibercept solution for intravitreal injection): Higher risk of intraocular pressure increase with the pre-filled syringe","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-04-15T11:51:00Z","last_updated_date":"2021-04-15T11:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-eylea-40-mgml-aflibercept-solution-intravitreal-injection-higher-risk-intraocular-pressure-increase-pre-filled-syringe_en.pdf"},
    {"id":"50988","name":"Direct healthcare professional communication (DHPC): COVID-19 Vaccine Janssen: link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-04-26T12:20:00Z","last_updated_date":"2021-04-26T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-covid-19-vaccine-janssen-link-between-vaccine-and-occurrence-thrombosis-combination-thrombocytopenia_en.pdf"},
    {"id":"51339","name":"Direct healthcare professional communication (DHPC): Vaxzevria/COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination with thrombocytopenia - Updated information","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-06-02T11:14:00Z","last_updated_date":"2021-06-02T11:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vaxzevriacovid-19-vaccine-astrazeneca-risk-thrombosis-combination-thrombocytopenia-updated-information_en.pdf"},
    {"id":"51349","name":"Direct healthcare professional communication (DHPC): INOmax (nitric oxide) - Difficulties in closing the cylinder valves after use: precautions for use when disconnecting the cylinders from pressure regulators","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-06-03T09:08:00Z","last_updated_date":"2021-06-03T09:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-inomax-nitric-oxide-difficulties-closing-cylinder-valves-after-use-precautions-use-when-disconnecting-cylinders-pressure-regulators_en.pdf"},
    {"id":"51390","name":"Direct healthcare professional communication (DHPC): Venclyxto - (venetoclax) film coated tablets:  Updated recommendations on tumour lysis syndrome (TLS) in CLL patients","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-06-10T11:15:00Z","last_updated_date":"2021-06-10T11:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-venclyxto-venetoclax-film-coated-tablets-updated-recommendations-tumour-lysis-syndrome-tls-cll-patients_en.pdf"},
    {"id":"51548","name":"Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): contraindication in individuals with previous capillary leak syndrome","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-06-23T09:32:00Z","last_updated_date":"2021-06-23T09:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca-contraindication-individuals-previous-capillary-leak-syndrome_en.pdf"},
    {"id":"51845","name":"Direct healthcare professional communication (DHPC): Xeljanz (tofacitinib): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-07-06T09:04:00Z","last_updated_date":"2021-07-06T09:04:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-xeljanz-tofacitinib-increased-risk-major-adverse-cardiovascular-events-and-malignancies-use-tofacitinib-relative-tnf-alpha-inhibitors_en.pdf"},
    {"id":"51937","name":"Direct healthcare professional communication (DHPC): Champix (varenicline) - lots to be recalled due to presence of impurity N-nitroso-varenicline above the Pfizer acceptable daily intake limit","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-07-15T13:12:00Z","last_updated_date":"2021-07-15T13:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-champix-varenicline-lots-be-recalled-due-presence-impurity-n-nitroso-varenicline-above-pfizer-acceptable-daily-intake-limit_en.pdf"},
    {"id":"51942","name":"Direct healthcare professional communication (DHPC): COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-07-19T12:34:00Z","last_updated_date":"2021-07-19T12:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-covid-19-vaccine-janssen-contraindication-individuals-previous-capillary-leak-syndrome-and-update-thrombosis-thrombocytopenia-syndrome_en.pdf"},
    {"id":"51943","name":"Direct healthcare professional communication (DHPC): COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-07-19T12:51:00Z","last_updated_date":"2021-07-19T12:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-covid-19-mrna-vaccines-comirnaty-and-spikevax-risk-myocarditis-and-pericarditis_en.pdf"},
    {"id":"52326","name":"Direct healthcare professional communication (DHPC): RoActemra (tocilizumab) - Temporary Supply Shortage for 162 mg solution for subcutaneous injection (pre-filled syringe and pre-filled pen) and RoActemra 20mg/mL concentrate for solution for infusion(IV)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-09-03T13:35:00Z","last_updated_date":"2021-09-03T13:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-roactemra-tocilizumab-temporary-supply-shortage-162-mg-solution-subcutaneous-injection-pre-filled-syringe-and-pre-filled-pen-and-roactemra-20mgml_en.pdf"},
    {"id":"52684","name":"Direct healthcare professional communication (DHPC): CHAMPIX (varenicline) - lots to be recalled due to presence of impurity N-nitroso-varenicline above the acceptable intake limit","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-09-30T12:50:00Z","last_updated_date":"2021-09-30T12:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-champix-varenicline-lots-be-recalled-due-presence-impurity-n-nitroso-varenicline-above-acceptable-intake-limit_en.pdf"},
    {"id":"52828","name":"Direct healthcare professional communication (DHPC): COVID-19 Vaccine Janssen: Risk for immune thrombocytopenia (ITP) and venous thromboembolism (VTE)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-10-13T11:18:00Z","last_updated_date":"2021-10-13T11:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-covid-19-vaccine-janssen-risk-immune-thrombocytopenia-itp-and-venous-thromboembolism-vte_en.pdf"},
    {"id":"52829","name":"Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): risk of thrombocytopenia (including immune thrombocytopenia) with or without associated bleeding","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-10-13T11:38:00Z","last_updated_date":"2021-10-13T11:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca-risk-thrombocytopenia-including-immune-thrombocytopenia-or-without-associated-bleeding_en.pdf"},
    {"id":"52990","name":"Direct healthcare professional communication (DHPC): Visudyne (verteporfin): Information on the continuing supply restriction until end Q1/2022","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-11-05T10:13:00Z","last_updated_date":"2021-11-05T10:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-visudyne-verteporfin-information-continuing-supply-restriction-until-end-q12022_en.pdf"},
    {"id":"52994","name":"Direct healthcare professional communication (DHPC): Beovu ® (brolucizumab): Updated recommendations to minimise the known risk of intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-11-05T11:06:00Z","last_updated_date":"2021-11-05T11:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-beovu-r-brolucizumab-updated-recommendations-minimise-known-risk-intraocular-inflammation-including-retinal-vasculitis-andor-retinal-vascular_en.pdf"},
    {"id":"53029","name":"Direct healthcare professional communication (DHPC): Supply Constraint of Sarilumab [Kevzara®]","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-11-09T13:26:00Z","last_updated_date":"2021-11-09T13:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-supply-constraint-sarilumab-kevzarar_en.pdf"},
    {"id":"53070","name":"Direct healthcare professional communication (DHPC): Forxiga (dapagliflozin) 5mg should no longer be used for the  treatment of Type 1 Diabetes Mellitus","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-11-11T13:47:00Z","last_updated_date":"2021-11-11T13:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-forxiga-dapagliflozin-5mg-should-no-longer-be-used-treatment-type-1-diabetes-mellitus_en.pdf"},
    {"id":"53378","name":"Direct healthcare professional communication: Lymphoseek (tilmanocept) 50 micrograms kit for radiopharmaceutical preparation: temporary extension of shelf life","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-12-07T09:02:00Z","last_updated_date":"2021-12-07T09:02:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-lymphoseek-tilmanocept-50-micrograms-kit-radiopharmaceutical-preparation-temporary-extension-shelf-life_en.pdf"},
    {"id":"53604","name":"Direct healthcare professional communication (DHPC): Briviact® (In Italy: Nubriveo®) (brivaracetam 10Mg/ml) Oral solution: Bottles with narrow neck diameter","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2021-12-20T13:26:00Z","last_updated_date":"2021-12-20T13:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-briviactr-italy-nubriveor-brivaracetam-10mgml-oral-solution-bottles-narrow-neck-diameter_en.pdf"},
    {"id":"53764","name":"Direct healthcare professional communication (DHPC): Nulojix (belatacept): Further extension of the temporary restriction in supply up until 3Q 2022","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-01-17T15:05:00Z","last_updated_date":"2022-01-17T15:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-nulojix-belatacept-further-extension-temporary-restriction-supply-until-3q-2022_en.pdf"},
    {"id":"54147","name":"Direct healthcare professional communication (DHPC): Mavenclad (cladribine) – risk of serious liver injury and new recommendations about liver function monitoring","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-02-14T10:23:00Z","last_updated_date":"2022-02-14T10:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-mavenclad-cladribine-risk-serious-liver-injury-and-new-recommendations-about-liver-function-monitoring_en.pdf"},
    {"id":"54246","name":"Direct healthcare professional communication (DHPC): Xagrid (anagrelide hydrochloride): Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-02-22T15:01:00Z","last_updated_date":"2022-02-22T15:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-xagrid-anagrelide-hydrochloride-risk-thrombosis-including-cerebral-infarction-upon-abrupt-treatment-discontinuation_en.pdf"},
    {"id":"54367","name":"Direct healthcare professional communication (DHPC): Infliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use of live vaccines in infants exposed in utero or during breastfeeding","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-03-07T17:05:00Z","last_updated_date":"2022-03-07T17:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-infliximab-remicade-flixabi-inflectra-remsima-and-zessly-use-live-vaccines-infants-exposed-utero-or-during-breastfeeding_en.pdf"},
    {"id":"54861","name":"Direct healthcare professional communication (DHPC): Natpar (parathyroid hormone) 100 micrograms/dose powder and solvent for solution for injection: expected shortage from June 30th, 2022","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-04-29T09:31:00Z","last_updated_date":"2022-04-29T09:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-natpar-parathyroid-hormone-100-microgramsdose-powder-and-solvent-solution-injection-expected-shortage-june-30th-2022_en.pdf"},
    {"id":"54913","name":"Direct healthcare professional communication (DHPC): Rucaparib (Rubraca® ): interim data from Study CO-338- 043 (ARIEL4) show a decrease in overall survival compared to standard of care","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-05-06T11:59:00Z","last_updated_date":"2022-05-06T11:59:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-rucaparib-rubracar-interim-data-study-co-338-043-ariel4-show-decrease-overall-survival-compared-standard-care_en.pdf"},
    {"id":"55108","name":"Direct healthcare professional communication (DHPC): Lymphoseek (tilmanocept) 50 micrograms kit for radiopharmaceutical preparation: temporary extension of shelf life","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-05-30T11:44:00Z","last_updated_date":"2022-05-30T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-lymphoseek-tilmanocept-50-micrograms-kit-radiopharmaceutical-preparation-temporary-extension-shelf-life_en.pdf"},
    {"id":"55154","name":"Direct healthcare professional communication (DHPC): Ocaliva (obeticholic acid) - New contraindication for the treatment of primary biliary cholangitis (PBC) in patients with decompensated liver cirrhosis or a history of prior hepatic decompensation","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-06-09T12:15:00Z","last_updated_date":"2022-06-09T12:15:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ocaliva-obeticholic-acid-new-contraindication-treatment-primary-biliary-cholangitis-pbc-patients-decompensated-liver-cirrhosis-or-history-prior_en.pdf"},
    {"id":"55194","name":"Direct healthcare professional communication (DHPC): Defitelio (defibrotide): Do not use for prophylaxis of veno-occlusive disease (VOD) after post-hematopoietic stem-cell transplantation (HSCT)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-06-13T09:20:00Z","last_updated_date":"2022-06-13T09:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-defitelio-defibrotide-do-not-use-prophylaxis-veno-occlusive-disease-vod-after-post-hematopoietic-stem-cell-transplantation-hsct_en.pdf"},
    {"id":"55247","name":"Direct healthcare professional communication (DHPC): Imlygic (talimogene laherparepvec): Special considerations to minimize the potential occurrence of adverse events in HSV-1 seronegative patients receiving vials from affected lots: injections from ...","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-06-16T11:39:00Z","last_updated_date":"2022-06-16T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-imlygic-talimogene-laherparepvec-special-considerations-minimize-potential-occurrence-adverse-events-hsv-1-seronegative-patients-receiving-vials_en.pdf"},
    {"id":"55254","name":"Direct healthcare professional communication (DHPC): Dexmedetomidine: Increased risk of mortality in intensive care unit (ICU) patients ≤65 years","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-06-16T09:43:00Z","last_updated_date":"2022-06-16T09:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-dexmedetomidine-increased-risk-mortality-intensive-care-unit-icu-patients-65-years_en.pdf"},
    {"id":"55413","name":"Direct healthcare professional communication (DHPC): Hydroxyethyl starch (HES) solutions for infusion: suspension of marketing authorisations due to continued use in contraindicated patient populations with increased risk of serious harm","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-06-30T11:39:00Z","last_updated_date":"2022-07-26T14:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-hydroxyethyl-starch-hes-solutions-infusion-suspension-marketing-authorisations-due-continued-use-contraindicated-patient-populations-increased-risk_en.pdf"},
    {"id":"55790","name":"Direct healthcare professional communication (DHPC): Rubraca  (rucaparib): restriction of indication","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-08-08T09:34:00Z","last_updated_date":"2022-08-08T09:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-rubraca-rucaparib-restriction-indication_en.pdf"},
    {"id":"55804","name":"Direct healthcare professional communication (DHPC): Cetrorelix acetate - Cetrotide® 0.25 mg Powder and solvent for injection: Temporary Shortage","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-08-09T11:39:00Z","last_updated_date":"2022-08-09T11:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-cetrorelix-acetate-cetrotider-025-mg-powder-and-solvent-injection-temporary-shortage_en.pdf"},
    {"id":"55812","name":"Direct animal healthcare professional communication (DaHPC): Hiprabovis IBR Marker Live (infectious bovine rhinotracheitis vaccine (live)) - Increase in the incidence of anaphylactic-type reactions in cattle","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-08-11T10:00:00Z","last_updated_date":"2022-08-11T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-animal-healthcare-professional-communication-dahpc-hiprabovis-ibr-marker-live-infectious-bovine-rhinotracheitis-vaccine-live-increase-incidence-anaphylactic-type-reactions-cattle_en.pdf"},
    {"id":"55814","name":"Direct healthcare professional communication (DHPC): Visudyne (verteporfin): Information on the continuing supply limitation until end of 2023","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-08-12T16:57:00Z","last_updated_date":"2022-08-12T16:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-visudyne-verteporfin-information-continuing-supply-limitation-until-end-2023_en.pdf"},
    {"id":"56057","name":"Direct healthcare professional communication (DHPC): Nulojix (belatacept): Risk of medication errors due to change in maintenance dose from 5 mg/kg to 6 mg/kg","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-09-12T16:57:00Z","last_updated_date":"2022-09-12T16:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-nulojix-belatacept-risk-medication-errors-due-change-maintenance-dose-5-mgkg-6-mgkg_en.pdf"},
    {"id":"56169","name":"Direct healthcare professional communication (DHPC) : Metalyse® (tenecteplase) 8000 units (40 mg) and 10000 units (50 mg) powder and solvent for solution for injection: temporary supply shortage","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-09-23T09:11:00Z","last_updated_date":"2022-09-23T09:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-metalyser-tenecteplase-8000-units-40-mg-and-10000-units-50-mg-powder-and-solvent-solution-injection-temporary-supply-shortage_en.pdf"},
    {"id":"56199","name":"Direct healthcare professional communication (DHPC): NULOJIX (belatacept): Further extension of the temporary restriction in supply up until 3Q 2023","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-09-28T12:18:00Z","last_updated_date":"2022-09-28T12:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-nulojix-belatacept-further-extension-temporary-restriction-supply-until-3q-2023_en.pdf"},
    {"id":"56310","name":"Direct healthcare professional communication (DHPC): Natpar (parathyroid hormone): Discontinuation of manufacturing at the end of 2024 and update on 100mcg shortage","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-10-04T11:57:00Z","last_updated_date":"2022-10-04T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-natpar-parathyroid-hormone-discontinuation-manufacturing-end-2024-and-update-100mcg-shortage_en.pdf"},
    {"id":"56430","name":"Direct healthcare professional communication (DHPC): Ozempic (semaglutide) solution for injection in pre-filled pen: supply shortage","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-10-19T11:57:00Z","last_updated_date":"2022-10-19T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ozempic-semaglutide-solution-injection-pre-filled-pen-supply-shortage_en.pdf"}    {"id":"56514","name":"Direct healthcare professional communication (DHPC): Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-11-03T11:57:00Z","last_updated_date":"2022-11-03T11:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-imbruvica-ibrutinib-new-risk-minimisation-measures-including-dose-modification-recommendations-due-increased-risk-serious-cardiac-events_en.pdf"},
    {"id":"56543","name":"Direct healthcare professional communication (DHPC): Nomegestrol and chlormadinone containing medicines: Measures to minimise the risk of meningioma","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-11-08T09:28:00Z","last_updated_date":"2022-11-08T09:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-nomegestrol-and-chlormadinone-containing-medicines-measures-minimise-risk-meningioma_en.pdf"},
    {"id":"57094","name":"Direct healthcare professional communication (DHPC): Terlipressin: Serious or fatal respiratory failure and sepsis/septic shock in patients with type 1 hepatorenal syndrome (type 1 HRS)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2022-12-20T09:36:00Z","last_updated_date":"2022-12-20T09:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-terlipressin-serious-or-fatal-respiratory-failure-and-sepsisseptic-shock-patients-type-1-hepatorenal-syndrome-type-1-hrs_en.pdf"},
    {"id":"57298","name":"Direct healthcare professional communication (DHPC): INSUMAN RAPID / INSUMAN BASAL / INSUMAN COMB 25 (insulin human): temporary supply shortage <and marketing cessation>","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-01-16T15:19:00Z","last_updated_date":"2023-01-16T15:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-insuman-rapid-insuman-basal-insuman-comb-25-insulin-human-temporary-supply-shortage_en.pdf"},
    {"id":"57385","name":"Pazenir® (paclitaxel formulated as albumin bound nanoparticles) 5 mg/ml powder for dispersion for infusion: temporary supply shortage","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-01-25T13:57:00Z","last_updated_date":"2023-01-25T13:57:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/pazenirr-paclitaxel-formulated-albumin-bound-nanoparticles-5-mgml-powder-dispersion-infusion-temporary-supply-shortage_en.pdf"},
    {"id":"57395","name":"Direct healthcare professional communication (DHPC): Lymphoseek (tilmanocept) 50 micrograms kit for radiopharmaceutical preparation: temporary extension of shelf life","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-01-31T09:00:00Z","last_updated_date":"2023-01-31T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-lymphoseek-tilmanocept-50-micrograms-kit-radiopharmaceutical-preparation-temporary-extension-shelf-life_en.pdf-0"},
    {"id":"57548","name":"Direct healthcare professional communication (DHPC) : Amfepramone-containing medicines will no longer be available on the EU market, as marketing authorisations will be revoked","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-02-08T09:00:00Z","last_updated_date":"2023-02-08T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-amfepramone-containing-medicines-will-no-longer-be-available-eu-market-marketing-authorisations-will-be-revoked_en.pdf"},
    {"id":"57658","name":"Direct healthcare professional communication (DHPC) : Adakveo (crizanlizumab): Phase III study (CSEG101A2301) shows no superiority of crizanlizumab over placebo","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-02-14T09:45:00Z","last_updated_date":"2023-02-14T09:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-adakveo-crizanlizumab-phase-iii-study-cseg101a2301-shows-no-superiority-crizanlizumab-over-placebo_en.pdf"},
    {"id":"57671","name":"Direct healthcare professional communication (DHPC): CYSTAGON (mercaptamine bitartrate)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-02-15T09:35:00Z","last_updated_date":"2023-02-15T09:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-cystagon-mercaptamine-bitartrate_en.pdf"},
    {"id":"57698","name":"Direct healthcare professional communication (DHPC) : Neofordex 40 mg (dexamethasone): removal of the score-line and the associated 20 mg posology","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-02-17T15:31:00Z","last_updated_date":"2023-02-17T15:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-neofordex-40-mg-dexamethasone-removal-score-line-and-associated-20-mg-posology_en.pdf"},
    {"id":"57699","name":"Direct healthcare professional communications (DHPC) : Supply shortage of Fasturtec (rasburicase) 7.5 mg/5 ml powder and solvent for concentrate for solution for infusion (EU/1/00/170/002)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-02-17T09:46:00Z","last_updated_date":"2023-02-17T09:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communications-dhpc-supply-shortage-fasturtec-rasburicase-75-mg5-ml-powder-and-solvent-concentrate-solution-infusion-eu100170002_en.pdf"},
    {"id":"57718","name":"Direct healthcare professional communication (DHPC): ZOLGENSMA (onasemnogene abeparvovec) - Fatal cases of acute liver failure","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-02-17T15:24:00Z","last_updated_date":"2023-02-17T15:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-zolgensma-onasemnogene-abeparvovec-fatal-cases-acute-liver-failure_en.pdf"},
    {"id":"57720","name":"Direct healthcare professional communication (DHPC): Terlipressin: Serious or fatal respiratory failure and sepsis/septic shock in patients with type 1 hepatorenal syndrome (type 1 HRS)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-02-17T16:24:00Z","last_updated_date":"2023-02-17T16:24:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-terlipressin-serious-or-fatal-respiratory-failure-and-sepsisseptic-shock-patients-type-1-hepatorenal-syndrome-type-1-hrs_en.pdf-0"},
    {"id":"57751","name":"Direct healthcare professional communication (DHPC): Spikevax bivalent Original/Omicron BA.1, pre-filled syringe - Labelling deviation","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-02-21T08:40:00Z","last_updated_date":"2023-02-21T08:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-spikevax-bivalent-originalomicron-ba1-pre-filled-syringe-labelling-deviation_en.pdf"},
    {"id":"57753","name":"Direct healthcare professional communication (DHPC): Xalkori (crizotinib): Vision disorders, including risk of severe visual loss, need for monitoring in paediatric patients","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-02-21T10:09:00Z","last_updated_date":"2023-02-21T10:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-xalkori-crizotinib-vision-disorders-including-risk-severe-visual-loss-need-monitoring-paediatric-patients_en.pdf"},
    {"id":"57832","name":"Direct healthcare professional communication (DHPC): Caprelsa (vandetanib): Restriction of indication","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-02-28T10:39:00Z","last_updated_date":"2023-02-28T10:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-caprelsa-vandetanib-restriction-indication_en.pdf"},
    {"id":"57998","name":"Direct healthcare professional communication (DHPC): Ozempic (semaglutide) solution for injection in pre-filled pen: supply shortage update","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-03-13T09:55:00Z","last_updated_date":"2023-03-13T09:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ozempic-semaglutide-solution-injection-pre-filled-pen-supply-shortage-update_en.pdf"},
    {"id":"58008","name":"Direct healthcare professional communication (DHPC) : Myalepta (metreleptin) 5.8 mg vial: shortage and mitigation plan","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-03-14T16:09:00Z","last_updated_date":"2023-03-14T16:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-myalepta-metreleptin-58-mg-vial-shortage-and-mitigation-plan_en.pdf"},
    {"id":"58155","name":"Direct healthcare professional communication (DHPC) : Pholcodine-containing medicinal products no longer available on the EU market","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-03-27T14:10:00Z","last_updated_date":"2023-03-27T14:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-pholcodine-containing-medicinal-products-no-longer-available-eu-market_en.pdf"},
    {"id":"58210","name":"Direct healthcare professional communication (DHPC) : Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-03-30T10:00:00Z","last_updated_date":"2023-03-30T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-updated-recommendations-minimise-risks-malignancy-major-adverse-cardiovascular-events-serious-infections-venous-thromboembolism-and-mortality-use_en.pdf"},
    {"id":"58363","name":"Direct healthcare professional communication (DHPC): Menopur (menotropins’ for injection) – quality defect leading to supply shortage","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-04-17T10:19:00Z","last_updated_date":"2023-04-17T10:19:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-menopur-menotropins-injection-quality-defect-leading-supply-shortage_en.pdf"},
    {"id":"58466","name":"Direct healthcare professional communication (DHPC) : SIMULECT (basiliximab): Do not use WFI ampoules co-packed with vials of sterile freeze-dried powder of Simulect 10mg and 20mg","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-04-20T08:30:00Z","last_updated_date":"2023-04-21T13:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-simulect-basiliximab-do-not-use-wfi-ampoules-co-packed-vials-sterile-freeze-dried-powder-simulect-10mg-and-20mg_en.pdf"},
    {"id":"58586","name":"Direct animal healthcare professional communication (DaHPC) : Arti-Cell® Forte and RenuTend® market recall of select product batches","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-05-04T08:30:00Z","last_updated_date":"2023-05-04T08:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-animal-healthcare-professional-communication-dahpc-arti-cellr-forte-and-renutendr-market-recall-select-product-batches_en.pdf"},
    {"id":"58882","name":"Direct healthcare professional communication (DHPC) : Systemic and inhaled fluoroquinolone antibiotics – reminder on restrictions of use","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-06-08T10:07:00Z","last_updated_date":"2023-06-08T10:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-systemic-and-inhaled-fluoroquinolone-antibiotics-reminder-restrictions-use_en.pdf"},
    {"id":"58948","name":"Direct healthcare professional communication (DHPC) :  ADAKVEO (crizanlizumab): revocation of EU marketing authorisation due to lack of therapeutic efficacy","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-06-15T09:00:00Z","last_updated_date":"2023-06-15T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-adakveo-crizanlizumab-revocation-eu-marketing-authorisation-due-lack-therapeutic-efficacy_en.pdf"},
    {"id":"58964","name":"Direct healthcare professional communication (DHPC): Gavreto (pralsetinib): Increased risk for tuberculosis and measures to minimise this risk","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-06-16T09:00:00Z","last_updated_date":"2023-06-16T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-gavreto-pralsetinib-increased-risk-tuberculosis-and-measures-minimise-risk_en.pdf"},
    {"id":"59585","name":"Direct healthcare professional communication (DHPC): Simponi (golimumab) 50 mg and 100 mg: important changes to the injection instructions for the SmartJect Pre-filled Pen","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-08-10T16:56:00Z","last_updated_date":"2023-08-10T16:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-simponi-golimumab-50-mg-and-100-mg-important-changes-injection-instructions-smartject-pre-filled-pen_en.pdf"},
    {"id":"59603","name":"Potential missing package leaflet in folding boxes of RoActemra (tocilizumab), Hemlibra (emicizumab), Herceptin (trastuzumab), Kadcyla (trastuzumab emtansine), MabThera (rituximab), Phesgo (pertuzumab / trastuzumab) and Tecentriq (atezolizumab)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-08-17T13:10:00Z","last_updated_date":"2023-08-17T13:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/potential-missing-package-leaflet-folding-boxes-roactemra-tocilizumab-hemlibra-emicizumab-herceptin-trastuzumab-kadcyla-trastuzumab-emtansine-mabthera-rituximab-phesgo-pertuzumab-trastuzumab-and_en.pdf"},
    {"id":"60076","name":"Direct healthcare professional communication (DHPC): Vaxneuvance (pneumococcal polysaccharide conjugate vaccine) suspension for injection: Important information regarding the potential for breakage of Vaxneuvance pre-filled syringes","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-09-20T14:48:00Z","last_updated_date":"2023-09-20T14:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vaxneuvance-pneumococcal-polysaccharide-conjugate-vaccine-suspension-injection-important-information-regarding-potential-breakage-vaxneuvance-pre_en.pdf"},
    {"id":"60930","name":"Topiramate and topiramate/phentermine combination: New restrictions to prevent exposure during pregnancy","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-11-21T13:12:55Z","last_updated_date":"2023-11-21T13:12:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/topiramate-and-topiramate-phentermine-combination-new-restrictions-prevent-exposure-during-pregnancy_en.pdf"},
    {"id":"60997","name":"Direct Healthcare Professional Communication (DHPC) Ozempic (semaglutide) and Victoza (liraglutide): Supply shortage","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-11-21T16:16:27Z","last_updated_date":"2023-12-01T11:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ozempic-semaglutide-victoza-liraglutide-supply-shortage_en.pdf"},
    {"id":"61174","name":"Direct healthcare professional communication (DHPC): Omega-3-acid ethyl ester medicines: dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T12:00:00Z","last_updated_date":"2023-12-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-omega-3-acid-ethyl-ester-medicines-dose-dependent-increased-risk-atrial-fibrillation-patients-established-cardiovascular-diseases-or-cardiovascular_en.pdf"},
    {"id":"61175","name":"Direct healthcare professional communication (DHPC): Integrilin (eptifibatide): Discontinuation of manufacturing of Integrilin","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2023-12-01T12:00:00Z","last_updated_date":"2023-12-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-integrilin-eptifibatide-discontinuation-manufacturing-integrilin_en.pdf"},
    {"id":"61840","name":"Direct healthcare professional communication (DHPC) : Leqvio (inclisiran) 284 mg solution for injection in pre-filled syringe: Important information regarding instructions for use before injection","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-01-23T12:39:53Z","last_updated_date":"2024-01-23T12:39:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-leqvio-inclisiran-284-mg-solution-injection-pre-filled-syringe-important-information-regarding-instructions-use-injection_en.pdf"},
    {"id":"61841","name":"Direct healthcare professional communication (DHPC) : Voxzogo (vosoritide): change to administration syringe and needle leading to product administration in Units (U) instead of mL","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-01-23T12:56:27Z","last_updated_date":"2024-01-23T12:56:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-voxzogo-vosoritide-change-administration-syringe-and-needle-leading-product-administration-units-u-instead-ml_en.pdf"},
    {"id":"62030","name":"Direct healthcare professional communication (DHPC) : Pseudoephedrine – Risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-02-08T09:32:36Z","last_updated_date":"2024-02-08T09:32:36Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-pseudoephedrine-risks-posterior-reversible-encephalopathy-syndrome-pres-reversible-cerebral-vasoconstriction-syndrome-rcvs_en.pdf"},
    {"id":"62215","name":"Direct healthcare professional communication (DHPC) : Valproate-containing medicines - new measures regarding the potential risk of neurodevelopmental disorders in children of fathers treated with valproate in the 3 months prior to conception","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-02-19T16:42:31Z","last_updated_date":"2024-02-19T16:42:31Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-valproate-containing-medicines-new-measures-regarding-potential-risk-neurodevelopmental-disorders-children-fathers-treated-valproate-3-months-prior_en.pdf"},
    {"id":"62666","name":"Direct healthcare professional communication (DHPC) : Paxlovid (nirmatrelvir; ritonavir): reminder of life-threatening and fatal drug-drug interactions with certain immunosuppressants, including tacrolimus","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-03-21T10:16:57Z","last_updated_date":"2024-03-21T10:16:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-paxlovid-nirmatrelvir-ritonavir-reminder-life-threatening-fatal-drug-drug-interactions-certain-immunosuppressants-including-tacrolimus_en.pdf"},
    {"id":"63305","name":"Direct healthcare professional communication (DHPC) : Giapreza (angiotensin II) 2.5mg/ml concentrate for solution for infusion: potentially low fill vials and important information regarding instructions for use","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-05-23T11:12:00Z","last_updated_date":"2024-05-23T11:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-giapreza-angiotensin-ii-25mg-ml-concentrate-solution-infusion-potentially-low-fill-vials-important-information-regarding-instructions-use_en.pdf"},
    {"id":"63498","name":"Direct animal healthcare professional communication (DaHPC) : Kexxtone 32.4 g continuous-release intraruminal device for cattle (monensin): marketing authorisation suspension and market recall of all batches","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-06-05T16:32:45Z","last_updated_date":"2024-12-11T13:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-animal-healthcare-professional-communication-dahpc-kexxtone-324-g-continuous-release-intraruminal-device-cattle-monensin-marketing-authorisation-suspension-market-recall-all-batches_en.pdf"},
    {"id":"63677","name":"Direct healthcare professional communication (DHPC) : Zypadhera (olanzapine pamoate monohydrate): Injection kits to temporarily include only three 38 mm safety needles instead of two 38 mm and two 50 mm safety needles","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-06-19T11:18:00Z","last_updated_date":"2024-06-19T11:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-zypadhera-olanzapine-pamoate-monohydrate-injection-kits-temporarily-include-only-three-38-mm-safety-needles-instead-two-38-mm-two-50-mm-safety-needles_en.pdf"},
    {"id":"64183","name":"Direct healthcare professional communication (DHPC) : Hydroxyprogesterone caproate (17-OHPC)-containing medicinal products : Suspension of the marketing authorisations of medicinal products containing hydroxyprogesterone caproate","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-07-17T11:21:23Z","last_updated_date":"2024-07-17T11:21:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-hydroxyprogesterone-caproate-17-ohpc-containing-medicinal-products-suspension-marketing-authorisations-medicinal-products-containing_en.pdf"},
    {"id":"64189","name":"Direct healthcare professional communication (DHPC) : Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta (CD19- or BCMA-directed CAR T-cell therapies): Risk of secondary malignancy of T-cell origin","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-07-18T10:18:00Z","last_updated_date":"2024-07-18T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-abecma-breyanzi-carvykti-kymriah-tecartus-yescarta-cd19-or-bcma-directed-car-t-cell-therapies-risk-secondary-malignancy-t-cell-origin_en.pdf"},
    {"id":"64226","name":"Direct healthcare professional communication (DHPC): Senvelgo (velagliflozin) 15 mg/ml oral solution for cats: Known risk of diabetic ketoacidosis (DKA) in cats with diabetes mellitus associated with the use of the product","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-07-19T13:15:29Z","last_updated_date":"2024-07-19T13:15:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-senvelgo-velagliflozin-15-mg-ml-oral-solution-cats-known-risk-diabetic-ketoacidosis-dka-cats-diabetes-mellitus-associated-use-product_en.pdf"},
    {"id":"64301","name":"Direct healthcare professional communication (DHPC) : Vabysmo (faricimab): tear in primary packaging of transfer filter needle (TFN) co-packaged with vial","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-07-25T09:05:00Z","last_updated_date":"2024-07-25T09:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vabysmo-faricimab-tear-primary-packaging-transfer-filter-needle-tfn-co-packaged-vial_en.pdf"},
    {"id":"64407","name":"Direct healthcare professional communication (DHPC) : Ocaliva (obeticholic acid): recommendation for revocation of the marketing authorisation in the European Union due to unconfirmed clinical benefit","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-07-31T09:00:00Z","last_updated_date":"2024-07-31T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ocaliva-obeticholic-acid-recommendation-revocation-marketing-authorisation-european-union-due-unconfirmed-clinical-benefit_en.pdf"},
    {"id":"64565","name":"Direct healthcare professional communication (DHPC) : Glatiramer acetate: Anaphylactic reactions may occur months up to years after treatment initiation","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-08-14T10:25:42Z","last_updated_date":"2024-08-14T10:25:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-glatiramer-acetate-anaphylactic-reactions-may-occur-months-years-after-treatment-initiation_en.pdf"},
    {"id":"64587","name":"Direct healthcare professional communication (DHPC) : NovoSeven (eptacog alfa): manufacturing issue leading to supply shortage","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-08-19T10:17:50Z","last_updated_date":"2024-08-19T10:17:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-novoseven-eptacog-alfa-manufacturing-issue-leading-supply-shortage_en.pdf"},
    {"id":"64610","name":"Direct healthcare professional communication (DHPC) : Privigen (human normal immunoglobulin (IVIg)) 10% 50 mL: flakes reported in some batches of finished product ","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-08-22T09:54:44Z","last_updated_date":"2024-08-22T09:54:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-privigen-human-normal-immunoglobulin-ivig-10-50-ml-flakes-reported-some-batches-finished-product_en.pdf"},
    {"id":"64684","name":"Direct healthcare professional communication (DHPC) : Update on Ozempic (semaglutide) and Victoza (liraglutide): Supply shortage","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-09-02T17:06:43Z","last_updated_date":"2024-09-02T17:06:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-update-ozempic-semaglutide-victoza-liraglutide-supply-shortage_en.pdf"},
    {"id":"65214","name":"Direct healthcare professional communication (DHPC) : Oxbryta (voxelotor): Suspension of EU marketing authorisation","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-10-07T12:00:00Z","last_updated_date":"2024-10-07T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-oxbryta-voxelotor-suspension-eu-marketing-authorisation_en.pdf"},
    {"id":"65262","name":"Direct healthcare professional communication (DHPC) : Synflorix: packaging issue potentially impacting the sterility of needle softpacks of Synflorix","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-10-10T10:00:00Z","last_updated_date":"2024-10-10T10:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-synflorix-packaging-issue-potentially-impacting-sterility-needle-softpacks-synflorix_en.pdf"},
    {"id":"65263","name":"Direct healthcare professional communication (DHPC) : Infanrix hexa Packaging issue potentially impacting the sterility of needle softpacks of Infanrix hexa","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-10-10T11:11:11Z","last_updated_date":"2024-10-10T11:11:11Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-infanrix-hexa-packaging-issue-potentially-impacting-sterility-needle-softpacks-infanrix-hexa_en.pdf"},
    {"id":"65312","name":"Direct healthcare professional communication (DHPC) : Vabysmo (faricimab): tear in primary packaging of transfer filter needle (TFN) co-packaged with vial","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-10-17T09:00:00Z","last_updated_date":"2024-10-17T09:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vabysmo-faricimab-tear-primary-packaging-transfer-filter-needle-tfn-co-packaged-vial_en.pdf-0"},
    {"id":"65412","name":"Direct healthcare professional communication (DHPC): Medicines containing 5-fluorouracil (i.v.): In patients with moderate or severe renal impairment, DPD deficiency by measuring blood uracil levels should be interpreted with caution","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-10-24T09:30:00Z","last_updated_date":"2024-10-24T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-medicines-containing-5-fluorouracil-iv-patients-moderate-or-severe-renal-impairment-dpd-deficiency-measuring-blood-uracil-levels-should-be-interpreted_en.pdf"},
    {"id":"65568","name":"Direct healthcare professional communication (DHPC): Pegasys (peginterferon alfa-2a): supply shortage of 90/135/180 micrograms solution for injection in pre-filled syringes","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-11-08T09:18:02Z","last_updated_date":"2024-11-08T09:18:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-pegasys-peginterferon-alfa-2a-supply-shortage-90-135-180-micrograms-solution-injection-pre-filled-syringes_en.pdf"},
    {"id":"65896","name":"Direct healthcare professional communication (DHPC): Metamizole-containing medicines: important measures to minimise the serious outcomes of known risk of agranulocytosis","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-12-03T09:22:03Z","last_updated_date":"2024-12-03T09:22:03Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-metamizole-containing-medicines-important-measures-minimise-serious-outcomes-known-risk-agranulocytosis_en.pdf"},
    {"id":"65985","name":"Direct healthcare professional communication (DHPC): Ibandronic acid Accord solution for injection 3 mg/3ml in pre-filled syringe (ibandronic acid) - product packaging issues (injection needle having a shorter expiration date than the product shelf-life)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-12-05T15:30:44Z","last_updated_date":"2024-12-05T15:30:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ibandronic-acid-accord-solution-injection-3-mg-3ml-pre-filled-syringe-ibandronic-acid-product-packaging-issues-injection-needle-having-shorter_en.pdf"},
    {"id":"66024","name":"Direct healthcare professional communication (DHPC): Cyanokit (hydroxocobalamin) 5 g powder for solution for infusion: Quality defect due to potential microbial contamination of certain batches resulting in a potential risk of infection","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-12-09T15:40:05Z","last_updated_date":"2024-12-09T15:40:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-cyanokit-hydroxocobalamin-5-g-powder-solution-infusion-quality-defect-due-potential-microbial-contamination-certain-batches-resulting-potential-risk_en.pdf"},
    {"id":"66158","name":"Direct healthcare professional communication (DHPC): Medroxyprogesterone-containing medicines: Risk of meningioma and measures to minimise this risk ","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-12-16T15:46:06Z","last_updated_date":"2024-12-16T15:46:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-medroxyprogesterone-containing-medicines-risk-meningioma-measures-minimise-risk_en.pdf"},
    {"id":"66193","name":"Direct healthcare professional communication (DHPC): Levetiracetam (Keppra and Levetiracetam UCB) oral solution (150ml bottle for children aged 6 months to 4 years): risk of medication error due to change of dosing syringe","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-12-18T10:59:20Z","last_updated_date":"2024-12-18T10:59:20Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-levetiracetam-keppra-levetiracetam-ucb-oral-solution-150ml-bottle-children-aged-6-months-4-years-risk-medication-error-due-change-dosing-syringe_en.pdf"},
    {"id":"66218","name":"Direct healthcare professional communication (DHPC): Alofisel (darvadstrocel): Withdrawal from the EU market as its clinical benefit is no longer demonstrated to justify its continued use","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2024-12-19T09:46:21Z","last_updated_date":"2024-12-19T09:46:21Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-alofisel-darvadstrocel-withdrawal-eu-market-its-clinical-benefit-no-longer-demonstrated-justify-its-continued-use_en.pdf"},
    {"id":"66434","name":"Direct healthcare professional communication (DHPC): Veoza (fezolinetant): risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-01-23T14:42:14Z","last_updated_date":"2025-01-23T14:42:14Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-veoza-fezolinetant-risk-drug-induced-liver-injury-new-recommendations-monitoring-liver-function-during-treatment_en.pdf"},
    {"id":"66919","name":"Direct healthcare professional communication (DHPC): Kisqali (ribociclib): change to storage conditions and shelf-life","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-02-24T17:14:07Z","last_updated_date":"2025-02-24T17:14:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-kisqali-ribociclib-change-storage-conditions-shelf-life_en.pdf"},
    {"id":"67364","name":"Direct healthcare professional communication (DHPC) : Emblaveo (Aztreonam/Avibactam) 1.5 g/0.5 g powder for concentrate for solution for infusion: potential for cracked or broken vials","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-03-20T10:28:38Z","last_updated_date":"2025-03-20T10:28:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-emblaveo-aztreonam-avibactam-15-g-05-g-powder-concentrate-solution-infusion-potential-cracked-or-broken-vials_en.pdf"},
    {"id":"67959","name":"Direct healthcare professional communication (DHPC) : Opzelura 15 mg/g cream (ruxolitinib phosphate): Important information regarding presence of particles in Opzelura cream","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-04-24T16:04:06Z","last_updated_date":"2025-04-24T16:04:06Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-opzelura-15-mg-g-cream-ruxolitinib-phosphate-important-information-regarding-presence-particles-opzelura-cream_en.pdf"},
    {"id":"68488","name":"Direct healthcare professional communication (DHPC): Ixchiq (Chikungunya vaccine (live)): new contraindication in patients aged 65 years and older while EU-wide review is ongoing","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-05-28T12:49:19Z","last_updated_date":"2025-05-28T12:49:19Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ixchiq-chikungunya-vaccine-live-new-contraindication-patients-aged-65-years-older-while-eu-wide-review-ongoing_en.pdf"},
    {"id":"69621","name":"Direct healthcare professional communication (DHPC): Rybelsus (oral semaglutide): risk of medication error due to introduction of new formulation with increased bioavailability","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-08-01T13:07:57Z","last_updated_date":"2025-08-01T13:07:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-rybelsus-oral-semaglutide-risk-medication-error-due-introduction-new-formulation-increased-bioavailability_en.pdf"},
    {"id":"69807","name":"Direct healthcare professional communication (DHPC): Evrysdi 0.75 mg/mL powder for oral solution (risdiplam): omission of mandatory labelling statement in the EU product label and  summary of product characteristics","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-08-21T09:50:04Z","last_updated_date":"2025-08-21T09:50:04Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-evrysdi-075-mg-ml-powder-oral-solution-risdiplam-omission-mandatory-labelling-statement-eu-product-label-summary-product-characteristics_en.pdf"},
    {"id":"70010","name":"Direct healthcare professional communication (DHPC): Clozapine: revised recommendations for routine blood count monitoring for the risk of agranulocytosis ","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-09-09T09:49:34Z","last_updated_date":"2025-09-09T09:49:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-clozapine-revised-recommendations-routine-blood-count-monitoring-risk-agranulocytosis_en.pdf"},
    {"id":"70181","name":"Direct healthcare professional communication (DHPC): Rapamune (sirolimus) 1 mg/mL oral solution: restricted use of affected lots due to misalignment between expiry dates on the syringe adapter and oral solution","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-09-19T09:30:01Z","last_updated_date":"2025-09-19T09:30:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-rapamune-sirolimus-1-mg-ml-oral-solution-restricted-use-affected-lots-due-misalignment-between-expiry-dates-syringe-adapter-oral-solution_en.pdf"},
    {"id":"70235","name":"Ixchiq (Chikungunya vaccine (live-attenuated)): lifting of temporary contraindication in adults 65 years and older; warning on severe adverse reactions, including encephalitis","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-09-23T16:12:58Z","last_updated_date":"2025-09-23T16:12:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/ixchiq-chikungunya-vaccine-live-attenuated-lifting-temporary-contraindication-adults-65-years-older-warning-severe-adverse-reactions-including-encephalitis_en.pdf"},
    {"id":"70462","name":"Direct healthcare professional communication (DHPC) : Finasteride, dutasteride – New measures to minimise the risk of suicidal ideation","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-10-07T10:04:30Z","last_updated_date":"2025-10-07T10:04:30Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-finasteride-dutasteride-new-measures-minimise-risk-suicidal-ideation_en.pdf"},
    {"id":"70522","name":"Direct healthcare professional communication (DHPC): Caspofungin: Avoid use of polyacrylonitrile membranes during continuous renal replacement therapy","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-10-09T17:19:28Z","last_updated_date":"2025-10-09T17:19:28Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-caspofungin-avoid-use-polyacrylonitrile-membranes-during-continuous-renal-replacement-therapy_en.pdf"},
    {"id":"70541","name":"Direct healthcare professional communication (DHPC) : Lecanemab, Leqembi 100 mg/mL concentrate for solution for infusion – Update to magnetic resonance imaging (MRI) schedule to include an MRI scan prior to the third infusion of Leqembi","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-10-14T11:32:17Z","last_updated_date":"2025-10-14T11:32:17Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-lecanemab-leqembi-100-mg-ml-concentrate-solution-infusion-update-magnetic-resonance-imaging-mri-schedule-include-mri-scan-prior-third-infusion-leqembi_en.pdf"},
    {"id":"70687","name":" Direct healthcare professional communication (DHPC): Crysvita (burosumab): Risk of severe hypercalcaemia","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-10-20T15:56:45Z","last_updated_date":"2025-10-20T15:56:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-crysvita-burosumab-risk-severe-hypercalcaemia_en.pdf"},
    {"id":"70893","name":"Direct healthcare professional communication (DHPC) : Lenalidomide Mylan (lenalidomide): potential for damaged capsules and precautionary handling measures","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-10-29T09:15:12Z","last_updated_date":"2025-10-29T09:15:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-lenalidomide-mylan-lenalidomide-potential-damaged-capsules-precautionary-handling-measures_en.pdf"},
    {"id":"71077","name":"Direct healthcare professional communication (DHPC) : Libtayo (cemiplimab) 350 mg concentrate for solution for infusion: Batch / lot number and expiry date may become illegible following sanitisation and wiping of vial label","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-11-10T16:25:05Z","last_updated_date":"2025-11-10T16:25:05Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-libtayo-cemiplimab-350-mg-concentrate-solution-infusion-batch-lot-number-expiry-date-may-become-illegible-following-sanitisation-wiping-vial-label_en.pdf"},
    {"id":"71560","name":"Direct healthcare professional communication (DHPC) : Remsima (infliximab): New IV formulation (100 mg and 350 mg concentrate for solution for infusion) contains sorbitol and is therefore contraindicated in patients with hereditary fructose intolerance","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-12-08T09:12:39Z","last_updated_date":"2025-12-08T09:12:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-remsima-infliximab-new-iv-formulation-100-mg-350-mg-concentrate-solution-infusion-contains-sorbitol-therefore-contraindicated-patients-hereditary_en.pdf"},
    {"id":"71681","name":"Direct healthcare professional communication (DHPC): Tranexamic acid intravenous formulations – Serious including fatal adverse reactions due to inadvertent intrathecal administration","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2025-12-11T08:44:40Z","last_updated_date":"2025-12-11T08:44:40Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-tranexamic-acid-intravenous-formulations-serious-including-fatal-adverse-reactions-due-inadvertent-intrathecal-administration_en.pdf"},
    {"id":"72115","name":"Direct healthcare professional communication (DHPC) : Mysimba (naltrexone/bupropion): long-term cardiovascular risk and new recommendations on annual assessment ","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2026-01-16T15:58:53Z","last_updated_date":"2026-01-16T15:58:53Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-mysimba-naltrexone-bupropion-long-term-cardiovascular-risk-new-recommendations-annual-assessment_en.pdf"},
    {"id":"72459","name":"Direct healthcare professional communication (DHPC) : Arixtra (fondaparinux sodium): Serious quality defect related to the needle in pre-filled syringe","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2026-02-09T17:04:50Z","last_updated_date":"2026-02-09T17:04:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-arixtra-fondaparinux-sodium-serious-quality-defect-related-needle-pre-filled-syringe_en.pdf"},
    {"id":"73314","name":"Direct healthcare professional communication (DHPC) : Avtozma 20 mg/mL concentrate for solution for infusion: incorrect strength stated on peel-off vial label for specific batches","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2026-04-07T10:13:43Z","last_updated_date":"2026-04-07T10:13:43Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-avtozma-20-mg-ml-concentrate-solution-infusion-incorrect-strength-stated-peel-vial-label-specific-batches_en.pdf"},
    {"id":"73474","name":"Direct healthcare professional communication (DHPC) : Levamisole-containing medicines will no longer be available on the EU market due to risk of leukoencephalopathy ","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2026-04-16T14:10:41Z","last_updated_date":"2026-04-16T14:10:41Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-levamisole-containing-medicines-will-no-longer-be-available-eu-market-due-risk-leukoencephalopathy_en.pdf"},
    {"id":"73545","name":"Direct healthcare professional communication (DHPC) : Savene (dexrazoxane) 20 mg/ml powder and solvent for concentrate for solution for infusion: potential contamination risk affecting a limited number of batches","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2026-04-23T15:11:26Z","last_updated_date":"2026-04-23T15:11:26Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-savene-dexrazoxane-20-mg-ml-powder-solvent-concentrate-solution-infusion-potential-contamination-risk-affecting-limited-number-batches_en.pdf"},
    {"id":"73735","name":"Direct healthcare professional communication (DHPC) : Ontozry (cenobamate):  new requirements for liver monitoring due to reports of severe liver injury","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2026-05-13T16:20:49Z","last_updated_date":"2026-05-13T16:20:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-ontozry-cenobamate-new-requirements-liver-monitoring-due-reports-severe-liver-injury_en.pdf"},
    {"id":"73736","name":"Direct healthcare professional communication (DHPC) : Tecovirimat SIGA (tecovirimat monohydrate): restriction of indication due to lack of efficacy shown in randomised clinical trials in patients with mpox","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2026-05-13T16:28:49Z","last_updated_date":"2026-05-13T16:28:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-tecovirimat-siga-tecovirimat-monohydrate-restriction-indication-due-lack-efficacy-shown-randomised-clinical-trials-patients-mpox_en.pdf"},
    {"id":"74174","name":"Direct healthcare professional communication (DHPC) : Evrysdi (risdiplam) 0.75 mg/mL powder for oral solution (PfOS)","type":"dhpc","status":"unknown","consultation_date":"","first_published_date":"2026-06-22T11:59:12Z","last_updated_date":"2026-06-22T11:59:12Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-evrysdi-risdiplam-075-mg-ml-powder-oral-solution-pfos_en.pdf"},
    {"id":"49475","name":"Mosquirix: Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2015-10-01T11:50:00Z","last_updated_date":"2025-09-15T12:26:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/mosquirix-product-information_en.pdf"},
    {"id":"51731","name":"Aluvia : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2010-01-29T16:35:00Z","last_updated_date":"2025-12-02T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/aluvia-product-information_en.pdf"},
    {"id":"51750","name":"Fexinidazole Winthrop : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T17:17:00Z","last_updated_date":"2025-10-17T12:11:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/fexinidazole-winthrop-product-information_en.pdf"},
    {"id":"51758","name":"Pyramax : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2012-06-29T17:53:00Z","last_updated_date":"2025-08-06T11:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/pyramax-product-information_en.pdf"},
    {"id":"51764","name":"Umbipro : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2016-07-01T17:53:00Z","last_updated_date":"2022-04-08T11:53:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/umbipro-product-information_en.pdf"},
    {"id":"51778","name":"Dapivirine Vaginal Ring 25 mg : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2021-01-04T11:47:00Z","last_updated_date":"2025-08-21T10:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/dapivirine-vaginal-ring-25-mg-product-information_en.pdf"},
    {"id":"51794","name":"Lamivudine ViiV : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2009-12-02T16:34:00Z","last_updated_date":"2015-12-21T16:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/lamivudine-viiv-product-information_en.pdf"},
    {"id":"51801","name":"Hemoprostol : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2014-04-10T16:51:00Z","last_updated_date":"2017-04-26T11:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/hemoprostol-product-information_en.pdf"},
    {"id":"51812","name":"Lamivudine/Zidovudine ViiV : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2009-04-28T17:37:00Z","last_updated_date":"2015-12-21T17:39:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/lamivudinezidovudine-viiv-product-information_en.pdf"},
    {"id":"51819","name":"Tritanrix HB : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2014-03-14T18:00:00Z","last_updated_date":"2014-03-14T18:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/tritanrix-hb-product-information_en.pdf"},
    {"id":"51829","name":"Hexaxim : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2012-12-04T14:21:00Z","last_updated_date":"2020-11-19T11:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/hexaxim-product-information_en.pdf"},
    {"id":"55634","name":"Actrapid : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T17:01:00Z","last_updated_date":"2022-07-22T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/actrapid-product-information_en.pdf"}    {"id":"55717","name":"Insulatard : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2022-07-28T10:42:00Z","last_updated_date":"2022-07-28T10:42:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/insulatard-product-information_en.pdf"},
    {"id":"57003","name":"Dengue Tetravalent Vaccine (Live, Attenuated) Takeda : Product Information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T12:52:00Z","last_updated_date":"2026-05-08T13:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/dengue-tetravalent-vaccine-live-attenuated-takeda-product-information_en.pdf"},
    {"id":"62049","name":"Arpraziquantel : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2024-02-08T13:34:02Z","last_updated_date":"2024-02-08T13:34:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/arpraziquantel-product-information_en.pdf"},
    {"id":"67337","name":"Ivermectin/Albendazole : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2025-03-18T16:06:10Z","last_updated_date":"2025-03-18T16:06:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/ivermectin-albendazole-product-information_en.pdf"},
    {"id":"69982","name":"Lenacapavir Gilead : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T16:20:56Z","last_updated_date":"2026-02-20T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/lenacapavir-gilead-product-information_en.pdf"},
    {"id":"73463","name":"Acoziborole Winthrop : Product information","type":"outside-EU-product-information","status":"unknown","consultation_date":"","first_published_date":"2026-04-15T15:47:15Z","last_updated_date":"2026-04-15T15:47:15Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-product-information/acoziborole-winthrop-product-information_en.pdf"},
    {"id":"49473","name":"CHMP summary of positive opinion for Mosquirix","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2015-07-24T11:50:00Z","last_updated_date":"2015-07-24T11:50:00Z","reference_number":"EMA/CHMP/464758/2015","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-mosquirix_en.pdf"},
    {"id":"51749","name":"CHMP summary of opinion for Fexinidazole Winthrop","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2018-11-16T17:14:00Z","last_updated_date":"2018-11-16T17:14:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-opinion-fexinidazole-winthrop_en.pdf"},
    {"id":"51757","name":"CHMP summary of opinion for Pyramax","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-02-17T17:51:00Z","last_updated_date":"2012-02-17T17:51:00Z","reference_number":"EMA/CHMP/95965/2012","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-opinion-pyramax_en.pdf"},
    {"id":"51763","name":"CHMP summary of positive opinion for Umbipro","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2016-04-29T17:51:00Z","last_updated_date":"2022-04-08T09:10:00Z","reference_number":"EMA/CHMP/244784/2016","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-umbipro_en.pdf"},
    {"id":"51800","name":"CHMP summary of positive opinion for Hemoprostol","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2014-01-24T16:49:00Z","last_updated_date":"2017-04-26T11:51:00Z","reference_number":"EMA/CHMP/750274/2013","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-hemoprostol_en.pdf"},
    {"id":"51818","name":"CHMP summary of positive opinion for Tritanrix HB","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2013-12-20T17:59:00Z","last_updated_date":"2013-12-20T17:59:00Z","reference_number":"EMA/CHMP/749396/2013","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-tritanrix-hb_en.pdf"},
    {"id":"51831","name":"CHMP summary of positive opinion for Hexaxim","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2012-06-22T10:23:00Z","last_updated_date":"2012-06-22T10:23:00Z","reference_number":"EMA/CHMP/409930/2012","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-hexaxim_en.pdf"},
    {"id":"54789","name":"CHMP summary of positive opinion for Actrapid","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2022-04-22T11:50:00Z","last_updated_date":"2022-04-22T11:50:00Z","reference_number":"EMA/CHMP/223178/2022","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-actrapid_en.pdf"},
    {"id":"61531","name":"CHMP summary of positive opinion for Arpraziquantel","type":"outside-EU-smop-initial","status":"unknown","consultation_date":"","first_published_date":"2023-12-19T17:12:33Z","last_updated_date":"2023-12-19T17:12:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-arpraziquantel_en.pdf"},
    {"id":"66528","name":"CHMP summary of positive opinion for Ivermectin/Albendazole","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-01-31T12:00:00Z","last_updated_date":"2025-01-31T12:00:00Z","reference_number":"EMA/CHMP/28710/2025","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-ivermectin-albendazole_en.pdf"},
    {"id":"69493","name":"CHMP summary of positive opinion for Lenacapavir Gilead","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2025-07-25T11:44:25Z","last_updated_date":"2025-07-25T11:44:25Z","reference_number":"EMA/CHMP/243443/2025","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-lenacapavir-gilead_en.pdf"},
    {"id":"72721","name":"CHMP summary of positive opinion for Acoziborole Winthrop","type":"outside-EU-smop-initial","status":"Adopted","consultation_date":"","first_published_date":"2026-02-27T14:23:19Z","last_updated_date":"2026-02-27T14:23:19Z","reference_number":"EMA/48340/2026","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop-initial/chmp-summary-positive-opinion-acoziborole-winthrop_en.pdf"},
    {"id":"51752","name":"CHMP post-authorisation summary of positive opinion for Pyramax","type":"outside-EU-smop","status":"Adopted","consultation_date":"","first_published_date":"2015-11-20T17:33:00Z","last_updated_date":"2015-11-20T17:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop/chmp-post-authorisation-summary-positive-opinion-pyramax_en.pdf"},
    {"id":"56418","name":"CHMP summary of positive opinion for Dengue Tetravalent Vaccine (Live, Attenuated) Takeda","type":"outside-EU-smop","status":"Adopted","consultation_date":"","first_published_date":"2022-10-14T12:17:00Z","last_updated_date":"2022-10-14T12:17:00Z","reference_number":"EMA/CHMP/781055/2022","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop/chmp-summary-positive-opinion-dengue-tetravalent-vaccine-live-attenuated-takeda_en.pdf"},
    {"id":"61439","name":"CHMP post-authorisation summary of positive opinion for Fexinidazole Winthrop  (II-16)","type":"outside-EU-smop","status":"Adopted","consultation_date":"","first_published_date":"2023-12-15T13:24:16Z","last_updated_date":"2023-12-15T13:24:16Z","reference_number":"EMA/CHMP/559550/2023","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop/chmp-post-authorisation-summary-positive-opinion-fexinidazole-winthrop-ii-16_en.pdf"},
    {"id":"67640","name":"CHMP post-authorisation summary of positive opinion for Mosquirix (II-86)","type":"outside-EU-smop","status":"Adopted","consultation_date":"","first_published_date":"2025-04-04T14:29:58Z","last_updated_date":"2025-04-04T14:29:58Z","reference_number":"EMA/CHMP/109053/2025","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop/chmp-post-authorisation-summary-positive-opinion-mosquirix-ii-86_en.pdf"},
    {"id":"68858","name":"CHMP post-authorisation summary of positive opinion for Dapivirine Vaginal Ring 25 mg (II-27)","type":"outside-EU-smop","status":"unknown","consultation_date":"","first_published_date":"2025-06-20T10:10:50Z","last_updated_date":"2025-06-20T10:10:50Z","reference_number":"EMA/CHMP/199904/2025","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-smop/chmp-post-authorisation-summary-positive-opinion-dapivirine-vaginal-ring-25-mg-ii-27_en.pdf"},
    {"id":"51755","name":"Pyramax-H-W-2319-II-0002 : Assessment report","type":"outside-EU-assessment-variation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-05T17:49:00Z","last_updated_date":"2016-06-05T17:49:00Z","reference_number":"EMA/15394/2016","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/pyramax-h-w-2319-ii-0002-assessment-report_en.pdf"},
    {"id":"51756","name":"Pyramax-H-W-2319-X-0008-G : Assessment report - Extension","type":"outside-EU-assessment-variation","status":"Adopted","consultation_date":"","first_published_date":"2016-02-05T17:50:00Z","last_updated_date":"2016-02-05T17:50:00Z","reference_number":"EMA/813257/2015","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/pyramax-h-w-2319-x-0008-g-assessment-report-extension_en.pdf"},
    {"id":"51832","name":"Hexaxim-H-W-2495-P46-004 : Assessment Report","type":"outside-EU-assessment-variation","status":"Adopted","consultation_date":"","first_published_date":"2016-06-03T13:50:00Z","last_updated_date":"2016-06-03T13:50:00Z","reference_number":"EMA/389260/2016","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/hexaxim-h-w-2495-p46-004-assessment-report_en.pdf"},
    {"id":"51833","name":"Hexaxim-H-W-2495-P46-006 : Assessment Report","type":"outside-EU-assessment-variation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-25T02:00:00Z","last_updated_date":"2016-04-25T02:00:00Z","reference_number":"EMA/245070/2016","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/hexaxim-h-w-2495-p46-006-assessment-report_en.pdf"},
    {"id":"51834","name":"Hexaxim-H-W-2495-P46-015 : Assessment Report","type":"outside-EU-assessment-variation","status":"Adopted","consultation_date":"","first_published_date":"2016-04-11T02:00:00Z","last_updated_date":"2016-04-11T02:00:00Z","reference_number":"EMA/245070/2016","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/hexaxim-h-w-2495-p46-015-assessment-report_en.pdf"},
    {"id":"51835","name":"Hexaxim-H-W-2495-P46-021 : Assessment Report","type":"outside-EU-assessment-variation","status":"Adopted","consultation_date":"","first_published_date":"2017-05-04T11:49:00Z","last_updated_date":"2017-05-04T11:49:00Z","reference_number":"EMA/237990/2017","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/hexaxim-h-w-2495-p46-021-assessment-report_en.pdf"},
    {"id":"51836","name":"Hexaxim-H-W-2495-P46-035 : Assessment Report","type":"outside-EU-assessment-variation","status":"Adopted","consultation_date":"","first_published_date":"2020-02-21T10:30:00Z","last_updated_date":"2020-02-21T10:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/hexaxim-h-w-2495-p46-035-assessment-report_en.pdf"},
    {"id":"51837","name":"Hexaxim-H-W-2495-WS-0702 : Assessment report - Variation","type":"outside-EU-assessment-variation","status":"Adopted","consultation_date":"","first_published_date":"2015-09-18T02:00:00Z","last_updated_date":"2015-09-18T02:00:00Z","reference_number":"EMA/CHMP/329785/2015","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/hexaxim-h-w-2495-ws-0702-assessment-report-variation_en.pdf"},
    {"id":"62311","name":"Fexinidazole Winthrop-H-W-2320-II-0016 : Assessment report - Variation","type":"outside-EU-assessment-variation","status":"Adopted","consultation_date":"","first_published_date":"2024-02-27T12:51:57Z","last_updated_date":"2024-02-27T12:51:57Z","reference_number":"EMA/582593/2023","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/fexinidazole-winthrop-h-w-2320-ii-0016-assessment-report-variation_en.pdf"},
    {"id":"69818","name":"Dapivirine Vaginal Ring 25 mg-H-W-00216-II-0027  : Assessment report - Extension","type":"outside-EU-assessment-variation","status":"unknown","consultation_date":"","first_published_date":"2025-08-21T14:00:11Z","last_updated_date":"2025-08-21T14:00:11Z","reference_number":"EMA/597357/2024","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-variation/dapivirine-vaginal-ring-25-mg-h-w-00216-ii-0027-assessment-report-extension_en.pdf"},
    {"id":"51781","name":"Withdrawal assessment report for Globorix","type":"outside-EU-assessment-withdrawal","status":"Adopted","consultation_date":"","first_published_date":"2007-12-18T12:07:00Z","last_updated_date":"2007-12-18T12:07:00Z","reference_number":"EMEA/CHMP/300656/2007","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-withdrawal/withdrawal-assessment-report-globorix_en.pdf"},
    {"id":"49471","name":"Mosquirix: Risk management plan","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2015-10-01T11:50:00Z","last_updated_date":"2026-03-18T11:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/mosquirix-risk-management-plan_en.pdf"},
    {"id":"51748","name":"Fexinidazole Winthrop : Risk management plan","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T17:13:00Z","last_updated_date":"2024-02-27T12:49:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/fexinidazole-winthrop-risk-management-plan_en.pdf"},
    {"id":"51767","name":"Dapivirine Vaginal Ring 25 mg : Risk-management-plan summary","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2021-01-04T17:45:00Z","last_updated_date":"2022-09-15T15:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/dapivirine-vaginal-ring-25-mg-risk-management-plan-summary_en.pdf"},
    {"id":"51797","name":"Hemoprostol : Risk-management-plan summary","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2014-04-10T16:41:00Z","last_updated_date":"2017-04-26T11:42:00Z","reference_number":"EMA/60511/2014","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/hemoprostol-risk-management-plan-summary_en.pdf"},
    {"id":"51817","name":"Tritanrix HB : Risk-management-plan summary","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2014-03-14T17:57:00Z","last_updated_date":"2014-03-14T17:57:00Z","reference_number":"EMA/14365/2014","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/tritanrix-hb-risk-management-plan-summary_en.pdf"},
    {"id":"55636","name":"Actrapid : Risk-management-plan summary","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T17:01:00Z","last_updated_date":"2022-07-22T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/actrapid-risk-management-plan-summary_en.pdf"},
    {"id":"55719","name":"Insulatard : Risk-management-plan summary","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2022-07-28T10:52:00Z","last_updated_date":"2022-07-28T10:52:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/insulatard-risk-management-plan-summary_en.pdf"},
    {"id":"57005","name":"Dengue Tetravalent Vaccine (Live, Attenuated) Takeda : Risk Management Plan","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T12:56:00Z","last_updated_date":"2024-12-10T16:11:51Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/dengue-tetravalent-vaccine-live-attenuated-takeda-risk-management-plan_en.pdf"},
    {"id":"60672","name":"Pyramax : EPAR - Risk management plan summary","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2022-05-10T14:51:00Z","last_updated_date":"2022-05-10T14:51:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/pyramax-epar-risk-management-plan-summary_en.pdf"},
    {"id":"62051","name":"Arpraziquantel : Risk management plan","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2024-02-08T13:38:47Z","last_updated_date":"2024-02-08T13:38:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/arpraziquantel-risk-management-plan_en.pdf"},
    {"id":"63069","name":"Teriflunomide Accord : EPAR - Risk management plan","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2024-04-25T14:00:00Z","last_updated_date":"2024-04-25T14:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/teriflunomide-accord-epar-risk-management-plan_en.pdf"},
    {"id":"67336","name":"Ivermectin/Albendazole : Risk management plan","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2025-03-18T16:04:45Z","last_updated_date":"2025-03-18T16:04:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/ivermectin-albendazole-risk-management-plan_en.pdf"},
    {"id":"69593","name":"Pyramax : Risk management plan","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2022-05-10T10:28:35Z","last_updated_date":"2025-08-06T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/pyramax-risk-management-plan_en.pdf"},
    {"id":"69816","name":"Dapivirine Vaginal Ring 25 mg : Risk management plan","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2025-08-21T13:55:50Z","last_updated_date":"2025-08-21T13:55:50Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/dapivirine-vaginal-ring-25-mg-risk-management-plan_en.pdf"},
    {"id":"69981","name":"Lenacapavir Gilead : Risk management plan","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T16:19:09Z","last_updated_date":"2025-09-05T16:19:09Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/lenacapavir-gilead-risk-management-plan_en.pdf"},
    {"id":"73462","name":"Acoziborole Winthrop : Risk management plan","type":"outside-EU-rmp-summary","status":"unknown","consultation_date":"","first_published_date":"2026-04-15T15:45:45Z","last_updated_date":"2026-04-15T15:45:45Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-rmp-summary/acoziborole-winthrop-risk-management-plan_en.pdf"},
    {"id":"49472","name":"Mosquirix: All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2015-10-01T11:50:00Z","last_updated_date":"2015-10-01T11:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/mosquirix-all-presentations_en.pdf"},
    {"id":"51727","name":"Aluvia : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2010-01-29T15:37:00Z","last_updated_date":"2010-01-29T15:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/aluvia-all-presentations_en.pdf"},
    {"id":"51738","name":"Fexinidazole Winthrop : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T11:18:00Z","last_updated_date":"2019-01-22T11:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/fexinidazole-winthrop-all-presentations_en.pdf"},
    {"id":"51753","name":"Pyramax : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2012-06-29T17:45:00Z","last_updated_date":"2016-02-05T11:46:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/pyramax-all-presentations_en.pdf"},
    {"id":"51761","name":"Umbipro : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2016-07-01T17:45:00Z","last_updated_date":"2022-04-08T09:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/umbipro-all-presentations_en.pdf"},
    {"id":"51766","name":"Dapivirine Vaginal Ring 25 mg : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2021-01-04T17:45:00Z","last_updated_date":"2021-01-04T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/dapivirine-vaginal-ring-25-mg-all-presentations_en.pdf"},
    {"id":"51790","name":"Lamivudine ViiV : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2009-12-02T16:29:00Z","last_updated_date":"2015-12-21T16:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/lamivudine-viiv-all-presentations_en.pdf"},
    {"id":"51798","name":"Hemoprostol : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2014-04-10T16:43:00Z","last_updated_date":"2017-04-26T11:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/hemoprostol-all-presentations_en.pdf"},
    {"id":"51807","name":"Lamivudine/Zidovudine ViiV : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2009-04-28T17:27:00Z","last_updated_date":"2015-12-21T17:28:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/lamivudinezidovudine-viiv-all-presentations_en.pdf"},
    {"id":"51815","name":"Tritanrix HB : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2014-03-14T17:54:00Z","last_updated_date":"2014-03-14T17:54:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/tritanrix-hb-all-presentations_en.pdf"},
    {"id":"51827","name":"Hexaxim : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2012-12-04T10:18:00Z","last_updated_date":"2012-12-04T10:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/hexaxim-all-presentations_en.pdf"},
    {"id":"55635","name":"Actrapid : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T17:01:00Z","last_updated_date":"2022-07-22T17:01:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/actrapid-all-presentations_en.pdf"},
    {"id":"55716","name":"Insulatard : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2022-07-28T10:38:00Z","last_updated_date":"2022-07-28T10:38:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/insulatard-all-presentations_en.pdf"},
    {"id":"62050","name":"Arpraziquantel - All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2024-02-08T13:36:33Z","last_updated_date":"2024-02-08T13:36:33Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/arpraziquantel-all-presentations_en.pdf"},
    {"id":"67338","name":"Ivermectin/Albendazole : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2025-03-18T16:08:49Z","last_updated_date":"2025-03-18T16:08:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/ivermectin-albendazole-all-presentations_en.pdf"},
    {"id":"69983","name":"Lenacapavir Gilead : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T16:24:01Z","last_updated_date":"2026-02-20T14:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/lenacapavir-gilead-all-presentations_en.pdf"},
    {"id":"73464","name":"Acoziborole Winthrop : All presentations","type":"outside-EU-all-presentations","status":"unknown","consultation_date":"","first_published_date":"2026-04-15T15:48:16Z","last_updated_date":"2026-04-15T15:48:16Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-all-presentations/acoziborole-winthrop-all-presentations_en.pdf"},
    {"id":"51728","name":"Aluvia : Scientific discussion","type":"outside-EU-scientific-discussion","status":"unknown","consultation_date":"","first_published_date":"2010-01-29T15:48:00Z","last_updated_date":"2010-01-29T15:48:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-scientific-discussion/aluvia-scientific-discussion_en.pdf"},
    {"id":"51791","name":"Lamivudine ViiV : Scientific discussion","type":"outside-EU-scientific-discussion","status":"unknown","consultation_date":"","first_published_date":"2009-12-02T16:30:00Z","last_updated_date":"2015-12-21T16:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-scientific-discussion/lamivudine-viiv-scientific-discussion_en.pdf"},
    {"id":"51808","name":"Lamivudine/Zidovudine ViiV : Scientific discussion","type":"outside-EU-scientific-discussion","status":"unknown","consultation_date":"","first_published_date":"2009-04-28T17:28:00Z","last_updated_date":"2015-12-21T17:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-scientific-discussion/lamivudinezidovudine-viiv-scientific-discussion_en.pdf"},
    {"id":"51811","name":"Lamivudine/Zidovudine ViiV : Lamivudine / Zidovudine GSK-H-W-672-II-0011 - Scientific discussion","type":"outside-EU-scientific-discussion","status":"unknown","consultation_date":"","first_published_date":"2009-04-28T17:36:00Z","last_updated_date":"2015-12-21T17:37:00Z","reference_number":"EMEA/H/C/0672/II/0011","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-scientific-discussion/lamivudinezidovudine-viiv-lamivudine-zidovudine-gsk-h-w-672-ii-0011-scientific-discussion_en.pdf"},
    {"id":"73671","name":"Dengue Tetravalent Vaccine (Live, Attenuated) Takeda - PSUR-0000308360 : Scientific conclusions and grounds for the variation to the terms of the marketing authorisation","type":"outside-EU-scientific-discussion","status":"unknown","consultation_date":"","first_published_date":"2026-05-08T15:17:00Z","last_updated_date":"2026-05-08T15:17:00Z","reference_number":"EMADOC-1700519818-3141937","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-scientific-discussion/dengue-tetravalent-vaccine-live-attenuated-takeda-psur-0000308360-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf"},
    {"id":"51729","name":"Aluvia : Procedural steps taken before scientific opinion","type":"outside-EU-steps-before","status":"unknown","consultation_date":"","first_published_date":"2010-01-29T15:50:00Z","last_updated_date":"2010-01-29T15:50:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps/aluvia-procedural-steps-taken-scientific-opinion_en.pdf"},
    {"id":"51792","name":"Lamivudine ViiV : Procedural steps taken before scientific opinion","type":"outside-EU-steps-before","status":"unknown","consultation_date":"","first_published_date":"2009-12-02T16:32:00Z","last_updated_date":"2015-12-21T16:33:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps/lamivudine-viiv-procedural-steps-taken-scientific-opinion_en.pdf"},
    {"id":"51809","name":"Lamivudine/Zidovudine ViiV : Procedural steps taken before opinion","type":"outside-EU-steps-before","status":"unknown","consultation_date":"","first_published_date":"2009-04-28T17:30:00Z","last_updated_date":"2015-12-21T17:31:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps/lamivudinezidovudine-viiv-procedural-steps-taken-opinion_en.pdf"},
    {"id":"49470","name":"Mosquirix: Procedural steps taken and scientific information after authorisation (archive)","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2018-02-12T11:50:00Z","last_updated_date":"2026-03-18T12:43:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/mosquirix-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf"},
    {"id":"51730","name":"Aluvia : Procedural steps taken and scientific information after opinion (archive)","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2010-01-29T16:34:00Z","last_updated_date":"2025-04-11T11:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/aluvia-procedural-steps-taken-scientific-information-after-opinion-archive_en.pdf"},
    {"id":"51754","name":"Pyramax : Procedural steps taken and scientific information after opinion","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2014-06-18T17:46:00Z","last_updated_date":"2025-08-06T11:55:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/pyramax-procedural-steps-taken-scientific-information-after-opinion_en.pdf"},
    {"id":"51760","name":"Umbipro : Procedural steps taken and scientific information after opinion","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2020-07-31T17:46:00Z","last_updated_date":"2022-04-08T09:05:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/umbipro-procedural-steps-taken-and-scientific-information-after-opinion_en.pdf"},
    {"id":"51769","name":"Dapivirine Vaginal Ring 25 mg : Procedural steps taken and scientific information after opinion","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2021-03-02T17:45:00Z","last_updated_date":"2021-03-02T17:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/dapivirine-vaginal-ring-25-mg-procedural-steps-taken-and-scientific-information-after-opinion_en.pdf"},
    {"id":"51779","name":"Dapivirine Vaginal Ring 25 mg : Procedural steps taken and scientific information after authorisation","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2021-03-02T11:48:00Z","last_updated_date":"2025-08-21T10:45:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/dapivirine-vaginal-ring-25-mg-procedural-steps-taken-scientific-information-after-authorisation_en.pdf"},
    {"id":"51793","name":"Lamivudine ViiV : Procedural steps taken and scientific information after opinion","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2009-12-02T16:33:00Z","last_updated_date":"2015-12-21T16:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/lamivudine-viiv-procedural-steps-taken-and-scientific-information-after-opinion_en.pdf"},
    {"id":"51796","name":"Hemoprostol : Procedural steps taken and scientific information after opinion","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2015-07-21T16:40:00Z","last_updated_date":"2017-04-26T09:41:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/hemoprostol-procedural-steps-taken-and-scientific-information-after-opinion_en.pdf"},
    {"id":"51810","name":"Lamivudine/Zidovudine ViiV : Procedural steps taken and scientific information after opinion","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2009-04-28T17:34:00Z","last_updated_date":"2015-12-21T17:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/lamivudinezidovudine-viiv-procedural-steps-taken-and-scientific-information-after-opinion_en.pdf"},
    {"id":"51830","name":"Hexaxim : Procedural steps taken and scientific information after opinion","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2013-01-18T10:22:00Z","last_updated_date":"2020-11-19T11:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/hexaxim-procedural-steps-taken-and-scientific-information-after-opinion_en.pdf"},
    {"id":"54478","name":"Fexinidazole Winthrop : Procedural steps taken and scientific information after opinion (archive)","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2022-03-16T10:48:00Z","last_updated_date":"2025-10-17T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/fexinidazole-winthrop-procedural-steps-taken-scientific-information-after-opinion-archive_en.pdf"},
    {"id":"65528","name":"Dengue Tetravalent Vaccine (Live, Attenuated) Takeda : Procedural steps taken and scientific information after authorisation (archive)","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2024-11-04T10:53:10Z","last_updated_date":"2025-12-01T11:11:01Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/dengue-tetravalent-vaccine-live-attenuated-takeda-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf"},
    {"id":"67754","name":"Aluvia : Procedural steps taken and scientific information after opinion","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2025-04-11T13:26:00Z","last_updated_date":"2025-12-02T15:56:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/aluvia-procedural-steps-taken-scientific-information-after-opinion_en.pdf"},
    {"id":"70629","name":"Fexinidazole Winthrop : Procedural steps taken and scientific information after opinion","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2025-10-17T11:31:44Z","last_updated_date":"2025-10-17T11:31:44Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/fexinidazole-winthrop-procedural-steps-taken-scientific-information-after-opinion_en.pdf"},
    {"id":"71438","name":"Dengue Tetravalent Vaccine (Live, Attenuated) Takeda : Procedural steps taken and scientific information after authorisation","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2025-12-01T14:19:30Z","last_updated_date":"2026-05-08T15:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/dengue-tetravalent-vaccine-live-attenuated-takeda-procedural-steps-taken-scientific-information-after-authorisation_en.pdf"},
    {"id":"72624","name":"Lenacapavir Gilead : Procedural steps taken and scientific information after opinion","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2026-02-20T14:39:29Z","last_updated_date":"2026-02-20T14:39:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/lenacapavir-gilead-procedural-steps-taken-scientific-information-after-opinion_en.pdf"},
    {"id":"73098","name":"Mosquirix: Procedural steps taken and scientific information after authorisation","type":"outside-EU-steps-after","status":"unknown","consultation_date":"","first_published_date":"2026-03-18T11:01:23Z","last_updated_date":"2026-03-18T11:01:23Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-steps-after/mosquirix-procedural-steps-taken-scientific-information-after-authorisation_en.pdf"},
    {"id":"51780","name":"Questions and answers on the withdrawal of the application for a scientific opinion for Globorix","type":"outside-EU-qanda","status":"unknown","consultation_date":"","first_published_date":"2007-10-24T12:04:00Z","last_updated_date":"2007-10-24T12:04:00Z","reference_number":"EMEA/475076/2007","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-qanda/questions-and-answers-withdrawal-application-scientific-opinion-globorix_en.pdf"},
    {"id":"49469","name":"Mosquirix : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2015-10-01T11:50:00Z","last_updated_date":"2025-05-16T12:00:00Z","reference_number":"EMA/518713/2015","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/mosquirix-medicine-overview_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/outside-eu-summary/mosquirix-medicine-overview_bg.pdf","es":"https://www.ema.europa.eu/es/documents/outside-eu-summary/mosquirix-medicine-overview_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/outside-eu-summary/mosquirix-medicine-overview_cs.pdf","da":"https://www.ema.europa.eu/da/documents/outside-eu-summary/mosquirix-medicine-overview_da.pdf","de":"https://www.ema.europa.eu/de/documents/outside-eu-summary/mosquirix-medicine-overview_de.pdf","et":"https://www.ema.europa.eu/et/documents/outside-eu-summary/mosquirix-medicine-overview_et.pdf","el":"https://www.ema.europa.eu/el/documents/outside-eu-summary/mosquirix-medicine-overview_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/outside-eu-summary/mosquirix-medicine-overview_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/outside-eu-summary/mosquirix-medicine-overview_hr.pdf","it":"https://www.ema.europa.eu/it/documents/outside-eu-summary/mosquirix-medicine-overview_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/outside-eu-summary/mosquirix-medicine-overview_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/outside-eu-summary/mosquirix-medicine-overview_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/outside-eu-summary/mosquirix-medicine-overview_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/outside-eu-summary/mosquirix-medicine-overview_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/outside-eu-summary/mosquirix-medicine-overview_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/outside-eu-summary/mosquirix-medicine-overview_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/outside-eu-summary/mosquirix-medicine-overview_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/outside-eu-summary/mosquirix-medicine-overview_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/outside-eu-summary/mosquirix-medicine-overview_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/outside-eu-summary/mosquirix-medicine-overview_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/outside-eu-summary/mosquirix-medicine-overview_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/outside-eu-summary/mosquirix-medicine-overview_sv.pdf"}},
    {"id":"51726","name":"Aluvia : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2020-01-29T15:35:00Z","last_updated_date":"2020-01-29T15:35:00Z","reference_number":"EMA/163129/2010","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/aluvia-medicine-overview_en.pdf"},
    {"id":"51737","name":"Fexinidazole Winthrop : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2019-01-22T11:16:00Z","last_updated_date":"2024-02-27T12:45:00Z","reference_number":"EMA/10655/2024","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/fexinidazole-winthrop-medicine-overview_en.pdf"},
    {"id":"51751","name":"Pyramax : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2012-06-29T17:31:00Z","last_updated_date":"2016-02-05T11:33:00Z","reference_number":"EMA/3102/2016","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/pyramax-medicine-overview_en.pdf"},
    {"id":"51759","name":"Umbipro : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2016-07-01T17:34:00Z","last_updated_date":"2022-04-08T09:04:00Z","reference_number":"EMA/311601/2016","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/umbipro-medicine-overview_en.pdf"},
    {"id":"51765","name":"Dapivirine Vaginal Ring 25 mg : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2020-07-24T17:34:00Z","last_updated_date":"2025-08-21T15:26:00Z","reference_number":"EMA/226804/2025","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_bg.pdf","es":"https://www.ema.europa.eu/es/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_cs.pdf","da":"https://www.ema.europa.eu/da/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_da.pdf","de":"https://www.ema.europa.eu/de/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_de.pdf","et":"https://www.ema.europa.eu/et/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_et.pdf","el":"https://www.ema.europa.eu/el/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_hr.pdf","it":"https://www.ema.europa.eu/it/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/outside-eu-summary/dapivirine-vaginal-ring-25-mg-medicine-overview_sv.pdf"}},
    {"id":"51788","name":"Lamivudine ViiV : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2009-12-02T16:23:00Z","last_updated_date":"2009-12-02T16:23:00Z","reference_number":"EMA/629364/2010","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/lamivudine-viiv-medicine-overview_en.pdf"}    {"id":"51795","name":"Hemoprostol : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2014-04-10T16:37:00Z","last_updated_date":"2017-04-26T11:38:00Z","reference_number":"EMA/51137/2014 ","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/hemoprostol-medicine-overview_en.pdf"},
    {"id":"51805","name":"Lamivudine/Zidovudine ViiV : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2009-04-28T17:24:00Z","last_updated_date":"2015-12-21T17:26:00Z","reference_number":"EMA/629356/2010","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/lamivudinezidovudine-viiv-medicine-overview_en.pdf"},
    {"id":"51814","name":"Tritanrix HB : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2014-03-14T17:52:00Z","last_updated_date":"2014-03-14T17:52:00Z","reference_number":"EMA/809058/2013","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/tritanrix-hb-medicine-overview_en.pdf"},
    {"id":"51826","name":"Hexaxim : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2012-12-04T10:16:00Z","last_updated_date":"2016-06-14T11:17:00Z","reference_number":"EMA/410207/2016","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/hexaxim-medicine-overview_en.pdf"},
    {"id":"55639","name":"Actrapid : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2022-07-22T17:19:00Z","last_updated_date":"2022-07-22T17:19:00Z","reference_number":"EMA/351860/2022","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/actrapid-medicine-overview_en.pdf"},
    {"id":"55715","name":"Insulatard : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2022-07-28T10:28:00Z","last_updated_date":"2022-07-28T10:28:00Z","reference_number":"EMA/351858/2022","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/insulatard-medicine-overview_en.pdf"},
    {"id":"57002","name":"Dengue Tetravalent Vaccine (Live, Attenuated) Takeda : Medicine Overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2022-12-14T12:50:00Z","last_updated_date":"2022-12-14T12:50:00Z","reference_number":"EMA/844704/2022","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/dengue-tetravalent-vaccine-live-attenuated-takeda-medicine-overview_en.pdf"},
    {"id":"62048","name":"Arpraziquantel : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2024-02-08T13:29:08Z","last_updated_date":"2024-02-08T13:29:08Z","reference_number":"EMA/10180/2024","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/arpraziquantel-medicine-overview_en.pdf"},
    {"id":"67335","name":"Ivermectin/Albendazole : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2025-03-18T16:00:27Z","last_updated_date":"2025-03-18T16:00:27Z","reference_number":"EMA/48961/2025","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/ivermectin-albendazole-medicine-overview_en.pdf"},
    {"id":"69980","name":"Lenacapavir Gilead : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2025-09-05T16:16:37Z","last_updated_date":"2025-09-05T16:16:37Z","reference_number":"EMA/259908/2025","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/lenacapavir-gilead-medicine-overview_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_bg.pdf","es":"https://www.ema.europa.eu/es/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_cs.pdf","da":"https://www.ema.europa.eu/da/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_da.pdf","de":"https://www.ema.europa.eu/de/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_de.pdf","et":"https://www.ema.europa.eu/et/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_et.pdf","el":"https://www.ema.europa.eu/el/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_hr.pdf","it":"https://www.ema.europa.eu/it/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/outside-eu-summary/lenacapavir-gilead-epar-medicine-overview_sv.pdf"}},
    {"id":"73461","name":"Acoziborole Winthrop : Medicine overview","type":"outside-EU-summary","status":"unknown","consultation_date":"","first_published_date":"2026-04-15T15:43:02Z","last_updated_date":"2026-04-15T15:43:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-summary/acoziborole-winthrop-medicine-overview_en.pdf","translations":{"bg":"https://www.ema.europa.eu/bg/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_bg.pdf","es":"https://www.ema.europa.eu/es/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_es.pdf","cs":"https://www.ema.europa.eu/cs/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_cs.pdf","da":"https://www.ema.europa.eu/da/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_da.pdf","de":"https://www.ema.europa.eu/de/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_de.pdf","et":"https://www.ema.europa.eu/et/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_et.pdf","el":"https://www.ema.europa.eu/el/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_el.pdf","fr":"https://www.ema.europa.eu/fr/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_fr.pdf","hr":"https://www.ema.europa.eu/hr/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_hr.pdf","it":"https://www.ema.europa.eu/it/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_it.pdf","lv":"https://www.ema.europa.eu/lv/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_lv.pdf","lt":"https://www.ema.europa.eu/lt/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_lt.pdf","hu":"https://www.ema.europa.eu/hu/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_hu.pdf","mt":"https://www.ema.europa.eu/mt/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_mt.pdf","nl":"https://www.ema.europa.eu/nl/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_nl.pdf","pl":"https://www.ema.europa.eu/pl/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_pl.pdf","pt":"https://www.ema.europa.eu/pt/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_pt.pdf","ro":"https://www.ema.europa.eu/ro/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_ro.pdf","sk":"https://www.ema.europa.eu/sk/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_sk.pdf","sl":"https://www.ema.europa.eu/sl/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_sl.pdf","fi":"https://www.ema.europa.eu/fi/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_fi.pdf","sv":"https://www.ema.europa.eu/sv/documents/outside-eu-qanda/acoziborole-winthrop-medicine-overview_sv.pdf"}},
    {"id":"49476","name":"Mosquirix: Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2015-10-01T09:43:00Z","last_updated_date":"2015-10-01T09:43:00Z","reference_number":"EMA/CHMP/439337/2015","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/mosquirix-public-assessment-report_en.pdf"},
    {"id":"51739","name":"Fexinidazole Winthrop : Assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2019-01-22T11:19:00Z","last_updated_date":"2019-03-04T11:22:00Z","reference_number":"EMA/CHMP/843546/2018","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/fexinidazole-winthrop-assessment-report_en.pdf"},
    {"id":"51762","name":"Umbipro : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2016-07-01T17:34:00Z","last_updated_date":"2022-04-08T09:07:00Z","reference_number":"EMA/343450/2016 ","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/umbipro-public-assessment-report_en.pdf"},
    {"id":"51768","name":"Dapivirine Vaginal Ring 25 mg : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2021-01-04T17:45:00Z","last_updated_date":"2021-01-04T17:45:00Z","reference_number":"EMA/430198/2020","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/dapivirine-vaginal-ring-25-mg-public-assessment-report_en.pdf"},
    {"id":"51799","name":"Hemoprostol : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2014-04-10T16:48:00Z","last_updated_date":"2017-04-26T11:49:00Z","reference_number":"EMA/CHMP/364824/2013","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/hemoprostol-public-assessment-report_en.pdf"},
    {"id":"51816","name":"Tritanrix HB : Public Assessment Report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2014-03-14T17:56:00Z","last_updated_date":"2014-03-14T17:56:00Z","reference_number":"EMA/CHMP/49887/2014","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/tritanrix-hb-public-assessment-report_en.pdf"},
    {"id":"51828","name":"Hexaxim : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2012-12-04T10:19:00Z","last_updated_date":"2012-12-04T10:19:00Z","reference_number":"EMA/560492/2012","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/hexaxim-public-assessment-report_en.pdf"},
    {"id":"51904","name":"Pyramax : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2021-06-29T10:40:00Z","last_updated_date":"2021-06-29T10:40:00Z","reference_number":"EMA/CHMP/61768/2012","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/pyramax-public-assessment-report_en.pdf"},
    {"id":"55638","name":"Actrapid : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2022-07-22T17:17:00Z","last_updated_date":"2022-07-22T17:17:00Z","reference_number":"EMA/254999/2022","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/actrapid-public-assessment-report_en.pdf"},
    {"id":"55718","name":"Insulatard : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2022-07-28T10:47:00Z","last_updated_date":"2022-07-28T10:47:00Z","reference_number":"EMA/255082/2022","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/insulatard-public-assessment-report_en.pdf"},
    {"id":"57006","name":"Dengue Tetravalent Vaccine (Live, Attenuated) Takeda : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2022-12-14T13:00:00Z","last_updated_date":"2022-12-14T13:00:00Z","reference_number":"EMA/862556/2022","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/dengue-tetravalent-vaccine-live-attenuated-takeda-public-assessment-report_en.pdf"},
    {"id":"62052","name":"Arpraziquantel : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2024-02-08T13:39:56Z","last_updated_date":"2024-02-08T13:39:56Z","reference_number":"EMA/18898/2024","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/arpraziquantel-public-assessment-report_en.pdf"},
    {"id":"67339","name":"Ivermectin/Albendazole : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2025-03-18T16:10:28Z","last_updated_date":"2025-11-27T12:20:00Z","reference_number":"EMA/59142/2025","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/ivermectin-albendazole-public-assessment-report_en.pdf"},
    {"id":"69984","name":"Lenacapavir Gilead : Assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2025-09-05T16:25:40Z","last_updated_date":"2025-09-05T16:25:40Z","reference_number":"EMA/265753/2025","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/lenacapavir-gilead-assessment-report_en.pdf"},
    {"id":"73465","name":"Acoziborole Winthrop : Public assessment report","type":"outside-EU-assessment-report","status":"Adopted","consultation_date":"","first_published_date":"2026-04-15T15:49:57Z","last_updated_date":"2026-04-15T15:49:57Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/acoziborole-winthrop-public-assessment-report_en.pdf"},
    {"id":"49967","name":"COVID-19 vaccine safety update for Comirnaty: 28 January 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-01-29T08:58:00Z","last_updated_date":"2021-01-29T08:58:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-28-january-2021_en.pdf"},
    {"id":"50071","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 5 February 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-02-05T14:47:00Z","last_updated_date":"2021-02-05T14:47:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-5-february-2021_en.pdf"},
    {"id":"50395","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 4 March 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T12:00:00Z","last_updated_date":"2021-03-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-4-march-2021_en.pdf"},
    {"id":"50396","name":"COVID-19 vaccine safety update for Comirnaty: 4 March 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-03-04T12:00:00Z","last_updated_date":"2021-03-04T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-4-march-2021_en.pdf"},
    {"id":"50737","name":"COVID-19 vaccine safety update for Comirnaty: 29 March 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-03-30T12:20:00Z","last_updated_date":"2021-03-30T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-29-march-2021_en.pdf"},
    {"id":"50738","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 29 March 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-03-30T12:20:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021_en.pdf"},
    {"id":"50739","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 29 March 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-03-30T12:20:00Z","last_updated_date":"2021-03-30T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-29-march-2021_en.pdf"},
    {"id":"50880","name":"COVID-19 vaccine safety update for Comirnaty: 14 April 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-04-16T11:40:00Z","last_updated_date":"2021-04-16T11:40:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-14-april-2021_en.pdf"},
    {"id":"50881","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 14 April 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-04-16T09:54:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-april-2021_en.pdf"},
    {"id":"50882","name":"COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 14 April 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-04-16T12:49:00Z","last_updated_date":"2024-08-09T12:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-14-april-2021_en.pdf"},
    {"id":"50968","name":"COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 22 April 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T13:53:00Z","last_updated_date":"2024-08-09T12:23:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-22-april-2021_en.pdf"},
    {"id":"51144","name":"COVID-19 vaccine safety update for Comirnaty: 11 May 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-05-12T13:27:00Z","last_updated_date":"2021-05-12T13:27:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-11-may-2021_en.pdf"},
    {"id":"51145","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 11 May 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-05-12T13:30:00Z","last_updated_date":"2021-05-12T13:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-may-2021_en.pdf"},
    {"id":"51146","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 11 May 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-05-12T13:32:00Z","last_updated_date":"2021-05-12T13:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-11-may-2021_en.pdf"},
    {"id":"51147","name":"COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 11 May 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-05-12T13:33:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-11-may-2021_en.pdf"},
    {"id":"51228","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 21 May 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T15:18:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-21-may-2021_en.pdf"},
    {"id":"51499","name":"COVID-19 vaccine safety update for Comirnaty: 18 June 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T16:10:00Z","last_updated_date":"2021-06-18T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-18-june-2021_en.pdf"},
    {"id":"51500","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 18 June 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T16:10:00Z","last_updated_date":"2021-06-18T16:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-18-june-2021_en.pdf"},
    {"id":"51501","name":"COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 18 June 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T16:10:00Z","last_updated_date":"2024-08-09T12:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-18-june-2021_en.pdf"},
    {"id":"51505","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 18 June 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-06-18T16:07:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-18-june-2021_en.pdf"},
    {"id":"51929","name":"COVID-19 vaccine safety update for Comirnaty: 14 July 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-07-14T15:32:00Z","last_updated_date":"2021-07-14T15:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-14-july-2021_en.pdf"},
    {"id":"51930","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 14 July 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-07-14T15:37:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf"},
    {"id":"51931","name":"COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 14 July 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-07-14T15:41:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-14-july-2021_en.pdf"},
    {"id":"51932","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 14 July 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-07-14T15:44:00Z","last_updated_date":"2021-07-14T15:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-14-july-2021_en.pdf"},
    {"id":"52213","name":"COVID-19 vaccine safety update for Comirnaty: 11 August 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-08-11T15:10:00Z","last_updated_date":"2021-08-11T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-11-august-2021_en.pdf"},
    {"id":"52214","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 11 August 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-08-11T15:13:00Z","last_updated_date":"2021-08-11T15:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-11-august-2021_en.pdf"},
    {"id":"52215","name":"COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 11 August 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-08-11T15:13:00Z","last_updated_date":"2024-08-09T12:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-11-august-2021_en.pdf"},
    {"id":"52216","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 11 August 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-08-11T15:12:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-august-2021_en.pdf"},
    {"id":"52371","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 8 September 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-09-08T15:25:00Z","last_updated_date":"2021-09-08T15:25:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-8-september-2021_en.pdf"},
    {"id":"52372","name":"COVID-19 vaccine safety update for Comirnaty: 8 September 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-09-08T15:22:00Z","last_updated_date":"2021-09-08T15:22:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-8-september-2021_en.pdf"},
    {"id":"52373","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 8 September 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-09-08T15:25:00Z","last_updated_date":"2024-05-07T11:36:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf"},
    {"id":"52374","name":"COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 8 September 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-09-08T15:27:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-8-september-2021_en.pdf"},
    {"id":"52756","name":"COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 6 October 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T17:00:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-6-october-2021_en.pdf"},
    {"id":"52759","name":"COVID-19 vaccine safety update for Comirnaty: 6 October 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T17:07:00Z","last_updated_date":"2021-10-06T17:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-6-october-2021_en.pdf"},
    {"id":"52760","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 6 October 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T17:00:00Z","last_updated_date":"2021-10-06T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-6-october-2021_en.pdf"},
    {"id":"52761","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 6 October 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-10-06T17:00:00Z","last_updated_date":"2021-10-06T17:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-6-october-2021_en.pdf"},
    {"id":"53055","name":"COVID-19 vaccine safety update for Comirnaty: 11 November 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-11-11T10:35:00Z","last_updated_date":"2021-11-11T10:35:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-11-november-2021_en.pdf"},
    {"id":"53057","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 11 November 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-11-11T10:37:00Z","last_updated_date":"2021-11-11T10:37:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-11-november-2021_en.pdf"},
    {"id":"53058","name":"COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 11 November 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-11-11T10:32:00Z","last_updated_date":"2024-08-09T12:18:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-11-november-2021_en.pdf"},
    {"id":"53061","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 11 November 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-11-11T10:34:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-november-2021_en.pdf"},
    {"id":"53426","name":"COVID-19 vaccine safety update for Comirnaty: 9 December 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-12-09T09:34:00Z","last_updated_date":"2021-12-09T09:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-9-december-2021_en.pdf"},
    {"id":"53427","name":"COVID-19 vaccine safety update for Spikevax (previously COVID-19 Vaccine Moderna): 9 December 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-12-09T09:30:00Z","last_updated_date":"2021-12-09T09:30:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-9-december-2021_en.pdf"},
    {"id":"53428","name":"COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 9 December 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-12-09T09:39:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-9-december-2021_en.pdf"},
    {"id":"53429","name":"COVID-19 vaccine safety update for Vaxzevria (previously COVID-19 Vaccine AstraZeneca): 9 December 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2021-12-09T09:37:00Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-9-december-2021_en.pdf"},
    {"id":"53850","name":"COVID-19 vaccines - Safety update: 20 January 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-01-20T11:31:00Z","last_updated_date":"2024-08-09T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-20-january-2022_en.pdf"},
    {"id":"54205","name":"COVID-19 vaccines - Safety update: 17 February 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-02-17T13:00:00Z","last_updated_date":"2024-08-09T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-17-february-2022_en.pdf"},
    {"id":"54510","name":"COVID-19 vaccines - Safety update: 17 March 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-03-17T14:43:00Z","last_updated_date":"2024-08-09T12:12:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-17-march-2022_en.pdf"},
    {"id":"54751","name":"COVID-19 vaccines - Safety update: 13 April 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-04-13T13:01:00Z","last_updated_date":"2024-08-09T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-13-april-2022_en.pdf"},
    {"id":"54952","name":"COVID-19 vaccines - Safety update: 12 May 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-05-12T12:05:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-12-may-2022_en.pdf"},
    {"id":"55268","name":"COVID-19 vaccines - Safety update: 17 June 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-06-17T14:11:00Z","last_updated_date":"2024-08-09T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-17-june-2022_en.pdf"},
    {"id":"55538","name":"COVID-19 vaccines - Safety update: 14 July 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-07-14T10:15:00Z","last_updated_date":"2024-08-09T12:14:00Z","reference_number":"Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-14-july-2022_en.pdf"},
    {"id":"56026","name":"COVID-19 vaccines - Safety update: 8 September 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-09-08T10:58:00Z","last_updated_date":"2024-08-09T12:13:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-september-2022_en.pdf"},
    {"id":"56329","name":"COVID-19 vaccines - Safety update: 6 October 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-10-06T10:10:00Z","last_updated_date":"2024-08-09T12:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-6-october-2022_en.pdf"},
    {"id":"56572","name":"COVID-19 vaccines - Safety update: 10 November 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-11-10T11:57:00Z","last_updated_date":"2024-08-09T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-10-november-2022_en.pdf"},
    {"id":"56908","name":"COVID-19 vaccines - Safety update: 8 December 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2022-12-08T14:00:00Z","last_updated_date":"2024-08-09T12:08:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-december-2022_en.pdf"},
    {"id":"59588","name":"Comirnaty : Periodic safety update report assessment: 19 December 2021 to 18 June 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-08-14T14:10:00Z","last_updated_date":"2023-08-14T14:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/comirnaty-periodic-safety-update-report-assessment-19-december-2021-18-june-2022_en.pdf"},
    {"id":"59593","name":"Replacement BAXJECT II / BAXJECT II Hi-Flow Reconstitution Devices co-packaged with Advate/Feiba/Rixubis","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-08-14T12:06:00Z","last_updated_date":"2023-08-14T12:06:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/replacement-baxject-ii-baxject-ii-hi-flow-reconstitution-devices-co-packaged-advate-feiba-rixubis_en.pdf"},
    {"id":"60175","name":"COVID-19 Vaccine (inactivated, adjuvanted) Valneva: Periodic safety update report assessment 28 February 2022 to 27 August 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-09-27T16:28:00Z","last_updated_date":"2023-12-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-inactivated-adjuvanted-valneva-periodic-safety-update-report-assessment-28-february-2022-27-august-2022_en.pdf"},
    {"id":"60357","name":"Jcovden (previously COVID-19 Vaccine Janssen): Periodic safety update report assessment 25 February 2022 to 24 August 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-10-10T16:59:00Z","last_updated_date":"2024-08-09T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/jcovden-previously-covid-19-vaccine-janssen-periodic-safety-update-report-assessment-25-february-2022-24-august-2022_en.pdf"},
    {"id":"60380","name":"Comirnaty : Periodic safety update report assessment 19 December 2021 to 18 June 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-08-14T12:34:00Z","last_updated_date":"2023-10-12T14:34:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/comirnaty-periodic-safety-update-report-assessment-19-december-2021-18-june-2022_en.pdf-0"},
    {"id":"60469","name":"Nuvaxovid: Periodic safety update report assessment 20 June 2022 to 19 December 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-10-24T12:17:00Z","last_updated_date":"2023-10-24T12:17:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/nuvaxovid-periodic-safety-update-report-assessment-20-june-2022-19-december-2022_en.pdf"},
    {"id":"60512","name":"COVID-19 Vaccine (inactivated, adjuvanted) Valneva : Periodic safety update report assessment 28 August 2022 to 27 February 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-10-30T17:43:00Z","last_updated_date":"2023-12-01T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-inactivated-adjuvanted-valneva-periodic-safety-update-report-assessment-28-august-2022-27-february-2023_en.pdf"},
    {"id":"61486","name":"Vaxzevria: Periodic safety update report assessment 29 December 2021 to 28 June 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-12-18T15:24:19Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/vaxzevria-periodic-safety-update-report-assessment-29-december-2021-28-june-2022_en.pdf"},
    {"id":"61487","name":"Comirnaty : Periodic safety update report assessment 19 June 2022 to 18 December 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-12-18T15:37:34Z","last_updated_date":"2023-12-18T15:37:34Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/comirnaty-periodic-safety-update-report-assessment-19-june-2022-18-december-2022_en.pdf"},
    {"id":"61577","name":"Spikevax : Periodic safety update report assessment 19 June 2022 to 17 December 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-12-21T16:23:58Z","last_updated_date":"2023-12-21T16:23:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/spikevax-periodic-safety-update-report-assessment-19-june-2022-17-december-2022_en.pdf"},
    {"id":"61578","name":"Vaxzevria: Periodic safety update report assessment 29 June 2022 to 28 December 2022","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2023-12-21T16:33:34Z","last_updated_date":"2024-05-07T11:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/vaxzevria-periodic-safety-update-report-assessment-29-june-2022-28-december-2022_en.pdf"},
    {"id":"62055","name":"Jcovden (previously COVID-19 Vaccine Janssen): Periodic safety update report assessment 25 August 2022 to 24 February 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-02-08T16:15:37Z","last_updated_date":"2024-08-09T12:16:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/jcovden-previously-covid-19-vaccine-janssen-periodic-safety-update-report-assessment-25-august-2022-24-february-2023_en.pdf"},
    {"id":"62222","name":"VidPrevtyn Beta: Periodic safety update report assessment 10 November 2022 to 9 May 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-02-20T16:35:26Z","last_updated_date":"2024-03-20T13:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/vidprevtyn-beta-periodic-safety-update-report-assessment-10-november-2022-9-may-2023_en.pdf"},
    {"id":"62532","name":"Comirnaty : Periodic safety update report assessment 19 December 2022 to 18 June 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-03-11T14:04:27Z","last_updated_date":"2024-03-11T14:04:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/comirnaty-periodic-safety-update-report-assessment-19-december-2022-18-june-2023_en.pdf"},
    {"id":"62655","name":"Nuvaxovid: Periodic safety update report assessment 20 December 2022 to 19 June 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-03-20T14:43:46Z","last_updated_date":"2024-03-20T14:43:46Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/nuvaxovid-periodic-safety-update-report-assessment-20-december-2022-19-june-2023_en.pdf"},
    {"id":"62738","name":"Spikevax : Periodic safety update report assessment 18 December 2022 to 17 June 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-03-26T14:24:49Z","last_updated_date":"2024-03-26T14:24:49Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/spikevax-periodic-safety-update-report-assessment-18-december-2022-17-june-2023_en.pdf"},
    {"id":"64402","name":"\tVidPrevtyn Beta: Periodic safety update report assessment 10 May 2023 to 9 November 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-07-30T14:27:47Z","last_updated_date":"2024-07-30T14:27:47Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/vidprevtyn-beta-periodic-safety-update-report-assessment-10-may-2023-9-november-2023_en.pdf"},
    {"id":"64564","name":"Nuvaxovid: Periodic safety update report assessment 20 June 2023 to 19 December 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-08-14T09:59:27Z","last_updated_date":"2024-08-14T09:59:27Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/nuvaxovid-periodic-safety-update-report-assessment-20-june-2023-19-december-2023_en.pdf"},
    {"id":"64620","name":"Vaxzevria: Periodic safety update report assessment 29 December 2022 to 28 December 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-08-22T16:15:55Z","last_updated_date":"2024-08-22T16:15:55Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/vaxzevria-periodic-safety-update-report-assessment-29-december-2022-28-december-2023_en.pdf"}    {"id":"64661","name":" Comirnaty : Periodic safety update report assessment 19 June 2021 to 18 December 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-08-29T17:26:38Z","last_updated_date":"2024-08-29T17:26:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/comirnaty-periodic-safety-update-report-assessment-19-june-2021-18-december-2021_en.pdf"},
    {"id":"64724","name":"Spikevax : Periodic safety update report assessment 18 June 2023 to 17 December 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-09-05T16:19:07Z","last_updated_date":"2024-09-05T16:19:07Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/spikevax-periodic-safety-update-report-assessment-18-june-2023-17-december-2023_en.pdf"},
    {"id":"65053","name":"Comirnaty : Periodic safety update report assessment 19 June 2023 to 18 December 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-09-27T16:18:29Z","last_updated_date":"2024-09-27T16:18:29Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/comirnaty-periodic-safety-update-report-assessment-19-june-2023-18-december-2023_en.pdf"},
    {"id":"65943","name":"Bimervax: Periodic safety update report assessment 30 March 2023 to 29 September 2023","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-12-04T13:02:39Z","last_updated_date":"2024-12-04T13:02:39Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/bimervax-periodic-safety-update-report-assessment-30-march-2023-29-september-2023_en.pdf"},
    {"id":"65954","name":"Jcovden : Periodic safety update report assessment 25 February 2023 to 24 February 2024","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2024-12-05T09:50:42Z","last_updated_date":"2024-12-05T09:50:42Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/jcovden-periodic-safety-update-report-assessment-25-february-2023-24-february-2024_en.pdf"},
    {"id":"66609","name":"Nuvaxovid: Periodic safety update report assessment 20 December 2023 to 19 June 2024","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2025-02-05T11:32:38Z","last_updated_date":"2025-02-05T11:32:38Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/nuvaxovid-periodic-safety-update-report-assessment-20-december-2023-19-june-2024_en.pdf"},
    {"id":"67027","name":"Comirnaty : Periodic safety update report assessment 19 December 2020 to 18 June 2021","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2025-02-27T17:18:02Z","last_updated_date":"2025-02-27T17:18:02Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/comirnaty-periodic-safety-update-report-assessment-19-december-2020-18-june-2021_en.pdf"},
    {"id":"69916","name":"Jcovden : Periodic safety update report assessment 25 February 2024 to 30 September 2024","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2025-09-01T15:42:47Z","last_updated_date":"2025-09-01T15:42:47Z","reference_number":"EMA/111356/2025","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/jcovden-periodic-safety-update-report-assessment-25-february-2024-30-september-2024_en.pdf"},
    {"id":"70528","name":"Spikevax : Periodic safety update report assessment 18 December 2023 - 17 December 2024","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2025-10-14T13:32:00Z","last_updated_date":"2025-10-14T13:32:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/spikevax-periodic-safety-update-report-assessment-18-december-2023-17-december-2024_en.pdf"},
    {"id":"71254","name":"Comirnaty : Periodic safety update report assessment 19 December 2023 to 18 December 2024","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2025-11-20T10:37:24Z","last_updated_date":"2025-11-20T10:37:24Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/comirnaty-periodic-safety-update-report-assessment-19-december-2023-18-december-2024_en.pdf"},
    {"id":"71628","name":"Bimervax: Periodic safety update report assessment 30 September 2024 - 29 March 2025","type":"covid-19-vaccine-safety-update","status":"unknown","consultation_date":"","first_published_date":"2025-12-09T16:09:58Z","last_updated_date":"2025-12-09T16:09:58Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/bimervax-periodic-safety-update-report-assessment-30-september-2024-29-march-2025_en.pdf"},
    {"id":"72608","name":"Nuvaxovid: Periodic safety update report assessment 20 June 2024 to 19 December 2024","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2026-02-19T15:10:00Z","last_updated_date":"2026-02-19T15:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/nuvaxovid-periodic-safety-update-report-assessment-20-june-2024-19-december-2024_en.pdf"},
    {"id":"73116","name":"Kostaive: Periodic safety update report assessment 28th November 2024 to 27th May 2025","type":"covid-19-vaccine-safety-update","status":"Adopted","consultation_date":"","first_published_date":"2026-03-19T10:30:26Z","last_updated_date":"2026-03-19T10:30:26Z","reference_number":"EMADOC-1700519818-2457701","document_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/kostaive-periodic-safety-update-report-assessment-28th-november-2024-27th-may-2025_en.pdf"},
    {"id":"2581","name":"Opinion of the CHMP pursuant to Article-5(3) of Regulation (EC) No 726/2004, on antidepressants","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2008-07-04T02:09:00Z","last_updated_date":"2008-07-04T02:09:00Z","reference_number":"EMEA/CHMP/266022/2008","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/opinion-chmp-pursuant-article-53-regulation-ec-no-726-2004-antidepressants_en.pdf"},
    {"id":"2879","name":"Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2011-10-20T19:00:00Z","last_updated_date":"2017-05-11T19:00:00Z","reference_number":"EMA/CHMP/834168/2011","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf"},
    {"id":"3774","name":"Assessment report for Article-5(3) procedure: Angiotensin II (type-1) receptor antagonists and risk of cancer","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2012-02-09T12:30:00Z","last_updated_date":"2012-02-09T12:30:00Z","reference_number":"EMEA/H/A-5(3)/1274","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-angiotensin-ii-type-1-receptor-antagonists-risk-cancer_en.pdf"},
    {"id":"4731","name":"Questions and answers on the review of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2012-10-19T12:30:00Z","last_updated_date":"2012-10-19T12:30:00Z","reference_number":"EMA/653433/2012","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/questions-answers-review-non-selective-non-steroidal-anti-inflammatory-drugs-nsaids-cardiovascular-risk_en.pdf"},
    {"id":"5122","name":"Assessment report for Article-5(3) procedure: Presence of endotoxins in Baxter peritoneal dialysis solutions","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2010-12-20T01:00:00Z","last_updated_date":"2010-12-20T01:00:00Z","reference_number":"EMA/833156/2010","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-presence-endotoxins-baxter-peritoneal-dialysis-solutions_en.pdf"},
    {"id":"5818","name":"Questions and answers on the detection of unexpected viral DNA in live attenuated vaccines","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2010-11-18T01:00:00Z","last_updated_date":"2010-11-18T01:00:00Z","reference_number":"EMA/718290/2010","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/questions-answers-detection-unexpected-viral-dna-live-attenuated-vaccines_en.pdf"},
    {"id":"5829","name":"Assessment report for Article-5(3) procedure: Immunological differences of pandemic vaccines (review of hypothesis on Pandemrix and development of narcolepsy)","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2012-11-12T15:10:00Z","last_updated_date":"2012-11-12T15:10:00Z","reference_number":"EMA/687578/2012","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-immunological-differences-pandemic-vaccines-review-hypothesis-pandemrix-development-narcolepsy_en.pdf"},
    {"id":"7107","name":"Adequacy of guidance on the elderly regarding medicinal products for human use","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2006-12-14T00:09:00Z","last_updated_date":"2006-12-14T00:09:00Z","reference_number":"EMEA/498920/2006","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/adequacy-guidance-elderly-regarding-medicinal-products-human-use_en.pdf"},
    {"id":"7669","name":"Questions and answers on the review of bisphosphonates and the risk of osteonecrosis of the jaw","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:09:21Z","last_updated_date":"2009-09-24T02:09:21Z","reference_number":"EMEA/CHMP/292475/2009","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/questions-answers-review-bisphosphonates-risk-osteonecrosis-jaw_en.pdf"},
    {"id":"7674","name":"Assessment report for Article-5(3) procedure: Detection by a highly sensitive new polymerase-chain-reaction technique of genomic fragments from endogenous and adventitious viral agents in live attenuated vaccines","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2012-02-09T01:00:00Z","last_updated_date":"2012-02-09T01:00:00Z","reference_number":"EMEA/H/A-5(3)/1269","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-detection-highly-sensitive-new-polymerase-chain-reaction-technique-genomic-fragments-endogenous-adventitious-viral-agents-live-attenuated-vaccines_en.pdf"},
    {"id":"8959","name":"Opinion of the CHMP pursuant to Article-5(3) of Regulation (EC) No 726/2004, for non-selective non-steroidal anti-inflammatory drugs (NSAIDs)","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2006-10-23T02:09:00Z","last_updated_date":"2006-10-23T02:09:00Z","reference_number":"EMEA/CHMP/410051/2006","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/opinion-chmp-pursuant-article-53-regulation-ec-no-726-2004-non-selective-non-steroidal-anti-inflammatory-drugs-nsaids_en.pdf"},
    {"id":"9120","name":"CHMP assessment report on antidepressants under Article 5(3) of Regulation (EC) No 726/2004","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:09:21Z","last_updated_date":"2008-05-30T02:09:21Z","reference_number":"EMEA/CHMP/266019/2008","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/chmp-assessment-report-antidepressants-under-article-53-regulation-ec-no-726-2004_en.pdf"},
    {"id":"11628","name":"Assessment report for Article-5(3) procedure: desloratadine-containing medicinal products","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2017-07-10T16:10:00Z","last_updated_date":"2019-02-25T16:10:00Z","reference_number":"EMA/421768/2017","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-desloratadine-containing-medicinal-products_en.pdf"},
    {"id":"11756","name":"Assessment report for Article-5(3) procedure: Teicoplanin-containing medicinal products","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2013-04-22T12:00:00Z","last_updated_date":"2013-04-22T12:00:00Z","reference_number":"EMA/194668/2013","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-teicoplanin-containing-medicinal-products_en.pdf"},
    {"id":"13000","name":"Questions and answers on heparins","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2008-06-05T02:09:00Z","last_updated_date":"2008-06-05T02:09:00Z","reference_number":"EMEA/276814/2008","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/questions-answers-heparins_en.pdf"},
    {"id":"13503","name":"Letter on request for opinion on non-selective NSAIDs under Article 5(3) of Regulation (EC) No 726/2004","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2006-09-21T02:09:00Z","last_updated_date":"2006-09-21T02:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/letter-request-opinion-non-selective-nsaids-under-article-53-regulation-ec-no-726-2004_en.pdf"},
    {"id":"14964","name":"Questions and answers on the use of antiviral medicines in case of novel influenza A/H1N1 pandemic","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2009-05-08T02:00:00Z","last_updated_date":"2009-05-08T02:00:00Z","reference_number":"EMEA/273535/2009","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/questions-answers-use-antiviral-medicines-case-novel-influenza-h1n1-pandemic_en.pdf"},
    {"id":"15128","name":"Opinion of the CHMP pursuant to Article-5(3) of Regulation (EC) No 726/2004, on bisphosphonates and osteonecrosis of the jaw","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2009-10-08T02:09:00Z","last_updated_date":"2009-10-08T02:09:00Z","reference_number":"EMEA/CHMP/292474/2009, EMEA/H/A-5(3)/1130","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/opinion-chmp-pursuant-article-53-regulation-ec-no-726-2004-bisphosphonates-osteonecrosis-jaw_en.pdf"},
    {"id":"16168","name":"Questions and answers on the presence of endotoxins in Baxter peritoneal dialysis solutions","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2010-12-17T01:00:00Z","last_updated_date":"2010-12-17T01:00:00Z","reference_number":"EMA/818936/2010","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/questions-answers-presence-endotoxins-baxter-peritoneal-dialysis-solutions_en.pdf"},
    {"id":"17039","name":"Assessment report for Article-5(3) procedure: Medicinal products under development for treatment of Ebola","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2016-03-14T14:10:00Z","last_updated_date":"2016-03-14T14:10:00Z","reference_number":"EMA/129754/2016","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-medicinal-products-under-development-treatment-ebola_en.pdf"},
    {"id":"19598","name":"Assessment report under Article 5(3) for particles on silicone tubing of diphtheria and tetanus toxoid (DT) and diphtheria/tetanus toxoid/pertussis (DTwP) antigen bulk containers","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2011-10-10T02:00:00Z","last_updated_date":"2011-10-10T02:00:00Z","reference_number":"EMA/474456/2011","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-under-article-53-particles-silicone-tubing-diphtheria-tetanus-toxoid-dt-diphtheria-tetanus-toxoid-pertussis-dtwp-antigen-bulk-containers_en.pdf"},
    {"id":"20210","name":"CHMP assessment report on bisphosphonates and osteonecrosis of the jaw - Procedure under Article 5(3) of Regulation (EC) No 726/2004","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2009-09-24T02:09:21Z","last_updated_date":"2009-09-24T02:09:21Z","reference_number":"EMEA/CHMP/291125/2009","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/chmp-assessment-report-bisphosphonates-osteonecrosis-jaw-procedure-under-article-53-regulation-ec-no-726-2004_en.pdf"},
    {"id":"20332","name":"Letter on efficacy of antidepressants","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2008-03-19T00:09:00Z","last_updated_date":"2008-03-19T00:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/letter-efficacy-antidepressants_en.pdf"},
    {"id":"22204","name":"Request for a scientific opinion letter","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2009-10-08T02:09:00Z","last_updated_date":"2009-10-08T02:09:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/request-scientific-opinion-letter_en.pdf"},
    {"id":"22703","name":"Assessment report for Article-5(3) procedure: Non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2012-11-12T15:11:00Z","last_updated_date":"2012-11-12T15:11:00Z","reference_number":"EMA/696137/2012","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-non-steroidal-anti-inflammatory-drugs-nsaids-cardiovascular-risk_en.pdf"},
    {"id":"22970","name":"Assessment report for Article-5(3) procedure: Octagam and associated names","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2013-05-28T19:34:00Z","last_updated_date":"2013-05-28T19:34:00Z","reference_number":"EMA/227216/2012","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-octagam-associated-names_en.pdf"},
    {"id":"24524","name":"Public CHMP assessment report for medicinal products containing non-selective non-steroidal anti-inflammatory drugs (NSAIDs)","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2006-11-07T00:09:00Z","last_updated_date":"2006-11-07T00:09:00Z","reference_number":"EMEA/CHMP/442130/2006","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/public-chmp-assessment-report-medicinal-products-containing-non-selective-non-steroidal-anti-inflammatory-drugs-nsaids_en.pdf"},
    {"id":"25428","name":"Questions and answers on the review of non-selective non-steroidal anti-inflammatory drugs","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2006-10-24T02:09:00Z","last_updated_date":"2006-10-24T02:09:00Z","reference_number":"EMEA/410862/2006","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/questions-answers-review-non-selective-non-steroidal-anti-inflammatory-drugs_en.pdf"},
    {"id":"27412","name":"Assessment report for Article-5(3) procedure: Protamine-containing medicinal products","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2012-12-06T14:33:00Z","last_updated_date":"2012-12-06T14:33:00Z","reference_number":"EMA/741250/2012","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-protamine-containing-medicinal-products_en.pdf"},
    {"id":"28413","name":"CHMP scientific Article-5(3) opinion on the potential risks of carcinogens, mutagens and substances toxic to reproduction when these substances are used as excipients of medicinal products for human use","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2007-10-18T02:00:00Z","last_updated_date":"2007-10-18T02:00:00Z","reference_number":"EMEA/CHMP/SWP/146166/2007","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/chmp-scientific-article-53-opinion-potential-risks-carcinogens-mutagens-substances-toxic-reproduction-when-these-substances-are-used-excipients-medicinal-products-human-use_en.pdf"},
    {"id":"29186","name":"Assessment report for celecoxib for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis, as an adjunct to surgery and further endoscopic surveillance","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2011-06-15T14:32:00Z","last_updated_date":"2011-06-15T14:32:00Z","reference_number":"EMA/416998/2011","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-celecoxib-reduction-number-adenomatous-intestinal-polyps-familial-adenomatous-polyposis-adjunct-surgery-further-endoscopic-surveillance_en.pdf"},
    {"id":"29235","name":"CHMP assessment report on novel influenza (H1N1) outbreak, Tamiflu (oseltamivir), Relenza (zanamivir)","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2009-05-07T02:00:00Z","last_updated_date":"2009-05-07T02:00:00Z","reference_number":"EMEA/CHMP/287662/2009","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/chmp-assessment-report-novel-influenza-h1n1-outbreak-tamiflu-oseltamivir-relenza-zanamivir_en.pdf"},
    {"id":"30601","name":"Assessment report for Article-5(3) procedure: GLP-1-based therapies","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2013-08-01T19:00:00Z","last_updated_date":"2013-08-01T19:00:00Z","reference_number":"EMA/474117/2013","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-glp-1-based-therapies_en.pdf"},
    {"id":"30866","name":"CHMP assessment report for medicinal products containing or derived from heparin under Article 5(3) of Regulation (EC) No 726/2004","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2008-05-30T02:09:21Z","last_updated_date":"2008-05-30T02:09:21Z","reference_number":"EMEA/CHMP/278280/2008","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/chmp-assessment-report-medicinal-products-containing-or-derived-heparin-under-article-53-regulation-ec-no-726-2004_en.pdf"},
    {"id":"32542","name":"Opinion of the CHMP pursuant to Article-5(3) of Regulation (EC) No 726/2004, on conventional antipsychotics","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2008-11-27T00:09:21Z","last_updated_date":"2008-11-27T00:09:21Z","reference_number":"EMEA/CHMP/590563/2008","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/opinion-chmp-pursuant-article-53-regulation-ec-no-726-2004-conventional-antipsychotics_en.pdf"},
    {"id":"33630","name":"Opinion of the CHMP pursuant to Article-5(3) of Regulation (EC) No 726/2004, on heparins","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2008-06-06T02:09:21Z","last_updated_date":"2008-06-06T02:09:21Z","reference_number":"EMEA/CHMP/271967/2008","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/opinion-chmp-pursuant-article-53-regulation-ec-no-726-2004-heparins_en.pdf"},
    {"id":"33944","name":"Assessment report for Article-5(3) procedure: Propylene glycol in medicinal products for children","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2014-03-27T16:00:00Z","last_updated_date":"2014-03-27T16:00:00Z","reference_number":"EMA/175205/2014","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-propylene-glycol-medicinal-products-children_en.pdf"},
    {"id":"35074","name":"Assessment report for Article-5(3) procedure: Anti-tuberculosis medicinal products containing isoniazid, rifampicin, pyrazinamide, ethambutol, rifabutin: posology in children","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2012-06-12T11:55:00Z","last_updated_date":"2012-06-12T11:55:00Z","reference_number":"EMA/227191/2012","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-anti-tuberculosis-medicinal-products-containing-isoniazid-rifampicin-pyrazinamide-ethambutol-rifabutin-posology-children_en.pdf"},
    {"id":"35381","name":"CHMP assessment report on conventional antipsychotics procedure under Article 5(3) of Regulation (EC) No 726/2004","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2008-11-20T00:09:21Z","last_updated_date":"2008-11-20T00:09:21Z","reference_number":"EMEA/CHMP/590557/2008","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/chmp-assessment-report-conventional-antipsychotics-procedure-under-article-53-regulation-ec-no-726-2004_en.pdf"},
    {"id":"36893","name":"Opinion of the CHMP pursuant to Article-5(3) of Regulation (EC) no 726/2004, on novel influenza (H1N1) outbreak, Tamiflu (oseltamivir), Relenza (zanamivir)","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2009-05-08T02:00:00Z","last_updated_date":"2009-05-08T02:00:00Z","reference_number":"EMEA/CHMP/278838/2009","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/opinion-chmp-pursuant-article-53-regulation-ec-no-726-2004-novel-influenza-h1n1-outbreak-tamiflu-oseltamivir-relenza-zanamivir_en.pdf"},
    {"id":"37378","name":"Interim assessment report for Article-5(3) procedure: Medicinal products under development for treatment of Ebola","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2014-12-16T11:00:00Z","last_updated_date":"2015-02-02T16:15:00Z","reference_number":"EMA/756544/2014 Rev. 1","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/interim-assessment-report-article-53-procedure-medicinal-products-under-development-treatment-ebola_en.pdf"},
    {"id":"38256","name":"Questions and answers on the review of the use of conventional antipsychotic medicines in elderly patients with dementia","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2008-11-27T00:09:21Z","last_updated_date":"2008-11-27T00:09:21Z","reference_number":"EMEA/637512/2008","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/questions-answers-review-use-conventional-antipsychotic-medicines-elderly-patients-dementia_en.pdf"},
    {"id":"42442","name":"Assessment report for Article-5(3) procedure: norethisterone and ethinylestradiol","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2018-10-26T16:15:00Z","last_updated_date":"2018-10-26T16:15:00Z","reference_number":"EMA/745160/2018","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-norethisterone-ethinylestradiol_en.pdf"},
    {"id":"42896","name":"Assessment report for Article-5(3) procedure: Gentamicin","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2018-12-03T11:43:00Z","last_updated_date":"2018-12-03T11:43:00Z","reference_number":"EMA/805330/201","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-gentamicin_en.pdf"},
    {"id":"43607","name":"Direct oral anticoagulants (DOACs) - EMA starts review of study on bleeding risk with direct oral anticoagulants","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2019-02-01T12:00:00Z","last_updated_date":"2019-02-01T12:00:00Z","reference_number":"EMA/37941/2019","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/direct-oral-anticoagulants-doacs-ema-starts-review-study-bleeding-risk-direct-oral-anticoagulants_en.pdf"},
    {"id":"44428","name":"Assessment report for Article-5(3) procedure: norethisterone and ethinylestradiol (EMEA/H/A-5(3)/1477)","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2019-05-06T10:26:00Z","last_updated_date":"2019-05-24T10:04:00Z","reference_number":"EMA/245512/2019 Corr.","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-norethisterone-ethinylestradiol-emea-h-53-1477_en.pdf"},
    {"id":"45441","name":"EMA to provide guidance on avoiding nitrosamines in human medicines","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2019-09-13T14:00:00Z","last_updated_date":"2019-09-13T14:00:00Z","reference_number":"EMA/500009/2019","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/ema-provide-guidance-avoiding-nitrosamines-human-medicines_en.pdf"},
    {"id":"45521","name":"Nitrosamines EMEA-H-A5(3)-1490 - Information on nitrosamines for marketing authorisation holders - Obsolete","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2019-09-26T12:00:00Z","last_updated_date":"2019-09-26T12:00:00Z","reference_number":"EMA/189634/2019","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/nitrosamines-emea-h-a53-1490-information-nitrosamines-marketing-authorisation-holders-obsolete_en.pdf"},
    {"id":"45522","name":"Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers on 'Information on nitrosamines for marketing authorisation holders' - Obsolete","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2019-09-26T12:00:00Z","last_updated_date":"2020-03-27T17:05:00Z","reference_number":"EMA/CHMP/428592/2019 Rev. 3","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/nitrosamines-emea-h-a53-1490-questions-answers-information-nitrosamines-marketing-authorisation-holders-obsolete_en.pdf"},
    {"id":"45526","name":"Nitrosamine impurities - Interim outcome of Article 5(3)","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2019-09-26T12:00:00Z","last_updated_date":"2019-09-26T12:00:00Z","reference_number":"EMA/511347/2019","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/nitrosamine-impurities-interim-outcome-article-53_en.pdf"},
    {"id":"47195","name":"No change is needed in use of direct oral anticoagulants following EMA-funded study","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2020-03-27T12:00:00Z","last_updated_date":"2020-03-27T12:00:00Z","reference_number":"EMA/94424/2020","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/no-change-needed-use-direct-oral-anticoagulants-following-ema-funded-study_en.pdf"},
    {"id":"47493","name":"Assessment report for Article-5(3) procedure: direct oral anticoagulants (DOACs)","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2020-04-28T10:25:00Z","last_updated_date":"2020-04-28T10:25:00Z","reference_number":"EMA/194375/2020","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/assessment-report-article-53-procedure-direct-oral-anticoagulants-doacs_en.pdf"},
    {"id":"48272","name":"Nitrosamine impurities - Final outcome of Article 5(3)","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2020-07-09T14:00:00Z","last_updated_date":"2020-07-09T14:00:00Z","reference_number":"EMA/341963/2020","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/nitrosamine-impurities-final-outcome-article-53_en.pdf"},
    {"id":"48273","name":"Nitrosamines EMEA-H-A5(3)-1490 - Assessment report","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2020-07-09T14:00:00Z","last_updated_date":"2020-07-09T14:00:00Z","reference_number":"EMA/369136/2020","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf"},
    {"id":"48555","name":"Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2020-08-06T13:04:00Z","last_updated_date":"2025-10-10T08:26:00Z","reference_number":"EMA/409815/2020 Rev.23","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf"},
    {"id":"48846","name":"Dexamethasone - COVID19 - Article-5(3) procedure: proposals for product information","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2020-09-18T12:00:00Z","last_updated_date":"2020-09-18T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/dexamethasone-covid19-article-53-procedure-proposals-product-information_en.pdf"},
    {"id":"48861","name":"EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2020-09-18T12:00:00Z","last_updated_date":"2020-09-18T12:00:00Z","reference_number":"EMA/483739/2020","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-or-mechanical-ventilation_en.pdf"},
    {"id":"48921","name":"Dexamethasone - COVID19 - Article-5(3) procedure: Assessment report","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2020-09-30T15:13:00Z","last_updated_date":"2020-09-30T15:13:00Z","reference_number":"EMA/509632/2020 ","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/dexamethasone-covid19-article-53-procedure-assessment-report_en.pdf"},
    {"id":"50220","name":"European Medicines Regulatory Network approach for the implementation of the CHMP Opinion pursuant to Article 5(3) of Regulation (EC) No 726/2004 for nitrosamine impurities in human medicines","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2021-02-19T15:04:00Z","last_updated_date":"2021-02-22T09:54:00Z","reference_number":"EMA/425645/2020","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/european-medicines-regulatory-network-approach-implementation-chmp-opinion-pursuant-article-53-regulation-ec-no-726-2004-nitrosamine-impurities-human-medicines_en.pdf"},
    {"id":"50281","name":"REGN-COV2 antibody combination (casirivimab / imdevimab) - COVID19 - Article-5(3) procedure: Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2021-02-26T12:00:00Z","last_updated_date":"2021-03-24T16:20:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/regn-cov2-antibody-combination-casirivimab-imdevimab-covid19-article-53-procedure-conditions-use-conditions-distribution-patients-targeted-conditions-safety-monitoring_en.pdf"},
    {"id":"50419","name":"Eli Lilly and Company Limited antibody combination (bamlanivimab / etesevimab - COVID19 - Article-5(3) procedure: Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2021-03-05T17:13:00Z","last_updated_date":"2021-03-11T13:07:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/eli-lilly-company-limited-antibody-combination-bamlanivimab-etesevimab-covid19-article-53-procedure-conditions-use-conditions-distribution-patients-targeted-conditions-safety-monitoring_en.pdf"},
    {"id":"50527","name":"REGN-COV2 antibody combination (casirivimab / imdevimab) - COVID19 - Article-5(3) procedure: Assessment report","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2021-03-11T15:43:00Z","last_updated_date":"2021-03-11T15:43:00Z","reference_number":"EMA/142650/2021","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/regn-cov2-antibody-combination-casirivimab-imdevimab-covid19-article-53-procedure-assessment-report_en.pdf"},
    {"id":"50695","name":"Eli Lilly and Company Limited antibody combination (bamlanivimab / etesevimab - COVID19 - Article-5(3) procedure: Assessment report","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-03-24T17:45:00Z","last_updated_date":"2021-03-24T17:45:00Z","reference_number":"EMA/177113/2021","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/eli-lilly-company-limited-antibody-combination-bamlanivimab-etesevimab-covid19-article-53-procedure-assessment-report_en.pdf"},
    {"id":"50726","name":"Celltrion use of regdanvimab for the treatment of COVID-19 - Article-5(3) procedure: Conditions of use, conditions for distribution and patients Targeted and conditions for safety monitoring addressed to Member States","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-03-26T12:00:00Z","last_updated_date":"2021-03-26T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/celltrion-use-regdanvimab-treatment-covid-19-article-53-procedure-conditions-use-conditions-distribution-patients-targeted-conditions-safety-monitoring-addressed-member-states_en.pdf"},
    {"id":"50823","name":"Letter from Commissioner Kyriakides asking EMA to follow up on Vaxzevria opinion after Council discussion","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2021-04-14T16:00:00Z","last_updated_date":"2021-04-14T16:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/letter-commissioner-kyriakides-asking-ema-follow-vaxzevria-opinion-after-council-discussion_en.pdf"},
    {"id":"50976","name":"Interim Opinion of the Committee for Medicinal products for Human Use pursuant to Article 5(3) of Regulation (EC) No 726/2004 for Vaxzevria","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-04-23T18:05:00Z","last_updated_date":"2021-04-23T18:05:00Z","reference_number":"EMA/CHMP/228681/2021","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/interim-opinion-committee-medicinal-products-human-use-pursuant-article-53-regulation-ec-no-726-2004-vaxzevria_en.pdf"},
    {"id":"50992","name":"Use of Vaxzevria to prevent COVID-19 - Article-5(3) procedure: Assessment report","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-04-26T17:54:00Z","last_updated_date":"2021-04-26T17:54:00Z","reference_number":"EMA/CHMP/214855/2021","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/use-vaxzevria-prevent-covid-19-article-53-procedure-assessment-report_en.pdf"},
    {"id":"51103","name":"Regdanvimab for the treatment of COVID-19 (Celltrion) - COVID-19 - Article-5(3) procedure: Assessment report","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-05-06T16:45:00Z","last_updated_date":"2021-05-06T16:45:00Z","reference_number":"EMA/192245/2021","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/regdanvimab-treatment-covid-19-celltrion-covid-19-article-53-procedure-assessment-report_en.pdf"},
    {"id":"51204","name":"Sotrovimab (also known as VIR-7831 and GSK4182136) - COVID19 - Article-5(3) procedure: Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-05-21T12:00:00Z","last_updated_date":"2021-05-21T12:00:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/sotrovimab-also-known-vir-7831-gsk4182136-covid19-article-53-procedure-conditions-use-conditions-distribution-patients-targeted-conditions-safety-monitoring_en.pdf"},
    {"id":"51421","name":"Sotrovimab (also known as VIR-7831 and GSK4182136) - COVID19 - Article-5(3) procedure: Assessment report","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-06-11T14:01:00Z","last_updated_date":"2021-06-11T14:01:00Z","reference_number":"EMA/304600/2021","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/sotrovimab-also-known-vir-7831-gsk4182136-covid19-article-53-procedure-assessment-report_en.pdf"},
    {"id":"52538","name":"Use of Vaxzevria to prevent COVID-19 - Article-5(3) procedure: Final assessment report","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-09-21T16:30:00Z","last_updated_date":"2021-09-21T16:30:00Z","reference_number":"EMA/530434/2021","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/use-vaxzevria-prevent-covid-19-article-53-procedure-final-assessment-report_en.pdf"},
    {"id":"53189","name":"Lagevrio (also known as molnupiravir or MK 4482) - COVID-19 - Article-5(3) procedure: Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-11-19T17:44:00Z","last_updated_date":"2021-11-19T17:44:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/lagevrio-also-known-molnupiravir-or-mk-4482-covid-19-article-53-procedure-conditions-use-conditions-distribution-patients-targeted-conditions-safety-monitoring_en.pdf"},
    {"id":"53363","name":"Lagevrio (also known as molnupiravir or MK 4482) - COVID-19 - Article-5(3) procedure: Assessment report","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-12-03T16:11:00Z","last_updated_date":"2021-12-09T16:14:00Z","reference_number":"EMA/719664/2021 Corr. 1","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/lagevrio-also-known-molnupiravir-or-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf"},
    {"id":"53617","name":"Paxlovid (PF-07321332 and ritonavir) - COVID-19 - Article-5(3) procedure: Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2021-12-22T11:10:00Z","last_updated_date":"2021-12-22T11:10:00Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-conditions-use-conditions-distribution-patients-targeted-conditions-safety-monitoring_en.pdf"},
    {"id":"53654","name":"Paxlovid (PF-07321332 and ritonavir) - COVID-19 - Article-5(3) procedure: Assessment report","type":"opinion-on-any-scientific-matter","status":"Adopted","consultation_date":"","first_published_date":"2022-01-10T09:10:00Z","last_updated_date":"2022-01-10T09:10:00Z","reference_number":"EMA/783153/2021","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-assessment-report_en.pdf"},
    {"id":"72907","name":"Male genital system prostheses - Notified Body 0477 - 17/04/2023 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)","type":"opinion-on-any-scientific-matter","status":"unknown","consultation_date":"","first_published_date":"2026-03-09T17:08:10Z","last_updated_date":"2026-03-09T17:08:10Z","reference_number":"","document_url":"https://www.ema.europa.eu/en/documents/opinion-any-scientific-matter/male-genital-system-prostheses-notified-body-0477-17-04-2023-expert-decision-opinion-context-clinical-evaluation-consultation-procedure-cecp_en.pdf"}
]
}